Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
UCEC	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.73	-0.43	5.55e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs9912468	1.000	rs9909004	chr17:64306133	C/T	cg19474267	chr17:64306194	PRKCA	-0.44	-6.18	-0.45	5.84e-9	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
UCEC	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.8	6.43	0.47	1.71e-9	Response to hepatitis C treatment;
UCEC	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.42	4.82	0.37	3.49e-6	Lung cancer;
UCEC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-5.41	-0.41	2.54e-7	Alcohol dependence;
UCEC	cis	rs6437061	0.520	rs3100589	chr2:232965541	A/G	cg02061626	chr2:233274167	ALPPL2	-0.49	-4.98	-0.38	1.78e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.72	-7.22	-0.51	2.64e-11	Aortic root size;
UCEC	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg01072550	chr1:21505969	NA	-0.51	-4.94	-0.38	2.12e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1165472	0.755	rs4927261	chr1:56161500	T/C	cg11523071	chr1:56160889	NA	-0.53	-5.28	-0.4	4.46e-7	Paclitaxel-induced neuropathy;
UCEC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.7	4.97	0.38	1.81e-6	Aortic root size;
UCEC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.92	-0.63	4.41e-18	Height;
UCEC	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.49	4.5	0.35	1.35e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
UCEC	cis	rs4820803	1.000	rs762817	chr22:29653929	G/T	cg07256473	chr22:29710276	RASL10A	-0.64	-5.07	-0.39	1.2e-6	Breast cancer;
UCEC	cis	rs3935996	0.965	rs6663328	chr1:56317874	C/T	cg11959316	chr1:57001742	PPAP2B	0.36	4.65	0.36	7.45e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
UCEC	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg13683864	chr3:40499215	RPL14	-0.59	-6.35	-0.46	2.47e-9	Renal cell carcinoma;
UCEC	cis	rs151997	0.893	rs27607	chr5:50228977	A/G	cg06027927	chr5:50259733	NA	-0.53	-4.91	-0.38	2.43e-6	Callous-unemotional behaviour;
UCEC	cis	rs4372836	0.675	rs72782280	chr2:28911349	C/T	cg09522027	chr2:28974177	PPP1CB	0.73	6.78	0.49	2.72e-10	Body mass index;
UCEC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg13870426	chr17:30244630	NA	-0.63	-4.56	-0.35	1.06e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.5	5.03	0.38	1.43e-6	Blood metabolite levels;
UCEC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg12024160	chr4:1254474	NA	-0.53	-5.62	-0.42	9.14e-8	Obesity-related traits;
UCEC	cis	rs7165102	1.000	rs28640237	chr15:66070962	T/C	cg11164506	chr15:66649558	TIPIN	-0.33	-4.57	-0.35	1.03e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.67	4.59	0.35	9.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.32	-0.4	3.71e-7	Pubertal anthropometrics;
UCEC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg13147721	chr7:65941812	NA	0.93	6.67	0.48	4.8e-10	Diabetic kidney disease;
UCEC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.39	-5.18	-0.39	7.19e-7	Dupuytren's disease;
UCEC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.46	4.91	0.38	2.43e-6	Smoking initiation;
UCEC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.71	7.05	0.5	6.41e-11	Aortic root size;
UCEC	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.8	8.75	0.59	4.63e-15	Body mass index (adult);
UCEC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	0.87	5.43	0.41	2.32e-7	Skin colour saturation;
UCEC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12681287	0.752	rs4463401	chr8:87250309	C/T	cg27223183	chr8:87520930	FAM82B	-0.57	-4.64	-0.36	7.72e-6	Caudate activity during reward;
UCEC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-4.61	-0.36	8.55e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	5.83	0.43	3.35e-8	Bone mineral density;
UCEC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.12	6.62	0.48	6.33e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg18171715	chr4:852160	GAK	0.48	4.53	0.35	1.21e-5	Obesity-related traits;
UCEC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.95	-0.44	1.92e-8	Parkinson's disease;
UCEC	cis	rs9383929	0.556	rs6909279	chr6:151895456	G/C	cg16336494	chr6:151188259	MTHFD1L	0.42	4.59	0.35	9.32e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.07	0.71	9.55e-24	Prudent dietary pattern;
UCEC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.8	0.49	2.47e-10	Motion sickness;
UCEC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.56	0.35	1.08e-5	Bipolar disorder;
UCEC	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg18681998	chr4:17616180	MED28	-0.64	-7.43	-0.52	8.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	4.58	0.35	9.87e-6	Joint mobility (Beighton score);
UCEC	cis	rs6669919	0.901	rs7527396	chr1:211667857	C/T	cg10512769	chr1:211675356	NA	-0.32	-4.94	-0.38	2.13e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg24562669	chr7:97807699	LMTK2	0.42	5.17	0.39	7.38e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs896543	0.702	rs6711119	chr2:237494334	C/T	cg25295825	chr2:237489920	CXCR7	0.63	8.24	0.56	8.49e-14	Alcohol dependence (age at onset);
UCEC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg04043695	chr12:129287642	SLC15A4	0.57	5.34	0.4	3.5e-7	Systemic lupus erythematosus;
UCEC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.41	0.41	2.45e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.51	-0.53	5.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs36051895	0.623	rs17426903	chr9:5203292	A/C	cg02405213	chr9:5042618	JAK2	-0.54	-4.68	-0.36	6.5e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.43	-4.65	-0.36	7.44e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.61	-5.26	-0.4	4.89e-7	Lung cancer in ever smokers;
UCEC	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg16583315	chr14:65563665	MAX	0.42	5.55	0.42	1.32e-7	Obesity-related traits;
UCEC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.77	8.54	0.58	1.51e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7766436	0.848	rs16901663	chr6:22598054	T/C	cg13666174	chr6:22585274	NA	-0.6	-6.08	-0.45	1.01e-8	Coronary artery disease;
UCEC	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg16583315	chr14:65563665	MAX	-0.44	-5.79	-0.43	4.09e-8	Obesity-related traits;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11502736	chr1:179923845	CEP350	0.57	6.78	0.49	2.73e-10	Warfarin maintenance dose;
UCEC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs4908768	0.906	rs11121213	chr1:8728187	C/A	cg13081009	chr1:8430745	RERE	0.48	4.8	0.37	3.91e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.42	4.94	0.38	2.1e-6	Colorectal cancer;
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.69	7.77	0.54	1.23e-12	Prudent dietary pattern;
UCEC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg04756594	chr16:24857601	SLC5A11	0.5	5.97	0.44	1.68e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg02580404	chr16:19729857	C16orf88;IQCK	-0.51	-4.53	-0.35	1.23e-5	Parkinson's disease;
UCEC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	7.59	0.53	3.3e-12	Smoking behavior;
UCEC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-5.12	-0.39	9.52e-7	Colorectal cancer;
UCEC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.93	12.01	0.7	1.39e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.66	-6.34	-0.46	2.69e-9	Menarche (age at onset);
UCEC	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.51	-4.93	-0.38	2.17e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.45	4.55	0.35	1.1e-5	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.64	6.89	0.49	1.49e-10	Coronary artery disease;
UCEC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1392935	0.620	rs9896174	chr17:49931598	A/C	cg06451949	chr17:48942959	NA	0.51	4.55	0.35	1.13e-5	Bacterial meningitis;
UCEC	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg04553112	chr3:125709451	NA	-0.65	-4.72	-0.36	5.37e-6	Blood pressure (smoking interaction);
UCEC	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-20.74	-0.86	1.68e-45	Myeloid white cell count;
UCEC	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.69	9.16	0.6	4.09e-16	Mean platelet volume;
UCEC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-7.86	-0.54	7.5e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7070678	0.934	rs7069035	chr10:29787438	A/C	cg19331777	chr10:30344362	KIAA1462	-0.31	-4.52	-0.35	1.26e-5	Platelet thrombus formation;
UCEC	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.59	5.8	0.43	4e-8	Retinal vascular caliber;
UCEC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.31	-0.46	3.16e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.8	9.61	0.62	2.92e-17	Monocyte count;
UCEC	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.52	-4.68	-0.36	6.58e-6	Colorectal cancer;
UCEC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.65	0.42	8.07e-8	Initial pursuit acceleration;
UCEC	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.08	-0.6	6.77e-16	Coffee consumption (cups per day);
UCEC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7246967	0.544	rs400275	chr19:23015856	T/A	cg24889512	chr19:22816950	ZNF492	0.48	4.67	0.36	6.77e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2839627	0.638	rs7276320	chr21:44269588	A/G	cg03543861	chr21:44258195	NA	-0.48	-5.04	-0.38	1.35e-6	Information processing speed;
UCEC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg11871910	chr12:69753446	YEATS4	1.07	13.57	0.75	1.05e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg10932868	chr11:921992	NA	0.43	5.6	0.42	1.03e-7	Alzheimer's disease (late onset);
UCEC	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.47	-4.55	-0.35	1.13e-5	Cardiac Troponin-T levels;
UCEC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.7	-7.38	-0.52	1.07e-11	Cognitive function;
UCEC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.52	-7.11	-0.51	4.63e-11	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.74	7.93	0.55	5.06e-13	Breast cancer;
UCEC	cis	rs7937612	1.000	rs7131597	chr11:120303939	G/T	cg12584626	chr11:120203529	NA	0.48	4.58	0.35	9.67e-6	Intraocular pressure;
UCEC	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-4.61	-0.36	8.78e-6	Red cell distribution width;
UCEC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.65	4.93	0.38	2.19e-6	Mean platelet volume;
UCEC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg06784218	chr1:46089804	CCDC17	0.54	6.32	0.46	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.82	8.79	0.59	3.7e-15	Longevity;
UCEC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg11632617	chr15:75315747	PPCDC	-0.62	-7.42	-0.52	8.8e-12	Blood trace element (Zn levels);
UCEC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg08798685	chr6:27730294	NA	-0.63	-4.58	-0.35	9.87e-6	Depression;
UCEC	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg06521331	chr12:34319734	NA	-0.65	-5.17	-0.39	7.38e-7	Morning vs. evening chronotype;
UCEC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.15	19.27	0.85	4.53e-42	IgG glycosylation;
UCEC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.5	5.24	0.4	5.48e-7	Prostate cancer;
UCEC	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-5.57	-0.42	1.18e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg08755490	chr11:65554678	OVOL1	0.5	5.31	0.4	3.89e-7	Acne (severe);
UCEC	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.82	-11.11	-0.68	3.41e-21	Body mass index;
UCEC	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.43	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.22	0.56	9.59e-14	Smoking behavior;
UCEC	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-5.26	-0.4	4.89e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.65	6.32	0.46	2.98e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	1.18	14.71	0.77	1.1e-30	Body mass index;
UCEC	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.05	7.53	0.53	4.64e-12	Sexual dysfunction (female);
UCEC	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.44	-0.57	2.83e-14	Colorectal cancer;
UCEC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg14438399	chr17:27053147	TLCD1	0.66	4.83	0.37	3.36e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.17	-17.23	-0.82	4.31e-37	Exhaled nitric oxide output;
UCEC	cis	rs4845570	0.920	rs3811414	chr1:151763246	A/G	cg07092448	chr1:151763213	TDRKH	-1.0	-12.9	-0.73	6.27e-26	Coronary artery disease;
UCEC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.75	8.41	0.57	3.26e-14	Menopause (age at onset);
UCEC	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.74	6.63	0.48	6.12e-10	Coronary artery disease;
UCEC	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.03	0.55	2.83e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.77	-8.73	-0.58	5.09e-15	Height;
UCEC	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.59	5.39	0.41	2.8e-7	Uric acid levels;
UCEC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	10.09	0.64	1.61e-18	Chronic sinus infection;
UCEC	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	0.84	6.11	0.45	8.58e-9	Skin colour saturation;
UCEC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg04473437	chr5:205334	CCDC127	-0.56	-4.53	-0.35	1.23e-5	Breast cancer;
UCEC	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs17123764	0.710	rs7952734	chr12:50062681	A/C	cg20471783	chr12:50157085	TMBIM6	0.62	4.76	0.37	4.5e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.55	-6.02	-0.44	1.36e-8	Blood metabolite levels;
UCEC	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.64	6.12	0.45	7.94e-9	Migraine;Coronary artery disease;
UCEC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.96	-0.55	4.31e-13	Monocyte count;
UCEC	cis	rs7122539	0.684	rs10896139	chr11:66650060	C/T	cg24851651	chr11:66362959	CCS	0.39	4.65	0.36	7.24e-6	HIV-1 susceptibility;
UCEC	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	4.81	0.37	3.64e-6	Schizophrenia;
UCEC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg07636037	chr3:49044803	WDR6	0.56	4.55	0.35	1.14e-5	Menarche (age at onset);
UCEC	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg18681998	chr4:17616180	MED28	0.89	11.47	0.69	3.67e-22	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.81	-4.98	-0.38	1.79e-6	Putamen volume;
UCEC	cis	rs10012307	1.000	rs12642556	chr4:137483885	T/A	cg12033966	chr4:138453416	PCDH18	-0.72	-5.04	-0.38	1.33e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.79	-6.28	-0.46	3.65e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.4	4.68	0.36	6.4e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs4244915	chr19:22854138	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.71	6.45	0.47	1.54e-9	Aortic root size;
UCEC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg24531977	chr5:56204891	C5orf35	-0.51	-4.6	-0.35	9.02e-6	Coronary artery disease;
UCEC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-14.36	-0.76	8.68e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.6	5.47	0.41	1.93e-7	Selective IgA deficiency;
UCEC	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.39	4.94	0.38	2.13e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-6.92	-0.5	1.28e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.48	6.96	0.5	1.07e-10	Homoarginine levels;
UCEC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.78	-0.37	4.19e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg21770322	chr7:97807741	LMTK2	0.51	6.39	0.47	2.11e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.58	-0.48	7.92e-10	Obesity-related traits;
UCEC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg00343986	chr7:65444356	GUSB	-0.51	-4.63	-0.36	8.02e-6	Aortic root size;
UCEC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg24416660	chr17:73865998	NA	-0.32	-4.61	-0.36	8.66e-6	Psoriasis;
UCEC	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.63	-0.42	8.87e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs5167	0.504	rs7246900	chr19:45454236	G/A	cg13119609	chr19:45449297	APOC2	0.42	5.92	0.44	2.14e-8	Blood protein levels;
UCEC	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg11621586	chr10:70884670	VPS26A	0.9	9.2	0.6	3.31e-16	Left atrial antero-posterior diameter;
UCEC	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.42	-5.7	-0.43	6.26e-8	Metabolite levels;
UCEC	cis	rs4499344	0.730	rs2868150	chr19:33098875	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	5.01	0.38	1.53e-6	Breast cancer;
UCEC	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-5.87	-0.44	2.81e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs968451	0.619	rs2267407	chr22:39747050	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.61	4.54	0.35	1.16e-5	Primary biliary cholangitis;
UCEC	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.51	-5.93	-0.44	2.12e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.57	6.73	0.49	3.5e-10	Testicular germ cell tumor;
UCEC	cis	rs10012307	1.000	rs2406017	chr4:137519330	A/C	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-0.96	-5.81	-0.43	3.7e-8	Diabetic kidney disease;
UCEC	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.61	-6.26	-0.46	3.96e-9	Platelet distribution width;
UCEC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs1545257	0.537	rs2702089	chr2:24643291	A/G	cg06627628	chr2:24431161	ITSN2	0.52	5.35	0.4	3.25e-7	Sjögren's syndrome;
UCEC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.88	12.1	0.71	7.96e-24	Metabolic syndrome;
UCEC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.57	4.88	0.37	2.73e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg01072550	chr1:21505969	NA	-0.61	-6.38	-0.47	2.21e-9	Superior frontal gyrus grey matter volume;
UCEC	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	1.18	10.64	0.66	5.85e-20	Dupuytren's disease;
UCEC	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.77	-5.96	-0.44	1.81e-8	Red blood cell count;
UCEC	cis	rs12980942	0.810	rs12974323	chr19:41807071	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.65	6.03	0.45	1.26e-8	Coronary artery disease;
UCEC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.71	-7.64	-0.53	2.54e-12	Lung cancer;
UCEC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg00316803	chr15:76480434	C15orf27	-0.45	-5.23	-0.4	5.69e-7	Blood metabolite levels;
UCEC	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.52	-4.66	-0.36	6.94e-6	Colorectal cancer;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.52	-5.63	-0.42	8.84e-8	Pubertal anthropometrics;
UCEC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.43e-8	Breast cancer;
UCEC	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.52	-5.51	-0.41	1.58e-7	Menarche (age at onset);
UCEC	cis	rs10208940	0.920	rs13400155	chr2:68723636	G/A	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg00086871	chr4:6988644	TBC1D14	0.81	5.7	0.43	6.27e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.02	-16.38	-0.8	5.72e-35	Testicular germ cell tumor;
UCEC	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs883115	1.000	rs883115	chr1:224807561	T/C	cg01808320	chr1:224927238	CNIH3	-0.36	-4.57	-0.35	1.03e-5	Cancer;
UCEC	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-0.98	-4.64	-0.36	7.53e-6	Mitochondrial DNA levels;
UCEC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.11	-0.45	8.61e-9	Parkinson's disease;
UCEC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.62	-7.23	-0.51	2.4e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.8	7.3	0.52	1.64e-11	Bladder cancer;
UCEC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.48	-5.1	-0.39	1.03e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg03959625	chr15:84868606	LOC388152	0.49	5.18	0.39	7.33e-7	Schizophrenia;
UCEC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.6	-6.46	-0.47	1.45e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.42	4.8	0.37	3.78e-6	Blood metabolite ratios;
UCEC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.78	7.84	0.54	8.41e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.61	5.66	0.42	7.6e-8	Lymphocyte counts;
UCEC	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.18e-21	Body mass index;
UCEC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	6.63	0.48	6.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.48	4.92	0.38	2.25e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.6	5.98	0.44	1.62e-8	Body mass index;
UCEC	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.0	8.15	0.56	1.46e-13	Exhaled nitric oxide output;
UCEC	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	7.63	0.53	2.65e-12	Post bronchodilator FEV1;
UCEC	cis	rs78761021	0.720	rs874175	chr17:9798595	T/G	cg26853458	chr17:9805074	RCVRN	0.38	4.7	0.36	5.92e-6	Type 2 diabetes;
UCEC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.66	0.48	5.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	6.96	0.5	1.02e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.55	-5.94	-0.44	1.95e-8	Bipolar disorder;
UCEC	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg04155231	chr12:9217510	LOC144571	0.4	5.06	0.39	1.22e-6	Sjögren's syndrome;
UCEC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	7.89	0.55	6.18e-13	Tonsillectomy;
UCEC	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-13.63	-0.75	7.33e-28	Schizophrenia;
UCEC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.69	7.72	0.54	1.67e-12	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	0.85	6.88	0.49	1.64e-10	Opioid sensitivity;
UCEC	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.53	5.85	0.43	3.09e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg19318889	chr4:1322082	MAEA	0.57	7.06	0.5	6.09e-11	Longevity;
UCEC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.69	7.15	0.51	3.75e-11	Dental caries;
UCEC	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.67	6.78	0.49	2.68e-10	Coronary artery disease;
UCEC	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.7	6.34	0.46	2.65e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs7302981	0.667	rs7136648	chr12:50624822	A/G	cg20014596	chr12:50898483	DIP2B	0.46	4.72	0.36	5.41e-6	Systolic blood pressure;
UCEC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.64	6.93	0.5	1.26e-10	Menopause (age at onset);
UCEC	cis	rs853679	0.585	rs201001	chr6:27808899	T/C	cg19041857	chr6:27730383	NA	-0.52	-4.6	-0.35	9.12e-6	Depression;
UCEC	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.51	5.39	0.41	2.76e-7	Breast cancer;
UCEC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.13	6.85	0.49	1.83e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.62	-4.74	-0.36	4.9e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.96	-0.44	1.82e-8	Cardiac Troponin-T levels;
UCEC	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	4.53	0.35	1.19e-5	Eosinophil percentage of white cells;
UCEC	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.46	-4.81	-0.37	3.73e-6	Height;
UCEC	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.43	5.96	0.44	1.78e-8	Superior crus of antihelix expression;
UCEC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.55	4.55	0.35	1.1e-5	Mean platelet volume;
UCEC	cis	rs8042680	0.518	rs8025699	chr15:91533816	A/G	cg14398957	chr15:91536180	PRC1	-0.44	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.28e-9	Platelet count;
UCEC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg20450318	chr11:65415260	SIPA1	0.4	4.52	0.35	1.24e-5	Acne (severe);
UCEC	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.82	10.49	0.65	1.48e-19	Body mass index;
UCEC	cis	rs7651039	0.641	rs2455810	chr3:15657082	A/T	cg16303742	chr3:15540471	COLQ	0.55	6.78	0.49	2.72e-10	Coronary heart disease;
UCEC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.61	5.77	0.43	4.58e-8	Corneal astigmatism;
UCEC	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.41	-4.52	-0.35	1.28e-5	Retinal vascular caliber;
UCEC	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-4.99	-0.38	1.68e-6	Colorectal cancer;
UCEC	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.66	-7.23	-0.51	2.4e-11	Crohn's disease;
UCEC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs6840360	0.573	rs4696249	chr4:152264647	A/G	cg25486957	chr4:152246857	NA	-0.44	-4.84	-0.37	3.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg00343986	chr7:65444356	GUSB	-0.52	-4.59	-0.35	9.47e-6	Aortic root size;
UCEC	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.5	5.32	0.4	3.74e-7	IgG glycosylation;
UCEC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.5	-0.35	1.35e-5	Longevity;
UCEC	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.54	5.36	0.4	3.2e-7	Blood protein levels;
UCEC	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.64	-0.36	7.53e-6	Schizophrenia;
UCEC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.46	-6.97	-0.5	1e-10	Primary biliary cholangitis;
UCEC	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg17279458	chr3:44753948	ZNF502	-0.48	-5.23	-0.4	5.77e-7	Depressive symptoms;
UCEC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.63	-5.36	-0.4	3.19e-7	Corneal astigmatism;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.57	-6.67	-0.48	4.78e-10	Prostate cancer;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg23556447	chr6:90529595	MDN1	-0.6	-6.71	-0.48	3.92e-10	Breast cancer;
UCEC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.13	-0.39	8.89e-7	Blood metabolite levels;
UCEC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.83	7.75	0.54	1.4e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.48	4.92	0.38	2.25e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.4	4.98	0.38	1.79e-6	Refractive error;
UCEC	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg21214455	chr15:72412075	SENP8	0.47	4.56	0.35	1.06e-5	Red blood cell count;
UCEC	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.49	4.8	0.37	3.82e-6	HDL cholesterol;
UCEC	cis	rs77724872	0.850	rs113724071	chr12:104664838	G/A	cg25935014	chr12:103889042	C12orf42	-0.56	-4.78	-0.37	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
UCEC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.43	-4.63	-0.36	8.12e-6	Parkinson's disease;
UCEC	cis	rs6540731	1.000	rs4500383	chr1:212391596	C/T	cg07569918	chr1:212002970	LPGAT1	-0.39	-4.93	-0.38	2.21e-6	Intelligence (childhood);
UCEC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg14438399	chr17:27053147	TLCD1	0.59	4.7	0.36	6.03e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-7.31	-0.52	1.56e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.49	-5.18	-0.39	7.04e-7	Educational attainment;
UCEC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-4.87	-0.37	2.9e-6	Personality dimensions;
UCEC	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.65	-7.24	-0.51	2.35e-11	Breast cancer;
UCEC	cis	rs3015497	0.586	rs12587821	chr14:51092554	A/G	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.37e-6	Mean platelet volume;
UCEC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	4.52	0.35	1.28e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.64	0.42	8.33e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.91	11.61	0.69	1.62e-22	Metabolic syndrome;
UCEC	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg01072550	chr1:21505969	NA	-0.59	-5.99	-0.44	1.58e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.51	-5.25	-0.4	5.17e-7	Pubertal anthropometrics;
UCEC	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.72	-8.51	-0.57	1.88e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	1.1	14.28	0.76	1.41e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	trans	rs925228	0.869	rs2712070	chr2:23985329	A/T	cg02894226	chr20:3190561	ITPA	0.67	6.81	0.49	2.26e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.57	-5.67	-0.42	7.21e-8	Prudent dietary pattern;
UCEC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.72	-8.55	-0.58	1.47e-14	Menarche (age at onset);
UCEC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.61	-6.93	-0.5	1.25e-10	Body mass index;
UCEC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.75	-9.48	-0.62	6.36e-17	White blood cell count (basophil);
UCEC	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.5	4.91	0.38	2.39e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.23	-0.4	5.83e-7	Breast cancer;
UCEC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.48	4.62	0.36	8.23e-6	Hemoglobin concentration;
UCEC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.43	-4.56	-0.35	1.07e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.97	5.46	0.41	1.99e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs7246967	0.673	rs57736314	chr19:22880272	T/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg21419209	chr3:44054225	NA	-0.49	-5.09	-0.39	1.09e-6	Coronary artery disease;
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.92	-0.44	2.2e-8	Platelet count;
UCEC	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.82	8.28	0.56	6.8e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.44	-5.84	-0.43	3.28e-8	Superior crus of antihelix expression;
UCEC	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Response to radiotherapy in cancer (late toxicity);
UCEC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-6.83	-0.49	2.13e-10	Initial pursuit acceleration;
UCEC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.53	5.05	0.38	1.31e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.94	10.07	0.64	1.83e-18	Cognitive function;
UCEC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-4.58	-0.35	9.77e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.93	0.55	5.01e-13	Platelet count;
UCEC	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.56	-5.17	-0.39	7.38e-7	Systemic lupus erythematosus;
UCEC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.7	7.72	0.54	1.62e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg18099408	chr3:52552593	STAB1	0.42	4.78	0.37	4.14e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.64	6.3	0.46	3.25e-9	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg13683864	chr3:40499215	RPL14	0.71	8.16	0.56	1.36e-13	Renal cell carcinoma;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.57	-0.42	1.16e-7	Pubertal anthropometrics;
UCEC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-8.85	-0.59	2.57e-15	Blood metabolite levels;
UCEC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg22974920	chr21:40686053	BRWD1	-0.54	-4.95	-0.38	2e-6	Cognitive function;
UCEC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg26061582	chr7:22766209	IL6	0.59	5.49	0.41	1.73e-7	Lung cancer;
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-6.48	-0.47	1.3e-9	Platelet count;
UCEC	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.48	-5.69	-0.42	6.67e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.72	8.05	0.55	2.53e-13	Waist circumference;Body mass index;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.76	-0.49	3.09e-10	Depression;
UCEC	cis	rs7646881	0.500	rs73022762	chr3:158290305	G/A	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.34e-6	Tetralogy of Fallot;
UCEC	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-4.95	-0.38	1.99e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.57	6.45	0.47	1.51e-9	Mean platelet volume;
UCEC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.54	-4.93	-0.38	2.21e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg02160872	chr5:212506	CCDC127	-0.7	-6.88	-0.49	1.59e-10	Breast cancer;
UCEC	cis	rs7246967	0.611	rs3951785	chr19:22851928	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-6.63	-0.48	6.12e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.54	4.57	0.35	1.01e-5	Colorectal cancer;
UCEC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg08875078	chr22:50639485	SELO	0.44	4.56	0.35	1.09e-5	Obesity-related traits;
UCEC	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.62	5.63	0.42	8.78e-8	Platelet count;
UCEC	cis	rs13098911	0.540	rs13069079	chr3:46000870	G/A	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.67	5.32	0.4	3.76e-7	Corneal astigmatism;
UCEC	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-4.92	-0.38	2.33e-6	Self-reported allergy;
UCEC	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.59	6.1	0.45	8.78e-9	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.63	6.69	0.48	4.42e-10	Retinal vascular caliber;
UCEC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg24881330	chr22:46731750	TRMU	0.73	7.36	0.52	1.18e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	12.05	0.7	1.11e-23	Platelet count;
UCEC	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg00086871	chr4:6988644	TBC1D14	0.66	4.6	0.35	9.04e-6	Granulocyte percentage of myeloid white cells;
UCEC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-0.96	-12.83	-0.73	9.39e-26	Height;
UCEC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.55	-6.02	-0.44	1.31e-8	Blood metabolite levels;
UCEC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.12	0.45	7.9e-9	Rheumatoid arthritis;
UCEC	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.17	6.25	0.46	4.18e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.48	-5.17	-0.39	7.45e-7	Menarche (age at onset);
UCEC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-4.67	-0.36	6.61e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.61	5.6	0.42	1.05e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs12579753	0.667	rs11115071	chr12:82284926	G/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-4.59	-0.35	9.55e-6	Resting heart rate;
UCEC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12681287	0.752	rs12677470	chr8:87260559	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-5.34	-0.4	3.48e-7	Caudate activity during reward;
UCEC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.94	7.28	0.51	1.84e-11	Initial pursuit acceleration;
UCEC	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.53	4.54	0.35	1.17e-5	Obesity-related traits;
UCEC	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	5.06	0.39	1.21e-6	Body mass index;
UCEC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-1.03	-11.95	-0.7	2e-23	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.51	5.02	0.38	1.5e-6	Menopause (age at onset);
UCEC	cis	rs3780378	0.875	rs7869668	chr9:5069837	G/A	cg02405213	chr9:5042618	JAK2	-0.5	-4.86	-0.37	3.03e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7246967	0.551	rs12974117	chr19:22867876	G/A	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.47	6.11	0.45	8.66e-9	Prudent dietary pattern;
UCEC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.63	9.13	0.6	5.01e-16	Prudent dietary pattern;
UCEC	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-7.43	-0.52	8.25e-12	Plateletcrit;Platelet count;
UCEC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs7307889	0.793	rs73047652	chr12:6015033	T/G	cg05660680	chr12:6400491	NA	-0.71	-4.61	-0.36	8.84e-6	Obesity-related traits;
UCEC	cis	rs12786942	0.569	rs12273188	chr11:101313615	A/C	cg03942599	chr11:101341554	TRPC6	0.51	5.91	0.44	2.32e-8	Facial depth;
UCEC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.43	4.61	0.36	8.66e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs75804782	0.630	rs74404946	chr2:239300772	C/G	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-7.71	-0.54	1.73e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.85	0.37	3.07e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.62	4.73	0.36	5.14e-6	Lung cancer;
UCEC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.1e-10	Chronic sinus infection;
UCEC	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.53	5.39	0.41	2.79e-7	Platelet count;
UCEC	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.55	-5.52	-0.41	1.51e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg08890418	chr1:21044141	KIF17	0.71	7.69	0.54	1.95e-12	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg21214455	chr15:72412075	SENP8	-0.51	-4.57	-0.35	1.03e-5	Red blood cell count;
UCEC	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.69	8.82	0.59	3.06e-15	Mean platelet volume;
UCEC	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg14784868	chr12:69753453	YEATS4	0.65	6.36	0.46	2.42e-9	Blood protein levels;
UCEC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.81	-7.53	-0.53	4.67e-12	Initial pursuit acceleration;
UCEC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.92	0.59	1.68e-15	Alzheimer's disease;
UCEC	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.54	-0.35	1.17e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	9.34	0.61	1.45e-16	Blood protein levels;
UCEC	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.43	4.78	0.37	4.15e-6	White matter hyperintensity burden;
UCEC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg13575925	chr12:9217583	LOC144571	0.42	5.14	0.39	8.48e-7	Sjögren's syndrome;
UCEC	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	0.96	11.17	0.68	2.32e-21	Ulcerative colitis;
UCEC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.44	4.63	0.36	7.87e-6	Prostate cancer;
UCEC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.51	0.35	1.34e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.79	6.2	0.46	5.4e-9	Major depressive disorder;
UCEC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.54	-4.74	-0.36	5.01e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.44	-0.47	1.62e-9	Pubertal anthropometrics;
UCEC	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg20469991	chr17:27169893	C17orf63	-0.75	-5.39	-0.41	2.7e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.93	0.44	2.04e-8	Breast cancer;
UCEC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.5	4.98	0.38	1.77e-6	Diastolic blood pressure;
UCEC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg12311346	chr5:56204834	C5orf35	-0.78	-5.87	-0.44	2.72e-8	Type 2 diabetes;
UCEC	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg26781129	chr3:44753946	ZNF502	-0.43	-4.61	-0.36	8.66e-6	Depressive symptoms;
UCEC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.82	8.94	0.59	1.48e-15	Breast cancer;
UCEC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg01072550	chr1:21505969	NA	-0.57	-5.54	-0.42	1.38e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9467773	1.000	rs6913462	chr6:26577530	A/G	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	9.09	0.6	6.36e-16	Platelet count;
UCEC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.61	0.42	9.76e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.68	6.6	0.48	6.95e-10	Aortic root size;
UCEC	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.91	8.62	0.58	9.52e-15	Colorectal adenoma (advanced);
UCEC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.67	5.23	0.4	5.69e-7	Corneal astigmatism;
UCEC	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-7.56	-0.53	4.03e-12	Blood protein levels;
UCEC	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.72	-8.23	-0.56	9.5e-14	Morning vs. evening chronotype;
UCEC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.54	-0.35	1.17e-5	Parkinson's disease;
UCEC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg20450318	chr11:65415260	SIPA1	0.45	5.03	0.38	1.41e-6	Acne (severe);
UCEC	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg09537434	chr19:41945824	ATP5SL	-0.67	-6.68	-0.48	4.61e-10	Height;
UCEC	cis	rs7597155	0.846	rs2312549	chr2:69958944	G/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.36	-0.4	3.2e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.61	5.04	0.38	1.34e-6	Lymphocyte counts;
UCEC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.15	0.56	1.42e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg13147721	chr7:65941812	NA	-0.91	-6.06	-0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13683864	chr3:40499215	RPL14	-0.97	-10.68	-0.66	4.61e-20	Renal cell carcinoma;
UCEC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg16524733	chr11:117070046	TAGLN	0.33	4.68	0.36	6.55e-6	Blood protein levels;
UCEC	cis	rs4654899	0.680	rs10916885	chr1:21188703	A/T	cg01072550	chr1:21505969	NA	0.53	5.45	0.41	2.11e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.83	-0.49	2.05e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.62	-6.37	-0.47	2.26e-9	Platelet distribution width;
UCEC	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.48	-4.69	-0.36	6.18e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.56	-5.13	-0.39	9e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg06096015	chr1:231504339	EGLN1	-0.47	-5.39	-0.41	2.8e-7	Hemoglobin concentration;
UCEC	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	5.85	0.43	3.08e-8	Response to antipsychotic treatment;
UCEC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg01689657	chr7:91764605	CYP51A1	-0.45	-5.78	-0.43	4.32e-8	Breast cancer;
UCEC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg21017887	chr14:105400489	NA	0.66	8.2	0.56	1.12e-13	Rheumatoid arthritis;
UCEC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.58	5.2	0.39	6.68e-7	Corneal astigmatism;
UCEC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.76	8.6	0.58	1.08e-14	Mortality in heart failure;
UCEC	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.74	7.32	0.52	1.46e-11	Mosquito bite size;
UCEC	cis	rs2190422	0.551	rs11976900	chr7:103162269	A/G	cg18108683	chr7:102477205	FBXL13	-0.58	-6.01	-0.44	1.43e-8	Morning vs. evening chronotype;
UCEC	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	5.89	0.44	2.53e-8	Lymphocyte counts;
UCEC	cis	rs9596863	0.861	rs4088520	chr13:54441906	C/T	ch.13.53330881F	chr13:54432880	NA	-0.56	-4.69	-0.36	6.22e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.73	7.34	0.52	1.36e-11	Menopause (age at onset);
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.73	9.33	0.61	1.47e-16	Menarche (age at onset);
UCEC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.38	4.82	0.37	3.57e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.91	-10.04	-0.64	2.2e-18	Schizophrenia;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg04871131	chr7:94954202	PON1	-0.53	-4.85	-0.37	3.13e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs60675447	chr19:22810892	G/A	cg08271804	chr19:22816896	ZNF492	0.61	5.89	0.44	2.54e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6728642	0.519	rs7589232	chr2:97566148	C/T	cg26665480	chr2:98280029	ACTR1B	-0.59	-5.0	-0.38	1.63e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.86	5.62	0.42	9.09e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.48	-5.69	-0.43	6.56e-8	Breast cancer;
UCEC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg19318889	chr4:1322082	MAEA	0.45	4.88	0.37	2.76e-6	Obesity-related traits;
UCEC	cis	rs56161922	1.000	rs56235509	chr1:207839769	C/G	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.45	-0.41	2.04e-7	Bipolar disorder;
UCEC	cis	rs1298062	0.771	rs4801833	chr19:50995932	T/G	cg11430371	chr19:50961752	MYBPC2	0.39	4.51	0.35	1.31e-5	Age of smoking initiation;
UCEC	cis	rs1355223	0.768	rs11032806	chr11:34692305	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-5.24	-0.4	5.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg24163568	chr5:669837	TPPP	0.37	4.67	0.36	6.77e-6	Obesity-related traits;
UCEC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.39	0.41	2.73e-7	Mood instability;
UCEC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.47	4.78	0.37	4.13e-6	Aortic root size;
UCEC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-5.02	-0.38	1.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.7	5.16	0.39	7.86e-7	Exhaled nitric oxide output;
UCEC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs8105895	1.000	rs2359820	chr19:22208114	G/T	cg20662725	chr19:22235022	ZNF257	-0.53	-4.8	-0.37	3.78e-6	Body mass index (change over time);
UCEC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg02106180	chr16:845767	CHTF18	0.44	4.86	0.37	2.92e-6	Mean corpuscular volume;
UCEC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.29	-0.4	4.3e-7	Schizophrenia;
UCEC	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	0.92	5.09	0.39	1.06e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.58	-5.22	-0.4	5.86e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7074356	0.688	rs7898558	chr10:82183505	G/T	cg26247508	chr10:82299669	SH2D4B	-0.38	-4.57	-0.35	1.03e-5	Borderline personality disorder;
UCEC	cis	rs9470794	1.000	rs73419930	chr6:38027990	T/C	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg18681998	chr4:17616180	MED28	0.8	9.41	0.61	9.26e-17	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.94	0.5	1.16e-10	Bipolar disorder;
UCEC	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.58	-5.35	-0.4	3.36e-7	Metabolite levels;
UCEC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.79	0.49	2.65e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.61	5.11	0.39	9.8e-7	Corneal astigmatism;
UCEC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-9.8	-0.63	9.19e-18	Cognitive function;
UCEC	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.56	-0.35	1.09e-5	Height;
UCEC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.76	-7.39	-0.52	1.04e-11	Initial pursuit acceleration;
UCEC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.43	-4.74	-0.36	5.03e-6	Asthma (sex interaction);
UCEC	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.7	6.29	0.46	3.39e-9	Subjective well-being;
UCEC	cis	rs77926410	0.685	rs2417898	chr12:10612897	G/A	cg25023291	chr12:11339792	TAS2R42	-0.38	-4.8	-0.37	3.93e-6	Mean corpuscular volume;
UCEC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.1e-6	Bipolar disorder;
UCEC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.58	6.03	0.45	1.26e-8	Red blood cell count;
UCEC	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.44	-5.2	-0.39	6.58e-7	HDL cholesterol;
UCEC	cis	rs7944735	0.817	rs6485774	chr11:47773226	C/T	cg08722104	chr11:47448306	PSMC3	-0.46	-4.52	-0.35	1.26e-5	Intraocular pressure;
UCEC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg04398451	chr17:18023971	MYO15A	0.61	6.77	0.49	2.82e-10	Total body bone mineral density;
UCEC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.52	5.36	0.4	3.17e-7	Monocyte count;
UCEC	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs78487399	0.710	rs7567685	chr2:43668169	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.93	-0.38	2.22e-6	Body mass index;
UCEC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.62	6.04	0.45	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg05775895	chr3:12838266	CAND2	0.56	6.25	0.46	4.3e-9	QRS complex (12-leadsum);
UCEC	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg05519781	chr21:40033154	ERG	0.78	8.81	0.59	3.24e-15	Coronary artery disease;
UCEC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.7	6.42	0.47	1.75e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg22771759	chr13:24902376	NA	0.44	4.71	0.36	5.77e-6	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.86	-9.4	-0.61	1.01e-16	Breast cancer;
UCEC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.87	13.23	0.74	8.05e-27	Birth weight;
UCEC	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.62	4.96	0.38	1.89e-6	Menarche (age at onset);
UCEC	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.86	-8.26	-0.56	7.81e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.49	-5.05	-0.38	1.3e-6	Pulse pressure;
UCEC	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg20368463	chr18:77673604	PQLC1	-0.74	-7.07	-0.5	5.87e-11	Schizophrenia;
UCEC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.83	8.54	0.58	1.53e-14	Parkinson's disease;
UCEC	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.57	5.42	0.41	2.41e-7	Bladder cancer;
UCEC	cis	rs2415984	0.846	rs11625716	chr14:46834362	C/A	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	4.76	0.37	4.51e-6	Schizophrenia;
UCEC	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.0	-0.38	1.6e-6	Systemic lupus erythematosus;
UCEC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.31	-0.4	3.93e-7	Breast cancer;
UCEC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.58	4.51	0.35	1.32e-5	Major depressive disorder;
UCEC	cis	rs61776719	0.806	rs28493395	chr1:38400558	C/T	cg18451016	chr1:38461880	NA	0.68	7.53	0.53	4.64e-12	Coronary artery disease;
UCEC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.6	-0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs4654899	0.643	rs651538	chr1:21097866	A/G	cg01072550	chr1:21505969	NA	-0.5	-5.1	-0.39	1.02e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.97	7.28	0.51	1.91e-11	Exhaled nitric oxide levels;
UCEC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.76	-6.99	-0.5	8.77e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg18016565	chr1:150552671	MCL1	0.47	4.51	0.35	1.33e-5	Melanoma;
UCEC	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.52	5.25	0.4	5.13e-7	Dupuytren's disease;
UCEC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg00339695	chr16:24857497	SLC5A11	0.48	5.6	0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.73	-8.21	-0.56	1.04e-13	Waist circumference;Body mass index;
UCEC	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.13	0.39	9e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.59	5.11	0.39	9.86e-7	Heart rate;
UCEC	cis	rs9309711	0.518	rs9752314	chr2:3494322	A/G	cg08493051	chr2:3487164	NA	-0.56	-5.09	-0.39	1.09e-6	Neurofibrillary tangles;
UCEC	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.88	-7.46	-0.52	7.01e-12	Coronary artery calcification;
UCEC	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-0.96	-7.28	-0.51	1.86e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.66	7.77	0.54	1.28e-12	Monocyte count;
UCEC	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg11965913	chr1:205819406	PM20D1	0.48	4.75	0.36	4.74e-6	Parkinson's disease;
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.44	4.53	0.35	1.19e-5	Longevity;Endometriosis;
UCEC	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	0.97	8.55	0.58	1.45e-14	Red blood cell traits;
UCEC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-5.26	-0.4	5.05e-7	Bipolar disorder;
UCEC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg06466757	chr4:1255808	NA	0.46	4.85	0.37	3.07e-6	Obesity-related traits;
UCEC	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.82	4.73	0.36	5.13e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.68	-6.44	-0.47	1.59e-9	Cocaine dependence;
UCEC	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.45	4.62	0.36	8.47e-6	Response to temozolomide;
UCEC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg05132306	chr1:1846340	CALML6	-0.38	-4.83	-0.37	3.43e-6	Body mass index;
UCEC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.8	8.14	0.56	1.55e-13	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.54	5.62	0.42	9.36e-8	Mood instability;
UCEC	cis	rs12982903	0.915	rs34831649	chr19:5957571	C/T	cg27649253	chr19:5245891	PTPRS	-0.64	-4.64	-0.36	7.63e-6	Heart rate variability traits (SDNN);
UCEC	cis	rs7246967	0.932	rs66737024	chr19:23031686	C/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7781557	0.696	rs55849741	chr7:102584069	C/G	cg06322601	chr7:102330635	NA	0.57	4.64	0.36	7.78e-6	Colorectal adenoma (advanced);
UCEC	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6493487	0.512	rs12907367	chr15:51265986	A/G	cg17676096	chr15:52263839	LEO1	-0.88	-5.25	-0.4	5.12e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg18681998	chr4:17616180	MED28	-0.65	-4.79	-0.37	4.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg17652424	chr22:38574118	PLA2G6	-0.4	-4.79	-0.37	4.12e-6	Cutaneous nevi;
UCEC	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.7	-7.56	-0.53	4.03e-12	Blood protein levels;
UCEC	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg08250081	chr4:10125330	NA	0.46	4.6	0.35	9.11e-6	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	1.1	10.09	0.64	1.61e-18	Mosquito bite size;
UCEC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.43	-4.9	-0.37	2.53e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs4478037	1.000	rs4074417	chr3:33161153	A/C	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.57	-5.1	-0.39	1.05e-6	Schizophrenia;
UCEC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.81	-9.3	-0.61	1.78e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg07776626	chr8:57350775	NA	-0.41	-4.68	-0.36	6.34e-6	Obesity-related traits;
UCEC	cis	rs77861329	1.000	rs17051977	chr3:52182944	A/G	cg08692210	chr3:52188851	WDR51A	0.8	6.57	0.48	8.08e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7015263	0.606	rs10102749	chr8:87407333	T/C	cg27223183	chr8:87520930	FAM82B	0.64	6.53	0.47	9.83e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg09654669	chr8:57350985	NA	-0.49	-4.52	-0.35	1.27e-5	Obesity-related traits;
UCEC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	5.93	0.44	2.08e-8	Breast cancer;
UCEC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.02	-0.5	7.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.54	-5.4	-0.41	2.62e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg16751203	chr2:127950803	CYP27C1	0.39	5.19	0.39	6.73e-7	Protein C levels;
UCEC	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.51	5.26	0.4	4.97e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg14008862	chr17:28927542	LRRC37B2	0.83	5.44	0.41	2.16e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.54	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.71	-6.85	-0.49	1.91e-10	Acne (severe);
UCEC	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.51	-5.05	-0.38	1.28e-6	Large artery stroke;
UCEC	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.24	-0.4	5.45e-7	Aortic root size;
UCEC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.73	7.72	0.54	1.63e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2242663	0.798	rs607736	chr11:66328877	G/A	cg24851651	chr11:66362959	CCS	0.5	6.26	0.46	3.92e-9	Bipolar disorder;
UCEC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.63	-5.12	-0.39	9.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-5.21	-0.39	6.3e-7	Schizophrenia;
UCEC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg15837086	chr1:46506065	PIK3R3	-0.39	-4.88	-0.37	2.73e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.6	-4.7	-0.36	5.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.7	-5.25	-0.4	5.2e-7	Macular telangiectasia type 2;
UCEC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.68	-6.22	-0.46	4.81e-9	Aortic root size;
UCEC	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.59	5.97	0.44	1.73e-8	Orofacial clefts;
UCEC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.76	7.38	0.52	1.1e-11	Cognitive function;
UCEC	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.79	6.91	0.5	1.38e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.88	-8.22	-0.56	9.63e-14	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.65	-0.36	7.19e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.59	6.36	0.46	2.35e-9	Heart rate;
UCEC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.73	6.56	0.48	8.66e-10	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.6	5.32	0.4	3.73e-7	Longevity;
UCEC	cis	rs7246967	0.673	rs3853649	chr19:22880460	C/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6893207	1.000	rs57487589	chr5:16401169	G/C	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.84	-0.7	3.94e-23	Monocyte count;
UCEC	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-10.2	-0.64	8.28e-19	Blood metabolite levels;
UCEC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	0.84	10.61	0.66	7.02e-20	Bone mineral density;
UCEC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg20607287	chr7:12443886	VWDE	-0.65	-4.7	-0.36	5.89e-6	Coronary artery disease;
UCEC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.37	0.4	3.07e-7	Hemoglobin concentration;
UCEC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg11871910	chr12:69753446	YEATS4	0.88	10.22	0.64	7.61e-19	Blood protein levels;
UCEC	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg02476566	chr12:106696527	TCP11L2	0.63	5.14	0.39	8.66e-7	Tourette syndrome;
UCEC	cis	rs7959452	0.905	rs4761234	chr12:69732105	T/C	cg14784868	chr12:69753453	YEATS4	0.78	7.9	0.55	6.11e-13	Blood protein levels;
UCEC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg13147721	chr7:65941812	NA	0.85	5.65	0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.41	4.7	0.36	5.94e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.6	-0.48	7.07e-10	Neutrophil percentage of white cells;
UCEC	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg23815491	chr16:72088622	HP	-0.4	-4.81	-0.37	3.75e-6	Fibrinogen levels;
UCEC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.61	5.29	0.4	4.33e-7	Major depressive disorder;
UCEC	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.51	-5.78	-0.43	4.37e-8	Retinal vascular caliber;
UCEC	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.62	6.13	0.45	7.52e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.45	4.73	0.36	5.23e-6	Eye color traits;
UCEC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.61	-5.08	-0.39	1.11e-6	Gut microbiome composition (summer);
UCEC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.5	5.65	0.42	7.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.74	5.03	0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.62	7.25	0.51	2.23e-11	Menarche (age at onset);
UCEC	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.43	-4.83	-0.37	3.41e-6	Depression;
UCEC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.26	-0.56	7.94e-14	Total body bone mineral density;
UCEC	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.52	5.49	0.41	1.73e-7	Platelet count;
UCEC	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	0.82	6.29	0.46	3.42e-9	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.59	5.7	0.43	6.41e-8	Corneal astigmatism;
UCEC	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.57	5.44	0.41	2.17e-7	Brain structure;
UCEC	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	4.95	0.38	1.98e-6	Height;
UCEC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	7.89	0.55	6.44e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.81	9.47	0.62	6.7e-17	Menopause (age at onset);
UCEC	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.42e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg10902566	chr4:727664	PCGF3	-0.61	-5.07	-0.39	1.18e-6	Systolic blood pressure;
UCEC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.44	5.22	0.4	5.95e-7	Total body bone mineral density;
UCEC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.58	-5.42	-0.41	2.41e-7	Lymphocyte counts;
UCEC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.76	7.32	0.52	1.49e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.6	-0.36	8.87e-6	Response to antipsychotic treatment;
UCEC	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.95	-14.71	-0.77	1.09e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs6945071	0.590	rs6945001	chr7:26128382	C/T	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.53	5.12	0.39	9.37e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs8105895	0.935	rs8110289	chr19:22239717	A/G	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.06e-7	Body mass index (change over time);
UCEC	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	1.14	6.03	0.45	1.27e-8	LDL cholesterol;
UCEC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.62	-5.35	-0.4	3.27e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.604	rs12975793	chr19:22862844	A/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-0.42	-4.54	-0.35	1.18e-5	IgG glycosylation;
UCEC	cis	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg12524725	chr2:239427019	NA	-0.67	-4.53	-0.35	1.21e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13683864	chr3:40499215	RPL14	-0.93	-9.08	-0.6	6.6e-16	Renal cell carcinoma;
UCEC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg06027949	chr8:82754900	SNX16	-0.62	-5.83	-0.43	3.45e-8	Diastolic blood pressure;
UCEC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.56	5.14	0.39	8.73e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.48	-5.6	-0.42	1e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4237845	0.591	rs10431506	chr12:58311524	G/A	cg02175503	chr12:58329896	NA	0.7	6.26	0.46	3.93e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2386661	0.826	rs7092383	chr10:5671101	A/C	cg17085576	chr10:5658249	NA	-0.47	-4.85	-0.37	3.11e-6	Breast cancer;
UCEC	cis	rs12753920	0.724	rs4658290	chr1:92572296	C/G	cg06442199	chr1:92414344	BRDT	0.42	4.58	0.35	9.78e-6	Systemic lupus erythematosus;
UCEC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.58	-7.09	-0.5	5.33e-11	Fibrinogen levels;
UCEC	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg07930552	chr6:133119739	C6orf192	0.94	8.59	0.58	1.17e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs2016266	1.000	rs2016266	chr12:53727955	A/G	cg26875137	chr12:53738046	NA	-0.53	-6.75	-0.49	3.21e-10	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs539514	0.587	rs689418	chr13:76322977	G/A	cg04757411	chr13:76259545	LMO7	-0.52	-6.18	-0.45	5.86e-9	Type 1 diabetes;
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.56	-7.02	-0.5	7.42e-11	Menarche (age at onset);
UCEC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.21	0.46	5.26e-9	Personality dimensions;
UCEC	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.33	4.64	0.36	7.59e-6	Schizophrenia;
UCEC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.7	-6.07	-0.45	1.03e-8	Diastolic blood pressure;
UCEC	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.57	6.47	0.47	1.34e-9	Vitiligo;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg09120320	chr17:61926383	NA	0.44	4.59	0.35	9.46e-6	Prudent dietary pattern;
UCEC	cis	rs593982	0.858	rs480989	chr11:65493992	A/G	cg08755490	chr11:65554678	OVOL1	1.26	12.54	0.72	5.39e-25	Atopic dermatitis;
UCEC	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.41	5.15	0.39	8.15e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-4.63	-0.36	8.01e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7267005	0.661	rs76013929	chr20:34427657	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg07153921	chr17:41440717	NA	-0.61	-7.63	-0.53	2.66e-12	Menopause (age at onset);
UCEC	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.5	5.73	0.43	5.6e-8	Neuroticism;
UCEC	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.74	-7.44	-0.52	7.82e-12	Mosquito bite size;
UCEC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.57e-6	Colorectal cancer;
UCEC	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.48	5.79	0.43	4.21e-8	Neuroticism;
UCEC	cis	rs2288327	0.818	rs16866373	chr2:179392080	A/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.7	-4.78	-0.37	4.28e-6	Atrial fibrillation;
UCEC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg14784868	chr12:69753453	YEATS4	0.55	4.62	0.36	8.38e-6	Response to diuretic therapy;
UCEC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	0.6	6.25	0.46	4.26e-9	Total cholesterol levels;
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.55	-5.15	-0.39	8.09e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg18681998	chr4:17616180	MED28	0.75	7.37	0.52	1.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg24069376	chr3:38537580	EXOG	0.36	4.72	0.36	5.37e-6	Electrocardiographic conduction measures;
UCEC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg26061582	chr7:22766209	IL6	0.61	5.59	0.42	1.08e-7	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-4.52	-0.35	1.28e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.89	9.74	0.63	1.31e-17	Cognitive function;
UCEC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg19784848	chr5:219127	SDHA;CCDC127	-0.61	-4.87	-0.37	2.81e-6	Breast cancer;
UCEC	cis	rs1161463	0.958	rs1161464	chr13:29430932	A/C	cg00806704	chr13:28539042	CDX2	0.37	4.62	0.36	8.28e-6	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
UCEC	cis	rs6832769	0.961	rs10009593	chr4:56436681	C/A	cg05960024	chr4:56376020	CLOCK	-0.57	-6.02	-0.44	1.34e-8	Personality dimensions;
UCEC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.68e-16	Breast cancer;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.25	-0.4	5.13e-7	Parkinson's disease;
UCEC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.13	0.39	8.93e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.76	-0.49	3.09e-10	Depression;
UCEC	cis	rs7709377	0.595	rs1644268	chr5:115640808	G/T	cg23108291	chr5:115420582	COMMD10	-0.51	-5.2	-0.39	6.67e-7	Metabolite levels  (X-11787);
UCEC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.41	-4.59	-0.35	9.44e-6	Glaucoma (primary open-angle);
UCEC	cis	rs11264213	0.591	rs3754076	chr1:36549157	A/G	cg27506609	chr1:36549197	TEKT2	-0.63	-6.47	-0.47	1.38e-9	Schizophrenia;
UCEC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03927661	chr16:89737216	C16orf55	0.45	4.72	0.36	5.46e-6	Vitiligo;
UCEC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg22598563	chr5:131563921	P4HA2	-0.34	-4.55	-0.35	1.11e-5	Blood metabolite levels;
UCEC	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg20129853	chr10:51489980	NA	0.41	4.93	0.38	2.16e-6	Prostate-specific antigen levels;
UCEC	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9400271	0.509	rs57695104	chr6:109640878	G/A	cg01475377	chr6:109611718	NA	0.47	5.2	0.39	6.6e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg09067967	chr4:39529342	UGDH	-0.55	-4.54	-0.35	1.14e-5	Plasma amyloid beta peptide concentrations (ABx-40);
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.46	5.03	0.38	1.38e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.53	-4.9	-0.37	2.54e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg19413350	chr8:57351067	NA	-0.42	-4.73	-0.36	5.13e-6	Obesity-related traits;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg04871131	chr7:94954202	PON1	-0.55	-5.47	-0.41	1.93e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs4478037	1.000	rs58995409	chr3:33161404	T/C	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs117623576	0.941	rs211423	chr10:32398777	A/G	cg03047570	chr10:32398778	NA	0.6	5.52	0.41	1.47e-7	Anti-saccade response;
UCEC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg06784218	chr1:46089804	CCDC17	-0.46	-5.24	-0.4	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.61	4.88	0.37	2.78e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.58	6.44	0.47	1.57e-9	Prostate cancer;
UCEC	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-0.54	-5.4	-0.41	2.64e-7	Pediatric autoimmune diseases;
UCEC	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.42	-4.94	-0.38	2.06e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg05874882	chr4:1763078	NA	0.67	6.43	0.47	1.71e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.57	-0.35	1.01e-5	Menarche (age at onset);
UCEC	cis	rs8177876	0.822	rs7204040	chr16:81113493	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.52	-5.43	-0.41	2.28e-7	Parkinson's disease;
UCEC	cis	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg17469321	chr7:55412551	NA	0.7	5.87	0.44	2.75e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.87	0.37	2.83e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs925228	0.793	rs6545184	chr2:24175914	A/T	cg16945982	chr2:25016118	CENPO;C2orf79	0.56	4.89	0.37	2.58e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.46	6.77	0.49	2.87e-10	Homoarginine levels;
UCEC	cis	rs17122693	1.000	rs72679549	chr14:51050822	G/A	cg04730355	chr14:51134070	SAV1	0.87	8.66	0.58	7.67e-15	Cognitive performance;
UCEC	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.57	4.77	0.37	4.34e-6	Lung cancer;
UCEC	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.44	4.95	0.38	1.97e-6	Prudent dietary pattern;
UCEC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs6723108	0.604	rs1374291	chr2:135654338	T/C	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	6.67	0.48	4.95e-10	Hemoglobin concentration;
UCEC	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.5	-5.97	-0.44	1.67e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.63	0.62	2.62e-17	Intelligence (multi-trait analysis);
UCEC	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.02	-7.79	-0.54	1.08e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-9.1	-0.6	6.03e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg09491104	chr22:46646882	C22orf40	-0.56	-6.48	-0.47	1.27e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.68	-7.19	-0.51	2.96e-11	Blood metabolite levels;
UCEC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.69	0.58	6.33e-15	Total body bone mineral density;
UCEC	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.72	7.21	0.51	2.79e-11	Primary sclerosing cholangitis;
UCEC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.45	-4.51	-0.35	1.33e-5	Hemoglobin concentration;
UCEC	cis	rs853679	0.546	rs200949	chr6:27835435	A/G	cg21204522	chr6:27730016	NA	-0.51	-4.54	-0.35	1.16e-5	Depression;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10620530	chr9:139922595	C9orf139;ABCA2	0.66	7.87	0.54	7.23e-13	Warfarin maintenance dose;
UCEC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.63	-5.52	-0.41	1.46e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.89	-7.47	-0.52	6.74e-12	Platelet count;
UCEC	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.68	-6.53	-0.47	1.03e-9	Schizophrenia;
UCEC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.38	-5.92	-0.44	2.19e-8	Body mass index;
UCEC	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.57	-5.69	-0.42	6.67e-8	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.15	-13.89	-0.75	1.48e-28	Breast cancer;
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg06238570	chr21:40685208	BRWD1	0.87	6.33	0.46	2.87e-9	Cognitive function;
UCEC	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.44	-4.96	-0.38	1.96e-6	Anterior chamber depth;
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.49	-5.26	-0.4	5.1e-7	Parkinson's disease;
UCEC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.49	-5.0	-0.38	1.64e-6	Aortic root size;
UCEC	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.82	-9.49	-0.62	5.95e-17	Coronary artery disease;
UCEC	cis	rs2384207	1.000	rs2384207	chr12:113607502	T/C	cg22376712	chr12:113623594	C12orf52;DDX54	0.67	4.85	0.37	3.04e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	5.15	0.39	8.2e-7	Coronary artery disease;
UCEC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.33	0.46	2.84e-9	Aortic root size;
UCEC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.71	0.58	5.66e-15	Total body bone mineral density;
UCEC	cis	rs10484885	0.618	rs292241	chr6:90603505	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.65	-5.48	-0.41	1.82e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7246967	0.800	rs2169794	chr19:23025768	G/C	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	4.92	0.38	2.32e-6	Lymphocyte counts;
UCEC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg06484146	chr7:12443880	VWDE	-0.84	-6.13	-0.45	7.56e-9	Coronary artery disease;
UCEC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.45	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.56	-5.78	-0.43	4.34e-8	Corneal astigmatism;
UCEC	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.9	7.86	0.54	7.59e-13	Body mass index;
UCEC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.47	-6.74	-0.49	3.41e-10	Homoarginine levels;
UCEC	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.2	0.51	2.92e-11	Motion sickness;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26614578	chr12:113623930	C12orf52;DDX54	0.54	6.83	0.49	2.05e-10	Warfarin maintenance dose;
UCEC	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.51	5.3	0.4	4.11e-7	Coronary artery disease;
UCEC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.62	6.31	0.46	3.14e-9	Blood metabolite levels;
UCEC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg05501817	chr11:14380813	RRAS2	-0.51	-4.83	-0.37	3.43e-6	Sense of smell;
UCEC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs2291738	0.558	rs7313455	chr12:56853231	G/T	cg23002907	chr12:56915593	RBMS2	0.41	4.56	0.35	1.05e-5	Axial length;
UCEC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg03264133	chr6:25882463	NA	-0.5	-4.56	-0.35	1.08e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	6.57	0.48	8.33e-10	Homoarginine levels;
UCEC	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg14196790	chr5:131705035	SLC22A5	0.43	4.67	0.36	6.83e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs6540731	1.000	rs11119884	chr1:212400146	C/T	cg07569918	chr1:212002970	LPGAT1	-0.39	-4.76	-0.37	4.55e-6	Intelligence (childhood);
UCEC	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.32	4.98	0.38	1.74e-6	Cancer;
UCEC	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.76	8.06	0.55	2.38e-13	Eosinophil percentage of white cells;
UCEC	cis	rs11697848	1.000	rs74404424	chr20:48582281	G/A	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.64	-0.42	8.29e-8	Fear of minor pain;
UCEC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg23217946	chr19:22817039	ZNF492	0.41	4.58	0.35	1e-5	Bronchopulmonary dysplasia;
UCEC	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.14	8.09	0.56	2.1e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs13065560	0.594	rs4575820	chr3:38886179	A/G	cg01426195	chr3:39028469	NA	0.51	5.37	0.41	2.97e-7	Interleukin-18 levels;
UCEC	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-4.78	-0.37	4.16e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-6.76	-0.49	3.06e-10	Electrocardiographic conduction measures;
UCEC	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.57	5.51	0.41	1.6e-7	Retinal vascular caliber;
UCEC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg13147721	chr7:65941812	NA	-0.86	-5.72	-0.43	5.87e-8	Diabetic kidney disease;
UCEC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.54	-5.94	-0.44	1.97e-8	Diastolic blood pressure;
UCEC	cis	rs4853036	0.538	rs2312553	chr2:70009640	A/T	cg02498382	chr2:70120550	SNRNP27	-0.46	-4.55	-0.35	1.12e-5	Colorectal or endometrial cancer;
UCEC	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.58	-5.49	-0.41	1.7e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.66	-5.79	-0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg13777783	chr17:79615861	NA	-0.32	-4.64	-0.36	7.5e-6	Eye color traits;
UCEC	cis	rs692804	0.757	rs537907	chr11:120078501	C/G	cg16775289	chr11:120081497	OAF	1.0	4.72	0.36	5.38e-6	Blood protein levels;
UCEC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-5.15	-0.39	8.2e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.21	0.51	2.79e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.55	0.42	1.32e-7	Rheumatoid arthritis;
UCEC	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.34	-4.67	-0.36	6.86e-6	Crohn's disease;
UCEC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg06466757	chr4:1255808	NA	0.46	4.85	0.37	3.07e-6	Obesity-related traits;
UCEC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.63	4.81	0.37	3.77e-6	Carotid intima media thickness;
UCEC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs35007247	chr19:22822923	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg11632617	chr15:75315747	PPCDC	-0.55	-4.86	-0.37	2.93e-6	Lung cancer;
UCEC	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.71	6.69	0.48	4.41e-10	Drug-induced liver injury (flucloxacillin);
UCEC	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg10935138	chr17:73851978	WBP2	0.7	6.57	0.48	7.97e-10	Psoriasis;
UCEC	cis	rs7781557	1.000	rs10487281	chr7:102477581	G/C	cg06322601	chr7:102330635	NA	0.82	6.84	0.49	2.03e-10	Colorectal adenoma (advanced);
UCEC	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.47	6.43	0.47	1.7e-9	Total body bone mineral density;
UCEC	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-5.55	-0.42	1.27e-7	Response to antipsychotic treatment;
UCEC	cis	rs4499344	0.556	rs438268	chr19:33109904	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	5.67	0.42	7.35e-8	Mean platelet volume;
UCEC	cis	rs10864302	0.747	rs6577440	chr1:7450006	C/G	cg22507406	chr1:7867939	PER3	-0.53	-4.92	-0.38	2.29e-6	Photic sneeze reflex;
UCEC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg26162295	chr17:38119207	GSDMA	0.29	4.57	0.35	1.04e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.57	5.64	0.42	8.29e-8	Colorectal cancer;
UCEC	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.45	-4.64	-0.36	7.58e-6	Height;
UCEC	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.64	-6.72	-0.48	3.64e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.23	0.51	2.49e-11	Coffee consumption (cups per day);
UCEC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg19468946	chr17:37922297	IKZF3	-0.42	-4.52	-0.35	1.29e-5	Self-reported allergy;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs9463078	0.845	rs1023090	chr6:45012381	T/C	cg25276700	chr6:44698697	NA	-0.44	-4.69	-0.36	6.25e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.42	-5.62	-0.42	9.19e-8	Alcohol dependence;
UCEC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.73	6.88	0.49	1.6e-10	Aortic root size;
UCEC	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg11859384	chr17:80120422	CCDC57	-0.47	-5.18	-0.39	7.19e-7	Life satisfaction;
UCEC	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.65	4.64	0.36	7.65e-6	Breast cancer;
UCEC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.75	-5.74	-0.43	5.29e-8	Alcohol dependence;
UCEC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg18016565	chr1:150552671	MCL1	0.59	6.61	0.48	6.56e-10	Tonsillectomy;
UCEC	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.56	-5.49	-0.41	1.73e-7	Schizophrenia;
UCEC	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg06784218	chr1:46089804	CCDC17	-0.53	-6.13	-0.45	7.87e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7070678	0.615	rs61849293	chr10:29796820	G/A	cg24350475	chr10:30316933	KIAA1462	0.5	4.99	0.38	1.68e-6	Platelet thrombus formation;
UCEC	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg09251680	chr3:45801144	SLC6A20	-0.37	-4.57	-0.35	1.02e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs7937612	0.965	rs11217840	chr11:120238655	A/G	cg12584626	chr11:120203529	NA	0.49	4.88	0.37	2.74e-6	Intraocular pressure;
UCEC	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.59	-4.61	-0.36	8.75e-6	Blood pressure (smoking interaction);
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg20821713	chr7:1055600	C7orf50	-0.48	-4.79	-0.37	4.07e-6	Longevity;Endometriosis;
UCEC	cis	rs7246967	0.611	rs8104327	chr19:22867159	C/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.4	5.12	0.39	9.53e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-6.38	-0.47	2.17e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.57	0.35	1.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.62	5.86	0.43	2.99e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.94	-9.1	-0.6	5.8e-16	Dilated cardiomyopathy;
UCEC	cis	rs735860	0.763	rs2817111	chr6:53125700	G/C	cg10236188	chr6:53219634	NA	-0.47	-4.92	-0.38	2.33e-6	Glaucoma;
UCEC	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg19041857	chr6:27730383	NA	-0.64	-4.87	-0.37	2.9e-6	Depression;
UCEC	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	1.01	5.75	0.43	5.01e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-4.91	-0.38	2.4e-6	Joint mobility (Beighton score);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05245099	chr19:50016504	FCGRT	0.58	6.71	0.48	3.84e-10	Warfarin maintenance dose;
UCEC	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.07	-0.64	1.85e-18	Height;
UCEC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg02820040	chr2:241836501	C2orf54	-0.39	-4.91	-0.38	2.37e-6	Urinary metabolites;
UCEC	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.55	5.68	0.42	6.85e-8	Tonsillectomy;
UCEC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-5.41	-0.41	2.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.39	4.52	0.35	1.24e-5	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.57	-4.72	-0.36	5.4e-6	Asthma;
UCEC	cis	rs151997	1.000	rs72758246	chr5:50246783	G/C	cg06027927	chr5:50259733	NA	0.53	4.95	0.38	2.05e-6	Callous-unemotional behaviour;
UCEC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg16616514	chr4:6324629	PPP2R2C	0.41	4.99	0.38	1.66e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.46	5.33	0.4	3.61e-7	Height;
UCEC	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.71	-6.89	-0.49	1.53e-10	Cocaine dependence;
UCEC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.71	-7.15	-0.51	3.72e-11	Aortic root size;
UCEC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg12024160	chr4:1254474	NA	0.63	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.55	5.21	0.39	6.2e-7	Lung cancer;
UCEC	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.86	12.3	0.71	2.41e-24	Leprosy;
UCEC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg12463550	chr7:65579703	CRCP	0.54	5.43	0.41	2.3e-7	Aortic root size;
UCEC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.45	-6.15	-0.45	6.9e-9	Mortality in heart failure;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.46	-5.13	-0.39	9.21e-7	Depression;
UCEC	cis	rs1630500	1.000	rs1630500	chr1:154855055	C/T	cg11267415	chr1:154975698	ZBTB7B	-0.79	-4.58	-0.35	9.78e-6	Parkinson's disease;
UCEC	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.91	-12.08	-0.71	9.21e-24	Primary sclerosing cholangitis;
UCEC	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.54	5.9	0.44	2.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg22974920	chr21:40686053	BRWD1	0.54	4.92	0.38	2.33e-6	Cognitive function;
UCEC	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg05623727	chr3:50126028	RBM5	0.36	4.62	0.36	8.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs35934224	0.891	rs5993850	chr22:19869703	C/T	cg00936699	chr22:20101830	TRMT2A	-0.43	-4.52	-0.35	1.26e-5	Glaucoma (primary open-angle);
UCEC	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.05	-0.45	1.15e-8	Aortic root size;
UCEC	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-7.26	-0.51	2.13e-11	Colorectal cancer;
UCEC	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.75	-0.36	4.8e-6	Response to antipsychotic treatment;
UCEC	trans	rs6909279	0.522	rs7741872	chr6:151893946	C/G	cg17233819	chr1:45266782	PLK3	0.62	7.21	0.51	2.66e-11	Bone mineral density;
UCEC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.62	-6.65	-0.48	5.35e-10	Bipolar disorder;
UCEC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-8.2	-0.56	1.11e-13	Height;
UCEC	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.48	-5.53	-0.41	1.45e-7	Height;
UCEC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.59	5.54	0.42	1.38e-7	Corneal astigmatism;
UCEC	cis	rs6437061	0.745	rs3116160	chr2:232858280	T/G	cg02061626	chr2:233274167	ALPPL2	-0.51	-5.67	-0.42	7.36e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.65	5.53	0.42	1.4e-7	Multiple sclerosis;
UCEC	cis	rs3750082	0.780	rs9638884	chr7:32913612	T/C	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.67	7.46	0.52	7e-12	Menarche (age at onset);
UCEC	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.82	9.58	0.62	3.37e-17	Ewing sarcoma;
UCEC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.71	6.16	0.45	6.59e-9	Alzheimer's disease;
UCEC	cis	rs12449964	0.524	rs7225934	chr17:17572544	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.45	-4.62	-0.36	8.31e-6	Coronary artery disease or ischemic stroke;
UCEC	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.8	8.86	0.59	2.47e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs11867410	0.744	rs77515582	chr17:63958034	T/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.65	-0.36	7.3e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.73	-6.88	-0.49	1.6e-10	Aortic root size;
UCEC	cis	rs4851266	1.000	rs4583487	chr2:100837126	G/T	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	0.91	5.68	0.42	6.98e-8	Type 2 diabetes nephropathy;
UCEC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.69	6.28	0.46	3.69e-9	Aortic root size;
UCEC	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg00815214	chr21:47717953	NA	-0.48	-5.8	-0.43	3.86e-8	Testicular germ cell tumor;
UCEC	cis	rs4372836	0.964	rs34627117	chr2:28930476	C/G	cg09522027	chr2:28974177	PPP1CB	0.73	7.34	0.52	1.35e-11	Body mass index;
UCEC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.42	-0.47	1.79e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs6717918	0.501	rs3100594	chr2:232975281	A/G	cg02061626	chr2:233274167	ALPPL2	-0.55	-6.12	-0.45	8.17e-9	Height;
UCEC	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.07	-0.39	1.18e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.72	-5.85	-0.43	3.13e-8	Coronary artery calcification;
UCEC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.48	-5.06	-0.39	1.23e-6	Body mass index;
UCEC	cis	rs7607369	0.559	rs13002060	chr2:219660394	G/T	cg02176678	chr2:219576539	TTLL4	-0.51	-5.09	-0.39	1.06e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.33	7.69	0.54	1.91e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs17012589	0.639	rs10779158	chr12:85724096	A/G	cg02569458	chr12:86230093	RASSF9	0.4	4.61	0.36	8.75e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.68	-6.05	-0.45	1.15e-8	Aortic root size;
UCEC	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.69	7.03	0.5	7.18e-11	Caffeine consumption;
UCEC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.04	14.43	0.77	5.78e-30	Schizophrenia;
UCEC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.66	-5.9	-0.44	2.43e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.6	6.16	0.45	6.5e-9	Diastolic blood pressure;
UCEC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.84	5.12	0.39	9.44e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.1	0.51	5.03e-11	Coffee consumption (cups per day);
UCEC	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg13683864	chr3:40499215	RPL14	-0.56	-5.82	-0.43	3.5e-8	Renal cell carcinoma;
UCEC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.84	-10.68	-0.66	4.7e-20	Height;
UCEC	cis	rs17106184	0.892	rs72900982	chr1:51190459	C/T	cg07174182	chr1:51127561	FAF1	-0.83	-5.25	-0.4	5.15e-7	Type 2 diabetes;
UCEC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	14.09	0.76	4.53e-29	Height;
UCEC	cis	rs9309473	0.500	rs4852953	chr2:73869908	G/A	cg20560298	chr2:73613845	ALMS1	0.53	5.02	0.38	1.47e-6	Metabolite levels;
UCEC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.77	8.47	0.57	2.32e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.53	-5.41	-0.41	2.44e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.49	5.34	0.4	3.42e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.6	5.51	0.41	1.54e-7	Pancreatic cancer;
UCEC	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.06	-0.39	1.24e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.92	12.13	0.71	6.56e-24	Monocyte count;
UCEC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg01262667	chr19:19385393	TM6SF2	0.51	6.9	0.49	1.45e-10	Tonsillectomy;
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.78	0.37	4.28e-6	Personality dimensions;
UCEC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg00500100	chr5:140098250	VTRNA1-2	0.33	4.51	0.35	1.34e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.41	4.88	0.37	2.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg03146154	chr1:46216737	IPP	-0.48	-4.64	-0.36	7.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg13575925	chr12:9217583	LOC144571	0.41	4.89	0.37	2.67e-6	Sjögren's syndrome;
UCEC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.48	-4.64	-0.36	7.8e-6	Aortic root size;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.58	6.52	0.47	1.05e-9	Red blood cell count;
UCEC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.63	5.61	0.42	9.84e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.7	5.77	0.43	4.49e-8	Corneal astigmatism;
UCEC	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs9467773	0.967	rs9461272	chr6:26579648	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.35	1.13e-5	Bladder cancer;
UCEC	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	0.8	6.31	0.46	3.12e-9	Corneal structure;
UCEC	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg19610905	chr11:61596333	FADS2	0.73	7.3	0.52	1.64e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg19715936	chr7:50634035	DDC	0.46	5.6	0.42	1.04e-7	Malaria;
UCEC	cis	rs6486730	0.534	rs7965575	chr12:129271459	T/C	cg04043695	chr12:129287642	SLC15A4	0.54	5.33	0.4	3.62e-7	Systemic lupus erythematosus;
UCEC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.57	5.87	0.44	2.81e-8	Prudent dietary pattern;
UCEC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.31	-0.46	3.16e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.53	5.96	0.44	1.75e-8	Retinal vascular caliber;
UCEC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.67	-6.01	-0.44	1.39e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.47	-4.54	-0.35	1.15e-5	Neurofibrillary tangles;
UCEC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.18	-0.39	7.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.94	10.85	0.67	1.6e-20	Breast cancer;
UCEC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.85	10.77	0.66	2.64e-20	IgG glycosylation;
UCEC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.36	5.29	0.4	4.41e-7	Ulcerative colitis;
UCEC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.46	-0.47	1.43e-9	Eye color traits;
UCEC	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg00639195	chr15:79103007	ADAMTS7	-0.58	-5.01	-0.38	1.54e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.83	8.14	0.56	1.5700000000000001e-13	Smoking behavior;
UCEC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.46	4.69	0.36	6.32e-6	Menarche (age at onset);
UCEC	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.2	0.46	5.35e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Primary biliary cholangitis;
UCEC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.27e-30	Chronic sinus infection;
UCEC	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg20936604	chr3:58311152	NA	-0.56	-4.77	-0.37	4.32e-6	Cholesterol, total;
UCEC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.58	5.81	0.43	3.65e-8	Colorectal cancer;
UCEC	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.11	4.92	0.38	2.31e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg03342759	chr3:160939853	NMD3	0.53	4.79	0.37	3.98e-6	Morning vs. evening chronotype;
UCEC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg16797656	chr11:68205561	LRP5	0.46	5.26	0.4	4.89e-7	Total body bone mineral density (age 45-60);
UCEC	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs2386661	0.956	rs10905489	chr10:5670541	G/C	cg17085576	chr10:5658249	NA	0.45	4.99	0.38	1.65e-6	Breast cancer;
UCEC	cis	rs6754311	0.769	rs1446585	chr2:136407479	A/G	cg07169764	chr2:136633963	MCM6	0.71	6.4	0.47	1.94e-9	Mosquito bite size;
UCEC	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.69	7.04	0.5	7e-11	Longevity;Endometriosis;
UCEC	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.39	4.67	0.36	6.69e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.77	6.94	0.5	1.18e-10	Body mass index;
UCEC	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.56	5.2	0.39	6.43e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.86	5.82	0.43	3.56e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.12	-0.39	9.52e-7	Mean platelet volume;
UCEC	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg23070574	chr3:14187308	XPC	-0.44	-4.65	-0.36	7.23e-6	Ovarian reserve;
UCEC	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.54	5.61	0.42	9.85e-8	Vitiligo;
UCEC	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	5.9	0.44	2.36e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.52	-4.68	-0.36	6.58e-6	Colorectal cancer;
UCEC	cis	rs1519814	0.956	rs6995843	chr8:121159867	C/T	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.47	-5.35	-0.4	3.32e-7	Coronary artery disease;Body mass index;
UCEC	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-8.62	-0.58	1.01e-14	Colorectal cancer;
UCEC	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg08271804	chr19:22816896	ZNF492	0.64	6.53	0.47	1.01e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.55	4.78	0.37	4.18e-6	Alzheimer's disease;
UCEC	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	0.83	5.25	0.4	5.22e-7	Arsenic metabolism;
UCEC	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg07169764	chr2:136633963	MCM6	-0.51	-4.61	-0.36	8.63e-6	Colorectal cancer;
UCEC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.09e-6	Height;
UCEC	cis	rs1575951	1.000	rs75317168	chr10:130452249	G/A	cg27041381	chr10:131357203	MGMT	0.66	5.13	0.39	8.88e-7	Plasma clusterin levels;
UCEC	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.52	-5.35	-0.4	3.29e-7	Vitiligo;
UCEC	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.94	10.0	0.64	2.76e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg09120320	chr17:61926383	NA	0.44	4.65	0.36	7.21e-6	Prudent dietary pattern;
UCEC	cis	rs7246967	0.673	rs11881740	chr19:22843844	T/C	cg05241461	chr19:22816980	ZNF492	0.53	5.84	0.43	3.28e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.65	6.92	0.5	1.3e-10	Lung cancer in ever smokers;
UCEC	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-0.94	-6.77	-0.49	2.86e-10	Blood pressure (smoking interaction);
UCEC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.54	-6.01	-0.44	1.41e-8	Prostate cancer;
UCEC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.64	0.58	8.67e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	0.92	8.56	0.58	1.39e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	5.71	0.43	6.09e-8	Cognitive test performance;
UCEC	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.46	4.77	0.37	4.31e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs10887741	0.646	rs2077773	chr10:89435501	G/A	cg13926569	chr10:89418898	PAPSS2	0.41	4.85	0.37	3.16e-6	Exercise (leisure time);
UCEC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18252515	chr7:66147081	NA	0.59	5.49	0.41	1.71e-7	Aortic root size;
UCEC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.5	-5.75	-0.43	5.07e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	0.8	5.99	0.44	1.51e-8	Economic and political preferences (immigration/crime);
UCEC	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	0.68	6.2	0.46	5.36e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.74	-6.41	-0.47	1.87e-9	Neurofibrillary tangles;
UCEC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.83	8.81	0.59	3.33e-15	Homoarginine levels;
UCEC	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.74	8.75	0.59	4.69e-15	Coronary artery disease;
UCEC	cis	rs445754	0.638	rs3729833	chr14:23883184	C/T	cg12853742	chr14:24780890	LTB4R;LTB4R2;CIDEB	0.45	4.77	0.37	4.44e-6	P wave terminal force;
UCEC	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.38	4.79	0.37	4.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-5.72	-0.43	5.71e-8	Prudent dietary pattern;
UCEC	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.59	4.89	0.37	2.61e-6	Type 2 diabetes;
UCEC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.7	5.9	0.44	2.4e-8	Smoking initiation;
UCEC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg24531977	chr5:56204891	C5orf35	0.53	5.19	0.39	6.96e-7	Coronary artery disease;
UCEC	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.41	4.57	0.35	1.03e-5	Mean corpuscular volume;
UCEC	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg18681998	chr4:17616180	MED28	-0.68	-7.58	-0.53	3.52e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs692916	0.716	rs540128	chr18:60544351	T/C	cg07187971	chr18:60481018	PHLPP1	-0.34	-4.75	-0.36	4.83e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg19318889	chr4:1322082	MAEA	0.49	4.75	0.36	4.81e-6	Obesity-related traits;
UCEC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.51	4.77	0.37	4.43e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06156847	chr2:113672199	IL1F7	0.36	4.91	0.38	2.35e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg13575925	chr12:9217583	LOC144571	0.42	4.75	0.36	4.74e-6	Sjögren's syndrome;
UCEC	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.7	6.6	0.48	6.88e-10	Bladder cancer;
UCEC	cis	rs159572	0.613	rs321817	chr5:55491274	C/T	cg04607372	chr5:54523900	NA	0.32	4.76	0.37	4.5e-6	Post-traumatic stress disorder;
UCEC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.63	-5.62	-0.42	9.27e-8	Aortic root size;
UCEC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	8.87e-20	Blood protein levels;
UCEC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-6.76	-0.49	3.07e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg18876405	chr7:65276391	NA	0.45	4.89	0.37	2.62e-6	Aortic root size;
UCEC	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg11871910	chr12:69753446	YEATS4	0.56	4.9	0.37	2.47e-6	Response to diuretic therapy;
UCEC	cis	rs7246967	0.673	rs7253063	chr19:22865897	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.62	-6.21	-0.46	5.03e-9	Strep throat;
UCEC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-9.01	-0.6	1.02e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.78	-8.8	-0.59	3.43e-15	Menopause (age at onset);
UCEC	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.42	-5.15	-0.39	8.11e-7	Subjective well-being;
UCEC	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.74	0.36	5.04e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs405956	1.000	rs923405	chr6:105618017	T/C	cg22580625	chr6:105627791	POPDC3	-0.56	-4.52	-0.35	1.27e-5	QT interval;
UCEC	cis	rs11697848	1.000	rs117045038	chr20:48572284	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15506890	chr2:3487001	NA	-0.65	-6.5	-0.47	1.17e-9	Neurofibrillary tangles;
UCEC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	0.9	5.61	0.42	9.75e-8	Type 2 diabetes nephropathy;
UCEC	cis	rs10924970	0.967	rs6680443	chr1:235480067	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	4.95	0.38	2e-6	Asthma;
UCEC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.81	0.37	3.65e-6	Breast cancer;
UCEC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	4.98e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.85	-0.37	3.05e-6	Dupuytren's disease;
UCEC	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.91	-9.82	-0.63	8.31e-18	Body mass index;
UCEC	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-0.51	-5.16	-0.39	7.92e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.64	6.05	0.45	1.13e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg03146154	chr1:46216737	IPP	0.47	4.78	0.37	4.24e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.6	6.23	0.46	4.62e-9	Pulse pressure;
UCEC	cis	rs13323323	0.728	rs1004631	chr3:44592979	T/G	cg26781129	chr3:44753946	ZNF502	-0.58	-4.92	-0.38	2.28e-6	IgG glycosylation;
UCEC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.67	6.19	0.45	5.8e-9	Corneal astigmatism;
UCEC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.6	6.43	0.47	1.67e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.1	-0.39	1.03e-6	Mean platelet volume;
UCEC	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.57	0.42	1.18e-7	Monocyte percentage of white cells;
UCEC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.95	11.91	0.7	2.54e-23	Multiple sclerosis;
UCEC	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.69	6.4	0.47	1.96e-9	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.92	-0.38	2.26e-6	Pulmonary function;
UCEC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	0.88	5.21	0.39	6.24e-7	Skin colour saturation;
UCEC	cis	rs2425143	1.000	rs6060578	chr20:34305445	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.72	-0.36	5.53e-6	Blood protein levels;
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.56	6.14e-14	Prudent dietary pattern;
UCEC	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg00105475	chr2:10696890	NA	-0.48	-6.64	-0.48	5.68e-10	Prostate cancer;
UCEC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg23782820	chr8:58130467	NA	0.51	4.88	0.37	2.73e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.67	-6.67	-0.48	4.76e-10	Coronary artery disease;
UCEC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg16497661	chr14:103986332	CKB	0.49	5.78	0.43	4.21e-8	Body mass index;
UCEC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg22166914	chr1:53195759	ZYG11B	0.59	6.18	0.45	6.1e-9	Monocyte count;
UCEC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	4.5	0.35	1.35e-5	Monocyte count;
UCEC	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.58	6.36	0.46	2.37e-9	Glomerular filtration rate (creatinine);
UCEC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.61	-5.25	-0.4	5.25e-7	Gut microbiome composition (summer);
UCEC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg17724175	chr1:150552817	MCL1	-0.42	-4.59	-0.35	9.55e-6	Tonsillectomy;
UCEC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18932078	chr1:2524107	MMEL1	0.35	6.05	0.45	1.13e-8	Ulcerative colitis;
UCEC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.49	4.53	0.35	1.2e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.59	5.11	0.39	9.86e-7	Heart rate;
UCEC	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.63	4.81	0.37	3.77e-6	Carotid intima media thickness;
UCEC	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-5.18	-0.39	7.19e-7	Height;
UCEC	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.7	-0.43	6.46e-8	Depression;
UCEC	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.59	4.66	0.36	7e-6	Lymphocyte counts;
UCEC	cis	rs17106184	1.000	rs2175794	chr1:51333179	A/T	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.52	-0.41	1.49e-7	Neutrophil percentage of white cells;
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs12692119	0.764	rs6761267	chr2:127647396	G/A	cg04330126	chr2:127727905	NA	-0.8	-4.8	-0.37	3.86e-6	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg05802129	chr4:122689817	NA	-0.55	-5.55	-0.42	1.31e-7	Type 2 diabetes;
UCEC	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.55	6.39	0.47	2.04e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg06784218	chr1:46089804	CCDC17	0.43	4.77	0.37	4.42e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg18478394	chr8:109455254	TTC35	0.49	5.04	0.38	1.37e-6	Dupuytren's disease;
UCEC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg16583315	chr14:65563665	MAX	-0.4	-4.66	-0.36	6.94e-6	Obesity-related traits;
UCEC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.62	7.01	0.5	7.95e-11	Tonsillectomy;
UCEC	cis	rs2721195	0.967	rs4925809	chr8:145686313	C/T	cg17328964	chr8:145687451	CYHR1	-0.79	-8.68	-0.58	7e-15	Age at first birth;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.54	5.72	0.43	5.67e-8	Diastolic blood pressure;
UCEC	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.61	0.53	3.07e-12	Platelet count;
UCEC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.54	5.87	0.44	2.8e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.6	5.27	0.4	4.75e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg01966129	chr22:22901880	PRAME;LOC648691	0.25	4.55	0.35	1.1e-5	Bone mineral density;
UCEC	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.58	-6.84	-0.49	1.94e-10	Oral cavity cancer;
UCEC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.68	-7.71	-0.54	1.75e-12	Menarche (age at onset);
UCEC	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.63	-5.07	-0.39	1.17e-6	Type 2 diabetes;
UCEC	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.48	-5.42	-0.41	2.4e-7	White matter hyperintensity burden;
UCEC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.42	-4.77	-0.37	4.44e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs151997	1.000	rs151997	chr5:50233199	A/G	cg06027927	chr5:50259733	NA	-0.53	-4.96	-0.38	1.92e-6	Callous-unemotional behaviour;
UCEC	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg12310025	chr6:25882481	NA	-0.58	-4.51	-0.35	1.31e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12579753	0.619	rs11115089	chr12:82311132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.51	-4.52	-0.35	1.27e-5	Resting heart rate;
UCEC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.65	-5.01	-0.38	1.54e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg00614314	chr15:82944287	LOC80154	0.66	6.33	0.46	2.82e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.77	-6.1	-0.45	9.02e-9	Cognitive test performance;
UCEC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.44	-4.78	-0.37	4.29e-6	Fibrinogen levels;
UCEC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.02	-0.5	7.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2134046	0.587	rs11854289	chr15:82558802	C/T	cg00614314	chr15:82944287	LOC80154	-0.52	-6.05	-0.45	1.16e-8	Cognitive ability;
UCEC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg14092571	chr14:90743983	NA	-0.45	-6.21	-0.46	5.26e-9	Mortality in heart failure;
UCEC	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.54	5.34	0.4	3.4e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
UCEC	cis	rs6834538	0.965	rs1580476	chr4:113493365	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	4.71	0.36	5.64e-6	Free thyroxine concentration;
UCEC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.51	4.64	0.36	7.7e-6	Menopause (age at onset);
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.76	8.8	0.59	3.38e-15	Menarche (age at onset);
UCEC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.66	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg15659132	chr6:26577336	NA	0.48	4.6	0.35	9.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.66	5.42	0.41	2.37e-7	Metabolite levels;
UCEC	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-1.1	-8.98	-0.6	1.19e-15	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.81	6.39	0.47	2.1e-9	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.29	-7.08	-0.5	5.53e-11	Atopic dermatitis;
UCEC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.66	-5.52	-0.41	1.46e-7	Type 2 diabetes;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.6	6.92	0.5	1.27e-10	Menarche (age at onset);
UCEC	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.97	-0.59	1.28e-15	Exhaled nitric oxide output;
UCEC	cis	rs10895987	1.000	rs9971407	chr11:64898226	C/T	cg02030452	chr11:65589615	NA	-0.49	-4.63	-0.36	7.9e-6	Blood protein levels;
UCEC	cis	rs713477	0.967	rs10150617	chr14:55916225	A/C	cg13175173	chr14:55914753	NA	0.45	5.14	0.39	8.73e-7	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.68	-5.97	-0.44	1.68e-8	Vitiligo;
UCEC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg04553112	chr3:125709451	NA	-0.65	-5.2	-0.39	6.42e-7	Blood pressure (smoking interaction);
UCEC	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.17	11.24	0.68	1.54e-21	Corneal structure;
UCEC	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.6	5.95	0.44	1.87e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7781557	0.640	rs6955064	chr7:102579571	T/C	cg06322601	chr7:102330635	NA	0.57	4.64	0.36	7.78e-6	Colorectal adenoma (advanced);
UCEC	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg01072550	chr1:21505969	NA	-0.58	-5.74	-0.43	5.2e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg14780466	chr2:20870812	GDF7	0.4	5.43	0.41	2.27e-7	Abdominal aortic aneurysm;
UCEC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.44	5.58	0.42	1.13e-7	Coronary artery disease;
UCEC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22857025	chr5:266934	NA	-0.92	-7.94	-0.55	4.75e-13	Asthma (childhood onset);
UCEC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-5.63	-0.42	8.82e-8	Alcohol dependence;
UCEC	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg16989719	chr2:238392110	NA	-0.36	-4.7	-0.36	5.88e-6	Prostate cancer;
UCEC	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.6	6.36	0.46	2.46e-9	Retinal vascular caliber;
UCEC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.5	-5.31	-0.4	3.96e-7	Total body bone mineral density;
UCEC	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.2	-0.46	5.37e-9	Resting heart rate;
UCEC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.09	-0.39	1.06e-6	Personality dimensions;
UCEC	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.84	-6.58	-0.48	7.73e-10	Red blood cell count;
UCEC	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.66	-0.36	6.96e-6	Schizophrenia;
UCEC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.63	0.36	7.81e-6	Menopause (age at onset);
UCEC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-5.12	-0.39	9.35e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.72	7.5	0.53	5.61e-12	Tonsillectomy;
UCEC	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-6.01	-0.44	1.42e-8	Hepatocellular carcinoma;
UCEC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.53	5.04	0.38	1.32e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28795989	0.795	rs2385910	chr4:7903151	G/C	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	6.16e-8	Intraocular pressure;
UCEC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg06238570	chr21:40685208	BRWD1	0.81	8.07	0.55	2.33e-13	Cognitive function;
UCEC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.77	-6.07	-0.45	1.01e-8	Birth weight;
UCEC	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.19e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.51	6.21	0.46	5.22e-9	Height;
UCEC	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.73	7.89	0.55	6.48e-13	Breast cancer;
UCEC	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg00814883	chr7:100076585	TSC22D4	-0.6	-5.36	-0.4	3.14e-7	Lung function (FEV1/FVC);
UCEC	cis	rs4654899	0.861	rs10916876	chr1:21169996	T/C	cg01072550	chr1:21505969	NA	0.48	4.69	0.36	6.06e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2742417	1.000	rs1609554	chr3:45735192	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg06027949	chr8:82754900	SNX16	-0.61	-5.13	-0.39	9.13e-7	Diastolic blood pressure;
UCEC	cis	rs6893807	0.778	rs16903285	chr5:87978252	T/C	cg09002922	chr5:87956389	LOC645323	-0.61	-5.65	-0.42	7.94e-8	Body mass index;
UCEC	cis	rs4588572	0.561	rs12697887	chr5:77804729	A/G	cg11547950	chr5:77652471	NA	-0.35	-4.95	-0.38	2.01e-6	Triglycerides;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg08397818	chr19:58514022	ZNF606	0.68	6.67	0.48	4.82e-10	Schizophrenia;
UCEC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.59	5.47	0.41	1.88e-7	Schizophrenia;
UCEC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg01256987	chr12:42539512	GXYLT1	0.41	4.75	0.36	4.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs16937	0.711	rs10900467	chr1:205160074	G/A	cg00857998	chr1:205179979	DSTYK	0.52	4.67	0.36	6.87e-6	Schizophrenia;
UCEC	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.48	5.12	0.39	9.6e-7	Red blood cell count;
UCEC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.7	7.68	0.54	2.08e-12	Lymphocyte counts;
UCEC	cis	rs7804356	0.813	rs76438067	chr7:26911904	C/T	cg09144964	chr7:27150262	HOXA3	0.55	4.57	0.35	1.03e-5	Type 1 diabetes;
UCEC	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-10.38	-0.65	2.78e-19	Renal cell carcinoma;
UCEC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.36	-5.52	-0.41	1.49e-7	Ulcerative colitis;
UCEC	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg01426195	chr3:39028469	NA	-0.77	-10.31	-0.65	4.22e-19	Handedness;
UCEC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg17420585	chr12:42539391	GXYLT1	0.4	5.15	0.39	8.23e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	1.04	8.4	0.57	3.43e-14	Vitiligo;
UCEC	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.76	-7.99	-0.55	3.62e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.86	-7.23	-0.51	2.5e-11	Coronary artery calcification;
UCEC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.86e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	5.01	0.38	1.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.64	-0.36	7.69e-6	Chronic sinus infection;
UCEC	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg19197139	chr17:4613644	ARRB2	-0.6	-5.05	-0.38	1.29e-6	Lymphocyte counts;
UCEC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.16	-13.73	-0.75	3.87e-28	Breast cancer;
UCEC	cis	rs6534441	0.697	rs7675996	chr4:125469932	C/A	cg21609808	chr4:125404261	NA	0.41	4.58	0.35	9.99e-6	Major depressive disorder;
UCEC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.19	-9.16	-0.6	4.18e-16	Gut microbiome composition (summer);
UCEC	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.65	-6.06	-0.45	1.1e-8	Body mass index;
UCEC	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.62	-5.23	-0.4	5.85e-7	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg23950597	chr19:37808831	NA	-0.86	-5.72	-0.43	5.69e-8	Coronary artery calcification;
UCEC	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	7.7	0.54	1.81e-12	Smoking behavior;
UCEC	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.22	-0.4	5.89e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.52	5.53	0.41	1.43e-7	Aortic root size;
UCEC	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.09	-0.45	9.34e-9	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.43	-4.69	-0.36	6.06e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.51	-4.86	-0.37	2.94e-6	Renal cell carcinoma;
UCEC	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	5.88	0.44	2.68e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.18	11.15	0.68	2.6e-21	Corneal structure;
UCEC	cis	rs4478037	1.000	rs4074418	chr3:33161165	G/T	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.5	5.32	0.4	3.85e-7	Monocyte percentage of white cells;
UCEC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg14067834	chr17:29058358	SUZ12P	0.58	4.53	0.35	1.21e-5	Body mass index;
UCEC	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.68	-7.36	-0.52	1.2e-11	Cognitive test performance;
UCEC	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-4.56	-0.35	1.08e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.61	0.36	8.6e-6	Bipolar disorder;
UCEC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.68	6.85	0.49	1.9e-10	Blood protein levels;
UCEC	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.11	-0.39	9.65e-7	Metabolite levels;
UCEC	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs7534824	0.507	rs7518380	chr1:101451262	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.54	4.73	0.36	5.3e-6	Refractive astigmatism;
UCEC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	5.59	0.42	1.08e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.55	-6.42	-0.47	1.8e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.49	-5.6	-0.42	1.04e-7	Aortic root size;
UCEC	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	0.82	6.0	0.44	1.5e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.67	-0.58	7.29e-15	Menarche (age at onset);
UCEC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.9	8.42	0.57	3.03e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-7.66	-0.53	2.27e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.95	0.38	2.03e-6	Platelet count;
UCEC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.83	10.12	0.64	1.37e-18	Longevity;Endometriosis;
UCEC	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.54	-6.23	-0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.77	-7.4	-0.52	9.82e-12	Initial pursuit acceleration;
UCEC	cis	rs10940138	0.830	rs6867554	chr5:67207725	A/G	ch.5.1281357F	chr5:67228439	NA	0.63	5.96	0.44	1.8e-8	Menarche (age at onset);
UCEC	cis	rs1576263	0.967	rs162279	chr6:8556968	T/G	cg21535247	chr6:8435926	SLC35B3	0.48	4.91	0.38	2.38e-6	Photic sneeze reflex;
UCEC	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.56	5.64	0.42	8.59e-8	Blood protein levels;
UCEC	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.18e-21	Body mass index;
UCEC	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-5.01	-0.38	1.54e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	0.75	9.64	0.62	2.34e-17	Monocyte percentage of white cells;
UCEC	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.83	-0.59	2.95e-15	Exhaled nitric oxide output;
UCEC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.63	-8.78	-0.59	3.95e-15	Cancer (pleiotropy);
UCEC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg26441486	chr22:50317300	CRELD2	0.75	5.13	0.39	9e-7	Mean platelet volume;
UCEC	cis	rs8105895	0.935	rs62110992	chr19:22261516	T/G	cg24175803	chr19:22235144	ZNF257	-0.62	-5.4	-0.41	2.62e-7	Body mass index (change over time);
UCEC	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.83	9.53	0.62	4.55e-17	Coronary artery disease;
UCEC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg19318889	chr4:1322082	MAEA	0.46	5.01	0.38	1.51e-6	Obesity-related traits;
UCEC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.6	4.58	0.35	9.79e-6	Corneal astigmatism;
UCEC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg22563815	chr15:78856949	CHRNA5	-0.38	-5.04	-0.38	1.34e-6	Sudden cardiac arrest;
UCEC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.46	0.41	2.02e-7	Breast cancer;
UCEC	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-8.48	-0.57	2.25e-14	Morning vs. evening chronotype;
UCEC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.54	-5.56	-0.42	1.22e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-5.2	-0.39	6.46e-7	Colorectal cancer;
UCEC	cis	rs10266483	0.881	rs665452	chr7:63749455	C/T	cg23304165	chr7:63498798	NA	-0.44	-4.79	-0.37	4.11e-6	Response to statin therapy;
UCEC	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.09	-0.39	1.08e-6	Neuroticism;
UCEC	cis	rs6484218	0.562	rs10840398	chr11:10394160	T/C	cg17542333	chr11:10673844	MRVI1	0.62	4.86	0.37	2.94e-6	Schizophrenia, bipolar disorder and depression (combined);
UCEC	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.46	-0.41	1.95e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.43	-5.08	-0.39	1.12e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.75	0.75	3.48e-28	Height;
UCEC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg12712729	chr8:7886076	NA	0.37	4.81	0.37	3.71e-6	Systolic blood pressure;
UCEC	cis	rs1576263	0.934	rs330111	chr6:8546711	A/G	cg07606381	chr6:8435919	SLC35B3	0.48	5.0	0.38	1.59e-6	Photic sneeze reflex;
UCEC	trans	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg02900749	chr2:68251473	NA	-0.96	-7.1	-0.51	4.94e-11	Pursuit maintenance gain;
UCEC	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg03342759	chr3:160939853	NMD3	0.56	5.4	0.41	2.62e-7	Morning vs. evening chronotype;
UCEC	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.36	-4.6	-0.35	9.12e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-5.62	-0.42	9.44e-8	Monocyte percentage of white cells;
UCEC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.33	0.61	1.51e-16	Alzheimer's disease;
UCEC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.48	-5.48	-0.41	1.77e-7	Aortic root size;
UCEC	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.24	-0.46	4.45e-9	Coffee consumption (cups per day);
UCEC	cis	rs354033	1.000	rs3735320	chr7:149246680	A/T	cg24335155	chr7:149193227	ZNF746	0.38	4.6	0.35	8.97e-6	Multiple sclerosis;
UCEC	cis	rs1635	0.655	rs9368532	chr6:27782010	A/G	cg02925601	chr6:27648605	NA	-0.6	-4.72	-0.36	5.33e-6	Schizophrenia;
UCEC	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.58	6.5	0.47	1.17e-9	Red blood cell count;
UCEC	cis	rs180358	0.588	rs2542062	chr11:116680449	G/A	cg08985259	chr11:116699649	APOC3	0.41	4.92	0.38	2.29e-6	Multiple sclerosis (severity);
UCEC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.66	-5.63	-0.42	8.82e-8	Alcohol dependence;
UCEC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	4.63	0.36	8.13e-6	Schizophrenia;
UCEC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.91	8.75	0.59	4.55e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.48	-4.73	-0.36	5.22e-6	Mortality in heart failure;
UCEC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.06	-0.45	1.09e-8	Cognitive function;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07080049	chr9:96214194	FAM120A;FAM120AOS	0.58	6.76	0.49	3e-10	Warfarin maintenance dose;
UCEC	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.4	-0.52	9.69e-12	Body mass index;
UCEC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.66	5.92	0.44	2.23e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.21	0.46	5.17e-9	Motion sickness;
UCEC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.41	6.19	0.45	5.75e-9	Crohn's disease;
UCEC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.52	-5.04	-0.38	1.33e-6	Cognitive test performance;
UCEC	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg08250081	chr4:10125330	NA	0.47	4.62	0.36	8.15e-6	Gout;Urate levels;Serum uric acid levels;
UCEC	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg05738196	chr6:26577821	NA	0.53	5.09	0.39	1.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.91	-0.49	1.4e-10	Pulmonary function;
UCEC	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.65	-6.85	-0.49	1.92e-10	Resting heart rate;
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.57	-6.27	-0.46	3.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.84	5.28	0.4	4.58e-7	Diisocyanate-induced asthma;
UCEC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg19477247	chr3:113955994	ZNF80	-0.33	-4.53	-0.35	1.2e-5	IgG glycosylation;
UCEC	cis	rs7246967	0.932	rs7256599	chr19:23045921	T/C	cg24889512	chr19:22816950	ZNF492	0.5	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.62	-4.99	-0.38	1.72e-6	Initial pursuit acceleration;
UCEC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg06096015	chr1:231504339	EGLN1	0.46	5.51	0.41	1.57e-7	Hemoglobin concentration;
UCEC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.59	6.36	0.46	2.39e-9	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.25	-0.4	5.3e-7	Mean platelet volume;
UCEC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.46	-4.58	-0.35	9.99e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.63	4.78	0.37	4.16e-6	Carotid intima media thickness;
UCEC	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.7	-6.55	-0.48	8.96e-10	Prostate cancer;
UCEC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg05695927	chr15:45694626	SPATA5L1	0.46	4.77	0.37	4.4e-6	Homoarginine levels;
UCEC	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.65	6.12	0.45	8.1e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg08461772	chr7:95026248	PON3	0.4	5.32	0.4	3.83e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs970548	1.000	rs10900224	chr10:46024534	C/T	cg15223267	chr10:46222474	FAM21C	0.54	4.84	0.37	3.25e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.43	5.57	0.42	1.17e-7	HIV-1 susceptibility;
UCEC	cis	rs256277	0.657	rs2456907	chr5:111371462	G/A	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.55	-4.56	-0.35	1.06e-5	Coronary artery disease;
UCEC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs6479527	0.933	rs10993058	chr9:96873151	C/A	cg13460858	chr9:96720652	NA	0.39	4.54	0.35	1.18e-5	Esophageal adenocarcinoma;
UCEC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.16e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4467006	0.519	rs4243654	chr14:77685535	A/G	cg22824376	chr14:77648248	TMEM63C	0.69	4.96	0.38	1.91e-6	Bipolar disorder;
UCEC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.88	0.37	2.73e-6	Hemoglobin concentration;
UCEC	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg26781129	chr3:44753946	ZNF502	-0.61	-5.24	-0.4	5.49e-7	IgG glycosylation;
UCEC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.62	-6.55	-0.48	8.88e-10	Neurofibrillary tangles;
UCEC	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.66	-6.87	-0.49	1.65e-10	Waist circumference;Body mass index;
UCEC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg23708337	chr7:1209742	NA	0.69	4.54	0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	7.05	0.5	6.4e-11	Metabolite levels;
UCEC	cis	rs2708377	0.858	rs68045377	chr12:11294452	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.74	6.15	0.45	6.92e-9	Bitter taste perception;
UCEC	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.49	6.29	0.46	3.36e-9	Osteoporosis;
UCEC	cis	rs4662945	0.688	rs876890	chr2:130195492	A/T	cg05962382	chr2:130345044	NA	-0.44	-4.98	-0.38	1.77e-6	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg03859395	chr2:55845619	SMEK2	1.05	15.19	0.78	6.32e-32	Metabolic syndrome;
UCEC	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-4.98	-0.38	1.74e-6	Monocyte percentage of white cells;
UCEC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg01689657	chr7:91764605	CYP51A1	0.43	5.39	0.41	2.72e-7	Breast cancer;
UCEC	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.47	5.13	0.39	8.91e-7	Oral cavity cancer;
UCEC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs8105441	chr19:22891466	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.54	0.47	9.57e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	9.37	0.61	1.2e-16	Platelet count;
UCEC	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg11632617	chr15:75315747	PPCDC	-0.67	-7.71	-0.54	1.75e-12	Lung cancer;
UCEC	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.52	-5.92	-0.44	2.2e-8	Pursuit maintenance gain;
UCEC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.45	4.93	0.38	2.2e-6	Pulse pressure;
UCEC	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.54	5.93	0.44	2.11e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs7175404	0.527	rs7183559	chr15:94054392	A/G	cg06054272	chr15:93956988	NA	0.7	5.06	0.39	1.21e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs6832769	1.000	rs1522106	chr4:56307214	A/C	cg05960024	chr4:56376020	CLOCK	-0.49	-4.67	-0.36	6.77e-6	Personality dimensions;
UCEC	cis	rs7246967	1.000	rs11882498	chr19:23060012	C/T	cg24889512	chr19:22816950	ZNF492	0.49	4.76	0.37	4.5e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.44	5.08	0.39	1.11e-6	Glycated hemoglobin levels;
UCEC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg00815214	chr21:47717953	NA	-0.39	-4.56	-0.35	1.09e-5	Testicular germ cell tumor;
UCEC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.61	-5.53	-0.42	1.41e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg12024160	chr4:1254474	NA	0.7	8.37	0.57	4.08e-14	Obesity-related traits;
UCEC	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.51	5.25	0.4	5.32e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.59	-0.48	7.23e-10	Aortic root size;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.13	-0.45	7.86e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.48	0.62	6.13e-17	Menopause (age at onset);
UCEC	cis	rs17122693	0.748	rs7159861	chr14:51144660	C/T	cg04730355	chr14:51134070	SAV1	-0.85	-9.02	-0.6	9.23e-16	Cognitive performance;
UCEC	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.66	6.67	0.48	4.78e-10	C-reactive protein levels;
UCEC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Bipolar disorder;
UCEC	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-8.2	-0.56	1.1e-13	Morning vs. evening chronotype;
UCEC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg18016565	chr1:150552671	MCL1	-0.51	-5.72	-0.43	5.79e-8	Tonsillectomy;
UCEC	cis	rs28530618	0.515	rs6579027	chr20:31239025	G/T	cg13636640	chr20:31349939	DNMT3B	-0.54	-4.94	-0.38	2.12e-6	Birth weight;
UCEC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.33	0.46	2.83e-9	Personality dimensions;
UCEC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.74	7.55	0.53	4.33e-12	Blood protein levels;
UCEC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.48	4.67	0.36	6.86e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs8067287	0.597	rs7223652	chr17:16864559	C/T	cg09796270	chr17:17721594	SREBF1	-0.48	-4.51	-0.35	1.32e-5	Diabetic kidney disease;
UCEC	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-12.73	-0.72	1.69e-25	Height;
UCEC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.65	-5.19	-0.39	6.79e-7	Initial pursuit acceleration;
UCEC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.55	5.78	0.43	4.35e-8	Red blood cell count;
UCEC	cis	rs7113850	0.541	rs56679749	chr11:24235649	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs10949834	0.730	rs2237503	chr7:73509326	G/C	cg07137043	chr7:73588983	EIF4H	-0.67	-4.64	-0.36	7.56e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	7.89	0.55	6.18e-13	Tonsillectomy;
UCEC	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg01072550	chr1:21505969	NA	-0.63	-6.49	-0.47	1.22e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.8	-7.02	-0.5	7.78e-11	Coronary artery calcification;
UCEC	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg03114573	chr12:45410052	DBX2	-0.48	-5.67	-0.42	7.31e-8	Gut microbiome composition (summer);
UCEC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg24375607	chr4:120327624	NA	0.48	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-4.51	-0.35	1.34e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs17681684	0.565	rs12150149	chr17:9764039	A/C	cg26853458	chr17:9805074	RCVRN	-0.38	-4.77	-0.37	4.37e-6	GIP levels in response to oral glucose tolerance test (fasting);
UCEC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.67	5.31	0.4	3.93e-7	Corneal astigmatism;
UCEC	cis	rs17122693	1.000	rs1018036	chr14:51085429	C/T	cg04730355	chr14:51134070	SAV1	0.72	7.28	0.51	1.83e-11	Cognitive performance;
UCEC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.46	-6.71	-0.48	3.86e-10	Homoarginine levels;
UCEC	cis	rs7870753	0.578	rs7044391	chr9:99159791	C/A	cg25260653	chr9:99212216	HABP4	0.51	4.82	0.37	3.48e-6	Height;
UCEC	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.8	-9.13	-0.6	4.94e-16	Blood metabolite levels;
UCEC	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	0.81	9.02	0.6	9.42e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs2302190	0.882	rs9903050	chr17:56636908	T/C	cg12560992	chr17:57184187	TRIM37	0.52	4.65	0.36	7.35e-6	Vitamin D levels;
UCEC	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.8	-10.03	-0.64	2.33e-18	Systemic sclerosis;
UCEC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.67	5.15	0.39	8.13e-7	Corneal astigmatism;
UCEC	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.5	-6.01	-0.44	1.37e-8	Coronary artery disease;
UCEC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	0.93	9.5	0.62	5.42e-17	Heart rate;
UCEC	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.52	-5.87	-0.44	2.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.74	7.45	0.52	7.21e-12	Blood protein levels;
UCEC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.17	-0.45	6.23e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.47	-4.57	-0.35	1.02e-5	Breast cancer;
UCEC	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.57	6.01	0.44	1.42e-8	Sudden cardiac arrest;
UCEC	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg00105475	chr2:10696890	NA	0.46	5.65	0.42	7.99e-8	Prostate cancer;
UCEC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.6	5.2	0.39	6.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-5.18	-0.39	7.21e-7	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.44	-4.75	-0.36	4.87e-6	Coronary artery disease;
UCEC	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	0.93	6.46	0.47	1.45e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.66	5.35	0.4	3.23e-7	Corneal astigmatism;
UCEC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg13147721	chr7:65941812	NA	-0.96	-7.13	-0.51	4.16e-11	Diabetic kidney disease;
UCEC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.06	-0.38	1.26e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.53	-5.69	-0.42	6.79e-8	Refractive error;
UCEC	cis	rs11697848	1.000	rs77116439	chr20:48509741	T/C	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-4.78	-0.37	4.26e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg04851639	chr8:1020857	NA	-0.37	-5.0	-0.38	1.59e-6	Schizophrenia;
UCEC	cis	rs12313068	0.709	rs10849698	chr12:110504798	C/G	cg12870014	chr12:110450643	ANKRD13A	0.75	8.25	0.56	8.08e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg21770322	chr7:97807741	LMTK2	0.71	10.28	0.65	5.12e-19	Breast cancer;
UCEC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.61	-5.71	-0.43	6.17e-8	Acne (severe);
UCEC	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-5.07	-0.39	1.16e-6	Hepatocellular carcinoma;
UCEC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.62	5.23	0.4	5.77e-7	Menopause (age at onset);
UCEC	cis	rs4778581	0.722	rs6495474	chr15:80377452	A/C	cg08257866	chr15:80351198	ZFAND6	-0.4	-4.85	-0.37	3.11e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-5.42	-0.41	2.39e-7	Height;
UCEC	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs554111	0.660	rs541464	chr1:21067095	C/T	cg08890418	chr1:21044141	KIF17	0.55	5.45	0.41	2.08e-7	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10746514	0.833	rs867844	chr1:232266278	A/T	cg09506761	chr1:232265262	NA	0.44	4.57	0.35	1.04e-5	Response to statin therapy;
UCEC	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg06265175	chr8:121136014	COL14A1	-0.48	-5.11	-0.39	9.75e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2498796	0.727	rs4983543	chr14:105212399	T/C	cg18664856	chr14:105240263	AKT1	-0.42	-4.61	-0.36	8.74e-6	Endometrial cancer;Endometrial endometrioid carcinoma;
UCEC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.69	-6.35	-0.46	2.54e-9	Schizophrenia;
UCEC	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	6.34	0.46	2.62e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs2735413	0.709	rs1319049	chr16:78084610	T/G	cg09132178	chr16:78079569	NA	0.47	5.15	0.39	8.26e-7	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs8105895	0.935	rs62112921	chr19:22227577	T/C	cg20662725	chr19:22235022	ZNF257	-0.64	-5.31	-0.4	3.95e-7	Body mass index (change over time);
UCEC	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.65	0.48	5.42e-10	Motion sickness;
UCEC	cis	rs12980942	0.630	rs7257825	chr19:41788344	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.63	5.65	0.42	8.15e-8	Coronary artery disease;
UCEC	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.77	-7.2	-0.51	2.87e-11	Mean corpuscular hemoglobin;
UCEC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.87	-11.2	-0.68	1.97e-21	Height;
UCEC	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.88	12.98	0.73	3.7e-26	Leprosy;
UCEC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.87	5.83	0.43	3.32e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.68	-5.9	-0.44	2.44e-8	Adiposity;
UCEC	cis	rs11543198	0.826	rs7174305	chr15:74728998	C/G	cg17852385	chr15:75019188	CYP1A1	0.76	4.75	0.36	4.88e-6	Bladder cancer;
UCEC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.34	5.13	0.39	9.17e-7	Ulcerative colitis;
UCEC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-10.33	-0.65	3.85e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs12542759	0.857	rs7007220	chr8:133034922	C/T	cg10591701	chr8:133787386	PHF20L1	-0.49	-4.65	-0.36	7.28e-6	Pit-and-Fissure caries;
UCEC	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.39	-4.7	-0.36	5.86e-6	Menopause (age at onset);
UCEC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.1	-0.39	1.04e-6	Colorectal cancer;
UCEC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg20203395	chr5:56204925	C5orf35	-0.62	-4.54	-0.35	1.14e-5	Initial pursuit acceleration;
UCEC	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.41	-4.94	-0.38	2.09e-6	Refractive error;
UCEC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.52	5.78	0.43	4.37e-8	Platelet count;
UCEC	cis	rs6840360	0.547	rs9991859	chr4:152265572	T/C	cg25486957	chr4:152246857	NA	-0.49	-5.35	-0.4	3.26e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg05660106	chr1:15850417	CASP9	0.51	5.04	0.38	1.37e-6	Systolic blood pressure;
UCEC	cis	rs713477	0.967	rs4901570	chr14:55915249	T/C	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.26e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg23260525	chr10:116636907	FAM160B1	0.33	4.53	0.35	1.23e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.61	5.57	0.42	1.17e-7	Morning vs. evening chronotype;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.93	11.66	0.69	1.16e-22	Menarche (age at onset);
UCEC	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg05855489	chr10:104503620	C10orf26	0.76	9.18	0.6	3.69e-16	Waist circumference;Hip circumference;
UCEC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.8	-6.67	-0.48	4.87e-10	Initial pursuit acceleration;
UCEC	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg03959625	chr15:84868606	LOC388152	0.46	4.84	0.37	3.21e-6	Schizophrenia;
UCEC	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	0.89	9.58	0.62	3.37e-17	Left atrial antero-posterior diameter;
UCEC	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.58	-6.37	-0.47	2.28e-9	Type 2 diabetes;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11077019	chr1:52520979	TXNDC12;BTF3L4	0.7	7.06	0.5	6.17e-11	Migraine with aura;
UCEC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.72	7.25	0.51	2.22e-11	Tonsillectomy;
UCEC	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.58	6.14	0.45	7.41e-9	Mean platelet volume;
UCEC	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg24088508	chr1:38156462	C1orf109	0.51	4.72	0.36	5.51e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg03078520	chr22:18463400	MICAL3	0.43	4.51	0.35	1.3e-5	Presence of antiphospholipid antibodies;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.29	-0.46	3.36e-9	Pubertal anthropometrics;
UCEC	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.99	8.9	0.59	1.92e-15	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24249390	chr15:90295951	MESP1	-0.43	-4.96	-0.38	1.93e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.74	7.75	0.54	1.37e-12	Vitamin D levels;
UCEC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg13695892	chr22:41940480	POLR3H	0.65	4.53	0.35	1.19e-5	Vitiligo;
UCEC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.8	8.82	0.59	3.13e-15	Immature fraction of reticulocytes;
UCEC	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.83	8.91	0.59	1.76e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg00612595	chr21:47717864	NA	-0.48	-5.2	-0.39	6.53e-7	Testicular germ cell tumor;
UCEC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg01973587	chr1:228161476	NA	0.39	5.25	0.4	5.29e-7	Diastolic blood pressure;
UCEC	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.81	-9.07	-0.6	7.12e-16	Post bronchodilator FEV1;
UCEC	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6717918	0.564	rs3116181	chr2:233028070	A/G	cg20569070	chr2:232597279	PDE6D	0.44	4.99	0.38	1.7e-6	Height;
UCEC	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.62	-4.58	-0.35	1e-5	HIV-1 control;
UCEC	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.65	-5.4	-0.41	2.6e-7	Immature fraction of reticulocytes;
UCEC	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.38	0.41	2.82e-7	Response to antipsychotic treatment;
UCEC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg06784218	chr1:46089804	CCDC17	0.46	5.74	0.43	5.26e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.6	5.64	0.42	8.39e-8	Birth weight;
UCEC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.65	6.59	0.48	7.45e-10	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.67	-6.26	-0.46	4e-9	Aortic root size;
UCEC	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Depression;
UCEC	cis	rs4778581	0.643	rs1533857	chr15:80397499	T/C	cg08257866	chr15:80351198	ZFAND6	0.44	5.23	0.4	5.85e-7	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.74	-4.7	-0.36	5.94e-6	Night sleep phenotypes;
UCEC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.7	-5.94	-0.44	1.95e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.5	-5.17	-0.39	7.47e-7	Schizophrenia;
UCEC	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.64	6.23	0.46	4.7e-9	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.61	6.77	0.49	2.83e-10	Red blood cell count;
UCEC	cis	rs12568771	0.845	rs1886303	chr1:17632382	C/T	cg11347165	chr1:17631644	NA	-0.33	-4.61	-0.36	8.8e-6	IgA nephropathy;
UCEC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.86	5.5	0.41	1.67e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.71	-0.48	3.93e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06462663	chr19:18546047	ISYNA1	0.43	5.43	0.41	2.31e-7	Breast cancer;
UCEC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg27068330	chr11:65405492	SIPA1	-0.53	-4.71	-0.36	5.7e-6	Breast cancer;
UCEC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.79	-0.37	4.02e-6	Parkinson's disease;
UCEC	cis	rs7709377	0.621	rs10075195	chr5:115422705	A/G	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.21	0.39	6.36e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs6663390	0.510	rs2267895	chr1:208081063	C/T	cg03990033	chr1:208084030	CD34	0.52	4.95	0.38	1.97e-6	Facial morphology (factor 18);
UCEC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg24961523	chr17:36618985	ARHGAP23	-0.39	-4.64	-0.36	7.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.53	6.68	0.48	4.63e-10	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
UCEC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.6	-6.26	-0.46	4.03e-9	Crohn's disease;
UCEC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.48	-4.61	-0.36	8.55e-6	Obesity-related traits;
UCEC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.13	0.39	8.94e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.66	-0.36	7.07e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg08741688	chr4:3415352	RGS12	0.5	4.56	0.35	1.09e-5	Serum sulfate level;
UCEC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.6	6.6	0.48	7.04e-10	Resting heart rate;
UCEC	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.02	-0.64	2.46e-18	Height;
UCEC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg17420585	chr12:42539391	GXYLT1	-0.44	-5.53	-0.42	1.41e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.47	5.61	0.42	9.88e-8	Prostate cancer;
UCEC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.73	7.44	0.52	7.9e-12	Vitamin D levels;
UCEC	cis	rs354033	1.000	rs354042	chr7:149297104	A/G	cg24335155	chr7:149193227	ZNF746	0.39	4.74	0.36	4.98e-6	Multiple sclerosis;
UCEC	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.8	0.37	3.94e-6	Multiple sclerosis;
UCEC	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg15506890	chr2:3487001	NA	-0.55	-5.05	-0.38	1.29e-6	Neurofibrillary tangles;
UCEC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg06238570	chr21:40685208	BRWD1	0.89	8.3	0.56	6.31e-14	Cognitive function;
UCEC	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.56	5.94	0.44	1.97e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.67	-7.25	-0.51	2.15e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01065977	chr19:18549689	ISYNA1	0.33	4.63	0.36	7.87e-6	Breast cancer;
UCEC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-0.84	-9.62	-0.62	2.68e-17	Height;
UCEC	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.07	15.92	0.8	8.52e-34	Schizophrenia;
UCEC	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.07	-0.39	1.2e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.53	5.45	0.41	2.1e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.54	-4.87	-0.37	2.85e-6	Longevity;
UCEC	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.1	9.17	0.6	3.88e-16	Vitiligo;
UCEC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.83	9.39	0.61	1.08e-16	Breast cancer;
UCEC	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.2	8.46	0.57	2.48e-14	Atopic dermatitis;
UCEC	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.54	-5.1	-0.39	1.03e-6	Coronary artery disease;
UCEC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.63	-5.02	-0.38	1.5e-6	Obesity-related traits;
UCEC	cis	rs875971	0.651	rs313829	chr7:65552497	A/G	cg11764359	chr7:65958608	NA	-0.68	-4.96	-0.38	1.93e-6	Aortic root size;
UCEC	cis	rs970548	0.954	rs61854096	chr10:45981184	A/C	cg15223267	chr10:46222474	FAM21C	0.52	4.83	0.37	3.34e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.35	-5.54	-0.42	1.38e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00339695	chr16:24857497	SLC5A11	0.51	5.49	0.41	1.7e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.02e-6	Sudden cardiac arrest;
UCEC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg07153921	chr17:41440717	NA	-0.62	-7.51	-0.53	5.4e-12	Menopause (age at onset);
UCEC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18854424	chr1:2615690	NA	-0.35	-5.05	-0.38	1.27e-6	Ulcerative colitis;
UCEC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg06238570	chr21:40685208	BRWD1	0.85	5.87	0.44	2.8e-8	Cognitive function;
UCEC	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-4.88	-0.37	2.67e-6	Homocysteine levels;
UCEC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.5	5.3	0.4	4.15e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04374321	chr14:90722782	PSMC1	0.64	6.87	0.49	1.67e-10	Mortality in heart failure;
UCEC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg25828445	chr12:7781288	NA	-0.61	-5.05	-0.38	1.32e-6	HDL cholesterol levels;
UCEC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg04310649	chr10:35416472	CREM	-0.49	-4.88	-0.37	2.7e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg14092571	chr14:90743983	NA	-0.37	-4.76	-0.37	4.55e-6	Mortality in heart failure;
UCEC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.26	0.51	2.12e-11	Smoking behavior;
UCEC	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.5	5.08	0.39	1.14e-6	Testicular germ cell tumor;
UCEC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.68	5.94	0.44	2e-8	Cognitive function;
UCEC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.48	-5.02	-0.38	1.48e-6	Aortic root size;
UCEC	cis	rs7246967	0.673	rs12971914	chr19:22888898	A/T	cg05241461	chr19:22816980	ZNF492	0.58	6.12	0.45	7.93e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.65	-7.41	-0.52	9.01e-12	Menarche (age at onset);
UCEC	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg09238746	chr17:78121135	EIF4A3	-0.55	-5.67	-0.42	7.37e-8	Yeast infection;
UCEC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg06494592	chr3:125709126	NA	-0.58	-4.53	-0.35	1.23e-5	Blood pressure (smoking interaction);
UCEC	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.83	6.66	0.48	5.17e-10	Response to hepatitis C treatment;
UCEC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.88	9.75	0.63	1.28e-17	Breast cancer;
UCEC	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg18436246	chr17:1640651	WDR81	0.47	4.87	0.37	2.83e-6	Serum albumin level;
UCEC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.48	-6.66	-0.48	5.17e-10	Mortality in heart failure;
UCEC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.72	-6.76	-0.49	3e-10	Response to antineoplastic agents;
UCEC	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	0.94	5.67	0.42	7.24e-8	Gut microbiota (bacterial taxa);
UCEC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg20307385	chr11:47447363	PSMC3	-0.65	-4.68	-0.36	6.58e-6	Axial length;
UCEC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-5.37	-0.4	3.06e-7	Obesity-related traits;
UCEC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-9.41	-0.61	9.71e-17	Schizophrenia;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.56	-6.28	-0.46	3.53e-9	Pubertal anthropometrics;
UCEC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.57	6.41	0.47	1.85e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.74	-7.68	-0.54	2.08e-12	Lymphocyte counts;
UCEC	cis	rs6752107	0.935	rs10929325	chr2:234151031	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	6.83	0.49	2.11e-10	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.67	-6.26	-0.46	4.02e-9	Metabolite levels;
UCEC	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.92	-13.51	-0.74	1.47e-27	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.6	6.58	0.48	7.68e-10	Resting heart rate;
UCEC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg16616514	chr4:6324629	PPP2R2C	0.41	4.99	0.38	1.66e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.85	-9.3	-0.61	1.79e-16	Breast cancer;
UCEC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg24562669	chr7:97807699	LMTK2	0.74	11.07	0.67	4.21e-21	Breast cancer;
UCEC	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.53	-6.61	-0.48	6.59e-10	Total body bone mineral density;
UCEC	cis	rs7937612	1.000	rs7937612	chr11:120278688	T/C	cg12584626	chr11:120203529	NA	0.52	5.14	0.39	8.52e-7	Intraocular pressure;
UCEC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.7	0.58	6.06e-15	Alzheimer's disease;
UCEC	cis	rs7246967	0.736	rs2546463	chr19:22994606	C/G	cg24889512	chr19:22816950	ZNF492	0.5	4.75	0.36	4.78e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	7.41	0.52	9.4e-12	IgG glycosylation;
UCEC	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	5.23	0.4	5.67e-7	Blood protein levels;
UCEC	cis	rs78487399	0.908	rs76765584	chr2:43808034	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-4.84	-0.37	3.19e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs73206853	0.702	rs7960516	chr12:110529238	T/A	cg12870014	chr12:110450643	ANKRD13A	0.68	6.22	0.46	4.86e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs77926410	0.685	rs2417741	chr12:10620205	T/C	cg25023291	chr12:11339792	TAS2R42	-0.38	-4.8	-0.37	3.93e-6	Mean corpuscular volume;
UCEC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg06096015	chr1:231504339	EGLN1	0.42	4.84	0.37	3.24e-6	Hemoglobin concentration;
UCEC	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg14078730	chr11:63896557	MACROD1	0.7	4.76	0.37	4.55e-6	Mean platelet volume;
UCEC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.36	8.82e-6	Breast cancer;
UCEC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	6.29	0.46	3.49e-9	Cognitive test performance;
UCEC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs34486957	0.600	rs61249093	chr14:60043734	G/A	cg12189551	chr14:60952945	C14orf39	0.36	4.52	0.35	1.27e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.1	-0.56	1.99e-13	Total cholesterol levels;
UCEC	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	0.87	5.43	0.41	2.32e-7	Skin colour saturation;
UCEC	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-5.28	-0.4	4.66e-7	Kawasaki disease;
UCEC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.75	8.68	0.58	7.04e-15	Monocyte count;
UCEC	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs6688613	1.000	rs6688613	chr1:166951869	A/G	cg07049167	chr1:166818506	POGK	-0.42	-4.52	-0.35	1.27e-5	Refractive astigmatism;
UCEC	cis	rs7709377	0.597	rs7732346	chr5:115502248	A/T	cg23108291	chr5:115420582	COMMD10	0.52	5.35	0.4	3.37e-7	Metabolite levels  (X-11787);
UCEC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg23791538	chr6:167370224	RNASET2	0.5	5.41	0.41	2.55e-7	Primary biliary cholangitis;
UCEC	cis	rs79815064	0.850	rs76733709	chr3:46281461	G/A	cg19145607	chr3:45983792	CXCR6;FYCO1	0.71	4.69	0.36	6.16e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	trans	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg22166914	chr1:53195759	ZYG11B	0.46	4.64	0.36	7.67e-6	Monocyte count;
UCEC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.52	0.62	4.84e-17	Menopause (age at onset);
UCEC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.68	6.79	0.49	2.61e-10	Metabolic syndrome;
UCEC	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.95	7.36	0.52	1.21e-11	Multiple sclerosis;
UCEC	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg05660106	chr1:15850417	CASP9	0.99	11.32	0.68	9.48e-22	Systolic blood pressure;
UCEC	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.51	5.34	0.4	3.51e-7	Blood metabolite levels;
UCEC	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.7	-7.76	-0.54	1.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.69	0.42	6.7e-8	Lung cancer;
UCEC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.61	5.78	0.43	4.21e-8	Corneal astigmatism;
UCEC	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.45	4.99	0.38	1.7e-6	HDL cholesterol;
UCEC	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	4.67	0.36	6.83e-6	Personality dimensions;
UCEC	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.57	6.15	0.45	6.8e-9	Red blood cell count;
UCEC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	7.62	0.53	2.84e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.58	6.56	0.48	8.49e-10	Red blood cell count;
UCEC	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	0.96	5.51	0.41	1.56e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.61	6.07	0.45	1.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.64	6.65	0.48	5.39e-10	Mood instability;
UCEC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.61	-0.72	3.52e-25	Height;
UCEC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg03354898	chr7:1950403	MAD1L1	-0.55	-5.33	-0.4	3.58e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.63	-5.46	-0.41	1.99e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.64	6.1	0.45	8.97e-9	Aortic root size;
UCEC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg22166914	chr1:53195759	ZYG11B	0.76	8.05	0.55	2.55e-13	Monocyte count;
UCEC	cis	rs2386661	0.826	rs10795723	chr10:5675983	C/T	cg17085576	chr10:5658249	NA	-0.49	-5.01	-0.38	1.54e-6	Breast cancer;
UCEC	cis	rs9364220	0.794	rs9346650	chr6:168492963	C/T	cg09046490	chr6:168390201	NA	0.46	4.77	0.37	4.45e-6	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
UCEC	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.04	-0.38	1.32e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.55	5.33	0.4	3.58e-7	Breast cancer;
UCEC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.42	4.71	0.36	5.76e-6	Permanent tooth development;
UCEC	cis	rs925228	0.869	rs2712070	chr2:23985329	A/T	cg13272742	chr2:24272458	FKBP1B	0.56	5.0	0.38	1.6e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.53	-0.47	1e-9	Initial pursuit acceleration;
UCEC	cis	rs2267681	0.583	rs10253277	chr7:139525978	A/G	cg14116596	chr7:139528673	TBXAS1	0.55	5.34	0.4	3.5e-7	Cervical cancer;
UCEC	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	0.88	5.8	0.43	3.98e-8	Arsenic metabolism;
UCEC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.39	4.52	0.35	1.25e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.62	-5.32	-0.4	3.82e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.12	0.39	9.51e-7	IgG glycosylation;
UCEC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.9e-15	Height;
UCEC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.74	-7.8	-0.54	1.04e-12	Menarche (age at onset);
UCEC	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.51	-4.82	-0.37	3.62e-6	Smoking behavior;
UCEC	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.51	-6.27	-0.46	3.9e-9	Total body bone mineral density;
UCEC	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.7	6.21	0.46	5.09e-9	Triglycerides;
UCEC	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.61	-6.14	-0.45	7.32e-9	C-reactive protein levels;
UCEC	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg13092806	chr2:177043255	NA	0.55	5.13	0.39	9.17e-7	IgG glycosylation;
UCEC	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.49	5.11	0.39	9.97e-7	Vitiligo;
UCEC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg12024160	chr4:1254474	NA	0.53	6.86	0.49	1.83e-10	Obesity-related traits;
UCEC	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	0.75	10.42	0.65	2.21e-19	Gut microbiome composition (winter);
UCEC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.46	5.6	0.42	1.03e-7	Coronary artery disease;
UCEC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.49	-5.17	-0.39	7.52e-7	Longevity;
UCEC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03576123	chr11:487126	PTDSS2	-1.04	-7.77	-0.54	1.24e-12	Body mass index;
UCEC	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.53	-0.35	1.21e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-13.12	-0.73	1.59e-26	Ulcerative colitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09740319	chr1:231004641	C1orf198	0.6	6.89	0.49	1.49e-10	Warfarin maintenance dose;
UCEC	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.59	5.26	0.4	4.99e-7	Corneal astigmatism;
UCEC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.86	-0.37	2.97e-6	Height;
UCEC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-5.74	-0.43	5.29e-8	Bipolar disorder;
UCEC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg21770322	chr7:97807741	LMTK2	-0.51	-6.1	-0.45	9.11e-9	Breast cancer;
UCEC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg06157570	chr12:6886703	LAG3	0.46	4.51	0.35	1.34e-5	HDL cholesterol levels;
UCEC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.76	9.35	0.61	1.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.6	0.58	1.1e-14	Prudent dietary pattern;
UCEC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-7.04	-0.5	6.84e-11	Cognitive function;
UCEC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg05347473	chr6:146136440	FBXO30	-0.53	-6.06	-0.45	1.07e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.7	7.92	0.55	5.38e-13	Menopause (age at onset);
UCEC	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg04155231	chr12:9217510	LOC144571	0.4	4.98	0.38	1.73e-6	Sjögren's syndrome;
UCEC	cis	rs8105895	0.877	rs62112919	chr19:22227145	T/C	cg24175803	chr19:22235144	ZNF257	-0.64	-5.51	-0.41	1.59e-7	Body mass index (change over time);
UCEC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.76	-7.41	-0.52	9.32e-12	Initial pursuit acceleration;
UCEC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18932078	chr1:2524107	MMEL1	-0.33	-5.43	-0.41	2.25e-7	Ulcerative colitis;
UCEC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg17420585	chr12:42539391	GXYLT1	0.4	5.14	0.39	8.8e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.51	4.64	0.36	7.65e-6	Aortic root size;
UCEC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-4.83	-0.37	3.39e-6	Tonsillectomy;
UCEC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg07636037	chr3:49044803	WDR6	-0.61	-4.82	-0.37	3.61e-6	Menarche (age at onset);
UCEC	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.3	-0.56	6.27e-14	Prevalent atrial fibrillation;
UCEC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.48	5.42	0.41	2.35e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.6	6.53	0.47	9.9e-10	Noise-induced hearing loss;
UCEC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.51	5.78	0.43	4.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6460942	0.730	rs73053536	chr7:12323131	C/G	cg06484146	chr7:12443880	VWDE	-0.83	-5.62	-0.42	9.14e-8	Coronary artery disease;
UCEC	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.49	5.37	0.41	3e-7	Platelet distribution width;
UCEC	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	0.95	7.9	0.55	5.91e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-5.37	-0.41	2.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.64	5.54	0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs7246967	0.866	rs12984122	chr19:23030674	G/A	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.53e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.96	0.38	1.9e-6	Personality dimensions;
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg20821713	chr7:1055600	C7orf50	-0.53	-5.27	-0.4	4.7e-7	Longevity;Endometriosis;
UCEC	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.85	12.3	0.71	2.38e-24	Leprosy;
UCEC	cis	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg12524725	chr2:239427019	NA	-0.67	-4.59	-0.35	9.6e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg07386859	chr16:1872102	HAGH	-0.5	-5.45	-0.41	2.05e-7	Insulin-like growth factors;
UCEC	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.88	-6.9	-0.49	1.45e-10	Multiple sclerosis;
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.65	0.42	8.09e-8	Platelet count;
UCEC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.85	-9.18	-0.6	3.62e-16	Cognitive function;
UCEC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-6.58	-0.48	7.83e-10	Chronic sinus infection;
UCEC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.44	0.61	7.71e-17	Cognitive function;
UCEC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.5	-5.48	-0.41	1.8e-7	Aortic root size;
UCEC	cis	rs2267681	0.583	rs764745	chr7:139529928	G/C	cg14116596	chr7:139528673	TBXAS1	0.51	5.03	0.38	1.4e-6	Cervical cancer;
UCEC	cis	rs7594321	0.901	rs6754310	chr2:230205624	A/G	cg20728704	chr2:230923774	SLC16A14	-0.5	-5.34	-0.4	3.49e-7	Pulmonary function (smoking interaction);
UCEC	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.46	-4.84	-0.37	3.19e-6	Body mass index;
UCEC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.22	-0.4	6.06e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.1	0.56	1.9e-13	Electrocardiographic conduction measures;
UCEC	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-4.94	-0.38	2.09e-6	Chronic sinus infection;
UCEC	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.74	7.56	0.53	4.09e-12	Parkinson's disease;
UCEC	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg01072550	chr1:21505969	NA	-0.6	-6.34	-0.46	2.62e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.73	-0.43	5.62e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.84	-0.43	3.15e-8	Depression;
UCEC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.42	-5.5	-0.41	1.67e-7	Monocyte count;
UCEC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11118844	0.696	rs11118859	chr1:221953193	A/T	cg04222084	chr1:221915650	DUSP10	-0.82	-5.79	-0.43	4.1e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.69	-7.49	-0.53	5.79e-12	Breast cancer;
UCEC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.73	-8.0	-0.55	3.45e-13	Menarche (age at onset);
UCEC	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.12	0.45	8.19e-9	Menarche (age at onset);
UCEC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.71	6.12	0.45	8.18e-9	Menopause (age at onset);
UCEC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.99	-11.5	-0.69	3.14e-22	Cognitive function;
UCEC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.47	-5.13	-0.39	8.86e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.67	-7.08	-0.5	5.36e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.61	5.96	0.44	1.76e-8	Lymphocyte counts;
UCEC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg11871910	chr12:69753446	YEATS4	0.89	10.31	0.65	4.27e-19	Blood protein levels;
UCEC	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.74	4.64	0.36	7.69e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7968440	0.808	rs7958114	chr12:51190692	C/T	cg00552387	chr12:51477546	CSRNP2	0.55	4.63	0.36	7.89e-6	Fibrinogen;
UCEC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.54	-4.53	-0.35	1.2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg00343986	chr7:65444356	GUSB	-0.52	-4.68	-0.36	6.41e-6	Aortic root size;
UCEC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18876405	chr7:65276391	NA	0.46	4.61	0.36	8.5e-6	Aortic root size;
UCEC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg15167202	chr5:149997153	SYNPO	-0.37	-4.6	-0.35	9.05e-6	HIV-1 control;
UCEC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01380346	chr19:18557039	ELL	-0.49	-5.09	-0.39	1.09e-6	Breast cancer;
UCEC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-4.71	-0.36	5.7e-6	Colorectal cancer;
UCEC	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.54	5.0	0.38	1.6e-6	Platelet distribution width;
UCEC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.49	4.74	0.36	5.1e-6	Vitiligo;
UCEC	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.46	4.73	0.36	5.23e-6	Schizophrenia;
UCEC	cis	rs17789174	0.951	rs12596553	chr16:85104752	G/T	cg01876612	chr16:85045424	ZDHHC7	0.62	4.52	0.35	1.29e-5	Dysphagia;
UCEC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.88	9.75	0.63	1.28e-17	Breast cancer;
UCEC	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.69	4.65	0.36	7.23e-6	Multiple sclerosis;
UCEC	cis	rs10924970	0.967	rs2152953	chr1:235417801	T/A	cg26050004	chr1:235667680	B3GALNT2	0.49	4.96	0.38	1.91e-6	Asthma;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.7	-7.64	-0.53	2.63e-12	Paraoxonase activity;
UCEC	cis	rs7088591	0.867	rs4503485	chr10:59780742	A/G	cg11142981	chr10:60273225	BICC1	0.64	4.59	0.35	9.34e-6	Blood pressure;
UCEC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.62	6.31	0.46	3.17e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.61	-4.73	-0.36	5.16e-6	Diabetic retinopathy;
UCEC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.69	6.74	0.49	3.33e-10	Colorectal cancer;
UCEC	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg03711944	chr11:47377212	SPI1	-0.51	-4.71	-0.36	5.77e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg01973587	chr1:228161476	NA	0.37	4.78	0.37	4.16e-6	Diastolic blood pressure;
UCEC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.46	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs12644436	0.965	rs10024946	chr4:88790584	A/G	cg27179352	chr4:88029472	AFF1	0.41	4.52	0.35	1.27e-5	HIV-1 viral setpoint;
UCEC	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.45	-4.66	-0.36	7.12e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.82	-0.43	3.5e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-6.42	-0.47	1.75e-9	Platelet distribution width;
UCEC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.48	5.5	0.41	1.61e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg22563815	chr15:78856949	CHRNA5	-0.36	-4.85	-0.37	3.05e-6	Sudden cardiac arrest;
UCEC	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs7113850	0.541	rs7129839	chr11:24208606	C/T	ch.11.24196551F	chr11:24239977	NA	0.67	4.92	0.38	2.29e-6	Bone fracture in osteoporosis;
UCEC	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.24	-0.4	5.44e-7	Mean corpuscular volume;
UCEC	cis	rs6690583	0.623	rs12042160	chr1:85504516	A/G	cg11262906	chr1:85462892	MCOLN2	0.76	4.78	0.37	4.12e-6	Serum sulfate level;
UCEC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg04553112	chr3:125709451	NA	-0.73	-5.07	-0.39	1.18e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.67	7.68	0.54	2.04e-12	Mean corpuscular volume;
UCEC	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-5.43	-0.41	2.32e-7	Morning vs. evening chronotype;
UCEC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.18	0.51	3.2e-11	Homoarginine levels;
UCEC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18932078	chr1:2524107	MMEL1	0.4	6.31	0.46	3.08e-9	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs151997	0.962	rs27612	chr5:50179120	G/A	cg06027927	chr5:50259733	NA	0.54	4.97	0.38	1.83e-6	Callous-unemotional behaviour;
UCEC	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.32	4.89	0.37	2.57e-6	Ulcerative colitis;
UCEC	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg26781129	chr3:44753946	ZNF502	-0.47	-5.16	-0.39	7.9e-7	Depressive symptoms;
UCEC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.61	-5.78	-0.43	4.28e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.47	0.41	1.89e-7	Breast cancer;
UCEC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs11190179	1.000	rs4919367	chr10:101366816	G/A	cg14256752	chr10:102295592	HIF1AN	-0.76	-4.54	-0.35	1.16e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
UCEC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.61	5.57	0.42	1.17e-7	Morning vs. evening chronotype;
UCEC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.78	8.28	0.56	7e-14	Blood protein levels;
UCEC	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.57	5.53	0.42	1.41e-7	Coronary artery disease;
UCEC	cis	rs3914502	0.593	rs482248	chr3:174499573	A/C	cg21145449	chr3:174580620	NAALADL2	-0.41	-4.66	-0.36	7e-6	Autism spectrum disorder;
UCEC	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.42	-5.34	-0.4	3.54e-7	Obesity-related traits;
UCEC	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.15	-8.94	-0.59	1.48e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	6.8	0.49	2.44e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.84	-7.4	-0.52	9.83e-12	Vitiligo;
UCEC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.16	-14.28	-0.76	1.46e-29	Breast cancer;
UCEC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.54	5.78	0.43	4.22e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg04202892	chr2:111875749	ACOXL	0.44	5.14	0.39	8.6e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.26	-0.4	4.94e-7	Metabolite levels;
UCEC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.21e-5	Parkinson's disease;
UCEC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg21770322	chr7:97807741	LMTK2	0.46	5.87	0.44	2.77e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg11632617	chr15:75315747	PPCDC	-0.58	-6.74	-0.49	3.38e-10	Blood trace element (Zn levels);
UCEC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.73	-0.36	5.11e-6	Parkinson's disease;
UCEC	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-1.09	-8.12	-0.56	1.74e-13	Height;
UCEC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.37	-8.68	-0.58	7.08e-15	Diabetic kidney disease;
UCEC	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.76	7.92	0.55	5.45e-13	Breast cancer;
UCEC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.09	0.45	9.59e-9	Rheumatoid arthritis;
UCEC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	0.8	5.04	0.38	1.32e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-8.15	-0.56	1.47e-13	Response to antipsychotic treatment;
UCEC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.65	5.47	0.41	1.91e-7	Cocaine dependence;
UCEC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs34091558	1	rs34091558	chr1:201886769	TA/T	cg26349606	chr1:201857840	SHISA4	-0.55	-4.51	-0.35	1.32e-5	Breast size;
UCEC	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.8	-0.37	3.9e-6	Height;
UCEC	cis	rs1919796	0.760	rs2699144	chr7:9289938	G/A	cg27477025	chr7:9765726	NA	-0.45	-4.97	-0.38	1.8e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.7	6.76	0.49	3.09e-10	Plateletcrit;Platelet count;
UCEC	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.48	-4.54	-0.35	1.15e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.92	8.3	0.57	6.02e-14	Bladder cancer;
UCEC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg23018236	chr17:30244563	NA	-0.67	-4.65	-0.36	7.34e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.88	8.39	0.57	3.66e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.46	-5.97	-0.44	1.69e-8	IgG glycosylation;
UCEC	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg00339695	chr16:24857497	SLC5A11	-0.42	-4.5	-0.35	1.36e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9283706	0.608	rs10053537	chr5:66332543	T/C	cg11590213	chr5:66331682	MAST4	0.45	5.81	0.43	3.82e-8	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.47	-5.4	-0.41	2.67e-7	Subjective well-being;
UCEC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.61	-5.25	-0.4	5.25e-7	Gut microbiome composition (summer);
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.36	0.46	2.41e-9	Platelet count;
UCEC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.39	-0.52	1.02e-11	Breast cancer;
UCEC	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg19554555	chr3:13937349	NA	-0.56	-5.81	-0.43	3.72e-8	Ovarian reserve;
UCEC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.45	-5.18	-0.39	7.21e-7	Total body bone mineral density;
UCEC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.51	5.26	0.4	5.1e-7	Colorectal cancer;
UCEC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.51	-5.19	-0.39	6.76e-7	Mortality in heart failure;
UCEC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg23625390	chr15:77176239	SCAPER	0.46	4.6	0.36	8.86e-6	Blood metabolite levels;
UCEC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.8	-5.57	-0.42	1.17e-7	Rheumatoid arthritis;
UCEC	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.4	-4.74	-0.36	4.94e-6	Multiple myeloma;
UCEC	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.67	-6.49	-0.47	1.26e-9	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.64	5.98	0.44	1.59e-8	Aortic root size;
UCEC	cis	rs7611694	0.609	rs10934228	chr3:113099461	C/G	cg12596171	chr3:113251061	SIDT1	0.58	5.92	0.44	2.13e-8	Prostate cancer;
UCEC	cis	rs72700829	0.593	rs4418603	chr1:150989274	A/G	cg00107782	chr1:151300621	NA	-0.67	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs7246967	0.608	rs453175	chr19:23014087	A/G	cg05241461	chr19:22816980	ZNF492	0.45	4.55	0.35	1.12e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs9341808	0.622	rs682482	chr6:80961139	A/G	cg08355045	chr6:80787529	NA	-0.36	-4.67	-0.36	6.79e-6	Sitting height ratio;
UCEC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.59	7.16	0.51	3.49e-11	Age at first birth;
UCEC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg23795048	chr12:9217529	LOC144571	0.42	4.97	0.38	1.86e-6	Sjögren's syndrome;
UCEC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18252515	chr7:66147081	NA	0.52	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg13683864	chr3:40499215	RPL14	-0.61	-6.75	-0.49	3.21e-10	Renal cell carcinoma;
UCEC	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-5.19	-0.39	6.74e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.55	7.89	0.55	6.32e-13	Total body bone mineral density;
UCEC	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	6.71	0.48	4e-10	Hip circumference;
UCEC	cis	rs3956705	1.000	rs35500246	chr7:32971773	C/T	cg05721444	chr7:32995514	FKBP9	-0.49	-4.9	-0.37	2.52e-6	Red cell distribution width;
UCEC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.62	6.01	0.44	1.43e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg24562669	chr7:97807699	LMTK2	0.48	5.79	0.43	4.2e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg22857025	chr5:266934	NA	-0.89	-8.36	-0.57	4.33e-14	Breast cancer;
UCEC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.43	-4.83	-0.37	3.46e-6	Prostate cancer;
UCEC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg20821713	chr7:1055600	C7orf50	0.56	5.92	0.44	2.19e-8	Longevity;Endometriosis;
UCEC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.78	-8.65	-0.58	8.34e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs2179367	0.887	rs2143076	chr6:149746451	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.37	-5.25	-0.4	5.32e-7	Dupuytren's disease;
UCEC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.51	5.24	0.4	5.37e-7	Vitiligo;
UCEC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.55	-5.0	-0.38	1.59e-6	Coronary artery disease;
UCEC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.5	4.7	0.36	5.83e-6	Gut microbiome composition (summer);
UCEC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22857025	chr5:266934	NA	-0.91	-7.57	-0.53	3.72e-12	Breast cancer;
UCEC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.51	-4.74	-0.36	5e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.64	-5.85	-0.43	3e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	6.22	0.46	4.79e-9	Hip circumference;
UCEC	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.62	4.79	0.37	4.02e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs56281245	1.000	rs7711332	chr5:145040920	A/T	cg14510905	chr5:145040858	NA	0.54	5.07	0.39	1.19e-6	Hepcidin levels;
UCEC	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg05660106	chr1:15850417	CASP9	0.49	4.72	0.36	5.33e-6	Systolic blood pressure;
UCEC	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg03748352	chr10:182365	ZMYND11	0.55	4.53	0.35	1.2e-5	Uric acid levels;
UCEC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.68	5.94	0.44	2e-8	Cognitive function;
UCEC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.54	5.45	0.41	2.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05472934	chr7:22766657	IL6	0.75	7.46	0.52	7.12e-12	Lung cancer;
UCEC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.38	-4.52	-0.35	1.29e-5	Abdominal aortic aneurysm;
UCEC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-5.38	-0.41	2.83e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.59	5.32	0.4	3.72e-7	Corneal astigmatism;
UCEC	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.91	0.5	1.38e-10	Ileal carcinoids;
UCEC	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.72	7.94	0.55	4.71e-13	Primary sclerosing cholangitis;
UCEC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg12850546	chr22:42539477	CYP2D7P1	-0.75	-5.99	-0.44	1.53e-8	Birth weight;
UCEC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.17	6.54	0.47	9.36e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.12	-0.45	7.9e-9	Aortic root size;
UCEC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.58	-4.68	-0.36	6.39e-6	Obesity-related traits;
UCEC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.42	0.41	2.41e-7	Prudent dietary pattern;
UCEC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg20007245	chr22:24372913	LOC391322	-0.57	-6.07	-0.45	1.01e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-4.9	-0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.75	8.25	0.56	8.34e-14	Menopause (age at onset);
UCEC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.49	5.23	0.4	5.72e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7088591	0.764	rs11819380	chr10:59789178	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs6763768	0.606	rs13082092	chr3:53373204	T/G	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.51	-5.57	-0.42	1.15e-7	Educational attainment;
UCEC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.5	-0.41	1.62e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.36	5.93	0.44	2.06e-8	Cancer;
UCEC	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.36	4.81	0.37	3.77e-6	Breast cancer;
UCEC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.9	-0.37	2.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.52	0.47	1.03e-9	Bladder cancer;
UCEC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg12436631	chr1:155007014	DCST1;DCST2	-0.35	-4.6	-0.35	9.06e-6	Prostate cancer;
UCEC	cis	rs17122693	1.000	rs35014209	chr14:51054598	A/G	cg04730355	chr14:51134070	SAV1	0.87	8.72	0.58	5.33e-15	Cognitive performance;
UCEC	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.76	7.04	0.5	6.65e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-4.83	-0.37	3.32e-6	Hemoglobin concentration;
UCEC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.79	-0.43	4.05e-8	Obesity-related traits;
UCEC	cis	rs295140	0.535	rs1975583	chr2:201225902	A/C	cg04283868	chr2:201171347	SPATS2L	0.54	4.61	0.36	8.8e-6	QT interval;
UCEC	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.37	-0.46	2.32e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-0.69	-8.19	-0.56	1.15e-13	Blood trace element (Zn levels);
UCEC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.16	-0.39	7.71e-7	Mean platelet volume;
UCEC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg06781209	chr11:61594997	FADS2	-0.49	-4.73	-0.36	5.24e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.64	-6.16	-0.45	6.54e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	4.68	0.36	6.54e-6	Diabetic retinopathy;
UCEC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-6.04	-0.45	1.21e-8	Chronic sinus infection;
UCEC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.44	5.11	0.39	9.66e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs10823500	0.545	rs7082562	chr10:71945684	A/G	cg19602370	chr10:72539427	C10orf27	-0.41	-4.59	-0.35	9.33e-6	Blood protein levels;
UCEC	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-6.15	-0.45	6.95e-9	Total cholesterol levels;
UCEC	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg19610905	chr11:61596333	FADS2	-0.7	-6.72	-0.48	3.77e-10	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.47	4.85	0.37	3.07e-6	Smoking initiation;
UCEC	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg13683864	chr3:40499215	RPL14	-0.51	-5.13	-0.39	9.19e-7	Renal cell carcinoma;
UCEC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-6.17	-0.45	6.34e-9	Birth weight;
UCEC	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.03	-8.74	-0.58	4.99e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.77	5.76	0.43	4.69e-8	Exhaled nitric oxide levels;
UCEC	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg19743168	chr1:23544995	NA	0.43	5.97	0.44	1.69e-8	Height;
UCEC	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.62	5.35	0.4	3.37e-7	Ulcerative colitis;
UCEC	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.5	-5.53	-0.41	1.43e-7	Facial morphology (factor 20);
UCEC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg11632617	chr15:75315747	PPCDC	-0.63	-7.48	-0.52	6.36e-12	Lung cancer;
UCEC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.6	7.33	0.52	1.42e-11	Menopause (age at onset);
UCEC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-0.68	-7.94	-0.55	4.68e-13	Blood trace element (Zn levels);
UCEC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	0.95	12.02	0.7	1.34e-23	Homoarginine levels;
UCEC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-7.02	-0.5	7.74e-11	Dental caries;
UCEC	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.57	5.82	0.43	3.5e-8	Hepatocellular carcinoma;
UCEC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg27124370	chr19:33622961	WDR88	0.55	5.06	0.39	1.21e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2288327	0.673	rs35504893	chr2:179421294	C/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.57	-4.59	-0.35	9.47e-6	Atrial fibrillation;
UCEC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg20965017	chr5:231967	SDHA	-0.62	-5.36	-0.4	3.17e-7	Breast cancer;
UCEC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.79	6.91	0.5	1.34e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.66	7.75	0.54	1.39e-12	Schizophrenia;
UCEC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.62	6.71	0.48	3.93e-10	Body mass index;
UCEC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.7	6.78	0.49	2.75e-10	Schizophrenia;
UCEC	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.43	-5.85	-0.43	3.02e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.67	6.61	0.48	6.67e-10	Gestational age at birth (maternal effect);
UCEC	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.74	7.8	0.54	1.04e-12	Eosinophil percentage of white cells;
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.56	-6.38	-0.47	2.17e-9	Depression;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.69	0.58	6.39e-15	Platelet count;
UCEC	cis	rs4509693	0.882	rs7900763	chr10:102492559	A/C	cg24127310	chr10:102502104	NA	0.8	6.69	0.48	4.44e-10	Alzheimer's disease;
UCEC	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.74	-4.7	-0.36	5.94e-6	Night sleep phenotypes;
UCEC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg06134567	chr22:46658398	PKDREJ	-0.45	-4.51	-0.35	1.32e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg15242686	chr22:24348715	GSTTP1	0.52	5.43	0.41	2.27e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	5.83	0.43	3.42e-8	IgG glycosylation;
UCEC	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.55	-8.12	-0.56	1.7e-13	Height;
UCEC	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-5.69	-0.42	6.67e-8	Total cholesterol levels;
UCEC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs2179367	0.887	rs6570965	chr6:149717476	C/A	cg16235748	chr6:149772707	ZC3H12D	-0.35	-4.71	-0.36	5.63e-6	Dupuytren's disease;
UCEC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.51	-4.81	-0.37	3.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24308560	chr3:49941425	MST1R	0.54	6.2	0.46	5.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10208940	0.920	rs7580719	chr2:68833572	A/G	cg12452813	chr2:68675892	NA	-0.48	-4.63	-0.36	7.91e-6	Urate levels in lean individuals;
UCEC	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg21231944	chr12:82153410	PPFIA2	-0.44	-4.58	-0.35	9.93e-6	Resting heart rate;
UCEC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg27624424	chr6:160112604	SOD2	0.57	5.39	0.41	2.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.11	9.34	0.61	1.39e-16	Corneal structure;
UCEC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg13777783	chr17:79615861	NA	-0.32	-4.55	-0.35	1.12e-5	Eye color traits;
UCEC	cis	rs2213920	0.516	rs6415818	chr9:118210588	A/G	cg13918206	chr9:118159781	DEC1	0.67	4.76	0.37	4.58e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.34	0.61	1.45e-16	Blood protein levels;
UCEC	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.6	-6.93	-0.5	1.22e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9739682	0.636	rs10877797	chr12:62523278	T/C	cg10081664	chr12:62102663	FAM19A2	-0.48	-4.65	-0.36	7.22e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs7611694	0.501	rs6438140	chr3:113064394	A/C	cg12596171	chr3:113251061	SIDT1	-0.52	-5.4	-0.41	2.68e-7	Prostate cancer;
UCEC	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	0.85	10.24	0.65	6.58e-19	Blood protein levels;
UCEC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.74	0.43	5.29e-8	Platelet count;
UCEC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.62	-6.37	-0.47	2.26e-9	Platelet distribution width;
UCEC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.48	-4.77	-0.37	4.37e-6	Dental caries;
UCEC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13683864	chr3:40499215	RPL14	-1.0	-10.24	-0.65	6.75e-19	Renal cell carcinoma;
UCEC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.64	7.6	0.53	3.3e-12	Obesity-related traits;
UCEC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.66	-0.42	7.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.7	-0.36	5.85e-6	Breast cancer;
UCEC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.91	11.53	0.69	2.55e-22	Metabolic syndrome;
UCEC	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.54	4.55	0.35	1.1e-5	Obesity-related traits;
UCEC	cis	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg20307385	chr11:47447363	PSMC3	0.5	4.57	0.35	1.03e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.29	-0.56	6.44e-14	Chronic sinus infection;
UCEC	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg04553112	chr3:125709451	NA	-0.69	-4.85	-0.37	3.07e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7070678	0.615	rs7909079	chr10:29799335	T/C	cg07724896	chr10:29780678	SVIL	-0.54	-4.52	-0.35	1.27e-5	Platelet thrombus formation;
UCEC	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.14	10.69	0.66	4.37e-20	Corneal structure;
UCEC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.87	9.61	0.62	2.84e-17	Parkinson's disease;
UCEC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	-0.57	-6.53	-0.47	9.88e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg05660106	chr1:15850417	CASP9	0.93	10.13	0.64	1.3e-18	Systolic blood pressure;
UCEC	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.32	-0.4	3.73e-7	Bone mineral density;
UCEC	cis	rs2029213	0.523	rs3773739	chr3:53268429	A/G	cg16894138	chr3:53270350	TKT	-0.41	-5.23	-0.4	5.72e-7	Heart rate;
UCEC	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.53	5.41	0.41	2.5e-7	Retinal vascular caliber;
UCEC	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.52	5.57	0.42	1.2e-7	Schizophrenia;
UCEC	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg18681998	chr4:17616180	MED28	0.76	8.68	0.58	6.98e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-6.33	-0.46	2.84e-9	Coffee consumption (cups per day);
UCEC	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.75	5.68	0.42	7.04e-8	Exhaled nitric oxide output;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg01689657	chr7:91764605	CYP51A1	0.5	6.47	0.47	1.38e-9	Breast cancer;
UCEC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	4.95	0.38	1.98e-6	IgG glycosylation;
UCEC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.56	0.42	1.26e-7	Hemoglobin concentration;
UCEC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.72	-7.23	-0.51	2.51e-11	Aortic root size;
UCEC	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.72	6.35	0.46	2.59e-9	Coronary artery disease;
UCEC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	5.92	0.44	2.21e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.53	-4.68	-0.36	6.59e-6	Migraine;Coronary artery disease;
UCEC	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.88e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs57968458	1.000	rs57968458	chr17:16820099	G/A	cg27492451	chr17:16520367	NA	-0.7	-5.49	-0.41	1.68e-7	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;
UCEC	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg18681998	chr4:17616180	MED28	0.73	8.61	0.58	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.58	-7.44	-0.52	7.63e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.76	6.14	0.45	7.17e-9	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	8.97	0.59	1.23e-15	Chronic sinus infection;
UCEC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	0.49	4.71	0.36	5.58e-6	Lewy body disease;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.38	-0.41	2.91e-7	Pubertal anthropometrics;
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg20119798	chr7:94954144	PON1	-0.5	-4.75	-0.36	4.77e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	7.65	0.53	2.41e-12	Tonsillectomy;
UCEC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.68	8.25	0.56	8.11e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.49	5.49	0.41	1.71e-7	Dental caries;
UCEC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.84	0.43	3.28e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg24687543	chr11:63912206	MACROD1	0.56	4.57	0.35	1.02e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-5.25	-0.4	5.31e-7	Morning vs. evening chronotype;
UCEC	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.43	-0.41	2.32e-7	Bipolar disorder;
UCEC	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.2	7.51	0.53	5.28e-12	Atopic dermatitis;
UCEC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-5.93	-0.44	2.1e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.22	0.4	6.05e-7	Cognitive test performance;
UCEC	cis	rs11760485	0.965	rs5021672	chr7:4399743	A/C	cg15613991	chr7:5277080	NA	-0.4	-4.86	-0.37	3e-6	Early childhood aggressive behavior;
UCEC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.83	9.21	0.6	3.08e-16	Breast cancer;
UCEC	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.44	4.62	0.36	8.4e-6	Schizophrenia;
UCEC	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.63	4.77	0.37	4.36e-6	Lymphocyte counts;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.49	-5.48	-0.41	1.81e-7	Pulmonary function;
UCEC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.57	5.13	0.39	9.09e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-8.66	-0.58	7.94e-15	Exhaled nitric oxide output;
UCEC	cis	rs2415984	0.846	rs12886911	chr14:46834994	T/C	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.72	7.14	0.51	3.99e-11	Parkinson's disease;
UCEC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.63	7.54	0.53	4.44e-12	Obesity-related traits;
UCEC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg04154034	chr17:28927549	LRRC37B2	0.78	4.89	0.37	2.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13939156	chr17:80058883	NA	0.36	4.58	0.35	9.65e-6	Life satisfaction;
UCEC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.44	-0.47	1.59e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.56	-6.34	-0.46	2.64e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg20368463	chr18:77673604	PQLC1	-0.63	-5.62	-0.42	9.35e-8	Opioid sensitivity;
UCEC	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.53	5.14	0.39	8.74e-7	Coronary artery disease;
UCEC	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.65	6.05	0.45	1.12e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.93e-9	Motion sickness;
UCEC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.49	-0.57	2.06e-14	Blood trace element (Zn levels);
UCEC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.15	15.6	0.79	5.45e-33	Cognitive function;
UCEC	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-4.79	-0.37	4.08e-6	Platelet distribution width;
UCEC	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9463078	0.547	rs116177834	chr6:44738548	C/A	cg25276700	chr6:44698697	NA	0.43	4.84	0.37	3.2e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-4.9	-0.37	2.51e-6	Life satisfaction;
UCEC	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs12681287	0.752	rs7822268	chr8:87306440	G/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.29	-0.46	3.36e-9	Caudate activity during reward;
UCEC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.46	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.24	-0.46	4.51e-9	Menarche (age at onset);
UCEC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-7.28	-0.52	1.82e-11	Cognitive function;
UCEC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.42	4.74	0.36	4.9100000000000004e-06	Schizophrenia;
UCEC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.58	-8.27	-0.56	7.52e-14	Total body bone mineral density;
UCEC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg04804543	chr8:142233427	SLC45A4	-0.52	-6.26	-0.46	3.95e-9	Immature fraction of reticulocytes;
UCEC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.58	0.35	9.8200000000000008e-06	Parkinson's disease;
UCEC	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.34	5.03	0.38	1.4e-6	Schizophrenia;
UCEC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.28	-0.46	3.66e-9	Personality dimensions;
UCEC	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg05206910	chr17:80230660	CSNK1D	-0.42	-4.51	-0.35	1.34e-5	Breast cancer;
UCEC	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.68	7.62	0.53	2.81e-12	Blood metabolite levels;
UCEC	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.64	5.39	0.41	2.78e-7	Bipolar disorder;
UCEC	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.43	4.64	0.36	7.79e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.39	6.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg05962950	chr11:130786565	SNX19	0.47	5.03	0.38	1.43e-6	Schizophrenia;
UCEC	cis	rs56050415	0.737	rs55760919	chr15:58560116	T/G	cg16896313	chr15:58552619	NA	0.43	4.68	0.36	6.55e-6	Metabolite levels (lipoprotein measures);
UCEC	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.56	5.67	0.42	7.22e-8	Testicular germ cell tumor;
UCEC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.45	-0.41	2.1e-7	Obesity-related traits;
UCEC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.72	-0.7	8.05e-23	Coronary artery disease;
UCEC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg13334819	chr7:99746414	C7orf59	-0.57	-5.35	-0.4	3.35e-7	Coronary artery disease;
UCEC	cis	rs10743315	0.778	rs7397459	chr12:19377578	C/G	cg02471346	chr12:19282374	PLEKHA5	0.55	5.53	0.41	1.45e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.6	7.11	0.51	4.71e-11	Metabolite levels;
UCEC	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	0.87	5.29	0.4	4.37e-7	Blood protein levels;
UCEC	cis	rs4654899	0.897	rs7545133	chr1:21206143	T/G	cg01072550	chr1:21505969	NA	0.51	5.09	0.39	1.1e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-0.72	-7.0	-0.5	8.64e-11	Breast cancer;
UCEC	cis	rs13401104	0.796	rs72620807	chr2:237114205	T/G	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.87	0.54	7.09e-13	Bipolar disorder;
UCEC	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.68	5.86	0.43	2.97e-8	Obesity (extreme);
UCEC	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.5	7.2	0.51	2.94e-11	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.93	-0.55	4.99e-13	Total cholesterol levels;
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg09120320	chr17:61926383	NA	0.44	4.5	0.35	1.35e-5	Prudent dietary pattern;
UCEC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.48	4.89	0.37	2.63e-6	Aortic root size;
UCEC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.71	8.9	0.59	1.95e-15	Mean platelet volume;
UCEC	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg13575925	chr12:9217583	LOC144571	0.4	4.68	0.36	6.55e-6	Sjögren's syndrome;
UCEC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-8.2	-0.56	1.11e-13	Gut microbiome composition (summer);
UCEC	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.78	0.43	4.26e-8	Height;
UCEC	cis	rs1468333	1.000	rs4835669	chr5:137473391	G/A	cg07848042	chr5:137667509	CDC25C	0.44	4.51	0.35	1.32e-5	Resting heart rate;
UCEC	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.54	-5.99	-0.44	1.51e-8	Pubertal anthropometrics;
UCEC	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.59	5.29	0.4	4.37e-7	Triglycerides;
UCEC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13683864	chr3:40499215	RPL14	-0.97	-10.02	-0.64	2.47e-18	Renal cell carcinoma;
UCEC	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.77	7.06	0.5	6.01e-11	Morning vs. evening chronotype;
UCEC	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg13695892	chr22:41940480	POLR3H	0.44	4.5	0.35	1.36e-5	Vitiligo;
UCEC	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.42	-4.87	-0.37	2.89e-6	Alcohol dependence;
UCEC	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2281636	0.754	rs4919364	chr10:101364704	G/T	cg02343648	chr10:102133165	C10orf75	0.51	5.26	0.4	4.94e-7	Obesity-related traits;
UCEC	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.14	12.17	0.71	5.35e-24	Opioid sensitivity;
UCEC	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-4.54	-0.35	1.17e-5	Alzheimer's disease (late onset);
UCEC	cis	rs7560272	0.501	rs12713793	chr2:73956114	T/C	cg20560298	chr2:73613845	ALMS1	0.51	4.82	0.37	3.52e-6	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.8e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12935418	0.616	rs11863536	chr16:80969674	C/T	cg22734315	chr16:81069742	ATMIN	0.67	4.64	0.36	7.58e-6	Mean corpuscular volume;
UCEC	cis	rs2200578	1.000	rs60025964	chr2:99880577	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.83	5.4	0.41	2.59e-7	IgG glycosylation;
UCEC	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	0.48	4.7	0.36	6.02e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg09149842	chr20:31351091	DNMT3B	-0.41	-4.52	-0.35	1.24e-5	Ulcerative colitis;
UCEC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.84	6.62	0.48	6.32e-10	Bone mineral density;
UCEC	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.55	5.91	0.44	2.3e-8	Neuroticism;
UCEC	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg24060327	chr5:131705240	SLC22A5	0.44	4.51	0.35	1.33e-5	Breast cancer;
UCEC	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18932078	chr1:2524107	MMEL1	0.42	6.6	0.48	7.1e-10	Ulcerative colitis;
UCEC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.57	-5.41	-0.41	2.45e-7	Blood protein levels;
UCEC	cis	rs295140	1.000	rs7584810	chr2:201167772	G/A	cg04283868	chr2:201171347	SPATS2L	0.53	5.18	0.39	7.14e-7	QT interval;
UCEC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	8.78	0.59	3.87e-15	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.65	-7.47	-0.52	6.46e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.43	-4.54	-0.35	1.16e-5	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs12428035	1.000	rs12429254	chr13:96299663	C/T	cg07859753	chr13:96300257	NA	0.64	4.97	0.38	1.8e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.36	0.46	2.36e-9	Alzheimer's disease;
UCEC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg06238570	chr21:40685208	BRWD1	0.79	7.16	0.51	3.53e-11	Cognitive function;
UCEC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.74	7.98	0.55	3.87e-13	Menopause (age at onset);
UCEC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.92	7.14	0.51	3.91e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.02	-8.13	-0.56	1.62e-13	Exhaled nitric oxide output;
UCEC	cis	rs7581030	0.874	rs4852772	chr2:71443645	A/G	cg07678644	chr2:71558969	ZNF638	0.6	4.67	0.36	6.85e-6	Testicular germ cell tumor;
UCEC	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.95e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg17105886	chr17:28927953	LRRC37B2	0.64	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-5.21	-0.39	6.28e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.58	6.16	0.45	6.66e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.46	4.52	0.35	1.26e-5	Motion sickness;
UCEC	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.65	5.68	0.42	6.85e-8	Bipolar disorder;
UCEC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg13683864	chr3:40499215	RPL14	-0.8	-8.83	-0.59	2.84e-15	Renal cell carcinoma;
UCEC	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg13683864	chr3:40499215	RPL14	-0.53	-5.43	-0.41	2.33e-7	Renal cell carcinoma;
UCEC	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg01072550	chr1:21505969	NA	0.64	6.84	0.49	2e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg05962950	chr11:130786565	SNX19	0.53	5.27	0.4	4.8e-7	Schizophrenia;
UCEC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg17747265	chr1:1875780	NA	-0.48	-6.44	-0.47	1.58e-9	Body mass index;
UCEC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.55	-4.84	-0.37	3.22e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.604	rs12975793	chr19:22862844	A/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.673	rs55684269	chr19:22924547	C/T	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.57	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04013166	chr16:89971882	TCF25	0.69	6.32	0.46	3.02e-9	Skin colour saturation;
UCEC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	5.91	0.44	2.29e-8	Lymphocyte counts;
UCEC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-6.22	-0.46	4.8e-9	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs6670533	0.571	rs6697800	chr1:24867540	G/A	cg07475527	chr1:24864545	NA	-0.74	-4.98	-0.38	1.8e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.89	-0.37	2.62e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.5	-6.23	-0.46	4.57e-9	Osteoporosis;
UCEC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.61	-6.03	-0.45	1.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.5	-5.84	-0.43	3.2e-8	Aortic root size;
UCEC	cis	rs9470794	1.000	rs752110	chr6:37953988	C/T	cg03458162	chr6:37400668	FTSJD2	-0.81	-4.81	-0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg21770322	chr7:97807741	LMTK2	0.45	5.82	0.43	3.59e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24249390	chr15:90295951	MESP1	-0.42	-4.76	-0.37	4.64e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.7	-5.05	-0.38	1.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.800	rs2169794	chr19:23025768	G/C	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.64	7.13	0.51	4.22e-11	Longevity;Endometriosis;
UCEC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	0.94	9.63	0.62	2.53e-17	Heart rate;
UCEC	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg24503407	chr1:205819492	PM20D1	-0.44	-4.62	-0.36	8.29e-6	Prostate-specific antigen levels;
UCEC	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.76	8.76	0.59	4.43e-15	Schizophrenia;
UCEC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.57	-6.53	-0.47	1.01e-9	White blood cell count (basophil);White blood cell count;
UCEC	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.49	-5.04	-0.38	1.37e-6	Metabolic traits;
UCEC	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.73	-6.46	-0.47	1.41e-9	Caudate activity during reward;
UCEC	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.61	5.87	0.44	2.73e-8	Morning vs. evening chronotype;
UCEC	cis	rs4880487	0.888	rs7074199	chr10:1251022	C/T	cg03183215	chr10:1252341	ADARB2	-0.46	-5.43	-0.41	2.3e-7	Migraine;
UCEC	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.53	-4.82	-0.37	3.51e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg12253828	chr6:101329408	ASCC3	0.46	4.59	0.35	9.32e-6	Neuroticism;
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.13	-0.51	4.14e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg13683864	chr3:40499215	RPL14	-0.57	-5.64	-0.42	8.33e-8	Renal cell carcinoma;
UCEC	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.69e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	trans	rs925228	0.910	rs1516427	chr2:24199259	T/C	cg18674340	chr17:45867686	NA	0.72	6.7	0.48	4.1e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.67	6.25	0.46	4.15e-9	Aortic root size;
UCEC	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.0	5.79	0.43	4.11e-8	Diabetic retinopathy;
UCEC	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg05425664	chr17:57184151	TRIM37	0.44	4.7	0.36	6.03e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.81	7.95	0.55	4.49e-13	Cognitive function;
UCEC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-6.31	-0.46	3.09e-9	Crohn's disease;
UCEC	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs12644436	0.826	rs4147247	chr4:88778267	C/G	cg27179352	chr4:88029472	AFF1	0.41	4.64	0.36	7.52e-6	HIV-1 viral setpoint;
UCEC	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.7	-7.66	-0.53	2.33e-12	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.5	5.44	0.41	2.13e-7	Longevity;Endometriosis;
UCEC	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.31	4.89	0.37	2.64e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.6	6.6	0.48	7.04e-10	Mood instability;
UCEC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg24163568	chr5:669837	TPPP	0.37	4.66	0.36	7.15e-6	Obesity-related traits;
UCEC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.48	5.04	0.38	1.32e-6	Longevity;Endometriosis;
UCEC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03352830	chr11:487213	PTDSS2	0.84	6.6	0.48	6.95e-10	Body mass index;
UCEC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg05072774	chr3:49840536	C3orf54	-0.5	-5.14	-0.39	8.8e-7	Resting heart rate;
UCEC	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.58	5.33	0.4	3.6e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	1.16	5.53	0.42	1.4e-7	LDL cholesterol;
UCEC	cis	rs394563	0.717	rs548848	chr6:149782009	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.9	-0.37	2.48e-6	Dupuytren's disease;
UCEC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.53	-5.88	-0.44	2.64e-8	Life satisfaction;
UCEC	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.58	-4.85	-0.37	3.1e-6	Corneal structure;
UCEC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.47	4.53	0.35	1.23e-5	Resting heart rate;
UCEC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.79	10.6	0.66	7.65e-20	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.7	-7.71	-0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.41	7.69	0.54	2e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.72	8.95	0.59	1.4e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	5.93	0.44	2.11e-8	IgG glycosylation;
UCEC	cis	rs1387221	0.904	rs4737510	chr8:59610321	T/C	cg24495373	chr8:59337659	UBXN2B	0.38	4.57	0.35	1.04e-5	Clozapine-induced cytotoxicity;
UCEC	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.57	-6.42	-0.47	1.75e-9	Prostate cancer;
UCEC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	5.51	0.41	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.46	-4.89	-0.37	2.64e-6	Calcium levels;
UCEC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.5	5.59	0.42	1.05e-7	Response to antineoplastic agents;
UCEC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.56	-5.16	-0.39	7.74e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.71	-0.54	1.74e-12	Total cholesterol levels;
UCEC	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.49	5.72	0.43	5.74e-8	White matter hyperintensity burden;
UCEC	cis	rs72717009	0.688	rs373579	chr1:161483484	A/G	cg23840854	chr1:161414152	NA	-0.83	-5.44	-0.41	2.22e-7	Rheumatoid arthritis;
UCEC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.59	4.92	0.38	2.28e-6	Blood metabolite levels;
UCEC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.64	-0.36	7.65e-6	Type 2 diabetes;
UCEC	cis	rs713477	0.967	rs12887653	chr14:55911030	T/A	cg13175173	chr14:55914753	NA	-0.4	-4.54	-0.35	1.18e-5	Pediatric bone mineral content (femoral neck);
UCEC	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.45	4.95	0.38	2.01e-6	Height;
UCEC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.5	-0.47	1.19e-9	Eye color traits;
UCEC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.83	-0.49	2.05e-10	Pubertal anthropometrics;
UCEC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.62	-6.63	-0.48	5.9e-10	Prostate cancer;
UCEC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg04155231	chr12:9217510	LOC144571	-0.46	-5.85	-0.43	3.09e-8	Sjögren's syndrome;
UCEC	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg10902566	chr4:727664	PCGF3	-0.55	-4.64	-0.36	7.58e-6	Systolic blood pressure;
UCEC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.58	5.18	0.39	7.26e-7	Corneal astigmatism;
UCEC	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.47	-5.45	-0.41	2.1e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg09301471	chr16:89349945	ANKRD11	-0.53	-4.97	-0.38	1.82e-6	Vitiligo;
UCEC	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.45	4.61	0.36	8.75e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.93	0.38	2.18e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.4	-4.7	-0.36	5.85e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.53	-6.06	-0.45	1.08e-8	Pubertal anthropometrics;
UCEC	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.75	-8.69	-0.58	6.37e-15	Height;
UCEC	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.8	0.37	3.94e-6	Multiple sclerosis;
UCEC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs6717918	1.000	rs6717918	chr2:233155110	T/C	cg02061626	chr2:233274167	ALPPL2	0.57	5.65	0.42	7.92e-8	Height;
UCEC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs4372836	0.518	rs1128416	chr2:29001691	A/G	cg09522027	chr2:28974177	PPP1CB	-0.79	-8.71	-0.58	5.73e-15	Body mass index;
UCEC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.77	-9.19	-0.6	3.42e-16	Bone mineral density;
UCEC	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.34	-0.46	2.65e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.53	6.85	0.49	1.86e-10	HDL cholesterol;
UCEC	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs7582720	1.000	rs80087860	chr2:203673072	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.96	0.38	1.89e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6813264	0.546	rs1390984	chr4:146593655	T/C	cg04181032	chr4:147165097	NA	-0.38	-4.62	-0.36	8.34e-6	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.74	7.5	0.53	5.7e-12	Cognitive function;
UCEC	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.21	0.39	6.27e-7	Rheumatoid arthritis;
UCEC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.64	-6.87	-0.49	1.66e-10	Crohn's disease;
UCEC	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.82	-10.47	-0.65	1.66e-19	White blood cell count (basophil);
UCEC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg20203395	chr5:56204925	C5orf35	0.53	4.78	0.37	4.23e-6	Coronary artery disease;
UCEC	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.53	-5.68	-0.42	7.12e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.62	5.55	0.42	1.29e-7	Corneal astigmatism;
UCEC	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.66	-0.48	4.99e-10	Total cholesterol levels;
UCEC	cis	rs11697848	0.867	rs6125794	chr20:48461992	A/T	cg17849948	chr20:48532315	SPATA2	1.03	5.08	0.39	1.13e-6	Systemic lupus erythematosus;
UCEC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.54	-5.45	-0.41	2.12e-7	Aortic root size;
UCEC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.53	5.3	0.4	4.12e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.77	-0.43	4.58e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg06265175	chr8:121136014	COL14A1	0.5	5.32	0.4	3.77e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.4	-0.47	1.98e-9	Platelet count;
UCEC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.6	5.56	0.42	1.24e-7	Corneal astigmatism;
UCEC	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6684428	0.706	rs12118218	chr1:56320445	C/T	cg11651538	chr1:56320950	NA	-0.48	-4.59	-0.35	9.46e-6	Airflow obstruction;
UCEC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.7	7.98	0.55	3.72e-13	Longevity;Endometriosis;
UCEC	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg02733842	chr7:1102375	C7orf50	-0.58	-4.91	-0.38	2.45e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.74	-0.36	4.9e-6	Response to antipsychotic treatment;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27467552	chr22:50353597	PIM3	-0.37	-4.53	-0.35	1.19e-5	Ulcerative colitis;
UCEC	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.46	5.25	0.4	5.24e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18252515	chr7:66147081	NA	-0.53	-5.16	-0.39	7.86e-7	Aortic root size;
UCEC	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-5.16	-0.39	7.83e-7	Prudent dietary pattern;
UCEC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg13395646	chr4:1353034	KIAA1530	-0.76	-6.67	-0.48	4.78e-10	Obesity-related traits;
UCEC	trans	rs6581612	0.643	rs11610822	chr12:65612499	G/A	cg12591315	chr12:10022688	CLEC2B	-0.76	-6.77	-0.49	2.92e-10	Hippocampal volume;
UCEC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg05962950	chr11:130786565	SNX19	0.5	4.96	0.38	1.9e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-6.36	-0.46	2.39e-9	Coffee consumption (cups per day);
UCEC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.45	0.41	2.04e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.56	-4.95	-0.38	2.04e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-4.97	-0.38	1.86e-6	Hemoglobin concentration;
UCEC	cis	rs8105895	1.000	rs116867513	chr19:22166026	C/T	cg24072202	chr19:22235272	ZNF257	-0.68	-4.65	-0.36	7.37e-6	Body mass index (change over time);
UCEC	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.22	0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.69	7.93	0.55	5.08e-13	Mean corpuscular volume;
UCEC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.45	-4.5	-0.35	1.36e-5	Total body bone mineral density;
UCEC	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.07	0.39	1.21e-6	Diabetic retinopathy;
UCEC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-0.56	-6.85	-0.49	1.87e-10	Total body bone mineral density;
UCEC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.42	4.81	0.37	3.62e-6	Platelet count;
UCEC	trans	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg02022102	chr7:27168609	HOXA4	0.6	6.78	0.49	2.67e-10	Protein biomarker;
UCEC	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.34	4.54	0.35	1.15e-5	Childhood ear infection;
UCEC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-0.92	-12.67	-0.72	2.51e-25	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17077154	1.000	rs2922809	chr8:6350464	A/T	cg26814335	chr8:6584320	AGPAT5	0.7	5.58	0.42	1.13e-7	Cytomegalovirus antibody response;
UCEC	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.55	4.66	0.36	7.09e-6	Systolic blood pressure;
UCEC	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.81	0.43	3.71e-8	Parkinson's disease;
UCEC	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.23	0.46	4.67e-9	Cognitive ability;
UCEC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.79	0.54	1.14e-12	Platelet count;
UCEC	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.44e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	6e-6	Cardiac Troponin-T levels;
UCEC	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.32	4.92	0.38	2.33e-6	Cancer;
UCEC	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg11519256	chr10:5708881	ASB13	0.44	4.54	0.35	1.18e-5	Childhood ear infection;
UCEC	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.42	-4.72	-0.36	5.38e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.88	-10.06	-0.64	1.89e-18	Cognitive function;
UCEC	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg01017244	chr2:74357527	NA	0.61	4.5	0.35	1.35e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg13575925	chr12:9217583	LOC144571	0.4	4.7	0.36	6.03e-6	Sjögren's syndrome;
UCEC	cis	rs12681287	0.752	rs10112123	chr8:87302328	T/C	cg27223183	chr8:87520930	FAM82B	-0.61	-5.27	-0.4	4.78e-7	Caudate activity during reward;
UCEC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.54	-6.57	-0.48	8.15e-10	Fibrinogen levels;
UCEC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.96	-0.44	1.75e-8	Obesity-related traits;
UCEC	cis	rs883565	0.655	rs9837975	chr3:39064293	T/C	cg01426195	chr3:39028469	NA	-0.7	-8.9	-0.59	1.93e-15	Handedness;
UCEC	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.63	7.71	0.54	1.73e-12	Mean platelet volume;
UCEC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-4.89	-0.37	2.67e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.96	0.38	1.93e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.39	0.41	2.7e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	5.28	0.4	4.57e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.82	-8.37	-0.57	4.14e-14	Caffeine consumption;
UCEC	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg12580275	chr1:205744413	RAB7L1	0.52	4.81	0.37	3.67e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg08975724	chr8:8085496	FLJ10661	0.56	4.99	0.38	1.71e-6	Red cell distribution width;
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg19678392	chr7:94953810	PON1	-0.58	-5.58	-0.42	1.11e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.58	-6.34	-0.46	2.64e-9	Glomerular filtration rate;
UCEC	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14019695	chr9:139328340	INPP5E	0.48	5.05	0.38	1.3e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.44	-4.62	-0.36	8.23e-6	Dilated cardiomyopathy;
UCEC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.66	6.02	0.44	1.32e-8	Corneal astigmatism;
UCEC	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.68	-5.05	-0.38	1.29e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.87	-7.89	-0.55	6.5e-13	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	6.13	0.45	7.61e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.57	5.29	0.4	4.28e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg01256987	chr12:42539512	GXYLT1	0.42	4.92	0.38	2.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.47	-4.83	-0.37	3.35e-6	Body mass index;
UCEC	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.87	-12.6	-0.72	3.72e-25	Urate levels in lean individuals;
UCEC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1165668	0.785	rs1165681	chr12:104325111	A/G	cg21863207	chr12:104234989	NT5DC3	-0.5	-4.73	-0.36	5.17e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg13844804	chr7:814759	HEATR2	0.67	4.88	0.37	2.73e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg18681998	chr4:17616180	MED28	0.73	8.61	0.58	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02355339	chr19:35517344	GRAMD1A	-0.64	-6.73	-0.49	3.61e-10	Smoking behavior;
UCEC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.89	-7.34	-0.52	1.32e-11	Coronary artery calcification;
UCEC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.79	-0.59	3.62e-15	Menarche (age at onset);
UCEC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.61	5.09	0.39	1.09e-6	Blood metabolite levels;
UCEC	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.56	-6.19	-0.45	5.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.0	0.5	8.35e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.67	0.36	6.87e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs12692119	0.764	rs11694557	chr2:127642433	A/T	cg04330126	chr2:127727905	NA	-0.85	-5.07	-0.39	1.2e-6	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg20203395	chr5:56204925	C5orf35	-0.54	-4.8	-0.37	3.9e-6	Coronary artery disease;
UCEC	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.6	0.42	1.02e-7	Blood protein levels;
UCEC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.57	-5.35	-0.4	3.35e-7	Initial pursuit acceleration;
UCEC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg22563815	chr15:78856949	CHRNA5	0.38	4.91	0.38	2.37e-6	Sudden cardiac arrest;
UCEC	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.69	-0.42	6.63e-8	Hemoglobin concentration;
UCEC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.44	-4.8	-0.37	3.93e-6	Blood metabolite levels;
UCEC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.23e-5	Chronic sinus infection;
UCEC	cis	rs4778581	0.868	rs3858955	chr15:80420525	T/C	cg08257866	chr15:80351198	ZFAND6	0.4	4.51	0.35	1.3e-5	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs968451	0.865	rs2007418	chr22:39712394	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.65	4.96	0.38	1.92e-6	Primary biliary cholangitis;
UCEC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.35	-4.54	-0.35	1.17e-5	Monocyte count;
UCEC	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.75	0.36	4.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg13334819	chr7:99746414	C7orf59	-0.56	-5.25	-0.4	5.29e-7	Coronary artery disease;
UCEC	cis	rs11867410	0.744	rs73349085	chr17:63941020	T/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs59918340	0.627	rs1865249	chr8:142215982	A/C	cg11945507	chr8:142233382	SLC45A4	-0.42	-4.57	-0.35	1.02e-5	Immature fraction of reticulocytes;
UCEC	cis	rs61776719	0.875	rs28435150	chr1:38407014	C/T	cg04673462	chr1:38461896	NA	0.57	5.93	0.44	2.03e-8	Coronary artery disease;
UCEC	cis	rs7246967	0.932	rs4932792	chr19:23032449	A/G	cg08271804	chr19:22816896	ZNF492	0.54	5.29	0.4	4.43e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-11.36	-0.68	7.11e-22	Cognitive function;
UCEC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg19318889	chr4:1322082	MAEA	0.48	5.2	0.39	6.46e-7	Obesity-related traits;
UCEC	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.73	-8.15	-0.56	1.46e-13	Waist circumference;Body mass index;
UCEC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.69	-4.85	-0.37	3.17e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.5	5.31	0.4	3.95e-7	Schizophrenia;
UCEC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.45	-4.88	-0.37	2.78e-6	Dementia with Lewy bodies;
UCEC	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.75	-10.57	-0.66	8.8e-20	Lung cancer;
UCEC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.62	0.48	6.3e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.65	0.53	2.41e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg00546932	chr16:1947055	NA	0.39	5.21	0.39	6.32e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.41	4.6	0.35	9.17e-6	Mean corpuscular volume;
UCEC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg26781129	chr3:44753946	ZNF502	-0.41	-4.57	-0.35	1.01e-5	Depressive symptoms;
UCEC	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26031613	chr14:104095156	KLC1	1.22	15.01	0.78	1.82e-31	Body mass index;
UCEC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.69	6.26	0.46	4.07e-9	Aortic root size;
UCEC	cis	rs75804782	0.625	rs72984594	chr2:239470169	G/A	cg12524725	chr2:239427019	NA	-0.67	-4.64	-0.36	7.59e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.75	7.29	0.52	1.74e-11	Tonsillectomy;
UCEC	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg05519781	chr21:40033154	ERG	0.66	6.76	0.49	3.01e-10	Coronary artery disease;
UCEC	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.58	4.71	0.36	5.69e-6	Eosinophilic esophagitis;
UCEC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.67	7.6	0.53	3.2e-12	Menopause (age at onset);
UCEC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.7	6.26	0.46	3.94e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	7.59	0.53	3.3e-12	Smoking behavior;
UCEC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg11871910	chr12:69753446	YEATS4	0.88	10.24	0.65	6.52e-19	Blood protein levels;
UCEC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-10.63	-0.66	6.03e-20	Renal cell carcinoma;
UCEC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.5	4.91	0.38	2.38e-6	Crohn's disease;
UCEC	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	6.13	0.45	7.78e-9	Coffee consumption (cups per day);
UCEC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.88	10.56	0.66	9.62e-20	Breast cancer;
UCEC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.69	6.14	0.45	7.5e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg09655341	chr17:79618100	PDE6G	-0.31	-4.54	-0.35	1.14e-5	Eye color traits;
UCEC	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.64	6.92	0.5	1.3100000000000001e-10	Crohn's disease;
UCEC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	7.74	0.54	1.48e-12	Homoarginine levels;
UCEC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.66	0.36	6.99e-6	Menarche (age at onset);
UCEC	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg21214455	chr15:72412075	SENP8	-0.49	-4.55	-0.35	1.13e-5	Red blood cell count;
UCEC	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.1	-6.38	-0.47	2.22e-9	Atopic dermatitis;
UCEC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg02413938	chr2:239008929	ESPNL	-0.35	-4.6	-0.35	9.04e-6	Prostate cancer;
UCEC	cis	rs9828933	0.786	rs62252368	chr3:63959465	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.79	-6.56	-0.48	8.56e-10	Type 2 diabetes;
UCEC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.96	-0.38	1.94e-6	Hemoglobin concentration;
UCEC	cis	rs35934224	0.783	rs34143881	chr22:19860093	A/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.8	-0.37	3.84e-6	Glaucoma (primary open-angle);
UCEC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.75	0.54	1.38e-12	Heart rate;
UCEC	cis	rs116095464	0.619	rs28731093	chr5:241028	T/C	cg20965017	chr5:231967	SDHA	-0.62	-5.38	-0.41	2.92e-7	Breast cancer;
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.79e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg18681998	chr4:17616180	MED28	-0.66	-6.2	-0.46	5.48e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.45	7.03	0.5	7.29e-11	Primary biliary cholangitis;
UCEC	cis	rs10012307	1.000	rs12639651	chr4:137502179	A/C	cg12033966	chr4:138453416	PCDH18	-0.71	-5.08	-0.39	1.12e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18252515	chr7:66147081	NA	0.48	4.83	0.37	3.44e-6	Aortic root size;
UCEC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.78	5.84	0.43	3.26e-8	Body mass index;
UCEC	cis	rs2376682	0.959	rs10056759	chr5:118029141	C/A	cg17593721	chr5:118788746	HSD17B4	0.5	4.61	0.36	8.57e-6	Diisocyanate-induced asthma;
UCEC	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.96	-0.9	9.85e-55	Myeloid white cell count;
UCEC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg14664628	chr15:75095509	CSK	-0.58	-5.83	-0.43	3.35e-8	Breast cancer;
UCEC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.69	5.4	0.41	2.58e-7	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.21	-8.07	-0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs678962	1.000	rs12082431	chr1:172234627	A/G	cg00042657	chr1:171753628	METTL13	-0.47	-4.71	-0.36	5.6e-6	Height;
UCEC	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.43	-5.6	-0.42	1.01e-7	Systolic blood pressure;
UCEC	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg25730555	chr22:47059586	GRAMD4	0.5	4.79	0.37	4.12e-6	Urate levels in obese individuals;
UCEC	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.54	4.93	0.38	2.22e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9326726	0.778	rs1588496	chr5:107689893	C/T	cg17432647	chr5:107996819	NA	-0.54	-4.68	-0.36	6.54e-6	Resting heart rate;
UCEC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg00316803	chr15:76480434	C15orf27	-0.45	-5.2	-0.39	6.5e-7	Blood metabolite levels;
UCEC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.6	-4.65	-0.36	7.38e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9470794	0.831	rs11759725	chr6:37982087	C/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.74	-5.9	-0.44	2.39e-8	Red blood cell count;
UCEC	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11584989	chr19:19387371	SF4	0.58	6.67	0.48	4.78e-10	Bipolar disorder;
UCEC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.4	-4.69	-0.36	6.28e-6	Post bronchodilator FEV1;
UCEC	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.01	-10.92	-0.67	1.07e-20	Exhaled nitric oxide output;
UCEC	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg04283868	chr2:201171347	SPATS2L	0.54	5.38	0.41	2.84e-7	QT interval;
UCEC	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.81	9.58	0.62	3.37e-17	Adiposity;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg21426387	chr16:11762806	SNN	-0.7	-4.87	-0.37	2.87e-6	Testicular germ cell tumor;
UCEC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg23307798	chr14:103986281	CKB	0.64	7.58	0.53	3.65e-12	Body mass index;
UCEC	cis	rs7246967	0.673	rs368144	chr19:23000787	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.18	0.45	6.09e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.31	0.46	3.13e-9	Platelet count;
UCEC	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.55	-4.77	-0.37	4.44e-6	Obesity-related traits;
UCEC	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-4.75	-0.36	4.85e-6	Schizophrenia;
UCEC	cis	rs72906064	1.000	rs72906058	chr2:156909768	C/T	cg14040602	chr2:157557294	NA	0.65	4.73	0.36	5.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7246967	0.932	rs4932800	chr19:23051648	G/A	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg18681998	chr4:17616180	MED28	0.71	6.78	0.49	2.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg09120320	chr17:61926383	NA	0.44	4.55	0.35	1.1e-5	Prudent dietary pattern;
UCEC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.52	-5.98	-0.44	1.64e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg09491104	chr22:46646882	C22orf40	-0.67	-7.84	-0.54	8.43e-13	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.57	4.79	0.37	4.08e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-5.53	-0.41	1.44e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.66	-7.5	-0.53	5.64e-12	Menarche (age at onset);
UCEC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.43	-4.79	-0.37	4.11e-6	Cardiac Troponin-T levels;
UCEC	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs7095607	0.560	rs2634709	chr10:69925789	C/T	cg18986048	chr10:69913749	MYPN	0.45	4.87	0.37	2.8e-6	Lung function (FVC);
UCEC	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg10123293	chr2:99228465	UNC50	0.49	5.41	0.41	2.5e-7	Bipolar disorder;
UCEC	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg05991184	chr2:219186017	PNKD	-0.58	-6.63	-0.48	5.87e-10	Colorectal cancer;
UCEC	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.52	5.85	0.43	3.04e-8	Retinal vascular caliber;
UCEC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs4588572	0.643	rs1019739	chr5:77770241	G/C	cg11547950	chr5:77652471	NA	-0.47	-5.45	-0.41	2.06e-7	Triglycerides;
UCEC	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.53	-5.09	-0.39	1.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7516138	1.000	rs4240896	chr1:9713500	A/G	cg26573321	chr1:9711663	PIK3CD	-0.6	-8.02	-0.55	3.11e-13	Monocyte count;
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.78	-6.03	-0.45	1.24e-8	Platelet count;
UCEC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.76	4.73	0.36	5.25e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.46	-4.81	-0.37	3.73e-6	Height;
UCEC	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.79e-11	Eye color traits;
UCEC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg20387954	chr3:183756860	HTR3D	0.5	6.09	0.45	9.2e-9	Anterior chamber depth;
UCEC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.51	4.8	0.37	3.87e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.91	-9.46	-0.62	6.99e-17	Cognitive function;
UCEC	cis	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg17469321	chr7:55412551	NA	0.7	5.87	0.44	2.75e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg17279458	chr3:44753948	ZNF502	-0.44	-4.65	-0.36	7.19e-6	Depressive symptoms;
UCEC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg20129853	chr10:51489980	NA	0.41	5.06	0.39	1.24e-6	Prostate-specific antigen levels;
UCEC	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.66	-6.68	-0.48	4.53e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	7.91	0.55	5.55e-13	Smoking behavior;
UCEC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-7.55	-0.53	4.13e-12	Type 2 diabetes;
UCEC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.71	-7.15	-0.51	3.76e-11	Blood metabolite levels;
UCEC	cis	rs9469578	0.892	rs6929527	chr6:33707976	G/T	cg18708504	chr6:33715942	IP6K3	0.52	5.11	0.39	9.93e-7	Phosphorus levels;
UCEC	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.42	-4.72	-0.36	5.35e-6	Pelvic organ prolapse;
UCEC	cis	rs4919044	0.641	rs7914449	chr10:94723370	G/T	cg00519463	chr10:94352821	KIF11	0.87	4.65	0.36	7.48e-6	Coronary artery disease;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.46	-4.63	-0.36	7.96e-6	Parkinson's disease;
UCEC	cis	rs9402633	0.938	rs9402628	chr6:135032734	C/T	cg16239184	chr6:135079577	NA	0.51	4.61	0.36	8.81e-6	Platelet count;
UCEC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg16497661	chr14:103986332	CKB	0.49	5.85	0.43	3.04e-8	Body mass index;
UCEC	cis	rs17122693	1.000	rs72679584	chr14:51092320	T/C	cg04730355	chr14:51134070	SAV1	0.92	9.15	0.6	4.41e-16	Cognitive performance;
UCEC	cis	rs12573330	1.000	rs59343228	chr10:98470886	C/G	cg10113589	chr10:98118853	OPALIN	0.46	4.52	0.35	1.27e-5	Monocyte percentage of white cells;
UCEC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.53	-0.47	1.03e-9	Tonsillectomy;
UCEC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.44	-5.79	-0.43	4.05e-8	Prostate cancer;
UCEC	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.41e-8	Height;
UCEC	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06762426	chr11:62420836	INTS5	0.93	5.36	0.4	3.12e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.45	5.12	0.39	9.28e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-5.41	-0.41	2.48e-7	Platelet count;
UCEC	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.54	5.32	0.4	3.77e-7	Asthma (sex interaction);
UCEC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-4.63	-0.36	8.05e-6	Dental caries;
UCEC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.14	-0.45	7.5e-9	Birth weight;
UCEC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	7.46	0.52	7.1e-12	Bone mineral density;
UCEC	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg21772509	chr8:41503840	NKX6-3	0.51	5.72	0.43	5.9e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg19554555	chr3:13937349	NA	-0.59	-5.82	-0.43	3.49e-8	Ovarian reserve;
UCEC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.12	0.51	4.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	9.79	0.63	9.91e-18	Blood protein levels;
UCEC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.81	9.27	0.61	2.21e-16	Chronic sinus infection;
UCEC	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.81	-5.62	-0.42	9.3e-8	Coronary artery calcification;
UCEC	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	0.86	7.27	0.51	1.96e-11	Orofacial clefts;
UCEC	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.75	7.89	0.55	6.42e-13	Mean corpuscular hemoglobin;
UCEC	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.65	-0.42	8.11e-8	Neutrophil percentage of white cells;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.9	10.87	0.67	1.45e-20	Menarche (age at onset);
UCEC	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.54	-5.01	-0.38	1.56e-6	Non-small cell lung cancer;
UCEC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.27	0.4	4.67e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	-0.58	-6.6	-0.48	7.1e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.52	-5.86	-0.44	2.95e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6684514	0.506	rs3762281	chr1:156304782	A/G	cg20302342	chr1:156215951	PAQR6	0.48	4.85	0.37	3.12e-6	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
UCEC	trans	rs66573146	1.000	rs6812771	chr4:6964048	G/A	cg07817883	chr1:32538562	TMEM39B	1.23	9.45	0.61	7.4e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.45	-5.34	-0.4	3.4e-7	Migraine;
UCEC	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.85	-8.97	-0.59	1.25e-15	Itch intensity from mosquito bite;
UCEC	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.4	4.98	0.38	1.74e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.45	-5.08	-0.39	1.11e-6	Superior crus of antihelix expression;
UCEC	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	0.82	5.49	0.41	1.71e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.59	-6.08	-0.45	9.99e-9	Blood protein levels;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.8	-9.38	-0.61	1.1e-16	Longevity;Endometriosis;
UCEC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.53	6.14	0.45	7.18e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs78487399	0.908	rs35478206	chr2:43831032	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-6.23	-0.46	4.58e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.11	-0.39	9.78e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg04310649	chr10:35416472	CREM	-0.49	-4.84	-0.37	3.25e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs117623576	0.941	rs7912584	chr10:32416623	C/T	cg03047570	chr10:32398778	NA	-0.56	-5.12	-0.39	9.59e-7	Anti-saccade response;
UCEC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg12870014	chr12:110450643	ANKRD13A	0.54	4.65	0.36	7.38e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg04155231	chr12:9217510	LOC144571	0.41	4.64	0.36	7.54e-6	Sjögren's syndrome;
UCEC	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	6.94	0.5	1.2e-10	Exhaled nitric oxide output;
UCEC	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.62	7.03	0.5	7.14e-11	Leprosy;
UCEC	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.55	5.93	0.44	2.02e-8	Platelet count;
UCEC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-0.97	-6.25	-0.46	4.12e-9	Diabetic kidney disease;
UCEC	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.64	-5.69	-0.42	6.64e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6746896	0.683	rs6576984	chr2:97454705	C/T	cg01950434	chr2:97203154	ARID5A	-0.46	-4.9	-0.37	2.5e-6	Bipolar disorder;
UCEC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.65	-6.0	-0.44	1.5e-8	Gut microbiome composition (summer);
UCEC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.73	0.36	5.13e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg23782820	chr8:58130467	NA	0.5	4.65	0.36	7.38e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11760485	0.965	rs4723690	chr7:4402953	T/C	cg15613991	chr7:5277080	NA	-0.42	-5.03	-0.38	1.43e-6	Early childhood aggressive behavior;
UCEC	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg24375607	chr4:120327624	NA	0.53	5.01	0.38	1.54e-6	Corneal astigmatism;
UCEC	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.6	-0.62	2.97e-17	Blood metabolite levels;
UCEC	cis	rs2882667	0.728	rs10068786	chr5:138276944	C/T	cg05839636	chr5:137878905	ETF1	0.55	4.63	0.36	8.09e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg08886695	chr4:3369023	RGS12	-0.5	-5.13	-0.39	9.19e-7	Serum sulfate level;
UCEC	cis	rs17122693	0.551	rs2934683	chr14:51058511	C/T	cg04730355	chr14:51134070	SAV1	0.65	7.13	0.51	4.13e-11	Cognitive performance;
UCEC	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.52	-0.41	1.47e-7	Vitiligo;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.85	7.57	0.53	3.89e-12	Body mass index;
UCEC	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.45	-6.16	-0.45	6.71e-9	Prostate cancer;
UCEC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg11985680	chr1:76251867	SNORD45C;RABGGTB	0.53	4.53	0.35	1.2e-5	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs6479901	0.895	rs1579045	chr10:64970448	G/A	cg12751693	chr12:62629162	NA	-0.54	-6.73	-0.49	3.49e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.61	6.03	0.45	1.25e-8	Lung cancer;
UCEC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.63	6.13	0.45	7.87e-9	Coronary artery disease;
UCEC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.66	6.56	0.48	8.66e-10	Aortic root size;
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg04871131	chr7:94954202	PON1	-0.52	-5.15	-0.39	8.14e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	6.0	0.44	1.47e-8	Platelet count;
UCEC	cis	rs9467773	1.000	rs1570060	chr6:26573562	A/G	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02851049	chr16:101260	POLR3K	0.7	4.62	0.36	8.33e-6	Glioblastoma;
UCEC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg11871910	chr12:69753446	YEATS4	0.54	4.81	0.37	3.72e-6	Response to diuretic therapy;
UCEC	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg11861562	chr11:117069780	TAGLN	0.35	4.67	0.36	6.62e-6	Blood protein levels;
UCEC	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.63	-7.23	-0.51	2.39e-11	Red blood cell count;
UCEC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.07	0.5	5.71e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.15	-0.45	7.06e-9	Depression;
UCEC	cis	rs847649	0.731	rs7785272	chr7:102671023	A/G	cg18108683	chr7:102477205	FBXL13	-0.49	-5.46	-0.41	2e-7	Morning vs. evening chronotype;
UCEC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg23791538	chr6:167370224	RNASET2	-0.47	-4.82	-0.37	3.49e-6	Primary biliary cholangitis;
UCEC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.68	-7.59	-0.53	3.42e-12	Lung function (FEV1);
UCEC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	6.74	0.49	3.31e-10	Chronic sinus infection;
UCEC	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.7	9.37	0.61	1.22e-16	Neuroticism;
UCEC	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.81	6.4	0.47	1.92e-9	Lymphocyte counts;
UCEC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg01689657	chr7:91764605	CYP51A1	-0.45	-5.7	-0.43	6.25e-8	Breast cancer;
UCEC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.57	-4.82	-0.37	3.58e-6	Menopause (age at onset);
UCEC	cis	rs12428035	0.764	rs72637833	chr13:96736814	C/G	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg07836142	chr6:28411423	ZSCAN23	-0.47	-4.88	-0.37	2.77e-6	Hepatitis A;
UCEC	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.55	5.36	0.4	3.1e-7	Vitamin D levels;
UCEC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.55	-5.21	-0.4	6.17e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	5.43	0.41	2.32e-7	Response to antipsychotic treatment;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg21160472	chr1:212782112	ATF3	-0.62	-6.76	-0.49	3.02e-10	Breast cancer;
UCEC	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.61	-6.11	-0.45	8.31e-9	Blood pressure (smoking interaction);
UCEC	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg02158880	chr13:53174818	NA	0.59	6.91	0.5	1.35e-10	Lewy body disease;
UCEC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.54	5.65	0.42	8.16e-8	Corneal astigmatism;
UCEC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.86	-9.65	-0.62	2.22e-17	Cognitive function;
UCEC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.06	0.5	6.19e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.6	5.7	0.43	6.2e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.07e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.97	5.43	0.41	2.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs6746896	0.734	rs7608661	chr2:97459920	A/G	cg01950434	chr2:97203154	ARID5A	-0.43	-4.77	-0.37	4.46e-6	Bipolar disorder;
UCEC	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg10902566	chr4:727664	PCGF3	-0.57	-4.97	-0.38	1.82e-6	Systolic blood pressure;
UCEC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.48	-4.54	-0.35	1.18e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg24961523	chr17:36618985	ARHGAP23	-0.36	-4.55	-0.35	1.1e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg02344993	chr17:57696989	CLTC	0.51	4.84	0.37	3.29e-6	Hemoglobin concentration;
UCEC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.6	-5.4	-0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.78	4.73	0.36	5.16e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	8.1	0.56	1.92e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.66	4.94	0.38	2.11e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-5.46	-0.41	1.94e-7	Depression;
UCEC	cis	rs6684428	0.706	rs10493183	chr1:56333648	T/C	cg11651538	chr1:56320950	NA	-0.76	-6.77	-0.49	2.86e-10	Airflow obstruction;
UCEC	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg18681998	chr4:17616180	MED28	0.66	7.67	0.53	2.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg00280220	chr17:61926910	NA	0.4	4.54	0.35	1.19e-5	Prudent dietary pattern;
UCEC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.14	0.39	8.59e-7	Rheumatoid arthritis;
UCEC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-0.91	-11.46	-0.69	4.05e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	6.05	0.45	1.12e-8	Breast cancer;
UCEC	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.34	0.4	3.49e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.51	5.6	0.42	1.03e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.21	-0.46	5.08e-9	Pubertal anthropometrics;
UCEC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.46	4.83	0.37	3.36e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.47	-5.07	-0.39	1.19e-6	Gut microbiome composition (summer);
UCEC	cis	rs10405744	0.744	rs7246986	chr19:20189967	A/T	cg19204924	chr19:20576478	ZNF826	-0.64	-5.96	-0.44	1.79e-8	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);
UCEC	cis	rs244899	0.935	rs2445786	chr5:167930877	G/A	cg06604206	chr5:167912465	RARS	-0.38	-4.66	-0.36	6.95e-6	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-5.26	-0.4	5.1e-7	Life satisfaction;
UCEC	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg11632617	chr15:75315747	PPCDC	-0.56	-5.5	-0.41	1.63e-7	Lung cancer;
UCEC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.54	5.4	0.41	2.63e-7	Aortic root size;
UCEC	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.68	6.06	0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.56	0.42	1.26e-7	Cognitive test performance;
UCEC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.9	10.86	0.67	1.49e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg11859384	chr17:80120422	CCDC57	-0.47	-5.26	-0.4	4.92e-7	Life satisfaction;
UCEC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg21053147	chr12:120880522	NA	0.63	5.17	0.39	7.5e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.52	5.78	0.43	4.41e-8	Retinal vascular caliber;
UCEC	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.18e-21	Body mass index;
UCEC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.23	-15.21	-0.78	5.67e-32	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.73	-8.26	-0.56	7.62e-14	Prudent dietary pattern;
UCEC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg12024160	chr4:1254474	NA	0.7	8.37	0.57	4.08e-14	Obesity-related traits;
UCEC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.75	7.73	0.54	1.52e-12	Testicular germ cell tumor;
UCEC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.4	0.41	2.62e-7	Rheumatoid arthritis;
UCEC	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	4.59	0.35	9.36e-6	IgG glycosylation;
UCEC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	7.26	0.51	2.11e-11	Platelet count;
UCEC	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.63	5.85	0.43	3.09e-8	Tonsillectomy;
UCEC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	8.4	0.57	3.51e-14	Chronic sinus infection;
UCEC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.09	0.39	1.08e-6	Rheumatoid arthritis;
UCEC	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg18223379	chr20:31619647	BPIL3	0.33	4.55	0.35	1.1e-5	Ulcerative colitis;
UCEC	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.61	-5.29	-0.4	4.26e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg17469321	chr7:55412551	NA	0.69	6.35	0.46	2.59e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-0.76	-8.41	-0.57	3.33e-14	Trans fatty acid levels;
UCEC	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg26067569	chr2:200525129	NA	0.54	4.57	0.35	1.04e-5	Schizophrenia;
UCEC	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.39	4.64	0.36	7.55e-6	Refractive error;
UCEC	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.57e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.69	5.98	0.44	1.63e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.63	-6.53	-0.47	1e-9	Initial pursuit acceleration;
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.45	-0.41	2.05e-7	Platelet count;
UCEC	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.52	-5.15	-0.39	8.29e-7	Large artery stroke;
UCEC	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.71	-9.23	-0.61	2.74e-16	Oral cavity cancer;
UCEC	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.77	7.71	0.54	1.72e-12	Ulcerative colitis;
UCEC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	8.51	0.57	1.82e-14	Prudent dietary pattern;
UCEC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.55	5.47	0.41	1.86e-7	Menopause (age at onset);
UCEC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	5.93	0.44	2.1e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.47	-0.47	1.37e-9	Parkinson's disease;
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.3	0.61	1.78e-16	Platelet count;
UCEC	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.58	-0.48	7.64e-10	Response to antipsychotic treatment;
UCEC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs7766436	0.885	rs1418312	chr6:22589704	C/T	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs2892463	0.796	rs9508554	chr13:30360860	T/C	cg18356743	chr13:30408050	UBL3	-0.41	-4.55	-0.35	1.14e-5	Non-word repetition;
UCEC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-0.64	-7.66	-0.53	2.27e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	5.17	0.39	7.38e-7	Platelet count;
UCEC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.43	4.76	0.37	4.67e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10924970	1.000	rs7339903	chr1:235337733	C/T	cg26050004	chr1:235667680	B3GALNT2	0.42	4.56	0.35	1.08e-5	Asthma;
UCEC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.38	4.98	0.38	1.73e-6	Coronary artery disease;
UCEC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.41	4.78	0.37	4.18e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.02	-11.77	-0.7	6.15e-23	Schizophrenia;
UCEC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.52	-5.1	-0.39	1.05e-6	Aortic root size;
UCEC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.53	-5.2	-0.39	6.61e-7	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.92	0.38	2.31e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg20129853	chr10:51489980	NA	-0.43	-4.81	-0.37	3.68e-6	Prostate-specific antigen levels;
UCEC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-5.02	-0.38	1.47e-6	Personality dimensions;
UCEC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.77	-0.49	2.85e-10	Obesity-related traits;
UCEC	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.7	8.18	0.56	1.2e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs28795989	0.795	rs938604	chr4:7904363	G/A	cg00251875	chr4:7801337	AFAP1	0.54	6.34	0.46	2.64e-9	Intraocular pressure;
UCEC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs58722170	0.627	rs12046650	chr1:38082123	C/T	cg17933807	chr1:38061675	GNL2	-0.62	-5.15	-0.39	8.33e-7	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.65	-6.18	-0.45	6.05e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs782107	0.614	rs1174596	chr12:58761336	C/T	cg19181132	chr12:59314527	LRIG3	-0.45	-4.84	-0.37	3.2e-6	Interleukin-12p70 levels;
UCEC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.47	5.35	0.4	3.34e-7	Emphysema distribution in smoking;
UCEC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.84	-0.37	3.29e-6	Dupuytren's disease;
UCEC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.72	7.57	0.53	3.69e-12	Lymphocyte counts;
UCEC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.56	-4.79	-0.37	3.98e-6	Menarche (age at onset);
UCEC	cis	rs13095912	1.000	rs6762208	chr3:185331165	A/C	cg11274856	chr3:185301563	NA	-0.53	-7.13	-0.51	4.31e-11	Systolic blood pressure;
UCEC	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.52	-8.99	-0.6	1.12e-15	Airflow obstruction;
UCEC	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.44	5.59	0.42	1.09e-7	Morning vs. evening chronotype;
UCEC	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg11569703	chr11:65557185	OVOL1	0.41	5.17	0.39	7.51e-7	Acne (severe);
UCEC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.69	-6.2	-0.46	5.53e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.72	6.61	0.48	6.75e-10	Alzheimer's disease;
UCEC	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.48	4.93	0.38	2.16e-6	Dupuytren's disease;
UCEC	cis	rs12635074	0.521	rs41521744	chr3:56311202	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	-0.34	-4.81	-0.37	3.74e-6	Morning vs. evening chronotype;
UCEC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg24163568	chr5:669837	TPPP	-0.41	-5.18	-0.39	7.05e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-7.04	-0.5	6.66e-11	Total body bone mineral density;
UCEC	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.54	5.72	0.43	5.67e-8	Diastolic blood pressure;
UCEC	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.89	-9.43	-0.61	8.38e-17	Obesity-related traits;
UCEC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.39	4.52	0.35	1.25e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.19	-0.39	6.98e-7	Coronary artery disease;
UCEC	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs7246967	0.866	rs62120784	chr19:23044735	A/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs883565	0.610	rs4676600	chr3:39157011	A/G	cg01426195	chr3:39028469	NA	-0.55	-6.56	-0.48	8.75e-10	Handedness;
UCEC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg21770322	chr7:97807741	LMTK2	0.51	6.38	0.47	2.21e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg10902566	chr4:727664	PCGF3	-0.56	-4.55	-0.35	1.1e-5	Systolic blood pressure;
UCEC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.82	9.76	0.63	1.14e-17	Menopause (age at onset);
UCEC	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	6.99	0.5	8.87e-11	Menopause (age at onset);
UCEC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg03714773	chr7:91764589	CYP51A1	0.47	5.72	0.43	5.79e-8	Breast cancer;
UCEC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg26031613	chr14:104095156	KLC1	-0.63	-6.29	-0.46	3.4e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.47	-5.66	-0.42	7.76e-8	Subjective well-being;
UCEC	cis	rs60871478	0.735	rs62432241	chr7:795360	G/A	cg05535760	chr7:792225	HEATR2	0.95	5.35	0.4	3.33e-7	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	4.55	0.35	1.11e-5	Depressive episodes in bipolar disorder;
UCEC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.98	0.44	1.63e-8	Height;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.73	-0.43	5.55e-8	Pulmonary function;
UCEC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7267005	0.661	rs8116093	chr20:34415114	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	1.01e-15	Menopause (age at onset);
UCEC	cis	rs6832769	0.961	rs2177127	chr4:56379959	A/C	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.45e-8	Personality dimensions;
UCEC	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg10978503	chr1:24200527	CNR2	0.36	4.68	0.36	6.34e-6	Immature fraction of reticulocytes;
UCEC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg12024160	chr4:1254474	NA	0.67	8.22	0.56	1e-13	Obesity-related traits;
UCEC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.61	-5.7	-0.43	6.42e-8	Mortality in heart failure;
UCEC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-24.33	-0.9	2.04e-53	Myeloid white cell count;
UCEC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.83	-7.51	-0.53	5.26e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1575951	1.000	rs61863392	chr10:130449441	A/G	cg27041381	chr10:131357203	MGMT	0.59	4.69	0.36	6.3e-6	Plasma clusterin levels;
UCEC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.84	5.09	0.39	1.1e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg19097150	chr7:2500200	NA	-0.35	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.71	6.72	0.48	3.73e-10	Bladder cancer;
UCEC	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-4.66	-0.36	6.94e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4778581	0.722	rs2461641	chr15:80364756	A/G	cg08257866	chr15:80351198	ZFAND6	0.4	4.86	0.37	2.96e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg14324370	chr2:177042789	NA	0.55	5.0	0.38	1.6e-6	IgG glycosylation;
UCEC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11697848	0.867	rs55948305	chr20:48507406	T/C	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.55	5.2	0.39	6.55e-7	Corneal astigmatism;
UCEC	cis	rs9715521	0.775	rs56957240	chr4:59847774	C/A	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg12586109	chr17:80790369	TBCD;ZNF750	0.43	4.62	0.36	8.48e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.72	7.16	0.51	3.49e-11	Post bronchodilator FEV1;
UCEC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.85e-6	Testicular germ cell tumor;
UCEC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	5.05	0.38	1.32e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.43	4.96	0.38	1.91e-6	Height;
UCEC	cis	rs782107	0.724	rs782099	chr12:58813930	C/G	cg19181132	chr12:59314527	LRIG3	-0.5	-5.29	-0.4	4.42e-7	Interleukin-12p70 levels;
UCEC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.42	-4.68	-0.36	6.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.81	6.29	0.46	3.37e-9	Exhaled nitric oxide output;
UCEC	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03452623	chr4:187889614	NA	-0.57	-7.12	-0.51	4.4e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg16583315	chr14:65563665	MAX	-0.45	-5.86	-0.44	2.96e-8	Obesity-related traits;
UCEC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs6893807	1.000	rs13163173	chr5:87943620	C/A	cg09002922	chr5:87956389	LOC645323	-0.59	-5.99	-0.44	1.58e-8	Body mass index;
UCEC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg22907277	chr7:1156413	C7orf50	0.98	6.14	0.45	7.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.69	-6.8	-0.49	2.51e-10	Blood metabolite levels;
UCEC	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.54	-4.75	-0.36	4.8e-6	Metabolite levels;
UCEC	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.97	-10.97	-0.67	7.78e-21	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.7	4.93	0.38	2.24e-6	Aortic root size;
UCEC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.12	10.82	0.67	1.94e-20	Vitiligo;
UCEC	cis	rs17106184	0.892	rs111701702	chr1:51284446	T/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.46	5.25	0.4	5.14e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.57	5.34	0.4	3.44e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.64	7.4	0.52	9.94e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg00074818	chr8:8560427	CLDN23	0.4	4.87	0.37	2.83e-6	Neuroticism;
UCEC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.29	-6.27	-0.46	3.74e-9	Thyroid stimulating hormone;
UCEC	cis	rs55670112	0.904	rs55970945	chr5:114279008	A/T	cg05461448	chr5:114880715	FEM1C	-0.44	-4.58	-0.35	9.96e-6	Epilepsy;
UCEC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17824620	0.548	rs74372924	chr12:113118220	C/T	cg26711794	chr12:112450906	ERP29;TMEM116	0.58	4.61	0.36	8.58e-6	Platelet count;
UCEC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18252515	chr7:66147081	NA	-0.57	-5.28	-0.4	4.52e-7	Aortic root size;
UCEC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.72	-5.33	-0.4	3.61e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.65	7.39	0.52	1.03e-11	Resting heart rate;
UCEC	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg13119609	chr19:45449297	APOC2	0.43	6.34	0.46	2.72e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	4.94	0.38	2.09e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.51	-5.45	-0.41	2.08e-7	Monocyte count;
UCEC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg21770322	chr7:97807741	LMTK2	0.53	6.64	0.48	5.71e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg04804543	chr8:142233427	SLC45A4	0.43	5.02	0.38	1.49e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.32	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.21	-0.51	2.71e-11	Multiple sclerosis;
UCEC	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.67	-7.31	-0.52	1.59e-11	Crohn's disease;
UCEC	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.77	-4.63	-0.36	7.99e-6	Putamen volume;
UCEC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.59	-5.17	-0.39	7.6e-7	Response to diuretic therapy;
UCEC	cis	rs7246967	0.673	rs2885221	chr19:22839387	A/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	6.11e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6446731	0.636	rs2157092	chr4:3273092	G/C	cg08886695	chr4:3369023	RGS12	-0.44	-4.92	-0.38	2.24e-6	Mean platelet volume;
UCEC	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.58	-5.95	-0.44	1.87e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg06238570	chr21:40685208	BRWD1	0.75	7.21	0.51	2.75e-11	Cognitive function;
UCEC	cis	rs28795989	0.795	rs2385910	chr4:7903151	G/C	cg12632249	chr4:7449638	SORCS2	0.32	4.53	0.35	1.2e-5	Intraocular pressure;
UCEC	cis	rs3770752	0.897	rs2041836	chr2:37509133	C/A	cg20091297	chr2:37572423	QPCT	0.48	4.79	0.37	3.99e-6	Schizophrenia;
UCEC	cis	rs6496667	0.865	rs10438436	chr15:90908781	A/G	cg03599575	chr15:90893182	GABARAPL3	-0.46	-4.71	-0.36	5.74e-6	Rheumatoid arthritis;
UCEC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.78	0.7	5.6e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.9	-0.49	1.42e-10	Caudate activity during reward;
UCEC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-9.66	-0.62	2.17e-17	Electrocardiographic conduction measures;
UCEC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg09491104	chr22:46646882	C22orf40	0.6	6.69	0.48	4.27e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2179367	0.959	rs2262617	chr6:149759726	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.4	-5.23	-0.4	5.63e-7	Dupuytren's disease;
UCEC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	7.67	0.53	2.18e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.1	9.63	0.62	2.51e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.55e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs692916	0.704	rs12606740	chr18:60605630	G/A	cg07187971	chr18:60481018	PHLPP1	0.37	4.62	0.36	8.39e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.7	-6.67	-0.48	4.82e-10	Pancreatic cancer;
UCEC	cis	rs10924970	0.934	rs10802572	chr1:235426121	A/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.68	0.36	6.54e-6	Asthma;
UCEC	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-5.94	-0.44	1.99e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.17	10.16	0.64	1.07e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg13319975	chr6:146136371	FBXO30	-0.48	-5.14	-0.39	8.59e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.77	8.54	0.58	1.51e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	0.87	4.69	0.36	6.24e-6	Age-related hearing impairment;
UCEC	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg19567339	chr10:100142640	NA	0.51	6.02	0.44	1.36e-8	Metabolite levels;
UCEC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-5.33	-0.4	3.67e-7	Aortic root size;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.67	8.27	0.56	7.2e-14	Menarche (age at onset);
UCEC	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.66	5.28	0.4	4.5e-7	Morning vs. evening chronotype;
UCEC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.56	-5.46	-0.41	1.95e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.56	-5.42	-0.41	2.38e-7	Asthma (sex interaction);
UCEC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg18681998	chr4:17616180	MED28	-0.56	-6.1	-0.45	8.78e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg11871910	chr12:69753446	YEATS4	0.71	7.5	0.53	5.51e-12	Blood protein levels;
UCEC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.62	6.84	0.49	1.96e-10	Longevity;Endometriosis;
UCEC	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.57	6.49	0.47	1.22e-9	Crohn's disease;
UCEC	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.49	-4.95	-0.38	2.05e-6	Breast cancer;
UCEC	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.6	-4.95	-0.38	1.97e-6	Obesity-related traits;
UCEC	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.65	5.83	0.43	3.4e-8	Morning vs. evening chronotype;
UCEC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg24163568	chr5:669837	TPPP	0.38	4.71	0.36	5.8e-6	Obesity-related traits;
UCEC	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-0.77	-8.48	-0.57	2.15e-14	Trans fatty acid levels;
UCEC	cis	rs11153730	0.503	rs188181	chr6:118620094	C/T	cg21191810	chr6:118973309	C6orf204	0.39	5.05	0.38	1.27e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-5.32	-0.4	3.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.9	10.95	0.67	8.94e-21	Breast cancer;
UCEC	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	8.55	0.58	1.47e-14	Ileal carcinoids;
UCEC	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.3	-0.46	3.32e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.69	-6.3	-0.46	3.27e-9	Aortic root size;
UCEC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg22868518	chr11:507468	RNH1	-0.58	-5.77	-0.43	4.47e-8	Systemic lupus erythematosus;
UCEC	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg17652424	chr22:38574118	PLA2G6	-0.37	-4.69	-0.36	6.17e-6	Cutaneous nevi;
UCEC	cis	rs2502731	0.584	rs3003578	chr9:130994179	C/T	cg09976142	chr9:130955436	CIZ1	0.45	5.15	0.39	8.42e-7	Attention deficit hyperactivity disorder;
UCEC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.73	-7.74	-0.54	1.44e-12	Sudden cardiac arrest;
UCEC	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.74	-7.86	-0.54	7.41e-13	Cognitive function;
UCEC	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg08551088	chr10:121631655	C10orf119	-0.63	-7.36	-0.52	1.19e-11	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.51	4.9	0.38	2.45e-6	Obesity-related traits;
UCEC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.55	0.35	1.12e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.69	-7.12	-0.51	4.55e-11	Ulcerative colitis;
UCEC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.66	-4.94	-0.38	2.05e-6	Aortic root size;
UCEC	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.39	-5.29	-0.4	4.26e-7	IgG glycosylation;
UCEC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.48	-4.55	-0.35	1.12e-5	Cardiac Troponin-T levels;
UCEC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.7	7.55	0.53	4.16e-12	Age at first birth;
UCEC	cis	rs2179367	0.887	rs2789488	chr6:149725290	A/G	cg03678062	chr6:149772716	ZC3H12D	0.34	4.73	0.36	5.18e-6	Dupuytren's disease;
UCEC	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.21	-10.04	-0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.55	-6.39	-0.47	2.06e-9	Bipolar disorder;
UCEC	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-6.78	-0.49	2.79e-10	Chronic sinus infection;
UCEC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg01256987	chr12:42539512	GXYLT1	0.4	4.71	0.36	5.75e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.76	7.98	0.55	3.86e-13	Eosinophil percentage of white cells;
UCEC	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6684428	1.000	rs12145137	chr1:56370557	A/T	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.55	5.0	0.38	1.62e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	0.96	5.37	0.41	2.99e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.83	9.54	0.62	4.39e-17	Metabolite levels;
UCEC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.54	4.57	0.35	1.03e-5	Alzheimer's disease;
UCEC	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.88	-7.22	-0.51	2.59e-11	Coronary artery calcification;
UCEC	cis	rs2862064	0.932	rs2221267	chr5:156401533	G/C	cg12943317	chr5:156479607	HAVCR1	-0.79	-6.0	-0.44	1.46e-8	Platelet count;
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.14e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.46	-4.56	-0.35	1.08e-5	Pubertal anthropometrics;
UCEC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-6.67	-0.48	4.74e-10	Life satisfaction;
UCEC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	7.18	0.51	3.2e-11	Homoarginine levels;
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.63	9.19	0.6	3.45e-16	Prudent dietary pattern;
UCEC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg20607287	chr7:12443886	VWDE	-0.63	-4.65	-0.36	7.47e-6	Coronary artery disease;
UCEC	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24249390	chr15:90295951	MESP1	-0.43	-4.97	-0.38	1.87e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs6800768	0.633	rs7623348	chr3:24130263	C/A	cg10674438	chr3:24145617	LOC152024	-0.45	-4.52	-0.35	1.24e-5	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	5.35	0.4	3.25e-7	Platelet count;
UCEC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg22166914	chr1:53195759	ZYG11B	0.6	6.18	0.45	5.97e-9	Monocyte count;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.45	4.69	0.36	6.21e-6	Height;
UCEC	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.78	-7.51	-0.53	5.18e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg18016565	chr1:150552671	MCL1	-0.53	-5.9	-0.44	2.4e-8	Tonsillectomy;
UCEC	cis	rs9825420	0.639	rs7642079	chr3:37607725	C/T	cg15682617	chr3:38589863	SCN5A	-0.57	-4.52	-0.35	1.26e-5	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7766436	0.885	rs7742025	chr6:22575798	A/T	cg13666174	chr6:22585274	NA	-0.59	-6.04	-0.45	1.21e-8	Coronary artery disease;
UCEC	cis	rs35934224	0.783	rs13056219	chr22:19860846	C/T	cg11182965	chr22:19864308	TXNRD2	-0.65	-6.3	-0.46	3.28e-9	Glaucoma (primary open-angle);
UCEC	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.48	-4.54	-0.35	1.16e-5	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.92	8.85	0.59	2.55e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs4400599	0.618	rs9804045	chr1:154191691	C/T	cg05139571	chr1:154127138	NUP210L	-0.43	-4.64	-0.36	7.65e-6	Platelet distribution width;
UCEC	cis	rs9402633	0.877	rs75638351	chr6:135068503	C/T	cg16239184	chr6:135079577	NA	0.5	4.54	0.35	1.18e-5	Platelet count;
UCEC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg00343986	chr7:65444356	GUSB	0.55	5.01	0.38	1.53e-6	Aortic root size;
UCEC	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.02	-0.38	1.45e-6	Coronary artery disease;
UCEC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Corneal astigmatism;
UCEC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.93	-0.44	2.06e-8	Pulmonary function;
UCEC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.56	5.2	0.39	6.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.48	-5.42	-0.41	2.36e-7	Height;
UCEC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg11632617	chr15:75315747	PPCDC	-0.58	-6.74	-0.49	3.38e-10	Blood trace element (Zn levels);
UCEC	cis	rs6840360	0.573	rs6810430	chr4:152259759	C/T	cg25486957	chr4:152246857	NA	-0.42	-4.51	-0.35	1.31e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.25	14.64	0.77	1.69e-30	Type 1 diabetes nephropathy;
UCEC	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.76	-0.43	4.64e-8	Urate levels in overweight individuals;
UCEC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg19097150	chr7:2500200	NA	-0.31	-4.54	-0.35	1.15e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg15147215	chr3:52552868	STAB1	0.43	4.57	0.35	1.04e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.68	7.13	0.51	4.12e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-6.17	-0.45	6.39e-9	Platelet count;
UCEC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg01112020	chr2:239008986	ESPNL	-0.37	-4.67	-0.36	6.72e-6	Prostate cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06824134	chr2:45878977	PRKCE	0.6	7.13	0.51	4.16e-11	Warfarin maintenance dose;
UCEC	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.48	-0.69	3.52e-22	Ulcerative colitis;
UCEC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.4	4.57	0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs12829704	0.636	rs71446756	chr12:21341140	T/C	cg02631767	chr12:20661554	PDE3A	-0.85	-4.59	-0.35	9.44e-6	Blood metabolite levels;
UCEC	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.86	-0.37	2.92e-6	Response to antipsychotic treatment;
UCEC	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.77	5.21	0.39	6.3e-7	Toenail selenium levels;
UCEC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.78	9.31	0.61	1.72e-16	Metabolic syndrome;
UCEC	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg23950597	chr19:37808831	NA	0.64	5.0	0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg04915414	chr1:154947654	SHC1;CKS1B	0.4	4.58	0.35	9.67e-6	Breast cancer;
UCEC	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.74	-4.81	-0.37	3.76e-6	Hair shape;
UCEC	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.9	-0.49	1.47e-10	Depression;
UCEC	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	6.68	0.48	4.64e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.79	-8.97	-0.59	1.31e-15	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg17800788	chr1:21766015	NBPF3	0.38	5.43	0.41	2.28e-7	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.79	-0.37	4.05e-6	Breast cancer;
UCEC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.08	-15.58	-0.79	6.14e-33	Chronic sinus infection;
UCEC	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.01	0.44	1.4e-8	IgG glycosylation;
UCEC	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.25	-0.46	4.22e-9	Resting heart rate;
UCEC	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.01	-0.38	1.57e-6	Huntington's disease progression;
UCEC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.48	-5.07	-0.39	1.18e-6	Prostate cancer;
UCEC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11958404	0.932	rs56204919	chr5:157431084	C/T	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.64	7.31	0.52	1.58e-11	Mean platelet volume;
UCEC	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-5.41	-0.41	2.46e-7	Response to antipsychotic treatment;
UCEC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.81e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.38	-4.8	-0.37	3.92e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
UCEC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg04756594	chr16:24857601	SLC5A11	0.46	5.45	0.41	2.12e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.85	7.55	0.53	4.19e-12	Blood metabolite levels;
UCEC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.65	7.58	0.53	3.57e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-4.52	-0.35	1.26e-5	Subjective well-being;
UCEC	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.78	-0.43	4.27e-8	Mortality in heart failure;
UCEC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.55	-5.28	-0.4	4.52e-7	Cognitive test performance;
UCEC	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.5	4.85	0.37	3.11e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.68	-4.96	-0.38	1.88e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-5.28	-0.4	4.58e-7	Colorectal cancer;
UCEC	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg24631222	chr15:78858424	CHRNA5	0.74	6.78	0.49	2.75e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs925228	0.955	rs6545162	chr2:24119241	C/T	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	0.92	12.78	0.73	1.25e-25	Homoarginine levels;
UCEC	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.86	4.74	0.36	4.95e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	8.13	0.56	1.64e-13	Post bronchodilator FEV1;
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-6.2	-0.46	5.5e-9	Platelet count;
UCEC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.59	5.17	0.39	7.36e-7	HDL cholesterol levels;
UCEC	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg23260525	chr10:116636907	FAM160B1	0.33	4.51	0.35	1.32e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.61	-6.0	-0.44	1.48e-8	Bipolar disorder;
UCEC	cis	rs1575951	1.000	rs61863393	chr10:130449511	T/C	cg27041381	chr10:131357203	MGMT	0.62	4.84	0.37	3.26e-6	Plasma clusterin levels;
UCEC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	4.74	0.36	4.95e-6	Breast cancer;
UCEC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.96	6.52	0.47	1.07e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	6.81	0.49	2.27e-10	Cognitive ability;
UCEC	cis	rs28669119	0.749	rs244750	chr5:88147192	T/C	cg18498987	chr5:88179539	MEF2C	0.73	4.64	0.36	7.75e-6	Schizophrenia;
UCEC	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.52	-4.86	-0.37	2.96e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	18.56	0.84	2.27e-40	Schizophrenia;
UCEC	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	4.97	0.38	1.82e-6	Mood instability;
UCEC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	0.73	7.12	0.51	4.47e-11	Breast cancer;
UCEC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.55	5.33	0.4	3.55e-7	Vitiligo;
UCEC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.37	-0.47	2.3e-9	Monocyte count;
UCEC	cis	rs78487399	0.808	rs7559842	chr2:43673442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-10.89	-0.67	1.31e-20	Vitiligo;
UCEC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.41	-4.6	-0.35	8.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.52	5.27	0.4	4.72e-7	N-glycan levels;
UCEC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg16235748	chr6:149772707	ZC3H12D	-0.45	-5.64	-0.42	8.61e-8	Dupuytren's disease;
UCEC	cis	rs10507349	0.632	rs555086	chr13:26816565	T/G	cg01600817	chr13:26797529	RNF6	0.45	5.01	0.38	1.56e-6	Type 2 diabetes;
UCEC	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.39	4.73	0.36	5.32e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	6.9	0.49	1.43e-10	Cognitive test performance;
UCEC	cis	rs7959452	0.836	rs12827594	chr12:69729434	G/A	cg20891283	chr12:69753455	YEATS4	0.73	7.51	0.53	5.34e-12	Blood protein levels;
UCEC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg24375607	chr4:120327624	NA	-0.5	-5.17	-0.39	7.59e-7	Corneal astigmatism;
UCEC	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.6	5.86	0.44	2.9e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.51	-4.79	-0.37	4.04e-6	Hepatocellular carcinoma;
UCEC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.55	-5.09	-0.39	1.1e-6	Initial pursuit acceleration;
UCEC	cis	rs57502260	0.704	rs72936570	chr11:68307139	A/G	cg20283391	chr11:68216788	NA	-0.7	-4.8	-0.37	3.79e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.62	5.71	0.43	6.1e-8	Multiple sclerosis;
UCEC	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg11871910	chr12:69753446	YEATS4	0.66	6.7	0.48	4.24e-10	Blood protein levels;
UCEC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.54	0.47	9.73e-10	Aortic root size;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.75	-0.36	4.84e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-5.21	-0.4	6.16e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.69	-4.53	-0.35	1.21e-5	White matter integrity;
UCEC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.36	-4.89	-0.37	2.65e-6	Eye color traits;
UCEC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg01256987	chr12:42539512	GXYLT1	0.4	4.71	0.36	5.65e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.59	-5.7	-0.43	6.46e-8	Pancreatic cancer;
UCEC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg20387954	chr3:183756860	HTR3D	0.5	6.0	0.44	1.46e-8	Anterior chamber depth;
UCEC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.5e-7	Tonsillectomy;
UCEC	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.64	0.42	8.28e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.54	5.18	0.39	7.08e-7	Lung cancer;
UCEC	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.63	6.62	0.48	6.39e-10	Skin colour saturation;
UCEC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg01017244	chr2:74357527	NA	0.63	5.85	0.43	3.06e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.99	6.73	0.49	3.55e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs4389974	0.932	rs10505162	chr8:112408142	G/C	cg22736090	chr17:62339926	TEX2	0.66	6.84	0.49	1.93e-10	Body mass index;
UCEC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-0.96	-5.81	-0.43	3.7e-8	Diabetic kidney disease;
UCEC	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg00122941	chr17:4613640	ARRB2	-0.57	-5.05	-0.38	1.28e-6	Lymphocyte counts;
UCEC	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-0.99	-11.37	-0.68	6.7e-22	Blood pressure (smoking interaction);
UCEC	cis	rs2415984	0.846	rs12891158	chr14:46832655	T/A	cg14871534	chr14:47121158	RPL10L	0.39	4.53	0.35	1.21e-5	Number of children ever born;
UCEC	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.46	-5.66	-0.42	7.58e-8	Subjective well-being;
UCEC	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	0.88	5.34	0.4	3.5e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7070678	0.615	rs61849293	chr10:29796820	G/A	cg07724896	chr10:29780678	SVIL	-0.53	-4.79	-0.37	4.06e-6	Platelet thrombus formation;
UCEC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.46	5.55	0.42	1.27e-7	Total body bone mineral density;
UCEC	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.23	-0.4	5.65e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.39	-4.7	-0.36	5.86e-6	Menopause (age at onset);
UCEC	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.7	-6.22	-0.46	4.78e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26035463	chr12:117627651	FBXO21	0.58	7.04	0.5	6.91e-11	Warfarin maintenance dose;
UCEC	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	0.67	7.17	0.51	3.48e-11	Homoarginine levels;
UCEC	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs78487399	0.808	rs7599781	chr2:43678726	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.47	-5.07	-0.39	1.2e-6	Monocyte count;
UCEC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.76	-0.37	4.65e-6	Breast cancer;
UCEC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.54	-4.91	-0.38	2.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg07537917	chr2:241836409	C2orf54	-0.33	-5.12	-0.39	9.62e-7	Urinary metabolites;
UCEC	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.28	0.4	4.63e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg11871910	chr12:69753446	YEATS4	0.88	10.24	0.65	6.52e-19	Blood protein levels;
UCEC	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	7.58	0.53	3.65e-12	Coronary artery disease;
UCEC	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.57	5.8	0.43	3.99e-8	Bipolar disorder;
UCEC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-6.05	-0.45	1.15e-8	Hemoglobin concentration;
UCEC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg17328964	chr8:145687451	CYHR1	-0.55	-5.66	-0.42	7.79e-8	Age at first birth;
UCEC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg20302342	chr1:156215951	PAQR6	0.53	5.45	0.41	2.03e-7	Tonsillectomy;
UCEC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg01256987	chr12:42539512	GXYLT1	-0.5	-5.79	-0.43	4.19e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-0.72	-10.04	-0.64	2.15e-18	Gut microbiome composition (winter);
UCEC	cis	rs8020441	0.786	rs59498790	chr14:51167929	T/A	cg04730355	chr14:51134070	SAV1	0.63	5.73	0.43	5.51e-8	Cognitive performance;
UCEC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-0.95	-12.99	-0.73	3.48e-26	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.6	-4.57	-0.35	1.03e-5	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.95	10.89	0.67	1.27e-20	Breast cancer;
UCEC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.72	6.77	0.49	2.8e-10	High light scatter reticulocyte count;
UCEC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.71	-6.44	-0.47	1.57e-9	Platelet distribution width;
UCEC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs7727544	0.526	rs17516457	chr5:131590387	T/C	cg14196790	chr5:131705035	SLC22A5	0.46	5.04	0.38	1.35e-6	Blood metabolite levels;
UCEC	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.97	-10.97	-0.67	7.78e-21	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.55	6.31	0.46	3.05e-9	Prostate cancer;
UCEC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.63	-5.73	-0.43	5.42e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.72	-7.22	-0.51	2.64e-11	Aortic root size;
UCEC	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg13683864	chr3:40499215	RPL14	0.58	6.08	0.45	1e-8	Renal cell carcinoma;
UCEC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.56	-5.88	-0.44	2.67e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.6	5.34	0.4	3.5e-7	Response to diuretic therapy;
UCEC	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Bladder cancer;
UCEC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.56	-0.53	3.94e-12	Breast cancer;
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	trans	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg15509575	chr4:2286509	ZFYVE28	0.42	7.38	0.52	1.07e-11	Rheumatoid arthritis;
UCEC	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.46	-4.77	-0.37	4.47e-6	Obesity-related traits;
UCEC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	1.0	13.26	0.74	6.7399999999999993e-27	Monocyte count;
UCEC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg00500100	chr5:140098250	VTRNA1-2	0.33	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs8105895	0.932	rs12150930	chr19:22223687	G/C	cg02912127	chr19:22235281	ZNF257	-0.54	-4.73	-0.36	5.13e-6	Body mass index (change over time);
UCEC	cis	rs7246967	0.673	rs56725192	chr19:22810938	T/G	cg05241461	chr19:22816980	ZNF492	0.52	5.45	0.41	2.04e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.08	0.39	1.13e-6	Rheumatoid arthritis;
UCEC	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.65	-6.57	-0.48	8.35e-10	Blood pressure (smoking interaction);
UCEC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.46	-4.57	-0.35	1.03e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.22	0.4	6.06e-7	Personality dimensions;
UCEC	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.55	0.42	1.31e-7	Birth weight;
UCEC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.76	-8.43	-0.57	2.92e-14	Height;
UCEC	cis	rs4499344	0.730	rs12460663	chr19:33098238	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.06	0.45	1.07e-8	Mean platelet volume;
UCEC	cis	rs256277	0.544	rs26560	chr5:111338466	C/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	0.53	5.05	0.38	1.27e-6	Coronary artery disease;
UCEC	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg04662943	chr10:102668895	NA	0.46	4.59	0.35	9.48e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.73	5.69	0.42	6.66e-8	Menarche (age at onset);
UCEC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.47	-5.91	-0.44	2.32e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs4853036	0.903	rs13021969	chr2:70117602	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-4.68	-0.36	6.48e-6	Colorectal or endometrial cancer;
UCEC	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.68	6.55	0.48	9.14e-10	Schizophrenia;
UCEC	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.4	-5.04	-0.38	1.37e-6	Carotid intima media thickness;
UCEC	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.34	4.91	0.38	2.38e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	7.59	0.53	3.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.03	-0.38	1.41e-6	Parkinson's disease;
UCEC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg01112020	chr2:239008986	ESPNL	-0.36	-4.75	-0.36	4.81e-6	Prostate cancer;
UCEC	cis	rs7714670	0.736	rs2973548	chr5:73091228	C/T	cg00119811	chr5:73092353	RGNEF	-0.38	-4.67	-0.36	6.81e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.61	-6.75	-0.49	3.12e-10	Prostate cancer;
UCEC	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.62	-4.96	-0.38	1.91e-6	Body mass index;
UCEC	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.41	4.59	0.35	9.37e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.95	-0.44	1.92e-8	Parkinson's disease;
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.62	8.38	0.57	3.92e-14	Skin aging (microtopography measurement);
UCEC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-1.01	-8.0	-0.55	3.36e-13	Bone mineral density;
UCEC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.57	-4.72	-0.36	5.37e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.98	-11.5	-0.69	3.16e-22	Obesity-related traits;
UCEC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.56	-5.34	-0.4	3.5e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.79	-8.13	-0.56	1.62e-13	Mosquito bite size;
UCEC	cis	rs8032158	0.963	rs16976600	chr15:56154635	C/T	cg10433327	chr15:56209506	NEDD4	-0.29	-4.81	-0.37	3.64e-6	Keloid;
UCEC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.56	-5.32	-0.4	3.75e-7	Obesity-related traits;
UCEC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg21253087	chr9:139290292	SNAPC4	0.43	4.75	0.36	4.89e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg19622623	chr12:86230825	RASSF9	-0.38	-4.59	-0.35	9.38e-6	Major depressive disorder;
UCEC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.26	-0.4	5.04e-7	Blood metabolite levels;
UCEC	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-4.62	-0.36	8.45e-6	Fear of minor pain;
UCEC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg10381502	chr11:71823885	C11orf51	1.03	4.57	0.35	1.03e-5	Severe influenza A (H1N1) infection;
UCEC	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.55	-5.53	-0.41	1.46e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg18681998	chr4:17616180	MED28	-0.66	-6.48	-0.47	1.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.49	4.8	0.37	3.87e-6	Colorectal cancer;
UCEC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg26114124	chr12:9217669	LOC144571	0.42	5.15	0.39	8.31e-7	Sjögren's syndrome;
UCEC	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.6	5.23	0.4	5.67e-7	Cocaine dependence;
UCEC	cis	rs9463078	0.625	rs1360197	chr6:44949630	T/C	cg25276700	chr6:44698697	NA	-0.42	-4.65	-0.36	7.26e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	trans	rs4389974	0.932	rs4354336	chr8:112390526	G/T	cg22736090	chr17:62339926	TEX2	0.66	6.83	0.49	2.04e-10	Body mass index;
UCEC	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.7	-7.64	-0.53	2.6e-12	Ear protrusion;
UCEC	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.47	-4.97	-0.38	1.88e-6	Alzheimer's disease;
UCEC	cis	rs2281845	0.507	rs10800760	chr1:201100439	G/A	cg06714761	chr1:201096289	NA	0.47	5.08	0.39	1.12e-6	Permanent tooth development;
UCEC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.3e-11	Blood protein levels;
UCEC	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.76	-6.82	-0.49	2.17e-10	Inflammatory bowel disease;
UCEC	trans	rs66573146	1.000	rs73202122	chr4:7005594	G/A	cg07817883	chr1:32538562	TMEM39B	1.28	8.86	0.59	2.4e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.65	6.8	0.49	2.44e-10	Longevity;Endometriosis;
UCEC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.47	4.78	0.37	4.16e-6	Blood metabolite levels;
UCEC	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.74	7.67	0.53	2.15e-12	Parkinson's disease;
UCEC	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.58	5.89	0.44	2.49e-8	Dental caries;
UCEC	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.59	-5.69	-0.42	6.73e-8	White matter hyperintensity burden;
UCEC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	10.23	0.64	7.08e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs240764	0.604	rs9373590	chr6:101212001	A/T	cg09795085	chr6:101329169	ASCC3	0.5	4.61	0.36	8.5e-6	Neuroticism;
UCEC	cis	rs17428704	1.000	rs62345049	chr5:14426328	C/T	cg24728912	chr5:14143221	TRIO	0.7	4.66	0.36	6.94e-6	Electroencephalogram traits;
UCEC	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.52	5.43	0.41	2.29e-7	Schizophrenia;
UCEC	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-6.85	-0.49	1.89e-10	Colorectal cancer;
UCEC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	-0.69	-4.7	-0.36	5.86e-6	Narcolepsy;
UCEC	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	14.66	0.77	1.5e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg10932868	chr11:921992	NA	0.44	5.84	0.43	3.3e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7812879	0.929	rs2254546	chr8:11343680	A/G	cg21775007	chr8:11205619	TDH	-0.62	-4.58	-0.35	9.79e-6	Systemic lupus erythematosus;
UCEC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.56	-6.46	-0.47	1.47e-9	Attention deficit hyperactivity disorder;
UCEC	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-5.09	-0.39	1.08e-6	Schizophrenia;
UCEC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.56	-6.23	-0.46	4.64e-9	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	6.04	0.45	1.22e-8	Bone mineral density;
UCEC	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.82	8.4	0.57	3.42e-14	Mean corpuscular hemoglobin;
UCEC	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24308560	chr3:49941425	MST1R	0.44	4.65	0.36	7.21e-6	Body mass index;
UCEC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.73	0.54	1.58e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.54	5.12	0.39	9.52e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs13401104	0.796	rs10929171	chr2:237115622	G/A	cg23897927	chr2:237117786	ASB18	-0.52	-4.51	-0.35	1.34e-5	Educational attainment;
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.66	-5.66	-0.42	7.51e-8	Platelet count;
UCEC	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.17	-0.51	3.3e-11	Total cholesterol levels;
UCEC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg20203395	chr5:56204925	C5orf35	-0.51	-4.53	-0.35	1.21e-5	Coronary artery disease;
UCEC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.62	-5.29	-0.4	4.34e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg17469321	chr7:55412551	NA	0.7	6.05	0.45	1.16e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs17106184	1.000	rs12085666	chr1:51391569	A/G	cg07174182	chr1:51127561	FAF1	-0.61	-5.06	-0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.16	14.9	0.78	3.46e-31	Cognitive function;
UCEC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.41	-5.02	-0.38	1.48e-6	Dupuytren's disease;
UCEC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.87	-0.44	2.75e-8	Hemoglobin concentration;
UCEC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.91e-7	Hemoglobin concentration;
UCEC	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs3956705	0.866	rs71532543	chr7:32998910	G/A	cg05721444	chr7:32995514	FKBP9	-0.5	-5.09	-0.39	1.09e-6	Red cell distribution width;
UCEC	cis	rs215614	0.593	rs215695	chr7:32397908	A/G	cg18961681	chr7:32467657	NA	-0.36	-4.69	-0.36	6.14e-6	Smoking behavior;
UCEC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.78	0.59	3.82e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Blood protein levels;
UCEC	cis	rs953387	1.000	rs4954566	chr2:136901513	A/G	cg07169764	chr2:136633963	MCM6	-0.52	-5.23	-0.4	5.74e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.16	-0.45	6.77e-9	Metabolite levels;
UCEC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg23719950	chr11:63933701	MACROD1	-0.66	-4.56	-0.35	1.05e-5	Mean platelet volume;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.74	7.47	0.52	6.44e-12	Longevity;Endometriosis;
UCEC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg16497661	chr14:103986332	CKB	-0.42	-4.88	-0.37	2.73e-6	Body mass index;
UCEC	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg06096015	chr1:231504339	EGLN1	0.44	4.85	0.37	3.11e-6	Hemoglobin concentration;
UCEC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12379764	chr21:47803548	PCNT	-0.46	-4.93	-0.38	2.21e-6	Testicular germ cell tumor;
UCEC	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.4	5.02	0.38	1.49e-6	Reticulocyte count;
UCEC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.56	-4.67	-0.36	6.61e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs1167827	0.839	rs794369	chr7:75162175	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.69	6.06	0.45	1.1e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	5.89	0.44	2.57e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-8.1	-0.56	1.96e-13	Body mass index;
UCEC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-6.51	-0.47	1.12e-9	Prostate cancer;
UCEC	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	11.52	0.69	2.7e-22	Exhaled nitric oxide output;
UCEC	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.4	4.85	0.37	3.16e-6	Height;
UCEC	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg16497661	chr14:103986332	CKB	0.49	5.84	0.43	3.17e-8	Body mass index;
UCEC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.5	-5.24	-0.4	5.35e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7309	0.967	rs3754970	chr2:162091836	T/C	cg08807892	chr2:162101083	NA	0.59	6.1	0.45	8.94e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	1.2	8.95	0.59	1.46e-15	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs10208940	0.920	rs6742045	chr2:68811850	G/A	cg12452813	chr2:68675892	NA	0.48	4.63	0.36	7.91e-6	Urate levels in lean individuals;
UCEC	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	8.4	0.57	3.51e-14	Chronic sinus infection;
UCEC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.6	-5.85	-0.43	3.05e-8	White matter hyperintensity burden;
UCEC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs11543198	0.826	rs7174305	chr15:74728998	C/G	cg22549041	chr15:75019251	CYP1A1	0.73	4.83	0.37	3.38e-6	Bladder cancer;
UCEC	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg05925327	chr15:68127851	NA	-0.53	-5.82	-0.43	3.63e-8	Restless legs syndrome;
UCEC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg16616514	chr4:6324629	PPP2R2C	0.47	5.77	0.43	4.42e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.55	5.5	0.41	1.62e-7	Aortic root size;
UCEC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	9.68	0.62	1.89e-17	Monocyte count;
UCEC	cis	rs4372836	0.729	rs6547874	chr2:28982030	A/G	cg09522027	chr2:28974177	PPP1CB	-0.69	-7.56	-0.53	4.06e-12	Body mass index;
UCEC	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	0.55	4.51	0.35	1.29e-5	Breast cancer (early onset);
UCEC	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.64	-5.68	-0.42	7.12e-8	Metabolite levels;
UCEC	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.98	-7.66	-0.53	2.25e-12	Dupuytren's disease;
UCEC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.56	5.79	0.43	4.14e-8	Dental caries;
UCEC	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg13319975	chr6:146136371	FBXO30	0.44	4.73	0.36	5.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2734839	0.929	rs11608185	chr11:113294976	T/C	cg14159747	chr11:113255604	NA	0.57	7.31	0.52	1.54e-11	Information processing speed;
UCEC	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	0.88	6.36	0.46	2.38e-9	Red blood cell traits;
UCEC	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg23229016	chr1:26872525	RPS6KA1	0.26	5.06	0.39	1.23e-6	Glucose homeostasis traits;
UCEC	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-8.76	-0.59	4.29e-15	Coffee consumption (cups per day);
UCEC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg24920358	chr1:40204285	PPIE	0.47	4.78	0.37	4.15e-6	Blood protein levels;
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.74	5.94	0.44	2e-8	Platelet count;
UCEC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg24562669	chr7:97807699	LMTK2	0.42	5.16	0.39	7.88e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18932078	chr1:2524107	MMEL1	0.4	6.3	0.46	3.21e-9	Ulcerative colitis;
UCEC	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.52	5.14	0.39	8.63e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.48	-5.29	-0.4	4.44e-7	Schizophrenia;
UCEC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-0.58	-7.13	-0.51	4.1e-11	Total body bone mineral density;
UCEC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10553204	chr2:20871195	GDF7	0.39	5.24	0.4	5.53e-7	Abdominal aortic aneurysm;
UCEC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-13.46	-0.74	2.05e-27	Height;
UCEC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.66	6.15	0.45	6.86e-9	Aortic root size;
UCEC	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.59	6.71	0.48	3.89e-10	Blood metabolite ratios;
UCEC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.51	5.47	0.41	1.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	4.6	0.35	9.2e-6	Cognitive test performance;
UCEC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.51	-0.53	5.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.53	4.89	0.37	2.65e-6	Night sleep phenotypes;
UCEC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-1.01	-11.73	-0.7	7.8e-23	Cognitive function;
UCEC	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13939156	chr17:80058883	NA	-0.36	-4.55	-0.35	1.11e-5	Life satisfaction;
UCEC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg13695892	chr22:41940480	POLR3H	0.66	4.64	0.36	7.77e-6	Vitiligo;
UCEC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.7	-6.85	-0.49	1.87e-10	Diastolic blood pressure;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg19610905	chr11:61596333	FADS2	-0.57	-4.62	-0.36	8.41e-6	Neutrophil count;Sum basophil neutrophil counts;
UCEC	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.54	-4.83	-0.37	3.4e-6	Carotid intima media thickness;
UCEC	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.64	4.93	0.38	2.2e-6	Orofacial clefts;
UCEC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.5	-4.93	-0.38	2.17e-6	Total body bone mineral density;
UCEC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.59	-6.61	-0.48	6.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	0.96	7.77	0.54	1.24e-12	Pediatric areal bone mineral density (radius);
UCEC	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-7.66	-0.53	2.29e-12	Morning vs. evening chronotype;
UCEC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.77	8.23	0.56	9.09e-14	Parkinson's disease;
UCEC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.61	-4.72	-0.36	5.44e-6	Coronary artery disease;
UCEC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.51	-4.77	-0.37	4.46e-6	Corneal structure;
UCEC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.56	5.94	0.44	1.97e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.66	6.96	0.5	1.03e-10	Dental caries;
UCEC	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.61	-4.58	-0.35	9.66e-6	Mean platelet volume;
UCEC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg14906510	chr12:7781169	NA	-0.56	-4.61	-0.36	8.71e-6	HDL cholesterol levels;
UCEC	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.31	-0.4	4.06e-7	Parkinson's disease;
UCEC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.72	-5.21	-0.39	6.22e-7	Mean platelet volume;
UCEC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00802000	chr16:706648	WDR90	-0.49	-5.76	-0.43	4.74e-8	Height;
UCEC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.82	8.9	0.59	1.86e-15	Longevity;
UCEC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.17	15.02	0.78	1.73e-31	Cognitive function;
UCEC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	0.93	9.77	0.63	1.08e-17	Breast cancer;
UCEC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18932078	chr1:2524107	MMEL1	0.4	6.53	0.47	1e-9	Ulcerative colitis;
UCEC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.53	5.95	0.44	1.89e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg24562669	chr7:97807699	LMTK2	0.48	5.88	0.44	2.71e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.19	0.39	7.01e-7	Blood protein levels;
UCEC	cis	rs4615376	1.000	rs9463408	chr6:13063824	A/G	cg11378619	chr6:12164359	HIVEP1	-0.49	-4.85	-0.37	3.1e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg04435241	chr20:2442475	SNRPB	-0.6	-6.69	-0.48	4.28e-10	Schizophrenia;
UCEC	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.8	-0.37	3.8e-6	Blood metabolite levels;
UCEC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-7.31	-0.52	1.56e-11	Breast cancer;
UCEC	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg04733989	chr22:42467013	NAGA	-0.48	-4.94	-0.38	2.06e-6	Cognitive function;
UCEC	cis	rs8177876	0.822	rs16954582	chr16:81114157	C/T	cg08591886	chr16:81111003	C16orf46	-0.75	-4.78	-0.37	4.17e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.23	0.4	5.62e-7	Electroencephalogram traits;
UCEC	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	4.5	0.35	1.36e-5	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs6909279	0.933	rs9479068	chr6:151872448	G/T	cg16336494	chr6:151188259	MTHFD1L	0.41	4.53	0.35	1.21e-5	Bone mineral density;
UCEC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.45	5.15	0.39	8.26e-7	Height;
UCEC	cis	rs77926410	0.725	rs11053808	chr12:10615173	G/A	cg25023291	chr12:11339792	TAS2R42	-0.38	-4.8	-0.37	3.93e-6	Mean corpuscular volume;
UCEC	cis	rs405956	1.000	rs405956	chr6:105554355	A/G	cg22580625	chr6:105627791	POPDC3	0.68	6.17	0.45	6.44e-9	QT interval;
UCEC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.46	-5.79	-0.43	4.06e-8	Electrocardiographic conduction measures;
UCEC	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.4	5.5	0.41	1.63e-7	Crohn's disease;
UCEC	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.47	0.41	1.87e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.69	6.46	0.47	1.43e-9	Aortic root size;
UCEC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.51	5.3	0.4	4.12e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	1.0	6.32	0.46	2.88e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-6.03	-0.45	1.27e-8	Prudent dietary pattern;
UCEC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	0.58	5.61	0.42	9.91e-8	Total cholesterol levels;
UCEC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-11.88	-0.7	3.06e-23	Coronary artery disease;
UCEC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.62	-6.45	-0.47	1.56e-9	Initial pursuit acceleration;
UCEC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.47	-4.93	-0.38	2.21e-6	Type 2 diabetes;
UCEC	cis	rs28374715	0.629	rs2118740	chr15:41577232	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.1	-10.46	-0.65	1.74e-19	Ulcerative colitis;
UCEC	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.28	-0.4	4.53e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg13092806	chr2:177043255	NA	0.55	5.2	0.39	6.55e-7	IgG glycosylation;
UCEC	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg03078520	chr22:18463400	MICAL3	-0.47	-4.81	-0.37	3.73e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.52	5.87	0.44	2.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-6.24	-0.46	4.51e-9	Menarche (age at onset);
UCEC	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.63	-5.98	-0.44	1.63e-8	Vitiligo;
UCEC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg05072774	chr3:49840536	C3orf54	-0.54	-5.59	-0.42	1.09e-7	Resting heart rate;
UCEC	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.58	5.34	0.4	3.41e-7	Coronary artery disease;
UCEC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg24562669	chr7:97807699	LMTK2	0.48	5.87	0.44	2.85e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	10.85	0.67	1.59e-20	Headache;
UCEC	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.45	4.77	0.37	4.34e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.65	4.69	0.36	6.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.86	5.69	0.42	6.62e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs7397861	1.000	rs4128354	chr12:66823686	A/T	cg21058506	chr12:66524791	LLPH	0.49	5.1	0.39	1.05e-6	Menopause (age at onset);
UCEC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	0.99	11.11	0.68	3.31e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9309473	0.519	rs13022145	chr2:73863473	G/A	cg20560298	chr2:73613845	ALMS1	0.53	5.03	0.38	1.38e-6	Metabolite levels;
UCEC	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.68	-5.23	-0.4	5.76e-7	Birth weight;
UCEC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.88	10.78	0.66	2.53e-20	Breast cancer;
UCEC	cis	rs2224391	0.590	rs2773298	chr6:5242067	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.53	-0.35	1.23e-5	Height;
UCEC	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.52	5.15	0.39	8.21e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-4.91	-0.38	2.34e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.72	9.11	0.6	5.55e-16	Testicular germ cell tumor;
UCEC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.46	4.94	0.38	2.06e-6	Smoking initiation;
UCEC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.69	7.89	0.55	6.33e-13	Menopause (age at onset);
UCEC	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.74	9.18	0.6	3.71e-16	Obesity-related traits;
UCEC	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.41	4.76	0.37	4.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg10503236	chr1:231470652	EXOC8	-0.41	-4.76	-0.37	4.68e-6	Hemoglobin concentration;
UCEC	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.79	-8.54	-0.58	1.59e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.61	-5.56	-0.42	1.26e-7	Monocyte percentage of white cells;
UCEC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.67	6.07	0.45	1.05e-8	Aortic root size;
UCEC	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.82	-0.49	2.21e-10	Mood instability;
UCEC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.8	-9.06	-0.6	7.3e-16	Height;
UCEC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg12024160	chr4:1254474	NA	0.65	7.77	0.54	1.25e-12	Obesity-related traits;
UCEC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-6.55	-0.48	8.86e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.28e-9	Platelet count;
UCEC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.81	8.81	0.59	3.17e-15	Breast cancer;
UCEC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.43	0.41	2.26e-7	Breast cancer;
UCEC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.61	0.42	9.55e-8	Heart rate;
UCEC	cis	rs17221323	1.000	rs17221323	chr10:618685	A/G	cg16386425	chr10:429943	DIP2C	-0.81	-5.99	-0.44	1.55e-8	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	0.85	5.57	0.42	1.2e-7	Iron status biomarkers;
UCEC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.78	-4.62	-0.36	8.43e-6	Inflammatory biomarkers;
UCEC	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.69e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.65	4.55	0.35	1.1e-5	Aortic root size;
UCEC	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.41	4.85	0.37	3.07e-6	Anterior chamber depth;
UCEC	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	8.85	0.59	2.61e-15	Bipolar disorder;
UCEC	cis	rs6437061	0.774	rs3103258	chr2:233000699	C/T	cg02061626	chr2:233274167	ALPPL2	-0.51	-5.7	-0.43	6.38e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.51	5.62	0.42	9.48e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs11697848	1.000	rs74837988	chr20:48541193	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.77	4.71	0.36	5.68e-6	Alzheimer's disease;
UCEC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.57	5.53	0.41	1.45e-7	Aortic root size;
UCEC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.84	7.75	0.54	1.38e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	5.08	0.39	1.13e-6	Electrocardiographic conduction measures;
UCEC	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.53	4.94	0.38	2.13e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	0.99	11.11	0.68	3.31e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.57e-6	Colorectal cancer;
UCEC	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg19715936	chr7:50634035	DDC	-0.48	-5.93	-0.44	2.03e-8	Malaria;
UCEC	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.72	7.56	0.53	4e-12	Primary sclerosing cholangitis;
UCEC	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.58	5.32	0.4	3.74e-7	Corneal astigmatism;
UCEC	cis	rs1978968	1.000	rs11704827	chr22:18450287	A/T	cg03078520	chr22:18463400	MICAL3	-0.52	-5.19	-0.39	6.99e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg11632617	chr15:75315747	PPCDC	-0.6	-6.93	-0.5	1.2e-10	Blood trace element (Zn levels);
UCEC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.81	9.17	0.6	3.86e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.37	-0.52	1.16e-11	Hypospadias;
UCEC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.05e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.7	-0.36	5.89e-6	Aortic root size;
UCEC	cis	rs73001065	0.901	rs73004967	chr19:19717056	A/G	cg03709012	chr19:19516395	GATAD2A	1.24	5.8	0.43	3.87e-8	LDL cholesterol;
UCEC	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.94	-0.55	4.8e-13	Exhaled nitric oxide output;
UCEC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.65	6.07	0.45	1.06e-8	Aortic root size;
UCEC	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.69	7.47	0.52	6.68e-12	Breast cancer;
UCEC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.71	-6.91	-0.5	1.35e-10	Aortic root size;
UCEC	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4372836	0.504	rs13030945	chr2:29087799	C/A	cg09522027	chr2:28974177	PPP1CB	-0.67	-7.07	-0.5	5.87e-11	Body mass index;
UCEC	cis	rs4975616	0.686	rs40182	chr5:1350397	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.52	-6.14	-0.45	7.36e-9	Lung cancer;
UCEC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.89	0.49	1.55e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.95	6.19	0.45	5.74e-9	Gut microbiome composition (summer);
UCEC	cis	rs7558233	0.614	rs4665213	chr2:23678781	A/G	cg00747342	chr2:23700632	KLHL29	0.5	4.53	0.35	1.23e-5	Cannabis use (initiation);
UCEC	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.02	-7.23	-0.51	2.45e-11	Gut microbiome composition (summer);
UCEC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.26	14.93	0.78	2.86e-31	Type 1 diabetes nephropathy;
UCEC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-12.3	-0.71	2.31e-24	Height;
UCEC	cis	rs749052	0.561	rs3116193	chr2:233059815	A/G	cg23548455	chr2:233377587	NA	0.69	4.56	0.35	1.05e-5	Height;
UCEC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.19	0.71	4.59e-24	Prudent dietary pattern;
UCEC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.56	5.69	0.42	6.68e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.52	-6.47	-0.47	1.39e-9	Total body bone mineral density;
UCEC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.6	-5.11	-0.39	9.85e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.21	-13.82	-0.75	2.26e-28	Breast cancer;
UCEC	cis	rs13401104	0.796	rs10929164	chr2:237110321	C/T	cg23897927	chr2:237117786	ASB18	-0.52	-4.53	-0.35	1.2e-5	Educational attainment;
UCEC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	5.44	0.41	2.14e-7	Platelet count;
UCEC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18932078	chr1:2524107	MMEL1	0.34	5.69	0.42	6.66e-8	Ulcerative colitis;
UCEC	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.67	7.57	0.53	3.69e-12	Crohn's disease;
UCEC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg18016565	chr1:150552671	MCL1	-0.54	-5.92	-0.44	2.22e-8	Tonsillectomy;
UCEC	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.48	-5.15	-0.39	8.26e-7	Pulse pressure;
UCEC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.54	-6.13	-0.45	7.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.68	-4.92	-0.38	2.29e-6	Multiple sclerosis;
UCEC	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.52	5.92	0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg01262667	chr19:19385393	TM6SF2	-0.49	-6.61	-0.48	6.75e-10	Tonsillectomy;
UCEC	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.89	-0.55	6.34e-13	Total cholesterol levels;
UCEC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.57	-6.92	-0.5	1.32e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7581030	1.000	rs12986712	chr2:71582308	C/G	cg07678644	chr2:71558969	ZNF638	-0.56	-5.14	-0.39	8.6e-7	Testicular germ cell tumor;
UCEC	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.54	4.57	0.35	1.01e-5	Colorectal cancer;
UCEC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg23307798	chr14:103986281	CKB	-0.61	-7.33	-0.52	1.39e-11	Body mass index;
UCEC	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.09	-6.27	-0.46	3.74e-9	Diabetic retinopathy;
UCEC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.69	5.35	0.4	3.36e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	8.06	0.55	2.46e-13	Mean corpuscular hemoglobin;
UCEC	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.57	-4.56	-0.35	1.07e-5	Migraine;Coronary artery disease;
UCEC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-6.48	-0.47	1.29e-9	Tonsillectomy;
UCEC	cis	rs7246967	0.673	rs8106180	chr19:22879360	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.48	0.47	1.29e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.74	8.18	0.56	1.26e-13	Menopause (age at onset);
UCEC	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	4.79	0.37	4.1e-6	Height;
UCEC	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg18499060	chr19:17611586	SLC27A1	-0.39	-4.68	-0.36	6.37e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.81	-8.11	-0.56	1.78e-13	Obesity-related traits;
UCEC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.58	-5.45	-0.41	2.12e-7	Blood protein levels;
UCEC	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.75	0.49	3.26e-10	Coronary artery disease;
UCEC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.94	10.3	0.65	4.68e-19	Cognitive function;
UCEC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.67	-5.66	-0.42	7.67e-8	Alcohol dependence;
UCEC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg09165964	chr15:75287851	SCAMP5	-0.45	-5.2	-0.39	6.63e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg02158880	chr13:53174818	NA	-0.42	-4.83	-0.37	3.35e-6	Lewy body disease;
UCEC	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	5.65	0.42	8.04e-8	Coffee consumption (cups per day);
UCEC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18932078	chr1:2524107	MMEL1	0.32	5.12	0.39	9.28e-7	Ulcerative colitis;
UCEC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg05738196	chr6:26577821	NA	0.63	7.42	0.52	8.57e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.84	8.44	0.57	2.73e-14	Blood protein levels;
UCEC	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.47	4.94	0.38	2.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.3e-8	Aortic root size;
UCEC	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.8	6.8	0.49	2.42e-10	Gastritis;
UCEC	cis	rs7246967	0.673	rs427709	chr19:22998163	A/G	cg05241461	chr19:22816980	ZNF492	0.52	4.84	0.37	3.25e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.25	0.71	3.18e-24	Prudent dietary pattern;
UCEC	cis	rs9470794	1.000	rs73419955	chr6:38045272	A/C	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs742614	0.533	rs2092737	chr20:32428135	A/C	cg06304546	chr20:32448765	NA	-0.44	-4.76	-0.37	4.53e-6	Stearic acid (18:0) levels;
UCEC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.83	9.41	0.61	9.22e-17	Menopause (age at onset);
UCEC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg22563815	chr15:78856949	CHRNA5	-0.36	-4.85	-0.37	3.05e-6	Sudden cardiac arrest;
UCEC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg08222913	chr3:52553049	STAB1	-0.4	-4.62	-0.36	8.38e-6	Bipolar disorder;
UCEC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.9	5.77	0.43	4.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.44	-4.89	-0.37	2.6e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg23978390	chr7:1156363	C7orf50	0.62	6.63	0.48	6.12e-10	Longevity;Endometriosis;
UCEC	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.67	6.67	0.48	4.78e-10	Itch intensity from mosquito bite;
UCEC	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg10820045	chr2:198174542	NA	-0.41	-4.98	-0.38	1.76e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.51	5.38	0.41	2.83e-7	Dupuytren's disease;
UCEC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00546932	chr16:1947055	NA	0.37	5.0	0.38	1.58e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg08798685	chr6:27730294	NA	-0.65	-4.56	-0.35	1.06e-5	Depression;
UCEC	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.64e-13	Chronic sinus infection;
UCEC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg24308560	chr3:49941425	MST1R	-0.51	-4.68	-0.36	6.32e-6	Resting heart rate;
UCEC	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	5.55	0.42	1.27e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.58	-4.58	-0.35	9.95e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg23093090	chr10:104574429	C10orf26	0.46	5.08	0.39	1.15e-6	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg05501817	chr11:14380813	RRAS2	0.51	5.02	0.38	1.47e-6	Sense of smell;
UCEC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.6	6.54	0.47	9.49e-10	Total body bone mineral density;
UCEC	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	4.84	0.37	3.3e-6	Response to antipsychotic treatment;
UCEC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	4.74	0.36	4.9e-6	Birth weight;
UCEC	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.53	4.69	0.36	6.19e-6	Height;
UCEC	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7560272	0.723	rs6729468	chr2:73765253	C/A	cg20560298	chr2:73613845	ALMS1	-0.51	-4.99	-0.38	1.72e-6	Schizophrenia;
UCEC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg08271804	chr19:22816896	ZNF492	0.64	6.53	0.47	1.01e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.55	-4.99	-0.38	1.65e-6	Systemic lupus erythematosus;
UCEC	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg21905437	chr5:178450457	ZNF879	0.64	7.17	0.51	3.47e-11	Pubertal anthropometrics;
UCEC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.72	7.13	0.51	4.23e-11	Smoking behavior;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg08877624	chr8:141521446	CHRAC1	0.64	6.77	0.49	2.9e-10	Schizophrenia;
UCEC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg16497661	chr14:103986332	CKB	-0.44	-5.22	-0.4	6.12e-7	Body mass index;
UCEC	cis	rs1165472	0.755	rs12239009	chr1:56166508	G/T	cg11523071	chr1:56160889	NA	0.49	4.5	0.35	1.35e-5	Paclitaxel-induced neuropathy;
UCEC	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-0.85	-7.8	-0.54	1.03e-12	Blood pressure (smoking interaction);
UCEC	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg14092571	chr14:90743983	NA	-0.42	-5.71	-0.43	6.05e-8	Mortality in heart failure;
UCEC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.57	5.38	0.41	2.92e-7	Blood metabolite levels;
UCEC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.58	5.33	0.4	3.67e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.74	-9.04	-0.6	8.36e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.45	-4.97	-0.38	1.87e-6	White matter hyperintensity burden;
UCEC	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.76	-8.62	-0.58	9.97e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.56	-4.92	-0.38	2.25e-6	Schizophrenia;
UCEC	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.97	0.44	1.72e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	5.1	0.39	1.03e-6	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.38	4.54	0.35	1.15e-5	Sitting height ratio;
UCEC	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27286337	chr10:134555280	INPP5A	0.62	5.48	0.41	1.77e-7	Migraine;
UCEC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.3e-8	Aortic root size;
UCEC	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.44	-0.57	2.77e-14	Total cholesterol levels;
UCEC	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg21419209	chr3:44054225	NA	-0.46	-4.64	-0.36	7.76e-6	Coronary artery disease;
UCEC	cis	rs9650657	0.812	rs6601522	chr8:10629061	G/T	cg00629382	chr8:10268916	MSRA	-0.49	-4.92	-0.38	2.27e-6	Neuroticism;
UCEC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.41	-0.57	3.29e-14	Obesity-related traits;
UCEC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.53	-5.8	-0.43	3.98e-8	Longevity;
UCEC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.2	-0.46	5.38e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg27631724	chr1:11040367	C1orf127	0.33	4.61	0.36	8.81e-6	Ewing sarcoma;
UCEC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.49	-4.65	-0.36	7.48e-6	Parkinson's disease;
UCEC	cis	rs12468557	0.527	rs11685955	chr2:211485476	T/A	cg07063745	chr2:211341572	LANCL1;CPS1	-0.63	-6.23	-0.46	4.76e-9	Body mass index in asthmatics;
UCEC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg22974920	chr21:40686053	BRWD1	-0.49	-4.87	-0.37	2.83e-6	Menarche (age at onset);
UCEC	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	5.53	0.42	1.41e-7	Mood instability;
UCEC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.67	6.09	0.45	9.6e-9	Body mass index;
UCEC	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	8.03	0.55	2.92e-13	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	5.47	0.41	1.92e-7	Monocyte percentage of white cells;
UCEC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.73	-9.05	-0.6	8.02e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1712517	0.904	rs7905968	chr10:105135319	C/T	cg05636881	chr10:105038444	INA	0.4	4.79	0.37	4.03e-6	Migraine;
UCEC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.37	0.57	4.24e-14	Prudent dietary pattern;
UCEC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7246967	0.866	rs35177997	chr19:23060227	T/C	cg24889512	chr19:22816950	ZNF492	0.49	4.99	0.38	1.68e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.84	5.52	0.41	1.48e-7	Psoriasis;
UCEC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs10242455	1.000	rs7808022	chr7:99220083	A/C	cg18809830	chr7:99032528	PTCD1	-0.54	-4.6	-0.35	9.15e-6	Blood metabolite levels;
UCEC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18402987	chr7:1209562	NA	0.45	4.7	0.36	5.93e-6	Longevity;Endometriosis;
UCEC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.54	-6.06	-0.45	1.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18252515	chr7:66147081	NA	-0.46	-4.73	-0.36	5.23e-6	Aortic root size;
UCEC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.94	0.38	2.08e-6	Breast cancer;
UCEC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.73	6.04	0.45	1.2e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-8.38	-0.57	3.85e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	7.89	0.55	6.51e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs7246967	0.673	rs34682021	chr19:22826728	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg20821713	chr7:1055600	C7orf50	-0.52	-5.13	-0.39	9.11e-7	Longevity;Endometriosis;
UCEC	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18252515	chr7:66147081	NA	0.46	4.69	0.36	6.27e-6	Aortic root size;
UCEC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.61	5.29	0.4	4.27e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs925550	1.000	rs6831934	chr4:123588836	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.54	-4.76	-0.37	4.58e-6	Primary biliary cholangitis;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18402987	chr7:1209562	NA	0.52	5.67	0.42	7.24e-8	Longevity;Endometriosis;
UCEC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.32	-4.53	-0.35	1.22e-5	Alzheimer's disease (late onset);
UCEC	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg22067481	chr19:53234126	ZNF611	0.49	5.27	0.4	4.82e-7	Response to paliperidone in schizophrenia (PANSS score);
UCEC	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	0.89	9.26	0.61	2.36e-16	Left atrial antero-posterior diameter;
UCEC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.64	-0.36	7.57e-6	Lung cancer in ever smokers;
UCEC	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.48	-4.76	-0.37	4.5e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs321358	0.731	rs7927998	chr11:111024596	C/G	cg08305652	chr11:111469057	NA	0.44	4.7	0.36	5.94e-6	Body mass index;
UCEC	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.64	6.96	0.5	1.04e-10	Eye color traits;
UCEC	cis	rs2862064	1.000	rs11747316	chr5:156422948	A/G	cg12943317	chr5:156479607	HAVCR1	-0.88	-6.58	-0.48	7.56e-10	Platelet count;
UCEC	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.12	-0.51	4.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.8	0.37	3.81e-6	Breast cancer;
UCEC	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg13683864	chr3:40499215	RPL14	1.01	12.63	0.72	3.16e-25	Renal cell carcinoma;
UCEC	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.51	-4.98	-0.38	1.74e-6	Refractive error;
UCEC	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	0.73	5.82	0.43	3.55e-8	Post bronchodilator FEV1;
UCEC	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.59	4.92	0.38	2.32e-6	Dental caries;
UCEC	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.68	-7.69	-0.54	1.91e-12	Breast cancer;
UCEC	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.6	-5.33	-0.4	3.54e-7	Pediatric autoimmune diseases;
UCEC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.46e-16	Height;
UCEC	cis	rs2693698	0.679	rs4905808	chr14:99692271	T/C	cg20500854	chr14:99707650	BCL11B	0.54	5.08	0.39	1.14e-6	Schizophrenia;
UCEC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.55	5.5	0.41	1.65e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1007190	0.881	rs11079378	chr17:42957462	A/G	cg15406952	chr17:42872593	NA	0.73	5.7	0.43	6.28e-8	DNA methylation (variation);
UCEC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.1	-0.45	9.05e-9	Blood metabolite levels;
UCEC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.37	-4.84	-0.37	3.29e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.15	-0.39	8.08e-7	Chronic sinus infection;
UCEC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.69	7.95	0.55	4.41e-13	Vitiligo;
UCEC	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.35	-0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.44	5.29	0.4	4.29e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.94	-0.55	4.8e-13	Exhaled nitric oxide output;
UCEC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs2839627	0.683	rs6586259	chr21:44315266	G/A	cg03543861	chr21:44258195	NA	0.52	5.16	0.39	7.86e-7	Information processing speed;
UCEC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.8	-8.96	-0.59	1.32e-15	Coronary artery disease;
UCEC	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.59	-5.98	-0.44	1.63e-8	Hepatocellular carcinoma;
UCEC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.6	5.27	0.4	4.75e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.73e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs73206853	0.764	rs7312939	chr12:110564108	G/A	cg12870014	chr12:110450643	ANKRD13A	0.77	6.15	0.45	6.98e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg23260525	chr10:116636907	FAM160B1	0.33	4.51	0.35	1.32e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	8.15	0.56	1.46e-13	Post bronchodilator FEV1;
UCEC	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.87	-12.56	-0.72	4.9e-25	Urate levels in lean individuals;
UCEC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg14530993	chr4:882597	GAK	0.71	4.9	0.37	2.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg11569703	chr11:65557185	OVOL1	-0.44	-6.2	-0.46	5.4e-9	Acne (severe);
UCEC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs16937	0.503	rs76939335	chr1:205178610	T/C	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-6.15	-0.45	6.98e-9	Total body bone mineral density;
UCEC	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.65	4.95	0.38	2.03e-6	Lymphocyte counts;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.63	-6.18	-0.45	6e-9	Longevity;Endometriosis;
UCEC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.51	-6.06	-0.45	1.09e-8	Prostate cancer;
UCEC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	7.91	0.55	5.7e-13	Bone mineral density;
UCEC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg11871910	chr12:69753446	YEATS4	0.57	5.15	0.39	8.11e-7	Response to diuretic therapy;
UCEC	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	5.12	0.39	9.33e-7	Breast cancer;
UCEC	cis	rs7246967	0.673	rs4627499	chr19:22832633	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.69	7.34	0.52	1.35e-11	Body mass index;
UCEC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	6.54	0.47	9.4e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	0.88	9.1	0.6	5.91e-16	Breast cancer;
UCEC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-6.36	-0.46	2.38e-9	Tonsillectomy;
UCEC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.05	-9.39	-0.61	1.06e-16	Vitiligo;
UCEC	cis	rs787274	0.718	rs2185768	chr9:115462645	C/T	cg13803584	chr9:115635662	SNX30	0.59	5.19	0.39	6.84e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.9	-9.9	-0.63	4.98e-18	Myeloid white cell count;
UCEC	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.5	-5.99	-0.44	1.56e-8	Neuroticism;
UCEC	cis	rs925228	0.869	rs4665643	chr2:24111742	C/G	cg13272742	chr2:24272458	FKBP1B	0.56	4.91	0.38	2.44e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.54	-5.84	-0.43	3.18e-8	Menarche (age at onset);
UCEC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg13683864	chr3:40499215	RPL14	-0.53	-5.34	-0.4	3.46e-7	Renal cell carcinoma;
UCEC	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	1.05	9.16	0.6	4.11e-16	Dupuytren's disease;
UCEC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.15	0.45	6.86e-9	Personality dimensions;
UCEC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.68	6.16	0.45	6.74e-9	Systemic lupus erythematosus;
UCEC	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	5.7	0.43	6.46e-8	Myopia (pathological);
UCEC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	1.01	9.43	0.61	8.14e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-6.64	-0.48	5.77e-10	Resting heart rate;
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.58	-5.47	-0.41	1.88e-7	Red cell distribution width;
UCEC	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.52	-4.98	-0.38	1.73e-6	Neuroticism;
UCEC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-6.0	-0.44	1.46e-8	Schizophrenia;
UCEC	cis	rs4705962	0.878	rs2897442	chr5:132049027	C/T	cg27309611	chr5:132113725	SEPT8	0.38	5.06	0.38	1.25e-6	Atopic dermatitis;
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg04871131	chr7:94954202	PON1	0.54	4.57	0.35	1.03e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg17330251	chr7:94953956	PON1	-0.56	-5.2	-0.39	6.71e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.21	9.67	0.62	1.96e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.51	-5.01	-0.38	1.54e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-7.47	-0.52	6.57e-12	Coffee consumption (cups per day);
UCEC	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.4	0.57	3.55e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg21770322	chr7:97807741	LMTK2	0.54	6.85	0.49	1.92e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs787274	0.867	rs786983	chr9:115458629	T/C	cg13803584	chr9:115635662	SNX30	0.62	5.6	0.42	1.04e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.76	7.07	0.5	5.8e-11	Bladder cancer;
UCEC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg24562669	chr7:97807699	LMTK2	0.49	6.03	0.45	1.27e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	4.87	0.37	2.87e-6	Coffee consumption (cups per day);
UCEC	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.73	-5.65	-0.42	8.09e-8	Orofacial clefts;
UCEC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.36	-5.48	-0.41	1.76e-7	Ulcerative colitis;
UCEC	cis	rs7757969	0.500	rs7746529	chr6:112176239	A/G	cg06351970	chr6:111280209	GTF3C6	-0.47	-4.78	-0.37	4.27e-6	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.61	-4.69	-0.36	6.31e-6	Corneal astigmatism;
UCEC	cis	rs7607369	0.536	rs13013510	chr2:219667227	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-5.07	-0.39	1.19e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.82	9.85	0.63	6.93e-18	Eotaxin levels;
UCEC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-6.69	-0.48	4.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	4.6	0.36	8.86e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.66	6.85	0.49	1.83e-10	Dental caries;
UCEC	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg08493051	chr2:3487164	NA	-0.71	-7.15	-0.51	3.78e-11	Neurofibrillary tangles;
UCEC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg04013166	chr16:89971882	TCF25	0.8	5.0	0.38	1.62e-6	Skin colour saturation;
UCEC	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.51	-5.13	-0.39	9.1e-7	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg13319975	chr6:146136371	FBXO30	0.46	5.01	0.38	1.54e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg12024160	chr4:1254474	NA	0.56	6.8	0.49	2.44e-10	Obesity-related traits;
UCEC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.72	-7.4	-0.52	9.56e-12	Ear protrusion;
UCEC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.54e-18	Height;
UCEC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.53	-5.76	-0.43	4.75e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg12339802	chr1:38156545	C1orf109	-0.62	-5.16	-0.39	7.91e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13683864	chr3:40499215	RPL14	-0.96	-9.79	-0.63	9.53e-18	Renal cell carcinoma;
UCEC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg19318889	chr4:1322082	MAEA	0.5	5.5	0.41	1.63e-7	Obesity-related traits;
UCEC	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	7.65	0.53	2.44e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4227	0.565	rs10438740	chr17:7472884	A/G	cg10607640	chr17:6915770	RNASEK	-0.4	-4.76	-0.37	4.62e-6	IgA nephropathy;
UCEC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.96	0.59	1.34e-15	Alzheimer's disease;
UCEC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.56	-4.99	-0.38	1.66e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.75	0.43	5e-8	Dupuytren's disease;
UCEC	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.42	-5.09	-0.39	1.06e-6	Refractive error;
UCEC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.65	-5.74	-0.43	5.17e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.0	-0.44	1.49e-8	Aortic root size;
UCEC	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.06	-0.39	1.25e-6	Bladder cancer;
UCEC	cis	rs17122693	1.000	rs17122683	chr14:51080422	G/A	cg04730355	chr14:51134070	SAV1	0.89	8.51	0.57	1.84e-14	Cognitive performance;
UCEC	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.98	11.46	0.69	4e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7581030	1.000	rs7581030	chr2:71572455	C/T	cg07678644	chr2:71558969	ZNF638	0.55	5.09	0.39	1.06e-6	Testicular germ cell tumor;
UCEC	cis	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg14992524	chr8:10586135	SOX7	0.31	4.93	0.38	2.22e-6	Neuroticism;
UCEC	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg26014689	chr19:7917955	EVI5L	-0.44	-4.68	-0.36	6.41e-6	Menarche (age at onset);
UCEC	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-6.22	-0.46	4.86e-9	Mean corpuscular volume;
UCEC	cis	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg24175803	chr19:22235144	ZNF257	0.39	5.0	0.38	1.64e-6	Telomere length;
UCEC	cis	rs3770752	0.928	rs11693917	chr2:37519969	A/G	cg20091297	chr2:37572423	QPCT	0.49	4.58	0.35	9.8200000000000008e-06	Schizophrenia;
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.56	6.18	0.45	5.89e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.12e-9	Tonsillectomy;
UCEC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.62	0.36	8.23e-6	Parkinson's disease;
UCEC	cis	rs4372836	1.000	rs11127188	chr2:28972852	G/A	cg09522027	chr2:28974177	PPP1CB	-0.6	-6.33	-0.46	2.83e-9	Body mass index;
UCEC	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg19041857	chr6:27730383	NA	-0.68	-4.94	-0.38	2.08e-6	Breast cancer;
UCEC	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.84	5.28	0.4	4.58e-7	Diisocyanate-induced asthma;
UCEC	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.78	-6.63	-0.48	5.88e-10	Obesity-related traits;
UCEC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.84	0.43	3.28e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.66	0.53	2.29e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.57	5.64	0.42	8.31e-8	Monocyte percentage of white cells;
UCEC	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.84	6.75	0.49	3.13e-10	Fibroblast growth factor basic levels;
UCEC	cis	rs10254160	1.000	rs17159615	chr7:112062821	A/G	cg12767726	chr7:112758502	LOC401397	-0.88	-4.56	-0.35	1.06e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs16939046	1.000	rs72656174	chr8:76133385	G/A	cg17407813	chr8:76323405	NA	0.81	4.69	0.36	6.13e-6	Information processing speed;
UCEC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg05802129	chr4:122689817	NA	-0.43	-4.55	-0.35	1.12e-5	Type 2 diabetes;
UCEC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg24163568	chr5:669837	TPPP	0.42	5.32	0.4	3.77e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.7	0.43	6.43e-8	Breast cancer;
UCEC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.55	5.52	0.41	1.51e-7	Asthma (sex interaction);
UCEC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.49	5.71	0.43	6.19e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.63	7.78	0.54	1.21e-12	Testicular germ cell tumor;
UCEC	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.51	-5.82	-0.43	3.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.62	6.54	0.47	9.35e-10	Immature fraction of reticulocytes;
UCEC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18932078	chr1:2524107	MMEL1	-0.39	-6.5	-0.47	1.17e-9	Ulcerative colitis;
UCEC	cis	rs9948	1.000	rs62152794	chr2:97485110	T/C	cg26665480	chr2:98280029	ACTR1B	-0.55	-4.64	-0.36	7.7e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs782107	0.724	rs782098	chr12:58814410	A/G	cg19181132	chr12:59314527	LRIG3	0.49	5.16	0.39	7.77e-7	Interleukin-12p70 levels;
UCEC	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.52	4.61	0.36	8.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg08461772	chr7:95026248	PON3	0.39	5.27	0.4	4.78e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	4.54	0.35	1.16e-5	Obesity-related traits;
UCEC	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg03146154	chr1:46216737	IPP	0.45	4.68	0.36	6.37e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.58	-5.2	-0.39	6.61e-7	Carotid intima media thickness;
UCEC	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.53	5.48	0.41	1.76e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.6e-9	Motion sickness;
UCEC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.48	-5.22	-0.4	5.86e-7	Adiponectin levels;
UCEC	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg22868518	chr11:507468	RNH1	-0.56	-5.57	-0.42	1.17e-7	Systemic lupus erythematosus;
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	9.59	0.62	3.2e-17	Platelet count;
UCEC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.48	-4.85	-0.37	3.18e-6	Blood metabolite levels;
UCEC	cis	rs9463078	0.753	rs1980265	chr6:44928868	C/A	cg25276700	chr6:44698697	NA	-0.42	-4.69	-0.36	6.32e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg24375607	chr4:120327624	NA	0.53	5.6	0.42	1.05e-7	Corneal astigmatism;
UCEC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs17012589	0.955	rs12814335	chr12:85648831	T/G	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.59	-0.35	9.26e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.6	-5.21	-0.39	6.21e-7	Obesity-related traits;
UCEC	cis	rs78487399	0.808	rs7556744	chr2:43672795	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.65	5.06	0.39	1.21e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.5	5.29	0.4	4.28e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6011674	1.000	rs6011674	chr20:61854452	A/G	cg06763829	chr20:61885236	FLJ16779;NKAIN4	-0.79	-5.42	-0.41	2.36e-7	Response to cytadine analogues (cytosine arabinoside);
UCEC	cis	rs240764	0.658	rs7768210	chr6:101261494	C/T	cg09795085	chr6:101329169	ASCC3	0.5	5.02	0.38	1.44e-6	Neuroticism;
UCEC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg14529643	chr1:1233542	ACAP3	0.43	4.67	0.36	6.73e-6	Body mass index;
UCEC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Blood protein levels;
UCEC	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	5.2	0.39	6.56e-7	Height;
UCEC	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.77	0.54	1.23e-12	Smoking behavior;
UCEC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.68	5.16	0.39	7.81e-7	Mean platelet volume;
UCEC	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg18681998	chr4:17616180	MED28	-0.56	-6.51	-0.47	1.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.63	4.83	0.37	3.36e-6	White matter hyperintensity burden;
UCEC	trans	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg15509575	chr4:2286509	ZFYVE28	0.41	7.16	0.51	3.52e-11	Rheumatoid arthritis;
UCEC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.93	10.12	0.64	1.38e-18	Cognitive function;
UCEC	cis	rs7766436	0.848	rs11759474	chr6:22580980	G/T	cg13666174	chr6:22585274	NA	-0.6	-6.23	-0.46	4.64e-9	Coronary artery disease;
UCEC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-0.82	-6.33	-0.46	2.83e-9	Coronary artery disease;
UCEC	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.53	-5.48	-0.41	1.79e-7	Breast cancer;
UCEC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24308560	chr3:49941425	MST1R	0.54	6.06	0.45	1.09e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.59	0.35	9.29e-6	Menopause (age at onset);
UCEC	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-6.22	-0.46	4.96e-9	Body mass index;
UCEC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.25	0.51	2.21e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.74	6.51	0.47	1.1e-9	Coronary artery disease;
UCEC	cis	rs2062225	1.000	rs2062225	chr2:111750872	A/T	cg23782758	chr2:111737646	ACOXL	-0.64	-4.63	-0.36	8.14e-6	Monocyte count;
UCEC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-6.3	-0.46	3.26e-9	Coffee consumption (cups per day);
UCEC	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg04058563	chr4:185651563	MLF1IP	-0.38	-4.57	-0.35	1.03e-5	Kawasaki disease;
UCEC	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.17	14.53	0.77	3.29e-30	Body mass index;
UCEC	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.05	5.44	0.41	2.2e-7	Diabetic retinopathy;
UCEC	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	1.01	7.68	0.54	2.06e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.9	8.26	0.56	7.64e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.66	-6.81	-0.49	2.33e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7095607	0.777	rs7919994	chr10:69931144	T/G	cg18986048	chr10:69913749	MYPN	0.54	6.35	0.46	2.54e-9	Lung function (FVC);
UCEC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.6	6.72	0.48	3.81e-10	Resting heart rate;
UCEC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.69	-6.88	-0.49	1.58e-10	Blood metabolite levels;
UCEC	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.02	-0.38	1.45e-6	Huntington's disease progression;
UCEC	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg06917450	chr1:38156652	C1orf109	-0.52	-5.37	-0.41	2.98e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.39	5.66	0.42	7.8e-8	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs7246967	0.673	rs3951783	chr19:22839264	T/A	cg03230154	chr19:22817176	ZNF492	0.45	4.55	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.54	4.72	0.36	5.41e-6	Lung function (FEV1/FVC);
UCEC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.74	0.36	4.94e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs36051895	0.632	rs9657576	chr9:5183028	T/G	cg02405213	chr9:5042618	JAK2	-0.54	-5.37	-0.4	3.02e-7	Pediatric autoimmune diseases;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.37	-0.4	3.06e-7	Pubertal anthropometrics;
UCEC	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.53	5.07	0.39	1.17e-6	Coronary artery disease;
UCEC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-4.57	-0.35	1.02e-5	Alzheimer's disease (late onset);
UCEC	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg19041857	chr6:27730383	NA	0.69	5.41	0.41	2.45e-7	Depression;
UCEC	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg11901034	chr3:128598214	ACAD9	-0.53	-4.68	-0.36	6.32e-6	IgG glycosylation;
UCEC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.78	8.62	0.58	9.71e-15	Immature fraction of reticulocytes;
UCEC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.55	-5.04	-0.38	1.33e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.57	-5.58	-0.42	1.11e-7	Acne (severe);
UCEC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-6.62	-0.48	6.33e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	6.04	0.45	1.21e-8	Platelet count;
UCEC	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.32	0.46	3e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.12	-0.51	4.45e-11	Prevalent atrial fibrillation;
UCEC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.51	-5.16	-0.39	8e-7	Monocyte percentage of white cells;
UCEC	cis	rs7113850	0.541	rs76005477	chr11:24233322	G/A	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Bone fracture in osteoporosis;
UCEC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg21053147	chr12:120880522	NA	-0.66	-5.45	-0.41	2.11e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.53	0.47	1.02e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.56	-6.54	-0.47	9.68e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs921968	1.000	rs4672891	chr2:219271530	G/A	cg02176678	chr2:219576539	TTLL4	-0.67	-6.47	-0.47	1.4e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	0.9	11.6	0.69	1.67e-22	Menarche (age at onset);
UCEC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.78	5.42	0.41	2.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7638909	0.512	rs7645178	chr3:38597558	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.51	-5.14	-0.39	8.7e-7	Electrocardiographic conduction measures;
UCEC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg20387954	chr3:183756860	HTR3D	0.38	4.55	0.35	1.12e-5	Anterior chamber depth;
UCEC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.74	8.03	0.55	2.84e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg03859395	chr2:55845619	SMEK2	0.94	12.6	0.72	3.74e-25	Metabolic syndrome;
UCEC	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.05	5.8	0.43	3.99e-8	Skin colour saturation;
UCEC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.68	-0.36	6.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17162190	0.698	rs4659443	chr1:26823631	C/T	cg23229016	chr1:26872525	RPS6KA1	0.26	4.58	0.35	9.66e-6	Mean corpuscular volume;
UCEC	cis	rs4778581	0.707	rs4778752	chr15:80404656	A/G	cg23708261	chr15:80264706	BCL2A1	0.41	4.81	0.37	3.71e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg06558623	chr16:89946397	TCF25	-0.47	-4.75	-0.36	4.88e-6	Vitiligo;
UCEC	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.54	-0.42	1.37e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05776053	chr2:74358815	NA	0.41	5.07	0.39	1.2e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.57	6.31	0.46	3.15e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.87	-0.37	2.9e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.58	-5.13	-0.39	8.86e-7	QRS complex (12-leadsum);
UCEC	cis	rs6788895	1.000	rs6440698	chr3:150516911	A/G	cg19584864	chr3:150127772	TSC22D2	-0.62	-4.67	-0.36	6.72e-6	Breast cancer;
UCEC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.42	-5.27	-0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.67	-0.36	6.61e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10510146	0.841	rs297223	chr10:127295915	A/G	cg07504718	chr10:127465376	MMP21	-0.48	-5.15	-0.39	8.41e-7	Non-alcoholic fatty liver disease histology (other);
UCEC	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.47	6.02	0.44	1.33e-8	Bipolar disorder;
UCEC	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.7	-7.36	-0.52	1.23e-11	Blood trace element (Zn levels);
UCEC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	7.09	0.5	5.26e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Depression;
UCEC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.31e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.48	-4.7	-0.36	6.04e-6	Dental caries;
UCEC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.11e-14	Chronic sinus infection;
UCEC	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg27246729	chr12:121163418	ACADS	0.49	4.53	0.35	1.23e-5	Urinary metabolites (H-NMR features);
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.86	-0.37	3.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg06768213	chr1:227963296	SNAP47	0.38	4.67	0.36	6.85e-6	Diastolic blood pressure;
UCEC	cis	rs7246967	0.551	rs57775631	chr19:22814461	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.32	0.46	3e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.25	-24.34	-0.9	1.99e-53	Myeloid white cell count;
UCEC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg13683864	chr3:40499215	RPL14	-0.57	-5.46	-0.41	1.94e-7	Renal cell carcinoma;
UCEC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.72	-4.54	-0.35	1.16e-5	Psoriasis;
UCEC	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.86	11.26	0.68	1.36e-21	Obesity-related traits;
UCEC	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg18827107	chr12:86230957	RASSF9	-0.43	-4.66	-0.36	7.09e-6	Major depressive disorder;
UCEC	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.47	4.98	0.38	1.77e-6	Type 2 diabetes;
UCEC	cis	rs4148689	1.000	rs1896887	chr7:117200481	C/G	cg21212505	chr7:117228958	CFTR	-0.4	-4.59	-0.35	9.4e-6	Gout;
UCEC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7709377	0.574	rs2416430	chr5:115466392	C/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs422249	0.819	rs174611	chr11:61627881	T/C	cg19610905	chr11:61596333	FADS2	-0.53	-4.78	-0.37	4.26e-6	Trans fatty acid levels;
UCEC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.62	5.23	0.4	5.62e-7	Alzheimer's disease;
UCEC	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.64	-7.36	-0.52	1.21e-11	Leprosy;
UCEC	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.67	9.18	0.6	3.61e-16	Alcohol dependence (age at onset);
UCEC	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.81	-0.37	3.65e-6	Response to antipsychotic treatment;
UCEC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg11871910	chr12:69753446	YEATS4	0.74	7.87	0.54	6.97e-13	Blood protein levels;
UCEC	cis	rs7937612	0.931	rs12417581	chr11:120216906	T/A	cg12584626	chr11:120203529	NA	0.5	5.3	0.4	4.12e-7	Intraocular pressure;
UCEC	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.51	5.77	0.43	4.62e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.75	5.74	0.43	5.3e-8	Platelet count;
UCEC	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.59	6.59	0.48	7.53e-10	Hip circumference;
UCEC	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg20129853	chr10:51489980	NA	-0.42	-4.7	-0.36	5.99e-6	Prostate-specific antigen levels;
UCEC	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.42	-0.52	8.45e-12	Hypospadias;
UCEC	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.78	4.53	0.35	1.23e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.58	5.56	0.42	1.22e-7	Calcium levels;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.81	-0.37	3.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12516959	chr21:47718080	NA	-0.39	-4.53	-0.35	1.21e-5	Testicular germ cell tumor;
UCEC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.47	4.5	0.35	1.35e-5	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg17764715	chr19:33622953	WDR88	0.62	6.04	0.45	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.5	5.04	0.38	1.37e-6	Colorectal cancer;
UCEC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.67	-7.34	-0.52	1.35e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.62	6.35	0.46	2.56e-9	Menopause (age at onset);
UCEC	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.98	-7.53	-0.53	4.82e-12	Ulcerative colitis;
UCEC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg04310649	chr10:35416472	CREM	0.47	4.66	0.36	7.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg06238570	chr21:40685208	BRWD1	0.82	8.19	0.56	1.17e-13	Cognitive function;
UCEC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.68	5.48	0.41	1.79e-7	Major depressive disorder;
UCEC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg13147721	chr7:65941812	NA	0.85	5.65	0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.24	-9.78	-0.63	1.06e-17	Gut microbiome composition (summer);
UCEC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg24562669	chr7:97807699	LMTK2	-0.45	-5.43	-0.41	2.33e-7	Breast cancer;
UCEC	cis	rs11760485	0.965	rs57205131	chr7:4401983	A/G	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.52	5.95	0.44	1.91e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.5	-4.94	-0.38	2.13e-6	Schizophrenia;
UCEC	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg04826882	chr13:114838756	RASA3	-0.58	-4.53	-0.35	1.21e-5	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg08890418	chr1:21044141	KIF17	-0.45	-4.56	-0.35	1.07e-5	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.79	-8.14	-0.56	1.5e-13	Mosquito bite size;
UCEC	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.78	0.43	4.33e-8	Colorectal cancer;
UCEC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.63	5.73	0.43	5.57e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.52	4.99	0.38	1.7e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.44	-0.41	2.16e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.79	6.01	0.44	1.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3750082	0.889	rs970673	chr7:32927727	A/G	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-6.41	-0.47	1.86e-9	Rheumatoid arthritis;
UCEC	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.84	9.58	0.62	3.5e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs35934224	0.724	rs35374520	chr22:19851149	A/G	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.32	-0.4	3.74e-7	Glaucoma (primary open-angle);
UCEC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.71	-7.1	-0.51	5.01e-11	Tonsillectomy;
UCEC	cis	rs6493487	0.512	rs7170009	chr15:51323648	C/A	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.47	4.87	0.37	2.89e-6	Schizophrenia;
UCEC	cis	rs13065560	0.714	rs4280575	chr3:38937645	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.47	-4.53	-0.35	1.19e-5	Interleukin-18 levels;
UCEC	cis	rs10924970	0.624	rs2297803	chr1:235410024	G/A	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs9341808	0.538	rs620147	chr6:80992090	G/A	cg08355045	chr6:80787529	NA	-0.34	-4.64	-0.36	7.7e-6	Sitting height ratio;
UCEC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg13147721	chr7:65941812	NA	-0.74	-5.3	-0.4	4.11e-7	Diabetic kidney disease;
UCEC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-8.15	-0.56	1.46e-13	Bipolar disorder and schizophrenia;
UCEC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.69	-5.67	-0.42	7.23e-8	Caudate activity during reward;
UCEC	cis	rs8105895	0.935	rs62112918	chr19:22227079	C/T	cg24072202	chr19:22235272	ZNF257	-0.56	-4.66	-0.36	6.89e-6	Body mass index (change over time);
UCEC	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.21	-0.39	6.22e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg00449821	chr1:155053823	EFNA3	0.4	4.7	0.36	6.04e-6	Breast cancer;
UCEC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	7.96	0.55	4.31e-13	Electrocardiographic conduction measures;
UCEC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20814179	chr4:940893	TMEM175	0.46	5.06	0.39	1.21e-6	Sjögren's syndrome;
UCEC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.38	-0.52	1.1e-11	Chronic sinus infection;
UCEC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg04154034	chr17:28927549	LRRC37B2	0.78	4.76	0.37	4.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.24	-7.74	-0.54	1.48e-12	Diabetic kidney disease;
UCEC	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.08	-0.5	5.63e-11	Colorectal cancer;
UCEC	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.57	-4.61	-0.36	8.59e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.77	5.95	0.44	1.84e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.75	8.42	0.57	3.04e-14	Menarche (age at onset);
UCEC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg26721908	chr21:47610096	LSS	0.36	4.54	0.35	1.17e-5	Testicular germ cell tumor;
UCEC	cis	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-4.58	-0.35	9.86e-6	Longevity;Endometriosis;
UCEC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	6.96	0.5	1.07e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-4.73	-0.36	5.31e-6	Response to antipsychotic treatment;
UCEC	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.28	0.4	4.66e-7	Birth weight;
UCEC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.74	7.59	0.53	3.44e-12	Diastolic blood pressure;
UCEC	cis	rs1957429	1.000	rs1998333	chr14:65353632	A/G	cg23373153	chr14:65346875	NA	0.94	7.43	0.52	8.34e-12	Pediatric areal bone mineral density (radius);
UCEC	cis	rs4668356	1.000	rs6746133	chr2:171937689	G/A	cg13882835	chr2:172017928	TLK1	0.66	4.51	0.35	1.32e-5	Cognitive performance;
UCEC	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg01072550	chr1:21505969	NA	-0.56	-5.21	-0.4	6.15e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.73	0.58	5.17e-15	Alzheimer's disease;
UCEC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.43	-5.06	-0.39	1.24e-6	Subjective well-being;
UCEC	cis	rs9341808	0.586	rs3805869	chr6:81045917	T/C	cg08355045	chr6:80787529	NA	0.37	4.55	0.35	1.1e-5	Sitting height ratio;
UCEC	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.74	6.48	0.47	1.3e-9	Cognitive function;
UCEC	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.4	5.02	0.38	1.48e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
UCEC	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	0.86	5.73	0.43	5.61e-8	Type 2 diabetes nephropathy;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg14547644	chr6:28411285	ZSCAN23	0.42	4.65	0.36	7.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.46	4.53	0.35	1.19e-5	Red cell distribution width;
UCEC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-5.59	-0.42	1.07e-7	Urinary metabolites;
UCEC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4372836	0.897	rs6707130	chr2:28973276	A/G	cg09522027	chr2:28974177	PPP1CB	-0.74	-7.56	-0.53	3.91e-12	Body mass index;
UCEC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26002218	chr14:103986227	CKB	0.36	5.21	0.4	6.17e-7	Body mass index;
UCEC	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.48	4.88	0.37	2.76e-6	Dental caries;
UCEC	cis	rs7246967	0.935	rs8112754	chr19:23060870	C/T	cg08271804	chr19:22816896	ZNF492	0.54	5.02	0.38	1.48e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	5.83	0.43	3.42e-8	IgG glycosylation;
UCEC	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.58	6.4	0.47	1.97e-9	Height;
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg21856205	chr7:94953877	PON1	-0.53	-4.82	-0.37	3.62e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.35	-5.64	-0.42	8.35e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs259282	0.605	rs60968670	chr19:33108982	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.55	4.99	0.38	1.66e-6	Schizophrenia;
UCEC	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.51	-4.65	-0.36	7.31e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg12463550	chr7:65579703	CRCP	-0.53	-5.43	-0.41	2.28e-7	Aortic root size;
UCEC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.49	-5.15	-0.39	8.14e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.61	7.87	0.54	6.94e-13	Bone mineral density;
UCEC	cis	rs12234571	1.000	rs3750127	chr7:77326748	G/T	cg20048109	chr7:78158112	MAGI2	-0.53	-4.81	-0.37	3.76e-6	Obesity-related traits;
UCEC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.95e-6	Tonsillectomy;
UCEC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.51	5.51	0.41	1.55e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.63	-0.42	8.87e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.38	0.52	1.07e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg13264159	chr8:625131	ERICH1	-1.08	-5.17	-0.39	7.45e-7	IgG glycosylation;
UCEC	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.49	-4.9	-0.37	2.56e-6	Total body bone mineral density;
UCEC	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	1.0	10.1	0.64	1.52e-18	Red cell distribution width;
UCEC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg13695892	chr22:41940480	POLR3H	0.63	4.57	0.35	1.03e-5	Vitiligo;
UCEC	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.78	7.8	0.54	1.05e-12	Primary sclerosing cholangitis;
UCEC	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-6.03	-0.45	1.3e-8	Coffee consumption (cups per day);
UCEC	cis	rs7766436	0.885	rs13209127	chr6:22597625	A/G	cg13666174	chr6:22585274	NA	0.61	6.18	0.45	6.05e-9	Coronary artery disease;
UCEC	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-0.53	-4.74	-0.36	4.96e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.62	-6.23	-0.46	4.65e-9	Body mass index;
UCEC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.73	5.15	0.39	8.36e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.54	4.59	0.35	9.44e-6	Malaria;
UCEC	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.68	5.82	0.43	3.64e-8	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	7.07	0.5	5.67e-11	Platelet count;
UCEC	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.57	4.99	0.38	1.7e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg24826892	chr11:71159390	DHCR7	0.48	4.51	0.35	1.33e-5	Vitamin D levels;
UCEC	cis	rs12935418	0.616	rs8047785	chr16:80969352	T/C	cg22734315	chr16:81069742	ATMIN	0.67	4.64	0.36	7.58e-6	Mean corpuscular volume;
UCEC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.27e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.69	5.7	0.43	6.4e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.54	5.72	0.43	5.85e-8	Fear of minor pain;
UCEC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.48	4.77	0.37	4.42e-6	Corneal astigmatism;
UCEC	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs11038871	1.000	rs7949371	chr11:46522304	C/T	cg23542274	chr11:45718455	NA	-0.34	-4.78	-0.37	4.18e-6	Immunoglobulin A;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.53	-5.6	-0.42	1.01e-7	Pubertal anthropometrics;
UCEC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.55e-9	Lung cancer;
UCEC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.5	6.55	0.48	8.94e-10	Bone mineral density;
UCEC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.72	-0.66	3.56e-20	Schizophrenia;
UCEC	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.74	6.44	0.47	1.62e-9	Caudate activity during reward;
UCEC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.7	-7.76	-0.54	1.31e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.64	-4.54	-0.35	1.17e-5	Bipolar disorder (body mass index interaction);
UCEC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg12310025	chr6:25882481	NA	0.56	5.01	0.38	1.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.65	4.7	0.36	6.01e-6	Gut microbiome composition (summer);
UCEC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.43	6.37	0.47	2.3e-9	Rheumatoid arthritis;
UCEC	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-4.75	-0.36	4.82e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg01072550	chr1:21505969	NA	-0.52	-4.9	-0.38	2.45e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.12	10.82	0.67	1.94e-20	Vitiligo;
UCEC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.86	-0.49	1.8e-10	Menarche (age at onset);
UCEC	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	0.72	5.57	0.42	1.19e-7	Post bronchodilator FEV1;
UCEC	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.5	4.87	0.37	2.82e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg09654669	chr8:57350985	NA	-0.54	-5.94	-0.44	1.93e-8	Obesity-related traits;
UCEC	cis	rs11760485	0.742	rs4236354	chr7:4407597	T/C	cg25842763	chr7:4870162	RADIL	-0.42	-4.78	-0.37	4.28e-6	Early childhood aggressive behavior;
UCEC	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.11	-0.39	1e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.54	5.38	0.41	2.89e-7	Pancreatic cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12417720	chr6:108878861	NA	0.51	7.24	0.51	2.29e-11	Warfarin maintenance dose;
UCEC	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.52	5.1	0.39	1.02e-6	Dilated cardiomyopathy;
UCEC	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.56	-4.94	-0.38	2.14e-6	Schizophrenia;
UCEC	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	13.8	0.75	2.55e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-4.79	-0.37	4.12e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.69	6.1	0.45	8.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.61	-4.65	-0.36	7.21e-6	Mean platelet volume;
UCEC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.82	-9.55	-0.62	4.04e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.62	-7.43	-0.52	8.05e-12	Prevalent atrial fibrillation;
UCEC	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg10902566	chr4:727664	PCGF3	-0.49	-4.73	-0.36	5.27e-6	Systolic blood pressure;
UCEC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.59	6.04	0.45	1.23e-8	Initial pursuit acceleration;
UCEC	cis	rs9309473	0.528	rs11126395	chr2:73564964	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.4	-0.41	2.57e-7	Metabolite levels;
UCEC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.48	-4.81	-0.37	3.63e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.58	-5.55	-0.42	1.29e-7	Corneal astigmatism;
UCEC	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.57	-5.53	-0.41	1.43e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.54	5.07	0.39	1.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.72	8.95	0.59	1.4e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.48	-5.27	-0.4	4.73e-7	Tonsillectomy;
UCEC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.45	5.08	0.39	1.11e-6	Plateletcrit;Mean corpuscular volume;
UCEC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.5	-4.7	-0.36	5.83e-6	Gut microbiome composition (summer);
UCEC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-5.19	-0.39	6.84e-7	Coffee consumption (cups per day);
UCEC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg11632617	chr15:75315747	PPCDC	-0.64	-7.5	-0.53	5.64e-12	Blood trace element (Zn levels);
UCEC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs2415984	0.846	rs60908678	chr14:46832433	G/A	cg14871534	chr14:47121158	RPL10L	0.39	4.53	0.35	1.21e-5	Number of children ever born;
UCEC	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg14004847	chr7:1930337	MAD1L1	0.47	4.53	0.35	1.22e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.91	7.84	0.54	8.23e-13	Body mass index;
UCEC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.67	5.64	0.42	8.45e-8	Alcohol dependence;
UCEC	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.51	6.62	0.48	6.14e-10	Sitting height ratio;
UCEC	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.11	-0.39	9.65e-7	Metabolite levels;
UCEC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.45	7.74e-9	Initial pursuit acceleration;
UCEC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-7.03	-0.5	7.09e-11	Breast cancer;
UCEC	cis	rs4654899	0.865	rs10916927	chr1:21385795	T/C	cg01072550	chr1:21505969	NA	-0.52	-4.84	-0.37	3.27e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.4	-5.34	-0.4	3.48e-7	Alcohol dependence;
UCEC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.97	12.52	0.72	6.32e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg23018236	chr17:30244563	NA	-0.53	-4.91	-0.38	2.4e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs17106184	1.000	rs113704493	chr1:50892538	C/G	cg07174182	chr1:51127561	FAF1	-0.78	-4.71	-0.36	5.72e-6	Type 2 diabetes;
UCEC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.79	9.12	0.6	5.2e-16	Lymphocyte counts;
UCEC	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg16797656	chr11:68205561	LRP5	-0.51	-6.74	-0.49	3.44e-10	Bone mineral density (spine);
UCEC	cis	rs6437061	0.717	rs3100617	chr2:232914378	A/G	cg02061626	chr2:233274167	ALPPL2	-0.49	-5.47	-0.41	1.85e-7	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.57	6.26	0.46	4.09e-9	Neutrophil percentage of white cells;
UCEC	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.44	4.95	0.38	1.97e-6	Prudent dietary pattern;
UCEC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg06768213	chr1:227963296	SNAP47	0.38	4.7	0.36	5.97e-6	Diastolic blood pressure;
UCEC	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.93	-6.04	-0.45	1.22e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.9	0.59	1.86e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	7.77	0.54	1.25e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.51	-0.53	5.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-6.3	-0.46	3.34e-9	Platelet count;
UCEC	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.65	0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.71	-8.26	-0.56	7.63e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	0.71	5.49	0.41	1.7e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg23730617	chr3:160823505	B3GALNT1	-0.4	-4.59	-0.35	9.3e-6	Morning vs. evening chronotype;
UCEC	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7095607	0.813	rs2087345	chr10:69922843	T/C	cg18986048	chr10:69913749	MYPN	0.53	6.29	0.46	3.35e-9	Lung function (FVC);
UCEC	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-5.13	-0.39	9.15e-7	Mean platelet volume;
UCEC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	7.97e-9	Prostate cancer;
UCEC	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.47	-6.5	-0.47	1.2e-9	Height;
UCEC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-4.61	-0.36	8.8e-6	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	4.79	0.37	3.97e-6	Platelet count;
UCEC	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.59	-5.88	-0.44	2.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.76	8.47	0.57	2.28e-14	Breast cancer;
UCEC	cis	rs7246967	0.932	rs34949383	chr19:23033858	G/C	cg05241461	chr19:22816980	ZNF492	0.48	5.15	0.39	8.37e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.43	5.43	0.41	2.3e-7	Urinary metabolites;
UCEC	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg19554555	chr3:13937349	NA	-0.43	-4.51	-0.35	1.3e-5	Ovarian reserve;
UCEC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.81	8.32	0.57	5.63e-14	Blood protein levels;
UCEC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	0.84	4.88	0.37	2.68e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-6.7	-0.48	4.06e-10	Platelet count;
UCEC	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.38	5.09	0.39	1.1e-6	Blood protein levels;
UCEC	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.49	-5.16	-0.39	7.99e-7	Height;
UCEC	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Blood protein levels;
UCEC	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.66	-8.0	-0.55	3.38e-13	IgG glycosylation;
UCEC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg12024160	chr4:1254474	NA	-0.6	-7.24	-0.51	2.26e-11	Obesity-related traits;
UCEC	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	5.05	0.38	1.3e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg13525197	chr6:28411240	ZSCAN23	0.54	6.16	0.45	6.65e-9	Cardiac Troponin-T levels;
UCEC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.54	-6.13	-0.45	7.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.58	-5.64	-0.42	8.29e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg07424592	chr7:64974309	NA	0.81	4.74	0.36	4.92e-6	Diabetic kidney disease;
UCEC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs7246967	0.551	rs16998998	chr19:22911116	T/C	cg08271804	chr19:22816896	ZNF492	0.66	6.37	0.47	2.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg03146154	chr1:46216737	IPP	-0.43	-4.65	-0.36	7.18e-6	Red blood cell count;Reticulocyte count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04380228	chr2:47142555	MCFD2	0.57	6.76	0.49	2.95e-10	Warfarin maintenance dose;
UCEC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26207909	chr14:103986467	CKB	0.54	6.03	0.45	1.26e-8	Body mass index;
UCEC	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.1	9.43	0.61	8.5e-17	Blood protein levels;
UCEC	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg23782820	chr8:58130467	NA	0.49	4.53	0.35	1.22e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg01072550	chr1:21505969	NA	-0.59	-6.19	-0.45	5.65e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1110701	0.525	rs11764792	chr7:50496841	C/T	cg18232548	chr7:50535776	DDC	-0.64	-7.61	-0.53	2.97e-12	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.68	-9.31	-0.61	1.66e-16	Systolic blood pressure;
UCEC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.55	-0.42	1.32e-7	Headache;
UCEC	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.46	4.57	0.35	1.01e-5	Prostate cancer;
UCEC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.0	0.64	2.79e-18	Electrocardiographic conduction measures;
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.82	8.08	0.55	2.16e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg17469321	chr7:55412551	NA	0.68	6.05	0.45	1.16e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.49	4.55	0.35	1.09e-5	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg01426195	chr3:39028469	NA	-0.7	-8.93	-0.59	1.57e-15	Handedness;
UCEC	cis	rs2398893	0.774	rs35888804	chr9:96887153	T/C	cg07076509	chr9:96720819	NA	0.49	4.84	0.37	3.24e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg15513719	chr13:114904418	NA	0.49	4.86	0.37	2.92e-6	Schizophrenia;
UCEC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg22974920	chr21:40686053	BRWD1	-0.49	-4.89	-0.37	2.6e-6	Menarche (age at onset);
UCEC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-5.9	-0.44	2.36e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.62	0.58	9.98e-15	Prudent dietary pattern;
UCEC	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg13683864	chr3:40499215	RPL14	-0.51	-5.13	-0.39	9.19e-7	Renal cell carcinoma;
UCEC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.7	7.79	0.54	1.11e-12	Ewing sarcoma;
UCEC	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.35	-4.59	-0.35	9.61e-6	Atrial fibrillation;
UCEC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	5.63	0.42	8.85e-8	Height;
UCEC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.6	5.78	0.43	4.38e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.71	-6.47	-0.47	1.37e-9	Initial pursuit acceleration;
UCEC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	4.83	0.37	3.44e-6	Bipolar disorder;
UCEC	cis	rs10924970	0.578	rs12025973	chr1:235463888	G/A	cg26050004	chr1:235667680	B3GALNT2	0.54	4.94	0.38	2.07e-6	Asthma;
UCEC	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg03549618	chr14:35838977	NA	-0.34	-4.52	-0.35	1.26e-5	Psoriasis;
UCEC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.48	-4.82	-0.37	3.53e-6	Bone properties (heel);
UCEC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-5.01	-0.38	1.55e-6	Mean platelet volume;
UCEC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg02158880	chr13:53174818	NA	0.77	8.9	0.59	1.9e-15	Lewy body disease;
UCEC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg01256987	chr12:42539512	GXYLT1	-0.47	-5.56	-0.42	1.25e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.75	-8.54	-0.58	1.55e-14	Facial morphology (factor 19);
UCEC	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.42	-4.69	-0.36	6.06e-6	Glaucoma (primary open-angle);
UCEC	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg10932868	chr11:921992	NA	0.43	5.55	0.42	1.3e-7	Alzheimer's disease (late onset);
UCEC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.12	14.35	0.76	9.19e-30	Cognitive function;
UCEC	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg17515076	chr17:73810948	UNK	-0.51	-5.73	-0.43	5.48e-8	White matter hyperintensity burden;
UCEC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.58	-0.35	1e-5	Extrinsic epigenetic age acceleration;
UCEC	cis	rs253959	0.921	rs13172482	chr5:115451836	C/A	cg23108291	chr5:115420582	COMMD10	0.51	5.2	0.39	6.5e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	6.97	0.5	1.01e-10	Motion sickness;
UCEC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.64	5.38	0.41	2.84e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg24881330	chr22:46731750	TRMU	-0.75	-7.13	-0.51	4.21e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	5.2	0.39	6.54e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.74	-4.79	-0.37	4.07e-6	Hair shape;
UCEC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.5	5.71	0.43	6.13e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.21	0.51	2.76e-11	Bladder cancer;
UCEC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.93	-0.38	2.19e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg07076509	chr9:96720819	NA	0.5	5.38	0.41	2.87e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.48	-5.22	-0.4	5.99e-7	Colorectal cancer;
UCEC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.44	5.12	0.39	9.23e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg19678392	chr7:94953810	PON1	-0.63	-6.05	-0.45	1.16e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.66	6.6	0.48	6.95e-10	Birth weight;
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.6	-4.96	-0.38	1.95e-6	Body mass index;
UCEC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.9	-11.7	-0.69	9.49e-23	Height;
UCEC	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.48	-4.67	-0.36	6.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06223018	chr3:49557076	DAG1	0.34	4.86	0.37	2.93e-6	Parkinson's disease;
UCEC	cis	rs259282	0.628	rs2287669	chr19:33110204	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.84	0.37	3.31e-6	Schizophrenia;
UCEC	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.19e-6	Vitiligo;
UCEC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.02	-0.5	7.79e-11	Breast cancer;
UCEC	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.58	6.42	0.47	1.74e-9	Heart rate;
UCEC	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.61	6.68	0.48	4.53e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs2862064	0.929	rs4704837	chr5:156464212	T/G	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg22974920	chr21:40686053	BRWD1	0.59	5.08	0.39	1.12e-6	Cognitive function;
UCEC	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.78	7.56	0.53	4.02e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.77	9.4	0.61	1.02e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.34	-0.4	3.41e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg17420585	chr12:42539391	GXYLT1	0.4	5.15	0.39	8.23e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1165472	0.755	rs9326037	chr1:56163458	G/A	cg11523071	chr1:56160889	NA	-0.53	-5.0	-0.38	1.63e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs466639	0.810	rs3767342	chr1:165387665	T/C	cg03421657	chr1:166039754	FAM78B	0.41	4.51	0.35	1.31e-5	Menarche (age at onset);
UCEC	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.52	4.55	0.35	1.14e-5	Cholesterol, total;
UCEC	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.93	7.47	0.52	6.63e-12	Platelet distribution width;
UCEC	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.92	-0.78	3.06e-31	Schizophrenia;
UCEC	cis	rs7246967	0.551	rs16998998	chr19:22911116	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.54	0.47	9.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6987853	0.527	rs2974298	chr8:42376477	T/C	cg09913449	chr8:42400586	C8orf40	-0.4	-4.53	-0.35	1.21e-5	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg26067569	chr2:200525129	NA	0.54	4.57	0.35	1.04e-5	Schizophrenia;
UCEC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.75	-7.95	-0.55	4.52e-13	Cognitive function;
UCEC	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg11859384	chr17:80120422	CCDC57	-0.42	-4.51	-0.35	1.3e-5	Life satisfaction;
UCEC	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.81	-0.49	2.31e-10	Eye color traits;
UCEC	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.71	4.72	0.36	5.49e-6	LDL cholesterol;
UCEC	cis	rs1575951	1.000	rs7092728	chr10:130437971	A/G	cg27041381	chr10:131357203	MGMT	0.6	5.16	0.39	7.85e-7	Plasma clusterin levels;
UCEC	cis	rs11048434	1.000	rs12824212	chr12:9153417	A/G	cg13575925	chr12:9217583	LOC144571	0.44	5.13	0.39	9.1e-7	Sjögren's syndrome;
UCEC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.58	-6.29	-0.46	3.42e-9	Glomerular filtration rate;
UCEC	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-11.53	-0.69	2.64e-22	Ulcerative colitis;
UCEC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.79	7.95	0.55	4.53e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	0.73	4.76	0.37	4.53e-6	Diabetic retinopathy;
UCEC	cis	rs2677744	0.626	rs12905855	chr15:91498429	G/C	cg23684204	chr15:91497937	RCCD1	0.49	4.54	0.35	1.17e-5	Attention deficit hyperactivity disorder;
UCEC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg18681998	chr4:17616180	MED28	0.89	10.93	0.67	1.01e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.46	4.84	0.37	3.24e-6	HDL cholesterol;
UCEC	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	4.56	0.35	1.06e-5	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.39	-4.99	-0.38	1.68e-6	Monocyte count;
UCEC	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	5.13	0.39	8.95e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg06634786	chr22:41940651	POLR3H	0.44	4.55	0.35	1.11e-5	Neuroticism;
UCEC	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-0.93	-9.01	-0.6	9.92e-16	Dilated cardiomyopathy;
UCEC	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.66	-6.37	-0.47	2.24e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs1483890	0.723	rs12631128	chr3:69411416	G/T	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs12681963	0.748	rs6468070	chr8:29896598	G/A	cg07899425	chr8:30585046	GSR	0.53	4.79	0.37	3.97e-6	Migraine;
UCEC	cis	rs1387221	0.904	rs16923680	chr8:59613227	T/C	cg24495373	chr8:59337659	UBXN2B	0.38	4.56	0.35	1.07e-5	Clozapine-induced cytotoxicity;
UCEC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.41	4.73	0.36	5.19e-6	Blood protein levels;
UCEC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg20387954	chr3:183756860	HTR3D	0.5	5.93	0.44	2.09e-8	Anterior chamber depth;
UCEC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.97	0.5	9.88e-11	Ileal carcinoids;
UCEC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.87	10.97	0.67	8.05e-21	Metabolic syndrome;
UCEC	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.62	6.01	0.44	1.38e-8	Retinal vascular caliber;
UCEC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.63	4.97	0.38	1.83e-6	Bladder cancer;
UCEC	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	6.04	0.45	1.2e-8	Schizophrenia;
UCEC	cis	rs10924970	0.649	rs12029822	chr1:235381342	T/G	cg26050004	chr1:235667680	B3GALNT2	0.52	4.73	0.36	5.31e-6	Asthma;
UCEC	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.43	-5.11	-0.39	9.66e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.48	4.85	0.37	3.16e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.68	6.5	0.47	1.19e-9	Bladder cancer;
UCEC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26207909	chr14:103986467	CKB	0.53	5.74	0.43	5.33e-8	Body mass index;
UCEC	cis	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg17412351	chr7:75678396	MDH2;STYXL1	-0.44	-4.79	-0.37	3.97e-6	Eotaxin levels;
UCEC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.82	-9.49	-0.62	5.95e-17	Coronary artery disease;
UCEC	cis	rs7246967	0.932	rs58238799	chr19:23040182	G/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.5	5.31	0.4	3.93e-7	Schizophrenia;
UCEC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-8.27	-0.56	7.51e-14	Menarche (age at onset);
UCEC	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.8	0.43	3.93e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-4.92	-0.38	2.26e-6	Gut microbiome composition (summer);
UCEC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg21770322	chr7:97807741	LMTK2	0.47	5.88	0.44	2.65e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.59	0.35	9.3e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.6e-7	Breast cancer;
UCEC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.36	0.4	3.15e-7	Rheumatoid arthritis;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.48	-4.94	-0.38	2.13e-6	Pubertal anthropometrics;
UCEC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.78	-8.68	-0.58	7.07e-15	Monocyte count;
UCEC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.54	5.67	0.42	7.5e-8	Platelet count;
UCEC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.54	5.34	0.4	3.38e-7	Vitiligo;
UCEC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.14	18.7	0.84	1.07e-40	Testicular germ cell tumor;
UCEC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.47	6.43	0.47	1.7e-9	Total body bone mineral density;
UCEC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.69	-0.48	4.26e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs10924970	0.649	rs10925195	chr1:235401342	C/A	cg26050004	chr1:235667680	B3GALNT2	0.5	4.63	0.36	7.85e-6	Asthma;
UCEC	cis	rs35934224	0.771	rs34820460	chr22:19869210	G/A	cg11182965	chr22:19864308	TXNRD2	-0.51	-6.41	-0.47	1.88e-9	Glaucoma (primary open-angle);
UCEC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg24562669	chr7:97807699	LMTK2	0.47	5.77	0.43	4.46e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.56	-5.0	-0.38	1.58e-6	Major depressive disorder;
UCEC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.76	-8.32	-0.57	5.5e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24308560	chr3:49941425	MST1R	-0.46	-4.98	-0.38	1.74e-6	Body mass index;
UCEC	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.64	6.39	0.47	2.02e-9	Coronary artery disease;
UCEC	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.51	4.79	0.37	4e-6	Coronary artery disease;
UCEC	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.39	-5.22	-0.4	5.98e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	9.36	0.61	1.27e-16	Mean corpuscular hemoglobin;
UCEC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg10914120	chr13:113893660	CUL4A	0.43	4.65	0.36	7.21e-6	Platelet distribution width;
UCEC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.61	5.76	0.43	4.71e-8	Tourette syndrome;
UCEC	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.47	0.52	6.69e-12	Bladder cancer;
UCEC	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.77	5.76	0.43	4.69e-8	Exhaled nitric oxide levels;
UCEC	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.95	-0.44	1.88e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.65	-6.22	-0.46	4.8e-9	Metabolic syndrome;
UCEC	cis	rs2120243	0.791	rs7615621	chr3:157152600	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.46	4.7	0.36	5.92e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs60311166	1.000	rs60311166	chr3:52671070	C/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	4.64	0.36	7.57e-6	CTACK levels;
UCEC	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	5.1	0.39	1.04e-6	Response to antipsychotic treatment;
UCEC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	4.85	0.37	3.06e-6	Breast cancer;
UCEC	cis	rs17123764	0.818	rs3815832	chr12:49948105	A/G	cg20471783	chr12:50157085	TMBIM6	0.65	5.43	0.41	2.27e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.49	-4.81	-0.37	3.64e-6	Aortic root size;
UCEC	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.68	7.79	0.54	1.08e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.52	-5.92	-0.44	2.2e-8	Tonsillectomy;
UCEC	cis	rs7582720	0.945	rs72932723	chr2:203647646	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.86	4.95	0.38	2e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.11	-0.39	9.68e-7	Life satisfaction;
UCEC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.55	5.41	0.41	2.47e-7	Menopause (age at onset);
UCEC	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.77	-9.58	-0.62	3.47e-17	Systemic sclerosis;
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.76	-5.44	-0.41	2.14e-7	Narcolepsy;
UCEC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.51	5.24	0.4	5.44e-7	Schizophrenia;
UCEC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg06238570	chr21:40685208	BRWD1	0.8	7.07	0.5	5.74e-11	Cognitive function;
UCEC	cis	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.7	0.36	5.93e-6	Breast cancer;
UCEC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.61	8.56	0.58	1.34e-14	Prudent dietary pattern;
UCEC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.47	4.5	0.35	1.35e-5	Platelet count;
UCEC	cis	rs4372836	0.796	rs7580078	chr2:28997001	G/C	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.2	-0.51	2.9e-11	Body mass index;
UCEC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg23815491	chr16:72088622	HP	0.46	6.11	0.45	8.46e-9	Fibrinogen levels;
UCEC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.72	-5.46	-0.41	1.95e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.71	6.94	0.5	1.19e-10	Coronary artery disease;
UCEC	cis	rs36051895	0.623	rs10975031	chr9:5253153	G/T	cg02405213	chr9:5042618	JAK2	-0.46	-4.57	-0.35	1.02e-5	Pediatric autoimmune diseases;
UCEC	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.15	9.39	0.61	1.05e-16	Uric acid levels;
UCEC	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg13683864	chr3:40499215	RPL14	1.11	16.0	0.8	5.29e-34	Renal cell carcinoma;
UCEC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	5.26	0.4	4.92e-7	Birth weight;
UCEC	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg11569703	chr11:65557185	OVOL1	-0.46	-6.61	-0.48	6.63e-10	Acne (severe);
UCEC	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.5	4.76	0.37	4.62e-6	Coronary artery disease;
UCEC	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	0.97	10.75	0.66	2.98e-20	Corneal structure;
UCEC	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.61	5.18	0.39	7.35e-7	Heart rate;
UCEC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24308560	chr3:49941425	MST1R	-0.42	-4.55	-0.35	1.1e-5	Body mass index;
UCEC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.68	-6.16	-0.45	6.57e-9	Cardiac Troponin-T levels;
UCEC	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg26769984	chr7:1090371	C7orf50	0.45	4.55	0.35	1.13e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.68	-5.8	-0.43	3.83e-8	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7246967	0.673	rs8104564	chr19:22867207	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.46	-0.72	8.76e-25	Ulcerative colitis;
UCEC	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg08027265	chr7:2291960	NA	-0.47	-5.56	-0.42	1.24e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg24069376	chr3:38537580	EXOG	0.39	4.77	0.37	4.37e-6	Electrocardiographic conduction measures;
UCEC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	5.33	0.4	3.6e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Bladder cancer;
UCEC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	4.76	0.37	4.55e-6	Response to antipsychotic treatment;
UCEC	cis	rs7215564	0.908	rs34710385	chr17:78676494	G/A	cg04242349	chr17:79082840	BAIAP2	0.5	4.7	0.36	5.82e-6	Myopia (pathological);
UCEC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.86	9.74	0.63	1.3e-17	Dental caries;
UCEC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg03859395	chr2:55845619	SMEK2	1.06	15.73	0.79	2.58e-33	Metabolic syndrome;
UCEC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.57	0.62	3.6e-17	Menopause (age at onset);
UCEC	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.63	-5.21	-0.39	6.2e-7	IgG glycosylation;
UCEC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.58	-5.16	-0.39	7.99e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.51	-4.98	-0.38	1.8e-6	Diastolic blood pressure;
UCEC	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.56	-5.09	-0.39	1.09e-6	Metabolite levels;
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg14547644	chr6:28411285	ZSCAN23	0.56	6.23	0.46	4.68e-9	Cardiac Troponin-T levels;
UCEC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.64	-0.58	8.61e-15	Monocyte count;
UCEC	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.41	-4.89	-0.37	2.58e-6	Menarche (age at onset);
UCEC	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.64	6.62	0.48	6.14e-10	Vitamin D levels;
UCEC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.04	0.38	1.36e-6	Rheumatoid arthritis;
UCEC	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.57	6.08	0.45	9.68e-9	Anterior chamber depth;
UCEC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	6.45	0.47	1.54e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.38	4.96	0.38	1.92e-6	Blood protein levels;
UCEC	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.43	5.58	0.42	1.12e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.65	7.85	0.54	8e-13	Menarche (age at onset);
UCEC	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.53	5.96	0.44	1.77e-8	Crohn's disease;
UCEC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg20821713	chr7:1055600	C7orf50	-0.66	-6.06	-0.45	1.08e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.52	-5.34	-0.4	3.52e-7	Monocyte count;
UCEC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.49	4.68	0.36	6.35e-6	Blood metabolite levels;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs2839627	0.513	rs67571721	chr21:44306446	A/T	cg03543861	chr21:44258195	NA	0.52	5.16	0.39	7.86e-7	Information processing speed;
UCEC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.46	5.26	0.4	5.01e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18252515	chr7:66147081	NA	-0.51	-4.8	-0.37	3.88e-6	Aortic root size;
UCEC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.47	6.68	0.48	4.63e-10	Primary biliary cholangitis;
UCEC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg22563815	chr15:78856949	CHRNA5	-0.37	-4.88	-0.37	2.76e-6	Sudden cardiac arrest;
UCEC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.15	6.69	0.48	4.32e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs7246967	0.932	rs34622638	chr19:23063652	C/T	cg01485075	chr19:22817371	ZNF492	0.45	4.55	0.35	1.1e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg04804543	chr8:142233427	SLC45A4	0.49	5.85	0.43	3.14e-8	Immature fraction of reticulocytes;
UCEC	cis	rs7870753	0.628	rs7860871	chr9:99187403	A/G	cg25260653	chr9:99212216	HABP4	0.52	4.88	0.37	2.75e-6	Height;
UCEC	cis	rs3845624	0.566	rs34982367	chr1:159182955	G/C	cg08279665	chr1:160146152	ATP1A4	0.5	4.52	0.35	1.25e-5	Inflammatory biomarkers;
UCEC	cis	rs201260	0.606	rs9396778	chr6:9976215	A/G	cg17697633	chr6:10420079	TFAP2A	0.54	4.76	0.37	4.64e-6	Electroencephalogram traits;
UCEC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.59	5.68	0.42	7.02e-8	Aortic root size;
UCEC	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-5.32	-0.4	3.75e-7	Pediatric autoimmune diseases;
UCEC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.72	-7.73	-0.54	1.59e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg11569703	chr11:65557185	OVOL1	-0.43	-6.06	-0.45	1.09e-8	Acne (severe);
UCEC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.58	-4.67	-0.36	6.87e-6	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg22166914	chr1:53195759	ZYG11B	0.59	6.03	0.45	1.26e-8	Monocyte count;
UCEC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.78	7.65	0.53	2.44e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.87	9.9	0.63	5.12e-18	Monocyte count;
UCEC	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.84	-0.7	3.94e-23	Monocyte count;
UCEC	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.47	5.39	0.41	2.74e-7	White matter hyperintensity burden;
UCEC	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	5.5	0.41	1.62e-7	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.47	-4.69	-0.36	6.06e-6	Monocyte count;
UCEC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg02160872	chr5:212506	CCDC127	0.71	7.42	0.52	8.71e-12	Breast cancer;
UCEC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.52	4.75	0.36	4.8e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg20575277	chr15:90728569	SEMA4B	0.44	4.62	0.36	8.15e-6	Rheumatoid arthritis;
UCEC	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.9	8.57	0.58	1.32e-14	Colorectal adenoma (advanced);
UCEC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.72	6.16	0.45	6.53e-9	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs4280164	0.830	rs2144494	chr14:24773387	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-4.79	-0.37	4.11e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.64	6.33	0.46	2.77e-9	Longevity;Endometriosis;
UCEC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg06784218	chr1:46089804	CCDC17	-0.46	-5.22	-0.4	6.06e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-5.66	-0.42	7.86e-8	Chronic sinus infection;
UCEC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.47	-4.98	-0.38	1.75e-6	Longevity;
UCEC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg21770322	chr7:97807741	LMTK2	0.85	14.84	0.77	4.96e-31	Breast cancer;
UCEC	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg16797656	chr11:68205561	LRP5	0.49	5.38	0.41	2.84e-7	Total body bone mineral density;
UCEC	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.54	4.7	0.36	5.9e-6	Red blood cell count;
UCEC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg18099408	chr3:52552593	STAB1	0.44	5.2	0.39	6.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.82	-8.44	-0.57	2.74e-14	Mosquito bite size;
UCEC	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.46	4.85	0.37	3.16e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.57	4.81	0.37	3.63e-6	Alzheimer's disease;
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg01874867	chr7:94954059	PON1	-0.52	-4.6	-0.35	9.21e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10432489	0.708	rs10189224	chr2:181764318	A/C	cg21995919	chr2:182322279	ITGA4	0.66	4.66	0.36	7.02e-6	QT interval;
UCEC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.84	-8.46	-0.57	2.42e-14	Obesity-related traits;
UCEC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg22907277	chr7:1156413	C7orf50	0.63	6.29	0.46	3.47e-9	Longevity;Endometriosis;
UCEC	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.48	0.62	6.28e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	7.59	0.53	3.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.62	6.8	0.49	2.41e-10	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-5.48	-0.41	1.8e-7	Colorectal cancer;
UCEC	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg00449821	chr1:155053823	EFNA3	0.41	4.61	0.36	8.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.67	-7.08	-0.5	5.45e-11	Blood protein levels;
UCEC	cis	rs1932064	0.536	rs72926263	chr1:71136586	G/C	cg15201877	chr1:71512973	PTGER3	-0.82	-5.43	-0.41	2.25e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	5.9	0.44	2.36e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-5.66	-0.42	7.68e-8	Monocyte percentage of white cells;
UCEC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.69	-4.9	-0.37	2.49e-6	Aortic root size;
UCEC	cis	rs7095607	0.813	rs7895717	chr10:69924100	A/G	cg18986048	chr10:69913749	MYPN	0.55	6.41	0.47	1.82e-9	Lung function (FVC);
UCEC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.0	0.5	8.66e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg06238570	chr21:40685208	BRWD1	0.81	7.99	0.55	3.59e-13	Cognitive function;
UCEC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.11	0.45	8.47e-9	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg14008862	chr17:28927542	LRRC37B2	0.62	4.87	0.37	2.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg22654517	chr2:96458247	NA	0.43	4.94	0.38	2.13e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.94	12.01	0.7	1.37e-23	Platelet distribution width;
UCEC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.85	0.37	3.07e-6	Breast cancer;
UCEC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.45	5.93	0.44	2.06e-8	Coronary artery disease;
UCEC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg19318889	chr4:1322082	MAEA	0.43	4.93	0.38	2.18e-6	Obesity-related traits;
UCEC	cis	rs3780378	0.934	rs10815146	chr9:5015901	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.69	-0.36	6.07e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs12623288	0.510	rs7577700	chr2:46610605	A/C	cg04518274	chr2:46525028	EPAS1	-0.61	-4.56	-0.35	1.08e-5	Hair morphology;
UCEC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.71	5.57	0.42	1.2e-7	Cisplatin-induced ototoxicity;
UCEC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	1.02	14.0	0.76	7.94e-29	Monocyte count;
UCEC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg13147721	chr7:65941812	NA	-0.69	-4.83	-0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg03609598	chr5:56110824	MAP3K1	0.72	5.56	0.42	1.25e-7	Initial pursuit acceleration;
UCEC	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.57	6.25	0.46	4.15e-9	Crohn's disease;
UCEC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.88	-10.06	-0.64	1.89e-18	Cognitive function;
UCEC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	4.9	0.37	2.53e-6	Breast cancer;
UCEC	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.62	6.78	0.49	2.69e-10	Motion sickness;
UCEC	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	1.2	8.95	0.59	1.46e-15	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.44	-5.08	-0.39	1.15e-6	Electroencephalogram traits;
UCEC	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.0	0.38	1.58e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.59e-7	Schizophrenia;
UCEC	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-4.77	-0.37	4.34e-6	Mean platelet volume;
UCEC	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg15167202	chr5:149997153	SYNPO	-0.36	-4.61	-0.36	8.52e-6	HIV-1 control;
UCEC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs11023332	0.706	rs11023380	chr11:14930058	A/G	cg19336497	chr11:14380999	RRAS2	-0.33	-4.97	-0.38	1.8e-6	Adiponectin levels;Vitamin D levels;
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.39	-4.97	-0.38	1.87e-6	Body mass index;
UCEC	cis	rs6832769	0.922	rs28726308	chr4:56234406	C/T	cg05960024	chr4:56376020	CLOCK	0.5	4.65	0.36	7.47e-6	Personality dimensions;
UCEC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.54	-6.18	-0.45	6.07e-9	Depression;
UCEC	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.63	5.7	0.43	6.41e-8	Obesity (extreme);
UCEC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.37	0.76	8.15e-30	Chronic sinus infection;
UCEC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg21231944	chr12:82153410	PPFIA2	0.47	5.23	0.4	5.77e-7	Resting heart rate;
UCEC	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.69	7.46	0.52	7.1e-12	Multiple system atrophy;
UCEC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.46	-5.36	-0.4	3.14e-7	Aortic root size;
UCEC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.74	7.68	0.54	2.05e-12	Vitamin D levels;
UCEC	cis	rs2900174	0.702	rs7312161	chr12:11561176	A/T	cg18383069	chr12:12510241	LOH12CR1;LOH12CR2	-0.57	-4.74	-0.36	5.02e-6	Survival in pancreatic cancer;Response to gemcitabine in pancreatic cancer;
UCEC	cis	rs7246967	0.673	rs2099341	chr19:22834360	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.49	-0.41	1.7e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7246967	0.611	rs66620859	chr19:22837230	G/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.61	4.73	0.36	5.27e-6	Breast cancer;
UCEC	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.81	-7.21	-0.51	2.73e-11	Vitiligo;
UCEC	cis	rs8044995	0.563	rs73615919	chr16:68398862	C/T	cg05110241	chr16:68378359	PRMT7	-0.48	-4.79	-0.37	4.03e-6	Schizophrenia;
UCEC	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg06660395	chr4:1396306	NA	-0.36	-4.53	-0.35	1.23e-5	Systolic blood pressure;
UCEC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.9	10.84	0.67	1.74e-20	Breast cancer;
UCEC	cis	rs6060717	0.653	rs2590962	chr20:34615363	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.19	-0.39	6.73e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.48	-4.97	-0.38	1.82e-6	Aortic root size;
UCEC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	5.37	0.41	2.96e-7	Height;
UCEC	cis	rs7215564	0.908	rs36100789	chr17:78701117	C/T	cg01498832	chr17:78682934	RPTOR	0.55	4.51	0.35	1.33e-5	Myopia (pathological);
UCEC	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.29	0.52	1.75e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-0.92	-5.79	-0.43	4.08e-8	Mitochondrial DNA levels;
UCEC	cis	rs7307889	0.793	rs59382088	chr12:5995398	G/A	cg23245485	chr12:6484219	SCNN1A	0.59	4.63	0.36	7.84e-6	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.49	-5.5	-0.41	1.68e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs73022763	chr19:22894216	C/T	cg24889512	chr19:22816950	ZNF492	0.63	6.68	0.48	4.53e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg21486944	chr6:28411378	ZSCAN23	0.55	6.38	0.47	2.12e-9	Pubertal anthropometrics;
UCEC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg22868518	chr11:507468	RNH1	-0.48	-4.69	-0.36	6.19e-6	Systemic lupus erythematosus;
UCEC	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.45	-4.69	-0.36	6.06e-6	Glaucoma;
UCEC	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.72	-0.36	5.42e-6	Obesity-related traits;
UCEC	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.65	-6.96	-0.5	1.04e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs925228	1.000	rs925228	chr2:24246679	A/G	cg13272742	chr2:24272458	FKBP1B	0.62	5.16	0.39	7.88e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4265793	0.512	rs11646974	chr16:19081446	A/G	cg06773604	chr16:18995157	TMC7	0.76	5.16	0.39	7.8e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.59	-4.7	-0.36	6.05e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.72	9.14	0.6	4.53e-16	Mean platelet volume;
UCEC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	6.74	0.49	3.3e-10	Bone mineral density;
UCEC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.71	5.13	0.39	8.94e-7	Menarche (age at onset);
UCEC	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.47	4.88	0.37	2.67e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.47	-5.07	-0.39	1.16e-6	Height;
UCEC	cis	rs8032158	0.702	rs1042477	chr15:56121886	C/A	cg10433327	chr15:56209506	NEDD4	-0.31	-4.84	-0.37	3.18e-6	Keloid;
UCEC	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.68	5.7	0.43	6.24e-8	Systolic blood pressure;
UCEC	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.86	10.05	0.64	2.1e-18	Tonsillectomy;
UCEC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18252515	chr7:66147081	NA	0.45	4.58	0.35	1e-5	Aortic root size;
UCEC	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.48e-16	Vitiligo;
UCEC	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.56	5.94	0.44	1.93e-8	Neuroticism;
UCEC	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.64	-8.11	-0.56	1.8e-13	Bipolar disorder;
UCEC	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.71	-6.51	-0.47	1.11e-9	Platelet distribution width;
UCEC	cis	rs1567532	0.774	rs12993353	chr2:79941636	A/G	cg11074070	chr2:80557293	CTNNA2	0.6	4.62	0.36	8.18e-6	Survival in pancreatic cancer;
UCEC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.6	6.92	0.5	1.33e-10	Longevity;
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.47	0.72	8.44e-25	Prudent dietary pattern;
UCEC	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.74	-5.49	-0.41	1.68e-7	Exhaled nitric oxide output;
UCEC	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.71	6.55	0.48	9.26e-10	Bladder cancer;
UCEC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.43	5.53	0.41	1.45e-7	Colorectal cancer;
UCEC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-5.16	-0.39	7.86e-7	Personality dimensions;
UCEC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg05738196	chr6:26577821	NA	0.63	7.27	0.51	1.99e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7246967	0.866	rs12981220	chr19:23021400	G/T	cg05241461	chr19:22816980	ZNF492	-0.51	-5.41	-0.41	2.52e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.52	-4.86	-0.37	2.96e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg04756594	chr16:24857601	SLC5A11	0.45	5.07	0.39	1.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.57	6.69	0.48	4.46e-10	Menarche (age at onset);
UCEC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.62	6.0	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg23460707	chr10:133558971	NA	-0.37	-4.81	-0.37	3.76e-6	Survival in rectal cancer;
UCEC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.63	6.84	0.49	1.96e-10	Homoarginine levels;
UCEC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs12618769	0.597	rs7585939	chr2:99219206	T/A	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.46e-7	Bipolar disorder;
UCEC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.59	5.26	0.4	5.1e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.54	-4.52	-0.35	1.29e-5	Major depressive disorder;
UCEC	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.14	-0.39	8.73e-7	Body mass index;
UCEC	trans	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg10732611	chr13:33700592	STARD13	-0.56	-6.69	-0.48	4.36e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.6	6.21	0.46	5.25e-9	Blood protein levels;
UCEC	cis	rs953387	0.824	rs6716987	chr2:136963494	G/T	cg07169764	chr2:136633963	MCM6	0.51	4.94	0.38	2.1e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs7246967	0.673	rs55932152	chr19:22873428	A/T	cg08271804	chr19:22816896	ZNF492	0.65	6.58	0.48	7.67e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7197653	0.748	rs11350	chr16:68335392	A/G	cg05110241	chr16:68378359	PRMT7	-0.53	-4.55	-0.35	1.13e-5	Magnesium levels;
UCEC	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg01072550	chr1:21505969	NA	-0.56	-5.21	-0.4	6.15e-7	Superior frontal gyrus grey matter volume;
UCEC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.95e-15	Height;
UCEC	cis	rs11697848	1.000	rs74597310	chr20:48462727	T/C	cg17849948	chr20:48532315	SPATA2	1.03	5.08	0.39	1.13e-6	Systemic lupus erythematosus;
UCEC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	8.07	0.55	2.23e-13	Bone mineral density;
UCEC	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.28	-0.61	2.01e-16	Height;
UCEC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	3.62e-18	Menopause (age at onset);
UCEC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-0.7	-8.15	-0.56	1.42e-13	Blood trace element (Zn levels);
UCEC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.37	0.46	2.33e-9	Aortic root size;
UCEC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	5.62	0.42	9.17e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg20387954	chr3:183756860	HTR3D	0.49	5.9	0.44	2.37e-8	Anterior chamber depth;
UCEC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.33	4.87	0.37	2.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9400271	0.527	rs9374083	chr6:109642957	C/G	cg01475377	chr6:109611718	NA	0.43	4.89	0.37	2.62e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg04202892	chr2:111875749	ACOXL	0.42	4.69	0.36	6.32e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-4.66	-0.36	6.96e-6	Alzheimer's disease (late onset);
UCEC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.36	4.52	0.35	1.29e-5	Obesity-related traits;
UCEC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.23	-0.4	5.72e-7	Bipolar disorder;
UCEC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.55	-0.42	1.3e-7	Hemoglobin concentration;
UCEC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.98	-7.04	-0.5	6.69e-11	Blood pressure (smoking interaction);
UCEC	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.59	-6.04	-0.45	1.2e-8	Strep throat;
UCEC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs11153730	0.503	rs283046	chr6:118627503	T/C	cg21191810	chr6:118973309	C6orf204	0.4	5.0	0.38	1.58e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg00651523	chr6:28411279	ZSCAN23	0.54	5.99	0.44	1.58e-8	Cardiac Troponin-T levels;
UCEC	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg05660106	chr1:15850417	CASP9	0.49	4.72	0.36	5.33e-6	Systolic blood pressure;
UCEC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.35	-0.4	3.35e-7	Breast cancer;
UCEC	cis	rs4372836	1.000	rs55835850	chr2:28949296	T/C	cg09522027	chr2:28974177	PPP1CB	0.75	7.6	0.53	3.21e-12	Body mass index;
UCEC	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.67	7.56	0.53	4.03e-12	Resting heart rate;
UCEC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.8	-0.37	3.83e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg11871910	chr12:69753446	YEATS4	0.57	5.0	0.38	1.62e-6	Response to diuretic therapy;
UCEC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.53	7.42	0.52	8.69e-12	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.63	4.78	0.37	4.16e-6	Carotid intima media thickness;
UCEC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.67	4.9	0.37	2.49e-6	Educational attainment;
UCEC	cis	rs7725337	0.931	rs6452803	chr5:88307285	A/G	cg26650655	chr5:88178400	MEF2C	0.42	4.53	0.35	1.19e-5	Total body bone mineral density;
UCEC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.75	-5.93	-0.44	2.07e-8	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.67	-0.36	6.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.85	9.18	0.6	3.75e-16	Parkinson's disease;
UCEC	cis	rs1639906	0.895	rs6972752	chr7:2196551	G/A	cg25193073	chr7:1967621	MAD1L1	-0.37	-5.12	-0.39	9.27e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.96	0.5	1.06e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.62	-5.08	-0.39	1.15e-6	Schizophrenia;
UCEC	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.77	7.97	0.55	4.15e-13	Parkinson's disease;
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.71	8.31	0.57	5.98e-14	Menarche (age at onset);
UCEC	cis	rs4499344	0.730	rs417823	chr19:33104561	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.33	0.46	2.77e-9	Mean platelet volume;
UCEC	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.75	-8.36	-0.57	4.5e-14	White blood cell count (basophil);
UCEC	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.56	-4.78	-0.37	4.17e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7106204	0.764	rs28833840	chr11:24206736	G/A	ch.11.24196551F	chr11:24239977	NA	0.65	4.56	0.35	1.07e-5	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg22974920	chr21:40686053	BRWD1	0.64	5.66	0.42	7.73e-8	Cognitive function;
UCEC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.67	-6.09	-0.45	9.43e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.46	-0.52	7.08e-12	Pursuit maintenance gain;
UCEC	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-5.82	-0.43	3.51e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs4499344	0.730	rs8103269	chr19:33097503	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.92	0.44	2.23e-8	Mean platelet volume;
UCEC	cis	rs6763768	0.606	rs11707463	chr3:53362565	A/G	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.74	8.54	0.58	1.57e-14	IgG glycosylation;
UCEC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.14	13.95	0.75	1.06e-28	Cognitive function;
UCEC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.47	0.41	1.88e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	4.77	0.37	4.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.677	rs11246386	chr11:1044938	C/T	cg18573204	chr11:798458	NA	-0.54	-4.53	-0.35	1.22e-5	Alzheimer's disease (late onset);
UCEC	cis	rs6723108	0.603	rs62168897	chr2:135717997	C/T	cg07169764	chr2:136633963	MCM6	0.51	4.96	0.38	1.93e-6	Type 2 diabetes;
UCEC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.63	-0.48	5.88e-10	Response to antipsychotic treatment;
UCEC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.47	0.41	1.88e-7	Cognitive test performance;
UCEC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	8.28	0.56	7.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg01072550	chr1:21505969	NA	-0.57	-5.58	-0.42	1.13e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.69	0.48	4.38e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs256277	0.657	rs154120	chr5:111375061	G/A	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.57	-4.76	-0.37	4.5e-6	Coronary artery disease;
UCEC	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	11.0	0.67	6.59e-21	Electrocardiographic conduction measures;
UCEC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.87	0.37	2.79e-6	Aortic root size;
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.18	0.45	6.05e-9	Platelet count;
UCEC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.79	6.84	0.49	1.98e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.52	-5.16	-0.39	7.81e-7	Diastolic blood pressure;
UCEC	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.44	4.68	0.36	6.46e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.55	-6.83	-0.49	2.1e-10	Pubertal anthropometrics;
UCEC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.67	-5.43	-0.41	2.25e-7	Menopause (age at onset);
UCEC	cis	rs6832769	1.000	rs9998146	chr4:56397977	C/T	cg05960024	chr4:56376020	CLOCK	-0.56	-5.7	-0.43	6.43e-8	Personality dimensions;
UCEC	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg26513180	chr16:89883248	FANCA	-0.72	-4.67	-0.36	6.67e-6	Caffeine consumption;
UCEC	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg16576597	chr16:28551801	NUPR1	-0.3	-4.67	-0.36	6.84e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.89	7.12	0.51	4.47e-11	Exhaled nitric oxide output;
UCEC	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.4	5.69	0.43	6.56e-8	Ulcerative colitis;
UCEC	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.51	-5.47	-0.41	1.9e-7	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.62	0.42	9.27e-8	Prudent dietary pattern;
UCEC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.45	4.63	0.36	8.07e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.76	-7.95	-0.55	4.45e-13	Breast cancer;
UCEC	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.83	-8.44	-0.57	2.8e-14	Resting heart rate;
UCEC	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	6.33	0.46	2.85e-9	Bone mineral density;
UCEC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.54	-6.26	-0.46	3.95e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg24687543	chr11:63912206	MACROD1	0.4	4.85	0.37	3.11e-6	Platelet count;
UCEC	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.65	-5.39	-0.41	2.79e-7	Psoriasis vulgaris;
UCEC	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.73	6.02	0.44	1.36e-8	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg01256987	chr12:42539512	GXYLT1	-0.41	-4.71	-0.36	5.68e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.65	4.96	0.38	1.9e-6	Corneal astigmatism;
UCEC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-4.54	-0.35	1.15e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.73	7.86	0.54	7.56e-13	Multiple system atrophy;
UCEC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.6	-7.13	-0.51	4.16e-11	Menopause (age at onset);
UCEC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.12	9.58	0.62	3.51e-17	Uric acid levels;
UCEC	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.6	5.69	0.42	6.73e-8	Coronary artery disease;
UCEC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.36	-5.79	-0.43	4.21e-8	Vitiligo;
UCEC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.74	-6.48	-0.47	1.31e-9	Gut microbiome composition (summer);
UCEC	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.71	0.43	6.08e-8	Bipolar disorder;
UCEC	cis	rs7095607	0.560	rs2087344	chr10:69922735	A/G	cg18986048	chr10:69913749	MYPN	-0.41	-4.53	-0.35	1.2e-5	Lung function (FVC);
UCEC	cis	rs3790645	1.000	rs444482	chr1:26890648	C/G	cg23229016	chr1:26872525	RPS6KA1	0.32	6.12	0.45	8.25e-9	Glucose homeostasis traits;
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.79	11.25	0.68	1.44e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg22974920	chr21:40686053	BRWD1	0.65	5.34	0.4	3.46e-7	Cognitive function;
UCEC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.67	-5.42	-0.41	2.35e-7	Type 2 diabetes;
UCEC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.69	7.57	0.53	3.89e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13379827	chr1:65468782	NA	-0.75	-7.05	-0.5	6.59e-11	Neuroticism;
UCEC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12516959	chr21:47718080	NA	-0.4	-4.57	-0.35	1.02e-5	Testicular germ cell tumor;
UCEC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.34	-0.46	2.7e-9	Pancreatic cancer;
UCEC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.46	0.41	1.98e-7	Cognitive test performance;
UCEC	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs10924970	0.967	rs2382617	chr1:235402230	A/G	cg26050004	chr1:235667680	B3GALNT2	0.42	4.5	0.35	1.35e-5	Asthma;
UCEC	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.13	9.46	0.62	6.86e-17	Opioid sensitivity;
UCEC	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.57	5.57	0.42	1.2e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.55	-6.0	-0.44	1.43e-8	Blood metabolite levels;
UCEC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.76	7.74	0.54	1.47e-12	Parkinson's disease;
UCEC	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.84	-7.4	-0.52	9.83e-12	Vitiligo;
UCEC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.55	6.33	0.46	2.8e-9	Prostate cancer;
UCEC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.45	-4.5	-0.35	1.35e-5	Aortic root size;
UCEC	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.49	4.6	0.36	8.88e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.47	5.98	0.44	1.65e-8	HDL cholesterol levels;
UCEC	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	0.86	10.33	0.65	3.73e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.46	-5.05	-0.38	1.3e-6	Gut microbiome composition (summer);
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.63	6.62	0.48	6.42e-10	Immature fraction of reticulocytes;
UCEC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.2	7.16	0.51	3.63e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.9	0.59	1.88e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.8	-0.63	9.01e-18	Monocyte count;
UCEC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.25	-0.46	4.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg02160872	chr5:212506	CCDC127	-0.68	-7.0	-0.5	8.52e-11	Breast cancer;
UCEC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-0.97	-7.23	-0.51	2.41e-11	Body mass index;
UCEC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.76	7.76	0.54	1.35e-12	Blood protein levels;
UCEC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.84	7.75	0.54	1.38e-12	Heart rate;
UCEC	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg21191810	chr6:118973309	C6orf204	-0.39	-5.34	-0.4	3.46e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.85	-9.4	-0.61	9.94e-17	Cognitive function;
UCEC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.57	6.81	0.49	2.37e-10	Total body bone mineral density;
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.48	-4.89	-0.37	2.57e-6	Parkinson's disease;
UCEC	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-1.15	-7.64	-0.53	2.52e-12	Height;
UCEC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06583696	chr2:26101536	ASXL2	0.61	7.5	0.53	5.53e-12	Warfarin maintenance dose;
UCEC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg20999797	chr1:1681921	NA	0.38	5.04	0.38	1.33e-6	Body mass index;
UCEC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.49e-6	Hemoglobin concentration;
UCEC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.96	6.62	0.48	6.33e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs6595838	0.954	rs4836378	chr5:127850979	A/T	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Systolic blood pressure;
UCEC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.64	-5.29	-0.4	4.37e-7	Alzheimer's disease;
UCEC	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.31	-0.4	3.96e-7	Metabolite levels;
UCEC	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.54	5.33	0.4	3.71e-7	Coronary artery disease;
UCEC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.5	-5.37	-0.41	2.98e-7	Schizophrenia;
UCEC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.79	7.95	0.55	4.53e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg19622623	chr12:86230825	RASSF9	-0.38	-4.59	-0.35	9.38e-6	Major depressive disorder;
UCEC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.32e-6	Breast cancer;
UCEC	cis	rs11697848	1.000	rs78700554	chr20:48522124	T/G	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.52	4.87	0.37	2.86e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg01874867	chr7:94954059	PON1	-0.54	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-0.96	-7.23	-0.51	2.42e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.58	-5.16	-0.39	7.92e-7	Hypospadias;
UCEC	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs12216499	1.000	rs2179699	chr6:159386594	G/T	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.54	-0.35	1.15e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.45	5.29	0.4	4.39e-7	Emphysema distribution in smoking;
UCEC	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs925228	0.955	rs12479331	chr2:24201701	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.54	4.67	0.36	6.84e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4778581	0.900	rs34579896	chr15:80398235	C/A	cg08257866	chr15:80351198	ZFAND6	0.41	4.53	0.35	1.23e-5	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7597155	0.811	rs6739661	chr2:69962499	C/T	cg02498382	chr2:70120550	SNRNP27	-0.41	-4.55	-0.35	1.09e-5	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9309473	0.898	rs10201159	chr2:73858965	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-5.05	-0.38	1.27e-6	Metabolite levels;
UCEC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.43	5.32	0.4	3.83e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.6	-4.58	-0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.49	-4.99	-0.38	1.68e-6	Height;
UCEC	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	7.53	0.53	4.71e-12	Nonalcoholic fatty liver disease;
UCEC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.58	5.14	0.39	8.61e-7	Corneal astigmatism;
UCEC	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.54	5.61	0.42	9.78e-8	Schizophrenia;
UCEC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.56	4.76	0.37	4.59e-6	Alzheimer's disease;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	0.93	5.5	0.41	1.64e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.7	-8.56	-0.58	1.35e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.77	7.4	0.52	9.62e-12	Vitamin D levels;
UCEC	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-5.32	-0.4	3.84e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.62	5.45	0.41	2.07e-7	Uric acid levels;
UCEC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	5.31	0.4	3.89e-7	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg01072550	chr1:21505969	NA	-0.51	-4.74	-0.36	5.01e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.51	5.27	0.4	4.8e-7	Breast cancer;
UCEC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-5.61	-0.42	9.78e-8	Menarche (age at onset);
UCEC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg03678062	chr6:149772716	ZC3H12D	0.41	5.25	0.4	5.28e-7	Dupuytren's disease;
UCEC	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.59	-5.85	-0.43	3.02e-8	White matter hyperintensity burden;
UCEC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.15	-0.45	7e-9	Prudent dietary pattern;
UCEC	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.33	0.57	5.11e-14	Menopause (age at onset);
UCEC	cis	rs11153730	0.503	rs283057	chr6:118625734	T/C	cg21191810	chr6:118973309	C6orf204	0.4	5.11	0.39	9.71e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.76	0.37	4.61e-6	Personality dimensions;
UCEC	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.59	7.22	0.51	2.61e-11	Testicular germ cell tumor;
UCEC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.44	-5.4	-0.41	2.56e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9936075	0.515	rs74010639	chr16:7390435	C/T	cg08230268	chr16:7489771	A2BP1	-0.39	-4.55	-0.35	1.11e-5	Platelet-derived growth factor BB levels;
UCEC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg06462663	chr19:18546047	ISYNA1	0.48	6.04	0.45	1.21e-8	Breast cancer;
UCEC	cis	rs7809615	0.515	rs11772470	chr7:99181096	G/A	cg24650262	chr7:98904301	NA	0.46	4.61	0.36	8.58e-6	Blood metabolite ratios;
UCEC	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-5.33	-0.4	3.68e-7	Body mass index;
UCEC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.58	5.13	0.39	8.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.8	-0.37	3.78e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.82	-8.86	-0.59	2.48e-15	Longevity;
UCEC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.14	-0.64	1.22e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.61	-0.36	8.58e-6	Pulmonary function;
UCEC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26002218	chr14:103986227	CKB	0.32	4.59	0.35	9.51e-6	Body mass index;
UCEC	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.62	-5.65	-0.42	8.23e-8	Acne (severe);
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.33	0.61	1.5e-16	Platelet count;
UCEC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.53	6.76	0.49	2.96e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.35	-0.57	4.76e-14	Total cholesterol levels;
UCEC	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg10104451	chr8:143696006	ARC	-0.55	-5.16	-0.39	8e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.87	7.97	0.55	4.08e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.6	5.67	0.42	7.28e-8	High light scatter reticulocyte count;
UCEC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs1318772	1.000	rs11738587	chr5:112693781	C/G	cg12552261	chr5:112820674	MCC	0.59	4.92	0.38	2.26e-6	F-cell distribution;
UCEC	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.36	5.05	0.38	1.26e-6	Fat distribution (HIV);
UCEC	cis	rs6696846	0.515	rs10900450	chr1:205106238	C/G	cg12580275	chr1:205744413	RAB7L1	0.45	5.31	0.4	4.03e-7	Red blood cell count;
UCEC	cis	rs9596863	0.950	rs6561749	chr13:54435195	G/C	ch.13.53330881F	chr13:54432880	NA	-0.53	-4.56	-0.35	1.07e-5	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	0.86	9.12	0.6	5.4e-16	Parkinson's disease;
UCEC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.57	-4.63	-0.36	7.88e-6	Initial pursuit acceleration;
UCEC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg12024160	chr4:1254474	NA	0.59	7.07	0.5	5.68e-11	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.55	0.42	1.28e-7	Prudent dietary pattern;
UCEC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.59	0.35	9.29e-6	Menopause (age at onset);
UCEC	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.05	-0.38	1.29e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs4845459	0.933	rs6662654	chr1:152593081	G/T	cg07796016	chr1:152779584	LCE1C	-0.42	-4.71	-0.36	5.75e-6	Psoriasis;
UCEC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg10932868	chr11:921992	NA	0.44	5.84	0.43	3.3e-8	Alzheimer's disease (late onset);
UCEC	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.97	0.55	4.09e-13	Menopause (age at onset);
UCEC	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg11859384	chr17:80120422	CCDC57	-0.47	-5.18	-0.39	7.19e-7	Life satisfaction;
UCEC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.53	5.24	0.4	5.5e-7	Aortic root size;
UCEC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	0.76	10.0	0.64	2.71e-18	Monocyte percentage of white cells;
UCEC	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.72	6.55	0.48	8.85e-10	Aortic root size;
UCEC	cis	rs924607	0.545	rs7378524	chr5:616946	T/C	cg24163568	chr5:669837	TPPP	-0.42	-5.31	-0.4	3.89e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg11150807	chr10:43354902	NA	0.61	4.77	0.37	4.32e-6	Blood protein levels;
UCEC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.4	4.71	0.36	5.59e-6	Obesity-related traits;
UCEC	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.73	-8.02	-0.55	3.09e-13	Sudden cardiac arrest;
UCEC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.95	0.44	1.86e-8	Monocyte percentage of white cells;
UCEC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.59	-6.35	-0.46	2.57e-9	Initial pursuit acceleration;
UCEC	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.57	6.21	0.46	5.05e-9	Menarche (age at onset);
UCEC	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg17652424	chr22:38574118	PLA2G6	0.38	4.74	0.36	5.07e-6	Cutaneous nevi;
UCEC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.6	-5.04	-0.38	1.37e-6	Alcohol dependence;
UCEC	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg24562669	chr7:97807699	LMTK2	0.61	8.15	0.56	1.46e-13	Breast cancer;
UCEC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.49	5.23	0.4	5.62e-7	Aortic root size;
UCEC	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.69	-5.04	-0.38	1.33e-6	Prostate cancer;
UCEC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.32	0.4	3.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.06	-0.39	1.23e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs9470794	1.000	rs12662543	chr6:38110010	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.2	-22.35	-0.88	3.97e-49	Myeloid white cell count;
UCEC	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.98	-7.66	-0.53	2.25e-12	Dupuytren's disease;
UCEC	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg07041428	chr4:1763019	NA	-0.4	-4.79	-0.37	3.97e-6	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-0.99	-8.63	-0.58	9.18e-15	Vitiligo;
UCEC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.5	4.79	0.37	3.97e-6	Intelligence;Intelligence (multi-trait analysis);
UCEC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.0	0.67	6.54e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.2	-0.39	6.67e-7	Red blood cell count;Reticulocyte count;
UCEC	trans	rs17594526	0.826	rs17596267	chr18:53141537	A/T	cg12963529	chr20:43540202	PABPC1L	-1.28	-6.82	-0.49	2.19e-10	Schizophrenia;
UCEC	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.57	6.02	0.44	1.32e-8	Red blood cell count;
UCEC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.68	-5.47	-0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.8	8.97	0.59	1.27e-15	Coronary artery disease;
UCEC	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.84	-8.92	-0.59	1.72e-15	Blood metabolite levels;
UCEC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.66	6.85	0.49	1.83e-10	Dental caries;
UCEC	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	4.51	0.35	1.33e-5	Personality dimensions;
UCEC	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg13683864	chr3:40499215	RPL14	-0.66	-6.65	-0.48	5.25e-10	Renal cell carcinoma;
UCEC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18402987	chr7:1209562	NA	0.48	4.85	0.37	3.1e-6	Longevity;Endometriosis;
UCEC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg20630560	chr1:228395858	OBSCN	0.3	4.58	0.35	9.95e-6	Diastolic blood pressure;
UCEC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.62	6.53	0.47	1.02e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	trans	rs66573146	1.000	rs6838042	chr4:6973049	G/T	cg07817883	chr1:32538562	TMEM39B	1.37	9.21	0.6	3.11e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.14	-0.45	7.16e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.25	-6.95	-0.5	1.12e-10	Atopic dermatitis;
UCEC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.32	0.4	3.78e-7	Breast cancer;
UCEC	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg10902566	chr4:727664	PCGF3	0.59	5.24	0.4	5.52e-7	Systolic blood pressure;
UCEC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	0.83	7.4	0.52	9.84e-12	Type 2 diabetes nephropathy;
UCEC	cis	rs1575951	1.000	rs7071745	chr10:130439737	T/G	cg27041381	chr10:131357203	MGMT	0.6	4.97	0.38	1.84e-6	Plasma clusterin levels;
UCEC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg03959625	chr15:84868606	LOC388152	0.48	4.95	0.38	2.04e-6	Schizophrenia;
UCEC	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.6	5.64	0.42	8.39e-8	Birth weight;
UCEC	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.45	-5.31	-0.4	3.99e-7	Prevalent atrial fibrillation;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.63	-0.48	5.92e-10	Depression;
UCEC	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.51	-5.26	-0.4	4.92e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.61	-0.42	9.75e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-4.6	-0.35	8.95e-6	Coronary artery disease;
UCEC	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-6.06	-0.45	1.08e-8	Hepatocellular carcinoma;
UCEC	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.43	5.03	0.38	1.39e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.02	13.4	0.74	2.87e-27	Chronic sinus infection;
UCEC	cis	rs9470794	1.000	rs73419996	chr6:38067381	T/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.8	0.37	3.94e-6	Type 2 diabetes;
UCEC	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.7	6.62	0.48	6.38e-10	Crohn's disease;
UCEC	cis	rs892864	0.803	rs75834886	chr5:127845278	A/T	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Multiple system atrophy;
UCEC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.04	10.63	0.66	6.06e-20	Cognitive ability;
UCEC	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.47	-4.96	-0.38	1.96e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg05991184	chr2:219186017	PNKD	0.52	5.63	0.42	8.66e-8	Colorectal cancer;
UCEC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.84	8.36	0.57	4.44e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs77861329	0.748	rs2334961	chr3:52173625	G/C	cg08692210	chr3:52188851	WDR51A	0.63	5.81	0.43	3.78e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg15837086	chr1:46506065	PIK3R3	-0.39	-4.93	-0.38	2.23e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.66	0.36	7.09e-6	Alzheimer's disease;
UCEC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-6.18	-0.45	5.92e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.57	4.54	0.35	1.19e-5	Platelet distribution width;
UCEC	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.92	-9.72	-0.63	1.46e-17	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.59	-0.48	7.46e-10	Mood instability;
UCEC	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.02	16.44	0.8	4.17e-35	Colorectal cancer;
UCEC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.66	6.49	0.47	1.26e-9	Breast cancer;
UCEC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.48	5.63	0.42	9.01e-8	Aortic root size;
UCEC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.84	0.43	3.28e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs939574	1.000	rs939574	chr2:220118531	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.67	-5.47	-0.41	1.9e-7	Platelet distribution width;
UCEC	cis	rs6717918	0.517	rs2853362	chr2:233122412	A/G	cg02061626	chr2:233274167	ALPPL2	0.49	5.01	0.38	1.54e-6	Height;
UCEC	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg20026190	chr17:76395443	PGS1	0.37	4.56	0.35	1.06e-5	HDL cholesterol levels;
UCEC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.59	0.35	9.29e-6	Menopause (age at onset);
UCEC	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg17085576	chr10:5658249	NA	-0.57	-5.92	-0.44	2.14e-8	Breast cancer;
UCEC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.61	-4.51	-0.35	1.32e-5	Iron status biomarkers;
UCEC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.49	4.99	0.38	1.67e-6	Blood metabolite levels;
UCEC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.55	-5.28	-0.4	4.52e-7	Cognitive test performance;
UCEC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.55	6.97	0.5	9.99e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8105895	0.935	rs62110988	chr19:22259956	C/T	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.07e-7	Body mass index (change over time);
UCEC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22117172	chr7:91764530	CYP51A1	-0.42	-5.2	-0.39	6.46e-7	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.9	11.04	0.67	5.06e-21	Prudent dietary pattern;
UCEC	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.74	5.03	0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.58	-0.48	7.62e-10	Pubertal anthropometrics;
UCEC	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	5.85	0.43	3.14e-8	Colorectal cancer;
UCEC	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.54	0.58	1.52e-14	Exhaled nitric oxide output;
UCEC	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg08890418	chr1:21044141	KIF17	-0.45	-4.52	-0.35	1.28e-5	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.46	4.65	0.36	7.26e-6	Obesity-related traits;
UCEC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.68	-6.07	-0.45	1.05e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.49	6.51	0.47	1.12e-9	Height;
UCEC	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg24069376	chr3:38537580	EXOG	0.47	5.89	0.44	2.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg24910161	chr17:38119198	GSDMA	0.31	4.53	0.35	1.2e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg17469321	chr7:55412551	NA	-0.68	-6.29	-0.46	3.38e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs8105895	0.935	rs62110986	chr19:22256771	G/A	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.07e-7	Body mass index (change over time);
UCEC	cis	rs7175404	0.591	rs17708628	chr15:94060378	T/C	cg25253948	chr15:93956996	NA	0.67	4.89	0.37	2.63e-6	Attention deficit hyperactivity disorder;
UCEC	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	15.35	0.78	2.5e-32	Colorectal cancer;
UCEC	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.61	-5.67	-0.42	7.27e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.66	5.38	0.41	2.94e-7	Metabolite levels;
UCEC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.57	6.2	0.46	5.34e-9	Neuroticism;
UCEC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.53	-4.78	-0.37	4.18e-6	Schizophrenia;
UCEC	trans	rs1459104	1.000	rs66510003	chr11:55160196	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.88	-6.41	-0.47	1.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg26818010	chr10:134567672	INPP5A	-0.6	-6.23	-0.46	4.73e-9	Migraine;
UCEC	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg00105475	chr2:10696890	NA	-0.37	-4.68	-0.36	6.54e-6	Prostate cancer;
UCEC	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.77	-5.44	-0.41	2.17e-7	Alzheimer's disease;
UCEC	cis	rs3015497	0.616	rs10131107	chr14:51062455	G/A	cg04730355	chr14:51134070	SAV1	-0.46	-4.81	-0.37	3.78e-6	Mean platelet volume;
UCEC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.43	5.21	0.4	6.15e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.51	-4.7	-0.36	5.81e-6	Sum neutrophil eosinophil counts;
UCEC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.61	5.62	0.42	9.29e-8	Aortic root size;
UCEC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.48	-5.06	-0.39	1.22e-6	Aortic root size;
UCEC	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.59	-5.6	-0.42	1.04e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.57	6.67	0.48	4.81e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.6	5.03	0.38	1.39e-6	Multiple sclerosis;
UCEC	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.54	5.3	0.4	4.24e-7	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg02160872	chr5:212506	CCDC127	-0.69	-7.12	-0.51	4.46e-11	Breast cancer;
UCEC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg11945507	chr8:142233382	SLC45A4	0.4	4.7	0.36	5.94e-6	Immature fraction of reticulocytes;
UCEC	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg17515076	chr17:73810948	UNK	-0.5	-5.61	-0.42	9.54e-8	White matter hyperintensity burden;
UCEC	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-4.68	-0.36	6.46e-6	LDL cholesterol levels;
UCEC	cis	rs79815064	0.850	rs78729754	chr3:46339185	C/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.79	4.6	0.35	9.06e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	8.08	0.55	2.19e-13	Tonsillectomy;
UCEC	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.58	6.18	0.45	6.02e-9	Mean platelet volume;
UCEC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.1	-0.39	1.04e-6	Colorectal cancer;
UCEC	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	5.95	0.44	1.92e-8	High light scatter reticulocyte count;
UCEC	cis	rs7611694	0.807	rs7630708	chr3:113274519	G/C	cg11138929	chr3:113251189	SIDT1	0.44	4.75	0.36	4.87e-6	Prostate cancer;
UCEC	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.57	4.77	0.37	4.31e-6	Lung cancer;
UCEC	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg00601450	chr5:74908170	NA	0.6	4.61	0.36	8.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg18681998	chr4:17616180	MED28	0.76	8.73	0.58	5.08e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10789491	1.000	rs4097354	chr1:47187073	T/G	cg15501359	chr1:47185051	KIAA0494	0.83	6.58	0.48	7.81e-10	Response to hepatitis C treatment;
UCEC	cis	rs9469578	0.892	rs73743334	chr6:33714094	G/C	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.42	-4.62	-0.36	8.43e-6	Response to antineoplastic agents;
UCEC	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.42	-4.59	-0.35	9.59e-6	Monocyte percentage of white cells;
UCEC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.17	0.39	7.68e-7	Body mass index;
UCEC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.38	-5.37	-0.41	2.95e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7474896	0.832	rs2799509	chr10:38234808	T/C	cg00409905	chr10:38381863	ZNF37A	0.6	4.6	0.35	9.01e-6	Obesity (extreme);
UCEC	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.53	-4.94	-0.38	2.11e-6	Corneal astigmatism;
UCEC	cis	rs17106184	1.000	rs1573012	chr1:51369991	T/C	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.47	0.62	6.69e-17	Alzheimer's disease;
UCEC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.18	0.45	6.02e-9	Breast cancer;
UCEC	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs12618769	0.625	rs3769736	chr2:99089119	C/T	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.67	-6.28	-0.46	3.55e-9	White blood cell count;
UCEC	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.57	5.02	0.38	1.45e-6	Coronary artery disease;
UCEC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg01380346	chr19:18557039	ELL	-0.44	-4.59	-0.35	9.31e-6	Breast cancer;
UCEC	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-1.0	-5.88	-0.44	2.62e-8	Mitochondrial DNA levels;
UCEC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg21770322	chr7:97807741	LMTK2	0.52	6.23	0.46	4.59e-9	Breast cancer;
UCEC	cis	rs4588572	0.643	rs1560195	chr5:77701913	A/G	cg11547950	chr5:77652471	NA	0.44	4.78	0.37	4.19e-6	Triglycerides;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.44	-0.41	2.2e-7	Platelet count;
UCEC	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg05962950	chr11:130786565	SNX19	0.62	6.64	0.48	5.73e-10	Schizophrenia;
UCEC	cis	rs9463078	0.715	rs9395049	chr6:44792718	C/T	cg25276700	chr6:44698697	NA	0.5	5.73	0.43	5.48e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.09	18.31	0.83	9.4e-40	Testicular germ cell tumor;
UCEC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.93	-8.71	-0.58	5.7e-15	Initial pursuit acceleration;
UCEC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.44	-4.63	-0.36	8.09e-6	Blood metabolite levels;
UCEC	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.62	-6.39	-0.47	2.1e-9	Platelet distribution width;
UCEC	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs13401104	0.796	rs11677552	chr2:237110230	T/C	cg23897927	chr2:237117786	ASB18	-0.52	-4.59	-0.35	9.51e-6	Educational attainment;
UCEC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.54	-6.1	-0.45	9.15e-9	Bipolar disorder;
UCEC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg21770322	chr7:97807741	LMTK2	0.52	6.54	0.47	9.69e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.73	7.7	0.54	1.88e-12	Breast cancer;
UCEC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg02413938	chr2:239008929	ESPNL	-0.36	-4.63	-0.36	8.06e-6	Prostate cancer;
UCEC	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-10.73	-0.66	3.36e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg14424070	chr14:75988820	BATF	-0.46	-4.69	-0.36	6.09e-6	IgG glycosylation;
UCEC	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg11161011	chr14:65562177	MAX	-0.75	-8.71	-0.58	5.88e-15	Obesity-related traits;
UCEC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.7	8.85	0.59	2.49e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.58	5.27	0.4	4.77e-7	Crohn's disease;
UCEC	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.54	-0.47	9.73e-10	Mood instability;
UCEC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.73	0.36	5.3e-6	Multiple sclerosis;
UCEC	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.55	5.06	0.39	1.21e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.07	0.6	7.03e-16	Platelet count;
UCEC	trans	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg02900749	chr2:68251473	NA	-1.01	-7.55	-0.53	4.16e-12	Pursuit maintenance gain;
UCEC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.79	7.0	0.5	8.33e-11	Longevity;
UCEC	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.78	6.9	0.49	1.42e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.55	-5.61	-0.42	9.6e-8	Hepatocellular carcinoma;
UCEC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	8.66	0.58	7.84e-15	Metabolite levels;
UCEC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.83	9.04	0.6	8.55e-16	Longevity;
UCEC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.65	-0.42	7.91e-8	Pancreatic cancer;
UCEC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.65	6.85	0.49	1.83e-10	Menopause (age at onset);
UCEC	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-5.72	-0.43	5.76e-8	Superior crus of antihelix expression;
UCEC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs6754311	0.589	rs2011724	chr2:136818006	A/G	cg07169764	chr2:136633963	MCM6	-0.68	-6.25	-0.46	4.18e-9	Mosquito bite size;
UCEC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	0.95	9.68	0.62	1.91e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg19554555	chr3:13937349	NA	-0.6	-5.99	-0.44	1.56e-8	Ovarian reserve;
UCEC	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.98	11.46	0.69	4e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.61	6.59	0.48	7.52e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3015497	0.616	rs6572678	chr14:51090115	T/G	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.37e-6	Mean platelet volume;
UCEC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.53	5.27	0.4	4.69e-7	Dupuytren's disease;
UCEC	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg22168087	chr7:27702803	HIBADH	-0.61	-6.01	-0.44	1.37e-8	Hypospadias;
UCEC	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.8	5.17	0.39	7.51e-7	Cognitive function;
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.49	-6.7	-0.48	4.05e-10	Body mass index;
UCEC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.44	0.65	1.97e-19	Chronic sinus infection;
UCEC	cis	rs9309473	0.948	rs7566385	chr2:73756817	G/T	cg20560298	chr2:73613845	ALMS1	-0.61	-5.46	-0.41	1.97e-7	Metabolite levels;
UCEC	cis	rs6493487	0.512	rs71471587	chr15:51281623	G/T	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg04756594	chr16:24857601	SLC5A11	0.44	5.3	0.4	4.13e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.74e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg13989528	chr11:64888932	FAU;MRPL49	0.41	4.68	0.36	6.37e-6	Urate levels in obese individuals;
UCEC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.5	0.47	1.2e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.09	-7.01	-0.5	8.04e-11	Schizophrenia;
UCEC	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg02158880	chr13:53174818	NA	0.57	6.67	0.48	4.84e-10	Lewy body disease;
UCEC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.48	-0.47	1.27e-9	Pubertal anthropometrics;
UCEC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg13695892	chr22:41940480	POLR3H	-0.64	-5.54	-0.42	1.36e-7	Vitiligo;
UCEC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	3.98e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.47	5.1	0.39	1.04e-6	Coronary artery disease;
UCEC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.79	7.61	0.53	3.02e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg23978390	chr7:1156363	C7orf50	0.46	4.65	0.36	7.43e-6	Longevity;Endometriosis;
UCEC	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.43	4.59	0.35	9.57e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.59	-5.27	-0.4	4.82e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.01	-6.55	-0.48	8.96e-10	Diabetic kidney disease;
UCEC	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.33	-4.65	-0.36	7.25e-6	IgG glycosylation;
UCEC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.42	0.41	2.36e-7	Birth weight;
UCEC	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14019695	chr9:139328340	INPP5E	0.5	6.29	0.46	3.38e-9	Monocyte percentage of white cells;
UCEC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.57	6.14	0.45	7.45e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg26721908	chr21:47610096	LSS	-0.37	-4.64	-0.36	7.6e-6	Testicular germ cell tumor;
UCEC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.53	6.25	0.46	4.15e-9	Type 2 diabetes;
UCEC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg18279126	chr7:2041391	MAD1L1	0.46	5.8	0.43	3.99e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-4.83	-0.37	3.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.49	4.84	0.37	3.24e-6	Coronary artery disease;
UCEC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	6.8	0.49	2.51e-10	Type 2 diabetes;
UCEC	cis	rs17122693	0.748	rs72679598	chr14:51107157	C/G	cg04730355	chr14:51134070	SAV1	0.98	10.27	0.65	5.57e-19	Cognitive performance;
UCEC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-5.27	-0.4	4.69e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.17	-0.39	7.36e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3770752	0.654	rs3770754	chr2:37575381	C/G	cg20091297	chr2:37572423	QPCT	-0.61	-6.05	-0.45	1.12e-8	Schizophrenia;
UCEC	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.52	0.53	4.98e-12	Ileal carcinoids;
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.69	7.52	0.53	5.12e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs6479901	0.895	rs7916224	chr10:64904603	T/C	cg12751693	chr12:62629162	NA	-0.56	-6.93	-0.5	1.22e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.12	0.45	8.22e-9	Aortic root size;
UCEC	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.84	5.22	0.4	5.89e-7	Diisocyanate-induced asthma;
UCEC	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg21466736	chr12:48725269	NA	0.34	4.52	0.35	1.29e-5	Plateletcrit;
UCEC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.39	5.85	0.43	3.06e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03762994	chr17:6899332	ALOX12	0.44	5.17	0.39	7.43e-7	Tonsillectomy;
UCEC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	0.72	7.45	0.52	7.48e-12	Breast cancer;
UCEC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg21770322	chr7:97807741	LMTK2	0.7	9.89	0.63	5.35e-18	Breast cancer;
UCEC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg04374321	chr14:90722782	PSMC1	0.52	4.61	0.36	8.81e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs4919044	1.000	rs17108042	chr10:94770488	A/C	cg00519463	chr10:94352821	KIF11	0.99	4.89	0.37	2.57e-6	Coronary artery disease;
UCEC	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg05072774	chr3:49840536	C3orf54	-0.54	-4.76	-0.37	4.68e-6	Resting heart rate;
UCEC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg13683864	chr3:40499215	RPL14	-0.67	-6.8	-0.49	2.45e-10	Renal cell carcinoma;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-6.48	-0.47	1.28e-9	Longevity;Endometriosis;
UCEC	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.68	5.92	0.44	2.18e-8	Bipolar disorder;
UCEC	cis	rs2213920	0.680	rs7863450	chr9:118242611	G/C	cg13918206	chr9:118159781	DEC1	0.75	5.2	0.39	6.56e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.68	0.42	6.97e-8	Coffee consumption (cups per day);
UCEC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-0.93	-9.64	-0.62	2.39e-17	Heart rate;
UCEC	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-5.2	-0.39	6.54e-7	Breast cancer;
UCEC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.77	7.62	0.53	2.86e-12	Eotaxin levels;
UCEC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	4.63	0.36	8.11e-6	Coronary artery disease;
UCEC	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg16583315	chr14:65563665	MAX	-0.49	-5.3	-0.4	4.15e-7	Obesity-related traits;
UCEC	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.1	9.58	0.62	3.45e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs539514	0.516	rs9318377	chr13:76410018	G/A	cg04757411	chr13:76259545	LMO7	0.44	4.97	0.38	1.87e-6	Type 1 diabetes;
UCEC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	3.97e-6	Alzheimer's disease;
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.33	0.71	1.97e-24	Prudent dietary pattern;
UCEC	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg19156104	chr2:198669113	PLCL1	-0.63	-4.53	-0.35	1.23e-5	Ulcerative colitis;
UCEC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	0.68	4.54	0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs78707713	0.841	rs12242391	chr10:71201504	C/T	cg12610070	chr10:71211762	TSPAN15	-0.44	-4.82	-0.37	3.59e-6	Venous thromboembolism;
UCEC	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg05855489	chr10:104503620	C10orf26	0.51	4.8	0.37	3.88e-6	Colorectal cancer;
UCEC	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22857025	chr5:266934	NA	-0.76	-5.79	-0.43	4.06e-8	Asthma (childhood onset);
UCEC	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.59	7.22	0.51	2.61e-11	Testicular germ cell tumor;
UCEC	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.34	-0.9	1.95e-53	Myeloid white cell count;
UCEC	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	19.7	0.85	4.41e-43	Schizophrenia;
UCEC	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	0.65	4.68	0.36	6.54e-6	Dental caries;
UCEC	cis	rs4233802	0.737	rs78826803	chr2:151186098	C/T	cg25300694	chr2:151184358	NA	-0.69	-4.74	-0.36	5.02e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
UCEC	cis	rs716595	0.786	rs10509912	chr10:112029405	T/A	cg19584136	chr10:111975951	MXI1	-0.71	-4.59	-0.35	9.3e-6	Normalized brain volume;
UCEC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	4.95	0.38	2.02e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg13777783	chr17:79615861	NA	-0.33	-4.77	-0.37	4.49e-6	Eye color traits;
UCEC	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.88	0.37	2.71e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.75	8.25	0.56	8.34e-14	Menopause (age at onset);
UCEC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.09	-0.39	1.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.57	4.59	0.35	9.35e-6	Longevity;
UCEC	cis	rs6890610	0.609	rs286624	chr5:154361613	A/C	cg02687067	chr5:153784852	GALNT10	0.5	4.51	0.35	1.34e-5	Breast cancer;
UCEC	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.43	4.73	0.36	5.22e-6	Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg03714773	chr7:91764589	CYP51A1	0.46	5.48	0.41	1.77e-7	Breast cancer;
UCEC	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.72	-7.31	-0.52	1.62e-11	Plateletcrit;Platelet count;
UCEC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.19	0.45	5.62e-9	Platelet count;
UCEC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.57	-5.69	-0.42	6.71e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-5.24	-0.4	5.4e-7	Colorectal cancer;
UCEC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs9992667	0.725	rs1466414	chr4:38664324	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.55	-4.99	-0.38	1.68e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.77	0.59	4.01e-15	Platelet count;
UCEC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.13	0.39	8.89e-7	Heart rate;
UCEC	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.59	6.77	0.49	2.92e-10	Skin colour saturation;
UCEC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.69	-8.19	-0.56	1.15e-13	Blood trace element (Zn levels);
UCEC	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	7.06	0.5	6.28e-11	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Bladder cancer;
UCEC	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.0	8.15	0.56	1.46e-13	Exhaled nitric oxide output;
UCEC	cis	rs4851266	0.966	rs13026283	chr2:100842638	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.35	0.46	2.53e-9	Educational attainment;
UCEC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.38	-0.47	2.19e-9	Aortic root size;
UCEC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg11871910	chr12:69753446	YEATS4	0.89	10.31	0.65	4.27e-19	Blood protein levels;
UCEC	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	5.0	0.38	1.63e-6	Rheumatoid arthritis;
UCEC	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.72	-7.69	-0.54	1.95e-12	Waist circumference;Body mass index;
UCEC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.43	5.78	0.43	4.26e-8	Bone mineral density;
UCEC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24308560	chr3:49941425	MST1R	0.47	5.22	0.4	5.88e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	0.864	rs11021349	chr11:95659474	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	5.67	0.42	7.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg21770322	chr7:97807741	LMTK2	0.59	7.28	0.51	1.89e-11	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4789452	1.000	rs35971812	chr17:75373362	C/A	cg21830368	chr17:75373327	SEPT9	-0.31	-4.57	-0.35	1.02e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.68	6.62	0.48	6.27e-10	Tonsillectomy;
UCEC	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.82	-8.02	-0.55	3.05e-13	Strep throat;
UCEC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.02	-0.44	1.34e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg11161011	chr14:65562177	MAX	-0.58	-5.86	-0.44	2.95e-8	Obesity-related traits;
UCEC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.58	5.29	0.4	4.33e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs6723108	0.603	rs1947112	chr2:135715957	A/G	cg07169764	chr2:136633963	MCM6	0.51	5.0	0.38	1.59e-6	Type 2 diabetes;
UCEC	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.76	-5.56	-0.42	1.22e-7	Response to hepatitis C treatment;
UCEC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg10978503	chr1:24200527	CNR2	0.36	4.75	0.37	4.71e-6	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
UCEC	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.4	-4.77	-0.37	4.47e-6	Longevity;
UCEC	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13683864	chr3:40499215	RPL14	-0.97	-10.02	-0.64	2.47e-18	Renal cell carcinoma;
UCEC	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.59	6.98	0.5	9.24e-11	Oral cavity cancer;
UCEC	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg09165964	chr15:75287851	SCAMP5	0.5	5.59	0.42	1.06e-7	Caffeine consumption;
UCEC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs600626	0.529	rs2008476	chr11:75470813	C/T	cg24262691	chr11:75473276	NA	0.38	4.62	0.36	8.32e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.02	-0.44	1.34e-8	Parkinson's disease;
UCEC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-10.15	-0.64	1.13e-18	Electrocardiographic conduction measures;
UCEC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg03354898	chr7:1950403	MAD1L1	-0.46	-5.09	-0.39	1.08e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7106204	1.000	rs7110656	chr11:24216034	G/T	ch.11.24196551F	chr11:24239977	NA	0.68	6.16	0.45	6.57e-9	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.36	4.52	0.35	1.28e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.38	-0.47	2.22e-9	Response to antipsychotic treatment;
UCEC	cis	rs4851266	0.702	rs11123820	chr2:100871186	A/G	cg14675211	chr2:100938903	LONRF2	0.64	6.43	0.47	1.71e-9	Educational attainment;
UCEC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.48	5.19	0.39	6.73e-7	Schizophrenia;
UCEC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.45	-4.89	-0.37	2.61e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.58	6.82	0.49	2.21e-10	Iron status biomarkers (transferrin levels);
UCEC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18252515	chr7:66147081	NA	-0.46	-4.61	-0.36	8.66e-6	Aortic root size;
UCEC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.98	4.53	0.35	1.19e-5	IgG glycosylation;
UCEC	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.6	-4.85	-0.37	3.09e-6	Coronary artery calcification;
UCEC	cis	rs514406	0.734	rs581118	chr1:53311324	T/C	cg22166914	chr1:53195759	ZYG11B	0.78	8.14	0.56	1.58e-13	Monocyte count;
UCEC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	7.91	0.55	5.55e-13	Smoking behavior;
UCEC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.58e-16	Height;
UCEC	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-7.54	-0.53	4.57e-12	Ileal carcinoids;
UCEC	cis	rs10924970	0.649	rs12736498	chr1:235464620	A/C	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.62	5.74	0.43	5.14e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	6.01	0.44	1.37e-8	Cognitive test performance;
UCEC	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.5	4.79	0.37	3.97e-6	Intelligence;Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.71	7.69	0.54	1.91e-12	Intelligence (multi-trait analysis);
UCEC	trans	rs1459104	1.000	rs12789360	chr11:55289751	C/T	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs4499344	0.521	rs259222	chr19:33136895	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs970548	0.690	rs10900220	chr10:45983922	A/G	cg15223267	chr10:46222474	FAM21C	0.49	4.83	0.37	3.41e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg14092571	chr14:90743983	NA	0.4	5.25	0.4	5.12e-7	Mortality in heart failure;
UCEC	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg19875535	chr5:140030758	IK	0.45	5.04	0.38	1.34e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1595825	0.838	rs79381203	chr2:198573762	A/G	cg19156104	chr2:198669113	PLCL1	-0.64	-4.64	-0.36	7.73e-6	Ulcerative colitis;
UCEC	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg19567339	chr10:100142640	NA	0.45	5.26	0.4	4.9e-7	Metabolite levels;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs883565	0.792	rs813669	chr3:39181723	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.54	-4.6	-0.35	9.02e-6	Handedness;
UCEC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.73	-6.0	-0.44	1.46e-8	Coronary artery calcification;
UCEC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.49	5.21	0.39	6.27e-7	Longevity;Endometriosis;
UCEC	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.54	5.79	0.43	4.17e-8	Red blood cell count;
UCEC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05472934	chr7:22766657	IL6	0.75	7.45	0.52	7.53e-12	Lung cancer;
UCEC	cis	rs6032067	0.516	rs1883829	chr20:43891253	G/C	cg00873616	chr20:43920241	NA	0.42	4.6	0.35	9.1e-6	Blood protein levels;
UCEC	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.58	6.73	0.49	3.62e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.92	9.0	0.6	1.04e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.77	0.37	4.31e-6	Rheumatoid arthritis;
UCEC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg26011156	chr1:156183096	PMF1	0.43	4.56	0.35	1.07e-5	Tonsillectomy;
UCEC	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.76	8.42	0.57	3.09e-14	Blood protein levels;
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.47	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.38	-4.82	-0.37	3.48e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.44	6.03	0.45	1.27e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.5	4.68	0.36	6.49e-6	Corneal astigmatism;
UCEC	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4919044	0.799	rs56024810	chr10:94753313	G/A	cg00519463	chr10:94352821	KIF11	0.89	4.76	0.37	4.66e-6	Coronary artery disease;
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg09120320	chr17:61926383	NA	0.44	4.57	0.35	1.03e-5	Prudent dietary pattern;
UCEC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.82	-8.9	-0.59	1.87e-15	Cognitive function;
UCEC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.6	6.78	0.49	2.71e-10	Height;
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.0	0.6	1.06e-15	Platelet count;
UCEC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-6.32	-0.46	3e-9	Menarche (age at onset);
UCEC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.6	5.81	0.43	3.7e-8	Blood protein levels;
UCEC	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.46	-4.56	-0.35	1.06e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs7582720	1.000	rs6705330	chr2:203662197	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.7	0.36	5.88e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs17106184	1.000	rs72904713	chr1:51312992	A/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs2708377	0.929	rs73053768	chr12:11155747	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.78	6.4	0.47	1.94e-9	Bitter taste perception;
UCEC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01380346	chr19:18557039	ELL	-0.5	-5.21	-0.39	6.21e-7	Breast cancer;
UCEC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.78	7.17	0.51	3.39e-11	White matter hyperintensity burden;
UCEC	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.18	-0.45	6.09e-9	Response to antipsychotic treatment;
UCEC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg03354898	chr7:1950403	MAD1L1	-0.57	-5.57	-0.42	1.17e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg12850546	chr22:42539477	CYP2D7P1	-1.21	-8.27	-0.56	7.48e-14	Birth weight;
UCEC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	12.76	0.72	1.46e-25	Prudent dietary pattern;
UCEC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.54	5.79	0.43	4.07e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs692916	0.704	rs2440196	chr18:60604575	A/G	cg07187971	chr18:60481018	PHLPP1	0.38	4.64	0.36	7.52e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg12334488	chr2:20871173	GDF7	-0.38	-4.5	-0.35	1.35e-5	Abdominal aortic aneurysm;
UCEC	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.55	-5.74	-0.43	5.11e-8	Autism;
UCEC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.86	9.36	0.61	1.24e-16	Breast cancer;
UCEC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.84	-7.95	-0.55	4.45e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg14196790	chr5:131705035	SLC22A5	-0.42	-4.58	-0.35	9.83e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	7.88	0.54	6.71e-13	Smoking behavior;
UCEC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg00983440	chr10:79422392	NA	-1.09	-8.44	-0.57	2.8e-14	Bone mineral density;
UCEC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.23	-0.4	5.71e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.4	4.6	0.35	8.93e-6	Height;
UCEC	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	7.99	0.55	3.61e-13	Response to antipsychotic treatment;
UCEC	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg01851573	chr8:8652454	MFHAS1	0.38	4.64	0.36	7.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs11760485	0.782	rs4236349	chr7:4407208	T/C	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.51	-4.93	-0.38	2.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4499344	0.730	rs7247597	chr19:33102257	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.52	-0.35	1.25e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.11	9.2	0.6	3.3e-16	Vitiligo;
UCEC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-0.72	-6.92	-0.5	1.28e-10	Breast cancer;
UCEC	cis	rs7597155	0.805	rs9711602	chr2:69976176	A/G	cg02498382	chr2:70120550	SNRNP27	-0.57	-6.12	-0.45	8.21e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.73	8.67	0.58	7.15e-15	Prudent dietary pattern;
UCEC	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	7.68	0.54	2.1e-12	Colorectal cancer;
UCEC	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	9.2	0.6	3.36e-16	Coffee consumption (cups per day);
UCEC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.55	5.47	0.41	1.93e-7	Menopause (age at onset);
UCEC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.95	-10.08	-0.64	1.71e-18	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.94	0.5	1.14e-10	Coronary artery disease;
UCEC	cis	rs12367572	0.620	rs2731040	chr12:45416383	G/A	cg03114573	chr12:45410052	DBX2	-0.55	-6.22	-0.46	4.88e-9	Gut microbiome composition (summer);
UCEC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg23950597	chr19:37808831	NA	-0.6	-4.69	-0.36	6.17e-6	Coronary artery calcification;
UCEC	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	0.87	7.01	0.5	7.92e-11	Blood protein levels;
UCEC	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg20129853	chr10:51489980	NA	-0.45	-5.6	-0.42	1.02e-7	Prostate-specific antigen levels;
UCEC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.96	13.75	0.75	3.58e-28	Bone mineral density;
UCEC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.65	6.24	0.46	4.32e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.47	-0.47	1.38e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.65	0.36	7.27e-6	Personality dimensions;
UCEC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18357526	chr6:26021779	HIST1H4A	0.55	4.59	0.35	9.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg11150807	chr10:43354902	NA	0.82	5.45	0.41	2.08e-7	Blood protein levels;
UCEC	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.81	6.6	0.48	6.82e-10	Lymphocyte counts;
UCEC	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.32	4.98	0.38	1.74e-6	Cancer;
UCEC	cis	rs35934224	0.783	rs7288170	chr22:19864252	C/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.88	-0.37	2.68e-6	Glaucoma (primary open-angle);
UCEC	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.31	-0.52	1.61e-11	Obesity-related traits;
UCEC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.87	8.16	0.56	1.35e-13	Cisplatin-induced ototoxicity;
UCEC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.32	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	0.91	8.48	0.57	2.22e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg22974920	chr21:40686053	BRWD1	0.58	4.74	0.36	5.02e-6	Cognitive function;
UCEC	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg04682699	chr3:50248845	SLC38A3	0.4	4.75	0.36	4.77e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs8177876	0.822	rs1563077	chr16:81107556	T/A	cg08591886	chr16:81111003	C16orf46	-0.75	-4.53	-0.35	1.23e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.82	-0.37	3.55e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.59	5.35	0.4	3.37e-7	Corneal astigmatism;
UCEC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.37	-0.46	2.32e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.56	-7.16	-0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.05	-5.67	-0.42	7.42e-8	Diabetic retinopathy;
UCEC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg18032046	chr6:28092343	ZSCAN16	0.6	5.01	0.38	1.53e-6	Depression;
UCEC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.79	6.8	0.49	2.4e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg03609598	chr5:56110824	MAP3K1	0.61	5.19	0.39	6.79e-7	Coronary artery disease;
UCEC	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg06671706	chr8:8559999	CLDN23	0.54	4.72	0.36	5.44e-6	Obesity-related traits;
UCEC	cis	rs2970992	0.741	rs10176355	chr2:101335078	G/A	cg01042948	chr2:101319752	NA	0.57	6.04	0.45	1.2e-8	Educational attainment;
UCEC	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.5	5.64	0.42	8.61e-8	Response to temozolomide;
UCEC	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.47	4.79	0.37	4.04e-6	Type 2 diabetes;
UCEC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.4	3.06e-7	Breast cancer;
UCEC	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.79	7.95	0.55	4.53e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.77	-7.51	-0.53	5.27e-12	Lung cancer;
UCEC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg02733842	chr7:1102375	C7orf50	-0.58	-5.03	-0.38	1.43e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg10932868	chr11:921992	NA	0.44	5.84	0.43	3.3e-8	Alzheimer's disease (late onset);
UCEC	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.59	-4.94	-0.38	2.09e-6	Corneal structure;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.64	-0.48	5.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg20307385	chr11:47447363	PSMC3	0.54	5.03	0.38	1.39e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	1.09	9.47	0.62	6.68e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg15848620	chr12:58087721	OS9	-0.5	-4.52	-0.35	1.25e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg12870014	chr12:110450643	ANKRD13A	0.62	5.03	0.38	1.44e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg23791538	chr6:167370224	RNASET2	-0.51	-4.98	-0.38	1.72e-6	Crohn's disease;
UCEC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	7.09	0.5	5.26e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs139371	0.713	rs139317	chr22:39499902	C/T	cg15548613	chr22:38610795	MAFF	0.45	4.62	0.36	8.39e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.38	5.44	0.41	2.14e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.65	-7.08	-0.5	5.47e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.9	9.45	0.61	7.57e-17	Cognitive function;
UCEC	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.23	-19.12	-0.84	1.07e-41	Exhaled nitric oxide output;
UCEC	cis	rs250585	0.736	rs40817	chr16:23422672	C/G	cg26562691	chr16:23850404	PRKCB	0.36	4.65	0.36	7.37e-6	Egg allergy;
UCEC	cis	rs9393813	0.529	rs7761966	chr6:27445703	C/T	cg27490387	chr6:26520793	HCG11	-0.4	-4.57	-0.35	1.03e-5	Bipolar disorder;
UCEC	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.48	-5.01	-0.38	1.52e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.73e-7	Headache;
UCEC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.66	6.21	0.46	5.08e-9	Corneal astigmatism;
UCEC	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg01072550	chr1:21505969	NA	-0.51	-5.02	-0.38	1.47e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.78	0.59	3.86e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.6	-0.48	6.97e-10	Total body bone mineral density;
UCEC	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.34	4.9	0.37	2.47e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	8.33	0.57	5.31e-14	Hip circumference;
UCEC	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.8	-0.37	3.9e-6	Height;
UCEC	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.5	4.68	0.36	6.49e-6	Corneal astigmatism;
UCEC	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.54	6.04	0.45	1.2e-8	Hip circumference;
UCEC	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.32	4.98	0.38	1.74e-6	Cancer;
UCEC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.67	-0.36	6.8e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.69	7.45	0.52	7.32e-12	Diastolic blood pressure;
UCEC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg04871131	chr7:94954202	PON1	-0.54	-5.12	-0.39	9.48e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.27	-0.4	4.68e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.76	-6.67	-0.48	4.94e-10	Initial pursuit acceleration;
UCEC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.76	8.41	0.57	3.33e-14	Blood metabolite levels;
UCEC	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.61	-7.0	-0.5	8.68e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.58	-5.74	-0.43	5.29e-8	Prudent dietary pattern;
UCEC	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg20045696	chr14:77926864	AHSA1	0.65	4.98	0.38	1.77e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg26114124	chr12:9217669	LOC144571	0.42	5.15	0.39	8.31e-7	Sjögren's syndrome;
UCEC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg14067834	chr17:29058358	SUZ12P	0.58	4.53	0.35	1.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.51	-4.62	-0.36	8.45e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	8.17	0.56	1.28e-13	Blood protein levels;
UCEC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg01262667	chr19:19385393	TM6SF2	0.49	6.74	0.49	3.3e-10	Tonsillectomy;
UCEC	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.56	-4.88	-0.37	2.73e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-9.16	-0.6	4.2e-16	Prudent dietary pattern;
UCEC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.49	-5.32	-0.4	3.72e-7	Diastolic blood pressure;
UCEC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.73	7.39	0.52	1.02e-11	Breast cancer;
UCEC	cis	rs7088591	0.717	rs78574804	chr10:59778308	A/T	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg03786743	chr4:53727781	RASL11B	0.67	4.74	0.36	5.1e-6	Optic nerve measurement (cup area);
UCEC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg06466757	chr4:1255808	NA	0.46	4.79	0.37	3.97e-6	Obesity-related traits;
UCEC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.6	-6.65	-0.48	5.28e-10	Menarche (age at onset);
UCEC	cis	rs2209875	0.640	rs10867154	chr9:91757712	G/A	cg00102996	chr9:92220617	GADD45G	-0.5	-4.56	-0.35	1.06e-5	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	0.69	8.88	0.59	2.13e-15	Gut microbiome composition (winter);
UCEC	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24249390	chr15:90295951	MESP1	-0.41	-4.69	-0.36	6.3e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.44	-4.64	-0.36	7.57e-6	Dilated cardiomyopathy;
UCEC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg14092571	chr14:90743983	NA	-0.36	-4.53	-0.35	1.23e-5	Mortality in heart failure;
UCEC	cis	rs7246967	0.611	rs16999571	chr19:22904764	C/A	cg05241461	chr19:22816980	ZNF492	0.56	5.87	0.44	2.74e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs1318772	0.877	rs34437714	chr5:112703375	G/C	cg12552261	chr5:112820674	MCC	0.57	4.96	0.38	1.92e-6	F-cell distribution;
UCEC	cis	rs7937612	1.000	rs4938804	chr11:120273865	G/A	cg12584626	chr11:120203529	NA	0.53	5.36	0.4	3.13e-7	Intraocular pressure;
UCEC	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	1.12	14.32	0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg07424592	chr7:64974309	NA	0.76	4.72	0.36	5.46e-6	Diabetic kidney disease;
UCEC	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.67	6.11	0.45	8.44e-9	Menopause (age at onset);
UCEC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06462663	chr19:18546047	ISYNA1	0.47	5.96	0.44	1.82e-8	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	5.82	0.43	3.49e-8	Platelet count;
UCEC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.87	10.97	0.67	7.83e-21	Metabolic syndrome;
UCEC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-8.92	-0.59	1.69e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.75	0.75	3.48e-28	Height;
UCEC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.88	10.15	0.64	1.15e-18	Neuroticism;
UCEC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.5	5.1	0.39	1.05e-6	Height;
UCEC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-0.97	-8.25	-0.56	8.1e-14	White matter hyperintensity burden;
UCEC	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.66	5.0	0.38	1.58e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.51	-4.64	-0.36	7.56e-6	Cognitive function;
UCEC	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	5.98	0.44	1.59e-8	Response to bleomycin (chromatid breaks);
UCEC	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.36	0.52	1.23e-11	Ileal carcinoids;
UCEC	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg05660106	chr1:15850417	CASP9	0.99	11.32	0.68	9.48e-22	Systolic blood pressure;
UCEC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.49	-5.9	-0.44	2.4e-8	Bipolar disorder;
UCEC	cis	rs7072216	0.770	rs942810	chr10:100167860	G/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-5.18	-0.39	7.15e-7	Metabolite levels;
UCEC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.54	4.69	0.36	6.09e-6	Menarche (age at onset);
UCEC	cis	rs9828933	0.516	rs704371	chr3:63867528	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.61	5.17	0.39	7.45e-7	Type 2 diabetes;
UCEC	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.6	-5.24	-0.4	5.56e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg01256987	chr12:42539512	GXYLT1	0.41	4.85	0.37	3.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.5	4.61	0.36	8.63e-6	Calcium levels;
UCEC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.72	-7.0	-0.5	8.32e-11	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.71	0.43	6.05e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11048434	1.000	rs12824212	chr12:9153417	A/G	cg20380214	chr12:9217688	LOC144571	0.39	4.84	0.37	3.19e-6	Sjögren's syndrome;
UCEC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.68	-6.92	-0.5	1.27e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs3733606	1.000	rs3733606	chr4:6883012	A/G	cg22288316	chr4:6007279	NA	-0.5	-4.54	-0.35	1.16e-5	Platelet count;
UCEC	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.72	6.67	0.48	4.79e-10	Height;
UCEC	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.78	7.81	0.54	9.94e-13	Ulcerative colitis;
UCEC	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.58	-6.84	-0.49	2.02e-10	Prevalent atrial fibrillation;
UCEC	cis	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg03264133	chr6:25882463	NA	-0.57	-4.5	-0.35	1.36e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-0.96	-7.95	-0.55	4.52e-13	White matter hyperintensity burden;
UCEC	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	0.72	5.45	0.41	2.1e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.79	-8.14	-0.56	1.52e-13	Mosquito bite size;
UCEC	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.34	-4.52	-0.35	1.26e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg06096015	chr1:231504339	EGLN1	0.46	5.32	0.4	3.87e-7	Hemoglobin concentration;
UCEC	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg22715954	chr12:58146426	CDK4	0.62	7.11	0.51	4.7e-11	Warfarin maintenance dose;
UCEC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.45	-0.52	7.34e-12	Body mass index;
UCEC	cis	rs892864	0.803	rs968008	chr5:127825485	C/T	cg17313118	chr5:127157258	NA	0.72	4.71	0.36	5.59e-6	Multiple system atrophy;
UCEC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.43	4.97	0.38	1.84e-6	Blood protein levels;
UCEC	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.47	-4.54	-0.35	1.15e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg20119798	chr7:94954144	PON1	0.5	4.72	0.36	5.35e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.57	6.15	0.45	6.8e-9	Red blood cell count;
UCEC	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03934478	chr11:495069	RNH1	0.71	5.08	0.39	1.12e-6	Body mass index;
UCEC	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg03959625	chr15:84868606	LOC388152	0.5	5.23	0.4	5.73e-7	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg22166914	chr1:53195759	ZYG11B	0.77	7.99	0.55	3.66e-13	Monocyte count;
UCEC	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.62	-6.83	-0.49	2.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg02308795	chr5:130599504	CDC42SE2	-0.46	-4.67	-0.36	6.75e-6	Blood metabolite levels;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.7	-0.36	6.04e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.5	5.42	0.41	2.42e-7	Aortic root size;
UCEC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-8.83	-0.59	2.88e-15	Dental caries;
UCEC	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	7.93e-6	Heart rate;
UCEC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.82	0.37	3.5e-6	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.99	-6.23	-0.46	4.71e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.55	-6.37	-0.47	2.23e-9	Type 2 diabetes;
UCEC	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.58	6.2	0.46	5.54e-9	Glomerular filtration rate;
UCEC	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.83	-10.33	-0.65	3.76e-19	White blood cell count (basophil);
UCEC	cis	rs2376682	1.000	rs62372203	chr5:117996319	T/C	cg17593721	chr5:118788746	HSD17B4	0.51	5.04	0.38	1.34e-6	Diisocyanate-induced asthma;
UCEC	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.74	7.52	0.53	5.09e-12	Blood pressure (smoking interaction);
UCEC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.84	0.37	3.22e-6	Breast cancer;
UCEC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2036402	0.513	rs9313401	chr5:156433342	C/T	cg24526056	chr5:156479556	HAVCR1	-0.47	-4.82	-0.37	3.49e-6	Hypertriglyceridemia;
UCEC	cis	rs9487051	0.676	rs9386780	chr6:109584410	A/G	cg01475377	chr6:109611718	NA	-0.44	-5.62	-0.42	9.31e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04013166	chr16:89971882	TCF25	-0.69	-6.02	-0.44	1.35e-8	Skin colour saturation;
UCEC	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.92	10.27	0.65	5.54e-19	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg01262667	chr19:19385393	TM6SF2	0.5	7.1	0.51	4.89e-11	Tonsillectomy;
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.04	0.55	2.7e-13	Alzheimer's disease;
UCEC	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.65	-5.63	-0.42	9.03e-8	Metabolite levels;
UCEC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.69	0.36	6.25e-6	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.65	6.81	0.49	2.28e-10	Tonsillectomy;
UCEC	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg16558253	chr16:72132732	DHX38	-0.43	-4.58	-0.35	9.69e-6	Blood protein levels;
UCEC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.9	11.85	0.7	3.74e-23	Metabolic syndrome;
UCEC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.65	6.3	0.46	3.27e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.66	-7.58	-0.53	3.67e-12	Body mass index;
UCEC	cis	rs1816854	0.938	rs10880571	chr12:44207279	T/C	cg20956634	chr12:44200518	TWF1	0.5	5.14	0.39	8.54e-7	Inflammatory bowel disease;
UCEC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.44	4.52	0.35	1.27e-5	Hypertriglyceridemia;
UCEC	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.77	-8.8	-0.59	3.45e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.62	6.21	0.46	5.26e-9	Blood metabolite levels;
UCEC	cis	rs970548	1.000	rs12257549	chr10:46029631	C/T	cg15223267	chr10:46222474	FAM21C	0.57	5.17	0.39	7.65e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.06	-0.39	1.21e-6	Parkinson's disease;
UCEC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.45	4.67	0.36	6.67e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg16023434	chr1:11395635	NA	0.36	4.57	0.35	1.03e-5	Body mass index;
UCEC	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg03342759	chr3:160939853	NMD3	0.57	5.42	0.41	2.41e-7	Morning vs. evening chronotype;
UCEC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.69	7.29	0.52	1.79e-11	Longevity;Endometriosis;
UCEC	cis	rs2224391	0.628	rs9504365	chr6:5256116	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-4.9	-0.38	2.45e-6	Height;
UCEC	cis	rs9469578	0.710	rs73743330	chr6:33713971	G/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs12216499	1.000	rs12190146	chr6:159414155	G/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-6.2	-0.46	5.39e-9	Initial pursuit acceleration;
UCEC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.2	6.79	0.49	2.58e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	6.79	0.49	2.63e-10	Platelet count;
UCEC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.52	-0.35	1.25e-5	Homocysteine levels;
UCEC	cis	rs3790645	0.958	rs2278979	chr1:26877708	G/A	cg23229016	chr1:26872525	RPS6KA1	0.29	5.01	0.38	1.51e-6	Glucose homeostasis traits;
UCEC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.53	4.64	0.36	7.8e-6	Menarche (age at onset);
UCEC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.68	-6.68	-0.48	4.66e-10	Blood metabolite levels;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.51	-6.45	-0.47	1.53e-9	Pubertal anthropometrics;
UCEC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	6.36	0.46	2.43e-9	Bone mineral density;
UCEC	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07169764	chr2:136633963	MCM6	-0.61	-5.51	-0.41	1.58e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.88	9.06	0.6	7.63e-16	Cognitive function;
UCEC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	6.73	0.49	3.57e-10	Tonsillectomy;
UCEC	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.4	5.37	0.4	3.01e-7	Alcohol dependence;
UCEC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.69	6.28	0.46	3.69e-9	Aortic root size;
UCEC	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	trans	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	0.98	7.46	0.52	7.14e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7709377	0.570	rs12656463	chr5:115443812	A/T	cg23108291	chr5:115420582	COMMD10	0.49	4.97	0.38	1.81e-6	Metabolite levels  (X-11787);
UCEC	cis	rs12681287	0.752	rs10103229	chr8:87248954	C/T	cg27223183	chr8:87520930	FAM82B	0.81	6.33	0.46	2.85e-9	Caudate activity during reward;
UCEC	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.56	-5.33	-0.4	3.56e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.33	-0.46	2.77e-9	Total body bone mineral density;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	15.77	0.79	2.09e-33	Testicular germ cell tumor;
UCEC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.8	-4.91	-0.38	2.39e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	8.16	0.56	1.41e-13	Bipolar disorder;
UCEC	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.7	-7.73	-0.54	1.57e-12	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs6429082	0.510	rs2803849	chr1:235503247	G/A	cg26050004	chr1:235667680	B3GALNT2	0.44	4.55	0.35	1.1e-5	Adiposity;
UCEC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs28795989	0.613	rs2385901	chr4:7921718	G/C	cg12632249	chr4:7449638	SORCS2	-0.35	-4.52	-0.35	1.27e-5	Intraocular pressure;
UCEC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs7246967	0.611	rs62120304	chr19:22872268	G/T	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.86	6.95	0.5	1.13e-10	Body mass index;
UCEC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	0.99	13.43	0.74	2.4e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.61	-5.15	-0.39	8.08e-7	Smoking behavior;
UCEC	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.53	5.56	0.42	1.25e-7	Platelet count;
UCEC	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.84	-8.54	-0.58	1.53e-14	Resting heart rate;
UCEC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	1.07	7.56	0.53	4.08e-12	Obesity-related traits;
UCEC	cis	rs9341808	0.538	rs9343980	chr6:81023432	A/G	cg08355045	chr6:80787529	NA	-0.34	-4.58	-0.35	9.8200000000000008e-06	Sitting height ratio;
UCEC	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05535760	chr7:792225	HEATR2	0.92	7.51	0.53	5.35e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs17152411	0.625	rs7099073	chr10:126609647	A/C	cg06847678	chr10:126629686	ZRANB1	-0.45	-4.67	-0.36	6.87e-6	Height;
UCEC	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg14092571	chr14:90743983	NA	0.44	5.24	0.4	5.46e-7	Mortality in heart failure;
UCEC	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg18681998	chr4:17616180	MED28	0.76	8.73	0.58	5.08e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	0.608	rs433579	chr19:23003127	T/C	cg08271804	chr19:22816896	ZNF492	0.58	5.23	0.4	5.61e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.76	-0.37	4.63e-6	Coronary artery disease;
UCEC	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.91	9.46	0.62	7.15e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.41	-4.75	-0.36	4.77e-6	Height;
UCEC	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.73e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg23782820	chr8:58130467	NA	0.62	4.81	0.37	3.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs67311347	0.635	rs62261855	chr3:40294938	C/T	cg13683864	chr3:40499215	RPL14	-0.54	-4.86	-0.37	2.96e-6	Renal cell carcinoma;
UCEC	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg17031739	chr1:67600172	NA	0.51	4.51	0.35	1.3e-5	Psoriasis;
UCEC	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.56	5.83	0.43	3.44e-8	Eye color traits;
UCEC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.22	6.5	0.47	1.15e-9	Schizophrenia;
UCEC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.13	0.39	9.21e-7	Parkinson's disease;
UCEC	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg05962950	chr11:130786565	SNX19	0.5	4.91	0.38	2.44e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.97	11.13	0.68	2.93e-21	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.69	5.29	0.4	4.33e-7	Blood pressure;
UCEC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	7.3	0.52	1.66e-11	Multiple sclerosis;
UCEC	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.89	0.44	2.5e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs7246967	0.673	rs6511374	chr19:22866370	T/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	8.69	0.58	6.45e-15	Mean platelet volume;
UCEC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.37	0.57	4.1e-14	Alzheimer's disease;
UCEC	cis	rs7106204	0.748	rs36092013	chr11:24211987	C/T	ch.11.24196551F	chr11:24239977	NA	0.53	5.48	0.41	1.83e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg20119798	chr7:94954144	PON1	-0.51	-4.83	-0.37	3.33e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.46	-5.78	-0.43	4.38e-8	Obesity-related traits;
UCEC	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-6.72	-0.48	3.72e-10	Primary sclerosing cholangitis;
UCEC	cis	rs10823500	0.604	rs10762345	chr10:71939374	A/G	cg19602370	chr10:72539427	C10orf27	-0.4	-4.57	-0.35	1.01e-5	Blood protein levels;
UCEC	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.8	-0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.49	-0.72	7.33e-25	Primary sclerosing cholangitis;
UCEC	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg05925327	chr15:68127851	NA	-0.53	-5.82	-0.43	3.63e-8	Restless legs syndrome;
UCEC	cis	rs7709909	0.720	rs408626	chr5:79951133	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.41	4.7	0.36	5.97e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg02569219	chr17:2266849	SGSM2	0.46	4.89	0.37	2.65e-6	Autism spectrum disorder;
UCEC	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.89	-7.61	-0.53	3.09e-12	Body mass index;
UCEC	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.95	8.79	0.59	3.58e-15	Diastolic blood pressure;
UCEC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.63	-7.2	-0.51	2.92e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.52	4.87	0.37	2.85e-6	Corneal astigmatism;
UCEC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.53	4.96	0.38	1.93e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-6.73	-0.49	3.55e-10	Neuroticism;
UCEC	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.47	4.54	0.35	1.15e-5	Menarche (age at onset);
UCEC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-4.52	-0.35	1.27e-5	Electroencephalogram traits;
UCEC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg16294425	chr4:1091520	RNF212	0.76	4.52	0.35	1.26e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.68	0.69	1.06e-22	Platelet count;
UCEC	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.54	-6.87	-0.49	1.69e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.5	-5.0	-0.38	1.6e-6	Schizophrenia;
UCEC	cis	rs75804782	0.630	rs56354063	chr2:239253919	A/G	cg11815105	chr2:239148849	HES6	1.03	4.64	0.36	7.53e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6722750	0.933	rs1370390	chr2:64410193	G/T	cg22352474	chr2:64371530	PELI1	0.46	4.58	0.35	9.97e-6	Neuroticism;
UCEC	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-5.34	-0.4	3.42e-7	Hepatocellular carcinoma;
UCEC	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.53	-5.36	-0.4	3.14e-7	Hepatocellular carcinoma;
UCEC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	8e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-22.75	-0.88	5.15e-50	Myeloid white cell count;
UCEC	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.77	-8.19	-0.56	1.17e-13	Caffeine consumption;
UCEC	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.07	-0.39	1.17e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	7.36	0.52	1.18e-11	Menopause (age at onset);
UCEC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg04155231	chr12:9217510	LOC144571	0.42	5.06	0.39	1.24e-6	Sjögren's syndrome;
UCEC	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs78487399	0.831	rs10495903	chr2:43806918	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.59	-0.35	9.4e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7072216	0.666	rs17109597	chr10:100142154	G/A	cg19567339	chr10:100142640	NA	0.67	8.21	0.56	1.06e-13	Metabolite levels;
UCEC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg17330251	chr7:94953956	PON1	-0.55	-5.0	-0.38	1.6e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg02851062	chr11:122848983	BSX	-0.36	-4.55	-0.35	1.09e-5	Menarche (age at onset);
UCEC	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg24881558	chr5:1294198	TERT	0.43	4.64	0.36	7.68e-6	Testicular germ cell tumor;Testicular germ cell cancer;
UCEC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-6.19	-0.45	5.58e-9	Hemoglobin concentration;
UCEC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg01689657	chr7:91764605	CYP51A1	0.53	7.0	0.5	8.44e-11	Breast cancer;
UCEC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.29e-6	Corneal astigmatism;
UCEC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.34	0.4	3.46e-7	Heart rate;
UCEC	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	4.81	0.37	3.74e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.52	-5.78	-0.43	4.24e-8	Longevity;
UCEC	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.5	5.36	0.4	3.21e-7	Type 2 diabetes;
UCEC	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.59	-6.54	-0.47	9.59e-10	Obesity-related traits;
UCEC	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.93e-9	Motion sickness;
UCEC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.12	-0.39	9.58e-7	Breast cancer;
UCEC	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.78	0.43	4.33e-8	Colorectal cancer;
UCEC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.41	-5.75	-0.43	4.99e-8	Alcohol dependence;
UCEC	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.44	4.94	0.38	2.14e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs7692395	0.660	rs6829893	chr4:183651765	G/A	cg11459773	chr19:45262055	BCL3	0.8	6.69	0.48	4.38e-10	Incident myocardial infarction;
UCEC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.77	-8.77	-0.59	4.04e-15	Immature fraction of reticulocytes;
UCEC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.72	-5.33	-0.4	3.64e-7	White matter hyperintensity burden;
UCEC	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.42	-0.41	2.37e-7	Morning vs. evening chronotype;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	7.86	0.54	7.61e-13	Platelet count;
UCEC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg14078730	chr11:63896557	MACROD1	-0.45	-4.97	-0.38	1.82e-6	Platelet count;
UCEC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg05802129	chr4:122689817	NA	-0.57	-5.68	-0.42	7.03e-8	Type 2 diabetes;
UCEC	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.61	5.36	0.4	3.1e-7	Subjective well-being;
UCEC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	8.09	0.56	2.03e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7204230	1.000	rs8049550	chr16:53324439	T/C	cg10109421	chr16:52641824	NA	0.41	4.59	0.35	9.33e-6	Fibrinogen;
UCEC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.79	8.72	0.58	5.39e-15	Immature fraction of reticulocytes;
UCEC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.48	-5.06	-0.39	1.23e-6	Longevity;
UCEC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.57	5.34	0.4	3.49e-7	Cocaine dependence;
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.38	-0.47	2.17e-9	Platelet count;
UCEC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.46	-5.0	-0.38	1.59e-6	Monocyte count;
UCEC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg01262667	chr19:19385393	TM6SF2	0.47	6.34	0.46	2.72e-9	Tonsillectomy;
UCEC	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg20129853	chr10:51489980	NA	0.44	5.34	0.4	3.44e-7	Prostate-specific antigen levels;
UCEC	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.65	6.77	0.49	2.87e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.21	11.12	0.68	3.14e-21	Corneal structure;
UCEC	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.26	10.91	0.67	1.15e-20	Corneal structure;
UCEC	cis	rs17102423	0.929	rs4902363	chr14:65601689	T/G	cg11161011	chr14:65562177	MAX	-0.7	-8.02	-0.55	3.06e-13	Obesity-related traits;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.62	6.74	0.49	3.29e-10	Menarche (age at onset);
UCEC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.78	5.8	0.43	3.88e-8	Aortic root size;
UCEC	trans	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.16e-5	Lung cancer;
UCEC	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.68	-4.7	-0.36	5.88e-6	Red blood cell traits;
UCEC	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.41	-0.77	6.65e-30	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.65	5.32	0.4	3.82e-7	Corneal astigmatism;
UCEC	cis	rs13396424	0.518	rs2595202	chr2:46192017	G/T	cg23644005	chr2:45241578	NA	0.49	4.82	0.37	3.61e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.88	-10.8	-0.67	2.19e-20	Blood metabolite levels;
UCEC	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.74	-7.43	-0.52	8.25e-12	Plateletcrit;Platelet count;
UCEC	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.35	-0.46	2.58e-9	Mood instability;
UCEC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.52	-4.85	-0.37	3.04e-6	Coronary artery disease;
UCEC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.68	-6.76	-0.49	3e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs858239	0.899	rs858271	chr7:23278283	G/T	cg17274742	chr7:23286539	GPNMB	0.41	4.83	0.37	3.37e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg07636037	chr3:49044803	WDR6	-0.62	-4.82	-0.37	3.51e-6	Menarche (age at onset);
UCEC	cis	rs7246657	0.598	rs28660259	chr19:37658681	C/T	cg23950597	chr19:37808831	NA	-0.85	-6.18	-0.45	5.89e-9	Coronary artery calcification;
UCEC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg23625390	chr15:77176239	SCAPER	0.48	4.69	0.36	6.12e-6	Blood metabolite levels;
UCEC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg09462578	chr12:12878428	APOLD1	-1.1	-11.1	-0.68	3.46e-21	Lymphocyte counts;
UCEC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.52	-4.82	-0.37	3.6e-6	Metabolic syndrome;
UCEC	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg03342759	chr3:160939853	NMD3	0.53	4.79	0.37	3.98e-6	Morning vs. evening chronotype;
UCEC	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.37	0.47	2.28e-9	Hip circumference;
UCEC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg10503236	chr1:231470652	EXOC8	0.38	4.72	0.36	5.43e-6	Hemoglobin concentration;
UCEC	cis	rs10242455	0.867	rs2222411	chr7:99310331	C/G	cg07715041	chr7:99302981	CYP3A7	-0.48	-4.97	-0.38	1.81e-6	Blood metabolite levels;
UCEC	cis	rs60311166	1.000	rs58725214	chr3:52593214	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.82	4.65	0.36	7.2e-6	CTACK levels;
UCEC	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	9.6	0.62	3.1e-17	Menopause (age at onset);
UCEC	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.51	4.68	0.36	6.54e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.64	-7.08	-0.5	5.4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.53	-5.8	-0.43	3.94e-8	Tonsillectomy;
UCEC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.95	0.38	1.97e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg18681998	chr4:17616180	MED28	0.91	11.69	0.69	9.72e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.6	6.29	0.46	3.52e-9	Retinal vascular caliber;
UCEC	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg07615347	chr10:60278583	BICC1	-0.45	-4.85	-0.37	3.06e-6	Refractive error;
UCEC	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.61	-4.97	-0.38	1.86e-6	Exhaled nitric oxide output;
UCEC	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.86	-9.59	-0.62	3.32e-17	Blood metabolite levels;
UCEC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.46	-5.25	-0.4	5.21e-7	Prostate cancer;
UCEC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg13695892	chr22:41940480	POLR3H	-0.64	-5.37	-0.41	2.96e-7	Vitiligo;
UCEC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.75	-8.51	-0.57	1.88e-14	Sudden cardiac arrest;
UCEC	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.47	4.67	0.36	6.73e-6	Migraine;
UCEC	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.68	0.42	6.83e-8	Lung cancer;
UCEC	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.5	5.7	0.43	6.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.55	-0.48	8.85e-10	Depression;
UCEC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg06238570	chr21:40685208	BRWD1	0.77	5.3	0.4	4.16e-7	Cognitive function;
UCEC	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.31	4.72	0.36	5.46e-6	Blood metabolite levels;
UCEC	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	4.83	0.37	3.46e-6	Schizophrenia;
UCEC	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg12024160	chr4:1254474	NA	0.44	4.65	0.36	7.37e-6	Longevity;
UCEC	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.52	4.78	0.37	4.26e-6	Night sleep phenotypes;
UCEC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-6.37	-0.46	2.32e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.74	-8.46	-0.57	2.49e-14	Extraversion;
UCEC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.51	-0.35	1.31e-5	Alzheimer's disease (late onset);
UCEC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04731861	chr2:219085781	ARPC2	0.41	4.55	0.35	1.1e-5	Colorectal cancer;
UCEC	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.5	5.3	0.4	4.17e-7	Type 2 diabetes;
UCEC	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.56	-4.87	-0.37	2.8e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg06096015	chr1:231504339	EGLN1	0.46	5.34	0.4	3.51e-7	Hemoglobin concentration;
UCEC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.6	5.67	0.42	7.3e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.67	7.37	0.52	1.12e-11	Menopause (age at onset);
UCEC	cis	rs1712517	0.740	rs4293062	chr10:105052624	G/A	cg05636881	chr10:105038444	INA	0.47	5.37	0.4	3e-7	Migraine;
UCEC	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.65	-5.87	-0.44	2.72e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	trans	rs925228	0.824	rs2675351	chr2:24083573	A/G	cg18674340	chr17:45867686	NA	0.74	6.97	0.5	9.8e-11	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.54	-5.18	-0.39	7.34e-7	Opioid sensitivity;
UCEC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg10503236	chr1:231470652	EXOC8	-0.45	-5.18	-0.39	7.35e-7	Hemoglobin concentration;
UCEC	cis	rs3015497	0.616	rs7154131	chr14:51046526	G/C	cg04730355	chr14:51134070	SAV1	-0.46	-4.82	-0.37	3.59e-6	Mean platelet volume;
UCEC	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.52	-4.95	-0.38	1.99e-6	Hepatocellular carcinoma;
UCEC	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg20290983	chr6:43655470	MRPS18A	0.84	8.28	0.56	6.89e-14	IgG glycosylation;
UCEC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg05738196	chr6:26577821	NA	0.64	7.6	0.53	3.21e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	6.46	0.47	1.43e-9	Total body bone mineral density;
UCEC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18252515	chr7:66147081	NA	0.52	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.93	-9.79	-0.63	9.72e-18	Cognitive function;
UCEC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.71	-7.15	-0.51	3.72e-11	Aortic root size;
UCEC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.41	4.66	0.36	7.09e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.58	6.27	0.46	3.83e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.68	-7.69	-0.54	1.91e-12	Breast cancer;
UCEC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.52	5.02	0.38	1.48e-6	Blood metabolite levels;
UCEC	trans	rs1552172	1.000	rs1552172	chr1:145704759	T/A	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.81	-0.49	2.36e-10	Breast cancer;
UCEC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.63	7.1	0.51	5.05e-11	Vitiligo;
UCEC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg06238570	chr21:40685208	BRWD1	0.7	6.69	0.48	4.47e-10	Cognitive function;
UCEC	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.46	-0.41	1.96e-7	Response to antipsychotic treatment;
UCEC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.56	5.76	0.43	4.83e-8	Prostate cancer;
UCEC	cis	rs11235843	0.571	rs12361257	chr11:73362198	C/T	cg23931323	chr11:73372278	PLEKHB1	0.62	4.85	0.37	3.17e-6	Hand grip strength;
UCEC	cis	rs1940013	0.545	rs4614464	chr11:132240142	A/C	cg11473001	chr11:131780499	NTM	-0.42	-4.98	-0.38	1.74e-6	Sleep-related phenotypes;
UCEC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18252515	chr7:66147081	NA	0.59	5.49	0.41	1.71e-7	Aortic root size;
UCEC	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg05660106	chr1:15850417	CASP9	1.03	11.77	0.7	6.02e-23	Systolic blood pressure;
UCEC	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.73	-7.23	-0.51	2.48e-11	Educational attainment (years of education);
UCEC	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-5.08	-0.39	1.15e-6	Total cholesterol levels;
UCEC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.5	-4.63	-0.36	8.03e-6	Response to diuretic therapy;
UCEC	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg23972785	chr8:11611189	GATA4	-0.37	-4.58	-0.35	9.95e-6	Systolic blood pressure;
UCEC	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg18436246	chr17:1640651	WDR81	0.47	4.86	0.37	3.02e-6	Serum albumin level;
UCEC	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg11632617	chr15:75315747	PPCDC	-0.6	-5.29	-0.4	4.34e-7	Lung cancer;
UCEC	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.56	-5.43	-0.41	2.32e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.56	6.51	0.47	1.11e-9	Aortic root size;
UCEC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.1	18.06	0.83	3.91e-39	Testicular germ cell tumor;
UCEC	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.1	-0.39	1.05e-6	Pulmonary function;
UCEC	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-0.53	-5.32	-0.4	3.79e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg04202892	chr2:111875749	ACOXL	0.42	4.66	0.36	7.01e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.77	-5.63	-0.42	8.86e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg21204522	chr6:27730016	NA	-0.57	-4.73	-0.36	5.32e-6	Depression;
UCEC	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.71	-7.09	-0.5	5.16e-11	Cocaine dependence;
UCEC	cis	rs9467773	0.901	rs10223789	chr6:26579609	C/T	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	5.83	0.43	3.33e-8	Calcium levels;
UCEC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg00343986	chr7:65444356	GUSB	-0.51	-4.53	-0.35	1.21e-5	Aortic root size;
UCEC	cis	rs1937680	1.000	rs1937683	chr10:53679060	C/T	cg20114739	chr10:53459604	PRKG1;CSTF2T	0.55	4.55	0.35	1.12e-5	Breast cancer;
UCEC	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg19567339	chr10:100142640	NA	0.54	6.37	0.47	2.27e-9	Metabolite levels;
UCEC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg12923728	chr3:195709715	SDHAP1	-0.58	-5.37	-0.41	3e-7	Pancreatic cancer;
UCEC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.52	-4.95	-0.38	1.97e-6	Schizophrenia;
UCEC	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg03078520	chr22:18463400	MICAL3	-0.5	-5.08	-0.39	1.12e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7246967	0.673	rs35007247	chr19:22822923	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.866	rs6511385	chr19:23036936	T/G	cg08271804	chr19:22816896	ZNF492	0.58	5.45	0.41	2.05e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	5.74	0.43	5.22e-8	Cognitive test performance;
UCEC	cis	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.58	5.27	0.4	4.8e-7	Corneal astigmatism;
UCEC	cis	rs787274	0.681	rs787270	chr9:115549092	C/T	cg13803584	chr9:115635662	SNX30	-0.69	-5.21	-0.39	6.36e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	7.31	0.52	1.6e-11	Platelet count;
UCEC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.41	2.96e-7	Breast cancer;
UCEC	cis	rs9309473	0.519	rs35421685	chr2:73910138	T/C	cg20560298	chr2:73613845	ALMS1	0.5	4.59	0.35	9.32e-6	Metabolite levels;
UCEC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg20607287	chr7:12443886	VWDE	-0.64	-4.69	-0.36	6.11e-6	Coronary artery disease;
UCEC	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.45	-6.13	-0.45	7.88e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg20307385	chr11:47447363	PSMC3	0.5	4.52	0.35	1.28e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.47	4.93	0.38	2.19e-6	Longevity;Endometriosis;
UCEC	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.54	5.94	0.44	2.01e-8	Hip circumference;
UCEC	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	4.63	0.36	7.84e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs2629540	0.580	rs2930796	chr10:126485684	A/G	cg08799069	chr10:126477246	METTL10	0.66	4.96	0.38	1.91e-6	Cocaine dependence;
UCEC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.96	5.44	0.41	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.83	8.9	0.59	1.92e-15	Breast cancer;
UCEC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.27	0.68	1.3e-21	Chronic sinus infection;
UCEC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg13319975	chr6:146136371	FBXO30	0.44	4.73	0.36	5.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg00409905	chr10:38381863	ZNF37A	0.49	4.68	0.36	6.45e-6	Obesity (extreme);
UCEC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.55	5.35	0.4	3.3e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.71	-5.41	-0.41	2.55e-7	Huntington's disease progression;
UCEC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.59	5.8	0.43	4e-8	Lung cancer;
UCEC	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.62	5.92	0.44	2.21e-8	Bladder cancer;
UCEC	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-5.18	-0.39	7.21e-7	Schizophrenia;
UCEC	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.55	-5.63	-0.42	8.94e-8	Autism;
UCEC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.72	7.66	0.53	2.31e-12	Sudden cardiac arrest;
UCEC	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	6.23	0.46	4.76e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2386661	0.523	rs61832677	chr10:5652477	A/G	cg17085576	chr10:5658249	NA	-0.45	-5.15	-0.39	8.38e-7	Breast cancer;
UCEC	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg24851651	chr11:66362959	CCS	-0.42	-5.24	-0.4	5.51e-7	Educational attainment (years of education);
UCEC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-0.88	-7.8	-0.54	1.08e-12	Vitiligo;
UCEC	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.44	5.09	0.39	1.08e-6	Blood metabolite ratios;
UCEC	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.69	6.78	0.49	2.66e-10	Resting heart rate;
UCEC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg06027949	chr8:82754900	SNX16	-0.53	-4.92	-0.38	2.27e-6	Diastolic blood pressure;
UCEC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3750082	0.889	rs55647647	chr7:32935020	C/T	cg05721444	chr7:32995514	FKBP9	0.53	5.87	0.44	2.81e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg03037974	chr15:76606532	NA	0.32	4.51	0.35	1.34e-5	Blood metabolite levels;
UCEC	cis	rs4523957	0.757	rs216208	chr17:2195146	T/A	cg16513277	chr17:2031491	SMG6	0.48	5.32	0.4	3.76e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.65	5.67	0.42	7.5e-8	Uric acid levels;
UCEC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs16957091	0.647	rs28564939	chr15:43376592	T/C	cg15904908	chr15:43213022	TTBK2	0.47	4.58	0.35	9.72e-6	MGMT methylation in smokers;
UCEC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.19e-10	Aortic root size;
UCEC	cis	rs881952	0.585	rs934791	chr2:60889037	G/C	cg24366913	chr2:61765510	XPO1	-0.53	-4.89	-0.37	2.64e-6	Glucose homeostasis traits;
UCEC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.72	6.54	0.47	9.44e-10	Aortic root size;
UCEC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.57	4.97	0.38	1.85e-6	Lung cancer;
UCEC	cis	rs6838801	0.752	rs6817407	chr4:77616338	C/G	cg17476223	chr4:77663285	SHROOM3	-0.49	-4.61	-0.36	8.64e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg20368463	chr18:77673604	PQLC1	-0.47	-4.54	-0.35	1.14e-5	Opioid sensitivity;
UCEC	cis	rs7072216	0.687	rs11189588	chr10:100154551	G/A	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg17105886	chr17:28927953	LRRC37B2	0.63	4.61	0.36	8.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.02e-6	Prudent dietary pattern;
UCEC	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.67	-7.54	-0.53	4.49e-12	Bone mineral density;
UCEC	cis	rs2502731	0.539	rs3003614	chr9:130994736	G/A	cg13642260	chr9:130955380	CIZ1	0.53	5.85	0.43	3e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.68	6.29	0.46	3.44e-9	Bladder cancer;
UCEC	cis	rs12216499	1.000	rs4709256	chr6:159409058	G/A	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	0.87	7.01	0.5	7.92e-11	Blood protein levels;
UCEC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.36	0.4	3.21e-7	Bipolar disorder;
UCEC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03775416	chr19:19368775	HAPLN4	-0.49	-4.53	-0.35	1.23e-5	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg09120320	chr17:61926383	NA	-0.44	-4.69	-0.36	6.23e-6	Prudent dietary pattern;
UCEC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7246967	0.673	rs8103012	chr19:22879285	C/T	cg05241461	chr19:22816980	ZNF492	0.54	5.82	0.43	3.55e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4400599	0.569	rs10797058	chr1:154200704	T/C	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg18016565	chr1:150552671	MCL1	-0.54	-5.83	-0.43	3.4e-8	Tonsillectomy;
UCEC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.61	-4.89	-0.37	2.64e-6	Initial pursuit acceleration;
UCEC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.55	6.06	0.45	1.07e-8	Neuroticism;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg23048660	chr19:45004795	ZNF180	0.62	6.71	0.48	3.91e-10	Schizophrenia;
UCEC	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg13073564	chr4:8508604	NA	-0.45	-5.0	-0.38	1.6e-6	Response to antineoplastic agents;
UCEC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs9463078	0.547	rs34907292	chr6:44729708	A/G	cg25276700	chr6:44698697	NA	0.43	4.84	0.37	3.2e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg24803719	chr17:45855879	NA	-0.47	-5.08	-0.39	1.11e-6	IgG glycosylation;
UCEC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.61	0.69	1.56e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg01874867	chr7:94954059	PON1	-0.54	-5.15	-0.39	8.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.62	6.07	0.45	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.6	-6.1	-0.45	8.83e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.46	6.37	0.47	2.27e-9	Alcohol dependence;
UCEC	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.53	-5.02	-0.38	1.49e-6	Morning vs. evening chronotype;
UCEC	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.78	-7.35	-0.52	1.26e-11	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.69	7.0	0.5	8.3e-11	Primary sclerosing cholangitis;
UCEC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.16	-14.4	-0.76	7.16e-30	Breast cancer;
UCEC	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	0.82	5.49	0.41	1.71e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.23	-0.68	1.67e-21	Headache;
UCEC	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs883565	0.740	rs6599006	chr3:39114276	T/G	cg01426195	chr3:39028469	NA	-0.68	-8.51	-0.57	1.83e-14	Handedness;
UCEC	cis	rs11048434	1.000	rs1805719	chr12:9151467	A/G	cg13575925	chr12:9217583	LOC144571	0.42	4.62	0.36	8.17e-6	Sjögren's syndrome;
UCEC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	4.92	0.38	2.32e-6	Neuroticism;
UCEC	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	6.14	0.45	7.19e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.63	-0.48	5.88e-10	Response to antipsychotic treatment;
UCEC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	4.96	0.38	1.91e-6	Cognitive test performance;
UCEC	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-5.65	-0.42	7.91e-8	Life satisfaction;
UCEC	cis	rs3736594	0.527	rs62141279	chr2:27771415	C/T	cg27432699	chr2:27873401	GPN1	0.5	4.65	0.36	7.46e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.7	6.84	0.49	2.01e-10	Cognitive ability;
UCEC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.48	4.68	0.36	6.48e-6	Menarche (age at onset);
UCEC	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	8.72	0.58	5.56e-15	Coffee consumption (cups per day);
UCEC	cis	rs7246967	0.932	rs35007403	chr19:23037447	T/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg18681998	chr4:17616180	MED28	0.79	9.31	0.61	1.69e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs11958404	0.932	rs55943686	chr5:157439591	G/C	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.85	-8.14	-0.56	1.53e-13	Post bronchodilator FEV1;
UCEC	cis	rs12980942	1.000	rs2241720	chr19:41829309	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.75	5.9	0.44	2.43e-8	Coronary artery disease;
UCEC	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.72	5.46	0.41	2.02e-7	Aortic root size;
UCEC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.48	5.36	0.4	3.22e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.54	4.8	0.37	3.79e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.63	6.94	0.5	1.16e-10	Homoarginine levels;
UCEC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.9	10.46	0.65	1.69e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs8099014	0.814	rs7227488	chr18:56113233	A/G	cg19165390	chr18:56932082	NA	0.36	4.64	0.36	7.59e-6	Platelet count;
UCEC	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.97	-15.52	-0.79	8.64e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg26940100	chr1:228395760	OBSCN	0.32	4.65	0.36	7.3e-6	Diastolic blood pressure;
UCEC	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	1.18	15.17	0.78	6.89e-32	Body mass index;
UCEC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	22.76	0.88	4.9e-50	Chronic sinus infection;
UCEC	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.81	0.49	2.28e-10	Coronary artery disease;
UCEC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.71	9.2	0.6	3.32e-16	Rheumatoid arthritis;
UCEC	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.62	6.79	0.49	2.59e-10	Motion sickness;
UCEC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.8	8.01	0.55	3.18e-13	Chronic sinus infection;
UCEC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg03354898	chr7:1950403	MAD1L1	-0.59	-5.88	-0.44	2.67e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.46	5.39	0.41	2.78e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	0.87	5.66	0.42	7.53e-8	Arsenic metabolism;
UCEC	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.95	-11.01	-0.67	6.22e-21	Height;
UCEC	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.54	-5.42	-0.41	2.43e-7	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg05660106	chr1:15850417	CASP9	0.88	8.26	0.56	7.6e-14	Systolic blood pressure;
UCEC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	6.14	0.45	7.15e-9	Tonsillectomy;
UCEC	cis	rs883565	0.502	rs4374473	chr3:38942618	C/T	cg01426195	chr3:39028469	NA	0.48	5.36	0.4	3.22e-7	Handedness;
UCEC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.01	-7.35	-0.52	1.26e-11	Body mass index;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.48	-0.41	1.78e-7	Pubertal anthropometrics;
UCEC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.79	0.49	2.55e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	0.83	6.52	0.47	1.05e-9	Lymphocyte counts;
UCEC	cis	rs13401104	0.796	rs1466204	chr2:237121154	C/A	cg23897927	chr2:237117786	ASB18	-0.5	-4.52	-0.35	1.28e-5	Educational attainment;
UCEC	cis	rs3780378	0.902	rs2381195	chr9:5145887	T/C	cg02405213	chr9:5042618	JAK2	-0.56	-5.58	-0.42	1.14e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.52	-0.41	1.47e-7	Vitiligo;
UCEC	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.62	6.83	0.49	2.07e-10	Blood metabolite ratios;
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	8.86	0.59	2.46e-15	Platelet count;
UCEC	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg14458575	chr2:238380390	NA	0.45	4.58	0.35	1e-5	Prostate cancer;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.96	-0.38	1.93e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-6.16	-0.45	6.53e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.53	-5.7	-0.43	6.21e-8	Diastolic blood pressure;
UCEC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.7	0.43	6.45e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.62	-6.34	-0.46	2.7e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.62	6.3	0.46	3.28e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg24531977	chr5:56204891	C5orf35	-0.6	-5.72	-0.43	5.8e-8	Coronary artery disease;
UCEC	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	0.92	12.25	0.71	3.14e-24	Primary sclerosing cholangitis;
UCEC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.52	5.24	0.4	5.47e-7	Monocyte percentage of white cells;
UCEC	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.39	4.59	0.35	9.49e-6	Platelet count;
UCEC	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.54	5.01	0.38	1.53e-6	Morning vs. evening chronotype;
UCEC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.17	-0.39	7.6e-7	Aortic root size;
UCEC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.9	0.44	2.39e-8	Mood instability;
UCEC	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.34	0.46	2.66e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs10924970	1.000	rs10924870	chr1:235359782	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.42	-4.6	-0.35	9.14e-6	Asthma;
UCEC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.29	0.46	3.47e-9	Tonsillectomy;
UCEC	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	5.91	0.44	2.3e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg15147215	chr3:52552868	STAB1	-0.46	-4.96	-0.38	1.89e-6	Bipolar disorder;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19243777	chr12:26278767	BHLHE41	0.62	7.35	0.52	1.31e-11	Warfarin maintenance dose;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.5	-5.31	-0.4	3.89e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12681287	0.927	rs2953517	chr8:87332013	C/T	cg27223183	chr8:87520930	FAM82B	-0.52	-4.6	-0.35	9.2e-6	Caudate activity during reward;
UCEC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	7.42	0.52	8.66e-12	Platelet count;
UCEC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.48	6.03	0.45	1.3e-8	Electrocardiographic conduction measures;
UCEC	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs12767760	0.714	rs7475851	chr10:99322061	G/C	cg17778955	chr10:99210596	ZDHHC16	-0.46	-4.69	-0.36	6.15e-6	Obesity-related traits;
UCEC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-5.29	-0.4	4.35e-7	Menarche (age at onset);
UCEC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.67	-5.36	-0.4	3.15e-7	Menopause (age at onset);
UCEC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	0.83	5.92	0.44	2.23e-8	Red blood cell traits;
UCEC	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg20821713	chr7:1055600	C7orf50	-0.73	-6.93	-0.5	1.25e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs6460942	0.591	rs4721082	chr7:12341804	A/G	cg06484146	chr7:12443880	VWDE	-0.6	-4.69	-0.36	6.08e-6	Coronary artery disease;
UCEC	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	1.09	10.02	0.64	2.48e-18	Corneal structure;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.41	-0.41	2.52e-7	Pubertal anthropometrics;
UCEC	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.25	-0.4	5.19e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.57	5.22	0.4	5.98e-7	Pancreatic cancer;
UCEC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.98	14.18	0.76	2.63e-29	Height;
UCEC	cis	rs7095607	0.967	rs7916821	chr10:69933969	A/G	cg18986048	chr10:69913749	MYPN	-0.51	-5.62	-0.42	9.34e-8	Lung function (FVC);
UCEC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg08320659	chr6:26088202	HFE	0.75	4.6	0.36	8.89e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg20007245	chr22:24372913	LOC391322	-0.49	-5.26	-0.4	5.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.55	-0.42	1.3e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.57	-0.35	1.03e-5	IgG glycosylation;
UCEC	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.51	4.76	0.37	4.57e-6	Height;
UCEC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	5.46	0.41	1.96e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10012307	1.000	rs7673926	chr4:137504716	T/C	cg12033966	chr4:138453416	PCDH18	-0.73	-5.13	-0.39	8.92e-7	DNA methylation (parent-of-origin);
UCEC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.5	-0.41	1.63e-7	Breast cancer;
UCEC	cis	rs60311166	1.000	rs934839	chr3:52683898	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.75	5.46	0.41	1.99e-7	CTACK levels;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.53	-6.34	-0.46	2.72e-9	Pubertal anthropometrics;
UCEC	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.87	-9.44	-0.61	7.82e-17	Height;
UCEC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg12024160	chr4:1254474	NA	0.54	6.91	0.5	1.34e-10	Obesity-related traits;
UCEC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12292205	chr6:26970375	C6orf41	-0.59	-4.65	-0.36	7.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-10.93	-0.67	9.87e-21	Vitiligo;
UCEC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	18.32	0.83	8.7e-40	Testicular germ cell tumor;
UCEC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-4.6	-0.35	9.21e-6	Menarche (age at onset);
UCEC	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.54	5.35	0.4	3.23e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg26721908	chr21:47610096	LSS	-0.36	-4.54	-0.35	1.17e-5	Testicular germ cell tumor;
UCEC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg07424592	chr7:64974309	NA	0.76	4.76	0.37	4.68e-6	Diabetic kidney disease;
UCEC	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg08320659	chr6:26088202	HFE	0.77	4.6	0.36	8.86e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.78	10.81	0.67	2.1e-20	Vitiligo;
UCEC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.61	-5.53	-0.42	1.41e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.74	7.6	0.53	3.23e-12	Breast cancer;
UCEC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.11	0.39	9.71e-7	Birth weight;
UCEC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.47	4.84	0.37	3.25e-6	Alcohol dependence;
UCEC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.45	4.93	0.38	2.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.64	6.3	0.46	3.25e-9	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.46	4.87	0.37	2.82e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs11697848	1.000	rs79663083	chr20:48534737	C/G	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.68	-7.33	-0.52	1.39e-11	Facial morphology (factor 23);
UCEC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg01689657	chr7:91764605	CYP51A1	-0.43	-5.54	-0.42	1.34e-7	Breast cancer;
UCEC	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.46	-5.53	-0.41	1.42e-7	Height;
UCEC	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.81	-8.27	-0.56	7.31e-14	Resting heart rate;
UCEC	cis	rs2398893	0.960	rs56335449	chr9:96748795	G/A	cg07076509	chr9:96720819	NA	0.5	5.17	0.39	7.47e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.75	7.13	0.51	4.24e-11	Metabolite levels;
UCEC	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.52	-5.6	-0.42	1.01e-7	Brugada syndrome;
UCEC	cis	rs7870753	0.838	rs10820682	chr9:99241587	T/G	cg25260653	chr9:99212216	HABP4	0.58	5.85	0.43	3.1e-8	Height;
UCEC	trans	rs4146922	0.793	rs6752931	chr2:56004219	G/T	cg20168479	chr3:32443031	CMTM7	0.66	6.67	0.48	4.76e-10	Height;
UCEC	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-4.88	-0.37	2.68e-6	Aortic root size;
UCEC	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.62	-6.79	-0.49	2.52e-10	Motion sickness;
UCEC	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.36	-0.46	2.35e-9	Metabolite levels;
UCEC	cis	rs1576263	0.967	rs9328489	chr6:8562117	G/T	cg07606381	chr6:8435919	SLC35B3	-0.46	-4.83	-0.37	3.46e-6	Photic sneeze reflex;
UCEC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	4.53	0.35	1.2e-5	Joint mobility (Beighton score);
UCEC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg24562669	chr7:97807699	LMTK2	-0.42	-4.98	-0.38	1.77e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.79	8.01	0.55	3.16e-13	Joint mobility (Beighton score);
UCEC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.56	5.04	0.38	1.34e-6	Response to antineoplastic agents;
UCEC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	7.07	0.5	5.67e-11	Platelet count;
UCEC	cis	rs9467773	1.000	rs1570059	chr6:26573325	C/T	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg14092571	chr14:90743983	NA	-0.43	-5.7	-0.43	6.3e-8	Mortality in heart failure;
UCEC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg17330251	chr7:94953956	PON1	-0.56	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-10.76	-0.66	2.75e-20	Ulcerative colitis;
UCEC	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg05539622	chr2:73298971	SFXN5	0.48	4.53	0.35	1.21e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7101446	0.704	rs7121823	chr11:63192829	C/T	cg21706343	chr11:62521476	ZBTB3	-0.53	-4.62	-0.36	8.38e-6	Economic and political preferences;
UCEC	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.5	5.73	0.43	5.6e-8	Neuroticism;
UCEC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.64	5.38	0.41	2.84e-7	High light scatter reticulocyte count;
UCEC	cis	rs1832871	0.599	rs1754413	chr6:158764741	C/T	cg07215822	chr6:158701037	NA	0.47	5.05	0.38	1.26e-6	Height;
UCEC	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.45	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-0.83	-9.63	-0.62	2.57e-17	Height;
UCEC	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.43	5.15	0.39	8.35e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.52	6.88	0.49	1.64e-10	Osteoporosis;
UCEC	cis	rs2983496	1.000	rs2983534	chr6:166015625	G/A	cg01649219	chr6:165032124	NA	0.6	4.75	0.36	4.88e-6	Cortisol levels (saliva);
UCEC	cis	rs9463078	0.764	rs1935551	chr6:44786035	T/G	cg25276700	chr6:44698697	NA	-0.48	-5.29	-0.4	4.3e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Body mass index;
UCEC	trans	rs1923834	0.541	rs11617006	chr13:28374501	A/C	cg04905392	chr12:132667060	NA	0.78	6.71	0.48	3.85e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin);
UCEC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.34	4.77	0.37	4.39e-6	Ewing sarcoma;
UCEC	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.59	5.03	0.38	1.43e-6	Blood protein levels;
UCEC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-0.95	-6.06	-0.45	1.11e-8	Diabetic kidney disease;
UCEC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.39	4.94	0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs3736594	0.513	rs1881396	chr2:27844601	G/T	cg27432699	chr2:27873401	GPN1	-0.54	-5.04	-0.38	1.34e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05013783	chr12:56652058	ANKRD52	0.63	7.82	0.54	9.51e-13	Warfarin maintenance dose;
UCEC	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.73	-8.74	-0.58	4.99e-15	Testicular germ cell tumor;
UCEC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.64	7.08	0.5	5.52e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.48	-5.08	-0.39	1.14e-6	Longevity;
UCEC	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.61	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.52	-6.15	-0.45	7.09e-9	Pubertal anthropometrics;
UCEC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7937612	0.931	rs34298380	chr11:120203559	A/G	cg12584626	chr11:120203529	NA	0.44	4.55	0.35	1.12e-5	Intraocular pressure;
UCEC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18932078	chr1:2524107	MMEL1	-0.39	-6.14	-0.45	7.44e-9	Multiple sclerosis;
UCEC	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.47	-4.83	-0.37	3.42e-6	Pubertal anthropometrics;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.73	-8.08	-0.55	2.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.54	-5.46	-0.41	1.94e-7	Pediatric autoimmune diseases;
UCEC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg11871910	chr12:69753446	YEATS4	1.07	13.47	0.74	1.87e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.71	-8.57	-0.58	1.27e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.57	4.74	0.36	4.89e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.71	4.83	0.37	3.39e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.52	5.82	0.43	3.62e-8	Life satisfaction;
UCEC	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.52	-4.83	-0.37	3.39e-6	Coronary artery disease;
UCEC	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.8	-9.94	-0.63	3.89e-18	Systemic sclerosis;
UCEC	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	4.68	0.36	6.59e-6	Colorectal cancer;
UCEC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.37	-8.68	-0.58	7.08e-15	Diabetic kidney disease;
UCEC	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.6	-5.4	-0.41	2.66e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.92	9.8	0.63	9.37e-18	Cognitive function;
UCEC	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	0.97	4.69	0.36	6.15e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg26721908	chr21:47610096	LSS	0.43	5.6	0.42	1.04e-7	Testicular germ cell tumor;
UCEC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.54	0.35	1.17e-5	Breast cancer;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.46	-5.13	-0.39	8.99e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg19338460	chr6:170058176	WDR27	-0.56	-4.52	-0.35	1.24e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	trans	rs925228	0.955	rs4665646	chr2:24144685	A/G	cg18674340	chr17:45867686	NA	0.73	6.75	0.49	3.24e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg16497277	chr3:49208875	KLHDC8B	-0.48	-4.81	-0.37	3.72e-6	Parkinson's disease;
UCEC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.99	11.0	0.67	6.49e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.63	-5.74	-0.43	5.16e-8	Recalcitrant atopic dermatitis;
UCEC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-1.05	-7.14	-0.51	4.07e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-4.87	-0.37	2.88e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-7.91	-0.55	5.7e-13	Colorectal cancer;
UCEC	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg13683864	chr3:40499215	RPL14	-0.65	-6.88	-0.49	1.59e-10	Renal cell carcinoma;
UCEC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.57	-0.42	1.19e-7	Bipolar disorder and schizophrenia;
UCEC	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.42	-0.57	3.16e-14	Colorectal cancer;
UCEC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	0.62	7.53	0.53	4.68e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.94	8.95	0.59	1.43e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.46	-4.83	-0.37	3.37e-6	Blood metabolite levels;
UCEC	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.11	-0.45	8.36e-9	Mean platelet volume;
UCEC	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.05	-13.35	-0.74	4.01e-27	Body mass index;
UCEC	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.6	6.56	0.48	8.51e-10	Noise-induced hearing loss;
UCEC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00776160	chr1:149815087	HIST2H2AA3;HIST2H2AA4	0.52	6.74	0.49	3.39e-10	Warfarin maintenance dose;
UCEC	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg19610905	chr11:61596333	FADS2	-0.5	-5.33	-0.4	3.57e-7	Trans fatty acid levels;
UCEC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18932078	chr1:2524107	MMEL1	0.33	5.48	0.41	1.77e-7	Multiple sclerosis;
UCEC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	4.57	0.35	1.02e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.28	14.94	0.78	2.77e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.66	-0.36	7.05e-6	Parkinson's disease;
UCEC	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.55	5.37	0.41	2.98e-7	High light scatter reticulocyte percentage of red cells;Plateletcrit;
UCEC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.02	-0.38	1.49e-6	Aortic root size;
UCEC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.55	-0.42	1.3e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.45	-5.28	-0.4	4.58e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	4.94	0.38	2.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.55	4.5	0.35	1.35e-5	Obesity-related traits;
UCEC	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.8	5.17	0.39	7.51e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6446731	0.593	rs6446728	chr4:3275650	A/G	cg08886695	chr4:3369023	RGS12	-0.44	-5.07	-0.39	1.19e-6	Mean platelet volume;
UCEC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.9	0.49	1.45e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.32	4.53	0.35	1.21e-5	Primary biliary cholangitis;
UCEC	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg21905437	chr5:178450457	ZNF879	0.64	7.06	0.5	6.25e-11	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.49	5.08	0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg15837086	chr1:46506065	PIK3R3	-0.39	-4.94	-0.38	2.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg05991184	chr2:219186017	PNKD	0.58	6.78	0.49	2.7e-10	Colorectal cancer;
UCEC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.69	0.36	6.12e-6	Blood metabolite levels;
UCEC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.59	4.56	0.35	1.09e-5	Corneal astigmatism;
UCEC	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-5.52	-0.41	1.49e-7	Body mass index;
UCEC	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg21419209	chr3:44054225	NA	-0.49	-5.22	-0.4	6.1e-7	Coronary artery disease;
UCEC	cis	rs7523273	1.000	rs12123251	chr1:207992546	G/A	cg22525895	chr1:207977042	MIR29B2	-0.51	-4.75	-0.36	4.77e-6	Schizophrenia;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.51	4.88	0.37	2.78e-6	Menarche (age at onset);
UCEC	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.73	7.86	0.54	7.64e-13	Sudden cardiac arrest;
UCEC	cis	rs11153730	0.503	rs283062	chr6:118621456	A/G	cg21191810	chr6:118973309	C6orf204	-0.4	-5.11	-0.39	9.71e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.57	5.81	0.43	3.77e-8	Blood protein levels;
UCEC	cis	rs10242455	0.557	rs77997620	chr7:99070415	G/T	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg05660106	chr1:15850417	CASP9	0.62	5.73	0.43	5.57e-8	Systolic blood pressure;
UCEC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.4	-5.36	-0.4	3.19e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg04310649	chr10:35416472	CREM	-0.49	-4.84	-0.37	3.25e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7246657	0.524	rs35080624	chr19:37456582	C/T	cg23950597	chr19:37808831	NA	-0.98	-5.53	-0.42	1.41e-7	Coronary artery calcification;
UCEC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	7.96	0.55	4.36e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.38	-0.41	2.81e-7	Longevity;Endometriosis;
UCEC	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	7.97	0.55	4.16e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18252515	chr7:66147081	NA	0.54	5.25	0.4	5.31e-7	Aortic root size;
UCEC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg19805062	chr22:46654627	PKDREJ	-0.44	-4.9	-0.37	2.53e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.58	6.54	0.47	9.37e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs16974263	1.000	rs16974263	chr19:40913539	A/G	cg14150973	chr19:40950431	SERTAD3	-0.68	-6.49	-0.47	1.24e-9	Otitis media;Otitis media (chronic);Otitis media (recurrent);
UCEC	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.71e-16	Vitiligo;
UCEC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.84	10.54	0.66	1.08e-19	Mortality in heart failure;
UCEC	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.66	0.42	7.72e-8	Colorectal cancer;
UCEC	cis	rs11958404	0.932	rs11950297	chr5:157419938	T/G	cg05962755	chr5:157440814	NA	0.64	4.76	0.37	4.68e-6	IgG glycosylation;
UCEC	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.09	7.63	0.53	2.68e-12	Sexual dysfunction (female);
UCEC	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg14851346	chr12:38532713	NA	-0.48	-4.62	-0.36	8.18e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4389656	0.857	rs274679	chr5:6751426	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.59	5.53	0.41	1.45e-7	Corneal astigmatism;
UCEC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7397861	1.000	rs4128354	chr12:66823686	A/T	cg00425708	chr12:66217779	HMGA2;RPSAP52	0.43	4.76	0.37	4.51e-6	Menopause (age at onset);
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-6.58	-0.48	7.75e-10	Platelet count;
UCEC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.79	9.16	0.6	4.19e-16	Lymphocyte counts;
UCEC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg11569703	chr11:65557185	OVOL1	-0.39	-4.91	-0.38	2.4e-6	Acne (severe);
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.77	-0.43	4.56e-8	Breast cancer;
UCEC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12618769	0.597	rs2278206	chr2:99172244	A/G	cg10123293	chr2:99228465	UNC50	0.44	4.85	0.37	3.06e-6	Bipolar disorder;
UCEC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg23855989	chr12:50355821	AQP5	0.86	6.22	0.46	4.86e-9	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7246967	0.673	rs4933026	chr19:22874492	A/T	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9402633	0.938	rs72986491	chr6:135042596	G/A	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.75	-0.36	4.8e-6	Response to antipsychotic treatment;
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.19	0.45	5.62e-9	Platelet count;
UCEC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.49	5.0	0.38	1.62e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.27	0.46	3.78e-9	Tonsillectomy;
UCEC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.73	5.69	0.42	6.66e-8	Menarche (age at onset);
UCEC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg04310649	chr10:35416472	CREM	-0.47	-4.59	-0.35	9.3e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.56	0.58	1.42e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.52	5.85	0.43	3.03e-8	Tonsillectomy;
UCEC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.54	5.98	0.44	1.6e-8	Life satisfaction;
UCEC	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.43	5.96	0.44	1.82e-8	Alcohol dependence;
UCEC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg14078730	chr11:63896557	MACROD1	-0.5	-5.62	-0.42	9.16e-8	Platelet count;
UCEC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.68	7.51	0.53	5.22e-12	Coronary artery disease;
UCEC	cis	rs7709377	0.514	rs11241365	chr5:115466102	C/A	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13683864	chr3:40499215	RPL14	-0.72	-7.65	-0.53	2.39e-12	Renal cell carcinoma;
UCEC	cis	rs10779751	0.887	rs2300095	chr1:11265717	A/G	cg08854313	chr1:11322531	MTOR	0.63	7.06	0.5	6.09e-11	Body mass index;
UCEC	cis	rs10789491	0.565	rs2897107	chr1:47206178	A/T	cg15501359	chr1:47185051	KIAA0494	0.85	6.53	0.47	1.01e-9	Response to hepatitis C treatment;
UCEC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg06784218	chr1:46089804	CCDC17	-0.55	-6.46	-0.47	1.42e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.91	11.4	0.69	5.6e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-5.83	-0.43	3.36e-8	Asthma;
UCEC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs870825	0.655	rs6845058	chr4:185653696	G/A	cg04058563	chr4:185651563	MLF1IP	-0.62	-6.8	-0.49	2.43e-10	Blood protein levels;
UCEC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.44	5.07	0.39	1.17e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.58	6.97	0.5	9.74e-11	Subjective well-being (multi-trait analysis);
UCEC	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg06562184	chr8:19319451	CSGALNACT1	0.45	4.64	0.36	7.56e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs1575951	1.000	rs7075201	chr10:130437955	C/G	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	1.02	7.47	0.52	6.5e-12	LDL cholesterol;
UCEC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg04310649	chr10:35416472	CREM	-0.49	-4.9	-0.37	2.49e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.62	7.5	0.53	5.57e-12	Obesity-related traits;
UCEC	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg03934865	chr2:198174659	NA	-0.43	-5.24	-0.4	5.43e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.67	8.16	0.56	1.36e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.59	-5.74	-0.43	5.3e-8	Dental caries;
UCEC	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg11569703	chr11:65557185	OVOL1	0.51	6.66	0.48	4.99e-10	Acne (severe);
UCEC	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg00786635	chr1:25594202	NA	0.49	4.86	0.37	3e-6	Plateletcrit;Mean corpuscular volume;
UCEC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.5	0.57	1.92e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7589342	0.831	rs6731173	chr2:106522928	A/G	cg14210321	chr2:106509881	NCK2	-0.49	-4.63	-0.36	8.14e-6	Addiction;
UCEC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.47	6.76	0.49	3.1e-10	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.75	7.74	0.54	1.51e-12	Joint mobility (Beighton score);
UCEC	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg24687543	chr11:63912206	MACROD1	0.56	4.86	0.37	2.94e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs7709377	0.574	rs10063392	chr5:115499800	C/T	cg23108291	chr5:115420582	COMMD10	0.52	5.22	0.4	6.01e-7	Metabolite levels  (X-11787);
UCEC	cis	rs12912251	0.591	rs10520103	chr15:39006243	C/G	cg10631289	chr15:39006617	NA	0.64	5.76	0.43	4.71e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	5.15	0.39	8.2e-7	Alzheimer's disease;
UCEC	cis	rs2398893	0.960	rs2153791	chr9:96744928	G/A	cg07076509	chr9:96720819	NA	0.5	5.17	0.39	7.47e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.46	4.52	0.35	1.26e-5	Motion sickness;
UCEC	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.87	8.76	0.59	4.39e-15	Post bronchodilator FEV1;
UCEC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.45	5.62	0.42	9.26e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7204230	1.000	rs8049913	chr16:53272216	A/C	cg10109421	chr16:52641824	NA	0.4	4.61	0.36	8.82e-6	Fibrinogen;
UCEC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg03146154	chr1:46216737	IPP	0.46	4.8	0.37	3.79e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.75	-5.16	-0.39	7.76e-7	Toenail selenium levels;
UCEC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.57	5.82	0.43	3.5e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.45	-5.25	-0.4	5.19e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	5.92	0.44	2.14e-8	Cognitive test performance;
UCEC	cis	rs7560272	0.501	rs2421674	chr2:73955432	G/A	cg20560298	chr2:73613845	ALMS1	0.49	4.59	0.35	9.33e-6	Schizophrenia;
UCEC	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.39	5.81	0.43	3.81e-8	Primary biliary cholangitis;
UCEC	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-6.58	-0.48	7.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.67	0.62	1.99e-17	Blood protein levels;
UCEC	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.5	5.66	0.42	7.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12980942	0.748	rs67511749	chr19:41825158	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.6	5.46	0.41	2e-7	Coronary artery disease;
UCEC	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg23782820	chr8:58130467	NA	0.51	4.75	0.36	4.8e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.44	5.12	0.39	9.4e-7	Obesity;
UCEC	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg08717414	chr16:71523259	ZNF19	-1.21	-8.64	-0.58	8.54e-15	Post bronchodilator FEV1;
UCEC	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg23752985	chr2:85803571	VAMP8	0.44	4.72	0.36	5.51e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.34	4.77	0.37	4.39e-6	Ewing sarcoma;
UCEC	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.78	-9.59	-0.62	3.33e-17	White blood cell count (basophil);
UCEC	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.22	-0.4	5.98e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.64	-4.68	-0.36	6.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.98	-0.5	9.46e-11	Tonsillectomy;
UCEC	cis	rs1712517	0.740	rs11191643	chr10:105057561	C/G	cg05636881	chr10:105038444	INA	0.46	5.91	0.44	2.33e-8	Migraine;
UCEC	cis	rs7246967	0.551	rs7249473	chr19:22906694	T/C	cg08271804	chr19:22816896	ZNF492	0.66	6.4	0.47	1.99e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.46	4.72	0.36	5.44e-6	Glaucoma;
UCEC	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-1.01	-12.24	-0.71	3.31e-24	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs35306767	0.855	rs72778229	chr10:951991	C/A	cg26597838	chr10:835615	NA	0.99	6.13	0.45	7.8e-9	Eosinophil percentage of granulocytes;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	ch.13.1783356F	chr13:111136316	COL4A2	-0.87	-4.92	-0.38	2.34e-6	Obesity-related traits;
UCEC	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg21419209	chr3:44054225	NA	-0.52	-5.58	-0.42	1.15e-7	Coronary artery disease;
UCEC	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg13206674	chr6:150067644	NUP43	0.57	5.72	0.43	5.73e-8	Lung cancer;
UCEC	cis	rs7246967	0.673	rs368144	chr19:23000787	C/T	cg24889512	chr19:22816950	ZNF492	0.59	5.73	0.43	5.53e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.61	-5.11	-0.39	9.7e-7	Corneal astigmatism;
UCEC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg05573133	chr3:46037470	FYCO1	-0.69	-6.86	-0.49	1.8e-10	Neuroticism;
UCEC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg18016565	chr1:150552671	MCL1	0.6	6.94	0.5	1.15e-10	Tonsillectomy;
UCEC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.25e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.53	-6.03	-0.45	1.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.55	4.66	0.36	7.09e-6	Systolic blood pressure;
UCEC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.46	-6.64	-0.48	5.68e-10	Urinary metabolites;
UCEC	cis	rs4356932	0.967	rs4859605	chr4:76965822	C/G	cg22252999	chr4:76996414	ART3	0.44	4.54	0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.59	6.08	0.45	9.7e-9	Breast cancer;
UCEC	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-6.35	-0.46	2.59e-9	Inflammatory bowel disease;
UCEC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.61	-6.73	-0.49	3.59e-10	Cardiac Troponin-T levels;
UCEC	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg08459430	chr5:81571289	RPS23	-0.48	-4.61	-0.36	8.71e-6	Breast cancer;
UCEC	cis	rs4499344	0.696	rs10402929	chr19:33100245	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs4899292	0.868	rs6573877	chr14:69659996	A/G	cg10376476	chr14:69952003	FLJ44817	-0.35	-4.54	-0.35	1.16e-5	Neuroticism;
UCEC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.68	0.36	6.42e-6	Cognitive ability;
UCEC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg23795048	chr12:9217529	LOC144571	0.42	5.01	0.38	1.53e-6	Sjögren's syndrome;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.49	-0.47	1.21e-9	Pubertal anthropometrics;
UCEC	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.61	-6.92	-0.5	1.27e-10	Mean corpuscular volume;
UCEC	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg13092806	chr2:177043255	NA	0.95	9.53	0.62	4.74e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.67	4.69	0.36	6.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg07424592	chr7:64974309	NA	0.81	4.8	0.37	3.9e-6	Diabetic kidney disease;
UCEC	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11584989	chr19:19387371	SF4	0.58	6.67	0.48	4.78e-10	Bipolar disorder;
UCEC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.15e-5	Lung cancer;
UCEC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg06027949	chr8:82754900	SNX16	0.6	5.07	0.39	1.18e-6	Diastolic blood pressure;
UCEC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs8049040	0.586	rs16972663	chr16:71460564	C/T	cg08717414	chr16:71523259	ZNF19	-0.55	-5.21	-0.39	6.26e-7	Blood protein levels;
UCEC	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-0.51	-4.72	-0.36	5.38e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.53	5.85	0.43	3e-8	Life satisfaction;
UCEC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.57	5.84	0.43	3.26e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs883565	0.740	rs7624734	chr3:39108503	G/A	cg01426195	chr3:39028469	NA	-0.68	-8.51	-0.57	1.83e-14	Handedness;
UCEC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.66e-10	Motion sickness;
UCEC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg19318889	chr4:1322082	MAEA	0.43	4.91	0.38	2.41e-6	Obesity-related traits;
UCEC	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.16	0.64	1.05e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg16386425	chr10:429943	DIP2C	0.56	4.61	0.36	8.85e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.35	5.76	0.43	4.72e-8	Cancer;
UCEC	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.63	6.69	0.48	4.42e-10	Retinal vascular caliber;
UCEC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.64	-5.99	-0.44	1.53e-8	Aortic root size;
UCEC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.26	-0.4	4.93e-7	Headache;
UCEC	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.83	-0.37	3.38e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-1.12	-6.88	-0.49	1.64e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs4074536	0.614	rs4075008	chr1:116298064	C/A	cg21648376	chr1:116311395	CASQ2	-0.55	-5.34	-0.4	3.45e-7	QRS duration;
UCEC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.9	-0.67	1.24e-20	Headache;
UCEC	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.48	5.46	0.41	2e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.86	-9.83	-0.63	7.57e-18	Dental caries;
UCEC	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.63	6.29	0.46	3.38e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs477692	0.935	rs502076	chr10:131413155	C/A	cg05714579	chr10:131428358	MGMT	0.49	5.17	0.39	7.36e-7	Response to temozolomide;
UCEC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.61	6.74	0.49	3.43e-10	Resting heart rate;
UCEC	cis	rs13253111	1.000	rs62500888	chr8:28061823	A/G	cg26534493	chr8:28060551	NA	0.52	6.1	0.45	8.92e-9	Childhood body mass index;
UCEC	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.71	-9.21	-0.61	3.03e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.51	-4.68	-0.36	6.55e-6	Bipolar disorder;
UCEC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.01	0.38	1.53e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.4	5.01	0.38	1.55e-6	Insulin-like growth factors;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg07404485	chr7:94953653	PON1	-0.47	-4.73	-0.36	5.19e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2729354	0.768	rs2584856	chr11:57267312	C/A	cg24343310	chr11:57249947	NA	0.42	4.74	0.36	5.01e-6	Blood protein levels;
UCEC	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg08890418	chr1:21044141	KIF17	0.66	7.29	0.52	1.75e-11	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.55	-6.02	-0.44	1.35e-8	Parkinson's disease;
UCEC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.06e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg13844804	chr7:814759	HEATR2	0.68	5.01	0.38	1.55e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.55	5.52	0.41	1.48e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.01	-11.03	-0.67	5.33e-21	Schizophrenia;
UCEC	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.7	5.68	0.42	7.09e-8	Type 2 diabetes;
UCEC	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.51	-4.68	-0.36	6.54e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.52	0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg14784868	chr12:69753453	YEATS4	0.53	4.55	0.35	1.11e-5	Response to diuretic therapy;
UCEC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg23307798	chr14:103986281	CKB	0.65	8.0	0.55	3.42e-13	Body mass index;
UCEC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.54	-5.53	-0.41	1.44e-7	Prostate cancer;
UCEC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.47	4.96	0.38	1.93e-6	Corneal astigmatism;
UCEC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg11569703	chr11:65557185	OVOL1	0.54	7.1	0.51	5.05e-11	Acne (severe);
UCEC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.62	-0.48	6.43e-10	Schizophrenia;
UCEC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	5.81	0.43	3.67e-8	Initial pursuit acceleration;
UCEC	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.33	-5.64	-0.42	8.36e-8	Mean corpuscular volume;
UCEC	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.63	4.95	0.38	2.04e-6	Carotid intima media thickness;
UCEC	cis	rs742614	0.533	rs6120395	chr20:32451693	A/G	cg06304546	chr20:32448765	NA	-0.75	-8.35	-0.57	4.55e-14	Stearic acid (18:0) levels;
UCEC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.53	5.11	0.39	9.98e-7	Height;
UCEC	cis	rs12980942	0.872	rs12976536	chr19:41799886	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.84	6.83	0.49	2.1e-10	Coronary artery disease;
UCEC	cis	rs9467773	0.967	rs10223792	chr6:26579616	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.51	4.51	0.35	1.33e-5	Urate levels;
UCEC	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.89	-0.37	2.67e-6	Bipolar disorder;
UCEC	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.74	-5.02	-0.38	1.49e-6	Mosquito bite size;
UCEC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.5	5.38	0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	5.15	0.39	8.36e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.53	-0.35	1.23e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10186876	0.728	rs13384238	chr2:44155986	A/G	cg10317145	chr2:44065680	ABCG8;ABCG5	-0.35	-4.84	-0.37	3.29e-6	Hand grip strength;
UCEC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.19e-10	Body mass index;
UCEC	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.11e-7	Body mass index;
UCEC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.68	5.16	0.39	7.81e-7	Mean platelet volume;
UCEC	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-5.43	-0.41	2.24e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.76	-6.82	-0.49	2.17e-10	Inflammatory bowel disease;
UCEC	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.67	7.16	0.51	3.5e-11	Vitamin D levels;
UCEC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	4.88	0.37	2.71e-6	Breast cancer;
UCEC	cis	rs6717918	0.509	rs3116173	chr2:233006046	C/T	cg20569070	chr2:232597279	PDE6D	0.42	4.76	0.37	4.61e-6	Height;
UCEC	cis	rs7072216	0.687	rs10786416	chr10:100153600	G/T	cg19567339	chr10:100142640	NA	0.58	7.38	0.52	1.07e-11	Metabolite levels;
UCEC	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.85	-0.43	3.09e-8	Depression;
UCEC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.56	5.4	0.41	2.62e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.68	-6.05	-0.45	1.15e-8	Aortic root size;
UCEC	cis	rs77861329	0.748	rs12629791	chr3:52175783	C/T	cg08692210	chr3:52188851	WDR51A	0.63	5.79	0.43	4.15e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.61	-7.1	-0.51	4.98e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.65	-0.36	7.37e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.68	9.25	0.61	2.48e-16	Systolic blood pressure;
UCEC	cis	rs7246967	0.544	rs420861	chr19:23005904	G/T	cg08271804	chr19:22816896	ZNF492	0.57	5.08	0.39	1.15e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.86	9.79	0.63	9.91e-18	Blood protein levels;
UCEC	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.5	-5.43	-0.41	2.23e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.47	-5.46	-0.41	1.99e-7	Aortic root size;
UCEC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.44	-4.6	-0.35	9.18e-6	Platelet distribution width;
UCEC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.41	5.06	0.39	1.23e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.82	5.74	0.43	5.15e-8	Alzheimer's disease (late onset);
UCEC	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg17294928	chr15:75287854	SCAMP5	0.47	4.8	0.37	3.83e-6	Caffeine consumption;
UCEC	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	4.8	0.37	3.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg23625390	chr15:77176239	SCAPER	0.47	4.53	0.35	1.21e-5	Blood metabolite levels;
UCEC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.84	-9.73	-0.63	1.38e-17	Coronary artery disease;
UCEC	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-6.79	-0.49	2.64e-10	Obesity-related traits;
UCEC	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.47	-5.33	-0.4	3.55e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.57	-5.57	-0.42	1.15e-7	Coronary artery disease;
UCEC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.56	-5.06	-0.38	1.26e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg20399509	chr21:47717575	C21orf57	-0.44	-4.74	-0.36	5.07e-6	Testicular germ cell tumor;
UCEC	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.47	-5.33	-0.4	3.64e-7	White matter hyperintensity burden;
UCEC	cis	rs7772486	0.875	rs2777482	chr6:146320341	A/C	cg23711669	chr6:146136114	FBXO30	0.61	6.31	0.46	3.17e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.47	-5.81	-0.43	3.76e-8	Neutrophil percentage of white cells;
UCEC	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	0.69	8.88	0.59	2.13e-15	Gut microbiome composition (winter);
UCEC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.41	-0.41	2.51e-7	Adiposity;
UCEC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg01112020	chr2:239008986	ESPNL	-0.36	-4.75	-0.36	4.8e-6	Prostate cancer;
UCEC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.65	0.36	7.37e-6	Rheumatoid arthritis;
UCEC	cis	rs61776719	0.840	rs35267671	chr1:38397369	C/T	cg04673462	chr1:38461896	NA	0.58	6.0	0.44	1.46e-8	Coronary artery disease;
UCEC	cis	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg14470869	chr13:79233116	RNF219	0.53	4.87	0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs7520050	0.966	rs11589562	chr1:46466721	C/T	cg15837086	chr1:46506065	PIK3R3	0.42	4.98	0.38	1.75e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg13683864	chr3:40499215	RPL14	0.71	8.66	0.58	7.97e-15	Renal cell carcinoma;
UCEC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.46	-5.56	-0.42	1.23e-7	Mortality in heart failure;
UCEC	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-5.22	-0.4	6.01e-7	Kawasaki disease;
UCEC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs1832871	0.521	rs878585	chr6:158815897	C/T	cg07215822	chr6:158701037	NA	-0.55	-4.72	-0.36	5.46e-6	Height;
UCEC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.51	5.93	0.44	2.1e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs11958404	0.932	rs6865373	chr5:157436728	A/G	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	6.08	0.45	9.9e-9	Total body bone mineral density;
UCEC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.91	12.28	0.71	2.62e-24	Metabolic syndrome;
UCEC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.62	-7.25	-0.51	2.24e-11	Hip circumference;
UCEC	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18854424	chr1:2615690	NA	0.36	5.25	0.4	5.3e-7	Ulcerative colitis;
UCEC	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.72	-8.14	-0.56	1.55e-13	Breast cancer;
UCEC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg00343986	chr7:65444356	GUSB	-0.52	-4.93	-0.38	2.21e-6	Aortic root size;
UCEC	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	7.52	0.53	5.05e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	6.13	0.45	7.64e-9	Personality dimensions;
UCEC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.49	-5.99	-0.44	1.52e-8	Total body bone mineral density;
UCEC	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.71	-0.48	3.95e-10	Caudate activity during reward;
UCEC	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg01851573	chr8:8652454	MFHAS1	0.39	4.84	0.37	3.25e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.74	-7.13	-0.51	4.16e-11	Initial pursuit acceleration;
UCEC	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.63	-6.08	-0.45	9.66e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	6.07	0.45	1.05e-8	Prudent dietary pattern;
UCEC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.68	-7.75	-0.54	1.39e-12	Prostate cancer;
UCEC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.7	0.36	5.97e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg13525197	chr6:28411240	ZSCAN23	0.54	6.16	0.45	6.74e-9	Cardiac Troponin-T levels;
UCEC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.11	17.67	0.82	3.47e-38	IgG glycosylation;
UCEC	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-0.58	-7.47	-0.52	6.53e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.65	-0.36	7.39e-6	Response to antipsychotic treatment;
UCEC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	0.87	10.1	0.64	1.52e-18	Breast cancer;
UCEC	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.55	-5.34	-0.4	3.52e-7	Post bronchodilator FEV1;
UCEC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg04310649	chr10:35416472	CREM	-0.48	-4.85	-0.37	3.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.73	-7.88	-0.55	6.63e-13	Morning vs. evening chronotype;
UCEC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.62	6.15	0.45	7.06e-9	Lymphocyte counts;
UCEC	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-4.57	-0.35	1.03e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.38	-0.41	2.82e-7	Breast cancer;
UCEC	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	7.88	0.55	6.56e-13	Alzheimer's disease;
UCEC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.66	-7.3	-0.52	1.66e-11	Menarche (age at onset);
UCEC	cis	rs7607369	0.536	rs12623740	chr2:219665715	T/A	cg02176678	chr2:219576539	TTLL4	-0.5	-4.95	-0.38	2.05e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.51	2.57e-11	Coronary artery disease;
UCEC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.83	0.37	3.46e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4662945	0.688	rs12993231	chr2:130206377	A/G	cg05962382	chr2:130345044	NA	-0.46	-5.27	-0.4	4.67e-7	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.48	6.57	0.48	8.26e-10	Eye color traits;
UCEC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.69	7.31	0.52	1.55e-11	Blood metabolite levels;
UCEC	cis	rs6686929	1.000	rs6686929	chr1:18244707	A/G	cg03861428	chr1:17380702	SDHB	-0.4	-4.51	-0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.38	0.76	8e-30	Height;
UCEC	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.64	-6.64	-0.48	5.69e-10	Waist circumference;Body mass index;
UCEC	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.51	-4.99	-0.38	1.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.47	-4.99	-0.38	1.68e-6	Menopause (age at onset);
UCEC	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.4	4.92	0.38	2.27e-6	Blood metabolite levels;
UCEC	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg17259809	chr10:104614391	C10orf32	-0.71	-4.67	-0.36	6.62e-6	Arsenic metabolism;
UCEC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.74	0.43	5.2e-8	Breast cancer;
UCEC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.64	-0.42	8.43e-8	Initial pursuit acceleration;
UCEC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs3750082	0.889	rs12154586	chr7:32923371	T/C	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.5	4.6	0.35	8.9e-6	Alcohol dependence;
UCEC	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.53	4.53	0.35	1.2e-5	Neutrophil percentage of white cells;
UCEC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.53	-5.36	-0.4	3.15e-7	Aortic root size;
UCEC	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.01e-5	Type 2 diabetes;
UCEC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.4	-0.41	2.57e-7	Initial pursuit acceleration;
UCEC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs4363385	0.782	rs310126	chr1:153019416	A/C	cg02907556	chr1:153902501	DENND4B	-0.35	-4.58	-0.35	9.75e-6	Inflammatory skin disease;
UCEC	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg11520003	chr13:113540631	ATP11A	-0.48	-4.61	-0.36	8.65e-6	Interstitial lung disease;
UCEC	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.66	-6.05	-0.45	1.17e-8	Prostate cancer;
UCEC	cis	rs16939046	1.000	rs72656143	chr8:76080190	A/C	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.25	0.4	5.27e-7	IgG glycosylation;
UCEC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.46	-5.1	-0.39	1.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	4.69	0.36	6.12e-6	Eosinophil percentage of white cells;
UCEC	cis	rs240764	0.578	rs62422070	chr6:101260827	T/G	cg09795085	chr6:101329169	ASCC3	0.52	4.84	0.37	3.3e-6	Neuroticism;
UCEC	cis	rs7095607	0.630	rs7069569	chr10:69955140	T/A	cg18986048	chr10:69913749	MYPN	0.52	5.68	0.42	6.97e-8	Lung function (FVC);
UCEC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.78	6.96	0.5	1.04e-10	Initial pursuit acceleration;
UCEC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.9	7.01	0.5	8.01e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg17325771	chr7:75508891	RHBDD2	-0.47	-5.52	-0.41	1.46e-7	Eotaxin levels;
UCEC	cis	rs1519814	0.956	rs6469900	chr8:121117378	C/T	cg22335954	chr8:121166405	COL14A1	-0.68	-5.57	-0.42	1.17e-7	Breast cancer;
UCEC	cis	rs7246967	0.673	rs4933026	chr19:22874492	A/T	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.77	-7.45	-0.52	7.47e-12	Cognitive function;
UCEC	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg05991184	chr2:219186017	PNKD	-0.54	-5.94	-0.44	1.97e-8	Colorectal cancer;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg24568646	chr21:30446238	CCT8	0.66	6.77	0.49	2.93e-10	Triglyceride levels;
UCEC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.65	6.72	0.48	3.65e-10	Body mass index;
UCEC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.11	-0.39	9.76e-7	Colorectal cancer;
UCEC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.84	8.92	0.59	1.69e-15	Parkinson's disease;
UCEC	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.78	8.57	0.58	1.28e-14	Eosinophil percentage of white cells;
UCEC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.07	0.45	1.02e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg03678062	chr6:149772716	ZC3H12D	0.48	5.81	0.43	3.79e-8	Dupuytren's disease;
UCEC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.58	5.34	0.4	3.4e-7	Lung cancer;
UCEC	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.44	5.12	0.39	9.4e-7	Obesity;
UCEC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.87	9.63	0.62	2.63e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.59	5.81	0.43	3.72e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg05962950	chr11:130786565	SNX19	0.57	5.95	0.44	1.85e-8	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Morning vs. evening chronotype;
UCEC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.63	-4.84	-0.37	3.3e-6	Type 2 diabetes;
UCEC	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.68	0.36	6.33e-6	Alzheimer's disease;
UCEC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg17077180	chr1:38461687	NA	0.63	6.03	0.45	1.24e-8	Coronary artery disease;
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	4.58	0.35	1e-5	Prudent dietary pattern;
UCEC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs377070	0.966	rs309419	chr4:123624001	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.6	5.14	0.39	8.8e-7	Mosquito bite size;
UCEC	cis	rs17102423	0.573	rs7144259	chr14:65537559	T/A	cg16583315	chr14:65563665	MAX	-0.49	-5.2	-0.39	6.66e-7	Obesity-related traits;
UCEC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.59	7.05	0.5	6.3e-11	Schizophrenia;
UCEC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.73	7.32	0.52	1.5e-11	Multiple myeloma (IgH translocation);
UCEC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg23791538	chr6:167370224	RNASET2	0.44	4.67	0.36	6.71e-6	Primary biliary cholangitis;
UCEC	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.54	-5.61	-0.42	9.57e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.54	0.42	1.34e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg07501729	chr16:846077	CHTF18	0.61	6.25	0.46	4.17e-9	Mean corpuscular volume;
UCEC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg24069376	chr3:38537580	EXOG	0.42	5.07	0.39	1.18e-6	Electrocardiographic conduction measures;
UCEC	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.82	-9.66	-0.62	2.12e-17	Facial morphology (factor 19);
UCEC	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.54	5.78	0.43	4.35e-8	Retinal vascular caliber;
UCEC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.69	-6.91	-0.5	1.38e-10	Blood metabolite levels;
UCEC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg12850546	chr22:42539477	CYP2D7P1	0.46	5.01	0.38	1.52e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.09	-12.76	-0.72	1.44e-25	Schizophrenia;
UCEC	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.39	-4.91	-0.38	2.44e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-7.09	-0.5	5.36e-11	Total cholesterol levels;
UCEC	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6684428	0.536	rs6588591	chr1:56402956	A/G	cg11651538	chr1:56320950	NA	-0.47	-4.73	-0.36	5.21e-6	Airflow obstruction;
UCEC	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7246967	0.932	rs34373479	chr19:23043862	A/G	cg08271804	chr19:22816896	ZNF492	0.58	5.45	0.41	2.05e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.7	8.17	0.56	1.32e-13	Menarche (age at onset);
UCEC	cis	rs4853036	1.000	rs1454499	chr2:70062939	T/C	cg02498382	chr2:70120550	SNRNP27	-0.53	-5.84	-0.43	3.28e-8	Colorectal or endometrial cancer;
UCEC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18932078	chr1:2524107	MMEL1	0.33	5.27	0.4	4.71e-7	Ulcerative colitis;
UCEC	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.97	-0.38	1.83e-6	Coronary artery disease;
UCEC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.59	5.68	0.42	7.11e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.85	-10.84	-0.67	1.77e-20	Height;
UCEC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.61	6.53	0.47	1.03e-9	Type 2 diabetes;
UCEC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.53	-0.42	1.39e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg20575277	chr15:90728569	SEMA4B	0.46	4.64	0.36	7.69e-6	Rheumatoid arthritis;
UCEC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.54	6.97	0.5	9.82e-11	Subjective well-being (multi-trait analysis);
UCEC	cis	rs10924970	0.934	rs4288584	chr1:235436631	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.81e-6	Asthma;
UCEC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.45	-6.43	-0.47	1.7e-9	Ulcerative colitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03399598	chr4:174091002	GALNT7	0.61	7.31	0.52	1.56e-11	Warfarin maintenance dose;
UCEC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.6	-6.85	-0.49	1.91e-10	Pubertal anthropometrics;
UCEC	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg01391022	chr12:122360665	WDR66	-0.38	-4.53	-0.35	1.2e-5	Mean corpuscular volume;
UCEC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg13695892	chr22:41940480	POLR3H	-0.69	-5.36	-0.4	3.21e-7	Vitiligo;
UCEC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.14	0.39	8.66e-7	Diabetic retinopathy;
UCEC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18252515	chr7:66147081	NA	0.51	5.28	0.4	4.66e-7	Aortic root size;
UCEC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg06784218	chr1:46089804	CCDC17	0.53	6.65	0.48	5.46e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg05660106	chr1:15850417	CASP9	0.99	11.32	0.68	9.48e-22	Systolic blood pressure;
UCEC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.04	-8.42	-0.57	3.05e-14	White matter hyperintensity burden;
UCEC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg06096015	chr1:231504339	EGLN1	-0.44	-4.77	-0.37	4.45e-6	Hemoglobin concentration;
UCEC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	7.7	0.54	1.85e-12	Chronic sinus infection;
UCEC	cis	rs228437	0.565	rs6569957	chr6:134939559	C/G	cg20986996	chr6:134210159	TCF21	0.38	4.51	0.35	1.33e-5	Melanoma;
UCEC	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg24562669	chr7:97807699	LMTK2	0.54	6.32	0.46	3.02e-9	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	19.57	0.85	8.95e-43	IgG glycosylation;
UCEC	cis	rs7246967	0.611	rs8104052	chr19:22857804	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg21782813	chr7:2030301	MAD1L1	0.62	7.15	0.51	3.7e-11	Bipolar disorder and schizophrenia;
UCEC	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27286337	chr10:134555280	INPP5A	0.62	5.47	0.41	1.91e-7	Migraine;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.59	-6.76	-0.49	2.95e-10	Longevity;Endometriosis;
UCEC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.27	-9.55	-0.62	4.2e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.67	7.72	0.54	1.67e-12	Prostate cancer;
UCEC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06223018	chr3:49557076	DAG1	0.32	4.61	0.36	8.66e-6	Parkinson's disease;
UCEC	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg10902566	chr4:727664	PCGF3	-0.57	-4.8	-0.37	3.84e-6	Systolic blood pressure;
UCEC	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.68	-8.14	-0.56	1.5700000000000001e-13	Prevalent atrial fibrillation;
UCEC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.8	8.4	0.57	3.5e-14	Diastolic blood pressure;
UCEC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg24562669	chr7:97807699	LMTK2	-0.49	-5.8	-0.43	4e-8	Breast cancer;
UCEC	cis	rs17600642	0.694	rs72814529	chr10:72444698	T/C	cg23422916	chr10:72218225	NA	-0.55	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.46	-5.37	-0.41	2.95e-7	Facial morphology (factor 20);
UCEC	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg04154034	chr17:28927549	LRRC37B2	0.81	4.86	0.37	2.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.73	0.43	5.4e-8	Prudent dietary pattern;
UCEC	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.58	-0.42	1.14e-7	Monocyte percentage of white cells;
UCEC	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.68	-5.6	-0.42	1.03e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	0.83	5.91	0.44	2.34e-8	Left atrial antero-posterior diameter;
UCEC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.25	-0.51	2.23e-11	Monocyte count;
UCEC	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	6.18	0.45	6.06e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.73	0.58	5.17e-15	Alzheimer's disease;
UCEC	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.77	8.83	0.59	2.84e-15	Brugada syndrome;
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.17e-14	Prudent dietary pattern;
UCEC	cis	rs7827290	0.686	rs13253108	chr8:142283565	A/G	cg17634588	chr8:141646421	EIF2C2	-0.62	-4.92	-0.38	2.3e-6	Bipolar disorder;
UCEC	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.47	-4.7	-0.36	5.93e-6	Longevity;
UCEC	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-4.81	-0.37	3.73e-6	Body mass index;
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg09120320	chr17:61926383	NA	0.43	4.61	0.36	8.85e-6	Prudent dietary pattern;
UCEC	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.67	-0.42	7.33e-8	Pancreatic cancer;
UCEC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.61	6.95	0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.56	-5.12	-0.39	9.23e-7	Metabolite levels;
UCEC	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.53	-5.91	-0.44	2.27e-8	IgG glycosylation;
UCEC	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.69	7.51	0.53	5.15e-12	IgG glycosylation;
UCEC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.53	0.47	1.03e-9	Cognitive test performance;
UCEC	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.73	8.54	0.58	1.52e-14	Testicular germ cell tumor;
UCEC	cis	rs11048434	0.932	rs12816518	chr12:9153132	G/A	cg23795048	chr12:9217529	LOC144571	0.49	5.56	0.42	1.26e-7	Sjögren's syndrome;
UCEC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.0	0.44	1.49e-8	Cognitive test performance;
UCEC	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.73	-7.85	-0.54	7.94e-13	Trans fatty acid levels;
UCEC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.05	-0.45	1.17e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg24562669	chr7:97807699	LMTK2	0.41	4.99	0.38	1.67e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.57	5.74	0.43	5.26e-8	Initial pursuit acceleration;
UCEC	trans	rs337161	0.719	rs337150	chr1:220941281	A/C	cg07378013	chr16:90088605	GAS8	0.63	6.8	0.49	2.43e-10	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.09	7.63	0.53	2.68e-12	Sexual dysfunction (female);
UCEC	cis	rs7607369	0.536	rs13033409	chr2:219666509	T/G	cg02176678	chr2:219576539	TTLL4	-0.57	-6.05	-0.45	1.15e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	1.02	11.49	0.69	3.25e-22	Cognitive function;
UCEC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg24562669	chr7:97807699	LMTK2	0.73	10.76	0.66	2.89e-20	Breast cancer;
UCEC	cis	rs4237845	0.611	rs4335583	chr12:58305111	T/C	cg02175503	chr12:58329896	NA	0.79	8.42	0.57	3.12e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs6460942	1.000	rs79659770	chr7:12326371	T/C	cg06484146	chr7:12443880	VWDE	-0.84	-5.84	-0.43	3.27e-8	Coronary artery disease;
UCEC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.61	-5.55	-0.42	1.3e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.64	-5.88	-0.44	2.6e-8	Menarche (age at onset);
UCEC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.57	-4.92	-0.38	2.29e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.72	6.67	0.48	4.89e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13063635	0.915	rs17764980	chr3:45939016	G/A	cg16320329	chr3:45981161	FYCO1	-0.82	-4.68	-0.36	6.38e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.13	0.56	1.6e-13	Alzheimer's disease;
UCEC	cis	rs2251301	0.891	rs11776159	chr8:11119886	G/A	cg10220992	chr8:11324327	FAM167A	-0.58	-4.54	-0.35	1.16e-5	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6749331	0.593	rs13425835	chr2:171450161	G/T	cg22070243	chr2:172378774	CYBRD1	0.47	4.76	0.37	4.53e-6	Obesity-related traits;
UCEC	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg17178900	chr1:205818956	PM20D1	0.54	6.46	0.47	1.41e-9	Menarche (age at onset);
UCEC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.63	5.32	0.4	3.86e-7	High light scatter reticulocyte count;
UCEC	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	10.61	0.66	6.98e-20	Primary sclerosing cholangitis;
UCEC	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.58	-4.99	-0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.65	-0.36	7.24e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg13298116	chr11:62369859	EML3;MTA2	-0.45	-5.39	-0.41	2.78e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	0.97	15.48	0.79	1.11e-32	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.49	4.77	0.37	4.44e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.41	-4.6	-0.35	8.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.14	14.21	0.76	2.25e-29	Cognitive function;
UCEC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg22974920	chr21:40686053	BRWD1	-0.52	-4.66	-0.36	6.99e-6	Cognitive function;
UCEC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.68	7.86	0.54	7.46e-13	Schizophrenia;
UCEC	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.79	10.09	0.64	1.66e-18	White blood cell count (basophil);
UCEC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.6	5.89	0.44	2.55e-8	Dental caries;
UCEC	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg06917450	chr1:38156652	C1orf109	-0.6	-5.64	-0.42	8.4e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg11632617	chr15:75315747	PPCDC	-0.62	-7.2	-0.51	2.96e-11	Blood trace element (Zn levels);
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg26794364	chr3:9691143	MTMR14	0.69	7.24	0.51	2.32e-11	Schizophrenia;
UCEC	cis	rs74542309	0.947	rs34054739	chr10:72550306	T/C	cg15763670	chr10:73473235	C10orf105;CDH23	-0.61	-4.74	-0.36	4.98e-6	Pursuit maintenance gain;
UCEC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.61	-7.14	-0.51	4e-11	Blood trace element (Zn levels);
UCEC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.12	-6.76	-0.49	2.95e-10	Breast cancer;
UCEC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.32	-4.51	-0.35	1.3e-5	Type 1 diabetes;
UCEC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg14008862	chr17:28927542	LRRC37B2	0.6	5.11	0.39	9.75e-7	Body mass index;
UCEC	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.18	0.39	7.05e-7	Hemoglobin concentration;
UCEC	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	5.72	0.43	5.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.7	-6.36	-0.46	2.42e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.68	7.73	0.54	1.53e-12	Menopause (age at onset);
UCEC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.07	0.39	1.21e-6	Diabetic retinopathy;
UCEC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.59	5.24	0.4	5.37e-7	Menarche (age at onset);
UCEC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18854424	chr1:2615690	NA	0.36	5.52	0.41	1.51e-7	Ulcerative colitis;
UCEC	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.79	6.55	0.48	8.96e-10	Schizophrenia;
UCEC	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg05874882	chr4:1763078	NA	-0.54	-5.6	-0.42	1.03e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-6.75	-0.49	3.26e-10	Personality dimensions;
UCEC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18252515	chr7:66147081	NA	0.52	5.12	0.39	9.53e-7	Aortic root size;
UCEC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.54	-5.36	-0.4	3.1e-7	Breast cancer;
UCEC	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	0.98	8.21	0.56	1.04e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.87	7.2	0.51	2.89e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs11760485	0.931	rs2057892	chr7:4399101	A/G	cg22450045	chr7:4839495	RADIL	-0.41	-4.79	-0.37	3.98e-6	Early childhood aggressive behavior;
UCEC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.53	0.35	1.23e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-4.62	-0.36	8.25e-6	Pulmonary function;
UCEC	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.63	-5.18	-0.39	7.07e-7	Huntington's disease progression;
UCEC	cis	rs12573330	1.000	rs12573330	chr10:98470341	A/C	cg10113589	chr10:98118853	OPALIN	0.47	4.57	0.35	1.01e-5	Monocyte percentage of white cells;
UCEC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.34	0.4	3.46e-7	Breast cancer;
UCEC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.48	5.61	0.42	9.76e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.73	5.85	0.43	3e-8	Menarche (age at onset);
UCEC	cis	rs10242455	0.867	rs2687141	chr7:99321479	T/C	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	0.81	8.6	0.58	1.12e-14	Parkinson's disease;
UCEC	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.71	-5.89	-0.44	2.52e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.75	0.36	4.83e-6	Personality dimensions;
UCEC	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.57	4.64	0.36	7.73e-6	Dental caries;
UCEC	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.97	7.52	0.53	4.89e-12	Primary sclerosing cholangitis;
UCEC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.54	4.72	0.36	5.56e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.81	-4.98	-0.38	1.79e-6	Putamen volume;
UCEC	cis	rs4499344	0.657	rs402862	chr19:33111102	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	5.34	0.4	3.53e-7	Mean platelet volume;
UCEC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.64	-5.12	-0.39	9.55e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2862064	1.000	rs1354163	chr5:156420703	C/T	cg12943317	chr5:156479607	HAVCR1	-0.89	-6.35	-0.46	2.51e-9	Platelet count;
UCEC	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.64	-6.5	-0.47	1.15e-9	Body mass index;
UCEC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.92	6.51	0.47	1.14e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7580658	0.521	rs35577992	chr2:127941324	C/T	cg16751203	chr2:127950803	CYP27C1	0.39	5.38	0.41	2.88e-7	Protein C levels;
UCEC	cis	rs295140	1.000	rs1431766	chr2:201191034	A/G	cg04283868	chr2:201171347	SPATS2L	0.52	5.18	0.39	7.29e-7	QT interval;
UCEC	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.45	-4.84	-0.37	3.25e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.46	4.72	0.36	5.39e-6	Schizophrenia;
UCEC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.48	5.86	0.43	2.97e-8	Anterior chamber depth;
UCEC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	6.16	0.45	6.53e-9	Bone mineral density;
UCEC	cis	rs756777	0.878	rs7040634	chr9:136665989	G/A	cg14069709	chr9:136671979	VAV2	-0.42	-5.05	-0.38	1.29e-6	IgG glycosylation;
UCEC	cis	rs7088591	0.867	rs11819308	chr10:59788876	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs3015497	0.752	rs6572682	chr14:51144800	A/T	cg04730355	chr14:51134070	SAV1	-0.48	-4.95	-0.38	1.98e-6	Mean platelet volume;
UCEC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	0.97	6.52	0.47	1.07e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.03	-8.47	-0.57	2.35e-14	Exhaled nitric oxide output;
UCEC	cis	rs7848679	0.935	rs12339894	chr9:107747145	C/T	cg00556719	chr9:108457484	TMEM38B	0.69	4.58	0.35	9.77e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
UCEC	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.57	-5.18	-0.39	7.13e-7	Hypospadias;
UCEC	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg16989719	chr2:238392110	NA	-0.41	-5.7	-0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.4	4.9	0.37	2.53e-6	Height;
UCEC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.23	0.51	2.5e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg15147215	chr3:52552868	STAB1	-0.42	-4.58	-0.35	1e-5	Electroencephalogram traits;
UCEC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.78	6.49	0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.47	5.39	0.41	2.74e-7	White matter hyperintensity burden;
UCEC	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.63	6.29	0.46	3.52e-9	Colorectal cancer;
UCEC	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.21	-0.4	6.15e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10924970	0.649	rs2185019	chr1:235402133	G/A	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.59	-5.33	-0.4	3.67e-7	Gut microbiome composition (summer);
UCEC	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg12566780	chr7:92157604	PEX1;C7orf64	0.46	4.78	0.37	4.25e-6	Breast cancer;
UCEC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.53	-5.74	-0.43	5.23e-8	Prostate cancer;
UCEC	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-0.83	-7.25	-0.51	2.24e-11	Post bronchodilator FEV1;
UCEC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.52	-5.78	-0.43	4.38e-8	Diastolic blood pressure;
UCEC	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.57	5.43	0.41	2.25e-7	Birth weight;
UCEC	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.79	4.59	0.35	9.46e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18099408	chr3:52552593	STAB1	0.42	4.84	0.37	3.22e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-4.53	-0.35	1.22e-5	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.61	5.38	0.41	2.88e-7	Alcohol dependence;
UCEC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.91	12.13	0.71	6.59e-24	Metabolic syndrome;
UCEC	cis	rs12644436	0.896	rs13144385	chr4:88785481	G/T	cg27179352	chr4:88029472	AFF1	0.41	4.51	0.35	1.32e-5	HIV-1 viral setpoint;
UCEC	cis	rs78487399	0.908	rs61754256	chr2:43805739	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.9	-0.37	2.52e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-5.35	-0.4	3.25e-7	Schizophrenia;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.27	-0.46	3.8e-9	Platelet count;
UCEC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.68	7.43	0.52	8.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7709377	0.546	rs1090077	chr5:115582050	A/G	cg23108291	chr5:115420582	COMMD10	0.47	4.62	0.36	8.23e-6	Metabolite levels  (X-11787);
UCEC	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.47	5.01	0.38	1.54e-6	Autism;
UCEC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.46	-4.66	-0.36	7.05e-6	Dental caries;
UCEC	cis	rs7709377	0.524	rs11750725	chr5:115465034	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18854424	chr1:2615690	NA	-0.36	-5.36	-0.4	3.13e-7	Ulcerative colitis;
UCEC	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.84	8.89	0.59	2e-15	Mean corpuscular hemoglobin;
UCEC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00684032	chr4:1343700	KIAA1530	-0.43	-4.66	-0.36	6.97e-6	Obesity-related traits;
UCEC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.48	-0.41	1.83e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.08	-0.71	8.95e-24	Primary sclerosing cholangitis;
UCEC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.66	6.82	0.49	2.17e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.88	12.98	0.73	3.7e-26	Leprosy;
UCEC	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.68	-6.37	-0.47	2.29e-9	Blood pressure (smoking interaction);
UCEC	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-0.72	-4.9	-0.37	2.54e-6	Blood protein levels;
UCEC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-5.56	-0.42	1.25e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.31	0.4	3.88e-7	Ileal carcinoids;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg07836142	chr6:28411423	ZSCAN23	0.57	6.29	0.46	3.4e-9	Pubertal anthropometrics;
UCEC	cis	rs2904967	0.929	rs10750761	chr11:65002091	A/C	cg01630869	chr11:65082120	CDC42EP2	-0.5	-4.7	-0.36	5.86e-6	Mean corpuscular volume;
UCEC	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.68	-6.25	-0.46	4.25e-9	Prostate cancer;
UCEC	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.41	-0.41	2.54e-7	Aortic root size;
UCEC	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.9	-0.49	1.41e-10	Response to antipsychotic treatment;
UCEC	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.63	-7.47	-0.52	6.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.71	0.36	5.6e-6	Prostate-specific antigen levels;
UCEC	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07741184	chr6:167504864	NA	-0.32	-4.51	-0.35	1.3e-5	Primary biliary cholangitis;
UCEC	cis	rs6688613	0.840	rs6699294	chr1:166955174	G/A	cg07049167	chr1:166818506	POGK	0.53	5.33	0.4	3.58e-7	Refractive astigmatism;
UCEC	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg04553112	chr3:125709451	NA	-0.65	-4.74	-0.36	4.9100000000000004e-06	Blood pressure (smoking interaction);
UCEC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	0.92	9.2	0.6	3.27e-16	Heart rate;
UCEC	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg13575925	chr12:9217583	LOC144571	0.39	4.69	0.36	6.12e-6	Sjögren's syndrome;
UCEC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.72	6.23	0.46	4.61e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4389656	0.857	rs274703	chr5:6728372	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg01485075	chr19:22817371	ZNF492	0.42	4.73	0.36	5.26e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.29	8.08	0.55	2.12e-13	Diabetic kidney disease;
UCEC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.71	7.51	0.53	5.38e-12	Lymphocyte counts;
UCEC	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.68	6.95	0.5	1.11e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.932	rs62120772	chr19:23037151	G/C	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.5	-5.45	-0.41	2.12e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.72	-0.36	5.56e-6	Response to antipsychotic treatment;
UCEC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg01262667	chr19:19385393	TM6SF2	-0.51	-7.13	-0.51	4.26e-11	Tonsillectomy;
UCEC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.5	5.21	0.39	6.39e-7	Aortic root size;
UCEC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.41	-4.57	-0.35	1.03e-5	Prostate cancer;
UCEC	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.67	7.02	0.5	7.41e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.58	5.21	0.39	6.33e-7	Corneal astigmatism;
UCEC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg24562669	chr7:97807699	LMTK2	0.61	8.15	0.56	1.46e-13	Breast cancer;
UCEC	cis	rs60311166	1.000	rs4532127	chr3:52727736	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.76	4.8	0.37	3.92e-6	CTACK levels;
UCEC	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.4	4.87	0.37	2.8e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg21856205	chr7:94953877	PON1	-0.56	-4.94	-0.38	2.07e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	0.72	7.36	0.52	1.24e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg12463550	chr7:65579703	CRCP	0.5	4.62	0.36	8.26e-6	Aortic root size;
UCEC	cis	rs11118844	0.793	rs11118854	chr1:221943678	T/C	cg04222084	chr1:221915650	DUSP10	-0.67	-6.06	-0.45	1.11e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.63	-5.61	-0.42	9.85e-8	Crohn's disease;
UCEC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.42	-5.04	-0.38	1.32e-6	Diastolic blood pressure;
UCEC	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.25	-7.15	-0.51	3.67e-11	Schizophrenia;
UCEC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	0.94	10.01	0.64	2.61e-18	Cognitive function;
UCEC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-10.35	-0.65	3.44e-19	Chronic sinus infection;
UCEC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.66	6.02	0.44	1.34e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs2806864	1.000	rs2806863	chr1:117469513	A/G	cg19765820	chr1:116518738	SLC22A15	-0.6	-4.52	-0.35	1.25e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-0.97	-7.23	-0.51	2.41e-11	Body mass index;
UCEC	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.49	5.27	0.4	4.79e-7	Total body bone mineral density;
UCEC	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.6	5.42	0.41	2.43e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
UCEC	cis	rs7246967	0.551	rs8102812	chr19:22879243	A/T	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.5	-4.78	-0.37	4.27e-6	Diabetic retinopathy;
UCEC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.25	-0.46	4.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.73	-0.43	5.54e-8	Cardiac Troponin-T levels;
UCEC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.44	-0.74	2.27e-27	Height;
UCEC	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.75	-0.43	4.99e-8	Alcohol dependence;
UCEC	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.45	14.39	0.76	7.31e-30	Atopic dermatitis;
UCEC	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg11871910	chr12:69753446	YEATS4	0.66	6.7	0.48	4.24e-10	Blood protein levels;
UCEC	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg15997130	chr1:24165203	NA	0.65	6.92	0.5	1.3100000000000001e-10	Immature fraction of reticulocytes;
UCEC	cis	rs2221651	0.588	rs17829411	chr6:131016898	A/T	cg16963127	chr6:131336044	EPB41L2	-0.53	-4.61	-0.36	8.74e-6	Monocyte percentage of white cells;
UCEC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.63	6.59	0.48	7.22e-10	Menopause (age at onset);
UCEC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.71	7.16	0.51	3.6e-11	Aortic root size;
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.34	-0.46	2.7e-9	Pubertal anthropometrics;
UCEC	cis	rs13287066	0.967	rs10761224	chr9:96166579	A/G	cg14181777	chr9:95479785	BICD2	0.42	4.79	0.37	3.95e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.49	-0.47	1.25e-9	Depression;
UCEC	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.56	-6.17	-0.45	6.39e-9	Neuroticism;
UCEC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg02160872	chr5:212506	CCDC127	-0.58	-5.18	-0.39	7.2e-7	Asthma (childhood onset);
UCEC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.55	0.69	2.25e-22	Prudent dietary pattern;
UCEC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.57	0.42	1.16e-7	Lung cancer in ever smokers;
UCEC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.56	-8.25	-0.56	8.12e-14	Sense of smell;
UCEC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.44	-5.33	-0.4	3.55e-7	Dupuytren's disease;
UCEC	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	6.97	0.5	9.97e-11	Caffeine consumption;
UCEC	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-4.59	-0.35	9.31e-6	Response to antipsychotic treatment;
UCEC	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.5	4.79	0.37	3.97e-6	Intelligence;Intelligence (multi-trait analysis);
UCEC	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.71	7.25	0.51	2.16e-11	Itch intensity from mosquito bite;
UCEC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg19743168	chr1:23544995	NA	0.44	6.2	0.46	5.39e-9	Height;
UCEC	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	6.09	0.45	9.56e-9	HDL cholesterol;
UCEC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	5.47	0.41	1.9e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.1	0.51	4.82e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-7.03	-0.5	7.23e-11	Morning vs. evening chronotype;
UCEC	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.66	-6.14	-0.45	7.3e-9	Lymphocyte counts;
UCEC	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg15133208	chr4:90757351	SNCA	0.38	5.18	0.39	7.12e-7	Dementia with Lewy bodies;
UCEC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.79	-0.37	4.05e-6	Breast cancer;
UCEC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.43	4.75	0.36	4.79e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs9467773	1.000	rs9467799	chr6:26578364	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.52	-5.3	-0.4	4.17e-7	Hepatocellular carcinoma;
UCEC	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03576123	chr11:487126	PTDSS2	-0.99	-6.23	-0.46	4.61e-9	Body mass index;
UCEC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.4	5.16	0.39	7.74e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	0.43	4.52	0.35	1.27e-5	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.5	-6.93	-0.5	1.2e-10	Total body bone mineral density;
UCEC	cis	rs7246967	0.866	rs35105042	chr19:23048352	A/C	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.53	-6.1	-0.45	8.94e-9	Educational attainment;
UCEC	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-0.67	-5.35	-0.4	3.24e-7	Morning vs. evening chronotype;
UCEC	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.66	6.67	0.48	4.84e-10	Body mass index;
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.69	7.91	0.55	5.59e-13	Developmental language disorder (linguistic errors);
UCEC	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	4.95	0.38	2.05e-6	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.77	-8.25	-0.56	8.27e-14	Menarche (age at onset);
UCEC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	0.92	12.81	0.73	1.07e-25	Homoarginine levels;
UCEC	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	0.95	4.86	0.37	2.95e-6	Diabetic retinopathy;
UCEC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.71	-5.66	-0.42	7.58e-8	Birth weight;
UCEC	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg08458637	chr1:231747906	TSNAX-DISC1	0.37	4.52	0.35	1.25e-5	Neuranatomic and neurocognitive phenotypes;
UCEC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.72	0.48	3.78e-10	Aortic root size;
UCEC	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.62	5.45	0.41	2.07e-7	Uric acid levels;
UCEC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg10503236	chr1:231470652	EXOC8	-0.45	-5.18	-0.39	7.35e-7	Hemoglobin concentration;
UCEC	cis	rs8074751	0.570	rs4791150	chr17:63631310	C/T	cg04531363	chr17:63634484	CCDC46	-0.42	-4.8	-0.37	3.83e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs3015497	0.789	rs2934688	chr14:51112360	G/A	cg04730355	chr14:51134070	SAV1	-0.54	-5.5	-0.41	1.64e-7	Mean platelet volume;
UCEC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.49	6.67	0.48	4.88e-10	Total body bone mineral density;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg14795047	chr12:38710433	ALG10B	-0.73	-6.69	-0.48	4.36e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.39	5.85	0.43	3.06e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.67	7.96	0.55	4.17e-13	Testicular germ cell tumor;
UCEC	cis	rs2892463	0.757	rs4769775	chr13:30361071	C/T	cg18356743	chr13:30408050	UBL3	-0.41	-4.51	-0.35	1.33e-5	Non-word repetition;
UCEC	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.53	-5.95	-0.44	1.85e-8	Retinal vascular caliber;
UCEC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.81	9.71	0.63	1.55e-17	Mortality in heart failure;
UCEC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.16	0.45	6.65e-9	Menarche (age at onset);
UCEC	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.5	4.76	0.37	4.5e-6	Menopause (age at onset);
UCEC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.53	4.95	0.38	1.98e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.67	-7.54	-0.53	4.37e-12	Resting heart rate;
UCEC	cis	rs9942541	1.000	rs9942541	chr6:39124682	C/T	cg01985396	chr6:39760833	DAAM2	-0.76	-4.79	-0.37	4.11e-6	Social communication problems;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.51	-0.35	1.3e-5	Cardiac Troponin-T levels;
UCEC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-6.96	-0.5	1.02e-10	Sudden cardiac arrest;
UCEC	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.57	5.25	0.4	5.22e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.62	6.72	0.49	3.64e-10	Neuroticism;
UCEC	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.46	-4.82	-0.37	3.6e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-9.41	-0.61	9.56e-17	Coffee consumption (cups per day);
UCEC	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.49	-4.8	-0.37	3.87e-6	Primary biliary cholangitis;
UCEC	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg27373749	chr11:63775612	MACROD1	0.45	5.11	0.39	1e-6	Pulse pressure;
UCEC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.9100000000000004e-06	Breast cancer;
UCEC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-0.97	-14.47	-0.77	4.68e-30	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.45	-6.29	-0.46	3.45e-9	Eye color traits;
UCEC	cis	rs7070678	0.662	rs35517756	chr10:29796598	A/G	cg07724896	chr10:29780678	SVIL	-0.57	-5.06	-0.39	1.24e-6	Platelet thrombus formation;
UCEC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	4.65	0.36	7.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9309473	0.519	rs2421667	chr2:73832459	T/C	cg20560298	chr2:73613845	ALMS1	0.52	5.08	0.39	1.14e-6	Metabolite levels;
UCEC	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.16	0.39	7.7e-7	IgG glycosylation;
UCEC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.41	0.41	2.52e-7	Cognitive function;
UCEC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.9	6.76	0.49	3e-10	Body mass index;
UCEC	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.46	4.79	0.37	3.95e-6	Blood metabolite levels;
UCEC	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.07	-0.45	1.04e-8	Bipolar disorder;
UCEC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.47	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg04756594	chr16:24857601	SLC5A11	0.45	4.98	0.38	1.76e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.76	8.06	0.55	2.38e-13	Eosinophil percentage of white cells;
UCEC	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.84	9.88	0.63	5.57e-18	Adiposity;
UCEC	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.38	-4.98	-0.38	1.74e-6	Total body bone mineral density;
UCEC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.41	-4.6	-0.35	9.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.56	5.13	0.39	9.15e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.61	7.34	0.52	1.33e-11	Gut microbiome composition (winter);
UCEC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-4.8	-0.37	3.82e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.57	6.69	0.48	4.38e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg20119798	chr7:94954144	PON1	-0.52	-4.62	-0.36	8.39e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.88	0.37	2.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.53	-0.41	1.45e-7	Hemoglobin concentration;
UCEC	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-0.84	-9.58	-0.62	3.39e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.54	5.02	0.38	1.49e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.23	-0.4	5.64e-7	Hemoglobin concentration;
UCEC	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg18436246	chr17:1640651	WDR81	0.47	4.85	0.37	3.17e-6	Serum albumin level;
UCEC	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-6.6	-0.48	7.17e-10	Morning vs. evening chronotype;
UCEC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	6.21	0.46	5.18e-9	Platelet count;
UCEC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-7.09	-0.5	5.26e-11	Initial pursuit acceleration;
UCEC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.51	5.38	0.41	2.81e-7	Pulse pressure;
UCEC	cis	rs17718580	0.536	rs56208926	chr14:51045042	C/T	cg04730355	chr14:51134070	SAV1	0.8	7.82	0.54	9.34e-13	Cognitive performance;
UCEC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg18279126	chr7:2041391	MAD1L1	-0.39	-4.74	-0.36	4.99e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7766436	0.813	rs7773580	chr6:22587114	C/T	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.74	0.63	1.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg04154034	chr17:28927549	LRRC37B2	0.76	5.35	0.4	3.27e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.81	-6.09	-0.45	9.35e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.56	-6.37	-0.46	2.31e-9	Type 2 diabetes;
UCEC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.58	5.3	0.4	4.19e-7	Corneal astigmatism;
UCEC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg05863683	chr7:1912471	MAD1L1	0.41	4.54	0.35	1.18e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs6426514	1.000	rs6426514	chr1:228880115	C/T	cg06637001	chr1:228463634	OBSCN	-0.76	-4.73	-0.36	5.13e-6	Type 2 diabetes;
UCEC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.72	8.49	0.57	2.12e-14	Prudent dietary pattern;
UCEC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	7.9	0.55	6.1e-13	Prudent dietary pattern;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.75	-8.93	-0.59	1.61e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.73	0.36	5.14e-6	Personality dimensions;
UCEC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.83	8.8	0.59	3.49e-15	Blood protein levels;
UCEC	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.32	5.03	0.38	1.4e-6	Cancer;
UCEC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	5.77	0.43	4.6e-8	Alzheimer's disease;
UCEC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.69	0.36	6.26e-6	Schizophrenia;
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg19678392	chr7:94953810	PON1	-0.58	-5.58	-0.42	1.11e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.47	4.62	0.36	8.24e-6	Monocyte count;
UCEC	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.93	-14.18	-0.76	2.56e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.7	-0.69	9.29e-23	Coronary artery disease;
UCEC	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.58	-4.76	-0.37	4.49e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.79	-8.53	-0.58	1.64e-14	Cognitive function;
UCEC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg03808351	chr9:123631620	PHF19	0.41	4.51	0.35	1.34e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.54	-5.46	-0.41	1.98e-7	Aortic root size;
UCEC	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.52	5.86	0.43	2.99e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-0.96	-4.92	-0.38	2.27e-6	Mitochondrial DNA levels;
UCEC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg10902566	chr4:727664	PCGF3	-0.6	-5.32	-0.4	3.82e-7	Systolic blood pressure;
UCEC	cis	rs4372836	0.658	rs11127189	chr2:28992020	T/G	cg09522027	chr2:28974177	PPP1CB	-0.69	-7.61	-0.53	3.01e-12	Body mass index;
UCEC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.9	-0.44	2.35e-8	Menarche (age at onset);
UCEC	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.83	8.25	0.56	8.18e-14	Post bronchodilator FEV1;
UCEC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg18478394	chr8:109455254	TTC35	0.52	5.0	0.38	1.62e-6	Dupuytren's disease;
UCEC	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.76	9.03	0.6	8.9e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg04154034	chr17:28927549	LRRC37B2	0.92	5.32	0.4	3.74e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.5	-4.73	-0.36	5.27e-6	Schizophrenia;
UCEC	cis	rs2652822	0.571	rs11858666	chr15:63526239	G/C	cg02713581	chr15:63449717	RPS27L	0.45	4.54	0.35	1.17e-5	Metabolic traits;
UCEC	cis	rs1816854	0.938	rs10880571	chr12:44207279	T/C	cg00106942	chr12:44200524	TWF1	0.52	5.42	0.41	2.37e-7	Inflammatory bowel disease;
UCEC	cis	rs7112925	0.608	rs5006008	chr11:66830560	A/T	cg06012016	chr11:67219631	GPR152	-0.43	-4.55	-0.35	1.1e-5	Height;
UCEC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26002218	chr14:103986227	CKB	0.36	5.16	0.39	7.75e-7	Body mass index;
UCEC	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.59	-6.01	-0.44	1.37e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.41	2.96e-7	Breast cancer;
UCEC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg13777783	chr17:79615861	NA	-0.35	-4.78	-0.37	4.13e-6	Eye color traits;
UCEC	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.71	6.56	0.48	8.39e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.49	4.7	0.36	5.92e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8005745	0.614	rs7143164	chr14:62166755	G/C	cg01748970	chr14:62088363	NA	0.5	4.53	0.35	1.2e-5	Select biomarker traits;
UCEC	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.42	-4.75	-0.36	4.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.83	9.96	0.63	3.45e-18	Metabolic syndrome;
UCEC	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.5	-6.12	-0.45	8.13e-9	Mean platelet volume;
UCEC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	0.97	5.32	0.4	3.83e-7	IgG glycosylation;
UCEC	cis	rs56341938	0.603	rs4955638	chr3:168819373	C/T	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.68	-8.08	-0.55	2.18e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs4713118	0.513	rs2294480	chr6:27583961	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.47	-4.79	-0.37	4.06e-6	Parkinson's disease;
UCEC	cis	rs10266483	0.656	rs670966	chr7:63762899	A/T	cg23304165	chr7:63498798	NA	-0.5	-5.41	-0.41	2.49e-7	Response to statin therapy;
UCEC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	7.85	0.54	8.1e-13	Bone mineral density;
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05195085	chr7:157951403	PTPRN2	0.38	5.56	0.42	1.23e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.15	9.39	0.61	1.05e-16	Uric acid levels;
UCEC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.56	6.4	0.47	1.99e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.88	0.37	2.76e-6	Personality dimensions;
UCEC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.8	9.05	0.6	7.76e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg12024160	chr4:1254474	NA	-0.51	-5.5	-0.41	1.65e-7	Obesity-related traits;
UCEC	cis	rs2862064	1.000	rs1910052	chr5:156429154	T/C	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.63	0.36	8.1e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.01	-11.71	-0.69	8.64e-23	Ulcerative colitis;
UCEC	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.81	-8.31	-0.57	5.75e-14	Caffeine consumption;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	8.91	0.59	1.77e-15	Platelet count;
UCEC	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.67	-4.53	-0.35	1.21e-5	LDL cholesterol levels;
UCEC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.45	-0.52	7.34e-12	Body mass index;
UCEC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.39	9.01	0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs4938174	0.662	rs161138	chr11:110892082	T/G	cg23711062	chr11:111636296	PPP2R1B	0.42	4.54	0.35	1.15e-5	Corneal structure;
UCEC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.52	7.6	0.53	3.14e-12	Crohn's disease;
UCEC	cis	rs7246967	0.673	rs59567211	chr19:22829882	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.64	-6.66	-0.48	5.07e-10	Longevity;Endometriosis;
UCEC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-7.26	-0.51	2.12e-11	Hypospadias;
UCEC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.48	-5.28	-0.4	4.64e-7	Bipolar disorder;
UCEC	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.78	-7.0	-0.5	8.52e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg01689657	chr7:91764605	CYP51A1	0.5	6.34	0.46	2.68e-9	Breast cancer;
UCEC	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	4.77	0.37	4.37e-6	Birth weight;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.27	-0.4	4.72e-7	Pubertal anthropometrics;
UCEC	cis	rs8105895	0.935	rs62110992	chr19:22261516	T/G	cg02912127	chr19:22235281	ZNF257	-0.63	-5.24	-0.4	5.45e-7	Body mass index (change over time);
UCEC	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.75	-0.37	4.72e-6	Blood metabolite levels;
UCEC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.57	5.76	0.43	4.79e-8	Asthma (sex interaction);
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.53	7.67	0.53	2.16e-12	Prudent dietary pattern;
UCEC	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg18827107	chr12:86230957	RASSF9	-0.41	-4.58	-0.35	9.76e-6	Major depressive disorder;
UCEC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg14078730	chr11:63896557	MACROD1	-0.69	-5.13	-0.39	8.93e-7	Mean platelet volume;
UCEC	cis	rs883565	0.568	rs6599004	chr3:39095678	C/T	cg01426195	chr3:39028469	NA	-0.75	-9.85	-0.63	6.98e-18	Handedness;
UCEC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.71	7.93	0.55	5.16e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-5.96	-0.44	1.78e-8	Birth weight;
UCEC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.8	8.27	0.56	7.19e-14	Joint mobility (Beighton score);
UCEC	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg06521331	chr12:34319734	NA	-0.63	-4.86	-0.37	2.95e-6	Morning vs. evening chronotype;
UCEC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.99	-0.38	1.72e-6	Initial pursuit acceleration;
UCEC	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-0.67	-4.79	-0.37	4.07e-6	Diabetic kidney disease;
UCEC	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.58	6.08	0.45	9.8e-9	Red blood cell count;
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.7	0.43	6.26e-8	Prudent dietary pattern;
UCEC	cis	rs7101446	0.704	rs7129183	chr11:63176979	C/T	cg21706343	chr11:62521476	ZBTB3	-0.54	-4.53	-0.35	1.23e-5	Economic and political preferences;
UCEC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.56	-6.96	-0.5	1.04e-10	Total body bone mineral density;
UCEC	cis	rs34585985	0.585	rs17759116	chr1:210531572	C/T	cg26758551	chr1:209921096	NA	0.84	4.53	0.35	1.23e-5	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in chronic obstructive pulmonary disease;
UCEC	cis	rs7872515	0.887	rs10992234	chr9:94877836	A/G	cg01248375	chr9:94877805	SPTLC1	0.44	4.68	0.36	6.34e-6	Bipolar disorder and schizophrenia;
UCEC	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Electroencephalogram traits;
UCEC	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.46	-4.53	-0.35	1.23e-5	Dupuytren's disease;
UCEC	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.41	-5.75	-0.43	4.94e-8	Prostate cancer;
UCEC	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.76	-9.14	-0.6	4.79e-16	Paraoxonase activity;
UCEC	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03576123	chr11:487126	PTDSS2	-0.96	-7.01	-0.5	8.17e-11	Body mass index;
UCEC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.43	-4.66	-0.36	7.01e-6	Parkinson's disease;
UCEC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.5	4.67	0.36	6.71e-6	Resting heart rate;
UCEC	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.58	-0.35	9.99e-6	Cardiac Troponin-T levels;
UCEC	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	5.65	0.42	8.04e-8	Coffee consumption (cups per day);
UCEC	cis	rs4851266	0.933	rs6709656	chr2:100806719	A/G	cg14675211	chr2:100938903	LONRF2	0.64	6.16	0.45	6.77e-9	Educational attainment;
UCEC	cis	rs12286929	0.644	rs7942036	chr11:115078356	G/C	cg04055981	chr11:115044050	NA	0.46	5.01	0.38	1.57e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.66	5.8	0.43	3.85e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.68	5.14	0.39	8.63e-7	Lymphocyte counts;
UCEC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.64	6.16	0.45	6.56e-9	Aortic root size;
UCEC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg21770322	chr7:97807741	LMTK2	0.65	8.9	0.59	1.97e-15	Breast cancer;
UCEC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.78	5.14	0.39	8.69e-7	Major depressive disorder;
UCEC	trans	rs4389974	0.899	rs62520640	chr8:112400556	G/A	cg22736090	chr17:62339926	TEX2	0.66	6.83	0.49	2.04e-10	Body mass index;
UCEC	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-10.76	-0.66	2.75e-20	Ulcerative colitis;
UCEC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg15848620	chr12:58087721	OS9	-0.52	-4.86	-0.37	2.99e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.22	-0.51	2.53e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg13147721	chr7:65941812	NA	-0.75	-5.14	-0.39	8.72e-7	Diabetic kidney disease;
UCEC	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.62	6.98	0.5	9.23e-11	Pubertal anthropometrics;
UCEC	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg04804543	chr8:142233427	SLC45A4	0.38	5.31	0.4	4.05e-7	Birth weight;
UCEC	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.66	-4.96	-0.38	1.96e-6	Narcolepsy;
UCEC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg00316803	chr15:76480434	C15orf27	-0.41	-4.93	-0.38	2.18e-6	Blood metabolite levels;
UCEC	cis	rs34486957	0.600	rs61985546	chr14:60043721	A/G	cg12189551	chr14:60952945	C14orf39	0.36	4.52	0.35	1.27e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs8020441	1.000	rs72681677	chr14:51173590	T/G	cg04730355	chr14:51134070	SAV1	0.7	6.17	0.45	6.27e-9	Cognitive performance;
UCEC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	5.89	0.44	2.58e-8	Menarche (age at onset);
UCEC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg17747265	chr1:1875780	NA	-0.48	-6.44	-0.47	1.58e-9	Body mass index;
UCEC	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.73	-8.25	-0.56	8.45e-14	Coronary artery disease;
UCEC	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.45	-4.55	-0.35	1.09e-5	Post bronchodilator FEV1;
UCEC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.2e-5	Chronic sinus infection;
UCEC	cis	rs782107	0.674	rs3899803	chr12:58799297	T/C	cg19181132	chr12:59314527	LRIG3	-0.43	-4.74	-0.36	5.03e-6	Interleukin-12p70 levels;
UCEC	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.63	-6.06	-0.45	1.07e-8	Acne (severe);
UCEC	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.65	4.58	0.35	9.73e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11867410	0.744	rs73336662	chr17:63955473	G/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.65	-0.36	7.3e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-6.88	-0.49	1.64e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.91	7.13	0.51	4.15e-11	Obesity-related traits;
UCEC	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.82	-8.67	-0.58	7.45e-15	Ulcerative colitis;
UCEC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-6.06	-0.45	1.07e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	6.58	0.48	7.7e-10	Cognitive test performance;
UCEC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg04756594	chr16:24857601	SLC5A11	0.47	5.24	0.4	5.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs66686620	1.000	rs4401244	chr2:69247005	A/G	cg12800200	chr2:69260302	ANTXR1	-0.5	-4.77	-0.37	4.45e-6	Breast cancer;
UCEC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.65	0.42	8.09e-8	Platelet count;
UCEC	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg00074818	chr8:8560427	CLDN23	-0.38	-4.64	-0.36	7.5e-6	Neuroticism;
UCEC	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg20575277	chr15:90728569	SEMA4B	0.43	4.55	0.35	1.11e-5	Rheumatoid arthritis;
UCEC	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.16	10.99	0.67	6.81e-21	Corneal structure;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.4	-4.68	-0.36	6.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.61	5.68	0.42	7.13e-8	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.72	6.54	0.47	9.44e-10	Aortic root size;
UCEC	cis	rs2120991	1.000	rs2120991	chr12:54270228	G/T	cg07927839	chr12:53491483	IGFBP6	0.44	4.62	0.36	8.23e-6	Biliary atresia;
UCEC	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	0.83	5.25	0.4	5.22e-7	Arsenic metabolism;
UCEC	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.44	4.8	0.37	3.82e-6	Blood metabolite levels;
UCEC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	0.87	4.94	0.38	2.06e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-6.72	-0.48	3.72e-10	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg20965017	chr5:231967	SDHA	-0.61	-4.82	-0.37	3.52e-6	Breast cancer;
UCEC	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.46	-0.41	1.96e-7	Dupuytren's disease;
UCEC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.65	6.03	0.45	1.24e-8	Aortic root size;
UCEC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg23625390	chr15:77176239	SCAPER	0.48	4.72	0.36	5.39e-6	Blood metabolite levels;
UCEC	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2302190	0.882	rs11658998	chr17:56655786	T/G	cg12560992	chr17:57184187	TRIM37	0.53	4.69	0.36	6.08e-6	Vitamin D levels;
UCEC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.64	6.9	0.49	1.41e-10	Coronary artery disease;
UCEC	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg23815491	chr16:72088622	HP	-0.37	-4.56	-0.35	1.05e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
UCEC	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.64	6.17	0.45	6.35e-9	Lymphocyte counts;
UCEC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.58	-6.8	-0.49	2.51e-10	Total body bone mineral density;
UCEC	cis	rs28795989	0.931	rs28726254	chr4:7897682	C/G	cg00251875	chr4:7801337	AFAP1	0.5	6.05	0.45	1.16e-8	Intraocular pressure;
UCEC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.49	5.24	0.4	5.55e-7	Alcohol dependence;
UCEC	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.51	5.44	0.41	2.22e-7	Schizophrenia;
UCEC	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.52	-5.04	-0.38	1.33e-6	Cognitive test performance;
UCEC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-4.9	-0.37	2.51e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg27068330	chr11:65405492	SIPA1	-0.52	-5.12	-0.39	9.54e-7	Acne (severe);
UCEC	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	5.84	0.43	3.3e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-1.21	-6.29	-0.46	3.39e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg22117172	chr7:91764530	CYP51A1	0.39	4.93	0.38	2.22e-6	Breast cancer;
UCEC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg11494091	chr17:61959527	GH2	-0.59	-7.5	-0.53	5.54e-12	Prudent dietary pattern;
UCEC	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.38	-5.71	-0.43	5.91e-8	Body mass index;
UCEC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.63	7.3	0.52	1.63e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg06238570	chr21:40685208	BRWD1	0.79	7.78	0.54	1.17e-12	Cognitive function;
UCEC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.69	-7.86	-0.54	7.36e-13	Menarche (age at onset);
UCEC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.57	7.28	0.51	1.87e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.69	-7.39	-0.52	1.02e-11	Menarche (age at onset);
UCEC	cis	rs1575951	1.000	rs7079353	chr10:130439158	G/C	cg27041381	chr10:131357203	MGMT	0.6	5.21	0.39	6.34e-7	Plasma clusterin levels;
UCEC	cis	rs644799	0.897	rs10831448	chr11:95663091	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	4.73	0.36	5.21e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7095607	0.935	rs12774635	chr10:69950477	T/A	cg18986048	chr10:69913749	MYPN	0.46	4.97	0.38	1.84e-6	Lung function (FVC);
UCEC	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.1	0.39	1.05e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.46	-5.16	-0.39	7.77e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.64	-5.07	-0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs8105895	1.000	rs8100042	chr19:22127841	T/A	cg02912127	chr19:22235281	ZNF257	-0.59	-4.91	-0.38	2.37e-6	Body mass index (change over time);
UCEC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.86e-6	Body mass index;
UCEC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.56	5.94	0.44	1.97e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13683864	chr3:40499215	RPL14	-0.67	-6.65	-0.48	5.45e-10	Renal cell carcinoma;
UCEC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.47	4.88	0.37	2.69e-6	Testicular germ cell tumor;
UCEC	trans	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg01451101	chr16:73099565	NA	0.73	7.72	0.54	1.67e-12	Coronary artery disease;
UCEC	cis	rs7578199	0.576	rs2074775	chr2:242396033	A/G	cg02201132	chr2:242212884	HDLBP	-0.41	-4.53	-0.35	1.23e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs12681287	0.608	rs13270090	chr8:87553297	T/A	cg27223183	chr8:87520930	FAM82B	0.72	6.37	0.47	2.3e-9	Caudate activity during reward;
UCEC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.71	-7.37	-0.52	1.14e-11	Blood metabolite levels;
UCEC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.67	0.36	6.63e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.59	4.79	0.37	4.03e-6	High light scatter reticulocyte count;
UCEC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.62	-5.55	-0.42	1.28e-7	Menarche (age at onset);
UCEC	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg23950597	chr19:37808831	NA	-0.64	-5.1	-0.39	1.03e-6	Coronary artery calcification;
UCEC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg02733842	chr7:1102375	C7orf50	-0.7	-6.59	-0.48	7.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-7.49	-0.53	5.88e-12	Parkinson's disease;
UCEC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.71	-8.38	-0.57	3.85e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg04871131	chr7:94954202	PON1	-0.54	-5.43	-0.41	2.31e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.56	8.54	0.58	1.56e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.65	6.03	0.45	1.24e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.52	5.64	0.42	8.52e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg04176532	chr22:50317003	CRELD2	0.52	5.12	0.39	9.59e-7	Schizophrenia;
UCEC	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.65	5.6	0.42	1e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.98	0.7	1.65e-23	Prudent dietary pattern;
UCEC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.44	-4.94	-0.38	2.09e-6	Blood protein levels;
UCEC	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.31	4.64	0.36	7.62e-6	Schizophrenia;
UCEC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.79	4.94	0.38	2.07e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.51	4.72	0.36	5.42e-6	Serum sulfate level;
UCEC	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	0.8	6.37	0.46	2.32e-9	Corneal structure;
UCEC	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs13253111	0.603	rs17058753	chr8:28090914	T/C	cg26534493	chr8:28060551	NA	0.49	5.23	0.4	5.76e-7	Childhood body mass index;
UCEC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg15848620	chr12:58087721	OS9	-0.53	-5.09	-0.39	1.07e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1712517	0.740	rs4917387	chr10:105108455	T/C	cg05636881	chr10:105038444	INA	0.45	5.21	0.39	6.28e-7	Migraine;
UCEC	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	1.07	9.47	0.62	6.68e-17	Mosquito bite size;
UCEC	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.67	-7.33	-0.52	1.41e-11	Ear protrusion;
UCEC	cis	rs6763768	0.565	rs11714096	chr3:53396145	G/C	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.06	-0.38	1.26e-6	Life satisfaction;
UCEC	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg11266682	chr4:10021025	SLC2A9	0.44	5.62	0.42	9.48e-8	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.6	5.4	0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.82	8.77	0.59	4.19e-15	Cognitive function;
UCEC	cis	rs7246967	0.604	rs58536761	chr19:22880331	G/C	cg03230154	chr19:22817176	ZNF492	0.46	4.55	0.35	1.13e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7809799	0.655	rs73157601	chr7:98854448	C/T	cg24555656	chr7:99717359	TAF6;CNPY4	-0.93	-4.76	-0.37	4.6e-6	Ulcerative colitis;
UCEC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.2	0.46	5.35e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	1.07	7.86	0.54	7.47e-13	Corneal structure;
UCEC	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.76	-6.78	-0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.71	4.91	0.38	2.38e-6	Multiple sclerosis;
UCEC	cis	rs4870684	0.509	rs11763804	chr7:57702125	G/C	cg01314568	chr7:57830625	NA	-0.72	-5.67	-0.42	7.25e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.38	-0.52	1.09e-11	Prevalent atrial fibrillation;
UCEC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-5.99	-0.44	1.51e-8	Schizophrenia;
UCEC	cis	rs2386661	0.523	rs2386663	chr10:5652739	C/T	cg17085576	chr10:5658249	NA	-0.45	-5.05	-0.38	1.27e-6	Breast cancer;
UCEC	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-6.45	-0.47	1.56e-9	Parkinson's disease;
UCEC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13102889	chr1:2463136	HES5	-0.35	-4.55	-0.35	1.11e-5	Body mass index;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.58	-0.48	7.56e-10	Pubertal anthropometrics;
UCEC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	4.82	0.37	3.47e-6	Platelet count;
UCEC	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.36	-5.03	-0.38	1.38e-6	Schizophrenia;
UCEC	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.25	-0.56	8.03e-14	Breast cancer;
UCEC	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs4146922	0.793	rs7590753	chr2:55996131	C/G	cg00879447	chr2:56412077	CCDC85A	0.5	5.08	0.39	1.13e-6	Height;
UCEC	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg16797656	chr11:68205561	LRP5	0.38	4.82	0.37	3.52e-6	Total body bone mineral density;
UCEC	cis	rs8020441	1.000	rs68157165	chr14:51169220	A/G	cg04730355	chr14:51134070	SAV1	0.57	5.27	0.4	4.84e-7	Cognitive performance;
UCEC	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.77	-5.34	-0.4	3.5e-7	Rheumatoid arthritis;
UCEC	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.62	0.42	9.11e-8	Platelet count;
UCEC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.7	6.26	0.46	3.94e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-0.75	-4.9	-0.37	2.55e-6	Blood protein levels;
UCEC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4664304	0.531	rs11691616	chr2:160758680	G/C	cg21319458	chr2:160472940	BAZ2B	-0.43	-4.5	-0.35	1.36e-5	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.57	-5.73	-0.43	5.41e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.84	0.59	2.78e-15	Prudent dietary pattern;
UCEC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-8.62	-0.58	9.71e-15	Coronary artery disease;
UCEC	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg03060546	chr3:49711283	APEH	0.6	6.6	0.48	6.93e-10	Resting heart rate;
UCEC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.47	5.23	0.4	5.63e-7	Emphysema distribution in smoking;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00779328	chr1:33745989	ZNF362	-0.58	-6.96	-0.5	1.05e-10	N-glycan levels;
UCEC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.44	4.62	0.36	8.4e-6	Schizophrenia;
UCEC	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.88	-0.44	2.62e-8	Menarche (age at onset);
UCEC	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.51	-5.2	-0.39	6.65e-7	Orofacial clefts;
UCEC	cis	rs6546886	1.000	rs6743073	chr2:74241037	A/G	cg14702570	chr2:74259524	NA	-0.45	-5.76	-0.43	4.83e-8	Dialysis-related mortality;
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.88e-9	Prudent dietary pattern;
UCEC	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg05660106	chr1:15850417	CASP9	0.89	10.27	0.65	5.36e-19	Systolic blood pressure;
UCEC	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.63	-5.74	-0.43	5.16e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.57	6.99	0.5	8.75e-11	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.53	-5.32	-0.4	3.85e-7	IgG glycosylation;
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg01874867	chr7:94954059	PON1	-0.54	-5.0	-0.38	1.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.75	5.0	0.38	1.64e-6	Blood protein levels;
UCEC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.79	7.99	0.55	3.64e-13	Cognitive function;
UCEC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.61e-6	Diabetic kidney disease;
UCEC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.96	13.75	0.75	3.42e-28	Bone mineral density;
UCEC	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-4.75	-0.36	4.8e-6	Metabolite levels;
UCEC	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.63	-5.65	-0.42	8.08e-8	Pulmonary function;
UCEC	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.11	-0.45	8.38e-9	Blood metabolite levels;
UCEC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.6	5.86	0.43	2.97e-8	Aortic root size;
UCEC	cis	rs61776719	0.817	rs2170169	chr1:38408164	G/A	cg18451016	chr1:38461880	NA	0.55	5.61	0.42	9.57e-8	Coronary artery disease;
UCEC	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.72	-6.32	-0.46	2.9e-9	Coronary artery disease;
UCEC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.73	7.29	0.52	1.79e-11	Coronary artery disease;
UCEC	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	5.11	0.39	9.95e-7	Eosinophil percentage of white cells;
UCEC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.47	5.29	0.4	4.27e-7	Aortic root size;
UCEC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.53	-5.8	-0.43	3.96e-8	Menarche (age at onset);
UCEC	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.48	5.73	0.43	5.46e-8	Kawasaki disease;
UCEC	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.5	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	6.11	0.45	8.57e-9	Schizophrenia;
UCEC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	6.74	0.49	3.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs7246967	0.611	rs2885222	chr19:22839944	T/G	cg24889512	chr19:22816950	ZNF492	0.6	6.46	0.47	1.46e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.27	0.56	7.44e-14	Headache;
UCEC	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg03576123	chr11:487126	PTDSS2	0.74	5.85	0.43	3.05e-8	Body mass index;
UCEC	cis	rs925228	0.830	rs2161784	chr2:24014300	T/G	cg13272742	chr2:24272458	FKBP1B	0.58	5.09	0.39	1.07e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07145255	chr5:59995354	DEPDC1B	0.55	6.73	0.49	3.58e-10	Warfarin maintenance dose;
UCEC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18252515	chr7:66147081	NA	-0.46	-4.62	-0.36	8.24e-6	Aortic root size;
UCEC	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.84	-10.76	-0.66	2.84e-20	Brugada syndrome;
UCEC	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg13695892	chr22:41940480	POLR3H	0.66	4.62	0.36	8.3e-6	Vitiligo;
UCEC	cis	rs4417855	0.762	rs1056932	chr3:187447032	C/T	cg27376355	chr3:186460384	KNG1	0.36	4.92	0.38	2.27e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-4.74	-0.36	5.04e-6	Obesity-related traits;
UCEC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.71	-5.18	-0.39	7.16e-7	Narcolepsy;
UCEC	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.58	-5.62	-0.42	9.21e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13315871	0.858	rs9848825	chr3:58239001	A/G	cg20936604	chr3:58311152	NA	-0.57	-4.66	-0.36	7.04e-6	Cholesterol, total;
UCEC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.67	6.12	0.45	8.13e-9	Aortic root size;
UCEC	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.78	6.7	0.48	4.12e-10	Menopause (age at onset);
UCEC	cis	rs12980942	0.872	rs7257583	chr19:41788117	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	4.99	0.38	1.71e-6	Coronary artery disease;
UCEC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	10.57	0.66	9.03e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.57	5.84	0.43	3.25e-8	Schizophrenia;
UCEC	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.97	-0.44	1.71e-8	Parkinson's disease;
UCEC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.46	-5.1	-0.39	1.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-5.91	-0.44	2.25e-8	Electrocardiographic conduction measures;
UCEC	cis	rs12039431	0.788	rs58284750	chr1:38042926	C/A	cg17933807	chr1:38061675	GNL2	-0.54	-4.65	-0.36	7.23e-6	Epithelial ovarian cancer;
UCEC	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.43	4.77	0.37	4.32e-6	Blood metabolite levels;
UCEC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.17	15.02	0.78	1.73e-31	Cognitive function;
UCEC	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg14675211	chr2:100938903	LONRF2	0.63	6.24	0.46	4.47e-9	Educational attainment;
UCEC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.75	-0.43	4.99e-8	Alcohol dependence;
UCEC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9309473	1.000	rs6546837	chr2:73677898	G/C	cg20560298	chr2:73613845	ALMS1	-0.65	-5.95	-0.44	1.84e-8	Metabolite levels;
UCEC	cis	rs6437061	0.745	rs3100588	chr2:232962909	A/G	cg02061626	chr2:233274167	ALPPL2	-0.49	-5.37	-0.41	2.99e-7	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.77	9.65	0.62	2.31e-17	Ulcerative colitis;
UCEC	cis	rs4789452	0.742	rs751633	chr17:75385775	C/A	cg21830368	chr17:75373327	SEPT9	-0.3	-4.71	-0.36	5.73e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.64	-7.03	-0.5	7.24e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.02	-8.36	-0.57	4.5e-14	Exhaled nitric oxide output;
UCEC	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.53	-5.85	-0.43	3.09e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-7.91	-0.55	5.54e-13	Colorectal cancer;
UCEC	cis	rs2235682	0.816	rs713641	chr22:36983961	A/G	cg13270055	chr22:36960499	CACNG2	0.4	4.52	0.35	1.26e-5	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.61	-6.21	-0.46	5.16e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01391022	chr12:122360665	WDR66	-0.44	-5.11	-0.39	9.73e-7	Mean corpuscular volume;
UCEC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	6.92	0.5	1.28e-10	Initial pursuit acceleration;
UCEC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.71	8.64	0.58	8.82e-15	Prudent dietary pattern;
UCEC	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.08	9.14	0.6	4.58e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2251301	0.891	rs6990463	chr8:11121260	C/T	cg23565663	chr8:10621935	NA	0.59	5.02	0.38	1.45e-6	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg20891283	chr12:69753455	YEATS4	0.58	4.97	0.38	1.84e-6	Response to diuretic therapy;
UCEC	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.49	-6.23	-0.46	4.72e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.62	7.03	0.5	7.14e-11	Leprosy;
UCEC	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9596863	1.000	rs9536557	chr13:54433190	A/G	ch.13.53330881F	chr13:54432880	NA	-0.53	-4.56	-0.35	1.07e-5	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.52	-4.76	-0.37	4.56e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs2224391	0.737	rs36117780	chr6:5262233	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-6.69	-0.48	4.39e-10	Height;
UCEC	cis	rs7607369	0.536	rs12623007	chr2:219665335	T/C	cg02176678	chr2:219576539	TTLL4	-0.57	-6.05	-0.45	1.15e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.81	-10.17	-0.64	9.89e-19	White blood cell count (basophil);
UCEC	cis	rs4372836	0.930	rs4233727	chr2:28977244	T/C	cg09522027	chr2:28974177	PPP1CB	-0.77	-8.15	-0.56	1.46e-13	Body mass index;
UCEC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.57	8.14	0.56	1.55e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.86	9.74	0.63	1.3e-17	Dental caries;
UCEC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.62	-6.88	-0.49	1.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.78	7.81	0.54	9.94e-13	Ulcerative colitis;
UCEC	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.78	-5.79	-0.43	4.02e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg01475377	chr6:109611718	NA	0.35	4.55	0.35	1.11e-5	Reticulocyte fraction of red cells;
UCEC	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.48	0.53	6.22e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	0.92	12.57	0.72	4.47e-25	Blood trace element (Zn levels);
UCEC	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.38	0.47	2.16e-9	Coffee consumption (cups per day);
UCEC	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg05804949	chr7:23719620	C7orf46	0.45	4.91	0.38	2.43e-6	Schizophrenia;
UCEC	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.92	7.1	0.51	4.93e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-5.03	-0.38	1.44e-6	Colorectal cancer;
UCEC	cis	rs6052563	1.000	rs6139427	chr20:4432150	A/G	cg03704756	chr20:4666787	PRNP	-0.77	-4.86	-0.37	3.02e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-7.6	-0.53	3.27e-12	Menarche (age at onset);
UCEC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg10932868	chr11:921992	NA	0.37	4.51	0.35	1.3e-5	Alzheimer's disease (late onset);
UCEC	cis	rs7246967	0.932	rs35735434	chr19:23039477	T/C	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.54e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4788439	0.901	rs16974243	chr16:24958985	G/A	cg04047827	chr16:24740859	TNRC6A	-0.5	-4.59	-0.35	9.59e-6	Blood metabolite levels;
UCEC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg24562669	chr7:97807699	LMTK2	0.48	5.88	0.44	2.71e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg11632617	chr15:75315747	PPCDC	0.49	5.03	0.38	1.41e-6	Blood trace element (Zn levels);
UCEC	cis	rs6493487	0.546	rs12904155	chr15:51356728	C/T	cg17676096	chr15:52263839	LEO1	0.8	4.99	0.38	1.69e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.36	-5.2	-0.39	6.43e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg09120320	chr17:61926383	NA	0.44	4.57	0.35	1.04e-5	Prudent dietary pattern;
UCEC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.65	-6.1	-0.45	8.92e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg22166914	chr1:53195759	ZYG11B	0.82	8.52	0.57	1.79e-14	Monocyte count;
UCEC	cis	rs1483890	0.723	rs13077078	chr3:69411402	C/A	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.52	5.86	0.43	2.99e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg22974920	chr21:40686053	BRWD1	0.62	5.47	0.41	1.87e-7	Cognitive function;
UCEC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Corneal astigmatism;
UCEC	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.38	-4.75	-0.37	4.71e-6	Menarche (age at onset);
UCEC	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.43	4.76	0.37	4.58e-6	Anxiety disorder;
UCEC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.82	0.75	2.28e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.47	4.99	0.38	1.67e-6	Red blood cell count;
UCEC	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.14	12.32	0.71	2.1e-24	Opioid sensitivity;
UCEC	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-8.72	-0.58	5.55e-15	Ulcerative colitis;
UCEC	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	9.13	0.6	4.84e-16	Ulcerative colitis;
UCEC	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.67	-5.56	-0.42	1.23e-7	Initial pursuit acceleration;
UCEC	cis	rs883565	0.684	rs811971	chr3:39168283	C/T	cg01426195	chr3:39028469	NA	-0.62	-7.38	-0.52	1.07e-11	Handedness;
UCEC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.56	-5.42	-0.41	2.43e-7	Morning vs. evening chronotype;
UCEC	cis	rs7095607	0.935	rs12415105	chr10:69958631	G/A	cg18986048	chr10:69913749	MYPN	0.44	4.79	0.37	4.07e-6	Lung function (FVC);
UCEC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.66	6.18	0.45	5.88e-9	Chronic sinus infection;
UCEC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.59	5.47	0.41	1.88e-7	Schizophrenia;
UCEC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.59	-0.48	7.23e-10	Aortic root size;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.81	10.6	0.66	7.39e-20	Menarche (age at onset);
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.48	-5.22	-0.4	5.94e-7	Pubertal anthropometrics;
UCEC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.36	-0.4	3.15e-7	Chronic sinus infection;
UCEC	cis	rs4778581	0.643	rs11631583	chr15:80402616	A/T	cg08257866	chr15:80351198	ZFAND6	0.42	4.93	0.38	2.17e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg00343986	chr7:65444356	GUSB	0.55	4.88	0.37	2.68e-6	Calcium levels;
UCEC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.55	-5.11	-0.39	9.87e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg05991184	chr2:219186017	PNKD	0.51	5.52	0.41	1.49e-7	Colorectal cancer;
UCEC	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	4.85	0.37	3.14e-6	Birth weight;
UCEC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.79	-7.39	-0.52	1.01e-11	IgG glycosylation;
UCEC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.74	-7.01	-0.5	8.07e-11	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg19743168	chr1:23544995	NA	0.43	6.22	0.46	5.02e-9	Height;
UCEC	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.16	-0.45	6.49e-9	Coffee consumption (cups per day);
UCEC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.48	4.93	0.38	2.17e-6	Bipolar disorder;
UCEC	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.27	0.46	3.88e-9	Coffee consumption (cups per day);
UCEC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.37	4.71	0.36	5.69e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.03	0.5	7.04e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-7.62	-0.53	2.95e-12	Personality dimensions;
UCEC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg06096015	chr1:231504339	EGLN1	0.42	4.59	0.35	9.32e-6	Hemoglobin concentration;
UCEC	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.62	-5.5	-0.41	1.62e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.15	-0.45	6.96e-9	Personality dimensions;
UCEC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs2708977	0.608	rs631033	chr2:97090430	C/T	cg22654517	chr2:96458247	NA	0.44	5.54	0.42	1.34e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	7.01	0.5	8.02e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.01	5.67	0.42	7.25e-8	Skin colour saturation;
UCEC	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg21231944	chr12:82153410	PPFIA2	-0.43	-4.53	-0.35	1.22e-5	Resting heart rate;
UCEC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg08805041	chr16:621841	PIGQ	-0.31	-4.77	-0.37	4.47e-6	Height;
UCEC	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.52	-5.58	-0.42	1.12e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.44	-5.14	-0.39	8.44e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.67	5.34	0.4	3.49e-7	Left atrial antero-posterior diameter;
UCEC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.46	6.44	0.47	1.62e-9	Eye color traits;
UCEC	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	7.94	0.55	4.67e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.42	-5.44	-0.41	2.17e-7	HIV-1 susceptibility;
UCEC	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-5.13	-0.39	8.96e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.72	-6.71	-0.48	4.03e-10	Initial pursuit acceleration;
UCEC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.15	15.67	0.79	3.7e-33	Cognitive function;
UCEC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.8	8.87	0.59	2.23e-15	Lymphocyte counts;
UCEC	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.7	-5.87	-0.44	2.79e-8	Toenail selenium levels;
UCEC	cis	rs8105895	0.733	rs62110979	chr19:22245152	T/C	cg24072202	chr19:22235272	ZNF257	-0.61	-5.33	-0.4	3.64e-7	Body mass index (change over time);
UCEC	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.85	-9.64	-0.62	2.47e-17	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.75	-4.76	-0.37	4.53e-6	Skin colour saturation;
UCEC	cis	rs7246967	0.932	rs4932792	chr19:23032449	A/G	cg05241461	chr19:22816980	ZNF492	0.48	5.12	0.39	9.3e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg07250515	chr12:56618133	OBFC2B	-0.57	-4.94	-0.38	2.09e-6	Psoriasis vulgaris;
UCEC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg06784218	chr1:46089804	CCDC17	0.46	5.74	0.43	5.26e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.73	-7.28	-0.51	1.84e-11	Plateletcrit;Platelet count;
UCEC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg18584368	chr5:314553	AHRR;PDCD6	0.52	4.57	0.35	1.02e-5	Asthma (childhood onset);
UCEC	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg02413938	chr2:239008929	ESPNL	-0.36	-4.64	-0.36	7.64e-6	Prostate cancer;
UCEC	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.59	5.73	0.43	5.43e-8	Tonsillectomy;
UCEC	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.61	7.36	0.52	1.24e-11	Oral cavity cancer;
UCEC	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.66	-7.71	-0.54	1.73e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6832769	1.000	rs4865010	chr4:56414962	A/C	cg05960024	chr4:56376020	CLOCK	-0.57	-5.87	-0.44	2.79e-8	Personality dimensions;
UCEC	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs72700829	0.593	rs80350997	chr1:150992010	G/A	cg00107782	chr1:151300621	NA	-0.67	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.72	6.17	0.45	6.39e-9	Coronary artery disease;
UCEC	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.32	0.46	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-4.58	-0.35	1e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg19610905	chr11:61596333	FADS2	-0.59	-4.9	-0.37	2.54e-6	Neutrophil count;Sum basophil neutrophil counts;
UCEC	cis	rs12367572	0.641	rs4285943	chr12:45404768	A/C	cg03114573	chr12:45410052	DBX2	0.47	5.19	0.39	6.73e-7	Gut microbiome composition (summer);
UCEC	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.5	5.64	0.42	8.61e-8	Response to temozolomide;
UCEC	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	0.9	6.81	0.49	2.32e-10	Lymphocyte counts;
UCEC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.77	-8.46	-0.57	2.52e-14	Immature fraction of reticulocytes;
UCEC	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.57	5.24	0.4	5.37e-7	Tonsillectomy;
UCEC	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.66	-0.42	7.83e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.59	7.69	0.54	1.97e-12	Bone mineral density;
UCEC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	6.08	0.45	9.68e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.13e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2622604	1.000	rs2622604	chr4:89078924	A/G	cg27387453	chr4:88533842	DSPP	-0.44	-4.59	-0.35	9.43e-6	LDL peak particle diameter (total fat intake interaction);
UCEC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-7.34	-0.52	1.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.64	6.73	0.49	3.59e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.81	9.14	0.6	4.6e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.57	-0.53	3.73e-12	Hypospadias;
UCEC	cis	rs4372836	0.518	rs12472549	chr2:28992004	T/C	cg09522027	chr2:28974177	PPP1CB	-0.76	-8.39	-0.57	3.63e-14	Body mass index;
UCEC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.56	5.06	0.39	1.25e-6	Corneal astigmatism;
UCEC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-5.72	-0.43	5.66e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.71	-7.79	-0.54	1.1e-12	Breast cancer;
UCEC	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg02628002	chr16:89649608	CPNE7	0.42	4.54	0.35	1.17e-5	Tanning;
UCEC	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.67	-6.38	-0.47	2.19e-9	Morning vs. evening chronotype;
UCEC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.38	-0.74	3.33e-27	Height;
UCEC	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.54	5.37	0.4	3.06e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs6723108	0.603	rs56271357	chr2:135720715	C/T	cg07169764	chr2:136633963	MCM6	0.5	4.78	0.37	4.15e-6	Type 2 diabetes;
UCEC	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-4.72	-0.36	5.34e-6	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.56	5.36	0.4	3.15e-7	Personality dimensions;
UCEC	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.6	5.59	0.42	1.07e-7	Vitiligo;
UCEC	cis	rs7246967	0.932	rs1478457	chr19:23065269	C/T	cg24889512	chr19:22816950	ZNF492	0.52	5.04	0.38	1.36e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.47	4.97	0.38	1.86e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.5	5.25	0.4	5.33e-7	Red blood cell count;
UCEC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.69	6.26	0.46	4e-9	Lymphocyte counts;
UCEC	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.74	-8.29	-0.56	6.38e-14	Facial morphology (factor 19);
UCEC	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.46	-5.83	-0.43	3.43e-8	Prudent dietary pattern;
UCEC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.55	7.04	0.5	6.93e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.91	-0.38	2.41e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.73	-0.49	3.62e-10	Platelet count;
UCEC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.8	6.5	0.47	1.2e-9	Initial pursuit acceleration;
UCEC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.56	-5.34	-0.4	3.5e-7	Coronary artery disease;
UCEC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs2280630	0.529	rs784505	chr3:39168757	G/A	cg01426195	chr3:39028469	NA	0.68	8.2	0.56	1.09e-13	Verbal declarative memory;
UCEC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.54	-5.45	-0.41	2.09e-7	Aortic root size;
UCEC	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.75	-6.42	-0.47	1.75e-9	Coronary artery disease;
UCEC	cis	rs6704644	0.516	rs2879871	chr2:234359137	C/G	cg16719865	chr2:234394478	USP40	-0.6	-6.03	-0.45	1.26e-8	Bilirubin levels;
UCEC	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg01493522	chr13:37497338	NA	-0.41	-4.57	-0.35	1.02e-5	Coronary artery disease;
UCEC	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.59	-4.94	-0.38	2.11e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg00266579	chr16:28619858	SULT1A1	0.63	4.66	0.36	6.98e-6	Platelet distribution width;
UCEC	cis	rs1635	0.655	rs9368532	chr6:27782010	A/G	cg02285791	chr6:27550747	NA	-0.72	-4.97	-0.38	1.86e-6	Schizophrenia;
UCEC	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.33	4.52	0.35	1.27e-5	Height;
UCEC	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-4.59	-0.35	9.41e-6	Hepatocellular carcinoma;
UCEC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.69	6.18	0.45	5.86e-9	Platelet distribution width;
UCEC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	0.94	9.63	0.62	2.53e-17	Heart rate;
UCEC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.51	4.91	0.38	2.37e-6	Emphysema distribution in smoking;
UCEC	cis	rs9463078	0.809	rs6933553	chr6:45027770	T/C	cg25276700	chr6:44698697	NA	-0.45	-4.81	-0.37	3.67e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.6	6.64	0.48	5.66e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg20821713	chr7:1055600	C7orf50	-0.91	-11.63	-0.69	1.39e-22	Bronchopulmonary dysplasia;
UCEC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.59	0.62	3.15e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.53	-5.82	-0.43	3.58e-8	Pubertal anthropometrics;
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-5.75	-0.43	4.88e-8	Platelet count;
UCEC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.52	-5.06	-0.38	1.25e-6	Schizophrenia;
UCEC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg06238570	chr21:40685208	BRWD1	0.78	7.58	0.53	3.54e-12	Cognitive function;
UCEC	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg15549821	chr19:49342101	PLEKHA4	-0.87	-6.03	-0.45	1.27e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.39	0.71	1.34e-24	Prudent dietary pattern;
UCEC	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.8	-0.63	9.01e-18	Monocyte count;
UCEC	cis	rs16937	0.711	rs11240385	chr1:205173101	A/G	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg13147721	chr7:65941812	NA	0.95	6.41	0.47	1.82e-9	Diabetic kidney disease;
UCEC	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.83	-0.49	2.05e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-4.53	-0.35	1.22e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.48	4.98	0.38	1.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.72	7.08	0.5	5.5e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.81	10.19	0.64	8.65e-19	Obesity-related traits;
UCEC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg13695892	chr22:41940480	POLR3H	-0.72	-5.58	-0.42	1.1e-7	Vitiligo;
UCEC	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.13	0.51	4.16e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg16060761	chr17:80687452	NA	-0.55	-4.79	-0.37	3.98e-6	Glycated hemoglobin levels;
UCEC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.69	7.75	0.54	1.39e-12	Menopause (age at onset);
UCEC	cis	rs117623576	0.941	rs11008775	chr10:32410307	T/C	cg03047570	chr10:32398778	NA	-0.54	-4.96	-0.38	1.91e-6	Anti-saccade response;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07589254	chr7:1705402	NA	-0.53	-4.55	-0.35	1.13e-5	Longevity;Endometriosis;
UCEC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg18016565	chr1:150552671	MCL1	0.45	4.61	0.36	8.55e-6	Melanoma;
UCEC	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg13695892	chr22:41940480	POLR3H	-0.6	-5.23	-0.4	5.71e-7	Vitiligo;
UCEC	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.44	0.52	7.61e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.12	-0.51	4.45e-11	Prevalent atrial fibrillation;
UCEC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.68	6.79	0.49	2.53e-10	Menopause (age at onset);
UCEC	cis	rs2473248	1.000	rs2744728	chr1:22540918	T/C	cg22683154	chr1:23345188	KDM1A	0.43	4.55	0.35	1.1e-5	Birth weight;
UCEC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg22814929	chr6:26458213	BTN2A1	-0.61	-4.52	-0.35	1.29e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.6	6.34	0.46	2.61e-9	Systolic blood pressure;
UCEC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.8	-9.91	-0.63	4.78e-18	Leprosy;
UCEC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg20007245	chr22:24372913	LOC391322	-0.63	-6.6	-0.48	6.86e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.65	6.16	0.45	6.73e-9	Aortic root size;
UCEC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg26721908	chr21:47610096	LSS	-0.38	-4.79	-0.37	4.07e-6	Testicular germ cell tumor;
UCEC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.57	6.12	0.45	8.27e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7246967	0.673	rs8106180	chr19:22879360	G/A	cg24889512	chr19:22816950	ZNF492	0.62	6.57	0.48	8.05e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7582720	0.945	rs72932722	chr2:203647598	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.86	4.95	0.38	2e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.78	-6.03	-0.45	1.29e-8	Platelet count;
UCEC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.08	8.71	0.58	5.85e-15	White matter hyperintensity burden;
UCEC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.65	5.64	0.42	8.39e-8	Uric acid levels;
UCEC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.55	5.17	0.39	7.62e-7	Calcium levels;
UCEC	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.48	4.7	0.36	6.02e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.5	-4.69	-0.36	6.3e-6	Handedness;
UCEC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-5.35	-0.4	3.24e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg05132306	chr1:1846340	CALML6	-0.38	-4.78	-0.37	4.2e-6	Body mass index;
UCEC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.9	9.26	0.61	2.28e-16	Cognitive function;
UCEC	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-5.65	-0.42	8.13e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs17123764	0.710	rs7956089	chr12:50153310	A/G	cg20471783	chr12:50157085	TMBIM6	0.63	5.06	0.39	1.23e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg24069376	chr3:38537580	EXOG	-0.43	-5.2	-0.39	6.56e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4851266	1.000	rs7566527	chr2:100811970	C/T	cg14675211	chr2:100938903	LONRF2	0.63	6.21	0.46	5.19e-9	Educational attainment;
UCEC	cis	rs1823913	0.927	rs13025919	chr2:192124901	T/C	cg15998761	chr2:191300784	MFSD6	0.39	4.57	0.35	1.05e-5	Obesity-related traits;
UCEC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.65	6.52	0.47	1.06e-9	Coronary artery disease;
UCEC	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg20368463	chr18:77673604	PQLC1	-0.49	-4.68	-0.36	6.5e-6	Opioid sensitivity;
UCEC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg05962950	chr11:130786565	SNX19	0.54	5.55	0.42	1.33e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.94	10.0	0.64	2.76e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.49	0.41	1.7e-7	Prudent dietary pattern;
UCEC	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.64	8.19	0.56	1.15e-13	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.61	5.49	0.41	1.7e-7	Corneal astigmatism;
UCEC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.43	4.71	0.36	5.73e-6	Pulse pressure;
UCEC	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.61	-6.99	-0.5	9.13e-11	Prostate cancer;
UCEC	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.37	4.64	0.36	7.69e-6	Renal cell carcinoma;
UCEC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	7.86	0.54	7.35e-13	Bone mineral density;
UCEC	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	trans	rs27434	0.605	rs2351012	chr5:96191747	A/G	cg13750061	chr11:118214845	CD3G;CD3D	0.58	6.68	0.48	4.69e-10	Ankylosing spondylitis;
UCEC	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.67	-6.05	-0.45	1.15e-8	Initial pursuit acceleration;
UCEC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg13147721	chr7:65941812	NA	-0.95	-6.41	-0.47	1.85e-9	Diabetic kidney disease;
UCEC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.6	-5.63	-0.42	9.03e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs798554	1.000	rs798551	chr7:2760338	A/T	cg19346786	chr7:2764209	NA	-0.52	-5.29	-0.4	4.36e-7	Height;
UCEC	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.73	5.54	0.42	1.34e-7	Bipolar disorder;
UCEC	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.64	6.3	0.46	3.2e-9	Bladder cancer;
UCEC	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.61	-5.27	-0.4	4.8e-7	Blood protein levels;
UCEC	cis	rs11038871	1.000	rs7949282	chr11:46522306	A/C	cg23542274	chr11:45718455	NA	-0.34	-4.78	-0.37	4.18e-6	Immunoglobulin A;
UCEC	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-5.97	-0.44	1.68e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.77	-7.79	-0.54	1.11e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg13683864	chr3:40499215	RPL14	0.86	9.84	0.63	7.08e-18	Renal cell carcinoma;
UCEC	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.94	-0.59	1.53e-15	Colorectal cancer;
UCEC	cis	rs28795989	0.896	rs7437984	chr4:7887588	T/C	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg16329650	chr2:213403929	ERBB4	0.44	4.58	0.35	9.94e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.7	6.91	0.5	1.38e-10	Morning vs. evening chronotype;
UCEC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-5.47	-0.41	1.87e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-6.63	-0.48	6.1e-10	Crohn's disease;
UCEC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.23	-13.71	-0.75	4.51e-28	Type 1 diabetes nephropathy;
UCEC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg07636037	chr3:49044803	WDR6	-0.61	-4.82	-0.37	3.61e-6	Menarche (age at onset);
UCEC	cis	rs10421328	0.821	rs2288867	chr19:19765568	C/T	cg01262667	chr19:19385393	TM6SF2	0.37	4.51	0.35	1.3e-5	Parental longevity (combined parental age at death);
UCEC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.46	4.76	0.37	4.64e-6	Blood protein levels;
UCEC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.83	9.06	0.6	7.51e-16	Cognitive function;
UCEC	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.55	5.83	0.43	3.38e-8	Schizophrenia;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg07838603	chr6:28411030	ZSCAN23	0.51	5.71	0.43	6.13e-8	Pubertal anthropometrics;
UCEC	cis	rs1832871	0.965	rs262827	chr6:158683646	A/T	cg07215822	chr6:158701037	NA	-0.53	-5.3	-0.4	4.09e-7	Height;
UCEC	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.28	9.55	0.62	4.03e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs8105895	0.932	rs12150930	chr19:22223687	G/C	cg20662725	chr19:22235022	ZNF257	-0.58	-5.13	-0.39	9.04e-7	Body mass index (change over time);
UCEC	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.48	-5.58	-0.42	1.15e-7	Breast cancer;
UCEC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.69	5.64	0.42	8.55e-8	Smoking initiation;
UCEC	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	5.03	0.38	1.44e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs35260072	1	rs35260072	chr5:131630852	A/C	cg14196790	chr5:131705035	SLC22A5	0.44	4.77	0.37	4.49e-6	Itch intensity from mosquito bite;
UCEC	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.77	7.07	0.5	5.71e-11	Morning vs. evening chronotype;
UCEC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg00815214	chr21:47717953	NA	-0.4	-4.63	-0.36	7.86e-6	Testicular germ cell tumor;
UCEC	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.65	6.47	0.47	1.35e-9	Plateletcrit;Platelet count;
UCEC	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.62	5.41	0.41	2.48e-7	Coronary artery disease;
UCEC	cis	rs1823913	0.599	rs13020656	chr2:192178923	T/C	cg15998761	chr2:191300784	MFSD6	0.39	4.51	0.35	1.31e-5	Obesity-related traits;
UCEC	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg13683864	chr3:40499215	RPL14	-0.57	-6.19	-0.45	5.63e-9	Renal cell carcinoma;
UCEC	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.55	6.36	0.46	2.45e-9	Blood metabolite ratios;
UCEC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-10.5	-0.65	1.34e-19	Schizophrenia;
UCEC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18252515	chr7:66147081	NA	0.46	4.7	0.36	5.89e-6	Aortic root size;
UCEC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.57	-7.59	-0.53	3.41e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.08	8.96	0.59	1.32e-15	Vitiligo;
UCEC	cis	rs7089973	1.000	rs7089973	chr10:116569565	A/C	cg23260525	chr10:116636907	FAM160B1	-0.31	-4.55	-0.35	1.13e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.69	6.11	0.45	8.36e-9	Adiposity;
UCEC	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.76	-5.33	-0.4	3.59e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.56	0.42	1.22e-7	Alzheimer's disease;
UCEC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg12463550	chr7:65579703	CRCP	0.54	5.51	0.41	1.54e-7	Aortic root size;
UCEC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.7	6.58	0.48	7.77e-10	High light scatter reticulocyte count;
UCEC	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.78	11.23	0.68	1.58e-21	Leprosy;
UCEC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.15	-10.75	-0.66	3.01e-20	Vitiligo;
UCEC	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.37e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.77	9.18	0.6	3.59e-16	Bone mineral density;
UCEC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	6.86	0.49	1.8e-10	Menarche (age at onset);
UCEC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	1.01	9.38	0.61	1.12e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.9	9.65	0.62	2.3e-17	Cognitive function;
UCEC	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.89	12.63	0.72	3.12e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	trans	rs1552172	0.887	rs12750384	chr1:145681484	T/C	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.86	-0.49	1.75e-10	Breast cancer;
UCEC	cis	rs11118844	0.793	rs7516292	chr1:221942413	C/T	cg04222084	chr1:221915650	DUSP10	-0.76	-7.39	-0.52	1.02e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-4.75	-0.36	4.78e-6	Bipolar disorder;
UCEC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg07836142	chr6:28411423	ZSCAN23	0.59	6.67	0.48	4.8e-10	Cardiac Troponin-T levels;
UCEC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.67	-5.53	-0.41	1.44e-7	Alcohol dependence;
UCEC	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-12.81	-0.73	1.08e-25	Body mass index;
UCEC	cis	rs11761441	0.602	rs6963983	chr7:93176	A/C	cg06458707	chr7:1083209	C7orf50	0.25	4.6	0.35	9.18e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs1564271	0.632	rs2368183	chr10:26998739	G/C	cg24343755	chr10:26987087	PDSS1	-0.55	-4.79	-0.37	3.95e-6	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
UCEC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.64	5.89	0.44	2.57e-8	Brain structure;
UCEC	cis	rs59918340	0.738	rs7007986	chr8:142217115	G/A	cg18755752	chr8:142205143	DENND3	-0.63	-5.71	-0.43	6.1e-8	Immature fraction of reticulocytes;
UCEC	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6662386	0.557	rs11590929	chr1:88214437	A/G	cg10042178	chr1:87794589	LMO4	-0.47	-4.56	-0.35	1.06e-5	Prostate-specific antigen levels;
UCEC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.59	6.04	0.45	1.19e-8	Colorectal cancer;
UCEC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.64	7.01	0.5	8.14e-11	Homoarginine levels;
UCEC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.7	-6.45	-0.47	1.53e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	1.06	7.63	0.53	2.75e-12	Exhaled nitric oxide output;
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.49	5.48	0.41	1.84e-7	Platelet count;
UCEC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.46	6.78	0.49	2.7e-10	Homoarginine levels;
UCEC	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg04043695	chr12:129287642	SLC15A4	0.7	7.0	0.5	8.35e-11	Systemic lupus erythematosus;
UCEC	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.51	5.68	0.42	6.87e-8	Blood metabolite ratios;
UCEC	cis	rs7175404	0.591	rs74379684	chr15:94050205	C/T	cg25253948	chr15:93956996	NA	0.68	4.57	0.35	1.03e-5	Attention deficit hyperactivity disorder;
UCEC	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	5.04	0.38	1.33e-6	IgG glycosylation;
UCEC	cis	rs11129176	0.959	rs4858678	chr3:25047446	A/G	cg02506578	chr3:25824554	NGLY1	0.61	4.76	0.37	4.62e-6	Optic disc area;
UCEC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.65	-5.74	-0.43	5.17e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.64	-7.13	-0.51	4.16e-11	Homoarginine levels;
UCEC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.72	8.68	0.58	6.77e-15	Vitiligo;
UCEC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg23307798	chr14:103986281	CKB	0.65	7.85	0.54	8e-13	Body mass index;
UCEC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.86	9.45	0.61	7.43e-17	Cognitive function;
UCEC	cis	rs2644899	0.785	rs7249450	chr19:41300771	T/C	cg15701203	chr19:40737740	AKT2	-0.52	-4.51	-0.35	1.34e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.71	-5.82	-0.43	3.62e-8	Birth weight;
UCEC	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.87	4.65	0.36	7.34e-6	Inflammatory bowel disease;
UCEC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg20821713	chr7:1055600	C7orf50	-0.57	-4.61	-0.36	8.79e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.71	6.76	0.49	3.09e-10	Monocyte count;
UCEC	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.57	7.06	0.5	6.18e-11	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.51	-4.83	-0.37	3.44e-6	Longevity;
UCEC	cis	rs9467773	1.000	rs1001687	chr6:26573218	C/G	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.47	-4.85	-0.37	3.1e-6	Schizophrenia;
UCEC	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg16511985	chr3:153974050	SGEF	0.57	5.48	0.41	1.78e-7	Coronary artery disease;
UCEC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg19318889	chr4:1322082	MAEA	0.43	4.93	0.38	2.18e-6	Obesity-related traits;
UCEC	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.44	-4.97	-0.38	1.86e-6	Glaucoma (primary open-angle);
UCEC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24308560	chr3:49941425	MST1R	0.52	5.92	0.44	2.16e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.74e-6	Emphysema distribution in smoking;
UCEC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.76	8.25	0.56	8.04e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.58	-5.28	-0.4	4.65e-7	Metabolite levels;
UCEC	cis	rs10507349	0.837	rs54433	chr13:26816956	C/T	cg01600817	chr13:26797529	RNF6	0.49	5.35	0.4	3.29e-7	Type 2 diabetes;
UCEC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-4.58	-0.35	9.88e-6	Alzheimer's disease (late onset);
UCEC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg01262667	chr19:19385393	TM6SF2	0.48	6.31	0.46	3.08e-9	Tonsillectomy;
UCEC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.64	6.64	0.48	5.78e-10	Gestational age at birth (maternal effect);
UCEC	cis	rs3790645	1.000	rs364977	chr1:26893836	G/A	cg23229016	chr1:26872525	RPS6KA1	0.25	4.67	0.36	6.79e-6	Glucose homeostasis traits;
UCEC	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.78	7.61	0.53	2.99e-12	Mosquito bite size;
UCEC	cis	rs7546668	1.000	rs6429746	chr1:15815579	A/G	cg05660106	chr1:15850417	CASP9	0.43	4.52	0.35	1.28e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.79	9.44	0.61	7.75e-17	Breast cancer;
UCEC	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07215822	chr6:158701037	NA	-0.71	-6.24	-0.46	4.4e-9	Height;
UCEC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-0.6	-6.99	-0.5	8.83e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg11738485	chr19:12877000	HOOK2	0.47	5.23	0.4	5.66e-7	Bipolar disorder;
UCEC	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.68	7.58	0.53	3.57e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.47	5.4	0.41	2.62e-7	Aortic root size;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg06540715	chr13:111568383	ANKRD10	-0.89	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs7175404	0.527	rs7183559	chr15:94054392	A/G	cg25253948	chr15:93956996	NA	0.67	4.89	0.37	2.63e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-5.77	-0.43	4.55e-8	Birth weight;
UCEC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-5.76	-0.43	4.77e-8	Morning vs. evening chronotype;
UCEC	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.56	6.46	0.47	1.42e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg20387954	chr3:183756860	HTR3D	0.51	6.24	0.46	4.39e-9	Anterior chamber depth;
UCEC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	8.1	0.56	1.98e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18252515	chr7:66147081	NA	-0.53	-5.0	-0.38	1.65e-6	Aortic root size;
UCEC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.5	-6.28	-0.46	3.53e-9	Electrocardiographic conduction measures;
UCEC	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.51	-5.18	-0.39	7.14e-7	Headache;
UCEC	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.73	7.26	0.51	2.13e-11	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.59	5.83	0.43	3.33e-8	Aortic root size;
UCEC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg13695892	chr22:41940480	POLR3H	-0.69	-4.88	-0.37	2.69e-6	Vitiligo;
UCEC	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.95	11.31	0.68	9.85e-22	Ulcerative colitis;
UCEC	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.64	-0.48	5.59e-10	Caudate activity during reward;
UCEC	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg02551604	chr5:131831745	NA	-0.66	-5.19	-0.39	6.73e-7	Asthma (sex interaction);
UCEC	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.7	-8.33	-0.57	5.21e-14	Testicular germ cell tumor;
UCEC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.59	-7.83	-0.54	9.1e-13	Prudent dietary pattern;
UCEC	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-0.81	-7.36	-0.52	1.24e-11	Blood protein levels;
UCEC	cis	rs7088591	1.000	rs4529850	chr10:59780725	T/C	cg11142981	chr10:60273225	BICC1	0.64	4.59	0.35	9.34e-6	Blood pressure;
UCEC	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.7	-0.36	6.06e-6	Resting heart rate;
UCEC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.59	8.49	0.57	2.07e-14	Prudent dietary pattern;
UCEC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.26	0.51	2.12e-11	Smoking behavior;
UCEC	trans	rs2274273	0.745	rs8005399	chr14:55542845	A/G	cg02022102	chr7:27168609	HOXA4	0.61	6.74	0.49	3.29e-10	Protein biomarker;
UCEC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.76	8.52	0.57	1.74e-14	Cognitive test performance;
UCEC	cis	rs17106184	1.000	rs72904771	chr1:51393412	A/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs534126	1.000	rs476826	chr7:142906434	C/T	cg04182207	chr7:143013161	CLCN1	0.38	5.47	0.41	1.91e-7	Cancer;
UCEC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.67	-6.81	-0.49	2.26e-10	Longevity;Endometriosis;
UCEC	cis	rs6684428	0.536	rs6660000	chr1:56399554	G/C	cg11651538	chr1:56320950	NA	-0.46	-4.75	-0.36	4.78e-6	Airflow obstruction;
UCEC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.87	5.56	0.42	1.24e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.58	-7.38	-0.52	1.09e-11	Bone mineral density;
UCEC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.92	9.8	0.63	9.37e-18	Cognitive function;
UCEC	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.66	-0.36	6.96e-6	Schizophrenia;
UCEC	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-4.66	-0.36	7.11e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.62	5.03	0.38	1.39e-6	Gut microbiome composition (summer);
UCEC	cis	rs5756391	0.546	rs4821560	chr22:37311806	G/T	cg08619048	chr22:37387314	C22orf33	-0.34	-4.58	-0.35	9.7e-6	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.53	-0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.37	4.9	0.37	2.46e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.76	-7.11	-0.51	4.58e-11	Alzheimer's disease;
UCEC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	8.33	0.57	5.15e-14	Coffee consumption (cups per day);
UCEC	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.66	-6.78	-0.49	2.78e-10	Intelligence (multi-trait analysis);
UCEC	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.5	-5.05	-0.38	1.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7246967	0.673	rs407989	chr19:22991586	C/G	cg08271804	chr19:22816896	ZNF492	-0.63	-5.58	-0.42	1.15e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.07	-0.39	1.17e-6	Personality dimensions;
UCEC	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.18	0.39	7.29e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg24088508	chr1:38156462	C1orf109	-0.57	-5.08	-0.39	1.11e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	5.96	0.44	1.78e-8	IgG glycosylation;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05657792	chr17:6899758	ALOX12	0.42	5.27	0.4	4.76e-7	Tonsillectomy;
UCEC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg18479299	chr3:125709523	NA	0.65	4.5	0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg11871910	chr12:69753446	YEATS4	0.89	10.31	0.65	4.27e-19	Blood protein levels;
UCEC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.48	-4.89	-0.37	2.56e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-25.18	-0.9	3.61e-55	Myeloid white cell count;
UCEC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg13695892	chr22:41940480	POLR3H	-0.7	-5.69	-0.43	6.56e-8	Vitiligo;
UCEC	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.8	5.59	0.42	1.07e-7	Psoriasis;
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.38	-0.47	2.19e-9	Response to antipsychotic treatment;
UCEC	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg05660106	chr1:15850417	CASP9	-0.49	-4.57	-0.35	1.01e-5	Systolic blood pressure;
UCEC	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.62	6.74	0.49	3.41e-10	Obesity-related traits;
UCEC	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.45	4.68	0.36	6.43e-6	Post bronchodilator FEV1;
UCEC	cis	rs7267005	0.661	rs74431448	chr20:34427680	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.76	7.97	0.55	4.1e-13	Caffeine consumption;
UCEC	cis	rs514475	0.759	rs6924473	chr6:138066687	G/A	cg26287741	chr6:138867125	NHSL1	0.68	4.73	0.36	5.29e-6	Inflammatory skin disease;
UCEC	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	5.91	0.44	2.27e-8	Schizophrenia;
UCEC	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.51	5.8	0.43	3.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.59	6.18	0.45	5.84e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-6.22	-0.46	4.92e-9	Hemoglobin concentration;
UCEC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg27068330	chr11:65405492	SIPA1	0.52	5.03	0.38	1.43e-6	Acne (severe);
UCEC	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg19197139	chr17:4613644	ARRB2	0.81	6.1	0.45	8.89e-9	Lymphocyte counts;
UCEC	cis	rs2415984	0.846	rs11626664	chr14:46847678	G/T	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.47	5.32	0.4	3.78e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.67	-8.2	-0.56	1.07e-13	Height;
UCEC	cis	rs8020441	0.541	rs72681665	chr14:51167012	C/A	cg04730355	chr14:51134070	SAV1	0.93	8.52	0.58	1.7e-14	Cognitive performance;
UCEC	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.5	-0.41	1.63e-7	Morning vs. evening chronotype;
UCEC	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs7781557	0.702	rs4377880	chr7:102473163	A/G	cg06322601	chr7:102330635	NA	0.76	4.91	0.38	2.43e-6	Colorectal adenoma (advanced);
UCEC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.57	-5.51	-0.41	1.6e-7	Platelet count;
UCEC	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg24687543	chr11:63912206	MACROD1	0.58	4.75	0.36	4.84e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.8	-0.37	3.88e-6	Major depressive disorder;
UCEC	cis	rs4713118	0.513	rs6915987	chr6:27515776	G/A	cg13525197	chr6:28411240	ZSCAN23	0.46	4.71	0.36	5.59e-6	Parkinson's disease;
UCEC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg11871910	chr12:69753446	YEATS4	0.56	4.9	0.37	2.47e-6	Response to diuretic therapy;
UCEC	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.8	7.3	0.52	1.64e-11	Bladder cancer;
UCEC	cis	rs4074961	0.544	rs11264067	chr1:37991458	C/T	cg17933807	chr1:38061675	GNL2	0.76	8.71	0.58	5.92e-15	Axial length;
UCEC	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.49	-0.72	7.33e-25	Primary sclerosing cholangitis;
UCEC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.46	-4.76	-0.37	4.6e-6	Schizophrenia;
UCEC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.53	0.47	1e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs151997	0.962	rs27256	chr5:50190264	G/C	cg06027927	chr5:50259733	NA	0.54	4.97	0.38	1.86e-6	Callous-unemotional behaviour;
UCEC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.42	-6.04	-0.45	1.18e-8	Rheumatoid arthritis;
UCEC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.37	5.14	0.39	8.42e-7	Eye color traits;
UCEC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.55	-0.58	1.47e-14	Monocyte count;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg11697111	chr7:1126903	GPER;C7orf50	-0.48	-4.77	-0.37	4.32e-6	Longevity;Endometriosis;
UCEC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1250259	0.519	rs2372544	chr2:216264270	G/T	cg17325911	chr2:216976926	XRCC5	0.46	4.92	0.38	2.28e-6	Coronary artery disease;Pulse pressure;
UCEC	cis	rs55670112	0.935	rs4292441	chr5:114279914	C/A	cg05461448	chr5:114880715	FEM1C	-0.45	-4.57	-0.35	1.04e-5	Epilepsy;
UCEC	cis	rs240764	0.541	rs9390693	chr6:101239935	T/C	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.9	9.65	0.62	2.3e-17	Cognitive function;
UCEC	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.52	-4.77	-0.37	4.46e-6	Coronary artery disease;
UCEC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.07	0.39	1.21e-6	Diabetic retinopathy;
UCEC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.61	5.99	0.44	1.58e-8	Post bronchodilator FEV1;
UCEC	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.57	-4.98	-0.38	1.76e-6	Colorectal cancer;
UCEC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.73	-6.88	-0.49	1.62e-10	Aortic root size;
UCEC	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.63	5.17	0.39	7.6e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg23888215	chr10:79422304	NA	-0.72	-6.01	-0.44	1.42e-8	Bone mineral density;
UCEC	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.36	0.57	4.34e-14	Menopause (age at onset);
UCEC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.82	-9.47	-0.62	6.72e-17	Coronary artery disease;
UCEC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.92	0.38	2.34e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-9.04	-0.6	8.36e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8105895	0.935	rs62112918	chr19:22227079	C/T	cg20662725	chr19:22235022	ZNF257	-0.64	-5.31	-0.4	3.95e-7	Body mass index (change over time);
UCEC	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.79	7.95	0.55	4.5e-13	Colorectal cancer;
UCEC	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-1.01	-4.58	-0.35	9.8e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.56	5.06	0.38	1.25e-6	Obesity-related traits;
UCEC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.63e-7	Headache;
UCEC	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.47	4.51	0.35	1.34e-5	Alzheimer's disease (late onset);
UCEC	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.62	6.54	0.47	9.69e-10	Retinal vascular caliber;
UCEC	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.65	5.53	0.42	1.41e-7	Coronary artery calcification;
UCEC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.49	0.41	1.73e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6688613	1.000	rs1327866	chr1:166952910	C/T	cg07049167	chr1:166818506	POGK	-0.45	-4.89	-0.37	2.65e-6	Refractive astigmatism;
UCEC	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.79	9.44	0.61	7.75e-17	Breast cancer;
UCEC	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	7.04	0.5	6.7e-11	Mean platelet volume;
UCEC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-6.22	-0.46	4.98e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.14	13.95	0.75	1.06e-28	Cognitive function;
UCEC	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.62	6.9	0.49	1.47e-10	Pubertal anthropometrics;
UCEC	cis	rs10507349	0.874	rs12869931	chr13:26780665	A/G	cg01600817	chr13:26797529	RNF6	-0.46	-4.53	-0.35	1.19e-5	Type 2 diabetes;
UCEC	cis	rs970548	0.865	rs12246131	chr10:45993782	A/T	cg15223267	chr10:46222474	FAM21C	0.54	5.15	0.39	8.09e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.67	-8.03	-0.55	2.92e-13	Prevalent atrial fibrillation;
UCEC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.69	6.16	0.45	6.57e-9	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.75	-6.65	-0.48	5.45e-10	Diastolic blood pressure;
UCEC	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.42	4.64	0.36	7.55e-6	Mean corpuscular volume;
UCEC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg23324259	chr8:82754387	SNX16	-0.54	-4.68	-0.36	6.33e-6	Diastolic blood pressure;
UCEC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12516959	chr21:47718080	NA	-0.4	-4.58	-0.35	9.9e-6	Testicular germ cell tumor;
UCEC	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.68	-0.36	6.57e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-4.91	-0.38	2.36e-6	Platelet distribution width;
UCEC	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-7.61	-0.53	3.04e-12	Vitiligo;
UCEC	cis	rs884366	0.964	rs4946953	chr6:109583631	A/G	cg01475377	chr6:109611718	NA	0.47	5.28	0.4	4.61e-7	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs7246967	0.673	rs12975767	chr19:22862809	A/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg18099408	chr3:52552593	STAB1	0.43	4.81	0.37	3.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-4.51	-0.35	1.32e-5	Menarche (age at onset);
UCEC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.23	7.34	0.52	1.38e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-4.57	-0.35	1.02e-5	Hemoglobin concentration;
UCEC	cis	rs7113850	0.541	rs77699762	chr11:24236448	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Bone fracture in osteoporosis;
UCEC	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.02	-7.79	-0.54	1.08e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg00343986	chr7:65444356	GUSB	-0.49	-4.54	-0.35	1.18e-5	Aortic root size;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.51	6.15	0.45	6.97e-9	Total body bone mineral density;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	9.03	0.6	8.7e-16	Platelet count;
UCEC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg17105886	chr17:28927953	LRRC37B2	0.64	4.7	0.36	5.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2062225	0.735	rs1384792	chr2:111766119	C/T	cg23782758	chr2:111737646	ACOXL	-0.48	-4.61	-0.36	8.85e-6	Monocyte count;
UCEC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.23	0.4	5.83e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.91	-7.02	-0.5	7.42e-11	Exhaled nitric oxide output;
UCEC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs787274	1.000	rs7859381	chr9:115546649	C/T	cg13803584	chr9:115635662	SNX30	-0.67	-4.96	-0.38	1.95e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	6.39	0.47	2.07e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.86	8.87	0.59	2.27e-15	Cognitive function;
UCEC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.71	-6.36	-0.46	2.46e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-6.35	-0.46	2.51e-9	Gut microbiome composition (summer);
UCEC	cis	rs76096589	0.557	rs12587721	chr14:51016600	A/G	cg24879595	chr14:50359859	ARF6	-0.59	-4.55	-0.35	1.12e-5	Diisocyanate-induced asthma;
UCEC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.54	0.42	1.38e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg21770322	chr7:97807741	LMTK2	0.63	7.55	0.53	4.24e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.43	-5.22	-0.4	5.9e-7	Refractive error;
UCEC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Bladder cancer;
UCEC	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-6.32	-0.46	2.99e-9	Blood protein levels;
UCEC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-8.32	-0.57	5.37e-14	Chronic sinus infection;
UCEC	cis	rs308403	0.509	rs7690409	chr4:123666757	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	8.28	0.56	6.96e-14	Blood protein levels;
UCEC	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-5.89	-0.44	2.5e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.67	6.79	0.49	2.58e-10	C-reactive protein levels;
UCEC	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-5.77	-0.43	4.47e-8	Educational attainment (years of education);
UCEC	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.51	-5.82	-0.43	3.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.74	-0.43	5.24e-8	Chronic sinus infection;
UCEC	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.59	-6.15	-0.45	7.06e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.52	-4.84	-0.37	3.18e-6	Diabetic retinopathy;
UCEC	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.9	11.35	0.68	7.85e-22	Height;
UCEC	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.68	-7.4	-0.52	9.77e-12	Homoarginine levels;
UCEC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.86	11.09	0.67	3.81e-21	Metabolic syndrome;
UCEC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	8.18e-8	Resting heart rate;
UCEC	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.65	8.25	0.56	8.33e-14	Testicular germ cell tumor;
UCEC	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg23625390	chr15:77176239	SCAPER	-0.8	-7.19	-0.51	3.1e-11	Blood metabolite levels;
UCEC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.93	-0.44	2.09e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	0.84	5.39	0.41	2.75e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs7552167	0.636	rs4090311	chr1:24513768	G/A	cg01960748	chr1:24522592	NA	-0.65	-5.63	-0.42	8.75e-8	Psoriasis vulgaris;
UCEC	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg24011408	chr12:48396354	COL2A1	0.52	4.65	0.36	7.22e-6	Lung cancer;
UCEC	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.76	8.76	0.59	4.33e-15	Extraversion;
UCEC	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.67	6.62	0.48	6.29e-10	Lymphocyte counts;
UCEC	cis	rs75804782	0.572	rs74979875	chr2:239302568	G/A	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.72	-0.36	5.39e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.41	-0.41	2.55e-7	Parkinson's disease;
UCEC	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.54	4.95	0.38	1.99e-6	Coronary artery disease;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.78	10.52	0.66	1.24e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-4.51	-0.35	1.32e-5	Mood instability;
UCEC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg04013166	chr16:89971882	TCF25	0.69	6.32	0.46	3.02e-9	Skin colour saturation;
UCEC	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.43	5.58	0.42	1.13e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg19875535	chr5:140030758	IK	0.43	4.8	0.37	3.78e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-0.6	-6.99	-0.5	8.83e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg21770322	chr7:97807741	LMTK2	-0.51	-6.17	-0.45	6.24e-9	Breast cancer;
UCEC	cis	rs944990	0.618	rs10992798	chr9:96362205	G/A	cg13787134	chr9:96362102	PHF2	-0.4	-5.41	-0.41	2.55e-7	Body mass index;
UCEC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg24375607	chr4:120327624	NA	0.48	4.98	0.38	1.74e-6	Corneal astigmatism;
UCEC	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.44	4.85	0.37	3.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.75	6.0	0.44	1.46e-8	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.73	-6.06	-0.45	1.09e-8	Response to diuretic therapy;
UCEC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.81	0.37	3.69e-6	Breast cancer;
UCEC	cis	rs28795989	0.761	rs1320075	chr4:7903244	C/A	cg00251875	chr4:7801337	AFAP1	0.49	5.71	0.43	5.94e-8	Intraocular pressure;
UCEC	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.4	0.47	2e-9	Bipolar disorder;
UCEC	cis	rs7246967	0.551	rs56968124	chr19:22814449	T/C	cg23217946	chr19:22817039	ZNF492	0.41	4.56	0.35	1.09e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs782107	0.674	rs782100	chr12:58808285	G/A	cg19181132	chr12:59314527	LRIG3	0.46	4.92	0.38	2.26e-6	Interleukin-12p70 levels;
UCEC	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07215822	chr6:158701037	NA	-0.66	-5.87	-0.44	2.83e-8	Height;
UCEC	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.81e-7	Heart rate;
UCEC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.66	5.94	0.44	1.95e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg04043695	chr12:129287642	SLC15A4	0.67	6.66	0.48	5.22e-10	Systemic lupus erythematosus;
UCEC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg14092571	chr14:90743983	NA	-0.4	-5.52	-0.41	1.5e-7	Mortality in heart failure;
UCEC	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.72	6.45	0.47	1.49e-9	Subjective well-being;
UCEC	cis	rs4727443	0.736	rs4727444	chr7:99614851	T/A	cg22004693	chr7:99632812	ZKSCAN1	0.52	4.53	0.35	1.19e-5	Interstitial lung disease;
UCEC	cis	rs6670533	0.571	rs6669881	chr1:24862749	A/G	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.66	7.85	0.54	7.94e-13	Hip circumference;
UCEC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.47	-5.11	-0.39	9.86e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.42	4.81	0.37	3.64e-6	Blood metabolite ratios;
UCEC	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	13.07	0.73	2.19e-26	Colorectal cancer;
UCEC	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.48	-4.76	-0.37	4.68e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.75	7.38	0.52	1.06e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.57	-6.04	-0.45	1.2e-8	Trans fatty acid levels;
UCEC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	0.93	9.48	0.62	6.08e-17	Heart rate;
UCEC	cis	rs11593576	0.579	rs1313056	chr10:80996351	A/G	cg18762849	chr10:81741832	NA	-0.5	-4.95	-0.38	2.05e-6	Vitiligo;
UCEC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-5.06	-0.38	1.25e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.83	6.78	0.49	2.66e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9467773	1.000	rs6918506	chr6:26577857	C/G	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	6.09	0.45	9.17e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-9.05	-0.6	7.85e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs427941	0.732	rs378011	chr7:101849396	A/G	cg08135718	chr7:101819329	CUX1	-0.44	-5.22	-0.4	5.95e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg04632378	chr13:21900426	NA	0.39	4.54	0.35	1.18e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs11760485	0.965	rs9655026	chr7:4402663	C/T	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.56	6.02	0.44	1.31e-8	Longevity;
UCEC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.01	-0.5	8.02e-11	Coronary artery disease;
UCEC	cis	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg03342759	chr3:160939853	NMD3	0.52	4.67	0.36	6.86e-6	Morning vs. evening chronotype;
UCEC	cis	rs6424115	0.830	rs6673210	chr1:24203534	A/G	cg10978503	chr1:24200527	CNR2	0.35	4.6	0.35	9.03e-6	Immature fraction of reticulocytes;
UCEC	cis	rs847649	0.699	rs10242028	chr7:102527785	C/G	cg18108683	chr7:102477205	FBXL13	-0.65	-8.07	-0.55	2.31e-13	Morning vs. evening chronotype;
UCEC	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	8.34	0.57	5.04e-14	Menopause (age at onset);
UCEC	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.62	-6.21	-0.46	5.03e-9	Strep throat;
UCEC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15356226	chr22:41843734	TOB2	-0.54	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg06265175	chr8:121136014	COL14A1	0.5	5.32	0.4	3.77e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03576123	chr11:487126	PTDSS2	0.77	6.14	0.45	7.16e-9	Body mass index;
UCEC	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.35	-0.4	3.28e-7	Acylcarnitine levels;
UCEC	cis	rs6723108	0.627	rs4954196	chr2:135662016	A/G	cg07169764	chr2:136633963	MCM6	0.47	4.52	0.35	1.24e-5	Type 2 diabetes;
UCEC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.45	5.08	0.39	1.14e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.43	-4.53	-0.35	1.23e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.71	4.6	0.35	9.22e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.38e-16	Breast cancer;
UCEC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08859206	chr1:53392774	SCP2	-0.58	-6.21	-0.46	5.02e-9	Monocyte count;
UCEC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.78e-7	Heart rate;
UCEC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-4.58	-0.35	9.96e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.64	-5.05	-0.38	1.31e-6	Platelet count;
UCEC	cis	rs6493487	0.512	rs35134521	chr15:51317759	C/G	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.74	-4.74	-0.36	4.93e-6	Night sleep phenotypes;
UCEC	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-4.83	-0.37	3.41e-6	Life satisfaction;
UCEC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.39	-4.6	-0.35	9.13e-6	Abdominal aortic aneurysm;
UCEC	cis	rs9400271	0.527	rs60248809	chr6:109640690	A/C	cg01475377	chr6:109611718	NA	0.44	4.87	0.37	2.81e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.49	5.27	0.4	4.77e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-5.52	-0.41	1.52e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg01426195	chr3:39028469	NA	-0.77	-10.31	-0.65	4.22e-19	Handedness;
UCEC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.7	-5.05	-0.38	1.27e-6	Narcolepsy;
UCEC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.36	0.46	2.46e-9	Tonsillectomy;
UCEC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg24803719	chr17:45855879	NA	-0.45	-5.05	-0.38	1.3e-6	IgG glycosylation;
UCEC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	4.65	0.36	7.4e-6	Aortic root size;
UCEC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.6	5.19	0.39	6.92e-7	Heart rate;
UCEC	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.71	6.04	0.45	1.21e-8	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.62	-5.07	-0.39	1.19e-6	Blood metabolite levels;
UCEC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.66	5.2	0.39	6.54e-7	Body mass index;
UCEC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13470333	chr7:1908714	MAD1L1	0.4	4.51	0.35	1.29e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.55	-4.83	-0.37	3.38e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg18681998	chr4:17616180	MED28	0.82	10.49	0.65	1.48e-19	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.36	-5.37	-0.4	3.01e-7	Schizophrenia;
UCEC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	4.57	0.35	1.03e-5	Lung function (FEV1/FVC);
UCEC	cis	rs692804	0.818	rs1287395	chr11:120085692	C/G	cg16775289	chr11:120081497	OAF	1.0	4.72	0.36	5.38e-6	Blood protein levels;
UCEC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-5.26	-0.4	4.96e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6593803	0.547	rs7528262	chr1:147248817	C/T	cg27546670	chr1:147246839	GJA5	-0.44	-4.53	-0.35	1.2e-5	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
UCEC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg14289826	chr9:140003911	NA	-0.39	-5.24	-0.4	5.45e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	6.98	0.5	9.63e-11	Hemoglobin concentration;
UCEC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs2376682	0.918	rs6894241	chr5:118058126	G/T	cg17593721	chr5:118788746	HSD17B4	0.5	5.02	0.38	1.49e-6	Diisocyanate-induced asthma;
UCEC	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.68	-7.26	-0.51	2.11e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.64	5.77	0.43	4.61e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.49	5.83	0.43	3.41e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.48	-5.11	-0.39	9.74e-7	Response to temozolomide;
UCEC	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.37	-0.47	2.3e-9	Morning vs. evening chronotype;
UCEC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.46	5.15	0.39	8.15e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg26102564	chr10:131424627	MGMT	-0.37	-4.66	-0.36	6.97e-6	Response to temozolomide;
UCEC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.57	-4.62	-0.36	8.32e-6	Menopause (age at onset);
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg00280220	chr17:61926910	NA	-0.43	-4.85	-0.37	3.05e-6	Prudent dietary pattern;
UCEC	cis	rs10924970	0.967	rs11585350	chr1:235482739	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	4.96	0.38	1.95e-6	Asthma;
UCEC	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.22	-0.4	5.89e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.95e-6	Tonsillectomy;
UCEC	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.51	6.25	0.46	4.29e-9	Mean platelet volume;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.35	0.57	4.77e-14	Platelet count;
UCEC	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.92	4.75	0.37	4.69e-6	Plasma clusterin levels;
UCEC	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.78	-0.49	2.66e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.43	-5.56	-0.42	1.25e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg16023434	chr1:11395635	NA	-0.37	-4.52	-0.35	1.28e-5	Body mass index;
UCEC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-7.71	-0.54	1.76e-12	Response to antipsychotic treatment;
UCEC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.71	7.56	0.53	3.98e-12	Primary sclerosing cholangitis;
UCEC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.46	-0.41	1.99e-7	Aortic root size;
UCEC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-6.44	-0.47	1.56e-9	Menarche (age at onset);
UCEC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs10012307	0.786	rs72985955	chr4:137499174	G/T	cg12033966	chr4:138453416	PCDH18	-0.8	-4.66	-0.36	7.14e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.44	4.83	0.37	3.41e-6	Life satisfaction;
UCEC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-7.43	-0.52	8.38e-12	Blood trace element (Zn levels);
UCEC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.61	-0.36	8.59e-6	Parkinson's disease;
UCEC	cis	rs2415984	0.846	rs8011178	chr14:46835148	C/T	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	6.21	0.46	5.12e-9	Menopause (age at onset);
UCEC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.57	-6.72	-0.48	3.66e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.78	-6.12	-0.45	8.21e-9	Menopause (age at onset);
UCEC	cis	rs11083475	0.654	rs11669249	chr19:39256808	A/T	cg07905965	chr19:39260460	NA	0.41	4.72	0.36	5.45e-6	Heart rate;
UCEC	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01391022	chr12:122360665	WDR66	-0.45	-4.64	-0.36	7.76e-6	Mean corpuscular volume;
UCEC	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg04283868	chr2:201171347	SPATS2L	0.58	5.75	0.43	5.01e-8	QT interval;
UCEC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg00409905	chr10:38381863	ZNF37A	0.48	4.63	0.36	8.05e-6	Obesity (extreme);
UCEC	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.97	7.8	0.54	1.05e-12	Monobrow;
UCEC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.69	6.9	0.49	1.44e-10	Menopause (age at onset);
UCEC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-4.84	-0.37	3.23e-6	Menarche (age at onset);
UCEC	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.11	0.51	4.76e-11	Morning vs. evening chronotype;
UCEC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.67	5.32	0.4	3.76e-7	Corneal astigmatism;
UCEC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	1.18	9.48	0.62	6.42e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg03748352	chr10:182365	ZMYND11	0.56	4.55	0.35	1.12e-5	Uric acid levels;
UCEC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.83	-8.89	-0.59	1.98e-15	Cognitive function;
UCEC	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.47	5.16	0.39	8.02e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18252515	chr7:66147081	NA	0.49	4.91	0.38	2.41e-6	Aortic root size;
UCEC	cis	rs12137294	0.866	rs1078362	chr1:205209530	A/G	cg12580275	chr1:205744413	RAB7L1	0.45	4.95	0.38	2.04e-6	Red cell distribution width;
UCEC	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.11	-0.45	8.35e-9	Response to antipsychotic treatment;
UCEC	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg03748352	chr10:182365	ZMYND11	0.56	4.55	0.35	1.12e-5	Uric acid levels;
UCEC	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-6.49	-0.47	1.23e-9	Joint mobility (Beighton score);
UCEC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.58	6.24	0.46	4.37e-9	Cognitive function;
UCEC	cis	rs8105895	0.935	rs8110975	chr19:22240233	C/G	cg20662725	chr19:22235022	ZNF257	-0.64	-5.39	-0.41	2.78e-7	Body mass index (change over time);
UCEC	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg21214455	chr15:72412075	SENP8	0.48	4.6	0.35	9.19e-6	Red blood cell count;
UCEC	cis	rs847649	0.732	rs56269620	chr7:102489456	A/G	cg18108683	chr7:102477205	FBXL13	-0.66	-8.53	-0.58	1.69e-14	Morning vs. evening chronotype;
UCEC	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.35	1.37e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg13147721	chr7:65941812	NA	-0.92	-5.8	-0.43	3.91e-8	Diabetic kidney disease;
UCEC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.11	9.81	0.63	8.94e-18	Vitiligo;
UCEC	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.56	-5.71	-0.43	6.19e-8	Hepatocellular carcinoma;
UCEC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.88	0.37	2.7e-6	Breast cancer;
UCEC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg04155231	chr12:9217510	LOC144571	0.41	5.08	0.39	1.12e-6	Sjögren's syndrome;
UCEC	cis	rs6437061	0.614	rs3100583	chr2:232944860	G/A	cg02061626	chr2:233274167	ALPPL2	-0.44	-4.79	-0.37	3.95e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.79	0.37	4.11e-6	Menopause (age at onset);
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.98	-0.38	1.78e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg16303742	chr3:15540471	COLQ	-0.41	-5.22	-0.4	5.93e-7	Mean platelet volume;
UCEC	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.74	8.68	0.58	6.99e-15	Blood metabolite levels;
UCEC	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.79	6.35	0.46	2.59e-9	Neuroticism;
UCEC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.77	0.59	4.01e-15	Platelet count;
UCEC	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-0.54	-6.52	-0.47	1.04e-9	Total body bone mineral density;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.47	5.26	0.4	4.92e-7	Longevity;Endometriosis;
UCEC	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.92	-0.55	5.4e-13	Mosquito bite size;
UCEC	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.58	4.72	0.36	5.37e-6	Psoriasis;
UCEC	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.81	-0.54	9.88e-13	Total cholesterol levels;
UCEC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.21e-5	Parkinson's disease;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.45	-5.15	-0.39	8.1e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7246967	0.736	rs436595	chr19:22993045	G/T	cg08271804	chr19:22816896	ZNF492	0.59	5.21	0.4	6.16e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.75	-5.8	-0.43	3.97e-8	Narcolepsy;
UCEC	cis	rs7246967	0.551	rs56968124	chr19:22814449	T/C	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.29e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.66	5.32	0.4	3.79e-7	Menopause (age at onset);
UCEC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26002218	chr14:103986227	CKB	0.36	5.16	0.39	7.75e-7	Body mass index;
UCEC	cis	rs883565	0.771	rs1053530	chr3:39138082	A/G	cg01426195	chr3:39028469	NA	0.75	9.54	0.62	4.28e-17	Handedness;
UCEC	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.63	5.8	0.43	3.94e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7204230	1.000	rs8052283	chr16:53283966	G/A	cg10109421	chr16:52641824	NA	0.4	4.66	0.36	6.88e-6	Fibrinogen;
UCEC	cis	rs11118844	0.696	rs11118860	chr1:221953558	A/G	cg04222084	chr1:221915650	DUSP10	0.76	5.55	0.42	1.27e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg18171715	chr4:852160	GAK	0.55	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs2299682	0.826	rs6086920	chr20:9479995	A/G	cg11931762	chr20:9488920	NA	-0.68	-5.06	-0.38	1.26e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.61	-6.53	-0.47	9.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.75	8.41	0.57	3.25e-14	Coronary artery disease;
UCEC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.73	6.79	0.49	2.61e-10	Selective IgA deficiency;
UCEC	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.7	0.36	5.81e-6	Educational attainment;
UCEC	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.6	6.58	0.48	7.68e-10	Resting heart rate;
UCEC	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.51	-5.84	-0.43	3.17e-8	Cardiac Troponin-T levels;
UCEC	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-0.86	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg21905437	chr5:178450457	ZNF879	0.63	7.06	0.5	6.14e-11	Pubertal anthropometrics;
UCEC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.35	-5.47	-0.41	1.9e-7	Ulcerative colitis;
UCEC	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-6.92	-0.5	1.32e-10	Ulcerative colitis;
UCEC	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.53	-5.97	-0.44	1.72e-8	Mean corpuscular volume;
UCEC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.41	-4.53	-0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246657	0.508	rs10419845	chr19:37491192	G/T	cg23950597	chr19:37808831	NA	-0.86	-5.55	-0.42	1.33e-7	Coronary artery calcification;
UCEC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.12	-7.21	-0.51	2.73e-11	Diabetic kidney disease;
UCEC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.81	9.78	0.63	1.05e-17	Mortality in heart failure;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg10263370	chr3:44754102	ZNF502	0.53	5.42	0.41	2.41e-7	Depressive symptoms;
UCEC	cis	rs1662342	0.800	rs16944619	chr18:3278633	A/G	cg26661543	chr18:2570950	NDC80;METTL4	-0.64	-4.65	-0.36	7.38e-6	QRS duration;
UCEC	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	0.61	6.19	0.45	5.61e-9	Vitiligo;
UCEC	cis	rs1832871	0.965	rs2105333	chr6:158755437	T/G	cg07215822	chr6:158701037	NA	0.48	4.88	0.37	2.69e-6	Height;
UCEC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.58	-6.21	-0.46	5.2e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs36051895	0.559	rs6476949	chr9:5208048	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-4.91	-0.38	2.41e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg08027265	chr7:2291960	NA	-0.47	-4.97	-0.38	1.88e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	4.6	0.35	9.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg01072550	chr1:21505969	NA	-0.52	-4.59	-0.35	9.48e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.53	4.99	0.38	1.65e-6	Coronary artery disease;
UCEC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.58	5.12	0.39	9.25e-7	Menarche (age at onset);
UCEC	cis	rs1576263	0.967	rs7753991	chr6:8561428	A/G	cg21535247	chr6:8435926	SLC35B3	0.48	4.97	0.38	1.8e-6	Photic sneeze reflex;
UCEC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.65	6.23	0.46	4.58e-9	Breast cancer;
UCEC	cis	rs9788682	0.747	rs4887053	chr15:78712699	A/C	cg24631222	chr15:78858424	CHRNA5	-0.75	-6.49	-0.47	1.21e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.33	0.52	1.39e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.58	6.1	0.45	8.98e-9	Breast cancer;
UCEC	trans	rs8026198	0.734	rs7163986	chr15:42696158	A/T	cg09637963	chr6:14798944	NA	-0.44	-6.81	-0.49	2.32e-10	Fibrinogen levels;
UCEC	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.57	5.23	0.4	5.74e-7	Coronary artery disease;
UCEC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.63	-5.73	-0.43	5.42e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.69	7.52	0.53	4.95e-12	IgG glycosylation;
UCEC	cis	rs12618769	0.597	rs11902825	chr2:99129137	T/C	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.64	-6.94	-0.5	1.17e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.45	4.71	0.36	5.58e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.63	7.7	0.54	1.85e-12	Mean platelet volume;
UCEC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.79	7.29	0.52	1.72e-11	Red cell distribution width;
UCEC	cis	rs55883249	1.000	rs60319753	chr2:9767944	A/G	cg23886495	chr2:9695866	ADAM17	0.69	4.56	0.35	1.09e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.51	-0.53	5.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.72	6.35	0.46	2.59e-9	Coronary artery disease;
UCEC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.58	5.49	0.41	1.76e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg12559939	chr2:27858050	GPN1	-0.48	-4.86	-0.37	2.98e-6	Oral cavity cancer;
UCEC	cis	rs2904967	0.929	rs3016001	chr11:65008771	G/A	cg01630869	chr11:65082120	CDC42EP2	-0.48	-4.64	-0.36	7.71e-6	Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10958397	chr10:127511832	BCCIP;UROS	0.6	7.06	0.5	6.13e-11	Warfarin maintenance dose;
UCEC	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	0.92	9.15	0.6	4.51e-16	Post bronchodilator FEV1;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg26769984	chr7:1090371	C7orf50	0.47	4.57	0.35	1.03e-5	Longevity;Endometriosis;
UCEC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.25	12.33	0.71	1.96e-24	Corneal structure;
UCEC	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24308560	chr3:49941425	MST1R	-0.46	-4.67	-0.36	6.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg11945507	chr8:142233382	SLC45A4	-0.41	-4.75	-0.36	4.75e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.53	4.86	0.37	3.01e-6	Lung cancer;
UCEC	cis	rs8177876	0.730	rs76656387	chr16:81117467	G/A	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.32	0.4	3.78e-7	Breast cancer;
UCEC	cis	rs56341938	0.679	rs13327022	chr3:168822748	G/T	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-5.08	-0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.5	-6.02	-0.44	1.31e-8	Total body bone mineral density;
UCEC	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg00122941	chr17:4613640	ARRB2	0.64	5.04	0.38	1.34e-6	Lymphocyte counts;
UCEC	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.44	0.41	2.17e-7	IgG glycosylation;
UCEC	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.82	7.4	0.52	9.48e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10510146	0.841	rs297222	chr10:127295894	C/T	cg07954108	chr10:127464368	MMP21	0.49	4.5	0.35	1.36e-5	Non-alcoholic fatty liver disease histology (other);
UCEC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-4.53	-0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.61	6.25	0.46	4.27e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.65	8.1	0.56	1.88e-13	Vitiligo;
UCEC	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg01072550	chr1:21505969	NA	-0.61	-6.27	-0.46	3.85e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.69	7.21	0.51	2.78e-11	Blood protein levels;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg24703168	chr6:28411309	ZSCAN23	-0.48	-5.12	-0.39	9.43e-7	Pubertal anthropometrics;
UCEC	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.4e-8	Height;
UCEC	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.67	7.27	0.51	1.93e-11	Stearic acid (18:0) levels;
UCEC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg17294928	chr15:75287854	SCAMP5	-0.49	-5.42	-0.41	2.39e-7	Breast cancer;
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07157834	chr1:205819609	PM20D1	0.86	9.71	0.63	1.59e-17	Menarche (age at onset);
UCEC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.46	4.71	0.36	5.79e-6	Blood metabolite levels;
UCEC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.49	6.05	0.45	1.13e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.92	8.3	0.57	6.02e-14	Bladder cancer;
UCEC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.6	-4.96	-0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.7	6.61	0.48	6.7e-10	Bladder cancer;
UCEC	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.73	6.04	0.45	1.23e-8	Coronary artery disease;
UCEC	cis	rs12618769	0.571	rs72821939	chr2:99138872	T/C	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg14008862	chr17:28927542	LRRC37B2	0.59	5.38	0.41	2.82e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg06462663	chr19:18546047	ISYNA1	0.39	4.79	0.37	4.04e-6	Breast cancer;
UCEC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	6.39	0.47	2.05e-9	Response to antipsychotic treatment;
UCEC	cis	rs2267681	0.603	rs2267679	chr7:139539218	C/T	cg14116596	chr7:139528673	TBXAS1	0.52	5.24	0.4	5.5e-7	Cervical cancer;
UCEC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-0.96	-5.81	-0.43	3.7e-8	Diabetic kidney disease;
UCEC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.6	6.69	0.48	4.38e-10	Longevity;
UCEC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.7	-7.26	-0.51	2.09e-11	Tonsillectomy;
UCEC	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13683864	chr3:40499215	RPL14	-1.03	-10.88	-0.67	1.39e-20	Renal cell carcinoma;
UCEC	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.44	4.75	0.36	4.84e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.66	6.77	0.49	2.84e-10	Systemic lupus erythematosus;
UCEC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.59	0.35	9.29e-6	Menopause (age at onset);
UCEC	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.95	-0.44	1.9e-8	Depression;
UCEC	cis	rs17718580	0.536	rs59807161	chr14:51091475	G/C	cg04730355	chr14:51134070	SAV1	0.89	9.04	0.6	8.54e-16	Cognitive performance;
UCEC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	5.96	0.44	1.76e-8	Monocyte percentage of white cells;
UCEC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.67	5.46	0.41	1.98e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.71	6.09	0.45	9.4e-9	Bipolar disorder;
UCEC	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.66	5.35	0.4	3.23e-7	Corneal astigmatism;
UCEC	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.75	7.16	0.51	3.63e-11	Schizophrenia;
UCEC	cis	rs2795502	0.630	rs3004257	chr10:43480529	C/T	cg11150807	chr10:43354902	NA	0.78	4.8	0.37	3.84e-6	Blood protein levels;
UCEC	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.67	-0.48	4.84e-10	HDL cholesterol;
UCEC	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs11958404	0.932	rs6859826	chr5:157429710	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs4687718	0.602	rs12054426	chr3:53278324	T/C	cg00836091	chr3:53290192	TKT	0.67	4.58	0.35	1e-5	QRS duration;
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.31	-0.46	3.12e-9	Platelet count;
UCEC	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.1	9.65	0.62	2.22e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs12681287	0.785	rs13263353	chr8:87244582	C/T	cg27223183	chr8:87520930	FAM82B	-0.63	-5.37	-0.41	2.98e-7	Caudate activity during reward;
UCEC	cis	rs6437061	0.737	rs3116191	chr2:233049441	G/A	cg20569070	chr2:232597279	PDE6D	0.42	4.9	0.37	2.51e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs2979489	0.945	rs11988541	chr8:30334273	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-5.57	-0.42	1.16e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs4372836	0.543	rs6747852	chr2:29009840	A/T	cg09522027	chr2:28974177	PPP1CB	-0.78	-8.26	-0.56	7.72e-14	Body mass index;
UCEC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg01966129	chr22:22901880	PRAME;LOC648691	-0.25	-4.6	-0.35	8.91e-6	Bone mineral density;
UCEC	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.59	5.28	0.4	4.46e-7	Crohn's disease;
UCEC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.32	0.52	1.53e-11	Homoarginine levels;
UCEC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.03	-0.38	1.42e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-8.22	-0.56	9.94e-14	Colorectal cancer;
UCEC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	23.33	0.89	2.88e-51	Chronic sinus infection;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	4.97	0.38	1.81e-6	Platelet count;
UCEC	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	5.27	0.4	4.87e-7	Personality dimensions;
UCEC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.4	-4.56	-0.35	1.07e-5	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs884366	1.000	rs4946956	chr6:109641115	C/T	cg01475377	chr6:109611718	NA	0.45	4.84	0.37	3.25e-6	HDL cholesterol levels;HDL cholesterol;
UCEC	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg16577123	chr5:140027231	NDUFA2;IK	0.47	4.89	0.37	2.65e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.6	5.55	0.42	1.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	1.13	8.89	0.59	2e-15	Bone mineral density;
UCEC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.73	0.36	5.15e-6	Bipolar disorder;
UCEC	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.96	0.5	1.03e-10	Coronary artery disease;
UCEC	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.69	-8.92	-0.59	1.73e-15	Bipolar disorder;
UCEC	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-5.14	-0.39	8.6e-7	Gut microbiome composition (summer);
UCEC	cis	rs36051895	0.732	rs7046736	chr9:5015732	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.78	-0.37	4.13e-6	Pediatric autoimmune diseases;
UCEC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg05072774	chr3:49840536	C3orf54	-0.57	-5.15	-0.39	8.21e-7	Resting heart rate;
UCEC	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.81	8.13	0.56	1.63e-13	Schizophrenia;
UCEC	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.94	0.5	1.16e-10	Eye color traits;
UCEC	cis	rs716804	0.740	rs35737881	chr11:10289130	C/A	cg23875677	chr11:10229755	SBF2	-0.46	-4.64	-0.36	7.77e-6	Neuroticism;
UCEC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.67	-0.53	2.2e-12	Body mass index;
UCEC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.53	-4.71	-0.36	5.71e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.46	-5.08	-0.39	1.14e-6	Asthma (sex interaction);
UCEC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.75	-8.32	-0.57	5.46e-14	Testicular germ cell tumor;
UCEC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg23307798	chr14:103986281	CKB	-0.5	-5.1	-0.39	1.05e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg03714773	chr7:91764589	CYP51A1	-0.43	-5.16	-0.39	8.04e-7	Breast cancer;
UCEC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs7246967	0.800	rs4932794	chr19:23036556	G/A	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs787274	0.850	rs2025544	chr9:115632969	C/T	cg13803584	chr9:115635662	SNX30	0.7	4.52	0.35	1.29e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.49	4.56	0.35	1.08e-5	Non-substance related behavioral disinhibition;
UCEC	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.46	4.63	0.36	7.98e-6	Coronary artery disease;
UCEC	cis	rs2288327	0.818	rs3731751	chr2:179405885	T/C	cg09915519	chr2:179397513	TTN;MIR548N	-0.67	-4.59	-0.35	9.54e-6	Atrial fibrillation;
UCEC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.67	7.66	0.53	2.35e-12	Electrocardiographic conduction measures;
UCEC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg08493051	chr2:3487164	NA	-0.6	-6.55	-0.48	9.11e-10	Neurofibrillary tangles;
UCEC	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg10005273	chr11:65197613	NA	0.5	4.64	0.36	7.64e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg01380346	chr19:18557039	ELL	-0.5	-5.22	-0.4	6.1e-7	Breast cancer;
UCEC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.82	8.07	0.55	2.29e-13	Cognitive function;
UCEC	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.68	5.8	0.43	3.9e-8	Prostate cancer;
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.09	0.39	1.06e-6	Bipolar disorder;
UCEC	cis	rs112873973	1	rs112873973	chr3:52567295	C/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.86	4.87	0.37	2.84e-6	CTACK levels;
UCEC	cis	rs10507349	0.913	rs34897738	chr13:26777711	A/T	cg19792403	chr13:26796018	RNF6	0.54	4.57	0.35	1.05e-5	Type 2 diabetes;
UCEC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.21	0.6	3.06e-16	Electrocardiographic conduction measures;
UCEC	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.5	4.85	0.37	3.11e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.71	8.77	0.59	4.11e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg18681998	chr4:17616180	MED28	0.52	5.75	0.43	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.69	4.95	0.38	1.98e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	4.59	0.35	9.62e-6	Hemoglobin concentration;
UCEC	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.89	-10.7	-0.66	4.18e-20	Blood metabolite levels;
UCEC	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.68	5.91	0.44	2.33e-8	Lymphocyte counts;
UCEC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.47	5.0	0.38	1.62e-6	Aortic root size;
UCEC	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.17	0.45	6.24e-9	IgG glycosylation;
UCEC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg06166341	chr4:1223170	CTBP1	0.6	5.32	0.4	3.83e-7	Systolic blood pressure;
UCEC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.1	0.51	5.03e-11	Coffee consumption (cups per day);
UCEC	trans	rs66573146	1.000	rs28729690	chr4:6962061	C/T	cg07817883	chr1:32538562	TMEM39B	1.05	8.01	0.55	3.17e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.51	-0.35	1.32e-5	Lung cancer in ever smokers;
UCEC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.75	-5.73	-0.43	5.52e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.59	6.57	0.48	8.19e-10	Red blood cell count;
UCEC	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.62	4.77	0.37	4.42e-6	Orofacial clefts;
UCEC	cis	rs12428035	1.000	rs11070148	chr13:96304666	C/T	cg07859753	chr13:96300257	NA	0.66	4.99	0.38	1.67e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs308403	0.600	rs309366	chr4:123661408	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	8.23	0.56	9.33e-14	Blood protein levels;
UCEC	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg10902566	chr4:727664	PCGF3	-0.62	-5.41	-0.41	2.46e-7	Systolic blood pressure;
UCEC	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.46	-6.08	-0.45	9.93e-9	Sense of smell;
UCEC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.1	0.56	1.9e-13	Electrocardiographic conduction measures;
UCEC	cis	rs17123764	0.710	rs7137976	chr12:50099067	A/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg02158880	chr13:53174818	NA	0.51	5.99	0.44	1.52e-8	Lewy body disease;
UCEC	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.85	-0.37	3.05e-6	Mood instability;
UCEC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.46	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg12740337	chr6:28058973	ZSCAN12L1	-0.33	-4.74	-0.36	5.07e-6	Depression;
UCEC	cis	rs9402633	0.938	rs6903141	chr6:135036121	C/T	cg16239184	chr6:135079577	NA	0.51	4.68	0.36	6.36e-6	Platelet count;
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.66	7.31	0.52	1.62e-11	Platelet count;
UCEC	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg11569703	chr11:65557185	OVOL1	-0.46	-6.56	-0.48	8.8e-10	Acne (severe);
UCEC	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.65	6.53	0.47	1.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg00639195	chr15:79103007	ADAMTS7	0.59	5.16	0.39	7.82e-7	Coronary artery disease or large artery stroke;
UCEC	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg04553112	chr3:125709451	NA	-0.69	-4.86	-0.37	2.96e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg05623727	chr3:50126028	RBM5	0.33	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Diabetic kidney disease;
UCEC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.68	5.94	0.44	2e-8	Cognitive function;
UCEC	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.5	5.21	0.4	6.15e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7517126	1.000	rs2336504	chr1:196843654	C/T	cg07209298	chr1:196795943	CFHR1	0.47	4.55	0.35	1.14e-5	Blood protein levels;
UCEC	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.11	-18.17	-0.83	2.07e-39	Colorectal cancer;
UCEC	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.55	4.97	0.38	1.82e-6	Crohn's disease;
UCEC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.62	-5.68	-0.42	6.87e-8	Tourette syndrome;
UCEC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-5.24	-0.4	5.49e-7	Hemoglobin concentration;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.66	8.51	0.57	1.86e-14	Menarche (age at onset);
UCEC	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.74	10.17	0.64	1.01e-18	Neuroticism;
UCEC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	7.05e-9	Aortic root size;
UCEC	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.77	-0.59	4.2e-15	Colorectal cancer;
UCEC	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-7.92	-0.55	5.44e-13	Parkinson's disease;
UCEC	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs3743832	1.000	rs7186921	chr16:9195703	T/G	cg08831531	chr16:9218945	NA	-0.48	-5.01	-0.38	1.57e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-4.72	-0.36	5.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg25110126	chr1:46999211	NA	-0.55	-4.87	-0.37	2.88e-6	Monobrow;
UCEC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.96	0.44	1.78e-8	Tonsillectomy;
UCEC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.5	5.3	0.4	4.1e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs732765	0.734	rs11844127	chr14:75139936	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.65	-0.36	7.29e-6	Non-small cell lung cancer;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.68	7.9	0.55	5.99e-13	Prudent dietary pattern;
UCEC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.83	0.43	3.41e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.56	-6.17	-0.45	6.42e-9	Monocyte percentage of white cells;
UCEC	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.62	-6.21	-0.46	5.03e-9	Strep throat;
UCEC	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.45	4.55	0.35	1.13e-5	Response to temozolomide;
UCEC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-5.66	-0.42	7.79e-8	Bipolar disorder and schizophrenia;
UCEC	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	0.97	15.48	0.79	1.11e-32	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs12982903	0.778	rs59174308	chr19:5950384	T/C	cg02441015	chr19:5244038	PTPRS	-0.57	-4.54	-0.35	1.16e-5	Heart rate variability traits (SDNN);
UCEC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.55	-5.24	-0.4	5.52e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.27	0.68	1.3e-21	Chronic sinus infection;
UCEC	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.76	8.52	0.57	1.74e-14	Cognitive test performance;
UCEC	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.64	5.05	0.38	1.31e-6	Resting heart rate;
UCEC	cis	rs2708377	0.858	rs68045377	chr12:11294452	T/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.59	4.73	0.36	5.28e-6	Bitter taste perception;
UCEC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg23795048	chr12:9217529	LOC144571	0.42	5.01	0.38	1.53e-6	Sjögren's syndrome;
UCEC	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.6	5.05	0.38	1.28e-6	Obesity-related traits;
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.36	0.57	4.48e-14	Platelet count;
UCEC	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	4.87	0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs10242455	0.867	rs2687075	chr7:99314986	A/G	cg07715041	chr7:99302981	CYP3A7	-0.51	-5.23	-0.4	5.68e-7	Blood metabolite levels;
UCEC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.14	18.7	0.84	1.07e-40	Testicular germ cell tumor;
UCEC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg19041857	chr6:27730383	NA	-0.7	-5.46	-0.41	1.94e-7	Depression;
UCEC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	1.0	10.85	0.67	1.63e-20	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10266483	0.739	rs679966	chr7:63767066	C/T	cg23304165	chr7:63498798	NA	-0.5	-5.41	-0.41	2.49e-7	Response to statin therapy;
UCEC	cis	rs6813264	0.772	rs4835010	chr4:146553303	T/C	cg04181032	chr4:147165097	NA	-0.38	-4.72	-0.36	5.4e-6	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.62	6.51	0.47	1.14e-9	Mean corpuscular volume;
UCEC	cis	rs3824488	0.790	rs1805155	chr9:98238379	C/T	cg14565164	chr9:98057177	FANCC	-0.6	-4.62	-0.36	8.18e-6	Neuroticism;
UCEC	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg14121845	chr20:25566513	NINL	0.4	4.78	0.37	4.29e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg20630560	chr1:228395858	OBSCN	-0.31	-4.54	-0.35	1.16e-5	Diastolic blood pressure;
UCEC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg03859395	chr2:55845619	SMEK2	-0.97	-13.67	-0.75	5.57e-28	Metabolic syndrome;
UCEC	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.56	-5.61	-0.42	9.66e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.86	10.81	0.67	2.03e-20	IgG glycosylation;
UCEC	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg18681998	chr4:17616180	MED28	0.86	10.58	0.66	8.58e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.82	9.82	0.63	8.23e-18	Body mass index;
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg05132306	chr1:1846340	CALML6	0.37	4.76	0.37	4.65e-6	Body mass index;
UCEC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.02	11.5	0.69	3.05e-22	IgG glycosylation;
UCEC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.89	-0.37	2.62e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs28795989	0.795	rs4696746	chr4:7904945	G/T	cg00251875	chr4:7801337	AFAP1	0.49	5.71	0.43	5.94e-8	Intraocular pressure;
UCEC	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.65	5.37	0.4	3.01e-7	Menarche (age at onset);
UCEC	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.58	6.98	0.5	9.22e-11	Weight;
UCEC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-4.87	-0.37	2.82e-6	Personality dimensions;
UCEC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs77861329	1.000	rs9847092	chr3:52199453	T/C	cg08692210	chr3:52188851	WDR51A	0.86	6.81	0.49	2.27e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-6.22	-0.46	4.96e-9	Hemoglobin concentration;
UCEC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	4.89	0.37	2.57e-6	Personality dimensions;
UCEC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.74	-0.36	5.03e-6	Resting heart rate;
UCEC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg03354898	chr7:1950403	MAD1L1	-0.46	-5.3	-0.4	4.19e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.32	-0.4	3.73e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs12644436	0.896	rs13143704	chr4:88785373	A/G	cg27179352	chr4:88029472	AFF1	0.41	4.51	0.35	1.32e-5	HIV-1 viral setpoint;
UCEC	cis	rs17490626	0.568	rs2033371	chr10:71212310	G/A	cg12610070	chr10:71211762	TSPAN15	-0.39	-6.56	-0.48	8.46e-10	Thrombosis;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.76	-9.77	-0.63	1.12e-17	Menarche (age at onset);
UCEC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	6.54	0.47	9.7e-10	Menopause (age at onset);
UCEC	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.59	4.72	0.36	5.41e-6	Resting heart rate;
UCEC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.45	-4.71	-0.36	5.78e-6	Body mass index;
UCEC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.66	7.29	0.52	1.73e-11	Coronary artery disease;
UCEC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg01256987	chr12:42539512	GXYLT1	-0.42	-4.65	-0.36	7.2e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs10208940	0.764	rs7583649	chr2:68830939	T/C	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.8	-8.18	-0.56	1.23e-13	Mosquito bite size;
UCEC	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	0.82	6.44	0.47	1.57e-9	Corneal structure;
UCEC	cis	rs78487399	0.908	rs75597324	chr2:43811239	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.92	-0.38	2.28e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg19318889	chr4:1322082	MAEA	0.59	7.27	0.51	1.94e-11	Longevity;
UCEC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg23217946	chr19:22817039	ZNF492	0.41	4.56	0.35	1.09e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg27535305	chr1:53392650	SCP2	-0.43	-5.49	-0.41	1.76e-7	Monocyte count;
UCEC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	0.98	13.14	0.73	1.41e-26	Eosinophil percentage of white cells;
UCEC	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.48	-5.65	-0.42	7.92e-8	Subjective well-being;
UCEC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.08	0.5	5.48e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.1	18.06	0.83	3.91e-39	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg24375607	chr4:120327624	NA	0.53	5.51	0.41	1.56e-7	Corneal astigmatism;
UCEC	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.57	0.42	1.18e-7	Alzheimer's disease;
UCEC	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.1	0.39	1.02e-6	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.66	5.3	0.4	4.21e-7	Type 2 diabetes nephropathy;
UCEC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg11871910	chr12:69753446	YEATS4	0.55	4.88	0.37	2.76e-6	Response to diuretic therapy;
UCEC	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.62	6.52	0.47	1.05e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.06	6.34	0.46	2.63e-9	Diabetic retinopathy;
UCEC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.37	0.52	1.13e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.48e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1545257	0.537	rs12988283	chr2:24642086	G/C	cg06627628	chr2:24431161	ITSN2	-0.54	-5.6	-0.42	1.01e-7	Sjögren's syndrome;
UCEC	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	14.15	0.76	3.16e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-5.39	-0.41	2.72e-7	Hepatocellular carcinoma;
UCEC	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.74	-6.23	-0.46	4.55e-9	Colorectal adenoma (advanced);
UCEC	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.8	-8.38	-0.57	3.88e-14	Mosquito bite size;
UCEC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.31	4.61	0.36	8.7e-6	Body mass index;
UCEC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.93	6.75	0.49	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg04155231	chr12:9217510	LOC144571	0.41	5.08	0.39	1.12e-6	Sjögren's syndrome;
UCEC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.3e-8	Aortic root size;
UCEC	cis	rs12644436	0.864	rs4147246	chr4:88778249	C/G	cg27179352	chr4:88029472	AFF1	0.42	4.66	0.36	6.91e-6	HIV-1 viral setpoint;
UCEC	cis	rs10853057	0.541	rs8076716	chr17:63048009	T/C	cg06875131	chr17:63554468	AXIN2	-0.78	-5.05	-0.38	1.28e-6	White matter microstructure (global fractional anisotropy);
UCEC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg19513890	chr22:42538836	CYP2D7P1	-0.45	-5.05	-0.38	1.31e-6	Schizophrenia;
UCEC	cis	rs10242455	0.764	rs2740564	chr7:99295693	T/C	cg18809830	chr7:99032528	PTCD1	0.53	4.56	0.35	1.05e-5	Blood metabolite levels;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg06872176	chr1:68697386	GPR177	0.7	7.28	0.51	1.86e-11	Triglyceride levels;
UCEC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.56	5.88	0.44	2.69e-8	Type 2 diabetes;
UCEC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.69	-7.59	-0.53	3.43e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.46	5.16	0.39	7.85e-7	Prudent dietary pattern;
UCEC	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg01451880	chr3:45801044	SLC6A20	0.39	5.06	0.39	1.23e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.76	-7.84	-0.54	8.38e-13	Cognitive function;
UCEC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	0.97	5.56	0.42	1.22e-7	IgG glycosylation;
UCEC	cis	rs4865169	0.934	rs12650737	chr4:57892475	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-5.12	-0.39	9.57e-7	Breast cancer;
UCEC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	6.48	0.47	1.28e-9	Bone mineral density;
UCEC	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.66	-5.23	-0.4	5.69e-7	Obesity-related traits;
UCEC	cis	rs4789452	0.967	rs12451315	chr17:75372126	C/G	cg21830368	chr17:75373327	SEPT9	-0.29	-4.61	-0.36	8.64e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	0.95	10.13	0.64	1.27e-18	Left atrial antero-posterior diameter;
UCEC	cis	rs829661	0.793	rs860487	chr2:30703971	G/A	cg17749961	chr2:30669863	LCLAT1	0.72	5.54	0.42	1.37e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.57	-6.24	-0.46	4.51e-9	Menarche (age at onset);
UCEC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.66	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.74	-8.4	-0.57	3.56e-14	Menarche (age at onset);
UCEC	cis	rs2806864	1.000	rs2250849	chr1:117462941	T/C	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.69	-0.36	6.13e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.67	-0.58	7.29e-15	Menarche (age at onset);
UCEC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-5.21	-0.39	6.3e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.93	8.65	0.58	8.41e-15	IgG glycosylation;
UCEC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.42	4.66	0.36	6.95e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.59	6.27	0.46	3.82e-9	Longevity;Endometriosis;
UCEC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.49	5.55	0.42	1.31e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.05	9.27	0.61	2.15e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	5.75	0.43	5.1e-8	Menarche (age at onset);
UCEC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg04154034	chr17:28927549	LRRC37B2	0.83	5.26	0.4	5.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.7	-6.22	-0.46	4.99e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.62	7.0	0.5	8.44e-11	Leprosy;
UCEC	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.47	-4.55	-0.35	1.09e-5	Tuberculosis;
UCEC	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.37e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.26	0.51	2.12e-11	Smoking behavior;
UCEC	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.5	-4.99	-0.38	1.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.57	-5.82	-0.43	3.58e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.58	-5.43	-0.41	2.3e-7	Left ventricular obstructive tract defect (inherited effect);
UCEC	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg26061582	chr7:22766209	IL6	0.92	5.54	0.42	1.34e-7	Tonsillectomy;
UCEC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.36	5.52	0.41	1.51e-7	Ulcerative colitis;
UCEC	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg23933602	chr10:16859644	RSU1	0.59	5.39	0.41	2.79e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs9356171	0.539	rs11755754	chr6:164325492	A/G	cg25752492	chr6:164341247	NA	-0.59	-5.89	-0.44	2.47e-8	Diisocyanate-induced asthma;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg18358662	chr13:111305805	CARS2	0.88	4.73	0.36	5.21e-6	Obesity-related traits;
UCEC	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg11569703	chr11:65557185	OVOL1	0.43	5.53	0.42	1.4e-7	Acne (severe);
UCEC	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.86	-0.37	2.94e-6	Height;
UCEC	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg23795048	chr12:9217529	LOC144571	0.44	5.06	0.38	1.25e-6	Sjögren's syndrome;
UCEC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-5.63	-0.42	8.82e-8	Alcohol dependence;
UCEC	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.59	-4.93	-0.38	2.23e-6	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-5.75	-0.43	5.01e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-9.44	-0.61	8.11e-17	Chronic sinus infection;
UCEC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg10503236	chr1:231470652	EXOC8	0.43	5.18	0.39	7.09e-7	Hemoglobin concentration;
UCEC	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.65	0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	0.94	8.1	0.56	1.94e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2041840	0.618	rs11124581	chr2:37576638	C/T	cg20091297	chr2:37572423	QPCT	0.45	4.67	0.36	6.75e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.48	-4.76	-0.37	4.49e-6	Post bronchodilator FEV1;
UCEC	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.7	7.08	0.5	5.59e-11	Primary sclerosing cholangitis;
UCEC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.7	-6.45	-0.47	1.53e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg08222913	chr3:52553049	STAB1	-0.43	-4.63	-0.36	8.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.46	-4.85	-0.37	3.12e-6	Acylcarnitine levels;
UCEC	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs394563	0.717	rs548848	chr6:149782009	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.41	-5.02	-0.38	1.48e-6	Dupuytren's disease;
UCEC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.49	-4.92	-0.38	2.31e-6	Lung cancer;
UCEC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	4.75	0.37	4.72e-6	Bipolar disorder;
UCEC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.53	5.95	0.44	1.87e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.74	0.36	5.07e-6	Height;
UCEC	cis	rs7246967	0.673	rs407989	chr19:22991586	C/G	cg05241461	chr19:22816980	ZNF492	-0.51	-4.86	-0.37	2.93e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg03354898	chr7:1950403	MAD1L1	-0.46	-5.29	-0.4	4.39e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg00614314	chr15:82944287	LOC80154	0.55	5.18	0.39	7.28e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.54	0.35	1.17e-5	Electroencephalogram traits;
UCEC	cis	rs35934224	0.783	rs6518585	chr22:19849501	C/T	cg11182965	chr22:19864308	TXNRD2	-0.35	-4.86	-0.37	3.03e-6	Glaucoma (primary open-angle);
UCEC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg15848620	chr12:58087721	OS9	-0.53	-5.09	-0.39	1.07e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs4778581	0.900	rs12441266	chr15:80405656	A/G	cg08257866	chr15:80351198	ZFAND6	0.41	4.6	0.35	9e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-6.63	-0.48	5.83e-10	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.36	-5.55	-0.42	1.27e-7	Ulcerative colitis;
UCEC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg06784218	chr1:46089804	CCDC17	-0.43	-4.93	-0.38	2.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.63	5.74	0.43	5.26e-8	Platelet count;
UCEC	cis	rs1079204	1.000	rs1567869	chr2:219126735	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.66	5.12	0.39	9.52e-7	Smooth-surface caries;
UCEC	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.78	-7.84	-0.54	8.3e-13	Mosquito bite size;
UCEC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.63	-6.29	-0.46	3.42e-9	Breast cancer;
UCEC	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	0.92	5.99	0.44	1.57e-8	Skin colour saturation;
UCEC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.47	-4.75	-0.36	4.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.53	4.95	0.38	1.98e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg05802129	chr4:122689817	NA	-0.55	-5.65	-0.42	8.05e-8	Type 2 diabetes;
UCEC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.55	-5.93	-0.44	2.05e-8	Blood metabolite levels;
UCEC	cis	rs66716358	0.562	rs10838258	chr11:44326859	G/C	cg02785814	chr11:44338707	NA	-0.48	-4.73	-0.36	5.23e-6	Monobrow;
UCEC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-5.55	-0.42	1.27e-7	Chronic sinus infection;
UCEC	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	6.58	0.48	7.78e-10	Alzheimer's disease;
UCEC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg13147721	chr7:65941812	NA	-0.92	-6.69	-0.48	4.48e-10	Diabetic kidney disease;
UCEC	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.64	-6.41	-0.47	1.86e-9	Pancreatic cancer;
UCEC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.65	-8.27	-0.56	7.27e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.59	-5.34	-0.4	3.47e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.39	4.89	0.37	2.66e-6	Birth weight;
UCEC	cis	rs12681287	0.752	rs10956786	chr8:87301237	T/C	cg27223183	chr8:87520930	FAM82B	-0.62	-5.32	-0.4	3.75e-7	Caudate activity during reward;
UCEC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.32	0.4	3.78e-7	Breast cancer;
UCEC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.39	4.53	0.35	1.21e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-4.76	-0.37	4.5e-6	Dental caries;
UCEC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-0.85	-11.29	-0.68	1.13e-21	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.56	4.73	0.36	5.21e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.62	5.33	0.4	3.56e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.43	5.11	0.39	1.01e-6	Subjective well-being;
UCEC	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.37	0.52	1.13e-11	Platelet count;
UCEC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.56	-5.38	-0.41	2.94e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.65	-7.17	-0.51	3.39e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg20965017	chr5:231967	SDHA	-0.68	-5.99	-0.44	1.55e-8	Breast cancer;
UCEC	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg15764593	chr10:829463	NA	0.63	4.7	0.36	5.82e-6	Uric acid levels;
UCEC	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.79	7.78	0.54	1.2e-12	Primary sclerosing cholangitis;
UCEC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.48	4.54	0.35	1.15e-5	Menopause (age at onset);
UCEC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.14	0.45	7.33e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.49	5.12	0.39	9.44e-7	Blood protein levels;
UCEC	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.34	-0.4	3.52e-7	Bipolar disorder;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00327072	chr5:172110477	NEURL1B	-0.61	-6.94	-0.5	1.19e-10	N-glycan levels;
UCEC	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-6.01	-0.44	1.42e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.22	0.46	4.97e-9	Menarche (age at onset);
UCEC	cis	rs13136331	0.642	rs2869681	chr4:88620187	A/G	cg01170486	chr4:88020856	AFF1	0.58	4.68	0.36	6.59e-6	Sitting height ratio;
UCEC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.89	-0.44	2.56e-8	Mortality in heart failure;
UCEC	cis	rs78487399	0.908	rs12474102	chr2:43835570	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.21	-0.39	6.35e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.34	4.55	0.35	1.1e-5	Childhood ear infection;
UCEC	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg10263370	chr3:44754102	ZNF502	-0.46	-4.59	-0.35	9.62e-6	Depressive symptoms;
UCEC	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.53	5.04	0.38	1.35e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.07	7.47	0.52	6.73e-12	Sexual dysfunction (female);
UCEC	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.48	7.5	0.53	5.54e-12	Airflow obstruction;
UCEC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg07424592	chr7:64974309	NA	0.78	4.63	0.36	7.82e-6	Diabetic kidney disease;
UCEC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.52	0.35	1.28e-5	Menopause (age at onset);
UCEC	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.83	6.59	0.48	7.38e-10	Body mass index;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.65	-6.81	-0.49	2.27e-10	Parkinson's disease;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.42	-0.41	2.39e-7	Pubertal anthropometrics;
UCEC	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.58	-6.39	-0.47	2.02e-9	Blood metabolite levels;
UCEC	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.66	-5.55	-0.42	1.31e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.67	6.46	0.47	1.43e-9	Monocyte count;
UCEC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.52	4.82	0.37	3.56e-6	Homoarginine levels;
UCEC	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.74	7.47	0.52	6.54e-12	Mosquito bite size;
UCEC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.72	-7.85	-0.54	8.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg16584290	chr5:462447	EXOC3	-0.54	-6.5	-0.47	1.18e-9	Cystic fibrosis severity;
UCEC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.43	-4.67	-0.36	6.83e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7246967	0.673	rs73022713	chr19:22876222	G/C	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	6.04	0.45	1.22e-8	Bone mineral density;
UCEC	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Bladder cancer;
UCEC	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.49	-4.9	-0.37	2.48e-6	IgG glycosylation;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.54	-6.53	-0.47	1.02e-9	Pubertal anthropometrics;
UCEC	cis	rs5770917	0.522	rs5770916	chr22:51016098	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	0.49	4.53	0.35	1.21e-5	Narcolepsy;
UCEC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.39	4.53	0.35	1.2e-5	Blood protein levels;
UCEC	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	9.3	0.61	1.83e-16	Leprosy;
UCEC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.75	0.43	5.04e-8	Breast cancer;
UCEC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.57	-0.35	1.02e-5	Lung cancer in ever smokers;
UCEC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.81	-0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	5.83	0.43	3.43e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.94	-0.44	1.97e-8	Chronic sinus infection;
UCEC	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.21	-0.39	6.2e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.55	5.09	0.39	1.09e-6	Neurofibrillary tangles;
UCEC	cis	rs10432489	0.708	rs4315481	chr2:181761394	T/C	cg21995919	chr2:182322279	ITGA4	0.72	5.34	0.4	3.51e-7	QT interval;
UCEC	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.57	6.05	0.45	1.17e-8	Mean platelet volume;
UCEC	cis	rs8105895	0.935	rs62111038	chr19:22286614	A/G	cg02912127	chr19:22235281	ZNF257	-0.55	-4.65	-0.36	7.44e-6	Body mass index (change over time);
UCEC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.43e-8	Breast cancer;
UCEC	cis	rs12618769	0.597	rs3769712	chr2:99153443	A/T	cg10123293	chr2:99228465	UNC50	0.44	4.7	0.36	5.97e-6	Bipolar disorder;
UCEC	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.67	-6.0	-0.44	1.46e-8	Platelet distribution width;
UCEC	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.42e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg18681998	chr4:17616180	MED28	0.71	8.27	0.56	7.25e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.6	-6.45	-0.47	1.51e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.2	-0.76	2.34e-29	Schizophrenia;
UCEC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs17123764	0.818	rs11169076	chr12:49975408	G/T	cg20471783	chr12:50157085	TMBIM6	0.61	5.29	0.4	4.36e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.0	0.38	1.63e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2319125	0.770	rs11079613	chr17:63962815	A/C	cg06996976	chr17:64576105	PRKCA	-0.44	-4.97	-0.38	1.85e-6	&beta2-Glycoprotein I (β2-GPI) plasma levels;
UCEC	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.57	-9.97	-0.64	3.37e-18	Airflow obstruction;
UCEC	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.13	0.6	4.97e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.54	5.17	0.39	7.55e-7	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.61	6.93	0.5	1.22e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.53	-5.52	-0.41	1.47e-7	Crohn's disease;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.77	-0.37	4.44e-6	Pulmonary function;
UCEC	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.68	0.36	6.33e-6	Alzheimer's disease;
UCEC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg14078730	chr11:63896557	MACROD1	0.49	5.45	0.41	2.03e-7	Platelet count;
UCEC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.72	8.77	0.59	4.15e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg07004394	chr14:106090750	NA	-0.42	-4.52	-0.35	1.28e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
UCEC	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-1.24	-8.99	-0.6	1.12e-15	Post bronchodilator FEV1;
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg07153921	chr17:41440717	NA	-0.47	-4.53	-0.35	1.22e-5	Menopause (age at onset);
UCEC	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.41	-4.57	-0.35	1.02e-5	Birth weight;
UCEC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg13525197	chr6:28411240	ZSCAN23	0.44	4.57	0.35	1.02e-5	Parkinson's disease;
UCEC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16346588	chr10:242978	ZMYND11	0.49	4.76	0.37	4.57e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs3015497	0.653	rs2356455	chr14:51093142	G/A	cg04730355	chr14:51134070	SAV1	-0.46	-4.91	-0.38	2.4e-6	Mean platelet volume;
UCEC	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.67	7.66	0.53	2.36e-12	Neutrophil count;
UCEC	cis	rs243088	1.000	rs243086	chr2:60571065	A/G	cg16665442	chr2:60585866	NA	-0.41	-5.09	-0.39	1.08e-6	Type 2 diabetes;
UCEC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.5	4.94	0.38	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.72	-5.85	-0.43	3.13e-8	Coronary artery calcification;
UCEC	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.71	7.25	0.51	2.16e-11	Itch intensity from mosquito bite;
UCEC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.86	0.43	2.98e-8	Breast cancer;
UCEC	cis	rs7246967	0.673	rs35335083	chr19:22869592	A/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18252515	chr7:66147081	NA	0.54	5.03	0.38	1.42e-6	Aortic root size;
UCEC	cis	rs4722166	0.532	rs1546763	chr7:22757843	G/A	cg05472934	chr7:22766657	IL6	0.57	5.45	0.41	2.09e-7	Lung cancer;
UCEC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.41	4.53	0.35	1.19e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	0.75	6.11	0.45	8.36e-9	Blood protein levels;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg21273098	chr6:109762418	SMPD2;PPIL6	0.63	6.95	0.5	1.1e-10	N-glycan levels;
UCEC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.41	-5.22	-0.4	5.99e-7	Colorectal cancer;
UCEC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05776053	chr2:74358815	NA	0.43	4.82	0.37	3.53e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.49	0.62	5.87e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg20965017	chr5:231967	SDHA	-0.59	-5.43	-0.41	2.24e-7	Breast cancer;
UCEC	trans	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg26043149	chr18:55253948	FECH	0.95	8.89	0.59	2.02e-15	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.66	-5.76	-0.43	4.79e-8	Obesity-related traits;
UCEC	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	0.9	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.39	9.01	0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.62	-5.48	-0.41	1.83e-7	Mortality in heart failure;
UCEC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-0.96	-7.96	-0.55	4.16e-13	White matter hyperintensity burden;
UCEC	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg04155231	chr12:9217510	LOC144571	0.41	4.97	0.38	1.8e-6	Sjögren's syndrome;
UCEC	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.03	-12.38	-0.71	1.43e-24	Dilated cardiomyopathy;
UCEC	cis	rs2149423	0.559	rs1928021	chr13:36773944	A/G	cg22940789	chr13:36704709	DCLK1	0.43	4.65	0.36	7.27e-6	Glucose homeostasis traits;
UCEC	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.46	4.63	0.36	7.9e-6	Blood metabolite levels;
UCEC	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	0.89	11.93	0.7	2.32e-23	Blood protein levels;
UCEC	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.67	0.48	4.87e-10	Coffee consumption (cups per day);
UCEC	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.78	-6.81	-0.49	2.32e-10	Gastritis;
UCEC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18252515	chr7:66147081	NA	0.52	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.63	-6.21	-0.46	5.03e-9	Huntington's disease progression;
UCEC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.8e-6	Breast cancer;
UCEC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.73	0.54	1.55e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.47	-5.51	-0.41	1.56e-7	Aortic root size;
UCEC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.5	-4.78	-0.37	4.2e-6	Schizophrenia;
UCEC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.49	-0.41	1.73e-7	Depression;
UCEC	cis	rs4778581	0.630	rs4778746	chr15:80382022	G/A	cg08257866	chr15:80351198	ZFAND6	0.4	4.74	0.36	4.98e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.75	0.54	1.4e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.611	rs56271774	chr19:22831327	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-4.94	-0.38	2.12e-6	Aortic root size;
UCEC	cis	rs1387221	0.904	rs4737513	chr8:59610784	T/G	cg24495373	chr8:59337659	UBXN2B	0.38	4.57	0.35	1.02e-5	Clozapine-induced cytotoxicity;
UCEC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.66	-4.64	-0.36	7.54e-6	Aortic root size;
UCEC	cis	rs7336933	0.799	rs2225439	chr13:42457807	T/C	cg18400088	chr13:41634674	WBP4	0.54	4.58	0.35	1e-5	Calcium levels;
UCEC	cis	rs56161922	1.000	rs74401244	chr1:207844799	T/C	cg09557387	chr1:207818395	CR1L	0.87	4.66	0.36	7.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg13683864	chr3:40499215	RPL14	-0.56	-5.91	-0.44	2.24e-8	Renal cell carcinoma;
UCEC	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg14092571	chr14:90743983	NA	-0.42	-5.72	-0.43	5.72e-8	Mortality in heart failure;
UCEC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.62	6.02	0.44	1.36e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18252515	chr7:66147081	NA	0.46	4.71	0.36	5.67e-6	Aortic root size;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21800906	chr11:32914818	QSER1	0.56	7.07	0.5	5.93e-11	Warfarin maintenance dose;
UCEC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.44	4.54	0.35	1.15e-5	Total body bone mineral density;
UCEC	cis	rs10012307	1.000	rs7658641	chr4:137484814	T/G	cg12033966	chr4:138453416	PCDH18	-0.72	-4.98	-0.38	1.75e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.78	-9.06	-0.6	7.3e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-4.67	-0.36	6.87e-6	Alzheimer's disease (late onset);
UCEC	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg17933807	chr1:38061675	GNL2	0.96	11.68	0.69	1.03e-22	Axial length;
UCEC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.51	4.67	0.36	6.73e-6	Menopause (age at onset);
UCEC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	Bipolar disorder;
UCEC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg18479299	chr3:125709523	NA	-0.67	-4.61	-0.36	8.59e-6	Blood pressure (smoking interaction);
UCEC	cis	rs9463078	0.739	rs1293467	chr6:44769204	C/G	cg25276700	chr6:44698697	NA	0.49	5.75	0.43	5.1e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.53	5.13	0.39	9.16e-7	Uric acid levels;
UCEC	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	4.52	0.35	1.24e-5	Protein C levels;
UCEC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg21160472	chr1:212782112	ATF3	-0.59	-7.13	-0.51	4.13e-11	Iris heterochromicity;
UCEC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	5.05	0.38	1.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-0.91	-8.1	-0.56	1.94e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.45	5.02	0.38	1.48e-6	Platelet distribution width;
UCEC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg01634758	chr19:2136136	AP3D1	-0.6	-6.94	-0.5	1.18e-10	N-glycan levels;
UCEC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.88	10.78	0.66	2.53e-20	Breast cancer;
UCEC	cis	rs1585440	0.605	rs11842457	chr13:66506497	C/T	cg06682556	chr13:65533139	NA	-0.38	-4.57	-0.35	1.02e-5	Pancreatic cancer;
UCEC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.66	-6.04	-0.45	1.2e-8	Systemic lupus erythematosus;
UCEC	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.69	-5.11	-0.39	9.9e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg03146154	chr1:46216737	IPP	0.44	4.7	0.36	5.93e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.6	5.62	0.42	9.35e-8	Parkinson's disease;
UCEC	cis	rs4865875	0.892	rs73126830	chr5:54071978	C/G	cg22421804	chr5:54100067	NA	-0.43	-4.59	-0.35	9.5e-6	Sense of smell;
UCEC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.56	5.93	0.44	2.11e-8	Type 2 diabetes;
UCEC	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.53	5.96	0.44	1.77e-8	Hip circumference;
UCEC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg08493051	chr2:3487164	NA	-0.61	-6.59	-0.48	7.47e-10	Neurofibrillary tangles;
UCEC	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.81	-9.14	-0.6	4.55e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.63	-6.3	-0.46	3.34e-9	Longevity;
UCEC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.68	-8.14	-0.56	1.54e-13	Obesity-related traits;
UCEC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.68	0.62	1.89e-17	Cognitive function;
UCEC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.68	-6.07	-0.45	1.05e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.73	-0.36	5.11e-6	Parkinson's disease;
UCEC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.57	5.37	0.41	2.97e-7	Blood metabolite levels;
UCEC	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.72	-7.7	-0.54	1.83e-12	Blood protein levels;
UCEC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.62	5.92	0.44	2.2e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7246967	0.932	rs7257731	chr19:23042803	A/C	cg24889512	chr19:22816950	ZNF492	0.5	5.32	0.4	3.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg23950597	chr19:37808831	NA	-0.82	-5.76	-0.43	4.76e-8	Coronary artery calcification;
UCEC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.73	8.85	0.59	2.49e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg18032046	chr6:28092343	ZSCAN16	0.67	6.03	0.45	1.29e-8	Depression;
UCEC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.46	-4.99	-0.38	1.66e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.54	-5.39	-0.41	2.7e-7	IgG glycosylation;
UCEC	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.57	6.18	0.45	6.12e-9	Red blood cell count;
UCEC	cis	rs7246967	0.673	rs8102172	chr19:22870019	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.62	6.17	0.45	6.37e-9	Pancreatic cancer;
UCEC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.76	-8.86	-0.59	2.49e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg14121845	chr20:25566513	NINL	0.39	4.52	0.35	1.28e-5	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-5.26	-0.4	5.04e-7	Multiple sclerosis;Ankylosing spondylitis;
UCEC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.58	6.25	0.46	4.17e-9	Cognitive function;
UCEC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.53	5.3	0.4	4.08e-7	Menopause (age at onset);
UCEC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.35	-4.67	-0.36	6.67e-6	Prostate cancer;
UCEC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.61	-4.7	-0.36	6.02e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.61	0.53	3.1e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg06456738	chr11:66361081	CCDC87;CCS	0.54	4.52	0.35	1.28e-5	Airway imaging phenotypes;
UCEC	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.71	-8.54	-0.58	1.59e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.46	-6.64	-0.48	5.67e-10	Urinary metabolites;
UCEC	cis	rs8074700	0.518	rs9646424	chr17:46705605	C/A	cg14009013	chr17:47300216	ABI3	0.41	4.64	0.36	7.72e-6	Body mass index in non-asthmatics;
UCEC	cis	rs1165472	0.755	rs115716306	chr1:56130204	T/A	cg11523071	chr1:56160889	NA	-0.53	-4.79	-0.37	4.05e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs350251	0.899	rs2664186	chr16:12210702	G/T	cg10322510	chr16:12136822	RUNDC2A	0.47	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	7.35	0.52	1.31e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-5.94	-0.44	1.93e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.72	-5.35	-0.4	3.33e-7	Narcolepsy;
UCEC	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.62	-6.08	-0.45	9.97e-9	Menopause (age at onset);
UCEC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.1e-7	Schizophrenia;
UCEC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8020441	0.541	rs2131837	chr14:51154779	A/G	cg04730355	chr14:51134070	SAV1	0.91	9.15	0.6	4.51e-16	Cognitive performance;
UCEC	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg18681998	chr4:17616180	MED28	0.68	7.89	0.55	6.29e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs16957091	0.647	rs8041432	chr15:43358759	C/T	cg15904908	chr15:43213022	TTBK2	0.48	4.72	0.36	5.47e-6	MGMT methylation in smokers;
UCEC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg24562669	chr7:97807699	LMTK2	0.73	10.79	0.66	2.38e-20	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.68	-5.44	-0.41	2.19e-7	Exhaled nitric oxide output;
UCEC	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.75	6.91	0.5	1.36e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Bladder cancer;
UCEC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.35	-6.72	-0.49	3.65e-10	Diabetic kidney disease;
UCEC	cis	rs713477	0.967	rs8009706	chr14:55914756	A/G	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.24e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg00376283	chr12:123451042	ABCB9	0.62	6.27	0.46	3.73e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.84	-9.65	-0.62	2.3e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.53	0.47	9.87e-10	Menarche (age at onset);
UCEC	cis	rs6684428	0.706	rs12058087	chr1:56319257	C/G	cg11651538	chr1:56320950	NA	-0.51	-4.72	-0.36	5.35e-6	Airflow obstruction;
UCEC	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.09	8.74	0.58	4.8e-15	Uric acid levels;
UCEC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	5.51	0.41	1.58e-7	Menarche (age at onset);
UCEC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.58	-0.42	1.1e-7	Cardiac Troponin-T levels;
UCEC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.69	-7.82	-0.54	9.23e-13	Coronary artery disease;
UCEC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg13250285	chr3:50228871	GNAT1	-0.36	-5.28	-0.4	4.49e-7	Menarche (age at onset);
UCEC	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg24416660	chr17:73865998	NA	-0.33	-4.75	-0.36	4.76e-6	Psoriasis;
UCEC	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg02158880	chr13:53174818	NA	0.43	4.77	0.37	4.32e-6	Lewy body disease;
UCEC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.22	0.46	4.91e-9	Platelet count;
UCEC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	6.14	0.45	7.44e-9	Cognitive test performance;
UCEC	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.87	-7.18	-0.51	3.26e-11	Coronary artery calcification;
UCEC	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.68	0.42	6.97e-8	Coffee consumption (cups per day);
UCEC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-5.24	-0.4	5.36e-7	Response to antipsychotic treatment;
UCEC	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.58	-5.05	-0.38	1.31e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg00325661	chr8:49890786	NA	0.53	5.5	0.41	1.62e-7	Sudden cardiac arrest;
UCEC	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.64	6.94	0.5	1.17e-10	Ulcerative colitis;
UCEC	cis	rs7307889	0.793	rs7489044	chr12:6009595	A/G	cg26215727	chr12:6485537	SCNN1A	0.49	4.5	0.35	1.35e-5	Obesity-related traits;
UCEC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.06e-14	Menarche (age at onset);
UCEC	cis	rs953387	0.824	rs4954578	chr2:136958593	T/C	cg07169764	chr2:136633963	MCM6	0.52	4.94	0.38	2.06e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.1e-10	Chronic sinus infection;
UCEC	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	0.76	7.79	0.54	1.09e-12	Parkinson's disease;
UCEC	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.53	-4.61	-0.36	8.72e-6	Multiple sclerosis;
UCEC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg14078730	chr11:63896557	MACROD1	0.67	5.25	0.4	5.29e-7	Mean platelet volume;
UCEC	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg00280220	chr17:61926910	NA	0.43	4.68	0.36	6.52e-6	Prudent dietary pattern;
UCEC	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	1.04	8.4	0.57	3.43e-14	Vitiligo;
UCEC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg19257562	chr1:2043853	PRKCZ	0.45	4.66	0.36	6.95e-6	Height;
UCEC	cis	rs1800795	0.599	rs1546762	chr7:22757503	C/T	cg05472934	chr7:22766657	IL6	0.57	5.45	0.41	2.09e-7	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
UCEC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.76	0.59	4.29e-15	Chronic sinus infection;
UCEC	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-9.28	-0.61	1.99e-16	Blood metabolite levels;
UCEC	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.09	9.85	0.63	6.66e-18	Vitiligo;
UCEC	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.62	6.75	0.49	3.26e-10	Blood metabolite ratios;
UCEC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.97	5.35	0.4	3.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.32	-10.49	-0.65	1.42e-19	Hip circumference adjusted for BMI;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17009717	chr2:113299708	POLR1B	0.65	7.51	0.53	5.15e-12	Warfarin maintenance dose;
UCEC	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	7.51	0.53	5.31e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.7	7.98	0.55	3.9e-13	Menopause (age at onset);
UCEC	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg26014689	chr19:7917955	EVI5L	-0.44	-4.7	-0.36	5.86e-6	Menarche (age at onset);
UCEC	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs925228	0.955	rs1156797	chr2:24117541	A/C	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.63	6.65	0.48	5.48e-10	Breast cancer;
UCEC	cis	rs4389656	0.767	rs274704	chr5:6728340	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg13695892	chr22:41940480	POLR3H	-0.64	-5.37	-0.41	2.96e-7	Vitiligo;
UCEC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.49	5.53	0.42	1.4e-7	Systemic lupus erythematosus;
UCEC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.26	0.51	2.12e-11	Smoking behavior;
UCEC	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-7.44	-0.52	7.71e-12	Response to antipsychotic treatment;
UCEC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-5.49	-0.41	1.74e-7	Large artery stroke;
UCEC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-6.03	-0.45	1.29e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs7246967	0.932	rs4932792	chr19:23032449	A/G	cg24889512	chr19:22816950	ZNF492	0.5	5.32	0.4	3.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	ch.11.42038R	chr11:967971	AP2A2	0.44	5.01	0.38	1.51e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.57	-6.67	-0.48	4.76e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.79	-9.02	-0.6	9.25e-16	Paraoxonase activity;
UCEC	cis	rs13253111	1.000	rs17411738	chr8:28060572	T/G	cg26534493	chr8:28060551	NA	0.49	5.56	0.42	1.25e-7	Childhood body mass index;
UCEC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.63	-6.39	-0.47	2.05e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.55	-5.64	-0.42	8.3e-8	Systolic blood pressure;
UCEC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.56	0.48	8.79e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-5.94	-0.44	1.93e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.61	5.49	0.41	1.7e-7	Corneal astigmatism;
UCEC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg13695892	chr22:41940480	POLR3H	0.7	5.64	0.42	8.26e-8	Vitiligo;
UCEC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.68e-16	Breast cancer;
UCEC	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg05527609	chr1:210001259	C1orf107	0.52	4.91	0.38	2.37e-6	Red blood cell count;
UCEC	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.63	0.53	2.74e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.43	4.86	0.37	2.95e-6	Lung cancer;
UCEC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-6.22	-0.46	4.97e-9	Menarche (age at onset);
UCEC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-6.64	-0.48	5.75e-10	Menarche (age at onset);
UCEC	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.1	-0.39	1.02e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg01426195	chr3:39028469	NA	-0.56	-6.22	-0.46	4.93e-9	Handedness;
UCEC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.41	-0.41	2.5e-7	Aortic root size;
UCEC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg06238570	chr21:40685208	BRWD1	0.78	7.68	0.54	2.01e-12	Cognitive function;
UCEC	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg21770322	chr7:97807741	LMTK2	0.52	6.59	0.48	7.43e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.66	6.15	0.45	7.07e-9	Menarche (age at onset);
UCEC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6788895	0.661	rs73010941	chr3:150474477	T/C	cg14056942	chr3:150127151	TSC22D2	-0.56	-4.54	-0.35	1.16e-5	Breast cancer;
UCEC	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.54	-5.3	-0.4	4.12e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
UCEC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.55	5.0	0.38	1.6e-6	Corneal astigmatism;
UCEC	cis	rs1028488	0.543	rs9460113	chr6:170627651	G/A	cg20370364	chr6:170703943	FAM120B	-0.48	-4.7	-0.36	6e-6	Interferon alpha levels in systemic lupus erythematosus;
UCEC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg26721908	chr21:47610096	LSS	-0.37	-4.57	-0.35	1.04e-5	Testicular germ cell tumor;
UCEC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.44	-4.88	-0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.78	0.59	3.82e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	5.92	0.44	2.2e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg08320659	chr6:26088202	HFE	0.73	4.6	0.35	9.18e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg13575925	chr12:9217583	LOC144571	0.38	4.53	0.35	1.2e-5	Sjögren's syndrome;
UCEC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.62	0.42	9.21e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-4.8	-0.37	3.93e-6	Hair shape;
UCEC	cis	rs3762637	0.943	rs28372690	chr3:122283095	G/A	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.92	0.38	2.32e-6	Breast cancer;
UCEC	cis	rs117623576	0.680	rs12269122	chr10:32367864	C/T	cg09476325	chr10:33189322	ITGB1	0.66	4.57	0.35	1.04e-5	Anti-saccade response;
UCEC	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.07	-8.14	-0.56	1.5e-13	Exhaled nitric oxide output;
UCEC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	6.02	0.44	1.34e-8	Breast cancer;
UCEC	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.73	7.68	0.54	2.08e-12	Multiple myeloma (IgH translocation);
UCEC	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.92	-0.38	2.31e-6	Gut microbiome composition (summer);
UCEC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.34	-0.4	3.49e-7	Breast cancer;
UCEC	cis	rs8105895	0.799	rs62112922	chr19:22228340	C/T	cg24175803	chr19:22235144	ZNF257	-0.64	-5.51	-0.41	1.59e-7	Body mass index (change over time);
UCEC	cis	rs77861329	1.000	rs1237830	chr3:52202820	T/C	cg08692210	chr3:52188851	WDR51A	0.84	6.49	0.47	1.23e-9	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.66	4.67	0.36	6.71e-6	Aortic root size;
UCEC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.49	-4.56	-0.35	1.05e-5	Calcium levels;
UCEC	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.45	-4.99	-0.38	1.66e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-4.66	-0.36	6.91e-6	Life satisfaction;
UCEC	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.63	-7.29	-0.52	1.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.75	8.41	0.57	3.32e-14	Menarche (age at onset);
UCEC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.61	-6.11	-0.45	8.67e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.56	-4.95	-0.38	1.97e-6	Pancreatic cancer;
UCEC	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.93	-0.38	2.22e-6	Body mass index;
UCEC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.64	6.24	0.46	4.43e-9	Morning vs. evening chronotype;
UCEC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	18.83	0.84	5.07e-41	IgG glycosylation;
UCEC	cis	rs11581903	0.866	rs11591099	chr1:53056597	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.8	4.94	0.38	2.13e-6	Joint mobility (Beighton score);
UCEC	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.59	-5.89	-0.44	2.51e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg01874867	chr7:94954059	PON1	-0.54	-5.15	-0.39	8.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1823913	0.525	rs7424440	chr2:192202645	A/T	cg15998761	chr2:191300784	MFSD6	0.4	4.72	0.36	5.35e-6	Obesity-related traits;
UCEC	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.77	-9.91	-0.63	4.74e-18	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.31	0.61	1.69e-16	Platelet count;
UCEC	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.48	-4.95	-0.38	1.99e-6	Height;
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.55	6.69	0.48	4.42e-10	Fibrinogen levels;
UCEC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.59	-5.72	-0.43	5.81e-8	Pulmonary function;
UCEC	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	6.0	0.44	1.48e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg17145862	chr1:211918768	LPGAT1	-0.71	-8.94	-0.59	1.54e-15	Leprosy;
UCEC	cis	rs13065560	0.594	rs4336049	chr3:38922068	G/A	cg01426195	chr3:39028469	NA	-0.5	-5.28	-0.4	4.61e-7	Interleukin-18 levels;
UCEC	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.29	0.4	4.35e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	5.1	0.39	1.03e-6	Monocyte percentage of white cells;
UCEC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.58	6.75	0.49	3.16e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.97	11.84	0.7	4.02e-23	Multiple sclerosis;
UCEC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.46	4.8	0.37	3.86e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.99	7.44	0.52	7.74e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.81	9.14	0.6	4.6e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.63	6.63	0.48	5.82e-10	Monocyte count;
UCEC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22117172	chr7:91764530	CYP51A1	0.39	5.16	0.39	8.04e-7	Breast cancer;
UCEC	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.62	5.59	0.42	1.05e-7	Uric acid levels;
UCEC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg26116260	chr4:7069785	GRPEL1	-0.59	-5.18	-0.39	7.31e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.55	-6.24	-0.46	4.41e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg15147215	chr3:52552868	STAB1	0.43	4.77	0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.87	10.97	0.67	8.05e-21	Metabolic syndrome;
UCEC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.1	18.72	0.84	9.4e-41	IgG glycosylation;
UCEC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.57	-4.93	-0.38	2.19e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.47	-4.63	-0.36	8.11e-6	Pubertal anthropometrics;
UCEC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	6.78	0.49	2.77e-10	Platelet count;
UCEC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.55	-5.87	-0.44	2.81e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	5.92	0.44	2.16e-8	Platelet count;
UCEC	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.59	-6.39	-0.47	2.03e-9	White blood cell count;
UCEC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	6.26	0.46	4.02e-9	Personality dimensions;
UCEC	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.88	0.37	2.68e-6	Rheumatoid arthritis;
UCEC	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.74	0.58	4.85e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.52	4.84	0.37	3.29e-6	Platelet count;
UCEC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.71	-8.09	-0.56	2e-13	Blood protein levels;
UCEC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.74	-7.15	-0.51	3.77e-11	Response to antineoplastic agents;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.53	-5.86	-0.43	2.98e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.81	-0.37	3.65e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg18681998	chr4:17616180	MED28	0.59	6.6	0.48	6.88e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg24562669	chr7:97807699	LMTK2	0.73	10.77	0.66	2.72e-20	Breast cancer;
UCEC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.52	-6.08	-0.45	9.82e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.77	0.43	4.48e-8	Lung cancer in ever smokers;
UCEC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-6.17	-0.45	6.34e-9	Birth weight;
UCEC	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.81	-0.49	2.31e-10	Eye color traits;
UCEC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07636037	chr3:49044803	WDR6	-0.61	-5.5	-0.41	1.65e-7	Menarche (age at onset);
UCEC	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.62	5.84	0.43	3.27e-8	Corneal astigmatism;
UCEC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.46	-4.53	-0.35	1.23e-5	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.59	5.53	0.41	1.44e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.23	10.95	0.67	9.1e-21	Corneal structure;
UCEC	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.88	0.49	1.61e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-4.98	-0.38	1.74e-6	Depression;
UCEC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.56	-5.04	-0.38	1.37e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-1.09	-14.15	-0.76	3.1e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg06466757	chr4:1255808	NA	0.46	4.85	0.37	3.07e-6	Obesity-related traits;
UCEC	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.0	-7.49	-0.53	5.86e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg24562669	chr7:97807699	LMTK2	0.61	8.15	0.56	1.46e-13	Breast cancer;
UCEC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	5.38	0.41	2.91e-7	Monocyte percentage of white cells;
UCEC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9830388	0.584	rs778468	chr3:23453561	G/A	cg13266188	chr3:23522396	UBE2E2	0.39	4.51	0.35	1.32e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
UCEC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.52	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.49	4.82	0.37	3.49e-6	Menopause (age at onset);
UCEC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg22563815	chr15:78856949	CHRNA5	-0.38	-4.94	-0.38	2.12e-6	Sudden cardiac arrest;
UCEC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.66	0.36	7.02e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.0	-7.54	-0.53	4.5e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-4.53	-0.35	1.23e-5	Menarche (age at onset);
UCEC	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg09910674	chr16:89028015	CBFA2T3	0.6	4.54	0.35	1.16e-5	Skin colour saturation;
UCEC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.69	0.42	6.75e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.63	-0.58	9.05e-15	Prevalent atrial fibrillation;
UCEC	cis	rs35934224	0.783	rs34545894	chr22:19857942	C/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.11	-0.39	1.01e-6	Glaucoma (primary open-angle);
UCEC	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.51	4.62	0.36	8.23e-6	Corneal astigmatism;
UCEC	cis	rs7302981	0.741	rs10783342	chr12:50628466	C/T	cg20014596	chr12:50898483	DIP2B	0.44	4.52	0.35	1.24e-5	Systolic blood pressure;
UCEC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.72	7.09	0.5	5.32e-11	Menarche (age at onset);
UCEC	cis	rs13253111	0.967	rs7821358	chr8:28060690	A/G	cg26534493	chr8:28060551	NA	0.49	5.56	0.42	1.25e-7	Childhood body mass index;
UCEC	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.65	-7.45	-0.52	7.3e-12	Menarche (age at onset);
UCEC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg04553112	chr3:125709451	NA	-0.74	-5.15	-0.39	8.37e-7	Blood pressure (smoking interaction);
UCEC	cis	rs11235843	0.571	rs11235834	chr11:73353731	C/A	cg23931323	chr11:73372278	PLEKHB1	0.68	5.41	0.41	2.46e-7	Hand grip strength;
UCEC	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.93	7.18	0.51	3.16e-11	Monobrow;
UCEC	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-9.24	-0.61	2.54e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10924970	0.935	rs12731746	chr1:235392546	T/C	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg13870426	chr17:30244630	NA	-0.63	-4.63	-0.36	7.92e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	7.83	0.54	8.89e-13	Migraine;Coronary artery disease;
UCEC	cis	rs9457247	0.935	rs2769345	chr6:167366394	T/C	cg23791538	chr6:167370224	RNASET2	0.64	6.8	0.49	2.46e-10	Crohn's disease;
UCEC	cis	rs9715521	0.803	rs62301188	chr4:59840423	A/G	cg11281224	chr4:60001000	NA	-0.53	-5.3	-0.4	4.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.72	6.37	0.46	2.34e-9	Coronary artery disease;
UCEC	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.56	6.4	0.47	1.99e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg05660106	chr1:15850417	CASP9	0.96	10.79	0.66	2.32e-20	Systolic blood pressure;
UCEC	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-0.9	-7.8	-0.54	1.03e-12	Post bronchodilator FEV1;
UCEC	cis	rs11958404	0.932	rs72816580	chr5:157432221	A/T	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.76	-8.62	-0.58	9.99e-15	Menarche (age at onset);
UCEC	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.26	5.87	0.44	2.78e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.59	6.4	0.47	2e-9	Crohn's disease;
UCEC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.52	4.89	0.37	2.56e-6	Chronic sinus infection;
UCEC	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg03078520	chr22:18463400	MICAL3	-0.49	-4.93	-0.38	2.17e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	4.56	0.35	1.08e-5	Platelet count;
UCEC	cis	rs10924970	0.649	rs12022924	chr1:235380147	G/T	cg26050004	chr1:235667680	B3GALNT2	0.52	4.76	0.37	4.64e-6	Asthma;
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.45	0.57	2.65e-14	Platelet count;
UCEC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.4	-0.52	9.61e-12	Joint mobility (Beighton score);
UCEC	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.46	5.58	0.42	1.13e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg07404485	chr7:94953653	PON1	-0.6	-6.89	-0.49	1.55e-10	Paraoxonase activity;
UCEC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.11	0.39	9.71e-7	Birth weight;
UCEC	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.69	-5.76	-0.43	4.73e-8	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.54	-6.03	-0.45	1.26e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	8.3	0.56	6.19e-14	Platelet count;
UCEC	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg03517284	chr6:25882590	NA	0.87	7.35	0.52	1.25e-11	Blood metabolite levels;
UCEC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.36	5.32	0.4	3.81e-7	Ulcerative colitis;
UCEC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg23795048	chr12:9217529	LOC144571	0.43	5.24	0.4	5.37e-7	Sjögren's syndrome;
UCEC	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.51	-5.04	-0.38	1.37e-6	Refractive error;
UCEC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.16	-14.37	-0.76	8.54e-30	Breast cancer;
UCEC	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.71	7.25	0.51	2.16e-11	Itch intensity from mosquito bite;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.62	-5.51	-0.41	1.54e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs4499344	0.730	rs259286	chr19:33164759	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	6.14	0.45	7.25e-9	Mean platelet volume;
UCEC	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.71	6.81	0.49	2.35e-10	Refractive astigmatism;
UCEC	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	5.24	0.4	5.36e-7	Response to antipsychotic treatment;
UCEC	cis	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.79	4.94	0.38	2.11e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	6.72	0.48	3.74e-10	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.46	4.97	0.38	1.88e-6	HDL cholesterol;
UCEC	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.36	4.58	0.35	9.65e-6	Immune response to smallpox vaccine (IL-6);
UCEC	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-5.2	-0.39	6.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.28	-0.51	1.85e-11	Coronary artery disease;
UCEC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.45	-4.72	-0.36	5.52e-6	Vitiligo;
UCEC	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.58	-5.44	-0.41	2.15e-7	High light scatter reticulocyte count;
UCEC	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.74	5.03	0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.77	6.51	0.47	1.11e-9	Menopause (age at onset);
UCEC	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.73	7.23	0.51	2.47e-11	Mosquito bite size;
UCEC	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-4.69	-0.36	6.23e-6	Bladder cancer;
UCEC	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs3743832	0.966	rs12708776	chr16:9183770	A/G	cg08831531	chr16:9218945	NA	-0.43	-4.56	-0.35	1.09e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-4.55	-0.35	1.1e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.6	5.9	0.44	2.41e-8	Calcium levels;
UCEC	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.65	5.45	0.41	2.06e-7	High light scatter reticulocyte count;
UCEC	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.7	-6.45	-0.47	1.55e-9	Mosquito bite size;
UCEC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.57	-5.45	-0.41	2.07e-7	Bipolar disorder and schizophrenia;
UCEC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.45e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.78	8.34	0.57	4.82e-14	Lung cancer in ever smokers;
UCEC	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.62	6.39	0.47	2.12e-9	Itch intensity from mosquito bite;
UCEC	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.75	8.7	0.58	6.31e-15	IgG glycosylation;
UCEC	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.71	-0.43	6.17e-8	Fear of minor pain;
UCEC	cis	rs7095607	1.000	rs4480432	chr10:69938665	C/T	cg18986048	chr10:69913749	MYPN	0.42	4.53	0.35	1.19e-5	Lung function (FVC);
UCEC	cis	rs8177876	0.822	rs9929586	chr16:81113021	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg08807892	chr2:162101083	NA	0.58	6.0	0.44	1.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs925228	0.955	rs12471864	chr2:24110135	C/T	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.78	0.37	4.18e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.47	-4.63	-0.36	8.05e-6	Dental caries;
UCEC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.43	-0.74	2.46e-27	Height;
UCEC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg08798685	chr6:27730294	NA	-0.63	-4.58	-0.35	9.87e-6	Depression;
UCEC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.11	-0.39	9.68e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.0	0.38	1.63e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.53	-6.1	-0.45	8.85e-9	Aortic root size;
UCEC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg10978503	chr1:24200527	CNR2	0.37	4.89	0.37	2.6e-6	Immature fraction of reticulocytes;
UCEC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.63	6.3	0.46	3.33e-9	Lung cancer;
UCEC	cis	rs2036402	0.531	rs6873137	chr5:156434253	T/C	cg24526056	chr5:156479556	HAVCR1	-0.47	-4.82	-0.37	3.49e-6	Hypertriglyceridemia;
UCEC	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.16	-0.56	1.37e-13	Total cholesterol levels;
UCEC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.01	-0.38	1.54e-6	Longevity;Endometriosis;
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	9.84	0.63	7.34e-18	Platelet count;
UCEC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-6.41	-0.47	1.85e-9	Crohn's disease;
UCEC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.85	0.54	7.95e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.67	0.42	7.31e-8	Cognitive test performance;
UCEC	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.05	-12.3	-0.71	2.32e-24	Ulcerative colitis;
UCEC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.6	-5.87	-0.44	2.83e-8	Coronary artery disease;
UCEC	cis	rs7911264	0.628	rs7078243	chr10:94414263	A/C	cg00519463	chr10:94352821	KIF11	-0.48	-4.74	-0.36	4.92e-6	Inflammatory bowel disease;
UCEC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg10902566	chr4:727664	PCGF3	-0.62	-5.15	-0.39	8.29e-7	Systolic blood pressure;
UCEC	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.74	-7.49	-0.53	6e-12	Parkinson's disease;
UCEC	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.01	-0.44	1.42e-8	Joint mobility (Beighton score);
UCEC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg11211951	chr8:145729740	GPT	-0.46	-5.52	-0.41	1.53e-7	Age at first birth;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06594919	chr10:102827590	NA	0.58	7.29	0.52	1.77e-11	Warfarin maintenance dose;
UCEC	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.65	-6.9	-0.49	1.44e-10	Lung cancer in ever smokers;
UCEC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.61	7.62	0.53	2.81e-12	Bone mineral density;
UCEC	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.85	6.56	0.48	8.74e-10	Lymphocyte counts;
UCEC	cis	rs713477	0.967	rs6573031	chr14:55913763	C/G	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.24e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.52	5.87	0.44	2.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.59	6.67	0.48	4.78e-10	Crohn's disease;
UCEC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg20891558	chr2:74357851	NA	0.66	6.3	0.46	3.33e-9	Gestational age at birth (maternal effect);
UCEC	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.62	7.03	0.5	7.14e-11	Leprosy;
UCEC	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-5.85	-0.43	3.09e-8	Glomerular filtration rate;
UCEC	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.71	7.4	0.52	9.56e-12	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-5.48	-0.41	1.8e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg10965384	chr11:64119977	CCDC88B	0.38	4.8	0.37	3.9e-6	Platelet count;
UCEC	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg05623727	chr3:50126028	RBM5	0.37	4.66	0.36	6.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.55	5.26	0.4	4.89e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs12234571	1.000	rs59033784	chr7:77482475	C/G	cg20048109	chr7:78158112	MAGI2	-0.5	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg12024160	chr4:1254474	NA	0.71	8.58	0.58	1.24e-14	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.56e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.97	0.44	1.7e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.0	7.98	0.55	3.79e-13	Vitiligo;
UCEC	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	0.95	7.88	0.54	6.6e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.86	-9.82	-0.63	8.18e-18	Cognitive function;
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.62	0.42	9.11e-8	Platelet count;
UCEC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	0.94	4.59	0.35	9.35e-6	IgG glycosylation;
UCEC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg11632617	chr15:75315747	PPCDC	-0.5	-5.14	-0.39	8.67e-7	Blood trace element (Zn levels);
UCEC	cis	rs1823913	0.927	rs56209234	chr2:192126474	T/C	cg15998761	chr2:191300784	MFSD6	0.4	4.6	0.35	9.13e-6	Obesity-related traits;
UCEC	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-11.83	-0.7	4.27e-23	Ulcerative colitis;
UCEC	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-4.67	-0.36	6.79e-6	Life satisfaction;
UCEC	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg05660106	chr1:15850417	CASP9	0.55	4.91	0.38	2.37e-6	Systolic blood pressure;
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.39e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.61	5.21	0.39	6.39e-7	Obesity-related traits;
UCEC	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	8.34	0.57	4.82e-14	Menopause (age at onset);
UCEC	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.56	5.85	0.43	3.06e-8	Mean platelet volume;
UCEC	cis	rs2288327	0.818	rs12618265	chr2:179382809	A/C	cg09915519	chr2:179397513	TTN;MIR548N	-0.66	-4.84	-0.37	3.19e-6	Atrial fibrillation;
UCEC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.94	11.62	0.69	1.48e-22	Coronary artery disease;
UCEC	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg05962950	chr11:130786565	SNX19	-0.49	-4.8	-0.37	3.78e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg15848620	chr12:58087721	OS9	-0.51	-4.82	-0.37	3.51e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.58	4.65	0.36	7.31e-6	Skin colour saturation;
UCEC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	5.65	0.42	8.19e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.72	7.57	0.53	3.84e-12	Caffeine consumption;
UCEC	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	7.46	0.52	6.83e-12	Exhaled nitric oxide output;
UCEC	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.76	-6.98	-0.5	9.28e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs7949030	0.523	rs67308910	chr11:62377359	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.5	4.68	0.36	6.49e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.8	8.18	0.56	1.2e-13	Parkinson's disease;
UCEC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg20965017	chr5:231967	SDHA	-0.58	-4.74	-0.36	5.07e-6	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23850377	chr2:20251576	LAPTM4A	0.59	6.94	0.5	1.18e-10	Warfarin maintenance dose;
UCEC	trans	rs66573146	0.901	rs55659111	chr4:7012338	G/T	cg07817883	chr1:32538562	TMEM39B	1.27	8.75	0.59	4.55e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.54	6.51	0.47	1.12e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.67	-6.65	-0.48	5.36e-10	Colorectal cancer;
UCEC	cis	rs11760485	0.782	rs2158630	chr7:4404550	G/A	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.41	0.41	2.46e-7	Obesity-related traits;
UCEC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg24851651	chr11:66362959	CCS	-0.47	-5.71	-0.43	6.12e-8	Educational attainment (years of education);
UCEC	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.39	4.97	0.38	1.86e-6	Insulin-like growth factors;
UCEC	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-9.13	-0.6	5.04e-16	Morning vs. evening chronotype;
UCEC	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.84	10.22	0.64	7.21e-19	Tonsillectomy;
UCEC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	6.05	0.45	1.14e-8	Platelet count;
UCEC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.9	-11.59	-0.69	1.76e-22	IgG glycosylation;
UCEC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg06462663	chr19:18546047	ISYNA1	0.49	6.19	0.45	5.72e-9	Breast cancer;
UCEC	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.72	0.36	5.48e-6	Breast cancer;
UCEC	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.7	4.55	0.35	1.11e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-0.54	-4.85	-0.37	3.1e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg13010344	chr12:123464640	ARL6IP4	-0.41	-4.53	-0.35	1.23e-5	Platelet count;
UCEC	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg13256891	chr4:100009986	ADH5	-0.69	-5.15	-0.39	8.11e-7	Alcohol dependence;
UCEC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg13575925	chr12:9217583	LOC144571	0.39	4.55	0.35	1.1e-5	Sjögren's syndrome;
UCEC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.49	4.77	0.37	4.37e-6	Obesity-related traits;
UCEC	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.84	8.15	0.56	1.47e-13	Resting heart rate;
UCEC	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.48	-5.16	-0.39	7.76e-7	HDL cholesterol;
UCEC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.01	0.38	1.55e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	8.7	0.58	6.14e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg23795048	chr12:9217529	LOC144571	-0.43	-5.35	-0.4	3.37e-7	Sjögren's syndrome;
UCEC	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.65	5.1	0.39	1.04e-6	Resting heart rate;
UCEC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.86e-7	Morning vs. evening chronotype;
UCEC	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.48	-5.15	-0.39	8.16e-7	Menarche (age at onset);
UCEC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	6.13	0.45	7.59e-9	Lymphocyte counts;
UCEC	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg04398451	chr17:18023971	MYO15A	0.6	6.57	0.48	8.17e-10	Total body bone mineral density;
UCEC	cis	rs4764487	0.760	rs4764488	chr12:6332910	A/G	cg08284733	chr12:6341482	CD9	0.4	4.87	0.37	2.84e-6	Mean platelet volume;
UCEC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.34	-0.46	2.63e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.55	6.11	0.45	8.33e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.85	-10.84	-0.67	1.77e-20	Height;
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-0.62	-8.83	-0.59	2.93e-15	Prudent dietary pattern;
UCEC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg03859395	chr2:55845619	SMEK2	-0.93	-11.32	-0.68	9.62e-22	Metabolic syndrome;
UCEC	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	0.89	4.6	0.35	8.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.66	0.36	6.9e-6	Parkinson's disease;
UCEC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.48	4.77	0.37	4.39e-6	Menopause (age at onset);
UCEC	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.94	0.5	1.16e-10	Eye color traits;
UCEC	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.76	8.52	0.57	1.74e-14	Cognitive test performance;
UCEC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg18402987	chr7:1209562	NA	0.7	4.73	0.36	5.31e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.56	-4.95	-0.38	2.02e-6	Serum thyroid-stimulating hormone levels;
UCEC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg22974920	chr21:40686053	BRWD1	0.55	4.86	0.37	3.04e-6	Cognitive function;
UCEC	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg23752985	chr2:85803571	VAMP8	0.44	4.75	0.36	4.83e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.04e-14	Menarche (age at onset);
UCEC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.63	-7.51	-0.53	5.18e-12	Obesity-related traits;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.24	0.71	3.51e-24	Prudent dietary pattern;
UCEC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.58	-6.74	-0.49	3.43e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01973587	chr1:228161476	NA	0.37	4.84	0.37	3.22e-6	Diastolic blood pressure;
UCEC	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.65	-5.84	-0.43	3.17e-8	Metabolite levels;
UCEC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.53	-4.83	-0.37	3.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.15	0.56	1.42e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.42	-0.57	3.07e-14	Exhaled nitric oxide output;
UCEC	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.94	0.5	1.16e-10	Eye color traits;
UCEC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg26781129	chr3:44753946	ZNF502	-0.42	-4.63	-0.36	8e-6	Depressive symptoms;
UCEC	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg18646521	chr2:111875858	NA	0.4	4.5	0.35	1.36e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	5.06	0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg08125972	chr19:36705377	ZNF565;ZNF146	-0.74	-7.03	-0.5	7.07e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg21770322	chr7:97807741	LMTK2	0.52	6.54	0.47	9.69e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-0.94	-9.97	-0.64	3.3e-18	Heart rate;
UCEC	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-6.05	-0.45	1.13e-8	Schizophrenia;
UCEC	trans	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02355339	chr19:35517344	GRAMD1A	-0.68	-6.99	-0.5	8.88e-11	Smoking behavior;
UCEC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg07636037	chr3:49044803	WDR6	-0.56	-4.53	-0.35	1.23e-5	Menarche (age at onset);
UCEC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6761276	0.649	rs12711751	chr2:113837765	T/G	cg09040174	chr2:113837401	NA	0.45	4.84	0.37	3.26e-6	Protein quantitative trait loci;
UCEC	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.83	6.85	0.49	1.86e-10	Gastritis;
UCEC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	7.01	0.5	8.07e-11	Cognitive test performance;
UCEC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.02e-6	Sudden cardiac arrest;
UCEC	cis	rs732765	0.734	rs35461658	chr14:75207264	T/C	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	0.9	9.21	0.6	3.11e-16	Left atrial antero-posterior diameter;
UCEC	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.38	-5.71	-0.43	5.91e-8	Body mass index;
UCEC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg13844804	chr7:814759	HEATR2	0.64	4.58	0.35	9.71e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.69	6.57	0.48	8.07e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.5	-6.22	-0.46	4.95e-9	Total body bone mineral density;
UCEC	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.73	0.49	3.62e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-4.91	-0.38	2.43e-6	Menarche (age at onset);
UCEC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.56	5.52	0.41	1.52e-7	Monocyte percentage of white cells;
UCEC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.97	0.55	4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.42	-0.41	2.37e-7	Depression;
UCEC	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.44	5.61	0.42	9.58e-8	Schizophrenia;
UCEC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg12024160	chr4:1254474	NA	0.52	5.72	0.43	5.85e-8	Longevity;
UCEC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.63	-5.36	-0.4	3.11e-7	Initial pursuit acceleration;
UCEC	cis	rs13065560	0.594	rs7620018	chr3:38886649	C/T	cg01426195	chr3:39028469	NA	-0.53	-5.67	-0.42	7.27e-8	Interleukin-18 levels;
UCEC	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.62	4.82	0.37	3.55e-6	Cocaine dependence;
UCEC	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	8.73	0.58	5.23e-15	Bipolar disorder;
UCEC	cis	rs12900413	0.959	rs28430604	chr15:90313782	C/T	cg09212610	chr15:90892496	GABARAPL3	0.46	4.57	0.35	1.01e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.5	5.1	0.39	1.02e-6	Vitiligo;
UCEC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg24562669	chr7:97807699	LMTK2	0.61	8.0	0.55	3.45e-13	Breast cancer;
UCEC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg11508081	chr17:41442227	NA	0.42	4.6	0.36	8.88e-6	Menopause (age at onset);
UCEC	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.95	10.87	0.67	1.45e-20	Breast cancer;
UCEC	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.5	4.87	0.37	2.87e-6	High light scatter reticulocyte count;
UCEC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.42	5.98	0.44	1.63e-8	Crohn's disease;
UCEC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg19645103	chr12:69753606	YEATS4	-0.56	-5.01	-0.38	1.56e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.11	0.39	9.92e-7	Mood instability;
UCEC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg14092571	chr14:90743983	NA	-0.43	-5.69	-0.43	6.56e-8	Mortality in heart failure;
UCEC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	13.8	0.75	2.55e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.83	-0.43	3.45e-8	Mortality in heart failure;
UCEC	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.75	-7.92	-0.55	5.41e-13	Breast cancer;
UCEC	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.48	4.68	0.36	6.59e-6	Schizophrenia;
UCEC	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-0.85	-11.32	-0.68	9.24e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs4865875	0.892	rs4282277	chr5:54074693	T/C	cg22421804	chr5:54100067	NA	0.39	4.77	0.37	4.49e-6	Sense of smell;
UCEC	cis	rs590820	1.000	rs590820	chr1:230309619	A/G	cg08705382	chr1:230322024	GALNT2	0.4	4.93	0.38	2.22e-6	Metabolite levels (lipoprotein measures);
UCEC	cis	rs12216499	1.000	rs74298058	chr6:159419953	C/A	cg10634217	chr6:160211790	TCP1;MRPL18	-0.67	-4.62	-0.36	8.16e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.56	6.0	0.44	1.46e-8	Total cholesterol levels;
UCEC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.74	7.85	0.54	7.74e-13	Menopause (age at onset);
UCEC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.93	9.86	0.63	6.47e-18	IgG glycosylation;
UCEC	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.91	-0.38	2.42e-6	Fear of minor pain;
UCEC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.6	7.07	0.5	5.8200000000000003e-11	Menopause (age at onset);
UCEC	cis	rs4705962	0.959	rs4426908	chr5:132022718	C/G	cg27309611	chr5:132113725	SEPT8	0.42	5.58	0.42	1.12e-7	Atopic dermatitis;
UCEC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg04553112	chr3:125709451	NA	-0.74	-5.15	-0.39	8.37e-7	Blood pressure (smoking interaction);
UCEC	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.55	5.17	0.39	7.43e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.47	5.09	0.39	1.08e-6	Headache;
UCEC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.67	-7.65	-0.53	2.38e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs847649	0.732	rs6465876	chr7:102497569	G/T	cg18108683	chr7:102477205	FBXL13	-0.67	-8.4	-0.57	3.39e-14	Morning vs. evening chronotype;
UCEC	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.63	4.87	0.37	2.87e-6	Lymphocyte counts;
UCEC	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-4.98	-0.38	1.75e-6	Bipolar disorder;
UCEC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.6	-6.37	-0.46	2.32e-9	Immature fraction of reticulocytes;
UCEC	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.65	4.57	0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.65	5.32	0.4	3.82e-7	Corneal astigmatism;
UCEC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg23795048	chr12:9217529	LOC144571	0.4	4.69	0.36	6.14e-6	Sjögren's syndrome;
UCEC	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg13683864	chr3:40499215	RPL14	-0.58	-6.07	-0.45	1.01e-8	Renal cell carcinoma;
UCEC	cis	rs7088591	0.717	rs4614392	chr10:59780593	A/G	cg11142981	chr10:60273225	BICC1	0.64	4.59	0.35	9.34e-6	Blood pressure;
UCEC	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-4.83	-0.37	3.39e-6	Gut microbiome composition (summer);
UCEC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg03959625	chr15:84868606	LOC388152	0.54	5.6	0.42	1.02e-7	Schizophrenia;
UCEC	cis	rs925228	0.955	rs12479331	chr2:24201701	A/G	cg13272742	chr2:24272458	FKBP1B	0.61	5.13	0.39	9.19e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.52	-5.3	-0.4	4.22e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs77861329	1.000	rs9809254	chr3:52111474	T/C	cg08692210	chr3:52188851	WDR51A	0.74	5.98	0.44	1.58e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-6.08	-0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.04	-0.45	1.18e-8	Response to antipsychotic treatment;
UCEC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.73	7.1	0.51	4.86e-11	Smoking behavior;
UCEC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg05132306	chr1:1846340	CALML6	-0.38	-4.8	-0.37	3.85e-6	Body mass index;
UCEC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.75	10.29	0.65	4.85e-19	Vitiligo;
UCEC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.52	-4.88	-0.37	2.7e-6	Coronary artery disease;
UCEC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18252515	chr7:66147081	NA	0.54	5.03	0.38	1.42e-6	Aortic root size;
UCEC	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.5	-5.09	-0.39	1.08e-6	Schizophrenia;
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.79	8.88	0.59	2.21e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.59	6.47	0.47	1.38e-9	Crohn's disease;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.22	0.46	4.91e-9	Platelet count;
UCEC	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg02158880	chr13:53174818	NA	0.56	6.58	0.48	7.65e-10	Lewy body disease;
UCEC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.47	0.57	2.33e-14	Prudent dietary pattern;
UCEC	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg13683864	chr3:40499215	RPL14	-0.64	-6.88	-0.49	1.62e-10	Renal cell carcinoma;
UCEC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.71	7.12	0.51	4.54e-11	Opioid sensitivity;
UCEC	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.87	5.69	0.42	6.8e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.48	5.2	0.39	6.66e-7	Aortic root size;
UCEC	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.58	-4.99	-0.38	1.71e-6	Reticulocyte count;
UCEC	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.64	5.18	0.39	7.04e-7	Corneal astigmatism;
UCEC	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	1.0	12.47	0.72	8.44e-25	Colorectal adenoma (advanced);
UCEC	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-8.51	-0.57	1.87e-14	Hip circumference;
UCEC	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.5	5.07	0.39	1.21e-6	Coronary heart disease;
UCEC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg06784218	chr1:46089804	CCDC17	0.55	6.41	0.47	1.83e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-6.24	-0.46	4.47e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.51	4.9	0.37	2.55e-6	Menopause (age at onset);
UCEC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg04756594	chr16:24857601	SLC5A11	-0.53	-6.32	-0.46	2.96e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.59	-0.35	9.47e-6	Tonsillectomy;
UCEC	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.82	9.76	0.63	1.14e-17	Menopause (age at onset);
UCEC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.9	0.37	2.54e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.55	5.06	0.39	1.22e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg06671706	chr8:8559999	CLDN23	0.68	5.43	0.41	2.23e-7	Obesity-related traits;
UCEC	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-6.35	-0.46	2.52e-9	Total cholesterol levels;
UCEC	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.61	-6.27	-0.46	3.73e-9	Vitiligo;
UCEC	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.8	10.12	0.64	1.35e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.4	4.85	0.37	3.16e-6	Height;
UCEC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.58	-0.35	9.93e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	7.96	0.55	4.31e-13	Electrocardiographic conduction measures;
UCEC	cis	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-4.83	-0.37	3.35e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.53	-0.42	1.42e-7	Platelet count;
UCEC	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.55	5.52	0.41	1.51e-7	Asthma (sex interaction);
UCEC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.59	4.69	0.36	6.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.92	10.98	0.67	7.35e-21	Breast cancer;
UCEC	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs73206853	0.841	rs78843188	chr12:110827923	G/C	cg12870014	chr12:110450643	ANKRD13A	0.61	4.73	0.36	5.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg06096015	chr1:231504339	EGLN1	-0.48	-5.56	-0.42	1.21e-7	Hemoglobin concentration;
UCEC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.23	-0.68	1.67e-21	Headache;
UCEC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.56	5.88	0.44	2.61e-8	Blood metabolite levels;
UCEC	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg13256891	chr4:100009986	ADH5	-0.69	-5.15	-0.39	8.11e-7	Alcohol dependence;
UCEC	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg06265175	chr8:121136014	COL14A1	0.48	5.2	0.39	6.53e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.45	-5.8	-0.43	3.82e-8	Blood metabolite levels;
UCEC	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.57	-4.97	-0.38	1.85e-6	Reticulocyte count;
UCEC	cis	rs1712517	0.771	rs11191676	chr10:105155066	C/A	cg05636881	chr10:105038444	INA	0.44	5.16	0.39	7.99e-7	Migraine;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg16991341	chr13:111554054	ANKRD10	0.9	5.16	0.39	7.95e-7	Obesity-related traits;
UCEC	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.38	-0.47	2.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.51	4.52	0.35	1.27e-5	Height;
UCEC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.84	7.99	0.55	3.63e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.6	5.32	0.4	3.73e-7	Longevity;
UCEC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.53	5.49	0.41	1.73e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4372836	0.964	rs56240884	chr2:28940154	C/T	cg09522027	chr2:28974177	PPP1CB	0.71	7.03	0.5	7.07e-11	Body mass index;
UCEC	cis	rs17102423	0.573	rs7144259	chr14:65537559	T/A	cg11161011	chr14:65562177	MAX	-1.03	-10.88	-0.67	1.35e-20	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.0	-0.38	1.64e-6	Breast cancer;
UCEC	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.95	-11.07	-0.67	4.41e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs925228	0.955	rs10166036	chr2:24193947	G/A	cg16945982	chr2:25016118	CENPO;C2orf79	0.54	4.73	0.36	5.29e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.72	8.7	0.58	6.17e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.5	-5.08	-0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-5.44	-0.41	2.14e-7	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.86e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.36	4.76	0.37	4.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.95	0.38	1.97e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10924970	0.967	rs12035746	chr1:235405654	C/T	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	5.03	0.38	1.4e-6	Breast cancer;
UCEC	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg26031613	chr14:104095156	KLC1	-0.51	-4.5	-0.35	1.36e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg18479299	chr3:125709523	NA	-0.67	-4.59	-0.35	9.33e-6	Blood pressure (smoking interaction);
UCEC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.47	-5.41	-0.41	2.54e-7	Aortic root size;
UCEC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.61	-4.91	-0.38	2.37e-6	Longevity;
UCEC	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-0.98	-7.48	-0.53	6.22e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.73	5.23	0.4	5.81e-7	Body mass index;
UCEC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-1.11	-6.09	-0.45	9.3e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.69	7.0	0.5	8.3e-11	Primary sclerosing cholangitis;
UCEC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.68	7.09	0.51	5.11e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs829661	0.947	rs2167969	chr2:30773746	A/T	cg17749961	chr2:30669863	LCLAT1	0.52	4.93	0.38	2.18e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.64	-7.08	-0.5	5.52e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.5	-4.59	-0.35	9.28e-6	Coronary artery disease;
UCEC	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.33	-0.4	3.66e-7	Metabolite levels;
UCEC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-0.92	-11.8	-0.7	5.05e-23	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2816938	0.618	rs2821349	chr1:199983963	C/T	cg11856688	chr1:200708343	CAMSAP1L1	-0.59	-4.6	-0.36	8.88e-6	Pancreatic cancer;
UCEC	cis	rs7106204	0.609	rs12276488	chr11:24250211	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	6.04	0.45	1.21e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.61	0.36	8.75e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.46	4.67	0.36	6.68e-6	Schizophrenia;
UCEC	cis	rs7560272	0.723	rs6744697	chr2:73765438	T/C	cg20560298	chr2:73613845	ALMS1	-0.51	-5.03	-0.38	1.4e-6	Schizophrenia;
UCEC	cis	rs9321099	1.000	rs12525721	chr6:128223935	A/G	cg25012434	chr6:128842125	PTPRK	0.61	4.66	0.36	7.07e-6	Sense of smell;
UCEC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg24375607	chr4:120327624	NA	0.45	4.63	0.36	7.89e-6	Corneal astigmatism;
UCEC	cis	rs10924970	0.967	rs10925270	chr1:235425875	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.68	0.36	6.54e-6	Asthma;
UCEC	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.72	7.34	0.52	1.37e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg10932868	chr11:921992	NA	0.43	5.73	0.43	5.58e-8	Alzheimer's disease (late onset);
UCEC	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.55	4.69	0.36	6.1e-6	Response to diuretic therapy;
UCEC	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg24268161	chr22:39747459	SYNGR1	-0.51	-5.76	-0.43	4.71e-8	Rheumatoid arthritis;
UCEC	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.61	-5.05	-0.38	1.28e-6	Depression;
UCEC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	0.98	9.66	0.62	2.08e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.42	-4.96	-0.38	1.95e-6	Bipolar disorder;
UCEC	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg27246729	chr12:121163418	ACADS	0.48	4.63	0.36	7.98e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg13683864	chr3:40499215	RPL14	-0.53	-5.43	-0.41	2.27e-7	Renal cell carcinoma;
UCEC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.61	-5.88	-0.44	2.72e-8	White matter hyperintensity burden;
UCEC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.15	6.69	0.48	4.32e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs7095607	0.560	rs2255381	chr10:69923535	C/T	cg18986048	chr10:69913749	MYPN	0.45	4.89	0.37	2.64e-6	Lung function (FVC);
UCEC	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.63	5.85	0.43	3.09e-8	Tonsillectomy;
UCEC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg24687543	chr11:63912206	MACROD1	0.44	5.14	0.39	8.73e-7	Platelet count;
UCEC	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-4.98	-0.38	1.74e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.76	0.59	4.29e-15	Chronic sinus infection;
UCEC	cis	rs116095464	0.681	rs1574220	chr5:314518	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.72	-0.43	5.85e-8	Breast cancer;
UCEC	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.18	0.45	5.9e-9	Cognitive ability;
UCEC	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg24069376	chr3:38537580	EXOG	0.38	4.73	0.36	5.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	8.01	0.55	3.23e-13	Menopause (age at onset);
UCEC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg22166914	chr1:53195759	ZYG11B	-0.46	-4.66	-0.36	6.98e-6	Monocyte count;
UCEC	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.82	9.42	0.61	9.11e-17	Blood protein levels;
UCEC	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-7.06	-0.5	6.17e-11	Exhaled nitric oxide output;
UCEC	cis	rs9810890	0.764	rs9846589	chr3:128560355	T/C	cg24249734	chr3:127872125	EEFSEC	-0.55	-4.65	-0.36	7.23e-6	Dental caries;
UCEC	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13683864	chr3:40499215	RPL14	-0.92	-9.13	-0.6	5.07e-16	Renal cell carcinoma;
UCEC	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.87	-11.14	-0.68	2.85e-21	Height;
UCEC	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.34	4.55	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-24.02	-0.89	9.48e-53	Myeloid white cell count;
UCEC	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.47	4.56	0.35	1.06e-5	Platelet distribution width;
UCEC	cis	rs7611694	0.532	rs7650538	chr3:113180678	C/T	cg12596171	chr3:113251061	SIDT1	-0.51	-5.12	-0.39	9.41e-7	Prostate cancer;
UCEC	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.58	5.69	0.42	6.7e-8	Lung cancer;
UCEC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.68	6.82	0.49	2.21e-10	Longevity;Endometriosis;
UCEC	cis	rs7580658	0.545	rs13001179	chr2:127952193	A/C	cg16751203	chr2:127950803	CYP27C1	0.4	5.38	0.41	2.82e-7	Protein C levels;
UCEC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.8	-0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.31	0.57	5.78e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs12644436	0.864	rs6854555	chr4:88776943	C/A	cg27179352	chr4:88029472	AFF1	0.41	4.8	0.37	3.94e-6	HIV-1 viral setpoint;
UCEC	cis	rs829883	0.668	rs829882	chr12:98880099	A/G	cg25150519	chr12:98850993	NA	0.54	4.67	0.36	6.71e-6	Colorectal adenoma (advanced);
UCEC	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.77	5.95	0.44	1.89e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.68	7.38	0.52	1.06e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.62	-6.81	-0.49	2.38e-10	Lung cancer;
UCEC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.91	-0.38	2.37e-6	Type 2 diabetes;
UCEC	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.71	0.54	1.72e-12	Bladder cancer;
UCEC	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.47	5.94	0.44	1.95e-8	HDL cholesterol levels;
UCEC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-5.06	-0.39	1.24e-6	Blood metabolite levels;
UCEC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg01380346	chr19:18557039	ELL	0.5	5.2	0.39	6.5e-7	Breast cancer;
UCEC	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.29	0.4	4.35e-7	Coronary artery disease;
UCEC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg00343986	chr7:65444356	GUSB	-0.53	-4.67	-0.36	6.74e-6	Aortic root size;
UCEC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg21770322	chr7:97807741	LMTK2	0.45	5.6	0.42	9.99e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.61	6.68	0.48	4.72e-10	Bipolar disorder;
UCEC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.81	0.37	3.72e-6	Personality dimensions;
UCEC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.81	-0.49	2.26e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg22105103	chr4:187893119	NA	0.43	5.12	0.39	9.28e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	15.34	0.78	2.57e-32	Colorectal cancer;
UCEC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	4.6	0.35	8.93e-6	Mean platelet volume;
UCEC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg24069376	chr3:38537580	EXOG	0.39	4.87	0.37	2.83e-6	Electrocardiographic conduction measures;
UCEC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.23	0.4	5.78e-7	Lung cancer in ever smokers;
UCEC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.87	-0.44	2.77e-8	Hemoglobin concentration;
UCEC	cis	rs73206853	0.764	rs68087637	chr12:110619797	T/C	cg12870014	chr12:110450643	ANKRD13A	0.59	5.27	0.4	4.8e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-0.86	-12.0	-0.7	1.5e-23	Triglycerides;
UCEC	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.51	4.88	0.37	2.74e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.47	0.47	1.35e-9	Diabetic retinopathy;
UCEC	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.59	4.89	0.37	2.61e-6	Type 2 diabetes;
UCEC	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.73	6.95	0.5	1.08e-10	Schizophrenia;
UCEC	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-5.27	-0.4	4.7e-7	Gut microbiome composition (summer);
UCEC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs8453	0.579	rs3121508	chr1:115348875	G/T	cg12756093	chr1:115239321	AMPD1	0.51	4.59	0.35	9.54e-6	Autism;
UCEC	cis	rs8105895	1.000	rs6511313	chr19:22215905	C/T	cg24175803	chr19:22235144	ZNF257	-0.49	-4.56	-0.35	1.06e-5	Body mass index (change over time);
UCEC	trans	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.59	-0.53	3.33e-12	Response to antipsychotic treatment;
UCEC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg20387954	chr3:183756860	HTR3D	0.49	5.86	0.44	2.88e-8	Anterior chamber depth;
UCEC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.65	7.45	0.52	7.46e-12	Coronary artery disease;
UCEC	cis	rs1919796	0.723	rs2699143	chr7:9289425	A/T	cg27477025	chr7:9765726	NA	-0.42	-4.63	-0.36	8.01e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-9.39	-0.61	1.09e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4389656	0.857	rs274680	chr5:6749085	T/G	cg10857441	chr5:6722123	POLS	-0.39	-4.54	-0.35	1.14e-5	Coronary artery disease;
UCEC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.73	-5.67	-0.42	7.26e-8	Orofacial clefts;
UCEC	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.73	7.87	0.54	7.13e-13	Lymphocyte counts;
UCEC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.52	5.78	0.43	4.35e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26002218	chr14:103986227	CKB	0.36	5.24	0.4	5.56e-7	Body mass index;
UCEC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.79	7.42	0.52	8.74e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.48	7.0	0.5	8.34e-11	Homoarginine levels;
UCEC	cis	rs12118280	0.921	rs72693452	chr1:108740482	G/A	cg11967332	chr1:108735228	SLC25A24	1.0	9.36	0.61	1.26e-16	Myeloid white cell count;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.93	-0.44	2.06e-8	Depression;
UCEC	cis	rs9654415	0.536	rs10070847	chr5:72532422	C/G	cg14913210	chr5:71756484	ZNF366	-0.51	-4.6	-0.35	9.05e-6	Eyebrow thickness;
UCEC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.58	-5.18	-0.39	7.21e-7	Longevity;
UCEC	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.59	5.27	0.4	4.8e-7	Menarche (age at onset);
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.6	0.58	1.12e-14	Platelet count;
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.59	8.69	0.58	6.69e-15	Prudent dietary pattern;
UCEC	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.63	-6.09	-0.45	9.47e-9	Metabolite levels;
UCEC	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-0.53	-5.37	-0.4	3.02e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.75	0.36	4.73e-6	Personality dimensions;
UCEC	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.57	6.45	0.47	1.53e-9	Crohn's disease;
UCEC	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.46	-5.16	-0.39	7.96e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.46	4.83	0.37	3.4e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.6	5.13	0.39	8.89e-7	Heart rate;
UCEC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	0.92	9.33	0.61	1.56e-16	Heart rate;
UCEC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.54	4.81	0.37	3.69e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-7.68	-0.54	2.04e-12	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.65	-6.08	-0.45	9.85e-9	Vitiligo;
UCEC	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.5	-0.41	1.66e-7	Depression;
UCEC	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg07930552	chr6:133119739	C6orf192	0.87	6.51	0.47	1.13e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.06	-0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.43	4.84	0.37	3.21e-6	Response to antineoplastic agents;
UCEC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.63	6.29	0.46	3.38e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.66	-5.7	-0.43	6.25e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs2455826	0.520	rs2654649	chr3:15776684	A/G	cg16303742	chr3:15540471	COLQ	-0.41	-4.78	-0.37	4.16e-6	Inflammatory skin disease;
UCEC	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.3	0.46	3.2e-9	Hip circumference;
UCEC	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg18681998	chr4:17616180	MED28	0.74	7.48	0.52	6.28e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.74	0.54	1.47e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.84	-7.98	-0.55	3.75e-13	Diastolic blood pressure;
UCEC	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.65	4.58	0.35	9.73e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.51	0.41	1.58e-7	Hemoglobin concentration;
UCEC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.7	-7.92	-0.55	5.47e-13	Coronary artery disease;
UCEC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.78	-7.09	-0.5	5.26e-11	Initial pursuit acceleration;
UCEC	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.31	-0.52	1.61e-11	Obesity-related traits;
UCEC	cis	rs9469578	1.000	rs73743323	chr6:33705355	C/T	cg18708504	chr6:33715942	IP6K3	0.55	5.3	0.4	4.07e-7	Phosphorus levels;
UCEC	cis	rs4919044	0.599	rs11187215	chr10:94670849	A/G	cg00519463	chr10:94352821	KIF11	0.91	4.87	0.37	2.81e-6	Coronary artery disease;
UCEC	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.4	-0.41	2.62e-7	Morning vs. evening chronotype;
UCEC	cis	rs11760485	0.965	rs28403109	chr7:4401876	G/A	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.69	6.67	0.48	4.73e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs79815064	0.850	rs75994669	chr3:46300863	T/G	cg08033130	chr3:45983597	CXCR6;FYCO1	0.73	4.58	0.35	9.85e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.52	4.6	0.35	9.17e-6	Diabetic retinopathy;
UCEC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.66	0.42	7.75e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.69	6.26	0.46	4.07e-9	Aortic root size;
UCEC	cis	rs240764	0.578	rs723743	chr6:101237504	T/C	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	1.0	8.28	0.56	6.85e-14	Multiple sclerosis;
UCEC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.54	4.78	0.37	4.2e-6	Obesity-related traits;
UCEC	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.74	-4.81	-0.37	3.67e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs4845459	0.967	rs10888503	chr1:152593549	C/T	cg07796016	chr1:152779584	LCE1C	-0.41	-4.63	-0.36	7.98e-6	Psoriasis;
UCEC	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.79	0.43	4.18e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs256277	0.657	rs154119	chr5:111375089	T/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.57	-4.76	-0.37	4.5e-6	Coronary artery disease;
UCEC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.1	13.49	0.74	1.68e-27	Cognitive function;
UCEC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg21521518	chr4:53727714	RASL11B	0.54	4.78	0.37	4.14e-6	Optic nerve measurement (cup area);
UCEC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.75	8.26	0.56	7.83e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.63	6.61	0.48	6.66e-10	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.5	4.74	0.36	4.98e-6	Coronary artery disease;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.07	-0.45	1.05e-8	Prudent dietary pattern;
UCEC	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.69	-7.41	-0.52	9.33e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg13147721	chr7:65941812	NA	-0.84	-5.48	-0.41	1.81e-7	Diabetic kidney disease;
UCEC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.09	8.55	0.58	1.43e-14	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.72	6.82	0.49	2.2e-10	Aortic root size;
UCEC	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg17259809	chr10:104614391	C10orf32	-0.68	-4.58	-0.35	9.92e-6	Arsenic metabolism;
UCEC	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.67	-6.15	-0.45	6.89e-9	Plateletcrit;Platelet count;
UCEC	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg02733842	chr7:1102375	C7orf50	-0.64	-5.96	-0.44	1.76e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg13844804	chr7:814759	HEATR2	0.69	4.7	0.36	5.94e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	8.3	0.56	6.26e-14	Mean platelet volume;
UCEC	cis	rs7870753	0.838	rs3802441	chr9:99220395	A/G	cg25260653	chr9:99212216	HABP4	0.54	5.41	0.41	2.47e-7	Height;
UCEC	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4919044	0.866	rs55853605	chr10:94825097	G/A	cg00519463	chr10:94352821	KIF11	0.96	5.36	0.4	3.11e-7	Coronary artery disease;
UCEC	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg18016565	chr1:150552671	MCL1	0.45	4.65	0.36	7.34e-6	Melanoma;
UCEC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg07776626	chr8:57350775	NA	-0.47	-5.33	-0.4	3.63e-7	Obesity-related traits;
UCEC	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs713477	0.935	rs4901564	chr14:55912409	G/T	cg13175173	chr14:55914753	NA	-0.4	-4.52	-0.35	1.24e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.26	-0.56	7.74e-14	Parkinson's disease;
UCEC	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.44	-4.93	-0.38	2.17e-6	White matter hyperintensity burden;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.82	-0.37	3.59e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13683864	chr3:40499215	RPL14	-0.94	-9.66	-0.62	2.17e-17	Renal cell carcinoma;
UCEC	cis	rs6670533	0.571	rs78336051	chr1:24860468	T/A	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	0.99	7.56	0.53	3.92e-12	Economic and political preferences (immigration/crime);
UCEC	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.5	5.84	0.43	3.29e-8	Longevity;
UCEC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	8.11	0.56	1.88e-13	Total body bone mineral density;
UCEC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.67	0.58	7.19e-15	Alzheimer's disease;
UCEC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	5.83	0.43	3.45e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.59	7.48	0.53	6.18e-12	Anterior chamber depth;
UCEC	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.65	-6.67	-0.48	4.82e-10	Systemic sclerosis;
UCEC	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-1.12	-6.89	-0.49	1.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs256277	0.544	rs26559	chr5:111329649	C/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-5.03	-0.38	1.38e-6	Coronary artery disease;
UCEC	cis	rs533123	0.701	rs204054	chr1:29160462	T/C	cg08366446	chr1:29138936	OPRD1	0.77	5.13	0.39	8.88e-7	Schizophrenia;
UCEC	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-1.03	-12.81	-0.73	1.06e-25	Body mass index;
UCEC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg26114124	chr12:9217669	LOC144571	0.4	4.85	0.37	3.05e-6	Sjögren's syndrome;
UCEC	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.45	-5.33	-0.4	3.63e-7	Dementia with Lewy bodies;
UCEC	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.78	8.21	0.56	1.02e-13	Caffeine consumption;
UCEC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.59	-5.68	-0.42	7.14e-8	Dental caries;
UCEC	cis	rs3812049	0.532	rs251390	chr5:127538346	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	5.32	0.4	3.78e-7	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.66	-6.6	-0.48	7.11e-10	Platelet distribution width;
UCEC	cis	rs6684428	0.706	rs10493185	chr1:56321789	A/G	cg11651538	chr1:56320950	NA	-0.76	-6.68	-0.48	4.55e-10	Airflow obstruction;
UCEC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-5.98	-0.44	1.64e-8	Prostate cancer;
UCEC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs970548	0.690	rs12269352	chr10:46055646	T/A	cg15223267	chr10:46222474	FAM21C	0.49	4.67	0.36	6.83e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.61	6.12	0.45	8.07e-9	Mood instability;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.43	5.07	0.39	1.18e-6	Tonsillectomy;
UCEC	cis	rs10924970	0.601	rs11581323	chr1:235395923	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	4.52	0.35	1.25e-5	Asthma;
UCEC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs876084	0.505	rs4409431	chr8:121104019	C/G	cg06265175	chr8:121136014	COL14A1	0.46	5.01	0.38	1.57e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg11871910	chr12:69753446	YEATS4	0.64	6.82	0.49	2.23e-10	Response to diuretic therapy;
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.92	0.59	1.67e-15	Prudent dietary pattern;
UCEC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.72	-7.54	-0.53	4.45e-12	Cognitive function;
UCEC	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.59	-4.57	-0.35	1.02e-5	Cerebrospinal P-tau181p levels;
UCEC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.58e-7	Acne (severe);
UCEC	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg21419209	chr3:44054225	NA	-0.46	-4.91	-0.38	2.44e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.82	5.34	0.4	3.39e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg07924653	chr4:16883525	LDB2	0.4	4.58	0.35	9.95e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7474896	0.895	rs2749559	chr10:38211422	G/A	cg00409905	chr10:38381863	ZNF37A	0.59	4.59	0.35	9.32e-6	Obesity (extreme);
UCEC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.6	5.29	0.4	4.4e-7	Prostate cancer;
UCEC	cis	rs7165102	1.000	rs2414885	chr15:66034624	T/C	cg11164506	chr15:66649558	TIPIN	-0.33	-4.56	-0.35	1.09e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.0	-7.96	-0.55	4.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.11	0.51	4.56e-11	Mosquito bite size;
UCEC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.63	0.36	8e-6	Parkinson's disease;
UCEC	cis	rs36715	1.000	rs36693	chr5:127548700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.37	0.4	3.04e-7	Breast cancer;
UCEC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.51	-5.41	-0.41	2.46e-7	Alcohol dependence;
UCEC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.81	-9.07	-0.6	6.92e-16	Prudent dietary pattern;
UCEC	cis	rs9341808	0.714	rs9448911	chr6:80913859	A/G	cg08355045	chr6:80787529	NA	0.41	5.15	0.39	8.25e-7	Sitting height ratio;
UCEC	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.65	6.2	0.46	5.53e-9	Cognitive ability;
UCEC	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	0.79	5.95	0.44	1.92e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	6.01	0.44	1.39e-8	Height;
UCEC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Bipolar disorder;
UCEC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg01262667	chr19:19385393	TM6SF2	0.52	7.37	0.52	1.11e-11	Tonsillectomy;
UCEC	cis	rs7246967	0.551	rs8112442	chr19:22893369	C/T	cg23217946	chr19:22817039	ZNF492	0.42	4.54	0.35	1.16e-5	Bronchopulmonary dysplasia;
UCEC	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.29	10.03	0.64	2.35e-18	Uric acid levels;
UCEC	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-5.89	-0.44	2.47e-8	Chronic sinus infection;
UCEC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg15358701	chr1:161410459	NA	-0.74	-5.07	-0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.64	5.59	0.42	1.07e-7	Alzheimer's disease;
UCEC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.77	0.43	4.47e-8	Breast cancer;
UCEC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.58	-6.44	-0.47	1.62e-9	Blood metabolite levels;
UCEC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.71	6.7	0.48	4.14e-10	High light scatter reticulocyte count;
UCEC	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.48	-5.02	-0.38	1.5e-6	Glaucoma;
UCEC	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-9.32	-0.61	1.66e-16	Ulcerative colitis;
UCEC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.76	7.62	0.53	2.86e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.78	-6.12	-0.45	8.1e-9	Corneal structure;
UCEC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	6.76	0.49	2.96e-10	Bipolar disorder and schizophrenia;
UCEC	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.82	8.95	0.59	1.46e-15	Colorectal cancer;
UCEC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.78	8.8	0.59	3.5e-15	Mortality in heart failure;
UCEC	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.41	-5.18	-0.39	7.33e-7	Height;
UCEC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.74	6.65	0.48	5.34e-10	Alzheimer's disease;
UCEC	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.58	-5.52	-0.41	1.51e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.07	-0.39	1.15e-6	Life satisfaction;
UCEC	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg03543861	chr21:44258195	NA	0.48	5.18	0.39	7.34e-7	Information processing speed;
UCEC	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.63	-0.42	8.88e-8	Depression;
UCEC	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.84	0.37	3.21e-6	Aortic root size;
UCEC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.69	-7.83	-0.54	8.69e-13	Menarche (age at onset);
UCEC	cis	rs1018836	0.700	rs7824376	chr8:91521498	T/C	cg16814680	chr8:91681699	NA	-0.72	-7.07	-0.5	5.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.65	-6.95	-0.5	1.13e-10	Parkinson's disease;
UCEC	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	8.22	0.56	9.79e-14	Mean platelet volume;
UCEC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.59	5.27	0.4	4.7e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs427691	0.625	rs845739	chr5:109018540	G/T	cg17395555	chr5:108820864	NA	0.67	4.83	0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs72700829	0.576	rs6695311	chr1:151002758	G/A	cg00107782	chr1:151300621	NA	-0.68	-4.67	-0.36	6.73e-6	Schizophrenia;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.52	-5.29	-0.4	4.27e-7	Longevity;Endometriosis;
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.65	-7.52	-0.53	4.92e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.62	-0.42	9.09e-8	Bipolar disorder and schizophrenia;
UCEC	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.76	6.86	0.49	1.78e-10	Morning vs. evening chronotype;
UCEC	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg05527609	chr1:210001259	C1orf107	-0.7	-5.58	-0.42	1.13e-7	Red blood cell count;
UCEC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg12463550	chr7:65579703	CRCP	0.64	5.5	0.41	1.67e-7	Aortic root size;
UCEC	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-6.72	-0.48	3.76e-10	Hypospadias;
UCEC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.51	5.46	0.41	1.99e-7	Melanoma;
UCEC	cis	rs6690583	0.623	rs12037219	chr1:85505951	G/A	cg11262906	chr1:85462892	MCOLN2	0.72	4.57	0.35	1.01e-5	Serum sulfate level;
UCEC	cis	rs7607369	0.559	rs4674340	chr2:219659799	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.8	-0.43	3.92e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-5.08	-0.39	1.14e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	15.37	0.79	2.15e-32	Colorectal cancer;
UCEC	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg00086871	chr4:6988644	TBC1D14	0.77	5.08	0.39	1.12e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg24562669	chr7:97807699	LMTK2	0.73	10.7	0.66	4.04e-20	Breast cancer;
UCEC	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg13175173	chr14:55914753	NA	0.43	4.54	0.35	1.16e-5	Protein biomarker;
UCEC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.7	6.12	0.45	8.21e-9	Alzheimer's disease;
UCEC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4499344	0.696	rs398990	chr19:33104244	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.41e-9	Mean platelet volume;
UCEC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs59104589	0.535	rs73002160	chr2:242321707	A/C	cg19488206	chr2:242435732	STK25	0.54	4.87	0.37	2.83e-6	Fibrinogen levels;
UCEC	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.69	8.06	0.55	2.5e-13	Mean corpuscular volume;
UCEC	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.24	0.61	2.58e-16	Post bronchodilator FEV1;
UCEC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.96	0.38	1.88e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.35	5.2	0.39	6.51e-7	Vitiligo;
UCEC	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.37e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.66	-6.13	-0.45	7.55e-9	Subjective well-being;
UCEC	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.49	0.47	1.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg12024160	chr4:1254474	NA	0.56	7.41	0.52	9.37e-12	Obesity-related traits;
UCEC	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.33	7.69	0.54	1.91e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg16583315	chr14:65563665	MAX	-0.49	-5.34	-0.4	3.39e-7	Obesity-related traits;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg19478983	chr7:120590592	ING3	-0.65	-7.45	-0.52	7.31e-12	Breast cancer;
UCEC	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.68	0.42	7.12e-8	Rheumatoid arthritis;
UCEC	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.41	-0.77	6.65e-30	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs1433085	chr19:22811099	T/A	cg24889512	chr19:22816950	ZNF492	0.54	5.6	0.42	1e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.56	5.78	0.43	4.3e-8	Ulcerative colitis;
UCEC	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.9	8.73	0.58	5.28e-15	Cognitive ability;
UCEC	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.54	6.03	0.45	1.27e-8	Life satisfaction;
UCEC	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg21419209	chr3:44054225	NA	-0.49	-4.99	-0.38	1.68e-6	Coronary artery disease;
UCEC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.55	5.22	0.4	5.97e-7	Aortic root size;
UCEC	cis	rs11235843	0.602	rs11235827	chr11:73346346	G/A	cg23931323	chr11:73372278	PLEKHB1	0.68	5.38	0.41	2.82e-7	Hand grip strength;
UCEC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.79	-8.78	-0.59	3.77e-15	Immature fraction of reticulocytes;
UCEC	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.54	5.8	0.43	3.89e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.48	4.9	0.37	2.51e-6	Red blood cell count;
UCEC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-6.01	-0.44	1.42e-8	Menarche (age at onset);
UCEC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.69	8.69	0.58	6.63e-15	Anterior chamber depth;
UCEC	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.81	-8.5	-0.57	1.98e-14	Caffeine consumption;
UCEC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.6	0.58	1.11e-14	Prudent dietary pattern;
UCEC	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg21466736	chr12:48725269	NA	-0.35	-4.78	-0.37	4.3e-6	Plateletcrit;
UCEC	cis	rs890835	0.881	rs2963292	chr5:175960851	C/T	cg17652716	chr5:176910622	PDLIM7	0.66	4.88	0.37	2.78e-6	Menopause (age at onset);
UCEC	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.43	-4.79	-0.37	3.99e-6	Prostate cancer;
UCEC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.5	5.17	0.39	7.54e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.44	-0.47	1.62e-9	Pubertal anthropometrics;
UCEC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.99	-0.44	1.57e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg26587870	chr6:27730563	NA	-0.55	-4.54	-0.35	1.16e-5	Depression;
UCEC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.72	-5.69	-0.42	6.75e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.64	7.03	0.5	7.02e-11	Monocyte count;
UCEC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.51	4.61	0.36	8.53e-6	Menarche (age at onset);
UCEC	cis	rs4871297	0.729	rs876742	chr8:123698785	C/A	cg17213048	chr8:124332861	ATAD2	0.41	4.66	0.36	6.98e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.81	-0.43	3.79e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.36	4.98	0.38	1.73e-6	Crohn's disease;
UCEC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs17106184	1.000	rs12063943	chr1:51223263	T/C	cg07174182	chr1:51127561	FAF1	-0.62	-4.54	-0.35	1.16e-5	Type 2 diabetes;
UCEC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.61	5.81	0.43	3.77e-8	Lung cancer;
UCEC	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.53	-6.91	-0.5	1.38e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.23	10.65	0.66	5.66e-20	Corneal structure;
UCEC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.44	-5.48	-0.41	1.83e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.5	5.42	0.41	2.4e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-6.5	-0.47	1.2e-9	Platelet distribution width;
UCEC	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs829661	0.947	rs844194	chr2:30753803	T/G	cg17749961	chr2:30669863	LCLAT1	0.49	4.66	0.36	7.1e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-6.16	-0.45	6.76e-9	Response to antipsychotic treatment;
UCEC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.65	-6.48	-0.47	1.29e-9	Lymphocyte counts;
UCEC	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.74	7.99	0.55	3.64e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	4.59	0.35	9.5e-6	Motion sickness;
UCEC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg11569703	chr11:65557185	OVOL1	0.53	6.88	0.49	1.64e-10	Acne (severe);
UCEC	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.62	-0.36	8.32e-6	Body mass index;
UCEC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.55	4.97	0.38	1.86e-6	Menarche (age at onset);
UCEC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.16	14.9	0.78	3.46e-31	Cognitive function;
UCEC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg03711944	chr11:47377212	SPI1	-0.47	-4.54	-0.35	1.17e-5	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg11871910	chr12:69753446	YEATS4	0.74	7.79	0.54	1.11e-12	Blood protein levels;
UCEC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg23791538	chr6:167370224	RNASET2	-0.54	-5.79	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.77	-7.43	-0.52	7.99e-12	Lung cancer;
UCEC	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.69	5.94	0.44	1.96e-8	Platelet count;
UCEC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-5.3	-0.4	4.22e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.82	8.66	0.58	7.9e-15	Parkinson's disease;
UCEC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.91	9.73	0.63	1.43e-17	Longevity;Endometriosis;
UCEC	cis	rs7246967	1.000	rs936525	chr19:23056189	C/T	cg05241461	chr19:22816980	ZNF492	0.47	4.93	0.38	2.18e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.49	4.72	0.36	5.37e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg01874867	chr7:94954059	PON1	-0.53	-4.63	-0.36	8.1e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.69	8.73	0.58	5.28e-15	Anterior chamber depth;
UCEC	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.93	0.38	2.22e-6	Hemoglobin concentration;
UCEC	cis	rs116095464	0.764	rs28710899	chr5:241029	G/A	cg02160872	chr5:212506	CCDC127	-0.67	-6.47	-0.47	1.37e-9	Breast cancer;
UCEC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.23	-0.4	5.71e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg17764715	chr19:33622953	WDR88	0.59	5.76	0.43	4.75e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	trans	rs925228	0.668	rs7579413	chr2:23933356	A/G	cg21054441	chr15:68871409	CORO2B	0.61	6.69	0.48	4.28e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-5.33	-0.4	3.68e-7	Body mass index;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.33	-0.4	3.64e-7	Pubertal anthropometrics;
UCEC	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.03	-12.45	-0.72	9.25e-25	Dilated cardiomyopathy;
UCEC	cis	rs10924970	0.967	rs8179454	chr1:235460719	C/G	cg26050004	chr1:235667680	B3GALNT2	0.45	4.74	0.36	4.95e-6	Asthma;
UCEC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	9.22	0.61	2.96e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.68	7.84	0.54	8.52e-13	Ulcerative colitis;
UCEC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.66	0.36	7.08e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.41	4.6	0.35	9.17e-6	Mean corpuscular volume;
UCEC	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.95	0.59	1.45e-15	Prudent dietary pattern;
UCEC	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.61	5.65	0.42	8.13e-8	Heart rate;
UCEC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2179367	0.959	rs2262617	chr6:149759726	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.38	-4.85	-0.37	3.12e-6	Dupuytren's disease;
UCEC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	8.18	0.56	1.19e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9356171	0.572	rs2281407	chr6:164325926	C/T	cg25752492	chr6:164341247	NA	-0.57	-5.72	-0.43	5.7e-8	Diisocyanate-induced asthma;
UCEC	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-8.6	-0.58	1.13e-14	Blood metabolite levels;
UCEC	cis	rs11582254	0.735	rs4912015	chr1:20011153	G/C	cg05446994	chr1:20960538	PINK1	0.46	4.64	0.36	7.64e-6	Nonsyndromic cleft lip with cleft palate;
UCEC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.63	7.4	0.52	9.8e-12	Prostate cancer;
UCEC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-5.99	-0.44	1.58e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg22974920	chr21:40686053	BRWD1	0.59	5.28	0.4	4.49e-7	Cognitive function;
UCEC	cis	rs62117911	1	rs62117911	chr19:16241886	G/A	cg07665718	chr19:16244068	HSH2D;RAB8A	0.71	5.35	0.4	3.35e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.68	7.01	0.5	8.11e-11	Eosinophil percentage of white cells;
UCEC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg26114124	chr12:9217669	LOC144571	0.4	4.59	0.35	9.29e-6	Sjögren's syndrome;
UCEC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.64	5.18	0.39	7.04e-7	Corneal astigmatism;
UCEC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.71	7.51	0.53	5.38e-12	Lymphocyte counts;
UCEC	cis	rs13437751	0.649	rs10278598	chr7:63356712	G/A	cg00787055	chr7:63562162	NA	0.39	4.66	0.36	6.91e-6	QT interval (drug interaction);
UCEC	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	1.0	10.16	0.64	1.06e-18	Post bronchodilator FEV1;
UCEC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.61	6.76	0.49	3.07e-10	Resting heart rate;
UCEC	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg03114573	chr12:45410052	DBX2	-0.45	-5.05	-0.38	1.29e-6	Gut microbiome composition (summer);
UCEC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.35	-0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg07150772	chr14:90864620	CALM1	-0.56	-5.49	-0.41	1.72e-7	Mortality in heart failure;
UCEC	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg23950597	chr19:37808831	NA	-0.85	-5.94	-0.44	2.01e-8	Coronary artery calcification;
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.89	0.59	2.07e-15	Prudent dietary pattern;
UCEC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08822215	chr16:89438651	ANKRD11	-0.55	-5.35	-0.4	3.24e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	0.94	5.75	0.43	4.97e-8	Skin colour saturation;
UCEC	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.45	-4.53	-0.35	1.22e-5	Non-alcoholic fatty liver disease histology (lobular);
UCEC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.13e-9	Tonsillectomy;
UCEC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg09654669	chr8:57350985	NA	-0.43	-4.53	-0.35	1.21e-5	Obesity-related traits;
UCEC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	6.24	0.46	4.53e-9	Menarche (age at onset);
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07000514	chr7:1090232	C7orf50	0.45	4.56	0.35	1.05e-5	Longevity;Endometriosis;
UCEC	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.54	-5.3	-0.4	4.25e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.46	-4.77	-0.37	4.47e-6	Dental caries;
UCEC	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.78	-9.21	-0.61	3.04e-16	White blood cell count (basophil);
UCEC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01973587	chr1:228161476	NA	0.38	4.95	0.38	2.04e-6	Diastolic blood pressure;
UCEC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs7639513	0.520	rs79141906	chr3:12711977	A/C	cg23032965	chr3:12705835	RAF1	0.73	7.24	0.51	2.26e-11	Itch intensity from mosquito bite;
UCEC	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	0.88	4.95	0.38	1.98e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs6429082	0.510	rs2789367	chr1:235506918	G/C	cg26050004	chr1:235667680	B3GALNT2	0.44	4.61	0.36	8.68e-6	Adiposity;
UCEC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg12463550	chr7:65579703	CRCP	-0.54	-5.36	-0.4	3.2e-7	Aortic root size;
UCEC	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.81	8.62	0.58	9.99e-15	Colorectal cancer;
UCEC	cis	rs4908768	0.594	rs11121227	chr1:8830640	C/T	cg13081009	chr1:8430745	RERE	0.42	4.56	0.35	1.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg09557387	chr1:207818395	CR1L	0.87	4.63	0.36	8.12e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg01770232	chr7:22766155	IL6	0.68	4.72	0.36	5.4e-6	Tonsillectomy;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.46	-5.48	-0.41	1.76e-7	Pubertal anthropometrics;
UCEC	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.53	-5.16	-0.39	7.95e-7	Tonsillectomy;
UCEC	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.79e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg05660106	chr1:15850417	CASP9	0.61	6.02	0.44	1.31e-8	Systolic blood pressure;
UCEC	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg06096015	chr1:231504339	EGLN1	0.42	4.77	0.37	4.32e-6	Hemoglobin concentration;
UCEC	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.5	4.93	0.38	2.2e-6	Height;
UCEC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.47	4.84	0.37	3.29e-6	Schizophrenia;
UCEC	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	6.9	0.49	1.47e-10	Coronary artery disease;
UCEC	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-0.64	-4.81	-0.37	3.68e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.65	6.71	0.48	3.95e-10	Obesity-related traits;
UCEC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.96	10.85	0.67	1.65e-20	Cognitive function;
UCEC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.98e-7	Aortic root size;
UCEC	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	0.72	5.45	0.41	2.1e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.49	-5.61	-0.42	9.8e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.5	-4.99	-0.38	1.66e-6	Longevity;Endometriosis;
UCEC	cis	rs17122693	1.000	rs72679560	chr14:51067379	C/T	cg04730355	chr14:51134070	SAV1	0.91	8.93	0.59	1.57e-15	Cognitive performance;
UCEC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16346588	chr10:242978	ZMYND11	0.48	4.73	0.36	5.29e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.5	4.93	0.38	2.22e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.52	5.27	0.4	4.71e-7	Monocyte count;
UCEC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.73	6.08	0.45	9.78e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.47	4.57	0.35	1.02e-5	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.5	5.17	0.39	7.68e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.51	-6.78	-0.49	2.69e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-6.69	-0.48	4.4e-10	Response to antipsychotic treatment;
UCEC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	4.73	0.36	5.21e-6	Lung cancer in ever smokers;
UCEC	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.51	-5.09	-0.39	1.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs253959	0.697	rs10463453	chr5:115414554	A/T	cg23108291	chr5:115420582	COMMD10	0.47	4.54	0.35	1.15e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.99	13.55	0.75	1.2e-27	Bone mineral density;
UCEC	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs75804782	0.625	rs72984524	chr2:239468692	G/T	cg12524725	chr2:239427019	NA	-0.67	-4.64	-0.36	7.59e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-0.89	-7.0	-0.5	8.42e-11	Left ventricular obstructive tract defect (inherited effect);
UCEC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.73	6.93	0.5	1.21e-10	Aortic root size;
UCEC	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.76	6.48	0.47	1.28e-9	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	7.88	0.54	6.82e-13	Response to antipsychotic treatment;
UCEC	cis	rs17123764	0.605	rs6580719	chr12:50071092	C/A	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.49e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.93	-0.38	2.22e-6	Breast cancer;
UCEC	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg20368463	chr18:77673604	PQLC1	0.68	5.42	0.41	2.41e-7	Opioid sensitivity;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg21486944	chr6:28411378	ZSCAN23	0.51	5.72	0.43	5.83e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.9	-6.75	-0.49	3.2e-10	Exhaled nitric oxide output;
UCEC	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.64	7.3	0.52	1.69e-11	Body mass index;
UCEC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg13695892	chr22:41940480	POLR3H	0.7	5.64	0.42	8.26e-8	Vitiligo;
UCEC	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.55	4.97	0.38	1.82e-6	Crohn's disease;
UCEC	cis	rs4778214	1.000	rs12050576	chr15:28219720	C/G	cg08281084	chr15:28459700	HERC2	-0.53	-4.69	-0.36	6.27e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
UCEC	cis	rs13437751	1.000	rs13437751	chr7:63346886	C/T	cg00787055	chr7:63562162	NA	0.36	4.57	0.35	1.02e-5	QT interval (drug interaction);
UCEC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9402633	0.938	rs28568459	chr6:135040792	A/G	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.45	4.95	0.38	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.53	-4.94	-0.38	2.09e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.64	-6.79	-0.49	2.65e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.85	7.77	0.54	1.24e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.58	5.75	0.43	5.02e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.88	11.04	0.67	5.17e-21	Longevity;Endometriosis;
UCEC	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.85	-10.53	-0.66	1.15e-19	Primary sclerosing cholangitis;
UCEC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-4.73	-0.36	5.11e-6	Platelet distribution width;
UCEC	cis	rs10924970	0.613	rs12027933	chr1:235440411	A/T	cg26050004	chr1:235667680	B3GALNT2	0.53	4.79	0.37	4.1e-6	Asthma;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.61	-0.48	6.56e-10	Depression;
UCEC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.5	5.04	0.38	1.37e-6	Colorectal cancer;
UCEC	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.76	7.96	0.55	4.24e-13	Breast cancer;
UCEC	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg00105475	chr2:10696890	NA	-0.45	-5.59	-0.42	1.09e-7	Prostate cancer;
UCEC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg22974920	chr21:40686053	BRWD1	0.61	5.33	0.4	3.54e-7	Cognitive function;
UCEC	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.5	4.67	0.36	6.8e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.61	4.75	0.36	4.82e-6	Alcohol dependence;
UCEC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.54	5.94	0.44	1.98e-8	Breast cancer;
UCEC	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.7	0.36	5.81e-6	Educational attainment;
UCEC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.58	4.65	0.36	7.31e-6	Skin colour saturation;
UCEC	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.41	-5.34	-0.4	3.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs732765	0.734	rs7153812	chr14:75173490	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.63	-0.36	8.04e-6	Non-small cell lung cancer;
UCEC	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg12024160	chr4:1254474	NA	0.54	7.01	0.5	7.84e-11	Obesity-related traits;
UCEC	cis	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg12524725	chr2:239427019	NA	-0.71	-4.52	-0.35	1.26e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.22	-0.4	6.1e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-6.14	-0.45	7.41e-9	Idiopathic membranous nephropathy;
UCEC	trans	rs4788570	0.566	rs16972808	chr16:71478717	A/G	cg18607411	chr13:80911808	SPRY2	0.78	6.91	0.5	1.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs78487399	0.808	rs111812200	chr2:43674278	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg22166914	chr1:53195759	ZYG11B	0.61	6.23	0.46	4.58e-9	Monocyte count;
UCEC	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.38	0.52	1.07e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg02344993	chr17:57696989	CLTC	0.51	4.84	0.37	3.29e-6	Hemoglobin concentration;
UCEC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg05962950	chr11:130786565	SNX19	0.46	4.63	0.36	8.11e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.51	5.17	0.39	7.56e-7	Dupuytren's disease;
UCEC	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.79	5.92	0.44	2.13e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.71	-7.06	-0.5	6e-11	Diastolic blood pressure;
UCEC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg01874867	chr7:94954059	PON1	-0.53	-4.92	-0.38	2.25e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	4.95	0.38	1.97e-6	Alzheimer's disease (late onset);
UCEC	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs11038871	1.000	rs11038871	chr11:46379442	C/T	cg23542274	chr11:45718455	NA	0.33	4.63	0.36	8.09e-6	Immunoglobulin A;
UCEC	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.49	-4.82	-0.37	3.54e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg11301795	chr4:187892539	NA	-0.6	-7.03	-0.5	7.32e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg13695892	chr22:41940480	POLR3H	-0.69	-5.31	-0.4	3.91e-7	Vitiligo;
UCEC	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.81	10.62	0.66	6.49e-20	Body mass index;
UCEC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.46	5.31	0.4	3.93e-7	Aortic root size;
UCEC	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.5	5.34	0.4	3.41e-7	Breast cancer;
UCEC	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.58	4.97	0.38	1.84e-6	Response to diuretic therapy;
UCEC	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.86	0.37	3.03e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.06	0.45	1.08e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.52	6.51	0.47	1.12e-9	Information processing speed;
UCEC	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.68	-0.69	1.01e-22	Primary sclerosing cholangitis;
UCEC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg26721908	chr21:47610096	LSS	-0.52	-6.28	-0.46	3.54e-9	Testicular germ cell tumor;
UCEC	cis	rs2179367	1.000	rs2179367	chr6:149762537	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.45	-6.17	-0.45	6.17e-9	Dupuytren's disease;
UCEC	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg03543861	chr21:44258195	NA	0.47	4.93	0.38	2.23e-6	Information processing speed;
UCEC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.54	0.42	1.34e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs174479	0.647	rs174457	chr11:61656975	T/C	cg01500311	chr11:61656094	FADS3	0.51	6.56	0.48	8.43e-10	Sphingolipid levels;
UCEC	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg08461772	chr7:95026248	PON3	0.34	4.79	0.37	4e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg08886695	chr4:3369023	RGS12	-0.56	-5.5	-0.41	1.62e-7	Serum sulfate level;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.47	-4.98	-0.38	1.76e-6	Pubertal anthropometrics;
UCEC	cis	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg27411982	chr8:10470053	RP1L1	0.44	4.63	0.36	7.87e-6	Neuroticism;
UCEC	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.71	0.58	5.87e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.52	-4.93	-0.38	2.23e-6	Schizophrenia;
UCEC	cis	rs2302190	0.769	rs6503864	chr17:56549671	C/A	cg12560992	chr17:57184187	TRIM37	0.57	4.52	0.35	1.29e-5	Vitamin D levels;
UCEC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.94	11.57	0.69	2.03e-22	Multiple sclerosis;
UCEC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.5	-5.18	-0.39	7.06e-7	Electroencephalogram traits;
UCEC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.76	7.79	0.54	1.08e-12	Tonsillectomy;
UCEC	cis	rs10503871	0.657	rs6997017	chr8:30341945	A/G	cg26383811	chr8:30366931	RBPMS	0.5	5.13	0.39	9.1e-7	Metabolite levels  (X-11787);
UCEC	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.87	-0.49	1.68e-10	Obesity-related traits;
UCEC	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.71	-0.58	5.82e-15	Coffee consumption (cups per day);
UCEC	cis	rs4517514	0.509	rs11018870	chr11:89871409	T/G	cg06174606	chr11:89959870	NA	-0.58	-4.62	-0.36	8.42e-6	Trans fatty acid levels;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.42	5.57	0.42	1.17e-7	Blood protein levels;
UCEC	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.51	-4.82	-0.37	3.5e-6	Addiction;
UCEC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	7.7	0.54	1.85e-12	Chronic sinus infection;
UCEC	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.21	-0.4	6.15e-7	Body mass index;
UCEC	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	1.05	12.35	0.71	1.71e-24	Diastolic blood pressure;
UCEC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.74	-7.15	-0.51	3.77e-11	Response to antineoplastic agents;
UCEC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg08027265	chr7:2291960	NA	-0.5	-5.35	-0.4	3.31e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.53	5.86	0.44	2.89e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.63	9.25	0.61	2.4e-16	Prudent dietary pattern;
UCEC	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.5	-5.25	-0.4	5.32e-7	Heart rate;
UCEC	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-0.85	-8.55	-0.58	1.5e-14	Height;
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7523273	1.000	rs7541230	chr1:207957555	T/C	cg22525895	chr1:207977042	MIR29B2	-0.5	-4.54	-0.35	1.15e-5	Schizophrenia;
UCEC	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-4.79	-0.37	4.11e-6	Endometrial cancer;
UCEC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.37	-0.47	2.23e-9	Aortic root size;
UCEC	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg13575925	chr12:9217583	LOC144571	-0.4	-4.66	-0.36	6.91e-6	Sjögren's syndrome;
UCEC	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.59	6.43	0.47	1.65e-9	Total body bone mineral density;
UCEC	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-13.41	-0.74	2.68e-27	Schizophrenia;
UCEC	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.98	-10.59	-0.66	8.12e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.93	-0.44	2.03e-8	Tonsillectomy;
UCEC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.62	7.5	0.53	5.55e-12	Vitiligo;
UCEC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.63	-6.62	-0.48	6.45e-10	Mean platelet volume;
UCEC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.61	-6.87	-0.49	1.69e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	0.82	5.95	0.44	1.84e-8	Economic and political preferences (immigration/crime);
UCEC	cis	rs4400599	0.618	rs1194582	chr1:154215973	A/G	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	14.7	0.77	1.19e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.55	-4.99	-0.38	1.71e-6	Cognitive function;
UCEC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.86	8.87	0.59	2.27e-15	Cognitive function;
UCEC	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.51	5.49	0.41	1.76e-7	Neuroticism;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-5.03	-0.38	1.4e-6	Pulmonary function;
UCEC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg18681998	chr4:17616180	MED28	0.67	6.45	0.47	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.76	-4.65	-0.36	7.24e-6	Mosquito bite size;
UCEC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg13395646	chr4:1353034	KIAA1530	-0.54	-5.59	-0.42	1.08e-7	Obesity-related traits;
UCEC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.67	5.78	0.43	4.29e-8	Cognitive function;
UCEC	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-1.03	-7.23	-0.51	2.5e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.57	6.22	0.46	4.86e-9	Neuroticism;
UCEC	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.49	-5.54	-0.42	1.37e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.61	7.46	0.52	7.1e-12	Bone mineral density;
UCEC	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs72906064	0.908	rs17245513	chr2:156933105	A/G	cg14040602	chr2:157557294	NA	-0.56	-4.8	-0.37	3.89e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7219021	0.926	rs10468517	chr17:46862114	C/T	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	4.64	0.36	7.7e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs968451	0.789	rs1569500	chr22:39683515	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.52	4.73	0.36	5.28e-6	Primary biliary cholangitis;
UCEC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.35	0.4	3.31e-7	Coronary artery disease;
UCEC	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.75	-0.36	4.8e-6	Response to antipsychotic treatment;
UCEC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.46	-4.95	-0.38	2.05e-6	Alcohol dependence;
UCEC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.52	4.84	0.37	3.2e-6	Menopause (age at onset);
UCEC	cis	rs7246967	0.673	rs73022763	chr19:22894216	C/T	cg08271804	chr19:22816896	ZNF492	0.67	6.57	0.48	8.11e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs12618769	0.625	rs2278207	chr2:99163261	T/A	cg10123293	chr2:99228465	UNC50	0.44	4.68	0.36	6.59e-6	Bipolar disorder;
UCEC	cis	rs10256972	0.900	rs4388364	chr7:1033045	T/G	cg04025307	chr7:1156635	C7orf50	0.56	5.79	0.43	4.06e-8	Longevity;Endometriosis;
UCEC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.58	5.55	0.42	1.3e-7	Corneal astigmatism;
UCEC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.79	7.32	0.52	1.51e-11	Diastolic blood pressure;
UCEC	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg05962950	chr11:130786565	SNX19	0.47	4.82	0.37	3.61e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.63	-6.27	-0.46	3.89e-9	C-reactive protein levels;
UCEC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-12.72	-0.72	1.83e-25	Height;
UCEC	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.49	-7.26	-0.51	2.07e-11	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.35	4.98	0.38	1.79e-6	Obesity-related traits;
UCEC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.77	11.31	0.68	9.85e-22	Leprosy;
UCEC	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.81	7.04	0.5	6.74e-11	Corneal structure;
UCEC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.96	-10.51	-0.66	1.28e-19	Cognitive function;
UCEC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.58	0.42	1.11e-7	Breast cancer;
UCEC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.77	7.46	0.52	6.84e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.64	-7.71	-0.54	1.72e-12	Menarche (age at onset);
UCEC	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg05660106	chr1:15850417	CASP9	0.54	4.91	0.38	2.35e-6	Systolic blood pressure;
UCEC	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.87	-8.1	-0.56	1.9e-13	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg13683864	chr3:40499215	RPL14	-0.67	-6.64	-0.48	5.73e-10	Renal cell carcinoma;
UCEC	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.05	8.53	0.58	1.65e-14	Gut microbiome composition (summer);
UCEC	cis	rs2075165	0.901	rs1804999	chr1:156219450	A/G	cg20302342	chr1:156215951	PAQR6	0.56	5.63	0.42	8.94e-8	Tonsillectomy;
UCEC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-4.97	-0.38	1.88e-6	Bipolar disorder;
UCEC	cis	rs4372836	1.000	rs2169751	chr2:28966758	G/C	cg09522027	chr2:28974177	PPP1CB	-0.78	-7.93	-0.55	5.13e-13	Body mass index;
UCEC	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.62	5.17	0.39	7.39e-7	Cocaine dependence;
UCEC	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.71	-6.94	-0.5	1.16e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs58235267	0.564	rs360808	chr2:62927475	T/C	cg17519650	chr2:63277830	OTX1	-0.58	-5.75	-0.43	4.95e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg02158880	chr13:53174818	NA	0.6	7.03	0.5	7.01e-11	Lewy body disease;
UCEC	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.91	0.5	1.38e-10	Morning vs. evening chronotype;
UCEC	cis	rs4434872	0.525	rs11264824	chr1:153973171	C/T	cg00151906	chr1:154548273	CHRNB2	0.64	4.9	0.37	2.49e-6	Conduct disorder (symptom count);
UCEC	cis	rs11760485	0.965	rs4723690	chr7:4402953	T/C	cg22450045	chr7:4839495	RADIL	-0.41	-5.08	-0.39	1.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs1712517	0.771	rs7921655	chr10:105113701	C/T	cg05636881	chr10:105038444	INA	0.44	5.15	0.39	8.41e-7	Migraine;
UCEC	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.53	-5.63	-0.42	8.7e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg04871131	chr7:94954202	PON1	-0.5	-4.94	-0.38	2.1e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.69	6.26	0.46	4.07e-9	Aortic root size;
UCEC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.47	1.11e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.63	-0.36	8.01e-6	Menopause (age at onset);
UCEC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.9	10.46	0.65	1.69e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs747782	0.537	rs10838835	chr11:48246457	C/T	cg20307385	chr11:47447363	PSMC3	0.57	4.59	0.35	9.4e-6	Intraocular pressure;
UCEC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.84	10.16	0.64	1.06e-18	Mortality in heart failure;
UCEC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.54	-6.0	-0.44	1.45e-8	Diastolic blood pressure;
UCEC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-15.77	-0.79	2e-33	Myeloid white cell count;
UCEC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-5.66	-0.42	7.61e-8	Blood metabolite levels;
UCEC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.69	-7.14	-0.51	4e-11	Mean platelet volume;
UCEC	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.93e-9	Motion sickness;
UCEC	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.23	10.74	0.66	3.22e-20	Corneal structure;
UCEC	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.35	5.74	0.43	5.16e-8	Cancer;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.63	6.77	0.49	2.88e-10	Menopause (age at onset);
UCEC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg23307798	chr14:103986281	CKB	0.56	5.33	0.4	3.63e-7	Body mass index;
UCEC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.65	6.83	0.49	2.04e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs12367572	0.620	rs2643151	chr12:45410808	A/G	cg03114573	chr12:45410052	DBX2	-0.6	-7.33	-0.52	1.42e-11	Gut microbiome composition (summer);
UCEC	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg05660106	chr1:15850417	CASP9	0.5	4.92	0.38	2.26e-6	Systolic blood pressure;
UCEC	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg15848620	chr12:58087721	OS9	-0.53	-4.87	-0.37	2.87e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.61	0.53	3.01e-12	Ileal carcinoids;
UCEC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg05738196	chr6:26577821	NA	0.53	5.2	0.39	6.61e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-4.92	-0.38	2.29e-6	Morning vs. evening chronotype;
UCEC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.58	-4.52	-0.35	1.29e-5	Gut microbiome composition (summer);
UCEC	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg17031739	chr1:67600172	NA	0.45	4.66	0.36	6.99e-6	Psoriasis;
UCEC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	0.98	7.38	0.52	1.08e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.69	7.26	0.51	2.11e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.13e-9	Tonsillectomy;
UCEC	cis	rs7597155	0.935	rs7577493	chr2:69980174	T/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.44	-0.41	2.14e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12216499	1.000	rs74298057	chr6:159417303	C/T	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.47	-5.82	-0.43	3.6e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.69	-7.87	-0.54	7.28e-13	Menarche (age at onset);
UCEC	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.67	-6.81	-0.49	2.33e-10	C-reactive protein levels;
UCEC	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg12463550	chr7:65579703	CRCP	0.5	4.6	0.35	8.92e-6	Aortic root size;
UCEC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.53	-5.44	-0.41	2.16e-7	Coronary artery disease;
UCEC	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-4.96	-0.38	1.93e-6	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.51	5.32	0.4	3.74e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.72	-0.48	3.79e-10	HDL cholesterol;
UCEC	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.77	6.31	0.46	3.1e-9	Schizophrenia;
UCEC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Blood protein levels;
UCEC	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.92	0.63	4.37e-18	Blood protein levels;
UCEC	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.68	5.67	0.42	7.38e-8	Prostate cancer;
UCEC	cis	rs8032158	0.702	rs2288345	chr15:56122461	T/C	cg10433327	chr15:56209506	NEDD4	-0.32	-4.99	-0.38	1.66e-6	Keloid;
UCEC	cis	rs2862064	1.000	rs2055429	chr5:156455113	C/G	cg12943317	chr5:156479607	HAVCR1	-0.91	-5.88	-0.44	2.62e-8	Platelet count;
UCEC	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.33	-0.4	3.7e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.53	6.01	0.44	1.37e-8	Retinal vascular caliber;
UCEC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.81e-7	Heart rate;
UCEC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-5.32	-0.4	3.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.72	7.33	0.52	1.44e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.56	5.09	0.39	1.07e-6	Cognitive ability;
UCEC	cis	rs11581903	0.568	rs11205978	chr1:53076057	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.83	4.58	0.35	9.96e-6	Joint mobility (Beighton score);
UCEC	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.42	-5.26	-0.4	5.03e-7	Obesity-related traits;
UCEC	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg27246729	chr12:121163418	ACADS	0.49	4.53	0.35	1.23e-5	Urinary metabolites (H-NMR features);
UCEC	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs1165668	0.785	rs2070908	chr12:104324182	C/G	cg21863207	chr12:104234989	NT5DC3	-0.62	-5.85	-0.43	3.12e-8	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.1e-10	Chronic sinus infection;
UCEC	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.51	-0.41	1.58e-7	Pubertal anthropometrics;
UCEC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.69	-6.73	-0.49	3.52e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs9790314	0.613	rs55956394	chr3:160590693	C/T	cg03342759	chr3:160939853	NMD3	0.56	5.23	0.4	5.7e-7	Morning vs. evening chronotype;
UCEC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.58	-5.08	-0.39	1.11e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.48	-6.67	-0.48	4.76e-10	Height;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.6	-6.74	-0.49	3.38e-10	Cardiac Troponin-T levels;
UCEC	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.74	-8.43	-0.57	2.87e-14	Extraversion;
UCEC	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.78	8.39	0.57	3.73e-14	Blood metabolite levels;
UCEC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg02461776	chr11:598696	PHRF1	0.47	5.09	0.39	1.06e-6	Systemic lupus erythematosus;
UCEC	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-6.51	-0.47	1.09e-9	Platelet distribution width;
UCEC	cis	rs151997	0.925	rs27286	chr5:50196324	G/T	cg06027927	chr5:50259733	NA	0.55	5.04	0.38	1.36e-6	Callous-unemotional behaviour;
UCEC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg26441486	chr22:50317300	CRELD2	0.59	5.47	0.41	1.89e-7	Schizophrenia;
UCEC	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs5770917	0.522	rs3752393	chr22:51015557	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.54	-4.54	-0.35	1.18e-5	Narcolepsy;
UCEC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.43	4.7	0.36	5.81e-6	Body mass index;
UCEC	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.11	9.61	0.62	2.96e-17	Opioid sensitivity;
UCEC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.66	-6.92	-0.5	1.28e-10	Height;
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.49	-5.17	-0.39	7.68e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.52	5.27	0.4	4.81e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.88	11.25	0.68	1.47e-21	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10242455	0.867	rs2257401	chr7:99306685	C/G	cg07715041	chr7:99302981	CYP3A7	-0.49	-4.99	-0.38	1.68e-6	Blood metabolite levels;
UCEC	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg19875535	chr5:140030758	IK	0.42	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg18755752	chr8:142205143	DENND3	-0.54	-4.94	-0.38	2.08e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg16336494	chr6:151188259	MTHFD1L	0.4	4.67	0.36	6.72e-6	Bone mineral density;
UCEC	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.92	-9.92	-0.63	4.55e-18	Body mass index;
UCEC	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.87	-9.39	-0.61	1.06e-16	Blood metabolite levels;
UCEC	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	14.7	0.77	1.19e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.65	-7.25	-0.51	2.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg23972785	chr8:11611189	GATA4	-0.37	-4.79	-0.37	4.02e-6	Neuroticism;
UCEC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.58	5.1	0.39	1.05e-6	Major depressive disorder;
UCEC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.78	6.7	0.48	4.12e-10	Menopause (age at onset);
UCEC	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.74	-8.27	-0.56	7.22e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.59	4.76	0.37	4.68e-6	Corneal astigmatism;
UCEC	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg15501526	chr10:2543763	NA	0.48	6.46	0.47	1.41e-9	Age-related hearing impairment;
UCEC	cis	rs73416724	1.000	rs70953680	chr6:43267831	G/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs73198271	0.562	rs73519953	chr8:8660278	G/T	cg01851573	chr8:8652454	MFHAS1	0.63	6.81	0.49	2.3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.51	-4.83	-0.37	3.46e-6	Renal cell carcinoma;
UCEC	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs3751972	0.748	rs4796172	chr17:26198381	C/T	cg13170807	chr17:25708208	NA	-0.44	-4.57	-0.35	1.01e-5	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg14008862	chr17:28927542	LRRC37B2	0.6	5.12	0.39	9.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-4.61	-0.36	8.8e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-5.24	-0.4	5.56e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg04155231	chr12:9217510	LOC144571	0.4	4.96	0.38	1.89e-6	Sjögren's syndrome;
UCEC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.75e-9	Blood metabolite levels;
UCEC	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.7	-5.28	-0.4	4.66e-7	Osteoarthritis;
UCEC	cis	rs925550	0.560	rs17006053	chr4:123629661	C/A	cg10495464	chr4:123653540	BBS12;LOC729338	-0.71	-7.54	-0.53	4.56e-12	Primary biliary cholangitis;
UCEC	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.7	-7.91	-0.55	5.79e-13	Extraversion;
UCEC	trans	rs6579967	1.000	rs6579967	chr5:152165010	A/G	cg10205403	chr12:95867231	METAP2	-1.26	-6.76	-0.49	2.99e-10	Facial morphology (factor 1, breadth of lateral portion of upper face);
UCEC	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.4	-4.55	-0.35	1.12e-5	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	5.12	0.39	9.52e-7	Headache;
UCEC	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24308560	chr3:49941425	MST1R	-0.47	-4.96	-0.38	1.94e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.79	-5.05	-0.38	1.27e-6	Psoriasis;
UCEC	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.44	-5.22	-0.4	6.12e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg18681998	chr4:17616180	MED28	-0.51	-5.73	-0.43	5.41e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs787274	1.000	rs1361720	chr9:115535579	G/A	cg13803584	chr9:115635662	SNX30	-0.68	-5.57	-0.42	1.19e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.5	-5.11	-0.39	9.79e-7	Pubertal anthropometrics;
UCEC	cis	rs1468333	1.000	rs3777113	chr5:137493897	T/C	cg07848042	chr5:137667509	CDC25C	0.46	4.77	0.37	4.31e-6	Resting heart rate;
UCEC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.45	-5.01	-0.38	1.52e-6	Prostate cancer;
UCEC	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.55	-5.54	-0.42	1.35e-7	White matter hyperintensity burden;
UCEC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.44	4.72	0.36	5.52e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12617721	0.756	rs3754889	chr2:99088633	T/G	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder with mood-incongruent psychosis;
UCEC	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.58	5.58	0.42	1.11e-7	Height;
UCEC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.69	7.2	0.51	2.81e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.71	-5.83	-0.43	3.36e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.56	4.65	0.36	7.46e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	8.85	0.59	2.54e-15	Total body bone mineral density;
UCEC	cis	rs60515486	0.702	rs11828339	chr11:47404314	C/T	cg20307385	chr11:47447363	PSMC3	-0.61	-4.64	-0.36	7.66e-6	Lymphocyte counts;
UCEC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.57	-0.42	1.17e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.76	0.37	4.6e-6	Cognitive ability;
UCEC	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07988820	chr12:82153109	PPFIA2	0.64	5.9	0.44	2.44e-8	Resting heart rate;
UCEC	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.18	9.62	0.62	2.69e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.53	0.58	1.67e-14	Total body bone mineral density;
UCEC	cis	rs10781543	0.839	rs1127152	chr9:139335599	A/G	cg14019695	chr9:139328340	INPP5E	0.45	4.86	0.37	3.02e-6	Monocyte percentage of white cells;
UCEC	cis	rs925228	0.955	rs10166036	chr2:24193947	G/A	cg13272742	chr2:24272458	FKBP1B	0.6	5.15	0.39	8.3e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6921919	1.000	rs6921919	chr6:28325201	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.69	-0.36	6.27e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.67	5.9	0.44	2.42e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.72e-25	Height;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.7	8.47	0.57	2.37e-14	Menarche (age at onset);
UCEC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	5.04	0.38	1.35e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.07	-0.55	2.36e-13	Total cholesterol levels;
UCEC	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.81	9.5	0.62	5.4e-17	Ewing sarcoma;
UCEC	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.46	4.72	0.36	5.44e-6	Glaucoma;
UCEC	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	7.76	0.54	1.31e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	0.99	10.49	0.65	1.44e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg05925327	chr15:68127851	NA	0.46	5.73	0.43	5.6e-8	Obesity;
UCEC	cis	rs713477	0.967	rs4901565	chr14:55912508	T/G	cg13175173	chr14:55914753	NA	-0.4	-4.52	-0.35	1.24e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg03959625	chr15:84868606	LOC388152	0.48	4.88	0.37	2.76e-6	Bipolar disorder lithium response (categorical) or schizophrenia;
UCEC	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.81	-5.79	-0.43	4.14e-8	Coronary artery calcification;
UCEC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.58	5.62	0.42	9.29e-8	Aortic root size;
UCEC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.68	6.69	0.48	4.46e-10	Aortic root size;
UCEC	cis	rs10924970	1.000	rs7339935	chr1:235337761	T/C	cg26050004	chr1:235667680	B3GALNT2	0.42	4.6	0.35	9.14e-6	Asthma;
UCEC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-5.64	-0.42	8.62e-8	Monocyte count;
UCEC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.64	-6.31	-0.46	3.09e-9	Acne (severe);
UCEC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.96	-0.55	4.31e-13	Monocyte count;
UCEC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.49	5.55	0.42	1.27e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.74	-0.43	5.29e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs7246967	0.611	rs1835993	chr19:22833037	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.63	-5.22	-0.4	5.91e-7	Extraversion;
UCEC	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	5.09	0.39	1.08e-6	Headache;
UCEC	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.62	6.97	0.5	9.96e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg13695892	chr22:41940480	POLR3H	-0.59	-4.89	-0.37	2.64e-6	Vitiligo;
UCEC	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg02158880	chr13:53174818	NA	0.43	4.67	0.36	6.67e-6	Lewy body disease;
UCEC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg23791538	chr6:167370224	RNASET2	-0.54	-5.63	-0.42	8.87e-8	Crohn's disease;
UCEC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg21231944	chr12:82153410	PPFIA2	-0.44	-5.05	-0.38	1.28e-6	Resting heart rate;
UCEC	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-6.08	-0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs1468333	1.000	rs2906127	chr5:137539466	G/A	cg07848042	chr5:137667509	CDC25C	0.47	4.62	0.36	8.41e-6	Resting heart rate;
UCEC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.86	-0.49	1.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.68	6.71	0.48	3.83e-10	Type 2 diabetes;
UCEC	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.62	4.77	0.37	4.43e-6	Lymphocyte counts;
UCEC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.37	4.67	0.36	6.77e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs8032158	1.000	rs66462353	chr15:56186767	T/C	cg10433327	chr15:56209506	NEDD4	-0.31	-5.06	-0.38	1.26e-6	Keloid;
UCEC	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.8	8.06	0.55	2.5e-13	Ulcerative colitis;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.29	-0.4	4.34e-7	Parkinson's disease;
UCEC	cis	rs59104589	0.550	rs62193172	chr2:242277715	G/C	cg19488206	chr2:242435732	STK25	0.53	4.76	0.37	4.53e-6	Fibrinogen levels;
UCEC	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.64	0.36	7.68e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.59	-6.53	-0.47	1.02e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.57	6.73	0.49	3.63e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg26114124	chr12:9217669	LOC144571	0.41	5.11	0.39	9.99e-7	Sjögren's syndrome;
UCEC	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.35	-5.19	-0.39	7.01e-7	Schizophrenia;
UCEC	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.38	0.61	1.13e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	trans	rs337161	0.719	rs421736	chr1:220938672	C/G	cg07378013	chr16:90088605	GAS8	0.61	6.78	0.49	2.7e-10	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.91	-0.55	5.73e-13	Total cholesterol levels;
UCEC	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.76	-6.29	-0.46	3.37e-9	Schizophrenia;
UCEC	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.36e-7	Subjective well-being;
UCEC	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.97	12.14	0.71	6.26e-24	Breast cancer;
UCEC	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.54	-6.23	-0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.56	-5.18	-0.39	7.07e-7	Body mass index;
UCEC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.6	4.91	0.38	2.36e-6	Menopause (age at onset);
UCEC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.8	-8.48	-0.57	2.19e-14	Schizophrenia;
UCEC	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.39	4.69	0.36	6.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.52	-4.76	-0.37	4.59e-6	Cognitive ability;
UCEC	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.51	-5.1	-0.39	1.03e-6	Breast cancer;Breast cancer (early onset);
UCEC	cis	rs1868673	0.679	rs7430585	chr3:150112041	G/A	cg24290546	chr3:150134309	TSC22D2	-0.5	-4.66	-0.36	7.1e-6	Waist circumference;
UCEC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.48	5.43	0.41	2.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.5	-0.35	1.35e-5	Blood protein levels;
UCEC	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13939156	chr17:80058883	NA	-0.39	-5.37	-0.41	2.94e-7	Life satisfaction;
UCEC	cis	rs77861329	0.800	rs6777340	chr3:52188308	T/C	cg08692210	chr3:52188851	WDR51A	0.63	5.81	0.43	3.78e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs2283228	1.000	rs2283228	chr11:2849530	A/C	cg23617121	chr11:3121460	OSBPL5	0.61	4.57	0.35	1.03e-5	Type 2 diabetes;
UCEC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.91	0.38	2.41e-6	Bipolar disorder;
UCEC	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.55	5.77	0.43	4.43e-8	N-glycan levels;
UCEC	cis	rs11761441	0.602	rs7794663	chr7:94105	C/T	cg06458707	chr7:1083209	C7orf50	0.25	4.53	0.35	1.23e-5	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.42	4.93	0.38	2.24e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.53	5.9	0.44	2.4e-8	Aortic root size;
UCEC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.62	-5.12	-0.39	9.26e-7	Gut microbiome composition (summer);
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg21486944	chr6:28411378	ZSCAN23	0.53	5.63	0.42	8.73e-8	Pubertal anthropometrics;
UCEC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.72	-0.54	1.67e-12	Monocyte count;
UCEC	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	0.9	12.5	0.72	6.94e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.42	-4.67	-0.36	6.65e-6	QRS complex (12-leadsum);
UCEC	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.14e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.52	5.13	0.39	9.18e-7	Platelet count;
UCEC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.76	-7.09	-0.5	5.2e-11	Initial pursuit acceleration;
UCEC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg12024160	chr4:1254474	NA	0.56	6.85	0.49	1.9e-10	Obesity-related traits;
UCEC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.49	5.39	0.41	2.8e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg19678392	chr7:94953810	PON1	-0.56	-5.13	-0.39	8.99e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs953387	1.000	rs2056297	chr2:136899116	G/T	cg07169764	chr2:136633963	MCM6	0.5	4.89	0.37	2.66e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.53	6.45	0.47	1.49e-9	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg08222913	chr3:52553049	STAB1	-0.47	-5.49	-0.41	1.74e-7	Bipolar disorder;
UCEC	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.44	-4.81	-0.37	3.76e-6	Tourette's syndrome or obsessive-compulsive disorder;
UCEC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg01973587	chr1:228161476	NA	0.39	5.18	0.39	7.16e-7	Diastolic blood pressure;
UCEC	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.65	7.48	0.52	6.39e-12	Mean corpuscular volume;
UCEC	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg24881330	chr22:46731750	TRMU	0.73	7.36	0.52	1.18e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs11958404	0.860	rs7723564	chr5:157449396	C/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.05	-0.55	2.52e-13	Total cholesterol levels;
UCEC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.48	-5.01	-0.38	1.52e-6	Obesity-related traits;
UCEC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.42	5.12	0.39	9.27e-7	Electroencephalogram traits;
UCEC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.89	10.8	0.67	2.23e-20	Breast cancer;
UCEC	cis	rs7246967	0.551	rs75360744	chr19:22857956	G/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.8	8.26	0.56	7.58e-14	Primary sclerosing cholangitis;
UCEC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.92	9.8	0.63	9.37e-18	Cognitive function;
UCEC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.43	4.54	0.35	1.18e-5	Eye color traits;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.42	4.55	0.35	1.13e-5	Lymphocyte counts;
UCEC	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.45	-5.05	-0.38	1.31e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.32	-4.84	-0.37	3.18e-6	Schizophrenia;
UCEC	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg05660106	chr1:15850417	CASP9	0.55	4.87	0.37	2.88e-6	Systolic blood pressure;
UCEC	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.38	-0.47	2.17e-9	Platelet count;
UCEC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.56	5.84	0.43	3.22e-8	Blood protein levels;
UCEC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.89	-0.55	6.27e-13	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg14008862	chr17:28927542	LRRC37B2	0.62	4.87	0.37	2.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.45	5.34	0.4	3.4e-7	Height;
UCEC	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.69	-7.59	-0.53	3.45e-12	Ear protrusion;
UCEC	cis	rs2974760	0.581	rs2541600	chr16:199540	G/A	cg08400316	chr16:204221	HBZ	0.68	6.27	0.46	3.88e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.69	6.89	0.49	1.49e-10	Menopause (age at onset);
UCEC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg13147721	chr7:65941812	NA	0.95	6.46	0.47	1.43e-9	Gout;
UCEC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.55	6.18	0.45	6.13e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	1.06	5.46	0.41	1.99e-7	IgG glycosylation;
UCEC	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.55	6.41	0.47	1.86e-9	Multiple myeloma;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02478379	chr5:170814123	NPM1	0.67	6.67	0.48	4.73e-10	Migraine with aura;
UCEC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.43	4.93	0.38	2.23e-6	Mortality in heart failure;
UCEC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.48	0.47	1.27e-9	Aortic root size;
UCEC	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.72	-7.39	-0.52	1.01e-11	Ear protrusion;
UCEC	cis	rs28386778	0.669	rs4968674	chr17:62015048	G/T	cg06873352	chr17:61820015	STRADA	-0.6	-5.91	-0.44	2.32e-8	Prudent dietary pattern;
UCEC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.22	6.99	0.5	8.83e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg26695010	chr11:65641043	EFEMP2	0.56	5.5	0.41	1.67e-7	Eosinophil percentage of white cells;
UCEC	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21178979	chr7:1889533	MAD1L1	0.4	4.63	0.36	8.02e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.7	-5.81	-0.43	3.79e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.66	-6.99	-0.5	9.16e-11	Ulcerative colitis;
UCEC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.24	-0.46	4.46e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.61	-5.17	-0.39	7.44e-7	LDL cholesterol levels;
UCEC	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.55	8.01	0.55	3.15e-13	Height;
UCEC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg06600287	chr1:53387719	ECHDC2	-0.33	-4.62	-0.36	8.28e-6	Monocyte count;
UCEC	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.55	6.02	0.44	1.32e-8	Mean platelet volume;
UCEC	cis	rs4919044	0.866	rs4919592	chr10:94823413	G/A	cg00519463	chr10:94352821	KIF11	0.96	5.36	0.4	3.11e-7	Coronary artery disease;
UCEC	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg21419209	chr3:44054225	NA	-0.51	-5.08	-0.39	1.12e-6	Coronary artery disease;
UCEC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	0.88	5.61	0.42	9.89e-8	Diabetic retinopathy;
UCEC	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	8.26	0.56	7.58e-14	Bipolar disorder;
UCEC	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.51	-4.68	-0.36	6.47e-6	Coronary artery disease;
UCEC	cis	rs9400271	0.527	rs77497373	chr6:109644125	A/G	cg01475377	chr6:109611718	NA	0.46	5.14	0.39	8.44e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.51	5.65	0.42	7.92e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.48	-0.84	3.68e-40	Exhaled nitric oxide output;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07677856	chr17:61926188	NA	0.44	4.61	0.36	8.76e-6	Prudent dietary pattern;
UCEC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.65	-0.53	2.49e-12	Tonsillectomy;
UCEC	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg23093090	chr10:104574429	C10orf26	0.41	4.52	0.35	1.25e-5	Waist circumference;Hip circumference;
UCEC	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.55	-5.43	-0.41	2.31e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.43	-5.3	-0.4	4.11e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-5.54	-0.42	1.36e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.59	-6.48	-0.47	1.3e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.63	6.07	0.45	1.03e-8	Brain structure;
UCEC	cis	rs9326726	0.844	rs71592749	chr5:107657999	C/A	cg17432647	chr5:107996819	NA	0.51	4.53	0.35	1.22e-5	Resting heart rate;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.16	-0.45	6.49e-9	Parkinson's disease;
UCEC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.33	-0.46	2.76e-9	Aortic root size;
UCEC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.48	4.88	0.37	2.71e-6	Response to temozolomide;
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14159672	chr1:205819179	PM20D1	0.82	9.79	0.63	9.67e-18	Menarche (age at onset);
UCEC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Educational attainment;
UCEC	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs60311166	1.000	rs72950437	chr3:52714400	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.79	5.26	0.4	4.91e-7	CTACK levels;
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.52	-5.45	-0.41	2.05e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg00316803	chr15:76480434	C15orf27	-0.46	-5.23	-0.4	5.67e-7	Blood metabolite levels;
UCEC	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.79e-11	Eye color traits;
UCEC	cis	rs6688613	1.000	rs7528849	chr1:166954870	A/G	cg07049167	chr1:166818506	POGK	0.44	4.64	0.36	7.76e-6	Refractive astigmatism;
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4265793	0.826	rs7188889	chr16:19040795	A/T	cg06773604	chr16:18995157	TMC7	0.73	5.51	0.41	1.53e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.73	-5.92	-0.44	2.15e-8	Alzheimer's disease (late onset);
UCEC	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.81	-8.19	-0.56	1.15e-13	Caffeine consumption;
UCEC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.32	0.4	3.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6665290	1.000	rs6665290	chr1:227201106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-20.9	-0.87	7.11e-46	Myeloid white cell count;
UCEC	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	7.92	0.55	5.43e-13	Migraine;Coronary artery disease;
UCEC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.53	4.76	0.37	4.58e-6	Urinary electrolytes (magnesium/calcium ratio);
UCEC	cis	rs2289681	0.525	rs2277617	chr17:42977073	T/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.47	-4.53	-0.35	1.21e-5	Cognitive function;
UCEC	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.51	5.66	0.42	7.79e-8	Life satisfaction;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.5	5.48	0.41	1.79e-7	Menarche (age at onset);
UCEC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg22862634	chr11:62369728	EML3;MTA2	-0.44	-5.75	-0.43	5.02e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg21770322	chr7:97807741	LMTK2	0.45	5.78	0.43	4.31e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg26114124	chr12:9217669	LOC144571	0.4	4.78	0.37	4.3e-6	Sjögren's syndrome;
UCEC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.78	-0.43	4.31e-8	Prudent dietary pattern;
UCEC	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-6.43	-0.47	1.64e-9	Morning vs. evening chronotype;
UCEC	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.72	8.47	0.57	2.28e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs308403	0.509	rs13122636	chr4:123671045	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.68	8.73	0.58	5.23e-15	Blood protein levels;
UCEC	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.59	6.09	0.45	9.47e-9	Coronary heart disease;
UCEC	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	6.64	0.48	5.54e-10	LDL cholesterol;
UCEC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.66	5.85	0.43	3.03e-8	Alzheimer's disease;
UCEC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg02160872	chr5:212506	CCDC127	-0.81	-8.1	-0.56	1.96e-13	Breast cancer;
UCEC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.46	-4.98	-0.38	1.78e-6	Platelet count;
UCEC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-6.33	-0.46	2.8e-9	Glomerular filtration rate;
UCEC	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg01072550	chr1:21505969	NA	-0.57	-5.63	-0.42	8.87e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-5.26	-0.4	5.11e-7	Colorectal cancer;
UCEC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.9	0.44	2.39e-8	Height;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.75	8.17	0.56	1.33e-13	Menopause (age at onset);
UCEC	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.53	5.75	0.43	5.08e-8	Schizophrenia;
UCEC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	5.22	0.4	5.95e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg02461776	chr11:598696	PHRF1	0.51	5.19	0.39	6.94e-7	Systemic lupus erythematosus;
UCEC	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.5	5.83	0.43	3.31e-8	Blood metabolite ratios;
UCEC	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.53	-5.28	-0.4	4.58e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7267005	0.661	rs78595762	chr20:34394462	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg04374321	chr14:90722782	PSMC1	-0.64	-5.61	-0.42	9.66e-8	Mortality in heart failure;
UCEC	cis	rs11822667	1.000	rs7109626	chr11:127451064	C/T	cg03180404	chr11:126907483	NA	-0.49	-4.76	-0.37	4.52e-6	Pit-and-Fissure caries;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.98	-0.38	1.78e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	5.49	0.41	1.74e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.51	6.24	0.46	4.51e-9	Cystic fibrosis severity;
UCEC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	5.31	0.4	3.96e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.54	5.72	0.43	5.77e-8	Diastolic blood pressure;
UCEC	cis	rs8099014	1.000	rs4940701	chr18:56110158	A/T	cg19165390	chr18:56932082	NA	0.35	4.77	0.37	4.36e-6	Platelet count;
UCEC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.83	0.59	2.8e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs17220352	0.557	rs76346015	chr9:119301290	C/T	cg13412550	chr9:120177700	ASTN2	-0.69	-4.63	-0.36	7.88e-6	Headache;
UCEC	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.48e-6	QRS complex (12-leadsum);
UCEC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg01489519	chr20:61493186	TCFL5	0.64	4.57	0.35	1.01e-5	Obesity-related traits;
UCEC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.91	0.55	5.76e-13	Chronic sinus infection;
UCEC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	6.14	0.45	7.44e-9	Cognitive test performance;
UCEC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.55	6.34	0.46	2.71e-9	Aortic root size;
UCEC	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.41	4.55	0.35	1.11e-5	Bipolar disorder;
UCEC	cis	rs1576263	0.967	rs7755191	chr6:8558640	A/C	cg07606381	chr6:8435919	SLC35B3	0.45	4.67	0.36	6.72e-6	Photic sneeze reflex;
UCEC	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	1.0	12.27	0.71	2.78e-24	Colorectal adenoma (advanced);
UCEC	cis	rs13063635	0.915	rs35525815	chr3:46006269	C/T	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.16	0.76	2.91e-29	Homoarginine levels;
UCEC	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	10.01	0.64	2.57e-18	Bipolar disorder;
UCEC	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg01072550	chr1:21505969	NA	-0.58	-6.31	-0.46	3.05e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.32	0.46	2.98e-9	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	1.17	6.59	0.48	7.45e-10	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.65	-6.61	-0.48	6.63e-10	Metabolic syndrome;
UCEC	cis	rs731174	0.722	rs553888	chr1:38152509	C/G	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.34e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.65	-0.48	5.26e-10	Cardiac Troponin-T levels;
UCEC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.65	-5.25	-0.4	5.27e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.68e-10	Vitamin D levels;
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.41	0.41	2.49e-7	Prudent dietary pattern;
UCEC	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.64	5.66	0.42	7.77e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18932078	chr1:2524107	MMEL1	0.39	6.23	0.46	4.56e-9	Ulcerative colitis;
UCEC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.61	0.53	3.1e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4233949	0.868	rs7607093	chr2:54659174	G/T	cg17376041	chr2:54856335	SPTBN1	-0.52	-4.86	-0.37	3.04e-6	Bone mineral density;
UCEC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.47	0.41	1.88e-7	Breast cancer;
UCEC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	0.83	5.09	0.39	1.06e-6	Alzheimer's disease;
UCEC	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.46	4.72	0.36	5.49e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.62	0.42	9.13e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.63	5.37	0.4	3.06e-7	Alcohol dependence;
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.46	0.52	7.01e-12	Platelet count;
UCEC	cis	rs7607369	0.559	rs4674341	chr2:219659911	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-5.09	-0.39	1.06e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.44	6.1	0.45	8.95e-9	Obesity-related traits;
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.73	9.0	0.6	1.06e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.74	7.78	0.54	1.2e-12	Response to antipsychotic treatment;
UCEC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18252515	chr7:66147081	NA	-0.47	-4.77	-0.37	4.46e-6	Aortic root size;
UCEC	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs6882076	0.925	rs4704826	chr5:156392082	C/A	cg12943317	chr5:156479607	HAVCR1	-0.55	-5.54	-0.42	1.34e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.49	4.71	0.36	5.66e-6	Testicular germ cell tumor;
UCEC	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.5	-5.07	-0.39	1.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.86	0.37	3.04e-6	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs394563	0.775	rs399673	chr6:149783221	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.9	-0.37	2.48e-6	Dupuytren's disease;
UCEC	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.75	6.1	0.45	9.01e-9	Menopause (age at onset);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg05107228	chr2:240205170	HDAC4	-0.57	-6.78	-0.49	2.71e-10	N-glycan levels;
UCEC	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-5.72	-0.43	5.71e-8	Prudent dietary pattern;
UCEC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.77	0.54	1.23e-12	Smoking behavior;
UCEC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-9.08	-0.6	6.51e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.45	0.61	7.27e-17	Platelet count;
UCEC	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.61	6.94	0.5	1.14e-10	Obesity-related traits;
UCEC	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.49	4.52	0.35	1.27e-5	Multiple myeloma (IgH translocation);
UCEC	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg05660106	chr1:15850417	CASP9	1.06	12.12	0.71	6.91e-24	Systolic blood pressure;
UCEC	cis	rs116095464	0.619	rs28731093	chr5:241028	T/C	cg02160872	chr5:212506	CCDC127	-0.67	-6.47	-0.47	1.37e-9	Breast cancer;
UCEC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg09910674	chr16:89028015	CBFA2T3	0.6	4.61	0.36	8.71e-6	Skin colour saturation;
UCEC	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg18681998	chr4:17616180	MED28	0.66	7.67	0.53	2.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.82	-8.64	-0.58	8.78e-15	Multiple sclerosis;
UCEC	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.58	-4.89	-0.37	2.62e-6	Corneal structure;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.22	-0.46	5e-9	Pubertal anthropometrics;
UCEC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.7	-6.81	-0.49	2.29e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.69	-6.5	-0.47	1.19e-9	Tonsillectomy;
UCEC	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-5.15	-0.39	8.09e-7	Gut microbiome composition (summer);
UCEC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg27624424	chr6:160112604	SOD2	0.56	5.22	0.4	5.87e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.71	6.02	0.44	1.33e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.67	-5.45	-0.41	2.09e-7	Asthma;
UCEC	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.55	-5.25	-0.4	5.35e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.58	-0.48	7.92e-10	Obesity-related traits;
UCEC	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-8.69	-0.58	6.59e-15	Blood metabolite levels;
UCEC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04013166	chr16:89971882	TCF25	0.7	7.52	0.53	4.97e-12	Skin colour saturation;
UCEC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.09	0.39	1.06e-6	Neutrophil percentage of white cells;
UCEC	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs1161463	0.958	rs1161462	chr13:29431492	G/T	cg00806704	chr13:28539042	CDX2	0.37	4.62	0.36	8.28e-6	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
UCEC	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-4.57	-0.35	1.02e-5	Response to antipsychotic treatment;
UCEC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-0.6	-6.96	-0.5	1.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18854424	chr1:2615690	NA	0.38	5.59	0.42	1.09e-7	Ulcerative colitis;
UCEC	cis	rs2979489	0.891	rs17627711	chr8:30338513	G/A	cg26383811	chr8:30366931	RBPMS	-0.72	-5.6	-0.42	1.02e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg18016565	chr1:150552671	MCL1	-0.44	-4.56	-0.35	1.06e-5	Melanoma;
UCEC	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.82	-11.11	-0.68	3.41e-21	Body mass index;
UCEC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.6	6.18	0.45	5.92e-9	Blood metabolite levels;
UCEC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.68	-0.58	7.08e-15	Diabetic kidney disease;
UCEC	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.75	-8.55	-0.58	1.44e-14	Facial morphology (factor 19);
UCEC	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs116095464	1.000	rs6863730	chr5:325003	G/T	cg02160872	chr5:212506	CCDC127	-0.8	-7.87	-0.54	7.22e-13	Breast cancer;
UCEC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg03859395	chr2:55845619	SMEK2	-1.0	-14.11	-0.76	3.97e-29	Metabolic syndrome;
UCEC	cis	rs847649	0.731	rs10808120	chr7:102672234	A/G	cg18108683	chr7:102477205	FBXL13	-0.5	-5.69	-0.42	6.78e-8	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs925228	1.000	rs2339938	chr2:24234974	C/T	cg13272742	chr2:24272458	FKBP1B	-0.57	-4.98	-0.38	1.72e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2806864	1.000	rs2250448	chr1:117465862	G/A	cg19765820	chr1:116518738	SLC22A15	-0.6	-4.52	-0.35	1.25e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.7	6.25	0.46	4.3e-9	Breast cancer;
UCEC	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.7	6.54	0.47	9.64e-10	Bipolar disorder;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.48	5.9	0.44	2.41e-8	Prudent dietary pattern;
UCEC	cis	rs7651039	0.641	rs2455916	chr3:15667383	C/T	cg16303742	chr3:15540471	COLQ	0.57	7.14	0.51	4.03e-11	Coronary heart disease;
UCEC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.5	-4.97	-0.38	1.85e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	7.93	0.55	5.06e-13	Hip circumference;
UCEC	trans	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.46	-0.52	7.08e-12	Pursuit maintenance gain;
UCEC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.59	6.63	0.48	5.83e-10	Platelet count;
UCEC	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.46	5.13	0.39	8.88e-7	Facial morphology (factor 20);
UCEC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.2e-7	Systemic lupus erythematosus;
UCEC	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.58	-7.32	-0.52	1.47e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg22467129	chr15:76604101	ETFA	-0.49	-5.11	-0.39	9.87e-7	Blood metabolite levels;
UCEC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.72	5.53	0.41	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.82	-0.43	3.5e-8	Hemoglobin concentration;
UCEC	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.43	4.62	0.36	8.31e-6	Uric acid clearance;
UCEC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.85	0.54	7.95e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	5.21	0.39	6.27e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg19610905	chr11:61596333	FADS2	-0.58	-4.79	-0.37	4.07e-6	Neutrophil count;Sum basophil neutrophil counts;
UCEC	cis	rs2398893	0.960	rs11788176	chr9:96829243	C/T	cg07076509	chr9:96720819	NA	0.46	4.62	0.36	8.21e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.05	-0.38	1.31e-6	Breast cancer;
UCEC	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	7.07	0.5	5.95e-11	Motion sickness;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.6	8.62	0.58	9.68e-15	Prudent dietary pattern;
UCEC	cis	rs970548	1.000	rs7086046	chr10:46076235	A/G	cg15223267	chr10:46222474	FAM21C	-0.51	-5.03	-0.38	1.44e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.51	5.49	0.41	1.74e-7	Breast cancer;
UCEC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg04756594	chr16:24857601	SLC5A11	0.52	5.94	0.44	1.99e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.55	6.38	0.47	2.15e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.49	-5.52	-0.41	1.47e-7	Longevity;
UCEC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs4282339	0.729	rs1979923	chr5:168265891	T/C	cg15232798	chr5:167719548	WWC1	-0.44	-4.79	-0.37	3.99e-6	Height;
UCEC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.74	0.49	3.41e-10	Breast cancer;
UCEC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.78	7.17	0.51	3.36e-11	Diastolic blood pressure;
UCEC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.61	5.66	0.42	7.56e-8	Lymphocyte counts;
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-0.93	-9.51	-0.62	5.16e-17	Heart rate;
UCEC	cis	rs7714670	0.736	rs1565005	chr5:73095635	C/T	cg00119811	chr5:73092353	RGNEF	-0.43	-5.39	-0.41	2.79e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg26138937	chr11:71823887	C11orf51	0.94	4.83	0.37	3.41e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.48	6.17	0.45	6.42e-9	HDL cholesterol levels;
UCEC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.46	-5.64	-0.42	8.5e-8	Obesity-related traits;
UCEC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.63	6.51	0.47	1.12e-9	Obesity-related traits;
UCEC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12311346	chr5:56204834	C5orf35	-0.52	-5.11	-0.39	9.86e-7	Coronary artery disease;
UCEC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8105895	0.800	rs62112872	chr19:22192425	T/C	cg24175803	chr19:22235144	ZNF257	-0.53	-4.75	-0.36	4.87e-6	Body mass index (change over time);
UCEC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.51	4.67	0.36	6.73e-6	Menopause (age at onset);
UCEC	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.42	7.6	0.53	3.25e-12	Cognitive function;
UCEC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.51	-6.56	-0.48	8.79e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg23708337	chr7:1209742	NA	0.69	4.54	0.35	1.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs975730	1.000	rs6989410	chr8:129332944	G/A	cg14920061	chr8:129326392	NA	0.39	4.97	0.38	1.86e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.63	-6.71	-0.48	3.88e-10	Neurofibrillary tangles;
UCEC	cis	rs2336384	1.000	rs1810563	chr1:12054030	A/G	cg13216073	chr1:12042593	MFN2	-0.46	-4.73	-0.36	5.11e-6	Platelet count;
UCEC	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.5	-6.45	-0.47	1.5e-9	Cystic fibrosis severity;
UCEC	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.71	-6.42	-0.47	1.81e-9	Asthma;
UCEC	cis	rs3790645	1.000	rs282177	chr1:26899125	C/T	cg17456097	chr1:26900765	RPS6KA1	0.46	4.6	0.35	8.91e-6	Glucose homeostasis traits;
UCEC	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.44	-0.41	2.22e-7	Body mass index;
UCEC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.89	-10.4	-0.65	2.44e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.35	-5.95	-0.44	1.85e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7113850	0.541	rs80336897	chr11:24224545	G/T	ch.11.24196551F	chr11:24239977	NA	0.7	4.69	0.36	6.24e-6	Bone fracture in osteoporosis;
UCEC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.82	-0.37	3.49e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.88	7.44	0.52	7.88e-12	Body mass index;
UCEC	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	0.54	6.16	0.45	6.68e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10266483	0.739	rs682662	chr7:63766485	C/T	cg23304165	chr7:63498798	NA	-0.5	-5.41	-0.41	2.49e-7	Response to statin therapy;
UCEC	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.47	6.08	0.45	1e-8	HDL cholesterol levels;
UCEC	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.65	-0.48	5.51e-10	Coffee consumption (cups per day);
UCEC	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.04	6.77	0.49	2.91e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.46	4.95	0.38	2.03e-6	HDL cholesterol;
UCEC	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.6	-7.68	-0.54	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.56	-5.43	-0.41	2.27e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.17	-0.39	7.6e-7	Aortic root size;
UCEC	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-5.18	-0.39	7.33e-7	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2862064	0.745	rs2902133	chr5:156445687	G/A	cg12943317	chr5:156479607	HAVCR1	-0.67	-5.11	-0.39	9.95e-7	Platelet count;
UCEC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.61	-0.36	8.69e-6	Breast cancer;
UCEC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.61	6.39	0.47	2.05e-9	QRS complex (12-leadsum);
UCEC	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	0.86	7.43	0.52	8.01e-12	Opioid sensitivity;
UCEC	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.47	5.21	0.4	6.16e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.82	0.37	3.62e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.53	-5.44	-0.41	2.19e-7	Psoriasis;
UCEC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.21	0.71	4.13e-24	Prudent dietary pattern;
UCEC	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.51	-6.29	-0.46	3.5e-9	Subjective well-being (multi-trait analysis);
UCEC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.69	6.89	0.49	1.49e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1476670	0.710	rs753637	chr1:44508927	A/G	cg09470012	chr1:44509516	NA	0.42	5.2	0.39	6.65e-7	Eotaxin levels;
UCEC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.67	-6.13	-0.45	7.83e-9	Response to antineoplastic agents;
UCEC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.63	6.63	0.48	5.82e-10	Monocyte count;
UCEC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg01689657	chr7:91764605	CYP51A1	0.46	6.04	0.45	1.23e-8	Breast cancer;
UCEC	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.55	4.58	0.35	9.77e-6	Lung cancer;
UCEC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.91	-0.38	2.41e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.49	4.51	0.35	1.29e-5	Lung cancer;
UCEC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.55	5.56	0.42	1.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg03859395	chr2:55845619	SMEK2	0.77	7.68	0.54	2.07e-12	Metabolic syndrome;
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.47	-5.24	-0.4	5.42e-7	Depression;
UCEC	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg19743168	chr1:23544995	NA	0.46	5.94	0.44	1.97e-8	Height;
UCEC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg13695892	chr22:41940480	POLR3H	-0.63	-4.94	-0.38	2.07e-6	Vitiligo;
UCEC	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-4.68	-0.36	6.38e-6	Asthma;
UCEC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.95	10.35	0.65	3.29e-19	Cognitive function;
UCEC	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs6684428	1.000	rs12124871	chr1:56372247	C/T	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs12234571	1.000	rs12672657	chr7:77362408	C/T	cg20048109	chr7:78158112	MAGI2	-0.52	-4.62	-0.36	8.28e-6	Obesity-related traits;
UCEC	cis	rs11697848	1.000	rs56230511	chr20:48468621	G/A	cg17849948	chr20:48532315	SPATA2	1.03	5.08	0.39	1.13e-6	Systemic lupus erythematosus;
UCEC	cis	rs8010715	0.636	rs2277480	chr14:24587515	G/A	cg20933586	chr14:24608199	FAM158A	0.36	4.8	0.37	3.82e-6	IgG glycosylation;
UCEC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-0.6	-6.96	-0.5	1.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11958404	0.932	rs6870115	chr5:157436960	T/C	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs151997	1.000	rs27247	chr5:50232299	T/C	cg06027927	chr5:50259733	NA	-0.53	-4.91	-0.38	2.43e-6	Callous-unemotional behaviour;
UCEC	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	6.72	0.48	3.68e-10	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.46	-6.02	-0.44	1.3e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs9309473	0.500	rs4852952	chr2:73869907	T/C	cg20560298	chr2:73613845	ALMS1	0.53	5.02	0.38	1.47e-6	Metabolite levels;
UCEC	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-4.58	-0.35	9.94e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.37	-5.6	-0.42	1e-7	Schizophrenia;
UCEC	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.14	-8.82	-0.59	3.06e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.92	0.38	2.32e-6	Aortic root size;
UCEC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.86	6.77	0.49	2.92e-10	Body mass index;
UCEC	cis	rs11958404	0.932	rs6894528	chr5:157434788	A/G	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.77	7.66	0.53	2.27e-12	Nonalcoholic fatty liver disease;
UCEC	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.97	0.38	1.86e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.57	0.42	1.18e-7	Cognitive test performance;
UCEC	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg07578070	chr6:150326732	RAET1K	0.43	4.6	0.35	9.02e-6	Alopecia areata;
UCEC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	0.8	4.76	0.37	4.6e-6	Eosinophil percentage of granulocytes;
UCEC	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-7.47	-0.52	6.45e-12	Red cell distribution width;
UCEC	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.77	8.23	0.56	9.02e-14	Mean corpuscular hemoglobin;
UCEC	cis	rs6952808	0.534	rs1113736	chr7:1992992	T/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-5.46	-0.41	2.02e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.51	-0.41	1.55e-7	Joint mobility (Beighton score);
UCEC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-0.92	-11.65	-0.69	1.23e-22	Coronary artery disease;
UCEC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg01380346	chr19:18557039	ELL	-0.47	-4.74	-0.36	4.96e-6	Breast cancer;
UCEC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.46	-5.36	-0.4	3.2e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.66	5.53	0.41	1.45e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-7.53	-0.53	4.7e-12	Blood protein levels;
UCEC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.57	-5.56	-0.42	1.22e-7	Myopia (pathological);
UCEC	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg03114573	chr12:45410052	DBX2	-0.46	-4.9	-0.37	2.52e-6	Gut microbiome composition (summer);
UCEC	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.49	5.56	0.42	1.25e-7	Anterior chamber depth;
UCEC	cis	rs12313068	0.709	rs73404675	chr12:110504102	G/A	cg12870014	chr12:110450643	ANKRD13A	0.77	8.48	0.57	2.16e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs308403	0.509	rs1849431	chr4:123674762	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.67	8.23	0.56	9.1e-14	Blood protein levels;
UCEC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	6.73	0.49	3.47e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.78	6.48	0.47	1.32e-9	Morning vs. evening chronotype;
UCEC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg05738196	chr6:26577821	NA	-0.67	-8.52	-0.57	1.79e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-4.56	-0.35	1.09e-5	Subjective well-being;
UCEC	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.78	-6.17	-0.45	6.2e-9	Calcium levels;
UCEC	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.44	4.58	0.35	9.9e-6	Height;
UCEC	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.59	-7.98	-0.55	3.76e-13	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs73206853	0.764	rs7312469	chr12:110889072	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7560272	0.723	rs4346412	chr2:73843571	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-5.15	-0.39	8.38e-7	Schizophrenia;
UCEC	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.01	0.55	3.25e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	0.99	10.0	0.64	2.8e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.55	7.11	0.51	4.74e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg12035532	chr1:1886765	KIAA1751	0.43	4.56	0.35	1.06e-5	Body mass index;
UCEC	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg21191810	chr6:118973309	C6orf204	0.4	5.5	0.41	1.64e-7	Electrocardiographic conduction measures;
UCEC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18252515	chr7:66147081	NA	0.45	4.61	0.36	8.64e-6	Aortic root size;
UCEC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg16558253	chr16:72132732	DHX38	-0.43	-5.13	-0.39	8.86e-7	Fibrinogen levels;
UCEC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-6.06	-0.45	1.11e-8	Metabolite levels;
UCEC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-8.35	-0.57	4.54e-14	Body mass index;
UCEC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg13844804	chr7:814759	HEATR2	0.65	4.77	0.37	4.49e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4668356	1.000	rs55885449	chr2:171933839	G/C	cg13882835	chr2:172017928	TLK1	0.66	4.51	0.35	1.32e-5	Cognitive performance;
UCEC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.68	5.59	0.42	1.08e-7	Corneal astigmatism;
UCEC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	trans	rs66573146	1.000	rs66712119	chr4:6965428	A/T	cg07817883	chr1:32538562	TMEM39B	1.23	9.45	0.61	7.4e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg04450003	chr12:50355995	AQP5	0.6	4.78	0.37	4.26e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.78	11.24	0.68	1.53e-21	Leprosy;
UCEC	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.5	4.91	0.38	2.34e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.57	4.8	0.37	3.87e-6	Coronary artery disease;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.59	-0.35	9.51e-6	Pubertal anthropometrics;
UCEC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.71	0.36	5.76e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg18681998	chr4:17616180	MED28	0.57	6.44	0.47	1.56e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.58	5.47	0.41	1.86e-7	Plateletcrit;Platelet count;
UCEC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.76	-7.24	-0.51	2.26e-11	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.58	4.67	0.36	6.85e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.33	-4.94	-0.38	2.08e-6	Crohn's disease;
UCEC	trans	rs6728642	1.000	rs6728642	chr2:97607071	A/G	cg18463001	chr5:180611085	NA	-0.76	-6.77	-0.49	2.93e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.76	8.3	0.57	6.04e-14	Itch intensity from mosquito bite;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg10098010	chr6:138483709	KIAA1244	0.7	7.36	0.52	1.19e-11	Triglyceride levels;
UCEC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.89	0.49	1.55e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.69	-7.74	-0.54	1.5e-12	Breast cancer;
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.43	-4.54	-0.35	1.15e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.99	11.84	0.7	4.02e-23	Obesity-related traits;
UCEC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.6	-4.84	-0.37	3.26e-6	Longevity;
UCEC	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.7	7.66	0.53	2.32e-12	Coronary artery disease;
UCEC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.81	-8.34	-0.57	4.87e-14	Obesity-related traits;
UCEC	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.58	6.44	0.47	1.57e-9	Prostate cancer;
UCEC	cis	rs2172802	0.560	rs12499359	chr4:62563415	A/G	cg04118610	chr4:62707027	LPHN3	0.41	4.63	0.36	7.95e-6	Partial epilepsies;
UCEC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.58	-6.04	-0.45	1.22e-8	Prudent dietary pattern;
UCEC	cis	rs7968440	1.000	rs2731443	chr12:51094138	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18854424	chr1:2615690	NA	0.45	6.49	0.47	1.22e-9	Ulcerative colitis;
UCEC	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.82	0.49	2.21e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs735860	0.763	rs6458912	chr6:53147965	G/A	cg10236188	chr6:53219634	NA	-0.45	-4.72	-0.36	5.51e-6	Glaucoma;
UCEC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.49	-4.95	-0.38	2.04e-6	Total body bone mineral density;
UCEC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.47	-4.78	-0.37	4.13e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.48	0.47	1.33e-9	Cognitive test performance;
UCEC	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-7.63	-0.53	2.72e-12	Ulcerative colitis;
UCEC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs377070	0.934	rs309392	chr4:123611542	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.6	5.04	0.38	1.34e-6	Mosquito bite size;
UCEC	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.54	4.9	0.37	2.54e-6	Refractive astigmatism;
UCEC	cis	rs6763768	0.577	rs35536048	chr3:53388950	C/G	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.74	0.58	4.85e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.54	-5.46	-0.41	2e-7	Aortic root size;
UCEC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg00791764	chr4:53727839	RASL11B	0.7	4.89	0.37	2.59e-6	Optic nerve measurement (cup area);
UCEC	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.79	0.43	4.17e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.47	-5.24	-0.4	5.48e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.62	4.96	0.38	1.89e-6	Menarche (age at onset);
UCEC	cis	rs7246967	0.551	rs7257333	chr19:22881149	C/T	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.48	5.99	0.44	1.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.09	-10.58	-0.66	8.64e-20	Vitiligo;
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.78	7.45	0.52	7.36e-12	Longevity;Endometriosis;
UCEC	cis	rs694419	0.602	rs1473980	chr18:60206676	C/T	cg01631325	chr18:60191404	ZCCHC2	0.45	4.5	0.35	1.35e-5	Serum albumin level;
UCEC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg01072550	chr1:21505969	NA	-0.57	-5.58	-0.42	1.13e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-5.2	-0.39	6.52e-7	Metabolite levels;
UCEC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg07424592	chr7:64974309	NA	-0.77	-4.77	-0.37	4.39e-6	Diabetic kidney disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06620762	chr15:76136437	UBE2Q2	0.55	6.72	0.48	3.8e-10	Warfarin maintenance dose;
UCEC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3914502	0.615	rs2140285	chr3:174511549	A/G	cg21145449	chr3:174580620	NAALADL2	-0.48	-5.82	-0.43	3.56e-8	Autism spectrum disorder;
UCEC	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg00500100	chr5:140098250	VTRNA1-2	-0.33	-4.54	-0.35	1.15e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.56	-5.21	-0.39	6.28e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs829661	0.793	rs829653	chr2:30714906	G/A	cg17749961	chr2:30669863	LCLAT1	0.71	5.82	0.43	3.53e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	0.65	6.82	0.49	2.16e-10	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.91	-0.38	2.42e-6	Immature fraction of reticulocytes;
UCEC	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.87	-7.36	-0.52	1.17e-11	Monobrow;
UCEC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.73	-8.51	-0.57	1.82e-14	Coronary artery disease;
UCEC	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.6	-6.49	-0.47	1.26e-9	Glomerular filtration rate;
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg12035532	chr1:1886765	KIAA1751	0.42	4.55	0.35	1.12e-5	Body mass index;
UCEC	cis	rs10892151	1	rs10892151	chr11:117531731	A/G	cg06646174	chr11:116948652	SIK3	0.68	5.13	0.39	9.16e-7	Triglycerides;
UCEC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg05738196	chr6:26577821	NA	0.65	7.63	0.53	2.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.55	-7.33	-0.52	1.39e-11	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.45	4.61	0.36	8.64e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.49	6.78	0.49	2.75e-10	Height;
UCEC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.62	5.07	0.39	1.16e-6	Menarche (age at onset);
UCEC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.45	-6.17	-0.45	6.25e-9	Mortality in heart failure;
UCEC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.58	5.53	0.41	1.45e-7	Mortality in heart failure;
UCEC	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg11859384	chr17:80120422	CCDC57	0.41	4.52	0.35	1.28e-5	Life satisfaction;
UCEC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.37	5.44	0.41	2.22e-7	Vitiligo;
UCEC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.51	5.0	0.38	1.61e-6	Mood instability;
UCEC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.54	5.47	0.41	1.88e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs3750965	0.575	rs3018691	chr11:68884543	C/T	cg01403660	chr11:68851641	TPCN2	0.44	4.56	0.35	1.07e-5	Hair color;
UCEC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.43	5.15	0.39	8.38e-7	Sjögren's syndrome;
UCEC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-6.76	-0.49	2.95e-10	Hemoglobin concentration;
UCEC	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs925228	0.955	rs13021384	chr2:24150632	G/A	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.81	0.37	3.68e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	7.06	0.5	6.24e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	0.9	12.41	0.72	1.18e-24	Blood protein levels;
UCEC	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.81	5.16	0.39	7.87e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.54	-5.45	-0.41	2.03e-7	Aortic root size;
UCEC	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.48	-4.76	-0.37	4.51e-6	Post bronchodilator FEV1;
UCEC	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.61	7.63	0.53	2.72e-12	Gut microbiome composition (winter);
UCEC	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.69	4.56	0.35	1.08e-5	Triglycerides;
UCEC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.12	-0.39	9.58e-7	Breast cancer;
UCEC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.53	-6.55	-0.48	9.1e-10	Monocyte percentage of white cells;
UCEC	cis	rs7851660	0.679	rs7033765	chr9:100591705	A/T	cg13688889	chr9:100608707	NA	0.54	5.47	0.41	1.91e-7	Strep throat;
UCEC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.93	10.12	0.64	1.38e-18	Cognitive function;
UCEC	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg23795048	chr12:9217529	LOC144571	0.42	4.97	0.38	1.86e-6	Sjögren's syndrome;
UCEC	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-6.02	-0.44	1.36e-8	Depression;
UCEC	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.28	12.07	0.71	9.43e-24	Corneal structure;
UCEC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.72	8.88	0.59	2.14e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs16865717	0.513	rs6431837	chr2:7036811	C/T	cg20486407	chr2:7037101	RSAD2	-0.58	-5.33	-0.4	3.7e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.68	-5.23	-0.4	5.76e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.42	-0.47	1.77e-9	Depression;
UCEC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.95	11.31	0.68	9.85e-22	Ulcerative colitis;
UCEC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9843304	0.585	rs9842139	chr3:149207517	T/C	cg08667024	chr3:149219783	TM4SF4	0.58	6.92	0.5	1.28e-10	Gallstone disease;
UCEC	cis	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg00614314	chr15:82944287	LOC80154	0.51	4.8	0.37	3.9e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.85	8.46	0.57	2.53e-14	Colorectal cancer;
UCEC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23156509	chr2:114033830	PAX8;LOC440839	-0.45	-4.61	-0.36	8.59e-6	Lymphocyte counts;
UCEC	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg17420585	chr12:42539391	GXYLT1	-0.42	-5.45	-0.41	2.12e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.89	0.49	1.55e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg20450318	chr11:65415260	SIPA1	0.41	4.57	0.35	1.01e-5	Acne (severe);
UCEC	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg19554555	chr3:13937349	NA	-0.54	-5.58	-0.42	1.11e-7	Ovarian reserve;
UCEC	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-10.61	-0.66	6.79e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7095607	0.704	rs1900013	chr10:69953929	A/G	cg18986048	chr10:69913749	MYPN	0.52	5.79	0.43	4.2e-8	Lung function (FVC);
UCEC	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.74	7.93	0.55	5.06e-13	Breast cancer;
UCEC	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-4.64	-0.36	7.6e-6	Major depressive disorder;
UCEC	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.75	7.7	0.54	1.87e-12	Caffeine consumption;
UCEC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.08	0.45	1e-8	Platelet count;
UCEC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.49	6.49	0.47	1.21e-9	Bone mineral density;
UCEC	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.66	-7.11	-0.51	4.77e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.65	6.29	0.46	3.5e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	8.9	0.59	1.91e-15	Mean platelet volume;
UCEC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.62	6.14	0.45	7.33e-9	Lung cancer;
UCEC	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.6	5.51	0.41	1.58e-7	Resting heart rate;
UCEC	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg26721908	chr21:47610096	LSS	-0.37	-4.65	-0.36	7.39e-6	Testicular germ cell tumor;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.53	-5.64	-0.42	8.34e-8	Parkinson's disease;
UCEC	cis	rs9470794	1.000	rs59996041	chr6:37952625	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.71	6.12	0.45	8.18e-9	Menopause (age at onset);
UCEC	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.74	0.58	4.85e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.45	5.46	0.41	1.99e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.56	-0.35	1.07e-5	Electroencephalogram traits;
UCEC	cis	rs36051895	0.559	rs7874495	chr9:5209804	A/G	cg02405213	chr9:5042618	JAK2	-0.55	-5.27	-0.4	4.81e-7	Pediatric autoimmune diseases;
UCEC	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.09	0.5	5.27e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg02366345	chr4:152330872	FAM160A1	0.35	4.83	0.37	3.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs34003335	chr19:22925602	T/C	cg24889512	chr19:22816950	ZNF492	0.63	6.4	0.47	1.94e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9341808	0.667	rs2490239	chr6:80826289	G/A	cg08355045	chr6:80787529	NA	0.4	4.83	0.37	3.42e-6	Sitting height ratio;
UCEC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.66	6.77	0.49	2.84e-10	Systemic lupus erythematosus;
UCEC	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-5.29	-0.4	4.39e-7	Smoking initiation;
UCEC	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg18721089	chr20:30220636	NA	-0.36	-4.94	-0.38	2.1e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.52	-5.29	-0.4	4.34e-7	Coronary artery disease;
UCEC	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.32	4.76	0.37	4.61e-6	Schizophrenia;
UCEC	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.94	-10.6	-0.66	7.41e-20	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1981331	0.609	rs76937225	chr21:48069682	C/T	cg23283320	chr21:48055893	PRMT2	1.65	7.68	0.54	2.04e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	5.34	0.4	3.44e-7	Bone mineral density;
UCEC	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.54	5.24	0.4	5.4e-7	Bipolar disorder;
UCEC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.62	-0.36	8.39e-6	Aortic root size;
UCEC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.76	9.1	0.6	5.85e-16	Breast cancer;
UCEC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.91	0.59	1.85e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.57	-4.81	-0.37	3.76e-6	Multiple sclerosis;
UCEC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.5e-6	Vitamin D levels;
UCEC	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.61	5.6	0.42	1.04e-7	Morning vs. evening chronotype;
UCEC	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.89	-10.72	-0.66	3.58e-20	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg04025307	chr7:1156635	C7orf50	0.81	5.42	0.41	2.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.58	5.19	0.39	6.74e-7	Corneal astigmatism;
UCEC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg05962950	chr11:130786565	SNX19	0.5	4.96	0.38	1.9e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.27	12.63	0.72	3.11e-25	Corneal structure;
UCEC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	0.45	4.64	0.36	7.8e-6	Lymphocyte counts;
UCEC	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-4.66	-0.36	6.94e-6	Major depressive disorder;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.55	5.99	0.44	1.52e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	4.52	0.35	1.27e-5	Diabetic retinopathy;
UCEC	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.46	-5.38	-0.41	2.87e-7	Subjective well-being;
UCEC	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.62	6.68	0.48	4.6e-10	Anterior chamber depth;
UCEC	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.77	5.41	0.41	2.54e-7	Blood pressure (smoking interaction);
UCEC	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.95	-8.81	-0.59	3.19e-15	Corneal structure;
UCEC	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4654899	0.772	rs951805	chr1:21060356	A/G	cg01072550	chr1:21505969	NA	0.52	4.59	0.35	9.43e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.79	-7.33	-0.52	1.42e-11	Diastolic blood pressure;
UCEC	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.8	-9.03	-0.6	8.82e-16	Ulcerative colitis;
UCEC	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.36	4.67	0.36	6.77e-6	Total body bone mineral density;
UCEC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.69	6.55	0.48	8.98e-10	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.51	5.09	0.39	1.07e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.77	-0.37	4.39e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg15764593	chr10:829463	NA	-0.55	-4.82	-0.37	3.56e-6	Uric acid levels;
UCEC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg04553112	chr3:125709451	NA	-0.69	-4.87	-0.37	2.8e-6	Blood pressure (smoking interaction);
UCEC	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7975161	0.882	rs4964270	chr12:104652398	A/G	cg25273343	chr12:104657179	TXNRD1	-0.67	-5.41	-0.41	2.45e-7	Toenail selenium levels;
UCEC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.43	6.21	0.46	5.08e-9	Schizophrenia;
UCEC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.59	-7.64	-0.53	2.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.45	5.77	0.43	4.46e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg20630560	chr1:228395858	OBSCN	0.3	4.71	0.36	5.63e-6	Diastolic blood pressure;
UCEC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.69	6.9	0.49	1.44e-10	Menopause (age at onset);
UCEC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg24910161	chr17:38119198	GSDMA	-0.33	-4.82	-0.37	3.55e-6	Self-reported allergy;
UCEC	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg01072550	chr1:21505969	NA	-0.53	-4.73	-0.36	5.24e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	4.9	0.37	2.53e-6	HDL cholesterol;
UCEC	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.62	4.96	0.38	1.89e-6	Menarche (age at onset);
UCEC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg19926144	chr10:661009	DIP2C	0.76	4.66	0.36	7.01e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.58	5.57	0.42	1.2e-7	Menopause (age at onset);
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.52	0.58	1.7e-14	Prudent dietary pattern;
UCEC	cis	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Intraocular pressure;
UCEC	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg19156104	chr2:198669113	PLCL1	-0.63	-4.54	-0.35	1.17e-5	Ulcerative colitis;
UCEC	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.27e-13	Parkinson's disease;
UCEC	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.54	5.36	0.4	3.21e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg13395646	chr4:1353034	KIAA1530	-0.85	-8.64	-0.58	8.63e-15	Obesity-related traits;
UCEC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-4.78	-0.37	4.28e-6	Bipolar disorder;
UCEC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.8	-8.94	-0.59	1.52e-15	Breast cancer;
UCEC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.54	-6.13	-0.45	7.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7106204	0.764	rs7949823	chr11:24213668	C/G	ch.11.24196551F	chr11:24239977	NA	0.66	5.69	0.43	6.53e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg19743168	chr1:23544995	NA	0.46	6.02	0.44	1.35e-8	Height;
UCEC	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg23793686	chr15:68133972	NA	-0.36	-4.7	-0.36	5.9e-6	Restless legs syndrome;
UCEC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.11	0.51	4.64e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.51	6.04	0.45	1.21e-8	Age at first birth;
UCEC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-4.9	-0.37	2.51e-6	Blood metabolite levels;
UCEC	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.57	-6.11	-0.45	8.55e-9	Schizophrenia;
UCEC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.83	-7.27	-0.51	1.93e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.63	6.83	0.49	2.04e-10	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.75	-6.57	-0.48	8.23e-10	Coronary artery disease;
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.54	6.82	0.49	2.25e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.55	5.89	0.44	2.58e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.5	-5.0	-0.38	1.59e-6	P wave terminal force;
UCEC	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.58	6.93	0.5	1.25e-10	Oral cavity cancer;
UCEC	cis	rs7968440	1.000	rs2731439	chr12:51060350	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs9534288	0.789	rs4942470	chr13:46636652	A/G	cg15192986	chr13:46630673	CPB2	-0.77	-7.7	-0.54	1.85e-12	Blood protein levels;
UCEC	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	7.32	0.52	1.51e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	5.52	0.41	1.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.46	-4.73	-0.36	5.32e-6	Breast size;
UCEC	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.43	-4.6	-0.35	9.13e-6	Birth weight;
UCEC	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.16e-9	Platelet count;
UCEC	cis	rs10242455	1.000	rs1859690	chr7:99227172	A/G	cg07715041	chr7:99302981	CYP3A7	0.48	4.79	0.37	4e-6	Blood metabolite levels;
UCEC	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.42	-4.87	-0.37	2.84e-6	Schizophrenia;
UCEC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.62	5.65	0.42	7.96e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.05	-6.61	-0.48	6.54e-10	Diabetic kidney disease;
UCEC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg04287289	chr16:89883240	FANCA	-0.52	-5.51	-0.41	1.56e-7	Vitiligo;
UCEC	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.53	6.25	0.46	4.15e-9	Type 2 diabetes;
UCEC	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-4.87	-0.37	2.8e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.61	-6.07	-0.45	1.03e-8	Parkinson's disease;
UCEC	cis	rs9467773	1.000	rs1570060	chr6:26573562	A/G	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.86	-8.16	-0.56	1.36e-13	Schizophrenia;
UCEC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-6.22	-0.46	4.98e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.5	5.24	0.4	5.48e-7	Monocyte count;
UCEC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.38e-17	Height;
UCEC	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.72	6.81	0.49	2.33e-10	Crohn's disease;
UCEC	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.45	5.82	0.43	3.6e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.45	4.57	0.35	1.01e-5	Blood metabolite levels;
UCEC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	cis	rs11625487	0.609	rs74063377	chr14:77951431	C/G	cg20045696	chr14:77926864	AHSA1	-0.68	-5.08	-0.39	1.13e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.54	5.09	0.39	1.06e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.53	-5.12	-0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9472138	0.756	rs2396083	chr6:43804808	C/G	cg05547260	chr6:43611905	RSPH9	-0.36	-4.57	-0.35	1.01e-5	Type 2 diabetes;Thyroid hormone levels;
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg20119798	chr7:94954144	PON1	-0.49	-4.65	-0.36	7.31e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.03	0.5	7.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.75	-0.43	4.97e-8	Cardiac Troponin-T levels;
UCEC	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.41	4.91	0.38	2.36e-6	Refractive error;
UCEC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg12559939	chr2:27858050	GPN1	0.47	4.85	0.37	3.15e-6	Oral cavity cancer;
UCEC	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.05	8.7	0.58	6.14e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg04871131	chr7:94954202	PON1	-0.52	-5.13	-0.39	9.07e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.83	7.53	0.53	4.65e-12	Corneal structure;
UCEC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.68	-8.01	-0.55	3.27e-13	Vitiligo;
UCEC	cis	rs1978968	0.763	rs9605479	chr22:18464611	T/C	cg03078520	chr22:18463400	MICAL3	-0.55	-6.98	-0.5	9.62e-11	Presence of antiphospholipid antibodies;
UCEC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.36	0.57	4.42e-14	Electrocardiographic conduction measures;
UCEC	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.36	-0.52	1.2e-11	Resting heart rate;
UCEC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.85	-0.37	3.06e-6	Breast cancer;
UCEC	cis	rs7818345	0.512	rs4922029	chr8:19304533	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.52	5.13	0.39	9.04e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-0.8	-4.71	-0.36	5.74e-6	Major depressive disorder;
UCEC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg11871910	chr12:69753446	YEATS4	0.74	8.16	0.56	1.37e-13	Blood protein levels;
UCEC	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.54	-6.87	-0.49	1.65e-10	Gut microbiome composition (winter);
UCEC	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.47	-5.25	-0.4	5.28e-7	Prostate cancer;
UCEC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.24	-0.4	5.38e-7	Hemoglobin concentration;
UCEC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.05	-0.55	2.52e-13	Total cholesterol levels;
UCEC	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.34	0.46	2.69e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs17122693	0.818	rs113230118	chr14:51160977	G/A	cg04730355	chr14:51134070	SAV1	0.84	8.05	0.55	2.51e-13	Cognitive performance;
UCEC	cis	rs9810890	0.764	rs59037701	chr3:128562299	A/G	cg11901034	chr3:128598214	ACAD9	-0.62	-5.42	-0.41	2.37e-7	Dental caries;
UCEC	cis	rs4851266	1.000	rs4851267	chr2:100824104	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.8	0.59	3.48e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-10.49	-0.65	1.49e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg13593689	chr9:129986794	NA	0.45	4.76	0.37	4.58e-6	Intraocular pressure;
UCEC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.76	7.52	0.53	5.07e-12	Primary sclerosing cholangitis;
UCEC	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.87	-0.37	2.84e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg26597838	chr10:835615	NA	0.85	5.2	0.39	6.49e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-4.68	-0.36	6.48e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.05	0.5	6.48e-11	Coffee consumption (cups per day);
UCEC	cis	rs6540731	1.000	rs951623	chr1:212399062	T/C	cg01168776	chr1:212002499	LPGAT1	-0.37	-4.61	-0.36	8.77e-6	Intelligence (childhood);
UCEC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg04155231	chr12:9217510	LOC144571	0.41	5.09	0.39	1.09e-6	Sjögren's syndrome;
UCEC	trans	rs9313296	0.661	rs2644724	chr5:165522347	A/G	cg03539051	chr19:56418660	NLRP13	1.11	6.93	0.5	1.23e-10	Weight;Waist circumference;
UCEC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-4.66	-0.36	7.12e-6	Total body bone mineral density;
UCEC	trans	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	7.69	0.54	1.95e-12	Chronic sinus infection;
UCEC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-5.8	-0.43	3.87e-8	Monocyte percentage of white cells;
UCEC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.73	8.71	0.58	5.86e-15	Prudent dietary pattern;
UCEC	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.43	5.79	0.43	4.19e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg06096015	chr1:231504339	EGLN1	0.44	4.85	0.37	3.11e-6	Hemoglobin concentration;
UCEC	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.59	-5.38	-0.41	2.89e-7	Metabolite levels;
UCEC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.06	0.45	1.08e-8	Cognitive test performance;
UCEC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.9	-0.37	2.53e-6	Initial pursuit acceleration;
UCEC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.27	6.89	0.49	1.52e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.61	5.82	0.43	3.54e-8	Coronary artery disease;
UCEC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg04756594	chr16:24857601	SLC5A11	0.42	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.49	-5.09	-0.39	1.1e-6	Breast cancer;
UCEC	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.66	7.81	0.54	1e-12	Breast cancer;
UCEC	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.46	6.46	0.47	1.42e-9	Superior crus of antihelix expression;
UCEC	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.03	-12.38	-0.71	1.43e-24	Dilated cardiomyopathy;
UCEC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.11	0.39	9.71e-7	Birth weight;
UCEC	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg19041857	chr6:27730383	NA	-0.63	-5.03	-0.38	1.43e-6	Lung cancer in ever smokers;
UCEC	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	1.17	8.2	0.56	1.09e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	5.08	0.39	1.13e-6	Headache;
UCEC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	1.02	14.58	0.77	2.45e-30	Bone mineral density;
UCEC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg22974920	chr21:40686053	BRWD1	-0.47	-4.67	-0.36	6.7e-6	Menarche (age at onset);
UCEC	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.62	5.91	0.44	2.34e-8	Schizophrenia;
UCEC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	6.23	0.46	4.59e-9	Platelet count;
UCEC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.89	-10.1	-0.64	1.48e-18	Dental caries;
UCEC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	8.17	0.56	1.29e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg13683864	chr3:40499215	RPL14	-0.57	-6.19	-0.45	5.57e-9	Renal cell carcinoma;
UCEC	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg06562184	chr8:19319451	CSGALNACT1	0.45	4.64	0.36	7.56e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.78	6.75	0.49	3.25e-10	Breast cancer;
UCEC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	5.48	0.41	1.77e-7	Breast cancer;
UCEC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.66	5.35	0.4	3.23e-7	Corneal astigmatism;
UCEC	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg03078520	chr22:18463400	MICAL3	-0.39	-4.51	-0.35	1.33e-5	Presence of antiphospholipid antibodies;
UCEC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	7.96	0.55	4.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.49	4.93	0.38	2.23e-6	Breast cancer;
UCEC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg24060327	chr5:131705240	SLC22A5	0.48	4.98	0.38	1.76e-6	Blood metabolite levels;
UCEC	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.68	-6.44	-0.47	1.59e-9	Cocaine dependence;
UCEC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.46	5.14	0.39	8.58e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.5	5.66	0.42	7.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	1.000	rs1570060	chr6:26573562	A/G	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.52	-0.53	4.88e-12	Exhaled nitric oxide output;
UCEC	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.67	-7.13	-0.51	4.26e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.71	-8.06	-0.55	2.46e-13	Coronary artery disease;
UCEC	trans	rs4146922	0.793	rs7601401	chr2:56004592	A/G	cg20168479	chr3:32443031	CMTM7	-0.69	-7.1	-0.51	4.95e-11	Height;
UCEC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg11871910	chr12:69753446	YEATS4	1.07	13.31	0.74	5.04e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg18755752	chr8:142205143	DENND3	-0.6	-5.52	-0.41	1.47e-7	Immature fraction of reticulocytes;
UCEC	cis	rs6723108	0.603	rs10166142	chr2:135710322	A/G	cg07169764	chr2:136633963	MCM6	0.51	5.0	0.38	1.62e-6	Type 2 diabetes;
UCEC	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.72	-7.21	-0.51	2.74e-11	Lymphocyte counts;
UCEC	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	6.42	0.47	1.73e-9	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-4.99	-0.38	1.65e-6	Blood metabolite levels;
UCEC	cis	rs11249243	0.623	rs55768255	chr1:25365365	C/T	cg05887270	chr1:26129627	SEPN1	0.58	4.56	0.35	1.06e-5	Male-pattern baldness;
UCEC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.59	4.83	0.37	3.38e-6	Alzheimer's disease;
UCEC	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.6	-7.56	-0.53	3.91e-12	Corneal structure;
UCEC	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.79	8.17	0.56	1.33e-13	Menopause (age at onset);
UCEC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.61	5.27	0.4	4.67e-7	Heart rate;
UCEC	cis	rs8042680	0.554	rs7179428	chr15:91532565	C/A	cg14398957	chr15:91536180	PRC1	-0.44	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs6840360	0.642	rs11726254	chr4:152438850	G/C	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.61	5.28	0.4	4.49e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.31	-10.45	-0.65	1.8e-19	Hip circumference adjusted for BMI;
UCEC	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.56	-5.59	-0.42	1.06e-7	Vitiligo;
UCEC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.56	-6.07	-0.45	1.01e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.69	0.48	4.45e-10	Coffee consumption (cups per day);
UCEC	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.43	4.73	0.36	5.12e-6	Blood metabolite levels;
UCEC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.53	0.35	1.23e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.6	-4.72	-0.36	5.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.72	0.43	5.78e-8	Breast cancer;
UCEC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg09654669	chr8:57350985	NA	0.43	4.73	0.36	5.2e-6	Obesity-related traits;
UCEC	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.69	7.98	0.55	3.75e-13	Mean corpuscular volume;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.52	-5.62	-0.42	9.11e-8	Pubertal anthropometrics;
UCEC	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.73	0.54	1.55e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.53	5.59	0.42	1.09e-7	Response to temozolomide;
UCEC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.48	-5.37	-0.41	2.99e-7	Life satisfaction;
UCEC	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg20560298	chr2:73613845	ALMS1	0.51	4.88	0.37	2.76e-6	Metabolite levels;
UCEC	cis	rs3743102	0.519	rs12592022	chr15:83235298	T/A	cg00614314	chr15:82944287	LOC80154	-0.8	-4.78	-0.37	4.17e-6	Colorectal adenoma (advanced);
UCEC	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.88	7.86	0.54	7.54e-13	Body mass index;
UCEC	cis	rs1981331	0.609	rs7279368	chr21:48065999	A/G	cg23283320	chr21:48055893	PRMT2	1.65	7.68	0.54	2.04e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.64	6.89	0.49	1.49e-10	Longevity;Endometriosis;
UCEC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg04155231	chr12:9217510	LOC144571	0.42	5.1	0.39	1.03e-6	Sjögren's syndrome;
UCEC	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg04155231	chr12:9217510	LOC144571	0.42	4.92	0.38	2.34e-6	Sjögren's syndrome;
UCEC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.48	-4.8	-0.37	3.85e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2120991	1.000	rs7133819	chr12:54262756	C/T	cg07927839	chr12:53491483	IGFBP6	0.45	4.74	0.36	4.9e-6	Biliary atresia;
UCEC	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.17	6.25	0.46	4.18e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg24375607	chr4:120327624	NA	0.45	4.63	0.36	7.89e-6	Corneal astigmatism;
UCEC	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.46	-4.57	-0.35	1.01e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.55	4.67	0.36	6.8e-6	Alzheimer's disease;
UCEC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.56	4.84	0.37	3.25e-6	Corneal astigmatism;
UCEC	cis	rs5743890	1.000	rs5743890	chr11:1325829	A/G	cg06066251	chr11:1309984	TOLLIP	0.65	4.61	0.36	8.83e-6	Idiopathic pulmonary fibrosis;
UCEC	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg03433033	chr1:76189801	ACADM	-0.48	-5.26	-0.4	5.01e-7	Daytime sleep phenotypes;
UCEC	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg06265175	chr8:121136014	COL14A1	0.48	5.2	0.39	6.53e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	4.51	0.35	1.33e-5	Obesity-related traits;
UCEC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.61	-6.16	-0.45	6.61e-9	Blood metabolite levels;
UCEC	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.73	-7.81	-0.54	9.77e-13	Ulcerative colitis;
UCEC	cis	rs11129176	1.000	rs11129176	chr3:25049310	G/A	cg02506578	chr3:25824554	NGLY1	0.62	4.87	0.37	2.84e-6	Optic disc area;
UCEC	cis	rs13315871	0.929	rs6769216	chr3:58238877	C/T	cg20936604	chr3:58311152	NA	-0.57	-4.66	-0.36	7.04e-6	Cholesterol, total;
UCEC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.43	4.54	0.35	1.18e-5	Eye color traits;
UCEC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	5.91	0.44	2.29e-8	Lymphocyte counts;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg01874867	chr7:94954059	PON1	-0.55	-5.23	-0.4	5.62e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs78487399	0.908	rs12474030	chr2:43812317	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.71	-0.36	5.61e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg13683864	chr3:40499215	RPL14	-0.68	-6.79	-0.49	2.59e-10	Renal cell carcinoma;
UCEC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg07153921	chr17:41440717	NA	0.6	7.06	0.5	6.08e-11	Menopause (age at onset);
UCEC	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	0.83	5.28	0.4	4.57e-7	Arsenic metabolism;
UCEC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.66	-4.81	-0.37	3.64e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg26769984	chr7:1090371	C7orf50	0.5	4.88	0.37	2.74e-6	Longevity;Endometriosis;
UCEC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.53	5.23	0.4	5.71e-7	Body mass index;
UCEC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-4.95	-0.38	2e-6	Colorectal cancer;
UCEC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.54	5.3	0.4	4.2e-7	Menopause (age at onset);
UCEC	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.68	7.92	0.55	5.23e-13	Magnesium levels;
UCEC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.73	8.14	0.56	1.56e-13	Bone mineral density;
UCEC	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.44	-4.91	-0.38	2.42e-6	Coronary artery disease;
UCEC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg20450318	chr11:65415260	SIPA1	0.4	4.55	0.35	1.13e-5	Acne (severe);
UCEC	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.66	-5.98	-0.44	1.62e-8	Neurofibrillary tangles;
UCEC	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-4.59	-0.35	9.58e-6	Major depressive disorder;
UCEC	cis	rs2708377	0.858	rs115781584	chr12:11304560	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.75	6.22	0.46	4.8e-9	Bitter taste perception;
UCEC	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg01072550	chr1:21505969	NA	-0.57	-5.62	-0.42	9.44e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.82	0.49	2.17e-10	Cognitive test performance;
UCEC	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.66	-7.08	-0.5	5.39e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-1.11	-11.86	-0.7	3.58e-23	Blood protein levels;
UCEC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg04553112	chr3:125709451	NA	-0.72	-5.05	-0.38	1.32e-6	Blood pressure (smoking interaction);
UCEC	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.48	-6.67	-0.48	4.76e-10	Height;
UCEC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18252515	chr7:66147081	NA	-0.51	-4.9	-0.37	2.51e-6	Aortic root size;
UCEC	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.66	-6.66	-0.48	5.13e-10	Diabetic kidney disease;
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.8	-0.49	2.46e-10	Obesity-related traits;
UCEC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.76	-8.29	-0.56	6.73e-14	Menarche (age at onset);
UCEC	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.53	5.26	0.4	5.04e-7	Vitiligo;
UCEC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.49	4.92	0.38	2.31e-6	Calcium levels;
UCEC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.66	5.17	0.39	7.5e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.28	-0.46	3.56e-9	Blood metabolite levels;
UCEC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	0.75	5.03	0.38	1.38e-6	Iron status biomarkers;
UCEC	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	5.82	0.43	3.58e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg15848620	chr12:58087721	OS9	-0.51	-4.81	-0.37	3.73e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.5	-5.32	-0.4	3.83e-7	Pubertal anthropometrics;
UCEC	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-5.0	-0.38	1.61e-6	Blood protein levels;
UCEC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.56	-0.42	1.26e-7	Personality dimensions;
UCEC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.47	-6.88	-0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs7520050	0.865	rs785515	chr1:46562662	A/C	cg15837086	chr1:46506065	PIK3R3	-0.39	-5.1	-0.39	1.03e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg02737609	chr1:26758790	DHDDS	-0.51	-4.64	-0.36	7.71e-6	Obesity-related traits;
UCEC	cis	rs7709377	0.570	rs10075063	chr5:115452613	A/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.35	-0.4	3.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.82	7.0	0.5	8.66e-11	Testicular germ cell tumor;
UCEC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.46	4.54	0.35	1.17e-5	Autism;
UCEC	cis	rs256277	0.544	rs255930	chr5:111345538	C/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.55	-5.14	-0.39	8.45e-7	Coronary artery disease;
UCEC	cis	rs2414095	0.527	rs10519297	chr15:51541660	C/T	cg19946085	chr15:51559439	CYP19A1	-0.45	-4.55	-0.35	1.12e-5	Follicule stimulating hormone;Hormone measurements;Total body bone mineral density;
UCEC	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.68	-5.12	-0.39	9.32e-7	White matter hyperintensity burden;
UCEC	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-7.12	-0.51	4.41e-11	Coronary artery disease;
UCEC	cis	rs713477	0.967	rs11158039	chr14:55906696	A/T	cg13175173	chr14:55914753	NA	-0.43	-4.87	-0.37	2.81e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22117172	chr7:91764530	CYP51A1	-0.38	-4.74	-0.36	4.96e-6	Breast cancer;
UCEC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg07645718	chr20:61493192	TCFL5	0.79	5.87	0.44	2.76e-8	Obesity-related traits;
UCEC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg18827107	chr12:86230957	RASSF9	-0.44	-4.78	-0.37	4.14e-6	Major depressive disorder;
UCEC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.75	-4.6	-0.35	8.96e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs76051363	0.500	rs4647934	chr4:1016279	C/T	cg03446427	chr4:1019985	FGFRL1	0.48	4.72	0.36	5.53e-6	Total body bone mineral density;
UCEC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.01	0.38	1.55e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.7	-8.65	-0.58	8.18e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.46	5.29	0.4	4.35e-7	Blood metabolite ratios;
UCEC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18252515	chr7:66147081	NA	-0.54	-5.06	-0.39	1.23e-6	Aortic root size;
UCEC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg07897659	chr22:50316901	CRELD2	0.54	4.61	0.36	8.83e-6	Schizophrenia;
UCEC	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	7.45	0.52	7.48e-12	Motion sickness;
UCEC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	0.78	6.7	0.48	4.19e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.51	6.43	0.47	1.68e-9	Prudent dietary pattern;
UCEC	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.6	-4.79	-0.37	4.03e-6	Depression;
UCEC	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.56	7.15	0.51	3.86e-11	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.62	6.37	0.47	2.23e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs4778581	0.722	rs2469600	chr15:80367831	G/C	cg08257866	chr15:80351198	ZFAND6	0.38	4.58	0.35	9.8200000000000008e-06	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.61	-5.16	-0.39	7.89e-7	LDL cholesterol levels;
UCEC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg04155231	chr12:9217510	LOC144571	0.41	4.84	0.37	3.23e-6	Sjögren's syndrome;
UCEC	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.51	5.4	0.41	2.65e-7	Type 2 diabetes;
UCEC	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.53	5.0	0.38	1.62e-6	Coronary artery disease;
UCEC	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.67	7.98	0.55	3.9e-13	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7088591	0.867	rs4481980	chr10:59781753	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.65	-4.94	-0.38	2.11e-6	Narcolepsy;
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-6.57	-0.48	8.14e-10	Platelet count;
UCEC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.82	8.73	0.58	5.22e-15	Blood protein levels;
UCEC	trans	rs4146922	0.793	rs62167689	chr2:56009480	A/T	cg03313676	chr20:62526047	DNAJC5	0.71	7.23	0.51	2.39e-11	Height;
UCEC	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.47	4.89	0.37	2.65e-6	Smoking initiation;
UCEC	cis	rs7870753	0.530	rs117847766	chr9:99191655	A/T	cg25260653	chr9:99212216	HABP4	0.53	4.95	0.38	1.99e-6	Height;
UCEC	cis	rs4713118	0.506	rs9366697	chr6:27633018	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.1	-0.39	1.02e-6	Parkinson's disease;
UCEC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.49	-4.66	-0.36	7.03e-6	Mean platelet volume;
UCEC	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.91	-0.38	2.44e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.45	4.52	0.35	1.27e-5	Vitiligo;
UCEC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.67	0.36	6.63e-6	Diabetic retinopathy;
UCEC	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.78	-0.37	4.26e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.99	6.4	0.47	1.98e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2386661	0.522	rs11258044	chr10:5644392	C/T	cg17085576	chr10:5658249	NA	-0.43	-4.52	-0.35	1.25e-5	Breast cancer;
UCEC	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.59	-4.84	-0.37	3.23e-6	Obesity-related traits;
UCEC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.69	-7.93	-0.55	4.93e-13	Menarche (age at onset);
UCEC	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg25627403	chr19:41769009	HNRNPUL1	-0.83	-6.48	-0.47	1.27e-9	Coronary artery disease;
UCEC	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg15352829	chr14:105391018	PLD4	-0.47	-6.8	-0.49	2.44e-10	Rheumatoid arthritis;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg02493798	chr17:6899577	ALOX12	0.46	5.51	0.41	1.55e-7	Tonsillectomy;
UCEC	cis	rs6763768	0.606	rs7649323	chr3:53332706	C/G	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-4.95	-0.38	2e-6	Colorectal cancer;
UCEC	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.76	8.02	0.55	3.09e-13	Breast cancer;
UCEC	cis	rs6584202	0.589	rs10883094	chr10:100188106	C/T	cg19567339	chr10:100142640	NA	0.59	7.45	0.52	7.54e-12	Obesity-related traits;
UCEC	cis	rs4372836	0.504	rs13024443	chr2:29046185	C/T	cg09522027	chr2:28974177	PPP1CB	-0.65	-6.68	-0.48	4.56e-10	Body mass index;
UCEC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.85	8.53	0.58	1.69e-14	Blood protein levels;
UCEC	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.87	-10.91	-0.67	1.11e-20	Brugada syndrome;
UCEC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.92	0.38	2.27e-6	Blood metabolite levels;
UCEC	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.9	13.21	0.74	9.01e-27	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg24562669	chr7:97807699	LMTK2	0.47	5.76	0.43	4.64e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.53	4.75	0.36	4.76e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg16616514	chr4:6324629	PPP2R2C	0.38	4.75	0.37	4.72e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.81	7.29	0.52	1.78e-11	Bladder cancer;
UCEC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26207909	chr14:103986467	CKB	0.53	5.76	0.43	4.78e-8	Body mass index;
UCEC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg21827317	chr3:136751795	NA	0.48	5.22	0.4	6.13e-7	Gestational age at birth (child effect);
UCEC	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.44	5.27	0.4	4.83e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.66	6.88	0.49	1.58e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-6.17	-0.45	6.39e-9	Platelet count;
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	-0.68	-4.68	-0.36	6.35e-6	Narcolepsy;
UCEC	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-5.12	-0.39	9.39e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs116095464	0.681	rs1574220	chr5:314518	T/C	cg22857025	chr5:266934	NA	-1.0	-9.74	-0.63	1.32e-17	Breast cancer;
UCEC	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.55	-6.06	-0.45	1.09e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.78	7.34	0.52	1.35e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.0	-0.38	1.58e-6	Coronary artery disease;
UCEC	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.8	0.49	2.44e-10	Coffee consumption (cups per day);
UCEC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg11871910	chr12:69753446	YEATS4	1.07	13.57	0.75	1.05e-27	Cerebrospinal fluid biomarker levels;
UCEC	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.11	9.61	0.62	2.96e-17	Opioid sensitivity;
UCEC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.49	4.82	0.37	3.49e-6	Menopause (age at onset);
UCEC	cis	rs6909279	0.933	rs7753676	chr6:151876815	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.47	-4.54	-0.35	1.17e-5	Bone mineral density;
UCEC	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	0.9	7.27	0.51	1.98e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.53	4.87	0.37	2.84e-6	Blood protein levels;
UCEC	cis	rs2016266	1.000	rs10783573	chr12:53728369	G/A	cg26875137	chr12:53738046	NA	0.52	6.56	0.48	8.6e-10	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg09654669	chr8:57350985	NA	-0.54	-6.1	-0.45	8.84e-9	Obesity-related traits;
UCEC	cis	rs2708977	0.698	rs772159	chr2:97036439	G/A	cg22654517	chr2:96458247	NA	0.47	5.82	0.43	3.48e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs8105895	0.866	rs62112908	chr19:22213956	A/G	cg24175803	chr19:22235144	ZNF257	-0.5	-4.61	-0.36	8.81e-6	Body mass index (change over time);
UCEC	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.59	-0.42	1.05e-7	Fear of minor pain;
UCEC	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	4.91	0.38	2.44e-6	IgG glycosylation;
UCEC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.48	4.58	0.35	9.85e-6	Diastolic blood pressure;
UCEC	cis	rs7246967	0.611	rs12973627	chr19:22867705	G/A	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.82e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.32	-4.74	-0.36	4.97e-6	Primary biliary cholangitis;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg19678392	chr7:94953810	PON1	-0.58	-5.63	-0.42	9.08e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.46	-0.52	6.88e-12	Resting heart rate;
UCEC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	4.93	0.38	2.21e-6	Mood instability;
UCEC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.54	-0.66	1.05e-19	Schizophrenia;
UCEC	cis	rs975730	1.000	rs62528369	chr8:129321534	T/C	cg14920061	chr8:129326392	NA	0.36	4.61	0.36	8.6e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.51	5.3	0.4	4.13e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7246967	0.932	rs62120780	chr19:23043714	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg11871910	chr12:69753446	YEATS4	1.07	13.57	0.75	1.05e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.67	-5.7	-0.43	6.47e-8	Schizophrenia;
UCEC	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.73	7.19	0.51	2.98e-11	Primary sclerosing cholangitis;
UCEC	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-1.01	-10.98	-0.67	7.56e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.33	-0.76	1.08e-29	Schizophrenia;
UCEC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-10.78	-0.66	2.5e-20	Schizophrenia;
UCEC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	9.27	0.61	2.12e-16	Platelet count;
UCEC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.88	9.99	0.64	2.9e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.07	6.68	0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.65	6.05	0.45	1.14e-8	Height;
UCEC	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	9.63	0.62	2.62e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.52	7.24	0.51	2.28e-11	Coronary artery disease or large artery stroke;
UCEC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.75	9.97	0.64	3.33e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg09074113	chr2:20870087	GDF7	-0.52	-6.69	-0.48	4.37e-10	Abdominal aortic aneurysm;
UCEC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18252515	chr7:66147081	NA	-0.58	-5.21	-0.39	6.33e-7	Aortic root size;
UCEC	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-0.73	-4.85	-0.37	3.13e-6	Mitochondrial DNA levels;
UCEC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.53	-5.6	-0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.65	-0.42	7.89e-8	Platelet count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10089324	chr1:51984752	EPS15	0.58	7.0	0.5	8.59e-11	Warfarin maintenance dose;
UCEC	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg05991184	chr2:219186017	PNKD	-0.41	-4.54	-0.35	1.19e-5	Ulcerative colitis;
UCEC	cis	rs4778581	0.604	rs2866369	chr15:80419797	T/G	cg08257866	chr15:80351198	ZFAND6	0.41	4.76	0.37	4.55e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.45	-5.15	-0.39	8.16e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.62	7.16	0.51	3.6e-11	Mean corpuscular volume;
UCEC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.67	5.79	0.43	4.08e-8	Menopause (age at onset);
UCEC	cis	rs11697848	1.000	rs41283584	chr20:48507781	G/A	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.47	-4.78	-0.37	4.14e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.64	4.85	0.37	3.06e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4919044	0.641	rs12357515	chr10:94725508	A/G	cg00519463	chr10:94352821	KIF11	0.87	4.65	0.36	7.48e-6	Coronary artery disease;
UCEC	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.73	0.36	5.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg27489772	chr12:121021490	NA	-0.53	-4.75	-0.37	4.71e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	6.23	0.46	4.63e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.99	0.64	2.97e-18	Cognitive function;
UCEC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.01	-6.55	-0.48	8.96e-10	Diabetic kidney disease;
UCEC	cis	rs9309473	1.000	rs10187416	chr2:73713741	T/G	cg20560298	chr2:73613845	ALMS1	-0.6	-5.35	-0.4	3.33e-7	Metabolite levels;
UCEC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.55	-5.45	-0.41	2.06e-7	Mortality in heart failure;
UCEC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.22	-6.97	-0.5	9.87e-11	Diabetic kidney disease;
UCEC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.69	0.36	6.14e-6	Tonsillectomy;
UCEC	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	5.09	0.39	1.08e-6	Blood protein levels;
UCEC	cis	rs350251	0.934	rs350209	chr16:12212818	G/C	cg01282078	chr16:12139025	RUNDC2A	-0.47	-4.61	-0.36	8.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.03	-0.55	2.93e-13	Breast cancer;
UCEC	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg08807101	chr21:30365312	RNF160	-0.52	-5.04	-0.38	1.33e-6	Cognitive test performance;
UCEC	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.79	0.59	3.62e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg25635316	chr7:23637023	CCDC126	0.4	4.51	0.35	1.31e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.45	-0.52	7.16e-12	Joint mobility (Beighton score);
UCEC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.78	8.19	0.56	1.15e-13	Multiple myeloma (IgH translocation);
UCEC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.64	0.36	7.58e-6	Bipolar disorder;
UCEC	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.53	-4.99	-0.38	1.7e-6	Large artery stroke;
UCEC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg19680485	chr15:31195859	MTMR15	-0.55	-4.72	-0.36	5.46e-6	Huntington's disease progression;
UCEC	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13683864	chr3:40499215	RPL14	0.86	9.84	0.63	7.08e-18	Renal cell carcinoma;
UCEC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01973587	chr1:228161476	NA	0.38	5.09	0.39	1.07e-6	Diastolic blood pressure;
UCEC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg03354898	chr7:1950403	MAD1L1	-0.45	-5.03	-0.38	1.42e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9341808	0.628	rs2490245	chr6:80892427	A/G	cg08355045	chr6:80787529	NA	0.41	5.15	0.39	8.37e-7	Sitting height ratio;
UCEC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg22868518	chr11:507468	RNH1	-0.69	-4.64	-0.36	7.52e-6	Body mass index;
UCEC	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg19875535	chr5:140030758	IK	0.44	4.91	0.38	2.35e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.52	-5.3	-0.4	4.22e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg04043695	chr12:129287642	SLC15A4	0.63	6.21	0.46	5.19e-9	Systemic lupus erythematosus;
UCEC	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-0.97	-4.75	-0.36	4.89e-6	Mitochondrial DNA levels;
UCEC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.79	5.04	0.38	1.37e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-0.87	-6.95	-0.5	1.09e-10	Blood protein levels;
UCEC	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.49	-5.7	-0.43	6.21e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	0.61	6.31	0.46	3.05e-9	Homoarginine levels;
UCEC	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.77	8.43	0.57	2.94e-14	Blood protein levels;
UCEC	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.65	0.53	2.41e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.61	-7.11	-0.51	4.62e-11	Prostate cancer;
UCEC	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.5	4.54	0.35	1.14e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.83	8.52	0.57	1.74e-14	Parkinson's disease;
UCEC	cis	rs79815064	0.850	rs75352297	chr3:46345151	T/C	cg19145607	chr3:45983792	CXCR6;FYCO1	0.71	4.58	0.35	9.87e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs77861329	1.000	rs171294	chr3:52203599	C/G	cg08692210	chr3:52188851	WDR51A	0.84	6.55	0.48	8.84e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.7	-7.94	-0.55	4.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-1.01	-7.39	-0.52	1.02e-11	Multiple sclerosis;
UCEC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.96	6.07	0.45	1.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg04944784	chr2:26401820	FAM59B	0.74	5.01	0.38	1.56e-6	Gut microbiome composition (summer);
UCEC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg20203395	chr5:56204925	C5orf35	-0.55	-5.11	-0.39	9.73e-7	Coronary artery disease;
UCEC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.96	-0.44	1.78e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.5	5.65	0.42	7.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.51	5.36	0.4	3.11e-7	Schizophrenia;
UCEC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.56	4.65	0.36	7.22e-6	Alzheimer's disease;
UCEC	cis	rs10242455	0.702	rs73713531	chr7:99222379	C/T	cg18809830	chr7:99032528	PTCD1	-0.77	-4.68	-0.36	6.39e-6	Blood metabolite levels;
UCEC	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs10924970	0.649	rs12748629	chr1:235425959	T/C	cg26050004	chr1:235667680	B3GALNT2	0.53	4.86	0.37	3.01e-6	Asthma;
UCEC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.68	6.7	0.48	4.2e-10	Response to antineoplastic agents;
UCEC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg20399509	chr21:47717575	C21orf57	-0.44	-4.77	-0.37	4.42e-6	Testicular germ cell tumor;
UCEC	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg03999872	chr20:62272968	STMN3	-0.48	-4.78	-0.37	4.27e-6	Atopic dermatitis;
UCEC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.16	14.9	0.78	3.46e-31	Cognitive function;
UCEC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.96	10.54	0.66	1.06e-19	Cognitive function;
UCEC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.57	6.24	0.46	4.49e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg01485075	chr19:22817371	ZNF492	0.41	4.51	0.35	1.3e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.32	-4.52	-0.35	1.24e-5	Iron status biomarkers;
UCEC	cis	rs12313068	0.709	rs11829777	chr12:110503770	T/C	cg12870014	chr12:110450643	ANKRD13A	0.77	8.48	0.57	2.16e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.63	-6.53	-0.47	1.01e-9	Mean platelet volume;
UCEC	trans	rs7874142	0.580	rs10858283	chr9:137708973	A/G	cg02902969	chr10:409431	DIP2C	-0.62	-6.86	-0.49	1.79e-10	Longevity;
UCEC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.86e-6	Body mass index;
UCEC	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.75	-0.54	1.39e-12	Caffeine consumption;
UCEC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.48	5.4	0.41	2.61e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.36	-0.4	3.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.16	0.39	7.77e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.11	0.39	9.7e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.49	6.78	0.49	2.75e-10	Height;
UCEC	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.52	0.53	4.98e-12	Ileal carcinoids;
UCEC	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	1.03	10.5	0.65	1.38e-19	Alcohol dependence;
UCEC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.49	4.53	0.35	1.19e-5	Lung cancer;
UCEC	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.51	-5.12	-0.39	9.58e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.52	-4.67	-0.36	6.86e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	7.88	0.54	6.7e-13	Chronic sinus infection;
UCEC	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.43	13.74	0.75	3.7e-28	Atopic dermatitis;
UCEC	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg13683864	chr3:40499215	RPL14	-0.67	-6.72	-0.48	3.71e-10	Renal cell carcinoma;
UCEC	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	6.66	0.48	5.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg20712883	chr12:51590929	POU6F1	0.64	6.46	0.47	1.47e-9	Cisplatin-induced ototoxicity;
UCEC	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.45	-5.33	-0.4	3.57e-7	Rheumatoid arthritis;
UCEC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg01874867	chr7:94954059	PON1	-0.53	-4.71	-0.36	5.73e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs4588572	0.602	rs10059672	chr5:77673317	G/C	cg11547950	chr5:77652471	NA	0.48	5.1	0.39	1.02e-6	Triglycerides;
UCEC	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.5	-0.53	5.51e-12	Exhaled nitric oxide output;
UCEC	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-4.76	-0.37	4.53e-6	Gut microbiome composition (summer);
UCEC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-5.04	-0.38	1.35e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg21770322	chr7:97807741	LMTK2	0.82	13.77	0.75	3.17e-28	Breast cancer;
UCEC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.52	5.73	0.43	5.54e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.67	0.48	4.84e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.6	6.32	0.46	2.91e-9	Initial pursuit acceleration;
UCEC	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	5.1	0.39	1.02e-6	Myopia (pathological);
UCEC	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.76	8.76	0.59	4.44e-15	Primary sclerosing cholangitis;
UCEC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.23	8.01	0.55	3.31e-13	Diabetic kidney disease;
UCEC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.42	-4.76	-0.37	4.58e-6	Prostate cancer;
UCEC	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.63	4.9	0.38	2.45e-6	Platelet distribution width;
UCEC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs9469578	0.636	rs16869463	chr6:33714983	A/G	cg18708504	chr6:33715942	IP6K3	-0.51	-5.23	-0.4	5.61e-7	Phosphorus levels;
UCEC	cis	rs7246967	0.800	rs2169794	chr19:23025768	G/C	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg13147721	chr7:65941812	NA	0.91	6.06	0.45	1.07e-8	Diabetic kidney disease;
UCEC	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.74	-6.86	-0.49	1.83e-10	IgG glycosylation;
UCEC	cis	rs12579753	0.719	rs12369450	chr12:82266940	A/G	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.32	-0.4	3.86e-7	Resting heart rate;
UCEC	cis	rs3015497	0.763	rs2934689	chr14:51118327	A/C	cg04730355	chr14:51134070	SAV1	-0.53	-5.66	-0.42	7.8e-8	Mean platelet volume;
UCEC	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.91	-0.9	1.28e-54	Myeloid white cell count;
UCEC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.56	-6.76	-0.49	3.02e-10	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Depression;
UCEC	cis	rs9549367	0.659	rs9549703	chr13:113885094	T/TTAG	cg18105134	chr13:113819100	PROZ	-0.68	-6.49	-0.47	1.23e-9	Platelet distribution width;
UCEC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.2	-0.51	2.94e-11	Monocyte count;
UCEC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.57	-0.42	1.16e-7	Hemoglobin concentration;
UCEC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.69	-0.36	6.22e-6	Breast cancer;
UCEC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.37	4.67	0.36	6.77e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.68	6.86	0.49	1.75e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.59	5.71	0.43	5.94e-8	Schizophrenia;
UCEC	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg00105475	chr2:10696890	NA	0.46	5.65	0.42	7.99e-8	Prostate cancer;
UCEC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.5	4.77	0.37	4.32e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.87	0.54	6.95e-13	Platelet count;
UCEC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.87e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7072216	0.770	rs7909131	chr10:100171471	A/G	cg19567339	chr10:100142640	NA	0.55	6.61	0.48	6.7e-10	Metabolite levels;
UCEC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.62	-7.19	-0.51	3e-11	Prostate cancer;
UCEC	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.86	-0.59	2.46e-15	Exhaled nitric oxide output;
UCEC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.78	-0.37	4.23e-6	Testicular germ cell tumor;
UCEC	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.73	-7.98	-0.55	3.73e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.64	-0.48	5.71e-10	Cardiac Troponin-T levels;
UCEC	cis	rs11760485	0.965	rs28403109	chr7:4401876	G/A	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs256277	0.657	rs255914	chr5:111389055	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.56	-4.53	-0.35	1.21e-5	Coronary artery disease;
UCEC	cis	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.78	-0.37	4.27e-6	Eotaxin levels;
UCEC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	7.84	0.54	8.49e-13	Alzheimer's disease;
UCEC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.69	-6.73	-0.49	3.54e-10	Neurofibrillary tangles;
UCEC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.58	-6.4	-0.47	1.97e-9	Menarche (age at onset);
UCEC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.6	0.62	3.13e-17	Menarche (age at onset);
UCEC	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-8.38	-0.57	3.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs41271951	0.512	rs16832976	chr1:151038135	T/C	cg00107782	chr1:151300621	NA	-0.67	-4.54	-0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.63	6.17	0.45	6.19e-9	Lung cancer;
UCEC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.4	0.41	2.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.72	6.45	0.47	1.53e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.73	-5.65	-0.42	8.09e-8	Orofacial clefts;
UCEC	cis	rs6424115	0.830	rs2501434	chr1:24203425	C/T	cg15997130	chr1:24165203	NA	0.65	6.76	0.49	3.04e-10	Immature fraction of reticulocytes;
UCEC	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.68	-4.85	-0.37	3.08e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.68	-7.25	-0.51	2.18e-11	Breast cancer;
UCEC	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-1.19	-8.44	-0.57	2.84e-14	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.67	-7.63	-0.53	2.66e-12	Menarche (age at onset);
UCEC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.54	5.28	0.4	4.46e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.38	-0.41	2.89e-7	Bipolar disorder;
UCEC	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.42	-5.29	-0.4	4.4e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.67	6.41	0.47	1.88e-9	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.58	5.61	0.42	9.57e-8	Interstitial lung disease;
UCEC	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	9.21	0.6	3.07e-16	Coffee consumption (cups per day);
UCEC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	0.79	9.73	0.63	1.39e-17	Multiple myeloma;
UCEC	cis	rs11867410	0.744	rs60350864	chr17:63943955	C/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg13683864	chr3:40499215	RPL14	0.73	7.92	0.55	5.33e-13	Renal cell carcinoma;
UCEC	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.43	-0.41	2.24e-7	Subjective well-being;
UCEC	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.93	-9.81	-0.63	8.56e-18	Cognitive ability;
UCEC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.45	-4.89	-0.37	2.61e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.49	5.12	0.39	9.44e-7	Blood protein levels;
UCEC	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.67	6.6	0.48	6.86e-10	Height;
UCEC	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.53	5.26	0.4	5.1e-7	Red cell distribution width;
UCEC	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-0.83	-7.29	-0.52	1.79e-11	Blood protein levels;
UCEC	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.49	-0.65	1.44e-19	Blood metabolite levels;
UCEC	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	0.91	9.18	0.6	3.6e-16	Coronary artery disease;
UCEC	cis	rs6457821	1.000	rs45558531	chr6:35435602	A/G	cg06087101	chr6:35551932	FKBP5	0.53	4.51	0.35	1.34e-5	Height;
UCEC	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.55	-5.21	-0.39	6.33e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.56	5.66	0.42	7.61e-8	Colorectal cancer;
UCEC	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg08755490	chr11:65554678	OVOL1	0.52	5.34	0.4	3.51e-7	Acne (severe);
UCEC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.68	7.48	0.52	6.33e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6460942	0.505	rs73290446	chr7:12358133	T/G	cg06484146	chr7:12443880	VWDE	-0.54	-4.52	-0.35	1.28e-5	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.75	9.97	0.64	3.33e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	5.94	0.44	1.95e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.44	5.01	0.38	1.53e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-6.33	-0.46	2.77e-9	Multiple sclerosis;
UCEC	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.68	-7.08	-0.5	5.6e-11	Dental caries;
UCEC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.45	-5.1	-0.39	1.03e-6	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.35	-0.46	2.59e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.61	-4.51	-0.35	1.32e-5	Iron status biomarkers;
UCEC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.95	9.33	0.61	1.56e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs56050415	0.687	rs7165301	chr15:58552606	A/G	cg16896313	chr15:58552619	NA	0.48	4.99	0.38	1.7e-6	Metabolite levels (lipoprotein measures);
UCEC	cis	rs925228	0.793	rs4665248	chr2:24167751	C/A	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg17420585	chr12:42539391	GXYLT1	0.36	4.55	0.35	1.12e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.51	0.41	1.58e-7	Ileal carcinoids;
UCEC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.57	-6.49	-0.47	1.22e-9	Lung cancer;
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg20999797	chr1:1681921	NA	0.36	4.93	0.38	2.16e-6	Body mass index;
UCEC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.39	-4.97	-0.38	1.82e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1018836	0.700	rs7824511	chr8:91521545	T/C	cg16814680	chr8:91681699	NA	-0.72	-7.07	-0.5	5.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.41	5.06	0.39	1.22e-6	Mean platelet volume;
UCEC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.57	-5.75	-0.43	5.07e-8	Body mass index;
UCEC	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.63	4.58	0.35	1e-5	Major depressive disorder;
UCEC	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.68	-7.11	-0.51	4.63e-11	Morning vs. evening chronotype;
UCEC	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg13683864	chr3:40499215	RPL14	-0.53	-5.36	-0.4	3.18e-7	Renal cell carcinoma;
UCEC	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg05132306	chr1:1846340	CALML6	-0.37	-4.67	-0.36	6.74e-6	Body mass index;
UCEC	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.51	-5.73	-0.43	5.57e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.67	-5.47	-0.41	1.93e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07215822	chr6:158701037	NA	-0.67	-5.74	-0.43	5.14e-8	Height;
UCEC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.7	5.88	0.44	2.65e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12635074	0.521	rs113062903	chr3:56304954	G/A	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.61	0.36	8.63e-6	Morning vs. evening chronotype;
UCEC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.67	0.62	2e-17	Menopause (age at onset);
UCEC	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.56	4.71	0.36	5.67e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg21053147	chr12:120880522	NA	0.63	5.07	0.39	1.19e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.56	5.72	0.43	5.76e-8	Longevity;
UCEC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.82e-15	Blood protein levels;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.54	-0.35	1.18e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.91	-11.1	-0.68	3.57e-21	Primary sclerosing cholangitis;
UCEC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.16	-0.39	7.75e-7	Aortic root size;
UCEC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.7	7.97	0.55	4.06e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1007190	0.881	rs8073674	chr17:42969337	A/C	cg15406952	chr17:42872593	NA	0.74	5.85	0.43	3.04e-8	DNA methylation (variation);
UCEC	cis	rs239198	0.568	rs34555037	chr6:101327153	G/C	cg09795085	chr6:101329169	ASCC3	0.5	4.75	0.36	4.88e-6	Menarche (age at onset);
UCEC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg05738196	chr6:26577821	NA	0.61	6.74	0.49	3.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.63	-4.94	-0.38	2.11e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.23	0.4	5.65e-7	Cognitive test performance;
UCEC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.48	4.55	0.35	1.11e-5	Blood metabolite levels;
UCEC	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-7.48	-0.52	6.4e-12	Parkinson's disease;
UCEC	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg27171509	chr10:82033454	MAT1A	-0.46	-4.99	-0.38	1.67e-6	Borderline personality disorder;
UCEC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.58	-4.61	-0.36	8.5e-6	Narcolepsy;
UCEC	trans	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg02900749	chr2:68251473	NA	-0.97	-7.12	-0.51	4.49e-11	Pursuit maintenance gain;
UCEC	trans	rs1459104	1.000	rs66654577	chr11:55168539	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.65	-7.24	-0.51	2.31e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7611694	0.532	rs9815835	chr3:113159741	C/T	cg12596171	chr3:113251061	SIDT1	-0.54	-5.46	-0.41	1.94e-7	Prostate cancer;
UCEC	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.64	5.8	0.43	3.93e-8	High light scatter reticulocyte count;
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg02158880	chr13:53174818	NA	0.62	7.48	0.53	6.17e-12	Lewy body disease;
UCEC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.67	6.19	0.45	5.8e-9	Corneal astigmatism;
UCEC	cis	rs3736594	1.000	rs3792252	chr2:27995931	A/G	cg27432699	chr2:27873401	GPN1	0.51	5.86	0.43	2.99e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.42	5.44	0.41	2.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	0.87	7.25	0.51	2.2e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.41	14.99	0.78	2.08e-31	Atopic dermatitis;
UCEC	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.55	5.87	0.44	2.76e-8	Neuroticism;
UCEC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	5.53	0.41	1.44e-7	Initial pursuit acceleration;
UCEC	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.74	6.86	0.49	1.79e-10	Morning vs. evening chronotype;
UCEC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.49	5.08	0.39	1.11e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.45	-4.75	-0.36	4.77e-6	Longevity;
UCEC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.52	-0.53	4.88e-12	Exhaled nitric oxide output;
UCEC	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.44	-4.87	-0.37	2.9e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	5.08	0.39	1.13e-6	Headache;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.53	-5.77	-0.43	4.58e-8	Pubertal anthropometrics;
UCEC	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	0.94	5.66	0.42	7.64e-8	Gut microbiota (bacterial taxa);
UCEC	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.75	-9.97	-0.64	3.33e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.13	0.39	8.9e-7	Menarche (age at onset);
UCEC	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.51	5.22	0.4	5.92e-7	Mean corpuscular hemoglobin;
UCEC	trans	rs4146922	0.793	rs62167689	chr2:56009480	A/T	cg20168479	chr3:32443031	CMTM7	0.67	6.68	0.48	4.66e-10	Height;
UCEC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.35	-0.4	3.35e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-6.41	-0.47	1.86e-9	Platelet count;
UCEC	cis	rs78761021	0.685	rs17744107	chr17:9795735	C/G	cg26853458	chr17:9805074	RCVRN	-0.38	-4.86	-0.37	2.95e-6	Type 2 diabetes;
UCEC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.63	-7.25	-0.51	2.23e-11	Body mass index;
UCEC	cis	rs4824093	0.544	rs73443951	chr22:50301251	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-4.62	-0.36	8.35e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg19554555	chr3:13937349	NA	0.59	5.92	0.44	2.16e-8	Ovarian reserve;
UCEC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.68	5.9	0.44	2.39e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs6684428	0.901	rs7516605	chr1:56343290	A/C	cg11651538	chr1:56320950	NA	-0.76	-6.41	-0.47	1.89e-9	Airflow obstruction;
UCEC	cis	rs12579753	0.692	rs9943807	chr12:82279404	T/A	cg07988820	chr12:82153109	PPFIA2	-0.61	-5.43	-0.41	2.3e-7	Resting heart rate;
UCEC	cis	rs7804356	0.813	rs76438067	chr7:26911904	C/T	cg02693607	chr7:27150598	HOXA3	0.57	4.64	0.36	7.81e-6	Type 1 diabetes;
UCEC	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg21770322	chr7:97807741	LMTK2	0.81	12.42	0.72	1.13e-24	Breast cancer;
UCEC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	7.6	0.53	3.21e-12	Bone mineral density;
UCEC	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.87	-9.53	-0.62	4.62e-17	Obesity-related traits;
UCEC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.6	-6.47	-0.47	1.39e-9	Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.77	-9.07	-0.6	6.94e-16	Leprosy;
UCEC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10789491	0.767	rs1595898	chr1:47193577	G/A	cg15501359	chr1:47185051	KIAA0494	0.83	6.4	0.47	1.99e-9	Response to hepatitis C treatment;
UCEC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7072216	0.881	rs2147895	chr10:100148308	T/G	cg19567339	chr10:100142640	NA	0.64	8.74	0.58	4.83e-15	Metabolite levels;
UCEC	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.49e-8	Depression;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.0	0.7	1.5e-23	Prudent dietary pattern;
UCEC	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.14	0.39	8.59e-7	Rheumatoid arthritis;
UCEC	cis	rs953387	1.000	rs10179271	chr2:136910834	T/C	cg07169764	chr2:136633963	MCM6	0.53	5.45	0.41	2.06e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg02461776	chr11:598696	PHRF1	0.44	4.66	0.36	6.9e-6	Systemic lupus erythematosus;
UCEC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	4.62	0.36	8.47e-6	Longevity;
UCEC	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.13	14.28	0.76	1.45e-29	Schizophrenia;
UCEC	cis	rs17106184	1.000	rs72902778	chr1:51276715	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs13177918	0.603	rs2343806	chr5:149831985	A/T	cg14059543	chr5:149831962	NA	-0.65	-6.28	-0.46	3.67e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs6546886	0.917	rs12713803	chr2:74238681	A/G	cg14702570	chr2:74259524	NA	-0.45	-5.76	-0.43	4.76e-8	Dialysis-related mortality;
UCEC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.88	-8.85	-0.59	2.53e-15	Prudent dietary pattern;
UCEC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	8.95	0.59	1.41e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg04851639	chr8:1020857	NA	-0.43	-5.62	-0.42	9.2e-8	Schizophrenia;
UCEC	cis	rs8032158	0.963	rs56333939	chr15:56124535	T/C	cg10433327	chr15:56209506	NEDD4	-0.31	-5.07	-0.39	1.19e-6	Keloid;
UCEC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.48	-4.85	-0.37	3.18e-6	Calcium levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16265552	chr3:113667068	ZDHHC23	0.55	7.11	0.51	4.58e-11	Warfarin maintenance dose;
UCEC	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.8	0.37	3.94e-6	Multiple sclerosis;
UCEC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.8	-8.79	-0.59	3.73e-15	Breast cancer;
UCEC	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.65	-0.48	5.47e-10	Crohn's disease;
UCEC	cis	rs7246967	0.611	rs34806882	chr19:22880104	T/C	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9309473	0.519	rs2421670	chr2:73886661	T/G	cg20560298	chr2:73613845	ALMS1	0.53	5.04	0.38	1.34e-6	Metabolite levels;
UCEC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.83	-0.37	3.46e-6	Gut microbiome composition (summer);
UCEC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.74	6.39	0.47	2.1e-9	Blood metabolite levels;
UCEC	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.58	5.06	0.39	1.21e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.96	6.62	0.48	6.33e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.79e-11	Eye color traits;
UCEC	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.95	-7.31	-0.52	1.61e-11	Exhaled nitric oxide output;
UCEC	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg01072550	chr1:21505969	NA	-0.57	-5.82	-0.43	3.48e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.68	-4.94	-0.38	2.06e-6	Mean platelet volume;
UCEC	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg13750949	chr14:105293957	NA	0.55	5.96	0.44	1.75e-8	IgG glycosylation;
UCEC	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.69	-7.57	-0.53	3.73e-12	Hypospadias;
UCEC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.63	0.36	7.81e-6	Menopause (age at onset);
UCEC	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.25	-0.4	5.19e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.54	4.55	0.35	1.1e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs2588809	0.941	rs7155764	chr14:68720610	A/G	cg01928902	chr14:69259640	ZFP36L1	-0.62	-4.8	-0.37	3.86e-6	Breast cancer;
UCEC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.65e-16	Height;
UCEC	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	0.83	6.5	0.47	1.17e-9	Lymphocyte counts;
UCEC	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.5	4.81	0.37	3.67e-6	Endometrial cancer;
UCEC	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg15837086	chr1:46506065	PIK3R3	-0.39	-4.91	-0.38	2.35e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.35	0.52	1.31e-11	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.54	5.25	0.4	5.24e-7	Bone properties (heel);
UCEC	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-6.36	-0.46	2.39e-9	HDL cholesterol;
UCEC	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.11	0.45	8.64e-9	Personality dimensions;
UCEC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.11	6.45	0.47	1.55e-9	Eosinophil percentage of granulocytes;
UCEC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.35	5.63	0.42	8.97e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.68	8.15	0.56	1.43e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs10924970	0.967	rs3845566	chr1:235449757	T/A	cg26050004	chr1:235667680	B3GALNT2	0.45	4.74	0.36	5.03e-6	Asthma;
UCEC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.47	5.39	0.41	2.77e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg04896959	chr15:78267971	NA	-0.37	-4.78	-0.37	4.28e-6	Sudden cardiac arrest;
UCEC	cis	rs6834538	1.000	rs2351761	chr4:113447911	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	4.73	0.36	5.31e-6	Free thyroxine concentration;
UCEC	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.75	5.03	0.38	1.38e-6	Iron status biomarkers;
UCEC	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.59	5.55	0.42	1.3e-7	Skin colour saturation;
UCEC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg06784218	chr1:46089804	CCDC17	0.55	6.46	0.47	1.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.69	-7.5	-0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs409224	0.533	rs28603325	chr7:101740277	G/T	cg08135718	chr7:101819329	CUX1	0.5	5.32	0.4	3.79e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg04837898	chr3:45731254	SACM1L	-0.41	-4.56	-0.35	1.05e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs829661	0.843	rs829632	chr2:30733617	G/A	cg17749961	chr2:30669863	LCLAT1	0.61	5.47	0.41	1.86e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.04	-0.55	2.73e-13	Total cholesterol levels;
UCEC	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg02158880	chr13:53174818	NA	0.39	4.52	0.35	1.28e-5	Lewy body disease;
UCEC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg24826892	chr11:71159390	DHCR7	0.52	5.05	0.38	1.26e-6	Vitamin D levels;
UCEC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.52	-7.0	-0.5	8.24e-11	Eye color traits;
UCEC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.56	-5.72	-0.43	5.73e-8	Longevity;Endometriosis;
UCEC	cis	rs8105895	0.935	rs62110981	chr19:22246013	A/G	cg02912127	chr19:22235281	ZNF257	-0.64	-5.35	-0.4	3.29e-7	Body mass index (change over time);
UCEC	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.29	10.03	0.64	2.35e-18	Uric acid levels;
UCEC	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.77	4.8	0.37	3.9e-6	Glioblastoma;
UCEC	cis	rs9309473	1.000	rs6546838	chr2:73679280	A/G	cg20560298	chr2:73613845	ALMS1	-0.65	-5.87	-0.44	2.74e-8	Metabolite levels;
UCEC	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs7709377	0.521	rs7723358	chr5:115548365	A/G	cg23108291	chr5:115420582	COMMD10	0.6	6.25	0.46	4.25e-9	Metabolite levels  (X-11787);
UCEC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	0.61	7.31	0.52	1.57e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.62	5.95	0.44	1.85e-8	Aortic root size;
UCEC	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.56	-5.34	-0.4	3.46e-7	Plateletcrit;Platelet count;
UCEC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg09654669	chr8:57350985	NA	-0.54	-6.05	-0.45	1.14e-8	Obesity-related traits;
UCEC	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-4.57	-0.35	1.02e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.76	6.41	0.47	1.87e-9	Longevity;
UCEC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg19805062	chr22:46654627	PKDREJ	0.46	4.64	0.36	7.53e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.61	6.04	0.45	1.2e-8	Lung cancer;
UCEC	cis	rs10924970	0.967	rs10754588	chr1:235438205	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.74e-6	Asthma;
UCEC	cis	rs1832871	0.521	rs62437409	chr6:158820221	G/C	cg07215822	chr6:158701037	NA	-0.55	-4.72	-0.36	5.46e-6	Height;
UCEC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg23217946	chr19:22817039	ZNF492	0.41	4.54	0.35	1.17e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.57	5.17	0.39	7.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.48	0.77	4.23e-30	Height;
UCEC	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.45	4.58	0.35	9.95e-6	Blood metabolite levels;
UCEC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg13695892	chr22:41940480	POLR3H	0.68	5.34	0.4	3.43e-7	Vitiligo;
UCEC	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.62	-6.87	-0.49	1.71e-10	Magnesium levels;
UCEC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.55	6.23	0.46	4.55e-9	Vitiligo;
UCEC	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-5.22	-0.4	6.01e-7	Kawasaki disease;
UCEC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.2e-5	Chronic sinus infection;
UCEC	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	0.92	5.68	0.42	7.02e-8	Skin colour saturation;
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg06238570	chr21:40685208	BRWD1	0.78	7.71	0.54	1.73e-12	Cognitive function;
UCEC	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.54	-5.3	-0.4	4.11e-7	Retinal vascular caliber;
UCEC	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.66	-6.46	-0.47	1.46e-9	Platelet distribution width;
UCEC	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.79	9.6	0.62	3.13e-17	Menarche (age at onset);
UCEC	cis	rs7709377	0.546	rs712561	chr5:115552945	G/T	cg23108291	chr5:115420582	COMMD10	-0.61	-6.3	-0.46	3.27e-9	Metabolite levels  (X-11787);
UCEC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.94	0.38	2.08e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10208940	0.920	rs35878577	chr2:68737456	C/T	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.56	-4.9	-0.37	2.49e-6	Carotid intima media thickness;
UCEC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	0.72	4.89	0.37	2.66e-6	Diabetic retinopathy;
UCEC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-5.63	-0.42	8.92e-8	Colorectal cancer;
UCEC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg14078730	chr11:63896557	MACROD1	0.63	4.87	0.37	2.79e-6	Mean platelet volume;
UCEC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg22166914	chr1:53195759	ZYG11B	0.76	7.97	0.55	4.06e-13	Monocyte count;
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.5	4.82	0.37	3.52e-6	Menarche (age at onset);
UCEC	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg00074818	chr8:8560427	CLDN23	0.39	4.74	0.36	5.1e-6	Neuroticism;
UCEC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.55	-5.74	-0.43	5.11e-8	Red cell distribution width;
UCEC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.73	6.43	0.47	1.68e-9	Cognitive function;
UCEC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg05991184	chr2:219186017	PNKD	0.53	5.86	0.43	2.98e-8	Colorectal cancer;
UCEC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg17330251	chr7:94953956	PON1	-0.54	-4.96	-0.38	1.96e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs78487399	0.908	rs6715003	chr2:43808659	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-4.6	-0.35	9.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg24687543	chr11:63912206	MACROD1	0.41	4.62	0.36	8.19e-6	Platelet count;
UCEC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.43e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.53	8.2	0.56	1.09e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.94	0.38	2.08e-6	Breast cancer;
UCEC	cis	rs7870753	0.838	rs10820739	chr9:99263821	A/G	cg25260653	chr9:99212216	HABP4	0.56	5.5	0.41	1.62e-7	Height;
UCEC	cis	rs6893207	0.661	rs6892949	chr5:16374727	A/C	cg11584519	chr5:16175867	MARCH11	-0.78	-4.94	-0.38	2.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs7246967	0.611	rs62118823	chr19:22844066	A/G	cg08271804	chr19:22816896	ZNF492	0.67	6.69	0.48	4.42e-10	Bronchopulmonary dysplasia;
UCEC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.76	10.19	0.64	8.63e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs883565	0.543	rs35628459	chr3:39174437	T/A	cg01426195	chr3:39028469	NA	0.66	7.8	0.54	1.04e-12	Handedness;
UCEC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.49	5.68	0.42	7.02e-8	Aortic root size;
UCEC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.79	0.49	2.55e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.59	6.21	0.46	5.16e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.72	-9.36	-0.61	1.25e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg22166914	chr1:53195759	ZYG11B	0.8	8.4	0.57	3.51e-14	Monocyte count;
UCEC	cis	rs56341938	0.640	rs9823097	chr3:168831430	G/C	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.73	7.54	0.53	4.54e-12	Breast cancer;
UCEC	cis	rs4372836	0.729	rs11684695	chr2:29088450	G/T	cg09522027	chr2:28974177	PPP1CB	0.85	9.23	0.61	2.71e-16	Body mass index;
UCEC	cis	rs7095607	0.560	rs2673794	chr10:69926097	T/C	cg18986048	chr10:69913749	MYPN	0.45	4.87	0.37	2.8e-6	Lung function (FVC);
UCEC	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	9.3	0.61	1.86e-16	Mean platelet volume;
UCEC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.22	0.4	6.02e-7	Rheumatoid arthritis;
UCEC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6416877	0.921	rs6502685	chr17:1334980	G/C	cg09375892	chr17:708413	NXN	-0.61	-4.56	-0.35	1.08e-5	Myeloid white cell count;
UCEC	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.64	6.37	0.46	2.33e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12618769	0.597	rs2278208	chr2:99154229	C/T	cg10123293	chr2:99228465	UNC50	0.44	4.7	0.36	5.97e-6	Bipolar disorder;
UCEC	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg14092571	chr14:90743983	NA	-0.37	-4.76	-0.37	4.55e-6	Mortality in heart failure;
UCEC	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg27432699	chr2:27873401	GPN1	0.51	4.9	0.37	2.52e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.79	-11.14	-0.68	2.88e-21	Vitiligo;
UCEC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg06521331	chr12:34319734	NA	-0.52	-4.61	-0.36	8.56e-6	Morning vs. evening chronotype;
UCEC	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.6	-5.75	-0.43	4.88e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs2241437	0.590	rs13394423	chr2:86840691	C/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.98	-4.5	-0.35	1.36e-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure);
UCEC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs975730	0.966	rs5002195	chr8:129347538	T/G	cg14920061	chr8:129326392	NA	0.39	4.85	0.37	3.09e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1161463	0.958	rs1417764	chr13:29421852	G/A	cg00806704	chr13:28539042	CDX2	0.38	4.55	0.35	1.12e-5	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
UCEC	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	0.64	4.7	0.36	5.98e-6	Schizophrenia;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.88	10.57	0.66	8.8e-20	Menarche (age at onset);
UCEC	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.82	0.43	3.53e-8	Monocyte percentage of white cells;
UCEC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.5	4.78	0.37	4.26e-6	Menopause (age at onset);
UCEC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	0.77	8.16	0.56	1.38e-13	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.61	-5.01	-0.38	1.55e-6	Obesity-related traits;
UCEC	cis	rs13065560	0.659	rs6599266	chr3:38926912	C/G	cg01426195	chr3:39028469	NA	-0.48	-4.94	-0.38	2.1e-6	Interleukin-18 levels;
UCEC	cis	rs9346649	0.616	rs1873337	chr6:168492160	T/G	cg09046490	chr6:168390201	NA	-0.38	-4.51	-0.35	1.34e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
UCEC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-5.71	-0.43	6.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg15358701	chr1:161410459	NA	-0.74	-5.07	-0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg19610905	chr11:61596333	FADS2	-0.55	-5.1	-0.39	1.05e-6	Trans fatty acid levels;
UCEC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.66	-6.54	-0.47	9.32e-10	Breast cancer;
UCEC	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	0.88	4.95	0.38	1.98e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.54	-5.05	-0.38	1.31e-6	Cognitive function;
UCEC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-4.92	-0.38	2.26e-6	Colorectal cancer;
UCEC	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.07	0.39	1.2e-6	Lung cancer in ever smokers;
UCEC	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-4.92	-0.38	2.28e-6	Height;
UCEC	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.48	-5.68	-0.42	7.08e-8	Subjective well-being;
UCEC	cis	rs1335645	0.570	rs2165145	chr1:111625213	C/T	cg00321911	chr1:111669324	DRAM2	-0.66	-4.65	-0.36	7.2e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.6	5.7	0.43	6.22e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.53	5.51	0.41	1.58e-7	Post bronchodilator FEV1;
UCEC	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.6e-9	Motion sickness;
UCEC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg04804543	chr8:142233427	SLC45A4	-0.5	-5.96	-0.44	1.81e-8	Immature fraction of reticulocytes;
UCEC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.63	-6.74	-0.49	3.36e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.57	5.25	0.4	5.28e-7	Corneal astigmatism;
UCEC	cis	rs253959	0.734	rs6897517	chr5:115705696	G/T	cg23108291	chr5:115420582	COMMD10	0.49	4.9	0.37	2.53e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11760485	0.965	rs5021673	chr7:4399638	C/G	cg15613991	chr7:5277080	NA	0.45	5.32	0.4	3.86e-7	Early childhood aggressive behavior;
UCEC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.54	-6.21	-0.46	5.03e-9	Bipolar disorder;
UCEC	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg18681998	chr4:17616180	MED28	0.83	10.84	0.67	1.7e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.59	-6.51	-0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.53	5.88	0.44	2.62e-8	Mean corpuscular volume;
UCEC	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.63	-5.97	-0.44	1.74e-8	Brugada syndrome;
UCEC	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.68	5.87	0.44	2.76e-8	Adiposity;
UCEC	cis	rs631288	0.793	rs10793659	chr1:146763438	A/G	cg25205988	chr1:146714368	CHD1L	0.77	4.85	0.37	3.17e-6	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg26061582	chr7:22766209	IL6	0.59	5.48	0.41	1.83e-7	Lung cancer;
UCEC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.96	8.09	0.56	2.02e-13	Obesity-related traits;
UCEC	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg18490616	chr2:88469792	THNSL2	0.91	4.88	0.37	2.68e-6	Plasma clusterin levels;
UCEC	cis	rs7267005	0.661	rs75792504	chr20:34425383	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs2455799	1.000	rs11923804	chr3:15827664	C/A	cg16303742	chr3:15540471	COLQ	-0.41	-4.77	-0.37	4.36e-6	Mean platelet volume;
UCEC	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.34	4.54	0.35	1.18e-5	Age of smoking initiation;
UCEC	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.49	-4.82	-0.37	3.51e-6	Pediatric autoimmune diseases;
UCEC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.13	-6.5	-0.47	1.16e-9	Breast cancer;
UCEC	cis	rs10746514	0.813	rs9724918	chr1:232248087	C/T	cg09506761	chr1:232265262	NA	0.53	5.36	0.4	3.15e-7	Response to statin therapy;
UCEC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs2194112	chr19:22926189	A/C	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg24375607	chr4:120327624	NA	0.48	5.05	0.38	1.32e-6	Corneal astigmatism;
UCEC	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg08027265	chr7:2291960	NA	-0.51	-5.3	-0.4	4.07e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.49	5.75	0.43	5.05e-8	Height;
UCEC	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.5	6.16	0.45	6.47e-9	Subjective well-being (multi-trait analysis);
UCEC	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.64	-6.73	-0.49	3.63e-10	Systemic sclerosis;
UCEC	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.45	-4.86	-0.37	2.96e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7523273	1.000	rs34385765	chr1:207993637	A/G	cg22525895	chr1:207977042	MIR29B2	-0.51	-4.75	-0.36	4.77e-6	Schizophrenia;
UCEC	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.58	-5.49	-0.41	1.75e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.21	0.39	6.42e-7	Cognitive test performance;
UCEC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.36	-5.11	-0.39	1.01e-6	Longevity;
UCEC	cis	rs6921919	0.848	rs56131013	chr6:28320677	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.59	-0.35	9.39e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.27	-0.4	4.72e-7	Blood metabolite levels;
UCEC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.7	-8.56	-0.58	1.35e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12618769	0.597	rs10514774	chr2:99028695	A/G	cg14361474	chr2:99058762	NA	-0.49	-4.83	-0.37	3.46e-6	Bipolar disorder;
UCEC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.59	6.34	0.46	2.6e-9	Longevity;Endometriosis;
UCEC	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.48	5.38	0.41	2.84e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.39	0.61	1.09e-16	Platelet count;
UCEC	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.65	4.61	0.36	8.66e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs4146922	0.793	rs62167688	chr2:56009382	C/A	cg03313676	chr20:62526047	DNAJC5	0.71	7.23	0.51	2.39e-11	Height;
UCEC	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.49	5.26	0.4	4.93e-7	Headache;
UCEC	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.75	-8.37	-0.57	4.03e-14	White blood cell count (basophil);
UCEC	cis	rs953387	1.000	rs12616955	chr2:136902666	C/T	cg07169764	chr2:136633963	MCM6	0.53	5.29	0.4	4.28e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	4.76	0.37	4.61e-6	Mood instability;
UCEC	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-5.1	-0.39	1.02e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg22974920	chr21:40686053	BRWD1	0.55	4.86	0.37	3e-6	Cognitive function;
UCEC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg12463550	chr7:65579703	CRCP	0.49	4.66	0.36	6.89e-6	Aortic root size;
UCEC	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs600626	0.541	rs11236528	chr11:75469476	T/C	cg24262691	chr11:75473276	NA	0.37	4.56	0.35	1.08e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.55	7.89	0.55	6.32e-13	Total body bone mineral density;
UCEC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.8	-8.94	-0.59	1.52e-15	Breast cancer;
UCEC	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.54	5.02	0.38	1.5e-6	Platelet count;
UCEC	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.65	-7.42	-0.52	8.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.36	0.61	1.24e-16	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-0.94	-6.02	-0.44	1.32e-8	Breast cancer;
UCEC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.55	5.4	0.41	2.59e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs4372836	0.930	rs7607844	chr2:28971738	T/A	cg09522027	chr2:28974177	PPP1CB	-0.77	-7.7	-0.54	1.85e-12	Body mass index;
UCEC	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.15	-0.39	8.36e-7	High light scatter reticulocyte count;
UCEC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.5	5.01	0.38	1.54e-6	Monocyte count;
UCEC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.44	5.28	0.4	4.63e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.85	0.49	1.91e-10	Motion sickness;
UCEC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg02160872	chr5:212506	CCDC127	-0.64	-6.46	-0.47	1.46e-9	Breast cancer;
UCEC	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.23	0.51	2.49e-11	Coffee consumption (cups per day);
UCEC	cis	rs4150161	0.591	rs3759977	chr16:84221170	T/A	cg10106505	chr16:84220380	TAF1C	-1.07	-5.14	-0.39	8.52e-7	Systolic blood pressure response to hydrochlorothiazide in hypertension;
UCEC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg06096015	chr1:231504339	EGLN1	0.46	5.34	0.4	3.51e-7	Hemoglobin concentration;
UCEC	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.53	5.91	0.44	2.33e-8	Menarche (age at onset);
UCEC	cis	rs7088591	0.867	rs60971133	chr10:59787524	T/G	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9467711	0.606	rs9393735	chr6:26582327	A/G	cg09904177	chr6:26538194	HMGN4	-0.83	-5.01	-0.38	1.56e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.62	6.65	0.48	5.37e-10	Neuroticism;
UCEC	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg00086871	chr4:6988644	TBC1D14	0.67	4.72	0.36	5.48e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs73206853	0.841	rs55885183	chr12:110877682	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs731174	0.759	rs575254	chr1:38149692	C/G	cg06917450	chr1:38156652	C1orf109	-0.58	-6.08	-0.45	9.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1372520	0.564	rs356197	chr4:90682750	G/A	cg15133208	chr4:90757351	SNCA	0.56	6.28	0.46	3.6e-9	Neuroticism;
UCEC	cis	rs12618769	0.652	rs2276603	chr2:99205962	C/T	cg10123293	chr2:99228465	UNC50	-0.5	-5.5	-0.41	1.66e-7	Bipolar disorder;
UCEC	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.58	-6.05	-0.45	1.13e-8	IgG glycosylation;
UCEC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.52	-4.51	-0.35	1.32e-5	Coronary artery disease;
UCEC	cis	rs7968440	1.000	rs2684898	chr12:51046825	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.59	0.35	9.32e-6	Fibrinogen;
UCEC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.58	5.33	0.4	3.67e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7072216	0.770	rs942810	chr10:100167860	G/C	cg19567339	chr10:100142640	NA	0.5	5.89	0.44	2.52e-8	Metabolite levels;
UCEC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	4.93	0.38	2.16e-6	Breast cancer;
UCEC	cis	rs6493487	0.505	rs11070814	chr15:51096567	A/G	cg20651644	chr15:50170642	ATP8B4	0.55	4.74	0.36	5.02e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.77	8.03	0.55	2.87e-13	Joint mobility (Beighton score);
UCEC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.53	6.52	0.47	1.05e-9	Total body bone mineral density;
UCEC	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.86	8.22	0.56	1e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.69	-0.42	6.71e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.52	-5.23	-0.4	5.85e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.66	6.77	0.49	2.84e-10	Systemic lupus erythematosus;
UCEC	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	5.38	0.41	2.89e-7	Response to antipsychotic treatment;
UCEC	cis	rs6746896	0.636	rs7586317	chr2:97447831	T/A	cg01950434	chr2:97203154	ARID5A	-0.46	-5.08	-0.39	1.14e-6	Bipolar disorder;
UCEC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg26688816	chr2:46740690	ATP6V1E2	0.64	6.19	0.45	5.62e-9	HDL cholesterol;
UCEC	cis	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18132159	chr1:238110295	NA	-0.4	-4.57	-0.35	1e-5	Pancreatic cancer;
UCEC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.97	5.35	0.4	3.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4662945	0.688	rs10496679	chr2:130201113	G/A	cg05962382	chr2:130345044	NA	-0.46	-5.27	-0.4	4.67e-7	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.57	6.27	0.46	3.81e-9	Crohn's disease;
UCEC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg23018236	chr17:30244563	NA	-0.69	-4.9	-0.37	2.54e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.48	-5.3	-0.4	4.09e-7	Depression;
UCEC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.83	8.17	0.56	1.27e-13	Cognitive function;
UCEC	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.57	-5.77	-0.43	4.42e-8	Pediatric autoimmune diseases;
UCEC	cis	rs838147	0.844	rs8104897	chr19:49249814	C/A	cg13540341	chr19:49222985	MAMSTR	0.37	4.62	0.36	8.2e-6	Dietary macronutrient intake;
UCEC	cis	rs11697848	1.000	rs78873470	chr20:48556099	C/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs2998286	0.541	rs332180	chr10:28910095	C/T	cg07964848	chr10:28035894	MKX	0.7	5.11	0.39	9.92e-7	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
UCEC	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg06917450	chr1:38156652	C1orf109	-0.54	-5.01	-0.38	1.56e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9512730	0.517	rs1967772	chr13:28036062	G/A	cg04070771	chr13:27998621	GTF3A	0.54	4.54	0.35	1.19e-5	Schizophrenia;
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg22852734	chr6:133119734	C6orf192	0.87	6.62	0.48	6.18e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg19318889	chr4:1322082	MAEA	0.48	5.1	0.39	1.03e-6	Obesity-related traits;
UCEC	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg27246729	chr12:121163418	ACADS	0.54	4.63	0.36	7.82e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.81	-9.63	-0.62	2.51e-17	White blood cell count (basophil);
UCEC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg05738196	chr6:26577821	NA	0.58	6.22	0.46	4.91e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-6.29	-0.46	3.37e-9	Platelet count;
UCEC	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.5	5.61	0.42	9.7e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2862064	0.932	rs1553316	chr5:156479509	A/G	cg12943317	chr5:156479607	HAVCR1	-0.65	-5.01	-0.38	1.57e-6	Platelet count;
UCEC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.68	4.53	0.35	1.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg13575925	chr12:9217583	LOC144571	0.41	4.9	0.37	2.53e-6	Sjögren's syndrome;
UCEC	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.56	0.53	3.96e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs729050	1.000	rs10135985	chr14:94099542	C/T	cg10861390	chr14:94442922	NA	0.32	4.52	0.35	1.24e-5	Body mass index;
UCEC	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.52	-5.3	-0.4	4.18e-7	Asthma;
UCEC	cis	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg12524725	chr2:239427019	NA	-0.67	-4.53	-0.35	1.21e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.53	4.8	0.37	3.83e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6584283	0.846	rs11190135	chr10:101286848	A/G	cg09788492	chr10:101292477	NKX2-3	0.42	4.58	0.35	9.79e-6	Ulcerative colitis;
UCEC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.65	-0.42	8.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07308232	chr7:1071921	C7orf50	-0.57	-5.81	-0.43	3.71e-8	Longevity;Endometriosis;
UCEC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.59	5.6	0.42	1.02e-7	Schizophrenia;
UCEC	cis	rs11867410	0.744	rs73992145	chr17:63949812	C/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs925550	0.932	rs12501008	chr4:123597440	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	-0.65	-5.79	-0.43	4.16e-8	Primary biliary cholangitis;
UCEC	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.77	0.37	4.43e-6	Personality dimensions;
UCEC	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.73	6.49	0.47	1.22e-9	Caudate activity during reward;
UCEC	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-9.32	-0.61	1.64e-16	Coffee consumption (cups per day);
UCEC	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.64	-8.23	-0.56	9.07e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.74	-7.53	-0.53	4.7e-12	Diastolic blood pressure;
UCEC	cis	rs6486730	0.534	rs4760583	chr12:129271508	T/C	cg04043695	chr12:129287642	SLC15A4	0.54	5.33	0.4	3.62e-7	Systemic lupus erythematosus;
UCEC	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.77	-8.01	-0.55	3.17e-13	Lung cancer;
UCEC	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.73	-6.83	-0.49	2.07e-10	Prostate cancer;
UCEC	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.3e-9	Coffee consumption (cups per day);
UCEC	cis	rs12681287	0.752	rs1080170	chr8:87310108	C/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.29	-0.46	3.36e-9	Caudate activity during reward;
UCEC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.61	6.72	0.49	3.64e-10	Hemoglobin concentration;
UCEC	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.63	8.09	0.56	2.02e-13	Weight;
UCEC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.72	-7.85	-0.54	8.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-4.63	-0.36	8.07e-6	Rheumatoid arthritis;
UCEC	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.76	7.14	0.51	4.01e-11	Height;
UCEC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.8	-6.43	-0.47	1.67e-9	Birth weight;
UCEC	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.67	-4.65	-0.36	7.32e-6	Body mass index;
UCEC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.61	6.88	0.49	1.59e-10	Pulmonary function decline;
UCEC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg14008862	chr17:28927542	LRRC37B2	0.73	5.05	0.38	1.27e-6	Body mass index;
UCEC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg13695892	chr22:41940480	POLR3H	-0.64	-4.96	-0.38	1.94e-6	Vitiligo;
UCEC	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.41	-4.98	-0.38	1.76e-6	Refractive error;
UCEC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-1.13	-7.01	-0.5	7.89e-11	Height;
UCEC	cis	rs6688613	0.685	rs10918599	chr1:166918786	T/C	cg07049167	chr1:166818506	POGK	0.54	5.18	0.39	7.11e-7	Refractive astigmatism;
UCEC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.6	0.42	1.01e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.83	6.88	0.49	1.58e-10	Gastritis;
UCEC	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.71	6.4	0.47	1.98e-9	Subjective well-being;
UCEC	cis	rs10242455	0.702	rs3823813	chr7:99049389	G/A	cg18809830	chr7:99032528	PTCD1	-0.89	-5.04	-0.38	1.34e-6	Blood metabolite levels;
UCEC	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.59	5.43	0.41	2.32e-7	Tonsillectomy;
UCEC	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.49	-5.95	-0.44	1.85e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.85	-10.77	-0.66	2.67e-20	White blood cell count (basophil);
UCEC	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.6	-5.18	-0.39	7.11e-7	Psoriasis vulgaris;
UCEC	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg20825769	chr15:43991375	CKMT1A	-0.55	-4.52	-0.35	1.25e-5	Lung cancer in ever smokers;
UCEC	cis	rs2502731	0.583	rs3003579	chr9:130995751	C/G	cg13642260	chr9:130955380	CIZ1	0.55	6.14	0.45	7.5e-9	Attention deficit hyperactivity disorder;
UCEC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.58	-5.45	-0.41	2.12e-7	Blood protein levels;
UCEC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.54	-6.15	-0.45	7.07e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.61	5.21	0.39	6.29e-7	Bipolar disorder;
UCEC	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.59	5.34	0.4	3.45e-7	Corneal astigmatism;
UCEC	cis	rs6499129	0.702	rs9934160	chr16:67211447	C/T	cg05986853	chr16:67920209	NRN1L	0.65	4.69	0.36	6.21e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.55	0.62	4.23e-17	Platelet count;
UCEC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-6.14	-0.45	7.31e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.6	-6.19	-0.45	5.56e-9	Eye color traits;
UCEC	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.8	0.37	3.94e-6	Multiple sclerosis;
UCEC	cis	rs12681287	0.752	rs4534114	chr8:87271956	A/G	cg27223183	chr8:87520930	FAM82B	-0.61	-5.11	-0.39	9.8e-7	Caudate activity during reward;
UCEC	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.45	4.66	0.36	7.13e-6	Schizophrenia;
UCEC	cis	rs540425	0.873	rs217376	chr7:44610490	A/G	cg07840972	chr7:44621897	TMED4	-0.51	-4.81	-0.37	3.76e-6	Schizophrenia;
UCEC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg05501817	chr11:14380813	RRAS2	-0.52	-5.06	-0.39	1.23e-6	Vitamin D levels;
UCEC	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.53	-5.29	-0.4	4.34e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.6	-5.18	-0.39	7.08e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg19554555	chr3:13937349	NA	-0.53	-5.53	-0.41	1.43e-7	Ovarian reserve;
UCEC	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.56	4.68	0.36	6.47e-6	Lung cancer;
UCEC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.81	0.37	3.65e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.48	0.47	1.29e-9	Bone mineral density;
UCEC	cis	rs6424115	0.830	rs6658703	chr1:24203416	G/T	cg15997130	chr1:24165203	NA	0.65	6.76	0.49	3.04e-10	Immature fraction of reticulocytes;
UCEC	cis	rs12980942	1.000	rs12972266	chr19:41810771	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.95	0.44	1.87e-8	Coronary artery disease;
UCEC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.53	4.99	0.38	1.69e-6	Menopause (age at onset);
UCEC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.79	7.95	0.55	4.53e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg03859395	chr2:55845619	SMEK2	1.03	15.11	0.78	1.03e-31	Metabolic syndrome;
UCEC	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.85	6.95	0.5	1.11e-10	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.9	-0.67	1.24e-20	Headache;
UCEC	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.29	-4.55	-0.35	1.11e-5	Mean corpuscular volume;
UCEC	cis	rs6893207	0.661	rs74569281	chr5:16392372	A/G	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-6.14	-0.45	7.17e-9	Platelet count;
UCEC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.67	-6.48	-0.47	1.32e-9	Pancreatic cancer;
UCEC	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg25410123	chr5:131825865	IRF1	-0.45	-4.58	-0.35	1e-5	Blood metabolite levels;
UCEC	cis	rs3780378	0.967	rs7043371	chr9:5040203	T/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.69	-0.36	6.07e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.45	5.2	0.39	6.66e-7	Caffeine consumption;
UCEC	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.52	5.96	0.44	1.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	1.000	rs936525	chr19:23056189	C/T	cg24889512	chr19:22816950	ZNF492	0.49	5.16	0.39	7.71e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.84	10.54	0.66	1.08e-19	Mortality in heart failure;
UCEC	cis	rs9341808	0.591	rs6454147	chr6:80916328	G/A	cg08355045	chr6:80787529	NA	0.41	5.15	0.39	8.25e-7	Sitting height ratio;
UCEC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.81	-0.37	3.65e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.47	0.52	6.66e-12	Smoking behavior;
UCEC	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	trans	rs1923243	0.649	rs7525762	chr1:73371816	T/C	cg17780956	chr4:156297616	MAP9	-0.65	-6.88	-0.49	1.6e-10	Migraine;
UCEC	cis	rs6576086	1.000	rs6576086	chr14:105873144	A/G	cg19499452	chr14:105830721	PACS2	-0.56	-4.6	-0.35	8.96e-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.73	-5.58	-0.42	1.13e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.57	6.32	0.46	3e-9	Bone mineral density;
UCEC	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg25486957	chr4:152246857	NA	-0.55	-5.28	-0.4	4.46e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.35	5.29	0.4	4.31e-7	Ulcerative colitis;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.37	-0.47	2.27e-9	Pulmonary function;
UCEC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.67	5.15	0.39	8.13e-7	Diabetic retinopathy;
UCEC	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.52	-5.93	-0.44	2.09e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg04154034	chr17:28927549	LRRC37B2	0.74	4.97	0.38	1.87e-6	Body mass index;
UCEC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg01485075	chr19:22817371	ZNF492	0.41	4.51	0.35	1.3e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg15501526	chr10:2543763	NA	-0.47	-4.99	-0.38	1.66e-6	Age-related hearing impairment;
UCEC	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg14196790	chr5:131705035	SLC22A5	0.45	4.81	0.37	3.71e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14019695	chr9:139328340	INPP5E	0.47	5.44	0.41	2.15e-7	Monocyte percentage of white cells;
UCEC	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.59	6.29	0.46	3.5e-9	Blood metabolite ratios;
UCEC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg01262667	chr19:19385393	TM6SF2	0.49	6.56	0.48	8.8e-10	Tonsillectomy;
UCEC	cis	rs12428035	0.649	rs2129006	chr13:96739578	C/G	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg12024160	chr4:1254474	NA	0.54	6.87	0.49	1.7e-10	Obesity-related traits;
UCEC	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-6.22	-0.46	4.98e-9	Response to antipsychotic treatment;
UCEC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.55	-6.31	-0.46	3.1e-9	Cognitive function;
UCEC	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-8.27	-0.56	7.4e-14	Colorectal cancer;
UCEC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.8	-0.37	3.83e-6	Bone mineral density;
UCEC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.09	0.55	2.11e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.55	-5.49	-0.41	1.69e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.65	-6.01	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-9.44	-0.61	8.11e-17	Vitiligo;
UCEC	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg00852783	chr1:26633632	UBXN11	-0.53	-5.82	-0.43	3.5e-8	Obesity-related traits;
UCEC	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	4.84	0.37	3.21e-6	Height;
UCEC	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.63	6.38	0.47	2.22e-9	C-reactive protein levels;
UCEC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.52	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg24631222	chr15:78858424	CHRNA5	-0.74	-7.09	-0.5	5.33e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2415984	0.846	rs12185005	chr14:46833926	C/T	cg14871534	chr14:47121158	RPL10L	0.41	4.77	0.37	4.45e-6	Number of children ever born;
UCEC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06223018	chr3:49557076	DAG1	0.34	4.86	0.37	2.92e-6	Parkinson's disease;
UCEC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.91	5.0	0.38	1.64e-6	Inflammatory bowel disease;
UCEC	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.81	5.71	0.43	5.94e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	1.0	11.92	0.7	2.38e-23	Colorectal adenoma (advanced);
UCEC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.65	7.3	0.52	1.68e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs4654899	0.897	rs10916859	chr1:21087956	A/G	cg01072550	chr1:21505969	NA	-0.5	-4.98	-0.38	1.79e-6	Superior frontal gyrus grey matter volume;
UCEC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.77	-8.29	-0.56	6.5e-14	Height;
UCEC	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.87	-8.1	-0.56	1.9e-13	Breast cancer;
UCEC	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.53	4.81	0.37	3.68e-6	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.8	-9.18	-0.6	3.65e-16	Coronary artery disease;
UCEC	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.62	6.98	0.5	9.2e-11	Schizophrenia;
UCEC	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.69	-6.85	-0.49	1.89e-10	Colorectal cancer;
UCEC	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.54	-5.45	-0.41	2.09e-7	Neuroticism;
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg06466757	chr4:1255808	NA	0.45	4.68	0.36	6.46e-6	Obesity-related traits;
UCEC	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.44	4.61	0.36	8.8e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.62	-5.78	-0.43	4.37e-8	Colorectal cancer;
UCEC	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.11	4.92	0.38	2.31e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg05484376	chr2:27715224	FNDC4	0.33	4.51	0.35	1.29e-5	Total body bone mineral density;
UCEC	cis	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg20307385	chr11:47447363	PSMC3	0.59	5.29	0.4	4.32e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.51	-4.73	-0.36	5.22e-6	Height;
UCEC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.46	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-4.5	-0.35	1.36e-5	Life satisfaction;
UCEC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs11671653	0.688	rs112508627	chr19:10842063	A/G	cg10640764	chr19:11216364	LDLR	-0.86	-4.72	-0.36	5.48e-6	LDL cholesterol;
UCEC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg22907277	chr7:1156413	C7orf50	0.99	6.25	0.46	4.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.81	0.49	2.33e-10	Motion sickness;
UCEC	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.76	8.96	0.59	1.33e-15	Metabolic syndrome;
UCEC	cis	rs36051895	0.559	rs7858422	chr9:5209797	G/T	cg02405213	chr9:5042618	JAK2	-0.56	-5.0	-0.38	1.6e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	8.0	0.55	3.42e-13	Coronary artery disease;
UCEC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.8	-9.0	-0.6	1.06e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.49	5.33	0.4	3.58e-7	Emphysema distribution in smoking;
UCEC	cis	rs9309473	1.000	rs3738848	chr2:73761881	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.39	-0.41	2.73e-7	Metabolite levels;
UCEC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg18584368	chr5:314553	AHRR;PDCD6	0.52	4.76	0.37	4.61e-6	Breast cancer;
UCEC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26002218	chr14:103986227	CKB	0.34	4.82	0.37	3.51e-6	Body mass index;
UCEC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	10.45	0.65	1.89e-19	Chronic sinus infection;
UCEC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.64	-7.81	-0.54	9.94e-13	Height;
UCEC	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.71	6.01	0.44	1.37e-8	Blood metabolite levels;
UCEC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.06e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg00614314	chr15:82944287	LOC80154	0.53	6.21	0.46	5.04e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs870825	0.548	rs12513029	chr4:185665118	G/A	cg04058563	chr4:185651563	MLF1IP	0.57	6.08	0.45	9.65e-9	Blood protein levels;
UCEC	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.63	7.1	0.51	5.05e-11	Vitiligo;
UCEC	cis	rs7246967	0.673	rs7245540	chr19:22881504	C/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	4.52	0.35	1.28e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.52	-5.95	-0.44	1.85e-8	Monocyte percentage of white cells;
UCEC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.47	-4.81	-0.37	3.64e-6	Blood metabolite levels;
UCEC	cis	rs7648466	0.592	rs7616215	chr3:46205686	A/G	cg19145607	chr3:45983792	CXCR6;FYCO1	-0.41	-4.62	-0.36	8.27e-6	Eotaxin levels;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.46	-5.17	-0.39	7.57e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.62	6.24	0.46	4.32e-9	Colorectal cancer;
UCEC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.62	6.74	0.49	3.28e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.29	0.46	3.39e-9	Platelet count;
UCEC	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	4.87	0.37	2.9e-6	Blood metabolite levels;
UCEC	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.01	-12.37	-0.71	1.51e-24	Dilated cardiomyopathy;
UCEC	cis	rs12980942	0.872	rs12985339	chr19:41801756	A/T	cg25627403	chr19:41769009	HNRNPUL1	-0.81	-6.75	-0.49	3.25e-10	Coronary artery disease;
UCEC	cis	rs4646450	0.838	rs10229569	chr7:99183704	G/A	cg24650262	chr7:98904301	NA	0.46	4.57	0.35	1.04e-5	Blood metabolite levels;
UCEC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.63	0.36	8.03e-6	Parkinson's disease;
UCEC	cis	rs731174	0.765	rs510121	chr1:38182960	C/T	cg12339802	chr1:38156545	C1orf109	-0.57	-4.83	-0.37	3.46e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.49	5.0	0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.63	0.36	8.1e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28795989	0.896	rs9330348	chr4:7883887	C/G	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.42e-14	Intelligence (multi-trait analysis);
UCEC	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.73	8.41	0.57	3.3e-14	Cognitive test performance;
UCEC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.73	6.48	0.47	1.32e-9	Cognitive function;
UCEC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08822215	chr16:89438651	ANKRD11	-0.5	-4.71	-0.36	5.64e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs11088226	0.692	rs2833861	chr21:33882345	C/T	cg03366312	chr21:34388564	NA	-0.34	-4.57	-0.35	1.02e-5	Gastritis;
UCEC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.52	4.85	0.37	3.11e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.6	-6.51	-0.47	1.12e-9	Asthma;
UCEC	cis	rs12579753	0.595	rs7398614	chr12:82286339	C/G	cg07988820	chr12:82153109	PPFIA2	-0.52	-4.59	-0.35	9.55e-6	Resting heart rate;
UCEC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.08	-15.93	-0.8	7.73e-34	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg06521331	chr12:34319734	NA	-0.62	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-5.32	-0.4	3.86e-7	Colorectal cancer;
UCEC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg01262667	chr19:19385393	TM6SF2	0.48	6.55	0.48	8.83e-10	Tonsillectomy;
UCEC	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.95	-7.41	-0.52	9.05e-12	Multiple sclerosis;
UCEC	cis	rs884366	1.000	rs6903519	chr6:109631315	A/C	cg01475377	chr6:109611718	NA	-0.44	-5.0	-0.38	1.62e-6	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2734839	0.964	rs7131440	chr11:113299910	A/G	cg14159747	chr11:113255604	NA	-0.52	-6.74	-0.49	3.32e-10	Information processing speed;
UCEC	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.05	-9.19	-0.6	3.39e-16	Corneal structure;
UCEC	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.56	-5.26	-0.4	4.98e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs459482	0.534	rs458255	chr21:42801128	G/A	cg14166395	chr21:42792516	MX1	0.54	4.98	0.38	1.76e-6	IgG glycosylation;
UCEC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg22166914	chr1:53195759	ZYG11B	0.78	8.35	0.57	4.55e-14	Monocyte count;
UCEC	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg26067569	chr2:200525129	NA	0.54	4.53	0.35	1.2e-5	Schizophrenia;
UCEC	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.56	-6.6	-0.48	6.95e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg26513180	chr16:89883248	FANCA	-0.46	-4.69	-0.36	6.18e-6	Vitiligo;
UCEC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.79	8.14	0.56	1.58e-13	Longevity;Endometriosis;
UCEC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.68	6.36	0.46	2.44e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg18681998	chr4:17616180	MED28	0.67	7.8	0.54	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.91	-0.55	5.73e-13	Total cholesterol levels;
UCEC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.28	0.46	3.67e-9	Cognitive test performance;
UCEC	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.36	5.72	0.43	5.72e-8	Cancer;
UCEC	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.27	-0.46	3.81e-9	Total cholesterol levels;
UCEC	cis	rs2803122	0.501	rs10811140	chr9:19230399	T/C	cg19584733	chr9:19298547	DENND4C	-0.63	-5.1	-0.39	1.01e-6	Pulse pressure;
UCEC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.67	5.93	0.44	2.11e-8	Aortic root size;
UCEC	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.7	7.46	0.52	7.02e-12	Coronary artery disease;
UCEC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.39	0.41	2.79e-7	Breast cancer;
UCEC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.73e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6756513	0.520	rs6546560	chr2:70173690	A/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.11	-0.39	9.79e-7	Breast cancer;Platelet count;
UCEC	cis	rs533123	0.877	rs1042114	chr1:29138975	G/T	cg08366446	chr1:29138936	OPRD1	0.8	4.97	0.38	1.82e-6	Schizophrenia;
UCEC	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2172802	0.576	rs10866120	chr4:62412441	T/C	cg18242907	chr4:62067393	NA	0.48	4.74	0.36	4.93e-6	Partial epilepsies;
UCEC	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.72	8.06	0.55	2.38e-13	Mortality in heart failure;
UCEC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.8	8.12	0.56	1.71e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.79	8.09	0.55	2.1e-13	Mosquito bite size;
UCEC	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	0.81	4.96	0.38	1.92e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	5.04	0.38	1.35e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2588809	0.941	rs1314919	chr14:68711973	T/C	cg01928902	chr14:69259640	ZFP36L1	-0.64	-4.78	-0.37	4.29e-6	Breast cancer;
UCEC	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg03078520	chr22:18463400	MICAL3	-0.59	-6.5	-0.47	1.2e-9	Presence of antiphospholipid antibodies;
UCEC	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.6	5.4	0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.52	5.76	0.43	4.64e-8	Retinal vascular caliber;
UCEC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.5	5.42	0.41	2.42e-7	Aortic root size;
UCEC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.61	-6.74	-0.49	3.31e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.5	-5.98	-0.44	1.63e-8	Pubertal anthropometrics;
UCEC	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-0.96	-4.92	-0.38	2.27e-6	Mitochondrial DNA levels;
UCEC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.75	6.37	0.47	2.25e-9	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs16937	0.711	rs10900465	chr1:205158183	C/T	cg12580275	chr1:205744413	RAB7L1	0.49	5.33	0.4	3.61e-7	Schizophrenia;
UCEC	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.66	4.75e-20	Body mass index;
UCEC	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.75	7.75	0.54	1.36e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.3	-0.4	4.22e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.49	-4.66	-0.36	7.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg22857025	chr5:266934	NA	-0.77	-5.56	-0.42	1.24e-7	Asthma (childhood onset);
UCEC	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.62	-6.7	-0.48	4.1e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.58	-6.1	-0.45	9.11e-9	Age at first birth;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg12035532	chr1:1886765	KIAA1751	0.44	4.57	0.35	1.01e-5	Body mass index;
UCEC	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.53	-4.55	-0.35	1.12e-5	Colorectal cancer;
UCEC	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.06	0.5	6.01e-11	Morning vs. evening chronotype;
UCEC	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.92	6.31	0.46	3.13e-9	Major depressive disorder;
UCEC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.5	0.47	1.18e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.44e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.74	-9.22	-0.61	2.95e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.81	-9.09	-0.6	6.23e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg08222913	chr3:52553049	STAB1	0.4	4.67	0.36	6.65e-6	Electroencephalogram traits;
UCEC	cis	rs7246967	0.673	rs55638152	chr19:23055294	G/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.6	6.69	0.48	4.29e-10	Hip circumference;
UCEC	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.82	6.47	0.47	1.4e-9	Obesity (early onset extreme);
UCEC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.37	-4.72	-0.36	5.54e-6	Dupuytren's disease;
UCEC	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7608623	0.509	rs4233703	chr2:24066193	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.42	4.51	0.35	1.31e-5	Obesity-related traits;
UCEC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.66	-7.32	-0.52	1.53e-11	Obesity-related traits;
UCEC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.93	10.06	0.64	1.98e-18	Cognitive function;
UCEC	cis	rs10924970	0.601	rs12402448	chr1:235448095	A/T	cg26050004	chr1:235667680	B3GALNT2	0.53	4.81	0.37	3.63e-6	Asthma;
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg12024160	chr4:1254474	NA	0.68	8.01	0.55	3.17e-13	Obesity-related traits;
UCEC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg04310649	chr10:35416472	CREM	-0.47	-4.53	-0.35	1.23e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs10949834	0.824	rs3801461	chr7:73536368	C/G	cg07137043	chr7:73588983	EIF4H	-0.79	-4.67	-0.36	6.72e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-5.47	-0.41	1.88e-7	Metabolite levels;
UCEC	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.49	5.14	0.39	8.73e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg18817426	chr15:75230435	COX5A	0.64	6.79	0.49	2.6200000000000003e-10	Schizophrenia;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg04724190	chr2:240029740	HDAC4	-0.56	-6.93	-0.5	1.21e-10	N-glycan levels;
UCEC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.61	4.75	0.36	4.83e-6	Breast cancer;
UCEC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg22598563	chr5:131563921	P4HA2	-0.36	-4.72	-0.36	5.39e-6	Blood metabolite levels;
UCEC	cis	rs7246967	0.551	rs6511367	chr19:22821270	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs17764205	0.778	rs77361854	chr19:3242384	A/C	cg09528496	chr19:3881225	ATCAY	-0.63	-4.81	-0.37	3.69e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.53	6.11	0.45	8.62e-9	Breast size;
UCEC	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.89	9.24	0.61	2.6e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.6	-5.8	-0.43	3.9e-8	Blood metabolite levels;
UCEC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.53	5.96	0.44	1.81e-8	Iron status biomarkers;
UCEC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.68	6.5	0.47	1.17e-9	Aortic root size;
UCEC	cis	rs10924970	0.781	rs10754614	chr1:235493804	G/A	cg26050004	chr1:235667680	B3GALNT2	0.45	4.65	0.36	7.26e-6	Asthma;
UCEC	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.6	5.57	0.42	1.17e-7	Coronary artery disease;
UCEC	cis	rs9309473	0.861	rs6546857	chr2:73837955	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-4.84	-0.37	3.29e-6	Metabolite levels;
UCEC	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.45	5.1	0.39	1.05e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-7.68	-0.54	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.49	5.66	0.42	7.61e-8	Glomerular filtration rate (creatinine);
UCEC	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-1.11	-9.86	-0.63	6.55e-18	Dupuytren's disease;
UCEC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.78	6.11	0.45	8.51e-9	Body mass index;
UCEC	cis	rs1852612	0.965	rs6960591	chr7:45402459	C/T	cg26127197	chr7:45030251	NA	-0.35	-4.5	-0.35	1.35e-5	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs56330463	1.000	rs56330463	chr5:148200011	T/C	cg16699715	chr5:148961007	FLJ41603	-0.43	-4.53	-0.35	1.21e-5	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
UCEC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.71	6.25	0.46	4.22e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.05	-0.38	1.27e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.46	4.73	0.36	5.31e-6	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
UCEC	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.29	5.97	0.44	1.67e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.8	-0.37	3.88e-6	Testicular germ cell tumor;
UCEC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.11	0.45	8.35e-9	Cognitive test performance;
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg15848620	chr12:58087721	OS9	-0.54	-5.17	-0.39	7.68e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.55	-5.53	-0.41	1.43e-7	Pulse pressure;
UCEC	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg10263370	chr3:44754102	ZNF502	-0.47	-4.76	-0.37	4.51e-6	Depressive symptoms;
UCEC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg07645718	chr20:61493192	TCFL5	0.68	4.52	0.35	1.27e-5	Obesity-related traits;
UCEC	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	7.32	0.52	1.53e-11	Body mass index (adult);
UCEC	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.46	-5.86	-0.44	2.88e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	6.39	0.47	2.05e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs10242455	0.702	rs6974831	chr7:99131605	A/G	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg17105886	chr17:28927953	LRRC37B2	0.51	4.8	0.37	3.79e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.43	-4.61	-0.36	8.5e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.59	-6.85	-0.49	1.88e-10	Prostate cancer;
UCEC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	4.52	0.35	1.27e-5	Diabetic retinopathy;
UCEC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.71	7.13	0.51	4.2e-11	Mood instability;
UCEC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.68	-5.68	-0.42	6.92e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.74	7.75	0.54	1.39e-12	Breast cancer;
UCEC	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	6.78	0.49	2.69e-10	Motion sickness;
UCEC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	5.7	0.43	6.2e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	6.84	0.49	2e-10	Menarche (age at onset);
UCEC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.74	-8.62	-0.58	9.6e-15	Menarche (age at onset);
UCEC	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.2	-0.51	2.9e-11	Monocyte count;
UCEC	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.71	0.54	1.76e-12	Ileal carcinoids;
UCEC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.72	-0.54	1.67e-12	Monocyte count;
UCEC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.55	-0.35	1.12e-5	Breast cancer;
UCEC	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.74	-5.41	-0.41	2.5e-7	Gut microbiome composition (summer);
UCEC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.83	-7.24	-0.51	2.32e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.56	-5.68	-0.42	7.03e-8	Primary sclerosing cholangitis;
UCEC	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	0.63	6.55	0.48	9.2e-10	Vitiligo;
UCEC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.67	-6.73	-0.49	3.53e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.49	-5.34	-0.4	3.43e-7	Aortic root size;
UCEC	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg13926569	chr10:89418898	PAPSS2	-0.57	-6.57	-0.48	8.14e-10	Magnesium levels;
UCEC	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.65	-6.57	-0.48	8.03e-10	Malaria;
UCEC	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	5.77	0.43	4.54e-8	Myopia (pathological);
UCEC	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.58	4.94	0.38	2.09e-6	Huntington's disease progression;
UCEC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.48	5.03	0.38	1.44e-6	Monocyte count;
UCEC	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg18877361	chr14:105973846	NA	-0.37	-4.54	-0.35	1.16e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
UCEC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg06238570	chr21:40685208	BRWD1	-0.64	-7.28	-0.51	1.84e-11	Menarche (age at onset);
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.77	8.35	0.57	4.52e-14	Longevity;Endometriosis;
UCEC	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.68	0.36	6.36e-6	Educational attainment;
UCEC	cis	rs1355223	0.902	rs34751755	chr11:34694243	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.64	-0.36	7.5e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7072216	0.666	rs2274248	chr10:100148542	C/T	cg19567339	chr10:100142640	NA	0.66	8.41	0.57	3.24e-14	Metabolite levels;
UCEC	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.77	5.04	0.38	1.33e-6	Exhaled nitric oxide output;
UCEC	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.74	-8.15	-0.56	1.47e-13	Ear protrusion;
UCEC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	9.6	0.62	3.13e-17	Blood protein levels;
UCEC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.59	-6.74	-0.49	3.31e-10	Cancer (pleiotropy);
UCEC	cis	rs883565	0.502	rs4496420	chr3:38942716	A/C	cg01426195	chr3:39028469	NA	0.45	4.93	0.38	2.23e-6	Handedness;
UCEC	cis	rs7246967	0.604	rs12981846	chr19:23021359	G/A	cg24889512	chr19:22816950	ZNF492	0.48	5.06	0.38	1.25e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.66	0.42	7.63e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.66	-6.46	-0.47	1.45e-9	Lymphocyte counts;
UCEC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs13253111	0.624	rs7357359	chr8:28094835	T/C	cg26534493	chr8:28060551	NA	0.48	5.31	0.4	4.05e-7	Childhood body mass index;
UCEC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg06784218	chr1:46089804	CCDC17	0.43	4.93	0.38	2.21e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.67e-9	Crohn's disease;
UCEC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg20387954	chr3:183756860	HTR3D	0.5	6.02	0.44	1.32e-8	Anterior chamber depth;
UCEC	cis	rs7246967	0.611	rs3853652	chr19:22871913	C/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs36051895	0.632	rs10217652	chr9:5119939	A/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.23	-0.4	5.68e-7	Pediatric autoimmune diseases;
UCEC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg21053147	chr12:120880522	NA	0.61	5.01	0.38	1.54e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.49	0.47	1.21e-9	Cognitive test performance;
UCEC	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.79	5.13	0.39	8.82e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.83	9.99	0.64	2.95e-18	Menopause (age at onset);
UCEC	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.21	10.62	0.66	6.53e-20	Corneal structure;
UCEC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.35	-5.19	-0.39	7.01e-7	Schizophrenia;
UCEC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.43	-5.21	-0.39	6.25e-7	Total body bone mineral density;
UCEC	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	5.99	0.44	1.52e-8	IgG glycosylation;
UCEC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.6	5.23	0.4	5.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg13753209	chr17:57696993	CLTC	0.48	4.7	0.36	5.87e-6	Hemoglobin concentration;
UCEC	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	5.49	0.41	1.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.01	-0.38	1.53e-6	Chronic sinus infection;
UCEC	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg19610905	chr11:61596333	FADS2	0.5	5.34	0.4	3.51e-7	Trans fatty acid levels;
UCEC	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.5	-4.99	-0.38	1.65e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.62	-0.36	8.26e-6	Breast cancer;
UCEC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.73	-6.75	-0.49	3.15e-10	Systolic blood pressure;
UCEC	cis	rs7709377	0.597	rs11241375	chr5:115519813	T/C	cg23108291	chr5:115420582	COMMD10	0.52	5.48	0.41	1.77e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs80337801	0.541	rs10515181	chr5:73715484	A/G	cg27626331	chr5:74162602	FAM169A	0.88	4.59	0.35	9.25e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs7968440	0.933	rs2684889	chr12:51079874	A/G	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs7736576	0.550	rs1948277	chr5:57244657	A/C	cg25565203	chr5:56989227	NA	-0.41	-4.61	-0.36	8.84e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-6.28	-0.46	3.57e-9	Gut microbiome composition (summer);
UCEC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.67	4.85	0.37	3.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg03859395	chr2:55845619	SMEK2	1.05	15.75	0.79	2.26e-33	Metabolic syndrome;
UCEC	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.56	5.78	0.43	4.39e-8	Eye color traits;
UCEC	cis	rs73416724	1.000	rs77626494	chr6:43286886	C/T	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.91	0.38	2.36e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg03859395	chr2:55845619	SMEK2	-0.85	-8.66	-0.58	7.65e-15	Metabolic syndrome;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.91	-0.44	2.34e-8	Pubertal anthropometrics;
UCEC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.87	0.44	2.83e-8	Total body bone mineral density;
UCEC	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.44	4.83	0.37	3.35e-6	Alcoholic chronic pancreatitis;
UCEC	cis	rs4668356	1.000	rs60730419	chr2:172025173	T/C	cg13882835	chr2:172017928	TLK1	0.67	4.53	0.35	1.2e-5	Cognitive performance;
UCEC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.44	4.63	0.36	7.97e-6	Coronary artery disease;
UCEC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg15168995	chr22:37914206	CARD10	-0.41	-4.7	-0.36	5.99e-6	Cutaneous nevi;
UCEC	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	6.15	0.45	7.01e-9	Menopause (age at onset);
UCEC	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-8.64	-0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-6.4	-0.47	1.91e-9	Parkinson's disease;
UCEC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-5.44	-0.41	2.14e-7	Initial pursuit acceleration;
UCEC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.49	0.41	1.75e-7	Hemoglobin concentration;
UCEC	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg13334819	chr7:99746414	C7orf59	-0.59	-4.95	-0.38	2.03e-6	Coronary artery disease;
UCEC	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	0.99	10.1	0.64	1.48e-18	Corneal structure;
UCEC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	trans	rs12755164	0.771	rs1405051	chr1:73348484	G/A	cg17780956	chr4:156297616	MAP9	-0.65	-6.93	-0.5	1.26e-10	Schizophrenia;
UCEC	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.57	-4.82	-0.37	3.49e-6	Menarche (age at onset);
UCEC	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.46	5.02	0.38	1.5e-6	Dental caries;
UCEC	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21515243	chr18:21033072	RIOK3	0.57	7.38	0.52	1.07e-11	Warfarin maintenance dose;
UCEC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg05695927	chr15:45694626	SPATA5L1	0.53	5.21	0.39	6.26e-7	Homoarginine levels;
UCEC	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg09823154	chr10:43332737	NA	-0.61	-4.7	-0.36	5.98e-6	Blood protein levels;
UCEC	cis	rs7246967	0.673	rs7249685	chr19:22882379	C/T	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs877674	1.000	rs4949223	chr1:32221913	G/A	cg07656362	chr1:32688117	C1orf91;EIF3I	0.84	4.88	0.37	2.71e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7113850	0.541	rs7935630	chr11:24222206	A/C	ch.11.24196551F	chr11:24239977	NA	0.62	4.71	0.36	5.67e-6	Bone fracture in osteoporosis;
UCEC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.47	5.51	0.41	1.55e-7	Aortic root size;
UCEC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.91	9.53	0.62	4.6e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.1	9.61	0.62	2.94e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.64	6.07	0.45	1.04e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.65	5.79	0.43	4.11e-8	Menopause (age at onset);
UCEC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.56	6.12	0.45	8.19e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.07	-0.5	5.74e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs78487399	0.908	rs17031116	chr2:43833013	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.68	-0.42	6.95e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.76	0.37	4.54e-6	Diabetic retinopathy;
UCEC	cis	rs1007190	0.764	rs4793153	chr17:42873792	T/C	cg15406952	chr17:42872593	NA	-0.67	-4.87	-0.37	2.87e-6	DNA methylation (variation);
UCEC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg27624424	chr6:160112604	SOD2	0.57	5.39	0.41	2.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.49	5.25	0.4	5.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	0.9	7.31	0.52	1.57e-11	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11697848	1.000	rs2268325	chr20:48529565	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.32	5.06	0.38	1.25e-6	Cancer;
UCEC	cis	rs6460942	0.591	rs80311633	chr7:12339690	G/C	cg06484146	chr7:12443880	VWDE	-0.58	-4.7	-0.36	5.85e-6	Coronary artery disease;
UCEC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	-0.57	-6.53	-0.47	9.88e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.9	11.24	0.68	1.56e-21	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14019695	chr9:139328340	INPP5E	0.52	6.24	0.46	4.41e-9	Monocyte percentage of white cells;
UCEC	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.67	6.71	0.48	3.88e-10	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.9	-0.37	2.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.39	-4.67	-0.36	6.6e-6	Mortality in heart failure;
UCEC	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.52	-6.23	-0.46	4.64e-9	Fibrinogen levels;
UCEC	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.67	-7.33	-0.52	1.41e-11	Height;
UCEC	cis	rs2213920	0.569	rs4979524	chr9:118177617	C/G	cg13918206	chr9:118159781	DEC1	0.67	5.42	0.41	2.35e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.38	5.2	0.39	6.66e-7	Fat distribution (HIV);
UCEC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-5.13	-0.39	9.08e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.72	-0.43	5.72e-8	Pulmonary function;
UCEC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.52	4.86	0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg06466757	chr4:1255808	NA	0.46	4.85	0.37	3.07e-6	Obesity-related traits;
UCEC	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.57	5.19	0.39	6.93e-7	Crohn's disease;
UCEC	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.64	5.59	0.42	1.06e-7	Coronary artery disease;
UCEC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg12024160	chr4:1254474	NA	0.72	7.74	0.54	1.45e-12	Obesity-related traits;
UCEC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1823913	0.538	rs35311234	chr2:192181678	G/A	cg15998761	chr2:191300784	MFSD6	0.39	4.56	0.35	1.08e-5	Obesity-related traits;
UCEC	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.44	4.55	0.35	1.1e-5	Height;
UCEC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg20387954	chr3:183756860	HTR3D	0.48	5.65	0.42	8.19e-8	Anterior chamber depth;
UCEC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.57	-4.51	-0.35	1.32e-5	Coronary artery calcification;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.15	-0.45	7.12e-9	Pubertal anthropometrics;
UCEC	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg10123293	chr2:99228465	UNC50	0.48	5.38	0.41	2.94e-7	Bipolar disorder;
UCEC	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.64	6.36	0.46	2.42e-9	Plateletcrit;Platelet count;
UCEC	cis	rs11867410	0.744	rs73336681	chr17:63960495	A/G	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.5	-5.38	-0.41	2.87e-7	Body mass index;
UCEC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg01689657	chr7:91764605	CYP51A1	0.43	5.47	0.41	1.88e-7	Breast cancer;
UCEC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.5	-5.37	-0.4	3.02e-7	Age at first birth;
UCEC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.45	4.73	0.36	5.23e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	5.93	0.44	2.1e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.38	-4.85	-0.37	3.17e-6	Body mass index;
UCEC	cis	rs12579753	0.574	rs7488890	chr12:82293300	C/T	cg07988820	chr12:82153109	PPFIA2	-0.53	-4.65	-0.36	7.19e-6	Resting heart rate;
UCEC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.35	1.2e-5	Menarche (age at onset);
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.57	-5.56	-0.42	1.21e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Crohn's disease;
UCEC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.66	-6.95	-0.5	1.13e-10	Neurofibrillary tangles;
UCEC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	0.92	6.32	0.46	2.91e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs1595825	0.786	rs75619425	chr2:198537281	A/G	cg19156104	chr2:198669113	PLCL1	-0.65	-4.71	-0.36	5.74e-6	Ulcerative colitis;
UCEC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.8	8.02	0.55	2.98e-13	Cognitive function;
UCEC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.58	5.18	0.39	7.18e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.61	-5.9	-0.44	2.42e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs12086130	0.773	rs72906827	chr1:51482411	C/G	cg07174182	chr1:51127561	FAF1	-0.81	-4.93	-0.38	2.21e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg24069376	chr3:38537580	EXOG	0.38	4.73	0.36	5.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.54	-5.45	-0.41	2.12e-7	Aortic root size;
UCEC	cis	rs6546886	0.912	rs10191539	chr2:74269926	T/C	cg14702570	chr2:74259524	NA	-0.43	-5.28	-0.4	4.48e-7	Dialysis-related mortality;
UCEC	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.77	-8.8	-0.59	3.45e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.59	-4.98	-0.38	1.74e-6	Corneal structure;
UCEC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	1.0	11.02	0.67	5.67e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6882076	0.925	rs1393207	chr5:156397540	T/A	cg12943317	chr5:156479607	HAVCR1	-0.5	-5.23	-0.4	5.73e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg20821713	chr7:1055600	C7orf50	-0.73	-6.94	-0.5	1.19e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.49	5.3	0.4	4.15e-7	Platelet distribution width;
UCEC	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.62	-6.16	-0.45	6.56e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.46	-4.61	-0.36	8.7e-6	Height;
UCEC	cis	rs4074536	0.622	rs12123600	chr1:116319088	G/A	cg21648376	chr1:116311395	CASQ2	-0.6	-5.67	-0.42	7.41e-8	QRS duration;
UCEC	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.45	0.41	2.03e-7	Cognitive function;
UCEC	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.55	5.19	0.39	6.89e-7	Tonsillectomy;
UCEC	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.69	-6.75	-0.49	3.22e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	5.16	0.39	8.04e-7	Initial pursuit acceleration;
UCEC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.65	-7.27	-0.51	1.94e-11	Menarche (age at onset);
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.69	-0.36	6.31e-6	Pubertal anthropometrics;
UCEC	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	9.21	0.6	3.11e-16	Blood protein levels;
UCEC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.63	8.94	0.59	1.48e-15	Prudent dietary pattern;
UCEC	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	4.96	0.38	1.88e-6	Response to antipsychotic treatment;
UCEC	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.61	-6.13	-0.45	7.62e-9	Cognitive ability;
UCEC	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg03714773	chr7:91764589	CYP51A1	0.47	5.7	0.43	6.4e-8	Breast cancer;
UCEC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.73	-7.05	-0.5	6.33e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	8.03e-6	Bladder cancer;
UCEC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.45	5.09	0.39	1.08e-6	Aortic root size;
UCEC	cis	rs7432375	0.583	rs1609391	chr3:136615268	G/A	cg21827317	chr3:136751795	NA	0.47	4.67	0.36	6.69e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.76	6.82	0.49	2.2e-10	Neutrophil percentage of white cells;
UCEC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg08805041	chr16:621841	PIGQ	-0.32	-4.69	-0.36	6.06e-6	Height;
UCEC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.62	-6.2	-0.46	5.51e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-0.98	-12.41	-0.72	1.23e-24	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg15133208	chr4:90757351	SNCA	-0.34	-4.7	-0.36	5.97e-6	Dementia with Lewy bodies;
UCEC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg13575925	chr12:9217583	LOC144571	0.4	4.64	0.36	7.49e-6	Sjögren's syndrome;
UCEC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.51	-5.01	-0.38	1.51e-6	Aortic root size;
UCEC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.45	4.57	0.35	1.01e-5	Blood metabolite levels;
UCEC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	7.26	0.51	2.07e-11	Type 2 diabetes;
UCEC	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.47	4.62	0.36	8.34e-6	Mammographic density (dense area);
UCEC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.16e-5	Lung cancer;
UCEC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.38	4.56	0.35	1.07e-5	Iron status biomarkers;
UCEC	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg09904177	chr6:26538194	HMGN4	-0.62	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.74	-5.95	-0.44	1.86e-8	Alzheimer's disease (late onset);
UCEC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg12292205	chr6:26970375	C6orf41	0.56	4.92	0.38	2.27e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7752643	0.786	rs1033656	chr6:84305673	A/T	cg24638849	chr6:84419360	SNAP91	0.37	4.5	0.35	1.36e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg05738196	chr6:26577821	NA	0.59	5.77	0.43	4.56e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11718455	0.585	rs6789465	chr3:43932045	G/A	cg08738300	chr3:44038990	NA	0.52	4.55	0.35	1.12e-5	Coronary artery disease;
UCEC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.66	-6.04	-0.45	1.2e-8	Systemic lupus erythematosus;
UCEC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg03354898	chr7:1950403	MAD1L1	0.59	5.79	0.43	4.07e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09985530	chr16:74700334	RFWD3	-0.64	-5.77	-0.43	4.46e-8	Energy expenditure (24h);
UCEC	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs11697848	1.000	rs56327845	chr20:48532306	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg14515064	chr17:81021472	NA	0.35	4.57	0.35	1.03e-5	Breast cancer;
UCEC	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.78	7.11	0.51	4.81e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.94	-7.35	-0.52	1.24e-11	Multiple sclerosis;
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.4	0.61	1.02e-16	Platelet count;
UCEC	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.76	-8.74	-0.58	4.89e-15	Waist circumference;Body mass index;
UCEC	cis	rs6840360	0.642	rs11735957	chr4:152427506	G/A	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.62	-5.08	-0.39	1.12e-6	Gut microbiome composition (summer);
UCEC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.5	4.77	0.37	4.31e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.7	6.42	0.47	1.75e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.54	-5.46	-0.41	1.95e-7	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.56	-5.1	-0.39	1.04e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.21	-0.51	2.71e-11	Multiple sclerosis;
UCEC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.67	5.0	0.38	1.58e-6	Body mass index;
UCEC	trans	rs1923834	0.541	rs17086022	chr13:28375086	G/T	cg04905392	chr12:132667060	NA	0.78	6.93	0.5	1.24e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin);
UCEC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.39	-0.41	2.75e-7	Breast cancer;
UCEC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.95	-0.5	1.08e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.73	7.88	0.54	6.7e-13	Paraoxonase activity;
UCEC	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.76	-8.7	-0.58	6.04e-15	Facial morphology (factor 19);
UCEC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs3769124	0.513	rs75696297	chr2:239481476	A/G	cg12524725	chr2:239427019	NA	-0.66	-4.76	-0.37	4.52e-6	Pulmonary function;
UCEC	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.5	6.79	0.49	2.59e-10	Height;
UCEC	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.4	5.02	0.38	1.49e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.48	-5.08	-0.39	1.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.72	-0.66	3.56e-20	Schizophrenia;
UCEC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.13	-0.39	8.82e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.63	6.1	0.45	8.92e-9	Coronary artery disease;
UCEC	cis	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-6.11	-0.45	8.35e-9	Chronic sinus infection;
UCEC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.76	8.95	0.59	1.46e-15	Mortality in heart failure;
UCEC	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	6.51	0.47	1.13e-9	Alzheimer's disease;
UCEC	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.47	-5.14	-0.39	8.76e-7	Facial morphology (factor 20);
UCEC	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg18479299	chr3:125709523	NA	-0.66	-4.55	-0.35	1.1e-5	Blood pressure (smoking interaction);
UCEC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.35	1.2e-5	Menarche (age at onset);
UCEC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.14	-0.45	7.21e-9	Parkinson's disease;
UCEC	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	7.4	0.52	9.47e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-6.0	-0.44	1.44e-8	Electroencephalogram traits;
UCEC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg05660106	chr1:15850417	CASP9	-1.02	-11.68	-0.69	1.05e-22	Systolic blood pressure;
UCEC	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.51	-4.56	-0.35	1.06e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg13147721	chr7:65941812	NA	-0.69	-4.83	-0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.2	0.46	5.35e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg23307798	chr14:103986281	CKB	0.62	6.4	0.47	1.94e-9	Body mass index;
UCEC	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.65	-5.39	-0.41	2.79e-7	Psoriasis vulgaris;
UCEC	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.66	-8.24	-0.56	8.47e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.56	-4.85	-0.37	3.12e-6	Metabolite levels;
UCEC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg08461772	chr7:95026248	PON3	0.4	5.51	0.41	1.58e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.68	-0.62	1.85e-17	Primary sclerosing cholangitis;
UCEC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.7	6.07	0.45	1.02e-8	Lymphocyte counts;
UCEC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.79	7.32	0.52	1.51e-11	Diastolic blood pressure;
UCEC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.62	5.96	0.44	1.8e-8	Lymphocyte counts;
UCEC	cis	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs12635074	0.547	rs7610622	chr3:56240117	A/G	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.51	0.35	1.32e-5	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.62	6.04	0.45	1.23e-8	Aortic root size;
UCEC	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.55	-5.28	-0.4	4.52e-7	Cognitive test performance;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.45	-5.24	-0.4	5.37e-7	Tonsillectomy;
UCEC	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.83	12.26	0.71	2.99e-24	Leprosy;
UCEC	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.51	-5.31	-0.4	3.97e-7	Height;
UCEC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.47	-4.76	-0.37	4.5e-6	Dental caries;
UCEC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.56	6.34	0.46	2.63e-9	Calcium levels;
UCEC	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-8.05	-0.55	2.6e-13	Body mass index;
UCEC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.7	-7.93	-0.55	5.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Depression;
UCEC	cis	rs740160	0.681	rs12531852	chr7:99009978	T/C	cg24650262	chr7:98904301	NA	0.56	5.0	0.38	1.64e-6	Dehydroepiandrosterone sulphate levels;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.52	-6.1	-0.45	9.05e-9	Pubertal anthropometrics;
UCEC	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg03859395	chr2:55845619	SMEK2	1.05	14.77	0.77	7.68e-31	Metabolic syndrome;
UCEC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-5.06	-0.39	1.22e-6	Metabolite levels;
UCEC	cis	rs4372836	0.504	rs13011935	chr2:29014746	C/T	cg09522027	chr2:28974177	PPP1CB	-0.71	-7.37	-0.52	1.11e-11	Body mass index;
UCEC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg09655341	chr17:79618100	PDE6G	-0.31	-4.75	-0.36	4.8e-6	Eye color traits;
UCEC	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.73	7.41	0.52	8.96e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Body mass index;
UCEC	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.7	-5.61	-0.42	9.75e-8	Asthma;
UCEC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.64	-5.87	-0.44	2.72e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs5167	0.504	rs3760627	chr19:45457180	T/C	cg13119609	chr19:45449297	APOC2	0.42	5.92	0.44	2.13e-8	Blood protein levels;
UCEC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.61	-5.45	-0.41	2.08e-7	Alzheimer's disease;
UCEC	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12292205	chr6:26970375	C6orf41	-0.66	-4.64	-0.36	7.62e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.42e-7	Alzheimer's disease (late onset);
UCEC	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg23793686	chr15:68133972	NA	-0.36	-4.67	-0.36	6.82e-6	Restless legs syndrome;
UCEC	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.74	-6.62	-0.48	6.33e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.41	4.51	0.35	1.29e-5	Mean platelet volume;
UCEC	cis	rs6832769	1.000	rs11726609	chr4:56400869	A/T	cg05960024	chr4:56376020	CLOCK	0.53	5.42	0.41	2.39e-7	Personality dimensions;
UCEC	cis	rs10266483	0.639	rs6952592	chr7:63754045	G/A	cg23304165	chr7:63498798	NA	-0.58	-6.13	-0.45	7.73e-9	Response to statin therapy;
UCEC	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.31	-0.4	3.97e-7	Resting heart rate;
UCEC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.7	-7.92	-0.55	5.47e-13	Coronary artery disease;
UCEC	cis	rs554111	0.858	rs10916855	chr1:21056382	T/C	cg08890418	chr1:21044141	KIF17	0.62	6.0	0.44	1.47e-8	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-5.21	-0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg12586109	chr17:80790369	TBCD;ZNF750	-0.42	-4.61	-0.36	8.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	1.3	8.5	0.57	1.94e-14	Night sleep phenotypes;
UCEC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.49	0.47	1.21e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.5	6.47	0.47	1.36e-9	Cystic fibrosis severity;
UCEC	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.13	-0.39	9e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	9.38	0.61	1.12e-16	Coffee consumption (cups per day);
UCEC	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13683864	chr3:40499215	RPL14	-0.93	-9.44	-0.61	7.82e-17	Renal cell carcinoma;
UCEC	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.32	4.64	0.36	7.57e-6	Schizophrenia;
UCEC	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.55	6.16	0.45	6.72e-9	Bipolar disorder;
UCEC	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	0.82	5.49	0.41	1.71e-7	Cerebrospinal fluid biomarker levels;
UCEC	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.6	4.58	0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg04155231	chr12:9217510	LOC144571	-0.41	-5.03	-0.38	1.42e-6	Sjögren's syndrome;
UCEC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.78	-0.59	3.9e-15	Monocyte count;
UCEC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg12024160	chr4:1254474	NA	0.63	7.42	0.52	8.88e-12	Obesity-related traits;
UCEC	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	5.04	0.38	1.33e-6	IgG glycosylation;
UCEC	cis	rs17433710	0.500	rs6700589	chr1:162628146	A/G	cg19264028	chr1:162630153	DDR2	-0.71	-4.89	-0.37	2.64e-6	Dupuytren's disease;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg25202407	chr1:205417560	MIR135B	0.37	4.66	0.36	6.96e-6	Menarche (age at onset);
UCEC	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg21419209	chr3:44054225	NA	-0.45	-4.62	-0.36	8.33e-6	Coronary artery disease;
UCEC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.92	9.8	0.63	9.37e-18	Cognitive function;
UCEC	cis	rs713477	0.817	rs55868790	chr14:55913275	T/C	cg13175173	chr14:55914753	NA	-0.43	-4.84	-0.37	3.31e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.75	7.15	0.51	3.78e-11	Schizophrenia;
UCEC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.6	4.59	0.35	9.57e-6	Gut microbiome composition (summer);
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg19678392	chr7:94953810	PON1	-0.59	-5.66	-0.42	7.56e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg06238570	chr21:40685208	BRWD1	0.78	6.98	0.5	9.32e-11	Cognitive function;
UCEC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs6684428	0.536	rs6670350	chr1:56391806	C/T	cg11651538	chr1:56320950	NA	0.44	4.73	0.36	5.11e-6	Airflow obstruction;
UCEC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg01874867	chr7:94954059	PON1	-0.54	-5.0	-0.38	1.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.54	-6.03	-0.45	1.26e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs8032158	1.000	rs8026172	chr15:56125182	T/A	cg10433327	chr15:56209506	NEDD4	-0.3	-4.98	-0.38	1.73e-6	Keloid;
UCEC	cis	rs7246967	0.932	rs35948178	chr19:23028519	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.58	6.11	0.45	8.35e-9	Blood protein levels;
UCEC	cis	rs4778581	0.722	rs12914285	chr15:80400221	C/G	cg08257866	chr15:80351198	ZFAND6	0.41	4.99	0.38	1.69e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.62	-6.66	-0.48	5e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.5	5.16	0.39	7.95e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.53	5.32	0.4	3.78e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg24069376	chr3:38537580	EXOG	0.47	5.89	0.44	2.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg04310649	chr10:35416472	CREM	-0.47	-4.58	-0.35	9.83e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-13.0	-0.73	3.39e-26	Height;
UCEC	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	0.85	5.9	0.44	2.4e-8	Inflammatory bowel disease;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.82	9.35	0.61	1.31e-16	Menarche (age at onset);
UCEC	cis	rs10924970	0.625	rs10925127	chr1:235378659	C/T	cg26050004	chr1:235667680	B3GALNT2	0.51	4.73	0.36	5.14e-6	Asthma;
UCEC	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-1.0	-8.83	-0.59	2.94e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.33	-4.51	-0.35	1.3e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.66	-7.18	-0.51	3.28e-11	QT interval;
UCEC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.68	-6.75	-0.49	3.25e-10	Blood metabolite levels;
UCEC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.49	7.37	0.52	1.17e-11	Homoarginine levels;
UCEC	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13683864	chr3:40499215	RPL14	-0.69	-7.23	-0.51	2.39e-11	Renal cell carcinoma;
UCEC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.48	5.38	0.41	2.88e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.49	-4.77	-0.37	4.38e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	11.5	0.69	3.12e-22	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.47	-0.47	1.35e-9	Parkinson's disease;
UCEC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.43	0.41	2.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.54	5.22	0.4	6.13e-7	Cleft lip with or without cleft palate;
UCEC	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.55	6.78	0.49	2.77e-10	Kawasaki disease;
UCEC	cis	rs12618769	0.947	rs72825711	chr2:99240243	A/T	cg10123293	chr2:99228465	UNC50	0.44	4.59	0.35	9.3e-6	Bipolar disorder;
UCEC	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.7	-0.36	5.89e-6	Coronary artery disease;
UCEC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg12317470	chr15:67143691	NA	-0.62	-4.96	-0.38	1.95e-6	Lung cancer (smoking interaction);
UCEC	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg02366345	chr4:152330872	FAM160A1	0.35	4.73	0.36	5.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6460942	0.591	rs62451461	chr7:12355480	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-4.94	-0.38	2.08e-6	Coronary artery disease;
UCEC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.89	-9.84	-0.63	7.24e-18	Lung cancer;
UCEC	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.86	5.53	0.41	1.45e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.17	0.51	3.44e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.58	7.34	0.52	1.32e-11	Breast cancer;
UCEC	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.88	-12.58	-0.72	4.25e-25	Urate levels in lean individuals;
UCEC	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.8	9.33	0.61	1.54e-16	Colorectal cancer;
UCEC	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.23	-0.4	5.78e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg19318889	chr4:1322082	MAEA	0.46	5.23	0.4	5.75e-7	Obesity-related traits;
UCEC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.77	0.37	4.46e-6	Rheumatoid arthritis;
UCEC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg04756594	chr16:24857601	SLC5A11	-0.41	-4.68	-0.36	6.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg04756594	chr16:24857601	SLC5A11	0.44	5.0	0.38	1.62e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.2	-0.56	1.09e-13	Breast cancer;
UCEC	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.47	-6.53	-0.47	9.88e-10	Eye color traits;
UCEC	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.12	-7.23	-0.51	2.51e-11	Schizophrenia;
UCEC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.5	4.94	0.38	2.1e-6	Menopause (age at onset);
UCEC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.89	-0.59	2.01e-15	Monocyte count;
UCEC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg11697111	chr7:1126903	GPER;C7orf50	-0.47	-5.07	-0.39	1.16e-6	Longevity;Endometriosis;
UCEC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.99	12.82	0.73	9.66e-26	Monocyte count;
UCEC	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.69	5.19	0.39	6.98e-7	Small cell lung carcinoma;
UCEC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg06238570	chr21:40685208	BRWD1	0.79	7.6	0.53	3.26e-12	Cognitive function;
UCEC	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.73	8.21	0.56	1.02e-13	Lymphocyte counts;
UCEC	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg11632617	chr15:75315747	PPCDC	-0.6	-5.26	-0.4	4.96e-7	Lung cancer;
UCEC	cis	rs4417704	0.551	rs4675843	chr2:241875494	C/T	cg26818257	chr2:241905806	NA	0.34	4.73	0.36	5.18e-6	Joint mobility (Beighton score);
UCEC	cis	rs3850699	0.609	rs12763720	chr10:104241983	T/C	cg05855489	chr10:104503620	C10orf26	0.6	4.93	0.38	2.22e-6	Prostate cancer;
UCEC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs539096	0.723	rs530373	chr1:44070032	C/T	cg11851915	chr1:44060116	PTPRF	-0.41	-4.62	-0.36	8.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg04155289	chr7:94953770	PON1	-0.48	-4.55	-0.35	1.11e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.64	6.65	0.48	5.28e-10	Primary sclerosing cholangitis;
UCEC	cis	rs713477	1.000	rs8014621	chr14:55906849	A/C	cg13175173	chr14:55914753	NA	-0.43	-4.68	-0.36	6.58e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215272	chr17:6899095	ALOX12	0.46	5.71	0.43	6.09e-8	Tonsillectomy;
UCEC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.51	5.15	0.39	8.27e-7	Blood protein levels;
UCEC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg23307798	chr14:103986281	CKB	0.56	5.28	0.4	4.61e-7	Body mass index;
UCEC	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.47	4.69	0.36	6.3e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg13319975	chr6:146136371	FBXO30	0.57	4.9	0.37	2.48e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-5.68	-0.42	6.97e-8	Morning vs. evening chronotype;
UCEC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.7	7.92	0.55	5.38e-13	Menopause (age at onset);
UCEC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-5.38	-0.41	2.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg04155231	chr12:9217510	LOC144571	-0.4	-5.11	-0.39	9.97e-7	Sjögren's syndrome;
UCEC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	23.33	0.89	2.88e-51	Chronic sinus infection;
UCEC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	5.2	0.39	6.64e-7	Response to antipsychotic treatment;
UCEC	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.79	-0.37	3.98e-6	Mood instability;
UCEC	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.89	-7.91	-0.55	5.77e-13	Red blood cell traits;
UCEC	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.66	6.92	0.5	1.3100000000000001e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.66	0.36	7.02e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.6e-8	Bipolar disorder;
UCEC	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.4	0.71	1.32e-24	Platelet count;
UCEC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Educational attainment;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg07838603	chr6:28411030	ZSCAN23	0.46	5.56	0.42	1.26e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.65	7.26	0.51	2.09e-11	Body mass index;
UCEC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.87	-11.36	-0.68	7.16e-22	Height;
UCEC	cis	rs2280630	0.898	rs1828678	chr3:39195517	C/G	cg01426195	chr3:39028469	NA	-0.52	-5.34	-0.4	3.5e-7	Verbal declarative memory;
UCEC	cis	rs12753920	0.775	rs2128648	chr1:92674474	C/T	cg10324998	chr1:92338262	TGFBR3	-0.46	-4.59	-0.35	9.62e-6	Systemic lupus erythematosus;
UCEC	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.65	-7.43	-0.52	8.27e-12	Menarche (age at onset);
UCEC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.9e-15	Height;
UCEC	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Kawasaki disease;
UCEC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	8.54	0.58	1.55e-14	Total body bone mineral density;
UCEC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-4.73	-0.36	5.24e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.44	5.92	0.44	2.13e-8	Bone mineral density;
UCEC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.55	-6.75	-0.49	3.16e-10	Total body bone mineral density;
UCEC	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.53	-5.32	-0.4	3.76e-7	Systemic lupus erythematosus;
UCEC	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg19875535	chr5:140030758	IK	0.42	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.77	-9.0	-0.6	1.05e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg01262667	chr19:19385393	TM6SF2	0.5	6.97	0.5	9.7e-11	Tonsillectomy;
UCEC	cis	rs17789174	0.903	rs12597107	chr16:85070381	G/T	cg02758499	chr16:85682440	KIAA0182	0.53	4.75	0.36	4.74e-6	Dysphagia;
UCEC	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.46	-4.58	-0.35	9.75e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	1.13	14.35	0.76	9.66e-30	Body mass index;
UCEC	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.08	5.72	0.43	5.85e-8	Type 2 diabetes;
UCEC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.06	-15.87	-0.79	1.13e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg22166914	chr1:53195759	ZYG11B	0.85	8.92	0.59	1.73e-15	Monocyte count;
UCEC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.54	0.35	1.18e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12292205	chr6:26970375	C6orf41	-0.58	-4.52	-0.35	1.27e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.49	5.41	0.41	2.54e-7	Life satisfaction;
UCEC	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.63	5.98	0.44	1.6e-8	Cognitive ability;
UCEC	cis	rs7968440	1.000	rs2700482	chr12:51083265	C/T	cg20014596	chr12:50898483	DIP2B	0.46	4.56	0.35	1.07e-5	Fibrinogen;
UCEC	cis	rs60311166	1.000	rs6780397	chr3:52767599	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.79	5.34	0.4	3.41e-7	CTACK levels;
UCEC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg18681998	chr4:17616180	MED28	0.61	6.76	0.49	3.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4448343	0.963	rs28620668	chr9:98267746	T/G	cg00638945	chr9:98266643	PTCH1	0.31	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg06096015	chr1:231504339	EGLN1	0.43	4.93	0.38	2.2e-6	Hemoglobin concentration;
UCEC	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.54	-5.51	-0.41	1.57e-7	Glomerular filtration rate;
UCEC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.66	-5.92	-0.44	2.17e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2302190	0.882	rs6503869	chr17:56637461	C/G	cg12560992	chr17:57184187	TRIM37	0.52	4.65	0.36	7.35e-6	Vitamin D levels;
UCEC	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.39	-5.21	-0.4	6.15e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.42	-5.05	-0.38	1.3e-6	Menopause (age at onset);
UCEC	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.53	-4.7	-0.36	5.88e-6	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.72	8.88	0.59	2.14e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.59	6.86	0.49	1.82e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg18016565	chr1:150552671	MCL1	0.45	4.53	0.35	1.19e-5	Melanoma;
UCEC	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg19513890	chr22:42538836	CYP2D7P1	0.44	4.96	0.38	1.88e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Educational attainment;
UCEC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.66	-7.6	-0.53	3.15e-12	Body mass index;
UCEC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	9.88	0.63	5.79e-18	Chronic sinus infection;
UCEC	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-1.06	-8.07	-0.55	2.29e-13	Multiple sclerosis;
UCEC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.21	0.46	5.15e-9	Menarche (age at onset);
UCEC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.12	-6.76	-0.49	2.95e-10	Breast cancer;
UCEC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	4.6	0.36	8.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.48	5.38	0.41	2.9e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.33	4.54	0.35	1.18e-5	Height;
UCEC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17554472	chr22:41940697	POLR3H	-0.43	-4.68	-0.36	6.39e-6	Vitiligo;
UCEC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg11859384	chr17:80120422	CCDC57	0.49	5.3	0.4	4.25e-7	Life satisfaction;
UCEC	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg14196790	chr5:131705035	SLC22A5	-0.42	-4.58	-0.35	9.83e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg16060761	chr17:80687452	NA	-0.54	-4.72	-0.36	5.33e-6	Glycated hemoglobin levels;
UCEC	cis	rs2734839	0.964	rs7122246	chr11:113304457	G/A	cg14159747	chr11:113255604	NA	0.57	7.1	0.51	5.04e-11	Information processing speed;
UCEC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.35	4.53	0.35	1.21e-5	Prostate cancer;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.89	10.56	0.66	9.3e-20	Menarche (age at onset);
UCEC	cis	rs539514	0.587	rs7320216	chr13:76332689	A/G	cg04757411	chr13:76259545	LMO7	-0.48	-5.66	-0.42	7.58e-8	Type 1 diabetes;
UCEC	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.41	5.93	0.44	2.13e-8	Airflow obstruction;
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	8.3	0.56	6.19e-14	Platelet count;
UCEC	cis	rs7095607	0.813	rs10997963	chr10:69921903	A/G	cg18986048	chr10:69913749	MYPN	-0.52	-6.04	-0.45	1.23e-8	Lung function (FVC);
UCEC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.82	11.11	0.68	3.41e-21	Body mass index;
UCEC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-4.9	-0.37	2.55e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-6.65	-0.48	5.35e-10	Eye color traits;
UCEC	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	5.81	0.43	3.75e-8	LDL cholesterol;
UCEC	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.6	0.42	9.99e-8	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.58	4.54	0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs7870753	0.838	rs10761013	chr9:99201939	T/C	cg25260653	chr9:99212216	HABP4	0.58	5.7	0.43	6.48e-8	Height;
UCEC	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.52	-5.26	-0.4	4.97e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.67	6.52	0.47	1.08e-9	Bladder cancer;
UCEC	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.99	7.96	0.55	4.24e-13	Exhaled nitric oxide output;
UCEC	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.78	5.77	0.43	4.53e-8	Exhaled nitric oxide output;
UCEC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	0.74	4.97	0.38	1.88e-6	Diabetic retinopathy;
UCEC	cis	rs11697848	1.000	rs1884738	chr20:48581651	C/G	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.49	-0.57	2.06e-14	Blood trace element (Zn levels);
UCEC	cis	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.71	-5.91	-0.44	2.25e-8	Initial pursuit acceleration;
UCEC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg26566898	chr11:117069891	TAGLN	0.37	4.81	0.37	3.74e-6	Blood protein levels;
UCEC	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	0.99	5.76	0.43	4.86e-8	Schizophrenia;
UCEC	cis	rs1126510	0.535	rs10420570	chr19:47134312	C/T	cg07844738	chr19:47129343	PTGIR	-0.43	-5.1	-0.39	1.04e-6	Ulcerative colitis;
UCEC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.47	0.41	1.85e-7	Prudent dietary pattern;
UCEC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.68	-7.04	-0.5	6.84e-11	Cognitive function;
UCEC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.37	-0.46	2.34e-9	Aortic root size;
UCEC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.72	-0.36	5.45e-6	Dupuytren's disease;
UCEC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.62	-0.36	8.35e-6	Type 2 diabetes;
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Depression;
UCEC	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg08320659	chr6:26088202	HFE	0.75	4.69	0.36	6.14e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.5	6.06	0.45	1.09e-8	Coronary artery disease;
UCEC	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg00784671	chr22:46762841	CELSR1	-0.53	-4.88	-0.37	2.69e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9393813	0.516	rs4711152	chr6:27380202	C/T	cg27490387	chr6:26520793	HCG11	0.41	4.59	0.35	9.49e-6	Bipolar disorder;
UCEC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.41	-5.41	-0.41	2.52e-7	Monocyte count;
UCEC	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg12586109	chr17:80790369	TBCD;ZNF750	0.41	4.54	0.35	1.17e-5	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.63	-0.53	2.73e-12	IgG glycosylation;
UCEC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.47	-4.87	-0.37	2.91e-6	Aortic root size;
UCEC	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.39	0.61	1.06e-16	Coffee consumption (cups per day);
UCEC	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.04	0.5	6.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.69	6.37	0.47	2.25e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-9.15	-0.6	4.31e-16	Schizophrenia;
UCEC	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.41e-8	HDL cholesterol levels;
UCEC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.85	7.59	0.53	3.44e-12	Body mass index;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11200644	chr18:72265018	LOC400657	0.6	6.94	0.5	1.15e-10	Warfarin maintenance dose;
UCEC	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.79	0.43	4.17e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.64	0.36	7.62e-6	Menopause (age at onset);
UCEC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-6.51	-0.47	1.12e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.51	0.35	1.34e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.1e-7	Schizophrenia;
UCEC	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.74	-5.44	-0.41	2.14e-7	Response to hepatitis C treatment;
UCEC	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9715521	0.803	rs28676590	chr4:59808524	T/C	cg11281224	chr4:60001000	NA	-0.5	-4.95	-0.38	1.98e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6754311	0.589	rs749873	chr2:136817088	C/T	cg07169764	chr2:136633963	MCM6	-0.68	-6.25	-0.46	4.18e-9	Mosquito bite size;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.78	0.37	4.29e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.37	5.07	0.39	1.18e-6	Breast cancer;
UCEC	cis	rs1414896	1.000	rs4146667	chr1:95703597	C/G	cg17104959	chr1:95696376	NA	-0.32	-4.93	-0.38	2.19e-6	Non-alcoholic fatty liver disease histology (AST);
UCEC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.59	-0.35	9.27e-6	Alzheimer's disease (late onset);
UCEC	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.58	5.21	0.39	6.28e-7	Crohn's disease;
UCEC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.57	0.58	1.29e-14	Platelet count;
UCEC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.63	-0.66	6.19e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg21856205	chr7:94953877	PON1	-0.54	-5.2	-0.39	6.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.59	5.65	0.42	8.14e-8	Bone properties (heel);
UCEC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.58	-4.84	-0.37	3.22e-6	Corneal structure;
UCEC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	4.67	0.36	6.71e-6	Breast cancer;
UCEC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.58	4.65	0.36	7.31e-6	Skin colour saturation;
UCEC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-4.99	-0.38	1.67e-6	Type 2 diabetes;
UCEC	cis	rs4372836	0.681	rs4477866	chr2:29009089	C/A	cg09522027	chr2:28974177	PPP1CB	-0.68	-7.1	-0.51	4.94e-11	Body mass index;
UCEC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.74	-0.36	4.97e-6	Breast cancer;
UCEC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.63	-5.15	-0.39	8.25e-7	Lung cancer in ever smokers;
UCEC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg05738196	chr6:26577821	NA	0.65	7.63	0.53	2.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.87	-9.73	-0.63	1.44e-17	Cognitive function;
UCEC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.54	-5.14	-0.39	8.53e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.65	-7.28	-0.51	1.87e-11	Menarche (age at onset);
UCEC	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg24069376	chr3:38537580	EXOG	0.43	5.29	0.4	4.26e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-1.08	-8.3	-0.56	6.16e-14	Multiple sclerosis;
UCEC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24249390	chr15:90295951	MESP1	-0.47	-5.39	-0.41	2.74e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs4132509	1.000	rs4553169	chr1:243900640	G/A	cg24304712	chr1:244624785	C1orf101	-0.52	-4.89	-0.37	2.63e-6	RR interval (heart rate);
UCEC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	5.9	0.44	2.43e-8	Menarche (age at onset);
UCEC	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	10.41	0.65	2.3e-19	Post bronchodilator FEV1;
UCEC	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg23260525	chr10:116636907	FAM160B1	0.33	4.54	0.35	1.16e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	6.95	0.5	1.09e-10	Blood protein levels;
UCEC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	6.76	0.49	2.96e-10	Bipolar disorder;
UCEC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.22	0.4	6.05e-7	Rheumatoid arthritis;
UCEC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.84	4.91	0.38	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.33	0.4	3.59e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.09	-6.67	-0.48	4.96e-10	Diabetic kidney disease;
UCEC	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.71	-9.21	-0.61	3.03e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.38	-4.52	-0.35	1.27e-5	Bipolar disorder;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11285937	chr4:39979757	PDS5A	0.65	7.62	0.53	2.82e-12	Warfarin maintenance dose;
UCEC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.7	6.37	0.46	2.34e-9	Breast cancer;
UCEC	cis	rs6763768	0.578	rs13090627	chr3:53406425	C/T	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.49	5.02	0.38	1.45e-6	Height;
UCEC	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg04202892	chr2:111875749	ACOXL	0.46	5.4	0.41	2.6e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	6.86	0.49	1.77e-10	Platelet count;
UCEC	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	0.79	7.03	0.5	7.24e-11	Testicular germ cell tumor;
UCEC	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.87	10.55	0.66	9.83e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	7.0	0.5	8.51e-11	Calcium levels;
UCEC	cis	rs11235843	0.571	rs10898928	chr11:73364847	G/A	cg23931323	chr11:73372278	PLEKHB1	0.61	4.76	0.37	4.6e-6	Hand grip strength;
UCEC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.55	5.13	0.39	9.03e-7	Corneal astigmatism;
UCEC	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.46	-0.41	2e-7	Response to antipsychotic treatment;
UCEC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.59	5.02	0.38	1.49e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.43	-4.97	-0.38	1.81e-6	Total body bone mineral density;
UCEC	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.53	5.76	0.43	4.76e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.86	-0.37	2.97e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.67	8.26	0.56	7.95e-14	Menarche (age at onset);
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	6.94	0.5	1.15e-10	Platelet count;
UCEC	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.67	7.88	0.54	6.76e-13	Eosinophil percentage of white cells;
UCEC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.48e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.71	4.85	0.37	3.12e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg06154544	chr16:764854	METRN	0.44	5.08	0.39	1.11e-6	Height;
UCEC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg09297252	chr8:7631214	NA	0.35	4.57	0.35	1.01e-5	Red cell distribution width;
UCEC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.7	8.3	0.56	6.12e-14	Vitiligo;
UCEC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg11569703	chr11:65557185	OVOL1	-0.42	-6.08	-0.45	9.66e-9	Acne (severe);
UCEC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	5.02	0.38	1.49e-6	Breast cancer;
UCEC	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.53	4.75	0.36	4.76e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg07256473	chr22:29710276	RASL10A	0.54	6.22	0.46	4.83e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs11088226	0.692	rs2833863	chr21:33886986	A/G	cg03366312	chr21:34388564	NA	-0.32	-4.59	-0.35	9.63e-6	Gastritis;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.38	-0.47	2.19e-9	Cardiac Troponin-T levels;
UCEC	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg00105475	chr2:10696890	NA	0.5	6.05	0.45	1.17e-8	Prostate cancer;
UCEC	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	7.3	0.52	1.67e-11	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg22974920	chr21:40686053	BRWD1	-0.47	-4.61	-0.36	8.53e-6	Menarche (age at onset);
UCEC	cis	rs4654899	0.931	rs7543140	chr1:21180250	G/A	cg01072550	chr1:21505969	NA	0.55	5.65	0.42	8.21e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	8.64	0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.94	0.5	1.16e-10	Eye color traits;
UCEC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-1.02	-6.94	-0.5	1.2e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.0	0.44	1.48e-8	Coffee consumption (cups per day);
UCEC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.67	6.78	0.49	2.69e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.47	-4.6	-0.35	9.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.17	-9.57	-0.62	3.63e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs970548	0.954	rs10900221	chr10:45988597	G/A	cg15223267	chr10:46222474	FAM21C	0.52	4.83	0.37	3.34e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg05802129	chr4:122689817	NA	-0.55	-5.54	-0.42	1.33e-7	Type 2 diabetes;
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.8	0.63	9.13e-18	Platelet count;
UCEC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.85	0.37	3.18e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4899292	0.868	rs4902699	chr14:69659659	C/T	cg10376476	chr14:69952003	FLJ44817	-0.35	-4.67	-0.36	6.67e-6	Neuroticism;
UCEC	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg25922239	chr6:33757077	LEMD2	0.59	4.87	0.37	2.82e-6	Crohn's disease;
UCEC	cis	rs1545257	0.537	rs4581852	chr2:24638256	C/A	cg06627628	chr2:24431161	ITSN2	-0.54	-5.53	-0.41	1.42e-7	Sjögren's syndrome;
UCEC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.6	-4.96	-0.38	1.95e-6	Depression;
UCEC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.62	5.15	0.39	8.07e-7	High light scatter reticulocyte count;
UCEC	cis	rs9297145	0.673	rs62473003	chr7:98725660	A/G	cg05967295	chr7:98741636	SMURF1	0.88	7.98	0.55	3.76e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05678938	chr3:179371510	USP13	0.61	7.38	0.52	1.1e-11	Warfarin maintenance dose;
UCEC	cis	rs10140922	0.567	rs8016860	chr14:35635320	T/C	cg20478089	chr14:35099711	SNX6	-0.43	-4.84	-0.37	3.26e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.59	-4.63	-0.36	7.87e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.38	-4.9	-0.37	2.48e-6	Dupuytren's disease;
UCEC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.33	0.4	3.64e-7	Cognitive test performance;
UCEC	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.59	5.77	0.43	4.53e-8	Tonsillectomy;
UCEC	cis	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	4.64	0.36	7.65e-6	Calcium levels;
UCEC	cis	rs11129176	0.959	rs12490228	chr3:25046463	C/T	cg02506578	chr3:25824554	NGLY1	0.6	4.73	0.36	5.15e-6	Optic disc area;
UCEC	cis	rs7944735	0.817	rs2305983	chr11:47858755	C/T	cg08722104	chr11:47448306	PSMC3	-0.46	-4.51	-0.35	1.3e-5	Intraocular pressure;
UCEC	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.45	4.6	0.35	9e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg04871131	chr7:94954202	PON1	-0.5	-4.69	-0.36	6.27e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg09120320	chr17:61926383	NA	0.44	4.55	0.35	1.1e-5	Prudent dietary pattern;
UCEC	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.54	-5.42	-0.41	2.43e-7	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.09	-10.59	-0.66	8.12e-20	Vitiligo;
UCEC	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg10902566	chr4:727664	PCGF3	-0.57	-4.8	-0.37	3.84e-6	Systolic blood pressure;
UCEC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs1007190	0.881	rs12937256	chr17:42981499	C/T	cg15406952	chr17:42872593	NA	0.73	5.72	0.43	5.77e-8	DNA methylation (variation);
UCEC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.65	-0.53	2.49e-12	Tonsillectomy;
UCEC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.55	6.01	0.44	1.41e-8	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg05738196	chr6:26577821	NA	0.51	5.3	0.4	4.23e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg19678392	chr7:94953810	PON1	-0.56	-5.1	-0.39	1.01e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.82	0.43	3.53e-8	Monocyte percentage of white cells;
UCEC	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.49	5.17	0.39	7.37e-7	Response to temozolomide;
UCEC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.49	4.53	0.35	1.23e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2415984	0.846	rs12433080	chr14:46839394	C/T	cg14871534	chr14:47121158	RPL10L	0.4	4.62	0.36	8.23e-6	Number of children ever born;
UCEC	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.42	-4.68	-0.36	6.34e-6	Response to temozolomide;
UCEC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs7307889	1.000	rs7488048	chr12:5984136	T/C	cg10294363	chr12:6480192	SCNN1A	0.63	4.99	0.38	1.7e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.99	-11.57	-0.69	1.99e-22	Cognitive function;
UCEC	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.4	-5.3	-0.4	4.07e-7	IgG glycosylation;
UCEC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.51	5.53	0.41	1.46e-7	Prostate cancer;
UCEC	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.99	-7.25	-0.51	2.14e-11	Multiple sclerosis;
UCEC	cis	rs12635074	0.521	rs17235494	chr3:56317848	A/G	cg20749059	chr3:57094404	ARHGEF3;SPATA12	-0.34	-4.74	-0.36	5.09e-6	Morning vs. evening chronotype;
UCEC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	4.98e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs829661	0.948	rs829655	chr2:30729654	G/C	cg17749961	chr2:30669863	LCLAT1	0.52	4.83	0.37	3.45e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.59	5.35	0.4	3.34e-7	Metabolite levels;
UCEC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22455342	chr2:225449267	CUL3	0.54	5.6	0.42	1.01e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.6	-7.61	-0.53	3.09e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-4.55	-0.35	1.12e-5	Self-reported allergy;
UCEC	cis	rs4974559	0.947	rs7659916	chr4:1361013	C/T	cg02980000	chr4:1222292	CTBP1	0.57	4.61	0.36	8.6e-6	Systolic blood pressure;
UCEC	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.53	0.42	1.4e-7	HDL cholesterol;
UCEC	cis	rs2172802	0.570	rs4860422	chr4:62524423	A/C	cg04118610	chr4:62707027	LPHN3	0.42	4.63	0.36	8.02e-6	Partial epilepsies;
UCEC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.09	7.7	0.54	1.88e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg00086871	chr4:6988644	TBC1D14	0.83	5.68	0.42	7.12e-8	Granulocyte percentage of myeloid white cells;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18125479	chr14:51411049	PYGL	0.54	6.87	0.49	1.68e-10	Warfarin maintenance dose;
UCEC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-4.72	-0.36	5.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3790645	1.000	rs3127013	chr1:26891360	T/G	cg23229016	chr1:26872525	RPS6KA1	0.32	6.25	0.46	4.15e-9	Glucose homeostasis traits;
UCEC	cis	rs10242455	0.867	rs2037498	chr7:99311550	G/A	cg07715041	chr7:99302981	CYP3A7	-0.51	-5.23	-0.4	5.68e-7	Blood metabolite levels;
UCEC	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.22	0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg23070574	chr3:14187308	XPC	0.48	5.54	0.42	1.37e-7	Ovarian reserve;
UCEC	cis	rs4499344	0.556	rs259230	chr19:33133865	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	0.88	6.62	0.48	6.24e-10	Lymphocyte counts;
UCEC	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg04155231	chr12:9217510	LOC144571	0.39	4.55	0.35	1.1e-5	Sjögren's syndrome;
UCEC	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg16023434	chr1:11395635	NA	0.36	4.76	0.37	4.61e-6	Body mass index;
UCEC	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg05991184	chr2:219186017	PNKD	0.58	6.81	0.49	2.29e-10	Colorectal cancer;
UCEC	cis	rs11235843	0.929	rs4944029	chr11:73407603	T/C	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.88	0.54	6.81e-13	Platelet count;
UCEC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.45	6.42	0.47	1.81e-9	Primary biliary cholangitis;
UCEC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.82	7.97	0.55	4.15e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03226245	chr19:36486125	SDHAF1	0.6	7.28	0.51	1.86e-11	Warfarin maintenance dose;
UCEC	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.58	6.0	0.44	1.48e-8	Breast cancer;
UCEC	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.46	-0.41	1.96e-7	Response to antipsychotic treatment;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.93e-8	Breast cancer;
UCEC	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-5.06	-0.39	1.22e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.64	0.42	8.43e-8	Coffee consumption (cups per day);
UCEC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.51	5.96	0.44	1.78e-8	Alcohol dependence;
UCEC	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	5.17	0.39	7.69e-7	Height;
UCEC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg04553112	chr3:125709451	NA	-0.74	-5.15	-0.39	8.37e-7	Blood pressure (smoking interaction);
UCEC	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.54	-6.22	-0.46	4.86e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg14456004	chr13:21872349	NA	-1.01	-8.73	-0.58	5.18e-15	White matter hyperintensity burden;
UCEC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.51	-5.43	-0.41	2.28e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.47	7.19	0.51	2.98e-11	Primary biliary cholangitis;
UCEC	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.57	6.14	0.45	7.19e-9	Red blood cell count;
UCEC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.81	-7.53	-0.53	4.67e-12	Initial pursuit acceleration;
UCEC	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.64	7.28	0.51	1.87e-11	Mean platelet volume;
UCEC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15320075	chr8:145703422	NA	-0.46	-4.56	-0.35	1.07e-5	Age at first birth;
UCEC	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.45	-6.9	-0.49	1.41e-10	Urate levels in overweight individuals;
UCEC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.32	4.6	0.35	9.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.87	10.99	0.67	6.84e-21	Metabolic syndrome;
UCEC	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.51	-5.45	-0.41	2.1e-7	Lung cancer;
UCEC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	4.86	0.37	2.99e-6	Breast cancer;
UCEC	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.6	-5.41	-0.41	2.51e-7	Corneal astigmatism;
UCEC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg20399509	chr21:47717575	C21orf57	-0.46	-4.84	-0.37	3.24e-6	Testicular germ cell tumor;
UCEC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.83	0.37	3.43e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.13e-9	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	5.19	0.39	6.86e-7	Bone mineral density;
UCEC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg11871910	chr12:69753446	YEATS4	0.84	9.79	0.63	9.97e-18	Blood protein levels;
UCEC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs7326068	0.610	rs8000601	chr13:21339384	G/A	cg04906043	chr13:21280425	IL17D	-0.48	-4.75	-0.37	4.7e-6	Schizophrenia, bipolar disorder and depression (combined);
UCEC	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg05962950	chr11:130786565	SNX19	0.5	5.06	0.38	1.26e-6	Schizophrenia;
UCEC	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.52	-4.86	-0.37	2.96e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.6	0.58	1.1e-14	Prudent dietary pattern;
UCEC	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.67	5.12	0.39	9.6e-7	Platelet distribution width;
UCEC	cis	rs9715521	0.900	rs7696259	chr4:59810032	T/A	cg11281224	chr4:60001000	NA	-0.5	-4.96	-0.38	1.95e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.62	5.33	0.4	3.68e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.59	6.76	0.49	3e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-4.65	-0.36	7.19e-6	Coronary artery disease;
UCEC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg03714773	chr7:91764589	CYP51A1	0.4	4.87	0.37	2.79e-6	Breast cancer;
UCEC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.53	5.09	0.39	1.1e-6	Menopause (age at onset);
UCEC	cis	rs10503871	0.690	rs7840384	chr8:30349914	A/G	cg26383811	chr8:30366931	RBPMS	0.5	5.05	0.38	1.3e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.15	0.39	8.17e-7	Breast cancer;
UCEC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-6.49	-0.47	1.21e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.07	0.5	5.71e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-9.34	-0.61	1.45e-16	Vitiligo;
UCEC	cis	rs7246967	0.551	rs73022749	chr19:22887260	A/T	cg08271804	chr19:22816896	ZNF492	0.7	4.65	0.36	7.22e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	7.07	0.5	5.66e-11	Schizophrenia;
UCEC	cis	rs2625529	0.526	rs62022789	chr15:72564492	C/T	cg21214455	chr15:72412075	SENP8	0.46	4.56	0.35	1.08e-5	Red blood cell count;
UCEC	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.48e-6	QRS complex (12-leadsum);
UCEC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.66	-5.19	-0.39	6.82e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg04553112	chr3:125709451	NA	-0.66	-4.8	-0.37	3.79e-6	Blood pressure (smoking interaction);
UCEC	cis	rs1126510	0.535	rs10419732	chr19:47133937	A/G	cg07844738	chr19:47129343	PTGIR	0.42	4.98	0.38	1.79e-6	Ulcerative colitis;
UCEC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.55	-5.24	-0.4	5.52e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.52	-5.07	-0.39	1.18e-6	Pediatric autoimmune diseases;
UCEC	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.87	5.69	0.42	6.8e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.33	4.8	0.37	3.79e-6	Schizophrenia;
UCEC	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13683864	chr3:40499215	RPL14	-0.67	-6.64	-0.48	5.73e-10	Renal cell carcinoma;
UCEC	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.83	-0.49	2.05e-10	Pubertal anthropometrics;
UCEC	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.59	5.66	0.42	7.68e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.44	4.56	0.35	1.06e-5	Obesity-related traits;
UCEC	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.32	4.7	0.36	5.9e-6	Schizophrenia;
UCEC	cis	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00847043	chr14:65381157	CHURC1	0.59	6.66	0.48	5.19e-10	N-glycan levels;
UCEC	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.8	-9.88	-0.63	5.62e-18	White blood cell count (basophil);
UCEC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	5.89	0.44	2.55e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.17	-14.42	-0.77	6.07e-30	Breast cancer;
UCEC	cis	rs13065560	0.594	rs4364115	chr3:38895359	C/T	cg01426195	chr3:39028469	NA	-0.46	-4.98	-0.38	1.79e-6	Interleukin-18 levels;
UCEC	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.56	-5.56	-0.42	1.25e-7	Rheumatoid arthritis;
UCEC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.16	0.39	7.76e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4853036	1.000	rs4853036	chr2:70059824	G/A	cg02498382	chr2:70120550	SNRNP27	-0.52	-5.69	-0.42	6.77e-8	Colorectal or endometrial cancer;
UCEC	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg21772509	chr8:41503840	NKX6-3	0.51	5.72	0.43	5.9e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17408923	chr2:109335769	RANBP2	0.65	7.87	0.54	7.31e-13	Warfarin maintenance dose;
UCEC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg26061582	chr7:22766209	IL6	-0.51	-4.67	-0.36	6.77e-6	Lung cancer;
UCEC	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	6.5	0.47	1.16e-9	Post bronchodilator FEV1;
UCEC	cis	rs9990333	0.544	rs11915082	chr3:195809139	G/A	cg12923728	chr3:195709715	SDHAP1	-0.48	-4.6	-0.35	9.11e-6	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
UCEC	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.7	8.74	0.58	4.91e-15	Mean platelet volume;
UCEC	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.43	-5.84	-0.43	3.28e-8	Prostate cancer;
UCEC	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.71	6.65	0.48	5.48e-10	Crohn's disease;
UCEC	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.45	-6.11	-0.45	8.53e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
UCEC	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.52	-0.35	1.27e-5	Bipolar disorder;
UCEC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.04	-0.38	1.37e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.42	-4.74	-0.36	4.89e-6	Platelet distribution width;
UCEC	cis	rs3015497	0.673	rs10140458	chr14:51153811	C/T	cg04730355	chr14:51134070	SAV1	-0.47	-4.72	-0.36	5.34e-6	Mean platelet volume;
UCEC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.94	-11.92	-0.7	2.34e-23	Coronary artery disease;
UCEC	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.53	4.59	0.35	9.51e-6	Gut microbiome composition (summer);
UCEC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg01072550	chr1:21505969	NA	-0.63	-6.58	-0.48	7.95e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.55	6.53	0.47	1.02e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4908768	0.906	rs12401496	chr1:8600401	C/T	cg13081009	chr1:8430745	RERE	0.42	4.57	0.35	1.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.98	0.38	1.73e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7851660	0.679	rs4297160	chr9:100585506	G/A	cg13688889	chr9:100608707	NA	-0.53	-5.51	-0.41	1.58e-7	Strep throat;
UCEC	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.53	-5.69	-0.42	6.72e-8	Blood metabolite levels;
UCEC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.65	4.6	0.36	8.88e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.82	-8.99	-0.6	1.11e-15	Cognitive function;
UCEC	cis	rs1355223	0.683	rs12803316	chr11:34677511	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.39	-0.41	2.69e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01391022	chr12:122360665	WDR66	-0.45	-4.64	-0.36	7.76e-6	Mean corpuscular volume;
UCEC	cis	rs72774609	0.662	rs11204533	chr1:248035466	G/T	cg04309258	chr1:247267873	ZNF669	0.44	4.7	0.36	6.05e-6	Red cell distribution width;
UCEC	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.58	6.52	0.47	1.05e-9	Red blood cell count;
UCEC	cis	rs3741798	1.000	rs3741798	chr12:12496086	C/T	cg08615371	chr12:12503544	MANSC1	0.77	4.61	0.36	8.59e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg01072550	chr1:21505969	NA	-0.57	-5.6	-0.42	1.02e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4615376	1.000	rs7738252	chr6:13060568	A/G	cg11378619	chr6:12164359	HIVEP1	-0.5	-4.81	-0.37	3.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	7.89	0.55	6.48e-13	Tonsillectomy;
UCEC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.68e-16	Breast cancer;
UCEC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.82	11.19	0.68	2.1e-21	Headache;
UCEC	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs8010715	0.636	rs2277482	chr14:24587795	C/T	cg20933586	chr14:24608199	FAM158A	0.34	4.52	0.35	1.25e-5	IgG glycosylation;
UCEC	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.68	-0.36	6.56e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg07387570	chr22:46663686	TTC38	-0.47	-4.63	-0.36	7.91e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.27	-0.4	4.88e-7	Pubertal anthropometrics;
UCEC	cis	rs4948496	0.609	rs725529	chr10:63814070	A/T	cg07886691	chr10:64028545	RTKN2	0.42	4.55	0.35	1.1e-5	Systemic lupus erythematosus;
UCEC	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.63	-6.37	-0.46	2.33e-9	Blood protein levels;
UCEC	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	4.7	0.36	5.91e-6	Protein C levels;
UCEC	cis	rs12447804	0.734	rs9926693	chr16:58097357	C/T	cg05418736	chr16:57219756	RSPRY1;FAM192A	0.45	4.57	0.35	1.03e-5	Pulmonary function;Pulmonary function (smoking interaction);
UCEC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.57	5.82	0.43	3.54e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs7246967	0.611	rs60021625	chr19:22829554	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-5.93	-0.44	2.08e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7246967	0.611	rs2885222	chr19:22839944	T/G	cg01485075	chr19:22817371	ZNF492	0.41	4.53	0.35	1.21e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.09	15.91	0.8	8.82e-34	Schizophrenia;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg19678392	chr7:94953810	PON1	-0.58	-5.65	-0.42	7.97e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-4.55	-0.35	1.12e-5	Depression;
UCEC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg00500100	chr5:140098250	VTRNA1-2	0.34	4.52	0.35	1.24e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg00546932	chr16:1947055	NA	0.39	5.38	0.41	2.86e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.52	5.16	0.39	7.74e-7	Morning vs. evening chronotype;
UCEC	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg03230154	chr19:22817176	ZNF492	0.44	4.54	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.63	5.69	0.43	6.51e-8	Coronary artery disease;
UCEC	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg09120320	chr17:61926383	NA	0.44	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.11	0.39	9.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.61	-4.99	-0.38	1.7e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg07460842	chr6:66804631	NA	0.74	5.36	0.4	3.16e-7	Exhaled nitric oxide output;
UCEC	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.77	9.03	0.6	8.69e-16	Breast cancer;
UCEC	cis	rs6580649	0.883	rs1793955	chr12:48393106	G/T	cg24011408	chr12:48396354	COL2A1	0.6	5.03	0.38	1.43e-6	Lung cancer;
UCEC	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.36	-4.73	-0.36	5.26e-6	Alcohol dependence;
UCEC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.71	-8.73	-0.58	5.28e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs7709377	0.620	rs11960815	chr5:115500207	A/C	cg23108291	chr5:115420582	COMMD10	0.52	5.35	0.4	3.37e-7	Metabolite levels  (X-11787);
UCEC	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg21419209	chr3:44054225	NA	-0.51	-5.1	-0.39	1.01e-6	Coronary artery disease;
UCEC	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.02	7.54	0.53	4.45e-12	Corneal structure;
UCEC	cis	rs9341808	0.600	rs668329	chr6:80968578	G/A	cg08355045	chr6:80787529	NA	-0.36	-4.66	-0.36	6.99e-6	Sitting height ratio;
UCEC	cis	rs2745967	0.936	rs11578508	chr1:208129065	A/G	cg04277893	chr1:208128984	NA	-0.4	-4.57	-0.35	1.01e-5	Resting heart rate;
UCEC	cis	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg27432699	chr2:27873401	GPN1	0.51	4.9	0.37	2.52e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg02820040	chr2:241836501	C2orf54	-0.38	-4.97	-0.38	1.82e-6	Urinary metabolites;
UCEC	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.53	5.76	0.43	4.76e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	1.2	14.57	0.77	2.6e-30	Post bronchodilator FEV1;
UCEC	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.86	12.52	0.72	6.04e-25	Leprosy;
UCEC	cis	rs1318937	0.764	rs60977744	chr3:15239971	C/A	cg21849552	chr3:14597650	NA	0.49	4.78	0.37	4.17e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.64	7.52	0.53	4.91e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg01689657	chr7:91764605	CYP51A1	0.46	6.24	0.46	4.36e-9	Breast cancer;
UCEC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.69	-0.42	6.8e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.56	-4.91	-0.38	2.36e-6	Carotid intima media thickness;
UCEC	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.29	-0.4	4.45e-7	Personality dimensions;
UCEC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg04553112	chr3:125709451	NA	-0.74	-5.15	-0.39	8.37e-7	Blood pressure (smoking interaction);
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg11728900	chr10:13203459	MCM10	-0.61	-6.75	-0.49	3.17e-10	Breast cancer;
UCEC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs2979489	0.786	rs2979505	chr8:30387242	T/C	cg26383811	chr8:30366931	RBPMS	-0.78	-5.58	-0.42	1.12e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	5.33	0.4	3.67e-7	Response to antipsychotic treatment;
UCEC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.72	-8.38	-0.57	3.96e-14	Coronary artery disease;
UCEC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.67	-7.33	-0.52	1.41e-11	Ear protrusion;
UCEC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.43	-4.91	-0.38	2.41e-6	Response to antineoplastic agents;
UCEC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.62	-0.42	9.26e-8	Crohn's disease;
UCEC	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg10902566	chr4:727664	PCGF3	-0.57	-5.02	-0.38	1.45e-6	Systolic blood pressure;
UCEC	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.71	8.02	0.55	3.05e-13	Menopause (age at onset);
UCEC	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.86	6.95	0.5	1.13e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.5	-5.08	-0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.34	0.46	2.72e-9	Blood protein levels;
UCEC	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.62	-5.46	-0.41	1.96e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.98	-0.44	1.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3741798	1.000	rs61922054	chr12:12499472	A/G	cg08615371	chr12:12503544	MANSC1	0.83	4.96	0.38	1.89e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs4713118	0.506	rs9366697	chr6:27633018	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.65	-0.36	7.23e-6	Parkinson's disease;
UCEC	cis	rs28795989	0.731	rs6857814	chr4:7916540	A/G	cg00251875	chr4:7801337	AFAP1	-0.56	-6.23	-0.46	4.54e-9	Intraocular pressure;
UCEC	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg12596171	chr3:113251061	SIDT1	0.46	4.58	0.35	1e-5	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.56	5.27	0.4	4.85e-7	Menarche (age at onset);
UCEC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.46	-4.75	-0.36	4.85e-6	Platelet count;
UCEC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg02413938	chr2:239008929	ESPNL	-0.36	-4.64	-0.36	7.58e-6	Prostate cancer;
UCEC	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg19413350	chr8:57351067	NA	-0.43	-5.02	-0.38	1.49e-6	Obesity-related traits;
UCEC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.08	-8.04	-0.55	2.72e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.4	-4.75	-0.36	4.77e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.38	-4.82	-0.37	3.57e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	6.45	0.47	1.52e-9	Bipolar disorder;
UCEC	cis	rs2892463	0.796	rs11147398	chr13:30359674	G/A	cg18356743	chr13:30408050	UBL3	-0.41	-4.58	-0.35	9.81e-6	Non-word repetition;
UCEC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.51	6.05	0.45	1.16e-8	Total body bone mineral density;
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.62	0.58	9.98e-15	Prudent dietary pattern;
UCEC	cis	rs883565	0.740	rs11925218	chr3:39081171	C/A	cg01426195	chr3:39028469	NA	-0.68	-8.52	-0.58	1.71e-14	Handedness;
UCEC	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg07930552	chr6:133119739	C6orf192	0.87	6.51	0.47	1.13e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.48e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.6	5.48	0.41	1.78e-7	Type 2 diabetes;
UCEC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.63	6.7	0.48	4.04e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.57	-5.78	-0.43	4.37e-8	Hepatocellular carcinoma;
UCEC	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.74	7.12	0.51	4.38e-11	Monocyte count;
UCEC	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.47	-0.41	1.9e-7	Breast cancer;
UCEC	cis	rs12086130	0.892	rs72906818	chr1:51470403	T/G	cg07174182	chr1:51127561	FAF1	-0.77	-4.71	-0.36	5.61e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.33	0.65	3.9e-19	Electrocardiographic conduction measures;
UCEC	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg05660106	chr1:15850417	CASP9	0.95	10.06	0.64	1.89e-18	Systolic blood pressure;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.62	6.83	0.49	2.07e-10	Longevity;Endometriosis;
UCEC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg26721908	chr21:47610096	LSS	-0.38	-4.74	-0.36	5.03e-6	Testicular germ cell tumor;
UCEC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-7.02	-0.5	7.4e-11	Hemoglobin concentration;
UCEC	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.39	4.86	0.37	2.95e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1519814	1.000	rs1519814	chr8:121115024	T/G	cg22335954	chr8:121166405	COL14A1	-0.67	-5.39	-0.41	2.79e-7	Breast cancer;
UCEC	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg23283320	chr21:48055893	PRMT2	1.02	4.64	0.36	7.75e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	4.77	0.37	4.36e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.47	5.49	0.41	1.71e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.62	6.65	0.48	5.43e-10	Neuroticism;
UCEC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.86	0.49	1.81e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.5e-8	Aortic root size;
UCEC	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.52	-5.21	-0.4	6.14e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg06722792	chr21:44073919	PDE9A	-0.49	-4.5	-0.35	1.36e-5	Mean corpuscular volume;
UCEC	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.8	-0.37	3.9e-6	Height;
UCEC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg14438399	chr17:27053147	TLCD1	0.6	4.64	0.36	7.79e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-6.57	-0.48	8.21e-10	Hypospadias;
UCEC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.11e-5	Alzheimer's disease;
UCEC	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.73	6.04	0.45	1.2e-8	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.96	11.73	0.7	7.79e-23	Bone mineral density;
UCEC	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs77972916	0.609	rs72790907	chr2:43575195	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.52	-0.35	1.26e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.6	8.76	0.59	4.24e-15	Prudent dietary pattern;
UCEC	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg17652424	chr22:38574118	PLA2G6	-0.39	-4.74	-0.36	4.94e-6	Cutaneous nevi;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.88	9.68	0.62	1.89e-17	Menarche (age at onset);
UCEC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Smoking initiation;
UCEC	trans	rs4534959	0.546	rs76539466	chr18:62060261	A/C	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.81	0.43	3.76e-8	Height;
UCEC	cis	rs17122693	0.748	rs1009292	chr14:51143683	A/T	cg04730355	chr14:51134070	SAV1	0.95	9.85	0.63	6.97e-18	Cognitive performance;
UCEC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.86	-0.37	2.92e-6	Breast cancer;
UCEC	cis	rs4654899	0.680	rs3125160	chr1:21127803	G/C	cg01072550	chr1:21505969	NA	0.53	5.5	0.41	1.67e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18854424	chr1:2615690	NA	0.37	5.74	0.43	5.29e-8	Ulcerative colitis;
UCEC	cis	rs3772130	0.564	rs4420917	chr3:121567863	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs4705962	0.959	rs2227284	chr5:132012725	G/T	cg27309611	chr5:132113725	SEPT8	-0.42	-5.58	-0.42	1.11e-7	Atopic dermatitis;
UCEC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	11.32	0.68	9.46e-22	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.53	-0.42	1.42e-7	Platelet count;
UCEC	cis	rs16932667	0.857	rs11063467	chr12:5133940	A/C	cg13404421	chr12:4382181	CCND2	0.46	4.62	0.36	8.26e-6	Intelligence (childhood);
UCEC	cis	rs2836633	0.965	rs2836615	chr21:40048039	C/T	cg05519781	chr21:40033154	ERG	0.78	8.82	0.59	3.03e-15	Coronary artery disease;
UCEC	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.67	-6.42	-0.47	1.77e-9	Platelet distribution width;
UCEC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-4.81	-0.37	3.64e-6	Blood metabolite levels;
UCEC	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.47	-4.86	-0.37	3.01e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.54	-5.11	-0.39	9.67e-7	Morning vs. evening chronotype;
UCEC	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.54e-18	Height;
UCEC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg18451016	chr1:38461880	NA	0.63	5.96	0.44	1.78e-8	Red cell distribution width;
UCEC	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.06	8.52	0.57	1.76e-14	Opioid sensitivity;
UCEC	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.78	-7.69	-0.54	1.95e-12	Parkinson's disease;
UCEC	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.63	7.42	0.52	8.83e-12	Schizophrenia;
UCEC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.61	6.39	0.47	2.05e-9	QRS complex (12-leadsum);
UCEC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.43	-0.41	2.32e-7	Hemoglobin concentration;
UCEC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.66	5.8	0.43	3.92e-8	Response to diuretic therapy;
UCEC	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.54	-5.8	-0.43	3.89e-8	Menarche (age at onset);
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs909685	0.590	rs3747177	chr22:39746168	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.63	4.78	0.37	4.29e-6	Rheumatoid arthritis;
UCEC	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.45	-0.52	7.51e-12	Total cholesterol levels;
UCEC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.64	5.28	0.4	4.62e-7	Menarche (age at onset);
UCEC	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg19773385	chr1:10388646	KIF1B	-0.59	-6.0	-0.44	1.46e-8	Hepatocellular carcinoma;
UCEC	cis	rs4372836	1.000	rs2276547	chr2:28975107	G/C	cg09522027	chr2:28974177	PPP1CB	-0.71	-7.44	-0.52	7.89e-12	Body mass index;
UCEC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.67	6.83	0.49	2.11e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.45	0.41	2.03e-7	Total body bone mineral density;
UCEC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.67	5.26	0.4	4.91e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.66	6.72	0.48	3.69e-10	Bipolar disorder;
UCEC	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.49	6.84	0.49	1.93e-10	Sitting height ratio;
UCEC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg16023434	chr1:11395635	NA	0.37	4.55	0.35	1.12e-5	Body mass index;
UCEC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg14067834	chr17:29058358	SUZ12P	0.64	4.6	0.35	9.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.47	-4.9	-0.37	2.46e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg22974920	chr21:40686053	BRWD1	0.63	5.5	0.41	1.68e-7	Cognitive function;
UCEC	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.78	0.49	2.67e-10	Cognitive ability;
UCEC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-1.09	-9.55	-0.62	4.07e-17	Dupuytren's disease;
UCEC	cis	rs8105895	0.935	rs62110992	chr19:22261516	T/G	cg24072202	chr19:22235272	ZNF257	-0.59	-5.08	-0.39	1.12e-6	Body mass index (change over time);
UCEC	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg13575925	chr12:9217583	LOC144571	0.39	4.72	0.36	5.55e-6	Sjögren's syndrome;
UCEC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.05	-9.44	-0.61	8.11e-17	Vitiligo;
UCEC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.61	6.67	0.48	4.79e-10	Monocyte count;
UCEC	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs7246967	0.673	rs427709	chr19:22998163	A/G	cg24889512	chr19:22816950	ZNF492	0.54	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.82	-0.49	2.22e-10	Longevity;Endometriosis;
UCEC	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.68	5.73	0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	0.87	5.16	0.39	8.02e-7	Blood protein levels;
UCEC	cis	rs1109861	0.663	rs658469	chr10:11221366	C/T	cg23397013	chr10:10571132	NA	0.34	4.55	0.35	1.1e-5	Urinary albumin-to-creatinine ratio;
UCEC	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-6.22	-0.46	4.91e-9	Platelet distribution width;
UCEC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	6.16	0.45	6.53e-9	Bone mineral density;
UCEC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.66	-7.22	-0.51	2.65e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg14851346	chr12:38532713	NA	-0.5	-4.83	-0.37	3.38e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.69	6.52	0.47	1.07e-9	Ovarian reserve;
UCEC	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.48	-5.98	-0.44	1.61e-8	Insulin-like growth factors;
UCEC	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.79	7.76	0.54	1.32e-12	Migraine;Coronary artery disease;
UCEC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.76	-10.18	-0.64	9.54e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg02160872	chr5:212506	CCDC127	0.78	8.05	0.55	2.51e-13	Breast cancer;
UCEC	cis	rs4792143	0.521	rs1513741	chr17:11366905	T/C	cg23400451	chr17:10373728	MYH4	0.35	4.99	0.38	1.7e-6	Ischemic stroke;
UCEC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.75	8.04	0.55	2.67e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7246967	0.673	rs8105441	chr19:22891466	T/C	cg08271804	chr19:22816896	ZNF492	0.67	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.55	0.42	1.32e-7	Rheumatoid arthritis;
UCEC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg00343986	chr7:65444356	GUSB	-0.52	-4.59	-0.35	9.47e-6	Aortic root size;
UCEC	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg06784218	chr1:46089804	CCDC17	-0.42	-4.81	-0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.55	5.21	0.39	6.32e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.43	-5.41	-0.41	2.54e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.57	-0.48	7.98e-10	Adiposity;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg19041857	chr6:27730383	NA	-0.44	-4.62	-0.36	8.39e-6	Depression;
UCEC	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.11	9.45	0.61	7.25e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	4.93	0.38	2.18e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs3780378	0.935	rs6476939	chr9:5084837	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.05	-0.38	1.26e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.79	8.7	0.58	6.05e-15	Eosinophil percentage of white cells;
UCEC	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.4	4.85	0.37	3.16e-6	Height;
UCEC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.35	4.52	0.35	1.25e-5	Coronary artery disease;
UCEC	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.61	-6.27	-0.46	3.75e-9	Obesity-related traits;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.59	-7.22	-0.51	2.6e-11	Pubertal anthropometrics;
UCEC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.55	0.42	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs17012589	0.866	rs7487061	chr12:85649748	A/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.59	-0.35	9.26e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.15	0.39	8.21e-7	Breast cancer;
UCEC	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.62	5.89	0.44	2.55e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2592394	0.596	rs711829	chr2:177001292	C/A	cg13092806	chr2:177043255	NA	0.77	5.21	0.39	6.39e-7	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.26	0.51	2.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.76	-8.69	-0.58	6.46e-15	Menarche (age at onset);
UCEC	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	0.95	8.22	0.56	9.68e-14	Nonalcoholic fatty liver disease;
UCEC	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.61	-5.18	-0.39	7.17e-7	Non-glioblastoma glioma;Glioma;
UCEC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	0.82	7.07	0.5	5.7e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg14008862	chr17:28927542	LRRC37B2	0.78	5.05	0.38	1.29e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.49	-0.41	1.73e-7	Systolic blood pressure;
UCEC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg13147721	chr7:65941812	NA	-1.02	-5.29	-0.4	4.42e-7	Diabetic kidney disease;
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.89	-7.57	-0.53	3.71e-12	Coronary artery calcification;
UCEC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	5.55	0.42	1.29e-7	Cognitive test performance;
UCEC	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.6	-4.64	-0.36	7.66e-6	LDL cholesterol levels;
UCEC	cis	rs853679	0.567	rs6905380	chr6:28374902	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.72	-0.36	5.41e-6	Depression;
UCEC	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg12870014	chr12:110450643	ANKRD13A	0.58	4.91	0.38	2.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.6	0.48	6.94e-10	Bone mineral density;
UCEC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg24416660	chr17:73865998	NA	-0.34	-4.93	-0.38	2.15e-6	Psoriasis;
UCEC	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.4e-8	Height;
UCEC	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg23752985	chr2:85803571	VAMP8	0.47	5.22	0.4	6.11e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs12980942	0.935	rs1865051	chr19:41824885	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.55	4.9	0.37	2.51e-6	Coronary artery disease;
UCEC	cis	rs2742417	1.000	rs2673036	chr3:45752471	C/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.59	7.24	0.51	2.37e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.66	5.17	0.39	7.5e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12145833	0.665	rs78871868	chr1:243422322	C/T	cg02356786	chr1:243265016	LOC731275	0.84	5.86	0.44	2.95e-8	Obesity (early onset extreme);
UCEC	cis	rs2288327	0.818	rs13029629	chr2:179380165	A/G	cg09915519	chr2:179397513	TTN;MIR548N	-0.69	-4.59	-0.35	9.45e-6	Atrial fibrillation;
UCEC	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.47	-4.78	-0.37	4.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-5.99	-0.44	1.56e-8	Blood metabolite levels;
UCEC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.55	4.85	0.37	3.05e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.98	-0.44	1.62e-8	Joint mobility (Beighton score);
UCEC	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.74	6.66	0.48	5.03e-10	Body mass index;
UCEC	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg01426195	chr3:39028469	NA	-0.77	-10.31	-0.65	4.22e-19	Handedness;
UCEC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7766436	0.885	rs13198323	chr6:22577065	C/T	cg13666174	chr6:22585274	NA	-0.53	-5.73	-0.43	5.48e-8	Coronary artery disease;
UCEC	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.48	-5.87	-0.44	2.77e-8	Neuroticism;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.74	0.58	4.99e-15	Platelet count;
UCEC	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/T	cg23422044	chr7:1970798	MAD1L1	-0.72	-4.68	-0.36	6.56e-6	Bipolar disorder;
UCEC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.67	-7.14	-0.51	4.06e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.73	-7.75	-0.54	1.39e-12	Cognitive function;
UCEC	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.71	-7.27	-0.51	2e-11	Body mass index;
UCEC	cis	rs17012589	0.866	rs34038703	chr12:85657198	C/G	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.59	-0.35	9.26e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs3914502	0.571	rs34369956	chr3:174479776	A/G	cg21145449	chr3:174580620	NAALADL2	-0.39	-4.66	-0.36	7.12e-6	Autism spectrum disorder;
UCEC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.13	0.39	9.03e-7	Electroencephalogram traits;
UCEC	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.36	-0.46	2.35e-9	Metabolite levels;
UCEC	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg13683864	chr3:40499215	RPL14	-0.59	-5.64	-0.42	8.59e-8	Renal cell carcinoma;
UCEC	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.55	4.73	0.36	5.2e-6	Pulmonary function decline;
UCEC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.79	0.37	4.03e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.91	-13.09	-0.73	1.88e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.73	-7.59	-0.53	3.46e-12	Body mass index;
UCEC	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.6	-4.99	-0.38	1.68e-6	Corneal structure;
UCEC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.45	-4.97	-0.38	1.87e-6	Longevity;
UCEC	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg21770322	chr7:97807741	LMTK2	0.7	9.89	0.63	5.35e-18	Breast cancer;
UCEC	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.56	0.53	4.04e-12	Bipolar disorder;
UCEC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.49	5.6	0.42	1.04e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.47	6.02	0.44	1.33e-8	Cystic fibrosis severity;
UCEC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.69	5.35	0.4	3.32e-7	Initial pursuit acceleration;
UCEC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg05962950	chr11:130786565	SNX19	0.46	4.66	0.36	6.98e-6	Schizophrenia;
UCEC	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.67	6.97	0.5	9.82e-11	Body mass index;
UCEC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Corneal astigmatism;
UCEC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.79	0.43	4.12e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.71	-7.69	-0.54	1.94e-12	Breast cancer;
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	12.48	0.72	7.92e-25	Platelet count;
UCEC	cis	rs13095912	1.000	rs6784948	chr3:185342787	C/T	cg11274856	chr3:185301563	NA	0.54	7.25	0.51	2.25e-11	Systolic blood pressure;
UCEC	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.88	-7.22	-0.51	2.59e-11	Coronary artery calcification;
UCEC	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.51	-4.94	-0.38	2.08e-6	Large artery stroke;
UCEC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.78	-0.43	4.33e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.61	6.21	0.46	5.13e-9	Dental caries;
UCEC	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-1.01	-7.34	-0.52	1.35e-11	Multiple sclerosis;
UCEC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg24069376	chr3:38537580	EXOG	-0.45	-5.41	-0.41	2.44e-7	Electrocardiographic conduction measures;
UCEC	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.04	-14.5	-0.77	3.96e-30	Myeloid white cell count;
UCEC	cis	rs6793245	0.845	rs4073796	chr3:38590849	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-5.19	-0.39	7.01e-7	QT interval;
UCEC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg15147215	chr3:52552868	STAB1	-0.42	-4.52	-0.35	1.27e-5	Electroencephalogram traits;
UCEC	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.73	7.47	0.52	6.44e-12	Colorectal cancer;
UCEC	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.54	4.78	0.37	4.21e-6	Menarche (age at onset);
UCEC	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.68	5.8	0.43	3.9e-8	Prostate cancer;
UCEC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	4.9	0.37	2.55e-6	Neuroticism;
UCEC	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.35	1.11e-5	Bladder cancer;
UCEC	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg15513719	chr13:114904418	NA	0.46	4.51	0.35	1.3e-5	Schizophrenia;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs3853653	chr19:22871932	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.45	0.41	2.04e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7781557	1.000	rs7781557	chr7:102481891	A/G	cg06322601	chr7:102330635	NA	-0.8	-6.7	-0.48	4.25e-10	Colorectal adenoma (advanced);
UCEC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-4.96	-0.38	1.96e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.36	4.57	0.35	1e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg03859395	chr2:55845619	SMEK2	1.0	13.62	0.75	7.62e-28	Metabolic syndrome;
UCEC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.88	9.82	0.63	8.08e-18	Cognitive function;
UCEC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.8	-9.99	-0.64	2.97e-18	Menarche (age at onset);
UCEC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	0.91	11.03	0.67	5.45e-21	Homoarginine levels;
UCEC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.6	6.23	0.46	4.56e-9	Diastolic blood pressure;
UCEC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.11	0.39	9.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	4.54	0.35	1.15e-5	Diisocyanate-induced asthma;
UCEC	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.51	5.57	0.42	1.16e-7	Platelet distribution width;
UCEC	cis	rs11662586	0.573	rs7238269	chr18:77706294	A/G	cg20368463	chr18:77673604	PQLC1	0.66	6.46	0.47	1.47e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
UCEC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg18755752	chr8:142205143	DENND3	-0.66	-6.39	-0.47	2.08e-9	Immature fraction of reticulocytes;
UCEC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	5.19	0.39	6.73e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg00122941	chr17:4613640	ARRB2	0.65	5.05	0.38	1.31e-6	Lymphocyte counts;
UCEC	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg22771759	chr13:24902376	NA	0.41	4.66	0.36	6.96e-6	Obesity-related traits;
UCEC	cis	rs12644436	1.000	rs11097174	chr4:88781851	C/T	cg27179352	chr4:88029472	AFF1	0.44	5.1	0.39	1.04e-6	HIV-1 viral setpoint;
UCEC	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.41	-4.55	-0.35	1.11e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.75	-8.3	-0.56	6.25e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg10224037	chr5:178157518	ZNF354A	0.72	5.6	0.42	1.02e-7	Neutrophil percentage of white cells;
UCEC	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.57	0.42	1.16e-7	Lung cancer in ever smokers;
UCEC	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	7.04	0.5	6.95e-11	Menopause (age at onset);
UCEC	cis	rs11697848	1.000	rs3210880	chr20:48506338	A/G	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.87	10.88	0.67	1.38e-20	Longevity;Endometriosis;
UCEC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11050527	chr8:54755511	ATP6V1H	0.55	6.79	0.49	2.55e-10	Warfarin maintenance dose;
UCEC	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.93	12.12	0.71	7.07e-24	Bone mineral density;
UCEC	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-5.21	-0.39	6.25e-7	Multiple sclerosis;
UCEC	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-1.04	-12.32	-0.71	2.03e-24	Schizophrenia;
UCEC	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-1.11	-5.49	-0.41	1.68e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.62	5.42	0.41	2.35e-7	Longevity;
UCEC	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.75	-8.15	-0.56	1.48e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.96	0.5	1.07e-10	Bladder cancer;
UCEC	cis	rs7246967	0.932	rs35007403	chr19:23037447	T/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.72	-8.21	-0.56	1.01e-13	Coronary artery disease;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.75	-0.36	4.88e-6	Pulmonary function;
UCEC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.83	9.54	0.62	4.39e-17	Metabolite levels;
UCEC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	7.26	0.51	2.07e-11	Type 2 diabetes;
UCEC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.59	5.74	0.43	5.14e-8	Lymphocyte counts;
UCEC	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-5.09	-0.39	1.06e-6	Morning vs. evening chronotype;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.72	-0.48	3.71e-10	Pubertal anthropometrics;
UCEC	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg05660106	chr1:15850417	CASP9	0.48	4.58	0.35	1e-5	Systolic blood pressure;
UCEC	cis	rs12705054	0.618	rs10278443	chr7:98857995	A/G	cg24650262	chr7:98904301	NA	0.54	4.51	0.35	1.33e-5	Facial emotion recognition (sad faces);
UCEC	cis	rs2742417	0.967	rs2742427	chr3:45736423	C/T	cg01451880	chr3:45801044	SLC6A20	0.4	5.17	0.39	7.58e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg05660106	chr1:15850417	CASP9	-1.05	-11.76	-0.7	6.57e-23	Systolic blood pressure;
UCEC	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs116095464	1.000	rs6863730	chr5:325003	G/T	cg04473437	chr5:205334	CCDC127	-0.69	-5.55	-0.42	1.27e-7	Breast cancer;
UCEC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.4	-0.47	1.94e-9	Aortic root size;
UCEC	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.78	-6.92	-0.5	1.29e-10	Caudate activity during reward;
UCEC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.17	6.73	0.49	3.45e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.52	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.86	5.77	0.43	4.56e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-5.62	-0.42	9.42e-8	Total body bone mineral density;
UCEC	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.94	-10.6	-0.66	7.41e-20	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg16286735	chr17:45371778	ITGB3	0.27	4.58	0.35	9.64e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs9831754	0.756	rs7653140	chr3:78419340	C/G	cg06138941	chr3:78371609	NA	-0.71	-5.49	-0.41	1.71e-7	Calcium levels;
UCEC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18252515	chr7:66147081	NA	0.57	5.33	0.4	3.55e-7	Aortic root size;
UCEC	cis	rs2302190	0.882	rs7216856	chr17:56472295	C/T	cg12560992	chr17:57184187	TRIM37	0.51	5.09	0.39	1.1e-6	Vitamin D levels;
UCEC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg00105475	chr2:10696890	NA	0.42	5.22	0.4	6.1e-7	Prostate cancer;
UCEC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.48	4.79	0.37	4.03e-6	Corneal astigmatism;
UCEC	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.93	0.5	1.22e-10	Bladder cancer;
UCEC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.09	8.55	0.58	1.43e-14	Vitiligo;
UCEC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	6.3	0.46	3.33e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.4	5.02	0.38	1.49e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.49	0.41	1.72e-7	Platelet count;
UCEC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.72	-0.36	5.51e-6	Parkinson's disease;
UCEC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.63	7.05	0.5	6.63e-11	Homoarginine levels;
UCEC	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.65	-5.98	-0.44	1.62e-8	Systemic lupus erythematosus;
UCEC	cis	rs4148689	1.000	rs4148691	chr7:117150118	G/C	cg21212505	chr7:117228958	CFTR	-0.41	-4.62	-0.36	8.24e-6	Gout;
UCEC	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg21191810	chr6:118973309	C6orf204	0.42	5.82	0.43	3.59e-8	Electrocardiographic conduction measures;
UCEC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12402800	chr5:56204917	C5orf35	-0.46	-4.62	-0.36	8.15e-6	Coronary artery disease;
UCEC	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-6.27	-0.46	3.8e-9	Vitiligo;
UCEC	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.62	6.56	0.48	8.8e-10	Colorectal cancer;
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.27	0.71	2.77e-24	Platelet count;
UCEC	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.51	5.3	0.4	4.13e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg23307798	chr14:103986281	CKB	0.65	8.0	0.55	3.42e-13	Body mass index;
UCEC	cis	rs773506	0.628	rs10820836	chr9:93928329	A/G	cg03243796	chr9:93920768	NA	-0.41	-5.09	-0.39	1.07e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.53	-5.96	-0.44	1.79e-8	Blood metabolite levels;
UCEC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.62	5.85	0.43	3.01e-8	Corneal astigmatism;
UCEC	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.73	-5.65	-0.42	8.09e-8	Orofacial clefts;
UCEC	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg16540259	chr10:75572220	NDST2	0.37	4.52	0.35	1.26e-5	Inflammatory bowel disease;
UCEC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.36	-0.4	3.09e-7	Breast cancer;
UCEC	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.7	6.06	0.45	1.1e-8	Alzheimer's disease;
UCEC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg15848620	chr12:58087721	OS9	-0.53	-4.88	-0.37	2.7e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs731174	0.797	rs686083	chr1:38149193	C/T	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.34e-6	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25998860	chr5:126853954	PRRC1	0.59	7.01	0.5	8.11e-11	Warfarin maintenance dose;
UCEC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.63	6.58	0.48	7.72e-10	Obesity-related traits;
UCEC	cis	rs2058350	0.636	rs3825374	chr12:3941415	C/A	cg23794848	chr12:3563020	NA	0.49	4.51	0.35	1.29e-5	Cognitive performance;
UCEC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg22117172	chr7:91764530	CYP51A1	-0.4	-4.72	-0.36	5.51e-6	Breast cancer;
UCEC	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.66	5.82	0.43	3.51e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18252515	chr7:66147081	NA	0.46	4.75	0.37	4.72e-6	Aortic root size;
UCEC	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.67	-7.06	-0.5	6.09e-11	Brain structure;
UCEC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.73	8.71	0.58	5.86e-15	Prudent dietary pattern;
UCEC	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg22139774	chr2:100720529	AFF3	-0.39	-5.01	-0.38	1.51e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.69	0.42	6.79e-8	Rheumatoid arthritis;
UCEC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.79	-8.57	-0.58	1.28e-14	Breast cancer;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.52	-5.67	-0.42	7.16e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7246967	0.608	rs396440	chr19:23002966	A/G	cg08271804	chr19:22816896	ZNF492	0.58	5.23	0.4	5.61e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.73	7.74	0.54	1.45e-12	Primary sclerosing cholangitis;
UCEC	cis	rs7113850	0.541	rs7927067	chr11:24232604	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.37	-5.86	-0.44	2.94e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9825420	1.000	rs9809758	chr3:37610360	C/T	cg15682617	chr3:38589863	SCN5A	-0.7	-4.67	-0.36	6.87e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.13e-9	Tonsillectomy;
UCEC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.74	-7.86	-0.54	7.41e-13	Cognitive function;
UCEC	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.51	5.36	0.4	3.14e-7	Autism;
UCEC	cis	rs925228	0.869	rs6545121	chr2:24044501	T/A	cg13272742	chr2:24272458	FKBP1B	-0.57	-4.98	-0.38	1.78e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.9	-6.89	-0.49	1.49e-10	Initial pursuit acceleration;
UCEC	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.81	-8.83	-0.59	2.91e-15	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1549118	0.595	rs28613643	chr14:78332161	G/A	cg18985109	chr14:78266276	ADCK1	-0.63	-5.17	-0.39	7.4e-7	Resting heart rate;
UCEC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.68	5.64	0.42	8.58e-8	Corneal astigmatism;
UCEC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg03714773	chr7:91764589	CYP51A1	0.4	4.98	0.38	1.76e-6	Breast cancer;
UCEC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.6	6.78	0.49	2.75e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.54	-0.42	1.36e-7	Fear of minor pain;
UCEC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.74	8.55	0.58	1.46e-14	Prudent dietary pattern;
UCEC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.51	-0.47	1.09e-9	Aortic root size;
UCEC	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-17.76	-0.83	2.07e-38	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg13319975	chr6:146136371	FBXO30	0.45	4.9	0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.46	6.79	0.49	2.57e-10	Homoarginine levels;
UCEC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.52	-0.35	1.27e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg18681998	chr4:17616180	MED28	0.9	11.82	0.7	4.49e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.64	6.3	0.46	3.33e-9	Itch intensity from mosquito bite;
UCEC	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.72	-8.79	-0.59	3.7e-15	Prevalent atrial fibrillation;
UCEC	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.85	5.78	0.43	4.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.83	10.28	0.65	5.1e-19	Mortality in heart failure;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.66	7.63	0.53	2.78e-12	Prudent dietary pattern;
UCEC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-4.69	-0.36	6.1e-6	Type 2 diabetes;
UCEC	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	6.26	0.46	4.08e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2806864	1.000	rs2250744	chr1:117463154	C/A	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.69	-0.36	6.13e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.8	6.8	0.49	2.4e-10	Menopause (age at onset);
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.48	-5.22	-0.4	5.99e-7	Depression;
UCEC	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.45	-4.8	-0.37	3.9e-6	Corneal astigmatism;
UCEC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs2801405	0.604	rs837575	chr10:100386062	T/C	cg25214158	chr10:101289600	NA	-0.37	-4.59	-0.35	9.53e-6	Obesity-related traits;
UCEC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.92	-12.8	-0.73	1.14e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.63	-5.91	-0.44	2.33e-8	Body mass index;
UCEC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.84	-0.37	3.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.09	13.33	0.74	4.46e-27	Cognitive function;
UCEC	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg04283868	chr2:201171347	SPATS2L	0.52	5.28	0.4	4.52e-7	QT interval;
UCEC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.96	13.77	0.75	3.1e-28	Bone mineral density;
UCEC	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.85	-6.4	-0.47	1.96e-9	Exhaled nitric oxide output;
UCEC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.48	5.66	0.42	7.74e-8	Aortic root size;
UCEC	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.48	4.7	0.36	6e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.7	7.68	0.54	2.08e-12	Lymphocyte counts;
UCEC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-5.5	-0.41	1.67e-7	Chronic sinus infection;
UCEC	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-5.41	-0.41	2.5e-7	Pediatric autoimmune diseases;
UCEC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-4.72	-0.36	5.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.46	-0.41	2e-7	Alcohol dependence;
UCEC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg04310649	chr10:35416472	CREM	-0.5	-4.75	-0.37	4.69e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-4.93	-0.38	2.21e-6	Alcohol dependence;
UCEC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg19678392	chr7:94953810	PON1	-0.57	-5.52	-0.41	1.51e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg05527609	chr1:210001259	C1orf107	-0.52	-4.75	-0.36	4.84e-6	Red blood cell count;
UCEC	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.37	-5.33	-0.4	3.6e-7	Schizophrenia;
UCEC	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.68	7.06	0.5	6.08e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.47	5.5	0.41	1.67e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg19477247	chr3:113955994	ZNF80	-0.35	-4.56	-0.35	1.06e-5	IgG glycosylation;
UCEC	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.18	-0.39	7.23e-7	Personality dimensions;
UCEC	cis	rs10208940	0.920	rs13422657	chr2:68706989	T/C	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.8	-7.43	-0.52	8.21e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.78	-0.43	4.32e-8	Height;
UCEC	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.8	8.75	0.59	4.49e-15	Eosinophil percentage of white cells;
UCEC	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.73	-5.89	-0.44	2.58e-8	Blood protein levels;
UCEC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.47	5.92	0.44	2.21e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.86	-0.44	2.87e-8	Initial pursuit acceleration;
UCEC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs787274	1.000	rs1891403	chr9:115527183	C/T	cg13803584	chr9:115635662	SNX30	-0.71	-5.85	-0.43	3e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.54	-5.93	-0.44	2.09e-8	Blood metabolite levels;
UCEC	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.49	6.2	0.46	5.3e-9	Electrocardiographic conduction measures;
UCEC	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.74	-0.36	5.01e-6	Depression;
UCEC	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	4.78	0.37	4.17e-6	Height;
UCEC	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.64	7.58	0.53	3.65e-12	Breast cancer;
UCEC	cis	rs4945829	0.545	rs77243579	chr6:109640864	A/G	cg01475377	chr6:109611718	NA	0.47	5.21	0.39	6.29e-7	Midgestational circulating levels of PCBs;
UCEC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.8	0.43	3.88e-8	Breast cancer;
UCEC	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.57	-6.6	-0.48	6.94e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-0.77	-5.23	-0.4	5.79e-7	Blood protein levels;
UCEC	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-6.6	-0.48	7.11e-10	Platelet distribution width;
UCEC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.25	-7.8	-0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.48	4.84	0.37	3.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	5.08	0.39	1.11e-6	Bone mineral density;
UCEC	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.83	8.36	0.57	4.34e-14	Post bronchodilator FEV1;
UCEC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.37	-4.88	-0.37	2.79e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.95	-6.72	-0.48	3.77e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.58	5.48	0.41	1.79e-7	Corneal astigmatism;
UCEC	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.72	5.98	0.44	1.65e-8	Coronary artery calcification;
UCEC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.65	6.16	0.45	6.56e-9	Systemic lupus erythematosus;
UCEC	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg05660106	chr1:15850417	CASP9	0.93	10.44	0.65	1.95e-19	Systolic blood pressure;
UCEC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-6.21	-0.46	5.09e-9	Bipolar disorder;
UCEC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	4.59	0.35	9.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.57	6.73	0.49	3.58e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.57	5.37	0.4	3.06e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.07	-0.45	1.04e-8	Parkinson's disease;
UCEC	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	trans	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg15509575	chr4:2286509	ZFYVE28	0.38	6.79	0.49	2.64e-10	Rheumatoid arthritis;
UCEC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg18451016	chr1:38461880	NA	0.61	5.84	0.43	3.17e-8	Coronary artery disease;
UCEC	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.69	-6.5	-0.47	1.18e-9	Morning vs. evening chronotype;
UCEC	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg11150807	chr10:43354902	NA	0.75	4.95	0.38	1.99e-6	Blood protein levels;
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs1165668	0.959	rs1165675	chr12:104320991	G/T	cg21863207	chr12:104234989	NT5DC3	-0.57	-5.03	-0.38	1.42e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.8	-9.0	-0.6	1.07e-15	Mean platelet volume;
UCEC	cis	rs253959	0.883	rs6594967	chr5:115710803	T/C	cg23108291	chr5:115420582	COMMD10	-0.48	-4.66	-0.36	6.98e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	0.83	9.96	0.63	3.56e-18	Bone mineral density;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.26	0.51	2.05e-11	Platelet count;
UCEC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs6867032	0.527	rs4975792	chr5:2010496	T/G	cg26168224	chr5:2018326	NA	0.57	6.94	0.5	1.19e-10	Gut microbiome composition (winter);
UCEC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-4.56	-0.35	1.07e-5	Corneal structure;
UCEC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg06096015	chr1:231504339	EGLN1	0.46	5.27	0.4	4.88e-7	Hemoglobin concentration;
UCEC	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.69	-7.66	-0.53	2.24e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.78	-0.77	7.19e-31	Schizophrenia;
UCEC	cis	rs4588572	0.686	rs2362823	chr5:77693623	A/G	cg11547950	chr5:77652471	NA	0.47	5.33	0.4	3.6e-7	Triglycerides;
UCEC	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.11	-0.45	8.35e-9	Response to antipsychotic treatment;
UCEC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.36	8.58e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs13098911	0.540	rs36039366	chr3:46003537	G/A	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.79	-0.37	4.1e-6	Cardiac Troponin-T levels;
UCEC	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg20129853	chr10:51489980	NA	-0.4	-4.79	-0.37	4.01e-6	Prostate-specific antigen levels;
UCEC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.43	-4.62	-0.36	8.17e-6	Total body bone mineral density;
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.41	4.79	0.37	4.02e-6	Obesity-related traits;
UCEC	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-4.69	-0.36	6.08e-6	Educational attainment;
UCEC	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.95	0.5	1.11e-10	Coffee consumption (cups per day);
UCEC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	6.57	0.48	8.37e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-0.92	-11.7	-0.69	9.41e-23	Coronary artery disease;
UCEC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	18.83	0.84	5.07e-41	IgG glycosylation;
UCEC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.3	-0.46	3.33e-9	Chronic sinus infection;
UCEC	cis	rs9715521	0.803	rs62301187	chr4:59840420	T/C	cg11281224	chr4:60001000	NA	-0.53	-5.3	-0.4	4.2e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.84	-0.37	3.27e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg11859384	chr17:80120422	CCDC57	-0.48	-5.34	-0.4	3.52e-7	Life satisfaction;
UCEC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg06784218	chr1:46089804	CCDC17	0.43	4.98	0.38	1.75e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg12317470	chr15:67143691	NA	-0.63	-5.95	-0.44	1.93e-8	Lung cancer (smoking interaction);
UCEC	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.63	6.3	0.46	3.19e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.54	-0.35	1.17e-5	Mood instability;
UCEC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.91	-10.74	-0.66	3.09e-20	Cognitive function;
UCEC	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg02158880	chr13:53174818	NA	0.41	4.84	0.37	3.32e-6	Lewy body disease;
UCEC	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	17.48	0.82	1.04e-37	Colorectal cancer;
UCEC	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg01072550	chr1:21505969	NA	-0.61	-6.49	-0.47	1.27e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.55	-5.28	-0.4	4.63e-7	Initial pursuit acceleration;
UCEC	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Obesity-related traits;
UCEC	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg04310649	chr10:35416472	CREM	-0.48	-4.79	-0.37	4.09e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg14851346	chr12:38532713	NA	0.52	5.02	0.38	1.47e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.58	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.84	-9.57	-0.62	3.69e-17	Intelligence (multi-trait analysis);
UCEC	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	0.7	7.94	0.55	4.72e-13	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs174449	0.603	rs174460	chr11:61657110	C/T	cg01500311	chr11:61656094	FADS3	0.52	6.36	0.46	2.44e-9	Trans fatty acid levels;
UCEC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg11871910	chr12:69753446	YEATS4	0.64	5.46	0.41	1.99e-7	Response to diuretic therapy;
UCEC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.48	0.57	2.21e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.72	-0.36	5.36e-6	Aortic root size;
UCEC	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.5	5.5	0.41	1.66e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.65	-6.0	-0.44	1.5e-8	Gut microbiome composition (summer);
UCEC	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22509189	chr2:225307070	NA	-0.55	-4.88	-0.37	2.72e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.41	-4.98	-0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.59	-0.35	9.44e-6	Depression;
UCEC	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.87	-10.71	-0.66	3.84e-20	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.57	5.26	0.4	5.03e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.72	-4.76	-0.37	4.54e-6	Hair shape;
UCEC	cis	rs7843479	0.526	rs3816788	chr8:21832494	A/C	cg17168535	chr8:21777572	XPO7	0.68	7.71	0.54	1.74e-12	Mean corpuscular volume;
UCEC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.63	6.36	0.46	2.41e-9	Blood metabolite levels;
UCEC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.39	-0.57	3.66e-14	Monocyte count;
UCEC	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.76	8.11	0.56	1.84e-13	Eosinophil percentage of white cells;
UCEC	cis	rs354033	0.837	rs6945729	chr7:149195972	A/T	cg24335155	chr7:149193227	ZNF746	0.4	4.54	0.35	1.16e-5	Multiple sclerosis;
UCEC	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.13	14.68	0.77	1.28e-30	Schizophrenia;
UCEC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.11	-0.39	9.76e-7	Colorectal cancer;
UCEC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.5	5.9	0.44	2.43e-8	Breast cancer;
UCEC	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.67	-0.36	6.67e-6	Resting heart rate;
UCEC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.1	0.39	1.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg19683494	chr5:74908142	NA	0.73	5.23	0.4	5.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg25811766	chr13:21894605	NA	-0.73	-5.3	-0.4	4.1e-7	White matter hyperintensity burden;
UCEC	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-8.42	-0.57	3.11e-14	Vitiligo;
UCEC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.03	-12.38	-0.71	1.43e-24	Dilated cardiomyopathy;
UCEC	cis	rs35275482	0.790	rs1437478	chr15:60111442	G/T	cg17563769	chr15:59949922	GTF2A2	0.63	4.52	0.35	1.28e-5	Gut microbiota (bacterial taxa);
UCEC	cis	rs394563	0.690	rs372205	chr6:149775267	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.44	-5.18	-0.39	7.15e-7	Dupuytren's disease;
UCEC	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.86	9.73	0.63	1.43e-17	Dental caries;
UCEC	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.72	-7.76	-0.54	1.34e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.66	7.63	0.53	2.73e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.68	-7.45	-0.52	7.39e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg21770322	chr7:97807741	LMTK2	-0.46	-5.55	-0.42	1.32e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg01500311	chr11:61656094	FADS3	-0.63	-8.56	-0.58	1.39e-14	Trans fatty acid levels;
UCEC	cis	rs1374313	0.872	rs11123521	chr2:120148826	A/G	cg23562675	chr2:120107745	C2orf76	-0.37	-4.52	-0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.46	-5.5	-0.41	1.66e-7	Neuroticism;
UCEC	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	4.88	0.37	2.76e-6	Blood metabolite levels;
UCEC	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg09654669	chr8:57350985	NA	-0.54	-5.43	-0.41	2.32e-7	Obesity-related traits;
UCEC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.66	0.36	7.15e-6	Bipolar disorder;
UCEC	cis	rs35934224	0.891	rs12158214	chr22:19871691	C/T	cg11182965	chr22:19864308	TXNRD2	-0.44	-5.87	-0.44	2.78e-8	Glaucoma (primary open-angle);
UCEC	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.63	0.53	2.74e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs77861329	0.920	rs9846049	chr3:52120214	A/G	cg08692210	chr3:52188851	WDR51A	0.73	5.88	0.44	2.66e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	6.2	0.46	5.49e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs6424115	0.644	rs2267960	chr1:24068544	T/C	cg15997130	chr1:24165203	NA	0.57	6.12	0.45	7.99e-9	Immature fraction of reticulocytes;
UCEC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-7.66	-0.53	2.36e-12	Menarche (age at onset);
UCEC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.69	0.36	6.25e-6	Schizophrenia;
UCEC	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.38	0.47	2.12e-9	Diabetic retinopathy;
UCEC	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	0.86	6.44	0.47	1.6e-9	Lymphocyte counts;
UCEC	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-6.06	-0.45	1.11e-8	Multiple sclerosis;
UCEC	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg06562184	chr8:19319451	CSGALNACT1	0.42	4.57	0.35	1.04e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.45	-0.41	2.04e-7	Bipolar disorder;
UCEC	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.73	-0.36	5.2e-6	Schizophrenia;
UCEC	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.84	-11.05	-0.67	4.73e-21	White blood cell count (basophil);
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg05738196	chr6:26577821	NA	0.59	6.44	0.47	1.6e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg24562669	chr7:97807699	LMTK2	0.5	6.08	0.45	9.94e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.46	5.16	0.39	7.87e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg21486944	chr6:28411378	ZSCAN23	-0.58	-6.76	-0.49	3.04e-10	Pubertal anthropometrics;
UCEC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.66	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.33	-4.78	-0.37	4.13e-6	Schizophrenia;
UCEC	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	7.57	0.53	3.79e-12	Coronary artery disease;
UCEC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.51	-4.77	-0.37	4.48e-6	Gut microbiome composition (summer);
UCEC	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-5.32	-0.4	3.74e-7	Kawasaki disease;
UCEC	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.91	-7.02	-0.5	7.42e-11	Exhaled nitric oxide output;
UCEC	cis	rs7766436	0.848	rs13207207	chr6:22579066	G/A	cg13666174	chr6:22585274	NA	-0.54	-5.76	-0.43	4.8e-8	Coronary artery disease;
UCEC	cis	rs13401104	0.740	rs12465430	chr2:237113578	C/T	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.83	6.24	0.46	4.33e-9	Multiple sclerosis;
UCEC	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.99	5.66	0.42	7.68e-8	Type 2 diabetes;
UCEC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.64	6.89	0.49	1.51e-10	Homoarginine levels;
UCEC	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.96	-0.38	1.93e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.63	-5.27	-0.4	4.73e-7	Strep throat;
UCEC	cis	rs7246967	1.000	rs35332070	chr19:23034266	G/A	cg24889512	chr19:22816950	ZNF492	0.5	5.12	0.39	9.34e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs5770917	1.000	rs2269384	chr22:51011115	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.7	-4.89	-0.37	2.56e-6	Narcolepsy;
UCEC	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.74	-5.24	-0.4	5.54e-7	Body mass index;
UCEC	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.54	6.12	0.45	7.98e-9	Aortic root size;
UCEC	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg18016565	chr1:150552671	MCL1	0.46	4.7	0.36	5.91e-6	Melanoma;
UCEC	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg06521331	chr12:34319734	NA	-0.62	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7804356	1.000	rs6461979	chr7:26888918	T/C	cg03456212	chr7:26904342	SKAP2	-0.61	-4.67	-0.36	6.63e-6	Type 1 diabetes;
UCEC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.59	7.05	0.5	6.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.54	-5.5	-0.41	1.65e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.93	6.53	0.47	1.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.2e-7	QRS complex (12-leadsum);
UCEC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg07076509	chr9:96720819	NA	-0.47	-5.23	-0.4	5.76e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.54	5.67	0.42	7.17e-8	Myopia (pathological);
UCEC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.62	7.11	0.51	4.79e-11	Longevity;
UCEC	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.51	-6.25	-0.46	4.19e-9	Mean platelet volume;
UCEC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.53	-5.27	-0.4	4.85e-7	Systemic lupus erythematosus;
UCEC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.61	0.53	3.1e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6834538	1.000	rs1486864	chr4:113465766	G/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.47	4.58	0.35	9.78e-6	Free thyroxine concentration;
UCEC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.61	7.22	0.51	2.63e-11	Vitiligo;
UCEC	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-4.87	-0.37	2.86e-6	Platelet distribution width;
UCEC	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.49	-5.12	-0.39	9.27e-7	Asthma;
UCEC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.51e-7	Hemoglobin concentration;
UCEC	cis	rs8016982	0.611	rs11159493	chr14:81639159	A/T	cg01989461	chr14:81687754	GTF2A1	0.71	6.9	0.49	1.46e-10	Schizophrenia;
UCEC	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.85e-8	Red blood cell count;
UCEC	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.58	5.97	0.44	1.74e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.7	6.58	0.48	7.65e-10	Lymphocyte counts;
UCEC	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.46	5.04	0.38	1.32e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	0.97	15.52	0.79	8.84e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.65	-4.82	-0.37	3.49e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg05991184	chr2:219186017	PNKD	-0.51	-5.53	-0.42	1.42e-7	Colorectal cancer;
UCEC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.5	-5.53	-0.41	1.45e-7	Aortic root size;
UCEC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.58	4.75	0.37	4.7e-6	Corneal astigmatism;
UCEC	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22857025	chr5:266934	NA	-1.18	-4.76	-0.37	4.52e-6	Breast cancer;
UCEC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg11871910	chr12:69753446	YEATS4	0.56	4.86	0.37	2.93e-6	Response to diuretic therapy;
UCEC	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg01493522	chr13:37497338	NA	-0.48	-4.91	-0.38	2.41e-6	Coronary artery disease;
UCEC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.87	-9.87	-0.63	6.07e-18	Cognitive function;
UCEC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg26566898	chr11:117069891	TAGLN	0.42	4.78	0.37	4.13e-6	Blood protein levels;
UCEC	cis	rs12618769	0.570	rs116051325	chr2:99056836	G/A	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.62	4.8	0.37	3.82e-6	Prostate cancer;
UCEC	cis	rs9039	1.000	rs1128001	chr16:9207003	T/C	cg08831531	chr16:9218945	NA	-0.43	-4.83	-0.37	3.4e-6	Menopause (age at onset);
UCEC	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-9.23	-0.61	2.74e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7204230	1.000	rs6499510	chr16:53288265	G/A	cg10109421	chr16:52641824	NA	0.4	4.66	0.36	6.88e-6	Fibrinogen;
UCEC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.5	5.36	0.4	3.09e-7	Schizophrenia;
UCEC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg01380346	chr19:18557039	ELL	-0.46	-4.76	-0.37	4.55e-6	Breast cancer;
UCEC	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-7.91	-0.55	5.84e-13	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg20387954	chr3:183756860	HTR3D	0.51	6.08	0.45	9.93e-9	Anterior chamber depth;
UCEC	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.56	4.73	0.36	5.21e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg04154034	chr17:28927549	LRRC37B2	0.82	5.2	0.39	6.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.1	7.97	0.55	4.14e-13	Alzheimer's disease (late onset);
UCEC	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	0.8	6.31	0.46	3.12e-9	Corneal structure;
UCEC	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.59	0.48	7.26e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.66	6.65	0.48	5.52e-10	Tonsillectomy;
UCEC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg24687543	chr11:63912206	MACROD1	0.39	4.82	0.37	3.5e-6	Platelet count;
UCEC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.41	-5.74	-0.43	5.22e-8	Prostate cancer;
UCEC	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.41	-4.73	-0.36	5.28e-6	Homocysteine levels;
UCEC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.54	-5.27	-0.4	4.77e-7	Diastolic blood pressure;
UCEC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.5	6.96	0.5	1.02e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.49	4.83	0.37	3.4e-6	Height;
UCEC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs17123764	0.710	rs11169109	chr12:50088363	A/T	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.54	4.7	0.36	5.81e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	7.45	0.52	7.48e-12	Motion sickness;
UCEC	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.48	5.39	0.41	2.72e-7	Response to temozolomide;
UCEC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.47	-4.76	-0.37	4.56e-6	Cardiac Troponin-T levels;
UCEC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.62	-8.09	-0.56	2e-13	Fibrinogen levels;
UCEC	cis	rs7709377	0.597	rs10042177	chr5:115467535	G/A	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.51	0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	0.83	5.92	0.44	2.16e-8	Red blood cell traits;
UCEC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.69	6.55	0.48	8.98e-10	Menarche (age at onset);
UCEC	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.08	8.85	0.59	2.55e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg21419209	chr3:44054225	NA	-0.5	-5.24	-0.4	5.44e-7	Coronary artery disease;
UCEC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7553864	0.667	rs4656143	chr1:87605208	G/A	cg17420885	chr1:87600446	LOC339524	-0.4	-4.51	-0.35	1.32e-5	Smoking behavior;
UCEC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.92	0.38	2.34e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	5.36	0.4	3.14e-7	Aortic root size;
UCEC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.6	5.35	0.4	3.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg13844804	chr7:814759	HEATR2	0.71	4.83	0.37	3.39e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg20637307	chr2:213403960	ERBB4	0.75	7.95	0.55	4.5e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.63	5.7	0.43	6.25e-8	Morning vs. evening chronotype;
UCEC	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.77	-6.89	-0.49	1.49e-10	Caudate activity during reward;
UCEC	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02711652	chr17:63555717	AXIN2	-0.49	-4.57	-0.35	1.02e-5	QT interval;
UCEC	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	6.23	0.46	4.56e-9	Bipolar disorder;
UCEC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.64	6.93	0.5	1.2e-10	Systolic blood pressure;
UCEC	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.5	5.51	0.41	1.56e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	0.92	7.22	0.51	2.65e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg15513719	chr13:114904418	NA	0.47	4.63	0.36	7.96e-6	Schizophrenia;
UCEC	cis	rs11867410	0.744	rs1391	chr17:63982072	C/T	cg06996976	chr17:64576105	PRKCA	-0.72	-4.55	-0.35	1.13e-5	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.66	-0.36	7.07e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.58	6.34	0.46	2.62e-9	Blood metabolite levels;
UCEC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.49	4.82	0.37	3.49e-6	Blood protein levels;
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.62	9.01	0.6	1.02e-15	Prudent dietary pattern;
UCEC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-6.07	-0.45	1.04e-8	HDL cholesterol;
UCEC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.87	-9.87	-0.63	6.07e-18	Cognitive function;
UCEC	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.08	0.39	1.11e-6	Height;
UCEC	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.44	5.34	0.4	3.41e-7	Metabolite levels;
UCEC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Smoking initiation;
UCEC	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.53	6.08	0.45	9.98e-9	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.99	0.64	2.95e-18	Menopause (age at onset);
UCEC	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.58	-5.16	-0.39	7.92e-7	Hypospadias;
UCEC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg13695892	chr22:41940480	POLR3H	-0.61	-4.5	-0.35	1.36e-5	Vitiligo;
UCEC	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	6.61	0.48	6.47e-10	Electrocardiographic conduction measures;
UCEC	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.83	-0.37	3.42e-6	Fear of minor pain;
UCEC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg22598563	chr5:131563921	P4HA2	-0.35	-4.68	-0.36	6.39e-6	Blood metabolite levels;
UCEC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.42	-4.75	-0.36	4.78e-6	Height;
UCEC	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.62	-4.81	-0.37	3.65e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-4.93	-0.38	2.18e-6	Menarche (age at onset);
UCEC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	0.99	5.76	0.43	4.86e-8	Schizophrenia;
UCEC	cis	rs2882667	0.964	rs12719517	chr5:138305502	C/T	cg04439458	chr5:138467593	SIL1	-0.42	-4.66	-0.36	7e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.71	8.05	0.55	2.58e-13	White blood cell count (basophil);
UCEC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg05738196	chr6:26577821	NA	0.58	6.22	0.46	4.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.51	5.22	0.4	5.9e-7	Breast cancer;
UCEC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08805041	chr16:621841	PIGQ	-0.32	-4.82	-0.37	3.51e-6	Height;
UCEC	cis	rs79162905	1	rs79162905	chr14:89796072	G/A	cg16284524	chr14:88852284	SPATA7	0.67	4.72	0.36	5.37e-6	Attention deficit hyperactivity disorder symptom score;
UCEC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.56	5.09	0.39	1.07e-6	Cognitive ability;
UCEC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.84	-9.4	-0.61	9.75e-17	Cognitive function;
UCEC	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.57	5.04	0.38	1.36e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.63	9.23	0.61	2.79e-16	Prudent dietary pattern;
UCEC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.79	6.87	0.49	1.68e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7246967	0.736	rs446058	chr19:23000061	G/A	cg08271804	chr19:22816896	ZNF492	0.63	5.67	0.42	7.35e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-0.62	-7.24	-0.51	2.28e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.49	5.12	0.39	9.44e-7	Blood protein levels;
UCEC	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.45	-0.47	1.56e-9	Crohn's disease;
UCEC	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-6.93	-0.5	1.24e-10	Colorectal cancer;
UCEC	cis	rs1545257	0.537	rs2339948	chr2:24641012	A/T	cg06627628	chr2:24431161	ITSN2	-0.53	-5.43	-0.41	2.24e-7	Sjögren's syndrome;
UCEC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg13777783	chr17:79615861	NA	0.32	4.65	0.36	7.4e-6	Eye color traits;
UCEC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.87	5.69	0.42	6.8e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.72	-5.87	-0.44	2.72e-8	Asthma;
UCEC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg18973586	chr4:963968	DGKQ	0.44	4.7	0.36	5.99e-6	Obesity-related traits;
UCEC	cis	rs7709377	0.595	rs11958648	chr5:115445224	C/T	cg23108291	chr5:115420582	COMMD10	0.49	4.97	0.38	1.81e-6	Metabolite levels  (X-11787);
UCEC	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.56	-5.52	-0.41	1.47e-7	Vitiligo;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.6	0.42	9.99e-8	Prudent dietary pattern;
UCEC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.81	7.96	0.55	4.26e-13	Cognitive function;
UCEC	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.69	6.81	0.49	2.31e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.8	0.37	3.81e-6	Breast cancer;
UCEC	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.57	5.28	0.4	4.5e-7	Lymphocyte counts;
UCEC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.43	4.8	0.37	3.83e-6	Bone mineral density;
UCEC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.6	0.35	8.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg13777783	chr17:79615861	NA	-0.32	-4.64	-0.36	7.5e-6	Eye color traits;
UCEC	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.18	6.27	0.46	3.74e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.13	0.45	7.87e-9	Cognitive test performance;
UCEC	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	0.91	8.09	0.56	2.02e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.36	-0.46	2.41e-9	Cardiac Troponin-T levels;
UCEC	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg08807892	chr2:162101083	NA	0.58	6.0	0.44	1.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.82e-6	Gut microbiome composition (summer);
UCEC	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.6	-5.54	-0.42	1.34e-7	Coronary artery disease;
UCEC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.7	6.96	0.5	1.07e-10	Primary sclerosing cholangitis;
UCEC	cis	rs11757661	0.748	rs12207463	chr6:89207518	C/T	cg02159996	chr6:89927233	GABRR1	0.71	4.63	0.36	7.92e-6	Subcutaneous adipose tissue;
UCEC	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.63	-6.58	-0.48	7.59e-10	Hypospadias;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.76	-9.01	-0.6	9.76e-16	Menarche (age at onset);
UCEC	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.71	-6.31	-0.46	3.17e-9	Systolic blood pressure;
UCEC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.54	0.35	1.16e-5	Breast cancer;
UCEC	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg09165964	chr15:75287851	SCAMP5	-0.52	-5.31	-0.4	4.04e-7	Lung cancer;
UCEC	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg26031613	chr14:104095156	KLC1	0.97	6.54	0.47	9.69e-10	Body mass index;
UCEC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg16497661	chr14:103986332	CKB	-0.44	-5.13	-0.39	9.11e-7	Body mass index;
UCEC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.34	5.13	0.39	9.17e-7	Ulcerative colitis;
UCEC	cis	rs7095607	0.730	rs1900012	chr10:69953942	G/A	cg18986048	chr10:69913749	MYPN	0.51	5.72	0.43	5.84e-8	Lung function (FVC);
UCEC	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.63	4.98	0.38	1.75e-6	Major depressive disorder;
UCEC	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.41	-4.83	-0.37	3.35e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.38	-4.85	-0.37	3.17e-6	Body mass index;
UCEC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.52	0.53	4.88e-12	Total body bone mineral density;
UCEC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.67	-6.63	-0.48	6.01e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg15147215	chr3:52552868	STAB1	-0.45	-5.01	-0.38	1.52e-6	Bipolar disorder;
UCEC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.67	7.88	0.55	6.55e-13	Schizophrenia;
UCEC	cis	rs1355223	0.872	rs12785367	chr11:34715269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.76	-0.37	4.55e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7739264	0.829	rs6456258	chr6:19748048	A/C	cg24950003	chr6:20566024	CDKAL1	0.42	4.51	0.35	1.34e-5	Endometriosis;
UCEC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.47	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs838147	0.760	rs12979144	chr19:49237547	G/A	cg13540341	chr19:49222985	MAMSTR	0.38	4.58	0.35	9.73e-6	Dietary macronutrient intake;
UCEC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.53	5.01	0.38	1.57e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7212590	0.881	rs7216675	chr17:57882674	T/C	cg10252138	chr17:58120427	NA	-0.68	-5.43	-0.41	2.33e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18252515	chr7:66147081	NA	0.49	4.89	0.37	2.6e-6	Aortic root size;
UCEC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.51	4.77	0.37	4.43e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg12463550	chr7:65579703	CRCP	-0.64	-6.15	-0.45	6.98e-9	Aortic root size;
UCEC	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.69	-7.38	-0.52	1.07e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.45	0.41	2.03e-7	Rheumatoid arthritis;
UCEC	cis	rs2415984	0.846	rs8011612	chr14:46835172	G/A	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs10242455	0.702	rs75156180	chr7:98964100	G/A	cg18809830	chr7:99032528	PTCD1	-0.88	-4.64	-0.36	7.53e-6	Blood metabolite levels;
UCEC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg13525197	chr6:28411240	ZSCAN23	0.42	4.6	0.35	9.17e-6	Systemic lupus erythematosus;
UCEC	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.52	-4.82	-0.37	3.54e-6	Coronary artery disease;
UCEC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.69	-0.42	6.8e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs61776719	0.905	rs28570969	chr1:38407146	A/G	cg04673462	chr1:38461896	NA	0.57	5.93	0.44	2.08e-8	Coronary artery disease;
UCEC	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	0.52	5.28	0.4	4.47e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.57	6.66	0.48	5.06e-10	Prostate cancer;
UCEC	cis	rs10509540	0.793	rs1035796	chr10:90051697	A/G	cg10205334	chr10:89622497	PTEN;KILLIN	0.46	4.57	0.35	1.03e-5	Type 1 diabetes;
UCEC	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg16235748	chr6:149772707	ZC3H12D	-0.44	-5.25	-0.4	5.33e-7	Dupuytren's disease;
UCEC	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg16060761	chr17:80687452	NA	0.49	4.94	0.38	2.11e-6	Glycated hemoglobin levels;
UCEC	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.63	-4.85	-0.37	3.13e-6	Platelet distribution width;
UCEC	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	6.42	0.47	1.74e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-5.17	-0.39	7.5e-7	Hemoglobin concentration;
UCEC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.59	0.42	1.05e-7	Monocyte percentage of white cells;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.47	-5.83	-0.43	3.44e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.59	-5.61	-0.42	9.77e-8	Menopause (age at onset);
UCEC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg22974920	chr21:40686053	BRWD1	0.56	4.91	0.38	2.4e-6	Cognitive function;
UCEC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg11871910	chr12:69753446	YEATS4	0.88	10.22	0.64	7.61e-19	Blood protein levels;
UCEC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.68	-7.06	-0.5	6.13e-11	Neurofibrillary tangles;
UCEC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg19438565	chr8:143695827	ARC	-0.46	-4.64	-0.36	7.78e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg05991184	chr2:219186017	PNKD	-0.48	-5.22	-0.4	5.88e-7	Colorectal cancer;
UCEC	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.75	-8.62	-0.58	9.78e-15	Menarche (age at onset);
UCEC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.56	-6.51	-0.47	1.14e-9	Hip circumference;
UCEC	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.33	-0.4	3.67e-7	Resting heart rate;
UCEC	cis	rs7709377	0.547	rs166204	chr5:115692083	G/A	cg23108291	chr5:115420582	COMMD10	-0.49	-4.9	-0.37	2.55e-6	Metabolite levels  (X-11787);
UCEC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.46	2.59e-9	Aortic root size;
UCEC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.49	0.57	2.11e-14	Prudent dietary pattern;
UCEC	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07215822	chr6:158701037	NA	0.65	5.91	0.44	2.29e-8	Height;
UCEC	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.71	0.43	5.91e-8	Prudent dietary pattern;
UCEC	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg11690979	chr1:151694320	C1orf230	0.38	4.8	0.37	3.93e-6	Coronary artery disease;
UCEC	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.0	7.35	0.52	1.3e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.91	11.49	0.69	3.36e-22	Breast cancer;
UCEC	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-5.44	-0.41	2.2e-7	HDL cholesterol;
UCEC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg07153921	chr17:41440717	NA	0.59	6.9	0.49	1.47e-10	Menopause (age at onset);
UCEC	cis	rs711830	0.965	rs6755777	chr2:177043226	T/G	cg13092806	chr2:177043255	NA	0.99	9.52	0.62	4.83e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.57	6.99	0.5	8.89e-11	Oral cavity cancer;
UCEC	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	9.04	0.6	8.35e-16	Lymphocyte percentage of white cells;
UCEC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.45	-5.0	-0.38	1.64e-6	Prostate cancer;
UCEC	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.73	-7.23	-0.51	2.49e-11	Blood protein levels;
UCEC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	6.15	0.45	6.95e-9	Personality dimensions;
UCEC	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg24562669	chr7:97807699	LMTK2	0.61	8.0	0.55	3.45e-13	Breast cancer;
UCEC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12311346	chr5:56204834	C5orf35	-0.52	-4.99	-0.38	1.7e-6	Coronary artery disease;
UCEC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.11	17.2	0.82	4.97e-37	IgG glycosylation;
UCEC	cis	rs377070	0.966	rs411043	chr4:123633221	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.62	5.35	0.4	3.28e-7	Mosquito bite size;
UCEC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.51	0.65	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03576123	chr11:487126	PTDSS2	-0.96	-7.01	-0.5	8.17e-11	Body mass index;
UCEC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.63	-6.23	-0.46	4.65e-9	Breast cancer;
UCEC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.65	7.25	0.51	2.2e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs10266483	0.705	rs1111649	chr7:63756813	G/T	cg23304165	chr7:63498798	NA	-0.56	-5.93	-0.44	2.1e-8	Response to statin therapy;
UCEC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs13095912	1.000	rs6784842	chr3:185342723	C/T	cg11274856	chr3:185301563	NA	0.54	7.23	0.51	2.39e-11	Systolic blood pressure;
UCEC	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg21905437	chr5:178450457	ZNF879	0.61	6.24	0.46	4.44e-9	Pubertal anthropometrics;
UCEC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.67	-0.36	6.65e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs74542309	0.947	rs71477515	chr10:72554625	C/A	cg15763670	chr10:73473235	C10orf105;CDH23	-0.61	-4.74	-0.36	4.98e-6	Pursuit maintenance gain;
UCEC	cis	rs308403	0.600	rs13129352	chr4:123633736	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.61	4.52	0.35	1.27e-5	Blood protein levels;
UCEC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.37	5.07	0.39	1.18e-6	Breast cancer;
UCEC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.37	-0.47	2.23e-9	Aortic root size;
UCEC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.53	5.67	0.42	7.2e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.62	-6.07	-0.45	1.04e-8	Neurofibrillary tangles;
UCEC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.88	9.3	0.61	1.77e-16	Cognitive function;
UCEC	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs9283706	0.623	rs3857275	chr5:66315536	T/C	cg11590213	chr5:66331682	MAST4	0.38	4.65	0.36	7.31e-6	Coronary artery disease;
UCEC	cis	rs6594713	0.796	rs6896843	chr5:112681157	T/C	cg06062378	chr5:112387002	MCC	-0.43	-5.03	-0.38	1.42e-6	Brain cytoarchitecture;
UCEC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.71	-6.8	-0.49	2.4e-10	Aortic root size;
UCEC	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.4	5.13	0.39	9.06e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.5	4.94	0.38	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.22	-12.48	-0.72	7.68e-25	Corneal structure;
UCEC	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.45	-4.97	-0.38	1.81e-6	Height;
UCEC	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.54	4.59	0.35	9.48e-6	Type 2 diabetes;
UCEC	cis	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg20307385	chr11:47447363	PSMC3	0.51	4.52	0.35	1.29e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6893207	0.661	rs58534540	chr5:16403232	C/T	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.36	-0.46	2.39e-9	Response to antipsychotic treatment;
UCEC	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.7	6.01	0.44	1.38e-8	Adiposity;
UCEC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.81	7.69	0.54	1.92e-12	Bladder cancer;
UCEC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.53	0.47	9.92e-10	Menarche (age at onset);
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.45	4.75	0.36	4.89e-6	Monocyte percentage of white cells;
UCEC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg04310649	chr10:35416472	CREM	0.47	4.9	0.37	2.54e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.57	6.0	0.44	1.45e-8	Mean platelet volume;
UCEC	cis	rs5167	0.504	rs73047641	chr19:45457377	G/A	cg09555818	chr19:45449301	APOC2	0.46	6.01	0.44	1.39e-8	Blood protein levels;
UCEC	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.57	-4.8	-0.37	3.82e-6	Mortality in heart failure;
UCEC	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg01451880	chr3:45801044	SLC6A20	-0.37	-4.77	-0.37	4.42e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.61	4.84	0.37	3.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.53e-6	Colorectal cancer;
UCEC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-4.97	-0.38	1.85e-6	Joint mobility (Beighton score);
UCEC	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg11632617	chr15:75315747	PPCDC	-0.6	-5.26	-0.4	4.96e-7	Lung cancer;
UCEC	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.16	-11.08	-0.67	3.96e-21	Ulcerative colitis;
UCEC	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13683864	chr3:40499215	RPL14	-0.69	-7.15	-0.51	3.87e-11	Renal cell carcinoma;
UCEC	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg19610905	chr11:61596333	FADS2	-0.5	-5.38	-0.41	2.88e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.92	0.38	2.31e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.49	-4.54	-0.35	1.15e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.61	5.58	0.42	1.11e-7	Coronary artery disease;
UCEC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg20450318	chr11:65415260	SIPA1	0.46	5.09	0.39	1.06e-6	Systemic lupus erythematosus;
UCEC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.6	5.59	0.42	1.06e-7	Aortic root size;
UCEC	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.86	6.95	0.5	1.13e-10	Body mass index;
UCEC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg04553112	chr3:125709451	NA	-0.67	-5.4	-0.41	2.63e-7	Blood pressure (smoking interaction);
UCEC	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg13147721	chr7:65941812	NA	-0.97	-6.48	-0.47	1.29e-9	Diabetic kidney disease;
UCEC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.57	5.8	0.43	3.94e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs539514	0.587	rs7320602	chr13:76332868	A/G	cg04757411	chr13:76259545	LMO7	-0.48	-5.66	-0.42	7.58e-8	Type 1 diabetes;
UCEC	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.78e-7	Heart rate;
UCEC	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.98	-0.5	9.49e-11	Eye color traits;
UCEC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.67	7.29	0.52	1.77e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7709377	0.595	rs253951	chr5:115633010	C/T	cg23108291	chr5:115420582	COMMD10	-0.52	-5.29	-0.4	4.41e-7	Metabolite levels  (X-11787);
UCEC	trans	rs66573146	1.000	rs7675281	chr4:7002120	C/T	cg07817883	chr1:32538562	TMEM39B	1.28	8.86	0.59	2.4e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1823913	0.503	rs35562914	chr2:192203695	A/G	cg15998761	chr2:191300784	MFSD6	0.4	4.72	0.36	5.35e-6	Obesity-related traits;
UCEC	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.6	5.1	0.39	1.05e-6	Systolic blood pressure;
UCEC	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.48	4.76	0.37	4.59e-6	Height;
UCEC	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-6.92	-0.5	1.27e-10	Ulcerative colitis;
UCEC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.71	-7.15	-0.51	3.72e-11	Aortic root size;
UCEC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.48	4.71	0.36	5.72e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg11871910	chr12:69753446	YEATS4	0.74	7.76	0.54	1.33e-12	Blood protein levels;
UCEC	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.64	-6.51	-0.47	1.1e-9	Dilated cardiomyopathy;
UCEC	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg14092571	chr14:90743983	NA	-0.43	-5.5	-0.41	1.62e-7	Mortality in heart failure;
UCEC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.45	4.89	0.37	2.56e-6	Obesity-related traits;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.03	-0.45	1.26e-8	Parkinson's disease;
UCEC	cis	rs11235843	0.571	rs9666549	chr11:73360581	C/T	cg23931323	chr11:73372278	PLEKHB1	0.62	4.85	0.37	3.17e-6	Hand grip strength;
UCEC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.69	-6.6	-0.48	7.03e-10	Multiple sclerosis;
UCEC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg14438399	chr17:27053147	TLCD1	0.62	4.87	0.37	2.91e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.73	-8.56	-0.58	1.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.52	5.22	0.4	6e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs78707713	0.512	rs35793747	chr10:71182165	A/G	cg12610070	chr10:71211762	TSPAN15	-0.34	-4.72	-0.36	5.42e-6	Venous thromboembolism;
UCEC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg22166914	chr1:53195759	ZYG11B	0.53	5.22	0.4	5.9e-7	Monocyte count;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg03530744	chr13:111270991	CARKD	0.73	4.54	0.35	1.17e-5	Obesity-related traits;
UCEC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.51	-4.52	-0.35	1.26e-5	Lymphocyte percentage of white cells;
UCEC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.51	-5.22	-0.4	6e-7	Refractive error;
UCEC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg07653901	chr22:50250238	ZBED4	0.77	5.0	0.38	1.59e-6	Mean platelet volume;
UCEC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.32	-0.52	1.5e-11	Blood trace element (Zn levels);
UCEC	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.59	5.84	0.43	3.25e-8	Uric acid levels;
UCEC	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg21856205	chr7:94953877	PON1	-0.55	-5.28	-0.4	4.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	0.85	5.57	0.42	1.2e-7	Iron status biomarkers;
UCEC	cis	rs806321	0.755	rs1985704	chr13:50784852	A/T	cg12964420	chr13:50975679	NA	-0.36	-4.51	-0.35	1.31e-5	Multiple sclerosis;
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.11	9.68	0.62	1.89e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7246967	0.673	rs7247191	chr19:22899585	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.63	0.48	6.02e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	6.4	0.47	1.98e-9	Alzheimer's disease;
UCEC	cis	rs10012307	1.000	rs4637466	chr4:137489544	C/A	cg12033966	chr4:138453416	PCDH18	-0.71	-4.89	-0.37	2.59e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg02158880	chr13:53174818	NA	0.4	4.65	0.36	7.23e-6	Lewy body disease;
UCEC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.36	-0.4	3.2e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.48	4.54	0.35	1.19e-5	Gut microbiome composition (summer);
UCEC	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Smoking initiation;
UCEC	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.63	0.42	9.07e-8	Psoriasis;
UCEC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.48	-5.99	-0.44	1.53e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-1.03	-7.79	-0.54	1.11e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.67	7.72	0.54	1.62e-12	Monocyte count;
UCEC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg06238570	chr21:40685208	BRWD1	0.83	8.21	0.56	1.04e-13	Cognitive function;
UCEC	cis	rs9463078	0.547	rs1338908	chr6:44728812	C/T	cg25276700	chr6:44698697	NA	0.43	4.84	0.37	3.2e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg13319975	chr6:146136371	FBXO30	0.43	4.53	0.35	1.23e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.49	5.96	0.44	1.76e-8	Alcoholic chronic pancreatitis;
UCEC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs7246967	0.551	rs35740274	chr19:22831413	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.48	4.59	0.35	9.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.56	6.15	0.45	6.91e-9	Mean platelet volume;
UCEC	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.13	-0.39	9.09e-7	Depression;
UCEC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	5.07	0.39	1.21e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-7.81	-0.54	9.72e-13	Chronic sinus infection;
UCEC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.41	4.82	0.37	3.48e-6	Survival in rectal cancer;
UCEC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.68	7.43	0.52	8.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	0.9	5.26	0.4	4.95e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	4.72	0.36	5.46e-6	Depressive episodes in bipolar disorder;
UCEC	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.68	-9.07	-0.6	7.18e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	8.99	0.6	1.12e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-5.96	-0.44	1.78e-8	Birth weight;
UCEC	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.55	5.59	0.42	1.06e-7	Neuroticism;
UCEC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.69	6.72	0.48	3.71e-10	Menarche (age at onset);
UCEC	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.7	-5.51	-0.41	1.58e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	1.0	7.57	0.53	3.76e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg01380346	chr19:18557039	ELL	-0.47	-4.74	-0.36	4.94e-6	Breast cancer;
UCEC	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.1	9.43	0.61	8.5e-17	Blood protein levels;
UCEC	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.86	5.87	0.44	2.79e-8	Psoriasis;
UCEC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	6.8	0.49	2.51e-10	Type 2 diabetes;
UCEC	cis	rs7113850	0.541	rs2896686	chr11:24213156	G/A	ch.11.24196551F	chr11:24239977	NA	0.66	5.69	0.43	6.53e-8	Bone fracture in osteoporosis;
UCEC	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.58	-5.43	-0.41	2.25e-7	Coronary artery disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13445258	chr3:128369860	RPN1	0.55	6.71	0.48	3.84e-10	Warfarin maintenance dose;
UCEC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg01262667	chr19:19385393	TM6SF2	-0.4	-4.6	-0.35	9.18e-6	Bipolar disorder;
UCEC	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.79	7.86	0.54	7.49e-13	Schizophrenia;
UCEC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.2	-0.76	2.34e-29	Schizophrenia;
UCEC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.46	-4.67	-0.36	6.63e-6	Dental caries;
UCEC	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg09654669	chr8:57350985	NA	-0.54	-5.43	-0.41	2.32e-7	Obesity-related traits;
UCEC	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.19	0.39	6.78e-7	IgG glycosylation;
UCEC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.08	9.67	0.62	1.96e-17	Corneal structure;
UCEC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.7	7.67	0.53	2.2e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.57	-5.81	-0.43	3.79e-8	Schizophrenia;
UCEC	cis	rs2629540	0.543	rs2559515	chr10:126513925	A/G	cg08799069	chr10:126477246	METTL10	0.65	4.61	0.36	8.68e-6	Cocaine dependence;
UCEC	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.61	-4.82	-0.37	3.59e-6	Schizophrenia;
UCEC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-4.66	-0.36	7.08e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.76	-7.33	-0.52	1.44e-11	Initial pursuit acceleration;
UCEC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg12024160	chr4:1254474	NA	0.7	8.37	0.57	4.08e-14	Obesity-related traits;
UCEC	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.51	-0.35	1.33e-5	Total body bone mineral density;
UCEC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg07776626	chr8:57350775	NA	-0.4	-4.7	-0.36	5.85e-6	Obesity-related traits;
UCEC	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg05110241	chr16:68378359	PRMT7	-0.52	-4.58	-0.35	1e-5	Magnesium levels;
UCEC	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	0.96	10.74	0.66	3.26e-20	Corneal structure;
UCEC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.93	10.4	0.65	2.43e-19	Cognitive function;
UCEC	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	0.87	6.46	0.47	1.47e-9	Lymphocyte counts;
UCEC	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.55	-6.12	-0.45	8.16e-9	Hip circumference;
UCEC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.68	5.73	0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7611694	0.501	rs6438146	chr3:113126043	C/T	cg11138929	chr3:113251189	SIDT1	-0.44	-5.06	-0.38	1.25e-6	Prostate cancer;
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.97	0.55	3.94e-13	Platelet count;
UCEC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-7.48	-0.53	6.12e-12	Exhaled nitric oxide output;
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg13206674	chr6:150067644	NUP43	0.52	4.74	0.36	5.07e-6	Testicular germ cell tumor;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.5	-5.79	-0.43	4.15e-8	Myopia;
UCEC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg12571892	chr4:120551256	PDE5A	-0.48	-4.55	-0.35	1.12e-5	Corneal astigmatism;
UCEC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.77	-8.61	-0.58	1.03e-14	Height;
UCEC	cis	rs1978968	0.763	rs9605478	chr22:18464410	G/A	cg03078520	chr22:18463400	MICAL3	-0.55	-6.98	-0.5	9.62e-11	Presence of antiphospholipid antibodies;
UCEC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg06466757	chr4:1255808	NA	0.46	4.86	0.37	2.96e-6	Obesity-related traits;
UCEC	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.8	6.43	0.47	1.71e-9	Response to hepatitis C treatment;
UCEC	cis	rs2904967	0.571	rs1212391	chr11:65017277	T/A	cg01630869	chr11:65082120	CDC42EP2	-0.53	-4.94	-0.38	2.06e-6	Mean corpuscular volume;
UCEC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg14008862	chr17:28927542	LRRC37B2	0.73	4.64	0.36	7.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.49	5.32	0.4	3.76e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg13593689	chr9:129986794	NA	0.45	4.74	0.36	4.93e-6	Intraocular pressure;
UCEC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.68	-5.73	-0.43	5.5e-8	Menopause (age at onset);
UCEC	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.61	0.62	2.9e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-0.66	-6.95	-0.5	1.11e-10	Blood trace element (Zn levels);
UCEC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg13319975	chr6:146136371	FBXO30	0.61	5.29	0.4	4.42e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13065560	0.515	rs2103150	chr3:39056026	T/C	cg01426195	chr3:39028469	NA	-0.54	-4.99	-0.38	1.71e-6	Interleukin-18 levels;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.85	-0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4372836	0.729	rs4132617	chr2:29031312	C/A	cg09522027	chr2:28974177	PPP1CB	-0.84	-9.27	-0.61	2.17e-16	Body mass index;
UCEC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.86	9.74	0.63	1.3e-17	Dental caries;
UCEC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.72	7.56	0.53	4.11e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg23793686	chr15:68133972	NA	-0.36	-4.7	-0.36	5.9e-6	Restless legs syndrome;
UCEC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.68	4.76	0.37	4.55e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2904967	1.000	rs630055	chr11:65087533	G/T	cg01630869	chr11:65082120	CDC42EP2	-0.49	-4.79	-0.37	3.99e-6	Mean corpuscular volume;
UCEC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.55	5.57	0.42	1.19e-7	Neutrophil percentage of white cells;
UCEC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	6.52	0.47	1.05e-9	Tonsillectomy;
UCEC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.32e-6	Breast cancer;
UCEC	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	5.6	0.42	1.04e-7	Ileal carcinoids;
UCEC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.65	-6.01	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.6	-6.7	-0.48	4.14e-10	Blood trace element (Zn levels);
UCEC	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.51	4.52	0.35	1.25e-5	Pulmonary function decline;
UCEC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.9	10.86	0.67	1.49e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.48	0.53	6.08e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.38	-4.8	-0.37	3.78e-6	Parkinson's disease;
UCEC	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.13	6.88	0.49	1.58e-10	Platelet distribution width;
UCEC	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs11764116	0.590	rs2078868	chr7:18824963	C/T	cg27013696	chr7:19158030	TWIST1	-0.45	-4.5	-0.35	1.36e-5	Ulcerative colitis;
UCEC	cis	rs7088591	0.867	rs7920373	chr10:59789517	A/G	cg11142981	chr10:60273225	BICC1	0.66	4.82	0.37	3.51e-6	Blood pressure;
UCEC	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.77	7.66	0.53	2.27e-12	Nonalcoholic fatty liver disease;
UCEC	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.15	8.08	0.55	2.15e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg01403660	chr11:68851641	TPCN2	0.45	4.71	0.36	5.67e-6	Hair color;
UCEC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg01178603	chr7:1976964	MAD1L1	-0.49	-5.0	-0.38	1.63e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246967	0.673	rs2915932	chr19:22843701	C/T	cg05241461	chr19:22816980	ZNF492	0.56	6.08	0.45	9.89e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg23939001	chr4:940644	TMEM175	0.53	4.99	0.38	1.7e-6	Sjögren's syndrome;
UCEC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.73	5.02	0.38	1.5e-6	Gut microbiome composition (summer);
UCEC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.54	5.71	0.43	5.94e-8	Pulse pressure;
UCEC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.35e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg03609598	chr5:56110824	MAP3K1	-0.62	-5.24	-0.4	5.57e-7	Coronary artery disease;
UCEC	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg06784218	chr1:46089804	CCDC17	0.47	5.83	0.43	3.36e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.83	0.77	5.42e-31	Homoarginine levels;
UCEC	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.68	-7.24	-0.51	2.27e-11	Breast cancer;
UCEC	cis	rs2901460	0.509	rs17573253	chr2:62101915	C/T	cg02183531	chr2:62113199	CCT4	0.54	4.62	0.36	8.18e-6	Mean corpuscular volume;
UCEC	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.53	4.86	0.37	2.99e-6	Coronary artery disease;
UCEC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.67	5.86	0.44	2.92e-8	Cognitive function;
UCEC	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.44	-4.73	-0.36	5.11e-6	Platelet distribution width;
UCEC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	0.93	9.54	0.62	4.29e-17	Heart rate;
UCEC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.61	-6.17	-0.45	6.32e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.8	9.57	0.62	3.66e-17	Longevity;Endometriosis;
UCEC	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.54	2e-12	IgG glycosylation;
UCEC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.83	8.97	0.59	1.25e-15	Breast cancer;
UCEC	cis	rs2062225	0.735	rs2341658	chr2:111767152	T/C	cg23782758	chr2:111737646	ACOXL	-0.49	-4.71	-0.36	5.62e-6	Monocyte count;
UCEC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg16989719	chr2:238392110	NA	-0.37	-5.04	-0.38	1.35e-6	Prostate cancer;
UCEC	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.4	4.81	0.37	3.75e-6	Multiple sclerosis;
UCEC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg00343986	chr7:65444356	GUSB	-0.52	-4.85	-0.37	3.16e-6	Aortic root size;
UCEC	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs600626	0.529	rs57188913	chr11:75473294	T/C	cg24262691	chr11:75473276	NA	0.39	4.8	0.37	3.92e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.7	-8.17	-0.56	1.32e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.69	9.09	0.6	6.31e-16	Alcohol dependence (age at onset);
UCEC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	0.67	4.77	0.37	4.44e-6	Body mass index;
UCEC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03934478	chr11:495069	RNH1	0.71	5.08	0.39	1.12e-6	Body mass index;
UCEC	cis	rs4654899	0.680	rs6704421	chr1:21220674	A/C	cg01072550	chr1:21505969	NA	0.58	6.34	0.46	2.68e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1355223	0.934	rs11602669	chr11:34695114	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.62	-0.36	8.48e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg26395211	chr5:140044315	WDR55	-0.44	-4.6	-0.35	9.14e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.45	-4.88	-0.37	2.78e-6	Dementia with Lewy bodies;
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.55	5.98	0.44	1.65e-8	Monocyte percentage of white cells;
UCEC	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06762426	chr11:62420836	INTS5	0.86	4.73	0.36	5.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	trans	rs6579967	1.000	rs72799180	chr5:152166502	G/A	cg10205403	chr12:95867231	METAP2	-1.26	-6.76	-0.49	2.99e-10	Facial morphology (factor 1, breadth of lateral portion of upper face);
UCEC	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	0.81	5.19	0.39	6.81e-7	Major depressive disorder;
UCEC	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.46	5.28	0.4	4.62e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.58	6.05	0.45	1.17e-8	Bipolar disorder;
UCEC	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.68	9.93	0.63	4.19e-18	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	4.8	0.37	3.87e-6	Obesity-related traits;
UCEC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.47	5.0	0.38	1.6e-6	Asthma (sex interaction);
UCEC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg05695927	chr15:45694626	SPATA5L1	-0.45	-4.54	-0.35	1.18e-5	Glomerular filtration rate;
UCEC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg00852783	chr1:26633632	UBXN11	-0.48	-4.67	-0.36	6.66e-6	Obesity-related traits;
UCEC	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.25	-7.15	-0.51	3.67e-11	Schizophrenia;
UCEC	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.45	4.74	0.36	4.98e-6	Autism;
UCEC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.46	4.8	0.37	3.8e-6	Schizophrenia;
UCEC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.85	5.98	0.44	1.63e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-5.91	-0.44	2.25e-8	Bipolar disorder and schizophrenia;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25515450	chr18:21030986	NA	-0.6	-6.87	-0.49	1.67e-10	Migraine with aura;
UCEC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.64	-7.17	-0.51	3.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg23307798	chr14:103986281	CKB	0.62	7.39	0.52	1.05e-11	Body mass index;
UCEC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	6.82	0.49	2.26e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	0.88	9.18	0.6	3.71e-16	Primary sclerosing cholangitis;
UCEC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.78	7.75	0.54	1.43e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.37	-4.55	-0.35	1.09e-5	Refractive error;
UCEC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-6.89	-0.49	1.55e-10	Total body bone mineral density;
UCEC	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.78	7.31	0.52	1.55e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.74	6.51	0.47	1.09e-9	Cognitive function;
UCEC	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.01e-5	Type 2 diabetes;
UCEC	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.35	-0.46	2.47e-9	Response to antipsychotic treatment;
UCEC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-6.67	-0.48	4.89e-10	Primary biliary cholangitis;
UCEC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.72	8.49	0.57	2.12e-14	Prudent dietary pattern;
UCEC	cis	rs10861661	0.569	rs10778514	chr12:107303577	G/A	cg13944111	chr12:107296891	NA	0.32	4.57	0.35	1.04e-5	Triglyceride levels;
UCEC	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg27246729	chr12:121163418	ACADS	0.52	4.59	0.35	9.61e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.78	-6.22	-0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg21853948	chr4:100867292	DNAJB14	0.49	5.05	0.38	1.31e-6	Alcohol dependence;
UCEC	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-5.18	-0.39	7.28e-7	Morning vs. evening chronotype;
UCEC	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.59	5.59	0.42	1.05e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7246967	0.932	rs7257731	chr19:23042803	A/C	cg05241461	chr19:22816980	ZNF492	0.48	5.12	0.39	9.3e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	5.95	0.44	1.9e-8	Aortic root size;
UCEC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs10924970	0.649	rs6697580	chr1:235484609	T/A	cg26050004	chr1:235667680	B3GALNT2	0.51	4.93	0.38	2.21e-6	Asthma;
UCEC	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.65	6.74	0.49	3.28e-10	Eosinophil percentage of white cells;
UCEC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg09823154	chr10:43332737	NA	-0.6	-4.53	-0.35	1.22e-5	Blood protein levels;
UCEC	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.66	6.25	0.46	4.25e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.39	-5.22	-0.4	5.98e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg16558253	chr16:72132732	DHX38	-0.48	-5.83	-0.43	3.36e-8	Fibrinogen levels;
UCEC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.59	0.42	1.09e-7	Monocyte percentage of white cells;
UCEC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.5	-4.78	-0.37	4.23e-6	Schizophrenia;
UCEC	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.65	-5.38	-0.41	2.9e-7	Schizophrenia;
UCEC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.73	-6.98	-0.5	9.42e-11	Aortic root size;
UCEC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs3743102	0.591	rs17841171	chr15:83358388	C/T	cg00614314	chr15:82944287	LOC80154	0.91	4.97	0.38	1.84e-6	Colorectal adenoma (advanced);
UCEC	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg11150807	chr10:43354902	NA	0.79	6.19	0.45	5.72e-9	Blood protein levels;
UCEC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	trans	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-4.61	-0.36	8.56e-6	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	-0.69	-4.7	-0.36	5.94e-6	Narcolepsy;
UCEC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.68	-8.21	-0.56	1.01e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.83	8.95	0.59	1.41e-15	Longevity;
UCEC	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.88	11.29	0.68	1.15e-21	Brugada syndrome;
UCEC	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	6.94	0.5	1.15e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.79	-0.43	4.13e-8	Life satisfaction;
UCEC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.5	5.17	0.39	7.58e-7	Schizophrenia;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.48	5.23	0.4	5.62e-7	Longevity;Endometriosis;
UCEC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	0.96	6.28	0.46	3.67e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.66	6.92	0.5	1.32e-10	Systemic lupus erythematosus;
UCEC	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.57	-5.76	-0.43	4.86e-8	Breast size;
UCEC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.58	5.25	0.4	5.34e-7	Corneal astigmatism;
UCEC	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.52	4.92	0.38	2.27e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.2	6.96	0.5	1.05e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.81	-8.31	-0.57	5.78e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg20821713	chr7:1055600	C7orf50	-0.54	-5.53	-0.41	1.45e-7	Longevity;Endometriosis;
UCEC	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.79	9.73	0.63	1.41e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-0.93	-7.21	-0.51	2.66e-11	Body mass index;
UCEC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-7.19	-0.51	2.98e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6893207	1.000	rs60212641	chr5:16380203	G/A	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.84	-8.4	-0.57	3.41e-14	Parkinson's disease;
UCEC	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.19	0.51	3.03e-11	Bladder cancer;
UCEC	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg22648282	chr17:21454238	C17orf51	-0.46	-5.26	-0.4	4.98e-7	Pelvic organ prolapse;
UCEC	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	0.76	6.17	0.45	6.24e-9	Blood protein levels;
UCEC	cis	rs1545257	0.505	rs894466	chr2:24633771	T/C	cg06627628	chr2:24431161	ITSN2	-0.52	-5.27	-0.4	4.76e-7	Sjögren's syndrome;
UCEC	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg19610905	chr11:61596333	FADS2	-0.55	-5.73	-0.43	5.5e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.72	0.48	3.82e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.79	-8.35	-0.57	4.53e-14	Cognitive function;
UCEC	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.57	0.42	1.18e-7	Alzheimer's disease;
UCEC	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.82	0.49	2.22e-10	Coffee consumption (cups per day);
UCEC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg05709478	chr1:6581295	PLEKHG5	0.69	5.13	0.39	8.86e-7	Body mass index;
UCEC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.94	-12.35	-0.71	1.75e-24	Coronary artery disease;
UCEC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.73	-9.05	-0.6	8.02e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.45	0.41	2.03e-7	Total body bone mineral density;
UCEC	cis	rs12548939	0.628	rs57639821	chr8:128916863	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.81	5.02	0.38	1.46e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs1575951	1.000	rs11016416	chr10:130451285	A/T	cg27041381	chr10:131357203	MGMT	0.6	4.89	0.37	2.61e-6	Plasma clusterin levels;
UCEC	cis	rs10924970	0.649	rs11805093	chr1:235461668	T/C	cg26050004	chr1:235667680	B3GALNT2	0.54	4.94	0.38	2.07e-6	Asthma;
UCEC	cis	rs10242455	0.867	rs776742	chr7:99292755	C/T	cg07715041	chr7:99302981	CYP3A7	0.47	4.83	0.37	3.33e-6	Blood metabolite levels;
UCEC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.54	5.77	0.43	4.49e-8	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.83	-10.79	-0.66	2.3e-20	White blood cell count (basophil);
UCEC	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.59	-0.53	3.33e-12	Response to antipsychotic treatment;
UCEC	cis	rs3769124	0.513	rs76339974	chr2:239481856	G/A	cg12524725	chr2:239427019	NA	-0.65	-4.68	-0.36	6.38e-6	Pulmonary function;
UCEC	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.58	-4.68	-0.36	6.46e-6	LDL cholesterol levels;
UCEC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg03934865	chr2:198174659	NA	-0.36	-4.63	-0.36	7.94e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.98	0.64	3.12e-18	Breast cancer;
UCEC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03934478	chr11:495069	RNH1	0.64	4.51	0.35	1.33e-5	Body mass index;
UCEC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.45	-4.92	-0.38	2.34e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg13092806	chr2:177043255	NA	0.56	5.3	0.4	4.12e-7	IgG glycosylation;
UCEC	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg11632617	chr15:75315747	PPCDC	-0.55	-5.35	-0.4	3.35e-7	Lung cancer;
UCEC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.48	-5.25	-0.4	5.33e-7	Asthma (sex interaction);
UCEC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.62	4.55	0.35	1.14e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	7.15	0.51	3.71e-11	Motion sickness;
UCEC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-6.12	-0.45	8.29e-9	Monocyte count;
UCEC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Educational attainment;
UCEC	cis	rs2516839	0.605	rs12749496	chr1:161021893	G/C	cg11161846	chr1:160990452	F11R	-0.39	-4.55	-0.35	1.11e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs4900538	0.963	rs1998422	chr14:102980993	G/C	cg18135206	chr14:102964638	TECPR2	1.02	12.6	0.72	3.85e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.73	-8.02	-0.55	3.05e-13	Extraversion;
UCEC	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.61	-7.6	-0.53	3.29e-12	Inhibitory control;
UCEC	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.65	-6.14	-0.45	7.35e-9	Aortic root size;
UCEC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg23093090	chr10:104574429	C10orf26	0.47	5.29	0.4	4.45e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg19715936	chr7:50634035	DDC	0.44	5.31	0.4	3.95e-7	Malaria;
UCEC	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.99	-0.44	1.55e-8	Bipolar disorder;
UCEC	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.5	5.65	0.42	7.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.43	4.72	0.36	5.44e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.53	5.52	0.41	1.5e-7	Longevity;
UCEC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.88	0.49	1.57e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.68	-6.1	-0.45	8.75e-9	Body mass index;
UCEC	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.69	-5.81	-0.43	3.75e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs9840016	0.838	rs2184638	chr3:159899867	A/C	cg07618101	chr3:160879687	NA	0.46	4.76	0.37	4.53e-6	Subjective well-being;
UCEC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.23	7.17	0.51	3.44e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.7	8.92	0.59	1.66e-15	Rheumatoid arthritis;
UCEC	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg11901034	chr3:128598214	ACAD9	-0.52	-4.57	-0.35	1.03e-5	IgG glycosylation;
UCEC	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	7.45	0.52	7.48e-12	Motion sickness;
UCEC	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.44	-5.67	-0.42	7.45e-8	Prostate cancer;
UCEC	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.54	-4.52	-0.35	1.25e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21790971	chr4:54244117	FIP1L1	0.54	6.68	0.48	4.58e-10	Warfarin maintenance dose;
UCEC	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.5	6.54	0.47	9.32e-10	Osteoporosis;
UCEC	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg24130564	chr14:104152367	KLC1	-0.49	-4.69	-0.36	6.09e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.63	-5.39	-0.41	2.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7267005	0.661	rs58121874	chr20:34431660	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg10932868	chr11:921992	NA	0.44	5.83	0.43	3.31e-8	Alzheimer's disease (late onset);
UCEC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.4	0.52	9.93e-12	Homoarginine levels;
UCEC	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.23	-0.51	2.47e-11	Kawasaki disease;
UCEC	cis	rs7766436	0.961	rs6900627	chr6:22570245	G/A	cg13666174	chr6:22585274	NA	-0.5	-5.38	-0.41	2.82e-7	Coronary artery disease;
UCEC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.38	0.76	8e-30	Height;
UCEC	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-1.08	-6.94	-0.5	1.19e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.36	0.4	3.17e-7	Monocyte count;
UCEC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.7	0.43	6.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.74	0.63	1.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.37	-0.47	2.3e-9	Morning vs. evening chronotype;
UCEC	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg16060761	chr17:80687452	NA	0.49	4.94	0.38	2.11e-6	Glycated hemoglobin levels;
UCEC	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg24851651	chr11:66362959	CCS	0.43	5.34	0.4	3.52e-7	Educational attainment (years of education);
UCEC	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg16303742	chr3:15540471	COLQ	-0.39	-4.77	-0.37	4.34e-6	Mean platelet volume;
UCEC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.42	4.52	0.35	1.28e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.51e-16	Post bronchodilator FEV1;
UCEC	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.54	6.3	0.46	3.26e-9	Mean corpuscular volume;
UCEC	cis	rs17433710	0.929	rs17486566	chr1:162670464	A/G	cg19264028	chr1:162630153	DDR2	1.19	6.34	0.46	2.66e-9	Dupuytren's disease;
UCEC	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.91	-9.82	-0.63	8.31e-18	Body mass index;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.69	-0.43	6.5e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.64	-6.96	-0.5	1.02e-10	Homoarginine levels;
UCEC	cis	rs4646312	0.555	rs8185002	chr22:19933048	G/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.46	4.66	0.36	6.94e-6	Schizophrenia;
UCEC	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.87	5.5	0.41	1.63e-7	Psoriasis;
UCEC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg06784218	chr1:46089804	CCDC17	0.44	5.08	0.39	1.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2708977	0.730	rs596069	chr2:97076642	C/T	cg22654517	chr2:96458247	NA	-0.47	-5.36	-0.4	3.14e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	5.18	0.39	7.13e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.09	9.83	0.63	7.55e-18	Vitiligo;
UCEC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-6.31	-0.46	3.16e-9	Platelet count;
UCEC	cis	rs2657880	0.502	rs3759091	chr12:56956213	A/G	cg24693620	chr12:56367689	RAB5B	0.5	4.59	0.35	9.49e-6	Metabolite levels;
UCEC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	4.65	0.36	7.47e-6	Mood instability;
UCEC	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg18681998	chr4:17616180	MED28	-0.71	-6.74	-0.49	3.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-4.91	-0.38	2.36e-6	Chronic sinus infection;
UCEC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.57	-6.21	-0.46	5.21e-9	Menarche (age at onset);
UCEC	cis	rs3862260	0.905	rs3850870	chr1:120161037	C/T	cg17939831	chr1:119836654	NA	-0.53	-5.26	-0.4	4.99e-7	Systemic lupus erythematosus;
UCEC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg12559939	chr2:27858050	GPN1	0.44	4.58	0.35	9.94e-6	Oral cavity cancer;
UCEC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg04310649	chr10:35416472	CREM	-0.49	-4.58	-0.35	1e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.4	4.52	0.35	1.28e-5	Lung cancer;
UCEC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.78	7.54	0.53	4.45e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.6	5.03	0.38	1.39e-6	Multiple sclerosis;
UCEC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.7	8.56	0.58	1.35e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-5.08	-0.39	1.14e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12039431	0.788	rs61776188	chr1:38021326	C/T	cg17933807	chr1:38061675	GNL2	-0.57	-5.17	-0.39	7.46e-7	Epithelial ovarian cancer;
UCEC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg07153921	chr17:41440717	NA	-0.47	-4.55	-0.35	1.1e-5	Menopause (age at onset);
UCEC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	1.0	12.13	0.71	6.62e-24	Cognitive function;
UCEC	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-9.31	-0.61	1.7e-16	Coffee consumption (cups per day);
UCEC	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	1.0	9.73	0.63	1.37e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.54	5.78	0.43	4.24e-8	Longevity;Endometriosis;
UCEC	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.47	-5.06	-0.39	1.21e-6	Response to temozolomide;
UCEC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.49	-5.38	-0.41	2.9e-7	Aortic root size;
UCEC	cis	rs7246967	0.611	rs3853652	chr19:22871913	C/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.88	8.55	0.58	1.44e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.7	7.32	0.52	1.5e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.2	-0.39	6.68e-7	Sudden cardiac arrest;
UCEC	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.6	5.78	0.43	4.36e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.71	8.77	0.59	4.11e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.59	7.52	0.53	4.98e-12	Bone mineral density;
UCEC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.69	0.54	1.99e-12	Total body bone mineral density;
UCEC	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-6.6	-0.48	7.02e-10	Sense of smell;
UCEC	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-5.07	-0.39	1.19e-6	Height;
UCEC	cis	rs13253111	1.000	rs13253111	chr8:28061974	C/T	cg26534493	chr8:28060551	NA	-0.5	-5.76	-0.43	4.73e-8	Childhood body mass index;
UCEC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26207909	chr14:103986467	CKB	-0.51	-5.62	-0.42	9.29e-8	Body mass index;
UCEC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.47	5.0	0.38	1.62e-6	Aortic root size;
UCEC	trans	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg02022102	chr7:27168609	HOXA4	0.59	6.71	0.48	3.89e-10	Protein biomarker;
UCEC	cis	rs6893807	0.778	rs7703782	chr5:87938557	A/T	cg09002922	chr5:87956389	LOC645323	-0.54	-5.03	-0.38	1.41e-6	Body mass index;
UCEC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.71	-7.18	-0.51	3.15e-11	Diastolic blood pressure;
UCEC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.5	-5.54	-0.42	1.38e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-8.05	-0.55	2.6e-13	Body mass index;
UCEC	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-7.92	-0.55	5.31e-13	Total cholesterol levels;
UCEC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.46	4.73	0.36	5.19e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.49	-4.64	-0.36	7.5e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg19477247	chr3:113955994	ZNF80	-0.33	-4.57	-0.35	1.03e-5	IgG glycosylation;
UCEC	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.07	10.35	0.65	3.34e-19	Psoriasis vulgaris;
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.97	-0.67	8.02e-21	Height;
UCEC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.46	4.85	0.37	3.09e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7709377	0.620	rs7729396	chr5:115461826	C/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-0.56	-5.6	-0.42	1.02e-7	Blood trace element (Zn levels);
UCEC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.45	4.51	0.35	1.29e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.49	-5.15	-0.39	8.14e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg00612595	chr21:47717864	NA	-0.49	-5.34	-0.4	3.46e-7	Testicular germ cell tumor;
UCEC	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26207909	chr14:103986467	CKB	0.49	4.61	0.36	8.8e-6	Body mass index;
UCEC	cis	rs4615376	1.000	rs34267578	chr6:13032449	T/C	cg11378619	chr6:12164359	HIVEP1	-0.61	-4.83	-0.37	3.33e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.46	-4.79	-0.37	4.06e-6	Alzheimer's disease (late onset);
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.63	-6.76	-0.49	3.02e-10	Parkinson's disease;
UCEC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg06784218	chr1:46089804	CCDC17	0.43	4.95	0.38	2.05e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-6.56	-0.48	8.65e-10	Platelet distribution width;
UCEC	cis	rs10266483	0.774	rs642909	chr7:63770321	T/C	cg23304165	chr7:63498798	NA	-0.5	-5.46	-0.41	1.97e-7	Response to statin therapy;
UCEC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.55	-6.36	-0.46	2.39e-9	Aortic root size;
UCEC	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	5.18	0.39	7.1e-7	Height;
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.78	-6.03	-0.45	1.29e-8	Platelet count;
UCEC	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	0.99	13.5	0.74	1.63e-27	Schizophrenia;
UCEC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.43	4.67	0.36	6.82e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.41	-0.47	1.9e-9	Crohn's disease;
UCEC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg04310649	chr10:35416472	CREM	-0.49	-4.9	-0.38	2.45e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg24562669	chr7:97807699	LMTK2	0.73	10.79	0.66	2.36e-20	Breast cancer;
UCEC	cis	rs10924970	0.649	rs11799507	chr1:235434099	T/G	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	6.98	0.5	9.4e-11	Platelet count;
UCEC	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	5.0	0.38	1.62e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4588572	0.643	rs1864172	chr5:77690945	T/C	cg11547950	chr5:77652471	NA	0.47	5.42	0.41	2.41e-7	Triglycerides;
UCEC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	7.09	0.5	5.14e-11	Cognitive test performance;
UCEC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.71	5.81	0.43	3.75e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.44	-5.25	-0.4	5.33e-7	Dupuytren's disease;
UCEC	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg08738300	chr3:44038990	NA	0.52	4.61	0.36	8.59e-6	Coronary artery disease;
UCEC	cis	rs7246967	0.673	rs34726149	chr19:22952111	A/G	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.34	4.71	0.36	5.62e-6	White blood cell count (basophil);White blood cell count;
UCEC	cis	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg12524725	chr2:239427019	NA	-0.67	-4.53	-0.35	1.21e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.52	4.7	0.36	5.9e-6	Lung cancer;
UCEC	cis	rs7246967	1.000	rs12980225	chr19:23026745	G/C	cg08271804	chr19:22816896	ZNF492	0.54	5.29	0.4	4.43e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.96	-0.44	1.78e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.38	4.59	0.35	9.61e-6	Hepatitis;
UCEC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.61	-6.15	-0.45	6.86e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.13	-0.39	8.86e-7	Aortic root size;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.78	-8.82	-0.59	3.06e-15	Paraoxonase activity;
UCEC	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.19	0.45	5.56e-9	Rheumatoid arthritis;
UCEC	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	7.99	0.55	3.55e-13	Post bronchodilator FEV1;
UCEC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.21	-0.46	5.06e-9	Blood protein levels;
UCEC	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.64	5.58	0.42	1.1e-7	Blood protein levels;
UCEC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.53	6.19	0.45	5.65e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6460942	0.591	rs6945587	chr7:12356992	G/A	cg06484146	chr7:12443880	VWDE	-0.62	-5.03	-0.38	1.44e-6	Coronary artery disease;
UCEC	cis	rs925228	1.000	rs7561675	chr2:24247818	A/G	cg13272742	chr2:24272458	FKBP1B	0.61	5.03	0.38	1.38e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.55	-5.11	-0.39	9.64e-7	Itch intensity from mosquito bite;
UCEC	cis	rs4448343	0.736	rs2236407	chr9:98237796	A/G	cg00638945	chr9:98266643	PTCH1	0.32	4.58	0.35	9.96e-6	Height;
UCEC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg09491104	chr22:46646882	C22orf40	-0.56	-6.28	-0.46	3.58e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.71	6.74	0.49	3.28e-10	Height;
UCEC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg21053147	chr12:120880522	NA	-0.66	-5.41	-0.41	2.49e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.69	-7.44	-0.52	7.88e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.83	-6.91	-0.5	1.36e-10	Initial pursuit acceleration;
UCEC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.75	6.69	0.48	4.27e-10	Coronary artery disease;
UCEC	cis	rs7809615	0.515	rs6961634	chr7:99181839	G/A	cg24650262	chr7:98904301	NA	0.46	4.61	0.36	8.58e-6	Blood metabolite ratios;
UCEC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs7646881	0.544	rs9872682	chr3:158309906	T/C	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.43e-6	Tetralogy of Fallot;
UCEC	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.51	5.85	0.43	3.13e-8	Mean corpuscular volume;
UCEC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.1	6.11	0.45	8.62e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.6	5.4	0.41	2.56e-7	Corneal astigmatism;
UCEC	cis	rs35934224	0.740	rs35142928	chr22:19847751	T/C	cg11182965	chr22:19864308	TXNRD2	-0.35	-4.8	-0.37	3.79e-6	Glaucoma (primary open-angle);
UCEC	cis	rs10266483	0.843	rs667644	chr7:63750558	C/A	cg23304165	chr7:63498798	NA	-0.44	-4.79	-0.37	4.11e-6	Response to statin therapy;
UCEC	cis	rs11583393	0.671	rs1334331	chr1:88441066	A/C	cg09365624	chr1:87597710	LOC339524	0.46	4.76	0.37	4.63e-6	Breast cancer;
UCEC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.44	-0.47	1.62e-9	Aortic root size;
UCEC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.33	4.55	0.35	1.09e-5	Prostate cancer;
UCEC	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.35	-0.4	3.37e-7	Hemoglobin concentration;
UCEC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.54	5.81	0.43	3.68e-8	Longevity;Endometriosis;
UCEC	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	0.77	8.07	0.55	2.31e-13	Primary sclerosing cholangitis;
UCEC	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg08461772	chr7:95026248	PON3	0.39	5.27	0.4	4.78e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10506710	0.901	rs10506711	chr12:73444509	A/G	cg13663218	chr12:72666976	LOC283392;TRHDE	0.33	4.88	0.37	2.68e-6	Systolic blood pressure;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20505218	chr17:80009845	GPS1;RFNG	0.63	7.73	0.54	1.52e-12	Warfarin maintenance dose;
UCEC	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.66	5.29	0.4	4.38e-7	Coronary artery disease;
UCEC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg05484376	chr2:27715224	FNDC4	-0.33	-4.76	-0.37	4.64e-6	Total body bone mineral density;
UCEC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg17294928	chr15:75287854	SCAMP5	0.51	5.63	0.42	8.89e-8	Breast cancer;
UCEC	cis	rs7570971	0.550	rs6735329	chr2:136273578	T/C	cg07169764	chr2:136633963	MCM6	0.7	6.28	0.46	3.53e-9	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg08461772	chr7:95026248	PON3	0.34	4.7	0.36	5.87e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7246967	0.551	rs6511367	chr19:22821270	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.75	-8.2	-0.56	1.1e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.8	9.96	0.63	3.56e-18	Body mass index;
UCEC	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.81	-7.37	-0.52	1.13e-11	Blood protein levels;
UCEC	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-5.94	-0.44	2.02e-8	Body mass index;
UCEC	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.47	-5.53	-0.41	1.44e-7	White matter hyperintensity burden;
UCEC	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.61	-5.09	-0.39	1.09e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.55	5.47	0.41	1.89e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs1886644	1.000	rs1886644	chr1:85350658	A/C	cg08479277	chr1:85350632	LPAR3	0.57	5.83	0.43	3.38e-8	Glucose homeostasis traits;
UCEC	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	5.01	0.38	1.55e-6	Ileal carcinoids;
UCEC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg07387570	chr22:46663686	TTC38	-0.49	-4.94	-0.38	2.1e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.28	-0.4	4.53e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11697848	1.000	rs55999915	chr20:48453736	A/C	cg17849948	chr20:48532315	SPATA2	1.02	5.13	0.39	8.95e-7	Systemic lupus erythematosus;
UCEC	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.61	-5.78	-0.43	4.24e-8	Metabolite levels;
UCEC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.78	7.51	0.53	5.31e-12	Cognitive function;
UCEC	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-0.68	-5.66	-0.42	7.55e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.49	4.52	0.35	1.27e-5	Economic and political preferences (feminism/equality);
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg13525197	chr6:28411240	ZSCAN23	0.54	6.14	0.45	7.16e-9	Pubertal anthropometrics;
UCEC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg22166914	chr1:53195759	ZYG11B	-0.82	-9.07	-0.6	7.02e-16	Monocyte count;
UCEC	cis	rs7246967	0.673	rs8102172	chr19:22870019	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.4	4.87	0.37	2.8e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.75	-9.38	-0.61	1.13e-16	Cancer (pleiotropy);
UCEC	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.74	6.28	0.46	3.64e-9	Corneal structure;
UCEC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.56	4.98	0.38	1.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13065560	0.659	rs4234135	chr3:38882479	C/T	cg01426195	chr3:39028469	NA	-0.47	-4.85	-0.37	3.13e-6	Interleukin-18 levels;
UCEC	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	8.42	0.57	3.14e-14	Hip circumference;
UCEC	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.89	0.49	1.56e-10	Motion sickness;
UCEC	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.53	-5.14	-0.39	8.8e-7	Pediatric autoimmune diseases;
UCEC	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg05855489	chr10:104503620	C10orf26	0.57	5.44	0.41	2.13e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.65	6.82	0.49	2.24e-10	Pubertal anthropometrics;
UCEC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.72	7.56	0.53	4.11e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.58	-0.35	9.96e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg13593689	chr9:129986794	NA	0.45	4.58	0.35	9.76e-6	Intraocular pressure;
UCEC	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.9	0.37	2.55e-6	Rheumatoid arthritis;
UCEC	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg14438399	chr17:27053147	TLCD1	0.58	4.63	0.36	7.99e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-10.79	-0.66	2.41e-20	Chronic sinus infection;
UCEC	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.73	8.18	0.56	1.23e-13	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.39	0.41	2.71e-7	HDL cholesterol;
UCEC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg26114124	chr12:9217669	LOC144571	0.4	4.85	0.37	3.05e-6	Sjögren's syndrome;
UCEC	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.71	7.4	0.52	9.56e-12	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-6.47	-0.47	1.34e-9	Hypospadias;
UCEC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	8.02	0.55	2.97e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs72906064	0.831	rs17244660	chr2:156921887	A/G	cg14040602	chr2:157557294	NA	0.62	4.59	0.35	9.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.66	-7.08	-0.5	5.39e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.46	5.11	0.39	9.98e-7	Blood metabolite levels;
UCEC	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-7.39	-0.52	9.95e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg19318889	chr4:1322082	MAEA	0.45	5.07	0.39	1.16e-6	Obesity-related traits;
UCEC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	1.02	6.43	0.47	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs78707713	0.841	rs7475662	chr10:71210744	G/C	cg12610070	chr10:71211762	TSPAN15	-0.44	-4.8	-0.37	3.9e-6	Venous thromboembolism;
UCEC	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg23950597	chr19:37808831	NA	-0.83	-5.79	-0.43	4.08e-8	Coronary artery calcification;
UCEC	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.57	6.04	0.45	1.21e-8	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs12428035	1.000	rs41277668	chr13:96295824	T/C	cg07859753	chr13:96300257	NA	0.65	5.52	0.41	1.48e-7	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.0	0.38	1.6e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2474937	0.561	rs6659955	chr1:118924037	A/C	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.32	-0.4	3.88e-7	Menopause (age at onset);
UCEC	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.6	-6.09	-0.45	9.38e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.43	4.85	0.37	3.06e-6	Smoking behavior;
UCEC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.7	7.49	0.53	5.95e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9947276	0.681	rs17243661	chr18:72503689	C/G	cg06007607	chr18:71959170	CYB5A	0.59	4.53	0.35	1.22e-5	Alcohol dependence (age at onset);
UCEC	cis	rs4372836	1.000	rs4372836	chr2:28973883	T/C	cg09522027	chr2:28974177	PPP1CB	-0.76	-7.89	-0.55	6.49e-13	Body mass index;
UCEC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	7.84	0.54	8.45e-13	Tonsillectomy;
UCEC	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.24	-0.46	4.45e-9	Coffee consumption (cups per day);
UCEC	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.84	-9.39	-0.61	1.06e-16	Blood metabolite levels;
UCEC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.12	0.39	9.33e-7	Breast cancer;
UCEC	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.87	-0.44	2.79e-8	Total cholesterol levels;
UCEC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.1	-0.56	1.97e-13	Total cholesterol levels;
UCEC	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.56	-5.04	-0.38	1.37e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.5	4.94	0.38	2.12e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.61	0.58	1.02e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs2708377	0.858	rs115781584	chr12:11304560	C/T	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.6	4.77	0.37	4.4e-6	Bitter taste perception;
UCEC	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.59	5.03	0.38	1.4e-6	Corneal astigmatism;
UCEC	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24249390	chr15:90295951	MESP1	0.42	4.96	0.38	1.94e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.27	-0.46	3.79e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	1.02	12.33	0.71	1.97e-24	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.7	4.97	0.38	1.81e-6	Aortic root size;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg21856205	chr7:94953877	PON1	-0.56	-4.94	-0.38	2.07e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.42	4.94	0.38	2.12e-6	Prostate cancer;
UCEC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.46	5.35	0.4	3.36e-7	Aortic root size;
UCEC	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.61	5.52	0.41	1.5e-7	Corneal astigmatism;
UCEC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.7	7.17	0.51	3.35e-11	Menopause (age at onset);
UCEC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.62	4.78	0.37	4.21e-6	Bladder cancer;
UCEC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-9.18	-0.6	3.76e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.77	6.8	0.49	2.48e-10	Prostate cancer;
UCEC	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg17420585	chr12:42539391	GXYLT1	-0.42	-5.14	-0.39	8.45e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-6.46	-0.47	1.47e-9	Longevity;Endometriosis;
UCEC	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-9.01	-0.6	1e-15	Exhaled nitric oxide output;
UCEC	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg13593689	chr9:129986794	NA	0.46	4.68	0.36	6.45e-6	Intraocular pressure;
UCEC	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs9790314	0.670	rs9864752	chr3:160937591	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-9.31	-0.61	1.72e-16	Morning vs. evening chronotype;
UCEC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.7	-0.36	5.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.63	0.42	8.91e-8	Prudent dietary pattern;
UCEC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.7	-7.4	-0.52	9.49e-12	Tonsillectomy;
UCEC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.59	5.98	0.44	1.59e-8	Hepatocellular carcinoma;
UCEC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.26	-0.56	7.94e-14	Total body bone mineral density;
UCEC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.76	8.2	0.56	1.08e-13	Menopause (age at onset);
UCEC	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.69	8.82	0.59	3.06e-15	Mean platelet volume;
UCEC	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	4.72	0.36	5.53e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.47	-5.45	-0.41	2.1e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.96	8.97	0.59	1.25e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.26	-0.4	4.99e-7	Mean corpuscular volume;
UCEC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg18973586	chr4:963968	DGKQ	0.46	4.79	0.37	4.1e-6	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg24562669	chr7:97807699	LMTK2	0.48	5.8	0.43	3.91e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg14092571	chr14:90743983	NA	-0.42	-5.71	-0.43	6.05e-8	Mortality in heart failure;
UCEC	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg21672276	chr3:44754072	ZNF502	-0.44	-4.57	-0.35	1.03e-5	Depressive symptoms;
UCEC	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.78	-8.95	-0.59	1.43e-15	Facial morphology (factor 19);
UCEC	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg19041857	chr6:27730383	NA	-0.6	-4.56	-0.35	1.06e-5	Depression;
UCEC	cis	rs4851266	0.966	rs13018640	chr2:100821545	T/C	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg02733842	chr7:1102375	C7orf50	-0.67	-5.65	-0.42	8.24e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-5.58	-0.42	1.14e-7	Blood metabolite levels;
UCEC	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.63	5.05	0.38	1.27e-6	Resting heart rate;
UCEC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg24375607	chr4:120327624	NA	0.48	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg18099408	chr3:52552593	STAB1	0.38	4.54	0.35	1.17e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.63	0.42	8.97e-8	Rheumatoid arthritis;
UCEC	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg03728395	chr2:85555865	TGOLN2	-0.36	-4.94	-0.38	2.09e-6	Ear protrusion;
UCEC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg14424070	chr14:75988820	BATF	-0.44	-4.51	-0.35	1.3e-5	IgG glycosylation;
UCEC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg21770322	chr7:97807741	LMTK2	0.51	6.38	0.47	2.21e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.78	-0.43	4.31e-8	Life satisfaction;
UCEC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.56	5.94	0.44	2.01e-8	Dupuytren's disease;
UCEC	cis	rs2167364	0.812	rs7809758	chr7:50573333	A/G	cg18232548	chr7:50535776	DDC	0.5	5.33	0.4	3.66e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.66	-8.26	-0.56	7.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg18279126	chr7:2041391	MAD1L1	-0.42	-5.09	-0.39	1.09e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-5.36	-0.4	3.1e-7	Metabolite levels;
UCEC	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.66	7.05	0.5	6.32e-11	Obesity-related traits;
UCEC	cis	rs17106184	1.000	rs2095865	chr1:51299687	C/T	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg05660106	chr1:15850417	CASP9	1.04	11.6	0.69	1.71e-22	Systolic blood pressure;
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.62	-0.36	8.4e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.26	0.51	2.07e-11	Tonsillectomy;
UCEC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.6	6.6	0.48	6.95e-10	Resting heart rate;
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.53	0.42	1.42e-7	Platelet count;
UCEC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg00316803	chr15:76480434	C15orf27	-0.43	-4.9	-0.37	2.54e-6	Blood metabolite levels;
UCEC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.67	-5.27	-0.4	4.74e-7	Exhaled nitric oxide output;
UCEC	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.5	5.36	0.4	3.21e-7	Type 2 diabetes;
UCEC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs2588809	0.941	rs1314918	chr14:68711676	A/G	cg01928902	chr14:69259640	ZFP36L1	-0.64	-4.78	-0.37	4.29e-6	Breast cancer;
UCEC	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.57	4.99	0.38	1.68e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg21121119	chr3:50228915	GNAT1	0.43	4.64	0.36	7.8e-6	Schizophrenia;
UCEC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.45	4.95	0.38	1.98e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6832769	1.000	rs10016506	chr4:56396674	G/T	cg05960024	chr4:56376020	CLOCK	-0.56	-5.85	-0.43	3.01e-8	Personality dimensions;
UCEC	cis	rs11235843	0.571	rs12361257	chr11:73362198	C/T	cg09185399	chr11:73372479	PLEKHB1	0.58	4.52	0.35	1.29e-5	Hand grip strength;
UCEC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-4.99	-0.38	1.71e-6	Lung cancer;
UCEC	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.54	-5.55	-0.42	1.3e-7	Height;
UCEC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.24e-30	Chronic sinus infection;
UCEC	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	1.15	6.1	0.45	8.86e-9	LDL cholesterol;
UCEC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg01689657	chr7:91764605	CYP51A1	0.47	5.88	0.44	2.63e-8	Breast cancer;
UCEC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs1537061	0.630	rs6692718	chr1:87748886	A/G	cg10042178	chr1:87794589	LMO4	-0.57	-4.89	-0.37	2.66e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.26	0.46	4.07e-9	Aortic root size;
UCEC	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.71	6.27	0.46	3.85e-9	Initial pursuit acceleration;
UCEC	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.23	-0.4	5.83e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.89	0.49	1.56e-10	Motion sickness;
UCEC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.23	0.4	5.73e-7	Hemoglobin concentration;
UCEC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.67	5.59	0.42	1.09e-7	Response to diuretic therapy;
UCEC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.61	-6.12	-0.45	7.93e-9	Blood metabolite levels;
UCEC	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.59	5.85	0.43	3.14e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	trans	rs1552172	0.845	rs17354594	chr1:145632500	A/G	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.86	-0.49	1.83e-10	Breast cancer;
UCEC	cis	rs1852612	0.965	rs1830263	chr7:45402645	C/T	cg26127197	chr7:45030251	NA	-0.35	-4.5	-0.35	1.35e-5	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg20999797	chr1:1681921	NA	0.37	4.95	0.38	2e-6	Body mass index;
UCEC	cis	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.54	5.9	0.44	2.44e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.7	6.02	0.44	1.33e-8	Coronary artery disease;
UCEC	cis	rs12234571	1.000	rs17156706	chr7:77337436	C/T	cg20048109	chr7:78158112	MAGI2	-0.53	-4.81	-0.37	3.76e-6	Obesity-related traits;
UCEC	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	15.37	0.79	2.18e-32	Colorectal cancer;
UCEC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.51	-5.22	-0.4	5.95e-7	Menopause (age at onset);
UCEC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg22598563	chr5:131563921	P4HA2	0.36	4.74	0.36	5.02e-6	Blood metabolite levels;
UCEC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg01689657	chr7:91764605	CYP51A1	-0.43	-5.7	-0.43	6.21e-8	Breast cancer;
UCEC	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg23752985	chr2:85803571	VAMP8	-0.46	-5.28	-0.4	4.49e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.88	-7.36	-0.52	1.23e-11	Monobrow;
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs10242455	0.867	rs2687142	chr7:99320570	A/G	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.34	-0.46	2.7e-9	Pancreatic cancer;
UCEC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg23093090	chr10:104574429	C10orf26	0.41	4.59	0.35	9.59e-6	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-5.18	-0.39	7.21e-7	Chronic sinus infection;
UCEC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg13695892	chr22:41940480	POLR3H	-0.53	-5.24	-0.4	5.54e-7	Vitiligo;
UCEC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.64	6.57	0.48	8.2e-10	Menopause (age at onset);
UCEC	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-5.1	-0.39	1.02e-6	Response to antipsychotic treatment;
UCEC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg03354898	chr7:1950403	MAD1L1	-0.56	-5.49	-0.41	1.7e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4448343	0.963	rs28620668	chr9:98267746	T/G	cg13456470	chr9:98266766	PTCH1	0.4	5.51	0.41	1.6e-7	Height;
UCEC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.65	4.55	0.35	1.1e-5	Aortic root size;
UCEC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.59	6.38	0.47	2.18e-9	Cognitive function;
UCEC	cis	rs4588572	0.706	rs72760906	chr5:77652457	T/C	cg11547950	chr5:77652471	NA	0.54	5.38	0.41	2.86e-7	Triglycerides;
UCEC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.51	-4.73	-0.36	5.18e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	0.74	5.03	0.38	1.42e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs12216499	1.000	rs77876414	chr6:159414811	C/T	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg04154034	chr17:28927549	LRRC37B2	0.52	4.5	0.35	1.36e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1324913	1.000	rs1324913	chr13:74635588	G/T	cg13696283	chr13:74707153	KLF12	0.42	5.0	0.38	1.63e-6	Menarche (age at onset);
UCEC	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.6	-5.35	-0.4	3.29e-7	Metabolite levels;
UCEC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg27033923	chr15:41106683	ZFYVE19	-0.48	-4.53	-0.35	1.2e-5	Ulcerative colitis;
UCEC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.52	5.27	0.4	4.76e-7	Corneal astigmatism;
UCEC	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-4.69	-0.36	6.18e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg07387570	chr22:46663686	TTC38	-0.49	-4.94	-0.38	2.1e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg18721089	chr20:30220636	NA	-0.37	-4.58	-0.35	9.96e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.88	-7.46	-0.52	7.01e-12	Coronary artery calcification;
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-5.01	-0.38	1.54e-6	Prudent dietary pattern;
UCEC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg17764715	chr19:33622953	WDR88	0.62	6.04	0.45	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1949733	1.000	rs3103099	chr4:8511567	G/A	cg11789530	chr4:8429930	ACOX3	-0.79	-7.62	-0.53	2.95e-12	Response to antineoplastic agents;
UCEC	cis	rs12980942	0.591	rs3760660	chr19:41769025	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.39	0.41	2.69e-7	Coronary artery disease;
UCEC	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.44	-5.14	-0.39	8.43e-7	Resting heart rate;
UCEC	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.56	-5.89	-0.44	2.5e-8	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.76	7.59	0.53	3.32e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4778214	1.000	rs1800410	chr15:28230184	T/C	cg08281084	chr15:28459700	HERC2	-0.51	-4.54	-0.35	1.16e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
UCEC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2282802	0.685	rs6580515	chr5:139698110	A/C	cg25419506	chr5:139927158	EIF4EBP3;ANKHD1-EIF4EBP3	-0.44	-4.73	-0.36	5.25e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.57	-7.67	-0.53	2.12e-12	Menarche (age at onset);
UCEC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.66	7.71	0.54	1.77e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.85	5.63	0.42	8.81e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs2386661	0.826	rs4749922	chr10:5680689	A/G	cg17085576	chr10:5658249	NA	-0.47	-4.7	-0.36	5.81e-6	Breast cancer;
UCEC	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.66	-5.0	-0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.67	5.8	0.43	3.89e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.63	5.88	0.44	2.59e-8	Platelet count;
UCEC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg14288399	chr11:64110785	CCDC88B	0.37	4.58	0.35	9.95e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.59	6.09	0.45	9.27e-9	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.62	6.98	0.5	9.23e-11	Pubertal anthropometrics;
UCEC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.56	-6.19	-0.45	5.75e-9	Menarche (age at onset);
UCEC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.42	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.61	6.18	0.45	5.85e-9	Lung cancer;
UCEC	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.72	6.36	0.46	2.42e-9	Caudate activity during reward;
UCEC	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.72	6.63	0.48	5.99e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-4.55	-0.35	1.14e-5	Endometrial cancer;
UCEC	cis	rs7937612	1.000	rs7117063	chr11:120238824	T/C	cg12584626	chr11:120203529	NA	0.54	5.47	0.41	1.89e-7	Intraocular pressure;
UCEC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.43	6.37	0.47	2.3e-9	Crohn's disease;
UCEC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.16	-14.08	-0.76	4.67e-29	Breast cancer;
UCEC	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.89	-6.97	-0.5	9.81e-11	Exhaled nitric oxide output;
UCEC	cis	rs7113850	0.541	rs7928230	chr11:24220604	A/G	ch.11.24196551F	chr11:24239977	NA	0.62	4.71	0.36	5.67e-6	Bone fracture in osteoporosis;
UCEC	cis	rs17122693	0.515	rs9323192	chr14:51198815	T/C	cg04730355	chr14:51134070	SAV1	0.64	5.71	0.43	5.93e-8	Cognitive performance;
UCEC	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.63	5.32	0.4	3.8e-7	Migraine;
UCEC	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Migraine;
UCEC	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.59	6.2	0.46	5.43e-9	Blood metabolite ratios;
UCEC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22857025	chr5:266934	NA	-0.96	-8.72	-0.58	5.48e-15	Breast cancer;
UCEC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg13147721	chr7:65941812	NA	-0.74	-5.3	-0.4	4.11e-7	Diabetic kidney disease;
UCEC	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.43	-5.95	-0.44	1.92e-8	Alcohol dependence;
UCEC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.58	5.32	0.4	3.74e-7	Coronary artery disease;
UCEC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.72	7.49	0.53	5.84e-12	Longevity;Endometriosis;
UCEC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.69	4.82	0.37	3.52e-6	Mitochondrial DNA levels;
UCEC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	7.0	0.5	8.34e-11	Homoarginine levels;
UCEC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.59	6.77	0.49	2.91e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.42	4.98	0.38	1.77e-6	QRS complex (12-leadsum);
UCEC	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.98e-6	Menarche (age at onset);
UCEC	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.73	-7.97	-0.55	4.13e-13	Body mass index (adult);
UCEC	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.58	-6.39	-0.47	2.02e-9	Blood metabolite levels;
UCEC	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.65	5.32	0.4	3.82e-7	Corneal astigmatism;
UCEC	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs10924970	0.649	rs12040676	chr1:235478808	A/T	cg26050004	chr1:235667680	B3GALNT2	-0.5	-4.79	-0.37	4.1e-6	Asthma;
UCEC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.72	7.59	0.53	3.32e-12	Breast cancer;
UCEC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.54	5.14	0.39	8.76e-7	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	4.8	0.37	3.8e-6	Breast cancer;
UCEC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	5.15	0.39	8.36e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs78707713	0.841	rs76628955	chr10:71208625	C/T	cg12610070	chr10:71211762	TSPAN15	-0.44	-4.8	-0.37	3.9e-6	Venous thromboembolism;
UCEC	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-5.42	-0.41	2.35e-7	Body mass index;
UCEC	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg00639195	chr15:79103007	ADAMTS7	-0.58	-5.01	-0.38	1.54e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs9715521	0.712	rs58171535	chr4:59847742	T/A	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.05	-0.55	2.52e-13	Total cholesterol levels;
UCEC	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	6.36	0.46	2.45e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.61	0.53	3.03e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4234798	1.000	rs4234798	chr4:7219933	G/T	cg18431297	chr4:7219810	SORCS2	-0.39	-4.91	-0.38	2.37e-6	Insulin-like growth factors;
UCEC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-6.36	-0.46	2.46e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.46	-4.61	-0.36	8.7e-6	Height;
UCEC	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.64	5.33	0.4	3.63e-7	Dental caries;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.24	0.71	3.51e-24	Prudent dietary pattern;
UCEC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-5.84	-0.43	3.29e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs4499344	0.556	rs259225	chr19:33135458	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.17	0.51	3.33e-11	Mean platelet volume;
UCEC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg08222913	chr3:52553049	STAB1	-0.42	-4.63	-0.36	8.1e-6	Bipolar disorder;
UCEC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.21	0.39	6.2e-7	Rheumatoid arthritis;
UCEC	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.64	-7.15	-0.51	3.73e-11	Ulcerative colitis;
UCEC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.26	0.51	2.07e-11	Tonsillectomy;
UCEC	cis	rs3780378	0.875	rs7032785	chr9:5042046	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-4.69	-0.36	6.07e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg10914120	chr13:113893660	CUL4A	-0.49	-4.71	-0.36	5.59e-6	Platelet distribution width;
UCEC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.93	-0.44	2.09e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1190596	0.525	rs34440178	chr14:102711201	G/C	cg04767283	chr14:102695768	RAGE	-0.42	-4.61	-0.36	8.71e-6	Behavioural disinhibition (generation interaction);
UCEC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.69	6.65	0.48	5.2400000000000005e-10	Aortic root size;
UCEC	cis	rs539514	0.690	rs34545980	chr13:76309637	C/A	cg04757411	chr13:76259545	LMO7	-0.37	-4.58	-0.35	9.81e-6	Type 1 diabetes;
UCEC	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg01072550	chr1:21505969	NA	-0.6	-6.34	-0.46	2.62e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-4.72	-0.36	5.41e-6	Tonsillectomy;
UCEC	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.76	8.3	0.57	6.04e-14	Itch intensity from mosquito bite;
UCEC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.67	-0.42	7.31e-8	Bipolar disorder;
UCEC	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.55	0.42	1.3e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.64	7.14	0.51	4.01e-11	Blood metabolite ratios;
UCEC	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.45	-4.55	-0.35	1.1e-5	Coronary artery disease;
UCEC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.78	-0.43	4.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.75	-9.71	-0.63	1.58e-17	Blood protein levels;
UCEC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg20821713	chr7:1055600	C7orf50	-0.7	-6.84	-0.49	1.96e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.44	-0.47	1.63e-9	Coronary artery disease;
UCEC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg05738196	chr6:26577821	NA	0.65	7.63	0.53	2.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18252515	chr7:66147081	NA	-0.55	-5.37	-0.4	3.02e-7	Aortic root size;
UCEC	cis	rs17012589	0.869	rs73165949	chr12:85690132	C/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.45	-4.51	-0.35	1.33e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.57	5.67	0.42	7.3e-8	Age at first birth;
UCEC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.68	-5.4	-0.41	2.67e-7	Alzheimer's disease (late onset);
UCEC	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.44	-5.21	-0.39	6.27e-7	Dupuytren's disease;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg21486944	chr6:28411378	ZSCAN23	0.53	5.63	0.42	8.73e-8	Pubertal anthropometrics;
UCEC	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg04283868	chr2:201171347	SPATS2L	0.54	5.38	0.41	2.84e-7	QT interval;
UCEC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	6.97	0.5	1.01e-10	Chronic sinus infection;
UCEC	cis	rs16932667	0.892	rs7303951	chr12:5132179	C/T	cg03854198	chr12:5541311	NTF3	0.39	4.54	0.35	1.17e-5	Intelligence (childhood);
UCEC	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.79	8.27	0.56	7.37e-14	Cognitive function;
UCEC	cis	rs139371	0.681	rs139306	chr22:39498834	T/C	cg15548613	chr22:38610795	MAFF	0.46	4.64	0.36	7.73e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.42	-4.52	-0.35	1.26e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.94	11.71	0.69	8.92e-23	Multiple sclerosis;
UCEC	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg19318889	chr4:1322082	MAEA	0.44	4.67	0.36	6.62e-6	Longevity;
UCEC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.49	0.47	1.26e-9	Personality dimensions;
UCEC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.0	12.87	0.73	7.12e-26	Platelet distribution width;
UCEC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-4.68	-0.36	6.41e-6	Platelet count;
UCEC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.53	-6.61	-0.48	6.67e-10	Total body bone mineral density;
UCEC	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg21419209	chr3:44054225	NA	-0.46	-4.72	-0.36	5.53e-6	Coronary artery disease;
UCEC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg20821713	chr7:1055600	C7orf50	-0.73	-6.39	-0.47	2.05e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7570971	0.617	rs935613	chr2:136022798	C/T	cg07169764	chr2:136633963	MCM6	0.71	6.71	0.48	4e-10	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-6.42	-0.47	1.79e-9	Schizophrenia;
UCEC	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs56341938	0.604	rs4955639	chr3:168825911	T/C	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.64	5.46	0.41	1.97e-7	Schizophrenia;
UCEC	cis	rs11867410	0.744	rs8066304	chr17:63945451	A/G	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.67	0.42	7.33e-8	Breast cancer;
UCEC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.46	-5.01	-0.38	1.51e-6	Rheumatoid arthritis;
UCEC	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg18032046	chr6:28092343	ZSCAN16	0.66	5.8	0.43	3.84e-8	Depression;
UCEC	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.72	6.35	0.46	2.59e-9	Coronary artery disease;
UCEC	cis	rs944990	0.618	rs10821169	chr9:96361119	C/T	cg13787134	chr9:96362102	PHF2	-0.34	-4.55	-0.35	1.13e-5	Body mass index;
UCEC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.72	0.48	3.76e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	6.88	0.49	1.62e-10	Menarche (age at onset);
UCEC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.56	-6.41	-0.47	1.86e-9	Prostate cancer;
UCEC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.49	5.02	0.38	1.45e-6	Lung cancer;
UCEC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.74	0.63	1.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg14092571	chr14:90743983	NA	0.43	5.83	0.43	3.34e-8	Mortality in heart failure;
UCEC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.59	0.42	1.09e-7	Height;
UCEC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.6	-6.08	-0.45	1e-8	Colorectal cancer;
UCEC	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	8.11	0.56	1.86e-13	Platelet distribution width;
UCEC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg17420585	chr12:42539391	GXYLT1	0.41	5.12	0.39	9.53e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.44	0.41	2.16e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-5.05	-0.38	1.26e-6	Bipolar disorder;
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-5.37	-0.41	2.95e-7	Platelet count;
UCEC	cis	rs2554380	0.891	rs2562781	chr15:84312568	G/A	cg25130800	chr15:85143846	ZSCAN2	-0.56	-4.52	-0.35	1.27e-5	Height;
UCEC	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.61	6.86	0.49	1.79e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.72	7.66	0.53	2.28e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7944735	0.817	rs7924699	chr11:47893120	A/T	cg08722104	chr11:47448306	PSMC3	-0.5	-4.98	-0.38	1.77e-6	Intraocular pressure;
UCEC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.76	-6.72	-0.48	3.77e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18932078	chr1:2524107	MMEL1	0.39	6.23	0.46	4.69e-9	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs4692589	0.965	rs7657455	chr4:170958843	C/G	cg19918862	chr4:170955249	NA	0.38	4.51	0.35	1.3e-5	Anxiety disorder;
UCEC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg10978503	chr1:24200527	CNR2	0.34	4.57	0.35	1.02e-5	Immature fraction of reticulocytes;
UCEC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.71	-8.09	-0.56	2e-13	Blood protein levels;
UCEC	cis	rs10858096	0.608	rs4970843	chr1:109887191	A/G	cg08367326	chr1:110052010	AMIGO1	0.49	4.61	0.36	8.64e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.61	-7.13	-0.51	4.25e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg26528668	chr16:1614120	IFT140	0.43	5.17	0.39	7.54e-7	Coronary artery disease;
UCEC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.59	0.42	1.05e-7	Monocyte percentage of white cells;
UCEC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg19926144	chr10:661009	DIP2C	0.77	4.61	0.36	8.73e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs10208940	0.920	rs7571506	chr2:68836317	C/A	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.58	-5.67	-0.42	7.17e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.51	-5.69	-0.42	6.71e-8	Response to antineoplastic agents;
UCEC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.84	10.45	0.65	1.81e-19	Body mass index;
UCEC	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.63	7.1	0.51	5.05e-11	Electrocardiographic conduction measures;
UCEC	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.81	-0.49	2.37e-10	Eye color traits;
UCEC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	5.95	0.44	1.88e-8	Menarche (age at onset);
UCEC	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.44	-4.88	-0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.79	-0.37	3.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg09120320	chr17:61926383	NA	0.44	4.59	0.35	9.52e-6	Prudent dietary pattern;
UCEC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.42	-0.41	2.41e-7	Initial pursuit acceleration;
UCEC	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-5.3	-0.4	4.22e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.25	-0.61	2.49e-16	Gout;
UCEC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg13870426	chr17:30244630	NA	-0.63	-4.56	-0.35	1.06e-5	Hip circumference adjusted for BMI;
UCEC	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.47	4.85	0.37	3.1e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.54	0.35	1.18e-5	Menopause (age at onset);
UCEC	cis	rs1318772	0.932	rs11739848	chr5:112948757	A/G	cg12552261	chr5:112820674	MCC	0.69	5.02	0.38	1.46e-6	F-cell distribution;
UCEC	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg03342759	chr3:160939853	NMD3	0.54	4.92	0.38	2.32e-6	Morning vs. evening chronotype;
UCEC	cis	rs6746896	0.683	rs6730773	chr2:97441643	A/G	cg01950434	chr2:97203154	ARID5A	-0.46	-5.08	-0.39	1.14e-6	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.16	-14.2	-0.76	2.35e-29	Breast cancer;
UCEC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs4372836	0.658	rs56178008	chr2:29098543	T/A	cg09522027	chr2:28974177	PPP1CB	0.79	8.39	0.57	3.67e-14	Body mass index;
UCEC	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg08266712	chr14:104979372	NA	-0.44	-4.63	-0.36	7.83e-6	Reticulocyte count;
UCEC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg11871910	chr12:69753446	YEATS4	0.57	5.15	0.39	8.11e-7	Response to diuretic therapy;
UCEC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.16	-14.09	-0.76	4.64e-29	Breast cancer;
UCEC	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg21905437	chr5:178450457	ZNF879	0.51	4.92	0.38	2.33e-6	Pubertal anthropometrics;
UCEC	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.51	5.32	0.4	3.87e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.71	-0.48	3.93e-10	Morning vs. evening chronotype;
UCEC	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.34	4.62	0.36	8.38e-6	Childhood ear infection;
UCEC	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-0.94	-12.21	-0.71	4.15e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.56	-0.42	1.27e-7	Body mass index;
UCEC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.75	-6.92	-0.5	1.3100000000000001e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-1.0	-12.09	-0.71	8.46e-24	Cognitive function;
UCEC	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg04310649	chr10:35416472	CREM	-0.48	-4.85	-0.37	3.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.16e-9	Prudent dietary pattern;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg17330251	chr7:94953956	PON1	-0.6	-5.76	-0.43	4.85e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.51	-0.53	5.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.63	-6.05	-0.45	1.12e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.59	-6.42	-0.47	1.8e-9	Longevity;
UCEC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.1	0.39	1.03e-6	Body mass index;
UCEC	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-4.72	-0.36	5.52e-6	Homocysteine levels;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg21871583	chr3:15374148	SH3BP5	0.62	6.84	0.49	2.01e-10	Schizophrenia;
UCEC	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.63	-5.45	-0.41	2.05e-7	Tonsillectomy;
UCEC	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-0.54	-5.78	-0.43	4.29e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.79	0.49	2.65e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.24	-0.46	4.34e-9	Parkinson's disease;
UCEC	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg20007245	chr22:24372913	LOC391322	-0.69	-7.38	-0.52	1.09e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs7246967	0.932	rs35039856	chr19:23031339	A/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.03	-0.38	1.42e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.54	4.91	0.38	2.35e-6	Coronary artery disease;
UCEC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg23018236	chr17:30244563	NA	-0.67	-4.65	-0.36	7.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.65	-6.8	-0.49	2.43e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	-0.56	-6.32	-0.46	2.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg02160872	chr5:212506	CCDC127	-0.69	-6.94	-0.5	1.18e-10	Breast cancer;
UCEC	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.31	-10.38	-0.65	2.78e-19	Hip circumference adjusted for BMI;
UCEC	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	1.07	7.46	0.52	7e-12	Obesity-related traits;
UCEC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.62	-6.67	-0.48	4.89e-10	Primary biliary cholangitis;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg08461772	chr7:95026248	PON3	0.35	4.86	0.37	3.01e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg20188282	chr9:135906200	GTF3C5	0.67	6.74	0.49	3.41e-10	Triglyceride levels;
UCEC	cis	rs2970992	0.764	rs2137669	chr2:101330992	G/T	cg01042948	chr2:101319752	NA	0.56	6.02	0.44	1.33e-8	Educational attainment;
UCEC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.63	5.76	0.43	4.85e-8	High light scatter reticulocyte count;
UCEC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	5.87	0.44	2.77e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.68	-5.24	-0.4	5.36e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.57	-6.56	-0.48	8.53e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.9	7.56	0.53	4.06e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.67	5.26	0.4	5.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7246967	0.673	rs9677019	chr19:22912659	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.51	0.47	1.1e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	9.5	0.62	5.56e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.43	5.06	0.38	1.25e-6	Blood metabolite ratios;
UCEC	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.85	-0.37	3.12e-6	Blood metabolite levels;
UCEC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg15105011	chr4:940614	TMEM175	0.45	4.61	0.36	8.72e-6	Sjögren's syndrome;
UCEC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg21770322	chr7:97807741	LMTK2	-0.4	-5.1	-0.39	1.02e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.52	-5.87	-0.44	2.82e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-7.71	-0.54	1.73e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.67	7.87	0.54	6.93e-13	Prudent dietary pattern;
UCEC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.5	-4.72	-0.36	5.43e-6	Aortic root size;
UCEC	cis	rs295140	0.903	rs3820888	chr2:201180023	T/C	cg04283868	chr2:201171347	SPATS2L	0.49	4.57	0.35	1.02e-5	QT interval;
UCEC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.8	7.53	0.53	4.65e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.75	-8.14	-0.56	1.52e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.0	12.84	0.73	8.93e-26	Platelet distribution width;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06666157	chr19:4791552	FEM1A	0.55	6.78	0.49	2.7e-10	Warfarin maintenance dose;
UCEC	cis	rs9283706	0.623	rs10055631	chr5:66305438	A/C	cg11590213	chr5:66331682	MAST4	0.43	4.71	0.36	5.76e-6	Coronary artery disease;
UCEC	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.7	6.72	0.48	3.78e-10	Crohn's disease;
UCEC	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.36	0.4	3.15e-7	Lung cancer in ever smokers;
UCEC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.45	-5.24	-0.4	5.39e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.58	-4.67	-0.36	6.84e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.68	5.74	0.43	5.27e-8	Menopause (age at onset);
UCEC	cis	rs6578185	0.810	rs3935446	chr8:142452954	C/T	cg09858281	chr8:142456070	FLJ43860	-0.32	-4.56	-0.35	1.06e-5	Endometriosis;
UCEC	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.57	-6.74	-0.49	3.42e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs847649	0.924	rs6960428	chr7:102589706	C/G	cg18108683	chr7:102477205	FBXL13	0.6	7.49	0.53	5.9e-12	Morning vs. evening chronotype;
UCEC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-5.95	-0.44	1.89e-8	Gut microbiome composition (summer);
UCEC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.21	0.39	6.32e-7	Personality dimensions;
UCEC	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg18827107	chr12:86230957	RASSF9	-0.42	-4.64	-0.36	7.6e-6	Major depressive disorder;
UCEC	cis	rs17764205	0.706	rs4807431	chr19:3245938	C/T	cg09528496	chr19:3881225	ATCAY	0.62	4.74	0.36	4.89e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7581030	0.874	rs4852784	chr2:71645890	G/C	cg07678644	chr2:71558969	ZNF638	0.52	4.75	0.36	4.87e-6	Testicular germ cell tumor;
UCEC	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.52	4.61	0.36	8.78e-6	Huntington's disease progression;
UCEC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	1.24	6.23	0.46	4.76e-9	Thyroid stimulating hormone;
UCEC	cis	rs10927875	0.929	rs10927879	chr1:16320028	G/A	cg21385522	chr1:16154831	NA	-0.67	-6.62	-0.48	6.17e-10	Dilated cardiomyopathy;
UCEC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg06768213	chr1:227963296	SNAP47	0.4	4.93	0.38	2.17e-6	Diastolic blood pressure;
UCEC	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-6.91	-0.49	1.39e-10	Prevalent atrial fibrillation;
UCEC	cis	rs1978968	0.751	rs5992139	chr22:18458636	A/G	cg03078520	chr22:18463400	MICAL3	-0.54	-5.99	-0.44	1.54e-8	Presence of antiphospholipid antibodies;
UCEC	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg19554555	chr3:13937349	NA	-0.54	-5.58	-0.42	1.11e-7	Ovarian reserve;
UCEC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.73	-6.79	-0.49	2.56e-10	Obesity-related traits;
UCEC	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg24169773	chr3:122142474	KPNA1	0.57	4.59	0.35	9.39e-6	LDL cholesterol levels;
UCEC	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.69	-5.74	-0.43	5.3e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.3e-9	Coffee consumption (cups per day);
UCEC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	0.99	6.01	0.44	1.4e-8	White matter hyperintensity burden;
UCEC	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.69	6.05	0.45	1.16e-8	Menopause (age at onset);
UCEC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg13870426	chr17:30244630	NA	-0.64	-4.62	-0.36	8.19e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.45	-6.01	-0.44	1.38e-8	Mean platelet volume;
UCEC	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.58	6.06	0.45	1.09e-8	Coronary heart disease;
UCEC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.76	-7.09	-0.5	5.16e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.82	5.29	0.4	4.33e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.87	-0.44	2.77e-8	Hemoglobin concentration;
UCEC	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.63	6.41	0.47	1.82e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.53	0.35	1.22e-5	Height;
UCEC	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.45	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.64	6.12	0.45	8.13e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.78	7.54	0.53	4.45e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	5.62	0.42	9.46e-8	Eosinophil percentage of white cells;
UCEC	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg01072550	chr1:21505969	NA	-0.61	-6.27	-0.46	3.85e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-6.25	-0.46	4.21e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg19610905	chr11:61596333	FADS2	-0.61	-4.66	-0.36	6.9e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.05	-0.45	1.14e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1832871	1.000	rs827858	chr6:158707396	T/C	cg07215822	chr6:158701037	NA	-0.5	-4.96	-0.38	1.89e-6	Height;
UCEC	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg17646820	chr3:66848679	NA	-0.59	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.58	-5.91	-0.44	2.25e-8	Ulcerative colitis;
UCEC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	15.52	0.79	9.07e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.52	4.84	0.37	3.3e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs11748684	1.000	rs7702341	chr5:42261601	C/G	cg23982445	chr2:394333	NA	1.01	6.95	0.5	1.12e-10	Response to taxane treatment (docetaxel);
UCEC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.86	9.34	0.61	1.41e-16	Dental caries;
UCEC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.63	-6.23	-0.46	4.69e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.91	-0.55	5.73e-13	Total cholesterol levels;
UCEC	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg07150772	chr14:90864620	CALM1	0.49	5.08	0.39	1.13e-6	Mortality in heart failure;
UCEC	trans	rs9481169	0.850	rs60962769	chr6:111919424	G/A	cg24793722	chr4:824416	NA	-0.89	-6.71	-0.48	3.89e-10	Inflammatory skin disease;
UCEC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.47	6.97	0.5	9.78e-11	Alcohol dependence;
UCEC	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.18e-21	Body mass index;
UCEC	cis	rs10412972	1.000	rs10412972	chr19:52154905	A/G	cg13729816	chr19:52954722	NA	-0.38	-4.53	-0.35	1.23e-5	Plasma plasminogen levels;
UCEC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.5	4.6	0.35	9.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	5.8	0.43	3.92e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.53	4.55	0.35	1.12e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg00651523	chr6:28411279	ZSCAN23	-0.49	-5.26	-0.4	4.96e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7607369	0.536	rs6436089	chr2:219668813	A/G	cg02176678	chr2:219576539	TTLL4	-0.51	-5.24	-0.4	5.51e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.45	-6.22	-0.46	4.84e-9	Eye color traits;
UCEC	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	0.6	6.23	0.46	4.74e-9	Yeast infection;
UCEC	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.54	4.83	0.37	3.4e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.79	-8.48	-0.57	2.18e-14	Mean platelet volume;
UCEC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.88	11.13	0.68	2.95e-21	IgG glycosylation;
UCEC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg05855489	chr10:104503620	C10orf26	0.56	5.08	0.39	1.13e-6	Waist circumference;Hip circumference;
UCEC	cis	rs7534016	0.817	rs61788352	chr1:59843096	G/C	cg18108087	chr1:59762112	FGGY	-0.58	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.52	0.53	4.98e-12	Ileal carcinoids;
UCEC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg08755490	chr11:65554678	OVOL1	-0.5	-5.31	-0.4	3.89e-7	Acne (severe);
UCEC	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg04846421	chr1:18800208	NA	-0.5	-5.68	-0.42	7.02e-8	Diabetic retinopathy;
UCEC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.5	4.93	0.38	2.16e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.46	4.58	0.35	9.83e-6	Blood metabolite levels;
UCEC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.62	-4.68	-0.36	6.38e-6	Obesity-related traits;
UCEC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	0.93	9.5	0.62	5.42e-17	Heart rate;
UCEC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.51	4.93	0.38	2.18e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.0	0.38	1.58e-6	Diabetic retinopathy;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.73	5.65	0.42	8.14e-8	AIDS;
UCEC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.58	5.28	0.4	4.63e-7	Corneal astigmatism;
UCEC	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.53	5.2	0.39	6.7e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.73	-6.22	-0.46	4.91e-9	Platelet distribution width;
UCEC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.5	4.53	0.35	1.2e-5	Cognitive ability;
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.55	-5.76	-0.43	4.77e-8	Parkinson's disease;
UCEC	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.41e-8	HDL cholesterol levels;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.81	10.69	0.66	4.24e-20	Menarche (age at onset);
UCEC	cis	rs4919044	0.641	rs56112656	chr10:94678966	A/G	cg00519463	chr10:94352821	KIF11	0.91	4.87	0.37	2.81e-6	Coronary artery disease;
UCEC	cis	rs883565	0.531	rs813668	chr3:39180867	G/T	cg01426195	chr3:39028469	NA	0.57	6.15	0.45	6.82e-9	Handedness;
UCEC	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-4.59	-0.35	9.47e-6	Monocyte percentage of white cells;
UCEC	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.18	0.39	7.03e-7	IgG glycosylation;
UCEC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.88	-0.44	2.59e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.47	-4.64	-0.36	7.78e-6	Schizophrenia;
UCEC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.5	5.18	0.39	7.2e-7	Type 2 diabetes;
UCEC	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-4.75	-0.36	4.75e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.66	-5.53	-0.42	1.4e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.43	-4.75	-0.37	4.69e-6	Neuroticism;
UCEC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.75	8.65	0.58	8e-15	Lymphocyte counts;
UCEC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.27	0.68	1.3e-21	Chronic sinus infection;
UCEC	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs7246967	0.736	rs423687	chr19:23000745	C/T	cg08271804	chr19:22816896	ZNF492	0.63	5.67	0.42	7.35e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.73	-6.9	-0.49	1.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.44	-6.37	-0.47	2.3e-9	Rheumatoid arthritis;
UCEC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.57	-6.67	-0.48	4.76e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs787274	0.619	rs10115576	chr9:115617822	T/C	cg13803584	chr9:115635662	SNX30	-0.56	-4.95	-0.38	2.03e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	7.0	0.5	8.44e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.53	-5.4	-0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.507	rs3740699	chr11:47504075	G/T	cg20307385	chr11:47447363	PSMC3	0.77	6.99	0.5	8.76e-11	Subjective well-being;
UCEC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs7520050	0.872	rs2486445	chr1:46605369	C/T	cg15837086	chr1:46506065	PIK3R3	-0.36	-4.7	-0.36	5.86e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.95	-6.75	-0.49	3.27e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.51	5.48	0.41	1.77e-7	Neuroticism;
UCEC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.59	8.49	0.57	2.12e-14	Prudent dietary pattern;
UCEC	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.63	-7.0	-0.5	8.63e-11	Type 2 diabetes;
UCEC	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.61	6.8	0.49	2.46e-10	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.56	5.18	0.39	7.24e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg20307385	chr11:47447363	PSMC3	0.54	4.76	0.37	4.64e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg13575925	chr12:9217583	LOC144571	0.41	4.85	0.37	3.09e-6	Sjögren's syndrome;
UCEC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.46	5.16	0.39	7.97e-7	Emphysema distribution in smoking;
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.66	7.15	0.51	3.69e-11	Platelet count;
UCEC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.39	6.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.87	7.75	0.54	1.42e-12	Type 2 diabetes nephropathy;
UCEC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.52	-5.27	-0.4	4.67e-7	Refractive error;
UCEC	cis	rs7474896	0.832	rs2738207	chr10:38306079	T/C	cg00409905	chr10:38381863	ZNF37A	0.61	4.66	0.36	7.14e-6	Obesity (extreme);
UCEC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs829661	0.948	rs829619	chr2:30749567	C/T	cg17749961	chr2:30669863	LCLAT1	0.49	4.66	0.36	7.1e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.66	-5.32	-0.4	3.88e-7	Menopause (age at onset);
UCEC	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	5.41	0.41	2.54e-7	Monocyte percentage of white cells;
UCEC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.71	-7.71	-0.54	1.72e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.64	5.93	0.44	2.04e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.41	5.59	0.42	1.06e-7	Alcohol dependence;
UCEC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.48	-4.77	-0.37	4.46e-6	Monocyte count;
UCEC	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.12	-9.01	-0.6	9.9e-16	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.61	6.8	0.49	2.49e-10	Longevity;Endometriosis;
UCEC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	-0.45	-4.61	-0.36	8.59e-6	Lymphocyte counts;
UCEC	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.4	-5.35	-0.4	3.23e-7	Alcohol dependence;
UCEC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.55	-5.53	-0.42	1.41e-7	Aortic root size;
UCEC	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	0.88	5.76	0.43	4.79e-8	Arsenic metabolism;
UCEC	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.78	0.59	3.76e-15	Coffee consumption (cups per day);
UCEC	cis	rs4849887	1.000	rs4848603	chr2:121243112	C/T	cg00421221	chr2:121106091	INHBB	0.43	4.52	0.35	1.26e-5	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.51	-5.86	-0.44	2.92e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.81	-7.85	-0.54	8.02e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg21466736	chr12:48725269	NA	-0.36	-4.76	-0.37	4.61e-6	Plateletcrit;
UCEC	cis	rs7197653	0.748	rs58542611	chr16:68350219	C/T	cg05110241	chr16:68378359	PRMT7	-0.52	-4.52	-0.35	1.28e-5	Magnesium levels;
UCEC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.47	4.99	0.38	1.69e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.79	5.13	0.39	8.82e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.39	-4.91	-0.38	2.39e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.71	6.41	0.47	1.87e-9	Response to diuretic therapy;
UCEC	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-13.98	-0.76	9.03e-29	Schizophrenia;
UCEC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg24562669	chr7:97807699	LMTK2	-0.5	-5.95	-0.44	1.88e-8	Breast cancer;
UCEC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.89	7.72	0.54	1.65e-12	Bladder cancer;
UCEC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.45	4.52	0.35	1.25e-5	Monocyte count;
UCEC	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs8105895	0.935	rs7252220	chr19:22245564	G/A	cg24072202	chr19:22235272	ZNF257	-0.61	-5.33	-0.4	3.64e-7	Body mass index (change over time);
UCEC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.52	6.08	0.45	9.85e-9	Breast cancer;
UCEC	cis	rs9463078	0.764	rs9369513	chr6:44789476	T/C	cg25276700	chr6:44698697	NA	-0.44	-4.88	-0.37	2.75e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.69	6.65	0.48	5.2400000000000005e-10	Aortic root size;
UCEC	cis	rs7246967	0.673	rs34376806	chr19:22900861	A/G	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	5.57	0.42	1.2e-7	Mood instability;
UCEC	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	1.18	14.71	0.77	1.1e-30	Body mass index;
UCEC	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.81	-10.07	-0.64	1.81e-18	White blood cell count (basophil);
UCEC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg17986701	chr20:44574422	PCIF1	0.48	4.95	0.38	1.97e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.43	5.68	0.42	6.86e-8	Abdominal aortic aneurysm;
UCEC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18932078	chr1:2524107	MMEL1	-0.33	-5.37	-0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.58	4.97	0.38	1.85e-6	Huntington's disease progression;
UCEC	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.41	5.25	0.4	5.34e-7	Carotid intima media thickness;
UCEC	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.63	-0.42	8.91e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg01973587	chr1:228161476	NA	0.37	4.78	0.37	4.19e-6	Diastolic blood pressure;
UCEC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.68	-7.07	-0.5	5.88e-11	Age at first birth;
UCEC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.54	4.84	0.37	3.24e-6	Lung cancer;
UCEC	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.6	-5.43	-0.41	2.26e-7	Metabolite levels;
UCEC	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-4.76	-0.37	4.65e-6	Breast cancer;
UCEC	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.78	11.31	0.68	9.94e-22	Leprosy;
UCEC	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.64	5.56	0.42	1.22e-7	Schizophrenia;
UCEC	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg09904177	chr6:26538194	HMGN4	-0.82	-5.2	-0.39	6.53e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	0.81	7.75	0.54	1.38e-12	Testicular germ cell tumor;
UCEC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18854424	chr1:2615690	NA	0.36	5.28	0.4	4.62e-7	Ulcerative colitis;
UCEC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.39	0.41	2.76e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-5.76	-0.43	4.75e-8	HDL cholesterol;
UCEC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06223018	chr3:49557076	DAG1	0.34	4.92	0.38	2.34e-6	Parkinson's disease;
UCEC	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-6.27	-0.46	3.88e-9	Chronic sinus infection;
UCEC	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg26114124	chr12:9217669	LOC144571	0.4	4.74	0.36	5.01e-6	Sjögren's syndrome;
UCEC	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.71	8.42	0.57	3.02e-14	Menarche (age at onset);
UCEC	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Diabetic kidney disease;
UCEC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.13e-6	Height;
UCEC	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.47	5.02	0.38	1.45e-6	Nonalcoholic fatty liver disease;
UCEC	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-4.52	-0.35	1.27e-5	Mean platelet volume;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.54	6.43	0.47	1.66e-9	Menarche (age at onset);
UCEC	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.49	-0.41	1.75e-7	Morning vs. evening chronotype;
UCEC	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.07	-0.8	3.51e-34	Myeloid white cell count;
UCEC	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.57	-5.72	-0.43	5.71e-8	Bipolar disorder;
UCEC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg04155231	chr12:9217510	LOC144571	-0.43	-5.53	-0.42	1.39e-7	Sjögren's syndrome;
UCEC	cis	rs6723108	0.603	rs6708336	chr2:135719132	T/A	cg07169764	chr2:136633963	MCM6	0.51	4.96	0.38	1.93e-6	Type 2 diabetes;
UCEC	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.44	-5.82	-0.43	3.5e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.92	-7.41	-0.52	9.1e-12	Monobrow;
UCEC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.88	0.37	2.68e-6	Diabetic retinopathy;
UCEC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.7	-6.22	-0.46	4.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg20560298	chr2:73613845	ALMS1	0.52	4.95	0.38	1.98e-6	Metabolite levels;
UCEC	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.62	4.83	0.37	3.33e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.64	-6.41	-0.47	1.86e-9	Pancreatic cancer;
UCEC	cis	rs860295	0.812	rs11264363	chr1:155318308	C/G	cg02153340	chr1:155202674	NA	-0.43	-4.61	-0.36	8.71e-6	Body mass index;
UCEC	cis	rs11583393	0.554	rs1413529	chr1:88445213	C/T	cg09365624	chr1:87597710	LOC339524	0.48	4.97	0.38	1.82e-6	Breast cancer;
UCEC	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.69	7.57	0.53	3.79e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	1.04	10.25	0.65	6.04e-19	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.68	7.45	0.52	7.39e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1940013	0.846	rs895919	chr11:132230702	T/C	cg11473001	chr11:131780499	NTM	-0.41	-4.88	-0.37	2.75e-6	Sleep-related phenotypes;
UCEC	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.37	4.73	0.36	5.17e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.9	9.9	0.63	4.98e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.62	7.11	0.51	4.64e-11	Tonsillectomy;
UCEC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.6	5.69	0.42	6.67e-8	Uric acid levels;
UCEC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg00343986	chr7:65444356	GUSB	0.55	5.01	0.38	1.53e-6	Aortic root size;
UCEC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.87	-9.51	-0.62	5.21e-17	Ulcerative colitis;
UCEC	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.76	4.91	0.38	2.41e-6	Height;
UCEC	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.67	-7.97	-0.55	4.02e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.62	0.48	6.43e-10	Aortic root size;
UCEC	cis	rs9463078	0.764	rs7754698	chr6:44782717	A/G	cg25276700	chr6:44698697	NA	-0.47	-5.21	-0.4	6.17e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.61	6.7	0.48	4.12e-10	Longevity;
UCEC	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.56	5.49	0.41	1.71e-7	Coronary artery disease;
UCEC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg22974920	chr21:40686053	BRWD1	-0.63	-5.41	-0.41	2.47e-7	Cognitive function;
UCEC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.53	-5.28	-0.4	4.63e-7	Aortic root size;
UCEC	cis	rs8105895	0.877	rs62112919	chr19:22227145	T/C	cg02912127	chr19:22235281	ZNF257	-0.58	-4.69	-0.36	6.25e-6	Body mass index (change over time);
UCEC	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.61	-6.54	-0.47	9.79e-10	Personality dimensions;
UCEC	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs10940138	0.830	rs16897180	chr5:67220196	A/C	ch.5.1281357F	chr5:67228439	NA	-0.6	-4.9	-0.37	2.52e-6	Menarche (age at onset);
UCEC	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.6	-4.71	-0.36	5.74e-6	Coronary artery calcification;
UCEC	cis	rs1387221	0.904	rs13266837	chr8:59614516	C/T	cg24495373	chr8:59337659	UBXN2B	0.38	4.56	0.35	1.07e-5	Clozapine-induced cytotoxicity;
UCEC	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.64	-5.57	-0.42	1.17e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.15	0.45	7.04e-9	Motion sickness;
UCEC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-4.68	-0.36	6.56e-6	Platelet count;
UCEC	cis	rs10242455	0.867	rs10282706	chr7:99217424	G/A	cg07715041	chr7:99302981	CYP3A7	0.46	4.66	0.36	7.01e-6	Blood metabolite levels;
UCEC	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg05519781	chr21:40033154	ERG	0.85	10.28	0.65	5.28e-19	Coronary artery disease;
UCEC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg27624424	chr6:160112604	SOD2	-0.54	-5.11	-0.39	9.73e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.68	6.33	0.46	2.83e-9	Schizophrenia;
UCEC	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	0.66	4.87	0.37	2.88e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs7766436	0.767	rs13206434	chr6:22608883	A/G	cg13666174	chr6:22585274	NA	-0.45	-4.63	-0.36	8.01e-6	Coronary artery disease;
UCEC	cis	rs12618769	0.656	rs56091613	chr2:99103761	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.81	-5.39	-0.41	2.7e-7	Rheumatoid arthritis;
UCEC	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg17515076	chr17:73810948	UNK	0.54	6.36	0.46	2.38e-9	White matter hyperintensity burden;
UCEC	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-10.02	-0.64	2.47e-18	Renal cell carcinoma;
UCEC	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.66	6.89	0.49	1.53e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.95	-0.55	4.6e-13	Bipolar disorder and schizophrenia;
UCEC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.62	-7.24	-0.51	2.31e-11	Iron status biomarkers (transferrin levels);
UCEC	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.5	5.66	0.42	7.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.34	4.77	0.37	4.39e-6	Ewing sarcoma;
UCEC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.54	-0.47	9.57e-10	Longevity;Endometriosis;
UCEC	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08822215	chr16:89438651	ANKRD11	-0.45	-4.72	-0.36	5.35e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg16351881	chr16:2010026	NDUFB10	0.5	5.11	0.39	1.01e-6	Insulin-like growth factors;
UCEC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.53	-5.52	-0.41	1.49e-7	Immature fraction of reticulocytes;
UCEC	cis	rs17106184	1.000	rs72904730	chr1:51342035	G/C	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs1007190	0.881	rs75199539	chr17:42930246	A/C	cg15406952	chr17:42872593	NA	0.68	5.18	0.39	7.17e-7	DNA methylation (variation);
UCEC	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.61	6.43	0.47	1.72e-9	Colorectal cancer;
UCEC	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.53	-4.89	-0.37	2.56e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.86	-10.59	-0.66	7.98e-20	Longevity;Endometriosis;
UCEC	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.56	5.55	0.42	1.31e-7	Corneal astigmatism;
UCEC	cis	rs4654899	0.931	rs935917	chr1:21167102	A/T	cg01072550	chr1:21505969	NA	-0.55	-5.75	-0.43	4.96e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	0.87	6.51	0.47	1.1e-9	Economic and political preferences (immigration/crime);
UCEC	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.48	4.99	0.38	1.69e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.59	5.32	0.4	3.86e-7	Uric acid levels;
UCEC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.15	14.66	0.77	1.48e-30	Cognitive function;
UCEC	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs56341938	0.679	rs4955640	chr3:168826881	G/C	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.51	5.24	0.4	5.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.49	-0.72	7.33e-25	Primary sclerosing cholangitis;
UCEC	cis	rs9302690	1.000	rs74809791	chr16:57472860	G/T	cg27017172	chr16:57497170	POLR2C	1.2	7.0	0.5	8.41e-11	Blood protein levels;
UCEC	cis	rs28386778	0.669	rs4968674	chr17:62015048	G/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.44	4.78	0.37	4.25e-6	Prudent dietary pattern;
UCEC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.83	7.76	0.54	1.34e-12	Diastolic blood pressure;
UCEC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.42	4.98	0.38	1.77e-6	QRS complex (12-leadsum);
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.77	8.1	0.56	1.9e-13	Menarche (age at onset);
UCEC	cis	rs791888	0.728	rs2255682	chr10:89419873	C/G	cg13926569	chr10:89418898	PAPSS2	-0.63	-7.36	-0.52	1.18e-11	Magnesium levels;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.37	4.75	0.36	4.78e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.49	-0.57	2.1e-14	Blood trace element (Zn levels);
UCEC	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.55	-5.98	-0.44	1.66e-8	Sitting height ratio;
UCEC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26002218	chr14:103986227	CKB	-0.33	-4.75	-0.37	4.69e-6	Body mass index;
UCEC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-10.28	-0.65	5.07e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.83	-9.89	-0.63	5.3e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg23625390	chr15:77176239	SCAPER	0.44	4.5	0.35	1.35e-5	Blood metabolite levels;
UCEC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg09626299	chr10:82213104	TSPAN14	-0.38	-5.86	-0.44	2.93e-8	Post bronchodilator FEV1;
UCEC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.64	-5.74	-0.43	5.28e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.27	-8.51	-0.57	1.88e-14	Diabetic kidney disease;
UCEC	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.35	-5.08	-0.39	1.11e-6	Schizophrenia;
UCEC	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.59	-5.93	-0.44	2.05e-8	Platelet distribution width;
UCEC	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.88	0.37	2.68e-6	Rheumatoid arthritis;
UCEC	cis	rs9467773	1.000	rs6913462	chr6:26577530	A/G	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg13206674	chr6:150067644	NUP43	0.57	5.72	0.43	5.73e-8	Lung cancer;
UCEC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.24	-0.4	5.49e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs740160	0.558	rs17161669	chr7:98908663	G/A	cg18809830	chr7:99032528	PTCD1	-0.59	-4.99	-0.38	1.72e-6	Dehydroepiandrosterone sulphate levels;
UCEC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24308560	chr3:49941425	MST1R	0.56	6.23	0.46	4.71e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.7	-8.14	-0.56	1.51e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7766436	0.848	rs66989470	chr6:22598707	G/C	cg13666174	chr6:22585274	NA	-0.6	-6.08	-0.45	1.01e-8	Coronary artery disease;
UCEC	cis	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg17412351	chr7:75678396	MDH2;STYXL1	0.44	4.78	0.37	4.21e-6	Eotaxin levels;
UCEC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.38e-17	Height;
UCEC	cis	rs7246967	0.611	rs3931771	chr19:22896820	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.07	0.45	1.03e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.32	-0.4	3.87e-7	Resting heart rate;
UCEC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.76	8.99	0.6	1.13e-15	Cognitive function;
UCEC	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.09e-5	Red blood cell count;
UCEC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.57	6.13	0.45	7.74e-9	Initial pursuit acceleration;
UCEC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.58	-5.88	-0.44	2.68e-8	Blood trace element (Zn levels);
UCEC	cis	rs2267681	0.603	rs194152	chr7:139539936	C/G	cg14116596	chr7:139528673	TBXAS1	-0.52	-5.17	-0.39	7.64e-7	Cervical cancer;
UCEC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.48	4.88	0.37	2.76e-6	Dental caries;
UCEC	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.59	5.72	0.43	5.89e-8	Asthma (sex interaction);
UCEC	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.66	-7.93	-0.55	5.15e-13	IgG glycosylation;
UCEC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg22166914	chr1:53195759	ZYG11B	0.59	6.03	0.45	1.26e-8	Monocyte count;
UCEC	cis	rs295140	0.586	rs4673904	chr2:201163454	A/T	cg04283868	chr2:201171347	SPATS2L	0.5	4.71	0.36	5.78e-6	QT interval;
UCEC	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.47	4.74	0.36	5.06e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.59	4.83	0.37	3.45e-6	High light scatter reticulocyte count;
UCEC	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.68	0.42	7.04e-8	Cognitive test performance;
UCEC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.05	0.55	2.57e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-7.32	-0.52	1.53e-11	Resting heart rate;
UCEC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.59	0.53	3.39e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.72	-7.07	-0.5	5.67e-11	Acne (severe);
UCEC	cis	rs10924970	0.649	rs1317238	chr1:235457580	G/A	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg00614314	chr15:82944287	LOC80154	0.52	4.9	0.38	2.45e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs6840360	0.573	rs4696080	chr4:152276465	A/T	cg25486957	chr4:152246857	NA	-0.44	-4.6	-0.36	8.88e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	1.000	rs7246967	chr19:23056346	T/G	cg24889512	chr19:22816950	ZNF492	0.49	4.98	0.38	1.76e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.58	6.73	0.49	3.62e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1405069	0.809	rs1063021	chr6:36932327	A/G	cg26433444	chr6:36932349	PI16	0.4	5.74	0.43	5.13e-8	Chemerin levels;
UCEC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg15358701	chr1:161410459	NA	-0.74	-5.07	-0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.6	-5.18	-0.39	7.25e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.52	0.35	1.26e-5	Menopause (age at onset);
UCEC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg15147215	chr3:52552868	STAB1	0.41	4.54	0.35	1.15e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.77	7.54	0.53	4.49e-12	Menarche (age at onset);
UCEC	cis	rs731174	0.759	rs12133523	chr1:38153110	T/A	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.34e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.82	0.37	3.62e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.6	0.42	1.02e-7	Height;
UCEC	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.49	4.7	0.36	5.92e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg21486944	chr6:28411378	ZSCAN23	-0.5	-5.37	-0.41	2.99e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.81	-9.09	-0.6	6.23e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg17469321	chr7:55412551	NA	0.69	6.28	0.46	3.59e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.55	6.01	0.44	1.38e-8	Schizophrenia;
UCEC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.67	5.43	0.41	2.28e-7	Cognitive test performance;
UCEC	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.65	-0.42	7.91e-8	Pancreatic cancer;
UCEC	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-5.4	-0.41	2.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg10631289	chr15:39006617	NA	0.57	5.21	0.39	6.39e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg05493336	chr16:89469845	ANKRD11	0.35	4.93	0.38	2.17e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.45	-4.87	-0.37	2.83e-6	Stearic acid (18:0) levels;
UCEC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.62	-7.84	-0.54	8.26e-13	Vitiligo;
UCEC	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.36	-5.04	-0.38	1.35e-6	Vitamin D levels;
UCEC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.47	-5.18	-0.39	7.19e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Bipolar disorder;
UCEC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.85	-10.42	-0.65	2.17e-19	Coronary artery disease;
UCEC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.72	-7.12	-0.51	4.35e-11	Aortic root size;
UCEC	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.79	8.48	0.57	2.21e-14	Diastolic blood pressure;
UCEC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.94	11.36	0.68	7.36e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg20936604	chr3:58311152	NA	-0.62	-4.57	-0.35	1.04e-5	Cholesterol, total;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24569045	chr5:39073701	RICTOR	0.57	7.14	0.51	3.97e-11	Warfarin maintenance dose;
UCEC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg04310649	chr10:35416472	CREM	-0.48	-4.68	-0.36	6.55e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.63	5.27	0.4	4.71e-7	Systolic blood pressure;
UCEC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.54	0.35	1.15e-5	Menopause (age at onset);
UCEC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.65	6.39	0.47	2.1e-9	Aortic root size;
UCEC	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09491104	chr22:46646882	C22orf40	-0.48	-4.58	-0.35	9.71e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg24562669	chr7:97807699	LMTK2	0.73	10.79	0.66	2.38e-20	Breast cancer;
UCEC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs10924970	0.649	rs12747368	chr1:235466687	A/G	cg26050004	chr1:235667680	B3GALNT2	0.5	4.78	0.37	4.26e-6	Asthma;
UCEC	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.73	6.8	0.49	2.46e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18854424	chr1:2615690	NA	0.45	6.49	0.47	1.22e-9	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.36	-13.38	-0.74	3.21e-27	Type 1 diabetes nephropathy;
UCEC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.8	8.58	0.58	1.2e-14	Blood protein levels;
UCEC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg20999797	chr1:1681921	NA	0.39	5.21	0.39	6.35e-7	Body mass index;
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.73	0.43	5.58e-8	Prudent dietary pattern;
UCEC	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.51	7.1	0.51	5.01e-11	Age-related hearing impairment;
UCEC	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.5	0.57	1.99e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.73	-7.09	-0.5	5.11e-11	Blood pressure (smoking interaction);
UCEC	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.47	4.97	0.38	1.86e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs2274471	0.680	rs10974907	chr9:5002188	C/A	cg03390472	chr9:5043263	JAK2	-0.52	-5.22	-0.4	5.93e-7	Crohn's disease;
UCEC	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	1.11	5.51	0.41	1.55e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.62	8.0	0.55	3.33e-13	Anterior chamber depth;
UCEC	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	1.11	13.99	0.76	8.29e-29	Schizophrenia;
UCEC	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-4.63	-0.36	7.87e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.58	5.34	0.4	3.46e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2213920	0.749	rs10121366	chr9:118244022	T/C	cg13918206	chr9:118159781	DEC1	0.64	4.98	0.38	1.73e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.93	-0.44	2.07e-8	Breast cancer;
UCEC	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.88	8.24	0.56	8.9e-14	Prostate cancer;
UCEC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.56	4.9	0.37	2.54e-6	Response to diuretic therapy;
UCEC	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-1.08	-9.46	-0.62	6.82e-17	Dupuytren's disease;
UCEC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.78	8.02	0.55	3.02e-13	Longevity;Endometriosis;
UCEC	cis	rs77861329	1.000	rs352147	chr3:52208285	A/G	cg08692210	chr3:52188851	WDR51A	0.84	6.48	0.47	1.27e-9	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.66	7.75	0.54	1.39e-12	Schizophrenia;
UCEC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.91	8.31	0.57	5.68e-14	Bladder cancer;
UCEC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.63	6.29	0.46	3.38e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.26	0.51	2.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs13401104	0.796	rs72620805	chr2:237113711	G/C	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.51	5.39	0.41	2.76e-7	Breast cancer;
UCEC	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-4.57	-0.35	1.04e-5	Hemoglobin concentration;
UCEC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.36	-13.67	-0.75	5.62e-28	Type 1 diabetes nephropathy;
UCEC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.02	-0.38	1.48e-6	Systemic lupus erythematosus;
UCEC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.58	5.57	0.42	1.19e-7	Aortic root size;
UCEC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.48e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.82	8.04	0.55	2.77e-13	Cognitive function;
UCEC	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.22	0.46	4.89e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg16497661	chr14:103986332	CKB	0.49	5.85	0.43	3.04e-8	Body mass index;
UCEC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg03859395	chr2:55845619	SMEK2	1.04	15.03	0.78	1.62e-31	Metabolic syndrome;
UCEC	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.62	6.65	0.48	5.41e-10	Body mass index;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.54	-6.11	-0.45	8.65e-9	Cardiac Troponin-T levels;
UCEC	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.64	-6.45	-0.47	1.55e-9	Body mass index;
UCEC	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.71	-8.49	-0.57	2.07e-14	Response to temozolomide;
UCEC	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.41	-5.16	-0.39	7.87e-7	Dilated cardiomyopathy;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg19678392	chr7:94953810	PON1	-0.59	-5.79	-0.43	4.02e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.78	-7.1	-0.51	5.08e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.52	0.47	1.07e-9	Coffee consumption (cups per day);
UCEC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.57	6.72	0.48	3.78e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.18	9.69	0.62	1.79e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg04043695	chr12:129287642	SLC15A4	0.57	5.52	0.41	1.46e-7	Systemic lupus erythematosus;
UCEC	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.69	-0.69	9.63e-23	Primary sclerosing cholangitis;
UCEC	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.73	-7.36	-0.52	1.18e-11	Plateletcrit;Platelet count;
UCEC	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.53	-6.18	-0.45	6.12e-9	Platelet count;
UCEC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg03609598	chr5:56110824	MAP3K1	0.7	5.42	0.41	2.35e-7	Initial pursuit acceleration;
UCEC	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.57	5.58	0.42	1.13e-7	Vitamin D levels;
UCEC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg05072774	chr3:49840536	C3orf54	-0.54	-5.62	-0.42	9.37e-8	Resting heart rate;
UCEC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-4.91	-0.38	2.35e-6	Hemoglobin concentration;
UCEC	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	0.87	5.29	0.4	4.37e-7	Blood protein levels;
UCEC	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.57	-6.24	-0.46	4.51e-9	Menarche (age at onset);
UCEC	cis	rs13095912	1.000	rs13072061	chr3:185326023	G/T	cg11274856	chr3:185301563	NA	0.55	7.38	0.52	1.05e-11	Systolic blood pressure;
UCEC	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.44	4.64	0.36	7.59e-6	Schizophrenia;
UCEC	cis	rs2288327	0.818	rs13034990	chr2:179386240	A/G	cg09915519	chr2:179397513	TTN;MIR548N	-0.68	-4.65	-0.36	7.26e-6	Atrial fibrillation;
UCEC	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.71	6.62	0.48	6.2e-10	Lymphocyte counts;
UCEC	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg16303742	chr3:15540471	COLQ	0.4	5.14	0.39	8.5e-7	Mean platelet volume;
UCEC	cis	rs10946940	0.965	rs6915266	chr6:27528643	G/A	cg07836142	chr6:28411423	ZSCAN23	0.43	4.54	0.35	1.15e-5	Systemic lupus erythematosus;
UCEC	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.12	0.45	8.14e-9	IgG glycosylation;
UCEC	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.54	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg14067834	chr17:29058358	SUZ12P	0.64	4.6	0.35	9.07e-6	Body mass index;
UCEC	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	7.15	0.51	3.87e-11	Total body bone mineral density;
UCEC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.94	0.44	1.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.72	7.33	0.52	1.44e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg12463550	chr7:65579703	CRCP	0.49	4.66	0.36	7.04e-6	Aortic root size;
UCEC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.86	5.76	0.43	4.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-4.97	-0.38	1.86e-6	Crohn's disease;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.16	-0.45	6.77e-9	Metabolite levels;
UCEC	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.48	4.87	0.37	2.79e-6	Autism;
UCEC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.54	-6.15	-0.45	7.07e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00802000	chr16:706648	WDR90	-0.4	-4.65	-0.36	7.47e-6	Height;
UCEC	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.61	5.62	0.42	9.29e-8	Aortic root size;
UCEC	cis	rs7246967	0.673	rs7254097	chr19:22865900	T/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.29	-0.4	4.44e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.66	-6.72	-0.48	3.72e-10	Dilated cardiomyopathy;
UCEC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.4	6.07	0.45	1.02e-8	Ulcerative colitis;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.49	-0.41	1.76e-7	Pubertal anthropometrics;
UCEC	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg06521331	chr12:34319734	NA	-0.55	-4.87	-0.37	2.79e-6	Morning vs. evening chronotype;
UCEC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.67	-7.05	-0.5	6.56e-11	Blood metabolite levels;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.78	9.5	0.62	5.46e-17	Bone mineral density;
UCEC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg23791538	chr6:167370224	RNASET2	-0.48	-4.92	-0.38	2.32e-6	Primary biliary cholangitis;
UCEC	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg23625390	chr15:77176239	SCAPER	0.46	4.73	0.36	5.12e-6	Blood metabolite levels;
UCEC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.06	-0.39	1.23e-6	Aortic root size;
UCEC	cis	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg00614314	chr15:82944287	LOC80154	0.52	4.66	0.36	6.9e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Electroencephalogram traits;
UCEC	cis	rs405956	0.769	rs2001119	chr6:105562120	G/A	cg22580625	chr6:105627791	POPDC3	-0.53	-4.87	-0.37	2.88e-6	QT interval;
UCEC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.63	8.21	0.56	1.03e-13	Anterior chamber depth;
UCEC	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg19041857	chr6:27730383	NA	-0.64	-5.05	-0.38	1.3e-6	Lung cancer in ever smokers;
UCEC	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.39	-4.52	-0.35	1.26e-5	Post bronchodilator FEV1;
UCEC	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.35	-4.56	-0.35	1.09e-5	Total body bone mineral density;
UCEC	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.63	6.15	0.45	6.91e-9	Sudden cardiac arrest;
UCEC	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.67	7.98	0.55	3.9e-13	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.86	0.37	3.03e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	0.94	9.97	0.64	3.3e-18	Heart rate;
UCEC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.71	6.59	0.48	7.26e-10	Menarche (age at onset);
UCEC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.54	-4.93	-0.38	2.21e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.47	-5.0	-0.38	1.6e-6	Glaucoma;
UCEC	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg13319975	chr6:146136371	FBXO30	-0.45	-4.86	-0.37	2.98e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.45	-5.06	-0.39	1.22e-6	Height;
UCEC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.57	4.77	0.37	4.34e-6	Lung cancer;
UCEC	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg08886695	chr4:3369023	RGS12	-0.51	-5.08	-0.39	1.14e-6	Serum sulfate level;
UCEC	cis	rs10432489	0.708	rs4541220	chr2:181746466	A/G	cg21995919	chr2:182322279	ITGA4	0.77	5.7	0.43	6.26e-8	QT interval;
UCEC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-7.36	-0.52	1.23e-11	Blood trace element (Zn levels);
UCEC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.65	-8.05	-0.55	2.51e-13	Menarche (age at onset);
UCEC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg04804543	chr8:142233427	SLC45A4	-0.51	-6.12	-0.45	7.91e-9	Immature fraction of reticulocytes;
UCEC	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.79	-8.16	-0.56	1.41e-13	Mosquito bite size;
UCEC	cis	rs847649	0.842	rs7789252	chr7:102624227	C/A	cg18108683	chr7:102477205	FBXL13	-0.57	-6.79	-0.49	2.56e-10	Morning vs. evening chronotype;
UCEC	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg17764715	chr19:33622953	WDR88	0.64	6.17	0.45	6.29e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg11189052	chr15:85197271	WDR73	0.57	4.58	0.35	9.94e-6	Schizophrenia;
UCEC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.53	0.58	1.62e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.41	-5.23	-0.4	5.73e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.93	0.44	2.09e-8	Ileal carcinoids;
UCEC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.53	4.54	0.35	1.15e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.64	6.3	0.46	3.2e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.05	0.55	2.53e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7004769	0.554	rs74781121	chr8:9169007	G/A	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs1832871	0.599	rs7752547	chr6:158751163	C/T	cg07215822	chr6:158701037	NA	0.51	5.46	0.41	1.97e-7	Height;
UCEC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg09491104	chr22:46646882	C22orf40	0.6	6.2	0.46	5.44e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg17085576	chr10:5658249	NA	0.6	5.48	0.41	1.83e-7	Breast cancer;
UCEC	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.52	-5.8	-0.43	3.86e-8	Cognitive function;
UCEC	cis	rs6761276	0.899	rs12466799	chr2:113835999	T/C	cg09040174	chr2:113837401	NA	0.52	5.78	0.43	4.38e-8	Protein quantitative trait loci;
UCEC	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.67	0.42	7.27e-8	Neuroticism;
UCEC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.46	-0.41	1.95e-7	Resting heart rate;
UCEC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-5.35	-0.4	3.24e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.8	8.94	0.59	1.5e-15	Breast cancer;
UCEC	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-7.16	-0.51	3.67e-11	Educational attainment (years of education);
UCEC	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.56	6.21	0.46	5.15e-9	Retinal vascular caliber;
UCEC	cis	rs7336933	0.866	rs9566874	chr13:42454094	T/A	cg18400088	chr13:41634674	WBP4	0.55	4.71	0.36	5.74e-6	Calcium levels;
UCEC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs10952927	1.000	rs11980910	chr7:88347536	A/C	cg05683227	chr7:87850031	SRI	-0.53	-4.66	-0.36	7.02e-6	Restless legs syndrome;
UCEC	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.74	-6.47	-0.47	1.38e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.38	-4.88	-0.37	2.77e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1355223	0.752	rs286893	chr11:34674882	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.52	5.2	0.39	6.58e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs11958404	0.932	rs6884954	chr5:157436772	C/T	cg05962755	chr5:157440814	NA	0.66	5.09	0.39	1.08e-6	IgG glycosylation;
UCEC	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.5	5.55	0.42	1.29e-7	Hip circumference;
UCEC	cis	rs7246967	0.866	rs62120784	chr19:23044735	A/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg10932868	chr11:921992	NA	0.37	4.58	0.35	9.74e-6	Alzheimer's disease (late onset);
UCEC	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.88	-0.73	6.92e-26	Height;
UCEC	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.61	0.62	2.8e-17	Coffee consumption (cups per day);
UCEC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.59	0.35	9.29e-6	Menopause (age at onset);
UCEC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	15.41	0.79	1.73e-32	Chronic sinus infection;
UCEC	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.58	-4.78	-0.37	4.15e-6	Corneal structure;
UCEC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-1.03	-7.78	-0.54	1.19e-12	Bone mineral density;
UCEC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1459104	0.714	rs36018195	chr11:55172856	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs8020441	0.541	rs113935613	chr14:51163847	C/T	cg04730355	chr14:51134070	SAV1	0.64	6.34	0.46	2.62e-9	Cognitive performance;
UCEC	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.79	0.37	4.1e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.67	5.46	0.41	2.02e-7	Smoking initiation;
UCEC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.47	-4.54	-0.35	1.15e-5	Cystic fibrosis severity;
UCEC	cis	rs9326726	0.844	rs34527417	chr5:107537210	T/C	cg17432647	chr5:107996819	NA	0.49	4.51	0.35	1.32e-5	Resting heart rate;
UCEC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.99	-12.45	-0.72	9.53e-25	Height;
UCEC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.82	11.19	0.68	2.1e-21	Headache;
UCEC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.57	-5.73	-0.43	5.42e-8	Refractive error;
UCEC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.69	7.76	0.54	1.32e-12	Menopause (age at onset);
UCEC	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg23950597	chr19:37808831	NA	-0.85	-5.93	-0.44	2.09e-8	Coronary artery calcification;
UCEC	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.53	5.13	0.39	8.9e-7	Uric acid levels;
UCEC	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.03	-0.5	7.22e-11	Colorectal cancer;
UCEC	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.65	-8.02	-0.55	3.12e-13	Response to temozolomide;
UCEC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.54	-5.39	-0.41	2.7e-7	IgG glycosylation;
UCEC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg09655341	chr17:79618100	PDE6G	-0.31	-4.75	-0.36	4.8e-6	Eye color traits;
UCEC	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg26207909	chr14:103986467	CKB	-0.47	-4.54	-0.35	1.17e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-5.02	-0.38	1.5e-6	HDL cholesterol;
UCEC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.5	5.19	0.39	6.94e-7	Schizophrenia;
UCEC	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.53	-4.58	-0.35	9.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17824620	0.935	rs4766988	chr12:113105030	G/A	cg26711794	chr12:112450906	ERP29;TMEM116	0.62	4.87	0.37	2.86e-6	Platelet count;
UCEC	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.65	4.61	0.36	8.66e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.66	-6.69	-0.48	4.36e-10	Metabolic syndrome;
UCEC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	0.89	9.33	0.61	1.56e-16	Red blood cell traits;
UCEC	cis	rs7308134	0.830	rs55779143	chr12:1991971	A/G	cg16046261	chr12:1602312	ERC1	0.62	4.65	0.36	7.38e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.73	9.87	0.63	6.07e-18	Vitiligo;
UCEC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.01	0.55	3.18e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.94	7.38	0.52	1.1e-11	Menarche (age at onset);
UCEC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg22974920	chr21:40686053	BRWD1	0.61	5.36	0.4	3.1e-7	Cognitive function;
UCEC	cis	rs362296	0.590	rs4690081	chr4:3262105	T/G	cg08886695	chr4:3369023	RGS12	0.45	4.77	0.37	4.32e-6	Parental longevity (mother's age at death);
UCEC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-5.16	-0.39	7.86e-7	Homoarginine levels;
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.59	-6.01	-0.44	1.4e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-5.23	-0.4	5.72e-7	Response to antipsychotic treatment;
UCEC	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.51	-6.22	-0.46	4.95e-9	Mean platelet volume;
UCEC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	0.91	4.78	0.37	4.18e-6	IgG glycosylation;
UCEC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.55	5.17	0.39	7.54e-7	Calcium levels;
UCEC	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.87	0.37	2.87e-6	Body mass index;
UCEC	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	5.68	0.42	6.84e-8	Cognitive test performance;
UCEC	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-0.53	-4.58	-0.35	9.76e-6	Post bronchodilator FEV1;
UCEC	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg05991184	chr2:219186017	PNKD	-0.49	-5.26	-0.4	4.94e-7	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs12579753	0.667	rs7485826	chr12:82301554	C/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-4.52	-0.35	1.27e-5	Resting heart rate;
UCEC	cis	rs11038871	1.000	rs3802890	chr11:46534546	A/G	cg23542274	chr11:45718455	NA	-0.32	-4.67	-0.36	6.67e-6	Immunoglobulin A;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20921688	chr2:71357800	MCEE;MPHOSPH10	0.59	6.95	0.5	1.12e-10	Warfarin maintenance dose;
UCEC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.55	-5.03	-0.38	1.38e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-5.78	-0.43	4.27e-8	Schizophrenia;
UCEC	cis	rs1275988	1.000	rs1275982	chr2:26919089	A/G	cg17265788	chr2:26785834	C2orf70	0.36	4.56	0.35	1.05e-5	Diastolic blood pressure;Systolic blood pressure;Pulse pressure;Mean arterial pressure;
UCEC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.6	6.38	0.47	2.16e-9	Longevity;Endometriosis;
UCEC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs4372836	1.000	rs4666118	chr2:28951698	C/T	cg09522027	chr2:28974177	PPP1CB	-0.79	-8.15	-0.56	1.5e-13	Body mass index;
UCEC	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.58	-5.1	-0.39	1.03e-6	Corneal astigmatism;
UCEC	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	6.97	0.5	1e-10	Prudent dietary pattern;
UCEC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	0.87	7.55	0.53	4.18e-12	Red blood cell traits;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.7	-0.48	4.04e-10	Joint mobility (Beighton score);
UCEC	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.47	-5.89	-0.44	2.48e-8	Obesity-related traits;
UCEC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-8.04	-0.55	2.75e-13	Chronic sinus infection;
UCEC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.58	5.75	0.43	5.06e-8	Retinal vascular caliber;
UCEC	cis	rs259282	0.562	rs28505804	chr19:33110047	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-0.98	-7.0	-0.5	8.37e-11	Body mass index;
UCEC	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.87	0.44	2.77e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg15358701	chr1:161410459	NA	-0.77	-5.1	-0.39	1.04e-6	Rheumatoid arthritis;
UCEC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	4.55	0.35	1.12e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs6867032	0.917	rs4975719	chr5:2010162	C/T	cg26168224	chr5:2018326	NA	0.73	9.54	0.62	4.3e-17	Gut microbiome composition (winter);
UCEC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.55	5.97	0.44	1.7e-8	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.56	-5.5	-0.41	1.61e-7	Corneal astigmatism;
UCEC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.51	0.57	1.81e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6761276	0.505	rs13019891	chr2:113829869	G/T	cg02302587	chr2:113829866	IL1F10	0.58	5.71	0.43	6.02e-8	Protein quantitative trait loci;
UCEC	cis	rs59104589	0.583	rs3771573	chr2:242387346	G/A	cg19488206	chr2:242435732	STK25	0.52	4.61	0.36	8.7e-6	Fibrinogen levels;
UCEC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.47	5.15	0.39	8.39e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.25e-7	Systemic lupus erythematosus;
UCEC	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.63	-6.16	-0.45	6.6e-9	C-reactive protein levels;
UCEC	cis	rs5770917	0.522	rs5770916	chr22:51016098	C/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	0.47	4.54	0.35	1.18e-5	Narcolepsy;
UCEC	cis	rs9402633	0.938	rs6902600	chr6:135035892	A/G	cg16239184	chr6:135079577	NA	0.51	4.66	0.36	7.16e-6	Platelet count;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg10840864	chr17:61903314	PSMC5;FTSJ3	-0.33	-4.65	-0.36	7.44e-6	Prudent dietary pattern;
UCEC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.69	7.13	0.51	4.23e-11	Dental caries;
UCEC	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.61	0.36	8.53e-6	Parkinson's disease;
UCEC	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg05962950	chr11:130786565	SNX19	0.52	5.51	0.41	1.57e-7	Schizophrenia;
UCEC	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.95	-0.59	1.4e-15	Exhaled nitric oxide output;
UCEC	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.64	5.34	0.4	3.52e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.5	5.57	0.42	1.16e-7	Anxiety disorder;
UCEC	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.67	-0.48	4.74e-10	Coffee consumption (cups per day);
UCEC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.28	-0.51	1.85e-11	Monocyte count;
UCEC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-1.21	-6.25	-0.46	4.2e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs5167	0.504	rs7259679	chr19:45457306	C/T	cg13119609	chr19:45449297	APOC2	0.44	6.5	0.47	1.19e-9	Blood protein levels;
UCEC	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	8.15e-8	Diabetic kidney disease;
UCEC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg17469321	chr7:55412551	NA	0.68	6.05	0.45	1.16e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.79	-0.37	4.02e-6	Personality dimensions;
UCEC	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.34	4.78	0.37	4.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	7.28	0.51	1.9e-11	Homoarginine levels;
UCEC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.67	-7.54	-0.53	4.58e-12	Breast cancer;
UCEC	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.4	-0.41	2.59e-7	Bipolar disorder;
UCEC	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg04202892	chr2:111875749	ACOXL	0.44	4.85	0.37	3.04e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2998286	0.774	rs2790442	chr10:28828526	T/C	cg07964848	chr10:28035894	MKX	0.59	4.5	0.35	1.36e-5	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
UCEC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.48	4.69	0.36	6.24e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.58	-6.2	-0.46	5.3e-9	Blood trace element (Cu levels);
UCEC	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg18646521	chr2:111875858	NA	0.41	4.64	0.36	7.68e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.83	-0.54	8.96e-13	Menarche (age at onset);
UCEC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.77	4.66	0.36	7e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.83	-0.37	3.42e-6	Fear of minor pain;
UCEC	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.45	0.61	7.27e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.54	-6.1	-0.45	8.84e-9	Type 2 diabetes;
UCEC	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.45	-4.55	-0.35	1.12e-5	Mean platelet volume;
UCEC	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.22	-0.4	5.87e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.76	6.15	0.45	6.89e-9	Initial pursuit acceleration;
UCEC	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-9.47	-0.62	6.78e-17	Blood metabolite levels;
UCEC	trans	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg15509575	chr4:2286509	ZFYVE28	0.4	6.96	0.5	1.02e-10	Rheumatoid arthritis;
UCEC	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.0	-0.38	1.61e-6	Personality dimensions;
UCEC	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.21	0.51	2.8e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.58	-5.95	-0.44	1.88e-8	Dental caries;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.84	-0.37	3.24e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg24562669	chr7:97807699	LMTK2	0.47	5.32	0.4	3.84e-7	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs1268789	0.726	rs986925	chr4:79347862	G/T	cg20863282	chr8:29214263	NA	-0.44	-6.68	-0.48	4.71e-10	Hair shape;Hair morphology;
UCEC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.26	0.51	2.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.42	-4.58	-0.35	9.65e-6	Longevity;
UCEC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg13575925	chr12:9217583	LOC144571	0.4	4.58	0.35	9.75e-6	Sjögren's syndrome;
UCEC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.56	-6.21	-0.46	5.04e-9	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg05660106	chr1:15850417	CASP9	0.52	4.58	0.35	9.66e-6	Systolic blood pressure;
UCEC	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg05925327	chr15:68127851	NA	-0.41	-4.96	-0.38	1.9e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg05527609	chr1:210001259	C1orf107	-0.53	-5.01	-0.38	1.55e-6	Red blood cell count;
UCEC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.51	-5.16	-0.39	7.79e-7	Symmetrical dimethylarginine levels;
UCEC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg04871131	chr7:94954202	PON1	-0.5	-4.52	-0.35	1.24e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.46	-4.99	-0.38	1.71e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.51	-4.65	-0.36	7.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.79	0.37	3.95e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-6.6	-0.48	6.9e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.54	5.41	0.41	2.46e-7	Obesity-related traits;
UCEC	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.56	6.54	0.47	9.44e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	6.01	0.44	1.39e-8	Height;
UCEC	cis	rs10924970	0.649	rs11590729	chr1:235422177	T/G	cg26050004	chr1:235667680	B3GALNT2	0.53	4.79	0.37	4.1e-6	Asthma;
UCEC	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.08	7.7	0.54	1.86e-12	Sexual dysfunction (female);
UCEC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.6	6.72	0.48	3.81e-10	Resting heart rate;
UCEC	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	0.77	9.23	0.61	2.76e-16	Multiple myeloma;
UCEC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.64	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs3729931	0.507	rs79945102	chr3:12711975	A/C	cg23032965	chr3:12705835	RAF1	0.74	7.69	0.54	1.98e-12	Cardiac hypertrophy;
UCEC	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.68	9.12	0.6	5.34e-16	Alcohol dependence (age at onset);
UCEC	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.87	-10.22	-0.64	7.34e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.63	-0.42	8.87e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	7.42	0.52	8.66e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg18681998	chr4:17616180	MED28	0.68	7.55	0.53	4.15e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg07537917	chr2:241836409	C2orf54	0.34	5.14	0.39	8.55e-7	Urinary metabolites;
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.49	-5.38	-0.41	2.87e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.7	5.23	0.4	5.71e-7	Aortic root size;
UCEC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.71	5.65	0.42	8.04e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.49	-7.48	-0.53	6.16e-12	Blood protein levels;
UCEC	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.76	7.87	0.54	6.94e-13	Breast cancer;
UCEC	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.54	-4.86	-0.37	3.04e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.89	0.37	2.63e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.44	6.26	0.46	3.94e-9	Ulcerative colitis;
UCEC	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.45	4.51	0.35	1.33e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.45	4.5	0.35	1.35e-5	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.37e-18	Height;
UCEC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.49	4.68	0.36	6.35e-6	Blood metabolite levels;
UCEC	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.49	-4.51	-0.35	1.34e-5	Pulmonary function decline;
UCEC	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	0.98	7.38	0.52	1.08e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.38	-4.5	-0.35	1.35e-5	Sudden cardiac arrest;
UCEC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.35	8.28	0.56	6.91e-14	Diabetic kidney disease;
UCEC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.45	-5.09	-0.39	1.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	5.81	0.43	3.81e-8	HIV-1 control;
UCEC	trans	rs6788895	1.000	rs7628776	chr3:150519043	A/G	cg04732357	chr2:96658324	NA	-0.85	-6.79	-0.49	2.59e-10	Breast cancer;
UCEC	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.37	-4.68	-0.36	6.4e-6	Cutaneous nevi;
UCEC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	6.24	0.46	4.52e-9	Breast cancer;
UCEC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.53	4.92	0.38	2.29e-6	Prostate cancer;
UCEC	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg05991184	chr2:219186017	PNKD	-0.43	-4.6	-0.35	8.92e-6	Colorectal cancer;
UCEC	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11688874	chr10:28822482	WAC	0.54	6.69	0.48	4.34e-10	Warfarin maintenance dose;
UCEC	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.41	5.12	0.39	9.49e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.87e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.76	-6.67	-0.48	4.94e-10	Initial pursuit acceleration;
UCEC	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.59	6.16	0.45	6.75e-9	Motion sickness;
UCEC	cis	rs3762637	0.943	rs9289198	chr3:122277160	G/T	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.35	4.59	0.35	9.28e-6	Sitting height ratio;
UCEC	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.77	-5.51	-0.41	1.57e-7	Body mass index;
UCEC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.63	5.14	0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs73416724	1.000	rs70953670	chr6:43264895	C/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.65	-0.53	2.49e-12	Tonsillectomy;
UCEC	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.15	-9.34	-0.61	1.45e-16	Vitiligo;
UCEC	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	0.69	4.84	0.37	3.22e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.54	5.44	0.41	2.19e-7	Age at first birth;
UCEC	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.29	0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-7.3	-0.52	1.64e-11	Bipolar disorder and schizophrenia;
UCEC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	6.04	0.45	1.22e-8	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.55	-5.28	-0.4	4.47e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.58	-4.79	-0.37	4.03e-6	Corneal structure;
UCEC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	1.03	6.13	0.45	7.81e-9	Skin colour saturation;
UCEC	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg24011408	chr12:48396354	COL2A1	0.6	5.16	0.39	7.95e-7	Lung cancer;
UCEC	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.88	-11.12	-0.68	3.07e-21	Height;
UCEC	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.49	-5.31	-0.4	4.03e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.71	-0.36	5.8e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.41	4.59	0.35	9.46e-6	Total body bone mineral density;
UCEC	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.63	5.49	0.41	1.7e-7	Uric acid levels;
UCEC	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.22	11.23	0.68	1.66e-21	Corneal structure;
UCEC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.49	5.75	0.43	5e-8	Tonsillectomy;
UCEC	cis	rs10242455	0.867	rs2687081	chr7:99300758	G/A	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.29e-6	Blood metabolite levels;
UCEC	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-0.89	-11.42	-0.69	5.1e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.51	6.3	0.46	3.25e-9	Subjective well-being (multi-trait analysis);
UCEC	cis	rs8010715	0.785	rs2877611	chr14:24595430	C/T	cg20933586	chr14:24608199	FAM158A	0.37	4.73	0.36	5.12e-6	IgG glycosylation;
UCEC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg19318889	chr4:1322082	MAEA	0.49	5.28	0.4	4.52e-7	Obesity-related traits;
UCEC	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-5.53	-0.41	1.43e-7	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs2179367	0.887	rs506268	chr6:149685617	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.35	-4.64	-0.36	7.7e-6	Dupuytren's disease;
UCEC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.81	7.82	0.54	9.31e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.83	8.8	0.59	3.47e-15	Breast cancer;
UCEC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg11569703	chr11:65557185	OVOL1	0.51	6.75	0.49	3.2e-10	Acne (severe);
UCEC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.5	-0.41	1.66e-7	Longevity;
UCEC	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.57	7.19	0.51	2.99e-11	Gut microbiome composition (winter);
UCEC	cis	rs350251	0.934	rs1641855	chr16:12214171	G/C	cg01282078	chr16:12139025	RUNDC2A	-0.46	-4.59	-0.35	9.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7267005	0.661	rs113183680	chr20:34395360	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg05855489	chr10:104503620	C10orf26	0.56	5.35	0.4	3.3e-7	Colorectal cancer;
UCEC	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.01	-7.61	-0.53	2.98e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.2	9.24	0.61	2.59e-16	Atopic dermatitis;
UCEC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.58	-0.42	1.14e-7	Hemoglobin concentration;
UCEC	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.7	-6.27	-0.46	3.88e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-4.68	-0.36	6.41e-6	Platelet count;
UCEC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg23752985	chr2:85803571	VAMP8	0.46	5.19	0.39	6.89e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.54	5.04	0.38	1.37e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs16937	0.711	rs4333898	chr1:205169613	C/T	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.88	0.37	2.76e-6	Lymphocyte counts;
UCEC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.5	4.85	0.37	3.11e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.67	7.52	0.53	4.86e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg21521518	chr4:53727714	RASL11B	0.54	4.77	0.37	4.33e-6	Optic nerve measurement (cup area);
UCEC	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	4.81	0.37	3.63e-6	Refractive astigmatism;
UCEC	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.7	6.62	0.48	6.29e-10	Ovarian reserve;
UCEC	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg23795048	chr12:9217529	LOC144571	0.42	4.84	0.37	3.23e-6	Sjögren's syndrome;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09273779	chr9:35605990	TESK1	0.58	7.45	0.52	7.39e-12	Warfarin maintenance dose;
UCEC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs7975161	0.671	rs4475991	chr12:104596756	A/G	cg25273343	chr12:104657179	TXNRD1	0.47	4.54	0.35	1.14e-5	Toenail selenium levels;
UCEC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.61	6.25	0.46	4.19e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9467773	1.000	rs6918854	chr6:26577924	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.51	-5.57	-0.42	1.19e-7	Diastolic blood pressure;
UCEC	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-11.26	-0.68	1.39e-21	Primary sclerosing cholangitis;
UCEC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18932078	chr1:2524107	MMEL1	0.33	5.37	0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.9e-9	Prudent dietary pattern;
UCEC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.12e-9	Tonsillectomy;
UCEC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.47	5.21	0.4	6.16e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.56	5.94	0.44	1.93e-8	Neuroticism;
UCEC	cis	rs7709377	0.570	rs10079903	chr5:115435153	A/T	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg10295955	chr4:187884368	NA	-0.97	-12.29	-0.71	2.54e-24	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.72	-9.87	-0.63	6.06e-18	Gut microbiota (bacterial taxa);
UCEC	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.58	5.21	0.39	6.33e-7	Corneal astigmatism;
UCEC	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7246967	0.673	rs12979264	chr19:22865134	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs2041840	0.503	rs3770756	chr2:37573897	T/C	cg25727520	chr2:37576821	QPCT	-0.52	-5.84	-0.43	3.26e-8	Chronic lymphocytic leukemia;
UCEC	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.79	-7.84	-0.54	8.3e-13	Breast cancer;
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.42	-4.66	-0.36	7.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.56	5.91	0.44	2.32e-8	Birth weight;
UCEC	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.08	-8.04	-0.55	2.72e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg00105475	chr2:10696890	NA	-0.37	-4.68	-0.36	6.54e-6	Prostate cancer;
UCEC	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg02569219	chr17:2266849	SGSM2	0.42	4.53	0.35	1.21e-5	Autism spectrum disorder;
UCEC	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	4.57	0.35	1.02e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg26513180	chr16:89883248	FANCA	-0.44	-4.66	-0.36	6.95e-6	Vitiligo;
UCEC	cis	rs6963954	1.000	rs2970503	chr7:30513209	A/G	cg26752613	chr7:30492160	NOD1	0.62	5.94	0.44	1.94e-8	Knee osteoarthritis;
UCEC	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.75	-5.07	-0.39	1.17e-6	Bipolar disorder;
UCEC	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.23	-0.46	4.68e-9	Menarche (age at onset);
UCEC	cis	rs16957091	0.821	rs7182479	chr15:42999565	G/A	cg24196017	chr15:43021976	CDAN1	-0.6	-6.02	-0.44	1.35e-8	MGMT methylation in smokers;
UCEC	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.53	5.0	0.38	1.63e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.48	-4.83	-0.37	3.37e-6	Dental caries;
UCEC	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg12473912	chr3:136751656	NA	0.44	5.04	0.38	1.34e-6	Gestational age at birth (child effect);
UCEC	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg27171509	chr10:82033454	MAT1A	-0.48	-5.08	-0.39	1.13e-6	Borderline personality disorder;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.53	5.64	0.42	8.51e-8	Longevity;Endometriosis;
UCEC	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.59	-6.03	-0.45	1.25e-8	Hepatocellular carcinoma;
UCEC	cis	rs10949834	0.642	rs2356530	chr7:73533221	T/A	cg07137043	chr7:73588983	EIF4H	-0.78	-4.65	-0.36	7.24e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.49	5.07	0.39	1.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs78487399	0.808	rs6752448	chr2:43682596	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.84	7.75	0.54	1.38e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.61	-6.33	-0.46	2.84e-9	Waist circumference;Body mass index;
UCEC	cis	rs77926410	0.615	rs7138294	chr12:10614934	A/G	cg25023291	chr12:11339792	TAS2R42	-0.38	-4.94	-0.38	2.07e-6	Mean corpuscular volume;
UCEC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	0.82	7.06	0.5	6.18e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.08	-0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs7640978	0.708	rs6793004	chr3:32531442	G/A	cg09329275	chr3:32509543	NA	0.66	5.29	0.4	4.39e-7	Cholesterol, total;LDL cholesterol;
UCEC	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.68	5.37	0.41	2.94e-7	Neutrophil percentage of white cells;
UCEC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.01	-0.67	6.03e-21	Chronic sinus infection;
UCEC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07988820	chr12:82153109	PPFIA2	-0.65	-5.61	-0.42	9.96e-8	Resting heart rate;
UCEC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.84	0.43	3.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.56	5.53	0.42	1.39e-7	Vitiligo;
UCEC	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg05539622	chr2:73298971	SFXN5	0.48	4.53	0.35	1.21e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg20007245	chr22:24372913	LOC391322	-0.49	-5.34	-0.4	3.48e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.65	-6.05	-0.45	1.16e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.46	-5.5	-0.41	1.6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.62	-8.11	-0.56	1.85e-13	Coronary artery disease;
UCEC	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.48	-5.12	-0.39	9.47e-7	Retinal vascular caliber;
UCEC	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.64	-0.42	8.34e-8	Bone mineral density;
UCEC	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.63	8.14	0.56	1.51e-13	Testicular germ cell tumor;
UCEC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.72	-6.52	-0.47	1.07e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.52	-5.57	-0.42	1.2e-7	QRS duration;
UCEC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.6	0.58	1.11e-14	Prudent dietary pattern;
UCEC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.49e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2806864	1.000	rs2250883	chr1:117462118	G/C	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.7	-0.36	6.06e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.7	7.11	0.51	4.69e-11	Caffeine consumption;
UCEC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg04756594	chr16:24857601	SLC5A11	-0.5	-5.91	-0.44	2.29e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.82	8.6	0.58	1.11e-14	Longevity;
UCEC	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14019695	chr9:139328340	INPP5E	0.42	4.69	0.36	6.27e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.51	6.28	0.46	3.68e-9	Total body bone mineral density;
UCEC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.74	-0.63	1.35e-17	Height;
UCEC	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.34	4.93	0.38	2.16e-6	Schizophrenia;
UCEC	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.57	-4.99	-0.38	1.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03775416	chr19:19368775	HAPLN4	-0.49	-4.53	-0.35	1.23e-5	Tonsillectomy;
UCEC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	0.83	5.26	0.4	5.06e-7	Diabetic retinopathy;
UCEC	cis	rs10924970	1.000	rs55969096	chr1:235352365	G/A	cg26050004	chr1:235667680	B3GALNT2	0.43	4.57	0.35	1.03e-5	Asthma;
UCEC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg10978503	chr1:24200527	CNR2	0.37	4.89	0.37	2.6e-6	Immature fraction of reticulocytes;
UCEC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.59	6.71	0.48	3.88e-10	Longevity;
UCEC	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.45	5.12	0.39	9.38e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg13395646	chr4:1353034	KIAA1530	-0.87	-9.08	-0.6	6.69e-16	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.69	6.65	0.48	5.2400000000000005e-10	Aortic root size;
UCEC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.64	7.01	0.5	8.14e-11	Homoarginine levels;
UCEC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	0.75	7.81	0.54	1.01e-12	Parkinson's disease;
UCEC	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	0.89	7.77	0.54	1.23e-12	Nonalcoholic fatty liver disease;
UCEC	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.66	-8.25	-0.56	8.23e-14	Hemoglobin concentration;
UCEC	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg01072550	chr1:21505969	NA	-0.56	-5.36	-0.4	3.1e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.52	4.96	0.38	1.96e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs74400468	0.786	rs73266166	chr10:43566759	T/C	cg05652102	chr10:43600862	RET	0.56	4.67	0.36	6.67e-6	Cannabis dependence symptom count;
UCEC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.67	7.53	0.53	4.85e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg23972785	chr8:11611189	GATA4	-0.34	-4.53	-0.35	1.22e-5	Neuroticism;
UCEC	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.99	9.44	0.61	7.8e-17	Diastolic blood pressure;
UCEC	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.53	-5.27	-0.4	4.87e-7	Height;
UCEC	cis	rs10432489	0.572	rs7586884	chr2:181675129	C/T	cg08065101	chr2:182521918	CERKL	-0.56	-4.51	-0.35	1.32e-5	QT interval;
UCEC	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.47	5.28	0.4	4.59e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	5.39	0.41	2.76e-7	Initial pursuit acceleration;
UCEC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.69	4.9	0.37	2.49e-6	Aortic root size;
UCEC	cis	rs925228	0.955	rs11687065	chr2:24132701	G/T	cg16945982	chr2:25016118	CENPO;C2orf79	-0.56	-4.95	-0.38	2.01e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.48	4.91	0.38	2.35e-6	Pulmonary function;
UCEC	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-7.29	-0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg21856205	chr7:94953877	PON1	-0.55	-5.28	-0.4	4.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.73	-0.36	5.11e-6	Hemoglobin concentration;
UCEC	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.64	6.25	0.46	4.13e-9	Menopause (age at onset);
UCEC	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.51	-4.73	-0.36	5.13e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.52	5.92	0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.67	7.27	0.51	2.01e-11	Menarche (age at onset);
UCEC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-5.93	-0.44	2.1e-8	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-12.56	-0.72	4.83e-25	Height;
UCEC	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.77	-7.26	-0.51	2.09e-11	Parkinson's disease;
UCEC	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	8.11	0.56	1.86e-13	Platelet distribution width;
UCEC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.52	-5.1	-0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs78487399	0.808	rs77527404	chr2:43678387	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.72	8.83	0.59	2.93e-15	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg12580275	chr1:205744413	RAB7L1	0.52	4.8	0.37	3.84e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.59	-6.62	-0.48	6.29e-10	Cardiac Troponin-T levels;
UCEC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg23307798	chr14:103986281	CKB	0.64	7.83	0.54	9.01e-13	Body mass index;
UCEC	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.76	-0.37	4.67e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6728642	0.808	rs113319086	chr2:97633267	G/C	cg26665480	chr2:98280029	ACTR1B	-0.74	-4.51	-0.35	1.33e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.56	5.59	0.42	1.09e-7	Vitamin D levels;
UCEC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.58	-5.29	-0.4	4.32e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.84	-0.49	1.99e-10	Breast cancer;
UCEC	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.29	10.03	0.64	2.35e-18	Uric acid levels;
UCEC	cis	rs10007810	0.760	rs4563532	chr4:41592185	C/G	cg24722073	chr4:41882163	NA	-0.43	-5.26	-0.4	5.06e-7	Longevity (90 years and older);
UCEC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg07776626	chr8:57350775	NA	-0.46	-4.79	-0.37	3.95e-6	Obesity-related traits;
UCEC	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-1.21	-6.49	-0.47	1.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.6	5.51	0.41	1.58e-7	Resting heart rate;
UCEC	cis	rs6686929	1.000	rs946737	chr1:18241271	C/G	cg03861428	chr1:17380702	SDHB	0.42	4.61	0.36	8.51e-6	Obesity-related traits;
UCEC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.08	-0.6	6.77e-16	Coffee consumption (cups per day);
UCEC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.23e-7	Prudent dietary pattern;
UCEC	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.5	-5.52	-0.41	1.51e-7	Response to temozolomide;
UCEC	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.32	0.52	1.51e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.59	-5.13	-0.39	8.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg03342759	chr3:160939853	NMD3	0.52	4.98	0.38	1.73e-6	Kawasaki disease;
UCEC	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.67	0.36	6.77e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7766436	0.885	rs10946567	chr6:22581302	T/C	cg13666174	chr6:22585274	NA	-0.52	-5.46	-0.41	2e-7	Coronary artery disease;
UCEC	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.39	-4.55	-0.35	1.13e-5	Neuroticism;
UCEC	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	0.95	9.67	0.62	2.02e-17	Height;
UCEC	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg00105475	chr2:10696890	NA	0.44	5.44	0.41	2.22e-7	Prostate cancer;
UCEC	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.72	-7.92	-0.55	5.45e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.58	-6.06	-0.45	1.07e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg13695892	chr22:41940480	POLR3H	-0.65	-4.69	-0.36	6.21e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.54e-21	Body mass index;
UCEC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg16165748	chr11:65030448	POLA2	0.39	4.52	0.35	1.25e-5	Non-alcoholic fatty liver disease histology (lobular);
UCEC	cis	rs751728	0.597	rs767895	chr6:33791463	C/G	cg25922239	chr6:33757077	LEMD2	0.59	4.81	0.37	3.7e-6	Crohn's disease;
UCEC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.7	0.48	4.07e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg13081009	chr1:8430745	RERE	-0.41	-4.63	-0.36	7.95e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.36	8.6e-6	Breast cancer;
UCEC	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4778581	0.750	rs11072879	chr15:80387125	G/T	cg08257866	chr15:80351198	ZFAND6	0.41	5.01	0.38	1.57e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.47	-6.52	-0.47	1.03e-9	Urinary metabolites;
UCEC	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg03714773	chr7:91764589	CYP51A1	0.42	5.29	0.4	4.26e-7	Breast cancer;
UCEC	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs4389656	0.857	rs274677	chr5:6754402	T/C	cg10857441	chr5:6722123	POLS	-0.41	-4.79	-0.37	3.95e-6	Coronary artery disease;
UCEC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.79	-8.53	-0.58	1.64e-14	Cognitive function;
UCEC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.54	5.34	0.4	3.4e-7	Aortic root size;
UCEC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.43	-0.74	2.46e-27	Height;
UCEC	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.49	4.82	0.37	3.58e-6	Alzheimer's disease (late onset);
UCEC	cis	rs10743315	0.643	rs12579951	chr12:19331186	C/T	cg02471346	chr12:19282374	PLEKHA5	0.68	4.66	0.36	6.88e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg10412286	chr16:89977652	TCF25	0.66	4.88	0.37	2.79e-6	Skin colour saturation;
UCEC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs4534959	0.546	rs78030028	chr18:62060574	G/C	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	5.61	0.42	9.58e-8	Breast cancer;
UCEC	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs7246967	0.551	rs3925175	chr19:22880958	G/A	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.7	5.68	0.42	7.09e-8	Type 2 diabetes;
UCEC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.73	-8.36	-0.57	4.29e-14	Menarche (age at onset);
UCEC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.5	5.31	0.4	4.05e-7	Lung cancer;
UCEC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.71	-5.15	-0.39	8.2e-7	Mean platelet volume;
UCEC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	6.45	0.47	1.51e-9	Motion sickness;
UCEC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg09655341	chr17:79618100	PDE6G	0.3	4.55	0.35	1.12e-5	Eye color traits;
UCEC	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.12e-7	Life satisfaction;
UCEC	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.88	-9.65	-0.62	2.32e-17	Corneal structure;
UCEC	cis	rs72906064	1.000	rs17244395	chr2:156916525	C/T	cg14040602	chr2:157557294	NA	-0.64	-4.66	-0.36	7.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs59104589	0.583	rs73002176	chr2:242332438	T/C	cg19488206	chr2:242435732	STK25	0.54	4.87	0.37	2.83e-6	Fibrinogen levels;
UCEC	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.81	10.63	0.66	6.02e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.41	15.0	0.78	1.95e-31	Atopic dermatitis;
UCEC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.49	5.04	0.38	1.35e-6	Vitiligo;
UCEC	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.52	-4.58	-0.35	9.71e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.6	7.01	0.5	7.82e-11	Height;
UCEC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs7870753	0.838	rs10991367	chr9:99253933	T/C	cg25260653	chr9:99212216	HABP4	0.48	4.73	0.36	5.3e-6	Height;
UCEC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.53	4.98	0.38	1.79e-6	Menopause (age at onset);
UCEC	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg13099542	chr13:114056351	NA	-0.31	-4.59	-0.35	9.27e-6	Glycated hemoglobin levels;
UCEC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.7	-4.66	-0.36	7.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg12310025	chr6:25882481	NA	-0.59	-4.64	-0.36	7.69e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg24851651	chr11:66362959	CCS	-0.4	-5.11	-0.39	9.79e-7	Educational attainment (years of education);
UCEC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.67	6.98	0.5	9.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.64	0.42	8.51e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.46	5.0	0.38	1.62e-6	Longevity;
UCEC	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.51	4.63	0.36	7.94e-6	Corneal astigmatism;
UCEC	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg00873616	chr20:43920241	NA	-0.5	-5.04	-0.38	1.35e-6	Blood protein levels;
UCEC	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.57	-7.47	-0.52	6.58e-12	Gut microbiota (bacterial taxa);
UCEC	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.65	5.09	0.39	1.08e-6	Body mass index;
UCEC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-0.62	-8.2	-0.56	1.1e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03264133	chr6:25882463	NA	-0.49	-4.68	-0.36	6.34e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs1552172	0.887	rs2040085	chr1:145651861	G/A	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.92	-0.5	1.32e-10	Breast cancer;
UCEC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.53	6.76	0.49	2.96e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.21	0.56	1.03e-13	Prudent dietary pattern;
UCEC	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg24687543	chr11:63912206	MACROD1	0.56	4.76	0.37	4.63e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.9	7.01	0.5	8.01e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.46	4.94	0.38	2.06e-6	Testicular germ cell tumor;
UCEC	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-6.38	-0.47	2.12e-9	Total body bone mineral density;
UCEC	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.6	-0.48	7.08e-10	Morning vs. evening chronotype;
UCEC	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.47	-4.71	-0.36	5.59e-6	Cognitive function;
UCEC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	-0.94	-8.99	-0.6	1.16e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22117172	chr7:91764530	CYP51A1	0.41	5.22	0.4	5.98e-7	Breast cancer;
UCEC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.43	4.8	0.37	3.83e-6	Bone mineral density;
UCEC	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	0.88	5.21	0.39	6.24e-7	Skin colour saturation;
UCEC	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.34	-0.4	3.5e-7	Bipolar disorder;
UCEC	cis	rs7709377	0.553	rs6889212	chr5:115461123	G/A	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs7088591	0.867	rs34755035	chr10:59778091	C/G	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg21905437	chr5:178450457	ZNF879	0.66	7.27	0.51	2.01e-11	Pubertal anthropometrics;
UCEC	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	1.18	9.48	0.62	6.42e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.05	7.44	0.52	7.68e-12	Diabetic kidney disease;
UCEC	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.77	-5.26	-0.4	5.05e-7	Blood pressure (smoking interaction);
UCEC	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.53	5.01	0.38	1.52e-6	Height;
UCEC	cis	rs8177876	0.822	rs1410	chr16:81115833	T/G	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	6.89	0.49	1.49e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-6.21	-0.46	5.21e-9	Platelet distribution width;
UCEC	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg27068330	chr11:65405492	SIPA1	0.44	4.51	0.35	1.32e-5	Acne (severe);
UCEC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.56	5.15	0.39	8.41e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.84	-0.49	1.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg01072550	chr1:21505969	NA	0.57	5.32	0.4	3.88e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7246967	0.866	rs4932695	chr19:23036377	T/C	cg24889512	chr19:22816950	ZNF492	0.51	5.39	0.41	2.8e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.54	0.35	1.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs57709857	0.801	rs7006757	chr8:38103239	T/A	cg08167846	chr8:38212404	WHSC1L1	0.47	4.61	0.36	8.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.7	-6.56	-0.48	8.42e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.68	7.46	0.52	7.07e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-10.89	-0.67	1.31e-20	Vitiligo;
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.47	0.41	1.88e-7	Prudent dietary pattern;
UCEC	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg15513719	chr13:114904418	NA	0.5	4.9	0.37	2.45e-6	Schizophrenia;
UCEC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	4.76	0.37	4.55e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	0.97	5.23	0.4	5.86e-7	Age-related hearing impairment;
UCEC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-6.33	-0.46	2.87e-9	Menarche (age at onset);
UCEC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.48	4.72	0.36	5.39e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.68	6.04	0.45	1.2e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.56	-5.71	-0.43	5.97e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-23.21	-0.89	5.14e-51	Myeloid white cell count;
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg07386859	chr16:1872102	HAGH	0.45	4.9	0.37	2.49e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-4.94	-0.38	2.1e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg12024160	chr4:1254474	NA	-0.54	-5.15	-0.39	8.22e-7	Longevity;
UCEC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	0.99	6.02	0.44	1.32e-8	Skin colour saturation;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677856	chr17:61926188	NA	0.44	4.66	0.36	6.91e-6	Prudent dietary pattern;
UCEC	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.66	7.45	0.52	7.48e-12	Motion sickness;
UCEC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.02e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-5.76	-0.43	4.82e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.57	5.18	0.39	7.18e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.45	-4.89	-0.37	2.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.8	8.11	0.56	1.83e-13	Parkinson's disease;
UCEC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24308560	chr3:49941425	MST1R	-0.44	-4.65	-0.36	7.29e-6	Body mass index;
UCEC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.58	6.24	0.46	4.52e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg17330251	chr7:94953956	PON1	-0.56	-5.11	-0.39	1e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.63	-0.36	7.88e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg00614314	chr15:82944287	LOC80154	0.53	6.19	0.45	5.81e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	1.01	7.31	0.52	1.6e-11	Blood pressure (smoking interaction);
UCEC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.66	5.47	0.41	1.85e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.47	-4.86	-0.37	3.04e-6	Aortic root size;
UCEC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7554547	0.667	rs7525521	chr1:11975166	G/A	cg13216073	chr1:12042593	MFN2	0.48	4.65	0.36	7.29e-6	Nonsyndromic cleft lip with cleft palate;
UCEC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.64	6.57	0.48	8.02e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs6882076	0.961	rs4704827	chr5:156392089	T/C	cg12943317	chr5:156479607	HAVCR1	-0.5	-5.23	-0.4	5.83e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg18681998	chr4:17616180	MED28	0.89	10.93	0.67	1.01e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	0.93	10.09	0.64	1.63e-18	Primary sclerosing cholangitis;
UCEC	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg20368463	chr18:77673604	PQLC1	-0.63	-4.76	-0.37	4.67e-6	Schizophrenia;
UCEC	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.75	7.19	0.51	2.97e-11	Schizophrenia;
UCEC	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.61	5.01	0.38	1.54e-6	Type 2 diabetes;
UCEC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	6.18	0.45	5.89e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs295140	0.934	rs74853338	chr2:201171651	C/T	cg04283868	chr2:201171347	SPATS2L	0.53	5.25	0.4	5.28e-7	QT interval;
UCEC	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg21770322	chr7:97807741	LMTK2	0.85	14.84	0.77	4.96e-31	Prostate cancer (SNP x SNP interaction);Prostate cancer;
UCEC	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg19567339	chr10:100142640	NA	0.57	5.98	0.44	1.66e-8	Metabolite levels;
UCEC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.95	10.95	0.67	8.63e-21	Cognitive function;
UCEC	cis	rs11686241	0.688	rs3806573	chr2:217278023	A/G	cg15830940	chr2:217278069	SMARCAL1	0.52	4.66	0.36	7.12e-6	Cancer;
UCEC	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.76	8.52	0.57	1.74e-14	Cognitive test performance;
UCEC	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs6546886	0.957	rs4416242	chr2:74259894	A/T	cg14702570	chr2:74259524	NA	-0.43	-5.63	-0.42	8.67e-8	Dialysis-related mortality;
UCEC	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg18681998	chr4:17616180	MED28	-0.53	-5.82	-0.43	3.61e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-6.08	-0.45	9.68e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.66	6.45	0.47	1.53e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2882667	0.858	rs11957633	chr5:138364394	T/C	cg04439458	chr5:138467593	SIL1	-0.45	-4.93	-0.38	2.17e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.61	-5.4	-0.41	2.68e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg26114124	chr12:9217669	LOC144571	0.41	4.98	0.38	1.72e-6	Sjögren's syndrome;
UCEC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-4.7	-0.36	5.91e-6	Mood instability;
UCEC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg19554555	chr3:13937349	NA	-0.54	-5.47	-0.41	1.92e-7	Ovarian reserve;
UCEC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.36	5.29	0.4	4.43e-7	Vitiligo;
UCEC	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.79	7.94	0.55	4.79e-13	Lung cancer;
UCEC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.32	4.6	0.35	9.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4499344	0.556	rs259236	chr19:33116122	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	6.26	0.46	4.07e-9	Mean platelet volume;
UCEC	cis	rs477895	0.713	rs7944061	chr11:63956839	A/T	cg14078730	chr11:63896557	MACROD1	0.63	6.09	0.45	9.42e-9	Mean platelet volume;
UCEC	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg20119798	chr7:94954144	PON1	0.52	4.98	0.38	1.72e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.43	-4.82	-0.37	3.49e-6	Total body bone mineral density;
UCEC	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg26114124	chr12:9217669	LOC144571	0.4	4.61	0.36	8.7e-6	Sjögren's syndrome;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg04871131	chr7:94954202	PON1	-0.51	-4.65	-0.36	7.47e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.51	4.72	0.36	5.42e-6	Hemoglobin concentration;
UCEC	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg11632617	chr15:75315747	PPCDC	-0.53	-4.86	-0.37	2.99e-6	Lung cancer;
UCEC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.58	-4.88	-0.37	2.79e-6	Gut microbiome composition (summer);
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.47	-4.94	-0.38	2.12e-6	Vitiligo;
UCEC	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.57	5.22	0.4	6.06e-7	Coronary artery disease;
UCEC	cis	rs7607369	0.536	rs7566656	chr2:219664519	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-5.89	-0.44	2.57e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg06096015	chr1:231504339	EGLN1	0.41	4.77	0.37	4.45e-6	Hemoglobin concentration;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg00815214	chr21:47717953	NA	-0.39	-4.55	-0.35	1.11e-5	Testicular germ cell tumor;
UCEC	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7072216	0.687	rs7907555	chr10:100155810	A/G	cg19567339	chr10:100142640	NA	-0.59	-7.28	-0.51	1.91e-11	Metabolite levels;
UCEC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	17.62	0.82	4.68e-38	IgG glycosylation;
UCEC	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	5.18	0.39	7.23e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.51	5.39	0.41	2.69e-7	Schizophrenia;
UCEC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-6.13	-0.45	7.55e-9	Parkinson's disease;
UCEC	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.46	6.02	0.44	1.3e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	5.77	0.43	4.51e-8	Total body bone mineral density;
UCEC	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.09	-6.98	-0.5	9.35e-11	Breast cancer;
UCEC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg21770322	chr7:97807741	LMTK2	0.85	14.84	0.77	4.96e-31	Breast cancer;
UCEC	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.39	5.63	0.42	8.88e-8	Ulcerative colitis;
UCEC	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.54	0.42	1.36e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.49	-5.8	-0.43	3.9e-8	Neuroticism;
UCEC	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	5.98	0.44	1.63e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.62	5.75	0.43	4.92e-8	Heart rate;
UCEC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.64	5.67	0.42	7.36e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.69	-0.54	1.95e-12	IgG glycosylation;
UCEC	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	4.88	0.37	2.73e-6	Platelet count;
UCEC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.59	5.76	0.43	4.82e-8	Tonsillectomy;
UCEC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg06784218	chr1:46089804	CCDC17	0.54	6.32	0.46	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.32	4.95	0.38	2.03e-6	Cancer;
UCEC	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.73	-7.74	-0.54	1.47e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.33	5.05	0.38	1.31e-6	Cancer;
UCEC	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.73	7.61	0.53	3.01e-12	Sudden cardiac arrest;
UCEC	cis	rs6662386	0.557	rs17467793	chr1:88209373	T/G	cg10042178	chr1:87794589	LMO4	0.49	4.78	0.37	4.26e-6	Prostate-specific antigen levels;
UCEC	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.97	0.59	1.3e-15	Bipolar disorder;
UCEC	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	trans	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg02900749	chr2:68251473	NA	-0.97	-7.12	-0.51	4.49e-11	Pursuit maintenance gain;
UCEC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.79	8.73	0.58	5.17e-15	Menopause (age at onset);
UCEC	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	4.58	0.35	1e-5	Coronary artery disease;
UCEC	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	4.87	0.37	2.79e-6	Breast cancer;
UCEC	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.3	-0.71	2.34e-24	Primary sclerosing cholangitis;
UCEC	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg03728395	chr2:85555865	TGOLN2	-0.36	-4.94	-0.38	2.07e-6	Ear protrusion;
UCEC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.07	0.39	1.21e-6	Diabetic retinopathy;
UCEC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	6.45	0.47	1.5e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.65	0.36	7.46e-6	Tonsillectomy;
UCEC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.49	-6.45	-0.47	1.5e-9	Urinary metabolites;
UCEC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs1575951	1.000	rs7071458	chr10:130439516	T/A	cg27041381	chr10:131357203	MGMT	0.61	5.25	0.4	5.13e-7	Plasma clusterin levels;
UCEC	cis	rs1165668	0.755	rs10735390	chr12:104311731	A/G	cg21863207	chr12:104234989	NT5DC3	0.63	5.83	0.43	3.35e-8	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg08250081	chr4:10125330	NA	0.46	4.51	0.35	1.31e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs4372836	0.729	rs4665436	chr2:29090227	T/C	cg09522027	chr2:28974177	PPP1CB	0.83	9.07	0.6	7.03e-16	Body mass index;
UCEC	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg12428399	chr10:135191333	PAOX	0.66	5.46	0.41	1.99e-7	Lifespan;
UCEC	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg09307838	chr4:120376055	NA	0.63	5.75	0.43	4.92e-8	Corneal astigmatism;
UCEC	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.76	0.49	3.09e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7424096	0.527	rs4670637	chr2:37164857	T/G	cg14987922	chr2:37194071	STRN	0.57	4.69	0.36	6.28e-6	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs12719740	0.638	rs8038620	chr15:99072920	A/G	cg18585722	chr15:99091410	NA	0.48	4.89	0.37	2.6e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.55	-6.37	-0.47	2.23e-9	Type 2 diabetes;
UCEC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg10381502	chr11:71823885	C11orf51	0.95	4.95	0.38	1.99e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.71	-7.62	-0.53	2.9e-12	Waist circumference;Body mass index;
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg20119798	chr7:94954144	PON1	-0.51	-4.74	-0.36	4.96e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.77	-8.18	-0.56	1.19e-13	Menarche (age at onset);
UCEC	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.44	-5.74	-0.43	5.26e-8	Urinary metabolites;
UCEC	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg05962950	chr11:130786565	SNX19	0.51	5.05	0.38	1.28e-6	Schizophrenia;
UCEC	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	0.9	4.6	0.35	8.9e-6	Mitochondrial DNA levels;
UCEC	cis	rs883115	1.000	rs6690184	chr1:224813400	G/C	cg01808320	chr1:224927238	CNIH3	-0.37	-4.74	-0.36	4.98e-6	Cancer;
UCEC	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.68	0.36	6.48e-6	Response to antipsychotic treatment;
UCEC	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.42	4.8	0.37	3.78e-6	Blood metabolite ratios;
UCEC	cis	rs12931792	0.748	rs11150585	chr16:30184286	A/G	cg17640201	chr16:30407289	ZNF48	0.57	5.78	0.43	4.23e-8	Tonsillectomy;
UCEC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.68	0.36	6.42e-6	Cognitive ability;
UCEC	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.45	4.58	0.35	1e-5	Mean platelet volume;
UCEC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.55	4.82	0.37	3.48e-6	Menarche (age at onset);
UCEC	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.58	-4.9	-0.37	2.48e-6	Systemic lupus erythematosus;
UCEC	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.37	5.71	0.43	6.15e-8	Multiple sclerosis;
UCEC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.44	-5.45	-0.41	2.05e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.51	-5.24	-0.4	5.56e-7	Pulse pressure;
UCEC	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.01	0.38	1.53e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.87	-6.3	-0.46	3.21e-9	Multiple sclerosis;
UCEC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.82	8.02	0.55	3.02e-13	Cognitive function;
UCEC	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	6.81	0.49	2.31e-10	Alzheimer's disease;
UCEC	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.53	-5.91	-0.44	2.28e-8	Menarche (age at onset);
UCEC	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.66	-4.99	-0.38	1.7e-6	Mean platelet volume;
UCEC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg12024160	chr4:1254474	NA	0.56	6.83	0.49	2.05e-10	Obesity-related traits;
UCEC	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.58	5.32	0.4	3.74e-7	Corneal astigmatism;
UCEC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	5.61	0.42	9.69e-8	Platelet count;
UCEC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg05805236	chr11:65401703	PCNXL3	-0.45	-4.85	-0.37	3.13e-6	Acne (severe);
UCEC	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-5.14	-0.39	8.6e-7	Gut microbiome composition (summer);
UCEC	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg03342759	chr3:160939853	NMD3	0.55	5.19	0.39	6.94e-7	Morning vs. evening chronotype;
UCEC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.17	0.51	3.45e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.47	-4.86	-0.37	2.92e-6	HDL cholesterol;
UCEC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.28	-0.4	4.62e-7	Hemoglobin concentration;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00392943	chr19:18391301	JUND	0.57	6.75	0.49	3.11e-10	Warfarin maintenance dose;
UCEC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.58	-0.35	1e-5	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg05660106	chr1:15850417	CASP9	0.49	4.72	0.36	5.33e-6	Systolic blood pressure;
UCEC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.59	6.04	0.45	1.23e-8	Initial pursuit acceleration;
UCEC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg12024160	chr4:1254474	NA	0.53	6.23	0.46	4.65e-9	Obesity-related traits;
UCEC	cis	rs791888	0.965	rs791877	chr10:89406863	A/G	cg13926569	chr10:89418898	PAPSS2	0.52	5.95	0.44	1.84e-8	Magnesium levels;
UCEC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.02	0.38	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg02158880	chr13:53174818	NA	0.48	5.63	0.42	8.68e-8	Lewy body disease;
UCEC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg07653901	chr22:50250238	ZBED4	0.93	5.6	0.42	1.02e-7	Schizophrenia;
UCEC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.47	5.36	0.4	3.18e-7	Iron status biomarkers (transferrin levels);
UCEC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg12035532	chr1:1886765	KIAA1751	0.43	4.59	0.35	9.62e-6	Body mass index;
UCEC	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.52	5.44	0.41	2.17e-7	Type 2 diabetes;
UCEC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.61	-7.4	-0.52	9.72e-12	Prostate cancer;
UCEC	cis	rs7246967	0.866	rs12981220	chr19:23021400	G/T	cg24889512	chr19:22816950	ZNF492	-0.51	-5.32	-0.4	3.77e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg18252515	chr7:66147081	NA	0.59	5.46	0.41	1.94e-7	Aortic root size;
UCEC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-5.01	-0.38	1.55e-6	Tonsillectomy;
UCEC	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.43	-4.54	-0.35	1.16e-5	Response to temozolomide;
UCEC	cis	rs7246967	0.800	rs2362131	chr19:23022436	T/C	cg08271804	chr19:22816896	ZNF492	0.52	5.01	0.38	1.56e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.57	-5.42	-0.41	2.33e-7	Coronary artery disease;
UCEC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.54	5.14	0.39	8.76e-7	Menopause (age at onset);
UCEC	cis	rs12980942	1.000	rs7257310	chr19:41827120	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	5.34	0.4	3.52e-7	Coronary artery disease;
UCEC	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.53	-4.69	-0.36	6.14e-6	Colorectal cancer;
UCEC	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.5	4.99	0.38	1.7e-6	Bladder cancer;
UCEC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg05738196	chr6:26577821	NA	0.57	5.35	0.4	3.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.58	-5.45	-0.41	2.05e-7	Tourette syndrome;
UCEC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.52	-6.54	-0.47	9.39e-10	Height;
UCEC	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-8.25	-0.56	8.42e-14	Hip circumference;
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg10503236	chr1:231470652	EXOC8	-0.4	-4.66	-0.36	6.92e-6	Hemoglobin concentration;
UCEC	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg22857025	chr5:266934	NA	-0.99	-9.13	-0.6	5.04e-16	Breast cancer;
UCEC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16624210	chr5:671434	TPPP	0.44	4.69	0.36	6.25e-6	Obesity-related traits;
UCEC	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.8	7.15	0.51	3.71e-11	Orofacial clefts;
UCEC	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.24	0.65	6.66e-19	Electrocardiographic conduction measures;
UCEC	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.09	16.3	0.8	9.01e-35	Schizophrenia;
UCEC	cis	rs10924970	0.967	rs10802617	chr1:235485768	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	4.96	0.38	1.95e-6	Asthma;
UCEC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.88	-0.37	2.73e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.62	-5.34	-0.4	3.42e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-6.15	-0.45	6.84e-9	Schizophrenia;
UCEC	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.59	4.85	0.37	3.18e-6	Coronary artery calcification;
UCEC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs2562152	0.515	rs2562176	chr16:146487	G/C	cg02949481	chr16:131562	MPG	0.95	6.41	0.47	1.87e-9	Glioblastoma;
UCEC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.81	0.37	3.75e-6	Aortic root size;
UCEC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.7	6.9	0.49	1.41e-10	Response to antineoplastic agents;
UCEC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.69	-6.29	-0.46	3.41e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs55670112	0.935	rs28536575	chr5:114277608	A/G	cg05461448	chr5:114880715	FEM1C	-0.44	-4.58	-0.35	9.96e-6	Epilepsy;
UCEC	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.9	-10.52	-0.66	1.2e-19	Height;
UCEC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.61	5.06	0.38	1.25e-6	Breast cancer;
UCEC	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.4	-5.4	-0.41	2.66e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg05180856	chr15:91428056	FES	0.41	5.22	0.4	5.96e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-6.21	-0.46	5.12e-9	Pancreatic cancer;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.74	8.9	0.59	1.89e-15	Menarche (age at onset);
UCEC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg02820040	chr2:241836501	C2orf54	-0.39	-4.86	-0.37	2.99e-6	Urinary metabolites;
UCEC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.48	4.97	0.38	1.81e-6	Platelet count;
UCEC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-4.78	-0.37	4.21e-6	Personality dimensions;
UCEC	cis	rs7766436	0.848	rs6903685	chr6:22605813	C/T	cg13666174	chr6:22585274	NA	-0.58	-5.92	-0.44	2.17e-8	Coronary artery disease;
UCEC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.54	6.12	0.45	8.02e-9	Aortic root size;
UCEC	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.66	-6.42	-0.47	1.74e-9	Mortality in heart failure;
UCEC	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg05874882	chr4:1763078	NA	-0.54	-5.6	-0.42	1.03e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00612595	chr21:47717864	NA	0.48	4.67	0.36	6.76e-6	Testicular germ cell tumor;
UCEC	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg03611598	chr17:48586076	MYCBPAP	0.46	5.25	0.4	5.22e-7	Visceral fat;
UCEC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.53	5.51	0.41	1.58e-7	Post bronchodilator FEV1;
UCEC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg18279126	chr7:2041391	MAD1L1	0.4	4.93	0.38	2.21e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1030877	0.515	rs1866038	chr2:105878522	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.73	5.66	0.42	7.53e-8	Obesity-related traits;
UCEC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg04155231	chr12:9217510	LOC144571	0.39	4.57	0.35	1.02e-5	Sjögren's syndrome;
UCEC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg13695892	chr22:41940480	POLR3H	-0.55	-4.73	-0.36	5.21e-6	Vitiligo;
UCEC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.32	0.61	1.62e-16	Electrocardiographic conduction measures;
UCEC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg25828445	chr12:7781288	NA	0.57	4.71	0.36	5.69e-6	HDL cholesterol levels;
UCEC	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.65	-6.05	-0.45	1.16e-8	Aortic root size;
UCEC	cis	rs73206853	0.841	rs2339511	chr12:110789372	C/T	cg12870014	chr12:110450643	ANKRD13A	0.64	5.37	0.41	2.97e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.88e-7	Hemoglobin concentration;
UCEC	cis	rs7106204	1.000	rs7931691	chr11:24221123	C/A	ch.11.24196551F	chr11:24239977	NA	0.66	5.73	0.43	5.56e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6717918	0.517	rs2633262	chr2:233130584	T/C	cg02061626	chr2:233274167	ALPPL2	0.5	5.05	0.38	1.27e-6	Height;
UCEC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	9.87	0.63	6.25e-18	Height;
UCEC	cis	rs60311166	1.000	rs57869735	chr3:52662850	A/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	4.64	0.36	7.57e-6	CTACK levels;
UCEC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs12635074	0.511	rs73080560	chr3:56264829	A/G	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.37	4.62	0.36	8.38e-6	Morning vs. evening chronotype;
UCEC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.58	-8.83	-0.59	2.95e-15	Prudent dietary pattern;
UCEC	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg04117972	chr1:227635322	NA	0.59	4.52	0.35	1.25e-5	Major depressive disorder;
UCEC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.51	4.89	0.37	2.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.39	0.47	2.02e-9	Motion sickness;
UCEC	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.69	-6.2	-0.46	5.39e-9	Initial pursuit acceleration;
UCEC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.82	7.24	0.51	2.35e-11	Blood metabolite levels;
UCEC	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg16329650	chr2:213403929	ERBB4	0.48	4.78	0.37	4.3e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs6693882	0.967	rs6688538	chr1:96145343	C/T	cg12448539	chr1:95364293	CNN3	0.48	4.55	0.35	1.14e-5	Pain;
UCEC	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.07	11.11	0.68	3.43e-21	Corneal structure;
UCEC	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.74	9.44	0.61	7.68e-17	Body mass index;
UCEC	cis	rs2950163	0.891	rs751051	chr2:6177737	A/G	cg04174211	chr2:7058432	RNF144A	0.52	4.51	0.35	1.33e-5	Response to metformin (IC50);
UCEC	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg18681998	chr4:17616180	MED28	0.79	9.26	0.61	2.32e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	0.93	8.14	0.56	1.51e-13	Red blood cell traits;
UCEC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.54	5.17	0.39	7.41e-7	Schizophrenia;
UCEC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.97	5.35	0.4	3.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.43	-5.24	-0.4	5.56e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs7766436	1.000	rs13217022	chr6:22612757	T/C	cg13666174	chr6:22585274	NA	-0.43	-4.52	-0.35	1.24e-5	Coronary artery disease;
UCEC	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.76	-6.64	-0.48	5.59e-10	Caudate activity during reward;
UCEC	cis	rs1610096	0.592	rs10411696	chr19:1060487	T/G	cg18950617	chr19:1066959	HMHA1	-0.49	-4.51	-0.35	1.31e-5	Neutrophil percentage of granulocytes;
UCEC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.67	4.86	0.37	2.96e-6	Height;
UCEC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg01256987	chr12:42539512	GXYLT1	-0.43	-4.84	-0.37	3.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.67	-7.25	-0.51	2.15e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg05527609	chr1:210001259	C1orf107	0.76	6.22	0.46	4.97e-9	Red blood cell count;
UCEC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.27	0.46	3.79e-9	Tonsillectomy;
UCEC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.67	8.53	0.58	1.69e-14	Menopause (age at onset);
UCEC	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.24	0.65	6.66e-19	Electrocardiographic conduction measures;
UCEC	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.58	-6.08	-0.45	9.87e-9	Rheumatoid arthritis;
UCEC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22857025	chr5:266934	NA	-0.99	-9.62	-0.62	2.74e-17	Breast cancer;
UCEC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.56	5.67	0.42	7.49e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs911263	0.561	rs2064912	chr14:68807132	C/T	cg14286928	chr14:67826449	EIF2S1;ATP6V1D	-0.5	-4.7	-0.36	5.88e-6	Primary biliary cholangitis;
UCEC	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.44	-0.57	2.83e-14	Colorectal cancer;
UCEC	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs3760776	1.000	rs3760776	chr19:5839746	C/T	cg25387410	chr19:5844109	FUT3	-0.64	-6.65	-0.48	5.27e-10	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
UCEC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs773506	0.628	rs10733739	chr9:93929515	C/T	cg03243796	chr9:93920768	NA	-0.4	-5.0	-0.38	1.61e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.6	-0.48	6.88e-10	Pubertal anthropometrics;
UCEC	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.59	-6.41	-0.47	1.89e-9	Obesity-related traits;
UCEC	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg06166341	chr4:1223170	CTBP1	-0.53	-4.88	-0.37	2.72e-6	Systolic blood pressure;
UCEC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.32	-4.53	-0.35	1.22e-5	Alzheimer's disease (late onset);
UCEC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.68	-6.63	-0.48	5.88e-10	Lymphocyte counts;
UCEC	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.64	0.42	8.43e-8	Coffee consumption (cups per day);
UCEC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-5.56	-0.42	1.22e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2167364	0.765	rs58612109	chr7:50573455	G/A	cg18232548	chr7:50535776	DDC	0.52	5.5	0.41	1.67e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-5.17	-0.39	7.39e-7	Bipolar disorder;
UCEC	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	0.82	6.44	0.47	1.57e-9	Corneal structure;
UCEC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.800	rs12985313	chr19:23037780	T/C	cg08271804	chr19:22816896	ZNF492	0.54	5.29	0.4	4.43e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.46	-6.64	-0.48	5.67e-10	Urinary metabolites;
UCEC	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg10902566	chr4:727664	PCGF3	-0.56	-4.88	-0.37	2.74e-6	Systolic blood pressure;
UCEC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.52	0.35	1.26e-5	Breast cancer;
UCEC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.48	4.76	0.37	4.59e-6	Height;
UCEC	cis	rs9470794	1.000	rs73421436	chr6:37937274	T/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs7937612	0.965	rs7932658	chr11:120211212	A/G	cg12584626	chr11:120203529	NA	-0.5	-5.18	-0.39	7.21e-7	Intraocular pressure;
UCEC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.69	10.09	0.64	1.64e-18	Height;
UCEC	cis	rs9463078	0.739	rs1293457	chr6:44758098	T/C	cg25276700	chr6:44698697	NA	0.49	5.65	0.42	7.89e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.58	5.84	0.43	3.29e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.56	0.53	4.04e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.39	4.73	0.36	5.32e-6	Prostate cancer;
UCEC	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg24375607	chr4:120327624	NA	0.44	4.8	0.37	3.85e-6	Corneal astigmatism;
UCEC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.55	-0.42	1.31e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg05962950	chr11:130786565	SNX19	0.61	6.69	0.48	4.43e-10	Schizophrenia;
UCEC	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13683864	chr3:40499215	RPL14	-0.96	-9.79	-0.63	9.53e-18	Renal cell carcinoma;
UCEC	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.71	-5.84	-0.43	3.2e-8	Parkinson's disease;
UCEC	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.76	-8.37	-0.57	4.16e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.68	-4.6	-0.35	8.92e-6	LDL cholesterol levels;
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.41	4.79	0.37	4.02e-6	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.65	5.54	0.42	1.33e-7	Obesity (extreme);
UCEC	cis	rs12634933	1.000	rs16853483	chr3:169031987	C/T	cg03603669	chr3:169896616	PHC3	-0.47	-4.62	-0.36	8.31e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.96	0.38	1.95e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.73	-7.74	-0.54	1.47e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.9e-15	Height;
UCEC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00612595	chr21:47717864	NA	-0.48	-4.63	-0.36	8.1e-6	Testicular germ cell tumor;
UCEC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-6.18	-0.45	5.88e-9	Tonsillectomy;
UCEC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.84	9.45	0.61	7.59e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.57	-6.01	-0.44	1.37e-8	Coronary artery disease;
UCEC	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.23	9.3	0.61	1.85e-16	Uric acid levels;
UCEC	cis	rs2054399	0.515	rs16829771	chr3:178284990	T/C	cg10634551	chr3:178254242	KCNMB2	-0.42	-4.56	-0.35	1.06e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24249390	chr15:90295951	MESP1	-0.39	-4.54	-0.35	1.17e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.63	-5.97	-0.44	1.74e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.52	4.86	0.37	3.02e-6	Blood trace element (Cu levels);
UCEC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.53	4.64	0.36	7.78e-6	Corneal astigmatism;
UCEC	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg01072550	chr1:21505969	NA	-0.58	-5.96	-0.44	1.78e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.56	-6.03	-0.45	1.27e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3914502	0.550	rs73174728	chr3:174479796	A/T	cg21145449	chr3:174580620	NAALADL2	-0.39	-4.66	-0.36	7.12e-6	Autism spectrum disorder;
UCEC	cis	rs17106184	1.000	rs72898971	chr1:50971408	A/G	cg07174182	chr1:51127561	FAF1	-0.84	-5.35	-0.4	3.33e-7	Type 2 diabetes;
UCEC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.84	10.06	0.64	1.98e-18	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.39	4.78	0.37	4.17e-6	Renal cell carcinoma;
UCEC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.84	9.27	0.61	2.21e-16	Breast cancer;
UCEC	cis	rs7101446	0.704	rs9665872	chr11:63185629	G/T	cg27030245	chr11:62559554	TMEM223	-0.52	-4.52	-0.35	1.26e-5	Economic and political preferences;
UCEC	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs79815064	0.651	rs79837477	chr3:46157154	C/T	cg19145607	chr3:45983792	CXCR6;FYCO1	0.83	4.99	0.38	1.72e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.52	-5.4	-0.41	2.62e-7	Hepatocellular carcinoma;
UCEC	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	9.52	0.62	4.78e-17	Colorectal cancer;
UCEC	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.2	-0.39	6.51e-7	Personality dimensions;
UCEC	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg13695892	chr22:41940480	POLR3H	-0.69	-5.65	-0.42	7.98e-8	Vitiligo;
UCEC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.57	4.9	0.37	2.46e-6	LDL cholesterol levels;
UCEC	trans	rs6008312	0.550	rs9615581	chr22:48073663	A/T	cg11520866	chr11:64856789	NA	0.84	6.75	0.49	3.14e-10	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.19	-0.39	6.74e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	8.31	0.57	5.93e-14	Prudent dietary pattern;
UCEC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.55	5.0	0.38	1.59e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs13065560	0.714	rs4280575	chr3:38937645	C/T	cg01426195	chr3:39028469	NA	0.42	4.54	0.35	1.14e-5	Interleukin-18 levels;
UCEC	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.46	5.24	0.4	5.4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg04154034	chr17:28927549	LRRC37B2	0.82	5.2	0.39	6.61e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2172802	0.576	rs1497915	chr4:62412922	T/C	cg18242907	chr4:62067393	NA	0.45	4.51	0.35	1.34e-5	Partial epilepsies;
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.83	0.43	3.34e-8	Platelet count;
UCEC	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.21	-10.04	-0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.46	4.69	0.36	6.24e-6	Body mass index;
UCEC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.61	-4.99	-0.38	1.65e-6	High light scatter reticulocyte count;
UCEC	cis	rs11235843	0.929	rs67167213	chr11:73422208	C/T	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	0.87	10.14	0.64	1.18e-18	Schizophrenia;
UCEC	cis	rs7246967	0.932	rs35039856	chr19:23031339	A/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.86	-9.0	-0.6	1.09e-15	Blood metabolite levels;
UCEC	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-5.13	-0.39	9.02e-7	Hemoglobin concentration;
UCEC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg01380346	chr19:18557039	ELL	-0.47	-4.73	-0.36	5.28e-6	Breast cancer;
UCEC	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg17420585	chr12:42539391	GXYLT1	0.36	4.52	0.35	1.25e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs7101446	0.545	rs631157	chr11:63176802	G/T	cg15769409	chr9:138372274	KIAA0649	0.66	6.77	0.49	2.85e-10	Economic and political preferences;
UCEC	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.58	5.36	0.4	3.18e-7	Tonsillectomy;
UCEC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg21419209	chr3:44054225	NA	-0.51	-4.83	-0.37	3.4e-6	Coronary artery disease;
UCEC	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.61	5.97	0.44	1.74e-8	Neuroticism;Neuroticism (multi-trait analysis);
UCEC	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-5.68	-0.42	7.11e-8	Bipolar disorder;
UCEC	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg19715936	chr7:50634035	DDC	-0.48	-5.93	-0.44	2.03e-8	Malaria;
UCEC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.45	-0.41	2.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-0.97	-6.31	-0.46	3.06e-9	Diabetic kidney disease;
UCEC	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.9	-10.09	-0.64	1.65e-18	Blood metabolite levels;
UCEC	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.57	6.74	0.49	3.35e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.38	-13.34	-0.74	4.34e-27	Type 1 diabetes nephropathy;
UCEC	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	6.94	0.5	1.17e-10	Neuroticism;
UCEC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs12216499	1.000	rs10455772	chr6:159396403	T/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.54	-0.35	1.15e-5	Bladder cancer (smoking interaction);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13389575	chr13:48890413	RB1	0.59	7.53	0.53	4.65e-12	Warfarin maintenance dose;
UCEC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.11	0.39	9.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs151997	1.000	rs26063	chr5:50216718	G/A	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.49	5.56	0.42	1.25e-7	Anterior chamber depth;
UCEC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.8	9.82	0.63	7.96e-18	Mean corpuscular volume;
UCEC	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.66	6.88	0.49	1.58e-10	Immature fraction of reticulocytes;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.5	5.61	0.42	9.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.62	-5.15	-0.39	8.14e-7	Initial pursuit acceleration;
UCEC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.61	5.82	0.43	3.47e-8	Blood protein levels;
UCEC	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.75	7.7	0.54	1.87e-12	Caffeine consumption;
UCEC	cis	rs10095849	0.576	rs10107204	chr8:39468899	T/A	cg24581462	chr8:38759627	PLEKHA2	0.36	4.7	0.36	5.98e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.5	-5.31	-0.4	3.94e-7	Dilated cardiomyopathy;
UCEC	cis	rs7246967	0.673	rs7249003	chr19:22887934	A/G	cg05241461	chr19:22816980	ZNF492	0.58	6.12	0.45	7.93e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.53	0.41	1.43e-7	Birth weight;
UCEC	cis	rs10507349	0.632	rs4770962	chr13:26816238	C/T	cg01600817	chr13:26797529	RNF6	0.43	4.76	0.37	4.5e-6	Type 2 diabetes;
UCEC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg04673462	chr1:38461896	NA	0.67	6.36	0.46	2.43e-9	Red cell distribution width;
UCEC	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg05660106	chr1:15850417	CASP9	0.61	5.61	0.42	9.68e-8	Systolic blood pressure;
UCEC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.5	4.56	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.49	5.43	0.41	2.3e-7	Life satisfaction;
UCEC	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg06521331	chr12:34319734	NA	-0.63	-4.86	-0.37	2.95e-6	Morning vs. evening chronotype;
UCEC	cis	rs12980942	0.748	rs35501756	chr19:41823497	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.75	5.88	0.44	2.68e-8	Coronary artery disease;
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.55	6.6	0.48	7.17e-10	Menarche (age at onset);
UCEC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.08	-0.39	1.14e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.74	-6.22	-0.46	4.96e-9	Colorectal adenoma (advanced);
UCEC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	0.84	10.56	0.66	9.21e-20	Bone mineral density;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.58	-6.7	-0.48	4.07e-10	Pubertal anthropometrics;
UCEC	cis	rs35934224	0.831	rs13057374	chr22:19871097	C/G	cg11182965	chr22:19864308	TXNRD2	-0.47	-5.83	-0.43	3.39e-8	Glaucoma (primary open-angle);
UCEC	cis	rs2281845	0.507	rs7547762	chr1:201088245	A/G	cg06714761	chr1:201096289	NA	0.54	5.91	0.44	2.3e-8	Permanent tooth development;
UCEC	cis	rs3914502	0.511	rs1965413	chr3:174505868	G/C	cg21145449	chr3:174580620	NAALADL2	-0.44	-5.08	-0.39	1.11e-6	Autism spectrum disorder;
UCEC	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.37	-4.64	-0.36	7.56e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs4705962	0.959	rs2227282	chr5:132013179	C/G	cg27309611	chr5:132113725	SEPT8	0.43	5.78	0.43	4.39e-8	Atopic dermatitis;
UCEC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.51	5.23	0.4	5.76e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs806321	0.755	rs2765762	chr13:50781256	C/G	cg12964420	chr13:50975679	NA	-0.36	-4.57	-0.35	1.05e-5	Multiple sclerosis;
UCEC	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg03859395	chr2:55845619	SMEK2	0.97	13.42	0.74	2.61e-27	Metabolic syndrome;
UCEC	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs7336933	0.866	rs2003064	chr13:42481712	C/T	cg18400088	chr13:41634674	WBP4	0.57	4.88	0.37	2.7e-6	Calcium levels;
UCEC	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.14	-0.51	3.95e-11	Joint mobility (Beighton score);
UCEC	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg05874882	chr4:1763078	NA	-0.53	-5.43	-0.41	2.25e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.24	0.4	5.43e-7	Electroencephalogram traits;
UCEC	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.67	7.8	0.54	1.05e-12	Eosinophil percentage of white cells;
UCEC	cis	rs829883	0.624	rs829881	chr12:98881228	T/G	cg25150519	chr12:98850993	NA	0.62	5.51	0.41	1.59e-7	Colorectal adenoma (advanced);
UCEC	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.6	-0.58	1.08e-14	Exhaled nitric oxide output;
UCEC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.69	6.07	0.45	1.03e-8	Bipolar disorder;
UCEC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.42	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-4.84	-0.37	3.23e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.85	9.54	0.62	4.43e-17	Breast cancer;
UCEC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.52	5.81	0.43	3.77e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7944735	0.817	rs6485784	chr11:47832260	C/T	cg08722104	chr11:47448306	PSMC3	-0.46	-4.54	-0.35	1.19e-5	Intraocular pressure;
UCEC	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.29e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7246967	0.932	rs7256599	chr19:23045921	T/C	cg08271804	chr19:22816896	ZNF492	0.58	5.45	0.41	2.05e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs17102423	0.623	rs12100752	chr14:65611546	G/C	cg11161011	chr14:65562177	MAX	-0.64	-5.72	-0.43	5.76e-8	Obesity-related traits;
UCEC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.63	-6.71	-0.48	3.88e-10	Neurofibrillary tangles;
UCEC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.56	0.35	1.06e-5	Breast cancer;
UCEC	cis	rs9321099	1.000	rs58415226	chr6:128229798	T/C	cg25012434	chr6:128842125	PTPRK	0.61	4.66	0.36	7.07e-6	Sense of smell;
UCEC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.63	9.1	0.6	6.03e-16	Prudent dietary pattern;
UCEC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.61	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg17420585	chr12:42539391	GXYLT1	0.4	5.02	0.38	1.44e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs4722166	0.599	rs7776857	chr7:22754768	G/T	cg26061582	chr7:22766209	IL6	0.58	4.82	0.37	3.49e-6	Lung cancer;
UCEC	cis	rs2304069	0.729	rs2066934	chr5:149433596	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	5.22	0.4	6.09e-7	HIV-1 control;
UCEC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg02160872	chr5:212506	CCDC127	0.74	7.91	0.55	5.63e-13	Breast cancer;
UCEC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg22974920	chr21:40686053	BRWD1	0.59	5.11	0.39	1e-6	Cognitive function;
UCEC	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg14092571	chr14:90743983	NA	-0.37	-4.83	-0.37	3.36e-6	Mortality in heart failure;
UCEC	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.64	-6.32	-0.46	2.91e-9	Metabolite levels;
UCEC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg24920358	chr1:40204285	PPIE	0.47	4.81	0.37	3.7e-6	Blood protein levels;
UCEC	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	4.69	0.36	6.3e-6	Height;
UCEC	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.6	7.0	0.5	8.33e-11	Blood metabolite ratios;
UCEC	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.8	0.37	3.88e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.09	-15.94	-0.8	7.64e-34	Myeloid white cell count;
UCEC	cis	rs7705819	1.000	rs4868277	chr5:172876006	T/G	cg14746387	chr5:172879299	NA	0.48	5.16	0.39	7.79e-7	Stroke;
UCEC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg10932868	chr11:921992	NA	0.44	5.84	0.43	3.3e-8	Alzheimer's disease (late onset);
UCEC	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.52	-4.7	-0.36	6.05e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-5.83	-0.43	3.37e-8	Colorectal cancer;
UCEC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg24375607	chr4:120327624	NA	0.47	4.74	0.36	5.01e-6	Corneal astigmatism;
UCEC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg07930552	chr6:133119739	C6orf192	0.82	6.11	0.45	8.71e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.49	-4.72	-0.36	5.43e-6	Neurofibrillary tangles;
UCEC	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg05962950	chr11:130786565	SNX19	0.51	5.22	0.4	5.97e-7	Schizophrenia;
UCEC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.1	7.86	0.54	7.43e-13	Alzheimer's disease (late onset);
UCEC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-4.74	-0.36	5e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg14675211	chr2:100938903	LONRF2	0.62	6.2	0.46	5.55e-9	Educational attainment;
UCEC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg13870426	chr17:30244630	NA	-0.64	-4.72	-0.36	5.4e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.5	5.45	0.41	2.04e-7	Menarche (age at onset);
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg21932190	chr1:1635647	CDK11A;CDK11B	0.46	4.74	0.36	5.01e-6	Body mass index;
UCEC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-6.46	-0.47	1.48e-9	Bipolar disorder;
UCEC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.57	-4.79	-0.37	4.11e-6	Initial pursuit acceleration;
UCEC	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	6.81	0.49	2.38e-10	Platelet count;
UCEC	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg04202892	chr2:111875749	ACOXL	0.44	4.85	0.37	3.04e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.57	-5.13	-0.39	9.19e-7	Corneal astigmatism;
UCEC	cis	rs2892463	0.796	rs7326253	chr13:30375270	C/T	cg18356743	chr13:30408050	UBL3	0.4	4.51	0.35	1.34e-5	Non-word repetition;
UCEC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	0.81	5.21	0.39	6.36e-7	Arsenic metabolism;
UCEC	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.45	-5.08	-0.39	1.13e-6	Subjective well-being;
UCEC	cis	rs7520050	0.966	rs11579634	chr1:46466391	A/G	cg15837086	chr1:46506065	PIK3R3	0.42	5.43	0.41	2.26e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg21191810	chr6:118973309	C6orf204	0.39	5.33	0.4	3.65e-7	Electrocardiographic conduction measures;
UCEC	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg06521331	chr12:34319734	NA	-0.63	-4.86	-0.37	2.95e-6	Morning vs. evening chronotype;
UCEC	cis	rs7246967	0.542	rs56355379	chr19:22900455	C/T	cg08271804	chr19:22816896	ZNF492	0.66	6.49	0.47	1.25e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.57	6.45	0.47	1.48e-9	Hip circumference;
UCEC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.68	5.23	0.4	5.67e-7	Mean platelet volume;
UCEC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	0.99	9.35	0.61	1.35e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.37	-0.4	3.02e-7	Bipolar disorder;
UCEC	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg02527881	chr3:46936655	PTH1R	-0.46	-5.98	-0.44	1.59e-8	Birth weight;
UCEC	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.54	7.37	0.52	1.13e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2970992	0.764	rs2090012	chr2:101330582	T/C	cg01042948	chr2:101319752	NA	0.56	6.02	0.44	1.33e-8	Educational attainment;
UCEC	cis	rs12767760	0.714	rs4919109	chr10:99297954	A/T	cg17778955	chr10:99210596	ZDHHC16	-0.5	-5.19	-0.39	6.86e-7	Obesity-related traits;
UCEC	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg09165964	chr15:75287851	SCAMP5	-0.55	-5.71	-0.43	5.93e-8	Lung cancer;
UCEC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.69	8.23	0.56	9.08e-14	Vitiligo;
UCEC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.57	5.08	0.39	1.15e-6	Response to diuretic therapy;
UCEC	cis	rs1892094	0.816	rs6427178	chr1:169095082	G/A	cg17859187	chr1:168147929	TIPRL	-0.47	-4.8	-0.37	3.9e-6	Coronary artery disease;
UCEC	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.72	6.58	0.48	7.56e-10	Vitiligo;
UCEC	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	1.01	9.43	0.61	8.14e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	9.67	0.62	1.96e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.75	9.28	0.61	2.04e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs60311166	1.000	rs72947583	chr3:52617358	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.77	5.36	0.4	3.11e-7	CTACK levels;
UCEC	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg10631289	chr15:39006617	NA	-0.61	-5.49	-0.41	1.74e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.83	-8.35	-0.57	4.58e-14	Post bronchodilator FEV1;
UCEC	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.14	0.45	7.31e-9	Platelet count;
UCEC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.68	-6.67	-0.48	4.93e-10	Initial pursuit acceleration;
UCEC	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.84	0.43	3.26e-8	Coffee consumption (cups per day);
UCEC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.85	-0.37	3.17e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2904967	0.810	rs507005	chr11:65045615	T/C	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg21419209	chr3:44054225	NA	-0.53	-5.25	-0.4	5.31e-7	Coronary artery disease;
UCEC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg14092571	chr14:90743983	NA	0.38	4.75	0.37	4.71e-6	Mortality in heart failure;
UCEC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.84	0.43	3.15e-8	Height;
UCEC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.64	7.01	0.5	8.14e-11	Homoarginine levels;
UCEC	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	8.34	0.57	4.93e-14	Lymphocyte percentage of white cells;
UCEC	cis	rs7224668	0.647	rs2292184	chr17:79244802	T/C	cg15215033	chr17:79258732	SLC38A10	0.33	4.82	0.37	3.52e-6	IgG glycosylation;
UCEC	cis	rs4851266	1.000	rs999052	chr2:100836106	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.62	-0.36	8.3e-6	Pulmonary function;
UCEC	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11118844	0.843	rs12403995	chr1:221921377	C/A	cg04222084	chr1:221915650	DUSP10	-0.75	-6.81	-0.49	2.34e-10	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.82	10.23	0.64	7.01e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs829661	1.000	rs829642	chr2:30699970	A/G	cg17749961	chr2:30669863	LCLAT1	0.51	4.7	0.36	5.86e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg22974920	chr21:40686053	BRWD1	-0.55	-5.01	-0.38	1.54e-6	Cognitive function;
UCEC	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.53	5.53	0.41	1.43e-7	Dupuytren's disease;
UCEC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg05962950	chr11:130786565	SNX19	0.57	6.05	0.45	1.13e-8	Schizophrenia;
UCEC	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg06637938	chr14:75390232	RPS6KL1	0.69	5.96	0.44	1.76e-8	Height;
UCEC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.82	-10.53	-0.66	1.11e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.64	0.62	2.38e-17	Heart rate;
UCEC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.51	6.26	0.46	3.98e-9	Total body bone mineral density;
UCEC	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.81	-8.62	-0.58	9.56e-15	Blood metabolite levels;
UCEC	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.49	-4.81	-0.37	3.69e-6	Height;
UCEC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs3743832	0.520	rs8045589	chr16:9210373	A/T	cg08831531	chr16:9218945	NA	0.5	5.93	0.44	2.05e-8	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs7246967	0.608	rs396440	chr19:23002966	A/G	cg05241461	chr19:22816980	ZNF492	0.5	4.83	0.37	3.46e-6	Bronchopulmonary dysplasia;
UCEC	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.89	12.63	0.72	3.12e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.62	-6.07	-0.45	1.04e-8	Blood metabolite levels;
UCEC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.01	0.38	1.55e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.89	8.02	0.55	2.99e-13	Morning vs. evening chronotype;
UCEC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	0.87	7.57	0.53	3.84e-12	Nonalcoholic fatty liver disease;
UCEC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.69	-8.43	-0.57	2.88e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-5.14	-0.39	8.67e-7	Height;
UCEC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.56	0.35	1.08e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	0.88	5.61	0.42	9.89e-8	Diabetic retinopathy;
UCEC	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg24505687	chr6:33548425	BAK1	0.45	5.01	0.38	1.57e-6	Platelet count;
UCEC	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.23	-9.68	-0.62	1.87e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.2	-0.39	6.62e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg12524725	chr2:239427019	NA	-0.62	-4.51	-0.35	1.31e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.9	11.53	0.69	2.54e-22	Longevity;Endometriosis;
UCEC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4372836	0.964	rs17007191	chr2:28932502	C/T	cg09522027	chr2:28974177	PPP1CB	0.75	7.39	0.52	1.01e-11	Body mass index;
UCEC	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.73	-6.22	-0.46	4.91e-9	Platelet distribution width;
UCEC	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.5	5.19	0.39	6.8e-7	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs7546668	1.000	rs10803388	chr1:15850097	G/A	cg05660106	chr1:15850417	CASP9	-0.46	-4.87	-0.37	2.88e-6	Glomerular filtration rate (creatinine);
UCEC	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	12.63	0.72	3.12e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.47	5.96	0.44	1.8e-8	Neuroticism;
UCEC	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.49	-0.53	5.91e-12	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg19554555	chr3:13937349	NA	-0.53	-5.61	-0.42	9.77e-8	Ovarian reserve;
UCEC	cis	rs12711979	0.875	rs11686157	chr2:3855020	C/G	cg17052675	chr2:3827356	NA	-0.37	-4.67	-0.36	6.86e-6	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg01262667	chr19:19385393	TM6SF2	0.52	6.79	0.49	2.61e-10	Tonsillectomy;
UCEC	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.92	9.25	0.61	2.48e-16	Post bronchodilator FEV1;
UCEC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.61	-6.41	-0.47	1.91e-9	Platelet distribution width;
UCEC	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.92	9.79	0.63	9.91e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs4434872	0.536	rs7527406	chr1:153863356	G/A	cg00151906	chr1:154548273	CHRNB2	-0.56	-4.55	-0.35	1.14e-5	Conduct disorder (symptom count);
UCEC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.55	-5.67	-0.42	7.4e-8	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02097616	chr17:62675921	NA	0.44	4.86	0.37	3e-6	QT interval;
UCEC	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.62	4.73	0.36	5.31e-6	Major depressive disorder;
UCEC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.36	0.4	3.12e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.87	-8.65	-0.58	8.36e-15	Post bronchodilator FEV1;
UCEC	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.37	4.69	0.36	6.2e-6	Mean platelet volume;
UCEC	cis	rs9326726	0.844	rs62359544	chr5:107644943	C/T	cg17432647	chr5:107996819	NA	0.52	4.61	0.36	8.58e-6	Resting heart rate;
UCEC	cis	rs3015497	0.789	rs1389652	chr14:51125240	T/C	cg04730355	chr14:51134070	SAV1	-0.48	-4.87	-0.37	2.88e-6	Mean platelet volume;
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-6.17	-0.45	6.39e-9	Platelet count;
UCEC	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.56	5.24	0.4	5.45e-7	Dental caries;
UCEC	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.49	4.7	0.36	5.92e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.87	-10.08	-0.64	1.77e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg06462663	chr19:18546047	ISYNA1	0.53	6.73	0.49	3.51e-10	Breast cancer;
UCEC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.91	10.82	0.67	1.9e-20	Ulcerative colitis;
UCEC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.59	-5.72	-0.43	5.73e-8	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.66	6.18	0.45	5.93e-9	Menarche (age at onset);
UCEC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.8	-0.49	2.46e-10	Coffee consumption (cups per day);
UCEC	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.44e-16	Hip circumference adjusted for BMI;
UCEC	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.12e-18	Height;
UCEC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	0.79	5.25	0.4	5.28e-7	Diabetic retinopathy;
UCEC	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.75	6.91	0.5	1.36e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg20607287	chr7:12443886	VWDE	-0.62	-4.54	-0.35	1.18e-5	Coronary artery disease;
UCEC	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.43	-5.41	-0.41	2.53e-7	Height;
UCEC	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.59	5.26	0.4	4.99e-7	Corneal astigmatism;
UCEC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	6.95	0.5	1.09e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.49	-5.58	-0.42	1.13e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.34	0.46	2.66e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06156847	chr2:113672199	IL1F7	-0.33	-4.55	-0.35	1.12e-5	Pulmonary function;
UCEC	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.75	0.54	1.39e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.56	-6.09	-0.45	9.32e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs7246967	0.551	rs7248993	chr19:22849152	G/C	cg08271804	chr19:22816896	ZNF492	0.64	6.38	0.47	2.18e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	0.839	rs56360354	chr17:57202927	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-7.33	-0.52	1.42e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs405956	1.000	rs1338020	chr6:105577686	C/T	cg22580625	chr6:105627791	POPDC3	-0.71	-6.69	-0.48	4.38e-10	QT interval;
UCEC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.64	-7.16	-0.51	3.5e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.75	-0.37	4.72e-6	Blood metabolite levels;
UCEC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.51e-7	Hemoglobin concentration;
UCEC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-4.8	-0.37	3.89e-6	Aortic root size;
UCEC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	4.95	0.38	1.99e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.85	-9.65	-0.62	2.23e-17	Blood metabolite levels;
UCEC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.69	-5.52	-0.41	1.49e-7	Initial pursuit acceleration;
UCEC	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.74	6.12	0.45	8.19e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.64	6.74	0.49	3.36e-10	Age at first birth;
UCEC	cis	rs1975974	0.748	rs67473406	chr17:21726745	G/A	cg11501438	chr17:20755949	NA	0.42	4.56	0.35	1.07e-5	Psoriasis;
UCEC	cis	rs7015630	1.000	rs7015630	chr8:90875918	T/C	cg02503933	chr8:90770146	RIPK2	0.48	4.6	0.35	8.97e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg07387570	chr22:46663686	TTC38	-0.46	-4.51	-0.35	1.3e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.06	12.86	0.73	7.88e-26	Schizophrenia;
UCEC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.81	-9.08	-0.6	6.46e-16	Blood metabolite levels;
UCEC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.57	4.56	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.41	-5.09	-0.39	1.09e-6	Colorectal cancer;
UCEC	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.36	5.33	0.4	3.68e-7	Vitiligo;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	6.0	0.44	1.46e-8	High light scatter reticulocyte count;
UCEC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.57	-6.44	-0.47	1.59e-9	Lung cancer;
UCEC	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-6.87	-0.49	1.73e-10	Morning vs. evening chronotype;
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.59	-6.27	-0.46	3.86e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.54	-0.42	1.37e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg03728395	chr2:85555865	TGOLN2	-0.36	-4.91	-0.38	2.43e-6	Ear protrusion;
UCEC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.11	0.45	8.55e-9	Breast cancer;
UCEC	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg00105475	chr2:10696890	NA	-0.37	-4.68	-0.36	6.54e-6	Prostate cancer;
UCEC	cis	rs6684428	1.000	rs61774842	chr1:56366173	A/G	cg11651538	chr1:56320950	NA	-0.71	-6.27	-0.46	3.81e-9	Airflow obstruction;
UCEC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg12463550	chr7:65579703	CRCP	0.49	4.98	0.38	1.79e-6	Aortic root size;
UCEC	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.46	-5.02	-0.38	1.49e-6	Longevity;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.56	-6.05	-0.45	1.13e-8	Cardiac Troponin-T levels;
UCEC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.72	7.53	0.53	4.83e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.71	6.42	0.47	1.77e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12516959	chr21:47718080	NA	-0.4	-4.58	-0.35	9.9e-6	Testicular germ cell tumor;
UCEC	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.35	-0.4	3.26e-7	Aortic root size;
UCEC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.62	-6.79	-0.49	2.55e-10	Menarche (age at onset);
UCEC	cis	rs3743832	0.933	rs7194736	chr16:9190749	A/T	cg08831531	chr16:9218945	NA	-0.48	-5.01	-0.38	1.57e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs7937612	1.000	rs10892567	chr11:120244192	A/G	cg12584626	chr11:120203529	NA	0.47	4.66	0.36	6.99e-6	Intraocular pressure;
UCEC	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	0.96	7.33	0.52	1.39e-11	Economic and political preferences (immigration/crime);
UCEC	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.61	6.76	0.49	2.98e-10	Morning vs. evening chronotype;
UCEC	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg21214455	chr15:72412075	SENP8	0.49	4.52	0.35	1.25e-5	Red blood cell count;
UCEC	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.86	6.18	0.45	6.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs8020441	1.000	rs67186984	chr14:51169287	C/T	cg04730355	chr14:51134070	SAV1	0.57	5.27	0.4	4.84e-7	Cognitive performance;
UCEC	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg14582100	chr15:45693742	SPATA5L1	0.34	4.6	0.35	9.19e-6	Homoarginine levels;
UCEC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.15	6.69	0.48	4.32e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg19318889	chr4:1322082	MAEA	0.48	5.09	0.39	1.1e-6	Obesity-related traits;
UCEC	cis	rs2120243	0.874	rs7616177	chr3:157153208	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.67	0.36	6.74e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.79	7.61	0.53	3.02e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-1.08	-9.49	-0.62	5.79e-17	Dupuytren's disease;
UCEC	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	5.86	0.44	2.88e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	8.28	0.56	7.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.38	4.58	0.35	9.89e-6	Blood metabolite levels;
UCEC	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg14008862	chr17:28927542	LRRC37B2	0.61	6.02	0.44	1.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.5	0.53	5.49e-12	Bipolar disorder;
UCEC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg11945507	chr8:142233382	SLC45A4	-0.45	-5.16	-0.39	7.92e-7	Immature fraction of reticulocytes;
UCEC	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.57	5.36	0.4	3.22e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4588572	0.643	rs10075726	chr5:77669053	T/A	cg11547950	chr5:77652471	NA	0.5	5.08	0.39	1.15e-6	Triglycerides;
UCEC	trans	rs2176263	0.900	rs6756419	chr2:24126904	A/G	cg01490821	chr2:170684022	UBR3	0.53	6.69	0.48	4.45e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10242455	0.867	rs2687145	chr7:99318644	C/T	cg07715041	chr7:99302981	CYP3A7	0.53	5.41	0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.53	5.88	0.44	2.72e-8	Retinal vascular caliber;
UCEC	cis	rs968451	0.526	rs5757617	chr22:39722714	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.64	5.93	0.44	2.09e-8	Primary biliary cholangitis;
UCEC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-5.1	-0.39	1.02e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-12.79	-0.73	1.22e-25	Height;
UCEC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.65	-5.61	-0.42	9.56e-8	Initial pursuit acceleration;
UCEC	cis	rs4642101	0.765	rs3732675	chr3:12858028	T/C	cg05775895	chr3:12838266	CAND2	0.58	5.2	0.39	6.61e-7	QRS complex (12-leadsum);
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.7	-0.36	5.92e-6	Cardiac Troponin-T levels;
UCEC	cis	rs35934224	0.783	rs7286104	chr22:19861226	T/C	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.77	-0.37	4.32e-6	Glaucoma (primary open-angle);
UCEC	cis	rs7937612	1.000	rs10790380	chr11:120233158	G/A	cg12584626	chr11:120203529	NA	0.51	5.24	0.4	5.39e-7	Intraocular pressure;
UCEC	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.6	-0.48	7.07e-10	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs7246967	0.673	rs34342502	chr19:22881428	C/A	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.62	7.48	0.52	6.32e-12	Schizophrenia;
UCEC	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.68	-6.09	-0.45	9.52e-9	Systolic blood pressure;
UCEC	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.44	-4.63	-0.36	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.79	-8.14	-0.56	1.5e-13	Mosquito bite size;
UCEC	cis	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg11707391	chr8:10001627	MSRA	-0.4	-4.8	-0.37	3.91e-6	Neuroticism;
UCEC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg22974920	chr21:40686053	BRWD1	0.48	4.88	0.37	2.79e-6	Menarche (age at onset);
UCEC	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.39	4.91	0.38	2.43e-6	DNA methylation (variation);
UCEC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.51	6.75	0.49	3.11e-10	Bone mineral density;
UCEC	cis	rs7975161	0.520	rs4502051	chr12:104695569	A/T	cg25273343	chr12:104657179	TXNRD1	-0.81	-5.11	-0.39	9.85e-7	Toenail selenium levels;
UCEC	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.56	5.59	0.42	1.06e-7	Blood metabolite levels;
UCEC	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.92	9.68	0.62	1.89e-17	Cognitive function;
UCEC	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	7.99	0.55	3.6e-13	Platelet distribution width;
UCEC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg10503236	chr1:231470652	EXOC8	-0.41	-4.77	-0.37	4.41e-6	Hemoglobin concentration;
UCEC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg06238570	chr21:40685208	BRWD1	0.78	7.71	0.54	1.73e-12	Cognitive function;
UCEC	cis	rs7246967	0.932	rs8105614	chr19:23038023	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1165472	0.806	rs12568471	chr1:56144766	C/T	cg11523071	chr1:56160889	NA	-0.57	-4.71	-0.36	5.6e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.75	-0.43	4.91e-8	Alcohol dependence;
UCEC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.13	18.83	0.84	5.19e-41	Testicular germ cell tumor;
UCEC	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg23782820	chr8:58130467	NA	0.62	4.81	0.37	3.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.88e-7	Hemoglobin concentration;
UCEC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.75	-8.2	-0.56	1.09e-13	Trans fatty acid levels;
UCEC	cis	rs11761441	0.602	rs10248329	chr7:92087	G/A	cg06458707	chr7:1083209	C7orf50	0.26	4.81	0.37	3.75e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	7.84	0.54	8.64e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.94	-14.35	-0.76	9.27e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-7.29	-0.52	1.77e-11	Coffee consumption (cups per day);
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg12035532	chr1:1886765	KIAA1751	0.43	4.56	0.35	1.06e-5	Body mass index;
UCEC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-6.58	-0.48	7.82e-10	HDL cholesterol;
UCEC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.36	-5.02	-0.38	1.51e-6	Longevity;
UCEC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	4.98	0.38	1.79e-6	LDL cholesterol;
UCEC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	4.9	0.37	2.51e-6	Breast cancer;
UCEC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg06238570	chr21:40685208	BRWD1	0.79	7.71	0.54	1.75e-12	Cognitive function;
UCEC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.61	5.37	0.4	3.04e-7	Response to diuretic therapy;
UCEC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg03714773	chr7:91764589	CYP51A1	0.42	4.98	0.38	1.78e-6	Breast cancer;
UCEC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	8.35	0.57	4.51e-14	Alzheimer's disease;
UCEC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.69	5.57	0.42	1.18e-7	Mean corpuscular volume;
UCEC	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	0.98	12.2	0.71	4.43e-24	Coronary artery disease;
UCEC	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg04311557	chr16:71523289	ZNF19	-0.7	-4.87	-0.37	2.88e-6	Post bronchodilator FEV1;
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.45	0.57	2.65e-14	Platelet count;
UCEC	cis	rs10924970	0.649	rs12727616	chr1:235421630	G/C	cg26050004	chr1:235667680	B3GALNT2	0.5	4.77	0.37	4.43e-6	Asthma;
UCEC	cis	rs7570971	0.583	rs1375132	chr2:135954405	A/G	cg07169764	chr2:136633963	MCM6	0.54	5.0	0.38	1.62e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	0.96	9.89	0.63	5.35e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-5.75	-0.43	4.97e-8	Metabolite levels;
UCEC	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.6	6.62	0.48	6.35e-10	Resting heart rate;
UCEC	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-0.91	-5.36	-0.4	3.22e-7	Diabetic kidney disease;
UCEC	cis	rs5167	0.504	rs7259679	chr19:45457306	C/T	cg09555818	chr19:45449301	APOC2	0.48	6.38	0.47	2.21e-9	Blood protein levels;
UCEC	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.5	5.24	0.4	5.57e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.62	4.73	0.36	5.11e-6	Lymphocyte counts;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14126863	chr5:157171503	LSM11	0.76	6.95	0.5	1.13e-10	Migraine with aura;
UCEC	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.57	5.02	0.38	1.49e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs1832871	0.965	rs10945541	chr6:158740218	A/G	cg07215822	chr6:158701037	NA	0.5	4.95	0.38	2.01e-6	Height;
UCEC	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18099408	chr3:52552593	STAB1	0.42	4.83	0.37	3.34e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-4.75	-0.36	4.74e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2648708	1.000	rs2768351	chr10:12604023	T/A	cg09346030	chr10:13390377	SEPHS1	0.53	4.56	0.35	1.08e-5	Calcium levels;
UCEC	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs925228	0.759	rs2551338	chr2:24006908	A/G	cg13272742	chr2:24272458	FKBP1B	0.59	5.19	0.39	6.86e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg05660106	chr1:15850417	CASP9	0.55	4.91	0.38	2.37e-6	Systolic blood pressure;
UCEC	cis	rs2134095	0.539	rs157861	chr1:165378161	C/G	cg09871424	chr1:164811491	PBX1	-0.44	-4.54	-0.35	1.17e-5	Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder;
UCEC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.64	-5.06	-0.38	1.25e-6	Body mass index;
UCEC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg22166914	chr1:53195759	ZYG11B	-0.64	-7.01	-0.5	8.17e-11	Monocyte count;
UCEC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.54	-4.81	-0.37	3.78e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.32e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.49	4.94	0.38	2.08e-6	Type 2 diabetes;
UCEC	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-4.93	-0.38	2.18e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.55	5.45	0.41	2.09e-7	Menopause (age at onset);
UCEC	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-6.92	-0.5	1.28e-10	Breast cancer;
UCEC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.92	13.13	0.73	1.54e-26	Menopause (age at onset);
UCEC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.16	14.76	0.77	8.32e-31	Cognitive function;
UCEC	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.72	6.56	0.48	8.57e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	7.12	0.51	4.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg23018236	chr17:30244563	NA	0.68	4.65	0.36	7.26e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6494849	0.620	rs8028949	chr15:70480964	C/T	cg22026918	chr15:70552251	NA	-0.45	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.47	-5.46	-0.41	1.99e-7	Aortic root size;
UCEC	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.41	-0.47	1.84e-9	Response to antipsychotic treatment;
UCEC	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg14675211	chr2:100938903	LONRF2	0.45	4.63	0.36	8.03e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	5.18	0.39	7.12e-7	Prudent dietary pattern;
UCEC	cis	rs2043599	1.000	rs116258115	chr19:56458317	C/T	cg12582959	chr19:56159199	CCDC106	0.63	4.53	0.35	1.22e-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.89	11.31	0.68	9.85e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7246967	0.611	rs12973264	chr19:22867749	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg20307385	chr11:47447363	PSMC3	0.58	4.93	0.38	2.18e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.68	7.99	0.55	3.71e-13	Metabolite levels;
UCEC	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.36	-0.4	3.09e-7	Breast cancer;
UCEC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg10978503	chr1:24200527	CNR2	-0.35	-5.18	-0.39	7.1e-7	Immature fraction of reticulocytes;
UCEC	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.55	5.16	0.39	7.93e-7	Lung cancer;
UCEC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.52	-0.35	1.25e-5	Parkinson's disease;
UCEC	cis	rs2901460	0.509	rs56944298	chr2:62090001	A/G	cg02183531	chr2:62113199	CCT4	-0.54	-4.54	-0.35	1.17e-5	Mean corpuscular volume;
UCEC	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.59	6.86	0.49	1.82e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.51	5.8	0.43	3.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1575951	1.000	rs7903216	chr10:130438675	G/A	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.75	6.05	0.45	1.17e-8	Mammographic density (dense area);
UCEC	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.71	0.58	5.82e-15	Coffee consumption (cups per day);
UCEC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	7.21	0.51	2.7e-11	LDL cholesterol;
UCEC	cis	rs12681287	0.752	rs9283958	chr8:87253048	T/C	cg27223183	chr8:87520930	FAM82B	-0.76	-6.24	-0.46	4.41e-9	Caudate activity during reward;
UCEC	cis	rs58742730	1.000	rs12569673	chr10:115203474	G/T	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.58	4.55	0.35	1.12e-5	Breast cancer;
UCEC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.56	-4.99	-0.38	1.66e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.7	6.05	0.45	1.12e-8	Cognitive function;
UCEC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg00614314	chr15:82944287	LOC80154	0.53	5.02	0.38	1.51e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6723108	0.627	rs6430554	chr2:135638461	C/T	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.58	6.44	0.47	1.57e-9	Prostate cancer;
UCEC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	7.87	0.54	7.17e-13	Tonsillectomy;
UCEC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.74	8.0	0.55	3.4e-13	Menopause (age at onset);
UCEC	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.53	-6.52	-0.47	1.05e-9	Total body bone mineral density;
UCEC	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg24687543	chr11:63912206	MACROD1	0.57	4.87	0.37	2.87e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.62	7.35	0.52	1.26e-11	Schizophrenia;
UCEC	cis	rs12618769	0.597	rs4069739	chr2:99049528	G/C	cg14361474	chr2:99058762	NA	-0.49	-4.83	-0.37	3.43e-6	Bipolar disorder;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16956456	chr5:172483378	C5orf41	0.65	8.33	0.57	5.19e-14	Warfarin maintenance dose;
UCEC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	18.36	0.83	6.96e-40	Chronic sinus infection;
UCEC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.7	7.13	0.51	4.17e-11	Body mass index;
UCEC	cis	rs13401104	0.796	rs60159414	chr2:237119178	T/C	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.51	-4.73	-0.36	5.32e-6	Platelet count;
UCEC	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.88	12.33	0.71	1.91e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.78	-10.22	-0.64	7.27e-19	Mean corpuscular volume;
UCEC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11235843	0.571	rs10898929	chr11:73365695	C/T	cg09185399	chr11:73372479	PLEKHB1	0.57	4.63	0.36	7.82e-6	Hand grip strength;
UCEC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Bipolar disorder;
UCEC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-4.98	-0.38	1.74e-6	Menarche (age at onset);
UCEC	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg05962950	chr11:130786565	SNX19	0.5	5.16	0.39	8.03e-7	Schizophrenia;
UCEC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.72	7.31	0.52	1.56e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg04202892	chr2:111875749	ACOXL	0.45	5.35	0.4	3.38e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg14008862	chr17:28927542	LRRC37B2	0.58	5.14	0.39	8.78e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg22974920	chr21:40686053	BRWD1	0.61	5.38	0.41	2.81e-7	Cognitive function;
UCEC	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24308560	chr3:49941425	MST1R	-0.47	-4.96	-0.38	1.94e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-9.62	-0.62	2.68e-17	Height;
UCEC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.4	4.71	0.36	5.59e-6	Obesity-related traits;
UCEC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.75	-0.43	4.97e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.76	-8.04	-0.55	2.77e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.7	5.74	0.43	5.17e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	7.54	0.53	4.51e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg19041857	chr6:27730383	NA	-0.7	-5.19	-0.39	6.91e-7	Depression;
UCEC	cis	rs6919211	0.842	rs9493690	chr6:133998573	A/G	cg10373887	chr6:134274107	TBPL1	-0.52	-4.51	-0.35	1.31e-5	Coronary artery disease;
UCEC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg12310025	chr6:25882481	NA	-0.51	-4.58	-0.35	9.71e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.1	0.56	1.89e-13	Alzheimer's disease;
UCEC	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.43	-4.61	-0.36	8.69e-6	Dilated cardiomyopathy;
UCEC	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.69	0.36	6.26e-6	Educational attainment;
UCEC	cis	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg17325771	chr7:75508891	RHBDD2	0.48	4.72	0.36	5.4e-6	Eotaxin levels;
UCEC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.31	0.57	5.86e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.83	-11.74	-0.7	7.34e-23	Leprosy;
UCEC	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.93	0.38	2.2e-6	Alzheimer's disease;
UCEC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg03934865	chr2:198174659	NA	-0.44	-5.72	-0.43	5.9e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg01262667	chr19:19385393	TM6SF2	0.5	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg19645103	chr12:69753606	YEATS4	-0.55	-5.0	-0.38	1.62e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.69	8.51	0.57	1.88e-14	Mean platelet volume;
UCEC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.52	-0.41	1.47e-7	Vitiligo;
UCEC	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.58	5.5	0.41	1.63e-7	Uric acid levels;
UCEC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.77	-0.37	4.36e-6	Obesity-related traits;
UCEC	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-8.05	-0.55	2.52e-13	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg18232548	chr7:50535776	DDC	-0.68	-7.66	-0.53	2.32e-12	Body mass index;
UCEC	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg19318889	chr4:1322082	MAEA	0.43	4.74	0.36	4.97e-6	Obesity-related traits;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg05962950	chr11:130786565	SNX19	0.52	5.14	0.39	8.6e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg09120320	chr17:61926383	NA	-0.46	-4.77	-0.37	4.31e-6	Prudent dietary pattern;
UCEC	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	6.1	0.45	9.08e-9	Schizophrenia;
UCEC	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.52	-5.29	-0.4	4.37e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	1.000	rs62331560	chr5:346785	G/C	cg22857025	chr5:266934	NA	-1.16	-5.1	-0.39	1.03e-6	Breast cancer;
UCEC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg03146154	chr1:46216737	IPP	-0.47	-5.09	-0.39	1.06e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.46	5.47	0.41	1.92e-7	Bone mineral density;
UCEC	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.29	-0.56	6.37e-14	Total cholesterol levels;
UCEC	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.68	0.36	6.33e-6	Alzheimer's disease;
UCEC	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-0.69	-6.38	-0.47	2.21e-9	Post bronchodilator FEV1;
UCEC	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.36	-0.76	9.02e-30	Schizophrenia;
UCEC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.61	5.61	0.42	9.98e-8	Red cell distribution width;
UCEC	cis	rs4908768	0.629	rs12410886	chr1:8878809	A/C	cg13081009	chr1:8430745	RERE	0.42	4.71	0.36	5.72e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.45	-5.01	-0.38	1.55e-6	Pulmonary function;
UCEC	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	0.94	10.22	0.64	7.56e-19	Primary sclerosing cholangitis;
UCEC	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.62	5.82	0.43	3.61e-8	Coronary artery disease;
UCEC	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-4.85	-0.37	3.05e-6	Electroencephalogram traits;
UCEC	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.36	-0.76	9.02e-30	Schizophrenia;
UCEC	cis	rs11169225	0.901	rs12372344	chr12:50348359	T/C	cg04450003	chr12:50355995	AQP5	0.85	5.95	0.44	1.89e-8	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.73	0.54	1.55e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.56	5.65	0.42	8.14e-8	Personality dimensions;
UCEC	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.0	13.08	0.73	2.09e-26	Platelet distribution width;
UCEC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.43	4.97	0.38	1.84e-6	Blood protein levels;
UCEC	cis	rs8032158	1.000	rs7176225	chr15:56126857	G/A	cg10433327	chr15:56209506	NEDD4	-0.3	-4.96	-0.38	1.94e-6	Keloid;
UCEC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg04310649	chr10:35416472	CREM	-0.5	-4.96	-0.38	1.88e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2398893	0.774	rs3909256	chr9:96889505	C/T	cg07076509	chr9:96720819	NA	-0.51	-5.25	-0.4	5.11e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-5.19	-0.39	6.9e-7	Height;
UCEC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.43	-4.6	-0.35	8.97e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6761276	0.899	rs11677088	chr2:113835603	A/G	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	6.53	0.47	9.93e-10	Hemoglobin concentration;
UCEC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Morning vs. evening chronotype;
UCEC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	0.45	4.93	0.38	2.18e-6	Longevity;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08809542	chr4:146858263	ZNF827	0.55	6.67	0.48	4.89e-10	Warfarin maintenance dose;
UCEC	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.87	-9.64	-0.62	2.46e-17	Blood metabolite levels;
UCEC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.3	7.55	0.53	4.26e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26207909	chr14:103986467	CKB	0.53	5.8	0.43	3.89e-8	Body mass index;
UCEC	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.73	-6.42	-0.47	1.8e-9	Caudate activity during reward;
UCEC	cis	rs7246967	0.611	rs2885222	chr19:22839944	T/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	6.11e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.51	-0.35	1.3e-5	Parkinson's disease;
UCEC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.69	-7.34	-0.52	1.34e-11	Breast cancer;
UCEC	cis	rs7246967	0.551	rs34907478	chr19:22928831	T/C	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs78487399	0.908	rs4339008	chr2:43834352	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.37	-0.4	3.02e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.72	0.43	5.77e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg04312967	chr16:1597521	IFT140;TMEM204	-0.46	-4.54	-0.35	1.16e-5	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.51	-4.65	-0.36	7.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs925228	0.955	rs12478037	chr2:24141469	T/C	cg13272742	chr2:24272458	FKBP1B	0.6	5.07	0.39	1.2e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg11632617	chr15:75315747	PPCDC	-0.63	-7.21	-0.51	2.75e-11	Blood trace element (Zn levels);
UCEC	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.76	-6.57	-0.48	8.37e-10	Menopause (age at onset);
UCEC	cis	rs10254160	1.000	rs28594984	chr7:112060730	C/T	cg12767726	chr7:112758502	LOC401397	-1.08	-4.9	-0.37	2.49e-6	Parental extreme longevity (95 years and older);
UCEC	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg24851651	chr11:66362959	CCS	-0.4	-5.11	-0.39	9.79e-7	Educational attainment (years of education);
UCEC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.24	-7.51	-0.53	5.14e-12	Diabetic kidney disease;
UCEC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	6.16	0.45	6.56e-9	High light scatter reticulocyte count;
UCEC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04476341	chr5:669733	TPPP	0.43	4.99	0.38	1.69e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.72	7.56	0.53	4e-12	Primary sclerosing cholangitis;
UCEC	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.93	-0.55	5.19e-13	Total cholesterol levels;
UCEC	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.45	-5.02	-0.38	1.48e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.6	7.18	0.51	3.23e-11	Obesity-related traits;
UCEC	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.87	0.54	7.09e-13	Bipolar disorder;
UCEC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.43	0.41	2.23e-7	Prudent dietary pattern;
UCEC	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.59	5.99	0.44	1.51e-8	Colorectal cancer;
UCEC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg24531977	chr5:56204891	C5orf35	-0.51	-4.68	-0.36	6.39e-6	Coronary artery disease;
UCEC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.75	0.36	4.89e-6	Rheumatoid arthritis;
UCEC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg04398451	chr17:18023971	MYO15A	-0.49	-6.03	-0.45	1.24e-8	Total body bone mineral density;
UCEC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs259282	0.605	rs8100423	chr19:33109003	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.55	5.03	0.38	1.41e-6	Schizophrenia;
UCEC	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg14784868	chr12:69753453	YEATS4	0.65	6.36	0.46	2.42e-9	Blood protein levels;
UCEC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.58	5.34	0.4	3.4e-7	Lung cancer;
UCEC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.08	-0.45	1.01e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.66	-5.0	-0.38	1.6e-6	Aortic root size;
UCEC	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	8.79	0.59	3.71e-15	Coffee consumption (cups per day);
UCEC	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.91	-0.38	2.35e-6	Height;
UCEC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.34	-4.69	-0.36	6.18e-6	Crohn's disease;
UCEC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.81	8.98	0.6	1.21e-15	Menopause (age at onset);
UCEC	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg21657780	chr14:105293878	NA	0.52	5.76	0.43	4.66e-8	IgG glycosylation;
UCEC	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg17294928	chr15:75287854	SCAMP5	-0.48	-4.61	-0.36	8.62e-6	Lung cancer;
UCEC	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	6.58	0.48	7.81e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-4.65	-0.36	7.35e-6	Longevity;
UCEC	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-6.64	-0.48	5.62e-10	Hypospadias;
UCEC	cis	rs3015497	0.554	rs8011039	chr14:51091267	C/T	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.36e-6	Mean platelet volume;
UCEC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.57	-8.25	-0.56	8.27e-14	Sense of smell;
UCEC	cis	rs77972916	0.609	rs72790903	chr2:43561985	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.5	-0.35	1.36e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.42	-5.84	-0.43	3.3e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg24562669	chr7:97807699	LMTK2	0.48	5.86	0.43	2.98e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7246967	0.673	rs34425596	chr19:22899779	T/C	cg08271804	chr19:22816896	ZNF492	0.68	6.63	0.48	6.02e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10851411	0.518	rs17767264	chr15:42886656	C/T	cg21293051	chr15:42870591	STARD9	0.73	4.75	0.36	4.81e-6	Glucose homeostasis traits;
UCEC	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.5	4.72	0.36	5.49e-6	Coronary artery disease;
UCEC	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg20916646	chr4:852691	GAK	0.53	4.72	0.36	5.55e-6	Sjögren's syndrome;
UCEC	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Axial length;
UCEC	cis	rs7072216	0.666	rs11189592	chr10:100155642	C/A	cg19567339	chr10:100142640	NA	0.65	8.08	0.55	2.2e-13	Metabolite levels;
UCEC	cis	rs7201929	1.000	rs11644151	chr16:28895660	G/A	cg10436792	chr16:28889110	ATP2A1	0.39	4.71	0.36	5.63e-6	QT interval;
UCEC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.36	-5.55	-0.42	1.27e-7	Ulcerative colitis;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.08	-0.45	9.75e-9	Pubertal anthropometrics;
UCEC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.73	6.86	0.49	1.76e-10	Selective IgA deficiency;
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.39	0.71	1.33e-24	Platelet count;
UCEC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.58	-5.51	-0.41	1.56e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
UCEC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg21053147	chr12:120880522	NA	-0.65	-5.38	-0.41	2.89e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-6.69	-0.48	4.46e-10	Platelet count;
UCEC	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.8	9.32	0.61	1.64e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.96	10.97	0.67	8.09e-21	Colorectal adenoma (advanced);
UCEC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-1.03	-6.85	-0.49	1.84e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.16	0.45	6.56e-9	Bipolar disorder;
UCEC	cis	rs17818399	0.817	rs17767994	chr2:46860079	G/T	cg21681030	chr2:46777652	RHOQ	-0.56	-4.66	-0.36	7e-6	Height;
UCEC	cis	rs8105895	1.000	rs116867513	chr19:22166026	C/T	cg20662725	chr19:22235022	ZNF257	-0.68	-4.52	-0.35	1.27e-5	Body mass index (change over time);
UCEC	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.63	7.33	0.52	1.43e-11	Hip circumference;
UCEC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg06784218	chr1:46089804	CCDC17	0.47	5.79	0.43	4.1e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.12	0.45	8.16e-9	Platelet count;
UCEC	cis	rs17162190	0.698	rs4659442	chr1:26823580	T/G	cg23229016	chr1:26872525	RPS6KA1	0.3	5.21	0.39	6.37e-7	Mean corpuscular volume;
UCEC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg06466757	chr4:1255808	NA	0.46	4.79	0.37	3.97e-6	Obesity-related traits;
UCEC	cis	rs7246967	0.673	rs28787949	chr19:22830356	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.66	-0.36	7.04e-6	Fear of minor pain;
UCEC	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.06	-6.52	-0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	0.9	7.69	0.54	1.95e-12	Red blood cell traits;
UCEC	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.6	-0.35	9.13e-6	Alzheimer's disease (late onset);
UCEC	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.61	5.49	0.41	1.74e-7	Coronary artery disease;
UCEC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.84	9.57	0.62	3.69e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.39	-4.97	-0.38	1.87e-6	Body mass index;
UCEC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.52	-5.07	-0.39	1.18e-6	Breast size;
UCEC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	8.68	0.58	7.1e-15	Monocyte count;
UCEC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.44	-6.22	-0.46	4.81e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.58	-5.11	-0.39	1e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.46	-4.79	-0.37	3.98e-6	Lung cancer;
UCEC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	8.1	0.56	1.95e-13	Total body bone mineral density;
UCEC	cis	rs1046896	0.521	rs3859206	chr17:80693128	G/A	cg19500275	chr17:80737654	TBCD	0.38	4.57	0.35	1.04e-5	Glycated hemoglobin levels;
UCEC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.47	-4.86	-0.37	3.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.6	-5.55	-0.42	1.31e-7	Blood protein levels;
UCEC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.53	5.24	0.4	5.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7088591	0.867	rs4284361	chr10:59779924	C/T	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg19318889	chr4:1322082	MAEA	0.45	4.63	0.36	7.86e-6	Obesity-related traits;
UCEC	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.62	7.03	0.5	7.14e-11	Leprosy;
UCEC	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.47	-6.09	-0.45	9.36e-9	IgG glycosylation;
UCEC	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.38	4.78	0.37	4.15e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2410182	0.615	rs462782	chr21:41193094	A/C	cg06560309	chr21:40720186	HMGN1	0.57	4.7	0.36	5.97e-6	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.67	-7.02	-0.5	7.46e-11	Height;
UCEC	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.58	6.09	0.45	9.37e-9	Schizophrenia;
UCEC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.7	7.71	0.54	1.76e-12	Cognitive function;
UCEC	cis	rs139371	0.713	rs139313	chr22:39499575	G/T	cg15548613	chr22:38610795	MAFF	0.46	4.64	0.36	7.64e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg21231944	chr12:82153410	PPFIA2	-0.44	-4.58	-0.35	9.93e-6	Resting heart rate;
UCEC	cis	rs4253772	0.872	rs4253776	chr22:46629479	C/T	cg09491104	chr22:46646882	C22orf40	0.51	5.2	0.39	6.46e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.52	4.76	0.37	4.5e-6	Menarche (age at onset);
UCEC	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg10381502	chr11:71823885	C11orf51	0.95	4.87	0.37	2.84e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg19041857	chr6:27730383	NA	-0.43	-4.5	-0.35	1.35e-5	Pubertal anthropometrics;
UCEC	cis	rs9341808	0.559	rs7762895	chr6:81061431	C/T	cg08355045	chr6:80787529	NA	0.37	4.5	0.35	1.37e-5	Sitting height ratio;
UCEC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.6	-7.28	-0.52	1.82e-11	Menopause (age at onset);
UCEC	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.65	6.02	0.44	1.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.56	-6.03	-0.45	1.3e-8	Longevity;
UCEC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	0.94	9.97	0.64	3.3e-18	Heart rate;
UCEC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08805041	chr16:621841	PIGQ	-0.33	-4.99	-0.38	1.68e-6	Height;
UCEC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.52	6.36	0.46	2.42e-9	Total body bone mineral density;
UCEC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.49	-4.86	-0.37	2.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.56	5.31	0.4	4e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg06521331	chr12:34319734	NA	-0.62	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs4908768	0.817	rs11587482	chr1:8743195	T/G	cg13081009	chr1:8430745	RERE	0.47	4.77	0.37	4.42e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg05962950	chr11:130786565	SNX19	0.47	4.82	0.37	3.61e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-5.59	-0.42	1.09e-7	Total body bone mineral density;
UCEC	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg20368463	chr18:77673604	PQLC1	0.66	4.83	0.37	3.35e-6	Opioid sensitivity;
UCEC	cis	rs58742730	0.935	rs61865257	chr10:115207259	G/A	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.63	4.63	0.36	7.87e-6	Breast cancer;
UCEC	cis	rs17122693	0.748	rs8014572	chr14:51095780	C/A	cg04730355	chr14:51134070	SAV1	0.77	8.1	0.56	1.99e-13	Cognitive performance;
UCEC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.81	5.61	0.42	9.82e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.09	-6.58	-0.48	7.94e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.55	-5.71	-0.43	5.96e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.42	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-8.05	-0.55	2.6e-13	Body mass index;
UCEC	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.57	-0.35	1.02e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.69	0.42	6.79e-8	Rheumatoid arthritis;
UCEC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg13147721	chr7:65941812	NA	0.94	6.91	0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs1978968	0.763	rs13055106	chr22:18465208	G/A	cg03078520	chr22:18463400	MICAL3	-0.57	-6.5	-0.47	1.17e-9	Presence of antiphospholipid antibodies;
UCEC	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.31e-5	Dementia with Lewy bodies;
UCEC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	0.94	11.93	0.7	2.27e-23	Homoarginine levels;
UCEC	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg14353649	chr10:135191496	PAOX	0.48	5.32	0.4	3.83e-7	Lifespan;
UCEC	cis	rs7106204	1.000	rs12798139	chr11:24220907	A/G	ch.11.24196551F	chr11:24239977	NA	0.66	5.73	0.43	5.56e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.01	6.69	0.48	4.45e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.57	-5.22	-0.4	6e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg23950597	chr19:37808831	NA	-0.86	-5.72	-0.43	5.69e-8	Coronary artery calcification;
UCEC	cis	rs7070678	0.638	rs61849289	chr10:29796378	T/C	cg24350475	chr10:30316933	KIAA1462	0.49	4.89	0.37	2.59e-6	Platelet thrombus formation;
UCEC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.71	5.91	0.44	2.26e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.48	4.54	0.35	1.14e-5	Blood metabolite levels;
UCEC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.46	2.58e-9	Aortic root size;
UCEC	cis	rs6840360	0.541	rs4696251	chr4:152266326	T/C	cg25486957	chr4:152246857	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.65	4.53	0.35	1.23e-5	Aortic root size;
UCEC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.37	-0.47	2.27e-9	Crohn's disease;
UCEC	cis	rs6546886	0.912	rs13006407	chr2:74280275	G/A	cg14702570	chr2:74259524	NA	-0.43	-5.33	-0.4	3.56e-7	Dialysis-related mortality;
UCEC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.9	10.86	0.67	1.49e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.94	11.93	0.7	2.27e-23	Homoarginine levels;
UCEC	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg00122941	chr17:4613640	ARRB2	0.65	5.05	0.38	1.31e-6	Lymphocyte counts;
UCEC	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.61	-6.33	-0.46	2.8e-9	Platelet distribution width;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg15133824	chr2:97523823	ANKRD39	0.6	6.85	0.49	1.91e-10	Schizophrenia;
UCEC	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg14851346	chr12:38532713	NA	-0.47	-4.59	-0.35	9.36e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.08	-10.96	-0.67	8.45e-21	Vitiligo;
UCEC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg04374321	chr14:90722782	PSMC1	0.56	4.76	0.37	4.66e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.42	4.75	0.37	4.71e-6	Total body bone mineral density;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg09682330	chr6:28411287	ZSCAN23	0.5	5.5	0.41	1.66e-7	Pubertal anthropometrics;
UCEC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.54	-5.94	-0.44	1.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.64	7.13	0.51	4.1e-11	Body mass index;
UCEC	cis	rs17106184	1.000	rs12073283	chr1:51219188	C/G	cg07174182	chr1:51127561	FAF1	-0.62	-4.54	-0.35	1.16e-5	Type 2 diabetes;
UCEC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.68	6.25	0.46	4.21e-9	Aortic root size;
UCEC	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg08717414	chr16:71523259	ZNF19	-0.52	-5.13	-0.39	9.03e-7	Blood protein levels;
UCEC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.69	-5.43	-0.41	2.25e-7	Cognitive test performance;
UCEC	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.11	12.02	0.7	1.34e-23	Blood protein levels;
UCEC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	cis	rs4148689	0.904	rs2402204	chr7:117146393	T/C	cg21212505	chr7:117228958	CFTR	-0.41	-4.62	-0.36	8.24e-6	Gout;
UCEC	cis	rs925228	0.955	rs10169690	chr2:24164735	C/G	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg19875535	chr5:140030758	IK	0.44	4.91	0.38	2.44e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1639906	0.729	rs17186614	chr7:2231002	G/A	cg14004847	chr7:1930337	MAD1L1	0.58	4.63	0.36	7.92e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.62	6.38	0.47	2.16e-9	Dental caries;
UCEC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.84	-9.14	-0.6	4.7e-16	Breast cancer;
UCEC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	0.93	8.77	0.59	3.98e-15	Cognitive function;
UCEC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.05	-0.38	1.29e-6	Blood metabolite levels;
UCEC	cis	rs731174	0.797	rs586252	chr1:38155265	G/C	cg06917450	chr1:38156652	C1orf109	-0.58	-6.07	-0.45	1.05e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.56	-5.72	-0.43	5.74e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.83	-9.3	-0.61	1.78e-16	Cognitive function;
UCEC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.76	7.9	0.55	6.13e-13	Sudden cardiac arrest;
UCEC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg26114124	chr12:9217669	LOC144571	0.41	5.08	0.39	1.12e-6	Sjögren's syndrome;
UCEC	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg24803719	chr17:45855879	NA	-0.39	-4.56	-0.35	1.07e-5	IgG glycosylation;
UCEC	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Depression;
UCEC	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.53	6.76	0.49	3.02e-10	Weight;
UCEC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.56	4.85	0.37	3.07e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.93	-7.23	-0.51	2.45e-11	Dupuytren's disease;
UCEC	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.61	7.19	0.51	3.01e-11	Prevalent atrial fibrillation;
UCEC	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.44	4.77	0.37	4.46e-6	Alcoholic chronic pancreatitis;
UCEC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.56	5.62	0.42	9.38e-8	Menopause (age at onset);
UCEC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.5	4.96	0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.56	-5.71	-0.43	5.94e-8	Longevity;Endometriosis;
UCEC	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	0.96	5.94	0.44	1.94e-8	Skin colour saturation;
UCEC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.42	-5.31	-0.4	4e-7	Colorectal cancer;
UCEC	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-0.77	-8.43	-0.57	2.88e-14	Trans fatty acid levels;
UCEC	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.5	-4.97	-0.38	1.88e-6	Platelet distribution width;
UCEC	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	6.27	0.46	3.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07215822	chr6:158701037	NA	-0.66	-5.71	-0.43	6.1e-8	Height;
UCEC	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.65	4.54	0.35	1.16e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg23972785	chr8:11611189	GATA4	-0.35	-4.51	-0.35	1.32e-5	Neuroticism;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.53	-5.79	-0.43	4.09e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.78	-7.84	-0.54	8.3e-13	Mosquito bite size;
UCEC	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.8	8.79	0.59	3.56e-15	Blood metabolite levels;
UCEC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.14	-0.45	7.21e-9	Parkinson's disease;
UCEC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.58	-5.18	-0.39	7.19e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.48	-5.06	-0.39	1.22e-6	Longevity;
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-5.25	-0.4	5.31e-7	Platelet count;
UCEC	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.77	0.43	4.58e-8	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg06037631	chr2:74942369	NA	-0.59	-6.91	-0.5	1.4e-10	Breast cancer;
UCEC	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	5.01	0.38	1.53e-6	Bone mineral density;
UCEC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-4.94	-0.38	2.08e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.45	4.93	0.38	2.2e-6	Pulse pressure;
UCEC	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.5	5.04	0.38	1.37e-6	Colorectal cancer;
UCEC	trans	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg02900749	chr2:68251473	NA	-0.99	-7.31	-0.52	1.6e-11	Pursuit maintenance gain;
UCEC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.62	-0.48	6.35e-10	Coffee consumption (cups per day);
UCEC	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.6	-6.14	-0.45	7.48e-9	C-reactive protein levels;
UCEC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.53	0.42	1.4e-7	Rheumatoid arthritis;
UCEC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.27	-0.51	2e-11	Eye color traits;
UCEC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.41	-4.59	-0.35	9.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg20399509	chr21:47717575	C21orf57	-0.46	-4.95	-0.38	2.02e-6	Testicular germ cell tumor;
UCEC	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg19678392	chr7:94953810	PON1	-0.58	-5.7	-0.43	6.45e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.88	-0.37	2.72e-6	Breast cancer;
UCEC	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg01426195	chr3:39028469	NA	0.53	5.9	0.44	2.45e-8	Handedness;
UCEC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.67	-7.45	-0.52	7.55e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.57	5.42	0.41	2.33e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4372836	0.504	rs6737027	chr2:29070805	A/G	cg09522027	chr2:28974177	PPP1CB	0.7	7.53	0.53	4.61e-12	Body mass index;
UCEC	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-9.98	-0.64	3.22e-18	Electrocardiographic conduction measures;
UCEC	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg24169773	chr3:122142474	KPNA1	-0.73	-4.79	-0.37	4.01e-6	LDL cholesterol levels;
UCEC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.73	8.58	0.58	1.27e-14	Menarche (age at onset);
UCEC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.63	5.82	0.43	3.63e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.66	7.54	0.53	4.38e-12	Hip circumference;
UCEC	cis	rs17433710	0.500	rs10917583	chr1:162630894	C/T	cg19264028	chr1:162630153	DDR2	-0.76	-5.13	-0.39	9.02e-7	Dupuytren's disease;
UCEC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg20965017	chr5:231967	SDHA	-0.66	-5.98	-0.44	1.62e-8	Breast cancer;
UCEC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.69	7.0	0.5	8.45e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12137294	0.866	rs1172151	chr1:205221659	A/C	cg15542880	chr1:205114634	DSTYK	0.39	4.56	0.35	1.05e-5	Red cell distribution width;
UCEC	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-5.09	-0.39	1.1e-6	Height;
UCEC	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	7.07	0.5	5.71e-11	Coronary artery disease;
UCEC	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.92	0.59	1.68e-15	Alzheimer's disease;
UCEC	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg03060546	chr3:49711283	APEH	0.68	4.89	0.37	2.58e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.48	-5.72	-0.43	5.85e-8	Subjective well-being;
UCEC	cis	rs2398893	0.774	rs10993047	chr9:96846500	C/T	cg07076509	chr9:96720819	NA	-0.45	-4.75	-0.36	4.89e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg21827317	chr3:136751795	NA	0.49	5.52	0.41	1.48e-7	Neuroticism;Schizophrenia;
UCEC	cis	rs34486957	0.600	rs35622266	chr14:60047121	C/A	cg12189551	chr14:60952945	C14orf39	0.36	4.51	0.35	1.34e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.86	-9.64	-0.62	2.44e-17	Cognitive function;
UCEC	cis	rs1712517	0.873	rs7894240	chr10:105000369	T/C	cg05636881	chr10:105038444	INA	-0.42	-5.07	-0.39	1.21e-6	Migraine;
UCEC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.65	-0.36	7.37e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10242455	0.717	rs776745	chr7:99291337	T/G	cg07715041	chr7:99302981	CYP3A7	0.47	4.83	0.37	3.33e-6	Blood metabolite levels;
UCEC	cis	rs2179367	0.959	rs4897125	chr6:149766208	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.37	-4.72	-0.36	5.43e-6	Dupuytren's disease;
UCEC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg04154034	chr17:28927549	LRRC37B2	0.82	5.2	0.39	6.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.19	0.45	5.75e-9	Cognitive test performance;
UCEC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg06238570	chr21:40685208	BRWD1	0.76	7.11	0.51	4.74e-11	Cognitive function;
UCEC	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg10503236	chr1:231470652	EXOC8	-0.41	-4.76	-0.37	4.68e-6	Hemoglobin concentration;
UCEC	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.99	-7.02	-0.5	7.8e-11	Platelet distribution width;
UCEC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.56	-5.49	-0.41	1.72e-7	Aortic root size;
UCEC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg22974920	chr21:40686053	BRWD1	-0.52	-4.66	-0.36	7.09e-6	Cognitive function;
UCEC	cis	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg17469321	chr7:55412551	NA	0.68	5.98	0.44	1.65e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.6	7.06	0.5	6.17e-11	Iron status biomarkers (transferrin levels);
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.53	-6.03	-0.45	1.25e-8	Pubertal anthropometrics;
UCEC	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs61776719	0.875	rs28435150	chr1:38407014	C/T	cg18451016	chr1:38461880	NA	0.67	7.45	0.52	7.15e-12	Coronary artery disease;
UCEC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.46	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	4.97	0.38	1.84e-6	Breast cancer;
UCEC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.47	4.77	0.37	4.42e-6	Body mass index;
UCEC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg07636037	chr3:49044803	WDR6	-0.61	-4.82	-0.37	3.61e-6	Menarche (age at onset);
UCEC	cis	rs7870753	0.838	rs7858287	chr9:99204516	A/C	cg25260653	chr9:99212216	HABP4	0.58	5.64	0.42	8.35e-8	Height;
UCEC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.67	6.42	0.47	1.75e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.45	0.41	2.09e-7	Prudent dietary pattern;
UCEC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	7.02	0.5	7.44e-11	Homoarginine levels;
UCEC	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.54	0.47	9.61e-10	Personality dimensions;
UCEC	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.79	-7.14	-0.51	3.9e-11	Menopause (age at onset);
UCEC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg03609598	chr5:56110824	MAP3K1	0.72	5.31	0.4	3.95e-7	Initial pursuit acceleration;
UCEC	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.5	0.53	5.49e-12	Bipolar disorder;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg01013738	chr7:1149705	C7orf50	-0.5	-4.78	-0.37	4.24e-6	Longevity;Endometriosis;
UCEC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	0.92	12.97	0.73	4.05e-26	Homoarginine levels;
UCEC	cis	rs11118844	0.744	rs11118857	chr1:221952209	C/T	cg04222084	chr1:221915650	DUSP10	-0.78	-5.45	-0.41	2.1e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg14196676	chr1:1911069	KIAA1751	-0.54	-5.86	-0.44	2.89e-8	Severe influenza A (H1N1) infection;
UCEC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-5.3	-0.4	4.23e-7	Height;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.48	-5.15	-0.39	8.2e-7	Pubertal anthropometrics;
UCEC	cis	rs565229	0.714	rs528090	chr11:122100324	T/C	cg14126608	chr11:122846540	NA	-0.63	-4.53	-0.35	1.19e-5	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg19041857	chr6:27730383	NA	-0.45	-4.58	-0.35	9.85e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.9	10.86	0.67	1.49e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2970992	0.728	rs1543103	chr2:101326223	G/T	cg01042948	chr2:101319752	NA	0.56	5.94	0.44	1.99e-8	Educational attainment;
UCEC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.66	6.06	0.45	1.08e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	0.98	5.26	0.4	5.11e-7	Thyroid stimulating hormone;
UCEC	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg20637307	chr2:213403960	ERBB4	0.76	8.16	0.56	1.39e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg23719950	chr11:63933701	MACROD1	-0.66	-4.56	-0.35	1.05e-5	Mean platelet volume;
UCEC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.49	5.54	0.42	1.36e-7	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
UCEC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.94	-0.38	2.09e-6	Myopia;Myopia (pathological);
UCEC	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg09872104	chr7:134855509	C7orf49	-1.05	-6.99	-0.5	8.78e-11	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs3743832	1.000	rs9929235	chr16:9192298	G/A	cg08831531	chr16:9218945	NA	-0.48	-5.01	-0.38	1.57e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.69	7.37	0.52	1.13e-11	Itch intensity from mosquito bite;
UCEC	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.59	6.62	0.48	6.22e-10	Mean platelet volume;
UCEC	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.29	5.84	0.43	3.2e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.84e-6	Breast cancer;
UCEC	cis	rs7113850	0.541	rs56732861	chr11:24234333	C/G	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs9393294	1.000	rs9393303	chr6:22501726	G/A	cg15541384	chr6:21886458	FLJ22536	-0.69	-4.64	-0.36	7.69e-6	Mean platelet volume;
UCEC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.2	0.51	2.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11048434	1.000	rs12824212	chr12:9153417	A/G	cg26114124	chr12:9217669	LOC144571	0.47	5.73	0.43	5.57e-8	Sjögren's syndrome;
UCEC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.82	7.96	0.55	4.23e-13	Cognitive function;
UCEC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.89	10.63	0.66	6.04e-20	Breast cancer;
UCEC	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.92	-5.84	-0.43	3.18e-8	Body mass index;
UCEC	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.91	-11.78	-0.7	5.51e-23	Height;
UCEC	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.47	4.76	0.37	4.51e-6	Breast cancer;
UCEC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-6.2	-0.46	5.3e-9	Gut microbiome composition (summer);
UCEC	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.56	5.65	0.42	8.01e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.35	-4.56	-0.35	1.08e-5	Type 2 diabetes;
UCEC	cis	rs28386778	0.669	rs4968674	chr17:62015048	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.71	-6.63	-0.48	6.01e-10	Prudent dietary pattern;
UCEC	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-6.61	-0.48	6.59e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	7.53	0.53	4.64e-12	Coronary artery disease;
UCEC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.36	-0.4	3.18e-7	Bladder cancer;
UCEC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.97	13.75	0.75	3.58e-28	Bone mineral density;
UCEC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg11871910	chr12:69753446	YEATS4	1.06	13.41	0.74	2.74e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-5.53	-0.42	1.42e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg12024160	chr4:1254474	NA	0.45	4.62	0.36	8.22e-6	Longevity;
UCEC	cis	rs9341808	0.538	rs615585	chr6:80986153	T/C	cg08355045	chr6:80787529	NA	-0.33	-4.58	-0.35	9.91e-6	Sitting height ratio;
UCEC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.62	-5.79	-0.43	4.19e-8	Dental caries;
UCEC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.57	5.13	0.39	9.18e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.86	9.53	0.62	4.74e-17	Breast cancer;
UCEC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg01689657	chr7:91764605	CYP51A1	0.43	4.89	0.37	2.6e-6	Breast cancer;
UCEC	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.33	-0.4	3.55e-7	Metabolite levels;
UCEC	cis	rs12618769	0.625	rs61180742	chr2:99148078	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.56	-0.35	1.07e-5	Bipolar disorder;
UCEC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-5.37	-0.4	3.05e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg23815491	chr16:72088622	HP	0.37	4.64	0.36	7.74e-6	Fibrinogen levels;
UCEC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.54	6.37	0.47	2.3e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg13695892	chr22:41940480	POLR3H	-0.46	-4.83	-0.37	3.36e-6	Vitiligo;
UCEC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.5	5.32	0.4	3.74e-7	Cognitive test performance;
UCEC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg04553112	chr3:125709451	NA	-0.72	-5.05	-0.38	1.32e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.89e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.56	5.73	0.43	5.38e-8	Prostate cancer;
UCEC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg11569703	chr11:65557185	OVOL1	0.46	5.72	0.43	5.87e-8	Acne (severe);
UCEC	cis	rs7607369	0.536	rs6436091	chr2:219669141	T/C	cg02176678	chr2:219576539	TTLL4	-0.52	-5.33	-0.4	3.68e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg19743168	chr1:23544995	NA	0.46	6.02	0.44	1.35e-8	Height;
UCEC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg00339695	chr16:24857497	SLC5A11	-0.55	-5.12	-0.39	9.28e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7307889	0.546	rs10160866	chr12:6014627	G/T	cg23245485	chr12:6484219	SCNN1A	0.52	4.76	0.37	4.52e-6	Obesity-related traits;
UCEC	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.5e-6	Aortic root size;
UCEC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs1712517	0.838	rs1891293	chr10:105001797	C/T	cg05636881	chr10:105038444	INA	-0.45	-5.62	-0.42	9.09e-8	Migraine;
UCEC	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.88	-7.21	-0.51	2.72e-11	Coronary artery calcification;
UCEC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.15	0.56	1.44e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.6	5.39	0.41	2.77e-7	Morning vs. evening chronotype;
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.49	5.37	0.41	2.98e-7	Longevity;Endometriosis;
UCEC	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.75	-8.61	-0.58	1.01e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.85	-0.43	3.02e-8	Breast cancer;
UCEC	cis	rs731174	0.797	rs679742	chr1:38156190	C/G	cg06917450	chr1:38156652	C1orf109	-0.61	-5.66	-0.42	7.71e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-10.62	-0.66	6.54e-20	Vitiligo;
UCEC	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.59	6.16	0.45	6.66e-9	HDL cholesterol;
UCEC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg21770322	chr7:97807741	LMTK2	0.78	12.36	0.71	1.61e-24	Breast cancer;
UCEC	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg19468946	chr17:37922297	IKZF3	0.42	4.63	0.36	8.14e-6	Self-reported allergy;
UCEC	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.78	5.03	0.38	1.39e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs78487399	0.808	rs7567535	chr2:43668261	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg22974920	chr21:40686053	BRWD1	-0.47	-4.66	-0.36	7.06e-6	Menarche (age at onset);
UCEC	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg21017887	chr14:105400489	NA	0.71	9.01	0.6	9.76e-16	Rheumatoid arthritis;
UCEC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.44	-5.12	-0.39	9.26e-7	Platelet distribution width;
UCEC	cis	rs883565	0.569	rs784508	chr3:39166484	C/T	cg01426195	chr3:39028469	NA	0.62	7.39	0.52	1.01e-11	Handedness;
UCEC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.7	7.75	0.54	1.37e-12	Ewing sarcoma;
UCEC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.79	7.61	0.53	3.02e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg20243544	chr17:37824526	PNMT	0.47	5.17	0.39	7.69e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.52	-5.99	-0.44	1.51e-8	Monocyte percentage of white cells;
UCEC	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.55	-6.59	-0.48	7.25e-10	Inhibitory control;
UCEC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.51	-4.85	-0.37	3.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	4.96	0.38	1.93e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.34	-4.97	-0.38	1.84e-6	Schizophrenia;
UCEC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.54	-5.91	-0.44	2.27e-8	Menarche (age at onset);
UCEC	cis	rs925550	0.867	rs309390	chr4:123610730	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	-0.58	-5.42	-0.41	2.37e-7	Primary biliary cholangitis;
UCEC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.77	8.23	0.56	9.09e-14	Parkinson's disease;
UCEC	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	0.64	4.63	0.36	7.83e-6	Dental caries;
UCEC	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.8	6.78	0.49	2.77e-10	Menopause (age at onset);
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.81	9.53	0.62	4.56e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.71	6.35	0.46	2.54e-9	Subjective well-being;
UCEC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs8105895	1.000	rs1849004	chr19:22142455	A/C	cg02912127	chr19:22235281	ZNF257	-0.59	-4.86	-0.37	2.95e-6	Body mass index (change over time);
UCEC	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	6.12	0.45	8.24e-9	Joint mobility (Beighton score);
UCEC	cis	rs883565	0.771	rs1053516	chr3:39137883	G/A	cg01426195	chr3:39028469	NA	-0.75	-9.6	-0.62	3.1e-17	Handedness;
UCEC	cis	rs2795502	0.630	rs2914988	chr10:43509354	A/T	cg11150807	chr10:43354902	NA	0.75	4.66	0.36	7.01e-6	Blood protein levels;
UCEC	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.63	5.88	0.44	2.59e-8	Platelet count;
UCEC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	0.83	5.46	0.41	2e-7	Alzheimer's disease;
UCEC	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg13683864	chr3:40499215	RPL14	1.14	16.42	0.8	4.58e-35	Renal cell carcinoma;
UCEC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.46	4.66	0.36	6.89e-6	Schizophrenia;
UCEC	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.49e-8	Depression;
UCEC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg12024160	chr4:1254474	NA	0.64	7.57	0.53	3.88e-12	Obesity-related traits;
UCEC	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.6	-5.26	-0.4	4.93e-7	Systolic blood pressure;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg09737314	chr17:6899359	ALOX12	0.47	5.54	0.42	1.37e-7	Tonsillectomy;
UCEC	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.44	-0.41	2.22e-7	Birth weight;
UCEC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.8	5.2	0.39	6.65e-7	LDL cholesterol;
UCEC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.59	5.19	0.39	6.72e-7	Breast cancer;
UCEC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-6.91	-0.49	1.4e-10	Coronary artery disease;
UCEC	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg03456212	chr7:26904342	SKAP2	-0.61	-4.53	-0.35	1.22e-5	Type 1 diabetes;
UCEC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg05072774	chr3:49840536	C3orf54	-0.58	-5.23	-0.4	5.6e-7	Resting heart rate;
UCEC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.95	10.95	0.67	8.63e-21	Cognitive function;
UCEC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.69	6.44	0.47	1.6e-9	Aortic root size;
UCEC	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.62	6.84	0.49	1.98e-10	Height;
UCEC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg18016565	chr1:150552671	MCL1	0.44	4.55	0.35	1.1e-5	Melanoma;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg20119798	chr7:94954144	PON1	0.64	6.64	0.48	5.56e-10	Paraoxonase activity;
UCEC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	6.86	0.49	1.79e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.57	5.99	0.44	1.55e-8	Mean platelet volume;
UCEC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg03711944	chr11:47377212	SPI1	-0.48	-4.51	-0.35	1.31e-5	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg02820040	chr2:241836501	C2orf54	-0.4	-5.01	-0.38	1.57e-6	Urinary metabolites;
UCEC	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.83	8.82	0.59	3.14e-15	Blood protein levels;
UCEC	cis	rs1712517	0.844	rs4918003	chr10:105044157	C/T	cg05636881	chr10:105038444	INA	0.5	6.33	0.46	2.79e-9	Migraine;
UCEC	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-6.88	-0.49	1.6e-10	Coffee consumption (cups per day);
UCEC	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.56	-6.32	-0.46	3.01e-9	Crohn's disease;
UCEC	cis	rs10940138	0.720	rs2372188	chr5:67233704	T/C	ch.5.1281357F	chr5:67228439	NA	0.56	5.16	0.39	7.87e-7	Menarche (age at onset);
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.82	0.59	3.13e-15	Platelet count;
UCEC	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.58	4.71	0.36	5.69e-6	Eosinophilic esophagitis;
UCEC	cis	rs58722170	0.610	rs55884510	chr1:38068943	G/A	cg17933807	chr1:38061675	GNL2	-0.59	-5.02	-0.38	1.48e-6	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.69	6.78	0.49	2.77e-10	Tonsillectomy;
UCEC	cis	rs9467773	1.000	rs6918854	chr6:26577924	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.68	7.46	0.52	7.07e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.57	-0.35	1.02e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.7	7.08	0.5	5.59e-11	Primary sclerosing cholangitis;
UCEC	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.9	7.51	0.53	5.27e-12	Cerebrospinal P-tau181p levels;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg00618725	chr10:131265159	MGMT	0.65	6.72	0.48	3.64e-10	Schizophrenia;
UCEC	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg17534202	chr9:96721102	NA	-0.45	-4.8	-0.37	3.82e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	9.89	0.63	5.26e-18	Migraine;Coronary artery disease;
UCEC	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7246967	0.932	rs35687548	chr19:23029147	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.47	4.77	0.37	4.31e-6	Blood metabolite levels;
UCEC	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.7	8.24	0.56	8.81e-14	Total cholesterol levels;
UCEC	cis	rs6893207	1.000	rs76759465	chr5:16406618	T/C	cg11584519	chr5:16175867	MARCH11	0.66	4.83	0.37	3.44e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.86	-0.37	3.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.32	-0.46	3.02e-9	Prudent dietary pattern;
UCEC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.79	7.08	0.5	5.57e-11	Red cell distribution width;
UCEC	cis	rs7246967	0.544	rs400275	chr19:23015856	T/A	cg05241461	chr19:22816980	ZNF492	0.49	4.79	0.37	4.09e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg22166914	chr1:53195759	ZYG11B	0.46	4.62	0.36	8.32e-6	Monocyte count;
UCEC	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.71	7.09	0.5	5.28e-11	Mosquito bite size;
UCEC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg09165964	chr15:75287851	SCAMP5	0.51	5.96	0.44	1.77e-8	Breast cancer;
UCEC	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.46	4.73	0.36	5.12e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7804356	0.859	rs2391362	chr7:26907123	T/C	cg03456212	chr7:26904342	SKAP2	-0.62	-4.61	-0.36	8.64e-6	Type 1 diabetes;
UCEC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.59	5.88	0.44	2.65e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs7870753	0.628	rs2406004	chr9:99193210	G/A	cg25260653	chr9:99212216	HABP4	0.54	5.1	0.39	1.03e-6	Height;
UCEC	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.62	6.39	0.47	2.09e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.88e-8	Red blood cell count;
UCEC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.83	-0.37	3.44e-6	Pulmonary function;
UCEC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.72	6.13	0.45	7.77e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9467773	1.000	rs6918360	chr6:26577867	A/T	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.58	-0.35	1e-5	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.66	0.42	7.77e-8	Height;
UCEC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg13147721	chr7:65941812	NA	-0.74	-5.01	-0.38	1.56e-6	Diabetic kidney disease;
UCEC	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.94	10.08	0.64	1.67e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.54	6.05	0.45	1.15e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.52	6.07	0.45	1.06e-8	Longevity;
UCEC	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.42	-4.7	-0.36	5.93e-6	Vitiligo;
UCEC	cis	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09386303	chr12:48551862	ASB8	-0.47	-4.8	-0.37	3.81e-6	Migraine with aura;
UCEC	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg02158880	chr13:53174818	NA	0.51	6.24	0.46	4.45e-9	Lewy body disease;
UCEC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.78	6.37	0.47	2.23e-9	Gut microbiome composition (summer);
UCEC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg13753209	chr17:57696993	CLTC	0.48	4.7	0.36	5.87e-6	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.09e-6	Prudent dietary pattern;
UCEC	cis	rs11718455	0.585	rs11710802	chr3:43930155	T/G	cg08738300	chr3:44038990	NA	0.54	4.72	0.36	5.39e-6	Coronary artery disease;
UCEC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.47	-4.93	-0.38	2.24e-6	IgG glycosylation;
UCEC	cis	rs6820391	0.816	rs1002824	chr4:54445980	A/C	cg04173182	chr4:54446035	LNX1	-0.38	-4.66	-0.36	7e-6	Cervical artery dissection;
UCEC	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	6.55	0.48	8.88e-10	Total body bone mineral density;
UCEC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.64e-7	Headache;
UCEC	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	0.49	5.03	0.38	1.38e-6	P wave duration;
UCEC	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	8.37	0.57	4.15e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.82	-10.33	-0.65	3.73e-19	White blood cell count (basophil);
UCEC	cis	rs12136530	0.774	rs4912098	chr1:19787686	G/A	cg25599739	chr1:19403133	UBR4	-0.59	-4.96	-0.38	1.9e-6	Lead levels in blood;
UCEC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.06	0.38	1.26e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.55	4.59	0.35	9.31e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg26721908	chr21:47610096	LSS	-0.37	-4.65	-0.36	7.39e-6	Testicular germ cell tumor;
UCEC	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.74	7.57	0.53	3.83e-12	Breast cancer;
UCEC	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.2	8.46	0.57	2.48e-14	Atopic dermatitis;
UCEC	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.25	0.4	5.16e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs12540874	0.524	rs4947684	chr7:50637799	G/A	cg18232548	chr7:50535776	DDC	-0.46	-4.54	-0.35	1.16e-5	Systemic sclerosis;
UCEC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-0.98	-12.55	-0.72	5.23e-25	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.47	0.41	1.93e-7	Breast cancer;
UCEC	cis	rs4372836	0.715	rs66904522	chr2:29080892	A/C	cg09522027	chr2:28974177	PPP1CB	0.83	9.07	0.6	7.03e-16	Body mass index;
UCEC	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.97	6.02	0.44	1.32e-8	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg05660106	chr1:15850417	CASP9	0.51	4.77	0.37	4.38e-6	Systolic blood pressure;
UCEC	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg24562669	chr7:97807699	LMTK2	0.41	5.04	0.38	1.38e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.8	0.49	2.5e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7212590	0.581	rs28539312	chr17:57834602	A/C	cg10252138	chr17:58120427	NA	-0.67	-4.59	-0.35	9.5e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg24675658	chr1:53192096	ZYG11B	0.76	8.04	0.55	2.73e-13	Monocyte count;
UCEC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.62	-6.7	-0.48	4.05e-10	Initial pursuit acceleration;
UCEC	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.4	-5.01	-0.38	1.53e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.66	7.2	0.51	2.9e-11	Body mass index (adult);
UCEC	cis	rs11169225	0.901	rs12372344	chr12:50348359	T/C	cg23855989	chr12:50355821	AQP5	0.96	6.63	0.48	5.98e-10	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.76	-6.54	-0.47	9.41e-10	Alzheimer's disease;
UCEC	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg09149842	chr20:31351091	DNMT3B	-0.42	-4.72	-0.36	5.47e-6	Ulcerative colitis;
UCEC	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.07	-0.64	1.85e-18	Height;
UCEC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.64	5.61	0.42	9.65e-8	Aortic root size;
UCEC	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg19875535	chr5:140030758	IK	0.43	4.84	0.37	3.24e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.51	-5.85	-0.43	3.09e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg17971929	chr21:40555470	PSMG1	0.81	8.34	0.57	5.01e-14	Cognitive function;
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.93	0.59	1.57e-15	Platelet count;
UCEC	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs1468333	0.964	rs2350306	chr5:137512178	G/A	cg07848042	chr5:137667509	CDC25C	-0.46	-4.74	-0.36	5.1e-6	Resting heart rate;
UCEC	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.78	-6.84	-0.49	2.01e-10	Caudate activity during reward;
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.4	-0.41	2.64e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg10503236	chr1:231470652	EXOC8	-0.41	-4.91	-0.38	2.39e-6	Hemoglobin concentration;
UCEC	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg05623727	chr3:50126028	RBM5	-0.34	-5.13	-0.39	9.1e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.78	8.48	0.57	2.22e-14	Longevity;Endometriosis;
UCEC	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.55	-5.52	-0.41	1.51e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg01262667	chr19:19385393	TM6SF2	-0.51	-7.18	-0.51	3.25e-11	Tonsillectomy;
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg21856205	chr7:94953877	PON1	-0.53	-4.82	-0.37	3.62e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6723108	0.627	rs4954197	chr2:135662244	G/A	cg07169764	chr2:136633963	MCM6	0.48	4.62	0.36	8.23e-6	Type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03956833	chr1:1051711	C1orf159	0.55	6.9	0.49	1.48e-10	Warfarin maintenance dose;
UCEC	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	5.01	0.38	1.51e-6	Non-small cell lung cancer;
UCEC	cis	rs17122693	0.551	rs3015456	chr14:51059923	T/C	cg04730355	chr14:51134070	SAV1	0.73	8.33	0.57	5.2e-14	Cognitive performance;
UCEC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.47	5.28	0.4	4.62e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.77	-0.49	2.85e-10	Obesity-related traits;
UCEC	cis	rs7165102	1.000	rs2727099	chr15:66063428	C/T	cg11164506	chr15:66649558	TIPIN	-0.33	-4.62	-0.36	8.36e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.59	4.63	0.36	8.14e-6	Longevity;
UCEC	cis	rs13095912	0.962	rs1568664	chr3:185312231	T/C	cg11274856	chr3:185301563	NA	0.56	7.39	0.52	1.05e-11	Systolic blood pressure;
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg19678392	chr7:94953810	PON1	-0.56	-5.13	-0.39	8.99e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.65	4.54	0.35	1.16e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9810890	0.764	rs9831652	chr3:128561127	G/A	cg11901034	chr3:128598214	ACAD9	-0.61	-5.4	-0.41	2.66e-7	Dental caries;
UCEC	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.67	-5.8	-0.43	3.99e-8	Obesity-related traits;
UCEC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.51	-5.65	-0.42	8.09e-8	Lung cancer;
UCEC	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.62	-6.09	-0.45	9.25e-9	Metabolite levels;
UCEC	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.46	-4.63	-0.36	8.08e-6	Height;
UCEC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg17077180	chr1:38461687	NA	0.47	4.57	0.35	1.01e-5	Coronary artery disease;
UCEC	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.41	-4.78	-0.37	4.26e-6	Homocysteine levels;
UCEC	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.56	-4.94	-0.38	2.14e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg05342682	chr7:94953680	PON1	-0.47	-5.32	-0.4	3.72e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs925550	0.932	rs6534358	chr4:123595191	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.64	-5.78	-0.43	4.27e-8	Primary biliary cholangitis;
UCEC	cis	rs12681287	0.752	rs2917557	chr8:87314071	C/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.27	-0.46	3.72e-9	Caudate activity during reward;
UCEC	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	7.36	0.52	1.21e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.45	-4.71	-0.36	5.73e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8105895	1.000	rs8105895	chr19:22215457	C/T	cg24175803	chr19:22235144	ZNF257	-0.5	-4.61	-0.36	8.81e-6	Body mass index (change over time);
UCEC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.73	6.94	0.5	1.14e-10	Aortic root size;
UCEC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.58	5.68	0.42	6.92e-8	Blood protein levels;
UCEC	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.39	-4.72	-0.36	5.41e-6	Cutaneous nevi;
UCEC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg07596299	chr11:71824057	C11orf51	0.93	4.72	0.36	5.46e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.76e-17	Menopause (age at onset);
UCEC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.23	-15.39	-0.79	1.9e-32	Breast cancer;
UCEC	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.12	-0.6	5.33e-16	Height;
UCEC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg08805041	chr16:621841	PIGQ	-0.32	-4.64	-0.36	7.56e-6	Height;
UCEC	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	5.32	0.4	3.83e-7	Alzheimer's disease;
UCEC	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.63	-7.93	-0.55	5.09e-13	Corneal structure;
UCEC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.56	-5.12	-0.39	9.4e-7	Systemic lupus erythematosus;
UCEC	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.59	-6.85	-0.49	1.86e-10	Bipolar disorder;
UCEC	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.35	-4.6	-0.35	9.01e-6	Metabolite levels;
UCEC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg05738196	chr6:26577821	NA	0.6	6.49	0.47	1.24e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.96	0.44	1.77e-8	Breast cancer;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg01256987	chr12:42539512	GXYLT1	0.4	4.71	0.36	5.61e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.82	-0.37	3.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg20119798	chr7:94954144	PON1	-0.49	-4.64	-0.36	7.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.6	-0.48	7.08e-10	Morning vs. evening chronotype;
UCEC	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.79	8.88	0.59	2.16e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.35	-5.83	-0.43	3.32e-8	Diastolic blood pressure;
UCEC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg22563815	chr15:78856949	CHRNA5	0.39	5.0	0.38	1.62e-6	Sudden cardiac arrest;
UCEC	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.64	7.07	0.5	5.83e-11	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21113776	chr7:2499915	NA	-0.39	-4.74	-0.36	4.94e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.44	-4.75	-0.36	4.75e-6	Pediatric non-alcoholic fatty liver disease activity score;
UCEC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg04374321	chr14:90722782	PSMC1	0.56	4.76	0.37	4.66e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	13.81	0.75	2.49e-28	Chronic sinus infection;
UCEC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.69	-0.36	6.27e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.36	-0.46	2.47e-9	Parkinson's disease;
UCEC	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.11	-0.45	8.61e-9	Aortic root size;
UCEC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg05962950	chr11:130786565	SNX19	0.75	7.07	0.5	5.7e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.74	6.76	0.49	3.05e-10	Lymphocyte counts;
UCEC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.45	-4.81	-0.37	3.73e-6	Lymphocyte counts;
UCEC	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.81	9.45	0.61	7.45e-17	Ewing sarcoma;
UCEC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-10.61	-0.66	6.79e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	7.89	0.55	6.23e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13683864	chr3:40499215	RPL14	-0.96	-9.74	-0.63	1.35e-17	Renal cell carcinoma;
UCEC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.62	-6.22	-0.46	4.82e-9	Blood metabolite levels;
UCEC	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.12	0.51	4.47e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.05	-0.38	1.3e-6	Aortic root size;
UCEC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.82	-9.41	-0.61	9.2e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg19413350	chr8:57351067	NA	-0.41	-4.85	-0.37	3.15e-6	Obesity-related traits;
UCEC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Blood protein levels;
UCEC	cis	rs883565	0.569	rs1274972	chr3:39161456	G/A	cg01426195	chr3:39028469	NA	-0.63	-7.61	-0.53	3.01e-12	Handedness;
UCEC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.97	12.45	0.72	9.42e-25	Multiple sclerosis;
UCEC	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg06562184	chr8:19319451	CSGALNACT1	0.48	4.99	0.38	1.68e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.87	8.43	0.57	2.94e-14	Breast cancer;
UCEC	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.75	0.49	3.19e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.83	4.72	0.36	5.37e-6	Diabetic retinopathy;
UCEC	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	5.07	0.39	1.2e-6	Response to antipsychotic treatment;
UCEC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.76e-17	Menopause (age at onset);
UCEC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.92	0.75	1.27e-28	Height;
UCEC	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.52	4.9	0.37	2.46e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.59	6.6	0.48	7.14e-10	Monocyte percentage of white cells;
UCEC	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.75	-7.13	-0.51	4.31e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-1.19	-8.55	-0.58	1.43e-14	Lung disease severity in cystic fibrosis;
UCEC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.45	5.08	0.39	1.14e-6	Prudent dietary pattern;
UCEC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.6	6.6	0.48	6.95e-10	Resting heart rate;
UCEC	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg04155231	chr12:9217510	LOC144571	0.39	5.04	0.38	1.37e-6	Sjögren's syndrome;
UCEC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg04155289	chr7:94953770	PON1	-0.48	-4.55	-0.35	1.11e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.46	4.62	0.36	8.3e-6	Menarche (age at onset);
UCEC	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	7.07	0.5	5.95e-11	Motion sickness;
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.7	8.44	0.57	2.81e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg00105475	chr2:10696890	NA	0.43	5.4	0.41	2.56e-7	Prostate cancer;
UCEC	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.74	7.0	0.5	8.28e-11	Bladder cancer;
UCEC	cis	rs2996428	0.709	rs6424052	chr1:3713746	A/G	cg13057898	chr1:3703894	LRRC47	0.54	5.09	0.39	1.09e-6	Red cell distribution width;
UCEC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.52	0.41	1.49e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.0	14.4	0.76	7.01e-30	Homoarginine levels;
UCEC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.62	6.66	0.48	4.98e-10	Menopause (age at onset);
UCEC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg07776626	chr8:57350775	NA	-0.47	-5.3	-0.4	4.18e-7	Obesity-related traits;
UCEC	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg05962950	chr11:130786565	SNX19	0.51	5.5	0.41	1.67e-7	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs7253063	chr19:22865897	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.46	-4.64	-0.36	7.7e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6893807	0.943	rs13166120	chr5:87948883	G/A	cg09002922	chr5:87956389	LOC645323	-0.57	-5.94	-0.44	1.98e-8	Body mass index;
UCEC	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	1.12	13.36	0.74	3.68e-27	Post bronchodilator FEV1;
UCEC	cis	rs6740322	0.748	rs13402621	chr2:43458611	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.48	-4.51	-0.35	1.3e-5	Coronary artery disease;
UCEC	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.44	-5.87	-0.44	2.78e-8	Metabolite levels;
UCEC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-6.24	-0.46	4.53e-9	Platelet count;
UCEC	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg20560298	chr2:73613845	ALMS1	0.53	5.16	0.39	7.87e-7	Schizophrenia;
UCEC	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	6.67	0.48	4.82e-10	Myopia (pathological);
UCEC	cis	rs12318506	0.826	rs34128238	chr12:75731819	T/C	cg04728562	chr12:75699417	CAPS2	-0.84	-4.79	-0.37	4.06e-6	Coronary artery calcification;
UCEC	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.6	-4.95	-0.38	1.98e-6	Coronary artery calcification;
UCEC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg23307798	chr14:103986281	CKB	0.56	5.38	0.41	2.89e-7	Body mass index;
UCEC	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.41	4.69	0.36	6.17e-6	Blood metabolite ratios;
UCEC	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.07	17.23	0.82	4.15e-37	Testicular germ cell tumor;
UCEC	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.69	8.44	0.57	2.76e-14	Mean platelet volume;
UCEC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.16	7.23	0.51	2.49e-11	Gut microbiome composition (summer);
UCEC	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.96	-0.59	1.34e-15	Exhaled nitric oxide output;
UCEC	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.66	-6.31	-0.46	3.12e-9	Cognitive ability;
UCEC	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.93	-13.65	-0.75	6.4e-28	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.69	-0.54	1.96e-12	Colorectal cancer;
UCEC	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.41	4.93	0.38	2.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs61776719	0.810	rs34655914	chr1:38397341	G/A	cg18451016	chr1:38461880	NA	0.68	7.52	0.53	5.13e-12	Coronary artery disease;
UCEC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.56	0.42	1.26e-7	Hemoglobin concentration;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18543035	chr10:8374526	NA	0.56	7.85	0.54	8.16e-13	Warfarin maintenance dose;
UCEC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7115242	0.800	rs519794	chr11:116859453	T/C	cg13068653	chr11:117074303	TAGLN	0.53	4.65	0.36	7.36e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
UCEC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.57	4.93	0.38	2.24e-6	Corneal astigmatism;
UCEC	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.43	-6.03	-0.45	1.27e-8	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.47	0.41	1.93e-7	Breast cancer;
UCEC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.54	0.35	1.14e-5	Breast cancer;
UCEC	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.47	4.97	0.38	1.85e-6	Blood metabolite levels;
UCEC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs2213920	0.679	rs4979533	chr9:118210764	C/T	cg13918206	chr9:118159781	DEC1	0.74	5.15	0.39	8.17e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.6	6.08	0.45	1.01e-8	Breast cancer;
UCEC	cis	rs892864	0.803	rs58295967	chr5:127834505	T/C	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Multiple system atrophy;
UCEC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.43	-4.7	-0.36	5.89e-6	Schizophrenia;
UCEC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.44	0.41	2.14e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.61	0.69	1.56e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.4	5.57	0.42	1.18e-7	Alcohol dependence;
UCEC	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.1	9.58	0.62	3.45e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.51	-5.66	-0.42	7.72e-8	Parkinson's disease;
UCEC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg11632617	chr15:75315747	PPCDC	-0.49	-4.96	-0.38	1.89e-6	Blood trace element (Zn levels);
UCEC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.25	-0.4	5.19e-7	Aortic root size;
UCEC	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg05090351	chr10:126851162	NA	0.42	4.95	0.38	2.03e-6	Menarche (age at onset);
UCEC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg06733568	chr4:1343273	KIAA1530	-0.54	-4.83	-0.37	3.36e-6	Systolic blood pressure;
UCEC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.59	5.29	0.4	4.44e-7	Corneal astigmatism;
UCEC	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg19760965	chr3:194868843	C3orf21	0.4	4.57	0.35	1.04e-5	Non-small cell lung cancer;
UCEC	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.43	-4.91	-0.38	2.44e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg01689657	chr7:91764605	CYP51A1	0.47	6.11	0.45	8.65e-9	Breast cancer;
UCEC	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	6.32	0.46	2.97e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg14324370	chr2:177042789	NA	0.55	5.71	0.43	5.97e-8	IgG glycosylation;
UCEC	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.09	10.99	0.67	7.01e-21	Corneal structure;
UCEC	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.53	-4.83	-0.37	3.42e-6	Longevity;
UCEC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg01112020	chr2:239008986	ESPNL	-0.35	-4.71	-0.36	5.79e-6	Prostate cancer;
UCEC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.88	-9.9	-0.63	5.11e-18	Cognitive function;
UCEC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	0.96	16.16	0.8	2.12e-34	Testicular germ cell tumor;
UCEC	cis	rs4692589	0.965	rs2291167	chr4:170950887	G/A	cg19918862	chr4:170955249	NA	0.4	4.56	0.35	1.08e-5	Anxiety disorder;
UCEC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-0.93	-13.77	-0.75	3.13e-28	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.41	-0.47	1.91e-9	Crohn's disease;
UCEC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.5	4.94	0.38	2.08e-6	Triglycerides;
UCEC	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.58	5.98	0.44	1.62e-8	Motion sickness;
UCEC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg27391334	chr7:1352002	NA	0.37	4.59	0.35	9.48e-6	Longevity;Endometriosis;
UCEC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.75	0.43	4.9e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.53	-0.42	1.42e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.49	5.15	0.39	8.16e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg04283868	chr2:201171347	SPATS2L	-0.54	-5.38	-0.41	2.84e-7	QT interval;
UCEC	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.61	0.36	8.71e-6	HDL cholesterol;
UCEC	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs7246967	0.611	rs3902164	chr19:22866281	T/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-7.22	-0.51	2.63e-11	Personality dimensions;
UCEC	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.32	-0.46	2.92e-9	Chronic sinus infection;
UCEC	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg08755490	chr11:65554678	OVOL1	0.52	5.37	0.4	3.07e-7	Acne (severe);
UCEC	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.94	0.5	1.15e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.63	-7.18	-0.51	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg18016565	chr1:150552671	MCL1	0.45	4.58	0.35	9.72e-6	Melanoma;
UCEC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.85	-10.42	-0.65	2.17e-19	Coronary artery disease;
UCEC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.76	0.37	4.54e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11958404	0.860	rs7730844	chr5:157461208	C/T	cg05962755	chr5:157440814	NA	0.75	5.59	0.42	1.07e-7	IgG glycosylation;
UCEC	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.7	-6.27	-0.46	3.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.32e-6	Breast cancer;
UCEC	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg13092806	chr2:177043255	NA	0.56	5.28	0.4	4.48e-7	IgG glycosylation;
UCEC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-5.77	-0.43	4.55e-8	Monocyte percentage of white cells;
UCEC	cis	rs798766	0.909	rs744658	chr4:1755074	C/T	cg05874882	chr4:1763078	NA	-0.54	-5.59	-0.42	1.06e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.85	9.02	0.6	9.64e-16	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg24562669	chr7:97807699	LMTK2	-0.47	-5.71	-0.43	5.98e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.66	5.84	0.43	3.19e-8	Lymphocyte counts;
UCEC	cis	rs10129255	0.584	rs11161001	chr14:107108679	G/C	cg03031183	chr14:106916953	NA	-0.43	-4.63	-0.36	8.06e-6	Kawasaki disease;
UCEC	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg06521331	chr12:34319734	NA	-0.65	-5.17	-0.39	7.38e-7	Morning vs. evening chronotype;
UCEC	cis	rs16944613	0.541	rs6496690	chr15:91097401	T/C	cg08919649	chr15:91565780	VPS33B	0.66	4.65	0.36	7.43e-6	Colorectal cancer;
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.09	0.51	5.11e-11	Platelet count;
UCEC	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.52	-5.1	-0.39	1.02e-6	Systemic lupus erythematosus;
UCEC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg23782820	chr8:58130467	NA	0.51	4.74	0.36	4.9100000000000004e-06	Developmental language disorder (linguistic errors);
UCEC	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	5.05	0.38	1.3e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg17469321	chr7:55412551	NA	-0.7	-5.87	-0.44	2.75e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.5	5.97	0.44	1.71e-8	Total body bone mineral density;
UCEC	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.38	0.83	6.17e-40	Schizophrenia;
UCEC	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg18681998	chr4:17616180	MED28	0.68	7.71	0.54	1.73e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.34	4.51	0.35	1.31e-5	Bone mineral density;
UCEC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg17469321	chr7:55412551	NA	0.68	5.98	0.44	1.65e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.42	-4.94	-0.38	2.14e-6	Alcoholic chronic pancreatitis;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg20701182	chr2:24300061	SF3B14	0.54	4.52	0.35	1.26e-5	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.71	6.12	0.45	8.18e-9	Menopause (age at onset);
UCEC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs2302105	0.812	rs11598215	chr10:117826992	A/G	cg27327268	chr10:118428651	C10orf82	0.4	4.97	0.38	1.83e-6	IgG glycosylation;
UCEC	cis	rs17106184	0.892	rs58836765	chr1:50896037	G/A	cg07174182	chr1:51127561	FAF1	-0.8	-4.91	-0.38	2.37e-6	Type 2 diabetes;
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.68	8.34	0.57	4.81e-14	Menarche (age at onset);
UCEC	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg05991184	chr2:219186017	PNKD	-0.53	-5.95	-0.44	1.89e-8	Colorectal cancer;
UCEC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg04756594	chr16:24857601	SLC5A11	-0.42	-5.18	-0.39	7.1e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg05962950	chr11:130786565	SNX19	0.5	4.55	0.35	1.13e-5	Schizophrenia;
UCEC	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg03342759	chr3:160939853	NMD3	0.56	5.23	0.4	5.66e-7	Morning vs. evening chronotype;
UCEC	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.46	-5.4	-0.41	2.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg13683864	chr3:40499215	RPL14	-0.6	-6.16	-0.45	6.79e-9	Renal cell carcinoma;
UCEC	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.68	7.55	0.53	4.17e-12	Coronary artery disease;
UCEC	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg15358701	chr1:161410459	NA	-0.73	-4.72	-0.36	5.45e-6	Rheumatoid arthritis;
UCEC	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1372520	0.564	rs356196	chr4:90682803	A/T	cg15133208	chr4:90757351	SNCA	0.56	6.28	0.46	3.6e-9	Neuroticism;
UCEC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.64	-0.36	7.69e-6	Menarche (age at onset);
UCEC	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.43	-5.58	-0.42	1.11e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-0.86	-9.36	-0.61	1.24e-16	Height;
UCEC	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.68	6.5	0.47	1.19e-9	Bladder cancer;
UCEC	cis	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.68	5.8	0.43	3.9e-8	Prostate cancer;
UCEC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg10503236	chr1:231470652	EXOC8	0.44	5.07	0.39	1.19e-6	Hemoglobin concentration;
UCEC	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.71	-9.21	-0.61	3.03e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.89	-0.37	2.57e-6	Breast cancer;
UCEC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-4.56	-0.35	1.07e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.77	-5.09	-0.39	1.08e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs791888	1.000	rs791882	chr10:89408258	C/T	cg13926569	chr10:89418898	PAPSS2	-0.58	-6.54	-0.47	9.34e-10	Magnesium levels;
UCEC	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg01072550	chr1:21505969	NA	-0.56	-5.24	-0.4	5.44e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.37e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11235843	0.571	rs4944850	chr11:73356096	A/C	cg23931323	chr11:73372278	PLEKHB1	0.63	4.93	0.38	2.24e-6	Hand grip strength;
UCEC	cis	rs12829704	0.541	rs71446757	chr12:21341150	T/G	cg02631767	chr12:20661554	PDE3A	-0.85	-4.59	-0.35	9.44e-6	Blood metabolite levels;
UCEC	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg05660106	chr1:15850417	CASP9	0.55	4.87	0.37	2.88e-6	Systolic blood pressure;
UCEC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	-0.57	-6.43	-0.47	1.68e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.36	4.67	0.36	6.66e-6	Total body bone mineral density;
UCEC	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.67	4.53	0.35	1.2e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.79	0.37	4.12e-6	Breast cancer;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-6.27	-0.46	3.9e-9	Platelet count;
UCEC	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg06784218	chr1:46089804	CCDC17	0.4	4.55	0.35	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4865169	0.691	rs1056364	chr4:57889677	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.52	-5.4	-0.41	2.62e-7	Breast cancer;
UCEC	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	0.56	6.31	0.46	3.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	4.74	0.36	4.95e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	0.68	8.74	0.58	4.74e-15	Gut microbiome composition (winter);
UCEC	cis	rs7106204	0.764	rs79427715	chr11:24247046	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.25	0.4	5.16e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs184074	1.000	rs184074	chr6:157216039	C/T	cg23222435	chr6:157204239	ARID1B	-0.5	-4.96	-0.38	1.91e-6	Vein graft stenosis in coronary artery bypass grafting;
UCEC	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.64	-4.72	-0.36	5.43e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.49e-8	Depression;
UCEC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg26781129	chr3:44753946	ZNF502	-0.43	-4.62	-0.36	8.39e-6	Depressive symptoms;
UCEC	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	8.38	0.57	3.92e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs7246967	0.673	rs34126042	chr19:22909218	G/A	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.68e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-6.32	-0.46	2.92e-9	Multiple sclerosis;
UCEC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	4.9	0.37	2.52e-6	Lung cancer in ever smokers;
UCEC	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.72	-7.91	-0.55	5.62e-13	Facial morphology (factor 19);
UCEC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.66	7.64	0.53	2.61e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg13147721	chr7:65941812	NA	-0.75	-5.06	-0.38	1.26e-6	Diabetic kidney disease;
UCEC	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.49	4.51	0.35	1.3e-5	Alcohol dependence;
UCEC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.6	4.53	0.35	1.19e-5	Height;
UCEC	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg15837086	chr1:46506065	PIK3R3	0.4	5.13	0.39	9.08e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.64	-0.42	8.46e-8	Pubertal anthropometrics;
UCEC	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-4.98	-0.38	1.74e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.67	6.52	0.47	1.08e-9	Bladder cancer;
UCEC	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-7.37	-0.52	1.11e-11	Exhaled nitric oxide output;
UCEC	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.46	-4.97	-0.38	1.83e-6	Retinal vascular caliber;
UCEC	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	0.91	10.76	0.66	2.79e-20	Schizophrenia;
UCEC	cis	rs295140	1.000	rs12614621	chr2:201171207	G/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.47	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.46	5.0	0.38	1.65e-6	Response to antineoplastic agents;
UCEC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.47	5.23	0.4	5.63e-7	Emphysema distribution in smoking;
UCEC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.89	8.11	0.56	1.8e-13	Bladder cancer;
UCEC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.43	-4.72	-0.36	5.42e-6	Testicular germ cell tumor;
UCEC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.68	6.67	0.48	4.92e-10	Aortic root size;
UCEC	cis	rs1575951	1.000	rs12246362	chr10:130448820	C/T	cg27041381	chr10:131357203	MGMT	0.57	4.77	0.37	4.42e-6	Plasma clusterin levels;
UCEC	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	4.64	0.36	7.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.13	-7.33	-0.52	1.39e-11	Diabetic kidney disease;
UCEC	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1109861	0.783	rs682971	chr10:11228984	G/A	cg23397013	chr10:10571132	NA	-0.35	-4.7	-0.36	6e-6	Urinary albumin-to-creatinine ratio;
UCEC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.8	-9.88	-0.63	5.62e-18	White blood cell count (basophil);
UCEC	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.08	-6.71	-0.48	3.87e-10	Diabetic kidney disease;
UCEC	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	8.11	0.56	1.79e-13	Total cholesterol levels;
UCEC	cis	rs78487399	0.808	rs74365854	chr2:43661482	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs16957091	0.821	rs7163030	chr15:42971620	A/G	cg24196017	chr15:43021976	CDAN1	-0.49	-4.7	-0.36	5.83e-6	MGMT methylation in smokers;
UCEC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.05	0.55	2.57e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg23782820	chr8:58130467	NA	-0.5	-4.55	-0.35	1.12e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.18	7.05	0.5	6.56e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs295140	0.903	rs7605146	chr2:201183888	A/G	cg04283868	chr2:201171347	SPATS2L	-0.54	-5.13	-0.39	8.91e-7	QT interval;
UCEC	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg26513180	chr16:89883248	FANCA	-0.46	-4.78	-0.37	4.3e-6	Vitiligo;
UCEC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg24733560	chr20:60626293	TAF4	0.39	4.64	0.36	7.66e-6	Body mass index;
UCEC	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg16797656	chr11:68205561	LRP5	0.54	5.16	0.39	7.75e-7	Bone mineral density (spine);
UCEC	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.21	0.4	6.17e-7	Educational attainment;
UCEC	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.62	-6.62	-0.48	6.17e-10	Waist circumference;Body mass index;
UCEC	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg04553112	chr3:125709451	NA	-0.65	-4.76	-0.37	4.58e-6	Blood pressure (smoking interaction);
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.51	-5.8	-0.43	3.98e-8	Pubertal anthropometrics;
UCEC	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.6	6.45	0.47	1.48e-9	Bipolar disorder;
UCEC	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.53	5.59	0.42	1.07e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.2	-0.46	5.49e-9	Mood instability;
UCEC	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.65	5.47	0.41	1.91e-7	Cocaine dependence;
UCEC	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.47	-5.14	-0.39	8.47e-7	Gut microbiome composition (summer);
UCEC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.89	6.1	0.45	8.86e-9	Gut microbiome composition (summer);
UCEC	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.69	5.95	0.44	1.92e-8	Morning vs. evening chronotype;
UCEC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	9.73	0.63	1.42e-17	Monocyte count;
UCEC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.74	-9.22	-0.61	2.95e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.49	5.8	0.43	3.86e-8	Breast cancer;
UCEC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-4.8	-0.37	3.88e-6	Blood protein levels;
UCEC	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.53	-4.53	-0.35	1.19e-5	Pediatric autoimmune diseases;
UCEC	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg14530993	chr4:882597	GAK	0.77	4.87	0.37	2.82e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg21053147	chr12:120880522	NA	0.59	4.84	0.37	3.31e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg14458575	chr2:238380390	NA	0.53	5.29	0.4	4.29e-7	Prostate cancer;
UCEC	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	17.29	0.82	3.01e-37	Colorectal cancer;
UCEC	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.65	-4.55	-0.35	1.13e-5	Coronary artery disease;
UCEC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.68	5.55	0.42	1.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.58	-5.57	-0.42	1.18e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	8.39	0.57	3.78e-14	Blood protein levels;
UCEC	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-8.01	-0.55	3.15e-13	Colorectal cancer;
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.66	7.66	0.53	2.36e-12	Menarche (age at onset);
UCEC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.57	4.84	0.37	3.24e-6	Lung cancer;
UCEC	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.11	-0.6	5.7e-16	Coffee consumption (cups per day);
UCEC	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg11150807	chr10:43354902	NA	0.78	6.51	0.47	1.12e-9	Blood protein levels;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03404566	chr17:6899310	ALOX12	0.45	5.32	0.4	3.88e-7	Tonsillectomy;
UCEC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-7.18	-0.51	3.18e-11	Chronic sinus infection;
UCEC	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg08886695	chr4:3369023	RGS12	-0.57	-5.51	-0.41	1.56e-7	Serum sulfate level;
UCEC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.78	7.56	0.53	3.91e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-4.78	-0.37	4.24e-6	Aortic root size;
UCEC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.59	5.32	0.4	3.72e-7	Corneal astigmatism;
UCEC	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.7	-5.61	-0.42	9.75e-8	Asthma;
UCEC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.81	-0.37	3.67e-6	Joint mobility (Beighton score);
UCEC	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg08886695	chr4:3369023	RGS12	-0.47	-5.67	-0.42	7.43e-8	Parental longevity (mother's age at death);
UCEC	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg27246729	chr12:121163418	ACADS	0.5	4.68	0.36	6.54e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.6	-6.16	-0.45	6.58e-9	Diastolic blood pressure;
UCEC	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.54	4.87	0.37	2.91e-6	Methadone dose in opioid dependence;
UCEC	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.72	-7.74	-0.54	1.46e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.2e-5	Parkinson's disease;
UCEC	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.44	-0.41	2.15e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs16937	0.711	rs3851289	chr1:205149657	G/T	cg00857998	chr1:205179979	DSTYK	0.51	4.58	0.35	9.79e-6	Schizophrenia;
UCEC	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.65	5.4	0.41	2.66e-7	Multiple sclerosis;
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.48	4.97	0.38	1.81e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
UCEC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.66	-0.42	7.83e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.44	-5.27	-0.4	4.7e-7	Colorectal cancer;
UCEC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-4.96	-0.38	1.96e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.99	-8.74	-0.58	4.74e-15	Platelet count;
UCEC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.68	-6.22	-0.46	4.81e-9	Aortic root size;
UCEC	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg15133208	chr4:90757351	SNCA	-0.37	-4.9	-0.37	2.52e-6	Dementia with Lewy bodies;
UCEC	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg23283320	chr21:48055893	PRMT2	0.91	5.75	0.43	5.02e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs7246967	0.673	rs34003335	chr19:22925602	T/C	cg08271804	chr19:22816896	ZNF492	0.66	6.16	0.45	6.59e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	6.14	0.45	7.26e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9947276	0.508	rs8085149	chr18:72611796	C/A	cg07131864	chr18:72797640	NA	-0.46	-4.86	-0.37	2.97e-6	Alcohol dependence (age at onset);
UCEC	cis	rs17106184	0.892	rs111779227	chr1:51328987	A/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-6.02	-0.44	1.33e-8	Personality dimensions;
UCEC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.3	-0.46	3.33e-9	Chronic sinus infection;
UCEC	cis	rs4702435	0.671	rs11134206	chr5:7179956	G/A	cg23188121	chr5:6378767	MED10	-0.51	-4.52	-0.35	1.28e-5	Obesity-related traits;
UCEC	cis	rs7274811	0.652	rs158672	chr20:32023286	T/C	cg18305480	chr20:32031707	SNTA1	0.47	4.52	0.35	1.27e-5	Height;
UCEC	cis	rs11867410	0.744	rs58433709	chr17:63939616	G/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg23307798	chr14:103986281	CKB	0.52	4.84	0.37	3.24e-6	Body mass index;
UCEC	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.17	-9.53	-0.62	4.7e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs11048434	1.000	rs11048434	chr12:9153932	G/A	cg26114124	chr12:9217669	LOC144571	0.43	4.63	0.36	7.9e-6	Sjögren's syndrome;
UCEC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg03714773	chr7:91764589	CYP51A1	0.45	5.7	0.43	6.44e-8	Breast cancer;
UCEC	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.66	-7.76	-0.54	1.3e-12	Post bronchodilator FEV1;
UCEC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.53	-6.08	-0.45	9.9e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.73	7.86	0.54	7.46e-13	Lymphocyte counts;
UCEC	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.05	-0.45	1.13e-8	Metabolite levels;
UCEC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.8	-7.62	-0.53	2.94e-12	Initial pursuit acceleration;
UCEC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg03808351	chr9:123631620	PHF19	0.47	5.35	0.4	3.34e-7	Birth weight;
UCEC	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg18681998	chr4:17616180	MED28	0.79	9.23	0.61	2.79e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg16006841	chr5:176797999	RGS14	0.5	4.56	0.35	1.08e-5	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.21	0.51	2.79e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-0.77	-7.03	-0.5	7.21e-11	Blood pressure (smoking interaction);
UCEC	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.49	4.94	0.38	2.09e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg22563815	chr15:78856949	CHRNA5	0.38	4.89	0.37	2.58e-6	Sudden cardiac arrest;
UCEC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg00612595	chr21:47717864	NA	-0.49	-5.38	-0.41	2.92e-7	Testicular germ cell tumor;
UCEC	cis	rs256277	0.657	rs255910	chr5:111369892	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-4.51	-0.35	1.32e-5	Coronary artery disease;
UCEC	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.65	-0.42	8.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.63	4.79	0.37	4.1e-6	Carotid intima media thickness;
UCEC	cis	rs3914502	0.593	rs512042	chr3:174492558	C/T	cg21145449	chr3:174580620	NAALADL2	0.42	4.9	0.38	2.45e-6	Autism spectrum disorder;
UCEC	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.54	6.56	0.48	8.79e-10	HDL cholesterol;
UCEC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs1576263	0.967	rs9505478	chr6:8550536	G/T	cg07606381	chr6:8435919	SLC35B3	0.47	4.83	0.37	3.4e-6	Photic sneeze reflex;
UCEC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.64	6.76	0.49	2.97e-10	Prostate cancer;
UCEC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-1.1	-10.8	-0.67	2.21e-20	Lymphocyte counts;
UCEC	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.27	0.46	3.88e-9	Coffee consumption (cups per day);
UCEC	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-4.92	-0.38	2.25e-6	Morning vs. evening chronotype;
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.76	0.63	1.16e-17	Platelet count;
UCEC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	5.49	0.41	1.7e-7	Cognitive test performance;
UCEC	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.01	0.64	2.65e-18	Menopause (age at onset);
UCEC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.71	7.16	0.51	3.6e-11	Aortic root size;
UCEC	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.41	-5.75	-0.43	4.94e-8	Prostate cancer;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg09120320	chr17:61926383	NA	0.48	4.97	0.38	1.86e-6	Prudent dietary pattern;
UCEC	cis	rs1853665	0.895	rs9478311	chr6:150287135	C/G	cg00126498	chr6:150286838	ULBP1	0.47	5.41	0.41	2.53e-7	Radiation response;
UCEC	cis	rs72906064	1.000	rs72906060	chr2:156910407	T/C	cg14040602	chr2:157557294	NA	0.65	4.72	0.36	5.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.41	0.69	5.25e-22	Prudent dietary pattern;
UCEC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.05	8.71	0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.35	5.12	0.39	9.56e-7	Ewing sarcoma;
UCEC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg03859395	chr2:55845619	SMEK2	1.0	14.54	0.77	3.04e-30	Metabolic syndrome;
UCEC	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	0.8	6.05	0.45	1.15e-8	Red blood cell traits;
UCEC	cis	rs7766436	0.885	rs13200219	chr6:22595428	C/T	cg13666174	chr6:22585274	NA	-0.61	-6.13	-0.45	7.52e-9	Coronary artery disease;
UCEC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.64	5.64	0.42	8.43e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.55	-5.12	-0.39	9.32e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.54	5.89	0.44	2.54e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.96	-0.55	4.18e-13	Headache;
UCEC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	1.02	5.51	0.41	1.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.45	6.27	0.46	3.77e-9	Height;
UCEC	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-6.86	-0.49	1.76e-10	Colorectal cancer;
UCEC	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.63	0.36	8.08e-6	Parkinson's disease;
UCEC	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.66	-5.42	-0.41	2.34e-7	Immature fraction of reticulocytes;
UCEC	cis	rs3750082	0.852	rs10260000	chr7:32898234	T/C	cg05721444	chr7:32995514	FKBP9	0.49	5.5	0.41	1.62e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.67	5.73	0.43	5.41e-8	Cognitive function;
UCEC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg20965017	chr5:231967	SDHA	-0.65	-5.79	-0.43	4.1e-8	Breast cancer;
UCEC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.74	-6.37	-0.47	2.25e-9	Motion sickness;
UCEC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.43	-6.23	-0.46	4.67e-9	Ulcerative colitis;
UCEC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7709377	0.570	rs1588267	chr5:115434969	T/A	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs925228	1.000	rs6545222	chr2:24235704	G/A	cg13272742	chr2:24272458	FKBP1B	0.63	5.37	0.41	3e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.58	-6.84	-0.49	1.94e-10	Oral cavity cancer;
UCEC	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.66	-0.66	5.04e-20	Primary sclerosing cholangitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19978540	chr12:3409405	NA	0.57	6.81	0.49	2.29e-10	Warfarin maintenance dose;
UCEC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24308560	chr3:49941425	MST1R	-0.46	-4.84	-0.37	3.2e-6	Body mass index;
UCEC	trans	rs26595	0.632	rs153742	chr5:115798501	C/T	cg02153584	chr22:29168773	CCDC117	-0.64	-6.8	-0.49	2.4e-10	Wegener's granulomatosis;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.74	-0.36	4.9100000000000004e-06	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.66	5.8	0.43	3.85e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs534126	0.813	rs526867	chr7:142904427	G/A	cg04182207	chr7:143013161	CLCN1	-0.37	-5.22	-0.4	5.95e-7	Cancer;
UCEC	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.64	-0.62	2.38e-17	Blood metabolite levels;
UCEC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.72	7.13	0.51	4.23e-11	Smoking behavior;
UCEC	cis	rs828999	0.713	rs476386	chr1:108737586	C/T	cg11967332	chr1:108735228	SLC25A24	0.53	6.33	0.46	2.83e-9	Monocyte percentage of white cells;
UCEC	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg19554555	chr3:13937349	NA	0.57	5.81	0.43	3.71e-8	Ovarian reserve;
UCEC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	10.01	0.64	2.66e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.44	-5.88	-0.44	2.59e-8	Breast cancer;
UCEC	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.56	-6.52	-0.47	1.08e-9	Educational attainment;
UCEC	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.71	-9.28	-0.61	2.06e-16	Oral cavity cancer;
UCEC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.42	-0.41	2.43e-7	Pubertal anthropometrics;
UCEC	cis	rs7608623	1.000	rs2081302	chr2:23945355	A/C	cg02551244	chr2:23608357	KLHL29	0.42	4.55	0.35	1.11e-5	Obesity-related traits;
UCEC	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs1519814	0.956	rs4871036	chr8:121101758	T/C	cg22335954	chr8:121166405	COL14A1	-0.57	-5.17	-0.39	7.67e-7	Breast cancer;
UCEC	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.76	6.92	0.5	1.29e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.62	5.51	0.41	1.57e-7	Uric acid levels;
UCEC	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.34e-8	Lung cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01353569	chr7:106810328	HBP1	0.61	7.46	0.52	7.13e-12	Warfarin maintenance dose;
UCEC	cis	rs925550	0.592	rs1026157	chr4:123623893	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.68	7.4	0.52	9.76e-12	Primary biliary cholangitis;
UCEC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.69	-7.72	-0.54	1.61e-12	Coronary artery disease;
UCEC	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-5.06	-0.38	1.25e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.48	-5.54	-0.42	1.36e-7	Oropharynx cancer;
UCEC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.68	-6.11	-0.45	8.61e-9	Aortic root size;
UCEC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs883565	0.740	rs9311203	chr3:39072079	T/C	cg01426195	chr3:39028469	NA	-0.67	-8.21	-0.56	1.04e-13	Handedness;
UCEC	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.56	-4.53	-0.35	1.21e-5	Obesity-related traits;
UCEC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.73	-9.31	-0.61	1.76e-16	Hip circumference;
UCEC	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.56	6.68	0.48	4.56e-10	Longevity;
UCEC	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg17105886	chr17:28927953	LRRC37B2	0.49	4.67	0.36	6.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.52	5.1	0.39	1.03e-6	Neuroticism;
UCEC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.52	-5.06	-0.38	1.25e-6	Schizophrenia;
UCEC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.11	8.78	0.59	3.95e-15	Cannabis dependence symptom count;
UCEC	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.87	0.44	2.77e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	trans	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg24132527	chr5:140019269	TMCO6	0.91	7.05	0.5	6.54e-11	Cognitive function;
UCEC	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg06818710	chr6:28411271	ZSCAN23	-0.43	-4.63	-0.36	7.88e-6	Parkinson's disease;
UCEC	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.46	4.73	0.36	5.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.45	0.41	2.11e-7	Platelet count;
UCEC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.55	6.34	0.46	2.68e-9	Calcium levels;
UCEC	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg09557387	chr1:207818395	CR1L	0.87	4.63	0.36	8.12e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.7	0.36	6.01e-6	Tonsillectomy;
UCEC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.6	-6.77	-0.49	2.89e-10	Blood protein levels;
UCEC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-0.6	-6.91	-0.5	1.36e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.05	8.71	0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.94	10.38	0.65	2.8e-19	Cognitive function;
UCEC	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg19554555	chr3:13937349	NA	-0.6	-5.99	-0.44	1.56e-8	Ovarian reserve;
UCEC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.52	-5.19	-0.39	6.75e-7	Lymphocyte counts;
UCEC	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.49	4.71	0.36	5.69e-6	Corneal structure;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.57	0.42	1.16e-7	Prudent dietary pattern;
UCEC	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.5	8.05	0.55	2.64e-13	Airflow obstruction;
UCEC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.55	0.58	1.5e-14	Prudent dietary pattern;
UCEC	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg00122941	chr17:4613640	ARRB2	0.64	4.99	0.38	1.66e-6	Lymphocyte counts;
UCEC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg01065977	chr19:18549689	ISYNA1	0.35	5.0	0.38	1.64e-6	Breast cancer;
UCEC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.42	5.47	0.41	1.85e-7	Fibrinogen levels;
UCEC	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.53	4.81	0.37	3.77e-6	Body mass index;
UCEC	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.32	0.46	3e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.75	9.87	0.63	6.24e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg24562669	chr7:97807699	LMTK2	-0.74	-10.48	-0.65	1.51e-19	Breast cancer;
UCEC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.2	-0.56	1.07e-13	Hemoglobin concentration;
UCEC	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.81	0.49	2.29e-10	Bipolar disorder;
UCEC	cis	rs3790645	1.000	rs188158	chr1:26898142	A/G	cg23229016	chr1:26872525	RPS6KA1	0.28	5.12	0.39	9.31e-7	Glucose homeostasis traits;
UCEC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg00316803	chr15:76480434	C15orf27	0.47	5.7	0.43	6.2e-8	Blood metabolite levels;
UCEC	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13683864	chr3:40499215	RPL14	-0.96	-9.79	-0.63	9.8e-18	Renal cell carcinoma;
UCEC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15541040	chr2:3486749	NA	0.62	6.32	0.46	2.88e-9	Neurofibrillary tangles;
UCEC	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs2172802	0.570	rs1542834	chr4:62540430	A/G	cg04118610	chr4:62707027	LPHN3	-0.42	-4.67	-0.36	6.63e-6	Partial epilepsies;
UCEC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.84	10.09	0.64	1.6e-18	Platelet distribution width;
UCEC	cis	rs7682481	0.620	rs28882170	chr4:123063077	T/A	cg10583651	chr4:123538969	IL21	-0.27	-4.54	-0.35	1.14e-5	Alopecia areata;
UCEC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.86	6.77	0.49	2.92e-10	Body mass index;
UCEC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.44	4.81	0.37	3.76e-6	Longevity;Endometriosis;
UCEC	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.52	4.99	0.38	1.68e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg06157570	chr12:6886703	LAG3	0.48	4.63	0.36	7.89e-6	HDL cholesterol levels;
UCEC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.69	5.95	0.44	1.92e-8	Blood metabolite levels;
UCEC	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg24562669	chr7:97807699	LMTK2	0.43	5.21	0.39	6.29e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	0.81	4.97	0.38	1.82e-6	Mitochondrial DNA levels;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.68	7.69	0.54	2e-12	Menarche (age at onset);
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-5.37	-0.4	3.03e-7	Menarche (age at onset);
UCEC	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg26114124	chr12:9217669	LOC144571	0.4	4.78	0.37	4.29e-6	Sjögren's syndrome;
UCEC	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg01256987	chr12:42539512	GXYLT1	0.47	5.59	0.42	1.05e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.7	-6.67	-0.48	4.9e-10	Pancreatic cancer;
UCEC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.6	8.74	0.58	4.98e-15	Birth weight;
UCEC	cis	rs11671653	0.688	rs11671888	chr19:10838381	C/T	cg10640764	chr19:11216364	LDLR	-0.91	-4.87	-0.37	2.82e-6	LDL cholesterol;
UCEC	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs1205863	0.607	rs1210621	chr6:11927921	A/G	cg25521853	chr6:11927664	NA	0.42	4.87	0.37	2.88e-6	Disc degeneration (lumbar);
UCEC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.82	-5.9	-0.44	2.39e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg13777783	chr17:79615861	NA	-0.33	-4.77	-0.37	4.49e-6	Eye color traits;
UCEC	cis	rs2882667	0.858	rs11956159	chr5:138408568	T/C	cg04439458	chr5:138467593	SIL1	-0.47	-5.14	-0.39	8.76e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.46	-5.15	-0.39	8.23e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.57	5.8	0.43	3.91e-8	Eosinophil percentage of white cells;
UCEC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg12024160	chr4:1254474	NA	0.71	7.96	0.55	4.33e-13	Obesity-related traits;
UCEC	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg13206674	chr6:150067644	NUP43	0.57	5.72	0.43	5.73e-8	Lung cancer;
UCEC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	5.84	0.43	3.25e-8	Platelet count;
UCEC	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg04283868	chr2:201171347	SPATS2L	0.59	5.71	0.43	6e-8	QT interval;
UCEC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.91	-0.38	2.42e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.5	5.13	0.39	9.17e-7	Glomerular filtration rate;
UCEC	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.44	5.05	0.38	1.31e-6	Blood metabolite ratios;
UCEC	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	0.9	5.52	0.41	1.53e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg19318889	chr4:1322082	MAEA	0.47	5.49	0.41	1.7e-7	Longevity;
UCEC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11679564	0.714	rs4389320	chr2:37172531	T/C	cg14987922	chr2:37194071	STRN	0.56	4.71	0.36	5.79e-6	Immature fraction of reticulocytes;
UCEC	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.76	-8.39	-0.57	3.61e-14	White blood cell count (basophil);
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.76	-8.29	-0.56	6.69e-14	Paraoxonase activity;
UCEC	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.73	-6.57	-0.48	8.03e-10	Resting heart rate;
UCEC	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.62e-7	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.89	0.37	2.65e-6	Breast cancer;
UCEC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.54	4.89	0.37	2.6e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.48	4.54	0.35	1.15e-5	Menopause (age at onset);
UCEC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs847649	0.692	rs10279449	chr7:102462636	T/C	cg18108683	chr7:102477205	FBXL13	-0.62	-7.7	-0.54	1.88e-12	Morning vs. evening chronotype;
UCEC	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.66	5.66	0.42	7.57e-8	Adiposity;
UCEC	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-9.67	-0.62	2.02e-17	Height;
UCEC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.86	9.66	0.62	2.07e-17	Breast cancer;
UCEC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.48	5.03	0.38	1.43e-6	Bipolar disorder;
UCEC	cis	rs7106204	0.764	rs11821644	chr11:24212686	T/C	ch.11.24196551F	chr11:24239977	NA	0.66	5.69	0.43	6.53e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-4.81	-0.37	3.73e-6	Body mass index;
UCEC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	5.8	0.43	3.98e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.22	0.4	6.05e-7	Colorectal cancer;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.63	-0.36	8.01e-6	Menopause (age at onset);
UCEC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.21	0.39	6.3e-7	Electroencephalogram traits;
UCEC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.72	6.97	0.5	9.98e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg15358701	chr1:161410459	NA	-0.73	-4.72	-0.36	5.45e-6	Rheumatoid arthritis;
UCEC	cis	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg08722104	chr11:47448306	PSMC3	-0.51	-5.6	-0.42	1e-7	Intraocular pressure;
UCEC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg04154034	chr17:28927549	LRRC37B2	0.53	4.76	0.37	4.62e-6	Body mass index;
UCEC	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.58	-6.28	-0.46	3.67e-9	Paraoxonase activity;
UCEC	cis	rs12234571	1.000	rs58695035	chr7:77438494	A/G	cg20048109	chr7:78158112	MAGI2	-0.5	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.51	5.02	0.38	1.48e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.45	4.54	0.35	1.16e-5	Schizophrenia;
UCEC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11760485	0.965	rs57205131	chr7:4401983	A/G	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs10012307	1.000	rs1989314	chr4:137515728	G/T	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg20965017	chr5:231967	SDHA	-0.65	-5.79	-0.43	4.1e-8	Breast cancer;
UCEC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.84	9.75	0.63	1.28e-17	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.51	4.53	0.35	1.2e-5	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.45	-4.71	-0.36	5.58e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.53	6.54	0.47	9.75e-10	Menarche (age at onset);
UCEC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg23795048	chr12:9217529	LOC144571	0.43	5.35	0.4	3.37e-7	Sjögren's syndrome;
UCEC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	6.18	0.45	6.03e-9	Lymphocyte counts;
UCEC	cis	rs12428035	0.764	rs72638031	chr13:96782949	A/G	cg07859753	chr13:96300257	NA	0.6	4.64	0.36	7.6e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	trans	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg19862616	chr7:65841803	NCRNA00174	0.78	7.34	0.52	1.34e-11	Eotaxin levels;
UCEC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.63	5.82	0.43	3.51e-8	Parkinson's disease;
UCEC	cis	rs10242455	0.867	rs15524	chr7:99245914	A/G	cg18809830	chr7:99032528	PTCD1	-0.54	-4.56	-0.35	1.06e-5	Blood metabolite levels;
UCEC	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.86	4.66	0.36	7.08e-6	Inflammatory bowel disease;
UCEC	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.18	11.38	0.68	6.49e-22	Corneal structure;
UCEC	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg20070536	chr11:9335581	TMEM41B	0.52	4.63	0.36	7.91e-6	Schizophrenia;
UCEC	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-6.43	-0.47	1.64e-9	Morning vs. evening chronotype;
UCEC	cis	rs1165668	0.959	rs2576954	chr12:104312254	C/T	cg21863207	chr12:104234989	NT5DC3	0.55	4.73	0.36	5.26e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs308403	0.640	rs13110096	chr4:123633932	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.61	4.52	0.35	1.27e-5	Blood protein levels;
UCEC	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg10902566	chr4:727664	PCGF3	-0.6	-5.07	-0.39	1.15e-6	Systolic blood pressure;
UCEC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg01380346	chr19:18557039	ELL	-0.47	-4.74	-0.36	4.94e-6	Breast cancer;
UCEC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-4.91	-0.38	2.36e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg11697111	chr7:1126903	GPER;C7orf50	-0.5	-4.95	-0.38	2.05e-6	Longevity;Endometriosis;
UCEC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.42	-6.03	-0.45	1.29e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.53	-5.82	-0.43	3.57e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.96e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.51	5.28	0.4	4.6e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.41	4.74	0.36	5.01e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.54	-6.01	-0.44	1.39e-8	Mean platelet volume;
UCEC	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.45	-5.27	-0.4	4.78e-7	Aortic root size;
UCEC	cis	rs28795989	0.896	rs13140108	chr4:7886532	C/T	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.78	0.43	4.32e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.61	8.93	0.59	1.59e-15	Prudent dietary pattern;
UCEC	cis	rs858239	0.730	rs858279	chr7:23251005	T/C	cg17274742	chr7:23286539	GPNMB	0.42	4.78	0.37	4.28e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.77	9.18	0.6	3.6e-16	Mortality in heart failure;
UCEC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-6.72	-0.48	3.67e-10	Platelet count;
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.43	-4.85	-0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg11871910	chr12:69753446	YEATS4	-0.73	-7.88	-0.54	6.9e-13	Blood protein levels;
UCEC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg08222913	chr3:52553049	STAB1	-0.46	-5.22	-0.4	5.98e-7	Bipolar disorder;
UCEC	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.73	-8.65	-0.58	8.43e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4908768	0.582	rs12410893	chr1:8878885	A/G	cg13081009	chr1:8430745	RERE	0.45	5.03	0.38	1.42e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	4.81	0.37	3.63e-6	Refractive astigmatism;
UCEC	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	7.1	0.51	5.03e-11	Bipolar disorder;
UCEC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.18	-6.53	-0.47	1.01e-9	Diabetic kidney disease;
UCEC	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.59	6.8	0.49	2.48e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	5.14	0.39	8.6e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.64	6.35	0.46	2.57e-9	Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.83	8.9	0.59	1.92e-15	Breast cancer;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.5	4.65	0.36	7.46e-6	Menarche (age at onset);
UCEC	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.69	8.38	0.57	3.86e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.56	-6.44	-0.47	1.61e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.05	7.95	0.55	4.54e-13	Vitiligo;
UCEC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-5.37	-0.4	3.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-5.45	-0.41	2.1e-7	Blood metabolite levels;
UCEC	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.68	7.39	0.52	1e-11	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.81	8.82	0.59	3.04e-15	Breast cancer;
UCEC	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs9283706	0.513	rs7707409	chr5:66351889	A/G	cg11590213	chr5:66331682	MAST4	0.46	5.31	0.4	4.04e-7	Coronary artery disease;
UCEC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.48	-5.24	-0.4	5.57e-7	Gut microbiome composition (winter);
UCEC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-6.06	-0.45	1.07e-8	Longevity;Endometriosis;
UCEC	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13683864	chr3:40499215	RPL14	-0.65	-6.53	-0.47	1.01e-9	Renal cell carcinoma;
UCEC	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.58	5.48	0.41	1.84e-7	Corneal astigmatism;
UCEC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.62	-6.7	-0.48	4.16e-10	Menarche (age at onset);
UCEC	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.28	9.66	0.62	2.16e-17	Atopic dermatitis;
UCEC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.38	-0.41	2.86e-7	Initial pursuit acceleration;
UCEC	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.44	4.78	0.37	4.28e-6	Prudent dietary pattern;
UCEC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg20965017	chr5:231967	SDHA	-0.59	-5.08	-0.39	1.15e-6	Breast cancer;
UCEC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg10503236	chr1:231470652	EXOC8	0.44	5.07	0.39	1.19e-6	Hemoglobin concentration;
UCEC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18252515	chr7:66147081	NA	-0.54	-5.07	-0.39	1.18e-6	Aortic root size;
UCEC	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.61	5.79	0.43	4.1e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	0.73	8.44	0.57	2.75e-14	Gut microbiome composition (winter);
UCEC	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.69	-7.12	-0.51	4.51e-11	Initial pursuit acceleration;
UCEC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.65	0.48	5.35e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14067834	chr17:29058358	SUZ12P	0.65	4.58	0.35	9.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10012307	1.000	rs72990058	chr4:137510969	C/T	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.76	6.91	0.5	1.35e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.84	11.04	0.67	5.01e-21	Body mass index;
UCEC	cis	rs7267005	0.661	rs76012919	chr20:34398546	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.46	-4.61	-0.36	8.53e-6	Aortic root size;
UCEC	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12516959	chr21:47718080	NA	-0.41	-4.62	-0.36	8.15e-6	Testicular germ cell tumor;
UCEC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-4.99	-0.38	1.7e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.58	6.46	0.47	1.42e-9	Red blood cell count;
UCEC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.58	6.76	0.49	3.01e-10	Menopause (age at onset);
UCEC	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-6.41	-0.47	1.88e-9	Dental caries;
UCEC	cis	rs7797990	1.000	rs6960202	chr7:156004276	A/C	cg24517467	chr7:155284331	NA	-0.37	-4.69	-0.36	6.16e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.42	-5.72	-0.43	5.75e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs4778581	0.722	rs12914832	chr15:80377571	C/T	cg08257866	chr15:80351198	ZFAND6	0.4	4.87	0.37	2.88e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.53	-5.29	-0.4	4.34e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12579753	0.667	rs10862391	chr12:82307080	A/G	cg07988820	chr12:82153109	PPFIA2	-0.51	-4.52	-0.35	1.27e-5	Resting heart rate;
UCEC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.45	4.67	0.36	6.79e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.51	4.99	0.38	1.7e-6	Emphysema distribution in smoking;
UCEC	cis	rs6882076	1.000	rs9715911	chr5:156394441	G/A	cg12943317	chr5:156479607	HAVCR1	-0.5	-5.23	-0.4	5.83e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.67	7.53	0.53	4.85e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.62	-4.71	-0.36	5.78e-6	Blood pressure (smoking interaction);
UCEC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.92	0.38	2.29e-6	Breast cancer;
UCEC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.51	4.52	0.35	1.24e-5	Alzheimer's disease in APOE e4+ carriers;
UCEC	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.33	0.52	1.44e-11	Obesity-related traits;
UCEC	cis	rs13401104	0.796	rs72620809	chr2:237116050	T/C	cg23897927	chr2:237117786	ASB18	-0.52	-4.51	-0.35	1.34e-5	Educational attainment;
UCEC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.47	5.07	0.39	1.17e-6	Headache;
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.71	8.4	0.57	3.5e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.47	5.04	0.38	1.38e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.19	0.45	5.62e-9	Platelet count;
UCEC	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.64	-5.09	-0.39	1.09e-6	Orofacial clefts;
UCEC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.4	0.72	1.26e-24	Platelet count;
UCEC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.58	9.9	0.63	5.12e-18	Bone mineral density;
UCEC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.55	-4.64	-0.36	7.63e-6	Initial pursuit acceleration;
UCEC	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	6.02	0.44	1.31e-8	Mood instability;
UCEC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-4.93	-0.38	2.18e-6	Menarche (age at onset);
UCEC	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.47	5.06	0.39	1.23e-6	Corneal astigmatism;
UCEC	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	-0.54	-6.15	-0.45	7.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.76	-0.43	4.83e-8	Breast cancer;
UCEC	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.66	4.95	0.38	2.03e-6	HIV-1 control;
UCEC	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.68	-0.42	6.85e-8	Personality dimensions;
UCEC	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.53	-4.73	-0.36	5.19e-6	Colorectal cancer;
UCEC	cis	rs3772130	0.583	rs58088236	chr3:121561765	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.5	-5.14	-0.39	8.45e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4478037	1.000	rs57477065	chr3:33162532	A/C	cg19404215	chr3:33155277	CRTAP	0.76	6.07	0.45	1.02e-8	Major depressive disorder;
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.38	-0.47	2.17e-9	Platelet count;
UCEC	cis	rs7246967	0.673	rs4933026	chr19:22874492	A/T	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1712517	0.771	rs61869827	chr10:105079439	T/C	cg05636881	chr10:105038444	INA	0.43	5.36	0.4	3.16e-7	Migraine;
UCEC	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.9	8.57	0.58	1.32e-14	Colorectal adenoma (advanced);
UCEC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.15	20.93	0.87	6.16e-46	IgG glycosylation;
UCEC	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs4280164	0.836	rs4981504	chr14:24791136	A/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.58	4.5	0.35	1.36e-5	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs3844535	1	rs3844535	chr14:81884515	A/G	cg02996355	chr14:81879375	NA	-0.6	-4.81	-0.37	3.68e-6	Plateletcrit;Platelet count;
UCEC	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.68	-0.36	6.42e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.18	0.39	7.11e-7	Blood protein levels;
UCEC	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.79	-6.96	-0.5	1.03e-10	Blood trace element (Cu levels);
UCEC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.94	-13.18	-0.74	1.09e-26	Homoarginine levels;
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.79	0.49	2.52e-10	Platelet count;
UCEC	cis	rs4851266	1.000	rs13034176	chr2:100833913	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.83	-11.35	-0.68	7.92e-22	Urate levels in lean individuals;
UCEC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg23791538	chr6:167370224	RNASET2	-0.48	-4.91	-0.38	2.4e-6	Primary biliary cholangitis;
UCEC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.5	-5.06	-0.39	1.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.7	-0.48	4.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.72	6.88	0.49	1.57e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.36	-0.4	3.2e-7	Adiposity;
UCEC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.46	6.78	0.49	2.7e-10	Homoarginine levels;
UCEC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.48	-4.83	-0.37	3.35e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg06410510	chr2:107458059	ST6GAL2	-0.75	-6.89	-0.49	1.53e-10	Prostate cancer;
UCEC	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.59	-6.33	-0.46	2.82e-9	Type 2 diabetes;
UCEC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.5	-5.03	-0.38	1.44e-6	Total body bone mineral density;
UCEC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.87	5.56	0.42	1.24e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.65	7.48	0.53	6.07e-12	Obesity-related traits;
UCEC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg06494592	chr3:125709126	NA	-0.57	-4.51	-0.35	1.34e-5	Blood pressure (smoking interaction);
UCEC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-8.71	-0.58	5.82e-15	Coffee consumption (cups per day);
UCEC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.62	7.29	0.52	1.75e-11	Longevity;Endometriosis;
UCEC	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	1.01	10.02	0.64	2.46e-18	Alcohol dependence;
UCEC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.71	8.76	0.59	4.24e-15	Rheumatoid arthritis;
UCEC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg16023434	chr1:11395635	NA	0.36	4.59	0.35	9.6e-6	Body mass index;
UCEC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg20965017	chr5:231967	SDHA	-0.67	-5.87	-0.44	2.82e-8	Breast cancer;
UCEC	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	8.81	0.59	3.18e-15	Coffee consumption (cups per day);
UCEC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.61	5.59	0.42	1.1e-7	Major depressive disorder;
UCEC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.1	-0.39	1.03e-6	Hemoglobin concentration;
UCEC	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.63	4.95	0.38	2e-6	AIDS;
UCEC	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.89	7.92	0.55	5.47e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.79	9.15	0.6	4.48e-16	Schizophrenia;
UCEC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.58	-6.0	-0.44	1.47e-8	Asthma;
UCEC	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.32	-0.4	3.85e-7	Metabolite levels;
UCEC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	6.26	0.46	4.01e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg12310025	chr6:25882481	NA	-0.51	-4.58	-0.35	9.71e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.52	-5.73	-0.43	5.42e-8	Life satisfaction;
UCEC	cis	rs7267005	0.661	rs79637847	chr20:34419527	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs12980942	1.000	rs12981053	chr19:41832456	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.78	5.26	0.4	5.1e-7	Coronary artery disease;
UCEC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.6	-0.36	8.87e-6	Response to antipsychotic treatment;
UCEC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.74	8.37	0.57	4.24e-14	Cognitive function;
UCEC	cis	rs2029213	0.523	rs2035450	chr3:53269317	C/T	cg16894138	chr3:53270350	TKT	0.41	5.27	0.4	4.8e-7	Heart rate;
UCEC	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.21	-0.4	6.14e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.29	-0.46	3.43e-9	Post bronchodilator FEV1;
UCEC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.76	-8.11	-0.56	1.82e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg22771759	chr13:24902376	NA	0.44	4.71	0.36	5.77e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.74	7.05	0.5	6.3e-11	Cognitive function;
UCEC	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.72	-8.31	-0.57	5.95e-14	Waist circumference;Body mass index;
UCEC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.78	-7.11	-0.51	4.77e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07213616	chr5:60725347	ZSWIM6	-0.6	-6.78	-0.49	2.69e-10	Warfarin maintenance dose;
UCEC	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.28	0.46	3.63e-9	Motion sickness;
UCEC	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg05991184	chr2:219186017	PNKD	-0.58	-6.63	-0.48	5.87e-10	Colorectal cancer;
UCEC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.75	7.95	0.55	4.51e-13	Lymphocyte counts;
UCEC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg06238570	chr21:40685208	BRWD1	0.81	8.1	0.56	1.91e-13	Cognitive function;
UCEC	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	5.91	0.44	2.24e-8	Breast cancer;
UCEC	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.57	0.35	1e-5	Multiple sclerosis;
UCEC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg23752985	chr2:85803571	VAMP8	-0.43	-4.64	-0.36	7.78e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg05636881	chr10:105038444	INA	0.45	5.14	0.39	8.6e-7	Migraine;
UCEC	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.46	-4.87	-0.37	2.83e-6	Gut microbiome composition (summer);
UCEC	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-4.96	-0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.58	-5.8	-0.43	4e-8	Retinal vascular caliber;
UCEC	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg12580275	chr1:205744413	RAB7L1	0.46	4.86	0.37	2.96e-6	Schizophrenia;
UCEC	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.64	7.04	0.5	6.79e-11	Longevity;Endometriosis;
UCEC	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg18681998	chr4:17616180	MED28	-0.68	-7.09	-0.51	5.11e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.65	-7.58	-0.53	3.54e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs8064299	0.503	rs62084914	chr17:72773110	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.52	4.95	0.38	2.03e-6	Monocyte count;
UCEC	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.62	-5.42	-0.41	2.44e-7	Menopause (age at onset);
UCEC	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg05962950	chr11:130786565	SNX19	0.46	4.53	0.35	1.22e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.09	-0.39	1.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.51	-5.73	-0.43	5.49e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg26566898	chr11:117069891	TAGLN	0.42	4.57	0.35	1.03e-5	Blood protein levels;
UCEC	cis	rs7175404	0.591	rs17708628	chr15:94060378	T/C	cg06054272	chr15:93956988	NA	0.7	5.06	0.39	1.21e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.67	7.16	0.51	3.65e-11	Longevity;Endometriosis;
UCEC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.51	5.93	0.44	2.04e-8	Alcohol dependence;
UCEC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.46	-4.74	-0.36	5.1e-6	Aortic root size;
UCEC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.48	6.11	0.45	8.59e-9	Electrocardiographic conduction measures;
UCEC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.46	0.57	2.4e-14	Alzheimer's disease;
UCEC	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.47	4.51	0.35	1.32e-5	Hemoglobin concentration;
UCEC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.55	5.95	0.44	1.86e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.54	-5.44	-0.41	2.17e-7	Aortic root size;
UCEC	cis	rs9715521	0.935	rs62301184	chr4:59836168	A/G	cg11281224	chr4:60001000	NA	-0.59	-5.89	-0.44	2.51e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06223018	chr3:49557076	DAG1	0.33	4.72	0.36	5.52e-6	Parkinson's disease;
UCEC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.55	0.35	1.1e-5	Menopause (age at onset);
UCEC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.02	-11.78	-0.7	5.62e-23	IgG glycosylation;
UCEC	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.61	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.58	6.22	0.46	4.82e-9	Retinal vascular caliber;
UCEC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.51	5.19	0.39	6.99e-7	Fibrinogen levels;
UCEC	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.69	-6.06	-0.45	1.08e-8	Coronary artery calcification;
UCEC	cis	rs4778214	1.000	rs4778221	chr15:28231279	C/G	cg08281084	chr15:28459700	HERC2	0.5	4.62	0.36	8.48e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
UCEC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.53	-5.36	-0.4	3.1e-7	Diastolic blood pressure;
UCEC	cis	rs4771996	0.561	rs9516953	chr13:98172508	C/T	cg11411600	chr13:98830116	RNF113B;FARP1	-0.46	-4.58	-0.35	9.64e-6	Obesity-related traits;
UCEC	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg05660106	chr1:15850417	CASP9	0.93	10.44	0.65	1.95e-19	Systolic blood pressure;
UCEC	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.36	5.1	0.39	1.04e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.85	-5.83	-0.43	3.42e-8	Exhaled nitric oxide output;
UCEC	cis	rs11264213	0.551	rs11263852	chr1:36554442	G/C	cg27506609	chr1:36549197	TEKT2	-0.63	-6.4	-0.47	1.94e-9	Schizophrenia;
UCEC	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg04310649	chr10:35416472	CREM	-0.49	-4.76	-0.37	4.61e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.71	-5.22	-0.4	6e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	0.84	9.94	0.63	3.93e-18	Bone mineral density;
UCEC	cis	rs7246967	0.673	rs2361260	chr19:22914144	C/T	cg05241461	chr19:22816980	ZNF492	-0.55	-5.74	-0.43	5.24e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	0.93	9.64	0.62	2.38e-17	Heart rate;
UCEC	cis	rs6882076	1.000	rs12657266	chr5:156396003	C/T	cg12943317	chr5:156479607	HAVCR1	-0.49	-5.09	-0.39	1.08e-6	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs9341808	0.644	rs62408577	chr6:80942024	T/A	cg08355045	chr6:80787529	NA	-0.4	-5.02	-0.38	1.46e-6	Sitting height ratio;
UCEC	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.74	5.68	0.42	7.06e-8	Chronic sinus infection;
UCEC	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg08501292	chr6:25962987	TRIM38	0.99	4.62	0.36	8.46e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.74	-8.21	-0.56	1.04e-13	Monocyte count;
UCEC	cis	rs72717009	0.688	rs373579	chr1:161483484	A/G	cg15358701	chr1:161410459	NA	-0.8	-4.9	-0.37	2.45e-6	Rheumatoid arthritis;
UCEC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.64	8.39	0.57	3.64e-14	Anterior chamber depth;
UCEC	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.55	4.73	0.36	5.32e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.56	-5.4	-0.41	2.59e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-24.38	-0.9	1.61e-53	Myeloid white cell count;
UCEC	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.8	-0.37	3.83e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.96	9.79	0.63	1e-17	IgG glycosylation;
UCEC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.46	5.24	0.4	5.52e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	0.53	5.47	0.41	1.91e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg24375607	chr4:120327624	NA	0.47	4.83	0.37	3.42e-6	Corneal astigmatism;
UCEC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.44	5.18	0.39	7.24e-7	Blood metabolite ratios;
UCEC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.78	8.14	0.56	1.55e-13	Body mass index;
UCEC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-4.78	-0.37	4.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.66	0.42	7.81e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6728642	0.901	rs7584641	chr2:97607655	A/T	cg26665480	chr2:98280029	ACTR1B	-0.54	-4.86	-0.37	2.99e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs4148689	0.951	rs1429566	chr7:117170774	G/A	cg21212505	chr7:117228958	CFTR	-0.41	-4.66	-0.36	6.96e-6	Gout;
UCEC	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.61	-0.62	2.81e-17	Primary sclerosing cholangitis;
UCEC	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg21191810	chr6:118973309	C6orf204	0.38	5.24	0.4	5.47e-7	Electrocardiographic conduction measures;
UCEC	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.31	-0.52	1.61e-11	Obesity-related traits;
UCEC	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.96	8.46	0.57	2.5e-14	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-5.92	-0.44	2.23e-8	Eye color traits;
UCEC	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	5.74	0.43	5.15e-8	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01391022	chr12:122360665	WDR66	-0.42	-4.83	-0.37	3.36e-6	Mean corpuscular volume;
UCEC	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-8.8	-0.59	3.37e-15	Exhaled nitric oxide output;
UCEC	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg02158880	chr13:53174818	NA	0.43	4.67	0.36	6.67e-6	Lewy body disease;
UCEC	cis	rs6715284	0.579	rs55731449	chr2:202468421	T/A	cg23517999	chr2:202814523	NA	-0.55	-4.56	-0.35	1.08e-5	Rheumatoid arthritis;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04871131	chr7:94954202	PON1	0.62	6.77	0.49	2.84e-10	Paraoxonase activity;
UCEC	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.62	6.83	0.49	2.07e-10	Blood metabolite ratios;
UCEC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	0.89	12.1	0.71	7.88e-24	Homoarginine levels;
UCEC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg02160872	chr5:212506	CCDC127	-0.69	-7.17	-0.51	3.33e-11	Breast cancer;
UCEC	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.56	-0.35	1.07e-5	Height;
UCEC	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.13	-0.45	7.74e-9	Total cholesterol levels;
UCEC	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.67	7.95	0.55	4.62e-13	Hip circumference;
UCEC	cis	rs6457821	1.000	rs11966402	chr6:35422542	C/T	cg06087101	chr6:35551932	FKBP5	0.53	4.51	0.35	1.34e-5	Height;
UCEC	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	0.94	10.03	0.64	2.27e-18	Corneal structure;
UCEC	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	8.98	0.6	1.18e-15	Coffee consumption (cups per day);
UCEC	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	4.94	0.38	2.14e-6	Homocysteine levels;
UCEC	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg23950597	chr19:37808831	NA	-0.64	-5.0	-0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	0.99	11.22	0.68	1.72e-21	Cognitive function;
UCEC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.37	5.45	0.41	2.1e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7246967	0.611	rs73022711	chr19:22875404	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.62	4.78	0.37	4.21e-6	Bladder cancer;
UCEC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.54	-5.5	-0.41	1.62e-7	Breast cancer;
UCEC	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.47	-5.52	-0.41	1.46e-7	Electroencephalogram traits;
UCEC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	0.82	5.26	0.4	4.96e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.52	-0.53	5.13e-12	Hypospadias;
UCEC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.9	9.31	0.61	1.73e-16	Cognitive function;
UCEC	cis	rs4972806	0.849	rs2113561	chr2:177030925	G/A	cg14324370	chr2:177042789	NA	0.56	5.75	0.43	4.92e-8	IgG glycosylation;
UCEC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.91	13.54	0.74	1.26e-27	Multiple system atrophy;
UCEC	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.79	-5.16	-0.39	7.95e-7	Alzheimer's disease (late onset);
UCEC	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.6	6.47	0.47	1.38e-9	Crohn's disease;
UCEC	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.31	10.18	0.64	9.32e-19	Uric acid levels;
UCEC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.44	-5.81	-0.43	3.71e-8	Urinary metabolites;
UCEC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.34	0.4	3.42e-7	Heart rate;
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.63	7.41	0.52	9.24e-12	Body mass index;
UCEC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.73	0.58	5.29e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9393294	1.000	rs9295551	chr6:22493376	C/G	cg15541384	chr6:21886458	FLJ22536	0.75	5.01	0.38	1.56e-6	Mean platelet volume;
UCEC	cis	rs12644436	0.859	rs4608762	chr4:88784222	C/T	cg27179352	chr4:88029472	AFF1	0.42	4.59	0.35	9.47e-6	HIV-1 viral setpoint;
UCEC	cis	rs6684428	1.000	rs7540772	chr1:56375368	C/G	cg11651538	chr1:56320950	NA	-0.56	-5.22	-0.4	6.07e-7	Airflow obstruction;
UCEC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.34	0.57	4.85e-14	Chronic sinus infection;
UCEC	cis	rs4900538	0.927	rs2403058	chr14:102964654	A/G	cg18135206	chr14:102964638	TECPR2	1.11	14.36	0.76	8.82e-30	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.75	7.33	0.52	1.43e-11	Monocyte count;
UCEC	cis	rs10895987	1.000	rs72932837	chr11:64876740	C/T	cg02030452	chr11:65589615	NA	-0.5	-4.71	-0.36	5.72e-6	Blood protein levels;
UCEC	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.7	-8.11	-0.56	1.79e-13	HDL cholesterol;
UCEC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg11871910	chr12:69753446	YEATS4	0.55	4.8	0.37	3.81e-6	Response to diuretic therapy;
UCEC	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-5.67	-0.42	7.16e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.63	5.49	0.41	1.71e-7	Subjective well-being;
UCEC	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.2e-8	Mammographic density (dense area);
UCEC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.65	-6.94	-0.5	1.15e-10	Longevity;Endometriosis;
UCEC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.45	4.76	0.37	4.69e-6	Corneal astigmatism;
UCEC	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-5.54	-0.42	1.36e-7	Height;
UCEC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.64	-6.14	-0.45	7.2e-9	Aortic root size;
UCEC	trans	rs6725041	0.784	rs13424619	chr2:213069927	T/C	cg19573490	chr17:79870317	PCYT2;SIRT7	0.58	6.95	0.5	1.1e-10	QT interval (ambient particulate matter interaction);
UCEC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.55	-6.07	-0.45	1.05e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.61	6.89	0.49	1.52e-10	Electrocardiographic conduction measures;
UCEC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg11871910	chr12:69753446	YEATS4	0.55	4.84	0.37	3.26e-6	Response to diuretic therapy;
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.8	11.33	0.68	8.62e-22	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.13	-0.45	7.64e-9	Aortic root size;
UCEC	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.25	0.51	2.16e-11	Ileal carcinoids;
UCEC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	0.93	9.5	0.62	5.42e-17	Heart rate;
UCEC	cis	rs2172802	0.570	rs11931258	chr4:62533602	A/G	cg04118610	chr4:62707027	LPHN3	0.4	4.51	0.35	1.32e-5	Partial epilepsies;
UCEC	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	6.89	0.49	1.51e-10	LDL cholesterol;
UCEC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.69	6.78	0.49	2.77e-10	Tonsillectomy;
UCEC	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.77	-6.13	-0.45	7.54e-9	Calcium levels;
UCEC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.08	13.14	0.73	1.42e-26	Cognitive function;
UCEC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs36051895	0.632	rs966871	chr9:5121070	A/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.32	-0.4	3.77e-7	Pediatric autoimmune diseases;
UCEC	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.42	-4.98	-0.38	1.73e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg02461776	chr11:598696	PHRF1	0.45	4.87	0.37	2.87e-6	Systemic lupus erythematosus;
UCEC	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	1.04	5.98	0.44	1.63e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
UCEC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.75	-6.18	-0.45	5.9e-9	Colorectal adenoma (advanced);
UCEC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.62	6.64	0.48	5.73e-10	Blood protein levels;
UCEC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg06238570	chr21:40685208	BRWD1	0.7	6.71	0.48	4.03e-10	Cognitive function;
UCEC	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg16797656	chr11:68205561	LRP5	0.47	5.28	0.4	4.57e-7	Total body bone mineral density;
UCEC	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg23070574	chr3:14187308	XPC	0.43	4.74	0.36	4.95e-6	Ovarian reserve;
UCEC	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.62	-4.78	-0.37	4.21e-6	Carotid intima media thickness;
UCEC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg04155231	chr12:9217510	LOC144571	0.41	4.97	0.38	1.8e-6	Sjögren's syndrome;
UCEC	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg24169773	chr3:122142474	KPNA1	-0.68	-4.65	-0.36	7.42e-6	LDL cholesterol levels;
UCEC	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.19	14.93	0.78	3.03e-31	Body mass index;
UCEC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs13095912	1.000	rs13072759	chr3:185326391	G/A	cg11274856	chr3:185301563	NA	0.57	7.55	0.53	4.21e-12	Systolic blood pressure;
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-5.9	-0.44	2.4e-8	Platelet count;
UCEC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg04043695	chr12:129287642	SLC15A4	-0.66	-6.22	-0.46	4.88e-9	Systemic lupus erythematosus;
UCEC	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.53	4.86	0.37	3.01e-6	Lung cancer;
UCEC	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.93e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg05962950	chr11:130786565	SNX19	-0.56	-5.98	-0.44	1.62e-8	Schizophrenia;
UCEC	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg21191810	chr6:118973309	C6orf204	0.43	6.08	0.45	9.65e-9	Electrocardiographic conduction measures;
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.89	-10.68	-0.66	4.6e-20	Prudent dietary pattern;
UCEC	cis	rs16932667	0.857	rs11063467	chr12:5133940	A/C	cg05667158	chr12:4381890	CCND2	0.51	4.72	0.36	5.4e-6	Intelligence (childhood);
UCEC	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.39	-5.28	-0.4	4.59e-7	Reticulocyte fraction of red cells;
UCEC	trans	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg18288967	chr1:45987694	PRDX1	0.94	6.85	0.49	1.86e-10	Obesity-related traits;
UCEC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-8.63	-0.58	9.02e-15	Cognitive function;
UCEC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.42	4.51	0.35	1.32e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.82	9.66	0.62	2.16e-17	Homoarginine levels;
UCEC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.2e-5	Parkinson's disease;
UCEC	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.61	4.92	0.38	2.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg00612595	chr21:47717864	NA	-0.49	-5.34	-0.4	3.46e-7	Testicular germ cell tumor;
UCEC	cis	rs7103648	0.569	rs10769282	chr11:47626492	T/G	cg03711944	chr11:47377212	SPI1	-0.53	-4.56	-0.35	1.05e-5	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.69	-8.27	-0.56	7.16e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.53	4.84	0.37	3.28e-6	Methadone dose in opioid dependence;
UCEC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-4.91	-0.38	2.35e-6	Hemoglobin concentration;
UCEC	cis	rs7246967	0.932	rs62120788	chr19:23051012	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.11	0.39	9.82e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Bipolar disorder;
UCEC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.51	0.41	1.54e-7	Menarche (age at onset);
UCEC	cis	rs884366	0.964	rs4945826	chr6:109575070	C/G	cg01475377	chr6:109611718	NA	0.44	5.01	0.38	1.52e-6	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.33	0.4	3.68e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.57	-5.18	-0.39	7.13e-7	Hypospadias;
UCEC	cis	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg20368463	chr18:77673604	PQLC1	0.53	4.88	0.37	2.75e-6	Opioid sensitivity;
UCEC	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.9	13.09	0.73	1.87e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.5	5.07	0.39	1.21e-6	Coronary heart disease;
UCEC	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.46	-5.44	-0.41	2.13e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.78	7.54	0.53	4.52e-12	Bladder cancer;
UCEC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00815214	chr21:47717953	NA	0.46	4.86	0.37	2.98e-6	Testicular germ cell tumor;
UCEC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg10792982	chr14:105748885	BRF1	0.42	4.88	0.37	2.73e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01380346	chr19:18557039	ELL	-0.49	-5.09	-0.39	1.07e-6	Breast cancer;
UCEC	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-7.49	-0.53	5.93e-12	Coronary artery disease;
UCEC	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.48	4.99	0.38	1.65e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs1575951	1.000	rs7075328	chr10:130438038	C/T	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9826463	0.759	rs115683937	chr3:142335548	G/A	cg20824294	chr3:142316082	PLS1	0.66	4.59	0.35	9.63e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs13255292	0.509	rs13268851	chr8:129100295	G/A	cg05261028	chr8:128494655	LOC727677	-0.45	-4.66	-0.36	6.97e-6	Diffuse large B cell lymphoma;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.4	4.73	0.36	5.3e-6	Tonsillectomy;
UCEC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.44	4.88	0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg26898376	chr11:64110657	CCDC88B	0.38	4.51	0.35	1.3e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg21521518	chr4:53727714	RASL11B	0.67	4.77	0.37	4.32e-6	Optic nerve measurement (cup area);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06523306	chr9:6413544	UHRF2	0.63	6.78	0.49	2.68e-10	Warfarin maintenance dose;
UCEC	cis	rs10992471	0.598	rs230222	chr9:95265558	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-4.95	-0.38	2e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	8.27	0.56	7.26e-14	Headache;
UCEC	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs7804356	1.000	rs3801819	chr7:26866698	T/G	cg03456212	chr7:26904342	SKAP2	-0.61	-4.67	-0.36	6.63e-6	Type 1 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16266895	chr12:101674004	UTP20	0.54	6.78	0.49	2.68e-10	Warfarin maintenance dose;
UCEC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.52	-5.02	-0.38	1.49e-6	Vitiligo;
UCEC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg07776626	chr8:57350775	NA	0.42	4.77	0.37	4.41e-6	Obesity-related traits;
UCEC	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	6.61	0.48	6.5e-10	Platelet distribution width;
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2625529	0.617	rs6494973	chr15:72145728	A/T	cg00334370	chr15:72668350	HEXA;C15orf34	0.56	5.38	0.41	2.82e-7	Red blood cell count;
UCEC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.99	9.18	0.6	3.63e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg17105886	chr17:28927953	LRRC37B2	0.54	4.9	0.37	2.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.56	-4.94	-0.38	2.14e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.6	7.25	0.51	2.16e-11	Oral cavity cancer;
UCEC	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.67	-0.36	6.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg05241461	chr19:22816980	ZNF492	0.57	5.87	0.44	2.78e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7219021	0.885	rs3848457	chr17:46866026	C/T	cg16584676	chr17:46985605	UBE2Z	-0.48	-4.56	-0.35	1.07e-5	Schizophrenia or bipolar disorder;
UCEC	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.44	5.16	0.39	7.82e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.34	-0.4	3.51e-7	Pubertal anthropometrics;
UCEC	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7937612	1.000	rs10892578	chr11:120308290	A/G	cg12584626	chr11:120203529	NA	0.48	4.59	0.35	9.43e-6	Intraocular pressure;
UCEC	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.63	5.62	0.42	9.37e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.83	9.25	0.61	2.48e-16	Breast cancer;
UCEC	cis	rs12793173	0.711	rs61881129	chr11:34856263	G/A	cg13523125	chr11:35072710	NA	0.52	4.58	0.35	9.66e-6	Cystic fibrosis severity;
UCEC	cis	rs2147959	0.941	rs1886774	chr1:228633718	C/T	cg25874119	chr1:228633904	NA	0.54	6.15	0.45	7.03e-9	Adult asthma;
UCEC	cis	rs4372836	0.729	rs11127190	chr2:29043212	G/C	cg09522027	chr2:28974177	PPP1CB	0.84	8.82	0.59	3e-15	Body mass index;
UCEC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.52	5.28	0.4	4.64e-7	Tonsillectomy;
UCEC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.6	-6.45	-0.47	1.49e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg01451880	chr3:45801044	SLC6A20	0.37	4.74	0.36	4.97e-6	Hirschsprung disease;
UCEC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.64	-5.74	-0.43	5.28e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.57	6.96	0.5	1.04e-10	Total body bone mineral density;
UCEC	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Educational attainment;
UCEC	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.25	-0.46	4.18e-9	Blood protein levels;
UCEC	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-7.98	-0.55	3.82e-13	Exhaled nitric oxide output;
UCEC	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	4.58	0.35	9.83e-6	Lung cancer in ever smokers;
UCEC	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg09788492	chr10:101292477	NKX2-3	0.42	4.53	0.35	1.22e-5	Dental caries;
UCEC	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	5.1	0.39	1.04e-6	Total cholesterol levels;
UCEC	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg05660106	chr1:15850417	CASP9	1.02	11.58	0.69	1.92e-22	Systolic blood pressure;
UCEC	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17377491	chr11:112096999	PTS	0.59	6.91	0.5	1.36e-10	Warfarin maintenance dose;
UCEC	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	7e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg22166914	chr1:53195759	ZYG11B	0.87	9.11	0.6	5.52e-16	Monocyte count;
UCEC	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.83	9.23	0.61	2.71e-16	Breast cancer;
UCEC	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-22.56	-0.88	1.31e-49	Myeloid white cell count;
UCEC	cis	rs806321	0.755	rs1007852	chr13:50784892	C/T	cg12964420	chr13:50975679	NA	-0.36	-4.51	-0.35	1.31e-5	Multiple sclerosis;
UCEC	cis	rs4926298	0.890	rs931067	chr19:13158783	A/G	cg11758861	chr19:13135514	NFIX	0.52	5.0	0.38	1.6e-6	Bipolar disorder;
UCEC	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.57	-0.48	7.98e-10	Adiposity;
UCEC	cis	rs652260	0.663	rs580984	chr19:7881030	C/T	cg26014689	chr19:7917955	EVI5L	-0.47	-5.12	-0.39	9.56e-7	Menarche (age at onset);
UCEC	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg16060761	chr17:80687452	NA	-0.53	-4.79	-0.37	4.1e-6	Glycated hemoglobin levels;
UCEC	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.63	6.45	0.47	1.52e-9	Blood metabolite levels;
UCEC	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.72	6.98	0.5	9.39e-11	Schizophrenia;
UCEC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.75	-8.53	-0.58	1.61e-14	Menarche (age at onset);
UCEC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.67	-7.84	-0.54	8.59e-13	Obesity-related traits;
UCEC	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg07930192	chr7:1003750	NA	0.43	4.55	0.35	1.12e-5	Longevity;Endometriosis;
UCEC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-4.81	-0.37	3.69e-6	Primary biliary cholangitis;
UCEC	cis	rs9470794	1.000	rs73419927	chr6:38020496	C/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.61	7.92	0.55	5.49e-13	Weight;
UCEC	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	0.81	5.22	0.4	6.1e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.66	-4.57	-0.35	1.04e-5	LDL cholesterol levels;
UCEC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	4.93	0.38	2.22e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg17279458	chr3:44753948	ZNF502	-0.65	-5.47	-0.41	1.87e-7	IgG glycosylation;
UCEC	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.57	-6.35	-0.46	2.57e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs13095912	1.000	rs1823238	chr3:185341970	G/A	cg11274856	chr3:185301563	NA	0.54	7.49	0.53	5.79e-12	Systolic blood pressure;
UCEC	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	6.05	0.45	1.17e-8	Coffee consumption (cups per day);
UCEC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs13437751	0.536	rs28438490	chr7:63332138	T/A	cg00787055	chr7:63562162	NA	0.49	4.69	0.36	6.15e-6	QT interval (drug interaction);
UCEC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.48	5.43	0.41	2.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7072216	0.881	rs7082192	chr10:100151844	T/C	cg19567339	chr10:100142640	NA	0.61	8.45	0.57	2.55e-14	Metabolite levels;
UCEC	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.8	-5.44	-0.41	2.17e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs12339094	0.527	rs9410635	chr9:90415664	G/A	cg14178383	chr9:91347716	NA	0.7	4.86	0.37	3e-6	Smoking quantity;
UCEC	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	4.61	0.36	8.68e-6	Depressive episodes in bipolar disorder;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg22723887	chr19:2226881	DOT1L	-0.58	-6.76	-0.49	3e-10	N-glycan levels;
UCEC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	1.1	14.28	0.76	1.41e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg18681998	chr4:17616180	MED28	0.79	9.99	0.64	2.92e-18	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10104451	chr8:143696006	ARC	-0.54	-5.09	-0.39	1.1e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.69	7.3	0.52	1.66e-11	Menarche (age at onset);
UCEC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-10.96	-0.67	8.5e-21	Chronic sinus infection;
UCEC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	5.52	0.41	1.49e-7	Alzheimer's disease;
UCEC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.3e-8	Aortic root size;
UCEC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.49	-5.12	-0.39	9.32e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-7.23	-0.51	2.39e-11	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs2172802	0.570	rs4860423	chr4:62537297	C/T	cg04118610	chr4:62707027	LPHN3	-0.43	-4.69	-0.36	6.23e-6	Partial epilepsies;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg17270843	chr10:99079074	FRAT1	0.64	7.02	0.5	7.65e-11	Schizophrenia;
UCEC	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.73	0.54	1.57e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg16616514	chr4:6324629	PPP2R2C	-0.38	-4.8	-0.37	3.89e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	7.92e-8	Resting heart rate;
UCEC	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.53	-5.34	-0.4	3.51e-7	IgG glycosylation;
UCEC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.24	-0.4	5.44e-7	Personality dimensions;
UCEC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.48	-4.67	-0.36	6.79e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03934478	chr11:495069	RNH1	0.71	5.08	0.39	1.12e-6	Body mass index;
UCEC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	0.92	12.97	0.73	4.05e-26	Homoarginine levels;
UCEC	cis	rs11867410	0.744	rs7219574	chr17:63990157	C/T	cg06996976	chr17:64576105	PRKCA	-0.72	-4.55	-0.35	1.13e-5	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.43	6.23	0.46	4.73e-9	Prudent dietary pattern;
UCEC	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.38	-4.84	-0.37	3.24e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-5.12	-0.39	9.32e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.63	5.57	0.42	1.21e-7	Uric acid levels;
UCEC	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.69	5.12	0.39	9.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg24803719	chr17:45855879	NA	-0.46	-5.02	-0.38	1.47e-6	IgG glycosylation;
UCEC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.75	0.59	4.54e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.58	0.48	7.7e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6717918	0.517	rs2633263	chr2:233127453	T/C	cg02061626	chr2:233274167	ALPPL2	0.5	5.05	0.38	1.27e-6	Height;
UCEC	cis	rs7246967	0.800	rs4932794	chr19:23036556	G/A	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.44	-4.97	-0.38	1.86e-6	Glaucoma (primary open-angle);
UCEC	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg16583315	chr14:65563665	MAX	-0.42	-5.62	-0.42	9.31e-8	Obesity-related traits;
UCEC	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-0.89	-4.86	-0.37	2.95e-6	Plateletcrit;
UCEC	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.34	-0.9	1.95e-53	Myeloid white cell count;
UCEC	cis	rs2742417	1.000	rs2742420	chr3:45732237	A/G	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.22	-0.4	5.99e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.78	8.77	0.59	4.17e-15	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.91	11.4	0.69	5.59e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.55	-6.11	-0.45	8.63e-9	Monocyte percentage of white cells;
UCEC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7729723	0.579	rs11748288	chr5:137805584	A/G	cg18180673	chr5:137827632	NA	0.47	4.54	0.35	1.14e-5	Amyotrophic lateral sclerosis (C9orf72 mutation interaction);
UCEC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg13175981	chr1:150552382	MCL1	0.61	6.11	0.45	8.42e-9	Tonsillectomy;
UCEC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.54	-5.84	-0.43	3.27e-8	Breast cancer;
UCEC	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg15506890	chr2:3487001	NA	-0.55	-5.05	-0.38	1.29e-6	Neurofibrillary tangles;
UCEC	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.73	7.96	0.55	4.24e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg12463550	chr7:65579703	CRCP	-0.53	-5.31	-0.4	4.01e-7	Aortic root size;
UCEC	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.74	7.58	0.53	3.62e-12	Itch intensity from mosquito bite;
UCEC	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.6e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs10242455	0.702	rs6977165	chr7:99269397	T/C	cg18809830	chr7:99032528	PTCD1	-0.75	-4.57	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.66	7.75	0.54	1.36e-12	Ulcerative colitis;
UCEC	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-5.99	-0.44	1.56e-8	Blood metabolite levels;
UCEC	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg26898376	chr11:64110657	CCDC88B	0.52	4.68	0.36	6.55e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.78	-7.46	-0.52	7.01e-12	Schizophrenia;
UCEC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.67e-9	Crohn's disease;
UCEC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.82	-9.48	-0.62	6.39e-17	Metabolic syndrome;
UCEC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.74	7.66	0.53	2.3e-12	Breast cancer;
UCEC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.63	-5.29	-0.4	4.29e-7	Blood metabolite levels;
UCEC	cis	rs4713118	0.591	rs2056924	chr6:27690174	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.7	-0.36	5.98e-6	Parkinson's disease;
UCEC	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.98	0.44	1.6e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.65	-0.36	7.2e-6	Cardiac Troponin-T levels;
UCEC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.52	-5.06	-0.38	1.25e-6	Schizophrenia;
UCEC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.81	8.67	0.58	7.25e-15	Breast cancer;
UCEC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.77	4.67	0.36	6.75e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.53	5.67	0.42	7.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3015497	0.616	rs4901043	chr14:51083594	C/T	cg04730355	chr14:51134070	SAV1	0.47	5.04	0.38	1.33e-6	Mean platelet volume;
UCEC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg00086871	chr4:6988644	TBC1D14	0.66	4.6	0.35	9.04e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.72	0.36	5.47e-6	Breast cancer;
UCEC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	5.1	0.39	1.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.48	4.99	0.38	1.68e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	4.62	0.36	8.48e-6	Birth weight;
UCEC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.02	0.44	1.33e-8	Life satisfaction;
UCEC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.53	5.54	0.42	1.37e-7	HDL cholesterol;
UCEC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.93e-8	Breast cancer;
UCEC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.97	-0.55	4.12e-13	Bipolar disorder and schizophrenia;
UCEC	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	7.17	0.51	3.47e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.52	-0.41	1.46e-7	Bone mineral density;
UCEC	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg01426195	chr3:39028469	NA	-0.75	-9.85	-0.63	6.98e-18	Handedness;
UCEC	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	17.82	0.83	1.47e-38	Colorectal cancer;
UCEC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg13870426	chr17:30244630	NA	-0.62	-4.52	-0.35	1.24e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.55	6.16	0.45	6.47e-9	Blood metabolite levels;
UCEC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	1.03	6.73	0.49	3.55e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.67	6.97	0.5	9.93e-11	Coronary artery disease;
UCEC	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-1.06	-5.58	-0.42	1.13e-7	Systolic blood pressure response to hydrochlorothiazide in hypertension;
UCEC	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	4.93	0.38	2.24e-6	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.74	6.65	0.48	5.34e-10	Alzheimer's disease;
UCEC	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.55	-5.61	-0.42	9.86e-8	Height;
UCEC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	0.8	7.07	0.5	5.93e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.02	-10.62	-0.66	6.51e-20	Vitiligo;
UCEC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.51	-4.83	-0.37	3.39e-6	Total body bone mineral density;
UCEC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-7.58	-0.53	3.63e-12	Gut microbiome composition (summer);
UCEC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.55	5.65	0.42	7.93e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.61	5.37	0.4	3.03e-7	Aortic root size;
UCEC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.86	5.01	0.38	1.54e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.611	rs34806882	chr19:22880104	T/C	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9633402	0.526	rs10788726	chr1:247997114	T/C	cg06626314	chr1:247338637	NA	0.68	4.78	0.37	4.25e-6	Systemic juvenile idiopathic arthritis;
UCEC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg12035532	chr1:1886765	KIAA1751	0.44	4.69	0.36	6.18e-6	Body mass index;
UCEC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-7.46	-0.52	6.86e-12	Menarche (age at onset);
UCEC	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Bladder cancer;
UCEC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.44	-0.47	1.62e-9	Eye color traits;
UCEC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.6e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.31	0.57	6e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.51	-4.73	-0.36	5.18e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.74	0.58	4.85e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.57	-6.63	-0.48	5.91e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.48	-5.44	-0.41	2.15e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.11	13.71	0.75	4.59e-28	Cognitive function;
UCEC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.59	7.54	0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.67	5.49	0.41	1.68e-7	IgG glycosylation;
UCEC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.53	0.42	1.41e-7	Initial pursuit acceleration;
UCEC	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.7	6.38	0.47	2.17e-9	Body mass index;
UCEC	cis	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Axial length;
UCEC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.5	4.89	0.37	2.64e-6	Monocyte percentage of white cells;
UCEC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.97	0.38	1.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.71	-8.54	-0.58	1.59e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg05660106	chr1:15850417	CASP9	0.85	9.76	0.63	1.18e-17	Systolic blood pressure;
UCEC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.6	-5.84	-0.43	3.26e-8	Aortic root size;
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.06	0.71	1.01e-23	Prudent dietary pattern;
UCEC	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg04553112	chr3:125709451	NA	-0.65	-4.76	-0.37	4.58e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.63	6.98	0.5	9.34e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.85	10.18	0.64	9.46e-19	Coronary artery disease;
UCEC	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.62	-4.83	-0.37	3.34e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.0	0.38	1.58e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg15837086	chr1:46506065	PIK3R3	-0.39	-5.0	-0.38	1.59e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg22974920	chr21:40686053	BRWD1	0.61	5.33	0.4	3.54e-7	Cognitive function;
UCEC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	1.0	9.06	0.6	7.56e-16	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13686143	chr2:201828163	ORC2L	0.6	7.28	0.51	1.86e-11	Warfarin maintenance dose;
UCEC	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg07537917	chr2:241836409	C2orf54	-0.33	-4.98	-0.38	1.76e-6	Urinary metabolites;
UCEC	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.74	7.73	0.54	1.54e-12	Menopause (age at onset);
UCEC	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.62	5.63	0.42	8.85e-8	Platelet count;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.6	-0.48	6.93e-10	Pubertal anthropometrics;
UCEC	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.05	9.27	0.61	2.15e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.81	7.81	0.54	9.83e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.42	-0.41	2.34e-7	Schizophrenia;
UCEC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.15	14.33	0.76	1.05e-29	Cognitive function;
UCEC	cis	rs7187365	0.554	rs889595	chr16:86512080	A/T	cg07689597	chr16:87337090	NA	-0.36	-4.56	-0.35	1.05e-5	Obesity (early onset extreme);
UCEC	cis	rs7709377	0.546	rs10079176	chr5:115454408	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.62	5.85	0.43	3.02e-8	Corneal astigmatism;
UCEC	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.87	-0.44	2.77e-8	Hemoglobin concentration;
UCEC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.12	-13.24	-0.74	7.88e-27	Breast cancer;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg23429981	chr6:97345948	NDUFAF4	0.67	6.83	0.49	2.11e-10	Schizophrenia;
UCEC	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.74	-9.92	-0.63	4.6e-18	Gut microbiota (bacterial taxa);
UCEC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.59	-6.61	-0.48	6.56e-10	Refractive error;
UCEC	cis	rs6600233	1.000	rs6600233	chr16:143503	A/G	cg02353723	chr16:163133	C16orf35	0.58	5.78	0.43	4.3e-8	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.14	18.4	0.84	5.65e-40	Schizophrenia;
UCEC	cis	rs72774609	0.662	rs11204530	chr1:248031766	C/G	cg04309258	chr1:247267873	ZNF669	-0.44	-4.67	-0.36	6.75e-6	Red cell distribution width;
UCEC	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.68	-7.97	-0.55	3.95e-13	Waist-hip ratio;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.54	-6.05	-0.45	1.16e-8	Pulmonary function;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.66	-7.56	-0.53	4e-12	Body mass index;
UCEC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs8020441	0.588	rs67963325	chr14:51181339	C/G	cg04730355	chr14:51134070	SAV1	0.68	5.9	0.44	2.38e-8	Cognitive performance;
UCEC	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg11859384	chr17:80120422	CCDC57	-0.44	-4.71	-0.36	5.7e-6	Life satisfaction;
UCEC	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.28e-9	Platelet count;
UCEC	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-4.93	-0.38	2.18e-6	Body mass index;
UCEC	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg07741184	chr6:167504864	NA	-0.33	-4.81	-0.37	3.69e-6	Primary biliary cholangitis;
UCEC	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg13593689	chr9:129986794	NA	-0.46	-4.81	-0.37	3.66e-6	Intraocular pressure;
UCEC	cis	rs256277	0.760	rs13169766	chr5:111294243	T/A	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.44	-4.62	-0.36	8.47e-6	Coronary artery disease;
UCEC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	0.85	5.35	0.4	3.34e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.47	-4.53	-0.35	1.21e-5	Dental caries;
UCEC	cis	rs13095912	1.000	rs13100034	chr3:185318804	G/A	cg11274856	chr3:185301563	NA	0.55	7.38	0.52	1.05e-11	Systolic blood pressure;
UCEC	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.81	-8.44	-0.57	2.7e-14	Mosquito bite size;
UCEC	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.74	-7.36	-0.52	1.18e-11	Prudent dietary pattern;
UCEC	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.58	-6.84	-0.49	1.99e-10	Response to temozolomide;
UCEC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg25811766	chr13:21894605	NA	-0.76	-6.04	-0.45	1.18e-8	White matter hyperintensity burden;
UCEC	cis	rs11671653	0.614	rs11672431	chr19:10823940	A/C	cg08291069	chr19:10531543	PDE4A	-0.74	-4.8	-0.37	3.91e-6	LDL cholesterol;
UCEC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.9	-0.44	2.42e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.47	5.48	0.41	1.77e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.28	-0.4	4.61e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2213920	0.749	rs6478172	chr9:118251281	C/T	cg13918206	chr9:118159781	DEC1	0.72	4.88	0.37	2.68e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.55	5.65	0.42	8.09e-8	N-glycan levels;
UCEC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.72	8.92	0.59	1.67e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	0.95	8.21	0.56	1.03e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.59	-7.26	-0.51	2.04e-11	Pubertal anthropometrics;
UCEC	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.71	10.0	0.64	2.84e-18	Neuroticism;
UCEC	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg15997130	chr1:24165203	NA	-0.67	-5.55	-0.42	1.27e-7	Immature fraction of reticulocytes;
UCEC	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	4.79	0.37	4.1e-6	Height;
UCEC	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.61	5.32	0.4	3.82e-7	Platelet count;
UCEC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-5.15	-0.39	8.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03760483	chr17:6899297	ALOX12	-0.44	-5.08	-0.39	1.14e-6	Tonsillectomy;
UCEC	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.69	-8.36	-0.57	4.45e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.66	6.75	0.49	3.17e-10	Body mass index;
UCEC	cis	rs7246967	1.000	rs12983770	chr19:23023614	A/G	cg08271804	chr19:22816896	ZNF492	0.52	5.01	0.38	1.56e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.72	8.14	0.56	1.58e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17122693	0.710	rs8011413	chr14:51160245	A/G	cg04730355	chr14:51134070	SAV1	0.87	8.36	0.57	4.38e-14	Cognitive performance;
UCEC	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.58	4.94	0.38	2.09e-6	Huntington's disease progression;
UCEC	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	1.07	14.89	0.78	3.66e-31	Ulcerative colitis;
UCEC	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.3	-0.4	4.07e-7	Depression;
UCEC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4757319	0.515	rs7125389	chr11:15438571	A/G	cg03245590	chr11:15329459	NA	0.42	4.7	0.36	5.81e-6	Breast cancer;
UCEC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.02	0.38	1.46e-6	HDL cholesterol;
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.55	-5.8	-0.43	3.94e-8	Parkinson's disease;
UCEC	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.85	-0.37	3.08e-6	Gut microbiome composition (summer);
UCEC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.66	6.7	0.48	4.09e-10	Tonsillectomy;
UCEC	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.54	4.66	0.36	7.01e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-6.27	-0.46	3.8e-9	Platelet count;
UCEC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24308560	chr3:49941425	MST1R	0.52	5.92	0.44	2.16e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg16165748	chr11:65030448	POLA2	0.4	4.56	0.35	1.06e-5	Non-alcoholic fatty liver disease histology (lobular);
UCEC	cis	rs12367572	0.663	rs1224436	chr12:45400397	C/T	cg03114573	chr12:45410052	DBX2	-0.53	-6.31	-0.46	3.17e-9	Gut microbiome composition (summer);
UCEC	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.5	-5.16	-0.39	8.02e-7	Dental caries;
UCEC	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.42	-4.6	-0.35	8.94e-6	Breast cancer;
UCEC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.51	5.89	0.44	2.49e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.8	0.49	2.5e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.6e-8	Bipolar disorder;
UCEC	cis	rs259282	0.605	rs8101007	chr19:33109557	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.55	4.91	0.38	2.36e-6	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg17105886	chr17:28927953	LRRC37B2	0.65	4.61	0.36	8.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.41	-4.91	-0.38	2.35e-6	Neuroticism;
UCEC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.95	0.44	1.84e-8	Breast cancer;
UCEC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.48	5.5	0.41	1.61e-7	White matter hyperintensity burden;
UCEC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	7.77	0.54	1.24e-12	Joint mobility (Beighton score);
UCEC	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	0.8	6.43	0.47	1.71e-9	Response to hepatitis C treatment;
UCEC	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.36	0.65	3.22e-19	Electrocardiographic conduction measures;
UCEC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-5.3	-0.4	4.24e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg24562669	chr7:97807699	LMTK2	-0.38	-4.54	-0.35	1.15e-5	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.54	4.63	0.36	8.1e-6	Methadone dose in opioid dependence;
UCEC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.08e-8	Breast cancer;
UCEC	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.56	6.09	0.45	9.24e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.83	0.37	3.37e-6	Personality dimensions;
UCEC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.68	6.04	0.45	1.21e-8	High light scatter reticulocyte count;
UCEC	cis	rs35934224	0.783	rs35969236	chr22:19860355	T/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.8	-0.37	3.84e-6	Glaucoma (primary open-angle);
UCEC	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg14092571	chr14:90743983	NA	0.37	4.68	0.36	6.39e-6	Mortality in heart failure;
UCEC	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.39	-0.41	2.73e-7	Metabolite levels;
UCEC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg21214455	chr15:72412075	SENP8	0.47	4.7	0.36	5.9e-6	Red blood cell count;
UCEC	cis	rs12634933	1.000	rs1006631	chr3:169012843	G/T	cg03603669	chr3:169896616	PHC3	-0.55	-4.71	-0.36	5.57e-6	Blood pressure (smoking interaction);
UCEC	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.61	-5.0	-0.38	1.6e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.68	7.21	0.51	2.73e-11	Menopause (age at onset);
UCEC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.83	-8.24	-0.56	8.91e-14	Obesity-related traits;
UCEC	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.45	4.91	0.38	2.37e-6	HDL cholesterol;
UCEC	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg24011408	chr12:48396354	COL2A1	0.61	5.13	0.39	8.96e-7	Lung cancer;
UCEC	cis	rs80337801	0.541	rs17558645	chr5:73712208	A/G	cg27626331	chr5:74162602	FAM169A	-0.88	-4.59	-0.35	9.25e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg12253828	chr6:101329408	ASCC3	0.47	4.78	0.37	4.19e-6	Neuroticism;
UCEC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg14008862	chr17:28927542	LRRC37B2	0.55	4.9	0.37	2.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.52	-0.57	1.79e-14	Mean platelet volume;
UCEC	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.2	-0.39	6.67e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	1.0	13.71	0.75	4.6e-28	Bone mineral density;
UCEC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.58	5.16	0.39	7.82e-7	Longevity;
UCEC	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.44	4.61	0.36	8.71e-6	HDL cholesterol;
UCEC	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.5	-5.18	-0.39	7.29e-7	Parkinson's disease;
UCEC	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.83	0.49	2.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.46	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.62	4.62	0.36	8.39e-6	Carotid intima media thickness;
UCEC	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg06521331	chr12:34319734	NA	-0.59	-4.62	-0.36	8.22e-6	Morning vs. evening chronotype;
UCEC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-5.6	-0.42	1.03e-7	Prostate cancer;
UCEC	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	6.96	0.5	1.03e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.41	-4.74	-0.36	5e-6	Parkinson's disease;
UCEC	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg01072550	chr1:21505969	NA	-0.54	-4.83	-0.37	3.41e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.63	-0.42	8.71e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	5.89	0.44	2.48e-8	Cognitive test performance;
UCEC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-1.03	-7.21	-0.51	2.68e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.76	-5.67	-0.42	7.22e-8	Narcolepsy;
UCEC	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.53	-5.19	-0.39	6.94e-7	Coronary artery disease;
UCEC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-1.12	-9.92	-0.63	4.4e-18	Post bronchodilator FEV1;
UCEC	cis	rs72906064	0.731	rs17185023	chr2:156921590	C/T	cg14040602	chr2:157557294	NA	0.62	4.59	0.35	9.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6832769	1.000	rs7667849	chr4:56388199	A/G	cg05960024	chr4:56376020	CLOCK	-0.56	-5.7	-0.43	6.43e-8	Personality dimensions;
UCEC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.74	-0.36	4.9100000000000004e-06	Alzheimer's disease (late onset);
UCEC	cis	rs847649	0.731	rs12666317	chr7:102704135	C/T	cg18108683	chr7:102477205	FBXL13	0.53	6.33	0.46	2.79e-9	Morning vs. evening chronotype;
UCEC	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.63	6.03	0.45	1.27e-8	Aortic root size;
UCEC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg12024160	chr4:1254474	NA	0.69	8.16	0.56	1.35e-13	Obesity-related traits;
UCEC	cis	rs10924970	0.625	rs2789366	chr1:235508270	G/A	cg26050004	chr1:235667680	B3GALNT2	0.5	4.69	0.36	6.15e-6	Asthma;
UCEC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.78	0.59	3.82e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.73	-6.02	-0.45	1.3e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24249390	chr15:90295951	MESP1	-0.46	-5.14	-0.39	8.48e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.09	-6.98	-0.5	9.35e-11	Breast cancer;
UCEC	cis	rs75504410	0.826	rs931023	chr4:38722580	C/T	cg26681822	chr4:38858561	TLR6	-0.52	-4.63	-0.36	7.87e-6	Eosinophil counts;Sum eosinophil basophil counts;
UCEC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.63	-6.36	-0.46	2.41e-9	Blood metabolite levels;
UCEC	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.79	-6.77	-0.49	2.94e-10	Type 2 diabetes;
UCEC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.64	5.92	0.44	2.17e-8	Menarche (age at onset);
UCEC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.57	-5.11	-0.39	9.75e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs6840360	0.642	rs2053566	chr4:152445831	A/C	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.66	-4.64	-0.36	7.54e-6	Aortic root size;
UCEC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg23978390	chr7:1156363	C7orf50	0.46	4.54	0.35	1.16e-5	Longevity;Endometriosis;
UCEC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.72	6.64	0.48	5.57e-10	Aortic root size;
UCEC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.61	5.27	0.4	4.8e-7	Blood protein levels;
UCEC	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg26781129	chr3:44753946	ZNF502	-0.47	-5.16	-0.39	7.9e-7	Depressive symptoms;
UCEC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.65	-7.43	-0.52	8.29e-12	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24249390	chr15:90295951	MESP1	-0.42	-4.76	-0.37	4.64e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs10254160	1.000	rs28594984	chr7:112060730	C/T	cg14158407	chr7:112758954	LOC401397	-1.02	-4.54	-0.35	1.15e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.72	7.5	0.53	5.63e-12	Primary sclerosing cholangitis;
UCEC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.54	-5.88	-0.44	2.63e-8	Tonsillectomy;
UCEC	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-0.43	-4.68	-0.36	6.51e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.68	-4.85	-0.37	3.17e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg02158880	chr13:53174818	NA	0.39	4.62	0.36	8.32e-6	Lewy body disease;
UCEC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.51	5.44	0.41	2.19e-7	Schizophrenia;
UCEC	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.94	-8.69	-0.58	6.6e-15	Dilated cardiomyopathy;
UCEC	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	0.87	11.76	0.7	6.45e-23	Multiple myeloma;
UCEC	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.62	7.32	0.52	1.53e-11	Coronary artery disease;
UCEC	cis	rs782107	0.614	rs12424547	chr12:58787122	A/C	cg19181132	chr12:59314527	LRIG3	-0.45	-4.79	-0.37	3.99e-6	Interleukin-12p70 levels;
UCEC	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.84	0.37	3.28e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.54	-5.36	-0.4	3.1e-7	Breast cancer;
UCEC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	5.95	0.44	1.89e-8	IgG glycosylation;
UCEC	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.87	-12.39	-0.71	1.33e-24	Urate levels in lean individuals;
UCEC	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.67	6.92	0.5	1.28e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg13395646	chr4:1353034	KIAA1530	-0.71	-6.56	-0.48	8.42e-10	Obesity-related traits;
UCEC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10254160	1.000	rs1014725	chr7:112050858	G/A	cg12767726	chr7:112758502	LOC401397	-1.08	-4.9	-0.37	2.49e-6	Parental extreme longevity (95 years and older);
UCEC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-0.83	-6.54	-0.47	9.61e-10	Body mass index;
UCEC	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-5.77	-0.43	4.58e-8	Pediatric autoimmune diseases;
UCEC	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.04	-12.94	-0.73	4.71e-26	Body mass index;
UCEC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.51	-5.62	-0.42	9.34e-8	Menopause (age at onset);
UCEC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-4.86	-0.37	2.97e-6	Hypospadias;
UCEC	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.49	4.89	0.37	2.56e-6	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-6.27	-0.46	3.88e-9	Dental caries;
UCEC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg26114124	chr12:9217669	LOC144571	0.41	4.97	0.38	1.83e-6	Sjögren's syndrome;
UCEC	cis	rs12145833	0.920	rs12354170	chr1:243457776	G/T	cg02356786	chr1:243265016	LOC731275	0.75	5.07	0.39	1.18e-6	Obesity (early onset extreme);
UCEC	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.28	0.4	4.47e-7	Total body bone mineral density;
UCEC	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg03859395	chr2:55845619	SMEK2	0.96	12.98	0.73	3.68e-26	Metabolic syndrome;
UCEC	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.55	6.39	0.47	2.04e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg01072550	chr1:21505969	NA	-0.6	-6.34	-0.46	2.62e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg13147721	chr7:65941812	NA	-0.7	-4.99	-0.38	1.65e-6	Diabetic kidney disease;
UCEC	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4074536	0.796	rs12562553	chr1:116309799	G/A	cg21648376	chr1:116311395	CASQ2	-0.5	-4.89	-0.37	2.66e-6	QRS duration;
UCEC	cis	rs9309473	0.950	rs10207264	chr2:73714097	G/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.35	-0.4	3.33e-7	Metabolite levels;
UCEC	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg26031613	chr14:104095156	KLC1	0.59	5.63	0.42	8.75e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	7.57	0.53	3.71e-12	Schizophrenia;
UCEC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.55	5.83	0.43	3.46e-8	Corneal astigmatism;
UCEC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	cis	rs7113850	0.541	rs11819948	chr11:24231257	A/C	ch.11.24196551F	chr11:24239977	NA	0.65	5.09	0.39	1.08e-6	Bone fracture in osteoporosis;
UCEC	cis	rs12618769	0.597	rs4850875	chr2:99069815	A/G	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	0.82	7.09	0.5	5.23e-11	Nonalcoholic fatty liver disease;
UCEC	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	0.98	8.19	0.56	1.14e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.41	4.77	0.37	4.39e-6	Blood metabolite levels;
UCEC	cis	rs7546668	1.000	rs4661640	chr1:15854882	T/G	cg05660106	chr1:15850417	CASP9	-0.45	-4.82	-0.37	3.57e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1043099	1.000	rs1043099	chr22:30681257	C/G	cg23383138	chr22:30885012	SEC14L4	-0.5	-4.51	-0.35	1.3e-5	Rheumatoid arthritis;
UCEC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.59	-4.6	-0.35	9.23e-6	Neutrophil percentage of white cells;
UCEC	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.58	5.88	0.44	2.67e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.63	-7.41	-0.52	9.24e-12	Body mass index;
UCEC	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1215050	0.558	rs35714120	chr4:98465844	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-4.69	-0.36	6.19e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.51	5.09	0.39	1.06e-6	Neuroticism;
UCEC	cis	rs2481665	0.777	rs17379217	chr1:62545085	C/T	cg18591186	chr1:62594603	INADL	-0.48	-5.11	-0.39	9.84e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs11748684	1.000	rs13357320	chr5:42313916	A/T	cg23982445	chr2:394333	NA	0.88	6.68	0.48	4.53e-10	Response to taxane treatment (docetaxel);
UCEC	cis	rs7336933	0.932	rs7320843	chr13:42529758	T/C	cg18400088	chr13:41634674	WBP4	0.56	4.71	0.36	5.78e-6	Calcium levels;
UCEC	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-6.78	-0.49	2.67e-10	Coffee consumption (cups per day);
UCEC	cis	rs7219021	0.886	rs3887854	chr17:46868710	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	4.59	0.35	9.36e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg17105886	chr17:28927953	LRRC37B2	0.63	4.61	0.36	8.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs883565	0.655	rs1608728	chr3:39089560	C/T	cg01426195	chr3:39028469	NA	-0.75	-9.83	-0.63	7.69e-18	Handedness;
UCEC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.51	5.24	0.4	5.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg17279458	chr3:44753948	ZNF502	-0.42	-4.6	-0.35	9.15e-6	Depressive symptoms;
UCEC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg15147215	chr3:52552868	STAB1	-0.42	-4.56	-0.35	1.07e-5	Electroencephalogram traits;
UCEC	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.53	5.13	0.39	9.04e-7	Systolic blood pressure;
UCEC	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.82	-6.33	-0.46	2.86e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.56	4.81	0.37	3.77e-6	Dental caries;
UCEC	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.71	-0.43	5.96e-8	Fear of minor pain;
UCEC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg03543861	chr21:44258195	NA	0.47	4.88	0.37	2.77e-6	Information processing speed;
UCEC	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.6	0.35	9.04e-6	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.58	5.59	0.42	1.09e-7	Corneal astigmatism;
UCEC	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.77	8.17	0.56	1.31e-13	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg16797656	chr11:68205561	LRP5	0.47	5.34	0.4	3.48e-7	Total body bone mineral density;
UCEC	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.63	-6.6	-0.48	7.14e-10	Magnesium levels;
UCEC	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.48	-6.72	-0.48	3.79e-10	Height;
UCEC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.34	-0.46	2.63e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.83	0.37	3.41e-6	Morning vs. evening chronotype;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.5	-0.41	1.67e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	0.82	6.99	0.5	8.86e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg03078520	chr22:18463400	MICAL3	-0.52	-5.19	-0.39	6.99e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.23	-14.01	-0.76	7.4e-29	Type 1 diabetes nephropathy;
UCEC	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.27	-7.19	-0.51	3.04e-11	Schizophrenia;
UCEC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg04473437	chr5:205334	CCDC127	-0.73	-5.33	-0.4	3.56e-7	Asthma (childhood onset);
UCEC	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.8	5.62	0.42	9.48e-8	Psoriasis;
UCEC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	6.15	0.45	6.92e-9	Joint mobility (Beighton score);
UCEC	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg01072550	chr1:21505969	NA	-0.53	-5.0	-0.38	1.6e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6546886	0.912	rs60279245	chr2:74312743	T/G	cg14702570	chr2:74259524	NA	-0.42	-5.36	-0.4	3.2e-7	Dialysis-related mortality;
UCEC	cis	rs2136093	0.506	rs12142230	chr1:90865496	C/T	cg01786362	chr1:90274359	NA	-0.42	-4.85	-0.37	3.16e-6	Response to antidepressants;
UCEC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg03714773	chr7:91764589	CYP51A1	-0.38	-4.64	-0.36	7.61e-6	Breast cancer;
UCEC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.56	-5.36	-0.4	3.22e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.71	-5.49	-0.41	1.71e-7	Calcium levels;
UCEC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	0.96	5.94	0.44	1.94e-8	Skin colour saturation;
UCEC	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.38	4.59	0.35	9.27e-6	Colorectal or endometrial cancer;
UCEC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg15358701	chr1:161410459	NA	0.9	5.37	0.4	3.05e-7	Rheumatoid arthritis;
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.08	-9.65	-0.62	2.3e-17	Platelet count;
UCEC	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.19	17.0	0.81	1.58e-36	Exhaled nitric oxide output;
UCEC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.69	-6.18	-0.45	5.93e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.68	5.62	0.42	9.16e-8	Corneal astigmatism;
UCEC	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-10.44	-0.65	2e-19	Chronic sinus infection;
UCEC	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.69	-4.93	-0.38	2.2e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.52	6.02	0.44	1.32e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1165472	0.806	rs67547117	chr1:56148536	A/G	cg11523071	chr1:56160889	NA	-0.57	-4.71	-0.36	5.6e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.53	7.57	0.53	3.69e-12	Multiple system atrophy;
UCEC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.97	0.38	1.84e-6	Personality dimensions;
UCEC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.52	-6.49	-0.47	1.23e-9	Age at first birth;
UCEC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.49	-4.64	-0.36	7.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.52	5.78	0.43	4.35e-8	Lymphocyte counts;
UCEC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-7.68	-0.53	2.09e-12	Coronary artery disease;
UCEC	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.64	4.93	0.38	2.2e-6	Orofacial clefts;
UCEC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.85	5.98	0.44	1.63e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg05695927	chr15:45694626	SPATA5L1	0.52	4.69	0.36	6.08e-6	Homoarginine levels;
UCEC	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.79	-7.86	-0.54	7.53e-13	Schizophrenia;
UCEC	cis	rs7246967	0.604	rs58536761	chr19:22880331	G/C	cg05241461	chr19:22816980	ZNF492	0.55	5.61	0.42	9.83e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.98	-0.38	1.78e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.47	4.72	0.36	5.46e-6	Adiposity;
UCEC	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-4.91	-0.38	2.38e-6	Pancreatic cancer;
UCEC	cis	rs9309473	0.500	rs12472502	chr2:73859184	C/T	cg20560298	chr2:73613845	ALMS1	0.53	5.06	0.39	1.21e-6	Metabolite levels;
UCEC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.65	-7.56	-0.53	3.94e-12	Vitiligo;
UCEC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.25	-0.46	4.32e-9	Aortic root size;
UCEC	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.82	-10.03	-0.64	2.26e-18	Coronary artery disease;
UCEC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.5	5.23	0.4	5.69e-7	Schizophrenia;
UCEC	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg01262667	chr19:19385393	TM6SF2	0.48	6.58	0.48	7.62e-10	Tonsillectomy;
UCEC	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.46	-4.76	-0.37	4.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.7	-6.22	-0.46	4.93e-9	Subjective well-being;
UCEC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.46e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.41	-4.8	-0.37	3.93e-6	Alcoholic chronic pancreatitis;
UCEC	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.17	0.45	6.44e-9	Rheumatoid arthritis;
UCEC	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.58	4.6	0.35	8.9e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.73	-0.49	3.48e-10	Eye color traits;
UCEC	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.53	5.72	0.43	5.88e-8	Lymphocyte counts;
UCEC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.45	4.54	0.35	1.15e-5	Initial pursuit acceleration;
UCEC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.47	4.66	0.36	7.13e-6	Waist circumference;Body mass index;
UCEC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.85	-0.37	3.14e-6	Testicular germ cell tumor;
UCEC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.44e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	5.59	0.42	1.06e-7	Cognitive test performance;
UCEC	cis	rs4132509	1.000	rs10803158	chr1:243923229	A/G	cg24304712	chr1:244624785	C1orf101	-0.46	-4.53	-0.35	1.23e-5	RR interval (heart rate);
UCEC	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.84	9.69	0.62	1.8e-17	Monocyte count;
UCEC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.46	5.75	0.43	5.05e-8	Monocyte count;
UCEC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.79	-7.59	-0.53	3.32e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.54	-4.54	-0.35	1.16e-5	Colorectal adenoma (advanced);
UCEC	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.58	-5.91	-0.44	2.29e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg01973587	chr1:228161476	NA	0.37	4.78	0.37	4.19e-6	Diastolic blood pressure;
UCEC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	5.35	0.4	3.25e-7	Platelet count;
UCEC	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.73	-5.49	-0.41	1.7e-7	HIV-1 control;
UCEC	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	4.98	0.38	1.75e-6	Bipolar disorder;
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.88	10.39	0.65	2.61e-19	Menarche (age at onset);
UCEC	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.67	7.57	0.53	3.69e-12	Crohn's disease;
UCEC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.84	-9.4	-0.61	9.75e-17	Cognitive function;
UCEC	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg03078520	chr22:18463400	MICAL3	-0.48	-4.91	-0.38	2.41e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.81	8.04	0.55	2.77e-13	Smoking behavior;
UCEC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg09491104	chr22:46646882	C22orf40	-0.68	-7.77	-0.54	1.26e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.36	8.58e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.83	-0.7	4.16e-23	Primary sclerosing cholangitis;
UCEC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg27535305	chr1:53392650	SCP2	0.43	5.33	0.4	3.6e-7	Monocyte count;
UCEC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.62	5.8	0.43	3.82e-8	Type 2 diabetes;
UCEC	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.83	6.5	0.47	1.17e-9	Lymphocyte counts;
UCEC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg12559939	chr2:27858050	GPN1	-0.45	-4.68	-0.36	6.48e-6	Oral cavity cancer;
UCEC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.75	8.37	0.57	4.13e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.63	5.53	0.41	1.44e-7	Cocaine dependence;
UCEC	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.88	-7.21	-0.51	2.72e-11	Coronary artery calcification;
UCEC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.57	-4.54	-0.35	1.14e-5	Menopause (age at onset);
UCEC	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.48	4.74	0.36	4.94e-6	Colorectal cancer;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.62	6.7	0.48	4.2e-10	Menarche (age at onset);
UCEC	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12379764	chr21:47803548	PCNT	-0.41	-4.66	-0.36	7.17e-6	Testicular germ cell tumor;
UCEC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.53	-6.03	-0.45	1.25e-8	Lung cancer;
UCEC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.48	-5.2	-0.39	6.56e-7	Pulse pressure;
UCEC	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-0.8	-7.12	-0.51	4.46e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.28	0.4	4.62e-7	Height;
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.29	0.4	4.43e-7	Platelet count;
UCEC	cis	rs1468333	1.000	rs2967784	chr5:137539239	C/T	cg07848042	chr5:137667509	CDC25C	0.47	4.62	0.36	8.41e-6	Resting heart rate;
UCEC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg14438399	chr17:27053147	TLCD1	0.58	4.63	0.36	8.07e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	7.42	0.52	8.66e-12	Platelet count;
UCEC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26207909	chr14:103986467	CKB	0.51	5.44	0.41	2.15e-7	Body mass index;
UCEC	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.43	5.08	0.39	1.13e-6	Height;
UCEC	cis	rs12475964	0.932	rs3856500	chr2:37387286	A/T	cg20091297	chr2:37572423	QPCT	0.47	4.56	0.35	1.06e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.58	7.05	0.5	6.56e-11	Menopause (age at onset);
UCEC	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg23795048	chr12:9217529	LOC144571	0.41	4.67	0.36	6.67e-6	Sjögren's syndrome;
UCEC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg23795048	chr12:9217529	LOC144571	0.42	5.22	0.4	5.95e-7	Sjögren's syndrome;
UCEC	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.41	0.41	2.47e-7	Rheumatoid arthritis;
UCEC	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.56	6.03	0.45	1.29e-8	Mean platelet volume;
UCEC	cis	rs4499344	0.696	rs2868153	chr19:33099277	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	6.2	0.46	5.51e-9	Mean platelet volume;
UCEC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.76	8.6	0.58	1.08e-14	Mortality in heart failure;
UCEC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.64	0.48	5.59e-10	Coffee consumption (cups per day);
UCEC	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.51	5.3	0.4	4.16e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.67	5.71	0.43	6.12e-8	Breast cancer;
UCEC	cis	rs7072216	0.687	rs7097625	chr10:100158922	A/T	cg19567339	chr10:100142640	NA	0.55	6.74	0.49	3.36e-10	Metabolite levels;
UCEC	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.56	6.13	0.45	7.73e-9	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
UCEC	cis	rs61776719	0.875	rs28435150	chr1:38407014	C/T	cg17077180	chr1:38461687	NA	0.62	6.79	0.49	2.63e-10	Coronary artery disease;
UCEC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.88	9.7	0.62	1.65e-17	Breast cancer;
UCEC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg22166914	chr1:53195759	ZYG11B	0.49	4.97	0.38	1.86e-6	Monocyte count;
UCEC	cis	rs1932064	0.536	rs72926259	chr1:71135793	G/T	cg15201877	chr1:71512973	PTGER3	-0.82	-5.43	-0.41	2.25e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg19041857	chr6:27730383	NA	-0.45	-4.58	-0.35	9.85e-6	Pubertal anthropometrics;
UCEC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.61	6.93	0.5	1.24e-10	QRS complex (12-leadsum);
UCEC	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.53	5.27	0.4	4.69e-7	Dupuytren's disease;
UCEC	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg14092571	chr14:90743983	NA	-0.44	-5.97	-0.44	1.69e-8	Mortality in heart failure;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.43	-5.13	-0.39	8.86e-7	Myopia;
UCEC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.56	-4.82	-0.37	3.56e-6	Menarche (age at onset);
UCEC	cis	rs6832769	0.961	rs2412647	chr4:56319105	C/T	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7709377	0.546	rs11950936	chr5:115447314	T/A	cg23108291	chr5:115420582	COMMD10	0.49	5.02	0.38	1.47e-6	Metabolite levels  (X-11787);
UCEC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg02160872	chr5:212506	CCDC127	-0.75	-7.25	-0.51	2.21e-11	Breast cancer;
UCEC	cis	rs7219021	0.926	rs56144347	chr17:46856640	C/T	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg20127549	chr11:118868876	CCDC84	-0.44	-4.51	-0.35	1.33e-5	Cholesterol, total;
UCEC	cis	rs713477	1.000	rs7148481	chr14:55909267	G/A	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.7	-8.15	-0.56	1.44e-13	Electrocardiographic conduction measures;
UCEC	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.31e-5	Dementia with Lewy bodies;
UCEC	cis	rs5770917	1.000	rs2269385	chr22:51010939	G/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.7	-4.89	-0.37	2.56e-6	Narcolepsy;
UCEC	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.76	-7.32	-0.52	1.49e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.47	4.6	0.36	8.87e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.2e-7	Systemic lupus erythematosus;
UCEC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.43	-0.41	2.27e-7	Platelet count;
UCEC	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg18681998	chr4:17616180	MED28	0.61	6.76	0.49	3.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	4.86	0.37	3.02e-6	Breast cancer;
UCEC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.59	4.7	0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.62	0.36	8.27e-6	Menopause (age at onset);
UCEC	cis	rs11761441	0.640	rs11772211	chr7:88552	T/C	cg06458707	chr7:1083209	C7orf50	0.25	4.65	0.36	7.34e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	5.44	0.41	2.18e-7	Eosinophil percentage of white cells;
UCEC	cis	rs10507349	1.000	rs35328831	chr13:26780341	T/C	cg01600817	chr13:26797529	RNF6	-0.49	-4.83	-0.37	3.46e-6	Type 2 diabetes;
UCEC	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg06660395	chr4:1396306	NA	-0.36	-4.56	-0.35	1.05e-5	Systolic blood pressure;
UCEC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.61	-5.87	-0.44	2.79e-8	Acne (severe);
UCEC	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg16583315	chr14:65563665	MAX	-0.4	-4.66	-0.36	6.94e-6	Obesity-related traits;
UCEC	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	0.92	5.99	0.44	1.57e-8	Skin colour saturation;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.21	-0.46	5.09e-9	Cardiac Troponin-T levels;
UCEC	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	6.09	0.45	9.37e-9	LDL cholesterol;
UCEC	cis	rs308403	0.509	rs9990804	chr4:123671984	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.71	9.13	0.6	4.89e-16	Blood protein levels;
UCEC	cis	rs78487399	0.808	rs17030818	chr2:43680318	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg09120320	chr17:61926383	NA	0.47	4.88	0.37	2.77e-6	Prudent dietary pattern;
UCEC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26314531	chr2:26401878	FAM59B	-0.63	-4.75	-0.36	4.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	-0.55	-6.32	-0.46	3.01e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.47	-4.77	-0.37	4.38e-6	Neuroticism;
UCEC	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.57	0.42	1.18e-7	Breast cancer;
UCEC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg23625390	chr15:77176239	SCAPER	0.5	4.95	0.38	1.98e-6	Blood metabolite levels;
UCEC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.87	10.76	0.66	2.83e-20	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.01	-5.02	-0.38	1.49e-6	Mitochondrial DNA levels;
UCEC	cis	rs12980942	0.935	rs34075897	chr19:41826598	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.59	5.37	0.4	3e-7	Coronary artery disease;
UCEC	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.56	5.98	0.44	1.66e-8	Mean platelet volume;
UCEC	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.57	6.04	0.45	1.23e-8	Blood protein levels;
UCEC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg23888215	chr10:79422304	NA	-0.99	-7.6	-0.53	3.24e-12	Bone mineral density;
UCEC	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.49	-4.87	-0.37	2.82e-6	IgG glycosylation;
UCEC	cis	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg27171509	chr10:82033454	MAT1A	-0.46	-4.89	-0.37	2.66e-6	Borderline personality disorder;
UCEC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.29	0.4	4.29e-7	Breast cancer;
UCEC	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.44	4.59	0.35	9.32e-6	Schizophrenia;
UCEC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.47	-4.71	-0.36	5.65e-6	Blood metabolite levels;
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-7.36	-0.52	1.22e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg20965017	chr5:231967	SDHA	-0.54	-4.99	-0.38	1.72e-6	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.6	0.42	9.99e-8	Prudent dietary pattern;
UCEC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg09910674	chr16:89028015	CBFA2T3	0.6	4.54	0.35	1.16e-5	Skin colour saturation;
UCEC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.7	0.48	4.21e-10	Cognitive test performance;
UCEC	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.43	4.51	0.35	1.33e-5	Response to temozolomide;
UCEC	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	0.77	4.73	0.36	5.17e-6	Cerebrospinal fluid biomarker levels;
UCEC	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.08	-0.5	5.57e-11	Colorectal cancer;
UCEC	cis	rs6832769	1.000	rs6832769	chr4:56298194	C/T	cg05960024	chr4:56376020	CLOCK	0.52	5.42	0.41	2.42e-7	Personality dimensions;
UCEC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg01262667	chr19:19385393	TM6SF2	0.51	6.9	0.49	1.45e-10	Tonsillectomy;
UCEC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg00800038	chr16:89945340	TCF25	-0.79	-4.61	-0.36	8.81e-6	Skin colour saturation;
UCEC	cis	rs7517126	1.000	rs7519492	chr1:196840125	T/C	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.55	-4.78	-0.37	4.27e-6	Longevity;
UCEC	cis	rs6717918	0.564	rs3116185	chr2:233036247	A/G	cg02061626	chr2:233274167	ALPPL2	-0.51	-5.48	-0.41	1.76e-7	Height;
UCEC	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.62	-5.27	-0.4	4.75e-7	Cardiac Troponin-T levels;
UCEC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg05695927	chr15:45694626	SPATA5L1	0.47	4.69	0.36	6.09e-6	Homoarginine levels;
UCEC	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.65	-7.7	-0.54	1.82e-12	Schizophrenia;
UCEC	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.58	5.89	0.44	2.49e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.04e-14	Menarche (age at onset);
UCEC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.58	5.18	0.39	7.18e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15320075	chr8:145703422	NA	0.55	5.29	0.4	4.34e-7	Age at first birth;
UCEC	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg13683864	chr3:40499215	RPL14	0.7	7.75	0.54	1.37e-12	Renal cell carcinoma;
UCEC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.06	-0.39	1.22e-6	Personality dimensions;
UCEC	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13683864	chr3:40499215	RPL14	0.86	10.4	0.65	2.47e-19	Renal cell carcinoma;
UCEC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.9	-11.57	-0.69	2.06e-22	Height;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12112058	chr1:224622605	WDR26	0.53	7.14	0.51	3.92e-11	Warfarin maintenance dose;
UCEC	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.55	-5.34	-0.4	3.39e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17106184	1.000	rs2137676	chr1:51217839	C/G	cg07174182	chr1:51127561	FAF1	-0.82	-5.25	-0.4	5.23e-7	Type 2 diabetes;
UCEC	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	4.95	0.38	1.97e-6	Personality dimensions;
UCEC	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg23070574	chr3:14187308	XPC	0.46	5.19	0.39	6.97e-7	Ovarian reserve;
UCEC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-9.06	-0.6	7.49e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.44	-4.95	-0.38	2e-6	Electroencephalogram traits;
UCEC	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs785830	0.717	rs600951	chr9:224742	A/G	cg14500300	chr9:211689	NA	0.37	4.91	0.38	2.35e-6	Platelet distribution width;
UCEC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.6	5.28	0.4	4.64e-7	Major depressive disorder;
UCEC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.78	-8.46	-0.57	2.47e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	9.27	0.61	2.12e-16	Platelet count;
UCEC	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.96	-0.38	1.93e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.62	-6.23	-0.46	4.73e-9	Parkinson's disease;
UCEC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg05738196	chr6:26577821	NA	0.63	7.3	0.52	1.66e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-5.33	-0.4	3.6e-7	Hepatocellular carcinoma;
UCEC	cis	rs3015497	0.616	rs4901044	chr14:51090295	A/G	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.37e-6	Mean platelet volume;
UCEC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.51	5.0	0.38	1.61e-6	Parkinson's disease;
UCEC	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.72	-0.48	3.81e-10	Eye color traits;
UCEC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg20965017	chr5:231967	SDHA	-0.62	-5.71	-0.43	6.13e-8	Breast cancer;
UCEC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.25	14.95	0.78	2.58e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.65	-7.46	-0.52	6.79e-12	Menarche (age at onset);
UCEC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg15145296	chr3:125709740	NA	-0.64	-4.54	-0.35	1.17e-5	Blood pressure (smoking interaction);
UCEC	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.61	-6.81	-0.49	2.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.82	-9.22	-0.61	2.97e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs7115242	0.800	rs4245168	chr11:116882638	C/A	cg13068653	chr11:117074303	TAGLN	0.53	4.59	0.35	9.3e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
UCEC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.68	7.11	0.51	4.64e-11	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg21856205	chr7:94953877	PON1	-0.55	-5.16	-0.39	7.96e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs77861329	1.000	rs9841469	chr3:52166596	C/A	cg08692210	chr3:52188851	WDR51A	0.86	6.58	0.48	7.74e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg17330251	chr7:94953956	PON1	-0.54	-4.71	-0.36	5.73e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.53	-0.35	1.2e-5	Height;
UCEC	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-4.97	-0.38	1.86e-6	Schizophrenia;
UCEC	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.5	4.89	0.37	2.62e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs7246967	0.866	rs12972095	chr19:23034510	C/A	cg24889512	chr19:22816950	ZNF492	0.5	5.12	0.39	9.34e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg11632617	chr15:75315747	PPCDC	-0.55	-4.88	-0.37	2.7e-6	Lung cancer;
UCEC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.65	6.85	0.49	1.83e-10	Menopause (age at onset);
UCEC	cis	rs427941	0.706	rs7788596	chr7:101839486	C/T	cg08135718	chr7:101819329	CUX1	0.45	5.26	0.4	4.99e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg04756594	chr16:24857601	SLC5A11	0.44	5.3	0.4	4.13e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	5.45	0.41	2.12e-7	Menarche (age at onset);
UCEC	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.2	-9.97	-0.64	3.38e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.68	7.22	0.51	2.63e-11	Menarche (age at onset);
UCEC	cis	rs61776719	0.840	rs35267671	chr1:38397369	C/T	cg17077180	chr1:38461687	NA	0.63	6.86	0.49	1.78e-10	Coronary artery disease;
UCEC	cis	rs3852527	0.673	rs3852529	chr11:2827486	C/T	cg03686395	chr11:1972199	MRPL23	0.75	4.62	0.36	8.39e-6	Bacterial meningitis;
UCEC	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07215822	chr6:158701037	NA	-0.68	-5.76	-0.43	4.85e-8	Height;
UCEC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Body mass index;
UCEC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.38	5.45	0.41	2.1e-7	Prostate cancer;
UCEC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.5	5.83	0.43	3.42e-8	Breast cancer;
UCEC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg22974920	chr21:40686053	BRWD1	0.61	5.36	0.4	3.1e-7	Cognitive function;
UCEC	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	1.12	14.07	0.76	4.96e-29	Body mass index;
UCEC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg09264619	chr17:80180166	NA	0.39	4.53	0.35	1.19e-5	Life satisfaction;
UCEC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg06562184	chr8:19319451	CSGALNACT1	-0.57	-6.04	-0.45	1.22e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs539096	0.749	rs12076635	chr1:44026656	G/C	cg11851915	chr1:44060116	PTPRF	0.42	4.65	0.36	7.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.62	5.99	0.44	1.57e-8	Lymphocyte counts;
UCEC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.51	4.85	0.37	3.13e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7336933	1.000	rs7319447	chr13:42551508	C/T	cg01440489	chr13:41593385	ELF1	0.71	4.96	0.38	1.96e-6	Calcium levels;
UCEC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	5.42	0.41	2.34e-7	Breast cancer;
UCEC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	0.97	6.52	0.47	1.07e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg19743168	chr1:23544995	NA	0.47	6.19	0.45	5.7e-9	Height;
UCEC	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.65	6.64	0.48	5.8e-10	Systemic lupus erythematosus;
UCEC	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg22907277	chr7:1156413	C7orf50	0.68	6.7	0.48	4.24e-10	Longevity;Endometriosis;
UCEC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.2	0.46	5.53e-9	Personality dimensions;
UCEC	cis	rs1491976	0.837	rs4680440	chr3:151167269	A/G	cg11178810	chr3:150479760	SIAH2	-0.55	-4.8	-0.37	3.85e-6	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs925550	0.932	rs6844999	chr4:123581235	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.61	-5.82	-0.43	3.52e-8	Primary biliary cholangitis;
UCEC	cis	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg20307385	chr11:47447363	PSMC3	0.65	4.68	0.36	6.58e-6	Axial length;
UCEC	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg18367735	chr17:79674897	NA	0.53	4.71	0.36	5.68e-6	Dental caries;
UCEC	cis	rs7103648	0.569	rs10769282	chr11:47626492	T/G	cg20307385	chr11:47447363	PSMC3	0.92	8.05	0.55	2.53e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg04374321	chr14:90722782	PSMC1	0.56	4.76	0.37	4.66e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.52	6.09	0.45	9.27e-9	Oral cavity cancer;
UCEC	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-6.41	-0.47	1.82e-9	Rheumatoid arthritis;
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.54	4.74	0.36	5.07e-6	Response to diuretic therapy;
UCEC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	4.67	0.36	6.79e-6	Obesity-related traits;
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	6.86	0.49	1.77e-10	Platelet count;
UCEC	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.56	4.65	0.36	7.45e-6	Lung cancer;
UCEC	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.34	-4.72	-0.36	5.51e-6	Cancer;
UCEC	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	6.19	0.45	5.7e-9	Coronary artery disease;
UCEC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6717918	0.545	rs3116196	chr2:233063576	G/C	cg02061626	chr2:233274167	ALPPL2	0.5	5.25	0.4	5.15e-7	Height;
UCEC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg00738919	chr7:1100172	C7orf50	0.74	4.59	0.35	9.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.62	-0.36	8.29e-6	Type 2 diabetes;
UCEC	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.64	6.45	0.47	1.55e-9	Body mass index;
UCEC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.64	6.57	0.48	8.2e-10	Menopause (age at onset);
UCEC	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg07636037	chr3:49044803	WDR6	0.58	4.71	0.36	5.73e-6	Menarche (age at onset);
UCEC	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.65	7.25	0.51	2.15e-11	Breast cancer;
UCEC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg13147721	chr7:65941812	NA	0.94	6.91	0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg24687543	chr11:63912206	MACROD1	0.45	5.36	0.4	3.12e-7	Platelet count;
UCEC	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.5	5.46	0.41	2e-7	Platelet distribution width;
UCEC	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.58	5.33	0.4	3.6e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.78	8.34	0.57	4.95e-14	Multiple sclerosis;
UCEC	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.62	7.13	0.51	4.16e-11	Blood metabolite ratios;
UCEC	cis	rs7246967	0.932	rs34373479	chr19:23043862	A/G	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.54e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.55	5.66	0.42	7.53e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.67	6.16	0.45	6.56e-9	Multiple sclerosis;
UCEC	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-5.11	-0.39	9.78e-7	Morning vs. evening chronotype;
UCEC	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.68	7.48	0.53	6.16e-12	Neuroticism;
UCEC	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg14092571	chr14:90743983	NA	0.41	5.45	0.41	2.08e-7	Mortality in heart failure;
UCEC	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs244899	0.935	rs590784	chr5:167917504	G/T	cg06604206	chr5:167912465	RARS	-0.35	-4.5	-0.35	1.36e-5	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-5.16	-0.39	7.84e-7	Hemoglobin concentration;
UCEC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.52	-5.4	-0.41	2.6e-7	Longevity;
UCEC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg08493051	chr2:3487164	NA	-0.58	-5.45	-0.41	2.09e-7	Neurofibrillary tangles;
UCEC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.47	0.57	2.33e-14	Prudent dietary pattern;
UCEC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.71	6.31	0.46	3.08e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-5.23	-0.4	5.75e-7	Platelet distribution width;
UCEC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.98e-7	Aortic root size;
UCEC	cis	rs4588572	0.606	rs2362828	chr5:77718835	C/T	cg11547950	chr5:77652471	NA	-0.37	-4.58	-0.35	9.8e-6	Triglycerides;
UCEC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.52	0.35	1.28e-5	Menopause (age at onset);
UCEC	cis	rs394563	0.839	rs584916	chr6:149790319	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.4	-4.85	-0.37	3.17e-6	Dupuytren's disease;
UCEC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg14675211	chr2:100938903	LONRF2	0.52	5.61	0.42	9.91e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-5.16	-0.39	7.9e-7	Blood metabolite levels;
UCEC	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.36	-4.96	-0.38	1.89e-6	Primary biliary cholangitis;
UCEC	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	1.04	8.4	0.57	3.43e-14	Vitiligo;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.81	8.9	0.59	1.92e-15	Longevity;Endometriosis;
UCEC	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.71	7.49	0.53	5.89e-12	Itch intensity from mosquito bite;
UCEC	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.46	4.75	0.36	4.72e-6	Height;
UCEC	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg27246729	chr12:121163418	ACADS	0.49	4.67	0.36	6.7e-6	Mean corpuscular volume;
UCEC	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.69	6.24	0.46	4.47e-9	Migraine;
UCEC	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg21770322	chr7:97807741	LMTK2	0.52	6.12	0.45	8.16e-9	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.43	-0.74	2.46e-27	Height;
UCEC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.83	0.37	3.4e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.81	-0.63	8.76e-18	Leprosy;
UCEC	cis	rs7246967	0.932	rs4932801	chr19:23051653	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05756301	chr6:128901562	NA	-0.55	-7.07	-0.5	5.9e-11	Warfarin maintenance dose;
UCEC	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.74	-9.43	-0.61	8.43e-17	Body mass index;
UCEC	cis	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg00086871	chr4:6988644	TBC1D14	0.84	6.01	0.44	1.38e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg24687543	chr11:63912206	MACROD1	0.41	4.62	0.36	8.23e-6	Platelet count;
UCEC	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.14	-0.39	8.65e-7	Morning vs. evening chronotype;
UCEC	cis	rs9309473	1.000	rs58603761	chr2:73726605	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-5.52	-0.41	1.51e-7	Metabolite levels;
UCEC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.65	6.36	0.46	2.4e-9	Aortic root size;
UCEC	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.52	-5.2	-0.39	6.5e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.49	-5.26	-0.4	4.93e-7	Response to temozolomide;
UCEC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.7	8.36	0.57	4.33e-14	Prudent dietary pattern;
UCEC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg18681998	chr4:17616180	MED28	0.7	7.58	0.53	3.67e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.53	6.56	0.48	8.71e-10	Total body bone mineral density;
UCEC	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.71	-7.79	-0.54	1.1e-12	Breast cancer;
UCEC	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.61	7.36	0.52	1.24e-11	Oral cavity cancer;
UCEC	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.68	-6.55	-0.48	8.9e-10	Platelet distribution width;
UCEC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.56	5.06	0.39	1.21e-6	Red cell distribution width;
UCEC	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	0.97	9.72	0.63	1.53e-17	Caffeine consumption;
UCEC	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.29e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.6	6.76	0.49	3.08e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-12.07	-0.71	9.84e-24	Ulcerative colitis;
UCEC	trans	rs1459104	1.000	rs12574577	chr11:55306742	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.58	-0.58	1.25e-14	Mean platelet volume;
UCEC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.4	-4.54	-0.35	1.18e-5	Diastolic blood pressure;
UCEC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.42	-5.06	-0.39	1.22e-6	Birth weight;
UCEC	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.51	4.64	0.36	7.62e-6	Hemoglobin concentration;
UCEC	cis	rs7560272	0.723	rs7609249	chr2:73813820	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.0	-0.38	1.63e-6	Schizophrenia;
UCEC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.63	6.99	0.5	8.89e-11	Tonsillectomy;
UCEC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	17.62	0.82	4.64e-38	IgG glycosylation;
UCEC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.95	0.5	1.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.34e-8	Lung cancer;
UCEC	cis	rs11697848	0.581	rs117940375	chr20:48546211	C/T	cg17849948	chr20:48532315	SPATA2	1.07	5.16	0.39	7.99e-7	Systemic lupus erythematosus;
UCEC	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.57	5.72	0.43	5.83e-8	Colorectal cancer;
UCEC	cis	rs17123764	0.710	rs12320556	chr12:49973011	A/G	cg20471783	chr12:50157085	TMBIM6	0.65	5.33	0.4	3.66e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.9	-0.49	1.41e-10	Response to antipsychotic treatment;
UCEC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.73	6.74	0.49	3.4e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2892463	0.757	rs2761940	chr13:30409870	A/G	cg18356743	chr13:30408050	UBL3	0.4	4.53	0.35	1.21e-5	Non-word repetition;
UCEC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.37	-8.68	-0.58	7.08e-15	Diabetic kidney disease;
UCEC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg13777783	chr17:79615861	NA	-0.34	-4.8	-0.37	3.88e-6	Eye color traits;
UCEC	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.79	-5.92	-0.44	2.15e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs1712517	0.771	rs11191672	chr10:105138961	C/T	cg05636881	chr10:105038444	INA	0.43	5.06	0.39	1.23e-6	Migraine;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.52	-5.65	-0.42	8.01e-8	Aortic root size;
UCEC	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.61	7.52	0.53	5.13e-12	Menopause (age at onset);
UCEC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05472934	chr7:22766657	IL6	0.76	7.5	0.53	5.55e-12	Lung cancer;
UCEC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.5	-5.16	-0.39	8.02e-7	Dental caries;
UCEC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.61	-0.48	6.59e-10	Pubertal anthropometrics;
UCEC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.69	-7.27	-0.51	1.93e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	5.68	0.42	6.9e-8	Systolic blood pressure;
UCEC	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.41	-5.26	-0.4	4.94e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg05738196	chr6:26577821	NA	0.59	5.65	0.42	7.88e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.55e-9	Lung cancer;
UCEC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.15	-0.45	7.12e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.55	5.05	0.38	1.31e-6	Selective IgA deficiency;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg25116125	chr15:45927086	SQRDL	0.56	6.71	0.48	4.03e-10	N-glycan levels;
UCEC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.35	-4.53	-0.35	1.22e-5	Refractive error;
UCEC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.79	-8.48	-0.57	2.21e-14	Longevity;Endometriosis;
UCEC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.68	8.21	0.56	1.01e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6835098	0.539	rs1383628	chr4:174194453	C/T	cg08422745	chr4:174089978	GALNT7	-0.65	-6.23	-0.46	4.63e-9	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9309473	0.898	rs10209517	chr2:73845392	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-4.92	-0.38	2.25e-6	Metabolite levels;
UCEC	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-1.06	-9.33	-0.61	1.49e-16	Dupuytren's disease;
UCEC	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.37	-0.47	2.3e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs4588572	0.643	rs9293747	chr5:77705567	A/G	cg11547950	chr5:77652471	NA	-0.44	-5.02	-0.38	1.45e-6	Triglycerides;
UCEC	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg13147721	chr7:65941812	NA	-0.97	-6.48	-0.47	1.29e-9	Diabetic kidney disease;
UCEC	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.53	-5.33	-0.4	3.6e-7	Hepatocellular carcinoma;
UCEC	cis	rs2839627	0.638	rs8134227	chr21:44257902	C/T	cg03543861	chr21:44258195	NA	0.51	5.27	0.4	4.71e-7	Information processing speed;
UCEC	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	0.95	5.76	0.43	4.85e-8	Gut microbiota (bacterial taxa);
UCEC	cis	rs2519974	0.586	rs208637	chr16:22915146	A/G	cg15042806	chr16:23652268	DCTN5;PALB2	-0.45	-4.99	-0.38	1.69e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide);
UCEC	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg06166341	chr4:1223170	CTBP1	0.6	5.48	0.41	1.82e-7	Systolic blood pressure;
UCEC	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13683864	chr3:40499215	RPL14	1.11	15.74	0.79	2.37e-33	Renal cell carcinoma;
UCEC	cis	rs6728642	0.519	rs59131346	chr2:97566768	C/T	cg26665480	chr2:98280029	ACTR1B	-0.59	-4.86	-0.37	3.03e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.69	0.48	4.39e-10	Coffee consumption (cups per day);
UCEC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg18681998	chr4:17616180	MED28	0.61	6.76	0.49	3.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.98	11.46	0.69	4e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.56	-6.25	-0.46	4.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.36	0.57	4.48e-14	Platelet count;
UCEC	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.41	0.52	8.93e-12	Eye color traits;
UCEC	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	0.68	7.44	0.52	7.65e-12	Homoarginine levels;
UCEC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg01657329	chr11:68192670	LRP5	-0.64	-4.65	-0.36	7.35e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg12463550	chr7:65579703	CRCP	0.51	5.08	0.39	1.15e-6	Aortic root size;
UCEC	cis	rs1298908	1.000	rs1298908	chr10:82013134	A/G	cg01528321	chr10:82214614	TSPAN14	-0.58	-5.69	-0.43	6.51e-8	Diabetic kidney disease;
UCEC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	6.97	0.5	9.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.7	0.58	6.08e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg27631724	chr1:11040367	C1orf127	0.33	4.61	0.36	8.81e-6	Ewing sarcoma;
UCEC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.7	6.18	0.45	6.08e-9	Cognitive function;
UCEC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs223116	0.515	rs7147552	chr14:23964203	C/T	cg15440973	chr14:24610792	FAM158A	0.53	4.56	0.35	1.06e-5	Resting heart rate;
UCEC	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.4	4.61	0.36	8.6e-6	Mean platelet volume;
UCEC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-13.27	-0.74	6.55e-27	Height;
UCEC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.67	-5.4	-0.41	2.61e-7	Response to diuretic therapy;
UCEC	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.65	-5.27	-0.4	4.77e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs16912285	0.748	rs7952223	chr11:24256443	G/C	ch.11.24196551F	chr11:24239977	NA	0.57	5.48	0.41	1.82e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.44	4.56	0.35	1.05e-5	Morning vs. evening chronotype;
UCEC	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.56	0.53	3.99e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.8	-5.43	-0.41	2.3e-7	Bipolar disorder;
UCEC	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	0.94	14.69	0.77	1.26e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg00343986	chr7:65444356	GUSB	-0.49	-4.61	-0.36	8.69e-6	Aortic root size;
UCEC	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14019695	chr9:139328340	INPP5E	0.49	5.24	0.4	5.37e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.92	9.25	0.61	2.48e-16	Post bronchodilator FEV1;
UCEC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.6	-6.51	-0.47	1.11e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-4.65	-0.36	7.44e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.64	-0.42	8.43e-8	Initial pursuit acceleration;
UCEC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg01689657	chr7:91764605	CYP51A1	0.48	6.07	0.45	1.03e-8	Breast cancer;
UCEC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.35	1.2e-5	Menarche (age at onset);
UCEC	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.76	0.37	4.51e-6	Educational attainment;
UCEC	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	6.78	0.49	2.69e-10	Motion sickness;
UCEC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.61	6.57	0.48	8.37e-10	Longevity;Endometriosis;
UCEC	cis	rs7517126	1.000	rs13375144	chr1:196841690	C/T	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.65	0.36	7.19e-6	Lung cancer;
UCEC	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26031613	chr14:104095156	KLC1	1.23	15.26	0.78	4.11e-32	Body mass index;
UCEC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg00983440	chr10:79422392	NA	-1.03	-8.12	-0.56	1.78e-13	Bone mineral density;
UCEC	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.93e-7	Celiac disease or Rheumatoid arthritis;
UCEC	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.62	-0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.66	5.59	0.42	1.06e-7	Lymphocyte counts;
UCEC	cis	rs6032067	0.852	rs6032064	chr20:43854827	A/G	cg00873616	chr20:43920241	NA	0.51	5.11	0.39	9.79e-7	Blood protein levels;
UCEC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.47	4.84	0.37	3.28e-6	Blood protein levels;
UCEC	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.1	-8.62	-0.58	1.01e-14	Vitiligo;
UCEC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.16e-5	Lung cancer;
UCEC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg20295408	chr7:1910781	MAD1L1	-0.48	-4.53	-0.35	1.23e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg11161011	chr14:65562177	MAX	-0.8	-7.61	-0.53	3.04e-12	Obesity-related traits;
UCEC	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg17274742	chr7:23286539	GPNMB	0.41	4.84	0.37	3.25e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10242455	0.867	rs2404769	chr7:99321716	T/C	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.7	-5.26	-0.4	4.99e-7	Obesity-related traits;
UCEC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.49	-4.71	-0.36	5.73e-6	Gut microbiome composition (summer);
UCEC	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	8.06	0.55	2.46e-13	Coronary artery disease;
UCEC	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.57	5.19	0.39	6.93e-7	Crohn's disease;
UCEC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.56	-5.99	-0.44	1.57e-8	Electroencephalogram traits;
UCEC	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg25150519	chr12:98850993	NA	0.57	5.22	0.4	5.89e-7	Colorectal adenoma (advanced);
UCEC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.1	-18.57	-0.84	2.22e-40	IgG glycosylation;
UCEC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.11	0.45	8.33e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg07424592	chr7:64974309	NA	0.8	4.69	0.36	6.32e-6	Diabetic kidney disease;
UCEC	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.67	-5.8	-0.43	3.99e-8	Obesity-related traits;
UCEC	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.74	8.54	0.58	1.57e-14	IgG glycosylation;
UCEC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.47	-4.87	-0.37	2.91e-6	Aortic root size;
UCEC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs1028488	0.511	rs7738104	chr6:170704196	C/G	cg20370364	chr6:170703943	FAM120B	-0.5	-5.0	-0.38	1.61e-6	Interferon alpha levels in systemic lupus erythematosus;
UCEC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.54	0.47	9.35e-10	Cognitive test performance;
UCEC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-7.13	-0.51	4.15e-11	Cognitive function;
UCEC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	trans	rs7692395	0.660	rs6822456	chr4:183650700	A/G	cg11459773	chr19:45262055	BCL3	0.8	6.68	0.48	4.71e-10	Incident myocardial infarction;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.61	-7.05	-0.5	6.47e-11	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9393813	0.529	rs2064093	chr6:27442247	C/T	cg27490387	chr6:26520793	HCG11	0.41	4.6	0.35	8.96e-6	Bipolar disorder;
UCEC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.46	-4.59	-0.35	9.27e-6	Systemic lupus erythematosus;
UCEC	cis	rs56281245	1.000	rs17103583	chr5:145044493	A/G	cg14510905	chr5:145040858	NA	-0.52	-5.24	-0.4	5.48e-7	Hepcidin levels;
UCEC	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.61	5.82	0.43	3.54e-8	Coronary artery disease;
UCEC	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.21	0.39	6.4e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.19	0.6	3.5e-16	Electrocardiographic conduction measures;
UCEC	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.36	-4.92	-0.38	2.26e-6	Primary biliary cholangitis;
UCEC	cis	rs11048434	1.000	rs1805719	chr12:9151467	A/G	cg23795048	chr12:9217529	LOC144571	0.49	5.56	0.42	1.26e-7	Sjögren's syndrome;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg24703168	chr6:28411309	ZSCAN23	0.49	5.39	0.41	2.7e-7	Cardiac Troponin-T levels;
UCEC	cis	rs41271951	0.512	rs12068365	chr1:151015868	G/A	cg00107782	chr1:151300621	NA	-0.69	-4.74	-0.36	5.04e-6	Blood protein levels;
UCEC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.99	0.38	1.66e-6	Aortic root size;
UCEC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.61	5.98	0.44	1.64e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.03	-10.24	-0.65	6.55e-19	Schizophrenia;
UCEC	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.72	7.47	0.52	6.45e-12	Primary sclerosing cholangitis;
UCEC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	12.57	0.72	4.6e-25	Height;
UCEC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.7	0.36	5.93e-6	Menopause (age at onset);
UCEC	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-5.16	-0.39	7.84e-7	Hemoglobin concentration;
UCEC	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-0.65	-7.06	-0.5	6.01e-11	Blood trace element (Zn levels);
UCEC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.61	5.73	0.43	5.51e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg02160872	chr5:212506	CCDC127	-0.67	-6.46	-0.47	1.44e-9	Breast cancer;
UCEC	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg00343986	chr7:65444356	GUSB	-0.52	-4.85	-0.37	3.16e-6	Aortic root size;
UCEC	cis	rs7246967	0.932	rs34897621	chr19:23027527	A/C	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs3770752	0.836	rs10176949	chr2:37487723	G/A	cg20091297	chr2:37572423	QPCT	0.48	4.7	0.36	5.81e-6	Schizophrenia;
UCEC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg26721908	chr21:47610096	LSS	-0.38	-4.74	-0.36	5.03e-6	Testicular germ cell tumor;
UCEC	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.19	-0.45	5.78e-9	Joint mobility (Beighton score);
UCEC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg01874867	chr7:94954059	PON1	-0.53	-5.02	-0.38	1.51e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-7.46	-0.52	7.09e-12	Educational attainment (years of education);
UCEC	cis	rs13213483	0.590	rs9455337	chr6:71833879	A/T	cg16351957	chr6:71874784	NA	0.71	5.24	0.4	5.43e-7	LDL peak particle diameter (total fat intake interaction);
UCEC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.95	11.82	0.7	4.55e-23	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.85	-10.53	-0.66	1.15e-19	Primary sclerosing cholangitis;
UCEC	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.85	10.42	0.65	2.23e-19	Leprosy;
UCEC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-5.83	-0.43	3.31e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg21214455	chr15:72412075	SENP8	0.5	4.71	0.36	5.76e-6	Red blood cell count;
UCEC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.64	5.45	0.41	2.06e-7	High light scatter reticulocyte count;
UCEC	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs11153730	0.503	rs283045	chr6:118628476	C/G	cg21191810	chr6:118973309	C6orf204	0.39	4.92	0.38	2.28e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg20283391	chr11:68216788	NA	-0.7	-4.81	-0.37	3.68e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.63	6.25	0.46	4.15e-9	Dental caries;
UCEC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg20007245	chr22:24372913	LOC391322	-0.63	-5.63	-0.42	8.98e-8	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.32	4.62	0.36	8.26e-6	Schizophrenia;
UCEC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.57	8.17	0.56	1.27e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.18e-5	Lung cancer;
UCEC	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.43	4.86	0.37	2.93e-6	HDL cholesterol;
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg00612595	chr21:47717864	NA	-0.56	-6.15	-0.45	6.99e-9	Testicular germ cell tumor;
UCEC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.54	4.74	0.36	5.07e-6	Response to diuretic therapy;
UCEC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.69	-0.48	4.43e-10	Aortic root size;
UCEC	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg16583315	chr14:65563665	MAX	-0.43	-5.76	-0.43	4.85e-8	Obesity-related traits;
UCEC	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.53	5.86	0.44	2.93e-8	Life satisfaction;
UCEC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.47	5.88	0.44	2.71e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7088591	0.867	rs74664821	chr10:59784226	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Bipolar disorder;
UCEC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	9.53	0.62	4.72e-17	Post bronchodilator FEV1;
UCEC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg21770322	chr7:97807741	LMTK2	0.85	14.96	0.78	2.41e-31	Breast cancer;
UCEC	cis	rs2692947	0.566	rs11676901	chr2:96370571	A/C	cg03595348	chr2:95999906	KCNIP3	0.46	4.81	0.37	3.63e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg14254433	chr6:34482411	PACSIN1	-0.64	-4.51	-0.35	1.34e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.55	4.62	0.36	8.28e-6	Neutrophil percentage of white cells;
UCEC	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.97	11.5	0.69	3.07e-22	Colorectal adenoma (advanced);
UCEC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.15	-7.31	-0.52	1.56e-11	Breast cancer;
UCEC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg16524733	chr11:117070046	TAGLN	-0.35	-4.56	-0.35	1.09e-5	Blood protein levels;
UCEC	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.87	-10.52	-0.66	1.18e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.77	8.74	0.58	4.87e-15	Menarche (age at onset);
UCEC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.55	-5.21	-0.4	6.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.85e-6	Testicular germ cell tumor;
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.0	0.44	1.46e-8	Platelet count;
UCEC	cis	rs79478560	0.504	rs10773046	chr12:124375210	A/G	cg17432688	chr12:123848618	NA	0.45	4.72	0.36	5.42e-6	Lymphocyte counts;
UCEC	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	4.78	0.37	4.26e-6	IgG glycosylation;
UCEC	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.67	-6.25	-0.46	4.16e-9	Body mass index;
UCEC	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.91	11.37	0.68	6.99e-22	Menarche (age at onset);
UCEC	cis	rs6813264	0.874	rs6537364	chr4:146554089	A/G	cg04181032	chr4:147165097	NA	-0.38	-4.72	-0.36	5.4e-6	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.72	-7.25	-0.51	2.23e-11	Mosquito bite size;
UCEC	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.92	-0.38	2.28e-6	Response to antipsychotic treatment;
UCEC	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg18681998	chr4:17616180	MED28	-0.57	-6.24	-0.46	4.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4869931	0.929	rs55646755	chr6:151007844	T/C	cg06471296	chr6:150259601	NA	0.35	4.54	0.35	1.14e-5	Systolic blood pressure in sickle cell anemia;
UCEC	cis	rs151997	0.962	rs28676922	chr5:50247221	C/T	cg06027927	chr5:50259733	NA	0.53	4.95	0.38	2.05e-6	Callous-unemotional behaviour;
UCEC	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.13	-0.45	7.58e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.44	0.57	2.83e-14	Smoking behavior;
UCEC	cis	rs6446731	0.593	rs6446726	chr4:3274214	T/C	cg08886695	chr4:3369023	RGS12	-0.44	-5.07	-0.39	1.19e-6	Mean platelet volume;
UCEC	cis	rs35306767	0.855	rs72778229	chr10:951991	C/A	cg20503657	chr10:835505	NA	0.9	5.31	0.4	3.91e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.74	-7.18	-0.51	3.22e-11	Body mass index;
UCEC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg27535305	chr1:53392650	SCP2	0.37	4.73	0.36	5.25e-6	Monocyte count;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05657792	chr17:6899758	ALOX12	0.44	5.49	0.41	1.73e-7	Tonsillectomy;
UCEC	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.05	0.38	1.27e-6	Rheumatoid arthritis;
UCEC	cis	rs7404928	0.681	rs66923906	chr16:23919079	C/T	cg01062539	chr16:23765258	CHP2	-0.54	-4.67	-0.36	6.87e-6	Primary biliary cholangitis;Rheumatoid arthritis;
UCEC	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.58	-0.42	1.14e-7	Hemoglobin concentration;
UCEC	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.86	6.06	0.45	1.11e-8	LDL cholesterol;
UCEC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.67	5.86	0.44	2.92e-8	Cognitive function;
UCEC	cis	rs7787478	0.515	rs117950322	chr7:97189094	C/T	cg07283849	chr7:97401062	NA	-0.79	-5.18	-0.39	7.26e-7	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.41	4.67	0.36	6.64e-6	Height;
UCEC	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.33	0.57	5.31e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg27542512	chr1:153963550	RPS27	-0.62	-6.81	-0.49	2.38e-10	Breast cancer;
UCEC	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.82	8.88	0.59	2.12e-15	Height;
UCEC	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.21	0.51	2.73e-11	Motion sickness;
UCEC	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.59	5.82	0.43	3.5e-8	Uric acid levels;
UCEC	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.79	8.59	0.58	1.19e-14	Eosinophil percentage of white cells;
UCEC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.5	-0.35	1.35e-5	Longevity;
UCEC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.17	0.39	7.58e-7	Bladder cancer;
UCEC	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg00873616	chr20:43920241	NA	0.51	5.0	0.38	1.62e-6	Blood protein levels;
UCEC	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.69	-6.8	-0.49	2.4e-10	Migraine;
UCEC	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.62	-5.98	-0.44	1.62e-8	Morning vs. evening chronotype;
UCEC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.94	11.35	0.68	8.02e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.46	4.73	0.36	5.29e-6	Pancreatic cancer;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.54	5.56	0.42	1.24e-7	Longevity;Endometriosis;
UCEC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.32e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.61	-6.78	-0.49	2.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	0.86	5.61	0.42	9.98e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.69	-7.56	-0.53	4.01e-12	Breast cancer;
UCEC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.23	-14.5	-0.77	3.92e-30	Breast cancer;
UCEC	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.49	5.28	0.4	4.57e-7	Colorectal or endometrial cancer;
UCEC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.4	-5.16	-0.39	7.89e-7	Hemoglobin concentration;
UCEC	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-4.73	-0.36	5.24e-6	Pediatric autoimmune diseases;
UCEC	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.53	-6.56	-0.48	8.71e-10	Total body bone mineral density;
UCEC	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.62	5.96	0.44	1.76e-8	Breast cancer;
UCEC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.71	-6.83	-0.49	2.11e-10	Aortic root size;
UCEC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-0.65	-5.62	-0.42	9.13e-8	Diastolic blood pressure;
UCEC	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.61	-5.67	-0.42	7.23e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs11867410	0.744	rs60038415	chr17:63959317	C/T	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.65	-5.59	-0.42	1.07e-7	Platelet count;
UCEC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs1912528	0.783	rs797090	chr4:140867514	A/G	cg01641771	chr4:140476319	SETD7	-0.45	-5.03	-0.38	1.41e-6	Educational attainment (years of education);
UCEC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	0.81	6.98	0.5	9.41e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.55	-5.52	-0.41	1.49e-7	Breast size;
UCEC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.55	-5.98	-0.44	1.62e-8	Total body bone mineral density;
UCEC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg06784218	chr1:46089804	CCDC17	-0.57	-7.34	-0.52	1.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	0.87	7.01	0.5	7.92e-11	Blood protein levels;
UCEC	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.61	-5.62	-0.42	9.19e-8	Lymphocyte counts;
UCEC	cis	rs6732160	0.656	rs2043093	chr2:73407342	G/C	cg05539622	chr2:73298971	SFXN5	0.48	4.68	0.36	6.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.44	6.43	0.47	1.69e-9	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.5	5.57	0.42	1.2e-7	Red blood cell count;
UCEC	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg10503236	chr1:231470652	EXOC8	0.39	4.54	0.35	1.15e-5	Hemoglobin concentration;
UCEC	cis	rs10256972	0.810	rs10257195	chr7:1032554	T/C	cg04025307	chr7:1156635	C7orf50	0.6	6.05	0.45	1.14e-8	Longevity;Endometriosis;
UCEC	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.46	4.8	0.37	3.92e-6	Total body bone mineral density;
UCEC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg05738196	chr6:26577821	NA	0.59	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.57	6.42	0.47	1.79e-9	Hip circumference;
UCEC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.44	-4.53	-0.35	1.23e-5	Glomerular filtration rate;
UCEC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.41	-5.75	-0.43	5.04e-8	Prostate cancer;
UCEC	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.65	5.52	0.41	1.47e-7	Multiple sclerosis;
UCEC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.49	-5.19	-0.39	6.89e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	5.67	0.42	7.25e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-5.29	-0.4	4.4e-7	Schizophrenia;
UCEC	cis	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg19041857	chr6:27730383	NA	-0.5	-4.93	-0.38	2.17e-6	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
UCEC	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.71	8.16	0.56	1.39e-13	Body mass index;
UCEC	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	4.54	0.35	1.15e-5	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6723108	0.627	rs2053727	chr2:135643298	C/T	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg11697111	chr7:1126903	GPER;C7orf50	-0.46	-4.86	-0.37	2.92e-6	Longevity;Endometriosis;
UCEC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06505273	chr16:24850292	NA	-0.46	-4.53	-0.35	1.19e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.51	4.98	0.38	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.673	rs2112610	chr19:22916851	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.11	0.45	8.45e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg03388025	chr16:89894329	SPIRE2	-0.55	-4.51	-0.35	1.32e-5	Caffeine consumption;
UCEC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.73	8.38	0.57	3.8e-14	Prudent dietary pattern;
UCEC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.8	-8.3	-0.56	6.29e-14	Uric acid levels;
UCEC	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.62	-6.67	-0.48	4.79e-10	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.86	5.44	0.41	2.15e-7	Psoriasis;
UCEC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.75	-5.73	-0.43	5.52e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	7.68	0.53	2.1e-12	Smoking behavior;
UCEC	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-1.01	-10.67	-0.66	4.92e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.88	0.44	2.65e-8	HDL cholesterol;
UCEC	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.72	-5.8	-0.43	3.82e-8	Asthma;
UCEC	cis	rs6688613	0.840	rs10918607	chr1:166957803	T/C	cg07049167	chr1:166818506	POGK	0.54	5.21	0.39	6.3e-7	Refractive astigmatism;
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.4	0.61	9.75e-17	Platelet count;
UCEC	cis	rs4975616	0.686	rs37009	chr5:1350339	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.52	-6.08	-0.45	1e-8	Lung cancer;
UCEC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.65	-4.74	-0.36	4.95e-6	Coronary artery disease;
UCEC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg14008862	chr17:28927542	LRRC37B2	0.82	4.81	0.37	3.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.88	9.75	0.63	1.28e-17	Breast cancer;
UCEC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.5	-4.57	-0.35	1.02e-5	Diabetic retinopathy;
UCEC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-8.37	-0.57	4.15e-14	Colorectal cancer;
UCEC	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.09	0.39	1.09e-6	Birth weight;
UCEC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.63	6.39	0.47	2.07e-9	Homoarginine levels;
UCEC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.61	-5.39	-0.41	2.8e-7	Mortality in heart failure;
UCEC	cis	rs7852296	0.541	rs75495991	chr9:126361723	A/T	cg13582060	chr9:127040032	NEK6	0.86	4.66	0.36	7.07e-6	Personality dimensions;
UCEC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.07	-0.39	1.16e-6	Breast cancer;
UCEC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg22974920	chr21:40686053	BRWD1	0.61	5.17	0.39	7.48e-7	Cognitive function;
UCEC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.71	-0.36	5.57e-6	Breast cancer;
UCEC	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.64	-4.78	-0.37	4.19e-6	Systemic lupus erythematosus;
UCEC	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-5.7	-0.43	6.24e-8	Monocyte percentage of white cells;
UCEC	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.29	-0.76	1.33e-29	Schizophrenia;
UCEC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.97	8.07	0.55	2.32e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.59	6.18	0.45	5.9e-9	Schizophrenia;
UCEC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	6.18	0.45	6.03e-9	Lymphocyte counts;
UCEC	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.8	7.9	0.55	6.14e-13	Alcohol dependence;
UCEC	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.84	-6.85	-0.49	1.91e-10	Coronary artery calcification;
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs75229567	0.618	rs75389984	chr12:70212879	A/G	cg10114359	chr12:70132523	RAB3IP	1.12	4.96	0.38	1.88e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs73206853	0.764	rs3026425	chr12:110688168	A/G	cg12870014	chr12:110450643	ANKRD13A	0.55	4.71	0.36	5.73e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.69	9.63	0.62	2.56e-17	Skin aging (microtopography measurement);
UCEC	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.51	-5.95	-0.44	1.88e-8	Type 2 diabetes;
UCEC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.75	-0.43	4.91e-8	Alcohol dependence;
UCEC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.05	-0.38	1.3e-6	Aortic root size;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.41	0.72	1.19e-24	Prudent dietary pattern;
UCEC	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.73	-5.44	-0.41	2.2e-7	Huntington's disease progression;
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.47	5.2	0.39	6.49e-7	Monocyte percentage of white cells;
UCEC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.78	8.15	0.56	1.48e-13	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.93	12.66	0.72	2.67e-25	Menarche (age at onset);
UCEC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg03999872	chr20:62272968	STMN3	0.43	4.73	0.36	5.24e-6	Atopic dermatitis;
UCEC	cis	rs243088	1.000	rs243091	chr2:60565568	A/G	cg16665442	chr2:60585866	NA	-0.38	-5.04	-0.38	1.37e-6	Type 2 diabetes;
UCEC	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.32e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg04202892	chr2:111875749	ACOXL	0.44	5.24	0.4	5.51e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	1.03	6.88	0.49	1.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6844506	1.000	rs6844506	chr4:185217148	C/T	cg12654155	chr4:185238627	NA	-0.51	-4.69	-0.36	6.2e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
UCEC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.72	-6.79	-0.49	2.65e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.932	rs11882432	chr19:23029703	A/G	cg24889512	chr19:22816950	ZNF492	0.5	5.32	0.4	3.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg00614314	chr15:82944287	LOC80154	-0.53	-4.73	-0.36	5.33e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.74	6.32	0.46	2.99e-9	Alzheimer's disease;
UCEC	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.54	5.3	0.4	4.15e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-4.53	-0.35	1.23e-5	Morning vs. evening chronotype;
UCEC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	4.51	0.35	1.34e-5	Response to antipsychotic treatment;
UCEC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	5.01	0.38	1.56e-6	Breast cancer;
UCEC	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18252515	chr7:66147081	NA	0.54	5.18	0.39	7.05e-7	Aortic root size;
UCEC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.31	-4.92	-0.38	2.31e-6	Cancer;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.5	-4.96	-0.38	1.89e-6	Parkinson's disease;
UCEC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.85	9.66	0.62	2.16e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs4706831	0.663	rs1984242	chr6:81051245	A/G	cg08355045	chr6:80787529	NA	0.37	4.55	0.35	1.1e-5	Joint mobility (Beighton score);
UCEC	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.41	5.25	0.4	5.34e-7	Carotid intima media thickness;
UCEC	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg13147721	chr7:65941812	NA	0.82	6.42	0.47	1.81e-9	Diabetic kidney disease;
UCEC	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.51	5.29	0.4	4.28e-7	Schizophrenia;
UCEC	cis	rs1505368	0.563	rs1394798	chr2:213230641	G/A	cg16329650	chr2:213403929	ERBB4	0.49	4.77	0.37	4.49e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.62	-7.08	-0.5	5.45e-11	Pubertal anthropometrics;
UCEC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg22974920	chr21:40686053	BRWD1	-0.53	-4.77	-0.37	4.31e-6	Cognitive function;
UCEC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg01689657	chr7:91764605	CYP51A1	0.46	5.84	0.43	3.3e-8	Breast cancer;
UCEC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg18016565	chr1:150552671	MCL1	0.68	7.26	0.51	2.08e-11	Blood protein levels;
UCEC	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	9.75	0.63	1.24e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg11901034	chr3:128598214	ACAD9	-0.52	-4.57	-0.35	1.03e-5	IgG glycosylation;
UCEC	cis	rs1424233	0.967	rs11150184	chr16:79684565	T/G	cg02501155	chr16:79263473	NA	0.34	4.59	0.35	9.42e-6	Obesity;
UCEC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.8	0.37	3.81e-6	Breast cancer;
UCEC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	1.07	5.04	0.38	1.38e-6	IgG glycosylation;
UCEC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.5	-5.56	-0.42	1.26e-7	Tonsillectomy;
UCEC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg21053147	chr12:120880522	NA	-0.66	-5.33	-0.4	3.65e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.8	-9.88	-0.63	5.62e-18	White blood cell count (basophil);
UCEC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.47	-5.36	-0.4	3.09e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg07153921	chr17:41440717	NA	0.62	7.54	0.53	4.52e-12	Menopause (age at onset);
UCEC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.56	-5.57	-0.42	1.19e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	7.01	0.5	8.05e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4654899	0.582	rs4654729	chr1:21224253	T/C	cg01072550	chr1:21505969	NA	0.57	6.06	0.45	1.11e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.45	-5.09	-0.39	1.08e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.82	0.49	2.17e-10	Bladder cancer;
UCEC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.66	-4.75	-0.36	4.72e-6	Aortic root size;
UCEC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.68	-0.42	7e-8	Pubertal anthropometrics;
UCEC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.07	-0.5	5.9e-11	Joint mobility (Beighton score);
UCEC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg12712729	chr8:7886076	NA	0.41	4.98	0.38	1.76e-6	Red cell distribution width;
UCEC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg17724175	chr1:150552817	MCL1	-0.43	-4.72	-0.36	5.4e-6	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.71	0.43	5.91e-8	Prudent dietary pattern;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.48	-5.1	-0.39	1.02e-6	Pubertal anthropometrics;
UCEC	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.48	4.54	0.35	1.16e-5	Menarche (age at onset);
UCEC	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.5	6.47	0.47	1.36e-9	Cystic fibrosis severity;
UCEC	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.54	5.68	0.42	6.92e-8	Motion sickness;
UCEC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14008862	chr17:28927542	LRRC37B2	0.68	6.49	0.47	1.23e-9	Body mass index;
UCEC	cis	rs1468333	1.000	rs17171772	chr5:137514853	A/G	cg07848042	chr5:137667509	CDC25C	0.46	4.68	0.36	6.44e-6	Resting heart rate;
UCEC	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	6.51	0.47	1.14e-9	Alzheimer's disease;
UCEC	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	5.81	0.43	3.81e-8	HIV-1 control;
UCEC	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.42	5.38	0.41	2.83e-7	HIV-1 susceptibility;
UCEC	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg04842962	chr6:43655489	MRPS18A	0.87	8.88	0.59	2.1e-15	IgG glycosylation;
UCEC	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.72	-7.86	-0.54	7.65e-13	White blood cell count (basophil);
UCEC	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs4900538	0.827	rs3742444	chr14:102971050	T/G	cg18135206	chr14:102964638	TECPR2	0.98	12.15	0.71	5.94e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Parkinson's disease;
UCEC	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg12473912	chr3:136751656	NA	0.44	5.04	0.38	1.34e-6	Gestational age at birth (child effect);
UCEC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.6	5.28	0.4	4.64e-7	Major depressive disorder;
UCEC	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.16	9.51	0.62	5.32e-17	Uric acid levels;
UCEC	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg11189052	chr15:85197271	WDR73	0.57	4.55	0.35	1.13e-5	Schizophrenia;
UCEC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.7	6.05	0.45	1.13e-8	Heart rate;
UCEC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg26721908	chr21:47610096	LSS	-0.36	-4.53	-0.35	1.21e-5	Testicular germ cell tumor;
UCEC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.76	8.29	0.56	6.4e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.59	-0.48	7.46e-10	Mood instability;
UCEC	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg21231944	chr12:82153410	PPFIA2	-0.44	-4.61	-0.36	8.73e-6	Resting heart rate;
UCEC	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.66	-5.0	-0.38	1.6e-6	Prostate cancer;
UCEC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.74	7.91	0.55	5.82e-13	Height;
UCEC	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-8.27	-0.56	7.26e-14	HDL cholesterol;
UCEC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-5.42	-0.41	2.41e-7	Chronic sinus infection;
UCEC	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01391022	chr12:122360665	WDR66	-0.44	-4.55	-0.35	1.12e-5	Mean corpuscular volume;
UCEC	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.59	6.3	0.46	3.2e-9	Noise-induced hearing loss;
UCEC	cis	rs10924970	0.967	rs1933246	chr1:235391446	T/C	cg26050004	chr1:235667680	B3GALNT2	0.42	4.5	0.35	1.35e-5	Asthma;
UCEC	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.49	4.94	0.38	2.06e-6	Dupuytren's disease;
UCEC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.8	-0.37	3.89e-6	Major depressive disorder;
UCEC	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.4	4.92	0.38	2.33e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs9650657	0.836	rs6601523	chr8:10635141	C/T	cg00629382	chr8:10268916	MSRA	-0.45	-4.52	-0.35	1.28e-5	Neuroticism;
UCEC	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	4.86	0.37	2.97e-6	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs4280164	0.945	rs11158635	chr14:24776769	G/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-4.66	-0.36	6.91e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09742643	chr7:157958748	PTPRN2	0.38	5.32	0.4	3.75e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.53	-5.73	-0.43	5.56e-8	Prostate cancer;
UCEC	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg20283391	chr11:68216788	NA	-0.7	-4.8	-0.37	3.79e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs7113850	0.541	rs4536215	chr11:24245374	C/A	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Bone fracture in osteoporosis;
UCEC	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.65	7.61	0.53	3.08e-12	Mean corpuscular volume;
UCEC	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.5	7.08	0.5	5.56e-11	Coronary artery disease or large artery stroke;
UCEC	cis	rs4919044	0.866	rs2478233	chr10:94778903	G/A	cg18197594	chr10:94334836	IDE	-0.55	-4.69	-0.36	6.19e-6	Coronary artery disease;
UCEC	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.48	-5.06	-0.39	1.21e-6	Retinal vascular caliber;
UCEC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.36	8.58e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.59	-6.39	-0.47	2.06e-9	Refractive error;
UCEC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.64	-6.57	-0.48	8.37e-10	Bipolar disorder;
UCEC	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg20560298	chr2:73613845	ALMS1	-0.6	-5.36	-0.4	3.08e-7	Metabolite levels;
UCEC	cis	rs1318772	0.932	rs348939	chr5:112824737	G/C	cg12552261	chr5:112820674	MCC	-0.82	-6.04	-0.45	1.23e-8	F-cell distribution;
UCEC	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.76	-5.2	-0.39	6.48e-7	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-6.44	-0.47	1.61e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9961915	1.000	rs7237657	chr18:24674585	T/A	cg25983544	chr18:23713626	PSMA8	-0.35	-4.51	-0.35	1.34e-5	Dental caries;
UCEC	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.65	-6.02	-0.44	1.33e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.53	-5.94	-0.44	1.93e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.45	-0.57	2.58e-14	Mean platelet volume;
UCEC	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.55	5.52	0.41	1.51e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.46	4.88	0.37	2.77e-6	Oropharynx cancer;
UCEC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.3	0.46	3.2e-9	Personality dimensions;
UCEC	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.85	-0.43	3.04e-8	Caffeine consumption;
UCEC	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.62	-6.13	-0.45	7.79e-9	Metabolite levels;
UCEC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.46	5.24	0.4	5.52e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg24069376	chr3:38537580	EXOG	-0.44	-5.4	-0.41	2.62e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg09491104	chr22:46646882	C22orf40	-0.68	-7.77	-0.54	1.26e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.76	-9.23	-0.61	2.74e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs17220352	0.502	rs62576686	chr9:119408202	A/G	cg13412550	chr9:120177700	ASTN2	-0.67	-4.54	-0.35	1.16e-5	Headache;
UCEC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg26061582	chr7:22766209	IL6	0.61	5.75	0.43	5.03e-8	Lung cancer;
UCEC	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.43	-4.55	-0.35	1.14e-5	Schizophrenia;
UCEC	cis	rs9467773	1.000	rs9467799	chr6:26578364	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.62	5.47	0.41	1.91e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg08886695	chr4:3369023	RGS12	0.54	5.45	0.41	2.07e-7	Serum sulfate level;
UCEC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg21204522	chr6:27730016	NA	-0.61	-4.89	-0.37	2.64e-6	Depression;
UCEC	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg21770322	chr7:97807741	LMTK2	0.81	12.42	0.72	1.13e-24	Breast cancer;
UCEC	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6761276	0.934	rs11682107	chr2:113835522	G/A	cg09040174	chr2:113837401	NA	0.52	5.72	0.43	5.72e-8	Protein quantitative trait loci;
UCEC	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.56	-5.25	-0.4	5.29e-7	Bipolar disorder;
UCEC	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.41	-0.47	1.88e-9	Metabolite levels;
UCEC	cis	rs7246967	0.673	rs16999519	chr19:22814076	A/G	cg24889512	chr19:22816950	ZNF492	-0.56	-6.11	-0.45	8.61e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-7.31	-0.52	1.6e-11	Parkinson's disease;
UCEC	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.45	4.68	0.36	6.48e-6	Total body bone mineral density;
UCEC	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.34	-0.9	1.95e-53	Myeloid white cell count;
UCEC	cis	rs78487399	0.908	rs7576643	chr2:43841269	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.74	-0.36	4.95e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.5	-5.72	-0.43	5.67e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs16937	0.711	rs3851284	chr1:205156080	A/T	cg12580275	chr1:205744413	RAB7L1	0.49	5.33	0.4	3.61e-7	Schizophrenia;
UCEC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg04310649	chr10:35416472	CREM	-0.47	-4.58	-0.35	9.83e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.44	-4.6	-0.35	9.19e-6	Coronary heart disease;
UCEC	trans	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg20587970	chr11:113659929	NA	-1.27	-8.27	-0.56	7.24e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg00316803	chr15:76480434	C15orf27	-0.46	-5.25	-0.4	5.2e-7	Blood metabolite levels;
UCEC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.82	10.16	0.64	1.04e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.75	-0.43	4.91e-8	Alcohol dependence;
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.79	-0.43	4.01e-8	Depression;
UCEC	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.13	-0.51	4.17e-11	Eye color traits;
UCEC	trans	rs9313296	0.661	rs2644729	chr5:165521122	C/T	cg03539051	chr19:56418660	NLRP13	1.13	7.18	0.51	3.16e-11	Weight;Waist circumference;
UCEC	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg07076509	chr9:96720819	NA	0.46	5.08	0.39	1.11e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	7.7	0.54	1.85e-12	Mean platelet volume;
UCEC	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.76	9.09	0.6	6.29e-16	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.6	7.45	0.52	7.47e-12	Testicular germ cell tumor;
UCEC	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.45	4.96	0.38	1.89e-6	Alcohol dependence;
UCEC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.6	0.42	1.03e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg20891283	chr12:69753455	YEATS4	0.57	4.84	0.37	3.31e-6	Response to diuretic therapy;
UCEC	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.85	8.52	0.57	1.74e-14	Colorectal cancer;
UCEC	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg24851651	chr11:66362959	CCS	0.46	5.22	0.4	6e-7	Educational attainment (years of education);
UCEC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.78	-0.43	4.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-6.63	-0.48	6.11e-10	Fibrinogen levels;
UCEC	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.68	8.35	0.57	4.74e-14	Testicular germ cell tumor;
UCEC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg11871910	chr12:69753446	YEATS4	0.87	9.18	0.6	3.72e-16	Blood protein levels;
UCEC	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-4.73	-0.36	5.23e-6	QRS duration;
UCEC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.83	0.37	3.46e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7781557	1.000	rs10487284	chr7:102470275	G/A	cg06322601	chr7:102330635	NA	0.56	5.11	0.39	9.87e-7	Colorectal adenoma (advanced);
UCEC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg08493051	chr2:3487164	NA	-0.62	-6.57	-0.48	7.96e-10	Neurofibrillary tangles;
UCEC	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-4.82	-0.37	3.54e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.09	13.1	0.73	1.76e-26	Cognitive function;
UCEC	cis	rs1595825	0.891	rs77946222	chr2:198533251	C/T	cg19156104	chr2:198669113	PLCL1	-0.63	-4.55	-0.35	1.12e-5	Ulcerative colitis;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg16595484	chr3:122512170	HSPBAP1	-0.64	-7.33	-0.52	1.42e-11	Breast cancer;
UCEC	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	4.61	0.36	8.67e-6	Height;
UCEC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.8	-0.59	3.48e-15	Headache;
UCEC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.64	-6.57	-0.48	8.34e-10	Coronary artery disease;
UCEC	cis	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg13256891	chr4:100009986	ADH5	-0.71	-5.3	-0.4	4.09e-7	Alcohol dependence;
UCEC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.8	4.91	0.38	2.37e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg20129853	chr10:51489980	NA	-0.43	-4.74	-0.36	4.95e-6	Prostate-specific antigen levels;
UCEC	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg03714773	chr7:91764589	CYP51A1	0.4	4.89	0.37	2.65e-6	Breast cancer;
UCEC	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.46	-5.08	-0.39	1.1e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.56	-5.07	-0.39	1.2e-6	Blood metabolite levels;
UCEC	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg08886695	chr4:3369023	RGS12	-0.61	-5.99	-0.44	1.51e-8	Serum sulfate level;
UCEC	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.48	0.41	1.77e-7	HIV-1 control;
UCEC	cis	rs2729354	0.693	rs2584862	chr11:57241956	T/A	cg24343310	chr11:57249947	NA	0.48	5.8	0.43	4e-8	Blood protein levels;
UCEC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.2	0.39	6.59e-7	Life satisfaction;
UCEC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.66	5.17	0.39	7.56e-7	Corneal astigmatism;
UCEC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg03859395	chr2:55845619	SMEK2	-0.96	-12.41	-0.72	1.22e-24	Metabolic syndrome;
UCEC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.24	-0.46	4.39e-9	Crohn's disease;
UCEC	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.39	-5.02	-0.38	1.47e-6	Dupuytren's disease;
UCEC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.45	0.41	2.07e-7	Tonsillectomy;
UCEC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg01262667	chr19:19385393	TM6SF2	-0.4	-4.5	-0.35	1.36e-5	Bipolar disorder;
UCEC	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.31	-0.4	4.06e-7	Parkinson's disease;
UCEC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.71	-6.45	-0.47	1.49e-9	Initial pursuit acceleration;
UCEC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.53	5.12	0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.92	12.41	0.72	1.2e-24	Ewing sarcoma;
UCEC	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.83	-0.37	3.37e-6	Fear of minor pain;
UCEC	cis	rs308403	0.506	rs309365	chr4:123659343	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.39	0.47	2.05e-9	Blood protein levels;
UCEC	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.58	4.93	0.38	2.22e-6	Lung cancer;
UCEC	cis	rs11760485	0.965	rs9655026	chr7:4402663	C/T	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.91	11.4	0.69	5.59e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.77	10.2	0.64	8.15e-19	Vitiligo;
UCEC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.78	10.57	0.66	9.18e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs9463078	0.764	rs3799968	chr6:44805377	C/T	cg25276700	chr6:44698697	NA	-0.41	-4.6	-0.35	9.17e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg23791538	chr6:167370224	RNASET2	-0.46	-4.62	-0.36	8.18e-6	Primary biliary cholangitis;
UCEC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.72	-7.27	-0.51	1.99e-11	Aortic root size;
UCEC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.45	-5.07	-0.39	1.17e-6	Obesity-related traits;
UCEC	cis	rs9715521	0.775	rs62301193	chr4:59844120	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs883565	0.655	rs7649923	chr3:39102137	G/A	cg01426195	chr3:39028469	NA	-0.75	-9.85	-0.63	6.98e-18	Handedness;
UCEC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.56	6.05	0.45	1.15e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.51	-5.52	-0.41	1.53e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg14092571	chr14:90743983	NA	-0.42	-5.7	-0.43	6.47e-8	Mortality in heart failure;
UCEC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.71	-6.66	-0.48	5.23e-10	Aortic root size;
UCEC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18932078	chr1:2524107	MMEL1	-0.34	-5.89	-0.44	2.47e-8	Ulcerative colitis;
UCEC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.5	-4.57	-0.35	1.02e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.7	7.04	0.5	6.98e-11	Blood protein levels;
UCEC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.64	-5.74	-0.43	5.28e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.3	0.4	4.2e-7	Coronary artery disease;
UCEC	trans	rs66573146	1.000	rs55688389	chr4:7030689	C/G	cg07817883	chr1:32538562	TMEM39B	1.23	8.51	0.57	1.87e-14	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	6.39	0.47	2.07e-9	Response to antipsychotic treatment;
UCEC	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.55	-4.81	-0.37	3.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.91	-7.02	-0.5	7.42e-11	Exhaled nitric oxide output;
UCEC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg01112020	chr2:239008986	ESPNL	-0.38	-5.07	-0.39	1.2e-6	Prostate cancer;
UCEC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.87	-11.31	-0.68	9.82e-22	Height;
UCEC	cis	rs8177876	0.822	rs1414	chr16:81115857	A/G	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26207909	chr14:103986467	CKB	0.51	5.62	0.42	9.11e-8	Body mass index;
UCEC	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.84	9.13	0.6	4.84e-16	Ulcerative colitis;
UCEC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.86	10.44	0.65	2.01e-19	Bone mineral density;
UCEC	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-4.73	-0.36	5.31e-6	Response to antipsychotic treatment;
UCEC	cis	rs6717918	0.564	rs12616262	chr2:233063658	T/C	cg02061626	chr2:233274167	ALPPL2	0.5	5.25	0.4	5.15e-7	Height;
UCEC	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.45	-4.66	-0.36	7.12e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg26721908	chr21:47610096	LSS	0.43	5.6	0.42	1.04e-7	Testicular germ cell tumor;
UCEC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg19743168	chr1:23544995	NA	0.44	6.29	0.46	3.37e-9	Height;
UCEC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13939156	chr17:80058883	NA	0.36	4.55	0.35	1.12e-5	Life satisfaction;
UCEC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.49	0.41	1.73e-7	Bone mineral density;
UCEC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06505273	chr16:24850292	NA	-0.51	-5.01	-0.38	1.55e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.68	6.98	0.5	9.22e-11	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.0	-0.44	1.49e-8	Aortic root size;
UCEC	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.03e-5	Type 2 diabetes;
UCEC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.55	0.77	2.79e-30	Homoarginine levels;
UCEC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.67	-0.36	6.79e-6	Breast cancer;
UCEC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.87	5.56	0.42	1.24e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.59	4.68	0.36	6.5e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg08859206	chr1:53392774	SCP2	-0.59	-6.31	-0.46	3.16e-9	Monocyte count;
UCEC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.45	4.93	0.38	2.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.59	5.65	0.42	8.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11958404	0.860	rs6885815	chr5:157437253	C/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.74	-8.59	-0.58	1.18e-14	Facial morphology (factor 19);
UCEC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.49	5.0	0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.41	4.57	0.35	1.02e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.73	7.22	0.51	2.56e-11	Parkinson's disease;
UCEC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.54	-5.11	-0.39	9.69e-7	Blood protein levels;
UCEC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg23791538	chr6:167370224	RNASET2	-0.52	-5.21	-0.39	6.35e-7	Crohn's disease;
UCEC	cis	rs2836633	0.501	rs73902704	chr21:40013878	C/T	cg12884169	chr21:40033163	ERG	0.47	4.84	0.37	3.19e-6	Coronary artery disease;
UCEC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg24881330	chr22:46731750	TRMU	0.6	5.84	0.43	3.24e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.81	-6.29	-0.46	3.37e-9	Exhaled nitric oxide output;
UCEC	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.76	8.0	0.55	3.32e-13	Menopause (age at onset);
UCEC	cis	rs10432489	0.541	rs6724902	chr2:181739323	A/T	cg21995919	chr2:182322279	ITGA4	0.69	5.2	0.39	6.55e-7	QT interval;
UCEC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg06466757	chr4:1255808	NA	0.46	4.79	0.37	3.97e-6	Obesity-related traits;
UCEC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.42	-4.96	-0.38	1.96e-6	Obesity-related traits;
UCEC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.68	5.97	0.44	1.73e-8	Aortic root size;
UCEC	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.79	0.49	2.61e-10	Motion sickness;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.35	-0.4	3.37e-7	Pubertal anthropometrics;
UCEC	cis	rs12681287	0.752	rs4472493	chr8:87251914	C/T	cg27223183	chr8:87520930	FAM82B	-0.57	-4.64	-0.36	7.72e-6	Caudate activity during reward;
UCEC	cis	rs2742417	1.000	rs2673037	chr3:45749094	A/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg00852783	chr1:26633632	UBXN11	-0.5	-4.87	-0.37	2.84e-6	Obesity-related traits;
UCEC	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.56	-6.38	-0.47	2.16e-9	Crohn's disease;
UCEC	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.27	10.96	0.67	8.59e-21	Corneal structure;
UCEC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.41	-4.53	-0.35	1.23e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.53	5.09	0.39	1.06e-6	Neutrophil percentage of white cells;
UCEC	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.42	-5.42	-0.41	2.4e-7	Dupuytren's disease;
UCEC	cis	rs4588572	0.601	rs1529500	chr5:77721643	C/T	cg11547950	chr5:77652471	NA	-0.44	-5.01	-0.38	1.51e-6	Triglycerides;
UCEC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.68	7.61	0.53	3.05e-12	Menopause (age at onset);
UCEC	cis	rs11235843	0.602	rs11235827	chr11:73346346	G/A	cg09185399	chr11:73372479	PLEKHB1	0.63	5.03	0.38	1.4e-6	Hand grip strength;
UCEC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.56	5.88	0.44	2.69e-8	Type 2 diabetes;
UCEC	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs8032158	1.000	rs10851599	chr15:56154064	T/G	cg10433327	chr15:56209506	NEDD4	-0.29	-4.78	-0.37	4.2e-6	Keloid;
UCEC	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.77	-8.9	-0.59	1.89e-15	Facial morphology (factor 19);
UCEC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.22	-0.56	9.59e-14	Hemoglobin concentration;
UCEC	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.44	6.32	0.46	2.88e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
UCEC	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.78	5.27	0.4	4.73e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.62	-5.71	-0.43	6.07e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-0.98	-7.42	-0.52	8.88e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.49	5.29	0.4	4.45e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.94e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.85	9.5	0.62	5.64e-17	Breast cancer;
UCEC	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.43	-5.64	-0.42	8.59e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	1.06	12.16	0.71	5.45e-24	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.43	-4.56	-0.35	1.07e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.64	6.11	0.45	8.7e-9	Prostate cancer;
UCEC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg19097150	chr7:2500200	NA	-0.31	-4.54	-0.35	1.15e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg12262378	chr17:6899522	ALOX12	-0.44	-5.04	-0.38	1.33e-6	Tonsillectomy;
UCEC	trans	rs12216499	0.584	rs79019671	chr6:159345144	T/A	cg03103158	chr8:28748202	INTS9;HMBOX1	-1.01	-6.74	-0.49	3.36e-10	Bladder cancer (smoking interaction);
UCEC	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg24578937	chr1:2090814	PRKCZ	-0.42	-4.98	-0.38	1.75e-6	Height;
UCEC	cis	rs8105895	0.935	rs62110985	chr19:22256077	A/G	cg24072202	chr19:22235272	ZNF257	-0.61	-5.31	-0.4	3.93e-7	Body mass index (change over time);
UCEC	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg06637938	chr14:75390232	RPS6KL1	0.48	4.52	0.35	1.29e-5	Height;
UCEC	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.63	7.51	0.53	5.33e-12	Obesity-related traits;
UCEC	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg05991184	chr2:219186017	PNKD	-0.49	-5.26	-0.4	4.94e-7	Colorectal cancer;
UCEC	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.6	-5.01	-0.38	1.53e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.65	5.49	0.41	1.72e-7	High light scatter reticulocyte count;
UCEC	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.79e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg00815214	chr21:47717953	NA	-0.39	-4.55	-0.35	1.1e-5	Testicular germ cell tumor;
UCEC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.83	9.23	0.61	2.71e-16	Breast cancer;
UCEC	cis	rs3951016	0.514	rs283067	chr6:118620030	T/A	cg21191810	chr6:118973309	C6orf204	0.37	4.52	0.35	1.26e-5	Resting heart rate;
UCEC	cis	rs829661	1.000	rs2692035	chr2:30672835	T/A	cg12454169	chr2:30669597	LCLAT1	0.51	4.74	0.36	4.99e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.54	-5.38	-0.41	2.93e-7	Blood metabolite levels;
UCEC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.54	5.45	0.41	2.06e-7	Menopause (age at onset);
UCEC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.55	-5.82	-0.43	3.54e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg20936604	chr3:58311152	NA	-0.56	-4.77	-0.37	4.32e-6	Cholesterol, total;
UCEC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-9.44	-0.61	8.11e-17	Chronic sinus infection;
UCEC	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.29	-8.0	-0.55	3.43e-13	Diabetic kidney disease;
UCEC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg05132306	chr1:1846340	CALML6	-0.39	-4.83	-0.37	3.42e-6	Body mass index;
UCEC	cis	rs2742417	1.000	rs1877932	chr3:45753539	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.48	6.14	0.45	7.38e-9	HDL cholesterol levels;
UCEC	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.1	9.43	0.61	8.5e-17	Blood protein levels;
UCEC	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg18681998	chr4:17616180	MED28	0.91	12.13	0.71	6.85e-24	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.5	-0.47	1.16e-9	Depression;
UCEC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg09655341	chr17:79618100	PDE6G	-0.31	-4.66	-0.36	7.06e-6	Eye color traits;
UCEC	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg15848620	chr12:58087721	OS9	-0.51	-4.82	-0.37	3.51e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.65	-6.24	-0.46	4.41e-9	Acne (severe);
UCEC	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.58	5.55	0.42	1.33e-7	Uric acid levels;
UCEC	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.48	-4.6	-0.35	8.97e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.53	-5.95	-0.44	1.85e-8	Lung cancer;
UCEC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.5	5.29	0.4	4.39e-7	Schizophrenia;
UCEC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.67	-5.78	-0.43	4.23e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.88	12.81	0.73	1.08e-25	Leprosy;
UCEC	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.67	7.09	0.5	5.15e-11	Malaria;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.64	-0.36	7.66e-6	Bipolar disorder;
UCEC	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	0.92	5.36	0.4	3.13e-7	Arsenic metabolism;
UCEC	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg16235748	chr6:149772707	ZC3H12D	0.42	5.27	0.4	4.77e-7	Dupuytren's disease;
UCEC	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg09654669	chr8:57350985	NA	-0.46	-5.28	-0.4	4.47e-7	Obesity-related traits;
UCEC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.8	8.64	0.58	8.7e-15	Cognitive function;
UCEC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.71	-5.12	-0.39	9.52e-7	Mean platelet volume;
UCEC	cis	rs7095607	1.000	rs7079974	chr10:69959397	G/A	cg18986048	chr10:69913749	MYPN	0.43	4.65	0.36	7.3e-6	Lung function (FVC);
UCEC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.67	6.98	0.5	9.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.38	-4.68	-0.36	6.41e-6	Coronary artery disease;
UCEC	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.42	5.11	0.39	9.68e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2224391	0.628	rs2773307	chr6:5244290	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.77	-0.37	4.32e-6	Height;
UCEC	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg17420585	chr12:42539391	GXYLT1	0.39	4.99	0.38	1.65e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.35	-4.6	-0.35	9.01e-6	Metabolite levels;
UCEC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.0	-0.38	1.61e-6	Breast cancer;
UCEC	trans	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.58	-4.65	-0.36	7.32e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.8	7.59	0.53	3.4e-12	Bladder cancer;
UCEC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-8.1	-0.56	1.91e-13	Hemoglobin concentration;
UCEC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.75	8.8	0.59	3.51e-15	Blood metabolite levels;
UCEC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.53	5.53	0.41	1.45e-7	Breast cancer;
UCEC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.92e-6	Breast cancer;
UCEC	cis	rs7580658	0.545	rs885276	chr2:127950904	A/T	cg16751203	chr2:127950803	CYP27C1	0.4	5.33	0.4	3.56e-7	Protein C levels;
UCEC	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg08886695	chr4:3369023	RGS12	0.52	5.69	0.43	6.56e-8	Parental longevity (mother's age at death);
UCEC	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.82	7.91	0.55	5.54e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-4.9	-0.37	2.55e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.89	-7.57	-0.53	3.71e-12	Coronary artery calcification;
UCEC	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.53	-5.5	-0.41	1.64e-7	Asthma;
UCEC	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.86	-7.04	-0.5	6.92e-11	Glomerular filtration rate in non diabetics (creatinine);
UCEC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.67	4.63	0.36	7.88e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg21770322	chr7:97807741	LMTK2	0.71	10.28	0.65	5.12e-19	Breast cancer;
UCEC	cis	rs1816854	0.872	rs11182275	chr12:44206289	T/G	cg00106942	chr12:44200524	TWF1	0.51	5.4	0.41	2.66e-7	Inflammatory bowel disease;
UCEC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs295140	1.000	rs12618057	chr2:201171355	T/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	7.02	0.5	7.79e-11	Mean corpuscular hemoglobin;
UCEC	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-0.98	-11.06	-0.67	4.42e-21	Blood pressure (smoking interaction);
UCEC	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-4.66	-0.36	7.01e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.82	11.19	0.68	2.1e-21	Headache;
UCEC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.58	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-9.41	-0.61	9.39e-17	Blood metabolite levels;
UCEC	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.59	5.54	0.42	1.35e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.24	-0.65	6.49e-19	Monocyte count;
UCEC	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.57	-4.99	-0.38	1.71e-6	Colorectal cancer;
UCEC	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.4	5.11	0.39	9.95e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-5.25	-0.4	5.26e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.78	-0.43	4.28e-8	Platelet count;
UCEC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg03859395	chr2:55845619	SMEK2	0.97	12.69	0.72	2.22e-25	Metabolic syndrome;
UCEC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.38	-13.31	-0.74	5.02e-27	Type 1 diabetes nephropathy;
UCEC	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs17123764	0.818	rs4045193	chr12:50003980	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.42	0.41	2.42e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs78761021	0.720	rs874174	chr17:9798619	C/T	cg26853458	chr17:9805074	RCVRN	-0.38	-4.81	-0.37	3.66e-6	Type 2 diabetes;
UCEC	cis	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg08722104	chr11:47448306	PSMC3	-0.48	-5.24	-0.4	5.58e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.42	0.41	2.42e-7	Neutrophil percentage of white cells;
UCEC	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.36	0.4	3.17e-7	Heart rate;
UCEC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg07153921	chr17:41440717	NA	-0.47	-4.69	-0.36	6.08e-6	Menopause (age at onset);
UCEC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.42	4.94	0.38	2.07e-6	Blood protein levels;
UCEC	cis	rs41271951	0.512	rs12070256	chr1:151070090	C/T	cg00107782	chr1:151300621	NA	-0.68	-4.58	-0.35	9.72e-6	Blood protein levels;
UCEC	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.39	6.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6547631	0.696	rs1866140	chr2:85921353	G/T	cg26394380	chr2:85896001	SFTPB	0.4	4.53	0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.55	4.92	0.38	2.28e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs17122693	0.748	rs57198801	chr14:51119456	T/C	cg04730355	chr14:51134070	SAV1	0.95	10.0	0.64	2.81e-18	Cognitive performance;
UCEC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.38	0.76	8e-30	Height;
UCEC	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.89	-0.44	2.55e-8	Mood instability;
UCEC	trans	rs6788895	1.000	rs6440698	chr3:150516911	A/G	cg04732357	chr2:96658324	NA	-0.86	-6.93	-0.5	1.23e-10	Breast cancer;
UCEC	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-6.07	-0.45	1.02e-8	Rheumatoid arthritis;
UCEC	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	6.54	0.47	9.7e-10	Menopause (age at onset);
UCEC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18252515	chr7:66147081	NA	-0.53	-5.15	-0.39	8.38e-7	Aortic root size;
UCEC	cis	rs11958404	0.932	rs72818109	chr5:157438340	A/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg13844804	chr7:814759	HEATR2	0.72	4.87	0.37	2.89e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.52	4.91	0.38	2.42e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.33	4.75	0.36	4.75e-6	Primary biliary cholangitis;
UCEC	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	6.13	0.45	7.73e-9	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs151997	0.925	rs26089	chr5:50172251	A/G	cg06027927	chr5:50259733	NA	-0.5	-4.66	-0.36	7.09e-6	Callous-unemotional behaviour;
UCEC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.9	9.05	0.6	8.12e-16	Schizophrenia;
UCEC	cis	rs4615376	1.000	rs13205960	chr6:13041534	A/C	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.57	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg08271804	chr19:22816896	ZNF492	0.66	6.62	0.48	6.39e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	6.31	0.46	3.09e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	0.73	6.48	0.47	1.3e-9	Neutrophil percentage of white cells;
UCEC	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.66	-7.53	-0.53	4.73e-12	Systemic sclerosis;
UCEC	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.47	4.86	0.37	2.93e-6	Prostate cancer;
UCEC	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	Androgen levels;
UCEC	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	1.18	9.48	0.62	6.42e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	5.8	0.43	3.95e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg19678392	chr7:94953810	PON1	0.62	5.15	0.39	8.24e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.75	7.11	0.51	4.66e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.05	0.5	6.53e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.81	-0.43	3.68e-8	Joint mobility (Beighton score);
UCEC	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.94	-0.44	1.99e-8	Parkinson's disease;
UCEC	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.49	-5.3	-0.4	4.08e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.65	5.97	0.44	1.7e-8	Schizophrenia;
UCEC	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.51	5.11	0.39	9.87e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.83	9.51	0.62	5.25e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.73	7.74	0.54	1.45e-12	Lymphocyte counts;
UCEC	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	0.82	5.74	0.43	5.36e-8	Blood protein levels;
UCEC	trans	rs2147959	0.724	rs10753452	chr1:228724604	G/C	cg17337874	chr7:2701641	TTYH3	0.62	6.7	0.48	4.16e-10	Adult asthma;
UCEC	cis	rs6761276	0.899	rs13389457	chr2:113834885	T/C	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-1.0	-9.55	-0.62	4.11e-17	Blood pressure (smoking interaction);
UCEC	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.65	-6.95	-0.5	1.12e-10	Waist circumference;Body mass index;
UCEC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.48	5.43	0.41	2.27e-7	Bone mineral density;
UCEC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	0.81	7.01	0.5	7.92e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.54	4.95	0.38	1.97e-6	Diabetic retinopathy;
UCEC	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.95	0.38	2.05e-6	HDL cholesterol;
UCEC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.52	-0.69	2.74e-22	Monocyte count;
UCEC	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.5	-5.43	-0.41	2.23e-7	Longevity;
UCEC	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.48	5.87	0.44	2.8e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	0.72	4.89	0.37	2.66e-6	Diabetic retinopathy;
UCEC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.49	5.0	0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.53	-4.94	-0.38	2.14e-6	Migraine;Coronary artery disease;
UCEC	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.48	-5.74	-0.43	5.28e-8	Glaucoma (primary open-angle);
UCEC	cis	rs539096	0.874	rs2842175	chr1:44023615	G/A	cg11851915	chr1:44060116	PTPRF	-0.47	-4.64	-0.36	7.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.44	5.29	0.4	4.29e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	8.11	0.56	1.86e-13	Platelet distribution width;
UCEC	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.72	6.93	0.5	1.25e-10	Crohn's disease;
UCEC	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.76	-6.18	-0.45	6.1e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.6	-4.62	-0.36	8.47e-6	Carotid intima media thickness;
UCEC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.62	-6.63	-0.48	5.9e-10	Prostate cancer;
UCEC	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.84	-0.49	1.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1007190	0.881	rs6503406	chr17:42937105	C/T	cg15406952	chr17:42872593	NA	0.69	5.12	0.39	9.5e-7	DNA methylation (variation);
UCEC	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.72	6.66	0.48	5.22e-10	Monocyte count;
UCEC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs28673728	0.868	rs28380108	chr1:38409103	G/C	cg17077180	chr1:38461687	NA	0.67	6.54	0.47	9.58e-10	Red cell distribution width;
UCEC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.64	-0.36	7.5e-6	Parkinson's disease;
UCEC	cis	rs861020	0.582	rs6675890	chr1:210022893	G/C	cg05527609	chr1:210001259	C1orf107	0.78	6.55	0.48	8.87e-10	Orofacial clefts;
UCEC	cis	rs2742417	1.000	rs2742418	chr3:45731920	C/T	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.22	-0.4	5.99e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.45	-5.33	-0.4	3.64e-7	Abdominal aortic aneurysm;
UCEC	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg23793686	chr15:68133972	NA	-0.36	-4.7	-0.36	5.9e-6	Restless legs syndrome;
UCEC	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-4.51	-0.35	1.31e-5	Alzheimer's disease (late onset);
UCEC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.55	-5.79	-0.43	4.05e-8	Autism;
UCEC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.62	6.56	0.48	8.8e-10	Colorectal cancer;
UCEC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg05738196	chr6:26577821	NA	-0.59	-6.96	-0.5	1.05e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg26114124	chr12:9217669	LOC144571	0.39	4.66	0.36	7.07e-6	Sjögren's syndrome;
UCEC	cis	rs12618769	0.625	rs3769726	chr2:99105827	G/C	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.57	-4.98	-0.38	1.74e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	cis	rs7646881	0.544	rs13318109	chr3:158313206	A/G	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.43e-6	Tetralogy of Fallot;
UCEC	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.7	7.08	0.5	5.59e-11	Primary sclerosing cholangitis;
UCEC	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.89	7.61	0.53	3.09e-12	Morning vs. evening chronotype;
UCEC	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.61	5.67	0.42	7.33e-8	Triglycerides;
UCEC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg15103426	chr22:29168792	CCDC117	0.7	7.02	0.5	7.77e-11	Lymphocyte counts;
UCEC	cis	rs925228	0.910	rs4665249	chr2:24174616	T/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.56	4.89	0.37	2.58e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg04553112	chr3:125709451	NA	-0.59	-4.55	-0.35	1.12e-5	Blood pressure (smoking interaction);
UCEC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	9.75	0.63	1.28e-17	Chronic sinus infection;
UCEC	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.47	5.95	0.44	1.84e-8	Neuroticism;
UCEC	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	8.21	0.56	1.01e-13	Post bronchodilator FEV1;
UCEC	cis	rs78707713	0.841	rs10998780	chr10:71201735	A/T	cg12610070	chr10:71211762	TSPAN15	-0.42	-4.76	-0.37	4.68e-6	Venous thromboembolism;
UCEC	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.53	5.7	0.43	6.38e-8	Neuroticism;
UCEC	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.83	9.54	0.62	4.41e-17	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7374004	0.655	rs7374826	chr3:38635589	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	5.86	0.44	2.94e-8	PR interval;
UCEC	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg05660106	chr1:15850417	CASP9	1.0	9.05	0.6	7.98e-16	Systolic blood pressure;
UCEC	cis	rs7975161	1.000	rs7960443	chr12:104645363	G/A	cg25273343	chr12:104657179	TXNRD1	-0.59	-5.3	-0.4	4.07e-7	Toenail selenium levels;
UCEC	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg09238746	chr17:78121135	EIF4A3	-0.53	-5.76	-0.43	4.64e-8	Yeast infection;
UCEC	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg23102388	chr7:1867652	MAD1L1	0.38	4.51	0.35	1.33e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs9283706	0.608	rs1991492	chr5:66328309	A/G	cg11590213	chr5:66331682	MAST4	0.45	5.77	0.43	4.53e-8	Coronary artery disease;
UCEC	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-0.74	-7.23	-0.51	2.47e-11	Height;
UCEC	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.57	5.02	0.38	1.47e-6	Crohn's disease;
UCEC	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.15	-0.39	8.4e-7	Sudden cardiac arrest;
UCEC	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg18681998	chr4:17616180	MED28	0.7	8.05	0.55	2.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.58	5.58	0.42	1.11e-7	Height;
UCEC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg12463550	chr7:65579703	CRCP	0.52	5.11	0.39	1e-6	Aortic root size;
UCEC	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02152992	chr13:48877591	RB1	0.58	6.95	0.5	1.12e-10	Warfarin maintenance dose;
UCEC	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.67	6.85	0.49	1.9e-10	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-10.3	-0.65	4.51e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.07	0.5	5.71e-11	Coronary artery disease;
UCEC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg03859395	chr2:55845619	SMEK2	1.02	14.69	0.77	1.22e-30	Metabolic syndrome;
UCEC	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.8	-8.26	-0.56	7.73e-14	Migraine;Coronary artery disease;
UCEC	cis	rs858239	0.896	rs1637193	chr7:23260251	G/T	cg17274742	chr7:23286539	GPNMB	0.39	4.64	0.36	7.58e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.83	0.37	3.35e-6	Bipolar disorder;
UCEC	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-8.56	-0.58	1.39e-14	Colorectal cancer;
UCEC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-5.07	-0.39	1.2e-6	Chronic sinus infection;
UCEC	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.52	4.98	0.38	1.77e-6	Height;
UCEC	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs4588572	0.643	rs35299318	chr5:77668322	A/C	cg11547950	chr5:77652471	NA	0.5	5.08	0.39	1.15e-6	Triglycerides;
UCEC	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.57	-6.61	-0.48	6.5e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.67	5.2	0.39	6.42e-7	Neutrophil percentage of white cells;
UCEC	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.61	5.41	0.41	2.48e-7	Obesity (extreme);
UCEC	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.18	0.39	7.11e-7	Blood protein levels;
UCEC	cis	rs6834538	0.894	rs34712587	chr4:113485894	A/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	4.7	0.36	6.05e-6	Free thyroxine concentration;
UCEC	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.7	-7.63	-0.53	2.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg22974920	chr21:40686053	BRWD1	-0.48	-4.69	-0.36	6.2e-6	Menarche (age at onset);
UCEC	cis	rs7246967	0.932	rs4932799	chr19:23051581	C/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs259842	0.761	rs1906012	chr2:180675669	T/C	cg21158027	chr2:180128889	SESTD1	-0.55	-4.6	-0.35	9.22e-6	Blood protein levels;
UCEC	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	0.99	5.76	0.43	4.86e-8	Schizophrenia;
UCEC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.69	-7.22	-0.51	2.6e-11	Breast cancer;
UCEC	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	5.6	0.42	1.05e-7	Initial pursuit acceleration;
UCEC	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg05528280	chr10:464225	DIP2C	-0.5	-4.6	-0.35	8.9e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg18681998	chr4:17616180	MED28	-0.67	-6.61	-0.48	6.64e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg24961523	chr17:36618985	ARHGAP23	-0.4	-5.1	-0.39	1.03e-6	Glomerular filtration rate (creatinine);
UCEC	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	8.22	0.56	9.74e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	1.0	9.54	0.62	4.43e-17	Diastolic blood pressure;
UCEC	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs8105895	1.000	rs62112917	chr19:22226580	C/T	cg20662725	chr19:22235022	ZNF257	-0.6	-5.26	-0.4	5.01e-7	Body mass index (change over time);
UCEC	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.18	10.18	0.64	9.16e-19	Lymphocyte percentage of white cells;
UCEC	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	5.92	0.44	2.17e-8	IgG glycosylation;
UCEC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.81	9.71	0.63	1.55e-17	Mortality in heart failure;
UCEC	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs6546886	0.833	rs12713804	chr2:74238709	C/T	cg14702570	chr2:74259524	NA	-0.38	-4.62	-0.36	8.34e-6	Dialysis-related mortality;
UCEC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.74	-5.88	-0.44	2.59e-8	Schizophrenia;
UCEC	cis	rs883565	0.569	rs784511	chr3:39165548	A/G	cg01426195	chr3:39028469	NA	0.62	7.39	0.52	1.01e-11	Handedness;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg13525197	chr6:28411240	ZSCAN23	0.52	6.33	0.46	2.76e-9	Pubertal anthropometrics;
UCEC	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.77	-0.49	2.8e-10	Coffee consumption (cups per day);
UCEC	cis	rs151997	0.925	rs28077	chr5:50191946	T/A	cg06027927	chr5:50259733	NA	0.53	4.95	0.38	2.02e-6	Callous-unemotional behaviour;
UCEC	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.55e-7	Schizophrenia;
UCEC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.83	9.51	0.62	5.25e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg04871131	chr7:94954202	PON1	-0.48	-4.53	-0.35	1.21e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs56161922	0.908	rs113826410	chr1:207849815	C/T	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-10.19	-0.64	8.63e-19	Electrocardiographic conduction measures;
UCEC	cis	rs4074961	0.527	rs2294875	chr1:38052445	C/T	cg17933807	chr1:38061675	GNL2	0.94	12.72	0.72	1.85e-25	Axial length;
UCEC	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.61	-6.23	-0.46	4.69e-9	Obesity-related traits;
UCEC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg19920283	chr7:105172520	RINT1	0.55	4.96	0.38	1.93e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.5	5.47	0.41	1.85e-7	Tonsillectomy;
UCEC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.47	4.67	0.36	6.76e-6	Dupuytren's disease;
UCEC	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.75e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg01571407	chr16:12009700	GSPT1	-0.76	-5.38	-0.41	2.92e-7	Testicular germ cell tumor;
UCEC	cis	rs732765	0.734	rs3784021	chr14:75200653	C/T	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.46	-4.65	-0.36	7.44e-6	Schizophrenia;
UCEC	cis	rs7709377	0.620	rs10079466	chr5:115477636	C/A	cg23108291	chr5:115420582	COMMD10	0.55	5.56	0.42	1.21e-7	Metabolite levels  (X-11787);
UCEC	cis	rs1712517	0.771	rs7074749	chr10:105116056	C/T	cg05636881	chr10:105038444	INA	0.44	5.16	0.39	7.95e-7	Migraine;
UCEC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg24531977	chr5:56204891	C5orf35	0.49	4.59	0.35	9.29e-6	Coronary artery disease;
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.8	0.63	9.13e-18	Platelet count;
UCEC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg26721908	chr21:47610096	LSS	-0.43	-5.64	-0.42	8.64e-8	Testicular germ cell tumor;
UCEC	cis	rs892864	0.685	rs78438940	chr5:127752157	C/T	cg17313118	chr5:127157258	NA	0.67	4.63	0.36	8.13e-6	Multiple system atrophy;
UCEC	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-6.22	-0.46	4.83e-9	Platelet distribution width;
UCEC	cis	rs2635047	0.615	rs2137287	chr18:44751856	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.93	-0.38	2.24e-6	Educational attainment;
UCEC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.82	10.16	0.64	1.04e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	7.22	0.51	2.61e-11	Alzheimer's disease;
UCEC	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.74	-5.92	-0.44	2.22e-8	Schizophrenia;
UCEC	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.52	5.04	0.38	1.36e-6	Resting heart rate;
UCEC	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg02158880	chr13:53174818	NA	0.42	4.83	0.37	3.37e-6	Lewy body disease;
UCEC	cis	rs12681287	0.752	rs4427148	chr8:87250668	G/A	cg27223183	chr8:87520930	FAM82B	-0.57	-4.64	-0.36	7.72e-6	Caudate activity during reward;
UCEC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	5.2	0.39	6.52e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.54	-5.98	-0.44	1.6e-8	Blood metabolite levels;
UCEC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.65	-7.13	-0.51	4.14e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.6	-5.65	-0.42	8.15e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9393294	0.608	rs12175390	chr6:22477389	C/T	cg15541384	chr6:21886458	FLJ22536	-0.6	-4.55	-0.35	1.12e-5	Mean platelet volume;
UCEC	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.61	-5.87	-0.44	2.85e-8	Blood pressure (smoking interaction);
UCEC	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg00334056	chr6:33755658	LEMD2	-0.46	-4.95	-0.38	2e-6	Crohn's disease;
UCEC	cis	rs12428035	0.764	rs72638023	chr13:96765232	C/G	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Bipolar disorder;
UCEC	cis	rs867371	1.000	rs8042464	chr15:82465536	A/G	cg00614314	chr15:82944287	LOC80154	0.54	4.94	0.38	2.14e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.55	5.1	0.39	1.02e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.55	-5.76	-0.43	4.73e-8	Colorectal cancer;
UCEC	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.55	5.2	0.39	6.51e-7	Bipolar disorder;
UCEC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-10.2	-0.64	8.22e-19	Blood metabolite levels;
UCEC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-6.75	-0.49	3.17e-10	Metabolite levels;
UCEC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.5	-4.69	-0.36	6.08e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3829109	0.564	rs12378717	chr9:139286060	G/C	cg14086826	chr9:138757010	CAMSAP1	0.54	4.53	0.35	1.22e-5	Peak insulin response;Acute insulin response;
UCEC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.54	-5.93	-0.44	2.09e-8	Blood metabolite levels;
UCEC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.47	-4.81	-0.37	3.62e-6	Lymphocyte counts;
UCEC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.66	-7.86	-0.54	7.71e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	0.98	9.51	0.62	5.13e-17	Initial pursuit acceleration;
UCEC	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.61	5.28	0.4	4.64e-7	Bipolar disorder;
UCEC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.52	0.35	1.26e-5	Parkinson's disease;
UCEC	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.56	7.5	0.53	5.53e-12	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	6.65	0.48	5.43e-10	Total body bone mineral density;
UCEC	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.08	-7.62	-0.53	2.93e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.66	-6.09	-0.45	9.22e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.92	11.45	0.69	4.26e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.53	-5.95	-0.44	1.84e-8	Pulmonary function;
UCEC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg27624424	chr6:160112604	SOD2	0.57	5.39	0.41	2.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg16329650	chr2:213403929	ERBB4	-0.47	-4.6	-0.35	8.98e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg20368463	chr18:77673604	PQLC1	0.52	4.67	0.36	6.8e-6	Opioid sensitivity;
UCEC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.69	-7.86	-0.54	7.36e-13	Menarche (age at onset);
UCEC	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.26	10.91	0.67	1.15e-20	Corneal structure;
UCEC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.62	5.56	0.42	1.22e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.71	8.35	0.57	4.61e-14	Menopause (age at onset);
UCEC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg06238570	chr21:40685208	BRWD1	0.61	6.2	0.46	5.46e-9	Cognitive function;
UCEC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	7.63	0.53	2.65e-12	Platelet count;
UCEC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.85	-0.43	3.1e-8	Menarche (age at onset);
UCEC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg20965017	chr5:231967	SDHA	-0.65	-5.79	-0.43	4.1e-8	Breast cancer;
UCEC	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-9.79	-0.63	9.84e-18	Electrocardiographic conduction measures;
UCEC	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.29	0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.53	2.09e-12	IgG glycosylation;
UCEC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.74	9.79	0.63	1.01e-17	Monocyte percentage of white cells;
UCEC	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	0.9	11.04	0.67	5.07e-21	Eosinophil percentage of white cells;
UCEC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg24634471	chr8:143751801	JRK	0.52	5.37	0.41	2.94e-7	Schizophrenia;
UCEC	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.49	5.19	0.39	6.93e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.61	0.36	8.69e-6	Breast cancer;
UCEC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg14324370	chr2:177042789	NA	0.55	5.72	0.43	5.8e-8	IgG glycosylation;
UCEC	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.63	6.96	0.5	1.04e-10	Crohn's disease;
UCEC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.6e-7	Breast cancer;
UCEC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Body mass index;
UCEC	cis	rs6733160	1.000	rs6733160	chr2:64364632	T/C	cg22352474	chr2:64371530	PELI1	0.44	4.66	0.36	7.14e-6	Allergic dermatitis (nickel);
UCEC	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.74	8.54	0.58	1.57e-14	IgG glycosylation;
UCEC	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.58	-5.54	-0.42	1.34e-7	Vitamin D levels;
UCEC	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs7267005	1.000	rs111883395	chr20:34385510	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.65	6.84	0.49	2.03e-10	Menopause (age at onset);
UCEC	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24249390	chr15:90295951	MESP1	-0.43	-4.81	-0.37	3.73e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.5	-6.12	-0.45	8.21e-9	Mean platelet volume;
UCEC	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.6	-5.95	-0.44	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.65	6.81	0.49	2.3e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.33	-4.59	-0.35	9.6e-6	Primary biliary cholangitis;
UCEC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg19041857	chr6:27730383	NA	-0.7	-5.46	-0.41	1.94e-7	Depression;
UCEC	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.84	5.92	0.44	2.2e-8	Body mass index;
UCEC	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.67	5.71	0.43	6.12e-8	Breast cancer;
UCEC	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg21466736	chr12:48725269	NA	0.35	4.7	0.36	5.99e-6	Plateletcrit;
UCEC	cis	rs4389656	0.857	rs274719	chr5:6720916	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.75	-0.36	4.75e-6	Coronary artery disease;
UCEC	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.67	7.86	0.54	7.43e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-4.7	-0.36	5.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.64	-5.65	-0.42	7.91e-8	Metabolite levels;
UCEC	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14019695	chr9:139328340	INPP5E	0.44	4.58	0.35	9.89e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
UCEC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg13870426	chr17:30244630	NA	-0.62	-4.52	-0.35	1.24e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-9.06	-0.6	7.49e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	7.89	0.55	6.52e-13	Menarche (age at onset);
UCEC	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.56	-6.01	-0.44	1.39e-8	Retinal vascular caliber;
UCEC	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.72	7.93	0.55	5.2e-13	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.62	-7.18	-0.51	3.16e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.88	12.98	0.73	3.7e-26	Leprosy;
UCEC	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.3	4.55	0.35	1.09e-5	Schizophrenia;
UCEC	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	6.95	0.5	1.08e-10	Response to bleomycin (chromatid breaks);
UCEC	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.54	4.63	0.36	7.94e-6	Alzheimer's disease;
UCEC	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	5.4	0.41	2.65e-7	Mood instability;
UCEC	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.55	6.22	0.46	4.97e-9	Hip circumference;
UCEC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	0.92	12.78	0.73	1.25e-25	Homoarginine levels;
UCEC	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.5	-5.69	-0.42	6.73e-8	Gout;
UCEC	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg26331595	chr3:39149181	GORASP1;TTC21A	0.53	5.21	0.39	6.38e-7	Handedness;
UCEC	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg24562669	chr7:97807699	LMTK2	0.42	5.21	0.4	6.15e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.77	7.53	0.53	4.85e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7246967	0.673	rs3853649	chr19:22880460	C/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.72	-0.36	5.51e-6	Parkinson's disease;
UCEC	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.54	4.57	0.35	1.01e-5	Colorectal cancer;
UCEC	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	9.39	0.61	1.08e-16	Bipolar disorder;
UCEC	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-5.36	-0.4	3.08e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.83	-7.13	-0.51	4.15e-11	Initial pursuit acceleration;
UCEC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.85	-10.84	-0.67	1.77e-20	Height;
UCEC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg12463550	chr7:65579703	CRCP	-0.53	-5.34	-0.4	3.4e-7	Aortic root size;
UCEC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.74	9.42	0.61	8.82e-17	Body mass index;
UCEC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	0.68	4.72	0.36	5.34e-6	Iron status biomarkers;
UCEC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.63	7.56	0.53	4e-12	Obesity-related traits;
UCEC	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.18e-13	Obesity-related traits;
UCEC	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.63	4.55	0.35	1.13e-5	Multiple sclerosis;
UCEC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12379764	chr21:47803548	PCNT	0.44	4.71	0.36	5.57e-6	Testicular germ cell tumor;
UCEC	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.5	4.55	0.35	1.1e-5	Morning vs. evening chronotype;
UCEC	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	10.01	0.64	2.59e-18	Cognitive ability;
UCEC	cis	rs7101446	0.738	rs7935983	chr11:63186092	G/A	cg21706343	chr11:62521476	ZBTB3	-0.53	-4.62	-0.36	8.38e-6	Economic and political preferences;
UCEC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.43	0.74	2.43e-27	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.22	-0.46	4.79e-9	Inflammatory bowel disease;
UCEC	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	0.75	7.65	0.53	2.47e-12	Height;
UCEC	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.58	5.06	0.39	1.23e-6	Multiple sclerosis;
UCEC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg02160872	chr5:212506	CCDC127	-0.79	-8.14	-0.56	1.52e-13	Breast cancer;
UCEC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.48	5.35	0.4	3.26e-7	Tonsillectomy;
UCEC	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg17927777	chr20:33865990	NA	0.56	4.77	0.37	4.48e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg12473912	chr3:136751656	NA	0.41	4.57	0.35	1.02e-5	Gestational age at birth (child effect);
UCEC	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.5	5.73	0.43	5.6e-8	Neuroticism;
UCEC	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.68	0.58	7.07e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1497406	0.802	rs7519043	chr1:16500523	C/T	cg15135617	chr1:17231562	NA	0.48	4.9	0.37	2.51e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.74	-8.52	-0.57	1.73e-14	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.53	5.45	0.41	2.09e-7	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.56	-5.65	-0.42	8.22e-8	Longevity;Endometriosis;
UCEC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.82	-11.37	-0.68	7.02e-22	Vitiligo;
UCEC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg02503808	chr4:7069936	GRPEL1	0.44	5.07	0.39	1.17e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg24562669	chr7:97807699	LMTK2	-0.75	-10.89	-0.67	1.3e-20	Breast cancer;
UCEC	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg00873616	chr20:43920241	NA	-0.51	-4.95	-0.38	2.03e-6	Blood protein levels;
UCEC	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.87	-9.44	-0.61	7.82e-17	Height;
UCEC	cis	rs7709377	0.597	rs10051072	chr5:115488499	C/T	cg23108291	chr5:115420582	COMMD10	0.55	5.58	0.42	1.14e-7	Metabolite levels  (X-11787);
UCEC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.45	4.73	0.36	5.22e-6	Schizophrenia;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.39	-4.6	-0.35	9.12e-6	Tonsillectomy;
UCEC	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.59	-5.43	-0.41	2.24e-7	Subjective well-being;
UCEC	cis	rs12980942	0.872	rs10421990	chr19:41797099	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.56	5.11	0.39	9.67e-7	Coronary artery disease;
UCEC	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.75	8.08	0.55	2.17e-13	Mosquito bite size;
UCEC	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg23795048	chr12:9217529	LOC144571	0.41	4.67	0.36	6.67e-6	Sjögren's syndrome;
UCEC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.57	-8.33	-0.57	5.35e-14	Refractive error;
UCEC	cis	rs56161922	1.000	rs55883147	chr1:207840002	C/T	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs17123764	0.642	rs11169127	chr12:50120901	A/C	cg20471783	chr12:50157085	TMBIM6	0.66	5.45	0.41	2.12e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6446731	0.593	rs2858083	chr4:3272331	T/A	cg08886695	chr4:3369023	RGS12	-0.4	-4.64	-0.36	7.59e-6	Mean platelet volume;
UCEC	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.92	9.79	0.63	9.91e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.47	-5.04	-0.38	1.37e-6	Retinal vascular caliber;
UCEC	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg13844804	chr7:814759	HEATR2	0.69	4.7	0.36	5.94e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg21905437	chr5:178450457	ZNF879	-0.45	-4.54	-0.35	1.18e-5	Pubertal anthropometrics;
UCEC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.94	9.98	0.64	3.14e-18	Cognitive function;
UCEC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-7.63	-0.53	2.77e-12	Ileal carcinoids;
UCEC	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.18	0.39	7.17e-7	IgG glycosylation;
UCEC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.79	7.45	0.52	7.37e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.91e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.48	4.57	0.35	1.03e-5	Personality dimensions;
UCEC	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.52	-5.23	-0.4	5.67e-7	Schizophrenia;
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	7.92	0.55	5.22e-13	Platelet count;
UCEC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.9e-8	Breast cancer;
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.63	4.79	0.37	4.02e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.26	-0.4	4.99e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg19318889	chr4:1322082	MAEA	0.42	5.04	0.38	1.33e-6	Obesity-related traits;
UCEC	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.71	-5.07	-0.39	1.19e-6	Systemic lupus erythematosus;
UCEC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.45	-0.41	2.09e-7	Birth weight;
UCEC	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.47	-5.55	-0.42	1.28e-7	Subjective well-being;
UCEC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-6.84	-0.49	1.94e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.5	0.35	1.36e-5	Menopause (age at onset);
UCEC	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.11	0.51	4.7e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.62	-6.16	-0.45	6.52e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-4.79	-0.37	4.08e-6	Platelet distribution width;
UCEC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg11632617	chr15:75315747	PPCDC	-0.5	-5.14	-0.39	8.67e-7	Blood trace element (Zn levels);
UCEC	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-19.54	-0.85	1.04e-42	Myeloid white cell count;
UCEC	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.67	-7.25	-0.51	2.15e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.65	7.38	0.52	1.08e-11	Body mass index;
UCEC	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-4.97	-0.38	1.81e-6	Schizophrenia;
UCEC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.73	-7.59	-0.53	3.46e-12	Menarche (age at onset);
UCEC	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-6.66	-0.48	5.1e-10	Morning vs. evening chronotype;
UCEC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	0.82	7.01	0.5	8.13e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.92	-10.24	-0.65	6.61e-19	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.25	-0.4	5.31e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.64	-5.23	-0.4	5.6e-7	Schizophrenia;
UCEC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.86	-0.49	1.8e-10	Menarche (age at onset);
UCEC	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.72	-8.17	-0.56	1.3e-13	Waist circumference;Body mass index;
UCEC	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	4.93	0.38	2.17e-6	Bipolar disorder;
UCEC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.09	-0.39	1.1e-6	Mean platelet volume;
UCEC	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs72906064	0.614	rs72904197	chr2:156887825	G/A	cg14040602	chr2:157557294	NA	0.67	4.77	0.37	4.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.59	-6.41	-0.47	1.84e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.69	5.48	0.41	1.8e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23978390	chr7:1156363	C7orf50	0.68	7.21	0.51	2.68e-11	Longevity;Endometriosis;
UCEC	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.37	4.93	0.38	2.18e-6	Sitting height ratio;
UCEC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.58	-0.42	1.1e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.32	-0.4	3.75e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-5.42	-0.41	2.4e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.48	-5.72	-0.43	5.9e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.81	-10.38	-0.65	2.78e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.44	4.64	0.36	7.66e-6	Prostate cancer;
UCEC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.61	-5.4	-0.41	2.68e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.79	7.55	0.53	4.27e-12	Longevity;Endometriosis;
UCEC	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.55	-6.37	-0.47	2.23e-9	Type 2 diabetes;
UCEC	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.69	-6.3	-0.46	3.29e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg13683864	chr3:40499215	RPL14	-0.58	-6.07	-0.45	1.01e-8	Renal cell carcinoma;
UCEC	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg17267710	chr20:61161232	C20orf166;MIR133A2	-0.35	-4.66	-0.36	7.11e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7246967	0.736	rs428299	chr19:22996252	T/C	cg08271804	chr19:22816896	ZNF492	0.55	4.87	0.37	2.83e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-0.98	-13.34	-0.74	4.09e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Body mass index;
UCEC	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19500275	chr17:80737654	TBCD	0.49	4.87	0.37	2.91e-6	Glycated hemoglobin levels;
UCEC	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.57	5.16	0.39	7.87e-7	Economic and political preferences (feminism/equality);
UCEC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.15	-0.51	3.78e-11	Breast cancer;
UCEC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.46	4.77	0.37	4.47e-6	Acylcarnitine levels;
UCEC	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg22872349	chr15:81410745	NA	-0.59	-5.21	-0.39	6.39e-7	QT interval (drug interaction);
UCEC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.69	6.26	0.46	4.07e-9	Aortic root size;
UCEC	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.12	0.39	9.45e-7	Blood protein levels;
UCEC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-10.05	-0.64	2.05e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-4.52	-0.35	1.27e-5	Hemoglobin concentration;
UCEC	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.77	-6.52	-0.47	1.05e-9	Lymphocyte percentage of white cells;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01258499	chr20:30540016	PDRG1	0.59	6.8	0.49	2.4e-10	Warfarin maintenance dose;
UCEC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19387228	chr4:8442570	ACOX3	0.6	7.27	0.51	2.01e-11	Warfarin maintenance dose;
UCEC	cis	rs1483890	0.723	rs6549208	chr3:69412134	T/G	cg22125112	chr3:69402811	FRMD4B	0.45	4.73	0.36	5.32e-6	Resting heart rate;
UCEC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.43	-0.41	2.27e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246967	0.611	rs3951784	chr19:22851926	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.68	6.04	0.45	1.21e-8	High light scatter reticulocyte count;
UCEC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.57	-6.37	-0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg03152288	chr2:177042942	NA	0.46	4.9	0.37	2.54e-6	IgG glycosylation;
UCEC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.72	5.39	0.41	2.8e-7	Diabetic retinopathy;
UCEC	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg07493874	chr5:1342172	CLPTM1L	-0.52	-6.17	-0.45	6.35e-9	Lung cancer;
UCEC	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	4.68	0.36	6.41e-6	Mean corpuscular hemoglobin;
UCEC	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.18	9.31	0.61	1.74e-16	Uric acid levels;
UCEC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.69	-7.82	-0.54	9.21e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.15	-8.43	-0.57	3e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg17515076	chr17:73810948	UNK	-0.51	-5.71	-0.43	6.17e-8	White matter hyperintensity burden;
UCEC	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.56	-5.64	-0.42	8.39e-8	White matter hyperintensity burden;
UCEC	cis	rs6722750	0.933	rs12999721	chr2:64407710	C/T	cg22352474	chr2:64371530	PELI1	0.46	4.58	0.35	9.97e-6	Neuroticism;
UCEC	cis	rs7580658	0.534	rs2089109	chr2:127951458	G/A	cg16751203	chr2:127950803	CYP27C1	0.39	5.08	0.39	1.15e-6	Protein C levels;
UCEC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.55	4.69	0.36	6.1e-6	Response to diuretic therapy;
UCEC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18932078	chr1:2524107	MMEL1	0.4	6.53	0.47	1e-9	Ulcerative colitis;
UCEC	cis	rs354225	0.544	rs13423873	chr2:54786677	A/G	cg09831207	chr2:55509334	PRDXDD1P	-0.47	-4.67	-0.36	6.78e-6	Schizophrenia;
UCEC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg27624424	chr6:160112604	SOD2	0.57	4.88	0.37	2.79e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.55	-5.12	-0.39	9.4e-7	Neurofibrillary tangles;
UCEC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.71	7.97	0.55	4.06e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.78	7.81	0.54	1.01e-12	Prudent dietary pattern;
UCEC	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	4.93	0.38	2.23e-6	Neuroticism;
UCEC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.48	4.7	0.36	5.95e-6	Longevity;Endometriosis;
UCEC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.74	-7.84	-0.54	8.53e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs10242455	0.702	rs73401510	chr7:99065812	A/C	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.85e-6	Blood metabolite levels;
UCEC	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-7.63	-0.53	2.76e-12	Hip circumference;
UCEC	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.68	10.28	0.65	5.2e-19	Total body bone mineral density;
UCEC	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.43	5.0	0.38	1.6e-6	Morning vs. evening chronotype;
UCEC	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.57	5.21	0.39	6.33e-7	Corneal astigmatism;
UCEC	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs150641967	1	rs150641967	chr19:19370340	TGACA/T	cg03709012	chr19:19516395	GATAD2A	1.18	5.5	0.41	1.61e-7	Triglyceride levels;Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11640544	chr10:43904468	HNRNPF	0.6	7.18	0.51	3.28e-11	Warfarin maintenance dose;
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.96	0.44	1.77e-8	Breast cancer;
UCEC	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.48	-4.71	-0.36	5.74e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.37	-8.66	-0.58	7.7e-15	Diabetic kidney disease;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.53	5.76	0.43	4.76e-8	Longevity;Endometriosis;
UCEC	cis	rs2892463	0.757	rs2761939	chr13:30408738	A/C	cg18356743	chr13:30408050	UBL3	0.4	4.53	0.35	1.21e-5	Non-word repetition;
UCEC	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg23307798	chr14:103986281	CKB	-0.48	-4.99	-0.38	1.65e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.32	-0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg19678392	chr7:94953810	PON1	-0.59	-5.38	-0.41	2.87e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs847577	0.609	rs705308	chr7:97695363	C/A	cg21770322	chr7:97807741	LMTK2	-0.81	-12.59	-0.72	4.04e-25	Breast cancer;
UCEC	cis	rs590820	1.000	rs609526	chr1:230308906	A/T	cg08705382	chr1:230322024	GALNT2	0.38	4.78	0.37	4.19e-6	Metabolite levels (lipoprotein measures);
UCEC	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.49	-4.62	-0.36	8.42e-6	Longevity;
UCEC	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-5.98	-0.44	1.59e-8	Hepatocellular carcinoma;
UCEC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.51	0.53	5.3e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.62	5.35	0.4	3.35e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.47	5.44	0.41	2.13e-7	Aortic root size;
UCEC	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.44	4.76	0.37	4.61e-6	Uric acid clearance;
UCEC	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	0.95	13.69	0.75	4.92e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.8	-7.46	-0.52	7.01e-12	Diastolic blood pressure;
UCEC	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Parkinson's disease;
UCEC	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.58	5.37	0.4	3.07e-7	Bone mineral density;
UCEC	cis	rs600806	0.745	rs12136063	chr1:110014170	A/G	cg02175308	chr1:109941060	SORT1	0.29	4.64	0.36	7.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg06138931	chr13:21896616	NA	0.6	4.56	0.35	1.09e-5	White matter hyperintensity burden;
UCEC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg00277334	chr10:82204260	NA	-0.48	-4.76	-0.37	4.49e-6	Post bronchodilator FEV1;
UCEC	cis	rs10242455	0.867	rs1818797	chr7:99296195	G/A	cg18809830	chr7:99032528	PTCD1	0.53	4.56	0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.73	6.52	0.47	1.03e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg03342759	chr3:160939853	NMD3	-0.55	-4.95	-0.38	2.05e-6	Morning vs. evening chronotype;
UCEC	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg03342759	chr3:160939853	NMD3	0.52	4.72	0.36	5.44e-6	Morning vs. evening chronotype;
UCEC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.58	0.48	7.64e-10	Tonsillectomy;
UCEC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.6	-4.64	-0.36	7.52e-6	Gut microbiome composition (summer);
UCEC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.53	-6.03	-0.45	1.27e-8	Fibrinogen levels;
UCEC	cis	rs2283228	0.737	rs7480855	chr11:2836085	C/T	cg23617121	chr11:3121460	OSBPL5	-0.57	-4.79	-0.37	4.11e-6	Type 2 diabetes;
UCEC	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.48	4.94	0.38	2.08e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs7246967	0.673	rs427709	chr19:22998163	A/G	cg08271804	chr19:22816896	ZNF492	0.65	5.63	0.42	9.02e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12545109	0.679	rs1973628	chr8:57429360	T/C	cg07776626	chr8:57350775	NA	-0.54	-4.51	-0.35	1.34e-5	Obesity-related traits;
UCEC	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-8.59	-0.58	1.14e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg20933586	chr14:24608199	FAM158A	0.41	5.22	0.4	5.87e-7	IgG glycosylation;
UCEC	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.56	6.67	0.48	4.87e-10	Menopause (age at onset);
UCEC	cis	rs7246967	0.673	rs62120313	chr19:22877183	G/C	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-5.05	-0.38	1.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.43	5.16	0.39	7.88e-7	Height;
UCEC	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.73	5.18	0.39	7.09e-7	Inflammatory bowel disease;
UCEC	cis	rs6832720	1.000	rs17087969	chr4:58195739	A/G	cg24819475	chr4:57397423	NA	-0.67	-4.92	-0.38	2.32e-6	Cotinine glucuronidation;
UCEC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.81	9.2	0.6	3.22e-16	Menopause (age at onset);
UCEC	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.27	-0.4	4.8e-7	Headache;
UCEC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.61	-0.36	8.84e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs13095912	0.962	rs11916386	chr3:185308069	G/T	cg11274856	chr3:185301563	NA	0.55	7.29	0.52	1.77e-11	Systolic blood pressure;
UCEC	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	6.45	0.47	1.51e-9	Motion sickness;
UCEC	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-5.94	-0.44	1.99e-8	Mean platelet volume;
UCEC	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	4.7	0.36	5.95e-6	IgG glycosylation;
UCEC	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.81	0.49	2.36e-10	Coffee consumption (cups per day);
UCEC	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.52	5.82	0.43	3.53e-8	Prostate cancer;
UCEC	cis	rs4499344	0.577	rs259289	chr19:33164927	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.17	0.39	7.69e-7	Mean platelet volume;
UCEC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-5.95	-0.44	1.88e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.89	0.63	5.5e-18	Cognitive function;
UCEC	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.99	-0.38	1.68e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs7219021	1.000	rs68012338	chr17:46856405	G/A	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg09655341	chr17:79618100	PDE6G	0.3	4.55	0.35	1.12e-5	Eye color traits;
UCEC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.53	4.91	0.38	2.35e-6	Menopause (age at onset);
UCEC	cis	rs4789294	0.806	rs11650513	chr17:74439196	T/A	cg06840243	chr17:74442338	UBE2O	0.4	4.56	0.35	1.06e-5	Lymphocyte percentage of white cells;
UCEC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.38	-0.47	2.18e-9	Aortic root size;
UCEC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.71	8.35	0.57	4.61e-14	Menopause (age at onset);
UCEC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.8	10.87	0.67	1.46e-20	Headache;
UCEC	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg12339802	chr1:38156545	C1orf109	-0.52	-4.77	-0.37	4.43e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2455799	1.000	rs13092817	chr3:15889398	C/G	cg16303742	chr3:15540471	COLQ	-0.4	-4.65	-0.36	7.21e-6	Mean platelet volume;
UCEC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.88	0.49	1.6e-10	Cognitive test performance;
UCEC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg01689657	chr7:91764605	CYP51A1	0.46	5.99	0.44	1.56e-8	Breast cancer;
UCEC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.5	-0.57	1.98e-14	Blood trace element (Zn levels);
UCEC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	0.82	5.23	0.4	5.64e-7	Arsenic metabolism;
UCEC	cis	rs16937	0.711	rs10900467	chr1:205160074	G/A	cg12580275	chr1:205744413	RAB7L1	0.49	5.33	0.4	3.61e-7	Schizophrenia;
UCEC	cis	rs7246967	0.551	rs8103204	chr19:22936517	T/A	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.1	-0.45	8.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11760485	0.965	rs11773381	chr7:4401128	C/T	cg15613991	chr7:5277080	NA	-0.41	-4.89	-0.37	2.65e-6	Early childhood aggressive behavior;
UCEC	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.72	-0.36	5.54e-6	Major depressive disorder;
UCEC	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.7	0.48	4.23e-10	Motion sickness;
UCEC	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.42	5.76	0.43	4.74e-8	Life satisfaction;
UCEC	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	0.87	9.01	0.6	9.85e-16	Primary sclerosing cholangitis;
UCEC	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.44	-4.88	-0.37	2.74e-6	White matter hyperintensity burden;
UCEC	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.52	7.32	0.52	1.53e-11	Height;
UCEC	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	4.71	0.36	5.62e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.07	-0.39	1.2e-6	Personality dimensions;
UCEC	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.56	-5.1	-0.39	1.02e-6	Morning vs. evening chronotype;
UCEC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg03354898	chr7:1950403	MAD1L1	-0.59	-5.78	-0.43	4.25e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.49	-4.86	-0.37	3.04e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18252515	chr7:66147081	NA	0.61	5.68	0.42	7.06e-8	Aortic root size;
UCEC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg12463550	chr7:65579703	CRCP	0.53	5.31	0.4	4.04e-7	Aortic root size;
UCEC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.55	5.12	0.39	9.29e-7	Tonsillectomy;
UCEC	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.67	7.66	0.53	2.27e-12	Mean corpuscular volume;
UCEC	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.74	-8.0	-0.55	3.35e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg01426195	chr3:39028469	NA	0.55	5.93	0.44	2.05e-8	Handedness;
UCEC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg27153327	chr16:1920815	C16orf73	-0.41	-4.58	-0.35	9.84e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.21	0.46	5.19e-9	Cognitive ability;
UCEC	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.65	7.38	0.52	1.08e-11	Body mass index;
UCEC	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.51	-5.39	-0.41	2.77e-7	Retinal vascular caliber;
UCEC	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.5	4.98	0.38	1.8e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.38	-4.88	-0.37	2.77e-6	Glomerular filtration rate (creatinine);
UCEC	trans	rs12476592	0.636	rs262493	chr2:63845066	G/T	cg20689730	chr22:20072653	MIR1306;DGCR8	0.69	6.99	0.5	9.06e-11	Childhood ear infection;
UCEC	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg14675211	chr2:100938903	LONRF2	0.45	4.63	0.36	8.03e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg26162295	chr17:38119207	GSDMA	0.32	4.87	0.37	2.88e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.64	-5.38	-0.41	2.81e-7	Coronary artery calcification;
UCEC	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.53	-7.08	-0.5	5.56e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg22117172	chr7:91764530	CYP51A1	-0.39	-4.73	-0.36	5.14e-6	Breast cancer;
UCEC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg22868518	chr11:507468	RNH1	-0.69	-4.64	-0.36	7.52e-6	Body mass index;
UCEC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.27	-0.46	3.87e-9	Post bronchodilator FEV1;
UCEC	cis	rs2302190	0.882	rs11656888	chr17:56546725	T/A	cg12560992	chr17:57184187	TRIM37	0.54	4.71	0.36	5.57e-6	Vitamin D levels;
UCEC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.81	6.47	0.47	1.36e-9	Body mass index;
UCEC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.74	-0.36	5.09e-6	Calcium levels;
UCEC	cis	rs2455799	0.593	rs13078487	chr3:15929590	G/T	cg16303742	chr3:15540471	COLQ	-0.39	-4.78	-0.37	4.18e-6	Mean platelet volume;
UCEC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.07	-0.45	1.04e-8	Bipolar disorder;
UCEC	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.47	-6.03	-0.45	1.25e-8	Refractive error;
UCEC	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.47	-4.86	-0.37	3.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	6.8	0.49	2.43e-10	Motion sickness;
UCEC	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs9309473	0.500	rs10865398	chr2:73741497	A/C	cg20560298	chr2:73613845	ALMS1	0.51	5.05	0.38	1.3e-6	Metabolite levels;
UCEC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.71	6.7	0.48	4.14e-10	High light scatter reticulocyte count;
UCEC	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.32	-0.46	2.88e-9	Resting heart rate;
UCEC	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.45	4.8	0.37	3.88e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.45	-4.51	-0.35	1.31e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.45	4.51	0.35	1.31e-5	Aortic root size;
UCEC	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.65	0.48	5.51e-10	Motion sickness;
UCEC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-4.99	-0.38	1.71e-6	Lung cancer in ever smokers;
UCEC	cis	rs36051895	0.589	rs1322222	chr9:5190444	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-5.32	-0.4	3.71e-7	Pediatric autoimmune diseases;
UCEC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	4.88	0.37	2.73e-6	Hemoglobin concentration;
UCEC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg07387570	chr22:46663686	TTC38	-0.49	-4.83	-0.37	3.41e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	14.48	0.77	4.37e-30	Birth weight;
UCEC	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.42	-5.39	-0.41	2.74e-7	Congenital heart disease (maternal effect);
UCEC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.59	5.36	0.4	3.09e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	4.59	0.35	9.28e-6	Breast cancer;
UCEC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.58	-4.57	-0.35	1.01e-5	Gut microbiome composition (summer);
UCEC	cis	rs7246967	0.736	rs453723	chr19:22998489	C/T	cg24889512	chr19:22816950	ZNF492	0.51	4.85	0.37	3.09e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-5.41	-0.41	2.51e-7	Heart rate;
UCEC	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.51	5.61	0.42	9.53e-8	Type 2 diabetes;
UCEC	trans	rs12474538	0.663	rs12464795	chr2:69515602	A/G	cg00409201	chr19:58559304	ZSCAN1	-1.01	-8.35	-0.57	4.54e-14	Breast cancer;
UCEC	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg19743168	chr1:23544995	NA	-0.43	-5.41	-0.41	2.53e-7	Height;
UCEC	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg12596171	chr3:113251061	SIDT1	-0.46	-4.58	-0.35	1e-5	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs2708977	0.637	rs675239	chr2:97076556	A/G	cg22654517	chr2:96458247	NA	0.42	5.17	0.39	7.61e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs713477	0.967	rs1572613	chr14:55909897	C/T	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.22	-0.4	5.89e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-11.33	-0.68	8.63e-22	Cognitive function;
UCEC	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.27	-0.4	4.72e-7	Blood metabolite levels;
UCEC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.66	7.71	0.54	1.76e-12	Longevity;
UCEC	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.53	4.7	0.36	5.87e-6	Hypospadias;
UCEC	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.68	-0.62	1.85e-17	Primary sclerosing cholangitis;
UCEC	cis	rs8017423	0.529	rs12898020	chr14:90835752	A/G	cg07150772	chr14:90864620	CALM1	0.52	4.56	0.35	1.05e-5	Mortality in heart failure;
UCEC	cis	rs2708977	0.671	rs582014	chr2:97075826	A/G	cg22654517	chr2:96458247	NA	0.45	5.78	0.43	4.35e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs884366	1.000	rs4946957	chr6:109641411	C/T	cg01475377	chr6:109611718	NA	0.44	4.83	0.37	3.44e-6	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	0.5	4.85	0.37	3.1e-6	Lewy body disease;
UCEC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.57	-0.35	1.01e-5	Breast cancer;
UCEC	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.62	4.94	0.38	2.14e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	4.7	0.36	5.91e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.21	0.46	5.19e-9	Cognitive ability;
UCEC	cis	rs829883	0.646	rs1641638	chr12:98891031	A/G	cg25150519	chr12:98850993	NA	0.62	5.52	0.41	1.47e-7	Colorectal adenoma (advanced);
UCEC	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-8.8	-0.59	3.37e-15	Exhaled nitric oxide output;
UCEC	cis	rs749052	0.561	rs3103289	chr2:233061267	C/A	cg23548455	chr2:233377587	NA	0.69	4.56	0.35	1.05e-5	Height;
UCEC	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.67	7.42	0.52	8.63e-12	Leprosy;
UCEC	cis	rs8032158	0.702	rs12910830	chr15:56122664	T/C	cg10433327	chr15:56209506	NEDD4	-0.32	-5.0	-0.38	1.64e-6	Keloid;
UCEC	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg03354898	chr7:1950403	MAD1L1	0.46	4.58	0.35	9.79e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.81	9.99	0.64	2.99e-18	Bone mineral density;
UCEC	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.51	-6.22	-0.46	4.86e-9	Mean platelet volume;
UCEC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg03859395	chr2:55845619	SMEK2	1.04	15.32	0.78	2.94e-32	Metabolic syndrome;
UCEC	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg03714773	chr7:91764589	CYP51A1	0.47	5.82	0.43	3.47e-8	Breast cancer;
UCEC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.43	-4.83	-0.37	3.46e-6	Prostate cancer;
UCEC	cis	rs782107	0.591	rs782085	chr12:58772624	G/T	cg19181132	chr12:59314527	LRIG3	0.45	4.84	0.37	3.2e-6	Interleukin-12p70 levels;
UCEC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.93	6.75	0.49	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2412819	0.571	rs66749753	chr15:43911799	C/T	cg24361265	chr15:44068668	ELL3	0.55	4.62	0.36	8.49e-6	Lung cancer;
UCEC	cis	rs7072216	0.881	rs1079179	chr10:100149346	T/C	cg19567339	chr10:100142640	NA	0.61	8.61	0.58	1.02e-14	Metabolite levels;
UCEC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs3015497	0.789	rs7147956	chr14:51142605	G/A	cg04730355	chr14:51134070	SAV1	-0.49	-5.02	-0.38	1.49e-6	Mean platelet volume;
UCEC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.13e-7	Aortic root size;
UCEC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.49	-4.91	-0.38	2.41e-6	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg04663916	chr13:50265991	EBPL	0.57	5.64	0.42	8.53e-8	Obesity-related traits;
UCEC	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.45	-4.68	-0.36	6.38e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-4.93	-0.38	2.22e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.48	6.23	0.46	4.73e-9	Age-related hearing impairment;
UCEC	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.88	11.18	0.68	2.18e-21	Metabolic syndrome;
UCEC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg01380346	chr19:18557039	ELL	-0.46	-4.72	-0.36	5.46e-6	Breast cancer;
UCEC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.75	8.38	0.57	4.02e-14	Lymphocyte counts;
UCEC	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	6.66	0.48	4.98e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg20560298	chr2:73613845	ALMS1	0.51	5.15	0.39	8.41e-7	Schizophrenia;
UCEC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.33	0.4	3.56e-7	Alzheimer's disease;
UCEC	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.56	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs539096	0.830	rs3000761	chr1:44026089	C/T	cg11851915	chr1:44060116	PTPRF	-0.42	-4.52	-0.35	1.24e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	5.61	0.42	9.53e-8	Monocyte percentage of white cells;
UCEC	cis	rs16866061	0.816	rs115900205	chr2:225467840	G/C	cg12698349	chr2:225449008	CUL3	0.86	8.33	0.57	5.21e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs8064299	0.503	rs11653346	chr17:72773333	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.52	4.94	0.38	2.12e-6	Monocyte count;
UCEC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.92	8.55	0.58	1.49e-14	Testicular germ cell tumor;
UCEC	cis	rs10242455	0.702	rs73403247	chr7:99088730	G/A	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.75	7.4	0.52	9.52e-12	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-10.07	-0.64	1.78e-18	Headache;
UCEC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg20203395	chr5:56204925	C5orf35	-0.54	-4.8	-0.37	3.9e-6	Coronary artery disease;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg09654669	chr8:57350985	NA	-0.55	-5.53	-0.41	1.45e-7	Obesity-related traits;
UCEC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.81e-7	Heart rate;
UCEC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-7.73	-0.54	1.55e-12	Coronary artery disease;
UCEC	cis	rs10924970	0.781	rs10802590	chr1:235444051	A/G	cg26050004	chr1:235667680	B3GALNT2	0.45	4.73	0.36	5.11e-6	Asthma;
UCEC	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.27	10.38	0.65	2.75e-19	Corneal structure;
UCEC	cis	rs9976767	0.932	rs9784206	chr21:43823380	T/G	cg00134539	chr21:43824071	UBASH3A	0.31	4.9	0.37	2.47e-6	Type 1 diabetes;
UCEC	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.83	9.25	0.61	2.48e-16	Breast cancer;
UCEC	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.8	-7.34	-0.52	1.38e-11	Diastolic blood pressure;
UCEC	cis	rs6546886	1.000	rs6546886	chr2:74245777	A/G	cg14702570	chr2:74259524	NA	-0.44	-5.77	-0.43	4.52e-8	Dialysis-related mortality;
UCEC	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	10.94	0.67	9.69e-21	Headache;
UCEC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.66	6.69	0.48	4.4e-10	Lymphocyte counts;
UCEC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.59	5.3	0.4	4.12e-7	Educational attainment;
UCEC	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg14092571	chr14:90743983	NA	0.43	4.81	0.37	3.69e-6	Mortality in heart failure;
UCEC	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.69	-7.07	-0.5	5.8e-11	Ear protrusion;
UCEC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.51	-4.82	-0.37	3.6e-6	Menarche (age at onset);
UCEC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.58	-4.91	-0.38	2.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26031613	chr14:104095156	KLC1	1.17	13.84	0.75	2.06e-28	Body mass index;
UCEC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs6546886	0.912	rs10164943	chr2:74306056	C/T	cg14702570	chr2:74259524	NA	-0.38	-4.53	-0.35	1.21e-5	Dialysis-related mortality;
UCEC	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.9	-0.49	1.46e-10	Mood instability;
UCEC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg13395646	chr4:1353034	KIAA1530	-0.51	-4.73	-0.36	5.29e-6	Obesity-related traits;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.83	0.43	3.34e-8	Platelet count;
UCEC	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.38	0.52	1.09e-11	Ileal carcinoids;
UCEC	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	0.79	4.54	0.35	1.18e-5	Height;
UCEC	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.43	4.54	0.35	1.14e-5	HDL cholesterol;
UCEC	cis	rs4588572	0.686	rs4703756	chr5:77683490	T/C	cg11547950	chr5:77652471	NA	0.49	5.38	0.41	2.86e-7	Triglycerides;
UCEC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.82	0.37	3.62e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.76	6.67	0.48	4.84e-10	Menopause (age at onset);
UCEC	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.55	-5.7	-0.43	6.31e-8	White matter hyperintensity burden;
UCEC	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.58	7.02	0.5	7.49e-11	Oral cavity cancer;
UCEC	cis	rs7870753	0.838	rs10991348	chr9:99247827	C/T	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.46	-4.74	-0.36	5.01e-6	Body mass index;
UCEC	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.27	-7.12	-0.51	4.35e-11	Schizophrenia;
UCEC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.39e-7	Aortic root size;
UCEC	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-7.5	-0.53	5.58e-12	Joint mobility (Beighton score);
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.59	8.69	0.58	6.69e-15	Prudent dietary pattern;
UCEC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg19041857	chr6:27730383	NA	-0.7	-5.46	-0.41	1.94e-7	Depression;
UCEC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.7	6.35	0.46	2.59e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.57	-5.95	-0.44	1.86e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.87	-10.99	-0.67	6.85e-21	Height;
UCEC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.6	6.4	0.47	1.91e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	0.54	5.47	0.41	1.9e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs405956	1.000	rs923404	chr6:105617761	A/G	cg22580625	chr6:105627791	POPDC3	0.56	4.52	0.35	1.27e-5	QT interval;
UCEC	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg12483005	chr1:23474871	LUZP1	0.41	4.62	0.36	8.19e-6	Height;
UCEC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	1.06	12.18	0.71	4.9e-24	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-5.0	-0.38	1.63e-6	Vitiligo;
UCEC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.55	5.01	0.38	1.51e-6	Metabolite levels;
UCEC	cis	rs2267681	0.544	rs2361644	chr7:139516316	G/A	cg14116596	chr7:139528673	TBXAS1	0.58	5.55	0.42	1.3e-7	Cervical cancer;
UCEC	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-6.71	-0.48	3.83e-10	Response to antipsychotic treatment;
UCEC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.55	-5.28	-0.4	4.63e-7	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.47	-5.61	-0.42	9.98e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-0.45	-4.52	-0.35	1.28e-5	Pediatric autoimmune diseases;
UCEC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.74	-6.48	-0.47	1.31e-9	Gut microbiome composition (summer);
UCEC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.72	8.21	0.56	1.02e-13	Monocyte count;
UCEC	cis	rs11581903	0.568	rs11205977	chr1:53068093	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.89	4.79	0.37	3.96e-6	Joint mobility (Beighton score);
UCEC	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg02344993	chr17:57696989	CLTC	0.49	4.73	0.36	5.29e-6	Hemoglobin concentration;
UCEC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.61	0.36	8.75e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.54	4.86	0.37	3.01e-6	Lung cancer;
UCEC	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.52	4.61	0.36	8.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.47	6.68	0.48	4.63e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs7246967	0.932	rs7257731	chr19:23042803	A/C	cg08271804	chr19:22816896	ZNF492	0.54	5.29	0.4	4.43e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.66	5.14	0.39	8.67e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg27246729	chr12:121163418	ACADS	0.47	4.67	0.36	6.84e-6	Mean corpuscular volume;
UCEC	cis	rs78487399	0.908	rs77994584	chr2:43817076	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.96	-0.38	1.88e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.76	-0.37	4.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.53	-5.99	-0.44	1.58e-8	Lung cancer;
UCEC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.68	5.46	0.41	1.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.71	5.65	0.42	7.97e-8	Obesity-related traits;
UCEC	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg01072550	chr1:21505969	NA	-0.52	-4.83	-0.37	3.34e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.59	5.53	0.41	1.45e-7	Corneal astigmatism;
UCEC	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.98	-7.04	-0.5	6.69e-11	Blood pressure (smoking interaction);
UCEC	cis	rs7119167	0.686	rs11824050	chr11:73011106	G/T	cg26742440	chr11:73472391	RAB6A	-0.43	-4.64	-0.36	7.79e-6	Blood protein levels;
UCEC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.53	5.18	0.39	7.26e-7	Blood metabolite levels;
UCEC	cis	rs554111	0.660	rs1985278	chr1:21091861	G/T	cg08890418	chr1:21044141	KIF17	-0.56	-5.05	-0.38	1.28e-6	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.74	-6.22	-0.46	4.96e-9	Colorectal adenoma (advanced);
UCEC	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs1712517	0.787	rs1163089	chr10:105043964	G/A	cg05636881	chr10:105038444	INA	0.49	5.56	0.42	1.24e-7	Migraine;
UCEC	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.88	0.37	2.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.24e-8	Systemic lupus erythematosus;
UCEC	cis	rs28530618	0.500	rs1885050	chr20:31226100	G/T	cg13636640	chr20:31349939	DNMT3B	-0.59	-5.21	-0.39	6.3e-7	Birth weight;
UCEC	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.42	4.53	0.35	1.23e-5	Schizophrenia;
UCEC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.15	-10.75	-0.66	3.01e-20	Vitiligo;
UCEC	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.76	-6.74	-0.49	3.29e-10	Inflammatory bowel disease;
UCEC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.76	8.6	0.58	1.09e-14	Mortality in heart failure;
UCEC	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.5	5.16	0.39	7.86e-7	Coronary heart disease;
UCEC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01973587	chr1:228161476	NA	0.37	4.95	0.38	2.05e-6	Diastolic blood pressure;
UCEC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.96	9.11	0.6	5.41e-16	IgG glycosylation;
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg20119798	chr7:94954144	PON1	-0.5	-4.75	-0.36	4.77e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg01256987	chr12:42539512	GXYLT1	0.41	4.75	0.36	4.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg22857025	chr5:266934	NA	-0.95	-8.45	-0.57	2.56e-14	Breast cancer;
UCEC	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	6.0	0.44	1.49e-8	Response to bleomycin (chromatid breaks);
UCEC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.8	-10.24	-0.65	6.67e-19	Menarche (age at onset);
UCEC	cis	rs12145833	1.000	rs10926984	chr1:243462153	T/G	cg02356786	chr1:243265016	LOC731275	0.74	5.03	0.38	1.42e-6	Obesity (early onset extreme);
UCEC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg19645103	chr12:69753606	YEATS4	-0.55	-5.0	-0.38	1.62e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg01260170	chr1:17020230	ESPNP	-0.46	-4.94	-0.38	2.12e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.9	-6.79	-0.49	2.59e-10	Exhaled nitric oxide output;
UCEC	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.27	0.46	3.85e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.67	-8.03	-0.55	2.92e-13	Prevalent atrial fibrillation;
UCEC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.61	5.24	0.4	5.53e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	1.12	13.32	0.74	4.78e-27	Post bronchodilator FEV1;
UCEC	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs10940138	0.774	rs57209938	chr5:67234233	A/G	ch.5.1281357F	chr5:67228439	NA	0.57	5.11	0.39	9.66e-7	Menarche (age at onset);
UCEC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.07	-0.39	1.15e-6	Life satisfaction;
UCEC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg06466757	chr4:1255808	NA	0.47	4.96	0.38	1.9e-6	Obesity-related traits;
UCEC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg23307798	chr14:103986281	CKB	0.56	5.34	0.4	3.48e-7	Body mass index;
UCEC	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.62	-6.09	-0.45	9.28e-9	Metabolite levels;
UCEC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.72	-6.92	-0.5	1.33e-10	Breast cancer;
UCEC	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg13575925	chr12:9217583	LOC144571	0.41	4.66	0.36	7.07e-6	Sjögren's syndrome;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg26587870	chr6:27730563	NA	-0.45	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.64	-5.66	-0.42	7.67e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1575951	1.000	rs10829456	chr10:130436141	A/C	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.88	0.37	2.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs9467773	1.000	rs9467799	chr6:26578364	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.49	5.25	0.4	5.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4851266	1.000	rs11684761	chr2:100826871	C/A	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs944990	0.640	rs10992797	chr9:96362115	C/T	cg13787134	chr9:96362102	PHF2	-0.39	-5.22	-0.4	5.91e-7	Body mass index;
UCEC	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs9907295	0.591	rs3817655	chr17:34199641	A/T	cg19411729	chr17:34207663	CCL5	0.43	4.77	0.37	4.46e-6	Fibroblast growth factor basic levels;
UCEC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.64	6.49	0.47	1.21e-9	Homoarginine levels;
UCEC	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.58	6.27	0.46	3.72e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.72	-8.3	-0.57	6.1e-14	Waist circumference;Body mass index;
UCEC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	6.02	0.44	1.33e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.43	-0.41	2.27e-7	Platelet count;
UCEC	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg05962950	chr11:130786565	SNX19	0.59	6.34	0.46	2.64e-9	Schizophrenia;
UCEC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	6.08	0.45	9.9e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.73	0.43	5.58e-8	Prudent dietary pattern;
UCEC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg14582100	chr15:45693742	SPATA5L1	-0.43	-5.64	-0.42	8.51e-8	Homoarginine levels;
UCEC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg04804543	chr8:142233427	SLC45A4	0.49	6.15	0.45	6.86e-9	Immature fraction of reticulocytes;
UCEC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.47	5.25	0.4	5.31e-7	Sjögren's syndrome;
UCEC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-5.27	-0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.66	6.15	0.45	7.07e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.63	-6.62	-0.48	6.45e-10	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs16999580	chr19:22923487	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg16060761	chr17:80687452	NA	-0.52	-4.77	-0.37	4.39e-6	Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18252515	chr7:66147081	NA	0.6	5.58	0.42	1.13e-7	Aortic root size;
UCEC	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.83	-9.68	-0.62	1.9e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.74	-8.17	-0.56	1.3e-13	White blood cell count (basophil);
UCEC	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg18232548	chr7:50535776	DDC	-0.71	-7.81	-0.54	1.01e-12	Body mass index;
UCEC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg23795048	chr12:9217529	LOC144571	-0.45	-5.55	-0.42	1.32e-7	Sjögren's syndrome;
UCEC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.56	4.95	0.38	2.03e-6	Mean platelet volume;
UCEC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.66	7.96	0.55	4.19e-13	Height;
UCEC	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.33	4.86	0.37	2.94e-6	Schizophrenia;
UCEC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg07424592	chr7:64974309	NA	-0.77	-4.51	-0.35	1.31e-5	Diabetic kidney disease;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg24503407	chr1:205819492	PM20D1	0.72	8.85	0.59	2.51e-15	Menarche (age at onset);
UCEC	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.08	9.14	0.6	4.58e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3219474	0.505	rs487174	chr1:46009536	C/T	cg03146154	chr1:46216737	IPP	0.8	4.97	0.38	1.81e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.61	5.2	0.39	6.5e-7	Alzheimer's disease;
UCEC	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg02158880	chr13:53174818	NA	-0.5	-6.27	-0.46	3.89e-9	Lewy body disease;
UCEC	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.68	5.82	0.43	3.64e-8	Coronary artery disease;
UCEC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.57	5.19	0.39	6.97e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27224392	chr10:104474430	SFXN2;ARL3	0.67	8.19	0.56	1.13e-13	Warfarin maintenance dose;
UCEC	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg05991184	chr2:219186017	PNKD	0.51	5.48	0.41	1.79e-7	Colorectal cancer;
UCEC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.55	6.11	0.45	8.44e-9	Aortic root size;
UCEC	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	14.66	0.77	1.5e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	0.86	8.43	0.57	2.91e-14	Left atrial antero-posterior diameter;
UCEC	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.95	7.34	0.52	1.35e-11	Monobrow;
UCEC	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.81	8.22	0.56	9.74e-14	Colorectal cancer;
UCEC	cis	rs999943	0.810	rs57088429	chr6:33644189	G/A	cg14003231	chr6:33640908	ITPR3	0.66	5.24	0.4	5.42e-7	Obesity (extreme);
UCEC	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.95e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg08722104	chr11:47448306	PSMC3	0.45	5.05	0.38	1.27e-6	Acute lymphoblastic leukemia (childhood);
UCEC	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs139371	0.684	rs139328	chr22:39502695	T/C	cg15548613	chr22:38610795	MAFF	0.51	5.32	0.4	3.86e-7	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs3750082	0.889	rs7785065	chr7:32915204	C/A	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	0.81	9.43	0.61	8.15e-17	Ewing sarcoma;
UCEC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.5	5.61	0.42	9.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1893767	1.000	rs1893767	chr11:123956466	A/G	cg15915129	chr11:124933008	SLC37A2	-0.52	-4.53	-0.35	1.23e-5	Obesity-related traits;
UCEC	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg03959625	chr15:84868606	LOC388152	0.48	4.88	0.37	2.76e-6	Schizophrenia;
UCEC	cis	rs17122693	1.000	rs72679576	chr14:51090881	G/A	cg04730355	chr14:51134070	SAV1	0.89	9.04	0.6	8.54e-16	Cognitive performance;
UCEC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.08	8.18	0.56	1.21e-13	Alzheimer's disease (late onset);
UCEC	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.24	0.4	5.6e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8032158	0.702	rs11632977	chr15:56131609	T/C	cg10433327	chr15:56209506	NEDD4	-0.33	-5.25	-0.4	5.13e-7	Keloid;
UCEC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.51	5.15	0.39	8.27e-7	Blood protein levels;
UCEC	cis	rs10924970	0.601	rs4659647	chr1:235379186	G/A	cg26050004	chr1:235667680	B3GALNT2	0.5	4.62	0.36	8.16e-6	Asthma;
UCEC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.78	-10.63	-0.66	6.08e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.46	4.78	0.37	4.3e-6	Red blood cell count;
UCEC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs16857609	0.628	rs2068972	chr2:218346451	A/G	cg23340935	chr2:218354150	DIRC3	-0.46	-4.57	-0.35	1.02e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg05484376	chr2:27715224	FNDC4	0.32	4.5	0.35	1.35e-5	Total body bone mineral density;
UCEC	cis	rs829661	0.739	rs829563	chr2:30695497	T/A	cg17749961	chr2:30669863	LCLAT1	0.54	5.04	0.38	1.33e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.64	5.41	0.41	2.49e-7	Alzheimer's disease;
UCEC	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.59	4.56	0.35	1.05e-5	Corneal astigmatism;
UCEC	cis	rs78487399	0.808	rs12105399	chr2:43676939	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Bipolar disorder;
UCEC	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg23795048	chr12:9217529	LOC144571	0.43	4.85	0.37	3.08e-6	Sjögren's syndrome;
UCEC	cis	rs11697848	1.000	rs34802008	chr20:48528349	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.46	5.44	0.41	2.14e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.64	5.31	0.4	4e-7	Obesity-related traits;
UCEC	cis	rs10432489	0.708	rs62178207	chr2:181747551	T/C	cg21995919	chr2:182322279	ITGA4	-0.91	-4.73	-0.36	5.28e-6	QT interval;
UCEC	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.45	4.81	0.37	3.69e-6	Menarche (age at onset);
UCEC	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.55	-4.81	-0.37	3.69e-6	Carotid intima media thickness;
UCEC	cis	rs17102423	0.547	rs10873185	chr14:65605855	G/A	cg11161011	chr14:65562177	MAX	-0.86	-9.01	-0.6	1.02e-15	Obesity-related traits;
UCEC	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.15	-0.64	1.12e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7246967	0.611	rs67531478	chr19:22889504	A/G	cg08271804	chr19:22816896	ZNF492	0.7	4.65	0.36	7.22e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg05132306	chr1:1846340	CALML6	-0.37	-4.76	-0.37	4.65e-6	Body mass index;
UCEC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs2302190	0.882	rs1974586	chr17:56640731	C/T	cg12560992	chr17:57184187	TRIM37	0.52	4.65	0.36	7.35e-6	Vitamin D levels;
UCEC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.49e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9400271	0.527	rs9386798	chr6:109639971	T/C	cg01475377	chr6:109611718	NA	0.45	5.0	0.38	1.6e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.58	7.26	0.51	2.07e-11	Metabolite levels;
UCEC	cis	rs883565	0.740	rs6796837	chr3:39076188	C/T	cg01426195	chr3:39028469	NA	-0.68	-8.52	-0.58	1.71e-14	Handedness;
UCEC	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg26781129	chr3:44753946	ZNF502	-0.58	-4.97	-0.38	1.83e-6	IgG glycosylation;
UCEC	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01391022	chr12:122360665	WDR66	-0.42	-4.83	-0.37	3.44e-6	Mean corpuscular volume;
UCEC	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.81	-10.17	-0.64	1.03e-18	White blood cell count (basophil);
UCEC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.52	6.29	0.46	3.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.96	11.17	0.68	2.27e-21	Ulcerative colitis;
UCEC	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-0.56	-5.55	-0.42	1.29e-7	Blood trace element (Zn levels);
UCEC	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.58	-6.32	-0.46	2.9e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.73	7.41	0.52	8.96e-12	Lymphocyte counts;
UCEC	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.13e-7	Body mass index;
UCEC	cis	rs17122693	0.818	rs72681645	chr14:51155209	G/A	cg04730355	chr14:51134070	SAV1	0.91	8.74	0.58	4.76e-15	Cognitive performance;
UCEC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.64	5.41	0.41	2.44e-7	Longevity;
UCEC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.77	0.54	1.23e-12	Smoking behavior;
UCEC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.49	-4.88	-0.37	2.77e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.31	-0.4	3.96e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg24851651	chr11:66362959	CCS	0.45	5.17	0.39	7.4e-7	Educational attainment (years of education);
UCEC	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.65e-10	Motion sickness;
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.44	-5.57	-0.42	1.18e-7	Prudent dietary pattern;
UCEC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.7	7.05	0.5	6.37e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	9.34	0.61	1.43e-16	Platelet count;
UCEC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.5	6.02	0.44	1.31e-8	Oral cavity cancer;
UCEC	cis	rs58749629	1.000	rs73128528	chr20:44582187	A/T	cg22967612	chr20:44601165	ZNF335	0.79	4.77	0.37	4.47e-6	Abdominal aortic aneurysm;
UCEC	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	6.93	0.5	1.2e-10	Neuroticism;
UCEC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.45	5.3	0.4	4.21e-7	Height;
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg19678392	chr7:94953810	PON1	-0.56	-5.13	-0.39	8.99e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.65	-0.36	7.25e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg11632617	chr15:75315747	PPCDC	-0.62	-7.21	-0.51	2.68e-11	Blood trace element (Zn levels);
UCEC	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.05	-14.93	-0.78	2.91e-31	Myeloid white cell count;
UCEC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.65	-7.31	-0.52	1.61e-11	Menarche (age at onset);
UCEC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.54	5.96	0.44	1.82e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs17123764	0.710	rs1574326	chr12:50090543	A/G	cg20471783	chr12:50157085	TMBIM6	0.63	5.3	0.4	4.17e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	4.56	0.35	1.08e-5	Coronary artery disease;
UCEC	cis	rs925228	0.869	rs13016006	chr2:24054510	C/T	cg13272742	chr2:24272458	FKBP1B	-0.55	-4.82	-0.37	3.48e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1863918	0.807	rs4701049	chr5:178545214	G/T	cg21905437	chr5:178450457	ZNF879	0.43	4.92	0.38	2.28e-6	Depression in response to interferon-based therapy in chronic hepatitis C;
UCEC	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	0.49	5.33	0.4	3.6e-7	Platelet distribution width;
UCEC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.34	-0.4	3.46e-7	Breast cancer;
UCEC	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.76	-5.39	-0.41	2.76e-7	Body mass index;
UCEC	cis	rs7113850	0.541	rs75347910	chr11:24213815	G/A	ch.11.24196551F	chr11:24239977	NA	0.73	4.72	0.36	5.46e-6	Bone fracture in osteoporosis;
UCEC	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.56	6.94	0.5	1.17e-10	Kawasaki disease;
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs77861329	1.000	rs6781635	chr3:52125343	A/G	cg08692210	chr3:52188851	WDR51A	0.75	5.58	0.42	1.11e-7	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs76076331	0.838	rs55748262	chr2:10982635	G/A	cg07314298	chr2:11723111	GREB1	0.46	4.53	0.35	1.22e-5	Educational attainment (college completion);Educational attainment (years of education);
UCEC	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-5.0	-0.38	1.6e-6	Mean corpuscular hemoglobin concentration;
UCEC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.49	5.27	0.4	4.79e-7	Total body bone mineral density;
UCEC	cis	rs970548	0.955	rs10900232	chr10:46157892	A/T	cg15223267	chr10:46222474	FAM21C	0.59	5.22	0.4	6.04e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18854424	chr1:2615690	NA	0.36	5.52	0.41	1.51e-7	Ulcerative colitis;
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.09	0.56	2.04e-13	Platelet count;
UCEC	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.72	6.95	0.5	1.1e-10	Crohn's disease;
UCEC	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.44	-5.76	-0.43	4.77e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.62	-7.35	-0.52	1.24e-11	Response to temozolomide;
UCEC	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg13683864	chr3:40499215	RPL14	-0.53	-5.27	-0.4	4.7e-7	Renal cell carcinoma;
UCEC	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-0.9	-7.61	-0.53	3e-12	Blood pressure (smoking interaction);
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.46	-6.24	-0.46	4.32e-9	Superior crus of antihelix expression;
UCEC	cis	rs151997	0.925	rs27260	chr5:50166696	C/T	cg06027927	chr5:50259733	NA	0.51	4.61	0.36	8.77e-6	Callous-unemotional behaviour;
UCEC	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg23070574	chr3:14187308	XPC	0.43	4.93	0.38	2.15e-6	Ovarian reserve;
UCEC	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.68	7.9	0.55	5.9e-13	Mean corpuscular volume;
UCEC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.48	5.05	0.38	1.31e-6	Pulse pressure;
UCEC	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.54	-0.35	1.17e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7246967	0.673	rs34795935	chr19:22865188	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.71	6.98	0.5	9.39e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg22598563	chr5:131563921	P4HA2	-0.34	-4.55	-0.35	1.12e-5	Blood metabolite levels;
UCEC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.44	-4.5	-0.35	1.35e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.53	6.03	0.45	1.25e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.78	-0.49	2.66e-10	Prostate cancer;
UCEC	cis	rs7933455	0.502	rs1385850	chr11:12234595	C/T	cg10383724	chr11:12228521	MICAL2	0.53	4.58	0.35	9.97e-6	Cold sores;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	8.31	0.57	5.93e-14	Prudent dietary pattern;
UCEC	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.52	5.39	0.41	2.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.69	-0.42	6.79e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4499344	0.556	rs259219	chr19:33138067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	6.08	0.45	9.98e-9	Mean platelet volume;
UCEC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg04154034	chr17:28927549	LRRC37B2	0.91	5.19	0.39	7.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.7	-5.04	-0.38	1.34e-6	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.42	4.8	0.37	3.81e-6	Height;
UCEC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.29	-0.56	6.44e-14	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.97	12.2	0.71	4.26e-24	Breast cancer;
UCEC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.56	-5.17	-0.39	7.57e-7	Coronary artery disease;
UCEC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.43	0.41	2.29e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.6	0.42	1.03e-7	Breast cancer;
UCEC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	6e-6	Cardiac Troponin-T levels;
UCEC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.66	-7.3	-0.52	1.66e-11	Menarche (age at onset);
UCEC	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.67	0.36	6.74e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.11	-6.4	-0.47	1.96e-9	Diabetic retinopathy;
UCEC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-4.76	-0.37	4.6e-6	Type 2 diabetes;
UCEC	cis	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg20307385	chr11:47447363	PSMC3	0.56	5.0	0.38	1.59e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg10932868	chr11:921992	NA	0.38	4.64	0.36	7.5e-6	Alzheimer's disease (late onset);
UCEC	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.7	7.92	0.55	5.38e-13	Menopause (age at onset);
UCEC	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.76	-0.49	3.03e-10	Coffee consumption (cups per day);
UCEC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.46	5.61	0.42	9.87e-8	Anterior chamber depth;
UCEC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.69	-6.98	-0.5	9.34e-11	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs75804782	0.572	rs76939124	chr2:239223478	C/T	cg11815105	chr2:239148849	HES6	1.09	5.05	0.38	1.27e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6460942	0.591	rs4721080	chr7:12337785	T/C	cg06484146	chr7:12443880	VWDE	-0.54	-4.5	-0.35	1.36e-5	Coronary artery disease;
UCEC	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.59	5.48	0.41	1.79e-7	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg04025307	chr7:1156635	C7orf50	0.81	5.42	0.41	2.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.46	4.66	0.36	7.13e-6	Schizophrenia;
UCEC	cis	rs1505368	0.505	rs12694279	chr2:213253406	C/A	cg16329650	chr2:213403929	ERBB4	0.5	4.91	0.38	2.35e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	7.63	0.53	2.65e-12	Platelet count;
UCEC	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.4	0.47	1.94e-9	Motion sickness;
UCEC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.01	0.5	7.95e-11	Tonsillectomy;
UCEC	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.48	-4.58	-0.35	9.98e-6	Personality dimensions;
UCEC	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-0.49	-4.66	-0.36	7.06e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.45	5.02	0.38	1.51e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.59	-6.71	-0.48	3.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg04804543	chr8:142233427	SLC45A4	-0.5	-6.16	-0.45	6.52e-9	Immature fraction of reticulocytes;
UCEC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.72	-7.3	-0.52	1.66e-11	Cognitive function;
UCEC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg19413350	chr8:57351067	NA	-0.41	-4.93	-0.38	2.19e-6	Obesity-related traits;
UCEC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-6.04	-0.45	1.2e-8	Dental caries;
UCEC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg04154034	chr17:28927549	LRRC37B2	0.58	5.2	0.39	6.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.69	5.98	0.44	1.6e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.59	-0.35	9.55e-6	Type 2 diabetes;
UCEC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18252515	chr7:66147081	NA	0.55	5.3	0.4	4.17e-7	Aortic root size;
UCEC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg08027265	chr7:2291960	NA	-0.44	-4.89	-0.37	2.58e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.03	0.38	1.4e-6	Rheumatoid arthritis;
UCEC	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg18755752	chr8:142205143	DENND3	-0.61	-5.65	-0.42	8.05e-8	Immature fraction of reticulocytes;
UCEC	cis	rs7246967	0.611	rs12973264	chr19:22867749	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg01874867	chr7:94954059	PON1	0.6	4.86	0.37	2.98e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg20750642	chr13:99100586	FARP1	0.43	4.67	0.36	6.61e-6	Neuroticism;
UCEC	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg16060761	chr17:80687452	NA	-0.59	-5.6	-0.42	1.01e-7	Glycated hemoglobin levels;
UCEC	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg00071950	chr4:10020882	SLC2A9	-0.5	-5.25	-0.4	5.16e-7	Blood metabolite levels;
UCEC	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs3743102	0.527	rs117959961	chr15:83339895	C/T	cg00614314	chr15:82944287	LOC80154	-0.88	-5.06	-0.39	1.21e-6	Colorectal adenoma (advanced);
UCEC	cis	rs10488360	0.708	rs7459304	chr7:4411828	A/G	cg25842763	chr7:4870162	RADIL	-0.41	-4.54	-0.35	1.17e-5	Factor VII;
UCEC	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg19197139	chr17:4613644	ARRB2	-0.6	-5.05	-0.38	1.29e-6	Lymphocyte counts;
UCEC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.37	-0.57	4.05e-14	Migraine;Coronary artery disease;
UCEC	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.85	9.64	0.62	2.45e-17	Dental caries;
UCEC	cis	rs6494849	0.563	rs16954285	chr15:70499098	A/G	cg22026918	chr15:70552251	NA	0.55	4.8	0.37	3.84e-6	Bipolar disorder;
UCEC	cis	rs7246967	0.551	rs8102812	chr19:22879243	A/T	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.48	4.68	0.36	6.48e-6	Menarche (age at onset);
UCEC	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg01689657	chr7:91764605	CYP51A1	0.4	5.12	0.39	9.48e-7	Breast cancer;
UCEC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg27489772	chr12:121021490	NA	0.47	4.64	0.36	7.72e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-5.11	-0.39	9.93e-7	Metabolite levels;
UCEC	cis	rs6686929	1.000	rs2152390	chr1:18240899	A/G	cg03861428	chr1:17380702	SDHB	0.45	5.08	0.39	1.14e-6	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.58	5.31	0.4	4.05e-7	Lupus nephritis in systemic lupus erythematosus;
UCEC	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.34	4.58	0.35	9.78e-6	Schizophrenia;
UCEC	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-7.8	-0.54	1.07e-12	Ulcerative colitis;
UCEC	trans	rs1392935	0.620	rs9896174	chr17:49931598	A/C	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.71	6.74	0.49	3.42e-10	Bacterial meningitis;
UCEC	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg06917634	chr15:78832804	PSMA4	0.67	6.38	0.47	2.16e-9	Sudden cardiac arrest;
UCEC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg11632617	chr15:75315747	PPCDC	-0.63	-7.32	-0.52	1.49e-11	Blood trace element (Zn levels);
UCEC	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.63	5.77	0.43	4.54e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	6.04	0.45	1.22e-8	Cognitive test performance;
UCEC	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	0.92	10.15	0.64	1.12e-18	Coronary artery disease;
UCEC	cis	rs96067	0.503	rs634335	chr1:36335862	T/G	cg27506609	chr1:36549197	TEKT2	0.48	4.61	0.36	8.59e-6	Corneal structure;
UCEC	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.61	8.1	0.56	1.97e-13	Skin aging (microtopography measurement);
UCEC	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg20891283	chr12:69753455	YEATS4	0.75	4.54	0.35	1.14e-5	Response to diuretic therapy;
UCEC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.83	9.23	0.61	2.71e-16	Breast cancer;
UCEC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg08027265	chr7:2291960	NA	-0.47	-5.11	-0.39	9.95e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.15	-0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.52	-5.48	-0.41	1.77e-7	Body mass index;
UCEC	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.49	5.06	0.38	1.26e-6	Breast cancer;
UCEC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.49	5.54	0.42	1.36e-7	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
UCEC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.61	-5.25	-0.4	5.16e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.56	-4.53	-0.35	1.22e-5	Menopause (age at onset);
UCEC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.5	-5.06	-0.39	1.23e-6	Prostate cancer;
UCEC	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.05	-7.67	-0.53	2.21e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs6540731	0.905	rs11119883	chr1:212387260	T/G	cg07569918	chr1:212002970	LPGAT1	-0.37	-4.58	-0.35	9.74e-6	Intelligence (childhood);
UCEC	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.74e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs66686620	0.667	rs11126210	chr2:69243251	C/T	ch.2.1546374F	chr2:68387810	PNO1	0.52	4.51	0.35	1.31e-5	Breast cancer;
UCEC	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-4.97	-0.38	1.88e-6	Type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.6e-7	Breast cancer;
UCEC	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.53	5.01	0.38	1.54e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.57e-7	Acne (severe);
UCEC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.74	-0.36	5.02e-6	Cardiac Troponin-T levels;
UCEC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.88	7.64	0.53	2.5e-12	Bladder cancer;
UCEC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.83	8.21	0.56	1.04e-13	Cognitive function;
UCEC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.75	8.24	0.56	8.54e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs16937	0.711	rs11240388	chr1:205177617	G/A	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs10256972	0.775	rs10259248	chr7:1018968	G/C	cg04025307	chr7:1156635	C7orf50	0.59	5.94	0.44	1.97e-8	Longevity;Endometriosis;
UCEC	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.47	-4.86	-0.37	3.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.63	0.48	5.99e-10	Coronary artery disease;
UCEC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18932078	chr1:2524107	MMEL1	0.33	5.48	0.41	1.79e-7	Multiple sclerosis;
UCEC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.5	4.95	0.38	2.04e-6	Emphysema distribution in smoking;
UCEC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg12024160	chr4:1254474	NA	-0.52	-4.92	-0.38	2.29e-6	Longevity;
UCEC	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.6	-4.72	-0.36	5.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7799006	0.929	rs745565	chr7:2256689	G/C	cg08027265	chr7:2291960	NA	-0.48	-4.59	-0.35	9.63e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.86	-9.21	-0.61	3.04e-16	Lung cancer;
UCEC	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.34	0.46	2.63e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.59	6.42	0.47	1.73e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.36	-4.95	-0.38	2.03e-6	Longevity;
UCEC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg22166914	chr1:53195759	ZYG11B	-0.62	-6.85	-0.49	1.88e-10	Monocyte count;
UCEC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.8	-8.41	-0.57	3.2e-14	Cognitive function;
UCEC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.88	9.06	0.6	7.63e-16	Cognitive function;
UCEC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.71	6.7	0.48	4.25e-10	High light scatter reticulocyte count;
UCEC	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-5.79	-0.43	4.02e-8	Chronic sinus infection;
UCEC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg20821713	chr7:1055600	C7orf50	0.75	7.36	0.52	1.21e-11	Bronchopulmonary dysplasia;
UCEC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg07153921	chr17:41440717	NA	-0.45	-4.5	-0.35	1.35e-5	Menopause (age at onset);
UCEC	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.68	6.15	0.45	7.01e-9	Corneal astigmatism;
UCEC	cis	rs6684428	0.706	rs12119904	chr1:56327241	G/T	cg11651538	chr1:56320950	NA	-0.76	-6.81	-0.49	2.29e-10	Airflow obstruction;
UCEC	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.54	-5.66	-0.42	7.5e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg12024160	chr4:1254474	NA	0.54	6.0	0.44	1.45e-8	Longevity;
UCEC	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.47	-4.61	-0.36	8.72e-6	Endometrial cancer;
UCEC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg05962950	chr11:130786565	SNX19	0.52	4.84	0.37	3.29e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.9	9.11	0.6	5.47e-16	Heart rate;
UCEC	cis	rs7246967	0.673	rs2194112	chr19:22926189	A/C	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	1.02	4.62	0.36	8.28e-6	Cannabis dependence symptom count;
UCEC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-6.34	-0.46	2.62e-9	Dental caries;
UCEC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.72	-8.5	-0.57	1.95e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg08222913	chr3:52553049	STAB1	-0.44	-5.05	-0.38	1.29e-6	Electroencephalogram traits;
UCEC	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg14008862	chr17:28927542	LRRC37B2	0.73	5.7	0.43	6.34e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2455799	0.613	rs11706879	chr3:15957130	A/C	cg16303742	chr3:15540471	COLQ	-0.49	-5.94	-0.44	1.99e-8	Mean platelet volume;
UCEC	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.37	5.18	0.39	7.23e-7	Myeloid white cell count;
UCEC	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-21.21	-0.87	1.41e-46	Myeloid white cell count;
UCEC	cis	rs6426514	1.000	rs2273271	chr1:228876434	G/A	cg06637001	chr1:228463634	OBSCN	-0.74	-4.56	-0.35	1.09e-5	Type 2 diabetes;
UCEC	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.44	-0.47	1.58e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-7.41	-0.52	9.06e-12	Hip circumference;
UCEC	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg12559939	chr2:27858050	GPN1	0.45	4.77	0.37	4.38e-6	Oral cavity cancer;
UCEC	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.62	6.72	0.49	3.64e-10	Neuroticism;
UCEC	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.32	-0.57	5.54e-14	Exhaled nitric oxide output;
UCEC	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.68	6.57	0.48	8.32e-10	Coronary artery disease;
UCEC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.67	-4.51	-0.35	1.31e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.57	-0.42	1.21e-7	Pubertal anthropometrics;
UCEC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.48	5.7	0.43	6.2e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.53	5.11	0.39	9.65e-7	Blood metabolite levels;
UCEC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.75	7.08	0.5	5.61e-11	Response to antipsychotic treatment;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.44	-5.06	-0.38	1.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.9	9.26	0.61	2.32e-16	Cognitive function;
UCEC	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.58	6.47	0.47	1.4e-9	Total body bone mineral density;
UCEC	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.74	7.98	0.55	3.79e-13	Red cell distribution width;
UCEC	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	6.36	0.46	2.36e-9	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.46	-4.75	-0.36	4.75e-6	Breast cancer;
UCEC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.76	0.37	4.6e-6	Cognitive ability;
UCEC	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.87	0.37	2.86e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.53	5.22	0.4	5.89e-7	Blood metabolite levels;
UCEC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-7.02	-0.5	7.56e-11	Mean platelet volume;
UCEC	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.4	-5.29	-0.4	4.27e-7	Blood protein levels;
UCEC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.58	5.61	0.42	9.82e-8	Aortic root size;
UCEC	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.89	-0.44	2.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs77861329	1.000	rs352151	chr3:52210272	C/G	cg08692210	chr3:52188851	WDR51A	0.84	6.59	0.48	7.36e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs3015497	0.626	rs7150204	chr14:51137355	T/C	cg04730355	chr14:51134070	SAV1	-0.47	-4.79	-0.37	4.03e-6	Mean platelet volume;
UCEC	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	4.69	0.36	6.06e-6	Bipolar disorder;
UCEC	cis	rs17123764	0.710	rs12299505	chr12:50019894	T/C	cg20471783	chr12:50157085	TMBIM6	0.62	5.32	0.4	3.73e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs9313296	0.661	rs1582437	chr5:165521971	A/T	cg03539051	chr19:56418660	NLRP13	1.11	6.93	0.5	1.23e-10	Weight;Waist circumference;
UCEC	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.45	0.47	1.53e-9	Motion sickness;
UCEC	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	1.1	9.55	0.62	4.1e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.84	9.58	0.62	3.5e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg00791764	chr4:53727839	RASL11B	0.67	4.93	0.38	2.16e-6	Optic nerve measurement (cup area);
UCEC	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.62	6.89	0.49	1.55e-10	Heart rate;
UCEC	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg02176678	chr2:219576539	TTLL4	-0.52	-5.19	-0.39	6.99e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.36	-5.29	-0.4	4.41e-7	Ulcerative colitis;
UCEC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.51	-5.41	-0.41	2.46e-7	Alcohol dependence;
UCEC	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.49	-4.76	-0.37	4.52e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.53	-5.27	-0.4	4.8e-7	Aortic root size;
UCEC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.78	-8.98	-0.6	1.23e-15	Menarche (age at onset);
UCEC	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.9	10.86	0.67	1.49e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg03078520	chr22:18463400	MICAL3	-0.46	-4.65	-0.36	7.45e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7968440	1.000	rs2700485	chr12:51103992	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs11867410	0.744	rs7207032	chr17:63948962	A/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.54	-6.21	-0.46	5.03e-9	Bipolar disorder;
UCEC	cis	rs2970992	0.817	rs10165648	chr2:101335235	A/G	cg01042948	chr2:101319752	NA	0.57	6.04	0.45	1.2e-8	Educational attainment;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12417590	chr20:42086612	SFRS6	0.57	6.81	0.49	2.32e-10	Warfarin maintenance dose;
UCEC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.44	0.65	1.97e-19	Chronic sinus infection;
UCEC	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	4.81	0.37	3.77e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-1.02	-12.42	-0.72	1.11e-24	Cognitive function;
UCEC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.13	11.05	0.67	4.9e-21	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.38	-0.65	2.82e-19	Blood metabolite levels;
UCEC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.6	-4.82	-0.37	3.53e-6	Gut microbiome composition (summer);
UCEC	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.72	5.81	0.43	3.76e-8	Menarche (age at onset);
UCEC	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg04013166	chr16:89971882	TCF25	0.74	9.59	0.62	3.24e-17	Skin colour saturation;
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg20307385	chr11:47447363	PSMC3	-0.65	-4.68	-0.36	6.58e-6	Axial length;
UCEC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg12463550	chr7:65579703	CRCP	0.5	4.63	0.36	8.1e-6	Aortic root size;
UCEC	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg17724175	chr1:150552817	MCL1	-0.42	-4.6	-0.35	9.1e-6	Tonsillectomy;
UCEC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-4.98	-0.38	1.77e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11118844	0.843	rs11118848	chr1:221926826	A/G	cg04222084	chr1:221915650	DUSP10	0.76	6.94	0.5	1.17e-10	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.42	-5.34	-0.4	3.54e-7	Obesity-related traits;
UCEC	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.59	5.36	0.4	3.21e-7	Corneal astigmatism;
UCEC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.1	9.17	0.6	3.88e-16	Vitiligo;
UCEC	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.74	8.81	0.59	3.16e-15	Breast cancer;
UCEC	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg19468946	chr17:37922297	IKZF3	0.44	4.87	0.37	2.86e-6	Self-reported allergy;
UCEC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.95	-0.38	2.03e-6	Breast cancer;
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.8	8.78	0.59	3.8e-15	Longevity;Endometriosis;
UCEC	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.32	-0.46	2.89e-9	Response to antipsychotic treatment;
UCEC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.51	-5.31	-0.4	3.98e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.45	-4.94	-0.38	2.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg13613210	chr9:99181598	ZNF367	-0.59	-5.19	-0.39	7e-7	Neuroticism;
UCEC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.3	0.4	4.13e-7	Prudent dietary pattern;
UCEC	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.74	7.96	0.55	4.26e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg08885076	chr2:99613938	TSGA10	-0.41	-4.75	-0.37	4.69e-6	Chronic sinus infection;
UCEC	cis	rs2708377	0.929	rs73066828	chr12:11270654	A/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.59	4.72	0.36	5.36e-6	Bitter taste perception;
UCEC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.18	0.45	6.02e-9	Breast cancer;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.6	8.76	0.59	4.24e-15	Prudent dietary pattern;
UCEC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Alcohol dependence;
UCEC	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	7.89	0.55	6.23e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	4.98	0.38	1.77e-6	Systolic blood pressure;
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.79	-0.49	2.64e-10	Total body bone mineral density;
UCEC	cis	rs1576263	0.967	rs162279	chr6:8556968	T/G	cg07606381	chr6:8435919	SLC35B3	0.45	4.67	0.36	6.72e-6	Photic sneeze reflex;
UCEC	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg06418219	chr1:154948305	SHC1;CKS1B	0.72	5.67	0.42	7.15e-8	Atrial fibrillation;
UCEC	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	1.12	13.32	0.74	4.78e-27	Post bronchodilator FEV1;
UCEC	trans	rs1552172	0.887	rs34695381	chr1:145683334	G/C	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.86	-0.49	1.75e-10	Breast cancer;
UCEC	cis	rs9467773	1.000	rs1570061	chr6:26575986	T/C	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-4.77	-0.37	4.48e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4588572	0.643	rs6874309	chr5:77774498	A/T	cg11547950	chr5:77652471	NA	0.47	5.4	0.41	2.59e-7	Triglycerides;
UCEC	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.6	6.45	0.47	1.51e-9	Triglycerides;
UCEC	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg13683864	chr3:40499215	RPL14	-0.57	-6.1	-0.45	8.91e-9	Renal cell carcinoma;
UCEC	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.66	5.63	0.42	8.72e-8	Aortic root size;
UCEC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.32	0.4	3.88e-7	Breast cancer;
UCEC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg13147721	chr7:65941812	NA	0.86	5.76	0.43	4.79e-8	Diabetic kidney disease;
UCEC	cis	rs78487399	0.908	rs6544675	chr2:43835952	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.46	-0.41	1.97e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-6.57	-0.48	8.31e-10	Personality dimensions;
UCEC	cis	rs6416877	0.885	rs12948875	chr17:1347649	A/C	cg09375892	chr17:708413	NXN	-0.61	-4.62	-0.36	8.16e-6	Myeloid white cell count;
UCEC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-0.97	-11.44	-0.69	4.39e-22	Blood pressure (smoking interaction);
UCEC	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-0.87	-6.95	-0.5	1.09e-10	Blood protein levels;
UCEC	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.79	-0.7	5.19e-23	Primary sclerosing cholangitis;
UCEC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22117172	chr7:91764530	CYP51A1	0.42	5.36	0.4	3.12e-7	Breast cancer;
UCEC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.69	5.38	0.41	2.92e-7	Corneal astigmatism;
UCEC	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-4.83	-0.37	3.41e-6	Life satisfaction;
UCEC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.48	6.36	0.46	2.42e-9	Bone mineral density;
UCEC	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg01072550	chr1:21505969	NA	-0.59	-5.76	-0.43	4.77e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.53	5.98	0.44	1.59e-8	Menarche (age at onset);
UCEC	cis	rs4713118	0.826	rs2893929	chr6:27738732	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-4.52	-0.35	1.28e-5	Parkinson's disease;
UCEC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.82	10.97	0.67	7.7e-21	Headache;
UCEC	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.38	4.79	0.37	4.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.8	-0.49	2.46e-10	Obesity-related traits;
UCEC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00802000	chr16:706648	WDR90	-0.49	-5.6	-0.42	1.02e-7	Height;
UCEC	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	0.82	6.29	0.46	3.42e-9	Granulocyte percentage of myeloid white cells;
UCEC	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs11153730	0.503	rs445099	chr6:118618252	T/C	cg21191810	chr6:118973309	C6orf204	0.39	5.05	0.38	1.27e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs6738485	0.557	rs12988865	chr2:106854386	G/A	cg16099169	chr2:106886729	NA	-0.43	-4.84	-0.37	3.18e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg20007245	chr22:24372913	LOC391322	-0.61	-6.86	-0.49	1.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6437061	0.707	rs3116167	chr2:232988345	A/G	cg02061626	chr2:233274167	ALPPL2	-0.46	-4.95	-0.38	2.03e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.59	-0.35	9.58e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs508970	1.000	rs508970	chr11:60906450	A/G	cg26254678	chr11:61511275	DAGLA	-0.36	-4.53	-0.35	1.23e-5	Rheumatoid arthritis;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.71	8.06	0.55	2.4e-13	Menarche (age at onset);
UCEC	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.65	6.86	0.49	1.82e-10	Endometriosis;
UCEC	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.56	5.06	0.39	1.25e-6	Corneal astigmatism;
UCEC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22857025	chr5:266934	NA	-0.89	-7.21	-0.51	2.7e-11	Asthma (childhood onset);
UCEC	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs731174	0.797	rs565316	chr1:38157624	T/C	cg06917450	chr1:38156652	C1orf109	-0.62	-5.64	-0.42	8.32e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.69	-6.91	-0.5	1.38e-10	Blood metabolite levels;
UCEC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.47	4.82	0.37	3.52e-6	Information processing speed;
UCEC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg21770322	chr7:97807741	LMTK2	0.48	6.05	0.45	1.14e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg03146154	chr1:46216737	IPP	-0.49	-4.65	-0.36	7.21e-6	High light scatter reticulocyte count;
UCEC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.5	4.75	0.36	4.72e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.69	-6.87	-0.49	1.68e-10	Morning vs. evening chronotype;
UCEC	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-0.76	-7.92	-0.55	5.25e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.02	-0.76	6.74e-29	Schizophrenia;
UCEC	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.81	-8.73	-0.58	5.14e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg13844804	chr7:814759	HEATR2	-0.61	-4.59	-0.35	9.29e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg05660106	chr1:15850417	CASP9	0.62	5.73	0.43	5.57e-8	Systolic blood pressure;
UCEC	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.56	5.49	0.41	1.72e-7	Breast cancer;
UCEC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.65	5.78	0.43	4.24e-8	Aortic root size;
UCEC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.56	-5.65	-0.42	8.19e-8	Blood trace element (Zn levels);
UCEC	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.21	-0.51	2.8e-11	Neuroticism;
UCEC	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-7.96	-0.55	4.32e-13	Hip circumference;
UCEC	cis	rs6910233	0.793	rs210133	chr6:33536797	C/G	cg13560919	chr6:33536144	NA	0.44	4.57	0.35	1.01e-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.83	10.29	0.65	4.81e-19	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.68	-6.38	-0.47	2.19e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.38	0.52	1.06e-11	Alzheimer's disease;
UCEC	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.64	7.14	0.51	4.06e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.37	-0.4	3.02e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.63	6.54	0.47	9.58e-10	Age at first birth;
UCEC	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	5.81	0.43	3.74e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.49	-5.31	-0.4	3.9e-7	Educational attainment;
UCEC	cis	rs2073016	0.925	rs2073014	chr6:41029109	C/T	cg21328082	chr6:41254471	TREM1	-0.51	-4.54	-0.35	1.15e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
UCEC	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg03773681	chr2:63815918	MDH1;C2orf86	0.7	7.19	0.51	2.96e-11	Triglyceride levels;
UCEC	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-4.69	-0.36	6.29e-6	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.83	9.01	0.6	1.02e-15	Breast cancer;
UCEC	cis	rs253959	0.768	rs929752	chr5:115698231	A/G	cg23108291	chr5:115420582	COMMD10	-0.52	-5.14	-0.39	8.7e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.43	-4.51	-0.35	1.32e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	0.92	11.6	0.69	1.66e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg03609598	chr5:56110824	MAP3K1	-0.52	-4.66	-0.36	6.93e-6	Coronary artery disease;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.88	-0.49	1.56e-10	Pubertal anthropometrics;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.29	-0.4	4.39e-7	Pubertal anthropometrics;
UCEC	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.58	-6.02	-0.44	1.33e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg26114124	chr12:9217669	LOC144571	0.41	4.84	0.37	3.29e-6	Sjögren's syndrome;
UCEC	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg01072550	chr1:21505969	NA	-0.54	-4.96	-0.38	1.89e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.91	-0.38	2.35e-6	Height;
UCEC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg11945507	chr8:142233382	SLC45A4	-0.45	-4.98	-0.38	1.73e-6	Immature fraction of reticulocytes;
UCEC	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg06096015	chr1:231504339	EGLN1	-0.47	-5.68	-0.42	7.08e-8	Hemoglobin concentration;
UCEC	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg04896959	chr15:78267971	NA	0.39	4.96	0.38	1.93e-6	Sudden cardiac arrest;
UCEC	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg03959625	chr15:84868606	LOC388152	0.46	4.84	0.37	3.21e-6	Schizophrenia;
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.18	0.45	6.05e-9	Platelet count;
UCEC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	5.16	0.39	7.88e-7	Bone mineral density;
UCEC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03352830	chr11:487213	PTDSS2	0.84	6.6	0.48	6.95e-10	Body mass index;
UCEC	cis	rs7968440	1.000	rs7968440	chr12:51134741	A/G	cg20014596	chr12:50898483	DIP2B	0.49	4.86	0.37	2.96e-6	Fibrinogen;
UCEC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg10503236	chr1:231470652	EXOC8	-0.45	-5.18	-0.39	7.35e-7	Hemoglobin concentration;
UCEC	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	5.11	0.39	9.86e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg05962950	chr11:130786565	SNX19	0.62	6.74	0.49	3.32e-10	Schizophrenia;
UCEC	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg12923728	chr3:195709715	SDHAP1	-0.61	-5.67	-0.42	7.19e-8	Mean corpuscular volume;
UCEC	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13683864	chr3:40499215	RPL14	-0.94	-9.64	-0.62	2.42e-17	Renal cell carcinoma;
UCEC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg06600287	chr1:53387719	ECHDC2	-0.33	-4.61	-0.36	8.85e-6	Monocyte count;
UCEC	cis	rs151997	0.962	rs27476	chr5:50178160	A/T	cg06027927	chr5:50259733	NA	-0.55	-4.96	-0.38	1.94e-6	Callous-unemotional behaviour;
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.53	-5.36	-0.4	3.08e-7	Parkinson's disease;
UCEC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg04553112	chr3:125709451	NA	-0.61	-4.6	-0.35	9.21e-6	Blood pressure (smoking interaction);
UCEC	cis	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg00614314	chr15:82944287	LOC80154	-0.64	-6.31	-0.46	3.17e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs8177876	0.822	rs9925943	chr16:81111007	T/C	cg08591886	chr16:81111003	C16orf46	-0.78	-4.87	-0.37	2.83e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg05962950	chr11:130786565	SNX19	0.51	5.16	0.39	7.74e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7088591	0.867	rs9943326	chr10:59780391	G/T	cg11142981	chr10:60273225	BICC1	0.64	4.59	0.35	9.34e-6	Blood pressure;
UCEC	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.47e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg08755490	chr11:65554678	OVOL1	0.51	5.26	0.4	5.03e-7	Acne (severe);
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	9.51	0.62	5.18e-17	Coffee consumption (cups per day);
UCEC	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg03627880	chr6:151815985	C6orf97	-0.73	-4.7	-0.36	5.97e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
UCEC	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg11839771	chr15:80205821	ST20	-0.43	-4.56	-0.35	1.06e-5	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.24	-7.51	-0.53	5.14e-12	Diabetic kidney disease;
UCEC	cis	rs7804356	0.906	rs73069540	chr7:26904770	C/T	cg02693607	chr7:27150598	HOXA3	0.58	4.85	0.37	3.07e-6	Type 1 diabetes;
UCEC	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	6.36	0.46	2.35e-9	Lung function (FEV1/FVC);
UCEC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.71	-6.52	-0.47	1.05e-9	Initial pursuit acceleration;
UCEC	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.77	0.37	4.39e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	8.86	0.59	2.4e-15	Bipolar disorder;
UCEC	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg25393495	chr8:12034317	NA	0.31	4.52	0.35	1.27e-5	Retinal vascular caliber;
UCEC	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.83	-9.92	-0.63	4.44e-18	Monocyte count;
UCEC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	5.34	0.4	3.47e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	0.88	10.21	0.64	7.63e-19	Schizophrenia;
UCEC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.29	-0.46	3.49e-9	Menarche (age at onset);
UCEC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.7	7.49	0.53	5.86e-12	Menarche (age at onset);
UCEC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs13401104	0.796	rs72617202	chr2:237108405	T/C	cg23897927	chr2:237117786	ASB18	-0.51	-4.56	-0.35	1.09e-5	Educational attainment;
UCEC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	8.16	0.56	1.4e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-6.08	-0.45	9.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg26114124	chr12:9217669	LOC144571	0.4	4.65	0.36	7.42e-6	Sjögren's syndrome;
UCEC	cis	rs9467773	0.967	rs6913877	chr6:26577488	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.07	0.55	2.26e-13	Sudden cardiac arrest;
UCEC	cis	rs77988765	0.908	rs7926071	chr11:70023357	C/A	cg02486268	chr11:69682825	NA	0.48	4.51	0.35	1.3e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	8.28	0.56	7.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.56	-5.46	-0.41	2.02e-7	Mortality in heart failure;
UCEC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.39	5.85	0.43	3.1e-8	Ulcerative colitis;
UCEC	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg18016565	chr1:150552671	MCL1	-0.51	-5.72	-0.43	5.79e-8	Tonsillectomy;
UCEC	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.5	4.97	0.38	1.87e-6	Dupuytren's disease;
UCEC	cis	rs925228	0.955	rs1400218	chr2:24145253	C/A	cg16945982	chr2:25016118	CENPO;C2orf79	0.56	4.82	0.37	3.52e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.61	-7.05	-0.5	6.47e-11	Pubertal anthropometrics;
UCEC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.49	-5.63	-0.42	8.7e-8	Glomerular filtration rate (creatinine);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20506460	chr20:43150682	SERINC3	0.62	7.57	0.53	3.83e-12	Warfarin maintenance dose;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.7	-7.34	-0.52	1.32e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg06784218	chr1:46089804	CCDC17	-0.53	-6.18	-0.45	6.02e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.68	5.69	0.42	6.71e-8	Menopause (age at onset);
UCEC	cis	rs7201929	1.000	rs7499878	chr16:28868464	C/T	cg10436792	chr16:28889110	ATP2A1	0.37	4.53	0.35	1.2e-5	QT interval;
UCEC	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.56	-5.12	-0.39	9.62e-7	Morning vs. evening chronotype;
UCEC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.59	-5.01	-0.38	1.57e-6	IgE levels in asthmatics (D.p. specific);
UCEC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.56	5.37	0.4	3.07e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.51	-4.81	-0.37	3.7e-6	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg17105886	chr17:28927953	LRRC37B2	0.52	4.79	0.37	4.02e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	5.27	0.4	4.81e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg24562669	chr7:97807699	LMTK2	0.74	11.04	0.67	5.08e-21	Breast cancer;
UCEC	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-6.77	-0.49	2.92e-10	Hemoglobin concentration;
UCEC	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.65	-0.36	7.27e-6	Response to antipsychotic treatment;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.45	-4.99	-0.38	1.67e-6	Pulmonary function;
UCEC	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.63	-6.4	-0.47	2e-9	Lymphocyte counts;
UCEC	cis	rs12428035	0.881	rs17879875	chr13:96363233	C/T	cg07859753	chr13:96300257	NA	0.54	4.52	0.35	1.27e-5	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg24562669	chr7:97807699	LMTK2	0.51	6.08	0.45	1e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.22	-0.4	6.12e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.51	-5.0	-0.38	1.59e-6	Red cell distribution width;
UCEC	cis	rs4372836	1.000	rs2169748	chr2:28957753	G/A	cg09522027	chr2:28974177	PPP1CB	0.76	7.46	0.52	7.04e-12	Body mass index;
UCEC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.64	-6.4	-0.47	1.91e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg01072550	chr1:21505969	NA	-0.59	-6.19	-0.45	5.65e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7246967	0.866	rs62120784	chr19:23044735	A/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.94	-0.44	1.99e-8	Parkinson's disease;
UCEC	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	4.68	0.36	6.59e-6	Colorectal cancer;
UCEC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg03714773	chr7:91764589	CYP51A1	0.47	5.88	0.44	2.66e-8	Breast cancer;
UCEC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.51	5.82	0.43	3.53e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs713477	0.967	rs4898865	chr14:55910998	G/A	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.54	-6.06	-0.45	1.09e-8	Diastolic blood pressure;
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	5.19	0.39	6.87e-7	Platelet count;
UCEC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4146922	0.793	rs6752931	chr2:56004219	G/T	cg00879447	chr2:56412077	CCDC85A	0.48	4.86	0.37	2.98e-6	Height;
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.69	-5.13	-0.39	9.14e-7	Narcolepsy;
UCEC	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg13854012	chr2:162103682	NA	0.44	5.04	0.38	1.37e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-5.96	-0.44	1.8e-8	Prudent dietary pattern;
UCEC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.9	-8.53	-0.58	1.61e-14	Breast cancer;
UCEC	cis	rs7912831	0.933	rs10795667	chr10:8691497	T/G	cg00797058	chr10:8137978	NA	0.38	4.54	0.35	1.16e-5	Colorectal cancer;
UCEC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.49	5.33	0.4	3.54e-7	Emphysema distribution in smoking;
UCEC	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.6e-7	Life satisfaction;
UCEC	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.53	6.35	0.46	2.58e-9	Kawasaki disease;
UCEC	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.47	-4.77	-0.37	4.36e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.7	5.88	0.44	2.65e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7307889	0.793	rs12317039	chr12:6005333	G/A	cg23245485	chr12:6484219	SCNN1A	0.53	4.76	0.37	4.55e-6	Obesity-related traits;
UCEC	cis	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg10438011	chr13:80915460	SPRY2	0.53	4.9	0.37	2.46e-6	Schizophrenia;
UCEC	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-7.49	-0.53	5.81e-12	Exhaled nitric oxide output;
UCEC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.14	-0.39	8.7e-7	Dupuytren's disease;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.93	11.32	0.68	9.51e-22	Prudent dietary pattern;
UCEC	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.15	8.08	0.55	2.15e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs13065560	0.659	rs6776510	chr3:38887253	C/T	cg01426195	chr3:39028469	NA	-0.45	-4.64	-0.36	7.71e-6	Interleukin-18 levels;
UCEC	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.76	0.49	3.09e-10	Coffee consumption (cups per day);
UCEC	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg00786635	chr1:25594202	NA	-0.48	-4.86	-0.37	3.01e-6	Plateletcrit;Mean corpuscular volume;
UCEC	cis	rs7175404	0.536	rs61557432	chr15:94053938	A/G	cg25253948	chr15:93956996	NA	0.65	4.71	0.36	5.57e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs7267005	0.661	rs75333313	chr20:34406615	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-5.95	-0.44	1.93e-8	Immature fraction of reticulocytes;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-12.66	-0.72	2.64e-25	Prudent dietary pattern;
UCEC	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.45	5.48	0.41	1.81e-7	Height;
UCEC	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.45	-5.11	-0.39	9.77e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9309473	0.950	rs13427832	chr2:73844818	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.0	-0.38	1.61e-6	Metabolite levels;
UCEC	cis	rs7246967	0.611	rs3902164	chr19:22866281	T/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg20293894	chr10:134779328	NA	-0.65	-4.97	-0.38	1.84e-6	Lifespan;
UCEC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-7.55	-0.53	4.32e-12	Cognitive function;
UCEC	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.72e-7	Heart rate;
UCEC	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg04310649	chr10:35416472	CREM	-0.49	-4.76	-0.37	4.61e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.67	7.23	0.51	2.42e-11	Breast cancer;
UCEC	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg24375607	chr4:120327624	NA	0.5	5.13	0.39	9.21e-7	Educational attainment;
UCEC	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg06096015	chr1:231504339	EGLN1	0.44	5.32	0.4	3.81e-7	Hemoglobin concentration;
UCEC	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.49	-0.41	1.75e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.88e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2172802	0.570	rs12233820	chr4:62545693	T/C	cg04118610	chr4:62707027	LPHN3	-0.44	-4.82	-0.37	3.48e-6	Partial epilepsies;
UCEC	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg17420585	chr12:42539391	GXYLT1	0.4	5.15	0.39	8.23e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.19e-14	Prudent dietary pattern;
UCEC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	9.28	0.61	2e-16	Monocyte count;
UCEC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.13	0.39	8.93e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4845459	0.967	rs4845454	chr1:152592184	C/T	cg07796016	chr1:152779584	LCE1C	-0.41	-4.52	-0.35	1.26e-5	Psoriasis;
UCEC	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	16.2	0.8	1.68e-34	Colorectal cancer;
UCEC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.47	4.55	0.35	1.11e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.59	4.92	0.38	2.28e-6	Blood metabolite levels;
UCEC	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.49	-5.39	-0.41	2.72e-7	Response to temozolomide;
UCEC	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg14851346	chr12:38532713	NA	0.51	5.0	0.38	1.59e-6	Heart rate;
UCEC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.51	5.39	0.41	2.76e-7	Breast cancer;
UCEC	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	6.16	0.45	6.72e-9	Motion sickness;
UCEC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	10.01	0.64	2.59e-18	Cognitive ability;
UCEC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.72	6.51	0.47	1.1e-9	Alzheimer's disease;
UCEC	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-7.6	-0.53	3.26e-12	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.47	4.66	0.36	6.99e-6	Gout;
UCEC	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.68	-5.99	-0.44	1.54e-8	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.52	7.45	0.52	7.35e-12	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.74	-0.43	5.22e-8	Alcohol dependence;
UCEC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.7	7.16	0.51	3.58e-11	Menopause (age at onset);
UCEC	cis	rs6882076	1.000	rs4704727	chr5:156380067	T/G	cg12943317	chr5:156479607	HAVCR1	-0.55	-5.57	-0.42	1.19e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.73	9.16	0.6	4.11e-16	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.73	7.19	0.51	3.02e-11	Aortic root size;
UCEC	cis	rs10242455	0.764	rs4646465	chr7:99304524	A/G	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	7e-7	Blood metabolite levels;
UCEC	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.57	5.78	0.43	4.21e-8	Bipolar disorder;
UCEC	cis	rs4400599	0.805	rs4845605	chr1:154158387	T/C	cg05139571	chr1:154127138	NUP210L	0.44	4.76	0.37	4.49e-6	Platelet distribution width;
UCEC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.45	5.06	0.39	1.23e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs526231	0.578	rs6860588	chr5:102280302	A/G	cg23492399	chr5:102201601	PAM	0.53	4.59	0.35	9.27e-6	Primary biliary cholangitis;
UCEC	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.07	7.47	0.52	6.73e-12	Sexual dysfunction (female);
UCEC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.54	5.18	0.39	7.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.6	6.6	0.48	6.95e-10	Resting heart rate;
UCEC	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-7.46	-0.52	6.87e-12	Parkinson's disease;
UCEC	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.29e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs554111	0.891	rs609880	chr1:21055891	A/G	cg08890418	chr1:21044141	KIF17	0.62	6.47	0.47	1.34e-9	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs2062225	0.735	rs2062223	chr2:111750569	T/C	cg23782758	chr2:111737646	ACOXL	-0.58	-5.03	-0.38	1.43e-6	Monocyte count;
UCEC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.5	5.3	0.4	4.1e-7	Total body bone mineral density;
UCEC	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.6	5.18	0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.35	-4.53	-0.35	1.22e-5	Refractive error;
UCEC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.78	-8.88	-0.59	2.11e-15	Menarche (age at onset);
UCEC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	5.48	0.41	1.76e-7	Lung cancer in ever smokers;
UCEC	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	0.82	8.48	0.57	2.2e-14	Psoriasis;
UCEC	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.42	0.41	2.39e-7	Aortic root size;
UCEC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-0.93	-8.31	-0.57	5.95e-14	Initial pursuit acceleration;
UCEC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-6.92	-0.5	1.33e-10	Breast cancer;
UCEC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-12.42	-0.72	1.12e-24	Prudent dietary pattern;
UCEC	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.46	4.76	0.37	4.5e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9788721	0.842	rs11852372	chr15:78801394	A/C	cg26578274	chr15:78832312	PSMA4	-0.52	-4.95	-0.38	2.01e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.87	-9.48	-0.62	6.29e-17	Blood metabolite levels;
UCEC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.78	-8.05	-0.55	2.57e-13	Longevity;Endometriosis;
UCEC	cis	rs10242455	0.571	rs73713595	chr7:99326659	G/A	cg18809830	chr7:99032528	PTCD1	-0.7	-4.55	-0.35	1.13e-5	Blood metabolite levels;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.61	-7.56	-0.53	4.04e-12	Pubertal anthropometrics;
UCEC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.05	0.38	1.28e-6	Mean platelet volume;
UCEC	cis	rs75804782	0.630	rs113725999	chr2:239287651	C/T	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.68	-6.18	-0.45	6.11e-9	Metabolite levels;
UCEC	cis	rs12216499	1.000	rs4709259	chr6:159419584	G/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs7246967	0.866	rs35105042	chr19:23048352	A/C	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.72	-0.36	5.45e-6	Personality dimensions;
UCEC	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.62	5.63	0.42	8.85e-8	Platelet count;
UCEC	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	0.78	9.6	0.62	3.07e-17	Multiple myeloma;
UCEC	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.52	5.43	0.41	2.23e-7	HDL cholesterol;
UCEC	cis	rs7095607	1.000	rs7081213	chr10:69954290	G/A	cg18986048	chr10:69913749	MYPN	0.46	5.07	0.39	1.18e-6	Lung function (FVC);
UCEC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg15848620	chr12:58087721	OS9	-0.53	-4.99	-0.38	1.72e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.17	-11.16	-0.68	2.55e-21	Vitiligo;
UCEC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	7.8	0.54	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.7	7.08	0.5	5.59e-11	Primary sclerosing cholangitis;
UCEC	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg18681998	chr4:17616180	MED28	0.66	6.25	0.46	4.22e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.21	-0.46	5.03e-9	Blood metabolite levels;
UCEC	cis	rs12540874	0.542	rs10238413	chr7:50648184	G/A	cg18232548	chr7:50535776	DDC	-0.46	-4.54	-0.35	1.16e-5	Systemic sclerosis;
UCEC	cis	rs6813264	0.546	rs11100892	chr4:146593011	A/G	cg04181032	chr4:147165097	NA	-0.38	-4.62	-0.36	8.34e-6	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.86	10.76	0.66	2.76e-20	Mortality in heart failure;
UCEC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.71	5.36	0.4	3.1e-7	Diabetic retinopathy;
UCEC	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg26068271	chr17:76253126	NA	0.45	5.23	0.4	5.62e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs12980942	0.810	rs8103839	chr19:41781493	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.83	6.35	0.46	2.56e-9	Coronary artery disease;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg16797656	chr11:68205561	LRP5	-0.51	-6.74	-0.49	3.44e-10	Bone mineral density (spine);
UCEC	cis	rs944990	0.618	rs10992799	chr9:96363918	T/C	cg13787134	chr9:96362102	PHF2	-0.37	-5.02	-0.38	1.48e-6	Body mass index;
UCEC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.62	6.78	0.49	2.69e-10	Motion sickness;
UCEC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.65	-7.3	-0.52	1.63e-11	Sitting height ratio;
UCEC	cis	rs10254160	1.000	rs17159613	chr7:112062655	A/T	cg12767726	chr7:112758502	LOC401397	-0.88	-4.56	-0.35	1.06e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.61	5.14	0.39	8.53e-7	Blood metabolite levels;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.4	4.74	0.36	4.9100000000000004e-06	Tonsillectomy;
UCEC	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.69	-7.79	-0.54	1.11e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-10.61	-0.66	7.09e-20	Vitiligo;
UCEC	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg05874882	chr4:1763078	NA	-0.64	-6.02	-0.44	1.36e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.89	-7.27	-0.51	1.95e-11	Coronary artery calcification;
UCEC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg05802129	chr4:122689817	NA	-0.54	-5.4	-0.41	2.63e-7	Type 2 diabetes;
UCEC	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.73	-7.37	-0.52	1.16e-11	Plateletcrit;Platelet count;
UCEC	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	0.88	6.38	0.47	2.19e-9	Red blood cell traits;
UCEC	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.16	0.39	7.77e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.58	6.56	0.48	8.64e-10	Red blood cell count;
UCEC	cis	rs308403	0.600	rs309367	chr4:123662211	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.79	8.23	0.56	9.33e-14	Blood protein levels;
UCEC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.43	0.41	2.29e-7	Aortic root size;
UCEC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.52	6.97	0.5	9.92e-11	Height;
UCEC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.53	5.13	0.39	9.04e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg20560298	chr2:73613845	ALMS1	0.49	4.9	0.37	2.53e-6	Schizophrenia;
UCEC	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7088591	0.867	rs11814795	chr10:59785318	T/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.8	-9.06	-0.6	7.3e-16	Height;
UCEC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.13	6.65	0.48	5.42e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.71	6.65	0.48	5.42e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.46	4.57	0.35	1.01e-5	Prostate cancer;
UCEC	cis	rs11190179	0.744	rs11190173	chr10:101358964	A/G	cg14256752	chr10:102295592	HIF1AN	-0.72	-4.65	-0.36	7.4e-6	&beta2-Glycoprotein I (&beta;2-GPI) plasma levels;
UCEC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.48	-5.07	-0.39	1.2e-6	Bipolar disorder;
UCEC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.79	-6.69	-0.48	4.36e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg01689657	chr7:91764605	CYP51A1	0.43	5.47	0.41	1.88e-7	Breast cancer;
UCEC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs4588572	0.643	rs7701154	chr5:77716621	G/A	cg11547950	chr5:77652471	NA	-0.43	-4.91	-0.38	2.44e-6	Triglycerides;
UCEC	cis	rs7607369	0.559	rs4674343	chr2:219660346	C/T	cg02176678	chr2:219576539	TTLL4	0.55	5.87	0.44	2.77e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-5.04	-0.38	1.35e-6	Personality dimensions;
UCEC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.42	-4.75	-0.36	4.83e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.43	0.47	1.67e-9	Coronary artery disease;
UCEC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Diabetic kidney disease;
UCEC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.49	-4.82	-0.37	3.61e-6	Menarche (age at onset);
UCEC	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.42	4.9	0.37	2.53e-6	Height;
UCEC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.73	-7.07	-0.5	5.8e-11	Cognitive test performance;
UCEC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	6.09	0.45	9.29e-9	Lymphocyte counts;
UCEC	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.65	0.53	2.44e-12	Ileal carcinoids;
UCEC	cis	rs6761276	0.752	rs12477866	chr2:113835908	C/T	cg09040174	chr2:113837401	NA	0.52	5.78	0.43	4.38e-8	Protein quantitative trait loci;
UCEC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.22	-6.97	-0.5	9.87e-11	Diabetic kidney disease;
UCEC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18252515	chr7:66147081	NA	0.62	5.75	0.43	5.07e-8	Aortic root size;
UCEC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg03354898	chr7:1950403	MAD1L1	-0.63	-6.14	-0.45	7.49e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg05738196	chr6:26577821	NA	0.6	6.49	0.47	1.24e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.57	5.16	0.39	7.86e-7	Brain structure;
UCEC	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.08	15.71	0.79	2.84e-33	IgG glycosylation;
UCEC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg04879645	chr16:947229	LMF1	0.37	4.59	0.35	9.37e-6	Coronary artery disease;
UCEC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.72	0.54	1.61e-12	Total body bone mineral density;
UCEC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg27310827	chr1:1163671	SDF4	-0.56	-6.72	-0.48	3.78e-10	N-glycan levels;
UCEC	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs7608623	0.804	rs11675585	chr2:24237180	T/C	cg25491145	chr3:194304769	NA	0.66	6.67	0.48	4.81e-10	Obesity-related traits;
UCEC	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg13147721	chr7:65941812	NA	-0.92	-5.8	-0.43	3.91e-8	Diabetic kidney disease;
UCEC	cis	rs73206853	0.609	rs12311902	chr12:110883799	T/C	cg12870014	chr12:110450643	ANKRD13A	0.64	5.62	0.42	9.28e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs250585	0.736	rs250551	chr16:23440611	C/G	cg26562691	chr16:23850404	PRKCB	0.36	4.65	0.36	7.37e-6	Egg allergy;
UCEC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg16060761	chr17:80687452	NA	-0.52	-4.8	-0.37	3.88e-6	Glycated hemoglobin levels;
UCEC	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.64	-4.81	-0.37	3.68e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg02158880	chr13:53174818	NA	0.42	4.56	0.35	1.05e-5	Lewy body disease;
UCEC	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg18681998	chr4:17616180	MED28	-0.66	-7.85	-0.54	7.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7937612	1.000	rs7107211	chr11:120262922	G/A	cg12584626	chr11:120203529	NA	0.5	5.01	0.38	1.51e-6	Intraocular pressure;
UCEC	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.34e-7	Body mass index;
UCEC	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.23	0.61	2.82e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.37	-0.41	2.95e-7	Alcohol dependence;
UCEC	cis	rs4372836	0.894	rs55877710	chr2:28929308	C/T	cg09522027	chr2:28974177	PPP1CB	0.74	7.52	0.53	5.09e-12	Body mass index;
UCEC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.69	-0.36	6.22e-6	Parkinson's disease;
UCEC	cis	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg12524725	chr2:239427019	NA	-0.71	-4.52	-0.35	1.26e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs713477	0.935	rs10144034	chr14:55914273	C/A	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.24e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.29	0.4	4.36e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg17330251	chr7:94953956	PON1	-0.6	-5.76	-0.43	4.85e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.95	0.55	4.54e-13	Chronic sinus infection;
UCEC	cis	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.48	4.94	0.38	2.07e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.88	-10.54	-0.66	1.1e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2376682	1.000	rs56001240	chr5:117998666	G/A	cg17593721	chr5:118788746	HSD17B4	0.51	4.88	0.37	2.77e-6	Diisocyanate-induced asthma;
UCEC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.26	-0.46	3.92e-9	Post bronchodilator FEV1;
UCEC	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg27246729	chr12:121163418	ACADS	0.47	4.62	0.36	8.25e-6	Mean corpuscular volume;
UCEC	cis	rs749052	0.561	rs3116192	chr2:233050670	T/C	cg23548455	chr2:233377587	NA	-0.69	-4.56	-0.35	1.05e-5	Height;
UCEC	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg20936604	chr3:58311152	NA	-0.56	-4.77	-0.37	4.32e-6	Cholesterol, total;
UCEC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.67	-5.67	-0.42	7.47e-8	Schizophrenia;
UCEC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.5	-5.44	-0.41	2.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.92	5.8	0.43	3.9e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04731861	chr2:219085781	ARPC2	0.41	4.63	0.36	7.89e-6	Colorectal cancer;
UCEC	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	4.97	0.38	1.88e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg16616514	chr4:6324629	PPP2R2C	0.42	5.09	0.39	1.06e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Kawasaki disease;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.58	-6.91	-0.5	1.36e-10	Paraoxonase activity;
UCEC	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.45	-4.78	-0.37	4.16e-6	Schizophrenia;
UCEC	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.46	4.86	0.37	3.03e-6	Type 2 diabetes;
UCEC	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-5.06	-0.39	1.22e-6	Metabolite levels;
UCEC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.48	-5.17	-0.39	7.66e-7	Alcohol dependence;
UCEC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.65	6.05	0.45	1.12e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03517284	chr6:25882590	NA	0.56	4.98	0.38	1.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.56	5.76	0.43	4.75e-8	Breast cancer;
UCEC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.43	-4.83	-0.37	3.47e-6	Prostate cancer;
UCEC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.48	-5.53	-0.42	1.41e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2302190	0.882	rs7213415	chr17:56672433	C/G	cg12560992	chr17:57184187	TRIM37	0.53	4.72	0.36	5.45e-6	Vitamin D levels;
UCEC	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg24675658	chr1:53192096	ZYG11B	-0.79	-8.81	-0.59	3.21e-15	Monocyte count;
UCEC	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg04374321	chr14:90722782	PSMC1	-0.63	-5.74	-0.43	5.19e-8	Mortality in heart failure;
UCEC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.06	0.45	1.09e-8	Tonsillectomy;
UCEC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.93	9.85	0.63	7e-18	Cognitive function;
UCEC	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.48e-6	QRS complex (12-leadsum);
UCEC	cis	rs7246967	0.673	rs3844578	chr19:22880610	G/C	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.65	4.93	0.38	2.19e-6	Mean platelet volume;
UCEC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.96	11.0	0.67	6.63e-21	Cognitive function;
UCEC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg03859395	chr2:55845619	SMEK2	0.99	13.85	0.75	1.94e-28	Metabolic syndrome;
UCEC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6832769	0.961	rs1873092	chr4:56444300	T/C	cg05960024	chr4:56376020	CLOCK	-0.54	-5.21	-0.39	6.27e-7	Personality dimensions;
UCEC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-5.24	-0.4	5.46e-7	Personality dimensions;
UCEC	cis	rs262147	0.562	rs2730207	chr7:158746411	A/G	cg15229765	chr7:158739774	NA	0.76	4.68	0.36	6.42e-6	Hippocampal volume;
UCEC	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg09654669	chr8:57350985	NA	0.44	4.72	0.36	5.42e-6	Obesity-related traits;
UCEC	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.65	-6.02	-0.44	1.36e-8	Mortality in heart failure;
UCEC	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	10.05	0.64	2.05e-18	Menopause (age at onset);
UCEC	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.17	0.6	3.94e-16	Coffee consumption (cups per day);
UCEC	cis	rs13098911	0.540	rs71325102	chr3:46015933	T/C	cg16320329	chr3:45981161	FYCO1	-0.78	-4.53	-0.35	1.22e-5	Celiac disease;
UCEC	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.62	-6.98	-0.5	9.19e-11	Heart rate;
UCEC	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.07	-0.64	1.85e-18	Height;
UCEC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	5.91	0.44	2.26e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg05874882	chr4:1763078	NA	-0.67	-6.3	-0.46	3.33e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs78487399	0.808	rs17030800	chr2:43671003	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.46	4.87	0.37	2.9e-6	Menopause (age at onset);
UCEC	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.82	-9.21	-0.6	3.1e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.0	0.5	8.36e-11	Tonsillectomy;
UCEC	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg10978503	chr1:24200527	CNR2	0.37	5.0	0.38	1.61e-6	Immature fraction of reticulocytes;
UCEC	cis	rs11702148	0.552	rs3787708	chr21:34906039	C/T	cg14850771	chr21:34775459	IFNGR2	0.46	4.69	0.36	6.25e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.83	0.37	3.35e-6	Rheumatoid arthritis;
UCEC	cis	rs4615376	1.000	rs13215349	chr6:13033110	G/A	cg11378619	chr6:12164359	HIVEP1	-0.61	-4.86	-0.37	2.94e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.53	5.43	0.41	2.24e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg05738196	chr6:26577821	NA	0.61	6.74	0.49	3.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.29	0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg13880726	chr7:1868755	MAD1L1	0.52	4.61	0.36	8.78e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.67	7.98	0.55	3.9e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg22868518	chr11:507468	RNH1	-0.68	-4.6	-0.35	9.07e-6	Body mass index;
UCEC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-6.02	-0.44	1.33e-8	Dental caries;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01086389	chr3:150321178	SELT	0.55	6.77	0.49	2.91e-10	Warfarin maintenance dose;
UCEC	cis	rs970548	0.909	rs55665473	chr10:46022005	G/A	cg15223267	chr10:46222474	FAM21C	0.56	4.99	0.38	1.65e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.55	5.94	0.44	1.99e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.71	-8.56	-0.58	1.41e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.54	5.04	0.38	1.33e-6	Blood metabolite levels;
UCEC	cis	rs56161922	0.730	rs74231794	chr1:207850717	G/A	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg24851651	chr11:66362959	CCS	0.45	5.38	0.41	2.86e-7	Educational attainment (years of education);
UCEC	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.57	5.03	0.38	1.42e-6	Multiple sclerosis;
UCEC	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Bladder cancer;
UCEC	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.67	0.48	4.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.9	-0.37	2.52e-6	Pulmonary function;
UCEC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.47e-6	QRS complex (12-leadsum);
UCEC	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-6.69	-0.48	4.4e-10	Response to antipsychotic treatment;
UCEC	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03517284	chr6:25882590	NA	0.53	5.14	0.39	8.68e-7	Blood metabolite levels;
UCEC	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.78	-5.29	-0.4	4.39e-7	Blood pressure (smoking interaction);
UCEC	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.79	-0.37	4.02e-6	Response to antipsychotic treatment;
UCEC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg01689657	chr7:91764605	CYP51A1	0.47	5.88	0.44	2.62e-8	Breast cancer;
UCEC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.46	6.4	0.47	1.93e-9	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-4.81	-0.37	3.72e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-1.07	-9.44	-0.61	7.92e-17	Dupuytren's disease;
UCEC	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-1.0	-8.31	-0.57	5.72e-14	White matter hyperintensity burden;
UCEC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.68	-6.48	-0.47	1.28e-9	Lymphocyte counts;
UCEC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.64	5.97	0.44	1.7e-8	Vitiligo;
UCEC	cis	rs1318937	0.764	rs58768954	chr3:15240305	C/T	cg21849552	chr3:14597650	NA	0.49	4.78	0.37	4.17e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.49	-5.46	-0.41	1.96e-7	Pulmonary function;
UCEC	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.42	-4.87	-0.37	2.9e-6	Pelvic organ prolapse;
UCEC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.69	8.83	0.59	2.85e-15	Vitiligo;
UCEC	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.44	4.58	0.35	9.69e-6	Coronary artery disease;
UCEC	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs6890610	0.657	rs11167705	chr5:154290751	G/T	cg02687067	chr5:153784852	GALNT10	-0.48	-4.55	-0.35	1.14e-5	Breast cancer;
UCEC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.46	6.45	0.47	1.51e-9	Eye color traits;
UCEC	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	4.6	0.35	9.2e-6	Cognitive test performance;
UCEC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg04013166	chr16:89971882	TCF25	0.73	4.59	0.35	9.44e-6	Skin colour saturation;
UCEC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.72	-8.9	-0.59	1.87e-15	Urate levels;
UCEC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg26061582	chr7:22766209	IL6	0.59	5.49	0.41	1.75e-7	Lung cancer;
UCEC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg03576123	chr11:487126	PTDSS2	0.73	5.57	0.42	1.16e-7	Body mass index;
UCEC	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.7	6.35	0.46	2.5e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs321358	0.731	rs527397	chr11:111030631	G/A	cg08305652	chr11:111469057	NA	0.44	4.72	0.36	5.48e-6	Body mass index;
UCEC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.8	9.86	0.63	6.6e-18	Brugada syndrome;
UCEC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	0.96	9.89	0.63	5.35e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.22	0.56	9.56e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6060717	0.536	rs7271036	chr20:34467215	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	4.56	0.35	1.05e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs11760485	0.928	rs4723687	chr7:4400977	C/T	cg15613991	chr7:5277080	NA	-0.4	-4.76	-0.37	4.58e-6	Early childhood aggressive behavior;
UCEC	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.52	6.51	0.47	1.09e-9	Information processing speed;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.55	-5.95	-0.44	1.85e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg02160872	chr5:212506	CCDC127	-0.72	-7.16	-0.51	3.53e-11	Breast cancer;
UCEC	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.59	-6.24	-0.46	4.4e-9	Type 2 diabetes;
UCEC	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg01851573	chr8:8652454	MFHAS1	0.41	4.67	0.36	6.71e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.73	0.36	5.27e-6	Menopause (age at onset);
UCEC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.43	0.52	8.27e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.49	-5.73	-0.43	5.44e-8	Aortic root size;
UCEC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg19041857	chr6:27730383	NA	-0.7	-5.46	-0.41	1.94e-7	Depression;
UCEC	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.72	-6.69	-0.48	4.26e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg03078520	chr22:18463400	MICAL3	-0.55	-5.32	-0.4	3.78e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.7	-9.43	-0.61	8.43e-17	Itch intensity from mosquito bite;
UCEC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.61	-0.42	9.55e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.73	-0.43	5.6e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.59	-5.43	-0.41	2.24e-7	Subjective well-being;
UCEC	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.44	-4.52	-0.35	1.25e-5	Glomerular filtration rate;
UCEC	cis	rs350251	0.899	rs2664186	chr16:12210702	G/T	cg02229097	chr16:11761951	SNN	-0.48	-4.53	-0.35	1.22e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.48	-4.79	-0.37	3.96e-6	Age at first birth;
UCEC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg10820045	chr2:198174542	NA	-0.45	-5.54	-0.42	1.37e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.61	5.27	0.4	4.84e-7	Coronary artery disease;
UCEC	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg23782820	chr8:58130467	NA	0.51	4.78	0.37	4.2e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-1.02	-8.37	-0.57	4.25e-14	White matter hyperintensity burden;
UCEC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.47	4.93	0.38	2.16e-6	Alzheimer's disease (late onset);
UCEC	cis	rs77106637	0.722	rs11605691	chr11:72419514	C/T	cg03713592	chr11:72463424	ARAP1	1.14	5.28	0.4	4.51e-7	Type 2 diabetes;
UCEC	cis	rs4478858	0.611	rs6425721	chr1:31714807	C/T	cg00250761	chr1:31883323	NA	-0.38	-4.85	-0.37	3.1e-6	Alcohol dependence;
UCEC	cis	rs968451	0.865	rs12627761	chr22:39724137	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.69	-4.66	-0.36	7.09e-6	Primary biliary cholangitis;
UCEC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.72	-4.93	-0.38	2.19e-6	Rheumatoid arthritis;
UCEC	cis	rs742614	0.533	rs736953	chr20:32415089	G/T	cg06304546	chr20:32448765	NA	-0.45	-4.75	-0.36	4.74e-6	Stearic acid (18:0) levels;
UCEC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg06466757	chr4:1255808	NA	0.46	4.9	0.37	2.54e-6	Obesity-related traits;
UCEC	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.52	5.82	0.43	3.62e-8	Life satisfaction;
UCEC	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.62	5.56	0.42	1.22e-7	Obesity (extreme);
UCEC	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.47	-4.89	-0.37	2.57e-6	Dental caries;
UCEC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.13	18.35	0.83	7.55e-40	Testicular germ cell tumor;
UCEC	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg11189052	chr15:85197271	WDR73	0.57	5.18	0.39	7.22e-7	Schizophrenia;
UCEC	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs2882667	0.931	rs1433009	chr5:138333784	G/A	cg04439458	chr5:138467593	SIL1	-0.37	-4.52	-0.35	1.26e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg14078730	chr11:63896557	MACROD1	0.65	5.06	0.39	1.22e-6	Mean platelet volume;
UCEC	cis	rs6669919	0.933	rs10863899	chr1:211666218	A/G	cg10512769	chr1:211675356	NA	-0.31	-4.58	-0.35	1e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.53	6.11	0.45	8.33e-9	Anterior chamber depth;
UCEC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.47	5.09	0.39	1.1e-6	Headache;
UCEC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg01689657	chr7:91764605	CYP51A1	0.43	5.6	0.42	1.03e-7	Breast cancer;
UCEC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg15167202	chr5:149997153	SYNPO	-0.36	-4.57	-0.35	1.04e-5	HIV-1 control;
UCEC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs72906064	0.901	rs72906053	chr2:156908598	A/G	cg14040602	chr2:157557294	NA	0.65	4.73	0.36	5.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg11859384	chr17:80120422	CCDC57	-0.47	-5.11	-0.39	9.86e-7	Life satisfaction;
UCEC	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.75	6.69	0.48	4.27e-10	Coronary artery disease;
UCEC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	5.41	0.41	2.54e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20750642	chr13:99100586	FARP1	0.47	5.36	0.4	3.16e-7	Neuroticism;
UCEC	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	8.93	0.59	1.63e-15	Coffee consumption (cups per day);
UCEC	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.47	-4.76	-0.37	4.5e-6	Dental caries;
UCEC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg06238570	chr21:40685208	BRWD1	0.76	7.51	0.53	5.2e-12	Cognitive function;
UCEC	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	0.72	5.34	0.4	3.52e-7	Blood protein levels;
UCEC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.97	12.6	0.72	3.88e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	4.55	0.35	1.11e-5	Longevity;
UCEC	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.64	7.29	0.52	1.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	4.92	0.38	2.34e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7611694	0.501	rs7623122	chr3:113136418	C/T	cg11138929	chr3:113251189	SIDT1	-0.4	-4.66	-0.36	7.04e-6	Prostate cancer;
UCEC	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.78	9.31	0.61	1.7e-16	Breast cancer;
UCEC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg23815491	chr16:72088622	HP	0.38	4.78	0.37	4.29e-6	Fibrinogen levels;
UCEC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg11985680	chr1:76251867	SNORD45C;RABGGTB	0.53	4.53	0.35	1.2e-5	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs8010715	0.596	rs12435995	chr14:24589464	A/C	cg20933586	chr14:24608199	FAM158A	0.43	5.42	0.41	2.42e-7	IgG glycosylation;
UCEC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.64	0.48	5.68e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg21191810	chr6:118973309	C6orf204	0.43	6.08	0.45	9.65e-9	Electrocardiographic conduction measures;
UCEC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.9	10.84	0.67	1.74e-20	Breast cancer;
UCEC	cis	rs4950937	0.790	rs10920586	chr1:203192820	C/T	cg20961782	chr1:203452697	PRELP	0.51	4.86	0.37	2.97e-6	Blood protein levels;
UCEC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg10932868	chr11:921992	NA	0.39	4.68	0.36	6.34e-6	Alzheimer's disease (late onset);
UCEC	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.49e-8	Depression;
UCEC	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.77	-5.66	-0.42	7.8e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs5770917	0.522	rs5770916	chr22:51016098	C/T	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	0.55	5.23	0.4	5.64e-7	Narcolepsy;
UCEC	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg14835575	chr10:16859367	RSU1	0.5	4.64	0.36	7.61e-6	Platelet distribution width;
UCEC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-0.61	-7.58	-0.53	3.52e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.48	0.62	6.28e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.7	-0.36	5.83e-6	Type 2 diabetes;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.54	-5.99	-0.44	1.51e-8	Pubertal anthropometrics;
UCEC	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.98	7.06	0.5	6.25e-11	Gut microbiome composition (summer);
UCEC	cis	rs10411936	1.000	rs873636	chr19:16514771	C/T	cg08200625	chr19:17001002	F2RL3	-0.34	-4.54	-0.35	1.17e-5	White blood cell count;Multiple sclerosis;
UCEC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.86	-0.43	2.98e-8	Prudent dietary pattern;
UCEC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.55	-5.65	-0.42	8.11e-8	Lymphocyte counts;
UCEC	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.52	5.82	0.43	3.6e-8	Hemoglobin concentration;
UCEC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs11118844	0.843	rs4601596	chr1:221914458	C/T	cg04222084	chr1:221915650	DUSP10	-0.81	-7.03	-0.5	7.12e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs9467773	1.000	rs12663894	chr6:26577370	C/T	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.95	10.71	0.66	3.91e-20	Chronic sinus infection;
UCEC	cis	rs758324	0.755	rs578637	chr5:131267609	G/A	cg23943829	chr5:132009111	IL4	-0.35	-4.53	-0.35	1.19e-5	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.08	-0.39	1.11e-6	Colorectal cancer;
UCEC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.61	-5.55	-0.42	1.29e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-4.67	-0.36	6.87e-6	HDL cholesterol;
UCEC	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.53	-5.61	-0.42	9.85e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.58	5.76	0.43	4.67e-8	Body mass index;
UCEC	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	0.58	5.69	0.42	6.75e-8	Total cholesterol levels;
UCEC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-7.15	-0.51	3.72e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.8	-7.13	-0.51	4.2e-11	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.79	0.43	4.17e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg06238570	chr21:40685208	BRWD1	0.75	7.37	0.52	1.16e-11	Cognitive function;
UCEC	cis	rs4865875	0.792	rs4519880	chr5:54102195	C/T	cg22421804	chr5:54100067	NA	0.45	5.08	0.39	1.14e-6	Sense of smell;
UCEC	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.55	-5.29	-0.4	4.31e-7	Post bronchodilator FEV1;
UCEC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg19318889	chr4:1322082	MAEA	0.42	4.89	0.37	2.57e-6	Longevity;
UCEC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.71	-7.22	-0.51	2.52e-11	Aortic root size;
UCEC	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg04837898	chr3:45731254	SACM1L	-0.4	-4.54	-0.35	1.15e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.52	5.54	0.42	1.39e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.57	-5.26	-0.4	5.01e-7	Corneal astigmatism;
UCEC	cis	rs7968440	1.000	rs7977690	chr12:51130414	A/G	cg20014596	chr12:50898483	DIP2B	0.49	4.95	0.38	2e-6	Fibrinogen;
UCEC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.47	4.56	0.35	1.06e-5	Menopause (age at onset);
UCEC	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.46	-5.09	-0.39	1.06e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.59	5.09	0.39	1.1e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg10820045	chr2:198174542	NA	-0.48	-5.95	-0.44	1.93e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg17077180	chr1:38461687	NA	0.63	6.18	0.45	6.01e-9	Red cell distribution width;
UCEC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.8	-8.94	-0.59	1.52e-15	Breast cancer;
UCEC	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.08	-13.26	-0.74	7e-27	Exhaled nitric oxide levels;
UCEC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.79	0.37	4.07e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.0	-6.87	-0.49	1.7e-10	Metabolite levels (HVA/5-HIAA ratio);
UCEC	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.96	-0.44	1.83e-8	Response to antipsychotic treatment;
UCEC	cis	rs7299538	0.966	rs7975603	chr12:46084377	A/G	cg24450400	chr12:46118477	NA	-0.49	-4.58	-0.35	9.95e-6	Gut microbiome composition (winter);
UCEC	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.75	4.51	0.35	1.34e-5	Eosinophil percentage of granulocytes;
UCEC	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.15	8.08	0.55	2.15e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.8e-7	Colorectal cancer;
UCEC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.68	6.6	0.48	6.95e-10	Aortic root size;
UCEC	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.1	9.17	0.6	3.88e-16	Vitiligo;
UCEC	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.47	-0.69	3.71e-22	Primary sclerosing cholangitis;
UCEC	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg10902566	chr4:727664	PCGF3	-0.61	-5.17	-0.39	7.67e-7	Systolic blood pressure;
UCEC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.98	-0.5	9.46e-11	Tonsillectomy;
UCEC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.64	7.18	0.51	3.16e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.84	0.37	3.22e-6	Rheumatoid arthritis;
UCEC	cis	rs1978968	0.956	rs35972244	chr22:18434038	C/G	cg03078520	chr22:18463400	MICAL3	-0.57	-5.44	-0.41	2.19e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	6.69	0.48	4.31e-10	HDL cholesterol;
UCEC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.65	6.9	0.49	1.43e-10	Menopause (age at onset);
UCEC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs787274	1.000	rs813101	chr9:115532907	C/G	cg13803584	chr9:115635662	SNX30	-0.73	-5.55	-0.42	1.28e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg13844804	chr7:814759	HEATR2	0.61	4.51	0.35	1.31e-5	Cerebrospinal P-tau181p levels;
UCEC	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.26	-0.4	4.92e-7	Parkinson's disease;
UCEC	cis	rs3750082	0.748	rs10248427	chr7:32898969	C/G	cg05721444	chr7:32995514	FKBP9	0.5	5.48	0.41	1.78e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs8010715	0.816	rs11574503	chr14:24601318	C/G	cg20933586	chr14:24608199	FAM158A	-0.38	-4.87	-0.37	2.81e-6	IgG glycosylation;
UCEC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs787274	1.000	rs4979153	chr9:115554984	G/A	cg13803584	chr9:115635662	SNX30	-0.69	-5.58	-0.42	1.13e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.61	-5.55	-0.42	1.3e-7	Bipolar disorder;
UCEC	cis	rs7582720	1.000	rs72932741	chr2:203661048	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.7	0.36	5.88e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.12	13.44	0.74	2.35e-27	Breast cancer;
UCEC	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg27124370	chr19:33622961	WDR88	0.52	4.88	0.37	2.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.55	-6.08	-0.45	9.93e-9	Bipolar disorder;
UCEC	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg07596299	chr11:71824057	C11orf51	0.86	5.09	0.39	1.08e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.66	0.75	6.11e-28	Homoarginine levels;
UCEC	cis	rs12681287	0.752	rs13277670	chr8:87259920	T/G	cg27223183	chr8:87520930	FAM82B	-0.76	-6.24	-0.46	4.41e-9	Caudate activity during reward;
UCEC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7307889	0.793	rs12314557	chr12:6009297	C/T	cg23245485	chr12:6484219	SCNN1A	0.54	4.8	0.37	3.8e-6	Obesity-related traits;
UCEC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.59	-6.48	-0.47	1.28e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.26	0.65	5.99e-19	Cognitive ability;
UCEC	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg24375607	chr4:120327624	NA	-0.5	-5.34	-0.4	3.42e-7	Corneal astigmatism;
UCEC	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	5.57	0.42	1.17e-7	Coffee consumption (cups per day);
UCEC	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.6	-4.52	-0.35	1.28e-5	Waist circumference adjusted for body mass index;
UCEC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.53	-5.3	-0.4	4.25e-7	Breast cancer;
UCEC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.7	7.12	0.51	4.47e-11	Menopause (age at onset);
UCEC	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.64	-0.36	7.53e-6	Schizophrenia;
UCEC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.32e-6	Breast cancer;
UCEC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.58	5.48	0.41	1.79e-7	Corneal astigmatism;
UCEC	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.72	-7.85	-0.54	8.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs73206853	0.841	rs56122570	chr12:110816291	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	4.73	0.36	5.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	1.34	6.09	0.45	9.32e-9	Cognitive function;
UCEC	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.62	6.75	0.49	3.26e-10	Blood metabolite ratios;
UCEC	cis	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg17325771	chr7:75508891	RHBDD2	-0.38	-4.51	-0.35	1.33e-5	Eotaxin levels;
UCEC	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.75	-7.4	-0.52	9.44e-12	Ileal carcinoids;
UCEC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs16857609	0.628	rs1478592	chr2:218346107	T/C	cg23340935	chr2:218354150	DIRC3	0.48	4.71	0.36	5.73e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.54	5.39	0.41	2.76e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.46	-5.11	-0.39	9.78e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	5.36	0.4	3.2e-7	Parkinson's disease;
UCEC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.27	-0.4	4.7e-7	Personality dimensions;
UCEC	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.93	-0.38	2.2e-6	Coronary artery disease;
UCEC	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	13.03	0.73	2.83e-26	Exhaled nitric oxide output;
UCEC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.43	5.15	0.39	8.17e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.88	8.55	0.58	1.44e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg18755752	chr8:142205143	DENND3	-0.59	-5.48	-0.41	1.78e-7	Immature fraction of reticulocytes;
UCEC	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs731174	0.759	rs591567	chr1:38149847	A/G	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.34e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.72	7.76	0.54	1.31e-12	Primary sclerosing cholangitis;
UCEC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.43	4.56	0.35	1.05e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7212590	0.655	rs62081824	chr17:57907950	A/G	cg10252138	chr17:58120427	NA	-0.68	-5.43	-0.41	2.33e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16672449	chr3:127842622	RUVBL1	0.58	6.88	0.49	1.62e-10	Warfarin maintenance dose;
UCEC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	18.13	0.83	2.55e-39	Chronic sinus infection;
UCEC	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg05660106	chr1:15850417	CASP9	0.49	4.72	0.36	5.33e-6	Systolic blood pressure;
UCEC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.53	5.48	0.41	1.82e-7	Acne (severe);
UCEC	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-6.56	-0.48	8.77e-10	Type 2 diabetes;
UCEC	cis	rs2063714	0.640	rs9397978	chr6:157193250	A/G	cg23222435	chr6:157204239	ARID1B	0.54	4.97	0.38	1.84e-6	Sitting height ratio;
UCEC	cis	rs7246967	0.673	rs55932152	chr19:22873428	A/T	cg24889512	chr19:22816950	ZNF492	0.6	6.5	0.47	1.17e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg27068330	chr11:65405492	SIPA1	-0.46	-4.71	-0.36	5.63e-6	Acne (severe);
UCEC	cis	rs1575951	1.000	rs7092697	chr10:130437904	A/G	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg08222913	chr3:52553049	STAB1	-0.4	-4.57	-0.35	1.01e-5	Bipolar disorder;
UCEC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-10.49	-0.65	1.42e-19	Schizophrenia;
UCEC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.54	4.9	0.37	2.54e-6	Body mass index;
UCEC	cis	rs735539	0.521	rs12430409	chr13:21349667	A/G	cg04906043	chr13:21280425	IL17D	-0.49	-4.82	-0.37	3.59e-6	Dental caries;
UCEC	cis	rs2979489	0.891	rs17551512	chr8:30330109	A/G	cg26383811	chr8:30366931	RBPMS	-0.72	-6.01	-0.44	1.37e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.76	9.98	0.64	3.14e-18	Menarche (age at onset);
UCEC	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.74	-4.83	-0.37	3.4e-6	Hair shape;
UCEC	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.66	-5.77	-0.43	4.61e-8	Obesity-related traits;
UCEC	cis	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	1.02	7.47	0.52	6.5e-12	LDL cholesterol;
UCEC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.9	10.97	0.67	8.08e-21	IgG glycosylation;
UCEC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg15147215	chr3:52552868	STAB1	0.42	4.65	0.36	7.42e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-6.34	-0.46	2.71e-9	Morning vs. evening chronotype;
UCEC	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.34	-0.46	2.61e-9	Parkinson's disease;
UCEC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15369054	chr17:80825471	TBCD	-0.57	-4.63	-0.36	7.98e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
UCEC	cis	rs9549260	1.000	rs9549260	chr13:41254104	G/T	cg21288729	chr13:41239152	FOXO1	0.49	4.73	0.36	5.28e-6	Red blood cell count;
UCEC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg15848620	chr12:58087721	OS9	-0.53	-5.09	-0.39	1.07e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg22974920	chr21:40686053	BRWD1	0.58	5.06	0.39	1.22e-6	Cognitive function;
UCEC	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg07387570	chr22:46663686	TTC38	-0.45	-4.69	-0.36	6.31e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.54	-5.67	-0.42	7.45e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.33	-0.4	3.67e-7	Resting heart rate;
UCEC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.71	-6.25	-0.46	4.17e-9	Platelet distribution width;
UCEC	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.02	0.5	7.61e-11	Morning vs. evening chronotype;
UCEC	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.79	-9.75	-0.63	1.24e-17	White blood cell count (basophil);
UCEC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg22166914	chr1:53195759	ZYG11B	0.78	8.12	0.56	1.73e-13	Monocyte count;
UCEC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.19	-0.51	2.96e-11	Monocyte count;
UCEC	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.65	-7.55	-0.53	4.2e-12	Hip circumference;
UCEC	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.25	0.51	2.22e-11	Eye color traits;
UCEC	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.45	-5.91	-0.44	2.26e-8	Mean platelet volume;
UCEC	cis	rs7088591	0.867	rs1475683	chr10:59776764	C/T	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.61	-5.71	-0.43	6.04e-8	Metabolite levels;
UCEC	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.82	-9.92	-0.63	4.55e-18	Body mass index;
UCEC	cis	rs293377	0.961	rs293370	chr15:89630476	A/G	cg21841583	chr15:89630450	ABHD2	0.58	7.84	0.54	8.55e-13	Gut microbiota (beta diversity);
UCEC	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.64	-5.07	-0.39	1.16e-6	Schizophrenia;
UCEC	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.51	5.58	0.42	1.13e-7	Menopause (age at onset);
UCEC	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.9	0.49	1.46e-10	Motion sickness;
UCEC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	0.83	5.94	0.44	1.93e-8	Iron status biomarkers;
UCEC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.55	-6.21	-0.46	5.15e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.76	7.53	0.53	4.66e-12	Vitamin D levels;
UCEC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Schizophrenia;
UCEC	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.8	5.18	0.39	7.24e-7	Body mass index;
UCEC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg15147215	chr3:52552868	STAB1	-0.42	-4.56	-0.35	1.07e-5	Electroencephalogram traits;
UCEC	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg22563815	chr15:78856949	CHRNA5	-0.37	-4.86	-0.37	2.96e-6	Sudden cardiac arrest;
UCEC	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.7	-4.52	-0.35	1.24e-5	Blood protein levels;
UCEC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs7968440	1.000	rs2731434	chr12:51109875	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.5	6.6	0.48	6.94e-10	Age-related hearing impairment;
UCEC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.56	-4.93	-0.38	2.22e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.65	-0.36	7.25e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.96	-0.44	1.8e-8	Mortality in heart failure;
UCEC	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.49	-5.52	-0.41	1.46e-7	Bipolar disorder;
UCEC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.04	9.62	0.62	2.66e-17	Vitiligo;
UCEC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.7	-8.02	-0.55	3.05e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.85	-9.65	-0.62	2.26e-17	Dental caries;
UCEC	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg04851639	chr8:1020857	NA	-0.39	-5.18	-0.39	7.09e-7	Schizophrenia;
UCEC	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg13870426	chr17:30244630	NA	0.69	4.81	0.37	3.73e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.53	6.28	0.46	3.65e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg12559939	chr2:27858050	GPN1	0.45	4.77	0.37	4.38e-6	Oral cavity cancer;
UCEC	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.55	-4.53	-0.35	1.23e-5	Initial pursuit acceleration;
UCEC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs60311166	1.000	rs72950424	chr3:52687190	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.78	5.28	0.4	4.61e-7	CTACK levels;
UCEC	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.72	-7.19	-0.51	2.98e-11	Tonsillectomy;
UCEC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.83	8.76	0.59	4.38e-15	Breast cancer;
UCEC	cis	rs2629540	0.544	rs2629529	chr10:126534415	A/C	cg08799069	chr10:126477246	METTL10	0.65	4.61	0.36	8.68e-6	Cocaine dependence;
UCEC	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.6	7.86	0.54	7.38e-13	Neuroticism;
UCEC	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg23283320	chr21:48055893	PRMT2	1.02	4.64	0.36	7.75e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.18e-7	Hemoglobin concentration;
UCEC	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.611	rs7250964	chr19:22822494	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.38	5.62	0.42	9.1e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.87	0.37	2.86e-6	Menarche (age at onset);
UCEC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg16060761	chr17:80687452	NA	-0.43	-4.75	-0.37	4.71e-6	Breast cancer;
UCEC	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.44	5.04	0.38	1.36e-6	Aortic root size;
UCEC	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs2213920	0.749	rs4978637	chr9:118222448	T/A	cg13918206	chr9:118159781	DEC1	0.74	5.07	0.39	1.19e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Kawasaki disease;
UCEC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.74	-9.24	-0.61	2.59e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg00873616	chr20:43920241	NA	-0.48	-4.51	-0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	0.87	6.62	0.48	6.18e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs7870753	0.838	rs7860447	chr9:99263937	T/C	cg25260653	chr9:99212216	HABP4	0.56	5.5	0.41	1.62e-7	Height;
UCEC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	6e-6	Cardiac Troponin-T levels;
UCEC	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-6.2	-0.46	5.44e-9	Dental caries;
UCEC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg24375607	chr4:120327624	NA	0.47	4.83	0.37	3.42e-6	Corneal astigmatism;
UCEC	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	0.77	5.99	0.44	1.51e-8	Blood protein levels;
UCEC	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs4615376	1.000	rs4715072	chr6:13043560	G/A	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.53	-4.51	-0.35	1.33e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg08755490	chr11:65554678	OVOL1	0.49	5.11	0.39	9.7e-7	Acne (severe);
UCEC	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.84	-0.43	3.17e-8	Fear of minor pain;
UCEC	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg01072550	chr1:21505969	NA	-0.58	-5.65	-0.42	8.17e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9309473	0.500	rs4286298	chr2:73882108	T/A	cg20560298	chr2:73613845	ALMS1	0.5	4.81	0.37	3.64e-6	Metabolite levels;
UCEC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs7975161	0.938	rs4964271	chr12:104652441	T/C	cg25273343	chr12:104657179	TXNRD1	-0.64	-5.32	-0.4	3.8e-7	Toenail selenium levels;
UCEC	cis	rs17012589	0.589	rs7316291	chr12:85699744	T/C	cg02569458	chr12:86230093	RASSF9	0.39	4.51	0.35	1.3e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs713477	0.967	rs10150596	chr14:55916167	A/G	cg13175173	chr14:55914753	NA	0.44	4.93	0.38	2.17e-6	Pediatric bone mineral content (femoral neck);
UCEC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.83	-10.08	-0.64	1.75e-18	Coronary artery disease;
UCEC	cis	rs829661	0.645	rs6759818	chr2:30780707	G/T	cg17749961	chr2:30669863	LCLAT1	0.67	5.91	0.44	2.25e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7811653	0.677	rs34949116	chr7:46496598	G/A	cg11343713	chr7:45749313	ADCY1	0.5	4.52	0.35	1.26e-5	Hypospadias;
UCEC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.34	-4.54	-0.35	1.18e-5	Monocyte count;
UCEC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-5.82	-0.43	3.5e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.01	-0.38	1.53e-6	Chronic sinus infection;
UCEC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg14008862	chr17:28927542	LRRC37B2	0.58	5.18	0.39	7.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs10053502	0.867	rs73082075	chr5:40049800	G/A	cg01062838	chr5:40831429	RPL37	0.64	4.56	0.35	1.08e-5	Myopia (pathological);
UCEC	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.45	-4.66	-0.36	7.05e-6	Vitiligo;
UCEC	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg13319975	chr6:146136371	FBXO30	0.46	5.04	0.38	1.32e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.53	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.31	0.52	1.54e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg23625390	chr15:77176239	SCAPER	0.46	4.58	0.35	1e-5	Blood metabolite levels;
UCEC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.88	-0.49	1.58e-10	Joint mobility (Beighton score);
UCEC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.99	0.5	8.94e-11	Mood instability;
UCEC	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.73	-7.67	-0.53	2.13e-12	Blood protein levels;
UCEC	cis	rs12136530	0.774	rs12562821	chr1:19786650	C/T	cg25599739	chr1:19403133	UBR4	-0.56	-4.71	-0.36	5.78e-6	Lead levels in blood;
UCEC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	11.21	0.68	1.82e-21	Electrocardiographic conduction measures;
UCEC	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.56	5.35	0.4	3.27e-7	Obesity-related traits;
UCEC	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.7	7.71	0.54	1.72e-12	Coronary artery disease;
UCEC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg00086871	chr4:6988644	TBC1D14	0.87	5.36	0.4	3.23e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg17764715	chr19:33622953	WDR88	0.62	6.04	0.45	1.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.9	-12.25	-0.71	3.3e-24	Menopause (age at onset);
UCEC	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.48	4.54	0.35	1.16e-5	Body mass index;
UCEC	cis	rs9549260	0.564	rs7997896	chr13:41268823	T/A	cg21288729	chr13:41239152	FOXO1	0.48	5.0	0.38	1.62e-6	Red blood cell count;
UCEC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.56	6.45	0.47	1.49e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg15837086	chr1:46506065	PIK3R3	-0.37	-4.58	-0.35	9.68e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.54	0.42	1.38e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.58	4.97	0.38	1.84e-6	Response to diuretic therapy;
UCEC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.65	6.32	0.46	2.92e-9	Multiple myeloma (IgH translocation);
UCEC	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.26e-9	Prudent dietary pattern;
UCEC	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.49	5.88	0.44	2.6e-8	Coronary artery disease;
UCEC	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-4.7	-0.36	5.86e-6	HDL cholesterol;
UCEC	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg23950597	chr19:37808831	NA	-0.64	-5.0	-0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.71	-6.04	-0.45	1.22e-8	Heart rate;
UCEC	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.54	-0.66	1.05e-19	Schizophrenia;
UCEC	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg05539622	chr2:73298971	SFXN5	0.48	4.53	0.35	1.21e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.608	rs433579	chr19:23003127	T/C	cg05241461	chr19:22816980	ZNF492	0.5	4.83	0.37	3.46e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.1	-0.39	1.04e-6	Colorectal cancer;
UCEC	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.57	-0.48	7.97e-10	Pubertal anthropometrics;
UCEC	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	1.15	6.23	0.46	4.77e-9	Type 2 diabetes;
UCEC	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.72e-25	Height;
UCEC	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.06	-0.5	6.24e-11	Eye color traits;
UCEC	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.59	6.36	0.46	2.39e-9	Neutrophil percentage of white cells;
UCEC	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.33	-0.57	5.1e-14	Prevalent atrial fibrillation;
UCEC	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	7.84	0.54	8.36e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg17294928	chr15:75287854	SCAMP5	-0.48	-4.61	-0.36	8.62e-6	Lung cancer;
UCEC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.67	4.81	0.37	3.74e-6	Body mass index;
UCEC	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.34	-4.84	-0.37	3.24e-6	Blood metabolite levels;
UCEC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg14008862	chr17:28927542	LRRC37B2	0.6	5.29	0.4	4.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.5	-4.66	-0.36	6.97e-6	Cognitive function;
UCEC	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.5	4.53	0.35	1.19e-5	Diabetic retinopathy;
UCEC	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs409224	0.510	rs10271680	chr7:101750105	C/T	cg08135718	chr7:101819329	CUX1	0.49	5.23	0.4	5.84e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	0.85	10.54	0.66	1.04e-19	Bone mineral density;
UCEC	cis	rs782107	0.761	rs782094	chr12:58817015	T/C	cg19181132	chr12:59314527	LRIG3	0.46	5.01	0.38	1.55e-6	Interleukin-12p70 levels;
UCEC	cis	rs6540731	1.000	rs3816912	chr1:212399849	A/G	cg01168776	chr1:212002499	LPGAT1	0.38	4.86	0.37	2.92e-6	Intelligence (childhood);
UCEC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.56	-5.44	-0.41	2.14e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.56	-0.42	1.23e-7	Life satisfaction;
UCEC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	4.84	0.37	3.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.43	-4.99	-0.38	1.65e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg18099408	chr3:52552593	STAB1	-0.44	-5.2	-0.39	6.6e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.41	5.33	0.4	3.65e-7	Blood protein levels;
UCEC	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.56	4.73	0.36	5.13e-6	Body mass index;
UCEC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg04871131	chr7:94954202	PON1	-0.49	-4.62	-0.36	8.22e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.89	8.12	0.56	1.76e-13	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.15	0.39	8.19e-7	Breast cancer;
UCEC	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-4.68	-0.36	6.41e-6	Platelet count;
UCEC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.74	0.63	1.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.46	4.71	0.36	5.7e-6	Colorectal cancer;
UCEC	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.01	0.38	1.51e-6	Bipolar disorder;
UCEC	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.21	-0.4	6.16e-7	Morning vs. evening chronotype;
UCEC	cis	rs4654899	0.733	rs10799677	chr1:21318456	A/C	cg01072550	chr1:21505969	NA	-0.53	-5.54	-0.42	1.34e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg27033923	chr15:41106683	ZFYVE19	-0.48	-4.53	-0.35	1.2e-5	Ulcerative colitis;
UCEC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.59	0.48	7.46e-10	Tonsillectomy;
UCEC	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.53	-4.7	-0.36	5.92e-6	Obesity-related traits;
UCEC	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13683864	chr3:40499215	RPL14	-0.99	-10.44	-0.65	1.91e-19	Renal cell carcinoma;
UCEC	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.53	5.46	0.41	1.97e-7	Systemic lupus erythematosus;
UCEC	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.39	-5.61	-0.42	9.72e-8	Ulcerative colitis;
UCEC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.88	-14.6	-0.77	2.08e-30	Birth weight;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.52	-6.17	-0.45	6.17e-9	Pubertal anthropometrics;
UCEC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg04871131	chr7:94954202	PON1	-0.5	-4.69	-0.36	6.27e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.77	0.43	4.58e-8	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg03342759	chr3:160939853	NMD3	0.56	5.42	0.41	2.35e-7	Morning vs. evening chronotype;
UCEC	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.56	5.82	0.43	3.64e-8	Prostate cancer;
UCEC	trans	rs6982751	0.611	rs56166963	chr8:10809045	G/A	cg19039765	chr13:110174231	NA	1.0	6.7	0.48	4.17e-10	Asthma and hay fever;
UCEC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.45	-4.51	-0.35	1.31e-5	Dental caries;
UCEC	cis	rs17012589	0.639	rs7306109	chr12:85696565	C/T	cg02569458	chr12:86230093	RASSF9	0.39	4.53	0.35	1.22e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.02	-0.64	2.46e-18	Height;
UCEC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg18755752	chr8:142205143	DENND3	-0.54	-4.94	-0.38	2.08e-6	Immature fraction of reticulocytes;
UCEC	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.34e-18	Height;
UCEC	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	5.61	0.42	9.89e-8	Response to antipsychotic treatment;
UCEC	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.75	-0.43	5.02e-8	Blood metabolite levels;
UCEC	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.92	9.25	0.61	2.48e-16	Post bronchodilator FEV1;
UCEC	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.11	17.43	0.82	1.33e-37	Schizophrenia;
UCEC	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.08	-8.04	-0.55	2.72e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.56	0.53	3.9e-12	Bladder cancer;
UCEC	cis	rs7804356	0.906	rs12540388	chr7:26905731	A/T	cg03456212	chr7:26904342	SKAP2	-0.62	-4.69	-0.36	6.21e-6	Type 1 diabetes;
UCEC	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs151997	0.925	rs26087	chr5:50172911	G/A	cg06027927	chr5:50259733	NA	0.54	5.04	0.38	1.35e-6	Callous-unemotional behaviour;
UCEC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	trans	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg06410510	chr2:107458059	ST6GAL2	-0.75	-6.89	-0.49	1.53e-10	Prostate cancer;
UCEC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.44	-4.82	-0.37	3.48e-6	Longevity;
UCEC	cis	rs10743315	0.778	rs7399032	chr12:19371546	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.51	-4.87	-0.37	2.79e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.6	5.13	0.39	8.83e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	7.36	0.52	1.18e-11	Menopause (age at onset);
UCEC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09491104	chr22:46646882	C22orf40	-0.48	-4.58	-0.35	9.71e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.56	4.9	0.37	2.54e-6	Response to diuretic therapy;
UCEC	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.62	-6.29	-0.46	3.39e-9	Cognitive ability;
UCEC	cis	rs8105895	0.877	rs62112919	chr19:22227145	T/C	cg24072202	chr19:22235272	ZNF257	-0.56	-4.66	-0.36	6.89e-6	Body mass index (change over time);
UCEC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	5.83	0.43	3.43e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.57	6.06	0.45	1.08e-8	Schizophrenia;
UCEC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.69	5.64	0.42	8.55e-8	Smoking initiation;
UCEC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg10932868	chr11:921992	NA	0.4	4.73	0.36	5.24e-6	Alzheimer's disease (late onset);
UCEC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	5.8	0.43	3.92e-8	Body mass index;
UCEC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.8	8.34	0.57	4.94e-14	Longevity;Endometriosis;
UCEC	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg22814929	chr6:26458213	BTN2A1	0.61	4.59	0.35	9.49e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.73	-0.54	1.59e-12	Total cholesterol levels;
UCEC	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	7.01	0.5	7.94e-11	Eye color traits;
UCEC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg26721908	chr21:47610096	LSS	-0.55	-6.78	-0.49	2.69e-10	Testicular germ cell tumor;
UCEC	cis	rs3777722	0.688	rs2757048	chr6:167351120	A/G	cg23869232	chr6:167175937	RPS6KA2	0.42	4.5	0.35	1.36e-5	Spontaneous preterm birth (preterm birth);
UCEC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.53	-6.29	-0.46	3.42e-9	Pubertal anthropometrics;
UCEC	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	6.48	0.47	1.28e-9	Motion sickness;
UCEC	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.12	-0.39	9.54e-7	Aortic root size;
UCEC	cis	rs362296	0.698	rs362279	chr4:3260072	G/A	cg08886695	chr4:3369023	RGS12	0.49	4.7	0.36	5.9e-6	Parental longevity (mother's age at death);
UCEC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.59	6.21	0.46	5.16e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.53	-5.43	-0.41	2.23e-7	Height;
UCEC	cis	rs925228	0.955	rs963726	chr2:24148538	A/C	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg23018236	chr17:30244563	NA	-0.66	-4.69	-0.36	6.11e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg05962950	chr11:130786565	SNX19	0.51	5.28	0.4	4.64e-7	Schizophrenia;
UCEC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-0.84	-5.98	-0.44	1.65e-8	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
UCEC	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.68	-7.5	-0.53	5.6e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs13065560	0.594	rs7633981	chr3:38889901	A/C	cg01426195	chr3:39028469	NA	-0.53	-5.61	-0.42	9.91e-8	Interleukin-18 levels;
UCEC	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg21642963	chr15:78858002	CHRNA5	0.49	4.61	0.36	8.55e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	trans	rs3769124	0.513	rs76475671	chr2:239492153	G/A	cg17833746	chr17:40489785	STAT3	0.62	6.89	0.49	1.48e-10	Pulmonary function;
UCEC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.66	0.48	5.2e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.76	7.9	0.55	6.17e-13	Breast cancer;
UCEC	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.56	-4.81	-0.37	3.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg11632617	chr15:75315747	PPCDC	-0.6	-6.86	-0.49	1.74e-10	Blood trace element (Zn levels);
UCEC	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.37	-6.39	-0.47	2.08e-9	Mean corpuscular volume;
UCEC	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.36	4.91	0.38	2.37e-6	Primary biliary cholangitis;
UCEC	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg21253087	chr9:139290292	SNAPC4	0.4	4.52	0.35	1.24e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	7.89	0.55	6.48e-13	Tonsillectomy;
UCEC	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	0.71	4.59	0.35	9.4e-6	Mitochondrial DNA levels;
UCEC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.89	7.53	0.53	4.69e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.69	-7.18	-0.51	3.23e-11	Cognitive function;
UCEC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.72	5.55	0.42	1.28e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.73	6.8	0.49	2.42e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.63	6.68	0.48	4.5e-10	Menopause (age at onset);
UCEC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.59	-6.82	-0.49	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	6.24	0.46	4.51e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-6.85	-0.49	1.85e-10	Resting heart rate;
UCEC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.46	-0.41	1.96e-7	Dupuytren's disease;
UCEC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.52	-5.08	-0.39	1.12e-6	Diastolic blood pressure;
UCEC	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.6	-6.7	-0.48	4.16e-10	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.07	8.84	0.59	2.78e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.47	-6.0	-0.44	1.47e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs59104589	0.617	rs6672	chr2:242293021	A/G	cg19488206	chr2:242435732	STK25	0.54	4.87	0.37	2.83e-6	Fibrinogen levels;
UCEC	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg00105475	chr2:10696890	NA	0.45	5.5	0.41	1.64e-7	Prostate cancer;
UCEC	cis	rs17123764	0.710	rs12316284	chr12:50158866	G/A	cg20471783	chr12:50157085	TMBIM6	0.63	4.98	0.38	1.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.65	5.46	0.41	2.02e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.22	0.4	6e-7	Prostate cancer;
UCEC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.52	5.76	0.43	4.83e-8	Menopause (age at onset);
UCEC	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.32	-0.57	5.65e-14	Exhaled nitric oxide output;
UCEC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.76	-6.89	-0.49	1.53e-10	Initial pursuit acceleration;
UCEC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg21770322	chr7:97807741	LMTK2	0.53	6.5	0.47	1.15e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg17764715	chr19:33622953	WDR88	0.65	6.13	0.45	7.75e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	trans	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg18288967	chr1:45987694	PRDX1	0.9	7.45	0.52	7.35e-12	Obesity-related traits;
UCEC	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg19610905	chr11:61596333	FADS2	-0.61	-4.66	-0.36	6.9e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs6867032	0.527	rs4975720	chr5:2010455	C/G	cg26168224	chr5:2018326	NA	0.57	6.94	0.5	1.19e-10	Gut microbiome composition (winter);
UCEC	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.98	7.92	0.55	5.25e-13	Exhaled nitric oxide output;
UCEC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.87	9.6	0.62	2.96e-17	Cognitive function;
UCEC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.58	-6.06	-0.45	1.07e-8	Prostate cancer;
UCEC	cis	rs732765	0.734	rs2270425	chr14:75179734	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.55	-0.35	1.12e-5	Non-small cell lung cancer;
UCEC	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg13575925	chr12:9217583	LOC144571	0.4	4.64	0.36	7.49e-6	Sjögren's syndrome;
UCEC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg03859395	chr2:55845619	SMEK2	0.96	12.95	0.73	4.56e-26	Metabolic syndrome;
UCEC	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg12024160	chr4:1254474	NA	0.49	6.3	0.46	3.32e-9	Obesity-related traits;
UCEC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.73	-8.24	-0.56	8.71e-14	Metabolic syndrome;
UCEC	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.97	-11.84	-0.7	3.95e-23	Body mass index;
UCEC	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.62	-0.42	9.51e-8	Urate levels in overweight individuals;
UCEC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	7.06	0.5	6.28e-11	Mood instability;
UCEC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg06784218	chr1:46089804	CCDC17	0.47	5.83	0.43	3.42e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.74	-8.62	-0.58	9.52e-15	Ulcerative colitis;
UCEC	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.62	-6.84	-0.49	2e-10	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.8	0.43	3.88e-8	Breast cancer;
UCEC	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.8	5.91	0.44	2.27e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.68	6.69	0.48	4.46e-10	Aortic root size;
UCEC	cis	rs858239	0.796	rs433395	chr7:23401955	G/T	cg17274742	chr7:23286539	GPNMB	0.39	4.54	0.35	1.16e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.67	5.15	0.39	8.34e-7	Mean platelet volume;
UCEC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	4.74	0.36	4.94e-6	Lung function (FEV1/FVC);
UCEC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.5	-4.88	-0.37	2.72e-6	Total body bone mineral density;
UCEC	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg13540341	chr19:49222985	MAMSTR	-0.4	-4.83	-0.37	3.38e-6	Dietary macronutrient intake;
UCEC	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg19729930	chr2:74357872	NA	0.69	6.55	0.48	9.21e-10	Gestational age at birth (maternal effect);
UCEC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg06466757	chr4:1255808	NA	0.45	4.68	0.36	6.46e-6	Obesity-related traits;
UCEC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.8	0.37	3.81e-6	Breast cancer;
UCEC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.23	-0.4	5.7e-7	Aortic root size;
UCEC	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.85	-7.2	-0.51	2.86e-11	Coronary artery calcification;
UCEC	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.55	6.0	0.44	1.48e-8	Height;
UCEC	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.09	0.5	5.22e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	9.24	0.61	2.63e-16	Monocyte count;
UCEC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.55	4.52	0.35	1.24e-5	Bladder cancer;
UCEC	cis	rs9463078	0.764	rs9369516	chr6:44833598	C/T	cg25276700	chr6:44698697	NA	-0.41	-4.5	-0.35	1.37e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg13319975	chr6:146136371	FBXO30	0.43	4.57	0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.57	4.63	0.36	7.97e-6	Pediatric autoimmune diseases;
UCEC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.5	7.46	0.52	7.04e-12	Homoarginine levels;
UCEC	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.47	4.62	0.36	8.31e-6	Coronary artery disease;
UCEC	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	5.55	0.42	1.32e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-4.54	-0.35	1.15e-5	Headache;
UCEC	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg18681998	chr4:17616180	MED28	0.66	7.7	0.54	1.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg05241461	chr19:22816980	ZNF492	0.58	6.36	0.46	2.37e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.51	5.51	0.41	1.54e-7	Platelet distribution width;
UCEC	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.59	6.67	0.48	4.96e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.85	6.91	0.5	1.35e-10	Response to hepatitis C treatment;
UCEC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26207909	chr14:103986467	CKB	0.5	5.54	0.42	1.34e-7	Body mass index;
UCEC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.44	-6.04	-0.45	1.22e-8	Prostate cancer;
UCEC	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg23283320	chr21:48055893	PRMT2	0.9	5.71	0.43	5.95e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg10932868	chr11:921992	NA	0.44	5.81	0.43	3.7e-8	Alzheimer's disease (late onset);
UCEC	cis	rs1113932	1.000	rs10931531	chr2:193046999	A/C	cg12404831	chr2:192114017	MYO1B	-0.62	-4.55	-0.35	1.14e-5	Hemoglobin A2 levels in sickle cell anemia;
UCEC	cis	rs12428035	1.000	rs12429385	chr13:96301936	A/G	cg07859753	chr13:96300257	NA	0.65	5.54	0.42	1.37e-7	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.58	-5.91	-0.44	2.25e-8	Ulcerative colitis;
UCEC	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.23	0.51	2.49e-11	Coffee consumption (cups per day);
UCEC	cis	rs749052	0.561	rs3116194	chr2:233061266	T/A	cg23548455	chr2:233377587	NA	0.69	4.56	0.35	1.05e-5	Height;
UCEC	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg01072550	chr1:21505969	NA	0.62	6.56	0.48	8.53e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.67	-7.25	-0.51	2.24e-11	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs9676498	chr19:22910510	A/G	cg08271804	chr19:22816896	ZNF492	0.66	6.36	0.46	2.35e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs9313296	0.661	rs2545512	chr5:165522626	G/A	cg03539051	chr19:56418660	NLRP13	1.08	6.85	0.49	1.86e-10	Weight;Waist circumference;
UCEC	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-6.46	-0.47	1.46e-9	Platelet distribution width;
UCEC	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.41	-5.53	-0.41	1.45e-7	Breast cancer;
UCEC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs13279522	0.536	rs11997605	chr8:66985624	C/T	cg00269606	chr8:67090928	CRH	0.35	4.59	0.35	9.42e-6	Coronary heart disease event reduction (statin therapy interaction);
UCEC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.53	-5.12	-0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-8.91	-0.59	1.79e-15	Ulcerative colitis;
UCEC	cis	rs1318937	0.764	rs66813829	chr3:15243721	C/T	cg21849552	chr3:14597650	NA	0.49	4.78	0.37	4.17e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.43	0.47	1.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10007810	0.760	rs10021226	chr4:41581289	C/T	cg24722073	chr4:41882163	NA	-0.37	-4.54	-0.35	1.14e-5	Longevity (90 years and older);
UCEC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.48	0.41	1.83e-7	Breast cancer;
UCEC	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.26e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.48	5.09	0.39	1.09e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	4.6	0.35	9.16e-6	Joint mobility (Beighton score);
UCEC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.84	7.27	0.51	1.99e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.53	-5.51	-0.41	1.58e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
UCEC	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.59	4.85	0.37	3.09e-6	Eosinophilic esophagitis;
UCEC	cis	rs11760485	0.929	rs11764749	chr7:4401547	T/C	cg15613991	chr7:5277080	NA	-0.41	-4.99	-0.38	1.68e-6	Early childhood aggressive behavior;
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-6.22	-0.46	4.97e-9	Platelet count;
UCEC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.49	-5.35	-0.4	3.31e-7	Longevity;
UCEC	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.65	-7.21	-0.51	2.68e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.61	5.7	0.43	6.37e-8	Type 2 diabetes;
UCEC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.71e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.02	14.12	0.76	3.85e-29	Height;
UCEC	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-4.52	-0.35	1.25e-5	Life satisfaction;
UCEC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.52	-5.97	-0.44	1.68e-8	Tonsillectomy;
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7106204	0.748	rs7101572	chr11:24213982	A/G	ch.11.24196551F	chr11:24239977	NA	0.53	5.48	0.41	1.83e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.55	6.68	0.48	4.54e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.15	19.7	0.85	4.41e-43	Schizophrenia;
UCEC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.46	4.86	0.37	3.03e-6	Type 2 diabetes;
UCEC	cis	rs6738485	0.567	rs7598745	chr2:106848216	A/T	cg16099169	chr2:106886729	NA	0.4	4.56	0.35	1.08e-5	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.21	-0.39	6.41e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg20387954	chr3:183756860	HTR3D	0.5	6.02	0.44	1.31e-8	Anterior chamber depth;
UCEC	cis	rs7004769	0.554	rs17659068	chr8:9174048	C/G	cg27598956	chr8:9758788	LOC157627	0.51	4.7	0.36	5.9e-6	Fibrinogen levels;
UCEC	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg20399509	chr21:47717575	C21orf57	-0.44	-4.74	-0.36	5.07e-6	Testicular germ cell tumor;
UCEC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.84	-8.54	-0.58	1.53e-14	Resting heart rate;
UCEC	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg13401533	chr1:37979913	MEAF6	0.59	4.91	0.38	2.43e-6	Axial length;
UCEC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg06027949	chr8:82754900	SNX16	0.59	5.0	0.38	1.63e-6	Diastolic blood pressure;
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.79	8.42	0.57	3.14e-14	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	20.35	0.86	1.36e-44	Chronic sinus infection;
UCEC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18932078	chr1:2524107	MMEL1	0.39	6.5	0.47	1.19e-9	Ulcerative colitis;
UCEC	cis	rs11247915	0.644	rs11588739	chr1:26653319	G/A	cg00852783	chr1:26633632	UBXN11	0.52	4.89	0.37	2.57e-6	Obesity-related traits;
UCEC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.44	-4.92	-0.38	2.27e-6	Prostate cancer;
UCEC	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.55	4.87	0.37	2.85e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.62	5.96	0.44	1.79e-8	Aortic root size;
UCEC	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.63	-6.2	-0.46	5.52e-9	Myopia;
UCEC	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.59	6.77	0.49	2.91e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	-0.59	-6.74	-0.49	3.32e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-5.05	-0.38	1.26e-6	Metabolite levels;
UCEC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.59	6.45	0.47	1.5e-9	Cognitive function;
UCEC	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.49	5.0	0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.67	7.25	0.51	2.24e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.82e-9	Blood protein levels;
UCEC	trans	rs4389974	0.899	rs62520650	chr8:112414762	T/G	cg22736090	chr17:62339926	TEX2	0.65	6.82	0.49	2.19e-10	Body mass index;
UCEC	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.55	4.87	0.37	2.83e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs7709377	0.523	rs10078121	chr5:115471838	A/G	cg23108291	chr5:115420582	COMMD10	-0.5	-4.95	-0.38	1.99e-6	Metabolite levels  (X-11787);
UCEC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-6.77	-0.49	2.83e-10	Initial pursuit acceleration;
UCEC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.36	4.93	0.38	2.24e-6	Eye color traits;
UCEC	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.52	-4.73	-0.36	5.24e-6	Educational attainment;
UCEC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.52	-5.57	-0.42	1.16e-7	Menarche (age at onset);
UCEC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	4.8	0.37	3.87e-6	Colorectal cancer;
UCEC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.56	-5.06	-0.38	1.26e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.66	6.18	0.45	5.93e-9	Menarche (age at onset);
UCEC	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-4.55	-0.35	1.12e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.42	4.98	0.38	1.77e-6	QRS complex (12-leadsum);
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.21	0.71	4.13e-24	Platelet count;
UCEC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.53	-5.08	-0.39	1.11e-6	Initial pursuit acceleration;
UCEC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-6.2	-0.46	5.3e-9	Gut microbiome composition (summer);
UCEC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg13147721	chr7:65941812	NA	-0.96	-6.5	-0.47	1.2e-9	Gout;
UCEC	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.58	0.53	3.63e-12	Total body bone mineral density;
UCEC	cis	rs2167364	0.812	rs2198144	chr7:50574254	A/C	cg18232548	chr7:50535776	DDC	0.52	5.67	0.42	7.48e-8	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.53	5.79	0.43	4.16e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	0.7	6.64	0.48	5.6e-10	Vitiligo;
UCEC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.49	-5.54	-0.42	1.35e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs1008126	0.800	rs2711853	chr7:103161290	C/T	cg18108683	chr7:102477205	FBXL13	-0.42	-4.54	-0.35	1.16e-5	Metabolite levels (Pyroglutamine);
UCEC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg21419209	chr3:44054225	NA	-0.51	-5.31	-0.4	3.89e-7	Coronary artery disease;
UCEC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.74	-8.3	-0.56	6.1e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.48	6.58	0.48	7.56e-10	Bone mineral density;
UCEC	cis	rs1832871	1.000	rs827857	chr6:158706497	C/T	cg07215822	chr6:158701037	NA	-0.5	-4.96	-0.38	1.89e-6	Height;
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.66	7.21	0.51	2.7e-11	Longevity;Endometriosis;
UCEC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05776053	chr2:74358815	NA	0.42	5.14	0.39	8.46e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.45	-4.66	-0.36	6.94e-6	Height;
UCEC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-6.16	-0.45	6.48e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.59	5.34	0.4	3.45e-7	Corneal astigmatism;
UCEC	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.65	-6.08	-0.45	9.85e-9	Vitiligo;
UCEC	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.76	-8.73	-0.58	5.24e-15	Primary sclerosing cholangitis;
UCEC	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.43	5.68	0.42	7.08e-8	Metabolite levels;
UCEC	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.47	-4.97	-0.38	1.84e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.84	9.32	0.61	1.59e-16	Breast cancer;
UCEC	cis	rs73206853	0.764	rs73206857	chr12:110767721	T/A	cg12870014	chr12:110450643	ANKRD13A	0.6	4.91	0.38	2.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-0.61	-7.0	-0.5	8.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.5	-4.92	-0.38	2.32e-6	Aortic root size;
UCEC	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.57	0.66	9.07e-20	Cognitive ability;
UCEC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18252515	chr7:66147081	NA	-0.54	-5.25	-0.4	5.19e-7	Aortic root size;
UCEC	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg23229016	chr1:26872525	RPS6KA1	-0.34	-6.45	-0.47	1.49e-9	Glucose homeostasis traits;
UCEC	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.55	-4.61	-0.36	8.58e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs12980942	0.872	rs11466359	chr19:41837615	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.74	5.75	0.43	4.94e-8	Coronary artery disease;
UCEC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.54	0.58	1.59e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.73	7.19	0.51	2.98e-11	Primary sclerosing cholangitis;
UCEC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.63	6.05	0.45	1.17e-8	Aortic root size;
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18402987	chr7:1209562	NA	0.48	4.93	0.38	2.2e-6	Longevity;Endometriosis;
UCEC	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	4.8	0.37	3.85e-6	Colorectal cancer;
UCEC	cis	rs1122900	1.000	rs1122900	chr5:36689181	A/C	cg24186104	chr5:36689192	NA	-0.54	-5.41	-0.41	2.49e-7	Aggressive periodontitis;
UCEC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.61	4.71	0.36	5.77e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg06265175	chr8:121136014	COL14A1	0.5	5.32	0.4	3.77e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.88	-9.8	-0.63	8.99e-18	Cognitive function;
UCEC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	11.53	0.69	2.67e-22	Chronic sinus infection;
UCEC	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	8.12	0.56	1.74e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.13	0.45	7.79e-9	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	0.64	6.71	0.48	3.88e-10	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-7.25	-0.51	2.2e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.46	4.96	0.38	1.93e-6	Height;
UCEC	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg04731861	chr2:219085781	ARPC2	0.42	4.67	0.36	6.69e-6	Colorectal cancer;
UCEC	cis	rs1007190	0.881	rs9915066	chr17:42962166	C/T	cg15406952	chr17:42872593	NA	0.73	5.7	0.43	6.28e-8	DNA methylation (variation);
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg09120320	chr17:61926383	NA	0.44	4.57	0.35	1.03e-5	Prudent dietary pattern;
UCEC	cis	rs7582720	1.000	rs72932770	chr2:203680954	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.97	0.38	1.81e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.53	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs78487399	0.908	rs74501107	chr2:43806012	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-4.6	-0.35	9.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.64	-4.92	-0.38	2.28e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	7.9	0.55	6.11e-13	Chronic sinus infection;
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.42	4.93	0.38	2.24e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7374004	0.628	rs7374289	chr3:38633071	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	5.79	0.43	4.12e-8	PR interval;
UCEC	cis	rs9283706	0.641	rs1990894	chr5:66331685	C/T	cg11590213	chr5:66331682	MAST4	0.45	5.8	0.43	3.98e-8	Coronary artery disease;
UCEC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.54	5.94	0.44	1.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.39	-4.76	-0.37	4.66e-6	Menarche (age at onset);
UCEC	cis	rs1940013	0.767	rs7105663	chr11:132231470	T/C	cg11473001	chr11:131780499	NTM	-0.43	-5.0	-0.38	1.62e-6	Sleep-related phenotypes;
UCEC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	6.14	0.45	7.44e-9	Gut microbiome composition (summer);
UCEC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.13	-13.23	-0.74	8.41e-27	Breast cancer;
UCEC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.09	0.39	1.1e-6	Personality dimensions;
UCEC	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg12473912	chr3:136751656	NA	0.44	5.04	0.38	1.34e-6	Gestational age at birth (child effect);
UCEC	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs12635074	0.521	rs12637784	chr3:56318675	C/A	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.76	0.37	4.64e-6	Morning vs. evening chronotype;
UCEC	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.43	-5.05	-0.38	1.29e-6	Smoking behavior;
UCEC	cis	rs7968440	0.931	rs2251024	chr12:51103633	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.65	0.36	7.36e-6	Fibrinogen;
UCEC	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.69	-7.43	-0.52	8.11e-12	Height;
UCEC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.79	-8.75	-0.59	4.53e-15	Menarche (age at onset);
UCEC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.61	5.38	0.41	2.88e-7	Alcohol dependence;
UCEC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg20965017	chr5:231967	SDHA	-0.59	-5.14	-0.39	8.47e-7	Breast cancer;
UCEC	cis	rs7246967	0.673	rs28787949	chr19:22830356	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.74	-9.22	-0.61	2.95e-16	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.1	17.25	0.82	3.87e-37	IgG glycosylation;
UCEC	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.54	-5.42	-0.41	2.43e-7	IgG glycosylation;
UCEC	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-6.63	-0.48	5.91e-10	Height;
UCEC	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg03342759	chr3:160939853	NMD3	0.51	4.75	0.36	4.77e-6	Morning vs. evening chronotype;
UCEC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.85	7.46	0.52	7.06e-12	Blood metabolite levels;
UCEC	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg13593689	chr9:129986794	NA	0.46	4.84	0.37	3.23e-6	Intraocular pressure;
UCEC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg13092806	chr2:177043255	NA	0.53	4.96	0.38	1.89e-6	IgG glycosylation;
UCEC	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs16937	0.711	rs10900471	chr1:205173134	A/G	cg12580275	chr1:205744413	RAB7L1	0.47	5.07	0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.73	6.14	0.45	7.43e-9	Initial pursuit acceleration;
UCEC	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.53	-4.74	-0.36	5.03e-6	Colorectal cancer;
UCEC	cis	rs11118844	0.843	rs58850477	chr1:221927229	G/A	cg04222084	chr1:221915650	DUSP10	-0.83	-6.43	-0.47	1.66e-9	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	5.01	0.38	1.57e-6	Eosinophil percentage of white cells;
UCEC	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	0.87	5.29	0.4	4.37e-7	Blood protein levels;
UCEC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.51	5.28	0.4	4.6e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.61	5.99	0.44	1.58e-8	Post bronchodilator FEV1;
UCEC	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.82e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.47	-5.55	-0.42	1.31e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs12980942	0.935	rs1865052	chr19:41824467	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.6	5.46	0.41	2e-7	Coronary artery disease;
UCEC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.6	-5.8	-0.43	3.9e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-5.23	-0.4	5.84e-7	Dementia with Lewy bodies;
UCEC	cis	rs12318506	0.793	rs71460129	chr12:75699427	C/T	cg04728562	chr12:75699417	CAPS2	-0.88	-5.74	-0.43	5.12e-8	Coronary artery calcification;
UCEC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.68	6.41	0.47	1.9e-9	Cerebrospinal fluid biomarker levels;
UCEC	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-7.46	-0.52	7.04e-12	Exhaled nitric oxide output;
UCEC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.95	0.55	4.44e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10851411	0.697	rs17766258	chr15:42785137	A/G	cg21293051	chr15:42870591	STARD9	-0.75	-4.72	-0.36	5.34e-6	Glucose homeostasis traits;
UCEC	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.53	4.65	0.36	7.19e-6	Menarche (age at onset);
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.97	0.59	1.3e-15	Platelet count;
UCEC	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg05855489	chr10:104503620	C10orf26	-0.47	-4.74	-0.36	5.1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7809615	0.515	rs10257273	chr7:99188589	A/T	cg24650262	chr7:98904301	NA	0.47	4.78	0.37	4.19e-6	Blood metabolite ratios;
UCEC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.75	8.17	0.56	1.33e-13	Menopause (age at onset);
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.45	-5.04	-0.38	1.34e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs6788895	0.661	rs2116685	chr3:150471469	C/T	cg17319849	chr1:155214564	GBA	-0.79	-6.71	-0.48	4e-10	Breast cancer;
UCEC	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.78	-6.13	-0.45	7.6e-9	Calcium levels;
UCEC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.48	4.77	0.37	4.31e-6	Blood metabolite levels;
UCEC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	-0.53	-6.01	-0.44	1.37e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.86e-7	Morning vs. evening chronotype;
UCEC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.54	5.41	0.41	2.45e-7	Menopause (age at onset);
UCEC	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.51	5.01	0.38	1.54e-6	Hemoglobin concentration;
UCEC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.42	0.52	8.58e-12	Homoarginine levels;
UCEC	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.43	-5.85	-0.43	3.06e-8	Alcohol dependence;
UCEC	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.6	5.94	0.44	2.01e-8	Acne (severe);
UCEC	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.64	8.38	0.57	3.92e-14	Anterior chamber depth;
UCEC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.82	8.78	0.59	3.76e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.78	-0.37	4.15e-6	Cardiac Troponin-T levels;
UCEC	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.52	7.61	0.53	3.09e-12	Coronary artery disease or large artery stroke;
UCEC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	15.4	0.79	1.86e-32	Chronic sinus infection;
UCEC	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.73	4.53	0.35	1.23e-5	Alzheimer's disease;
UCEC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.55	6.99	0.5	9.1e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.38	4.61	0.36	8.55e-6	QRS complex (12-leadsum);
UCEC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg07636037	chr3:49044803	WDR6	-0.56	-4.52	-0.35	1.27e-5	Menarche (age at onset);
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg26769984	chr7:1090371	C7orf50	0.49	4.76	0.37	4.56e-6	Longevity;Endometriosis;
UCEC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.6	5.85	0.43	3.02e-8	Aortic root size;
UCEC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.75	8.07	0.55	2.24e-13	Breast cancer;
UCEC	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.65	-7.58	-0.53	3.57e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-5.22	-0.4	5.99e-7	Schizophrenia;
UCEC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.57	6.28	0.46	3.65e-9	Blood metabolite levels;
UCEC	cis	rs7246967	0.673	rs56725192	chr19:22810938	T/G	cg08271804	chr19:22816896	ZNF492	0.61	5.89	0.44	2.54e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.8	-0.37	3.83e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg14288399	chr11:64110785	CCDC88B	-0.49	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.54	4.8	0.37	3.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.71	6.43	0.47	1.66e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.44	-4.59	-0.35	9.55e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7539409	0.833	rs2057083	chr1:84269942	T/G	cg10977910	chr1:84465055	TTLL7	0.79	4.73	0.36	5.16e-6	Alzheimer's disease;
UCEC	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.19	-0.39	6.96e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg13695892	chr22:41940480	POLR3H	0.67	5.17	0.39	7.44e-7	Vitiligo;
UCEC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg11632617	chr15:75315747	PPCDC	-0.5	-5.14	-0.39	8.67e-7	Blood trace element (Zn levels);
UCEC	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06223018	chr3:49557076	DAG1	0.34	4.9	0.37	2.51e-6	Parkinson's disease;
UCEC	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.68	5.11	0.39	1.01e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.72	5.67	0.42	7.26e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs12980942	1.000	rs4456618	chr19:41813957	G/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	5.31	0.4	4.03e-7	Coronary artery disease;
UCEC	cis	rs4705962	0.959	rs6885996	chr5:132021296	C/A	cg27309611	chr5:132113725	SEPT8	0.38	4.99	0.38	1.68e-6	Atopic dermatitis;
UCEC	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg13147721	chr7:65941812	NA	0.74	5.02	0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.5	5.3	0.4	4.17e-7	Type 2 diabetes;
UCEC	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	4.75	0.36	4.89e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg02628002	chr16:89649608	CPNE7	0.43	4.65	0.36	7.35e-6	Tanning;
UCEC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs405956	1.000	rs1018810	chr6:105559609	A/G	cg22580625	chr6:105627791	POPDC3	-0.68	-6.29	-0.46	3.38e-9	QT interval;
UCEC	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.56	5.6	0.42	1.04e-7	Lung cancer;
UCEC	cis	rs9443189	0.502	rs2312933	chr6:76577665	C/T	cg01950844	chr6:76311363	SENP6	-0.71	-5.16	-0.39	7.82e-7	Prostate cancer;
UCEC	cis	rs4851266	0.966	rs4851270	chr2:100832656	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.3	0.46	3.24e-9	Educational attainment;
UCEC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.65	-5.01	-0.38	1.54e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.59	6.02	0.44	1.3e-8	Hepatocellular carcinoma;
UCEC	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.53	4.53	0.35	1.2e-5	Methadone dose in opioid dependence;
UCEC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.58	-6.34	-0.46	2.73e-9	Refractive error;
UCEC	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg24803719	chr17:45855879	NA	-0.47	-5.11	-0.39	1e-6	IgG glycosylation;
UCEC	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.45	-4.91	-0.38	2.35e-6	HDL cholesterol;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.65	-0.42	8.24e-8	Pubertal anthropometrics;
UCEC	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-6.24	-0.46	4.46e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg21191810	chr6:118973309	C6orf204	0.42	5.82	0.43	3.47e-8	Electrocardiographic conduction measures;
UCEC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.67	7.35	0.52	1.27e-11	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.79	8.73	0.58	5.17e-15	Menopause (age at onset);
UCEC	cis	rs1318937	0.764	rs9853971	chr3:15225347	C/T	cg21849552	chr3:14597650	NA	0.49	4.76	0.37	4.62e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.64	0.42	8.27e-8	Cognitive test performance;
UCEC	cis	rs1483890	0.723	rs12629224	chr3:69411188	T/C	cg22125112	chr3:69402811	FRMD4B	0.44	4.64	0.36	7.7e-6	Resting heart rate;
UCEC	cis	rs4784934	0.589	rs12932284	chr16:58468579	C/T	cg27102864	chr16:58535418	NDRG4	0.44	5.13	0.39	9.19e-7	QT interval;
UCEC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.58	-0.48	7.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg14078730	chr11:63896557	MACROD1	-0.44	-4.95	-0.38	1.99e-6	Platelet count;
UCEC	cis	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg23623107	chr2:128284154	IWS1	-0.48	-4.55	-0.35	1.14e-5	Protein C levels;
UCEC	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.93	12.36	0.71	1.6e-24	Metabolic syndrome;
UCEC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.72	-8.31	-0.57	5.95e-14	Waist circumference;Body mass index;
UCEC	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.59	-5.26	-0.4	4.94e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.53	5.43	0.41	2.25e-7	Monocyte percentage of white cells;
UCEC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.53	-5.28	-0.4	4.63e-7	Aortic root size;
UCEC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg10820045	chr2:198174542	NA	-0.47	-5.77	-0.43	4.57e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	6.07	0.45	1.02e-8	Mood instability;
UCEC	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.36	-6.21	-0.46	5.08e-9	Cancer;
UCEC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg08755490	chr11:65554678	OVOL1	-0.49	-5.23	-0.4	5.86e-7	Acne (severe);
UCEC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01380346	chr19:18557039	ELL	-0.51	-5.47	-0.41	1.89e-7	Breast cancer;
UCEC	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.65	6.56	0.48	8.53e-10	C-reactive protein levels;
UCEC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.58	6.48	0.47	1.32e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.88	0.37	2.68e-6	Rheumatoid arthritis;
UCEC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs8020441	0.541	rs67447434	chr14:51156101	G/A	cg04730355	chr14:51134070	SAV1	0.81	7.23	0.51	2.41e-11	Cognitive performance;
UCEC	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.72	7.25	0.51	2.15e-11	Vitamin D levels;
UCEC	cis	rs4146922	0.793	rs62167689	chr2:56009480	A/T	cg00879447	chr2:56412077	CCDC85A	0.47	4.7	0.36	6.04e-6	Height;
UCEC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg24531977	chr5:56204891	C5orf35	-0.6	-5.77	-0.43	4.61e-8	Coronary artery disease;
UCEC	cis	rs2267681	0.508	rs10277705	chr7:139519293	C/G	cg14116596	chr7:139528673	TBXAS1	0.57	5.45	0.41	2.11e-7	Cervical cancer;
UCEC	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.53	-5.83	-0.43	3.34e-8	IgG glycosylation;
UCEC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.65	-7.03	-0.5	7.38e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.71	7.02	0.5	7.69e-11	Type 2 diabetes;
UCEC	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.33	0.46	2.75e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12379764	chr21:47803548	PCNT	0.43	4.82	0.37	3.58e-6	Testicular germ cell tumor;
UCEC	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	8.02	0.55	2.98e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.7	-0.48	4.15e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg01689657	chr7:91764605	CYP51A1	0.46	6.18	0.45	6.02e-9	Breast cancer;
UCEC	cis	rs7246967	0.932	rs34949383	chr19:23033858	G/C	cg08271804	chr19:22816896	ZNF492	0.53	5.23	0.4	5.65e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7646881	0.544	rs7638606	chr3:158286839	A/G	cg05743054	chr3:158288903	MLF1	-0.57	-5.23	-0.4	5.68e-7	Tetralogy of Fallot;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.53	-6.05	-0.45	1.17e-8	Pulmonary function;
UCEC	cis	rs4265793	0.655	rs7185466	chr16:19094796	T/C	cg06773604	chr16:18995157	TMC7	0.75	5.34	0.4	3.41e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg10932868	chr11:921992	NA	0.39	4.63	0.36	8.04e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs16939046	1.000	rs72656161	chr8:76102376	T/A	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	trans	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg09872104	chr7:134855509	C7orf49	-1.05	-6.99	-0.5	8.78e-11	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.51	5.28	0.4	4.63e-7	Longevity;Endometriosis;
UCEC	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg18681998	chr4:17616180	MED28	-0.69	-7.56	-0.53	4.1e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.62	-7.79	-0.54	1.1e-12	Vitiligo;
UCEC	cis	rs3770752	0.866	rs9309004	chr2:37518447	T/A	cg20091297	chr2:37572423	QPCT	0.45	4.66	0.36	6.89e-6	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.02	13.12	0.73	1.6e-26	Chronic sinus infection;
UCEC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-5.3	-0.4	4.11e-7	Aortic root size;
UCEC	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.59	6.18	0.45	6.07e-9	White matter hyperintensity burden;
UCEC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.15	-6.98	-0.5	9.47e-11	Breast cancer;
UCEC	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	5.43	0.41	2.28e-7	Mood instability;
UCEC	cis	rs253959	0.842	rs9326986	chr5:115427056	A/C	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.52	-0.41	1.49e-7	Life satisfaction;
UCEC	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.77	-5.21	-0.39	6.37e-7	Blood pressure (smoking interaction);
UCEC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg07776626	chr8:57350775	NA	-0.47	-5.33	-0.4	3.63e-7	Obesity-related traits;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg00612595	chr21:47717864	NA	-0.55	-6.04	-0.45	1.2e-8	Testicular germ cell tumor;
UCEC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.57	-5.68	-0.42	7.11e-8	White matter hyperintensity burden;
UCEC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.55	-5.07	-0.39	1.19e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.65	-7.38	-0.52	1.06e-11	Extrinsic epigenetic age acceleration;
UCEC	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg17279458	chr3:44753948	ZNF502	-0.43	-4.68	-0.36	6.42e-6	Depressive symptoms;
UCEC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.55	6.11	0.45	8.37e-9	Aortic root size;
UCEC	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-7.07	-0.5	5.75e-11	Response to antipsychotic treatment;
UCEC	cis	rs11825709	1.000	rs908754	chr11:93651071	A/G	cg08980396	chr11:93474735	C11orf54;TAF1D	-0.94	-4.63	-0.36	7.95e-6	Obesity-related traits;
UCEC	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.89	-0.59	2.01e-15	Exhaled nitric oxide output;
UCEC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.5	-5.55	-0.42	1.32e-7	Headache;
UCEC	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.42	-5.78	-0.43	4.33e-8	Metabolite levels;
UCEC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.49	-0.47	1.24e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg14008862	chr17:28927542	LRRC37B2	0.63	4.96	0.38	1.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.64	6.04	0.45	1.22e-8	Sudden cardiac arrest;
UCEC	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg24088508	chr1:38156462	C1orf109	-0.56	-5.01	-0.38	1.54e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.65	6.58	0.48	7.72e-10	Prudent dietary pattern;
UCEC	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.64	7.4	0.52	9.77e-12	Breast cancer;
UCEC	cis	rs7611694	0.501	rs9869141	chr3:113116059	A/G	cg12596171	chr3:113251061	SIDT1	-0.51	-5.23	-0.4	5.66e-7	Prostate cancer;
UCEC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.43	-5.19	-0.39	6.91e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.24	-0.46	4.51e-9	Total cholesterol levels;
UCEC	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.01	6.51	0.47	1.09e-9	Diabetic retinopathy;
UCEC	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.55	-5.69	-0.43	6.55e-8	IgG glycosylation;
UCEC	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.77	5.76	0.43	4.69e-8	Exhaled nitric oxide levels;
UCEC	cis	rs7246967	0.673	rs2361245	chr19:22834530	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	5.78	0.43	4.4e-8	Bone mineral density;
UCEC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.56	6.03	0.45	1.27e-8	Prostate cancer;
UCEC	cis	rs7264396	0.561	rs57545942	chr20:34183479	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.2	-0.39	6.64e-7	Total cholesterol levels;
UCEC	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg24169773	chr3:122142474	KPNA1	-0.67	-4.53	-0.35	1.21e-5	LDL cholesterol levels;
UCEC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.72	5.53	0.41	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	5.13	0.39	8.94e-7	Multiple sclerosis;
UCEC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.57	-4.62	-0.36	8.32e-6	Menopause (age at onset);
UCEC	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg04283868	chr2:201171347	SPATS2L	0.6	5.95	0.44	1.92e-8	QT interval;
UCEC	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.63	6.88	0.49	1.56e-10	Retinal vascular caliber;
UCEC	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg09795085	chr6:101329169	ASCC3	-0.48	-4.53	-0.35	1.19e-5	Neuroticism;
UCEC	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.53	-5.63	-0.42	9.06e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
UCEC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.07	-0.45	1.05e-8	Prudent dietary pattern;
UCEC	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.16	14.2	0.76	2.32e-29	Body mass index;
UCEC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs13437751	0.536	rs10238457	chr7:63349214	T/C	cg00787055	chr7:63562162	NA	0.49	5.1	0.39	1.01e-6	QT interval (drug interaction);
UCEC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg24703168	chr6:28411309	ZSCAN23	0.43	4.9	0.37	2.54e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.83	6.56	0.48	8.76e-10	Lymphocyte counts;
UCEC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.44	-0.74	2.27e-27	Height;
UCEC	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.67	6.14	0.45	7.17e-9	Schizophrenia;
UCEC	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.6	6.93	0.5	1.21e-10	Obesity-related traits;
UCEC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.59	7.13	0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.52	4.89	0.37	2.61e-6	Height;
UCEC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-6.43	-0.47	1.7e-9	Schizophrenia;
UCEC	cis	rs2376682	0.959	rs12515064	chr5:118028928	C/A	cg17593721	chr5:118788746	HSD17B4	0.5	4.61	0.36	8.57e-6	Diisocyanate-induced asthma;
UCEC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6820391	0.781	rs7680855	chr4:54447248	G/A	cg04173182	chr4:54446035	LNX1	0.36	4.54	0.35	1.16e-5	Cervical artery dissection;
UCEC	cis	rs2862064	0.613	rs2862060	chr5:156443895	A/C	cg12943317	chr5:156479607	HAVCR1	-0.67	-5.12	-0.39	9.49e-7	Platelet count;
UCEC	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs17854409	0.764	rs3761301	chr20:61494021	C/T	cg05147244	chr20:61493195	TCFL5	1.02	5.8	0.43	3.83e-8	Obesity-related traits;
UCEC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.46	5.08	0.39	1.11e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs7560272	0.501	rs12624267	chr2:73986931	C/T	cg12436443	chr2:73114314	SPR	-0.45	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.52	-5.06	-0.38	1.25e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.21	8.55	0.58	1.51e-14	Atopic dermatitis;
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.5	5.58	0.42	1.11e-7	Monocyte percentage of white cells;
UCEC	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.59	-4.91	-0.38	2.37e-6	Corneal structure;
UCEC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg24562669	chr7:97807699	LMTK2	0.43	5.26	0.4	5.08e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.6	5.64	0.42	8.39e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
UCEC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.45	4.88	0.37	2.77e-6	Mean corpuscular volume;
UCEC	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.49	-5.06	-0.38	1.25e-6	P wave terminal force;
UCEC	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.71	8.98	0.6	1.19e-15	Testicular germ cell tumor;
UCEC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.49	-4.62	-0.36	8.41e-6	Prostate cancer;
UCEC	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.64	5.97	0.44	1.7e-8	Vitiligo;
UCEC	cis	rs7106204	0.748	rs6484028	chr11:24222438	A/G	ch.11.24196551F	chr11:24239977	NA	0.51	5.15	0.39	8.11e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.85	-7.2	-0.51	2.86e-11	Coronary artery calcification;
UCEC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg22166914	chr1:53195759	ZYG11B	0.59	6.03	0.45	1.26e-8	Monocyte count;
UCEC	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.54	-5.65	-0.42	7.91e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg22166914	chr1:53195759	ZYG11B	0.56	5.56	0.42	1.23e-7	Monocyte count;
UCEC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.49	5.12	0.39	9.46e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.59	5.65	0.42	8.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.71	-7.06	-0.5	6.14e-11	Plateletcrit;Platelet count;
UCEC	cis	rs7246967	0.611	rs3951785	chr19:22851928	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.52	7.3	0.52	1.72e-11	Blood protein levels;
UCEC	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg22166914	chr1:53195759	ZYG11B	0.79	8.62	0.58	9.84e-15	Monocyte count;
UCEC	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-9.55	-0.62	4.16e-17	Blood metabolite levels;
UCEC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg01262667	chr19:19385393	TM6SF2	0.46	6.15	0.45	7.06e-9	Tonsillectomy;
UCEC	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.44	4.7	0.36	5.86e-6	Menopause (age at onset);
UCEC	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.37	5.26	0.4	4.89e-7	Obesity-related traits;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11487977	chr19:9879695	ZNF846	0.62	7.06	0.5	6e-11	Warfarin maintenance dose;
UCEC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg04176532	chr22:50317003	CRELD2	0.51	4.99	0.38	1.69e-6	Schizophrenia;
UCEC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.53	-5.45	-0.41	2.04e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	0.73	6.13	0.45	7.76e-9	Alzheimer's disease;
UCEC	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg18232548	chr7:50535776	DDC	-0.67	-7.49	-0.53	5.85e-12	Body mass index;
UCEC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.76	7.74	0.54	1.47e-12	Parkinson's disease;
UCEC	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.64	6.39	0.47	2.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	4.93	0.38	2.22e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12681287	0.752	rs13262673	chr8:87293600	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-5.38	-0.41	2.93e-7	Caudate activity during reward;
UCEC	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.57	5.67	0.42	7.4e-8	Red cell distribution width;
UCEC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.53	-5.14	-0.39	8.64e-7	Corneal astigmatism;
UCEC	cis	rs13098911	0.540	rs35827997	chr3:46001720	T/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.45	-4.78	-0.37	4.27e-6	Platelet count;
UCEC	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.18	0.39	7.34e-7	Hemoglobin concentration;
UCEC	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	6.0	0.44	1.47e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.7	0.48	4.25e-10	Cognitive test performance;
UCEC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.66	-7.6	-0.53	3.15e-12	Body mass index;
UCEC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.52	7.01	0.5	8.19e-11	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.69	-7.9	-0.55	5.86e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.95	8.79	0.59	3.58e-15	Diastolic blood pressure;
UCEC	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	4.59	0.35	9.37e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6690583	0.623	rs12033900	chr1:85478559	T/C	cg11262906	chr1:85462892	MCOLN2	0.72	4.6	0.35	9.09e-6	Serum sulfate level;
UCEC	cis	rs7709377	0.570	rs1396478	chr5:115454608	A/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.65	-6.01	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.9	-0.37	2.51e-6	Testicular germ cell tumor;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.74	9.46	0.62	6.96e-17	Menarche (age at onset);
UCEC	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.59	-5.91	-0.44	2.34e-8	Bipolar disorder;
UCEC	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.69	0.43	6.53e-8	Menopause (age at onset);
UCEC	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	0.94	11.42	0.69	5.07e-22	Ulcerative colitis;
UCEC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg06768213	chr1:227963296	SNAP47	0.41	5.1	0.39	1.05e-6	Diastolic blood pressure;
UCEC	cis	rs2386661	0.826	rs10905519	chr10:5672483	C/A	cg17085576	chr10:5658249	NA	-0.5	-5.1	-0.39	1.04e-6	Breast cancer;
UCEC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.1	7.99	0.55	3.58e-13	Alzheimer's disease (late onset);
UCEC	cis	rs60311166	1.000	rs56259931	chr3:52574365	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.82	4.65	0.36	7.2e-6	CTACK levels;
UCEC	cis	rs10506710	0.791	rs7975555	chr12:73443125	G/T	cg13663218	chr12:72666976	LOC283392;TRHDE	-0.32	-4.64	-0.36	7.65e-6	Systolic blood pressure;
UCEC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.12e-9	Tonsillectomy;
UCEC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.44	5.12	0.39	9.23e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.43	4.53	0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Morning vs. evening chronotype;
UCEC	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg12580275	chr1:205744413	RAB7L1	0.44	4.93	0.38	2.22e-6	Schizophrenia;
UCEC	cis	rs8042680	0.518	rs6496745	chr15:91532630	C/T	cg14398957	chr15:91536180	PRC1	-0.44	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9463078	0.838	rs9357470	chr6:45065613	C/T	cg25276700	chr6:44698697	NA	-0.47	-5.02	-0.38	1.48e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg08266712	chr14:104979372	NA	-0.43	-4.57	-0.35	1.03e-5	Reticulocyte count;
UCEC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.78	-8.32	-0.57	5.43e-14	Cognitive function;
UCEC	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.66	-5.08	-0.39	1.14e-6	Alcohol dependence;
UCEC	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-5.96	-0.44	1.78e-8	Birth weight;
UCEC	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.6	-4.52	-0.35	1.28e-5	Waist circumference adjusted for body mass index;
UCEC	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.54	-6.11	-0.45	8.56e-9	Aortic root size;
UCEC	cis	rs876084	0.505	rs9297614	chr8:121105444	C/T	cg06265175	chr8:121136014	COL14A1	0.47	5.04	0.38	1.33e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	1.25	5.7	0.43	6.3e-8	Parkinson's disease;
UCEC	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg11150807	chr10:43354902	NA	0.7	4.64	0.36	7.71e-6	Blood protein levels;
UCEC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.95	-7.29	-0.52	1.76e-11	Bone mineral density;
UCEC	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg04837898	chr3:45731254	SACM1L	-0.41	-4.56	-0.35	1.05e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.58	-5.93	-0.44	2.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	1.0	15.24	0.78	4.8e-32	Bone mineral density;
UCEC	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg15848620	chr12:58087721	OS9	-0.51	-4.88	-0.37	2.79e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.71	6.08	0.45	9.95e-9	Coronary artery disease;
UCEC	trans	rs6728642	1.000	rs57035274	chr2:97608124	C/A	cg18463001	chr5:180611085	NA	-0.76	-6.82	-0.49	2.22e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.63	6.21	0.46	5.06e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.62	6.64	0.48	5.73e-10	Motion sickness;
UCEC	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg07741184	chr6:167504864	NA	-0.32	-4.64	-0.36	7.54e-6	Primary biliary cholangitis;
UCEC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.48	-5.01	-0.38	1.52e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.77	-8.71	-0.58	5.75e-15	White blood cell count (basophil);
UCEC	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.89	-7.94	-0.55	4.74e-13	Blood metabolite levels;
UCEC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.56	4.88	0.37	2.78e-6	HDL cholesterol levels;
UCEC	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.78	5.77	0.43	4.53e-8	Exhaled nitric oxide output;
UCEC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg00815214	chr21:47717953	NA	-0.39	-4.56	-0.35	1.08e-5	Testicular germ cell tumor;
UCEC	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.64	-7.27	-0.51	1.92e-11	Ulcerative colitis;
UCEC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.64	-6.41	-0.47	1.83e-9	Lymphocyte counts;
UCEC	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-5.5	-0.41	1.61e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-9.23	-0.61	2.74e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.79	-8.16	-0.56	1.41e-13	Mosquito bite size;
UCEC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.5e-6	Aortic root size;
UCEC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.07	8.88	0.59	2.2e-15	Vitiligo;
UCEC	cis	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg16427743	chr14:65210080	PLEKHG3	-0.44	-5.36	-0.4	3.12e-7	N-glycan levels;
UCEC	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.79	-5.92	-0.44	2.15e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg06784218	chr1:46089804	CCDC17	0.54	6.3	0.46	3.19e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.69	7.37	0.52	1.11e-11	Blood protein levels;
UCEC	cis	rs17818399	0.815	rs35837037	chr2:46861300	C/T	cg21681030	chr2:46777652	RHOQ	0.56	4.51	0.35	1.32e-5	Height;
UCEC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-6.47	-0.47	1.34e-9	Menarche (age at onset);
UCEC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.57	-4.58	-0.35	9.78e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.63	5.54	0.42	1.39e-7	Response to diuretic therapy;
UCEC	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.6e-7	Life satisfaction;
UCEC	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.57	6.04	0.45	1.19e-8	Red blood cell count;
UCEC	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg12292205	chr6:26970375	C6orf41	0.65	7.65	0.53	2.5e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.59	-5.17	-0.39	7.66e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-4.69	-0.36	6.28e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	3.14e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.37	0.57	4.2e-14	Smoking behavior;
UCEC	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.61	-5.49	-0.41	1.68e-7	Monocyte percentage of white cells;
UCEC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.52	-5.49	-0.41	1.74e-7	Prostate cancer;
UCEC	cis	rs6929812	0.546	rs2393962	chr6:27462824	T/C	cg27490387	chr6:26520793	HCG11	-0.42	-4.86	-0.37	3e-6	Neuroticism (multi-trait analysis);
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.66	-0.36	6.94e-6	Pubertal anthropometrics;
UCEC	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.63	5.08	0.39	1.14e-6	Height;
UCEC	cis	rs4148689	1.000	rs34855237	chr7:117199457	A/G	cg21212505	chr7:117228958	CFTR	-0.41	-4.66	-0.36	7.08e-6	Gout;
UCEC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.51	-5.04	-0.38	1.37e-6	Refractive error;
UCEC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.0	-0.64	2.71e-18	Monocyte count;
UCEC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg17652424	chr22:38574118	PLA2G6	-0.42	-5.25	-0.4	5.29e-7	Cutaneous nevi;
UCEC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg14092571	chr14:90743983	NA	-0.45	-6.36	-0.46	2.39e-9	Mortality in heart failure;
UCEC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg13395646	chr4:1353034	KIAA1530	-0.7	-6.15	-0.45	6.97e-9	Obesity-related traits;
UCEC	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	9.79	0.63	9.91e-18	Blood protein levels;
UCEC	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.62	-6.11	-0.45	8.38e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.78	-8.41	-0.57	3.26e-14	Cognitive function;
UCEC	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-0.77	-7.84	-0.54	8.2e-13	Height;
UCEC	cis	rs7246967	0.611	rs62118823	chr19:22844066	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.52	0.35	1.26e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.61	-5.06	-0.39	1.23e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs8067287	0.634	rs7225344	chr17:16840498	C/T	cg25330878	chr17:17379109	MED9	-0.4	-4.53	-0.35	1.21e-5	Diabetic kidney disease;
UCEC	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.99	11.36	0.68	7.36e-22	Cognitive function;
UCEC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-6.67	-0.48	4.92e-10	Platelet distribution width;
UCEC	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg24851651	chr11:66362959	CCS	0.45	5.37	0.41	2.97e-7	Educational attainment (years of education);
UCEC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	4.68	0.36	6.39e-6	Platelet count;
UCEC	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.46	6.45	0.47	1.51e-9	Alcohol dependence;
UCEC	cis	rs12618769	0.597	rs3769737	chr2:99088873	C/G	cg14361474	chr2:99058762	NA	0.47	4.61	0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg24920358	chr1:40204285	PPIE	0.47	4.81	0.37	3.7e-6	Blood protein levels;
UCEC	trans	rs26595	0.545	rs258017	chr5:115809050	C/T	cg02153584	chr22:29168773	CCDC117	-0.67	-6.77	-0.49	2.86e-10	Wegener's granulomatosis;
UCEC	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.66	-4.59	-0.35	9.44e-6	Hair shape;
UCEC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7927997	0.965	rs7927894	chr11:76301316	A/G	cg17647271	chr11:76299819	NA	0.46	4.64	0.36	7.78e-6	Gut microbiota (functional units);Crohn's disease;
UCEC	cis	rs3104435	0.837	rs262609	chr1:31015727	C/T	cg25303761	chr1:31256028	NA	0.48	4.56	0.35	1.07e-5	Low high density lipoprotein cholesterol levels;
UCEC	cis	rs8177876	0.822	rs8177939	chr16:81119196	A/G	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.72	-0.66	3.56e-20	Schizophrenia;
UCEC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.94	10.92	0.67	1.04e-20	Breast cancer;
UCEC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg20007245	chr22:24372913	LOC391322	-0.63	-6.75	-0.49	3.15e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.81e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	0.8	7.09	0.5	5.3e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.47	-6.11	-0.45	8.48e-9	Body mass index;
UCEC	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-0.98	-12.41	-0.72	1.23e-24	Blood pressure (smoking interaction);
UCEC	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.52	-6.19	-0.45	5.72e-9	Attention deficit hyperactivity disorder;
UCEC	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-0.61	-6.67	-0.48	4.75e-10	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.67	5.15	0.39	8.13e-7	Diabetic retinopathy;
UCEC	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg12524725	chr2:239427019	NA	-0.62	-4.5	-0.35	1.36e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	0.94	9.63	0.62	2.53e-17	Heart rate;
UCEC	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg14078730	chr11:63896557	MACROD1	0.65	5.06	0.39	1.22e-6	Mean platelet volume;
UCEC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.87	-0.54	6.93e-13	Joint mobility (Beighton score);
UCEC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.41	4.8	0.37	3.81e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.23	-19.12	-0.84	1.07e-41	Exhaled nitric oxide output;
UCEC	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.59	-6.14	-0.45	7.38e-9	Bipolar disorder;
UCEC	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.66	-0.36	6.9e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-9.6	-0.62	3.03e-17	Blood metabolite levels;
UCEC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.49	-5.49	-0.41	1.73e-7	Longevity;
UCEC	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-4.8	-0.37	3.86e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.31e-5	Dementia with Lewy bodies;
UCEC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.39	4.52	0.35	1.24e-5	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.48e-6	QRS complex (12-leadsum);
UCEC	cis	rs10208940	0.920	rs12713643	chr2:68724129	C/G	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.52	-5.03	-0.38	1.4e-6	Metabolite levels;
UCEC	trans	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg15743833	chr17:6376638	PITPNM3	-0.78	-6.91	-0.5	1.38e-10	Lung cancer;
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg20007245	chr22:24372913	LOC391322	-0.49	-5.26	-0.4	5.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.59	5.83	0.43	3.44e-8	Colorectal cancer;
UCEC	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.61	-6.04	-0.45	1.22e-8	White blood cell count (basophil);
UCEC	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg03609598	chr5:56110824	MAP3K1	-0.62	-4.91	-0.38	2.37e-6	Initial pursuit acceleration;
UCEC	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.45	0.41	2.1e-7	Ileal carcinoids;
UCEC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.56	-6.04	-0.45	1.22e-8	Refractive error;
UCEC	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg00631329	chr6:26305371	NA	-0.44	-5.16	-0.39	7.9e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.29	0.46	3.39e-9	Subjective well-being;
UCEC	cis	rs10924970	0.870	rs2382569	chr1:235469032	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	4.84	0.37	3.21e-6	Asthma;
UCEC	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	0.87	7.01	0.5	7.92e-11	Blood protein levels;
UCEC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.47	0.47	1.35e-9	Alzheimer's disease;
UCEC	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.71	6.45	0.47	1.48e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-4.68	-0.36	6.46e-6	Pediatric autoimmune diseases;
UCEC	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg06521331	chr12:34319734	NA	-0.55	-4.94	-0.38	2.07e-6	Morning vs. evening chronotype;
UCEC	cis	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.46	-4.67	-0.36	6.87e-6	Pubertal anthropometrics;
UCEC	cis	rs883565	0.655	rs6768957	chr3:39100094	G/A	cg01426195	chr3:39028469	NA	-0.74	-9.74	-0.63	1.3e-17	Handedness;
UCEC	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.42	4.9	0.37	2.55e-6	Blood metabolite ratios;
UCEC	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.78	-8.87	-0.59	2.27e-15	Metabolic syndrome;
UCEC	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs12980942	0.872	rs7248164	chr19:41807700	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.58	5.44	0.41	2.15e-7	Coronary artery disease;
UCEC	cis	rs4467006	1.000	rs4467006	chr14:77684670	C/G	cg26375263	chr14:76843202	ESRRB	-0.47	-4.78	-0.37	4.22e-6	Bipolar disorder;
UCEC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.87	10.81	0.67	2.07e-20	Longevity;Endometriosis;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg07836142	chr6:28411423	ZSCAN23	-0.57	-6.23	-0.46	4.62e-9	Pubertal anthropometrics;
UCEC	cis	rs1952138	0.615	rs2339791	chr10:53310770	A/G	cg03780264	chr10:54170977	NA	-0.7	-4.66	-0.36	6.94e-6	IgG glycosylation;
UCEC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.58	5.75	0.43	5.04e-8	Post bronchodilator FEV1;
UCEC	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.79	6.88	0.49	1.62e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7246967	0.673	rs34003335	chr19:22925602	T/C	cg05241461	chr19:22816980	ZNF492	0.56	5.63	0.42	9.06e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-4.86	-0.37	2.94e-6	Gut microbiome composition (summer);
UCEC	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	0.77	9.37	0.61	1.18e-16	Multiple myeloma;
UCEC	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg04553112	chr3:125709451	NA	-0.65	-4.74	-0.36	4.9100000000000004e-06	Blood pressure (smoking interaction);
UCEC	cis	rs883565	0.569	rs7613766	chr3:39152248	C/G	cg01426195	chr3:39028469	NA	-0.64	-7.44	-0.52	7.73e-12	Handedness;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.82	-0.49	2.16e-10	Pubertal anthropometrics;
UCEC	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.53	5.98	0.44	1.63e-8	Hip circumference;
UCEC	cis	rs3736594	0.513	rs60854669	chr2:27786929	T/C	cg27432699	chr2:27873401	GPN1	0.53	5.12	0.39	9.4e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.66	-5.78	-0.43	4.25e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg19413350	chr8:57351067	NA	-0.42	-4.97	-0.38	1.86e-6	Obesity-related traits;
UCEC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg18099408	chr3:52552593	STAB1	0.45	5.15	0.39	8.35e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.83	7.19	0.51	3.12e-11	Longevity;
UCEC	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.49	-4.66	-0.36	6.91e-6	Rheumatoid arthritis;
UCEC	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.58	-5.99	-0.44	1.52e-8	Rheumatoid arthritis;
UCEC	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-7.16	-0.51	3.6e-11	Obesity-related traits;
UCEC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.61	-5.7	-0.43	6.42e-8	Mortality in heart failure;
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.56	6.05	0.45	1.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.38	0.61	1.13e-16	Platelet count;
UCEC	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg21770322	chr7:97807741	LMTK2	-0.42	-5.16	-0.39	7.84e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8074751	0.625	rs6504335	chr17:63634508	G/A	cg04531363	chr17:63634484	CCDC46	0.41	4.69	0.36	6.22e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.48	-5.44	-0.41	2.17e-7	Rheumatoid arthritis;
UCEC	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.74	-8.59	-0.58	1.18e-14	Facial morphology (factor 19);
UCEC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.5	-0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.87	-0.44	2.8e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs1978968	0.700	rs10854521	chr22:18482600	C/T	cg03078520	chr22:18463400	MICAL3	-0.46	-4.64	-0.36	7.68e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.93	0.38	2.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.84	-8.46	-0.57	2.42e-14	Obesity-related traits;
UCEC	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.84	5.58	0.42	1.12e-7	Psoriasis;
UCEC	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.53	6.54	0.47	9.41e-10	Coronary heart disease;
UCEC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	4.93	0.38	2.16e-6	Breast cancer;
UCEC	cis	rs1502337	0.532	rs11065688	chr12:111082142	A/G	cg21426559	chr12:111619406	CUX2	0.48	4.59	0.35	9.49e-6	Body mass index;
UCEC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.83	8.14	0.56	1.5700000000000001e-13	Smoking behavior;
UCEC	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.62	6.76	0.49	3.03e-10	Monocyte count;
UCEC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	7.17	0.51	3.4e-11	Initial pursuit acceleration;
UCEC	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.39	4.73	0.36	5.32e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs4713118	0.868	rs742047	chr6:27739380	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-4.52	-0.35	1.28e-5	Parkinson's disease;
UCEC	cis	rs17718580	0.536	rs56285552	chr14:51044852	G/C	cg04730355	chr14:51134070	SAV1	0.82	8.04	0.55	2.75e-13	Cognitive performance;
UCEC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg05738196	chr6:26577821	NA	0.64	7.61	0.53	2.98e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg20387954	chr3:183756860	HTR3D	0.52	6.23	0.46	4.76e-9	Anterior chamber depth;
UCEC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.96	0.44	1.77e-8	Breast cancer;
UCEC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.7	6.31	0.46	3.14e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-6.7	-0.48	4.14e-10	Blood trace element (Zn levels);
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.41	5.06	0.39	1.24e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg05855489	chr10:104503620	C10orf26	-0.52	-5.52	-0.41	1.5e-7	Waist circumference;Hip circumference;
UCEC	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.24	-0.51	2.32e-11	Heart rate;
UCEC	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg05962950	chr11:130786565	SNX19	0.5	5.16	0.39	7.8e-7	Schizophrenia;
UCEC	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.87	-6.6	-0.48	6.96e-10	Exhaled nitric oxide output;
UCEC	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg26752888	chr8:11627280	NEIL2	1.02	7.31	0.52	1.58e-11	Alcohol dependence;Nicotine use;
UCEC	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.75	-8.37	-0.57	4.03e-14	White blood cell count (basophil);
UCEC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.75	8.25	0.56	8.34e-14	Menopause (age at onset);
UCEC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg12024160	chr4:1254474	NA	0.65	7.46	0.52	7.04e-12	Obesity-related traits;
UCEC	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.68	5.87	0.44	2.76e-8	Adiposity;
UCEC	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.77	-8.81	-0.59	3.15e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.28	0.4	4.66e-7	Birth weight;
UCEC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.58	-5.92	-0.44	2.22e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	6.66	0.48	5.09e-10	Coronary artery disease;
UCEC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.8	0.37	3.89e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.47	4.66	0.36	6.99e-6	Gout;
UCEC	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-0.77	-5.63	-0.42	8.9e-8	Response to hepatitis C treatment;
UCEC	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.48	-6.09	-0.45	9.44e-9	Mean platelet volume;
UCEC	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.57	-5.01	-0.38	1.57e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00692763	chr18:47088373	LIPG	0.56	6.86	0.49	1.82e-10	Warfarin maintenance dose;
UCEC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-1.0	-12.24	-0.71	3.46e-24	Cognitive function;
UCEC	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.52	-6.17	-0.45	6.17e-9	Prostate cancer;
UCEC	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg16329650	chr2:213403929	ERBB4	0.48	4.78	0.37	4.22e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs2734839	0.964	rs12798900	chr11:113298996	G/T	cg14159747	chr11:113255604	NA	0.58	7.54	0.53	4.58e-12	Information processing speed;
UCEC	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	0.74	8.74	0.58	5e-15	Multiple myeloma;
UCEC	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.78	4.61	0.36	8.65e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.46	4.84	0.37	3.3e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg23750338	chr8:142222470	SLC45A4	-0.47	-4.98	-0.38	1.78e-6	Immature fraction of reticulocytes;
UCEC	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.72	6.47	0.47	1.33e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.33	-0.57	5.2e-14	Total cholesterol levels;
UCEC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg03609598	chr5:56110824	MAP3K1	0.52	4.51	0.35	1.29e-5	Type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.14	-0.45	7.32e-9	Prudent dietary pattern;
UCEC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.81	7.81	0.54	9.83e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.63	5.79	0.43	4.12e-8	Major depressive disorder;
UCEC	cis	rs4478037	1.000	rs56733391	chr3:33161434	G/A	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.44	5.12	0.39	9.4e-7	Obesity;
UCEC	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.72	7.15	0.51	3.71e-11	Blood protein levels;
UCEC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.65	-7.24	-0.51	2.31e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg04058563	chr4:185651563	MLF1IP	-0.39	-4.58	-0.35	9.85e-6	Kawasaki disease;
UCEC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06462663	chr19:18546047	ISYNA1	0.44	5.59	0.42	1.09e-7	Breast cancer;
UCEC	cis	rs6460942	1.000	rs7808819	chr7:12297440	C/T	cg06484146	chr7:12443880	VWDE	-0.77	-5.59	-0.42	1.06e-7	Coronary artery disease;
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	7.15	0.51	3.7e-11	Platelet count;
UCEC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-4.69	-0.36	6.06e-6	Waist circumference adjusted for body mass index;
UCEC	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.62	5.64	0.42	8.48e-8	Mammographic density (dense area);
UCEC	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	6.66	0.48	5.2e-10	Menopause (age at onset);
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg05790982	chr4:4861404	MSX1	0.7	7.37	0.52	1.15e-11	Schizophrenia;
UCEC	cis	rs6882076	0.883	rs1553318	chr5:156479323	G/C	cg12943317	chr5:156479607	HAVCR1	-0.56	-6.0	-0.44	1.45e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.38	0.41	2.82e-7	Response to antipsychotic treatment;
UCEC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.55	5.0	0.38	1.62e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg26354017	chr1:205819088	PM20D1	0.79	9.82	0.63	8.12e-18	Menarche (age at onset);
UCEC	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg12024160	chr4:1254474	NA	0.51	5.88	0.44	2.69e-8	Obesity-related traits;
UCEC	cis	rs1430128	0.584	rs872707	chr2:218579511	A/C	cg11417360	chr2:218955163	RUFY4	0.45	4.51	0.35	1.3e-5	Congenital heart disease (inherited effect);
UCEC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.77	10.13	0.64	1.25e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11644478	chr21:40555479	PSMG1	0.59	4.72	0.36	5.44e-6	Cognitive function;
UCEC	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.81	10.95	0.67	9.01e-21	Blood protein levels;
UCEC	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	5.3	0.4	4.25e-7	Bipolar disorder;
UCEC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.95	10.85	0.67	1.65e-20	Breast cancer;
UCEC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.64	6.88	0.49	1.64e-10	Homoarginine levels;
UCEC	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg05660106	chr1:15850417	CASP9	0.96	10.7	0.66	3.98e-20	Systolic blood pressure;
UCEC	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg24130564	chr14:104152367	KLC1	-0.54	-4.68	-0.36	6.38e-6	Reticulocyte count;
UCEC	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg23625390	chr15:77176239	SCAPER	-0.78	-6.94	-0.5	1.19e-10	Blood metabolite levels;
UCEC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg04154034	chr17:28927549	LRRC37B2	0.75	4.61	0.36	8.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.53	5.4	0.41	2.59e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.46	4.64	0.36	7.63e-6	Total body bone mineral density;
UCEC	cis	rs6723108	0.603	rs6430555	chr2:135647659	A/C	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.55	7.04	0.5	6.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs4784256	0.721	rs28529785	chr16:52805172	T/C	cg00925156	chr12:7917828	LOC360030	0.58	6.76	0.49	3.03e-10	Morning vs. evening chronotype;
UCEC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.51	6.9	0.49	1.41e-10	Eye color traits;
UCEC	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg14851346	chr12:38532713	NA	-0.47	-4.59	-0.35	9.36e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg06917450	chr1:38156652	C1orf109	-0.54	-5.24	-0.4	5.4e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1239947	0.826	rs1239948	chr13:51106522	A/T	cg07121900	chr13:50706912	NA	0.33	5.03	0.38	1.4e-6	Height;
UCEC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.71	0.43	6.16e-8	Menarche (age at onset);
UCEC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.6	4.58	0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.48	5.02	0.38	1.47e-6	Gut microbiome composition (summer);
UCEC	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	7.03	0.5	7.14e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.69	5.33	0.4	3.62e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.46	-4.59	-0.35	9.52e-6	Hemoglobin concentration;
UCEC	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.89	-0.59	2.01e-15	Exhaled nitric oxide output;
UCEC	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.53	-5.69	-0.42	6.71e-8	Cardiac Troponin-T levels;
UCEC	cis	rs10242455	0.867	rs2687078	chr7:99304712	C/T	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.48e-6	Blood metabolite levels;
UCEC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.57	6.23	0.46	4.67e-9	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs735860	0.726	rs209517	chr6:53206989	A/T	cg10236188	chr6:53219634	NA	0.44	4.61	0.36	8.54e-6	Glaucoma;
UCEC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.56	-6.01	-0.44	1.43e-8	Prostate cancer;
UCEC	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	2.01e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs41271951	0.512	rs6664387	chr1:151021509	A/G	cg00107782	chr1:151300621	NA	-0.72	-4.83	-0.37	3.45e-6	Blood protein levels;
UCEC	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.14	-0.39	8.43e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.08	-0.45	9.83e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.77	0.37	4.45e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.78	5.84	0.43	3.19e-8	Lymphocyte counts;
UCEC	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	1.16	7.27	0.51	1.92e-11	Sexual dysfunction (female);
UCEC	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.65	6.03	0.45	1.26e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg22563815	chr15:78856949	CHRNA5	-0.41	-5.36	-0.4	3.22e-7	Sudden cardiac arrest;
UCEC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1545257	0.514	rs2584940	chr2:24641639	A/C	cg06627628	chr2:24431161	ITSN2	-0.53	-5.51	-0.41	1.6e-7	Sjögren's syndrome;
UCEC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.43	4.64	0.36	7.56e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg07537917	chr2:241836409	C2orf54	-0.33	-5.12	-0.39	9.62e-7	Urinary metabolites;
UCEC	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-7.12	-0.51	4.41e-11	Coronary artery disease;
UCEC	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.63	-5.41	-0.41	2.51e-7	Coronary artery disease;
UCEC	cis	rs7246967	0.611	rs35355374	chr19:22837701	C/T	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.71	7.09	0.5	5.28e-11	Mosquito bite size;
UCEC	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs9470794	0.920	rs11758747	chr6:38056271	C/T	cg03458162	chr6:37400668	FTSJD2	0.81	5.06	0.39	1.21e-6	Type 2 diabetes;
UCEC	cis	rs773506	0.655	rs4744037	chr9:93932488	C/G	cg03243796	chr9:93920768	NA	-0.39	-5.05	-0.38	1.27e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.71	-8.06	-0.55	2.48e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	0.67	5.35	0.4	3.29e-7	Left atrial antero-posterior diameter;
UCEC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.69	7.72	0.54	1.6e-12	Menopause (age at onset);
UCEC	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.19	8.55	0.58	1.43e-14	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.78	-0.54	1.16e-12	Total cholesterol levels;
UCEC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-8.33	-0.57	5.08e-14	Electrocardiographic conduction measures;
UCEC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg20630560	chr1:228395858	OBSCN	-0.31	-4.54	-0.35	1.16e-5	Diastolic blood pressure;
UCEC	cis	rs13095912	1.000	rs4686666	chr3:185342847	T/C	cg11274856	chr3:185301563	NA	0.54	7.25	0.51	2.25e-11	Systolic blood pressure;
UCEC	trans	rs7246760	0.867	rs2336089	chr19:9849972	C/T	cg02900749	chr2:68251473	NA	-0.99	-7.48	-0.53	6.1e-12	Pursuit maintenance gain;
UCEC	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs7267348	0.550	rs562954	chr20:48092076	A/G	cg24905333	chr20:48732474	UBE2V1;TMEM189-UBE2V1	-0.48	-4.73	-0.36	5.15e-6	Schizophrenia;
UCEC	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg01072550	chr1:21505969	NA	-0.61	-6.27	-0.46	3.85e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.65	-6.0	-0.44	1.49e-8	Aortic root size;
UCEC	cis	rs10497394	0.632	rs7562888	chr2:174295558	A/T	cg12191300	chr2:174873689	NA	0.46	4.6	0.35	9.04e-6	Otitis media (chronic/recurrent);
UCEC	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.18	9.79	0.63	9.71e-18	Vitiligo;
UCEC	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.63	-5.39	-0.41	2.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg01380346	chr19:18557039	ELL	-0.45	-4.63	-0.36	8.14e-6	Breast cancer;
UCEC	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.92	-6.31	-0.46	3.05e-9	Mitochondrial DNA levels;
UCEC	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.71	-0.36	5.68e-6	Body mass index;
UCEC	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg05072774	chr3:49840536	C3orf54	-0.51	-5.26	-0.4	4.9e-7	Resting heart rate;
UCEC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg20387954	chr3:183756860	HTR3D	0.53	6.33	0.46	2.82e-9	Anterior chamber depth;
UCEC	cis	rs7818345	0.967	rs6990357	chr8:19276681	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.43	4.61	0.36	8.78e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.52	-5.04	-0.38	1.33e-6	Cognitive test performance;
UCEC	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-5.82	-0.43	3.49e-8	Heart rate;
UCEC	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.4	4.58	0.35	9.65e-6	Multiple sclerosis;
UCEC	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.05	0.38	1.32e-6	Coronary artery disease;
UCEC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.71	-6.28	-0.46	3.66e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.58	6.39	0.47	2.02e-9	Type 2 diabetes;
UCEC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg13695892	chr22:41940480	POLR3H	-0.65	-5.22	-0.4	6.02e-7	Vitiligo;
UCEC	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.64	6.31	0.46	3.09e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.62	6.4	0.47	1.99e-9	Retinal vascular caliber;
UCEC	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	6.84	0.49	2e-10	Menarche (age at onset);
UCEC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.56	-4.67	-0.36	6.61e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.49	-5.55	-0.42	1.3e-7	Aortic root size;
UCEC	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.72	-8.17	-0.56	1.3e-13	Waist circumference;Body mass index;
UCEC	cis	rs6728642	1.000	rs11890407	chr2:97621647	G/C	cg26665480	chr2:98280029	ACTR1B	-0.72	-6.28	-0.46	3.54e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-7.41	-0.52	9.01e-12	Hemoglobin concentration;
UCEC	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.68	0.36	6.42e-6	Cognitive ability;
UCEC	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.51	-4.72	-0.36	5.5e-6	Diabetic retinopathy;
UCEC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.67	8.12	0.56	1.74e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7212590	0.655	rs34687426	chr17:57997857	A/G	cg10252138	chr17:58120427	NA	-0.72	-4.63	-0.36	7.85e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-0.99	-8.71	-0.58	5.75e-15	White matter hyperintensity burden;
UCEC	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	0.93	9.98	0.64	3.22e-18	Corneal structure;
UCEC	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.31	0.46	3.04e-9	Hip circumference;
UCEC	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg18681998	chr4:17616180	MED28	0.86	10.61	0.66	7.15e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	4.55	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.42	6.01	0.44	1.42e-8	Crohn's disease;
UCEC	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg17279458	chr3:44753948	ZNF502	-0.51	-5.54	-0.42	1.37e-7	Depressive symptoms;
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg21856205	chr7:94953877	PON1	-0.55	-5.28	-0.4	4.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	6.14	0.45	7.49e-9	Response to antipsychotic treatment;
UCEC	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.64	5.99	0.44	1.51e-8	Coronary artery disease;
UCEC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg24562669	chr7:97807699	LMTK2	0.48	5.92	0.44	2.23e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.08	9.05	0.6	8.15e-16	Cannabis dependence symptom count;
UCEC	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.79	-7.94	-0.55	4.77e-13	Menopause (age at onset);
UCEC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg26031613	chr14:104095156	KLC1	0.58	5.63	0.42	8.84e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12018865	chr2:38406881	C2orf58	-0.67	-6.83	-0.49	2.06e-10	Migraine with aura;
UCEC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04709771	chr16:646395	RAB40C	0.42	4.92	0.38	2.31e-6	Height;
UCEC	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.15	8.49	0.57	2.07e-14	Uric acid levels;
UCEC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.65	5.45	0.41	2.09e-7	Initial pursuit acceleration;
UCEC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.39	-0.57	3.64e-14	Blood trace element (Zn levels);
UCEC	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.68	0.36	6.33e-6	Alzheimer's disease;
UCEC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg14780466	chr2:20870812	GDF7	-0.44	-5.5	-0.41	1.61e-7	Abdominal aortic aneurysm;
UCEC	cis	rs9470794	0.915	rs76277811	chr6:37851890	G/C	cg03458162	chr6:37400668	FTSJD2	0.82	4.83	0.37	3.33e-6	Type 2 diabetes;
UCEC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.58	5.92	0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.57	6.1	0.45	8.76e-9	Cognitive function;
UCEC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.48	4.82	0.37	3.5e-6	Obesity-related traits;
UCEC	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.1400000000000003e-13	Parkinson's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21866054	chr4:103748674	UBE2D3	0.65	8.16	0.56	1.4e-13	Warfarin maintenance dose;
UCEC	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.49	4.94	0.38	2.1e-6	Blood metabolite levels;
UCEC	cis	rs6832769	0.961	rs28445925	chr4:56435849	T/C	cg05960024	chr4:56376020	CLOCK	-0.55	-5.51	-0.41	1.55e-7	Personality dimensions;
UCEC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.52	4.64	0.36	7.51e-6	Cholesterol, total;
UCEC	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-4.7	-0.36	5.92e-6	Personality dimensions;
UCEC	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.55	-5.04	-0.38	1.34e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.55	-5.47	-0.41	1.9e-7	Aortic root size;
UCEC	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg25922239	chr6:33757077	LEMD2	0.55	4.91	0.38	2.43e-6	Crohn's disease;
UCEC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.16	-9.17	-0.6	3.99e-16	Gut microbiome composition (summer);
UCEC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.03	0.38	1.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7611694	0.501	rs6438143	chr3:113117829	T/C	cg11138929	chr3:113251189	SIDT1	-0.42	-4.93	-0.38	2.22e-6	Prostate cancer;
UCEC	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg24060327	chr5:131705240	SLC22A5	0.51	5.05	0.38	1.26e-6	Acylcarnitine levels;
UCEC	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	0.94	10.02	0.64	2.44e-18	Breast cancer;
UCEC	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.74	8.53	0.58	1.67e-14	IgG glycosylation;
UCEC	cis	rs4372836	1.000	rs4549034	chr2:28972579	C/T	cg09522027	chr2:28974177	PPP1CB	-0.75	-7.84	-0.54	8.27e-13	Body mass index;
UCEC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.1	0.39	1.05e-6	Colorectal cancer;
UCEC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.35e-7	Breast cancer;
UCEC	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-0.65	-6.22	-0.46	4.85e-9	Acne (severe);
UCEC	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-4.92	-0.38	2.29e-6	Total body bone mineral density;
UCEC	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	0.77	4.85	0.37	3.09e-6	Height;
UCEC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13279522	0.908	rs6990045	chr8:66989935	G/T	cg00269606	chr8:67090928	CRH	0.34	4.62	0.36	8.22e-6	Coronary heart disease event reduction (statin therapy interaction);
UCEC	cis	rs7113850	0.541	rs11826483	chr11:24237730	C/T	ch.11.24196551F	chr11:24239977	NA	0.65	5.25	0.4	5.18e-7	Bone fracture in osteoporosis;
UCEC	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.72	-7.01	-0.5	8.06e-11	Response to antineoplastic agents;
UCEC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.59	4.56	0.35	1.05e-5	Corneal astigmatism;
UCEC	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg01262667	chr19:19385393	TM6SF2	0.5	6.97	0.5	9.7e-11	Tonsillectomy;
UCEC	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.83	0.37	3.4e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	1.23	5.49	0.41	1.75e-7	Parkinson's disease;
UCEC	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.13	-10.68	-0.66	4.52e-20	Vitiligo;
UCEC	cis	rs7246967	0.611	rs60021625	chr19:22829554	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	5.37	0.4	3.05e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.85	0.37	3.11e-6	Multiple sclerosis;
UCEC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg15147215	chr3:52552868	STAB1	-0.56	-5.98	-0.44	1.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-5.26	-0.4	4.9e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs12928939	0.911	rs12917983	chr16:71835243	A/C	cg03805757	chr16:71968109	PKD1L3	-0.46	-4.67	-0.36	6.71e-6	Post bronchodilator FEV1;
UCEC	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	8.46	0.57	2.53e-14	Exhaled nitric oxide output;
UCEC	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.4	4.89	0.37	2.59e-6	Monocyte percentage of white cells;
UCEC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg08807892	chr2:162101083	NA	0.58	6.0	0.44	1.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-1.16	-5.97	-0.44	1.7e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.49	4.54	0.35	1.18e-5	Interstitial lung disease;
UCEC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.85	8.17	0.56	1.3e-13	Alzheimer's disease;
UCEC	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg21419209	chr3:44054225	NA	-0.5	-5.05	-0.38	1.27e-6	Coronary artery disease;
UCEC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.6	0.42	1.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2425143	1.000	rs6058303	chr20:34290281	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.66	-0.36	7.12e-6	Blood protein levels;
UCEC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.84	-7.61	-0.53	2.98e-12	Initial pursuit acceleration;
UCEC	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.6	-0.48	7.15e-10	Caudate activity during reward;
UCEC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-1.09	-6.83	-0.49	2.07e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.41	-0.41	2.49e-7	Pubertal anthropometrics;
UCEC	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.75	-11.62	-0.69	1.53e-22	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.47	4.88	0.37	2.78e-6	Blood protein levels;
UCEC	cis	rs75804782	0.625	rs72984533	chr2:239470005	T/C	cg12524725	chr2:239427019	NA	-0.67	-4.64	-0.36	7.59e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.42	-4.55	-0.35	1.11e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.79	-8.57	-0.58	1.28e-14	Breast cancer;
UCEC	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.52	-4.86	-0.37	2.96e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.78	-7.42	-0.52	8.49e-12	Type 2 diabetes;
UCEC	cis	rs4499344	0.556	rs865659	chr19:33139967	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg18681998	chr4:17616180	MED28	0.9	11.82	0.7	4.49e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg02158880	chr13:53174818	NA	0.52	6.15	0.45	7.1e-9	Lewy body disease;
UCEC	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.26e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.46	5.55	0.42	1.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	5.3	0.4	4.17e-7	IgG glycosylation;
UCEC	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.53	5.55	0.42	1.31e-7	Schizophrenia;
UCEC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18252515	chr7:66147081	NA	0.53	4.97	0.38	1.81e-6	Aortic root size;
UCEC	cis	rs644799	0.864	rs11021349	chr11:95659474	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	4.67	0.36	6.62e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11235843	1.000	rs11235843	chr11:73373996	A/G	cg23931323	chr11:73372278	PLEKHB1	-0.74	-4.78	-0.37	4.22e-6	Hand grip strength;
UCEC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.48	-5.04	-0.38	1.36e-6	Schizophrenia;
UCEC	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.58	4.8	0.37	3.86e-6	Multiple sclerosis;
UCEC	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.6	6.4	0.47	1.91e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.51	4.55	0.35	1.12e-5	Corneal astigmatism;
UCEC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.49	4.92	0.38	2.32e-6	Corneal astigmatism;
UCEC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.04	8.56	0.58	1.4e-14	Gut microbiome composition (summer);
UCEC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg26027669	chr1:92952467	GFI1	-0.47	-4.58	-0.35	9.89e-6	Breast cancer;
UCEC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.76	-7.65	-0.53	2.39e-12	Cognitive function;
UCEC	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.79	4.81	0.37	3.76e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs9341808	0.600	rs2505930	chr6:80837058	A/G	cg08355045	chr6:80787529	NA	0.4	4.81	0.37	3.63e-6	Sitting height ratio;
UCEC	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.86	-10.31	-0.65	4.18e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.04	0.38	1.33e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.43	6.47	0.47	1.39e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.57	6.03	0.45	1.28e-8	Lung cancer;
UCEC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-5.64	-0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.6	5.46	0.41	1.97e-7	Morning vs. evening chronotype;
UCEC	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.82	-8.44	-0.57	2.74e-14	Mosquito bite size;
UCEC	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.5	-0.57	1.98e-14	Blood trace element (Zn levels);
UCEC	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-5.57	-0.42	1.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.53	5.98	0.44	1.59e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4372836	0.964	rs2045884	chr2:28964355	C/T	cg09522027	chr2:28974177	PPP1CB	-0.71	-7.35	-0.52	1.27e-11	Body mass index;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.69	8.62	0.58	9.59e-15	Menarche (age at onset);
UCEC	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-22.9	-0.88	2.41e-50	Myeloid white cell count;
UCEC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.49	5.56	0.42	1.25e-7	Alcohol dependence;
UCEC	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg17652424	chr22:38574118	PLA2G6	-0.39	-4.66	-0.36	6.96e-6	Cutaneous nevi;
UCEC	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.65	6.94	0.5	1.17e-10	Resting heart rate;
UCEC	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.96	-15.18	-0.78	6.53e-32	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7095607	0.777	rs2101483	chr10:69922987	G/A	cg18986048	chr10:69913749	MYPN	0.53	6.29	0.46	3.35e-9	Lung function (FVC);
UCEC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.64	-4.61	-0.36	8.54e-6	Gut microbiome composition (summer);
UCEC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.6	-5.52	-0.41	1.47e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.06	-0.67	4.63e-21	Headache;
UCEC	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-7.25	-0.51	2.18e-11	Response to antipsychotic treatment;
UCEC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.64	-0.36	7.6e-6	Parkinson's disease;
UCEC	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg07636037	chr3:49044803	WDR6	-0.59	-4.7	-0.36	5.97e-6	Menarche (age at onset);
UCEC	cis	rs151997	0.962	rs26088	chr5:50172670	T/G	cg06027927	chr5:50259733	NA	0.55	5.15	0.39	8.1e-7	Callous-unemotional behaviour;
UCEC	cis	rs9864370	1.000	rs9860851	chr3:168919295	G/A	cg18504196	chr3:168331449	C3orf50	0.62	4.75	0.36	4.88e-6	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.5	6.47	0.47	1.36e-9	Cystic fibrosis severity;
UCEC	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.52	-5.26	-0.4	4.97e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.75	-6.15	-0.45	6.84e-9	Schizophrenia;
UCEC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.76	-6.51	-0.47	1.1e-9	Type 2 diabetes;
UCEC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.52	5.21	0.4	6.15e-7	Platelet distribution width;
UCEC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	8.05	0.55	2.57e-13	Alzheimer's disease;
UCEC	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.64	-5.01	-0.38	1.53e-6	Alopecia areata;
UCEC	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.59	7.14	0.51	3.97e-11	Oral cavity cancer;
UCEC	cis	rs7302981	0.775	rs7301566	chr12:50581647	T/C	cg20014596	chr12:50898483	DIP2B	-0.51	-5.02	-0.38	1.47e-6	Systolic blood pressure;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.43	-4.91	-0.38	2.43e-6	Prudent dietary pattern;
UCEC	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg04510874	chr15:91427884	FES	0.42	5.02	0.38	1.48e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.56	0.48	8.66e-10	Aortic root size;
UCEC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.61	-6.93	-0.5	1.26e-10	Waist-hip ratio;
UCEC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.51	5.16	0.39	7.97e-7	Colorectal cancer;
UCEC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.12	13.93	0.75	1.17e-28	Cognitive function;
UCEC	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.49	-4.67	-0.36	6.81e-6	Primary biliary cholangitis;
UCEC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.79	8.55	0.58	1.48e-14	Caffeine consumption;
UCEC	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9403521	0.673	rs3934959	chr6:143979710	A/G	cg18240653	chr6:144019428	PHACTR2	-0.55	-4.58	-0.35	1e-5	Obesity-related traits;
UCEC	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg21905437	chr5:178450457	ZNF879	0.64	7.17	0.51	3.47e-11	Pubertal anthropometrics;
UCEC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg00250761	chr1:31883323	NA	0.41	5.7	0.43	6.48e-8	Alcohol dependence;
UCEC	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.74	-9.36	-0.61	1.26e-16	Leprosy;
UCEC	cis	rs9911578	0.839	rs7214098	chr17:57204632	C/T	cg05425664	chr17:57184151	TRIM37	-0.64	-7.26	-0.51	2.09e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.64	5.88	0.44	2.65e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.42	5.0	0.38	1.65e-6	Mean platelet volume;
UCEC	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.85	-10.42	-0.65	2.17e-19	Brugada syndrome;
UCEC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08822215	chr16:89438651	ANKRD11	-0.54	-5.21	-0.39	6.21e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs10095849	0.680	rs13276944	chr8:39457035	G/A	cg24581462	chr8:38759627	PLEKHA2	0.36	4.61	0.36	8.8e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg04242349	chr17:79082840	BAIAP2	0.48	4.56	0.35	1.09e-5	Myopia (pathological);
UCEC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.52	4.98	0.38	1.76e-6	Systolic blood pressure;
UCEC	cis	rs4851266	1.000	rs13013169	chr2:100814087	A/C	cg14675211	chr2:100938903	LONRF2	0.65	6.2	0.46	5.34e-9	Educational attainment;
UCEC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.61	6.33	0.46	2.84e-9	Smoking behavior;
UCEC	cis	rs2721195	0.967	rs4925809	chr8:145686313	C/T	cg11211951	chr8:145729740	GPT	0.61	7.07	0.5	5.83e-11	Age at first birth;
UCEC	cis	rs259282	0.851	rs174083	chr19:33141180	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.77	7.74	0.54	1.47e-12	Schizophrenia;
UCEC	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	5.13	0.39	9.12e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	0.92	7.65	0.53	2.44e-12	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	5.13	0.39	9.13e-7	Ileal carcinoids;
UCEC	cis	rs7072216	0.881	rs2274247	chr10:100150148	G/C	cg19567339	chr10:100142640	NA	0.62	8.76	0.59	4.32e-15	Metabolite levels;
UCEC	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.67	7.23	0.51	2.42e-11	Breast cancer;
UCEC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg01072550	chr1:21505969	NA	-0.56	-5.41	-0.41	2.49e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.47	4.7	0.36	6.01e-6	Corneal astigmatism;
UCEC	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-5.78	-0.43	4.25e-8	Chronic sinus infection;
UCEC	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.92	0.38	2.31e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.7	8.44	0.57	2.8e-14	Longevity;
UCEC	cis	rs7246967	0.673	rs57736314	chr19:22880272	T/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.51	4.63	0.36	7.83e-6	Alzheimer's disease;
UCEC	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg20302342	chr1:156215951	PAQR6	0.53	5.45	0.41	2.03e-7	Tonsillectomy;
UCEC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.64	7.78	0.54	1.15e-12	Height;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.56	4.98	0.38	1.76e-6	Longevity;
UCEC	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-6.01	-0.44	1.36e-8	Eye color traits;
UCEC	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.38	-4.68	-0.36	6.4e-6	Subjective well-being;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18151425	chr2:69093574	BMP10	-0.63	-6.78	-0.49	2.66e-10	Migraine with aura;
UCEC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.1e-7	Hemoglobin concentration;
UCEC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-5.62	-0.42	9.14e-8	Obesity-related traits;
UCEC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.49	-5.2	-0.39	6.64e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs10924970	0.934	rs3856241	chr1:235429692	G/A	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.84e-6	Asthma;
UCEC	cis	rs7766436	0.885	rs1954272	chr6:22586499	A/G	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs7246967	0.673	rs4933027	chr19:22903972	A/C	cg05241461	chr19:22816980	ZNF492	-0.53	-5.56	-0.42	1.24e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.29	0.4	4.27e-7	Rheumatoid arthritis;
UCEC	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.68	0.48	4.64e-10	Coffee consumption (cups per day);
UCEC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.67	6.8	0.49	2.39e-10	Smoking behavior;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.43	-4.76	-0.37	4.54e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.42	5.1	0.39	1.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.91	8.62	0.58	9.52e-15	Colorectal adenoma (advanced);
UCEC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.51	7.11	0.51	4.79e-11	Homoarginine levels;
UCEC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg21770322	chr7:97807741	LMTK2	0.52	6.47	0.47	1.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.65	5.55	0.42	1.29e-7	Body mass index;
UCEC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.84	-0.37	3.24e-6	Menarche (age at onset);
UCEC	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.8	5.93	0.44	2.04e-8	Red blood cell count;
UCEC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.51	4.98	0.38	1.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	0.5	5.49	0.41	1.72e-7	Yeast infection;
UCEC	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.48	4.71	0.36	5.77e-6	Mean platelet volume;
UCEC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.93	10.65	0.66	5.43e-20	Multiple sclerosis;
UCEC	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.83	9.42	0.61	9.16e-17	Ulcerative colitis;
UCEC	cis	rs7246967	0.541	rs74169641	chr19:22830576	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	5.73	0.43	5.47e-8	Monocyte percentage of white cells;
UCEC	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg13147721	chr7:65941812	NA	0.9	6.08	0.45	9.9e-9	Diabetic kidney disease;
UCEC	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs7088591	0.867	rs73290938	chr10:59784657	C/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9470794	1.000	rs28740822	chr6:38008290	G/A	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.71	6.69	0.48	4.41e-10	Parkinson's disease;
UCEC	cis	rs2474937	0.535	rs4659080	chr1:118923069	A/T	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.05e-5	Congenital heart malformation;
UCEC	cis	rs7101446	0.704	rs9665872	chr11:63185629	G/T	cg21706343	chr11:62521476	ZBTB3	-0.53	-4.51	-0.35	1.29e-5	Economic and political preferences;
UCEC	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.28	-0.4	4.5e-7	Bone mineral density;
UCEC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.31	4.52	0.35	1.25e-5	Crohn's disease;
UCEC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.42	0.41	2.42e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	7.09	0.51	5.1e-11	Cognitive test performance;
UCEC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.63	9.25	0.61	2.4e-16	Prudent dietary pattern;
UCEC	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.42	-5.7	-0.43	6.36e-8	IgG glycosylation;
UCEC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.81	8.98	0.6	1.21e-15	Menopause (age at onset);
UCEC	cis	rs1978968	0.763	rs9605475	chr22:18463306	T/C	cg03078520	chr22:18463400	MICAL3	-0.55	-6.95	-0.5	1.08e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.75	-0.43	4.91e-8	Prudent dietary pattern;
UCEC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.93	0.38	2.23e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8177876	0.822	rs1412	chr16:81115842	A/G	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg01874867	chr7:94954059	PON1	-0.55	-4.83	-0.37	3.44e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.55	-5.09	-0.39	1.09e-6	Plateletcrit;Platelet count;
UCEC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg09998033	chr7:158218633	PTPRN2	0.51	5.45	0.41	2.1e-7	Obesity-related traits;
UCEC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg12024160	chr4:1254474	NA	-0.51	-5.5	-0.41	1.65e-7	Obesity-related traits;
UCEC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.64	7.18	0.51	3.28e-11	Menarche (age at onset);
UCEC	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-5.33	-0.4	3.68e-7	Body mass index;
UCEC	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.98	-7.13	-0.51	4.12e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.06	-8.18	-0.56	1.24e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-6.63	-0.48	5.91e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	8.58	0.58	1.23e-14	Platelet count;
UCEC	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	4.54	0.35	1.16e-5	Lung function (FEV1/FVC);
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.33	-0.4	3.69e-7	Pubertal anthropometrics;
UCEC	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.65	-0.53	2.46e-12	Coronary artery disease;
UCEC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-4.52	-0.35	1.27e-5	Hemoglobin concentration;
UCEC	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.41	14.99	0.78	2.08e-31	Atopic dermatitis;
UCEC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.91	-8.83	-0.59	2.94e-15	Lymphocyte counts;
UCEC	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.74	0.7	7.26e-23	Chronic sinus infection;
UCEC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.67	-0.36	6.82e-6	Bipolar disorder;
UCEC	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg24562669	chr7:97807699	LMTK2	0.43	5.31	0.4	3.99e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg20368463	chr18:77673604	PQLC1	-0.63	-4.76	-0.37	4.67e-6	Schizophrenia;
UCEC	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	7.4	0.52	9.47e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.77	0.75	3.19e-28	Height;
UCEC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.65	0.36	7.3e-6	Menopause (age at onset);
UCEC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.8	0.37	3.87e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2502731	0.583	rs3003579	chr9:130995751	C/G	cg09976142	chr9:130955436	CIZ1	0.5	5.75	0.43	5.04e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.7	9.61	0.62	2.87e-17	Itch intensity from mosquito bite;
UCEC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.67	0.36	6.77e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg10523679	chr1:76189770	ACADM	-0.46	-4.92	-0.38	2.28e-6	Daytime sleep phenotypes;
UCEC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs7955901	0.591	rs6581987	chr12:71432168	G/T	cg24606773	chr12:72148487	RAB21	0.62	4.77	0.37	4.46e-6	Type 2 diabetes;
UCEC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	7.61	0.53	3.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.11	-0.39	9.98e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.81	-0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.57	5.77	0.43	4.49e-8	Immature fraction of reticulocytes;
UCEC	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.57	-4.98	-0.38	1.74e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.74	-8.25	-0.56	8.27e-14	Blood protein levels;
UCEC	cis	rs7307889	1.000	rs57049008	chr12:5980788	T/C	cg10294363	chr12:6480192	SCNN1A	0.63	4.99	0.38	1.7e-6	Obesity-related traits;
UCEC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.42	5.43	0.41	2.24e-7	Bone mineral density;
UCEC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.74	-7.01	-0.5	7.96e-11	Response to antineoplastic agents;
UCEC	cis	rs256277	0.597	rs459277	chr5:111365635	C/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-4.54	-0.35	1.15e-5	Coronary artery disease;
UCEC	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg24703168	chr6:28411309	ZSCAN23	0.5	5.38	0.41	2.91e-7	Pubertal anthropometrics;
UCEC	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18932078	chr1:2524107	MMEL1	-0.33	-5.38	-0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.62	5.57	0.42	1.2e-7	Corneal astigmatism;
UCEC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.59	5.69	0.43	6.56e-8	Type 2 diabetes;
UCEC	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.71	-6.86	-0.49	1.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.68	8.03	0.55	2.83e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.47	-4.71	-0.36	5.77e-6	Glomerular filtration rate;
UCEC	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.38	-4.86	-0.37	2.98e-6	Thyroid hormone levels;
UCEC	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.53	7.12	0.51	4.49e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.45	4.98	0.38	1.78e-6	HDL cholesterol;
UCEC	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.52	-4.87	-0.37	2.9e-6	Morning vs. evening chronotype;
UCEC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.04	-0.45	1.19e-8	Aortic root size;
UCEC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-10.0	-0.64	2.79e-18	Electrocardiographic conduction measures;
UCEC	cis	rs2970992	0.764	rs2942885	chr2:101322332	C/T	cg01042948	chr2:101319752	NA	0.51	5.41	0.41	2.55e-7	Educational attainment;
UCEC	cis	rs11697848	1.000	rs55994402	chr20:48467013	C/T	cg17849948	chr20:48532315	SPATA2	1.03	5.08	0.39	1.13e-6	Systemic lupus erythematosus;
UCEC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs3914502	0.593	rs578337	chr3:174489253	G/C	cg21145449	chr3:174580620	NAALADL2	-0.42	-4.67	-0.36	6.86e-6	Autism spectrum disorder;
UCEC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.58	6.49	0.47	1.24e-9	Hip circumference;
UCEC	cis	rs713477	0.967	rs8020152	chr14:55907025	T/A	cg13175173	chr14:55914753	NA	-0.41	-4.63	-0.36	8.04e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg14092571	chr14:90743983	NA	0.45	5.21	0.39	6.22e-7	Mortality in heart failure;
UCEC	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-4.56	-0.35	1.08e-5	Total cholesterol levels;
UCEC	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg16583315	chr14:65563665	MAX	0.43	5.68	0.42	6.83e-8	Obesity-related traits;
UCEC	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.46	5.86	0.44	2.86e-8	HDL cholesterol levels;
UCEC	cis	rs11958404	0.932	rs72816587	chr5:157434144	T/A	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.66	5.12	0.39	9.35e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.4	5.6	0.42	1e-7	Crohn's disease;
UCEC	cis	rs17027625	1	rs17027625	chr3:31445580	A/G	cg15835817	chr3:32433905	CMTM7	-0.86	-4.7	-0.36	6.06e-6	HIV-1 control;
UCEC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.61	0.36	8.76e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.43	-4.91	-0.38	2.41e-6	Response to antineoplastic agents;
UCEC	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.47	1.11e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.56	5.22	0.4	6e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.94	0.7	2.1e-23	Prudent dietary pattern;
UCEC	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.56	5.1	0.39	1.01e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg19554555	chr3:13937349	NA	-0.59	-5.82	-0.43	3.49e-8	Ovarian reserve;
UCEC	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.42	4.51	0.35	1.34e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12367572	0.620	rs2731054	chr12:45410570	T/C	cg03114573	chr12:45410052	DBX2	-0.6	-7.33	-0.52	1.42e-11	Gut microbiome composition (summer);
UCEC	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.47	4.67	0.36	6.86e-6	Methadone dose in opioid dependence;
UCEC	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.84	-7.62	-0.53	2.8e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.64	6.29	0.46	3.35e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.66	-7.73	-0.54	1.57e-12	Vitiligo;
UCEC	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.15	-0.45	6.96e-9	Personality dimensions;
UCEC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.07	-0.39	1.17e-6	Personality dimensions;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg07836142	chr6:28411423	ZSCAN23	-0.53	-5.82	-0.43	3.57e-8	Cardiac Troponin-T levels;
UCEC	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.75	8.59	0.58	1.18e-14	Facial morphology (factor 19);
UCEC	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg04804543	chr8:142233427	SLC45A4	-0.52	-6.3	-0.46	3.34e-9	Immature fraction of reticulocytes;
UCEC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg23950597	chr19:37808831	NA	-0.64	-5.0	-0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs4372836	0.704	rs966250	chr2:28974139	G/T	cg09522027	chr2:28974177	PPP1CB	-0.85	-9.11	-0.6	5.59e-16	Body mass index;
UCEC	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	trans	rs10886558	0.565	rs10886554	chr10:121743563	T/C	cg14429847	chr1:239550578	NA	0.57	7.56	0.53	3.97e-12	Shingles;
UCEC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.6	-7.58	-0.53	3.65e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.56	-5.7	-0.43	6.33e-8	White matter hyperintensity burden;
UCEC	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-7.44	-0.52	7.71e-12	Response to antipsychotic treatment;
UCEC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.72	-6.86	-0.49	1.82e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.84	8.04	0.55	2.66e-13	Colorectal cancer;
UCEC	cis	rs9815925	0.702	rs9869435	chr3:184756694	G/A	cg00151007	chr3:184769954	VPS8	0.46	4.84	0.37	3.2e-6	Heschl's gyrus morphology;
UCEC	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.3	0.46	3.2e-9	Hip circumference;
UCEC	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	9.78	0.63	1.04e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs8105895	0.935	rs62112920	chr19:22227149	A/G	cg02912127	chr19:22235281	ZNF257	-0.58	-4.69	-0.36	6.25e-6	Body mass index (change over time);
UCEC	cis	rs282587	0.569	rs447717	chr13:113415038	A/G	cg23551120	chr13:113375848	ATP11A	-0.36	-4.56	-0.35	1.05e-5	Glycated hemoglobin levels;
UCEC	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.67	7.9	0.55	5.86e-13	Mean corpuscular volume;
UCEC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.7	8.37	0.57	4.07e-14	Breast cancer;
UCEC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.54	5.07	0.39	1.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg17267710	chr20:61161232	C20orf166;MIR133A2	-0.35	-4.66	-0.36	7.11e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7517126	1.000	rs57809726	chr1:196841377	A/G	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg17800788	chr1:21766015	NBPF3	0.38	5.43	0.41	2.28e-7	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.67	0.36	6.87e-6	Educational attainment;
UCEC	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.74	-8.06	-0.55	2.37e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.75	8.24	0.56	8.54e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.61	5.47	0.41	1.9e-7	Corneal astigmatism;
UCEC	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.89	-0.44	2.55e-8	Prudent dietary pattern;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.51	4.86	0.37	3.02e-6	Vitiligo;
UCEC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.44	-4.98	-0.38	1.74e-6	Alcohol dependence;
UCEC	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg19426459	chr12:132554069	EP400	0.67	6.95	0.5	1.13e-10	Lung cancer;
UCEC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.47e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7246967	0.611	rs3931771	chr19:22896820	A/G	cg08271804	chr19:22816896	ZNF492	0.68	6.63	0.48	6.02e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs12505328	0.514	rs7699342	chr4:174390593	G/A	cg22660207	chr4:174320772	SCRG1	-0.46	-4.67	-0.36	6.82e-6	Chin dimples;
UCEC	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	0.87	8.32	0.57	5.49e-14	Breast cancer;
UCEC	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.71	-7.99	-0.55	3.63e-13	White blood cell count (basophil);
UCEC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.47	-4.57	-0.35	1.03e-5	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	6.07	0.45	1.04e-8	Bone mineral density;
UCEC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.56	5.38	0.41	2.84e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs6746896	0.708	rs994430	chr2:97439001	A/T	cg01950434	chr2:97203154	ARID5A	-0.46	-5.08	-0.39	1.14e-6	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg17105886	chr17:28927953	LRRC37B2	0.51	4.8	0.37	3.79e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.67	-5.96	-0.44	1.8e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.61	5.65	0.42	8.03e-8	Type 2 diabetes;
UCEC	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.62	-6.83	-0.49	2.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.54	5.72	0.43	5.85e-8	Multiple myeloma;
UCEC	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.45	-0.41	2.09e-7	Eye color traits;
UCEC	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.9	9.95	0.63	3.73e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-5.88	-0.44	2.65e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.41	-4.56	-0.35	1.09e-5	Height;
UCEC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.65	5.93	0.44	2.05e-8	Corneal astigmatism;
UCEC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.5	-4.55	-0.35	1.1e-5	Bipolar disorder;
UCEC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.72	6.77	0.49	2.8e-10	High light scatter reticulocyte count;
UCEC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.6	4.91	0.38	2.4e-6	Menopause (age at onset);
UCEC	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg21905437	chr5:178450457	ZNF879	0.63	7.08	0.5	5.36e-11	Pubertal anthropometrics;
UCEC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.8	7.14	0.51	3.98e-11	Longevity;
UCEC	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-7.78	-0.54	1.15e-12	Ulcerative colitis;
UCEC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	7.02	0.5	7.76e-11	Total body bone mineral density;
UCEC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.82	0.59	3.14e-15	Blood protein levels;
UCEC	cis	rs9309473	1.000	rs6546835	chr2:73664715	G/A	cg20560298	chr2:73613845	ALMS1	-0.65	-5.93	-0.44	2.05e-8	Metabolite levels;
UCEC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.56	-4.96	-0.38	1.96e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6722750	0.818	rs12104940	chr2:64385774	A/G	cg22352474	chr2:64371530	PELI1	0.58	5.49	0.41	1.73e-7	Neuroticism;
UCEC	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	0.98	8.21	0.56	1.04e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	5.01	0.38	1.54e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.52	-5.06	-0.38	1.25e-6	Schizophrenia;
UCEC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg19645103	chr12:69753606	YEATS4	-0.56	-5.0	-0.38	1.62e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.59	5.44	0.41	2.21e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.09	0.45	9.47e-9	Cognitive test performance;
UCEC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	1.05	12.37	0.71	1.55e-24	Diastolic blood pressure;
UCEC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	6.61	0.48	6.5e-10	Platelet distribution width;
UCEC	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg14851346	chr12:38532713	NA	-0.47	-4.59	-0.35	9.36e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs17718580	1.000	rs17718580	chr14:50973632	A/G	cg04730355	chr14:51134070	SAV1	-1.05	-5.04	-0.38	1.38e-6	Cognitive performance;
UCEC	cis	rs7709377	0.570	rs10065554	chr5:115426746	T/C	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg08461772	chr7:95026248	PON3	0.4	5.47	0.41	1.87e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.51	-5.31	-0.4	3.97e-7	Height;
UCEC	cis	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg16814680	chr8:91681699	NA	0.49	5.34	0.4	3.46e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6032067	0.759	rs1007138	chr20:43816835	A/C	cg00873616	chr20:43920241	NA	0.4	4.52	0.35	1.27e-5	Blood protein levels;
UCEC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.9	10.84	0.67	1.74e-20	Breast cancer;
UCEC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.42	4.51	0.35	1.34e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7709377	0.570	rs11738674	chr5:115443149	C/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	9.5	0.62	5.39e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs17012589	0.639	rs10862966	chr12:85705255	G/A	cg02569458	chr12:86230093	RASSF9	0.39	4.53	0.35	1.22e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.52	5.63	0.42	8.97e-8	Tonsillectomy;
UCEC	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.49	5.19	0.39	6.93e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.72	0.58	5.62e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4588572	0.643	rs10440686	chr5:77688331	A/G	cg11547950	chr5:77652471	NA	0.47	5.42	0.41	2.44e-7	Triglycerides;
UCEC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg08027265	chr7:2291960	NA	-0.46	-4.91	-0.38	2.4e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg05132306	chr1:1846340	CALML6	-0.36	-4.59	-0.35	9.46e-6	Body mass index;
UCEC	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.61	-6.29	-0.46	3.44e-9	Mortality in heart failure;
UCEC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.78	0.37	4.17e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs58521262	0.556	rs289322	chr19:23157270	G/T	cg08486875	chr19:23386892	NA	-0.32	-4.55	-0.35	1.09e-5	Testicular germ cell tumor;
UCEC	cis	rs139320	1	rs139320	chr22:39501196	T/C	cg15548613	chr22:38610795	MAFF	0.45	4.62	0.36	8.39e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs321358	0.731	rs536579	chr11:111016472	T/C	cg08305652	chr11:111469057	NA	0.42	4.52	0.35	1.26e-5	Body mass index;
UCEC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	0.97	6.87	0.49	1.66e-10	Alzheimer's disease (late onset);
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.47	0.41	1.85e-7	Platelet count;
UCEC	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg22771759	chr13:24902376	NA	-0.42	-4.72	-0.36	5.38e-6	Obesity-related traits;
UCEC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.72	0.36	5.43e-6	Tonsillectomy;
UCEC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.85	6.71	0.48	3.87e-10	Body mass index;
UCEC	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-1.01	-11.72	-0.7	8.01e-23	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs2213920	0.679	rs6415819	chr9:118212492	A/C	cg13918206	chr9:118159781	DEC1	0.77	4.73	0.36	5.15e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs12635074	0.547	rs35721039	chr3:56267809	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.36	4.51	0.35	1.29e-5	Morning vs. evening chronotype;
UCEC	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.47	-5.05	-0.38	1.27e-6	Coronary heart disease;
UCEC	cis	rs1519814	0.696	rs2139439	chr8:121037091	A/G	cg22335954	chr8:121166405	COL14A1	-0.59	-4.59	-0.35	9.31e-6	Breast cancer;
UCEC	cis	rs6670533	0.571	rs1055703	chr1:24863478	A/C	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.21	0.51	2.72e-11	Platelet count;
UCEC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.53	6.76	0.49	2.96e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.81	-10.05	-0.64	2.01e-18	White blood cell count (basophil);
UCEC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.45	-4.63	-0.36	7.97e-6	Breast cancer;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.53	-5.59	-0.42	1.06e-7	Cardiac Troponin-T levels;
UCEC	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.56	6.66	0.48	5.15e-10	Oral cavity cancer;
UCEC	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.51	5.15	0.39	8.41e-7	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.5	-5.01	-0.38	1.52e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.55	-5.47	-0.41	1.9e-7	Breast cancer;
UCEC	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg01072550	chr1:21505969	NA	-0.53	-5.01	-0.38	1.57e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.47	-4.83	-0.37	3.35e-6	Body mass index;
UCEC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.6	-6.5	-0.47	1.2e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.87	10.01	0.64	2.65e-18	Menopause (age at onset);
UCEC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.69	5.64	0.42	8.55e-8	Smoking initiation;
UCEC	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.86	-0.59	2.46e-15	Exhaled nitric oxide output;
UCEC	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.55	-5.09	-0.39	1.09e-6	Plateletcrit;Platelet count;
UCEC	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.58	6.27	0.46	3.85e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1576263	0.967	rs162282	chr6:8553033	T/A	cg07606381	chr6:8435919	SLC35B3	0.44	4.53	0.35	1.2e-5	Photic sneeze reflex;
UCEC	cis	rs16932667	0.857	rs10774296	chr12:5137306	T/C	cg18770669	chr12:5541220	NTF3	0.41	4.57	0.35	1.01e-5	Intelligence (childhood);
UCEC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13683864	chr3:40499215	RPL14	-0.98	-9.95	-0.63	3.82e-18	Renal cell carcinoma;
UCEC	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.39	-4.56	-0.35	1.05e-5	Subjective well-being;
UCEC	cis	rs2554380	0.891	rs2244838	chr15:84298598	C/T	cg25130800	chr15:85143846	ZSCAN2	-0.57	-4.67	-0.36	6.86e-6	Height;
UCEC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3015497	0.648	rs10144512	chr14:51082271	A/C	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.34e-6	Mean platelet volume;
UCEC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg04756594	chr16:24857601	SLC5A11	0.42	5.11	0.39	1.01e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18252515	chr7:66147081	NA	0.54	5.25	0.4	5.27e-7	Aortic root size;
UCEC	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	5.32	0.4	3.73e-7	Response to antipsychotic treatment;
UCEC	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	0.83	9.02	0.6	9.49e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg23625390	chr15:77176239	SCAPER	0.48	4.77	0.37	4.33e-6	Blood metabolite levels;
UCEC	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.37	-4.58	-0.35	9.73e-6	Height;
UCEC	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.14	-0.39	8.6e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.44	-4.8	-0.37	3.93e-6	Blood metabolite levels;
UCEC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg14008862	chr17:28927542	LRRC37B2	0.62	4.87	0.37	2.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-10.61	-0.66	6.94e-20	Ulcerative colitis;
UCEC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.47	-0.41	1.89e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.09	9.05	0.6	8.14e-16	Vitiligo;
UCEC	cis	rs6761276	0.899	rs11891557	chr2:113835319	G/A	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.38	0.52	1.07e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.63	5.33	0.4	3.59e-7	Alzheimer's disease;
UCEC	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.49	0.41	1.73e-7	Hemoglobin concentration;
UCEC	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-4.69	-0.36	6.23e-6	Bladder cancer;
UCEC	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.46	4.88	0.37	2.69e-6	Schizophrenia;
UCEC	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.38	0.47	2.16e-9	Coffee consumption (cups per day);
UCEC	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.67	-7.53	-0.53	4.64e-12	Resting heart rate;
UCEC	cis	rs17122693	0.710	rs77598393	chr14:51159342	T/G	cg04730355	chr14:51134070	SAV1	0.83	7.9	0.55	6.07e-13	Cognitive performance;
UCEC	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg01072550	chr1:21505969	NA	-0.59	-6.19	-0.45	5.65e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.63	5.22	0.4	5.89e-7	Obesity-related traits;
UCEC	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs6722750	0.933	rs4671555	chr2:64411137	C/G	cg22352474	chr2:64371530	PELI1	-0.47	-4.67	-0.36	6.63e-6	Neuroticism;
UCEC	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.37	-4.69	-0.36	6.29e-6	Bone mineral density (spine);
UCEC	cis	rs786425	0.711	rs1060637	chr12:124110122	A/T	cg26804387	chr12:123758006	CDK2AP1	-0.39	-4.64	-0.36	7.72e-6	Pubertal anthropometrics;
UCEC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.88	-0.59	2.18e-15	Menarche (age at onset);
UCEC	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	6.72	0.48	3.67e-10	Menarche (age at onset);
UCEC	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.29	4.59	0.35	9.62e-6	Cancer;
UCEC	cis	rs782107	0.736	rs782110	chr12:58831670	T/C	cg19181132	chr12:59314527	LRIG3	0.48	5.08	0.39	1.11e-6	Interleukin-12p70 levels;
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg26061582	chr7:22766209	IL6	0.59	5.49	0.41	1.73e-7	Lung cancer;
UCEC	cis	rs4478037	1.000	rs59229836	chr3:33162622	T/C	cg19404215	chr3:33155277	CRTAP	0.76	6.07	0.45	1.02e-8	Major depressive disorder;
UCEC	cis	rs16957091	0.647	rs4924705	chr15:43380260	C/T	cg15904908	chr15:43213022	TTBK2	0.48	4.74	0.36	4.93e-6	MGMT methylation in smokers;
UCEC	cis	rs7959452	0.836	rs12827594	chr12:69729434	G/A	cg11871910	chr12:69753446	YEATS4	0.66	6.7	0.48	4.24e-10	Blood protein levels;
UCEC	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.57	-4.89	-0.37	2.62e-6	Type 2 diabetes;
UCEC	cis	rs57502260	0.680	rs7104806	chr11:68222188	C/T	cg16797656	chr11:68205561	LRP5	0.53	4.87	0.37	2.79e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.66	-5.55	-0.42	1.27e-7	Alopecia areata;
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.6	5.15	0.39	8.07e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.68	9.16	0.6	4.17e-16	Systolic blood pressure;
UCEC	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg02158880	chr13:53174818	NA	0.52	6.15	0.45	7.1e-9	Lewy body disease;
UCEC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.58	5.03	0.38	1.39e-6	Response to diuretic therapy;
UCEC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.6	0.48	7.02e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-6.82	-0.49	2.18e-10	Eye color traits;
UCEC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-6.2	-0.46	5.3e-9	Gut microbiome composition (summer);
UCEC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg13147721	chr7:65941812	NA	-0.75	-5.07	-0.39	1.19e-6	Diabetic kidney disease;
UCEC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.67	6.78	0.49	2.75e-10	Body mass index;
UCEC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg00343986	chr7:65444356	GUSB	-0.51	-4.52	-0.35	1.29e-5	Aortic root size;
UCEC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.74	-9.39	-0.61	1.03e-16	Cancer (pleiotropy);
UCEC	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.69	5.49	0.41	1.73e-7	Neutrophil percentage of white cells;
UCEC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.45	-0.47	1.49e-9	Aortic root size;
UCEC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-8.61	-0.58	1.05e-14	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.65	-7.76	-0.54	1.28e-12	IgG glycosylation;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg08461772	chr7:95026248	PON3	0.35	4.86	0.37	3.01e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-12.62	-0.72	3.28e-25	Myeloid white cell count;
UCEC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.48	4.63	0.36	7.88e-6	Gait speed in old age;
UCEC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.4	4.71	0.36	5.59e-6	Obesity-related traits;
UCEC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.88	-0.44	2.69e-8	Life satisfaction;
UCEC	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs11235843	0.929	rs67488767	chr11:73432689	A/C	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.67	9.77	0.63	1.12e-17	Height;
UCEC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.52	4.59	0.35	9.36e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.42	5.43	0.41	2.27e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-5.46	-0.41	2e-7	Total cholesterol levels;
UCEC	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg22654517	chr2:96458247	NA	0.43	4.94	0.38	2.1e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.68	0.58	6.96e-15	Platelet count;
UCEC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.73	0.49	3.47e-10	Aortic root size;
UCEC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg23795048	chr12:9217529	LOC144571	0.4	4.82	0.37	3.59e-6	Sjögren's syndrome;
UCEC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg23307798	chr14:103986281	CKB	-0.57	-6.72	-0.48	3.69e-10	Body mass index;
UCEC	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.13	0.64	1.29e-18	Cognitive ability;
UCEC	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	0.68	8.74	0.58	4.74e-15	Gut microbiome composition (winter);
UCEC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.21	-0.46	5.1e-9	Crohn's disease;
UCEC	cis	rs11235843	0.929	rs4944033	chr11:73448646	C/T	cg23931323	chr11:73372278	PLEKHB1	0.66	4.53	0.35	1.23e-5	Hand grip strength;
UCEC	cis	rs7246967	0.673	rs34126042	chr19:22909218	G/A	cg24889512	chr19:22816950	ZNF492	0.62	6.6	0.48	7.1e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-5.32	-0.4	3.75e-7	Pediatric autoimmune diseases;
UCEC	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.44	4.56	0.35	1.06e-5	Schizophrenia;
UCEC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-7.01	-0.5	8.19e-11	Mean platelet volume;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg20007245	chr22:24372913	LOC391322	0.62	6.79	0.49	2.59e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg01403660	chr11:68851641	TPCN2	0.44	4.57	0.35	1.02e-5	Hair color;
UCEC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs6832769	0.925	rs2412663	chr4:56455816	C/A	cg05960024	chr4:56376020	CLOCK	-0.56	-5.85	-0.43	3.07e-8	Personality dimensions;
UCEC	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.8	-9.23	-0.61	2.7e-16	Primary sclerosing cholangitis;
UCEC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.76	6.09	0.45	9.48e-9	Neuroticism;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.58	8.34	0.57	4.91e-14	Prudent dietary pattern;
UCEC	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg19567339	chr10:100142640	NA	0.42	4.88	0.37	2.77e-6	Metabolite levels;
UCEC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.49	-5.29	-0.4	4.43e-7	Vitiligo;
UCEC	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-4.92	-0.38	2.28e-6	Height;
UCEC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg05072774	chr3:49840536	C3orf54	-0.56	-5.16	-0.39	8.03e-7	Resting heart rate;
UCEC	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.44	5.14	0.39	8.62e-7	Aortic root size;
UCEC	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	0.62	6.33	0.46	2.78e-9	Vitiligo;
UCEC	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.7	-0.48	4.15e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg24069376	chr3:38537580	EXOG	-0.38	-4.72	-0.36	5.35e-6	Electrocardiographic conduction measures;
UCEC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	5.05	0.38	1.31e-6	Bone mineral density;
UCEC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.61	-6.33	-0.46	2.84e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.56	-5.06	-0.39	1.22e-6	Metabolite levels;
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12379764	chr21:47803548	PCNT	-0.43	-4.56	-0.35	1.05e-5	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.46	0.41	2.01e-7	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.68	0.42	6.95e-8	Breast cancer;
UCEC	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.54	-5.72	-0.43	5.82e-8	Red blood cell count;
UCEC	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.84	-10.19	-0.64	8.65e-19	Brugada syndrome;
UCEC	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.7	7.3	0.52	1.63e-11	Menarche (age at onset);
UCEC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.5	0.57	1.92e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.79	9.58	0.62	3.53e-17	Breast cancer;
UCEC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.69	-6.3	-0.46	3.33e-9	Aortic root size;
UCEC	cis	rs892864	0.685	rs2063248	chr5:127750402	C/G	cg17313118	chr5:127157258	NA	0.67	4.63	0.36	8.13e-6	Multiple system atrophy;
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.95	-12.14	-0.71	6.37e-24	Prudent dietary pattern;
UCEC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.67	-5.95	-0.44	1.89e-8	Aortic root size;
UCEC	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.61	5.01	0.38	1.52e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9532580	0.619	rs2755211	chr13:41142223	C/T	cg21288729	chr13:41239152	FOXO1	0.48	4.8	0.37	3.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.66	-5.88	-0.44	2.65e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.73	9.02	0.6	9.19e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.69e-12	Eye color traits;
UCEC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.63	-4.88	-0.37	2.72e-6	Menopause (age at onset);
UCEC	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.66	4.75e-20	Body mass index;
UCEC	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.59	5.18	0.39	7.16e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg13695892	chr22:41940480	POLR3H	-0.61	-5.25	-0.4	5.29e-7	Vitiligo;
UCEC	cis	rs2179367	0.887	rs506268	chr6:149685617	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.36	-4.99	-0.38	1.68e-6	Dupuytren's disease;
UCEC	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.51	-5.2	-0.39	6.43e-7	Post bronchodilator FEV1;
UCEC	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.48	-6.69	-0.48	4.3e-10	Eye color traits;
UCEC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.41	5.73	0.43	5.39e-8	Crohn's disease;
UCEC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.23	-0.51	2.47e-11	Parkinson's disease;
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.8	8.81	0.59	3.2e-15	Longevity;Endometriosis;
UCEC	cis	rs4713847	1.000	rs4713847	chr6:35239470	A/T	cg03355690	chr6:35265616	DEF6	-0.56	-4.55	-0.35	1.14e-5	Tonsillectomy;
UCEC	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.35	-0.46	2.56e-9	Crohn's disease;
UCEC	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg24069376	chr3:38537580	EXOG	0.47	5.89	0.44	2.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.61	0.69	1.56e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	0.96	10.47	0.65	1.65e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs782107	0.614	rs782087	chr12:58778228	T/C	cg19181132	chr12:59314527	LRIG3	0.45	4.77	0.37	4.45e-6	Interleukin-12p70 levels;
UCEC	cis	rs7797990	0.963	rs4717019	chr7:156011060	G/T	cg24517467	chr7:155284331	NA	0.34	4.58	0.35	9.73e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg06238570	chr21:40685208	BRWD1	0.8	7.04	0.5	6.93e-11	Cognitive function;
UCEC	cis	rs7611694	0.501	rs35935366	chr3:113145642	G/A	cg11138929	chr3:113251189	SIDT1	-0.42	-4.92	-0.38	2.3e-6	Prostate cancer;
UCEC	cis	rs9470794	1.000	rs11753054	chr6:37991800	C/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs12618769	0.652	rs72823788	chr2:99213080	C/T	cg10123293	chr2:99228465	UNC50	0.5	5.44	0.41	2.14e-7	Bipolar disorder;
UCEC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-8.59	-0.58	1.16e-14	Dental caries;
UCEC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.3	-0.4	4.07e-7	Mean platelet volume;
UCEC	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.81	-4.76	-0.37	4.54e-6	Inflammatory biomarkers;
UCEC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-4.63	-0.36	8.05e-6	Dental caries;
UCEC	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	6.34	0.46	2.62e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.92	-10.5	-0.65	1.38e-19	Breast cancer;
UCEC	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg18681998	chr4:17616180	MED28	0.53	5.87	0.44	2.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.65	5.0	0.38	1.58e-6	Corneal astigmatism;
UCEC	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.72	6.46	0.47	1.47e-9	Bipolar disorder;
UCEC	cis	rs7474896	0.832	rs11011401	chr10:38207418	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-4.75	-0.36	4.85e-6	Obesity (extreme);
UCEC	cis	rs11760485	0.893	rs4723685	chr7:4400870	C/A	cg15613991	chr7:5277080	NA	-0.42	-5.08	-0.39	1.12e-6	Early childhood aggressive behavior;
UCEC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.46	0.47	1.43e-9	Aortic root size;
UCEC	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.77	-8.56	-0.58	1.39e-14	Ulcerative colitis;
UCEC	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.61	4.9	0.37	2.46e-6	RR interval (heart rate);
UCEC	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.43	-4.9	-0.37	2.51e-6	Aortic root size;
UCEC	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg20936604	chr3:58311152	NA	-0.59	-4.96	-0.38	1.89e-6	Cholesterol, total;
UCEC	cis	rs10096908	0.892	rs73623029	chr8:41652879	T/G	cg01513060	chr8:40802449	NA	0.68	4.53	0.35	1.2e-5	Hypertension;Blood pressure traits (multi-trait analysis);Systolic blood pressure;
UCEC	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg18681998	chr4:17616180	MED28	0.58	6.57	0.48	8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.56	5.11	0.39	9.87e-7	Educational attainment;
UCEC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.72	6.55	0.48	9.17e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs2386661	0.826	rs4749834	chr10:5671808	G/A	cg17085576	chr10:5658249	NA	-0.49	-4.97	-0.38	1.84e-6	Breast cancer;
UCEC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg11632617	chr15:75315747	PPCDC	-0.62	-7.2	-0.51	2.96e-11	Blood trace element (Zn levels);
UCEC	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	1.01	12.6	0.72	3.79e-25	Colorectal adenoma (advanced);
UCEC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.43	4.68	0.36	6.48e-6	Prudent dietary pattern;
UCEC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg18279126	chr7:2041391	MAD1L1	0.45	5.55	0.42	1.31e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-7.6	-0.53	3.27e-12	Menarche (age at onset);
UCEC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.44	-4.78	-0.37	4.18e-6	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg21770322	chr7:97807741	LMTK2	0.52	6.54	0.47	9.69e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.56	-8.17	-0.56	1.31e-13	Sense of smell;
UCEC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.54	5.58	0.42	1.12e-7	Corneal astigmatism;
UCEC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.66	5.3	0.4	4.09e-7	Smoking initiation;
UCEC	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.57	-6.0	-0.44	1.46e-8	Blood protein levels;
UCEC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-8.7	-0.58	6.16e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg02160872	chr5:212506	CCDC127	0.7	7.4	0.52	9.93e-12	Breast cancer;
UCEC	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.64	7.19	0.51	2.99e-11	Body mass index;
UCEC	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-7.92	-0.55	5.44e-13	Parkinson's disease;
UCEC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.64	-7.0	-0.5	8.28e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.29	-0.46	3.36e-9	Metabolite levels;
UCEC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs34585985	0.792	rs112308052	chr1:210504959	C/T	cg26758551	chr1:209921096	NA	-0.84	-4.56	-0.35	1.07e-5	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in chronic obstructive pulmonary disease;
UCEC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.86	5.98	0.44	1.61e-8	Body mass index;
UCEC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg13575925	chr12:9217583	LOC144571	0.4	4.63	0.36	8.11e-6	Sjögren's syndrome;
UCEC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg05738196	chr6:26577821	NA	0.63	7.44	0.52	7.89e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	4.69	0.36	6.12e-6	Birth weight;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg00651523	chr6:28411279	ZSCAN23	0.52	5.7	0.43	6.25e-8	Cardiac Troponin-T levels;
UCEC	cis	rs9309473	0.519	rs12618600	chr2:73890682	T/C	cg20560298	chr2:73613845	ALMS1	0.53	5.05	0.38	1.28e-6	Metabolite levels;
UCEC	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.44	-4.82	-0.37	3.47e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg16797656	chr11:68205561	LRP5	-0.56	-7.56	-0.53	3.94e-12	Bone mineral density (spine);
UCEC	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg09654669	chr8:57350985	NA	-0.55	-5.62	-0.42	9.35e-8	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.26e-9	Prudent dietary pattern;
UCEC	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.48	6.14	0.45	7.38e-9	HDL cholesterol levels;
UCEC	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg05660106	chr1:15850417	CASP9	0.93	10.44	0.65	1.95e-19	Systolic blood pressure;
UCEC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.46	2.58e-9	Aortic root size;
UCEC	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.62	4.56	0.35	1.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7106204	0.514	rs7126508	chr11:24255147	G/A	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.64	0.58	8.67e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg04202892	chr2:111875749	ACOXL	0.42	4.63	0.36	8.02e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.41	-4.9	-0.37	2.47e-6	Neuroticism;
UCEC	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.45	0.52	7.21e-12	Alzheimer's disease;
UCEC	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.51	4.62	0.36	8.23e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	7.94	0.55	4.66e-13	Tonsillectomy;
UCEC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.35	-0.4	3.35e-7	Breast cancer;
UCEC	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.37e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.41	-5.08	-0.39	1.15e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	7.91	0.55	5.76e-13	Tonsillectomy;
UCEC	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	5.17	0.39	7.63e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.97	13.42	0.74	2.58e-27	Eosinophil percentage of white cells;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.76	-0.49	3.06e-10	Pubertal anthropometrics;
UCEC	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.52	4.69	0.36	6.18e-6	Systemic sclerosis;
UCEC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.56	-5.06	-0.38	1.26e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.88	9.38	0.61	1.14e-16	Cognitive function;
UCEC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.32	4.53	0.35	1.21e-5	Primary biliary cholangitis;
UCEC	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg12580275	chr1:205744413	RAB7L1	0.52	4.82	0.37	3.53e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg16336494	chr6:151188259	MTHFD1L	0.42	4.81	0.37	3.69e-6	Bone mineral density;
UCEC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.97	5.35	0.4	3.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.63	-0.48	5.92e-10	Depression;
UCEC	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.78	8.14	0.56	1.5700000000000001e-13	Mosquito bite size;
UCEC	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.47	5.4	0.41	2.67e-7	Height;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.47	-5.13	-0.39	9.1e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.66	-0.42	7.76e-8	Breast cancer;
UCEC	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg23307798	chr14:103986281	CKB	0.56	5.21	0.39	6.41e-7	Body mass index;
UCEC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.03	0.6	8.67e-16	Alzheimer's disease;
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.59	-5.7	-0.43	6.41e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.61	-5.32	-0.4	3.79e-7	Major depressive disorder;
UCEC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-6.14	-0.45	7.24e-9	Tonsillectomy;
UCEC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg20203395	chr5:56204925	C5orf35	-0.68	-5.2	-0.39	6.53e-7	Initial pursuit acceleration;
UCEC	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-5.25	-0.4	5.15e-7	Life satisfaction;
UCEC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg00343986	chr7:65444356	GUSB	0.49	4.59	0.35	9.31e-6	Aortic root size;
UCEC	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.62	5.7	0.43	6.46e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.55	5.09	0.39	1.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10031466	0.935	rs28637448	chr4:189019896	C/T	cg03652810	chr4:189026682	TRIML2	-0.51	-6.17	-0.45	6.31e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs953387	1.000	rs953387	chr2:136907170	A/C	cg07169764	chr2:136633963	MCM6	0.53	5.26	0.4	4.94e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-7.7	-0.54	1.87e-12	Heart rate;
UCEC	cis	rs7246967	0.673	rs16994997	chr19:22879610	T/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.7	7.64	0.53	2.52e-12	Coronary artery disease;
UCEC	cis	rs4713118	0.868	rs7756968	chr6:27734954	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-4.52	-0.35	1.28e-5	Parkinson's disease;
UCEC	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.55	5.32	0.4	3.81e-7	Blood metabolite levels;
UCEC	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.69	-6.77	-0.49	2.93e-10	Menopause (age at onset);
UCEC	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2084898	0.527	rs561498	chr11:120002927	C/T	cg07435449	chr11:120005650	TRIM29	0.51	5.38	0.41	2.83e-7	Stroke (pediatric);
UCEC	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.87	0.37	2.79e-6	Aortic root size;
UCEC	cis	rs8020441	0.945	rs72681670	chr14:51169272	C/T	cg04730355	chr14:51134070	SAV1	0.58	5.4	0.41	2.59e-7	Cognitive performance;
UCEC	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.73	0.36	5.21e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg17640201	chr16:30407289	ZNF48	0.57	5.78	0.43	4.23e-8	Tonsillectomy;
UCEC	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.05	-0.38	1.27e-6	Coronary artery disease;
UCEC	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.53	-0.35	1.21e-5	Response to antipsychotic treatment;
UCEC	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.94e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9467773	1.000	rs12665431	chr6:26577308	T/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.44	-6.16	-0.45	6.64e-9	Prostate cancer;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.07	-0.39	1.15e-6	Pulmonary function;
UCEC	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.74	7.94	0.55	4.72e-13	Acylcarnitine levels;
UCEC	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.9	10.32	0.65	4.06e-19	Ulcerative colitis;
UCEC	cis	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg01165560	chr11:49911386	NA	-0.31	-4.72	-0.36	5.54e-6	Coronary artery disease;
UCEC	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg05962950	chr11:130786565	SNX19	0.46	4.57	0.35	1.02e-5	Schizophrenia;
UCEC	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg04202892	chr2:111875749	ACOXL	0.45	4.94	0.38	2.09e-6	Chronic lymphocytic leukemia;
UCEC	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.97	7.23	0.51	2.5e-11	Blood pressure (smoking interaction);
UCEC	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	6.51	0.47	1.13e-9	Alzheimer's disease;
UCEC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	6.4	0.47	1.94e-9	Motion sickness;
UCEC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.74	0.36	5.07e-6	Height;
UCEC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.72	4.91	0.38	2.37e-6	Alzheimer's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03469472	chr1:173991446	NA	0.62	7.81	0.54	9.98e-13	Warfarin maintenance dose;
UCEC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.55	-5.15	-0.39	8.18e-7	Cognitive function;
UCEC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.53	5.95	0.44	1.91e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9810089	0.843	rs834304	chr3:136111658	G/T	cg21827317	chr3:136751795	NA	0.46	4.51	0.35	1.33e-5	Gestational age at birth (child effect);
UCEC	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.58	6.17	0.45	6.41e-9	Obesity-related traits;
UCEC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs7870753	1.000	rs7024214	chr9:99239173	T/C	cg25260653	chr9:99212216	HABP4	0.48	4.86	0.37	3.02e-6	Height;
UCEC	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.72	8.38	0.57	3.96e-14	Coronary artery disease;
UCEC	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.21	0.39	6.3e-7	Electroencephalogram traits;
UCEC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.65	-0.42	7.91e-8	Pancreatic cancer;
UCEC	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.13	0.39	9.05e-7	Rheumatoid arthritis;
UCEC	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.59	6.67	0.48	4.96e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.59	0.42	1.09e-7	Breast cancer;
UCEC	cis	rs883565	0.655	rs4676628	chr3:39095965	G/A	cg01426195	chr3:39028469	NA	-0.75	-9.85	-0.63	6.98e-18	Handedness;
UCEC	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg14078730	chr11:63896557	MACROD1	0.62	4.85	0.37	3.14e-6	Mean platelet volume;
UCEC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.49	-4.55	-0.35	1.12e-5	Coronary artery disease;
UCEC	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg03342759	chr3:160939853	NMD3	-0.54	-5.28	-0.4	4.66e-7	Kawasaki disease;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.62	6.89	0.49	1.55e-10	Menarche (age at onset);
UCEC	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.4e-8	Height;
UCEC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.64	7.1	0.51	4.97e-11	Monocyte count;
UCEC	cis	rs9831754	0.756	rs2872626	chr3:78435049	A/T	cg06138941	chr3:78371609	NA	-0.72	-5.56	-0.42	1.23e-7	Calcium levels;
UCEC	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg26138937	chr11:71823887	C11orf51	1.02	4.53	0.35	1.22e-5	Severe influenza A (H1N1) infection;
UCEC	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.74	8.17	0.56	1.28e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.53	-5.14	-0.39	8.7e-7	Total body bone mineral density;
UCEC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.43	0.52	8.34e-12	Tonsillectomy;
UCEC	cis	rs17123764	0.710	rs12310510	chr12:50066244	T/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.49	0.41	1.76e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg27489772	chr12:121021490	NA	-0.57	-5.23	-0.4	5.66e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.57	-6.35	-0.46	2.54e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs1318937	0.748	rs78988883	chr3:15277507	C/T	cg08692541	chr3:14716288	C3orf20	0.68	4.78	0.37	4.2e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.86	0.37	2.94e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg00105475	chr2:10696890	NA	0.46	5.6	0.42	1.02e-7	Prostate cancer;
UCEC	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg12317470	chr15:67143691	NA	0.62	5.34	0.4	3.44e-7	Lung cancer (smoking interaction);
UCEC	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.53	-5.32	-0.4	3.84e-7	Asthma;
UCEC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.24	-0.65	6.48e-19	Monocyte count;
UCEC	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	4.51	0.35	1.3e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	0.91	9.1	0.6	5.79e-16	Heart rate;
UCEC	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.5	4.94	0.38	2.12e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	trans	rs6479901	0.895	rs907	chr10:64936679	A/G	cg12751693	chr12:62629162	NA	-0.59	-7.44	-0.52	7.85e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.58	5.25	0.4	5.17e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.54	4.7	0.36	5.81e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs12618769	0.597	rs72819996	chr2:99059983	G/A	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.81	-5.64	-0.42	8.3e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.61	5.75	0.43	5.04e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.49	5.57	0.42	1.16e-7	Oropharynx cancer;
UCEC	cis	rs7246967	0.932	rs34622638	chr19:23063652	C/T	cg24889512	chr19:22816950	ZNF492	0.53	4.94	0.38	2.11e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.63	7.28	0.51	1.86e-11	Mean corpuscular volume;
UCEC	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.66	6.34	0.46	2.69e-9	Cognitive ability;
UCEC	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.27	6.12	0.45	8.29e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4668356	1.000	rs16859121	chr2:171882754	A/G	cg13882835	chr2:172017928	TLK1	-0.66	-4.56	-0.35	1.09e-5	Cognitive performance;
UCEC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.35	-0.46	2.51e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.53	4.53	0.35	1.2e-5	Neutrophil percentage of white cells;
UCEC	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.59	5.46	0.41	1.99e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18252515	chr7:66147081	NA	0.58	5.41	0.41	2.51e-7	Aortic root size;
UCEC	trans	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg06410510	chr2:107458059	ST6GAL2	0.76	6.93	0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.7	-7.29	-0.52	1.74e-11	Cognitive function;
UCEC	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.13	-0.56	1.62e-13	Exhaled nitric oxide output;
UCEC	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.63	-6.05	-0.45	1.13e-8	Rheumatoid arthritis;
UCEC	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.84	-10.11	-0.64	1.47e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg22166914	chr1:53195759	ZYG11B	-0.64	-7.01	-0.5	8.17e-11	Monocyte count;
UCEC	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	0.68	7.5	0.53	5.68e-12	Gut microbiome composition (winter);
UCEC	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.16	-11.1	-0.68	3.61e-21	Ulcerative colitis;
UCEC	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.46	-6.36	-0.46	2.36e-9	Height;
UCEC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	8.53	0.58	1.68e-14	Alzheimer's disease;
UCEC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.42	-4.91	-0.38	2.41e-6	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.51	4.89	0.37	2.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-7.1	-0.51	5e-11	Menopause (age at onset);
UCEC	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-9.08	-0.6	6.84e-16	Ulcerative colitis;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.48	-5.77	-0.43	4.46e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	0.9	9.07	0.6	6.89e-16	Total cholesterol levels;
UCEC	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	trans	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg15509575	chr4:2286509	ZFYVE28	0.39	6.94	0.5	1.16e-10	Rheumatoid arthritis;
UCEC	cis	rs4272720	0.950	rs56027486	chr10:50275532	T/C	cg12771178	chr10:50342081	FAM170B	-0.43	-4.53	-0.35	1.19e-5	Platelet count;Plateletcrit;
UCEC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.68e-16	Breast cancer;
UCEC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg14008862	chr17:28927542	LRRC37B2	0.52	4.51	0.35	1.29e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01973587	chr1:228161476	NA	0.38	4.98	0.38	1.79e-6	Diastolic blood pressure;
UCEC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg23791538	chr6:167370224	RNASET2	0.51	5.28	0.4	4.59e-7	Primary biliary cholangitis;
UCEC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg02160872	chr5:212506	CCDC127	-0.72	-7.37	-0.52	1.12e-11	Breast cancer;
UCEC	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	1.09	9.98	0.64	3.07e-18	Corneal structure;
UCEC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.46	4.59	0.35	9.31e-6	Body mass index;
UCEC	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.51	4.7	0.36	5.91e-6	Uric acid levels;
UCEC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	7.12	0.51	4.46e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-0.98	-12.41	-0.72	1.23e-24	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-4.69	-0.36	6.19e-6	Platelet distribution width;
UCEC	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.74	0.36	4.94e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.56	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg24375607	chr4:120327624	NA	0.48	5.04	0.38	1.34e-6	Corneal astigmatism;
UCEC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg18099408	chr3:52552593	STAB1	0.43	5.09	0.39	1.1e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-9.64	-0.62	2.4e-17	Ulcerative colitis;
UCEC	cis	rs7088591	1.000	rs76080267	chr10:59786029	C/T	cg11142981	chr10:60273225	BICC1	0.64	4.52	0.35	1.26e-5	Blood pressure;
UCEC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.65	6.49	0.47	1.25e-9	Coronary artery disease;
UCEC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.83	7.1	0.51	4.87e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-6.04	-0.45	1.23e-8	Platelet count;
UCEC	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.58	6.76	0.49	3.01e-10	Mean corpuscular volume;
UCEC	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.75	-7.69	-0.54	1.94e-12	Mosquito bite size;
UCEC	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.57	-7.46	-0.52	6.94e-12	Corneal structure;
UCEC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	6.78	0.49	2.7e-10	Homoarginine levels;
UCEC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg20999797	chr1:1681921	NA	0.36	4.81	0.37	3.65e-6	Body mass index;
UCEC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.63	0.36	8.03e-6	Parkinson's disease;
UCEC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.47	-4.54	-0.35	1.15e-5	Cystic fibrosis severity;
UCEC	cis	rs17012589	0.869	rs35338871	chr12:85681136	C/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.47	-4.62	-0.36	8.29e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.87	10.53	0.66	1.12e-19	Breast cancer;
UCEC	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.65	-6.22	-0.46	4.85e-9	Acne (severe);
UCEC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg05802129	chr4:122689817	NA	-0.54	-5.54	-0.42	1.36e-7	Type 2 diabetes;
UCEC	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg13683864	chr3:40499215	RPL14	0.49	5.04	0.38	1.35e-6	Renal cell carcinoma;
UCEC	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.36	-0.4	3.12e-7	Neutrophil percentage of white cells;
UCEC	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.74	-11.13	-0.68	2.92e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.35	-4.53	-0.35	1.22e-5	Refractive error;
UCEC	cis	rs3750082	0.889	rs13230763	chr7:32912965	C/T	cg05721444	chr7:32995514	FKBP9	0.52	5.83	0.43	3.42e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg23791538	chr6:167370224	RNASET2	-0.47	-4.82	-0.37	3.49e-6	Primary biliary cholangitis;
UCEC	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.62	6.5	0.47	1.18e-9	Retinal vascular caliber;
UCEC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	6.98	0.5	9.4e-11	Platelet count;
UCEC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21178979	chr7:1889533	MAD1L1	0.39	5.24	0.4	5.5e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg26741686	chr4:186318356	ANKRD37	-0.27	-4.51	-0.35	1.34e-5	Kawasaki disease;
UCEC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.4	4.59	0.35	9.32e-6	Pulse pressure;
UCEC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Parkinson's disease;
UCEC	cis	rs6600233	0.770	rs7185768	chr16:165781	G/A	cg02353723	chr16:163133	C16orf35	-0.61	-6.9	-0.49	1.43e-10	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-6.3	-0.46	3.31e-9	Hypospadias;
UCEC	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.54	-6.1	-0.45	9.1e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.64	-0.36	7.59e-6	Breast cancer;
UCEC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg20965017	chr5:231967	SDHA	-0.66	-6.12	-0.45	7.99e-9	Breast cancer;
UCEC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs2267681	0.583	rs764746	chr7:139530089	G/A	cg14116596	chr7:139528673	TBXAS1	0.52	5.13	0.39	8.92e-7	Cervical cancer;
UCEC	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.41e-6	Putamen volume;
UCEC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg03609598	chr5:56110824	MAP3K1	-0.55	-4.7	-0.36	5.88e-6	Coronary artery disease;
UCEC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg27153327	chr16:1920815	C16orf73	0.42	4.78	0.37	4.22e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.55	-4.52	-0.35	1.28e-5	Colorectal cancer;
UCEC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.77	8.47	0.57	2.38e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.09	-0.39	1.07e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.86	-6.39	-0.47	2.05e-9	Multiple sclerosis;
UCEC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.54	6.28	0.46	3.67e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg18681998	chr4:17616180	MED28	0.78	7.8	0.54	1.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.6	-4.72	-0.36	5.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg01380346	chr19:18557039	ELL	-0.47	-4.78	-0.37	4.2e-6	Breast cancer;
UCEC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.66	6.15	0.45	6.86e-9	Aortic root size;
UCEC	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg21197973	chr3:49027347	P4HTM	1.01	4.63	0.36	7.92e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.8	-8.39	-0.57	3.6e-14	Breast cancer;
UCEC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18252515	chr7:66147081	NA	-0.5	-5.13	-0.39	9.08e-7	Aortic root size;
UCEC	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.7	5.62	0.42	9.12e-8	Schizophrenia;
UCEC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-0.94	-7.02	-0.5	7.77e-11	Body mass index;
UCEC	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	1.04	11.99	0.7	1.6e-23	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.54	-4.98	-0.38	1.75e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.61	5.22	0.4	5.94e-7	Bipolar disorder;
UCEC	cis	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg12964065	chr18:77638022	KCNG2	-0.32	-4.67	-0.36	6.72e-6	Opioid sensitivity;
UCEC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.72	8.04	0.55	2.76e-13	Chronic sinus infection;
UCEC	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg24299074	chr11:15133087	INSC	-0.36	-4.68	-0.36	6.33e-6	Vitamin D levels;
UCEC	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.96	0.44	1.77e-8	Platelet count;
UCEC	cis	rs9309473	0.500	rs2421664	chr2:73858881	C/T	cg20560298	chr2:73613845	ALMS1	0.54	5.2	0.39	6.62e-7	Metabolite levels;
UCEC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.52	6.01	0.44	1.43e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6715284	0.579	rs78269632	chr2:202453235	G/T	cg23517999	chr2:202814523	NA	-0.56	-4.57	-0.35	1.01e-5	Rheumatoid arthritis;
UCEC	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.57	-5.55	-0.42	1.28e-7	Large artery stroke;
UCEC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.71	8.35	0.57	4.61e-14	Menopause (age at onset);
UCEC	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	6.88	0.49	1.62e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.53	4.64	0.36	7.6e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.59	5.0	0.38	1.59e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.45	4.55	0.35	1.11e-5	Initial pursuit acceleration;
UCEC	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg05660106	chr1:15850417	CASP9	1.06	12.01	0.7	1.35e-23	Systolic blood pressure;
UCEC	cis	rs10053502	0.867	rs10078497	chr5:40047633	T/A	cg01062838	chr5:40831429	RPL37	0.64	4.56	0.35	1.08e-5	Myopia (pathological);
UCEC	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.71	8.9	0.59	1.95e-15	Mean platelet volume;
UCEC	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.7	-7.96	-0.55	4.32e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.89	-9.69	-0.62	1.76e-17	Cognitive function;
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.72	8.5	0.57	1.96e-14	Menarche (age at onset);
UCEC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg00316803	chr15:76480434	C15orf27	-0.45	-5.18	-0.39	7.17e-7	Blood metabolite levels;
UCEC	cis	rs12545912	0.609	rs12549128	chr8:9799769	C/T	cg18461678	chr8:10472980	RP1L1	0.47	4.67	0.36	6.8e-6	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.62	-5.84	-0.43	3.28e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.93	-0.44	2.1e-8	Platelet count;
UCEC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg04154034	chr17:28927549	LRRC37B2	0.76	5.35	0.4	3.27e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.53	-5.39	-0.41	2.7e-7	Breast cancer;
UCEC	cis	rs7246967	0.608	rs370734	chr19:23012586	C/G	cg05241461	chr19:22816980	ZNF492	0.45	4.55	0.35	1.12e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg24687543	chr11:63912206	MACROD1	0.44	5.14	0.39	8.73e-7	Platelet count;
UCEC	cis	rs883565	0.740	rs11708354	chr3:39115626	A/T	cg01426195	chr3:39028469	NA	-0.68	-8.51	-0.57	1.83e-14	Handedness;
UCEC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.64	5.91	0.44	2.31e-8	Corneal astigmatism;
UCEC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.46	-6.53	-0.47	1.02e-9	Metabolite levels;
UCEC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg13147721	chr7:65941812	NA	-0.94	-6.91	-0.49	1.4e-10	Diabetic kidney disease;
UCEC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.51	-4.98	-0.38	1.74e-6	Refractive error;
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg05855489	chr10:104503620	C10orf26	0.48	5.31	0.4	3.96e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.58	5.47	0.41	1.92e-7	Uric acid levels;
UCEC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.31	-0.52	1.61e-11	Obesity-related traits;
UCEC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.54	-4.91	-0.38	2.43e-6	Systemic lupus erythematosus;
UCEC	cis	rs7106204	0.614	rs117122818	chr11:24245880	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	4.57	0.35	1.04e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.46	5.17	0.39	7.66e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.54	-4.64	-0.36	7.67e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.46	4.72	0.36	5.4e-6	Schizophrenia;
UCEC	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.52	5.51	0.41	1.56e-7	Schizophrenia;
UCEC	cis	rs2415984	0.846	rs8009287	chr14:46838876	A/G	cg14871534	chr14:47121158	RPL10L	0.4	4.62	0.36	8.23e-6	Number of children ever born;
UCEC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg19318889	chr4:1322082	MAEA	0.55	5.71	0.43	6.09e-8	Obesity-related traits;
UCEC	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.41	4.74	0.36	5.01e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg16583315	chr14:65563665	MAX	-0.43	-5.77	-0.43	4.61e-8	Obesity-related traits;
UCEC	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.54	6.12	0.45	7.96e-9	Breast size;
UCEC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-5.13	-0.39	9.11e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.4	5.26	0.4	5.03e-7	Alcohol dependence;
UCEC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.35	-5.47	-0.41	1.9e-7	Ulcerative colitis;
UCEC	cis	rs7246967	0.673	rs34425596	chr19:22899779	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.68	0.48	4.67e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg10932868	chr11:921992	NA	0.38	4.64	0.36	7.61e-6	Alzheimer's disease (late onset);
UCEC	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.29	5.97	0.44	1.67e-8	Cognitive function;
UCEC	cis	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg00614314	chr15:82944287	LOC80154	0.54	5.02	0.38	1.5e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.62	-6.58	-0.48	7.69e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	1.000	rs8113312	chr19:23061182	G/C	cg08271804	chr19:22816896	ZNF492	0.54	5.02	0.38	1.48e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.59	5.7	0.43	6.47e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.9	12.01	0.7	1.37e-23	Metabolic syndrome;
UCEC	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.76	-5.39	-0.41	2.77e-7	Systemic lupus erythematosus;
UCEC	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.98	-0.38	1.74e-6	Depression;
UCEC	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.61	-6.8	-0.49	2.49e-10	Blood protein levels;
UCEC	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.31	4.56	0.35	1.06e-5	Schizophrenia;
UCEC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg17279458	chr3:44753948	ZNF502	-0.43	-4.66	-0.36	7.14e-6	Depressive symptoms;
UCEC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg22166914	chr1:53195759	ZYG11B	0.59	6.03	0.45	1.26e-8	Monocyte count;
UCEC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-1.0	-12.22	-0.71	3.78e-24	Obesity-related traits;
UCEC	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg12596171	chr3:113251061	SIDT1	-0.54	-4.85	-0.37	3.17e-6	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.87	-9.82	-0.63	7.97e-18	Cognitive function;
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	4.97	0.38	1.81e-6	Platelet count;
UCEC	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.46	-4.88	-0.37	2.7e-6	Asthma;
UCEC	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-12.23	-0.71	3.65e-24	Schizophrenia;
UCEC	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg08459430	chr5:81571289	RPS23	-0.48	-4.64	-0.36	7.52e-6	Breast cancer;
UCEC	cis	rs308403	0.509	rs10016979	chr4:123673192	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.71	9.04	0.6	8.59e-16	Blood protein levels;
UCEC	cis	rs7870753	1.000	rs1590973	chr9:99246159	C/T	cg25260653	chr9:99212216	HABP4	0.48	4.86	0.37	3.03e-6	Height;
UCEC	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg08458637	chr1:231747906	TSNAX-DISC1	0.37	4.52	0.35	1.25e-5	Neuranatomic and neurocognitive phenotypes;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.53	5.64	0.42	8.51e-8	Longevity;Endometriosis;
UCEC	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg17652424	chr22:38574118	PLA2G6	-0.42	-5.25	-0.4	5.29e-7	Cutaneous nevi;
UCEC	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.72	6.36	0.46	2.42e-9	Caudate activity during reward;
UCEC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.5	-0.47	1.19e-9	Eye color traits;
UCEC	cis	rs9463078	0.553	rs227837	chr6:44683123	A/G	cg25276700	chr6:44698697	NA	-0.43	-4.67	-0.36	6.68e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2862064	1.000	rs9313400	chr5:156433341	A/G	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.73	-0.43	5.52e-8	Platelet count;
UCEC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-5.62	-0.42	9.3e-8	Urinary metabolites;
UCEC	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg19554555	chr3:13937349	NA	0.6	6.1	0.45	8.76e-9	Ovarian reserve;
UCEC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.73	7.58	0.53	3.49e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.83	11.78	0.7	5.76e-23	Vitiligo;
UCEC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	0.77	8.16	0.56	1.38e-13	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.0	0.7	1.52e-23	Prudent dietary pattern;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg03235761	chr16:11038308	CLEC16A	-0.64	-4.51	-0.35	1.33e-5	Testicular germ cell tumor;
UCEC	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.79	5.13	0.39	8.82e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs4774830	0.744	rs12438427	chr15:56295062	A/T	cg24530489	chr15:56299380	NA	0.72	5.17	0.39	7.45e-7	Delta-5 desaturase activity;
UCEC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-0.99	-8.13	-0.56	1.67e-13	White matter hyperintensity burden;
UCEC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg24733560	chr20:60626293	TAF4	0.39	4.63	0.36	8.13e-6	Body mass index;
UCEC	cis	rs7546668	1.000	rs7546668	chr1:15855123	G/C	cg05660106	chr1:15850417	CASP9	-0.43	-4.54	-0.35	1.18e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs13095912	1.000	rs9714158	chr3:185328780	C/T	cg11274856	chr3:185301563	NA	0.57	7.64	0.53	2.51e-12	Systolic blood pressure;
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.58	0.58	1.24e-14	Platelet count;
UCEC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.42	-5.06	-0.39	1.21e-6	Lung cancer;
UCEC	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.72	6.25	0.46	4.28e-9	Coronary artery disease;
UCEC	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg00701064	chr4:6280414	WFS1	0.51	6.28	0.46	3.69e-9	Cisplatin-induced ototoxicity;
UCEC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.49	-5.56	-0.42	1.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.27e-6	Breast cancer;
UCEC	cis	rs9393813	0.516	rs4713099	chr6:27405202	T/G	cg27490387	chr6:26520793	HCG11	-0.42	-4.76	-0.37	4.66e-6	Bipolar disorder;
UCEC	cis	rs9469578	1.000	rs60447213	chr6:33715159	G/T	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.64	0.42	8.51e-8	Breast cancer;
UCEC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg20450318	chr11:65415260	SIPA1	0.4	4.54	0.35	1.17e-5	Acne (severe);
UCEC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.63	6.38	0.47	2.22e-9	C-reactive protein levels;
UCEC	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.64	-6.14	-0.45	7.41e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.75	7.08	0.5	5.44e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg07615347	chr10:60278583	BICC1	0.41	4.61	0.36	8.71e-6	Refractive error;
UCEC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.6	-7.43	-0.52	8.35e-12	Inhibitory control;
UCEC	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.77	-7.32	-0.52	1.53e-11	Initial pursuit acceleration;
UCEC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg22974920	chr21:40686053	BRWD1	-0.48	-4.69	-0.36	6.2e-6	Menarche (age at onset);
UCEC	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg10932868	chr11:921992	NA	0.39	5.07	0.39	1.2e-6	Alzheimer's disease (late onset);
UCEC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.59	4.74	0.36	4.93e-6	Longevity;
UCEC	cis	rs9325081	1	rs9325081	chr5:147551346	G/A	cg02292949	chr5:147648492	SPINK5L3	0.58	4.64	0.36	7.69e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg03354898	chr7:1950403	MAD1L1	-0.44	-5.06	-0.38	1.25e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.48	4.88	0.37	2.76e-6	Dental caries;
UCEC	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg01178603	chr7:1976964	MAD1L1	-0.55	-4.76	-0.37	4.66e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	7.28	0.51	1.91e-11	Menopause (age at onset);
UCEC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg13575925	chr12:9217583	LOC144571	0.39	4.74	0.36	5.07e-6	Sjögren's syndrome;
UCEC	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg17470449	chr10:769945	NA	0.5	4.63	0.36	8.14e-6	Uric acid levels;
UCEC	cis	rs9947276	0.508	rs8085262	chr18:72596179	A/C	cg07131864	chr18:72797640	NA	0.46	4.87	0.37	2.82e-6	Alcohol dependence (age at onset);
UCEC	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.42	-5.69	-0.42	6.67e-8	Alcohol dependence;
UCEC	cis	rs17607347	0.505	rs76220403	chr16:72340605	T/G	cg07209034	chr16:72459825	NA	-0.91	-4.52	-0.35	1.24e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs362272	0.525	rs2798286	chr4:3046173	A/G	cg20739912	chr4:3294241	NA	0.49	4.75	0.36	4.85e-6	Serum sulfate level;
UCEC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.82	8.7	0.58	6.3e-15	Cognitive function;
UCEC	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	4.86	0.37	2.92e-6	Aortic root size;
UCEC	cis	rs308403	0.509	rs7690133	chr4:123673809	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.67	8.19	0.56	1.14e-13	Blood protein levels;
UCEC	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.9	9.9	0.63	4.98e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs13253111	0.624	rs1979329	chr8:28096772	C/G	cg26534493	chr8:28060551	NA	0.48	5.31	0.4	4.05e-7	Childhood body mass index;
UCEC	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.74	7.57	0.53	3.88e-12	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.58	0.35	9.77e-6	Menopause (age at onset);
UCEC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.63	-5.67	-0.42	7.26e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-6.74	-0.49	3.38e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.59	-6.15	-0.45	6.96e-9	Systemic lupus erythematosus;
UCEC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.55	-4.66	-0.36	7.17e-6	Alzheimer's disease;
UCEC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.42	-4.53	-0.35	1.23e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12428035	1.000	rs12428035	chr13:96300872	A/G	cg07859753	chr13:96300257	NA	-0.66	-5.51	-0.41	1.56e-7	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg22974920	chr21:40686053	BRWD1	0.61	5.38	0.41	2.81e-7	Cognitive function;
UCEC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.71	-6.71	-0.48	3.96e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.76	7.65	0.53	2.37e-12	Cognitive function;
UCEC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg15506890	chr2:3487001	NA	-0.54	-4.9	-0.37	2.53e-6	Neurofibrillary tangles;
UCEC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.69	-6.34	-0.46	2.71e-9	Aortic root size;
UCEC	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	5.62	0.42	9.45e-8	Myopia (pathological);
UCEC	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.64	4.85	0.37	3.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.63	5.44	0.41	2.18e-7	Heart rate;
UCEC	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg24889512	chr19:22816950	ZNF492	0.59	6.47	0.47	1.38e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	5.82	0.43	3.49e-8	Platelet count;
UCEC	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.56	-5.12	-0.39	9.4e-7	Systemic lupus erythematosus;
UCEC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.13	-19.28	-0.85	4.31e-42	Testicular germ cell tumor;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25147835	chr19:8510289	HNRNPM	0.62	6.7	0.48	4.17e-10	Warfarin maintenance dose;
UCEC	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.32	-5.48	-0.41	1.83e-7	Mean corpuscular volume;
UCEC	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg06265175	chr8:121136014	COL14A1	0.51	5.48	0.41	1.82e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	7.23	0.51	2.48e-11	Ileal carcinoids;
UCEC	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	7.88	0.55	6.66e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	0.85	10.19	0.64	8.92e-19	Breast cancer;
UCEC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.37	-4.79	-0.37	4.07e-6	Body mass index;
UCEC	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg03934865	chr2:198174659	NA	-0.4	-5.05	-0.38	1.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-8.47	-0.57	2.37e-14	Chronic sinus infection;
UCEC	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.51	5.18	0.39	7.16e-7	Longevity;Endometriosis;
UCEC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.61	6.75	0.49	3.18e-10	Red blood cell count;
UCEC	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.6	5.87	0.44	2.85e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs1712517	0.771	rs2008530	chr10:105058839	G/A	cg05636881	chr10:105038444	INA	0.44	5.01	0.38	1.53e-6	Migraine;
UCEC	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.49	-5.06	-0.39	1.22e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs1355223	0.902	rs286862	chr11:34718779	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	4.58	0.35	9.9e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.45	-5.2	-0.39	6.65e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7709377	0.597	rs2063253	chr5:115472544	G/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.55	6.02	0.44	1.32e-8	Prostate cancer;
UCEC	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.49	5.74	0.43	5.15e-8	Menarche (age at onset);
UCEC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.65	5.98	0.44	1.66e-8	Joint mobility (Beighton score);
UCEC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.5	-0.41	1.62e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.5	5.0	0.38	1.59e-6	Menopause (age at onset);
UCEC	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg18681998	chr4:17616180	MED28	0.66	7.71	0.54	1.78e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.55	-5.43	-0.41	2.32e-7	Morning vs. evening chronotype;
UCEC	cis	rs2376682	0.959	rs62370469	chr5:118040811	T/C	cg17593721	chr5:118788746	HSD17B4	0.49	4.68	0.36	6.5e-6	Diisocyanate-induced asthma;
UCEC	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.9	-8.49	-0.57	2.02e-14	Blood metabolite levels;
UCEC	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.62	5.96	0.44	1.81e-8	Aortic root size;
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.51	-5.24	-0.4	5.54e-7	Bipolar disorder;
UCEC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.57	6.94	0.5	1.15e-10	Oral cavity cancer;
UCEC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.77	7.91	0.55	5.66e-13	Multiple sclerosis;
UCEC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-7.47	-0.52	6.46e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs7611694	0.843	rs1513287	chr3:113272208	G/A	cg11138929	chr3:113251189	SIDT1	0.44	4.52	0.35	1.27e-5	Prostate cancer;
UCEC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.47	6.51	0.47	1.13e-9	Eye color traits;
UCEC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13939156	chr17:80058883	NA	0.38	4.79	0.37	4.03e-6	Life satisfaction;
UCEC	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	8.23	0.56	9.34e-14	Menopause (age at onset);
UCEC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg01262667	chr19:19385393	TM6SF2	0.5	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.55	5.32	0.4	3.73e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs847649	1.000	rs847648	chr7:102553850	C/T	cg18108683	chr7:102477205	FBXL13	-0.6	-7.59	-0.53	3.35e-12	Morning vs. evening chronotype;
UCEC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg06742321	chr12:123595122	PITPNM2	0.48	4.88	0.37	2.74e-6	Platelet count;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.03	-0.45	1.24e-8	Prudent dietary pattern;
UCEC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg12463550	chr7:65579703	CRCP	-0.64	-6.14	-0.45	7.2e-9	Aortic root size;
UCEC	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10766546	chr14:60337674	RTN1	0.57	7.22	0.51	2.52e-11	Warfarin maintenance dose;
UCEC	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.47	4.66	0.36	7.17e-6	Type 2 diabetes;
UCEC	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.08	-8.04	-0.55	2.72e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.43	4.66	0.36	7.13e-6	Blood metabolite levels;
UCEC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.76	-8.06	-0.55	2.38e-13	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs4662945	0.652	rs35707860	chr2:130200219	C/T	cg05962382	chr2:130345044	NA	-0.46	-5.27	-0.4	4.67e-7	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	1.17	12.59	0.72	4.09e-25	Body mass index;
UCEC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.68	-7.23	-0.51	2.48e-11	Breast cancer;
UCEC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg13777783	chr17:79615861	NA	-0.34	-4.64	-0.36	7.56e-6	Eye color traits;
UCEC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg08885076	chr2:99613938	TSGA10	0.41	4.56	0.35	1.07e-5	Chronic sinus infection;
UCEC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg19318889	chr4:1322082	MAEA	0.49	5.28	0.4	4.52e-7	Obesity-related traits;
UCEC	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.48	-4.82	-0.37	3.52e-6	Blood metabolite levels;
UCEC	cis	rs10924970	0.967	rs2382615	chr1:235454955	G/A	cg26050004	chr1:235667680	B3GALNT2	0.45	4.74	0.36	4.95e-6	Asthma;
UCEC	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.53	5.49	0.41	1.72e-7	Systolic blood pressure;
UCEC	cis	rs9463078	0.715	rs1891411	chr6:44760903	G/C	cg25276700	chr6:44698697	NA	0.49	5.65	0.42	7.89e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs4372836	0.741	rs4563180	chr2:29093695	C/G	cg09522027	chr2:28974177	PPP1CB	0.81	8.47	0.57	2.38e-14	Body mass index;
UCEC	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg04553112	chr3:125709451	NA	-0.69	-4.85	-0.37	3.07e-6	Blood pressure (smoking interaction);
UCEC	cis	rs883565	0.606	rs6763607	chr3:39091596	C/G	cg01426195	chr3:39028469	NA	-0.7	-8.93	-0.59	1.63e-15	Handedness;
UCEC	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.71	8.04	0.55	2.66e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3743832	0.965	rs12149709	chr16:9207753	T/C	cg08831531	chr16:9218945	NA	-0.44	-4.67	-0.36	6.61e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.53	-5.4	-0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10746514	0.833	rs12039526	chr1:232272599	C/T	cg09506761	chr1:232265262	NA	-0.47	-4.52	-0.35	1.28e-5	Response to statin therapy;
UCEC	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.15	-0.45	7e-9	Metabolite levels;
UCEC	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.22	-0.56	9.59e-14	Hemoglobin concentration;
UCEC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.58	-6.51	-0.47	1.09e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.7	5.9	0.44	2.4e-8	Smoking initiation;
UCEC	trans	rs1552172	0.853	rs4970859	chr1:145605318	A/G	cg09213929	chr11:111170578	C11orf93;C11orf92	0.65	7.02	0.5	7.55e-11	Breast cancer;
UCEC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.03	-0.45	1.27e-8	Aortic root size;
UCEC	cis	rs2199161	0.550	rs3101186	chr5:71409569	A/C	cg15412498	chr5:71403320	MAP1B	0.84	5.16	0.39	7.83e-7	Attention deficit hyperactivity disorder;
UCEC	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-5.77	-0.43	4.55e-8	Electrocardiographic conduction measures;
UCEC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.54	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg20387954	chr3:183756860	HTR3D	-0.48	-5.74	-0.43	5.13e-8	Anterior chamber depth;
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	6.59	0.48	7.17e-10	Platelet count;
UCEC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.41	-4.8	-0.37	3.81e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-4.62	-0.36	8.22e-6	Blood metabolite levels;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.61	-7.66	-0.53	2.31e-12	Pubertal anthropometrics;
UCEC	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	5.26	0.4	4.91e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.6	-0.35	8.99e-6	Pulmonary function;
UCEC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.59	4.55	0.35	1.11e-5	Obesity-related traits;
UCEC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.27	-0.46	3.8e-9	Platelet count;
UCEC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.84	-9.35	-0.61	1.37e-16	Cognitive function;
UCEC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.74	0.36	4.92e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24249390	chr15:90295951	MESP1	-0.4	-4.72	-0.36	5.53e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.45	-4.79	-0.37	4.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg06466757	chr4:1255808	NA	0.45	4.66	0.36	7.09e-6	Obesity-related traits;
UCEC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg04804543	chr8:142233427	SLC45A4	-0.5	-6.09	-0.45	9.2e-9	Immature fraction of reticulocytes;
UCEC	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.74	-8.96	-0.59	1.38e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.6	0.35	9.06e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	0.94	9.63	0.62	2.53e-17	Heart rate;
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.0	0.44	1.48e-8	Platelet count;
UCEC	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18099408	chr3:52552593	STAB1	0.42	4.83	0.37	3.34e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.64	-4.59	-0.35	9.41e-6	Aortic root size;
UCEC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs7246967	0.736	rs436595	chr19:22993045	G/T	cg24889512	chr19:22816950	ZNF492	0.53	5.03	0.38	1.43e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg12596171	chr3:113251061	SIDT1	-0.53	-4.56	-0.35	1.06e-5	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg19875535	chr5:140030758	IK	0.42	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	trans	rs6479901	0.895	rs7918743	chr10:65093062	T/C	cg12751693	chr12:62629162	NA	-0.59	-7.19	-0.51	3.09e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs7248107	chr19:22878529	G/T	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg23018236	chr17:30244563	NA	-0.72	-5.27	-0.4	4.73e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.5e-8	Aortic root size;
UCEC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	4.83	0.37	3.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.32	-0.4	3.87e-7	Resting heart rate;
UCEC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.45	-5.3	-0.4	4.21e-7	Testicular germ cell tumor;
UCEC	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.35	0.4	3.27e-7	Blood protein levels;
UCEC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.53	5.0	0.38	1.6e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.62	6.78	0.49	2.79e-10	Vitiligo;
UCEC	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.53	-5.8	-0.43	3.92e-8	Diastolic blood pressure;
UCEC	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg23972785	chr8:11611189	GATA4	-0.35	-4.51	-0.35	1.32e-5	Neuroticism;
UCEC	cis	rs73416724	1.000	rs80193186	chr6:43362324	G/T	cg15032444	chr6:43027766	KLC4;MRPL2	0.84	4.53	0.35	1.24e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7570971	0.761	rs3940549	chr2:136138627	A/G	cg07169764	chr2:136633963	MCM6	0.65	5.81	0.43	3.81e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.47	4.61	0.36	8.71e-6	Morning vs. evening chronotype;
UCEC	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.5	0.41	1.63e-7	Personality dimensions;
UCEC	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg00105475	chr2:10696890	NA	0.4	4.82	0.37	3.58e-6	Prostate cancer;
UCEC	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.58	-6.47	-0.47	1.35e-9	Bipolar disorder;
UCEC	cis	rs7246967	0.611	rs4933024	chr19:22867063	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.77	-0.43	4.48e-8	Fear of minor pain;
UCEC	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.61	5.7	0.43	6.31e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.46	-6.38	-0.47	2.2e-9	Metabolite levels;
UCEC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.19	0.39	6.9e-7	Breast cancer;
UCEC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.48	-5.29	-0.4	4.25e-7	Longevity;
UCEC	cis	rs3813359	0.668	rs62433320	chr6:130607631	T/C	cg10100811	chr6:131116068	NA	0.6	4.56	0.35	1.08e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.9	8.05	0.55	2.51e-13	Bladder cancer;
UCEC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.83	9.51	0.62	5.25e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.62	7.1	0.51	4.82e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	0.47	5.15	0.39	8.09e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.46	-6.5	-0.47	1.15e-9	Rheumatoid arthritis;
UCEC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg13870426	chr17:30244630	NA	-0.63	-4.56	-0.35	1.06e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs10242455	0.571	rs13438288	chr7:98916414	T/G	cg18809830	chr7:99032528	PTCD1	-0.94	-5.01	-0.38	1.51e-6	Blood metabolite levels;
UCEC	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	1.23	9.76	0.63	1.16e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.85	8.52	0.57	1.74e-14	Colorectal cancer;
UCEC	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.45	5.1	0.39	1.05e-6	Response to temozolomide;
UCEC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.66	-0.42	7.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg06238570	chr21:40685208	BRWD1	-0.65	-7.41	-0.52	9.01e-12	Menarche (age at onset);
UCEC	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg07506560	chr2:240697449	NA	0.5	5.59	0.42	1.06e-7	Obesity-related traits;
UCEC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg08461772	chr7:95026248	PON3	0.34	4.56	0.35	1.07e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg21770322	chr7:97807741	LMTK2	-0.59	-6.86	-0.49	1.74e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-5.26	-0.4	4.99e-7	Resting heart rate;
UCEC	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg02158880	chr13:53174818	NA	0.42	4.56	0.35	1.05e-5	Lewy body disease;
UCEC	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.48	4.91	0.38	2.43e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.59	-5.88	-0.44	2.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.78	8.8	0.59	3.5e-15	Mortality in heart failure;
UCEC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.33	0.4	3.64e-7	Cognitive test performance;
UCEC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	5.72	0.43	5.68e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.65	4.96	0.38	1.92e-6	Lymphocyte counts;
UCEC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.59	5.56	0.42	1.25e-7	Red cell distribution width;
UCEC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.67	-6.29	-0.46	3.47e-9	Aortic root size;
UCEC	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	7.92	0.55	5.34e-13	Post bronchodilator FEV1;
UCEC	cis	rs12618769	0.597	rs72821956	chr2:99159966	G/T	cg10123293	chr2:99228465	UNC50	0.44	4.65	0.36	7.21e-6	Bipolar disorder;
UCEC	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19500275	chr17:80737654	TBCD	-0.39	-4.62	-0.36	8.23e-6	Glycated hemoglobin levels;
UCEC	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.37	5.71	0.43	5.94e-8	Ulcerative colitis;
UCEC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.33	4.57	0.35	1.03e-5	Prostate cancer;
UCEC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.76	5.65	0.42	8.07e-8	Initial pursuit acceleration;
UCEC	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.47	6.17	0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.71	-8.96	-0.59	1.35e-15	Prevalent atrial fibrillation;
UCEC	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.51	5.44	0.41	2.19e-7	Schizophrenia;
UCEC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.45	4.93	0.38	2.15e-6	Obesity-related traits;
UCEC	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.66	-7.87	-0.54	7.11e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg07153921	chr17:41440717	NA	-0.48	-4.54	-0.35	1.17e-5	Menopause (age at onset);
UCEC	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12826209	chr6:26865740	GUSBL1	0.53	4.92	0.38	2.33e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.64	6.98	0.5	9.64e-11	Homoarginine levels;
UCEC	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.76	7.88	0.54	6.82e-13	Breast cancer;
UCEC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.29	-0.4	4.37e-7	Blood metabolite levels;
UCEC	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs1832871	0.619	rs262823	chr6:158676149	G/C	cg07215822	chr6:158701037	NA	-0.52	-5.55	-0.42	1.28e-7	Height;
UCEC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.63	-5.32	-0.4	3.85e-7	Response to metformin (IC50);
UCEC	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.87	0.44	2.76e-8	Response to antipsychotic treatment;
UCEC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.68	6.42	0.47	1.76e-9	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.58	6.2	0.46	5.31e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.92	-0.38	2.3e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26294578	chr17:79319535	NA	0.55	6.73	0.49	3.6e-10	Warfarin maintenance dose;
UCEC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.5	4.55	0.35	1.13e-5	Obesity-related traits;
UCEC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	0.89	8.23	0.56	9.43e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.32	-0.52	1.53e-11	Total cholesterol levels;
UCEC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg17724175	chr1:150552817	MCL1	-0.43	-4.72	-0.36	5.4e-6	Tonsillectomy;
UCEC	cis	rs244899	0.935	rs2432643	chr5:167925030	G/T	cg06604206	chr5:167912465	RARS	-0.39	-4.72	-0.36	5.5e-6	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg02413938	chr2:239008929	ESPNL	-0.36	-4.76	-0.37	4.5e-6	Prostate cancer;
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.5	-0.47	1.19e-9	Platelet count;
UCEC	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.67	-0.36	6.75e-6	Response to antipsychotic treatment;
UCEC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.6	-5.36	-0.4	3.21e-7	Mortality in heart failure;
UCEC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.68	-5.92	-0.44	2.21e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.69	5.91	0.44	2.24e-8	HIV-1 control;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-6.37	-0.47	2.3e-9	Morning vs. evening chronotype;
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.64	-6.64	-0.48	5.58e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	5.8	0.43	3.92e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.77	-8.44	-0.57	2.73e-14	Body mass index;
UCEC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	5.9	0.44	2.39e-8	Personality dimensions;
UCEC	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg24687543	chr11:63912206	MACROD1	0.56	4.86	0.37	2.94e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.53	5.87	0.44	2.77e-8	HDL cholesterol;
UCEC	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.69e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.74	5.84	0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.86	-8.92	-0.59	1.72e-15	Height;
UCEC	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-5.55	-0.42	1.3e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg25174290	chr11:3078921	CARS	0.52	4.75	0.37	4.71e-6	Longevity;
UCEC	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	0.69	5.06	0.38	1.26e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	4.61	0.36	8.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs12635074	0.547	rs17235431	chr3:56242176	T/C	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.51	0.35	1.29e-5	Morning vs. evening chronotype;
UCEC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.51	4.67	0.36	6.73e-6	Menopause (age at onset);
UCEC	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.43	-0.41	2.29e-7	Obesity-related traits;
UCEC	cis	rs7554547	0.630	rs4845889	chr1:11971345	T/C	cg13216073	chr1:12042593	MFN2	0.49	4.74	0.36	5.01e-6	Nonsyndromic cleft lip with cleft palate;
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.8	-8.87	-0.59	2.34e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs10924970	0.649	rs1933248	chr1:235439323	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.47	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18932078	chr1:2524107	MMEL1	-0.35	-6.13	-0.45	7.85e-9	Ulcerative colitis;
UCEC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.66	0.48	5.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.63	7.28	0.51	1.92e-11	Menopause (age at onset);
UCEC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Schizophrenia;
UCEC	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.57	5.39	0.41	2.8e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.61	-6.2	-0.46	5.44e-9	Dental caries;
UCEC	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg26114124	chr12:9217669	LOC144571	-0.4	-5.03	-0.38	1.44e-6	Sjögren's syndrome;
UCEC	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	0.9	10.75	0.66	3e-20	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg22974920	chr21:40686053	BRWD1	0.55	4.82	0.37	3.47e-6	Cognitive function;
UCEC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	7.12	0.51	4.46e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-4.79	-0.37	4.11e-6	Colorectal cancer;
UCEC	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.76	5.92	0.44	2.13e-8	Orofacial clefts;
UCEC	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.74	-6.46	-0.47	1.47e-9	Asthma;
UCEC	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.75	8.04	0.55	2.74e-13	Mean corpuscular hemoglobin;
UCEC	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.81	-0.63	8.76e-18	Leprosy;
UCEC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs116095464	0.681	rs1574220	chr5:314518	T/C	cg02160872	chr5:212506	CCDC127	-0.78	-8.0	-0.55	3.38e-13	Breast cancer;
UCEC	cis	rs17106184	1.000	rs72900983	chr1:51192756	T/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.25	-0.4	5.15e-7	Type 2 diabetes;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.4	0.72	1.26e-24	Platelet count;
UCEC	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.54	4.52	0.35	1.29e-5	Colorectal cancer;
UCEC	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.8	7.59	0.53	3.4e-12	Bladder cancer;
UCEC	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg18681998	chr4:17616180	MED28	-0.52	-5.5	-0.41	1.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.04	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.41	4.99	0.38	1.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13939156	chr17:80058883	NA	0.36	4.57	0.35	1.03e-5	Life satisfaction;
UCEC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.51	5.17	0.39	7.64e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.64	-5.7	-0.43	6.24e-8	Parkinson's disease;
UCEC	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg23244877	chr17:73518230	TSEN54	0.41	6.1	0.45	8.76e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
UCEC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.31	-4.58	-0.35	9.93e-6	Body mass index;
UCEC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.86	8.78	0.59	3.77e-15	Blood protein levels;
UCEC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Diabetic kidney disease;
UCEC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.44	-4.85	-0.37	3.06e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.61	5.57	0.42	1.17e-7	Morning vs. evening chronotype;
UCEC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.34	-0.46	2.7e-9	Pancreatic cancer;
UCEC	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg11569703	chr11:65557185	OVOL1	-0.44	-6.2	-0.46	5.4e-9	Acne (severe);
UCEC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.64	-6.62	-0.48	6.35e-10	Dental caries;
UCEC	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.61	-4.73	-0.36	5.3e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6437061	0.707	rs3116167	chr2:232988345	A/G	cg20569070	chr2:232597279	PDE6D	0.43	4.93	0.38	2.2e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.57	-6.5	-0.47	1.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.4	0.41	2.63e-7	Breast cancer;
UCEC	cis	rs10924970	0.649	rs12753233	chr1:235487094	C/T	cg26050004	chr1:235667680	B3GALNT2	0.51	4.85	0.37	3.1e-6	Asthma;
UCEC	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.46	4.84	0.37	3.24e-6	HDL cholesterol;
UCEC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.97	-0.38	1.82e-6	Immature fraction of reticulocytes;
UCEC	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg24803719	chr17:45855879	NA	-0.49	-5.49	-0.41	1.74e-7	IgG glycosylation;
UCEC	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4148689	1.000	rs4148697	chr7:117172783	C/T	cg21212505	chr7:117228958	CFTR	-0.4	-4.6	-0.35	9.23e-6	Gout;
UCEC	cis	rs1355223	0.752	rs17293467	chr11:34677360	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.58	-5.31	-0.4	4e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.77	5.7	0.43	6.48e-8	Initial pursuit acceleration;
UCEC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.34	0.52	1.37e-11	Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.9	9.28	0.61	2.05e-16	Cognitive function;
UCEC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.47	4.5	0.35	1.35e-5	Aortic root size;
UCEC	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.39	4.73	0.36	5.32e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs12618769	0.597	rs3769724	chr2:99105981	C/T	cg14361474	chr2:99058762	NA	-0.48	-4.61	-0.36	8.57e-6	Bipolar disorder;
UCEC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg01380346	chr19:18557039	ELL	-0.47	-4.74	-0.36	4.96e-6	Breast cancer;
UCEC	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.58	-4.86	-0.37	3.02e-6	Systemic lupus erythematosus;
UCEC	cis	rs11761441	0.602	rs7801619	chr7:94006	C/T	cg06458707	chr7:1083209	C7orf50	-0.25	-4.52	-0.35	1.27e-5	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-7.42	-0.52	8.54e-12	Body mass index;
UCEC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.36	0.46	2.46e-9	Tonsillectomy;
UCEC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.58e-7	Acne (severe);
UCEC	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.74	-9.36	-0.61	1.26e-16	Leprosy;
UCEC	cis	rs838147	0.844	rs8105137	chr19:49249888	G/A	cg13540341	chr19:49222985	MAMSTR	0.37	4.62	0.36	8.2e-6	Dietary macronutrient intake;
UCEC	cis	rs78487399	0.908	rs6726404	chr2:43834163	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.55	5.22	0.4	5.89e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-4.84	-0.37	3.31e-6	Homocysteine levels;
UCEC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.97	0.38	1.87e-6	Breast cancer;
UCEC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.95	7.1	0.51	5.04e-11	Exhaled nitric oxide levels;
UCEC	cis	rs12883884	0.524	rs10130486	chr14:70483276	C/T	cg19735627	chr14:70233737	SFRS5;LOC100289511	-0.5	-4.7	-0.36	5.98e-6	Cystic fibrosis severity;
UCEC	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.56	6.06	0.45	1.12e-8	Schizophrenia;
UCEC	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs36029703	chr19:22906188	C/A	cg08271804	chr19:22816896	ZNF492	0.66	6.4	0.47	1.99e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.72	-6.17	-0.45	6.3e-9	Adiposity;
UCEC	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.64	4.95	0.38	1.98e-6	Inflammatory bowel disease;
UCEC	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.23	10.74	0.66	3.22e-20	Corneal structure;
UCEC	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.4	4.63	0.36	7.87e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10924970	0.649	rs4659653	chr1:235382775	T/C	cg26050004	chr1:235667680	B3GALNT2	0.47	4.6	0.35	9.17e-6	Asthma;
UCEC	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg00651523	chr6:28411279	ZSCAN23	-0.47	-5.19	-0.39	6.72e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.46	4.89	0.37	2.66e-6	Total body bone mineral density;
UCEC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.74	-0.36	5.06e-6	Bipolar disorder;
UCEC	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	7.59	0.53	3.34e-12	Homoarginine levels;
UCEC	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.51	5.05	0.38	1.29e-6	High light scatter reticulocyte count;
UCEC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg06466757	chr4:1255808	NA	0.46	4.85	0.37	3.07e-6	Obesity-related traits;
UCEC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Schizophrenia;
UCEC	cis	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9467773	1.000	rs6456735	chr6:26574149	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.5	-5.63	-0.42	8.73e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg03714773	chr7:91764589	CYP51A1	-0.45	-5.56	-0.42	1.26e-7	Breast cancer;
UCEC	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21178979	chr7:1889533	MAD1L1	0.39	4.9	0.37	2.46e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	5.96	0.44	1.76e-8	Monocyte percentage of white cells;
UCEC	cis	rs10242455	0.764	rs2687084	chr7:99298132	C/A	cg18809830	chr7:99032528	PTCD1	0.54	4.69	0.36	6.25e-6	Blood metabolite levels;
UCEC	cis	rs2742417	1.000	rs2673038	chr3:45748632	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.84	10.19	0.64	9.08e-19	Longevity;Endometriosis;
UCEC	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.47	-4.56	-0.35	1.06e-5	Blood pressure (smoking interaction);
UCEC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg20450318	chr11:65415260	SIPA1	0.4	4.55	0.35	1.13e-5	Acne (severe);
UCEC	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.69	-8.51	-0.57	1.87e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.6	-0.69	1.74e-22	Height;
UCEC	cis	rs10946940	0.930	rs10807029	chr6:27573463	G/A	cg07836142	chr6:28411423	ZSCAN23	0.44	4.71	0.36	5.68e-6	Systemic lupus erythematosus;
UCEC	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.52	-4.95	-0.38	2.01e-6	Coronary artery disease;
UCEC	cis	rs12428035	1.000	rs2274292	chr13:96295321	A/G	cg07859753	chr13:96300257	NA	0.64	4.92	0.38	2.31e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs9402633	0.818	rs75233203	chr6:135077425	C/T	cg16239184	chr6:135079577	NA	0.52	4.57	0.35	1.01e-5	Platelet count;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg17330251	chr7:94953956	PON1	-0.63	-6.0	-0.44	1.45e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs894344	0.584	rs11985416	chr8:135634005	A/G	cg07888246	chr8:135877498	NA	-0.42	-4.78	-0.37	4.27e-6	Systolic blood pressure;
UCEC	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.59	-6.08	-0.45	9.79e-9	Rheumatoid arthritis;
UCEC	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-7.02	-0.5	7.74e-11	Dental caries;
UCEC	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.72	-5.78	-0.43	4.35e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs8044995	0.501	rs7189887	chr16:68353915	C/T	cg05110241	chr16:68378359	PRMT7	-0.52	-4.55	-0.35	1.1e-5	Schizophrenia;
UCEC	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg21770322	chr7:97807741	LMTK2	0.53	6.65	0.48	5.4e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.63	-4.75	-0.36	4.73e-6	Narcolepsy;
UCEC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.66	-4.61	-0.36	8.73e-6	Red blood cell traits;
UCEC	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.55	5.46	0.41	1.97e-7	Cognitive test performance;
UCEC	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-9.47	-0.62	6.64e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.55	-5.21	-0.39	6.33e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg13683864	chr3:40499215	RPL14	0.54	5.68	0.42	6.93e-8	Renal cell carcinoma;
UCEC	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.44	4.58	0.35	9.93e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.74	-8.51	-0.57	1.88e-14	Facial morphology (factor 19);
UCEC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.43	-5.49	-0.41	1.76e-7	Monocyte count;
UCEC	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.88e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg12394014	chr15:79171566	MORF4L1	0.46	4.63	0.36	8.14e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.01	-0.44	1.43e-8	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.79e-11	Eye color traits;
UCEC	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	6.33	0.46	2.83e-9	Bipolar disorder;
UCEC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.47	4.8	0.37	3.78e-6	Dilated cardiomyopathy;
UCEC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs59918340	0.627	rs1865249	chr8:142215982	A/C	cg18755752	chr8:142205143	DENND3	-0.63	-5.76	-0.43	4.7e-8	Immature fraction of reticulocytes;
UCEC	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.17	0.39	7.54e-7	Cognitive test performance;
UCEC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.42	-4.8	-0.37	3.95e-6	Total body bone mineral density;
UCEC	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	8.59	0.58	1.16e-14	Nonalcoholic fatty liver disease;
UCEC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.71	-7.85	-0.54	8.06e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.52	6.53	0.47	1.01e-9	Subjective well-being (multi-trait analysis);
UCEC	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.43	4.66	0.36	7.05e-6	Blood metabolite levels;
UCEC	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg13319975	chr6:146136371	FBXO30	0.44	4.73	0.36	5.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.52	4.97	0.38	1.85e-6	Alcohol dependence;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg07838603	chr6:28411030	ZSCAN23	-0.47	-5.21	-0.39	6.39e-7	Cardiac Troponin-T levels;
UCEC	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg06521331	chr12:34319734	NA	-0.59	-4.62	-0.36	8.16e-6	Morning vs. evening chronotype;
UCEC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.81	9.25	0.61	2.37e-16	Menopause (age at onset);
UCEC	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	7.62	0.53	2.9e-12	Nonalcoholic fatty liver disease;
UCEC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg00268149	chr4:184017790	NA	-0.39	-4.6	-0.35	8.93e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
UCEC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.47	4.59	0.35	9.5e-6	Motion sickness;
UCEC	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.09	-0.45	9.34e-9	Metabolite levels;
UCEC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg14438399	chr17:27053147	TLCD1	0.58	4.7	0.36	5.87e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.65	4.94	0.38	2.12e-6	Lymphocyte counts;
UCEC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.17	0.39	7.6e-7	Personality dimensions;
UCEC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.69	5.59	0.42	1.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.89	-9.53	-0.62	4.66e-17	Homoarginine levels;
UCEC	cis	rs2299682	0.826	rs6086910	chr20:9469003	C/T	cg11931762	chr20:9488920	NA	-0.77	-5.94	-0.44	1.93e-8	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24308560	chr3:49941425	MST1R	0.56	6.32	0.46	2.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.59	-0.48	7.23e-10	Aortic root size;
UCEC	cis	rs77861329	1.000	rs59890038	chr3:52147850	A/G	cg08692210	chr3:52188851	WDR51A	0.86	6.67	0.48	4.91e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg21486944	chr6:28411378	ZSCAN23	0.49	5.08	0.39	1.12e-6	Pubertal anthropometrics;
UCEC	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	11.43	0.69	4.87e-22	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.58	6.39	0.47	2.04e-9	Eye color traits;
UCEC	cis	rs10012307	0.892	rs12649638	chr4:137487709	C/G	cg12033966	chr4:138453416	PCDH18	-0.72	-4.94	-0.38	2.08e-6	DNA methylation (parent-of-origin);
UCEC	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-0.84	-9.59	-0.62	3.24e-17	Height;
UCEC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.68	5.65	0.42	8.16e-8	Blood metabolite levels;
UCEC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	7.22	0.51	2.61e-11	Hip circumference adjusted for BMI;
UCEC	trans	rs17416314	0.706	rs17507185	chr5:31802554	A/G	cg20685554	chr6:150185632	LRP11	-1.39	-7.06	-0.5	6.26e-11	Colorectal cancer;
UCEC	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.59	-5.03	-0.38	1.44e-6	Reticulocyte count;
UCEC	cis	rs10946940	0.965	rs9393830	chr6:27587027	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.44	-4.55	-0.35	1.1e-5	Systemic lupus erythematosus;
UCEC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.54	-5.09	-0.39	1.08e-6	Non-response to antidepressants and depression;
UCEC	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg17652424	chr22:38574118	PLA2G6	-0.36	-4.58	-0.35	9.73e-6	Breast cancer;
UCEC	cis	rs6715284	0.579	rs73989514	chr2:202466181	A/G	cg23517999	chr2:202814523	NA	-0.56	-4.63	-0.36	7.81e-6	Rheumatoid arthritis;
UCEC	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.56	6.4	0.47	1.95e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.54	5.23	0.4	5.71e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.2	-0.46	5.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.02	-7.4	-0.52	9.84e-12	Body mass index;
UCEC	cis	rs7246967	0.611	rs3951784	chr19:22851926	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	0.72	5.57	0.42	1.19e-7	Post bronchodilator FEV1;
UCEC	cis	rs2658084	0.626	rs925208	chr5:10141350	G/A	cg09877593	chr5:10564514	ANKRD33B	0.53	5.13	0.39	9.18e-7	Iris color (L* coordinate);
UCEC	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg13683864	chr3:40499215	RPL14	-0.51	-5.1	-0.39	1.03e-6	Renal cell carcinoma;
UCEC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.49	4.55	0.35	1.11e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	6.48	0.47	1.3e-9	Hip circumference;
UCEC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.63	7.05	0.5	6.63e-11	Homoarginine levels;
UCEC	cis	rs6840360	0.642	rs1443089	chr4:152450300	A/G	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs7607369	0.536	rs6436090	chr2:219669002	A/G	cg02176678	chr2:219576539	TTLL4	-0.58	-6.17	-0.45	6.35e-9	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.75	-0.43	4.95e-8	Life satisfaction;
UCEC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.17	-0.39	7.6e-7	Aortic root size;
UCEC	cis	rs829661	0.847	rs829622	chr2:30753445	T/C	cg17749961	chr2:30669863	LCLAT1	0.52	4.93	0.38	2.18e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg13525197	chr6:28411240	ZSCAN23	0.47	5.13	0.39	8.95e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	7.96	0.55	4.24e-13	Platelet count;
UCEC	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08392591	chr16:89556376	ANKRD11	-0.52	-4.94	-0.38	2.14e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.78	0.54	1.2e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.44	-5.69	-0.42	6.65e-8	Urinary metabolites;
UCEC	cis	rs7155454	0.815	rs11627485	chr14:65487694	T/C	cg11161011	chr14:65562177	MAX	-0.63	-5.76	-0.43	4.8e-8	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
UCEC	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	8.03	0.55	2.92e-13	Caffeine consumption;
UCEC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.44	5.16	0.39	8.05e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	4.59	0.35	9.49e-6	Multiple sclerosis;
UCEC	cis	rs6890610	0.657	rs158134	chr5:154359159	A/C	cg02687067	chr5:153784852	GALNT10	0.52	4.77	0.37	4.33e-6	Breast cancer;
UCEC	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.6	8.52	0.58	1.7e-14	Height;
UCEC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.9	-10.05	-0.64	2.01e-18	Cognitive function;
UCEC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.55	-5.88	-0.44	2.69e-8	Monocyte count;
UCEC	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.49	4.88	0.37	2.69e-6	Migraine;
UCEC	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7517126	1.000	rs7519501	chr1:196840173	T/C	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.54	4.64	0.36	7.8e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-0.93	-5.44	-0.41	2.21e-7	Diabetic kidney disease;
UCEC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.66	6.87	0.49	1.72e-10	Longevity;Endometriosis;
UCEC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.67	-8.12	-0.56	1.71e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-9.1	-0.6	6.03e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg01689657	chr7:91764605	CYP51A1	0.4	4.63	0.36	7.92e-6	Breast cancer;
UCEC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg12559939	chr2:27858050	GPN1	0.43	4.52	0.35	1.26e-5	Oral cavity cancer;
UCEC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.68	-7.45	-0.52	7.5e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs2136093	0.506	rs12127465	chr1:90835677	C/T	cg01786362	chr1:90274359	NA	-0.39	-4.67	-0.36	6.78e-6	Response to antidepressants;
UCEC	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg22875332	chr1:76189707	ACADM	-0.47	-5.29	-0.4	4.3e-7	Daytime sleep phenotypes;
UCEC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.07	0.5	5.76e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg13683864	chr3:40499215	RPL14	0.81	8.68	0.58	7.01e-15	Renal cell carcinoma;
UCEC	cis	rs9715521	0.775	rs11931812	chr4:59844473	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	5.33	0.4	3.55e-7	Alzheimer's disease;
UCEC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18876405	chr7:65276391	NA	0.46	4.56	0.35	1.08e-5	Aortic root size;
UCEC	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.51	-4.79	-0.37	4.04e-6	Hepatocellular carcinoma;
UCEC	cis	rs116095464	0.764	rs28710899	chr5:241029	G/A	cg22857025	chr5:266934	NA	-1.15	-12.4	-0.71	1.29e-24	Breast cancer;
UCEC	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.51	-5.04	-0.38	1.32e-6	P wave terminal force;
UCEC	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.73	8.21	0.56	1.05e-13	IgG glycosylation;
UCEC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-10.73	-0.66	3.37e-20	Vitiligo;
UCEC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.47	-4.83	-0.37	3.39e-6	Prostate cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02422812	chr5:154062204	NA	0.58	7.26	0.51	2.09e-11	Warfarin maintenance dose;
UCEC	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs11118844	0.793	rs17010720	chr1:221946403	A/G	cg04222084	chr1:221915650	DUSP10	-0.76	-7.21	-0.51	2.71e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	6.01	0.44	1.37e-8	Myopia (pathological);
UCEC	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.96	6.3	0.46	3.3e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.69	4.9	0.37	2.49e-6	Aortic root size;
UCEC	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.63	5.33	0.4	3.59e-7	Alzheimer's disease;
UCEC	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.44	5.45	0.41	2.05e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.45	-4.95	-0.38	1.98e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.8	10.29	0.65	4.82e-19	Vitiligo;
UCEC	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs883565	0.569	rs1274971	chr3:39161464	G/A	cg01426195	chr3:39028469	NA	-0.63	-7.61	-0.53	3.01e-12	Handedness;
UCEC	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.85	-0.54	8.17e-13	Migraine;Coronary artery disease;
UCEC	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.67	7.78	0.54	1.17e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg13695892	chr22:41940480	POLR3H	0.7	5.45	0.41	2.04e-7	Vitiligo;
UCEC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.55	-4.94	-0.38	2.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.01	-0.5	8.18e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7106204	0.541	rs75552854	chr11:24231824	G/A	ch.11.24196551F	chr11:24239977	NA	0.65	5.09	0.39	1.08e-6	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.59	6.3	0.46	3.2e-9	Height;
UCEC	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.46	-5.87	-0.44	2.74e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg22974920	chr21:40686053	BRWD1	0.61	5.31	0.4	4e-7	Cognitive function;
UCEC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.4	0.52	9.82e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.67	-6.12	-0.45	7.93e-9	Prostate cancer;
UCEC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.56	-6.46	-0.47	1.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.28	0.51	1.91e-11	Bladder cancer;
UCEC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	4.8	0.37	3.8e-6	Diabetic retinopathy;
UCEC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.55	-5.62	-0.42	9.3e-8	Bipolar disorder;
UCEC	cis	rs73069940	1.000	rs72501962	chr4:1246038	A/T	cg07110949	chr4:1309878	MAEA	-0.66	-4.56	-0.35	1.08e-5	Type 2 diabetes;
UCEC	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-23.78	-0.89	3.1e-52	Myeloid white cell count;
UCEC	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.65	5.89	0.44	2.5e-8	Asthma;
UCEC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	9.28	0.61	2.05e-16	Electrocardiographic conduction measures;
UCEC	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.55	5.76	0.43	4.64e-8	Age at first birth;
UCEC	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg21419209	chr3:44054225	NA	0.49	5.09	0.39	1.09e-6	Coronary artery disease;
UCEC	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.83	6.56	0.48	8.76e-10	Lymphocyte counts;
UCEC	cis	rs731174	0.559	rs66536721	chr1:38195582	A/G	cg24088508	chr1:38156462	C1orf109	-0.58	-4.58	-0.35	9.65e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.51	4.86	0.37	2.97e-6	Glomerular filtration rate;
UCEC	cis	rs78587638	0.790	rs76588671	chr2:119163727	T/C	cg22657351	chr2:119752078	MARCO	0.5	4.62	0.36	8.31e-6	Mosquito bite size;
UCEC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg17724175	chr1:150552817	MCL1	-0.42	-4.8	-0.37	3.84e-6	Tonsillectomy;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.68	8.34	0.57	4.8e-14	Menarche (age at onset);
UCEC	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.37	4.75	0.36	4.78e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	0.98	14.29	0.76	1.32e-29	Homoarginine levels;
UCEC	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.59	-6.61	-0.48	6.64e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.44	-4.88	-0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.66	5.88	0.44	2.63e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	0.66	5.59	0.42	1.08e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg05660106	chr1:15850417	CASP9	1.01	11.43	0.69	4.84e-22	Systolic blood pressure;
UCEC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	8.47	0.57	2.34e-14	Bipolar disorder;
UCEC	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	0.76	4.68	0.36	6.39e-6	Diabetic retinopathy;
UCEC	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg26061582	chr7:22766209	IL6	0.57	5.34	0.4	3.53e-7	Lung cancer;
UCEC	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg13683864	chr3:40499215	RPL14	-0.7	-7.79	-0.54	1.12e-12	Renal cell carcinoma;
UCEC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.34	-0.46	2.63e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-6.0	-0.44	1.48e-8	Bipolar disorder;
UCEC	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs6756513	0.501	rs7581977	chr2:70174054	C/T	cg02498382	chr2:70120550	SNRNP27	0.47	5.1	0.39	1.03e-6	Breast cancer;Platelet count;
UCEC	cis	rs2657888	0.628	rs2638335	chr12:56880672	C/T	cg23002907	chr12:56915593	RBMS2	-0.41	-5.54	-0.42	1.38e-7	Adiponectin levels;
UCEC	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	8.14	0.56	1.54e-13	Menopause (age at onset);
UCEC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.81	11.02	0.67	5.66e-21	Headache;
UCEC	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg19338460	chr6:170058176	WDR27	-1.03	-5.2	-0.39	6.56e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs4713118	0.513	rs2294480	chr6:27583961	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.52	-0.35	1.29e-5	Parkinson's disease;
UCEC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.58	6.17	0.45	6.23e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6060717	0.536	rs3829829	chr20:34537160	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.6	-0.35	8.94e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.51	6.74	0.49	3.3e-10	Bone mineral density;
UCEC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	6.41	0.47	1.82e-9	Platelet count;
UCEC	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.66	-0.42	7.65e-8	Mood instability;
UCEC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.47	-4.99	-0.38	1.65e-6	Cardiac Troponin-T levels;
UCEC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg12463550	chr7:65579703	CRCP	-0.52	-4.92	-0.38	2.27e-6	Calcium levels;
UCEC	cis	rs7095607	0.579	rs6480308	chr10:69952953	T/C	cg18986048	chr10:69913749	MYPN	0.52	5.69	0.42	6.62e-8	Lung function (FVC);
UCEC	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.61	6.83	0.49	2.04e-10	Red blood cell count;
UCEC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.7	-4.97	-0.38	1.88e-6	Aortic root size;
UCEC	cis	rs4975616	0.714	rs37010	chr5:1349535	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.76	-8.11	-0.56	1.86e-13	Lung cancer;
UCEC	cis	rs3015497	0.594	rs35637875	chr14:51132533	T/G	cg04730355	chr14:51134070	SAV1	-0.45	-4.58	-0.35	9.9e-6	Mean platelet volume;
UCEC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.7	7.69	0.54	1.93e-12	Mortality in heart failure;
UCEC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg26114124	chr12:9217669	LOC144571	-0.44	-5.48	-0.41	1.84e-7	Sjögren's syndrome;
UCEC	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.88	8.2	0.56	1.12e-13	Prostate cancer;
UCEC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	5.21	0.39	6.39e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-6.65	-0.48	5.4e-10	Chronic sinus infection;
UCEC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg22974920	chr21:40686053	BRWD1	0.63	5.17	0.39	7.62e-7	Cognitive function;
UCEC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.74	-7.56	-0.53	3.94e-12	Neurofibrillary tangles;
UCEC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.63	5.77	0.43	4.6e-8	Alzheimer's disease;
UCEC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6728642	0.519	rs4260285	chr2:97570081	A/G	cg26665480	chr2:98280029	ACTR1B	-0.6	-4.92	-0.38	2.27e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs8105895	0.935	rs62110992	chr19:22261516	T/G	cg20662725	chr19:22235022	ZNF257	-0.65	-5.46	-0.41	2.01e-7	Body mass index (change over time);
UCEC	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.74	-7.05	-0.5	6.36e-11	Parkinson's disease;
UCEC	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs1483890	0.723	rs900669	chr3:69406802	T/A	cg22125112	chr3:69402811	FRMD4B	0.44	4.69	0.36	6.18e-6	Resting heart rate;
UCEC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.64	-6.95	-0.5	1.1e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg01689657	chr7:91764605	CYP51A1	-0.45	-5.66	-0.42	7.57e-8	Breast cancer;
UCEC	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg02176678	chr2:219576539	TTLL4	-0.62	-5.62	-0.42	9.18e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.55	-6.22	-0.46	4.99e-9	Lung cancer;
UCEC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.46	0.41	1.99e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4865875	0.892	rs73126822	chr5:54064917	T/C	cg22421804	chr5:54100067	NA	-0.48	-5.05	-0.38	1.3e-6	Sense of smell;
UCEC	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg18099408	chr3:52552593	STAB1	0.41	4.65	0.36	7.29e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.54	-5.92	-0.44	2.23e-8	Prostate cancer;
UCEC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg02820040	chr2:241836501	C2orf54	-0.39	-4.86	-0.37	2.99e-6	Urinary metabolites;
UCEC	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	8.51	0.57	1.82e-14	Total cholesterol levels;
UCEC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg10412286	chr16:89977652	TCF25	0.63	4.68	0.36	6.37e-6	Skin colour saturation;
UCEC	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg04283868	chr2:201171347	SPATS2L	0.48	4.61	0.36	8.67e-6	QT interval;
UCEC	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.59	-0.53	3.33e-12	Response to antipsychotic treatment;
UCEC	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.2	-0.39	6.54e-7	Neuroticism;
UCEC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.42	4.53	0.35	1.23e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	4.75	0.36	4.81e-6	Longevity;
UCEC	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg16576597	chr16:28551801	NUPR1	0.32	4.8	0.37	3.79e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.69	4.95	0.38	2.05e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.39	-0.41	2.7e-7	Cardiac Troponin-T levels;
UCEC	cis	rs9467773	1.000	rs1570061	chr6:26575986	T/C	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg17294928	chr15:75287854	SCAMP5	-0.48	-4.61	-0.36	8.6e-6	Lung cancer;
UCEC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.42	-4.61	-0.36	8.71e-6	Coronary artery disease;
UCEC	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.45	0.47	1.49e-9	Motion sickness;
UCEC	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.31	4.64	0.36	7.62e-6	Schizophrenia;
UCEC	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.34	5.17	0.39	7.64e-7	Ulcerative colitis;
UCEC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.84	0.75	2.02e-28	Homoarginine levels;
UCEC	cis	rs2455799	1.000	rs2166758	chr3:15856233	C/T	cg16303742	chr3:15540471	COLQ	-0.42	-4.8	-0.37	3.84e-6	Mean platelet volume;
UCEC	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.7	-5.63	-0.42	8.7e-8	Corneal structure;
UCEC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.61	4.58	0.35	9.88e-6	Mean platelet volume;
UCEC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	4.86	0.37	2.97e-6	Menopause (age at onset);
UCEC	cis	rs9467773	1.000	rs9467798	chr6:26575697	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.48	5.87	0.44	2.8e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.52	5.04	0.38	1.36e-6	Resting heart rate;
UCEC	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.7	-0.62	1.68e-17	Leprosy;
UCEC	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg04473437	chr5:205334	CCDC127	-0.58	-4.6	-0.35	9.1e-6	Breast cancer;
UCEC	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.61	6.78	0.49	2.78e-10	Tonsillectomy;
UCEC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.55	5.92	0.44	2.23e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.61	5.08	0.39	1.12e-6	Blood metabolite levels;
UCEC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13870426	chr17:30244630	NA	-0.68	-5.15	-0.39	8.05e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.21	-13.69	-0.75	4.93e-28	Type 1 diabetes nephropathy;
UCEC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.57	5.73	0.43	5.47e-8	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.64	0.42	8.64e-8	Breast cancer;
UCEC	cis	rs631288	0.793	rs7523954	chr1:146764072	A/T	cg25205988	chr1:146714368	CHD1L	0.89	4.57	0.35	1.01e-5	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.43	-5.28	-0.4	4.54e-7	HDL cholesterol;
UCEC	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-8.19	-0.56	1.18e-13	Blood metabolite levels;
UCEC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg23307798	chr14:103986281	CKB	0.65	8.0	0.55	3.42e-13	Body mass index;
UCEC	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	0.99	11.2	0.68	1.94e-21	Corneal structure;
UCEC	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.64	5.49	0.41	1.7e-7	Pancreatic cancer;
UCEC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg22907277	chr7:1156413	C7orf50	1.02	6.11	0.45	8.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	4.86	0.37	3.01e-6	Parkinson's disease;
UCEC	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.64	6.08	0.45	9.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg05738196	chr6:26577821	NA	0.61	6.74	0.49	3.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.5	4.89	0.37	2.61e-6	Dupuytren's disease;
UCEC	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.57	6.18	0.45	5.89e-9	Bipolar disorder;
UCEC	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.19	-0.45	5.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg13525197	chr6:28411240	ZSCAN23	0.43	4.73	0.36	5.24e-6	Systemic lupus erythematosus;
UCEC	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.37	-0.41	2.98e-7	Morning vs. evening chronotype;
UCEC	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.45	-4.86	-0.37	2.96e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg03714773	chr7:91764589	CYP51A1	0.39	4.67	0.36	6.71e-6	Breast cancer;
UCEC	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-8.31	-0.57	5.72e-14	Coffee consumption (cups per day);
UCEC	trans	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs6534441	0.727	rs7666484	chr4:125463652	G/A	cg21609808	chr4:125404261	NA	0.4	4.6	0.35	9.05e-6	Major depressive disorder;
UCEC	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.1	-0.51	4.86e-11	Neuroticism;
UCEC	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.61	0.36	8.67e-6	Lung cancer;
UCEC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.69	-0.36	6.11e-6	Educational attainment (years of education);
UCEC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.6	-5.35	-0.4	3.29e-7	Mortality in heart failure;
UCEC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.61	-7.1	-0.51	4.98e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.37	-4.6	-0.35	9.14e-6	Life satisfaction;
UCEC	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-5.12	-0.39	9.33e-7	Mean platelet volume;
UCEC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.44	6.42	0.47	1.78e-9	Blood protein levels;
UCEC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.63	0.42	8.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	4.57	0.35	1.04e-5	Post bronchodilator FEV1;
UCEC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.78	5.85	0.43	3.02e-8	Body mass index;
UCEC	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg24851651	chr11:66362959	CCS	-0.41	-5.15	-0.39	8.28e-7	Educational attainment (years of education);
UCEC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.53	7.74	0.54	1.47e-12	Crohn's disease;
UCEC	cis	rs8105895	0.935	rs75025987	chr19:22230669	T/A	cg02912127	chr19:22235281	ZNF257	-0.58	-4.69	-0.36	6.25e-6	Body mass index (change over time);
UCEC	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.48	-5.53	-0.42	1.41e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs853679	0.585	rs201000	chr6:27809159	C/T	cg19041857	chr6:27730383	NA	-0.52	-4.6	-0.35	9.12e-6	Depression;
UCEC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.53	6.69	0.48	4.35e-10	Total body bone mineral density;
UCEC	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.6	5.4	0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.73	0.36	5.11e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-5.08	-0.39	1.13e-6	Longevity;
UCEC	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	6.76	0.49	2.96e-10	Bipolar disorder;
UCEC	cis	rs4654899	0.931	rs2275468	chr1:21220375	T/G	cg01072550	chr1:21505969	NA	0.5	5.03	0.38	1.41e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.64	8.38	0.57	3.92e-14	Anterior chamber depth;
UCEC	cis	rs13095912	1.000	rs2034343	chr3:185337854	A/T	cg11274856	chr3:185301563	NA	0.54	7.25	0.51	2.25e-11	Systolic blood pressure;
UCEC	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs11958404	0.860	rs72818117	chr5:157441130	G/A	cg05962755	chr5:157440814	NA	0.72	5.24	0.4	5.59e-7	IgG glycosylation;
UCEC	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.33	4.88	0.37	2.76e-6	Schizophrenia;
UCEC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.6	6.58	0.48	7.68e-10	Resting heart rate;
UCEC	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	6.23	0.46	4.59e-9	Menopause (age at onset);
UCEC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg03859395	chr2:55845619	SMEK2	1.01	14.09	0.76	4.4e-29	Metabolic syndrome;
UCEC	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.59	-6.44	-0.47	1.59e-9	Menopause (age at onset);
UCEC	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	7.0	0.5	8.3e-11	Coronary artery disease;
UCEC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-1.0	-12.14	-0.71	6.28e-24	Cognitive function;
UCEC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.61	6.74	0.49	3.31e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.36	-4.82	-0.37	3.5e-6	Total body bone mineral density;
UCEC	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.42	-4.51	-0.35	1.3e-5	Presence of antiphospholipid antibodies;
UCEC	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.39	0.52	1.04e-11	Morning vs. evening chronotype;
UCEC	cis	rs4839421	0.565	rs17680634	chr1:111023490	C/T	cg06880108	chr1:111021908	CYMP	0.43	4.81	0.37	3.66e-6	Response to bupropion in depression;
UCEC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.73	6.88	0.49	1.6e-10	Aortic root size;
UCEC	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs308403	0.568	rs309358	chr4:123653926	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	6.24	0.46	4.4e-9	Blood protein levels;
UCEC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.41	-5.5	-0.41	1.61e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg11859384	chr17:80120422	CCDC57	0.46	5.2	0.39	6.59e-7	Life satisfaction;
UCEC	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.52	5.15	0.39	8.33e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.77	0.43	4.48e-8	Breast cancer;
UCEC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18252515	chr7:66147081	NA	-0.54	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.46	5.01	0.38	1.53e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	6.31	0.46	3.04e-9	Hip circumference;
UCEC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.8	8.11	0.56	1.83e-13	Parkinson's disease;
UCEC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.63	-6.7	-0.48	4.07e-10	Diastolic blood pressure;
UCEC	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.74	-7.46	-0.52	6.9e-12	Cognitive function;
UCEC	cis	rs2901460	0.509	rs11125898	chr2:62079895	T/C	cg02183531	chr2:62113199	CCT4	-0.54	-4.54	-0.35	1.17e-5	Mean corpuscular volume;
UCEC	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.65	7.38	0.52	1.09e-11	Ulcerative colitis;
UCEC	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg21521518	chr4:53727714	RASL11B	0.67	4.77	0.37	4.32e-6	Optic nerve measurement (cup area);
UCEC	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	7.19	0.51	3.09e-11	Total body bone mineral density;
UCEC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.6	-6.39	-0.47	2.06e-9	Neutrophil percentage of white cells;
UCEC	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.69	8.95	0.59	1.41e-15	Mean platelet volume;
UCEC	cis	rs56341938	0.679	rs6804720	chr3:168828996	C/A	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs2190422	0.551	rs10262559	chr7:103158027	C/G	cg18108683	chr7:102477205	FBXL13	-0.57	-5.96	-0.44	1.82e-8	Morning vs. evening chronotype;
UCEC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg14078730	chr11:63896557	MACROD1	0.46	4.54	0.35	1.15e-5	Platelet count;
UCEC	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.39	4.76	0.37	4.66e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	0.82	7.07	0.5	5.7e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.57	5.49	0.41	1.72e-7	Height;
UCEC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.69	5.9	0.44	2.36e-8	Blood metabolite levels;
UCEC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.55	5.05	0.38	1.31e-6	Selective IgA deficiency;
UCEC	cis	rs829661	0.894	rs1252625	chr2:30747398	C/A	cg17749961	chr2:30669863	LCLAT1	0.49	4.66	0.36	7.1e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.61	-5.16	-0.39	7.89e-7	LDL cholesterol levels;
UCEC	cis	rs7246967	0.611	rs3951784	chr19:22851926	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.61	6.11	0.45	8.61e-9	Lung cancer;
UCEC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.35	5.74	0.43	5.16e-8	Cancer;
UCEC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg03859395	chr2:55845619	SMEK2	1.02	14.91	0.78	3.39e-31	Metabolic syndrome;
UCEC	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg18681998	chr4:17616180	MED28	0.76	8.74	0.58	4.96e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1852612	0.965	rs2331236	chr7:45400583	G/A	cg26127197	chr7:45030251	NA	-0.35	-4.54	-0.35	1.18e-5	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg26721908	chr21:47610096	LSS	-0.37	-4.64	-0.36	7.6e-6	Testicular germ cell tumor;
UCEC	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs7011192	0.793	rs13269921	chr8:10520913	A/G	cg04501334	chr8:10513686	RP1L1	0.54	5.14	0.39	8.54e-7	Suicide;
UCEC	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg05775895	chr3:12838266	CAND2	0.59	5.88	0.44	2.65e-8	QRS complex (12-leadsum);
UCEC	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.64	6.02	0.44	1.35e-8	Height;
UCEC	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg26114124	chr12:9217669	LOC144571	0.4	4.85	0.37	3.11e-6	Sjögren's syndrome;
UCEC	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs8105895	0.733	rs62110979	chr19:22245152	T/C	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.64e-7	Body mass index (change over time);
UCEC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.94	9.26	0.61	2.28e-16	Initial pursuit acceleration;
UCEC	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.42	0.41	2.39e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg06096015	chr1:231504339	EGLN1	0.5	5.99	0.44	1.57e-8	Hemoglobin concentration;
UCEC	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg24130564	chr14:104152367	KLC1	-0.56	-4.82	-0.37	3.59e-6	Reticulocyte count;
UCEC	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.63	5.13	0.39	8.9e-7	Menarche (age at onset);
UCEC	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg13256891	chr4:100009986	ADH5	-0.69	-5.15	-0.39	8.11e-7	Alcohol dependence;
UCEC	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.49	4.5	0.35	1.35e-5	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
UCEC	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.7	5.68	0.42	7.09e-8	Type 2 diabetes;
UCEC	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	9.72	0.63	1.49e-17	Electrocardiographic conduction measures;
UCEC	cis	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg14992524	chr8:10586135	SOX7	-0.28	-4.67	-0.36	6.74e-6	Neuroticism;
UCEC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.33	0.4	3.65e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs12979264	chr19:22865134	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg19513890	chr22:42538836	CYP2D7P1	0.45	4.99	0.38	1.68e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.57	5.95	0.44	1.85e-8	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg13683864	chr3:40499215	RPL14	-0.53	-5.43	-0.41	2.27e-7	Renal cell carcinoma;
UCEC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.64	-5.83	-0.43	3.4e-8	Initial pursuit acceleration;
UCEC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg04154034	chr17:28927549	LRRC37B2	0.72	5.22	0.4	6.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.55	4.8	0.37	3.91e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	0.79	5.62	0.42	9.18e-8	Mitochondrial DNA levels;
UCEC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.6	5.55	0.42	1.3e-7	Aortic root size;
UCEC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.36	0.46	2.36e-9	Tonsillectomy;
UCEC	cis	rs9467773	1.000	rs1977201	chr6:26573674	T/C	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.58e-6	Diabetic kidney disease;
UCEC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs61776719	0.806	rs28493395	chr1:38400558	C/T	cg17077180	chr1:38461687	NA	0.63	6.87	0.49	1.68e-10	Coronary artery disease;
UCEC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.59	-0.42	1.06e-7	Life satisfaction;
UCEC	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24249390	chr15:90295951	MESP1	-0.39	-4.51	-0.35	1.33e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.74	9.09	0.6	6.09e-16	Menarche (age at onset);
UCEC	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.7	7.22	0.51	2.53e-11	Menopause (age at onset);
UCEC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.59	6.12	0.45	8.06e-9	Longevity;Endometriosis;
UCEC	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.56	5.97	0.44	1.7e-8	HDL cholesterol;
UCEC	cis	rs6446731	0.517	rs2071667	chr4:3269926	C/A	cg08886695	chr4:3369023	RGS12	0.43	4.91	0.38	2.4e-6	Mean platelet volume;
UCEC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.52	-4.56	-0.35	1.05e-5	Urate levels;
UCEC	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-9.23	-0.61	2.79e-16	Monocyte count;
UCEC	cis	rs10208940	0.920	rs35005506	chr2:68814238	A/T	cg12452813	chr2:68675892	NA	0.48	4.63	0.36	7.91e-6	Urate levels in lean individuals;
UCEC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.24	-0.4	5.6e-7	Breast cancer;
UCEC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg26114124	chr12:9217669	LOC144571	0.4	4.77	0.37	4.45e-6	Sjögren's syndrome;
UCEC	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.29	0.46	3.37e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs9534288	0.619	rs1326397	chr13:46682122	T/C	cg15192986	chr13:46630673	CPB2	-0.5	-4.7	-0.36	5.81e-6	Blood protein levels;
UCEC	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.79	0.37	4.08e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs7246967	0.673	rs73020703	chr19:22844339	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	0.94	9.97	0.64	3.3e-18	Heart rate;
UCEC	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	4.97	0.38	1.82e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.73	8.36	0.57	4.32e-14	Menarche (age at onset);
UCEC	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.51	7.23	0.51	2.39e-11	Height;
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.43	-4.74	-0.36	4.96e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.72	-5.69	-0.42	6.75e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.5	5.45	0.41	2.07e-7	Tumor biomarkers;
UCEC	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs1239947	0.826	rs1239948	chr13:51106522	A/T	cg14857764	chr13:50706663	NA	0.41	4.55	0.35	1.13e-5	Height;
UCEC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Alcohol dependence;
UCEC	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21607453	chr9:98783545	NCRNA00092	0.52	6.69	0.48	4.46e-10	Warfarin maintenance dose;
UCEC	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg13683864	chr3:40499215	RPL14	-0.55	-5.91	-0.44	2.3e-8	Renal cell carcinoma;
UCEC	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg05660106	chr1:15850417	CASP9	0.57	5.03	0.38	1.42e-6	Systolic blood pressure;
UCEC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.57	-6.66	-0.48	5.08e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.2	-9.82	-0.63	8.35e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	5.78	0.43	4.27e-8	Joint mobility (Beighton score);
UCEC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.26	0.51	2.12e-11	Smoking behavior;
UCEC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-9.07	-0.6	7.22e-16	Gut microbiome composition (summer);
UCEC	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg11150807	chr10:43354902	NA	-0.8	-4.95	-0.38	1.97e-6	Blood protein levels;
UCEC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.63	6.72	0.48	3.71e-10	Platelet count;
UCEC	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.45	4.73	0.36	5.12e-6	Longevity;Endometriosis;
UCEC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.52	4.79	0.37	4.05e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs11697848	1.000	rs56307853	chr20:48579186	A/G	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.85	-7.03	-0.5	7.05e-11	Bronchopulmonary dysplasia;
UCEC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	5.74	0.43	5.17e-8	Cognitive test performance;
UCEC	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.81	-9.8	-0.63	9.19e-18	Leprosy;
UCEC	cis	rs3790645	0.958	rs7543005	chr1:26879376	T/C	cg23229016	chr1:26872525	RPS6KA1	0.35	6.53	0.47	1.01e-9	Glucose homeostasis traits;
UCEC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.58	-4.86	-0.37	2.98e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.02	-0.44	1.31e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.81	-4.76	-0.37	4.54e-6	Inflammatory biomarkers;
UCEC	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.69	7.05	0.5	6.34e-11	Coronary artery disease;
UCEC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.4	0.52	9.83e-12	Total body bone mineral density;
UCEC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.5	-4.65	-0.36	7.28e-6	Renal cell carcinoma;
UCEC	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-0.91	-9.15	-0.6	4.52e-16	Height;
UCEC	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	4.61	0.36	8.64e-6	Ileal carcinoids;
UCEC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.48	4.77	0.37	4.39e-6	Menopause (age at onset);
UCEC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs115344852	0.598	rs2531815	chr6:28436060	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.45	-4.72	-0.36	5.38e-6	Epithelial ovarian cancer;
UCEC	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.49	5.25	0.4	5.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs16957091	0.779	rs6493062	chr15:43017919	G/A	cg24196017	chr15:43021976	CDAN1	-0.45	-4.71	-0.36	5.74e-6	MGMT methylation in smokers;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.43	-4.68	-0.36	6.46e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg20999797	chr1:1681921	NA	0.35	4.62	0.36	8.39e-6	Body mass index;
UCEC	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	0.9	5.4	0.41	2.61e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs2267137	0.903	rs2072051	chr22:29755888	C/T	cg07256473	chr22:29710276	RASL10A	-0.53	-5.9	-0.44	2.38e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.46	-4.67	-0.36	6.64e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs4959677	0.792	rs6923507	chr6:2474347	T/C	cg16306259	chr6:1595099	NA	-0.4	-4.6	-0.36	8.89e-6	Orthostatic hypotension;
UCEC	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.44	4.55	0.35	1.13e-5	Schizophrenia;
UCEC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.7	7.65	0.53	2.42e-12	Mortality in heart failure;
UCEC	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.98	-7.13	-0.51	4.12e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg20307385	chr11:47447363	PSMC3	0.56	4.9	0.37	2.53e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9039	1.000	rs9039	chr16:9205363	A/G	cg08831531	chr16:9218945	NA	-0.47	-5.23	-0.4	5.69e-7	Menopause (age at onset);
UCEC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-5.33	-0.4	3.62e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.4	-4.61	-0.36	8.83e-6	Total body bone mineral density;
UCEC	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg23950597	chr19:37808831	NA	-0.65	-5.07	-0.39	1.2e-6	Coronary artery calcification;
UCEC	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg24127310	chr10:102502104	NA	1.12	11.29	0.68	1.1e-21	Alzheimer's disease;
UCEC	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg23791538	chr6:167370224	RNASET2	-0.54	-5.73	-0.43	5.62e-8	Primary biliary cholangitis;
UCEC	cis	rs2041895	0.509	rs2072559	chr12:107307287	T/G	cg13944111	chr12:107296891	NA	0.36	4.85	0.37	3.06e-6	Glaucoma (low intraocular pressure);
UCEC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	4.54	0.35	1.18e-5	Lung function (FEV1/FVC);
UCEC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.48	4.63	0.36	7.89e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.53	-5.12	-0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.59	-5.1	-0.39	1.02e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.6	-5.11	-0.39	1e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	4.86	0.37	2.94e-6	Schizophrenia;
UCEC	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.56	-5.68	-0.42	6.95e-8	Systemic lupus erythematosus;
UCEC	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.32	-0.52	1.5e-11	Hypospadias;
UCEC	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-1.08	-9.49	-0.62	5.79e-17	Dupuytren's disease;
UCEC	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	6.57	0.48	8.37e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.47	-4.63	-0.36	7.91e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.42	0.41	2.39e-7	Breast cancer;
UCEC	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.47	5.2	0.39	6.69e-7	Menarche (age at onset);
UCEC	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg24060327	chr5:131705240	SLC22A5	-0.51	-4.97	-0.38	1.84e-6	Acylcarnitine levels;
UCEC	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.46	-4.55	-0.35	1.13e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.47	4.79	0.37	4e-6	Dupuytren's disease;
UCEC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg03609598	chr5:56110824	MAP3K1	0.66	5.25	0.4	5.19e-7	Initial pursuit acceleration;
UCEC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg08805041	chr16:621841	PIGQ	-0.32	-4.64	-0.36	7.56e-6	Height;
UCEC	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg05090351	chr10:126851162	NA	0.41	4.61	0.36	8.65e-6	Menarche (age at onset);
UCEC	cis	rs256277	0.507	rs10463624	chr5:111299458	T/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-5.33	-0.4	3.63e-7	Coronary artery disease;
UCEC	cis	rs9309473	1.000	rs6756987	chr2:73687077	G/T	cg20560298	chr2:73613845	ALMS1	-0.63	-5.66	-0.42	7.6e-8	Metabolite levels;
UCEC	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.83	6.74	0.49	3.28e-10	Type 2 diabetes;
UCEC	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-10.16	-0.64	1.08e-18	Ulcerative colitis;
UCEC	cis	rs58521262	0.585	rs2927366	chr19:23229962	A/G	cg08486875	chr19:23386892	NA	0.34	4.65	0.36	7.45e-6	Testicular germ cell tumor;
UCEC	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.62	6.05	0.45	1.17e-8	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
UCEC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.59	-5.77	-0.43	4.45e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.56	5.98	0.44	1.63e-8	Schizophrenia;
UCEC	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.67	-4.92	-0.38	2.3e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.5	-4.93	-0.38	2.21e-6	Schizophrenia;
UCEC	cis	rs6761276	0.868	rs13386602	chr2:113834820	A/C	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg21053147	chr12:120880522	NA	-0.63	-5.23	-0.4	5.68e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.57	-5.02	-0.38	1.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.932	rs62120780	chr19:23043714	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1576263	0.967	rs1796698	chr6:8552469	A/G	cg07606381	chr6:8435919	SLC35B3	0.44	4.53	0.35	1.23e-5	Photic sneeze reflex;
UCEC	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.64	4.76	0.37	4.59e-6	Multiple sclerosis;
UCEC	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	7.27	0.51	2.02e-11	Eye color traits;
UCEC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.62	5.43	0.41	2.27e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.83	8.87	0.59	2.29e-15	Blood protein levels;
UCEC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	5.72	0.43	5.83e-8	Menarche (age at onset);
UCEC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.65	-6.0	-0.44	1.48e-8	Aortic root size;
UCEC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.71	-7.16	-0.51	3.53e-11	Blood metabolite levels;
UCEC	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.69	5.41	0.41	2.45e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4851266	1.000	rs1160543	chr2:100832182	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.32	0.46	3.01e-9	Educational attainment;
UCEC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	5.01	0.38	1.54e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.79	-7.32	-0.52	1.53e-11	Total cholesterol levels;
UCEC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.41	4.73	0.36	5.32e-6	Pulse pressure;
UCEC	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.59	5.48	0.41	1.79e-7	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.51	4.69	0.36	6.25e-6	Menopause (age at onset);
UCEC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.72	5.22	0.4	5.93e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.57	5.04	0.38	1.35e-6	Corneal astigmatism;
UCEC	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-9.63	-0.62	2.59e-17	Coffee consumption (cups per day);
UCEC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.58	5.98	0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.46	-5.19	-0.39	6.93e-7	Systemic lupus erythematosus;
UCEC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg12524725	chr2:239427019	NA	-0.65	-4.52	-0.35	1.25e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.55	4.97	0.38	1.82e-6	Crohn's disease;
UCEC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.7	-6.15	-0.45	7.04e-9	Response to metformin (IC50);
UCEC	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.33	4.5	0.35	1.37e-5	Height;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05215272	chr17:6899095	ALOX12	0.45	5.66	0.42	7.73e-8	Tonsillectomy;
UCEC	cis	rs1564271	0.528	rs2489589	chr10:26983095	A/G	cg24343755	chr10:26987087	PDSS1	-0.51	-4.55	-0.35	1.11e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
UCEC	cis	rs11077815	0.733	rs4516263	chr17:74432562	A/G	cg06840243	chr17:74442338	UBE2O	0.35	4.65	0.36	7.36e-6	Lymphocyte counts;
UCEC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	4.98	0.38	1.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-6.61	-0.48	6.6e-10	Primary biliary cholangitis;
UCEC	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-4.77	-0.37	4.37e-6	Pediatric autoimmune diseases;
UCEC	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	0.82	5.95	0.44	1.84e-8	Economic and political preferences (immigration/crime);
UCEC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	-1.01	-13.01	-0.73	3.04e-26	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.7	7.86	0.54	7.5e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.73	4.83	0.37	3.33e-6	Mitochondrial DNA levels;
UCEC	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.62	6.14	0.45	7.36e-9	Lung cancer;
UCEC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg20573242	chr4:122745356	CCNA2	0.6	5.42	0.41	2.43e-7	Type 2 diabetes;
UCEC	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.74	7.05	0.5	6.58e-11	Crohn's disease;
UCEC	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs1502337	0.561	rs12313391	chr12:110797730	C/T	cg21426559	chr12:111619406	CUX2	-0.48	-4.59	-0.35	9.54e-6	Body mass index;
UCEC	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.55	-4.79	-0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.74	-5.15	-0.39	8.14e-7	Facial morphology (factor 23);
UCEC	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.86e-7	Morning vs. evening chronotype;
UCEC	cis	rs13253111	0.583	rs6993376	chr8:28096300	A/C	cg26534493	chr8:28060551	NA	0.48	5.31	0.4	4.05e-7	Childhood body mass index;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20032723	chr11:126174041	DCPS	0.66	8.85	0.59	2.56e-15	Warfarin maintenance dose;
UCEC	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg13695892	chr22:41940480	POLR3H	-0.66	-4.62	-0.36	8.3e-6	Vitiligo;
UCEC	cis	rs7404928	0.609	rs56213545	chr16:23936910	G/A	cg01062539	chr16:23765258	CHP2	-0.54	-4.74	-0.36	4.99e-6	Primary biliary cholangitis;Rheumatoid arthritis;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.51	-5.36	-0.4	3.16e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.72	7.33	0.52	1.44e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg11871910	chr12:69753446	YEATS4	-0.55	-4.91	-0.38	2.36e-6	Response to diuretic therapy;
UCEC	cis	rs55692468	0.606	rs1878632	chr2:153323158	A/C	cg20171711	chr2:153307345	FMNL2	-0.5	-4.73	-0.36	5.2e-6	Intraocular pressure;
UCEC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg05501817	chr11:14380813	RRAS2	-0.48	-4.71	-0.36	5.75e-6	Vitamin D levels;
UCEC	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	7.18	0.51	3.21e-11	LDL cholesterol;
UCEC	cis	rs11867410	0.744	rs56329569	chr17:63928492	C/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2041895	0.509	rs10861676	chr12:107311235	G/A	cg13944111	chr12:107296891	NA	0.34	4.53	0.35	1.23e-5	Glaucoma (low intraocular pressure);
UCEC	cis	rs7246967	0.866	rs12984122	chr19:23030674	G/A	cg08271804	chr19:22816896	ZNF492	0.59	5.6	0.42	1.03e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.67	-6.23	-0.46	4.73e-9	Aortic root size;
UCEC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18252515	chr7:66147081	NA	0.52	5.44	0.41	2.14e-7	Aortic root size;
UCEC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.0	0.5	8.48e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.63	-5.41	-0.41	2.49e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.99	-0.38	1.7e-6	Metabolite levels;
UCEC	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.56	-5.65	-0.42	7.93e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	8.79	0.59	3.62e-15	Hip circumference;
UCEC	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	0.94	14.47	0.77	4.73e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2251301	0.891	rs11776159	chr8:11119886	G/A	cg23565663	chr8:10621935	NA	0.55	4.61	0.36	8.75e-6	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	6.99	0.5	8.75e-11	Coffee consumption (cups per day);
UCEC	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.38	-4.89	-0.37	2.57e-6	Type 2 diabetes;
UCEC	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs60311166	1.000	rs1987234	chr3:52598359	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.85	4.75	0.37	4.69e-6	CTACK levels;
UCEC	cis	rs11761441	0.602	rs11769996	chr7:88722	C/T	cg06458707	chr7:1083209	C7orf50	0.25	4.63	0.36	7.9e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.6	7.82	0.54	9.38e-13	Coronary artery disease;
UCEC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.28	-0.51	1.89e-11	Blood trace element (Zn levels);
UCEC	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.77	7.41	0.52	8.97e-12	Response to antipsychotic treatment;
UCEC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-9.64	-0.62	2.47e-17	Height;
UCEC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.65	7.42	0.52	8.58e-12	Homoarginine levels;
UCEC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.95	-0.44	1.89e-8	Blood metabolite levels;
UCEC	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.42	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.45	-4.54	-0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.41	4.82	0.37	3.57e-6	Height;
UCEC	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.46	-4.58	-0.35	1e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.72	6.73	0.49	3.61e-10	Aortic root size;
UCEC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.38	-4.71	-0.36	5.68e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24308560	chr3:49941425	MST1R	0.44	4.74	0.36	4.99e-6	Body mass index;
UCEC	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.59	-5.34	-0.4	3.4e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7646881	0.544	rs10154917	chr3:158332700	G/T	cg05743054	chr3:158288903	MLF1	-0.51	-4.59	-0.35	9.54e-6	Tetralogy of Fallot;
UCEC	cis	rs829661	0.947	rs829669	chr2:30720752	A/G	cg17749961	chr2:30669863	LCLAT1	0.51	4.69	0.36	6.21e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.45	-4.97	-0.38	1.84e-6	Mosquito bite size;
UCEC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.85	-9.09	-0.6	6.14e-16	Lung cancer;
UCEC	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.61	5.53	0.42	1.4e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg04682699	chr3:50248845	SLC38A3	-0.38	-4.95	-0.38	2.02e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.98	-0.44	1.6e-8	Chronic sinus infection;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.63	6.21	0.46	5.25e-9	Longevity;Endometriosis;
UCEC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.53	-0.53	4.75e-12	Breast cancer;
UCEC	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.48	-6.32	-0.46	2.99e-9	Neutrophil percentage of white cells;
UCEC	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.55	-0.35	1.11e-5	Joint mobility (Beighton score);
UCEC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.02	0.44	1.35e-8	Cognitive test performance;
UCEC	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	0.94	7.05	0.5	6.41e-11	Major depression and alcohol dependence;
UCEC	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-4.85	-0.37	3.17e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg15513719	chr13:114904418	NA	0.49	4.86	0.37	2.92e-6	Schizophrenia;
UCEC	cis	rs1545257	0.505	rs12988810	chr2:24635093	G/T	cg06627628	chr2:24431161	ITSN2	-0.52	-5.16	-0.39	7.78e-7	Sjögren's syndrome;
UCEC	cis	rs953387	1.000	rs4954564	chr2:136895508	A/G	cg07169764	chr2:136633963	MCM6	0.55	5.54	0.42	1.34e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs3790645	0.874	rs9438508	chr1:26893069	T/C	cg23229016	chr1:26872525	RPS6KA1	0.31	5.74	0.43	5.29e-8	Glucose homeostasis traits;
UCEC	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg23795048	chr12:9217529	LOC144571	0.42	4.89	0.37	2.63e-6	Sjögren's syndrome;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg08461772	chr7:95026248	PON3	0.38	5.02	0.38	1.49e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17162190	0.685	rs7530096	chr1:26820218	G/A	cg23229016	chr1:26872525	RPS6KA1	0.27	4.6	0.35	9.01e-6	Mean corpuscular volume;
UCEC	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	0.55	6.91	0.5	1.34e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2425143	0.818	rs6060726	chr20:34555878	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.77	-0.37	4.36e-6	Blood protein levels;
UCEC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg20999797	chr1:1681921	NA	0.39	5.21	0.39	6.35e-7	Body mass index;
UCEC	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg24562669	chr7:97807699	LMTK2	0.49	6.05	0.45	1.15e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.51e-16	Post bronchodilator FEV1;
UCEC	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.53	5.96	0.44	1.81e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	0.99	11.11	0.68	3.27e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg11161011	chr14:65562177	MAX	-0.56	-5.72	-0.43	5.83e-8	Obesity-related traits;
UCEC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.55	-4.54	-0.35	1.16e-5	Depression;
UCEC	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.85	-13.02	-0.73	2.97e-26	Birth weight;
UCEC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.51	4.9	0.37	2.52e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.6	-6.6	-0.48	7.12e-10	Asthma;
UCEC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.63	7.21	0.51	2.72e-11	Body mass index;
UCEC	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14298792	chr15:30685198	CHRFAM7A	0.57	4.84	0.37	3.23e-6	Huntington's disease progression;
UCEC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.47	-4.76	-0.37	4.6e-6	Testicular germ cell tumor;
UCEC	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.84	9.58	0.62	3.5e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7656342	0.897	rs7685396	chr4:9794724	C/A	cg11266682	chr4:10021025	SLC2A9	0.43	4.93	0.38	2.24e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg05539622	chr2:73298971	SFXN5	0.49	4.89	0.37	2.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.58	4.89	0.37	2.64e-6	Neutrophil percentage of white cells;
UCEC	cis	rs2882667	0.858	rs11242444	chr5:138406379	T/A	cg04439458	chr5:138467593	SIL1	-0.46	-5.11	-0.39	1e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.65	-5.16	-0.39	7.84e-7	Huntington's disease progression;
UCEC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.7	-6.5	-0.47	1.18e-9	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-6.43	-0.47	1.64e-9	Mean platelet volume;
UCEC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.25	0.4	5.32e-7	Birth weight;
UCEC	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.33	-0.4	3.67e-7	Resting heart rate;
UCEC	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	7.81	0.54	9.94e-13	Ulcerative colitis;
UCEC	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.5	-4.76	-0.37	4.63e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.76	7.69	0.54	2e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.58	-0.35	9.66e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2455799	0.929	rs2455850	chr3:15782711	A/C	cg16303742	chr3:15540471	COLQ	-0.42	-4.82	-0.37	3.58e-6	Mean platelet volume;
UCEC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.14	15.04	0.78	1.52e-31	Cognitive function;
UCEC	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.49	4.75	0.37	4.71e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs884366	1.000	rs4946955	chr6:109639710	C/G	cg01475377	chr6:109611718	NA	0.46	5.11	0.39	9.82e-7	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.77	6.96	0.5	1.05e-10	Menopause (age at onset);
UCEC	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.73	8.28	0.56	7.13e-14	Schizophrenia;
UCEC	cis	rs73416724	1.000	rs74766084	chr6:43287804	G/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.07	4.9	0.37	2.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6460942	1.000	rs112794590	chr7:12319426	G/A	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.43	4.6	0.35	9.23e-6	Eye color traits;
UCEC	cis	rs692916	0.669	rs615308	chr18:60521113	A/G	cg07187971	chr18:60481018	PHLPP1	-0.34	-4.69	-0.36	6.25e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.58	5.98	0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.43	4.51	0.35	1.31e-5	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	8.64	0.58	8.66e-15	Blood protein levels;
UCEC	cis	rs8032158	0.963	rs1912402	chr15:56161919	C/T	cg10433327	chr15:56209506	NEDD4	-0.3	-4.86	-0.37	3.01e-6	Keloid;
UCEC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg06238570	chr21:40685208	BRWD1	0.81	8.07	0.55	2.33e-13	Cognitive function;
UCEC	cis	rs7113850	0.551	rs4365050	chr11:24245730	G/A	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Bone fracture in osteoporosis;
UCEC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.69	5.7	0.43	6.4e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.09	18.26	0.83	1.25e-39	Testicular germ cell tumor;
UCEC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg13844804	chr7:814759	HEATR2	0.68	5.01	0.38	1.52e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18252515	chr7:66147081	NA	0.52	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	6.79	0.49	2.6200000000000003e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.77	-10.01	-0.64	2.6e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.57	-6.25	-0.46	4.15e-9	Bipolar disorder;
UCEC	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.83	-0.49	2.11e-10	Total cholesterol levels;
UCEC	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.64	-6.01	-0.44	1.37e-8	Aortic root size;
UCEC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg13073564	chr4:8508604	NA	-0.46	-5.03	-0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Axial length;
UCEC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg03609598	chr5:56110824	MAP3K1	0.71	5.46	0.41	2.01e-7	Initial pursuit acceleration;
UCEC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.82	0.75	2.28e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg01689657	chr7:91764605	CYP51A1	0.51	6.73	0.49	3.46e-10	Breast cancer;
UCEC	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg16797656	chr11:68205561	LRP5	0.47	5.43	0.41	2.24e-7	Total body bone mineral density;
UCEC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg13695892	chr22:41940480	POLR3H	-0.68	-5.44	-0.41	2.21e-7	Vitiligo;
UCEC	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.42	0.47	1.73e-9	Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs1570059	chr6:26573325	C/T	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.89	7.53	0.53	4.69e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.59	0.53	3.42e-12	Menopause (age at onset);
UCEC	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.91	9.95	0.63	3.77e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.62	-5.53	-0.41	1.44e-7	Mortality in heart failure;
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18932078	chr1:2524107	MMEL1	0.39	6.23	0.46	4.69e-9	Ulcerative colitis;
UCEC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.62	7.33	0.52	1.46e-11	Vitiligo;
UCEC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.41	-4.67	-0.36	6.76e-6	Post bronchodilator FEV1;
UCEC	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs8105895	1.000	rs11882234	chr19:22145727	C/T	cg20662725	chr19:22235022	ZNF257	-0.66	-5.5	-0.41	1.61e-7	Body mass index (change over time);
UCEC	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Parkinson's disease;
UCEC	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg18681998	chr4:17616180	MED28	0.9	11.82	0.7	4.49e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg19318889	chr4:1322082	MAEA	0.5	5.5	0.41	1.63e-7	Obesity-related traits;
UCEC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg03433033	chr1:76189801	ACADM	-0.54	-4.81	-0.37	3.68e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-4.9	-0.37	2.53e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.52	-5.19	-0.39	7e-7	Bladder cancer;
UCEC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg01112020	chr2:239008986	ESPNL	-0.36	-4.73	-0.36	5.28e-6	Prostate cancer;
UCEC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.48	5.24	0.4	5.57e-7	Systemic lupus erythematosus;
UCEC	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18932078	chr1:2524107	MMEL1	-0.32	-5.16	-0.39	7.74e-7	Ulcerative colitis;
UCEC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.89	-9.8	-0.63	9.27e-18	Cognitive function;
UCEC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg13870426	chr17:30244630	NA	-0.62	-4.52	-0.35	1.24e-5	Hip circumference adjusted for BMI;
UCEC	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.29	10.84	0.67	1.74e-20	Uric acid levels;
UCEC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	13.98	0.76	8.75e-29	Height;
UCEC	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.21	0.39	6.37e-7	Alzheimer's disease;
UCEC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.58	0.48	7.7e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.54	0.35	1.18e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.65	4.96	0.38	1.95e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7219021	0.961	rs9906942	chr17:46864634	G/A	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.55	0.35	1.1e-5	Menarche (age at onset);
UCEC	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.62	0.58	9.76e-15	Platelet count;
UCEC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg23307798	chr14:103986281	CKB	0.56	5.23	0.4	5.66e-7	Body mass index;
UCEC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	7.18	0.51	3.27e-11	Body mass index (adult);
UCEC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.15	-0.51	3.85e-11	Breast cancer;
UCEC	cis	rs7937612	0.897	rs7126413	chr11:120207405	A/G	cg12584626	chr11:120203529	NA	0.49	5.19	0.39	6.89e-7	Intraocular pressure;
UCEC	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg20560298	chr2:73613845	ALMS1	0.53	5.16	0.39	7.87e-7	Schizophrenia;
UCEC	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.52	6.51	0.47	1.09e-9	Mean platelet volume;
UCEC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.57	-4.52	-0.35	1.25e-5	Lymphocyte percentage of white cells;
UCEC	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.76	-8.4	-0.57	3.41e-14	Ulcerative colitis;
UCEC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.54	-5.62	-0.42	9.22e-8	Breast cancer;
UCEC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	7.0	0.5	8.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.8	-0.37	3.92e-6	Response to antipsychotic treatment;
UCEC	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg27246729	chr12:121163418	ACADS	0.46	4.53	0.35	1.22e-5	Mean corpuscular volume;
UCEC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.61	5.73	0.43	5.51e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg13393036	chr8:95962371	TP53INP1	-0.39	-4.82	-0.37	3.56e-6	Type 2 diabetes;
UCEC	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.75	-8.42	-0.57	3.1e-14	Extraversion;
UCEC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	4.9	0.37	2.47e-6	Parkinson's disease;
UCEC	cis	rs9309473	1.000	rs10496193	chr2:73773503	G/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.47	-0.41	1.92e-7	Metabolite levels;
UCEC	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.45	-0.41	2.1e-7	Aortic root size;
UCEC	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.85	-0.49	1.88e-10	Menarche (age at onset);
UCEC	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.71	-5.87	-0.44	2.79e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.51	-7.36	-0.52	1.2e-11	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.82	9.4	0.61	1.01e-16	Metabolite levels;
UCEC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.48	-4.77	-0.37	4.37e-6	Dental caries;
UCEC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.78	8.92	0.59	1.72e-15	Menopause (age at onset);
UCEC	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-4.54	-0.35	1.17e-5	Rheumatoid arthritis;
UCEC	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.55	-5.04	-0.38	1.34e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg18681998	chr4:17616180	MED28	0.78	9.1	0.6	5.77e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-6.71	-0.48	3.92e-10	Platelet distribution width;
UCEC	cis	rs7766436	0.885	rs13202434	chr6:22583694	G/C	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs1030877	1.000	rs2254301	chr2:105880734	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.87	11.53	0.69	2.61e-22	Obesity-related traits;
UCEC	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.47	-5.1	-0.39	1.02e-6	Alcohol dependence;
UCEC	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.5	-0.41	1.61e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg24375607	chr4:120327624	NA	0.45	4.58	0.35	9.93e-6	Corneal astigmatism;
UCEC	cis	rs7106204	0.514	rs2099889	chr11:24255971	A/G	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.65	-5.47	-0.41	1.92e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg02356786	chr1:243265016	LOC731275	0.84	5.87	0.44	2.75e-8	Obesity (early onset extreme);
UCEC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	6.74	0.49	3.3e-10	Bone mineral density;
UCEC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.56	-0.35	1.08e-5	Monocyte percentage of white cells;
UCEC	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.58	4.97	0.38	1.85e-6	Huntington's disease progression;
UCEC	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.44	5.12	0.39	9.23e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.6	0.42	1.02e-7	Height;
UCEC	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg21770322	chr7:97807741	LMTK2	0.51	6.39	0.47	2.07e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.65	-0.58	8.2e-15	Menarche (age at onset);
UCEC	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.86	8.55	0.58	1.46e-14	Colorectal cancer;
UCEC	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.47	4.72	0.36	5.53e-6	Prostate cancer;
UCEC	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.29	-0.56	6.44e-14	Chronic sinus infection;
UCEC	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.5	6.29	0.46	3.49e-9	Educational attainment (years of education);
UCEC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-6.22	-0.46	4.89e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24308560	chr3:49941425	MST1R	-0.49	-5.35	-0.4	3.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.76	7.74	0.54	1.47e-12	Parkinson's disease;
UCEC	cis	rs7011507	0.545	rs7825510	chr8:49075009	T/C	ch.8.1073630F	chr8:48637817	KIAA0146	-0.49	-4.61	-0.36	8.6e-6	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.61	-7.58	-0.53	3.63e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg17469321	chr7:55412551	NA	0.67	6.17	0.45	6.38e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.54	-5.35	-0.4	3.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.67	8.07	0.55	2.32e-13	Testicular germ cell tumor;
UCEC	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg14675211	chr2:100938903	LONRF2	-0.59	-6.12	-0.45	8.19e-9	Educational attainment;
UCEC	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.23	0.4	5.64e-7	Blood protein levels;
UCEC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.54	5.84	0.43	3.16e-8	Schizophrenia;
UCEC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.6	4.84	0.37	3.21e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
UCEC	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.95	12.1	0.71	8.24e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg25828445	chr12:7781288	NA	0.57	4.61	0.36	8.56e-6	HDL cholesterol levels;
UCEC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.1	0.39	1.03e-6	Breast cancer;
UCEC	cis	rs2944755	0.919	rs2944754	chr8:141574350	A/G	cg08444833	chr8:141574162	EIF2C2	0.71	5.04	0.38	1.35e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.51	-4.65	-0.36	7.31e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-4.51	-0.35	1.29e-5	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.59	6.23	0.46	4.69e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.91	6.44	0.47	1.58e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4880487	0.888	rs67699390	chr10:1252427	G/A	cg03183215	chr10:1252341	ADARB2	-0.48	-5.64	-0.42	8.58e-8	Migraine;
UCEC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg24687543	chr11:63912206	MACROD1	0.39	4.8	0.37	3.87e-6	Platelet count;
UCEC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.6	-5.83	-0.43	3.41e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.76	5.02	0.38	1.49e-6	Major depressive disorder;
UCEC	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.47	5.18	0.39	7.25e-7	Menarche (age at onset);
UCEC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.78	-6.33	-0.46	2.81e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.55	-5.94	-0.44	1.95e-8	Bipolar disorder;
UCEC	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.0	-15.41	-0.79	1.7e-32	Colorectal cancer;
UCEC	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.72	8.14	0.56	1.58e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7968440	0.966	rs1521516	chr12:51055708	C/T	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.85	10.61	0.66	7.02e-20	Mortality in heart failure;
UCEC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-6.77	-0.49	2.88e-10	Schizophrenia;
UCEC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.35	4.83	0.37	3.42e-6	Eye color traits;
UCEC	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.43	4.64	0.36	7.53e-6	Obesity-related traits;
UCEC	cis	rs61776719	0.905	rs17465420	chr1:38398588	T/C	cg18451016	chr1:38461880	NA	0.68	7.53	0.53	4.64e-12	Coronary artery disease;
UCEC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg22166914	chr1:53195759	ZYG11B	0.87	9.8	0.63	9.01e-18	Monocyte count;
UCEC	cis	rs732765	0.734	rs12897105	chr14:75188122	G/T	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.83	-0.37	3.44e-6	Pulmonary function;
UCEC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.56	5.08	0.39	1.13e-6	White matter hyperintensity burden;
UCEC	cis	rs12681287	1.000	rs12681287	chr8:87269536	A/C	cg27223183	chr8:87520930	FAM82B	0.57	5.31	0.4	4.01e-7	Caudate activity during reward;
UCEC	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.43	5.21	0.39	6.35e-7	Migraine;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg14035550	chr2:10861421	ATP6V1C2	0.6	6.88	0.49	1.64e-10	Schizophrenia;
UCEC	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.83	-10.21	-0.64	7.68e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.98	-7.66	-0.53	2.25e-12	Dupuytren's disease;
UCEC	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.68	-6.11	-0.45	8.61e-9	Aortic root size;
UCEC	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.69	8.42	0.57	3.15e-14	Prevalent atrial fibrillation;
UCEC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-6.02	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	7.54	0.53	4.38e-12	Menarche (age at onset);
UCEC	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.56	5.78	0.43	4.37e-8	Eosinophil percentage of white cells;
UCEC	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-6.86	-0.49	1.82e-10	Coronary artery disease;
UCEC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.66	-7.66	-0.53	2.33e-12	Headache;
UCEC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.8	6.34	0.46	2.65e-9	Body mass index;
UCEC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	5.0	0.38	1.62e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs75804782	0.515	rs75251934	chr2:239288387	A/C	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	5.05	0.38	1.3e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg13695892	chr22:41940480	POLR3H	0.67	4.76	0.37	4.66e-6	Vitiligo;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02008951	chr19:5703619	LONP1	-0.57	-6.83	-0.49	2.05e-10	N-glycan levels;
UCEC	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg10503236	chr1:231470652	EXOC8	-0.42	-5.1	-0.39	1.02e-6	Hemoglobin concentration;
UCEC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.48	5.13	0.39	8.95e-7	Pulse pressure;
UCEC	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.9	10.0	0.64	2.85e-18	Ulcerative colitis;
UCEC	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg13575925	chr12:9217583	LOC144571	0.4	4.54	0.35	1.14e-5	Sjögren's syndrome;
UCEC	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.69	6.07	0.45	1.03e-8	Bipolar disorder;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.52	-5.68	-0.42	7.06e-8	Cardiac Troponin-T levels;
UCEC	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.03	0.55	2.83e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-5.52	-0.41	1.52e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	0.76	4.98	0.38	1.77e-6	Diabetic retinopathy;
UCEC	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.77	-9.58	-0.62	3.43e-17	Leprosy;
UCEC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.69	-7.7	-0.54	1.88e-12	Coronary artery disease;
UCEC	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.51	5.59	0.42	1.05e-7	HDL cholesterol;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.53	-0.47	9.79e-10	Pubertal anthropometrics;
UCEC	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.34	5.53	0.41	1.45e-7	Diastolic blood pressure;
UCEC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-6.69	-0.48	4.35e-10	Initial pursuit acceleration;
UCEC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg04310649	chr10:35416472	CREM	-0.47	-4.69	-0.36	6.3e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Primary biliary cholangitis;
UCEC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.43	-4.85	-0.37	3.09e-6	Body mass index;
UCEC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-5.95	-0.44	1.88e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.91	11.49	0.69	3.36e-22	Breast cancer;
UCEC	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg18681998	chr4:17616180	MED28	0.67	7.8	0.54	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.17	0.39	7.62e-7	Response to antipsychotic treatment;
UCEC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.68	7.45	0.52	7.46e-12	Menopause (age at onset);
UCEC	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-6.42	-0.47	1.81e-9	Asthma;
UCEC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-5.96	-0.44	1.77e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.65	-0.42	8.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.42	6.04	0.45	1.22e-8	Primary biliary cholangitis;
UCEC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.19	-0.45	5.8e-9	Menarche (age at onset);
UCEC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.71	-7.16	-0.51	3.53e-11	Blood metabolite levels;
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.38	-0.41	2.81e-7	Longevity;Endometriosis;
UCEC	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.01	6.29	0.46	3.51e-9	Skin colour saturation;
UCEC	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.55	4.62	0.36	8.38e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs7258465	0.563	rs10854166	chr19:18652844	A/G	cg06462663	chr19:18546047	ISYNA1	-0.44	-5.0	-0.38	1.62e-6	Breast cancer;
UCEC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.96	6.62	0.48	6.33e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg04310649	chr10:35416472	CREM	-0.48	-4.85	-0.37	3.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18252515	chr7:66147081	NA	-0.53	-5.15	-0.39	8.38e-7	Aortic root size;
UCEC	cis	rs8177876	0.822	rs10514515	chr16:81115322	T/C	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.53	-5.33	-0.4	3.68e-7	Prostate cancer;
UCEC	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.63	-6.03	-0.45	1.3e-8	Urate levels in obese individuals;
UCEC	cis	rs12618769	0.597	rs3754886	chr2:99107677	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14019695	chr9:139328340	INPP5E	0.49	5.24	0.4	5.37e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.36	-0.4	3.18e-7	Hemoglobin concentration;
UCEC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.39	-5.19	-0.39	6.86e-7	Type 2 diabetes;
UCEC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.73	0.36	5.19e-6	Tonsillectomy;
UCEC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg00277334	chr10:82204260	NA	-0.42	-4.55	-0.35	1.13e-5	Post bronchodilator FEV1;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.61	-6.37	-0.47	2.26e-9	Parkinson's disease;
UCEC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.57	5.84	0.43	3.29e-8	Obesity-related traits;
UCEC	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.78	8.48	0.57	2.15e-14	Metabolite levels;
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.54	-6.58	-0.48	7.86e-10	Pubertal anthropometrics;
UCEC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.59	-5.7	-0.43	6.21e-8	Schizophrenia;
UCEC	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg21419209	chr3:44054225	NA	-0.47	-5.01	-0.38	1.57e-6	Coronary artery disease;
UCEC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.48	4.71	0.36	5.72e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	6.93	0.5	1.21e-10	Platelet count;
UCEC	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.89	9.96	0.63	3.47e-18	Ulcerative colitis;
UCEC	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.53	2.09e-12	IgG glycosylation;
UCEC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.57	5.57	0.42	1.18e-7	Asthma (sex interaction);
UCEC	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg20560298	chr2:73613845	ALMS1	0.54	5.12	0.39	9.55e-7	Metabolite levels;
UCEC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	5.78	0.43	4.32e-8	Colorectal cancer;
UCEC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.68	5.73	0.43	5.5e-8	Menopause (age at onset);
UCEC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	5.48	0.41	1.84e-7	Personality dimensions;
UCEC	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.72	5.63	0.42	8.79e-8	Obesity-related traits;
UCEC	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Parkinson's disease;
UCEC	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.44	4.55	0.35	1.13e-5	Response to temozolomide;
UCEC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.8	-8.77	-0.59	3.98e-15	Breast cancer;
UCEC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.52	5.53	0.42	1.39e-7	Breast cancer;
UCEC	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.15	9.39	0.61	1.05e-16	Uric acid levels;
UCEC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.67	-7.13	-0.51	4.27e-11	Height;
UCEC	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.58	7.65	0.53	2.47e-12	Height;
UCEC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.55	-5.21	-0.4	6.17e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs59104589	0.617	rs3755400	chr2:242379795	A/C	cg19488206	chr2:242435732	STK25	-0.54	-4.81	-0.37	3.68e-6	Fibrinogen levels;
UCEC	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.58	6.27	0.46	3.85e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.73	-0.36	5.23e-6	Aortic root size;
UCEC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.67	7.61	0.53	3.06e-12	Menopause (age at onset);
UCEC	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.07	0.45	1.02e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.82	-8.48	-0.57	2.24e-14	Caffeine consumption;
UCEC	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.19	0.39	6.99e-7	Aortic root size;
UCEC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	5.29	0.4	4.38e-7	Cognitive test performance;
UCEC	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg03354898	chr7:1950403	MAD1L1	0.51	5.76	0.43	4.8e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2075165	0.901	rs2296374	chr1:156287403	T/C	cg20302342	chr1:156215951	PAQR6	0.52	5.42	0.41	2.39e-7	Tonsillectomy;
UCEC	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg20399509	chr21:47717575	C21orf57	-0.46	-4.97	-0.38	1.81e-6	Testicular germ cell tumor;
UCEC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg07153921	chr17:41440717	NA	-0.56	-5.88	-0.44	2.64e-8	Menopause (age at onset);
UCEC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.77	-0.49	2.85e-10	Obesity-related traits;
UCEC	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg18681998	chr4:17616180	MED28	0.78	8.56	0.58	1.35e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg22166914	chr1:53195759	ZYG11B	-0.68	-7.28	-0.52	1.81e-11	Monocyte count;
UCEC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.51	-5.08	-0.39	1.13e-6	Obesity-related traits;
UCEC	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.32	0.4	3.78e-7	Breast cancer;
UCEC	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	6.54	0.48	9.3e-10	Ileal carcinoids;
UCEC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.82	0.54	9.46e-13	Platelet count;
UCEC	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg26408565	chr15:76604113	ETFA	-0.45	-4.59	-0.35	9.58e-6	Blood metabolite levels;
UCEC	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg04176532	chr22:50317003	CRELD2	0.47	4.73	0.36	5.12e-6	Schizophrenia;
UCEC	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg06462663	chr19:18546047	ISYNA1	0.39	4.79	0.37	4.04e-6	Breast cancer;
UCEC	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-5.26	-0.4	4.91e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs539514	0.627	rs9544034	chr13:76293764	G/A	cg04757411	chr13:76259545	LMO7	-0.38	-4.56	-0.35	1.08e-5	Type 1 diabetes;
UCEC	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.32	-0.46	2.96e-9	Response to antipsychotic treatment;
UCEC	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	4.67	0.36	6.73e-6	Educational attainment;
UCEC	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.44e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.95	-14.71	-0.77	1.09e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs427941	0.521	rs73187852	chr7:101878336	C/T	cg08135718	chr7:101819329	CUX1	0.56	5.71	0.43	5.93e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg11871910	chr12:69753446	YEATS4	1.06	13.41	0.74	2.74e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.6	-6.07	-0.45	1.05e-8	Homoarginine levels;
UCEC	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	13.08	0.73	2.11e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.5	6.06	0.45	1.09e-8	Coronary artery disease;
UCEC	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.57	0.53	3.81e-12	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.23	-14.63	-0.77	1.8e-30	Breast cancer;
UCEC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.57	-4.93	-0.38	2.18e-6	Coronary artery disease;
UCEC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg27153327	chr16:1920815	C16orf73	-0.43	-4.68	-0.36	6.35e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7224668	0.647	rs9892688	chr17:79252517	C/G	cg15215033	chr17:79258732	SLC38A10	0.33	4.69	0.36	6.22e-6	IgG glycosylation;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.97	-0.38	1.83e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.63	6.65	0.48	5.27e-10	Skin colour saturation;
UCEC	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.57	-5.79	-0.43	4.16e-8	Bipolar disorder;
UCEC	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.8	-9.95	-0.63	3.87e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs1552244	0.608	rs2302786	chr3:9979660	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	5.16	0.39	7.88e-7	Alzheimer's disease;
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg24503407	chr1:205819492	PM20D1	0.87	10.58	0.66	8.29e-20	Menarche (age at onset);
UCEC	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg17279458	chr3:44753948	ZNF502	-0.58	-4.85	-0.37	3.17e-6	IgG glycosylation;
UCEC	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	5.87	0.44	2.83e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	0.97	7.41	0.52	9.35e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.74	-6.22	-0.46	4.96e-9	Colorectal adenoma (advanced);
UCEC	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	4.96	0.38	1.92e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.8	-0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.66	5.22	0.4	6.03e-7	Testicular germ cell tumor;
UCEC	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.44	-4.64	-0.36	7.52e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6576086	1.000	rs6576086	chr14:105873144	A/G	cg27100511	chr14:105927968	MTA1	0.71	6.23	0.46	4.6e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs2283228	0.737	rs7480855	chr11:2836085	C/T	cg06582202	chr11:2889886	KCNQ1DN	0.63	4.76	0.37	4.59e-6	Type 2 diabetes;
UCEC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.67	0.42	7.24e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.48	5.29	0.4	4.26e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.61	0.42	9.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.84	9.07	0.6	7.11e-16	Blood protein levels;
UCEC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.44	-5.55	-0.42	1.28e-7	Abdominal aortic aneurysm;
UCEC	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	1.2	8.95	0.59	1.46e-15	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17122693	1.000	rs1018039	chr14:51085793	C/T	cg04730355	chr14:51134070	SAV1	0.78	7.87	0.54	7.23e-13	Cognitive performance;
UCEC	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg24562669	chr7:97807699	LMTK2	0.48	5.82	0.43	3.51e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.57	7.96	0.55	4.2e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.56	-6.3	-0.46	3.19e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.56	5.51	0.41	1.59e-7	Facial morphology (factor 23);
UCEC	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg03354898	chr7:1950403	MAD1L1	-0.5	-5.38	-0.41	2.85e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.45	-5.18	-0.39	7.21e-7	Total body bone mineral density;
UCEC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg19034708	chr8:17780168	PCM1	0.7	6.91	0.5	1.34e-10	Triglyceride levels;
UCEC	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-1.03	-10.51	-0.65	1.29e-19	Alcohol dependence;
UCEC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.82	8.73	0.58	5.22e-15	Blood protein levels;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-4.66	-0.36	7.11e-6	Pediatric autoimmune diseases;
UCEC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg10503236	chr1:231470652	EXOC8	0.44	5.07	0.39	1.19e-6	Hemoglobin concentration;
UCEC	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg06096015	chr1:231504339	EGLN1	0.41	4.77	0.37	4.45e-6	Hemoglobin concentration;
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.8	0.59	3.41e-15	Platelet count;
UCEC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.46	4.96	0.38	1.93e-6	Smoking initiation;
UCEC	cis	rs787274	1.000	rs787272	chr9:115549547	C/T	cg13803584	chr9:115635662	SNX30	0.63	4.73	0.36	5.26e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.66	-7.26	-0.51	2.06e-11	Homoarginine levels;
UCEC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	6.44	0.47	1.62e-9	Cognitive test performance;
UCEC	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.12	10.82	0.67	1.94e-20	Vitiligo;
UCEC	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.55	-5.37	-0.4	3.04e-7	Cocaine dependence;
UCEC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg23324259	chr8:82754387	SNX16	0.56	4.89	0.37	2.59e-6	Diastolic blood pressure;
UCEC	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.47	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs970548	0.954	rs11239536	chr10:45978598	T/A	cg15223267	chr10:46222474	FAM21C	0.54	5.14	0.39	8.58e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.53	-0.53	4.76e-12	Total cholesterol levels;
UCEC	cis	rs1816854	0.938	rs11182280	chr12:44209584	T/C	cg00106942	chr12:44200524	TWF1	0.5	5.04	0.38	1.36e-6	Inflammatory bowel disease;
UCEC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.88	10.72	0.66	3.51e-20	Cognitive function;
UCEC	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg20713898	chr8:124780851	FAM91A1	0.47	4.94	0.38	2.07e-6	Pancreatic cancer;
UCEC	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.7	6.29	0.46	3.39e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs626657	1.000	rs626657	chr17:37332963	A/C	cg20555674	chr17:37321631	ARL5C	-0.4	-4.91	-0.38	2.42e-6	IgG glycosylation;
UCEC	cis	rs10012307	0.901	rs2897300	chr4:137520337	C/A	cg12033966	chr4:138453416	PCDH18	-0.67	-4.55	-0.35	1.12e-5	DNA methylation (parent-of-origin);
UCEC	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.48	-5.41	-0.41	2.46e-7	Response to temozolomide;
UCEC	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07741184	chr6:167504864	NA	-0.32	-4.76	-0.37	4.6e-6	Primary biliary cholangitis;
UCEC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg11501438	chr17:20755949	NA	0.42	4.58	0.35	9.97e-6	Psoriasis;
UCEC	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.62	-5.72	-0.43	5.67e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
UCEC	cis	rs692916	0.704	rs560169	chr18:60595329	A/G	cg07187971	chr18:60481018	PHLPP1	0.37	4.61	0.36	8.51e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.1	9.17	0.6	3.88e-16	Vitiligo;
UCEC	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg26383811	chr8:30366931	RBPMS	0.65	5.22	0.4	5.95e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-5.2	-0.39	6.67e-7	Gut microbiome composition (summer);
UCEC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.42	4.95	0.38	1.98e-6	Iron status biomarkers;
UCEC	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	0.99	8.76	0.59	4.35e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg01874867	chr7:94954059	PON1	-0.54	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7212590	1.000	rs7212590	chr17:57885709	C/T	cg10252138	chr17:58120427	NA	-0.68	-5.43	-0.41	2.33e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg01072550	chr1:21505969	NA	-0.57	-5.46	-0.41	2.02e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7015263	1.000	rs12546331	chr8:87505968	C/T	cg27223183	chr8:87520930	FAM82B	-0.46	-4.57	-0.35	1.01e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs925228	0.668	rs12470949	chr2:23934816	A/G	cg13272742	chr2:24272458	FKBP1B	0.5	4.54	0.35	1.14e-5	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.6	-4.96	-0.38	1.95e-6	Depression;
UCEC	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	5.49	0.41	1.75e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.6	6.37	0.46	2.33e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.57	-5.75	-0.43	4.92e-8	Refractive error;
UCEC	cis	rs7267005	0.661	rs17093134	chr20:34429740	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	0.76	9.28	0.61	2.01e-16	Multiple myeloma;
UCEC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.77	-8.17	-0.56	1.28e-13	Height;
UCEC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18252515	chr7:66147081	NA	0.45	4.61	0.36	8.64e-6	Aortic root size;
UCEC	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-6.46	-0.47	1.41e-9	Coronary artery disease;
UCEC	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	5.26	0.4	5e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.88	0.37	2.69e-6	Alzheimer's disease;
UCEC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.48	-5.02	-0.38	1.48e-6	Aortic root size;
UCEC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs12579753	0.642	rs11115072	chr12:82284991	T/A	cg07988820	chr12:82153109	PPFIA2	-0.52	-4.59	-0.35	9.55e-6	Resting heart rate;
UCEC	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.55	-5.28	-0.4	4.48e-7	Obesity-related traits;
UCEC	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.04	0.45	1.19e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.56	-5.56	-0.42	1.25e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.54	-5.36	-0.4	3.17e-7	Systemic lupus erythematosus;
UCEC	cis	rs7246967	0.673	rs73022763	chr19:22894216	C/T	cg23217946	chr19:22817039	ZNF492	0.42	4.54	0.35	1.16e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg19743168	chr1:23544995	NA	0.41	5.51	0.41	1.57e-7	Height;
UCEC	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.01	-0.5	8.18e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	4.66	0.36	7e-6	Response to antipsychotic treatment;
UCEC	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.61	5.14	0.39	8.45e-7	Obesity-related traits;
UCEC	cis	rs1318937	0.764	rs2129947	chr3:15222262	G/A	cg21849552	chr3:14597650	NA	0.49	4.78	0.37	4.15e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs1007190	0.881	rs3816275	chr17:42957327	G/A	cg15406952	chr17:42872593	NA	0.74	5.85	0.43	3.04e-8	DNA methylation (variation);
UCEC	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.7	-5.92	-0.44	2.22e-8	Obesity-related traits;
UCEC	cis	rs7246967	0.932	rs62120766	chr19:23029947	G/A	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4880487	0.888	rs10794731	chr10:1251905	T/A	cg03183215	chr10:1252341	ADARB2	-0.46	-5.43	-0.41	2.3e-7	Migraine;
UCEC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.55	6.25	0.46	4.23e-9	Prostate cancer;
UCEC	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.7	-0.36	5.95e-6	Educational attainment (years of education);
UCEC	cis	rs7089973	0.523	rs7099590	chr10:116749706	G/A	cg06443354	chr10:116043534	VWA2	0.37	4.51	0.35	1.31e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.17	-0.45	6.15e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.7	-0.48	4.2e-10	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg01689657	chr7:91764605	CYP51A1	-0.45	-5.59	-0.42	1.06e-7	Breast cancer;
UCEC	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg02503808	chr4:7069936	GRPEL1	0.5	5.51	0.41	1.58e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs7147624	0.938	rs7147231	chr14:66212371	A/G	cg03016385	chr14:66212404	NA	-0.81	-5.75	-0.43	5.1e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08695707	chr1:197871847	C1orf53	0.56	7.05	0.5	6.57e-11	Warfarin maintenance dose;
UCEC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg06027949	chr8:82754900	SNX16	-0.63	-5.31	-0.4	4.03e-7	Diastolic blood pressure;
UCEC	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.78	6.56	0.48	8.65e-10	Menopause (age at onset);
UCEC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg17105886	chr17:28927953	LRRC37B2	0.65	4.61	0.36	8.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.77	-9.3	-0.61	1.83e-16	Monocyte count;
UCEC	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.67	-5.96	-0.44	1.8e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.69	6.36	0.46	2.43e-9	Lymphocyte counts;
UCEC	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.62	4.82	0.37	3.58e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10875746	0.903	rs11168370	chr12:48435280	A/C	cg10037049	chr12:48276633	VDR	0.42	4.75	0.36	4.73e-6	Longevity (90 years and older);
UCEC	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	5.56	0.42	1.24e-7	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.58	5.81	0.43	3.75e-8	Pubertal anthropometrics;
UCEC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.29	0.4	4.29e-7	Breast cancer;
UCEC	cis	rs9400271	0.527	rs57749539	chr6:109640667	T/C	cg01475377	chr6:109611718	NA	0.44	4.87	0.37	2.81e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs787274	0.850	rs10759604	chr9:115639748	G/A	cg13803584	chr9:115635662	SNX30	-0.69	-5.75	-0.43	5.08e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.77	7.08	0.5	5.4e-11	Coronary artery disease;
UCEC	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.12	12.36	0.71	1.65e-24	Blood protein levels;
UCEC	cis	rs17818399	0.620	rs3087822	chr2:46852033	C/T	cg02822958	chr2:46747628	ATP6V1E2	-0.46	-4.95	-0.38	2.03e-6	Height;
UCEC	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.88	12.98	0.73	3.7e-26	Leprosy;
UCEC	cis	rs16937	0.711	rs3851284	chr1:205156080	A/T	cg00857998	chr1:205179979	DSTYK	0.52	4.67	0.36	6.87e-6	Schizophrenia;
UCEC	cis	rs62344088	1.000	rs7716917	chr5:93387	A/C	cg22857025	chr5:266934	NA	-0.73	-5.13	-0.39	8.92e-7	Asthma (childhood onset);
UCEC	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.63	-5.52	-0.41	1.46e-7	Colorectal cancer;
UCEC	cis	rs12912251	0.591	rs3102119	chr15:39003601	C/T	cg10631289	chr15:39006617	NA	0.67	6.02	0.44	1.31e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.41	5.03	0.38	1.41e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.66	6.5	0.47	1.15e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.71	-7.16	-0.51	3.53e-11	Blood metabolite levels;
UCEC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-12.09	-0.71	8.78e-24	Coronary artery disease;
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.39	0.71	1.33e-24	Platelet count;
UCEC	cis	rs41271951	0.512	rs11204765	chr1:151016757	G/A	cg00107782	chr1:151300621	NA	-0.69	-4.57	-0.35	1.01e-5	Blood protein levels;
UCEC	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.51	5.47	0.41	1.88e-7	Body mass index;
UCEC	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg03161606	chr19:29218774	NA	0.54	4.63	0.36	8.1e-6	Methadone dose in opioid dependence;
UCEC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.47	-5.74	-0.43	5.15e-8	Dupuytren's disease;
UCEC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.67	6.09	0.45	9.17e-9	Aortic root size;
UCEC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.67	6.25	0.46	4.15e-9	Aortic root size;
UCEC	cis	rs2970992	0.764	rs4851368	chr2:101324320	G/A	cg01042948	chr2:101319752	NA	0.51	5.41	0.41	2.55e-7	Educational attainment;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11342046	chr2:242641489	ING5	0.63	7.6	0.53	3.25e-12	Warfarin maintenance dose;
UCEC	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs17123764	0.818	rs2005195	chr12:49983479	A/G	cg20471783	chr12:50157085	TMBIM6	0.62	5.27	0.4	4.8e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.06	0.39	1.21e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.32	4.62	0.36	8.26e-6	Schizophrenia;
UCEC	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg23795048	chr12:9217529	LOC144571	0.39	4.7	0.36	5.89e-6	Sjögren's syndrome;
UCEC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26207909	chr14:103986467	CKB	-0.5	-5.5	-0.41	1.66e-7	Body mass index;
UCEC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.73	8.67	0.58	7.15e-15	Prudent dietary pattern;
UCEC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.56	5.75	0.43	5.01e-8	Motion sickness;
UCEC	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.33e-8	Lung cancer;
UCEC	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg01072550	chr1:21505969	NA	-0.6	-5.98	-0.44	1.66e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.71	5.05	0.38	1.29e-6	Body mass index;
UCEC	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.61	6.8	0.49	2.47e-10	Red blood cell count;
UCEC	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	0.91	9.18	0.6	3.6e-16	Coronary artery disease;
UCEC	cis	rs77633900	0.614	rs2469241	chr15:76873908	A/G	cg21673338	chr15:77095150	SCAPER	-0.62	-5.67	-0.42	7.26e-8	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg27624424	chr6:160112604	SOD2	0.57	5.44	0.41	2.15e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.88e-8	Red blood cell count;
UCEC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg12024160	chr4:1254474	NA	0.62	7.23	0.51	2.4e-11	Obesity-related traits;
UCEC	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.77	-7.25	-0.51	2.17e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.66	6.68	0.48	4.56e-10	Tonsillectomy;
UCEC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.8	-9.6	-0.62	3.07e-17	Bone mineral density;
UCEC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.56	5.26	0.4	4.95e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.39	0.47	2.07e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg26437564	chr7:45808727	SEPT13	0.69	5.65	0.42	7.88e-8	Subjective response to lithium treatment in bipolar disorder;
UCEC	cis	rs3987765	1.000	rs1566577	chr19:51699823	A/G	cg15143070	chr19:52097626	NA	-0.78	-4.98	-0.38	1.76e-6	HIV-1 susceptibility;
UCEC	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16346588	chr10:242978	ZMYND11	0.49	4.76	0.37	4.62e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg02413938	chr2:239008929	ESPNL	-0.38	-4.66	-0.36	6.89e-6	Prostate cancer;
UCEC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.66	-7.43	-0.52	8.29e-12	Menarche (age at onset);
UCEC	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.5	-5.61	-0.42	9.6e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg24069376	chr3:38537580	EXOG	-0.43	-5.23	-0.4	5.76e-7	Electrocardiographic conduction measures;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.42	-5.0	-0.38	1.62e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.55	6.42	0.47	1.77e-9	Mean corpuscular volume;
UCEC	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg04851639	chr8:1020857	NA	-0.43	-5.62	-0.42	9.2e-8	Schizophrenia;
UCEC	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg20936604	chr3:58311152	NA	-0.59	-4.96	-0.38	1.89e-6	Cholesterol, total;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg21856205	chr7:94953877	PON1	-0.54	-5.19	-0.39	6.72e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg21486944	chr6:28411378	ZSCAN23	-0.44	-4.63	-0.36	7.97e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8105895	0.935	rs62110988	chr19:22259956	C/T	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.63e-7	Body mass index (change over time);
UCEC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.5	-0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs1712517	0.771	rs59744322	chr10:105146692	G/T	cg05636881	chr10:105038444	INA	0.45	5.18	0.39	7.07e-7	Migraine;
UCEC	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	6.73	0.49	3.45e-10	Eye color traits;
UCEC	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01391022	chr12:122360665	WDR66	-0.46	-4.68	-0.36	6.35e-6	Mean corpuscular volume;
UCEC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.67	6.25	0.46	4.15e-9	Aortic root size;
UCEC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.51	5.72	0.43	5.74e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.14	0.45	7.24e-9	Aortic root size;
UCEC	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.65	6.61	0.48	6.69e-10	Adiposity;
UCEC	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.53	4.98	0.38	1.74e-6	HDL cholesterol;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.51	-5.57	-0.42	1.15e-7	Cardiac Troponin-T levels;
UCEC	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.22	10.95	0.67	8.91e-21	Corneal structure;
UCEC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.58	6.36	0.46	2.38e-9	Monocyte count;
UCEC	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.53	6.07	0.45	1.04e-8	Mean corpuscular volume;
UCEC	cis	rs10924970	0.967	rs61836169	chr1:235466798	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	5.0	0.38	1.63e-6	Asthma;
UCEC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.71	5.43	0.41	2.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.17	6.2	0.46	5.42e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.54	5.92	0.44	2.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg03146154	chr1:46216737	IPP	-0.46	-4.78	-0.37	4.16e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.6	8.66	0.58	7.59e-15	Prudent dietary pattern;
UCEC	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.52	4.88	0.37	2.73e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.44	-5.2	-0.39	6.46e-7	Subjective well-being;
UCEC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.54	0.42	1.38e-7	Rheumatoid arthritis;
UCEC	cis	rs7246967	0.551	rs57775631	chr19:22814461	T/C	cg23217946	chr19:22817039	ZNF492	0.41	4.56	0.35	1.09e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.4	3.06e-7	Breast cancer;
UCEC	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.85	-0.54	8.17e-13	Migraine;Coronary artery disease;
UCEC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg12024160	chr4:1254474	NA	0.71	8.9	0.59	1.93e-15	Obesity-related traits;
UCEC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg18478394	chr8:109455254	TTC35	-0.48	-4.66	-0.36	6.98e-6	Dupuytren's disease;
UCEC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.65	6.81	0.49	2.28e-10	Tonsillectomy;
UCEC	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.51	-6.27	-0.46	3.85e-9	Total body bone mineral density;
UCEC	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg23283320	chr21:48055893	PRMT2	1.04	4.57	0.35	1.01e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	5.14	0.39	8.77e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.66	7.06	0.5	6.15e-11	Height;
UCEC	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.55	5.99	0.44	1.51e-8	Oral cavity cancer;
UCEC	cis	rs7870753	0.838	rs16910858	chr9:99234557	G/T	cg25260653	chr9:99212216	HABP4	-0.58	-5.86	-0.44	2.93e-8	Height;
UCEC	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.65	-6.48	-0.47	1.29e-9	Plateletcrit;Platelet count;
UCEC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-0.91	-9.19	-0.6	3.42e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs4654899	0.895	rs10916866	chr1:21137768	C/A	cg01072550	chr1:21505969	NA	0.54	5.5	0.41	1.64e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs17372114	0.771	rs1569746	chr1:57246968	A/G	cg06957848	chr1:57286154	C1orf168	-0.57	-4.69	-0.36	6.3e-6	Resistin levels;
UCEC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.49	-4.95	-0.38	1.98e-6	Total body bone mineral density;
UCEC	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.8	-0.49	2.51e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.56	-5.16	-0.39	7.96e-7	Breast cancer;
UCEC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.79	-8.42	-0.57	3.11e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.43	4.93	0.38	2.23e-6	Mortality in heart failure;
UCEC	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg14675211	chr2:100938903	LONRF2	-0.43	-4.53	-0.35	1.23e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg07153921	chr17:41440717	NA	-0.59	-7.03	-0.5	7.08e-11	Menopause (age at onset);
UCEC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg14784868	chr12:69753453	YEATS4	0.54	4.52	0.35	1.27e-5	Response to diuretic therapy;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.81	10.35	0.65	3.34e-19	Menarche (age at onset);
UCEC	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.41	-4.77	-0.37	4.4e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs1483890	0.662	rs6780513	chr3:69405494	G/A	cg22125112	chr3:69402811	FRMD4B	0.45	4.91	0.38	2.43e-6	Resting heart rate;
UCEC	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-0.91	-7.44	-0.52	7.72e-12	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.75	-8.7	-0.58	6.25e-15	Menarche (age at onset);
UCEC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.49	5.1	0.39	1.05e-6	Type 2 diabetes;
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg11697111	chr7:1126903	GPER;C7orf50	-0.49	-4.75	-0.37	4.72e-6	Longevity;Endometriosis;
UCEC	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	5.92	0.44	2.17e-8	IgG glycosylation;
UCEC	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.81	7.27	0.51	1.98e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.78	8.21	0.56	1.02e-13	Caffeine consumption;
UCEC	cis	rs1981331	0.609	rs77725404	chr21:48080376	C/T	cg23283320	chr21:48055893	PRMT2	1.65	7.68	0.54	2.04e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg11871910	chr12:69753446	YEATS4	0.88	10.24	0.65	6.52e-19	Blood protein levels;
UCEC	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.23	-19.17	-0.85	7.79e-42	Exhaled nitric oxide output;
UCEC	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg16584290	chr5:462447	EXOC3	-0.44	-4.57	-0.35	1.03e-5	Cystic fibrosis severity;
UCEC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg23625390	chr15:77176239	SCAPER	-0.46	-4.69	-0.36	6.23e-6	Blood metabolite levels;
UCEC	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.59	5.73	0.43	5.38e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg27299712	chr1:6550532	PLEKHG5	0.51	4.78	0.37	4.13e-6	Body mass index;
UCEC	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	0.73	4.73	0.36	5.21e-6	Mitochondrial DNA levels;
UCEC	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-0.71	-6.97	-0.5	9.88e-11	Trans fatty acid levels;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.69	7.79	0.54	1.13e-12	Prudent dietary pattern;
UCEC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.67	-7.15	-0.51	3.76e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.71	-7.26	-0.51	2.12e-11	Menarche (age at onset);
UCEC	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.46	6.37	0.47	2.27e-9	Alcohol dependence;
UCEC	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.74	-5.44	-0.41	2.21e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.4	4.63	0.36	7.97e-6	Monocyte percentage of white cells;
UCEC	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.2e-7	QRS complex (12-leadsum);
UCEC	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg19610905	chr11:61596333	FADS2	-0.59	-4.9	-0.37	2.45e-6	Neutrophil count;Sum basophil neutrophil counts;
UCEC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.67	-7.65	-0.53	2.38e-12	Menopause (age at onset);
UCEC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.56	6.08	0.45	9.98e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.73	0.49	3.56e-10	Homoarginine levels;
UCEC	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.83	6.56	0.48	8.76e-10	Lymphocyte counts;
UCEC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.98	-0.5	9.46e-11	Tonsillectomy;
UCEC	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg19404215	chr3:33155277	CRTAP	0.77	5.19	0.39	6.79e-7	Major depressive disorder;
UCEC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg00083072	chr11:65415190	SIPA1	0.44	4.71	0.36	5.64e-6	Acne (severe);
UCEC	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	0.92	5.68	0.42	7.02e-8	Skin colour saturation;
UCEC	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.36	4.67	0.36	6.66e-6	Total body bone mineral density;
UCEC	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.6	-0.35	9.21e-6	Menarche (age at onset);
UCEC	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.64	-6.91	-0.5	1.35e-10	Severe influenza A (H1N1) infection;
UCEC	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.64	6.29	0.46	3.38e-9	Bladder cancer;
UCEC	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg24069376	chr3:38537580	EXOG	0.47	5.66	0.42	7.7e-8	Electrocardiographic conduction measures;
UCEC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13395646	chr4:1353034	KIAA1530	-0.74	-6.97	-0.5	1e-10	Obesity-related traits;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.89	11.2	0.68	1.95e-21	Menarche (age at onset);
UCEC	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.55	4.97	0.38	1.82e-6	Crohn's disease;
UCEC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.4	4.72	0.36	5.49e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4908768	0.717	rs12119207	chr1:8829499	A/G	cg13081009	chr1:8430745	RERE	0.42	4.56	0.35	1.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg07153921	chr17:41440717	NA	-0.47	-4.69	-0.36	6.08e-6	Menopause (age at onset);
UCEC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.75	-6.32	-0.46	3.01e-9	Obesity (early onset extreme);
UCEC	cis	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg05636881	chr10:105038444	INA	-0.44	-5.0	-0.38	1.61e-6	Migraine;
UCEC	cis	rs8010715	0.816	rs6573572	chr14:24599230	C/A	cg20933586	chr14:24608199	FAM158A	0.37	4.73	0.36	5.12e-6	IgG glycosylation;
UCEC	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.37	5.45	0.41	2.1e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.54	-0.35	1.18e-5	Pediatric autoimmune diseases;
UCEC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.65	7.02	0.5	7.44e-11	Menopause (age at onset);
UCEC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg11871910	chr12:69753446	YEATS4	-0.52	-4.6	-0.35	8.93e-6	Response to diuretic therapy;
UCEC	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-1.22	-9.48	-0.62	6.18e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.32	-0.46	2.99e-9	Tonsillectomy;
UCEC	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.76	7.77	0.54	1.24e-12	Systolic blood pressure;
UCEC	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-5.11	-0.39	9.93e-7	Metabolite levels;
UCEC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18932078	chr1:2524107	MMEL1	0.34	5.45	0.41	2.06e-7	Ulcerative colitis;
UCEC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.47	5.05	0.38	1.31e-6	Aortic root size;
UCEC	cis	rs10924970	0.649	rs12403014	chr1:235393963	G/A	cg26050004	chr1:235667680	B3GALNT2	0.53	4.92	0.38	2.27e-6	Asthma;
UCEC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.58	5.66	0.42	7.84e-8	Colorectal cancer;
UCEC	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-4.68	-0.36	6.38e-6	Reticulocyte count;
UCEC	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs2729354	0.817	rs2250673	chr11:57268170	T/C	cg24343310	chr11:57249947	NA	0.42	4.74	0.36	5.06e-6	Blood protein levels;
UCEC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.55	0.42	1.29e-7	Rheumatoid arthritis;
UCEC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.57	0.42	1.18e-7	Tonsillectomy;
UCEC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.57	0.77	2.48e-30	Height;
UCEC	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.27e-7	Life satisfaction;
UCEC	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.08	-6.36	-0.46	2.36e-9	Diabetic retinopathy;
UCEC	cis	rs9309473	0.653	rs6718843	chr2:73852505	C/A	cg20560298	chr2:73613845	ALMS1	-0.55	-4.74	-0.36	4.94e-6	Metabolite levels;
UCEC	cis	rs8067354	0.874	rs8065615	chr17:57798165	T/C	cg02344993	chr17:57696989	CLTC	0.46	4.57	0.35	1.04e-5	Hemoglobin concentration;
UCEC	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.82	4.91	0.38	2.44e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.51	6.9	0.49	1.41e-10	Eye color traits;
UCEC	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg18016565	chr1:150552671	MCL1	0.47	4.74	0.36	4.9e-6	Melanoma;
UCEC	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.77	5.69	0.43	6.51e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.45	-4.79	-0.37	4.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg22052955	chr12:53625898	RARG	0.6	6.87	0.49	1.68e-10	Warfarin maintenance dose;
UCEC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg19090574	chr1:205240910	TMCC2	-0.48	-4.88	-0.37	2.67e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.55	-0.35	1.1e-5	Tonsillectomy;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.58	-6.33	-0.46	2.86e-9	Cardiac Troponin-T levels;
UCEC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	6.97	0.5	9.98e-11	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs116095464	0.764	rs28710899	chr5:241029	G/A	cg20965017	chr5:231967	SDHA	-0.62	-5.38	-0.41	2.92e-7	Breast cancer;
UCEC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.47	-7.07	-0.5	5.8200000000000003e-11	Primary biliary cholangitis;
UCEC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.15	-0.56	1.48e-13	Total body bone mineral density;
UCEC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.9	5.77	0.43	4.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.73	7.1	0.51	4.86e-11	Smoking behavior;
UCEC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.66	-6.6	-0.48	7.17e-10	Morning vs. evening chronotype;
UCEC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.74	0.36	5.07e-6	Height;
UCEC	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg23950597	chr19:37808831	NA	-0.64	-5.0	-0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg21521518	chr4:53727714	RASL11B	0.74	5.12	0.39	9.44e-7	Optic nerve measurement (cup area);
UCEC	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs3015497	0.789	rs2356457	chr14:51116863	C/T	cg04730355	chr14:51134070	SAV1	-0.53	-5.68	-0.42	7.09e-8	Mean platelet volume;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.63	7.1	0.51	4.87e-11	Menarche (age at onset);
UCEC	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.81	0.43	3.75e-8	Rheumatoid arthritis;
UCEC	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.84	-9.96	-0.63	3.44e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-0.76	-9.4	-0.61	1.02e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.27	-0.4	4.73e-7	Aortic root size;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg26721908	chr21:47610096	LSS	-0.45	-5.84	-0.43	3.15e-8	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.38	-0.47	2.17e-9	Prudent dietary pattern;
UCEC	cis	rs731174	0.797	rs686083	chr1:38149193	C/T	cg06917450	chr1:38156652	C1orf109	-0.58	-6.08	-0.45	9.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.53	5.07	0.39	1.16e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	1.02	7.64	0.53	2.56e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg09904177	chr6:26538194	HMGN4	-0.54	-4.6	-0.35	8.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.5	-5.13	-0.39	9.02e-7	Bladder cancer;
UCEC	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.55	-5.09	-0.39	1.06e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	5.27	0.4	4.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10432489	0.708	rs12328545	chr2:181771545	T/A	cg21995919	chr2:182322279	ITGA4	-0.77	-5.29	-0.4	4.28e-7	QT interval;
UCEC	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.35	-4.98	-0.38	1.8e-6	Obesity-related traits;
UCEC	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.94	7.13	0.51	4.31e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.61	5.28	0.4	4.56e-7	Heart rate;
UCEC	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-5.79	-0.43	4.08e-8	Gut microbiome composition (summer);
UCEC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	0.94	9.67	0.62	1.96e-17	Heart rate;
UCEC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg22598563	chr5:131563921	P4HA2	-0.36	-4.75	-0.37	4.71e-6	Blood metabolite levels;
UCEC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg15541040	chr2:3486749	NA	-0.61	-5.42	-0.41	2.4e-7	Neurofibrillary tangles;
UCEC	cis	rs12086130	0.892	rs57331401	chr1:51451372	G/A	cg07174182	chr1:51127561	FAF1	-0.78	-4.79	-0.37	3.99e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.75	7.76	0.54	1.35e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.97	-0.44	1.73e-8	Initial pursuit acceleration;
UCEC	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg20368463	chr18:77673604	PQLC1	0.72	5.25	0.4	5.16e-7	Opioid sensitivity;
UCEC	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	0.95	12.24	0.71	3.38e-24	Primary sclerosing cholangitis;
UCEC	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.58	5.51	0.41	1.56e-7	Migraine;Coronary artery disease;
UCEC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.5	4.85	0.37	3.15e-6	Menopause (age at onset);
UCEC	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.51	5.7	0.43	6.38e-8	Mean platelet volume;
UCEC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	7.35	0.52	1.24e-11	Bone mineral density;
UCEC	cis	rs75804782	0.625	rs56411186	chr2:239466753	A/C	cg12524725	chr2:239427019	NA	-0.67	-4.64	-0.36	7.59e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.6	-6.16	-0.45	6.76e-9	Rheumatoid arthritis;
UCEC	cis	rs7224668	0.647	rs7219316	chr17:79248320	A/C	cg15215033	chr17:79258732	SLC38A10	0.34	4.93	0.38	2.21e-6	IgG glycosylation;
UCEC	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.14	-0.45	7.17e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.53	-5.36	-0.4	3.1e-7	Diastolic blood pressure;
UCEC	cis	rs17123764	0.710	rs59849800	chr12:50116773	C/T	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.68	-4.74	-0.36	5.01e-6	Aortic root size;
UCEC	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg05991184	chr2:219186017	PNKD	0.52	5.48	0.41	1.81e-7	Colorectal cancer;
UCEC	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-0.85	-9.75	-0.63	1.22e-17	Breast cancer;
UCEC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05776053	chr2:74358815	NA	0.42	5.15	0.39	8.37e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.84	8.43	0.57	2.94e-14	Blood protein levels;
UCEC	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.59	5.03	0.38	1.39e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-5.8	-0.43	3.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.85	-10.2	-0.64	8.52e-19	Paraoxonase activity;
UCEC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg03609598	chr5:56110824	MAP3K1	-0.55	-4.77	-0.37	4.43e-6	Coronary artery disease;
UCEC	cis	rs925228	0.955	rs12478037	chr2:24141469	T/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.56	4.82	0.37	3.52e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.8	8.78	0.59	3.8e-15	Longevity;Endometriosis;
UCEC	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.59	-5.99	-0.44	1.55e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12292205	chr6:26970375	C6orf41	-0.7	-5.1	-0.39	1.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg14092571	chr14:90743983	NA	-0.43	-5.96	-0.44	1.8e-8	Mortality in heart failure;
UCEC	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.11	9.47	0.62	6.77e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.69	8.98	0.6	1.18e-15	Glycated hemoglobin levels;
UCEC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.79	8.33	0.57	5.12e-14	Longevity;Endometriosis;
UCEC	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-4.55	-0.35	1.13e-5	Response to antipsychotic treatment;
UCEC	cis	rs13095912	1.000	rs34965813	chr3:185333012	T/C	cg11274856	chr3:185301563	NA	0.56	7.51	0.53	5.31e-12	Systolic blood pressure;
UCEC	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.52	5.53	0.41	1.45e-7	Lymphocyte counts;
UCEC	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.8	-8.49	-0.57	2.01e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9650657	0.871	rs7814142	chr8:10637552	G/A	cg00629382	chr8:10268916	MSRA	-0.47	-4.85	-0.37	3.09e-6	Neuroticism;
UCEC	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-6.07	-0.45	1.05e-8	Calcium levels;
UCEC	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.47	5.2	0.39	6.69e-7	Menarche (age at onset);
UCEC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.58	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.07	0.5	5.93e-11	Chronic sinus infection;
UCEC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg24562669	chr7:97807699	LMTK2	0.61	8.15	0.56	1.46e-13	Breast cancer;
UCEC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.55	5.64	0.42	8.37e-8	Corneal astigmatism;
UCEC	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7709377	0.595	rs803967	chr5:115605119	A/G	cg23108291	chr5:115420582	COMMD10	0.5	4.99	0.38	1.66e-6	Metabolite levels  (X-11787);
UCEC	cis	rs782590	0.811	rs9917139	chr2:55728217	G/T	cg18811423	chr2:55921094	PNPT1	0.53	5.35	0.4	3.28e-7	Metabolic syndrome;
UCEC	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.31	-0.57	5.67e-14	Total cholesterol levels;
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-5.9	-0.44	2.4e-8	Platelet count;
UCEC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg13264159	chr8:625131	ERICH1	0.78	4.54	0.35	1.17e-5	IgG glycosylation;
UCEC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.48	6.72	0.48	3.69e-10	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.58	5.68	0.42	6.83e-8	Lung cancer;
UCEC	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg03230154	chr19:22817176	ZNF492	0.44	4.54	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.56	5.09	0.39	1.07e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg04871131	chr7:94954202	PON1	-0.57	-6.03	-0.45	1.26e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.56	4.91	0.38	2.41e-6	Carotid intima media thickness;
UCEC	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	5.72	0.43	5.88e-8	Bipolar disorder and schizophrenia;
UCEC	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.04	-7.2	-0.51	2.82e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.54	6.66	0.48	5.22e-10	Schizophrenia;
UCEC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg07387570	chr22:46663686	TTC38	-0.47	-4.75	-0.36	4.85e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg17469321	chr7:55412551	NA	0.69	5.76	0.43	4.77e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.5	-0.47	1.2e-9	Eye color traits;
UCEC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.16	0.39	7.91e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg23950597	chr19:37808831	NA	-0.81	-5.89	-0.44	2.49e-8	Coronary artery calcification;
UCEC	cis	rs9309473	0.500	rs12996463	chr2:73655496	T/C	cg20560298	chr2:73613845	ALMS1	0.47	4.68	0.36	6.49e-6	Metabolite levels;
UCEC	cis	rs3849046	0.817	rs11959184	chr5:137931878	A/G	cg18180673	chr5:137827632	NA	-0.47	-4.78	-0.37	4.21e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs4627499	chr19:22832633	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.15	-0.39	8.06e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.8	7.94	0.55	4.84e-13	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.54	5.13	0.39	9.05e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.65	7.49	0.53	6.06e-12	Bone mineral density;
UCEC	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.4	4.84	0.37	3.22e-6	Subjective well-being;
UCEC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.85	-6.34	-0.46	2.72e-9	Type 2 diabetes;
UCEC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.72	-9.47	-0.62	6.61e-17	Rheumatoid arthritis;
UCEC	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	13.21	0.74	9.01e-27	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-4.63	-0.36	7.97e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-7.96	-0.55	4.27e-13	Electrocardiographic conduction measures;
UCEC	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Obesity-related traits;
UCEC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.72	7.07	0.5	5.92e-11	Menarche (age at onset);
UCEC	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.65	-5.9	-0.44	2.38e-8	Obesity-related traits;
UCEC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.48	-5.51	-0.41	1.53e-7	Lung cancer;
UCEC	cis	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg17469321	chr7:55412551	NA	-0.7	-6.41	-0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	9.13	0.6	5.02e-16	Mean platelet volume;
UCEC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg26513180	chr16:89883248	FANCA	-0.45	-4.72	-0.36	5.46e-6	Vitiligo;
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg08461772	chr7:95026248	PON3	0.34	4.79	0.37	4e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg19645103	chr12:69753606	YEATS4	-0.56	-5.01	-0.38	1.56e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-5.82	-0.43	3.59e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs4908768	0.817	rs11577530	chr1:8743444	C/T	cg13081009	chr1:8430745	RERE	0.47	4.77	0.37	4.42e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.47	4.79	0.37	4.04e-6	Type 2 diabetes;
UCEC	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.7	7.87	0.54	7.21e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs7246967	0.673	rs3853650	chr19:22880490	A/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.5	5.59	0.42	1.05e-7	Response to antineoplastic agents;
UCEC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-6.63	-0.48	5.98e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28735056	0.620	rs4799108	chr18:77671830	A/C	cg20368463	chr18:77673604	PQLC1	-0.72	-6.23	-0.46	4.55e-9	Schizophrenia;
UCEC	cis	rs787274	0.718	rs7869100	chr9:115628533	T/C	cg13803584	chr9:115635662	SNX30	-0.7	-4.55	-0.35	1.11e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg09491104	chr22:46646882	C22orf40	-0.68	-7.77	-0.54	1.26e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg05738196	chr6:26577821	NA	-0.46	-4.59	-0.35	9.55e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.55	5.75	0.43	4.97e-8	Vitiligo;
UCEC	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	5.75	0.43	4.94e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.1	-0.39	1.04e-6	Colorectal cancer;
UCEC	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.38	5.35	0.4	3.37e-7	Obesity-related traits;
UCEC	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.55	-0.42	1.3e-7	Alcohol dependence;
UCEC	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.61	6.17	0.45	6.28e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.69	-7.22	-0.51	2.53e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.67	-7.45	-0.52	7.55e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg11859384	chr17:80120422	CCDC57	-0.51	-5.65	-0.42	8.08e-8	Life satisfaction;
UCEC	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.49	-5.07	-0.39	1.17e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7709377	0.595	rs253959	chr5:115568757	T/C	cg23108291	chr5:115420582	COMMD10	0.6	6.1	0.45	8.76e-9	Metabolite levels  (X-11787);
UCEC	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.77	6.44	0.47	1.59e-9	Heart rate;
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.71	0.58	5.94e-15	Platelet count;
UCEC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06223018	chr3:49557076	DAG1	-0.33	-4.68	-0.36	6.57e-6	Menarche (age at onset);
UCEC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.75	-0.49	3.12e-10	Pubertal anthropometrics;
UCEC	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Body mass index;
UCEC	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-5.78	-0.43	4.38e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-0.84	-4.72	-0.36	5.34e-6	Inflammatory biomarkers;
UCEC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.06	-0.38	1.25e-6	Personality dimensions;
UCEC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.54	6.07	0.45	1.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg23782820	chr8:58130467	NA	0.51	4.88	0.37	2.73e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg04691961	chr3:161091175	C3orf57	-0.48	-5.35	-0.4	3.33e-7	Morning vs. evening chronotype;
UCEC	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg06521331	chr12:34319734	NA	-0.52	-4.61	-0.36	8.56e-6	Morning vs. evening chronotype;
UCEC	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	6.21	0.46	5.09e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg18681998	chr4:17616180	MED28	0.66	7.4	0.52	9.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg22974920	chr21:40686053	BRWD1	0.59	4.56	0.35	1.07e-5	Cognitive function;
UCEC	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	Bipolar disorder;
UCEC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.74	7.53	0.53	4.67e-12	Blood protein levels;
UCEC	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.73	7.38	0.52	1.07e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.53	-4.91	-0.38	2.36e-6	Cognitive function;
UCEC	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg20891283	chr12:69753455	YEATS4	0.66	5.69	0.42	6.8e-8	Response to diuretic therapy;
UCEC	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg05991184	chr2:219186017	PNKD	-0.48	-5.16	-0.39	7.84e-7	Colorectal cancer;
UCEC	cis	rs4615376	1.000	rs4373361	chr6:13038305	A/G	cg11378619	chr6:12164359	HIVEP1	-0.59	-4.65	-0.36	7.48e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.94e-7	Aortic root size;
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.48	5.93	0.44	2.08e-8	Electrocardiographic conduction measures;
UCEC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.5	-0.53	5.73e-12	Body mass index;
UCEC	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	0.87	9.93	0.63	4.35e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg22532475	chr10:104410764	TRIM8	-0.5	-5.84	-0.43	3.2e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.61	5.57	0.42	1.17e-7	Morning vs. evening chronotype;
UCEC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.63	6.81	0.49	2.29e-10	Monocyte count;
UCEC	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.5	5.73	0.43	5.43e-8	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs6604026	0.740	rs10782946	chr1:93352669	G/A	cg17283838	chr1:93427260	FAM69A	-0.45	-4.57	-0.35	1.01e-5	Multiple sclerosis;
UCEC	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.41	4.93	0.38	2.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-4.62	-0.36	8.35e-6	Opioid sensitivity;
UCEC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs41271951	0.512	rs12074309	chr1:151087827	T/C	cg00107782	chr1:151300621	NA	-0.68	-4.58	-0.35	9.72e-6	Blood protein levels;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.67	-7.64	-0.53	2.63e-12	Paraoxonase activity;
UCEC	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs17106184	1.000	rs72900938	chr1:51118527	T/C	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	1.0	5.82	0.43	3.62e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7155454	0.815	rs11627485	chr14:65487694	T/C	cg16583315	chr14:65563665	MAX	-0.49	-5.53	-0.41	1.43e-7	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
UCEC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.23	-0.46	4.75e-9	Prudent dietary pattern;
UCEC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.04e-6	Sudden cardiac arrest;
UCEC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-0.7	-6.65	-0.48	5.49e-10	Breast cancer;
UCEC	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg18681998	chr4:17616180	MED28	0.58	6.53	0.47	9.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.59	0.42	1.06e-7	Cognitive test performance;
UCEC	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	0.93	6.99	0.5	9e-11	Obesity-related traits;
UCEC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg05709478	chr1:6581295	PLEKHG5	0.64	4.77	0.37	4.46e-6	Body mass index;
UCEC	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.43	-4.57	-0.35	1.05e-5	Height;
UCEC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg06636001	chr8:8085503	FLJ10661	0.59	6.37	0.46	2.31e-9	Mood instability;
UCEC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.79	6.01	0.44	1.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs711830	0.576	rs72916141	chr2:177069364	G/T	cg13092806	chr2:177043255	NA	-0.94	-8.24	-0.56	8.86e-14	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.81	-0.43	3.74e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7944735	0.817	rs7101582	chr11:47714610	G/A	cg08722104	chr11:47448306	PSMC3	-0.49	-5.01	-0.38	1.56e-6	Intraocular pressure;
UCEC	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-4.72	-0.36	5.38e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs3736757	1.000	rs9658937	chr1:184667371	C/A	cg05045817	chr1:184633523	NA	0.37	4.5	0.35	1.34e-5	Obesity-related traits;
UCEC	cis	rs10415976	1.000	rs10415976	chr19:941603	C/T	cg01997529	chr19:913524	C19orf22	-0.56	-5.1	-0.39	1.03e-6	Primary biliary cholangitis;
UCEC	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.62	-4.8	-0.37	3.93e-6	Carotid intima media thickness;
UCEC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.46	4.91	0.38	2.37e-6	Alcohol dependence;
UCEC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.42	-4.51	-0.35	1.29e-5	Retinal vascular caliber;
UCEC	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.49	-0.41	1.69e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.58	-5.87	-0.44	2.72e-8	Menarche (age at onset);
UCEC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.51	-5.72	-0.43	5.89e-8	Tonsillectomy;
UCEC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg20821713	chr7:1055600	C7orf50	-0.9	-11.65	-0.69	1.22e-22	Bronchopulmonary dysplasia;
UCEC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.42	-5.96	-0.44	1.79e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	trans	rs4665630	0.614	rs6739646	chr2:23946840	A/C	cg14021555	chr22:43485536	TTLL1	0.77	6.75	0.49	3.21e-10	Hypertension;
UCEC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg06096015	chr1:231504339	EGLN1	0.49	5.77	0.43	4.63e-8	Hemoglobin concentration;
UCEC	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.02	0.64	2.54e-18	Electrocardiographic conduction measures;
UCEC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg12024160	chr4:1254474	NA	0.64	7.3	0.52	1.63e-11	Obesity-related traits;
UCEC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.52	5.82	0.43	3.62e-8	Life satisfaction;
UCEC	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.55	5.84	0.43	3.24e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.77	-6.64	-0.48	5.8e-10	Educational attainment;
UCEC	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg02022102	chr7:27168609	HOXA4	0.59	6.71	0.48	3.95e-10	Protein biomarker;
UCEC	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg11494091	chr17:61959527	GH2	-0.64	-8.93	-0.59	1.6e-15	Prudent dietary pattern;
UCEC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs4148689	1.000	rs3757802	chr7:117127739	A/C	cg21212505	chr7:117228958	CFTR	-0.44	-4.85	-0.37	3.08e-6	Gout;
UCEC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.65	-6.61	-0.48	6.62e-10	Sudden cardiac arrest;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.64	-7.34	-0.52	1.32e-11	Menarche (age at onset);
UCEC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.673	rs12975767	chr19:22862809	A/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.69	6.77	0.49	2.8e-10	Alcohol dependence;
UCEC	cis	rs2657888	0.628	rs2638334	chr12:56882528	A/C	cg23002907	chr12:56915593	RBMS2	0.43	5.59	0.42	1.08e-7	Adiponectin levels;
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.58	-6.8	-0.49	2.51e-10	Total body bone mineral density;
UCEC	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.55	-5.43	-0.41	2.27e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg14664628	chr15:75095509	CSK	-0.57	-5.7	-0.43	6.42e-8	Breast cancer;
UCEC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.56	-5.69	-0.42	6.8e-8	Menarche (age at onset);
UCEC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.53	5.45	0.41	2.06e-7	Longevity;Endometriosis;
UCEC	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.6	-5.84	-0.43	3.29e-8	Pediatric autoimmune diseases;
UCEC	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-0.98	-11.03	-0.67	5.57e-21	Blood pressure (smoking interaction);
UCEC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.74	7.65	0.53	2.41e-12	Tonsillectomy;
UCEC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.66	-7.32	-0.52	1.53e-11	Obesity-related traits;
UCEC	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.69	8.82	0.59	3.06e-15	Mean platelet volume;
UCEC	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.47	-6.45	-0.47	1.52e-9	Height;
UCEC	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.9	10.31	0.65	4.2e-19	Ulcerative colitis;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.54	-6.03	-0.45	1.29e-8	Pubertal anthropometrics;
UCEC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.73	-8.3	-0.56	6.25e-14	Immature fraction of reticulocytes;
UCEC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.24	0.4	5.44e-7	Mean platelet volume;
UCEC	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.62	5.28	0.4	4.63e-7	RR interval (heart rate);
UCEC	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg24531977	chr5:56204891	C5orf35	-0.52	-4.7	-0.36	5.85e-6	Coronary artery disease;
UCEC	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg27246729	chr12:121163418	ACADS	0.5	4.73	0.36	5.26e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.88	8.5	0.57	1.94e-14	Corneal structure;
UCEC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.1e-7	Hemoglobin concentration;
UCEC	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.74	-8.21	-0.56	1.02e-13	Trans fatty acid levels;
UCEC	cis	rs4654899	0.931	rs10799671	chr1:21196764	C/T	cg01072550	chr1:21505969	NA	0.51	5.13	0.39	9.02e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.41	-4.97	-0.38	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1978968	0.763	rs8137857	chr22:18465616	T/C	cg03078520	chr22:18463400	MICAL3	-0.56	-7.17	-0.51	3.34e-11	Presence of antiphospholipid antibodies;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.76	-0.37	4.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.67	6.3	0.46	3.32e-9	Response to diuretic therapy;
UCEC	cis	rs36051895	0.626	rs9695934	chr9:5153108	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-5.02	-0.38	1.46e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.78	7.31	0.52	1.6e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16346588	chr10:242978	ZMYND11	0.47	4.55	0.35	1.12e-5	Psychosis in Alzheimer's disease;
UCEC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs7088591	0.867	rs914766	chr10:59789877	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs6684428	1.000	rs10888948	chr1:56382722	G/A	cg11651538	chr1:56320950	NA	-0.72	-6.44	-0.47	1.58e-9	Airflow obstruction;
UCEC	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.53	-4.83	-0.37	3.46e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.16	0.64	1.09e-18	Cognitive ability;
UCEC	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.38	5.36	0.4	3.19e-7	Obesity-related traits;
UCEC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.58	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.65	-5.31	-0.4	3.9e-7	Height;
UCEC	cis	rs7611694	0.501	rs6768117	chr3:113151841	A/G	cg11138929	chr3:113251189	SIDT1	-0.4	-4.66	-0.36	7.04e-6	Prostate cancer;
UCEC	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.01	-0.38	1.53e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.5	5.36	0.4	3.19e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs1519814	1.000	rs7000609	chr8:121106264	C/T	cg22335954	chr8:121166405	COL14A1	0.71	5.65	0.42	8.04e-8	Breast cancer;
UCEC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.78	-7.86	-0.54	7.36e-13	Obesity-related traits;
UCEC	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.91	-11.78	-0.7	5.51e-23	Height;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.72	-0.48	3.67e-10	Pubertal anthropometrics;
UCEC	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg16164276	chr3:11034345	SLC6A1	-0.47	-4.54	-0.35	1.17e-5	Alzheimer's disease;
UCEC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.47	4.5	0.35	1.35e-5	Schizophrenia;
UCEC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-5.31	-0.4	4.01e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg18681998	chr4:17616180	MED28	0.89	11.62	0.69	1.46e-22	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10432489	0.708	rs12693263	chr2:181740210	A/G	cg21995919	chr2:182322279	ITGA4	0.75	5.4	0.41	2.64e-7	QT interval;
UCEC	cis	rs61776719	0.810	rs34655914	chr1:38397341	G/A	cg17077180	chr1:38461687	NA	0.63	6.86	0.49	1.78e-10	Coronary artery disease;
UCEC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg05425664	chr17:57184151	TRIM37	0.47	4.89	0.37	2.63e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.41	4.88	0.37	2.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg11871910	chr12:69753446	YEATS4	0.57	5.18	0.39	7.21e-7	Response to diuretic therapy;
UCEC	cis	rs9463078	0.625	rs12190136	chr6:44767072	A/G	cg25276700	chr6:44698697	NA	-0.41	-4.7	-0.36	6.01e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg21905437	chr5:178450457	ZNF879	0.64	7.1	0.51	4.95e-11	Pubertal anthropometrics;
UCEC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.81	8.36	0.57	4.28e-14	Longevity;
UCEC	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.63	6.17	0.45	6.15e-9	Caffeine consumption;
UCEC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.59	-4.56	-0.35	1.08e-5	Blood pressure (smoking interaction);
UCEC	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.6	-6.58	-0.48	7.73e-10	Blood trace element (Zn levels);
UCEC	cis	rs240764	0.578	rs6928418	chr6:101175347	T/C	cg09795085	chr6:101329169	ASCC3	0.45	4.79	0.37	4.1e-6	Neuroticism;
UCEC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.53	4.82	0.37	3.54e-6	Obesity-related traits;
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.64	8.25	0.56	8.2e-14	Menarche (age at onset);
UCEC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01065977	chr19:18549689	ISYNA1	-0.36	-5.1	-0.39	1.05e-6	Breast cancer;
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.71	8.11	0.56	1.83e-13	Longevity;Endometriosis;
UCEC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.47	0.41	1.88e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.68	6.3	0.46	3.19e-9	Aortic root size;
UCEC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.66	-6.49	-0.47	1.26e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.62	6.14	0.45	7.36e-9	Lung cancer;
UCEC	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.08	-0.5	5.57e-11	Colorectal cancer;
UCEC	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.49	-5.08	-0.39	1.13e-6	Response to temozolomide;
UCEC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.3	-0.4	4.1e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	0.83	11.55	0.69	2.24e-22	Multiple myeloma;
UCEC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.54	5.41	0.41	2.45e-7	Menopause (age at onset);
UCEC	cis	rs11697848	1.000	rs76939398	chr20:48590587	C/T	cg17849948	chr20:48532315	SPATA2	1.01	4.59	0.35	9.45e-6	Systemic lupus erythematosus;
UCEC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.86	10.88	0.67	1.35e-20	IgG glycosylation;
UCEC	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg05484376	chr2:27715224	FNDC4	0.34	4.68	0.36	6.53e-6	Total body bone mineral density;
UCEC	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.45	4.7	0.36	5.83e-6	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.64	-5.77	-0.43	4.43e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.33	0.71	1.97e-24	Prudent dietary pattern;
UCEC	cis	rs7088591	0.867	rs16911622	chr10:59777537	A/C	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.83	5.0	0.38	1.63e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.32	-0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.69	6.51	0.47	1.14e-9	Height;
UCEC	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.58	-5.35	-0.4	3.23e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.5	6.06	0.45	1.1e-8	Total body bone mineral density;
UCEC	cis	rs77988765	0.908	rs78243950	chr11:70021144	G/A	cg02486268	chr11:69682825	NA	0.48	4.51	0.35	1.3e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg18478394	chr8:109455254	TTC35	0.49	4.85	0.37	3.05e-6	Dupuytren's disease;
UCEC	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	1.06	5.3	0.4	4.18e-7	Parkinson's disease;
UCEC	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.17	-9.28	-0.61	2.08e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.83	0.43	3.34e-8	Platelet count;
UCEC	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.78	-7.93	-0.55	5.03e-13	Resting heart rate;
UCEC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.45	5.11	0.39	1.01e-6	Obesity-related traits;
UCEC	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.48	-4.58	-0.35	9.98e-6	Personality dimensions;
UCEC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.51	4.98	0.38	1.74e-6	Vitiligo;
UCEC	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.48	4.72	0.36	5.48e-6	Autism;
UCEC	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18252515	chr7:66147081	NA	0.53	5.02	0.38	1.49e-6	Aortic root size;
UCEC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4460629	0.742	rs6427158	chr1:155074903	G/T	cg02153340	chr1:155202674	NA	-0.42	-4.7	-0.36	5.94e-6	Serum magnesium levels;
UCEC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg01256987	chr12:42539512	GXYLT1	0.41	4.75	0.36	4.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.84	8.36	0.57	4.44e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.04	-0.45	1.18e-8	Pubertal anthropometrics;
UCEC	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	5.93	0.44	2.12e-8	Coffee consumption (cups per day);
UCEC	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.31	-10.38	-0.65	2.89e-19	Hip circumference adjusted for BMI;
UCEC	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.82	-8.66	-0.58	7.85e-15	Itch intensity from mosquito bite;
UCEC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.55	-5.93	-0.44	2.12e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.19	9.75	0.63	1.27e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.33	4.52	0.35	1.27e-5	Height;
UCEC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg09654669	chr8:57350985	NA	-0.54	-6.09	-0.45	9.53e-9	Obesity-related traits;
UCEC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg05738196	chr6:26577821	NA	0.59	6.48	0.47	1.33e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.83	9.08	0.6	6.46e-16	Breast cancer;
UCEC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg06238570	chr21:40685208	BRWD1	-0.77	-7.67	-0.53	2.19e-12	Cognitive function;
UCEC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-4.95	-0.38	1.99e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-0.92	-5.79	-0.43	4.08e-8	Mitochondrial DNA levels;
UCEC	cis	rs847577	0.569	rs35101190	chr7:97695888	G/A	cg24562669	chr7:97807699	LMTK2	0.74	10.49	0.65	1.46e-19	Breast cancer;
UCEC	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg13683864	chr3:40499215	RPL14	-0.58	-6.07	-0.45	1.01e-8	Renal cell carcinoma;
UCEC	cis	rs565229	0.714	rs537119	chr11:122143668	C/G	cg14126608	chr11:122846540	NA	-0.56	-4.58	-0.35	1e-5	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs9961915	1.000	rs6508470	chr18:24676047	T/C	cg25983544	chr18:23713626	PSMA8	-0.35	-4.51	-0.35	1.34e-5	Dental caries;
UCEC	cis	rs12286929	0.639	rs10891802	chr11:115043888	C/A	cg04055981	chr11:115044050	NA	0.48	5.37	0.4	3.04e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg13175173	chr14:55914753	NA	0.43	4.5	0.35	1.35e-5	Protein biomarker;
UCEC	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.56	6.4	0.47	1.93e-9	Longevity;
UCEC	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.8	-8.34	-0.57	4.81e-14	Mosquito bite size;
UCEC	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-0.61	-7.0	-0.5	8.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.63	6.96	0.5	1.03e-10	Tonsillectomy;
UCEC	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.32	4.88	0.37	2.7e-6	Ulcerative colitis;
UCEC	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-5.21	-0.39	6.29e-7	Hemoglobin concentration;
UCEC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.73	8.25	0.56	8.24e-14	Lymphocyte counts;
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.73	-5.2	-0.39	6.53e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.54	5.05	0.38	1.29e-6	Schizophrenia;
UCEC	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg01262667	chr19:19385393	TM6SF2	0.48	6.63	0.48	6.09e-10	Tonsillectomy;
UCEC	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.19e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16346588	chr10:242978	ZMYND11	0.47	4.55	0.35	1.12e-5	Psychosis in Alzheimer's disease;
UCEC	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg20011983	chr2:74347215	NA	-0.7	-5.42	-0.41	2.42e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.57	6.18	0.45	5.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs7894051	0.764	rs11101725	chr10:135194608	A/G	cg14353649	chr10:135191496	PAOX	-0.46	-5.04	-0.38	1.37e-6	Lifespan;
UCEC	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.64	8.34	0.57	4.85e-14	Testicular germ cell tumor;
UCEC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	7.66	0.53	2.36e-12	Alzheimer's disease;
UCEC	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.13	-11.02	-0.67	5.65e-21	Vitiligo;
UCEC	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.68	-6.46	-0.47	1.42e-9	Platelet distribution width;
UCEC	cis	rs4074961	0.509	rs4653300	chr1:38024054	A/G	cg17933807	chr1:38061675	GNL2	0.79	10.34	0.65	3.65e-19	Axial length;
UCEC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.64	-0.42	8.51e-8	Neutrophil percentage of white cells;
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.44	0.52	7.98e-12	Platelet count;
UCEC	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.52	-5.19	-0.39	6.94e-7	Retinal vascular caliber;
UCEC	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.76	0.49	3.09e-10	Coffee consumption (cups per day);
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.69	-0.36	6.31e-6	Pubertal anthropometrics;
UCEC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.12	0.45	7.91e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.85	-0.49	1.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs740698	0.521	rs9891713	chr17:60789405	C/T	cg13195520	chr17:60813227	MARCH10	0.37	4.73	0.36	5.29e-6	Pulse pressure;
UCEC	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.43	-5.64	-0.42	8.58e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.45	4.85	0.37	3.13e-6	Smoking initiation;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg12386808	chr3:44762171	ZNF502	-0.45	-4.61	-0.36	8.82e-6	Depressive symptoms;
UCEC	cis	rs782107	0.674	rs10783889	chr12:58808029	A/G	cg19181132	chr12:59314527	LRIG3	-0.48	-5.06	-0.39	1.22e-6	Interleukin-12p70 levels;
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg05132306	chr1:1846340	CALML6	-0.37	-4.72	-0.36	5.51e-6	Body mass index;
UCEC	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-4.87	-0.37	2.84e-6	Bipolar disorder;
UCEC	cis	rs11760485	0.782	rs2107836	chr7:4404741	A/G	cg25842763	chr7:4870162	RADIL	-0.42	-4.78	-0.37	4.28e-6	Early childhood aggressive behavior;
UCEC	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg19041857	chr6:27730383	NA	-0.67	-4.97	-0.38	1.86e-6	Breast cancer;
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg21856205	chr7:94953877	PON1	-0.54	-5.2	-0.39	6.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-4.99	-0.38	1.7e-6	Chronic sinus infection;
UCEC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg26721908	chr21:47610096	LSS	-0.37	-4.66	-0.36	6.95e-6	Testicular germ cell tumor;
UCEC	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.53	-5.63	-0.42	8.7e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.86	4.74	0.36	4.95e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg02175308	chr1:109941060	SORT1	-0.29	-4.58	-0.35	9.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-5.65	-0.42	8.19e-8	Longevity;
UCEC	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.25	-10.61	-0.66	6.92e-20	Lymphocyte percentage of white cells;
UCEC	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.34	5.02	0.38	1.45e-6	Ulcerative colitis;
UCEC	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-1.0	-8.84	-0.59	2.69e-15	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	18.3	0.83	9.66e-40	IgG glycosylation;
UCEC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg05991184	chr2:219186017	PNKD	0.52	5.65	0.42	7.87e-8	Colorectal cancer;
UCEC	cis	rs57237364	1	rs57237364	chr7:102465232	CTTT/C	cg18108683	chr7:102477205	FBXL13	-0.62	-7.68	-0.53	2.11e-12	Breast cancer;
UCEC	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.78	-8.95	-0.59	1.43e-15	Facial morphology (factor 19);
UCEC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.54	0.47	9.78e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs12118280	1.000	rs12118280	chr1:108738780	T/C	cg11967332	chr1:108735228	SLC25A24	1.0	9.41	0.61	9.34e-17	Myeloid white cell count;
UCEC	cis	rs239198	0.521	rs13198473	chr6:101337779	C/T	cg09795085	chr6:101329169	ASCC3	0.49	4.71	0.36	5.59e-6	Menarche (age at onset);
UCEC	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.57	-5.69	-0.42	6.65e-8	White matter hyperintensity burden;
UCEC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.68	6.11	0.45	8.7e-9	Aortic root size;
UCEC	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.01	7.48	0.52	6.36e-12	Alzheimer's disease (late onset);
UCEC	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-4.92	-0.38	2.29e-6	Morning vs. evening chronotype;
UCEC	cis	rs11760485	1.000	rs11760485	chr7:4401550	C/T	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.82	10.27	0.65	5.6e-19	Mortality in heart failure;
UCEC	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-0.9	-6.79	-0.49	2.57e-10	Educational attainment;
UCEC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.55	6.33	0.46	2.8e-9	Prostate cancer;
UCEC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg22974920	chr21:40686053	BRWD1	-0.51	-4.5	-0.35	1.34e-5	Cognitive function;
UCEC	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.72	7.18	0.51	3.29e-11	Aortic root size;
UCEC	cis	rs13401104	0.796	rs72620811	chr2:237118733	C/A	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg06521331	chr12:34319734	NA	-0.72	-7.44	-0.52	7.67e-12	Morning vs. evening chronotype;
UCEC	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.13	-0.39	9.2e-7	Bipolar disorder;
UCEC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.84	0.59	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7709377	0.597	rs6594952	chr5:115488032	A/C	cg23108291	chr5:115420582	COMMD10	0.55	5.58	0.42	1.14e-7	Metabolite levels  (X-11787);
UCEC	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.91	-11.08	-0.67	3.98e-21	Blood metabolite levels;
UCEC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.53	-6.26	-0.46	3.96e-9	Multiple myeloma;
UCEC	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.45	4.76	0.37	4.69e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.62	7.3	0.52	1.71e-11	Schizophrenia;
UCEC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.57	6.0	0.44	1.5e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg08994789	chr17:28903642	LRRC37B2	0.44	5.39	0.41	2.77e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.49	-5.63	-0.42	8.7e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.62	4.94	0.38	2.14e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-4.65	-0.36	7.44e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg00339695	chr16:24857497	SLC5A11	0.48	5.6	0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg21827317	chr3:136751795	NA	0.49	5.56	0.42	1.26e-7	Gestational age at birth (child effect);
UCEC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	6.2	0.46	5.38e-9	Menarche (age at onset);
UCEC	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.57	-8.2	-0.56	1.08e-13	Sense of smell;
UCEC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.73	8.08	0.55	2.18e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.51	5.28	0.4	4.6e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg02344993	chr17:57696989	CLTC	0.51	4.84	0.37	3.29e-6	Obesity-related traits;
UCEC	cis	rs2274471	0.555	rs10815151	chr9:5070905	C/T	cg03390472	chr9:5043263	JAK2	-0.48	-4.86	-0.37	3.03e-6	Crohn's disease;
UCEC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.43	-0.74	2.46e-27	Height;
UCEC	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg13334819	chr7:99746414	C7orf59	-0.55	-5.37	-0.4	3.02e-7	Coronary artery disease;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg20007245	chr22:24372913	LOC391322	-0.58	-6.14	-0.45	7.44e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.48	4.86	0.37	2.95e-6	Colorectal cancer;
UCEC	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg13962466	chr20:25176127	ENTPD6	0.49	4.76	0.37	4.65e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.43	-4.52	-0.35	1.28e-5	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg11871910	chr12:69753446	YEATS4	0.55	4.88	0.37	2.76e-6	Response to diuretic therapy;
UCEC	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg20965017	chr5:231967	SDHA	-0.68	-5.65	-0.42	8.01e-8	Asthma (childhood onset);
UCEC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg25306006	chr11:71932630	FOLR2	-0.4	-4.57	-0.35	1.04e-5	Vitamin D levels;
UCEC	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.65	5.28	0.4	4.47e-7	Corneal astigmatism;
UCEC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.65	4.55	0.35	1.12e-5	Aortic root size;
UCEC	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-4.85	-0.37	3.06e-6	Schizophrenia;
UCEC	cis	rs713477	1.000	rs12886860	chr14:55911150	G/C	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.73	5.15	0.39	8.36e-7	Body mass index;
UCEC	cis	rs10012307	1.000	rs2406018	chr4:137519606	C/A	cg12033966	chr4:138453416	PCDH18	-0.71	-5.0	-0.38	1.63e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg00086871	chr4:6988644	TBC1D14	0.85	5.44	0.41	2.18e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.8	-8.01	-0.55	3.22e-13	Prudent dietary pattern;
UCEC	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.84	-0.37	3.21e-6	Tonsillectomy;
UCEC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.45	4.77	0.37	4.41e-6	Longevity;Endometriosis;
UCEC	cis	rs72720396	0.803	rs114328297	chr1:91190854	T/G	cg13456504	chr1:91191583	NA	0.58	4.83	0.37	3.36e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg16060761	chr17:80687452	NA	0.49	4.94	0.38	2.11e-6	Glycated hemoglobin levels;
UCEC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.65	-7.04	-0.5	7e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	4.98	0.38	1.76e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.44e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	-0.54	-6.15	-0.45	7.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.67	7.62	0.53	2.86e-12	Proinsulin levels;
UCEC	cis	rs7902334	1.000	rs7902334	chr10:12645941	A/C	cg26231267	chr10:12648032	CAMK1D	-0.78	-4.91	-0.38	2.35e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.65	7.79	0.54	1.09e-12	Height;
UCEC	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.58	6.56	0.48	8.58e-10	Total body bone mineral density;
UCEC	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg19875535	chr5:140030758	IK	0.42	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.68	-6.97	-0.5	9.98e-11	Neurofibrillary tangles;
UCEC	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-6.08	-0.45	9.96e-9	Morning vs. evening chronotype;
UCEC	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.69	6.37	0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.41e-6	Putamen volume;
UCEC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg07653901	chr22:50250238	ZBED4	0.77	5.0	0.38	1.59e-6	Schizophrenia;
UCEC	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.66	4.94	0.38	2.1e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg07153921	chr17:41440717	NA	-0.46	-5.14	-0.39	8.58e-7	Menopause (age at onset);
UCEC	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.73	-9.73	-0.63	1.39e-17	Skin colour saturation;
UCEC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.48	4.69	0.36	6.25e-6	Height;
UCEC	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.83	9.88	0.63	5.64e-18	Mortality in heart failure;
UCEC	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.82	7.07	0.5	5.68e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.38	-0.41	2.9e-7	Depression;
UCEC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-1.05	-7.14	-0.51	4.07e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6137726	0.508	rs2424456	chr20:22643662	C/A	cg08244522	chr20:23030533	THBD	-0.47	-4.77	-0.37	4.35e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.45	-4.94	-0.38	2.12e-6	Schizophrenia;
UCEC	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.45	4.95	0.38	1.98e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.35	1.11e-5	Bladder cancer;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.47	4.78	0.37	4.22e-6	Prudent dietary pattern;
UCEC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.44	-5.05	-0.38	1.29e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.76	-9.24	-0.61	2.54e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.47	4.69	0.36	6.31e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg03549618	chr14:35838977	NA	-0.35	-4.64	-0.36	7.5e-6	Psoriasis;
UCEC	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.9	0.37	2.46e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.34	0.61	1.45e-16	Blood protein levels;
UCEC	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg11632617	chr15:75315747	PPCDC	-0.66	-7.68	-0.54	2.07e-12	Lung cancer;
UCEC	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg22681709	chr2:178499509	PDE11A	-0.47	-5.48	-0.41	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	9.79	0.63	9.54e-18	Menopause (age at onset);
UCEC	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg04439458	chr5:138467593	SIL1	0.42	4.62	0.36	8.24e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg07776626	chr8:57350775	NA	0.44	4.71	0.36	5.75e-6	Obesity-related traits;
UCEC	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.55	-5.83	-0.43	3.42e-8	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg14078730	chr11:63896557	MACROD1	0.46	4.7	0.36	6.03e-6	Platelet count;
UCEC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	0.96	14.24	0.76	1.81e-29	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg23782820	chr8:58130467	NA	0.48	4.57	0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.38	-4.78	-0.37	4.2e-6	Sitting height ratio;
UCEC	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.25	-0.4	5.22e-7	Headache;
UCEC	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-6.0	-0.44	1.49e-8	Prudent dietary pattern;
UCEC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.52	5.74	0.43	5.15e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.55	5.13	0.39	9e-7	Resting heart rate;
UCEC	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg18032046	chr6:28092343	ZSCAN16	0.7	6.33	0.46	2.86e-9	Parkinson's disease;
UCEC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	6.77	0.49	2.85e-10	High light scatter reticulocyte count;
UCEC	trans	rs6725041	0.934	rs12694267	chr2:213069051	T/C	cg19573490	chr17:79870317	PCYT2;SIRT7	0.58	6.95	0.5	1.1e-10	QT interval (ambient particulate matter interaction);
UCEC	cis	rs829661	0.689	rs829696	chr2:30651080	C/T	cg17749961	chr2:30669863	LCLAT1	-0.66	-5.33	-0.4	3.69e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.8	-0.37	3.79e-6	Resting heart rate;
UCEC	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.54	-5.87	-0.44	2.84e-8	Blood metabolite levels;
UCEC	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.68	5.49	0.41	1.68e-7	Smoking initiation;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.56	-5.91	-0.44	2.33e-8	Pubertal anthropometrics;
UCEC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	4.51	0.35	1.3e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs4523957	0.855	rs9893573	chr17:2126003	A/G	cg16513277	chr17:2031491	SMG6	-0.44	-4.78	-0.37	4.15e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs74225573	1	rs74225573	chr1:11280994	T/C	cg18435880	chr1:11160013	EXOSC10	0.82	4.61	0.36	8.81e-6	Corneal curvature;
UCEC	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.74	-8.68	-0.58	6.78e-15	Extraversion;
UCEC	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.59	-5.29	-0.4	4.28e-7	Metabolite levels;
UCEC	cis	rs11958404	0.932	rs7711898	chr5:157430688	A/G	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.73	0.54	1.57e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.5	4.53	0.35	1.19e-5	Obesity-related traits;
UCEC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.6	0.35	9.09e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.69	-4.81	-0.37	3.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.68	6.35	0.46	2.51e-9	Tonsillectomy;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.87	10.35	0.65	3.42e-19	Menarche (age at onset);
UCEC	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg18232548	chr7:50535776	DDC	0.61	6.63	0.48	6.13e-10	Systemic sclerosis;
UCEC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.44	5.01	0.38	1.52e-6	Mortality in heart failure;
UCEC	cis	rs7709377	0.620	rs12054994	chr5:115477172	A/C	cg23108291	chr5:115420582	COMMD10	0.55	5.56	0.42	1.21e-7	Metabolite levels  (X-11787);
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg24703168	chr6:28411309	ZSCAN23	0.48	5.27	0.4	4.82e-7	Cardiac Troponin-T levels;
UCEC	cis	rs259282	0.605	rs17692992	chr19:33099430	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.58	4.78	0.37	4.23e-6	Schizophrenia;
UCEC	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs6893807	0.778	rs7721099	chr5:87936379	A/G	cg09002922	chr5:87956389	LOC645323	-0.58	-5.61	-0.42	9.57e-8	Body mass index;
UCEC	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-6.15	-0.45	6.92e-9	Crohn's disease;
UCEC	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	7.71	0.54	1.72e-12	Schizophrenia;
UCEC	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs16932667	0.823	rs11063476	chr12:5140982	A/G	cg03854198	chr12:5541311	NTF3	0.48	5.45	0.41	2.05e-7	Intelligence (childhood);
UCEC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs6838801	0.752	rs13138237	chr4:77616562	C/G	cg17476223	chr4:77663285	SHROOM3	0.49	4.61	0.36	8.64e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg07838603	chr6:28411030	ZSCAN23	0.51	5.96	0.44	1.77e-8	Pubertal anthropometrics;
UCEC	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	4.91	0.38	2.43e-6	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12216499	0.786	rs12200704	chr6:159422197	T/G	cg10634217	chr6:160211790	TCP1;MRPL18	-0.69	-4.63	-0.36	7.89e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.56	6.66	0.48	5.19e-10	Blood metabolite ratios;
UCEC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg04043695	chr12:129287642	SLC15A4	0.59	5.86	0.44	2.91e-8	Systemic lupus erythematosus;
UCEC	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.44	5.12	0.39	9.4e-7	Facial morphology (factor 20);
UCEC	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04837898	chr3:45731254	SACM1L	0.42	4.94	0.38	2.09e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4851266	1.000	rs4303732	chr2:100830040	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs10924970	0.649	rs12745603	chr1:235405211	G/A	cg26050004	chr1:235667680	B3GALNT2	0.53	4.79	0.37	4.1e-6	Asthma;
UCEC	cis	rs1832871	0.619	rs262821	chr6:158665197	C/T	cg07215822	chr6:158701037	NA	-0.54	-5.6	-0.42	1.02e-7	Height;
UCEC	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02851049	chr16:101260	POLR3K	0.7	4.62	0.36	8.33e-6	Glioblastoma;
UCEC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-4.78	-0.37	4.21e-6	Prostate cancer;
UCEC	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.58	-7.57	-0.53	3.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg20965017	chr5:231967	SDHA	-0.65	-6.02	-0.44	1.32e-8	Breast cancer;
UCEC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg06238570	chr21:40685208	BRWD1	0.78	7.8	0.54	1.04e-12	Cognitive function;
UCEC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.47	4.71	0.36	5.65e-6	Blood metabolite levels;
UCEC	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.43	4.83	0.37	3.34e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.29	4.52	0.35	1.29e-5	HDL cholesterol levels;
UCEC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.63	6.66	0.48	5.14e-10	Colorectal cancer;
UCEC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.51	-5.57	-0.42	1.15e-7	Educational attainment;
UCEC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.68	-6.12	-0.45	8.04e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.59	5.08	0.39	1.14e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.42	-4.83	-0.37	3.45e-6	HDL cholesterol levels;
UCEC	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	6.33	0.46	2.85e-9	Bone mineral density;
UCEC	cis	rs8105895	1.000	rs17450788	chr19:22224755	T/C	cg20662725	chr19:22235022	ZNF257	-0.55	-4.94	-0.38	2.11e-6	Body mass index (change over time);
UCEC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg16989719	chr2:238392110	NA	-0.42	-5.8	-0.43	3.85e-8	Prostate cancer;
UCEC	cis	rs12635074	0.520	rs991335	chr3:56234932	G/A	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.36	4.62	0.36	8.35e-6	Morning vs. evening chronotype;
UCEC	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.69	-7.52	-0.53	4.98e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-0.72	-5.01	-0.38	1.53e-6	Mitochondrial DNA levels;
UCEC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.78	0.49	2.78e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-5.7	-0.43	6.44e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.54	4.86	0.37	3.01e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg04804543	chr8:142233427	SLC45A4	-0.49	-5.91	-0.44	2.34e-8	Immature fraction of reticulocytes;
UCEC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-4.58	-0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	5.29	0.4	4.35e-7	Personality dimensions;
UCEC	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg13683864	chr3:40499215	RPL14	-0.67	-6.64	-0.48	5.73e-10	Renal cell carcinoma;
UCEC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.78	4.68	0.36	6.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg23307798	chr14:103986281	CKB	-0.6	-7.22	-0.51	2.64e-11	Body mass index;
UCEC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7597155	0.846	rs1912118	chr2:69954387	G/A	cg02498382	chr2:70120550	SNRNP27	-0.52	-5.65	-0.42	8.25e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.64	-5.01	-0.38	1.57e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.53	-6.95	-0.5	1.11e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.61	0.48	6.7e-10	Bladder cancer;
UCEC	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	0.75	5.03	0.38	1.43e-6	Diabetic retinopathy;
UCEC	cis	rs2425143	0.908	rs6060632	chr20:34422601	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.53	-0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.66	4.7	0.36	5.99e-6	Pediatric autoimmune diseases;
UCEC	cis	rs3750082	0.785	rs4720085	chr7:32968136	C/T	cg05721444	chr7:32995514	FKBP9	-0.53	-6.27	-0.46	3.74e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.52	5.27	0.4	4.71e-7	Monocyte count;
UCEC	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg20007245	chr22:24372913	LOC391322	-0.5	-5.39	-0.41	2.78e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.75	-9.95	-0.63	3.86e-18	Urate levels in lean individuals;
UCEC	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.86	6.79	0.49	2.53e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-6.25	-0.46	4.22e-9	Personality dimensions;
UCEC	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg26612420	chr16:74919680	WDR59	0.49	4.53	0.35	1.21e-5	Energy expenditure (24h);
UCEC	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.33	5.0	0.38	1.61e-6	Ulcerative colitis;
UCEC	cis	rs151997	1.000	rs152854	chr5:50223206	G/A	cg06027927	chr5:50259733	NA	-0.55	-5.02	-0.38	1.49e-6	Callous-unemotional behaviour;
UCEC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.71	5.57	0.42	1.2e-7	Cisplatin-induced ototoxicity;
UCEC	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.19e-7	QRS complex (12-leadsum);
UCEC	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.71	-0.48	3.95e-10	Caudate activity during reward;
UCEC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.49	4.76	0.37	4.52e-6	Gut microbiome composition (summer);
UCEC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.91	-0.38	2.42e-6	Bipolar disorder;
UCEC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18932078	chr1:2524107	MMEL1	-0.39	-6.5	-0.47	1.17e-9	Ulcerative colitis;
UCEC	cis	rs13253111	0.624	rs1979330	chr8:28096051	T/A	cg26534493	chr8:28060551	NA	0.49	5.43	0.41	2.31e-7	Childhood body mass index;
UCEC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.63	-6.11	-0.45	8.56e-9	Acne (severe);
UCEC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-5.49	-0.41	1.76e-7	Monocyte count;
UCEC	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.58	-5.95	-0.44	1.88e-8	Dental caries;
UCEC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs12086130	1.000	rs76183105	chr1:51413964	G/A	cg07174182	chr1:51127561	FAF1	-0.84	-5.06	-0.39	1.23e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg11871910	chr12:69753446	YEATS4	1.07	13.47	0.74	1.87e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11153730	0.503	rs369383	chr6:118618400	T/A	cg21191810	chr6:118973309	C6orf204	0.39	5.05	0.38	1.27e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.62	5.82	0.43	3.5e-8	Tonsillectomy;
UCEC	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.87	-10.27	-0.65	5.32e-19	Blood metabolite levels;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.63	-7.1	-0.51	5.01e-11	Cardiac Troponin-T levels;
UCEC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.76	10.33	0.65	3.88e-19	Vitiligo;
UCEC	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.03	0.38	1.4e-6	Breast cancer;
UCEC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.33	0.4	3.59e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.14	-0.45	7.38e-9	Cardiac Troponin-T levels;
UCEC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg22467129	chr15:76604101	ETFA	-0.46	-4.75	-0.36	4.8e-6	Blood metabolite levels;
UCEC	cis	rs925228	0.955	rs10182357	chr2:24153132	T/A	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.61	7.92	0.55	5.49e-13	Weight;
UCEC	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.62	-5.98	-0.44	1.62e-8	Aortic root size;
UCEC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.89	0.37	2.6e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2882667	0.931	rs7706391	chr5:138349164	G/A	cg04439458	chr5:138467593	SIL1	-0.38	-4.64	-0.36	7.49e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	7.99	0.55	3.55e-13	Post bronchodilator FEV1;
UCEC	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg09507928	chr5:140027484	IK;NDUFA2	-0.63	-7.09	-0.5	5.36e-11	Breast cancer;
UCEC	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg14008862	chr17:28927542	LRRC37B2	0.55	4.94	0.38	2.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.49	0.47	1.22e-9	Personality dimensions;
UCEC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.59	-7.63	-0.53	2.79e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg20129853	chr10:51489980	NA	0.42	4.98	0.38	1.78e-6	Prostate-specific antigen levels;
UCEC	cis	rs7582720	1.000	rs72932763	chr2:203678658	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.96	0.38	1.89e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.46	4.91	0.38	2.39e-6	Neuroticism;
UCEC	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg05539622	chr2:73298971	SFXN5	0.5	4.79	0.37	4.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8127571	0.551	rs2838986	chr21:47145374	C/T	cg16942644	chr21:46867867	COL18A1	-0.63	-4.6	-0.35	8.98e-6	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.58	0.53	3.5e-12	Ileal carcinoids;
UCEC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.14	-0.71	6.33e-24	Primary sclerosing cholangitis;
UCEC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.49	-0.41	1.68e-7	Pubertal anthropometrics;
UCEC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.48	4.67	0.36	6.83e-6	Menopause (age at onset);
UCEC	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.5	-5.24	-0.4	5.54e-7	Pubertal anthropometrics;
UCEC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.5	4.94	0.38	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.56	6.35	0.46	2.52e-9	Calcium levels;
UCEC	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.49	-0.47	1.24e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.48	-5.42	-0.41	2.42e-7	Dental caries;
UCEC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-4.51	-0.35	1.29e-5	Parkinson's disease;
UCEC	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg21053147	chr12:120880522	NA	0.69	5.07	0.39	1.18e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.64	6.21	0.46	5.22e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.58	5.67	0.42	7.3e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	6.13	0.45	7.55e-9	Total body bone mineral density;
UCEC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.56	5.43	0.41	2.29e-7	Platelet distribution width;
UCEC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg23795048	chr12:9217529	LOC144571	0.41	5.09	0.39	1.1e-6	Sjögren's syndrome;
UCEC	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.46	5.75	0.43	5.1e-8	HDL cholesterol levels;
UCEC	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.59	7.13	0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.75	9.62	0.62	2.67e-17	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.66	-7.25	-0.51	2.22e-11	Diastolic blood pressure;
UCEC	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.78	-8.43	-0.57	2.89e-14	Colorectal cancer;
UCEC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.72	9.16	0.6	4.16e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2644899	0.821	rs4803368	chr19:41301714	A/G	cg15701203	chr19:40737740	AKT2	-0.52	-4.51	-0.35	1.34e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.53	-5.14	-0.39	8.63e-7	Lung cancer;
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.47	0.57	2.39e-14	Platelet count;
UCEC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.69	-5.4	-0.41	2.62e-7	Aortic root size;
UCEC	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.81	-8.5	-0.57	1.98e-14	Caffeine consumption;
UCEC	cis	rs10012307	1.000	rs10519392	chr4:137485929	G/A	cg12033966	chr4:138453416	PCDH18	-0.71	-4.92	-0.38	2.29e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs9321099	1.000	rs6905392	chr6:128228833	A/G	cg25012434	chr6:128842125	PTPRK	0.61	4.66	0.36	7.07e-6	Sense of smell;
UCEC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg18681998	chr4:17616180	MED28	0.72	6.64	0.48	5.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.52	5.92	0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.86e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.49	-5.5	-0.41	1.68e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.44	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs731174	0.759	rs575254	chr1:38149692	C/G	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.34e-6	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg15509575	chr4:2286509	ZFYVE28	0.4	7.0	0.5	8.26e-11	Rheumatoid arthritis;
UCEC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.46	5.0	0.38	1.58e-6	Longevity;Endometriosis;
UCEC	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.66	5.45	0.41	2.06e-7	Menopause (age at onset);
UCEC	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Body mass index;
UCEC	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.85	10.89	0.67	1.31e-20	Metabolic syndrome;
UCEC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.59	6.59	0.48	7.42e-10	Prostate cancer;
UCEC	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg24060327	chr5:131705240	SLC22A5	0.5	4.74	0.36	4.96e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.45	-5.33	-0.4	3.67e-7	Monocyte percentage of white cells;
UCEC	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.6	6.52	0.47	1.06e-9	Mean platelet volume;
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.48	-5.26	-0.4	5.08e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.53	5.11	0.39	9.8e-7	Resting heart rate;
UCEC	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-6.83	-0.49	2.13e-10	Colorectal cancer;
UCEC	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg08027265	chr7:2291960	NA	-0.49	-5.22	-0.4	6.04e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs6504663	0.525	rs557	chr17:48563234	C/T	cg03611598	chr17:48586076	MYCBPAP	0.49	5.41	0.41	2.45e-7	Visceral fat;
UCEC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-5.77	-0.43	4.57e-8	Monocyte percentage of white cells;
UCEC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.74	0.36	4.92e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	5.74	0.43	5.3e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.58	4.75	0.36	4.86e-6	Breast cancer;
UCEC	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg09044154	chr16:88155775	NA	-0.55	-4.53	-0.35	1.21e-5	Menopause (age at onset);
UCEC	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.75	-7.84	-0.54	8.34e-13	Mosquito bite size;
UCEC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.47	-5.41	-0.41	2.44e-7	Depression;
UCEC	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	8.39	0.57	3.63e-14	Menopause (age at onset);
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.32	-0.46	2.9e-9	Prudent dietary pattern;
UCEC	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	6.31	0.46	3.09e-9	Response to antipsychotic treatment;
UCEC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.57	4.85	0.37	3.17e-6	Neutrophil percentage of white cells;
UCEC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.23	-0.46	4.58e-9	Tonsillectomy;
UCEC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.44	4.72	0.36	5.35e-6	Longevity;Endometriosis;
UCEC	cis	rs9463078	0.764	rs1854547	chr6:44912366	G/A	cg25276700	chr6:44698697	NA	-0.42	-4.77	-0.37	4.4e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.04e-6	Schizophrenia;
UCEC	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.69	-0.36	6.27e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.5	-6.72	-0.48	3.73e-10	Eye color traits;
UCEC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.35	-0.4	3.25e-7	Homoarginine levels;
UCEC	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.66	-8.26	-0.56	7.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.21	7.88	0.54	6.86e-13	Atopic dermatitis;
UCEC	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.05	0.55	2.58e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.78	-5.79	-0.43	4.02e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.46	4.57	0.35	1.01e-5	Prostate cancer;
UCEC	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.68	-6.91	-0.5	1.34e-10	Body mass index;
UCEC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-5.45	-0.41	2.05e-7	Platelet count;
UCEC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.65	5.28	0.4	4.47e-7	Corneal astigmatism;
UCEC	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.5	5.83	0.43	3.31e-8	Blood metabolite ratios;
UCEC	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	5.69	0.42	6.7e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4372836	0.964	rs4665431	chr2:28938168	T/C	cg09522027	chr2:28974177	PPP1CB	0.55	5.49	0.41	1.71e-7	Body mass index;
UCEC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13939156	chr17:80058883	NA	0.37	4.79	0.37	4.04e-6	Life satisfaction;
UCEC	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg10932868	chr11:921992	NA	0.46	5.71	0.43	5.95e-8	Alzheimer's disease (late onset);
UCEC	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.57	5.42	0.41	2.41e-7	Bladder cancer;
UCEC	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.81	-6.25	-0.46	4.17e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7932813	0.825	rs12804488	chr11:7697913	A/G	cg27431761	chr11:8361327	NA	0.42	4.53	0.35	1.2e-5	Waist circumference;
UCEC	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.48	4.77	0.37	4.33e-6	Blood metabolite levels;
UCEC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs2806864	1.000	rs2250439	chr1:117466050	T/A	cg19765820	chr1:116518738	SLC22A15	-0.6	-4.52	-0.35	1.25e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg08459430	chr5:81571289	RPS23	0.47	4.5	0.35	1.36e-5	Breast cancer;
UCEC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.89	7.72	0.54	1.65e-12	Bladder cancer;
UCEC	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-4.91	-0.38	2.42e-6	Monocyte percentage of white cells;
UCEC	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg10123293	chr2:99228465	UNC50	0.49	5.51	0.41	1.58e-7	Bipolar disorder;
UCEC	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.92	0.38	2.32e-6	Aortic root size;
UCEC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.91	12.31	0.71	2.23e-24	Metabolic syndrome;
UCEC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.02	-0.38	1.49e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07147234	chr12:56522077	ESYT1	0.55	6.83	0.49	2.1e-10	Warfarin maintenance dose;
UCEC	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.6	5.96	0.44	1.79e-8	Lung cancer;
UCEC	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-4.68	-0.36	6.38e-6	Reticulocyte count;
UCEC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.78	7.46	0.52	7.1e-12	Initial pursuit acceleration;
UCEC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.77	-9.17	-0.6	3.85e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-0.81	-4.6	-0.35	9.11e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.5	7.08	0.5	5.57e-11	Gait variability;
UCEC	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.11	4.92	0.38	2.31e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.59	-4.56	-0.35	1.08e-5	Blood pressure (smoking interaction);
UCEC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-6.43	-0.47	1.71e-9	Prudent dietary pattern;
UCEC	cis	rs12635074	0.547	rs12639313	chr3:56233180	A/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.52	0.35	1.26e-5	Morning vs. evening chronotype;
UCEC	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	1.06	5.96	0.44	1.75e-8	Type 2 diabetes;
UCEC	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.46	-5.24	-0.4	5.5e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	0.97	8.62	0.58	9.83e-15	Red blood cell traits;
UCEC	cis	rs847577	0.569	rs2394817	chr7:97690438	C/T	cg24562669	chr7:97807699	LMTK2	0.74	10.49	0.65	1.46e-19	Breast cancer;
UCEC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.5	-4.79	-0.37	3.97e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg13588346	chr9:123947445	RAB14	0.41	4.64	0.36	7.79e-6	Rheumatoid arthritis;
UCEC	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.5	-5.02	-0.38	1.48e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg26721908	chr21:47610096	LSS	0.36	4.54	0.35	1.17e-5	Testicular germ cell tumor;
UCEC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.69	6.54	0.47	9.66e-10	Aortic root size;
UCEC	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.23	0.51	2.49e-11	Coffee consumption (cups per day);
UCEC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.52	5.14	0.39	8.79e-7	Colorectal cancer;
UCEC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.72	-0.63	1.49e-17	Height;
UCEC	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.54	5.38	0.41	2.85e-7	Uric acid levels;
UCEC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg20387954	chr3:183756860	HTR3D	0.5	5.99	0.44	1.58e-8	Anterior chamber depth;
UCEC	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.43	0.69	4.84e-22	Chronic sinus infection;
UCEC	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg20485758	chr6:26088446	HFE	0.71	4.61	0.36	8.64e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.36	-0.46	2.35e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.7	8.29	0.56	6.46e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.41	0.69	5.25e-22	Prudent dietary pattern;
UCEC	cis	rs2172802	0.570	rs12233859	chr4:62545435	G/A	cg04118610	chr4:62707027	LPHN3	-0.44	-4.82	-0.37	3.48e-6	Partial epilepsies;
UCEC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	5.93	0.44	2.11e-8	Menarche (age at onset);
UCEC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.56	-5.12	-0.39	9.4e-7	Systemic lupus erythematosus;
UCEC	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg19715936	chr7:50634035	DDC	0.45	5.37	0.41	2.99e-7	Malaria;
UCEC	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.4	-4.55	-0.35	1.12e-5	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.72	5.67	0.42	7.15e-8	Atrial fibrillation;
UCEC	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.61	-0.62	2.81e-17	Primary sclerosing cholangitis;
UCEC	cis	rs11760485	0.824	rs73051242	chr7:4400401	G/A	cg15613991	chr7:5277080	NA	-0.44	-5.2	-0.39	6.64e-7	Early childhood aggressive behavior;
UCEC	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg26061582	chr7:22766209	IL6	0.87	5.37	0.4	3.01e-7	Tonsillectomy;
UCEC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.67	-7.04	-0.5	6.73e-11	Height;
UCEC	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.42	4.92	0.38	2.25e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg12637676	chr8:11587161	GATA4	-0.36	-4.61	-0.36	8.65e-6	Retinal vascular caliber;
UCEC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.9	-10.26	-0.65	5.73e-19	Dental caries;
UCEC	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.54	4.95	0.38	1.97e-6	Diabetic retinopathy;
UCEC	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.78	-7.89	-0.55	6.46e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg23795048	chr12:9217529	LOC144571	0.42	5.09	0.39	1.1e-6	Sjögren's syndrome;
UCEC	cis	rs17122693	0.748	rs72681608	chr14:51116090	C/T	cg04730355	chr14:51134070	SAV1	0.98	10.27	0.65	5.57e-19	Cognitive performance;
UCEC	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.43	5.45	0.41	2.07e-7	Electrocardiographic conduction measures;
UCEC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs466639	0.636	rs285480	chr1:165403903	A/G	cg03421657	chr1:166039754	FAM78B	0.32	4.97	0.38	1.87e-6	Menarche (age at onset);
UCEC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.92	6.81	0.49	2.27e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-6.28	-0.46	3.68e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7246967	0.611	rs66620859	chr19:22837230	G/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-0.81	-5.25	-0.4	5.33e-7	Blood protein levels;
UCEC	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.49	5.31	0.4	4.06e-7	Platelet distribution width;
UCEC	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-0.77	-6.84	-0.49	2.03e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.65	-7.67	-0.53	2.23e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs7870753	0.945	rs6477489	chr9:99239841	A/C	cg25260653	chr9:99212216	HABP4	0.48	4.86	0.37	3.02e-6	Height;
UCEC	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.44	5.25	0.4	5.17e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.6	6.35	0.46	2.58e-9	Initial pursuit acceleration;
UCEC	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-0.97	-4.58	-0.35	9.79e-6	Mitochondrial DNA levels;
UCEC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.45	5.96	0.44	1.75e-8	Fibrinogen levels;
UCEC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg21770322	chr7:97807741	LMTK2	0.54	6.75	0.49	3.16e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-6.0	-0.44	1.48e-8	Gut microbiome composition (summer);
UCEC	cis	rs2041840	0.503	rs10179447	chr2:37578208	C/T	cg20091297	chr2:37572423	QPCT	0.48	5.12	0.39	9.6e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.57	6.74	0.49	3.35e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.79	7.31	0.52	1.55e-11	Diastolic blood pressure;
UCEC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.55	-5.47	-0.41	1.88e-7	Aortic root size;
UCEC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.61	-5.38	-0.41	2.85e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.82	0.49	2.19e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-6.13	-0.45	7.74e-9	Total cholesterol levels;
UCEC	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	6.16	0.45	6.62e-9	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-0.61	-7.0	-0.5	8.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg01874867	chr7:94954059	PON1	-0.53	-4.71	-0.36	5.73e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg05738196	chr6:26577821	NA	0.64	7.6	0.53	3.21e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	0.7	5.51	0.41	1.59e-7	Post bronchodilator FEV1;
UCEC	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.41	4.54	0.35	1.18e-5	Bipolar disorder;
UCEC	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg13695892	chr22:41940480	POLR3H	0.62	4.52	0.35	1.29e-5	Vitiligo;
UCEC	cis	rs3750082	0.815	rs6964458	chr7:32935224	G/T	cg05721444	chr7:32995514	FKBP9	0.53	5.87	0.44	2.81e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg05660106	chr1:15850417	CASP9	0.51	4.88	0.37	2.71e-6	Systolic blood pressure;
UCEC	cis	rs11958404	0.932	rs72818127	chr5:157452227	C/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.63	-0.48	5.92e-10	Pulmonary function;
UCEC	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-10.44	-0.65	1.93e-19	Renal cell carcinoma;
UCEC	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.42	-4.62	-0.36	8.29e-6	Menopause (age at onset);
UCEC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.49	4.61	0.36	8.55e-6	Menopause (age at onset);
UCEC	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.52	-5.31	-0.4	3.88e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.11	0.39	9.71e-7	Birth weight;
UCEC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.67	8.36	0.57	4.44e-14	Bone mineral density;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.61	-7.02	-0.5	7.47e-11	Pubertal anthropometrics;
UCEC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.83	0.49	2.07e-10	Coffee consumption (cups per day);
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.64	-7.37	-0.52	1.14e-11	Body mass index;
UCEC	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs4774830	0.744	rs60931351	chr15:56305541	A/T	cg24530489	chr15:56299380	NA	-0.69	-4.65	-0.36	7.29e-6	Delta-5 desaturase activity;
UCEC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.47	0.57	2.33e-14	Prudent dietary pattern;
UCEC	cis	rs4237845	0.622	rs10783859	chr12:58332794	C/A	cg02175503	chr12:58329896	NA	0.63	6.17	0.45	6.3e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	8.56	0.58	1.38e-14	Electrocardiographic conduction measures;
UCEC	cis	rs151997	0.962	rs27714	chr5:50180396	G/C	cg06027927	chr5:50259733	NA	0.54	4.98	0.38	1.79e-6	Callous-unemotional behaviour;
UCEC	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.49	-4.8	-0.37	3.88e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	1.01	9.96	0.63	3.63e-18	Alcohol dependence;
UCEC	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.4	-4.55	-0.35	1.12e-5	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.75	-0.49	3.21e-10	Chronic sinus infection;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.37	-0.4	3.06e-7	Pubertal anthropometrics;
UCEC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-7.43	-0.52	8.09e-12	Morning vs. evening chronotype;
UCEC	cis	rs11625487	0.609	rs45493395	chr14:77976468	T/C	cg20045696	chr14:77926864	AHSA1	-0.64	-4.85	-0.37	3.15e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.78	8.3	0.56	6.22e-14	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.63	-6.16	-0.45	6.59e-9	C-reactive protein levels;
UCEC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.03	0.38	1.38e-6	Breast cancer;
UCEC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.82	-0.49	2.24e-10	Aortic root size;
UCEC	cis	rs2592394	0.675	rs711819	chr2:176985696	C/T	cg13092806	chr2:177043255	NA	-0.67	-4.7	-0.36	6.05e-6	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	0.67	4.87	0.37	2.9e-6	Diabetic retinopathy;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.5	-5.91	-0.44	2.23e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7872515	0.775	rs1970121	chr9:94870152	A/C	cg01248375	chr9:94877805	SPTLC1	-0.45	-4.8	-0.37	3.9e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.44	-4.76	-0.37	4.51e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.33	-0.46	2.78e-9	Coffee consumption (cups per day);
UCEC	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	5.98e-9	Colorectal cancer;
UCEC	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.11e-9	Coffee consumption (cups per day);
UCEC	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.65	-5.81	-0.43	3.8e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10924970	0.967	rs12027832	chr1:235385934	A/G	cg26050004	chr1:235667680	B3GALNT2	0.44	4.59	0.35	9.41e-6	Asthma;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.78	0.43	4.29e-8	Prudent dietary pattern;
UCEC	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.53	-5.79	-0.43	4.08e-8	Neuroticism;
UCEC	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg12850546	chr22:42539477	CYP2D7P1	1.16	7.65	0.53	2.5e-12	Birth weight;
UCEC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.65	6.32	0.46	2.98e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7597155	0.935	rs7589995	chr2:69980427	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.46	-0.41	1.98e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.51	5.16	0.39	7.84e-7	Bipolar disorder;
UCEC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.35	-4.6	-0.35	9.11e-6	Prostate cancer;
UCEC	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.78	-8.95	-0.59	1.43e-15	Facial morphology (factor 19);
UCEC	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.45	5.01	0.38	1.54e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.67	5.7	0.43	6.35e-8	Blood protein levels;
UCEC	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	4.89	0.37	2.61e-6	Rheumatoid arthritis;
UCEC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg05991184	chr2:219186017	PNKD	-0.45	-4.8	-0.37	3.8e-6	Colorectal cancer;
UCEC	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.71	7.95	0.55	4.62e-13	Mortality in heart failure;
UCEC	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.71	8.95	0.59	1.43e-15	Testicular germ cell tumor;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.56	-5.72	-0.43	5.73e-8	Longevity;Endometriosis;
UCEC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.57	5.29	0.4	4.33e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.81	0.43	3.74e-8	Breast cancer;
UCEC	trans	rs4534959	0.546	rs79445293	chr18:62061909	A/G	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs12542759	0.963	rs1604292	chr8:133033089	C/T	cg10591701	chr8:133787386	PHF20L1	-0.51	-4.82	-0.37	3.55e-6	Pit-and-Fissure caries;
UCEC	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg03543861	chr21:44258195	NA	0.46	4.84	0.37	3.26e-6	Information processing speed;
UCEC	cis	rs7937612	1.000	rs12417256	chr11:120337519	A/C	cg12584626	chr11:120203529	NA	0.51	5.03	0.38	1.43e-6	Intraocular pressure;
UCEC	trans	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg06784218	chr1:46089804	CCDC17	0.55	6.49	0.47	1.25e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7113850	0.541	rs7118538	chr11:24223615	C/T	ch.11.24196551F	chr11:24239977	NA	0.62	4.71	0.36	5.67e-6	Bone fracture in osteoporosis;
UCEC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs1467979	0.527	rs12601285	chr17:78061274	C/T	cg11447922	chr17:78161572	CARD14	0.6	4.51	0.35	1.29e-5	IgG glycosylation;
UCEC	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg24375607	chr4:120327624	NA	0.5	5.21	0.4	6.15e-7	Educational attainment;
UCEC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.88	0.37	2.72e-6	Rheumatoid arthritis;
UCEC	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.64	6.3	0.46	3.19e-9	Itch intensity from mosquito bite;
UCEC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.75	0.59	4.59e-15	Alzheimer's disease;
UCEC	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.53	4.96	0.38	1.95e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.46	-5.01	-0.38	1.51e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs13063635	0.915	rs41289616	chr3:45997263	T/C	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.68	-6.58	-0.48	7.67e-10	Sudden cardiac arrest;
UCEC	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg14547644	chr6:28411285	ZSCAN23	0.61	7.69	0.54	1.91e-12	Pubertal anthropometrics;
UCEC	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01391022	chr12:122360665	WDR66	-0.45	-5.3	-0.4	4.12e-7	Mean corpuscular volume;
UCEC	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.74	9.01	0.6	1.02e-15	Monocyte count;
UCEC	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.66	-0.36	6.96e-6	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg09120320	chr17:61926383	NA	0.44	4.59	0.35	9.52e-6	Prudent dietary pattern;
UCEC	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.9100000000000004e-06	Breast cancer;
UCEC	cis	rs7307889	0.793	rs12314557	chr12:6009297	C/T	cg10294363	chr12:6480192	SCNN1A	0.58	4.69	0.36	6.22e-6	Obesity-related traits;
UCEC	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.49	-4.75	-0.37	4.69e-6	Obesity-related traits;
UCEC	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.62	5.28	0.4	4.61e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.0	0.7	1.45e-23	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg19468946	chr17:37922297	IKZF3	-0.42	-4.55	-0.35	1.11e-5	Lymphocyte counts;
UCEC	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg04896959	chr15:78267971	NA	-0.69	-6.68	-0.48	4.5e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.87	-0.37	2.82e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.74	6.3	0.46	3.2e-9	Schizophrenia;
UCEC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.28	0.4	4.66e-7	Birth weight;
UCEC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.37	0.57	4.05e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg27535305	chr1:53392650	SCP2	-0.36	-4.56	-0.35	1.05e-5	Monocyte count;
UCEC	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.56	5.84	0.43	3.16e-8	Diastolic blood pressure;
UCEC	cis	rs1576263	0.967	rs7753991	chr6:8561428	A/G	cg07606381	chr6:8435919	SLC35B3	0.46	4.77	0.37	4.4e-6	Photic sneeze reflex;
UCEC	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.92	-7.84	-0.54	8.57e-13	Body mass index;
UCEC	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.61	-0.62	2.81e-17	Primary sclerosing cholangitis;
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.79	0.54	1.1e-12	Platelet count;
UCEC	cis	rs10924970	0.624	rs12755851	chr1:235477806	G/C	cg26050004	chr1:235667680	B3GALNT2	0.5	4.84	0.37	3.23e-6	Asthma;
UCEC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.57	6.5	0.47	1.16e-9	Aortic root size;
UCEC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.48	5.46	0.41	1.98e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.41	5.17	0.39	7.59e-7	HIV-1 susceptibility;
UCEC	cis	rs1171113	0.758	rs217345	chr6:84335225	C/T	cg25640892	chr6:84743294	MRAP2	-0.6	-4.62	-0.36	8.47e-6	Bipolar disorder with mood-incongruent psychosis;
UCEC	cis	rs2892463	0.796	rs9506229	chr13:30367959	A/C	cg18356743	chr13:30408050	UBL3	0.41	4.56	0.35	1.06e-5	Non-word repetition;
UCEC	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.03	0.38	1.43e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.9	9.32	0.61	1.63e-16	Cognitive function;
UCEC	cis	rs13401104	0.686	rs72620812	chr2:237118765	C/T	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs7072216	0.687	rs10786418	chr10:100157368	C/T	cg19567339	chr10:100142640	NA	0.57	7.16	0.51	3.53e-11	Metabolite levels;
UCEC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.69	7.57	0.53	3.89e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.64	-5.32	-0.4	3.73e-7	Alopecia areata;
UCEC	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.66	-4.86	-0.37	2.94e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-7.91	-0.55	5.68e-13	Chronic sinus infection;
UCEC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.17	-0.6	3.94e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.7	6.34	0.46	2.65e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.6	5.65	0.42	8.13e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs10838687	0.673	rs77532017	chr11:47284317	C/T	cg19229622	chr11:47291485	MADD	-0.47	-4.57	-0.35	1.03e-5	Proinsulin levels;
UCEC	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	0.79	8.14	0.56	1.56e-13	Parkinson's disease;
UCEC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg02951883	chr7:2050386	MAD1L1	-0.51	-4.67	-0.36	6.72e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7618501	0.570	rs7613875	chr3:49971514	C/A	cg24308560	chr3:49941425	MST1R	-0.53	-5.9	-0.44	2.43e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg18002602	chr11:66138449	SLC29A2	-0.41	-5.06	-0.39	1.21e-6	Educational attainment (years of education);
UCEC	cis	rs308403	0.600	rs376131	chr4:123629225	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	6.19	0.45	5.66e-9	Blood protein levels;
UCEC	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.53	5.17	0.39	7.49e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.53	5.39	0.41	2.77e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.47	5.32	0.4	3.82e-7	White matter hyperintensity burden;
UCEC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.43	-5.84	-0.43	3.28e-8	Prostate cancer;
UCEC	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs847577	0.587	rs34307903	chr7:97728449	C/A	cg24562669	chr7:97807699	LMTK2	0.73	10.76	0.66	2.89e-20	Breast cancer;
UCEC	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.61	6.6	0.48	6.9e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.44	-4.53	-0.35	1.21e-5	Urinary electrolytes (magnesium/calcium ratio);
UCEC	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.58	-0.66	8.26e-20	Blood metabolite levels;
UCEC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.61	5.66	0.42	7.6e-8	Lymphocyte counts;
UCEC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg22974920	chr21:40686053	BRWD1	0.56	5.02	0.38	1.5e-6	Cognitive function;
UCEC	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg04553112	chr3:125709451	NA	-0.66	-4.85	-0.37	3.17e-6	Blood pressure (smoking interaction);
UCEC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.46	4.93	0.38	2.21e-6	Headache;
UCEC	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.75	0.43	4.87e-8	Coffee consumption (cups per day);
UCEC	cis	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg00086871	chr4:6988644	TBC1D14	0.81	5.24	0.4	5.39e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.88	-12.58	-0.72	4.25e-25	Urate levels in lean individuals;
UCEC	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg05738196	chr6:26577821	NA	0.56	5.28	0.4	4.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.58	6.02	0.44	1.31e-8	IgG glycosylation;
UCEC	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.5	5.69	0.42	6.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs595018	0.505	rs56401304	chr11:60595396	T/G	cg01235581	chr11:60605718	NA	0.45	4.59	0.35	9.35e-6	Wegener's granulomatosis;
UCEC	cis	rs877282	0.731	rs67369760	chr10:791583	C/T	cg17470449	chr10:769945	NA	0.58	5.18	0.39	7.15e-7	Uric acid levels;
UCEC	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.58	5.16	0.39	7.97e-7	Corneal astigmatism;
UCEC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.77	-0.37	4.35e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg23018236	chr17:30244563	NA	-0.67	-4.65	-0.36	7.34e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.77	0.37	4.33e-6	Breast cancer;
UCEC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.49	4.77	0.37	4.47e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	5.65	0.42	8.21e-8	Coffee consumption (cups per day);
UCEC	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.49e-8	Depression;
UCEC	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.18	0.39	7.03e-7	IgG glycosylation;
UCEC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg12024160	chr4:1254474	NA	0.7	8.37	0.57	4.08e-14	Obesity-related traits;
UCEC	cis	rs7937612	0.965	rs10892563	chr11:120224544	A/G	cg12584626	chr11:120203529	NA	0.49	4.92	0.38	2.3e-6	Intraocular pressure;
UCEC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg13147721	chr7:65941812	NA	-0.73	-4.87	-0.37	2.84e-6	Diabetic kidney disease;
UCEC	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg21419209	chr3:44054225	NA	-0.5	-5.05	-0.38	1.27e-6	Coronary artery disease;
UCEC	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	1.0	8.43	0.57	2.86e-14	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.74	4.64	0.36	7.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11235843	0.929	rs12366033	chr11:73378974	C/T	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.73	9.49	0.62	5.74e-17	Vitiligo;
UCEC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg13147721	chr7:65941812	NA	-0.75	-5.06	-0.38	1.26e-6	Diabetic kidney disease;
UCEC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.91	9.71	0.63	1.61e-17	Cognitive function;
UCEC	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.93e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-5.26	-0.4	5.04e-7	Bipolar disorder;
UCEC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.47	1.11e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.91	-9.82	-0.63	8.31e-18	Body mass index;
UCEC	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-8.61	-0.58	1.04e-14	Exhaled nitric oxide output;
UCEC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.36	-0.4	3.15e-7	Chronic sinus infection;
UCEC	cis	rs6746896	0.683	rs6576983	chr2:97454650	T/G	cg01950434	chr2:97203154	ARID5A	-0.46	-4.9	-0.37	2.5e-6	Bipolar disorder;
UCEC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.78	10.51	0.66	1.3e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.46	5.15	0.39	8.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.43	5.42	0.41	2.43e-7	Obesity-related traits;
UCEC	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.06	0.5	6.28e-11	Motion sickness;
UCEC	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.27	0.51	1.98e-11	Bladder cancer;
UCEC	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.36	-5.55	-0.42	1.27e-7	Ulcerative colitis;
UCEC	cis	rs16857609	0.628	rs1072086	chr2:218351950	A/T	cg23340935	chr2:218354150	DIRC3	0.49	4.82	0.37	3.57e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.58	8.22	0.56	9.74e-14	Total body bone mineral density;
UCEC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.68	-6.11	-0.45	8.61e-9	Aortic root size;
UCEC	cis	rs6576086	1.000	rs6576086	chr14:105873144	A/G	cg12425861	chr14:105830606	PACS2	-0.6	-5.07	-0.39	1.21e-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.55	5.37	0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.57	-5.8	-0.43	3.94e-8	Breast size;
UCEC	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.99	-11.14	-0.68	2.81e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.42	4.81	0.37	3.67e-6	Blood protein levels;
UCEC	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg21642963	chr15:78858002	CHRNA5	0.5	4.7	0.36	5.94e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.43	5.69	0.43	6.56e-8	Panic disorder;
UCEC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.41	-5.09	-0.39	1.09e-6	Colorectal cancer;
UCEC	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.77	-6.84	-0.49	1.94e-10	Resting heart rate;
UCEC	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.99	-0.38	1.66e-6	Coronary artery disease;
UCEC	cis	rs2041840	0.597	rs10865124	chr2:37576553	A/G	cg25727520	chr2:37576821	QPCT	-0.44	-4.87	-0.37	2.8e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg14008862	chr17:28927542	LRRC37B2	0.58	5.16	0.39	7.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg26031613	chr14:104095156	KLC1	1.24	16.36	0.8	6.49e-35	Body mass index;
UCEC	cis	rs970548	0.690	rs10900222	chr10:45997366	G/T	cg15223267	chr10:46222474	FAM21C	0.5	4.85	0.37	3.05e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.43	5.03	0.38	1.41e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.6	4.57	0.35	1.01e-5	Gut microbiome composition (summer);
UCEC	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.54	5.51	0.41	1.56e-7	Post bronchodilator FEV1;
UCEC	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg02176678	chr2:219576539	TTLL4	-0.64	-6.94	-0.5	1.14e-10	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.92	-0.44	2.13e-8	Height;
UCEC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.51	-4.67	-0.36	6.72e-6	Prudent dietary pattern;
UCEC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.64	-6.85	-0.49	1.91e-10	Menopause (age at onset);
UCEC	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	6.61	0.48	6.5e-10	Platelet distribution width;
UCEC	cis	rs9469578	0.792	rs79297236	chr6:33713930	T/C	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs6717918	0.564	rs3116185	chr2:233036247	A/G	cg20569070	chr2:232597279	PDE6D	0.41	4.6	0.35	9.21e-6	Height;
UCEC	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs4722166	0.532	rs6963866	chr7:22757341	C/T	cg05472934	chr7:22766657	IL6	0.5	4.76	0.37	4.52e-6	Lung cancer;
UCEC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.61	6.01	0.44	1.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.673	rs3844578	chr19:22880610	G/C	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.73	7.44	0.52	7.9e-12	Vitamin D levels;
UCEC	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.65	8.25	0.56	8.18e-14	Systolic blood pressure;
UCEC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.9	5.71	0.43	6.06e-8	Plasma clusterin levels;
UCEC	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.56	-6.0	-0.44	1.49e-8	Coronary artery disease;
UCEC	cis	rs12618769	0.572	rs4851141	chr2:99112966	A/C	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.56	6.64	0.48	5.77e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.44	4.85	0.37	3.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg22974920	chr21:40686053	BRWD1	0.6	5.32	0.4	3.73e-7	Cognitive function;
UCEC	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.25	-0.56	8.03e-14	Breast cancer;
UCEC	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-8.47	-0.57	2.37e-14	Coffee consumption (cups per day);
UCEC	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg06096015	chr1:231504339	EGLN1	0.42	4.59	0.35	9.32e-6	Hemoglobin concentration;
UCEC	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.78	0.49	2.68e-10	Motion sickness;
UCEC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.54	5.34	0.4	3.39e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.66	-5.63	-0.42	8.66e-8	Longevity;
UCEC	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg22563815	chr15:78856949	CHRNA5	0.39	4.77	0.37	4.4e-6	Sudden cardiac arrest;
UCEC	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.85	-8.29	-0.56	6.64e-14	Blood metabolite levels;
UCEC	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.36	5.03	0.38	1.42e-6	Height;
UCEC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.44	5.98	0.44	1.59e-8	Mean corpuscular volume;
UCEC	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg09003973	chr2:102972529	NA	0.89	5.44	0.41	2.18e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.69	-4.91	-0.38	2.44e-6	Aortic root size;
UCEC	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.49	4.75	0.36	4.74e-6	Dilated cardiomyopathy;
UCEC	trans	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg17145862	chr1:211918768	LPGAT1	0.68	8.01	0.55	3.25e-13	Leprosy;
UCEC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.86	-9.21	-0.61	3.04e-16	Lung cancer;
UCEC	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.52	-0.41	1.48e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg23978390	chr7:1156363	C7orf50	0.46	4.76	0.37	4.57e-6	Longevity;Endometriosis;
UCEC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.43	-4.61	-0.36	8.66e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs12618769	0.652	rs7585747	chr2:99219071	T/C	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.46e-7	Bipolar disorder;
UCEC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.11	9.61	0.62	2.86e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.54	5.92	0.44	2.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.61	-6.05	-0.45	1.17e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.67	0.58	7.35e-15	Platelet count;
UCEC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs12618769	0.625	rs12618524	chr2:99064029	T/A	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.52	0.35	1.26e-5	Height;
UCEC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.46	4.56	0.35	1.08e-5	Aortic root size;
UCEC	cis	rs6032067	1.000	rs6017519	chr20:43854677	C/T	cg00873616	chr20:43920241	NA	0.51	5.11	0.39	9.79e-7	Blood protein levels;
UCEC	cis	rs2376682	1.000	rs28880625	chr5:118005179	A/G	cg17593721	chr5:118788746	HSD17B4	0.48	4.77	0.37	4.4e-6	Diisocyanate-induced asthma;
UCEC	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.77	7.98	0.55	3.84e-13	Parkinson's disease;
UCEC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.63	6.01	0.44	1.4e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.06	-0.5	6.05e-11	Blood trace element (Zn levels);
UCEC	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg04837898	chr3:45731254	SACM1L	-0.41	-4.62	-0.36	8.31e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.24	-0.46	4.51e-9	Total cholesterol levels;
UCEC	cis	rs7709377	0.595	rs7730551	chr5:115419186	G/T	cg23108291	chr5:115420582	COMMD10	0.52	5.42	0.41	2.39e-7	Metabolite levels  (X-11787);
UCEC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.62	9.02	0.6	9.26e-16	Prudent dietary pattern;
UCEC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.57	6.26	0.46	4.09e-9	Neutrophil percentage of white cells;
UCEC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.1e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	5.27	0.4	4.86e-7	Ileal carcinoids;
UCEC	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg05925327	chr15:68127851	NA	-0.47	-5.72	-0.43	5.82e-8	Obesity;
UCEC	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.81	-8.19	-0.56	1.15e-13	Caffeine consumption;
UCEC	cis	rs892864	0.685	rs10046007	chr5:127762653	C/T	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.69	6.83	0.49	2.12e-10	Aortic root size;
UCEC	cis	rs56161922	1.000	rs12567945	chr1:207841934	T/C	cg09557387	chr1:207818395	CR1L	0.87	4.66	0.36	7.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	0.88	5.61	0.42	9.89e-8	Diabetic retinopathy;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.7	8.36	0.57	4.33e-14	Prudent dietary pattern;
UCEC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.54	-6.79	-0.49	2.57e-10	Total body bone mineral density;
UCEC	cis	rs7558233	0.614	rs763456	chr2:23675180	A/G	cg00747342	chr2:23700632	KLHL29	0.53	4.7	0.36	5.98e-6	Cannabis use (initiation);
UCEC	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.31	-4.51	-0.35	1.34e-5	Iron status biomarkers;
UCEC	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.73	6.34	0.46	2.72e-9	Coronary artery disease;
UCEC	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.72	7.94	0.55	4.71e-13	Primary sclerosing cholangitis;
UCEC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg22974920	chr21:40686053	BRWD1	0.63	5.13	0.39	8.92e-7	Cognitive function;
UCEC	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	5.2	0.39	6.61e-7	Coronary artery disease;
UCEC	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.72	6.27	0.46	3.88e-9	Caudate activity during reward;
UCEC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.44	-4.54	-0.35	1.18e-5	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg18512352	chr11:47633146	NA	-0.47	-5.42	-0.41	2.39e-7	Neuroticism;
UCEC	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.81	6.4	0.47	1.92e-9	Lymphocyte counts;
UCEC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.89	-0.44	2.5e-8	Chronic sinus infection;
UCEC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg04804543	chr8:142233427	SLC45A4	-0.5	-5.96	-0.44	1.81e-8	Immature fraction of reticulocytes;
UCEC	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-5.17	-0.39	7.45e-7	Morning vs. evening chronotype;
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.65	-4.95	-0.38	2.02e-6	Narcolepsy;
UCEC	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Body mass index;
UCEC	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.52	-4.85	-0.37	3.09e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.88	9.78	0.63	1.03e-17	Ulcerative colitis;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg13525197	chr6:28411240	ZSCAN23	-0.52	-5.82	-0.43	3.55e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-5.41	-0.41	2.48e-7	Platelet count;
UCEC	cis	rs57968458	0.708	rs16961828	chr17:16820224	C/G	cg27492451	chr17:16520367	NA	0.59	5.08	0.39	1.14e-6	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;
UCEC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.9	12.1	0.71	7.99e-24	Bone mineral density;
UCEC	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg13683864	chr3:40499215	RPL14	-0.57	-6.19	-0.45	5.6e-9	Renal cell carcinoma;
UCEC	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13683864	chr3:40499215	RPL14	0.92	9.57	0.62	3.57e-17	Renal cell carcinoma;
UCEC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.49	4.71	0.36	5.7e-6	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.86	9.68	0.62	1.84e-17	Breast cancer;
UCEC	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.91	9.77	0.63	1.11e-17	Post bronchodilator FEV1;
UCEC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	7.9	0.55	5.84e-13	Smoking behavior;
UCEC	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	0.96	9.89	0.63	5.35e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	4.95	0.38	1.99e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-4.8	-0.37	3.87e-6	LDL cholesterol levels;
UCEC	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.0	11.25	0.68	1.46e-21	IgG glycosylation;
UCEC	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg03342759	chr3:160939853	NMD3	-0.57	-5.58	-0.42	1.13e-7	Morning vs. evening chronotype;
UCEC	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-9.5	-0.62	5.41e-17	Morning vs. evening chronotype;
UCEC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg04726090	chr17:41856008	DUSP3	0.47	4.55	0.35	1.1e-5	Triglycerides;
UCEC	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.7	-4.89	-0.37	2.56e-6	Narcolepsy;
UCEC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.51e-7	Hemoglobin concentration;
UCEC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.56	-4.52	-0.35	1.26e-5	Initial pursuit acceleration;
UCEC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.65	-6.0	-0.44	1.47e-8	Aortic root size;
UCEC	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg01072550	chr1:21505969	NA	0.64	6.83	0.49	2.07e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg22563815	chr15:78856949	CHRNA5	0.39	4.77	0.37	4.4e-6	Sudden cardiac arrest;
UCEC	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.4	5.16	0.39	7.88e-7	Bone mineral density;
UCEC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.47	4.79	0.37	4.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs151997	1.000	rs27249	chr5:50232678	A/G	cg06027927	chr5:50259733	NA	0.54	4.94	0.38	2.15e-6	Callous-unemotional behaviour;
UCEC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.81	9.25	0.61	2.37e-16	Menopause (age at onset);
UCEC	cis	rs10432489	0.708	rs3922472	chr2:181772262	C/T	cg21995919	chr2:182322279	ITGA4	-0.77	-5.26	-0.4	4.93e-7	QT interval;
UCEC	cis	rs9356171	0.572	rs13198847	chr6:164326504	T/C	cg25752492	chr6:164341247	NA	-0.58	-5.74	-0.43	5.11e-8	Diisocyanate-induced asthma;
UCEC	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.54	5.71	0.43	6.19e-8	Height;
UCEC	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg09307838	chr4:120376055	NA	0.6	5.31	0.4	3.97e-7	Educational attainment;
UCEC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg11477892	chr4:106580295	NA	-0.45	-4.68	-0.36	6.48e-6	Post bronchodilator FEV1;
UCEC	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg21214455	chr15:72412075	SENP8	0.48	4.51	0.35	1.3e-5	Red blood cell count;
UCEC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg22974920	chr21:40686053	BRWD1	0.64	5.22	0.4	5.99e-7	Cognitive function;
UCEC	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.8	4.91	0.38	2.37e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08822215	chr16:89438651	ANKRD11	-0.53	-5.07	-0.39	1.17e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.58	-6.2	-0.46	5.4e-9	Blood protein levels;
UCEC	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-6.6	-0.48	7.08e-10	Morning vs. evening chronotype;
UCEC	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.38	0.41	2.82e-7	Response to antipsychotic treatment;
UCEC	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	0.82	5.14	0.39	8.71e-7	Eosinophil percentage of granulocytes;
UCEC	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	10.38	0.65	2.84e-19	Exhaled nitric oxide output;
UCEC	cis	rs9961915	1.000	rs9952135	chr18:24675506	A/G	cg25983544	chr18:23713626	PSMA8	-0.35	-4.51	-0.35	1.3e-5	Dental caries;
UCEC	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg14121845	chr20:25566513	NINL	0.42	4.65	0.36	7.41e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.64	-7.58	-0.53	3.56e-12	Prevalent atrial fibrillation;
UCEC	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.57	-5.37	-0.4	3.03e-7	Menarche (age at onset);
UCEC	cis	rs9961915	1.000	rs1385753	chr18:24663034	T/C	cg25983544	chr18:23713626	PSMA8	-0.36	-4.64	-0.36	7.7e-6	Dental caries;
UCEC	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.6	0.35	9.12e-6	Educational attainment;
UCEC	cis	rs151997	0.962	rs27272	chr5:50181865	A/G	cg06027927	chr5:50259733	NA	0.54	4.98	0.38	1.79e-6	Callous-unemotional behaviour;
UCEC	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	4.59	0.35	9.63e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs7106204	0.514	rs34587986	chr11:24253053	T/C	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.4	0.41	2.56e-7	Rheumatoid arthritis;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.99	-0.44	1.54e-8	Prudent dietary pattern;
UCEC	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.35	-0.46	2.5e-9	Response to antipsychotic treatment;
UCEC	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.5e-7	Alcohol dependence;
UCEC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.1	0.51	4.82e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28530618	0.603	rs4594522	chr20:31254984	T/C	cg13636640	chr20:31349939	DNMT3B	-0.52	-4.89	-0.37	2.58e-6	Birth weight;
UCEC	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.64	6.87	0.49	1.72e-10	Homoarginine levels;
UCEC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.63	-5.66	-0.42	7.86e-8	Systolic blood pressure;
UCEC	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	7.96	0.55	4.28e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.7	7.87	0.54	7.21e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs12618769	0.597	rs4850876	chr2:99112069	C/T	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.71	7.93	0.55	5.16e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg24631222	chr15:78858424	CHRNA5	-0.7	-6.08	-0.45	9.83e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	6.81e-9	Aortic root size;
UCEC	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg18681998	chr4:17616180	MED28	-0.52	-5.78	-0.43	4.37e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.65	-6.33	-0.46	2.79e-9	Lymphocyte counts;
UCEC	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg06238570	chr21:40685208	BRWD1	0.78	7.58	0.53	3.54e-12	Cognitive function;
UCEC	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.16	12.59	0.72	4.12e-25	Psoriasis vulgaris;
UCEC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.0	-0.67	6.69e-21	Chronic sinus infection;
UCEC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.45	5.16	0.39	7.83e-7	Mortality in heart failure;
UCEC	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.43	4.88	0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.56	-5.8	-0.43	3.98e-8	Bipolar disorder;
UCEC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg05738196	chr6:26577821	NA	0.61	6.74	0.49	3.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg05738196	chr6:26577821	NA	0.59	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7095607	0.538	rs2634706	chr10:69917590	A/C	cg18986048	chr10:69913749	MYPN	0.63	6.95	0.5	1.1e-10	Lung function (FVC);
UCEC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.66	6.76	0.49	3.01e-10	Body mass index;
UCEC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.44	4.88	0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.74	6.45	0.47	1.49e-9	Bipolar disorder;
UCEC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-6.12	-0.45	7.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.54	2e-12	IgG glycosylation;
UCEC	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.95	-0.44	1.91e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.61	5.59	0.42	1.07e-7	Selective IgA deficiency;
UCEC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.63	7.08	0.5	5.61e-11	Tonsillectomy;
UCEC	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg19554555	chr3:13937349	NA	-0.53	-5.7	-0.43	6.49e-8	Ovarian reserve;
UCEC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18252515	chr7:66147081	NA	0.62	5.62	0.42	9.26e-8	Aortic root size;
UCEC	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.28e-21	Prostate cancer (SNP x SNP interaction);Prostate cancer;
UCEC	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg06671706	chr8:8559999	CLDN23	0.62	5.28	0.4	4.51e-7	Obesity-related traits;
UCEC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg13695892	chr22:41940480	POLR3H	0.68	4.91	0.38	2.44e-6	Vitiligo;
UCEC	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.53	-5.64	-0.42	8.54e-8	IgG glycosylation;
UCEC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.68	5.57	0.42	1.16e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.74	-8.06	-0.55	2.37e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.77	-7.04	-0.5	6.95e-11	Initial pursuit acceleration;
UCEC	cis	rs2204008	0.526	rs2320448	chr12:38224180	G/A	cg14851346	chr12:38532713	NA	-0.48	-4.55	-0.35	1.12e-5	Bladder cancer;
UCEC	cis	rs13063635	0.915	rs35280891	chr3:45951647	G/A	cg16320329	chr3:45981161	FYCO1	-0.83	-4.74	-0.36	4.92e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs7709377	0.574	rs11241366	chr5:115469128	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.36	4.65	0.36	7.31e-6	Obesity-related traits;
UCEC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.85	0.54	7.81e-13	Alzheimer's disease;
UCEC	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.71	-7.87	-0.54	7.07e-13	Waist circumference;Body mass index;
UCEC	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.67	7.16	0.51	3.5e-11	Vitamin D levels;
UCEC	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	4.52	0.35	1.24e-5	Lung cancer in ever smokers;
UCEC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	5.4	0.41	2.57e-7	Obesity-related traits;
UCEC	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-5.82	-0.43	3.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-9.58	-0.62	3.48e-17	Chronic sinus infection;
UCEC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.21	-0.39	6.24e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.57	-0.35	1.01e-5	Parkinson's disease;
UCEC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.33	0.46	2.84e-9	Aortic root size;
UCEC	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg13683864	chr3:40499215	RPL14	0.87	10.15	0.64	1.11e-18	Renal cell carcinoma;
UCEC	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.52	5.59	0.42	1.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.07	-0.39	1.19e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.3	0.46	3.28e-9	Personality dimensions;
UCEC	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.87	-0.44	2.8e-8	Mortality in heart failure;
UCEC	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.6	5.77	0.43	4.51e-8	Tonsillectomy;
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	10.44	0.65	1.99e-19	Platelet count;
UCEC	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.47	5.06	0.39	1.24e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18252515	chr7:66147081	NA	0.57	5.31	0.4	3.97e-7	Aortic root size;
UCEC	cis	rs11958404	0.932	rs6895484	chr5:157429159	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.55	-6.11	-0.45	8.44e-9	Aortic root size;
UCEC	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.6	0.42	1.02e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs7709377	0.620	rs7734295	chr5:115432208	G/A	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.87	5.9	0.44	2.39e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.71	-8.76	-0.59	4.35e-15	Hip circumference;
UCEC	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.76	5.18	0.39	7.31e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	7.57	0.53	3.86e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg05925327	chr15:68127851	NA	-0.4	-4.66	-0.36	6.93e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.56	5.09	0.39	1.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.48	5.63	0.42	9.01e-8	Aortic root size;
UCEC	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.54	-5.09	-0.39	1.08e-6	Non-response to antidepressants and depression;
UCEC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs174479	0.677	rs174456	chr11:61656182	G/T	cg01500311	chr11:61656094	FADS3	0.48	6.04	0.45	1.19e-8	Sphingolipid levels;
UCEC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.58	-5.95	-0.44	1.88e-8	Dental caries;
UCEC	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.56	5.58	0.42	1.13e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.55	-8.12	-0.56	1.7e-13	Height;
UCEC	cis	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg00614314	chr15:82944287	LOC80154	0.53	4.85	0.37	3.05e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.5	-0.47	1.17e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.07	15.99	0.8	5.4400000000000004e-34	IgG glycosylation;
UCEC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg20965017	chr5:231967	SDHA	-0.62	-5.69	-0.42	6.61e-8	Breast cancer;
UCEC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.55	0.42	1.31e-7	Cognitive test performance;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.19	-0.39	6.73e-7	Pubertal anthropometrics;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.52	-5.14	-0.39	8.57e-7	Parkinson's disease;
UCEC	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.61	6.77	0.49	2.83e-10	Eosinophil counts;
UCEC	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.12e-7	Life satisfaction;
UCEC	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.53	-4.91	-0.38	2.43e-6	Pancreatic cancer;
UCEC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.67	-0.36	6.61e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.67	-0.36	6.79e-6	Electroencephalogram traits;
UCEC	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	trans	rs4841134	0.513	rs12155833	chr8:9234847	A/T	cg10923313	chr14:99943086	SETD3	-0.6	-6.67	-0.48	4.74e-10	Age-related disease endophenotypes;
UCEC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.65	5.35	0.4	3.3e-7	Body mass index;
UCEC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.39	-4.82	-0.37	3.55e-6	Total body bone mineral density;
UCEC	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.56	6.58	0.48	7.73e-10	Prostate cancer;
UCEC	cis	rs7870753	0.782	rs10991346	chr9:99247758	C/T	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs12367572	0.501	rs8181757	chr12:45486220	G/A	cg03114573	chr12:45410052	DBX2	-0.44	-4.57	-0.35	1.05e-5	Gut microbiome composition (summer);
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg24687543	chr11:63912206	MACROD1	0.44	5.27	0.4	4.7e-7	Platelet count;
UCEC	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg26818010	chr10:134567672	INPP5A	-0.6	-6.38	-0.47	2.22e-9	Migraine;
UCEC	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.65	6.64	0.48	5.55e-10	Itch intensity from mosquito bite;
UCEC	cis	rs59104589	0.617	rs16843642	chr2:242351379	T/G	cg19488206	chr2:242435732	STK25	0.54	4.91	0.38	2.38e-6	Fibrinogen levels;
UCEC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg01262667	chr19:19385393	TM6SF2	0.5	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg22166914	chr1:53195759	ZYG11B	0.74	7.59	0.53	3.46e-12	Monocyte count;
UCEC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.69	-6.92	-0.5	1.28e-10	Tonsillectomy;
UCEC	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg13786083	chr1:19110734	NA	-0.39	-4.6	-0.36	8.88e-6	Drug-induced liver injury (nitrofurantoin);
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg24163568	chr5:669837	TPPP	-0.44	-5.51	-0.41	1.54e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-21.24	-0.87	1.23e-46	Myeloid white cell count;
UCEC	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.08	-9.16	-0.6	4.15e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.54	4.97	0.38	1.84e-6	Lung cancer;
UCEC	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg18232548	chr7:50535776	DDC	-0.54	-5.7	-0.43	6.47e-8	Body mass index;
UCEC	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs1079204	1.000	rs7600989	chr2:219119134	G/T	cg05728596	chr2:219128475	GPBAR1	0.69	5.42	0.41	2.36e-7	Smooth-surface caries;
UCEC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.38	0.41	2.9e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.66	-0.36	7.12e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.5	-4.86	-0.37	2.98e-6	Electroencephalogram traits;
UCEC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22117172	chr7:91764530	CYP51A1	-0.4	-5.1	-0.39	1.04e-6	Breast cancer;
UCEC	cis	rs12618769	0.597	rs3769715	chr2:99146855	C/T	cg14361474	chr2:99058762	NA	-0.49	-4.62	-0.36	8.3e-6	Bipolar disorder;
UCEC	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg02158880	chr13:53174818	NA	0.42	4.83	0.37	3.37e-6	Lewy body disease;
UCEC	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.21	0.64	8.05e-19	Electrocardiographic conduction measures;
UCEC	cis	rs17034641	1.000	rs10495930	chr2:46372675	A/G	cg12428440	chr2:46370979	PRKCE	0.6	4.87	0.37	2.8e-6	Hemoglobin;Hematocrit;
UCEC	cis	rs34486957	0.600	rs12896075	chr14:60046630	A/G	cg12189551	chr14:60952945	C14orf39	0.37	4.58	0.35	9.92e-6	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.11	8.24	0.56	8.85e-14	Alzheimer's disease (late onset);
UCEC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.59	5.39	0.41	2.74e-7	Corneal astigmatism;
UCEC	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg24069376	chr3:38537580	EXOG	0.38	4.79	0.37	4.06e-6	Electrocardiographic conduction measures;
UCEC	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg21856205	chr7:94953877	PON1	-0.59	-5.54	-0.42	1.39e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg21466736	chr12:48725269	NA	0.35	4.7	0.36	5.99e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.34	0.61	1.41e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.34	0.52	1.35e-11	Coffee consumption (cups per day);
UCEC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg24562669	chr7:97807699	LMTK2	-0.61	-8.01	-0.55	3.17e-13	Breast cancer;
UCEC	cis	rs7246967	0.673	rs8106180	chr19:22879360	G/A	cg05241461	chr19:22816980	ZNF492	0.58	6.14	0.45	7.25e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.01	5.67	0.42	7.25e-8	Skin colour saturation;
UCEC	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-7.0	-0.5	8.32e-11	Obesity-related traits;
UCEC	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg18681998	chr4:17616180	MED28	0.69	6.06	0.45	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg24789503	chr3:195384528	SDHAP2	-0.65	-4.89	-0.37	2.61e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.55	4.69	0.36	6.1e-6	Response to diuretic therapy;
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.7	7.24	0.51	2.3e-11	Smoking behavior;
UCEC	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.5	4.76	0.37	4.52e-6	HDL cholesterol;
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.47	0.72	8.44e-25	Prudent dietary pattern;
UCEC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.71	7.04	0.5	6.93e-11	Blood protein levels;
UCEC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.59	6.99	0.5	8.7e-11	Menopause (age at onset);
UCEC	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.53	4.8	0.37	3.83e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	0.86	7.71	0.54	1.74e-12	Mitochondrial DNA levels;
UCEC	cis	rs7246967	0.673	rs12979173	chr19:22820681	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	0.89	7.9	0.55	5.95e-13	Orofacial clefts;
UCEC	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-0.89	-9.75	-0.63	1.25e-17	Height;
UCEC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.32	-0.4	3.84e-7	Aortic root size;
UCEC	cis	rs2172802	0.560	rs996208	chr4:62559531	A/C	cg04118610	chr4:62707027	LPHN3	-0.42	-4.63	-0.36	8.06e-6	Partial epilepsies;
UCEC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.95	10.48	0.65	1.56e-19	Cognitive function;
UCEC	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.29	-0.4	4.33e-7	Metabolite levels;
UCEC	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-5.37	-0.4	3.04e-7	Resting heart rate;
UCEC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.47	5.26	0.4	4.93e-7	Prostate cancer;
UCEC	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg00814883	chr7:100076585	TSC22D4	-0.6	-5.36	-0.4	3.14e-7	Lung function (FEV1/FVC);
UCEC	cis	rs13401104	0.796	rs12464503	chr2:237113007	C/T	cg23897927	chr2:237117786	ASB18	-0.51	-4.55	-0.35	1.11e-5	Educational attainment;
UCEC	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.22	-0.61	2.98e-16	Coffee consumption (cups per day);
UCEC	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	0.8	9.71	0.62	1.61e-17	Multiple myeloma;
UCEC	trans	rs12822507	0.732	rs10492241	chr12:12750509	C/T	cg09875661	chr10:3143354	PFKP	0.56	6.9	0.49	1.46e-10	Systemic lupus erythematosus;
UCEC	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg12596171	chr3:113251061	SIDT1	-0.49	-4.82	-0.37	3.61e-6	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.68	-4.6	-0.35	8.92e-6	LDL cholesterol levels;
UCEC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg00738919	chr7:1100172	C7orf50	0.72	4.53	0.35	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.65	-4.88	-0.37	2.73e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.6	5.59	0.42	1.08e-7	Corneal astigmatism;
UCEC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg00343986	chr7:65444356	GUSB	-0.53	-4.75	-0.37	4.7e-6	Aortic root size;
UCEC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.59	6.32	0.46	2.96e-9	Longevity;Endometriosis;
UCEC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.14	-0.51	3.94e-11	Schizophrenia;
UCEC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.55	6.29	0.46	3.37e-9	Menopause (age at onset);
UCEC	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.62	6.98	0.5	9.34e-11	Leprosy;
UCEC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.78	6.12	0.45	8.16e-9	Body mass index;
UCEC	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.62	9.02	0.6	9.26e-16	Prudent dietary pattern;
UCEC	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.62	5.7	0.43	6.47e-8	Type 2 diabetes;
UCEC	cis	rs2734839	0.929	rs7131627	chr11:113299829	G/A	cg14159747	chr11:113255604	NA	0.52	6.74	0.49	3.32e-10	Information processing speed;
UCEC	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.02e-5	Type 2 diabetes;
UCEC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.53	-5.49	-0.41	1.75e-7	Systemic lupus erythematosus;
UCEC	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg26031613	chr14:104095156	KLC1	1.23	15.16	0.78	7.48e-32	Body mass index;
UCEC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.67	-7.62	-0.53	2.92e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs4778581	0.722	rs7169400	chr15:80399738	G/A	cg08257866	chr15:80351198	ZFAND6	0.4	4.8	0.37	3.82e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.57	-5.56	-0.42	1.21e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.59	-5.95	-0.44	1.84e-8	Hepatocellular carcinoma;
UCEC	cis	rs7870753	0.782	rs6477496	chr9:99256412	C/T	cg25260653	chr9:99212216	HABP4	0.54	5.13	0.39	8.92e-7	Height;
UCEC	cis	rs2904967	0.852	rs1858783	chr11:65042941	A/G	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg06640241	chr16:89574553	SPG7	0.56	5.34	0.4	3.39e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.7	8.5	0.57	1.9e-14	Hip circumference;
UCEC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.8	7.86	0.54	7.63e-13	Cognitive function;
UCEC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18932078	chr1:2524107	MMEL1	-0.35	-6.04	-0.45	1.2e-8	Ulcerative colitis;
UCEC	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-9.49	-0.62	5.84e-17	Blood metabolite levels;
UCEC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.73	-0.36	5.11e-6	Parkinson's disease;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.65	-5.59	-0.42	1.07e-7	Platelet count;
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	9.03	0.6	8.89e-16	Platelet count;
UCEC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.6	4.73	0.36	5.25e-6	Lymphocyte counts;
UCEC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.41	-4.66	-0.36	7.09e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg01256987	chr12:42539512	GXYLT1	0.41	4.88	0.37	2.71e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.69	7.36	0.52	1.17e-11	Platelet distribution width;
UCEC	cis	rs3891355	1.000	rs3891355	chr12:106950695	A/G	cg02476566	chr12:106696527	TCP11L2	0.78	4.71	0.36	5.74e-6	Cognitive test performance;
UCEC	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.63	6.77	0.49	2.88e-10	Menopause (age at onset);
UCEC	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg19743168	chr1:23544995	NA	0.47	6.29	0.46	3.5e-9	Height;
UCEC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.14	18.7	0.84	1.07e-40	Testicular germ cell tumor;
UCEC	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg23018236	chr17:30244563	NA	-0.54	-5.15	-0.39	8.28e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.6	5.69	0.42	6.73e-8	Coronary artery disease;
UCEC	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.18	11.38	0.68	6.49e-22	Corneal structure;
UCEC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.7	8.84	0.59	2.71e-15	Anterior chamber depth;
UCEC	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18252515	chr7:66147081	NA	0.45	4.54	0.35	1.16e-5	Aortic root size;
UCEC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.63	6.93	0.5	1.24e-10	Tonsillectomy;
UCEC	cis	rs7219021	0.926	rs10468570	chr17:46862085	G/A	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.78	8.82	0.59	2.97e-15	Coronary artery disease;
UCEC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs10932679	0.545	rs11891615	chr2:217643889	G/A	cg21348497	chr2:217499286	IGFBP2	-0.38	-4.55	-0.35	1.13e-5	Pulse pressure;
UCEC	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.14	10.09	0.64	1.61e-18	Corneal structure;
UCEC	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.71	-6.24	-0.46	4.42e-9	Cognitive test performance;
UCEC	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.78	-0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.65	6.79	0.49	2.56e-10	Tonsillectomy;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677856	chr17:61926188	NA	-0.43	-4.52	-0.35	1.26e-5	Prudent dietary pattern;
UCEC	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.76	4.73	0.36	5.18e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	6.15	0.45	6.81e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9470794	1.000	rs11757323	chr6:37996089	A/G	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.51	-5.93	-0.44	2.05e-8	Tonsillectomy;
UCEC	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.57	6.28	0.46	3.63e-9	Menarche (age at onset);
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.61	-6.67	-0.48	4.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-6.21	-0.46	5.16e-9	Platelet count;
UCEC	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.39	4.71	0.36	5.76e-6	Refractive error;
UCEC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.77	-10.23	-0.65	6.82e-19	Blood protein levels;
UCEC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-8.9	-0.59	1.87e-15	Cognitive function;
UCEC	cis	rs4668356	1.000	rs16859176	chr2:171993126	G/A	cg13882835	chr2:172017928	TLK1	0.66	4.51	0.35	1.32e-5	Cognitive performance;
UCEC	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18932078	chr1:2524107	MMEL1	-0.35	-6.06	-0.45	1.07e-8	Ulcerative colitis;
UCEC	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.48e-7	Hemoglobin concentration;
UCEC	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.52	-7.17	-0.51	3.37e-11	Refractive error;
UCEC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-0.77	-6.99	-0.5	8.7e-11	Breast cancer;
UCEC	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.82	-8.68	-0.58	6.76e-15	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs925228	1.000	rs12611913	chr2:24231659	T/G	cg13272742	chr2:24272458	FKBP1B	0.6	4.81	0.37	3.64e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-4.83	-0.37	3.35e-6	Smoking behavior;
UCEC	cis	rs3824488	0.920	rs3780573	chr9:98239503	G/A	cg14565164	chr9:98057177	FANCC	0.68	4.98	0.38	1.74e-6	Neuroticism;
UCEC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7175404	0.591	rs57153897	chr15:94057102	G/A	cg06054272	chr15:93956988	NA	0.7	5.06	0.39	1.21e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.98	0.7	1.65e-23	Prudent dietary pattern;
UCEC	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.88	0.44	2.61e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg21191810	chr6:118973309	C6orf204	0.44	6.21	0.46	5.27e-9	Electrocardiographic conduction measures;
UCEC	cis	rs9341808	0.538	rs7756067	chr6:81019794	C/T	cg08355045	chr6:80787529	NA	-0.34	-4.58	-0.35	9.8200000000000008e-06	Sitting height ratio;
UCEC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg13844804	chr7:814759	HEATR2	0.65	4.77	0.37	4.49e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-4.55	-0.35	1.13e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.72	6.25	0.46	4.28e-9	Coronary artery disease;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.55	-0.42	1.27e-7	Cardiac Troponin-T levels;
UCEC	cis	rs13257518	0.614	rs10503929	chr8:32613983	T/C	cg00792687	chr8:33370099	C8orf41	-0.81	-5.26	-0.4	5.07e-7	Refractive astigmatism;
UCEC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs6684428	0.706	rs11206673	chr1:56326340	C/T	cg11651538	chr1:56320950	NA	0.74	6.55	0.48	9.13e-10	Airflow obstruction;
UCEC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.73	0.36	5.27e-6	Tonsillectomy;
UCEC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg04756594	chr16:24857601	SLC5A11	-0.48	-5.74	-0.43	5.35e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs308447	0.516	rs13142203	chr4:123679002	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.6	5.42	0.41	2.38e-7	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.07	-0.64	1.85e-18	Height;
UCEC	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.58	-6.35	-0.46	2.49e-9	Crohn's disease;
UCEC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.82	5.04	0.38	1.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg08320659	chr6:26088202	HFE	0.72	4.71	0.36	5.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.11e-7	Body mass index;
UCEC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.57	5.78	0.43	4.34e-8	Blood metabolite levels;
UCEC	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.73	7.38	0.52	1.1e-11	Plateletcrit;Platelet count;
UCEC	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.4	-4.59	-0.35	9.5e-6	Schizophrenia;
UCEC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg08493051	chr2:3487164	NA	0.59	6.29	0.46	3.48e-9	Neurofibrillary tangles;
UCEC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.63	5.89	0.44	2.5e-8	Coronary artery disease;
UCEC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	5.39	0.41	2.76e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs2904967	0.852	rs668735	chr11:65045725	G/T	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-0.83	-10.51	-0.65	1.31e-19	Bone mineral density;
UCEC	cis	rs7011507	0.545	rs4130805	chr8:49084580	T/A	ch.8.1073630F	chr8:48637817	KIAA0146	-0.49	-4.61	-0.36	8.81e-6	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg19318889	chr4:1322082	MAEA	0.42	4.74	0.36	4.92e-6	Obesity-related traits;
UCEC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.7	0.36	5.93e-6	Menopause (age at onset);
UCEC	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg04439458	chr5:138467593	SIL1	-0.44	-4.81	-0.37	3.76e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.22	-0.76	2.08e-29	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.59	6.67	0.48	4.96e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.49	4.75	0.37	4.7e-6	Obesity-related traits;
UCEC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.51e-7	Hemoglobin concentration;
UCEC	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg03114573	chr12:45410052	DBX2	-0.47	-4.83	-0.37	3.39e-6	Gut microbiome composition (summer);
UCEC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.27	-7.74	-0.54	1.45e-12	Diabetic kidney disease;
UCEC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.86	0.44	2.95e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.82	8.11	0.56	1.8e-13	Selective IgA deficiency;
UCEC	cis	rs7246967	0.611	rs73030508	chr19:22826032	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg22166914	chr1:53195759	ZYG11B	0.79	8.51	0.57	1.85e-14	Monocyte count;
UCEC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.66	5.67	0.42	7.36e-8	High light scatter reticulocyte count;
UCEC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.78	5.8	0.43	3.85e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.86	-5.64	-0.42	8.45e-8	Bipolar disorder;
UCEC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.54	-5.39	-0.41	2.73e-7	Diastolic blood pressure;
UCEC	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg15837086	chr1:46506065	PIK3R3	-0.38	-4.89	-0.37	2.66e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2644899	0.859	rs2644898	chr19:41299015	G/A	cg15701203	chr19:40737740	AKT2	-0.52	-4.51	-0.35	1.34e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1575951	1.000	rs10466108	chr10:130438888	C/T	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs17123764	0.892	rs12314795	chr12:50147864	G/A	cg20471783	chr12:50157085	TMBIM6	0.62	4.91	0.38	2.43e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	6.14	0.45	7.19e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs3743102	0.591	rs76037357	chr15:83399490	A/G	cg00614314	chr15:82944287	LOC80154	-0.78	-4.59	-0.35	9.36e-6	Colorectal adenoma (advanced);
UCEC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	6.02	0.45	1.3e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.48	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.8	-9.29	-0.61	1.96e-16	Menopause (age at onset);
UCEC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.87	8.97	0.59	1.24e-15	Cognitive function;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00437443	chr6:11094621	LOC221710	0.61	7.5	0.53	5.72e-12	Warfarin maintenance dose;
UCEC	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.68	-6.73	-0.49	3.52e-10	Blood protein levels;
UCEC	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.52	-6.43	-0.47	1.7e-9	Total body bone mineral density;
UCEC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-5.76	-0.43	4.66e-8	Crohn's disease;
UCEC	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-7.78	-0.54	1.2e-12	Waist circumference;Body mass index;
UCEC	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.46	5.48	0.41	1.78e-7	Prostate cancer;
UCEC	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12826209	chr6:26865740	GUSBL1	-0.53	-4.92	-0.38	2.33e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.44	0.41	2.14e-7	Ileal carcinoids;
UCEC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.54	5.28	0.4	4.65e-7	Resting heart rate;
UCEC	cis	rs12980942	0.872	rs2304230	chr19:41774064	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.62	5.54	0.42	1.37e-7	Coronary artery disease;
UCEC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.64	-4.92	-0.38	2.31e-6	Menarche (age at onset);
UCEC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2862064	1.000	rs905211	chr5:156447218	A/T	cg12943317	chr5:156479607	HAVCR1	-0.63	-4.8	-0.37	3.83e-6	Platelet count;
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.41	4.82	0.37	3.59e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17017335	chr3:97540665	NA	0.57	6.73	0.49	3.58e-10	Warfarin maintenance dose;
UCEC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.8	-8.63	-0.58	9.44e-15	Height;
UCEC	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-5.03	-0.38	1.39e-6	Height;
UCEC	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.59	5.98	0.44	1.66e-8	Schizophrenia;
UCEC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.99	11.92	0.7	2.41e-23	Cognitive function;
UCEC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.64	-0.36	7.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg20368463	chr18:77673604	PQLC1	0.75	5.37	0.41	2.98e-7	Opioid sensitivity;
UCEC	cis	rs10924970	0.967	rs4659678	chr1:235396697	A/G	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.52	-5.91	-0.44	2.24e-8	Pubertal anthropometrics;
UCEC	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.61	5.85	0.43	3.13e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.42	4.7	0.36	5.82e-6	Pulse pressure;
UCEC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.8	-8.54	-0.58	1.54e-14	Longevity;
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.02e-6	Prudent dietary pattern;
UCEC	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.53	6.65	0.48	5.25e-10	Total body bone mineral density;
UCEC	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.61	6.47	0.47	1.38e-9	Motion sickness;
UCEC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.45	4.51	0.35	1.31e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467711	0.559	rs13214027	chr6:26573631	C/G	cg09904177	chr6:26538194	HMGN4	-0.75	-4.76	-0.37	4.62e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	1.25	5.71	0.43	6.02e-8	Parkinson's disease;
UCEC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.75	8.05	0.55	2.63e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs73416724	1.000	rs77538445	chr6:43285773	A/C	cg24109273	chr6:43484729	YIPF3;POLR1C	1.07	4.9	0.37	2.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.58	-6.05	-0.45	1.15e-8	Testicular germ cell tumor;
UCEC	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08859206	chr1:53392774	SCP2	0.61	6.39	0.47	2.06e-9	Monocyte count;
UCEC	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.66	-0.42	7.56e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs1712517	1.000	rs1712517	chr10:105033015	C/T	cg05636881	chr10:105038444	INA	0.42	5.36	0.4	3.17e-7	Migraine;
UCEC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg22868518	chr11:507468	RNH1	-0.68	-4.6	-0.35	9.07e-6	Body mass index;
UCEC	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-4.8	-0.37	3.82e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.59	6.15	0.45	7.09e-9	Initial pursuit acceleration;
UCEC	cis	rs6546886	0.957	rs6546887	chr2:74250781	C/G	cg14702570	chr2:74259524	NA	-0.41	-5.24	-0.4	5.48e-7	Dialysis-related mortality;
UCEC	trans	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg15509575	chr4:2286509	ZFYVE28	0.41	6.8	0.49	2.4e-10	Rheumatoid arthritis;
UCEC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-0.85	-8.26	-0.56	7.97e-14	Coronary artery disease;
UCEC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg20821713	chr7:1055600	C7orf50	-0.91	-11.82	-0.7	4.45e-23	Bronchopulmonary dysplasia;
UCEC	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg19875535	chr5:140030758	IK	0.45	4.97	0.38	1.82e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg23752985	chr2:85803571	VAMP8	0.44	4.67	0.36	6.85e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.48	6.84	0.49	1.99e-10	Superior crus of antihelix expression;
UCEC	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.77	-5.14	-0.39	8.73e-7	Bipolar disorder;
UCEC	cis	rs3780378	1.000	rs7847294	chr9:5097281	A/C	cg02405213	chr9:5042618	JAK2	-0.47	-4.56	-0.35	1.05e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-6.8	-0.49	2.5e-10	Morning vs. evening chronotype;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27309677	chr11:28129805	METT5D1;KIF18A	0.59	6.98	0.5	9.47e-11	Warfarin maintenance dose;
UCEC	cis	rs7095607	0.560	rs10997955	chr10:69914664	C/T	cg18986048	chr10:69913749	MYPN	0.79	11.19	0.68	2.12e-21	Lung function (FVC);
UCEC	cis	rs9321099	0.786	rs12663781	chr6:128227074	C/T	cg25012434	chr6:128842125	PTPRK	0.69	4.65	0.36	7.4e-6	Sense of smell;
UCEC	cis	rs10924970	0.649	rs10925128	chr1:235378767	T/G	cg26050004	chr1:235667680	B3GALNT2	0.52	4.76	0.37	4.64e-6	Asthma;
UCEC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16164276	chr3:11034345	SLC6A1	0.49	4.62	0.36	8.33e-6	Alzheimer's disease;
UCEC	cis	rs7106204	0.514	rs7118022	chr11:24253352	C/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.43	-5.49	-0.41	1.76e-7	Monocyte count;
UCEC	cis	rs12753816	0.789	rs2050119	chr1:169144715	T/G	cg03848065	chr1:168212210	NA	0.37	4.63	0.36	8.01e-6	Coronary artery disease;
UCEC	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg24375607	chr4:120327624	NA	0.51	5.31	0.4	3.89e-7	Corneal astigmatism;
UCEC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	4.64	0.36	7.53e-6	Diabetic retinopathy;
UCEC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.88	-10.18	-0.64	9.62e-19	Blood metabolite levels;
UCEC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.79	0.49	2.64e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.55	5.08	0.39	1.11e-6	Schizophrenia;
UCEC	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.67	5.95	0.44	1.92e-8	High light scatter reticulocyte count;
UCEC	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	6.24	0.46	4.48e-9	Schizophrenia;
UCEC	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	5.16	0.39	7.96e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs925228	0.869	rs2712051	chr2:24060032	T/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.91	0.38	2.39e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06762426	chr11:62420836	INTS5	0.86	4.73	0.36	5.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.77	-7.09	-0.5	5.23e-11	Strep throat;
UCEC	cis	rs73206853	0.841	rs3759382	chr12:110889483	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	4.6	0.35	9.15e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg05501817	chr11:14380813	RRAS2	-0.52	-4.92	-0.38	2.34e-6	Sense of smell;
UCEC	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.82	0.43	3.63e-8	HDL cholesterol;
UCEC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.5	4.68	0.36	6.55e-6	Heart rate;
UCEC	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.82	8.47	0.57	2.36e-14	Mosquito bite size;
UCEC	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	4.63	0.36	8.02e-6	Lung cancer in ever smokers;
UCEC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs35934224	0.891	rs13054713	chr22:19867914	C/A	cg11182965	chr22:19864308	TXNRD2	-0.57	-7.23	-0.51	2.47e-11	Glaucoma (primary open-angle);
UCEC	cis	rs7246967	0.673	rs7249003	chr19:22887934	A/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.05e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.38	-0.52	1.1e-11	Chronic sinus infection;
UCEC	cis	rs1832871	0.579	rs828006	chr6:158775014	T/C	cg07215822	chr6:158701037	NA	0.48	5.17	0.39	7.7e-7	Height;
UCEC	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.83	-10.57	-0.66	8.75e-20	White blood cell count (basophil);
UCEC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-7.47	-0.52	6.46e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.52	4.71	0.36	5.74e-6	Electrocardiographic conduction measures;
UCEC	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.49	-4.64	-0.36	7.74e-6	Morning vs. evening chronotype;
UCEC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.47	5.61	0.42	9.54e-8	Coronary artery disease;
UCEC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg22598563	chr5:131563921	P4HA2	-0.34	-4.55	-0.35	1.11e-5	Blood metabolite levels;
UCEC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.61	-0.42	9.7e-8	Longevity;
UCEC	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg03924805	chr2:242211663	HDLBP	0.45	4.59	0.35	9.44e-6	Joint mobility (Beighton score);
UCEC	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.35	-0.4	3.29e-7	Response to antipsychotic treatment;
UCEC	cis	rs7246967	0.542	rs56355379	chr19:22900455	C/T	cg24889512	chr19:22816950	ZNF492	0.62	6.61	0.48	6.47e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.48	-5.9	-0.44	2.43e-8	Mean platelet volume;
UCEC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-6.12	-0.45	8.29e-9	Monocyte count;
UCEC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.56	-6.65	-0.48	5.27e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.0	-0.44	1.49e-8	Aortic root size;
UCEC	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.71	6.37	0.47	2.3e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.7	5.99	0.44	1.51e-8	Bipolar disorder;
UCEC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg23018236	chr17:30244563	NA	-0.73	-6.54	-0.48	9.31e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg02476566	chr12:106696527	TCP11L2	-0.61	-5.05	-0.38	1.27e-6	Tourette syndrome;
UCEC	cis	rs6670533	0.571	rs11801906	chr1:24861287	T/G	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.71	6.77	0.49	2.85e-10	High light scatter reticulocyte count;
UCEC	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.51	5.69	0.42	6.59e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.2	8.85	0.59	2.6e-15	Atopic dermatitis;
UCEC	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	14.66	0.77	1.5e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs61776719	0.905	rs17465420	chr1:38398588	T/C	cg04673462	chr1:38461896	NA	0.58	6.01	0.44	1.42e-8	Coronary artery disease;
UCEC	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.59	5.4	0.41	2.61e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.5	-4.78	-0.37	4.2e-6	Schizophrenia;
UCEC	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.03	0.55	2.83e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg11871910	chr12:69753446	YEATS4	0.56	4.9	0.37	2.47e-6	Response to diuretic therapy;
UCEC	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.96	-10.8	-0.67	2.2e-20	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.14	-0.39	8.46e-7	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.47	6.53	0.47	1.02e-9	Primary biliary cholangitis;
UCEC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.12	-12.29	-0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.41	4.51	0.35	1.32e-5	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg01689657	chr7:91764605	CYP51A1	0.43	5.48	0.41	1.79e-7	Breast cancer;
UCEC	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg07988820	chr12:82153109	PPFIA2	-0.57	-5.03	-0.38	1.4e-6	Resting heart rate;
UCEC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	7.66	0.53	2.32e-12	Total body bone mineral density;
UCEC	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	0.92	10.47	0.65	1.65e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	5.35	0.4	3.35e-7	Initial pursuit acceleration;
UCEC	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.84	-0.54	8.4e-13	Total cholesterol levels;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.24	-0.46	4.46e-9	Cardiac Troponin-T levels;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.87	11.31	0.68	9.95e-22	Menarche (age at onset);
UCEC	cis	rs6539267	0.923	rs4964175	chr12:106753984	A/G	cg02476566	chr12:106696527	TCP11L2	-0.59	-4.75	-0.36	4.77e-6	Tourette syndrome;
UCEC	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.58	5.48	0.41	1.8e-7	Morning vs. evening chronotype;
UCEC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	7.63	0.53	2.65e-12	Tonsillectomy;
UCEC	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.37	5.0	0.38	1.63e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs2481665	0.626	rs2481664	chr1:62593893	T/C	cg18591186	chr1:62594603	INADL	-0.49	-5.61	-0.42	9.7e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg12253828	chr6:101329408	ASCC3	0.46	4.71	0.36	5.64e-6	Neuroticism;
UCEC	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.54	-5.21	-0.39	6.29e-7	Coronary artery disease;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.65	-0.42	8.24e-8	Cardiac Troponin-T levels;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.49	-0.41	1.68e-7	Pubertal anthropometrics;
UCEC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.76	-7.23	-0.51	2.49e-11	Pancreatic cancer;
UCEC	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.35	-5.25	-0.4	5.18e-7	Ulcerative colitis;
UCEC	cis	rs7705819	1.000	rs11134801	chr5:172879282	G/T	cg14746387	chr5:172879299	NA	-0.47	-4.9	-0.37	2.55e-6	Stroke;
UCEC	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.72	7.25	0.51	2.21e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.86	-7.31	-0.52	1.57e-11	Ulcerative colitis;
UCEC	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.81	-9.22	-0.61	2.96e-16	Primary sclerosing cholangitis;
UCEC	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs1519814	0.956	rs4871040	chr8:121131611	A/G	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.67	-7.02	-0.5	7.4e-11	Tonsillectomy;
UCEC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.65	6.57	0.48	8.33e-10	Homoarginine levels;
UCEC	cis	rs1335645	0.570	rs10494126	chr1:111671707	A/C	cg00321911	chr1:111669324	DRAM2	0.64	4.68	0.36	6.33e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg23888215	chr10:79422304	NA	0.79	6.3	0.46	3.24e-9	Bone mineral density;
UCEC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.6	6.68	0.48	4.65e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.71	6.96	0.5	1.06e-10	Bladder cancer;
UCEC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.4	4.71	0.36	5.61e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.55	-7.89	-0.55	6.46e-13	Blood protein levels;
UCEC	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.68	7.43	0.52	8.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs73206853	0.841	rs56251637	chr12:110833869	T/G	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	7.95	0.55	4.47e-13	Total body bone mineral density;
UCEC	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.7	6.16	0.45	6.6e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs57709857	0.801	rs16887275	chr8:38101099	T/G	cg08167846	chr8:38212404	WHSC1L1	0.47	4.61	0.36	8.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.61	-0.42	9.61e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Inflammatory skin disease;
UCEC	cis	rs12449964	0.524	rs7224756	chr17:17572342	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.45	-4.52	-0.35	1.25e-5	Coronary artery disease or ischemic stroke;
UCEC	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.69	4.9	0.37	2.49e-6	Aortic root size;
UCEC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.12e-9	Tonsillectomy;
UCEC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.62	-6.14	-0.45	7.3e-9	Lymphocyte counts;
UCEC	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.47	5.28	0.4	4.61e-7	Menarche (age at onset);
UCEC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.55	-5.15	-0.39	8.18e-7	Cognitive function;
UCEC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs7246967	0.673	rs8102006	chr19:22870103	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2377585	0.898	rs73053848	chr12:8837330	C/T	cg03761649	chr12:8850719	RIMKLB	0.62	4.92	0.38	2.34e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00791764	chr4:53727839	RASL11B	0.47	4.73	0.36	5.33e-6	Optic nerve measurement (cup area);
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg20007245	chr22:24372913	LOC391322	0.71	7.68	0.53	2.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9283706	0.608	rs1428407	chr5:66330416	C/T	cg11590213	chr5:66331682	MAST4	0.45	5.08	0.39	1.1e-6	Coronary artery disease;
UCEC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.51	5.54	0.42	1.35e-7	Menopause (age at onset);
UCEC	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	0.91	6.32	0.46	2.99e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs17106184	1.000	rs12067513	chr1:51310062	G/A	cg07174182	chr1:51127561	FAF1	-0.63	-4.6	-0.35	9.11e-6	Type 2 diabetes;
UCEC	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-4.81	-0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.51	4.68	0.36	6.56e-6	Aortic root size;
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.61	0.62	2.92e-17	Platelet count;
UCEC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.6	4.64	0.36	7.54e-6	Lung cancer;
UCEC	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	4.83	0.37	3.34e-6	Height;
UCEC	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.51	-5.1	-0.39	1.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-5.57	-0.42	1.2e-7	Colorectal cancer;
UCEC	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-6.07	-0.45	1.03e-8	Vitamin D levels;
UCEC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.91	-13.08	-0.73	1.99e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs3914502	0.615	rs9290518	chr3:174523783	C/T	cg21145449	chr3:174580620	NAALADL2	0.44	5.14	0.39	8.47e-7	Autism spectrum disorder;
UCEC	cis	rs7709377	0.574	rs13162293	chr5:115507893	A/G	cg23108291	chr5:115420582	COMMD10	0.52	5.28	0.4	4.49e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.86	-0.43	2.97e-8	Adiposity;
UCEC	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13683864	chr3:40499215	RPL14	-0.97	-9.95	-0.63	3.74e-18	Renal cell carcinoma;
UCEC	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	1.17	5.73	0.43	5.54e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.37	-0.52	1.16e-11	Hypospadias;
UCEC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.59	6.36	0.46	2.39e-9	Neutrophil percentage of white cells;
UCEC	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.83	0.49	2.12e-10	Eye color traits;
UCEC	cis	rs12931792	0.687	rs8057425	chr16:30182541	T/C	cg17640201	chr16:30407289	ZNF48	0.57	5.78	0.43	4.23e-8	Tonsillectomy;
UCEC	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.65	-5.24	-0.4	5.44e-7	HIV-1 control;
UCEC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.93	-0.44	2.08e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	6.08	0.45	1e-8	Blood protein levels;
UCEC	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.88	9.67	0.62	2.01e-17	Breast cancer;
UCEC	cis	rs11048434	0.966	rs1805677	chr12:9153559	C/G	cg04155231	chr12:9217510	LOC144571	-0.46	-5.01	-0.38	1.53e-6	Sjögren's syndrome;
UCEC	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-6.16	-0.45	6.72e-9	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.69	-5.76	-0.43	4.73e-8	Lung disease severity in cystic fibrosis;
UCEC	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.39	4.84	0.37	3.22e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7709377	0.570	rs11746439	chr5:115453030	T/C	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.86	9.35	0.61	1.32e-16	Mean corpuscular hemoglobin;
UCEC	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.57	5.05	0.38	1.27e-6	Menarche (age at onset);
UCEC	trans	rs62103177	0.733	rs80114941	chr18:77671740	G/A	cg05926928	chr17:57297772	GDPD1	0.9	6.69	0.48	4.4e-10	Opioid sensitivity;
UCEC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.67	5.46	0.41	1.98e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.63	7.7	0.54	1.82e-12	Warfarin maintenance dose;
UCEC	cis	rs10431058	0.930	rs11212297	chr11:107475371	T/C	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.49	4.78	0.37	4.25e-6	Common traits (Other);
UCEC	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg23307798	chr14:103986281	CKB	0.56	5.28	0.4	4.61e-7	Body mass index;
UCEC	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9309473	0.950	rs6705977	chr2:73849170	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-4.83	-0.37	3.42e-6	Metabolite levels;
UCEC	cis	rs7597155	0.935	rs7563401	chr2:69980193	C/T	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.44	-0.41	2.14e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.51	0.35	1.3e-5	Breast cancer;
UCEC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.65	6.96	0.5	1.03e-10	Mortality in heart failure;
UCEC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs253959	0.696	rs12516272	chr5:115701870	T/C	cg23108291	chr5:115420582	COMMD10	-0.49	-4.96	-0.38	1.89e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.59	5.73	0.43	5.43e-8	Tonsillectomy;
UCEC	cis	rs10494745	0.920	rs12724106	chr1:197127578	A/G	cg05128414	chr1:197882836	LHX9	-0.82	-4.72	-0.36	5.42e-6	Blood protein levels;
UCEC	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-8.8	-0.59	3.34e-15	Colorectal cancer;
UCEC	cis	rs6761276	1.000	rs6761276	chr2:113832312	C/T	cg09040174	chr2:113837401	NA	-0.51	-5.72	-0.43	5.68e-8	Protein quantitative trait loci;
UCEC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	18.83	0.84	5.07e-41	IgG glycosylation;
UCEC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg09165964	chr15:75287851	SCAMP5	0.51	5.96	0.44	1.77e-8	Breast cancer;
UCEC	cis	rs11867410	0.744	rs73338619	chr17:63967448	T/C	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg19318889	chr4:1322082	MAEA	0.55	6.52	0.47	1.08e-9	Longevity;
UCEC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.09	-0.56	2.05e-13	Coronary artery disease;
UCEC	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	7.02	0.5	7.71e-11	Cognitive ability;
UCEC	cis	rs3026445	0.761	rs67917264	chr12:110554818	A/G	cg12870014	chr12:110450643	ANKRD13A	0.45	4.88	0.37	2.7e-6	QT interval;
UCEC	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg13844804	chr7:814759	HEATR2	0.61	4.71	0.36	5.79e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.7	6.73	0.49	3.58e-10	Aortic root size;
UCEC	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-4.6	-0.36	8.89e-6	Major depressive disorder;
UCEC	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.32	5.06	0.38	1.25e-6	Cancer;
UCEC	cis	rs731174	0.759	rs591567	chr1:38149847	A/G	cg06917450	chr1:38156652	C1orf109	-0.58	-6.08	-0.45	9.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg06238570	chr21:40685208	BRWD1	0.63	7.25	0.51	2.26e-11	Menarche (age at onset);
UCEC	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.68	-0.36	6.51e-6	Monocyte percentage of white cells;
UCEC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.83	7.43	0.52	8.1e-12	Blood metabolite levels;
UCEC	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg01403660	chr11:68851641	TPCN2	-0.48	-5.31	-0.4	3.93e-7	Hair color;
UCEC	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg16583315	chr14:65563665	MAX	-0.43	-5.75	-0.43	4.93e-8	Obesity-related traits;
UCEC	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg03999872	chr20:62272968	STMN3	-0.49	-4.65	-0.36	7.45e-6	Atopic dermatitis;
UCEC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-6.15	-0.45	6.93e-9	Prudent dietary pattern;
UCEC	cis	rs78487399	0.808	rs17039133	chr2:43694570	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.67	5.6	0.42	1.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.82	9.27	0.61	2.15e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.24	0.4	5.44e-7	Mean platelet volume;
UCEC	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg20825769	chr15:43991375	CKMT1A	-0.6	-4.65	-0.36	7.24e-6	Lung cancer in ever smokers;
UCEC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.68	-5.46	-0.41	1.96e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4662945	0.737	rs896793	chr2:130216695	G/T	cg05962382	chr2:130345044	NA	-0.39	-4.56	-0.35	1.08e-5	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.66	-0.48	5.15e-10	Crohn's disease;
UCEC	cis	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg21605333	chr4:119757512	SEC24D	0.91	4.66	0.36	7.06e-6	Cannabis dependence symptom count;
UCEC	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg08890418	chr1:21044141	KIF17	0.6	5.68	0.42	7.08e-8	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.77	0.43	4.47e-8	Breast cancer;
UCEC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1355223	0.902	rs11819839	chr11:34715778	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.76	-0.37	4.55e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.59	7.17	0.51	3.44e-11	Oral cavity cancer;
UCEC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.0	-0.38	1.65e-6	Aortic root size;
UCEC	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg04896959	chr15:78267971	NA	0.51	7.16	0.51	3.57e-11	Coronary artery disease or large artery stroke;
UCEC	cis	rs970548	0.690	rs12265787	chr10:46063654	C/T	cg15223267	chr10:46222474	FAM21C	0.49	4.67	0.36	6.83e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg05241461	chr19:22816980	ZNF492	0.57	6.32	0.46	3e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-5.56	-0.42	1.22e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.53	0.62	4.52e-17	Bipolar disorder;
UCEC	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.75	-7.43	-0.52	8.24e-12	Menopause (age at onset);
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.57	-6.31	-0.46	3.06e-9	Pubertal anthropometrics;
UCEC	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-5.58	-0.42	1.12e-7	Brugada syndrome;
UCEC	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-5.01	-0.38	1.55e-6	Tonsillectomy;
UCEC	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg05738196	chr6:26577821	NA	0.59	6.5	0.47	1.16e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.15	-11.88	-0.7	3.03e-23	Psoriasis vulgaris;
UCEC	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.59	-6.61	-0.48	6.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.61	6.93	0.5	1.26e-10	Menarche (age at onset);
UCEC	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-4.9	-0.37	2.52e-6	Life satisfaction;
UCEC	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.73	7.5	0.53	5.63e-12	Menopause (age at onset);
UCEC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-4.67	-0.36	6.68e-6	Menarche (age at onset);
UCEC	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.1	0.51	5.04e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18252515	chr7:66147081	NA	-0.46	-4.63	-0.36	8e-6	Aortic root size;
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-6.48	-0.47	1.32e-9	Platelet count;
UCEC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg07424592	chr7:64974309	NA	0.81	4.8	0.37	3.9e-6	Diabetic kidney disease;
UCEC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	6.83	0.49	2.12e-10	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	1.02	11.44	0.69	4.54e-22	Cognitive function;
UCEC	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg06096015	chr1:231504339	EGLN1	0.46	5.42	0.41	2.34e-7	Hemoglobin concentration;
UCEC	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg23000734	chr10:126850823	CTBP2	0.59	7.79	0.54	1.11e-12	Menarche (age at onset);
UCEC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg23752985	chr2:85803571	VAMP8	0.44	4.67	0.36	6.71e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg06758158	chr16:89114156	NA	-0.71	-4.7	-0.36	5.82e-6	Red blood cell count;
UCEC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg26031613	chr14:104095156	KLC1	1.25	15.78	0.79	1.92e-33	Body mass index;
UCEC	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.77	-0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.61	5.7	0.43	6.44e-8	Coronary artery disease;
UCEC	cis	rs259282	0.605	rs34727912	chr19:33110058	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.6	-6.58	-0.48	7.77e-10	Obesity-related traits;
UCEC	cis	rs10129255	0.530	rs8008811	chr14:107108288	G/A	cg03031183	chr14:106916953	NA	-0.44	-4.66	-0.36	7.12e-6	Kawasaki disease;
UCEC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.66	6.33	0.46	2.87e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.91e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg25922239	chr6:33757077	LEMD2	0.64	5.18	0.39	7.14e-7	Crohn's disease;
UCEC	cis	rs11048434	0.932	rs12817960	chr12:9153127	C/T	cg26114124	chr12:9217669	LOC144571	0.45	5.08	0.39	1.14e-6	Sjögren's syndrome;
UCEC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.37	4.54	0.35	1.18e-5	Multiple sclerosis;
UCEC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg18099408	chr3:52552593	STAB1	0.43	5.02	0.38	1.45e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-7.21	-0.51	2.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.67	-5.81	-0.43	3.7e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2708377	0.929	rs73053768	chr12:11155747	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.61	4.88	0.37	2.71e-6	Bitter taste perception;
UCEC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.57	-6.56	-0.48	8.53e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.47	-4.78	-0.37	4.14e-6	Cardiac Troponin-T levels;
UCEC	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.53	5.02	0.38	1.48e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-5.24	-0.4	5.43e-7	HDL cholesterol;
UCEC	cis	rs4662945	0.762	rs28510974	chr2:130215288	G/A	cg05962382	chr2:130345044	NA	-0.41	-4.57	-0.35	1.04e-5	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.61	6.79	0.49	2.61e-10	Red blood cell count;
UCEC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs847649	0.699	rs10241865	chr7:102527517	G/A	cg18108683	chr7:102477205	FBXL13	-0.65	-8.29	-0.56	6.73e-14	Morning vs. evening chronotype;
UCEC	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.79	-0.37	3.97e-6	Height;
UCEC	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	4.56	0.35	1.09e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg18681998	chr4:17616180	MED28	0.61	6.74	0.49	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg07532072	chr22:42016555	PPPDE2;XRCC6	-0.66	-7.45	-0.52	7.17e-12	Breast cancer;
UCEC	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.56	4.88	0.37	2.71e-6	Corneal astigmatism;
UCEC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.7	-8.51	-0.57	1.87e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	0.77	11.34	0.68	8.29e-22	Gut microbiome composition (winter);
UCEC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13683864	chr3:40499215	RPL14	-1.0	-10.24	-0.65	6.75e-19	Renal cell carcinoma;
UCEC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg19318889	chr4:1322082	MAEA	0.42	5.01	0.38	1.54e-6	Longevity;
UCEC	cis	rs4755351	0.504	rs12418119	chr11:33347977	G/A	cg05567920	chr11:33183001	CSTF3	0.57	4.58	0.35	9.8200000000000008e-06	Lung cancer in ever smokers;
UCEC	cis	rs151997	0.925	rs26090	chr5:50170071	C/T	cg06027927	chr5:50259733	NA	-0.55	-5.1	-0.39	1.03e-6	Callous-unemotional behaviour;
UCEC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01067626	chr5:133512870	SKP1	-0.68	-6.72	-0.48	3.73e-10	Gut microbiome composition (summer);
UCEC	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.8	-0.37	3.9e-6	Height;
UCEC	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	5.51	0.41	1.6e-7	Schizophrenia;
UCEC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.69	-0.36	6.28e-6	Obesity-related traits;
UCEC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.59	5.66	0.42	7.68e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs3790645	1.000	rs657227	chr1:26892104	T/A	cg23229016	chr1:26872525	RPS6KA1	0.32	6.12	0.45	8.25e-9	Glucose homeostasis traits;
UCEC	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.33	4.53	0.35	1.22e-5	Crohn's disease;
UCEC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg05738196	chr6:26577821	NA	-0.6	-6.91	-0.5	1.36e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.51	4.7	0.36	5.91e-6	Uric acid levels;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.69	-6.82	-0.49	2.25e-10	Longevity;Endometriosis;
UCEC	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.62	-5.42	-0.41	2.39e-7	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-0.7	-8.15	-0.56	1.42e-13	Blood trace element (Zn levels);
UCEC	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg13777783	chr17:79615861	NA	-0.33	-4.77	-0.37	4.49e-6	Eye color traits;
UCEC	cis	rs16879308	0.867	rs114115105	chr5:51248477	A/T	cg10599735	chr5:52096100	ITGA1;PELO	0.93	4.89	0.37	2.57e-6	Migraine without aura;
UCEC	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.75	0.54	1.39e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	1.03	13.66	0.75	6.07e-28	Coronary artery disease;
UCEC	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg04804543	chr8:142233427	SLC45A4	-0.46	-5.52	-0.41	1.47e-7	Immature fraction of reticulocytes;
UCEC	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.66	-6.53	-0.47	9.99e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	5.37	0.41	2.96e-7	Mood instability;
UCEC	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.66	0.42	7.79e-8	Lung cancer;
UCEC	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg13683864	chr3:40499215	RPL14	-0.57	-6.13	-0.45	7.55e-9	Renal cell carcinoma;
UCEC	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.46	0.41	1.97e-7	Psoriasis;
UCEC	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.61	-4.74	-0.36	4.99e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg00280220	chr17:61926910	NA	0.43	4.65	0.36	7.43e-6	Prudent dietary pattern;
UCEC	cis	rs6832769	1.000	rs59804446	chr4:56429541	A/C	cg05960024	chr4:56376020	CLOCK	-0.5	-4.7	-0.36	5.98e-6	Personality dimensions;
UCEC	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.46	-4.58	-0.35	9.8200000000000008e-06	Colorectal cancer;
UCEC	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.07	-0.39	1.19e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.69	6.63	0.48	6.04e-10	Coronary artery disease;
UCEC	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.78	0.49	2.69e-10	Bladder cancer;
UCEC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.61	6.04	0.45	1.21e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.11	-0.39	9.99e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.38	-0.47	2.19e-9	Response to antipsychotic treatment;
UCEC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg02951883	chr7:2050386	MAD1L1	0.48	5.03	0.38	1.43e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.55	6.11	0.45	8.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.84	7.27	0.51	1.99e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	5.97	0.44	1.67e-8	Menarche (age at onset);
UCEC	cis	rs2179367	0.887	rs6570965	chr6:149717476	C/A	cg03678062	chr6:149772716	ZC3H12D	-0.37	-5.16	-0.39	7.91e-7	Dupuytren's disease;
UCEC	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-5.01	-0.38	1.54e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg14780466	chr2:20870812	GDF7	-0.46	-5.67	-0.42	7.22e-8	Abdominal aortic aneurysm;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.13	-0.45	7.72e-9	Cardiac Troponin-T levels;
UCEC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.69	-7.23	-0.51	2.41e-11	Cognitive function;
UCEC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.39	9.01	0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.64	6.09	0.45	9.17e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs12635074	0.521	rs6763275	chr3:56307703	A/G	cg20749059	chr3:57094404	ARHGEF3;SPATA12	-0.35	-4.89	-0.37	2.63e-6	Morning vs. evening chronotype;
UCEC	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg17526145	chr2:23869158	KLHL29	0.43	4.89	0.37	2.64e-6	Asthma;
UCEC	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.73	6.29	0.46	3.43e-9	Coronary artery disease;
UCEC	cis	rs17012589	0.592	rs4761130	chr12:85702265	C/T	cg02569458	chr12:86230093	RASSF9	0.39	4.51	0.35	1.3e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg13844804	chr7:814759	HEATR2	0.6	4.62	0.36	8.48e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-6.94	-0.5	1.17e-10	Total cholesterol levels;
UCEC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.65	7.23	0.51	2.43e-11	Homoarginine levels;
UCEC	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.71	8.95	0.59	1.43e-15	Testicular germ cell tumor;
UCEC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.68	-0.36	6.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.48	-4.94	-0.38	2.13e-6	Aortic root size;
UCEC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg13660082	chr14:53194042	PSMC6	-0.72	-6.15	-0.45	6.96e-9	Alzheimer's disease (late onset);
UCEC	cis	rs9470794	1.000	rs10947710	chr6:38002748	T/A	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg19318889	chr4:1322082	MAEA	0.47	5.16	0.39	7.87e-7	Obesity-related traits;
UCEC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.64	-6.98	-0.5	9.24e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs883565	0.606	rs7650682	chr3:39079418	C/A	cg01426195	chr3:39028469	NA	-0.7	-8.93	-0.59	1.63e-15	Handedness;
UCEC	cis	rs7246967	0.551	rs8112442	chr19:22893369	C/T	cg24889512	chr19:22816950	ZNF492	0.63	6.68	0.48	4.53e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-4.55	-0.35	1.1e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.91	9.92	0.63	4.58e-18	Post bronchodilator FEV1;
UCEC	cis	rs422249	0.819	rs174608	chr11:61627484	A/G	cg19610905	chr11:61596333	FADS2	-0.53	-4.78	-0.37	4.26e-6	Trans fatty acid levels;
UCEC	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.48	5.38	0.41	2.88e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.69	6.03	0.45	1.24e-8	Bipolar disorder;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	6.82	0.49	2.21e-10	Prudent dietary pattern;
UCEC	cis	rs8105895	0.877	rs62112919	chr19:22227145	T/C	cg20662725	chr19:22235022	ZNF257	-0.64	-5.31	-0.4	3.95e-7	Body mass index (change over time);
UCEC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.59	-6.56	-0.48	8.72e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1823913	0.503	rs34716486	chr2:192208061	C/T	cg15998761	chr2:191300784	MFSD6	0.41	4.74	0.36	4.94e-6	Obesity-related traits;
UCEC	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.44	-5.48	-0.41	1.82e-7	Beta-trace protein levels;
UCEC	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.15	14.61	0.77	2.01e-30	Cognitive function;
UCEC	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-0.96	-5.82	-0.43	3.6e-8	Diabetic kidney disease;
UCEC	cis	rs10924970	0.967	rs12731177	chr1:235463173	T/G	cg26050004	chr1:235667680	B3GALNT2	0.45	4.84	0.37	3.25e-6	Asthma;
UCEC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	6.92	0.5	1.3100000000000001e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.55	5.23	0.4	5.84e-7	Aortic root size;
UCEC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.14	-14.21	-0.76	2.16e-29	Breast cancer;
UCEC	cis	rs11760485	0.931	rs2057892	chr7:4399101	A/G	cg15613991	chr7:5277080	NA	-0.47	-5.58	-0.42	1.14e-7	Early childhood aggressive behavior;
UCEC	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.45	-7.15	-0.51	3.82e-11	Urate levels in overweight individuals;
UCEC	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.27e-13	Parkinson's disease;
UCEC	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.65	6.87	0.49	1.72e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2425143	1.000	rs8124505	chr20:34307247	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.57	-0.35	1.03e-5	Blood protein levels;
UCEC	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg21905437	chr5:178450457	ZNF879	0.6	6.09	0.45	9.28e-9	Pubertal anthropometrics;
UCEC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.47	-4.6	-0.35	9.18e-6	Birth weight;
UCEC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.57	0.77	2.48e-30	Height;
UCEC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.45	-0.41	2.08e-7	Alcohol dependence;
UCEC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.48	-0.41	1.83e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.98	-0.44	1.62e-8	Parkinson's disease;
UCEC	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg18681998	chr4:17616180	MED28	-0.49	-5.59	-0.42	1.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.7	8.91	0.59	1.76e-15	Mean platelet volume;
UCEC	cis	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg20307385	chr11:47447363	PSMC3	0.56	5.09	0.39	1.06e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg19784848	chr5:219127	SDHA;CCDC127	-0.62	-4.85	-0.37	3.14e-6	Breast cancer;
UCEC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.34	4.83	0.37	3.35e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.57	-6.59	-0.48	7.5e-10	Menarche (age at onset);
UCEC	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.66	-5.11	-0.39	1e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-5.41	-0.41	2.48e-7	Platelet count;
UCEC	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13470333	chr7:1908714	MAD1L1	0.4	4.51	0.35	1.29e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.91	-0.38	2.37e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg05738196	chr6:26577821	NA	-0.64	-7.5	-0.53	5.5e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6546886	0.912	rs13021880	chr2:74310787	C/G	cg14702570	chr2:74259524	NA	-0.43	-5.53	-0.42	1.4e-7	Dialysis-related mortality;
UCEC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg22974920	chr21:40686053	BRWD1	0.61	5.38	0.41	2.81e-7	Cognitive function;
UCEC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-4.57	-0.35	1.01e-5	Response to antipsychotic treatment;
UCEC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.66	-5.49	-0.41	1.73e-7	Initial pursuit acceleration;
UCEC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.57	0.35	1.04e-5	Height;
UCEC	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs60311166	1.000	rs57319306	chr3:52575251	G/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.82	4.65	0.36	7.2e-6	CTACK levels;
UCEC	cis	rs16937	0.686	rs3851285	chr1:205155753	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.67	0.36	6.87e-6	Schizophrenia;
UCEC	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.04	-12.5	-0.72	6.86e-25	Dilated cardiomyopathy;
UCEC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.77	9.36	0.61	1.31e-16	Breast cancer;
UCEC	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.67	-6.98	-0.5	9.43e-11	Menopause (age at onset);
UCEC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.72	-7.23	-0.51	2.51e-11	Aortic root size;
UCEC	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg26781129	chr3:44753946	ZNF502	-0.42	-4.52	-0.35	1.27e-5	Depressive symptoms;
UCEC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.13	0.6	4.97e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.67	7.78	0.54	1.19e-12	Monocyte count;
UCEC	cis	rs10096908	0.892	rs28689087	chr8:41662671	C/G	cg01513060	chr8:40802449	NA	0.67	4.51	0.35	1.3e-5	Hypertension;Blood pressure traits (multi-trait analysis);Systolic blood pressure;
UCEC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	3.62e-18	Menopause (age at onset);
UCEC	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-0.94	-5.92	-0.44	2.19e-8	Mitochondrial DNA levels;
UCEC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.67	5.19	0.39	6.79e-7	Corneal astigmatism;
UCEC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.62	4.87	0.37	2.88e-6	Longevity;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.58	-7.13	-0.51	4.31e-11	Menarche (age at onset);
UCEC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.5	-0.41	1.62e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.25	-6.95	-0.5	1.12e-10	Atopic dermatitis;
UCEC	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-7.3	-0.52	1.7e-11	Morning vs. evening chronotype;
UCEC	cis	rs7766436	0.610	rs13195654	chr6:22601416	C/G	cg13666174	chr6:22585274	NA	-0.46	-4.65	-0.36	7.3e-6	Coronary artery disease;
UCEC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.44	6.56	0.48	8.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13683864	chr3:40499215	RPL14	-0.69	-6.9	-0.49	1.45e-10	Renal cell carcinoma;
UCEC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	12.51	0.72	6.7e-25	Height;
UCEC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.24	0.56	8.77e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.85	-0.43	3.09e-8	Depression;
UCEC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.6	5.75	0.43	4.99e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs7246967	0.866	rs35177997	chr19:23060227	T/C	cg05241461	chr19:22816980	ZNF492	0.48	4.84	0.37	3.23e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7204230	1.000	rs7191436	chr16:53287543	T/C	cg10109421	chr16:52641824	NA	0.4	4.66	0.36	6.88e-6	Fibrinogen;
UCEC	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.52	5.33	0.4	3.62e-7	Corneal astigmatism;
UCEC	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.59	-5.63	-0.42	8.73e-8	Menopause (age at onset);
UCEC	cis	rs1165668	1.000	rs10778305	chr12:104311974	C/G	cg21863207	chr12:104234989	NT5DC3	0.54	4.61	0.36	8.63e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	8.15	0.56	1.44e-13	Bipolar disorder;
UCEC	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.51	5.56	0.42	1.25e-7	Body mass index;
UCEC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-9.95	-0.63	3.8e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs420259	0.516	rs11074565	chr16:23533008	G/A	cg26562691	chr16:23850404	PRKCB	-0.34	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.83	0.59	2.82e-15	Platelet count;
UCEC	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg14078730	chr11:63896557	MACROD1	0.76	5.3	0.4	4.19e-7	Mean platelet volume;
UCEC	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	6.64	0.48	5.79e-10	Alzheimer's disease;
UCEC	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs13098911	0.540	rs33910087	chr3:46009487	G/A	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.67	4.63	0.36	7.88e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.3e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.67	-4.99	-0.38	1.65e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.99	-11.5	-0.69	3.14e-22	Cognitive function;
UCEC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01380346	chr19:18557039	ELL	-0.46	-4.85	-0.37	3.14e-6	Breast cancer;
UCEC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.0	0.38	1.63e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.43	-5.61	-0.42	9.95e-8	Obesity-related traits;
UCEC	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg04154034	chr17:28927549	LRRC37B2	0.76	4.72	0.36	5.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-5.96	-0.44	1.82e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.54	-5.86	-0.44	2.92e-8	Neutrophil percentage of white cells;
UCEC	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.74	-7.08	-0.5	5.54e-11	Aortic root size;
UCEC	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.5	-4.55	-0.35	1.1e-5	Diabetic retinopathy;
UCEC	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.54	4.97	0.38	1.88e-6	Selective IgA deficiency;
UCEC	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.57	6.73	0.49	3.5e-10	Testicular germ cell tumor;
UCEC	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.66	-5.77	-0.43	4.61e-8	Obesity-related traits;
UCEC	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.83	6.88	0.49	1.58e-10	Gastritis;
UCEC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs9788721	0.842	rs11852372	chr15:78801394	A/C	cg18825076	chr15:78729989	IREB2	-0.52	-4.78	-0.37	4.28e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs7517126	0.858	rs12740961	chr1:196660733	C/T	cg07209298	chr1:196795943	CFHR1	0.48	4.55	0.35	1.1e-5	Blood protein levels;
UCEC	cis	rs12318506	0.826	rs11180433	chr12:75661470	T/C	cg04728562	chr12:75699417	CAPS2	-0.8	-5.0	-0.38	1.6e-6	Coronary artery calcification;
UCEC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.82	8.02	0.55	3.02e-13	Cognitive function;
UCEC	cis	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.51	-4.95	-0.38	1.98e-6	Menarche (age at onset);
UCEC	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.63	-6.61	-0.48	6.56e-10	Response to temozolomide;
UCEC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg18681998	chr4:17616180	MED28	0.69	8.08	0.55	2.2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs9326726	0.844	rs2966830	chr5:107640719	G/C	cg17432647	chr5:107996819	NA	0.5	4.55	0.35	1.14e-5	Resting heart rate;
UCEC	cis	rs9469578	1.000	rs73743328	chr6:33713550	G/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs9283706	0.594	rs10515036	chr5:66343787	A/G	cg11590213	chr5:66331682	MAST4	-0.42	-4.97	-0.38	1.88e-6	Coronary artery disease;
UCEC	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	0.61	4.53	0.35	1.2e-5	Economic and political preferences (immigration/crime);
UCEC	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.9	-0.37	2.47e-6	Height;
UCEC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.69	8.66	0.58	7.67e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	0.94	9.97	0.64	3.3e-18	Heart rate;
UCEC	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.49	4.93	0.38	2.22e-6	Dupuytren's disease;
UCEC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg13147721	chr7:65941812	NA	-0.73	-5.22	-0.4	5.87e-7	Diabetic kidney disease;
UCEC	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg05527609	chr1:210001259	C1orf107	-0.51	-4.6	-0.35	8.92e-6	Red blood cell count;
UCEC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12635074	0.521	rs60900173	chr3:56312036	A/G	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.33	4.56	0.35	1.08e-5	Morning vs. evening chronotype;
UCEC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg23307798	chr14:103986281	CKB	0.56	5.28	0.4	4.61e-7	Body mass index;
UCEC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.98	-0.38	1.76e-6	Testicular germ cell tumor;
UCEC	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.37	-4.69	-0.36	6.29e-6	Bone mineral density (spine);
UCEC	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg18681998	chr4:17616180	MED28	0.73	8.61	0.58	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.5	5.27	0.4	4.7e-7	Alcohol dependence;
UCEC	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.41	-5.2	-0.39	6.57e-7	Prostate cancer;
UCEC	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg15764593	chr10:829463	NA	-0.56	-4.68	-0.36	6.45e-6	Uric acid levels;
UCEC	cis	rs8105895	0.736	rs2359835	chr19:22242690	A/G	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.06e-7	Body mass index (change over time);
UCEC	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg11189052	chr15:85197271	WDR73	0.57	4.6	0.36	8.87e-6	Schizophrenia;
UCEC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.46	-5.03	-0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.74	-8.49	-0.57	2.11e-14	Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs9467800	chr6:26578525	A/C	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.63	7.1	0.51	4.9e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.42	4.63	0.36	7.92e-6	Mean corpuscular volume;
UCEC	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-0.98	-7.48	-0.53	6.22e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg19743168	chr1:23544995	NA	0.44	6.2	0.46	5.39e-9	Height;
UCEC	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.92	9.25	0.61	2.48e-16	Post bronchodilator FEV1;
UCEC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-5.16	-0.39	7.8e-7	Schizophrenia;
UCEC	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24375607	chr4:120327624	NA	0.51	4.63	0.36	7.95e-6	Corneal astigmatism;
UCEC	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	6.36	0.46	2.35e-9	Mood instability;
UCEC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg23370820	chr17:17987590	NA	0.38	4.74	0.36	4.9e-6	Total body bone mineral density;
UCEC	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-4.86	-0.37	3.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.7e-9	Crohn's disease;
UCEC	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.24	-0.46	4.51e-9	Total cholesterol levels;
UCEC	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.42	-4.79	-0.37	4.05e-6	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.84	-9.1	-0.6	5.81e-16	Prudent dietary pattern;
UCEC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9470004	1	rs9470004	chr6:35341850	C/T	cg10418263	chr6:35265544	DEF6	1.06	4.52	0.35	1.28e-5	Height;
UCEC	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg04553112	chr3:125709451	NA	-0.64	-4.72	-0.36	5.53e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7267005	0.661	rs80149515	chr20:34392784	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	1.18	9.48	0.62	6.42e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg03934865	chr2:198174659	NA	-0.41	-5.27	-0.4	4.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	-0.54	-6.02	-0.44	1.36e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.54	-6.25	-0.46	4.16e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg20399509	chr21:47717575	C21orf57	-0.46	-4.95	-0.38	2.02e-6	Testicular germ cell tumor;
UCEC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.67	6.41	0.47	1.84e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.65	-0.36	7.36e-6	Alzheimer's disease (late onset);
UCEC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.5	-5.63	-0.42	8.73e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-9.01	-0.6	1.02e-15	Gut microbiome composition (summer);
UCEC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.84	-9.35	-0.61	1.37e-16	Cognitive function;
UCEC	cis	rs11048434	1.000	rs11048434	chr12:9153932	G/A	cg04155231	chr12:9217510	LOC144571	0.44	4.9	0.37	2.48e-6	Sjögren's syndrome;
UCEC	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg18646521	chr2:111875858	NA	0.4	4.62	0.36	8.39e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	8.11	0.56	1.86e-13	Platelet distribution width;
UCEC	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.46	-0.72	8.76e-25	Ulcerative colitis;
UCEC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.57	-6.23	-0.46	4.69e-9	Menarche (age at onset);
UCEC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.45	4.62	0.36	8.49e-6	Blood metabolite levels;
UCEC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.25	-0.51	2.18e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.12	0.45	7.9e-9	Rheumatoid arthritis;
UCEC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.51	0.65	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.12	-0.39	9.39e-7	Metabolite levels;
UCEC	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.45	-4.7	-0.36	5.99e-6	Monocyte count;
UCEC	cis	rs6429082	0.510	rs6699644	chr1:235495476	G/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.56	0.35	1.08e-5	Adiposity;
UCEC	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-4.91	-0.38	2.38e-6	Hemoglobin concentration;
UCEC	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-5.34	-0.4	3.48e-7	Schizophrenia;
UCEC	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.8	-7.85	-0.54	7.99e-13	Corneal structure;
UCEC	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.69	6.24	0.46	4.47e-9	Migraine;
UCEC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	6.37	0.47	2.3e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.83	-7.61	-0.53	3.1e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.71	7.19	0.51	2.97e-11	Multiple myeloma (IgH translocation);
UCEC	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.61	-5.16	-0.39	7.89e-7	LDL cholesterol levels;
UCEC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.53	5.51	0.41	1.54e-7	Obesity-related traits;
UCEC	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	0.86	6.86	0.49	1.81e-10	Blood protein levels;
UCEC	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.95	11.31	0.68	9.85e-22	Ulcerative colitis;
UCEC	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.51	-5.42	-0.41	2.44e-7	Brugada syndrome;
UCEC	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.54	4.55	0.35	1.1e-5	Obesity-related traits;
UCEC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg14078730	chr11:63896557	MACROD1	0.66	5.11	0.39	9.94e-7	Mean platelet volume;
UCEC	cis	rs7818345	0.967	rs10107416	chr8:19286253	A/G	cg06562184	chr8:19319451	CSGALNACT1	-0.46	-4.86	-0.37	2.99e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.76	7.69	0.54	2e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	20.35	0.86	1.36e-44	Chronic sinus infection;
UCEC	cis	rs8010715	0.816	rs762093	chr14:24591918	G/C	cg20933586	chr14:24608199	FAM158A	0.37	4.74	0.36	5.03e-6	IgG glycosylation;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.37	5.39	0.41	2.68e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg22857025	chr5:266934	NA	-1.0	-9.77	-0.63	1.13e-17	Breast cancer;
UCEC	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.4	6.12	0.45	8.11e-9	Body mass index;
UCEC	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.41	4.91	0.38	2.43e-6	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	5.35	0.4	3.27e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-7.55	-0.53	4.34e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.51	0.47	1.11e-9	Cognitive test performance;
UCEC	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-7.81	-0.54	9.78e-13	Vitiligo;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24243429	chr4:148653539	ARHGAP10	0.64	8.04	0.55	2.69e-13	Warfarin maintenance dose;
UCEC	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.51	5.58	0.42	1.15e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-0.81	-5.81	-0.43	3.7e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg18721089	chr20:30220636	NA	0.36	4.77	0.37	4.34e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs7607369	0.559	rs6741592	chr2:219658609	C/T	cg02176678	chr2:219576539	TTLL4	-0.49	-4.74	-0.36	5.1e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg11859384	chr17:80120422	CCDC57	0.49	5.46	0.41	1.95e-7	Life satisfaction;
UCEC	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg12339802	chr1:38156545	C1orf109	-0.5	-4.55	-0.35	1.1e-5	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.56	-5.4	-0.41	2.67e-7	Coronary artery disease;
UCEC	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.49	4.5	0.35	1.36e-5	Response to diuretic therapy;
UCEC	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.51	5.62	0.42	9.3e-8	Menopause (age at onset);
UCEC	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.81	6.02	0.44	1.34e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs116095464	0.619	rs28731093	chr5:241028	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.61	0.36	8.62e-6	Breast cancer;
UCEC	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.78	4.53	0.35	1.23e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.45	-4.55	-0.35	1.09e-5	Platelet count;
UCEC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	7.58	0.53	3.58e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs72949976	0.678	rs7573232	chr2:214040425	C/T	cg08319019	chr2:214017104	IKZF2	-0.77	-6.01	-0.44	1.41e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg11632617	chr15:75315747	PPCDC	0.51	5.56	0.42	1.23e-7	Blood trace element (Zn levels);
UCEC	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.88e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.86	0.44	2.95e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.78	-0.37	4.24e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.43	6.37	0.47	2.3e-9	Crohn's disease;
UCEC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.5	-5.73	-0.43	5.36e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.55	-5.7	-0.43	6.31e-8	White matter hyperintensity burden;
UCEC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg18681998	chr4:17616180	MED28	0.77	7.77	0.54	1.24e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs782590	0.840	rs10181648	chr2:55725948	A/G	cg18811423	chr2:55921094	PNPT1	0.53	5.3	0.4	4.13e-7	Metabolic syndrome;
UCEC	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.47	-0.47	1.38e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs10783487	0.749	rs6580850	chr12:52487062	A/G	cg03068838	chr12:52549986	NA	0.49	4.62	0.36	8.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg04310649	chr10:35416472	CREM	-0.49	-4.58	-0.35	1e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.61	6.35	0.46	2.49e-9	C-reactive protein levels;
UCEC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-4.77	-0.37	4.35e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	-0.51	-5.72	-0.43	5.8e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.43	5.25	0.4	5.25e-7	Coronary artery disease;
UCEC	cis	rs9739682	0.636	rs10877799	chr12:62524923	A/G	cg10081664	chr12:62102663	FAM19A2	-0.49	-4.78	-0.37	4.3e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.51	5.02	0.38	1.47e-6	Posterior cortical atrophy and Alzheimer's disease;
UCEC	trans	rs2699783	0.636	rs13427967	chr2:66210538	A/C	cg13338734	chr19:13113668	NFIX	0.75	7.15	0.51	3.8e-11	Bipolar disorder (body mass index interaction);
UCEC	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.95	-9.26	-0.61	2.28e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7212590	0.581	rs6503940	chr17:57842736	G/T	cg10252138	chr17:58120427	NA	-0.72	-5.81	-0.43	3.73e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.47	-5.33	-0.4	3.65e-7	Cotinine glucuronidation;
UCEC	cis	rs3780378	0.967	rs7852988	chr9:5010751	C/A	cg02405213	chr9:5042618	JAK2	-0.48	-4.82	-0.37	3.59e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	4.98	0.38	1.77e-6	Response to antipsychotic treatment;
UCEC	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.52	-5.57	-0.42	1.17e-7	Educational attainment;
UCEC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.5	-5.47	-0.41	1.89e-7	Aortic root size;
UCEC	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg14092571	chr14:90743983	NA	0.49	5.69	0.42	6.58e-8	Mortality in heart failure;
UCEC	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.23	-0.4	5.65e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.54	5.33	0.4	3.71e-7	Coronary artery disease;
UCEC	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.69	7.64	0.53	2.62e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs7581030	0.958	rs6725892	chr2:71516191	C/T	cg07678644	chr2:71558969	ZNF638	0.58	5.4	0.41	2.62e-7	Testicular germ cell tumor;
UCEC	cis	rs7095607	0.704	rs34869044	chr10:69953763	C/T	cg18986048	chr10:69913749	MYPN	0.52	5.79	0.43	4.2e-8	Lung function (FVC);
UCEC	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7246967	0.932	rs66737024	chr19:23031686	C/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg13147721	chr7:65941812	NA	-0.7	-4.99	-0.38	1.65e-6	Diabetic kidney disease;
UCEC	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.65	6.46	0.47	1.47e-9	Menopause (age at onset);
UCEC	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Smoking initiation;
UCEC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.98	5.48	0.41	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg18681998	chr4:17616180	MED28	0.81	9.88	0.63	5.57e-18	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-23.91	-0.89	1.59e-52	Myeloid white cell count;
UCEC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.21	-7.57	-0.53	3.9e-12	Diabetic kidney disease;
UCEC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.69	4.84	0.37	3.32e-6	Gut microbiome composition (summer);
UCEC	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-5.91	-0.44	2.27e-8	Hemoglobin concentration;
UCEC	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg19318889	chr4:1322082	MAEA	0.44	5.04	0.38	1.36e-6	Longevity;
UCEC	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.45	-4.86	-0.37	2.96e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.67	6.51	0.47	1.1e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.52	4.88	0.37	2.75e-6	Platelet count;
UCEC	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.7	7.95	0.55	4.64e-13	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs11958404	0.932	rs76601259	chr5:157430337	C/T	cg05962755	chr5:157440814	NA	0.75	5.27	0.4	4.79e-7	IgG glycosylation;
UCEC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.68	-7.69	-0.54	1.91e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.39	4.78	0.37	4.17e-6	Renal cell carcinoma;
UCEC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg04155231	chr12:9217510	LOC144571	0.43	5.44	0.41	2.19e-7	Sjögren's syndrome;
UCEC	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg26068271	chr17:76253126	NA	0.42	4.63	0.36	7.99e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.6e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.93	9.16	0.6	4.14e-16	Post bronchodilator FEV1;
UCEC	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs7307889	0.793	rs7314675	chr12:6018045	C/T	cg23245485	chr12:6484219	SCNN1A	0.59	4.68	0.36	6.4e-6	Obesity-related traits;
UCEC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.55	0.42	1.27e-7	Obesity-related traits;
UCEC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	6.4	0.47	1.92e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg14456004	chr13:21872349	NA	-1.02	-8.76	-0.59	4.37e-15	White matter hyperintensity burden;
UCEC	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.12	17.95	0.83	6.94e-39	Schizophrenia;
UCEC	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.84	0.59	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.85	-5.83	-0.43	3.42e-8	Exhaled nitric oxide output;
UCEC	cis	rs4865875	0.892	rs59664922	chr5:54069985	T/C	cg22421804	chr5:54100067	NA	-0.43	-4.59	-0.35	9.5e-6	Sense of smell;
UCEC	cis	rs539096	0.830	rs2494995	chr1:44022303	A/C	cg11851915	chr1:44060116	PTPRF	-0.43	-4.8	-0.37	3.81e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.72	-8.37	-0.57	4.17e-14	IgG glycosylation;
UCEC	cis	rs2377585	0.653	rs10505735	chr12:8841741	A/G	cg03761649	chr12:8850719	RIMKLB	0.61	4.6	0.35	9.23e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.64	6.21	0.46	5.11e-9	Platelet distribution width;
UCEC	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.58	-4.94	-0.38	2.13e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4919044	0.641	rs11187225	chr10:94714427	C/G	cg00519463	chr10:94352821	KIF11	0.87	4.65	0.36	7.48e-6	Coronary artery disease;
UCEC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.77	0.49	2.89e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-12.31	-0.71	2.29e-24	Ulcerative colitis;
UCEC	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.83	11.14	0.68	2.82e-21	Height;
UCEC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.91	12.05	0.7	1.08e-23	Metabolic syndrome;
UCEC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.73	-6.87	-0.49	1.66e-10	Aortic root size;
UCEC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	0.66	7.55	0.53	4.19e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.37	-4.79	-0.37	4.06e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg17330251	chr7:94953956	PON1	-0.58	-5.52	-0.41	1.5e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-0.82	-7.36	-0.52	1.19e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.82	-8.44	-0.57	2.74e-14	Mosquito bite size;
UCEC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.75	7.33	0.52	1.45e-11	Smoking behavior;
UCEC	cis	rs308447	0.576	rs7673491	chr4:123710875	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.62	7.21	0.51	2.66e-11	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.14	9.94	0.63	3.91e-18	Corneal structure;
UCEC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.64	-6.39	-0.47	2.07e-9	Itch intensity from mosquito bite;
UCEC	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg16329650	chr2:213403929	ERBB4	-0.46	-4.52	-0.35	1.26e-5	Symmetrical dimethylarginine levels;
UCEC	cis	rs10129255	0.507	rs58656539	chr14:107109278	G/C	cg03031183	chr14:106916953	NA	-0.43	-4.63	-0.36	8.06e-6	Kawasaki disease;
UCEC	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg06521331	chr12:34319734	NA	-0.61	-4.73	-0.36	5.23e-6	Morning vs. evening chronotype;
UCEC	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.06	-0.67	4.63e-21	Headache;
UCEC	cis	rs6722750	0.506	rs12612392	chr2:64373635	G/A	cg22352474	chr2:64371530	PELI1	0.62	5.71	0.43	6.02e-8	Neuroticism;
UCEC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.42	0.41	2.44e-7	Breast cancer;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg14082963	chr4:89444434	PIGY	0.63	6.77	0.49	2.91e-10	Triglyceride levels;
UCEC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.56	6.08	0.45	9.73e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.64	5.54	0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg01475377	chr6:109611718	NA	-0.42	-5.3	-0.4	4.15e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	trans	rs4389974	0.899	rs62520636	chr8:112394774	T/C	cg22736090	chr17:62339926	TEX2	0.66	6.83	0.49	2.04e-10	Body mass index;
UCEC	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	5.65	0.42	8.04e-8	Mood instability;
UCEC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.66	7.53	0.53	4.61e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	14.05	0.76	5.58e-29	Height;
UCEC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.77	7.22	0.51	2.51e-11	Menopause (age at onset);
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.59	-6.85	-0.49	1.91e-10	Pubertal anthropometrics;
UCEC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-5.26	-0.4	4.92e-7	Prudent dietary pattern;
UCEC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.63	6.01	0.44	1.42e-8	Lymphocyte counts;
UCEC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg17105886	chr17:28927953	LRRC37B2	0.46	4.5	0.35	1.36e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.64	7.14	0.51	4.01e-11	Blood metabolite ratios;
UCEC	cis	rs9302690	1.000	rs4151118	chr16:57451334	G/A	cg27017172	chr16:57497170	POLR2C	1.24	6.14	0.45	7.42e-9	Blood protein levels;
UCEC	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg27223183	chr8:87520930	FAM82B	-0.55	-4.89	-0.37	2.61e-6	Caudate activity during reward;
UCEC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.62	-6.37	-0.47	2.3e-9	Lymphocyte counts;
UCEC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.17	-0.51	3.33e-11	Joint mobility (Beighton score);
UCEC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.84e-7	Corneal astigmatism;
UCEC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg06784218	chr1:46089804	CCDC17	0.41	4.64	0.36	7.8e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.67	6.6	0.48	6.86e-10	Height;
UCEC	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.83	6.96	0.5	1.02e-10	Initial pursuit acceleration;
UCEC	cis	rs7246967	0.611	rs7250285	chr19:22837108	C/T	cg08271804	chr19:22816896	ZNF492	0.63	6.25	0.46	4.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.58	-6.84	-0.49	1.99e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg11632617	chr15:75315747	PPCDC	-0.63	-7.22	-0.51	2.63e-11	Blood trace element (Zn levels);
UCEC	cis	rs2812533	0.689	rs2999168	chr10:71434663	G/A	cg04292442	chr10:72124092	LRRC20	-0.43	-4.51	-0.35	1.33e-5	Type 2 diabetes;
UCEC	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.37	-4.69	-0.36	6.29e-6	Bone mineral density (spine);
UCEC	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.59	-5.08	-0.39	1.12e-6	Systemic lupus erythematosus;
UCEC	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.38	-4.56	-0.35	1.07e-5	Gout;
UCEC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.79	7.59	0.53	3.32e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.69	6.51	0.47	1.09e-9	Height;
UCEC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.1e-7	Hemoglobin concentration;
UCEC	cis	rs1425902	0.554	rs6473795	chr8:54130678	A/C	cg01281904	chr8:54164757	OPRK1	0.42	5.15	0.39	8.38e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-7.77	-0.54	1.25e-12	Schizophrenia;
UCEC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.52	-5.07	-0.39	1.19e-6	Coronary artery disease;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-6.21	-0.46	5.16e-9	Platelet count;
UCEC	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.95	-0.5	1.09e-10	Urate levels in overweight individuals;
UCEC	cis	rs12039431	0.706	rs61779866	chr1:37978897	G/A	cg17933807	chr1:38061675	GNL2	-0.54	-4.56	-0.35	1.05e-5	Epithelial ovarian cancer;
UCEC	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.44	4.7	0.36	5.84e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.8	8.11	0.56	1.81e-13	Schizophrenia;
UCEC	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.78	-0.37	4.16e-6	Multiple sclerosis;
UCEC	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.78	-9.28	-0.61	2.02e-16	Age at first birth;
UCEC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.53	5.38	0.41	2.91e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	5.54	0.42	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.58	-5.46	-0.41	1.97e-7	Blood protein levels;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.53	0.62	4.73e-17	Platelet count;
UCEC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.52	-5.8	-0.43	3.99e-8	Corneal structure;
UCEC	cis	rs6446731	0.636	rs2157091	chr4:3273099	G/A	cg08886695	chr4:3369023	RGS12	-0.44	-4.92	-0.38	2.24e-6	Mean platelet volume;
UCEC	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	6.28	0.46	3.57e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.88	9.75	0.63	1.28e-17	Breast cancer;
UCEC	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg18681998	chr4:17616180	MED28	0.66	7.4	0.52	9.64e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4460629	0.742	rs4625273	chr1:155076043	C/T	cg02153340	chr1:155202674	NA	-0.4	-4.58	-0.35	1e-5	Serum magnesium levels;
UCEC	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg10902566	chr4:727664	PCGF3	-0.61	-5.17	-0.39	7.67e-7	Systolic blood pressure;
UCEC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.51	4.87	0.37	2.85e-6	Blood metabolite levels;
UCEC	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg21533262	chr7:107110551	COG5;GPR22	-0.43	-4.82	-0.37	3.57e-6	Coronary artery disease;
UCEC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-4.78	-0.37	4.16e-6	Monocyte percentage of white cells;
UCEC	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.6	6.84	0.49	1.97e-10	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.8	9.27	0.61	2.1e-16	Homoarginine levels;
UCEC	cis	rs7246967	0.736	rs428299	chr19:22996252	T/C	cg24889512	chr19:22816950	ZNF492	0.49	4.71	0.36	5.66e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.91	0.5	1.38e-10	Bladder cancer;
UCEC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.49	5.35	0.4	3.31e-7	Menopause (age at onset);
UCEC	cis	rs524281	0.731	rs10791838	chr11:65789854	T/G	cg25010124	chr11:64981596	SLC22A20	-0.41	-4.55	-0.35	1.11e-5	Electroencephalogram traits;
UCEC	trans	rs9313296	0.661	rs2431313	chr5:165522021	T/C	cg03539051	chr19:56418660	NLRP13	1.11	6.93	0.5	1.23e-10	Weight;Waist circumference;
UCEC	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.78	11.23	0.68	1.58e-21	Leprosy;
UCEC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.76	-6.99	-0.5	8.77e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.54	-5.9	-0.44	2.43e-8	Refractive error;
UCEC	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.42	4.93	0.38	2.24e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.64	6.17	0.45	6.42e-9	Morning vs. evening chronotype;
UCEC	cis	rs78487399	0.908	rs55855805	chr2:43808490	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-4.6	-0.35	9.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7937612	1.000	rs10790382	chr11:120288372	T/C	cg12584626	chr11:120203529	NA	0.51	5.02	0.38	1.47e-6	Intraocular pressure;
UCEC	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.5	-5.05	-0.38	1.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	6.95	0.5	1.12e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.51	5.75	0.43	4.9e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.56	-6.29	-0.46	3.36e-9	Monocyte percentage of white cells;
UCEC	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.72	6.36	0.46	2.42e-9	Caudate activity during reward;
UCEC	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.65	-5.51	-0.41	1.54e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.6	5.33	0.4	3.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.46	-6.22	-0.46	4.86e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg23260525	chr10:116636907	FAM160B1	0.33	4.54	0.35	1.14e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.46	0.41	1.94e-7	Personality dimensions;
UCEC	cis	rs4499344	0.730	rs7250272	chr19:33100338	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.46e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.53	-5.34	-0.4	3.44e-7	Diastolic blood pressure;
UCEC	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.11e-9	Coffee consumption (cups per day);
UCEC	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.55	4.57	0.35	1.04e-5	Alzheimer's disease;
UCEC	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.66	6.93	0.5	1.23e-10	Dental caries;
UCEC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.61	-7.1	-0.51	4.98e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg14664628	chr15:75095509	CSK	-0.52	-5.19	-0.39	6.84e-7	Breast cancer;
UCEC	cis	rs747782	0.583	rs11039300	chr11:47587062	G/A	cg08722104	chr11:47448306	PSMC3	0.45	4.69	0.36	6.19e-6	Intraocular pressure;
UCEC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.07	0.45	1.02e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2806864	1.000	rs2247145	chr1:117470312	T/C	cg19765820	chr1:116518738	SLC22A15	-0.61	-4.56	-0.35	1.09e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24249390	chr15:90295951	MESP1	-0.39	-4.53	-0.35	1.2e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.74	0.49	3.32e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs10242455	0.867	rs3735453	chr7:99229435	C/T	cg07715041	chr7:99302981	CYP3A7	-0.47	-4.74	-0.36	5.07e-6	Blood metabolite levels;
UCEC	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.52	-5.25	-0.4	5.27e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-0.98	-6.12	-0.45	8.04e-9	Diabetic kidney disease;
UCEC	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs2274471	0.591	rs7034539	chr9:5081585	C/T	cg03390472	chr9:5043263	JAK2	0.51	4.93	0.38	2.21e-6	Crohn's disease;
UCEC	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg05660106	chr1:15850417	CASP9	0.96	9.02	0.6	9.21e-16	Systolic blood pressure;
UCEC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.45	6.0	0.44	1.47e-8	Total body bone mineral density;
UCEC	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.77	-5.26	-0.4	5.06e-7	Blood pressure (smoking interaction);
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.47	-4.63	-0.36	7.93e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.71	-7.16	-0.51	3.56e-11	Obesity-related traits;
UCEC	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg05874882	chr4:1763078	NA	-0.52	-5.4	-0.41	2.63e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.49	-4.54	-0.35	1.16e-5	Lung cancer;
UCEC	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.9	6.29	0.46	3.38e-9	Major depressive disorder;
UCEC	cis	rs2062225	1.000	rs3789095	chr2:111749921	A/C	cg23782758	chr2:111737646	ACOXL	-0.64	-4.63	-0.36	8.14e-6	Monocyte count;
UCEC	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.73	-7.01	-0.5	7.83e-11	Obesity-related traits;
UCEC	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg05527609	chr1:210001259	C1orf107	0.6	4.86	0.37	2.94e-6	Red blood cell count;
UCEC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.87	-10.8	-0.67	2.26e-20	Metabolic syndrome;
UCEC	cis	rs28530618	0.603	rs11167173	chr20:31241612	A/T	cg13636640	chr20:31349939	DNMT3B	-0.55	-5.01	-0.38	1.52e-6	Birth weight;
UCEC	cis	rs8105895	0.935	rs62110989	chr19:22260299	A/G	cg20662725	chr19:22235022	ZNF257	-0.65	-5.46	-0.41	2.01e-7	Body mass index (change over time);
UCEC	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.31	10.08	0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs12755606	0.571	rs16842484	chr1:159646924	A/G	cg25313772	chr1:160331687	NA	-0.45	-5.29	-0.4	4.36e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
UCEC	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg24060327	chr5:131705240	SLC22A5	-0.45	-4.67	-0.36	6.65e-6	Breast cancer;
UCEC	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.69	6.69	0.48	4.48e-10	Schizophrenia;
UCEC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.76	7.85	0.54	8.04e-13	Chronic sinus infection;
UCEC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg07153921	chr17:41440717	NA	-0.57	-6.07	-0.45	1.02e-8	Menopause (age at onset);
UCEC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	1.02	13.54	0.75	1.24e-27	Monocyte count;
UCEC	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.56	5.82	0.43	3.56e-8	Mean platelet volume;
UCEC	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.48	-4.54	-0.35	1.18e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.88	-10.06	-0.64	1.9e-18	Cognitive function;
UCEC	cis	rs8099014	0.814	rs4245272	chr18:56115145	T/A	cg19165390	chr18:56932082	NA	0.38	4.78	0.37	4.18e-6	Platelet count;
UCEC	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.48	0.52	6.32e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	0.68	6.51	0.47	1.13e-9	Vitiligo;
UCEC	cis	rs6546886	1.000	rs12988533	chr2:74243034	A/G	cg14702570	chr2:74259524	NA	-0.44	-5.65	-0.42	7.88e-8	Dialysis-related mortality;
UCEC	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg00786635	chr1:25594202	NA	0.63	6.35	0.46	2.55e-9	Plateletcrit;Mean corpuscular volume;
UCEC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.12	0.6	5.24e-16	Electrocardiographic conduction measures;
UCEC	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.49	4.91	0.38	2.39e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.3	-0.46	3.21e-9	Depression;
UCEC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.14	0.6	4.62e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg15133208	chr4:90757351	SNCA	0.34	4.59	0.35	9.45e-6	Dementia with Lewy bodies;
UCEC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.12	-0.39	9.58e-7	Breast cancer;
UCEC	cis	rs11235843	0.929	rs3211165	chr11:73471778	A/G	cg09185399	chr11:73372479	PLEKHB1	0.67	4.62	0.36	8.19e-6	Hand grip strength;
UCEC	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	7.78	0.54	1.15e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.63	-6.84	-0.49	2e-10	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.79	8.73	0.58	5.17e-15	Menopause (age at onset);
UCEC	cis	rs4615376	0.950	rs35273948	chr6:13045486	C/T	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.67	-0.36	6.82e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-4.73	-0.36	5.23e-6	Prudent dietary pattern;
UCEC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.69	-7.86	-0.54	7.36e-13	Menarche (age at onset);
UCEC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.72	7.97	0.55	3.98e-13	Total cholesterol levels;
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.6	-8.84	-0.59	2.74e-15	Prudent dietary pattern;
UCEC	cis	rs12980942	0.872	rs12972949	chr19:41774935	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.89	5.72	0.43	5.87e-8	Coronary artery disease;
UCEC	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.13	0.39	9.17e-7	Rheumatoid arthritis;
UCEC	cis	rs12634933	0.737	rs59164328	chr3:169031715	A/G	cg03603669	chr3:169896616	PHC3	-0.47	-4.62	-0.36	8.31e-6	Blood pressure (smoking interaction);
UCEC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.79	-8.49	-0.57	2.08e-14	Longevity;
UCEC	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.42	5.12	0.39	9.27e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.65	8.25	0.56	8.27e-14	Anterior chamber depth;
UCEC	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.48	-4.64	-0.36	7.53e-6	Extraversion;
UCEC	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	7.49	0.53	5.9e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-10.85	-0.67	1.59e-20	Headache;
UCEC	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.72	-7.81	-0.54	1.02e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg13695892	chr22:41940480	POLR3H	-0.66	-4.62	-0.36	8.3e-6	Vitiligo;
UCEC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-4.84	-0.37	3.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.51	-4.83	-0.37	3.46e-6	Renal cell carcinoma;
UCEC	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.91	-7.02	-0.5	7.42e-11	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.44	0.47	1.61e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.66	5.64	0.42	8.56e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7909670	0.836	rs7098280	chr10:12933866	C/T	cg18678121	chr10:12170807	SEC61A2	0.45	4.66	0.36	6.93e-6	Height;
UCEC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.43	5.0	0.38	1.59e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7072216	0.770	rs7909131	chr10:100171471	A/G	cg26618903	chr10:100175079	PYROXD2	-0.39	-5.17	-0.39	7.45e-7	Metabolite levels;
UCEC	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.83	-0.37	3.45e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2882667	0.858	rs11242442	chr5:138380489	C/T	cg04439458	chr5:138467593	SIL1	-0.44	-4.68	-0.36	6.34e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.66	0.42	7.74e-8	Breast cancer;
UCEC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04476341	chr5:669733	TPPP	-0.4	-4.76	-0.37	4.57e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.87	-0.49	1.69e-10	Colorectal cancer;
UCEC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg03609598	chr5:56110824	MAP3K1	-0.54	-4.66	-0.36	6.95e-6	Coronary artery disease;
UCEC	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.66	6.42	0.47	1.78e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.73	6.34	0.46	2.7e-9	Cognitive function;
UCEC	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.5	-0.41	1.6e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.46	4.63	0.36	7.98e-6	Coronary artery disease;
UCEC	cis	rs256277	0.544	rs255928	chr5:111342333	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.53	-5.0	-0.38	1.61e-6	Coronary artery disease;
UCEC	cis	rs12363310	0.665	rs4754022	chr11:101672001	A/G	cg00202702	chr11:101918157	C11orf70	0.43	4.88	0.37	2.78e-6	Systemic sclerosis;
UCEC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.44	-5.74	-0.43	5.26e-8	Urinary metabolites;
UCEC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg04726090	chr17:41856008	DUSP3	0.47	4.55	0.35	1.1e-5	Triglycerides;
UCEC	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.61	-5.01	-0.38	1.55e-6	Coronary artery calcification;
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg19678392	chr7:94953810	PON1	-0.58	-5.58	-0.42	1.11e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.1	7.86	0.54	7.43e-13	Alzheimer's disease (late onset);
UCEC	cis	rs7246967	0.932	rs62120766	chr19:23029947	G/A	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.68	6.4	0.47	2.01e-9	Ovarian reserve;
UCEC	cis	rs17123764	0.710	rs60402517	chr12:50098471	A/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.72	6.99	0.5	8.82e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-4.81	-0.37	3.71e-6	Neuroticism;
UCEC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs9470794	0.915	rs57160603	chr6:38006399	G/C	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	4.79	0.37	4.1e-6	Height;
UCEC	cis	rs12931792	0.748	rs11150585	chr16:30184286	A/G	cg06985993	chr16:30040055	FAM57B	0.39	5.04	0.38	1.32e-6	Tonsillectomy;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.8	7.56	0.53	4.06e-12	Multiple sclerosis;
UCEC	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.93	-6.61	-0.48	6.54e-10	Bone mineral density;
UCEC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.65	6.03	0.45	1.24e-8	Aortic root size;
UCEC	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg07076509	chr9:96720819	NA	0.49	5.27	0.4	4.85e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7246967	0.932	rs35706770	chr19:23059262	T/C	cg24889512	chr19:22816950	ZNF492	0.49	4.76	0.37	4.5e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.67	-7.0	-0.5	8.32e-11	Obesity-related traits;
UCEC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg14078730	chr11:63896557	MACROD1	-0.47	-5.16	-0.39	7.88e-7	Platelet count;
UCEC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg21482837	chr2:85581528	ELMOD3;RETSAT	-0.57	-6.89	-0.49	1.55e-10	Iris heterochromicity;
UCEC	cis	rs17106184	1.000	rs113119450	chr1:51235816	T/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.33	-0.4	3.69e-7	Type 2 diabetes;
UCEC	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg04439458	chr5:138467593	SIL1	-0.47	-5.35	-0.4	3.26e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg03714773	chr7:91764589	CYP51A1	0.42	4.93	0.38	2.16e-6	Breast cancer;
UCEC	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.58	-5.99	-0.44	1.57e-8	White matter hyperintensity burden;
UCEC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.09	-10.73	-0.66	3.32e-20	Vitiligo;
UCEC	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg21770322	chr7:97807741	LMTK2	0.52	6.47	0.47	1.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.51	-4.76	-0.37	4.68e-6	Body mass index;
UCEC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.58	-5.45	-0.41	2.12e-7	Blood protein levels;
UCEC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.67	5.64	0.42	8.27e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.38	-4.98	-0.38	1.74e-6	Total body bone mineral density;
UCEC	cis	rs1468333	1.000	rs7729926	chr5:137514641	A/T	cg07848042	chr5:137667509	CDC25C	0.46	4.68	0.36	6.44e-6	Resting heart rate;
UCEC	cis	rs7870753	0.628	rs2406005	chr9:99197655	A/C	cg25260653	chr9:99212216	HABP4	0.54	4.93	0.38	2.19e-6	Height;
UCEC	cis	rs787274	1.000	rs2645993	chr9:115536267	T/A	cg13803584	chr9:115635662	SNX30	-0.69	-5.64	-0.42	8.63e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.63	6.02	0.44	1.33e-8	Lymphocyte counts;
UCEC	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	4.72	0.36	5.51e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.77	-5.26	-0.4	5.05e-7	Blood pressure (smoking interaction);
UCEC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.81	-8.46	-0.57	2.49e-14	Cognitive function;
UCEC	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.79	-9.62	-0.62	2.68e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2179367	0.919	rs4897124	chr6:149763209	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.39	-5.18	-0.39	7.08e-7	Dupuytren's disease;
UCEC	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.33	-0.52	1.39e-11	Eye color traits;
UCEC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.7	8.04	0.55	2.67e-13	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.89	0.44	2.59e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg06462663	chr19:18546047	ISYNA1	0.5	6.37	0.47	2.28e-9	Breast cancer;
UCEC	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	0.71	4.93	0.38	2.18e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs1712517	0.844	rs1163087	chr10:105043289	G/A	cg05636881	chr10:105038444	INA	0.49	5.56	0.42	1.24e-7	Migraine;
UCEC	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.93	0.63	4.12e-18	Blood protein levels;
UCEC	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.54	-4.86	-0.37	3e-6	Diastolic blood pressure;
UCEC	cis	rs1007190	0.570	rs7224712	chr17:42874218	G/T	cg15406952	chr17:42872593	NA	-0.7	-5.11	-0.39	9.99e-7	DNA methylation (variation);
UCEC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.52	5.02	0.38	1.47e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1595825	0.891	rs76308665	chr2:198518062	C/T	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs16937	0.662	rs10900464	chr1:205157100	T/C	cg12580275	chr1:205744413	RAB7L1	0.52	5.51	0.41	1.59e-7	Schizophrenia;
UCEC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg04709771	chr16:646395	RAB40C	0.42	4.97	0.38	1.85e-6	Height;
UCEC	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	6.47	0.47	1.38e-9	Motion sickness;
UCEC	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.66	6.71	0.48	3.93e-10	Menopause (age at onset);
UCEC	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.65	5.47	0.41	1.91e-7	Cocaine dependence;
UCEC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.8	-7.73	-0.54	1.6e-12	Initial pursuit acceleration;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg01013738	chr7:1149705	C7orf50	-0.5	-4.8	-0.37	3.91e-6	Longevity;Endometriosis;
UCEC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.94	0.7	2.1e-23	Prudent dietary pattern;
UCEC	cis	rs1502337	0.532	rs11065688	chr12:111082142	A/G	cg25737040	chr12:111374205	NA	0.44	4.63	0.36	7.92e-6	Body mass index;
UCEC	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.83	8.91	0.59	1.76e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg26528668	chr16:1614120	IFT140	0.45	5.13	0.39	9.19e-7	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs5743289	0.547	rs5743266	chr16:50731096	C/T	cg02864757	chr16:51184583	SALL1	-0.48	-4.53	-0.35	1.19e-5	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	0.67	8.65	0.58	8.06e-15	Gut microbiome composition (winter);
UCEC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.67	-6.22	-0.46	4.9e-9	Aortic root size;
UCEC	cis	rs17106184	1.000	rs72898980	chr1:50986747	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.76	7.52	0.53	5.09e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg24851651	chr11:66362959	CCS	-0.4	-5.12	-0.39	9.52e-7	Educational attainment (years of education);
UCEC	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7246967	0.932	rs34622638	chr19:23063652	C/T	cg05241461	chr19:22816980	ZNF492	0.55	5.23	0.4	5.67e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.53	4.8	0.37	3.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.6	0.58	1.12e-14	Platelet count;
UCEC	cis	rs8010715	0.816	rs7153156	chr14:24598846	A/G	cg20933586	chr14:24608199	FAM158A	0.37	4.73	0.36	5.12e-6	IgG glycosylation;
UCEC	cis	rs6806528	0.778	rs7639425	chr3:69268933	C/T	cg15909737	chr3:69811645	MITF	0.65	4.93	0.38	2.2e-6	Celiac disease;
UCEC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.56	5.05	0.38	1.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.46	-5.19	-0.39	7.02e-7	Subjective well-being;
UCEC	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	5.34	0.4	3.45e-7	Aortic root size;
UCEC	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	7.01	0.5	8.05e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.58	-0.53	3.54e-12	Tonsillectomy;
UCEC	cis	rs1483890	0.642	rs9825845	chr3:69404572	C/A	cg22125112	chr3:69402811	FRMD4B	0.47	4.78	0.37	4.12e-6	Resting heart rate;
UCEC	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	5.1	0.39	1.02e-6	Myopia (pathological);
UCEC	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.01	0.64	2.65e-18	Menopause (age at onset);
UCEC	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg13150564	chr14:74318418	PTGR2	-0.46	-4.68	-0.36	6.53e-6	Caffeine consumption;
UCEC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.51	-5.01	-0.38	1.51e-6	Aortic root size;
UCEC	cis	rs1940013	0.680	rs1939961	chr11:132245683	G/A	cg11473001	chr11:131780499	NTM	-0.4	-4.64	-0.36	7.76e-6	Sleep-related phenotypes;
UCEC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.32	-0.4	3.84e-7	Aortic root size;
UCEC	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.01	-18.98	-0.84	2.31e-41	Colorectal cancer;
UCEC	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.67	7.12	0.51	4.5e-11	White blood cell count (basophil);
UCEC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.4	5.22	0.4	6.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.86	-10.59	-0.66	7.98e-20	Longevity;Endometriosis;
UCEC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.41	5.19	0.39	6.74e-7	Bone mineral density;
UCEC	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.6	5.44	0.41	2.15e-7	Mammographic density (dense area);
UCEC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.31	-0.52	1.61e-11	Obesity-related traits;
UCEC	cis	rs7582720	1.000	rs74675536	chr2:203673073	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.96	0.38	1.89e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg05991184	chr2:219186017	PNKD	0.43	4.58	0.35	9.97e-6	Ulcerative colitis;
UCEC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg05802129	chr4:122689817	NA	-0.5	-5.26	-0.4	5.06e-7	Type 2 diabetes;
UCEC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.2	-0.51	2.96e-11	Breast cancer;
UCEC	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.73	-6.44	-0.47	1.62e-9	Asthma;
UCEC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	4.93	0.38	2.19e-6	Breast cancer;
UCEC	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.89	-9.69	-0.62	1.76e-17	Cognitive function;
UCEC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.45	0.41	2.03e-7	Tonsillectomy;
UCEC	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg26061582	chr7:22766209	IL6	0.59	5.63	0.42	8.73e-8	Lung cancer;
UCEC	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.61	5.74	0.43	5.34e-8	Vitamin D levels;
UCEC	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.5	5.5	0.41	1.6e-7	Life satisfaction;
UCEC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.42	7.62	0.53	2.84e-12	Cognitive function;
UCEC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.77	-6.01	-0.44	1.38e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01391022	chr12:122360665	WDR66	-0.49	-5.15	-0.39	8.31e-7	Mean corpuscular volume;
UCEC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.61	5.6	0.42	1.02e-7	Selective IgA deficiency;
UCEC	cis	rs7088591	1.000	rs16911636	chr10:59782369	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.69	7.1	0.51	4.95e-11	Bladder cancer;
UCEC	cis	rs7546668	0.947	rs4645989	chr1:15850343	A/G	cg05660106	chr1:15850417	CASP9	-0.45	-4.83	-0.37	3.37e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.74	8.89	0.59	2.08e-15	Menarche (age at onset);
UCEC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-9.56	-0.62	3.92e-17	Vitiligo;
UCEC	cis	rs72792324	1.000	rs67622091	chr5:140767902	C/A	cg17023770	chr5:140624874	PCDHB15	-0.57	-4.55	-0.35	1.1e-5	Mean platelet volume;
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg05481257	chr2:20870211	GDF7	-0.41	-4.71	-0.36	5.8e-6	Abdominal aortic aneurysm;
UCEC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	1.0	12.47	0.72	8.44e-25	Colorectal adenoma (advanced);
UCEC	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.8	-0.37	3.87e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.69	7.85	0.54	7.89e-13	Coronary artery disease;
UCEC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.73	7.44	0.52	7.69e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18252515	chr7:66147081	NA	-0.51	-4.9	-0.37	2.51e-6	Aortic root size;
UCEC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg24338752	chr11:2182672	INS;INS-IGF2	-0.29	-4.53	-0.35	1.21e-5	DNA methylation (variation);
UCEC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.7	0.43	6.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.41	-0.47	1.85e-9	Gout;
UCEC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg00083072	chr11:65415190	SIPA1	0.45	5.02	0.38	1.44e-6	Acne (severe);
UCEC	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg05925327	chr15:68127851	NA	-0.48	-5.42	-0.41	2.36e-7	Restless legs syndrome;
UCEC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.16e-5	Lung cancer;
UCEC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-0.94	-6.81	-0.49	2.31e-10	Body mass index;
UCEC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg17279458	chr3:44753948	ZNF502	-0.41	-4.65	-0.36	7.3e-6	Depressive symptoms;
UCEC	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	0.97	7.86	0.54	7.35e-13	Pediatric areal bone mineral density (radius);
UCEC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.68	6.15	0.45	7.01e-9	Corneal astigmatism;
UCEC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12137294	0.794	rs1172160	chr1:205207015	G/A	cg12580275	chr1:205744413	RAB7L1	0.43	4.78	0.37	4.2e-6	Red cell distribution width;
UCEC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.09	-0.39	1.07e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.85	-8.32	-0.57	5.45e-14	Cognitive function;
UCEC	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.85	0.59	2.56e-15	Coffee consumption (cups per day);
UCEC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg17724175	chr1:150552817	MCL1	0.53	5.93	0.44	2.12e-8	Tonsillectomy;
UCEC	trans	rs2823035	1.000	rs2823035	chr21:16442304	C/T	cg01909242	chr12:130498375	NA	0.78	7.18	0.51	3.14e-11	Left ventricle wall thickness;
UCEC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.55	-5.09	-0.39	1.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18252515	chr7:66147081	NA	0.46	4.7	0.36	5.89e-6	Aortic root size;
UCEC	cis	rs14403	1.000	rs12134270	chr1:243662668	T/G	cg21452805	chr1:244014465	NA	0.55	4.7	0.36	5.89e-6	Schizophrenia;
UCEC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	5.92	0.44	2.14e-8	Cognitive test performance;
UCEC	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.58	-5.99	-0.44	1.57e-8	White matter hyperintensity burden;
UCEC	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.63	0.62	2.62e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.31e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.65	6.07	0.45	1.06e-8	Aortic root size;
UCEC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-7.22	-0.51	2.55e-11	Platelet distribution width;
UCEC	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-5.21	-0.4	6.17e-7	Monocyte percentage of white cells;
UCEC	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	5.9	0.44	2.36e-8	Coffee consumption (cups per day);
UCEC	cis	rs7302981	0.741	rs8181679	chr12:50611020	T/C	cg20014596	chr12:50898483	DIP2B	-0.46	-4.67	-0.36	6.79e-6	Systolic blood pressure;
UCEC	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.66	-6.24	-0.46	4.45e-9	Cocaine dependence;
UCEC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.71	8.09	0.56	2.02e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	9.13	0.6	5.02e-16	Mean platelet volume;
UCEC	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06156847	chr2:113672199	IL1F7	0.37	4.91	0.38	2.39e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg08461772	chr7:95026248	PON3	0.4	5.47	0.41	1.87e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg08886695	chr4:3369023	RGS12	0.49	5.24	0.4	5.5e-7	Parental longevity (mother's age at death);
UCEC	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	4.89	0.37	2.62e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.89	9.21	0.61	3.02e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.54	6.84	0.49	1.96e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	0.85	6.14	0.45	7.34e-9	Economic and political preferences (immigration/crime);
UCEC	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.72	6.25	0.46	4.28e-9	Coronary artery disease;
UCEC	cis	rs13095912	0.962	rs34505819	chr3:185340721	C/T	cg11274856	chr3:185301563	NA	0.54	7.25	0.51	2.25e-11	Systolic blood pressure;
UCEC	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.13	-0.45	7.76e-9	Inflammatory bowel disease;
UCEC	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs539096	0.830	rs11580074	chr1:44024484	A/G	cg11851915	chr1:44060116	PTPRF	0.47	4.61	0.36	8.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.76	-7.15	-0.51	3.73e-11	Initial pursuit acceleration;
UCEC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.89	-6.97	-0.5	9.81e-11	Exhaled nitric oxide output;
UCEC	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.83	-9.67	-0.62	1.99e-17	Blood protein levels;
UCEC	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	0.53	5.34	0.4	3.44e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.48	-4.64	-0.36	7.63e-6	Cardiac Troponin-T levels;
UCEC	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.85	10.18	0.64	9.46e-19	Coronary artery disease;
UCEC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.04	0.5	6.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.28	-10.05	-0.64	2.08e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	0.93	9.48	0.62	6.08e-17	Heart rate;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg13610241	chr3:184032169	EIF4G1	-0.6	-6.83	-0.49	2.12e-10	Breast cancer;
UCEC	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg12463550	chr7:65579703	CRCP	0.47	4.51	0.35	1.31e-5	Aortic root size;
UCEC	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.53	5.13	0.39	9.1e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.64	-7.09	-0.5	5.3e-11	Vitiligo;
UCEC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.72	8.27	0.56	7.39e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.77	0.37	4.45e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-5.62	-0.42	9.25e-8	Glomerular filtration rate;
UCEC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.82	-5.8	-0.43	3.91e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg00086871	chr4:6988644	TBC1D14	0.84	6.01	0.44	1.38e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs679087	0.833	rs302342	chr12:29939628	A/G	cg14258853	chr12:29935411	TMTC1	-0.55	-4.53	-0.35	1.19e-5	Schizophrenia;
UCEC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.71	-5.2	-0.39	6.43e-7	Narcolepsy;
UCEC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.86	-9.22	-0.61	2.83e-16	Lung cancer;
UCEC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.58	-0.48	7.92e-10	Obesity-related traits;
UCEC	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.47	5.04	0.38	1.32e-6	Body mass index;
UCEC	cis	rs11867410	0.744	rs73349019	chr17:63928565	A/G	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.94	10.86	0.67	1.51e-20	Breast cancer;
UCEC	cis	rs143756727	1	rs143756727	chr13:36335725	TAC/T	cg03014934	chr13:36050901	MIR548F5;NBEA;MAB21L1	0.5	4.85	0.37	3.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg07676300	chr19:11285258	KANK2	-0.58	-6.7	-0.48	4.09e-10	N-glycan levels;
UCEC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg23625390	chr15:77176239	SCAPER	0.48	4.72	0.36	5.38e-6	Blood metabolite levels;
UCEC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.45	4.84	0.37	3.25e-6	Height;
UCEC	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.5	-5.06	-0.38	1.25e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	7.91	0.55	5.63e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg16797656	chr11:68205561	LRP5	0.48	5.45	0.41	2.03e-7	Total body bone mineral density;
UCEC	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg23782820	chr8:58130467	NA	0.64	5.06	0.39	1.21e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	4.92	0.38	2.34e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.49	5.31	0.4	4.06e-7	Platelet distribution width;
UCEC	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg01072550	chr1:21505969	NA	-0.61	-6.27	-0.46	3.85e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.6	-6.75	-0.49	3.22e-10	Hip circumference;
UCEC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.51	-4.82	-0.37	3.55e-6	Schizophrenia;
UCEC	cis	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg26352726	chr7:75508125	RHBDD2	-0.5	-4.54	-0.35	1.18e-5	Eotaxin levels;
UCEC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.64	6.16	0.45	6.56e-9	Aortic root size;
UCEC	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	0.93	9.48	0.62	6.08e-17	Heart rate;
UCEC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.6	6.62	0.48	6.44e-10	Resting heart rate;
UCEC	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.7	-6.58	-0.48	7.78e-10	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-1.1	-13.94	-0.75	1.13e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.55	-0.35	1.13e-5	Joint mobility (Beighton score);
UCEC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.48	4.68	0.36	6.48e-6	Menarche (age at onset);
UCEC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.53	-5.34	-0.4	3.47e-7	Vitiligo;
UCEC	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs2806864	1.000	rs2250337	chr1:117466243	C/T	cg19765820	chr1:116518738	SLC22A15	-0.6	-4.52	-0.35	1.25e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.7	-7.06	-0.5	6.28e-11	Mean platelet volume;
UCEC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.32e-6	Breast cancer;
UCEC	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg19610905	chr11:61596333	FADS2	-0.49	-5.23	-0.4	5.61e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-5.23	-0.4	5.63e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.71	7.64	0.53	2.5e-12	Immature fraction of reticulocytes;
UCEC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.79	6.04	0.45	1.19e-8	Body mass index;
UCEC	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.7	-7.29	-0.52	1.73e-11	Cognitive function;
UCEC	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.58	-6.02	-0.44	1.33e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs970548	0.954	rs12243153	chr10:46002060	T/A	cg15223267	chr10:46222474	FAM21C	0.54	5.18	0.39	7.09e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.6	-0.42	1.03e-7	Pubertal anthropometrics;
UCEC	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.2	-0.39	6.62e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs7611694	0.532	rs9815835	chr3:113159741	C/T	cg11138929	chr3:113251189	SIDT1	-0.42	-4.85	-0.37	3.06e-6	Prostate cancer;
UCEC	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.75	10.47	0.65	1.63e-19	Neuroticism;
UCEC	cis	rs11118844	0.739	rs10863653	chr1:221943926	T/C	cg04222084	chr1:221915650	DUSP10	-0.76	-7.15	-0.51	3.79e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.65	-7.24	-0.51	2.31e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.43e-15	Height;
UCEC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-11.87	-0.7	3.2e-23	Chronic sinus infection;
UCEC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg13339708	chr4:185549367	CASP3	-0.46	-4.59	-0.35	9.52e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
UCEC	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.25	-7.6	-0.53	3.14e-12	Schizophrenia;
UCEC	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg24860332	chr8:6827800	DEFA10P	-0.37	-5.28	-0.4	4.64e-7	IgA nephropathy;
UCEC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.5	5.42	0.41	2.41e-7	Prostate cancer;
UCEC	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.53	-4.77	-0.37	4.46e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg04837898	chr3:45731254	SACM1L	-0.4	-4.53	-0.35	1.23e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.52	-0.35	1.27e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg18099408	chr3:52552593	STAB1	0.41	4.98	0.38	1.74e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.55	4.97	0.38	1.82e-6	Crohn's disease;
UCEC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.94	-9.34	-0.61	1.43e-16	Initial pursuit acceleration;
UCEC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.81	7.86	0.54	7.62e-13	Cognitive function;
UCEC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.63	-4.89	-0.37	2.62e-6	Initial pursuit acceleration;
UCEC	cis	rs7246967	0.866	rs6511385	chr19:23036936	T/G	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.54e-6	Bronchopulmonary dysplasia;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg16248277	chr10:103536063	FGF8	0.67	7.13	0.51	4.12e-11	Schizophrenia;
UCEC	cis	rs7707921	0.957	rs226205	chr5:81593654	C/T	cg08459430	chr5:81571289	RPS23	-0.7	-4.6	-0.35	9.16e-6	Breast cancer;
UCEC	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-8.25	-0.56	8.35e-14	Vitiligo;
UCEC	cis	rs7224668	0.647	rs2271090	chr17:79246605	A/G	cg15215033	chr17:79258732	SLC38A10	0.32	4.65	0.36	7.22e-6	IgG glycosylation;
UCEC	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.66	7.31	0.52	1.62e-11	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg14675211	chr2:100938903	LONRF2	0.64	6.41	0.47	1.9e-9	Educational attainment;
UCEC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.49	4.53	0.35	1.23e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.62	5.57	0.42	1.2e-7	Corneal astigmatism;
UCEC	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg04450003	chr12:50355995	AQP5	0.67	4.95	0.38	2.05e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.41	0.41	2.51e-7	Ileal carcinoids;
UCEC	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.46	-0.41	1.94e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.54	5.43	0.41	2.31e-7	Longevity;Endometriosis;
UCEC	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.21	-0.51	2.71e-11	Multiple sclerosis;
UCEC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.54	4.8	0.37	3.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.48	5.46	0.41	2.02e-7	White matter hyperintensity burden;
UCEC	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.66	7.44	0.52	7.87e-12	Body mass index (adult);
UCEC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.59	4.63	0.36	8.14e-6	Longevity;
UCEC	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.07	-7.05	-0.5	6.53e-11	Schizophrenia;
UCEC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.54	5.81	0.43	3.74e-8	Prostate cancer;
UCEC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-5.82	-0.43	3.52e-8	Longevity;
UCEC	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.05	0.55	2.58e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs11867410	0.744	rs59707640	chr17:63956470	A/G	cg06996976	chr17:64576105	PRKCA	-0.78	-4.65	-0.36	7.3e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.66	-6.67	-0.48	4.91e-10	Ulcerative colitis;
UCEC	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.58	-5.49	-0.41	1.75e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.54	-0.35	1.15e-5	Hepatitis A;
UCEC	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg21419209	chr3:44054225	NA	0.5	5.51	0.41	1.56e-7	Coronary artery disease;
UCEC	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg05539622	chr2:73298971	SFXN5	0.5	4.75	0.36	4.88e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.76	0.43	4.72e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg11569703	chr11:65557185	OVOL1	-0.42	-6.08	-0.45	9.66e-9	Acne (severe);
UCEC	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.3	-0.46	3.19e-9	Mood instability;
UCEC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.95	11.18	0.68	2.14e-21	Chronic sinus infection;
UCEC	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.88	-9.93	-0.63	4.31e-18	Cognitive function;
UCEC	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.59	5.75	0.43	4.92e-8	Tonsillectomy;
UCEC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.52	-5.66	-0.42	7.74e-8	Menopause (age at onset);
UCEC	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg01072550	chr1:21505969	NA	-0.61	-6.38	-0.47	2.21e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.7	-5.08	-0.39	1.11e-6	Mean platelet volume;
UCEC	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.52	4.92	0.38	2.25e-6	Dilated cardiomyopathy;
UCEC	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg04374321	chr14:90722782	PSMC1	0.54	4.53	0.35	1.2e-5	Gut microbiota (bacterial taxa);
UCEC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg20965017	chr5:231967	SDHA	-0.64	-5.99	-0.44	1.53e-8	Breast cancer;
UCEC	cis	rs7611694	0.501	rs6438148	chr3:113138080	A/G	cg12596171	chr3:113251061	SIDT1	-0.54	-5.37	-0.4	3.08e-7	Prostate cancer;
UCEC	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.42	-4.6	-0.35	9.07e-6	Schizophrenia;
UCEC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.58	4.9	0.37	2.46e-6	Resting heart rate;
UCEC	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.52	-4.77	-0.37	4.46e-6	Coronary artery disease;
UCEC	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-10.78	-0.66	2.45e-20	Primary sclerosing cholangitis;
UCEC	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.61	4.6	0.35	9.03e-6	Platelet distribution width;
UCEC	cis	rs911555	0.570	rs942862	chr14:104022124	G/C	cg26031613	chr14:104095156	KLC1	0.58	5.51	0.41	1.56e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	6.93	0.5	1.23e-10	Bipolar disorder;
UCEC	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24249390	chr15:90295951	MESP1	-0.41	-4.73	-0.36	5.22e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs925228	0.955	rs10169690	chr2:24164735	C/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs631288	0.793	rs10900334	chr1:146764058	C/T	cg25205988	chr1:146714368	CHD1L	0.89	4.57	0.35	1.01e-5	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	4.83	0.37	3.39e-6	Eosinophil percentage of white cells;
UCEC	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.58	5.36	0.4	3.17e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2473248	0.622	rs2744725	chr1:22539323	T/C	cg22683154	chr1:23345188	KDM1A	0.46	4.84	0.37	3.28e-6	Birth weight;
UCEC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.49	4.82	0.37	3.61e-6	Colorectal cancer;
UCEC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.73	7.12	0.51	4.37e-11	Parkinson's disease;
UCEC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-4.96	-0.38	1.9e-6	Longevity;Endometriosis;
UCEC	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.73	7.12	0.51	4.37e-11	Parkinson's disease;
UCEC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.43	-5.14	-0.39	8.51e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg01262667	chr19:19385393	TM6SF2	-0.49	-6.66	-0.48	5.05e-10	Tonsillectomy;
UCEC	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg21905437	chr5:178450457	ZNF879	0.66	7.27	0.51	2.01e-11	Pubertal anthropometrics;
UCEC	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.61	5.81	0.43	3.76e-8	Aortic root size;
UCEC	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg05855489	chr10:104503620	C10orf26	0.79	9.28	0.61	2.08e-16	Waist circumference;Hip circumference;
UCEC	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.57	5.99	0.44	1.57e-8	Initial pursuit acceleration;
UCEC	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.54	6.01	0.44	1.38e-8	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.77	-0.37	4.38e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7975161	0.630	rs4246264	chr12:104637743	C/G	cg25273343	chr12:104657179	TXNRD1	-0.79	-4.89	-0.37	2.64e-6	Toenail selenium levels;
UCEC	cis	rs7665590	1	rs7665590	chr4:99796784	T/C	cg12011299	chr4:100065546	ADH4	-0.44	-5.42	-0.41	2.36e-7	Primary biliary cholangitis;
UCEC	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	0.93	8.98	0.6	1.17e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-7.01	-0.5	8.19e-11	Mean platelet volume;
UCEC	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg24851651	chr11:66362959	CCS	0.4	4.92	0.38	2.26e-6	Educational attainment (years of education);
UCEC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg24562669	chr7:97807699	LMTK2	0.48	5.88	0.44	2.71e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg18681998	chr4:17616180	MED28	0.89	11.69	0.69	9.64e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	5.94	0.44	1.95e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg23719950	chr11:63933701	MACROD1	-0.6	-5.04	-0.38	1.34e-6	Mean platelet volume;
UCEC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	5.98	0.44	1.61e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg14664628	chr15:75095509	CSK	-0.48	-4.8	-0.37	3.89e-6	Caffeine consumption;
UCEC	cis	rs6840360	0.642	rs11099819	chr4:152430178	T/C	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs58502974	0.605	rs4702496	chr5:7795063	T/C	cg12187999	chr5:6845652	NA	0.37	4.61	0.36	8.59e-6	Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder;Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs4372836	1.000	rs11688129	chr2:28952581	T/C	cg09522027	chr2:28974177	PPP1CB	0.75	7.84	0.54	8.27e-13	Body mass index;
UCEC	cis	rs4237845	0.591	rs10431506	chr12:58311524	G/A	cg00677455	chr12:58241039	CTDSP2	0.53	4.69	0.36	6.27e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.67	5.45	0.41	2.09e-7	Obesity-related traits;
UCEC	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg24687543	chr11:63912206	MACROD1	0.57	4.87	0.37	2.87e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.56	-4.75	-0.36	4.8e-6	Menarche (age at onset);
UCEC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.85	-8.36	-0.57	4.39e-14	Obesity-related traits;
UCEC	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.46	-4.51	-0.35	1.33e-5	Morning vs. evening chronotype;
UCEC	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg23307798	chr14:103986281	CKB	0.53	4.68	0.36	6.51e-6	Body mass index;
UCEC	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.38	4.6	0.35	8.94e-6	Coronary artery disease;
UCEC	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.48	5.03	0.38	1.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs3015497	0.789	rs3015498	chr14:51112824	T/C	cg04730355	chr14:51134070	SAV1	-0.55	-5.83	-0.43	3.35e-8	Mean platelet volume;
UCEC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.52	4.81	0.37	3.69e-6	Blood protein levels;
UCEC	cis	rs7804356	0.906	rs12540388	chr7:26905731	A/T	cg02693607	chr7:27150598	HOXA3	0.58	4.85	0.37	3.07e-6	Type 1 diabetes;
UCEC	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.42	5.13	0.39	8.86e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg24961523	chr17:36618985	ARHGAP23	0.38	4.78	0.37	4.28e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.65	-4.65	-0.36	7.37e-6	Gut microbiome composition (summer);
UCEC	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg13683864	chr3:40499215	RPL14	0.51	5.09	0.39	1.09e-6	Renal cell carcinoma;
UCEC	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.46	-5.67	-0.42	7.21e-8	Monocyte percentage of white cells;
UCEC	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-0.97	-8.17	-0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.86	-9.4	-0.61	1.01e-16	Breast cancer;
UCEC	cis	rs78487399	0.908	rs76450091	chr2:43767189	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-5.03	-0.38	1.39e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.08	-0.45	9.72e-9	Parkinson's disease;
UCEC	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.78	9.37	0.61	1.18e-16	Mean corpuscular volume;
UCEC	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.58	-6.75	-0.49	3.23e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.17	16.05	0.8	4.03e-34	Cognitive function;
UCEC	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.35	-5.38	-0.41	2.85e-7	Ulcerative colitis;
UCEC	cis	rs6893807	1.000	rs6893807	chr5:87965021	C/T	cg09002922	chr5:87956389	LOC645323	0.59	6.14	0.45	7.5e-9	Body mass index;
UCEC	cis	rs7843479	0.965	rs4872104	chr8:21780744	A/G	cg17168535	chr8:21777572	XPO7	0.56	6.5	0.47	1.19e-9	Mean corpuscular volume;
UCEC	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.61	6.91	0.49	1.4e-10	Longevity;
UCEC	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.55	4.65	0.36	7.48e-6	Colorectal cancer;
UCEC	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.64	7.21	0.51	2.74e-11	Leprosy;
UCEC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.6	5.13	0.39	8.89e-7	Heart rate;
UCEC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg15147215	chr3:52552868	STAB1	-0.45	-4.9	-0.37	2.5e-6	Bipolar disorder;
UCEC	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	7.04	0.5	6.95e-11	Alzheimer's disease;
UCEC	cis	rs9470794	1.000	rs57142729	chr6:38028899	C/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-4.61	-0.36	8.7e-6	Coronary artery disease;
UCEC	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.4	-4.51	-0.35	1.3e-5	Motion sickness;
UCEC	cis	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg11274856	chr3:185301563	NA	0.54	7.44	0.52	7.57e-12	Systolic blood pressure;
UCEC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.51	-4.72	-0.36	5.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg17515076	chr17:73810948	UNK	-0.5	-5.61	-0.42	9.54e-8	White matter hyperintensity burden;
UCEC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.74	7.73	0.54	1.52e-12	Longevity;Endometriosis;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.53	6.54	0.47	9.75e-10	Menarche (age at onset);
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.68	-5.57	-0.42	1.19e-7	Platelet count;
UCEC	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg08222618	chr4:941054	TMEM175	0.56	5.17	0.39	7.4e-7	Sjögren's syndrome;
UCEC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.59e-7	Schizophrenia;
UCEC	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-4.86	-0.37	2.96e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	0.88	7.56	0.53	4.09e-12	Orofacial clefts;
UCEC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18932078	chr1:2524107	MMEL1	0.34	5.44	0.41	2.15e-7	Ulcerative colitis;
UCEC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.45	4.87	0.37	2.91e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	1.06	10.42	0.65	2.26e-19	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.7	-6.51	-0.47	1.12e-9	Aortic root size;
UCEC	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.86	-6.13	-0.45	7.71e-9	Orofacial clefts;
UCEC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.79	5.76	0.43	4.67e-8	Major depressive disorder;
UCEC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.37	-4.59	-0.35	9.37e-6	Body mass index;
UCEC	trans	rs4665630	0.522	rs2712100	chr2:23931925	A/T	cg14021555	chr22:43485536	TTLL1	0.75	6.77	0.49	2.92e-10	Hypertension;
UCEC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-4.86	-0.37	2.98e-6	Blood metabolite levels;
UCEC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	0.65	6.22	0.46	4.82e-9	Vitiligo;
UCEC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.5	4.94	0.38	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.72	9.01	0.6	1.02e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.61	5.13	0.39	8.82e-7	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.04	-13.35	-0.74	3.95e-27	Body mass index;
UCEC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.18	0.39	7.09e-7	Birth weight;
UCEC	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.58	6.65	0.48	5.33e-10	Dialysis-related mortality;
UCEC	cis	rs1165668	0.727	rs2722176	chr12:104313943	T/C	cg21863207	chr12:104234989	NT5DC3	0.62	5.8	0.43	3.94e-8	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4588572	0.643	rs1864173	chr5:77691158	C/T	cg11547950	chr5:77652471	NA	0.47	5.42	0.41	2.41e-7	Triglycerides;
UCEC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs17106184	1.000	rs2095864	chr1:51299597	A/G	cg07174182	chr1:51127561	FAF1	0.73	4.96	0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.68	-6.05	-0.45	1.12e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg11494091	chr17:61959527	GH2	-0.59	-7.5	-0.53	5.54e-12	Prudent dietary pattern;
UCEC	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg08886695	chr4:3369023	RGS12	-0.53	-5.71	-0.43	6.04e-8	Parental longevity (mother's age at death);
UCEC	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.54	-6.17	-0.45	6.4e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.52	5.38	0.41	2.92e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.42	4.68	0.36	6.52e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17434043	chr11:2907123	CDKN1C	0.68	8.29	0.56	6.62e-14	Warfarin maintenance dose;
UCEC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.71	7.68	0.54	2.07e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4615376	1.000	rs9463423	chr6:13069359	T/C	cg23946962	chr6:12515937	NA	-0.42	-4.59	-0.35	9.45e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs420259	0.516	rs432477	chr16:23600573	T/C	cg26562691	chr16:23850404	PRKCB	0.34	4.55	0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.66	6.34	0.46	2.67e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.42	5.96	0.44	1.75e-8	Plasma amyloid beta peptide concentrations (ABx-42);
UCEC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	4.95	0.38	2.03e-6	Longevity;
UCEC	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.55	-4.8	-0.37	3.78e-6	Subjective well-being;
UCEC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.5	5.65	0.42	7.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.94	10.94	0.67	9.16e-21	Breast cancer;
UCEC	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.87	9.48	0.62	6.21e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.57	-5.88	-0.44	2.67e-8	Hepatocellular carcinoma;
UCEC	cis	rs9650657	0.711	rs7007318	chr8:10592278	C/G	cg27411982	chr8:10470053	RP1L1	-0.46	-4.52	-0.35	1.26e-5	Neuroticism;
UCEC	cis	rs76439304	1.000	rs2344965	chr12:27029096	C/T	cg19407459	chr12:26986763	ITPR2	0.97	5.43	0.41	2.24e-7	Mean corpuscular volume;
UCEC	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.69	-4.96	-0.38	1.93e-6	Aortic root size;
UCEC	cis	rs8105895	0.800	rs62112872	chr19:22192425	T/C	cg20662725	chr19:22235022	ZNF257	-0.59	-5.21	-0.39	6.3e-7	Body mass index (change over time);
UCEC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7766436	0.885	rs13198355	chr6:22577119	C/G	cg13666174	chr6:22585274	NA	-0.59	-6.15	-0.45	7.11e-9	Coronary artery disease;
UCEC	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.11	-0.45	8.35e-9	Response to antipsychotic treatment;
UCEC	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.75	4.53	0.35	1.22e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs8032158	1.000	rs12232351	chr15:56140995	T/A	cg10433327	chr15:56209506	NEDD4	-0.31	-4.97	-0.38	1.88e-6	Keloid;
UCEC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.19	0.45	5.7e-9	Breast cancer;
UCEC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.54	-0.47	9.49e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.63	-5.79	-0.43	4.19e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.75	-8.07	-0.55	2.33e-13	Dental caries;
UCEC	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.64	-6.33	-0.46	2.87e-9	IgG glycosylation;
UCEC	cis	rs6493487	0.505	rs28858690	chr15:51104606	G/C	cg20651644	chr15:50170642	ATP8B4	0.55	4.72	0.36	5.45e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs36051895	0.659	rs57299248	chr9:5062932	C/G	cg02405213	chr9:5042618	JAK2	-0.46	-4.65	-0.36	7.28e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.65	-5.39	-0.41	2.79e-7	Psoriasis vulgaris;
UCEC	cis	rs7246967	0.604	rs12975793	chr19:22862844	A/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs200880	0.755	rs200887	chr20:1764620	A/G	cg11784305	chr20:1757812	NA	0.58	4.69	0.36	6.15e-6	Mean platelet volume;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg07836142	chr6:28411423	ZSCAN23	0.6	6.91	0.5	1.34e-10	Pubertal anthropometrics;
UCEC	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.85	-5.98	-0.44	1.62e-8	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs13136331	0.606	rs7686829	chr4:88639710	A/G	cg01170486	chr4:88020856	AFF1	0.56	4.52	0.35	1.27e-5	Sitting height ratio;
UCEC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg07645718	chr20:61493192	TCFL5	0.71	5.18	0.39	7.24e-7	Obesity-related traits;
UCEC	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg05660106	chr1:15850417	CASP9	0.95	10.16	0.64	1.09e-18	Systolic blood pressure;
UCEC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.41	4.51	0.35	1.33e-5	Systemic lupus erythematosus;
UCEC	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg20387954	chr3:183756860	HTR3D	0.46	5.1	0.39	1.05e-6	Anterior chamber depth;
UCEC	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.61	7.1	0.51	4.89e-11	Blood metabolite ratios;
UCEC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-1.02	-12.29	-0.71	2.48e-24	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg11871910	chr12:69753446	YEATS4	0.66	6.48	0.47	1.31e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	6.24	0.46	4.43e-9	Alzheimer's disease;
UCEC	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-6.24	-0.46	4.42e-9	IgG glycosylation;
UCEC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.77	-7.98	-0.55	3.9e-13	Cognitive function;
UCEC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.9	12.06	0.71	1.03e-23	Metabolic syndrome;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.65	-0.42	8.12e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1980946	1.000	rs4339017	chr20:48345066	A/G	cg01159004	chr20:48330681	B4GALT5	-0.57	-4.5	-0.35	1.36e-5	Palmitic acid (16:0) levels;
UCEC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.98	-0.38	1.74e-6	Testicular germ cell tumor;
UCEC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg13695892	chr22:41940480	POLR3H	-0.63	-5.33	-0.4	3.69e-7	Vitiligo;
UCEC	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	0.95	9.73	0.63	1.39e-17	Height;
UCEC	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.93	-6.04	-0.45	1.22e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-4.81	-0.37	3.66e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-5.88	-0.44	2.6e-8	Menarche (age at onset);
UCEC	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.9	12.22	0.71	3.91e-24	Metabolic syndrome;
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.68	5.51	0.41	1.57e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.06	5.83	0.43	3.34e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs876084	0.505	rs7815878	chr8:121103137	C/T	cg06265175	chr8:121136014	COL14A1	0.46	5.01	0.38	1.57e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.82	10.91	0.67	1.12e-20	Body mass index;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.55	-5.72	-0.43	5.82e-8	Parkinson's disease;
UCEC	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.68	7.82	0.54	9.61e-13	Mean corpuscular volume;
UCEC	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg21419209	chr3:44054225	NA	-0.53	-5.47	-0.41	1.9e-7	Coronary artery disease;
UCEC	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.64	-5.32	-0.4	3.77e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg13777783	chr17:79615861	NA	-0.34	-4.8	-0.37	3.81e-6	Eye color traits;
UCEC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.32	0.4	3.78e-7	Multiple sclerosis;
UCEC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.95	7.34	0.52	1.35e-11	Monobrow;
UCEC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.68	6.18	0.45	6.08e-9	Corneal astigmatism;
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.52	-5.57	-0.42	1.15e-7	Body mass index;
UCEC	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.89	-10.7	-0.66	4.18e-20	Blood metabolite levels;
UCEC	cis	rs10242455	0.867	rs2687086	chr7:99295450	C/T	cg07715041	chr7:99302981	CYP3A7	-0.47	-4.83	-0.37	3.33e-6	Blood metabolite levels;
UCEC	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.46	-5.53	-0.41	1.46e-7	HDL cholesterol;
UCEC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.56	6.34	0.46	2.69e-9	Aortic root size;
UCEC	cis	rs514475	1.000	rs514475	chr6:138038905	A/C	cg05880829	chr6:138867080	NHSL1	0.83	5.21	0.39	6.31e-7	Inflammatory skin disease;
UCEC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.83	7.43	0.52	8.1e-12	Blood metabolite levels;
UCEC	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.65	-5.97	-0.44	1.7e-8	Schizophrenia;
UCEC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.36	5.06	0.39	1.22e-6	Coronary artery disease;
UCEC	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.44	-4.55	-0.35	1.1e-5	Electroencephalogram traits;
UCEC	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg18099408	chr3:52552593	STAB1	0.42	5.23	0.4	5.73e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7106204	0.764	rs4508205	chr11:24218850	C/T	ch.11.24196551F	chr11:24239977	NA	0.62	5.29	0.4	4.37e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.66	6.93	0.5	1.23e-10	Dental caries;
UCEC	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg20560298	chr2:73613845	ALMS1	0.52	4.95	0.38	1.98e-6	Metabolite levels;
UCEC	cis	rs12216499	1.000	rs78552657	chr6:159417840	G/A	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	8.65	0.58	8.37e-15	Alzheimer's disease;
UCEC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.84	10.54	0.66	1.08e-19	Mortality in heart failure;
UCEC	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7307889	0.793	rs12317039	chr12:6005333	G/A	cg10294363	chr12:6480192	SCNN1A	0.58	4.67	0.36	6.85e-6	Obesity-related traits;
UCEC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.56	6.14	0.45	7.35e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.07	0.5	5.71e-11	Coronary artery disease;
UCEC	cis	rs4372836	0.681	rs6547875	chr2:28997140	G/T	cg09522027	chr2:28974177	PPP1CB	-0.55	-5.62	-0.42	9.2e-8	Body mass index;
UCEC	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.21	10.66	0.66	5.1e-20	Corneal structure;
UCEC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06223018	chr3:49557076	DAG1	0.33	4.77	0.37	4.49e-6	Parkinson's disease;
UCEC	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.82	7.24	0.51	2.35e-11	Blood metabolite levels;
UCEC	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.75	-8.2	-0.56	1.09e-13	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.49	7.09	0.5	5.21e-11	Primary biliary cholangitis;
UCEC	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-0.53	-5.24	-0.4	5.51e-7	Blood trace element (Zn levels);
UCEC	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.5	5.32	0.4	3.81e-7	Schizophrenia;
UCEC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.08	-15.93	-0.8	7.73e-34	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.52	4.84	0.37	3.2e-6	Menopause (age at onset);
UCEC	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.72	-5.28	-0.4	4.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg13683864	chr3:40499215	RPL14	-0.51	-5.13	-0.39	8.96e-7	Renal cell carcinoma;
UCEC	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.54	-0.58	1.56e-14	Monocyte count;
UCEC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.85	-0.37	3.05e-6	Chronic sinus infection;
UCEC	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.64	5.97	0.44	1.7e-8	Vitiligo;
UCEC	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.22	-0.4	6.13e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.58	-5.56	-0.42	1.23e-7	White matter hyperintensity burden;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.44	-4.94	-0.38	2.08e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.6	7.02	0.5	7.45e-11	Obesity-related traits;
UCEC	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.75	6.86	0.49	1.75e-10	Bladder cancer;
UCEC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.74e-9	Lung cancer;
UCEC	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.46	4.7	0.36	6.05e-6	Information processing speed;
UCEC	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.78	8.51	0.57	1.86e-14	Metabolite levels;
UCEC	cis	rs12635074	0.547	rs6763223	chr3:56240424	A/G	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.51	0.35	1.29e-5	Morning vs. evening chronotype;
UCEC	cis	rs205391	0.689	rs205412	chr16:28064827	A/G	cg16462073	chr16:28995843	SPNS1;LAT	0.34	4.6	0.35	9.23e-6	Obesity-related traits;
UCEC	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.43	-4.93	-0.38	2.21e-6	Aortic root size;
UCEC	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.51	-5.11	-0.39	1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3750082	0.817	rs2060731	chr7:32968346	G/A	cg05721444	chr7:32995514	FKBP9	-0.54	-6.16	-0.45	6.55e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg05738196	chr6:26577821	NA	0.63	7.42	0.52	8.57e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg16497277	chr3:49208875	KLHDC8B	0.49	4.91	0.38	2.44e-6	Parkinson's disease;
UCEC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.98	0.44	1.63e-8	Height;
UCEC	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	trans	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg15509575	chr4:2286509	ZFYVE28	0.43	7.29	0.52	1.79e-11	Rheumatoid arthritis;
UCEC	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg13695892	chr22:41940480	POLR3H	-0.66	-5.15	-0.39	8.25e-7	Vitiligo;
UCEC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	5.55	0.42	1.29e-7	Height;
UCEC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.52	5.78	0.43	4.23e-8	Tonsillectomy;
UCEC	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	6.11	0.45	8.55e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg27543922	chr1:1231878	ACAP3	0.42	4.51	0.35	1.29e-5	Body mass index;
UCEC	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.55	5.13	0.39	8.87e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.53	4.77	0.37	4.43e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs8105895	0.935	rs75025987	chr19:22230669	T/A	cg24175803	chr19:22235144	ZNF257	-0.64	-5.51	-0.41	1.59e-7	Body mass index (change over time);
UCEC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.63	-0.36	7.88e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246967	0.932	rs35687548	chr19:23029147	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.6	-6.77	-0.49	2.79e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.53	5.32	0.4	3.87e-7	Corneal astigmatism;
UCEC	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.63	6.38	0.47	2.17e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.59	6.58	0.48	7.86e-10	Menarche (age at onset);
UCEC	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg19715936	chr7:50634035	DDC	-0.44	-4.74	-0.36	5.09e-6	Malaria;
UCEC	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.6	0.42	9.99e-8	Prudent dietary pattern;
UCEC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.51	-5.22	-0.4	5.86e-7	Pulmonary function;
UCEC	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg02158880	chr13:53174818	NA	0.51	6.0	0.44	1.48e-8	Lewy body disease;
UCEC	cis	rs12980942	0.935	rs16958996	chr19:41825138	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.6	5.46	0.41	2e-7	Coronary artery disease;
UCEC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg26513180	chr16:89883248	FANCA	-0.46	-4.69	-0.36	6.18e-6	Vitiligo;
UCEC	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.81	0.63	8.71e-18	Blood protein levels;
UCEC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg02366345	chr4:152330872	FAM160A1	0.34	4.62	0.36	8.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17621444	0.723	rs10886561	chr10:121759747	A/G	cg10562114	chr10:120790501	NANOS1	-0.36	-4.66	-0.36	6.92e-6	IgG glycosylation;
UCEC	cis	rs9469578	1.000	rs9469578	chr6:33706479	C/T	cg18708504	chr6:33715942	IP6K3	0.51	5.08	0.39	1.13e-6	Phosphorus levels;
UCEC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg08461772	chr7:95026248	PON3	0.34	4.79	0.37	4e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.56	4.6	0.35	9.16e-6	Obesity-related traits;
UCEC	cis	rs16937	0.662	rs10900468	chr1:205163057	A/G	cg12580275	chr1:205744413	RAB7L1	0.52	5.51	0.41	1.59e-7	Schizophrenia;
UCEC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.24	0.46	4.36e-9	Breast cancer;
UCEC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.87	10.92	0.67	1.05e-20	Metabolic syndrome;
UCEC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.66	-7.22	-0.51	2.65e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.44	-4.52	-0.35	1.25e-5	Systemic lupus erythematosus;
UCEC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.52	-0.35	1.24e-5	Longevity;
UCEC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.05	-0.45	1.17e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.7	4.61	0.36	8.81e-6	Breast cancer;
UCEC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	4.83	0.37	3.44e-6	Bipolar disorder;
UCEC	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.53	-5.59	-0.42	1.09e-7	Crohn's disease and psoriasis;
UCEC	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg06096015	chr1:231504339	EGLN1	0.46	5.51	0.41	1.57e-7	Hemoglobin concentration;
UCEC	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.56	-0.66	9.36e-20	Primary sclerosing cholangitis;
UCEC	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.66	-8.2	-0.56	1.1e-13	Endometriosis;
UCEC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12104412	1	rs12104412	chr19:36731058	A/T	cg11502800	chr19:36705772	ZNF146;ZNF565	0.98	5.06	0.38	1.25e-6	Methadone dose in opioid dependence;
UCEC	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.85	-0.54	8.17e-13	Migraine;Coronary artery disease;
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs7113850	0.541	rs7102578	chr11:24244671	G/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.6	6.75	0.49	3.18e-10	QRS complex (12-leadsum);
UCEC	cis	rs7709377	0.546	rs2063250	chr5:115436807	A/G	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.46	6.71	0.48	3.89e-10	Homoarginine levels;
UCEC	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.88	12.97	0.73	3.93e-26	Leprosy;
UCEC	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-5.2	-0.39	6.49e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.6	-7.09	-0.5	5.35e-11	Menarche (age at onset);
UCEC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.74	9.34	0.61	1.47e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg09491104	chr22:46646882	C22orf40	-0.61	-6.91	-0.5	1.36e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.78	-5.64	-0.42	8.25e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.98	-0.5	9.24e-11	Coronary artery disease;
UCEC	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.69	-6.5	-0.47	1.16e-9	Tonsillectomy;
UCEC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg07387570	chr22:46663686	TTC38	-0.47	-4.62	-0.36	8.32e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg04310649	chr10:35416472	CREM	-0.49	-4.76	-0.37	4.61e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.63	-5.78	-0.43	4.34e-8	Tonsillectomy;
UCEC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-5.61	-0.42	9.76e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs78487399	0.808	rs116451849	chr2:43662911	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.46	-6.37	-0.46	2.32e-9	Mortality in heart failure;
UCEC	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg13147721	chr7:65941812	NA	-0.97	-6.48	-0.47	1.29e-9	Diabetic kidney disease;
UCEC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.66	-6.73	-0.49	3.57e-10	Blood metabolite levels;
UCEC	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-5.16	-0.39	7.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.59	5.26	0.4	4.97e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.75	5.92	0.44	2.14e-8	Schizophrenia;
UCEC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.95	0.44	1.84e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.48	-4.91	-0.38	2.41e-6	Breast cancer;
UCEC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs8105895	0.733	rs62110979	chr19:22245152	T/C	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.06e-7	Body mass index (change over time);
UCEC	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.48	5.09	0.39	1.08e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.89	-0.49	1.49e-10	Mood instability;
UCEC	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.39	4.78	0.37	4.17e-6	Renal cell carcinoma;
UCEC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.19	-0.51	3.04e-11	Breast cancer;
UCEC	cis	rs9324268	0.654	rs116290920	chr13:112850381	C/T	cg15059558	chr13:112729515	NA	-0.49	-4.67	-0.36	6.67e-6	Renal transplant outcome;
UCEC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg21770322	chr7:97807741	LMTK2	0.52	6.47	0.47	1.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.07	-0.39	1.17e-6	Morning vs. evening chronotype;
UCEC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.68	-6.68	-0.48	4.56e-10	Blood metabolite levels;
UCEC	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13683864	chr3:40499215	RPL14	-0.94	-9.66	-0.62	2.17e-17	Renal cell carcinoma;
UCEC	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg04374321	chr14:90722782	PSMC1	0.76	8.3	0.57	6.06e-14	Mortality in heart failure;
UCEC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg23307798	chr14:103986281	CKB	0.56	5.34	0.4	3.48e-7	Body mass index;
UCEC	cis	rs7246967	1.000	rs62120832	chr19:23064264	A/G	cg05241461	chr19:22816980	ZNF492	0.5	4.77	0.37	4.42e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg12571892	chr4:120551256	PDE5A	-0.46	-4.53	-0.35	1.19e-5	Corneal astigmatism;
UCEC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.5	5.3	0.4	4.1e-7	Schizophrenia;
UCEC	cis	rs466639	0.714	rs176110	chr1:165382552	G/A	cg03421657	chr1:166039754	FAM78B	0.43	4.54	0.35	1.19e-5	Menarche (age at onset);
UCEC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.11	-0.39	9.76e-7	Colorectal cancer;
UCEC	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.59	-5.64	-0.42	8.65e-8	Asthma;
UCEC	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.55	6.12	0.45	8.08e-9	Height;
UCEC	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.18	-0.39	7.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.44	-4.94	-0.38	2.14e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-1.0	-12.13	-0.71	6.62e-24	Cognitive function;
UCEC	cis	rs7870753	0.786	rs7031099	chr9:99245690	T/C	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.53	-5.67	-0.42	7.43e-8	Post bronchodilator FEV1;
UCEC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.78	0.49	2.75e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.48	4.73	0.36	5.32e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.65	-6.65	-0.48	5.52e-10	Initial pursuit acceleration;
UCEC	cis	rs2585417	0.934	rs3479	chr20:52844765	T/G	cg14415559	chr20:52836060	PFDN4	-0.4	-4.64	-0.36	7.74e-6	Obesity-related traits;
UCEC	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.53	-6.25	-0.46	4.15e-9	Type 2 diabetes;
UCEC	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg13683864	chr3:40499215	RPL14	-0.53	-5.3	-0.4	4.11e-7	Renal cell carcinoma;
UCEC	cis	rs10242455	0.867	rs2687079	chr7:99304618	A/T	cg07715041	chr7:99302981	CYP3A7	0.5	5.19	0.39	7e-7	Blood metabolite levels;
UCEC	cis	rs10242455	0.867	rs2687076	chr7:99307268	G/A	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.04	-0.38	1.37e-6	Blood metabolite levels;
UCEC	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.69	-6.66	-0.48	5.09e-10	Schizophrenia;
UCEC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.51	-5.57	-0.42	1.19e-7	Diastolic blood pressure;
UCEC	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg21191810	chr6:118973309	C6orf204	0.44	6.25	0.46	4.16e-9	Electrocardiographic conduction measures;
UCEC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.78	4.73	0.36	5.16e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11958404	1.000	rs72816527	chr5:157409633	C/T	cg05962755	chr5:157440814	NA	0.63	4.57	0.35	1.04e-5	IgG glycosylation;
UCEC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.85	9.68	0.62	1.94e-17	Post bronchodilator FEV1;
UCEC	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.46	4.59	0.35	9.45e-6	Motion sickness;
UCEC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.49	-5.48	-0.41	1.84e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.3	0.56	6.29e-14	Headache;
UCEC	cis	rs4460629	0.742	rs11264312	chr1:155075888	T/C	cg02153340	chr1:155202674	NA	-0.4	-4.58	-0.35	1e-5	Serum magnesium levels;
UCEC	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.59	4.99	0.38	1.68e-6	Dental caries;
UCEC	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.34	-0.4	3.41e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.38	-4.89	-0.37	2.57e-6	Type 2 diabetes;
UCEC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.5	4.99	0.38	1.71e-6	Menarche (age at onset);
UCEC	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg20450318	chr11:65415260	SIPA1	0.4	4.56	0.35	1.08e-5	Acne (severe);
UCEC	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.69	-7.24	-0.51	2.26e-11	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.47	4.52	0.35	1.24e-5	Coronary artery disease;
UCEC	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.45	5.05	0.38	1.29e-6	Facial morphology (factor 20);
UCEC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-1.03	-8.61	-0.58	1.06e-14	White matter hyperintensity burden;
UCEC	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.19e-6	Vitiligo;
UCEC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.52	5.2	0.39	6.69e-7	Monocyte percentage of white cells;
UCEC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.46	-4.65	-0.36	7.48e-6	Menarche (age at onset);
UCEC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg18451016	chr1:38461880	NA	0.6	5.65	0.42	8.14e-8	Coronary artery disease;
UCEC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.65	0.36	7.42e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.5	-5.52	-0.41	1.51e-7	Parkinson's disease;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg14547644	chr6:28411285	ZSCAN23	0.59	6.68	0.48	4.68e-10	Pubertal anthropometrics;
UCEC	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.65	-4.59	-0.35	9.27e-6	Gut microbiome composition (summer);
UCEC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	5.11	0.39	1e-6	Neuroticism;
UCEC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.4	-5.1	-0.39	1.01e-6	Monocyte count;
UCEC	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-5.5	-0.41	1.61e-7	Hepatocellular carcinoma;
UCEC	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg21211680	chr2:198530	NA	-0.88	-4.67	-0.36	6.65e-6	Blood protein levels;
UCEC	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.82	-7.18	-0.51	3.21e-11	Vitiligo;
UCEC	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.56	4.93	0.38	2.17e-6	Monobrow;
UCEC	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.32	-5.56	-0.42	1.25e-7	Mean corpuscular volume;
UCEC	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	0.91	6.44	0.47	1.63e-9	Economic and political preferences (immigration/crime);
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.45	-4.8	-0.37	3.82e-6	Parkinson's disease;
UCEC	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-5.53	-0.42	1.41e-7	Asthma;
UCEC	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg02160872	chr5:212506	CCDC127	-0.78	-8.04	-0.55	2.73e-13	Breast cancer;
UCEC	cis	rs34034915	1	rs34034915	chr6:27720703	T/TG	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.51	-0.35	1.3e-5	Hepatitis A;
UCEC	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.13	-0.45	7.68e-9	Mean platelet volume;
UCEC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.58	-0.72	4.3e-25	Height;
UCEC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg08885076	chr2:99613938	TSGA10	0.41	4.65	0.36	7.42e-6	Chronic sinus infection;
UCEC	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.7	-6.7	-0.48	4.25e-10	Tonsillectomy;
UCEC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.7	-0.48	4.2e-10	Schizophrenia;
UCEC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg06970220	chr1:156163860	SLC25A44	0.46	4.65	0.36	7.31e-6	Testicular germ cell tumor;
UCEC	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg19318889	chr4:1322082	MAEA	0.44	5.12	0.39	9.41e-7	Longevity;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg04024692	chr11:16760046	C11orf58	0.72	7.51	0.53	5.32e-12	Triglyceride levels;
UCEC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg24163568	chr5:669837	TPPP	-0.43	-5.49	-0.41	1.73e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs4509693	0.882	rs7911997	chr10:102492380	A/G	cg24127310	chr10:102502104	NA	0.94	8.62	0.58	9.82e-15	Alzheimer's disease;
UCEC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.62	7.05	0.5	6.34e-11	Longevity;
UCEC	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-1.0	-10.51	-0.66	1.28e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	5.18	0.39	7.13e-7	IgG glycosylation;
UCEC	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-8.15	-0.56	1.5e-13	Colorectal cancer;
UCEC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg22166914	chr1:53195759	ZYG11B	0.68	7.26	0.51	2.07e-11	Monocyte count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24689420	chr5:179126339	CANX	0.59	7.05	0.5	6.35e-11	Warfarin maintenance dose;
UCEC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	4.6	0.35	8.93e-6	Schizophrenia;
UCEC	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.34	-5.0	-0.38	1.59e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	6.59	0.48	7.35e-10	Total cholesterol levels;
UCEC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.81	-9.05	-0.6	7.94e-16	Breast cancer;
UCEC	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.66	-0.42	7.82e-8	Life satisfaction;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03489495	chr6:33588875	ITPR3	0.59	7.1	0.51	4.84e-11	Warfarin maintenance dose;
UCEC	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.77	8.72	0.58	5.36e-15	Longevity;Endometriosis;
UCEC	cis	rs79815064	0.850	rs75352297	chr3:46345151	T/C	cg08033130	chr3:45983597	CXCR6;FYCO1	0.73	4.6	0.35	9.2e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.18	0.71	4.85e-24	Platelet count;
UCEC	cis	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg08722104	chr11:47448306	PSMC3	-0.41	-4.54	-0.35	1.18e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.5	5.24	0.4	5.57e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.62	8.04	0.55	2.76e-13	Anterior chamber depth;
UCEC	cis	rs7246967	0.673	rs62120313	chr19:22877183	G/C	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-7.81	-0.54	1.02e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.57	5.46	0.41	1.99e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg24562669	chr7:97807699	LMTK2	0.48	5.82	0.43	3.59e-8	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg18016565	chr1:150552671	MCL1	-0.55	-5.94	-0.44	2.02e-8	Tonsillectomy;
UCEC	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.92	-10.55	-0.66	1e-19	Height;
UCEC	cis	rs2279817	0.863	rs12139706	chr1:18026435	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.48	5.16	0.39	7.96e-7	Neuroticism;
UCEC	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg04154034	chr17:28927549	LRRC37B2	0.82	5.2	0.39	6.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.65	-7.74	-0.54	1.44e-12	Prevalent atrial fibrillation;
UCEC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-7.65	-0.53	2.41e-12	Chronic sinus infection;
UCEC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.73	6.95	0.5	1.13e-10	Aortic root size;
UCEC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.64	5.98	0.44	1.6e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.69	7.81	0.54	1.01e-12	Menopause (age at onset);
UCEC	cis	rs6547631	0.670	rs4832181	chr2:85916005	A/G	cg26394380	chr2:85896001	SFTPB	0.41	4.73	0.36	5.12e-6	Blood protein levels;
UCEC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.8	9.53	0.62	4.7e-17	Bone mineral density;
UCEC	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.68	5.73	0.43	5.53e-8	Adiposity;
UCEC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg22974920	chr21:40686053	BRWD1	-0.55	-5.15	-0.39	8.18e-7	Cognitive function;
UCEC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg24881330	chr22:46731750	TRMU	-0.58	-5.25	-0.4	5.26e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.54	-5.15	-0.39	8.22e-7	Vitiligo;
UCEC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.62	6.02	0.44	1.33e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs5770917	1.000	rs2269385	chr22:51010939	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.73	-4.86	-0.37	2.93e-6	Narcolepsy;
UCEC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg11871910	chr12:69753446	YEATS4	0.65	6.97	0.5	9.99e-11	Response to diuretic therapy;
UCEC	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.54	0.53	4.52e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4478037	1.000	rs4478037	chr3:33160407	G/A	cg19404215	chr3:33155277	CRTAP	-0.8	-6.65	-0.48	5.35e-10	Major depressive disorder;
UCEC	cis	rs2730245	0.608	rs2657391	chr7:158741776	T/C	cg24397884	chr7:158709396	WDR60	-0.9	-9.6	-0.62	2.99e-17	Height;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00177013	chr20:62339100	ARFRP1;ZGPAT	0.62	8.13	0.56	1.61e-13	Warfarin maintenance dose;
UCEC	cis	rs12982903	0.841	rs274796	chr19:5918207	G/A	cg27420590	chr19:5206640	PTPRS	-0.43	-4.57	-0.35	1.05e-5	Heart rate variability traits (SDNN);
UCEC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.93	-0.44	2.03e-8	Tonsillectomy;
UCEC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.47	-5.32	-0.4	3.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-11.87	-0.7	3.2e-23	Chronic sinus infection;
UCEC	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.49e-8	Depression;
UCEC	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	8.34	0.57	4.82e-14	Menopause (age at onset);
UCEC	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg05660106	chr1:15850417	CASP9	0.84	9.52	0.62	5.03e-17	Systolic blood pressure;
UCEC	cis	rs8010715	1.000	rs8010715	chr14:24609147	T/C	cg20933586	chr14:24608199	FAM158A	0.48	6.09	0.45	9.37e-9	IgG glycosylation;
UCEC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.47	-4.57	-0.35	1.02e-5	Parkinson's disease;
UCEC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg02551604	chr5:131831745	NA	-0.54	-4.88	-0.37	2.68e-6	Asthma (sex interaction);
UCEC	cis	rs798766	1.000	rs2305188	chr4:1739592	A/G	cg05874882	chr4:1763078	NA	-0.55	-5.8	-0.43	3.99e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7246967	0.673	rs12974988	chr19:22925965	G/T	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.45	6.13	0.45	7.88e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.54	-7.68	-0.54	2e-12	Height;
UCEC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg15848620	chr12:58087721	OS9	0.5	4.79	0.37	4.04e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.15	14.33	0.76	1.05e-29	Cognitive function;
UCEC	cis	rs787274	1.000	rs787276	chr9:115551891	T/C	cg13803584	chr9:115635662	SNX30	-0.69	-5.58	-0.42	1.13e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.04	11.79	0.7	5.47e-23	IgG glycosylation;
UCEC	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.61	-4.97	-0.38	1.86e-6	Exhaled nitric oxide output;
UCEC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.75	8.59	0.58	1.14e-14	Menarche (age at onset);
UCEC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg10902566	chr4:727664	PCGF3	-0.61	-5.12	-0.39	9.33e-7	Systolic blood pressure;
UCEC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.31	0.52	1.59e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	6.76	0.49	2.96e-10	Bipolar disorder and schizophrenia;
UCEC	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.68	7.42	0.52	8.64e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.53	-7.08	-0.5	5.56e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-5.06	-0.39	1.21e-6	Gut microbiome composition (summer);
UCEC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.89	11.99	0.7	1.53e-23	Bone mineral density;
UCEC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.71	-7.87	-0.54	7.19e-13	Menarche (age at onset);
UCEC	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.77	6.1	0.45	9.15e-9	Neuroticism;
UCEC	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.53	-0.35	1.2e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.62	-6.21	-0.46	5.12e-9	Blood metabolite levels;
UCEC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.55	5.1	0.39	1.04e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg21856205	chr7:94953877	PON1	-0.54	-5.2	-0.39	6.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs692916	0.704	rs493082	chr18:60597730	G/A	cg07187971	chr18:60481018	PHLPP1	-0.38	-4.69	-0.36	6.24e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg18232548	chr7:50535776	DDC	-0.67	-7.61	-0.53	3.1e-12	Body mass index;
UCEC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg22974920	chr21:40686053	BRWD1	-0.47	-4.66	-0.36	7.06e-6	Menarche (age at onset);
UCEC	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg18240653	chr6:144019428	PHACTR2	-0.63	-4.69	-0.36	6.31e-6	Obesity-related traits;
UCEC	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.57	0.35	1.03e-5	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.36	-5.22	-0.4	6.13e-7	Vitamin D levels;
UCEC	cis	rs7725816	0.792	rs10059165	chr5:147496963	C/T	cg10994339	chr5:147443536	SPINK5	-0.54	-4.57	-0.35	1.03e-5	Yeast infection;
UCEC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.75	-0.36	4.81e-6	Alzheimer's disease (late onset);
UCEC	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.25	-0.4	5.27e-7	Metabolite levels;
UCEC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-6.58	-0.48	7.9e-10	Total body bone mineral density;
UCEC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.6	4.67	0.36	6.7e-6	Gestational age at birth (maternal effect);
UCEC	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.15	-8.94	-0.59	1.48e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.67	-6.84	-0.49	2.02e-10	Prostate cancer;
UCEC	cis	rs4851266	1.000	rs11693324	chr2:100827753	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.62	-7.02	-0.5	7.8e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs925228	0.635	rs7591482	chr2:23933378	G/A	cg16901991	chr2:24272451	FKBP1B	0.53	5.02	0.38	1.46e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.57	-6.27	-0.46	3.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.57	-6.61	-0.48	6.5e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14159672	chr1:205819179	PM20D1	0.67	8.05	0.55	2.61e-13	Menarche (age at onset);
UCEC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.96	0.55	4.19e-13	Chronic sinus infection;
UCEC	cis	rs7011507	0.545	rs9298548	chr8:49071937	C/T	ch.8.1073630F	chr8:48637817	KIAA0146	-0.49	-4.57	-0.35	1.02e-5	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.58	-5.91	-0.44	2.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.71	6.8	0.49	2.43e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg11644478	chr21:40555479	PSMG1	0.81	8.21	0.56	1.05e-13	Cognitive function;
UCEC	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-6.35	-0.46	2.52e-9	Response to antipsychotic treatment;
UCEC	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.7	6.89	0.49	1.49e-10	Refractive astigmatism;
UCEC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.57	0.48	8.16e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.97	-0.44	1.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.94	9.26	0.61	2.28e-16	Initial pursuit acceleration;
UCEC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-5.12	-0.39	9.29e-7	Menarche (age at onset);
UCEC	cis	rs2540226	0.844	rs2716727	chr2:39953746	C/T	cg06149733	chr2:39876715	NA	-0.37	-4.61	-0.36	8.6e-6	Personality dimensions;
UCEC	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.55	4.96	0.38	1.9e-6	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs34795935	chr19:22865188	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.78	4.73	0.36	5.16e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.78	9.31	0.61	1.7e-16	Breast cancer;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	11.79	0.7	5.22e-23	Prudent dietary pattern;
UCEC	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-8.61	-0.58	1.04e-14	Total body bone mineral density;
UCEC	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg22974920	chr21:40686053	BRWD1	-0.53	-4.84	-0.37	3.28e-6	Cognitive function;
UCEC	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.45	-4.88	-0.37	2.73e-6	Height;
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.53	0.62	4.73e-17	Platelet count;
UCEC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg00339695	chr16:24857497	SLC5A11	0.52	5.91	0.44	2.31e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg04439458	chr5:138467593	SIL1	0.45	5.01	0.38	1.56e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg24851651	chr11:66362959	CCS	-0.41	-5.17	-0.39	7.55e-7	Educational attainment (years of education);
UCEC	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.64	6.25	0.46	4.2e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.95	-10.54	-0.66	1.05e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.61	4.76	0.37	4.51e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.91	8.31	0.57	5.68e-14	Bladder cancer;
UCEC	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-5.03	-0.38	1.43e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg07776626	chr8:57350775	NA	-0.46	-5.26	-0.4	5.05e-7	Obesity-related traits;
UCEC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.97	0.44	1.68e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7646881	0.544	rs13315529	chr3:158328274	C/T	cg05743054	chr3:158288903	MLF1	-0.54	-4.96	-0.38	1.89e-6	Tetralogy of Fallot;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.46	-4.88	-0.37	2.78e-6	Pubertal anthropometrics;
UCEC	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.87	-7.16	-0.51	3.51e-11	Coronary artery calcification;
UCEC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-9.44	-0.61	8.11e-17	Chronic sinus infection;
UCEC	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.85	-8.77	-0.59	4.19e-15	Itch intensity from mosquito bite;
UCEC	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.0	0.38	1.59e-6	Educational attainment;
UCEC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-4.51	-0.35	1.29e-5	Life satisfaction;
UCEC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-4.54	-0.35	1.17e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.81e-7	Heart rate;
UCEC	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.55	5.63	0.42	8.73e-8	Body mass index;
UCEC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg07153921	chr17:41440717	NA	-0.47	-4.69	-0.36	6.08e-6	Menopause (age at onset);
UCEC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.65	6.03	0.45	1.24e-8	Aortic root size;
UCEC	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	6.27	0.46	3.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs8105895	0.935	rs62110985	chr19:22256077	A/G	cg02912127	chr19:22235281	ZNF257	-0.63	-5.33	-0.4	3.6e-7	Body mass index (change over time);
UCEC	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.73	-4.75	-0.36	4.89e-6	Hair shape;
UCEC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.98	0.44	1.61e-8	Rheumatoid arthritis;
UCEC	cis	rs731174	0.840	rs525379	chr1:38151705	T/C	cg06917450	chr1:38156652	C1orf109	-0.58	-6.08	-0.45	9.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.57	6.02	0.44	1.35e-8	IgG glycosylation;
UCEC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.93	0.7	2.33e-23	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs240764	0.555	rs6919283	chr6:101235769	C/T	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.58	-6.32	-0.46	2.94e-9	Pubertal anthropometrics;
UCEC	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	7.34	0.52	1.38e-11	Coffee consumption (cups per day);
UCEC	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.54	-5.36	-0.4	3.17e-7	Systemic lupus erythematosus;
UCEC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.53	6.52	0.47	1.05e-9	Total body bone mineral density;
UCEC	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.81	-8.51	-0.57	1.81e-14	Lung cancer;
UCEC	cis	rs295140	0.903	rs10931898	chr2:201171191	C/G	cg04283868	chr2:201171347	SPATS2L	0.48	4.58	0.35	1e-5	QT interval;
UCEC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg22166914	chr1:53195759	ZYG11B	0.59	6.03	0.45	1.26e-8	Monocyte count;
UCEC	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.66	6.41	0.47	1.88e-9	Systemic lupus erythematosus;
UCEC	cis	rs4851266	1.000	rs4851268	chr2:100825864	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg08755490	chr11:65554678	OVOL1	0.5	5.31	0.4	3.89e-7	Acne (severe);
UCEC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.54	-6.75	-0.49	3.2e-10	Fibrinogen levels;
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.91	10.16	0.64	1.06e-18	Menarche (age at onset);
UCEC	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.42	-4.69	-0.36	6.22e-6	Pursuit maintenance gain;
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.5	-0.47	1.19e-9	Platelet count;
UCEC	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.8	4.94	0.38	2.09e-6	Arsenic metabolism;
UCEC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.63	6.77	0.49	2.88e-10	Menopause (age at onset);
UCEC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.61	-6.35	-0.46	2.58e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg13695892	chr22:41940480	POLR3H	-0.7	-5.49	-0.41	1.71e-7	Vitiligo;
UCEC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.48	5.13	0.39	9e-7	Corneal astigmatism;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.59	-0.75	9.52e-28	Schizophrenia;
UCEC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.06	-0.6	7.3e-16	Height;
UCEC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.54	-5.86	-0.44	2.94e-8	Obesity-related traits;
UCEC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg11569703	chr11:65557185	OVOL1	0.43	5.43	0.41	2.25e-7	Acne (severe);
UCEC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg14078730	chr11:63896557	MACROD1	0.6	4.8	0.37	3.9e-6	Mean platelet volume;
UCEC	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.33	-0.46	2.78e-9	Parkinson's disease;
UCEC	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.69	7.13	0.51	4.24e-11	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.69	6.18	0.45	5.88e-9	Subjective well-being;
UCEC	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.37	-5.84	-0.43	3.19e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.61	6.25	0.46	4.24e-9	Lymphocyte counts;
UCEC	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.64	0.48	5.77e-10	Coffee consumption (cups per day);
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.96	-0.38	1.96e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.72	5.36	0.4	3.2e-7	Menopause (age at onset);
UCEC	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg04756594	chr16:24857601	SLC5A11	0.5	5.78	0.43	4.33e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-5.77	-0.43	4.55e-8	Glomerular filtration rate;
UCEC	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.2	-0.51	2.92e-11	Heart rate;
UCEC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.52	5.88	0.44	2.69e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.96	10.49	0.65	1.47e-19	Cognitive function;
UCEC	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.51	5.97	0.44	1.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.62	5.96	0.44	1.79e-8	Calcium levels;
UCEC	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.49	-5.49	-0.41	1.68e-7	Life satisfaction;
UCEC	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.58	-5.74	-0.43	5.19e-8	Strep throat;
UCEC	cis	rs7246967	0.673	rs12984634	chr19:22833744	C/T	cg05241461	chr19:22816980	ZNF492	0.56	6.03	0.45	1.25e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg19567339	chr10:100142640	NA	0.54	6.37	0.47	2.27e-9	Metabolite levels;
UCEC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg27153327	chr16:1920815	C16orf73	-0.4	-4.62	-0.36	8.49e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg20399509	chr21:47717575	C21orf57	0.44	4.82	0.37	3.5e-6	Testicular germ cell tumor;
UCEC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.68	5.65	0.42	7.89e-8	Menopause (age at onset);
UCEC	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.57	-6.5	-0.47	1.19e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.55	6.36	0.46	2.45e-9	Blood metabolite ratios;
UCEC	cis	rs13401104	0.796	rs11887905	chr2:237114756	C/T	cg23897927	chr2:237117786	ASB18	-0.53	-4.74	-0.36	5e-6	Educational attainment;
UCEC	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg20485758	chr6:26088446	HFE	0.82	4.7	0.36	6e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.54	-0.35	1.17e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.44e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs12744221	1	rs12744221	chr1:145645606	C/T	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.62	-6.82	-0.49	2.25e-10	Epilepsy (remission after treatment);
UCEC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.44	-4.63	-0.36	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs334147	1.000	rs2176595	chr2:128230794	C/T	cg14478610	chr2:127864964	BIN1	-0.49	-4.84	-0.37	3.32e-6	Educational attainment;
UCEC	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.51	6.25	0.46	4.29e-9	Mean platelet volume;
UCEC	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-5.11	-0.39	9.87e-7	Bipolar disorder;
UCEC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-0.8	-9.59	-0.62	3.22e-17	Bone mineral density;
UCEC	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.7	-6.01	-0.44	1.37e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.8	-0.49	2.46e-10	Coffee consumption (cups per day);
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.78	6.0	0.44	1.49e-8	Platelet count;
UCEC	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.52	5.23	0.4	5.82e-7	Corneal astigmatism;
UCEC	cis	rs7709377	0.574	rs10062347	chr5:115495077	T/G	cg23108291	chr5:115420582	COMMD10	0.51	5.12	0.39	9.64e-7	Metabolite levels  (X-11787);
UCEC	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.56	6.21	0.46	5.08e-9	Platelet count;
UCEC	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.71	-7.14	-0.51	4.02e-11	Blood metabolite levels;
UCEC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.41	-0.47	1.85e-9	Crohn's disease;
UCEC	cis	rs2425143	0.730	rs6579259	chr20:34462550	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.56	-0.35	1.05e-5	Blood protein levels;
UCEC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.7	6.97	0.5	9.75e-11	Lymphocyte counts;
UCEC	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.88	-0.37	2.67e-6	Response to antipsychotic treatment;
UCEC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg11871910	chr12:69753446	YEATS4	0.79	8.54	0.58	1.59e-14	Blood protein levels;
UCEC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.84	-9.36	-0.61	1.26e-16	Cognitive function;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13338022	chr15:43029438	CDAN1	0.62	7.37	0.52	1.16e-11	Warfarin maintenance dose;
UCEC	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg13175173	chr14:55914753	NA	0.43	4.54	0.35	1.16e-5	Protein biomarker;
UCEC	cis	rs73129298	0.515	rs4647957	chr20:48600924	A/G	cg25655593	chr20:48599521	SNAI1	-0.57	-4.5	-0.35	1.35e-5	Inflammatory skin disease;
UCEC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05776053	chr2:74358815	NA	0.42	5.14	0.39	8.46e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs1003719	0.667	rs2298682	chr21:38444890	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.55	5.83	0.43	3.32e-8	Eye color traits;
UCEC	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.51	5.28	0.4	4.63e-7	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg21905437	chr5:178450457	ZNF879	0.63	7.06	0.5	6.14e-11	Pubertal anthropometrics;
UCEC	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.65	7.0	0.5	8.51e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg07930552	chr6:133119739	C6orf192	0.76	5.2	0.39	6.54e-7	Type 2 diabetes nephropathy;
UCEC	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.55	0.42	1.29e-7	Lung cancer in ever smokers;
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg04871131	chr7:94954202	PON1	-0.53	-5.19	-0.39	6.74e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.51	-5.43	-0.41	2.28e-7	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.08	-6.58	-0.48	7.7e-10	Breast cancer;
UCEC	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.56	-0.66	9.36e-20	Primary sclerosing cholangitis;
UCEC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.11	0.39	9.77e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6446731	0.614	rs7661630	chr4:3280106	G/A	cg08886695	chr4:3369023	RGS12	-0.4	-4.62	-0.36	8.36e-6	Mean platelet volume;
UCEC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.58	-5.45	-0.41	2.12e-7	Blood protein levels;
UCEC	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.63	-5.26	-0.4	4.89e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.54	6.23	0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.54	4.85	0.37	3.07e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2299682	0.826	rs3746547	chr20:9462036	C/T	cg11931762	chr20:9488920	NA	-0.66	-4.68	-0.36	6.56e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.67	6.5	0.47	1.19e-9	Triglycerides;
UCEC	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.57	-4.62	-0.36	8.39e-6	Blood protein levels;
UCEC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg22814929	chr6:26458213	BTN2A1	-0.61	-4.52	-0.35	1.29e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05776053	chr2:74358815	NA	0.43	4.82	0.37	3.53e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.44	-5.74	-0.43	5.27e-8	Prudent dietary pattern;
UCEC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs78487399	0.808	rs114563746	chr2:43760880	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-4.69	-0.36	6.1e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.85	7.61	0.53	3.06e-12	Body mass index;
UCEC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18252515	chr7:66147081	NA	-0.54	-5.27	-0.4	4.87e-7	Aortic root size;
UCEC	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.17	7.3	0.52	1.64e-11	Sexual dysfunction (female);
UCEC	cis	rs4372836	0.504	rs10177006	chr2:29088256	A/G	cg09522027	chr2:28974177	PPP1CB	-0.67	-7.11	-0.51	4.64e-11	Body mass index;
UCEC	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-4.52	-0.35	1.27e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.6	6.92	0.5	1.27e-10	Menarche (age at onset);
UCEC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg05991184	chr2:219186017	PNKD	-0.45	-4.81	-0.37	3.62e-6	Colorectal cancer;
UCEC	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.76	8.22	0.56	9.91e-14	Itch intensity from mosquito bite;
UCEC	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.57	-5.81	-0.43	3.76e-8	Colorectal cancer;
UCEC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg13147721	chr7:65941812	NA	-0.69	-4.83	-0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.95	-0.44	1.91e-8	Platelet count;
UCEC	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.69	7.63	0.53	2.74e-12	Graves' disease;
UCEC	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.73	-5.36	-0.4	3.22e-7	Fibroblast growth factor basic levels;
UCEC	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg24163568	chr5:669837	TPPP	0.4	4.73	0.36	5.13e-6	Obesity-related traits;
UCEC	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.49	5.0	0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.63	-5.39	-0.41	2.75e-7	Tonsillectomy;
UCEC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg14456004	chr13:21872349	NA	0.51	5.09	0.39	1.09e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.25	7.8	0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.49	-5.38	-0.41	2.9e-7	Aortic root size;
UCEC	cis	rs9467773	1.000	rs6918854	chr6:26577924	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.67	6.89	0.49	1.49e-10	Smoking behavior;
UCEC	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.56	5.04	0.38	1.37e-6	Corneal astigmatism;
UCEC	cis	rs10779169	0.860	rs11116841	chr12:85882558	C/T	cg10794058	chr12:85673918	ALX1	0.4	4.62	0.36	8.45e-6	Nose size;
UCEC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.23	0.4	5.73e-7	Birth weight;
UCEC	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.61	4.93	0.38	2.18e-6	Metabolite levels;
UCEC	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg14438399	chr17:27053147	TLCD1	0.58	4.67	0.36	6.84e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.16	-9.29	-0.61	1.95e-16	Vitiligo;
UCEC	trans	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg09045935	chr12:6379348	NA	-1.08	-6.99	-0.5	8.72e-11	Blood metabolite levels;
UCEC	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.55	-5.31	-0.4	3.98e-7	Cocaine dependence;
UCEC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg09904177	chr6:26538194	HMGN4	-0.74	-4.76	-0.37	4.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.4	-4.65	-0.36	7.29e-6	Blood protein levels;
UCEC	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs2079515	0.585	rs11077529	chr17:68902551	A/G	cg00928751	chr17:68172571	KCNJ2	-0.36	-4.51	-0.35	1.33e-5	Childhood and early adolescence aggressive behavior;
UCEC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.64	-5.29	-0.4	4.34e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.56	-4.99	-0.38	1.66e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.8	-6.97	-0.5	9.81e-11	Cognitive test performance;
UCEC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.44	5.27	0.4	4.77e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.800	rs7256135	chr19:23039121	A/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.22	-0.4	5.87e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-8.41	-0.57	3.26e-14	Cognitive function;
UCEC	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.41	-4.97	-0.38	1.87e-6	Dupuytren's disease;
UCEC	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.58	-0.42	1.11e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.01	0.55	3.25e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6060717	0.536	rs11697024	chr20:34546500	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.62	-0.36	8.41e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs4588572	0.686	rs116246588	chr5:77683144	T/G	cg11547950	chr5:77652471	NA	0.49	5.38	0.41	2.86e-7	Triglycerides;
UCEC	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.56	-5.37	-0.4	3.06e-7	Pediatric autoimmune diseases;
UCEC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.65	-6.27	-0.46	3.77e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7246967	0.673	rs12979173	chr19:22820681	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.52	4.95	0.38	1.99e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.63	5.82	0.43	3.63e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg22166914	chr1:53195759	ZYG11B	0.68	7.28	0.52	1.81e-11	Monocyte count;
UCEC	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg03114573	chr12:45410052	DBX2	-0.48	-5.67	-0.42	7.31e-8	Gut microbiome composition (summer);
UCEC	cis	rs7095607	0.813	rs4451608	chr10:69933238	C/A	cg18986048	chr10:69913749	MYPN	0.54	6.33	0.46	2.79e-9	Lung function (FVC);
UCEC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg04013166	chr16:89971882	TCF25	0.69	6.32	0.46	3.02e-9	Skin colour saturation;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg07838603	chr6:28411030	ZSCAN23	0.4	4.64	0.36	7.71e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg07817883	chr1:32538562	TMEM39B	1.16	9.38	0.61	1.15e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.44	5.05	0.38	1.27e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg05738196	chr6:26577821	NA	0.61	6.74	0.49	3.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg19743168	chr1:23544995	NA	0.46	6.43	0.47	1.67e-9	Height;
UCEC	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg12463550	chr7:65579703	CRCP	0.49	4.6	0.35	8.97e-6	Calcium levels;
UCEC	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.58	-5.98	-0.44	1.59e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.55	-5.73	-0.43	5.45e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4450798	0.553	rs59673460	chr3:13752594	A/C	cg21666675	chr3:14165843	TMEM43;CHCHD4	-0.46	-4.6	-0.35	8.94e-6	Bipolar disorder with mood-incongruent psychosis;
UCEC	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg06521331	chr12:34319734	NA	-0.58	-5.13	-0.39	9.18e-7	Morning vs. evening chronotype;
UCEC	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.48	-4.64	-0.36	7.61e-6	Tonsillectomy;
UCEC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	7.79	0.54	1.08e-12	Tonsillectomy;
UCEC	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.67	5.59	0.42	1.06e-7	Menopause (age at onset);
UCEC	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.62	-6.18	-0.45	6.04e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.8	0.49	2.44e-10	Coffee consumption (cups per day);
UCEC	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.95	-0.44	1.89e-8	Blood metabolite levels;
UCEC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.59	6.63	0.48	6.09e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.68	6.09	0.45	9.58e-9	Adiposity;
UCEC	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.48	5.22	0.4	5.87e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs3112255	0.512	rs11123842	chr2:101337982	A/G	cg01042948	chr2:101319752	NA	-0.45	-4.62	-0.36	8.28e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg09120320	chr17:61926383	NA	-0.44	-4.65	-0.36	7.18e-6	Prudent dietary pattern;
UCEC	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	19.67	0.85	5.22e-43	Schizophrenia;
UCEC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg16616514	chr4:6324629	PPP2R2C	0.42	5.05	0.38	1.29e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg21191810	chr6:118973309	C6orf204	0.44	5.98	0.44	1.6e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-10.34	-0.65	3.57e-19	Primary sclerosing cholangitis;
UCEC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12379764	chr21:47803548	PCNT	0.44	4.85	0.37	3.08e-6	Testicular germ cell tumor;
UCEC	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.5	4.79	0.37	4.06e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.63	-7.29	-0.52	1.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21584983	chr19:11640070	ECSIT	0.55	6.88	0.49	1.59e-10	Warfarin maintenance dose;
UCEC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.48	-4.66	-0.36	6.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs17123764	0.710	rs7962645	chr12:50150939	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	4.98	0.38	1.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.56	-4.92	-0.38	2.29e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs12318506	0.826	rs17804612	chr12:75671271	T/C	cg04728562	chr12:75699417	CAPS2	-0.8	-4.99	-0.38	1.7e-6	Coronary artery calcification;
UCEC	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg21419209	chr3:44054225	NA	-0.52	-5.56	-0.42	1.24e-7	Coronary artery disease;
UCEC	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.66	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.89	7.53	0.53	4.69e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.57	7.23	0.51	2.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg13695892	chr22:41940480	POLR3H	0.7	5.52	0.41	1.53e-7	Vitiligo;
UCEC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.82	8.83	0.59	2.81e-15	Blood protein levels;
UCEC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-7.2	-0.51	2.9e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg24069376	chr3:38537580	EXOG	0.46	5.69	0.42	6.59e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg22532475	chr10:104410764	TRIM8	0.37	4.58	0.35	9.86e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-5.12	-0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg16336494	chr6:151188259	MTHFD1L	0.42	4.81	0.37	3.69e-6	Bone mineral density;
UCEC	cis	rs740698	0.522	rs1024653	chr17:60791818	A/C	cg13195520	chr17:60813227	MARCH10	-0.36	-4.58	-0.35	9.88e-6	Pulse pressure;
UCEC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26207909	chr14:103986467	CKB	0.53	5.76	0.43	4.64e-8	Body mass index;
UCEC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.86	-0.43	2.97e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg20607287	chr7:12443886	VWDE	-0.64	-4.69	-0.36	6.11e-6	Coronary artery disease;
UCEC	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.41	4.84	0.37	3.31e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.61	5.72	0.43	5.78e-8	Aortic root size;
UCEC	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs7937612	0.965	rs4938801	chr11:120223399	C/T	cg12584626	chr11:120203529	NA	0.49	5.15	0.39	8.35e-7	Intraocular pressure;
UCEC	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg05347473	chr6:146136440	FBXO30	-0.41	-4.62	-0.36	8.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs10412972	0.623	rs2902879	chr19:52162859	A/G	cg02098413	chr6:105308735	HACE1	-0.87	-7.08	-0.5	5.44e-11	Plasma plasminogen levels;
UCEC	cis	rs2998286	0.678	rs332184	chr10:28912971	T/G	cg07964848	chr10:28035894	MKX	0.64	4.74	0.36	5.05e-6	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
UCEC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg19318889	chr4:1322082	MAEA	0.41	4.94	0.38	2.15e-6	Obesity-related traits;
UCEC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.51	5.4	0.41	2.59e-7	Sjögren's syndrome;
UCEC	cis	rs12618769	0.625	rs4850877	chr2:99112154	C/T	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.45	-0.41	2.04e-7	Bipolar disorder;
UCEC	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.29	-0.4	4.4e-7	Breast cancer;
UCEC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.53	4.95	0.38	1.97e-6	Blood metabolite levels;
UCEC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.64	5.45	0.41	2.06e-7	High light scatter reticulocyte count;
UCEC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.81	7.19	0.51	3.05e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	0.82	6.96	0.5	1.05e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6820391	0.816	rs7683461	chr4:54447863	C/T	cg04173182	chr4:54446035	LNX1	0.36	4.54	0.35	1.16e-5	Cervical artery dissection;
UCEC	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.69	-7.64	-0.53	2.62e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.78	9.27	0.61	2.13e-16	Platelet count;
UCEC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg24375607	chr4:120327624	NA	0.53	5.51	0.41	1.56e-7	Corneal astigmatism;
UCEC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.69	-0.42	6.8e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.75	6.23	0.46	4.72e-9	Fibroblast growth factor basic levels;
UCEC	cis	rs9596863	1.000	rs4471558	chr13:54413349	A/T	ch.13.53330881F	chr13:54432880	NA	0.55	4.94	0.38	2.11e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.73	7.89	0.55	6.48e-13	Breast cancer;
UCEC	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-6.25	-0.46	4.18e-9	Blood protein levels;
UCEC	cis	rs3772130	0.540	rs7627354	chr3:121562434	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.58	4.54	0.35	1.14e-5	White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg18099408	chr3:52552593	STAB1	0.38	4.58	0.35	9.96e-6	Body mass index;
UCEC	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg05874882	chr4:1763078	NA	-0.6	-6.91	-0.5	1.38e-10	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs1832871	1.000	rs1832871	chr6:158722034	C/T	cg07215822	chr6:158701037	NA	-0.56	-5.56	-0.42	1.26e-7	Height;
UCEC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg13147721	chr7:65941812	NA	-0.93	-5.86	-0.44	2.86e-8	Diabetic kidney disease;
UCEC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs350251	0.934	rs350256	chr16:12207491	G/A	cg01282078	chr16:12139025	RUNDC2A	-0.52	-4.92	-0.38	2.32e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg10820045	chr2:198174542	NA	-0.47	-5.77	-0.43	4.57e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg12024160	chr4:1254474	NA	0.65	7.77	0.54	1.25e-12	Obesity-related traits;
UCEC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg10596483	chr8:143751796	JRK	0.47	5.02	0.38	1.48e-6	Schizophrenia;
UCEC	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.68	9.26	0.61	2.36e-16	Systolic blood pressure;
UCEC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg05738196	chr6:26577821	NA	0.58	5.57	0.42	1.16e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs80130819	0.591	rs3803182	chr12:48398223	G/A	cg24011408	chr12:48396354	COL2A1	0.6	4.87	0.37	2.88e-6	Prostate cancer;
UCEC	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	1.01	9.79	0.63	1.01e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.5	4.72	0.36	5.34e-6	High light scatter reticulocyte count;
UCEC	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.5	-4.9	-0.37	2.51e-6	Coronary artery disease;
UCEC	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.65	-4.74	-0.36	4.95e-6	Coronary artery disease;
UCEC	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.75	7.69	0.54	1.94e-12	Parkinson's disease;
UCEC	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.78	-0.37	4.15e-6	Blood metabolite levels;
UCEC	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-0.69	-6.9	-0.49	1.45e-10	Height;
UCEC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.82	8.09	0.55	2.07e-13	Cognitive function;
UCEC	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.38	0.61	1.13e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.52	4.97	0.38	1.85e-6	Blood metabolite levels;
UCEC	cis	rs1595825	0.786	rs77218291	chr2:198565011	A/G	cg19156104	chr2:198669113	PLCL1	-0.63	-4.55	-0.35	1.12e-5	Ulcerative colitis;
UCEC	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.85	11.42	0.69	5e-22	Body mass index;
UCEC	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-4.99	-0.38	1.67e-6	Alzheimer's disease (late onset);
UCEC	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.5	4.75	0.36	4.83e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03264133	chr6:25882463	NA	0.57	5.15	0.39	8.16e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.63	-4.87	-0.37	2.86e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.55	6.04	0.45	1.23e-8	Aortic root size;
UCEC	cis	rs2179367	0.959	rs4895789	chr6:149764654	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.37	-4.74	-0.36	4.9100000000000004e-06	Dupuytren's disease;
UCEC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-8.24	-0.56	8.61e-14	Colorectal cancer;
UCEC	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.6	-6.02	-0.44	1.34e-8	Systemic lupus erythematosus;
UCEC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	5.98	0.44	1.6e-8	Cognitive test performance;
UCEC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.47	4.81	0.37	3.66e-6	Monocyte count;
UCEC	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg18681998	chr4:17616180	MED28	-0.57	-5.9	-0.44	2.42e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01973587	chr1:228161476	NA	0.37	4.95	0.38	2.02e-6	Diastolic blood pressure;
UCEC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.47	4.85	0.37	3.07e-6	Aortic root size;
UCEC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.6	6.63	0.48	5.95e-10	Total body bone mineral density;
UCEC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg11569703	chr11:65557185	OVOL1	0.4	4.55	0.35	1.11e-5	Acne (severe);
UCEC	cis	rs892864	0.614	rs11951790	chr5:127754746	A/G	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.66	4.74	0.36	4.9100000000000004e-06	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.73	-8.73	-0.58	5.09e-15	HDL cholesterol;
UCEC	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.53	8.95	0.59	1.44e-15	Airflow obstruction;
UCEC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg05802129	chr4:122689817	NA	-0.52	-5.27	-0.4	4.69e-7	Type 2 diabetes;
UCEC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.64	4.99	0.38	1.68e-6	Menopause (age at onset);
UCEC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-5.37	-0.4	3.04e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.79	8.51	0.57	1.9e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.46	4.89	0.37	2.62e-6	Height;
UCEC	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14019695	chr9:139328340	INPP5E	0.49	5.32	0.4	3.8e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11760485	0.838	rs4236351	chr7:4407317	C/A	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.58	-4.81	-0.37	3.65e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg13319975	chr6:146136371	FBXO30	0.42	4.53	0.35	1.21e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.51	-5.63	-0.42	8.67e-8	Breast cancer;
UCEC	cis	rs4778581	0.966	rs11072881	chr15:80400892	G/C	cg08257866	chr15:80351198	ZFAND6	0.4	4.58	0.35	9.67e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.88	-0.44	2.59e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.91	-0.44	2.28e-8	Response to antipsychotic treatment;
UCEC	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.82	0.37	3.61e-6	Rheumatoid arthritis;
UCEC	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg13175173	chr14:55914753	NA	-0.45	-4.7	-0.36	5.82e-6	Protein biomarker;
UCEC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg01973587	chr1:228161476	NA	0.37	4.94	0.38	2.11e-6	Diastolic blood pressure;
UCEC	cis	rs10012307	1.000	rs12649734	chr4:137510635	C/T	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.49	5.21	0.39	6.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.49	4.96	0.38	1.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg05962950	chr11:130786565	SNX19	0.75	6.94	0.5	1.17e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg14092571	chr14:90743983	NA	-0.44	-5.97	-0.44	1.69e-8	Mortality in heart failure;
UCEC	cis	rs7709377	0.571	rs6886944	chr5:115413042	C/T	cg23108291	chr5:115420582	COMMD10	0.46	4.5	0.35	1.36e-5	Metabolite levels  (X-11787);
UCEC	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7246967	1.000	rs12983770	chr19:23023614	A/G	cg05241461	chr19:22816980	ZNF492	0.46	4.81	0.37	3.75e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7178375	0.607	rs7171212	chr15:31207711	C/T	cg03767031	chr15:31195708	MTMR15	0.71	4.87	0.37	2.85e-6	Hypertriglyceridemia;
UCEC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-7.08	-0.5	5.44e-11	Cognitive function;
UCEC	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.47	5.23	0.4	5.63e-7	Emphysema distribution in smoking;
UCEC	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.79	-6.56	-0.48	8.67e-10	Corneal structure;
UCEC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.19	0.45	5.62e-9	Tonsillectomy;
UCEC	cis	rs10949834	0.540	rs810552	chr7:73489298	A/G	cg07137043	chr7:73588983	EIF4H	0.6	5.33	0.4	3.62e-7	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	0.99	11.11	0.68	3.31e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg23795048	chr12:9217529	LOC144571	0.43	5.03	0.38	1.38e-6	Sjögren's syndrome;
UCEC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.04	0.38	1.33e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.91	-11.78	-0.7	5.51e-23	Height;
UCEC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12516959	chr21:47718080	NA	-0.43	-4.52	-0.35	1.28e-5	Testicular germ cell tumor;
UCEC	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg25251562	chr2:3704773	ALLC	-0.41	-4.59	-0.35	9.32e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg12463550	chr7:65579703	CRCP	0.5	4.6	0.35	9.18e-6	Calcium levels;
UCEC	cis	rs13095912	1.000	rs7374856	chr3:185311964	A/C	cg11274856	chr3:185301563	NA	0.55	7.29	0.52	1.77e-11	Systolic blood pressure;
UCEC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.62	-5.2	-0.39	6.59e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs9463078	0.809	rs9357469	chr6:45049811	C/T	cg25276700	chr6:44698697	NA	-0.46	-5.01	-0.38	1.53e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Axial length;
UCEC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg03859395	chr2:55845619	SMEK2	0.99	13.59	0.75	9.11e-28	Metabolic syndrome;
UCEC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.88	-9.62	-0.62	2.74e-17	Obesity-related traits;
UCEC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	3.62e-18	Menopause (age at onset);
UCEC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.64	0.58	8.82e-15	Prudent dietary pattern;
UCEC	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.52	6.51	0.47	1.12e-9	Information processing speed;
UCEC	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.45	-4.74	-0.36	5.07e-6	Neutrophil percentage of white cells;
UCEC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.78	-0.37	4.26e-6	Parkinson's disease;
UCEC	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.73	8.55	0.58	1.43e-14	Menarche (age at onset);
UCEC	cis	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.6	-5.04	-0.38	1.33e-6	Parkinson's disease;
UCEC	cis	rs10012307	1.000	rs7696487	chr4:137488784	T/C	cg12033966	chr4:138453416	PCDH18	-0.71	-4.89	-0.37	2.59e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.2	0.56	1.07e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12118280	0.512	rs11185301	chr1:108741228	G/A	cg11967332	chr1:108735228	SLC25A24	0.69	4.81	0.37	3.67e-6	Myeloid white cell count;
UCEC	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.57	6.75	0.49	3.23e-10	Total body bone mineral density;
UCEC	cis	rs7580658	0.545	rs13001184	chr2:127952206	A/G	cg16751203	chr2:127950803	CYP27C1	0.4	5.38	0.41	2.82e-7	Protein C levels;
UCEC	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.37	-4.83	-0.37	3.33e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.9	10.95	0.67	8.94e-21	Breast cancer;
UCEC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18252515	chr7:66147081	NA	-0.53	-5.0	-0.38	1.65e-6	Aortic root size;
UCEC	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.79	8.75	0.59	4.62e-15	Metabolite levels;
UCEC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	7.8	0.54	1.07e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg19090574	chr1:205240910	TMCC2	-0.44	-4.52	-0.35	1.27e-5	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg13206674	chr6:150067644	NUP43	0.52	4.69	0.36	6.11e-6	Testicular germ cell tumor;
UCEC	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24249390	chr15:90295951	MESP1	-0.43	-4.97	-0.38	1.87e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.2	6.79	0.49	2.58e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.7	6.8	0.49	2.5e-10	Monocyte count;
UCEC	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.43	4.83	0.37	3.34e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.76	-8.44	-0.57	2.73e-14	Monocyte count;
UCEC	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.78	-0.37	4.15e-6	Blood metabolite levels;
UCEC	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.69	-6.16	-0.45	6.51e-9	Adiposity;
UCEC	cis	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.47	4.68	0.36	6.58e-6	Monocyte percentage of white cells;
UCEC	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg11632617	chr15:75315747	PPCDC	-0.55	-4.88	-0.37	2.7e-6	Lung cancer;
UCEC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-6.98	-0.5	9.57e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.57	6.46	0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs10208940	0.920	rs11886343	chr2:68750336	G/A	cg12452813	chr2:68675892	NA	0.48	4.59	0.35	9.31e-6	Urate levels in lean individuals;
UCEC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-9.41	-0.61	9.25e-17	Chronic sinus infection;
UCEC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg14067834	chr17:29058358	SUZ12P	0.64	4.58	0.35	9.8200000000000008e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.49	-5.32	-0.4	3.8e-7	Longevity;
UCEC	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.88	0.37	2.68e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	0.94	9.63	0.62	2.53e-17	Heart rate;
UCEC	cis	rs11761441	0.602	rs11771377	chr7:88622	A/G	cg06458707	chr7:1083209	C7orf50	0.25	4.63	0.36	7.9e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.7	-7.29	-0.52	1.73e-11	Cognitive function;
UCEC	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.75	8.41	0.57	3.38e-14	Coronary artery disease;
UCEC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.51	7.44	0.52	7.85e-12	Crohn's disease;
UCEC	cis	rs295137	0.798	rs1900706	chr2:201214071	A/C	cg04283868	chr2:201171347	SPATS2L	-0.63	-6.33	-0.46	2.86e-9	Asthma (bronchodilator response);
UCEC	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-17.08	-0.82	9.81e-37	Exhaled nitric oxide output;
UCEC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.36	-5.29	-0.4	4.41e-7	Ulcerative colitis;
UCEC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.84	-0.43	3.16e-8	Breast cancer;
UCEC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.49	0.47	1.21e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.56	6.38	0.47	2.19e-9	Longevity;Endometriosis;
UCEC	cis	rs45544231	1.000	rs45544231	chr16:52632730	G/C	cg09051775	chr16:52580266	TOX3	0.43	4.55	0.35	1.13e-5	Restless legs syndrome;
UCEC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-5.23	-0.4	5.76e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.51	0.47	1.11e-9	Coffee consumption (cups per day);
UCEC	cis	rs7404928	0.557	rs10775269	chr16:23912136	A/C	cg01062539	chr16:23765258	CHP2	-0.34	-4.91	-0.38	2.37e-6	Primary biliary cholangitis;Rheumatoid arthritis;
UCEC	cis	rs256277	0.657	rs255924	chr5:111378780	A/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	0.57	4.76	0.37	4.5e-6	Coronary artery disease;
UCEC	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07636037	chr3:49044803	WDR6	0.53	4.61	0.36	8.65e-6	Menarche (age at onset);
UCEC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.81	-0.49	2.27e-10	Tonsillectomy;
UCEC	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.54	-6.23	-0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.74	-4.81	-0.37	3.67e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.84	8.36	0.57	4.44e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs56804039	0.524	rs11785096	chr8:8372814	G/A	cg09615915	chr8:7625446	FAM90A10	-0.39	-4.6	-0.36	8.86e-6	Cervical cancer;
UCEC	trans	rs4389974	1.000	rs7001996	chr8:112382047	T/C	cg22736090	chr17:62339926	TEX2	0.66	6.98	0.5	9.62e-11	Body mass index;
UCEC	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.54	-5.32	-0.4	3.71e-7	Pediatric autoimmune diseases;
UCEC	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18252515	chr7:66147081	NA	-0.64	-6.14	-0.45	7.14e-9	Aortic root size;
UCEC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.77	7.94	0.55	4.8e-13	Parkinson's disease;
UCEC	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.71	-7.79	-0.54	1.1e-12	Breast cancer;
UCEC	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.19	0.45	5.79e-9	Platelet count;
UCEC	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.48	-4.7	-0.36	5.93e-6	Pediatric autoimmune diseases;
UCEC	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.58	5.32	0.4	3.74e-7	Coronary artery disease;
UCEC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.54	5.22	0.4	6.07e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.53	-5.33	-0.4	3.68e-7	Prostate cancer;
UCEC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.73	-6.77	-0.49	2.92e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-4.66	-0.36	6.98e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.86	-9.19	-0.6	3.46e-16	Lung cancer;
UCEC	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.17	0.64	1.02e-18	Electrocardiographic conduction measures;
UCEC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-5.99	-0.44	1.55e-8	Lymphocyte counts;
UCEC	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.38	-0.41	2.85e-7	Response to antipsychotic treatment;
UCEC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.88	9.28	0.61	1.99e-16	Cognitive function;
UCEC	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.69	-7.88	-0.54	6.73e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.65	-5.44	-0.41	2.18e-7	IgE levels in asthmatics (D.p. specific);
UCEC	trans	rs6581612	0.509	rs68078950	chr12:65618637	A/G	cg12591315	chr12:10022688	CLEC2B	-0.67	-6.74	-0.49	3.44e-10	Hippocampal volume;
UCEC	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-5.34	-0.4	3.5e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.65	-6.43	-0.47	1.64e-9	Morning vs. evening chronotype;
UCEC	cis	rs9362426	0.708	rs9342112	chr6:88092491	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	4.86	0.37	2.93e-6	Depressive episodes in bipolar disorder;
UCEC	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-6.47	-0.47	1.37e-9	Idiopathic membranous nephropathy;
UCEC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.48	5.28	0.4	4.54e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-5.08	-0.39	1.13e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.7	6.85	0.49	1.93e-10	Diastolic blood pressure;
UCEC	cis	rs12625057	1.000	rs12625057	chr20:57790436	G/T	cg15428904	chr20:57394097	GNASAS;MIR298;MIR296	-0.76	-4.71	-0.36	5.8e-6	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-5.99	-0.44	1.57e-8	Bipolar disorder;
UCEC	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.43	0.74	2.49e-27	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.72	7.25	0.51	2.21e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.53	6.76	0.49	3.03e-10	Weight;
UCEC	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs7246967	0.932	rs35968517	chr19:23027040	T/C	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.54e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.17	-0.56	1.33e-13	Exhaled nitric oxide output;
UCEC	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.13	0.39	8.89e-7	Heart rate;
UCEC	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.03	-13.03	-0.73	2.73e-26	Body mass index;
UCEC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.17	-0.45	6.2e-9	Aortic root size;
UCEC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.58	5.1	0.39	1.05e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.64	-5.88	-0.44	2.6e-8	Menarche (age at onset);
UCEC	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg15229765	chr7:158739774	NA	0.76	4.54	0.35	1.18e-5	Height;
UCEC	cis	rs10503871	0.625	rs4416792	chr8:30303833	A/C	cg26383811	chr8:30366931	RBPMS	0.43	4.51	0.35	1.3e-5	Metabolite levels  (X-11787);
UCEC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.65	0.42	8.09e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	0.84	5.39	0.41	2.75e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.93	0.38	2.22e-6	Tonsillectomy;
UCEC	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.44	5.0	0.38	1.63e-6	Migraine;
UCEC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.81	11.19	0.68	2.05e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23422044	chr7:1970798	MAD1L1	-0.42	-4.66	-0.36	7.1e-6	Neuroticism;
UCEC	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.49	5.39	0.41	2.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-6.02	-0.44	1.34e-8	Prevalent atrial fibrillation;
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.06	-0.39	1.21e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.5	5.23	0.4	5.7e-7	Red blood cell count;
UCEC	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg13683864	chr3:40499215	RPL14	0.87	10.15	0.64	1.11e-18	Renal cell carcinoma;
UCEC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg01097406	chr16:89675127	NA	0.37	5.44	0.41	2.21e-7	Vitiligo;
UCEC	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18252515	chr7:66147081	NA	0.46	4.72	0.36	5.33e-6	Aortic root size;
UCEC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg14008862	chr17:28927542	LRRC37B2	0.62	4.78	0.37	4.13e-6	Body mass index;
UCEC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.53	0.35	1.22e-5	Rheumatoid arthritis;
UCEC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.68	6.27	0.46	3.78e-9	Corneal astigmatism;
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs4654899	0.897	rs10799668	chr1:21169385	T/C	cg01072550	chr1:21505969	NA	0.47	4.66	0.36	7.01e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.14	-0.45	7.24e-9	Prudent dietary pattern;
UCEC	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.65	-9.06	-0.6	7.38e-16	Proinsulin levels;
UCEC	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.62	4.76	0.37	4.52e-6	Educational attainment;
UCEC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	5.24	0.4	5.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.59	5.06	0.39	1.21e-6	Menarche (age at onset);
UCEC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.62	-5.63	-0.42	8.94e-8	Gut microbiome composition (summer);
UCEC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg23307798	chr14:103986281	CKB	0.63	6.68	0.48	4.56e-10	Body mass index;
UCEC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg23018236	chr17:30244563	NA	-0.67	-4.83	-0.37	3.43e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs11867410	0.744	rs73992144	chr17:63949643	G/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg19268477	chr7:157951471	PTPRN2	0.38	6.2	0.46	5.34e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.76	7.04	0.5	6.65e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.73	8.95	0.59	1.41e-15	Total cholesterol levels;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.64	-6.79	-0.49	2.51e-10	Parkinson's disease;
UCEC	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.73	9.0	0.6	1.07e-15	Menarche (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02541231	chr11:2398776	CD81	0.56	6.83	0.49	2.1e-10	Warfarin maintenance dose;
UCEC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.64	-0.36	7.57e-6	Breast cancer;
UCEC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.66	6.89	0.49	1.55e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg00651523	chr6:28411279	ZSCAN23	-0.57	-6.87	-0.49	1.7e-10	Pubertal anthropometrics;
UCEC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.6e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.37	-4.89	-0.37	2.6e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg24562669	chr7:97807699	LMTK2	0.48	5.86	0.44	2.93e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7246967	0.611	rs57013651	chr19:22863027	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.14	0.45	7.36e-9	Lung cancer;
UCEC	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.99	-10.83	-0.67	1.86e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.64	7.1	0.51	4.97e-11	Monocyte count;
UCEC	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg00074818	chr8:8560427	CLDN23	0.39	4.77	0.37	4.31e-6	Neuroticism;
UCEC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.67	-7.7	-0.54	1.88e-12	Menarche (age at onset);
UCEC	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.55	-5.23	-0.4	5.77e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs295140	1.000	rs4516413	chr2:201163920	T/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs7781557	1.000	rs12113073	chr7:102482527	T/C	cg06322601	chr7:102330635	NA	0.67	5.62	0.42	9.26e-8	Colorectal adenoma (advanced);
UCEC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	1.01e-15	Menopause (age at onset);
UCEC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-1.0	-12.97	-0.73	3.91e-26	Monocyte count;
UCEC	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.83	0.49	2.06e-10	Coronary artery disease;
UCEC	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-10.38	-0.65	2.84e-19	Exhaled nitric oxide output;
UCEC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.54	-6.22	-0.46	5e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	1.04	14.04	0.76	6.14e-29	Ulcerative colitis;
UCEC	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.2	-0.39	6.62e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.72	8.45	0.57	2.6e-14	Body mass index;
UCEC	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.83	-10.21	-0.64	7.68e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.2	-0.64	8.28e-19	Blood metabolite levels;
UCEC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.63	6.05	0.45	1.17e-8	Aortic root size;
UCEC	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.48	5.01	0.38	1.56e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg20307385	chr11:47447363	PSMC3	-0.62	-5.26	-0.4	4.94e-7	Acute lymphoblastic leukemia (childhood);
UCEC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.54e-18	Height;
UCEC	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.43	4.95	0.38	2.02e-6	Alzheimer's disease (late onset);
UCEC	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.93	-0.38	2.22e-6	Coronary artery disease;
UCEC	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.43	-5.81	-0.43	3.64e-8	IgG glycosylation;
UCEC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.5	-0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.62	9.03	0.6	9.11e-16	Prudent dietary pattern;
UCEC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.44	4.66	0.36	6.98e-6	Longevity;Endometriosis;
UCEC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg01689657	chr7:91764605	CYP51A1	0.42	5.2	0.39	6.44e-7	Breast cancer;
UCEC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.64	-6.51	-0.47	1.09e-9	Body mass index;
UCEC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.57	-4.64	-0.36	7.65e-6	Gut microbiome composition (summer);
UCEC	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.54	5.65	0.42	8.16e-8	Corneal astigmatism;
UCEC	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.92	0.38	2.31e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg05962950	chr11:130786565	SNX19	-0.49	-4.8	-0.37	3.91e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.72	-5.84	-0.43	3.2e-8	Asthma;
UCEC	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.52	-5.26	-0.4	4.97e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-4.77	-0.37	4.39e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12292205	chr6:26970375	C6orf41	-0.65	-4.57	-0.35	1.05e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.51	-4.71	-0.36	5.72e-6	Diabetic retinopathy;
UCEC	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.08	8.14	0.56	1.56e-13	Corneal structure;
UCEC	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	0.82	6.55	0.48	9.1e-10	Response to hepatitis C treatment;
UCEC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.3	0.61	1.84e-16	Menopause (age at onset);
UCEC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg13147721	chr7:65941812	NA	0.94	6.91	0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.63	-6.79	-0.49	2.64e-10	Endometriosis;
UCEC	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.67	7.73	0.54	1.57e-12	Colorectal cancer;
UCEC	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.68	6.89	0.49	1.5e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs1575951	1.000	rs10829461	chr10:130445219	G/A	cg27041381	chr10:131357203	MGMT	0.6	5.08	0.39	1.11e-6	Plasma clusterin levels;
UCEC	cis	rs28795989	0.795	rs4696779	chr4:7919375	T/C	cg00251875	chr4:7801337	AFAP1	-0.56	-6.22	-0.46	4.79e-9	Intraocular pressure;
UCEC	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.54	-5.51	-0.41	1.53e-7	Blood protein levels;
UCEC	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.51	5.93	0.44	2.04e-8	Alcohol dependence;
UCEC	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.51	5.5	0.41	1.64e-7	Menarche (age at onset);
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	7.79	0.54	1.14e-12	Platelet count;
UCEC	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18854424	chr1:2615690	NA	0.39	5.85	0.43	3.1e-8	Ulcerative colitis;
UCEC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24308560	chr3:49941425	MST1R	0.43	4.68	0.36	6.42e-6	Body mass index;
UCEC	cis	rs6717918	0.564	rs3116181	chr2:233028070	A/G	cg02061626	chr2:233274167	ALPPL2	-0.54	-5.96	-0.44	1.77e-8	Height;
UCEC	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.38	-0.52	1.1e-11	Chronic sinus infection;
UCEC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.73	-0.49	3.48e-10	Total body bone mineral density;
UCEC	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.83	-8.76	-0.59	4.26e-15	Height;
UCEC	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.47	7.23	0.51	2.45e-11	Airflow obstruction;
UCEC	cis	rs405956	0.769	rs4945716	chr6:105573741	C/T	cg22580625	chr6:105627791	POPDC3	-0.54	-5.07	-0.39	1.17e-6	QT interval;
UCEC	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs76051363	0.500	rs73070422	chr4:1016645	C/G	cg03446427	chr4:1019985	FGFRL1	0.51	4.94	0.38	2.11e-6	Total body bone mineral density;
UCEC	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.64	5.93	0.44	2.07e-8	Refractive astigmatism;
UCEC	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg01072550	chr1:21505969	NA	0.63	6.59	0.48	7.4e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg03934865	chr2:198174659	NA	-0.41	-5.15	-0.39	8.23e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09564133	chr5:176738847	MXD3	0.59	7.41	0.52	8.93e-12	Warfarin maintenance dose;
UCEC	cis	rs11760485	0.782	rs2107837	chr7:4404751	C/A	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.64	4.67	0.36	6.65e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.65	7.01	0.5	7.84e-11	Lewy body disease;
UCEC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.44	5.1	0.39	1.01e-6	Mortality in heart failure;
UCEC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg24881330	chr22:46731750	TRMU	0.75	7.51	0.53	5.23e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.64	7.68	0.53	2.09e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.34e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.49	-5.74	-0.43	5.13e-8	Pulse pressure;
UCEC	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.38	-4.89	-0.37	2.57e-6	Type 2 diabetes;
UCEC	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.56	5.02	0.38	1.45e-6	Corneal astigmatism;
UCEC	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.45	-0.41	2.08e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs2299682	0.826	rs6077547	chr20:9467132	C/T	cg11931762	chr20:9488920	NA	-0.72	-5.21	-0.39	6.32e-7	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg05623727	chr3:50126028	RBM5	0.35	4.53	0.35	1.19e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.1	-0.45	8.75e-9	Parkinson's disease;
UCEC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.5	-5.48	-0.41	1.8e-7	Aortic root size;
UCEC	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.62	7.13	0.51	4.16e-11	Blood metabolite ratios;
UCEC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-4.67	-0.36	6.87e-6	Life satisfaction;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.59	-6.09	-0.45	9.45e-9	Parkinson's disease;
UCEC	cis	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg00614314	chr15:82944287	LOC80154	0.68	6.53	0.47	1.01e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.02	-8.46	-0.57	2.5e-14	Exhaled nitric oxide output;
UCEC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	trans	rs6479901	0.895	rs1904296	chr10:64932779	C/G	cg12751693	chr12:62629162	NA	-0.57	-7.21	-0.51	2.76e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-4.69	-0.36	6.27e-6	Tonsillectomy;
UCEC	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.59	5.49	0.41	1.71e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.54	-6.17	-0.45	6.3e-9	Mean platelet volume;
UCEC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.46	4.69	0.36	6.18e-6	Schizophrenia;
UCEC	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg07386859	chr16:1872102	HAGH	-0.46	-4.96	-0.38	1.93e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	0.91	12.01	0.7	1.42e-23	Menarche (age at onset);
UCEC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg26721908	chr21:47610096	LSS	-0.37	-4.65	-0.36	7.3e-6	Testicular germ cell tumor;
UCEC	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-5.68	-0.42	7.12e-8	Metabolite levels;
UCEC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.62	5.6	0.42	9.99e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1867485	0.649	rs9674202	chr16:86672941	C/T	cg02124446	chr16:85783537	C16orf74	-0.38	-5.37	-0.4	3.06e-7	Obesity-related traits;
UCEC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.66	5.38	0.41	2.87e-7	Corneal astigmatism;
UCEC	cis	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg11437231	chr11:47291487	MADD	-0.54	-5.53	-0.42	1.41e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.99	6.37	0.47	2.28e-9	LDL cholesterol;
UCEC	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.71	-0.36	5.62e-6	Blood metabolite levels;
UCEC	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg20825769	chr15:43991375	CKMT1A	-0.5	-4.67	-0.36	6.59e-6	Lung cancer in ever smokers;
UCEC	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	2.01e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.52	-7.0	-0.5	8.24e-11	Eye color traits;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.75	9.29	0.61	1.9e-16	Menarche (age at onset);
UCEC	trans	rs4534959	0.546	rs79468097	chr18:62061342	A/G	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs61776719	0.905	rs28570969	chr1:38407146	A/G	cg18451016	chr1:38461880	NA	0.67	7.44	0.52	7.82e-12	Coronary artery disease;
UCEC	cis	rs28795989	0.795	rs17770447	chr4:7903572	T/C	cg00251875	chr4:7801337	AFAP1	0.48	5.7	0.43	6.41e-8	Intraocular pressure;
UCEC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.95e-6	Breast cancer;
UCEC	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg16584290	chr5:462447	EXOC3	-0.44	-4.57	-0.35	1.03e-5	Cystic fibrosis severity;
UCEC	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg19792802	chr11:65647270	CTSW	0.5	4.63	0.36	8.11e-6	Crohn's disease;
UCEC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.54	-5.3	-0.4	4.09e-7	Menopause (age at onset);
UCEC	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg19773385	chr1:10388646	KIF1B	-0.47	-4.95	-0.38	2.05e-6	Hepatocellular carcinoma;
UCEC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.41	4.76	0.37	4.65e-6	Total body bone mineral density;
UCEC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.59	6.26	0.46	4.03e-9	Red cell distribution width;
UCEC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.1	17.94	0.83	7.3e-39	IgG glycosylation;
UCEC	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.33	4.87	0.37	2.88e-6	Ulcerative colitis;
UCEC	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.71	8.16	0.56	1.35e-13	Body mass index;
UCEC	trans	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.78	-9.08	-0.6	6.79e-16	Longevity;Endometriosis;
UCEC	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.9	10.04	0.64	2.18e-18	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-4.86	-0.37	2.92e-6	Longevity;Endometriosis;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.82	-9.79	-0.63	9.63e-18	Coronary artery disease;
UCEC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.83	-8.49	-0.57	2.02e-14	Breast cancer;
UCEC	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg14092571	chr14:90743983	NA	-0.42	-5.72	-0.43	5.65e-8	Mortality in heart failure;
UCEC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.87	0.37	2.86e-6	Aortic root size;
UCEC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.77	-9.02	-0.6	9.67e-16	Menarche (age at onset);
UCEC	cis	rs2386661	0.826	rs11255996	chr10:5670832	G/A	cg17085576	chr10:5658249	NA	-0.47	-4.85	-0.37	3.11e-6	Breast cancer;
UCEC	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	17.97	0.83	6.28e-39	Colorectal cancer;
UCEC	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.54	5.61	0.42	9.94e-8	Breast cancer;
UCEC	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg03354898	chr7:1950403	MAD1L1	-0.53	-6.31	-0.46	3.18e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.56	5.15	0.39	8.22e-7	Pulse pressure;
UCEC	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.95	-0.59	1.4e-15	Exhaled nitric oxide output;
UCEC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.53	-4.8	-0.37	3.81e-6	Corneal astigmatism;
UCEC	cis	rs3956705	0.966	rs1037324	chr7:32981161	A/C	cg05721444	chr7:32995514	FKBP9	-0.5	-4.95	-0.38	2.01e-6	Red cell distribution width;
UCEC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.55	6.86	0.49	1.82e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4588572	0.643	rs7716529	chr5:77738637	A/T	cg11547950	chr5:77652471	NA	-0.45	-4.75	-0.37	4.7e-6	Triglycerides;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.44	-0.41	2.2e-7	Depression;
UCEC	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.67	-8.09	-0.55	2.09e-13	IgG glycosylation;
UCEC	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-7.72	-0.54	1.66e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.69	-6.67	-0.48	4.88e-10	HDL cholesterol;
UCEC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.55	5.42	0.41	2.36e-7	Response to diuretic therapy;
UCEC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.7	7.46	0.52	6.78e-12	Coronary artery disease;
UCEC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.61	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.44	4.56	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.33	-4.63	-0.36	7.87e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4853036	0.762	rs4853017	chr2:70011316	T/C	cg02498382	chr2:70120550	SNRNP27	-0.47	-4.68	-0.36	6.55e-6	Colorectal or endometrial cancer;
UCEC	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.49	5.58	0.42	1.15e-7	Educational attainment;
UCEC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg23795048	chr12:9217529	LOC144571	0.4	4.69	0.36	6.14e-6	Sjögren's syndrome;
UCEC	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.63	0.42	9.08e-8	Tonsillectomy;
UCEC	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.71	-7.73	-0.54	1.55e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.56	5.29	0.4	4.44e-7	Red cell distribution width;
UCEC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.5	-0.47	1.17e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6893807	0.778	rs13173305	chr5:87945377	A/G	cg09002922	chr5:87956389	LOC645323	-0.56	-5.35	-0.4	3.27e-7	Body mass index;
UCEC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	7.01	0.5	8.17e-11	Homoarginine levels;
UCEC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.89	7.12	0.51	4.47e-11	Exhaled nitric oxide output;
UCEC	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.38	0.52	1.07e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg05132306	chr1:1846340	CALML6	-0.36	-4.61	-0.36	8.74e-6	Body mass index;
UCEC	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg23260525	chr10:116636907	FAM160B1	0.34	4.59	0.35	9.63e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.32	-0.46	2.96e-9	Response to antipsychotic treatment;
UCEC	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs3824488	0.790	rs28520225	chr9:98243187	A/C	cg14565164	chr9:98057177	FANCC	0.67	4.89	0.37	2.57e-6	Neuroticism;
UCEC	cis	rs2302190	0.769	rs8082396	chr17:56632193	C/T	cg12560992	chr17:57184187	TRIM37	0.53	4.7	0.36	6.02e-6	Vitamin D levels;
UCEC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	6.84	0.49	2.02e-10	Platelet count;
UCEC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs41997	0.758	rs41919	chr7:117913648	G/A	cg08545129	chr7:117854304	NA	-0.38	-4.63	-0.36	7.93e-6	Response to platinum-based chemotherapy in non-small-cell lung cancer;
UCEC	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-7.47	-0.52	6.57e-12	Coffee consumption (cups per day);
UCEC	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	4.55	0.35	1.1e-5	Refractive astigmatism;
UCEC	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg13683864	chr3:40499215	RPL14	0.65	6.86	0.49	1.75e-10	Renal cell carcinoma;
UCEC	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.53	4.9	0.38	2.45e-6	Morning vs. evening chronotype;
UCEC	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.54	6.33	0.46	2.83e-9	Mean corpuscular volume;
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs4778581	0.808	rs1056018	chr15:80424934	A/G	cg08257866	chr15:80351198	ZFAND6	0.4	4.65	0.36	7.28e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.87	-12.82	-0.73	9.89e-26	Leprosy;
UCEC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.53	5.45	0.41	2.04e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	1.02	11.19	0.68	2.01e-21	Corneal structure;
UCEC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.53	4.82	0.37	3.53e-6	Platelet count;
UCEC	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg03264133	chr6:25882463	NA	-0.58	-4.62	-0.36	8.22e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/A	cg04311860	chr7:1937321	MAD1L1	0.56	4.53	0.35	1.22e-5	Neuroticism;
UCEC	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	0.72	5.34	0.4	3.52e-7	Blood protein levels;
UCEC	cis	rs3026445	0.791	rs7309141	chr12:110587637	G/A	cg12870014	chr12:110450643	ANKRD13A	0.45	4.88	0.37	2.7e-6	QT interval;
UCEC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg09655341	chr17:79618100	PDE6G	-0.31	-4.76	-0.37	4.53e-6	Eye color traits;
UCEC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg02175503	chr12:58329896	NA	0.55	4.63	0.36	7.95e-6	Multiple sclerosis;
UCEC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.61	-6.21	-0.46	5.03e-9	Blood metabolite levels;
UCEC	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-4.56	-0.35	1.08e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.51	4.68	0.36	6.54e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	5.05	0.38	1.28e-6	Height;
UCEC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.89	-0.37	2.6e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.56	5.52	0.41	1.49e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-6.03	-0.45	1.26e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-8.13	-0.56	1.62e-13	Morning vs. evening chronotype;
UCEC	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.57e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.43	5.39	0.41	2.78e-7	Tonsillectomy;
UCEC	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.75	6.23	0.46	4.72e-9	Fibroblast growth factor basic levels;
UCEC	cis	rs28795989	0.896	rs34685551	chr4:7887463	C/A	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.74	-7.68	-0.54	2.08e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.34	0.61	1.46e-16	Coffee consumption (cups per day);
UCEC	cis	rs4499344	0.730	rs259279	chr19:33161274	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.9	-9.19	-0.6	3.5e-16	Mean platelet volume;
UCEC	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg00546932	chr16:1947055	NA	0.37	5.18	0.39	7.16e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs749052	0.561	rs6756741	chr2:233026178	A/C	cg23548455	chr2:233377587	NA	-0.69	-4.53	-0.35	1.23e-5	Height;
UCEC	cis	rs4372836	0.504	rs6547881	chr2:29032746	C/T	cg09522027	chr2:28974177	PPP1CB	0.69	7.13	0.51	4.3e-11	Body mass index;
UCEC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.55	4.79	0.37	4.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.5	4.58	0.35	9.7e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.36	5.17	0.39	7.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-4.93	-0.38	2.17e-6	Metabolite levels;
UCEC	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.62	6.11	0.45	8.51e-9	Colorectal cancer;
UCEC	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.55	6.06	0.45	1.12e-8	Neuroticism;
UCEC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.6	-5.79	-0.43	4.17e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-4.83	-0.37	3.38e-6	Pediatric autoimmune diseases;
UCEC	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.54	5.25	0.4	5.19e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7709377	0.570	rs6876901	chr5:115432690	T/G	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg10845886	chr2:3471009	TTC15	-0.54	-4.83	-0.37	3.43e-6	Neurofibrillary tangles;
UCEC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.62	0.48	6.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	6.16	0.45	6.52e-9	Personality dimensions;
UCEC	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.65	6.79	0.49	2.57e-10	Mean corpuscular volume;
UCEC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.43	5.41	0.41	2.55e-7	Migraine;
UCEC	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.69	-5.98	-0.44	1.59e-8	Diastolic blood pressure;
UCEC	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.62	0.42	9.11e-8	Platelet count;
UCEC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.72	-5.46	-0.41	1.97e-7	White matter hyperintensity burden;
UCEC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.38	0.47	2.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg15147215	chr3:52552868	STAB1	-0.44	-4.67	-0.36	6.84e-6	Electroencephalogram traits;
UCEC	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-5.65	-0.42	7.89e-8	Hemoglobin concentration;
UCEC	cis	rs10946940	0.930	rs10807029	chr6:27573463	G/A	cg13525197	chr6:28411240	ZSCAN23	0.43	4.73	0.36	5.24e-6	Systemic lupus erythematosus;
UCEC	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg03078520	chr22:18463400	MICAL3	-0.53	-4.99	-0.38	1.69e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs9810890	0.764	rs59037701	chr3:128562299	A/G	cg24249734	chr3:127872125	EEFSEC	-0.63	-5.32	-0.4	3.86e-7	Dental caries;
UCEC	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-0.67	-6.79	-0.49	2.59e-10	Platelet distribution width;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.58	-6.56	-0.48	8.41e-10	Pubertal anthropometrics;
UCEC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.54	-5.92	-0.44	2.23e-8	Prostate cancer;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.04	-0.38	1.34e-6	Parkinson's disease;
UCEC	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-1.29	-6.88	-0.49	1.61e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg27624424	chr6:160112604	SOD2	0.57	4.52	0.35	1.26e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.63	7.01	0.5	7.99e-11	Body mass index;
UCEC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.86	0.43	2.98e-8	Breast cancer;
UCEC	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.5	4.94	0.38	2.08e-6	Triglycerides;
UCEC	cis	rs1575951	1.000	rs7903070	chr10:130438539	G/A	cg27041381	chr10:131357203	MGMT	0.6	5.23	0.4	5.71e-7	Plasma clusterin levels;
UCEC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.22	-6.97	-0.5	9.87e-11	Diabetic kidney disease;
UCEC	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.51	-5.67	-0.42	7.31e-8	Life satisfaction;
UCEC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg04310649	chr10:35416472	CREM	0.48	4.76	0.37	4.63e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-13.17	-0.74	1.17e-26	Schizophrenia;
UCEC	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	7.45	0.52	7.48e-12	Motion sickness;
UCEC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg01973587	chr1:228161476	NA	0.37	4.94	0.38	2.12e-6	Diastolic blood pressure;
UCEC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	trans	rs4389974	0.932	rs989848	chr8:112411563	G/A	cg22736090	chr17:62339926	TEX2	0.66	6.88	0.49	1.58e-10	Body mass index;
UCEC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-4.67	-0.36	6.61e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.9	12.01	0.7	1.39e-23	Metabolic syndrome;
UCEC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.55	-0.48	9.07e-10	Blood metabolite levels;
UCEC	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg25258258	chr7:157415380	PTPRN2	-0.45	-4.54	-0.35	1.16e-5	Colorectal cancer;
UCEC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg24562669	chr7:97807699	LMTK2	0.48	5.93	0.44	2.09e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.81	10.45	0.65	1.87e-19	Menarche (age at onset);
UCEC	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs58722170	0.659	rs61776209	chr1:38090323	C/T	cg17933807	chr1:38061675	GNL2	-0.64	-5.62	-0.42	9.13e-8	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg20821713	chr7:1055600	C7orf50	-0.57	-6.13	-0.45	7.58e-9	Longevity;Endometriosis;
UCEC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg10820045	chr2:198174542	NA	-0.47	-5.91	-0.44	2.27e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	11.07	0.67	4.16e-21	Leprosy;
UCEC	cis	rs6437061	0.805	rs1078093	chr2:233087245	G/A	cg20569070	chr2:232597279	PDE6D	-0.43	-4.9	-0.37	2.54e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.73	-8.71	-0.58	5.74e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	6.24	0.46	4.5e-9	Platelet count;
UCEC	cis	rs4372836	0.729	rs7567861	chr2:29035849	C/T	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.77	-0.54	1.27e-12	Body mass index;
UCEC	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.71	-8.96	-0.59	1.34e-15	Prevalent atrial fibrillation;
UCEC	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.88	9.36	0.61	1.3e-16	Ulcerative colitis;
UCEC	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-5.34	-0.4	3.46e-7	Alcohol dependence;
UCEC	cis	rs7246967	0.544	rs420861	chr19:23005904	G/T	cg24889512	chr19:22816950	ZNF492	0.49	4.64	0.36	7.54e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.71	6.04	0.45	1.23e-8	Lung function (FEV1/FVC);
UCEC	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg13206674	chr6:150067644	NUP43	0.52	4.78	0.37	4.26e-6	Testicular germ cell tumor;
UCEC	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.52	6.44	0.47	1.61e-9	Total body bone mineral density;
UCEC	cis	rs7246967	0.611	rs4933019	chr19:22831986	A/G	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7095607	0.693	rs7896727	chr10:69952376	C/T	cg18986048	chr10:69913749	MYPN	0.52	5.79	0.43	4.2e-8	Lung function (FVC);
UCEC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.68	-6.15	-0.45	6.86e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7709377	0.597	rs11951865	chr5:115492280	G/T	cg23108291	chr5:115420582	COMMD10	0.53	5.39	0.41	2.72e-7	Metabolite levels  (X-11787);
UCEC	cis	rs1519814	1.000	rs6469902	chr8:121171911	A/T	cg22335954	chr8:121166405	COL14A1	-0.66	-5.35	-0.4	3.32e-7	Breast cancer;
UCEC	cis	rs883565	0.569	rs784509	chr3:39166355	G/A	cg01426195	chr3:39028469	NA	0.62	7.39	0.52	1.01e-11	Handedness;
UCEC	cis	rs11867410	0.744	rs78474542	chr17:63970343	C/T	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg14078730	chr11:63896557	MACROD1	0.76	5.3	0.4	4.19e-7	Mean platelet volume;
UCEC	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-7.37	-0.52	1.16e-11	Hypospadias;
UCEC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.83	0.37	3.38e-6	Personality dimensions;
UCEC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.39	-9.01	-0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	6.66	0.48	5.09e-10	Platelet count;
UCEC	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.68	-0.62	1.85e-17	Primary sclerosing cholangitis;
UCEC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.67	-6.96	-0.5	1.06e-10	Breast cancer;
UCEC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.9	8.57	0.58	1.32e-14	Colorectal adenoma (advanced);
UCEC	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.41	9.26	0.61	2.27e-16	Gout;
UCEC	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18932078	chr1:2524107	MMEL1	-0.33	-5.37	-0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs7709377	0.595	rs712591	chr5:115657285	G/A	cg23108291	chr5:115420582	COMMD10	-0.45	-4.6	-0.36	8.89e-6	Metabolite levels  (X-11787);
UCEC	cis	rs4757319	0.515	rs4313573	chr11:15330598	A/G	cg03245590	chr11:15329459	NA	0.48	5.91	0.44	2.25e-8	Breast cancer;
UCEC	cis	rs4654899	0.604	rs12031023	chr1:21148839	A/G	cg01072550	chr1:21505969	NA	0.52	5.22	0.4	6.05e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.67	6.36	0.46	2.41e-9	Bladder cancer;
UCEC	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.75	-8.27	-0.56	7.41e-14	Ulcerative colitis;
UCEC	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.82	10.91	0.67	1.12e-20	Body mass index;
UCEC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.46	5.29	0.4	4.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg04155231	chr12:9217510	LOC144571	0.41	5.08	0.39	1.12e-6	Sjögren's syndrome;
UCEC	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.51	4.86	0.37	2.97e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.5	-4.89	-0.37	2.59e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.57	6.07	0.45	1.03e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs78487399	0.808	rs17031005	chr2:43761299	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.01	-0.38	1.56e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs240764	0.659	rs240776	chr6:101020453	T/C	cg09795085	chr6:101329169	ASCC3	-0.48	-5.3	-0.4	4.17e-7	Neuroticism;
UCEC	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.78	7.11	0.51	4.76e-11	Morning vs. evening chronotype;
UCEC	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.26	-0.4	4.92e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg08994789	chr17:28903642	LRRC37B2	0.46	5.48	0.41	1.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.69	5.83	0.43	3.35e-8	Alzheimer's disease;
UCEC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.45	-5.03	-0.38	1.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.6	5.79	0.43	4.16e-8	Vitamin D levels;
UCEC	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.34	-0.46	2.66e-9	Parkinson's disease;
UCEC	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.51	5.49	0.41	1.74e-7	Breast cancer;
UCEC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-0.72	-7.1	-0.51	4.83e-11	Breast cancer;
UCEC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.99	7.33	0.52	1.43e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.46	5.23	0.4	5.6e-7	Blood protein levels;
UCEC	cis	rs7246967	0.673	rs3853653	chr19:22871932	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs2389217	0.614	rs7309229	chr12:33592681	C/G	cg12743970	chr17:64536520	PRKCA	-0.58	-6.88	-0.49	1.57e-10	Morning vs. evening chronotype;
UCEC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-5.72	-0.43	5.66e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.54	5.84	0.43	3.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.81	-0.37	3.75e-6	Parkinson's disease;
UCEC	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	4.99	0.38	1.69e-6	Monocyte count;
UCEC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.65	4.59	0.35	9.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.92	9.83	0.63	7.61e-18	Cognitive function;
UCEC	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.57	5.26	0.4	5.09e-7	QRS complex (12-leadsum);
UCEC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg24069376	chr3:38537580	EXOG	0.46	5.68	0.42	6.83e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg23625390	chr15:77176239	SCAPER	0.48	4.77	0.37	4.33e-6	Blood metabolite levels;
UCEC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.17e-21	Breast cancer;
UCEC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.66	-7.56	-0.53	4.02e-12	Body mass index;
UCEC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.75	-6.42	-0.47	1.78e-9	Type 2 diabetes;
UCEC	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-7.12	-0.51	4.33e-11	Ulcerative colitis;
UCEC	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.67	6.2	0.46	5.41e-9	Schizophrenia;
UCEC	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.58	5.72	0.43	5.81e-8	Lung cancer;
UCEC	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-4.9	-0.37	2.46e-6	Bone mineral density;
UCEC	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.57	6.69	0.48	4.29e-10	Multiple myeloma;
UCEC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.14	15.2	0.78	5.94e-32	Cognitive function;
UCEC	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg01112020	chr2:239008986	ESPNL	-0.35	-4.73	-0.36	5.17e-6	Prostate cancer;
UCEC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.43	-4.9	-0.37	2.53e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg10932868	chr11:921992	NA	-0.43	-5.79	-0.43	4.16e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.58	-5.85	-0.43	3.02e-8	Retinal vascular caliber;
UCEC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.74	4.61	0.36	8.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.22	5.24	0.4	5.42e-7	Psoriasis vulgaris;
UCEC	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.61	-6.12	-0.45	8.19e-9	Blood metabolite levels;
UCEC	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg13264159	chr8:625131	ERICH1	-1.04	-5.27	-0.4	4.73e-7	IgG glycosylation;
UCEC	cis	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg17469321	chr7:55412551	NA	0.7	5.87	0.44	2.75e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.1400000000000003e-13	Parkinson's disease;
UCEC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg26898376	chr11:64110657	CCDC88B	-0.48	-6.38	-0.47	2.21e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.59	5.0	0.38	1.61e-6	Eosinophilic esophagitis;
UCEC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg05738196	chr6:26577821	NA	-0.53	-4.87	-0.37	2.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.6	4.87	0.37	2.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.45	-6.21	-0.46	5.28e-9	Mortality in heart failure;
UCEC	cis	rs7246967	0.551	rs7249473	chr19:22906694	T/C	cg05241461	chr19:22816980	ZNF492	0.56	5.87	0.44	2.8e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.14	-0.76	3.42e-29	Schizophrenia;
UCEC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.58	6.78	0.49	2.77e-10	Aortic root size;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg19041857	chr6:27730383	NA	-0.5	-4.92	-0.38	2.32e-6	Pubertal anthropometrics;
UCEC	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.64	-4.79	-0.37	3.95e-6	Autism;
UCEC	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.53	-5.61	-0.42	9.88e-8	Platelet count;
UCEC	cis	rs12618769	0.597	rs4851140	chr2:99079339	T/C	cg14361474	chr2:99058762	NA	-0.47	-4.63	-0.36	8.06e-6	Bipolar disorder;
UCEC	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.78	-0.37	4.22e-6	Response to antipsychotic treatment;
UCEC	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg21905437	chr5:178450457	ZNF879	0.66	7.27	0.51	2.01e-11	Pubertal anthropometrics;
UCEC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.61	4.85	0.37	3.07e-6	Bladder cancer;
UCEC	cis	rs8105895	0.935	rs62111038	chr19:22286614	A/G	cg24175803	chr19:22235144	ZNF257	-0.52	-4.5	-0.35	1.34e-5	Body mass index (change over time);
UCEC	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.79	-8.68	-0.58	7.02e-15	Colorectal cancer;
UCEC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.63	0.53	2.77e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.56	5.9	0.44	2.41e-8	Trans fatty acid levels;
UCEC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.64	5.61	0.42	9.65e-8	Aortic root size;
UCEC	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-5.14	-0.39	8.6e-7	Gut microbiome composition (summer);
UCEC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.66	-6.79	-0.49	2.58e-10	Immature fraction of reticulocytes;
UCEC	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg10820045	chr2:198174542	NA	-0.41	-5.06	-0.38	1.25e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.89	-0.49	1.49e-10	Total cholesterol levels;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.55	-0.48	8.89e-10	Cardiac Troponin-T levels;
UCEC	cis	rs253959	0.729	rs6594966	chr5:115710468	C/G	cg23108291	chr5:115420582	COMMD10	-0.51	-4.82	-0.37	3.56e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.5	-5.79	-0.43	4.06e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.47	4.59	0.35	9.56e-6	Autism;
UCEC	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.53	0.35	1.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	5.56	0.42	1.24e-7	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	0.97	10.71	0.66	3.89e-20	Corneal structure;
UCEC	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.56	5.94	0.44	1.97e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.65	4.57	0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.71	0.43	5.91e-8	Prudent dietary pattern;
UCEC	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.05e-9	Diabetic retinopathy;
UCEC	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.64	5.61	0.42	9.65e-8	Aortic root size;
UCEC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.63	7.05	0.5	6.63e-11	Homoarginine levels;
UCEC	cis	rs11118844	0.744	rs10863655	chr1:221952515	A/G	cg04222084	chr1:221915650	DUSP10	-0.8	-5.67	-0.42	7.44e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg20936604	chr3:58311152	NA	-0.6	-4.91	-0.38	2.43e-6	Cholesterol, total;
UCEC	cis	rs1564271	0.528	rs1980756	chr10:26979371	G/C	cg24343755	chr10:26987087	PDSS1	-0.56	-4.95	-0.38	2.03e-6	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
UCEC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-5.0	-0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.37	5.03	0.38	1.4e-6	Breast cancer;
UCEC	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13683864	chr3:40499215	RPL14	-0.65	-6.35	-0.46	2.59e-9	Renal cell carcinoma;
UCEC	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg14092571	chr14:90743983	NA	-0.42	-5.61	-0.42	9.93e-8	Mortality in heart failure;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg22359107	chr11:18655812	SPTY2D1	0.62	7.1	0.51	4.98e-11	Warfarin maintenance dose;
UCEC	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.51	4.87	0.37	2.85e-6	Blood metabolite levels;
UCEC	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13939156	chr17:80058883	NA	0.39	4.9	0.37	2.47e-6	Life satisfaction;
UCEC	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.83	5.13	0.39	9.02e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.57	-0.42	1.17e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7113850	0.541	rs77868378	chr11:24233684	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Bone fracture in osteoporosis;
UCEC	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.73	-4.76	-0.37	4.67e-6	Hair shape;
UCEC	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.25	-0.51	2.15e-11	Obesity-related traits;
UCEC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.36	5.09	0.39	1.09e-6	Coronary artery disease;
UCEC	cis	rs12234571	1.000	rs73374113	chr7:77361946	C/G	cg20048109	chr7:78158112	MAGI2	-0.52	-4.62	-0.36	8.28e-6	Obesity-related traits;
UCEC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.51	4.86	0.37	2.99e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.44	5.27	0.4	4.83e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12145833	0.596	rs12134228	chr1:243447618	C/T	cg02356786	chr1:243265016	LOC731275	0.84	5.84	0.43	3.24e-8	Obesity (early onset extreme);
UCEC	cis	rs4083242	0.764	rs2289430	chr16:86367189	A/G	cg00465277	chr16:86121393	NA	-0.28	-4.57	-0.35	1.03e-5	Obesity-related traits;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg13525197	chr6:28411240	ZSCAN23	-0.55	-5.98	-0.44	1.61e-8	Pubertal anthropometrics;
UCEC	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg19041857	chr6:27730383	NA	-0.68	-4.94	-0.38	2.08e-6	Breast cancer;
UCEC	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs321358	0.731	rs576877	chr11:111018196	G/A	cg08305652	chr11:111469057	NA	0.42	4.52	0.35	1.26e-5	Body mass index;
UCEC	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.55	-5.48	-0.41	1.78e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6813264	0.839	rs2242370	chr4:146539235	A/T	cg04181032	chr4:147165097	NA	-0.38	-4.62	-0.36	8.22e-6	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	0.87	5.29	0.4	4.37e-7	Blood protein levels;
UCEC	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.66	5.29	0.4	4.34e-7	Small cell lung carcinoma;
UCEC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	7.11	0.51	4.64e-11	Type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10251347	chr1:52344305	NRD1	0.61	7.4	0.52	9.69e-12	Warfarin maintenance dose;
UCEC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.41	4.6	0.35	9.03e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg17267710	chr20:61161232	C20orf166;MIR133A2	0.34	4.52	0.35	1.27e-5	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.67	-7.3	-0.52	1.67e-11	Lung cancer in ever smokers;
UCEC	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg26781129	chr3:44753946	ZNF502	-0.44	-4.78	-0.37	4.19e-6	Depressive symptoms;
UCEC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.48	-5.2	-0.39	6.56e-7	Pulse pressure;
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	5.94	0.44	2.01e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.93	8.77	0.59	4.13e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.65	-5.47	-0.41	1.92e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.67	7.65	0.53	2.38e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.58	0.53	3.53e-12	Ileal carcinoids;
UCEC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.66	5.71	0.43	6.15e-8	Alcohol dependence;
UCEC	cis	rs925228	0.869	rs12614496	chr2:24091141	T/C	cg13272742	chr2:24272458	FKBP1B	0.57	4.86	0.37	2.93e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.63	6.37	0.46	2.32e-9	Menopause (age at onset);
UCEC	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.49	-4.6	-0.36	8.88e-6	Blood trace element (Cu levels);
UCEC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.46	4.52	0.35	1.27e-5	Prostate cancer;
UCEC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	6.57	0.48	8.3e-10	Platelet count;
UCEC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.65	-5.53	-0.42	1.41e-7	Coronary artery calcification;
UCEC	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.46	-5.19	-0.39	6.91e-7	Serum albumin level;
UCEC	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.65	6.03	0.45	1.29e-8	Lymphocyte counts;
UCEC	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.72	-0.43	5.63e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.55	5.95	0.44	1.89e-8	Anterior chamber depth;
UCEC	cis	rs2970992	0.764	rs4850948	chr2:101324333	C/T	cg01042948	chr2:101319752	NA	-0.5	-5.31	-0.4	3.9e-7	Educational attainment;
UCEC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs6728642	1.000	rs73959416	chr2:97604518	A/T	cg26665480	chr2:98280029	ACTR1B	-0.7	-7.04	-0.5	6.8e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs4372836	0.729	rs12475612	chr2:29030006	T/G	cg09522027	chr2:28974177	PPP1CB	0.85	9.01	0.6	9.88e-16	Body mass index;
UCEC	cis	rs8099014	1.000	rs8099014	chr18:56109859	C/A	cg19165390	chr18:56932082	NA	0.35	4.78	0.37	4.22e-6	Platelet count;
UCEC	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.57	4.87	0.37	2.81e-6	Corneal astigmatism;
UCEC	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.13	0.64	1.29e-18	Cognitive ability;
UCEC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.64	-4.62	-0.36	8.43e-6	Gut microbiome composition (summer);
UCEC	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.69	-7.54	-0.53	4.55e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg13147721	chr7:65941812	NA	-0.93	-6.49	-0.47	1.26e-9	Diabetic kidney disease;
UCEC	cis	rs60311166	1.000	rs57757646	chr3:52636808	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.8	4.54	0.35	1.16e-5	CTACK levels;
UCEC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.34	0.52	1.32e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg24910161	chr17:38119198	GSDMA	-0.34	-4.74	-0.36	5.05e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.7	8.82	0.59	2.97e-15	Vitiligo;
UCEC	cis	rs7709377	0.595	rs10463676	chr5:115455536	C/G	cg23108291	chr5:115420582	COMMD10	0.52	5.44	0.41	2.21e-7	Metabolite levels  (X-11787);
UCEC	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.62	6.3	0.46	3.28e-9	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.91	0.38	2.43e-6	Breast cancer;
UCEC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.82	0.37	3.48e-6	Height;
UCEC	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.45	-0.41	2.11e-7	Metabolite levels;
UCEC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	5.42	0.41	2.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.52	5.96	0.44	1.78e-8	Anterior chamber depth;
UCEC	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.6	-6.77	-0.49	2.89e-10	Blood protein levels;
UCEC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.55	5.57	0.42	1.19e-7	Neutrophil percentage of white cells;
UCEC	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg02527881	chr3:46936655	PTH1R	-0.36	-4.54	-0.35	1.14e-5	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.53e-8	Breast cancer;
UCEC	cis	rs7611694	0.609	rs10934228	chr3:113099461	C/G	cg11138929	chr3:113251189	SIDT1	0.49	5.88	0.44	2.7e-8	Prostate cancer;
UCEC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg13870426	chr17:30244630	NA	-0.62	-4.52	-0.35	1.24e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.62	-7.1	-0.51	4.85e-11	Hip circumference;
UCEC	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	0.8	6.08	0.45	9.65e-9	Obesity (early onset extreme);
UCEC	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg13926569	chr10:89418898	PAPSS2	0.64	7.9	0.55	5.98e-13	Magnesium levels;
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.7	8.38	0.57	3.97e-14	Prudent dietary pattern;
UCEC	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.56	6.5	0.47	1.18e-9	Crohn's disease;
UCEC	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.41	5.19	0.39	6.84e-7	Bone mineral density;
UCEC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs10507349	1.000	rs3759469	chr13:26797320	C/G	cg01600817	chr13:26797529	RNF6	-0.49	-4.83	-0.37	3.37e-6	Type 2 diabetes;
UCEC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.57	6.19	0.45	5.67e-9	Total body bone mineral density;
UCEC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-4.56	-0.35	1.08e-5	Gut microbiome composition (summer);
UCEC	cis	rs16957091	0.909	rs12912064	chr15:43004170	C/T	cg24196017	chr15:43021976	CDAN1	-0.55	-5.53	-0.41	1.42e-7	MGMT methylation in smokers;
UCEC	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	0.68	4.66	0.36	7.11e-6	Blood protein levels;
UCEC	cis	rs3824488	0.790	rs28372566	chr9:98244978	C/T	cg14565164	chr9:98057177	FANCC	0.65	4.57	0.35	1.04e-5	Neuroticism;
UCEC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg22532475	chr10:104410764	TRIM8	-0.5	-5.61	-0.42	9.56e-8	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.64	6.29	0.46	3.38e-9	Bladder cancer;
UCEC	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.68	5.41	0.41	2.54e-7	Neutrophil percentage of white cells;
UCEC	cis	rs77861329	1.000	rs9843852	chr3:52132029	C/G	cg08692210	chr3:52188851	WDR51A	0.75	5.58	0.42	1.11e-7	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs422249	0.896	rs174449	chr11:61640379	A/G	cg01500311	chr11:61656094	FADS3	-0.36	-4.75	-0.36	4.73e-6	Trans fatty acid levels;
UCEC	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.64	-7.53	-0.53	4.82e-12	Crohn's disease;
UCEC	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.69	0.48	4.47e-10	Cognitive test performance;
UCEC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.53	5.0	0.38	1.59e-6	Blood metabolite levels;
UCEC	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	0.88	5.42	0.41	2.44e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg20821713	chr7:1055600	C7orf50	-0.57	-6.16	-0.45	6.49e-9	Longevity;Endometriosis;
UCEC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.58	5.91	0.44	2.29e-8	Bipolar disorder;
UCEC	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-4.6	-0.35	8.98e-6	Body mass index;
UCEC	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.12	19.21	0.85	6.51e-42	Schizophrenia;
UCEC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg06238570	chr21:40685208	BRWD1	0.82	6.94	0.5	1.16e-10	Cognitive function;
UCEC	cis	rs2554380	0.943	rs2585042	chr15:84341748	T/C	cg25130800	chr15:85143846	ZSCAN2	-0.59	-4.52	-0.35	1.26e-5	Height;
UCEC	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.73	0.36	5.21e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.57	-4.8	-0.37	3.79e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg08886695	chr4:3369023	RGS12	-0.61	-5.99	-0.44	1.51e-8	Serum sulfate level;
UCEC	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg11130432	chr3:121712080	ILDR1	0.49	5.17	0.39	7.41e-7	Multiple sclerosis;
UCEC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	5.53	0.41	1.45e-7	Cognitive test performance;
UCEC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.55	-6.36	-0.46	2.39e-9	Aortic root size;
UCEC	trans	rs12476592	0.571	rs964903	chr2:63741548	C/T	cg20689730	chr22:20072653	MIR1306;DGCR8	0.69	6.89	0.49	1.5e-10	Childhood ear infection;
UCEC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.74	9.32	0.61	1.64e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg01072550	chr1:21505969	NA	-0.58	-5.74	-0.43	5.2e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs17106184	1.000	rs72902760	chr1:51252471	A/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.56	-6.2	-0.46	5.41e-9	Lung cancer;
UCEC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.64	6.7	0.48	4.09e-10	Longevity;Endometriosis;
UCEC	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg14582100	chr15:45693742	SPATA5L1	0.34	4.62	0.36	8.46e-6	Homoarginine levels;
UCEC	cis	rs17123764	0.710	rs2278068	chr12:49944588	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.16	0.39	7.82e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.57	-6.4	-0.47	1.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.45	4.58	0.35	9.98e-6	Prostate cancer;
UCEC	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	0.81	5.39	0.41	2.7e-7	Diabetic retinopathy;
UCEC	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg23950597	chr19:37808831	NA	-0.77	-5.49	-0.41	1.72e-7	Coronary artery calcification;
UCEC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-5.24	-0.4	5.45e-7	Aortic root size;
UCEC	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.62	-5.53	-0.41	1.44e-7	Mortality in heart failure;
UCEC	cis	rs2474937	0.561	rs6428744	chr1:118925443	T/C	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs16939046	0.908	rs60096506	chr8:76084401	G/C	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.59	-5.25	-0.4	5.24e-7	Mortality in heart failure;
UCEC	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-5.14	-0.39	8.66e-7	Coronary artery disease;
UCEC	cis	rs867371	0.896	rs8033831	chr15:82513294	C/A	cg00614314	chr15:82944287	LOC80154	0.56	5.13	0.39	8.83e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.42	5.69	0.42	6.67e-8	Life satisfaction;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.79e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg26114124	chr12:9217669	LOC144571	0.4	4.71	0.36	5.73e-6	Sjögren's syndrome;
UCEC	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-5.04	-0.38	1.35e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg05991184	chr2:219186017	PNKD	-0.53	-5.82	-0.43	3.58e-8	Colorectal cancer;
UCEC	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs16937	0.662	rs11588199	chr1:205164580	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.61	0.36	8.62e-6	Schizophrenia;
UCEC	cis	rs925228	0.668	rs12470949	chr2:23934816	A/G	cg16901991	chr2:24272451	FKBP1B	0.53	5.13	0.39	8.88e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1545257	0.537	rs3108793	chr2:24648138	A/C	cg06627628	chr2:24431161	ITSN2	-0.49	-5.04	-0.38	1.37e-6	Sjögren's syndrome;
UCEC	cis	rs6728642	1.000	rs116171118	chr2:97695036	C/A	cg26665480	chr2:98280029	ACTR1B	-0.74	-4.51	-0.35	1.34e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs11718455	0.585	rs11710794	chr3:43930119	T/G	cg08738300	chr3:44038990	NA	0.54	4.74	0.36	5.04e-6	Coronary artery disease;
UCEC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.12	-6.76	-0.49	2.95e-10	Breast cancer;
UCEC	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.65	-5.55	-0.42	1.27e-7	Adiposity;
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	8.04e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.62	7.02	0.5	7.63e-11	Pulmonary function decline;
UCEC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	5.95	0.44	1.86e-8	Childhood ear infection;
UCEC	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.62	6.1	0.45	9.13e-9	Orofacial clefts;
UCEC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg19318889	chr4:1322082	MAEA	0.53	6.34	0.46	2.61e-9	Obesity-related traits;
UCEC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.67	8.38	0.57	3.83e-14	Bone mineral density;
UCEC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02733842	chr7:1102375	C7orf50	-0.62	-5.45	-0.41	2.12e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.55	-5.97	-0.44	1.69e-8	Cardiac Troponin-T levels;
UCEC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.55	-6.12	-0.45	8.16e-9	Refractive error;
UCEC	cis	rs2742417	0.904	rs2251021	chr3:45796657	A/G	cg01451880	chr3:45801044	SLC6A20	0.36	4.53	0.35	1.21e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.45	-4.97	-0.38	1.82e-6	Tanning;
UCEC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.45	5.09	0.39	1.07e-6	QRS complex (12-leadsum);
UCEC	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.62	6.39	0.47	2.04e-9	Dental caries;
UCEC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	7.39	0.52	9.97e-12	Homoarginine levels;
UCEC	cis	rs2708977	0.637	rs679414	chr2:97087788	A/C	cg22654517	chr2:96458247	NA	0.41	4.92	0.38	2.34e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.53	4.62	0.36	8.45e-6	Alzheimer's disease;
UCEC	cis	rs7937612	1.000	rs11601535	chr11:120333801	A/G	cg12584626	chr11:120203529	NA	0.48	4.78	0.37	4.2e-6	Intraocular pressure;
UCEC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.35e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.68	-0.69	1.01e-22	Primary sclerosing cholangitis;
UCEC	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.22	0.56	9.83e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.7	-7.49	-0.53	6.04e-12	Breast cancer;
UCEC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.52	5.58	0.42	1.14e-7	Aortic root size;
UCEC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.7	-7.18	-0.51	3.27e-11	Blood metabolite levels;
UCEC	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-4.8	-0.37	3.86e-6	Educational attainment;
UCEC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.42	-4.53	-0.35	1.21e-5	Iron status biomarkers;
UCEC	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.5	-0.41	1.61e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.47	4.78	0.37	4.19e-6	Systolic blood pressure;
UCEC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.08	0.39	1.15e-6	Obesity-related traits;
UCEC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.75	9.14	0.6	4.73e-16	Age at first birth;
UCEC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	5.07	0.39	1.17e-6	Obesity-related traits;
UCEC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-5.18	-0.39	7.17e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.68	5.82	0.43	3.55e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.86	-0.43	2.99e-8	Cardiac Troponin-T levels;
UCEC	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.44	5.43	0.41	2.28e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.18	0.6	3.61e-16	Coffee consumption (cups per day);
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.45	-4.62	-0.36	8.45e-6	Body mass index;
UCEC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.9	-0.44	2.45e-8	Bipolar disorder;
UCEC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.45e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.68	6.42	0.47	1.81e-9	Bladder cancer;
UCEC	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.67e-12	Body mass index;
UCEC	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.86	5.53	0.41	1.43e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.57	4.77	0.37	4.31e-6	Lung cancer;
UCEC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg16423285	chr20:60520624	NA	0.52	4.69	0.36	6.28e-6	Obesity-related traits;
UCEC	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.88	-9.56	-0.62	3.98e-17	Post bronchodilator FEV1;
UCEC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.79	-9.95	-0.63	3.79e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-10.38	-0.65	2.74e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.75	8.11	0.56	1.88e-13	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	3.62e-18	Menopause (age at onset);
UCEC	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg10902566	chr4:727664	PCGF3	-0.62	-5.03	-0.38	1.4e-6	Systolic blood pressure;
UCEC	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.81	9.99	0.64	3.01e-18	Bone mineral density;
UCEC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.55	4.86	0.37	2.98e-6	Prostate cancer;
UCEC	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-4.83	-0.37	3.37e-6	Self-reported allergy;
UCEC	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs731174	0.797	rs670692	chr1:38148124	G/A	cg06917450	chr1:38156652	C1orf109	-0.64	-6.11	-0.45	8.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.62	6.83	0.49	2.07e-10	Blood metabolite ratios;
UCEC	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.01	8.06	0.55	2.42e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.35	0.57	4.74e-14	Platelet count;
UCEC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg20821713	chr7:1055600	C7orf50	-0.59	-6.25	-0.46	4.12e-9	Longevity;Endometriosis;
UCEC	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	0.89	5.57	0.42	1.21e-7	Skin colour saturation;
UCEC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.59	-5.0	-0.38	1.59e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg11211951	chr8:145729740	GPT	0.49	5.65	0.42	7.91e-8	Age at first birth;
UCEC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-7.81	-0.54	9.78e-13	Chronic sinus infection;
UCEC	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.44	-5.14	-0.39	8.44e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.81	6.85	0.49	1.9e-10	Gastritis;
UCEC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.18	7.05	0.5	6.56e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.55	-5.65	-0.42	8.18e-8	Lymphocyte counts;
UCEC	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-5.14	-0.39	8.73e-7	Bipolar disorder;
UCEC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.75	7.11	0.51	4.66e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.64	5.45	0.41	2.06e-7	High light scatter reticulocyte count;
UCEC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg10978503	chr1:24200527	CNR2	0.35	4.61	0.36	8.53e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.39	-0.41	2.69e-7	Alcohol dependence;
UCEC	cis	rs4853036	0.586	rs7559354	chr2:70019868	C/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-4.56	-0.35	1.08e-5	Colorectal or endometrial cancer;
UCEC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.62	5.67	0.42	7.29e-8	Aortic root size;
UCEC	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.51	7.03	0.5	7.24e-11	Height;
UCEC	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.1	-9.92	-0.63	4.38e-18	Uric acid levels;
UCEC	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12311346	chr5:56204834	C5orf35	-0.45	-4.68	-0.36	6.49e-6	Breast cancer;Breast cancer (early onset);
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.56	-0.42	1.25e-7	Cardiac Troponin-T levels;
UCEC	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.54	-0.47	9.57e-10	Response to antipsychotic treatment;
UCEC	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.52	4.76	0.37	4.66e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.62	-4.71	-0.36	5.57e-6	Facial morphology (factor 23);
UCEC	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-5.19	-0.39	6.99e-7	Multiple sclerosis;
UCEC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg10503236	chr1:231470652	EXOC8	-0.41	-4.76	-0.37	4.68e-6	Hemoglobin concentration;
UCEC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg01262667	chr19:19385393	TM6SF2	0.53	7.27	0.51	1.93e-11	Tonsillectomy;
UCEC	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.62	-6.12	-0.45	7.93e-9	Lung cancer;
UCEC	cis	rs1007738	0.542	rs11603373	chr11:47203245	C/T	cg18879828	chr11:46942432	NA	-0.46	-4.58	-0.35	1e-5	Bone mineral density (hip);
UCEC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	0.95	10.33	0.65	3.88e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs7267005	0.661	rs112277543	chr20:34392122	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.8	11.19	0.68	2.05e-21	Leprosy;
UCEC	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.61	-5.55	-0.42	1.28e-7	Systolic blood pressure;
UCEC	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.78	5.84	0.43	3.19e-8	Lymphocyte counts;
UCEC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	5.65	0.42	8.19e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.45	-5.15	-0.39	8.09e-7	Prostate cancer;
UCEC	cis	rs6722750	0.783	rs4671550	chr2:64389314	T/A	cg22352474	chr2:64371530	PELI1	0.5	4.66	0.36	6.98e-6	Neuroticism;
UCEC	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.46	4.76	0.37	4.5e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.73	8.25	0.56	8.24e-14	Lymphocyte counts;
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.64	5.11	0.39	1.01e-6	Resting heart rate;
UCEC	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg11150807	chr10:43354902	NA	0.79	5.21	0.39	6.41e-7	Blood protein levels;
UCEC	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.79	8.54	0.58	1.52e-14	Menopause (age at onset);
UCEC	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.51	-5.58	-0.42	1.15e-7	Total body bone mineral density;
UCEC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	3.98e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.61e-6	Diabetic kidney disease;
UCEC	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg04756594	chr16:24857601	SLC5A11	0.42	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg21770322	chr7:97807741	LMTK2	0.52	6.59	0.48	7.43e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs78487399	0.808	rs17030998	chr2:43758199	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-4.69	-0.36	6.1e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.56	5.4	0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs60515486	0.702	rs78524236	chr11:47415895	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-4.59	-0.35	9.28e-6	Lymphocyte counts;
UCEC	cis	rs16937	0.711	rs10900461	chr1:205153208	C/T	cg12580275	chr1:205744413	RAB7L1	0.46	5.14	0.39	8.59e-7	Schizophrenia;
UCEC	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.51	5.55	0.42	1.28e-7	Body mass index;
UCEC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg05738196	chr6:26577821	NA	0.58	5.62	0.42	9.5e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	4.52	0.35	1.28e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.96	0.38	1.93e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs6882716	1.000	rs4702730	chr5:10799879	T/A	cg14521931	chr5:10832172	NA	-0.57	-4.72	-0.36	5.47e-6	Alcohol consumption (maxi-drinks);
UCEC	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg06521331	chr12:34319734	NA	-0.54	-4.77	-0.37	4.36e-6	Morning vs. evening chronotype;
UCEC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.81	-0.49	2.27e-10	Tonsillectomy;
UCEC	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.79	-7.92	-0.55	5.22e-13	Post bronchodilator FEV1;
UCEC	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg22654517	chr2:96458247	NA	0.48	5.6	0.42	1.01e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg13147721	chr7:65941812	NA	-0.75	-5.09	-0.39	1.1e-6	Diabetic kidney disease;
UCEC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg13695892	chr22:41940480	POLR3H	0.62	4.9	0.37	2.5e-6	Vitiligo;
UCEC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.4	5.6	0.42	1.03e-7	Crohn's disease;
UCEC	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.57	-4.89	-0.37	2.63e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.48	7.29	0.52	1.76e-11	Primary biliary cholangitis;
UCEC	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.51	-4.78	-0.37	4.22e-6	Red blood cell count;
UCEC	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.04	8.52	0.57	1.76e-14	Uric acid levels;
UCEC	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-0.56	-7.25	-0.51	2.18e-11	Cancer (pleiotropy);
UCEC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.67	7.61	0.53	3.06e-12	Menopause (age at onset);
UCEC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.05	8.71	0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs17123764	0.818	rs13066	chr12:49960551	C/A	cg20471783	chr12:50157085	TMBIM6	0.61	5.29	0.4	4.36e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11697848	1.000	rs117900399	chr20:48511139	A/G	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs7709377	0.521	rs7701723	chr5:115718668	G/T	cg23108291	chr5:115420582	COMMD10	0.52	5.29	0.4	4.42e-7	Metabolite levels  (X-11787);
UCEC	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.04	0.38	1.34e-6	Rheumatoid arthritis;
UCEC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.66	-0.36	7.05e-6	Parkinson's disease;
UCEC	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-5.17	-0.39	7.51e-7	Aortic root size;
UCEC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27261136	chr1:202113704	ARL8A	0.6	6.85	0.49	1.85e-10	Warfarin maintenance dose;
UCEC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.56	0.35	1.06e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg04155231	chr12:9217510	LOC144571	0.4	4.96	0.38	1.89e-6	Sjögren's syndrome;
UCEC	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.39	0.47	2.02e-9	Coronary artery disease;
UCEC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg06238570	chr21:40685208	BRWD1	0.79	8.04	0.55	2.68e-13	Cognitive function;
UCEC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	7.24	0.51	2.36e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.36	4.54	0.35	1.19e-5	Acylcarnitine levels;
UCEC	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.62	4.9	0.37	2.52e-6	Dental caries;
UCEC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg10932868	chr11:921992	NA	0.44	5.88	0.44	2.7e-8	Alzheimer's disease (late onset);
UCEC	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.6	5.28	0.4	4.64e-7	Major depressive disorder;
UCEC	cis	rs9715521	0.691	rs60007977	chr4:59847637	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.78	-9.04	-0.6	8.43e-16	Primary sclerosing cholangitis;
UCEC	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.96	-7.23	-0.51	2.45e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6748734	0.857	rs10933641	chr2:241813788	T/C	cg07537917	chr2:241836409	C2orf54	-0.38	-5.32	-0.4	3.72e-7	Urinary metabolites;
UCEC	cis	rs17433710	0.778	rs66950460	chr1:162675029	G/A	cg19264028	chr1:162630153	DDR2	1.07	4.65	0.36	7.3e-6	Dupuytren's disease;
UCEC	cis	rs10208940	0.920	rs10211211	chr2:68718191	G/C	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.58	-5.93	-0.44	2.09e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.59	-6.4	-0.47	1.98e-9	Motion sickness;
UCEC	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.53	-0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.71	-6.4	-0.47	1.94e-9	Aortic root size;
UCEC	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.78	-8.09	-0.56	2.06e-13	Plateletcrit;Platelet count;
UCEC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.52	-4.95	-0.38	1.97e-6	Schizophrenia;
UCEC	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	0.9	5.33	0.4	3.63e-7	Diabetic retinopathy;
UCEC	cis	rs13098911	0.540	rs71615438	chr3:46039868	A/G	cg16320329	chr3:45981161	FYCO1	-0.81	-4.54	-0.35	1.18e-5	Celiac disease;
UCEC	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.45	-4.74	-0.36	4.92e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.57	-6.54	-0.47	9.63e-10	Bipolar disorder;
UCEC	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg03859395	chr2:55845619	SMEK2	1.01	14.02	0.76	7.07e-29	Metabolic syndrome;
UCEC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18252515	chr7:66147081	NA	0.46	4.72	0.36	5.33e-6	Aortic root size;
UCEC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.39	-0.41	2.69e-7	Alcohol dependence;
UCEC	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg04374321	chr14:90722782	PSMC1	-0.64	-5.72	-0.43	5.89e-8	Mortality in heart failure;
UCEC	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-0.9	-7.61	-0.53	3e-12	Blood pressure (smoking interaction);
UCEC	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-7.97	-0.55	4.08e-13	Parkinson's disease;
UCEC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg01767885	chr16:1147214	C1QTNF8	-0.31	-4.63	-0.36	7.92e-6	Height;
UCEC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.72	6.13	0.45	7.77e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.55	-5.01	-0.38	1.55e-6	Systemic lupus erythematosus;
UCEC	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.48	5.43	0.41	2.26e-7	Mean platelet volume;
UCEC	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.43	-4.67	-0.36	6.68e-6	Hemoglobin concentration;
UCEC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-5.82	-0.43	3.55e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs12644436	1.000	rs6858412	chr4:88789543	G/C	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	HIV-1 viral setpoint;
UCEC	cis	rs240764	0.604	rs9322173	chr6:101203889	G/A	cg09795085	chr6:101329169	ASCC3	0.5	4.61	0.36	8.5e-6	Neuroticism;
UCEC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.61e-6	Diabetic kidney disease;
UCEC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.15	14.53	0.77	3.22e-30	Cognitive function;
UCEC	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	0.97	6.98	0.5	9.19e-11	Cannabis dependence symptom count;
UCEC	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs1832871	1.000	rs705930	chr6:158711855	T/C	cg07215822	chr6:158701037	NA	-0.5	-4.96	-0.38	1.89e-6	Height;
UCEC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg18765565	chr5:669397	TPPP	-0.46	-4.71	-0.36	5.68e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.61	-4.67	-0.36	6.77e-6	HIV-1 control;
UCEC	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.77	0.63	1.08e-17	Platelet count;
UCEC	cis	rs925228	0.955	rs4665646	chr2:24144685	A/G	cg13272742	chr2:24272458	FKBP1B	0.6	5.07	0.39	1.2e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.6	0.42	9.99e-8	Cognitive test performance;
UCEC	cis	rs9811216	1.000	rs9860874	chr3:169486271	C/A	cg16622863	chr3:169387280	NA	-0.44	-4.55	-0.35	1.12e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.7	-0.48	4.2e-10	Schizophrenia;
UCEC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.62	0.48	6.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.79	-0.37	4.02e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.68	6.94	0.5	1.16e-10	Multiple sclerosis;
UCEC	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.67	7.94	0.55	4.91e-13	Testicular germ cell tumor;
UCEC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.53	5.54	0.42	1.35e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.44	-4.93	-0.38	2.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.53	6.12	0.45	8.09e-9	Mean corpuscular volume;
UCEC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.91	-11.78	-0.7	5.51e-23	Height;
UCEC	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.35	0.52	1.3e-11	Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.85	-8.48	-0.57	2.26e-14	Cognitive function;
UCEC	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.55	-4.79	-0.37	4.09e-6	Blood pressure (smoking interaction);
UCEC	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.51	4.56	0.35	1.09e-5	Pulmonary function decline;
UCEC	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-5.19	-0.39	6.81e-7	Response to antipsychotic treatment;
UCEC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.47	-6.34	-0.46	2.66e-9	Body mass index;
UCEC	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.59	-5.17	-0.39	7.6e-7	Pediatric autoimmune diseases;
UCEC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.34	-4.55	-0.35	1.09e-5	Breast cancer;
UCEC	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	4.8	0.37	3.91e-6	Gut microbiome composition (summer);
UCEC	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.97	12.5	0.72	7.07e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.54	5.3	0.4	4.11e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-10.3	-0.65	4.51e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.83	0.59	2.8e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.69	-5.11	-0.39	9.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg06166341	chr4:1223170	CTBP1	-0.61	-5.4	-0.41	2.66e-7	Systolic blood pressure;
UCEC	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-4.54	-0.35	1.16e-5	Monocyte percentage of white cells;
UCEC	cis	rs41271951	0.512	rs79122717	chr1:151093526	G/A	cg00107782	chr1:151300621	NA	-0.69	-4.65	-0.36	7.48e-6	Blood protein levels;
UCEC	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.6	6.62	0.48	6.35e-10	Resting heart rate;
UCEC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.28	0.4	4.55e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.6	6.17	0.45	6.19e-9	Colorectal cancer;
UCEC	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg12580275	chr1:205744413	RAB7L1	0.51	4.67	0.36	6.73e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-5.74	-0.43	5.23e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-5.64	-0.42	8.37e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.45	4.58	0.35	9.86e-6	Response to temozolomide;
UCEC	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.47	4.89	0.37	2.59e-6	Vitiligo;
UCEC	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg25212365	chr15:78441641	IDH3A	-0.44	-4.55	-0.35	1.13e-5	Coronary artery disease;
UCEC	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.57	6.02	0.44	1.3e-8	Diastolic blood pressure;
UCEC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg01851573	chr8:8652454	MFHAS1	0.4	4.99	0.38	1.69e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.99	-12.68	-0.72	2.28e-25	Breast cancer;
UCEC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.8	-0.43	3.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.8	10.31	0.65	4.21e-19	Vitiligo;
UCEC	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.51	-5.53	-0.41	1.46e-7	Diastolic blood pressure;
UCEC	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.39	-5.01	-0.38	1.56e-6	Prostate cancer;
UCEC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.63	6.68	0.48	4.5e-10	Menopause (age at onset);
UCEC	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.66	7.01	0.5	8.19e-11	Coronary artery disease;
UCEC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg26781129	chr3:44753946	ZNF502	-0.41	-4.55	-0.35	1.1e-5	Depressive symptoms;
UCEC	cis	rs4265793	1.000	rs4782193	chr16:19035682	G/A	cg06773604	chr16:18995157	TMC7	0.75	5.78	0.43	4.29e-8	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.94	0.38	2.08e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.7	0.36	5.92e-6	Aortic root size;
UCEC	cis	rs7088591	1.000	rs16911644	chr10:59782682	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs12118280	0.531	rs12402496	chr1:108732781	G/A	cg11967332	chr1:108735228	SLC25A24	0.69	6.85	0.49	1.92e-10	Myeloid white cell count;
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.49	0.41	1.74e-7	Platelet count;
UCEC	cis	rs7070678	0.638	rs61849289	chr10:29796378	T/C	cg07724896	chr10:29780678	SVIL	-0.55	-5.0	-0.38	1.62e-6	Platelet thrombus formation;
UCEC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.53	-5.28	-0.4	4.63e-7	Cognitive test performance;
UCEC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.49	-5.29	-0.4	4.3e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.65	6.99	0.5	9.08e-11	Mortality in heart failure;
UCEC	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg26818010	chr10:134567672	INPP5A	-0.61	-6.17	-0.45	6.16e-9	Migraine;
UCEC	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.64	-6.0	-0.44	1.5e-8	Vitiligo;
UCEC	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.57	6.15	0.45	6.8e-9	Red blood cell count;
UCEC	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.66	-0.36	7.13e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.07	-0.55	2.34e-13	Monocyte count;
UCEC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg00983440	chr10:79422392	NA	-0.74	-6.14	-0.45	7.46e-9	Bone mineral density;
UCEC	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.7	6.17	0.45	6.38e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.55	6.27	0.46	3.72e-9	Bipolar disorder;
UCEC	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-14.6	-0.77	2.06e-30	Schizophrenia;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.56	-0.42	1.21e-7	Depression;
UCEC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	1.01	13.48	0.74	1.76e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs295140	0.564	rs296790	chr2:201232862	C/G	cg04283868	chr2:201171347	SPATS2L	-0.47	-4.54	-0.35	1.15e-5	QT interval;
UCEC	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	10.01	0.64	2.65e-18	Menopause (age at onset);
UCEC	cis	rs4588572	0.643	rs10043115	chr5:77692019	T/C	cg11547950	chr5:77652471	NA	0.47	5.33	0.4	3.6e-7	Triglycerides;
UCEC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.45	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg04155231	chr12:9217510	LOC144571	0.42	5.21	0.4	6.16e-7	Sjögren's syndrome;
UCEC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	7.47	0.52	6.41e-12	Personality dimensions;
UCEC	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.17	-0.39	7.55e-7	Dupuytren's disease;
UCEC	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.13	0.39	9.02e-7	Life satisfaction;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg14529643	chr1:1233542	ACAP3	0.43	4.51	0.35	1.31e-5	Body mass index;
UCEC	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg04310649	chr10:35416472	CREM	-0.49	-4.58	-0.35	1e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg23070574	chr3:14187308	XPC	0.46	5.19	0.39	6.97e-7	Ovarian reserve;
UCEC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.45	5.54	0.42	1.39e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.6	-7.59	-0.53	3.42e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg07776626	chr8:57350775	NA	-0.47	-5.3	-0.4	4.18e-7	Obesity-related traits;
UCEC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-6.58	-0.48	7.56e-10	Monocyte count;
UCEC	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.61	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.56	6.65	0.48	5.43e-10	Mean corpuscular volume;
UCEC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.77	-8.75	-0.59	4.66e-15	Height;
UCEC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-6.38	-0.47	2.22e-9	Initial pursuit acceleration;
UCEC	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	8.9	0.59	1.91e-15	Mean platelet volume;
UCEC	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.63	6.82	0.49	2.18e-10	Retinal vascular caliber;
UCEC	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg16350314	chr8:27169081	TRIM35;PTK2B	0.45	4.56	0.35	1.05e-5	Neuroticism;
UCEC	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.65	7.56	0.53	4.11e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.23	0.51	2.51e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg16989719	chr2:238392110	NA	-0.37	-5.04	-0.38	1.35e-6	Prostate cancer;
UCEC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.55	5.45	0.41	2.09e-7	Menopause (age at onset);
UCEC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.69	-9.13	-0.6	5.08e-16	Height;
UCEC	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.17	9.57	0.62	3.63e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.68	-5.87	-0.44	2.81e-8	Platelet count;
UCEC	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.82	-8.44	-0.57	2.74e-14	Mosquito bite size;
UCEC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg03354898	chr7:1950403	MAD1L1	-0.5	-5.29	-0.4	4.35e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7070678	0.530	rs11007635	chr10:29803478	A/T	cg07724896	chr10:29780678	SVIL	-0.59	-4.79	-0.37	4.07e-6	Platelet thrombus formation;
UCEC	cis	rs71658797	0.505	rs12042881	chr1:77968443	A/G	cg25272065	chr1:77334678	ST6GALNAC5	0.45	4.6	0.35	9.11e-6	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
UCEC	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.73	-7.36	-0.52	1.18e-11	Plateletcrit;Platelet count;
UCEC	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.48	5.03	0.38	1.4e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs16999519	chr19:22814076	A/G	cg08271804	chr19:22816896	ZNF492	-0.61	-6.15	-0.45	6.95e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.6	-6.19	-0.45	5.63e-9	Blood trace element (Zn levels);
UCEC	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.4	-4.74	-0.36	4.9100000000000004e-06	Subjective well-being;
UCEC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.74	-9.17	-0.6	3.9e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.6	7.32	0.52	1.51e-11	Age at first birth;
UCEC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.56	0.35	1.08e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg04553112	chr3:125709451	NA	-0.7	-4.94	-0.38	2.08e-6	Blood pressure (smoking interaction);
UCEC	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg01072550	chr1:21505969	NA	-0.6	-6.35	-0.46	2.49e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.41	-4.86	-0.37	2.96e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.59	-5.93	-0.44	2.11e-8	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	-1.02	-13.05	-0.73	2.45e-26	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs3750082	0.852	rs34724897	chr7:32899526	T/A	cg05721444	chr7:32995514	FKBP9	-0.52	-5.7	-0.43	6.3e-8	Glomerular filtration rate (creatinine);
UCEC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	1.02	10.07	0.64	1.87e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-4.64	-0.36	7.6e-6	Major depressive disorder;
UCEC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.09	-0.45	9.43e-9	Aortic root size;
UCEC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg22974920	chr21:40686053	BRWD1	0.51	4.59	0.35	9.57e-6	Cognitive function;
UCEC	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.43	4.92	0.38	2.3e-6	Aortic root size;
UCEC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.59	5.98	0.44	1.61e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.54	5.72	0.43	5.77e-8	Diastolic blood pressure;
UCEC	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg05962950	chr11:130786565	SNX19	-0.56	-5.37	-0.4	3.07e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7246967	0.551	rs1835994	chr19:22833045	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.673	rs4932784	chr19:22874251	A/C	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs10073892	0.711	rs10074392	chr5:101596412	A/G	cg23492399	chr5:102201601	PAM	-0.67	-4.76	-0.37	4.51e-6	Cognitive decline (age-related);
UCEC	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg17031739	chr1:67600172	NA	0.45	4.66	0.36	6.99e-6	Psoriasis;
UCEC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.66	-5.7	-0.43	6.25e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.67	7.68	0.54	2.02e-12	Multiple system atrophy;
UCEC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.17e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.56	6.69	0.48	4.48e-10	Menarche (age at onset);
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.46	5.31	0.4	4.04e-7	Monocyte percentage of white cells;
UCEC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg26383811	chr8:30366931	RBPMS	-0.65	-5.22	-0.4	5.95e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs2979489	0.945	rs34960391	chr8:30332723	G/A	cg26383811	chr8:30366931	RBPMS	-0.71	-5.89	-0.44	2.52e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	5.73	0.43	5.44e-8	Rheumatoid arthritis;
UCEC	cis	rs7364180	0.920	rs2269657	chr22:42264269	G/T	cg17401067	chr22:41840292	TOB2	-0.39	-4.51	-0.35	1.31e-5	Alzheimer's disease biomarkers;
UCEC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.84	10.11	0.64	1.45e-18	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.43	-4.84	-0.37	3.23e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.53	5.2	0.39	6.67e-7	Menopause (age at onset);
UCEC	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.52	-0.53	4.96e-12	Response to antipsychotic treatment;
UCEC	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	6.71	0.48	3.89e-10	Homoarginine levels;
UCEC	cis	rs6498142	0.882	rs12708713	chr16:11072459	A/G	cg07657131	chr16:11762803	SNN	0.49	4.58	0.35	9.74e-6	Immunoglobulin A;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.68	-6.87	-0.49	1.66e-10	Longevity;Endometriosis;
UCEC	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.8	9.41	0.61	9.31e-17	Mortality in heart failure;
UCEC	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.72	-7.81	-0.54	1.02e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Crohn's disease;
UCEC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.84	-7.68	-0.54	2e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg18016565	chr1:150552671	MCL1	0.6	6.63	0.48	6.13e-10	Tonsillectomy;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.35	-0.4	3.37e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11235843	0.929	rs3211165	chr11:73471778	A/G	cg23931323	chr11:73372278	PLEKHB1	0.69	4.69	0.36	6.07e-6	Hand grip strength;
UCEC	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-5.18	-0.39	7.19e-7	Height;
UCEC	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.76e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs151997	0.962	rs27271	chr5:50183369	A/G	cg06027927	chr5:50259733	NA	0.53	4.85	0.37	3.06e-6	Callous-unemotional behaviour;
UCEC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.4	5.05	0.38	1.31e-6	Bone mineral density;
UCEC	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.15	-0.39	8.38e-7	Aortic root size;
UCEC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg12024160	chr4:1254474	NA	0.59	7.62	0.53	2.81e-12	Obesity-related traits;
UCEC	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19346786	chr7:2764209	NA	-0.46	-4.61	-0.36	8.7e-6	Height;
UCEC	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.62	5.18	0.39	7.1e-7	Bipolar disorder;
UCEC	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.48	-4.57	-0.35	1e-5	Body mass index;
UCEC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.53	4.87	0.37	2.83e-6	Tonsillectomy;
UCEC	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.03	-0.38	1.42e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.37	5.3	0.4	4.11e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.7	5.91	0.44	2.29e-8	Nonalcoholic fatty liver disease;
UCEC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg14078730	chr11:63896557	MACROD1	0.67	5.28	0.4	4.64e-7	Mean platelet volume;
UCEC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.97	0.38	1.86e-6	Breast cancer;
UCEC	cis	rs7106204	1.000	rs35876423	chr11:24214859	G/T	ch.11.24196551F	chr11:24239977	NA	0.68	6.19	0.45	5.73e-9	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.64	6.97	0.5	1e-10	Longevity;Endometriosis;
UCEC	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.91	-11.78	-0.7	5.51e-23	Height;
UCEC	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.31	-4.62	-0.36	8.19e-6	Blood metabolite levels;
UCEC	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg07930552	chr6:133119739	C6orf192	0.86	5.58	0.42	1.12e-7	Type 2 diabetes nephropathy;
UCEC	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.39	5.16	0.39	7.71e-7	Sitting height ratio;
UCEC	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.6	7.33	0.52	1.41e-11	Multiple myeloma;
UCEC	cis	rs9283706	0.607	rs10471696	chr5:66304823	T/C	cg11590213	chr5:66331682	MAST4	0.43	4.86	0.37	3.01e-6	Coronary artery disease;
UCEC	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.49	6.16	0.45	6.54e-9	HDL cholesterol levels;
UCEC	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.39	-5.63	-0.42	9.01e-8	Obesity-related traits;
UCEC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.69	-7.0	-0.5	8.5e-11	Blood metabolite levels;
UCEC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.44	0.57	2.83e-14	Smoking behavior;
UCEC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.68	6.6	0.48	6.95e-10	Aortic root size;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.55	-5.91	-0.44	2.3e-8	Pubertal anthropometrics;
UCEC	cis	rs7246967	0.673	rs73020703	chr19:22844339	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.43	4.89	0.37	2.66e-6	Lung cancer;
UCEC	cis	rs970548	0.955	rs61854156	chr10:46138664	G/A	cg15223267	chr10:46222474	FAM21C	0.57	5.11	0.39	1e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.75	-9.3	-0.61	1.78e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	4.98	0.38	1.79e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.55	5.79	0.43	4.1e-8	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg14008862	chr17:28927542	LRRC37B2	0.68	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.96	-0.44	1.79e-8	Blood metabolite levels;
UCEC	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.68	6.06	0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.65	-8.09	-0.56	2.02e-13	Height;
UCEC	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-8.1	-0.56	1.92e-13	Neuroticism;
UCEC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.62	6.0	0.44	1.49e-8	Lung cancer;
UCEC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg22563815	chr15:78856949	CHRNA5	-0.4	-5.32	-0.4	3.78e-7	Sudden cardiac arrest;
UCEC	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg05874882	chr4:1763078	NA	-0.61	-5.8	-0.43	3.84e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.64	6.75	0.49	3.27e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg09655341	chr17:79618100	PDE6G	-0.31	-4.76	-0.37	4.53e-6	Eye color traits;
UCEC	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.65	8.31	0.57	6e-14	Systolic blood pressure;
UCEC	cis	rs644799	0.897	rs10831448	chr11:95663091	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	5.68	0.42	6.91e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.74	7.67	0.53	2.21e-12	Blood protein levels;
UCEC	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.81	-8.64	-0.58	8.9e-15	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg22139774	chr2:100720529	AFF3	0.36	4.55	0.35	1.13e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.49	-0.47	1.21e-9	Aortic root size;
UCEC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.43	4.77	0.37	4.32e-6	Blood metabolite levels;
UCEC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.8	-0.49	2.51e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.45	-5.79	-0.43	4.13e-8	Height;
UCEC	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg16329650	chr2:213403929	ERBB4	0.5	4.93	0.38	2.17e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs8105895	1.000	rs62112907	chr19:22209569	A/G	cg20662725	chr19:22235022	ZNF257	-0.53	-4.8	-0.37	3.78e-6	Body mass index (change over time);
UCEC	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.63	0.48	6.08e-10	Coronary artery disease;
UCEC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.44	-4.55	-0.35	1.11e-5	Monocyte count;
UCEC	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg06917450	chr1:38156652	C1orf109	-0.54	-5.01	-0.38	1.56e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg16751203	chr2:127950803	CYP27C1	0.4	5.27	0.4	4.72e-7	Protein C levels;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg02931753	chr4:154074737	TRIM2	0.66	7.07	0.5	5.76e-11	Triglyceride levels;
UCEC	cis	rs876084	0.545	rs10096311	chr8:121102031	A/G	cg06265175	chr8:121136014	COL14A1	0.46	5.01	0.38	1.57e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	4.63	0.36	7.98e-6	Bipolar disorder;
UCEC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg26061582	chr7:22766209	IL6	0.59	5.48	0.41	1.83e-7	Lung cancer;
UCEC	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.47	4.61	0.36	8.74e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.74	7.98	0.55	3.87e-13	Menopause (age at onset);
UCEC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-4.69	-0.36	6.27e-6	Tonsillectomy;
UCEC	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.65	5.71	0.43	6.02e-8	Platelet count;
UCEC	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.93	0.38	2.18e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.56	0.53	3.94e-12	Platelet count;
UCEC	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg06134567	chr22:46658398	PKDREJ	-0.47	-4.52	-0.35	1.25e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.19	0.56	1.13e-13	Prudent dietary pattern;
UCEC	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.44	-0.41	2.2e-7	Pulmonary function;
UCEC	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-5.94	-0.44	1.99e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.4	3.06e-7	Breast cancer;
UCEC	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg03859395	chr2:55845619	SMEK2	1.04	15.08	0.78	1.22e-31	Metabolic syndrome;
UCEC	cis	rs76096589	0.557	rs1603015	chr14:51034338	A/T	cg18894781	chr14:51955716	FRMD6	-0.5	-5.08	-0.39	1.12e-6	Diisocyanate-induced asthma;
UCEC	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.68	-5.23	-0.4	5.76e-7	Birth weight;
UCEC	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-9.16	-0.6	4.15e-16	Blood metabolite levels;
UCEC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.67	6.84	0.49	2e-10	Menopause (age at onset);
UCEC	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.43	4.56	0.35	1.05e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.61	6.6	0.48	7.12e-10	Menopause (age at onset);
UCEC	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.62	-6.75	-0.49	3.19e-10	Type 2 diabetes;
UCEC	cis	rs11048434	1.000	rs7971932	chr12:9157346	G/A	cg26114124	chr12:9217669	LOC144571	0.46	4.9	0.37	2.48e-6	Sjögren's syndrome;
UCEC	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07215822	chr6:158701037	NA	0.64	5.92	0.44	2.19e-8	Height;
UCEC	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-9.75	-0.63	1.26e-17	Ulcerative colitis;
UCEC	cis	rs9322193	0.923	rs958953	chr6:150161871	C/T	cg13206674	chr6:150067644	NUP43	0.57	5.62	0.42	9.16e-8	Lung cancer;
UCEC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-4.81	-0.37	3.74e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg11697111	chr7:1126903	GPER;C7orf50	-0.49	-4.81	-0.37	3.74e-6	Longevity;Endometriosis;
UCEC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.78e-8	Bipolar disorder;
UCEC	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.51	-5.36	-0.4	3.22e-7	Waist circumference adjusted for body mass index;
UCEC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg24562669	chr7:97807699	LMTK2	0.47	5.82	0.43	3.59e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.14	-14.6	-0.77	2.06e-30	Schizophrenia;
UCEC	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.48	7.34	0.52	1.32e-11	Primary biliary cholangitis;
UCEC	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	12.85	0.73	8.32e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.5	6.6	0.48	7.07e-10	Neutrophil percentage of white cells;
UCEC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.82	-0.49	2.26e-10	Prostate cancer;
UCEC	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.51	-4.96	-0.38	1.93e-6	Mean corpuscular hemoglobin concentration;
UCEC	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12311346	chr5:56204834	C5orf35	-0.45	-4.66	-0.36	6.99e-6	Breast cancer;Breast cancer (early onset);
UCEC	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.92	-0.38	2.34e-6	Aortic root size;
UCEC	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.35	1.11e-5	Bladder cancer;
UCEC	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.5	5.21	0.39	6.29e-7	Prostate cancer;
UCEC	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.6	-7.75	-0.54	1.39e-12	Corneal structure;
UCEC	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.71	6.72	0.48	3.73e-10	Bladder cancer;
UCEC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.55	5.8	0.43	3.88e-8	Platelet count;
UCEC	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.78	0.49	2.72e-10	Coronary artery disease;
UCEC	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.82	0.37	3.52e-6	Breast cancer;
UCEC	cis	rs7246967	0.673	rs12979848	chr19:22820798	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	0.63	6.48	0.47	1.31e-9	Monocyte percentage of white cells;
UCEC	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.63	5.54	0.42	1.39e-7	Response to diuretic therapy;
UCEC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9942416	0.533	rs12109251	chr5:75024240	C/A	cg19683494	chr5:74908142	NA	0.64	4.56	0.35	1.07e-5	Age-related disease endophenotypes;
UCEC	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.44	5.34	0.4	3.46e-7	Alcohol dependence;
UCEC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.54	6.11	0.45	8.7e-9	Menopause (age at onset);
UCEC	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.9	13.09	0.73	1.87e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	0.88	4.95	0.38	1.98e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg08461772	chr7:95026248	PON3	0.34	4.79	0.37	4e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg02461776	chr11:598696	PHRF1	0.47	5.11	0.39	9.71e-7	Systemic lupus erythematosus;
UCEC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg05738196	chr6:26577821	NA	0.58	6.32	0.46	3.01e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.56e-7	Kawasaki disease;
UCEC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg18230493	chr5:56204884	C5orf35	-0.54	-5.11	-0.39	9.76e-7	Coronary artery disease;
UCEC	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.76	-0.37	4.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg24375607	chr4:120327624	NA	0.47	4.83	0.37	3.42e-6	Corneal astigmatism;
UCEC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.49	0.41	1.71e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.42	-4.92	-0.38	2.31e-6	Blood metabolite ratios;
UCEC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.7	-6.98	-0.5	9.25e-11	Tonsillectomy;
UCEC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.85	-0.43	3.1e-8	Cardiac Troponin-T levels;
UCEC	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	7.27	0.51	1.99e-11	Cognitive ability;
UCEC	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.56	-5.26	-0.4	5.02e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.52	-7.17	-0.51	3.37e-11	Refractive error;
UCEC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.54	-6.08	-0.45	9.74e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.69	7.55	0.53	4.15e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.49	5.0	0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg23000734	chr10:126850823	CTBP2	0.59	7.78	0.54	1.17e-12	Menarche (age at onset);
UCEC	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.67	-8.11	-0.56	1.84e-13	IgG glycosylation;
UCEC	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	0.87	7.01	0.5	7.92e-11	Blood protein levels;
UCEC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	7.97e-9	Prostate cancer;
UCEC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs10924970	0.967	rs12739707	chr1:235466564	C/G	cg26050004	chr1:235667680	B3GALNT2	0.46	4.83	0.37	3.38e-6	Asthma;
UCEC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg07153921	chr17:41440717	NA	-0.58	-6.93	-0.5	1.24e-10	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs13279522	0.536	rs13264487	chr8:67008429	A/G	cg00269606	chr8:67090928	CRH	0.34	4.54	0.35	1.17e-5	Coronary heart disease event reduction (statin therapy interaction);
UCEC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.5	4.76	0.37	4.5e-6	Menopause (age at onset);
UCEC	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg00250761	chr1:31883323	NA	0.38	5.08	0.39	1.12e-6	Alcohol dependence;
UCEC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.6	5.62	0.42	9.48e-8	Vitiligo;
UCEC	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.59	-5.04	-0.38	1.32e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.4	-4.83	-0.37	3.32e-6	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.52	-4.6	-0.36	8.89e-6	Corneal astigmatism;
UCEC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg03859395	chr2:55845619	SMEK2	0.95	12.02	0.7	1.3e-23	Metabolic syndrome;
UCEC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.63	7.36	0.52	1.22e-11	Schizophrenia;
UCEC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.89	-7.57	-0.53	3.71e-12	Coronary artery calcification;
UCEC	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg08886695	chr4:3369023	RGS12	-0.47	-5.55	-0.42	1.27e-7	Parental longevity (mother's age at death);
UCEC	cis	rs925228	1.000	rs12475277	chr2:24231982	C/T	cg13272742	chr2:24272458	FKBP1B	0.59	4.79	0.37	4.09e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.05	0.38	1.27e-6	Cognitive function;
UCEC	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.53	5.49	0.41	1.72e-7	Systolic blood pressure;
UCEC	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.68	-8.79	-0.59	3.7e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.52	4.96	0.38	1.96e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-6.98	-0.5	9.19e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs925228	0.955	rs6545162	chr2:24119241	C/T	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.91	-7.02	-0.5	7.42e-11	Exhaled nitric oxide output;
UCEC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg23307798	chr14:103986281	CKB	0.59	7.19	0.51	3.05e-11	Body mass index;
UCEC	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg11459648	chr5:138714337	SLC23A1	-0.43	-4.61	-0.36	8.66e-6	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.4	-4.76	-0.37	4.63e-6	Menopause (age at onset);
UCEC	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.73	7.54	0.53	4.54e-12	Breast cancer;
UCEC	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.68	6.09	0.45	9.45e-9	Adiposity;
UCEC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.64	-4.58	-0.35	9.69e-6	Schizophrenia;
UCEC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	6.75	0.49	3.14e-10	Bone mineral density;
UCEC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.86	-0.37	3e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-7.35	-0.52	1.25e-11	Morning vs. evening chronotype;
UCEC	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.48	4.54	0.35	1.14e-5	Blood metabolite levels;
UCEC	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.54	5.13	0.39	8.99e-7	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	7.22	0.51	2.59e-11	Coffee consumption (cups per day);
UCEC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg24562669	chr7:97807699	LMTK2	0.41	5.09	0.39	1.08e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	0.8	6.05	0.45	1.15e-8	Red blood cell traits;
UCEC	cis	rs3914502	0.615	rs1818565	chr3:174516821	A/G	cg21145449	chr3:174580620	NAALADL2	0.44	5.05	0.38	1.28e-6	Autism spectrum disorder;
UCEC	cis	rs829661	0.947	rs829618	chr2:30748321	A/G	cg17749961	chr2:30669863	LCLAT1	0.49	4.66	0.36	7.1e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.52	5.63	0.42	8.84e-8	Tonsillectomy;
UCEC	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg02158880	chr13:53174818	NA	0.58	6.79	0.49	2.58e-10	Lewy body disease;
UCEC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.65	6.11	0.45	8.57e-9	Corneal astigmatism;
UCEC	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.51	4.93	0.38	2.2e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.31	8.18	0.56	1.25e-13	Diabetic kidney disease;
UCEC	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.99	-11.93	-0.7	2.25e-23	Obesity-related traits;
UCEC	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01391022	chr12:122360665	WDR66	0.45	4.64	0.36	7.68e-6	Mean corpuscular volume;
UCEC	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.5	6.05	0.45	1.16e-8	Prudent dietary pattern;
UCEC	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.03	-0.38	1.44e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-7.44	-0.52	7.71e-12	Response to antipsychotic treatment;
UCEC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg01256987	chr12:42539512	GXYLT1	0.41	4.67	0.36	6.79e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.59	6.25	0.46	4.14e-9	Prostate cancer;
UCEC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.54	4.78	0.37	4.2e-6	Obesity-related traits;
UCEC	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24249390	chr15:90295951	MESP1	-0.39	-4.54	-0.35	1.17e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.4	5.16	0.39	7.74e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.53	-0.35	1.19e-5	Dementia with Lewy bodies;
UCEC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg06784218	chr1:46089804	CCDC17	-0.39	-4.85	-0.37	3.13e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.51	6.9	0.49	1.41e-10	Eye color traits;
UCEC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg01874867	chr7:94954059	PON1	-0.52	-4.64	-0.36	7.64e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg00105475	chr2:10696890	NA	0.44	5.42	0.41	2.34e-7	Prostate cancer;
UCEC	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.67	4.71	0.36	5.57e-6	Small cell lung carcinoma;
UCEC	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.46	4.57	0.35	1.04e-5	Lung disease severity in cystic fibrosis;
UCEC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.32	0.4	3.86e-7	Mean platelet volume;
UCEC	cis	rs9309473	0.948	rs2421550	chr2:73658686	A/G	cg20560298	chr2:73613845	ALMS1	-0.62	-5.65	-0.42	8.2e-8	Metabolite levels;
UCEC	cis	rs6684428	0.831	rs4313435	chr1:56338281	C/A	cg11651538	chr1:56320950	NA	-0.63	-5.77	-0.43	4.59e-8	Airflow obstruction;
UCEC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.53	5.57	0.42	1.19e-7	Schizophrenia;
UCEC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.46	6.72	0.48	3.75e-10	Homoarginine levels;
UCEC	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.41	4.52	0.35	1.25e-5	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	6.29	0.46	3.41e-9	Bipolar disorder;
UCEC	cis	rs12767760	0.714	rs11189270	chr10:99299480	A/G	cg17778955	chr10:99210596	ZDHHC16	-0.46	-4.62	-0.36	8.27e-6	Obesity-related traits;
UCEC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.54	-5.46	-0.41	2.02e-7	Vitiligo;
UCEC	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.41	-0.77	6.65e-30	Schizophrenia;
UCEC	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg19554555	chr3:13937349	NA	-0.59	-5.9	-0.44	2.38e-8	Ovarian reserve;
UCEC	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.62	4.84	0.37	3.2e-6	Educational attainment;
UCEC	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.69	0.36	6.29e-6	Rheumatoid arthritis;
UCEC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.51	5.02	0.38	1.5e-6	Menopause (age at onset);
UCEC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.53	-5.27	-0.4	4.8e-7	Aortic root size;
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	8.55	0.58	1.47e-14	Prudent dietary pattern;
UCEC	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg16989719	chr2:238392110	NA	-0.36	-4.74	-0.36	4.93e-6	Prostate cancer;
UCEC	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Parkinson's disease;
UCEC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.61	7.04	0.5	6.96e-11	Height;
UCEC	cis	rs8105895	1.000	rs62112917	chr19:22226580	C/T	cg24175803	chr19:22235144	ZNF257	-0.58	-5.24	-0.4	5.52e-7	Body mass index (change over time);
UCEC	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg02580895	chr19:2754563	NA	-0.51	-4.91	-0.38	2.43e-6	Total cholesterol levels;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.24	-0.46	4.54e-9	Pubertal anthropometrics;
UCEC	cis	rs7246967	0.932	rs35039856	chr19:23031339	A/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	5.92	0.44	2.16e-8	Platelet count;
UCEC	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg06784218	chr1:46089804	CCDC17	0.44	5.07	0.39	1.2e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg16576597	chr16:28551801	NUPR1	0.31	4.6	0.35	8.91e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.58	-0.48	7.56e-10	Pubertal anthropometrics;
UCEC	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.19	-0.45	5.7e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.57	4.84	0.37	3.24e-6	Lung cancer;
UCEC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.66	4.69	0.36	6.09e-6	Aortic root size;
UCEC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.71	-7.14	-0.51	4.02e-11	Blood metabolite levels;
UCEC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.73	7.51	0.53	5.27e-12	Sudden cardiac arrest;
UCEC	cis	rs7246967	0.673	rs12974988	chr19:22925965	G/T	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	7.61	0.53	2.99e-12	Coronary artery disease;
UCEC	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.76	6.14	0.45	7.46e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.46	-5.06	-0.39	1.24e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg21770322	chr7:97807741	LMTK2	-0.52	-6.6	-0.48	7.08e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.67	-6.25	-0.46	4.22e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs998584	1.000	rs998584	chr6:43757896	A/C	cg24804436	chr6:42955017	PPP2R5D	-0.39	-4.67	-0.36	6.62e-6	Waist circumference adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Triglycerides;HDL cholesterol;Waist circumference adjusted for BMI in non-smokers;Body mass index;White blood cell count;Adiponectin levels;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist circumference adjusted for BMI in active individuals;Reticulocyte count;
UCEC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg11200568	chr7:226540	FAM20C	-0.48	-4.7	-0.36	5.83e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.35	4.84	0.37	3.27e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg09033563	chr22:24373618	LOC391322	-0.5	-4.99	-0.38	1.68e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.99	10.87	0.67	1.42e-20	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	0.87	5.43	0.41	2.32e-7	Skin colour saturation;
UCEC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.7	-9.16	-0.6	4.19e-16	Oral cavity cancer;
UCEC	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg16060761	chr17:80687452	NA	0.54	6.15	0.45	6.93e-9	Breast cancer;
UCEC	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg23070574	chr3:14187308	XPC	0.46	5.36	0.4	3.2e-7	Ovarian reserve;
UCEC	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.69	-6.2	-0.46	5.3e-9	Neurofibrillary tangles;
UCEC	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.91	-0.9	1.28e-54	Myeloid white cell count;
UCEC	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	0.7	4.51	0.35	1.29e-5	Blood metabolite levels;
UCEC	cis	rs9287719	0.572	rs1038690	chr2:10813244	C/T	cg00105475	chr2:10696890	NA	-0.37	-4.54	-0.35	1.14e-5	Prostate cancer;
UCEC	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.63	4.79	0.37	4.1e-6	Carotid intima media thickness;
UCEC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.88	-0.44	2.64e-8	Life satisfaction;
UCEC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg08216368	chr11:237063	SIRT3;PSMD13	0.42	4.55	0.35	1.1e-5	Alzheimer's disease (late onset);
UCEC	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.42	-0.47	1.77e-9	Platelet count;
UCEC	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.5	-5.64	-0.42	8.61e-8	Response to temozolomide;
UCEC	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.76	-5.29	-0.4	4.33e-7	Multiple sclerosis;
UCEC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.65	0.36	7.2e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.55	4.77	0.37	4.37e-6	Corneal astigmatism;
UCEC	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.45	4.51	0.35	1.33e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.27	11.85	0.7	3.59e-23	Corneal structure;
UCEC	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.51	4.71	0.36	5.74e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.72	8.04	0.55	2.66e-13	Menarche (age at onset);
UCEC	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-1.01	-8.09	-0.56	2.03e-13	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg13319975	chr6:146136371	FBXO30	0.45	4.9	0.37	2.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg21770322	chr7:97807741	LMTK2	0.5	6.32	0.46	2.96e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg15659132	chr6:26577336	NA	0.5	4.69	0.36	6.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs7944735	0.508	rs9666924	chr11:47540007	C/T	cg08722104	chr11:47448306	PSMC3	0.45	4.67	0.36	6.76e-6	Intraocular pressure;
UCEC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.62	7.18	0.51	3.15e-11	Menarche (age at onset);
UCEC	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.39	-4.51	-0.35	1.32e-5	Total body bone mineral density;
UCEC	cis	rs8032158	1.000	rs2288344	chr15:56122347	T/G	cg10433327	chr15:56209506	NEDD4	-0.31	-5.07	-0.39	1.19e-6	Keloid;
UCEC	cis	rs9283706	0.608	rs71626484	chr5:66334502	A/T	cg11590213	chr5:66331682	MAST4	0.45	5.62	0.42	9.42e-8	Coronary artery disease;
UCEC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.59	-5.28	-0.4	4.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.74	-6.37	-0.47	2.27e-9	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg01689657	chr7:91764605	CYP51A1	0.48	6.18	0.45	5.98e-9	Breast cancer;
UCEC	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.51	5.04	0.38	1.35e-6	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.56	6.03	0.45	1.26e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg01874867	chr7:94954059	PON1	-0.52	-4.6	-0.35	9.21e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18854424	chr1:2615690	NA	0.46	6.69	0.48	4.4e-10	Ulcerative colitis;
UCEC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18252515	chr7:66147081	NA	0.55	5.16	0.39	7.95e-7	Aortic root size;
UCEC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs7781557	0.640	rs6968036	chr7:102555920	G/C	cg06322601	chr7:102330635	NA	0.57	4.57	0.35	1.03e-5	Colorectal adenoma (advanced);
UCEC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.81	9.74	0.63	1.3e-17	Menopause (age at onset);
UCEC	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg24642439	chr20:33292090	TP53INP2	0.53	4.74	0.36	5.04e-6	Coronary artery disease;
UCEC	cis	rs944990	0.618	rs10821173	chr9:96362455	C/G	cg13787134	chr9:96362102	PHF2	-0.38	-5.12	-0.39	9.25e-7	Body mass index;
UCEC	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	0.77	5.18	0.39	7.3e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.65	-5.76	-0.43	4.73e-8	Body mass index;
UCEC	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.73	7.12	0.51	4.48e-11	Height;
UCEC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-4.65	-0.36	7.26e-6	Schizophrenia;
UCEC	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.94	-9.56	-0.62	3.89e-17	Height;
UCEC	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.51	-4.98	-0.38	1.74e-6	Refractive error;
UCEC	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.62	-0.75	7.56e-28	Schizophrenia;
UCEC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-5.93	-0.44	2.1e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.68	-6.75	-0.49	3.15e-10	Dilated cardiomyopathy;
UCEC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg05991184	chr2:219186017	PNKD	0.5	5.38	0.41	2.87e-7	Colorectal cancer;
UCEC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.73	4.9	0.37	2.51e-6	Gut microbiome composition (summer);
UCEC	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Depression;
UCEC	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.74	-6.23	-0.46	4.77e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.66	5.57	0.42	1.17e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26850624	chr5:429559	AHRR	-0.49	-4.68	-0.36	6.45e-6	Cystic fibrosis severity;
UCEC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.58e-7	Acne (severe);
UCEC	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	5.99	0.44	1.56e-8	Breast cancer;
UCEC	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.49	-4.88	-0.37	2.75e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg06166341	chr4:1223170	CTBP1	0.7	6.49	0.47	1.21e-9	Systolic blood pressure;
UCEC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs174479	0.677	rs1000778	chr11:61655305	A/G	cg01500311	chr11:61656094	FADS3	0.51	6.61	0.48	6.48e-10	Sphingolipid levels;
UCEC	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.56	5.22	0.4	6.05e-7	Systemic lupus erythematosus;
UCEC	cis	rs10095849	0.576	rs4584120	chr8:39447072	C/T	cg24581462	chr8:38759627	PLEKHA2	0.36	4.61	0.36	8.73e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg12035532	chr1:1886765	KIAA1751	-0.43	-4.59	-0.35	9.62e-6	Body mass index;
UCEC	cis	rs7156960	0.866	rs935331	chr14:76699532	A/G	cg13981132	chr14:76734493	NA	0.49	5.05	0.38	1.31e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.57	-6.13	-0.45	7.68e-9	Heart rate;
UCEC	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg21466736	chr12:48725269	NA	0.38	4.57	0.35	1.02e-5	Glycated hemoglobin levels;
UCEC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg20007245	chr22:24372913	LOC391322	0.54	4.89	0.37	2.57e-6	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.21	-0.46	5.1e-9	Crohn's disease;
UCEC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.54	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg01380346	chr19:18557039	ELL	-0.48	-4.87	-0.37	2.84e-6	Breast cancer;
UCEC	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01380346	chr19:18557039	ELL	-0.46	-4.85	-0.37	3.14e-6	Breast cancer;
UCEC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.6	-0.48	7.04e-10	Aortic root size;
UCEC	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.49	4.6	0.35	9.19e-6	Hypertension (SNP x SNP interaction);
UCEC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg27153327	chr16:1920815	C16orf73	0.42	4.78	0.37	4.22e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.73	9.18	0.6	3.76e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	0.96	10.47	0.65	1.65e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs773506	0.602	rs10761110	chr9:93929884	A/G	cg03243796	chr9:93920768	NA	-0.41	-5.05	-0.38	1.26e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.52	5.15	0.39	8.42e-7	Testicular germ cell tumor;
UCEC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.77	-0.37	4.45e-6	Breast cancer;
UCEC	trans	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg02900749	chr2:68251473	NA	-0.96	-7.1	-0.51	4.94e-11	Pursuit maintenance gain;
UCEC	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.65	6.86	0.49	1.82e-10	Coronary artery disease;
UCEC	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.39	-5.29	-0.4	4.26e-7	IgG glycosylation;
UCEC	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.72	-7.67	-0.53	2.18e-12	Breast cancer;
UCEC	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.51	-5.82	-0.43	3.62e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg12024160	chr4:1254474	NA	0.65	7.77	0.54	1.25e-12	Obesity-related traits;
UCEC	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-0.94	-6.81	-0.49	2.31e-10	Body mass index;
UCEC	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg09007058	chr12:13043755	GPRC5A	0.44	4.56	0.35	1.06e-5	Coronary artery calcification;
UCEC	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-4.85	-0.37	3.05e-6	Bladder cancer;
UCEC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg26162295	chr17:38119207	GSDMA	-0.31	-4.53	-0.35	1.22e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg23625390	chr15:77176239	SCAPER	0.48	4.72	0.36	5.39e-6	Blood metabolite levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19672329	chr7:98923317	ARPC1A	0.58	6.99	0.5	8.94e-11	Warfarin maintenance dose;
UCEC	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.65	6.18	0.45	5.94e-9	Vitamin D levels;
UCEC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs6684428	0.610	rs12120132	chr1:56322054	G/A	cg11651538	chr1:56320950	NA	-0.76	-6.68	-0.48	4.55e-10	Airflow obstruction;
UCEC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.38	-5.72	-0.43	5.66e-8	Body mass index;
UCEC	cis	rs4851266	0.966	rs13017207	chr2:100841235	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.33	0.46	2.85e-9	Educational attainment;
UCEC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.59	5.05	0.38	1.32e-6	Alzheimer's disease;
UCEC	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.81	-9.17	-0.6	3.86e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.58	7.04	0.5	6.85e-11	Testicular germ cell tumor;
UCEC	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.71	0.54	1.72e-12	Alzheimer's disease;
UCEC	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.8	0.49	2.45e-10	Personality dimensions;
UCEC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.9	9.31	0.61	1.73e-16	Cognitive function;
UCEC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-0.78	-8.2	-0.56	1.12e-13	Breast cancer;
UCEC	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg20965017	chr5:231967	SDHA	-0.63	-5.29	-0.4	4.26e-7	Breast cancer;
UCEC	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg10932868	chr11:921992	NA	-0.45	-5.94	-0.44	2.01e-8	Alzheimer's disease (late onset);
UCEC	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg03924805	chr2:242211663	HDLBP	-0.45	-4.58	-0.35	9.65e-6	Joint mobility (Beighton score);
UCEC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.9100000000000004e-06	Breast cancer;
UCEC	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg09297252	chr8:7631214	NA	0.38	4.91	0.38	2.43e-6	Red cell distribution width;
UCEC	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	1.06	5.84	0.43	3.21e-8	Age-related hearing impairment;
UCEC	cis	rs1978968	0.751	rs5992138	chr22:18458621	A/C	cg03078520	chr22:18463400	MICAL3	-0.54	-5.99	-0.44	1.54e-8	Presence of antiphospholipid antibodies;
UCEC	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.52	-7.22	-0.51	2.61e-11	Height;
UCEC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg01262667	chr19:19385393	TM6SF2	0.5	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg06784218	chr1:46089804	CCDC17	-0.42	-4.81	-0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg03714773	chr7:91764589	CYP51A1	0.41	5.05	0.38	1.26e-6	Breast cancer;
UCEC	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.89	0.49	1.55e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.6	6.77	0.49	2.83e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	5.23	0.4	5.75e-7	Hemoglobin concentration;
UCEC	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.49	-5.74	-0.43	5.13e-8	Pulse pressure;
UCEC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.44	4.83	0.37	3.44e-6	Monocyte count;
UCEC	cis	rs2299682	0.826	rs6086899	chr20:9463441	T/G	cg11931762	chr20:9488920	NA	-0.7	-4.88	-0.37	2.76e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg03264133	chr6:25882463	NA	-0.58	-4.62	-0.36	8.22e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.67	8.01	0.55	3.2e-13	Menarche (age at onset);
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.73	9.16	0.6	4.11e-16	Menarche (age at onset);
UCEC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.53	5.56	0.42	1.22e-7	Pulse pressure;
UCEC	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.56	-5.73	-0.43	5.6e-8	Non-response to antidepressants and depression;
UCEC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.71	8.14	0.56	1.52e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.74	-6.04	-0.45	1.21e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.3	-0.57	6.04e-14	Breast cancer;
UCEC	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	7.36	0.52	1.19e-11	IgG glycosylation;
UCEC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.11	0.39	9.93e-7	Parkinson's disease;
UCEC	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.48	4.67	0.36	6.82e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-5.15	-0.39	8.17e-7	Hemoglobin concentration;
UCEC	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24308560	chr3:49941425	MST1R	0.48	5.22	0.4	6.12e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg03859395	chr2:55845619	SMEK2	1.0	13.75	0.75	3.61e-28	Metabolic syndrome;
UCEC	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg12473912	chr3:136751656	NA	0.44	5.04	0.38	1.33e-6	Neuroticism;Schizophrenia;
UCEC	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.49	-5.4	-0.41	2.58e-7	Life satisfaction;
UCEC	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.67	7.64	0.53	2.51e-12	Body mass index;
UCEC	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	8.91	0.59	1.81e-15	Mean platelet volume;
UCEC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg10932868	chr11:921992	NA	-0.46	-6.05	-0.45	1.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-0.61	-7.58	-0.53	3.52e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.69e-7	Menarche (age at onset);
UCEC	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.22	12.35	0.71	1.77e-24	Corneal structure;
UCEC	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.99	9.44	0.61	7.8e-17	Diastolic blood pressure;
UCEC	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-7.92	-0.55	5.49e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.79	7.99	0.55	3.56e-13	Cognitive function;
UCEC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.66	-0.36	7.05e-6	Parkinson's disease;
UCEC	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.75	-8.25	-0.56	8.44e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.57	5.81	0.43	3.79e-8	Tonsillectomy;
UCEC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.5e-7	Tonsillectomy;
UCEC	cis	rs17106184	1.000	rs72902736	chr1:51239976	A/G	cg07174182	chr1:51127561	FAF1	-0.89	-5.66	-0.42	7.66e-8	Type 2 diabetes;
UCEC	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.47	-4.88	-0.37	2.67e-6	Monocyte count;
UCEC	trans	rs7397861	1.000	rs4128354	chr12:66823686	A/T	cg18479068	chr2:216878351	MREG	0.64	7.01	0.5	8.13e-11	Menopause (age at onset);
UCEC	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-9.25	-0.61	2.5e-16	Blood metabolite levels;
UCEC	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-9.32	-0.61	1.64e-16	Coffee consumption (cups per day);
UCEC	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs10924970	0.649	rs12021964	chr1:235434543	A/G	cg26050004	chr1:235667680	B3GALNT2	0.53	4.92	0.38	2.27e-6	Asthma;
UCEC	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.82	11.16	0.68	2.53e-21	Headache;
UCEC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.61	5.34	0.4	3.53e-7	Heart rate;
UCEC	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	5.27	0.4	4.7e-7	Monocyte percentage of white cells;
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00002236	chr18:67873061	RTTN	0.58	6.82	0.49	2.21e-10	Warfarin maintenance dose;
UCEC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.52	-5.07	-0.39	1.2e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.54	4.98	0.38	1.73e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.82	-5.77	-0.43	4.51e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	8.14	0.56	1.5e-13	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.52	5.0	0.38	1.58e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.87	0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg05962950	chr11:130786565	SNX19	-0.55	-5.29	-0.4	4.39e-7	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2474937	0.561	rs2359838	chr1:118925731	G/T	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	6.61	0.48	6.66e-10	Alzheimer's disease;
UCEC	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.49	5.7	0.43	6.29e-8	Bone mineral density;
UCEC	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.6	7.52	0.53	5.14e-12	Testicular germ cell tumor;
UCEC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg08027265	chr7:2291960	NA	-0.46	-4.91	-0.38	2.4e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg17086141	chr17:45608114	NPEPPS	0.34	4.62	0.36	8.17e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.77	-8.9	-0.59	1.9e-15	Mortality in heart failure;
UCEC	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg06782697	chr22:19743336	TBX1	-0.3	-4.57	-0.35	1.03e-5	Metabolite levels;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-8.71	-0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.0	0.6	1.06e-15	Platelet count;
UCEC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.35	-4.59	-0.35	9.47e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.23	-0.46	4.58e-9	Tonsillectomy;
UCEC	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.51	-5.82	-0.43	3.51e-8	Breast size;
UCEC	cis	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg20307385	chr11:47447363	PSMC3	0.61	5.09	0.39	1.08e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs4799710	0.659	rs6507051	chr18:31208453	A/G	cg02896073	chr18:31799784	NOL4	0.4	4.59	0.35	9.37e-6	Pulmonary function;
UCEC	cis	rs732765	0.734	rs10438025	chr14:75183239	G/A	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.54	4.87	0.37	2.9e-6	Corneal astigmatism;
UCEC	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	0.51	4.71	0.36	5.64e-6	Pulmonary function decline;
UCEC	cis	rs7106204	0.764	rs79362440	chr11:24212972	G/A	ch.11.24196551F	chr11:24239977	NA	0.69	5.31	0.4	3.95e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-5.1	-0.39	1.03e-6	Personality dimensions;
UCEC	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.52	-5.6	-0.42	1.01e-7	Type 2 diabetes;
UCEC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	6.45	0.47	1.56e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-6.68	-0.48	4.59e-10	Bipolar disorder;
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.88	-11.39	-0.68	5.96e-22	Height;
UCEC	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.24e-18	Height;
UCEC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.62	9.03	0.6	9.11e-16	Prudent dietary pattern;
UCEC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.55	4.69	0.36	6.1e-6	Response to diuretic therapy;
UCEC	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.51	4.63	0.36	7.93e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.43	4.53	0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg06818710	chr6:28411271	ZSCAN23	0.54	6.44	0.47	1.6e-9	Cardiac Troponin-T levels;
UCEC	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.68	-6.05	-0.45	1.15e-8	Aortic root size;
UCEC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg00343986	chr7:65444356	GUSB	0.52	4.75	0.37	4.72e-6	Aortic root size;
UCEC	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.59	4.6	0.35	9.02e-6	Obesity-related traits;
UCEC	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18932078	chr1:2524107	MMEL1	0.33	5.49	0.41	1.74e-7	Ulcerative colitis;
UCEC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.58	-6.17	-0.45	6.25e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.63	6.81	0.49	2.27e-10	Colorectal cancer;
UCEC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.54	0.35	1.15e-5	Menopause (age at onset);
UCEC	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg08886695	chr4:3369023	RGS12	0.47	4.92	0.38	2.28e-6	Parental longevity (mother's age at death);
UCEC	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.59	-5.9	-0.44	2.38e-8	Hepatocellular carcinoma;
UCEC	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.54	4.83	0.37	3.33e-6	Obesity-related traits;
UCEC	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.51	-6.56	-0.48	8.51e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.61	5.78	0.43	4.38e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.79	8.41	0.57	3.31e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.94	7.19	0.51	2.97e-11	Initial pursuit acceleration;
UCEC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg03934865	chr2:198174659	NA	-0.43	-5.3	-0.4	4.14e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.69	5.66	0.42	7.84e-8	Major depressive disorder;
UCEC	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.47	-4.57	-0.35	1.02e-5	High light scatter reticulocyte count;
UCEC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-5.52	-0.41	1.48e-7	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.49	-6.54	-0.47	9.42e-10	Osteoporosis;
UCEC	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg22689016	chr5:506129	SLC9A3	0.67	4.69	0.36	6.31e-6	Breast cancer;
UCEC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.65	-5.75	-0.43	4.87e-8	IgG glycosylation;
UCEC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg10950441	chr12:67439808	NA	-0.45	-4.79	-0.37	3.98e-6	White blood cell count (basophil);
UCEC	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.54	5.01	0.38	1.56e-6	Corneal astigmatism;
UCEC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.58	6.36	0.46	2.38e-9	Monocyte count;
UCEC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.67	5.49	0.41	1.73e-7	Initial pursuit acceleration;
UCEC	cis	rs17123764	0.710	rs1470906	chr12:50146055	G/C	cg20471783	chr12:50157085	TMBIM6	0.62	4.91	0.38	2.43e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs970548	0.862	rs10900230	chr10:46130389	C/T	cg15223267	chr10:46222474	FAM21C	0.57	5.11	0.39	1e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-4.59	-0.35	9.54e-6	Homocysteine levels;
UCEC	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.52	5.69	0.42	6.58e-8	Immature fraction of reticulocytes;
UCEC	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg04154034	chr17:28927549	LRRC37B2	0.82	5.14	0.39	8.7e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.32	-0.4	3.75e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.68	-7.56	-0.53	4.07e-12	Menarche (age at onset);
UCEC	cis	rs12367572	0.620	rs2544102	chr12:45420127	A/G	cg03114573	chr12:45410052	DBX2	-0.59	-7.03	-0.5	7.18e-11	Gut microbiome composition (summer);
UCEC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.71	6.33	0.46	2.76e-9	Neutrophil percentage of white cells;
UCEC	cis	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg19041857	chr6:27730383	NA	-0.48	-4.7	-0.36	5.82e-6	Breast cancer;
UCEC	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.48	5.39	0.41	2.73e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg04154034	chr17:28927549	LRRC37B2	0.78	4.89	0.37	2.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.49	5.79	0.43	4.13e-8	Total body bone mineral density;
UCEC	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.58	6.45	0.47	1.48e-9	Retinal vascular caliber;
UCEC	cis	rs6684428	1.000	rs12070494	chr1:56348904	C/T	cg11651538	chr1:56320950	NA	-0.71	-6.14	-0.45	7.23e-9	Airflow obstruction;
UCEC	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.61	5.57	0.42	1.17e-7	Morning vs. evening chronotype;
UCEC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.78	-10.63	-0.66	6.08e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.76	-7.92	-0.55	5.45e-13	Breast cancer;
UCEC	cis	rs11760485	0.928	rs5021674	chr7:4399614	C/T	cg15613991	chr7:5277080	NA	-0.47	-5.58	-0.42	1.14e-7	Early childhood aggressive behavior;
UCEC	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2302190	0.882	rs2270098	chr17:56572081	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.66	0.36	6.9e-6	Vitamin D levels;
UCEC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.58	-5.21	-0.39	6.22e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.98	0.38	1.74e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-5.96	-0.44	1.77e-8	Mitochondrial DNA levels;
UCEC	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.78	-9.94	-0.63	3.88e-18	Menarche (age at onset);
UCEC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.79	8.73	0.58	5.17e-15	Menopause (age at onset);
UCEC	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg05962950	chr11:130786565	SNX19	0.5	5.2	0.39	6.65e-7	Schizophrenia;
UCEC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10924970	0.776	rs72758049	chr1:235465045	G/T	cg26050004	chr1:235667680	B3GALNT2	0.45	4.74	0.36	5.03e-6	Asthma;
UCEC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.83	5.15	0.39	8.06e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-7.91	-0.55	5.77e-13	Parkinson's disease;
UCEC	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.65	6.03	0.45	1.24e-8	Aortic root size;
UCEC	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.72	7.4	0.52	9.51e-12	Parkinson's disease;
UCEC	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.74	-6.46	-0.47	1.47e-9	Asthma;
UCEC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.82	7.28	0.51	1.87e-11	Longevity;
UCEC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.69	-7.3	-0.52	1.67e-11	Body mass index;
UCEC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.58	4.96	0.38	1.9e-6	Alzheimer's disease;
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	9.27	0.61	2.12e-16	Platelet count;
UCEC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.83	8.97	0.59	1.27e-15	Longevity;
UCEC	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.71	6.9	0.49	1.42e-10	Coronary artery disease;
UCEC	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.46	6.09	0.45	9.41e-9	Blood protein levels;
UCEC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.54	6.19	0.45	5.62e-9	Blood metabolite levels;
UCEC	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	1.21	6.75	0.49	3.26e-10	Thyroid stimulating hormone;
UCEC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.73	0.66	3.45e-20	Electrocardiographic conduction measures;
UCEC	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.47	-5.58	-0.42	1.14e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	8.73	0.58	5.25e-15	Coffee consumption (cups per day);
UCEC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg17328964	chr8:145687451	CYHR1	-0.8	-9.02	-0.6	9.4e-16	Age at first birth;
UCEC	cis	rs12980942	0.935	rs2241718	chr19:41829606	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.75	5.88	0.44	2.68e-8	Coronary artery disease;
UCEC	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.82	-0.49	2.26e-10	Prostate cancer;
UCEC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg06168204	chr6:27570548	NA	-0.43	-4.77	-0.37	4.4e-6	Parkinson's disease;
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.42	5.1	0.39	1.04e-6	Prudent dietary pattern;
UCEC	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.55	5.79	0.43	4.1e-8	Testicular germ cell tumor;
UCEC	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.74	-7.78	-0.54	1.18e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.73	7.97	0.55	4.13e-13	Breast cancer;
UCEC	cis	rs8177876	0.822	rs4324142	chr16:81114903	G/C	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs6479779	0.512	rs17215180	chr10:63688728	C/T	cg24734792	chr10:64580360	EGR2	-0.31	-4.77	-0.37	4.39e-6	IgG glycosylation;
UCEC	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-6.01	-0.44	1.4e-8	Platelet distribution width;
UCEC	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.47	5.11	0.39	9.93e-7	Platelet distribution width;
UCEC	cis	rs5167	0.504	rs892101	chr19:45455458	G/A	cg13119609	chr19:45449297	APOC2	0.42	5.92	0.44	2.14e-8	Blood protein levels;
UCEC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.35	-4.5	-0.35	1.35e-5	Type 2 diabetes;
UCEC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.48	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.84	-7.26	-0.51	2.11e-11	Platelet count;
UCEC	cis	rs7106204	0.764	rs58215218	chr11:24234720	G/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.81	-10.49	-0.65	1.48e-19	Extrinsic epigenetic age acceleration;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg04940109	chr2:203240432	BMPR2	0.69	7.43	0.52	8.1e-12	Triglyceride levels;
UCEC	cis	rs970548	0.955	rs11239551	chr10:46026107	G/A	cg15223267	chr10:46222474	FAM21C	0.54	4.84	0.37	3.25e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.65	0.36	7.18e-6	Menarche (age at onset);
UCEC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.75	-7.51	-0.53	5.16e-12	Aortic root size;
UCEC	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.81	-4.98	-0.38	1.79e-6	Putamen volume;
UCEC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.5	0.41	1.62e-7	Prudent dietary pattern;
UCEC	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.4	-4.55	-0.35	1.1e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg24803719	chr17:45855879	NA	-0.45	-5.22	-0.4	5.89e-7	IgG glycosylation;
UCEC	cis	rs8105895	0.935	rs62110985	chr19:22256077	A/G	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.63e-7	Body mass index (change over time);
UCEC	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.5	4.94	0.38	2.08e-6	Triglycerides;
UCEC	cis	rs5763662	1.000	rs5763742	chr22:30448524	A/G	cg07498879	chr22:30663041	OSM	0.51	4.53	0.35	1.21e-5	LDL cholesterol levels;LDL cholesterol;
UCEC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.61	6.74	0.49	3.43e-10	Resting heart rate;
UCEC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	19.92	0.85	1.35e-43	Chronic sinus infection;
UCEC	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2376682	0.959	rs10070759	chr5:117986200	G/A	cg17593721	chr5:118788746	HSD17B4	0.57	5.39	0.41	2.72e-7	Diisocyanate-induced asthma;
UCEC	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.54	5.1	0.39	1.05e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.62	-7.18	-0.51	3.18e-11	Pubertal anthropometrics;
UCEC	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	4.9	0.37	2.52e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg17294928	chr15:75287854	SCAMP5	0.56	6.13	0.45	7.7e-9	Breast cancer;
UCEC	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.93	10.19	0.64	8.84e-19	Alcohol dependence;
UCEC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.08	-0.39	1.11e-6	Colorectal cancer;
UCEC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.57	6.94	0.5	1.15e-10	Oral cavity cancer;
UCEC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.75	-0.63	1.27e-17	Monocyte count;
UCEC	cis	rs7581030	0.959	rs6744076	chr2:71596407	G/C	cg07678644	chr2:71558969	ZNF638	0.55	4.97	0.38	1.83e-6	Testicular germ cell tumor;
UCEC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.18	0.51	3.29e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.95	-7.41	-0.52	9.05e-12	Multiple sclerosis;
UCEC	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg20368463	chr18:77673604	PQLC1	0.67	5.25	0.4	5.23e-7	Opioid sensitivity;
UCEC	cis	rs7709377	0.620	rs7736189	chr5:115471425	T/C	cg23108291	chr5:115420582	COMMD10	0.52	5.4	0.41	2.61e-7	Metabolite levels  (X-11787);
UCEC	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.58	4.52	0.35	1.25e-5	Major depressive disorder;
UCEC	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.44	4.7	0.36	5.84e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.59	-5.2	-0.39	6.65e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.53	5.98	0.44	1.62e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.75	8.01	0.55	3.26e-13	Breast cancer;
UCEC	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg21253087	chr9:139290292	SNAPC4	-0.42	-4.66	-0.36	7.09e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.12	-0.39	9.6e-7	Longevity;Endometriosis;
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg08461772	chr7:95026248	PON3	0.36	5.03	0.38	1.39e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.78	7.76	0.54	1.34e-12	Smoking behavior;
UCEC	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.35	-5.35	-0.4	3.26e-7	Ulcerative colitis;
UCEC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.55	-6.17	-0.45	6.37e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs73206853	0.841	rs3026483	chr12:110780905	A/G	cg12870014	chr12:110450643	ANKRD13A	0.63	5.07	0.39	1.19e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.84	7.27	0.51	1.99e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.52	5.33	0.4	3.64e-7	Menarche (age at onset);
UCEC	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.8	-8.95	-0.59	1.46e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg20119798	chr7:94954144	PON1	-0.49	-4.64	-0.36	7.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	9.48	0.62	6.26e-17	Coffee consumption (cups per day);
UCEC	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.58	-4.61	-0.36	8.74e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.54	4.62	0.36	8.16e-6	Menarche (age at onset);
UCEC	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.54	5.78	0.43	4.24e-8	Longevity;Endometriosis;
UCEC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.78	-0.49	2.66e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.51	4.89	0.37	2.65e-6	HDL cholesterol;
UCEC	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.3	-0.4	4.07e-7	Depression;
UCEC	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.49	4.7	0.36	5.92e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13683864	chr3:40499215	RPL14	-0.97	-10.68	-0.66	4.61e-20	Renal cell carcinoma;
UCEC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.98	0.38	1.79e-6	Breast cancer;
UCEC	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	1.18	14.71	0.77	1.1e-30	Body mass index;
UCEC	cis	rs829661	1.000	rs2692035	chr2:30672835	T/A	cg17749961	chr2:30669863	LCLAT1	0.51	4.8	0.37	3.93e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg06742321	chr12:123595122	PITPNM2	0.48	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs12318506	0.826	rs11180431	chr12:75661200	G/A	cg04728562	chr12:75699417	CAPS2	-0.8	-5.0	-0.38	1.6e-6	Coronary artery calcification;
UCEC	cis	rs7095607	0.813	rs7911060	chr10:69929058	T/C	cg18986048	chr10:69913749	MYPN	0.54	6.35	0.46	2.54e-9	Lung function (FVC);
UCEC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.88	0.44	2.65e-8	HDL cholesterol;
UCEC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.55	-5.34	-0.4	3.46e-7	Aortic root size;
UCEC	cis	rs742614	0.533	rs2747541	chr20:32418772	G/T	cg06304546	chr20:32448765	NA	-0.45	-4.75	-0.36	4.74e-6	Stearic acid (18:0) levels;
UCEC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.9	-0.49	1.43e-10	Mood instability;
UCEC	cis	rs12447804	0.734	rs9926693	chr16:58097357	C/T	cg14010159	chr16:58078951	MMP15	0.41	4.64	0.36	7.65e-6	Pulmonary function;Pulmonary function (smoking interaction);
UCEC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-1.09	-7.94	-0.55	4.75e-13	Height;
UCEC	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.61	-6.63	-0.48	5.83e-10	Refractive error;
UCEC	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.59	6.04	0.45	1.19e-8	Colorectal cancer;
UCEC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01380346	chr19:18557039	ELL	-0.52	-5.54	-0.42	1.34e-7	Breast cancer;
UCEC	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg06782697	chr22:19743336	TBX1	-0.3	-4.57	-0.35	1.03e-5	Metabolite levels;
UCEC	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.86	-10.42	-0.65	2.23e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.38	-5.81	-0.43	3.81e-8	Body mass index;
UCEC	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.67	-0.36	6.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-5.21	-0.4	6.14e-7	Bipolar disorder;
UCEC	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg02820040	chr2:241836501	C2orf54	-0.4	-5.1	-0.39	1.03e-6	Urinary metabolites;
UCEC	cis	rs8105895	0.799	rs62112922	chr19:22228340	C/T	cg20662725	chr19:22235022	ZNF257	-0.64	-5.31	-0.4	3.95e-7	Body mass index (change over time);
UCEC	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.97	-10.51	-0.65	1.31e-19	Corneal structure;
UCEC	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.59	5.01	0.38	1.51e-6	RR interval (heart rate);
UCEC	cis	rs1476670	0.710	rs2477616	chr1:44504809	G/A	cg09470012	chr1:44509516	NA	0.42	5.23	0.4	5.76e-7	Eotaxin levels;
UCEC	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.86	-11.05	-0.67	4.72e-21	Brugada syndrome;
UCEC	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.52	-5.93	-0.44	2.09e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.62	2.32e-17	Breast cancer;
UCEC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg22974920	chr21:40686053	BRWD1	0.55	4.76	0.37	4.68e-6	Cognitive function;
UCEC	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	0.92	5.65	0.42	8.1e-8	Skin colour saturation;
UCEC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.24	0.46	4.35e-9	Cognitive test performance;
UCEC	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.53	-5.21	-0.39	6.38e-7	Multiple sclerosis;
UCEC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.65	0.42	7.9e-8	Breast cancer;
UCEC	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.51	4.86	0.37	2.98e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-7.32	-0.52	1.52e-11	Resting heart rate;
UCEC	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.81	-0.43	3.7e-8	Cardiac Troponin-T levels;
UCEC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	0.52	6.07	0.45	1.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6746896	0.762	rs878919	chr2:97437990	T/C	cg01950434	chr2:97203154	ARID5A	-0.45	-4.75	-0.36	4.72e-6	Bipolar disorder;
UCEC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.62	6.2	0.46	5.39e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.9	-8.49	-0.57	2.02e-14	Blood metabolite levels;
UCEC	cis	rs17012589	0.910	rs7484730	chr12:85661849	C/A	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.59	-0.35	9.26e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.63	-0.36	8.1e-6	Type 2 diabetes;
UCEC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg27068330	chr11:65405492	SIPA1	-0.59	-5.79	-0.43	4.14e-8	Acne (severe);
UCEC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.1	0.71	8.2e-24	Prudent dietary pattern;
UCEC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.7	-6.99	-0.5	8.71e-11	Bipolar disorder and schizophrenia;
UCEC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.97	0.5	9.8e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.68	5.33	0.4	3.66e-7	Corneal astigmatism;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg26671554	chr17:57784674	TMEM49;PTRH2	-0.6	-6.72	-0.48	3.81e-10	Breast cancer;
UCEC	cis	rs78707713	0.512	rs12772559	chr10:71184356	C/G	cg12610070	chr10:71211762	TSPAN15	-0.34	-4.98	-0.38	1.75e-6	Venous thromboembolism;
UCEC	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg21770322	chr7:97807741	LMTK2	0.47	5.84	0.43	3.16e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.47	-4.68	-0.36	6.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.03	0.38	1.4e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs10242455	0.702	rs73711293	chr7:99081595	C/T	cg18809830	chr7:99032528	PTCD1	-0.92	-5.26	-0.4	4.95e-7	Blood metabolite levels;
UCEC	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-0.43	-4.68	-0.36	6.51e-6	IgG glycosylation;
UCEC	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-4.51	-0.35	1.34e-5	Electroencephalogram traits;
UCEC	cis	rs7336933	0.932	rs9532958	chr13:42535935	G/A	cg18400088	chr13:41634674	WBP4	0.55	4.62	0.36	8.4e-6	Calcium levels;
UCEC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.72	6.64	0.48	5.57e-10	Aortic root size;
UCEC	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.62	-8.09	-0.56	2e-13	Fibrinogen levels;
UCEC	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-6.0	-0.44	1.44e-8	Schizophrenia;
UCEC	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.94	-0.38	2.12e-6	Depression;
UCEC	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-5.65	-0.42	8.06e-8	Colorectal cancer;
UCEC	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.86	-9.59	-0.62	3.32e-17	Blood metabolite levels;
UCEC	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	0.66	6.27	0.46	3.88e-9	Vitiligo;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg17966709	chr11:57435952	ZDHHC5	0.65	6.77	0.49	2.9e-10	Schizophrenia;
UCEC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.56	6.46	0.47	1.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.66	-5.46	-0.41	1.98e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg00800038	chr16:89945340	TCF25	-0.84	-4.59	-0.35	9.39e-6	Skin colour saturation;
UCEC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg15848620	chr12:58087721	OS9	0.51	4.88	0.37	2.79e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg04553112	chr3:125709451	NA	-0.65	-4.74	-0.36	4.9100000000000004e-06	Blood pressure (smoking interaction);
UCEC	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.57	5.8	0.43	3.93e-8	Radiation response;
UCEC	cis	rs7570971	0.876	rs1561277	chr2:136092061	C/A	cg07169764	chr2:136633963	MCM6	0.7	6.56	0.48	8.72e-10	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.43	-5.22	-0.4	5.9e-7	Refractive error;
UCEC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21178979	chr7:1889533	MAD1L1	0.37	4.71	0.36	5.57e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.56	6.67	0.48	4.89e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg13870426	chr17:30244630	NA	-0.63	-4.73	-0.36	5.32e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.96	0.59	1.38e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.51	-0.35	1.29e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20307385	chr11:47447363	PSMC3	-0.64	-5.57	-0.42	1.17e-7	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.54	-5.95	-0.44	1.88e-8	Blood metabolite levels;
UCEC	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.51	-4.8	-0.37	3.88e-6	Diabetic retinopathy;
UCEC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.51	-0.35	1.31e-5	Alzheimer's disease (late onset);
UCEC	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.64	6.3	0.46	3.26e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg14675211	chr2:100938903	LONRF2	0.63	6.25	0.46	4.1e-9	Educational attainment;
UCEC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.69	-6.68	-0.48	4.5e-10	Morning vs. evening chronotype;
UCEC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.61	-7.73	-0.54	1.57e-12	Fibrinogen levels;
UCEC	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.46	5.23	0.4	5.86e-7	Mean corpuscular volume;
UCEC	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.76	-6.29	-0.46	3.37e-9	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.9	-8.95	-0.59	1.45e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs9470794	0.920	rs2145887	chr6:38097774	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.8	0.37	3.94e-6	Type 2 diabetes;
UCEC	cis	rs10924970	0.649	rs4659493	chr1:235482272	T/C	cg26050004	chr1:235667680	B3GALNT2	0.51	4.93	0.38	2.21e-6	Asthma;
UCEC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs10199521	0.861	rs1706859	chr2:2517233	T/C	cg22060041	chr2:1796155	MYT1L	-0.39	-5.02	-0.38	1.49e-6	Diabetic retinopathy;
UCEC	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-8.16	-0.56	1.4e-13	Chronic sinus infection;
UCEC	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.5	-5.61	-0.42	9.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.932	rs7256599	chr19:23045921	T/C	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.54e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.932	rs35706770	chr19:23059262	T/C	cg08271804	chr19:22816896	ZNF492	0.55	4.95	0.38	2.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9469578	1.000	rs16869456	chr6:33714622	G/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.58	-9.87	-0.63	5.98e-18	Bone mineral density;
UCEC	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.43	-4.53	-0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.74	-0.36	5e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg09555818	chr19:45449301	APOC2	0.5	6.74	0.49	3.29e-10	Blood protein levels;
UCEC	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.63	5.17	0.39	7.48e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-5.0	-0.38	1.61e-6	Response to antipsychotic treatment;
UCEC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg08222913	chr3:52553049	STAB1	-0.44	-5.13	-0.39	8.97e-7	Bipolar disorder;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01074628	chr11:74204917	LIPT2	0.68	8.29	0.56	6.52e-14	Warfarin maintenance dose;
UCEC	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg00122941	chr17:4613640	ARRB2	-0.56	-4.99	-0.38	1.66e-6	Lymphocyte counts;
UCEC	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.49	-4.53	-0.35	1.19e-5	Morning vs. evening chronotype;
UCEC	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.15	9.4	0.61	1.03e-16	Vitiligo;
UCEC	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg04283868	chr2:201171347	SPATS2L	-0.47	-4.62	-0.36	8.22e-6	QT interval;
UCEC	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.87	6.68	0.48	4.51e-10	Lymphocyte counts;
UCEC	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.61	4.62	0.36	8.43e-6	Lymphocyte counts;
UCEC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.82	7.37	0.52	1.16e-11	Bladder cancer;
UCEC	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.61	7.32	0.52	1.5e-11	Mean corpuscular volume;
UCEC	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.3	4.79	0.37	4.07e-6	Cancer;
UCEC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-1.05	-7.14	-0.51	4.07e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.45	4.54	0.35	1.16e-5	Longevity;Endometriosis;
UCEC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.77	4.67	0.36	6.75e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.71	7.36	0.52	1.18e-11	Smoking behavior;
UCEC	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg23972785	chr8:11611189	GATA4	-0.37	-4.58	-0.35	9.95e-6	Systolic blood pressure;
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.64	-7.16	-0.51	3.63e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.25	-7.8	-0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs6723108	0.604	rs2322251	chr2:135671302	C/T	cg07169764	chr2:136633963	MCM6	0.48	4.56	0.35	1.07e-5	Type 2 diabetes;
UCEC	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.38	-0.47	2.19e-9	Aortic root size;
UCEC	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.61	-0.36	8.5e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.57	-8.15	-0.56	1.45e-13	Refractive error;
UCEC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.53	5.0	0.38	1.6e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.02	-0.5	7.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs34676724	chr19:22918473	A/C	cg24889512	chr19:22816950	ZNF492	0.63	6.61	0.48	6.65e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.62	6.35	0.46	2.56e-9	Menopause (age at onset);
UCEC	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-5.15	-0.39	8.4e-7	Extraversion;
UCEC	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.6	6.68	0.48	4.52e-10	Red blood cell count;
UCEC	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12681287	0.752	rs12681438	chr8:87293089	G/A	cg27223183	chr8:87520930	FAM82B	-0.66	-5.46	-0.41	1.97e-7	Caudate activity during reward;
UCEC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-9.78	-0.63	1.04e-17	Electrocardiographic conduction measures;
UCEC	cis	rs1028488	0.511	rs7738313	chr6:170704356	C/A	cg20370364	chr6:170703943	FAM120B	-0.48	-4.75	-0.36	4.81e-6	Interferon alpha levels in systemic lupus erythematosus;
UCEC	cis	rs731174	0.802	rs609437	chr1:38184316	T/C	cg12339802	chr1:38156545	C1orf109	-0.55	-4.66	-0.36	6.96e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.35	4.64	0.36	7.54e-6	Depression;
UCEC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg23795048	chr12:9217529	LOC144571	0.41	4.98	0.38	1.76e-6	Sjögren's syndrome;
UCEC	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg05962950	chr11:130786565	SNX19	0.75	6.94	0.5	1.17e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg19318889	chr4:1322082	MAEA	0.41	4.69	0.36	6.25e-6	Longevity;
UCEC	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg23307798	chr14:103986281	CKB	0.58	6.17	0.45	6.4e-9	Body mass index;
UCEC	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.61	6.39	0.47	2.05e-9	QRS complex (12-leadsum);
UCEC	cis	rs7246967	0.673	rs2082445	chr19:22834587	A/G	cg05241461	chr19:22816980	ZNF492	0.56	6.03	0.45	1.25e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.84	-0.43	3.15e-8	Depression;
UCEC	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.72	5.88	0.44	2.69e-8	Cerebrospinal P-tau181p levels;
UCEC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.99	10.99	0.67	6.94e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.9	-10.42	-0.65	2.19e-19	Cognitive function;
UCEC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg26587870	chr6:27730563	NA	-0.57	-4.55	-0.35	1.11e-5	Depression;
UCEC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.75	7.44	0.52	7.68e-12	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.65	6.33	0.46	2.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.19e-6	Vitiligo;
UCEC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg12024160	chr4:1254474	NA	0.64	7.3	0.52	1.63e-11	Obesity-related traits;
UCEC	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	8.94	0.59	1.52e-15	Bipolar disorder;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.93	-0.44	2.06e-8	Depression;
UCEC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	9.28	0.61	2.02e-16	Mean platelet volume;
UCEC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg26528668	chr16:1614120	IFT140	0.45	5.14	0.39	8.78e-7	Coronary artery disease;
UCEC	cis	rs7709377	0.595	rs712601	chr5:115660706	G/A	cg23108291	chr5:115420582	COMMD10	-0.46	-4.62	-0.36	8.2e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.37	4.63	0.36	7.85e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.67	-7.48	-0.53	6.17e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7246657	0.943	rs10404945	chr19:38022358	T/C	cg23950597	chr19:37808831	NA	-0.69	-5.82	-0.43	3.54e-8	Coronary artery calcification;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.46	-5.0	-0.38	1.64e-6	Pulmonary function;
UCEC	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.66	7.91	0.55	5.65e-13	Hip circumference;
UCEC	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg05991184	chr2:219186017	PNKD	0.53	5.86	0.43	2.98e-8	Colorectal cancer;
UCEC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.79	0.37	4.05e-6	Tonsillectomy;
UCEC	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.51	-5.12	-0.39	9.51e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs12786942	0.569	rs4271356	chr11:101313984	T/C	cg03942599	chr11:101341554	TRPC6	0.51	5.91	0.44	2.32e-8	Facial depth;
UCEC	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.13e-7	Body mass index;
UCEC	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	0.86	5.47	0.41	1.91e-7	Arsenic metabolism;
UCEC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.87	5.48	0.41	1.83e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	8.57	0.58	1.32e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.42e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.09e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6832769	0.961	rs7684810	chr4:56352794	C/T	cg05960024	chr4:56376020	CLOCK	0.49	4.51	0.35	1.34e-5	Personality dimensions;
UCEC	cis	rs17123764	0.710	rs7296281	chr12:49964558	A/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.43	0.41	2.23e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-6.58	-0.48	7.91e-10	Heart rate;
UCEC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg11945507	chr8:142233382	SLC45A4	-0.45	-5.13	-0.39	9.14e-7	Immature fraction of reticulocytes;
UCEC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.52	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.63	5.53	0.41	1.44e-7	Corneal astigmatism;
UCEC	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.75	7.7	0.54	1.87e-12	Caffeine consumption;
UCEC	cis	rs17122693	1.000	rs3759588	chr14:51062357	G/A	cg04730355	chr14:51134070	SAV1	0.89	8.7	0.58	6e-15	Cognitive performance;
UCEC	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.58	0.42	1.15e-7	Breast cancer;
UCEC	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs117623576	0.941	rs211422	chr10:32398589	A/G	cg03047570	chr10:32398778	NA	0.59	5.44	0.41	2.19e-7	Anti-saccade response;
UCEC	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs4879656	0.564	rs1888869	chr9:32998237	C/G	cg09633881	chr9:33002021	APTX	0.37	4.6	0.35	8.99e-6	Menopause (age at onset);
UCEC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.33	-0.57	5.3e-14	Hemoglobin concentration;
UCEC	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.65	5.67	0.42	7.5e-8	Uric acid levels;
UCEC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.7	7.25	0.51	2.19e-11	Menopause (age at onset);
UCEC	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-4.64	-0.36	7.72e-6	Breast cancer;
UCEC	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.47	4.92	0.38	2.25e-6	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.49	6.65	0.48	5.47e-10	Height;
UCEC	cis	rs73416724	1.000	rs78014492	chr6:43289599	C/T	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8105895	0.932	rs60548522	chr19:22214874	G/A	cg20662725	chr19:22235022	ZNF257	-0.53	-4.8	-0.37	3.78e-6	Body mass index (change over time);
UCEC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.98	-11.37	-0.68	6.73e-22	Height;
UCEC	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs7805747	0.961	rs17173238	chr7:151406220	A/G	cg17611936	chr7:151411526	PRKAG2	0.67	5.74	0.43	5.12e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
UCEC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg18681998	chr4:17616180	MED28	0.7	6.98	0.5	9.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2708377	0.656	rs116607079	chr12:11262044	C/T	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.59	4.72	0.36	5.36e-6	Bitter taste perception;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.73	8.57	0.58	1.33e-14	Menarche (age at onset);
UCEC	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.32	-0.71	2.05e-24	Primary sclerosing cholangitis;
UCEC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.54	-0.47	9.48e-10	Chronic sinus infection;
UCEC	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.79	9.14	0.6	4.65e-16	Lymphocyte counts;
UCEC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.2e-5	Chronic sinus infection;
UCEC	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.55	5.48	0.41	1.82e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg04155231	chr12:9217510	LOC144571	0.41	4.99	0.38	1.71e-6	Sjögren's syndrome;
UCEC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.45	-0.41	2.09e-7	Birth weight;
UCEC	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21178979	chr7:1889533	MAD1L1	0.38	5.03	0.38	1.41e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10924970	0.967	rs2152955	chr1:235417773	G/A	cg26050004	chr1:235667680	B3GALNT2	0.46	4.81	0.37	3.74e-6	Asthma;
UCEC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05776053	chr2:74358815	NA	0.4	4.53	0.35	1.21e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.46	5.16	0.39	7.97e-7	Emphysema distribution in smoking;
UCEC	cis	rs12644436	0.864	rs56698994	chr4:88777704	G/A	cg27179352	chr4:88029472	AFF1	0.4	4.63	0.36	7.85e-6	HIV-1 viral setpoint;
UCEC	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.75	-8.37	-0.57	4.03e-14	White blood cell count (basophil);
UCEC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.35	-0.4	3.27e-7	Initial pursuit acceleration;
UCEC	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-5.76	-0.43	4.75e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.79	0.49	2.55e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs4972806	0.814	rs966801	chr2:177037827	G/A	cg14324370	chr2:177042789	NA	0.56	5.79	0.43	4.17e-8	IgG glycosylation;
UCEC	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.66	-7.5	-0.53	5.65e-12	Ulcerative colitis;
UCEC	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.67	-6.17	-0.45	6.23e-9	Initial pursuit acceleration;
UCEC	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.98	11.46	0.69	4e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs350251	0.899	rs1704116	chr16:12209658	A/G	cg01282078	chr16:12139025	RUNDC2A	-0.47	-4.58	-0.35	9.8e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-9.06	-0.6	7.31e-16	Gut microbiome composition (summer);
UCEC	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.55	-4.77	-0.37	4.37e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.81e-7	Heart rate;
UCEC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	0.96	6.56	0.48	8.61e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs7106204	0.748	rs11827778	chr11:24211321	G/A	ch.11.24196551F	chr11:24239977	NA	0.53	5.48	0.41	1.83e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7246967	0.673	rs7250343	chr19:22822845	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.83	0.59	2.82e-15	Platelet count;
UCEC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg25011176	chr20:3776985	CDC25B	-0.64	-6.12	-0.45	8.13e-9	Bipolar disorder;
UCEC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.56	4.76	0.37	4.59e-6	Alzheimer's disease;
UCEC	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.91	12.02	0.7	1.31e-23	Metabolic syndrome;
UCEC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.66	-5.97	-0.44	1.73e-8	Prudent dietary pattern;
UCEC	cis	rs10242455	0.867	rs2740560	chr7:99322320	T/A	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.36	-0.4	3.12e-7	Blood metabolite levels;
UCEC	cis	rs16944613	0.588	rs8030799	chr15:91109374	G/C	cg08919649	chr15:91565780	VPS33B	0.62	4.82	0.37	3.48e-6	Colorectal cancer;
UCEC	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.56	5.63	0.42	8.96e-8	Neuroticism;
UCEC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg12024160	chr4:1254474	NA	0.63	7.28	0.51	1.84e-11	Obesity-related traits;
UCEC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.62	7.11	0.51	4.62e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.48	-5.38	-0.41	2.82e-7	Retinal vascular caliber;
UCEC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.64	5.59	0.42	1.08e-7	Urinary electrolytes (magnesium/calcium ratio);
UCEC	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-5.09	-0.39	1.1e-6	Height;
UCEC	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-7.84	-0.54	8.48e-13	Schizophrenia;
UCEC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	7.36	0.52	1.21e-11	Exhaled nitric oxide levels;
UCEC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg09491104	chr22:46646882	C22orf40	-0.65	-7.55	-0.53	4.29e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.68	7.93	0.55	5.13e-13	Testicular germ cell tumor;
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.93	0.55	5.01e-13	Platelet count;
UCEC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.42	4.61	0.36	8.81e-6	Obesity-related traits;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19419581	chr17:79482410	NA	0.56	6.88	0.49	1.64e-10	Warfarin maintenance dose;
UCEC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg06096015	chr1:231504339	EGLN1	0.45	4.95	0.38	2.04e-6	Hemoglobin concentration;
UCEC	cis	rs57244888	0.929	rs2162377	chr2:16460901	C/T	cg02487026	chr2:15701516	NBAS	0.58	4.95	0.38	2.02e-6	Basal cell carcinoma;
UCEC	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-4.69	-0.36	6.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1079204	1.000	rs11888211	chr2:219146988	G/A	cg05728596	chr2:219128475	GPBAR1	0.65	5.28	0.4	4.56e-7	Smooth-surface caries;
UCEC	cis	rs7246967	0.673	rs34682021	chr19:22826728	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.932	rs62120788	chr19:23051012	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.35	-4.85	-0.37	3.14e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs11048434	1.000	rs12824212	chr12:9153417	A/G	cg23795048	chr12:9217529	LOC144571	0.47	5.68	0.42	6.85e-8	Sjögren's syndrome;
UCEC	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.45	-6.16	-0.45	6.71e-9	Prostate cancer;
UCEC	cis	rs7712401	0.755	rs27740	chr5:122204772	A/T	cg18764291	chr5:122110994	SNX2	-0.51	-4.85	-0.37	3.11e-6	Mean platelet volume;
UCEC	cis	rs3743832	0.965	rs7185073	chr16:9209122	T/A	cg08831531	chr16:9218945	NA	-0.43	-4.64	-0.36	7.75e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.29e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	4.7	0.36	5.81e-6	Menarche (age at onset);
UCEC	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.56	-6.16	-0.45	6.57e-9	Menarche (age at onset);
UCEC	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg19413350	chr8:57351067	NA	-0.44	-5.21	-0.39	6.42e-7	Obesity-related traits;
UCEC	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs797973	0.606	rs811300	chr17:27595829	C/G	cg04532153	chr17:27046900	SNORD42B;RPL23A	-0.44	-4.55	-0.35	1.13e-5	Type 2 diabetes;
UCEC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.07	-0.39	1.18e-6	Personality dimensions;
UCEC	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.46	-5.05	-0.38	1.31e-6	Gut microbiome composition (winter);
UCEC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.4	5.22	0.4	6.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.53	-5.83	-0.43	3.34e-8	IgG glycosylation;
UCEC	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.72	6.69	0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.55	4.97	0.38	1.86e-6	Menarche (age at onset);
UCEC	cis	rs4908768	0.906	rs2144463	chr1:8583293	C/A	cg13081009	chr1:8430745	RERE	0.42	4.57	0.35	1.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg17526145	chr2:23869158	KLHL29	0.46	4.94	0.38	2.06e-6	Asthma;
UCEC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.44	0.41	2.14e-7	Height;
UCEC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg22974920	chr21:40686053	BRWD1	0.56	4.76	0.37	4.57e-6	Cognitive function;
UCEC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.53	5.24	0.4	5.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.86	6.77	0.49	2.92e-10	Body mass index;
UCEC	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg05775895	chr3:12838266	CAND2	0.55	4.82	0.37	3.51e-6	QRS complex (12-leadsum);
UCEC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.54	-5.05	-0.38	1.31e-6	Cognitive function;
UCEC	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.78	6.66	0.48	5.15e-10	Menopause (age at onset);
UCEC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.42	4.57	0.35	1.03e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.03e-6	Sudden cardiac arrest;
UCEC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27654505	chr4:99579615	TSPAN5	-0.55	-5.41	-0.41	2.54e-7	Gut microbiome composition (summer);
UCEC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	6.99	0.5	9e-11	Body mass index;
UCEC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.81	9.45	0.61	7.35e-17	Bone mineral density;
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	8.3	0.56	6.36e-14	Platelet count;
UCEC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg03354898	chr7:1950403	MAD1L1	-0.46	-4.98	-0.38	1.73e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.71	6.45	0.47	1.54e-9	Aortic root size;
UCEC	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-4.72	-0.36	5.46e-6	Monocyte percentage of white cells;
UCEC	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.85	-8.49	-0.57	2.07e-14	Resting heart rate;
UCEC	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg13319975	chr6:146136371	FBXO30	0.68	6.0	0.44	1.45e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg18016565	chr1:150552671	MCL1	0.63	6.91	0.49	1.39e-10	Melanoma;
UCEC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.34	-4.53	-0.35	1.2e-5	Longevity;
UCEC	cis	rs12681287	0.752	rs34279109	chr8:87247944	G/A	cg27223183	chr8:87520930	FAM82B	-0.63	-5.43	-0.41	2.32e-7	Caudate activity during reward;
UCEC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg05802129	chr4:122689817	NA	-0.54	-5.54	-0.42	1.36e-7	Type 2 diabetes;
UCEC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg11871910	chr12:69753446	YEATS4	0.62	6.91	0.5	1.35e-10	Blood protein levels;
UCEC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.71	6.73	0.49	3.59e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7430852	0.510	rs1530705	chr3:85781164	A/G	cg05152589	chr3:85008678	CADM2	-0.64	-4.68	-0.36	6.42e-6	Mumps;
UCEC	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.49	-4.76	-0.37	4.57e-6	Endometrial cancer;
UCEC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.49	5.76	0.43	4.81e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.69	-6.66	-0.48	5.08e-10	Platelet distribution width;
UCEC	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg18646521	chr2:111875858	NA	0.4	4.62	0.36	8.39e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-22.65	-0.88	8.39e-50	Myeloid white cell count;
UCEC	cis	rs7607369	0.559	rs13027908	chr2:219660374	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-5.09	-0.39	1.06e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg14675211	chr2:100938903	LONRF2	0.63	6.25	0.46	4.1e-9	Educational attainment;
UCEC	cis	rs2862064	1.000	rs7715467	chr5:156468654	C/G	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.41	5.61	0.42	9.63e-8	Mean corpuscular volume;
UCEC	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09597638	chr17:3907349	NA	-0.4	-4.89	-0.37	2.66e-6	Type 2 diabetes;
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	7.73	0.54	1.56e-12	Platelet count;
UCEC	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	0.69	5.4	0.41	2.63e-7	Blood protein levels;
UCEC	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.67	5.85	0.43	3e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.6	-6.48	-0.47	1.27e-9	Lung cancer;
UCEC	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg06521331	chr12:34319734	NA	-0.65	-5.17	-0.39	7.38e-7	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.47	4.5	0.35	1.35e-5	Aortic root size;
UCEC	cis	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg17469321	chr7:55412551	NA	0.7	6.36	0.46	2.38e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1595825	0.891	rs78198610	chr2:198522769	T/C	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.15	0.56	1.42e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	20.41	0.86	9.52e-45	Chronic sinus infection;
UCEC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.34	4.68	0.36	6.55e-6	Prostate cancer;
UCEC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	7.07	0.5	5.9e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-0.99	-9.7	-0.62	1.68e-17	Initial pursuit acceleration;
UCEC	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.69	7.01	0.5	7.83e-11	Itch intensity from mosquito bite;
UCEC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.67	-5.51	-0.41	1.56e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg16325326	chr1:53192061	ZYG11B	-0.76	-8.66	-0.58	7.68e-15	Monocyte count;
UCEC	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	5.98	0.44	1.63e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg07153921	chr17:41440717	NA	-0.6	-7.3	-0.52	1.64e-11	Menopause (age at onset);
UCEC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.54	6.72	0.48	3.73e-10	Age at first birth;
UCEC	cis	rs73206853	0.841	rs73206894	chr12:110876328	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.62	-6.21	-0.46	5.03e-9	Strep throat;
UCEC	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.87	0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-7.86	-0.54	7.5e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.38	-5.71	-0.43	5.91e-8	Body mass index;
UCEC	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg21905437	chr5:178450457	ZNF879	0.65	7.26	0.51	2.12e-11	Pubertal anthropometrics;
UCEC	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg22166914	chr1:53195759	ZYG11B	-0.77	-7.8	-0.54	1.02e-12	Monocyte count;
UCEC	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg21770322	chr7:97807741	LMTK2	0.84	14.48	0.77	4.35e-30	Breast cancer;
UCEC	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.38	0.57	3.83e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.55	-6.08	-0.45	9.69e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.68	-0.62	1.85e-17	Primary sclerosing cholangitis;
UCEC	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.69	6.24	0.46	4.47e-9	Menopause (age at onset);
UCEC	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.59	-5.59	-0.42	1.06e-7	Immature fraction of reticulocytes;
UCEC	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.48	-4.84	-0.37	3.27e-6	Total body bone mineral density;
UCEC	cis	rs11958404	0.932	rs72816584	chr5:157433190	G/A	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs883565	0.569	rs1274970	chr3:39163252	A/G	cg01426195	chr3:39028469	NA	0.63	7.61	0.53	3.01e-12	Handedness;
UCEC	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.12	-0.39	9.33e-7	Morning vs. evening chronotype;
UCEC	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	0.86	6.86	0.49	1.81e-10	Blood protein levels;
UCEC	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.41	-5.04	-0.38	1.36e-6	Refractive error;
UCEC	cis	rs2415984	0.818	rs11625708	chr14:46834241	G/A	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.68	7.11	0.51	4.75e-11	Blood metabolite levels;
UCEC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.58	5.03	0.38	1.39e-6	Response to diuretic therapy;
UCEC	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.49	-6.51	-0.47	1.12e-9	Body mass index;
UCEC	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.89	-12.01	-0.7	1.39e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-7.31	-0.52	1.61e-11	Obesity-related traits;
UCEC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.54	-5.85	-0.43	3e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.69	-5.94	-0.44	1.98e-8	Parkinson's disease;
UCEC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.54	-6.01	-0.44	1.41e-8	Prostate cancer;
UCEC	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.53	5.56	0.42	1.26e-7	Type 2 diabetes;
UCEC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.67	5.0	0.38	1.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.53	5.51	0.41	1.57e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.39	-4.7	-0.36	5.86e-6	Menopause (age at onset);
UCEC	trans	rs9821348	1.000	rs13321096	chr3:106782614	G/C	cg22693702	chr11:62105635	ASRGL1	-1.03	-6.69	-0.48	4.35e-10	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs9402633	0.938	rs9402631	chr6:135039514	A/T	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.69	5.91	0.44	2.24e-8	HIV-1 control;
UCEC	cis	rs7809615	0.636	rs12538826	chr7:99030228	T/C	cg24650262	chr7:98904301	NA	0.49	4.95	0.38	2.04e-6	Blood metabolite ratios;
UCEC	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.04	-0.38	1.33e-6	Diabetic retinopathy;
UCEC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.51	-4.65	-0.36	7.33e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.78	8.57	0.58	1.28e-14	Eosinophil percentage of white cells;
UCEC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.93	8.28	0.56	7.09e-14	Initial pursuit acceleration;
UCEC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.45	-0.41	2.04e-7	Blood metabolite levels;
UCEC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.81	7.86	0.54	7.62e-13	Cognitive function;
UCEC	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.62	-5.79	-0.43	4.15e-8	Metabolite levels;
UCEC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.5	4.96	0.38	1.92e-6	Menopause (age at onset);
UCEC	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.64	-6.72	-0.48	3.64e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.73e-8	Depression;
UCEC	cis	rs7072216	0.687	rs10883087	chr10:100156990	T/A	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg20007245	chr22:24372913	LOC391322	-0.66	-7.34	-0.52	1.32e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-4.58	-0.35	9.8200000000000008e-06	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.1e-7	Hemoglobin concentration;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00843398	chr6:24403479	MRS2	0.6	7.31	0.52	1.54e-11	Warfarin maintenance dose;
UCEC	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs4771996	0.561	rs9556728	chr13:98138719	A/G	cg11411600	chr13:98830116	RNF113B;FARP1	0.47	4.76	0.37	4.67e-6	Obesity-related traits;
UCEC	cis	rs7215564	0.908	rs34969384	chr17:78678716	A/G	cg04242349	chr17:79082840	BAIAP2	0.47	4.51	0.35	1.34e-5	Myopia (pathological);
UCEC	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg04851639	chr8:1020857	NA	-0.37	-5.0	-0.38	1.59e-6	Schizophrenia;
UCEC	cis	rs7870753	0.838	rs16910870	chr9:99247103	A/G	cg25260653	chr9:99212216	HABP4	0.55	5.71	0.43	6.04e-8	Height;
UCEC	cis	rs7246967	0.673	rs2361245	chr19:22834530	A/G	cg08271804	chr19:22816896	ZNF492	0.63	6.25	0.46	4.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.94	10.83	0.67	1.86e-20	Breast cancer;
UCEC	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.07	9.56	0.62	3.77e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.21	0.39	6.3e-7	Electroencephalogram traits;
UCEC	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.28	-0.4	4.61e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.51	5.13	0.39	8.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1547374	1.000	rs1547374	chr21:43778895	C/T	cg01320040	chr21:43430494	ZNF295	0.5	4.84	0.37	3.26e-6	Pancreatic cancer;
UCEC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.66	7.59	0.53	3.33e-12	Menarche (age at onset);
UCEC	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.89	7.57	0.53	3.71e-12	Coronary artery calcification;
UCEC	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.6	5.44	0.41	2.15e-7	Mammographic density (dense area);
UCEC	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-7.43	-0.52	8.25e-12	Plateletcrit;Platelet count;
UCEC	cis	rs7517126	1.000	rs35002268	chr1:196838511	G/A	cg07209298	chr1:196795943	CFHR1	0.51	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs4851266	0.832	rs10865037	chr2:100871361	T/C	cg14675211	chr2:100938903	LONRF2	0.67	6.61	0.48	6.54e-10	Educational attainment;
UCEC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.65	-6.32	-0.46	2.89e-9	Blood metabolite levels;
UCEC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg01256987	chr12:42539512	GXYLT1	-0.43	-4.84	-0.37	3.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.68	-7.69	-0.54	1.91e-12	Breast cancer;
UCEC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg01485075	chr19:22817371	ZNF492	0.41	4.51	0.35	1.3e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.46	4.57	0.35	1.01e-5	Blood metabolite levels;
UCEC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.51	-4.86	-0.37	2.98e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2970992	0.764	rs7558261	chr2:101324632	A/T	cg01042948	chr2:101319752	NA	0.43	4.9	0.37	2.47e-6	Educational attainment;
UCEC	cis	rs953387	0.956	rs4954572	chr2:136926719	G/T	cg07169764	chr2:136633963	MCM6	0.51	5.04	0.38	1.32e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs11858159	0.532	rs12898466	chr15:24424834	C/G	cg22159025	chr15:25201020	SNRPN;SNURF	0.49	5.14	0.39	8.66e-7	Platelet thrombus formation;
UCEC	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.5	-5.09	-0.39	1.09e-6	Idiopathic membranous nephropathy;
UCEC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg13695892	chr22:41940480	POLR3H	0.69	5.36	0.4	3.1e-7	Vitiligo;
UCEC	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.57	5.27	0.4	4.88e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Body mass index;
UCEC	cis	rs8099014	0.770	rs1135519	chr18:56117145	C/T	cg19165390	chr18:56932082	NA	0.38	4.86	0.37	3.04e-6	Platelet count;
UCEC	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg20781238	chr11:787685	CEND1	-0.47	-4.93	-0.38	2.15e-6	Breast cancer;
UCEC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.79	-8.13	-0.56	1.6e-13	Multiple sclerosis;
UCEC	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.06	0.5	6.28e-11	Motion sickness;
UCEC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.49	5.3	0.4	4.25e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.41	-0.41	2.47e-7	Initial pursuit acceleration;
UCEC	cis	rs10896135	0.554	rs3741364	chr11:66451178	C/T	cg24851651	chr11:66362959	CCS	0.47	4.84	0.37	3.2e-6	Bipolar disorder;
UCEC	cis	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg20307385	chr11:47447363	PSMC3	-0.65	-4.68	-0.36	6.58e-6	Intraocular pressure;
UCEC	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	5.45	0.41	2.05e-7	Ileal carcinoids;
UCEC	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.08	-0.67	3.92e-21	Ulcerative colitis;
UCEC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.83	-0.37	3.4e-6	Colorectal cancer;
UCEC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.32	0.4	3.77e-7	Aortic root size;
UCEC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg00983440	chr10:79422392	NA	-1.13	-8.56	-0.58	1.35e-14	Bone mineral density;
UCEC	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg13695892	chr22:41940480	POLR3H	0.66	4.65	0.36	7.48e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs76419734	1.000	rs10050333	chr4:106765813	T/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.54	4.58	0.35	9.85e-6	Post bronchodilator FEV1;
UCEC	cis	rs35934224	0.891	rs73148965	chr22:19872935	G/A	cg11182965	chr22:19864308	TXNRD2	-0.63	-5.96	-0.44	1.77e-8	Glaucoma (primary open-angle);
UCEC	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.39	5.57	0.42	1.18e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.41	-4.87	-0.37	2.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg24163568	chr5:669837	TPPP	0.44	5.53	0.42	1.42e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg05962950	chr11:130786565	SNX19	-0.51	-5.23	-0.4	5.62e-7	Schizophrenia;
UCEC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.53	4.99	0.38	1.66e-6	Menopause (age at onset);
UCEC	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-4.99	-0.38	1.7e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.5	-0.41	1.62e-7	Bipolar disorder and schizophrenia;
UCEC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	7.09	0.5	5.26e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.61	-0.36	8.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.42	5.36	0.4	3.13e-7	Coronary artery disease;
UCEC	cis	rs595018	0.505	rs11230501	chr11:60598075	G/A	cg07268726	chr11:60701918	TMEM132A	-0.56	-5.15	-0.39	8.13e-7	Wegener's granulomatosis;
UCEC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Corneal astigmatism;
UCEC	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.49	-5.34	-0.4	3.38e-7	Longevity;
UCEC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.61	7.17	0.51	3.46e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	4.73	0.36	5.21e-6	Lung cancer in ever smokers;
UCEC	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.58	0.53	3.53e-12	Ileal carcinoids;
UCEC	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.57	-4.83	-0.37	3.38e-6	Serum sulfate level;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.45	-5.15	-0.39	8.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.69	8.54	0.58	1.53e-14	Vitiligo;
UCEC	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.63	5.88	0.44	2.59e-8	Platelet count;
UCEC	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.59	5.32	0.4	3.86e-7	Uric acid levels;
UCEC	cis	rs6688613	1.000	rs12130629	chr1:166953284	C/T	cg07049167	chr1:166818506	POGK	0.42	4.52	0.35	1.27e-5	Refractive astigmatism;
UCEC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.05	-0.38	1.27e-6	Personality dimensions;
UCEC	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.59	4.99	0.38	1.66e-6	Huntington's disease progression;
UCEC	cis	rs12900413	0.687	rs28493563	chr15:90309505	C/T	cg24249390	chr15:90295951	MESP1	-0.39	-4.55	-0.35	1.11e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-6.19	-0.45	5.6e-9	Platelet count;
UCEC	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.5	4.7	0.36	6.03e-6	Menarche (age at onset);
UCEC	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg14078730	chr11:63896557	MACROD1	0.76	5.3	0.4	4.19e-7	Mean platelet volume;
UCEC	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.72	8.27	0.56	7.26e-14	Headache;
UCEC	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.52	-5.92	-0.44	2.17e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10242455	0.867	rs1879859	chr7:99294762	C/T	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	6.74e-7	Blood metabolite levels;
UCEC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg14008862	chr17:28927542	LRRC37B2	0.61	5.08	0.39	1.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-8.76	-0.59	4.29e-15	Coffee consumption (cups per day);
UCEC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.66	5.85	0.43	3e-8	Menarche (age at onset);
UCEC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.38	5.35	0.4	3.35e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.46	5.19	0.39	6.98e-7	Blood metabolite levels;
UCEC	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.59	-5.19	-0.39	6.87e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-8.61	-0.58	1.06e-14	Bipolar disorder and schizophrenia;
UCEC	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.67	5.86	0.43	2.98e-8	Phospholipid levels (plasma);
UCEC	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	0.89	4.71	0.36	5.65e-6	IgG glycosylation;
UCEC	cis	rs7246967	0.673	rs59567211	chr19:22829882	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.967	rs6913877	chr6:26577488	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-5.8	-0.43	3.96e-8	HDL cholesterol;
UCEC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.88	-8.55	-0.58	1.48e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.33	0.57	5.11e-14	Menopause (age at onset);
UCEC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.19e-10	Aortic root size;
UCEC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.72	-8.22	-0.56	9.95e-14	Menarche (age at onset);
UCEC	cis	rs79815064	0.619	rs75719572	chr3:46183180	C/G	cg19145607	chr3:45983792	CXCR6;FYCO1	0.76	4.69	0.36	6.29e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-4.67	-0.36	6.85e-6	Diastolic blood pressure;
UCEC	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg23752985	chr2:85803571	VAMP8	0.43	4.64	0.36	7.78e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.52	-6.49	-0.47	1.22e-9	Pubertal anthropometrics;
UCEC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg26031613	chr14:104095156	KLC1	0.59	5.63	0.42	8.75e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-4.63	-0.36	7.94e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg18681998	chr4:17616180	MED28	0.7	8.05	0.55	2.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.55	-6.22	-0.46	4.99e-9	Lung cancer;
UCEC	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.73	6.27	0.46	3.79e-9	Platelet distribution width;
UCEC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.63	6.53	0.47	1.02e-9	Menopause (age at onset);
UCEC	cis	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg00614314	chr15:82944287	LOC80154	0.5	4.56	0.35	1.07e-5	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	0.83	9.46	0.62	6.98e-17	Blood trace element (Zn levels);
UCEC	cis	rs7246967	0.611	rs73030511	chr19:22826034	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.69	10.73	0.66	3.35e-20	Total body bone mineral density;
UCEC	cis	rs75804782	0.630	rs56328549	chr2:239226553	T/G	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.36e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.58	-5.36	-0.4	3.13e-7	Hypospadias;
UCEC	cis	rs8177876	0.822	rs9925940	chr16:81110984	T/G	cg08591886	chr16:81111003	C16orf46	-0.78	-4.87	-0.37	2.83e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.66	-5.27	-0.4	4.69e-7	Huntington's disease progression;
UCEC	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	0.88	8.61	0.58	1.05e-14	Left atrial antero-posterior diameter;
UCEC	cis	rs829661	0.790	rs1252651	chr2:30703758	C/A	cg17749961	chr2:30669863	LCLAT1	0.72	5.54	0.42	1.37e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.61	6.58	0.48	7.89e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06671706	chr8:8559999	CLDN23	0.66	5.34	0.4	3.47e-7	Obesity-related traits;
UCEC	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg23000734	chr10:126850823	CTBP2	0.39	4.62	0.36	8.3e-6	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg03714773	chr7:91764589	CYP51A1	0.46	5.48	0.41	1.77e-7	Breast cancer;
UCEC	cis	rs7246967	0.551	rs1835994	chr19:22833045	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.88	-9.75	-0.63	1.24e-17	Ulcerative colitis;
UCEC	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.48	4.52	0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.55	6.26	0.46	4.07e-9	Prostate cancer;
UCEC	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg24375607	chr4:120327624	NA	0.48	5.1	0.39	1.04e-6	Corneal astigmatism;
UCEC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.64	-7.37	-0.52	1.14e-11	Body mass index;
UCEC	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-5.22	-0.4	6.13e-7	Vitamin D levels;
UCEC	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-4.86	-0.37	3.03e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.93	10.12	0.64	1.38e-18	Cognitive function;
UCEC	cis	rs9467773	1.000	rs1001687	chr6:26573218	C/G	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.58	-5.05	-0.38	1.31e-6	Glomerular filtration rate (creatinine);
UCEC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.46e-16	Height;
UCEC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	5.09	0.39	1.1e-6	Platelet count;
UCEC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.89	9.4	0.61	1.01e-16	Cognitive function;
UCEC	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.42	-4.55	-0.35	1.09e-5	Schizophrenia;
UCEC	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.55	5.71	0.43	6.17e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.8	8.94	0.59	1.5e-15	Breast cancer;
UCEC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	6.09	0.45	9.46e-9	Initial pursuit acceleration;
UCEC	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07215822	chr6:158701037	NA	-0.68	-5.62	-0.42	9.46e-8	Lipoprotein (a) - cholesterol levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09455096	chr2:61765470	XPO1	0.58	7.34	0.52	1.34e-11	Warfarin maintenance dose;
UCEC	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg19567339	chr10:100142640	NA	0.51	6.02	0.44	1.36e-8	Metabolite levels;
UCEC	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.55	-4.8	-0.37	3.86e-6	White matter integrity;Neutrophil percentage of white cells;
UCEC	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.87	-0.49	1.72e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.61	5.72	0.43	5.77e-8	Corneal astigmatism;
UCEC	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.67	-7.32	-0.52	1.51e-11	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg19318889	chr4:1322082	MAEA	0.41	5.03	0.38	1.41e-6	Obesity-related traits;
UCEC	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.74e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.71	-4.53	-0.35	1.19e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12145833	0.596	rs61833906	chr1:243419706	T/C	cg02356786	chr1:243265016	LOC731275	0.84	5.86	0.44	2.95e-8	Obesity (early onset extreme);
UCEC	cis	rs2658084	0.647	rs2662408	chr5:10139461	T/C	cg09877593	chr5:10564514	ANKRD33B	0.52	5.11	0.39	1e-6	Iris color (L* coordinate);
UCEC	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14019695	chr9:139328340	INPP5E	0.57	6.26	0.46	3.93e-9	Monocyte percentage of white cells;
UCEC	cis	rs6813264	0.590	rs4835236	chr4:146538871	A/G	cg04181032	chr4:147165097	NA	-0.36	-4.56	-0.35	1.07e-5	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs7246967	0.673	rs3853653	chr19:22871932	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.63	-5.64	-0.42	8.27e-8	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.67	-5.43	-0.41	2.26e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.6	-4.65	-0.36	7.37e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg05501817	chr11:14380813	RRAS2	0.5	4.77	0.37	4.34e-6	Sense of smell;
UCEC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.68	5.87	0.44	2.81e-8	Blood metabolite levels;
UCEC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.61	7.31	0.52	1.6e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	1.16	9.38	0.61	1.14e-16	Uric acid levels;
UCEC	cis	rs2742417	1.000	rs938362	chr3:45746365	T/C	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7106204	0.514	rs12789549	chr11:24254726	C/G	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs925228	0.910	rs4564735	chr2:24164237	T/G	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.49	5.17	0.39	7.38e-7	Schizophrenia;
UCEC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05776053	chr2:74358815	NA	0.4	4.52	0.35	1.27e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	0.95	7.81	0.54	9.78e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.21	-8.07	-0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs28795989	0.795	rs7694650	chr4:7903416	A/G	cg00251875	chr4:7801337	AFAP1	0.49	5.71	0.43	5.94e-8	Intraocular pressure;
UCEC	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg04310649	chr10:35416472	CREM	-0.52	-5.11	-0.39	9.66e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg00500100	chr5:140098250	VTRNA1-2	0.34	4.6	0.35	9.24e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.64	6.46	0.47	1.47e-9	Mood instability;
UCEC	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.49	4.86	0.37	3.03e-6	HDL cholesterol;
UCEC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg13147721	chr7:65941812	NA	-1.1	-5.91	-0.44	2.32e-8	Diabetic kidney disease;
UCEC	cis	rs7246967	0.673	rs67631531	chr19:22830466	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.43	5.13	0.39	9e-7	Total body bone mineral density;
UCEC	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs6578185	0.810	rs7816220	chr8:142453585	T/C	cg09858281	chr8:142456070	FLJ43860	-0.34	-4.69	-0.36	6.18e-6	Endometriosis;
UCEC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.54	-0.58	1.55e-14	Total body bone mineral density;
UCEC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.61	-6.3	-0.46	3.26e-9	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Corneal astigmatism;
UCEC	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.74	5.34	0.4	3.45e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.64	7.04	0.5	6.82e-11	Menarche (age at onset);
UCEC	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs7011049	1.000	rs11997774	chr8:53833370	T/A	cg26025543	chr8:53854495	NA	0.61	4.52	0.35	1.29e-5	Systolic blood pressure;
UCEC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.08	0.39	1.15e-6	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs7709377	0.597	rs10063312	chr5:115520611	A/G	cg23108291	chr5:115420582	COMMD10	0.52	5.45	0.41	2.12e-7	Metabolite levels  (X-11787);
UCEC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.67	-0.42	7.32e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.51	-4.82	-0.37	3.49e-6	Aortic root size;
UCEC	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-6.45	-0.47	1.53e-9	Morning vs. evening chronotype;
UCEC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg01767885	chr16:1147214	C1QTNF8	0.3	4.51	0.35	1.32e-5	Height;
UCEC	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.42	-5.11	-0.39	9.67e-7	Refractive error;
UCEC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.86	9.02	0.6	9.61e-16	Parkinson's disease;
UCEC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.73	-4.65	-0.36	7.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.54	-0.35	1.17e-5	Parkinson's disease;
UCEC	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	8.3	0.56	6.26e-14	Menopause (age at onset);
UCEC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21178979	chr7:1889533	MAD1L1	0.36	4.78	0.37	4.15e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg12024160	chr4:1254474	NA	0.49	4.59	0.35	9.49e-6	Longevity;
UCEC	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.55	-6.11	-0.45	8.58e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	0.98	8.22	0.56	9.98e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	7.91	0.55	5.76e-13	Tonsillectomy;
UCEC	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.9	-8.12	-0.56	1.74e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs925228	0.955	rs13021384	chr2:24150632	G/A	cg13272742	chr2:24272458	FKBP1B	0.58	5.0	0.38	1.61e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	0.93	8.57	0.58	1.3e-14	Primary sclerosing cholangitis;
UCEC	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.94	-0.44	1.99e-8	Parkinson's disease;
UCEC	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs7246967	0.604	rs8112577	chr19:22893471	C/T	cg08271804	chr19:22816896	ZNF492	0.7	4.65	0.36	7.47e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.96	-0.44	1.83e-8	Response to antipsychotic treatment;
UCEC	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	9.67	0.62	1.97e-17	Post bronchodilator FEV1;
UCEC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.66	-0.42	7.57e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg07636037	chr3:49044803	WDR6	-0.57	-4.66	-0.36	7.14e-6	Menarche (age at onset);
UCEC	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.16	-10.09	-0.64	1.67e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.65	5.32	0.4	3.82e-7	Corneal astigmatism;
UCEC	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg23217946	chr19:22817039	ZNF492	0.41	4.56	0.35	1.09e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg27248073	chr17:6347727	FAM64A	0.63	6.96	0.5	1.07e-10	Schizophrenia;
UCEC	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.68	-7.46	-0.52	7.05e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs57709857	0.801	rs6992943	chr8:38096299	A/G	cg08167846	chr8:38212404	WHSC1L1	0.47	4.54	0.35	1.17e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.37	5.14	0.39	8.78e-7	Crohn's disease;
UCEC	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.55	4.88	0.37	2.69e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.12	0.45	8.14e-9	IgG glycosylation;
UCEC	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.51	5.61	0.42	9.95e-8	Asthma;
UCEC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.5	4.77	0.37	4.4e-6	Obesity (extreme);
UCEC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg01689657	chr7:91764605	CYP51A1	-0.45	-5.66	-0.42	7.57e-8	Breast cancer;
UCEC	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.67	-5.19	-0.39	6.78e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.67	8.56	0.58	1.4e-14	Vitiligo;
UCEC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg17724175	chr1:150552817	MCL1	-0.44	-4.58	-0.35	1e-5	Tonsillectomy;
UCEC	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.44	-5.04	-0.38	1.36e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11958404	0.860	rs72818111	chr5:157438361	A/G	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.69	0.48	4.43e-10	Coronary artery disease;
UCEC	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.37	-0.47	2.29e-9	Blood pressure (smoking interaction);
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.25	0.71	3.21e-24	Platelet count;
UCEC	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.46	-4.97	-0.38	1.86e-6	Neuroticism;
UCEC	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.79	-0.37	3.98e-6	Tonsillectomy;
UCEC	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg13147721	chr7:65941812	NA	-0.84	-5.48	-0.41	1.81e-7	Diabetic kidney disease;
UCEC	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.78	-0.37	4.22e-6	Response to antipsychotic treatment;
UCEC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.67	4.6	0.35	9.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8177876	0.822	rs9933184	chr16:81111176	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg00747342	chr2:23700632	KLHL29	0.49	4.8	0.37	3.9e-6	Cannabis use (initiation);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03356760	chr6:37665051	MDGA1	0.6	6.81	0.49	2.33e-10	Warfarin maintenance dose;
UCEC	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.62	0.48	6.17e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg03539765	chr12:9217390	LOC144571	0.4	4.57	0.35	1.02e-5	Sjögren's syndrome;
UCEC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.64	6.4	0.47	1.98e-9	Lymphocyte counts;
UCEC	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.48	-4.58	-0.35	9.98e-6	Personality dimensions;
UCEC	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.14	6.24	0.46	4.37e-9	Schizophrenia;
UCEC	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-4.58	-0.35	9.87e-6	Subjective well-being;
UCEC	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.42	4.58	0.35	9.84e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg06917450	chr1:38156652	C1orf109	-0.57	-5.19	-0.39	6.86e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-6.56	-0.48	8.67e-10	Heart rate;
UCEC	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.62	-6.84	-0.49	1.95e-10	Pubertal anthropometrics;
UCEC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-0.47	-4.59	-0.35	9.48e-6	Pediatric autoimmune diseases;
UCEC	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.38	0.52	1.08e-11	Total body bone mineral density;
UCEC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.57	6.53	0.47	1.01e-9	Tuberculosis;
UCEC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-0.75	-4.77	-0.37	4.44e-6	Diabetic retinopathy;
UCEC	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg24889512	chr19:22816950	ZNF492	0.59	6.47	0.47	1.38e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-5.16	-0.39	7.86e-7	Depression;
UCEC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.6	6.63	0.48	5.86e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.41	-4.77	-0.37	4.4e-6	Coronary artery disease;
UCEC	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.78	-8.8	-0.59	3.36e-15	Facial morphology (factor 19);
UCEC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.96	11.93	0.7	2.26e-23	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.52	5.66	0.42	7.79e-8	HDL cholesterol;
UCEC	cis	rs10012307	1.000	rs56966074	chr4:137504870	G/A	cg12033966	chr4:138453416	PCDH18	-0.71	-5.08	-0.39	1.12e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.47	4.6	0.35	9.02e-6	Colorectal cancer;
UCEC	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.53	6.0	0.44	1.46e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg03934865	chr2:198174659	NA	0.45	5.77	0.43	4.59e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.71	6.16	0.45	6.59e-9	Alzheimer's disease;
UCEC	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg09655341	chr17:79618100	PDE6G	-0.31	-4.78	-0.37	4.18e-6	Eye color traits;
UCEC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-6.14	-0.45	7.43e-9	Menarche (age at onset);
UCEC	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.58	-5.9	-0.44	2.45e-8	Glomerular filtration rate;
UCEC	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg18681998	chr4:17616180	MED28	0.7	8.09	0.55	2.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.61	5.32	0.4	3.81e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.67	-7.21	-0.51	2.69e-11	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.89	0.49	1.52e-10	Morning vs. evening chronotype;
UCEC	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-0.94	-7.02	-0.5	7.77e-11	Body mass index;
UCEC	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.51	6.97	0.5	9.75e-11	Information processing speed;
UCEC	cis	rs7112925	0.966	rs11602157	chr11:66827319	G/A	cg06012016	chr11:67219631	GPR152	-0.43	-4.8	-0.37	3.83e-6	Height;
UCEC	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-0.92	-8.82	-0.59	3.1e-15	Height;
UCEC	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg13575925	chr12:9217583	LOC144571	0.4	4.68	0.36	6.55e-6	Sjögren's syndrome;
UCEC	cis	rs78487399	0.808	rs75126888	chr2:43664007	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg18016565	chr1:150552671	MCL1	-0.54	-5.87	-0.44	2.79e-8	Tonsillectomy;
UCEC	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg16099169	chr2:106886729	NA	-0.44	-4.8	-0.37	3.87e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.68	-6.75	-0.49	3.25e-10	Blood metabolite levels;
UCEC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.5	-4.78	-0.37	4.15e-6	Vitamin D levels;
UCEC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.72	7.25	0.51	2.22e-11	Tonsillectomy;
UCEC	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.39	-5.27	-0.4	4.79e-7	Reticulocyte fraction of red cells;
UCEC	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.67	-7.3	-0.52	1.7e-11	Coronary artery disease;
UCEC	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.61	0.36	8.84e-6	Height;
UCEC	cis	rs295140	1.000	rs13005573	chr2:201164696	G/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.31	-4.57	-0.35	1.01e-5	Blood metabolite levels;
UCEC	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Bladder cancer;
UCEC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.84	5.6	0.42	1e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg02693607	chr7:27150598	HOXA3	-0.6	-5.03	-0.38	1.42e-6	Type 1 diabetes;
UCEC	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.54	5.67	0.42	7.3e-8	Longevity;
UCEC	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.57	7.22	0.51	2.63e-11	Anterior chamber depth;
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.7	8.36	0.57	4.33e-14	Prudent dietary pattern;
UCEC	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg19097150	chr7:2500200	NA	-0.34	-4.62	-0.36	8.25e-6	Schizophrenia;
UCEC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg06600287	chr1:53387719	ECHDC2	-0.33	-4.62	-0.36	8.28e-6	Monocyte count;
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.07	-9.19	-0.6	3.42e-16	Platelet count;
UCEC	cis	rs9283706	0.594	rs7734953	chr5:66349943	G/T	cg11590213	chr5:66331682	MAST4	0.47	5.6	0.42	1.04e-7	Coronary artery disease;
UCEC	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	8.11	0.56	1.86e-13	Platelet distribution width;
UCEC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg03321784	chr17:37729644	NA	-0.39	-4.84	-0.37	3.23e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg06238570	chr21:40685208	BRWD1	0.82	8.07	0.55	2.29e-13	Cognitive function;
UCEC	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.33	-0.52	1.39e-11	Urate levels in overweight individuals;
UCEC	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.64	6.0	0.44	1.49e-8	Mammographic density (dense area);
UCEC	cis	rs11697848	1.000	rs77642050	chr20:48517046	G/A	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.42	-4.65	-0.36	7.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.65	4.57	0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg03859395	chr2:55845619	SMEK2	0.99	13.85	0.75	1.94e-28	Metabolic syndrome;
UCEC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg18230493	chr5:56204884	C5orf35	0.61	5.19	0.39	6.82e-7	Initial pursuit acceleration;
UCEC	cis	rs12118280	0.512	rs7418288	chr1:108754099	G/A	cg11967332	chr1:108735228	SLC25A24	0.73	5.05	0.38	1.31e-6	Myeloid white cell count;
UCEC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg20965017	chr5:231967	SDHA	-0.59	-5.36	-0.4	3.13e-7	Breast cancer;
UCEC	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg26114124	chr12:9217669	LOC144571	0.41	4.7	0.36	6.01e-6	Sjögren's syndrome;
UCEC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg11871910	chr12:69753446	YEATS4	0.55	4.88	0.37	2.76e-6	Response to diuretic therapy;
UCEC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12292205	chr6:26970375	C6orf41	0.6	4.74	0.36	5.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.52	5.74	0.43	5.35e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.59	5.47	0.41	1.86e-7	Response to antineoplastic agents;
UCEC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.73	0.58	5.17e-15	Alzheimer's disease;
UCEC	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.44	5.18	0.39	7.24e-7	Blood metabolite ratios;
UCEC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.7	-7.25	-0.51	2.25e-11	Blood metabolite levels;
UCEC	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.39	-8.68	-0.58	7.01e-15	Diabetic kidney disease;
UCEC	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.78	9.41	0.61	9.7e-17	Mean corpuscular volume;
UCEC	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg05738196	chr6:26577821	NA	0.48	4.87	0.37	2.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.69	7.37	0.52	1.11e-11	Blood protein levels;
UCEC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.86	11.09	0.67	3.81e-21	Metabolic syndrome;
UCEC	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.73	5.23	0.4	5.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs4074536	0.625	rs3827737	chr1:116312824	C/T	cg21648376	chr1:116311395	CASQ2	-0.59	-5.49	-0.41	1.74e-7	QRS duration;
UCEC	cis	rs17122693	0.748	rs72679596	chr14:51103595	C/T	cg04730355	chr14:51134070	SAV1	0.96	10.07	0.64	1.85e-18	Cognitive performance;
UCEC	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.85	-8.49	-0.57	2.07e-14	Resting heart rate;
UCEC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.59	-7.52	-0.53	5e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.78	5.94	0.44	1.95e-8	Psoriasis;
UCEC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.67	-0.58	7.29e-15	Menarche (age at onset);
UCEC	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.08	7.7	0.54	1.86e-12	Sexual dysfunction (female);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20540327	chr15:72668275	HEXA;C15orf34	0.63	7.8	0.54	1.05e-12	Warfarin maintenance dose;
UCEC	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-7.7	-0.54	1.87e-12	Gut microbiome composition (summer);
UCEC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.03	-0.38	1.39e-6	Gut microbiome composition (summer);
UCEC	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.48	5.08	0.39	1.15e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs10743315	0.643	rs12578443	chr12:19321893	G/C	cg02471346	chr12:19282374	PLEKHA5	0.69	4.78	0.37	4.21e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.59	5.24	0.4	5.37e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.72	-0.43	5.78e-8	Depression;
UCEC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.59	6.2	0.46	5.4e-9	Mean platelet volume;
UCEC	cis	rs1468333	1.000	rs2906128	chr5:137550054	C/T	cg07848042	chr5:137667509	CDC25C	0.48	4.71	0.36	5.61e-6	Resting heart rate;
UCEC	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg06636001	chr8:8085503	FLJ10661	0.71	7.21	0.51	2.7e-11	Joint mobility (Beighton score);
UCEC	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-0.73	-6.7	-0.48	4.25e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-1.03	-15.24	-0.78	4.68e-32	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs16847609	1.000	rs16847598	chr3:137640548	T/C	cg10731507	chr3:138067853	MRAS	-0.54	-4.69	-0.36	6.27e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Intraocular pressure;
UCEC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.77	-6.77	-0.49	2.83e-10	Initial pursuit acceleration;
UCEC	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.45	5.13	0.39	8.87e-7	Systemic lupus erythematosus;
UCEC	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.53	-5.64	-0.42	8.56e-8	Monocyte count;
UCEC	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-25.18	-0.9	3.61e-55	Myeloid white cell count;
UCEC	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	4.87	0.37	2.89e-6	Height;
UCEC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg19678392	chr7:94953810	PON1	-0.55	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.66	0.48	5.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2901460	0.509	rs10165560	chr2:62059398	A/C	cg02183531	chr2:62113199	CCT4	-0.55	-4.58	-0.35	9.85e-6	Mean corpuscular volume;
UCEC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.62	-6.57	-0.48	8.14e-10	Prostate cancer;
UCEC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	7.69	0.54	1.98e-12	Tonsillectomy;
UCEC	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.73	7.6	0.53	3.16e-12	Breast cancer;
UCEC	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.69	5.76	0.43	4.82e-8	Major depressive disorder;
UCEC	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.47	-5.67	-0.42	7.43e-8	Mean platelet volume;
UCEC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.63	6.36	0.46	2.46e-9	Type 2 diabetes;
UCEC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.69	-7.56	-0.53	4.09e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	1.000	rs12983770	chr19:23023614	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.06	0.38	1.25e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.54	6.78	0.49	2.77e-10	Anterior chamber depth;
UCEC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.69	-5.27	-0.4	4.69e-7	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-5.14	-0.39	8.81e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.18	-0.39	7.25e-7	Personality dimensions;
UCEC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.49	4.67	0.36	6.83e-6	Menopause (age at onset);
UCEC	cis	rs7582720	1.000	rs72932753	chr2:203670122	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	4.99	0.38	1.72e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.91	11.62	0.69	1.5e-22	Breast cancer;
UCEC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.92	-10.89	-0.67	1.26e-20	Cognitive function;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	9.45	0.61	7.35e-17	Platelet count;
UCEC	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.64	6.6	0.48	6.84e-10	C-reactive protein levels;
UCEC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-6.17	-0.45	6.41e-9	Diastolic blood pressure;
UCEC	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-4.74	-0.36	5.01e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-4.69	-0.36	6.07e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.84	-7.58	-0.53	3.66e-12	Coronary artery calcification;
UCEC	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-6.9	-0.49	1.42e-10	Hypospadias;
UCEC	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.81	-7.49	-0.53	5.74e-12	Neurofibrillary tangles;
UCEC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg23795048	chr12:9217529	LOC144571	0.41	5.01	0.38	1.54e-6	Sjögren's syndrome;
UCEC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-7.66	-0.53	2.25e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.54	-0.66	1.05e-19	Schizophrenia;
UCEC	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.53	6.1	0.45	8.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.46	4.81	0.37	3.66e-6	Total body bone mineral density;
UCEC	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.47	-5.13	-0.39	9.06e-7	Platelet count;
UCEC	cis	rs939574	0.660	rs6716253	chr2:220127016	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	6.82	0.49	2.17e-10	Platelet distribution width;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.53	-5.45	-0.41	2.07e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.71	6.72	0.48	3.73e-10	Bladder cancer;
UCEC	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.5	-5.41	-0.41	2.47e-7	Retinal vascular caliber;
UCEC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.96	-0.44	1.77e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg19318889	chr4:1322082	MAEA	0.46	4.94	0.38	2.14e-6	Obesity-related traits;
UCEC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.5	4.71	0.36	5.73e-6	Renal cell carcinoma;
UCEC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.71	-4.86	-0.37	2.98e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-5.49	-0.41	1.69e-7	Monocyte count;
UCEC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18252515	chr7:66147081	NA	-0.61	-5.71	-0.43	6.07e-8	Aortic root size;
UCEC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.0	0.38	1.59e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.75	6.99	0.5	9.16e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.62	6.72	0.49	3.64e-10	Neuroticism;
UCEC	cis	rs858239	0.712	rs200717	chr7:23392271	A/G	cg17274742	chr7:23286539	GPNMB	0.41	4.58	0.35	9.87e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.65	-0.48	5.51e-10	Coffee consumption (cups per day);
UCEC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.68	6.96	0.5	1.04e-10	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.6e-7	Breast cancer;
UCEC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.44	0.57	2.83e-14	Smoking behavior;
UCEC	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.75	5.68	0.42	7.07e-8	Type 2 diabetes;
UCEC	cis	rs12318506	0.623	rs12313311	chr12:75768327	A/T	cg04728562	chr12:75699417	CAPS2	-0.78	-4.61	-0.36	8.64e-6	Coronary artery calcification;
UCEC	cis	rs6684428	0.611	rs6657176	chr1:56328238	G/T	cg11651538	chr1:56320950	NA	-0.62	-5.74	-0.43	5.2e-8	Airflow obstruction;
UCEC	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-0.85	-8.55	-0.58	1.5e-14	Height;
UCEC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.96	-0.44	1.78e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	4.9	0.37	2.52e-6	Electrocardiographic conduction measures;
UCEC	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.64	6.39	0.47	2.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.69	-7.65	-0.53	2.45e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	6.08	0.45	1e-8	Multiple sclerosis;
UCEC	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.41	14.99	0.78	2.08e-31	Atopic dermatitis;
UCEC	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.06	-11.34	-0.68	8.2e-22	Ulcerative colitis;
UCEC	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.69	7.44	0.52	7.91e-12	Platelet distribution width;
UCEC	cis	rs11153730	0.503	rs283042	chr6:118631282	G/A	cg21191810	chr6:118973309	C6orf204	0.39	4.92	0.38	2.28e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs9309473	0.528	rs11126396	chr2:73565143	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-5.5	-0.41	1.68e-7	Metabolite levels;
UCEC	cis	rs4908768	0.534	rs11586056	chr1:8845199	G/T	cg13081009	chr1:8430745	RERE	0.45	4.61	0.36	8.83e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.73	-7.67	-0.53	2.13e-12	Blood protein levels;
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.77	0.59	4.14e-15	Prudent dietary pattern;
UCEC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.99	12.82	0.73	9.66e-26	Monocyte count;
UCEC	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.85	9.93	0.63	4.23e-18	Blood metabolite levels;
UCEC	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.65	-6.08	-0.45	1e-8	Brugada syndrome;
UCEC	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	1.25	5.71	0.43	6.02e-8	Parkinson's disease;
UCEC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.84	0.43	3.15e-8	Height;
UCEC	cis	rs838147	0.733	rs12978499	chr19:49237552	A/C	cg13540341	chr19:49222985	MAMSTR	0.38	4.58	0.35	9.73e-6	Dietary macronutrient intake;
UCEC	cis	rs13437751	0.649	rs73123050	chr7:63353261	A/G	cg00787055	chr7:63562162	NA	0.4	4.89	0.37	2.63e-6	QT interval (drug interaction);
UCEC	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.61	-0.36	8.68e-6	Height;
UCEC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg21770322	chr7:97807741	LMTK2	0.53	6.68	0.48	4.63e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs4372836	0.729	rs10198789	chr2:28968811	C/T	cg09522027	chr2:28974177	PPP1CB	-0.85	-9.13	-0.6	4.88e-16	Body mass index;
UCEC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.52	0.41	1.47e-7	Breast cancer;
UCEC	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	0.45	4.66	0.36	6.92e-6	P wave duration;
UCEC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	1.06	12.16	0.71	5.45e-24	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.5	5.1	0.39	1.03e-6	Height;
UCEC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.53	5.67	0.42	7.2e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.97	0.44	1.71e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.42	4.57	0.35	1.03e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg12524725	chr2:239427019	NA	-0.67	-4.59	-0.35	9.6e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.8	7.6	0.53	3.26e-12	Morning vs. evening chronotype;
UCEC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg22974920	chr21:40686053	BRWD1	0.64	5.66	0.42	7.73e-8	Cognitive function;
UCEC	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg16060761	chr17:80687452	NA	-0.59	-5.62	-0.42	9.24e-8	Glycated hemoglobin levels;
UCEC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.9	8.33	0.57	5.31e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	4.59	0.35	9.53e-6	Joint mobility (Beighton score);
UCEC	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.59	6.44	0.47	1.6e-9	Platelet count;
UCEC	cis	rs7175404	0.591	rs75029049	chr15:94061120	C/T	cg06054272	chr15:93956988	NA	0.7	5.06	0.39	1.21e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.52	-6.6	-0.48	6.93e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.45	-5.68	-0.42	7.06e-8	Migraine;
UCEC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.66	-5.67	-0.42	7.47e-8	Longevity;
UCEC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.44	-6.22	-0.46	4.81e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.76	5.55	0.42	1.32e-7	Fibroblast growth factor basic levels;
UCEC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.64	7.64	0.53	2.63e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	1.000	rs9467798	chr6:26575697	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.5	6.55	0.48	8.94e-10	Bone mineral density;
UCEC	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.4	-4.7	-0.36	6.02e-6	Schizophrenia;
UCEC	cis	rs7937612	1.000	rs11217841	chr11:120238721	C/A	cg12584626	chr11:120203529	NA	0.54	5.47	0.41	1.89e-7	Intraocular pressure;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs13095912	1.000	rs13100229	chr3:185343200	C/T	cg11274856	chr3:185301563	NA	0.57	7.68	0.54	2.04e-12	Systolic blood pressure;
UCEC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.7	7.95	0.55	4.62e-13	Longevity;Endometriosis;
UCEC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.45	4.68	0.36	6.34e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs17718580	0.793	rs113053719	chr14:50958256	C/A	cg04730355	chr14:51134070	SAV1	1.15	5.58	0.42	1.13e-7	Cognitive performance;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12332454	chr11:19138563	ZDHHC13	0.6	6.72	0.48	3.79e-10	Warfarin maintenance dose;
UCEC	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.53	6.12	0.45	8.09e-9	Mean corpuscular volume;
UCEC	cis	rs10266483	0.739	rs2692104	chr7:63760955	G/C	cg23304165	chr7:63498798	NA	-0.53	-5.7	-0.43	6.5e-8	Response to statin therapy;
UCEC	cis	rs6763768	0.606	rs9942027	chr3:53392663	C/T	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg08250081	chr4:10125330	NA	0.46	4.56	0.35	1.07e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.23	-0.4	5.61e-7	Hemoglobin concentration;
UCEC	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.78	-8.99	-0.6	1.14e-15	Obesity-related traits;
UCEC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.61	-0.36	8.57e-6	Breast cancer;
UCEC	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	0.91	9.1	0.6	5.79e-16	Heart rate;
UCEC	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.53	4.92	0.38	2.25e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs2677744	1.000	rs2677744	chr15:91450441	A/G	cg14166756	chr15:90894880	ZNF774	-0.34	-4.59	-0.35	9.42e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg07776626	chr8:57350775	NA	-0.47	-5.3	-0.4	4.18e-7	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.47	0.41	1.88e-7	Breast cancer;
UCEC	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-5.66	-0.42	7.7e-8	Colorectal cancer;
UCEC	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.73	7.83	0.54	8.88e-13	Sudden cardiac arrest;
UCEC	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.75	6.39	0.47	2.04e-9	Alzheimer's disease;
UCEC	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Bladder cancer;
UCEC	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06223018	chr3:49557076	DAG1	0.32	4.61	0.36	8.66e-6	Parkinson's disease;
UCEC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg14067834	chr17:29058358	SUZ12P	0.65	4.51	0.35	1.31e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.63	5.19	0.39	6.98e-7	Gut microbiome composition (summer);
UCEC	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.61	6.76	0.49	3.07e-10	Multiple myeloma;
UCEC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg00815214	chr21:47717953	NA	-0.4	-4.58	-0.35	9.71e-6	Testicular germ cell tumor;
UCEC	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.61	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.56	-5.61	-0.42	9.57e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg13319975	chr6:146136371	FBXO30	0.44	4.73	0.36	5.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs4372836	0.504	rs13025081	chr2:29083850	C/A	cg09522027	chr2:28974177	PPP1CB	-0.64	-6.75	-0.49	3.17e-10	Body mass index;
UCEC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.09	-6.98	-0.5	9.35e-11	Breast cancer;
UCEC	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.86	9.1	0.6	5.97e-16	Ulcerative colitis;
UCEC	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.77	6.3	0.46	3.21e-9	Triglycerides;
UCEC	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg16797656	chr11:68205561	LRP5	0.5	5.59	0.42	1.05e-7	Total body bone mineral density;
UCEC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-0.94	-12.69	-0.72	2.21e-25	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.28	0.4	4.61e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.22	-0.4	6.11e-7	Schizophrenia;
UCEC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.52	4.59	0.35	9.36e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.14e-7	Body mass index;
UCEC	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.71	8.34	0.57	4.98e-14	Mean corpuscular volume;
UCEC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.83	10.39	0.65	2.64e-19	Menopause (age at onset);
UCEC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.59	5.75	0.43	4.92e-8	Tonsillectomy;
UCEC	cis	rs4919044	0.599	rs10882131	chr10:94711319	C/T	cg00519463	chr10:94352821	KIF11	0.87	4.86	0.37	3.03e-6	Coronary artery disease;
UCEC	cis	rs1126510	0.897	rs12459883	chr19:47126614	C/G	cg07844738	chr19:47129343	PTGIR	0.37	4.58	0.35	9.76e-6	Ulcerative colitis;
UCEC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.1e-7	Hemoglobin concentration;
UCEC	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.99	9.3	0.61	1.77e-16	Exhaled nitric oxide output;
UCEC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.69	-6.18	-0.45	5.86e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.96	12.67	0.72	2.48e-25	Bone mineral density;
UCEC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.45	-5.85	-0.43	3.13e-8	Coronary artery disease;
UCEC	cis	rs2398893	0.596	rs13299181	chr9:96887457	G/A	cg07076509	chr9:96720819	NA	0.49	4.84	0.37	3.24e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs354033	1.000	rs56707870	chr7:149265728	T/C	cg24335155	chr7:149193227	ZNF746	0.39	4.69	0.36	6.31e-6	Multiple sclerosis;
UCEC	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.95	-9.33	-0.61	1.48e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg03714773	chr7:91764589	CYP51A1	0.45	5.4	0.41	2.6e-7	Breast cancer;
UCEC	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.35	4.75	0.36	4.85e-6	Blood protein levels;
UCEC	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02216295	chr16:89557994	ANKRD11	0.66	6.88	0.49	1.59e-10	Migraine with aura;
UCEC	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.54	-5.47	-0.41	1.9e-7	Hepatocellular carcinoma;
UCEC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	4.86	0.37	2.93e-6	Breast cancer;
UCEC	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	0.95	7.32	0.52	1.5e-11	Exhaled nitric oxide output;
UCEC	trans	rs808225	0.874	rs1092209	chr14:58377060	A/G	cg12462816	chr6:127836107	C6orf174	0.57	6.84	0.49	2e-10	Pulmonary function;
UCEC	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.78	7.9	0.55	6.09e-13	Ulcerative colitis;
UCEC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.43	4.87	0.37	2.87e-6	Bone mineral density;
UCEC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.44	-4.73	-0.36	5.11e-6	Platelet distribution width;
UCEC	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09672890	chr17:70536484	NA	0.57	7.08	0.5	5.53e-11	Warfarin maintenance dose;
UCEC	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.3	-0.46	3.28e-9	Response to antipsychotic treatment;
UCEC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	5.94	0.44	1.95e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.25	-0.56	8.03e-14	Breast cancer;
UCEC	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.64	6.3	0.46	3.25e-9	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.59	-6.74	-0.49	3.43e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.57	-5.69	-0.42	6.74e-8	Lymphocyte counts;
UCEC	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	6.26	0.46	4.06e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	6.02	0.45	1.3e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.42	-5.42	-0.41	2.4e-7	Dupuytren's disease;
UCEC	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.57	-7.15	-0.51	3.77e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg00677455	chr12:58241039	CTDSP2	0.56	5.75	0.43	4.99e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs692916	0.668	rs814481	chr18:60588143	C/T	cg07187971	chr18:60481018	PHLPP1	-0.39	-4.73	-0.36	5.13e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.44	6.14	0.45	7.28e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11048434	1.000	rs1805719	chr12:9151467	A/G	cg04155231	chr12:9217510	LOC144571	0.48	5.54	0.42	1.36e-7	Sjögren's syndrome;
UCEC	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-4.86	-0.37	3.01e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18932078	chr1:2524107	MMEL1	0.33	5.42	0.41	2.41e-7	Ulcerative colitis;
UCEC	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg21770322	chr7:97807741	LMTK2	0.46	5.81	0.43	3.79e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.49	-0.41	1.73e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.72	6.64	0.48	5.63e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.53	5.26	0.4	5.1e-7	Schizophrenia;
UCEC	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.11	9.55	0.62	4.13e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.75	-0.49	3.21e-10	Joint mobility (Beighton score);
UCEC	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.47	4.86	0.37	2.96e-6	Response to temozolomide;
UCEC	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs692916	0.704	rs625090	chr18:60593492	A/G	cg07187971	chr18:60481018	PHLPP1	-0.38	-4.71	-0.36	5.66e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.51	5.34	0.4	3.51e-7	Autism;
UCEC	cis	rs12635074	0.521	rs12629096	chr3:56309634	A/C	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.33	4.64	0.36	7.74e-6	Morning vs. evening chronotype;
UCEC	cis	rs256277	0.507	rs26545	chr5:111311760	T/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.56	-5.47	-0.41	1.85e-7	Coronary artery disease;
UCEC	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg02733842	chr7:1102375	C7orf50	-0.47	-4.66	-0.36	7.13e-6	Longevity;Endometriosis;
UCEC	cis	rs11867410	0.744	rs73338625	chr17:63968699	G/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.1	0.45	8.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.48	5.46	0.41	2e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-6.22	-0.46	4.97e-9	Menarche (age at onset);
UCEC	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.45	4.71	0.36	5.58e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg20119798	chr7:94954144	PON1	-0.49	-4.62	-0.36	8.38e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.11	6.84	0.49	2e-10	Platelet distribution width;
UCEC	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.48	-4.88	-0.37	2.71e-6	Morning vs. evening chronotype;
UCEC	cis	rs7560272	0.644	rs6749680	chr2:73685852	G/A	cg20560298	chr2:73613845	ALMS1	0.53	5.16	0.39	8.03e-7	Schizophrenia;
UCEC	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.64	-0.36	7.5e-6	Parkinson's disease;
UCEC	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.69	7.0	0.5	8.3e-11	Primary sclerosing cholangitis;
UCEC	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.59	-0.53	3.33e-12	Response to antipsychotic treatment;
UCEC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	7.02	0.5	7.79e-11	Coffee consumption (cups per day);
UCEC	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.88e-8	Red blood cell count;
UCEC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.55	5.39	0.41	2.8e-7	Colorectal cancer;
UCEC	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-6.2	-0.46	5.55e-9	Response to antipsychotic treatment;
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.51	0.53	5.22e-12	Platelet count;
UCEC	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.89	0.49	1.56e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.54	5.14	0.39	8.76e-7	Menopause (age at onset);
UCEC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.45	4.68	0.36	6.34e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.05	-0.38	1.32e-6	Personality dimensions;
UCEC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.82	0.59	3.14e-15	Blood protein levels;
UCEC	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg14851346	chr12:38532713	NA	0.47	4.55	0.35	1.13e-5	Bladder cancer;
UCEC	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg13683864	chr3:40499215	RPL14	-0.53	-5.37	-0.4	3.08e-7	Renal cell carcinoma;
UCEC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.59	-6.71	-0.48	3.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.56	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	8.11	0.56	1.78e-13	Bone mineral density;
UCEC	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg04920474	chr2:44395004	PPM1B	0.46	4.59	0.35	9.62e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
UCEC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.6	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-10.26	-0.65	5.79e-19	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.28e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22117172	chr7:91764530	CYP51A1	0.39	5.16	0.39	8.04e-7	Breast cancer;
UCEC	cis	rs56341938	0.679	rs9844078	chr3:168828224	A/G	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.2	0.56	1.07e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	6.89	0.49	1.51e-10	LDL cholesterol;
UCEC	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.68	-6.53	-0.47	1.02e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-5.28	-0.4	4.48e-7	Childhood ear infection;
UCEC	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	0.89	11.97	0.7	1.77e-23	Bone mineral density;
UCEC	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg05738196	chr6:26577821	NA	0.57	5.55	0.42	1.33e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.21	0.39	6.3e-7	Bipolar disorder;
UCEC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.52	5.92	0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs925228	1.000	rs7561675	chr2:24247818	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.57	4.77	0.37	4.4e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg13695892	chr22:41940480	POLR3H	0.64	4.79	0.37	3.96e-6	Vitiligo;
UCEC	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.61	-0.36	8.8e-6	Coronary artery disease;
UCEC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.99	-12.1	-0.71	8.04e-24	Cognitive function;
UCEC	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.57	4.53	0.35	1.2e-5	Menarche (age at onset);
UCEC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.75	-4.6	-0.35	8.96e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.23	-7.07	-0.5	5.9e-11	Diabetic kidney disease;
UCEC	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.57	-4.96	-0.38	1.94e-6	Reticulocyte count;
UCEC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18252515	chr7:66147081	NA	0.53	5.1	0.39	1.02e-6	Aortic root size;
UCEC	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.85	9.43	0.61	8.39e-17	Breast cancer;
UCEC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.2e-5	Chronic sinus infection;
UCEC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.18	0.39	7.09e-7	Birth weight;
UCEC	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.58	5.03	0.38	1.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	5.13	0.39	8.84e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.47	5.15	0.39	8.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.68	-8.13	-0.56	1.63e-13	Headache;
UCEC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.66	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.86	5.62	0.42	9.09e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs4972806	0.775	rs2857534	chr2:177035676	G/T	cg14324370	chr2:177042789	NA	0.56	5.76	0.43	4.85e-8	IgG glycosylation;
UCEC	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.52	5.14	0.39	8.66e-7	Total body bone mineral density;
UCEC	cis	rs13065560	0.560	rs4491835	chr3:39005889	T/C	cg01426195	chr3:39028469	NA	-0.52	-4.64	-0.36	7.5e-6	Interleukin-18 levels;
UCEC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg03539765	chr12:9217390	LOC144571	-0.4	-4.74	-0.36	4.98e-6	Sjögren's syndrome;
UCEC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	0.96	8.01	0.55	3.2e-13	Obesity-related traits;
UCEC	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-5.22	-0.4	6.13e-7	Vitamin D levels;
UCEC	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.57	-4.61	-0.36	8.73e-6	Menopause (age at onset);
UCEC	cis	rs9512730	0.559	rs9512739	chr13:28102482	G/T	cg04070771	chr13:27998621	GTF3A	0.59	5.1	0.39	1.04e-6	Schizophrenia;
UCEC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	7.84	0.54	8.49e-13	Alzheimer's disease;
UCEC	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.69	7.18	0.51	3.26e-11	Menopause (age at onset);
UCEC	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.5	5.66	0.42	7.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.6	-6.98	-0.5	9.56e-11	Prostate cancer;
UCEC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.59	-4.61	-0.36	8.75e-6	Blood pressure (smoking interaction);
UCEC	trans	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg25653947	chr8:144443217	NA	-0.5	-6.76	-0.49	3.09e-10	Coronary artery disease;
UCEC	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.44	-5.19	-0.39	6.98e-7	Neuroticism;
UCEC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.64	5.27	0.4	4.79e-7	Type 2 diabetes nephropathy;
UCEC	cis	rs2415984	0.818	rs12147964	chr14:46819022	C/G	cg14871534	chr14:47121158	RPL10L	0.39	4.59	0.35	9.54e-6	Number of children ever born;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg18515171	chr17:58156344	HEATR6	-0.61	-6.83	-0.49	2.08e-10	Breast cancer;
UCEC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	5.12	0.39	9.27e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.59	5.13	0.39	8.89e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs17123764	0.710	rs11169133	chr12:50126058	T/C	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	1.12	8.04	0.55	2.73e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7512898	0.583	rs6427852	chr1:200676208	A/T	cg19099833	chr1:201476290	CSRP1	-0.5	-4.97	-0.38	1.81e-6	Electrocardiographic conduction measures;
UCEC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	5.46	0.41	2.01e-7	Monocyte percentage of white cells;
UCEC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.73	7.23	0.51	2.47e-11	Blood protein levels;
UCEC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.71	0.36	5.79e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.46	-5.01	-0.38	1.51e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.37	8.99	0.6	1.1e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs3540	0.513	rs2589957	chr15:90903311	A/G	cg22089800	chr15:90895588	ZNF774	0.69	7.11	0.51	4.64e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.69	7.54	0.53	4.38e-12	Menopause (age at onset);
UCEC	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.46	4.72	0.36	5.51e-6	Coronary artery disease;
UCEC	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.61	6.25	0.46	4.16e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.47	5.01	0.38	1.56e-6	Type 2 diabetes;
UCEC	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.69	0.58	6.52e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs7072216	0.687	rs11189590	chr10:100154605	T/G	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg17105886	chr17:28927953	LRRC37B2	0.64	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.58	0.48	7.59e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.48	5.2	0.39	6.44e-7	Aortic root size;
UCEC	cis	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg20368463	chr18:77673604	PQLC1	0.54	5.11	0.39	9.74e-7	Opioid sensitivity;
UCEC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.52	-5.71	-0.43	6.14e-8	Schizophrenia;
UCEC	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.68	-6.19	-0.45	5.83e-9	Coronary artery disease;
UCEC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs4615376	1.000	rs13205551	chr6:13041170	A/G	cg11378619	chr6:12164359	HIVEP1	-0.59	-4.65	-0.36	7.48e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg24562669	chr7:97807699	LMTK2	0.48	5.86	0.43	2.98e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.4e-8	Height;
UCEC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg09462578	chr12:12878428	APOLD1	-1.1	-11.22	-0.68	1.68e-21	Lymphocyte counts;
UCEC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.65	-5.76	-0.43	4.75e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.63	-6.02	-0.44	1.34e-8	Mortality in heart failure;
UCEC	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	5.59	0.42	1.09e-7	Breast cancer;
UCEC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg07153921	chr17:41440717	NA	-0.55	-5.81	-0.43	3.73e-8	Menopause (age at onset);
UCEC	cis	rs3790645	1.000	rs369385	chr1:26893229	C/T	cg23229016	chr1:26872525	RPS6KA1	0.3	5.58	0.42	1.11e-7	Glucose homeostasis traits;
UCEC	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.04	8.64	0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.63	-6.35	-0.46	2.55e-9	Blood metabolite levels;
UCEC	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.51	-6.42	-0.47	1.81e-9	Congenital heart disease (maternal effect);
UCEC	cis	rs9831754	0.756	rs1512476	chr3:78434219	G/A	cg06138941	chr3:78371609	NA	-0.72	-5.56	-0.42	1.23e-7	Calcium levels;
UCEC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-5.12	-0.39	9.29e-7	Menarche (age at onset);
UCEC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.62	5.74	0.43	5.14e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg01874867	chr7:94954059	PON1	-0.55	-4.83	-0.37	3.44e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg11945507	chr8:142233382	SLC45A4	-0.44	-5.05	-0.38	1.28e-6	Immature fraction of reticulocytes;
UCEC	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.57	5.37	0.41	2.95e-7	Resting heart rate;
UCEC	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.59	5.31	0.4	3.92e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg02900749	chr2:68251473	NA	-0.78	-6.87	-0.49	1.74e-10	Pursuit maintenance gain;
UCEC	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg26898376	chr11:64110657	CCDC88B	0.38	4.51	0.35	1.3e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.56	4.74	0.36	5.1e-6	Obesity-related traits;
UCEC	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.74	-8.4	-0.57	3.54e-14	IgG glycosylation;
UCEC	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	5.34	0.4	3.41e-7	Birth weight;
UCEC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.17	0.39	7.49e-7	Diabetic retinopathy;
UCEC	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs253959	0.881	rs1669135	chr5:115611875	C/G	cg23108291	chr5:115420582	COMMD10	0.49	4.95	0.38	1.97e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.69	8.25	0.56	8.28e-14	Menarche (age at onset);
UCEC	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.63	4.81	0.37	3.77e-6	Carotid intima media thickness;
UCEC	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.83	-8.44	-0.57	2.8e-14	Resting heart rate;
UCEC	cis	rs533123	0.877	rs482692	chr1:29154255	T/C	cg08366446	chr1:29138936	OPRD1	0.77	5.13	0.39	8.88e-7	Schizophrenia;
UCEC	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.49	4.51	0.35	1.32e-5	Pulmonary function decline;
UCEC	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg18279126	chr7:2041391	MAD1L1	0.39	4.71	0.36	5.59e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8042680	0.554	rs73502775	chr15:91536225	G/A	cg14398957	chr15:91536180	PRC1	-0.44	-4.57	-0.35	1e-5	Type 2 diabetes;
UCEC	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.64	-5.3	-0.4	4.14e-7	Alopecia areata;
UCEC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg04756594	chr16:24857601	SLC5A11	0.44	5.22	0.4	5.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-0.94	-12.69	-0.72	2.21e-25	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18986451	chr3:100428869	TFG	0.61	7.21	0.51	2.68e-11	Warfarin maintenance dose;
UCEC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.63	5.79	0.43	4.12e-8	Major depressive disorder;
UCEC	cis	rs2280630	0.529	rs1274957	chr3:39185077	G/A	cg01426195	chr3:39028469	NA	0.67	8.19	0.56	1.15e-13	Verbal declarative memory;
UCEC	cis	rs61776719	0.806	rs28493395	chr1:38400558	C/T	cg04673462	chr1:38461896	NA	0.58	6.01	0.44	1.42e-8	Coronary artery disease;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.41	-4.7	-0.36	5.84e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9470794	1.000	rs59578279	chr6:38047306	A/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg26721908	chr21:47610096	LSS	0.41	4.75	0.36	4.87e-6	Testicular germ cell tumor;
UCEC	cis	rs7709377	0.595	rs785373	chr5:115655585	G/C	cg23108291	chr5:115420582	COMMD10	-0.47	-4.77	-0.37	4.41e-6	Metabolite levels  (X-11787);
UCEC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.69	-7.35	-0.52	1.28e-11	Age at first birth;
UCEC	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.54	6.12	0.45	7.98e-9	Calcium levels;
UCEC	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.11	-0.6	5.7e-16	Coffee consumption (cups per day);
UCEC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	6.27	0.46	3.72e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.55	5.49	0.41	1.72e-7	Corneal astigmatism;
UCEC	cis	rs2742417	1.000	rs1969626	chr3:45746836	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.53	-5.46	-0.41	2.01e-7	Schizophrenia;
UCEC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	0.5	4.96	0.38	1.96e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.1	-7.45	-0.52	7.27e-12	Diabetic kidney disease;
UCEC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.65	-4.79	-0.37	3.97e-6	Coronary artery disease;
UCEC	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.65	7.68	0.54	2.08e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg13695892	chr22:41940480	POLR3H	-0.61	-5.27	-0.4	4.79e-7	Vitiligo;
UCEC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.33	-4.74	-0.36	4.98e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs5770917	0.522	rs3752393	chr22:51015557	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.58	-5.23	-0.4	5.68e-7	Narcolepsy;
UCEC	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-5.38	-0.41	2.89e-7	Alcohol dependence;
UCEC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg03714773	chr7:91764589	CYP51A1	0.41	5.16	0.39	7.96e-7	Breast cancer;
UCEC	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.76	7.84	0.54	8.47e-13	Mosquito bite size;
UCEC	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.04	0.38	1.35e-6	Lung cancer;
UCEC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.32	-0.52	1.5e-11	Blood trace element (Zn levels);
UCEC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.54	6.37	0.47	2.3e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.34	4.71	0.36	5.7e-6	Prostate cancer;
UCEC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg10412286	chr16:89977652	TCF25	-0.69	-4.94	-0.38	2.13e-6	Skin colour saturation;
UCEC	cis	rs4282339	0.868	rs2974433	chr5:168268387	A/G	cg15232798	chr5:167719548	WWC1	-0.42	-4.75	-0.37	4.69e-6	Height;
UCEC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.19	-0.45	5.64e-9	Personality dimensions;
UCEC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.79	8.14	0.56	1.5e-13	Longevity;Endometriosis;
UCEC	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.47	-6.84	-0.49	1.96e-10	Obesity-related traits;
UCEC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.38	-4.94	-0.38	2.09e-6	Body mass index;
UCEC	cis	rs295140	1.000	rs7580924	chr2:201172628	G/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.18	0.39	7.29e-7	QT interval;
UCEC	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg11871910	chr12:69753446	YEATS4	1.07	13.31	0.74	5.04e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.42	4.7	0.36	5.94e-6	Renal cell carcinoma;
UCEC	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.83	-10.21	-0.64	7.67e-19	Brugada syndrome;
UCEC	cis	rs77861329	0.748	rs893055	chr3:52177348	T/C	cg08692210	chr3:52188851	WDR51A	0.62	5.66	0.42	7.78e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.72	0.36	5.37e-6	Schizophrenia;
UCEC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.49	-6.45	-0.47	1.54e-9	Eye color traits;
UCEC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.81	-8.55	-0.58	1.49e-14	Cognitive function;
UCEC	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.65	6.85	0.49	1.83e-10	Crohn's disease;
UCEC	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.46	5.58	0.42	1.13e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	5.05	0.38	1.31e-6	Bone mineral density;
UCEC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.08	-0.45	9.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	0.89	4.71	0.36	5.65e-6	IgG glycosylation;
UCEC	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.76	-0.37	4.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg22974920	chr21:40686053	BRWD1	0.57	5.08	0.39	1.12e-6	Cognitive function;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.2	-0.46	5.48e-9	Parkinson's disease;
UCEC	cis	rs10949834	0.824	rs2285026	chr7:73530404	C/T	cg07137043	chr7:73588983	EIF4H	-0.77	-4.57	-0.35	1.03e-5	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg00343986	chr7:65444356	GUSB	-0.52	-4.85	-0.37	3.16e-6	Aortic root size;
UCEC	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.66	6.71	0.48	3.85e-10	Body mass index;
UCEC	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.76	8.25	0.56	8.04e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs4372836	0.518	rs4632297	chr2:29008425	T/A	cg09522027	chr2:28974177	PPP1CB	-0.61	-6.27	-0.46	3.83e-9	Body mass index;
UCEC	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.71	-5.13	-0.39	9.02e-7	Orofacial clefts;
UCEC	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg07645718	chr20:61493192	TCFL5	0.71	5.2	0.39	6.44e-7	Obesity-related traits;
UCEC	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-8.33	-0.57	5.07e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6763768	0.606	rs931253	chr3:53298604	A/C	cg10956333	chr3:53294961	NA	0.39	4.57	0.35	1.03e-5	Bacterial meningitis;
UCEC	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-4.59	-0.35	9.46e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.35	-4.59	-0.35	9.34e-6	Schizophrenia;
UCEC	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13683864	chr3:40499215	RPL14	-0.97	-10.02	-0.64	2.47e-18	Renal cell carcinoma;
UCEC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.49	5.51	0.41	1.58e-7	Longevity;
UCEC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.69	-6.83	-0.49	2.04e-10	Body mass index;
UCEC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.84	-10.48	-0.65	1.54e-19	Coronary artery disease;
UCEC	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	1.03	10.57	0.66	9.06e-20	Alcohol dependence;
UCEC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg22563815	chr15:78856949	CHRNA5	0.4	4.96	0.38	1.92e-6	Sudden cardiac arrest;
UCEC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.6	5.86	0.43	2.97e-8	Calcium levels;
UCEC	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.33	0.52	1.43e-11	Response to antipsychotic treatment;
UCEC	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.65	-7.56	-0.53	3.91e-12	Response to temozolomide;
UCEC	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.56	5.65	0.42	8.14e-8	Breast cancer;
UCEC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.83	7.21	0.51	2.71e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.65	7.3	0.52	1.68e-11	Glomerular filtration rate (creatinine);
UCEC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.18	-9.54	-0.62	4.33e-17	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.57	4.53	0.35	1.21e-5	Blood protein levels;
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.88	8.03	0.55	2.93e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-8.51	-0.57	1.82e-14	Vitiligo;
UCEC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg12024160	chr4:1254474	NA	0.58	6.91	0.49	1.39e-10	Obesity-related traits;
UCEC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.66	-6.68	-0.48	4.58e-10	Body mass index;
UCEC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.62	4.97	0.38	1.88e-6	Bladder cancer;
UCEC	cis	rs11760485	0.965	rs10233780	chr7:4404058	C/G	cg15613991	chr7:5277080	NA	-0.42	-5.23	-0.4	5.72e-7	Early childhood aggressive behavior;
UCEC	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.56	5.33	0.4	3.69e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.72	-5.87	-0.44	2.77e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs11761441	0.602	rs10266170	chr7:91905	T/C	cg06458707	chr7:1083209	C7orf50	0.25	4.63	0.36	7.9e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg04013166	chr16:89971882	TCF25	0.68	6.15	0.45	6.84e-9	Skin colour saturation;
UCEC	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.09	8.74	0.58	4.8e-15	Uric acid levels;
UCEC	cis	rs7646881	0.544	rs41272617	chr3:158320892	C/G	cg05743054	chr3:158288903	MLF1	-0.54	-4.96	-0.38	1.89e-6	Tetralogy of Fallot;
UCEC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.42	-5.28	-0.4	4.48e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.46	4.67	0.36	6.6e-6	Morning vs. evening chronotype;
UCEC	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.68	-6.12	-0.45	8.14e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12681288	0.821	rs2701944	chr8:1034525	T/A	cg04851639	chr8:1020857	NA	-0.39	-5.24	-0.4	5.46e-7	Schizophrenia;
UCEC	cis	rs713477	1.000	rs7149622	chr14:55909402	T/C	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.65	0.42	8.16e-8	Prudent dietary pattern;
UCEC	cis	rs735860	0.763	rs1429146	chr6:53130285	C/T	cg10236188	chr6:53219634	NA	-0.47	-5.13	-0.39	8.82e-7	Glaucoma;
UCEC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.6	6.45	0.47	1.54e-9	Colorectal cancer;
UCEC	cis	rs4654899	0.895	rs7515590	chr1:21216664	T/C	cg01072550	chr1:21505969	NA	0.5	5.03	0.38	1.41e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.71	-5.87	-0.44	2.79e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7937612	1.000	rs10892566	chr11:120241923	T/C	cg12584626	chr11:120203529	NA	0.52	5.22	0.4	5.95e-7	Intraocular pressure;
UCEC	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg22852734	chr6:133119734	C6orf192	0.92	8.52	0.57	1.78e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.75	0.43	5.04e-8	Breast cancer;
UCEC	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.56	-5.69	-0.42	6.71e-8	Pulse pressure;
UCEC	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg12310025	chr6:25882481	NA	-0.59	-4.64	-0.36	7.69e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.53	4.96	0.38	1.93e-6	Schizophrenia;
UCEC	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.86	-10.35	-0.65	3.3e-19	Monocyte count;
UCEC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg15848620	chr12:58087721	OS9	-0.53	-5.09	-0.39	1.07e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.5	4.74	0.36	5.07e-6	Bipolar disorder;
UCEC	cis	rs925228	1.000	rs925228	chr2:24246679	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.57	4.82	0.37	3.49e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.78	-0.37	4.29e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.64	5.27	0.4	4.77e-7	Type 2 diabetes;
UCEC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg18230493	chr5:56204884	C5orf35	0.5	4.7	0.36	5.88e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs10864907	0.553	rs7580877	chr2:113718310	C/A	cg06156847	chr2:113672199	IL1F7	-0.31	-4.61	-0.36	8.5e-6	Pulmonary function;
UCEC	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.33	-0.52	1.39e-11	Urate levels in overweight individuals;
UCEC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.82	7.91	0.55	5.54e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg09120320	chr17:61926383	NA	0.44	4.65	0.36	7.21e-6	Prudent dietary pattern;
UCEC	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.41e-8	Height;
UCEC	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.6	-5.26	-0.4	4.98e-7	Major depressive disorder;
UCEC	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg01256987	chr12:42539512	GXYLT1	0.42	4.73	0.36	5.24e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2871865	0.544	rs1319868	chr15:99186979	A/C	cg03625665	chr15:99602038	NA	0.48	4.51	0.35	1.34e-5	Height;
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs6688613	0.840	rs6669886	chr1:166956710	T/C	cg07049167	chr1:166818506	POGK	0.54	5.21	0.39	6.3e-7	Refractive astigmatism;
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs73206853	0.925	rs12297709	chr12:110901758	A/G	cg12870014	chr12:110450643	ANKRD13A	0.55	4.58	0.35	9.68e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.54	6.28	0.46	3.55e-9	Hemoglobin concentration;
UCEC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.5	0.62	5.42e-17	Heart rate;
UCEC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg26721908	chr21:47610096	LSS	-0.39	-4.86	-0.37	3.01e-6	Testicular germ cell tumor;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.46	-0.41	1.96e-7	Depression;
UCEC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.57	-5.36	-0.4	3.16e-7	Blood protein levels;
UCEC	cis	rs8032158	0.927	rs7179116	chr15:56174827	A/G	cg10433327	chr15:56209506	NEDD4	-0.28	-4.65	-0.36	7.2e-6	Keloid;
UCEC	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	4.97	0.38	1.84e-6	Educational attainment;
UCEC	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.47	-5.44	-0.41	2.19e-7	White matter hyperintensity burden;
UCEC	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.3e-9	Coffee consumption (cups per day);
UCEC	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.38	5.62	0.42	9.1e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.71	4.54	0.35	1.17e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg03678062	chr6:149772716	ZC3H12D	-0.45	-5.44	-0.41	2.16e-7	Dupuytren's disease;
UCEC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.64	-6.95	-0.5	1.11e-10	Homoarginine levels;
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg08320659	chr6:26088202	HFE	0.72	4.71	0.36	5.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	0.71	4.6	0.35	9.22e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.78	-6.97	-0.5	9.75e-11	Bladder cancer;
UCEC	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-9.41	-0.61	9.69e-17	Coronary artery disease;
UCEC	trans	rs2270927	0.790	rs4613682	chr5:75576455	G/C	cg13563193	chr19:33072644	PDCD5	0.88	7.26	0.51	2.13e-11	Mean corpuscular volume;
UCEC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg27624424	chr6:160112604	SOD2	0.57	5.39	0.41	2.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs968451	0.547	rs11704319	chr22:39722886	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.62	-5.82	-0.43	3.49e-8	Primary biliary cholangitis;
UCEC	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg10483660	chr13:112241077	NA	0.43	4.72	0.36	5.44e-6	Menarche (age at onset);
UCEC	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.54	9.74	0.63	1.31e-17	Airflow obstruction;
UCEC	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.49	0.62	5.83e-17	Platelet count;
UCEC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.68	-7.01	-0.5	7.89e-11	Breast cancer;
UCEC	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.72	-0.36	5.39e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg22974920	chr21:40686053	BRWD1	-0.49	-4.86	-0.37	2.92e-6	Menarche (age at onset);
UCEC	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.53	6.56	0.48	8.71e-10	Total body bone mineral density;
UCEC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.64	0.42	8.64e-8	Breast cancer;
UCEC	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	4.67	0.36	6.75e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.23	-7.07	-0.5	5.9e-11	Diabetic kidney disease;
UCEC	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-4.85	-0.37	3.18e-6	Coronary artery disease;
UCEC	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.81	-0.37	3.65e-6	Response to antipsychotic treatment;
UCEC	cis	rs6722750	0.905	rs10170666	chr2:64379672	G/A	cg22352474	chr2:64371530	PELI1	0.64	5.81	0.43	3.69e-8	Neuroticism;
UCEC	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.57	-5.67	-0.42	7.27e-8	Calcium levels;
UCEC	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.38	-4.58	-0.35	9.96e-6	Educational attainment (years of education);
UCEC	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	6.67	0.48	4.96e-10	Bipolar disorder;
UCEC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.47	4.68	0.36	6.58e-6	Monocyte percentage of white cells;
UCEC	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg01072550	chr1:21505969	NA	-0.62	-6.59	-0.48	7.42e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg18223379	chr20:31619647	BPIL3	-0.38	-4.65	-0.36	7.24e-6	Ulcerative colitis;
UCEC	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg10902566	chr4:727664	PCGF3	-0.61	-4.99	-0.38	1.69e-6	Systolic blood pressure;
UCEC	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.73	6.15	0.45	7.07e-9	Blood metabolite levels;
UCEC	cis	rs11235843	0.503	rs11601905	chr11:73358923	C/T	cg23931323	chr11:73372278	PLEKHB1	0.62	4.85	0.37	3.17e-6	Hand grip strength;
UCEC	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs4588572	0.601	rs10942855	chr5:77737529	G/A	cg11547950	chr5:77652471	NA	-0.45	-4.7	-0.36	6.03e-6	Triglycerides;
UCEC	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.77	-0.59	4.2e-15	Colorectal cancer;
UCEC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.7	-5.74	-0.43	5.2100000000000003e-08	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.01	8.23	0.56	9.01e-14	Platelet distribution width;
UCEC	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.36	5.09	0.39	1.07e-6	Fat distribution (HIV);
UCEC	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.26	0.4	4.96e-7	Rheumatoid arthritis;
UCEC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.87	11.03	0.67	5.38e-21	Longevity;Endometriosis;
UCEC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg03859395	chr2:55845619	SMEK2	1.0	14.54	0.77	3.04e-30	Metabolic syndrome;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.38	-0.41	2.94e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.5	5.57	0.42	1.18e-7	Response to antineoplastic agents;
UCEC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.73	7.1	0.51	4.86e-11	Smoking behavior;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg09682330	chr6:28411287	ZSCAN23	0.49	5.29	0.4	4.4e-7	Cardiac Troponin-T levels;
UCEC	cis	rs12428035	0.536	rs72637837	chr13:96739916	T/A	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-4.89	-0.37	2.57e-6	Aortic root size;
UCEC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg03808351	chr9:123631620	PHF19	0.47	5.35	0.4	3.28e-7	Birth weight;
UCEC	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.5	-6.65	-0.48	5.26e-10	Eye color traits;
UCEC	cis	rs151997	0.962	rs28090	chr5:50177509	T/C	cg06027927	chr5:50259733	NA	0.54	4.99	0.38	1.66e-6	Callous-unemotional behaviour;
UCEC	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.45	0.61	7.27e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	0.72	5.31	0.4	4.06e-7	Blood protein levels;
UCEC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.97	0.38	1.84e-6	Monocyte percentage of white cells;
UCEC	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-4.99	-0.38	1.68e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.8	-7.83	-0.54	8.71e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg20368463	chr18:77673604	PQLC1	-0.62	-4.71	-0.36	5.65e-6	Schizophrenia;
UCEC	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg10932868	chr11:921992	NA	0.44	5.86	0.43	2.97e-8	Alzheimer's disease (late onset);
UCEC	cis	rs9309473	0.500	rs1528169	chr2:73669186	T/C	cg20560298	chr2:73613845	ALMS1	0.53	5.15	0.39	8.28e-7	Metabolite levels;
UCEC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg27535305	chr1:53392650	SCP2	-0.44	-5.61	-0.42	9.81e-8	Monocyte count;
UCEC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg10965384	chr11:64119977	CCDC88B	0.37	4.52	0.35	1.28e-5	Platelet count;
UCEC	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.67	9.02	0.6	9.25e-16	Systolic blood pressure;
UCEC	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.31	-0.4	4.03e-7	Dupuytren's disease;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.67	7.73	0.54	1.6e-12	Prudent dietary pattern;
UCEC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.81	-0.37	3.75e-6	Parkinson's disease;
UCEC	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg24851651	chr11:66362959	CCS	0.45	5.38	0.41	2.86e-7	Educational attainment (years of education);
UCEC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.47	-5.5	-0.41	1.6e-7	Aortic root size;
UCEC	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	4.59	0.35	9.55e-6	Schizophrenia;
UCEC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-7.42	-0.52	8.67e-12	Hemoglobin concentration;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg09682330	chr6:28411287	ZSCAN23	0.45	5.12	0.39	9.63e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.37	0.52	1.17e-11	Total body bone mineral density;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-6.14	-0.45	7.17e-9	Platelet count;
UCEC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg05738196	chr6:26577821	NA	0.58	6.22	0.46	4.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13870426	chr17:30244630	NA	-0.47	-4.51	-0.35	1.31e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.53	5.45	0.41	2.06e-7	Longevity;Endometriosis;
UCEC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs16937	0.711	rs12142514	chr1:205122529	A/G	cg12580275	chr1:205744413	RAB7L1	0.44	5.09	0.39	1.09e-6	Schizophrenia;
UCEC	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.54	5.75	0.43	5.01e-8	Schizophrenia;
UCEC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg24531977	chr5:56204891	C5orf35	-0.5	-4.63	-0.36	8.1e-6	Coronary artery disease;
UCEC	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg21419209	chr3:44054225	NA	-0.52	-5.5	-0.41	1.61e-7	Coronary artery disease;
UCEC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg24562669	chr7:97807699	LMTK2	0.48	5.82	0.43	3.51e-8	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.82	-9.47	-0.62	6.72e-17	Coronary artery disease;
UCEC	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.55	-0.42	1.3e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.27e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2625529	0.556	rs35603965	chr15:72523043	C/T	cg21214455	chr15:72412075	SENP8	0.46	4.71	0.36	5.68e-6	Red blood cell count;
UCEC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.87	9.08	0.6	6.79e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.56	5.14	0.39	8.6e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.56	4.98	0.38	1.74e-6	Metabolite levels;
UCEC	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.91	-11.02	-0.67	5.77e-21	Personality dimensions;
UCEC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg22771759	chr13:24902376	NA	0.4	4.66	0.36	7.12e-6	Obesity-related traits;
UCEC	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.84	-9.49	-0.62	5.79e-17	Blood metabolite levels;
UCEC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.85	8.87	0.59	2.23e-15	Longevity;Endometriosis;
UCEC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.79	8.36	0.57	4.27e-14	Tonsillectomy;
UCEC	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-4.73	-0.36	5.27e-6	Response to antipsychotic treatment;
UCEC	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-4.98	-0.38	1.78e-6	Educational attainment;
UCEC	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.53	-5.56	-0.42	1.25e-7	Myopia (pathological);
UCEC	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg18230493	chr5:56204884	C5orf35	-0.55	-5.03	-0.38	1.41e-6	Coronary artery disease;
UCEC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.75	6.91	0.5	1.36e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.28	-0.4	4.62e-7	Hemoglobin concentration;
UCEC	cis	rs12973672	0.812	rs12979792	chr19:35748706	A/G	cg12095397	chr19:35769544	USF2	0.51	4.85	0.37	3.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.54	0.35	1.18e-5	Bipolar disorder;
UCEC	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.48	5.03	0.38	1.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg04013166	chr16:89971882	TCF25	0.73	4.59	0.35	9.44e-6	Skin colour saturation;
UCEC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.81	5.07	0.39	1.18e-6	Lung function (FEV1/FVC);
UCEC	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg09491104	chr22:46646882	C22orf40	-0.51	-5.04	-0.38	1.36e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.66	-5.77	-0.43	4.61e-8	Obesity-related traits;
UCEC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg09473613	chr1:24152604	HMGCL	0.32	4.51	0.35	1.31e-5	Immature fraction of reticulocytes;
UCEC	cis	rs1483890	0.642	rs1010315	chr3:69402165	C/T	cg22125112	chr3:69402811	FRMD4B	0.47	4.84	0.37	3.32e-6	Resting heart rate;
UCEC	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.98	-0.5	9.49e-11	Eye color traits;
UCEC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.47	-4.76	-0.37	4.5e-6	Dental caries;
UCEC	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	0.91	9.93	0.63	4.28e-18	Coronary artery disease;
UCEC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.43	-0.47	1.66e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12145833	1.000	rs76473275	chr1:243460555	T/C	cg02356786	chr1:243265016	LOC731275	0.73	4.91	0.38	2.44e-6	Obesity (early onset extreme);
UCEC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.2	-14.79	-0.77	6.85e-31	Breast cancer;
UCEC	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.69	-5.91	-0.44	2.32e-8	Platelet distribution width;
UCEC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18252515	chr7:66147081	NA	-0.56	-5.02	-0.38	1.46e-6	Aortic root size;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.81	-0.43	3.74e-8	Prudent dietary pattern;
UCEC	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.39	6.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.36	-4.9	-0.37	2.46e-6	Eye color traits;
UCEC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg19318889	chr4:1322082	MAEA	-0.46	-5.62	-0.42	9.32e-8	Obesity-related traits;
UCEC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.64	7.14	0.51	4.06e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.76	7.34	0.52	1.38e-11	Mosquito bite size;
UCEC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.08	0.45	9.87e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.6	5.29	0.4	4.36e-7	Uric acid levels;
UCEC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.5	-5.53	-0.41	1.45e-7	Aortic root size;
UCEC	cis	rs7095607	0.813	rs4746732	chr10:69931881	C/T	cg18986048	chr10:69913749	MYPN	0.54	6.35	0.46	2.54e-9	Lung function (FVC);
UCEC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg18479299	chr3:125709523	NA	-0.65	-4.5	-0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.36	-0.52	1.17e-11	Joint mobility (Beighton score);
UCEC	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.65	-7.69	-0.54	1.98e-12	Prevalent atrial fibrillation;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.99	-0.44	1.54e-8	Platelet count;
UCEC	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.55	5.85	0.43	3.08e-8	Ulcerative colitis;
UCEC	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg01072550	chr1:21505969	NA	-0.56	-5.72	-0.43	5.85e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.7	-6.71	-0.48	3.87e-10	Aortic root size;
UCEC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-1.0	-13.26	-0.74	6.7399999999999993e-27	Monocyte count;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.51	-6.2	-0.46	5.4e-9	Pubertal anthropometrics;
UCEC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.6e-6	Electroencephalogram traits;
UCEC	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.43	-4.64	-0.36	7.62e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.88	8.55	0.58	1.44e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.86	5.75	0.43	5.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.62	6.76	0.49	3.03e-10	Monocyte count;
UCEC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18932078	chr1:2524107	MMEL1	0.34	5.87	0.44	2.85e-8	Ulcerative colitis;
UCEC	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.75	6.96	0.5	1.07e-10	Bladder cancer;
UCEC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.54	6.05	0.45	1.16e-8	Breast cancer;
UCEC	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg23972785	chr8:11611189	GATA4	-0.35	-4.51	-0.35	1.32e-5	Neuroticism;
UCEC	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.77	-6.73	-0.49	3.51e-10	Platelet distribution width;
UCEC	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.47	-5.53	-0.42	1.41e-7	Total body bone mineral density;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24859228	chr10:12391835	CAMK1D	0.6	7.36	0.52	1.21e-11	Warfarin maintenance dose;
UCEC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.56	0.48	8.66e-10	Aortic root size;
UCEC	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.73	-6.0	-0.44	1.46e-8	Coronary artery calcification;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.64	-7.37	-0.52	1.14e-11	Body mass index;
UCEC	cis	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg20307385	chr11:47447363	PSMC3	0.59	5.13	0.39	9.07e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.12	0.39	9.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2795502	0.630	rs2282443	chr10:43474169	A/G	cg11150807	chr10:43354902	NA	0.78	4.8	0.37	3.84e-6	Blood protein levels;
UCEC	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg05991184	chr2:219186017	PNKD	-0.54	-5.94	-0.44	1.97e-8	Colorectal cancer;
UCEC	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg10596483	chr8:143751796	JRK	0.51	5.38	0.41	2.84e-7	Schizophrenia;
UCEC	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.52	5.81	0.43	3.68e-8	Immature fraction of reticulocytes;
UCEC	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.07	-0.45	1.04e-8	Parkinson's disease;
UCEC	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	0.9	8.72	0.58	5.62e-15	Vitiligo;
UCEC	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.71	-7.14	-0.51	4.02e-11	Blood metabolite levels;
UCEC	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.61	4.73	0.36	5.27e-6	Breast cancer;
UCEC	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.16	0.39	7.99e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4722166	0.532	rs1404008	chr7:22756000	A/T	cg05472934	chr7:22766657	IL6	0.55	5.36	0.4	3.22e-7	Lung cancer;
UCEC	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.66	-8.71	-0.58	5.93e-15	Coronary artery disease or large artery stroke;
UCEC	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.43	4.51	0.35	1.32e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.61	-5.96	-0.44	1.75e-8	Metabolite levels;
UCEC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-4.95	-0.38	1.99e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-4.54	-0.35	1.17e-5	Alzheimer's disease (late onset);
UCEC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.52e-7	Hemoglobin concentration;
UCEC	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.38	0.61	1.13e-16	Platelet count;
UCEC	cis	rs4900538	0.750	rs12590618	chr14:102808330	C/T	cg18135206	chr14:102964638	TECPR2	-1.0	-9.76	-0.63	1.2e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg13593689	chr9:129986794	NA	0.46	4.63	0.36	7.84e-6	Intraocular pressure;
UCEC	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.38	5.75	0.43	5.04e-8	Blood protein levels;
UCEC	cis	rs2979489	0.699	rs62508370	chr8:30417026	G/A	cg26383811	chr8:30366931	RBPMS	-0.64	-4.92	-0.38	2.28e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4908768	1.000	rs12122666	chr1:8741438	A/C	cg13081009	chr1:8430745	RERE	-0.48	-4.87	-0.37	2.86e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg00500100	chr5:140098250	VTRNA1-2	0.34	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.12	17.62	0.82	4.64e-38	IgG glycosylation;
UCEC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.67	5.3	0.4	4.24e-7	Corneal astigmatism;
UCEC	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.44	-5.49	-0.41	1.71e-7	Obesity-related traits;
UCEC	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg18681998	chr4:17616180	MED28	0.5	5.76	0.43	4.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	5.81	0.43	3.78e-8	Colorectal cancer;
UCEC	cis	rs1712517	0.771	rs61350103	chr10:105069120	A/C	cg05636881	chr10:105038444	INA	0.43	5.4	0.41	2.66e-7	Migraine;
UCEC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.57	7.23	0.51	2.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-5.14	-0.39	8.58e-7	Bone mineral density;
UCEC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.5	-5.07	-0.39	1.17e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs62392365	0.536	rs77078042	chr6:25148056	C/T	cg12449049	chr6:25088999	CMAH	0.78	4.51	0.35	1.3e-5	Schizophrenia;Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg24069376	chr3:38537580	EXOG	0.43	5.3	0.4	4.19e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.16	0.39	7.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs7072216	0.621	rs3750604	chr10:100175581	G/A	cg19567339	chr10:100142640	NA	0.58	6.11	0.45	8.47e-9	Metabolite levels;
UCEC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg23307798	chr14:103986281	CKB	0.64	7.83	0.54	8.82e-13	Body mass index;
UCEC	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg13683864	chr3:40499215	RPL14	-0.52	-5.33	-0.4	3.67e-7	Renal cell carcinoma;
UCEC	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.54	-0.53	4.53e-12	Exhaled nitric oxide output;
UCEC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.56	0.42	1.21e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg02773041	chr1:40204384	PPIE	0.56	5.46	0.41	2.02e-7	Blood protein levels;
UCEC	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg07256473	chr22:29710276	RASL10A	0.54	6.16	0.45	6.48e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs9843304	0.772	rs4681515	chr3:149212076	A/G	cg08667024	chr3:149219783	TM4SF4	0.4	4.76	0.37	4.66e-6	Gallstone disease;
UCEC	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.53	-0.35	1.21e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7336933	0.932	rs4942082	chr13:42528971	G/C	cg18400088	chr13:41634674	WBP4	0.56	4.69	0.36	6.07e-6	Calcium levels;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.85	-0.43	3.14e-8	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.72	8.7	0.58	6.17e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2370759	0.945	rs11592205	chr10:32646499	C/T	cg01819863	chr10:32635814	EPC1	1.16	7.28	0.51	1.89e-11	Sexual dysfunction (female);
UCEC	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.66	7.18	0.51	3.2e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs4926298	0.890	rs745610	chr19:13157280	C/G	cg11758861	chr19:13135514	NFIX	-0.5	-4.71	-0.36	5.69e-6	Bipolar disorder;
UCEC	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.0	-7.99	-0.55	3.6e-13	Exhaled nitric oxide output;
UCEC	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs17433710	0.778	rs79936905	chr1:162675046	G/C	cg19264028	chr1:162630153	DDR2	1.02	4.56	0.35	1.06e-5	Dupuytren's disease;
UCEC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.48	5.43	0.41	2.33e-7	Recombination rate (males);
UCEC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.59	6.36	0.46	2.39e-9	Neutrophil percentage of white cells;
UCEC	cis	rs2172802	0.598	rs13115278	chr4:62539481	A/G	cg04118610	chr4:62707027	LPHN3	-0.43	-4.69	-0.36	6.12e-6	Partial epilepsies;
UCEC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.5	5.3	0.4	4.18e-7	Aortic root size;
UCEC	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.65	5.34	0.4	3.45e-7	Obesity-related traits;
UCEC	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg18681998	chr4:17616180	MED28	0.7	8.11	0.56	1.85e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2882667	0.824	rs12173085	chr5:138480025	A/G	cg04439458	chr5:138467593	SIL1	-0.49	-5.6	-0.42	1.01e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg20560298	chr2:73613845	ALMS1	-0.58	-5.14	-0.39	8.63e-7	Metabolite levels;
UCEC	cis	rs6494849	0.620	rs8030168	chr15:70480929	C/T	cg22026918	chr15:70552251	NA	0.41	4.73	0.36	5.2e-6	Bipolar disorder;
UCEC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg04154034	chr17:28927549	LRRC37B2	0.79	5.24	0.4	5.5e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg23791538	chr6:167370224	RNASET2	0.47	4.74	0.36	5.04e-6	Primary biliary cholangitis;
UCEC	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg02503808	chr4:7069936	GRPEL1	-0.41	-4.56	-0.35	1.08e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	5.02	0.38	1.44e-6	Joint mobility (Beighton score);
UCEC	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.53	-5.09	-0.39	1.08e-6	Metabolite levels;
UCEC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.01	0.44	1.41e-8	Menarche (age at onset);
UCEC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.77	-6.11	-0.45	8.39e-9	Narcolepsy;
UCEC	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.68	5.09	0.39	1.06e-6	Aortic root size;
UCEC	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.85	-0.37	3.17e-6	Personality dimensions;
UCEC	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.64	6.64	0.48	5.75e-10	Ulcerative colitis;
UCEC	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.52	-4.9	-0.37	2.5e-6	Large artery stroke;
UCEC	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg11632617	chr15:75315747	PPCDC	-0.61	-6.31	-0.46	3.18e-9	Lung cancer;
UCEC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.69	0.36	6.25e-6	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.47	5.03	0.38	1.42e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-7.45	-0.52	7.49e-12	Personality dimensions;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg02984193	chr15:91260561	BLM	0.7	6.79	0.49	2.52e-10	Schizophrenia;
UCEC	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg17526145	chr2:23869158	KLHL29	0.41	4.63	0.36	7.97e-6	Asthma;
UCEC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg06466757	chr4:1255808	NA	0.47	4.96	0.38	1.9e-6	Obesity-related traits;
UCEC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.52	5.19	0.39	6.86e-7	Schizophrenia;
UCEC	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.44e-16	Hip circumference adjusted for BMI;
UCEC	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.06	-0.6	7.3e-16	Height;
UCEC	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.77	6.35	0.46	2.49e-9	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.36	-8.55	-0.58	1.43e-14	Diabetic kidney disease;
UCEC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.45	4.77	0.37	4.48e-6	Primary tooth development (time to first tooth eruption);
UCEC	cis	rs6684428	1.000	rs12141666	chr1:56370556	T/C	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	7.74	0.54	1.49e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.75	-7.13	-0.51	4.14e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs7106204	0.858	rs2403889	chr11:24210226	T/C	ch.11.24196551F	chr11:24239977	NA	0.53	5.28	0.4	4.6e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs308403	0.509	rs13117125	chr4:123670824	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	8.13	0.56	1.6e-13	Blood protein levels;
UCEC	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.5	-4.55	-0.35	1.11e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs59104589	0.617	rs56390510	chr2:242274489	G/C	cg19488206	chr2:242435732	STK25	0.53	4.76	0.37	4.53e-6	Fibrinogen levels;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-6.69	-0.48	4.46e-10	Platelet count;
UCEC	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.47	-4.75	-0.36	4.74e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7246967	0.866	rs7250801	chr19:23035957	G/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.4	5.51	0.41	1.58e-7	Obesity-related traits;
UCEC	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.07	14.32	0.76	1.11e-29	Schizophrenia;
UCEC	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.63	-6.85	-0.49	1.87e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg23070574	chr3:14187308	XPC	0.45	5.01	0.38	1.52e-6	Ovarian reserve;
UCEC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.73	7.83	0.54	8.88e-13	Sudden cardiac arrest;
UCEC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.45	4.51	0.35	1.31e-5	Aortic root size;
UCEC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg26441486	chr22:50317300	CRELD2	-0.75	-5.13	-0.39	9.03e-7	Schizophrenia;
UCEC	cis	rs16957091	1.000	rs16957091	chr15:43017426	G/T	cg24196017	chr15:43021976	CDAN1	0.61	6.5	0.47	1.18e-9	MGMT methylation in smokers;
UCEC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	8.0	0.55	3.49e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-6.23	-0.46	4.57e-9	Coffee consumption (cups per day);
UCEC	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.55	5.45	0.41	2.09e-7	Menopause (age at onset);
UCEC	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-4.92	-0.38	2.28e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.45	-4.66	-0.36	7.12e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Body mass index;
UCEC	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	0.75	4.53	0.35	1.21e-5	Fat distribution (HIV);
UCEC	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.4	-5.21	-0.4	6.14e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.48	-4.64	-0.36	7.65e-6	Bone mineral density;
UCEC	cis	rs9843304	0.526	rs9850213	chr3:149202590	C/T	cg08667024	chr3:149219783	TM4SF4	0.57	6.47	0.47	1.39e-9	Gallstone disease;
UCEC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	4.98	0.38	1.78e-6	Breast cancer;
UCEC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.29	-0.4	4.3e-7	Breast cancer;
UCEC	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.81	-8.35	-0.57	4.6e-14	Mosquito bite size;
UCEC	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.65	-0.36	7.36e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2566255	0.717	rs2566252	chr11:4595332	A/G	cg16469099	chr11:4629432	TRIM68	0.87	4.52	0.35	1.27e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg13010344	chr12:123464640	ARL6IP4	-0.41	-4.5	-0.35	1.35e-5	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs36051895	0.603	rs11795305	chr9:5179920	G/C	cg02405213	chr9:5042618	JAK2	-0.58	-4.65	-0.36	7.19e-6	Pediatric autoimmune diseases;
UCEC	cis	rs732765	0.734	rs6574189	chr14:75166493	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	4.56	0.35	1.05e-5	Non-small cell lung cancer;
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg01874867	chr7:94954059	PON1	-0.56	-5.55	-0.42	1.3e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.33	0.52	1.43e-11	Response to antipsychotic treatment;
UCEC	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.52	5.82	0.43	3.62e-8	Life satisfaction;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07167872	chr1:205819463	PM20D1	0.61	6.93	0.5	1.24e-10	Menarche (age at onset);
UCEC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.43	5.27	0.4	4.83e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg14768367	chr16:72042858	DHODH	-0.71	-4.68	-0.36	6.37e-6	Blood protein levels;
UCEC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.87e-7	Heart rate;
UCEC	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.66	-0.36	6.9e-6	Type 2 diabetes;
UCEC	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.53	5.0	0.38	1.63e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.84	-0.37	3.25e-6	Breast cancer;
UCEC	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.19e-6	Vitiligo;
UCEC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg17986701	chr20:44574422	PCIF1	0.51	5.19	0.39	6.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.88	12.1	0.71	7.96e-24	Metabolic syndrome;
UCEC	cis	rs7249142	0.563	rs11669860	chr19:19277296	G/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.67	7.34	0.52	1.34e-11	IgG glycosylation;
UCEC	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.15	-0.39	8.1e-7	Metabolite levels;
UCEC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.61	6.5	0.47	1.15e-9	Diastolic blood pressure;
UCEC	cis	rs847649	0.842	rs4729873	chr7:102731781	G/A	cg18108683	chr7:102477205	FBXL13	0.59	6.93	0.5	1.25e-10	Morning vs. evening chronotype;
UCEC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.81	7.82	0.54	9.31e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.57	-5.76	-0.43	4.74e-8	Schizophrenia;
UCEC	cis	rs4400599	0.618	rs4845610	chr1:154205428	T/C	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg00786635	chr1:25594202	NA	0.48	4.71	0.36	5.59e-6	Plateletcrit;Mean corpuscular volume;
UCEC	cis	rs11048434	0.966	rs1805677	chr12:9153559	C/G	cg26114124	chr12:9217669	LOC144571	-0.45	-4.84	-0.37	3.28e-6	Sjögren's syndrome;
UCEC	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.67	-5.4	-0.41	2.58e-7	Gut microbiome composition (summer);
UCEC	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.67	-5.53	-0.41	1.46e-7	Schizophrenia;
UCEC	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.64	-7.21	-0.51	2.67e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	trans	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg07817883	chr1:32538562	TMEM39B	1.16	8.75	0.59	4.55e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg18016565	chr1:150552671	MCL1	0.48	4.72	0.36	5.46e-6	Melanoma;
UCEC	cis	rs9403521	1.000	rs12528456	chr6:144003706	A/G	cg18240653	chr6:144019428	PHACTR2	-0.62	-4.62	-0.36	8.35e-6	Obesity-related traits;
UCEC	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.49	-5.08	-0.39	1.13e-6	Blood metabolite levels;
UCEC	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.51	4.52	0.35	1.27e-5	Height;
UCEC	cis	rs8020441	0.945	rs61410944	chr14:51166736	A/G	cg04730355	chr14:51134070	SAV1	0.56	5.22	0.4	5.99e-7	Cognitive performance;
UCEC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.5	-4.77	-0.37	4.32e-6	Total body bone mineral density;
UCEC	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.95	-7.48	-0.53	6.14e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.64	-7.13	-0.51	4.27e-11	Heart rate;
UCEC	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.96	10.5	0.65	1.4e-19	Cognitive function;
UCEC	cis	rs834603	0.965	rs700755	chr7:47445641	A/G	cg23694490	chr7:47445681	TNS3	-0.32	-5.1	-0.39	1.02e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.6	-4.76	-0.37	4.64e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg24851651	chr11:66362959	CCS	-0.41	-5.15	-0.39	8.28e-7	Educational attainment (years of education);
UCEC	cis	rs7119167	0.901	rs1939382	chr11:73179718	G/T	cg25756853	chr11:74022558	P4HA3	-0.45	-4.62	-0.36	8.35e-6	Blood protein levels;
UCEC	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg06671706	chr8:8559999	CLDN23	0.65	5.5	0.41	1.62e-7	Obesity-related traits;
UCEC	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.59	-6.41	-0.47	1.91e-9	Crohn's disease;
UCEC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.61	7.51	0.53	5.31e-12	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-0.9	-7.61	-0.53	3e-12	Blood pressure (smoking interaction);
UCEC	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-5.92	-0.44	2.22e-8	Glomerular filtration rate;
UCEC	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.42	-0.52	8.45e-12	Hypospadias;
UCEC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.44	-6.22	-0.46	4.81e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.76	-0.37	4.59e-6	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg17105886	chr17:28927953	LRRC37B2	0.53	4.84	0.37	3.24e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.74	-4.81	-0.37	3.76e-6	Hair shape;
UCEC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.92	0.59	1.68e-15	Alzheimer's disease;
UCEC	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg02476566	chr12:106696527	TCP11L2	0.64	5.37	0.4	3.06e-7	Tourette syndrome;
UCEC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.45	5.92	0.44	2.19e-8	Fibrinogen levels;
UCEC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	10.86	0.67	1.54e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.75	-9.4	-0.61	9.76e-17	Cancer (pleiotropy);
UCEC	cis	rs8010715	1.000	rs3742500	chr14:24611978	G/T	cg20933586	chr14:24608199	FAM158A	0.46	5.8	0.43	3.86e-8	IgG glycosylation;
UCEC	cis	rs4948275	0.530	rs2139778	chr10:63134943	A/T	cg16139770	chr10:63661496	ARID5B	-0.44	-4.62	-0.36	8.44e-6	Night sleep phenotypes;
UCEC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.68	-6.58	-0.48	7.79e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg26929925	chr5:138714136	SLC23A1	-0.42	-4.51	-0.35	1.33e-5	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.85	-7.51	-0.53	5.41e-12	Coronary artery calcification;
UCEC	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-9.79	-0.63	9.65e-18	Exhaled nitric oxide output;
UCEC	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg18681998	chr4:17616180	MED28	0.58	6.55	0.48	9.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs944990	0.618	rs10761243	chr9:96369258	T/G	cg13787134	chr9:96362102	PHF2	-0.38	-5.3	-0.4	4.23e-7	Body mass index;
UCEC	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.51	5.6	0.42	1.01e-7	Tonsillectomy;
UCEC	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.29	10.8	0.67	2.18e-20	Uric acid levels;
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs10924970	0.781	rs10802589	chr1:235444049	A/G	cg26050004	chr1:235667680	B3GALNT2	0.45	4.73	0.36	5.11e-6	Asthma;
UCEC	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.43	-5.41	-0.41	2.53e-7	Refractive error;
UCEC	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.66	5.94	0.44	2.02e-8	Graves' disease;
UCEC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.87	-8.82	-0.59	3.09e-15	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13401104	0.755	rs55787207	chr2:237106584	A/T	cg23897927	chr2:237117786	ASB18	-0.51	-4.53	-0.35	1.21e-5	Educational attainment;
UCEC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.7	-5.52	-0.41	1.48e-7	Triglycerides;
UCEC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg08886695	chr4:3369023	RGS12	0.5	4.9	0.37	2.5e-6	Serum sulfate level;
UCEC	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.44	5.01	0.38	1.57e-6	Aortic root size;
UCEC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg24789503	chr3:195384528	SDHAP2	-0.64	-4.79	-0.37	4.12e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg08250081	chr4:10125330	NA	0.45	4.52	0.35	1.27e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.44	5.93	0.44	2.1e-8	Bone mineral density;
UCEC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.74	8.24	0.56	8.64e-14	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.69	5.93	0.44	2.08e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.47	5.13	0.39	9.16e-7	Aortic root size;
UCEC	cis	rs2708977	0.637	rs618454	chr2:97080093	C/G	cg22654517	chr2:96458247	NA	0.42	5.02	0.38	1.49e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.11	-0.39	9.76e-7	Colorectal cancer;
UCEC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.62	-0.42	9.21e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.45	-4.87	-0.37	2.88e-6	White matter hyperintensity burden;
UCEC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg13695892	chr22:41940480	POLR3H	0.67	4.7	0.36	5.87e-6	Vitiligo;
UCEC	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.39	-4.61	-0.36	8.73e-6	Depression;
UCEC	cis	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.51	5.83	0.43	3.44e-8	Testicular germ cell tumor;
UCEC	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.58	-4.98	-0.38	1.8e-6	Reticulocyte count;
UCEC	trans	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg15509575	chr4:2286509	ZFYVE28	0.38	6.79	0.49	2.64e-10	Rheumatoid arthritis;
UCEC	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	6.34	0.46	2.6e-9	Bone mineral density;
UCEC	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg24562669	chr7:97807699	LMTK2	0.48	5.87	0.44	2.85e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.62	-0.48	6.2e-10	HDL cholesterol;
UCEC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	6.67	0.48	4.95e-10	Hemoglobin concentration;
UCEC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg24889512	chr19:22816950	ZNF492	0.61	6.83	0.49	2.1e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.37	-4.84	-0.37	3.29e-6	Mean corpuscular hemoglobin;
UCEC	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.97	-15.52	-0.79	8.64e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	13.59	0.75	9.11e-28	Homoarginine levels;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg21486944	chr6:28411378	ZSCAN23	0.48	5.02	0.38	1.46e-6	Cardiac Troponin-T levels;
UCEC	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.72	9.14	0.6	4.54e-16	Mean platelet volume;
UCEC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.45	-4.58	-0.35	9.8200000000000008e-06	Systemic lupus erythematosus;
UCEC	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.78	-7.52	-0.53	4.97e-12	Blood metabolite levels;
UCEC	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.46	6.03	0.45	1.26e-8	Total body bone mineral density;
UCEC	cis	rs8177876	0.731	rs74882687	chr16:81118920	C/A	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg14078730	chr11:63896557	MACROD1	0.67	5.21	0.39	6.28e-7	Mean platelet volume;
UCEC	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.31	-10.43	-0.65	2.05e-19	Hip circumference adjusted for BMI;
UCEC	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	17.62	0.82	4.64e-38	IgG glycosylation;
UCEC	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	5.8	0.43	3.9e-8	Response to antipsychotic treatment;
UCEC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.54	-5.44	-0.41	2.17e-7	Aortic root size;
UCEC	cis	rs10053502	0.867	rs28452170	chr5:40046775	G/T	cg01062838	chr5:40831429	RPL37	0.66	4.59	0.35	9.28e-6	Myopia (pathological);
UCEC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.86	9.53	0.62	4.74e-17	Breast cancer;
UCEC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.51	4.65	0.36	7.32e-6	Aortic root size;
UCEC	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.47	5.04	0.38	1.32e-6	Body mass index;
UCEC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.67	5.93	0.44	2.04e-8	Aortic root size;
UCEC	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs4851266	0.966	rs11689199	chr2:100820421	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.9	0.37	2.54e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.64	-4.79	-0.37	3.99e-6	Systemic lupus erythematosus;
UCEC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg00339695	chr16:24857497	SLC5A11	-0.49	-5.69	-0.42	6.58e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.63	-6.73	-0.49	3.6e-10	Coronary artery disease;
UCEC	cis	rs78487399	0.808	rs6746058	chr2:43687542	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs16937	0.711	rs10751430	chr1:205107497	A/G	cg12580275	chr1:205744413	RAB7L1	0.49	5.69	0.43	6.52e-8	Schizophrenia;
UCEC	cis	rs7766436	0.848	rs13211568	chr6:22573180	A/T	cg13666174	chr6:22585274	NA	-0.59	-6.15	-0.45	7.11e-9	Coronary artery disease;
UCEC	cis	rs17012589	0.592	rs10862969	chr12:85718630	A/G	cg02569458	chr12:86230093	RASSF9	0.39	4.53	0.35	1.23e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs28795989	0.896	rs13151529	chr4:7885983	G/A	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.53	5.43	0.41	2.24e-7	Mood instability;
UCEC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	7.61	0.53	3.02e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	20.38	0.86	1.16e-44	Chronic sinus infection;
UCEC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.62	8.05	0.55	2.55e-13	Anterior chamber depth;
UCEC	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.46	-5.37	-0.41	2.96e-7	White matter hyperintensity burden;
UCEC	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.47	5.23	0.4	5.69e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-6.84	-0.49	1.94e-10	Resting heart rate;
UCEC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-8.22	-0.56	9.75e-14	Cognitive function;
UCEC	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.51	-0.53	5.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	6.02	0.44	1.33e-8	Alzheimer's disease;
UCEC	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.55	-0.35	1.1e-5	Tonsillectomy;
UCEC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.26	-0.4	4.97e-7	Aortic root size;
UCEC	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-4.8	-0.37	3.94e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13870426	chr17:30244630	NA	-0.68	-5.15	-0.39	8.05e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.57	6.6	0.48	6.97e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	9.15	0.6	4.37e-16	Mean platelet volume;
UCEC	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.53	4.85	0.37	3.11e-6	Coronary artery disease;
UCEC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.47	-5.21	-0.39	6.39e-7	Cardiac Troponin-T levels;
UCEC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.76	0.37	4.6e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.55	7.32	0.52	1.52e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.54	6.06	0.45	1.08e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9469578	1.000	rs16869458	chr6:33714639	C/T	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg05539622	chr2:73298971	SFXN5	0.5	4.63	0.36	7.94e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg05072774	chr3:49840536	C3orf54	-0.53	-5.51	-0.41	1.53e-7	Resting heart rate;
UCEC	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.33e-11	Bladder cancer;
UCEC	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.59	6.3	0.46	3.2e-9	Noise-induced hearing loss;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.43	-4.52	-0.35	1.28e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.35	-5.17	-0.39	7.57e-7	Vitamin D levels;
UCEC	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg00105475	chr2:10696890	NA	0.45	5.5	0.41	1.64e-7	Prostate cancer;
UCEC	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.43	6.36	0.46	2.4e-9	Crohn's disease;
UCEC	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg16262614	chr3:133464971	TF	-0.39	-4.61	-0.36	8.82e-6	Iron status biomarkers;
UCEC	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.34	5.31	0.4	3.92e-7	Cancer;
UCEC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg18490616	chr2:88469792	THNSL2	0.89	5.78	0.43	4.3e-8	Plasma clusterin levels;
UCEC	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg18232548	chr7:50535776	DDC	-0.65	-7.09	-0.5	5.28e-11	Body mass index;
UCEC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs6545977	1.000	rs6545977	chr2:63301164	G/A	cg17519650	chr2:63277830	OTX1	-0.62	-6.76	-0.49	2.95e-10	Prostate cancer;
UCEC	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.75	6.74	0.49	3.29e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-4.76	-0.37	4.6e-6	Colorectal cancer;
UCEC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06462663	chr19:18546047	ISYNA1	0.5	6.32	0.46	3e-9	Breast cancer;
UCEC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg18225595	chr11:63971243	STIP1	0.45	4.54	0.35	1.15e-5	Platelet count;
UCEC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.46	-4.67	-0.36	6.84e-6	Breast cancer;
UCEC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs4662945	0.688	rs62174139	chr2:130202775	G/C	cg05962382	chr2:130345044	NA	-0.46	-5.27	-0.4	4.67e-7	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.36	-0.4	3.09e-7	Breast cancer;
UCEC	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.59	-5.34	-0.4	3.47e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7113850	0.541	rs7129631	chr11:24208560	A/G	ch.11.24196551F	chr11:24239977	NA	0.67	4.96	0.38	1.9e-6	Bone fracture in osteoporosis;
UCEC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.43	0.41	2.26e-7	Breast cancer;
UCEC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.53	7.6	0.53	3.18e-12	Height;
UCEC	cis	rs36051895	0.632	rs10115335	chr9:5140963	A/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.41	-0.41	2.53e-7	Pediatric autoimmune diseases;
UCEC	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	1.01	12.84	0.73	8.91e-26	Coronary artery disease;
UCEC	cis	rs253959	0.883	rs7708765	chr5:115714698	T/C	cg23108291	chr5:115420582	COMMD10	-0.48	-4.71	-0.36	5.73e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.64	6.2	0.46	5.39e-9	Menopause (age at onset);
UCEC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.73	-5.97	-0.44	1.73e-8	Initial pursuit acceleration;
UCEC	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.68	5.72	0.43	5.73e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.89	-10.97	-0.67	7.95e-21	Blood metabolite levels;
UCEC	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.53	5.31	0.4	3.98e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg02820040	chr2:241836501	C2orf54	-0.39	-4.86	-0.37	2.99e-6	Urinary metabolites;
UCEC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs405956	0.769	rs1190278	chr6:105598184	C/T	cg22580625	chr6:105627791	POPDC3	0.51	4.68	0.36	6.41e-6	QT interval;
UCEC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.83	-9.66	-0.62	2.14e-17	Neuroticism;
UCEC	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.64	5.86	0.44	2.92e-8	Schizophrenia;
UCEC	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	6.87	0.49	1.74e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.6	-6.58	-0.48	7.68e-10	Obesity-related traits;
UCEC	cis	rs508970	0.874	rs2154678	chr11:60902731	T/C	cg26254678	chr11:61511275	DAGLA	-0.36	-4.53	-0.35	1.23e-5	Rheumatoid arthritis;
UCEC	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.61	-6.11	-0.45	8.61e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg20203395	chr5:56204925	C5orf35	0.66	5.26	0.4	5.09e-7	Initial pursuit acceleration;
UCEC	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.51	5.77	0.43	4.43e-8	Height;
UCEC	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg00639195	chr15:79103007	ADAMTS7	-0.59	-5.08	-0.39	1.13e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08651674	chr6:7108441	RREB1	0.6	7.56	0.53	3.91e-12	Warfarin maintenance dose;
UCEC	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg23307798	chr14:103986281	CKB	-0.48	-4.99	-0.38	1.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg09491104	chr22:46646882	C22orf40	-0.65	-7.72	-0.54	1.69e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	7.85	0.54	8.1e-13	Bone mineral density;
UCEC	cis	rs1595825	0.891	rs16867018	chr2:198521490	C/T	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.54	5.88	0.44	2.71e-8	Total cholesterol levels;
UCEC	cis	rs4654899	0.931	rs3125161	chr1:21126346	A/G	cg01072550	chr1:21505969	NA	0.48	4.67	0.36	6.85e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.46	-5.4	-0.41	2.66e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs3736485	0.966	rs10467923	chr15:51767265	A/C	cg26694487	chr15:51058035	SPPL2A	0.43	4.56	0.35	1.07e-5	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs1697938	0.640	rs4957144	chr5:40914326	C/A	cg00786952	chr1:21763130	NA	0.59	6.7	0.48	4.14e-10	Multiple system atrophy;
UCEC	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.31	-10.38	-0.65	2.78e-19	Hip circumference adjusted for BMI;
UCEC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.46	-0.47	1.47e-9	Pubertal anthropometrics;
UCEC	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.56	-5.19	-0.39	6.99e-7	Pulmonary function decline;
UCEC	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	6.37	0.47	2.28e-9	Hip circumference;
UCEC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	4.92	0.38	2.32e-6	Breast cancer;
UCEC	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.63	-7.8	-0.54	1.03e-12	Endometriosis;
UCEC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.51	-0.57	1.87e-14	Total body bone mineral density;
UCEC	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.48	5.91	0.44	2.32e-8	Age-related hearing impairment;
UCEC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18252515	chr7:66147081	NA	0.45	4.61	0.36	8.64e-6	Aortic root size;
UCEC	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.61	-6.03	-0.45	1.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11761441	0.640	rs9642261	chr7:87973	C/G	cg06458707	chr7:1083209	C7orf50	-0.26	-4.7	-0.36	5.84e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.68	-5.24	-0.4	5.59e-7	Schizophrenia;
UCEC	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg15167202	chr5:149997153	SYNPO	-0.37	-4.6	-0.35	9.05e-6	HIV-1 control;
UCEC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs782107	0.761	rs782104	chr12:58835880	T/C	cg19181132	chr12:59314527	LRIG3	0.47	4.98	0.38	1.8e-6	Interleukin-12p70 levels;
UCEC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg02820040	chr2:241836501	C2orf54	-0.39	-4.87	-0.37	2.87e-6	Urinary metabolites;
UCEC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg09165964	chr15:75287851	SCAMP5	-0.52	-5.28	-0.4	4.62e-7	Lung cancer;
UCEC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.71	-7.06	-0.5	6.1e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.45	-0.47	1.49e-9	Aortic root size;
UCEC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg01689657	chr7:91764605	CYP51A1	-0.45	-6.08	-0.45	1.01e-8	Breast cancer;
UCEC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs17673138	0.584	rs77325783	chr8:32694621	A/G	cg26289712	chr8:33578994	NA	0.48	4.77	0.37	4.33e-6	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);
UCEC	cis	rs2136093	0.620	rs12568716	chr1:90921851	C/T	cg01786362	chr1:90274359	NA	-0.34	-4.58	-0.35	9.72e-6	Response to antidepressants;
UCEC	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.02e-5	Type 2 diabetes;
UCEC	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.75	7.93	0.55	5.11e-13	Primary sclerosing cholangitis;
UCEC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.9	0.37	2.45e-6	Aortic root size;
UCEC	cis	rs10432489	0.708	rs75187125	chr2:181752561	C/T	cg21995919	chr2:182322279	ITGA4	-0.91	-4.73	-0.36	5.28e-6	QT interval;
UCEC	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.69	6.68	0.48	4.64e-10	Schizophrenia;
UCEC	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.551	rs57775631	chr19:22814461	T/C	cg08271804	chr19:22816896	ZNF492	0.64	6.53	0.47	1.01e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.53	5.7	0.43	6.36e-8	Height;
UCEC	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.65	5.41	0.41	2.51e-7	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	4.9	0.37	2.54e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	8.02	0.55	3.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg18584368	chr5:314553	AHRR;PDCD6	0.58	5.11	0.39	9.91e-7	Asthma (childhood onset);
UCEC	cis	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-5.01	-0.38	1.51e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.59	5.43	0.41	2.32e-7	Tonsillectomy;
UCEC	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.71	5.0	0.38	1.62e-6	Lymphocyte counts;
UCEC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.44	5.22	0.4	6.1e-7	Colorectal cancer;
UCEC	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.8	-7.79	-0.54	1.12e-12	Migraine;Coronary artery disease;
UCEC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg10965384	chr11:64119977	CCDC88B	0.37	4.57	0.35	1.02e-5	Platelet count;
UCEC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.61	6.17	0.45	6.34e-9	Blood metabolite levels;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.74	-0.43	5.24e-8	Cardiac Troponin-T levels;
UCEC	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.57	-5.18	-0.39	7.13e-7	Hypospadias;
UCEC	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.79	8.14	0.56	1.56e-13	Parkinson's disease;
UCEC	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1079204	1.000	rs2292549	chr2:219128506	C/T	cg05728596	chr2:219128475	GPBAR1	-0.94	-10.81	-0.67	2.07e-20	Smooth-surface caries;
UCEC	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.58	5.39	0.41	2.7e-7	Lung cancer;
UCEC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.72	-8.2	-0.56	1.11e-13	Monocyte count;
UCEC	cis	rs250585	0.736	rs499812	chr16:23410419	T/C	cg26562691	chr16:23850404	PRKCB	0.34	4.59	0.35	9.26e-6	Egg allergy;
UCEC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.66	-6.5	-0.47	1.17e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.77	-8.04	-0.55	2.79e-13	Ulcerative colitis;
UCEC	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-14.02	-0.76	6.79e-29	Schizophrenia;
UCEC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.55	-6.22	-0.46	4.99e-9	Lung cancer;
UCEC	cis	rs13253111	0.624	rs4732844	chr8:28104473	A/G	cg26534493	chr8:28060551	NA	-0.47	-4.61	-0.36	8.59e-6	Childhood body mass index;
UCEC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.99	9.43	0.61	8.36e-17	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	5.94	0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg02366345	chr4:152330872	FAM160A1	0.35	4.73	0.36	5.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg14664628	chr15:75095509	CSK	-0.51	-4.84	-0.37	3.23e-6	Caffeine consumption;
UCEC	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.62	5.12	0.39	9.61e-7	Systolic blood pressure;
UCEC	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.66	6.45	0.47	1.52e-9	Bladder cancer;
UCEC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	7.13	0.51	4.12e-11	Chronic sinus infection;
UCEC	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg20575277	chr15:90728569	SEMA4B	0.43	4.56	0.35	1.07e-5	Rheumatoid arthritis;
UCEC	cis	rs7246967	0.673	rs2082445	chr19:22834587	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg09491104	chr22:46646882	C22orf40	0.54	5.57	0.42	1.2e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg26114124	chr12:9217669	LOC144571	0.39	4.66	0.36	7.07e-6	Sjögren's syndrome;
UCEC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.78	10.95	0.67	8.88e-21	Vitiligo;
UCEC	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.1	0.51	5.03e-11	Coffee consumption (cups per day);
UCEC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg05132306	chr1:1846340	CALML6	-0.38	-4.8	-0.37	3.85e-6	Body mass index;
UCEC	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.37	-4.6	-0.35	9.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.73	-7.95	-0.55	4.52e-13	Ulcerative colitis;
UCEC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.54	5.03	0.38	1.42e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs8105895	1.000	rs2359811	chr19:22152876	A/G	cg24072202	chr19:22235272	ZNF257	-0.65	-4.73	-0.36	5.15e-6	Body mass index (change over time);
UCEC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.23	-0.4	5.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18932078	chr1:2524107	MMEL1	0.33	5.37	0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	0.81	8.94	0.59	1.48e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs36051895	0.632	rs12337904	chr9:5144606	C/G	cg02405213	chr9:5042618	JAK2	-0.5	-4.89	-0.37	2.63e-6	Pediatric autoimmune diseases;
UCEC	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.55	4.92	0.38	2.3e-6	Uric acid levels;
UCEC	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.1	-0.39	1.02e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg15147215	chr3:52552868	STAB1	-0.46	-5.05	-0.38	1.3e-6	Bipolar disorder;
UCEC	cis	rs7246967	0.866	rs6511385	chr19:23036936	T/G	cg24889512	chr19:22816950	ZNF492	0.5	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.53	5.12	0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.36	-0.4	3.08e-7	Cardiac Troponin-T levels;
UCEC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.55e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	7.63	0.53	2.65e-12	Tonsillectomy;
UCEC	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.53	-5.75	-0.43	4.9e-8	Coronary artery disease;
UCEC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.61	6.23	0.46	4.6e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs10208940	0.777	rs6726966	chr2:68855856	A/G	cg12452813	chr2:68675892	NA	0.47	4.54	0.35	1.16e-5	Urate levels in lean individuals;
UCEC	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg14008862	chr17:28927542	LRRC37B2	0.65	4.7	0.36	5.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-5.81	-0.43	3.77e-8	Primary biliary cholangitis;
UCEC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.46	6.01	0.44	1.39e-8	Bone mineral density;
UCEC	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.61	4.8	0.37	3.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.99	-10.76	-0.66	2.84e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.03	0.38	1.38e-6	HIV-1 control;
UCEC	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.52	5.28	0.4	4.64e-7	IgG glycosylation;
UCEC	cis	rs4871297	0.729	rs11774246	chr8:123696613	A/G	cg12254515	chr8:124054090	DERL1	0.48	4.53	0.35	1.21e-5	Type 1 diabetes nephropathy;
UCEC	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.87	-8.29	-0.56	6.45e-14	Corneal structure;
UCEC	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.43	-4.71	-0.36	5.75e-6	Height;
UCEC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.46	-4.78	-0.37	4.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.72	-8.14	-0.56	1.55e-13	Breast cancer;
UCEC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24308560	chr3:49941425	MST1R	-0.5	-5.43	-0.41	2.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.61	6.12	0.45	8.27e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.44	4.93	0.38	2.22e-6	Blood protein levels;
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.82	-9.62	-0.62	2.78e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.82	8.07	0.55	2.29e-13	Cognitive function;
UCEC	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.72	6.77	0.49	2.8e-10	High light scatter reticulocyte count;
UCEC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	7.3	0.52	1.69e-11	Platelet count;
UCEC	cis	rs2197308	0.549	rs10785517	chr12:38577992	G/T	cg14851346	chr12:38532713	NA	0.51	4.87	0.37	2.87e-6	Morning vs. evening chronotype;
UCEC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.84	5.09	0.39	1.1e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.53	-0.42	1.42e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.72e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg04287289	chr16:89883240	FANCA	-0.5	-5.27	-0.4	4.8e-7	Vitiligo;
UCEC	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.73	5.31	0.4	3.92e-7	Menarche (age at onset);
UCEC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.73	0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.68	-6.16	-0.45	6.69e-9	Metabolite levels;
UCEC	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs4372836	0.576	rs6547880	chr2:29018889	T/C	cg09522027	chr2:28974177	PPP1CB	-0.84	-9.25	-0.61	2.48e-16	Body mass index;
UCEC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.88	-0.37	2.74e-6	Alzheimer's disease (late onset);
UCEC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.51	-5.45	-0.41	2.06e-7	Pulse pressure;
UCEC	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-8.88	-0.59	2.2e-15	Coffee consumption (cups per day);
UCEC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.71	9.18	0.6	3.74e-16	Rheumatoid arthritis;
UCEC	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.62	5.88	0.44	2.65e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.54	4.79	0.37	4.07e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.46	-6.34	-0.46	2.72e-9	Mortality in heart failure;
UCEC	cis	rs79815064	0.920	rs80054040	chr3:46340285	C/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.79	4.6	0.35	9.06e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26207909	chr14:103986467	CKB	0.5	4.91	0.38	2.37e-6	Body mass index;
UCEC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.15	-0.68	2.56e-21	Headache;
UCEC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.21	0.51	2.79e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs59104589	0.617	rs16842449	chr2:242354979	C/T	cg19488206	chr2:242435732	STK25	0.53	4.7	0.36	5.95e-6	Fibrinogen levels;
UCEC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.47	5.26	0.4	5.05e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.4	4.51	0.35	1.3e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.56	6.15	0.45	6.91e-9	Bipolar disorder;
UCEC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.89	-9.69	-0.62	1.76e-17	Cognitive function;
UCEC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg00343986	chr7:65444356	GUSB	-0.49	-4.54	-0.35	1.18e-5	Aortic root size;
UCEC	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.65	5.65	0.42	8.01e-8	Platelet distribution width;
UCEC	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.58	-0.42	1.11e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6723108	0.627	rs766271	chr2:135667131	C/T	cg07169764	chr2:136633963	MCM6	0.48	4.62	0.36	8.46e-6	Type 2 diabetes;
UCEC	cis	rs7646881	0.508	rs6779054	chr3:158305447	G/A	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.43e-6	Tetralogy of Fallot;
UCEC	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg00325661	chr8:49890786	NA	0.53	5.57	0.42	1.19e-7	Sudden cardiac arrest;
UCEC	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.26	0.4	4.92e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.83	9.0	0.6	1.08e-15	Blood protein levels;
UCEC	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.57	6.26	0.46	4.09e-9	Neutrophil percentage of white cells;
UCEC	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.5	-5.58	-0.42	1.13e-7	Superior crus of antihelix expression;
UCEC	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.81	-10.4	-0.65	2.42e-19	White blood cell count (basophil);
UCEC	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.85	-0.37	3.12e-6	Blood metabolite levels;
UCEC	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-4.72	-0.36	5.42e-6	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg01072550	chr1:21505969	NA	-0.48	-4.68	-0.36	6.56e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.69	5.68	0.42	7.05e-8	Psoriasis vulgaris;
UCEC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.57	5.58	0.42	1.12e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs944990	0.668	rs10821168	chr9:96358301	C/T	cg13787134	chr9:96362102	PHF2	-0.4	-5.3	-0.4	4.19e-7	Body mass index;
UCEC	cis	rs7106204	1.000	rs4622259	chr11:24215789	A/G	ch.11.24196551F	chr11:24239977	NA	0.68	6.16	0.45	6.57e-9	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2280630	0.898	rs1828679	chr3:39195507	C/T	cg01426195	chr3:39028469	NA	-0.52	-5.34	-0.4	3.5e-7	Verbal declarative memory;
UCEC	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.45	5.54	0.42	1.38e-7	Height;
UCEC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg10596483	chr8:143751796	JRK	0.5	5.36	0.4	3.13e-7	Schizophrenia;
UCEC	cis	rs4234798	1.000	rs4234797	chr4:7219907	C/T	cg18431297	chr4:7219810	SORCS2	0.38	4.56	0.35	1.08e-5	Insulin-like growth factors;
UCEC	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-7.29	-0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.09e-6	Height;
UCEC	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.84	0.43	3.28e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.88	8.51	0.57	1.81e-14	Platelet count;
UCEC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.55	5.79	0.43	4.17e-8	Blood metabolite levels;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.64	-6.79	-0.49	2.63e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1823913	0.526	rs35340557	chr2:192203414	G/C	cg15998761	chr2:191300784	MFSD6	0.4	4.72	0.36	5.35e-6	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.41	-4.6	-0.35	9.22e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.49	0.41	1.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	0.9	13.09	0.73	1.87e-26	Multiple system atrophy;
UCEC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.66	0.58	7.7e-15	Prudent dietary pattern;
UCEC	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.7	7.41	0.52	9.36e-12	Lymphocyte counts;
UCEC	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	11.6	0.69	1.74e-22	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg06784218	chr1:46089804	CCDC17	-0.47	-5.79	-0.43	4.1e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14019695	chr9:139328340	INPP5E	0.49	5.81	0.43	3.76e-8	Monocyte percentage of white cells;
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.32	-0.46	2.9e-9	Prudent dietary pattern;
UCEC	cis	rs4499344	0.730	rs421607	chr19:33104951	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.96	0.44	1.77e-8	Mean platelet volume;
UCEC	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.48	4.91	0.38	2.39e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-7.33	-0.52	1.41e-11	Resting heart rate;
UCEC	cis	rs2299682	0.826	rs6086921	chr20:9480120	A/T	cg11931762	chr20:9488920	NA	-0.54	-4.65	-0.36	7.21e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs2062225	0.735	rs2341657	chr2:111773960	C/T	cg23782758	chr2:111737646	ACOXL	-0.48	-4.56	-0.35	1.06e-5	Monocyte count;
UCEC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg17420585	chr12:42539391	GXYLT1	-0.45	-5.6	-0.42	1.01e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.44	-4.98	-0.38	1.76e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.59	-5.74	-0.43	5.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8177876	0.731	rs7188508	chr16:81113702	T/C	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.36	-0.46	2.47e-9	Parkinson's disease;
UCEC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.63	-6.84	-0.49	2e-10	Menarche (age at onset);
UCEC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.55	5.61	0.42	9.78e-8	Dupuytren's disease;
UCEC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.6	5.53	0.42	1.4e-7	Gestational age at birth (maternal effect);
UCEC	trans	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg01134012	chr8:144635316	GSDMD	0.61	7.07	0.5	5.7e-11	Response to antipsychotic treatment;
UCEC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.44	0.65	1.97e-19	Chronic sinus infection;
UCEC	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.41	4.75	0.36	4.86e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.37	-5.46	-0.41	1.96e-7	Ulcerative colitis;
UCEC	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.59	-5.88	-0.44	2.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.5	6.56	0.48	8.54e-10	IgG glycosylation;
UCEC	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.78	8.73	0.58	5.04e-15	Dental caries;
UCEC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18932078	chr1:2524107	MMEL1	-0.33	-5.39	-0.41	2.72e-7	Ulcerative colitis;
UCEC	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.31	0.52	1.54e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2236176	0.812	rs6047244	chr20:21077903	A/G	cg09698166	chr20:21106763	PLK1S1	-0.47	-4.55	-0.35	1.13e-5	Body mass index;
UCEC	cis	rs4356932	0.871	rs4859606	chr4:76965879	C/T	cg22252999	chr4:76996414	ART3	0.44	4.54	0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs2209875	0.640	rs7864748	chr9:91713387	T/C	cg00102996	chr9:92220617	GADD45G	-0.51	-4.59	-0.35	9.29e-6	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs11673344	0.704	rs510757	chr19:37422802	C/T	cg08692348	chr19:37642883	ZNF585A	-0.42	-4.77	-0.37	4.39e-6	Obesity-related traits;
UCEC	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	6.81	0.49	2.27e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.89	-12.63	-0.72	3.12e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.52	-4.75	-0.36	4.77e-6	Longevity;
UCEC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26207909	chr14:103986467	CKB	0.53	5.81	0.43	3.78e-8	Body mass index;
UCEC	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.54	5.62	0.42	9.3e-8	Retinal vascular caliber;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.27	-0.4	4.81e-7	Myopia;
UCEC	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-0.41	-4.53	-0.35	1.23e-5	IgG glycosylation;
UCEC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.28e-10	Homoarginine levels;
UCEC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-7.56	-0.53	4.11e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.54	5.81	0.43	3.8e-8	Red blood cell count;
UCEC	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.16e-9	Prudent dietary pattern;
UCEC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.39	-0.41	2.78e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.8	4.68	0.36	6.35e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg03609598	chr5:56110824	MAP3K1	-0.57	-4.71	-0.36	5.69e-6	Type 2 diabetes;
UCEC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.49	-5.18	-0.39	7.08e-7	Cognitive function;
UCEC	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.74	-5.7	-0.43	6.33e-8	Alzheimer's disease (late onset);
UCEC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03352830	chr11:487213	PTDSS2	0.84	6.6	0.48	6.95e-10	Body mass index;
UCEC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-7.34	-0.52	1.31e-11	Menarche (age at onset);
UCEC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	6.36	0.46	2.42e-9	Platelet count;
UCEC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.66	7.36	0.52	1.23e-11	Lymphocyte counts;
UCEC	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.57	-5.68	-0.42	7.04e-8	Pulse pressure;
UCEC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.49	-4.71	-0.36	5.73e-6	Gut microbiome composition (summer);
UCEC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg21197973	chr3:49027347	P4HTM	0.97	4.94	0.38	2.12e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg05132306	chr1:1846340	CALML6	-0.37	-4.72	-0.36	5.51e-6	Body mass index;
UCEC	cis	rs2425143	0.730	rs6060626	chr20:34415073	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-4.67	-0.36	6.78e-6	Blood protein levels;
UCEC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.63	-0.36	7.83e-6	Hemoglobin concentration;
UCEC	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	-0.51	-5.73	-0.43	5.43e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.14	-0.45	7.32e-9	Mood instability;
UCEC	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.72	-6.06	-0.45	1.1e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.12	14.65	0.77	1.6e-30	Schizophrenia;
UCEC	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.58	-0.35	1e-5	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.31	0.46	3.08e-9	Cognitive ability;
UCEC	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg11871910	chr12:69753446	YEATS4	-1.06	-13.17	-0.74	1.18e-26	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg21253087	chr9:139290292	SNAPC4	0.43	4.75	0.36	4.89e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7766436	0.885	rs4712698	chr6:22592807	C/T	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	5.3	0.4	4.09e-7	Bipolar disorder;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.72	9.21	0.6	3.08e-16	Menarche (age at onset);
UCEC	cis	rs4615376	0.950	rs13192747	chr6:13045138	G/T	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg00791764	chr4:53727839	RASL11B	0.67	4.93	0.38	2.16e-6	Optic nerve measurement (cup area);
UCEC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.59	-6.03	-0.45	1.24e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7095607	0.967	rs7095603	chr10:69957340	G/A	cg18986048	chr10:69913749	MYPN	0.46	5.03	0.38	1.42e-6	Lung function (FVC);
UCEC	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.37	0.47	2.24e-9	Tonsillectomy;
UCEC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	1.01e-15	Menopause (age at onset);
UCEC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.46	5.14	0.39	8.69e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.84	9.38	0.61	1.14e-16	Dental caries;
UCEC	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.8e-6	Body mass index;
UCEC	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.91	9.71	0.63	1.61e-17	Cognitive function;
UCEC	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.67	7.68	0.54	2.03e-12	Body mass index (adult);
UCEC	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg24733560	chr20:60626293	TAF4	0.41	4.63	0.36	7.83e-6	Body mass index;
UCEC	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.24	-0.46	4.51e-9	Menarche (age at onset);
UCEC	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11890956	chr21:40555474	PSMG1	0.83	6.94	0.5	1.15e-10	Cognitive function;
UCEC	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-6.66	-0.48	4.99e-10	Asthma;
UCEC	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.0	11.3	0.68	1.05e-21	Exhaled nitric oxide output;
UCEC	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs76866386	1.000	rs11887534	chr2:44066247	G/C	cg10069809	chr2:45028604	NA	0.8	4.58	0.35	9.96e-6	Cholesterol, total;
UCEC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-4.94	-0.38	2.08e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.73	-6.61	-0.48	6.52e-10	Adiposity;
UCEC	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.59	-4.93	-0.38	2.16e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg21770322	chr7:97807741	LMTK2	0.84	14.37	0.76	8.24e-30	Breast cancer;
UCEC	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	7.89	0.55	6.42e-13	Hip circumference;
UCEC	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg17259809	chr10:104614391	C10orf32	-0.72	-4.67	-0.36	6.69e-6	Arsenic metabolism;
UCEC	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.51	-4.83	-0.37	3.44e-6	Longevity;
UCEC	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Corneal astigmatism;
UCEC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.5	5.03	0.38	1.42e-6	Prostate cancer;
UCEC	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	0.97	9.68	0.62	1.85e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.55	-5.7	-0.43	6.29e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.73	7.86	0.54	7.56e-13	Multiple system atrophy;
UCEC	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.67	7.95	0.55	4.62e-13	Hip circumference;
UCEC	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.53	6.76	0.49	2.96e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.19	8.04	0.55	2.74e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.43	6.3	0.46	3.18e-9	Crohn's disease;
UCEC	cis	rs17106184	1.000	rs72902767	chr1:51260999	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg13695892	chr22:41940480	POLR3H	-0.66	-4.62	-0.36	8.3e-6	Vitiligo;
UCEC	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg16303742	chr3:15540471	COLQ	-0.47	-5.62	-0.42	9.16e-8	Mean platelet volume;
UCEC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.9	12.22	0.71	3.91e-24	Metabolic syndrome;
UCEC	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg14092571	chr14:90743983	NA	0.48	5.63	0.42	8.7e-8	Mortality in heart failure;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg20007245	chr22:24372913	LOC391322	-0.68	-7.13	-0.51	4.2e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg13092806	chr2:177043255	NA	0.56	5.2	0.39	6.69e-7	IgG glycosylation;
UCEC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18252515	chr7:66147081	NA	0.51	5.34	0.4	3.51e-7	Aortic root size;
UCEC	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg19554555	chr3:13937349	NA	-0.54	-5.58	-0.42	1.11e-7	Ovarian reserve;
UCEC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg20387954	chr3:183756860	HTR3D	0.41	4.99	0.38	1.68e-6	Anterior chamber depth;
UCEC	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	0.91	5.91	0.44	2.34e-8	Left atrial antero-posterior diameter;
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.52	0.62	5.03e-17	Platelet count;
UCEC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg24562669	chr7:97807699	LMTK2	0.47	5.74	0.43	5.14e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.7	-6.5	-0.47	1.18e-9	Aortic root size;
UCEC	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg17279458	chr3:44753948	ZNF502	-0.46	-4.88	-0.37	2.71e-6	Depressive symptoms;
UCEC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.49	-5.47	-0.41	1.9e-7	Fibrinogen levels;
UCEC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.89	9.74	0.63	1.31e-17	Cognitive function;
UCEC	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	9.15	0.6	4.51e-16	Post bronchodilator FEV1;
UCEC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.52	4.86	0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	6.83	0.49	2.1e-10	Menarche (age at onset);
UCEC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg18681998	chr4:17616180	MED28	0.74	7.38	0.52	1.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg18681998	chr4:17616180	MED28	0.67	6.42	0.47	1.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg25037677	chr1:2437047	NA	0.38	4.71	0.36	5.57e-6	Height;
UCEC	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-0.9	-8.07	-0.55	2.33e-13	Mitochondrial DNA levels;
UCEC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg20203395	chr5:56204925	C5orf35	-0.55	-4.93	-0.38	2.19e-6	Coronary artery disease;
UCEC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	0.81	6.9	0.49	1.47e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.24	-14.45	-0.77	5.17e-30	Type 1 diabetes nephropathy;
UCEC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.89	-9.9	-0.63	5.16e-18	Cognitive function;
UCEC	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.68	7.58	0.53	3.66e-12	Ewing sarcoma;
UCEC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs57709857	0.801	rs56365338	chr8:38100688	G/A	cg08167846	chr8:38212404	WHSC1L1	0.47	4.61	0.36	8.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.42	-0.41	2.43e-7	Pulmonary function;
UCEC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.59	6.43	0.47	1.64e-9	Cognitive function;
UCEC	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.67	-4.97	-0.38	1.83e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.55	6.49	0.47	1.25e-9	Menarche (age at onset);
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.79	0.49	2.52e-10	Platelet count;
UCEC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg23093090	chr10:104574429	C10orf26	0.46	5.14	0.39	8.43e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.63	-4.96	-0.38	1.91e-6	Carotid intima media thickness;
UCEC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-1.13	-8.87	-0.59	2.28e-15	Bone mineral density;
UCEC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-6.63	-0.48	5.94e-10	Platelet count;
UCEC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.69	5.74	0.43	5.27e-8	Neurofibrillary tangles;
UCEC	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	0.7	5.47	0.41	1.89e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.65	9.02	0.6	9.68e-16	Systolic blood pressure;
UCEC	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-4.8	-0.37	3.82e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs78487399	0.908	rs17031106	chr2:43829056	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-6.22	-0.46	4.78e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.43	-5.41	-0.41	2.52e-7	Prostate cancer;
UCEC	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.23	0.4	5.83e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.11	-0.45	8.61e-9	Parkinson's disease;
UCEC	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.57	-4.55	-0.35	1.11e-5	Body mass index;
UCEC	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.56	-0.42	1.23e-7	Life satisfaction;
UCEC	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.8	-5.64	-0.42	8.65e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22117172	chr7:91764530	CYP51A1	0.41	5.2	0.39	6.49e-7	Breast cancer;
UCEC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.09	0.45	9.46e-9	Aortic root size;
UCEC	cis	rs17123764	0.892	rs12321169	chr12:50115917	G/C	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.73	-6.75	-0.49	3.13e-10	Diastolic blood pressure;
UCEC	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg07537917	chr2:241836409	C2orf54	-0.33	-5.12	-0.39	9.62e-7	Urinary metabolites;
UCEC	cis	rs2708977	0.637	rs585781	chr2:97088623	C/A	cg22654517	chr2:96458247	NA	0.44	5.6	0.42	1.04e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.55	-5.62	-0.42	9.47e-8	Aortic root size;
UCEC	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.77	-9.36	-0.61	1.25e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg03859395	chr2:55845619	SMEK2	1.04	15.11	0.78	1.01e-31	Metabolic syndrome;
UCEC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.49	-5.0	-0.38	1.64e-6	Bipolar disorder;
UCEC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.17	-9.14	-0.6	4.75e-16	Vitiligo;
UCEC	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.38	4.85	0.37	3.09e-6	Thyroid hormone levels;
UCEC	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg11569703	chr11:65557185	OVOL1	-0.42	-6.08	-0.45	9.66e-9	Acne (severe);
UCEC	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	15.34	0.78	2.57e-32	Colorectal cancer;
UCEC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.66	-5.85	-0.43	3.11e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2200578	1.000	rs12053519	chr2:99875018	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.81	6.01	0.44	1.43e-8	IgG glycosylation;
UCEC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.51	5.59	0.42	1.08e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.53	5.7	0.43	6.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.75	-8.63	-0.58	9.43e-15	Obesity-related traits;
UCEC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.24	0.46	4.47e-9	Coffee consumption (cups per day);
UCEC	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.56	-5.33	-0.4	3.56e-7	White matter hyperintensity burden;
UCEC	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.33	-0.57	5.1e-14	Prevalent atrial fibrillation;
UCEC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg22166914	chr1:53195759	ZYG11B	0.46	4.5	0.35	1.35e-5	Monocyte count;
UCEC	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.62	-5.21	-0.39	6.35e-7	Coronary artery calcification;
UCEC	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.18e-21	Body mass index;
UCEC	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.39	-4.51	-0.35	1.29e-5	Inflammatory bowel disease;
UCEC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.45	-0.52	7.34e-12	Body mass index;
UCEC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.42	5.2	0.39	6.69e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.74	7.57	0.53	3.83e-12	Breast cancer;
UCEC	cis	rs7350721	0.712	rs8011441	chr14:56300374	C/T	cg23678254	chr14:55647471	DLGAP5	0.36	5.06	0.39	1.25e-6	Body mass index (ever vs never smoking interaction);Body mass index  (smoking years interaction);
UCEC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.94	9.24	0.61	2.64e-16	Initial pursuit acceleration;
UCEC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.13	-0.39	8.86e-7	Aortic root size;
UCEC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.95	9.33	0.61	1.56e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.74	-9.56	-0.62	3.98e-17	Vitiligo;
UCEC	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.42	4.82	0.37	3.49e-6	Lung cancer;
UCEC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.08	11.42	0.69	5.14e-22	Cognitive function;
UCEC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.91	6.99	0.5	8.79e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.9	-10.87	-0.67	1.41e-20	Blood metabolite levels;
UCEC	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.39	4.73	0.36	5.32e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.88	0.37	2.73e-6	Rheumatoid arthritis;
UCEC	cis	rs2041840	0.538	rs6708524	chr2:37572687	C/T	cg25727520	chr2:37576821	QPCT	-0.46	-5.23	-0.4	5.76e-7	Chronic lymphocytic leukemia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08273200	chr1:39338480	MYCBP	0.62	7.56	0.53	3.97e-12	Warfarin maintenance dose;
UCEC	cis	rs12121840	0.703	rs12137629	chr1:165518042	C/T	cg07017636	chr1:165567312	NA	-0.64	-5.1	-0.39	1.04e-6	Interleukin-1-receptor antagonist levels;
UCEC	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.01e-5	Type 2 diabetes;
UCEC	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.44	-4.61	-0.36	8.68e-6	Height;
UCEC	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg24069376	chr3:38537580	EXOG	-0.44	-5.4	-0.41	2.66e-7	Electrocardiographic conduction measures;
UCEC	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.9	5.8	0.43	3.83e-8	Cognitive function;
UCEC	cis	rs17122693	0.748	rs72681636	chr14:51145871	G/T	cg04730355	chr14:51134070	SAV1	0.95	9.85	0.63	6.97e-18	Cognitive performance;
UCEC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.55	4.78	0.37	4.17e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.99	7.33	0.52	1.43e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.81	7.46	0.52	6.88e-12	Resting heart rate;
UCEC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.3	0.4	4.21e-7	Rheumatoid arthritis;
UCEC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.67	-7.81	-0.54	1.01e-12	Menarche (age at onset);
UCEC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.46	-4.59	-0.35	9.28e-6	Monocyte count;
UCEC	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.59	4.81	0.37	3.65e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs8177876	0.822	rs28672349	chr16:81114373	T/C	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7246967	0.736	rs423687	chr19:23000745	C/T	cg24889512	chr19:22816950	ZNF492	0.57	5.61	0.42	9.94e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg08250081	chr4:10125330	NA	0.46	4.51	0.35	1.31e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs16937	0.711	rs4951172	chr1:205137578	A/G	cg12580275	chr1:205744413	RAB7L1	-0.47	-5.13	-0.39	8.94e-7	Schizophrenia;
UCEC	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	5.75	0.43	5.02e-8	Tonsillectomy;
UCEC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.5	-0.47	1.17e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-1.11	-5.49	-0.41	1.68e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg03354898	chr7:1950403	MAD1L1	-0.46	-4.53	-0.35	1.22e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs2190422	0.551	rs10282605	chr7:103162370	C/T	cg18108683	chr7:102477205	FBXL13	0.58	6.01	0.44	1.43e-8	Morning vs. evening chronotype;
UCEC	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.49	4.83	0.37	3.36e-6	Blood metabolite levels;
UCEC	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg13683864	chr3:40499215	RPL14	-0.58	-6.33	-0.46	2.74e-9	Renal cell carcinoma;
UCEC	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.76	7.55	0.53	4.2e-12	Mosquito bite size;
UCEC	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.71	-6.73	-0.49	3.53e-10	Cognitive ability;
UCEC	cis	rs1318772	1.000	rs164252	chr5:112791801	T/A	cg12552261	chr5:112820674	MCC	-0.86	-6.06	-0.45	1.06e-8	F-cell distribution;
UCEC	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.5	4.61	0.36	8.62e-6	Night sleep phenotypes;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	5.38	0.41	2.86e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg00614314	chr15:82944287	LOC80154	0.53	4.85	0.37	3.05e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.58	-4.89	-0.37	2.62e-6	Corneal structure;
UCEC	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.64	-5.85	-0.43	3.03e-8	Bitter taste perception;
UCEC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06505273	chr16:24850292	NA	0.54	4.9	0.37	2.5e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.54	-5.12	-0.39	9.59e-7	Obesity-related traits;
UCEC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg24562669	chr7:97807699	LMTK2	0.74	11.0	0.67	6.5e-21	Breast cancer;
UCEC	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg08501292	chr6:25962987	TRIM38	-0.99	-4.93	-0.38	2.17e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24249390	chr15:90295951	MESP1	-0.43	-4.97	-0.38	1.87e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.67	6.25	0.46	4.15e-9	Aortic root size;
UCEC	cis	rs731174	0.592	rs11264093	chr1:38194156	G/A	cg24088508	chr1:38156462	C1orf109	-0.58	-4.59	-0.35	9.32e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.67	-6.87	-0.49	1.72e-10	Neurofibrillary tangles;
UCEC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.7	-5.84	-0.43	3.23e-8	Initial pursuit acceleration;
UCEC	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-1.0	-7.32	-0.52	1.51e-11	Blood pressure (smoking interaction);
UCEC	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.74	-8.07	-0.55	2.35e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.59	5.78	0.43	4.32e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.55	5.87	0.44	2.85e-8	Neuroticism;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.45	0.41	2.09e-7	Prudent dietary pattern;
UCEC	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.02	10.66	0.66	5.25e-20	Heart rate;
UCEC	cis	rs17106184	0.786	rs72900944	chr1:51126914	C/T	cg07174182	chr1:51127561	FAF1	-0.77	-4.9	-0.37	2.46e-6	Type 2 diabetes;
UCEC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.77	-8.77	-0.59	4.04e-15	Menarche (age at onset);
UCEC	trans	rs1459104	1.000	rs2903534	chr11:55054044	A/G	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.16e-10	Body mass index;
UCEC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13683864	chr3:40499215	RPL14	-1.01	-10.69	-0.66	4.38e-20	Renal cell carcinoma;
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.57	-6.31	-0.46	3.13e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.6	-6.51	-0.47	1.12e-9	Asthma;
UCEC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.79	6.04	0.45	1.19e-8	Body mass index;
UCEC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.6	5.06	0.39	1.23e-6	Eosinophilic esophagitis;
UCEC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.66	8.82	0.59	2.97e-15	Anterior chamber depth;
UCEC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-7.04	-0.5	6.88e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-6.66	-0.48	5.15e-10	Crohn's disease;
UCEC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg13147721	chr7:65941812	NA	-0.94	-6.91	-0.49	1.4e-10	Diabetic kidney disease;
UCEC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	5.93	0.44	2.12e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.81	9.68	0.62	1.89e-17	Blood protein levels;
UCEC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.78	-8.59	-0.58	1.17e-14	Vitiligo;
UCEC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg00316803	chr15:76480434	C15orf27	-0.44	-5.08	-0.39	1.14e-6	Blood metabolite levels;
UCEC	cis	rs4448343	0.736	rs2297088	chr9:98242984	G/A	cg13456470	chr9:98266766	PTCH1	0.38	4.96	0.38	1.88e-6	Height;
UCEC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	0.64	6.74	0.49	3.44e-10	Homoarginine levels;
UCEC	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-0.54	-5.78	-0.43	4.29e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-7.58	-0.53	3.49e-12	Menarche (age at onset);
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.28	-0.46	3.69e-9	Pulmonary function;
UCEC	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg00852783	chr1:26633632	UBXN11	0.51	4.85	0.37	3.06e-6	Obesity-related traits;
UCEC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg18681998	chr4:17616180	MED28	0.69	8.1	0.56	1.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.5	-4.92	-0.38	2.31e-6	Height;
UCEC	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.5	-5.1	-0.39	1.03e-6	Systemic lupus erythematosus;
UCEC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg24846343	chr22:24311635	DDTL	0.66	6.38	0.47	2.13e-9	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs6952808	0.500	rs3823631	chr7:2190100	A/G	cg08027265	chr7:2291960	NA	-0.45	-4.8	-0.37	3.82e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.21e-6	Breast cancer;
UCEC	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-8.8	-0.59	3.43e-15	Exhaled nitric oxide output;
UCEC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-4.78	-0.37	4.28e-6	Bipolar disorder;
UCEC	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.98	0.38	1.74e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.57e-6	Colorectal cancer;
UCEC	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.56	5.22	0.4	6e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.65	-6.49	-0.47	1.22e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.87	7.76	0.54	1.35e-12	Body mass index;
UCEC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg01485075	chr19:22817371	ZNF492	0.41	4.51	0.35	1.3e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs4523957	0.928	rs8074850	chr17:2187931	C/A	cg16513277	chr17:2031491	SMG6	-0.43	-4.84	-0.37	3.22e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.62	5.33	0.4	3.68e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg03999872	chr20:62272968	STMN3	-0.48	-4.6	-0.36	8.88e-6	Atopic dermatitis;
UCEC	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.17	-0.39	7.65e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.72	-8.36	-0.57	4.31e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	4.56	0.35	1.07e-5	Fibroblast growth factor basic levels;
UCEC	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg04154034	chr17:28927549	LRRC37B2	0.83	5.26	0.4	5.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.71	6.69	0.48	4.35e-10	High light scatter reticulocyte count;
UCEC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.57	5.84	0.43	3.22e-8	Longevity;Endometriosis;
UCEC	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	4.66	0.36	6.95e-6	Hemoglobin concentration;
UCEC	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.75	7.16	0.51	3.53e-11	Schizophrenia;
UCEC	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.67	9.11	0.6	5.69e-16	Systolic blood pressure;
UCEC	cis	rs1978968	0.788	rs12169946	chr22:18468105	A/G	cg03078520	chr22:18463400	MICAL3	-0.41	-4.55	-0.35	1.11e-5	Presence of antiphospholipid antibodies;
UCEC	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.87	-10.47	-0.65	1.6e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	0.74	5.73	0.43	5.45e-8	Post bronchodilator FEV1;
UCEC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	7.64	0.53	2.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.47	5.47	0.41	1.86e-7	Aortic root size;
UCEC	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.73	5.54	0.42	1.34e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.41	-5.37	-0.4	3.08e-7	Systolic blood pressure;
UCEC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.48	-4.78	-0.37	4.19e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-5.5	-0.41	1.66e-7	Monocyte percentage of white cells;
UCEC	cis	rs12118280	0.959	rs61799377	chr1:108741774	T/A	cg11967332	chr1:108735228	SLC25A24	1.0	9.36	0.61	1.26e-16	Myeloid white cell count;
UCEC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg14008862	chr17:28927542	LRRC37B2	0.88	4.71	0.36	5.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.61	6.57	0.48	8.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.75	-7.27	-0.51	1.99e-11	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.54	4.75	0.37	4.72e-6	Corneal astigmatism;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg11003573	chr3:44754125	ZNF502	0.45	4.6	0.35	9.1e-6	Depressive symptoms;
UCEC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4372836	0.964	rs11683296	chr2:28925404	A/G	cg09522027	chr2:28974177	PPP1CB	0.72	7.23	0.51	2.41e-11	Body mass index;
UCEC	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.49	-6.51	-0.47	1.13e-9	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	22.91	0.88	2.27e-50	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.36	-0.4	3.09e-7	Breast cancer;
UCEC	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg13753209	chr17:57696993	CLTC	0.48	4.7	0.36	5.87e-6	Hemoglobin concentration;
UCEC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.56	0.35	1.08e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.14	-0.76	3.42e-29	Schizophrenia;
UCEC	cis	rs4148689	0.904	rs2402205	chr7:117146448	T/C	cg21212505	chr7:117228958	CFTR	-0.41	-4.62	-0.36	8.24e-6	Gout;
UCEC	cis	rs6925255	0.647	rs2322450	chr6:80467462	G/A	cg09116618	chr6:81233028	NA	0.32	4.55	0.35	1.11e-5	Aging;
UCEC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.58	-5.94	-0.44	2.01e-8	Menarche (age at onset);
UCEC	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.51	4.79	0.37	4.04e-6	Platelet count;
UCEC	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.77	6.51	0.47	1.11e-9	Menopause (age at onset);
UCEC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg00343986	chr7:65444356	GUSB	-0.46	-4.54	-0.35	1.16e-5	Aortic root size;
UCEC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-6.03	-0.45	1.27e-8	Menarche (age at onset);
UCEC	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.53	5.63	0.42	9.04e-8	Motion sickness;
UCEC	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06558623	chr16:89946397	TCF25	0.93	5.67	0.42	7.42e-8	Skin colour saturation;
UCEC	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.39	0.47	2.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg01112020	chr2:239008986	ESPNL	-0.35	-4.73	-0.36	5.17e-6	Prostate cancer;
UCEC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.63	5.14	0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.53	-5.28	-0.4	4.47e-7	IgG glycosylation;
UCEC	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.42	0.41	2.42e-7	Height;
UCEC	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.51	5.39	0.41	2.76e-7	Breast cancer;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.65	7.05	0.5	6.57e-11	Menarche (age at onset);
UCEC	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.39	5.11	0.39	1.01e-6	Thyroid hormone levels;
UCEC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.35	5.2	0.39	6.51e-7	Vitiligo;
UCEC	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.49	6.65	0.48	5.47e-10	Height;
UCEC	cis	rs3790645	1.000	rs392814	chr1:26892009	T/C	cg23229016	chr1:26872525	RPS6KA1	0.31	5.83	0.43	3.45e-8	Glucose homeostasis traits;
UCEC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.76	6.99	0.5	8.91e-11	Selective IgA deficiency;
UCEC	cis	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9811216	1.000	rs9822885	chr3:169486144	A/G	cg16622863	chr3:169387280	NA	-0.44	-4.55	-0.35	1.12e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs17106184	0.786	rs113611542	chr1:51129203	T/C	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.53	-0.74	1.3e-27	Schizophrenia;
UCEC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg09521647	chr2:100722408	AFF3	0.31	4.85	0.37	3.15e-6	Chronic sinus infection;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-4.65	-0.36	7.3e-6	Prudent dietary pattern;
UCEC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.94	0.44	1.96e-8	Platelet count;
UCEC	cis	rs16912285	0.535	rs7936178	chr11:24252515	G/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg11632617	chr15:75315747	PPCDC	-0.56	-4.96	-0.38	1.92e-6	Lung cancer;
UCEC	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.49	4.53	0.35	1.19e-5	Lung cancer;
UCEC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.86	10.76	0.66	2.76e-20	Mortality in heart failure;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.56	-0.35	1.06e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.61	5.59	0.42	1.09e-7	Corneal astigmatism;
UCEC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.53	5.5	0.41	1.63e-7	Vitiligo;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg20821713	chr7:1055600	C7orf50	-0.53	-5.27	-0.4	4.7e-7	Longevity;Endometriosis;
UCEC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.65	6.17	0.45	6.24e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg26721908	chr21:47610096	LSS	-0.44	-5.59	-0.42	1.06e-7	Testicular germ cell tumor;
UCEC	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.59	-6.43	-0.47	1.67e-9	Obesity-related traits;
UCEC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	4.57	0.35	1.04e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.23	0.46	4.77e-9	Cognitive test performance;
UCEC	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.72	4.55	0.35	1.1e-5	Neuroticism;
UCEC	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.71	-7.79	-0.54	1.1e-12	Breast cancer;
UCEC	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.32	-0.74	4.8400000000000004e-27	Schizophrenia;
UCEC	cis	rs308403	0.509	rs6811183	chr4:123671551	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.71	9.13	0.6	4.89e-16	Blood protein levels;
UCEC	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.56	5.14	0.39	8.43e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg02176678	chr2:219576539	TTLL4	0.52	5.12	0.39	9.37e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.38	0.47	2.22e-9	Educational attainment;
UCEC	cis	rs7870753	1.000	rs7857261	chr9:99219779	C/T	cg25260653	chr9:99212216	HABP4	0.46	4.56	0.35	1.07e-5	Height;
UCEC	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg18827107	chr12:86230957	RASSF9	-0.44	-4.86	-0.37	2.94e-6	Major depressive disorder;
UCEC	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.58	6.05	0.45	1.15e-8	Triglycerides;
UCEC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.9	8.42	0.57	3.03e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1832871	0.619	rs262825	chr6:158678631	C/T	cg07215822	chr6:158701037	NA	0.41	4.53	0.35	1.21e-5	Height;
UCEC	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.42	4.63	0.36	8.07e-6	Height;
UCEC	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-0.94	-9.41	-0.61	9.52e-17	Height;
UCEC	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg18681998	chr4:17616180	MED28	0.7	8.09	0.55	2.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.8	11.24	0.68	1.51e-21	Leprosy;
UCEC	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.16	-8.83	-0.59	2.86e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg20387954	chr3:183756860	HTR3D	0.53	6.29	0.46	3.37e-9	Anterior chamber depth;
UCEC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.78	9.24	0.61	2.65e-16	Cognitive function;
UCEC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.64	6.21	0.46	5.22e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs8105895	0.935	rs62112920	chr19:22227149	A/G	cg20662725	chr19:22235022	ZNF257	-0.64	-5.31	-0.4	3.95e-7	Body mass index (change over time);
UCEC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.83	9.8	0.63	9.06e-18	Monocyte count;
UCEC	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.31	-0.52	1.62e-11	Resting heart rate;
UCEC	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg24375607	chr4:120327624	NA	0.53	5.51	0.41	1.56e-7	Corneal astigmatism;
UCEC	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.57	4.69	0.36	6.07e-6	Obesity-related traits;
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.58	-5.67	-0.42	7.17e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.12	0.39	9.45e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1564271	0.553	rs9334138	chr10:26978929	G/A	cg24343755	chr10:26987087	PDSS1	-0.51	-4.57	-0.35	1.01e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
UCEC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg14008862	chr17:28927542	LRRC37B2	0.75	5.24	0.4	5.51e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17123764	0.710	rs12315791	chr12:50083547	C/T	cg20471783	chr12:50157085	TMBIM6	0.61	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg14851346	chr12:38532713	NA	0.47	4.53	0.35	1.2e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	12.85	0.73	8.32e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.51	-5.59	-0.42	1.07e-7	Coronary artery disease or ischemic stroke;
UCEC	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg20560298	chr2:73613845	ALMS1	0.52	4.96	0.38	1.95e-6	Metabolite levels;
UCEC	cis	rs9341808	0.538	rs9443742	chr6:81016929	T/G	cg08355045	chr6:80787529	NA	-0.33	-4.52	-0.35	1.27e-5	Sitting height ratio;
UCEC	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.79e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.65	-5.76	-0.43	4.72e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.68	-0.42	6.91e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.46	5.85	0.43	3.09e-8	HDL cholesterol levels;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg24350213	chr17:39943012	JUP	0.68	6.81	0.49	2.31e-10	Schizophrenia;
UCEC	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.56	6.58	0.48	7.73e-10	Prostate cancer;
UCEC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg05110241	chr16:68378359	PRMT7	-0.58	-4.82	-0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs256277	0.657	rs255923	chr5:111380052	G/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.58	-4.8	-0.37	3.92e-6	Coronary artery disease;
UCEC	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.77	-6.94	-0.5	1.17e-10	Smoking behavior;
UCEC	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.64e-7	Life satisfaction;
UCEC	cis	rs228437	0.565	rs6569956	chr6:134939428	C/T	cg20986996	chr6:134210159	TCF21	0.38	4.51	0.35	1.33e-5	Melanoma;
UCEC	cis	rs7201929	0.801	rs9933198	chr16:28888409	C/T	cg10436792	chr16:28889110	ATP2A1	0.37	4.6	0.35	9.1e-6	QT interval;
UCEC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.59	6.11	0.45	8.34e-9	Pulse pressure;
UCEC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-6.48	-0.47	1.29e-9	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	0.94	10.34	0.65	3.55e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.6	5.67	0.42	7.28e-8	High light scatter reticulocyte count;
UCEC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.85	-10.84	-0.67	1.77e-20	Height;
UCEC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.53	4.64	0.36	7.8e-6	Menarche (age at onset);
UCEC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs9810089	0.749	rs664088	chr3:136036986	T/C	cg21827317	chr3:136751795	NA	0.47	4.56	0.35	1.06e-5	Gestational age at birth (child effect);
UCEC	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.5	5.14	0.39	8.45e-7	Initial pursuit acceleration;
UCEC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	0.66	4.93	0.38	2.22e-6	Body mass index;
UCEC	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.75	-5.39	-0.41	2.75e-7	Body mass index;
UCEC	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-8.28	-0.56	6.93e-14	Headache;
UCEC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg20999797	chr1:1681921	NA	0.41	5.7	0.43	6.41e-8	Body mass index;
UCEC	cis	rs4615376	0.951	rs4715064	chr6:13029514	C/T	cg11378619	chr6:12164359	HIVEP1	-0.6	-4.8	-0.37	3.82e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.53	-0.41	1.43e-7	Hemoglobin concentration;
UCEC	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.46	4.73	0.36	5.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.58	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg20965017	chr5:231967	SDHA	0.64	5.86	0.44	2.85e-8	Breast cancer;
UCEC	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.6e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg24826892	chr11:71159390	DHCR7	0.53	5.02	0.38	1.47e-6	Vitamin D levels;
UCEC	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.94	-0.55	4.8e-13	Exhaled nitric oxide output;
UCEC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg19041857	chr6:27730383	NA	-0.69	-5.24	-0.4	5.51e-7	Depression;
UCEC	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.49	4.7	0.36	5.92e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17490626	0.533	rs12771890	chr10:71189483	T/A	cg12610070	chr10:71211762	TSPAN15	-0.34	-4.72	-0.36	5.42e-6	Thrombosis;
UCEC	cis	rs4499344	0.730	rs34270210	chr19:33103945	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.41e-9	Mean platelet volume;
UCEC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	5.75	0.43	4.87e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.81	0.49	2.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.52	5.01	0.38	1.54e-6	HDL cholesterol;
UCEC	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg18681998	chr4:17616180	MED28	0.62	7.23	0.51	2.4e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.52	-5.57	-0.42	1.16e-7	Menarche (age at onset);
UCEC	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.07	6.25	0.46	4.19e-9	Diabetic retinopathy;
UCEC	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24249390	chr15:90295951	MESP1	-0.39	-4.58	-0.35	9.94e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.73	7.53	0.53	4.86e-12	Caffeine consumption;
UCEC	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg03934865	chr2:198174659	NA	-0.37	-4.68	-0.36	6.36e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs731174	0.759	rs12133523	chr1:38153110	T/A	cg06917450	chr1:38156652	C1orf109	-0.58	-6.08	-0.45	9.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.57	0.53	3.81e-12	Schizophrenia;
UCEC	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.81	7.5	0.53	5.5e-12	Menopause (age at onset);
UCEC	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.55	-4.99	-0.38	1.67e-6	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.69	-8.22	-0.56	9.64e-14	Eosinophil percentage of white cells;
UCEC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.43	0.41	2.24e-7	Breast cancer;
UCEC	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg00738113	chr16:70207722	CLEC18C	0.43	5.43	0.41	2.28e-7	Sjögren's syndrome;
UCEC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.53	6.17	0.45	6.17e-9	Bone mineral density;
UCEC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg08493051	chr2:3487164	NA	-0.61	-6.59	-0.48	7.47e-10	Neurofibrillary tangles;
UCEC	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24249390	chr15:90295951	MESP1	-0.46	-5.11	-0.39	9.8e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	7.86	0.54	7.61e-13	Platelet count;
UCEC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.59	4.96	0.38	1.93e-6	Prostate cancer;
UCEC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg13695892	chr22:41940480	POLR3H	-0.68	-4.75	-0.36	4.84e-6	Vitiligo;
UCEC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg17724175	chr1:150552817	MCL1	-0.42	-4.62	-0.36	8.41e-6	Tonsillectomy;
UCEC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.1	-6.86	-0.49	1.82e-10	Diabetic kidney disease;
UCEC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs13095912	1.000	rs17523471	chr3:185304018	T/C	cg11274856	chr3:185301563	NA	0.57	7.72	0.54	1.67e-12	Systolic blood pressure;
UCEC	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.94	-0.44	1.99e-8	Parkinson's disease;
UCEC	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.49	-5.66	-0.42	7.68e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.49	4.78	0.37	4.26e-6	Dilated cardiomyopathy;
UCEC	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.03	-0.38	1.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	1.01e-15	Menopause (age at onset);
UCEC	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg00250761	chr1:31883323	NA	-0.38	-5.06	-0.39	1.21e-6	Alcohol dependence;
UCEC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.51	0.35	1.31e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.57	5.75	0.43	5.08e-8	Colorectal cancer;
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.88e-9	Prudent dietary pattern;
UCEC	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.49	-5.36	-0.4	3.13e-7	Life satisfaction;
UCEC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.67	5.57	0.42	1.16e-7	Alcohol dependence;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.23	-0.4	5.75e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.72	0.36	5.38e-6	Blood metabolite levels;
UCEC	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.78	-6.98	-0.5	9.36e-11	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs16937	0.711	rs12130817	chr1:205140305	C/T	cg00857998	chr1:205179979	DSTYK	0.5	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.49	4.73	0.36	5.3e-6	Prostate cancer;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.24	-0.46	4.46e-9	Cardiac Troponin-T levels;
UCEC	cis	rs35934224	0.891	rs34249993	chr22:19872170	G/T	cg11182965	chr22:19864308	TXNRD2	-0.58	-7.3	-0.52	1.63e-11	Glaucoma (primary open-angle);
UCEC	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	1.17	8.48	0.57	2.24e-14	Uric acid levels;
UCEC	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.6	6.8	0.49	2.4e-10	Hemoglobin concentration;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.63	6.21	0.46	5.25e-9	Longevity;Endometriosis;
UCEC	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.94	10.42	0.65	2.21e-19	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs174479	0.677	rs174463	chr11:61657838	G/A	cg01500311	chr11:61656094	FADS3	0.5	6.34	0.46	2.64e-9	Sphingolipid levels;
UCEC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.84	9.32	0.61	1.59e-16	Breast cancer;
UCEC	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	5.09	0.39	1.08e-6	Alzheimer's disease;
UCEC	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.27	11.7	0.69	9.26e-23	Type 1 diabetes nephropathy;
UCEC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.63	5.25	0.4	5.32e-7	Blood metabolite levels;
UCEC	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-5.07	-0.39	1.2e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.63	5.63	0.42	8.91e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	0.97	15.52	0.79	9.07e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4646450	0.838	rs10257758	chr7:99188988	A/C	cg24650262	chr7:98904301	NA	0.46	4.69	0.36	6.17e-6	Blood metabolite levels;
UCEC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg06970220	chr1:156163860	SLC25A44	0.46	4.84	0.37	3.2e-6	Testicular germ cell tumor;
UCEC	cis	rs11697848	1.000	rs75621680	chr20:48576524	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.7	7.49	0.53	5.95e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6546886	0.956	rs6546885	chr2:74245492	G/A	cg14702570	chr2:74259524	NA	-0.41	-5.23	-0.4	5.76e-7	Dialysis-related mortality;
UCEC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg22974920	chr21:40686053	BRWD1	-0.53	-4.77	-0.37	4.31e-6	Cognitive function;
UCEC	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.06	-0.6	7.3e-16	Height;
UCEC	cis	rs256277	0.657	rs469316	chr5:111366581	A/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-4.54	-0.35	1.15e-5	Coronary artery disease;
UCEC	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg13073564	chr4:8508604	NA	0.52	5.85	0.43	3.05e-8	Response to antineoplastic agents;
UCEC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg19318889	chr4:1322082	MAEA	0.48	5.34	0.4	3.52e-7	Obesity-related traits;
UCEC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.51	4.96	0.38	1.96e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.73	5.76	0.43	4.86e-8	Arsenic metabolism;
UCEC	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18932078	chr1:2524107	MMEL1	-0.31	-5.04	-0.38	1.37e-6	Ulcerative colitis;
UCEC	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg05775895	chr3:12838266	CAND2	0.59	5.09	0.39	1.08e-6	QRS complex (12-leadsum);
UCEC	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.11	-0.6	5.7e-16	Coffee consumption (cups per day);
UCEC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.71	-5.86	-0.44	2.87e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.92	11.11	0.68	3.33e-21	Breast cancer;
UCEC	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg14196790	chr5:131705035	SLC22A5	0.45	5.24	0.4	5.38e-7	Blood metabolite levels;
UCEC	cis	rs78707713	0.836	rs112843485	chr10:71211707	T/C	cg12610070	chr10:71211762	TSPAN15	-0.44	-4.8	-0.37	3.9e-6	Venous thromboembolism;
UCEC	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg13683864	chr3:40499215	RPL14	-0.51	-5.0	-0.38	1.58e-6	Renal cell carcinoma;
UCEC	cis	rs8105895	0.935	rs7252220	chr19:22245564	G/A	cg02912127	chr19:22235281	ZNF257	-0.64	-5.35	-0.4	3.29e-7	Body mass index (change over time);
UCEC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.59	6.67	0.48	4.78e-10	Crohn's disease;
UCEC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.75	-6.9	-0.49	1.47e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs7106204	0.513	rs7131144	chr11:24249486	A/G	ch.11.24196551F	chr11:24239977	NA	0.53	4.73	0.36	5.12e-6	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.54	-5.8	-0.43	3.85e-8	Prostate cancer;
UCEC	cis	rs644799	0.897	rs10831445	chr11:95660386	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.57	5.8	0.43	3.82e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	8.19	0.56	1.17e-13	Breast cancer;
UCEC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.83	-0.59	2.95e-15	Exhaled nitric oxide output;
UCEC	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg21419209	chr3:44054225	NA	0.47	4.83	0.37	3.38e-6	Coronary artery disease;
UCEC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	8.02	0.55	2.97e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.64	-6.19	-0.45	5.6e-9	Rheumatoid arthritis;
UCEC	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.68	5.82	0.43	3.64e-8	Coronary artery disease;
UCEC	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.94	-0.5	1.15e-10	Blood trace element (Zn levels);
UCEC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.67	7.2	0.51	2.84e-11	Menopause (age at onset);
UCEC	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.62	6.98	0.5	9.23e-11	Pubertal anthropometrics;
UCEC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-0.98	-7.21	-0.51	2.71e-11	Body mass index;
UCEC	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.64	7.65	0.53	2.5e-12	Schizophrenia;
UCEC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg20399509	chr21:47717575	C21orf57	-0.45	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.58	0.48	7.7e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7975161	0.630	rs4964257	chr12:104633262	T/C	cg25273343	chr12:104657179	TXNRD1	-0.76	-4.76	-0.37	4.52e-6	Toenail selenium levels;
UCEC	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.68	8.35	0.57	4.74e-14	Testicular germ cell tumor;
UCEC	cis	rs13315871	0.860	rs9842759	chr3:58244748	C/T	cg20936604	chr3:58311152	NA	-0.57	-4.73	-0.36	5.26e-6	Cholesterol, total;
UCEC	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.15	-0.39	8.06e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.45	-4.68	-0.36	6.38e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg01938476	chr12:7076853	SCARNA12;PHB2	0.31	4.53	0.35	1.21e-5	IgG glycosylation;
UCEC	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg14008862	chr17:28927542	LRRC37B2	0.54	5.02	0.38	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3752645	0.881	rs116695179	chr7:106783205	A/G	cg24384195	chr7:106505370	PIK3CG	-0.54	-4.64	-0.36	7.54e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs55670112	0.904	rs4537052	chr5:114272843	G/A	cg05461448	chr5:114880715	FEM1C	-0.43	-4.51	-0.35	1.34e-5	Epilepsy;
UCEC	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.53	-5.75	-0.43	5.07e-8	Menarche (age at onset);
UCEC	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg14092571	chr14:90743983	NA	-0.42	-5.61	-0.42	9.93e-8	Mortality in heart failure;
UCEC	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg11644478	chr21:40555479	PSMG1	0.77	7.75	0.54	1.43e-12	Cognitive function;
UCEC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.34	0.52	1.38e-11	Platelet count;
UCEC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.64	-6.87	-0.49	1.7e-10	Platelet distribution width;
UCEC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.79	-9.17	-0.6	4.01e-16	Menarche (age at onset);
UCEC	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg19920283	chr7:105172520	RINT1	0.52	4.69	0.36	6.08e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.59	6.14	0.45	7.36e-9	Initial pursuit acceleration;
UCEC	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg07636037	chr3:49044803	WDR6	-0.58	-4.66	-0.36	7e-6	Menarche (age at onset);
UCEC	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-5.07	-0.39	1.18e-6	Pediatric autoimmune diseases;
UCEC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.17	-0.56	1.29e-13	Chronic sinus infection;
UCEC	cis	rs1250259	0.519	rs10172425	chr2:216268355	C/T	cg17325911	chr2:216976926	XRCC5	0.44	4.72	0.36	5.33e-6	Coronary artery disease;Pulse pressure;
UCEC	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.49	5.43	0.41	2.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs73416724	1.000	rs17209379	chr6:43265231	A/C	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.7	5.89	0.44	2.51e-8	Systolic blood pressure;
UCEC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.81	-0.37	3.68e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	4.71	0.36	5.69e-6	Lung cancer in ever smokers;
UCEC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.51	4.8	0.37	3.93e-6	Blood metabolite levels;
UCEC	cis	rs9341808	0.538	rs688867	chr6:80939228	A/G	cg08355045	chr6:80787529	NA	0.4	5.02	0.38	1.5e-6	Sitting height ratio;
UCEC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.66	0.48	4.99e-10	Coffee consumption (cups per day);
UCEC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.87	10.0	0.64	2.86e-18	Menarche (age at onset);
UCEC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.63	6.97	0.5	1.02e-10	Cognitive function;
UCEC	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	6.24	0.46	4.41e-9	Bipolar disorder;
UCEC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg03714773	chr7:91764589	CYP51A1	0.43	5.45	0.41	2.09e-7	Breast cancer;
UCEC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.58	6.58	0.48	7.56e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.89	9.45	0.61	7.65e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-1.09	-9.57	-0.62	3.64e-17	Dupuytren's disease;
UCEC	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.42	6.52	0.47	1.07e-9	Primary biliary cholangitis;
UCEC	cis	rs4499344	0.556	rs259243	chr19:33144726	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	5.69	0.42	6.6e-8	Mean platelet volume;
UCEC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-6.13	-0.45	7.59e-9	Gut microbiome composition (summer);
UCEC	cis	rs359466	0.529	rs62376928	chr5:173288146	T/C	cg08267245	chr5:172410984	ATP6V0E1	0.51	4.54	0.35	1.14e-5	QRS complex (Sokolow-Lyon);
UCEC	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.7	7.66	0.53	2.29e-12	Coronary artery disease;
UCEC	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.75	-8.2	-0.56	1.09e-13	LDL cholesterol;
UCEC	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.5	5.17	0.39	7.53e-7	Cognitive function;
UCEC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.81	0.37	3.69e-6	Breast cancer;
UCEC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.48	5.87	0.44	2.8e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.8	-7.74	-0.54	1.45e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.34	0.57	4.85e-14	Chronic sinus infection;
UCEC	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	0.9	8.42	0.57	3.13e-14	Heart rate;
UCEC	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.54	-0.58	1.55e-14	Total body bone mineral density;
UCEC	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs9467773	1.000	rs9467798	chr6:26575697	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg14067834	chr17:29058358	SUZ12P	0.58	4.53	0.35	1.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.62	5.41	0.41	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.41	5.25	0.4	5.34e-7	Carotid intima media thickness;
UCEC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg04315214	chr1:2043799	PRKCZ	0.46	5.38	0.41	2.9e-7	Height;
UCEC	cis	rs5167	0.504	rs10426750	chr19:45457684	G/C	cg09555818	chr19:45449301	APOC2	0.45	5.9	0.44	2.46e-8	Blood protein levels;
UCEC	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-4.99	-0.38	1.65e-6	Body mass index;
UCEC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-1.05	-7.14	-0.51	4.07e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.51	5.29	0.4	4.31e-7	Breast cancer;
UCEC	cis	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg17412351	chr7:75678396	MDH2;STYXL1	-0.42	-4.67	-0.36	6.62e-6	Eotaxin levels;
UCEC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.28	15.07	0.78	1.3e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-13.22	-0.74	8.57e-27	Schizophrenia;
UCEC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg06238570	chr21:40685208	BRWD1	0.84	7.63	0.53	2.76e-12	Cognitive function;
UCEC	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-5.56	-0.42	1.23e-7	Height;
UCEC	cis	rs9309473	0.519	rs1881246	chr2:73650122	T/A	cg20560298	chr2:73613845	ALMS1	0.52	5.18	0.39	7.3e-7	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.06	0.71	1.01e-23	Prudent dietary pattern;
UCEC	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-5.45	-0.41	2.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10242455	0.717	rs776745	chr7:99291337	T/G	cg18809830	chr7:99032528	PTCD1	-0.53	-4.56	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.53	5.06	0.39	1.24e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.86	10.44	0.65	2.01e-19	Bone mineral density;
UCEC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg20999797	chr1:1681921	NA	0.34	4.51	0.35	1.33e-5	Body mass index;
UCEC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.53	0.41	1.45e-7	Subjective well-being;
UCEC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg19318889	chr4:1322082	MAEA	0.49	6.03	0.45	1.26e-8	Obesity-related traits;
UCEC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.93	11.69	0.69	9.97e-23	IgG glycosylation;
UCEC	cis	rs9810089	0.843	rs681783	chr3:136035303	C/T	cg21827317	chr3:136751795	NA	0.46	4.63	0.36	8.1e-6	Gestational age at birth (child effect);
UCEC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.54	-5.94	-0.44	1.97e-8	Diastolic blood pressure;
UCEC	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.85	0.43	3.02e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.88	8.66	0.58	7.61e-15	Platelet count;
UCEC	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.75	-7.71	-0.54	1.78e-12	Plateletcrit;Platelet count;
UCEC	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.57	-4.99	-0.38	1.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.35	5.25	0.4	5.12e-7	Ulcerative colitis;
UCEC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.65	0.36	7.4e-6	Bipolar disorder;
UCEC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.02	-0.38	1.49e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.47	4.79	0.37	4.12e-6	HDL cholesterol;
UCEC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-4.81	-0.37	3.69e-6	Total body bone mineral density;
UCEC	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-0.77	-5.04	-0.38	1.37e-6	Blood protein levels;
UCEC	cis	rs7560272	0.588	rs4852959	chr2:73880601	C/A	cg20560298	chr2:73613845	ALMS1	0.52	4.94	0.38	2.13e-6	Schizophrenia;
UCEC	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.7	6.34	0.46	2.65e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.29	-0.46	3.41e-9	Cardiac Troponin-T levels;
UCEC	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.52	6.51	0.47	1.12e-9	Information processing speed;
UCEC	cis	rs508970	0.874	rs7876	chr11:60897912	C/T	cg26254678	chr11:61511275	DAGLA	0.36	4.51	0.35	1.3e-5	Rheumatoid arthritis;
UCEC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.69	6.01	0.44	1.38e-8	Alzheimer's disease;
UCEC	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.55	-4.91	-0.38	2.4e-6	Monobrow;
UCEC	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.62	6.92	0.5	1.32e-10	Pubertal anthropometrics;
UCEC	cis	rs10208940	0.920	rs35118992	chr2:68699460	G/A	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-4.93	-0.38	2.17e-6	Gut microbiome composition (summer);
UCEC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.49	5.12	0.39	9.44e-7	Blood protein levels;
UCEC	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.33	-0.4	3.7e-7	Bipolar disorder;
UCEC	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg12292205	chr6:26970375	C6orf41	0.57	5.09	0.39	1.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.57	-5.15	-0.39	8.09e-7	Gut microbiome composition (summer);
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.86	-0.37	3.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.85	7.74	0.54	1.48e-12	Body mass index;
UCEC	cis	rs13253111	0.603	rs28605937	chr8:28099179	A/G	cg26534493	chr8:28060551	NA	0.49	5.4	0.41	2.66e-7	Childhood body mass index;
UCEC	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.53	-5.89	-0.44	2.53e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	0.72	7.45	0.52	7.48e-12	Breast cancer;
UCEC	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg14196790	chr5:131705035	SLC22A5	0.45	4.81	0.37	3.71e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.5	-7.23	-0.51	2.48e-11	Urinary metabolites;
UCEC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.39	-5.3	-0.4	4.15e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	0.91	12.17	0.71	5.33e-24	Blood protein levels;
UCEC	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs953387	1.000	rs4954567	chr2:136901587	G/T	cg07169764	chr2:136633963	MCM6	0.54	5.59	0.42	1.09e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg18016565	chr1:150552671	MCL1	0.44	4.55	0.35	1.1e-5	Melanoma;
UCEC	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.22	18.03	0.83	4.41e-39	Exhaled nitric oxide output;
UCEC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs1823913	0.599	rs13002286	chr2:192150352	A/G	cg15998761	chr2:191300784	MFSD6	-0.38	-4.55	-0.35	1.13e-5	Obesity-related traits;
UCEC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.53	5.27	0.4	4.86e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.78	6.12	0.45	8.16e-9	Body mass index;
UCEC	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg18681998	chr4:17616180	MED28	0.72	7.75	0.54	1.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-7.87	-0.54	7.14e-13	Mosquito bite size;
UCEC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg23795048	chr12:9217529	LOC144571	0.41	4.96	0.38	1.92e-6	Sjögren's syndrome;
UCEC	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.4	-5.1	-0.39	1.02e-6	Mean platelet volume;
UCEC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg24961523	chr17:36618985	ARHGAP23	-0.36	-4.55	-0.35	1.1e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.6	-5.2	-0.39	6.69e-7	Response to antineoplastic agents;
UCEC	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.1	18.06	0.83	3.91e-39	Testicular germ cell tumor;
UCEC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg09626299	chr10:82213104	TSPAN14	-0.38	-5.93	-0.44	2.08e-8	Post bronchodilator FEV1;
UCEC	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.73	-6.22	-0.46	4.91e-9	Platelet distribution width;
UCEC	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.55	-5.18	-0.39	7.26e-7	Serum sulfate level;
UCEC	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.79e-11	Eye color traits;
UCEC	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg13683864	chr3:40499215	RPL14	-0.89	-10.36	-0.65	3.24e-19	Renal cell carcinoma;
UCEC	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg06784218	chr1:46089804	CCDC17	0.44	5.06	0.39	1.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg10503236	chr1:231470652	EXOC8	-0.4	-4.87	-0.37	2.82e-6	Hemoglobin concentration;
UCEC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.49	-5.07	-0.39	1.17e-6	Prostate cancer;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.13	-0.45	7.72e-9	Cardiac Troponin-T levels;
UCEC	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.57	-0.35	1.02e-5	Cardiac Troponin-T levels;
UCEC	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.71	-6.25	-0.46	4.13e-9	Asthma;
UCEC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.76	8.25	0.56	8.04e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.36	-0.76	9.02e-30	Schizophrenia;
UCEC	cis	rs2028201	0.931	rs7565519	chr2:201293649	C/T	cg04283868	chr2:201171347	SPATS2L	0.5	4.55	0.35	1.13e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
UCEC	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg13683864	chr3:40499215	RPL14	0.71	7.25	0.51	2.18e-11	Renal cell carcinoma;
UCEC	cis	rs7246967	0.551	rs57775631	chr19:22814461	T/C	cg24889512	chr19:22816950	ZNF492	0.59	6.47	0.47	1.38e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.82	5.2	0.39	6.47e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.62	-7.15	-0.51	3.83e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.51	5.56	0.42	1.22e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.21	-0.51	2.69e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg12024160	chr4:1254474	NA	0.42	4.65	0.36	7.47e-6	Longevity;
UCEC	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.66	-6.97	-0.5	9.75e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.9	10.84	0.67	1.77e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.89	7.48	0.53	6.12e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.75	8.32	0.57	5.43e-14	Blood metabolite levels;
UCEC	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-6.3	-0.46	3.25e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.6	-0.35	9.01e-6	Homocysteine levels;
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg19678392	chr7:94953810	PON1	-0.58	-5.58	-0.42	1.11e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg06521331	chr12:34319734	NA	-0.53	-4.67	-0.36	6.68e-6	Morning vs. evening chronotype;
UCEC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.6	-6.61	-0.48	6.62e-10	Refractive error;
UCEC	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.54	-5.07	-0.39	1.17e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.93	11.7	0.69	9.17e-23	Height;
UCEC	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-6.97	-0.5	1.01e-10	Sudden cardiac arrest;
UCEC	cis	rs2979489	1.000	rs2979469	chr8:30285091	C/G	cg26383811	chr8:30366931	RBPMS	0.56	4.56	0.35	1.07e-5	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.97	12.68	0.72	2.32e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg07636037	chr3:49044803	WDR6	0.56	4.54	0.35	1.15e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs73020703	chr19:22844339	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.69	7.89	0.55	6.33e-13	Menopause (age at onset);
UCEC	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg11150807	chr10:43354902	NA	0.74	4.63	0.36	7.83e-6	Blood protein levels;
UCEC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg08027265	chr7:2291960	NA	-0.47	-5.12	-0.39	9.46e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
UCEC	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-0.69	-4.56	-0.35	1.06e-5	Mitochondrial DNA levels;
UCEC	cis	rs7150255	0.820	rs4274376	chr14:104963402	T/A	cg27100511	chr14:105927968	MTA1	0.4	4.54	0.35	1.19e-5	Gut microbiome composition (summer and winter);
UCEC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	5.4	0.41	2.59e-7	Rheumatoid arthritis;
UCEC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.34	0.52	1.31e-11	Homoarginine levels;
UCEC	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.15	8.59	0.58	1.14e-14	Uric acid levels;
UCEC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.15	-0.64	1.12e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.86	9.35	0.61	1.39e-16	Breast cancer;
UCEC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.76	8.74	0.58	4.73e-15	Prudent dietary pattern;
UCEC	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.5	-7.26	-0.51	2.03e-11	Urinary metabolites;
UCEC	cis	rs11016883	1.000	rs7073892	chr10:131493946	G/A	cg24160823	chr10:132284938	NA	-0.39	-4.56	-0.35	1.05e-5	Waist-to-hip circumference ratio (ever vs never smoking interaction);
UCEC	cis	rs7572733	0.765	rs2164068	chr2:198943852	T/A	cg02462912	chr2:198318262	COQ10B	0.45	4.51	0.35	1.34e-5	Dermatomyositis;
UCEC	cis	rs7246967	0.673	rs368144	chr19:23000787	C/T	cg05241461	chr19:22816980	ZNF492	0.56	5.43	0.41	2.29e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.37e-6	Breast cancer;
UCEC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.32	-0.52	1.5e-11	Blood trace element (Zn levels);
UCEC	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.9	10.26	0.65	5.79e-19	Dental caries;
UCEC	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	1.07	9.47	0.62	6.77e-17	Dupuytren's disease;
UCEC	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.22	-0.46	4.84e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.42	-5.34	-0.4	3.54e-7	Obesity-related traits;
UCEC	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg00298065	chr19:58715577	ZNF274	0.38	4.59	0.35	9.52e-6	Mean platelet volume;
UCEC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.54	5.49	0.41	1.76e-7	Aortic root size;
UCEC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.87	11.58	0.69	1.97e-22	Menopause (age at onset);
UCEC	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.52	-6.76	-0.49	3.01e-10	Gut microbiota (bacterial taxa);
UCEC	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.57	-5.86	-0.44	2.92e-8	Schizophrenia;
UCEC	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	8.2	0.56	1.1e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.73	-4.8	-0.37	3.86e-6	White matter integrity;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02374837	chr16:8891602	PMM2;TMEM186	0.56	6.67	0.48	4.89e-10	Warfarin maintenance dose;
UCEC	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-5.3	-0.4	4.21e-7	Life satisfaction;
UCEC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg27391334	chr7:1352002	NA	0.36	4.53	0.35	1.22e-5	Longevity;Endometriosis;
UCEC	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.52	4.83	0.37	3.38e-6	Coronary artery disease;
UCEC	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.77	-5.26	-0.4	5.05e-7	Blood pressure (smoking interaction);
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.7	8.52	0.57	1.74e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.44	4.64	0.36	7.53e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.55	6.06	0.45	1.09e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg07169764	chr2:136633963	MCM6	-0.77	-7.47	-0.52	6.42e-12	Mosquito bite size;
UCEC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.09	0.55	2.11e-13	Smoking behavior;
UCEC	cis	rs354033	1.000	rs354045	chr7:149300608	G/T	cg24335155	chr7:149193227	ZNF746	-0.38	-4.62	-0.36	8.35e-6	Multiple sclerosis;
UCEC	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg01874867	chr7:94954059	PON1	-0.54	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.71	5.85	0.43	3.07e-8	Menopause (age at onset);
UCEC	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg13926569	chr10:89418898	PAPSS2	-0.53	-6.29	-0.46	3.42e-9	Magnesium levels;
UCEC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.57	6.66	0.48	5.22e-10	Monocyte percentage of white cells;
UCEC	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.66	5.8	0.43	3.92e-8	Response to diuretic therapy;
UCEC	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.51	5.48	0.41	1.77e-7	Neuroticism;
UCEC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.55	-0.48	9.07e-10	Blood metabolite levels;
UCEC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-5.21	-0.39	6.29e-7	Hemoglobin concentration;
UCEC	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg18230493	chr5:56204884	C5orf35	-0.55	-5.05	-0.38	1.29e-6	Coronary artery disease;
UCEC	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.49	5.41	0.41	2.5e-7	Immature fraction of reticulocytes;
UCEC	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.91	-0.9	1.28e-54	Myeloid white cell count;
UCEC	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg16294425	chr4:1091520	RNF212	0.77	4.54	0.35	1.15e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.37	4.75	0.36	4.78e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg06096015	chr1:231504339	EGLN1	-0.44	-4.94	-0.38	2.1e-6	Red blood cell count;
UCEC	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.48	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs116175783	0.557	rs16845844	chr2:162265270	C/T	cg06347928	chr2:163175126	IFIH1	0.56	4.54	0.35	1.15e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.39	-0.57	3.64e-14	Blood trace element (Zn levels);
UCEC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.72	7.34	0.52	1.35e-11	Breast cancer;
UCEC	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.39	-4.7	-0.36	5.86e-6	Menopause (age at onset);
UCEC	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.53	5.73	0.43	5.5e-8	Red blood cell count;
UCEC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg21204522	chr6:27730016	NA	-0.57	-4.73	-0.36	5.32e-6	Depression;
UCEC	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg20560298	chr2:73613845	ALMS1	0.51	5.15	0.39	8.41e-7	Metabolite levels;
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.02e-6	Prudent dietary pattern;
UCEC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.54	4.96	0.38	1.91e-6	Menopause (age at onset);
UCEC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	4.81	0.37	3.74e-6	Personality dimensions;
UCEC	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.63	0.53	2.74e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	5.45	0.41	2.09e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.98	-0.38	1.74e-6	Depression;
UCEC	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.78	5.19	0.39	6.82e-7	Cognitive function;
UCEC	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.44	-4.93	-0.38	2.2e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs12974988	chr19:22925965	G/T	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-5.27	-0.4	4.73e-7	Blood protein levels;
UCEC	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.73	-7.74	-0.54	1.51e-12	Ulcerative colitis;
UCEC	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg21905437	chr5:178450457	ZNF879	0.64	7.17	0.51	3.47e-11	Pubertal anthropometrics;
UCEC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg24562669	chr7:97807699	LMTK2	0.5	6.18	0.45	5.85e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.91	10.18	0.64	9.37e-19	Post bronchodilator FEV1;
UCEC	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.63	5.83	0.43	3.46e-8	Parkinson's disease;
UCEC	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.5	5.06	0.39	1.21e-6	Serum dimethylarginine levels (asymmetric/symetric ratio);
UCEC	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.09	-6.24	-0.46	4.34e-9	Diabetic retinopathy;
UCEC	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.57	5.99	0.44	1.56e-8	Neuroticism;
UCEC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg19805062	chr22:46654627	PKDREJ	0.48	5.15	0.39	8.41e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	7.94	0.55	4.71e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.57	-6.29	-0.46	3.4e-9	Pubertal anthropometrics;
UCEC	cis	rs751728	0.571	rs4713691	chr6:33790415	A/G	cg25922239	chr6:33757077	LEMD2	-0.56	-4.67	-0.36	6.65e-6	Crohn's disease;
UCEC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg19413350	chr8:57351067	NA	-0.4	-4.6	-0.35	8.94e-6	Obesity-related traits;
UCEC	cis	rs7246967	0.611	rs117717959	chr19:22828678	C/T	cg08271804	chr19:22816896	ZNF492	0.68	4.72	0.36	5.55e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.46	4.63	0.36	8.02e-6	Systolic blood pressure;
UCEC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.6	-4.64	-0.36	7.52e-6	Gut microbiome composition (summer);
UCEC	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.37	4.77	0.37	4.42e-6	Educational attainment (years of education);
UCEC	cis	rs3824488	0.920	rs28446116	chr9:98243385	A/G	cg14565164	chr9:98057177	FANCC	0.65	4.57	0.35	1.04e-5	Neuroticism;
UCEC	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.08	0.39	1.13e-6	Height;
UCEC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.8	-0.49	2.51e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.57	6.55	0.48	8.97e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg11871910	chr12:69753446	YEATS4	0.54	4.81	0.37	3.72e-6	Response to diuretic therapy;
UCEC	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.87	0.59	2.28e-15	Platelet count;
UCEC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.79	7.32	0.52	1.51e-11	Diastolic blood pressure;
UCEC	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.12	12.36	0.71	1.65e-24	Blood protein levels;
UCEC	cis	rs2172802	0.598	rs1391320	chr4:62544596	C/T	cg04118610	chr4:62707027	LPHN3	-0.44	-4.82	-0.37	3.48e-6	Partial epilepsies;
UCEC	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg07150772	chr14:90864620	CALM1	0.55	5.13	0.39	8.98e-7	Mortality in heart failure;
UCEC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.5	5.03	0.38	1.42e-6	Prostate cancer;
UCEC	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.88	5.94	0.44	1.93e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.56	5.8	0.43	3.93e-8	IgG glycosylation;
UCEC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.63	6.5	0.47	1.19e-9	Metabolic syndrome;
UCEC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg00343986	chr7:65444356	GUSB	0.5	4.72	0.36	5.46e-6	Aortic root size;
UCEC	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.88	-6.29	-0.46	3.4e-9	Orofacial clefts;
UCEC	cis	rs2455799	1.000	rs2700009	chr3:15781005	C/T	cg16303742	chr3:15540471	COLQ	-0.41	-4.78	-0.37	4.16e-6	Mean platelet volume;
UCEC	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg11632617	chr15:75315747	PPCDC	-0.49	-4.97	-0.38	1.81e-6	Blood trace element (Zn levels);
UCEC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.53	5.03	0.38	1.4e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs17867775	0.623	rs117265970	chr7:126655024	G/C	cg05967129	chr7:127544716	SND1	-0.74	-4.68	-0.36	6.35e-6	Anti-saccade response;
UCEC	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.4	5.08	0.39	1.15e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.82	-0.37	3.59e-6	Parkinson's disease;
UCEC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.34	0.76	1.01e-29	Chronic sinus infection;
UCEC	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg05241461	chr19:22816980	ZNF492	0.56	5.77	0.43	4.61e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg12292205	chr6:26970375	C6orf41	0.56	5.06	0.39	1.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17012589	0.869	rs4074726	chr12:85671452	C/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.59	-0.35	9.27e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.51	-4.61	-0.36	8.77e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.48	-5.24	-0.4	5.51e-7	Aortic root size;
UCEC	cis	rs6684428	1.000	rs59959484	chr1:56345876	C/T	cg11651538	chr1:56320950	NA	-0.74	-6.35	-0.46	2.5e-9	Airflow obstruction;
UCEC	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.64	-6.97	-0.5	9.92e-11	Hypospadias;
UCEC	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg06238570	chr21:40685208	BRWD1	0.84	8.18	0.56	1.22e-13	Cognitive function;
UCEC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.57	-4.61	-0.36	8.59e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.898	rs7799782	chr7:1868039	A/G	cg03354898	chr7:1950403	MAD1L1	0.5	5.56	0.42	1.24e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-5.92	-0.44	2.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.92	0.38	2.31e-6	Diabetic retinopathy;
UCEC	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.16	-0.56	1.35e-13	Total cholesterol levels;
UCEC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg10932868	chr11:921992	NA	0.41	5.22	0.4	6.05e-7	Alzheimer's disease (late onset);
UCEC	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.58	5.31	0.4	4.05e-7	Lupus nephritis in systemic lupus erythematosus;
UCEC	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.58	5.95	0.44	1.89e-8	Personality dimensions;
UCEC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.05	-0.38	1.29e-6	Blood metabolite levels;
UCEC	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	7.91	0.55	5.71e-13	Post bronchodilator FEV1;
UCEC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg22166914	chr1:53195759	ZYG11B	0.64	7.05	0.5	6.64e-11	Monocyte count;
UCEC	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.43	-5.31	-0.4	3.99e-7	Subjective well-being;
UCEC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg04804543	chr8:142233427	SLC45A4	-0.5	-6.09	-0.45	9.2e-9	Immature fraction of reticulocytes;
UCEC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.87	-10.14	-0.64	1.21e-18	Dental caries;
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.73	0.43	5.58e-8	Prudent dietary pattern;
UCEC	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-0.73	-6.12	-0.45	8.01e-9	Alzheimer's disease;
UCEC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.69	-8.76	-0.59	4.26e-15	Height;
UCEC	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	9.3	0.61	1.77e-16	Mean platelet volume;
UCEC	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg13175981	chr1:150552382	MCL1	0.57	5.21	0.39	6.21e-7	Monocyte chemoattractant protein-1 levels;
UCEC	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.64	5.12	0.39	9.26e-7	Bladder cancer;
UCEC	cis	rs6542838	0.641	rs11123756	chr2:99508012	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.54	5.63	0.42	9.01e-8	Fear of minor pain;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg24703168	chr6:28411309	ZSCAN23	-0.53	-6.43	-0.47	1.71e-9	Pubertal anthropometrics;
UCEC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg02228329	chr11:64053129	BAD;GPR137	0.66	6.65	0.48	5.49e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.43	4.57	0.35	1.04e-5	Depressive episodes in bipolar disorder;
UCEC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg14324370	chr2:177042789	NA	0.63	6.76	0.49	3.08e-10	IgG glycosylation;
UCEC	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.5	5.2	0.39	6.56e-7	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs9790314	0.582	rs11708813	chr3:160589852	G/A	cg03342759	chr3:160939853	NMD3	0.56	5.23	0.4	5.81e-7	Morning vs. evening chronotype;
UCEC	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.57	6.01	0.44	1.42e-8	Sudden cardiac arrest;
UCEC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.9	9.04	0.6	8.59e-16	Cognitive function;
UCEC	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.53	-4.85	-0.37	3.11e-6	Coronary artery disease;
UCEC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.45	-6.16	-0.45	6.73e-9	Prostate cancer;
UCEC	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.96e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.1	0.39	1.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-5.89	-0.44	2.52e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.54	-0.66	1.05e-19	Schizophrenia;
UCEC	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-5.19	-0.39	6.98e-7	Congenital heart disease (maternal effect);
UCEC	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-5.97	-0.44	1.7e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs7088591	0.867	rs73292709	chr10:59787061	T/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.52	4.81	0.37	3.69e-6	Blood protein levels;
UCEC	cis	rs11867410	0.744	rs7225773	chr17:63948466	C/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.22	-0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.52	-4.8	-0.37	3.82e-6	Coronary artery disease;
UCEC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-6.18	-0.45	5.88e-9	Tonsillectomy;
UCEC	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.8	7.59	0.53	3.4e-12	Bladder cancer;
UCEC	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg24687543	chr11:63912206	MACROD1	0.54	4.71	0.36	5.65e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.55	5.1	0.39	1.03e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs11910985	0.546	rs113970410	chr21:48080896	C/G	cg17243659	chr21:48055224	PRMT2	1.04	4.51	0.35	1.32e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07215822	chr6:158701037	NA	-0.68	-5.78	-0.43	4.32e-8	Height;
UCEC	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.53	5.99	0.44	1.52e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	6.6	0.48	6.97e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.48	5.24	0.4	5.46e-7	Pulse pressure;
UCEC	cis	rs12681287	0.752	rs67615966	chr8:87255203	C/A	cg27223183	chr8:87520930	FAM82B	-0.64	-5.34	-0.4	3.48e-7	Caudate activity during reward;
UCEC	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.64	5.84	0.43	3.29e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.04	7.99	0.55	3.62e-13	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.59	-5.88	-0.44	2.65e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.69	-7.09	-0.5	5.11e-11	Response to antineoplastic agents;
UCEC	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg18240653	chr6:144019428	PHACTR2	-0.63	-4.69	-0.36	6.31e-6	Obesity-related traits;
UCEC	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-5.6	-0.42	1.05e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.64	-0.36	7.5e-6	Parkinson's disease;
UCEC	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.21	0.39	6.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg21856205	chr7:94953877	PON1	-0.53	-4.79	-0.37	4.05e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.45	0.47	1.56e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.43	4.83	0.37	3.34e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	0.76	7.79	0.54	1.11e-12	Parkinson's disease;
UCEC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg05991184	chr2:219186017	PNKD	0.52	5.69	0.43	6.56e-8	Colorectal cancer;
UCEC	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.57	-6.16	-0.45	6.58e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.71	6.72	0.48	3.73e-10	Bladder cancer;
UCEC	cis	rs12618769	0.652	rs4851144	chr2:99220707	T/C	cg10123293	chr2:99228465	UNC50	0.49	5.51	0.41	1.56e-7	Bipolar disorder;
UCEC	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.46	-4.75	-0.36	4.83e-6	Metabolite levels (Pyroglutamine);
UCEC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.51	5.27	0.4	4.7e-7	Obesity-related traits;
UCEC	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.36	-0.4	3.15e-7	Chronic sinus infection;
UCEC	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.87	-0.37	2.79e-6	Aortic root size;
UCEC	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.39	4.76	0.37	4.52e-6	Refractive error;
UCEC	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.59	5.24	0.4	5.39e-7	Corneal astigmatism;
UCEC	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.87	-12.6	-0.72	3.72e-25	Urate levels in lean individuals;
UCEC	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.57	5.18	0.39	7.09e-7	Systemic lupus erythematosus;
UCEC	cis	rs2274471	0.532	rs7868821	chr9:5065642	A/G	cg03390472	chr9:5043263	JAK2	-0.44	-4.55	-0.35	1.12e-5	Crohn's disease;
UCEC	cis	rs12137294	0.866	rs896318	chr1:205205784	A/G	cg12580275	chr1:205744413	RAB7L1	0.43	4.78	0.37	4.2e-6	Red cell distribution width;
UCEC	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg01072550	chr1:21505969	NA	-0.59	-5.62	-0.42	9.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.46	4.7	0.36	5.84e-6	Coronary artery disease;
UCEC	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs9341808	0.667	rs583426	chr6:80946687	G/A	cg08355045	chr6:80787529	NA	-0.39	-4.96	-0.38	1.96e-6	Sitting height ratio;
UCEC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg26114124	chr12:9217669	LOC144571	0.4	4.78	0.37	4.3e-6	Sjögren's syndrome;
UCEC	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.1	5.31	0.4	4.05e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.62	-5.34	-0.4	3.5e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.56	6.67	0.48	4.89e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.91	-0.9	1.28e-54	Myeloid white cell count;
UCEC	cis	rs7246967	0.673	rs34376806	chr19:22900861	A/G	cg24889512	chr19:22816950	ZNF492	0.62	6.62	0.48	6.15e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.56	-6.36	-0.46	2.39e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-7.36	-0.52	1.23e-11	Resting heart rate;
UCEC	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-0.93	-7.82	-0.54	9.57e-13	Carotid plaque burden;
UCEC	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-10.52	-0.66	1.21e-19	Ulcerative colitis;
UCEC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.45	-4.95	-0.38	1.98e-6	Electroencephalogram traits;
UCEC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.73	-7.29	-0.52	1.75e-11	Aortic root size;
UCEC	cis	rs11083866	0.695	rs10418576	chr19:29750629	A/T	cg03065476	chr19:29284229	NA	0.44	5.3	0.4	4.17e-7	Lentiform nucleus volume;
UCEC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.56	5.17	0.39	7.54e-7	Coronary artery disease;
UCEC	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.59	5.81	0.43	3.74e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	0.8	6.25	0.46	4.24e-9	Corneal structure;
UCEC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.56	6.08	0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10503871	0.685	rs7824823	chr8:30322735	G/T	cg26383811	chr8:30366931	RBPMS	-0.49	-5.09	-0.39	1.09e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.53	0.35	1.23e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.49	4.95	0.38	1.97e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.54	7.91	0.55	5.57e-13	Coronary artery disease or large artery stroke;
UCEC	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.6e-9	Motion sickness;
UCEC	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.67	-7.04	-0.5	6.74e-11	Blood metabolite levels;
UCEC	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.11	7.26	0.51	2.05e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.61	5.75	0.43	4.94e-8	Lung cancer;
UCEC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg08755490	chr11:65554678	OVOL1	0.49	5.11	0.39	9.7e-7	Acne (severe);
UCEC	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.66	5.08	0.39	1.12e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.53	-5.51	-0.41	1.55e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.51	4.67	0.36	6.73e-6	Lung cancer;
UCEC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10053473	chr17:62856997	LRRC37A3	-0.71	-7.63	-0.53	2.72e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.55	4.67	0.36	6.67e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.69	5.17	0.39	7.37e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.87	5.85	0.43	3.08e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23156509	chr2:114033830	PAX8;LOC440839	-0.45	-4.63	-0.36	7.84e-6	Lymphocyte counts;
UCEC	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.36	5.09	0.39	1.1e-6	Melanoma;
UCEC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg14438399	chr17:27053147	TLCD1	0.59	4.79	0.37	3.95e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.86	-8.92	-0.59	1.72e-15	Height;
UCEC	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-8.33	-0.57	5.22e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	4.55	0.35	1.1e-5	Obesity-related traits;
UCEC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg26011156	chr1:156183096	PMF1	0.43	4.69	0.36	6.19e-6	Tonsillectomy;
UCEC	cis	rs6793245	0.960	rs7373779	chr3:38593943	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-5.2	-0.39	6.55e-7	QT interval;
UCEC	cis	rs9650657	0.812	rs11250073	chr8:10632236	G/T	cg00629382	chr8:10268916	MSRA	-0.48	-4.75	-0.37	4.7e-6	Neuroticism;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.61	-0.42	9.85e-8	Pubertal anthropometrics;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.39	-4.51	-0.35	1.3e-5	Myopia;
UCEC	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg05962950	chr11:130786565	SNX19	0.5	4.66	0.36	6.96e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4478037	1.000	rs59622575	chr3:33162249	A/C	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs7712401	0.791	rs6872932	chr5:122145636	A/G	cg18764291	chr5:122110994	SNX2	0.48	4.63	0.36	7.81e-6	Mean platelet volume;
UCEC	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.59	4.6	0.35	9.02e-6	Obesity-related traits;
UCEC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.5	6.09	0.45	9.39e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg06456738	chr11:66361081	CCDC87;CCS	0.56	4.65	0.36	7.23e-6	Airway imaging phenotypes;
UCEC	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.78	0.54	1.2e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.69	7.81	0.54	1.01e-12	Menopause (age at onset);
UCEC	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.45	-5.15	-0.39	8.16e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.14	0.51	3.88e-11	Tonsillectomy;
UCEC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.55	-6.38	-0.47	2.14e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.71	-6.83	-0.49	2.11e-10	Aortic root size;
UCEC	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.45	-4.66	-0.36	7.12e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg11632617	chr15:75315747	PPCDC	-0.6	-6.76	-0.49	3.02e-10	Lung cancer;
UCEC	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-5.0	-0.38	1.64e-6	Response to antipsychotic treatment;
UCEC	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.53	4.93	0.38	2.16e-6	Lung cancer;
UCEC	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-0.67	-5.4	-0.41	2.64e-7	Morning vs. evening chronotype;
UCEC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.74	-0.43	5.24e-8	Chronic sinus infection;
UCEC	cis	rs17122693	1.000	rs17122693	chr14:51084235	C/T	cg04730355	chr14:51134070	SAV1	-0.89	-9.04	-0.6	8.57e-16	Cognitive performance;
UCEC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.78	-8.68	-0.58	7.07e-15	Monocyte count;
UCEC	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-0.85	-8.26	-0.56	7.56e-14	Coronary artery disease;
UCEC	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.86	7.15	0.51	3.75e-11	Prostate cancer;
UCEC	cis	rs1639906	0.560	rs1108036	chr7:2263354	A/G	cg13470333	chr7:1908714	MAD1L1	0.41	4.63	0.36	8.14e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg21419209	chr3:44054225	NA	0.45	4.62	0.36	8.33e-6	Coronary artery disease;
UCEC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.46	4.66	0.36	7.12e-6	Schizophrenia;
UCEC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg05962950	chr11:130786565	SNX19	0.51	5.2	0.39	6.43e-7	Schizophrenia;
UCEC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.53	4.76	0.37	4.55e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	0.87	5.08	0.39	1.11e-6	Diabetic retinopathy;
UCEC	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.28e-21	Breast cancer;
UCEC	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg26703956	chr19:39260304	NA	-0.38	-4.77	-0.37	4.32e-6	Heart rate;
UCEC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg06238570	chr21:40685208	BRWD1	0.78	7.58	0.53	3.54e-12	Cognitive function;
UCEC	cis	rs17106184	0.892	rs72900928	chr1:51103180	T/G	cg07174182	chr1:51127561	FAF1	-0.73	-4.69	-0.36	6.08e-6	Type 2 diabetes;
UCEC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg24069376	chr3:38537580	EXOG	0.4	5.04	0.38	1.37e-6	Electrocardiographic conduction measures;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.49	-0.47	1.25e-9	Longevity;Endometriosis;
UCEC	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.63	-6.93	-0.5	1.26e-10	Neurofibrillary tangles;
UCEC	cis	rs12545109	0.807	rs13263281	chr8:57346582	C/A	cg09654669	chr8:57350985	NA	-0.45	-4.99	-0.38	1.72e-6	Obesity-related traits;
UCEC	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-5.82	-0.43	3.62e-8	Gut microbiome composition (summer);
UCEC	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.54	-0.42	1.37e-7	Metabolite levels;
UCEC	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-5.83	-0.43	3.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7246967	0.673	rs8105441	chr19:22891466	T/C	cg05241461	chr19:22816980	ZNF492	0.58	6.12	0.45	8e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs883115	1.000	rs1353837	chr1:224816039	T/G	cg01808320	chr1:224927238	CNIH3	-0.38	-4.51	-0.35	1.33e-5	Cancer;
UCEC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.42	4.91	0.38	2.43e-6	Blood protein levels;
UCEC	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg20119798	chr7:94954144	PON1	-0.49	-4.62	-0.36	8.38e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.67	7.01	0.5	7.93e-11	Lymphocyte counts;
UCEC	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.72	-7.81	-0.54	1.02e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.79	-8.86	-0.59	2.48e-15	Breast cancer;
UCEC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg18681998	chr4:17616180	MED28	0.91	11.94	0.7	2.17e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.56	6.27	0.46	3.89e-9	Platelet count;
UCEC	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.67	5.31	0.4	4.03e-7	Corneal astigmatism;
UCEC	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.46	5.29	0.4	4.35e-7	Blood metabolite ratios;
UCEC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.66	7.03	0.5	7.28e-11	Longevity;Endometriosis;
UCEC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.57	5.64	0.42	8.53e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.73	-8.03	-0.55	2.91e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.53	7.17	0.51	3.32e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.22	0.4	6.07e-7	Electroencephalogram traits;
UCEC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.35	4.91	0.38	2.43e-6	Crohn's disease;
UCEC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.58	6.74	0.49	3.42e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.72	-8.31	-0.57	5.95e-14	Waist circumference;Body mass index;
UCEC	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.5	5.84	0.43	3.25e-8	Longevity;
UCEC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg01485075	chr19:22817371	ZNF492	0.41	4.51	0.35	1.3e-5	Bronchopulmonary dysplasia;
UCEC	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg06096015	chr1:231504339	EGLN1	0.46	5.32	0.4	3.79e-7	Hemoglobin concentration;
UCEC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg02160872	chr5:212506	CCDC127	-0.7	-6.27	-0.46	3.73e-9	Asthma (childhood onset);
UCEC	cis	rs1816854	0.938	rs10506231	chr12:44206027	C/T	cg00106942	chr12:44200524	TWF1	0.51	5.4	0.41	2.66e-7	Inflammatory bowel disease;
UCEC	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.58	-5.8	-0.43	3.99e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg12524725	chr2:239427019	NA	-0.62	-4.53	-0.35	1.23e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-0.93	-5.42	-0.41	2.42e-7	Mitochondrial DNA levels;
UCEC	cis	rs2882667	0.654	rs10044432	chr5:138274896	C/T	cg05839636	chr5:137878905	ETF1	0.55	4.51	0.35	1.3e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg04673462	chr1:38461896	NA	0.65	6.25	0.46	4.16e-9	Coronary artery disease;
UCEC	cis	rs9469578	1.000	rs6923565	chr6:33707112	G/A	cg18708504	chr6:33715942	IP6K3	0.52	5.11	0.39	9.93e-7	Phosphorus levels;
UCEC	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.46	5.04	0.38	1.32e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.47	0.41	1.88e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg08271804	chr19:22816896	ZNF492	0.66	6.62	0.48	6.39e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.43	5.77	0.43	4.57e-8	Alcohol dependence;
UCEC	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.41	0.41	2.49e-7	Aortic root size;
UCEC	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.6	-6.15	-0.45	7.01e-9	Platelet distribution width;
UCEC	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.07	-0.39	1.18e-6	Total cholesterol levels;
UCEC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	7.25	0.51	2.2e-11	Homoarginine levels;
UCEC	cis	rs4372836	0.543	rs10204329	chr2:28998077	C/G	cg09522027	chr2:28974177	PPP1CB	-0.73	-8.15	-0.56	1.42e-13	Body mass index;
UCEC	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.68	-7.69	-0.54	1.91e-12	Breast cancer;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.46	-5.11	-0.39	9.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17123764	0.710	rs11169118	chr12:50102535	C/T	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.37	5.34	0.4	3.49e-7	Ulcerative colitis;
UCEC	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.49	4.89	0.37	2.58e-6	Migraine;
UCEC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.28	10.69	0.66	4.29e-20	Uric acid levels;
UCEC	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.61	-6.72	-0.48	3.67e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs77972916	0.561	rs72788900	chr2:43559087	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.78	-0.37	4.19e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.49	-6.01	-0.44	1.37e-8	Mean platelet volume;
UCEC	cis	rs259282	0.524	rs3760941	chr19:33130866	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.54	0.42	1.37e-7	Schizophrenia;
UCEC	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.38	-4.94	-0.38	2.14e-6	Type 2 diabetes;
UCEC	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg05874882	chr4:1763078	NA	-0.55	-5.8	-0.43	3.99e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.78	6.13	0.45	7.7e-9	Lymphocyte counts;
UCEC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.69	-7.86	-0.54	7.64e-13	Menopause (age at onset);
UCEC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.6	6.63	0.48	5.86e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.65	-6.89	-0.49	1.53e-10	Systemic sclerosis;
UCEC	cis	rs2519974	0.530	rs1012004	chr16:22911748	C/T	cg15042806	chr16:23652268	DCTN5;PALB2	0.42	4.67	0.36	6.65e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide);
UCEC	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg01236616	chr12:121019343	POP5	0.57	4.6	0.35	9.16e-6	High light scatter reticulocyte count;
UCEC	cis	rs7212590	0.529	rs60283440	chr17:57994248	T/C	cg10252138	chr17:58120427	NA	-0.72	-4.63	-0.36	7.85e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs9326726	0.844	rs34413	chr5:107529421	C/T	cg17432647	chr5:107996819	NA	0.51	4.82	0.37	3.47e-6	Resting heart rate;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.63	6.91	0.5	1.34e-10	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-6.03	-0.45	1.28e-8	Bipolar disorder;
UCEC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	5.44	0.41	2.14e-7	Platelet count;
UCEC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.64	-5.54	-0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.63	4.96	0.38	1.94e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.25	-0.51	2.23e-11	Monocyte count;
UCEC	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.54	5.49	0.41	1.68e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.56	-7.11	-0.51	4.79e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.6	-7.09	-0.5	5.14e-11	Breast cancer;
UCEC	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg11150807	chr10:43354902	NA	0.78	6.52	0.47	1.05e-9	Blood protein levels;
UCEC	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.66	-6.31	-0.46	3.16e-9	Acne (severe);
UCEC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.97	5.43	0.41	2.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.61	-5.71	-0.43	6.17e-8	Acne (severe);
UCEC	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6820391	0.590	rs4864802	chr4:54450331	T/C	cg04173182	chr4:54446035	LNX1	0.38	4.67	0.36	6.66e-6	Cervical artery dissection;
UCEC	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.72e-7	Heart rate;
UCEC	cis	rs4965359	0.737	rs7169099	chr15:101575202	G/T	cg15200994	chr15:101606846	LRRK1	-0.48	-5.51	-0.41	1.55e-7	Central corneal thickness;
UCEC	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05472934	chr7:22766657	IL6	0.77	7.69	0.54	1.94e-12	Lung cancer;
UCEC	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg00325661	chr8:49890786	NA	-0.52	-5.58	-0.42	1.14e-7	Sudden cardiac arrest;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.51	5.18	0.39	7.16e-7	Longevity;Endometriosis;
UCEC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.82	8.76	0.59	4.41e-15	Blood protein levels;
UCEC	cis	rs1401999	0.541	rs6765152	chr3:183756780	A/C	cg01324343	chr3:183735012	ABCC5	0.61	6.38	0.47	2.19e-9	Anterior chamber depth;
UCEC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg02160872	chr5:212506	CCDC127	-0.7	-7.39	-0.52	1.02e-11	Breast cancer;
UCEC	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.72	6.78	0.49	2.76e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.42	5.04	0.38	1.35e-6	Prostate cancer;
UCEC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18252515	chr7:66147081	NA	0.45	4.61	0.36	8.64e-6	Aortic root size;
UCEC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	6.05	0.45	1.17e-8	Prudent dietary pattern;
UCEC	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.26	-0.46	4.07e-9	Caudate activity during reward;
UCEC	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.49	-6.52	-0.47	1.07e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.69	-7.07	-0.5	5.73e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg08027265	chr7:2291960	NA	-0.47	-4.95	-0.38	1.97e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	6.09	0.45	9.46e-9	Initial pursuit acceleration;
UCEC	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.8	0.37	3.94e-6	Multiple sclerosis;
UCEC	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.55	6.12	0.45	8.08e-9	Height;
UCEC	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg05802129	chr4:122689817	NA	-0.55	-5.54	-0.42	1.33e-7	Type 2 diabetes;
UCEC	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	6.43	0.47	1.7e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04584833	chr17:1928794	RTN4RL1	0.58	6.88	0.49	1.57e-10	Warfarin maintenance dose;
UCEC	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.32	5.06	0.38	1.25e-6	Cancer;
UCEC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.67	5.15	0.39	8.34e-7	Mean platelet volume;
UCEC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.34	0.4	3.47e-7	Rheumatoid arthritis;
UCEC	cis	rs12618769	0.597	rs3769713	chr2:99151434	A/G	cg10123293	chr2:99228465	UNC50	0.43	4.77	0.37	4.31e-6	Bipolar disorder;
UCEC	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.62	-6.53	-0.47	9.81e-10	Autism;
UCEC	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.64	5.38	0.41	2.84e-7	High light scatter reticulocyte count;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.77	8.84	0.59	2.65e-15	Menarche (age at onset);
UCEC	cis	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.38	4.59	0.35	9.27e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.32	-0.4	3.71e-7	Pediatric autoimmune diseases;
UCEC	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.51	6.8	0.49	2.4e-10	Bone mineral density;
UCEC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.65	-7.05	-0.5	6.59e-11	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg08890418	chr1:21044141	KIF17	0.61	6.38	0.47	2.16e-9	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg17325771	chr7:75508891	RHBDD2	0.49	5.9	0.44	2.46e-8	Eotaxin levels;
UCEC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-5.01	-0.38	1.55e-6	Morning vs. evening chronotype;
UCEC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg03354898	chr7:1950403	MAD1L1	-0.48	-4.56	-0.35	1.05e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg03543861	chr21:44258195	NA	0.48	5.18	0.39	7.34e-7	Information processing speed;
UCEC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12980942	0.591	rs11879435	chr19:41757603	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.72	0.43	5.8e-8	Coronary artery disease;
UCEC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.66	6.28	0.46	3.7e-9	Lymphocyte counts;
UCEC	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1e-7	Life satisfaction;
UCEC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.55	4.69	0.36	6.07e-6	Selective IgA deficiency;
UCEC	cis	rs9467773	0.967	rs1321482	chr6:26575154	T/C	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.94	8.24	0.56	8.96e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18099408	chr3:52552593	STAB1	-0.49	-5.75	-0.43	4.88e-8	Bipolar disorder;
UCEC	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg18681998	chr4:17616180	MED28	-0.52	-5.82	-0.43	3.54e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg24733560	chr20:60626293	TAF4	0.38	4.53	0.35	1.21e-5	Body mass index;
UCEC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg23815491	chr16:72088622	HP	0.37	4.64	0.36	7.74e-6	Fibrinogen levels;
UCEC	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.56	5.08	0.39	1.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.78	-8.08	-0.55	2.16e-13	Blood protein levels;
UCEC	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.35	0.46	2.49e-9	Coronary artery disease;
UCEC	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.54	5.88	0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg13460858	chr9:96720652	NA	0.41	4.59	0.35	9.28e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg26114124	chr12:9217669	LOC144571	0.39	4.67	0.36	6.87e-6	Sjögren's syndrome;
UCEC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-4.51	-0.35	1.32e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg02366345	chr4:152330872	FAM160A1	0.35	4.73	0.36	5.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.48	5.29	0.4	4.4e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.55	4.79	0.37	4.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7517126	1.000	rs13375150	chr1:196841839	C/T	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.6	-5.19	-0.39	6.99e-7	Systemic lupus erythematosus;
UCEC	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.63	6.62	0.48	6.42e-10	Immature fraction of reticulocytes;
UCEC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.4	-4.62	-0.36	8.26e-6	Total body bone mineral density;
UCEC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.87	0.59	2.29e-15	Blood protein levels;
UCEC	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.14	12.16	0.71	5.45e-24	Opioid sensitivity;
UCEC	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg08493051	chr2:3487164	NA	-0.58	-5.45	-0.41	2.09e-7	Neurofibrillary tangles;
UCEC	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.62	-5.58	-0.42	1.1e-7	Pulmonary function;
UCEC	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.74e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.71	6.16	0.45	6.59e-9	Alzheimer's disease;
UCEC	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.91	-6.79	-0.49	2.63e-10	Exhaled nitric oxide output;
UCEC	cis	rs939574	0.586	rs3731892	chr2:220136351	G/C	cg01357713	chr2:219696528	PRKAG3	0.77	5.7	0.43	6.34e-8	Platelet distribution width;
UCEC	cis	rs7246967	0.866	rs34752785	chr19:23044573	T/A	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.46	-7.14	-0.51	4e-11	Ulcerative colitis;
UCEC	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.63	-6.09	-0.45	9.47e-9	Metabolite levels;
UCEC	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.52	5.26	0.4	4.92e-7	Colorectal cancer;
UCEC	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.89	11.29	0.68	1.14e-21	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg06798572	chr14:100842754	WARS;WDR25	0.42	4.62	0.36	8.47e-6	Alzheimer's disease (survival time);
UCEC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg19318889	chr4:1322082	MAEA	0.52	5.58	0.42	1.13e-7	Obesity-related traits;
UCEC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	0.84	7.32	0.52	1.48e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg14092571	chr14:90743983	NA	-0.44	-5.83	-0.43	3.4e-8	Mortality in heart failure;
UCEC	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	4.5	0.35	1.35e-5	Monocyte count;
UCEC	cis	rs36051895	0.555	rs6476953	chr9:5248742	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-4.58	-0.35	9.98e-6	Pediatric autoimmune diseases;
UCEC	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg22166914	chr1:53195759	ZYG11B	-0.64	-7.01	-0.5	8.17e-11	Monocyte count;
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.79	-7.16	-0.51	3.64e-11	Corneal structure;
UCEC	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Amyotrophic lateral sclerosis (age of onset);
UCEC	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg23950597	chr19:37808831	NA	-0.81	-5.08	-0.39	1.14e-6	Coronary artery calcification;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.35	-0.4	3.37e-7	Pubertal anthropometrics;
UCEC	cis	rs829661	0.894	rs1252624	chr2:30747083	G/T	cg17749961	chr2:30669863	LCLAT1	0.5	4.63	0.36	8.09e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.79	6.88	0.49	1.64e-10	Longevity;
UCEC	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.71	-6.72	-0.48	3.72e-10	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.09	-0.39	1.08e-6	Parkinson's disease;
UCEC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.43	-0.47	1.71e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg05072774	chr3:49840536	C3orf54	-0.52	-5.33	-0.4	3.6e-7	Resting heart rate;
UCEC	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.51	5.15	0.39	8.21e-7	Breast cancer;
UCEC	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.6	5.69	0.42	6.72e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs11867410	0.744	rs56281632	chr17:63981910	C/T	cg06996976	chr17:64576105	PRKCA	-0.72	-4.55	-0.35	1.13e-5	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.88	0.37	2.7e-6	Rheumatoid arthritis;
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2795502	0.564	rs11239826	chr10:43403097	T/C	cg11150807	chr10:43354902	NA	0.79	5.05	0.38	1.29e-6	Blood protein levels;
UCEC	cis	rs17600642	0.694	rs56055213	chr10:72445307	T/C	cg23422916	chr10:72218225	NA	-0.55	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs7113850	0.541	rs7107667	chr11:24224091	T/A	ch.11.24196551F	chr11:24239977	NA	0.7	4.69	0.36	6.24e-6	Bone fracture in osteoporosis;
UCEC	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.63	7.53	0.53	4.81e-12	Prevalent atrial fibrillation;
UCEC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs2062225	1.000	rs1471691	chr2:111742329	T/A	cg23782758	chr2:111737646	ACOXL	-0.64	-4.63	-0.36	8.14e-6	Monocyte count;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.37	-0.47	2.27e-9	Pulmonary function;
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.76	7.99	0.55	3.56e-13	Prudent dietary pattern;
UCEC	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.53	-5.43	-0.41	2.3e-7	Refractive error;
UCEC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg04013166	chr16:89971882	TCF25	0.71	4.55	0.35	1.11e-5	Skin colour saturation;
UCEC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.74	-8.54	-0.58	1.59e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.31	0.52	1.59e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.53	5.15	0.39	8.1e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs883565	0.528	rs35946914	chr3:38992107	A/G	cg01426195	chr3:39028469	NA	-0.46	-5.12	-0.39	9.41e-7	Handedness;
UCEC	cis	rs151997	1.000	rs27284	chr5:50198086	A/G	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg10820045	chr2:198174542	NA	-0.46	-5.84	-0.43	3.16e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg04155289	chr7:94953770	PON1	-0.48	-4.83	-0.37	3.35e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4499344	0.623	rs259278	chr19:33161126	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	9.07	0.6	7.03e-16	Mean platelet volume;
UCEC	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg00334056	chr6:33755658	LEMD2	-0.42	-4.55	-0.35	1.11e-5	Crohn's disease;
UCEC	cis	rs9402633	0.938	rs9385695	chr6:135035372	C/T	cg16239184	chr6:135079577	NA	0.5	4.77	0.37	4.46e-6	Platelet count;
UCEC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg22166914	chr1:53195759	ZYG11B	-0.64	-6.95	-0.5	1.09e-10	Monocyte count;
UCEC	cis	rs17123764	0.818	rs3887728	chr12:49972332	G/A	cg20471783	chr12:50157085	TMBIM6	0.61	4.89	0.37	2.65e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg02900749	chr2:68251473	NA	-0.84	-6.85	-0.49	1.84e-10	Pursuit maintenance gain;
UCEC	cis	rs262147	0.562	rs2730207	chr7:158746411	A/G	cg24397884	chr7:158709396	WDR60	-1.0	-6.15	-0.45	6.9e-9	Hippocampal volume;
UCEC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.89	7.72	0.54	1.65e-12	Bladder cancer;
UCEC	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.85	-0.37	3.13e-6	Type 2 diabetes;
UCEC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.64	-0.36	7.57e-6	Lung cancer in ever smokers;
UCEC	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg02160872	chr5:212506	CCDC127	-0.66	-5.65	-0.42	8.14e-8	Asthma (childhood onset);
UCEC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	0.96	9.89	0.63	5.27e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-7.42	-0.52	8.63e-12	Hemoglobin concentration;
UCEC	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.51	-5.33	-0.4	3.7e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg22139774	chr2:100720529	AFF3	-0.37	-4.7	-0.36	5.88e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.0	8.12	0.56	1.72e-13	Exhaled nitric oxide output;
UCEC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg26898376	chr11:64110657	CCDC88B	0.48	6.1	0.45	9.12e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	0.82	9.74	0.63	1.33e-17	Bone mineral density;
UCEC	cis	rs6493487	0.512	rs1438926	chr15:51351145	G/T	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.93	5.89	0.44	2.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.86	5.24	0.4	5.57e-7	Putamen volume;
UCEC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.74	-7.69	-0.54	1.91e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.53	4.52	0.35	1.28e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs28588043	1.000	rs7882102	chr1:170985569	C/T	cg04892409	chr1:170501224	GORAB	-0.57	-4.74	-0.36	5.02e-6	Number of children (6+ vs. 0 or 1);
UCEC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg05962950	chr11:130786565	SNX19	0.52	5.02	0.38	1.49e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.58	5.35	0.4	3.34e-7	Coronary artery disease;
UCEC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.48	4.93	0.38	2.23e-6	Longevity;Endometriosis;
UCEC	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs60311166	1.000	rs56156188	chr3:52730699	T/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	4.64	0.36	7.57e-6	CTACK levels;
UCEC	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-0.66	-5.97	-0.44	1.74e-8	Alzheimer's disease or small vessel stroke;
UCEC	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.71	7.04	0.5	6.66e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	5.05	0.38	1.3e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.75	-8.62	-0.58	9.78e-15	Menarche (age at onset);
UCEC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.79	8.34	0.57	4.94e-14	Longevity;Endometriosis;
UCEC	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	5.79	0.43	4.21e-8	Joint mobility (Beighton score);
UCEC	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2892463	0.796	rs9550494	chr13:30376259	C/G	cg18356743	chr13:30408050	UBL3	0.41	4.58	0.35	9.74e-6	Non-word repetition;
UCEC	cis	rs2473248	0.935	rs2744729	chr1:22546110	T/C	cg22683154	chr1:23345188	KDM1A	0.43	4.53	0.35	1.22e-5	Birth weight;
UCEC	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.26	-0.51	2.07e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-6.03	-0.45	1.26e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.62	4.96	0.38	1.89e-6	Menarche (age at onset);
UCEC	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.48	4.69	0.36	6.29e-6	Neuroticism;
UCEC	cis	rs925228	0.910	rs1516427	chr2:24199259	T/C	cg13272742	chr2:24272458	FKBP1B	0.6	5.15	0.39	8.3e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.01	0.64	2.65e-18	Menopause (age at onset);
UCEC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg09655341	chr17:79618100	PDE6G	-0.3	-4.54	-0.35	1.15e-5	Eye color traits;
UCEC	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg14092571	chr14:90743983	NA	-0.38	-4.7	-0.36	5.94e-6	Mortality in heart failure;
UCEC	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.65	-0.42	8.15e-8	Hemoglobin concentration;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.65	7.05	0.5	6.57e-11	Menarche (age at onset);
UCEC	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.59	4.81	0.37	3.66e-6	Lymphocyte counts;
UCEC	cis	rs7246967	0.673	rs12980342	chr19:22849357	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.7	9.13	0.6	5.02e-16	Mean platelet volume;
UCEC	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.8	-6.22	-0.46	4.84e-9	Corneal structure;
UCEC	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.15	-0.64	1.12e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7975161	0.753	rs7972034	chr12:104640881	G/T	cg25273343	chr12:104657179	TXNRD1	-0.79	-4.89	-0.37	2.64e-6	Toenail selenium levels;
UCEC	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs9467773	1.000	rs6918360	chr6:26577867	A/T	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.63	-7.09	-0.5	5.17e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.78	-7.84	-0.54	8.3e-13	Mosquito bite size;
UCEC	cis	rs4919044	0.866	rs11187265	chr10:94824166	G/A	cg00519463	chr10:94352821	KIF11	0.96	5.36	0.4	3.11e-7	Coronary artery disease;
UCEC	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.54	-6.0	-0.44	1.45e-8	Diastolic blood pressure;
UCEC	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.75	-4.77	-0.37	4.33e-6	Night sleep phenotypes;
UCEC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.33	-5.75	-0.43	4.91e-8	Mean corpuscular volume;
UCEC	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.64	-7.04	-0.5	6.84e-11	Vitiligo;
UCEC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.47	4.53	0.35	1.19e-5	Obesity-related traits;
UCEC	cis	rs6737417	1.000	rs10498108	chr2:222209541	A/G	cg13231700	chr2:222435709	EPHA4	0.42	5.15	0.39	8.31e-7	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
UCEC	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.67	5.72	0.43	5.8e-8	Obesity (extreme);
UCEC	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.54	-5.61	-0.42	9.81e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	4.55	0.35	1.13e-5	IgG glycosylation;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg15687855	chr3:44754131	ZNF502	0.45	4.7	0.36	5.81e-6	Depressive symptoms;
UCEC	cis	rs2425143	0.558	rs7274724	chr20:34539466	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.6	-0.35	8.93e-6	Blood protein levels;
UCEC	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.49	0.62	5.74e-17	Platelet count;
UCEC	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	5.88	0.44	2.67e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.44	-0.41	2.2e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.4	4.9	0.37	2.46e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.43	-0.72	1.07e-24	Ulcerative colitis;
UCEC	cis	rs7611694	0.501	rs6438144	chr3:113123328	A/G	cg11138929	chr3:113251189	SIDT1	0.4	4.58	0.35	9.83e-6	Prostate cancer;
UCEC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.63	6.29	0.46	3.38e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg19875535	chr5:140030758	IK	0.44	4.87	0.37	2.91e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg26114124	chr12:9217669	LOC144571	0.41	5.08	0.39	1.12e-6	Sjögren's syndrome;
UCEC	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.69	5.66	0.42	7.84e-8	Major depressive disorder;
UCEC	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.39	5.25	0.4	5.14e-7	Urate levels in overweight individuals;
UCEC	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.54	-5.68	-0.42	6.93e-8	Glomerular filtration rate;
UCEC	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-5.5	-0.41	1.61e-7	Hepatocellular carcinoma;
UCEC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	4.72	0.36	5.34e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs9283706	0.623	rs1567316	chr5:66312103	T/G	cg11590213	chr5:66331682	MAST4	0.44	5.03	0.38	1.41e-6	Coronary artery disease;
UCEC	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.89	6.22	0.46	4.9e-9	Major depressive disorder;
UCEC	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg01072550	chr1:21505969	NA	0.6	6.23	0.46	4.74e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.38	-4.8	-0.37	3.94e-6	Blood protein levels;
UCEC	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.01	8.54	0.58	1.53e-14	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-4.81	-0.37	3.66e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2862064	1.000	rs2902128	chr5:156421347	C/T	cg12943317	chr5:156479607	HAVCR1	-0.88	-6.58	-0.48	7.56e-10	Platelet count;
UCEC	cis	rs758129	0.501	rs1054875	chr15:89879126	A/T	cg23124613	chr15:89731485	ABHD2	-0.42	-4.79	-0.37	4.09e-6	Schizophrenia;
UCEC	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.33	-0.4	3.55e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	0.74	6.12	0.45	8.25e-9	Type 2 diabetes nephropathy;
UCEC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.68	6.24	0.46	4.34e-9	Aortic root size;
UCEC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs8105895	0.935	rs62112920	chr19:22227149	A/G	cg24072202	chr19:22235272	ZNF257	-0.56	-4.66	-0.36	6.89e-6	Body mass index (change over time);
UCEC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	6.85	0.49	1.87e-10	Eye color traits;
UCEC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.43	-5.7	-0.43	6.35e-8	Prostate cancer;
UCEC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	0.898	rs11253353	chr10:766862	C/A	cg17470449	chr10:769945	NA	0.58	4.93	0.38	2.21e-6	Uric acid levels;
UCEC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg22974920	chr21:40686053	BRWD1	0.61	5.43	0.41	2.27e-7	Cognitive function;
UCEC	cis	rs72949976	0.734	rs62189579	chr2:214016984	T/A	cg08319019	chr2:214017104	IKZF2	-0.69	-6.51	-0.47	1.13e-9	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.55	-6.0	-0.44	1.47e-8	Diastolic blood pressure;
UCEC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.53	5.39	0.41	2.79e-7	Aortic root size;
UCEC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.6	0.53	3.21e-12	Total cholesterol levels;
UCEC	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.71	7.29	0.52	1.81e-11	Longevity;Endometriosis;
UCEC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg18827107	chr12:86230957	RASSF9	-0.44	-4.77	-0.37	4.32e-6	Major depressive disorder;
UCEC	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22857025	chr5:266934	NA	1.0	9.74	0.63	1.32e-17	Breast cancer;
UCEC	cis	rs75804782	0.515	rs79557340	chr2:239297952	G/A	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.02	-0.44	1.33e-8	Resting heart rate;
UCEC	cis	rs7917772	0.715	rs7077678	chr10:104438565	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.47	4.86	0.37	2.99e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-0.98	-8.56	-0.58	1.39e-14	White matter hyperintensity burden;
UCEC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.78	0.43	4.33e-8	Menarche (age at onset);
UCEC	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.74	5.03	0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.62	-0.36	8.37e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.46	2.58e-9	Aortic root size;
UCEC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-4.98	-0.38	1.79e-6	Blood metabolite levels;
UCEC	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg19041857	chr6:27730383	NA	-0.61	-4.98	-0.38	1.75e-6	Depression;
UCEC	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.53	-5.09	-0.39	1.06e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.61	6.21	0.46	5.12e-9	Dental caries;
UCEC	cis	rs12618769	0.652	rs72823796	chr2:99227812	C/T	cg10123293	chr2:99228465	UNC50	0.49	5.37	0.4	3.03e-7	Bipolar disorder;
UCEC	cis	rs10940138	1.000	rs10940138	chr5:67194469	C/T	ch.5.1281357F	chr5:67228439	NA	0.64	6.6	0.48	6.83e-10	Menarche (age at onset);
UCEC	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.87	-5.81	-0.43	3.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg00800038	chr16:89945340	TCF25	-0.79	-4.61	-0.36	8.81e-6	Skin colour saturation;
UCEC	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	1.1	6.53	0.47	1.01e-9	Parkinson's disease;
UCEC	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.65	6.34	0.46	2.6e-9	Bladder cancer;
UCEC	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-4.78	-0.37	4.14e-6	Mitochondrial DNA levels;
UCEC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.92	-11.5	-0.69	3.08e-22	Monocyte count;
UCEC	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	4.8	0.37	3.83e-6	Electrocardiographic conduction measures;
UCEC	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.93	8.11	0.56	1.81e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.31	4.55	0.35	1.11e-5	Body mass index;
UCEC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.29	0.4	4.34e-7	Cognitive test performance;
UCEC	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	7.76	0.54	1.35e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.77	4.82	0.37	3.62e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17106184	1.000	rs12089041	chr1:51381594	C/T	cg07174182	chr1:51127561	FAF1	-0.64	-4.95	-0.38	1.98e-6	Type 2 diabetes;
UCEC	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.61	-6.29	-0.46	3.42e-9	Retinal vascular caliber;
UCEC	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.42	4.59	0.35	9.56e-6	Mean corpuscular volume;
UCEC	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.73	5.27	0.4	4.88e-7	Bipolar disorder;
UCEC	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.55	-4.62	-0.36	8.43e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.52	-5.4	-0.41	2.67e-7	Hepatocellular carcinoma;
UCEC	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.42	4.74	0.36	5e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg26114124	chr12:9217669	LOC144571	0.41	4.86	0.37	2.98e-6	Sjögren's syndrome;
UCEC	cis	rs10242455	0.867	rs2687136	chr7:99325882	C/T	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.42	-5.5	-0.41	1.67e-7	Monocyte count;
UCEC	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-5.71	-0.43	6.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs944990	0.618	rs10821174	chr9:96362629	G/A	cg13787134	chr9:96362102	PHF2	-0.37	-4.96	-0.38	1.92e-6	Body mass index;
UCEC	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-4.54	-0.35	1.18e-5	Mood instability;
UCEC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13683864	chr3:40499215	RPL14	-0.84	-8.1	-0.56	1.93e-13	Renal cell carcinoma;
UCEC	cis	rs10242455	0.867	rs2687087	chr7:99294472	G/A	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.29e-6	Blood metabolite levels;
UCEC	cis	rs3750082	0.855	rs6462430	chr7:32921831	G/A	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.45	5.48	0.41	1.8e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs250585	0.736	rs250581	chr16:23411837	G/A	cg26562691	chr16:23850404	PRKCB	0.34	4.51	0.35	1.32e-5	Egg allergy;
UCEC	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.59	5.14	0.39	8.77e-7	Cocaine dependence;
UCEC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.53	-5.28	-0.4	4.53e-7	Prostate cancer;
UCEC	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.4	6.01	0.44	1.38e-8	Body mass index;
UCEC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-13.15	-0.74	1.31e-26	Height;
UCEC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg11697111	chr7:1126903	GPER;C7orf50	-0.45	-4.65	-0.36	7.29e-6	Longevity;Endometriosis;
UCEC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.64	-5.54	-0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.52	-4.59	-0.35	9.6e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.79	-8.73	-0.58	5.13e-15	Cognitive function;
UCEC	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg21191810	chr6:118973309	C6orf204	0.44	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg16584290	chr5:462447	EXOC3	-0.47	-4.82	-0.37	3.52e-6	Cystic fibrosis severity;
UCEC	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.3	-0.4	4.11e-7	Aortic root size;
UCEC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.76	-8.62	-0.58	9.99e-15	Menarche (age at onset);
UCEC	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.46	-4.94	-0.38	2.13e-6	White matter hyperintensity burden;
UCEC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg01013738	chr7:1149705	C7orf50	-0.52	-4.9	-0.37	2.56e-6	Longevity;Endometriosis;
UCEC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.75	8.03	0.55	2.87e-13	Breast cancer;
UCEC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.55	5.21	0.39	6.39e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.68	6.27	0.46	3.78e-9	Corneal astigmatism;
UCEC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.38	5.91	0.44	2.24e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.59	-6.55	-0.48	8.92e-10	Bipolar disorder;
UCEC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs12216499	1.000	rs12202783	chr6:159388629	T/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.54	-0.35	1.15e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.63	-6.1	-0.45	8.89e-9	Colorectal cancer;
UCEC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.5	5.82	0.43	3.52e-8	Total body bone mineral density;
UCEC	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.52	5.3	0.4	4.2e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.48	5.37	0.4	3.07e-7	Prudent dietary pattern;
UCEC	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs36051895	0.695	rs10974922	chr9:5028813	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-4.84	-0.37	3.2e-6	Pediatric autoimmune diseases;
UCEC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.52	-7.0	-0.5	8.24e-11	Eye color traits;
UCEC	cis	rs16937	0.711	rs6682400	chr1:205173519	T/G	cg12580275	chr1:205744413	RAB7L1	0.48	5.15	0.39	8.09e-7	Schizophrenia;
UCEC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.58	5.25	0.4	5.34e-7	Corneal astigmatism;
UCEC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.73	-7.36	-0.52	1.21e-11	Height;
UCEC	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.85	-0.37	3.12e-6	Blood metabolite levels;
UCEC	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg00105475	chr2:10696890	NA	0.42	5.17	0.39	7.53e-7	Prostate cancer;
UCEC	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-5.84	-0.43	3.2e-8	Hepatocellular carcinoma;
UCEC	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.6	-4.52	-0.35	1.28e-5	Waist circumference adjusted for body mass index;
UCEC	cis	rs7246967	0.673	rs8103012	chr19:22879285	C/T	cg24889512	chr19:22816950	ZNF492	0.56	6.0	0.44	1.47e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg21419209	chr3:44054225	NA	-0.46	-4.87	-0.37	2.86e-6	Coronary artery disease;
UCEC	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.4	4.73	0.36	5.19e-6	Coronary artery disease;
UCEC	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18252515	chr7:66147081	NA	0.46	4.57	0.35	1.04e-5	Cotinine glucuronidation;
UCEC	cis	rs2116941	1.000	rs2116941	chr19:10334443	A/C	cg01850179	chr19:10340795	S1PR2	-0.48	-5.55	-0.42	1.3e-7	Pulse pressure;
UCEC	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-8.72	-0.58	5.42e-15	Total cholesterol levels;
UCEC	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.67	6.73	0.49	3.47e-10	Bladder cancer;
UCEC	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.6	5.44	0.41	2.14e-7	Obesity-related traits;
UCEC	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.94	0.59	1.54e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.43	-4.77	-0.37	4.34e-6	Height;
UCEC	cis	rs6910233	1.000	rs6910233	chr6:33534726	A/C	cg13560919	chr6:33536144	NA	0.48	4.93	0.38	2.16e-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.44	0.41	2.2e-7	Total body bone mineral density;
UCEC	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.66	-0.42	7.64e-8	Life satisfaction;
UCEC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.68	7.33	0.52	1.41e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs420259	0.516	rs9302410	chr16:23511372	C/T	cg26562691	chr16:23850404	PRKCB	-0.34	-4.56	-0.35	1.08e-5	Bipolar disorder;
UCEC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg20387954	chr3:183756860	HTR3D	0.49	5.89	0.44	2.48e-8	Anterior chamber depth;
UCEC	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.54	-5.5	-0.41	1.64e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.61	5.49	0.41	1.7e-7	Corneal astigmatism;
UCEC	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.35	-0.46	2.47e-9	Response to antipsychotic treatment;
UCEC	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.43	-5.14	-0.39	8.6e-7	Educational attainment;
UCEC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.53	5.29	0.4	4.39e-7	Aortic root size;
UCEC	cis	rs4499344	0.633	rs259239	chr19:33141090	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.74	7.53	0.53	4.75e-12	Mean platelet volume;
UCEC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.52	5.01	0.38	1.57e-6	Menopause (age at onset);
UCEC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg05695927	chr15:45694626	SPATA5L1	-0.48	-4.61	-0.36	8.57e-6	Homoarginine levels;
UCEC	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.5	-0.41	1.65e-7	Resting heart rate;
UCEC	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.62	-5.59	-0.42	1.09e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs60515486	0.646	rs4752992	chr11:47410751	G/T	cg20307385	chr11:47447363	PSMC3	-0.63	-4.56	-0.35	1.05e-5	Lymphocyte counts;
UCEC	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg13575925	chr12:9217583	LOC144571	0.4	4.55	0.35	1.13e-5	Sjögren's syndrome;
UCEC	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg18681998	chr4:17616180	MED28	-0.69	-7.54	-0.53	4.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-6.04	-0.45	1.21e-8	Chronic sinus infection;
UCEC	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.57	-6.33	-0.46	2.74e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6693882	0.903	rs1509181	chr1:96146782	G/T	cg12448539	chr1:95364293	CNN3	0.53	4.97	0.38	1.86e-6	Pain;
UCEC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.48	-4.88	-0.37	2.68e-6	Corneal astigmatism;
UCEC	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.72	-5.96	-0.44	1.76e-8	Cerebrospinal P-tau181p levels;
UCEC	cis	rs17106184	1.000	rs72898961	chr1:50966976	G/A	cg07174182	chr1:51127561	FAF1	-0.85	-5.33	-0.4	3.64e-7	Type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.55	-5.02	-0.38	1.49e-6	Menarche (age at onset);
UCEC	cis	rs2179367	0.887	rs2143076	chr6:149746451	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.36	-4.92	-0.38	2.25e-6	Dupuytren's disease;
UCEC	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.57	6.78	0.49	2.71e-10	Longevity;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.62	-6.89	-0.49	1.48e-10	Cardiac Troponin-T levels;
UCEC	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg10932868	chr11:921992	NA	0.43	5.79	0.43	4.08e-8	Alzheimer's disease (late onset);
UCEC	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.67	-4.84	-0.37	3.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.57	-5.27	-0.4	4.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.49	-5.17	-0.39	7.46e-7	Vitiligo;
UCEC	cis	rs11153730	0.503	rs4946336	chr6:118632335	A/C	cg21191810	chr6:118973309	C6orf204	0.39	4.92	0.38	2.28e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-4.6	-0.35	8.94e-6	Morning vs. evening chronotype;
UCEC	cis	rs4615376	1.000	rs36119782	chr6:13054433	G/A	cg11378619	chr6:12164359	HIVEP1	-0.54	-4.67	-0.36	6.73e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-4.73	-0.36	5.24e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.46	0.41	2.01e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.46	-4.76	-0.37	4.64e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg18681998	chr4:17616180	MED28	0.69	8.1	0.56	1.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.52	-0.35	1.25e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.64	5.41	0.41	2.49e-7	Alzheimer's disease;
UCEC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.64	0.42	8.65e-8	Cognitive test performance;
UCEC	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.6	6.01	0.44	1.38e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6457821	1.000	rs73415611	chr6:35437630	T/C	cg06087101	chr6:35551932	FKBP5	0.53	4.51	0.35	1.34e-5	Height;
UCEC	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.68	-6.94	-0.5	1.14e-10	Ulcerative colitis;
UCEC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	4.54	0.35	1.15e-5	Cognitive test performance;
UCEC	cis	rs7246967	0.673	rs7249003	chr19:22887934	A/G	cg08271804	chr19:22816896	ZNF492	0.67	6.51	0.47	1.1e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-6.3	-0.46	3.34e-9	Personality dimensions;
UCEC	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-9.69	-0.62	1.78e-17	Vitiligo;
UCEC	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-5.03	-0.38	1.38e-6	Diabetic retinopathy;
UCEC	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.5	4.75	0.36	4.75e-6	Blood protein levels;
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg19678392	chr7:94953810	PON1	-0.61	-6.33	-0.46	2.78e-9	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.87	0.59	2.29e-15	Blood protein levels;
UCEC	cis	rs6429082	0.510	rs2789369	chr1:235503515	A/G	cg26050004	chr1:235667680	B3GALNT2	0.44	4.61	0.36	8.51e-6	Adiposity;
UCEC	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg05991184	chr2:219186017	PNKD	0.52	5.63	0.42	8.66e-8	Colorectal cancer;
UCEC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.44	-6.05	-0.45	1.15e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-4.57	-0.35	1.02e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.39	-4.56	-0.35	1.07e-5	Subjective well-being;
UCEC	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.66	6.85	0.49	1.86e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
UCEC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.72	8.25	0.56	8.07e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.57	-6.38	-0.47	2.15e-9	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.68	8.86	0.59	2.37e-15	Bipolar disorder;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.74	8.11	0.56	1.87e-13	Menarche (age at onset);
UCEC	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.33	-4.5	-0.35	1.35e-5	Post-traumatic stress disorder;
UCEC	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.44	-0.41	2.2e-7	Platelet count;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7937612	1.000	rs11217852	chr11:120261187	A/G	cg12584626	chr11:120203529	NA	0.48	4.96	0.38	1.89e-6	Intraocular pressure;
UCEC	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.09	7.7	0.54	1.8e-12	Sexual dysfunction (female);
UCEC	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	5.37	0.4	3.04e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.71	0.54	1.72e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg18230493	chr5:56204884	C5orf35	-0.51	-4.54	-0.35	1.16e-5	Coronary artery disease;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.64	-0.48	5.63e-10	Cardiac Troponin-T levels;
UCEC	cis	rs73129298	0.551	rs6020160	chr20:48592388	A/T	cg25655593	chr20:48599521	SNAI1	0.63	5.21	0.39	6.34e-7	Inflammatory skin disease;
UCEC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.71	5.78	0.43	4.32e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg24562669	chr7:97807699	LMTK2	0.49	5.85	0.43	3.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.84	9.92	0.63	4.46e-18	Menopause (age at onset);
UCEC	cis	rs7150255	0.820	rs4372620	chr14:104963414	T/C	cg27100511	chr14:105927968	MTA1	0.4	4.54	0.35	1.19e-5	Gut microbiome composition (summer and winter);
UCEC	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.49	-5.44	-0.41	2.13e-7	Life satisfaction;
UCEC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.8	10.09	0.64	1.6e-18	Body mass index;
UCEC	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	0.65	7.53	0.53	4.78e-12	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.06	-0.38	1.25e-6	Personality dimensions;
UCEC	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.63	4.54	0.35	1.16e-5	Blood pressure;
UCEC	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-5.64	-0.42	8.54e-8	Schizophrenia;
UCEC	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.42	-4.66	-0.36	6.95e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.23e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg14008862	chr17:28927542	LRRC37B2	0.78	5.05	0.38	1.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg17085576	chr10:5658249	NA	-0.5	-5.03	-0.38	1.39e-6	Breast cancer;
UCEC	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.67	6.77	0.49	2.8e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.61	0.36	8.69e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg03859395	chr2:55845619	SMEK2	-0.97	-12.56	-0.72	4.99e-25	Metabolic syndrome;
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg26031613	chr14:104095156	KLC1	-0.66	-6.51	-0.47	1.14e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.32	-4.56	-0.35	1.08e-5	Alzheimer's disease (late onset);
UCEC	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.58	6.31	0.46	3.08e-9	Red blood cell count;
UCEC	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.55	5.71	0.43	5.98e-8	Schizophrenia;
UCEC	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13569146	chr6:26330589	NA	-0.55	-4.75	-0.37	4.7e-6	Educational attainment;
UCEC	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-5.02	-0.38	1.47e-6	Height;
UCEC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.59	5.83	0.43	3.44e-8	Colorectal cancer;
UCEC	cis	rs4434872	0.536	rs12023578	chr1:153881548	G/A	cg00151906	chr1:154548273	CHRNB2	0.56	4.55	0.35	1.1e-5	Conduct disorder (symptom count);
UCEC	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.5	4.85	0.37	3.1e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.7	9.25	0.61	2.46e-16	Neuroticism;
UCEC	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.55	5.55	0.42	1.31e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs1007190	0.764	rs758020	chr17:42872579	C/A	cg15406952	chr17:42872593	NA	-0.7	-5.11	-0.39	9.99e-7	DNA methylation (variation);
UCEC	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg13683864	chr3:40499215	RPL14	0.5	5.1	0.39	1.05e-6	Renal cell carcinoma;
UCEC	cis	rs78487399	0.908	rs7559723	chr2:43832049	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-6.29	-0.46	3.46e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg07424592	chr7:64974309	NA	0.81	4.8	0.37	3.9e-6	Diabetic kidney disease;
UCEC	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-1.0	-11.47	-0.69	3.71e-22	IgG glycosylation;
UCEC	cis	rs7095607	0.606	rs6480311	chr10:69956848	T/C	cg18986048	chr10:69913749	MYPN	0.43	4.52	0.35	1.27e-5	Lung function (FVC);
UCEC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.46	4.56	0.35	1.05e-5	Colorectal cancer;
UCEC	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg21466736	chr12:48725269	NA	-0.36	-4.8	-0.37	3.91e-6	Plateletcrit;
UCEC	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg02344993	chr17:57696989	CLTC	0.49	4.73	0.36	5.29e-6	Hemoglobin concentration;
UCEC	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.54	-6.95	-0.5	1.09e-10	Gut microbiome composition (winter);
UCEC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.66	0.42	7.69e-8	Breast cancer;
UCEC	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.43	-5.45	-0.41	2.1e-7	Coronary artery disease;
UCEC	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.6	4.91	0.38	2.36e-6	Menopause (age at onset);
UCEC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.55	0.42	1.31e-7	Cognitive test performance;
UCEC	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.81	10.52	0.66	1.21e-19	Body mass index;
UCEC	cis	rs12145833	1.000	rs61833916	chr1:243469946	C/T	cg02356786	chr1:243265016	LOC731275	0.73	4.94	0.38	2.07e-6	Obesity (early onset extreme);
UCEC	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg15997130	chr1:24165203	NA	-0.62	-5.12	-0.39	9.37e-7	Immature fraction of reticulocytes;
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.93	-0.44	2.1e-8	Platelet count;
UCEC	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-4.85	-0.37	3.05e-6	Urinary metabolites;
UCEC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.41	2.96e-7	Breast cancer;
UCEC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.54	6.37	0.47	2.3e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg19318889	chr4:1322082	MAEA	0.5	5.46	0.41	1.95e-7	Obesity-related traits;
UCEC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.93	-10.43	-0.65	2.07e-19	Cognitive function;
UCEC	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.6	-5.12	-0.39	9.54e-7	Obesity-related traits;
UCEC	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	4.98	0.38	1.74e-6	Menarche (age at onset);
UCEC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.55	-6.35	-0.46	2.51e-9	Aortic root size;
UCEC	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	4.97	0.38	1.84e-6	Educational attainment;
UCEC	cis	rs6732160	0.809	rs13416592	chr2:73365056	C/T	cg05539622	chr2:73298971	SFXN5	0.49	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.34	-4.75	-0.36	4.84e-6	Longevity;
UCEC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.78	-7.51	-0.53	5.18e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.39	4.62	0.36	8.41e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.33	5.05	0.38	1.31e-6	Cancer;
UCEC	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg04374321	chr14:90722782	PSMC1	0.73	7.7	0.54	1.83e-12	Mortality in heart failure;
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	7.86	0.54	7.61e-13	Platelet count;
UCEC	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.62	-6.21	-0.46	5.03e-9	Strep throat;
UCEC	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg18681998	chr4:17616180	MED28	0.78	9.1	0.6	5.77e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12618769	0.597	rs4850879	chr2:99113082	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg23972785	chr8:11611189	GATA4	-0.33	-4.65	-0.36	7.18e-6	Retinal vascular caliber;
UCEC	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.41	4.53	0.35	1.21e-5	Renal cell carcinoma;
UCEC	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12292205	chr6:26970375	C6orf41	0.44	4.6	0.35	9.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	5.56	0.42	1.24e-7	Response to antipsychotic treatment;
UCEC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.58	4.9	0.37	2.53e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.51	-0.47	1.12e-9	Platelet count;
UCEC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.72	8.42	0.57	3.18e-14	Menopause (age at onset);
UCEC	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg23795048	chr12:9217529	LOC144571	-0.45	-5.52	-0.41	1.47e-7	Sjögren's syndrome;
UCEC	cis	rs7580658	0.545	rs12477559	chr2:127951797	C/T	cg16751203	chr2:127950803	CYP27C1	0.39	5.09	0.39	1.09e-6	Protein C levels;
UCEC	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	6.8	0.49	2.51e-10	Menarche (age at onset);
UCEC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.34	-0.4	3.52e-7	Breast cancer;
UCEC	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.53	0.41	1.43e-7	Birth weight;
UCEC	cis	rs4372836	0.602	rs11685682	chr2:29056801	T/A	cg09522027	chr2:28974177	PPP1CB	0.81	8.63	0.58	9.35e-15	Body mass index;
UCEC	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-5.67	-0.42	7.29e-8	Height;
UCEC	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.52	4.9	0.37	2.47e-6	Dupuytren's disease;
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.91	-13.09	-0.73	1.88e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.38	4.8	0.37	3.81e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg20399509	chr21:47717575	C21orf57	-0.43	-4.6	-0.35	8.95e-6	Testicular germ cell tumor;
UCEC	cis	rs7523273	0.526	rs3849274	chr1:208021557	T/A	cg22525895	chr1:207977042	MIR29B2	-0.47	-4.72	-0.36	5.51e-6	Schizophrenia;
UCEC	cis	rs514475	0.759	rs6924473	chr6:138066687	G/A	cg05880829	chr6:138867080	NHSL1	0.73	5.0	0.38	1.63e-6	Inflammatory skin disease;
UCEC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.0	8.97	0.59	1.26e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg13250285	chr3:50228871	GNAT1	-0.34	-4.99	-0.38	1.7e-6	Menarche (age at onset);
UCEC	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg13695892	chr22:41940480	POLR3H	-0.6	-5.23	-0.4	5.71e-7	Vitiligo;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.86	-9.4	-0.61	1.02e-16	Blood metabolite levels;
UCEC	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.77	5.21	0.39	6.19e-7	Blood pressure (smoking interaction);
UCEC	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.32	4.7	0.36	5.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.48	0.62	6.28e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg21191810	chr6:118973309	C6orf204	0.42	5.83	0.43	3.35e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg13385521	chr17:29058706	SUZ12P	0.62	4.7	0.36	5.85e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7582720	1.000	rs72932727	chr2:203649501	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	4.56	0.35	1.08e-5	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.19	0.56	1.16e-13	Chronic sinus infection;
UCEC	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.61	6.17	0.45	6.28e-9	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs12286929	0.617	rs11607801	chr11:115077367	A/C	cg04055981	chr11:115044050	NA	0.43	4.63	0.36	7.92e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs10012307	1.000	rs72990066	chr4:137514633	C/A	cg12033966	chr4:138453416	PCDH18	-0.77	-5.3	-0.4	4.22e-7	DNA methylation (parent-of-origin);
UCEC	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	4.79	0.37	4.08e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	13.77	0.75	3.04e-28	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.43	0.41	2.26e-7	Breast cancer;
UCEC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	6.07	0.45	1.02e-8	Platelet count;
UCEC	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.29	-0.56	6.37e-14	Total cholesterol levels;
UCEC	cis	rs12618769	0.652	rs3203856	chr2:99226021	C/T	cg10123293	chr2:99228465	UNC50	0.5	5.57	0.42	1.17e-7	Bipolar disorder;
UCEC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.13	0.39	9.04e-7	IgG glycosylation;
UCEC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.45	0.41	2.04e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.78	-6.13	-0.45	7.74e-9	Calcium levels;
UCEC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.46	-6.53	-0.47	9.85e-10	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg16583315	chr14:65563665	MAX	0.41	4.78	0.37	4.17e-6	Obesity-related traits;
UCEC	cis	rs7937612	0.965	rs4938806	chr11:120274353	C/A	cg12584626	chr11:120203529	NA	0.51	5.18	0.39	7.13e-7	Intraocular pressure;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.76	-0.37	4.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.63	-7.3	-0.52	1.68e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7165102	0.864	rs2253166	chr15:66091647	T/G	cg11164506	chr15:66649558	TIPIN	-0.33	-4.6	-0.35	8.94e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg06462663	chr19:18546047	ISYNA1	0.51	6.25	0.46	4.25e-9	Breast cancer;
UCEC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg13147721	chr7:65941812	NA	-0.71	-5.07	-0.39	1.19e-6	Diabetic kidney disease;
UCEC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.1e-10	Chronic sinus infection;
UCEC	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.44	5.4	0.41	2.63e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.69	8.66	0.58	7.67e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.42	-4.68	-0.36	6.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.9	-0.37	2.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.65	-0.58	8.42e-15	Menarche (age at onset);
UCEC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg24069376	chr3:38537580	EXOG	0.44	5.51	0.41	1.56e-7	Electrocardiographic conduction measures;
UCEC	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-0.79	-6.23	-0.46	4.61e-9	Body mass index;
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.16e-9	Prudent dietary pattern;
UCEC	cis	rs3743832	0.931	rs9939607	chr16:9216739	A/T	cg08831531	chr16:9218945	NA	-0.44	-4.69	-0.36	6.16e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.59	-5.77	-0.43	4.52e-8	Breast cancer;
UCEC	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.56	5.86	0.44	2.92e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.65	5.49	0.41	1.75e-7	High light scatter reticulocyte count;
UCEC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	6.2	0.46	5.42e-9	Monocyte count;
UCEC	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg09165964	chr15:75287851	SCAMP5	0.9	12.09	0.71	8.31e-24	Blood trace element (Zn levels);
UCEC	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	6.08	0.45	9.92e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.74	-6.47	-0.47	1.38e-9	Caudate activity during reward;
UCEC	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.45	4.63	0.36	8.07e-6	Schizophrenia;
UCEC	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-5.9	-0.44	2.39e-8	Birth weight;
UCEC	cis	rs59104589	0.617	rs3771566	chr2:242358299	G/T	cg19488206	chr2:242435732	STK25	0.54	4.89	0.37	2.65e-6	Fibrinogen levels;
UCEC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22117172	chr7:91764530	CYP51A1	0.43	5.42	0.41	2.4e-7	Breast cancer;
UCEC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.75	-6.05	-0.45	1.16e-8	Alzheimer's disease (late onset);
UCEC	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.41	-4.58	-0.35	9.64e-6	Pelvic organ prolapse;
UCEC	cis	rs11958404	0.932	rs72816574	chr5:157429882	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.61	-6.28	-0.46	3.58e-9	Dental caries;
UCEC	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18854424	chr1:2615690	NA	0.45	6.5	0.47	1.19e-9	Ulcerative colitis;
UCEC	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.54	5.19	0.39	6.87e-7	Uric acid levels;
UCEC	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.43	4.57	0.35	1.03e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.83	-8.48	-0.57	2.21e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.85e-6	Blood metabolite levels;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.95	0.38	2.03e-6	Platelet count;
UCEC	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.5	-4.87	-0.37	2.87e-6	Birth weight;
UCEC	trans	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg18288967	chr1:45987694	PRDX1	0.89	7.28	0.51	1.88e-11	Obesity-related traits;
UCEC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg24826892	chr11:71159390	DHCR7	0.52	4.74	0.36	5.04e-6	Vitamin D levels;
UCEC	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.5	5.54	0.42	1.37e-7	Blood metabolite levels;
UCEC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.62	6.33	0.46	2.87e-9	Immature fraction of reticulocytes;
UCEC	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.76	-9.14	-0.6	4.67e-16	Monocyte count;
UCEC	cis	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-4.54	-0.35	1.14e-5	Intraocular pressure;
UCEC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	13.66	0.75	6.11e-28	Homoarginine levels;
UCEC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.67	6.07	0.45	1.04e-8	High light scatter reticulocyte count;
UCEC	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	5.39	0.41	2.77e-7	Platelet distribution width;
UCEC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg17294928	chr15:75287854	SCAMP5	0.55	6.14	0.45	7.34e-9	Breast cancer;
UCEC	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-25.18	-0.9	3.61e-55	Myeloid white cell count;
UCEC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.75	7.13	0.51	4.3e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.54	-4.78	-0.37	4.27e-6	Carotid intima media thickness;
UCEC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg01262667	chr19:19385393	TM6SF2	0.52	7.37	0.52	1.17e-11	Tonsillectomy;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg20999797	chr1:1681921	NA	0.38	5.02	0.38	1.5e-6	Body mass index;
UCEC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	6.05e-9	Colorectal cancer;
UCEC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.68	7.01	0.5	8.19e-11	Body mass index;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19729279	chr5:133861951	PHF15	0.55	6.86	0.49	1.82e-10	Warfarin maintenance dose;
UCEC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.87	-9.6	-0.62	2.96e-17	Cognitive function;
UCEC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-5.28	-0.4	4.58e-7	Colorectal cancer;
UCEC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.92	0.38	2.31e-6	Diabetic retinopathy;
UCEC	cis	rs7656342	0.653	rs6831580	chr4:9852750	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	4.52	0.35	1.25e-5	Gut microbiota (bacterial taxa);
UCEC	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18932078	chr1:2524107	MMEL1	0.32	5.26	0.4	5.07e-7	Ulcerative colitis;
UCEC	cis	rs77926410	0.725	rs2417897	chr12:10612961	A/C	cg25023291	chr12:11339792	TAS2R42	-0.38	-4.8	-0.37	3.93e-6	Mean corpuscular volume;
UCEC	cis	rs4919044	0.641	rs11187232	chr10:94737477	A/G	cg00519463	chr10:94352821	KIF11	0.87	4.65	0.36	7.48e-6	Coronary artery disease;
UCEC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.59	5.32	0.4	3.72e-7	Corneal astigmatism;
UCEC	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg13683864	chr3:40499215	RPL14	-0.55	-5.92	-0.44	2.16e-8	Renal cell carcinoma;
UCEC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	0.67	5.51	0.41	1.58e-7	Gut microbiome composition (summer);
UCEC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.7e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs13095912	0.925	rs11924016	chr3:185307879	A/T	cg11274856	chr3:185301563	NA	0.56	7.17	0.51	3.38e-11	Systolic blood pressure;
UCEC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.72	-7.22	-0.51	2.64e-11	Aortic root size;
UCEC	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.66	-5.66	-0.42	7.76e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.5e-16	Height;
UCEC	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.96	-0.55	4.31e-13	Monocyte count;
UCEC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.65	-4.81	-0.37	3.68e-6	Coronary artery disease;
UCEC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.43e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg13683864	chr3:40499215	RPL14	1.1	15.63	0.79	4.78e-33	Renal cell carcinoma;
UCEC	cis	rs75804782	0.521	rs72993065	chr2:239409001	C/T	cg12524725	chr2:239427019	NA	-0.67	-4.53	-0.35	1.21e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.54	5.41	0.41	2.46e-7	Obesity-related traits;
UCEC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.55	6.06	0.45	1.09e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.63	5.54	0.42	1.39e-7	Response to diuretic therapy;
UCEC	cis	rs7095607	0.813	rs10823148	chr10:69926334	C/G	cg18986048	chr10:69913749	MYPN	0.56	6.58	0.48	7.95e-10	Lung function (FVC);
UCEC	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	5.51	0.41	1.55e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6546886	0.912	rs6745236	chr2:74283728	C/T	cg14702570	chr2:74259524	NA	-0.42	-5.01	-0.38	1.56e-6	Dialysis-related mortality;
UCEC	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	0.81	9.5	0.62	5.4e-17	Ewing sarcoma;
UCEC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.46	4.72	0.36	5.49e-6	Aortic root size;
UCEC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.24	0.4	5.43e-7	Bipolar disorder;
UCEC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	4.81	0.37	3.66e-6	Alzheimer's disease (late onset);
UCEC	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.67	5.95	0.44	1.84e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.71	-8.05	-0.55	2.62e-13	Extraversion;
UCEC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.48	0.41	1.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7106204	0.686	rs12803558	chr11:24288205	C/A	ch.11.24196551F	chr11:24239977	NA	0.62	4.92	0.38	2.32e-6	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.66	5.85	0.43	3.03e-8	Alzheimer's disease;
UCEC	cis	rs3770752	0.808	rs2287093	chr2:37425629	A/G	cg20091297	chr2:37572423	QPCT	0.47	4.65	0.36	7.37e-6	Schizophrenia;
UCEC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-10.05	-0.64	2.05e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.46	4.72	0.36	5.49e-6	Aortic root size;
UCEC	cis	rs4853036	0.671	rs2168116	chr2:70004328	C/A	cg02498382	chr2:70120550	SNRNP27	-0.46	-4.57	-0.35	1.01e-5	Colorectal or endometrial cancer;
UCEC	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	6.96	0.5	1.05e-10	Menarche (age at onset);
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.49	0.41	1.72e-7	Platelet count;
UCEC	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-8.31	-0.57	5.84e-14	Morning vs. evening chronotype;
UCEC	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.27	-0.46	3.74e-9	Morning vs. evening chronotype;
UCEC	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.58	6.19	0.45	5.58e-9	Mean platelet volume;
UCEC	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	0.87	5.29	0.4	4.37e-7	Blood protein levels;
UCEC	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.76	6.14	0.45	7.24e-9	Response to hepatitis C treatment;
UCEC	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-6.82	-0.49	2.22e-10	Colorectal cancer;
UCEC	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg06562184	chr8:19319451	CSGALNACT1	0.5	5.24	0.4	5.57e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-10.14	-0.64	1.21e-18	Electrocardiographic conduction measures;
UCEC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg09132178	chr16:78079569	NA	-0.44	-4.9	-0.37	2.49e-6	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.64	6.03	0.45	1.28e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg23307798	chr14:103986281	CKB	0.52	4.77	0.37	4.31e-6	Body mass index;
UCEC	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.59	5.54	0.42	1.39e-7	Pulmonary function;
UCEC	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.46	5.22	0.4	5.96e-7	White matter hyperintensity burden;
UCEC	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.27	-0.61	2.11e-16	Gut microbiome composition (summer);
UCEC	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.04	7.99	0.55	3.62e-13	Vitiligo;
UCEC	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.89	7.72	0.54	1.65e-12	Bladder cancer;
UCEC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.09	9.99	0.64	3.03e-18	Vitiligo;
UCEC	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.37	4.66	0.36	6.91e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.6	-5.1	-0.39	1.02e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.29	0.56	6.6e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.05	0.38	1.27e-6	Cognitive function;
UCEC	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-1.07	-12.33	-0.71	2e-24	Post bronchodilator FEV1;
UCEC	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.78	-7.9	-0.55	5.88e-13	Parkinson's disease;
UCEC	cis	rs16932667	0.857	rs12424672	chr12:5140168	G/A	cg18770669	chr12:5541220	NTF3	0.42	4.66	0.36	7.01e-6	Intelligence (childhood);
UCEC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.47	4.92	0.38	2.29e-6	Pulse pressure;
UCEC	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.76	7.0	0.5	8.6e-11	Morning vs. evening chronotype;
UCEC	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.78	-7.37	-0.52	1.12e-11	Initial pursuit acceleration;
UCEC	cis	rs2224391	0.822	rs36055504	chr6:5262230	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-6.69	-0.48	4.39e-10	Height;
UCEC	cis	rs11676348	0.772	rs10932745	chr2:218942976	T/C	cg05991184	chr2:219186017	PNKD	0.44	4.9	0.37	2.55e-6	Ulcerative colitis;
UCEC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.11	0.39	9.83e-7	Breast cancer;
UCEC	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16346588	chr10:242978	ZMYND11	0.48	4.62	0.36	8.32e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg19041857	chr6:27730383	NA	-0.69	-5.2	-0.39	6.52e-7	Depression;
UCEC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.44	-6.24	-0.46	4.47e-9	Rheumatoid arthritis;
UCEC	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.58	-5.7	-0.43	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.66	-5.49	-0.41	1.71e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.42	-4.73	-0.36	5.19e-6	Neuroticism;
UCEC	cis	rs883565	0.569	rs1298712	chr3:39169693	A/G	cg01426195	chr3:39028469	NA	0.6	6.73	0.49	3.48e-10	Handedness;
UCEC	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.73	-5.92	-0.44	2.15e-8	Alzheimer's disease (late onset);
UCEC	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.51	4.79	0.37	4.04e-6	Platelet count;
UCEC	cis	rs732765	0.734	rs17782707	chr14:75179102	T/A	cg11740921	chr14:74946960	NPC2	-0.44	-4.6	-0.35	8.91e-6	Non-small cell lung cancer;
UCEC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.71	-6.27	-0.46	3.79e-9	Initial pursuit acceleration;
UCEC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18402987	chr7:1209562	NA	0.49	5.03	0.38	1.39e-6	Longevity;Endometriosis;
UCEC	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	6.71	0.48	3.94e-10	Exhaled nitric oxide output;
UCEC	trans	rs1552172	0.887	rs4970874	chr1:145709394	T/C	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.81	-0.49	2.36e-10	Breast cancer;
UCEC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs58742730	1.000	rs12569838	chr10:115199340	G/C	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.62	4.57	0.35	1.03e-5	Breast cancer;
UCEC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg04154034	chr17:28927549	LRRC37B2	0.53	4.86	0.37	2.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs756777	0.702	rs12337328	chr9:136681696	G/T	cg14069709	chr9:136671979	VAV2	-0.39	-4.68	-0.36	6.33e-6	IgG glycosylation;
UCEC	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg05738196	chr6:26577821	NA	0.64	7.59	0.53	3.32e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.55	6.18	0.45	6.09e-9	Monocyte percentage of white cells;
UCEC	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.65	6.15	0.45	6.92e-9	Lymphocyte counts;
UCEC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.06	6.34	0.46	2.63e-9	Diabetic retinopathy;
UCEC	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.59	6.46	0.47	1.42e-9	Total body bone mineral density;
UCEC	cis	rs4077515	0.967	rs4078099	chr9:139267533	G/A	cg14019695	chr9:139328340	INPP5E	0.48	5.1	0.39	1.03e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11969893	0.655	rs67724651	chr6:101417004	T/G	cg12253828	chr6:101329408	ASCC3	0.98	5.63	0.42	8.79e-8	Economic and political preferences (immigration/crime);
UCEC	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	13.91	0.75	1.33e-28	Height;
UCEC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.51	5.02	0.38	1.5e-6	Menopause (age at onset);
UCEC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-10.48	-0.65	1.49e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.8	-0.49	2.51e-10	Developmental language disorder (linguistic errors);
UCEC	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs1502337	0.561	rs12313391	chr12:110797730	C/T	cg25737040	chr12:111374205	NA	-0.49	-5.11	-0.39	9.76e-7	Body mass index;
UCEC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.32	0.46	2.98e-9	Menarche (age at onset);
UCEC	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-6.34	-0.46	2.6e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg22117172	chr7:91764530	CYP51A1	-0.38	-5.06	-0.38	1.25e-6	Breast cancer;
UCEC	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.69	0.36	6.3e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.53	4.63	0.36	7.96e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.65	6.53	0.47	1.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.57	6.18	0.45	5.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.46	-6.02	-0.44	1.3e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg14067834	chr17:29058358	SUZ12P	0.54	4.52	0.35	1.24e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.42	-0.41	2.43e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.71	6.45	0.47	1.51e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.62	-5.96	-0.44	1.79e-8	Aortic root size;
UCEC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.82	7.38	0.52	1.1e-11	Bladder cancer;
UCEC	cis	rs7709377	0.553	rs7715759	chr5:115471298	A/G	cg23108291	chr5:115420582	COMMD10	0.53	5.47	0.41	1.9e-7	Metabolite levels  (X-11787);
UCEC	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.69	6.54	0.47	9.56e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7611694	0.501	rs6438146	chr3:113126043	C/T	cg12596171	chr3:113251061	SIDT1	-0.57	-5.7	-0.43	6.24e-8	Prostate cancer;
UCEC	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs10507419	0.737	rs9541523	chr13:35214466	C/A	cg03337263	chr13:35574522	NBEA	0.47	4.51	0.35	1.33e-5	Immunoglobulin light chain (AL) amyloidosis (serum Ig lambda profile);Immunoglobulin light chain (AL) amyloidosis (serum IgG profile);
UCEC	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.8	0.43	3.91e-8	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.68	5.97	0.44	1.73e-8	Aortic root size;
UCEC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.7	-6.49	-0.47	1.22e-9	Inflammatory bowel disease;
UCEC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.65	6.33	0.46	2.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24308560	chr3:49941425	MST1R	0.54	6.2	0.46	5.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg12463550	chr7:65579703	CRCP	0.53	5.33	0.4	3.68e-7	Aortic root size;
UCEC	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg18827107	chr12:86230957	RASSF9	-0.42	-4.64	-0.36	7.6e-6	Major depressive disorder;
UCEC	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	0.89	9.58	0.62	3.37e-17	Left atrial antero-posterior diameter;
UCEC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18932078	chr1:2524107	MMEL1	0.4	6.53	0.47	1e-9	Ulcerative colitis;
UCEC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.53	5.98	0.44	1.59e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.55	-5.47	-0.41	1.93e-7	QRS complex (12-leadsum);
UCEC	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.48	4.72	0.36	5.51e-6	Emphysema distribution in smoking;
UCEC	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.83	-9.3	-0.61	1.79e-16	Blood metabolite levels;
UCEC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	6.35	0.46	2.5e-9	Personality dimensions;
UCEC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-5.75	-0.43	4.98e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	0.71	5.43	0.41	2.24e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg00409905	chr10:38381863	ZNF37A	0.49	4.68	0.36	6.45e-6	Obesity (extreme);
UCEC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.65	0.42	7.9e-8	Breast cancer;
UCEC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs751728	0.965	rs756137	chr6:33755890	T/C	cg25922239	chr6:33757077	LEMD2	0.57	5.08	0.39	1.11e-6	Crohn's disease;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.43	-4.54	-0.35	1.15e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-0.76	-5.17	-0.39	7.61e-7	Post bronchodilator FEV1;
UCEC	cis	rs9790314	0.613	rs11716265	chr3:160602111	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-5.1	-0.39	1.04e-6	Morning vs. evening chronotype;
UCEC	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.87	9.42	0.61	9.03e-17	Blood metabolite levels;
UCEC	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.67	-7.06	-0.5	6.18e-11	Height;
UCEC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg05660106	chr1:15850417	CASP9	0.54	4.91	0.38	2.35e-6	Systolic blood pressure;
UCEC	cis	rs7246967	0.673	rs2112610	chr19:22916851	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.79	0.49	2.58e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg08216368	chr11:237063	SIRT3;PSMD13	0.46	4.57	0.35	1.01e-5	Alzheimer's disease (late onset);
UCEC	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg14851346	chr12:38532713	NA	0.49	4.74	0.36	4.92e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.65	-5.91	-0.44	2.25e-8	Aortic root size;
UCEC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg10932868	chr11:921992	NA	0.44	5.59	0.42	1.08e-7	Alzheimer's disease (late onset);
UCEC	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.77	5.85	0.43	3.14e-8	Obesity (early onset extreme);
UCEC	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg03859395	chr2:55845619	SMEK2	0.97	13.95	0.75	1.04e-28	Metabolic syndrome;
UCEC	cis	rs4588572	0.643	rs6861678	chr5:77764613	G/C	cg11547950	chr5:77652471	NA	-0.49	-5.55	-0.42	1.3e-7	Triglycerides;
UCEC	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-6.8	-0.49	2.45e-10	Personality dimensions;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19580633	chr5:172386539	RPL26L1;LOC100268168	0.69	6.78	0.49	2.65e-10	Migraine with aura;
UCEC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg06238570	chr21:40685208	BRWD1	0.81	7.97	0.55	3.97e-13	Cognitive function;
UCEC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.65	4.59	0.35	9.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg22974920	chr21:40686053	BRWD1	0.6	4.79	0.37	4.06e-6	Cognitive function;
UCEC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-4.55	-0.35	1.1e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg20825769	chr15:43991375	CKMT1A	-0.51	-4.69	-0.36	6.3e-6	Lung cancer in ever smokers;
UCEC	cis	rs1205863	0.573	rs85219	chr6:11919929	G/A	cg25521853	chr6:11927664	NA	0.4	4.75	0.36	4.75e-6	Disc degeneration (lumbar);
UCEC	cis	rs6832769	1.000	rs12646078	chr4:56368204	T/C	cg05960024	chr4:56376020	CLOCK	0.54	5.06	0.39	1.25e-6	Personality dimensions;
UCEC	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.7	5.16	0.39	7.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.68	6.15	0.45	7.07e-9	Lymphocyte counts;
UCEC	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.37	0.57	4.2e-14	Smoking behavior;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs9912468	1.000	rs7210446	chr17:64307014	C/T	cg19474267	chr17:64306194	PRKCA	-0.42	-5.74	-0.43	5.35e-8	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
UCEC	cis	rs7597155	0.846	rs6705820	chr2:69973737	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.84	-0.37	3.32e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.67	-6.62	-0.48	6.2e-10	Blood metabolite levels;
UCEC	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg17031739	chr1:67600172	NA	0.46	4.89	0.37	2.66e-6	Psoriasis;
UCEC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.66	-4.86	-0.37	2.96e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.77	8.89	0.59	2.02e-15	Menopause (age at onset);
UCEC	cis	rs78487399	0.808	rs7601039	chr2:43828637	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.6	-0.35	9.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.57	0.35	1.04e-5	Height;
UCEC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.61	6.49	0.47	1.25e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2288327	0.818	rs16866397	chr2:179421470	G/T	cg09915519	chr2:179397513	TTN;MIR548N	0.65	4.51	0.35	1.33e-5	Atrial fibrillation;
UCEC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.87	-0.37	2.82e-6	Personality dimensions;
UCEC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg02413938	chr2:239008929	ESPNL	-0.36	-4.74	-0.36	4.94e-6	Prostate cancer;
UCEC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-4.62	-0.36	8.31e-6	Morning vs. evening chronotype;
UCEC	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg13334819	chr7:99746414	C7orf59	0.64	5.23	0.4	5.66e-7	Coronary artery disease;
UCEC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.51	-6.27	-0.46	3.9e-9	Total body bone mineral density;
UCEC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.2	-0.51	2.9e-11	Monocyte count;
UCEC	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg04837898	chr3:45731254	SACM1L	-0.41	-4.76	-0.37	4.63e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs295140	1.000	rs1367857	chr2:201160765	T/C	cg04283868	chr2:201171347	SPATS2L	0.53	5.25	0.4	5.2e-7	QT interval;
UCEC	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.71	6.4	0.47	1.92e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.6	4.9	0.37	2.55e-6	Gut microbiome composition (summer);
UCEC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg19567339	chr10:100142640	NA	0.54	6.44	0.47	1.56e-9	Metabolite levels;
UCEC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.96	12.29	0.71	2.54e-24	Monocyte count;
UCEC	cis	rs11169552	0.510	rs10876043	chr12:50904144	C/T	cg11053966	chr12:51476537	CSRNP2	-0.54	-5.16	-0.39	7.93e-7	Colorectal cancer;
UCEC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.51	5.44	0.41	2.17e-7	Schizophrenia;
UCEC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.59	0.35	9.59e-6	Bipolar disorder;
UCEC	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-4.5	-0.35	1.37e-5	Life satisfaction;
UCEC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.89	-0.37	2.59e-6	Breast cancer;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.53	6.01	0.44	1.39e-8	Menarche (age at onset);
UCEC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg12463550	chr7:65579703	CRCP	0.49	4.6	0.35	9.22e-6	Calcium levels;
UCEC	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.54	5.18	0.39	7.17e-7	Blood metabolite levels;
UCEC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg22166914	chr1:53195759	ZYG11B	0.78	8.07	0.55	2.32e-13	Monocyte count;
UCEC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6540731	1.000	rs6540731	chr1:212392163	A/G	cg07569918	chr1:212002970	LPGAT1	0.38	4.78	0.37	4.25e-6	Intelligence (childhood);
UCEC	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.81	-8.27	-0.56	7.31e-14	Resting heart rate;
UCEC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.64	4.81	0.37	3.69e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg04155231	chr12:9217510	LOC144571	0.43	5.06	0.39	1.23e-6	Sjögren's syndrome;
UCEC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10949834	0.504	rs150862	chr7:73524207	C/T	cg07137043	chr7:73588983	EIF4H	0.58	4.72	0.36	5.33e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg11150807	chr10:43354902	NA	0.85	6.94	0.5	1.15e-10	Blood protein levels;
UCEC	cis	rs7246967	0.673	rs12980342	chr19:22849357	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-4.58	-0.35	9.85e-6	Asthma;
UCEC	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.58	6.06	0.45	1.07e-8	Eye color traits;
UCEC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.69	-7.54	-0.53	4.51e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6594713	0.717	rs2972689	chr5:112945966	C/T	cg08939847	chr5:112655559	MCC	-0.47	-4.54	-0.35	1.18e-5	Brain cytoarchitecture;
UCEC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	1.0	9.81	0.63	8.83e-18	Alcohol dependence;
UCEC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.26	-0.4	4.96e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-5.19	-0.39	6.81e-7	Aortic root size;
UCEC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.47	-4.85	-0.37	3.06e-6	Body mass index;
UCEC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.5	-4.98	-0.38	1.77e-6	Diastolic blood pressure;
UCEC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.44	5.04	0.38	1.32e-6	Blood protein levels;
UCEC	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.01	9.73	0.63	1.42e-17	Corneal structure;
UCEC	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.73	7.86	0.54	7.46e-13	Lymphocyte counts;
UCEC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg16524733	chr11:117070046	TAGLN	0.33	4.68	0.36	6.55e-6	Blood protein levels;
UCEC	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	4.92	0.38	2.34e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.86	5.75	0.43	5.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg24881330	chr22:46731750	TRMU	0.73	7.36	0.52	1.18e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.89	7.92	0.55	5.47e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs73206853	0.841	rs28404862	chr12:110850241	C/G	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.19	0.45	5.65e-9	Cognitive test performance;
UCEC	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2554380	0.628	rs6602993	chr15:84482362	C/G	cg18393722	chr15:85113863	UBE2QP1	0.51	4.69	0.36	6.19e-6	Height;
UCEC	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.99	0.38	1.66e-6	Rheumatoid arthritis;
UCEC	cis	rs8105895	1.000	rs62112917	chr19:22226580	C/T	cg02912127	chr19:22235281	ZNF257	-0.55	-4.72	-0.36	5.44e-6	Body mass index (change over time);
UCEC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.77	-9.2	-0.6	3.27e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg17469321	chr7:55412551	NA	0.69	6.07	0.45	1.03e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.48	4.8	0.37	3.84e-6	Body mass index;
UCEC	cis	rs2839627	0.564	rs2839595	chr21:44298966	G/A	cg03543861	chr21:44258195	NA	0.52	5.16	0.39	7.86e-7	Information processing speed;
UCEC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.5	5.19	0.39	6.79e-7	Vitiligo;
UCEC	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.51	4.87	0.37	2.88e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.56	-6.31	-0.46	3.09e-9	Depression;
UCEC	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg00343986	chr7:65444356	GUSB	0.48	4.51	0.35	1.31e-5	Aortic root size;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.87	0.59	2.28e-15	Platelet count;
UCEC	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.99	-9.76	-0.63	1.18e-17	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.62	5.41	0.41	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.59	5.54	0.42	1.38e-7	Corneal astigmatism;
UCEC	cis	rs60515486	0.702	rs11824864	chr11:47411736	A/G	cg20307385	chr11:47447363	PSMC3	-0.63	-4.59	-0.35	9.28e-6	Lymphocyte counts;
UCEC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg23307798	chr14:103986281	CKB	0.64	7.83	0.54	9.01e-13	Body mass index;
UCEC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.6	0.48	7.02e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.6	-6.15	-0.45	7.06e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.32	5.03	0.38	1.38e-6	Cancer;
UCEC	cis	rs7106204	0.748	rs11820336	chr11:24219701	G/A	ch.11.24196551F	chr11:24239977	NA	0.51	5.15	0.39	8.11e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.6	-4.72	-0.36	5.39e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-5.33	-0.4	3.62e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg12024160	chr4:1254474	NA	0.71	8.9	0.59	1.93e-15	Obesity-related traits;
UCEC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg14582100	chr15:45693742	SPATA5L1	-0.45	-5.89	-0.44	2.54e-8	Homoarginine levels;
UCEC	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg19041857	chr6:27730383	NA	-0.59	-4.66	-0.36	6.98e-6	Breast cancer;
UCEC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.68	5.16	0.39	7.81e-7	Mean platelet volume;
UCEC	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	Cognitive function;
UCEC	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.83	8.91	0.59	1.76e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.96	0.59	1.34e-15	Alzheimer's disease;
UCEC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.67	6.12	0.45	8.11e-9	Cognitive function;
UCEC	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-4.94	-0.38	2.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-7.1	-0.51	5.03e-11	Colorectal cancer;
UCEC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.59	6.43	0.47	1.65e-9	Total body bone mineral density;
UCEC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.5	0.62	5.51e-17	Alzheimer's disease;
UCEC	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.69	0.36	6.29e-6	Rheumatoid arthritis;
UCEC	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.7	-7.56	-0.53	4.03e-12	Blood protein levels;
UCEC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.69	-6.8	-0.49	2.51e-10	Blood metabolite levels;
UCEC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.83	-10.25	-0.65	6.35e-19	Height;
UCEC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-5.73	-0.43	5.36e-8	Menarche (age at onset);
UCEC	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.32	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.5	5.61	0.42	9.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.54	-6.01	-0.44	1.41e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.67	-0.42	7.29e-8	Depression;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16857181	chr7:32931955	KBTBD2	0.62	7.6	0.53	3.14e-12	Warfarin maintenance dose;
UCEC	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg09795085	chr6:101329169	ASCC3	0.5	5.0	0.38	1.62e-6	Neuroticism;
UCEC	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.49	4.94	0.38	2.13e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.92	-11.49	-0.69	3.32e-22	Homoarginine levels;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.15	-0.45	7.06e-9	Depression;
UCEC	cis	rs7580658	0.521	rs2404535	chr2:127947709	A/G	cg16751203	chr2:127950803	CYP27C1	-0.39	-5.38	-0.41	2.92e-7	Protein C levels;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg21486944	chr6:28411378	ZSCAN23	-0.47	-5.04	-0.38	1.33e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg04310649	chr10:35416472	CREM	-0.48	-4.54	-0.35	1.15e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.58	-6.32	-0.46	2.95e-9	Obesity-related traits;
UCEC	cis	rs4687718	0.929	rs62256001	chr3:53281076	A/G	cg19378537	chr3:53290327	TKT	0.73	4.53	0.35	1.21e-5	QRS duration;
UCEC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.78	-6.92	-0.5	1.29e-10	Caudate activity during reward;
UCEC	cis	rs17123764	0.818	rs7973389	chr12:49980745	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.18	0.39	7.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs60311166	1.000	rs6762788	chr3:52792311	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.79	5.28	0.4	4.56e-7	CTACK levels;
UCEC	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-0.92	-9.38	-0.61	1.12e-16	Height;
UCEC	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg19920283	chr7:105172520	RINT1	0.54	4.78	0.37	4.27e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.29	-0.46	3.48e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.66	6.32	0.46	2.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.51	4.78	0.37	4.17e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4654899	0.643	rs12145181	chr1:21086046	C/A	cg01072550	chr1:21505969	NA	-0.48	-4.75	-0.36	4.74e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.47	6.33	0.46	2.77e-9	Blood protein levels;
UCEC	cis	rs7932354	0.537	rs2290884	chr11:46890388	C/G	cg04661747	chr11:46264818	NA	0.45	4.64	0.36	7.71e-6	Bone mineral density (hip);Bone mineral density;
UCEC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	7.72	0.54	1.62e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7119038	0.818	rs6589684	chr11:118610957	A/G	cg04208787	chr11:118966294	H2AFX	0.57	4.88	0.37	2.74e-6	Sjögren's syndrome;
UCEC	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.53	-5.42	-0.41	2.34e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	0.81	4.55	0.35	1.11e-5	Skin colour saturation;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.51	-6.05	-0.45	1.13e-8	Pubertal anthropometrics;
UCEC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg14008862	chr17:28927542	LRRC37B2	0.6	4.76	0.37	4.6e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6012564	0.893	rs6012579	chr20:47623420	G/T	cg03505427	chr20:47662643	CSE1L	-0.46	-4.51	-0.35	1.34e-5	Anger;
UCEC	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.45	-4.92	-0.38	2.27e-6	IgG glycosylation;
UCEC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.59	-6.12	-0.45	8.21e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg20534287	chr10:135191450	PAOX	0.69	6.71	0.48	3.9e-10	Lifespan;
UCEC	cis	rs731174	0.802	rs609437	chr1:38184316	T/C	cg06917450	chr1:38156652	C1orf109	-0.56	-5.19	-0.39	6.87e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg12024160	chr4:1254474	NA	0.63	7.28	0.51	1.84e-11	Obesity-related traits;
UCEC	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00852783	chr1:26633632	UBXN11	0.47	5.33	0.4	3.6e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.55	0.42	1.3e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	4.93	0.38	2.16e-6	Breast cancer;
UCEC	cis	rs4788439	1.000	rs28540434	chr16:24930548	T/C	cg01669482	chr16:25043131	NA	-0.47	-4.56	-0.35	1.07e-5	Blood metabolite levels;
UCEC	cis	rs4372836	0.504	rs12185717	chr2:29069551	C/A	cg09522027	chr2:28974177	PPP1CB	-0.59	-5.82	-0.43	3.53e-8	Body mass index;
UCEC	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg01072550	chr1:21505969	NA	-0.57	-5.32	-0.4	3.74e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-6.13	-0.45	7.88e-9	Parkinson's disease;
UCEC	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.52	0.62	4.9e-17	Gut microbiome composition (summer);
UCEC	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.65	-5.79	-0.43	4.1e-8	Caudate activity during reward;
UCEC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg20203395	chr5:56204925	C5orf35	-0.65	-5.04	-0.38	1.32e-6	Initial pursuit acceleration;
UCEC	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.46	4.55	0.35	1.1e-5	Longevity;
UCEC	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.5	5.1	0.39	1.03e-6	Coronary heart disease;
UCEC	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.13	18.83	0.84	5.07e-41	IgG glycosylation;
UCEC	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.79	8.75	0.59	4.62e-15	Metabolite levels;
UCEC	cis	rs508970	0.874	rs10792304	chr11:60910591	C/T	cg26254678	chr11:61511275	DAGLA	-0.35	-4.53	-0.35	1.21e-5	Rheumatoid arthritis;
UCEC	cis	rs151997	1.000	rs152817	chr5:50230879	T/A	cg06027927	chr5:50259733	NA	-0.53	-4.91	-0.38	2.43e-6	Callous-unemotional behaviour;
UCEC	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-5.07	-0.39	1.2e-6	Mean platelet volume;
UCEC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg10412286	chr16:89977652	TCF25	0.63	4.68	0.36	6.37e-6	Skin colour saturation;
UCEC	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.67	6.22	0.46	4.78e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg01689657	chr7:91764605	CYP51A1	0.47	6.25	0.46	4.31e-9	Breast cancer;
UCEC	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.19	6.85	0.49	1.86e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs2970992	0.817	rs10176262	chr2:101335019	A/G	cg01042948	chr2:101319752	NA	-0.54	-5.71	-0.43	6.07e-8	Educational attainment;
UCEC	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	5.32	0.4	3.75e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.65	0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.42	-5.91	-0.44	2.32e-8	Alcohol dependence;
UCEC	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg23782820	chr8:58130467	NA	0.6	4.68	0.36	6.59e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg08499158	chr17:42289980	UBTF	-0.39	-4.54	-0.35	1.19e-5	Total body bone mineral density;
UCEC	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.58	-5.53	-0.41	1.46e-7	Aortic root size;
UCEC	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg18681998	chr4:17616180	MED28	0.78	9.1	0.6	5.77e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.79	8.89	0.59	2e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs17106184	0.892	rs58029717	chr1:51162128	A/G	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.78	9.21	0.6	3.05e-16	Monocyte count;
UCEC	cis	rs6882076	1.000	rs7724832	chr5:156381370	C/T	cg12943317	chr5:156479607	HAVCR1	-0.54	-5.48	-0.41	1.77e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg00409905	chr10:38381863	ZNF37A	0.48	4.57	0.35	1.03e-5	Obesity (extreme);
UCEC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16164276	chr3:11034345	SLC6A1	-0.5	-4.72	-0.36	5.42e-6	Alzheimer's disease;
UCEC	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	6.76	0.49	3.04e-10	Mood instability;
UCEC	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.45	-5.31	-0.4	3.92e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.49	-4.96	-0.38	1.93e-6	Body mass index;
UCEC	cis	rs1483890	0.632	rs111868405	chr3:69412154	A/T	cg22125112	chr3:69402811	FRMD4B	0.45	4.73	0.36	5.32e-6	Resting heart rate;
UCEC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.59	6.5	0.47	1.17e-9	Longevity;
UCEC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg04310649	chr10:35416472	CREM	-0.48	-4.78	-0.37	4.2e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.78	6.01	0.44	1.43e-8	Alopecia areata;
UCEC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.65	6.59	0.48	7.19e-10	Tonsillectomy;
UCEC	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-6.58	-0.48	7.73e-10	Schizophrenia;
UCEC	cis	rs2729354	0.768	rs2729384	chr11:57258617	T/C	cg24343310	chr11:57249947	NA	0.44	5.05	0.38	1.3e-6	Blood protein levels;
UCEC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.49	-6.5	-0.47	1.18e-9	Birth weight;
UCEC	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	4.64	0.36	7.78e-6	Mood instability;
UCEC	cis	rs970548	0.954	rs11239549	chr10:46018831	A/G	cg15223267	chr10:46222474	FAM21C	0.55	5.22	0.4	5.89e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-7.57	-0.53	3.77e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09491104	chr22:46646882	C22orf40	-0.5	-4.64	-0.36	7.68e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.54	5.71	0.43	5.94e-8	Aortic root size;
UCEC	cis	rs4662945	0.688	rs62174140	chr2:130202893	C/T	cg05962382	chr2:130345044	NA	-0.47	-5.4	-0.41	2.58e-7	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.62	-6.91	-0.49	1.4e-10	Type 2 diabetes;
UCEC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.49	-5.55	-0.42	1.3e-7	Aortic root size;
UCEC	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.73	-7.51	-0.53	5.34e-12	Mosquito bite size;
UCEC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.69	4.68	0.36	6.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.4e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.44	0.41	2.14e-7	Blood protein levels;
UCEC	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg04287289	chr16:89883240	FANCA	-0.52	-5.56	-0.42	1.24e-7	Vitiligo;
UCEC	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.63	6.53	0.47	9.96e-10	Bipolar disorder;
UCEC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Body mass index;
UCEC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.67	-7.63	-0.53	2.75e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg18032046	chr6:28092343	ZSCAN16	0.66	6.07	0.45	1.05e-8	Parkinson's disease;
UCEC	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.07	-0.5	5.67e-11	Prevalent atrial fibrillation;
UCEC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.67	5.1	0.39	1.03e-6	Corneal astigmatism;
UCEC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.0	-0.67	6.69e-21	Chronic sinus infection;
UCEC	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.95	-0.44	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg09655341	chr17:79618100	PDE6G	-0.31	-4.71	-0.36	5.73e-6	Eye color traits;
UCEC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.14	15.53	0.79	8.35e-33	Cognitive function;
UCEC	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-0.53	-4.91	-0.38	2.41e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.17e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.52	4.8	0.37	3.9e-6	Schizophrenia;
UCEC	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.58	-6.56	-0.48	8.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.57	5.6	0.42	1.04e-7	Hemoglobin concentration;
UCEC	cis	rs1079204	0.826	rs6743642	chr2:219122466	C/T	cg05728596	chr2:219128475	GPBAR1	-0.89	-10.29	-0.65	4.82e-19	Smooth-surface caries;
UCEC	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.09	7.48	0.53	6.18e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.35	-0.46	2.59e-9	Parkinson's disease;
UCEC	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.6	7.69	0.54	1.99e-12	Bone mineral density;
UCEC	cis	rs4871297	0.729	rs11774246	chr8:123696613	A/G	cg17213048	chr8:124332861	ATAD2	-0.44	-4.89	-0.37	2.58e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.42	-5.12	-0.39	9.44e-7	Refractive error;
UCEC	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.61	5.53	0.42	1.41e-7	Schizophrenia;
UCEC	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15556689	chr8:8085844	FLJ10661	0.5	4.95	0.38	2.01e-6	Joint mobility (Beighton score);
UCEC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	0.87	12.47	0.72	8.41e-25	Leprosy;
UCEC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.61	6.64	0.48	5.82e-10	Resting heart rate;
UCEC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-5.34	-0.4	3.47e-7	Neutrophil percentage of white cells;
UCEC	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.32	0.4	3.88e-7	Ileal carcinoids;
UCEC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.7	-7.55	-0.53	4.23e-12	Height;
UCEC	cis	rs3750082	0.889	rs9639669	chr7:32913395	T/C	cg05721444	chr7:32995514	FKBP9	0.52	5.83	0.43	3.42e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-7.37	-0.52	1.11e-11	Exhaled nitric oxide output;
UCEC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg01072550	chr1:21505969	NA	-0.5	-4.59	-0.35	9.36e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.38	-5.06	-0.38	1.26e-6	Dupuytren's disease;
UCEC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg07776626	chr8:57350775	NA	-0.47	-5.27	-0.4	4.78e-7	Obesity-related traits;
UCEC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg13695892	chr22:41940480	POLR3H	-0.69	-5.31	-0.4	3.91e-7	Vitiligo;
UCEC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.92	-0.59	1.69e-15	Height;
UCEC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.51	5.83	0.43	3.44e-8	Testicular germ cell tumor;
UCEC	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.28	0.4	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg19318889	chr4:1322082	MAEA	0.49	5.31	0.4	3.9e-7	Obesity-related traits;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.78	-8.82	-0.59	3.11e-15	Paraoxonase activity;
UCEC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.55	0.35	1.1e-5	Menopause (age at onset);
UCEC	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.36	-0.46	2.35e-9	Metabolite levels;
UCEC	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg04439458	chr5:138467593	SIL1	-0.46	-5.1	-0.39	1.02e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg03146154	chr1:46216737	IPP	0.48	5.04	0.38	1.35e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	5.79	0.43	4.2e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs12216499	0.605	rs4513825	chr6:159341760	C/T	cg03103158	chr8:28748202	INTS9;HMBOX1	-1.01	-6.75	-0.49	3.21e-10	Bladder cancer (smoking interaction);
UCEC	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.96	-0.55	4.31e-13	Monocyte count;
UCEC	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.5	-5.43	-0.41	2.23e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.12	0.6	5.24e-16	Electrocardiographic conduction measures;
UCEC	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-4.94	-0.38	2.11e-6	Selective IgA deficiency;
UCEC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.1e-10	Chronic sinus infection;
UCEC	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg14067834	chr17:29058358	SUZ12P	-0.69	-4.71	-0.36	5.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.66	6.32	0.46	2.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg13206674	chr6:150067644	NUP43	0.54	5.1	0.39	1.02e-6	Lung cancer;
UCEC	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	0.9	6.48	0.47	1.3e-9	Schizophrenia (inflammation and infection response interaction);
UCEC	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg23815491	chr16:72088622	HP	0.38	4.78	0.37	4.2e-6	Fibrinogen levels;
UCEC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg19318889	chr4:1322082	MAEA	0.43	4.84	0.37	3.22e-6	Obesity-related traits;
UCEC	cis	rs828999	0.713	rs547364	chr1:108742123	C/G	cg11967332	chr1:108735228	SLC25A24	0.53	6.26	0.46	3.96e-9	Monocyte percentage of white cells;
UCEC	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs7088591	0.867	rs60184203	chr10:59788674	G/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.29	0.4	4.3e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	7.42	0.52	8.58e-12	Homoarginine levels;
UCEC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.79	0.37	3.95e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs12644436	0.791	rs931031	chr4:88778410	G/A	cg27179352	chr4:88029472	AFF1	0.41	4.64	0.36	7.52e-6	HIV-1 viral setpoint;
UCEC	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.0	0.5	8.35e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg05855489	chr10:104503620	C10orf26	-0.61	-6.59	-0.48	7.53e-10	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg07387570	chr22:46663686	TTC38	-0.46	-4.75	-0.36	4.74e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-9.07	-0.6	7.18e-16	Blood metabolite levels;
UCEC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.84e-6	Breast cancer;
UCEC	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.47	-4.73	-0.36	5.28e-6	Acne (severe);
UCEC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.52	-0.41	1.47e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.53	5.24	0.4	5.54e-7	Immature fraction of reticulocytes;
UCEC	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.48	6.63	0.48	5.83e-10	Osteoporosis;
UCEC	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.69	6.29	0.46	3.43e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7975161	0.515	rs7299866	chr12:104576197	C/T	cg25273343	chr12:104657179	TXNRD1	-0.76	-5.11	-0.39	9.92e-7	Toenail selenium levels;
UCEC	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.65	-7.98	-0.55	3.73e-13	Hip circumference;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.55	-0.42	1.27e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.67	5.1	0.39	1.03e-6	Prostate cancer;
UCEC	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.37	-4.73	-0.36	5.24e-6	Body mass index;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.53	-6.05	-0.45	1.15e-8	Depression;
UCEC	cis	rs8080784	0.673	rs7211975	chr17:58830030	T/C	cg22641952	chr17:58219985	NA	-0.55	-4.95	-0.38	1.97e-6	Coronary artery disease;
UCEC	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	7.76	0.54	1.35e-12	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg22166914	chr1:53195759	ZYG11B	0.58	6.05	0.45	1.14e-8	Monocyte count;
UCEC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.86	9.64	0.62	2.4e-17	Breast cancer;
UCEC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-6.17	-0.45	6.34e-9	Birth weight;
UCEC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	0.89	8.96	0.59	1.38e-15	Heart rate;
UCEC	cis	rs10242455	0.867	rs2740565	chr7:99293475	A/T	cg07715041	chr7:99302981	CYP3A7	0.45	4.77	0.37	4.45e-6	Blood metabolite levels;
UCEC	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.45	5.1	0.39	1.05e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.46	-4.64	-0.36	7.8e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg19554555	chr3:13937349	NA	-0.59	-6.0	-0.44	1.47e-8	Ovarian reserve;
UCEC	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg19041857	chr6:27730383	NA	-0.63	-5.05	-0.38	1.29e-6	Lung cancer in ever smokers;
UCEC	cis	rs7175404	0.527	rs78236986	chr15:94052865	G/A	cg06054272	chr15:93956988	NA	0.73	4.8	0.37	3.88e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.92	6.81	0.49	2.27e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg21419209	chr3:44054225	NA	-0.5	-5.1	-0.39	1.01e-6	Coronary artery disease;
UCEC	cis	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.59	-0.35	9.44e-6	Depression;
UCEC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Bone mineral density;
UCEC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.57	4.91	0.38	2.44e-6	Heart rate;
UCEC	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.54	-5.28	-0.4	4.64e-7	Longevity;
UCEC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.53	6.33	0.46	2.76e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg22974920	chr21:40686053	BRWD1	0.59	5.28	0.4	4.49e-7	Cognitive function;
UCEC	cis	rs883565	0.569	rs7614000	chr3:39152575	C/G	cg01426195	chr3:39028469	NA	-0.64	-7.44	-0.52	7.73e-12	Handedness;
UCEC	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.57	-6.4	-0.47	1.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg06784218	chr1:46089804	CCDC17	0.43	5.04	0.38	1.36e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs11697848	0.867	rs77083750	chr20:48548465	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	0.9	7.4	0.52	9.78e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.42	4.53	0.35	1.2e-5	Obesity-related traits;
UCEC	cis	rs36715	1.000	rs251386	chr5:127547298	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.47	0.41	1.89e-7	Breast cancer;
UCEC	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	0.91	8.48	0.57	2.22e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs589249	0.565	rs219008	chr1:37146466	C/T	cg26235710	chr1:36184717	C1orf216	0.52	4.97	0.38	1.82e-6	Neuroticism (multi-trait analysis);Schizophrenia;
UCEC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-4.71	-0.36	5.71e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.52	5.17	0.39	7.39e-7	High light scatter reticulocyte count;
UCEC	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.11	-9.56	-0.62	3.98e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs968451	0.865	rs5757609	chr22:39707845	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	5.23	0.4	5.66e-7	Primary biliary cholangitis;
UCEC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.08	-10.61	-0.66	7.09e-20	Vitiligo;
UCEC	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.62	-6.6	-0.48	7.07e-10	Vitiligo;
UCEC	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	5.01	0.38	1.55e-6	Eosinophil percentage of white cells;
UCEC	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.16	0.39	7.77e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3790645	1.000	rs282176	chr1:26898956	T/C	cg23229016	chr1:26872525	RPS6KA1	0.29	5.57	0.42	1.19e-7	Glucose homeostasis traits;
UCEC	cis	rs2862064	1.000	rs1948759	chr5:156442657	C/T	cg12943317	chr5:156479607	HAVCR1	0.56	4.69	0.36	6.28e-6	Platelet count;
UCEC	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-0.9	-8.37	-0.57	4.12e-14	Vitiligo;
UCEC	cis	rs12137294	0.866	rs896320	chr1:205205347	T/C	cg12580275	chr1:205744413	RAB7L1	0.43	4.71	0.36	5.71e-6	Red cell distribution width;
UCEC	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-6.89	-0.49	1.53e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.49	0.41	1.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.56	-8.17	-0.56	1.31e-13	Sense of smell;
UCEC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-4.69	-0.36	6.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.73	9.18	0.6	3.61e-16	Hip circumference;
UCEC	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-6.06	-0.45	1.08e-8	Hepatocellular carcinoma;
UCEC	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.67	0.36	6.74e-6	Coronary artery disease;
UCEC	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.59	-8.39	-0.57	3.66e-14	Total body bone mineral density;
UCEC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01906197	chr14:23067002	ABHD4	0.57	7.46	0.52	6.77e-12	Warfarin maintenance dose;
UCEC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg11569703	chr11:65557185	OVOL1	0.51	6.68	0.48	4.63e-10	Acne (severe);
UCEC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-7.16	-0.51	3.49e-11	Morning vs. evening chronotype;
UCEC	cis	rs9463078	0.764	rs10948190	chr6:44942300	C/T	cg25276700	chr6:44698697	NA	-0.43	-4.95	-0.38	2.04e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2136093	0.506	rs61770072	chr1:90861032	A/G	cg01786362	chr1:90274359	NA	-0.42	-4.85	-0.37	3.16e-6	Response to antidepressants;
UCEC	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg17652424	chr22:38574118	PLA2G6	-0.39	-4.87	-0.37	2.89e-6	Cutaneous nevi;
UCEC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.46	5.24	0.4	5.57e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.48	-5.26	-0.4	5.11e-7	Longevity;
UCEC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.32	-4.53	-0.35	1.22e-5	Alzheimer's disease (late onset);
UCEC	cis	rs10924970	0.934	rs12402243	chr1:235431792	A/C	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.84e-6	Asthma;
UCEC	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg05527609	chr1:210001259	C1orf107	-0.67	-5.55	-0.42	1.28e-7	Red blood cell count;
UCEC	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-5.59	-0.42	1.08e-7	Morning vs. evening chronotype;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.21	0.51	2.76e-11	Platelet count;
UCEC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs7204230	1.000	rs1477027	chr16:53284922	T/C	cg10109421	chr16:52641824	NA	0.4	4.58	0.35	9.66e-6	Fibrinogen;
UCEC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg11871910	chr12:69753446	YEATS4	1.06	13.39	0.74	3.05e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg22974920	chr21:40686053	BRWD1	-0.47	-4.61	-0.36	8.53e-6	Menarche (age at onset);
UCEC	cis	rs6446731	0.517	rs2071671	chr4:3269787	C/G	cg08886695	chr4:3369023	RGS12	0.41	4.67	0.36	6.62e-6	Mean platelet volume;
UCEC	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg20965017	chr5:231967	SDHA	-0.66	-6.12	-0.45	7.99e-9	Breast cancer;
UCEC	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg06096015	chr1:231504339	EGLN1	0.4	4.6	0.35	9.22e-6	Hemoglobin concentration;
UCEC	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.6	0.48	6.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg23307798	chr14:103986281	CKB	0.56	5.38	0.41	2.89e-7	Body mass index;
UCEC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	6.04	0.45	1.22e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.69	-7.67	-0.53	2.17e-12	Monocyte count;
UCEC	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.81	0.37	3.65e-6	Breast cancer;
UCEC	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.44	-5.81	-0.43	3.68e-8	Urinary metabolites;
UCEC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.59	-5.32	-0.4	3.79e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-6.38	-0.47	2.16e-9	Crohn's disease;
UCEC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	5.02	0.38	1.44e-6	Monocyte percentage of white cells;
UCEC	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg05709478	chr1:6581295	PLEKHG5	0.57	5.37	0.41	3e-7	Body mass index;
UCEC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.48	-5.13	-0.39	9.04e-7	Monocyte count;
UCEC	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg24060327	chr5:131705240	SLC22A5	-0.45	-4.65	-0.36	7.18e-6	Breast cancer;
UCEC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.49	0.41	1.68e-7	Smoking initiation;
UCEC	cis	rs4363385	0.775	rs427470	chr1:153017353	G/A	cg02907556	chr1:153902501	DENND4B	-0.38	-4.56	-0.35	1.06e-5	Inflammatory skin disease;
UCEC	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-5.44	-0.41	2.17e-7	Body mass index;
UCEC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.39	5.11	0.39	1.01e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.53	-5.46	-0.41	2.01e-7	Schizophrenia;
UCEC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.65	6.82	0.49	2.19e-10	Longevity;Endometriosis;
UCEC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.59	5.09	0.39	1.1e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7870753	0.628	rs10820598	chr9:99189255	A/G	cg25260653	chr9:99212216	HABP4	0.53	4.95	0.38	1.99e-6	Height;
UCEC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.6	-7.0	-0.5	8.27e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.48	6.15	0.45	7.06e-9	Electrocardiographic conduction measures;
UCEC	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	0.73	5.23	0.4	5.75e-7	Blood protein levels;
UCEC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.21e-6	Breast cancer;
UCEC	cis	rs308403	0.530	rs13135766	chr4:123664427	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.58	-4.58	-0.35	9.71e-6	Blood protein levels;
UCEC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	5.04	0.38	1.35e-6	Breast cancer;
UCEC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.99	7.34	0.52	1.35e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2304069	0.729	rs2066933	chr5:149433597	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	5.22	0.4	6.09e-7	HIV-1 control;
UCEC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg09165964	chr15:75287851	SCAMP5	0.54	6.41	0.47	1.91e-9	Breast cancer;
UCEC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.87	0.37	2.81e-6	Parkinson's disease;
UCEC	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.9	-7.33	-0.52	1.41e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.68e-16	Breast cancer;
UCEC	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.47	-5.6	-0.42	1.01e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg17330251	chr7:94953956	PON1	-0.58	-5.52	-0.41	1.5e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.62	4.83	0.37	3.46e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	6.24	0.46	4.43e-9	Alzheimer's disease;
UCEC	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-0.76	-8.41	-0.57	3.38e-14	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	4.6	0.35	9.2e-6	Cognitive test performance;
UCEC	cis	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg03999872	chr20:62272968	STMN3	-0.49	-4.65	-0.36	7.45e-6	Atopic dermatitis;
UCEC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.93	8.16	0.56	1.34e-13	Initial pursuit acceleration;
UCEC	cis	rs10946940	0.965	rs6921256	chr6:27587518	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.44	-4.62	-0.36	8.41e-6	Systemic lupus erythematosus;
UCEC	cis	rs3104435	0.739	rs904257	chr1:31022237	A/G	cg25303761	chr1:31256028	NA	0.45	4.66	0.36	7.16e-6	Low high density lipoprotein cholesterol levels;
UCEC	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg00449821	chr1:155053823	EFNA3	0.39	4.55	0.35	1.12e-5	Serum magnesium levels;
UCEC	cis	rs4148689	0.951	rs957461	chr7:117172257	G/A	cg21212505	chr7:117228958	CFTR	-0.41	-4.66	-0.36	6.96e-6	Gout;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.61	0.48	6.56e-10	Platelet count;
UCEC	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.61	6.55	0.48	8.98e-10	Intelligence (multi-trait analysis);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg12485161	chr19:30156461	PLEKHF1	0.57	6.68	0.48	4.61e-10	N-glycan levels;
UCEC	cis	rs4372836	0.504	rs6730321	chr2:29004299	T/C	cg09522027	chr2:28974177	PPP1CB	-0.72	-7.62	-0.53	2.89e-12	Body mass index;
UCEC	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.45	4.88	0.37	2.77e-6	Mean corpuscular volume;
UCEC	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.34	0.57	4.85e-14	Chronic sinus infection;
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs953387	1.000	rs12473760	chr2:136905697	C/A	cg07169764	chr2:136633963	MCM6	0.54	5.4	0.41	2.64e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.59	-4.81	-0.37	3.74e-6	Coronary artery calcification;
UCEC	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.48	4.59	0.35	9.46e-6	Obesity (extreme);
UCEC	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.06	12.34	0.71	1.85e-24	Corneal structure;
UCEC	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.14e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.69	0.58	6.39e-15	Platelet count;
UCEC	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.0	9.17	0.6	3.83e-16	Corneal structure;
UCEC	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg01851573	chr8:8652454	MFHAS1	-0.39	-4.86	-0.37	2.93e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.69	10.09	0.64	1.64e-18	Height;
UCEC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.75	-8.2	-0.56	1.08e-13	Breast cancer;
UCEC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.68	-4.77	-0.37	4.47e-6	Aortic root size;
UCEC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.57	5.07	0.39	1.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg24562669	chr7:97807699	LMTK2	0.41	5.07	0.39	1.2e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.54	5.84	0.43	3.29e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.57	-6.67	-0.48	4.76e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.76	9.07	0.6	7.19e-16	Ulcerative colitis;
UCEC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg04025307	chr7:1156635	C7orf50	0.78	5.28	0.4	4.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	6.02	0.44	1.33e-8	IgG glycosylation;
UCEC	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-4.64	-0.36	7.56e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.61	6.17	0.45	6.2e-9	Bipolar disorder;
UCEC	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.7	-6.44	-0.47	1.56e-9	Platelet distribution width;
UCEC	cis	rs847649	1.000	rs4620204	chr7:102594217	T/C	cg18108683	chr7:102477205	FBXL13	0.63	7.92	0.55	5.45e-13	Morning vs. evening chronotype;
UCEC	cis	rs9739682	0.515	rs12370310	chr12:62525409	A/T	cg10081664	chr12:62102663	FAM19A2	-0.49	-4.78	-0.37	4.3e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.51	-6.17	-0.45	6.27e-9	Pubertal anthropometrics;
UCEC	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.32	0.57	5.65e-14	Exhaled nitric oxide output;
UCEC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg12311346	chr5:56204834	C5orf35	-0.6	-5.26	-0.4	5e-7	Type 2 diabetes;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.73	0.58	5.09e-15	Platelet count;
UCEC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	7.84	0.54	8.51e-13	Tonsillectomy;
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.09	-0.39	1.07e-6	Body mass index;
UCEC	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.9	-0.49	1.41e-10	Response to antipsychotic treatment;
UCEC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.75	8.19	0.56	1.13e-13	Breast cancer;
UCEC	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.63	5.54	0.42	1.39e-7	Response to diuretic therapy;
UCEC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.46	-4.68	-0.36	6.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.57	-6.02	-0.44	1.32e-8	Monocyte count;
UCEC	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg13683864	chr3:40499215	RPL14	-0.53	-5.37	-0.4	3.08e-7	Renal cell carcinoma;
UCEC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.66	7.63	0.53	2.73e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.67	7.02	0.5	7.8e-11	Tonsillectomy;
UCEC	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.64	-0.48	5.59e-10	Caudate activity during reward;
UCEC	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.3	-0.46	3.28e-9	Response to antipsychotic treatment;
UCEC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg26061582	chr7:22766209	IL6	0.59	5.52	0.41	1.48e-7	Lung cancer;
UCEC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.4	-4.75	-0.36	4.74e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg02158880	chr13:53174818	NA	0.46	5.48	0.41	1.76e-7	Lewy body disease;
UCEC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.51	-7.35	-0.52	1.24e-11	Multiple system atrophy;
UCEC	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.4	-4.82	-0.37	3.58e-6	Obesity;
UCEC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	4.74	0.36	4.94e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.51	6.21	0.46	5.17e-9	Prudent dietary pattern;
UCEC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg20560298	chr2:73613845	ALMS1	0.5	4.92	0.38	2.26e-6	Metabolite levels;
UCEC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.98	11.41	0.69	5.46e-22	Cognitive function;
UCEC	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.01	-5.81	-0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.22	-0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.63	5.6	0.42	1.01e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-1.01	-9.83	-0.63	7.64e-18	Breast cancer;
UCEC	cis	rs7633770	0.698	rs877681	chr3:46702573	C/G	cg11219411	chr3:46661640	NA	0.47	5.5	0.41	1.61e-7	Coronary artery disease;
UCEC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg13844804	chr7:814759	HEATR2	0.69	5.11	0.39	9.92e-7	Cerebrospinal P-tau181p levels;
UCEC	cis	rs34421088	0.506	rs4841518	chr8:11145963	G/C	cg21775007	chr8:11205619	TDH	0.46	4.81	0.37	3.66e-6	Neuroticism;
UCEC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.66	-6.6	-0.48	7.11e-10	Platelet distribution width;
UCEC	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.19	-0.39	6.95e-7	Resting heart rate;
UCEC	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-5.39	-0.41	2.69e-7	Neuroticism;
UCEC	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.55	-6.75	-0.49	3.16e-10	Total body bone mineral density;
UCEC	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg10596483	chr8:143751796	JRK	-0.51	-4.51	-0.35	1.34e-5	Urinary tract infection frequency;
UCEC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00802000	chr16:706648	WDR90	-0.51	-5.97	-0.44	1.69e-8	Height;
UCEC	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg06096015	chr1:231504339	EGLN1	0.42	4.92	0.38	2.24e-6	Hemoglobin concentration;
UCEC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	7.72	0.54	1.61e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.64	-0.48	5.78e-10	Crohn's disease;
UCEC	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.6	-4.7	-0.36	5.81e-6	Iris characteristics;
UCEC	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.02	-9.48	-0.62	6.17e-17	Vitiligo;
UCEC	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.9	-8.53	-0.58	1.6e-14	Colorectal adenoma (advanced);
UCEC	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs28795989	0.795	rs6848540	chr4:7904779	T/A	cg00251875	chr4:7801337	AFAP1	0.49	5.71	0.43	5.94e-8	Intraocular pressure;
UCEC	cis	rs11760485	0.965	rs28629195	chr7:4401934	T/C	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.26	0.4	5.08e-7	Rheumatoid arthritis;
UCEC	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.71	-4.87	-0.37	2.85e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.18	0.45	6.13e-9	Cognitive test performance;
UCEC	cis	rs78487399	0.808	rs79271345	chr2:43746094	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-4.88	-0.37	2.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	0.99	11.11	0.68	3.27e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.51	5.03	0.38	1.42e-6	Aortic root size;
UCEC	cis	rs9653442	0.609	rs10209110	chr2:100672692	C/T	cg22139774	chr2:100720529	AFF3	-0.38	-4.88	-0.37	2.73e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.47	-4.97	-0.38	1.83e-6	Obesity;
UCEC	cis	rs16937	0.618	rs6659069	chr1:205182031	A/G	cg12580275	chr1:205744413	RAB7L1	0.48	5.16	0.39	7.78e-7	Schizophrenia;
UCEC	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.6	-7.16	-0.51	3.54e-11	Prevalent atrial fibrillation;
UCEC	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg05925327	chr15:68127851	NA	-0.49	-5.58	-0.42	1.1e-7	Restless legs syndrome;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs10507349	0.609	rs624893	chr13:26816953	G/A	cg01600817	chr13:26797529	RNF6	0.45	5.01	0.38	1.56e-6	Type 2 diabetes;
UCEC	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.65	-6.26	-0.46	3.92e-9	Plateletcrit;Platelet count;
UCEC	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14019695	chr9:139328340	INPP5E	0.43	4.66	0.36	7.01e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.44	-4.51	-0.35	1.32e-5	Body mass index;
UCEC	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.54	-5.02	-0.38	1.5e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.72	-4.6	-0.35	9.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.49	5.24	0.4	5.55e-7	Alcohol dependence;
UCEC	cis	rs9992101	1.000	rs9992101	chr4:77360431	A/G	cg12814384	chr4:76836032	NAAA	-0.5	-4.78	-0.37	4.29e-6	Creatinine levels;
UCEC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-5.8	-0.43	3.83e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7072216	0.555	rs2296432	chr10:100184063	C/G	cg19567339	chr10:100142640	NA	0.56	5.97	0.44	1.67e-8	Metabolite levels;
UCEC	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.57	-0.48	8.16e-10	Mood instability;
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.43	-4.61	-0.36	8.5e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.54	-5.09	-0.39	1.09e-6	Coronary artery disease;
UCEC	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-6.37	-0.47	2.31e-9	Gut microbiome composition (summer);
UCEC	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.64	-6.84	-0.49	1.95e-10	Coronary artery disease;
UCEC	cis	rs890835	0.572	rs4868647	chr5:175947309	A/G	cg17652716	chr5:176910622	PDLIM7	-0.63	-4.83	-0.37	3.42e-6	Menopause (age at onset);
UCEC	cis	rs1712517	0.771	rs11191664	chr10:105118476	C/T	cg05636881	chr10:105038444	INA	0.44	5.16	0.39	7.92e-7	Migraine;
UCEC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.3	0.52	1.69e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.61	-6.59	-0.48	7.35e-10	Monocyte count;
UCEC	cis	rs17106184	1.000	rs57839936	chr1:51306273	T/C	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.46	2.58e-9	Aortic root size;
UCEC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.45	-4.58	-0.35	9.94e-6	Body mass index;
UCEC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.18e-6	Vitiligo;
UCEC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg12884169	chr21:40033163	ERG	0.36	4.67	0.36	6.81e-6	Coronary artery disease;
UCEC	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.47	-6.12	-0.45	8.11e-9	IgG glycosylation;
UCEC	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-6.29	-0.46	3.51e-9	Body mass index;
UCEC	cis	rs4974559	0.947	rs7659916	chr4:1361013	C/T	cg10902566	chr4:727664	PCGF3	-0.55	-4.59	-0.35	9.57e-6	Systolic blood pressure;
UCEC	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9923856	0.570	rs9652599	chr16:11079161	A/G	cg07657131	chr16:11762803	SNN	0.46	4.58	0.35	9.74e-6	Atopic dermatitis;Adult asthma;
UCEC	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg24069376	chr3:38537580	EXOG	-0.43	-5.23	-0.4	5.76e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg06733568	chr4:1343273	KIAA1530	-0.51	-4.55	-0.35	1.1e-5	Systolic blood pressure;
UCEC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.71	6.33	0.46	2.76e-9	Neutrophil percentage of white cells;
UCEC	cis	rs10507349	0.913	rs9581589	chr13:26779252	A/G	cg19792403	chr13:26796018	RNF6	-0.54	-4.66	-0.36	6.96e-6	Type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg23950597	chr19:37808831	NA	-0.58	-4.71	-0.36	5.59e-6	Coronary artery calcification;
UCEC	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg13147721	chr7:65941812	NA	-0.83	-5.63	-0.42	8.7e-8	Diabetic kidney disease;
UCEC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg06027949	chr8:82754900	SNX16	0.59	4.99	0.38	1.71e-6	Diastolic blood pressure;
UCEC	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.58	0.48	7.64e-10	Personality dimensions;
UCEC	cis	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg12524725	chr2:239427019	NA	0.67	4.53	0.35	1.21e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.7	5.94	0.44	1.97e-8	Birth weight;
UCEC	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.51	4.7	0.36	6.04e-6	Resting heart rate;
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.48	5.71	0.43	5.96e-8	Prudent dietary pattern;
UCEC	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	0.99	11.2	0.68	1.94e-21	Corneal structure;
UCEC	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.54	6.04	0.45	1.19e-8	Monocyte percentage of white cells;
UCEC	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.89	0.37	2.57e-6	Aortic root size;
UCEC	cis	rs308403	0.600	rs309364	chr4:123658859	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.8	-8.6	-0.58	1.07e-14	Blood protein levels;
UCEC	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.44	5.34	0.4	3.41e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.52	-5.04	-0.38	1.35e-6	Platelet count;
UCEC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.51	0.35	1.29e-5	Breast cancer;
UCEC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.63	-6.31	-0.46	3.14e-9	Blood metabolite levels;
UCEC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg24375607	chr4:120327624	NA	0.52	5.48	0.41	1.77e-7	Corneal astigmatism;
UCEC	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs4824093	0.544	rs73443957	chr22:50305515	T/C	cg09872104	chr7:134855509	C7orf49	-0.97	-6.72	-0.48	3.71e-10	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.54	5.22	0.4	6.03e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.48	-5.11	-0.39	9.73e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.63	5.77	0.43	4.45e-8	Menarche (age at onset);
UCEC	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg20129853	chr10:51489980	NA	-0.45	-5.68	-0.42	6.93e-8	Prostate-specific antigen levels;
UCEC	cis	rs1832871	0.619	rs827861	chr6:158710074	C/A	cg07215822	chr6:158701037	NA	-0.48	-5.1	-0.39	1.01e-6	Height;
UCEC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-6.02	-0.44	1.33e-8	Dental caries;
UCEC	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.57	6.35	0.46	2.53e-9	Height;
UCEC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg19784848	chr5:219127	SDHA;CCDC127	0.58	4.73	0.36	5.3e-6	Breast cancer;
UCEC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg20007245	chr22:24372913	LOC391322	0.49	4.87	0.37	2.84e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg05874882	chr4:1763078	NA	-0.53	-5.54	-0.42	1.36e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.84	0.59	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.46	4.76	0.37	4.64e-6	Blood protein levels;
UCEC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.36	4.65	0.36	7.41e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.52	-6.27	-0.46	3.88e-9	Fibrinogen levels;
UCEC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.59	5.0	0.38	1.64e-6	Response to diuretic therapy;
UCEC	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	1.0	9.87	0.63	6.12e-18	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.53	-5.64	-0.42	8.56e-8	Monocyte count;
UCEC	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	7.85	0.54	8.1e-13	Bone mineral density;
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-5.38	-0.41	2.86e-7	Platelet count;
UCEC	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.54	-0.47	9.57e-10	Response to antipsychotic treatment;
UCEC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg17085576	chr10:5658249	NA	-0.5	-4.83	-0.37	3.44e-6	Breast cancer;
UCEC	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg14008862	chr17:28927542	LRRC37B2	0.54	4.65	0.36	7.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg21419209	chr3:44054225	NA	-0.5	-4.9	-0.37	2.45e-6	Coronary artery disease;
UCEC	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.37	4.55	0.35	1.12e-5	Refractive error;
UCEC	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18932078	chr1:2524107	MMEL1	0.39	6.23	0.46	4.69e-9	Ulcerative colitis;
UCEC	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-5.49	-0.41	1.69e-7	Schizophrenia;
UCEC	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.52	5.57	0.42	1.17e-7	Body mass index;
UCEC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.46	-5.68	-0.42	7.01e-8	Prudent dietary pattern;
UCEC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.69	7.88	0.55	6.56e-13	Menopause (age at onset);
UCEC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	trans	rs9351104	0.967	rs1935596	chr6:87368368	A/G	cg26042490	chr8:143869328	LY6D	0.51	6.81	0.49	2.28e-10	Age-related hearing impairment;
UCEC	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	0.89	7.93	0.55	5.03e-13	Orofacial clefts;
UCEC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.39	4.64	0.36	7.68e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.5	4.53	0.35	1.21e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg21100191	chr22:23484243	RTDR1	0.69	7.74	0.54	1.45e-12	Bone mineral density;
UCEC	cis	rs2635047	0.615	rs938134	chr18:44751374	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.93	-0.38	2.24e-6	Educational attainment;
UCEC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.58	5.23	0.4	5.78e-7	Corneal astigmatism;
UCEC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.7	-7.55	-0.53	4.23e-12	Height;
UCEC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.62	6.72	0.48	3.7e-10	Menarche (age at onset);
UCEC	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg00074818	chr8:8560427	CLDN23	0.4	5.04	0.38	1.32e-6	Neuroticism;
UCEC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.64	7.01	0.5	8.14e-11	Homoarginine levels;
UCEC	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-8.07	-0.55	2.23e-13	Menarche (age at onset);
UCEC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.36	0.4	3.14e-7	Rheumatoid arthritis;
UCEC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.49	4.7	0.36	6.01e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.42	-5.84	-0.43	3.3e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg10932868	chr11:921992	NA	0.44	5.88	0.44	2.7e-8	Alzheimer's disease (late onset);
UCEC	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.97	7.02	0.5	7.49e-11	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.47	-4.93	-0.38	2.21e-6	Type 2 diabetes;
UCEC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.5	0.41	1.66e-7	Diabetic retinopathy;
UCEC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-6.13	-0.45	7.69e-9	Platelet count;
UCEC	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg24375607	chr4:120327624	NA	0.52	5.47	0.41	1.87e-7	Corneal astigmatism;
UCEC	cis	rs12644436	0.864	rs931033	chr4:88778917	T/C	cg27179352	chr4:88029472	AFF1	0.41	4.64	0.36	7.52e-6	HIV-1 viral setpoint;
UCEC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.55	-6.36	-0.46	2.46e-9	Aortic root size;
UCEC	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.44	-4.91	-0.38	2.38e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg05738196	chr6:26577821	NA	0.65	7.63	0.53	2.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2376682	0.959	rs11739738	chr5:118040960	A/C	cg17593721	chr5:118788746	HSD17B4	0.49	4.68	0.36	6.5e-6	Diisocyanate-induced asthma;
UCEC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-5.84	-0.43	3.17e-8	Longevity;Endometriosis;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.2	-0.46	5.38e-9	Depression;
UCEC	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.49	4.99	0.38	1.71e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.7	-5.61	-0.42	9.75e-8	Asthma;
UCEC	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4372836	0.704	rs3190	chr2:29025479	A/G	cg09522027	chr2:28974177	PPP1CB	-0.72	-8.1	-0.56	1.91e-13	Body mass index;
UCEC	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-6.61	-0.48	6.53e-10	Platelet distribution width;
UCEC	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.67	7.64	0.53	2.51e-12	Body mass index;
UCEC	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg08755490	chr11:65554678	OVOL1	0.51	5.26	0.4	5.03e-7	Acne (severe);
UCEC	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.68	-5.6	-0.42	1.03e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs13177918	0.603	rs2748241	chr5:149827494	C/T	cg14059543	chr5:149831962	NA	-0.64	-6.19	-0.45	5.58e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.72	6.66	0.48	5.19e-10	Cisplatin-induced ototoxicity;
UCEC	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.73	6.18	0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	7.9	0.55	5.84e-13	Smoking behavior;
UCEC	cis	rs6565681	0.943	rs6565683	chr17:78362300	A/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.67	-4.66	-0.36	7.11e-6	Moyamoya disease;
UCEC	cis	rs3743832	0.966	rs4566166	chr16:9183435	A/G	cg08831531	chr16:9218945	NA	-0.44	-5.03	-0.38	1.38e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.62	-7.15	-0.51	3.85e-11	Hip circumference;
UCEC	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg21770322	chr7:97807741	LMTK2	0.79	12.53	0.72	5.71e-25	Breast cancer;
UCEC	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.3	9.98	0.64	3.13e-18	Uric acid levels;
UCEC	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.05	7.52	0.53	5.13e-12	Sexual dysfunction (female);
UCEC	cis	rs1519814	0.956	rs7016388	chr8:121101865	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-5.21	-0.39	6.36e-7	Breast cancer;
UCEC	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg17145862	chr1:211918768	LPGAT1	-0.75	-9.13	-0.6	4.98e-16	Leprosy;
UCEC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.49	5.61	0.42	9.91e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.38	-5.41	-0.41	2.56e-7	Vitamin D levels;
UCEC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.55	-5.46	-0.41	1.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg13319975	chr6:146136371	FBXO30	0.44	4.67	0.36	6.79e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.54	4.59	0.35	9.43e-6	Coronary artery disease;
UCEC	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.64	5.78	0.43	4.24e-8	Colorectal cancer;
UCEC	cis	rs894344	0.584	rs2315837	chr8:135622341	T/C	cg07888246	chr8:135877498	NA	-0.44	-5.16	-0.39	7.82e-7	Systolic blood pressure;
UCEC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	6.19	0.45	5.59e-9	Ileal carcinoids;
UCEC	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs7095607	0.785	rs7081820	chr10:69914009	C/T	cg18986048	chr10:69913749	MYPN	0.56	6.38	0.47	2.14e-9	Lung function (FVC);
UCEC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.43	-4.52	-0.35	1.25e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-8.51	-0.57	1.82e-14	Vitiligo;
UCEC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.41	-5.13	-0.39	9.07e-7	Life satisfaction;
UCEC	cis	rs8099014	0.911	rs4245269	chr18:56110730	G/A	cg19165390	chr18:56932082	NA	0.35	4.77	0.37	4.36e-6	Platelet count;
UCEC	cis	rs10507349	0.866	rs9581587	chr13:26777083	A/C	cg19792403	chr13:26796018	RNF6	0.54	4.57	0.35	1.05e-5	Type 2 diabetes;
UCEC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	5.08	0.39	1.11e-6	Personality dimensions;
UCEC	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.65	-5.05	-0.38	1.3e-6	Migraine;Coronary artery disease;
UCEC	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.91	0.59	1.84e-15	Bipolar disorder;
UCEC	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.82	9.58	0.62	3.37e-17	Ewing sarcoma;
UCEC	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.65	5.29	0.4	4.42e-7	Testicular germ cell tumor;
UCEC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.75	-4.6	-0.35	8.96e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.71	-7.16	-0.51	3.53e-11	Blood metabolite levels;
UCEC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.67	6.24	0.46	4.51e-9	Aortic root size;
UCEC	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs925228	0.955	rs2339935	chr2:24205429	T/G	cg13272742	chr2:24272458	FKBP1B	0.6	5.12	0.39	9.62e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.63	-5.78	-0.43	4.36e-8	Coronary artery disease;
UCEC	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-4.62	-0.36	8.22e-6	Blood metabolite levels;
UCEC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.61	-6.93	-0.5	1.2e-10	Vitiligo;
UCEC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-1.15	-8.66	-0.58	7.75e-15	Bone mineral density;
UCEC	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.66	5.9	0.44	2.4e-8	High light scatter reticulocyte count;
UCEC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg06462663	chr19:18546047	ISYNA1	0.53	6.73	0.49	3.51e-10	Breast cancer;
UCEC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.7	-7.84	-0.54	8.43e-13	Facial morphology (factor 23);
UCEC	cis	rs10216189	0.785	rs4623325	chr7:5526807	C/T	cg11800390	chr7:5515995	FBXL18	-0.64	-7.62	-0.53	2.84e-12	Relative hand skill in reading disability;
UCEC	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.49	-5.91	-0.44	2.28e-8	Neuroticism;
UCEC	cis	rs10242455	0.867	rs10211	chr7:99302994	C/T	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.29e-6	Blood metabolite levels;
UCEC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.47	-5.02	-0.38	1.46e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.65	6.9	0.49	1.43e-10	Menopause (age at onset);
UCEC	cis	rs7944735	0.702	rs60515486	chr11:47682725	A/T	cg08722104	chr11:47448306	PSMC3	-0.5	-5.2	-0.39	6.45e-7	Intraocular pressure;
UCEC	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg00646381	chr17:77835854	NA	0.44	5.04	0.38	1.32e-6	Glucocorticoid-induced osteonecrosis (age 10 years and older);
UCEC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.53	-4.98	-0.38	1.73e-6	Corneal astigmatism;
UCEC	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.67	-7.03	-0.5	7.22e-11	Magnesium levels;
UCEC	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.38	0.41	2.81e-7	Breast cancer;
UCEC	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.66	8.03	0.55	2.88e-13	Hip circumference;
UCEC	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.82	9.37	0.61	1.21e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10012307	1.000	rs12650324	chr4:137516318	G/A	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg04043695	chr12:129287642	SLC15A4	0.63	6.2	0.46	5.4e-9	Systemic lupus erythematosus;
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.53	-0.47	9.97e-10	Platelet count;
UCEC	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.65	-5.53	-0.42	1.41e-7	Coronary artery calcification;
UCEC	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06156847	chr2:113672199	IL1F7	-0.33	-4.53	-0.35	1.19e-5	Pulmonary function;
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.5	-0.47	1.19e-9	Platelet count;
UCEC	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.57	0.42	1.19e-7	Cognitive test performance;
UCEC	cis	rs2554380	0.891	rs1155070	chr15:84303084	T/C	cg25130800	chr15:85143846	ZSCAN2	-0.57	-4.55	-0.35	1.11e-5	Height;
UCEC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.1e-7	Schizophrenia;
UCEC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.0	-7.25	-0.51	2.22e-11	Body mass index;
UCEC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg00815214	chr21:47717953	NA	-0.39	-4.55	-0.35	1.1e-5	Testicular germ cell tumor;
UCEC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.62	8.04	0.55	2.76e-13	Anterior chamber depth;
UCEC	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.63	5.81	0.43	3.76e-8	Tourette syndrome;
UCEC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.58	-5.46	-0.41	1.97e-7	Blood protein levels;
UCEC	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.49	-5.61	-0.42	9.61e-8	Depression;
UCEC	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.41	14.99	0.78	2.08e-31	Atopic dermatitis;
UCEC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.83	9.41	0.61	9.22e-17	Menopause (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.61	7.58	0.53	3.62e-12	Warfarin maintenance dose;
UCEC	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.21	0.46	5.06e-9	Motion sickness;
UCEC	cis	rs7072216	0.881	rs2182168	chr10:100148353	C/G	cg19567339	chr10:100142640	NA	0.63	8.71	0.58	5.69e-15	Metabolite levels;
UCEC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.13	14.03	0.76	6.64e-29	Cognitive function;
UCEC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg15412446	chr2:106886593	NA	0.61	5.85	0.43	3.14e-8	Facial morphology (factor 23);
UCEC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg08493051	chr2:3487164	NA	-0.7	-7.13	-0.51	4.27e-11	Neurofibrillary tangles;
UCEC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg22166914	chr1:53195759	ZYG11B	0.59	5.96	0.44	1.81e-8	Monocyte count;
UCEC	cis	rs7015263	0.715	rs6999022	chr8:87523170	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-6.31	-0.46	3.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.54	5.88	0.44	2.66e-8	Retinal vascular caliber;
UCEC	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-1.0	-12.18	-0.71	4.99e-24	Obesity-related traits;
UCEC	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg13683864	chr3:40499215	RPL14	0.82	9.17	0.6	3.9e-16	Renal cell carcinoma;
UCEC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg01874867	chr7:94954059	PON1	-0.51	-4.59	-0.35	9.54e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.55	0.77	2.79e-30	Homoarginine levels;
UCEC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.38	-4.86	-0.37	3.04e-6	Refractive error;
UCEC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.62	6.08	0.45	1.01e-8	Lymphocyte counts;
UCEC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.52	-6.22	-0.46	4.94e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg06784218	chr1:46089804	CCDC17	0.54	6.31	0.46	3.15e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.57	0.42	1.19e-7	Cognitive test performance;
UCEC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.44	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.4	4.91	0.38	2.4e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.81	10.97	0.67	7.77e-21	Headache;
UCEC	cis	rs892864	1.000	rs892864	chr5:127835859	A/T	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Multiple system atrophy;
UCEC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	4.77	0.37	4.33e-6	Lymphocyte counts;
UCEC	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.7	-5.63	-0.42	8.7e-8	Corneal structure;
UCEC	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.51	5.63	0.42	8.8e-8	HDL cholesterol;
UCEC	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	6.44	0.47	1.58e-9	Hemoglobin concentration;
UCEC	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs9467773	1.000	rs9467802	chr6:26581168	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.14	0.51	4.04e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs1161463	1.000	rs1161461	chr13:29431850	G/A	cg00806704	chr13:28539042	CDX2	0.37	4.62	0.36	8.28e-6	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	-0.68	-4.68	-0.36	6.4e-6	Narcolepsy;
UCEC	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.44e-8	Depression;
UCEC	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.42	-4.97	-0.38	1.81e-6	Obesity-related traits;
UCEC	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg23815491	chr16:72088622	HP	0.53	5.48	0.41	1.79e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
UCEC	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.39	-9.01	-0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.21	-0.46	5.25e-9	Pancreatic cancer;
UCEC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.73	7.81	0.54	9.99e-13	Lymphocyte counts;
UCEC	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg05962950	chr11:130786565	SNX19	0.6	6.56	0.48	8.62e-10	Schizophrenia;
UCEC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs807669	0.770	rs807458	chr22:19220648	G/A	cg00504285	chr22:20019887	C22orf25;MIR185	-0.67	-4.52	-0.35	1.28e-5	Metabolite levels;
UCEC	cis	rs10786436	0.572	rs4917839	chr10:100285529	T/C	cg24343515	chr10:99400468	PI4K2A	-0.47	-4.77	-0.37	4.4e-6	Type 1 diabetes;
UCEC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.72	6.35	0.46	2.48e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.11	-0.6	5.7e-16	Coffee consumption (cups per day);
UCEC	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs3750082	0.889	rs6972006	chr7:32938292	T/C	cg05721444	chr7:32995514	FKBP9	0.54	5.96	0.44	1.81e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	0.84	6.36	0.46	2.41e-9	Gut microbiome composition (summer);
UCEC	cis	rs4757319	0.515	rs10832402	chr11:15334036	C/T	cg03245590	chr11:15329459	NA	-0.43	-4.89	-0.37	2.62e-6	Breast cancer;
UCEC	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.66	-7.34	-0.52	1.35e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	7.04	0.5	6.91e-11	Platelet count;
UCEC	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.47	4.68	0.36	6.59e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16346588	chr10:242978	ZMYND11	0.48	4.69	0.36	6.11e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg21486944	chr6:28411378	ZSCAN23	-0.47	-4.78	-0.37	4.14e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg23950597	chr19:37808831	NA	-0.61	-4.82	-0.37	3.47e-6	Coronary artery calcification;
UCEC	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-4.99	-0.38	1.68e-6	Colorectal cancer;
UCEC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.89	-8.35	-0.57	4.6e-14	Alzheimer's disease;
UCEC	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-5.23	-0.4	5.62e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4722166	0.532	rs4719712	chr7:22755807	C/T	cg05472934	chr7:22766657	IL6	0.54	5.12	0.39	9.61e-7	Lung cancer;
UCEC	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.6	6.17	0.45	6.19e-9	Colorectal cancer;
UCEC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Smoking initiation;
UCEC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	6.59	0.48	7.51e-10	Total body bone mineral density;
UCEC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-0.67	-6.79	-0.49	2.59e-10	Platelet distribution width;
UCEC	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.9	8.66	0.58	7.57e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs427941	0.521	rs73187849	chr7:101865834	C/G	cg08135718	chr7:101819329	CUX1	0.53	5.45	0.41	2.05e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.02	-0.44	1.34e-8	Mean platelet volume;
UCEC	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg00105475	chr2:10696890	NA	0.42	5.27	0.4	4.67e-7	Prostate cancer;
UCEC	cis	rs630539	0.793	rs683344	chr17:40696750	G/A	cg09397798	chr17:40696263	NAGLU	0.6	4.7	0.36	5.95e-6	Systolic blood pressure change trajectories;
UCEC	cis	rs10007810	0.760	rs4593169	chr4:41585284	A/G	cg24722073	chr4:41882163	NA	-0.39	-4.64	-0.36	7.74e-6	Longevity (90 years and older);
UCEC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg03146154	chr1:46216737	IPP	0.44	4.7	0.36	5.93e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.46	4.56	0.35	1.06e-5	Parkinson's disease;
UCEC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.37	-0.47	2.23e-9	Aortic root size;
UCEC	cis	rs9467773	1.000	rs1977201	chr6:26573674	T/C	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.89	12.76	0.72	1.41e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg13319975	chr6:146136371	FBXO30	0.52	5.87	0.44	2.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.48	-5.04	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.7	-6.7	-0.48	4.08e-10	Tonsillectomy;
UCEC	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Obesity-related traits;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05214047	chr5:56112645	MAP3K1	0.6	7.36	0.52	1.23e-11	Warfarin maintenance dose;
UCEC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.75	-8.62	-0.58	9.78e-15	Menarche (age at onset);
UCEC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.73	8.03	0.55	2.83e-13	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg12596171	chr3:113251061	SIDT1	-0.53	-5.38	-0.41	2.89e-7	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg27624424	chr6:160112604	SOD2	-0.53	-4.99	-0.38	1.7e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	6.81	0.49	2.38e-10	Platelet count;
UCEC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.44	-5.4	-0.41	2.56e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.55	5.64	0.42	8.38e-8	Tonsillectomy;
UCEC	cis	rs11867410	0.744	rs78037912	chr17:63966283	G/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs4534636	0.812	rs7314690	chr12:8671274	A/C	cg00911551	chr12:8234647	NECAP1	-0.49	-4.51	-0.35	1.33e-5	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
UCEC	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.63	5.35	0.4	3.24e-7	High light scatter reticulocyte count;
UCEC	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-7.14	-0.51	3.9e-11	Heart rate;
UCEC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.54	-5.46	-0.41	2e-7	Aortic root size;
UCEC	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.55	5.63	0.42	8.83e-8	Testicular germ cell tumor;
UCEC	cis	rs7246967	0.673	rs6511374	chr19:22866370	T/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.48	-4.97	-0.38	1.81e-6	Temperament;
UCEC	cis	rs12428035	0.764	rs72637840	chr13:96742287	C/T	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.81	-4.98	-0.38	1.79e-6	Putamen volume;
UCEC	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.42	-4.64	-0.36	7.58e-6	Pelvic organ prolapse;
UCEC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.63	-6.62	-0.48	6.45e-10	Mean platelet volume;
UCEC	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.78	-0.37	4.23e-6	Monocyte percentage of white cells;
UCEC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.54	5.83	0.43	3.45e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.18	-0.39	7.14e-7	Personality dimensions;
UCEC	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14019695	chr9:139328340	INPP5E	0.42	4.64	0.36	7.58e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	6.5	0.47	1.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs17489649	1.000	rs3776933	chr5:109141623	C/G	cg17436293	chr5:109223084	NA	-0.36	-4.59	-0.35	9.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg09457645	chr17:33443370	RAD51L3	0.61	4.63	0.36	8.11e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.6	-5.57	-0.42	1.17e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.69	0.36	6.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs4908768	0.556	rs11121230	chr1:8834706	C/T	cg13081009	chr1:8430745	RERE	0.45	5.0	0.38	1.61e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.6	5.22	0.4	5.99e-7	Coronary artery disease;
UCEC	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg22482690	chr17:47019901	SNF8	-0.46	-5.9	-0.44	2.41e-8	Type 2 diabetes;
UCEC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.36	-4.62	-0.36	8.37e-6	Coronary artery disease;
UCEC	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg10202436	chr5:138733726	SPATA24	-0.3	-4.52	-0.35	1.27e-5	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.97	10.64	0.66	5.95e-20	Cognitive function;
UCEC	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.61	6.57	0.48	8.23e-10	Vitiligo;
UCEC	cis	rs2213920	0.679	rs10759786	chr9:118241188	A/G	cg13918206	chr9:118159781	DEC1	0.6	4.94	0.38	2.11e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.68	6.18	0.45	5.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg04154034	chr17:28927549	LRRC37B2	-0.78	-5.22	-0.4	5.93e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg05855489	chr10:104503620	C10orf26	0.53	4.74	0.36	5.1e-6	Arsenic metabolism;
UCEC	cis	rs1056265	0.544	rs80184323	chr9:71448742	G/C	cg00794837	chr9:72287772	APBA1	-0.51	-4.57	-0.35	1.04e-5	Angiotensin-converting enzyme inhibitor intolerance;
UCEC	cis	rs4372836	0.964	rs4665432	chr2:28952026	G/A	cg09522027	chr2:28974177	PPP1CB	0.79	8.16	0.56	1.36e-13	Body mass index;
UCEC	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.89	-7.36	-0.52	1.23e-11	Coronary artery calcification;
UCEC	cis	rs4778214	0.858	rs10775262	chr15:28233905	T/C	cg08281084	chr15:28459700	HERC2	-0.5	-4.51	-0.35	1.29e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
UCEC	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.6	-6.66	-0.48	5.17e-10	Hemoglobin concentration;
UCEC	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg08250081	chr4:10125330	NA	0.47	4.62	0.36	8.15e-6	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.33	0.61	1.52e-16	Electrocardiographic conduction measures;
UCEC	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs7204230	1.000	rs12596466	chr16:53342860	C/T	cg06492821	chr16:53537101	AKTIP	0.46	4.58	0.35	9.89e-6	Fibrinogen;
UCEC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22509189	chr2:225307070	NA	-0.55	-4.81	-0.37	3.66e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	5.13	0.39	9.18e-7	Cognitive test performance;
UCEC	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg04311557	chr16:71523289	ZNF19	-0.77	-5.41	-0.41	2.49e-7	Post bronchodilator FEV1;
UCEC	cis	rs35934224	0.783	rs7287073	chr22:19864335	G/A	cg11182965	chr22:19864308	TXNRD2	-0.67	-6.35	-0.46	2.54e-9	Glaucoma (primary open-angle);
UCEC	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.84	-0.37	3.23e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.85	-5.83	-0.43	3.42e-8	Exhaled nitric oxide output;
UCEC	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.2	-0.76	2.34e-29	Schizophrenia;
UCEC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.0	-0.67	6.69e-21	Chronic sinus infection;
UCEC	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.69	7.28	0.51	1.88e-11	Blood protein levels;
UCEC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.57	5.26	0.4	5.06e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.49	5.39	0.41	2.7e-7	Response to temozolomide;
UCEC	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.58	5.9	0.44	2.4e-8	White matter hyperintensity burden;
UCEC	cis	rs78487399	0.520	rs7609256	chr2:43672499	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-4.52	-0.35	1.29e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs1362602	1.000	rs1362602	chr12:14838469	G/T	cg08964024	chr12:14923326	NA	-0.47	-4.56	-0.35	1.09e-5	Pediatric bone mineral content (radius);
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.88e-7	Hemoglobin concentration;
UCEC	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-4.58	-0.35	1e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3736757	1.000	rs9425633	chr1:184657251	T/C	cg05045817	chr1:184633523	NA	0.39	4.61	0.36	8.81e-6	Obesity-related traits;
UCEC	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.33	4.86	0.37	2.94e-6	Schizophrenia;
UCEC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11871910	chr12:69753446	YEATS4	0.67	6.64	0.48	5.61e-10	Response to diuretic therapy;
UCEC	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.31	-0.52	1.57e-11	Coronary artery disease;
UCEC	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.59	-0.35	9.27e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.7	-8.16	-0.56	1.41e-13	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	6.26	0.46	3.91e-9	Systemic lupus erythematosus;
UCEC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.85	7.46	0.52	7.03e-12	Initial pursuit acceleration;
UCEC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18402987	chr7:1209562	NA	0.47	4.74	0.36	5.05e-6	Longevity;Endometriosis;
UCEC	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.52	5.39	0.41	2.69e-7	Dupuytren's disease;
UCEC	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.55	-7.16	-0.51	3.55e-11	Inflammatory skin disease;
UCEC	cis	rs2134046	0.555	rs11854483	chr15:82559558	T/C	cg00614314	chr15:82944287	LOC80154	0.5	5.75	0.43	4.97e-8	Cognitive ability;
UCEC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-4.61	-0.36	8.76e-6	Pediatric autoimmune diseases;
UCEC	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.53	-4.74	-0.36	5.03e-6	Colorectal cancer;
UCEC	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.71	-4.95	-0.38	1.98e-6	Toenail selenium levels;
UCEC	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg12637676	chr8:11587161	GATA4	-0.39	-4.53	-0.35	1.19e-5	Triglycerides;
UCEC	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.21	-0.76	2.17e-29	Schizophrenia;
UCEC	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.52	4.56	0.35	1.05e-5	Economic and political preferences (feminism/equality);
UCEC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	9.83	0.63	7.74e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg04025307	chr7:1156635	C7orf50	0.79	5.31	0.4	3.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	0.9	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg14517863	chr17:44321492	NA	0.4	5.2	0.39	6.59e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs2288327	0.730	rs16866358	chr2:179380096	A/G	cg09915519	chr2:179397513	TTN;MIR548N	-0.69	-4.59	-0.35	9.45e-6	Atrial fibrillation;
UCEC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.38	-5.82	-0.43	3.48e-8	Body mass index;
UCEC	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.92	-14.15	-0.76	3.14e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg20965017	chr5:231967	SDHA	-0.62	-5.74	-0.43	5.29e-8	Breast cancer;
UCEC	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.77	-8.38	-0.57	3.88e-14	Height;
UCEC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.66	8.76	0.59	4.38e-15	Anterior chamber depth;
UCEC	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.56	-5.71	-0.43	6.01e-8	Retinal vascular caliber;
UCEC	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.62	6.79	0.49	2.6e-10	IgG glycosylation;
UCEC	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg24375607	chr4:120327624	NA	0.48	5.1	0.39	1.04e-6	Educational attainment;
UCEC	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.5	-5.61	-0.42	9.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.52	-0.35	1.25e-5	Homocysteine levels;
UCEC	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg18681998	chr4:17616180	MED28	-0.54	-5.99	-0.44	1.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.01	-0.38	1.56e-6	Total cholesterol levels;
UCEC	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.4	-5.04	-0.38	1.37e-6	Cutaneous nevi;
UCEC	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	1.05	9.16	0.6	4.11e-16	Dupuytren's disease;
UCEC	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.36	0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.59	-6.01	-0.44	1.4e-8	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg27171509	chr10:82033454	MAT1A	-0.48	-5.07	-0.39	1.17e-6	Borderline personality disorder;
UCEC	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg10513866	chr5:139070639	NA	0.46	6.14	0.45	7.31e-9	Schizophrenia;
UCEC	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.46	-0.72	8.76e-25	Ulcerative colitis;
UCEC	cis	rs4778581	0.643	rs1522636	chr15:80414173	C/G	cg08257866	chr15:80351198	ZFAND6	0.41	4.9	0.37	2.53e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-10.34	-0.65	3.58e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.08	-0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs66573146	1.000	rs7686186	chr4:6986094	C/T	cg07817883	chr1:32538562	TMEM39B	1.13	9.6	0.62	3.04e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs758129	0.501	rs3176205	chr15:89865692	T/C	cg23124613	chr15:89731485	ABHD2	-0.4	-4.63	-0.36	8.11e-6	Schizophrenia;
UCEC	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2425143	0.818	rs11700299	chr20:34548865	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.79	-0.37	4.07e-6	Blood protein levels;
UCEC	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.58	6.73	0.49	3.45e-10	Aortic root size;
UCEC	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.57	5.09	0.39	1.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.67	4.63	0.36	7.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.95	-0.5	1.09e-10	Blood trace element (Zn levels);
UCEC	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.26e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03760483	chr17:6899297	ALOX12	0.47	5.63	0.42	8.87e-8	Tonsillectomy;
UCEC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.86	10.27	0.65	5.32e-19	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.51	5.84	0.43	3.18e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg13695892	chr22:41940480	POLR3H	0.65	4.53	0.35	1.19e-5	Cannabis dependence symptom count;
UCEC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.7	7.49	0.53	5.95e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	6.34	0.46	2.65e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00802000	chr16:706648	WDR90	-0.49	-5.58	-0.42	1.11e-7	Height;
UCEC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.59	-5.3	-0.4	4.21e-7	Menarche (age at onset);
UCEC	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	7.89	0.55	6.51e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs7246967	0.673	rs73022763	chr19:22894216	C/T	cg05241461	chr19:22816980	ZNF492	0.58	6.12	0.45	8.18e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-8.25	-0.56	8.27e-14	Sense of smell;
UCEC	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.99	0.38	1.72e-6	Breast cancer;
UCEC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.99	7.44	0.52	7.74e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg09521647	chr2:100722408	AFF3	0.3	4.63	0.36	7.95e-6	Chronic sinus infection;
UCEC	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.59	5.75	0.43	4.88e-8	Colorectal cancer;
UCEC	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.61	-5.16	-0.39	7.89e-7	LDL cholesterol levels;
UCEC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-10.38	-0.65	2.74e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4026608	0.896	rs899844	chr12:66398933	A/C	cg16292773	chr12:66211550	RPSAP52	-0.45	-4.53	-0.35	1.21e-5	Aortic root size;
UCEC	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.54	6.21	0.46	5.1e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs12234571	1.000	rs77445032	chr7:77387494	T/C	cg20048109	chr7:78158112	MAGI2	-0.5	-5.05	-0.38	1.31e-6	Obesity-related traits;
UCEC	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.72	-5.77	-0.43	4.5e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.56	-4.75	-0.36	4.8e-6	Menarche (age at onset);
UCEC	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs4974559	0.697	rs4974550	chr4:1315658	G/T	cg07110949	chr4:1309878	MAEA	-0.68	-4.7	-0.36	5.84e-6	Systolic blood pressure;
UCEC	cis	rs9549367	0.664	rs3794419	chr13:113851874	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-6.26	-0.46	4.09e-9	Platelet distribution width;
UCEC	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.52	5.02	0.38	1.46e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.1	-0.39	1.03e-6	Mean platelet volume;
UCEC	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg17031739	chr1:67600172	NA	0.45	4.66	0.36	6.94e-6	Psoriasis;
UCEC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.42	4.55	0.35	1.13e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.61	-5.54	-0.42	1.37e-7	Birth weight;
UCEC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.75	-8.62	-0.58	9.87e-15	Age at first birth;
UCEC	cis	rs847649	1.000	rs9718453	chr7:102594976	T/G	cg18108683	chr7:102477205	FBXL13	0.61	7.79	0.54	1.12e-12	Morning vs. evening chronotype;
UCEC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg02413938	chr2:239008929	ESPNL	-0.36	-4.64	-0.36	7.64e-6	Prostate cancer;
UCEC	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.44	-0.47	1.57e-9	Crohn's disease;
UCEC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.73	7.86	0.54	7.56e-13	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg20825769	chr15:43991375	CKMT1A	-0.57	-4.62	-0.36	8.34e-6	Lung cancer in ever smokers;
UCEC	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.43	-4.72	-0.36	5.49e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.5	-4.87	-0.37	2.91e-6	Obesity-related traits;
UCEC	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.86	-6.0	-0.44	1.47e-8	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.48	0.77	4.23e-30	Height;
UCEC	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg12870014	chr12:110450643	ANKRD13A	0.58	4.91	0.38	2.4e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.69	0.42	6.66e-8	Rheumatoid arthritis;
UCEC	cis	rs6728642	1.000	rs6728642	chr2:97607071	A/G	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.05	-0.5	6.38e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.6	5.4	0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg14008862	chr17:28927542	LRRC37B2	0.68	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.85	7.57	0.53	3.89e-12	Body mass index;
UCEC	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.44	5.17	0.39	7.65e-7	Blood metabolite ratios;
UCEC	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.52	5.94	0.44	2.01e-8	Mean corpuscular volume;
UCEC	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg18755752	chr8:142205143	DENND3	-0.58	-5.36	-0.4	3.19e-7	Immature fraction of reticulocytes;
UCEC	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.66	5.81	0.43	3.74e-8	Coronary artery disease;
UCEC	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.2	-0.39	6.55e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.48	5.45	0.41	2.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.72	-8.38	-0.57	3.88e-14	Body mass index;
UCEC	cis	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.95	0.44	1.84e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.58	6.42	0.47	1.77e-9	Mean platelet volume;
UCEC	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg04155231	chr12:9217510	LOC144571	0.42	5.23	0.4	5.68e-7	Sjögren's syndrome;
UCEC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.5	5.17	0.39	7.48e-7	Schizophrenia;
UCEC	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.76	-8.23	-0.56	9.17e-14	Breast cancer;
UCEC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg07169764	chr2:136633963	MCM6	-0.65	-6.01	-0.44	1.36e-8	Mosquito bite size;
UCEC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.51	4.88	0.37	2.79e-6	Emphysema distribution in smoking;
UCEC	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg26068271	chr17:76253126	NA	0.45	5.23	0.4	5.62e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.55	-6.64	-0.48	5.72e-10	Paraoxonase activity;
UCEC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.61	6.26	0.46	4.02e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg21466736	chr12:48725269	NA	0.38	4.59	0.35	9.31e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.61	5.95	0.44	1.86e-8	Red cell distribution width;
UCEC	cis	rs74542309	0.947	rs2244206	chr10:72544588	G/C	cg15763670	chr10:73473235	C10orf105;CDH23	-0.61	-4.75	-0.36	4.85e-6	Pursuit maintenance gain;
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.54	-0.47	9.71e-10	Platelet count;
UCEC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-0.93	-12.94	-0.73	4.68e-26	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg02160872	chr5:212506	CCDC127	-0.69	-7.19	-0.51	3.04e-11	Breast cancer;
UCEC	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg13147721	chr7:65941812	NA	-0.96	-6.5	-0.47	1.2e-9	Gout;
UCEC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-5.34	-0.4	3.48e-7	Schizophrenia;
UCEC	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.51	5.37	0.4	3.06e-7	Systolic blood pressure;
UCEC	cis	rs1405069	0.809	rs1046279	chr6:36932571	C/T	cg26433444	chr6:36932349	PI16	-0.4	-5.71	-0.43	5.91e-8	Chemerin levels;
UCEC	cis	rs36051895	0.672	rs12353218	chr9:5162828	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-4.78	-0.37	4.22e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs8105895	1.000	rs11881224	chr19:22220340	G/A	cg24175803	chr19:22235144	ZNF257	-0.52	-4.74	-0.36	4.9e-6	Body mass index (change over time);
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg09120320	chr17:61926383	NA	0.44	4.62	0.36	8.2e-6	Prudent dietary pattern;
UCEC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.46	-5.41	-0.41	2.47e-7	Breast cancer;
UCEC	cis	rs7766436	0.687	rs10485012	chr6:22607026	A/C	cg13666174	chr6:22585274	NA	-0.45	-4.6	-0.36	8.87e-6	Coronary artery disease;
UCEC	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.76	-7.81	-0.54	1.01e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.68	6.71	0.48	3.83e-10	Type 2 diabetes;
UCEC	cis	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg00614314	chr15:82944287	LOC80154	0.51	5.82	0.43	3.58e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.69	-4.93	-0.38	2.18e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg04492929	chr16:2155436	PKD1	0.49	4.6	0.36	8.86e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.54	5.28	0.4	4.55e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.62	6.56	0.48	8.8e-10	Colorectal cancer;
UCEC	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.56	-5.52	-0.41	1.47e-7	Vitiligo;
UCEC	cis	rs3750082	0.889	rs13244998	chr7:32912910	T/C	cg05721444	chr7:32995514	FKBP9	0.52	5.83	0.43	3.42e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs8105895	0.935	rs75025987	chr19:22230669	T/A	cg24072202	chr19:22235272	ZNF257	-0.56	-4.66	-0.36	6.89e-6	Body mass index (change over time);
UCEC	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg10596483	chr8:143751796	JRK	-0.44	-4.55	-0.35	1.11e-5	Schizophrenia;
UCEC	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.56	-4.75	-0.36	4.8e-6	Menarche (age at onset);
UCEC	cis	rs7246967	0.866	rs438972	chr19:23019827	A/G	cg08271804	chr19:22816896	ZNF492	0.52	5.0	0.38	1.61e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1424233	0.967	rs8058676	chr16:79684133	C/G	cg02501155	chr16:79263473	NA	0.34	4.59	0.35	9.42e-6	Obesity;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg10536369	chr2:170335894	BBS5	-0.6	-7.08	-0.5	5.63e-11	Breast cancer;
UCEC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.6	0.35	9.01e-6	Parkinson's disease;
UCEC	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.82	0.43	3.49e-8	Life satisfaction;
UCEC	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.27e-8	Systemic lupus erythematosus;
UCEC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg21053147	chr12:120880522	NA	-0.66	-5.43	-0.41	2.23e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.56	-4.99	-0.38	1.68e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.54	7.91	0.55	5.57e-13	Coronary artery disease or large artery stroke;
UCEC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.98	-11.54	-0.69	2.43e-22	Cognitive function;
UCEC	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-7.9	-0.55	5.89e-13	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.44	5.03	0.38	1.42e-6	Lung cancer;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.6	-6.78	-0.49	2.69e-10	Cardiac Troponin-T levels;
UCEC	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-5.07	-0.39	1.17e-6	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg00105475	chr2:10696890	NA	0.42	5.14	0.39	8.53e-7	Prostate cancer;
UCEC	cis	rs55665837	0.539	rs731042	chr11:14874975	A/T	cg19336497	chr11:14380999	RRAS2	-0.31	-4.53	-0.35	1.22e-5	Vitamin D levels;
UCEC	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg06166341	chr4:1223170	CTBP1	0.58	5.11	0.39	9.81e-7	Systolic blood pressure;
UCEC	cis	rs7147624	1.000	rs7150233	chr14:66200816	A/G	cg03016385	chr14:66212404	NA	-0.8	-5.7	-0.43	6.2e-8	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs4820803	1.000	rs2301290	chr22:29661341	C/T	cg07256473	chr22:29710276	RASL10A	-0.7	-5.01	-0.38	1.56e-6	Breast cancer;
UCEC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.55	5.09	0.39	1.09e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg03714773	chr7:91764589	CYP51A1	0.41	4.75	0.36	4.8e-6	Breast cancer;
UCEC	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.53	4.85	0.37	3.11e-6	Coronary artery disease;
UCEC	cis	rs7101446	0.568	rs629907	chr11:63176534	T/C	cg22625903	chr11:62313283	AHNAK	-0.5	-4.59	-0.35	9.42e-6	Economic and political preferences;
UCEC	cis	rs9321099	1.000	rs9402003	chr6:128220319	C/T	cg25012434	chr6:128842125	PTPRK	0.72	5.03	0.38	1.41e-6	Sense of smell;
UCEC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	5.56	0.42	1.21e-7	Bipolar disorder;
UCEC	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.8	-9.96	-0.63	3.59e-18	White blood cell count (basophil);
UCEC	cis	rs4668356	1.000	rs16859087	chr2:171855833	G/A	cg13882835	chr2:172017928	TLK1	0.66	4.53	0.35	1.21e-5	Cognitive performance;
UCEC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.59	6.21	0.46	5.16e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-0.61	-7.16	-0.51	3.59e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.81	4.56	0.35	1.06e-5	Diabetic retinopathy;
UCEC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs7215564	0.908	rs35112467	chr17:78677562	C/T	cg04242349	chr17:79082840	BAIAP2	0.5	4.7	0.36	5.82e-6	Myopia (pathological);
UCEC	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.63	6.25	0.46	4.18e-9	Coronary artery disease;
UCEC	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.8	8.45	0.57	2.68e-14	Menopause (age at onset);
UCEC	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-0.9	-7.7	-0.54	1.86e-12	Blood pressure (smoking interaction);
UCEC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.52	-4.95	-0.38	1.97e-6	Schizophrenia;
UCEC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.76	9.34	0.61	1.47e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs892864	0.803	rs78409309	chr5:127853260	T/C	cg17313118	chr5:127157258	NA	0.77	4.71	0.36	5.59e-6	Multiple system atrophy;
UCEC	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs17123764	0.710	rs11169106	chr12:50078567	T/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.64	-5.49	-0.41	1.69e-7	Cocaine dependence;
UCEC	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.13	-0.39	9.12e-7	Personality dimensions;
UCEC	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	0.93	6.69	0.48	4.38e-10	Economic and political preferences (immigration/crime);
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg07404485	chr7:94953653	PON1	0.51	4.58	0.35	9.93e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.71	-7.14	-0.51	4.02e-11	Blood metabolite levels;
UCEC	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg17031739	chr1:67600172	NA	-0.45	-4.88	-0.37	2.74e-6	Psoriasis;
UCEC	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg10950441	chr12:67439808	NA	-0.41	-4.54	-0.35	1.15e-5	White blood cell count (basophil);
UCEC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.67	-6.87	-0.49	1.7e-10	Multiple sclerosis;
UCEC	trans	rs11169552	0.510	rs10876043	chr12:50904144	C/T	cg24095088	chr6:160210874	MRPL18;TCP1	-0.7	-7.54	-0.53	4.5e-12	Colorectal cancer;
UCEC	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.7	-7.51	-0.53	5.17e-12	Blood protein levels;
UCEC	cis	rs35934224	0.783	rs28360650	chr22:19857061	A/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.11	-0.39	1.01e-6	Glaucoma (primary open-angle);
UCEC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.46	-4.82	-0.37	3.53e-6	Response to antineoplastic agents;
UCEC	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	7.04	0.5	6.95e-11	Alzheimer's disease;
UCEC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg06238570	chr21:40685208	BRWD1	0.83	7.54	0.53	4.42e-12	Cognitive function;
UCEC	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.48	5.14	0.39	8.73e-7	Response to temozolomide;
UCEC	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg13575925	chr12:9217583	LOC144571	0.42	4.97	0.38	1.83e-6	Sjögren's syndrome;
UCEC	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.66	6.45	0.47	1.48e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs16957091	0.865	rs67391479	chr15:43004351	G/A	cg24196017	chr15:43021976	CDAN1	-0.55	-5.54	-0.42	1.38e-7	MGMT methylation in smokers;
UCEC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.83	0.37	3.34e-6	Breast cancer;
UCEC	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-6.43	-0.47	1.64e-9	Morning vs. evening chronotype;
UCEC	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.58	-5.96	-0.44	1.75e-8	Ulcerative colitis;
UCEC	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.61	6.19	0.45	5.63e-9	Homoarginine levels;
UCEC	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg05660106	chr1:15850417	CASP9	0.62	5.71	0.43	6.01e-8	Systolic blood pressure;
UCEC	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.44	-4.79	-0.37	3.99e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-9.59	-0.62	3.24e-17	Blood metabolite levels;
UCEC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.63	-6.92	-0.5	1.27e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.35	-4.53	-0.35	1.22e-5	Refractive error;
UCEC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.08e-8	Breast cancer;
UCEC	cis	rs6578185	0.782	rs6578184	chr8:142453003	A/G	cg09858281	chr8:142456070	FLJ43860	-0.32	-4.61	-0.36	8.59e-6	Endometriosis;
UCEC	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.56	6.12	0.45	8.05e-9	Red blood cell count;
UCEC	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	11.37	0.68	6.71e-22	Platelet count;
UCEC	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.24	0.46	4.44e-9	Cognitive test performance;
UCEC	cis	rs2167364	0.773	rs11575375	chr7:50571779	G/A	cg18232548	chr7:50535776	DDC	0.52	5.48	0.41	1.76e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	5.95	0.44	1.85e-8	Joint mobility (Beighton score);
UCEC	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.66	6.06	0.45	1.09e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.59	6.72	0.48	3.79e-10	Schizophrenia;
UCEC	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.08	-0.45	1e-8	Morning vs. evening chronotype;
UCEC	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg00105475	chr2:10696890	NA	0.42	5.12	0.39	9.57e-7	Prostate cancer;
UCEC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.99	0.44	1.57e-8	Tonsillectomy;
UCEC	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.84	-8.54	-0.58	1.58e-14	Primary sclerosing cholangitis;
UCEC	cis	rs4756059	0.649	rs2959104	chr11:46065036	G/A	cg15637527	chr11:46700234	ARHGAP1	0.76	4.53	0.35	1.22e-5	Menarche (age at onset);
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.62	7.12	0.51	4.47e-11	Menarche (age at onset);
UCEC	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.7	4.61	0.36	8.56e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg13777783	chr17:79615861	NA	-0.33	-4.68	-0.36	6.49e-6	Eye color traits;
UCEC	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.66	5.24	0.4	5.48e-7	Obesity-related traits;
UCEC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.46	-6.64	-0.48	5.67e-10	Urinary metabolites;
UCEC	cis	rs3824488	0.920	rs28418339	chr9:98253476	G/A	cg14565164	chr9:98057177	FANCC	0.72	5.02	0.38	1.47e-6	Neuroticism;
UCEC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.38	-0.41	2.82e-7	Breast cancer;
UCEC	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.5	4.69	0.36	6.31e-6	Diabetic retinopathy;
UCEC	cis	rs6715284	0.579	rs7573128	chr2:202462471	G/A	cg23517999	chr2:202814523	NA	0.45	4.53	0.35	1.21e-5	Rheumatoid arthritis;
UCEC	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg20387954	chr3:183756860	HTR3D	0.47	5.56	0.42	1.21e-7	Anterior chamber depth;
UCEC	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.63	-6.9	-0.49	1.44e-10	Paraoxonase activity;
UCEC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.72	8.85	0.59	2.55e-15	Vitiligo;
UCEC	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.67	-7.25	-0.51	2.15e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.41	-4.62	-0.36	8.26e-6	Inflammatory bowel disease;
UCEC	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg23978390	chr7:1156363	C7orf50	0.51	4.59	0.35	9.57e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg04154034	chr17:28927549	LRRC37B2	-0.56	-4.95	-0.38	2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs9283706	0.608	rs12523505	chr5:66334631	C/T	cg11590213	chr5:66331682	MAST4	0.45	5.62	0.42	9.42e-8	Coronary artery disease;
UCEC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	1.04	11.34	0.68	8.39e-22	Breast cancer;
UCEC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	5.67	0.42	7.25e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs73206853	0.841	rs73206882	chr12:110840515	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.77	6.51	0.47	1.11e-9	Menopause (age at onset);
UCEC	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.84	6.89	0.49	1.49e-10	Gastritis;
UCEC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.54	5.17	0.39	7.41e-7	Schizophrenia;
UCEC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.61	5.99	0.44	1.54e-8	Colorectal cancer;
UCEC	cis	rs7766436	0.885	rs12524244	chr6:22585287	T/C	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01973587	chr1:228161476	NA	-0.39	-4.94	-0.38	2.13e-6	Diastolic blood pressure;
UCEC	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.93	-6.31	-0.46	3.16e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-4.53	-0.35	1.22e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs354033	1.000	rs354034	chr7:149290497	G/A	cg24335155	chr7:149193227	ZNF746	0.37	4.6	0.35	8.94e-6	Multiple sclerosis;
UCEC	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.6	5.2	0.39	6.55e-7	Crohn's disease;
UCEC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-5.18	-0.39	7.28e-7	Colorectal cancer;
UCEC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.63	-0.48	6.13e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.77	-6.07	-0.45	1.01e-8	Birth weight;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.58	-6.48	-0.47	1.28e-9	Longevity;Endometriosis;
UCEC	cis	rs72700829	0.593	rs7526955	chr1:150990913	C/G	cg00107782	chr1:151300621	NA	-0.67	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.8	8.11	0.56	1.86e-13	Schizophrenia;
UCEC	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-0.54	-5.44	-0.41	2.16e-7	Pediatric autoimmune diseases;
UCEC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg20821713	chr7:1055600	C7orf50	-0.57	-6.22	-0.46	4.87e-9	Longevity;Endometriosis;
UCEC	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg06096015	chr1:231504339	EGLN1	0.47	5.57	0.42	1.17e-7	Hemoglobin concentration;
UCEC	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	5.02	0.38	1.48e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg02160872	chr5:212506	CCDC127	-0.64	-5.58	-0.42	1.13e-7	Asthma (childhood onset);
UCEC	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.54	4.63	0.36	8e-6	Birth weight;
UCEC	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg13683864	chr3:40499215	RPL14	-0.96	-10.65	-0.66	5.49e-20	Renal cell carcinoma;
UCEC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg06818710	chr6:28411271	ZSCAN23	0.43	4.64	0.36	7.78e-6	Parkinson's disease;
UCEC	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.89	-8.05	-0.55	2.5e-13	Blood protein levels;
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.94	0.38	2.06e-6	Breast cancer;
UCEC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.84	-0.7	3.94e-23	Monocyte count;
UCEC	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-0.84	-5.66	-0.42	7.68e-8	Arsenic metabolism;
UCEC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg06484146	chr7:12443880	VWDE	-0.79	-5.88	-0.44	2.64e-8	Coronary artery disease;
UCEC	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg13944111	chr12:107296891	NA	0.34	4.53	0.35	1.23e-5	Glaucoma (low intraocular pressure);
UCEC	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.44e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.34	4.78	0.37	4.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.85	10.7	0.66	4.04e-20	Menarche (age at onset);
UCEC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg01380346	chr19:18557039	ELL	-0.48	-4.89	-0.37	2.6e-6	Breast cancer;
UCEC	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	5.83	0.43	3.37e-8	Response to antipsychotic treatment;
UCEC	cis	rs7581030	0.958	rs2058898	chr2:71524757	G/A	cg07678644	chr2:71558969	ZNF638	0.58	5.33	0.4	3.67e-7	Testicular germ cell tumor;
UCEC	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg21214455	chr15:72412075	SENP8	0.48	4.5	0.35	1.35e-5	Red blood cell count;
UCEC	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.85	-0.37	3.09e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.48	4.83	0.37	3.33e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.99	-12.0	-0.7	1.46e-23	Obesity-related traits;
UCEC	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	1.03	14.18	0.76	2.55e-29	Ulcerative colitis;
UCEC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.14	14.36	0.76	9.12e-30	Type 1 diabetes nephropathy;
UCEC	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg15358701	chr1:161410459	NA	-0.74	-5.07	-0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.54	-5.26	-0.4	5e-7	Asthma (sex interaction);
UCEC	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.46	-6.0	-0.44	1.49e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg14664628	chr15:75095509	CSK	-0.51	-4.92	-0.38	2.31e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.35e-18	Height;
UCEC	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.56	6.61	0.48	6.64e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	8.64	0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.83	10.23	0.64	6.95e-19	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26002218	chr14:103986227	CKB	0.34	4.81	0.37	3.69e-6	Body mass index;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.57	-5.98	-0.44	1.61e-8	Pubertal anthropometrics;
UCEC	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg15147215	chr3:52552868	STAB1	0.42	4.71	0.36	5.57e-6	Bipolar disorder;
UCEC	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.57	4.87	0.37	2.83e-6	Lung cancer;
UCEC	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg03859395	chr2:55845619	SMEK2	-0.89	-9.74	-0.63	1.29e-17	Metabolic syndrome;
UCEC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	7.9	0.55	5.84e-13	Smoking behavior;
UCEC	cis	rs7113850	0.541	rs74708033	chr11:24223512	C/T	ch.11.24196551F	chr11:24239977	NA	0.62	4.71	0.36	5.67e-6	Bone fracture in osteoporosis;
UCEC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.55	7.0	0.5	8.48e-11	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.68	-7.04	-0.5	6.81e-11	Neurofibrillary tangles;
UCEC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.26	0.51	2.07e-11	Tonsillectomy;
UCEC	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs7959452	0.905	rs4761234	chr12:69732105	T/C	cg20891283	chr12:69753455	YEATS4	0.86	9.22	0.61	2.92e-16	Blood protein levels;
UCEC	cis	rs7709377	0.595	rs10056823	chr5:115609454	C/G	cg23108291	chr5:115420582	COMMD10	0.57	5.96	0.44	1.82e-8	Metabolite levels  (X-11787);
UCEC	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-0.84	-5.67	-0.42	7.29e-8	Blood protein levels;
UCEC	cis	rs4499344	0.696	rs2868154	chr19:33099305	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	6.2	0.46	5.51e-9	Mean platelet volume;
UCEC	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.57	-4.62	-0.36	8.32e-6	Menopause (age at onset);
UCEC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.98	0.38	1.78e-6	Cognitive ability;
UCEC	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.6	-5.36	-0.4	3.17e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg14092571	chr14:90743983	NA	-0.44	-5.97	-0.44	1.69e-8	Mortality in heart failure;
UCEC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.86e-6	Body mass index;
UCEC	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.91	0.5	1.38e-10	Resting heart rate;
UCEC	cis	rs155346	0.901	rs265179	chr5:139365452	C/G	cg01090482	chr5:139365336	NRG2	-0.38	-4.52	-0.35	1.26e-5	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
UCEC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.55	5.52	0.41	1.48e-7	Obesity-related traits;
UCEC	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06671706	chr8:8559999	CLDN23	0.64	5.3	0.4	4.06e-7	Obesity-related traits;
UCEC	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	6.3	0.46	3.2e-9	Alzheimer's disease;
UCEC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.73	7.4	0.52	9.7e-12	Itch intensity from mosquito bite;
UCEC	cis	rs953387	1.000	rs6715785	chr2:136910273	C/T	cg07169764	chr2:136633963	MCM6	0.53	5.26	0.4	4.94e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.63	-5.87	-0.44	2.83e-8	Resting heart rate;
UCEC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-9.04	-0.6	8.36e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg02461776	chr11:598696	PHRF1	0.51	5.19	0.39	6.94e-7	Systemic lupus erythematosus;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg21856205	chr7:94953877	PON1	-0.56	-5.32	-0.4	3.8e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-4.51	-0.35	1.33e-5	Osteoarthritis;
UCEC	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-6.05	-0.45	1.14e-8	Mean platelet volume;
UCEC	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg05527609	chr1:210001259	C1orf107	-0.6	-4.57	-0.35	1.01e-5	Red blood cell count;
UCEC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13870426	chr17:30244630	NA	-0.62	-5.44	-0.41	2.17e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.17	0.51	3.32e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.46	0.41	1.94e-7	Prudent dietary pattern;
UCEC	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.41	5.69	0.42	6.79e-8	Sitting height ratio;
UCEC	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg11859384	chr17:80120422	CCDC57	-0.52	-5.76	-0.43	4.65e-8	Life satisfaction;
UCEC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	8.2	0.56	1.09e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.6	5.31	0.4	3.88e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.25e-9	Skin colour saturation;
UCEC	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	6.62	0.48	6.3e-10	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.56	-4.61	-0.36	8.6e-6	Alopecia areata;
UCEC	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg26718707	chr10:518370	DIP2C	-0.42	-4.8	-0.37	3.89e-6	Psychosis in Alzheimer's disease;
UCEC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.74	-7.99	-0.55	3.69e-13	Coronary artery disease;
UCEC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.53	5.36	0.4	3.1e-7	Corneal astigmatism;
UCEC	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.58	5.49	0.41	1.73e-7	High light scatter reticulocyte count;
UCEC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.96	6.08	0.45	9.79e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.63e-7	Life satisfaction;
UCEC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.47	6.43	0.47	1.7e-9	Blood protein levels;
UCEC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.87	-9.82	-0.63	7.97e-18	Cognitive function;
UCEC	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.1	9.43	0.61	8.5e-17	Blood protein levels;
UCEC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg27624424	chr6:160112604	SOD2	0.58	4.75	0.36	4.86e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9546434	0.793	rs7339267	chr13:36648068	G/A	cg20704442	chr13:36052768	MIR548F5;NBEA	-0.47	-4.85	-0.37	3.14e-6	Optic cup area;
UCEC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.87	-9.73	-0.63	1.44e-17	Cognitive function;
UCEC	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.61	6.73	0.49	3.51e-10	Longevity;
UCEC	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.65	5.11	0.39	9.77e-7	Type 2 diabetes;
UCEC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.81	-7.58	-0.53	3.59e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.43	4.76	0.37	4.66e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	0.69	7.84	0.54	8.53e-13	Homoarginine levels;
UCEC	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.41	5.49	0.41	1.71e-7	Breast cancer;
UCEC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-5.18	-0.39	7.06e-7	Aortic root size;
UCEC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-5.75	-0.43	5.05e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.48	6.01	0.44	1.37e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.54	-6.03	-0.45	1.3e-8	Life satisfaction;
UCEC	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-5.59	-0.42	1.08e-7	Morning vs. evening chronotype;
UCEC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.46	5.2	0.39	6.64e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-4.73	-0.36	5.29e-6	QRS duration;
UCEC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.65	6.71	0.48	3.95e-10	Obesity-related traits;
UCEC	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.77	7.79	0.54	1.09e-12	Response to antineoplastic agents;
UCEC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.56	5.22	0.4	6.08e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.57	4.84	0.37	3.31e-6	Response to diuretic therapy;
UCEC	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs7246967	0.611	rs2361022	chr19:22816533	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.56	0.35	1.09e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9831754	1.000	rs1028024	chr3:78371577	A/C	cg06138941	chr3:78371609	NA	-0.79	-6.28	-0.46	3.54e-9	Calcium levels;
UCEC	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg22654517	chr2:96458247	NA	0.43	4.91	0.38	2.38e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.86	0.44	2.88e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.79	-9.41	-0.61	9.58e-17	Morning vs. evening chronotype;
UCEC	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.97	7.31	0.52	1.59e-11	Obesity-related traits;
UCEC	cis	rs7646881	0.544	rs73024790	chr3:158324404	A/C	cg05743054	chr3:158288903	MLF1	-0.54	-4.96	-0.38	1.89e-6	Tetralogy of Fallot;
UCEC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.64	6.56	0.48	8.48e-10	Menopause (age at onset);
UCEC	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Kawasaki disease;
UCEC	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-6.1	-0.45	8.75e-9	Parkinson's disease;
UCEC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-4.84	-0.37	3.25e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	cis	rs2307449	0.929	rs3176238	chr15:89860427	C/T	cg23124613	chr15:89731485	ABHD2	-0.42	-4.97	-0.38	1.87e-6	Menopause (age at onset);
UCEC	cis	rs728616	0.510	rs7074356	chr10:82191334	C/T	cg27210863	chr10:82299606	SH2D4B	-0.37	-4.79	-0.37	3.97e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg19567339	chr10:100142640	NA	-0.41	-4.7	-0.36	5.98e-6	Metabolite levels;
UCEC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs9470794	0.850	rs10947717	chr6:38159873	C/T	cg01504030	chr6:38141879	BTBD9	-0.8	-5.15	-0.39	8.39e-7	Type 2 diabetes;
UCEC	cis	rs7709377	0.547	rs253961	chr5:115687715	A/G	cg23108291	chr5:115420582	COMMD10	0.49	4.83	0.37	3.39e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	6.4	0.47	1.95e-9	Blood metabolite levels;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.85	-0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.64	-6.62	-0.48	6.44e-10	Prostate cancer;
UCEC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.67	-6.26	-0.46	4e-9	Aortic root size;
UCEC	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.67	7.18	0.51	3.13e-11	Mean corpuscular volume;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.82	11.0	0.67	6.65e-21	Menarche (age at onset);
UCEC	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.82	8.14	0.56	1.55e-13	Schizophrenia;
UCEC	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.41	4.6	0.35	9.17e-6	Mean corpuscular volume;
UCEC	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.5	-4.63	-0.36	8.13e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.24e-10	Aortic root size;
UCEC	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.65	0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.53e-8	Breast cancer;
UCEC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.46	-5.22	-0.4	5.97e-7	Response to antineoplastic agents;
UCEC	cis	rs59104589	0.617	rs7568	chr2:242291743	A/G	cg19488206	chr2:242435732	STK25	0.51	4.52	0.35	1.28e-5	Fibrinogen levels;
UCEC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	6.02	0.44	1.35e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1639906	0.560	rs1639915	chr7:2258084	C/G	cg13470333	chr7:1908714	MAD1L1	0.4	4.55	0.35	1.14e-5	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.03	0.38	1.42e-6	Diabetic retinopathy;
UCEC	cis	rs1940013	0.767	rs7932411	chr11:132232532	T/C	cg11473001	chr11:131780499	NTM	-0.43	-5.07	-0.39	1.16e-6	Sleep-related phenotypes;
UCEC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-1.01	-7.43	-0.52	8.3e-12	Mean corpuscular volume;
UCEC	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.42	-5.73	-0.43	5.52e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.23	-15.21	-0.78	5.67e-32	Breast cancer;
UCEC	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	0.7	5.45	0.41	2.09e-7	Blood protein levels;
UCEC	cis	rs11235843	1.000	rs2272248	chr11:73371942	A/C	cg23931323	chr11:73372278	PLEKHB1	0.75	4.75	0.36	4.78e-6	Hand grip strength;
UCEC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-4.93	-0.38	2.17e-6	Gut microbiome composition (summer);
UCEC	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.68	7.99	0.55	3.71e-13	Metabolite levels;
UCEC	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-1.06	-8.07	-0.55	2.29e-13	Multiple sclerosis;
UCEC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg05241461	chr19:22816980	ZNF492	0.58	6.36	0.46	2.37e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.35e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg24687543	chr11:63912206	MACROD1	0.43	5.07	0.39	1.19e-6	Platelet count;
UCEC	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.66	7.24	0.51	2.31e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	5.85	0.43	3.11e-8	Platelet count;
UCEC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.64	6.87	0.49	1.73e-10	Age at first birth;
UCEC	cis	rs692916	0.905	rs562185	chr18:60538263	G/A	cg07187971	chr18:60481018	PHLPP1	-0.41	-5.51	-0.41	1.57e-7	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg06768213	chr1:227963296	SNAP47	0.38	4.67	0.36	6.85e-6	Diastolic blood pressure;
UCEC	cis	rs9341808	0.600	rs590641	chr6:80966483	A/G	cg08355045	chr6:80787529	NA	0.39	5.21	0.39	6.36e-7	Sitting height ratio;
UCEC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.82	-0.49	2.26e-10	Prostate cancer;
UCEC	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.97	-0.5	1e-10	Colorectal cancer;
UCEC	cis	rs11697848	1.000	rs74928591	chr20:48521878	A/C	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.04	-0.7	1.19e-23	Ulcerative colitis;
UCEC	cis	rs7607369	0.536	rs6436092	chr2:219669148	T/A	cg02176678	chr2:219576539	TTLL4	-0.52	-5.33	-0.4	3.68e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.69	-6.23	-0.46	4.54e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg00343986	chr7:65444356	GUSB	0.59	5.21	0.39	6.36e-7	Calcium levels;
UCEC	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	5.37	0.41	2.96e-7	Coronary artery disease;
UCEC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg06238570	chr21:40685208	BRWD1	-0.64	-7.14	-0.51	3.97e-11	Menarche (age at onset);
UCEC	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.55	5.36	0.4	3.21e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.57	0.42	1.18e-7	Alzheimer's disease;
UCEC	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.45	-0.47	1.49e-9	Response to antipsychotic treatment;
UCEC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.84	0.37	3.27e-6	Breast cancer;
UCEC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.81	7.82	0.54	9.31e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.57	0.42	1.19e-7	Cognitive test performance;
UCEC	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg21521518	chr4:53727714	RASL11B	-0.62	-4.87	-0.37	2.81e-6	Optic nerve measurement (cup area);
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg27568321	chr4:113152709	AP1AR	-0.59	-6.71	-0.48	3.93e-10	Breast cancer;
UCEC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-6.82	-0.49	2.22e-10	Breast cancer;
UCEC	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-4.63	-0.36	7.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.57	-5.41	-0.41	2.45e-7	Blood protein levels;
UCEC	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-5.46	-0.41	1.96e-7	Height;
UCEC	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.62	7.1	0.51	4.88e-11	Leprosy;
UCEC	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.7	-7.56	-0.53	4.03e-12	Blood protein levels;
UCEC	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.56	4.93	0.38	2.16e-6	Smoking initiation;
UCEC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.3	-0.46	3.33e-9	Chronic sinus infection;
UCEC	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg17534202	chr9:96721102	NA	0.48	5.13	0.39	8.95e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.72	-8.17	-0.56	1.3e-13	Waist circumference;Body mass index;
UCEC	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-7.25	-0.51	2.18e-11	Response to antipsychotic treatment;
UCEC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs79976124	0.797	rs2226266	chr6:66617302	C/T	cg07460842	chr6:66804631	NA	0.75	5.63	0.42	8.81e-8	Type 2 diabetes;
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.52	4.86	0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.61	-6.35	-0.46	2.58e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	1.16	5.95	0.44	1.87e-8	LDL cholesterol;
UCEC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.79	-6.25	-0.46	4.14e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg18877361	chr14:105973846	NA	-0.38	-4.52	-0.35	1.26e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
UCEC	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.57	-5.59	-0.42	1.06e-7	Acne (severe);
UCEC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.69	-7.03	-0.5	7.28e-11	Blood metabolite levels;
UCEC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.02	0.44	1.3e-8	Aortic root size;
UCEC	cis	rs7101446	0.681	rs4357693	chr11:63176861	G/T	cg21706343	chr11:62521476	ZBTB3	-0.54	-4.53	-0.35	1.23e-5	Economic and political preferences;
UCEC	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.69	0.36	6.18e-6	Colorectal cancer;
UCEC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg17077180	chr1:38461687	NA	0.63	6.13	0.45	7.87e-9	Coronary artery disease;
UCEC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.4	-0.57	3.47e-14	Chronic sinus infection;
UCEC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.69	7.54	0.53	4.38e-12	Menopause (age at onset);
UCEC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.04	-0.38	1.37e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4448343	0.963	rs3758302	chr9:98272630	G/C	cg13456470	chr9:98266766	PTCH1	0.41	5.56	0.42	1.22e-7	Height;
UCEC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.11	-0.45	8.61e-9	Parkinson's disease;
UCEC	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.35	-5.32	-0.4	3.73e-7	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.79	6.01	0.44	1.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg15167202	chr5:149997153	SYNPO	-0.36	-4.62	-0.36	8.42e-6	HIV-1 control;
UCEC	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs259282	0.538	rs12151311	chr19:33112707	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.66	0.36	7.01e-6	Schizophrenia;
UCEC	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.53	5.14	0.39	8.71e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.6	4.78	0.37	4.19e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.6	-0.35	9.09e-6	Breast cancer;
UCEC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.5	5.38	0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.78	5.92	0.44	2.15e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg24562669	chr7:97807699	LMTK2	0.48	5.88	0.44	2.71e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.49	-4.79	-0.37	4.05e-6	Primary biliary cholangitis;
UCEC	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.54	4.7	0.36	5.84e-6	Corneal astigmatism;
UCEC	cis	rs17123764	0.710	rs11169125	chr12:50115404	T/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	1.05	8.48	0.57	2.18e-14	Cannabis dependence symptom count;
UCEC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg09021430	chr5:549028	NA	-0.61	-4.57	-0.35	1.03e-5	Lung disease severity in cystic fibrosis;
UCEC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs838147	0.815	rs28400015	chr19:49250633	G/A	cg13540341	chr19:49222985	MAMSTR	0.39	4.92	0.38	2.27e-6	Dietary macronutrient intake;
UCEC	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.65	5.75	0.43	4.88e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.42	-4.64	-0.36	7.54e-6	IgG glycosylation;
UCEC	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.57	-0.35	1.03e-5	Blood protein levels;
UCEC	cis	rs239198	0.577	rs34716527	chr6:101284416	T/C	cg09795085	chr6:101329169	ASCC3	0.47	4.56	0.35	1.08e-5	Menarche (age at onset);
UCEC	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.42	5.4	0.41	2.65e-7	Schizophrenia;
UCEC	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.84	0.54	8.39e-13	Total body bone mineral density;
UCEC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.89	-9.88	-0.63	5.87e-18	Cognitive function;
UCEC	cis	rs9283706	0.689	rs11956654	chr5:66318196	A/G	cg11590213	chr5:66331682	MAST4	0.46	4.98	0.38	1.74e-6	Coronary artery disease;
UCEC	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs7246967	0.673	rs597906	chr19:22868205	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.61	0.36	8.58e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.62	7.46	0.52	7.02e-12	Oral cavity cancer;
UCEC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.51	0.35	1.3e-5	Breast cancer;
UCEC	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.51	5.3	0.4	4.11e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg24375607	chr4:120327624	NA	0.53	5.51	0.41	1.56e-7	Educational attainment;
UCEC	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg21770322	chr7:97807741	LMTK2	0.54	6.75	0.49	3.16e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.55	5.13	0.39	9.1e-7	Coronary artery disease;
UCEC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.25	0.71	3.18e-24	Prudent dietary pattern;
UCEC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.6	-7.12	-0.51	4.33e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.39	4.85	0.37	3.06e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg16797656	chr11:68205561	LRP5	0.64	8.98	0.6	1.17e-15	Total body bone mineral density;
UCEC	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-6.47	-0.47	1.37e-9	Platelet distribution width;
UCEC	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.42	6.01	0.44	1.42e-8	Crohn's disease;
UCEC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg12024160	chr4:1254474	NA	0.65	7.77	0.54	1.25e-12	Obesity-related traits;
UCEC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg19715936	chr7:50634035	DDC	0.44	4.64	0.36	7.7e-6	Malaria;
UCEC	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.83	-7.53	-0.53	4.68e-12	Resting heart rate;
UCEC	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4460629	0.680	rs10796938	chr1:155072055	C/A	cg02153340	chr1:155202674	NA	-0.42	-4.69	-0.36	6.14e-6	Serum magnesium levels;
UCEC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.71	8.02	0.55	3.05e-13	Menopause (age at onset);
UCEC	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg08798685	chr6:27730294	NA	-0.63	-4.58	-0.35	9.87e-6	Depression;
UCEC	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	1.01	5.85	0.43	3.02e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs925550	0.932	rs60318098	chr4:123599898	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.67	-5.74	-0.43	5.17e-8	Primary biliary cholangitis;
UCEC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.64	-7.21	-0.51	2.78e-11	Ulcerative colitis;
UCEC	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	1.15	7.25	0.51	2.24e-11	Sexual dysfunction (female);
UCEC	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg26781129	chr3:44753946	ZNF502	-0.44	-4.82	-0.37	3.6e-6	Depressive symptoms;
UCEC	cis	rs7246967	0.673	rs7249685	chr19:22882379	C/T	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.49	4.96	0.38	1.88e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.54	-5.91	-0.44	2.28e-8	Parkinson's disease;
UCEC	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.56	5.42	0.41	2.41e-7	Coronary artery disease;
UCEC	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.41	5.6	0.42	1.05e-7	Crohn's disease;
UCEC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.58	5.02	0.38	1.45e-6	Response to diuretic therapy;
UCEC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.73	-6.96	-0.5	1.05e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs28735056	0.967	rs56071379	chr18:77647406	G/A	cg20368463	chr18:77673604	PQLC1	-0.63	-4.83	-0.37	3.39e-6	Schizophrenia;
UCEC	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.46	4.86	0.37	3.02e-6	Red blood cell count;
UCEC	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	5.74	0.43	5.3e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.8	-8.4	-0.57	3.58e-14	Blood metabolite levels;
UCEC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.49	-5.49	-0.41	1.72e-7	Longevity;
UCEC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.84	-9.27	-0.61	2.22e-16	Cognitive function;
UCEC	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg04283868	chr2:201171347	SPATS2L	0.58	5.75	0.43	5.01e-8	QT interval;
UCEC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.52	-5.37	-0.41	2.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg20575277	chr15:90728569	SEMA4B	0.44	4.6	0.35	9.01e-6	Rheumatoid arthritis;
UCEC	cis	rs925228	0.869	rs13016006	chr2:24054510	C/T	cg16945982	chr2:25016118	CENPO;C2orf79	-0.54	-4.86	-0.37	2.99e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	5.28	0.4	4.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.62	7.07	0.5	5.86e-11	Retinal vascular caliber;
UCEC	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg01072550	chr1:21505969	NA	-0.51	-5.01	-0.38	1.51e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.64	0.42	8.28e-8	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.66	-7.38	-0.52	1.06e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg18279126	chr7:2041391	MAD1L1	0.38	4.62	0.36	8.18e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03533382	chr5:126853128	PRRC1	0.59	7.58	0.53	3.5e-12	Warfarin maintenance dose;
UCEC	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.29	13.08	0.73	2.04e-26	Corneal structure;
UCEC	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.49	5.31	0.4	4.06e-7	Platelet distribution width;
UCEC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.48	-5.16	-0.39	7.7300000000000005e-07	Platelet count;
UCEC	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.94	0.38	2.08e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.87	-8.82	-0.59	3.09e-15	Obesity-related traits;
UCEC	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.02	-0.76	7.05e-29	Schizophrenia;
UCEC	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg24562669	chr7:97807699	LMTK2	0.48	5.8	0.43	3.91e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.57	5.78	0.43	4.21e-8	Bipolar disorder;
UCEC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg22974920	chr21:40686053	BRWD1	0.6	5.16	0.39	7.93e-7	Cognitive function;
UCEC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.45	-4.59	-0.35	9.5e-6	Glomerular filtration rate;
UCEC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-4.88	-0.37	2.74e-6	Headache;
UCEC	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-10.0	-0.64	2.79e-18	Blood metabolite levels;
UCEC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-11.7	-0.69	9.41e-23	Coronary artery disease;
UCEC	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.89	4.6	0.35	8.95e-6	Major depressive disorder;
UCEC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.74	0.43	5.35e-8	Rheumatoid arthritis;
UCEC	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.5	4.75	0.36	4.83e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.58	5.86	0.44	2.88e-8	Obesity-related traits;
UCEC	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24308560	chr3:49941425	MST1R	0.45	4.82	0.37	3.61e-6	Body mass index;
UCEC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg00983440	chr10:79422392	NA	1.16	9.22	0.61	2.9e-16	Bone mineral density;
UCEC	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.38	-5.04	-0.38	1.35e-6	Obesity-related traits;
UCEC	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.56	5.23	0.4	5.62e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs11235843	0.571	rs9666549	chr11:73360581	C/T	cg09185399	chr11:73372479	PLEKHB1	0.58	4.52	0.35	1.29e-5	Hand grip strength;
UCEC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-0.77	-7.17	-0.51	3.34e-11	Breast cancer;
UCEC	cis	rs7937612	1.000	rs10750174	chr11:120292097	C/T	cg12584626	chr11:120203529	NA	0.54	5.3	0.4	4.12e-7	Intraocular pressure;
UCEC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.67	7.02	0.5	7.8e-11	Tonsillectomy;
UCEC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.16	15.15	0.78	8.04e-32	Cognitive function;
UCEC	trans	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs4588572	0.643	rs3885254	chr5:77686468	G/A	cg11547950	chr5:77652471	NA	0.47	5.15	0.39	8.41e-7	Triglycerides;
UCEC	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg06265175	chr8:121136014	COL14A1	0.47	5.04	0.38	1.33e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.67	-7.3	-0.52	1.7e-11	Morning vs. evening chronotype;
UCEC	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.66	-5.28	-0.4	4.64e-7	Educational attainment;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.99	-12.59	-0.72	4.11e-25	Prudent dietary pattern;
UCEC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.62	-5.83	-0.43	3.38e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.15	0.39	8.35e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.77	-6.12	-0.45	8.14e-9	Narcolepsy;
UCEC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.67	5.31	0.4	4.03e-7	Corneal astigmatism;
UCEC	cis	rs2299682	0.826	rs6086903	chr20:9464399	A/G	cg11931762	chr20:9488920	NA	-0.71	-5.24	-0.4	5.54e-7	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-5.46	-0.41	1.97e-7	Chronic sinus infection;
UCEC	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.63	-6.26	-0.46	3.92e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.72	8.06	0.55	2.45e-13	Bone mineral density;
UCEC	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.42	-4.74	-0.36	4.89e-6	Platelet distribution width;
UCEC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.73	7.46	0.52	7.06e-12	Vitamin D levels;
UCEC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.5	6.19	0.45	5.69e-9	Total body bone mineral density;
UCEC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13939156	chr17:80058883	NA	-0.38	-4.78	-0.37	4.15e-6	Life satisfaction;
UCEC	cis	rs3790645	1.000	rs35245195	chr1:26884039	C/G	cg23229016	chr1:26872525	RPS6KA1	0.34	6.34	0.46	2.66e-9	Glucose homeostasis traits;
UCEC	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.52	-5.01	-0.38	1.54e-6	Multiple sclerosis;
UCEC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	8.1	0.56	1.93e-13	Smoking behavior;
UCEC	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.83	8.68	0.58	6.92e-15	Lung cancer;
UCEC	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.85	-10.3	-0.65	4.56e-19	Brugada syndrome;
UCEC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg06096015	chr1:231504339	EGLN1	0.45	5.05	0.38	1.27e-6	Hemoglobin concentration;
UCEC	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg24375607	chr4:120327624	NA	0.47	4.99	0.38	1.66e-6	Corneal astigmatism;
UCEC	cis	rs6430585	0.592	rs2016636	chr2:136058820	G/A	cg07169764	chr2:136633963	MCM6	0.71	6.71	0.48	4e-10	Corneal structure;
UCEC	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.76	-6.82	-0.49	2.17e-10	Inflammatory bowel disease;
UCEC	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-5.96	-0.44	1.78e-8	Birth weight;
UCEC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.54	4.66	0.36	6.99e-6	Pancreatic cancer;
UCEC	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	0.92	5.09	0.39	1.06e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.46	-0.47	1.44e-9	Aortic root size;
UCEC	cis	rs7611694	0.501	rs2895413	chr3:113037942	C/T	cg12596171	chr3:113251061	SIDT1	0.59	5.93	0.44	2.09e-8	Prostate cancer;
UCEC	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.88	5.08	0.39	1.14e-6	Alzheimer's disease;
UCEC	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.56	4.64	0.36	7.56e-6	Colorectal cancer;
UCEC	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.73	-7.67	-0.53	2.18e-12	Breast cancer;
UCEC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg04310649	chr10:35416472	CREM	-0.49	-4.51	-0.35	1.34e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7646881	0.544	rs9849437	chr3:158299401	C/G	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.43e-6	Tetralogy of Fallot;
UCEC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.02e-29	Breast cancer;
UCEC	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg12310025	chr6:25882481	NA	-0.51	-4.58	-0.35	9.71e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.45	4.8	0.37	3.8e-6	Alcohol dependence;
UCEC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs17220352	0.502	rs41266675	chr9:119347032	T/C	cg13412550	chr9:120177700	ASTN2	-0.81	-5.44	-0.41	2.13e-7	Headache;
UCEC	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.65	5.52	0.41	1.5e-7	High light scatter reticulocyte count;
UCEC	cis	rs78761021	0.720	rs7221637	chr17:9797209	C/T	cg26853458	chr17:9805074	RCVRN	0.38	4.66	0.36	7.07e-6	Type 2 diabetes;
UCEC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg19318889	chr4:1322082	MAEA	0.43	4.84	0.37	3.3e-6	Obesity-related traits;
UCEC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.49	4.53	0.35	1.19e-5	Lung cancer;
UCEC	cis	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg17469321	chr7:55412551	NA	0.71	5.7	0.43	6.36e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.55	5.78	0.43	4.4e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18932078	chr1:2524107	MMEL1	0.34	5.57	0.42	1.16e-7	Ulcerative colitis;
UCEC	cis	rs7705819	0.802	rs11747282	chr5:172875769	A/G	cg14746387	chr5:172879299	NA	0.47	4.99	0.38	1.68e-6	Stroke;
UCEC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20916646	chr4:852691	GAK	0.51	5.3	0.4	4.24e-7	Sjögren's syndrome;
UCEC	cis	rs7246967	0.932	rs4932798	chr19:23051507	G/A	cg05241461	chr19:22816980	ZNF492	0.49	5.01	0.38	1.53e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.15	-0.45	6.9e-9	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.62	0.36	8.27e-6	Menopause (age at onset);
UCEC	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg21770322	chr7:97807741	LMTK2	-0.51	-6.38	-0.47	2.22e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg03609598	chr5:56110824	MAP3K1	-0.57	-5.0	-0.38	1.58e-6	Coronary artery disease;
UCEC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg20387954	chr3:183756860	HTR3D	0.5	6.19	0.45	5.82e-9	Anterior chamber depth;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.43	-0.47	1.71e-9	Pubertal anthropometrics;
UCEC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.06	7.86	0.54	7.64e-13	Alzheimer's disease (late onset);
UCEC	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg06521331	chr12:34319734	NA	-0.56	-4.5	-0.35	1.35e-5	Morning vs. evening chronotype;
UCEC	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg25410123	chr5:131825865	IRF1	-0.45	-4.58	-0.35	1e-5	Blood metabolite levels;
UCEC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.5	5.31	0.4	3.95e-7	Schizophrenia;
UCEC	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.44	-5.91	-0.44	2.29e-8	Urate levels in overweight individuals;
UCEC	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg23283320	chr21:48055893	PRMT2	1.02	4.64	0.36	7.75e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	0.81	7.19	0.51	3.05e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg20399509	chr21:47717575	C21orf57	-0.45	-4.86	-0.37	2.93e-6	Testicular germ cell tumor;
UCEC	cis	rs925550	0.867	rs309391	chr4:123610764	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.57	-5.26	-0.4	4.95e-7	Primary biliary cholangitis;
UCEC	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.55e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.37	-4.72	-0.36	5.5e-6	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.92	11.11	0.68	3.33e-21	Breast cancer;
UCEC	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.71	-6.29	-0.46	3.48e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.7	8.95	0.59	1.45e-15	Vitiligo;
UCEC	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.62	4.51	0.35	1.31e-5	Macular telangiectasia type 2;
UCEC	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.95	-0.5	1.09e-10	Urate levels in overweight individuals;
UCEC	cis	rs4588572	0.643	rs1035950	chr5:77785858	G/A	cg11547950	chr5:77652471	NA	-0.44	-4.95	-0.38	1.98e-6	Triglycerides;
UCEC	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.07e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.45	5.12	0.39	9.56e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg23819836	chr6:15663134	DTNBP1	0.73	7.03	0.5	7.03e-11	Schizophrenia;
UCEC	cis	rs2708977	0.698	rs772161	chr2:97043803	C/A	cg22654517	chr2:96458247	NA	0.45	5.57	0.42	1.16e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.77	7.45	0.52	7.48e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.53	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.58	6.18	0.45	6.02e-9	Mean platelet volume;
UCEC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-5.24	-0.4	5.36e-7	Bipolar disorder;
UCEC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.85	7.74	0.54	1.48e-12	Body mass index;
UCEC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.46	7.66	0.53	2.35e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Parkinson's disease;
UCEC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.68	-6.07	-0.45	1.04e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.67	5.95	0.44	1.89e-8	Corneal astigmatism;
UCEC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg14530993	chr4:882597	GAK	0.69	4.58	0.35	9.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-4.68	-0.36	6.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.47	-6.78	-0.49	2.78e-10	Homoarginine levels;
UCEC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.78	6.76	0.49	3.07e-10	Initial pursuit acceleration;
UCEC	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg05623727	chr3:50126028	RBM5	0.35	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-7.0	-0.5	8.49e-11	Mean platelet volume;
UCEC	cis	rs73129298	0.551	rs6091076	chr20:48592317	A/G	cg25655593	chr20:48599521	SNAI1	0.63	5.25	0.4	5.3e-7	Inflammatory skin disease;
UCEC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.61	6.29	0.46	3.51e-9	Initial pursuit acceleration;
UCEC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.76	0.37	4.67e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-4.94	-0.38	2.07e-6	Morning vs. evening chronotype;
UCEC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg10965384	chr11:64119977	CCDC88B	0.37	4.52	0.35	1.28e-5	Platelet count;
UCEC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg13695892	chr22:41940480	POLR3H	0.7	5.45	0.41	2.04e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.67	-5.53	-0.42	1.39e-7	Alcohol dependence;
UCEC	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.68	7.46	0.52	7.07e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	0.68	7.51	0.53	5.25e-12	Homoarginine levels;
UCEC	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24249390	chr15:90295951	MESP1	-0.44	-4.83	-0.37	3.4e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24511898	chr2:242576823	ATG4B;THAP4	0.59	7.23	0.51	2.49e-11	Warfarin maintenance dose;
UCEC	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg04310649	chr10:35416472	CREM	-0.49	-4.88	-0.37	2.7e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.02	6.46	0.47	1.47e-9	Diabetic kidney disease;
UCEC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.74e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24249390	chr15:90295951	MESP1	-0.46	-5.14	-0.39	8.48e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs4789452	1.000	rs11659109	chr17:75375859	C/T	cg21830368	chr17:75373327	SEPT9	-0.32	-5.0	-0.38	1.64e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.79	-9.75	-0.63	1.24e-17	White blood cell count (basophil);
UCEC	cis	rs2882667	0.822	rs13187096	chr5:138404088	C/A	cg04439458	chr5:138467593	SIL1	-0.46	-5.03	-0.38	1.38e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.88	10.22	0.64	7.34e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.541	rs74169641	chr19:22830576	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.59	-6.04	-0.45	1.2e-8	Strep throat;
UCEC	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.44	6.1	0.45	8.96e-9	Life satisfaction;
UCEC	cis	rs9341808	0.519	rs607130	chr6:80999233	T/C	cg08355045	chr6:80787529	NA	-0.34	-4.64	-0.36	7.7e-6	Sitting height ratio;
UCEC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.77	10.13	0.64	1.25e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	10.95	0.67	8.64e-21	Electrocardiographic conduction measures;
UCEC	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.95	-10.81	-0.67	2.12e-20	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	15.41	0.79	1.73e-32	Chronic sinus infection;
UCEC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg02160872	chr5:212506	CCDC127	-0.72	-7.51	-0.53	5.42e-12	Breast cancer;
UCEC	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.63	0.36	8.03e-6	Parkinson's disease;
UCEC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.37	-5.86	-0.44	2.94e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg24069376	chr3:38537580	EXOG	0.37	4.6	0.35	9.07e-6	Electrocardiographic conduction measures;
UCEC	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.49	5.53	0.41	1.44e-7	White matter hyperintensity burden;
UCEC	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.14e-7	Body mass index;
UCEC	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.77	0.37	4.36e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs73206853	0.841	rs4131851	chr12:110812345	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	4.73	0.36	5.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.08	8.18	0.56	1.21e-13	Alzheimer's disease (late onset);
UCEC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.53	5.92	0.44	2.22e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.61	5.77	0.43	4.55e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.66	-5.41	-0.41	2.52e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.65	-7.62	-0.53	2.9e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.47	5.45	0.41	2.07e-7	Aortic root size;
UCEC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.55	-5.83	-0.43	3.42e-8	Blood metabolite levels;
UCEC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.07	6.55	0.48	9.08e-10	Diabetic retinopathy;
UCEC	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.1	-0.56	1.89e-13	Total cholesterol levels;
UCEC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.85	9.11	0.6	5.68e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg02366345	chr4:152330872	FAM160A1	0.35	4.73	0.36	5.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.44	0.41	2.14e-7	Blood protein levels;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.81	9.09	0.6	6.1e-16	Longevity;Endometriosis;
UCEC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.71	-6.36	-0.46	2.42e-9	Aortic root size;
UCEC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	0.78	9.27	0.61	2.15e-16	Bone mineral density;
UCEC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.63	6.38	0.47	2.22e-9	C-reactive protein levels;
UCEC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.56	4.88	0.37	2.78e-6	HDL cholesterol levels;
UCEC	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.03	14.33	0.76	1.06e-29	Schizophrenia;
UCEC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg27624424	chr6:160112604	SOD2	0.56	5.18	0.39	7.2e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00802000	chr16:706648	WDR90	-0.48	-5.47	-0.41	1.87e-7	Height;
UCEC	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg12483005	chr1:23474871	LUZP1	0.41	4.52	0.35	1.24e-5	Height;
UCEC	cis	rs11118844	0.744	rs10863656	chr1:221952703	T/A	cg04222084	chr1:221915650	DUSP10	-0.8	-5.67	-0.42	7.44e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.54	-0.35	1.18e-5	Type 2 diabetes;
UCEC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg18099408	chr3:52552593	STAB1	0.42	4.87	0.37	2.79e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.61	5.79	0.43	4.15e-8	Morning vs. evening chronotype;
UCEC	cis	rs4654899	0.897	rs1021077	chr1:21106016	A/G	cg01072550	chr1:21505969	NA	-0.48	-4.75	-0.37	4.72e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.14	-0.6	4.68e-16	Coffee consumption (cups per day);
UCEC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	5.86	0.43	2.98e-8	Menarche (age at onset);
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04155289	chr7:94953770	PON1	0.48	4.53	0.35	1.21e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.17e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs992037	0.902	rs12055483	chr6:162021640	T/C	cg03969305	chr6:161188183	NA	0.4	4.54	0.35	1.18e-5	Metabolite levels;
UCEC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg26114124	chr12:9217669	LOC144571	0.41	4.86	0.37	2.98e-6	Sjögren's syndrome;
UCEC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.95	0.63	3.84e-18	Chronic sinus infection;
UCEC	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-6.79	-0.49	2.64e-10	Obesity-related traits;
UCEC	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.52	-7.37	-0.52	1.13e-11	Sitting height ratio;
UCEC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.53	-0.42	1.41e-7	Aortic root size;
UCEC	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.75	-9.44	-0.61	7.92e-17	Leprosy;
UCEC	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.57	-5.51	-0.41	1.55e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.76	5.24	0.4	5.46e-7	LDL cholesterol;
UCEC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.6	-6.9	-0.49	1.44e-10	Body mass index;
UCEC	cis	rs7959452	0.905	rs4761234	chr12:69732105	T/C	cg11871910	chr12:69753446	YEATS4	0.8	8.48	0.57	2.25e-14	Blood protein levels;
UCEC	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg18512352	chr11:47633146	NA	-0.39	-4.9	-0.37	2.48e-6	Subjective well-being;
UCEC	cis	rs240764	0.619	rs6903665	chr6:101148234	T/C	cg09795085	chr6:101329169	ASCC3	0.44	4.72	0.36	5.51e-6	Neuroticism;
UCEC	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg05925327	chr15:68127851	NA	-0.4	-5.15	-0.39	8.19e-7	Obesity;
UCEC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg11859384	chr17:80120422	CCDC57	-0.54	-5.97	-0.44	1.74e-8	Life satisfaction;
UCEC	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.65	-7.18	-0.51	3.22e-11	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.49	-5.06	-0.38	1.26e-6	Age at first birth;
UCEC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04731861	chr2:219085781	ARPC2	0.41	4.6	0.36	8.88e-6	Colorectal cancer;
UCEC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg14092571	chr14:90743983	NA	0.39	4.89	0.37	2.67e-6	Mortality in heart failure;
UCEC	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.7	6.87	0.49	1.71e-10	Bladder cancer;
UCEC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.55	6.33	0.46	2.8e-9	Prostate cancer;
UCEC	cis	rs4389656	0.857	rs416847	chr5:6739567	A/G	cg10857441	chr5:6722123	POLS	-0.41	-4.77	-0.37	4.34e-6	Coronary artery disease;
UCEC	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.71	9.15	0.6	4.37e-16	Rheumatoid arthritis;
UCEC	cis	rs7246967	0.551	rs34897132	chr19:22826891	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.59	8.69	0.58	6.69e-15	Prudent dietary pattern;
UCEC	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.63	5.28	0.4	4.48e-7	RR interval (heart rate);
UCEC	cis	rs7607369	0.536	rs4674344	chr2:219669875	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.34	-0.4	3.49e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-4.61	-0.36	8.8e-6	Coronary artery disease;
UCEC	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.4	4.84	0.37	3.22e-6	Subjective well-being;
UCEC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-6.8	-0.49	2.48e-10	Schizophrenia;
UCEC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.74	8.19	0.56	1.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.59	-5.74	-0.43	5.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.28	0.4	4.66e-7	Birth weight;
UCEC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.52e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.78	8.06	0.55	2.45e-13	Smoking behavior;
UCEC	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.59	-4.95	-0.38	2.02e-6	Alcohol dependence;
UCEC	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-4.59	-0.35	9.41e-6	Hepatocellular carcinoma;
UCEC	cis	rs7246967	0.800	rs2061774	chr19:23025775	C/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.3	0.4	4.13e-7	Prudent dietary pattern;
UCEC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-6.66	-0.48	5.06e-10	Eye color traits;
UCEC	cis	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg20307385	chr11:47447363	PSMC3	0.51	4.52	0.35	1.29e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14019695	chr9:139328340	INPP5E	0.45	5.2	0.39	6.49e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.54	5.71	0.43	5.94e-8	Aortic root size;
UCEC	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.56	-5.7	-0.43	6.33e-8	White matter hyperintensity burden;
UCEC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.84e-6	Breast cancer;
UCEC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.95e-6	Tonsillectomy;
UCEC	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg18099408	chr3:52552593	STAB1	0.41	4.96	0.38	1.92e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.65	6.7	0.48	4.11e-10	Breast cancer;
UCEC	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-0.88	-9.54	-0.62	4.4e-17	Height;
UCEC	trans	rs11046430	0.551	rs10842031	chr12:22668319	A/T	cg12672713	chr8:30889709	PURG;WRN	-0.57	-6.9	-0.49	1.48e-10	Coronary artery calcification;
UCEC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.39	4.5	0.35	1.35e-5	Menarche (age at onset);
UCEC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-6.39	-0.47	2.09e-9	Schizophrenia;
UCEC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.43	0.74	2.49e-27	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18252515	chr7:66147081	NA	0.52	5.37	0.4	3.04e-7	Aortic root size;
UCEC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.69	-0.36	6.17e-6	Blood protein levels;
UCEC	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.79	-8.54	-0.58	1.59e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.71	6.39	0.47	2.1e-9	Aortic root size;
UCEC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.66	-7.38	-0.52	1.06e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs1572072	0.545	rs7999982	chr13:24128568	C/T	cg24350296	chr13:24144486	TNFRSF19	0.37	4.57	0.35	1.05e-5	Nasopharyngeal carcinoma;
UCEC	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.85	6.78	0.49	2.75e-10	Fibroblast growth factor basic levels;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.66	7.05	0.5	6.52e-11	Obesity-related traits;
UCEC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.58	-5.14	-0.39	8.7e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.74	9.24	0.61	2.64e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.65	-5.87	-0.44	2.72e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.07	0.5	5.71e-11	Hip circumference adjusted for BMI;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27556566	chr18:29671984	RNF138	0.63	7.84	0.54	8.54e-13	Warfarin maintenance dose;
UCEC	cis	rs7246967	1.000	rs936526	chr19:23055987	A/C	cg08271804	chr19:22816896	ZNF492	0.55	5.15	0.39	8.38e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.53	5.16	0.39	7.97e-7	Colorectal cancer;
UCEC	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.47	4.6	0.35	9.12e-6	Obesity (extreme);
UCEC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.9	9.26	0.61	2.32e-16	Cognitive function;
UCEC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-5.72	-0.43	5.82e-8	Urinary metabolites;
UCEC	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.66	-6.04	-0.45	1.2e-8	Systemic lupus erythematosus;
UCEC	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-13.77	-0.75	3.14e-28	Schizophrenia;
UCEC	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.63	-5.39	-0.41	2.75e-7	Tonsillectomy;
UCEC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4778581	0.900	rs8025843	chr15:80426713	T/C	cg08257866	chr15:80351198	ZFAND6	0.41	4.58	0.35	9.65e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.98	-0.44	1.6e-8	Platelet count;
UCEC	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.57	4.84	0.37	3.24e-6	Lung cancer;
UCEC	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.56	6.7	0.48	4.07e-10	Longevity;
UCEC	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.25	0.61	2.37e-16	Menopause (age at onset);
UCEC	cis	rs9815925	0.702	rs7616305	chr3:184583828	A/G	cg00151007	chr3:184769954	VPS8	0.47	4.59	0.35	9.29e-6	Heschl's gyrus morphology;
UCEC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04476341	chr5:669733	TPPP	0.41	4.9	0.37	2.54e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.47	-4.56	-0.35	1.09e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	1.03	7.61	0.53	3.11e-12	LDL cholesterol;
UCEC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.55	4.69	0.36	6.1e-6	Response to diuretic therapy;
UCEC	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.05	-0.76	5.6e-29	Schizophrenia;
UCEC	cis	rs11760485	0.965	rs57518719	chr7:4402398	T/A	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.13	0.51	4.23e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-5.63	-0.42	8.81e-8	Rheumatoid arthritis;
UCEC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-5.17	-0.39	7.6e-7	Aortic root size;
UCEC	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.53	-5.4	-0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-7.97	-0.55	4.08e-13	Parkinson's disease;
UCEC	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.6	5.89	0.44	2.56e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.43	-5.7	-0.43	6.35e-8	Prostate cancer;
UCEC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.69	7.88	0.55	6.56e-13	Menopause (age at onset);
UCEC	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	8.34	0.57	4.85e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.68	0.36	6.48e-6	Response to antipsychotic treatment;
UCEC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.45	-0.47	1.52e-9	Tonsillectomy;
UCEC	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.22	-0.4	5.98e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	-0.59	-6.74	-0.49	3.32e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.84	-0.37	3.32e-6	Response to antipsychotic treatment;
UCEC	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg03114573	chr12:45410052	DBX2	-0.45	-4.69	-0.36	6.06e-6	Gut microbiome composition (summer);
UCEC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.07	7.33	0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.52	-5.95	-0.44	1.87e-8	Tonsillectomy;
UCEC	cis	rs7106204	0.748	rs6484024	chr11:24210079	T/C	ch.11.24196551F	chr11:24239977	NA	0.54	5.56	0.42	1.25e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.47	5.34	0.4	3.42e-7	Breast cancer;
UCEC	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-5.45	-0.41	2.11e-7	Colorectal cancer;
UCEC	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.56	5.07	0.39	1.2e-6	Coronary artery disease;
UCEC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg24910161	chr17:38119198	GSDMA	0.32	4.54	0.35	1.14e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg21856205	chr7:94953877	PON1	-0.54	-4.83	-0.37	3.41e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.71	-9.17	-0.6	3.97e-16	Vitiligo;
UCEC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.15	-0.51	3.85e-11	Breast cancer;
UCEC	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.88	-12.58	-0.72	4.25e-25	Urate levels in lean individuals;
UCEC	cis	rs7709377	0.621	rs1133187	chr5:115420547	T/C	cg23108291	chr5:115420582	COMMD10	0.45	4.55	0.35	1.11e-5	Metabolite levels  (X-11787);
UCEC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.56	-6.02	-0.44	1.33e-8	Bipolar disorder;
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg21770322	chr7:97807741	LMTK2	0.71	10.28	0.65	5.12e-19	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.57	-6.28	-0.46	3.54e-9	Refractive error;
UCEC	cis	rs2474937	0.545	rs55722937	chr1:118904194	G/C	cg10572355	chr1:119549145	NA	0.43	4.51	0.35	1.32e-5	Congenital heart malformation;
UCEC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	7.9e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	0.74	6.18	0.45	6.1e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg05738196	chr6:26577821	NA	0.65	7.63	0.53	2.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.76	6.11	0.45	8.67e-9	Tonometry;
UCEC	trans	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg06410510	chr2:107458059	ST6GAL2	0.76	6.93	0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.71	-6.35	-0.46	2.55e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	5.72	0.43	5.65e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs12618769	0.597	rs17505088	chr2:99149473	C/T	cg14361474	chr2:99058762	NA	-0.48	-4.67	-0.36	6.76e-6	Bipolar disorder;
UCEC	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.57	5.63	0.42	8.99e-8	Blood protein levels;
UCEC	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	7.7	0.54	1.89e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.87	-7.18	-0.51	3.26e-11	Coronary artery calcification;
UCEC	cis	rs36051895	0.623	rs4358852	chr9:5251238	C/T	cg02405213	chr9:5042618	JAK2	-0.46	-4.56	-0.35	1.09e-5	Pediatric autoimmune diseases;
UCEC	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg18230493	chr5:56204884	C5orf35	-0.51	-4.56	-0.35	1.09e-5	Coronary artery disease;
UCEC	cis	rs7336933	0.740	rs1331038	chr13:42409843	C/T	cg18400088	chr13:41634674	WBP4	0.54	4.75	0.36	4.81e-6	Calcium levels;
UCEC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.75	-7.94	-0.55	4.72e-13	Cognitive function;
UCEC	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs8044995	0.501	rs73613952	chr16:68352808	G/C	cg05110241	chr16:68378359	PRMT7	-0.52	-4.52	-0.35	1.24e-5	Schizophrenia;
UCEC	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.58	6.02	0.44	1.31e-8	IgG glycosylation;
UCEC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.64	-5.99	-0.44	1.53e-8	Aortic root size;
UCEC	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg02461776	chr11:598696	PHRF1	0.48	5.13	0.39	8.96e-7	Systemic lupus erythematosus;
UCEC	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.56	6.27	0.46	3.81e-9	Breast cancer;
UCEC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg24069376	chr3:38537580	EXOG	-0.46	-5.87	-0.44	2.81e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7534824	0.625	rs61782084	chr1:101515298	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.6	4.91	0.38	2.39e-6	Refractive astigmatism;
UCEC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg03714773	chr7:91764589	CYP51A1	0.43	5.19	0.39	6.77e-7	Breast cancer;
UCEC	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-5.22	-0.4	6.06e-7	Response to antipsychotic treatment;
UCEC	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Primary biliary cholangitis;
UCEC	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg20560298	chr2:73613845	ALMS1	0.49	4.9	0.37	2.53e-6	Schizophrenia;
UCEC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.57	4.84	0.37	3.24e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.86	-9.79	-0.63	9.87e-18	Cognitive function;
UCEC	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.83	8.91	0.59	1.81e-15	Height;
UCEC	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.8	-9.96	-0.63	3.59e-18	White blood cell count (basophil);
UCEC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.63	-0.48	6.08e-10	Tonsillectomy;
UCEC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg22974920	chr21:40686053	BRWD1	0.55	4.86	0.37	3e-6	Cognitive function;
UCEC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.52	7.51	0.53	5.18e-12	Height;
UCEC	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.41	5.6	0.42	1e-7	Obesity-related traits;
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.89	10.48	0.65	1.54e-19	Menarche (age at onset);
UCEC	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.78	6.26	0.46	3.92e-9	Neuroticism;
UCEC	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.57	5.19	0.39	6.93e-7	Crohn's disease;
UCEC	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.34	0.46	2.72e-9	Cognitive test performance;
UCEC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.16	14.9	0.78	3.46e-31	Cognitive function;
UCEC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	4.55	0.35	1.13e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.71	7.42	0.52	8.85e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.53	-6.31	-0.46	3.06e-9	Pubertal anthropometrics;
UCEC	cis	rs2036402	0.531	rs10076475	chr5:156422231	G/A	cg24526056	chr5:156479556	HAVCR1	-0.42	-4.62	-0.36	8.28e-6	Hypertriglyceridemia;
UCEC	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.51	5.17	0.39	7.52e-7	Dental caries;
UCEC	cis	rs829661	0.901	rs829620	chr2:30750660	C/A	cg17749961	chr2:30669863	LCLAT1	0.52	4.93	0.38	2.18e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.5	4.84	0.37	3.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg12559939	chr2:27858050	GPN1	0.44	4.58	0.35	9.71e-6	Oral cavity cancer;
UCEC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs7611694	0.501	rs1906142	chr3:113154223	C/T	cg12596171	chr3:113251061	SIDT1	0.55	5.43	0.41	2.23e-7	Prostate cancer;
UCEC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.1	-0.56	1.94e-13	Monocyte count;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg02366228	chr19:33667241	NA	-0.75	-7.26	-0.51	2.07e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.59	-0.42	1.05e-7	Blood metabolite levels;
UCEC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs7597155	0.846	rs2872073	chr2:69963046	A/G	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.37	-0.41	2.99e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.65	5.0	0.38	1.6e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.54	5.63	0.42	8.92e-8	Orofacial clefts;
UCEC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	0.64	7.49	0.53	5.95e-12	Obesity-related traits;
UCEC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.97	10.9	0.67	1.23e-20	Cognitive function;
UCEC	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.56	-7.11	-0.51	4.75e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	7.92e-8	Resting heart rate;
UCEC	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg27449745	chr7:23145252	KLHL7	-0.43	-4.55	-0.35	1.11e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6688613	0.685	rs2142615	chr1:166922731	G/C	cg07049167	chr1:166818506	POGK	0.54	5.25	0.4	5.13e-7	Refractive astigmatism;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.6	-0.42	1.04e-7	Pubertal anthropometrics;
UCEC	cis	rs6722750	0.840	rs6712700	chr2:64374041	A/G	cg22352474	chr2:64371530	PELI1	0.61	5.66	0.42	7.64e-8	Neuroticism;
UCEC	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.53	5.25	0.4	5.13e-7	Aortic root size;
UCEC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.64	-6.17	-0.45	6.28e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.75	8.28	0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg06466757	chr4:1255808	NA	0.45	4.77	0.37	4.35e-6	Obesity-related traits;
UCEC	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06156847	chr2:113672199	IL1F7	-0.33	-4.53	-0.35	1.19e-5	Pulmonary function;
UCEC	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg17105886	chr17:28927953	LRRC37B2	0.65	4.61	0.36	8.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.56	-5.68	-0.42	6.95e-8	Sudden cardiac arrest;
UCEC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.34e-18	Height;
UCEC	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	4.55	0.35	1.1e-5	Aortic root size;
UCEC	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs968451	0.813	rs5757614	chr22:39717554	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	4.77	0.37	4.43e-6	Primary biliary cholangitis;
UCEC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.65	0.36	7.3e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs61776719	0.810	rs34655914	chr1:38397341	G/A	cg04673462	chr1:38461896	NA	0.58	6.0	0.44	1.46e-8	Coronary artery disease;
UCEC	cis	rs3736594	0.513	rs6751087	chr2:27778016	T/C	cg27432699	chr2:27873401	GPN1	0.48	4.53	0.35	1.23e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1978968	1.000	rs5013014	chr22:18449927	T/C	cg03078520	chr22:18463400	MICAL3	-0.52	-5.19	-0.39	6.99e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.46	5.11	0.39	9.67e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-5.3	-0.4	4.19e-7	Blood metabolite levels;
UCEC	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	0.89	9.19	0.6	3.53e-16	Left atrial antero-posterior diameter;
UCEC	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.05	-0.76	5.6e-29	Schizophrenia;
UCEC	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-0.73	-6.7	-0.48	4.25e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.67	-8.09	-0.55	2.09e-13	IgG glycosylation;
UCEC	cis	rs7523273	0.526	rs1204708	chr1:208024062	G/C	cg22525895	chr1:207977042	MIR29B2	-0.48	-4.86	-0.37	2.99e-6	Schizophrenia;
UCEC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg22868518	chr11:507468	RNH1	-0.57	-5.54	-0.42	1.33e-7	Systemic lupus erythematosus;
UCEC	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	0.87	6.68	0.48	4.51e-10	Lymphocyte counts;
UCEC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg00750074	chr16:89608354	SPG7	-0.43	-4.63	-0.36	7.87e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.34e-6	Hemoglobin concentration;
UCEC	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	4.56	0.35	1.06e-5	Hemoglobin concentration;
UCEC	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24308560	chr3:49941425	MST1R	0.56	6.32	0.46	2.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg05660106	chr1:15850417	CASP9	0.52	5.05	0.38	1.28e-6	Systolic blood pressure;
UCEC	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.83	-0.49	2.13e-10	Response to antipsychotic treatment;
UCEC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.46	6.3	0.46	3.31e-9	Bone mineral density;
UCEC	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.68	8.18	0.56	1.21e-13	Neuroticism;
UCEC	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.39	5.39	0.41	2.71e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4727027	0.769	rs2140957	chr7:148758885	A/G	cg23583168	chr7:148888333	NA	-0.66	-7.21	-0.51	2.69e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.64	-5.31	-0.4	4e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.49	4.87	0.37	2.83e-6	Diastolic blood pressure;
UCEC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.49	-4.97	-0.38	1.81e-6	Blood protein levels;
UCEC	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.67	6.08	0.45	9.67e-9	Migraine;
UCEC	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-6.96	-0.5	1.06e-10	Coronary artery disease;
UCEC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.51	5.31	0.4	3.89e-7	Monocyte count;
UCEC	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-6.95	-0.5	1.09e-10	Mitochondrial DNA levels;
UCEC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18932078	chr1:2524107	MMEL1	0.34	5.44	0.41	2.15e-7	Ulcerative colitis;
UCEC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.01	11.27	0.68	1.28e-21	IgG glycosylation;
UCEC	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	0.88	4.97	0.38	1.81e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg13844804	chr7:814759	HEATR2	0.64	4.63	0.36	7.9e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14019695	chr9:139328340	INPP5E	0.48	4.97	0.38	1.8e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg04906043	chr13:21280425	IL17D	-0.45	-4.6	-0.35	8.98e-6	Dental caries;
UCEC	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg14121845	chr20:25566513	NINL	0.39	4.52	0.35	1.28e-5	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs7246967	1.000	rs11879853	chr19:23029434	C/T	cg05241461	chr19:22816980	ZNF492	-0.49	-5.27	-0.4	4.79e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg13256891	chr4:100009986	ADH5	-0.69	-5.15	-0.39	8.11e-7	Alcohol dependence;
UCEC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.65	6.0	0.44	1.5e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.44	6.22	0.46	5e-9	Crohn's disease;
UCEC	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.04	-8.31	-0.57	5.72e-14	Exhaled nitric oxide output;
UCEC	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.57	7.23	0.51	2.46e-11	Bone mineral density;
UCEC	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.76	5.14	0.39	8.58e-7	Cognitive function;
UCEC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.55	5.41	0.41	2.47e-7	Menopause (age at onset);
UCEC	cis	rs10012307	1.000	rs12645764	chr4:137502172	G/C	cg12033966	chr4:138453416	PCDH18	-0.71	-5.08	-0.39	1.12e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	6.14	0.45	7.15e-9	Tonsillectomy;
UCEC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	0.81	6.9	0.49	1.47e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-4.67	-0.36	6.65e-6	Kawasaki disease;
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.53	-6.28	-0.46	3.69e-9	Depression;
UCEC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs883565	0.569	rs784515	chr3:39163848	C/T	cg01426195	chr3:39028469	NA	0.63	7.61	0.53	3.01e-12	Handedness;
UCEC	cis	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg14992524	chr8:10586135	SOX7	0.26	4.61	0.36	8.52e-6	Neuroticism;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.51	-5.59	-0.42	1.08e-7	Cardiac Troponin-T levels;
UCEC	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.45	-6.13	-0.45	7.88e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.59	-4.63	-0.36	8.14e-6	Cholesterol, total;
UCEC	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-6.74	-0.49	3.28e-10	Longevity;Endometriosis;
UCEC	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.82	-7.08	-0.5	5.47e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.58	-0.35	9.72e-6	Hip circumference adjusted for BMI;
UCEC	trans	rs6462411	0.509	rs6980085	chr7:3874237	C/T	cg13622657	chr9:34620508	DCTN3	-0.62	-6.71	-0.48	4e-10	Quantitative traits;
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.45	-4.79	-0.37	4.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9469578	0.792	rs73743331	chr6:33714036	G/T	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.3	4.6	0.35	9.03e-6	HDL cholesterol levels;
UCEC	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.67	-7.18	-0.51	3.27e-11	Breast cancer;
UCEC	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.46	-7.19	-0.51	3.04e-11	Urate levels in overweight individuals;
UCEC	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg04851639	chr8:1020857	NA	-0.38	-5.08	-0.39	1.12e-6	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	5.12	0.39	9.36e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.6	-6.45	-0.47	1.54e-9	Glomerular filtration rate;
UCEC	cis	rs73206853	0.660	rs12313068	chr12:110597304	C/T	cg12870014	chr12:110450643	ANKRD13A	0.68	6.79	0.49	2.64e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.53	-6.61	-0.48	6.59e-10	Total body bone mineral density;
UCEC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.8	-8.64	-0.58	8.78e-15	Breast cancer;
UCEC	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.8	7.3	0.52	1.64e-11	Dupuytren's disease;
UCEC	cis	rs6738485	0.588	rs12712247	chr2:106849382	C/T	cg16099169	chr2:106886729	NA	-0.41	-4.74	-0.36	4.99e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.13	-13.23	-0.74	8.41e-27	Breast cancer;
UCEC	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.68	5.73	0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.48	4.97	0.38	1.81e-6	Vitiligo;
UCEC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.15	-14.22	-0.76	2.07e-29	Breast cancer;
UCEC	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.64	-6.11	-0.45	8.6e-9	Brugada syndrome;
UCEC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.49	-4.95	-0.38	1.98e-6	Total body bone mineral density;
UCEC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.44	-5.42	-0.41	2.36e-7	Abdominal aortic aneurysm;
UCEC	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.9	0.37	2.54e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.73	8.0	0.55	3.35e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.08	0.5	5.52e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.6	7.23	0.51	2.43e-11	Metabolite levels;
UCEC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.53	5.23	0.4	5.74e-7	Aortic root size;
UCEC	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07741184	chr6:167504864	NA	0.37	5.62	0.42	9.21e-8	Primary biliary cholangitis;
UCEC	cis	rs420259	0.516	rs2072061	chr16:23541223	G/A	cg26562691	chr16:23850404	PRKCB	-0.34	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg05539622	chr2:73298971	SFXN5	0.49	4.74	0.36	4.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.2e-7	QRS complex (12-leadsum);
UCEC	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg11150807	chr10:43354902	NA	0.8	6.54	0.47	9.43e-10	Blood protein levels;
UCEC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.66	-7.45	-0.52	7.4e-12	Vitiligo;
UCEC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.54	5.22	0.4	6.01e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.66	7.38	0.52	1.07e-11	Lymphocyte counts;
UCEC	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	5.37	0.4	3.04e-7	Lung cancer in ever smokers;
UCEC	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.44	5.01	0.38	1.52e-6	Mortality in heart failure;
UCEC	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	8.39	0.57	3.76e-14	Body mass index (adult);
UCEC	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.26	-0.4	5.11e-7	Acylcarnitine levels;
UCEC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	5.07	0.39	1.17e-6	Breast cancer;
UCEC	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs8105895	0.867	rs116220423	chr19:22237041	G/A	cg20662725	chr19:22235022	ZNF257	-0.59	-5.14	-0.39	8.6e-7	Body mass index (change over time);
UCEC	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.96	11.17	0.68	2.27e-21	Ulcerative colitis;
UCEC	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.42	5.03	0.38	1.44e-6	Bone mineral density;
UCEC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.65	6.21	0.46	5.19e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.73	-7.59	-0.53	3.46e-12	Body mass index;
UCEC	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.72	6.13	0.45	7.7e-9	Coronary artery disease;
UCEC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	0.82	4.54	0.35	1.15e-5	IgG glycosylation;
UCEC	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.92	-0.63	4.41e-18	Height;
UCEC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.82	8.07	0.55	2.29e-13	Cognitive function;
UCEC	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg16303742	chr3:15540471	COLQ	-0.41	-5.18	-0.39	7.19e-7	Mean platelet volume;
UCEC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.73	-0.36	5.11e-6	Parkinson's disease;
UCEC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.54	-5.19	-0.39	6.75e-7	Prudent dietary pattern;
UCEC	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.75	0.36	4.83e-6	Personality dimensions;
UCEC	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.73	0.36	5.21e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.55	5.56	0.42	1.22e-7	Breast cancer;
UCEC	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.4	5.4	0.41	2.66e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg13777783	chr17:79615861	NA	-0.32	-4.55	-0.35	1.12e-5	Eye color traits;
UCEC	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.66	4.94	0.38	2.1e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs2742417	0.935	rs2248991	chr3:45754749	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	5.12	0.39	9.52e-7	HIV-1 control;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg22874627	chr3:31575329	STT3B	0.58	6.82	0.49	2.26e-10	Warfarin maintenance dose;
UCEC	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.48	-5.15	-0.39	8.16e-7	Menarche (age at onset);
UCEC	cis	rs4389656	0.857	rs5001282	chr5:6757668	T/C	cg10857441	chr5:6722123	POLS	-0.41	-4.8	-0.37	3.89e-6	Coronary artery disease;
UCEC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg03714773	chr7:91764589	CYP51A1	0.5	6.22	0.46	4.94e-9	Breast cancer;
UCEC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.6	-5.31	-0.4	3.97e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.63	4.98	0.38	1.75e-6	Major depressive disorder;
UCEC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.77	8.89	0.59	2.02e-15	Menopause (age at onset);
UCEC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.0	-0.38	1.65e-6	Aortic root size;
UCEC	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg18016565	chr1:150552671	MCL1	-0.54	-5.86	-0.43	2.98e-8	Lymphocyte counts;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg20026190	chr17:76395443	PGS1	0.37	4.5	0.35	1.35e-5	HDL cholesterol;
UCEC	trans	rs4146922	0.793	rs62167688	chr2:56009382	C/A	cg20168479	chr3:32443031	CMTM7	0.67	6.68	0.48	4.66e-10	Height;
UCEC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.9	7.56	0.53	4.06e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg11498726	chr8:26250323	BNIP3L	-0.52	-5.02	-0.38	1.47e-6	Red cell distribution width;
UCEC	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.61	5.99	0.44	1.56e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.08	-0.39	1.11e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.73	-6.99	-0.5	8.87e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.78	6.71	0.48	3.85e-10	White matter hyperintensity burden;
UCEC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.66	-0.36	7.05e-6	Parkinson's disease;
UCEC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.85	7.8	0.54	1.07e-12	Body mass index;
UCEC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.05	0.45	1.17e-8	Menarche (age at onset);
UCEC	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg11150807	chr10:43354902	NA	-0.8	-4.95	-0.38	1.97e-6	Blood protein levels;
UCEC	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.58	-5.52	-0.41	1.52e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.5	-4.97	-0.38	1.81e-6	Schizophrenia;
UCEC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-7.38	-0.52	1.09e-11	Multiple sclerosis;
UCEC	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg21466736	chr12:48725269	NA	0.35	4.63	0.36	7.92e-6	Plateletcrit;
UCEC	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.42	-5.09	-0.39	1.09e-6	Menopause (age at onset);
UCEC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.45	4.65	0.36	7.33e-6	Mood instability;
UCEC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.77	5.1	0.39	1.02e-6	Lung function (FEV1/FVC);
UCEC	cis	rs944990	0.640	rs10761240	chr9:96361922	G/A	cg13787134	chr9:96362102	PHF2	-0.39	-5.1	-0.39	1.02e-6	Body mass index;
UCEC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg23018236	chr17:30244563	NA	-0.65	-4.72	-0.36	5.44e-6	Hip circumference adjusted for BMI;
UCEC	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	7.01	0.5	7.97e-11	Leprosy;
UCEC	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg06238570	chr21:40685208	BRWD1	0.76	7.5	0.53	5.6e-12	Cognitive function;
UCEC	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-8.02	-0.55	3.12e-13	Electrocardiographic conduction measures;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.75	-0.49	3.12e-10	Pubertal anthropometrics;
UCEC	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.71	8.28	0.56	6.77e-14	Mean corpuscular volume;
UCEC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.69	6.55	0.48	9.21e-10	Gestational age at birth (maternal effect);
UCEC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.81	-0.49	2.27e-10	Tonsillectomy;
UCEC	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.37	5.41	0.41	2.52e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.64	8.25	0.56	8.2e-14	Menarche (age at onset);
UCEC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg05132306	chr1:1846340	CALML6	-0.38	-4.8	-0.37	3.85e-6	Body mass index;
UCEC	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.63	-6.27	-0.46	3.89e-9	C-reactive protein levels;
UCEC	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.71	6.12	0.45	8.18e-9	Menopause (age at onset);
UCEC	cis	rs17123764	0.540	rs7313738	chr12:50086551	C/G	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	6.53	0.47	9.82e-10	Motion sickness;
UCEC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg22166914	chr1:53195759	ZYG11B	-0.48	-4.68	-0.36	6.33e-6	Monocyte count;
UCEC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.69	6.23	0.46	4.69e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.69	-7.88	-0.54	6.85e-13	Blood protein levels;
UCEC	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-5.0	-0.38	1.6e-6	Alzheimer's disease (late onset);
UCEC	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.77	-8.71	-0.58	5.79e-15	Waist circumference;Body mass index;
UCEC	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.77	7.39	0.52	1.03e-11	Morning vs. evening chronotype;
UCEC	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.42	5.69	0.42	6.67e-8	Life satisfaction;
UCEC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	5.67	0.42	7.25e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	7.29	0.52	1.78e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.61	6.01	0.44	1.39e-8	Lung cancer;
UCEC	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.54	5.03	0.38	1.41e-6	Diabetic retinopathy;
UCEC	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.5	6.97	0.5	1.01e-10	Age-related hearing impairment;
UCEC	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.66	-6.3	-0.46	3.19e-9	Body mass index;
UCEC	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.53	-5.8	-0.43	3.96e-8	Waist circumference adjusted for body mass index;
UCEC	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18854424	chr1:2615690	NA	0.45	6.58	0.48	7.93e-10	Ulcerative colitis;
UCEC	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg04154034	chr17:28927549	LRRC37B2	0.7	5.09	0.39	1.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.62	6.65	0.48	5.37e-10	Neuroticism;
UCEC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26002218	chr14:103986227	CKB	0.35	4.53	0.35	1.19e-5	Body mass index;
UCEC	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.42e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-6.12	-0.45	8.2e-9	Mean platelet volume;
UCEC	cis	rs13205180	0.555	rs9296670	chr6:51949245	C/T	cg08959645	chr6:52281315	NA	0.43	4.52	0.35	1.25e-5	Diastolic blood pressure;
UCEC	cis	rs79815064	0.850	rs76733709	chr3:46281461	G/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.73	4.63	0.36	7.91e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.46	5.39	0.41	2.78e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg19318889	chr4:1322082	MAEA	0.59	7.1	0.51	4.92e-11	Longevity;
UCEC	trans	rs11169552	0.510	rs10876043	chr12:50904144	C/T	cg10025462	chr17:27046956	SNORD42B;RPL23A	-0.73	-7.52	-0.53	4.88e-12	Colorectal cancer;
UCEC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.57	-6.23	-0.46	4.59e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-4.67	-0.36	6.79e-6	Life satisfaction;
UCEC	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg12379764	chr21:47803548	PCNT	0.61	5.02	0.38	1.45e-6	Lymphocyte counts;
UCEC	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-0.7	-9.38	-0.61	1.11e-16	Gut microbiome composition (winter);
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg07404485	chr7:94953653	PON1	-0.48	-4.65	-0.36	7.47e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.65	-5.76	-0.43	4.84e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg11569703	chr11:65557185	OVOL1	-0.44	-5.55	-0.42	1.29e-7	Acne (severe);
UCEC	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.41	0.41	2.46e-7	Heart rate;
UCEC	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04374321	chr14:90722782	PSMC1	0.7	7.7	0.54	1.81e-12	Mortality in heart failure;
UCEC	cis	rs334147	1.000	rs777549	chr2:128277597	T/A	cg14478610	chr2:127864964	BIN1	-0.5	-4.9	-0.37	2.48e-6	Educational attainment;
UCEC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.65	-6.07	-0.45	1.06e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	7.56	0.53	4e-12	Type 2 diabetes;
UCEC	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg09238746	chr17:78121135	EIF4A3	-0.69	-7.06	-0.5	6.28e-11	Yeast infection;
UCEC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-7.71	-0.54	1.79e-12	Longevity;Endometriosis;
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.18	0.71	4.85e-24	Platelet count;
UCEC	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.55	-5.17	-0.39	7.61e-7	Plateletcrit;Platelet count;
UCEC	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1978968	0.826	rs34596632	chr22:18463254	A/C	cg03078520	chr22:18463400	MICAL3	-0.56	-5.54	-0.42	1.37e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.59	5.56	0.42	1.22e-7	Multiple sclerosis;
UCEC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.53	6.65	0.48	5.25e-10	Total body bone mineral density;
UCEC	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-4.66	-0.36	6.95e-6	Pediatric autoimmune diseases;
UCEC	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.53	-5.65	-0.42	8.13e-8	Gut microbiome composition (summer);
UCEC	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.64	5.67	0.42	7.36e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.56	-5.36	-0.4	3.19e-7	Psoriasis;
UCEC	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg18016565	chr1:150552671	MCL1	0.44	4.53	0.35	1.23e-5	Melanoma;
UCEC	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg00105475	chr2:10696890	NA	0.45	5.6	0.42	1.01e-7	Prostate cancer;
UCEC	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg22166914	chr1:53195759	ZYG11B	0.59	6.03	0.45	1.27e-8	Monocyte count;
UCEC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.53	4.99	0.38	1.69e-6	Menopause (age at onset);
UCEC	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.42	4.58	0.35	9.78e-6	Schizophrenia;
UCEC	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.53	-4.8	-0.37	3.88e-6	Coronary artery disease;
UCEC	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.24	0.51	2.26e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.54	-5.68	-0.42	7.05e-8	Sudden cardiac arrest;
UCEC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.96	-11.16	-0.68	2.41e-21	Breast cancer;
UCEC	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.49	-4.7	-0.36	5.81e-6	Pediatric autoimmune diseases;
UCEC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-0.6	-6.96	-0.5	1.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.45	-5.07	-0.39	1.16e-6	Tonsillectomy;
UCEC	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	0.83	5.92	0.44	2.23e-8	Red blood cell traits;
UCEC	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	4.76	0.37	4.67e-6	Parkinson's disease;
UCEC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.41	-0.41	2.47e-7	Menarche (age at onset);
UCEC	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Bladder cancer;
UCEC	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.55	0.42	1.27e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.59	-0.35	9.27e-6	Alzheimer's disease (late onset);
UCEC	cis	rs692916	0.628	rs656993	chr18:60564921	C/G	cg07187971	chr18:60481018	PHLPP1	-0.4	-5.01	-0.38	1.53e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs11867410	0.744	rs73338702	chr17:63986352	C/T	cg06996976	chr17:64576105	PRKCA	-0.72	-4.55	-0.35	1.13e-5	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg01689657	chr7:91764605	CYP51A1	-0.47	-5.89	-0.44	2.5e-8	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.72	8.45	0.57	2.67e-14	Prudent dietary pattern;
UCEC	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.68	7.14	0.51	4.03e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12973672	0.812	rs12986033	chr19:35748782	A/G	cg12095397	chr19:35769544	USF2	0.51	4.85	0.37	3.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.65	5.95	0.44	1.87e-8	Menarche (age at onset);
UCEC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.57	4.82	0.37	3.53e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.75	6.23	0.46	4.72e-9	Fibroblast growth factor basic levels;
UCEC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.44	-4.65	-0.36	7.19e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg05738196	chr6:26577821	NA	0.58	6.27	0.46	3.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.53	-5.27	-0.4	4.8e-7	Aortic root size;
UCEC	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	0.88	6.95	0.5	1.09e-10	Pediatric areal bone mineral density (radius);
UCEC	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.26	0.4	5.06e-7	Mean platelet volume;
UCEC	cis	rs75804782	0.625	rs72984530	chr2:239469431	C/T	cg12524725	chr2:239427019	NA	-0.67	-4.64	-0.36	7.59e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.69	6.37	0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.52	-4.68	-0.36	6.58e-6	Colorectal cancer;
UCEC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.58	5.79	0.43	4.02e-8	Lymphocyte counts;
UCEC	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.68	-7.06	-0.5	6.27e-11	Waist circumference;Body mass index;
UCEC	cis	rs4869931	0.929	rs9480531	chr6:151008498	C/T	cg06471296	chr6:150259601	NA	-0.35	-4.58	-0.35	9.87e-6	Systolic blood pressure in sickle cell anemia;
UCEC	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.74	8.25	0.56	8.45e-14	Coronary artery disease;
UCEC	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.57	5.99	0.44	1.58e-8	Mean platelet volume;
UCEC	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.76	-6.76	-0.49	3.09e-10	Caudate activity during reward;
UCEC	cis	rs7246967	0.866	rs12972095	chr19:23034510	C/A	cg08271804	chr19:22816896	ZNF492	0.59	5.57	0.42	1.16e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.73	-7.59	-0.53	3.46e-12	Menarche (age at onset);
UCEC	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg24505687	chr6:33548425	BAK1	0.47	5.22	0.4	5.86e-7	Platelet count;
UCEC	cis	rs9715521	0.746	rs57464801	chr4:59851169	C/G	cg11281224	chr4:60001000	NA	-0.58	-5.7	-0.43	6.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-7.81	-0.54	9.78e-13	Chronic sinus infection;
UCEC	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.72e-7	Heart rate;
UCEC	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.35	-4.53	-0.35	1.19e-5	Dupuytren's disease;
UCEC	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.98	-0.5	9.24e-11	Coronary artery disease;
UCEC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg00612595	chr21:47717864	NA	-0.49	-5.34	-0.4	3.41e-7	Testicular germ cell tumor;
UCEC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-4.59	-0.35	9.47e-6	Bipolar disorder;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg11697111	chr7:1126903	GPER;C7orf50	-0.46	-4.54	-0.35	1.17e-5	Longevity;Endometriosis;
UCEC	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.83	0.49	2.12e-10	Eye color traits;
UCEC	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	0.94	9.34	0.61	1.43e-16	Corneal structure;
UCEC	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg17279458	chr3:44753948	ZNF502	-0.43	-4.54	-0.35	1.16e-5	Depressive symptoms;
UCEC	cis	rs7634260	0.667	rs6766065	chr3:9658520	A/G	cg02053257	chr3:10353648	SEC13	-0.51	-4.71	-0.36	5.65e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Delta-6 desaturase activity;Delta-5 desaturase activity;
UCEC	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.58	-5.91	-0.44	2.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.61	6.62	0.48	6.17e-10	Coronary artery disease;
UCEC	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.53	-4.69	-0.36	6.23e-6	Blood pressure (smoking interaction);
UCEC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.86	6.72	0.48	3.75e-10	Body mass index;
UCEC	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.69	6.49	0.47	1.21e-9	Menopause (age at onset);
UCEC	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.88	10.6	0.66	7.61e-20	Height;
UCEC	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-7.34	-0.52	1.37e-11	Parkinson's disease;
UCEC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg26721908	chr21:47610096	LSS	-0.59	-6.64	-0.48	5.72e-10	Testicular germ cell tumor;
UCEC	cis	rs892864	0.730	rs80299601	chr5:127816862	T/C	cg17313118	chr5:127157258	NA	0.76	4.68	0.36	6.54e-6	Multiple system atrophy;
UCEC	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.63	6.73	0.49	3.51e-10	Colorectal cancer;
UCEC	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.72	7.47	0.52	6.45e-12	Primary sclerosing cholangitis;
UCEC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.49	5.67	0.42	7.18e-8	Total body bone mineral density;
UCEC	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.89	-6.69	-0.48	4.33e-10	Exhaled nitric oxide output;
UCEC	cis	rs9899728	0.539	rs12940199	chr17:73054759	C/T	cg27626185	chr17:73056755	KCTD2	-0.63	-5.58	-0.42	1.1e-7	Alzheimer's disease or small vessel stroke;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	8.83	0.59	2.96e-15	Platelet count;
UCEC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.65	-5.91	-0.44	2.32e-8	Menarche (age at onset);
UCEC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.72	0.58	5.45e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.59	-0.81	1.67e-35	Myeloid white cell count;
UCEC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.66	-0.42	7.51e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2302190	0.882	rs7226008	chr17:56644633	T/C	cg12560992	chr17:57184187	TRIM37	0.52	4.65	0.36	7.35e-6	Vitamin D levels;
UCEC	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	0.82	5.14	0.39	8.71e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-5.49	-0.41	1.74e-7	Height;
UCEC	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.61	0.53	3.02e-12	Bipolar disorder;
UCEC	cis	rs3914502	0.593	rs9290516	chr3:174523444	A/C	cg21145449	chr3:174580620	NAALADL2	0.44	5.05	0.38	1.28e-6	Autism spectrum disorder;
UCEC	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.54	-6.29	-0.46	3.52e-9	Type 2 diabetes;
UCEC	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15664640	chr17:80829946	TBCD	0.51	4.84	0.37	3.23e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
UCEC	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.35	-5.13	-0.39	9.02e-7	Childhood ear infection;
UCEC	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg00334056	chr6:33755658	LEMD2	-0.42	-4.55	-0.35	1.11e-5	Crohn's disease;
UCEC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.19	0.56	1.13e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.55	-6.27	-0.46	3.72e-9	Type 2 diabetes;
UCEC	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg01380346	chr19:18557039	ELL	-0.44	-4.56	-0.35	1.07e-5	Breast cancer;
UCEC	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.22	11.23	0.68	1.66e-21	Corneal structure;
UCEC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.42	-5.28	-0.4	4.58e-7	Colorectal cancer;
UCEC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.8	-7.97	-0.55	4.08e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12635074	0.547	rs17634512	chr3:56237810	C/A	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.52	0.35	1.26e-5	Morning vs. evening chronotype;
UCEC	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.49	-5.62	-0.42	9.39e-8	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	5.8	0.43	3.87e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs16857609	0.628	rs2373066	chr2:218352374	C/T	cg23340935	chr2:218354150	DIRC3	0.49	4.82	0.37	3.57e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs78487399	0.808	rs6746610	chr2:43677253	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg17330251	chr7:94953956	PON1	-0.56	-5.39	-0.41	2.77e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.49	-4.52	-0.35	1.24e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-5.02	-0.38	1.46e-6	Morning vs. evening chronotype;
UCEC	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg24088508	chr1:38156462	C1orf109	-0.57	-5.08	-0.39	1.11e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.81	6.6	0.48	6.82e-10	Lymphocyte counts;
UCEC	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.6	8.03	0.55	2.85e-13	Height;
UCEC	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.41	-0.47	1.9e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg20965017	chr5:231967	SDHA	-0.62	-5.6	-0.42	1.04e-7	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.07	0.71	9.55e-24	Prudent dietary pattern;
UCEC	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	4.89	0.37	2.64e-6	Bipolar disorder;
UCEC	cis	rs259282	0.605	rs8101920	chr19:33109270	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.55	4.91	0.38	2.36e-6	Schizophrenia;
UCEC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.6	-0.35	8.93e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.18	0.45	5.9e-9	Cognitive ability;
UCEC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18932078	chr1:2524107	MMEL1	0.4	6.3	0.46	3.21e-9	Ulcerative colitis;
UCEC	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.92	0.44	2.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-4.62	-0.36	8.35e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.5	-5.14	-0.39	8.48e-7	Cardiac Troponin-T levels;
UCEC	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg16797656	chr11:68205561	LRP5	0.58	4.61	0.36	8.78e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs12681963	0.748	rs12546409	chr8:29902956	A/T	cg07899425	chr8:30585046	GSR	-0.5	-4.51	-0.35	1.34e-5	Migraine;
UCEC	cis	rs7175404	0.591	rs57153897	chr15:94057102	G/A	cg25253948	chr15:93956996	NA	0.67	4.89	0.37	2.63e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg14008862	chr17:28927542	LRRC37B2	0.62	4.78	0.37	4.13e-6	Body mass index;
UCEC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-6.85	-0.49	1.88e-10	Breast cancer;
UCEC	cis	rs8020441	0.945	rs67713610	chr14:51168830	C/T	cg04730355	chr14:51134070	SAV1	0.57	5.27	0.4	4.84e-7	Cognitive performance;
UCEC	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.54	4.75	0.37	4.72e-6	Corneal astigmatism;
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.48	4.67	0.36	6.66e-6	Obesity-related traits;
UCEC	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg20203395	chr5:56204925	C5orf35	-0.51	-4.87	-0.37	2.87e-6	Coronary artery disease;
UCEC	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.44	-4.91	-0.38	2.45e-6	Facial morphology (factor 20);
UCEC	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-9.8	-0.63	9.3e-18	Ulcerative colitis;
UCEC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg23888215	chr10:79422304	NA	-1.12	-7.96	-0.55	4.22e-13	Bone mineral density;
UCEC	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg00266579	chr16:28619858	SULT1A1	0.63	4.57	0.35	1.05e-5	Platelet distribution width;
UCEC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-5.44	-0.41	2.16e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.64	-5.54	-0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.77	-8.8	-0.59	3.45e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-5.75	-0.43	4.96e-8	Chronic sinus infection;
UCEC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.71	8.35	0.57	4.61e-14	Menopause (age at onset);
UCEC	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	8.78	0.59	3.94e-15	Monocyte count;
UCEC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.47	-5.46	-0.41	1.99e-7	Aortic root size;
UCEC	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.48	4.67	0.36	6.7e-6	Colorectal cancer;
UCEC	cis	rs17106184	0.901	rs72904745	chr1:51363273	C/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.65	5.95	0.44	1.88e-8	Asthma;
UCEC	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg00406319	chr10:126851303	NA	0.38	4.52	0.35	1.28e-5	Menarche (age at onset);
UCEC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-4.54	-0.35	1.18e-5	Cognitive test performance;
UCEC	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	9.6	0.62	3.13e-17	Blood protein levels;
UCEC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.31	0.4	3.95e-7	Bipolar disorder;
UCEC	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.62	6.27	0.46	3.88e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg06521331	chr12:34319734	NA	-0.62	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.66	0.42	7.63e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs7611694	0.501	rs2171293	chr3:113100342	A/G	cg11138929	chr3:113251189	SIDT1	-0.39	-4.67	-0.36	6.86e-6	Prostate cancer;
UCEC	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	5.56	0.42	1.21e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.58	-5.12	-0.39	9.64e-7	Multiple sclerosis;
UCEC	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.52	5.13	0.39	8.96e-7	Pediatric autoimmune diseases;
UCEC	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.63	4.81	0.37	3.77e-6	Carotid intima media thickness;
UCEC	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.47	-6.4	-0.47	1.96e-9	Height;
UCEC	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	4.82	0.37	3.56e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8032158	0.963	rs12102020	chr15:56125578	G/A	cg10433327	chr15:56209506	NEDD4	-0.3	-4.98	-0.38	1.73e-6	Keloid;
UCEC	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.67	-7.56	-0.53	4e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg24843389	chr22:30685747	GATSL3	-0.46	-4.69	-0.36	6.14e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.93	0.38	2.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	trans	rs4146922	0.793	rs6752931	chr2:56004219	G/T	cg03313676	chr20:62526047	DNAJC5	0.7	7.19	0.51	3.01e-11	Height;
UCEC	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.66	6.65	0.48	5.52e-10	Tonsillectomy;
UCEC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg20007245	chr22:24372913	LOC391322	0.62	6.88	0.49	1.61e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.73	7.7	0.54	1.85e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg23791538	chr6:167370224	RNASET2	-0.58	-5.95	-0.44	1.91e-8	Crohn's disease;
UCEC	cis	rs7560272	0.529	rs2421672	chr2:73955540	G/A	cg20560298	chr2:73613845	ALMS1	0.48	4.52	0.35	1.27e-5	Schizophrenia;
UCEC	cis	rs11760485	0.858	rs11767003	chr7:4401503	G/A	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.33	4.52	0.35	1.25e-5	Childhood ear infection;
UCEC	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs4730268	1.000	rs4730268	chr7:107443386	C/T	cg18560240	chr7:107437656	SLC26A3	-0.77	-6.29	-0.46	3.48e-9	IgG glycosylation;
UCEC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.19	-0.45	5.69e-9	Response to antipsychotic treatment;
UCEC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18252515	chr7:66147081	NA	0.53	5.02	0.38	1.49e-6	Aortic root size;
UCEC	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.78e-7	Heart rate;
UCEC	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg13147721	chr7:65941812	NA	-0.85	-6.0	-0.44	1.47e-8	Diabetic kidney disease;
UCEC	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg14008862	chr17:28927542	LRRC37B2	0.52	4.51	0.35	1.29e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs36051895	0.664	rs10121077	chr9:5098411	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-5.27	-0.4	4.86e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.62	6.2	0.46	5.39e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12332430	1.000	rs12332430	chr5:147550297	C/T	cg02292949	chr5:147648492	SPINK5L3	0.58	4.64	0.36	7.69e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-10.49	-0.65	1.49e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.7	6.63	0.48	6.11e-10	Height;
UCEC	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.79	-8.06	-0.55	2.38e-13	Plateletcrit;Platelet count;
UCEC	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg25767906	chr1:53392781	SCP2	-0.45	-4.65	-0.36	7.48e-6	Monocyte count;
UCEC	cis	rs10242455	0.764	rs12360	chr7:99303094	G/A	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	6.74e-7	Blood metabolite levels;
UCEC	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.55	-5.9	-0.44	2.44e-8	Sudden cardiac arrest;
UCEC	cis	rs1978968	0.763	rs8140977	chr22:18463608	C/T	cg03078520	chr22:18463400	MICAL3	-0.55	-6.98	-0.5	9.62e-11	Presence of antiphospholipid antibodies;
UCEC	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.86	-8.72	-0.58	5.32e-15	Blood metabolite levels;
UCEC	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg14784868	chr12:69753453	YEATS4	0.53	4.55	0.35	1.11e-5	Response to diuretic therapy;
UCEC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.73	-8.39	-0.57	3.69e-14	Menarche (age at onset);
UCEC	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.95	-9.33	-0.61	1.48e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.99	0.6	1.16e-15	Prudent dietary pattern;
UCEC	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.29	-0.68	1.1e-21	Chronic sinus infection;
UCEC	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.9	-9.67	-0.62	2e-17	Schizophrenia;
UCEC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg01262667	chr19:19385393	TM6SF2	0.46	6.21	0.46	5.02e-9	Tonsillectomy;
UCEC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.63	7.05	0.5	6.63e-11	Homoarginine levels;
UCEC	cis	rs308403	0.533	rs309377	chr4:123676353	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.9	13.13	0.73	1.49e-26	Blood protein levels;
UCEC	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	6.34	0.46	2.68e-9	Response to bleomycin (chromatid breaks);
UCEC	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.06	0.5	6.01e-11	Morning vs. evening chronotype;
UCEC	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.71	5.94	0.44	1.97e-8	Alzheimer's disease;
UCEC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.48	-5.9	-0.44	2.43e-8	Mean platelet volume;
UCEC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg01657329	chr11:68192670	LRP5	0.4	4.54	0.35	1.17e-5	Bone mineral density (spine);
UCEC	cis	rs295140	1.000	rs295140	chr2:201160699	T/C	cg04283868	chr2:201171347	SPATS2L	-0.49	-4.96	-0.38	1.96e-6	QT interval;
UCEC	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.58	-0.42	1.1e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.67	5.0	0.38	1.63e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.65	-7.85	-0.54	8.02e-13	Hip circumference;
UCEC	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	7.01	0.5	7.94e-11	Eye color traits;
UCEC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.09	16.27	0.8	1.12e-34	IgG glycosylation;
UCEC	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.62	5.01	0.38	1.52e-6	Systolic blood pressure;
UCEC	cis	rs17433710	0.500	rs10799858	chr1:162630279	A/G	cg19264028	chr1:162630153	DDR2	0.78	5.3	0.4	4.14e-7	Dupuytren's disease;
UCEC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg00612595	chr21:47717864	NA	-0.45	-4.73	-0.36	5.12e-6	Testicular germ cell tumor;
UCEC	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.23	-0.4	5.61e-7	Hemoglobin concentration;
UCEC	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.84	9.42	0.61	8.99e-17	Body mass index (adult);
UCEC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg23888215	chr10:79422304	NA	-1.02	-7.66	-0.53	2.25e-12	Bone mineral density;
UCEC	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg18099408	chr3:52552593	STAB1	0.42	4.88	0.37	2.76e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.71	6.9	0.49	1.47e-10	Aortic root size;
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.74	6.36	0.46	2.41e-9	Platelet count;
UCEC	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg17294928	chr15:75287854	SCAMP5	0.51	5.68	0.42	6.99e-8	Breast cancer;
UCEC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.61	6.03	0.45	1.28e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.56	5.2	0.39	6.64e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.57	4.95	0.38	2.01e-6	Corneal astigmatism;
UCEC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg11697111	chr7:1126903	GPER;C7orf50	-0.45	-4.53	-0.35	1.19e-5	Longevity;Endometriosis;
UCEC	cis	rs12767760	0.714	rs11189274	chr10:99311629	A/G	cg17778955	chr10:99210596	ZDHHC16	-0.46	-4.71	-0.36	5.62e-6	Obesity-related traits;
UCEC	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.48	-4.71	-0.36	5.67e-6	Mortality in heart failure;
UCEC	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.64	8.22	0.56	9.9e-14	Anterior chamber depth;
UCEC	cis	rs4959677	0.703	rs4959672	chr6:2473242	T/A	cg07083902	chr6:1596254	NA	-0.37	-4.51	-0.35	1.29e-5	Orthostatic hypotension;
UCEC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	5.8	0.43	3.94e-8	Platelet count;
UCEC	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.49	-4.79	-0.37	4.05e-6	Primary biliary cholangitis;
UCEC	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.76	7.56	0.53	4.09e-12	Menopause (age at onset);
UCEC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.5	-5.65	-0.42	8.01e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.76	0.37	4.68e-6	Menarche (age at onset);
UCEC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs890835	0.892	rs890834	chr5:175955814	A/G	cg17652716	chr5:176910622	PDLIM7	-0.67	-4.77	-0.37	4.44e-6	Menopause (age at onset);
UCEC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.02	-8.17	-0.56	1.33e-13	Exhaled nitric oxide output;
UCEC	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.41	5.49	0.41	1.71e-7	Breast cancer;
UCEC	cis	rs925228	0.955	rs6730855	chr2:24192801	A/G	cg13272742	chr2:24272458	FKBP1B	0.6	5.15	0.39	8.3e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11958404	0.932	rs72816595	chr5:157435957	A/G	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg05738196	chr6:26577821	NA	-0.58	-7.23	-0.51	2.5e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.54	-5.4	-0.41	2.62e-7	Menopause (age at onset);
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.48	-5.0	-0.38	1.65e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg03146154	chr1:46216737	IPP	0.45	4.68	0.36	6.37e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.6	-6.37	-0.46	2.32e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.07	0.71	9.55e-24	Prudent dietary pattern;
UCEC	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg00316803	chr15:76480434	C15orf27	0.47	5.7	0.43	6.2e-8	Blood metabolite levels;
UCEC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.74	-7.96	-0.55	4.23e-13	Menarche (age at onset);
UCEC	cis	rs13418717	1.000	rs13418717	chr2:127662897	A/T	cg12632573	chr2:127783243	NA	0.59	4.55	0.35	1.09e-5	Heart failure;
UCEC	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.2	0.39	6.61e-7	Bipolar disorder;
UCEC	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.36	5.09	0.39	1.07e-6	Fat distribution (HIV);
UCEC	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.7	-0.36	5.89e-6	Aortic root size;
UCEC	cis	rs8105895	0.935	rs62112921	chr19:22227577	T/C	cg24072202	chr19:22235272	ZNF257	-0.56	-4.66	-0.36	6.89e-6	Body mass index (change over time);
UCEC	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.77	-0.49	2.87e-10	Urate levels in overweight individuals;
UCEC	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.36	-0.76	9.02e-30	Schizophrenia;
UCEC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.43	4.88	0.37	2.68e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-0.56	-5.37	-0.41	3e-7	Pediatric autoimmune diseases;
UCEC	cis	rs10924970	0.935	rs4659674	chr1:235392354	T/A	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.57	-5.09	-0.39	1.07e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.69	-8.03	-0.55	2.9e-13	Prudent dietary pattern;
UCEC	cis	rs2455799	1.000	rs13078364	chr3:15855507	T/A	cg16303742	chr3:15540471	COLQ	-0.41	-4.79	-0.37	4.1e-6	Mean platelet volume;
UCEC	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.39	0.47	2.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-4.94	-0.38	2.14e-6	Personality dimensions;
UCEC	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.56	6.2	0.46	5.34e-9	Bipolar disorder;
UCEC	cis	rs4588572	0.644	rs891150	chr5:77761794	G/A	cg11547950	chr5:77652471	NA	-0.38	-4.58	-0.35	9.83e-6	Triglycerides;
UCEC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.12	-0.39	9.36e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg18681998	chr4:17616180	MED28	0.69	8.08	0.55	2.2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.42	-6.03	-0.45	1.3e-8	Multiple sclerosis;
UCEC	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.59	5.41	0.41	2.47e-7	Mean corpuscular volume;
UCEC	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg09165964	chr15:75287851	SCAMP5	0.5	5.53	0.42	1.4e-7	Caffeine consumption;
UCEC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.44	-5.37	-0.4	3.02e-7	Mortality in heart failure;
UCEC	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg12884169	chr21:40033163	ERG	0.44	5.76	0.43	4.64e-8	Coronary artery disease;
UCEC	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.67	-6.51	-0.47	1.14e-9	C-reactive protein levels;
UCEC	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.65	-7.69	-0.54	1.95e-12	IgG glycosylation;
UCEC	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.68	9.25	0.61	2.48e-16	Systolic blood pressure;
UCEC	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.76	-8.16	-0.56	1.34e-13	Body mass index;
UCEC	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-12.27	-0.71	2.87e-24	Height;
UCEC	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.49	-4.99	-0.38	1.7e-6	Retinal vascular caliber;
UCEC	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.54	-5.69	-0.42	6.72e-8	Breast cancer;
UCEC	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg00852783	chr1:26633632	UBXN11	0.51	4.89	0.37	2.61e-6	Obesity-related traits;
UCEC	cis	rs2172802	0.584	rs6857007	chr4:62510516	T/G	cg04118610	chr4:62707027	LPHN3	-0.42	-4.74	-0.36	5.09e-6	Partial epilepsies;
UCEC	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.53	-5.5	-0.41	1.62e-7	Anterior chamber depth;
UCEC	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-5.29	-0.4	4.37e-7	Morning vs. evening chronotype;
UCEC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs925228	0.910	rs4564735	chr2:24164237	T/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.57	-5.5	-0.41	1.6e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs975730	1.000	rs4470994	chr8:129330268	A/G	cg14920061	chr8:129326392	NA	-0.38	-5.0	-0.38	1.6e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Body mass index;
UCEC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17433710	0.516	rs4411113	chr1:162668008	G/T	cg04915463	chr1:162039957	NOS1AP	0.48	4.79	0.37	4.1e-6	Dupuytren's disease;
UCEC	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.62	6.56	0.48	8.62e-10	Motion sickness;
UCEC	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg11861562	chr11:117069780	TAGLN	0.35	4.67	0.36	6.62e-6	Blood protein levels;
UCEC	cis	rs6437061	0.737	rs3103295	chr2:233034472	T/C	cg20569070	chr2:232597279	PDE6D	0.45	5.33	0.4	3.61e-7	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	5.96	0.44	1.83e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.44	0.47	1.61e-9	Cognitive test performance;
UCEC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.67	5.95	0.44	1.9e-8	Initial pursuit acceleration;
UCEC	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.53	-5.0	-0.38	1.59e-6	Menopause (age at onset);
UCEC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.44	-5.59	-0.42	1.07e-7	Urinary metabolites;
UCEC	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.09	6.27	0.46	3.74e-9	Diabetic retinopathy;
UCEC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.91	-11.78	-0.7	5.51e-23	Height;
UCEC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.09	-11.2	-0.68	1.94e-21	Breast cancer;
UCEC	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg05738196	chr6:26577821	NA	0.65	7.63	0.53	2.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs12979848	chr19:22820798	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.22	-0.64	7.22e-19	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.44	-0.47	1.62e-9	Aortic root size;
UCEC	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-6.45	-0.47	1.51e-9	Morning vs. evening chronotype;
UCEC	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.72	-5.16	-0.39	7.74e-7	Systemic lupus erythematosus;
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs75804782	0.630	rs56108200	chr2:239276888	C/T	cg11815105	chr2:239148849	HES6	0.99	4.63	0.36	8e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.42	-4.63	-0.36	7.98e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.14	6.79	0.49	2.59e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs6688613	0.721	rs2312675	chr1:166922533	T/C	cg07049167	chr1:166818506	POGK	0.57	5.58	0.42	1.1e-7	Refractive astigmatism;
UCEC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.32	-0.4	3.77e-7	Aortic root size;
UCEC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.35	-0.46	2.51e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs17818399	0.501	rs13413254	chr2:46802934	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-5.03	-0.38	1.4e-6	Height;
UCEC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg06462663	chr19:18546047	ISYNA1	0.51	6.37	0.47	2.23e-9	Breast cancer;
UCEC	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.7	-9.06	-0.6	7.57e-16	Oral cavity cancer;
UCEC	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.67	-7.52	-0.53	5.04e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs7246967	0.673	rs2112610	chr19:22916851	C/T	cg24889512	chr19:22816950	ZNF492	0.61	6.6	0.48	6.84e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.93	11.84	0.7	3.94e-23	Monocyte count;
UCEC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.87	-12.6	-0.72	3.72e-25	Urate levels in lean individuals;
UCEC	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.24e-8	Systemic lupus erythematosus;
UCEC	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.5	-5.07	-0.39	1.18e-6	Total body bone mineral density;
UCEC	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	0.85	7.73	0.54	1.52e-12	Nonalcoholic fatty liver disease;
UCEC	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.6	6.68	0.48	4.65e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7781557	0.591	rs56314487	chr7:102535721	G/T	cg06322601	chr7:102330635	NA	0.57	4.58	0.35	9.97e-6	Colorectal adenoma (advanced);
UCEC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.54	5.72	0.43	5.86e-8	Red blood cell count;
UCEC	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.79	-9.41	-0.61	9.2e-17	Mortality in heart failure;
UCEC	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.41	-5.03	-0.38	1.39e-6	Urinary tract infection frequency;
UCEC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.67	-7.08	-0.5	5.55e-11	Ulcerative colitis;
UCEC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.56	-6.48	-0.47	1.32e-9	Prostate cancer;
UCEC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.75	8.75	0.59	4.55e-15	Cognitive function;
UCEC	trans	rs12755164	0.771	rs1464952	chr1:73362999	A/C	cg17780956	chr4:156297616	MAP9	-0.65	-6.93	-0.5	1.26e-10	Schizophrenia;
UCEC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.5	5.17	0.39	7.58e-7	Schizophrenia;
UCEC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.87	0.54	6.95e-13	Platelet count;
UCEC	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.57	4.66	0.36	7.13e-6	Bipolar disorder;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.71	-0.43	5.98e-8	Pubertal anthropometrics;
UCEC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.64	-4.65	-0.36	7.45e-6	Narcolepsy;
UCEC	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.64	-5.59	-0.42	1.1e-7	Adiposity;
UCEC	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.66	6.67	0.48	4.83e-10	Colorectal cancer;
UCEC	cis	rs79815064	0.790	rs79629761	chr3:46340630	C/T	cg08033130	chr3:45983597	CXCR6;FYCO1	0.79	4.6	0.35	9.06e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.66	7.18	0.51	3.3e-11	Breast cancer;
UCEC	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.59	5.38	0.41	2.87e-7	Corneal astigmatism;
UCEC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg05962950	chr11:130786565	SNX19	0.53	5.26	0.4	4.88e-7	Schizophrenia;
UCEC	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg11742103	chr11:62369870	EML3;MTA2	-0.36	-4.65	-0.36	7.4e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	6.23	0.46	4.6e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-9.01	-0.6	1.01e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.65	-7.24	-0.51	2.27e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	0.87	9.71	0.63	1.57e-17	Breast cancer;
UCEC	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.76	-9.24	-0.61	2.54e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.9	0.37	2.55e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	0.54	5.48	0.41	1.82e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs4668356	1.000	rs56934523	chr2:171972766	C/T	cg13882835	chr2:172017928	TLK1	0.67	4.5	0.35	1.35e-5	Cognitive performance;
UCEC	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.57	5.52	0.41	1.52e-7	Monocyte percentage of white cells;
UCEC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-6.96	-0.5	1.07e-10	Cognitive function;
UCEC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.74	8.68	0.58	6.79e-15	Prudent dietary pattern;
UCEC	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	6.05e-9	Colorectal cancer;
UCEC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.7	7.56	0.53	3.9e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.43	5.06	0.38	1.25e-6	Blood metabolite ratios;
UCEC	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05472934	chr7:22766657	IL6	0.77	7.69	0.54	1.94e-12	Lung cancer;
UCEC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs828999	0.872	rs663045	chr1:108743059	G/C	cg11967332	chr1:108735228	SLC25A24	0.49	5.77	0.43	4.6e-8	Monocyte percentage of white cells;
UCEC	cis	rs66686620	1.000	rs6711429	chr2:69260070	A/T	cg12800200	chr2:69260302	ANTXR1	-0.56	-5.4	-0.41	2.65e-7	Breast cancer;
UCEC	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.57	-5.61	-0.42	9.53e-8	Post bronchodilator FEV1;
UCEC	cis	rs6137726	0.652	rs2209796	chr20:22659450	A/G	cg08244522	chr20:23030533	THBD	0.49	5.23	0.4	5.69e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.53	5.56	0.42	1.21e-7	Schizophrenia;
UCEC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	6.06	0.45	1.08e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg06096015	chr1:231504339	EGLN1	0.4	4.52	0.35	1.24e-5	Hemoglobin concentration;
UCEC	cis	rs732765	0.819	rs2058920	chr14:75311329	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	5.09	0.39	1.09e-6	Non-small cell lung cancer;
UCEC	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.54	5.39	0.41	2.74e-7	Height;
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.0	0.44	1.46e-8	Platelet count;
UCEC	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs2521634	0.646	rs13235705	chr7:24377125	A/G	cg03240301	chr7:23387383	IGF2BP3	0.73	4.63	0.36	8.02e-6	Periodontitis;
UCEC	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.49	-5.2	-0.39	6.53e-7	Retinal vascular caliber;
UCEC	cis	rs7597155	0.935	rs10181122	chr2:69980910	C/T	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.44	-0.41	2.14e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2267137	0.836	rs2283855	chr22:29796775	T/C	cg07256473	chr22:29710276	RASL10A	0.54	5.39	0.41	2.77e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.57	4.73	0.36	5.13e-6	Obesity-related traits;
UCEC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg21770322	chr7:97807741	LMTK2	-0.46	-5.8	-0.43	3.92e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.05	-0.45	1.15e-8	Aortic root size;
UCEC	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.86	-9.78	-0.63	1.07e-17	Blood metabolite levels;
UCEC	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.63	5.52	0.41	1.52e-7	Lung function (FEV1/FVC);
UCEC	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.63	-0.48	5.88e-10	Response to antipsychotic treatment;
UCEC	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.67	7.71	0.54	1.72e-12	Mosquito bite size;
UCEC	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-4.89	-0.37	2.67e-6	Pediatric autoimmune diseases;
UCEC	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.54e-18	Height;
UCEC	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg11150807	chr10:43354902	NA	0.81	6.96	0.5	1.07e-10	Blood protein levels;
UCEC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.48	4.81	0.37	3.63e-6	Prostate cancer;
UCEC	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Blood protein levels;
UCEC	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-4.79	-0.37	4.08e-6	Platelet distribution width;
UCEC	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.64	6.24	0.46	4.39e-9	Coronary artery disease;
UCEC	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.64	-0.9	4.76e-54	Myeloid white cell count;
UCEC	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.57	6.69	0.48	4.33e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.61	-6.05	-0.45	1.16e-8	Blood metabolite levels;
UCEC	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-6.41	-0.47	1.82e-9	Rheumatoid arthritis;
UCEC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26002218	chr14:103986227	CKB	0.37	5.27	0.4	4.71e-7	Body mass index;
UCEC	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.51	-4.73	-0.36	5.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg03678062	chr6:149772716	ZC3H12D	-0.46	-5.87	-0.44	2.77e-8	Dupuytren's disease;
UCEC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.83	-8.02	-0.55	3.08e-13	Alzheimer's disease;
UCEC	cis	rs7246967	0.611	rs73030508	chr19:22826032	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs1814175	0.720	rs56884483	chr11:49594333	A/T	cg03929089	chr4:120376271	NA	-0.75	-7.84	-0.54	8.26e-13	Height;
UCEC	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.78e-7	Heart rate;
UCEC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-6.07	-0.45	1.06e-8	Hepatocellular carcinoma;
UCEC	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.74	-8.18	-0.56	1.21e-13	Ear protrusion;
UCEC	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.46	4.83	0.37	3.35e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.41	0.41	2.45e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	0.84	5.8	0.43	3.95e-8	Mitochondrial DNA levels;
UCEC	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.58	4.72	0.36	5.51e-6	Corneal astigmatism;
UCEC	cis	rs2204008	0.743	rs11495614	chr12:38156358	C/T	cg26384229	chr12:38710491	ALG10B	0.8	6.82	0.49	2.25e-10	Bladder cancer;
UCEC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.4	0.47	1.99e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs350251	0.934	rs350210	chr16:12212689	T/G	cg01282078	chr16:12139025	RUNDC2A	-0.47	-4.61	-0.36	8.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.9	8.65	0.58	8.25e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.67	6.8	0.49	2.46e-10	Sudden cardiac arrest;
UCEC	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.48	-0.47	1.32e-9	Total cholesterol levels;
UCEC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.62	-5.68	-0.42	6.88e-8	Aortic root size;
UCEC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg11200568	chr7:226540	FAM20C	-0.49	-4.53	-0.35	1.19e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs2180233	0.789	rs28453847	chr1:30676922	G/A	cg00108524	chr1:30559124	NA	-0.51	-4.61	-0.36	8.76e-6	Attention deficit hyperactivity disorder and conduct disorder;
UCEC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs1079204	1.000	rs10178462	chr2:219083353	G/T	cg05728596	chr2:219128475	GPBAR1	0.75	5.94	0.44	1.97e-8	Smooth-surface caries;
UCEC	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.32	5.0	0.38	1.59e-6	Cancer;
UCEC	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg01851573	chr8:8652454	MFHAS1	0.41	4.53	0.35	1.23e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	0.94	9.7	0.62	1.73e-17	Heart rate;
UCEC	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.85e-8	Red blood cell count;
UCEC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3750082	0.889	rs6462432	chr7:32935524	C/T	cg05721444	chr7:32995514	FKBP9	0.53	6.02	0.44	1.34e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.62	0.53	2.83e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg10415171	chr14:77413900	NA	0.46	4.88	0.37	2.69e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05485520	chr3:45883628	LZTFL1	0.57	7.13	0.51	4.3e-11	Warfarin maintenance dose;
UCEC	cis	rs12137294	0.866	rs1077883	chr1:205210415	G/T	cg12580275	chr1:205744413	RAB7L1	0.44	4.95	0.38	2.05e-6	Red cell distribution width;
UCEC	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.57	5.92	0.44	2.14e-8	Schizophrenia;
UCEC	cis	rs1815787	1	rs1815787	chr11:116921397	T/C	cg13068653	chr11:117074303	TAGLN	0.54	4.74	0.36	4.93e-6	Subjective well-being;
UCEC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.64	-6.08	-0.45	9.7e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.52	6.56	0.48	8.39e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs711830	1.000	rs1562315	chr2:177045482	T/A	cg13092806	chr2:177043255	NA	0.98	9.99	0.64	2.96e-18	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg05962950	chr11:130786565	SNX19	0.5	5.1	0.39	1.05e-6	Schizophrenia;
UCEC	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.41	0.61	9.24e-17	Post bronchodilator FEV1;
UCEC	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	8.33	0.57	5.21e-14	Ulcerative colitis;
UCEC	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	18.94	0.84	2.85e-41	Schizophrenia;
UCEC	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.64	5.31	0.4	4e-7	Obesity-related traits;
UCEC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	6.92	0.5	1.27e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.62	5.43	0.41	2.31e-7	Schizophrenia;
UCEC	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg02176678	chr2:219576539	TTLL4	-0.71	-7.22	-0.51	2.54e-11	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg16652651	chr11:10472161	AMPD3	0.66	6.83	0.49	2.11e-10	Schizophrenia;
UCEC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.45	5.74	0.43	5.31e-8	Blood metabolite levels;
UCEC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.74	0.36	5.09e-6	Diabetic retinopathy;
UCEC	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.11	9.47	0.62	6.77e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.7	6.82	0.49	2.15e-10	Refractive astigmatism;
UCEC	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.34	-5.23	-0.4	5.84e-7	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.37	0.52	1.16e-11	Alzheimer's disease;
UCEC	cis	rs151997	0.777	rs3846500	chr5:50254488	A/T	cg06027927	chr5:50259733	NA	-0.54	-5.03	-0.38	1.41e-6	Callous-unemotional behaviour;
UCEC	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.36	6.17	0.45	6.3e-9	Cancer;
UCEC	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.56	5.9	0.44	2.35e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3780378	0.967	rs7023146	chr9:5040163	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.69	-0.36	6.07e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs2267681	0.544	rs10237429	chr7:139528596	C/G	cg14116596	chr7:139528673	TBXAS1	0.51	5.0	0.38	1.58e-6	Cervical cancer;
UCEC	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.43	-5.64	-0.42	8.58e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.51	5.15	0.39	8.27e-7	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-4.81	-0.37	3.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.46	5.28	0.4	4.48e-7	White matter hyperintensity burden;
UCEC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.74	7.95	0.55	4.51e-13	Coronary artery disease;
UCEC	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-5.33	-0.4	3.67e-7	Height;
UCEC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-5.91	-0.44	2.3e-8	Chronic sinus infection;
UCEC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.64	5.53	0.41	1.44e-7	Gut microbiome composition (summer);
UCEC	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg18681998	chr4:17616180	MED28	0.77	9.33	0.61	1.52e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	5.91	0.44	2.27e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	1.16	13.74	0.75	3.7e-28	Body mass index;
UCEC	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.41	4.58	0.35	9.77e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg02022102	chr7:27168609	HOXA4	0.6	6.8	0.49	2.51e-10	Protein biomarker;
UCEC	cis	rs7709377	0.595	rs149131	chr5:115639459	T/A	cg23108291	chr5:115420582	COMMD10	-0.53	-5.36	-0.4	3.09e-7	Metabolite levels  (X-11787);
UCEC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.2	0.46	5.35e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.06e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.4	0.71	1.32e-24	Platelet count;
UCEC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-10.49	-0.65	1.49e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.89	7.48	0.53	6.12e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.51	-4.92	-0.38	2.33e-6	Bipolar disorder;
UCEC	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.78	7.44	0.52	7.9e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7582720	1.000	rs72932737	chr2:203654540	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.7	0.36	6.02e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.71	8.74	0.58	4.96e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35934224	0.783	rs7288061	chr22:19864239	C/T	cg11182965	chr22:19864308	TXNRD2	-0.67	-6.35	-0.46	2.54e-9	Glaucoma (primary open-angle);
UCEC	cis	rs9463078	0.683	rs227855	chr6:44702352	T/C	cg25276700	chr6:44698697	NA	0.44	4.86	0.37	2.97e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.58	5.42	0.41	2.38e-7	Corneal astigmatism;
UCEC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg12463550	chr7:65579703	CRCP	0.52	5.23	0.4	5.72e-7	Aortic root size;
UCEC	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.05	7.49	0.53	5.81e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg15358701	chr1:161410459	NA	-0.75	-4.89	-0.37	2.6e-6	Rheumatoid arthritis;
UCEC	cis	rs4778581	0.750	rs12594035	chr15:80405098	C/G	cg08257866	chr15:80351198	ZFAND6	0.41	5.03	0.38	1.42e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs9321099	1.000	rs9402004	chr6:128238286	C/G	cg25012434	chr6:128842125	PTPRK	-0.65	-5.34	-0.4	3.47e-7	Sense of smell;
UCEC	trans	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg07817883	chr1:32538562	TMEM39B	1.16	9.43	0.61	8.15e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs6964969	0.535	rs2167364	chr7:50565827	C/T	cg18232548	chr7:50535776	DDC	-0.48	-4.5	-0.35	1.36e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.6	6.88	0.49	1.57e-10	Obesity-related traits;
UCEC	cis	rs5751614	0.537	rs5996508	chr22:23612628	G/A	cg21889604	chr22:23607606	BCR	0.44	4.74	0.36	5.01e-6	Height;
UCEC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.03e-6	Sudden cardiac arrest;
UCEC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.58	-0.35	9.96e-6	Bipolar disorder;
UCEC	cis	rs115344852	0.598	rs2531815	chr6:28436060	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.47	-4.66	-0.36	6.98e-6	Epithelial ovarian cancer;
UCEC	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.69	-8.33	-0.57	5.17e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.77	-8.8	-0.59	3.45e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg00677455	chr12:58241039	CTDSP2	0.53	4.69	0.36	6.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-6.84	-0.49	2e-10	Response to antipsychotic treatment;
UCEC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.71	7.17	0.51	3.47e-11	Menarche (age at onset);
UCEC	cis	rs9463078	0.764	rs1576382	chr6:44957553	G/A	cg25276700	chr6:44698697	NA	-0.45	-5.06	-0.39	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs13401104	0.796	rs35819191	chr2:237119051	T/C	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.55	-5.34	-0.4	3.52e-7	Post bronchodilator FEV1;
UCEC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	7.7	0.54	1.85e-12	Chronic sinus infection;
UCEC	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg04155231	chr12:9217510	LOC144571	0.42	4.99	0.38	1.68e-6	Sjögren's syndrome;
UCEC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg06466757	chr4:1255808	NA	0.46	4.85	0.37	3.07e-6	Obesity-related traits;
UCEC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.0	-0.38	1.58e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1545257	0.514	rs7581577	chr2:24638107	C/T	cg06627628	chr2:24431161	ITSN2	-0.54	-5.53	-0.41	1.42e-7	Sjögren's syndrome;
UCEC	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg08250081	chr4:10125330	NA	0.45	4.52	0.35	1.27e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg16558253	chr16:72132732	DHX38	-0.43	-5.02	-0.38	1.47e-6	Fibrinogen levels;
UCEC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.49	-6.51	-0.47	1.12e-9	Body mass index;
UCEC	cis	rs7870753	0.838	rs6477493	chr9:99253082	C/T	cg25260653	chr9:99212216	HABP4	0.53	5.3	0.4	4.18e-7	Height;
UCEC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg05989775	chr11:2906934	CDKN1C	0.67	6.72	0.48	3.75e-10	Schizophrenia;
UCEC	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.54	5.13	0.39	8.82e-7	Plateletcrit;Platelet count;
UCEC	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.56	-6.14	-0.45	7.32e-9	Menarche (age at onset);
UCEC	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.5	4.65	0.36	7.42e-6	Blood metabolite levels;
UCEC	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.68	-5.99	-0.44	1.53e-8	Adiposity;
UCEC	cis	rs9463078	0.547	rs720576	chr6:44729974	A/T	cg25276700	chr6:44698697	NA	0.43	4.84	0.37	3.2e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.6	5.62	0.42	9.48e-8	Vitiligo;
UCEC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	4.99	0.38	1.72e-6	Breast cancer;
UCEC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.43	-6.27	-0.46	3.84e-9	Rheumatoid arthritis;
UCEC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.67	6.41	0.47	1.86e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	0.79	6.81	0.49	2.31e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6838801	0.725	rs1493362	chr4:77606024	G/A	cg17476223	chr4:77663285	SHROOM3	0.48	4.59	0.35	9.24e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	5.48	0.41	1.82e-7	Breast cancer;
UCEC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.67	6.98	0.5	9.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.93	0.38	2.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.69	-7.54	-0.53	4.55e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.69	6.24	0.46	4.44e-9	Breast cancer;
UCEC	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.62	6.72	0.49	3.64e-10	Neuroticism;
UCEC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.14	13.95	0.75	1.06e-28	Cognitive function;
UCEC	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6832769	1.000	rs1522111	chr4:56329563	T/A	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.45	-5.52	-0.41	1.48e-7	Menarche (age at onset);
UCEC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	4.84	0.37	3.21e-6	Menarche (age at onset);
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.49	0.41	1.74e-7	Platelet count;
UCEC	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.58	6.11	0.45	8.3e-9	Blood protein levels;
UCEC	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.79	9.56	0.62	3.97e-17	Mean corpuscular volume;
UCEC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.43	-5.0	-0.38	1.62e-6	Lung cancer;
UCEC	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.59	0.42	1.08e-7	Rheumatoid arthritis;
UCEC	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.16	-0.39	7.94e-7	Personality dimensions;
UCEC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.49	-5.51	-0.41	1.57e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg01874867	chr7:94954059	PON1	-0.54	-5.0	-0.38	1.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.63	6.53	0.47	1e-9	Retinal vascular caliber;
UCEC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.78	6.49	0.47	1.21e-9	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-7.84	-0.54	8.64e-13	Cognitive function;
UCEC	cis	rs12365397	0.609	rs11037366	chr11:43244906	A/G	cg07515919	chr11:43391688	TTC17	-0.5	-5.84	-0.43	3.21e-8	Migraine;
UCEC	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.47	4.97	0.38	1.86e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.47	-4.66	-0.36	7.13e-6	Retinal vascular caliber;
UCEC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs34486957	0.600	rs36060680	chr14:60045651	T/C	cg12189551	chr14:60952945	C14orf39	0.36	4.52	0.35	1.27e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg11569703	chr11:65557185	OVOL1	0.43	5.09	0.39	1.06e-6	Acne (severe);
UCEC	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-0.43	-4.68	-0.36	6.51e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg18016565	chr1:150552671	MCL1	-0.65	-7.39	-0.52	1.04e-11	Tonsillectomy;
UCEC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.49	6.19	0.45	5.76e-9	Total body bone mineral density;
UCEC	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.45	-6.01	-0.44	1.38e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-4.99	-0.38	1.69e-6	Coronary artery disease;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg21486944	chr6:28411378	ZSCAN23	-0.45	-4.6	-0.35	9.03e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	1.04	11.97	0.7	1.81e-23	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs829661	0.947	rs829634	chr2:30735763	T/C	cg17749961	chr2:30669863	LCLAT1	0.52	4.93	0.38	2.18e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg27299712	chr1:6550532	PLEKHG5	0.53	4.71	0.36	5.66e-6	Body mass index;
UCEC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.8e-6	Body mass index;
UCEC	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03775416	chr19:19368775	HAPLN4	-0.49	-4.53	-0.35	1.23e-5	Tonsillectomy;
UCEC	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-7.54	-0.53	4.41e-12	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.92	-10.5	-0.65	1.38e-19	Breast cancer;
UCEC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.46	6.79	0.49	2.57e-10	Homoarginine levels;
UCEC	cis	rs78487399	0.908	rs6712944	chr2:43834118	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.69	-0.42	6.81e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs10242455	0.867	rs2687081	chr7:99300758	G/A	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	6.74e-7	Blood metabolite levels;
UCEC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.55	-7.06	-0.5	6.18e-11	Prudent dietary pattern;
UCEC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg13147721	chr7:65941812	NA	-0.93	-6.9	-0.49	1.42e-10	Diabetic kidney disease;
UCEC	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.73	7.56	0.53	4.07e-12	Eosinophil percentage of white cells;
UCEC	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.63	6.35	0.46	2.56e-9	Dupuytren's disease;
UCEC	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.06	0.39	1.21e-6	Height;
UCEC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-5.99	-0.44	1.53e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	9.28	0.61	2.02e-16	Mean platelet volume;
UCEC	cis	rs16937	0.711	rs12130817	chr1:205140305	C/T	cg12580275	chr1:205744413	RAB7L1	0.49	5.36	0.4	3.2e-7	Schizophrenia;
UCEC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.08	0.39	1.15e-6	Obesity-related traits;
UCEC	cis	rs7246967	0.608	rs2569728	chr19:23014004	C/T	cg05241461	chr19:22816980	ZNF492	0.45	4.55	0.35	1.12e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.56	5.08	0.39	1.1e-6	Lung cancer;
UCEC	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.75	0.43	4.9e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2806561	0.780	rs12751560	chr1:23407081	C/A	cg19743168	chr1:23544995	NA	-0.39	-4.83	-0.37	3.38e-6	Height;
UCEC	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.47	-5.86	-0.44	2.92e-8	Migraine;
UCEC	cis	rs3750082	0.889	rs6962267	chr7:32939774	G/A	cg05721444	chr7:32995514	FKBP9	0.56	6.2	0.46	5.31e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg04154034	chr17:28927549	LRRC37B2	0.56	4.51	0.35	1.33e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.53	6.42	0.47	1.76e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.21	-10.04	-0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg00546932	chr16:1947055	NA	-0.37	-5.07	-0.39	1.18e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.51	5.56	0.42	1.25e-7	Body mass index;
UCEC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.26	0.4	4.89e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg22974920	chr21:40686053	BRWD1	-0.46	-4.59	-0.35	9.6e-6	Menarche (age at onset);
UCEC	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.57	8.38	0.57	3.93e-14	Height;
UCEC	cis	rs4730268	0.950	rs2158837	chr7:107440451	C/T	cg18560240	chr7:107437656	SLC26A3	-0.77	-6.29	-0.46	3.48e-9	IgG glycosylation;
UCEC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg04155231	chr12:9217510	LOC144571	0.42	5.21	0.4	6.16e-7	Sjögren's syndrome;
UCEC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs3015497	0.789	rs3015496	chr14:51114051	T/C	cg04730355	chr14:51134070	SAV1	-0.55	-5.83	-0.43	3.35e-8	Mean platelet volume;
UCEC	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.94	-11.92	-0.7	2.34e-23	Coronary artery disease;
UCEC	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.89	0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs10924970	0.625	rs61836167	chr1:235465059	C/T	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	trans	rs4146922	0.793	rs7601401	chr2:56004592	A/G	cg03313676	chr20:62526047	DNAJC5	-0.71	-7.29	-0.52	1.75e-11	Height;
UCEC	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18252515	chr7:66147081	NA	0.59	5.49	0.41	1.71e-7	Aortic root size;
UCEC	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.85	-0.43	3.03e-8	Mortality in heart failure;
UCEC	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.63	5.32	0.4	3.8e-7	Migraine;
UCEC	cis	rs11083475	0.686	rs73040728	chr19:39257601	C/G	cg07905965	chr19:39260460	NA	0.39	4.51	0.35	1.32e-5	Heart rate;
UCEC	cis	rs4972806	0.814	rs966801	chr2:177037827	G/A	cg13092806	chr2:177043255	NA	0.55	5.17	0.39	7.5e-7	IgG glycosylation;
UCEC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.48	-4.81	-0.37	3.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.57	-5.26	-0.4	4.93e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.64	0.42	8.27e-8	Cognitive test performance;
UCEC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg18404041	chr3:52824283	ITIH1	-0.43	-4.53	-0.35	1.2e-5	Bipolar disorder;
UCEC	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.5	-5.97	-0.44	1.67e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.91	11.49	0.69	3.36e-22	Breast cancer;
UCEC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.33	-5.16	-0.39	7.8e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6670533	0.571	rs7540973	chr1:24864576	G/T	cg07475527	chr1:24864545	NA	-0.75	-5.46	-0.41	2.01e-7	Fasting blood insulin (BMI interaction);
UCEC	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg20825769	chr15:43991375	CKMT1A	0.55	4.51	0.35	1.29e-5	Lung cancer in ever smokers;
UCEC	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	6.08	0.45	9.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-4.87	-0.37	2.83e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.67	6.8	0.49	2.39e-10	Smoking behavior;
UCEC	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.42	-9.32	-0.61	1.58e-16	Diabetic kidney disease;
UCEC	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.76	-6.01	-0.44	1.39e-8	Calcium levels;
UCEC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18252515	chr7:66147081	NA	-0.51	-4.79	-0.37	3.95e-6	Aortic root size;
UCEC	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-4.86	-0.37	2.93e-6	Personality dimensions;
UCEC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06505273	chr16:24850292	NA	0.54	4.92	0.38	2.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.85	0.37	3.16e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.27	0.56	7.38e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.74	0.36	4.97e-6	Breast cancer;
UCEC	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-5.57	-0.42	1.18e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.59	6.5	0.47	1.17e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs12635074	0.521	rs73086405	chr3:56306062	T/A	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.34	4.61	0.36	8.76e-6	Morning vs. evening chronotype;
UCEC	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.48	-4.69	-0.36	6.24e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.39	0.71	1.34e-24	Prudent dietary pattern;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg02394263	chr16:12897821	CPPED1	-0.67	-4.79	-0.37	4e-6	Testicular germ cell tumor;
UCEC	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.56	-6.56	-0.48	8.41e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs12618769	0.625	rs78518453	chr2:99213899	T/C	cg10123293	chr2:99228465	UNC50	0.5	5.46	0.41	1.94e-7	Bipolar disorder;
UCEC	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.52	5.18	0.39	7.15e-7	Cleft lip with or without cleft palate;
UCEC	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	1.47	6.68	0.48	4.69e-10	Blood protein levels;
UCEC	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg05738196	chr6:26577821	NA	-0.63	-7.7	-0.54	1.83e-12	Intelligence (multi-trait analysis);
UCEC	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.06	0.5	6.01e-11	Morning vs. evening chronotype;
UCEC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.79	4.94	0.38	2.07e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs7204230	1.000	rs8053033	chr16:53322913	C/G	cg10109421	chr16:52641824	NA	0.41	4.58	0.35	9.88e-6	Fibrinogen;
UCEC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.36	-4.91	-0.38	2.37e-6	Primary biliary cholangitis;
UCEC	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg03714773	chr7:91764589	CYP51A1	-0.43	-5.16	-0.39	8.04e-7	Breast cancer;
UCEC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs295140	0.933	rs10931900	chr2:201177193	T/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.18	0.39	7.09e-7	QT interval;
UCEC	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-4.99	-0.38	1.7e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12826209	chr6:26865740	GUSBL1	0.5	4.78	0.37	4.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg00983440	chr10:79422392	NA	-1.17	-8.87	-0.59	2.24e-15	Bone mineral density;
UCEC	cis	rs8105895	0.935	rs7252220	chr19:22245564	G/A	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.06e-7	Body mass index (change over time);
UCEC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	7.09	0.5	5.18e-11	Bone mineral density;
UCEC	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.74	-6.94	-0.5	1.16e-10	Aortic root size;
UCEC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.47	-0.47	1.4e-9	Crohn's disease;
UCEC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	8.97	0.59	1.3e-15	Bipolar disorder;
UCEC	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.54	-6.73	-0.49	3.49e-10	Fibrinogen levels;
UCEC	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.69	-7.54	-0.53	4.55e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.69	-6.79	-0.49	2.56e-10	Blood metabolite levels;
UCEC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg25037677	chr1:2437047	NA	0.38	4.71	0.36	5.57e-6	Height;
UCEC	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg24163568	chr5:669837	TPPP	0.37	4.62	0.36	8.38e-6	Obesity-related traits;
UCEC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	0.99	9.35	0.61	1.35e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs7072216	0.881	rs7916469	chr10:100148653	T/C	cg19567339	chr10:100142640	NA	0.62	8.8	0.59	3.46e-15	Metabolite levels;
UCEC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.82	-0.49	2.26e-10	Prostate cancer;
UCEC	cis	rs740160	0.558	rs68164591	chr7:98904440	C/T	cg18809830	chr7:99032528	PTCD1	-0.58	-4.85	-0.37	3.17e-6	Dehydroepiandrosterone sulphate levels;
UCEC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.5	6.49	0.47	1.21e-9	Bone mineral density;
UCEC	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.45	4.74	0.36	5.07e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs16937	0.662	rs11588199	chr1:205164580	C/T	cg12580275	chr1:205744413	RAB7L1	0.52	5.51	0.41	1.59e-7	Schizophrenia;
UCEC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg20203395	chr5:56204925	C5orf35	-0.63	-4.76	-0.37	4.51e-6	Type 2 diabetes;
UCEC	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-7.96	-0.55	4.37e-13	Menarche (age at onset);
UCEC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.58	4.81	0.37	3.68e-6	Bladder cancer;
UCEC	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.58	5.34	0.4	3.46e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.51	5.18	0.39	7.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg14008862	chr17:28927542	LRRC37B2	0.75	5.08	0.39	1.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg00631329	chr6:26305371	NA	-0.45	-5.23	-0.4	5.83e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs7709377	0.521	rs2416426	chr5:115437470	T/C	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg02158880	chr13:53174818	NA	0.42	4.67	0.36	6.7e-6	Lewy body disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02209504	chr10:64576388	EGR2	0.59	7.33	0.52	1.42e-11	Warfarin maintenance dose;
UCEC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.17	-0.39	7.6e-7	Aortic root size;
UCEC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.72	5.53	0.41	1.43e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.71	6.86	0.49	1.75e-10	Longevity;
UCEC	cis	rs2180233	0.683	rs6659140	chr1:30676063	T/G	cg00108524	chr1:30559124	NA	-0.52	-4.96	-0.38	1.92e-6	Attention deficit hyperactivity disorder and conduct disorder;
UCEC	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.5	5.58	0.42	1.13e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg19041857	chr6:27730383	NA	-0.64	-5.05	-0.38	1.3e-6	Lung cancer in ever smokers;
UCEC	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.84	9.45	0.61	7.48e-17	Metabolite levels;
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	6.02	0.44	1.33e-8	Platelet count;
UCEC	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.47	-5.3	-0.4	4.2e-7	Retinal vascular caliber;
UCEC	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg10932868	chr11:921992	NA	0.43	5.55	0.42	1.28e-7	Alzheimer's disease (late onset);
UCEC	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.05	-0.45	1.13e-8	Mean platelet volume;
UCEC	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.21	-0.51	2.71e-11	Multiple sclerosis;
UCEC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	6.18	0.45	5.88e-9	Prudent dietary pattern;
UCEC	cis	rs7225537	0.559	rs7214429	chr17:17059872	A/G	cg26176665	chr17:16994978	MPRIP	-0.54	-6.41	-0.47	1.87e-9	Mean platelet volume;
UCEC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.82e-15	Blood protein levels;
UCEC	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.01	0.5	8.22e-11	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.89	-0.37	2.58e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg11150807	chr10:43354902	NA	0.79	5.21	0.39	6.41e-7	Blood protein levels;
UCEC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.68	-6.8	-0.49	2.39e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	0.86	5.21	0.39	6.41e-7	Arsenic metabolism;
UCEC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.8	8.09	0.56	1.99e-13	Breast cancer;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.18	-0.45	6.06e-9	Depression;
UCEC	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.88	11.34	0.68	8.17e-22	Metabolic syndrome;
UCEC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.49	-6.74	-0.49	3.28e-10	Obesity-related traits;
UCEC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg02580895	chr19:2754563	NA	-0.51	-4.83	-0.37	3.42e-6	Total cholesterol levels;
UCEC	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	1.02	10.4	0.65	2.46e-19	Post bronchodilator FEV1;
UCEC	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	0.95	7.12	0.51	4.36e-11	Obesity-related traits;
UCEC	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.34	-4.84	-0.37	3.22e-6	Height;
UCEC	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.39	0.41	2.77e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.46	5.22	0.4	5.96e-7	White matter hyperintensity burden;
UCEC	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-8.96	-0.59	1.36e-15	Morning vs. evening chronotype;
UCEC	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg00105475	chr2:10696890	NA	-0.47	-5.69	-0.42	6.78e-8	Prostate cancer;
UCEC	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.52	-6.27	-0.46	3.88e-9	Fibrinogen levels;
UCEC	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-0.94	-5.91	-0.44	2.33e-8	Mitochondrial DNA levels;
UCEC	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.55e-22	Cognitive function;
UCEC	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.61	5.96	0.44	1.81e-8	Plateletcrit;Platelet count;
UCEC	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.53	6.48	0.47	1.32e-9	Total body bone mineral density;
UCEC	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs12216499	1.000	rs4709258	chr6:159412010	T/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.67	-4.63	-0.36	7.82e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.4	0.41	2.56e-7	Rheumatoid arthritis;
UCEC	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg26203845	chr14:105293866	NA	0.44	4.52	0.35	1.24e-5	IgG glycosylation;
UCEC	cis	rs12681287	0.752	rs6985427	chr8:87302745	C/T	cg27223183	chr8:87520930	FAM82B	-0.69	-5.69	-0.42	6.78e-8	Caudate activity during reward;
UCEC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-5.99	-0.44	1.54e-8	Menarche (age at onset);
UCEC	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-7.81	-0.54	1.01e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg18478394	chr8:109455254	TTC35	0.5	5.02	0.38	1.49e-6	Dupuytren's disease;
UCEC	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg22901726	chr8:27089804	NA	-0.36	-4.53	-0.35	1.19e-5	Neuroticism;
UCEC	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.92	-0.38	2.33e-6	Type 2 diabetes;
UCEC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-6.08	-0.45	9.73e-9	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.61	-0.36	8.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.52	4.68	0.36	6.44e-6	Coronary artery disease;
UCEC	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.51	5.44	0.41	2.19e-7	Schizophrenia;
UCEC	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg24375607	chr4:120327624	NA	0.47	4.84	0.37	3.29e-6	Corneal astigmatism;
UCEC	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs12900413	0.687	rs7176948	chr15:90315707	A/T	cg03539051	chr19:56418660	NLRP13	1.08	6.81	0.49	2.29e-10	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9470794	1.000	rs55786703	chr6:37973035	G/A	cg03458162	chr6:37400668	FTSJD2	0.86	5.07	0.39	1.17e-6	Type 2 diabetes;
UCEC	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs2425143	0.908	rs6060625	chr20:34414318	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-4.6	-0.35	8.97e-6	Blood protein levels;
UCEC	cis	rs4372836	0.929	rs11675572	chr2:28931376	G/T	cg09522027	chr2:28974177	PPP1CB	0.73	7.34	0.52	1.35e-11	Body mass index;
UCEC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	6.36	0.46	2.42e-9	Platelet count;
UCEC	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16164276	chr3:11034345	SLC6A1	-0.51	-4.63	-0.36	7.98e-6	Alzheimer's disease;
UCEC	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg05991184	chr2:219186017	PNKD	-0.44	-4.56	-0.35	1.08e-5	High light scatter reticulocyte percentage of red cells;Plateletcrit;
UCEC	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.09	8.74	0.58	4.8e-15	Uric acid levels;
UCEC	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.26e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg16032841	chr13:111522222	C13orf29	-0.6	-6.07	-0.45	1.03e-8	Sitting height ratio;
UCEC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-10.78	-0.66	2.45e-20	Primary sclerosing cholangitis;
UCEC	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.65	7.34	0.52	1.37e-11	Body mass index;
UCEC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.07	-15.87	-0.79	1.16e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.79	-8.31	-0.57	5.81e-14	Cognitive function;
UCEC	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.62	5.55	0.42	1.29e-7	Corneal astigmatism;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.09	0.39	1.06e-6	Bipolar disorder;
UCEC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.09	0.39	1.08e-6	Obesity-related traits;
UCEC	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.34	4.88	0.37	2.7e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs11760485	0.928	rs5021674	chr7:4399614	C/T	cg22450045	chr7:4839495	RADIL	-0.41	-4.79	-0.37	3.98e-6	Early childhood aggressive behavior;
UCEC	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.57	-6.58	-0.48	7.85e-10	Sum eosinophil basophil counts;
UCEC	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.81	-8.33	-0.57	5.25e-14	Resting heart rate;
UCEC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.48	-5.69	-0.42	6.73e-8	Bipolar disorder;
UCEC	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.42	4.56	0.35	1.06e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08822215	chr16:89438651	ANKRD11	-0.51	-4.94	-0.38	2.13e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.6	-4.75	-0.36	4.73e-6	Exhaled nitric oxide output;
UCEC	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.69	4.81	0.37	3.73e-6	Aortic root size;
UCEC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.84	0.37	3.3e-6	Breast cancer;
UCEC	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.39	4.85	0.37	3.14e-6	Alcohol dependence;
UCEC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.48	-4.94	-0.38	2.13e-6	Aortic root size;
UCEC	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.41	6.03	0.45	1.28e-8	Electrocardiographic conduction measures;
UCEC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs4372836	0.729	rs6547882	chr2:29037001	T/C	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.77	-0.54	1.27e-12	Body mass index;
UCEC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.55	-4.91	-0.38	2.4e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	6.83	0.49	2.05e-10	Platelet count;
UCEC	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.52	-5.81	-0.43	3.73e-8	Aortic root size;
UCEC	cis	rs73206853	0.764	rs3026447	chr12:110724272	C/T	cg12870014	chr12:110450643	ANKRD13A	0.55	4.79	0.37	4.1e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg08461772	chr7:95026248	PON3	0.36	5.03	0.38	1.39e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.61	-6.66	-0.48	5.19e-10	Heart rate;
UCEC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.25	0.4	5.29e-7	Cognitive test performance;
UCEC	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.73	-7.16	-0.51	3.52e-11	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.58	6.05	0.45	1.17e-8	Vitiligo;
UCEC	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg23795048	chr12:9217529	LOC144571	0.42	4.86	0.37	2.92e-6	Sjögren's syndrome;
UCEC	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.83	0.37	3.42e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.54	6.77	0.49	2.86e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg00612595	chr21:47717864	NA	-0.43	-4.65	-0.36	7.22e-6	Testicular germ cell tumor;
UCEC	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg06027949	chr8:82754900	SNX16	0.61	5.6	0.42	1.03e-7	Diastolic blood pressure;
UCEC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.44	-0.47	1.62e-9	Aortic root size;
UCEC	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.53	-4.85	-0.37	3.13e-6	Pancreatic cancer;
UCEC	cis	rs7267005	0.661	rs60828070	chr20:34431747	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.24	-7.51	-0.53	5.14e-12	Diabetic kidney disease;
UCEC	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg20936604	chr3:58311152	NA	-0.58	-4.88	-0.37	2.74e-6	Cholesterol, total;
UCEC	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.57	-6.2	-0.46	5.32e-9	Lung cancer;
UCEC	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.56	6.14e-14	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg21237687	chr17:6899380	ALOX12	0.45	5.38	0.41	2.84e-7	Tonsillectomy;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg19041857	chr6:27730383	NA	-0.44	-4.53	-0.35	1.21e-5	Depression;
UCEC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.57	-4.63	-0.36	7.88e-6	Initial pursuit acceleration;
UCEC	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-4.57	-0.35	1.02e-5	Response to antipsychotic treatment;
UCEC	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.33	4.86	0.37	2.94e-6	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.52	0.35	1.28e-5	Menopause (age at onset);
UCEC	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	4.89	0.37	2.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7246967	0.611	rs12984903	chr19:22833881	A/G	cg08271804	chr19:22816896	ZNF492	0.63	6.25	0.46	4.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.93	0.44	2.07e-8	Breast cancer;
UCEC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26002218	chr14:103986227	CKB	0.35	5.03	0.38	1.41e-6	Body mass index;
UCEC	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.41	-0.41	2.49e-7	Resting heart rate;
UCEC	cis	rs151997	0.962	rs27936	chr5:50181418	T/A	cg06027927	chr5:50259733	NA	0.54	4.98	0.38	1.79e-6	Callous-unemotional behaviour;
UCEC	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.81	8.06	0.55	2.42e-13	Smoking behavior;
UCEC	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.61	-5.38	-0.41	2.92e-7	Colorectal cancer;
UCEC	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.81	9.05	0.6	7.87e-16	Metabolite levels;
UCEC	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.52	-4.77	-0.37	4.46e-6	Obesity-related traits;
UCEC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-0.52	-5.09	-0.39	1.08e-6	Blood trace element (Zn levels);
UCEC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg24531977	chr5:56204891	C5orf35	-0.6	-5.72	-0.43	5.8e-8	Coronary artery disease;
UCEC	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg05991184	chr2:219186017	PNKD	0.53	5.89	0.44	2.55e-8	Colorectal cancer;
UCEC	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.62	-6.63	-0.48	6.01e-10	Crohn's disease;
UCEC	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	0.73	9.93	0.63	4.11e-18	Gut microbiome composition (winter);
UCEC	cis	rs282258	0.874	rs4674860	chr2:224921814	C/T	cg00491335	chr2:224705654	NA	0.39	4.54	0.35	1.18e-5	Interleukin-10 levels;Interleukin-12p70 levels;
UCEC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.52	-5.65	-0.42	8.21e-8	Menarche (age at onset);
UCEC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.56	5.08	0.39	1.11e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.86	-8.51	-0.57	1.89e-14	Parkinson's disease;
UCEC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg03609598	chr5:56110824	MAP3K1	-0.62	-5.05	-0.38	1.3e-6	Type 2 diabetes;
UCEC	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.75	9.57	0.62	3.72e-17	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6893807	0.623	rs112862634	chr5:87970352	G/C	cg09002922	chr5:87956389	LOC645323	-0.59	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.68	-6.14	-0.45	7.4e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs1113932	0.901	rs73984914	chr2:193058675	T/C	cg12404831	chr2:192114017	MYO1B	-0.68	-4.53	-0.35	1.21e-5	Hemoglobin A2 levels in sickle cell anemia;
UCEC	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.95	-7.72	-0.54	1.64e-12	Blood protein levels;
UCEC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg12428399	chr10:135191333	PAOX	0.66	5.51	0.41	1.54e-7	Lifespan;
UCEC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-5.41	-0.41	2.56e-7	Aortic root size;
UCEC	cis	rs892864	0.803	rs80302694	chr5:127838445	G/T	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Multiple system atrophy;
UCEC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.48	-4.82	-0.37	3.52e-6	Blood metabolite levels;
UCEC	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.57	-5.67	-0.42	7.45e-8	White matter hyperintensity burden;
UCEC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	7.76	0.54	1.32e-12	Menopause (age at onset);
UCEC	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.91	9.92	0.63	4.58e-18	Post bronchodilator FEV1;
UCEC	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.3e-9	Coffee consumption (cups per day);
UCEC	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.35	10.1	0.64	1.53e-18	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.59	-0.35	9.63e-6	Total body bone mineral density;
UCEC	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg12923728	chr3:195709715	SDHAP1	-0.61	-5.67	-0.42	7.19e-8	Mean corpuscular volume;
UCEC	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg20485758	chr6:26088446	HFE	0.71	4.61	0.36	8.64e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.22	-0.4	5.89e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.64	6.53	0.47	1.02e-9	Blood metabolite levels;
UCEC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.76e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6746896	0.639	rs1318597	chr2:97463095	T/C	cg01950434	chr2:97203154	ARID5A	-0.44	-4.78	-0.37	4.24e-6	Bipolar disorder;
UCEC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.64	5.91	0.44	2.31e-8	Corneal astigmatism;
UCEC	cis	rs17106184	1.000	rs12095997	chr1:51391845	C/T	cg07174182	chr1:51127561	FAF1	-0.61	-4.79	-0.37	4.02e-6	Type 2 diabetes;
UCEC	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.6	-4.96	-0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-4.56	-0.35	1.06e-5	Gut microbiome composition (summer);
UCEC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.83e-6	Tonsillectomy;
UCEC	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.52	5.01	0.38	1.55e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.45	6.73	0.49	3.56e-10	Blood protein levels;
UCEC	cis	rs35934224	0.783	rs16984299	chr22:19863593	C/T	cg11182965	chr22:19864308	TXNRD2	0.35	4.62	0.36	8.19e-6	Glaucoma (primary open-angle);
UCEC	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.53	5.15	0.39	8.1e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.44	-4.93	-0.38	2.19e-6	Migraine;
UCEC	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-4.82	-0.37	3.6e-6	Mitochondrial DNA levels;
UCEC	trans	rs4389974	0.932	rs4876603	chr8:112391681	T/C	cg22736090	chr17:62339926	TEX2	0.66	6.83	0.49	2.04e-10	Body mass index;
UCEC	cis	rs4851266	1.000	rs11695383	chr2:100826098	G/T	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.35	-4.53	-0.35	1.22e-5	Refractive error;
UCEC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.9	-0.44	2.45e-8	Menarche (age at onset);
UCEC	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.64	5.55	0.42	1.32e-7	Menopause (age at onset);
UCEC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg22166914	chr1:53195759	ZYG11B	0.78	8.12	0.56	1.73e-13	Monocyte count;
UCEC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.7	-6.5	-0.47	1.14e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.67	-7.56	-0.53	4.09e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.54	-6.18	-0.45	5.89e-9	Crohn's disease;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.36	-4.53	-0.35	1.23e-5	Coronary artery disease;
UCEC	cis	rs9302690	0.744	rs62037113	chr16:57451388	A/T	cg27017172	chr16:57497170	POLR2C	1.24	6.14	0.45	7.42e-9	Blood protein levels;
UCEC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.79	8.08	0.55	2.15e-13	Caffeine consumption;
UCEC	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.57	5.55	0.42	1.31e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg23950597	chr19:37808831	NA	-0.87	-5.82	-0.43	3.55e-8	Coronary artery calcification;
UCEC	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.77	-8.42	-0.57	3.13e-14	Ulcerative colitis;
UCEC	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.99	8.11	0.56	1.86e-13	Platelet distribution width;
UCEC	cis	rs17123764	0.818	rs17123808	chr12:49979413	C/T	cg20471783	chr12:50157085	TMBIM6	0.61	5.29	0.4	4.36e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.27e-6	Breast cancer;
UCEC	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-4.65	-0.36	7.23e-6	Pediatric autoimmune diseases;
UCEC	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	0.96	10.43	0.65	2.12e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg04607235	chr12:12878440	APOLD1	-0.98	-9.9	-0.63	5.09e-18	Lymphocyte counts;
UCEC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-10.58	-0.66	8.51e-20	Chronic sinus infection;
UCEC	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.19	0.45	5.7e-9	Breast cancer;
UCEC	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	0.84	10.14	0.64	1.23e-18	Bone mineral density;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07869135	chr8:123794843	ZHX2	0.6	7.42	0.52	8.84e-12	Warfarin maintenance dose;
UCEC	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.52	-5.21	-0.39	6.28e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg23855989	chr12:50355821	AQP5	0.73	5.34	0.4	3.47e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs58502974	0.673	rs3816620	chr5:7790217	C/A	cg12187999	chr5:6845652	NA	0.37	4.51	0.35	1.3e-5	Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder;Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7224668	0.647	rs8070092	chr17:79246818	A/C	cg15215033	chr17:79258732	SLC38A10	0.33	4.82	0.37	3.62e-6	IgG glycosylation;
UCEC	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	6.92	0.5	1.26e-10	Platelet distribution width;
UCEC	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	0.79	10.63	0.66	6.05e-20	Multiple myeloma;
UCEC	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.55	4.65	0.36	7.43e-6	Dental caries;
UCEC	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	4.67	0.36	6.73e-6	Educational attainment;
UCEC	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg16797656	chr11:68205561	LRP5	-0.5	-5.69	-0.42	6.8e-8	Total body bone mineral density;
UCEC	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.51	6.19	0.45	5.69e-9	Total body bone mineral density;
UCEC	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.72	7.33	0.52	1.44e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg06550200	chr5:1325588	CLPTM1L	-0.69	-7.33	-0.52	1.46e-11	Lung cancer;
UCEC	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-13.22	-0.74	8.95e-27	Schizophrenia;
UCEC	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.45	4.85	0.37	3.13e-6	Smoking initiation;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03404566	chr17:6899310	ALOX12	-0.45	-5.05	-0.38	1.29e-6	Tonsillectomy;
UCEC	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.31	-10.43	-0.65	2.05e-19	Hip circumference adjusted for BMI;
UCEC	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.56	-5.13	-0.39	9e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.2	-0.51	2.92e-11	Heart rate;
UCEC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.84	0.59	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg20965017	chr5:231967	SDHA	-0.67	-5.89	-0.44	2.56e-8	Breast cancer;
UCEC	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg19318889	chr4:1322082	MAEA	0.48	5.36	0.4	3.1e-7	Obesity-related traits;
UCEC	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.52	4.62	0.36	8.23e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	9.12	0.6	5.36e-16	Platelet count;
UCEC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.4	-4.58	-0.35	9.99e-6	Emphysema distribution in smoking;
UCEC	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg04155231	chr12:9217510	LOC144571	0.42	5.01	0.38	1.51e-6	Sjögren's syndrome;
UCEC	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.55	5.36	0.4	3.1e-7	Platelet distribution width;
UCEC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg03859395	chr2:55845619	SMEK2	-0.78	-7.81	-0.54	9.84e-13	Metabolic syndrome;
UCEC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.28	-0.46	3.69e-9	Pulmonary function;
UCEC	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.4	5.02	0.38	1.44e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.7	7.3	0.52	1.68e-11	Caffeine consumption;
UCEC	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs4448343	1.000	rs16909919	chr9:98265780	A/G	cg13456470	chr9:98266766	PTCH1	-0.34	-4.75	-0.36	4.79e-6	Height;
UCEC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	5.73	0.43	5.59e-8	Neuroticism;
UCEC	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.27	-10.66	-0.66	5.24e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.81	0.49	2.34e-10	Motion sickness;
UCEC	cis	rs7246967	0.673	rs16994997	chr19:22879610	T/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs728616	0.510	rs34817075	chr10:81749740	A/G	cg05935833	chr10:81318306	SFTPA2	-0.37	-4.55	-0.35	1.1e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	7.35	0.52	1.3e-11	Platelet count;
UCEC	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.71	6.45	0.47	1.48e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	0.72	5.86	0.44	2.88e-8	Post bronchodilator FEV1;
UCEC	cis	rs2029213	0.523	rs3773745	chr3:53270424	A/G	cg16894138	chr3:53270350	TKT	-0.43	-5.42	-0.41	2.4e-7	Heart rate;
UCEC	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.2	-0.46	5.36e-9	Bipolar disorder;
UCEC	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg17515076	chr17:73810948	UNK	-0.49	-5.48	-0.41	1.82e-7	White matter hyperintensity burden;
UCEC	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.77	8.35	0.57	4.52e-14	Mean corpuscular hemoglobin;
UCEC	cis	rs8177876	0.818	rs59177227	chr16:81115129	G/T	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.61	-6.23	-0.46	4.69e-9	Obesity-related traits;
UCEC	cis	rs7597155	1.000	rs6727897	chr2:69987384	A/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-4.91	-0.38	2.44e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.46	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg04043695	chr12:129287642	SLC15A4	0.63	6.41	0.47	1.84e-9	Systemic lupus erythematosus;
UCEC	cis	rs1008375	0.897	rs4334752	chr4:17615430	C/T	cg18681998	chr4:17616180	MED28	0.71	8.01	0.55	3.23e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.65	4.63	0.36	7.96e-6	Cerebrospinal P-tau181p levels;
UCEC	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.09	17.58	0.82	5.91e-38	IgG glycosylation;
UCEC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.81	0.43	3.68e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.72	-5.6	-0.42	1.05e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.91	11.62	0.69	1.5e-22	Breast cancer;
UCEC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.86	-10.93	-0.67	1.03e-20	Height;
UCEC	cis	rs17718580	0.826	rs72679533	chr14:50996692	G/T	cg04730355	chr14:51134070	SAV1	1.09	5.14	0.39	8.56e-7	Cognitive performance;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg13525197	chr6:28411240	ZSCAN23	0.42	4.78	0.37	4.24e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.44	-4.82	-0.37	3.57e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.62	-0.42	9.51e-8	Urate levels in overweight individuals;
UCEC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg23307798	chr14:103986281	CKB	0.64	7.64	0.53	2.54e-12	Body mass index;
UCEC	cis	rs883565	0.569	rs1274969	chr3:39169712	T/C	cg01426195	chr3:39028469	NA	0.6	6.91	0.49	1.4e-10	Handedness;
UCEC	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.67	6.31	0.46	3.16e-9	Smoking behavior;
UCEC	cis	rs76419734	0.850	rs7660534	chr4:106796047	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.56	4.6	0.35	9.04e-6	Post bronchodilator FEV1;
UCEC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg06462663	chr19:18546047	ISYNA1	0.51	6.45	0.47	1.52e-9	Breast cancer;
UCEC	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.66	7.22	0.51	2.54e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	1.000	rs12980225	chr19:23026745	G/C	cg05241461	chr19:22816980	ZNF492	0.48	5.12	0.39	9.3e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.67	-7.42	-0.52	8.81e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.08	0.39	1.14e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	10.53	0.66	1.16e-19	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg05639522	chr1:247681581	NA	-0.37	-5.03	-0.38	1.44e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.68	6.16	0.45	6.78e-9	Parkinson's disease;
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	5.47	0.41	1.9e-7	Total cholesterol levels;
UCEC	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.58	5.45	0.41	2.05e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs250585	0.736	rs540719	chr16:23456578	T/C	cg26562691	chr16:23850404	PRKCB	0.35	4.61	0.36	8.8e-6	Egg allergy;
UCEC	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.7	7.12	0.51	4.47e-11	Menopause (age at onset);
UCEC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.75	0.36	4.82e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.7	5.9	0.44	2.43e-8	Menopause (age at onset);
UCEC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.36	0.46	2.35e-9	Cognitive test performance;
UCEC	cis	rs282587	0.627	rs388242	chr13:113415188	T/C	cg23551120	chr13:113375848	ATP11A	-0.36	-4.55	-0.35	1.1e-5	Glycated hemoglobin levels;
UCEC	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.54	5.1	0.39	1.05e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.64	-4.68	-0.36	6.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg24562669	chr7:97807699	LMTK2	0.5	6.06	0.45	1.11e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.72	-7.81	-0.54	1.02e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg10820045	chr2:198174542	NA	-0.46	-5.63	-0.42	8.68e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.74	8.02	0.55	3.05e-13	Immature fraction of reticulocytes;
UCEC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	5.27	0.4	4.7e-7	Monocyte percentage of white cells;
UCEC	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg02900749	chr2:68251473	NA	-0.79	-6.67	-0.48	4.85e-10	Pursuit maintenance gain;
UCEC	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-4.69	-0.36	6.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.07	-0.45	1.04e-8	Parkinson's disease;
UCEC	cis	rs3762637	0.943	rs9289199	chr3:122277172	G/A	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.95	-6.76	-0.49	3.03e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.42	4.86	0.37	2.96e-6	Height;
UCEC	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.78	5.77	0.43	4.53e-8	Exhaled nitric oxide output;
UCEC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs4074536	0.740	rs6659025	chr1:116301019	A/G	cg21648376	chr1:116311395	CASQ2	-0.53	-5.41	-0.41	2.46e-7	QRS duration;
UCEC	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.49	5.19	0.39	6.93e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.09	0.39	1.09e-6	Personality dimensions;
UCEC	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-0.98	-7.46	-0.52	7.14e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.33	-0.46	2.76e-9	Aortic root size;
UCEC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-1.0	-12.1	-0.71	7.91e-24	Cognitive function;
UCEC	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.18	6.29	0.46	3.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4509693	0.943	rs6584393	chr10:102497206	C/G	cg24127310	chr10:102502104	NA	1.11	10.95	0.67	8.7e-21	Alzheimer's disease;
UCEC	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.51	-5.06	-0.39	1.22e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.61	5.59	0.42	1.1e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.58	5.73	0.43	5.42e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.45	4.83	0.37	3.37e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	7.92	0.55	5.22e-13	Platelet count;
UCEC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.49	5.35	0.4	3.3e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.71	8.16	0.56	1.39e-13	Body mass index;
UCEC	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.53	-5.91	-0.44	2.28e-8	Menarche (age at onset);
UCEC	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.65	6.26	0.46	4.07e-9	Height;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.46	-0.47	1.47e-9	Pubertal anthropometrics;
UCEC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.75	8.24	0.56	8.54e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	7.27	0.51	2.02e-11	Eye color traits;
UCEC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.91	8.31	0.57	5.68e-14	Bladder cancer;
UCEC	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg13683864	chr3:40499215	RPL14	-0.93	-9.27	-0.61	2.21e-16	Renal cell carcinoma;
UCEC	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg20560298	chr2:73613845	ALMS1	-0.61	-5.37	-0.4	3.05e-7	Metabolite levels;
UCEC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.68	6.35	0.46	2.56e-9	Menarche (age at onset);
UCEC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.51	-0.35	1.31e-5	Alzheimer's disease (late onset);
UCEC	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.71e-16	Cannabis dependence symptom count;
UCEC	cis	rs7246967	0.551	rs34897132	chr19:22826891	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg01262667	chr19:19385393	TM6SF2	-0.39	-4.53	-0.35	1.22e-5	Bipolar disorder;
UCEC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	1.0	11.02	0.67	5.67e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2377585	0.851	rs11046759	chr12:8836472	T/C	cg03761649	chr12:8850719	RIMKLB	0.6	4.73	0.36	5.32e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.58	-4.94	-0.38	2.09e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.4	5.16	0.39	7.97e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.96	11.89	0.7	2.95e-23	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.75	7.25	0.51	2.14e-11	Menopause (age at onset);
UCEC	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.09	0.56	2.01e-13	Mean corpuscular hemoglobin;
UCEC	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg21053147	chr12:120880522	NA	0.59	4.69	0.36	6.09e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.81	-0.43	3.74e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.56	-6.44	-0.47	1.56e-9	Crohn's disease;
UCEC	cis	rs9469578	1.000	rs9469581	chr6:33715904	C/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.97	0.38	1.87e-6	Platelet count;
UCEC	cis	rs4774830	0.661	rs62045239	chr15:56294642	G/A	cg24530489	chr15:56299380	NA	-0.67	-4.72	-0.36	5.4e-6	Delta-5 desaturase activity;
UCEC	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	0.94	9.99	0.64	3.01e-18	Breast cancer;
UCEC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.67	4.66	0.36	6.9e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2041895	0.509	rs1838445	chr12:107314585	T/A	cg13944111	chr12:107296891	NA	0.33	4.6	0.35	9.15e-6	Glaucoma (low intraocular pressure);
UCEC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg01072550	chr1:21505969	NA	-0.55	-5.06	-0.39	1.22e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.75	7.76	0.54	1.29e-12	Personality dimensions;
UCEC	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.8	-7.62	-0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.8	-7.77	-0.54	1.26e-12	Multiple sclerosis;
UCEC	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	0.93	5.5	0.41	1.64e-7	Gut microbiota (bacterial taxa);
UCEC	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4372836	1.000	rs4640348	chr2:28965479	T/C	cg09522027	chr2:28974177	PPP1CB	-0.78	-7.93	-0.55	5.13e-13	Body mass index;
UCEC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg09491104	chr22:46646882	C22orf40	-0.68	-7.77	-0.54	1.26e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.74	-7.08	-0.5	5.53e-11	Prudent dietary pattern;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.55	-6.15	-0.45	6.92e-9	Pulmonary function;
UCEC	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	0.87	5.66	0.42	7.7e-8	Arsenic metabolism;
UCEC	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg10596483	chr8:143751796	JRK	-0.51	-4.51	-0.35	1.34e-5	Urinary tract infection frequency;
UCEC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.9	-10.07	-0.64	1.84e-18	Cognitive function;
UCEC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.44	4.73	0.36	5.14e-6	Longevity;Endometriosis;
UCEC	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.59	5.37	0.41	2.95e-7	Corneal astigmatism;
UCEC	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.51	4.93	0.38	2.15e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs12980942	0.872	rs7258749	chr19:41806647	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.65	6.03	0.45	1.26e-8	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg03714773	chr7:91764589	CYP51A1	0.43	5.19	0.39	6.77e-7	Breast cancer;
UCEC	cis	rs8105895	0.935	rs7252380	chr19:22245715	G/A	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.64e-7	Body mass index (change over time);
UCEC	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.67	-7.43	-0.52	8.29e-12	Ulcerative colitis;
UCEC	cis	rs11723261	0.582	rs116471062	chr4:163522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	5.0	0.38	1.64e-6	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs78487399	0.808	rs12104615	chr2:43676938	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg03146154	chr1:46216737	IPP	-0.48	-5.09	-0.39	1.09e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.6	-4.64	-0.36	7.52e-6	Gut microbiome composition (summer);
UCEC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.64	-6.0	-0.44	1.43e-8	Aortic root size;
UCEC	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.56	-0.53	4.01e-12	Total cholesterol levels;
UCEC	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-6.63	-0.48	5.86e-10	Personality dimensions;
UCEC	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg05072774	chr3:49840536	C3orf54	-0.54	-5.56	-0.42	1.25e-7	Resting heart rate;
UCEC	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.62	-6.06	-0.45	1.1e-8	Coronary artery disease;
UCEC	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.67	9.28	0.61	2.09e-16	Alcoholic chronic pancreatitis;
UCEC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.39	0.41	2.75e-7	Breast cancer;
UCEC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.61	-4.55	-0.35	1.09e-5	Diabetic retinopathy;
UCEC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.67	-4.7	-0.36	5.92e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg21770322	chr7:97807741	LMTK2	0.52	6.46	0.47	1.45e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.53	7.52	0.53	5.02e-12	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.7	8.17	0.56	1.32e-13	Menarche (age at onset);
UCEC	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.66	-6.77	-0.49	2.82e-10	Itch intensity from mosquito bite;
UCEC	cis	rs13401104	0.796	rs61160252	chr2:237119074	A/G	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs1043099	0.912	rs929454	chr22:30692353	A/T	cg23383138	chr22:30885012	SEC14L4	0.51	4.62	0.36	8.34e-6	Rheumatoid arthritis;
UCEC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.13	6.52	0.47	1.04e-9	Diabetic kidney disease;
UCEC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg00677455	chr12:58241039	CTDSP2	0.57	5.6	0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14019695	chr9:139328340	INPP5E	0.51	6.34	0.46	2.61e-9	Monocyte percentage of white cells;
UCEC	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.63	-5.59	-0.42	1.05e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.73	-0.43	5.55e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.39	5.19	0.39	6.77e-7	Obesity-related traits;
UCEC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22455342	chr2:225449267	CUL3	0.54	5.6	0.42	1e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.52	5.9	0.44	2.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs11850957	0.563	rs11849193	chr14:25538999	A/G	cg11775837	chr14:25519611	STXBP6	0.53	4.57	0.35	1.03e-5	Subcutaneous adipose tissue;
UCEC	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.52	5.78	0.43	4.23e-8	Tonsillectomy;
UCEC	trans	rs273573	0.925	rs273593	chr11:30878012	T/C	cg20973129	chr6:33548009	BAK1	0.66	6.88	0.49	1.57e-10	Total body bone mineral density;
UCEC	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg03342759	chr3:160939853	NMD3	0.52	4.72	0.36	5.54e-6	Morning vs. evening chronotype;
UCEC	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	0.94	5.11	0.39	1e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.61	6.2	0.46	5.3e-9	Homoarginine levels;
UCEC	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.44	-4.58	-0.35	1e-5	Depression;
UCEC	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.38	0.52	1.06e-11	Alzheimer's disease;
UCEC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg26114124	chr12:9217669	LOC144571	-0.41	-5.08	-0.39	1.12e-6	Sjögren's syndrome;
UCEC	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.62	6.81	0.49	2.29e-10	Melanoma;
UCEC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.75	6.91	0.5	1.36e-10	Bladder cancer;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.68	-0.42	6.93e-8	Longevity;Endometriosis;
UCEC	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.65	6.8	0.49	2.39e-10	Coronary artery disease;
UCEC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.47	-6.11	-0.45	8.48e-9	Body mass index;
UCEC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.69	6.64	0.48	5.6e-10	Smoking behavior;
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg21856205	chr7:94953877	PON1	-0.55	-5.16	-0.39	7.96e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.6	-5.99	-0.44	1.53e-8	Red cell distribution width;
UCEC	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.63	5.01	0.38	1.51e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.67	5.62	0.42	9.35e-8	Breast cancer;
UCEC	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-8.66	-0.58	7.69e-15	Total cholesterol levels;
UCEC	cis	rs7088591	0.867	rs35378101	chr10:59778100	G/T	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.77	-0.37	4.32e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.58	5.41	0.41	2.55e-7	Schizophrenia;
UCEC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	1.03	15.24	0.78	4.68e-32	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.58	-0.35	9.9e-6	Menarche (age at onset);
UCEC	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	14.7	0.77	1.19e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.74	9.47	0.62	6.55e-17	Testicular germ cell tumor;
UCEC	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.4	5.17	0.39	7.51e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs883565	0.569	rs2949565	chr3:39163425	G/A	cg01426195	chr3:39028469	NA	0.63	7.61	0.53	3.01e-12	Handedness;
UCEC	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg25482853	chr8:67687455	SGK3	1.07	7.81	0.54	1e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.24	-0.4	5.44e-7	Mean corpuscular volume;
UCEC	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.47e-6	QRS complex (12-leadsum);
UCEC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.88	-0.54	6.7e-13	Bipolar disorder and schizophrenia;
UCEC	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-4.82	-0.37	3.58e-6	LDL cholesterol levels;LDL cholesterol;
UCEC	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	9.44	0.61	8.1e-17	Platelet count;
UCEC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	4.53	0.35	1.19e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs2742417	1.000	rs9829631	chr3:45740558	T/C	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.33e-5	Total body bone mineral density;
UCEC	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.78	7.56	0.53	4.02e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.45	-5.17	-0.39	7.4e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.66	7.33	0.52	1.43e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.57	5.85	0.43	3.09e-8	Pursuit maintenance gain;
UCEC	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg09655341	chr17:79618100	PDE6G	-0.32	-4.82	-0.37	3.58e-6	Eye color traits;
UCEC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg22974920	chr21:40686053	BRWD1	0.63	5.17	0.39	7.62e-7	Cognitive function;
UCEC	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.26e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.96	11.93	0.7	2.26e-23	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.55	0.58	1.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs4356932	0.729	rs6855257	chr4:76964788	T/C	cg22252999	chr4:76996414	ART3	0.44	4.54	0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.51	5.46	0.41	1.95e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.99	-8.21	-0.56	1.05e-13	Exhaled nitric oxide output;
UCEC	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.7	-5.34	-0.4	3.5e-7	Alzheimer's disease (late onset);
UCEC	cis	rs13063635	0.915	rs35855315	chr3:46006239	A/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs2862064	1.000	rs7731951	chr5:156449685	A/T	cg12943317	chr5:156479607	HAVCR1	0.77	5.77	0.43	4.57e-8	Platelet count;
UCEC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.36	-5.31	-0.4	3.93e-7	Ulcerative colitis;
UCEC	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg01256987	chr12:42539512	GXYLT1	-0.42	-4.73	-0.36	5.16e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7088591	0.867	rs79643571	chr10:59784899	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9470794	0.736	rs11756301	chr6:38142316	C/T	cg01504030	chr6:38141879	BTBD9	-0.79	-5.7	-0.43	6.19e-8	Type 2 diabetes;
UCEC	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.56	5.92	0.44	2.22e-8	Neuroticism;
UCEC	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.74	-9.36	-0.61	1.26e-16	Leprosy;
UCEC	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	0.9	5.3	0.4	4.08e-7	Red blood cell traits;
UCEC	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg19554555	chr3:13937349	NA	0.61	6.3	0.46	3.28e-9	Ovarian reserve;
UCEC	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs2149423	0.544	rs1328641	chr13:36745029	C/T	cg22940789	chr13:36704709	DCLK1	-0.45	-4.94	-0.38	2.1e-6	Glucose homeostasis traits;
UCEC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg01831904	chr17:28903510	LRRC37B2	0.45	4.96	0.38	1.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.63	-0.58	9.17e-15	Total cholesterol levels;
UCEC	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.73	-0.49	3.58e-10	Depression;
UCEC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg19926144	chr10:661009	DIP2C	0.82	4.87	0.37	2.84e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.53	5.98	0.44	1.62e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-7.25	-0.51	2.19e-11	Coffee consumption (cups per day);
UCEC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.05	0.38	1.31e-6	IgG glycosylation;
UCEC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.96	7.41	0.52	9.3e-12	LDL cholesterol;
UCEC	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg00277334	chr10:82204260	NA	-0.42	-4.55	-0.35	1.09e-5	Post bronchodilator FEV1;
UCEC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.56	-5.45	-0.41	2.06e-7	Obesity-related traits;
UCEC	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	0.48	4.74	0.36	4.95e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-4.54	-0.35	1.18e-5	Initial pursuit acceleration;
UCEC	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.74	7.87	0.54	7.29e-13	Primary sclerosing cholangitis;
UCEC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24308560	chr3:49941425	MST1R	-0.5	-5.4	-0.41	2.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.93	0.55	5.01e-13	Platelet count;
UCEC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.66	-6.1	-0.45	9.07e-9	Pancreatic cancer;
UCEC	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.44	-4.79	-0.37	4.12e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.54	5.71	0.43	5.94e-8	Aortic root size;
UCEC	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.51	4.8	0.37	3.94e-6	Corneal astigmatism;
UCEC	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.41	-4.55	-0.35	1.12e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27480539	chr19:16770792	TMEM38A;C19orf42	0.57	7.07	0.5	5.89e-11	Warfarin maintenance dose;
UCEC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.91	-9.37	-0.61	1.22e-16	Heart rate;
UCEC	cis	rs12234571	1.000	rs4729710	chr7:77393739	T/C	cg20048109	chr7:78158112	MAGI2	-0.5	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.58	-5.56	-0.42	1.23e-7	White matter hyperintensity burden;
UCEC	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.48	6.21	0.46	5.05e-9	Mean platelet volume;
UCEC	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg18681998	chr4:17616180	MED28	0.77	8.44	0.57	2.72e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.13	0.39	9.12e-7	Morning vs. evening chronotype;
UCEC	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.56	0.48	8.66e-10	Aortic root size;
UCEC	cis	rs17106184	0.892	rs72900998	chr1:51205760	T/C	cg07174182	chr1:51127561	FAF1	-0.65	-4.54	-0.35	1.17e-5	Type 2 diabetes;
UCEC	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	0.93	7.02	0.5	7.66e-11	Economic and political preferences (immigration/crime);
UCEC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	0.68	7.44	0.52	7.65e-12	Homoarginine levels;
UCEC	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.38	-4.82	-0.37	3.57e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.53	-4.91	-0.38	2.44e-6	Cognitive function;
UCEC	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-8.36	-0.57	4.38e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.81	9.5	0.62	5.4e-17	Ewing sarcoma;
UCEC	cis	rs871392	0.591	rs80046882	chr12:42175864	A/G	cg20693580	chr12:42326382	NA	-0.76	-4.59	-0.35	9.34e-6	Biochemical measures;
UCEC	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-5.08	-0.39	1.11e-6	Personality dimensions;
UCEC	cis	rs2075165	0.901	rs6701440	chr1:156249505	A/G	cg26011156	chr1:156183096	PMF1	0.43	4.69	0.36	6.19e-6	Tonsillectomy;
UCEC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.78	-8.85	-0.59	2.49e-15	Height;
UCEC	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.22e-25	Height;
UCEC	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.64	-5.3	-0.4	4.14e-7	Alopecia areata;
UCEC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	4.99	0.38	1.66e-6	Cognitive test performance;
UCEC	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.69	4.79	0.37	4.11e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.44	-6.11	-0.45	8.65e-9	Prostate cancer;
UCEC	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Parkinson's disease;
UCEC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22857025	chr5:266934	NA	-1.01	-9.82	-0.63	8.26e-18	Breast cancer;
UCEC	cis	rs1671400	1.000	rs919586	chr8:13174671	A/G	cg00476317	chr8:12990213	DLC1	-0.65	-4.62	-0.36	8.3e-6	Obesity-related traits;
UCEC	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg11871910	chr12:69753446	YEATS4	0.56	4.9	0.37	2.47e-6	Response to diuretic therapy;
UCEC	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.51	0.41	1.54e-7	Menarche (age at onset);
UCEC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.71	6.67	0.48	4.78e-10	Menarche (age at onset);
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.87	10.03	0.64	2.31e-18	Menarche (age at onset);
UCEC	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg22654517	chr2:96458247	NA	0.42	4.83	0.37	3.34e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.46	4.72	0.36	5.49e-6	Aortic root size;
UCEC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.87	9.9	0.63	5.12e-18	Monocyte count;
UCEC	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.77	-6.94	-0.5	1.17e-10	Smoking behavior;
UCEC	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg04837898	chr3:45731254	SACM1L	-0.41	-4.62	-0.36	8.31e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.82	-9.65	-0.62	2.26e-17	Tonsillectomy;
UCEC	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg19257562	chr1:2043853	PRKCZ	0.46	4.84	0.37	3.21e-6	Height;
UCEC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.71	9.18	0.6	3.74e-16	Rheumatoid arthritis;
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.8	8.04	0.55	2.71e-13	Longevity;Endometriosis;
UCEC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.8	9.35	0.61	1.35e-16	Homoarginine levels;
UCEC	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.78	-9.48	-0.62	6.39e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg21770322	chr7:97807741	LMTK2	0.7	9.89	0.63	5.35e-18	Breast cancer;
UCEC	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.92	0.59	1.72e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg24826892	chr11:71159390	DHCR7	0.51	5.08	0.39	1.13e-6	Vitamin D levels;
UCEC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.54	-6.36	-0.46	2.42e-9	Educational attainment;
UCEC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg23625390	chr15:77176239	SCAPER	0.46	4.5	0.35	1.35e-5	Blood metabolite levels;
UCEC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.83	8.87	0.59	2.29e-15	Blood protein levels;
UCEC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg12024160	chr4:1254474	NA	-0.53	-5.84	-0.43	3.15e-8	Obesity-related traits;
UCEC	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.78	8.59	0.58	1.18e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26207909	chr14:103986467	CKB	-0.49	-4.86	-0.37	3.04e-6	Body mass index;
UCEC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.26	-0.46	3.92e-9	Post bronchodilator FEV1;
UCEC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	5.05	0.38	1.29e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.53	-6.16	-0.45	6.69e-9	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00811051	chr4:100868099	DNAJB14	-0.49	-4.85	-0.37	3.08e-6	Gut microbiome composition (summer);
UCEC	cis	rs78761021	0.720	rs56086072	chr17:9798412	C/T	cg26853458	chr17:9805074	RCVRN	0.39	4.93	0.38	2.19e-6	Type 2 diabetes;
UCEC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.48	-4.95	-0.38	2.01e-6	Smoking initiation;
UCEC	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg17267710	chr20:61161232	C20orf166;MIR133A2	-0.36	-4.77	-0.37	4.35e-6	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg03211192	chr7:3018607	CARD11	-0.57	-6.69	-0.48	4.44e-10	N-glycan levels;
UCEC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	0.79	5.25	0.4	5.28e-7	Diabetic retinopathy;
UCEC	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.59	6.67	0.48	4.96e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.88	-11.33	-0.68	8.6e-22	Height;
UCEC	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.33	-0.4	3.7e-7	Bone mineral density;
UCEC	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	8.0	0.55	3.43e-13	Total cholesterol levels;
UCEC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15506890	chr2:3487001	NA	-0.65	-6.37	-0.47	2.29e-9	Neurofibrillary tangles;
UCEC	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.64	-5.82	-0.43	3.51e-8	Systemic lupus erythematosus;
UCEC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg13385521	chr17:29058706	SUZ12P	0.59	4.51	0.35	1.32e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.54	-0.84	2.53e-40	Exhaled nitric oxide output;
UCEC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.44	4.78	0.37	4.28e-6	Prudent dietary pattern;
UCEC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.55e-9	Lung cancer;
UCEC	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.65	7.68	0.54	2.08e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.55	-6.37	-0.47	2.23e-9	Type 2 diabetes;
UCEC	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.93	7.86	0.54	7.71e-13	Exhaled nitric oxide levels;
UCEC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.55	7.78	0.54	1.18e-12	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg13147721	chr7:65941812	NA	-0.92	-6.69	-0.48	4.48e-10	Diabetic kidney disease;
UCEC	cis	rs4233802	0.737	rs78386925	chr2:151184011	C/T	cg25300694	chr2:151184358	NA	-0.69	-4.74	-0.36	5.02e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
UCEC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.71	7.56	0.53	4e-12	Type 2 diabetes;
UCEC	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.74	7.59	0.53	3.46e-12	Lymphocyte counts;
UCEC	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.6	5.27	0.4	4.87e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.29	0.46	3.46e-9	Motion sickness;
UCEC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.16	7.1	0.51	4.94e-11	Gut microbiome composition (summer);
UCEC	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.44	-4.73	-0.36	5.21e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.98	0.44	1.63e-8	Height;
UCEC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.71	-5.71	-0.43	6.11e-8	Neutrophil percentage of white cells;
UCEC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.73	0.36	5.31e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-4.57	-0.35	1.03e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.6	5.07	0.39	1.2e-6	Coronary artery disease;
UCEC	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.98	-7.66	-0.53	2.25e-12	Dupuytren's disease;
UCEC	cis	rs6684428	0.505	rs6588581	chr1:56393537	C/T	cg11651538	chr1:56320950	NA	-0.45	-4.63	-0.36	7.82e-6	Airflow obstruction;
UCEC	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.77	8.83	0.59	2.84e-15	Brugada syndrome;
UCEC	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg03728395	chr2:85555865	TGOLN2	-0.36	-4.91	-0.38	2.43e-6	Ear protrusion;
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.38	4.98	0.38	1.76e-6	Body mass index;
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.48	-5.19	-0.39	6.89e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.5	4.78	0.37	4.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-7.29	-0.52	1.79e-11	Mood instability;
UCEC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-5.69	-0.43	6.56e-8	Bipolar disorder;
UCEC	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.65	-7.42	-0.52	8.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	6.89	0.49	1.49e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg12850546	chr22:42539477	CYP2D7P1	0.46	5.0	0.38	1.63e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.77	7.93	0.55	5.01e-13	Breast cancer;
UCEC	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	9.41	0.61	9.56e-17	Coffee consumption (cups per day);
UCEC	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-6.21	-0.46	5.27e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs12618769	0.625	rs4850878	chr2:99112180	T/A	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.83	-10.64	-0.66	5.95e-20	White blood cell count (basophil);
UCEC	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.6	-6.11	-0.45	8.5e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.48	5.02	0.38	1.49e-6	Plateletcrit;Platelet count;
UCEC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.86	7.8	0.54	1.04e-12	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.46	4.65	0.36	7.21e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.58	-0.35	9.91e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.36	-0.4	3.18e-7	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.72	7.13	0.51	4.24e-11	Breast cancer;
UCEC	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg27223183	chr8:87520930	FAM82B	-0.76	-6.29	-0.46	3.36e-9	Caudate activity during reward;
UCEC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg04756594	chr16:24857601	SLC5A11	0.47	5.24	0.4	5.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.39	4.94	0.38	2.13e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg18032046	chr6:28092343	ZSCAN16	0.58	4.89	0.37	2.65e-6	Depression;
UCEC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs6832769	1.000	rs10002541	chr4:56395011	T/C	cg05960024	chr4:56376020	CLOCK	-0.56	-5.85	-0.43	3.01e-8	Personality dimensions;
UCEC	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.45	4.62	0.36	8.35e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.36	0.61	1.24e-16	Platelet count;
UCEC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.21	-0.4	6.14e-7	Aortic root size;
UCEC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg23888215	chr10:79422304	NA	-1.01	-8.23	-0.56	9.31e-14	Bone mineral density;
UCEC	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.61	-5.18	-0.39	7.24e-7	Obesity-related traits;
UCEC	cis	rs7560272	0.501	rs6755500	chr2:73942233	C/T	cg20560298	chr2:73613845	ALMS1	0.5	4.76	0.37	4.54e-6	Schizophrenia;
UCEC	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	6.23	0.46	4.6e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.99	0.38	1.69e-6	Breast cancer;
UCEC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.87	9.9	0.63	5.12e-18	Monocyte count;
UCEC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.46	5.8	0.43	3.96e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.6	5.13	0.39	8.9e-7	Phospholipid levels (plasma);
UCEC	cis	rs2179367	0.959	rs4897125	chr6:149766208	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.4	-5.21	-0.39	6.39e-7	Dupuytren's disease;
UCEC	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.86	-10.8	-0.67	2.2e-20	Coronary artery disease;
UCEC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.47	-4.74	-0.36	4.95e-6	Cardiac Troponin-T levels;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.56	-6.57	-0.48	8.15e-10	Pubertal anthropometrics;
UCEC	cis	rs10031466	0.935	rs28637448	chr4:189019896	C/T	cg17565478	chr4:189026658	TRIML2	-0.36	-4.54	-0.35	1.16e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs4499344	0.693	rs382416	chr19:33107938	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.71	-5.98	-0.44	1.62e-8	Mean platelet volume;
UCEC	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.5	4.97	0.38	1.86e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.87	-7.18	-0.51	3.26e-11	Coronary artery calcification;
UCEC	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.51	5.73	0.43	5.56e-8	Blood metabolite levels;
UCEC	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	4.99	0.38	1.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.84	-9.3	-0.61	1.78e-16	Cognitive function;
UCEC	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.46	4.79	0.37	4e-6	Response to temozolomide;
UCEC	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07169764	chr2:136633963	MCM6	-0.78	-7.84	-0.54	8.3e-13	Mosquito bite size;
UCEC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.75	-8.35	-0.57	4.55e-14	White blood cell count (basophil);
UCEC	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.84	-11.48	-0.69	3.6e-22	Body mass index;
UCEC	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg17652424	chr22:38574118	PLA2G6	-0.41	-5.11	-0.39	9.94e-7	Cutaneous nevi;
UCEC	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg05660106	chr1:15850417	CASP9	1.06	12.01	0.7	1.35e-23	Systolic blood pressure;
UCEC	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.68	-6.53	-0.47	1.02e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	8.09	0.56	2.04e-13	Platelet count;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	7.8	0.54	1.06e-12	Bone mineral density;
UCEC	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24249390	chr15:90295951	MESP1	-0.46	-5.14	-0.39	8.48e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.32	4.53	0.35	1.22e-5	Crohn's disease;
UCEC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.01	-0.38	1.55e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.57	6.59	0.48	7.43e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.86e-6	Body mass index;
UCEC	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	0.83	4.96	0.38	1.94e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.4	5.16	0.39	7.74e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.57	6.73	0.49	3.63e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.800	rs7256135	chr19:23039121	A/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-5.12	-0.39	9.52e-7	Type 2 diabetes;
UCEC	cis	rs1868673	0.679	rs1463229	chr3:150167912	C/T	cg24290546	chr3:150134309	TSC22D2	0.48	4.52	0.35	1.25e-5	Waist circumference;
UCEC	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.76	7.51	0.53	5.26e-12	Vitamin D levels;
UCEC	cis	rs256277	0.507	rs26542	chr5:111348069	T/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.57	-5.47	-0.41	1.86e-7	Coronary artery disease;
UCEC	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.57	5.46	0.41	1.99e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs11697848	0.737	rs79102316	chr20:48453876	C/T	cg17849948	chr20:48532315	SPATA2	1.02	5.13	0.39	8.95e-7	Systemic lupus erythematosus;
UCEC	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg23815491	chr16:72088622	HP	0.45	5.85	0.43	3.06e-8	Fibrinogen levels;
UCEC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.54	-5.33	-0.4	3.58e-7	Coronary artery disease;
UCEC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-5.91	-0.44	2.34e-8	Menarche (age at onset);
UCEC	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.51	4.73	0.36	5.21e-6	Night sleep phenotypes;
UCEC	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.5	8.05	0.55	2.64e-13	Airflow obstruction;
UCEC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs6534441	0.727	rs7654000	chr4:125469871	T/G	cg21609808	chr4:125404261	NA	0.41	4.58	0.35	9.99e-6	Major depressive disorder;
UCEC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.35	-0.52	1.25e-11	Blood trace element (Zn levels);
UCEC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.83	9.25	0.61	2.48e-16	Breast cancer;
UCEC	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.56	-8.33	-0.57	5.34e-14	Height;
UCEC	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.79	-8.53	-0.58	1.64e-14	Cognitive function;
UCEC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.48	-5.17	-0.39	7.4e-7	Lymphocyte counts;
UCEC	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg01426195	chr3:39028469	NA	-0.79	-10.36	-0.65	3.19e-19	Handedness;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.74	8.95	0.59	1.39e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.53	-5.73	-0.43	5.57e-8	Pubertal anthropometrics;
UCEC	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.91	-0.9	1.28e-54	Myeloid white cell count;
UCEC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.49	5.29	0.4	4.3e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.11	-0.39	9.77e-7	Pediatric autoimmune diseases;
UCEC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.48	-4.87	-0.37	2.81e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-5.03	-0.38	1.44e-6	Response to antipsychotic treatment;
UCEC	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.11e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.52	-4.66	-0.36	6.94e-6	Colorectal cancer;
UCEC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.58	7.04	0.5	6.8e-11	Menopause (age at onset);
UCEC	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg16797656	chr11:68205561	LRP5	0.48	5.45	0.41	2.03e-7	Total body bone mineral density;
UCEC	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.81	9.14	0.6	4.6e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.46	5.75	0.43	5.1e-8	HDL cholesterol levels;
UCEC	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.58	6.48	0.47	1.28e-9	Obesity-related traits;
UCEC	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg05660106	chr1:15850417	CASP9	0.52	5.05	0.38	1.28e-6	Systolic blood pressure;
UCEC	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.39	0.47	2.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.69	-8.36	-0.57	4.41e-14	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs1046896	0.521	rs3859206	chr17:80693128	G/A	cg16060761	chr17:80687452	NA	-0.66	-8.6	-0.58	1.12e-14	Glycated hemoglobin levels;
UCEC	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	1.08	10.08	0.64	1.74e-18	Dupuytren's disease;
UCEC	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.54	-6.63	-0.48	6.04e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-5.4	-0.41	2.57e-7	Blood metabolite levels;
UCEC	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.2	-0.46	5.54e-9	Pubertal anthropometrics;
UCEC	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.79	6.25	0.46	4.26e-9	Colorectal adenoma (advanced);
UCEC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.44	-4.61	-0.36	8.5e-6	Glaucoma;
UCEC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.55	-5.68	-0.42	6.85e-8	Dental caries;
UCEC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.61	5.38	0.41	2.88e-7	Alcohol dependence;
UCEC	cis	rs3736594	0.513	rs56725354	chr2:27824168	G/C	cg27432699	chr2:27873401	GPN1	0.53	5.09	0.39	1.08e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.79	-9.62	-0.62	2.68e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg18653534	chr16:772142	FAM173A	0.47	5.54	0.42	1.37e-7	Height;
UCEC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.47	-5.45	-0.41	2.12e-7	Neuroticism;
UCEC	cis	rs6137726	0.652	rs6082784	chr20:22660395	C/T	cg08244522	chr20:23030533	THBD	0.5	5.35	0.4	3.37e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.22	-0.4	6.13e-7	Morning vs. evening chronotype;
UCEC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.91	11.62	0.69	1.5e-22	Breast cancer;
UCEC	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg21905437	chr5:178450457	ZNF879	0.67	7.2	0.51	2.82e-11	Pubertal anthropometrics;
UCEC	cis	rs4074536	0.740	rs11578967	chr1:116301670	T/G	cg21648376	chr1:116311395	CASQ2	-0.52	-5.28	-0.4	4.65e-7	QRS duration;
UCEC	cis	rs2882667	0.788	rs11959691	chr5:138481088	C/T	cg04439458	chr5:138467593	SIL1	-0.46	-5.01	-0.38	1.54e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4654899	0.680	rs3890762	chr1:21198265	G/A	cg01072550	chr1:21505969	NA	0.53	5.31	0.4	3.95e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.97	-9.14	-0.6	4.57e-16	Exhaled nitric oxide output;
UCEC	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.55	4.97	0.38	1.82e-6	Crohn's disease;
UCEC	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.86	-6.6	-0.48	6.9e-10	Exhaled nitric oxide output;
UCEC	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.68	6.06	0.45	1.08e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2862064	1.000	rs1501910	chr5:156418790	A/G	cg12943317	chr5:156479607	HAVCR1	-0.75	-5.97	-0.44	1.68e-8	Platelet count;
UCEC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.72	8.17	0.56	1.33e-13	Menarche (age at onset);
UCEC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.48	4.6	0.35	9.2e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg10597661	chr8:8256332	NA	-0.77	-4.83	-0.37	3.35e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg17294928	chr15:75287854	SCAMP5	0.82	9.41	0.61	9.66e-17	Blood trace element (Zn levels);
UCEC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.76	-8.62	-0.58	9.99e-15	Menarche (age at onset);
UCEC	cis	rs6832769	1.000	rs6824057	chr4:56367278	G/C	cg05960024	chr4:56376020	CLOCK	0.54	5.06	0.39	1.25e-6	Personality dimensions;
UCEC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-6.02	-0.44	1.33e-8	Personality dimensions;
UCEC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.47	0.41	1.85e-7	Prudent dietary pattern;
UCEC	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg05660106	chr1:15850417	CASP9	1.06	12.0	0.7	1.5e-23	Systolic blood pressure;
UCEC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs9309473	0.519	rs13017182	chr2:73891004	G/T	cg20560298	chr2:73613845	ALMS1	0.5	4.86	0.37	3e-6	Metabolite levels;
UCEC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg06096015	chr1:231504339	EGLN1	-0.42	-4.71	-0.36	5.76e-6	Hemoglobin concentration;
UCEC	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.4	4.85	0.37	3.16e-6	Height;
UCEC	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.71	-8.95	-0.59	1.42e-15	Hip circumference;
UCEC	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.84	-9.16	-0.6	4.1e-16	Blood metabolite levels;
UCEC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.44	-5.06	-0.38	1.26e-6	Resting heart rate;
UCEC	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg14121845	chr20:25566513	NINL	0.4	4.78	0.37	4.29e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.64	6.94	0.5	1.18e-10	Mortality in heart failure;
UCEC	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.43	-4.97	-0.38	1.87e-6	Total body bone mineral density;
UCEC	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.51	-5.13	-0.39	9.11e-7	Systemic lupus erythematosus;
UCEC	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.61	5.01	0.38	1.51e-6	Lung cancer;
UCEC	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	0.97	9.68	0.62	1.85e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg16576597	chr16:28551801	NUPR1	-0.32	-4.79	-0.37	4.1e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.43	4.74	0.36	5.07e-6	Hemoglobin concentration;
UCEC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-0.99	-12.38	-0.71	1.47e-24	Coronary artery disease;
UCEC	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg22166914	chr1:53195759	ZYG11B	0.75	7.76	0.54	1.3e-12	Monocyte count;
UCEC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.6	4.58	0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg14078730	chr11:63896557	MACROD1	0.45	4.88	0.37	2.74e-6	Platelet count;
UCEC	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	6.53	0.47	1.02e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.86	-9.64	-0.62	2.45e-17	Cognitive function;
UCEC	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-7.47	-0.52	6.67e-12	Morning vs. evening chronotype;
UCEC	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg04154034	chr17:28927549	LRRC37B2	0.71	4.96	0.38	1.95e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.86	-0.59	2.46e-15	Exhaled nitric oxide output;
UCEC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.08	0.39	1.15e-6	Obesity-related traits;
UCEC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.69	6.98	0.5	9.39e-11	Menopause (age at onset);
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg00651523	chr6:28411279	ZSCAN23	0.53	5.82	0.43	3.58e-8	Pubertal anthropometrics;
UCEC	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.84	8.92	0.59	1.69e-15	Parkinson's disease;
UCEC	trans	rs1552172	0.853	rs11591191	chr1:145675931	T/C	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.86	-0.49	1.75e-10	Breast cancer;
UCEC	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	0.88	4.95	0.38	1.98e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg23260525	chr10:116636907	FAM160B1	0.33	4.51	0.35	1.32e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.12	-0.39	9.53e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12365397	0.775	rs11037365	chr11:43243675	C/T	cg07515919	chr11:43391688	TTC17	0.48	5.01	0.38	1.53e-6	Migraine;
UCEC	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.38e-17	Height;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-6.86	-0.49	1.76e-10	Platelet count;
UCEC	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.66	-7.92	-0.55	5.32e-13	IgG glycosylation;
UCEC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg11632617	chr15:75315747	PPCDC	-0.6	-7.01	-0.5	8.23e-11	Blood trace element (Zn levels);
UCEC	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg07615347	chr10:60278583	BICC1	0.41	4.74	0.36	5e-6	Refractive error;
UCEC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.5	6.29	0.46	3.51e-9	Homoarginine levels;
UCEC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.44	-0.47	1.62e-9	Eye color traits;
UCEC	cis	rs2398893	1.000	rs12004383	chr9:96826239	G/T	cg07076509	chr9:96720819	NA	0.47	4.72	0.36	5.39e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-4.85	-0.37	3.06e-6	Blood metabolite levels;
UCEC	cis	rs8034595	0.737	rs980168	chr15:96720754	C/G	cg15898874	chr15:96515411	NA	-0.42	-4.56	-0.35	1.07e-5	Optic disc area;
UCEC	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg18681998	chr4:17616180	MED28	0.52	5.75	0.43	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.72	-8.17	-0.56	1.3e-13	Waist circumference;Body mass index;
UCEC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.71	6.32	0.46	2.91e-9	Cognitive function;
UCEC	cis	rs6893807	1.000	rs1422191	chr5:87949158	G/A	cg09002922	chr5:87956389	LOC645323	-0.58	-5.99	-0.44	1.56e-8	Body mass index;
UCEC	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.52	5.11	0.39	9.67e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.89	-0.44	2.56e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.57	-5.82	-0.43	3.53e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg01112020	chr2:239008986	ESPNL	-0.37	-4.94	-0.38	2.11e-6	Prostate cancer;
UCEC	cis	rs6684428	1.000	rs55769330	chr1:56357825	G/C	cg11651538	chr1:56320950	NA	-0.71	-6.14	-0.45	7.23e-9	Airflow obstruction;
UCEC	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.91	-11.54	-0.69	2.4e-22	Coronary artery disease;
UCEC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.48	-4.84	-0.37	3.29e-6	Parkinson's disease;
UCEC	cis	rs3750082	0.889	rs6462431	chr7:32935439	A/G	cg05721444	chr7:32995514	FKBP9	0.53	5.87	0.44	2.81e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.5	-4.85	-0.37	3.05e-6	Electroencephalogram traits;
UCEC	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18932078	chr1:2524107	MMEL1	0.32	5.12	0.39	9.28e-7	Ulcerative colitis;
UCEC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.49	-5.7	-0.43	6.21e-8	Testicular germ cell tumor;
UCEC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-8.04	-0.55	2.75e-13	Chronic sinus infection;
UCEC	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.12	0.51	4.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.6	8.76	0.59	4.24e-15	Prudent dietary pattern;
UCEC	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	8.37	0.57	4.22e-14	Coffee consumption (cups per day);
UCEC	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.28	0.4	4.63e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	4.52	0.35	1.27e-5	Diabetic retinopathy;
UCEC	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.59	-0.35	9.57e-6	Height;
UCEC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.7	-7.06	-0.5	6.04e-11	Breast cancer;
UCEC	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.33	0.46	2.79e-9	Rheumatoid arthritis;
UCEC	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.55	-5.4	-0.41	2.59e-7	Acne (severe);
UCEC	cis	rs2281845	0.507	rs942703	chr1:201092979	A/G	cg06714761	chr1:201096289	NA	-0.63	-6.81	-0.49	2.38e-10	Permanent tooth development;
UCEC	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	5.05	0.38	1.27e-6	Bone mineral density;
UCEC	cis	rs10432489	0.708	rs62178208	chr2:181749599	A/G	cg21995919	chr2:182322279	ITGA4	-0.91	-4.73	-0.36	5.28e-6	QT interval;
UCEC	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.33	7.69	0.54	1.91e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.64	-0.53	2.51e-12	Prevalent atrial fibrillation;
UCEC	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.65	-0.36	7.19e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10924970	0.934	rs56681442	chr1:235466800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.46	4.83	0.37	3.35e-6	Asthma;
UCEC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.61	7.18	0.51	3.26e-11	Menopause (age at onset);
UCEC	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.42	-4.91	-0.38	2.42e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19935506	chr2:242626874	DTYMK	0.58	6.69	0.48	4.41e-10	Warfarin maintenance dose;
UCEC	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.92	8.63	0.58	9.25e-15	Colorectal cancer;
UCEC	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.46	5.01	0.38	1.53e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-5.32	-0.4	3.73e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.53	-4.85	-0.37	3.16e-6	Body mass index;
UCEC	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg23795048	chr12:9217529	LOC144571	0.41	4.99	0.38	1.7e-6	Sjögren's syndrome;
UCEC	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg20129853	chr10:51489980	NA	-0.42	-4.76	-0.37	4.68e-6	Prostate-specific antigen levels;
UCEC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.38	5.4	0.41	2.65e-7	Alcohol dependence;
UCEC	cis	rs4654899	0.897	rs12121807	chr1:21069129	A/C	cg01072550	chr1:21505969	NA	-0.48	-4.51	-0.35	1.29e-5	Superior frontal gyrus grey matter volume;
UCEC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg23307798	chr14:103986281	CKB	0.54	5.19	0.39	6.9e-7	Body mass index;
UCEC	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.61	5.43	0.41	2.32e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.27	0.51	1.98e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg14078730	chr11:63896557	MACROD1	0.49	5.42	0.41	2.34e-7	Platelet count;
UCEC	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.55	5.75	0.43	5.06e-8	Birth weight;
UCEC	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.54	5.06	0.38	1.25e-6	Menarche (age at onset);
UCEC	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg13575925	chr12:9217583	LOC144571	0.39	4.84	0.37	3.18e-6	Sjögren's syndrome;
UCEC	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.44	-4.78	-0.37	4.29e-6	Fibrinogen levels;
UCEC	cis	rs750338	0.529	rs67134762	chr11:125177631	T/C	cg13181079	chr11:125757629	HYLS1	-0.58	-4.53	-0.35	1.24e-5	Alcohol dependence symptom count;Alcohol dependence;
UCEC	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.6	-6.16	-0.45	6.51e-9	Breast cancer;
UCEC	cis	rs7175404	0.702	rs10438446	chr15:94053269	A/G	cg06054272	chr15:93956988	NA	0.74	4.71	0.36	5.79e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.55	-5.12	-0.39	9.32e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.48	-4.52	-0.35	1.26e-5	Aortic root size;
UCEC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.52	5.5	0.41	1.61e-7	Menopause (age at onset);
UCEC	cis	rs35934224	0.783	rs45465601	chr22:19868678	T/C	cg11182965	chr22:19864308	TXNRD2	-0.46	-5.82	-0.43	3.47e-8	Glaucoma (primary open-angle);
UCEC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.47	0.41	1.88e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	4.76	0.37	4.65e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7004769	0.554	rs76493204	chr8:9168372	A/G	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.66	7.88	0.54	6.71e-13	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7088591	0.867	rs73290915	chr10:59779581	A/T	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	trans	rs629535	1.000	rs629535	chr8:70007938	C/T	cg21567404	chr3:27674614	NA	-1.07	-9.81	-0.63	8.88e-18	Dupuytren's disease;
UCEC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.59	-6.44	-0.47	1.56e-9	Menarche (age at onset);
UCEC	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.6	5.29	0.4	4.32e-7	Psoriasis vulgaris;
UCEC	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.01	-0.5	7.87e-11	Neuroticism;
UCEC	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.6	-5.18	-0.39	7.11e-7	Psoriasis vulgaris;
UCEC	cis	rs2274471	0.540	rs10815162	chr9:5122291	G/C	cg03390472	chr9:5043263	JAK2	-0.52	-5.04	-0.38	1.34e-6	Crohn's disease;
UCEC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.92e-6	Breast cancer;
UCEC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg19318889	chr4:1322082	MAEA	0.6	7.26	0.51	2.09e-11	Longevity;
UCEC	cis	rs1568889	1.000	rs58502944	chr11:28060943	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	7.48	0.52	6.41e-12	Bipolar disorder;
UCEC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.91	-10.41	-0.65	2.36e-19	Cognitive function;
UCEC	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.47	-5.04	-0.38	1.37e-6	Retinal vascular caliber;
UCEC	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.55	-6.34	-0.46	2.64e-9	Longevity;
UCEC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.75	-8.4	-0.57	3.51e-14	Extraversion;
UCEC	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.52	5.1	0.39	1.02e-6	Dilated cardiomyopathy;
UCEC	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.78	-0.43	4.32e-8	Height;
UCEC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg14008862	chr17:28927542	LRRC37B2	0.6	5.29	0.4	4.26e-7	Body mass index;
UCEC	cis	rs4074961	0.544	rs11264067	chr1:37991458	C/T	cg13401533	chr1:37979913	MEAF6	0.55	4.93	0.38	2.22e-6	Axial length;
UCEC	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg05991184	chr2:219186017	PNKD	-0.45	-4.63	-0.36	7.82e-6	Colorectal cancer;
UCEC	cis	rs1978968	0.731	rs9605469	chr22:18461231	T/C	cg03078520	chr22:18463400	MICAL3	-0.55	-6.61	-0.48	6.56e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.47	0.52	6.69e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9341808	0.667	rs1408292	chr6:80883906	G/T	cg08355045	chr6:80787529	NA	0.41	5.15	0.39	8.37e-7	Sitting height ratio;
UCEC	cis	rs7246967	0.673	rs35335083	chr19:22869592	A/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-8.14	-0.56	1.54e-13	Monocyte count;
UCEC	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg24505687	chr6:33548425	BAK1	0.41	4.56	0.35	1.06e-5	Platelet count;
UCEC	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	4.77	0.37	4.33e-6	Lymphocyte counts;
UCEC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	6.24	0.46	4.5e-9	Platelet count;
UCEC	cis	rs7011049	1.000	rs11993171	chr8:53832898	C/A	cg26025543	chr8:53854495	NA	0.61	4.52	0.35	1.29e-5	Systolic blood pressure;
UCEC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.46	-6.67	-0.48	4.81e-10	Metabolite levels;
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.51	0.53	5.36e-12	Platelet count;
UCEC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.54	5.06	0.38	1.26e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	0.97	5.31	0.4	3.99e-7	IgG glycosylation;
UCEC	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10887741	0.646	rs11202501	chr10:89437208	C/T	cg13926569	chr10:89418898	PAPSS2	0.41	4.85	0.37	3.16e-6	Exercise (leisure time);
UCEC	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.44	-4.58	-0.35	1e-5	Depression;
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg19678392	chr7:94953810	PON1	-0.58	-5.65	-0.42	7.97e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.67	5.18	0.39	7.19e-7	Breast cancer;
UCEC	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.66	-7.02	-0.5	7.49e-11	Breast cancer;
UCEC	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg18479299	chr3:125709523	NA	-0.67	-4.59	-0.35	9.33e-6	Blood pressure (smoking interaction);
UCEC	cis	rs2030401	0.603	rs1727301	chr12:123664514	G/A	cg00376283	chr12:123451042	ABCB9	0.64	6.47	0.47	1.37e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.6	5.56	0.42	1.24e-7	Corneal astigmatism;
UCEC	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.32	-5.31	-0.4	4.04e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.53	5.0	0.38	1.58e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.73	-5.64	-0.42	8.37e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.35	-0.4	3.32e-7	Metabolite levels;
UCEC	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.52	-7.25	-0.51	2.16e-11	Refractive error;
UCEC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg22974920	chr21:40686053	BRWD1	-0.56	-4.87	-0.37	2.79e-6	Cognitive function;
UCEC	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.6	5.73	0.43	5.42e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.49	4.59	0.35	9.29e-6	Bipolar disorder;
UCEC	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg04283868	chr2:201171347	SPATS2L	-0.54	-5.38	-0.41	2.84e-7	QT interval;
UCEC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.66	0.42	7.77e-8	Height;
UCEC	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-6.52	-0.47	1.06e-9	Blood protein levels;
UCEC	cis	rs77861329	1.000	rs9815010	chr3:52196548	C/T	cg08692210	chr3:52188851	WDR51A	0.82	6.55	0.48	9e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.6	-6.68	-0.48	4.61e-10	Asthma;
UCEC	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.79	9.18	0.6	3.73e-16	Adiposity;
UCEC	cis	rs9467773	1.000	rs9467800	chr6:26578525	A/C	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.63	6.71	0.48	3.94e-10	Diastolic blood pressure;
UCEC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.63	8.93	0.59	1.56e-15	Prudent dietary pattern;
UCEC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.78	-8.68	-0.58	7.07e-15	Monocyte count;
UCEC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.61	5.38	0.41	2.82e-7	Longevity;
UCEC	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.84	0.37	3.25e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2474937	0.561	rs6428746	chr1:118926970	G/A	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.09e-5	Congenital heart malformation;
UCEC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.63	-5.43	-0.41	2.29e-7	Initial pursuit acceleration;
UCEC	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.63	7.36	0.52	1.22e-11	Obesity-related traits;
UCEC	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-0.58	-4.57	-0.35	1.02e-5	Obesity-related traits;
UCEC	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg06456738	chr11:66361081	CCDC87;CCS	0.59	4.69	0.36	6.23e-6	Airway imaging phenotypes;
UCEC	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-0.94	-9.07	-0.6	7.19e-16	Vitiligo;
UCEC	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.59	5.77	0.43	4.53e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.57	-5.67	-0.42	7.23e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.79	8.64	0.58	8.51e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg10263370	chr3:44754102	ZNF502	-0.49	-4.95	-0.38	2e-6	Depressive symptoms;
UCEC	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.69	-8.41	-0.57	3.36e-14	Leprosy;
UCEC	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.57	6.47	0.47	1.35e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.44	4.56	0.35	1.06e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg23950597	chr19:37808831	NA	-0.61	-4.79	-0.37	3.99e-6	Coronary artery calcification;
UCEC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg05738196	chr6:26577821	NA	0.64	7.15	0.51	3.79e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg16060761	chr17:80687452	NA	-0.49	-4.52	-0.35	1.27e-5	Glycated hemoglobin levels;
UCEC	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-7.56	-0.53	4.03e-12	Blood protein levels;
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.69	5.54	0.42	1.34e-7	Platelet count;
UCEC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.66	-6.16	-0.45	6.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-10.35	-0.65	3.3e-19	Vitiligo;
UCEC	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.48	-4.77	-0.37	4.37e-6	Dental caries;
UCEC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.47	4.84	0.37	3.29e-6	Blood protein levels;
UCEC	cis	rs12618769	0.652	rs17033813	chr2:99196483	A/G	cg10123293	chr2:99228465	UNC50	-0.47	-5.4	-0.41	2.59e-7	Bipolar disorder;
UCEC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.65	6.7	0.48	4.24e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg02158880	chr13:53174818	NA	0.56	6.58	0.48	7.65e-10	Lewy body disease;
UCEC	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.55	-5.66	-0.42	7.85e-8	Hepatocellular carcinoma;
UCEC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg08755490	chr11:65554678	OVOL1	0.5	5.3	0.4	4.07e-7	Acne (severe);
UCEC	cis	rs7204230	1.000	rs8052956	chr16:53291544	T/C	cg10109421	chr16:52641824	NA	0.4	4.58	0.35	9.66e-6	Fibrinogen;
UCEC	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg24687543	chr11:63912206	MACROD1	0.54	4.71	0.36	5.65e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs17106184	1.000	rs59524047	chr1:51399215	G/A	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.3e-6	Sjögren's syndrome;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.24	-0.46	4.37e-9	Pubertal anthropometrics;
UCEC	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.65	5.52	0.41	1.47e-7	Multiple sclerosis;
UCEC	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.7	6.01	0.44	1.37e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.09	-0.5	5.2e-11	Eye color traits;
UCEC	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg06784218	chr1:46089804	CCDC17	0.53	6.65	0.48	5.46e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.67	9.14	0.6	4.53e-16	Neuroticism;
UCEC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	6.05e-9	Colorectal cancer;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.52	-5.99	-0.44	1.58e-8	Pubertal anthropometrics;
UCEC	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.71	10.65	0.66	5.4e-20	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.74	-8.26	-0.56	7.94e-14	Sudden cardiac arrest;
UCEC	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.56	-6.11	-0.45	8.47e-9	Red blood cell count;
UCEC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.82	11.26	0.68	1.32e-21	Headache;
UCEC	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	5.11	0.39	1.01e-6	Platelet count;
UCEC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.56	7.15	0.51	3.74e-11	Prudent dietary pattern;
UCEC	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.87	-12.39	-0.71	1.33e-24	Urate levels in lean individuals;
UCEC	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.18	-0.51	3.24e-11	Parkinson's disease;
UCEC	cis	rs115344852	0.598	rs2531815	chr6:28436060	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.17	-0.39	7.51e-7	Epithelial ovarian cancer;
UCEC	cis	rs17106184	1.000	rs58446086	chr1:50971801	A/G	cg07174182	chr1:51127561	FAF1	-0.84	-5.35	-0.4	3.33e-7	Type 2 diabetes;
UCEC	cis	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg07460842	chr6:66804631	NA	0.66	5.44	0.41	2.19e-7	Metabolite levels;
UCEC	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg27153327	chr16:1920815	C16orf73	0.44	5.04	0.38	1.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.57	-5.34	-0.4	3.45e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.85	5.79	0.43	4.03e-8	Psoriasis;
UCEC	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	7.32	0.52	1.5e-11	Motion sickness;
UCEC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.69	7.75	0.54	1.42e-12	Age at first birth;
UCEC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-0.98	-11.06	-0.67	4.42e-21	Blood pressure (smoking interaction);
UCEC	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.46	6.79	0.49	2.57e-10	Homoarginine levels;
UCEC	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg26721908	chr21:47610096	LSS	-0.36	-4.54	-0.35	1.17e-5	Testicular germ cell tumor;
UCEC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.42e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg24069376	chr3:38537580	EXOG	0.42	5.24	0.4	5.44e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2282802	0.685	rs6580515	chr5:139698110	A/C	cg01081189	chr5:139537190	NA	-0.47	-4.52	-0.35	1.28e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2071426	0.633	rs12780874	chr10:96765018	T/C	cg09036531	chr10:96991505	NA	-0.58	-4.59	-0.35	9.63e-6	Blood metabolite levels;
UCEC	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.19	0.51	3.02e-11	Menopause (age at onset);
UCEC	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.76	8.05	0.55	2.55e-13	Multiple myeloma (IgH translocation);
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03407747	chr17:6899364	ALOX12	0.47	5.62	0.42	9.42e-8	Tonsillectomy;
UCEC	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.48	-4.85	-0.37	3.08e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.62	-5.5	-0.41	1.62e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg21856205	chr7:94953877	PON1	-0.55	-5.16	-0.39	7.96e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg26162295	chr17:38119207	GSDMA	0.3	4.53	0.35	1.19e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.36	-5.52	-0.41	1.49e-7	Ulcerative colitis;
UCEC	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg12339802	chr1:38156545	C1orf109	-0.52	-4.59	-0.35	9.42e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.58	4.69	0.36	6.07e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7781557	1.000	rs2041094	chr7:102495434	C/T	cg06322601	chr7:102330635	NA	0.66	5.51	0.41	1.59e-7	Colorectal adenoma (advanced);
UCEC	cis	rs17433710	0.500	rs988383	chr1:162625756	C/T	cg19264028	chr1:162630153	DDR2	-0.88	-5.95	-0.44	1.85e-8	Dupuytren's disease;
UCEC	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.44	0.41	2.14e-7	Blood protein levels;
UCEC	cis	rs6670533	0.571	rs56386478	chr1:24861128	G/A	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	6e-6	Cardiac Troponin-T levels;
UCEC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.54	5.19	0.39	6.88e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	0.92	5.68	0.42	7.02e-8	Skin colour saturation;
UCEC	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.29	0.52	1.75e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.9	-0.49	1.42e-10	Caudate activity during reward;
UCEC	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.42	5.98	0.44	1.59e-8	Ulcerative colitis;
UCEC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.7e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12618769	0.652	rs76525766	chr2:99221088	A/G	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.46e-7	Bipolar disorder;
UCEC	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-17.76	-0.83	2.07e-38	Exhaled nitric oxide output;
UCEC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.56	5.37	0.4	3.06e-7	Chronic sinus infection;
UCEC	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.81	0.49	2.3e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18932078	chr1:2524107	MMEL1	-0.33	-5.38	-0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg01493522	chr13:37497338	NA	-0.46	-4.96	-0.38	1.9e-6	Coronary artery disease;
UCEC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.41	-4.58	-0.35	1e-5	Bipolar disorder;
UCEC	cis	rs7474896	0.778	rs11011440	chr10:38364141	T/C	cg00409905	chr10:38381863	ZNF37A	-0.6	-4.65	-0.36	7.39e-6	Obesity (extreme);
UCEC	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg20965017	chr5:231967	SDHA	-0.65	-5.83	-0.43	3.42e-8	Breast cancer;
UCEC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.61	5.77	0.43	4.58e-8	Corneal astigmatism;
UCEC	cis	rs7246967	0.866	rs34752785	chr19:23044573	T/A	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.5	5.61	0.42	9.7e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	5.1	0.39	1.05e-6	Hemoglobin concentration;
UCEC	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg14092571	chr14:90743983	NA	-0.42	-5.69	-0.42	6.63e-8	Mortality in heart failure;
UCEC	cis	rs1165668	1.000	rs1165668	chr12:104317996	G/A	cg21863207	chr12:104234989	NT5DC3	0.53	4.66	0.36	6.9e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.53	-6.54	-0.47	9.34e-10	Depression;
UCEC	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.58	-6.22	-0.46	4.82e-9	Crohn's disease;
UCEC	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg07169764	chr2:136633963	MCM6	-0.75	-7.28	-0.51	1.82e-11	Mosquito bite size;
UCEC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.58	-5.74	-0.43	5.29e-8	Platelet count;
UCEC	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg21191810	chr6:118973309	C6orf204	0.44	6.14	0.45	7.34e-9	Electrocardiographic conduction measures;
UCEC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.5	-5.06	-0.39	1.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.79	-0.37	3.97e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg11632617	chr15:75315747	PPCDC	-0.63	-7.05	-0.5	6.56e-11	Lung cancer;
UCEC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.5	-5.68	-0.42	6.82e-8	Prostate cancer;
UCEC	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.65e-11	Eye color traits;
UCEC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.73	-8.36	-0.57	4.29e-14	Menarche (age at onset);
UCEC	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.61	4.66	0.36	7.01e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	5.64	0.42	8.27e-8	Coffee consumption (cups per day);
UCEC	cis	rs56341938	0.679	rs4955637	chr3:168815099	A/G	cg21477417	chr3:169490753	MYNN	0.47	4.66	0.36	7.12e-6	Lung function (FEV1/FVC);
UCEC	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.32	-0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs13063635	0.915	rs71325092	chr3:45947018	A/G	cg16320329	chr3:45981161	FYCO1	-0.81	-4.54	-0.35	1.16e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	4.79	0.37	4.11e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.58	-5.13	-0.39	8.83e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.85	0.37	3.16e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.57	-5.97	-0.44	1.71e-8	Blood protein levels;
UCEC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.58	-0.35	9.8200000000000008e-06	Bipolar disorder and schizophrenia;
UCEC	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.58	5.24	0.4	5.6e-7	Morning vs. evening chronotype;
UCEC	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.91	8.62	0.58	9.52e-15	Colorectal adenoma (advanced);
UCEC	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg07606381	chr6:8435919	SLC35B3	-0.56	-4.86	-0.37	3.04e-6	Motion sickness;
UCEC	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg12580275	chr1:205744413	RAB7L1	0.44	4.87	0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.82	-0.43	3.62e-8	Primary biliary cholangitis;
UCEC	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg19610905	chr11:61596333	FADS2	-0.58	-5.01	-0.38	1.53e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.53	-0.47	1e-9	Initial pursuit acceleration;
UCEC	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.46	-5.03	-0.38	1.41e-6	Longevity;
UCEC	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.55	5.38	0.41	2.82e-7	Coronary artery disease;
UCEC	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.58	-5.73	-0.43	5.55e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.7	6.65	0.48	5.4e-10	Aortic root size;
UCEC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.26	0.51	2.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.58	6.59	0.48	7.37e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9739682	0.636	rs10877798	chr12:62523616	G/T	cg10081664	chr12:62102663	FAM19A2	-0.49	-4.78	-0.37	4.3e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.52	4.53	0.35	1.2e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2172802	0.570	rs10007614	chr4:62534527	G/C	cg04118610	chr4:62707027	LPHN3	-0.42	-4.58	-0.35	9.83e-6	Partial epilepsies;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.83	10.71	0.66	3.7799999999999997e-20	Longevity;Endometriosis;
UCEC	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.46	4.72	0.36	5.44e-6	Glaucoma;
UCEC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.7	0.43	6.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-7.98	-0.55	3.82e-13	Exhaled nitric oxide output;
UCEC	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg17145862	chr1:211918768	LPGAT1	-0.74	-9.41	-0.61	9.54e-17	Leprosy;
UCEC	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg15764593	chr10:829463	NA	-0.62	-4.63	-0.36	8.04e-6	Uric acid levels;
UCEC	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg13593689	chr9:129986794	NA	0.46	4.68	0.36	6.45e-6	Intraocular pressure;
UCEC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.53	0.35	1.22e-5	Rheumatoid arthritis;
UCEC	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.39	0.47	2.02e-9	Motion sickness;
UCEC	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg24069376	chr3:38537580	EXOG	0.43	5.31	0.4	3.91e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.46	5.39	0.41	2.78e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.39	-4.66	-0.36	7.05e-6	Gout;
UCEC	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.77	7.29	0.52	1.76e-11	Lung function (FEV1/FVC);
UCEC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg10820045	chr2:198174542	NA	-0.48	-5.81	-0.43	3.71e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs2386661	0.826	rs7073741	chr10:5671213	G/A	cg17085576	chr10:5658249	NA	-0.45	-4.72	-0.36	5.53e-6	Breast cancer;
UCEC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs16932667	0.929	rs7303820	chr12:5132061	G/A	cg03854198	chr12:5541311	NTF3	0.43	4.93	0.38	2.16e-6	Intelligence (childhood);
UCEC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.82	9.16	0.6	4.15e-16	Breast cancer;
UCEC	trans	rs6479901	0.895	rs10822157	chr10:65089480	A/G	cg12751693	chr12:62629162	NA	-0.59	-7.19	-0.51	3.09e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.49	4.75	0.37	4.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg16099169	chr2:106886729	NA	-0.43	-4.76	-0.37	4.6e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg07481335	chr14:65879396	FUT8;LOC645431	0.47	5.05	0.38	1.32e-6	N-glycan levels;
UCEC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs11235843	0.571	rs11235834	chr11:73353731	C/A	cg09185399	chr11:73372479	PLEKHB1	0.62	5.01	0.38	1.52e-6	Hand grip strength;
UCEC	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.56	4.63	0.36	7.86e-6	Obesity-related traits;
UCEC	cis	rs7246967	0.673	rs3951783	chr19:22839264	T/A	cg08271804	chr19:22816896	ZNF492	0.66	6.54	0.47	9.37e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	0.87	11.69	0.69	9.86e-23	Monocyte percentage of white cells;
UCEC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg17833184	chr10:135191291	PAOX	0.6	5.1	0.39	1.04e-6	Lifespan;
UCEC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.67	-8.0	-0.55	3.49e-13	Mean corpuscular volume;
UCEC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.47	4.7	0.36	5.87e-6	Blood protein levels;
UCEC	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg12339802	chr1:38156545	C1orf109	-0.59	-4.91	-0.38	2.36e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-5.1	-0.39	1.02e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg07041428	chr4:1763019	NA	0.45	4.58	0.35	9.9e-6	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs75804782	0.572	rs76084375	chr2:239301193	T/C	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg01072550	chr1:21505969	NA	-0.62	-6.6	-0.48	7.11e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.24e-8	Systemic lupus erythematosus;
UCEC	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.06	-0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	5.08	0.39	1.13e-6	Electrocardiographic conduction measures;
UCEC	cis	rs10924970	0.967	rs10495362	chr1:235390396	T/C	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12311346	chr5:56204834	C5orf35	-0.52	-4.99	-0.38	1.7e-6	Coronary artery disease;
UCEC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg09654669	chr8:57350985	NA	-0.57	-6.46	-0.47	1.44e-9	Obesity-related traits;
UCEC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg26114124	chr12:9217669	LOC144571	0.4	4.78	0.37	4.3e-6	Sjögren's syndrome;
UCEC	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.72	-8.89	-0.59	2e-15	Hip circumference;
UCEC	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.8	5.17	0.39	7.51e-7	Cognitive function;
UCEC	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.54	5.67	0.42	7.31e-8	Longevity;
UCEC	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-1.03	-4.56	-0.35	1.08e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.57	-6.03	-0.45	1.25e-8	Bone properties (heel);
UCEC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.64	5.31	0.4	4e-7	Obesity-related traits;
UCEC	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.83	8.97	0.59	1.24e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-0.85	-6.05	-0.45	1.14e-8	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
UCEC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.89	10.39	0.65	2.62e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.46	4.68	0.36	6.37e-6	Aortic root size;
UCEC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg03146154	chr1:46216737	IPP	0.44	4.7	0.36	5.93e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.54	5.3	0.4	4.21e-7	Mammographic density (dense area);
UCEC	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.11	-0.6	5.62e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.77	0.37	4.33e-6	Diabetic retinopathy;
UCEC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.5	5.97	0.44	1.74e-8	Oral cavity cancer;
UCEC	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.48	4.73	0.36	5.27e-6	Colorectal cancer;
UCEC	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.72	7.56	0.53	4e-12	Primary sclerosing cholangitis;
UCEC	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	trans	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg15509575	chr4:2286509	ZFYVE28	0.41	7.19	0.51	3.08e-11	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.53	-6.06	-0.45	1.1e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.92e-6	Breast cancer;
UCEC	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.63	6.15	0.45	6.88e-9	Vitamin D levels;
UCEC	cis	rs4237845	0.611	rs7978588	chr12:58304783	G/C	cg02175503	chr12:58329896	NA	0.79	8.31	0.57	5.85e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1109861	0.783	rs609854	chr10:11231959	C/G	cg23397013	chr10:10571132	NA	-0.35	-4.7	-0.36	5.95e-6	Urinary albumin-to-creatinine ratio;
UCEC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.44	-6.04	-0.45	1.22e-8	Prostate cancer;
UCEC	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg08886695	chr4:3369023	RGS12	-0.53	-5.85	-0.43	3e-8	Serum sulfate level;
UCEC	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.9	-0.55	6.12e-13	Total cholesterol levels;
UCEC	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg16060761	chr17:80687452	NA	-0.54	-5.12	-0.39	9.54e-7	Glycated hemoglobin levels;
UCEC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.58	6.46	0.47	1.43e-9	Monocyte percentage of white cells;
UCEC	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	1.03	9.91	0.63	4.91e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.78	-0.37	4.22e-6	Response to antipsychotic treatment;
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.78	0.59	3.81e-15	Prudent dietary pattern;
UCEC	cis	rs10412972	0.943	rs8105064	chr19:52158712	A/G	cg13729816	chr19:52954722	NA	-0.4	-4.51	-0.35	1.31e-5	Plasma plasminogen levels;
UCEC	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.65	4.57	0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.09	-0.39	1.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg21772509	chr8:41503840	NKX6-3	0.51	5.72	0.43	5.9e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	0.76	6.17	0.45	6.24e-9	Blood protein levels;
UCEC	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.9	-10.87	-0.67	1.41e-20	Blood metabolite levels;
UCEC	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg21253087	chr9:139290292	SNAPC4	0.42	4.68	0.36	6.33e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.93	-0.44	2.08e-8	Response to antipsychotic treatment;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.51	-6.56	-0.48	8.78e-10	Pubertal anthropometrics;
UCEC	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg13695892	chr22:41940480	POLR3H	0.7	5.64	0.42	8.26e-8	Vitiligo;
UCEC	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	0.92	9.15	0.6	4.51e-16	Post bronchodilator FEV1;
UCEC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.54	4.77	0.37	4.47e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.76	8.25	0.56	8.11e-14	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.61	5.62	0.42	9.29e-8	Aortic root size;
UCEC	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	0.98	7.31	0.52	1.56e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	0.92	8.56	0.58	1.39e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.75	-7.72	-0.54	1.68e-12	Tonsillectomy;
UCEC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.53	6.29	0.46	3.49e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-6.44	-0.47	1.58e-9	Glomerular filtration rate;
UCEC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.51	4.79	0.37	4.04e-6	Platelet count;
UCEC	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.4	-0.47	1.95e-9	Coffee consumption (cups per day);
UCEC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.92e-6	Breast cancer;
UCEC	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.79e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.95	12.1	0.71	8.22e-24	Monocyte count;
UCEC	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.22	-0.4	5.94e-7	Bipolar disorder;
UCEC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg16479474	chr6:28041457	NA	0.46	4.69	0.36	6.22e-6	Depression;
UCEC	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.33	-5.67	-0.42	7.5e-8	Mean corpuscular volume;
UCEC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg05962950	chr11:130786565	SNX19	0.52	4.99	0.38	1.67e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2588809	0.941	rs1080321	chr14:68712521	G/T	cg01928902	chr14:69259640	ZFP36L1	-0.64	-4.77	-0.37	4.37e-6	Breast cancer;
UCEC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.19e-10	Body mass index;
UCEC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.89	9.76	0.63	1.18e-17	Parkinson's disease;
UCEC	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg13147721	chr7:65941812	NA	-0.96	-6.6	-0.48	7.15e-10	Diabetic kidney disease;
UCEC	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg17279458	chr3:44753948	ZNF502	-0.44	-4.6	-0.36	8.89e-6	Depressive symptoms;
UCEC	cis	rs6688613	0.840	rs6695609	chr1:166953866	A/C	cg07049167	chr1:166818506	POGK	-0.57	-5.3	-0.4	4.2e-7	Refractive astigmatism;
UCEC	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg17031739	chr1:67600172	NA	0.46	4.58	0.35	9.83e-6	Psoriasis;
UCEC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-5.84	-0.43	3.17e-8	Personality dimensions;
UCEC	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.7	5.05	0.38	1.27e-6	Blood protein levels;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.54	-4.73	-0.36	5.2e-6	Carotid intima media thickness;
UCEC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-0.78	-8.07	-0.55	2.25e-13	Urate levels;
UCEC	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-9.08	-0.6	6.82e-16	Coffee consumption (cups per day);
UCEC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.22	-0.4	6.11e-7	Morning vs. evening chronotype;
UCEC	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.64	5.67	0.42	7.36e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg05775895	chr3:12838266	CAND2	0.58	5.13	0.39	8.89e-7	QRS complex (12-leadsum);
UCEC	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.86	6.77	0.49	2.92e-10	Body mass index;
UCEC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.07	-0.45	1.04e-8	Cardiac Troponin-T levels;
UCEC	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	5.43	0.41	2.27e-7	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13683864	chr3:40499215	RPL14	-0.96	-9.42	-0.61	8.72e-17	Renal cell carcinoma;
UCEC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.73	6.45	0.47	1.55e-9	Plateletcrit;Platelet count;
UCEC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.86	-10.87	-0.67	1.45e-20	Height;
UCEC	cis	rs2288327	0.841	rs16866418	chr2:179490954	C/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.54	-4.63	-0.36	8.09e-6	Atrial fibrillation;
UCEC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.67	-6.1	-0.45	9.04e-9	Diastolic blood pressure;
UCEC	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.52	-5.18	-0.39	7.11e-7	Multiple sclerosis;
UCEC	cis	rs2635047	0.638	rs2668777	chr18:44748683	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.93	-0.38	2.24e-6	Educational attainment;
UCEC	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.46	4.72	0.36	5.39e-6	Schizophrenia;
UCEC	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.73	7.22	0.51	2.56e-11	Parkinson's disease;
UCEC	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.63	-5.25	-0.4	5.29e-7	Alopecia areata;
UCEC	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.62	6.51	0.47	1.11e-9	Colorectal cancer;
UCEC	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	4.56	0.35	1.07e-5	Motion sickness;
UCEC	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.56	6.49	0.47	1.26e-9	Height;
UCEC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.46	6.45	0.47	1.51e-9	Alcohol dependence;
UCEC	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.6	7.18	0.51	3.23e-11	Obesity-related traits;
UCEC	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg04311557	chr16:71523289	ZNF19	-0.65	-5.46	-0.41	2.01e-7	Post bronchodilator FEV1;
UCEC	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg22563815	chr15:78856949	CHRNA5	0.39	5.05	0.38	1.29e-6	Sudden cardiac arrest;
UCEC	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.6	-4.85	-0.37	3.09e-6	Coronary artery calcification;
UCEC	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	5.9	0.44	2.37e-8	Bone mineral density;
UCEC	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.37	4.73	0.36	5.21e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13939156	chr17:80058883	NA	0.36	4.68	0.36	6.48e-6	Life satisfaction;
UCEC	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.59	-6.46	-0.47	1.48e-9	Type 2 diabetes;
UCEC	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.54	4.95	0.38	2.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.64	6.19	0.45	5.69e-9	Bladder cancer;
UCEC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.6	5.58	0.42	1.15e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	0.604	rs8107322	chr19:22897432	A/C	cg08271804	chr19:22816896	ZNF492	0.68	6.63	0.48	6.02e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.56	-6.22	-0.46	4.89e-9	Menarche (age at onset);
UCEC	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.51	-5.11	-0.39	9.71e-7	Total body bone mineral density;
UCEC	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.69	0.36	6.31e-6	Blood metabolite levels;
UCEC	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.63	5.5	0.41	1.63e-7	Menopause (age at onset);
UCEC	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.6	5.91	0.44	2.27e-8	Retinal vascular caliber;
UCEC	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg13695892	chr22:41940480	POLR3H	0.63	4.58	0.35	9.99e-6	Cannabis dependence symptom count;
UCEC	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Morning vs. evening chronotype;
UCEC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.71	7.85	0.54	8.06e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.59	-7.63	-0.53	2.79e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg04155231	chr12:9217510	LOC144571	0.42	5.19	0.39	6.76e-7	Sjögren's syndrome;
UCEC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.0	0.44	1.46e-8	Platelet count;
UCEC	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg00786635	chr1:25594202	NA	0.46	4.52	0.35	1.25e-5	Erythrocyte sedimentation rate;
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg20821713	chr7:1055600	C7orf50	-0.53	-5.16	-0.39	7.92e-7	Longevity;Endometriosis;
UCEC	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.96	10.53	0.66	1.1e-19	Cognitive function;
UCEC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.59e-7	Schizophrenia;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.59	-0.42	1.05e-7	Pubertal anthropometrics;
UCEC	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.2	-0.39	6.45e-7	Morning vs. evening chronotype;
UCEC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.32	-5.48	-0.41	1.77e-7	Mean corpuscular volume;
UCEC	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.64	-6.85	-0.49	1.87e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.14	9.68	0.62	1.9e-17	Opioid sensitivity;
UCEC	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.52	-5.56	-0.42	1.23e-7	Gut microbiome composition (summer);
UCEC	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.46	0.47	1.44e-9	Motion sickness;
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.49	-6.59	-0.48	7.22e-10	Body mass index;
UCEC	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.15	11.84	0.7	3.87e-23	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.24	0.46	4.36e-9	Breast cancer;
UCEC	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg19743168	chr1:23544995	NA	-0.43	-5.41	-0.41	2.53e-7	Height;
UCEC	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.71	7.52	0.53	5.04e-12	Lymphocyte counts;
UCEC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.77	-0.43	4.58e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg05714579	chr10:131428358	MGMT	-0.6	-6.75	-0.49	3.19e-10	Response to temozolomide;
UCEC	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg04202892	chr2:111875749	ACOXL	0.45	4.95	0.38	2.05e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.49	6.15	0.45	7.09e-9	Information processing speed;
UCEC	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-5.53	-0.42	1.41e-7	Asthma;
UCEC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.27e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg20307385	chr11:47447363	PSMC3	0.58	5.09	0.39	1.09e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.51	0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.18	0.39	7.09e-7	Birth weight;
UCEC	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg11189052	chr15:85197271	WDR73	0.57	4.55	0.35	1.13e-5	Schizophrenia;
UCEC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.54	-5.98	-0.44	1.6e-8	Blood metabolite levels;
UCEC	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.52	-6.28	-0.46	3.65e-9	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	4.84	0.37	3.21e-6	Height;
UCEC	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.05	0.38	1.32e-6	Blood protein levels;
UCEC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.75	7.22	0.51	2.64e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs731174	0.802	rs579908	chr1:38187447	A/G	cg06917450	chr1:38156652	C1orf109	-0.5	-4.77	-0.37	4.32e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg12024160	chr4:1254474	NA	-0.54	-5.15	-0.39	8.34e-7	Longevity;
UCEC	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-7.26	-0.51	2.07e-11	Response to antipsychotic treatment;
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.09	-0.45	9.19e-9	Parkinson's disease;
UCEC	cis	rs7246967	0.673	rs16999519	chr19:22814076	A/G	cg05241461	chr19:22816980	ZNF492	-0.54	-5.88	-0.44	2.65e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.61	0.36	8.6e-6	Bipolar disorder;
UCEC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.67	-5.98	-0.44	1.66e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.47	4.82	0.37	3.55e-6	Aortic root size;
UCEC	cis	rs8177876	0.822	rs8177940	chr16:81117394	G/A	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.67	10.14	0.64	1.23e-18	Height;
UCEC	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.55	5.99	0.44	1.53e-8	Anterior chamber depth;
UCEC	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.67	7.86	0.54	7.43e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg20965017	chr5:231967	SDHA	-0.62	-5.69	-0.42	6.61e-8	Breast cancer;
UCEC	cis	rs2376682	0.959	rs6883043	chr5:118026065	G/T	cg17593721	chr5:118788746	HSD17B4	0.5	4.61	0.36	8.57e-6	Diisocyanate-induced asthma;
UCEC	cis	rs7246967	0.544	rs400275	chr19:23015856	T/A	cg08271804	chr19:22816896	ZNF492	0.55	5.0	0.38	1.58e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.69	-8.96	-0.59	1.32e-15	Menarche (age at onset);
UCEC	cis	rs7336933	0.877	rs9525554	chr13:42505507	C/T	cg18400088	chr13:41634674	WBP4	0.57	4.88	0.37	2.7e-6	Calcium levels;
UCEC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	6.15	0.45	7e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.65	-7.42	-0.52	8.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	7.91	0.55	5.76e-13	Tonsillectomy;
UCEC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.94	10.3	0.65	4.68e-19	Cognitive function;
UCEC	cis	rs11625487	0.522	rs11845884	chr14:77966268	C/T	cg10415171	chr14:77413900	NA	0.43	4.58	0.35	9.68e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs7246967	0.611	rs16999571	chr19:22904764	C/A	cg08271804	chr19:22816896	ZNF492	0.67	6.45	0.47	1.5e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.57	-6.89	-0.49	1.51e-10	Oral cavity cancer;
UCEC	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg22598563	chr5:131563921	P4HA2	0.35	4.61	0.36	8.62e-6	Blood metabolite levels;
UCEC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.73	-6.88	-0.49	1.63e-10	Aortic root size;
UCEC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg14008862	chr17:28927542	LRRC37B2	0.69	5.14	0.39	8.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.39	-5.02	-0.38	1.47e-6	Dupuytren's disease;
UCEC	cis	rs711830	0.965	rs2072590	chr2:177042633	A/C	cg13092806	chr2:177043255	NA	0.94	9.46	0.61	7.22e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg18512352	chr11:47633146	NA	-0.42	-4.77	-0.37	4.44e-6	Subjective well-being;
UCEC	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.47	-4.64	-0.36	7.76e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.04e-6	Sudden cardiac arrest;
UCEC	cis	rs6746896	0.614	rs7582249	chr2:97463529	G/A	cg01950434	chr2:97203154	ARID5A	-0.44	-4.75	-0.36	4.83e-6	Bipolar disorder;
UCEC	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg07924653	chr4:16883525	LDB2	0.4	4.59	0.35	9.44e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.52	-4.68	-0.36	6.58e-6	Colorectal cancer;
UCEC	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg05962950	chr11:130786565	SNX19	0.47	4.82	0.37	3.61e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	0.8	10.21	0.64	7.76e-19	Monocyte percentage of white cells;
UCEC	cis	rs12367572	0.620	rs2731053	chr12:45410728	G/A	cg03114573	chr12:45410052	DBX2	-0.6	-7.33	-0.52	1.42e-11	Gut microbiome composition (summer);
UCEC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg23217946	chr19:22817039	ZNF492	0.41	4.54	0.35	1.17e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.4	4.67	0.36	6.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	0.88	9.77	0.63	1.12e-17	Dental caries;
UCEC	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.17e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.61	5.58	0.42	1.12e-7	Body mass index;
UCEC	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-5.97	-0.44	1.66e-8	Myopia (pathological);
UCEC	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-6.9	-0.49	1.44e-10	Ulcerative colitis;
UCEC	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.75	-6.23	-0.46	4.72e-9	Fibroblast growth factor basic levels;
UCEC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.98	-11.37	-0.68	6.73e-22	Height;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.83	-0.43	3.36e-8	Mortality in heart failure;
UCEC	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.57	8.37	0.57	4.24e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.33	-4.77	-0.37	4.42e-6	Alzheimer's disease (late onset);
UCEC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.72	4.85	0.37	3.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.46	-4.85	-0.37	3.08e-6	Height;
UCEC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.97	8.03	0.55	2.85e-13	Obesity-related traits;
UCEC	cis	rs11235843	0.790	rs11235881	chr11:73438237	C/T	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.99	-0.44	1.51e-8	Resting heart rate;
UCEC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-5.88	-0.44	2.62e-8	Platelet count;
UCEC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg16303742	chr3:15540471	COLQ	-0.42	-5.18	-0.39	7.3e-7	Mean platelet volume;
UCEC	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.58	5.4	0.41	2.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg17420585	chr12:42539391	GXYLT1	-0.42	-5.19	-0.39	6.94e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-5.84	-0.43	3.15e-8	Glaucoma (primary open-angle);
UCEC	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg12024160	chr4:1254474	NA	0.42	4.68	0.36	6.51e-6	Longevity;
UCEC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.43	-0.41	2.27e-7	Bipolar disorder and schizophrenia;
UCEC	trans	rs9351104	0.874	rs2225450	chr6:87399088	C/T	cg26042490	chr8:143869328	LY6D	0.5	6.69	0.48	4.37e-10	Age-related hearing impairment;
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg14078730	chr11:63896557	MACROD1	0.67	5.28	0.4	4.64e-7	Mean platelet volume;
UCEC	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg16797656	chr11:68205561	LRP5	0.46	5.1	0.39	1.05e-6	Total body bone mineral density;
UCEC	cis	rs78707713	0.535	rs3812705	chr10:71211146	A/G	cg12610070	chr10:71211762	TSPAN15	-0.4	-6.44	-0.47	1.6e-9	Venous thromboembolism;
UCEC	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.8	0.49	2.44e-10	Coffee consumption (cups per day);
UCEC	cis	rs16932667	0.929	rs7303678	chr12:5131947	G/A	cg03854198	chr12:5541311	NTF3	0.42	4.72	0.36	5.51e-6	Intelligence (childhood);
UCEC	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.94	9.41	0.61	9.34e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs9400271	0.527	rs11153169	chr6:109643521	G/T	cg01475377	chr6:109611718	NA	0.44	4.92	0.38	2.27e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg21419209	chr3:44054225	NA	-0.52	-5.58	-0.42	1.15e-7	Coronary artery disease;
UCEC	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.6	-5.72	-0.43	5.71e-8	Coronary artery disease;
UCEC	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18932078	chr1:2524107	MMEL1	-0.35	-6.06	-0.45	1.07e-8	Ulcerative colitis;
UCEC	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg19477247	chr3:113955994	ZNF80	-0.33	-4.56	-0.35	1.09e-5	IgG glycosylation;
UCEC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.49	5.24	0.4	5.55e-7	Alcohol dependence;
UCEC	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.04	-0.38	1.37e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg21419209	chr3:44054225	NA	-0.45	-4.62	-0.36	8.33e-6	Coronary artery disease;
UCEC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.36	-4.95	-0.38	2.03e-6	Longevity;
UCEC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg12024160	chr4:1254474	NA	0.61	7.04	0.5	6.65e-11	Obesity-related traits;
UCEC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.8	7.95	0.55	4.55e-13	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	6.58	0.48	7.65e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.58	0.53	3.53e-12	Ileal carcinoids;
UCEC	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-6.56	-0.48	8.67e-10	Heart rate;
UCEC	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.61	-5.06	-0.39	1.23e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.55	4.85	0.37	3.08e-6	Pulse pressure;
UCEC	cis	rs7546668	1.000	rs12124078	chr1:15869899	A/G	cg05660106	chr1:15850417	CASP9	-0.44	-4.6	-0.35	9.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg02733842	chr7:1102375	C7orf50	-0.65	-5.74	-0.43	5.17e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2281845	0.507	rs1536127	chr1:201086894	C/A	cg06714761	chr1:201096289	NA	0.55	5.9	0.44	2.38e-8	Permanent tooth development;
UCEC	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.41	0.52	8.96e-12	Eye color traits;
UCEC	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg19438565	chr8:143695827	ARC	-0.46	-4.64	-0.36	7.78e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg22974920	chr21:40686053	BRWD1	0.48	4.62	0.36	8.28e-6	Cognitive function;
UCEC	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.8200000000000008e-06	Urate levels;
UCEC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg04756594	chr16:24857601	SLC5A11	-0.5	-5.58	-0.42	1.13e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-5.55	-0.42	1.31e-7	Monocyte percentage of white cells;
UCEC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.31	0.46	3.09e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9947276	0.508	rs968685	chr18:72597283	C/T	cg07131864	chr18:72797640	NA	-0.46	-4.85	-0.37	3.1e-6	Alcohol dependence (age at onset);
UCEC	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.61	5.08	0.39	1.12e-6	Blood metabolite levels;
UCEC	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	0.97	12.02	0.7	1.28e-23	Coronary artery disease;
UCEC	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	6.57	0.48	8.37e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.5	5.79	0.43	4.1e-8	Longevity;
UCEC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.56	-5.46	-0.41	1.95e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7709377	0.574	rs11241372	chr5:115502656	T/C	cg23108291	chr5:115420582	COMMD10	0.52	5.35	0.4	3.37e-7	Metabolite levels  (X-11787);
UCEC	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg25019722	chr6:37503610	NA	-0.3	-4.73	-0.36	5.21e-6	Cognitive performance;
UCEC	cis	rs16974263	1.000	rs16974263	chr19:40913539	A/G	cg14588209	chr19:40950453	SERTAD3	-0.54	-4.84	-0.37	3.24e-6	Otitis media;Otitis media (chronic);Otitis media (recurrent);
UCEC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg06238570	chr21:40685208	BRWD1	0.78	7.71	0.54	1.69e-12	Cognitive function;
UCEC	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.63	7.09	0.5	5.14e-11	Hemoglobin concentration;
UCEC	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	0.88	5.35	0.4	3.37e-7	Skin colour saturation;
UCEC	cis	rs2862064	1.000	rs1910053	chr5:156463063	G/A	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg17515076	chr17:73810948	UNK	-0.51	-5.64	-0.42	8.31e-8	White matter hyperintensity burden;
UCEC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.44	-0.41	2.2e-7	Depression;
UCEC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.57	-6.59	-0.48	7.41e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.02	-0.38	1.46e-6	Huntington's disease progression;
UCEC	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.63	6.23	0.46	4.58e-9	Alcohol dependence;
UCEC	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg08717414	chr16:71523259	ZNF19	-0.6	-5.96	-0.44	1.77e-8	Blood protein levels;
UCEC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.63	5.14	0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.59	-7.22	-0.51	2.53e-11	Pubertal anthropometrics;
UCEC	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.76	-9.23	-0.61	2.74e-16	Extrinsic epigenetic age acceleration;
UCEC	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.05	9.27	0.61	2.15e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg26769984	chr7:1090371	C7orf50	0.5	4.88	0.37	2.74e-6	Longevity;Endometriosis;
UCEC	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.76	-0.43	4.76e-8	Fear of minor pain;
UCEC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.85	-5.38	-0.41	2.9e-7	Rheumatoid arthritis;
UCEC	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-1.1	-7.03	-0.5	7.06e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.85	9.64	0.62	2.45e-17	Dental caries;
UCEC	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.48	-4.56	-0.35	1.09e-5	Dialysis-related mortality;
UCEC	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.53	-4.65	-0.36	7.19e-6	Coronary artery disease;
UCEC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.83	0.37	3.46e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.5	4.85	0.37	3.11e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.68	5.64	0.42	8.58e-8	Corneal astigmatism;
UCEC	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.29	-0.4	4.35e-7	Morning vs. evening chronotype;
UCEC	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.73	0.54	1.59e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.13e-6	Height;
UCEC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg05738196	chr6:26577821	NA	0.64	7.34	0.52	1.35e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.45	-0.41	2.03e-7	Breast cancer;
UCEC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	5.93	0.44	2.06e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12118280	0.572	rs2152562	chr1:108732508	T/C	cg11967332	chr1:108735228	SLC25A24	0.73	7.08	0.5	5.44e-11	Myeloid white cell count;
UCEC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg13298116	chr11:62369859	EML3;MTA2	-0.44	-5.39	-0.41	2.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.73	7.04	0.5	6.97e-11	Monocyte count;
UCEC	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg00105475	chr2:10696890	NA	0.43	5.4	0.41	2.56e-7	Prostate cancer;
UCEC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.62	6.97	0.5	1e-10	Prostate cancer;
UCEC	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.64	-5.35	-0.4	3.27e-7	Initial pursuit acceleration;
UCEC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.86	8.05	0.55	2.64e-13	Body mass index;
UCEC	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.54	-6.0	-0.44	1.46e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.53	-4.83	-0.37	3.42e-6	Longevity;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.49	-5.88	-0.44	2.7e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.5	-5.37	-0.41	3e-7	Total body bone mineral density;
UCEC	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.38	-4.55	-0.35	1.13e-5	Alzheimer's disease (late onset);
UCEC	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	0.84	4.65	0.36	7.31e-6	Mitochondrial DNA levels;
UCEC	cis	rs713477	0.967	rs34652660	chr14:55919480	C/A	cg13175173	chr14:55914753	NA	-0.42	-4.55	-0.35	1.12e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg04374321	chr14:90722782	PSMC1	-0.6	-5.6	-0.42	1.03e-7	Mortality in heart failure;
UCEC	cis	rs7165102	1.000	rs28556680	chr15:66023799	G/T	cg11164506	chr15:66649558	TIPIN	-0.33	-4.63	-0.36	7.82e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.85	-10.77	-0.66	2.7e-20	White blood cell count (basophil);
UCEC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg22598563	chr5:131563921	P4HA2	-0.36	-4.75	-0.37	4.71e-6	Blood metabolite levels;
UCEC	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.81	8.07	0.55	2.35e-13	Corneal structure;
UCEC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.32	0.4	3.8e-7	Diabetic retinopathy;
UCEC	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.56	5.86	0.44	2.96e-8	Sudden cardiac arrest;
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg11965913	chr1:205819406	PM20D1	0.9	10.44	0.65	1.93e-19	Menarche (age at onset);
UCEC	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg23070574	chr3:14187308	XPC	0.41	4.63	0.36	7.82e-6	Ovarian reserve;
UCEC	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.47	5.12	0.39	9.46e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs883565	0.606	rs883349	chr3:39067925	T/C	cg01426195	chr3:39028469	NA	-0.7	-8.9	-0.59	1.93e-15	Handedness;
UCEC	cis	rs5743618	0.537	rs7694115	chr4:38779094	A/G	cg06935464	chr4:38784597	TLR10	0.44	4.54	0.35	1.14e-5	Asthma;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.9	0.44	2.42e-8	Monocyte percentage of white cells;
UCEC	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.53	-5.49	-0.41	1.74e-7	Electroencephalogram traits;
UCEC	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.59	5.03	0.38	1.42e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs59104589	0.517	rs1064767	chr2:242167337	T/C	cg12761732	chr2:242547234	THAP4	0.58	4.71	0.36	5.68e-6	Fibrinogen levels;
UCEC	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.23	-0.56	9.35e-14	Total cholesterol levels;
UCEC	cis	rs2742417	0.967	rs2742427	chr3:45736423	C/T	cg04837898	chr3:45731254	SACM1L	0.4	4.5	0.35	1.36e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.52	5.74	0.43	5.34e-8	Platelet distribution width;
UCEC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.46	-4.64	-0.36	7.5e-6	Alcohol dependence;
UCEC	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.44	4.68	0.36	6.59e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.52	-6.0	-0.44	1.44e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.5	-4.5	-0.35	1.35e-5	Pancreatic cancer;
UCEC	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	4.93	0.38	2.2e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.86	-0.37	2.96e-6	Resting heart rate;
UCEC	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-6.06	-0.45	1.1e-8	Coronary artery disease;
UCEC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.8	8.52	0.58	1.72e-14	Longevity;Endometriosis;
UCEC	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg16583315	chr14:65563665	MAX	-0.43	-5.39	-0.41	2.72e-7	Obesity-related traits;
UCEC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg17105886	chr17:28927953	LRRC37B2	0.64	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-4.93	-0.38	2.18e-6	Menarche (age at onset);
UCEC	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg08890418	chr1:21044141	KIF17	-0.47	-4.78	-0.37	4.15e-6	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs17106184	0.892	rs72900979	chr1:51190314	T/C	cg07174182	chr1:51127561	FAF1	-0.77	-4.94	-0.38	2.06e-6	Type 2 diabetes;
UCEC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.62	-6.37	-0.47	2.3e-9	Lymphocyte counts;
UCEC	cis	rs4372836	0.681	rs6419696	chr2:29010339	G/A	cg09522027	chr2:28974177	PPP1CB	-0.84	-9.24	-0.61	2.57e-16	Body mass index;
UCEC	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.59	-6.55	-0.48	9.13e-10	Refractive error;
UCEC	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.66	6.45	0.47	1.53e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.52	5.13	0.39	9.09e-7	Dilated cardiomyopathy;
UCEC	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg17764715	chr19:33622953	WDR88	0.64	6.01	0.44	1.37e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg18478394	chr8:109455254	TTC35	0.52	5.0	0.38	1.62e-6	Dupuytren's disease;
UCEC	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.66	-0.42	7.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.56	-4.98	-0.38	1.77e-6	Colorectal cancer;
UCEC	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg19743168	chr1:23544995	NA	0.48	6.18	0.45	6.14e-9	Height;
UCEC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.71	7.42	0.52	8.85e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.74	8.54	0.58	1.56e-14	IgG glycosylation;
UCEC	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.96	11.51	0.69	2.89e-22	Colorectal adenoma (advanced);
UCEC	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg04155231	chr12:9217510	LOC144571	0.39	4.82	0.37	3.48e-6	Sjögren's syndrome;
UCEC	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-0.64	-8.62	-0.58	9.92e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.04	-14.5	-0.77	3.96e-30	Myeloid white cell count;
UCEC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.46	-4.67	-0.36	6.82e-6	Dental caries;
UCEC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg07424592	chr7:64974309	NA	0.77	4.77	0.37	4.39e-6	Diabetic kidney disease;
UCEC	cis	rs2841277	0.720	rs11160827	chr14:105422228	C/T	cg15352829	chr14:105391018	PLD4	-0.43	-6.2	-0.46	5.32e-9	Rheumatoid arthritis;
UCEC	cis	rs10877945	0.935	rs11174747	chr12:63404105	A/G	cg00089798	chr12:62585204	FAM19A2	0.42	4.8	0.37	3.89e-6	Obesity-related traits;
UCEC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	6.31	0.46	3.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.7	7.61	0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg26721908	chr21:47610096	LSS	0.43	5.6	0.42	1.04e-7	Testicular germ cell tumor;
UCEC	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.64	5.92	0.44	2.17e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.65	-5.9	-0.44	2.36e-8	Body mass index;
UCEC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	6.78	0.49	2.69e-10	Type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.87	-10.57	-0.66	8.9e-20	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.85	-8.85	-0.59	2.61e-15	Prudent dietary pattern;
UCEC	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.73	0.58	5.17e-15	Alzheimer's disease;
UCEC	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg01065977	chr19:18549689	ISYNA1	-0.33	-4.57	-0.35	1.04e-5	Breast cancer;
UCEC	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.67	4.53	0.35	1.2e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.62	-4.74	-0.36	5.05e-6	Blood protein levels;
UCEC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.54	5.41	0.41	2.45e-7	Menopause (age at onset);
UCEC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.65	7.05	0.5	6.39e-11	Longevity;Endometriosis;
UCEC	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	4.98e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.75	0.36	4.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.61	-5.16	-0.39	7.89e-7	LDL cholesterol levels;
UCEC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	7.57	0.53	3.74e-12	Alzheimer's disease;
UCEC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.5	7.2	0.51	2.95e-11	Crohn's disease;
UCEC	cis	rs8181588	0.661	rs3852528	chr11:2826617	A/G	cg06582202	chr11:2889886	KCNQ1DN	-0.67	-4.54	-0.35	1.18e-5	Type 2 diabetes;
UCEC	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg01072550	chr1:21505969	NA	-0.65	-6.83	-0.49	2.06e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4499344	0.589	rs259218	chr19:33138125	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	5.42	0.41	2.42e-7	Mean platelet volume;
UCEC	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.49	5.67	0.42	7.27e-8	Glomerular filtration rate (creatinine);
UCEC	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-17.19	-0.82	5.25e-37	Exhaled nitric oxide output;
UCEC	cis	rs7120489	0.748	rs72860953	chr11:12443948	A/G	cg16908669	chr11:12441385	PARVA	-0.82	-4.63	-0.36	8.06e-6	Mortality in heart failure;
UCEC	cis	rs13098911	0.540	rs34324101	chr3:46000728	T/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg23752985	chr2:85803571	VAMP8	0.43	4.62	0.36	8.41e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.31	-0.4	3.97e-7	Resting heart rate;
UCEC	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-8.44	-0.57	2.74e-14	Colorectal cancer;
UCEC	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg20283391	chr11:68216788	NA	-0.7	-4.8	-0.37	3.79e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs6446626	0.668	rs13128495	chr4:7787049	G/A	cg06161099	chr4:7973701	ABLIM2	0.4	4.75	0.37	4.7e-6	Granulocyte-colony stimulating factor levels;
UCEC	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13939156	chr17:80058883	NA	-0.35	-4.53	-0.35	1.21e-5	Life satisfaction;
UCEC	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.55	5.06	0.39	1.21e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.46	4.72	0.36	5.44e-6	Glaucoma;
UCEC	cis	rs78487399	0.908	rs7568901	chr2:43814984	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.24	-0.4	5.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs174479	0.647	rs174461	chr11:61657401	A/C	cg01500311	chr11:61656094	FADS3	0.5	6.37	0.47	2.3e-9	Sphingolipid levels;
UCEC	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg18827107	chr12:86230957	RASSF9	-0.43	-4.72	-0.36	5.45e-6	Major depressive disorder;
UCEC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	5.61	0.42	9.82e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.61	6.23	0.46	4.66e-9	Information processing speed;
UCEC	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.59	5.55	0.42	1.3e-7	Skin colour saturation;
UCEC	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg24127310	chr10:102502104	NA	1.11	10.95	0.67	8.7e-21	Alzheimer's disease;
UCEC	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.87	0.37	2.87e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9534288	0.699	rs2146884	chr13:46660392	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-6.7	-0.48	4.18e-10	Blood protein levels;
UCEC	cis	rs9400271	0.527	rs4945829	chr6:109638828	T/C	cg01475377	chr6:109611718	NA	0.46	5.22	0.4	6.01e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.75	-7.92	-0.55	5.26e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.5	4.84	0.37	3.25e-6	Blood protein levels;
UCEC	cis	rs9472138	0.756	rs2396084	chr6:43804825	A/G	cg05547260	chr6:43611905	RSPH9	-0.37	-4.69	-0.36	6.23e-6	Type 2 diabetes;Thyroid hormone levels;
UCEC	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg16583315	chr14:65563665	MAX	-0.44	-5.83	-0.43	3.34e-8	Obesity-related traits;
UCEC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.38	-6.02	-0.44	1.36e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	5.31	0.4	3.88e-7	Ileal carcinoids;
UCEC	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.69	6.89	0.49	1.49e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7870753	0.838	rs6477497	chr9:99256570	T/C	cg25260653	chr9:99212216	HABP4	0.52	5.11	0.39	1e-6	Height;
UCEC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg13870426	chr17:30244630	NA	-0.63	-4.56	-0.35	1.06e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	7.82	0.54	9.45e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.6	8.81	0.59	3.28e-15	Prudent dietary pattern;
UCEC	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.52	4.76	0.37	4.66e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12363310	0.556	rs55854918	chr11:101672298	C/T	cg11843188	chr11:102322558	TMEM123	0.51	4.55	0.35	1.1e-5	Systemic sclerosis;
UCEC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.72	-5.3	-0.4	4.07e-7	Mean platelet volume;
UCEC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.88	-0.37	2.73e-6	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs11235843	0.571	rs10898927	chr11:73364750	G/A	cg23931323	chr11:73372278	PLEKHB1	0.63	4.85	0.37	3.05e-6	Hand grip strength;
UCEC	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.56	6.62	0.48	6.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.47	-7.01	-0.5	8.13e-11	Urinary metabolites;
UCEC	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.55	5.61	0.42	9.76e-8	Motion sickness;
UCEC	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.8	10.87	0.67	1.46e-20	Headache;
UCEC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.69	-7.0	-0.5	8.29e-11	Blood metabolite levels;
UCEC	cis	rs6715284	0.579	rs2349727	chr2:202460662	A/G	cg23517999	chr2:202814523	NA	0.45	4.53	0.35	1.21e-5	Rheumatoid arthritis;
UCEC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg13695892	chr22:41940480	POLR3H	-0.59	-4.89	-0.37	2.64e-6	Vitiligo;
UCEC	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.84	-7.71	-0.54	1.75e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1043099	0.912	rs4823085	chr22:30686226	T/C	cg23383138	chr22:30885012	SEC14L4	-0.51	-4.62	-0.36	8.34e-6	Rheumatoid arthritis;
UCEC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg09491104	chr22:46646882	C22orf40	-0.68	-7.77	-0.54	1.26e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	5.15	0.39	8.18e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.65	-6.79	-0.49	2.61e-10	Diastolic blood pressure;
UCEC	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-8.52	-0.57	1.78e-14	Exhaled nitric oxide output;
UCEC	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-0.94	-9.34	-0.61	1.43e-16	Height;
UCEC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.59	-5.56	-0.42	1.26e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg01689657	chr7:91764605	CYP51A1	0.46	5.75	0.43	5.04e-8	Breast cancer;
UCEC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.59	5.84	0.43	3.25e-8	Uric acid levels;
UCEC	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.43	6.19	0.45	5.81e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
UCEC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.6	-7.11	-0.51	4.75e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.54	-5.23	-0.4	5.81e-7	White matter hyperintensity burden;
UCEC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-6.0	-0.44	1.46e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.43	-5.85	-0.43	3.06e-8	Alcohol dependence;
UCEC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.48	-4.82	-0.37	3.6e-6	Breast cancer;
UCEC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.8	-7.97	-0.55	4.08e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-4.56	-0.35	1.08e-5	Longevity;
UCEC	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.08	-7.62	-0.53	2.93e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7246967	0.551	rs7250608	chr19:22853056	C/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.6	-6.48	-0.47	1.33e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-5.66	-0.42	7.79e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.75	7.0	0.5	8.53e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.88e-9	Prudent dietary pattern;
UCEC	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13939156	chr17:80058883	NA	0.37	4.68	0.36	6.58e-6	Life satisfaction;
UCEC	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.47	5.79	0.43	4.12e-8	Mean platelet volume;
UCEC	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.38	-0.47	2.15e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.61	-5.58	-0.42	1.12e-7	Initial pursuit acceleration;
UCEC	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg20825769	chr15:43991375	CKMT1A	-0.55	-4.52	-0.35	1.25e-5	Lung cancer in ever smokers;
UCEC	cis	rs350251	0.837	rs1641850	chr16:12188433	C/G	cg01282078	chr16:12139025	RUNDC2A	-0.54	-5.04	-0.38	1.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18932078	chr1:2524107	MMEL1	-0.37	-5.66	-0.42	7.81e-8	Ulcerative colitis;
UCEC	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.61	6.55	0.48	9.06e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg00083072	chr11:65415190	SIPA1	0.42	4.56	0.35	1.05e-5	Acne (severe);
UCEC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.51	-5.68	-0.42	7.04e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18854424	chr1:2615690	NA	0.36	5.28	0.4	4.62e-7	Ulcerative colitis;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg08208917	chr15:42565872	GANC;TMEM87A	0.64	6.71	0.48	3.84e-10	Triglyceride levels;
UCEC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.71	-6.46	-0.47	1.46e-9	Initial pursuit acceleration;
UCEC	cis	rs12234571	1.000	rs73372301	chr7:77352819	C/T	cg20048109	chr7:78158112	MAGI2	-0.52	-4.62	-0.36	8.28e-6	Obesity-related traits;
UCEC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.61	6.01	0.44	1.43e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.78	5.94	0.44	1.95e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.64	4.77	0.37	4.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.07	-0.45	1.03e-8	Prudent dietary pattern;
UCEC	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.66	6.09	0.45	9.21e-9	Corneal astigmatism;
UCEC	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.78	9.73	0.63	1.38e-17	Vitiligo;
UCEC	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.49	5.13	0.39	9.2e-7	Schizophrenia;
UCEC	cis	rs394563	0.775	rs412894	chr6:149781175	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.41	-5.0	-0.38	1.59e-6	Dupuytren's disease;
UCEC	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.5	5.15	0.39	8.34e-7	Coronary heart disease;
UCEC	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.5	6.49	0.47	1.21e-9	Bone mineral density;
UCEC	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg27529037	chr20:44575021	PCIF1	0.45	4.65	0.36	7.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.57	5.03	0.38	1.44e-6	Smoking initiation;
UCEC	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	8.07	0.55	2.25e-13	Tonsillectomy;
UCEC	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.73	0.36	5.21e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.26	-0.4	4.96e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.51	-5.08	-0.39	1.12e-6	Large artery stroke;
UCEC	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-5.55	-0.42	1.3e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.67	0.42	7.2e-8	Prudent dietary pattern;
UCEC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	5.22	0.4	5.93e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg00105475	chr2:10696890	NA	0.4	4.99	0.38	1.7e-6	Prostate cancer;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.45	-4.5	-0.35	1.35e-5	Aortic root size;
UCEC	cis	rs7870753	0.735	rs34476861	chr9:99247166	T/G	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-4.68	-0.36	6.54e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.77	8.47	0.57	2.32e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2708977	0.609	rs670498	chr2:97090227	A/G	cg22654517	chr2:96458247	NA	0.41	4.9	0.37	2.55e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.13	-0.39	8.85e-7	Parkinson's disease;
UCEC	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.47	-5.4	-0.41	2.62e-7	White matter hyperintensity burden;
UCEC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.72	5.53	0.41	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01366085	chr8:103668528	KLF10	0.55	6.7	0.48	4.19e-10	Warfarin maintenance dose;
UCEC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6942756	0.774	rs6946288	chr7:129004277	A/G	cg02491457	chr7:128862824	NA	-0.44	-4.89	-0.37	2.62e-6	White matter hyperintensity burden;
UCEC	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-7.71	-0.54	1.73e-12	Glomerular filtration rate (creatinine);
UCEC	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	1.07	7.46	0.52	7e-12	Obesity-related traits;
UCEC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg04155231	chr12:9217510	LOC144571	0.42	5.17	0.39	7.44e-7	Sjögren's syndrome;
UCEC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.89	8.35	0.57	4.62e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	8.18e-8	Resting heart rate;
UCEC	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.8	-0.37	3.79e-6	Resting heart rate;
UCEC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.07	0.39	1.2e-6	Rheumatoid arthritis;
UCEC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.15	0.39	8.07e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.63	6.09	0.45	9.33e-9	Lymphocyte counts;
UCEC	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.54	4.98	0.38	1.76e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.84	-6.49	-0.47	1.21e-9	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	6.0	0.44	1.46e-8	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs3743102	0.519	rs76496098	chr15:83229141	T/C	cg00614314	chr15:82944287	LOC80154	-0.79	-4.63	-0.36	7.97e-6	Colorectal adenoma (advanced);
UCEC	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg22598563	chr5:131563921	P4HA2	0.35	4.72	0.36	5.47e-6	Blood metabolite levels;
UCEC	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg04553112	chr3:125709451	NA	-0.7	-4.96	-0.38	1.96e-6	Blood pressure (smoking interaction);
UCEC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	8.84	0.59	2.75e-15	Mean platelet volume;
UCEC	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg15167202	chr5:149997153	SYNPO	-0.36	-4.57	-0.35	1.04e-5	HIV-1 control;
UCEC	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.04	-14.5	-0.77	3.82e-30	Myeloid white cell count;
UCEC	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.36	0.4	3.14e-7	Breast cancer;
UCEC	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.43	4.82	0.37	3.48e-6	Prudent dietary pattern;
UCEC	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg00334370	chr15:72668350	HEXA;C15orf34	0.5	4.58	0.35	9.88e-6	Red blood cell count;
UCEC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.58	4.78	0.37	4.2e-6	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg23950597	chr19:37808831	NA	-0.59	-4.66	-0.36	6.9e-6	Coronary artery calcification;
UCEC	cis	rs7246967	1.000	rs8113312	chr19:23061182	G/C	cg05241461	chr19:22816980	ZNF492	0.48	4.84	0.37	3.23e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.86	0.54	7.38e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.57	-0.35	1.03e-5	Parkinson's disease;
UCEC	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	1.04	11.7	0.69	9.33e-23	Alcohol dependence;
UCEC	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.67	-5.05	-0.38	1.27e-6	Fibroblast growth factor basic levels;
UCEC	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.5	4.77	0.37	4.4e-6	Obesity (extreme);
UCEC	cis	rs12118280	0.512	rs11185301	chr1:108741228	G/A	cg08942192	chr1:108735334	SLC25A24	0.67	4.81	0.37	3.75e-6	Myeloid white cell count;
UCEC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.64	6.11	0.45	8.35e-9	Mortality in heart failure;
UCEC	cis	rs7709377	0.597	rs11241364	chr5:115466026	T/C	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg11632617	chr15:75315747	PPCDC	0.6	5.62	0.42	9.18e-8	Lung cancer;
UCEC	cis	rs7517126	1.000	rs13375236	chr1:196842271	A/G	cg07209298	chr1:196795943	CFHR1	-0.47	-4.74	-0.36	5.08e-6	Blood protein levels;
UCEC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.5	0.62	5.42e-17	Heart rate;
UCEC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	4.69	0.36	6.3e-6	Height;
UCEC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.0	10.75	0.66	3.01e-20	White matter hyperintensity burden;
UCEC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27481254	chr8:94753071	RBM12B	0.55	6.75	0.49	3.15e-10	Warfarin maintenance dose;
UCEC	cis	rs939574	0.656	rs113370390	chr2:220132837	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.1	6.89	0.49	1.51e-10	Platelet distribution width;
UCEC	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.52	-5.28	-0.4	4.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.68	-5.79	-0.43	4.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7709377	0.597	rs55783029	chr5:115511262	A/G	cg23108291	chr5:115420582	COMMD10	0.52	5.36	0.4	3.21e-7	Metabolite levels  (X-11787);
UCEC	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.44	-5.19	-0.39	6.98e-7	Subjective well-being;
UCEC	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.62	-5.15	-0.39	8.26e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs420259	0.516	rs4968014	chr16:23523875	G/T	cg26562691	chr16:23850404	PRKCB	-0.34	-4.57	-0.35	1.04e-5	Bipolar disorder;
UCEC	cis	rs6546886	0.912	rs6745792	chr2:74284033	G/A	cg14702570	chr2:74259524	NA	-0.42	-5.2	-0.39	6.57e-7	Dialysis-related mortality;
UCEC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-5.52	-0.41	1.48e-7	Obesity-related traits;
UCEC	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.8	6.75	0.49	3.11e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-5.37	-0.4	3.02e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.41	-5.05	-0.38	1.32e-6	Subjective well-being;
UCEC	cis	rs151997	0.962	rs27475	chr5:50180439	A/C	cg06027927	chr5:50259733	NA	0.53	4.86	0.37	3.01e-6	Callous-unemotional behaviour;
UCEC	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.45	-4.65	-0.36	7.18e-6	Prostate cancer;
UCEC	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-6.63	-0.48	6.12e-10	Response to antipsychotic treatment;
UCEC	cis	rs7593468	0.867	rs7572592	chr2:36937005	C/T	cg17326313	chr2:37383568	EIF2AK2	-0.73	-4.81	-0.37	3.64e-6	Prudent dietary pattern;
UCEC	cis	rs59104589	0.617	rs60178325	chr2:242300651	A/T	cg19488206	chr2:242435732	STK25	0.54	4.87	0.37	2.83e-6	Fibrinogen levels;
UCEC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.71	7.21	0.51	2.76e-11	Menopause (age at onset);
UCEC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.48	-5.11	-0.39	9.83e-7	Colorectal cancer;
UCEC	cis	rs2309757	1	rs2309757	chr2:100807725	T/C	cg14675211	chr2:100938903	LONRF2	0.64	6.18	0.45	5.93e-9	Educational attainment (college completion);
UCEC	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.57	-6.09	-0.45	9.43e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg01874867	chr7:94954059	PON1	-0.57	-4.98	-0.38	1.73e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.32	-0.46	2.92e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg26721908	chr21:47610096	LSS	-0.37	-4.66	-0.36	7.04e-6	Testicular germ cell tumor;
UCEC	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.73	6.29	0.46	3.43e-9	Coronary artery disease;
UCEC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18252515	chr7:66147081	NA	-0.51	-5.2	-0.39	6.47e-7	Aortic root size;
UCEC	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.78	-6.64	-0.48	5.64e-10	Type 2 diabetes;
UCEC	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs773506	0.628	rs4743820	chr9:93928416	C/T	cg03243796	chr9:93920768	NA	-0.4	-5.0	-0.38	1.61e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg14092571	chr14:90743983	NA	-0.37	-4.83	-0.37	3.36e-6	Mortality in heart failure;
UCEC	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	1.05	11.95	0.7	1.98e-23	Post bronchodilator FEV1;
UCEC	cis	rs5743618	0.516	rs10024216	chr4:38764112	C/T	cg06935464	chr4:38784597	TLR10	0.44	4.63	0.36	8.01e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.56	-4.79	-0.37	3.98e-6	Menarche (age at onset);
UCEC	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-4.6	-0.36	8.87e-6	Chronic sinus infection;
UCEC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.25	-7.8	-0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.62	6.2	0.46	5.39e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.27	-0.4	4.83e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.67	-6.04	-0.45	1.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg13683864	chr3:40499215	RPL14	-0.69	-7.06	-0.5	6.19e-11	Renal cell carcinoma;
UCEC	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg12826209	chr6:26865740	GUSBL1	0.49	4.71	0.36	5.64e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs16939046	1.000	rs72656147	chr8:76082652	G/C	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.16	0.6	4.05e-16	Coffee consumption (cups per day);
UCEC	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.43	-5.45	-0.41	2.03e-7	Urinary tract infection frequency;
UCEC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg18479299	chr3:125709523	NA	-0.65	-4.5	-0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.57	-4.63	-0.36	7.88e-6	Initial pursuit acceleration;
UCEC	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.5	-6.08	-0.45	9.93e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.55	-8.12	-0.56	1.7e-13	Height;
UCEC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.59	-6.51	-0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg26769984	chr7:1090371	C7orf50	0.44	4.56	0.35	1.07e-5	Longevity;Endometriosis;
UCEC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg14067834	chr17:29058358	SUZ12P	0.58	4.53	0.35	1.21e-5	Body mass index;
UCEC	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.85	-0.49	1.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.73	6.51	0.47	1.11e-9	Coronary artery disease;
UCEC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg14078730	chr11:63896557	MACROD1	0.52	5.79	0.43	4.13e-8	Platelet count;
UCEC	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-6.58	-0.48	7.87e-10	Coronary artery disease;
UCEC	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.75	-5.36	-0.4	3.19e-7	Systemic lupus erythematosus;
UCEC	cis	rs9790314	0.589	rs9790132	chr3:160627289	A/T	cg03342759	chr3:160939853	NMD3	0.55	5.09	0.39	1.08e-6	Morning vs. evening chronotype;
UCEC	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg00409905	chr10:38381863	ZNF37A	0.47	4.51	0.35	1.34e-5	Obesity (extreme);
UCEC	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	8.52	0.57	1.79e-14	Exhaled nitric oxide output;
UCEC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.81	-0.37	3.68e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.57	5.93	0.44	2.12e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.75	0.75	3.48e-28	Height;
UCEC	cis	rs883565	0.792	rs784501	chr3:39183895	A/G	cg01426195	chr3:39028469	NA	0.59	5.95	0.44	1.92e-8	Handedness;
UCEC	cis	rs883565	0.569	rs1274973	chr3:39160441	G/A	cg01426195	chr3:39028469	NA	-0.63	-7.61	-0.53	3.01e-12	Handedness;
UCEC	cis	rs4880487	0.853	rs883490	chr10:1249567	G/C	cg03183215	chr10:1252341	ADARB2	-0.45	-5.26	-0.4	5.09e-7	Migraine;
UCEC	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg14675211	chr2:100938903	LONRF2	0.63	6.16	0.45	6.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-0.98	-4.64	-0.36	7.53e-6	Mitochondrial DNA levels;
UCEC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg16497661	chr14:103986332	CKB	0.51	5.91	0.44	2.25e-8	Body mass index;
UCEC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.67	7.6	0.53	3.2e-12	Menopause (age at onset);
UCEC	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.77	6.44	0.47	1.59e-9	Heart rate;
UCEC	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg14078730	chr11:63896557	MACROD1	0.54	4.5	0.35	1.36e-5	Mean platelet volume;
UCEC	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.61	6.14	0.45	7.26e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18252515	chr7:66147081	NA	-0.54	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.43	4.66	0.36	6.93e-6	Prostate cancer;
UCEC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.73	6.33	0.46	2.76e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg15167202	chr5:149997153	SYNPO	-0.36	-4.58	-0.35	9.98e-6	HIV-1 control;
UCEC	cis	rs7088591	0.867	rs11815367	chr10:59788952	G/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.43	4.7	0.36	5.99e-6	Monocyte count;
UCEC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.62	6.07	0.45	1.03e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-4.99	-0.38	1.7e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.62	-4.85	-0.37	3.08e-6	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.23	-0.4	5.71e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.63	6.69	0.48	4.42e-10	Retinal vascular caliber;
UCEC	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg14851346	chr12:38532713	NA	-0.48	-4.66	-0.36	6.95e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.69	6.91	0.5	1.37e-10	IgG glycosylation;
UCEC	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.59	6.05	0.45	1.17e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	5.53	0.41	1.44e-7	Joint mobility (Beighton score);
UCEC	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.5	4.68	0.36	6.49e-6	Corneal astigmatism;
UCEC	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.46	-5.25	-0.4	5.31e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.09	8.24	0.56	8.61e-14	Corneal structure;
UCEC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.47	-5.57	-0.42	1.18e-7	Cognitive function;
UCEC	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg22166914	chr1:53195759	ZYG11B	-0.75	-7.75	-0.54	1.4e-12	Monocyte count;
UCEC	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.5	5.27	0.4	4.82e-7	Schizophrenia;
UCEC	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg18827107	chr12:86230957	RASSF9	-0.42	-4.68	-0.36	6.42e-6	Major depressive disorder;
UCEC	cis	rs4654899	0.895	rs10916865	chr1:21136610	C/T	cg01072550	chr1:21505969	NA	0.54	5.51	0.41	1.55e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3011225	0.697	rs3791050	chr1:44252546	G/T	cg18124588	chr1:44821109	ERI3	0.8	4.74	0.36	5.1e-6	Amyotrophic lateral sclerosis (age of onset);
UCEC	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.84	0.43	3.15e-8	Height;
UCEC	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.89	-11.66	-0.69	1.21e-22	Height;
UCEC	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.47	4.73	0.36	5.24e-6	Vitiligo;
UCEC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.7	-6.19	-0.45	5.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.68	7.79	0.54	1.08e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	6.39	0.47	2.05e-9	Response to antipsychotic treatment;
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.58	-5.67	-0.42	7.17e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.56	6.09	0.45	9.24e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.62	4.91	0.38	2.38e-6	Gut microbiome composition (summer);
UCEC	cis	rs7246967	0.932	rs4932800	chr19:23051648	G/A	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.87	-12.6	-0.72	3.72e-25	Urate levels in lean individuals;
UCEC	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg23950597	chr19:37808831	NA	0.64	5.0	0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	0.98	9.15	0.6	4.48e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.54	4.82	0.37	3.53e-6	Prudent dietary pattern;
UCEC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-5.41	-0.41	2.49e-7	Blood protein levels;
UCEC	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.73	6.8	0.49	2.51e-10	Morning vs. evening chronotype;
UCEC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.91	8.3	0.56	6.34e-14	Bladder cancer;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg20119798	chr7:94954144	PON1	-0.51	-4.53	-0.35	1.19e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.7	7.79	0.54	1.11e-12	Ewing sarcoma;
UCEC	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.67	-7.9	-0.55	5.88e-13	Immature fraction of reticulocytes;
UCEC	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg11632617	chr15:75315747	PPCDC	-0.5	-5.0	-0.38	1.63e-6	Blood trace element (Zn levels);
UCEC	cis	rs7617773	0.823	rs9839446	chr3:48194666	T/A	cg11946769	chr3:48343235	NME6	-0.56	-4.81	-0.37	3.65e-6	Coronary artery disease;
UCEC	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	6.9	0.49	1.43e-10	Cognitive test performance;
UCEC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.4	4.67	0.36	6.87e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	1.0	11.82	0.7	4.54e-23	Cognitive function;
UCEC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.61	6.12	0.45	7.93e-9	Blood metabolite levels;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.31	-0.46	3.05e-9	Pubertal anthropometrics;
UCEC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.7	-0.36	5.85e-6	Breast cancer;
UCEC	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.58	4.74	0.36	5.09e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.34	0.4	3.49e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	0.9	7.58	0.53	3.53e-12	Orofacial clefts;
UCEC	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.81	6.4	0.47	1.92e-9	Lymphocyte counts;
UCEC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.46	-6.3	-0.46	3.23e-9	Vitamin D levels;
UCEC	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	1.08	13.99	0.76	8.42e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs73206853	0.764	rs28569834	chr12:110826208	T/G	cg12870014	chr12:110450643	ANKRD13A	0.57	5.24	0.4	5.46e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs731174	0.722	rs553888	chr1:38152509	C/G	cg06917450	chr1:38156652	C1orf109	-0.58	-6.08	-0.45	9.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.48	-4.7	-0.36	5.95e-6	Adiposity;
UCEC	trans	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-4.92	-0.38	2.28e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.65	5.84	0.43	3.19e-8	Cognitive function;
UCEC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.56	4.9	0.37	2.54e-6	Response to diuretic therapy;
UCEC	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.3e-7	Life satisfaction;
UCEC	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.45	-0.52	7.46e-12	Coronary artery disease;
UCEC	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.09	-0.39	1.1e-6	Acylcarnitine levels;
UCEC	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.59	-6.03	-0.45	1.27e-8	Age at first birth;
UCEC	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg20129853	chr10:51489980	NA	-0.4	-4.73	-0.36	5.28e-6	Prostate-specific antigen levels;
UCEC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.48	0.47	1.29e-9	Bone mineral density;
UCEC	cis	rs7246967	1.000	rs34629498	chr19:23060720	C/T	cg24889512	chr19:22816950	ZNF492	0.49	4.76	0.37	4.5e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.41	4.89	0.37	2.64e-6	Subjective well-being;
UCEC	cis	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.59	-0.35	9.44e-6	Depression;
UCEC	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.13	-13.42	-0.74	2.54e-27	Breast cancer;
UCEC	trans	rs4534959	0.546	rs77068661	chr18:62059760	C/T	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	0.78	5.14	0.39	8.67e-7	Diabetic retinopathy;
UCEC	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	1.11	11.28	0.68	1.17e-21	Corneal structure;
UCEC	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg19920283	chr7:105172520	RINT1	0.54	4.78	0.37	4.27e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.83	6.66	0.48	5.13e-10	Response to hepatitis C treatment;
UCEC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	0.88	5.61	0.42	9.89e-8	Diabetic retinopathy;
UCEC	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	7.55	0.53	4.27e-12	Bipolar disorder;
UCEC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	6.15	0.45	6.95e-9	Personality dimensions;
UCEC	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-7.1	-0.51	4.99e-11	Morning vs. evening chronotype;
UCEC	cis	rs3770752	0.791	rs11683872	chr2:37520079	G/T	cg20091297	chr2:37572423	QPCT	0.5	4.98	0.38	1.72e-6	Schizophrenia;
UCEC	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-8.79	-0.59	3.62e-15	Menarche (age at onset);
UCEC	cis	rs11867410	0.744	rs73349077	chr17:63939948	G/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.67	5.94	0.44	1.94e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg22974920	chr21:40686053	BRWD1	-0.53	-4.87	-0.37	2.82e-6	Cognitive function;
UCEC	cis	rs36051895	0.658	rs72699568	chr9:5007138	C/T	cg02405213	chr9:5042618	JAK2	-0.45	-4.51	-0.35	1.3e-5	Pediatric autoimmune diseases;
UCEC	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.41	4.94	0.38	2.08e-6	Anterior chamber depth;
UCEC	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg04155231	chr12:9217510	LOC144571	0.41	4.74	0.36	5.01e-6	Sjögren's syndrome;
UCEC	cis	rs7246967	0.932	rs62120766	chr19:23029947	G/A	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs259282	0.562	rs2021772	chr19:33107651	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.44	0.41	2.2e-7	Schizophrenia;
UCEC	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.59	-5.76	-0.43	4.81e-8	Coronary artery disease;
UCEC	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.58	-4.77	-0.37	4.48e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3802344	0.590	rs75559434	chr9:133604694	A/G	cg01474677	chr9:133586259	NA	-0.95	-4.67	-0.36	6.78e-6	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	0.92	11.66	0.69	1.18e-22	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	0.95	9.6	0.62	3.04e-17	Corneal structure;
UCEC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.41	4.53	0.35	1.19e-5	Permanent tooth development;
UCEC	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.92	0.38	2.29e-6	Breast cancer;
UCEC	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg18681998	chr4:17616180	MED28	0.62	6.7	0.48	4.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.66	6.51	0.47	1.1e-9	Lymphocyte counts;
UCEC	cis	rs13063635	0.748	rs17280623	chr3:46006341	C/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs2376682	1.000	rs6883679	chr5:118003800	A/G	cg17593721	chr5:118788746	HSD17B4	0.51	5.0	0.38	1.6e-6	Diisocyanate-induced asthma;
UCEC	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg14008862	chr17:28927542	LRRC37B2	0.72	5.46	0.41	1.94e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.68	7.66	0.53	2.25e-12	Longevity;Endometriosis;
UCEC	cis	rs847577	0.569	rs7804318	chr7:97796635	A/G	cg21770322	chr7:97807741	LMTK2	-0.86	-14.6	-0.77	2.13e-30	Breast cancer;
UCEC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.68	-6.22	-0.46	4.81e-9	Aortic root size;
UCEC	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.35	7.78	0.54	1.19e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs7570971	0.793	rs6759321	chr2:136322676	G/T	cg07169764	chr2:136633963	MCM6	0.74	7.1	0.51	5.02e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.11	-0.39	9.65e-7	Metabolite levels;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.59	-0.42	1.05e-7	Pubertal anthropometrics;
UCEC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.68	7.51	0.53	5.22e-12	Coronary artery disease;
UCEC	cis	rs7072216	0.687	rs10786417	chr10:100153904	C/T	cg19567339	chr10:100142640	NA	0.57	7.32	0.52	1.5e-11	Metabolite levels;
UCEC	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.55	-6.13	-0.45	7.65e-9	Menarche (age at onset);
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg13108194	chr13:111367256	ING1	-0.83	-4.53	-0.35	1.23e-5	Obesity-related traits;
UCEC	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.72	7.01	0.5	7.84e-11	Menopause (age at onset);
UCEC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.64	-5.85	-0.43	3e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1298062	0.825	rs1673018	chr19:50987694	A/G	cg11430371	chr19:50961752	MYBPC2	0.4	4.58	0.35	9.92e-6	Age of smoking initiation;
UCEC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.55	-4.88	-0.37	2.74e-6	Blood metabolite levels;
UCEC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13870426	chr17:30244630	NA	-0.47	-4.51	-0.35	1.31e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.59	-5.11	-0.39	1.01e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-7.23	-0.51	2.43e-11	Longevity;Endometriosis;
UCEC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	9.94	0.63	4.04e-18	Electrocardiographic conduction measures;
UCEC	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg23795048	chr12:9217529	LOC144571	0.4	4.82	0.37	3.59e-6	Sjögren's syndrome;
UCEC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.73	0.43	5.45e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.56	-5.29	-0.4	4.31e-7	Cognitive function;
UCEC	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.67	-4.87	-0.37	2.85e-6	Multiple sclerosis;
UCEC	cis	rs7937612	1.000	rs6589812	chr11:120278359	T/C	cg12584626	chr11:120203529	NA	0.52	5.14	0.39	8.52e-7	Intraocular pressure;
UCEC	cis	rs12618769	1.000	rs72825704	chr2:99239164	T/C	cg10123293	chr2:99228465	UNC50	0.46	4.82	0.37	3.48e-6	Bipolar disorder;
UCEC	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.6	-6.25	-0.46	4.24e-9	Crohn's disease;
UCEC	cis	rs7095607	0.606	rs7095774	chr10:69957554	C/T	cg18986048	chr10:69913749	MYPN	0.43	4.52	0.35	1.27e-5	Lung function (FVC);
UCEC	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.81	10.25	0.65	6.2e-19	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-0.58	-4.77	-0.37	4.35e-6	Schizophrenia;
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.83	-8.81	-0.59	3.26e-15	Prudent dietary pattern;
UCEC	cis	rs16864714	0.547	rs80070504	chr3:152640123	T/C	cg07546334	chr3:152557119	NA	0.76	4.57	0.35	1.04e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.4	4.94	0.38	2.08e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.98	9.42	0.61	8.86e-17	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.56	5.93	0.44	2.06e-8	Age at first birth;
UCEC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg05962950	chr11:130786565	SNX19	0.46	4.56	0.35	1.07e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.45	-4.93	-0.38	2.2e-6	Gout;
UCEC	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.79	0.49	2.56e-10	Motion sickness;
UCEC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.53	-5.67	-0.42	7.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	5.25	0.4	5.12e-7	Bone mineral density;
UCEC	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg05991184	chr2:219186017	PNKD	-0.55	-5.99	-0.44	1.56e-8	Colorectal cancer;
UCEC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.77	0.43	4.48e-8	Breast cancer;
UCEC	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.67	-6.41	-0.47	1.87e-9	Blood pressure (smoking interaction);
UCEC	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.75	-8.29	-0.56	6.55e-14	Facial morphology (factor 19);
UCEC	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	13.09	0.73	1.87e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.65	6.64	0.48	5.82e-10	Adiposity;
UCEC	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.86	6.18	0.45	6.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-8.36	-0.57	4.26e-14	Coronary artery disease;
UCEC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.47	-4.75	-0.36	4.75e-6	Platelet count;
UCEC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.72	7.18	0.51	3.29e-11	Aortic root size;
UCEC	cis	rs3743832	0.965	rs12448512	chr16:9215143	T/C	cg08831531	chr16:9218945	NA	-0.43	-4.57	-0.35	1.03e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.79	4.85	0.37	3.07e-6	Gut microbiome composition (summer);
UCEC	cis	rs7936323	1	rs7936323	chr11:76293758	G/A	cg17647271	chr11:76299819	NA	-0.55	-5.93	-0.44	2.07e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of white cells;Allergy;Allergic disease (asthma, hay fever or eczema);Asthma;
UCEC	cis	rs35934224	0.504	rs7288631	chr22:19836148	C/T	cg11182965	chr22:19864308	TXNRD2	-0.69	-6.94	-0.5	1.16e-10	Glaucoma (primary open-angle);
UCEC	cis	rs17123764	0.892	rs13906	chr12:49952394	C/T	cg20471783	chr12:50157085	TMBIM6	0.63	5.19	0.39	6.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs847649	0.842	rs11976237	chr7:102641383	A/G	cg18108683	chr7:102477205	FBXL13	0.61	7.41	0.52	9.32e-12	Morning vs. evening chronotype;
UCEC	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-4.85	-0.37	3.14e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.65	6.13	0.45	7.88e-9	Lymphocyte counts;
UCEC	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.63e-7	Life satisfaction;
UCEC	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.1	8.76	0.59	4.34e-15	Uric acid levels;
UCEC	cis	rs13401104	0.796	rs1466205	chr2:237121194	A/G	cg23897927	chr2:237117786	ASB18	-0.5	-4.52	-0.35	1.28e-5	Educational attainment;
UCEC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.35	-5.64	-0.42	8.35e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs8105895	0.932	rs12150930	chr19:22223687	G/C	cg24175803	chr19:22235144	ZNF257	-0.51	-4.67	-0.36	6.8e-6	Body mass index (change over time);
UCEC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.45	5.29	0.4	4.32e-7	Obesity-related traits;
UCEC	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.33	4.92	0.38	2.26e-6	Ulcerative colitis;
UCEC	cis	rs9914578	1.000	rs10459917	chr17:2009752	G/T	cg16513277	chr17:2031491	SMG6	0.47	4.82	0.37	3.54e-6	Body mass index;
UCEC	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.54	-5.48	-0.41	1.83e-7	Migraine;
UCEC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.68	-6.97	-0.5	9.74e-11	Cognitive function;
UCEC	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.55	-4.65	-0.36	7.23e-6	Pulmonary function decline;
UCEC	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.59	5.7	0.43	6.3e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.55	4.86	0.37	3.03e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	4.51	0.35	1.29e-5	Height;
UCEC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	5.1	0.39	1.04e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs4372836	0.505	rs6710082	chr2:28989977	A/C	cg09522027	chr2:28974177	PPP1CB	-0.76	-8.39	-0.57	3.63e-14	Body mass index;
UCEC	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.75	7.49	0.53	5.97e-12	Menarche (age at onset);
UCEC	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-1.12	-10.15	-0.64	1.11e-18	Dupuytren's disease;
UCEC	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-5.64	-0.42	8.44e-8	Life satisfaction;
UCEC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.62	6.0	0.44	1.48e-8	Lymphocyte counts;
UCEC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs2299682	0.826	rs116587576	chr20:9476405	T/A	cg11931762	chr20:9488920	NA	-0.72	-4.8	-0.37	3.92e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs13063635	0.915	rs1994493	chr3:45960700	C/T	cg16320329	chr3:45981161	FYCO1	-0.83	-4.76	-0.37	4.5e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.62	5.83	0.43	3.45e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.45	-6.22	-0.46	4.84e-9	Eye color traits;
UCEC	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.8	-0.37	3.78e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.12	9.31	0.61	1.69e-16	Vitiligo;
UCEC	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.72	7.63	0.53	2.65e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.49	-4.94	-0.38	2.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.92	-13.43	-0.74	2.43e-27	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.66	-0.42	7.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.42	4.97	0.38	1.86e-6	Obesity;
UCEC	cis	rs6662386	0.557	rs35214987	chr1:88226329	C/G	cg10042178	chr1:87794589	LMO4	-0.47	-4.52	-0.35	1.25e-5	Prostate-specific antigen levels;
UCEC	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	14.59	0.77	2.28e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7267005	0.661	rs78098129	chr20:34396239	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	trans	rs6788895	0.661	rs73010941	chr3:150474477	T/C	cg17319849	chr1:155214564	GBA	-0.8	-6.79	-0.49	2.53e-10	Breast cancer;
UCEC	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	5.85	0.43	3.07e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-6.39	-0.47	2.06e-9	Personality dimensions;
UCEC	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.91	13.19	0.74	1.05e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg04553112	chr3:125709451	NA	-0.72	-5.05	-0.38	1.32e-6	Blood pressure (smoking interaction);
UCEC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.49	5.11	0.39	9.95e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.68	7.92	0.55	5.31e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.12	-0.56	1.71e-13	Monocyte count;
UCEC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	5.02	0.38	1.47e-6	Breast cancer;
UCEC	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.98	-14.22	-0.76	2.05e-29	Bone mineral density;
UCEC	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs9467773	1.000	rs6918360	chr6:26577867	A/T	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg05660106	chr1:15850417	CASP9	0.54	4.85	0.37	3.14e-6	Systolic blood pressure;
UCEC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	10.62	0.66	6.49e-20	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg18016565	chr1:150552671	MCL1	0.47	4.62	0.36	8.43e-6	Melanoma;
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.7	8.24	0.56	8.86e-14	Prudent dietary pattern;
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.14	-0.39	8.72e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs16957091	0.647	rs7170376	chr15:43327104	G/C	cg15904908	chr15:43213022	TTBK2	0.49	4.77	0.37	4.33e-6	MGMT methylation in smokers;
UCEC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.89	-0.44	2.53e-8	Personality dimensions;
UCEC	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg18681998	chr4:17616180	MED28	0.62	7.23	0.51	2.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.14	18.22	0.83	1.58e-39	IgG glycosylation;
UCEC	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	4.78	0.37	4.27e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg19197139	chr17:4613644	ARRB2	0.82	6.18	0.45	5.92e-9	Lymphocyte counts;
UCEC	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.56	-6.98	-0.5	9.34e-11	Kawasaki disease;
UCEC	cis	rs7709377	0.525	rs28031	chr5:115694410	C/G	cg23108291	chr5:115420582	COMMD10	-0.5	-4.92	-0.38	2.29e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	0.52	5.84	0.43	3.25e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs240764	0.594	rs7356804	chr6:101078438	A/G	cg09795085	chr6:101329169	ASCC3	0.46	4.87	0.37	2.91e-6	Neuroticism;
UCEC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.66	-0.42	7.57e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg17279458	chr3:44753948	ZNF502	0.51	5.65	0.42	8.09e-8	Depressive symptoms;
UCEC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.52	5.32	0.4	3.87e-7	Post bronchodilator FEV1;
UCEC	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg14438399	chr17:27053147	TLCD1	0.59	4.79	0.37	3.95e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.51	6.2	0.46	5.48e-9	Total body bone mineral density;
UCEC	cis	rs4074536	0.740	rs10158386	chr1:116310189	A/C	cg21648376	chr1:116311395	CASQ2	-0.51	-5.0	-0.38	1.6e-6	QRS duration;
UCEC	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.77	-9.0	-0.6	1.05e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.59	6.59	0.48	7.25e-10	Crohn's disease;
UCEC	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.48	5.93	0.44	2.09e-8	Mean platelet volume;
UCEC	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-4.63	-0.36	7.83e-6	Menarche (age at onset);
UCEC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.7	-7.51	-0.53	5.19e-12	Lung cancer;
UCEC	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.78	7.57	0.53	3.82e-12	Myeloid white cell count;
UCEC	cis	rs912062	1.000	rs942073	chr9:840971	A/G	cg14267263	chr9:841436	DMRT1	0.67	4.83	0.37	3.46e-6	Obesity-related traits;
UCEC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.57	-8.25	-0.56	8.27e-14	Sense of smell;
UCEC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.46	4.83	0.37	3.42e-6	Platelet count;
UCEC	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06762426	chr11:62420836	INTS5	0.86	4.73	0.36	5.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.56	-5.68	-0.42	7.03e-8	Primary sclerosing cholangitis;
UCEC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.39	-9.01	-0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-7.13	-0.51	4.14e-11	Heart rate;
UCEC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24308560	chr3:49941425	MST1R	0.43	4.52	0.35	1.29e-5	Body mass index;
UCEC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	0.94	5.75	0.43	4.97e-8	Skin colour saturation;
UCEC	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.21	-0.4	6.15e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.84	0.43	3.23e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.71	4.6	0.35	8.94e-6	Obsessive-compulsive symptoms;
UCEC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	7.09	0.5	5.26e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg22974920	chr21:40686053	BRWD1	0.62	5.52	0.41	1.53e-7	Cognitive function;
UCEC	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.51	4.98	0.38	1.73e-6	Dupuytren's disease;
UCEC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.35	4.91	0.38	2.43e-6	Crohn's disease;
UCEC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.85	9.21	0.6	3.16e-16	Dental caries;
UCEC	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.74	-6.86	-0.49	1.79e-10	Morning vs. evening chronotype;
UCEC	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.43	-5.32	-0.4	3.88e-7	Refractive error;
UCEC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.0	0.5	8.35e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7113850	0.541	rs7948382	chr11:24246608	T/C	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7246967	0.932	rs4932801	chr19:23051653	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs34172651	1.000	rs34172651	chr16:24766841	T/C	cg00339695	chr16:24857497	SLC5A11	0.48	5.48	0.41	1.83e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.76	-8.88	-0.59	2.19e-15	Menarche (age at onset);
UCEC	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.7	-0.36	6.01e-6	Coronary artery disease;
UCEC	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.68	6.63	0.48	6.03e-10	Mood instability;
UCEC	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.58	-5.02	-0.38	1.47e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg13683864	chr3:40499215	RPL14	-0.58	-6.36	-0.46	2.41e-9	Renal cell carcinoma;
UCEC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.78	8.1	0.56	1.94e-13	Parkinson's disease;
UCEC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.63	-5.18	-0.39	7.3e-7	Initial pursuit acceleration;
UCEC	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.65	4.63	0.36	7.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg21605333	chr4:119757512	SEC24D	0.89	4.62	0.36	8.47e-6	Cannabis dependence symptom count;
UCEC	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.66	5.95	0.44	1.9e-8	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.62	6.54	0.47	9.35e-10	Immature fraction of reticulocytes;
UCEC	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.77	9.23	0.61	2.7e-16	Coronary artery disease;
UCEC	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.81	0.49	2.29e-10	Bipolar disorder;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.52	-5.84	-0.43	3.15e-8	Pubertal anthropometrics;
UCEC	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.43	-4.91	-0.38	2.37e-6	Glycated hemoglobin levels;
UCEC	cis	rs7246967	0.673	rs2915932	chr19:22843701	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.42	0.47	1.75e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.56	8.21	0.56	1.04e-13	Sense of smell;
UCEC	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.53	-0.35	1.2e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg03714773	chr7:91764589	CYP51A1	0.42	4.91	0.38	2.41e-6	Breast cancer;
UCEC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.57	-5.69	-0.42	6.74e-8	Lymphocyte counts;
UCEC	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.8	-8.83	-0.59	2.89e-15	Height;
UCEC	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg01072550	chr1:21505969	NA	0.62	6.56	0.48	8.53e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg12483005	chr1:23474871	LUZP1	0.41	4.62	0.36	8.19e-6	Height;
UCEC	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.6	-6.62	-0.48	6.34e-10	Crohn's disease;
UCEC	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.67	7.57	0.53	3.69e-12	Crohn's disease;
UCEC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	0.89	8.32	0.57	5.42e-14	Cognitive function;
UCEC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.64	6.49	0.47	1.21e-9	Dental caries;
UCEC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.63	0.36	8.1e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg13147721	chr7:65941812	NA	0.92	6.04	0.45	1.18e-8	Diabetic kidney disease;
UCEC	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.71	8.59	0.58	1.17e-14	Crohn's disease;
UCEC	cis	rs925228	0.955	rs4665646	chr2:24144685	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.56	4.82	0.37	3.52e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.75	7.5	0.53	5.73e-12	Post bronchodilator FEV1;
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.34	-0.46	2.72e-9	Depression;
UCEC	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	9.03	0.6	9.01e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4924997	0.772	rs2018675	chr17:19441531	A/G	cg19949948	chr17:19361230	NA	0.41	5.05	0.38	1.28e-6	Lymphocyte counts;
UCEC	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	4.98e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.67	5.85	0.43	3e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	0.59	7.27	0.51	1.92e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.7	7.25	0.51	2.19e-11	Menopause (age at onset);
UCEC	cis	rs1978968	0.763	rs35276871	chr22:18459040	C/T	cg03078520	chr22:18463400	MICAL3	-0.57	-6.12	-0.45	8.03e-9	Presence of antiphospholipid antibodies;
UCEC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.94	-9.0	-0.6	1.07e-15	Initial pursuit acceleration;
UCEC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.73	0.58	5.29e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg07930552	chr6:133119739	C6orf192	0.81	4.58	0.35	9.84e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.53	5.96	0.44	1.78e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.69	7.57	0.53	3.89e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.94	0.59	1.54e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.71	-6.51	-0.47	1.1e-9	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.49	4.96	0.38	1.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs611744	0.870	rs672243	chr8:109098742	G/A	cg18478394	chr8:109455254	TTC35	0.52	5.57	0.42	1.18e-7	Dupuytren's disease;
UCEC	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.33	4.77	0.37	4.36e-6	Sense of smell;
UCEC	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.83	8.59	0.58	1.15e-14	Longevity;Endometriosis;
UCEC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.57	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.75e-9	Blood metabolite levels;
UCEC	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.67	-0.36	6.74e-6	Monocyte percentage of white cells;
UCEC	cis	rs7122539	0.734	rs2513658	chr11:66628249	G/A	cg24851651	chr11:66362959	CCS	-0.42	-5.32	-0.4	3.75e-7	HIV-1 susceptibility;
UCEC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.51	5.67	0.42	7.37e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.82	-11.41	-0.69	5.37e-22	Post bronchodilator FEV1;
UCEC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.69	5.93	0.44	2.12e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg14008862	chr17:28927542	LRRC37B2	0.8	4.73	0.36	5.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.85	8.28	0.56	7.08e-14	Schizophrenia;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg27391334	chr7:1352002	NA	0.35	4.54	0.35	1.14e-5	Longevity;Endometriosis;
UCEC	cis	rs4774830	0.744	rs62046381	chr15:56300281	T/G	cg24530489	chr15:56299380	NA	-0.66	-4.64	-0.36	7.69e-6	Delta-5 desaturase activity;
UCEC	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.56	-5.93	-0.44	2.11e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg14008862	chr17:28927542	LRRC37B2	0.73	4.95	0.38	2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.71	0.36	5.71e-6	Parkinson's disease;
UCEC	cis	rs9287719	0.639	rs2357649	chr2:10696788	C/T	cg00105475	chr2:10696890	NA	-0.43	-5.63	-0.42	8.89e-8	Prostate cancer;
UCEC	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.79	-7.86	-0.54	7.53e-13	Schizophrenia;
UCEC	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.61	-5.88	-0.44	2.72e-8	White matter hyperintensity burden;
UCEC	cis	rs17433710	0.500	rs7411405	chr1:162626910	G/A	cg19264028	chr1:162630153	DDR2	-0.89	-6.22	-0.46	4.93e-9	Dupuytren's disease;
UCEC	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.65	6.32	0.46	3e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg21521518	chr4:53727714	RASL11B	0.72	4.94	0.38	2.1e-6	Optic nerve measurement (cup area);
UCEC	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg07930552	chr6:133119739	C6orf192	0.94	8.59	0.58	1.17e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg13736514	chr6:26305472	NA	-0.41	-4.54	-0.35	1.17e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs6722750	0.870	rs35899183	chr2:64408776	C/G	cg22352474	chr2:64371530	PELI1	0.54	5.09	0.39	1.06e-6	Neuroticism;
UCEC	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg18016565	chr1:150552671	MCL1	0.48	4.78	0.37	4.23e-6	Melanoma;
UCEC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg17420585	chr12:42539391	GXYLT1	-0.45	-5.66	-0.42	7.69e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs10012307	1.000	rs1878312	chr4:137489394	G/A	cg12033966	chr4:138453416	PCDH18	-0.71	-4.89	-0.37	2.59e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-4.91	-0.38	2.36e-6	Total cholesterol levels;
UCEC	cis	rs5167	0.504	rs7246900	chr19:45454236	G/A	cg09555818	chr19:45449301	APOC2	0.45	5.89	0.44	2.51e-8	Blood protein levels;
UCEC	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.95	8.79	0.59	3.58e-15	Diastolic blood pressure;
UCEC	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.63	-5.87	-0.44	2.83e-8	Resting heart rate;
UCEC	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.58	-6.37	-0.47	2.28e-9	Type 2 diabetes;
UCEC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.13	14.03	0.76	6.64e-29	Cognitive function;
UCEC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg26031613	chr14:104095156	KLC1	0.64	6.48	0.47	1.28e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.48	-4.94	-0.38	2.13e-6	Aortic root size;
UCEC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.71	6.09	0.45	9.3e-9	Coronary artery disease;
UCEC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg16414796	chr11:1413890	BRSK2	-0.34	-4.52	-0.35	1.24e-5	Alzheimer's disease (late onset);
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg01013738	chr7:1149705	C7orf50	-0.5	-4.82	-0.37	3.57e-6	Longevity;Endometriosis;
UCEC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18252515	chr7:66147081	NA	0.54	5.25	0.4	5.27e-7	Aortic root size;
UCEC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.67	6.73	0.49	3.56e-10	Lymphocyte counts;
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.65	7.5	0.53	5.43e-12	Menarche (age at onset);
UCEC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.49	5.47	0.41	1.9e-7	Tonsillectomy;
UCEC	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.38	4.78	0.37	4.21e-6	Blood metabolite levels;
UCEC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.62	0.48	6.3e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.65	5.28	0.4	4.47e-7	Corneal astigmatism;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.61	8.23	0.56	9.48e-14	Prudent dietary pattern;
UCEC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.11	14.19	0.76	2.46e-29	Cognitive function;
UCEC	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.55	7.93	0.55	5.17e-13	Coronary artery disease or large artery stroke;
UCEC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.51	-6.81	-0.49	2.31e-10	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.51	6.02	0.44	1.35e-8	Sitting height ratio;
UCEC	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg22166914	chr1:53195759	ZYG11B	0.78	8.18	0.56	1.2e-13	Monocyte count;
UCEC	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg01689657	chr7:91764605	CYP51A1	-0.43	-5.32	-0.4	3.87e-7	Breast cancer;
UCEC	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	6.02	0.44	1.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs12928939	0.911	rs77823468	chr16:71828616	C/T	cg03805757	chr16:71968109	PKD1L3	-0.46	-4.67	-0.36	6.71e-6	Post bronchodilator FEV1;
UCEC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.07	0.39	1.2e-6	Rheumatoid arthritis;
UCEC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.94	10.94	0.67	9.16e-21	Breast cancer;
UCEC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.37	4.77	0.37	4.37e-6	Body mass index;
UCEC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.54	4.86	0.37	2.92e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.11	-0.39	9.65e-7	Joint mobility (Beighton score);
UCEC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.56	4.91	0.38	2.37e-6	Corneal astigmatism;
UCEC	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.0	-0.38	1.58e-6	Bipolar disorder;
UCEC	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.45	4.56	0.35	1.05e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-0.97	-7.23	-0.51	2.41e-11	Body mass index;
UCEC	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.54	-6.77	-0.49	2.89e-10	Monocyte percentage of white cells;
UCEC	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.59	6.08	0.45	1e-8	Retinal vascular caliber;
UCEC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.93	-0.44	2.03e-8	Tonsillectomy;
UCEC	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.72	7.13	0.51	4.23e-11	Smoking behavior;
UCEC	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg18232548	chr7:50535776	DDC	-0.66	-7.45	-0.52	7.55e-12	Body mass index;
UCEC	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.65	-0.75	6.28e-28	Schizophrenia;
UCEC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.65	4.6	0.35	8.93e-6	Schizophrenia;
UCEC	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.52	-5.77	-0.43	4.49e-8	Life satisfaction;
UCEC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.69	-7.09	-0.5	5.35e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	-0.56	-6.29	-0.46	3.41e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.53	0.42	1.39e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.59	5.26	0.4	4.99e-7	Corneal astigmatism;
UCEC	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.54	0.35	1.16e-5	Tonsillectomy;
UCEC	cis	rs4654899	0.580	rs1977296	chr1:21091543	G/T	cg01072550	chr1:21505969	NA	-0.48	-4.75	-0.36	4.74e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg06521331	chr12:34319734	NA	-0.61	-4.84	-0.37	3.18e-6	Morning vs. evening chronotype;
UCEC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-1.02	-8.51	-0.57	1.89e-14	White matter hyperintensity burden;
UCEC	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.41	-5.0	-0.38	1.59e-6	Dilated cardiomyopathy;
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.81	0.37	3.66e-6	Platelet count;
UCEC	cis	rs12367572	0.641	rs7964973	chr12:45402893	T/C	cg03114573	chr12:45410052	DBX2	-0.51	-5.74	-0.43	5.11e-8	Gut microbiome composition (summer);
UCEC	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.67	7.78	0.54	1.17e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.82	9.02	0.6	9.6e-16	Menarche (age at onset);
UCEC	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg06784218	chr1:46089804	CCDC17	-0.42	-4.81	-0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.53	-5.01	-0.38	1.52e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.88	9.3	0.61	1.77e-16	Cognitive function;
UCEC	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.15e-6	Coronary artery calcification;
UCEC	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.51	-6.25	-0.46	4.19e-9	Mean platelet volume;
UCEC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26207909	chr14:103986467	CKB	0.52	5.71	0.43	6.09e-8	Body mass index;
UCEC	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.54	6.11	0.45	8.41e-9	Breast size;
UCEC	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg23625390	chr15:77176239	SCAPER	0.48	4.72	0.36	5.38e-6	Blood metabolite levels;
UCEC	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg20560298	chr2:73613845	ALMS1	-0.5	-4.89	-0.37	2.66e-6	Schizophrenia;
UCEC	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	4.71	0.36	5.57e-6	IgG glycosylation;
UCEC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.46	-5.31	-0.4	3.97e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.61	7.31	0.52	1.6e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.88e-9	Prudent dietary pattern;
UCEC	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg05714579	chr10:131428358	MGMT	0.49	5.15	0.39	8.09e-7	Response to temozolomide;
UCEC	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	15.89	0.8	9.78e-34	Testicular germ cell tumor;
UCEC	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.51	-4.9	-0.37	2.54e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg17294928	chr15:75287854	SCAMP5	0.48	5.0	0.38	1.6e-6	Caffeine consumption;
UCEC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg27624424	chr6:160112604	SOD2	0.56	4.55	0.35	1.1e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11871910	chr12:69753446	YEATS4	0.66	6.58	0.48	7.67e-10	Response to diuretic therapy;
UCEC	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-10.12	-0.64	1.33e-18	Schizophrenia;
UCEC	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	1.16	7.31	0.52	1.62e-11	Sexual dysfunction (female);
UCEC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	0.83	10.38	0.65	2.81e-19	Bone mineral density;
UCEC	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg23795048	chr12:9217529	LOC144571	0.41	4.89	0.37	2.6e-6	Sjögren's syndrome;
UCEC	cis	rs883565	0.569	rs7637036	chr3:38997778	C/T	cg01426195	chr3:39028469	NA	-0.58	-6.86	-0.49	1.76e-10	Handedness;
UCEC	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg14517863	chr17:44321492	NA	0.4	5.29	0.4	4.29e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	5.12	0.39	9.33e-7	Breast cancer;
UCEC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.74	6.59	0.48	7.19e-10	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.64	5.65	0.42	8.19e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg09491104	chr22:46646882	C22orf40	-0.67	-7.6	-0.53	3.22e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.62	0.42	9.13e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-0.96	-4.57	-0.35	1.02e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.86	8.87	0.59	2.22e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.44	-5.47	-0.41	1.87e-7	Fibrinogen levels;
UCEC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg19318889	chr4:1322082	MAEA	0.49	5.28	0.4	4.52e-7	Obesity-related traits;
UCEC	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.49	0.41	1.71e-7	LDL cholesterol;
UCEC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.57	-5.53	-0.42	1.4e-7	Lymphocyte counts;
UCEC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Body mass index;
UCEC	cis	rs2901460	0.509	rs6750080	chr2:62071542	C/T	cg02183531	chr2:62113199	CCT4	-0.56	-4.72	-0.36	5.45e-6	Mean corpuscular volume;
UCEC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.5	5.18	0.39	7.1e-7	Blood protein levels;
UCEC	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	1.18	14.71	0.77	1.1e-30	Body mass index;
UCEC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.58	-6.74	-0.49	3.34e-10	Prostate cancer;
UCEC	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg20560298	chr2:73613845	ALMS1	-0.61	-5.52	-0.41	1.51e-7	Metabolite levels;
UCEC	cis	rs1519814	0.740	rs2326433	chr8:121043723	T/A	cg22335954	chr8:121166405	COL14A1	-0.53	-4.52	-0.35	1.26e-5	Breast cancer;
UCEC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.7	0.48	4.25e-10	Cognitive test performance;
UCEC	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg01657329	chr11:68192670	LRP5	-0.44	-5.08	-0.39	1.14e-6	Total body bone mineral density;
UCEC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg01689657	chr7:91764605	CYP51A1	0.48	6.07	0.45	1.03e-8	Breast cancer;
UCEC	cis	rs12738007	0.544	rs12045777	chr1:29429004	A/G	cg05928980	chr1:29567425	PTPRU	-0.44	-4.82	-0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	0.64	7.26	0.51	2.13e-11	Triglycerides;
UCEC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	17.62	0.82	4.64e-38	IgG glycosylation;
UCEC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg26721908	chr21:47610096	LSS	-0.38	-4.7	-0.36	5.94e-6	Testicular germ cell tumor;
UCEC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-4.56	-0.35	1.08e-5	Gut microbiome composition (summer);
UCEC	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.99	0.76	8.13e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-1.03	-10.14	-0.64	1.21e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.71	6.77	0.49	2.84e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7246967	0.611	rs7250964	chr19:22822494	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24249390	chr15:90295951	MESP1	-0.39	-4.54	-0.35	1.17e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.51	5.0	0.38	1.6e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.83	6.98	0.5	9.21e-11	Alzheimer's disease (late onset);
UCEC	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.66	5.24	0.4	5.48e-7	Obesity-related traits;
UCEC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg08994789	chr17:28903642	LRRC37B2	0.41	4.75	0.36	4.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg09491104	chr22:46646882	C22orf40	0.69	7.47	0.52	6.68e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg10932868	chr11:921992	NA	0.38	4.54	0.35	1.18e-5	Alzheimer's disease (late onset);
UCEC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg14008862	chr17:28927542	LRRC37B2	0.63	6.0	0.44	1.43e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs678962	1.000	rs2422074	chr1:172232833	T/C	cg00042657	chr1:171753628	METTL13	-0.47	-4.77	-0.37	4.37e-6	Height;
UCEC	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.49	0.53	5.93e-12	Schizophrenia;
UCEC	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.63	6.45	0.47	1.52e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-8.24	-0.56	8.96e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.64	8.44	0.57	2.81e-14	Anterior chamber depth;
UCEC	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.41	-4.53	-0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.59	-5.56	-0.42	1.25e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.45	4.74	0.36	5.07e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.49	-4.64	-0.36	7.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	1.04	5.74	0.43	5.14e-8	Skin colour saturation;
UCEC	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.59	5.36	0.4	3.2e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7945705	0.715	rs10840123	chr11:8819015	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	4.71	0.36	5.77e-6	Hemoglobin concentration;
UCEC	cis	rs1483890	0.723	rs1483888	chr3:69413329	G/T	cg22125112	chr3:69402811	FRMD4B	0.42	4.57	0.35	1.01e-5	Resting heart rate;
UCEC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.64	8.38	0.57	3.92e-14	Anterior chamber depth;
UCEC	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.46	-0.41	2e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg07169764	chr2:136633963	MCM6	0.77	7.47	0.52	6.42e-12	Mosquito bite size;
UCEC	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg13683864	chr3:40499215	RPL14	0.61	6.49	0.47	1.26e-9	Renal cell carcinoma;
UCEC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.61	6.25	0.46	4.19e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg01072550	chr1:21505969	NA	-0.57	-5.58	-0.42	1.13e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.69	6.33	0.46	2.78e-9	Aortic root size;
UCEC	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg05991184	chr2:219186017	PNKD	-0.58	-6.63	-0.48	5.87e-10	Colorectal cancer;
UCEC	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-6.38	-0.47	2.13e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	5.98	0.44	1.61e-8	Response to bleomycin (chromatid breaks);
UCEC	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.66	7.62	0.53	2.88e-12	Vitiligo;
UCEC	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.68	-8.22	-0.56	9.92e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg10503236	chr1:231470652	EXOC8	-0.41	-4.77	-0.37	4.38e-6	Hemoglobin concentration;
UCEC	cis	rs6761276	0.525	rs12711752	chr2:113837840	C/T	cg09040174	chr2:113837401	NA	-0.49	-5.59	-0.42	1.06e-7	Protein quantitative trait loci;
UCEC	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.52	5.49	0.41	1.69e-7	Red blood cell count;
UCEC	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.5	-4.88	-0.37	2.78e-6	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.62	6.25	0.46	4.24e-9	Mean corpuscular volume;
UCEC	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg23283320	chr21:48055893	PRMT2	1.02	4.64	0.36	7.75e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.0	-0.38	1.6e-6	Personality dimensions;
UCEC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18252515	chr7:66147081	NA	-0.54	-5.25	-0.4	5.19e-7	Aortic root size;
UCEC	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.44	-0.41	2.19e-7	Metabolite levels;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-6.23	-0.46	4.65e-9	Body mass index;
UCEC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.74	-7.13	-0.51	4.26e-11	Initial pursuit acceleration;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.09	0.51	5.11e-11	Platelet count;
UCEC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.71	-7.1	-0.51	4.97e-11	Aortic root size;
UCEC	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.0	0.5	8.35e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg12024160	chr4:1254474	NA	0.48	4.51	0.35	1.29e-5	Longevity;
UCEC	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg21770322	chr7:97807741	LMTK2	-0.7	-9.94	-0.63	4.04e-18	Breast cancer;
UCEC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-5.94	-0.44	2.02e-8	Menarche (age at onset);
UCEC	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.09	-0.6	6.35e-16	Coffee consumption (cups per day);
UCEC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.45	-4.89	-0.37	2.61e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.27	-0.4	4.78e-7	Blood metabolite levels;
UCEC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12311346	chr5:56204834	C5orf35	-0.49	-4.84	-0.37	3.2e-6	Coronary artery disease;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.68	-0.48	4.6e-10	Pubertal anthropometrics;
UCEC	cis	rs4499344	0.730	rs614361	chr19:33106387	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.64	0.42	8.58e-8	Mean platelet volume;
UCEC	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.47	-6.17	-0.45	6.37e-9	Body mass index;
UCEC	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg04896959	chr15:78267971	NA	0.49	5.38	0.41	2.89e-7	Sudden cardiac arrest;
UCEC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.58	-6.79	-0.49	2.57e-10	Longevity;
UCEC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.62	-0.87	1.68e-47	Myeloid white cell count;
UCEC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	5.55	0.42	1.29e-7	Platelet count;
UCEC	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-6.63	-0.48	5.91e-10	Height;
UCEC	cis	rs8020441	1.000	rs72681672	chr14:51169600	C/T	cg04730355	chr14:51134070	SAV1	0.55	5.14	0.39	8.47e-7	Cognitive performance;
UCEC	cis	rs8105895	0.935	rs8110289	chr19:22239717	A/G	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.64e-7	Body mass index (change over time);
UCEC	cis	rs7709377	0.597	rs7733128	chr5:115474841	G/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.73	-0.49	3.46e-10	HDL cholesterol;
UCEC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg06238570	chr21:40685208	BRWD1	0.78	6.98	0.5	9.32e-11	Cognitive function;
UCEC	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.21	8.07	0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.55e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs787274	0.867	rs787279	chr9:115539514	T/C	cg13803584	chr9:115635662	SNX30	-0.66	-5.34	-0.4	3.41e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.93	0.55	5e-13	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1567532	0.574	rs13007809	chr2:79936545	A/C	cg11074070	chr2:80557293	CTNNA2	0.59	4.69	0.36	6.3e-6	Survival in pancreatic cancer;
UCEC	cis	rs7607369	0.536	rs12694443	chr2:219664977	G/T	cg02176678	chr2:219576539	TTLL4	-0.58	-6.07	-0.45	1.02e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-5.47	-0.41	1.85e-7	Multiple sclerosis;
UCEC	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.57	-5.87	-0.44	2.73e-8	Menarche (age at onset);
UCEC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.1	13.63	0.75	7.24e-28	Cognitive function;
UCEC	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	6.55	0.48	8.94e-10	Bone mineral density;
UCEC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	5.71	0.43	5.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.07	0.71	9.55e-24	Prudent dietary pattern;
UCEC	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.04	-8.64	-0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.59	4.93	0.38	2.19e-6	Longevity;
UCEC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-5.01	-0.38	1.57e-6	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.43	4.55	0.35	1.12e-5	Schizophrenia;
UCEC	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.54	4.69	0.36	6.21e-6	Response to diuretic therapy;
UCEC	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg07435449	chr11:120005650	TRIM29	0.46	4.61	0.36	8.71e-6	Stroke (pediatric);
UCEC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.4	4.68	0.36	6.35e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg09491104	chr22:46646882	C22orf40	-0.61	-6.91	-0.5	1.36e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.8	8.34	0.57	4.82e-14	Menopause (age at onset);
UCEC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.47	4.73	0.36	5.31e-6	Prostate cancer;
UCEC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-5.09	-0.39	1.06e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.96	0.38	1.94e-6	Personality dimensions;
UCEC	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.7	5.95	0.44	1.88e-8	Alzheimer's disease;
UCEC	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.82	-8.9	-0.59	1.87e-15	Cognitive function;
UCEC	cis	rs11235843	0.929	rs11235882	chr11:73443001	G/A	cg23931323	chr11:73372278	PLEKHB1	0.66	4.53	0.35	1.23e-5	Hand grip strength;
UCEC	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-4.5	-0.35	1.36e-5	Coronary artery disease;
UCEC	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.8	-8.32	-0.57	5.6e-14	Mosquito bite size;
UCEC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.63	7.34	0.52	1.34e-11	Height;
UCEC	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.02	-0.5	7.68e-11	Post bronchodilator FEV1;
UCEC	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.46	-0.41	2.02e-7	Life satisfaction;
UCEC	cis	rs7870753	0.838	rs10820741	chr9:99267553	T/C	cg25260653	chr9:99212216	HABP4	0.57	5.35	0.4	3.27e-7	Height;
UCEC	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.72	0.36	5.52e-6	Colorectal cancer;
UCEC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.59	0.35	9.39e-6	Rheumatoid arthritis;
UCEC	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-7.99	-0.55	3.61e-13	Personality dimensions;
UCEC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.55	-5.28	-0.4	4.59e-7	Homoarginine levels;
UCEC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.49	5.34	0.4	3.45e-7	Schizophrenia;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg25703541	chr22:24373054	LOC391322	-0.7	-7.19	-0.51	3.09e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-5.69	-0.42	6.67e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12365397	0.674	rs11037344	chr11:43221539	G/T	cg07515919	chr11:43391688	TTC17	-0.46	-5.51	-0.41	1.59e-7	Migraine;
UCEC	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg18681998	chr4:17616180	MED28	0.77	8.44	0.57	2.72e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg20821713	chr7:1055600	C7orf50	0.52	5.09	0.39	1.1e-6	Longevity;Endometriosis;
UCEC	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-4.86	-0.37	2.96e-6	Menarche (age at onset);
UCEC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.46	5.75	0.43	5.05e-8	Monocyte count;
UCEC	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.5	4.79	0.37	4.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs11718455	0.526	rs67553643	chr3:43928130	C/T	cg08738300	chr3:44038990	NA	0.54	4.72	0.36	5.39e-6	Coronary artery disease;
UCEC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.55	5.47	0.41	1.87e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs7710178	0.756	rs72803018	chr5:156144735	G/C	cg12943317	chr5:156479607	HAVCR1	0.74	4.51	0.35	1.29e-5	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg18681998	chr4:17616180	MED28	0.67	7.8	0.54	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10509540	0.793	rs7097903	chr10:90049968	G/C	cg10205334	chr10:89622497	PTEN;KILLIN	0.49	4.75	0.36	4.79e-6	Type 1 diabetes;
UCEC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg18721089	chr20:30220636	NA	-0.41	-5.23	-0.4	5.63e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.58	-6.87	-0.49	1.72e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.79	-0.37	3.98e-6	Tonsillectomy;
UCEC	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.26	0.46	3.94e-9	Coffee consumption (cups per day);
UCEC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.54	-5.53	-0.41	1.45e-7	Prostate cancer;
UCEC	cis	rs7766436	0.524	rs66992531	chr6:22511065	T/C	cg13666174	chr6:22585274	NA	-0.56	-4.52	-0.35	1.27e-5	Coronary artery disease;
UCEC	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	5.94	0.44	1.94e-8	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.05	0.45	1.16e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-6.17	-0.45	6.34e-9	Birth weight;
UCEC	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.55	5.74	0.43	5.26e-8	Autism;
UCEC	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg24848339	chr3:12840334	CAND2	0.4	5.04	0.38	1.32e-6	QRS complex (12-leadsum);
UCEC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.59	-6.9	-0.49	1.45e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-5.81	-0.43	3.64e-8	Hepatocellular carcinoma;
UCEC	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-1.1	-5.32	-0.4	3.78e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17102423	0.964	rs11623603	chr14:65602287	T/A	cg11161011	chr14:65562177	MAX	-0.7	-8.02	-0.55	3.06e-13	Obesity-related traits;
UCEC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.7	-8.56	-0.58	1.35e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.49	5.07	0.39	1.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs372883	0.509	rs28462110	chr21:30544318	C/T	cg24692254	chr21:30365293	RNF160	-0.56	-4.96	-0.38	1.95e-6	Pancreatic cancer;
UCEC	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.68	6.42	0.47	1.79e-9	Ovarian reserve;
UCEC	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg16797656	chr11:68205561	LRP5	0.64	8.98	0.6	1.17e-15	Total body bone mineral density;
UCEC	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.94	7.73	0.54	1.53e-12	Pediatric areal bone mineral density (radius);
UCEC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.59	-5.36	-0.4	3.12e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.51	-5.87	-0.44	2.77e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.8e-6	Breast cancer;
UCEC	cis	rs7088591	0.867	rs16911628	chr10:59779383	C/T	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.57	-5.11	-0.39	9.86e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4975616	0.714	rs37010	chr5:1349535	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.53	-6.19	-0.45	5.79e-9	Lung cancer;
UCEC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.53	4.94	0.38	2.06e-6	Alzheimer's disease;
UCEC	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.18	11.49	0.69	3.39e-22	Corneal structure;
UCEC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg14008862	chr17:28927542	LRRC37B2	0.75	4.74	0.36	4.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.21	0.46	5.19e-9	Cognitive ability;
UCEC	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	0.75	6.14	0.45	7.46e-9	Blood protein levels;
UCEC	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.69	0.58	6.52e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.93	11.11	0.68	3.45e-21	Multiple sclerosis;
UCEC	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.61	-4.68	-0.36	6.45e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.56	0.53	3.95e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.61	5.69	0.42	6.64e-8	Colorectal cancer;
UCEC	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.98	-10.53	-0.66	1.15e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.97	-0.38	1.82e-6	Colorectal cancer;
UCEC	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.51	4.8	0.37	3.94e-6	Corneal astigmatism;
UCEC	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.56	0.53	3.95e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.67	7.05	0.5	6.49e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.54	-0.42	1.35e-7	Blood metabolite levels;
UCEC	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.49	-5.73	-0.43	5.36e-8	Age at first birth;
UCEC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg21053147	chr12:120880522	NA	0.65	5.31	0.4	4.03e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.56	-6.5	-0.47	1.18e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.16	-17.4	-0.82	1.61e-37	Exhaled nitric oxide output;
UCEC	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.43	4.83	0.37	3.34e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2415984	0.846	rs11847489	chr14:46833287	A/G	cg14871534	chr14:47121158	RPL10L	0.39	4.54	0.35	1.18e-5	Number of children ever born;
UCEC	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.97	-11.29	-0.68	1.09e-21	Height;
UCEC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg18681998	chr4:17616180	MED28	0.78	7.8	0.54	1.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	0.85	8.92	0.59	1.69e-15	Primary sclerosing cholangitis;
UCEC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.61	5.06	0.38	1.25e-6	Breast cancer;
UCEC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-5.57	-0.42	1.18e-7	Chronic sinus infection;
UCEC	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg01426195	chr3:39028469	NA	-0.75	-9.83	-0.63	7.69e-18	Handedness;
UCEC	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.97	9.01	0.6	9.88e-16	Diastolic blood pressure;
UCEC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.37	-4.57	-0.35	1.02e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	0.62	6.33	0.46	2.78e-9	Vitiligo;
UCEC	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.46	-0.52	6.88e-12	Resting heart rate;
UCEC	cis	rs7072216	0.687	rs7924303	chr10:100155963	C/T	cg19567339	chr10:100142640	NA	-0.58	-7.38	-0.52	1.06e-11	Metabolite levels;
UCEC	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.1	-11.3	-0.68	1.08e-21	Post bronchodilator FEV1;
UCEC	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.93	7.24	0.51	2.35e-11	Initial pursuit acceleration;
UCEC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg21856205	chr7:94953877	PON1	-0.58	-5.09	-0.39	1.07e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg00786635	chr1:25594202	NA	0.5	5.0	0.38	1.61e-6	Erythrocyte sedimentation rate;
UCEC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg03714773	chr7:91764589	CYP51A1	0.45	5.34	0.4	3.48e-7	Breast cancer;
UCEC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-5.88	-0.44	2.69e-8	Height;
UCEC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	10.01	0.64	2.59e-18	Cognitive ability;
UCEC	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.4	0.52	9.87e-12	Homoarginine levels;
UCEC	cis	rs10012307	1.000	rs57952042	chr4:137483740	G/A	cg12033966	chr4:138453416	PCDH18	-0.72	-5.04	-0.38	1.33e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.44	-5.33	-0.4	3.67e-7	Mortality in heart failure;
UCEC	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.59	-5.32	-0.4	3.86e-7	Metabolite levels;
UCEC	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.44	4.61	0.36	8.74e-6	Schizophrenia;
UCEC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.05	8.71	0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.36	-0.52	1.2e-11	Eye color traits;
UCEC	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.59	-5.25	-0.4	5.24e-7	Mortality in heart failure;
UCEC	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg18279126	chr7:2041391	MAD1L1	0.37	4.81	0.37	3.74e-6	Schizophrenia;
UCEC	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.94	11.07	0.67	4.29e-21	Ulcerative colitis;
UCEC	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg21905437	chr5:178450457	ZNF879	0.52	5.01	0.38	1.56e-6	Pubertal anthropometrics;
UCEC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.65	-0.42	7.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.6	-6.02	-0.44	1.34e-8	Systemic lupus erythematosus;
UCEC	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.54	-4.76	-0.37	4.54e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.66	6.48	0.47	1.27e-9	Aortic root size;
UCEC	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-11.34	-0.68	8.22e-22	Primary sclerosing cholangitis;
UCEC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs78761021	0.720	rs55740146	chr17:9796599	G/A	cg26853458	chr17:9805074	RCVRN	0.38	4.66	0.36	7.07e-6	Type 2 diabetes;
UCEC	cis	rs17433710	0.500	rs72711557	chr1:162669776	G/A	cg19264028	chr1:162630153	DDR2	1.11	6.29	0.46	3.43e-9	Dupuytren's disease;
UCEC	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-4.68	-0.36	6.59e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
UCEC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.09	0.39	1.1e-6	Rheumatoid arthritis;
UCEC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.21	11.97	0.7	1.73e-23	Corneal structure;
UCEC	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg14008862	chr17:28927542	LRRC37B2	0.66	4.91	0.38	2.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.5	4.67	0.36	6.84e-6	Testicular germ cell tumor;
UCEC	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.65	-4.82	-0.37	3.49e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.11	-0.39	9.68e-7	Life satisfaction;
UCEC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg20965017	chr5:231967	SDHA	-0.59	-5.26	-0.4	5.1e-7	Breast cancer;
UCEC	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.52	5.29	0.4	4.41e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.64	-7.41	-0.52	9.02e-12	Body mass index;
UCEC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.5	6.87	0.49	1.69e-10	Homoarginine levels;
UCEC	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	5.25	0.4	5.29e-7	Mood instability;
UCEC	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.61	-4.93	-0.38	2.16e-6	Breast cancer;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.46	-4.57	-0.35	1.01e-5	Pubertal anthropometrics;
UCEC	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.01	0.67	6.15e-21	Corneal structure;
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.53	5.35	0.4	3.32e-7	Mean corpuscular hemoglobin concentration;
UCEC	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.63	5.88	0.44	2.59e-8	Platelet count;
UCEC	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.53	-5.91	-0.44	2.28e-8	Menarche (age at onset);
UCEC	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	0.86	5.96	0.44	1.78e-8	Red blood cell traits;
UCEC	trans	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3750082	0.582	rs3750079	chr7:32969419	G/A	cg05721444	chr7:32995514	FKBP9	0.56	5.99	0.44	1.52e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.34e-8	Lung cancer;
UCEC	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.63	-4.52	-0.35	1.25e-5	Gut microbiome composition (summer);
UCEC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.56	-4.67	-0.36	6.82e-6	Initial pursuit acceleration;
UCEC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg06784218	chr1:46089804	CCDC17	0.43	4.98	0.38	1.75e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-4.83	-0.37	3.39e-6	Neuroticism;
UCEC	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.71	5.12	0.39	9.26e-7	Systemic lupus erythematosus;
UCEC	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-4.62	-0.36	8.45e-6	Fear of minor pain;
UCEC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2694528	0.764	rs112511311	chr5:59872002	G/A	cg11474532	chr5:59995715	DEPDC1B	0.61	4.6	0.35	9.17e-6	Parkinson's disease;
UCEC	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.52	6.55	0.48	8.96e-10	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.49	4.98	0.38	1.73e-6	Vitiligo;
UCEC	cis	rs970548	0.954	rs2291429	chr10:45958881	A/C	cg15223267	chr10:46222474	FAM21C	0.55	5.14	0.39	8.73e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg10965384	chr11:64119977	CCDC88B	0.38	4.61	0.36	8.74e-6	Platelet count;
UCEC	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.58	6.08	0.45	9.8e-9	Motion sickness;
UCEC	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg18479299	chr3:125709523	NA	-0.6	-4.73	-0.36	5.18e-6	Blood pressure (smoking interaction);
UCEC	cis	rs259282	0.514	rs10420153	chr19:33112957	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.51	4.72	0.36	5.56e-6	Schizophrenia;
UCEC	cis	rs6876348	0.520	rs10037758	chr5:128288397	G/A	cg02841155	chr5:128301328	SLC27A6	-0.37	-5.05	-0.38	1.27e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.58	7.39	0.52	1e-11	Bone mineral density;
UCEC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.52	-4.82	-0.37	3.6e-6	Metabolic syndrome;
UCEC	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.7	6.01	0.44	1.37e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.57	7.96	0.55	4.2e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg07776626	chr8:57350775	NA	-0.43	-4.72	-0.36	5.51e-6	Obesity-related traits;
UCEC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg19318889	chr4:1322082	MAEA	0.7	8.14	0.56	1.5e-13	Longevity;
UCEC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.5	4.68	0.36	6.37e-6	Menopause (age at onset);
UCEC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg14092571	chr14:90743983	NA	0.38	4.75	0.37	4.71e-6	Mortality in heart failure;
UCEC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg05802129	chr4:122689817	NA	-0.56	-5.75	-0.43	4.99e-8	Type 2 diabetes;
UCEC	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-5.46	-0.41	1.94e-7	Subjective well-being;
UCEC	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.62	-5.43	-0.41	2.27e-7	Coronary artery disease;
UCEC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-5.07	-0.39	1.2e-6	Aortic root size;
UCEC	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.69	7.52	0.53	4.96e-12	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.54	-6.26	-0.46	4.09e-9	Type 2 diabetes;
UCEC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg05738196	chr6:26577821	NA	0.59	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7095607	0.538	rs2255136	chr10:69921733	T/A	cg18986048	chr10:69913749	MYPN	0.61	6.68	0.48	4.67e-10	Lung function (FVC);
UCEC	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-5.66	-0.42	7.52e-8	Multiple sclerosis;
UCEC	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.47	4.97	0.38	1.83e-6	Blood metabolite levels;
UCEC	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.87e-11	Mosquito bite size;
UCEC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs3853650	chr19:22880490	A/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.54	-5.12	-0.39	9.43e-7	Multiple sclerosis;
UCEC	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.55	6.82	0.49	2.17e-10	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg18032046	chr6:28092343	ZSCAN16	0.6	4.96	0.38	1.95e-6	Depression;
UCEC	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.5	6.47	0.47	1.36e-9	Cystic fibrosis severity;
UCEC	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg23000734	chr10:126850823	CTBP2	0.58	7.83	0.54	8.96e-13	Menarche (age at onset);
UCEC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.55	5.54	0.42	1.35e-7	Aortic root size;
UCEC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg14008862	chr17:28927542	LRRC37B2	0.62	4.84	0.37	3.21e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	5.05	0.38	1.29e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.71	-7.19	-0.51	2.97e-11	Breast cancer;
UCEC	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.57	5.19	0.39	6.81e-7	Hypospadias;
UCEC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.99	11.0	0.67	6.49e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-0.91	-7.78	-0.54	1.2e-12	Post bronchodilator FEV1;
UCEC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	5.49	0.41	1.76e-7	Menarche (age at onset);
UCEC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.54	5.62	0.42	9.3e-8	Red blood cell count;
UCEC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg21856205	chr7:94953877	PON1	-0.54	-4.87	-0.37	2.84e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.25	7.82	0.54	9.24e-13	Diabetic kidney disease;
UCEC	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg13683864	chr3:40499215	RPL14	-0.66	-6.55	-0.48	9.05e-10	Renal cell carcinoma;
UCEC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.94	11.71	0.69	8.92e-23	Multiple sclerosis;
UCEC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	10.03	0.64	2.3e-18	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.44	4.58	0.35	9.93e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.8	8.38	0.57	3.88e-14	Mosquito bite size;
UCEC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.54	6.75	0.49	3.11e-10	Total body bone mineral density;
UCEC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.6	-4.87	-0.37	2.91e-6	Gut microbiome composition (summer);
UCEC	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-5.32	-0.4	3.8e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.08	-0.45	1e-8	Morning vs. evening chronotype;
UCEC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.32	4.74	0.36	5.04e-6	Vitiligo;
UCEC	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24249390	chr15:90295951	MESP1	-0.41	-4.67	-0.36	6.83e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.67	-6.86	-0.49	1.74e-10	Breast cancer;
UCEC	cis	rs2708377	0.929	rs73053785	chr12:11162411	T/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.6	4.77	0.37	4.4e-6	Bitter taste perception;
UCEC	cis	rs12216499	1.000	rs16889325	chr6:159417132	G/A	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.31	0.61	1.69e-16	Platelet count;
UCEC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.54	4.51	0.35	1.33e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18252515	chr7:66147081	NA	-0.5	-4.61	-0.36	8.79e-6	Aortic root size;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs895636	1.000	rs895636	chr2:45188353	A/G	cg14345917	chr2:45180089	NA	0.53	4.78	0.37	4.21e-6	Metabolite levels;Fasting plasma glucose;
UCEC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Bipolar disorder;
UCEC	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.69	-8.14	-0.56	1.56e-13	Facial morphology (factor 23);
UCEC	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.11	-0.39	9.99e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	0.92	12.78	0.73	1.25e-25	Homoarginine levels;
UCEC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg15790184	chr11:494944	RNH1	0.54	4.61	0.36	8.57e-6	Body mass index;
UCEC	cis	rs4851266	1.000	rs12991254	chr2:100817933	T/C	cg14675211	chr2:100938903	LONRF2	0.67	6.29	0.46	3.49e-9	Educational attainment;
UCEC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	5.36	0.4	3.15e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.54	-7.0	-0.5	8.65e-11	Cancer (pleiotropy);
UCEC	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.52	-5.57	-0.42	1.2e-7	IgG glycosylation;
UCEC	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-5.22	-0.4	5.91e-7	Morning vs. evening chronotype;
UCEC	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.01	-12.37	-0.71	1.51e-24	Dilated cardiomyopathy;
UCEC	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.63	5.82	0.43	3.63e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.56	4.81	0.37	3.65e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.73	4.53	0.35	1.19e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs10121009	0.587	rs723877	chr9:35407431	A/G	cg14286155	chr9:34620395	DCTN3	-0.47	-4.58	-0.35	9.95e-6	Parkinson's disease;
UCEC	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.89	11.25	0.68	1.45e-21	Platelet distribution width;
UCEC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-5.13	-0.39	8.89e-7	Blood metabolite levels;
UCEC	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.92	8.85	0.59	2.55e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-12.0	-0.7	1.46e-23	Ulcerative colitis;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.64	-6.78	-0.49	2.75e-10	Parkinson's disease;
UCEC	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.73	7.89	0.55	6.48e-13	Breast cancer;
UCEC	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.73	-8.85	-0.59	2.54e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.62	-6.52	-0.47	1.05e-9	Menarche (age at onset);
UCEC	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16092991	chr4:15004611	CPEB2	0.61	7.34	0.52	1.31e-11	Warfarin maintenance dose;
UCEC	cis	rs6723108	0.603	rs1592	chr2:135722143	A/C	cg07169764	chr2:136633963	MCM6	0.52	5.01	0.38	1.54e-6	Type 2 diabetes;
UCEC	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.12e-7	Life satisfaction;
UCEC	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.59	5.44	0.41	2.14e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg12463550	chr7:65579703	CRCP	0.51	5.08	0.39	1.12e-6	Aortic root size;
UCEC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.84	0.37	3.23e-6	Tonsillectomy;
UCEC	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.48	6.46	0.47	1.43e-9	Age-related hearing impairment;
UCEC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.6	-7.59	-0.53	3.42e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.74	-9.52	-0.62	4.78e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.52	0.62	5.06e-17	Blood protein levels;
UCEC	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg21770322	chr7:97807741	LMTK2	0.52	6.46	0.47	1.45e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.6	-6.46	-0.47	1.45e-9	Asthma;
UCEC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg10978503	chr1:24200527	CNR2	0.37	5.01	0.38	1.56e-6	Immature fraction of reticulocytes;
UCEC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg03859395	chr2:55845619	SMEK2	1.05	14.98	0.78	2.25e-31	Metabolic syndrome;
UCEC	cis	rs60311166	1.000	rs72960212	chr3:52720489	T/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.8	5.37	0.41	3e-7	CTACK levels;
UCEC	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg09615915	chr8:7625446	FAM90A10	0.31	4.87	0.37	2.84e-6	Mood instability;
UCEC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.75	7.98	0.55	3.84e-13	Menopause (age at onset);
UCEC	cis	rs10507349	0.632	rs54434	chr13:26816934	G/C	cg01600817	chr13:26797529	RNF6	0.45	5.01	0.38	1.56e-6	Type 2 diabetes;
UCEC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.45	5.16	0.39	7.97e-7	Aortic root size;
UCEC	cis	rs1415259	0.963	rs11579850	chr1:162067222	G/T	cg19130550	chr1:161994277	OLFML2B	0.43	4.52	0.35	1.28e-5	Electrocardiographic traits;
UCEC	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.57	5.13	0.39	9.16e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg20368463	chr18:77673604	PQLC1	-0.64	-5.07	-0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.77	0.37	4.33e-6	Breast cancer;
UCEC	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-5.47	-0.41	1.86e-7	Crohn's disease;
UCEC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.93	12.01	0.7	1.39e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.47	4.89	0.37	2.65e-6	Smoking initiation;
UCEC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.48	-4.77	-0.37	4.37e-6	Dental caries;
UCEC	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.36	-5.26	-0.4	4.92e-7	Schizophrenia;
UCEC	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.7	-7.43	-0.52	8.39e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22117172	chr7:91764530	CYP51A1	0.42	5.21	0.39	6.24e-7	Breast cancer;
UCEC	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs1165472	0.755	rs6669971	chr1:56155543	A/G	cg11523071	chr1:56160889	NA	-0.53	-5.16	-0.39	7.91e-7	Paclitaxel-induced neuropathy;
UCEC	cis	rs56341938	0.679	rs7610649	chr3:168831069	C/T	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.86	5.62	0.42	9.09e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13939156	chr17:80058883	NA	0.36	4.57	0.35	1.02e-5	Life satisfaction;
UCEC	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.46	5.04	0.38	1.32e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.65	5.28	0.4	4.54e-7	Corneal astigmatism;
UCEC	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.35	-6.01	-0.44	1.4e-8	Cancer;
UCEC	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.69	-7.88	-0.54	6.85e-13	Blood protein levels;
UCEC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.09	-0.64	1.58e-18	Chronic sinus infection;
UCEC	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01391022	chr12:122360665	WDR66	0.38	4.51	0.35	1.33e-5	Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg03714773	chr7:91764589	CYP51A1	-0.42	-4.97	-0.38	1.81e-6	Breast cancer;
UCEC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.02	-0.38	1.5e-6	Aortic root size;
UCEC	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.68	-7.04	-0.5	6.84e-11	Cognitive function;
UCEC	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.18	0.39	7.35e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs10242455	0.764	rs12360	chr7:99303094	G/A	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.29e-6	Blood metabolite levels;
UCEC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.91	8.31	0.57	5.68e-14	Bladder cancer;
UCEC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11867410	0.744	rs8066786	chr17:63945725	C/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	7.61	0.53	3.11e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.59	-5.43	-0.41	2.24e-7	Subjective well-being;
UCEC	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.55	-5.22	-0.4	6.08e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.46	-4.85	-0.37	3.12e-6	Acylcarnitine levels;
UCEC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg22166914	chr1:53195759	ZYG11B	0.76	7.97	0.55	4.06e-13	Monocyte count;
UCEC	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.47	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.81	5.15	0.39	8.05e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.57	5.72	0.43	5.83e-8	Colorectal cancer;
UCEC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg06742321	chr12:123595122	PITPNM2	0.52	5.48	0.41	1.82e-7	Platelet count;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	6.86	0.49	1.77e-10	Platelet count;
UCEC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg19318889	chr4:1322082	MAEA	0.51	5.04	0.38	1.32e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.91	-10.13	-0.64	1.28e-18	Cognitive function;
UCEC	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	7.89	0.55	6.34e-13	Response to antipsychotic treatment;
UCEC	cis	rs7088591	0.867	rs7077622	chr10:59778439	C/T	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	6.11	0.45	8.51e-9	Menarche (age at onset);
UCEC	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.64	5.97	0.44	1.71e-8	Bipolar disorder;
UCEC	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.75	-0.36	4.81e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.43	-0.41	2.27e-7	Mood instability;
UCEC	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg17646820	chr3:66848679	NA	0.61	4.56	0.35	1.09e-5	Type 2 diabetes;
UCEC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.5	-5.69	-0.43	6.52e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg01262667	chr19:19385393	TM6SF2	0.5	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.46	-0.57	2.52e-14	Prevalent atrial fibrillation;
UCEC	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.72	-5.56	-0.42	1.21e-7	Orofacial clefts;
UCEC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-6.37	-0.47	2.31e-9	Gut microbiome composition (summer);
UCEC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.72	8.42	0.57	3.18e-14	Menopause (age at onset);
UCEC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.61	6.07	0.45	1.06e-8	Post bronchodilator FEV1;
UCEC	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg13683864	chr3:40499215	RPL14	-0.68	-6.79	-0.49	2.59e-10	Renal cell carcinoma;
UCEC	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	6.8	0.49	2.4e-10	Cognitive ability;
UCEC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.9	-0.37	2.47e-6	Aortic root size;
UCEC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.51	5.43	0.41	2.31e-7	Aortic root size;
UCEC	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.71e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg06484146	chr7:12443880	VWDE	0.79	5.87	0.44	2.79e-8	Coronary artery disease;
UCEC	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	8.64	0.58	8.66e-15	Blood protein levels;
UCEC	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.52	5.15	0.39	8.07e-7	Red cell distribution width;
UCEC	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.69	7.57	0.53	3.79e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.68	6.24	0.46	4.54e-9	Aortic root size;
UCEC	cis	rs3741798	1.000	rs28372890	chr12:12503519	C/A	cg08615371	chr12:12503544	MANSC1	1.06	5.79	0.43	4.06e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.12	-0.51	4.46e-11	Breast cancer;
UCEC	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg17145862	chr1:211918768	LPGAT1	0.63	7.06	0.5	6.18e-11	Leprosy;
UCEC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.56	-6.31	-0.46	3.13e-9	Bipolar disorder;
UCEC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs7607369	0.536	rs7600248	chr2:219665963	C/T	cg02176678	chr2:219576539	TTLL4	-0.57	-6.09	-0.45	9.58e-9	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.48	-5.3	-0.4	4.1e-7	Migraine;
UCEC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg05738196	chr6:26577821	NA	0.49	4.56	0.35	1.06e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.5	0.47	1.19e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.43	4.75	0.36	4.79e-6	Neuroticism;
UCEC	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.7	-7.97	-0.55	4.09e-13	Brugada syndrome;
UCEC	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg23950597	chr19:37808831	NA	-0.59	-4.5	-0.35	1.36e-5	Coronary artery calcification;
UCEC	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.87	0.37	2.86e-6	Lymphocyte counts;
UCEC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.67	-0.36	6.6e-6	Aortic root size;
UCEC	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg05991184	chr2:219186017	PNKD	0.49	5.13	0.39	9.11e-7	Colorectal cancer;
UCEC	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	4.88	0.37	2.75e-6	Rheumatoid arthritis;
UCEC	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.62	-0.58	9.92e-15	Prevalent atrial fibrillation;
UCEC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg08461772	chr7:95026248	PON3	0.36	5.03	0.38	1.39e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs445754	0.680	rs3729825	chr14:23886264	C/T	cg12853742	chr14:24780890	LTB4R;LTB4R2;CIDEB	0.43	4.7	0.36	5.94e-6	P wave terminal force;
UCEC	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.44	-4.65	-0.36	7.37e-6	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.63	0.36	7.86e-6	Breast cancer;
UCEC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.5	-0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.56	-6.48	-0.47	1.29e-9	Vitiligo;
UCEC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg03859395	chr2:55845619	SMEK2	0.97	12.69	0.72	2.22e-25	Metabolic syndrome;
UCEC	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg03342759	chr3:160939853	NMD3	-0.62	-5.82	-0.43	3.56e-8	Morning vs. evening chronotype;
UCEC	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	6.45	0.47	1.51e-9	Motion sickness;
UCEC	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.75	7.11	0.51	4.66e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.69	-5.43	-0.41	2.24e-7	Asthma;
UCEC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.56	-4.75	-0.36	4.8e-6	Menarche (age at onset);
UCEC	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.78	-7.9	-0.55	5.88e-13	Parkinson's disease;
UCEC	cis	rs3750082	0.817	rs4723221	chr7:32954207	C/T	cg05721444	chr7:32995514	FKBP9	-0.58	-6.49	-0.47	1.24e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs7246967	0.551	rs16998998	chr19:22911116	T/C	cg05241461	chr19:22816980	ZNF492	0.55	5.76	0.43	4.69e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.75	-0.63	1.27e-17	Monocyte count;
UCEC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.57	0.48	8.27e-10	Coffee consumption (cups per day);
UCEC	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg23000734	chr10:126850823	CTBP2	0.57	7.11	0.51	4.78e-11	Menarche (age at onset);
UCEC	cis	rs58521262	0.556	rs1908942	chr19:23184109	A/G	cg08486875	chr19:23386892	NA	0.33	4.57	0.35	1.04e-5	Testicular germ cell tumor;
UCEC	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.51	6.72	0.48	3.79e-10	Gut microbiota (bacterial taxa);
UCEC	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.81	7.27	0.51	1.98e-11	Bladder cancer;
UCEC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.45	-4.85	-0.37	3.14e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.73	-8.21	-0.56	1.04e-13	Waist circumference;Body mass index;
UCEC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg21053147	chr12:120880522	NA	-0.65	-5.32	-0.4	3.75e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg20999797	chr1:1681921	NA	0.36	4.88	0.37	2.69e-6	Body mass index;
UCEC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	1.0	12.84	0.73	8.63e-26	Monocyte count;
UCEC	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.04	7.99	0.55	3.62e-13	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7264396	0.836	rs961020	chr20:34182069	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-4.84	-0.37	3.29e-6	Total cholesterol levels;
UCEC	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	8.65	0.58	8.35e-15	Post bronchodilator FEV1;
UCEC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.71	-5.74	-0.43	5.19e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg24851651	chr11:66362959	CCS	0.46	5.19	0.39	6.79e-7	Educational attainment (years of education);
UCEC	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs16957091	0.779	rs6493061	chr15:42988412	C/A	cg24196017	chr15:43021976	CDAN1	-0.64	-6.61	-0.48	6.59e-10	MGMT methylation in smokers;
UCEC	cis	rs77926410	0.615	rs10743899	chr12:10642477	T/C	cg25023291	chr12:11339792	TAS2R42	-0.39	-4.85	-0.37	3.09e-6	Mean corpuscular volume;
UCEC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.59	-6.48	-0.47	1.3e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg11632617	chr15:75315747	PPCDC	-0.6	-6.76	-0.49	3.02e-10	Lung cancer;
UCEC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11625487	0.505	rs12887556	chr14:77966473	C/G	cg10415171	chr14:77413900	NA	0.49	5.33	0.4	3.67e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-6.77	-0.49	2.84e-10	Multiple sclerosis;
UCEC	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.65	5.32	0.4	3.8e-7	Eosinophilic esophagitis;
UCEC	cis	rs713477	0.967	rs2152975	chr14:55907919	C/T	cg13175173	chr14:55914753	NA	-0.41	-4.63	-0.36	8.04e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.71	9.18	0.6	3.74e-16	Rheumatoid arthritis;
UCEC	cis	rs2302190	0.882	rs7210714	chr17:56675666	A/C	cg12560992	chr17:57184187	TRIM37	0.53	4.59	0.35	9.3e-6	Vitamin D levels;
UCEC	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.11	9.68	0.62	1.89e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.77	0.54	1.23e-12	Smoking behavior;
UCEC	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.11	-0.39	9.77e-7	Pediatric autoimmune diseases;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.35	0.46	2.58e-9	Aortic root size;
UCEC	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.7	-0.54	1.88e-12	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23104823	chr14:45553408	PRPF39	0.55	6.78	0.49	2.65e-10	Warfarin maintenance dose;
UCEC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg14008862	chr17:28927542	LRRC37B2	0.6	5.12	0.39	9.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7546668	1.000	rs6686966	chr1:15835472	C/T	cg05660106	chr1:15850417	CASP9	-0.46	-4.87	-0.37	2.88e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	0.98	7.11	0.51	4.65e-11	Alzheimer's disease (late onset);
UCEC	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	9.13	0.6	4.87e-16	Coffee consumption (cups per day);
UCEC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg11859384	chr17:80120422	CCDC57	-0.58	-6.31	-0.46	3.12e-9	Life satisfaction;
UCEC	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg16060761	chr17:80687452	NA	-0.54	-4.78	-0.37	4.25e-6	Glycated hemoglobin levels;
UCEC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.68	-4.6	-0.35	8.92e-6	LDL cholesterol levels;
UCEC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg19318889	chr4:1322082	MAEA	0.41	4.63	0.36	8.14e-6	Longevity;
UCEC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.63	-6.64	-0.48	5.54e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.09	9.99	0.64	3.03e-18	Vitiligo;
UCEC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.66	-0.42	7.83e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.7	-6.1	-0.45	8.82e-9	Metabolite levels;
UCEC	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg23791538	chr6:167370224	RNASET2	-0.54	-5.79	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	5.85	0.43	3.12e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-4.77	-0.37	4.47e-6	Schizophrenia;
UCEC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.51	-4.87	-0.37	2.89e-6	Bipolar disorder;
UCEC	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	5.23	0.4	5.68e-7	Mood instability;
UCEC	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg23018236	chr17:30244563	NA	-0.66	-4.64	-0.36	7.75e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg01380346	chr19:18557039	ELL	-0.48	-4.87	-0.37	2.84e-6	Breast cancer;
UCEC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.37	5.22	0.4	6.06e-7	Coronary artery disease;
UCEC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.75	8.68	0.58	7.04e-15	Monocyte count;
UCEC	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg05709478	chr1:6581295	PLEKHG5	0.65	5.09	0.39	1.06e-6	Body mass index;
UCEC	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.83	-8.81	-0.59	3.16e-15	Blood metabolite levels;
UCEC	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.58	-6.03	-0.45	1.27e-8	Orofacial clefts;
UCEC	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-5.61	-0.42	9.58e-8	Pancreatic cancer;
UCEC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.53	5.88	0.44	2.69e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.73	-6.19	-0.45	5.58e-9	Corneal structure;
UCEC	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-5.62	-0.42	9.29e-8	Response to antipsychotic treatment;
UCEC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.44	4.95	0.38	1.98e-6	Alcohol dependence;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.88	10.17	0.64	1.03e-18	Menarche (age at onset);
UCEC	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	6.55	0.48	9e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	4.7	0.36	5.84e-6	Cognitive ability;
UCEC	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.8	-8.79	-0.59	3.53e-15	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg05660106	chr1:15850417	CASP9	1.0	11.22	0.68	1.75e-21	Systolic blood pressure;
UCEC	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.68	-6.17	-0.45	6.35e-9	Body mass index;
UCEC	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.53	5.17	0.39	7.49e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.82	9.91	0.63	4.82e-18	Metabolite levels;
UCEC	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.55	-5.4	-0.41	2.61e-7	Coronary artery disease;
UCEC	cis	rs6136489	0.592	rs4470399	chr20:1930704	C/T	cg08074820	chr20:2733358	EBF4	-0.41	-4.56	-0.35	1.08e-5	Platelet distribution width;Mean platelet volume;
UCEC	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg18681998	chr4:17616180	MED28	0.69	8.01	0.55	3.15e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.82	-8.67	-0.58	7.15e-15	Cognitive function;
UCEC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.7	-4.89	-0.37	2.56e-6	Narcolepsy;
UCEC	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-5.55	-0.42	1.32e-7	Bipolar disorder;
UCEC	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.62	6.76	0.49	3.03e-10	Monocyte count;
UCEC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.43	-5.89	-0.44	2.49e-8	Prostate cancer;
UCEC	cis	rs12365397	0.748	rs1845821	chr11:43258997	T/C	cg07515919	chr11:43391688	TTC17	0.47	4.91	0.38	2.39e-6	Migraine;
UCEC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.61	5.65	0.42	8.03e-8	Type 2 diabetes;
UCEC	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-4.98	-0.38	1.75e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs7312774	0.609	rs2374655	chr12:107380162	T/C	cg16260113	chr12:107380972	MTERFD3	1.12	6.26	0.46	4.02e-9	Severe influenza A (H1N1) infection;
UCEC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.49	-5.54	-0.42	1.38e-7	Neuroticism;
UCEC	cis	rs7246967	0.866	rs4932694	chr19:23032707	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.72	7.27	0.51	1.99e-11	Coronary artery disease;
UCEC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg13844804	chr7:814759	HEATR2	0.68	4.96	0.38	1.93e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-6.03	-0.45	1.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg24562669	chr7:97807699	LMTK2	0.49	5.85	0.43	3.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.09e-6	Height;
UCEC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.05	11.4	0.69	5.71e-22	White matter hyperintensity burden;
UCEC	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.53	-5.2	-0.39	6.63e-7	Placebo response in major depressive disorder (% change in symptom score);
UCEC	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	0.69	8.88	0.59	2.13e-15	Gut microbiome composition (winter);
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.49	-0.47	1.25e-9	Longevity;Endometriosis;
UCEC	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.68	5.32	0.4	3.79e-7	Corneal astigmatism;
UCEC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg13147721	chr7:65941812	NA	-0.69	-4.83	-0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs7246967	0.673	rs12984634	chr19:22833744	C/T	cg08271804	chr19:22816896	ZNF492	0.63	6.25	0.46	4.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.39	-4.66	-0.36	7.11e-6	Type 2 diabetes;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.68	8.31	0.57	5.7e-14	Menarche (age at onset);
UCEC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.2	-0.39	6.56e-7	Personality dimensions;
UCEC	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg25826404	chr17:18061566	MYO15A	0.48	4.86	0.37	3.04e-6	Multiple sclerosis;
UCEC	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.92	10.43	0.65	2.07e-19	Obesity-related traits;
UCEC	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.84	0.37	3.29e-6	Personality dimensions;
UCEC	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs2933343	0.953	rs2933344	chr3:128658715	A/G	cg11901034	chr3:128598214	ACAD9	-0.51	-4.89	-0.37	2.58e-6	IgG glycosylation;
UCEC	cis	rs6060717	0.553	rs2590958	chr20:34616590	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.11	-0.39	1.01e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.77	-10.39	-0.65	2.64e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.54	4.84	0.37	3.21e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-6.19	-0.45	5.69e-9	Caudate activity during reward;
UCEC	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.66	6.63	0.48	5.99e-10	Coronary artery disease;
UCEC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg24163568	chr5:669837	TPPP	0.45	5.66	0.42	7.87e-8	Obesity-related traits;
UCEC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.55	-6.2	-0.46	5.43e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg15837086	chr1:46506065	PIK3R3	-0.39	-5.02	-0.38	1.47e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.67	6.98	0.5	9.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.604	rs12981846	chr19:23021359	G/A	cg05241461	chr19:22816980	ZNF492	0.46	4.81	0.37	3.75e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	0.83	8.32	0.57	5.52e-14	Primary sclerosing cholangitis;
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.57	-4.57	-0.35	1.01e-5	Narcolepsy;
UCEC	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg05855489	chr10:104503620	C10orf26	-0.53	-5.65	-0.42	8.21e-8	Waist circumference;Hip circumference;
UCEC	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/T	cg04311860	chr7:1937321	MAD1L1	0.75	4.9	0.37	2.48e-6	Bipolar disorder;
UCEC	trans	rs1552172	0.887	rs2318299	chr1:145662666	C/T	cg09213929	chr11:111170578	C11orf93;C11orf92	0.64	6.9	0.49	1.42e-10	Breast cancer;
UCEC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.12	13.93	0.75	1.17e-28	Cognitive function;
UCEC	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.49	4.95	0.38	1.99e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.78	7.11	0.51	4.76e-11	Morning vs. evening chronotype;
UCEC	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.85	10.25	0.65	6.2e-19	Menopause (age at onset);
UCEC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg18279126	chr7:2041391	MAD1L1	0.46	5.8	0.43	3.99e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.37	5.14	0.39	8.78e-7	Crohn's disease;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.89	11.63	0.69	1.38e-22	Menarche (age at onset);
UCEC	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.69	4.68	0.36	6.53e-6	Psoriasis;
UCEC	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.49	4.73	0.36	5.27e-6	Type 2 diabetes;
UCEC	cis	rs4478037	0.555	rs60749629	chr3:33105319	G/A	cg19404215	chr3:33155277	CRTAP	0.92	4.98	0.38	1.76e-6	Major depressive disorder;
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-5.03	-0.38	1.41e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg19318889	chr4:1322082	MAEA	0.43	4.84	0.37	3.22e-6	Obesity-related traits;
UCEC	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.43	-0.72	1.07e-24	Ulcerative colitis;
UCEC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-5.05	-0.38	1.3e-6	Longevity;Endometriosis;
UCEC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.02	-0.38	1.48e-6	Systemic lupus erythematosus;
UCEC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	5.61	0.42	9.53e-8	Monocyte percentage of white cells;
UCEC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.53	-5.39	-0.41	2.8e-7	Parkinson's disease;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs925228	0.955	rs6729507	chr2:24163121	T/G	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.89	8.67	0.58	7.41e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9309711	0.518	rs9752314	chr2:3494322	A/G	cg10845886	chr2:3471009	TTC15	-0.54	-4.67	-0.36	6.66e-6	Neurofibrillary tangles;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.57	-6.38	-0.47	2.12e-9	Pubertal anthropometrics;
UCEC	cis	rs925228	0.668	rs7579413	chr2:23933356	A/G	cg16901991	chr2:24272451	FKBP1B	0.49	4.7	0.36	6.02e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.64	-8.67	-0.58	7.5e-15	Systolic blood pressure;
UCEC	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg01072550	chr1:21505969	NA	0.66	7.05	0.5	6.34e-11	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg14121845	chr20:25566513	NINL	0.39	4.52	0.35	1.28e-5	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6722750	0.846	rs13394665	chr2:64391431	A/C	cg22352474	chr2:64371530	PELI1	-0.53	-4.9	-0.37	2.46e-6	Neuroticism;
UCEC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.55	5.17	0.39	7.46e-7	Aortic root size;
UCEC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	0.54	6.1	0.45	9.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7781557	0.696	rs73192019	chr7:102547081	G/A	cg06322601	chr7:102330635	NA	0.57	4.58	0.35	9.97e-6	Colorectal adenoma (advanced);
UCEC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.48	-6.4	-0.47	2e-9	Urinary metabolites;
UCEC	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs7975161	0.630	rs4964260	chr12:104634270	A/G	cg25273343	chr12:104657179	TXNRD1	-0.79	-4.89	-0.37	2.64e-6	Toenail selenium levels;
UCEC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg08493051	chr2:3487164	NA	-0.57	-5.27	-0.4	4.68e-7	Neurofibrillary tangles;
UCEC	cis	rs7246967	0.799	rs12983185	chr19:23030575	A/G	cg24889512	chr19:22816950	ZNF492	0.5	5.37	0.41	2.98e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs116095464	0.764	rs28710899	chr5:241029	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.61	0.36	8.62e-6	Breast cancer;
UCEC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	8.95	0.59	1.4e-15	Menarche (age at onset);
UCEC	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg24903633	chr5:55946094	NA	-0.45	-4.64	-0.36	7.73e-6	Coronary artery disease;
UCEC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.76	-0.54	1.35e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs12545109	0.879	rs7845180	chr8:57324431	C/T	cg19413350	chr8:57351067	NA	0.44	5.26	0.4	4.91e-7	Obesity-related traits;
UCEC	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.5	7.08	0.5	5.56e-11	Coronary artery disease or large artery stroke;
UCEC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.68	-7.02	-0.5	7.75e-11	Response to temozolomide;
UCEC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.6	0.48	7.12e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.54	-5.25	-0.4	5.34e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg09655341	chr17:79618100	PDE6G	-0.31	-4.75	-0.36	4.8e-6	Eye color traits;
UCEC	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg17515076	chr17:73810948	UNK	0.51	5.65	0.42	8.15e-8	White matter hyperintensity burden;
UCEC	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-6.22	-0.46	4.78e-9	Migraine;Coronary artery disease;
UCEC	trans	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg02340915	chr12:121904480	KDM2B	-0.75	-6.67	-0.48	4.76e-10	Parkinson's disease;
UCEC	cis	rs7709377	0.570	rs6896479	chr5:115425582	A/C	cg23108291	chr5:115420582	COMMD10	-0.48	-4.85	-0.37	3.06e-6	Metabolite levels  (X-11787);
UCEC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.9	-0.44	2.42e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.1	-0.39	1.03e-6	Sudden cardiac arrest;
UCEC	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.51	5.56	0.42	1.27e-7	Body mass index;
UCEC	cis	rs12979813	1.000	rs17001244	chr19:11340057	C/T	cg00767042	chr19:11517436	RGL3	-0.32	-4.59	-0.35	9.35e-6	HDL cholesterol;
UCEC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.65	-0.42	8.11e-8	Neutrophil percentage of white cells;
UCEC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	17.99	0.83	5.77e-39	IgG glycosylation;
UCEC	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-5.84	-0.43	3.2e-8	Hepatocellular carcinoma;
UCEC	cis	rs7766436	0.922	rs2066338	chr6:22611393	C/T	cg13666174	chr6:22585274	NA	-0.59	-6.01	-0.44	1.38e-8	Coronary artery disease;
UCEC	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg00546932	chr16:1947055	NA	-0.37	-5.09	-0.39	1.08e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.65	0.36	7.3e-6	Menopause (age at onset);
UCEC	cis	rs7617773	1.000	rs6442109	chr3:48192981	G/A	cg11946769	chr3:48343235	NME6	-0.56	-4.81	-0.37	3.65e-6	Coronary artery disease;
UCEC	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	0.89	6.01	0.44	1.42e-8	Iron status biomarkers;
UCEC	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.18e-6	Vitiligo;
UCEC	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg07930192	chr7:1003750	NA	0.43	4.55	0.35	1.12e-5	Longevity;Endometriosis;
UCEC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.46	4.56	0.35	1.05e-5	Longevity;
UCEC	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	4.65	0.36	7.28e-6	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26002218	chr14:103986227	CKB	0.36	5.2	0.39	6.5e-7	Body mass index;
UCEC	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.67	-6.5	-0.47	1.16e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.47	4.67	0.36	6.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.54	-5.59	-0.42	1.05e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1595825	0.786	rs75415672	chr2:198535679	G/A	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.06e-5	Ulcerative colitis;
UCEC	cis	rs253959	0.752	rs11953135	chr5:115511471	A/G	cg23108291	chr5:115420582	COMMD10	0.52	5.36	0.4	3.21e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg21856205	chr7:94953877	PON1	-0.54	-5.2	-0.39	6.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.65	-6.32	-0.46	2.89e-9	Blood metabolite levels;
UCEC	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg07256473	chr22:29710276	RASL10A	0.63	6.97	0.5	9.79e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.11	0.39	9.93e-7	Parkinson's disease;
UCEC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.46	-4.59	-0.35	9.34e-6	Cardiac Troponin-T levels;
UCEC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.57	-6.56	-0.48	8.53e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-0.73	-7.21	-0.51	2.66e-11	Height;
UCEC	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.15	-8.94	-0.59	1.48e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	0.78	5.14	0.39	8.67e-7	Diabetic retinopathy;
UCEC	cis	rs4900538	0.712	rs1998420	chr14:102979624	G/C	cg18135206	chr14:102964638	TECPR2	0.79	9.31	0.61	1.72e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-1.02	-8.51	-0.57	1.89e-14	White matter hyperintensity burden;
UCEC	cis	rs12428035	0.764	rs11618108	chr13:96741862	T/G	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg06238570	chr21:40685208	BRWD1	0.84	7.7	0.54	1.83e-12	Cognitive function;
UCEC	cis	rs4722166	0.532	rs4719711	chr7:22755688	A/G	cg05472934	chr7:22766657	IL6	-0.52	-5.05	-0.38	1.28e-6	Lung cancer;
UCEC	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.49	5.02	0.38	1.45e-6	Lung cancer;
UCEC	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.6	5.67	0.42	7.15e-8	Lung cancer;
UCEC	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg24562669	chr7:97807699	LMTK2	0.48	5.92	0.44	2.23e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10242455	0.867	rs3735453	chr7:99229435	C/T	cg18809830	chr7:99032528	PTCD1	0.54	4.63	0.36	8.1e-6	Blood metabolite levels;
UCEC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-4.89	-0.37	2.65e-6	Testicular germ cell tumor;
UCEC	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg12923728	chr3:195709715	SDHAP1	0.66	5.37	0.4	3.03e-7	Red cell distribution width;
UCEC	cis	rs11023332	0.706	rs10766197	chr11:14921880	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-4.9	-0.37	2.56e-6	Adiponectin levels;Vitamin D levels;
UCEC	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.88	0.37	2.68e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	6.9	0.49	1.43e-10	Cognitive test performance;
UCEC	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.59	5.7	0.43	6.47e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.59	-5.48	-0.41	1.8e-7	QRS complex (12-leadsum);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24022402	chr3:9834453	ARPC4;TADA3	0.6	7.04	0.5	6.79e-11	Warfarin maintenance dose;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.76	9.07	0.6	6.86e-16	Menarche (age at onset);
UCEC	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg01072550	chr1:21505969	NA	-0.57	-5.61	-0.42	9.88e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.59	-5.12	-0.39	9.39e-7	Reticulocyte count;
UCEC	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	6.07	0.45	1.03e-8	Mood instability;
UCEC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.56	5.69	0.42	6.75e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.87	8.76	0.59	4.39e-15	Post bronchodilator FEV1;
UCEC	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	0.92	9.51	0.62	5.22e-17	Heart rate;
UCEC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.94	10.94	0.67	9.16e-21	Breast cancer;
UCEC	cis	rs9341808	0.529	rs4706840	chr6:81057769	T/A	cg08355045	chr6:80787529	NA	0.37	4.5	0.35	1.37e-5	Sitting height ratio;
UCEC	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.47	-4.66	-0.36	7.02e-6	Monocyte count;
UCEC	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.89	-0.49	1.55e-10	Coffee consumption (cups per day);
UCEC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.59	5.47	0.41	1.92e-7	Type 2 diabetes;
UCEC	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.12	-6.94	-0.5	1.18e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.86	0.44	2.87e-8	Life satisfaction;
UCEC	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	7.9	0.55	6e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg03999872	chr20:62272968	STMN3	-0.49	-4.65	-0.36	7.45e-6	Atopic dermatitis;
UCEC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg02733842	chr7:1102375	C7orf50	-0.48	-4.6	-0.36	8.88e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg18479299	chr3:125709523	NA	-0.61	-4.87	-0.37	2.82e-6	Blood pressure (smoking interaction);
UCEC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	7.51	0.53	5.17e-12	Alzheimer's disease;
UCEC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.83	9.75	0.63	1.24e-17	Menopause (age at onset);
UCEC	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.52	-0.41	1.5e-7	Blood metabolite levels;
UCEC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.81	7.82	0.54	9.31e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.62	-5.55	-0.42	1.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.64	6.01	0.44	1.43e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg18827107	chr12:86230957	RASSF9	-0.42	-4.73	-0.36	5.2e-6	Major depressive disorder;
UCEC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-10.73	-0.66	3.32e-20	Vitiligo;
UCEC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.31	4.91	0.38	2.39e-6	Cancer;
UCEC	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-9.39	-0.61	1.06e-16	Blood metabolite levels;
UCEC	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.55	0.35	1.1e-5	Menarche (age at onset);
UCEC	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-5.14	-0.39	8.59e-7	Gut microbiome composition (summer);
UCEC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.32	4.51	0.35	1.33e-5	Menopause (age at onset);
UCEC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.64	-5.68	-0.42	6.86e-8	Coronary artery disease;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.47	-4.96	-0.38	1.91e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg13777783	chr17:79615861	NA	-0.33	-4.68	-0.36	6.49e-6	Eye color traits;
UCEC	cis	rs2041840	0.618	rs11124581	chr2:37576638	C/T	cg25727520	chr2:37576821	QPCT	-0.41	-4.55	-0.35	1.13e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg02413938	chr2:239008929	ESPNL	-0.36	-4.57	-0.35	1.04e-5	Prostate cancer;
UCEC	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.62	-7.42	-0.52	8.81e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.47	7.19	0.51	2.98e-11	Primary biliary cholangitis;
UCEC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.73	6.24	0.46	4.46e-9	Schizophrenia;
UCEC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.61	6.78	0.49	2.72e-10	Age at first birth;
UCEC	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.68	5.99	0.44	1.57e-8	Mammographic density (dense area);
UCEC	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg17010769	chr15:79165973	MORF4L1	-0.45	-4.88	-0.37	2.72e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	5.92	0.44	2.15e-8	Initial pursuit acceleration;
UCEC	trans	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg18288967	chr1:45987694	PRDX1	0.92	6.88	0.49	1.63e-10	Obesity-related traits;
UCEC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.78	7.69	0.54	1.93e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-8.16	-0.56	1.39e-13	Colorectal cancer;
UCEC	cis	rs7246967	0.736	rs2617779	chr19:22998321	G/A	cg08271804	chr19:22816896	ZNF492	0.65	5.63	0.42	9.02e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg03714773	chr7:91764589	CYP51A1	0.44	5.18	0.39	7.3e-7	Breast cancer;
UCEC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-1.02	-6.92	-0.5	1.28e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs1712517	0.873	rs7903004	chr10:105004101	G/A	cg05636881	chr10:105038444	INA	-0.44	-5.41	-0.41	2.48e-7	Migraine;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg09682330	chr6:28411287	ZSCAN23	-0.48	-4.99	-0.38	1.69e-6	Pubertal anthropometrics;
UCEC	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.33	0.71	1.96e-24	Corneal structure;
UCEC	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.67	6.52	0.47	1.08e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.74	-6.05	-0.45	1.13e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs1712517	0.836	rs11191649	chr10:105067037	T/C	cg05636881	chr10:105038444	INA	0.37	4.73	0.36	5.22e-6	Migraine;
UCEC	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.72	-6.18	-0.45	5.95e-9	Coronary artery disease;
UCEC	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.07	0.39	1.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2041840	0.538	rs3821142	chr2:37575287	C/T	cg25727520	chr2:37576821	QPCT	-0.46	-5.32	-0.4	3.81e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.61	6.31	0.46	3.13e-9	Colorectal cancer;
UCEC	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg06784218	chr1:46089804	CCDC17	0.41	4.84	0.37	3.18e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	5.72	0.43	5.86e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	6.18	0.45	5.99e-9	Alzheimer's disease;
UCEC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg24826892	chr11:71159390	DHCR7	0.53	5.02	0.38	1.47e-6	Vitamin D levels;
UCEC	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.41	0.52	8.93e-12	Eye color traits;
UCEC	cis	rs7246967	0.541	rs16999009	chr19:22909658	A/G	cg05241461	chr19:22816980	ZNF492	-0.54	-5.55	-0.42	1.27e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.9	12.22	0.71	3.91e-24	Metabolic syndrome;
UCEC	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.62	4.62	0.36	8.39e-6	Carotid intima media thickness;
UCEC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	0.92	5.99	0.44	1.57e-8	Skin colour saturation;
UCEC	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-5.57	-0.42	1.2e-7	Colorectal cancer;
UCEC	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.77	5.1	0.39	1.01e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg20965017	chr5:231967	SDHA	0.63	5.76	0.43	4.85e-8	Breast cancer;
UCEC	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.67	-8.09	-0.56	2.02e-13	IgG glycosylation;
UCEC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.69	6.06	0.45	1.08e-8	Alzheimer's disease;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.6	6.65	0.48	5.27e-10	Menarche (age at onset);
UCEC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24308560	chr3:49941425	MST1R	-0.45	-4.85	-0.37	3.1e-6	Body mass index;
UCEC	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.76	-7.64	-0.53	2.54e-12	Schizophrenia;
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.17	-0.39	7.61e-7	Platelet count;
UCEC	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	0.8	6.02	0.44	1.32e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.88	5.04	0.38	1.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1712517	0.744	rs4293063	chr10:105052976	G/T	cg05636881	chr10:105038444	INA	0.47	5.37	0.4	3e-7	Migraine;
UCEC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg13695892	chr22:41940480	POLR3H	-0.59	-4.87	-0.37	2.83e-6	Vitiligo;
UCEC	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.67	0.53	2.13e-12	Total body bone mineral density;
UCEC	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10924970	0.601	rs3765797	chr1:235387000	A/G	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.61e-6	Asthma;
UCEC	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.63	5.3	0.4	4.12e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg25011176	chr20:3776985	CDC25B	-0.47	-4.81	-0.37	3.66e-6	Bipolar disorder;
UCEC	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.53	-4.88	-0.37	2.7e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7646881	0.544	rs16829135	chr3:158325838	A/G	cg05743054	chr3:158288903	MLF1	-0.54	-4.96	-0.38	1.89e-6	Tetralogy of Fallot;
UCEC	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.31	-0.68	1.02e-21	Primary sclerosing cholangitis;
UCEC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg08755490	chr11:65554678	OVOL1	0.5	5.31	0.4	3.89e-7	Acne (severe);
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg11697111	chr7:1126903	GPER;C7orf50	-0.49	-4.81	-0.37	3.74e-6	Longevity;Endometriosis;
UCEC	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.88	10.44	0.65	1.97e-19	Blood metabolite levels;
UCEC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.08	-6.99	-0.5	8.7e-11	Platelet count;
UCEC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	6.28	0.46	3.58e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.57	7.23	0.51	2.39e-11	Information processing speed;
UCEC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.57	6.45	0.47	1.53e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.55	5.43	0.41	2.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.55	0.42	1.32e-7	Rheumatoid arthritis;
UCEC	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.58	5.66	0.42	7.75e-8	Platelet count;
UCEC	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-10.16	-0.64	1.08e-18	Ulcerative colitis;
UCEC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.68	-4.93	-0.38	2.23e-6	Rheumatoid arthritis;
UCEC	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.51	5.28	0.4	4.55e-7	Height;
UCEC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg04310649	chr10:35416472	CREM	-0.47	-4.61	-0.36	8.68e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg14092571	chr14:90743983	NA	0.4	4.53	0.35	1.22e-5	Mortality in heart failure;
UCEC	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs2862064	0.872	rs6555776	chr5:156403505	C/A	cg12943317	chr5:156479607	HAVCR1	-0.92	-6.52	-0.47	1.06e-9	Platelet count;
UCEC	cis	rs7808935	0.768	rs739704	chr7:27989768	G/A	cg08865099	chr7:27281581	EVX1	-0.35	-4.54	-0.35	1.18e-5	Prostate cancer;
UCEC	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.93	7.24	0.51	2.35e-11	Initial pursuit acceleration;
UCEC	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.88	9.67	0.62	2.01e-17	Breast cancer;
UCEC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg05738196	chr6:26577821	NA	0.66	7.8	0.54	1.07e-12	Intelligence (multi-trait analysis);
UCEC	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-1.09	-9.57	-0.62	3.64e-17	Dupuytren's disease;
UCEC	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.2e-8	Mammographic density (dense area);
UCEC	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.5	4.85	0.37	3.11e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs7095607	0.967	rs10998018	chr10:69962954	G/A	cg18986048	chr10:69913749	MYPN	0.43	4.51	0.35	1.32e-5	Lung function (FVC);
UCEC	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.64	7.28	0.51	1.87e-11	Mean platelet volume;
UCEC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.41	-5.75	-0.43	4.94e-8	Prostate cancer;
UCEC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.23	-0.4	5.65e-7	Aortic root size;
UCEC	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.53	5.5	0.41	1.65e-7	Height;
UCEC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.98e-7	Aortic root size;
UCEC	cis	rs1852612	0.965	rs6463284	chr7:45401591	G/C	cg26127197	chr7:45030251	NA	-0.36	-4.67	-0.36	6.75e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg06462663	chr19:18546047	ISYNA1	0.54	6.88	0.49	1.62e-10	Breast cancer;
UCEC	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg00105475	chr2:10696890	NA	0.46	5.68	0.42	7.09e-8	Prostate cancer;
UCEC	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	0.9	5.55	0.42	1.27e-7	Skin colour saturation;
UCEC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg18681998	chr4:17616180	MED28	0.72	6.71	0.48	3.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12618769	0.625	rs76362434	chr2:99118005	C/T	cg10123293	chr2:99228465	UNC50	0.44	4.54	0.35	1.14e-5	Bipolar disorder;
UCEC	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.84	-9.47	-0.62	6.78e-17	Blood metabolite levels;
UCEC	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-1.02	-12.33	-0.71	1.97e-24	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	trans	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.38	-0.47	2.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg03264133	chr6:25882463	NA	0.87	7.47	0.52	6.63e-12	Blood metabolite levels;
UCEC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.59	-6.61	-0.48	6.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.71	9.09	0.6	6.32e-16	Testicular germ cell tumor;
UCEC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.83	8.79	0.59	3.73e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs10129255	0.542	rs8009795	chr14:107108302	T/C	cg03031183	chr14:106916953	NA	-0.44	-4.66	-0.36	7.12e-6	Kawasaki disease;
UCEC	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.86	5.82	0.43	3.56e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.82	11.26	0.68	1.32e-21	Headache;
UCEC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.62	5.83	0.43	3.43e-8	Tourette syndrome;
UCEC	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.65	-0.36	7.25e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.46	4.69	0.36	6.13e-6	Menopause (age at onset);
UCEC	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.21	-10.19	-0.64	9.01e-19	Vitiligo;
UCEC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-0.98	-6.21	-0.46	5.15e-9	Diabetic kidney disease;
UCEC	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs12980942	0.591	rs4591267	chr19:41765407	A/C	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.68	0.42	6.88e-8	Coronary artery disease;
UCEC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	8.79	0.59	3.65e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.56	4.95	0.38	2.05e-6	Obesity-related traits;
UCEC	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.73	0.54	1.57e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg13683864	chr3:40499215	RPL14	-0.51	-5.13	-0.39	8.93e-7	Renal cell carcinoma;
UCEC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.81	-0.49	2.27e-10	Tonsillectomy;
UCEC	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.82	6.49	0.47	1.21e-9	Type 2 diabetes;
UCEC	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.13	-0.39	8.93e-7	Aortic root size;
UCEC	cis	rs2742417	1.000	rs2742369	chr3:45754487	C/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.98e-6	Tonsillectomy;
UCEC	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.68	0.36	6.33e-6	Alzheimer's disease;
UCEC	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.73	4.83	0.37	3.33e-6	Mitochondrial DNA levels;
UCEC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.59	-0.35	9.5e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.83	-0.7	4.16e-23	Primary sclerosing cholangitis;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	0.48	4.76	0.37	4.52e-6	Pubertal anthropometrics;
UCEC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.99	-0.44	1.55e-8	Menarche (age at onset);
UCEC	cis	rs944990	0.618	rs10821176	chr9:96364456	T/C	cg13787134	chr9:96362102	PHF2	-0.37	-5.06	-0.39	1.25e-6	Body mass index;
UCEC	cis	rs11245387	0.564	rs7915429	chr10:126510089	T/C	cg08799069	chr10:126477246	METTL10	-0.69	-6.3	-0.46	3.3e-9	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
UCEC	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00857998	chr1:205179979	DSTYK	0.54	4.68	0.36	6.47e-6	Red blood cell count;
UCEC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.36	-0.46	2.47e-9	Parkinson's disease;
UCEC	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.69	-6.61	-0.48	6.71e-10	Blood pressure (smoking interaction);
UCEC	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg01072550	chr1:21505969	NA	-0.58	-5.71	-0.43	6.18e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4499344	0.556	rs259220	chr19:33137629	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.67	-0.42	7.33e-8	Pancreatic cancer;
UCEC	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.58	7.27	0.51	1.92e-11	Inhibitory control;
UCEC	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.7	-8.15	-0.56	1.45e-13	Vitiligo;
UCEC	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.5	-5.33	-0.4	3.67e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.63	-6.37	-0.46	2.32e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg18827107	chr12:86230957	RASSF9	0.41	4.57	0.35	1.01e-5	Major depressive disorder;
UCEC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.48	4.94	0.38	2.11e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs59104589	0.617	rs3771567	chr2:242358619	G/A	cg19488206	chr2:242435732	STK25	0.48	4.68	0.36	6.45e-6	Fibrinogen levels;
UCEC	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.61	5.81	0.43	3.76e-8	Aortic root size;
UCEC	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.51	-5.33	-0.4	3.65e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.57	5.26	0.4	5.02e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.59	-6.48	-0.47	1.3e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg11859384	chr17:80120422	CCDC57	-0.43	-4.67	-0.36	6.79e-6	Life satisfaction;
UCEC	cis	rs75804782	0.625	rs72984535	chr2:239470022	T/C	cg12524725	chr2:239427019	NA	-0.67	-4.64	-0.36	7.59e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9463078	0.683	rs911524	chr6:44747204	G/A	cg25276700	chr6:44698697	NA	0.44	4.82	0.37	3.49e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.24	-0.4	5.45e-7	Aortic root size;
UCEC	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.79	0.49	2.55e-10	Motion sickness;
UCEC	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.89	0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.81	0.49	2.29e-10	Bipolar disorder;
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs1030877	0.824	rs2576738	chr2:105891644	C/A	cg02079111	chr2:105885981	TGFBRAP1	0.8	10.47	0.65	1.62e-19	Obesity-related traits;
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	10.25	0.65	6.04e-19	Platelet count;
UCEC	cis	rs9309473	0.950	rs6711001	chr2:73850820	C/G	cg20560298	chr2:73613845	ALMS1	-0.56	-4.83	-0.37	3.42e-6	Metabolite levels;
UCEC	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg19743168	chr1:23544995	NA	0.46	5.97	0.44	1.68e-8	Height;
UCEC	cis	rs56161922	1.000	rs17045979	chr1:207842704	T/C	cg09557387	chr1:207818395	CR1L	0.87	4.66	0.36	7.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12311346	chr5:56204834	C5orf35	-0.52	-5.09	-0.39	1.07e-6	Coronary artery disease;
UCEC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.48	-4.82	-0.37	3.62e-6	Aortic root size;
UCEC	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.66	0.48	5.17e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.41	-4.66	-0.36	7.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg19413350	chr8:57351067	NA	0.42	4.98	0.38	1.8e-6	Obesity-related traits;
UCEC	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-9.66	-0.62	2.09e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs77861329	0.925	rs72964042	chr3:52088485	A/C	cg08692210	chr3:52188851	WDR51A	0.63	4.53	0.35	1.19e-5	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.63	-7.4	-0.52	9.54e-12	Body mass index;
UCEC	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7219021	0.886	rs9897440	chr17:46868142	C/G	cg16584676	chr17:46985605	UBE2Z	-0.5	-4.92	-0.38	2.34e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.9e-9	Prudent dietary pattern;
UCEC	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Systemic lupus erythematosus;
UCEC	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.78	4.53	0.35	1.23e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-5.55	-0.42	1.32e-7	Myopia (pathological);
UCEC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.67	-4.56	-0.35	1.06e-5	Moyamoya disease;
UCEC	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.19	-12.09	-0.71	8.78e-24	Corneal structure;
UCEC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	0.92	8.67	0.58	7.37e-15	Cognitive function;
UCEC	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.72	7.02	0.5	7.66e-11	Lymphocyte counts;
UCEC	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	8.93	0.59	1.57e-15	Coffee consumption (cups per day);
UCEC	cis	rs8105895	1.000	rs117638181	chr19:22163014	C/G	cg20662725	chr19:22235022	ZNF257	-0.57	-5.01	-0.38	1.53e-6	Body mass index (change over time);
UCEC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.22	0.4	5.88e-7	Cognitive test performance;
UCEC	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.47	5.12	0.39	9.32e-7	Schizophrenia;
UCEC	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.64	-5.57	-0.42	1.17e-7	Immature fraction of reticulocytes;
UCEC	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.91	5.11	0.39	9.79e-7	Fat distribution (HIV);
UCEC	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	8.77	0.59	4.08e-15	Coffee consumption (cups per day);
UCEC	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.46	5.24	0.4	5.57e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.44	0.52	7.59e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.39	-4.67	-0.36	6.85e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.62	4.67	0.36	6.62e-6	Mean platelet volume;
UCEC	cis	rs4908768	0.600	rs77137441	chr1:8895866	C/T	cg13081009	chr1:8430745	RERE	0.47	4.78	0.37	4.17e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.71	-8.15	-0.56	1.47e-13	Menarche (age at onset);
UCEC	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.56	-5.5	-0.41	1.68e-7	White matter hyperintensity burden;
UCEC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13939156	chr17:80058883	NA	-0.37	-4.55	-0.35	1.12e-5	Life satisfaction;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg08348990	chr13:110425835	IRS2	0.79	4.66	0.36	6.9e-6	Obesity-related traits;
UCEC	cis	rs17123764	0.539	rs7979262	chr12:50065146	T/C	cg20471783	chr12:50157085	TMBIM6	0.66	5.56	0.42	1.23e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg21770322	chr7:97807741	LMTK2	0.85	14.84	0.77	4.96e-31	Breast cancer;
UCEC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.74	-7.77	-0.54	1.28e-12	Mosquito bite size;
UCEC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.71	-6.83	-0.49	2.11e-10	Aortic root size;
UCEC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.52	5.22	0.4	5.9e-7	Calcium levels;
UCEC	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.88	12.98	0.73	3.7e-26	Leprosy;
UCEC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.86	-10.87	-0.67	1.47e-20	Coronary artery disease;
UCEC	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	5.75	0.43	4.94e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.62e-8	Aortic root size;
UCEC	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.44	4.63	0.36	8.03e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05962382	chr2:130345044	NA	-0.5	-5.94	-0.44	2e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.73	5.46	0.41	2.03e-7	Initial pursuit acceleration;
UCEC	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.43	-4.62	-0.36	8.19e-6	Longevity;
UCEC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.72	-6.78	-0.49	2.76e-10	HDL cholesterol;
UCEC	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.89	0.49	1.54e-10	Cognitive test performance;
UCEC	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.72	7.87	0.54	7.04e-13	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.4	-5.04	-0.38	1.34e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
UCEC	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.88	5.17	0.39	7.65e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg04155231	chr12:9217510	LOC144571	0.41	4.84	0.37	3.23e-6	Sjögren's syndrome;
UCEC	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.49	5.61	0.42	9.74e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg21770322	chr7:97807741	LMTK2	0.53	6.94	0.5	1.15e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.49	-7.05	-0.5	6.32e-11	Urinary metabolites;
UCEC	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg00277334	chr10:82204260	NA	-0.52	-5.02	-0.38	1.48e-6	Post bronchodilator FEV1;
UCEC	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.87	-0.63	6.02e-18	Leprosy;
UCEC	cis	rs7088591	0.867	rs73290914	chr10:59779500	G/A	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.65	6.84	0.49	2.03e-10	Menopause (age at onset);
UCEC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg06784218	chr1:46089804	CCDC17	0.51	6.31	0.46	3.16e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.95	-10.17	-0.64	9.91e-19	Cognitive function;
UCEC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.52	-5.65	-0.42	8.01e-8	Aortic root size;
UCEC	cis	rs17106184	0.892	rs12084054	chr1:51242141	C/T	cg07174182	chr1:51127561	FAF1	-0.63	-4.63	-0.36	8.01e-6	Type 2 diabetes;
UCEC	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.68	8.01	0.55	3.15e-13	Post bronchodilator FEV1;
UCEC	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.4	-4.98	-0.38	1.74e-6	Urinary tract infection frequency;
UCEC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.85	-0.37	3.17e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg10978503	chr1:24200527	CNR2	0.36	4.77	0.37	4.38e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-7.71	-0.54	1.69e-12	Ulcerative colitis;
UCEC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10266483	0.661	rs608769	chr7:63753161	T/C	cg23304165	chr7:63498798	NA	-0.59	-6.17	-0.45	6.23e-9	Response to statin therapy;
UCEC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.63	-5.18	-0.39	7.17e-7	Initial pursuit acceleration;
UCEC	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.51	4.62	0.36	8.28e-6	Optic nerve measurement (cup area);
UCEC	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.85	-8.77	-0.59	4.19e-15	Itch intensity from mosquito bite;
UCEC	cis	rs1996152	0.543	rs11650701	chr17:72386274	G/A	cg23221732	chr17:72383708	NA	-0.42	-4.51	-0.35	1.33e-5	Interleukin-12p70 levels;
UCEC	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.22	0.46	4.93e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.27	-0.4	4.8e-7	Headache;
UCEC	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-5.03	-0.38	1.42e-6	Bipolar disorder;
UCEC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.57e-6	Colorectal cancer;
UCEC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.52	-5.65	-0.42	8.07e-8	IgG glycosylation;
UCEC	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.19	8.55	0.58	1.43e-14	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9467773	1.000	rs12665431	chr6:26577308	T/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.56	-5.39	-0.41	2.73e-7	Diastolic blood pressure;
UCEC	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-5.33	-0.4	3.68e-7	Body mass index;
UCEC	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.69	0.48	4.39e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.61	-6.57	-0.48	8.07e-10	Neuroticism;
UCEC	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	0.71	5.64	0.42	8.32e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs239198	0.578	rs13193416	chr6:101299602	A/T	cg09795085	chr6:101329169	ASCC3	0.47	4.52	0.35	1.27e-5	Menarche (age at onset);
UCEC	cis	rs10242455	0.702	rs73711294	chr7:99088714	G/A	cg18809830	chr7:99032528	PTCD1	-0.99	-5.18	-0.39	7.13e-7	Blood metabolite levels;
UCEC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.64	7.08	0.5	5.52e-11	Intelligence (multi-trait analysis);
UCEC	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.55	-6.31	-0.46	3.08e-9	Monocyte percentage of white cells;
UCEC	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.67	-7.29	-0.52	1.74e-11	Hypospadias;
UCEC	cis	rs10186029	0.509	rs2371793	chr2:213945082	G/C	cg08319019	chr2:214017104	IKZF2	-0.48	-4.64	-0.36	7.61e-6	Systemic sclerosis;
UCEC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	5.63	0.42	8.76e-8	Personality dimensions;
UCEC	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.78	4.61	0.36	8.65e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.6	6.44	0.47	1.63e-9	Bipolar disorder;
UCEC	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.59	-4.57	-0.35	1.01e-5	Blood pressure (smoking interaction);
UCEC	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.79	8.2	0.56	1.11e-13	Height;
UCEC	cis	rs10924970	0.649	rs4659492	chr1:235482207	T/G	cg26050004	chr1:235667680	B3GALNT2	0.51	4.93	0.38	2.21e-6	Asthma;
UCEC	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.73	-6.28	-0.46	3.6e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	7.4	0.52	9.94e-12	Motion sickness;
UCEC	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.66	-6.26	-0.46	4.02e-9	Body mass index;
UCEC	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.57	0.66	9.07e-20	Cognitive ability;
UCEC	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.61	5.76	0.43	4.81e-8	Corneal astigmatism;
UCEC	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.44	4.64	0.36	7.59e-6	Schizophrenia;
UCEC	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.51	-5.09	-0.39	1.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.97	0.44	1.68e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-5.02	-0.38	1.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10242455	0.717	rs2687133	chr7:99332083	C/T	cg07715041	chr7:99302981	CYP3A7	-0.5	-4.97	-0.38	1.85e-6	Blood metabolite levels;
UCEC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg17933807	chr1:38061675	GNL2	0.98	11.73	0.7	7.74e-23	Axial length;
UCEC	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.43	4.72	0.36	5.35e-6	Monocyte count;
UCEC	cis	rs4866650	0.803	rs16869638	chr5:2448538	A/G	cg22547775	chr5:2537634	NA	-0.47	-4.59	-0.35	9.48e-6	Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction);
UCEC	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.47	0.41	1.87e-7	IgG glycosylation;
UCEC	cis	rs12481680	1.000	rs7273940	chr20:56419323	G/A	cg02468966	chr20:56287198	PMEPA1	0.45	4.8	0.37	3.83e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-8.61	-0.58	1.06e-14	Bipolar disorder and schizophrenia;
UCEC	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.84	-8.78	-0.59	3.84e-15	Itch intensity from mosquito bite;
UCEC	cis	rs4280164	0.945	rs4366641	chr14:24771101	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-4.77	-0.37	4.45e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg20307385	chr11:47447363	PSMC3	0.59	5.09	0.39	1.09e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.42	5.25	0.4	5.23e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
UCEC	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg21770322	chr7:97807741	LMTK2	0.52	6.46	0.47	1.45e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg22166914	chr1:53195759	ZYG11B	-0.59	-6.12	-0.45	8.07e-9	Monocyte count;
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	5.05	0.38	1.27e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.3	0.4	4.25e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.92	11.09	0.67	3.78e-21	Breast cancer;
UCEC	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.61	5.75	0.43	4.94e-8	Lung cancer;
UCEC	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	5.02	0.38	1.48e-6	Birth weight;
UCEC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.66	9.35	0.61	1.37e-16	Height;
UCEC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-4.68	-0.36	6.55e-6	Coronary artery disease;
UCEC	cis	rs3227	0.626	rs3818528	chr6:33661091	C/T	cg16492833	chr6:33679775	C6orf125	0.43	4.63	0.36	7.84e-6	Educational attainment;
UCEC	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.52	-0.41	1.51e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13683864	chr3:40499215	RPL14	-0.66	-6.58	-0.48	7.95e-10	Renal cell carcinoma;
UCEC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-0.59	-4.53	-0.35	1.19e-5	Plateletcrit;
UCEC	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.69	5.98	0.44	1.63e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg05501817	chr11:14380813	RRAS2	-0.52	-4.92	-0.38	2.34e-6	Sense of smell;
UCEC	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-0.99	-5.94	-0.44	1.99e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.79	-0.49	2.56e-10	Chronic sinus infection;
UCEC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.76	-7.31	-0.52	1.56e-11	Initial pursuit acceleration;
UCEC	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.38	-5.03	-0.38	1.43e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.65	8.44	0.57	2.75e-14	Anterior chamber depth;
UCEC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.01	-0.38	1.53e-6	Chronic sinus infection;
UCEC	cis	rs13095912	0.752	rs7613002	chr3:185353235	T/C	cg11274856	chr3:185301563	NA	0.65	7.91	0.55	5.65e-13	Systolic blood pressure;
UCEC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-4.63	-0.36	8.13e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	6.99	0.5	8.8e-11	Body mass index (adult);
UCEC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg03354898	chr7:1950403	MAD1L1	-0.57	-5.35	-0.4	3.24e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Body mass index;
UCEC	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.38	-5.66	-0.42	7.74e-8	Schizophrenia;
UCEC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.64	4.87	0.37	2.82e-6	Mean platelet volume;
UCEC	cis	rs17489649	1.000	rs11747338	chr5:109150731	C/T	cg17436293	chr5:109223084	NA	-0.36	-4.59	-0.35	9.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.71	7.53	0.53	4.61e-12	Lymphocyte counts;
UCEC	cis	rs4849887	1.000	rs4848602	chr2:121243108	C/T	cg00421221	chr2:121106091	INHBB	0.43	4.52	0.35	1.26e-5	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs9393294	1.000	rs2153804	chr6:22499320	G/A	cg15541384	chr6:21886458	FLJ22536	-0.69	-4.64	-0.36	7.69e-6	Mean platelet volume;
UCEC	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.13	0.45	7.87e-9	Cognitive test performance;
UCEC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4499344	0.519	rs259226	chr19:33134965	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs6546886	0.957	rs4364046	chr2:74256305	A/G	cg14702570	chr2:74259524	NA	0.42	5.5	0.41	1.67e-7	Dialysis-related mortality;
UCEC	cis	rs3818285	0.959	rs492943	chr10:111629030	A/T	cg00817464	chr10:111662876	XPNPEP1	0.35	4.56	0.35	1.05e-5	Superior crus of antihelix expression;
UCEC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.09	0.39	1.1e-6	Rheumatoid arthritis;
UCEC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.96	9.35	0.61	1.35e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.78	-8.68	-0.58	7.07e-15	Monocyte count;
UCEC	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.8	0.37	3.81e-6	Breast cancer;
UCEC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg13695892	chr22:41940480	POLR3H	0.67	4.7	0.36	5.87e-6	Vitiligo;
UCEC	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.52	5.82	0.43	3.62e-8	Life satisfaction;
UCEC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.85	9.76	0.63	1.2e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg16584290	chr5:462447	EXOC3	-0.44	-4.57	-0.35	1.03e-5	Cystic fibrosis severity;
UCEC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8099014	1.000	rs4940698	chr18:56108914	G/A	cg19165390	chr18:56932082	NA	0.35	4.77	0.37	4.36e-6	Platelet count;
UCEC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.71	6.32	0.46	2.97e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.82	0.54	9.17e-13	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs139371	0.742	rs139322	chr22:39501285	T/A	cg15548613	chr22:38610795	MAFF	0.45	4.74	0.36	4.97e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.58	-0.35	1e-5	Type 2 diabetes;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.62	-7.86	-0.54	7.57e-13	Pubertal anthropometrics;
UCEC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.86	0.44	2.88e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs7246967	0.551	rs7248993	chr19:22849152	G/C	cg05241461	chr19:22816980	ZNF492	0.57	6.23	0.46	4.61e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.57	6.73	0.49	3.63e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.69	-6.65	-0.48	5.47e-10	Blood pressure (smoking interaction);
UCEC	cis	rs2806864	1.000	rs2806864	chr1:117469781	C/G	cg19765820	chr1:116518738	SLC22A15	-0.65	-4.8	-0.37	3.82e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg21770322	chr7:97807741	LMTK2	0.52	6.5	0.47	1.19e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.5	5.15	0.39	8.09e-7	Schizophrenia;
UCEC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00791764	chr4:53727839	RASL11B	0.69	4.77	0.37	4.35e-6	Optic nerve measurement (cup area);
UCEC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	6.85	0.49	1.9e-10	Homoarginine levels;
UCEC	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs12644436	1.000	rs2126649	chr4:88789795	A/G	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	HIV-1 viral setpoint;
UCEC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18252515	chr7:66147081	NA	0.46	4.69	0.36	6.18e-6	Aortic root size;
UCEC	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.8	6.74	0.49	3.44e-10	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.6	5.51	0.41	1.58e-7	Subjective well-being;
UCEC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg09998033	chr7:158218633	PTPRN2	-0.46	-4.68	-0.36	6.41e-6	Obesity-related traits;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.27	-0.4	4.74e-7	Pubertal anthropometrics;
UCEC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.48	-5.28	-0.4	4.62e-7	Schizophrenia;
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.71	-6.69	-0.48	4.32e-10	Cocaine dependence;
UCEC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg17724175	chr1:150552817	MCL1	-0.42	-4.51	-0.35	1.34e-5	Tonsillectomy;
UCEC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg06238570	chr21:40685208	BRWD1	0.83	8.21	0.56	1.04e-13	Cognitive function;
UCEC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg05802129	chr4:122689817	NA	-0.46	-4.67	-0.36	6.77e-6	Type 2 diabetes;
UCEC	cis	rs11760485	0.965	rs56098795	chr7:4402225	G/A	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.6	-4.84	-0.37	3.19e-6	Migraine;Coronary artery disease;
UCEC	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.54	-5.3	-0.4	4.25e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	0.54	5.81	0.43	3.77e-8	QRS complex (12-leadsum);
UCEC	cis	rs9843304	0.528	rs9880421	chr3:149183359	C/T	cg08667024	chr3:149219783	TM4SF4	0.49	5.55	0.42	1.31e-7	Gallstone disease;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.48	-5.18	-0.39	7.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs77216612	1.000	rs77216612	chr12:12877983	A/G	cg09462578	chr12:12878428	APOLD1	-1.1	-11.22	-0.68	1.68e-21	Lymphocyte counts;
UCEC	cis	rs420259	0.516	rs9933261	chr16:23515952	G/A	cg26562691	chr16:23850404	PRKCB	-0.34	-4.56	-0.35	1.08e-5	Bipolar disorder;
UCEC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg04311557	chr16:71523289	ZNF19	-0.65	-4.58	-0.35	9.9e-6	Post bronchodilator FEV1;
UCEC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.52	5.27	0.4	4.71e-7	Monocyte count;
UCEC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg10932868	chr11:921992	NA	0.39	4.61	0.36	8.69e-6	Alzheimer's disease (late onset);
UCEC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.38e-17	Height;
UCEC	cis	rs2862064	0.872	rs6555822	chr5:156473185	A/G	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.09e-17	Heart rate;
UCEC	cis	rs9463078	0.764	rs6458415	chr6:44881592	G/C	cg25276700	chr6:44698697	NA	-0.41	-4.54	-0.35	1.14e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.66	6.24	0.46	4.51e-9	Aortic root size;
UCEC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.58	5.48	0.41	1.79e-7	Corneal astigmatism;
UCEC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.54	-0.47	9.49e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6445967	0.933	rs6796069	chr3:58332508	C/T	cg23715586	chr3:58305044	RPP14	0.39	4.7	0.36	5.89e-6	Platelet count;
UCEC	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-6.56	-0.48	8.4e-10	Parkinson's disease;
UCEC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.88	9.75	0.63	1.28e-17	Breast cancer;
UCEC	cis	rs8105895	1.000	rs8105895	chr19:22215457	C/T	cg20662725	chr19:22235022	ZNF257	-0.53	-4.8	-0.37	3.78e-6	Body mass index (change over time);
UCEC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.79	0.37	4.11e-6	Menopause (age at onset);
UCEC	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg24375607	chr4:120327624	NA	0.57	4.81	0.37	3.71e-6	Corneal astigmatism;
UCEC	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg01072550	chr1:21505969	NA	-0.59	-5.88	-0.44	2.59e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.72	7.11	0.51	4.69e-11	Schizophrenia;
UCEC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.98	0.44	1.63e-8	Height;
UCEC	cis	rs7546668	1.000	rs3795759	chr1:15853628	C/T	cg05660106	chr1:15850417	CASP9	-0.46	-4.86	-0.37	3.04e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs12980942	0.591	rs1946613	chr19:41767785	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.68	0.42	6.88e-8	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.54	0.35	1.18e-5	Menopause (age at onset);
UCEC	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-7.3	-0.52	1.64e-11	Parkinson's disease;
UCEC	cis	rs250585	0.736	rs250579	chr16:23425585	A/G	cg26562691	chr16:23850404	PRKCB	0.36	4.74	0.36	5.08e-6	Egg allergy;
UCEC	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.68	-5.72	-0.43	5.71e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.81	-8.5	-0.57	1.98e-14	Caffeine consumption;
UCEC	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	0.99	11.57	0.69	2e-22	Mitochondrial DNA levels;
UCEC	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg26513180	chr16:89883248	FANCA	-0.46	-4.78	-0.37	4.3e-6	Vitiligo;
UCEC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.61	6.46	0.47	1.45e-9	Monocyte count;
UCEC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg12024160	chr4:1254474	NA	0.71	8.9	0.59	1.93e-15	Obesity-related traits;
UCEC	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	0.57	7.11	0.51	4.63e-11	Platelet distribution width;
UCEC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg22974920	chr21:40686053	BRWD1	0.59	5.28	0.4	4.49e-7	Cognitive function;
UCEC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg09491104	chr22:46646882	C22orf40	-0.51	-5.04	-0.38	1.36e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.54	5.32	0.4	3.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.83	10.04	0.64	2.13e-18	Mortality in heart failure;
UCEC	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-0.94	-5.91	-0.44	2.33e-8	Mitochondrial DNA levels;
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.74	7.87	0.54	7.29e-13	Primary sclerosing cholangitis;
UCEC	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.49	-5.39	-0.41	2.73e-7	Platelet count;
UCEC	cis	rs7126328	1	rs7126328	chr11:120244577	C/T	cg12584626	chr11:120203529	NA	0.53	5.37	0.4	3.07e-7	Intraocular pressure;
UCEC	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.57	6.04	0.45	1.22e-8	Pubertal anthropometrics;
UCEC	cis	rs4148689	1.000	rs35608825	chr7:117164863	T/C	cg21212505	chr7:117228958	CFTR	-0.4	-4.6	-0.35	9.23e-6	Gout;
UCEC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.58	0.48	7.59e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6754311	1.000	rs182549	chr2:136616754	C/T	cg07169764	chr2:136633963	MCM6	-0.63	-5.86	-0.43	2.97e-8	Mosquito bite size;
UCEC	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.59	-5.93	-0.44	2.11e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs925228	0.955	rs2339935	chr2:24205429	T/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.54	4.69	0.36	6.25e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.46	5.28	0.4	4.5e-7	Electroencephalogram traits;
UCEC	cis	rs240764	0.578	rs9399688	chr6:101215786	C/T	cg09795085	chr6:101329169	ASCC3	0.5	4.61	0.36	8.5e-6	Neuroticism;
UCEC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.57	5.38	0.41	2.83e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.55	5.79	0.43	4.05e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.58	-5.7	-0.43	6.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.33	-0.46	2.86e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.92	9.8	0.63	9.37e-18	Cognitive function;
UCEC	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.44	5.61	0.42	9.58e-8	Schizophrenia;
UCEC	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-0.66	-6.95	-0.5	1.11e-10	Blood trace element (Zn levels);
UCEC	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.52	4.97	0.38	1.83e-6	HDL cholesterol;
UCEC	cis	rs7155603	0.700	rs17103360	chr14:75959341	A/G	cg01624173	chr14:75981868	NA	0.54	5.03	0.38	1.39e-6	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.66	-7.38	-0.52	1.06e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.92	0.38	2.3e-6	Schizophrenia;
UCEC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.55	5.72	0.43	5.76e-8	Prostate cancer;
UCEC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.82	11.24	0.68	1.5e-21	Headache;
UCEC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.42	-5.22	-0.4	6.13e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.01	-0.38	1.57e-6	Sudden cardiac arrest;
UCEC	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg14675211	chr2:100938903	LONRF2	-0.47	-5.0	-0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg05660106	chr1:15850417	CASP9	0.63	5.77	0.43	4.51e-8	Systolic blood pressure;
UCEC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.79	0.49	2.55e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg06027949	chr8:82754900	SNX16	-0.59	-4.98	-0.38	1.8e-6	Diastolic blood pressure;
UCEC	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.34	-4.55	-0.35	1.12e-5	Glomerular filtration rate;
UCEC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	18.02	0.83	4.65e-39	Chronic sinus infection;
UCEC	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.82	8.63	0.58	9.36e-15	Longevity;Endometriosis;
UCEC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.63	5.61	0.42	9.84e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg22974920	chr21:40686053	BRWD1	-0.55	-5.11	-0.39	1e-6	Cognitive function;
UCEC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.87	9.51	0.62	5.37e-17	Cognitive function;
UCEC	cis	rs1940013	0.680	rs1939964	chr11:132252265	A/C	cg11473001	chr11:131780499	NTM	-0.4	-4.66	-0.36	6.95e-6	Sleep-related phenotypes;
UCEC	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.43	4.56	0.35	1.05e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.82	-11.43	-0.69	4.77e-22	Urate levels in lean individuals;
UCEC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.45	4.61	0.36	8.8e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg06784218	chr1:46089804	CCDC17	0.42	4.68	0.36	6.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	6.64	0.48	5.79e-10	Alzheimer's disease;
UCEC	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.69	-7.88	-0.54	6.85e-13	Blood protein levels;
UCEC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10851411	0.559	rs62019322	chr15:42897374	T/C	cg21293051	chr15:42870591	STARD9	0.75	4.82	0.37	3.48e-6	Glucose homeostasis traits;
UCEC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.43	0.41	2.23e-7	Prudent dietary pattern;
UCEC	trans	rs4389974	1.000	rs4389974	chr8:112381796	A/C	cg22736090	chr17:62339926	TEX2	0.66	7.05	0.5	6.3e-11	Body mass index;
UCEC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg19318889	chr4:1322082	MAEA	0.48	5.1	0.39	1.03e-6	Obesity-related traits;
UCEC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.58	-5.42	-0.41	2.35e-7	Blood protein levels;
UCEC	cis	rs13253111	0.624	rs35990565	chr8:28107815	C/T	cg26534493	chr8:28060551	NA	0.47	4.83	0.37	3.38e-6	Childhood body mass index;
UCEC	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg06671706	chr8:8559999	CLDN23	0.69	5.62	0.42	9.4e-8	Obesity-related traits;
UCEC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.62	6.7	0.48	4.16e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	6.51	0.47	1.1e-9	Initial pursuit acceleration;
UCEC	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.98	0.44	1.6e-8	HDL cholesterol;
UCEC	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.6	6.94	0.5	1.14e-10	Obesity-related traits;
UCEC	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.69	-6.23	-0.46	4.68e-9	Prostate cancer;
UCEC	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs1318772	0.932	rs17333442	chr5:112947050	A/C	cg12552261	chr5:112820674	MCC	0.75	4.85	0.37	3.12e-6	F-cell distribution;
UCEC	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.11	-0.39	9.68e-7	Life satisfaction;
UCEC	cis	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.86	6.77	0.49	2.92e-10	Body mass index;
UCEC	cis	rs6677604	1.000	rs6689009	chr1:196698463	A/G	cg07209298	chr1:196795943	CFHR1	0.44	4.58	0.35	9.7e-6	IgA nephropathy;Nephropathy;Blood protein levels;
UCEC	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.67	-8.09	-0.55	2.09e-13	IgG glycosylation;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00568128	chr10:115934100	MIR2110;C10orf118	0.58	6.92	0.5	1.3100000000000001e-10	Warfarin maintenance dose;
UCEC	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.53	-5.04	-0.38	1.37e-6	Gut microbiome composition (winter);
UCEC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.47	-4.63	-0.36	8.08e-6	Breast size;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.48	-5.42	-0.41	2.4e-7	Pubertal anthropometrics;
UCEC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.61	5.13	0.39	9.1e-7	Blood metabolite levels;
UCEC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.64	0.36	7.61e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	4.92	0.38	2.28e-6	Menarche (age at onset);
UCEC	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg05639522	chr1:247681581	NA	-0.36	-4.94	-0.38	2.1e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg02820040	chr2:241836501	C2orf54	-0.39	-4.81	-0.37	3.66e-6	Urinary metabolites;
UCEC	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.78	-10.1	-0.64	1.55e-18	Blood protein levels;
UCEC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.66	-0.36	6.9e-6	Type 2 diabetes;
UCEC	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.93	0.44	2.08e-8	Coffee consumption (cups per day);
UCEC	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.63	6.54	0.47	9.72e-10	Menopause (age at onset);
UCEC	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	0.87	6.97	0.5	9.86e-11	Blood protein levels;
UCEC	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-22.5	-0.88	1.87e-49	Myeloid white cell count;
UCEC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.69	-4.67	-0.36	6.85e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18252515	chr7:66147081	NA	0.46	4.67	0.36	6.72e-6	Aortic root size;
UCEC	cis	rs6460942	0.908	rs78374554	chr7:12242285	G/A	cg06484146	chr7:12443880	VWDE	-0.78	-4.67	-0.36	6.64e-6	Coronary artery disease;
UCEC	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.54	-5.87	-0.44	2.83e-8	Menarche (age at onset);
UCEC	cis	rs1545257	0.505	rs67786999	chr2:24637160	T/G	cg06627628	chr2:24431161	ITSN2	-0.53	-5.33	-0.4	3.67e-7	Sjögren's syndrome;
UCEC	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.54	-5.53	-0.42	1.4e-7	Eye color traits;
UCEC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.64	6.09	0.45	9.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-9.05	-0.6	8.1e-16	Chronic sinus infection;
UCEC	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg22974920	chr21:40686053	BRWD1	0.5	4.76	0.37	4.51e-6	Cognitive function;
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07589254	chr7:1705402	NA	-0.54	-4.76	-0.37	4.67e-6	Longevity;Endometriosis;
UCEC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.79	0.43	4.18e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.4	-0.41	2.64e-7	Pubertal anthropometrics;
UCEC	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-5.21	-0.39	6.32e-7	Morning vs. evening chronotype;
UCEC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.49	5.33	0.4	3.58e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	4.7	0.36	6.02e-6	Height;
UCEC	cis	rs4499344	0.730	rs405858	chr19:33106621	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.53	-4.82	-0.37	3.48e-6	Mean platelet volume;
UCEC	cis	rs9914578	1.000	rs4061660	chr17:2004377	C/T	cg16513277	chr17:2031491	SMG6	-0.49	-4.87	-0.37	2.82e-6	Body mass index;
UCEC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg13147721	chr7:65941812	NA	0.85	5.65	0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.53	5.84	0.43	3.28e-8	Platelet count;
UCEC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.53	5.0	0.38	1.64e-6	Menopause (age at onset);
UCEC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.3	10.07	0.64	1.79e-18	Uric acid levels;
UCEC	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg05527609	chr1:210001259	C1orf107	-0.52	-4.75	-0.37	4.7e-6	Red blood cell count;
UCEC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg20387954	chr3:183756860	HTR3D	0.51	5.99	0.44	1.57e-8	Anterior chamber depth;
UCEC	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg01072550	chr1:21505969	NA	-0.59	-5.62	-0.42	9.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg14008862	chr17:28927542	LRRC37B2	0.66	4.92	0.38	2.29e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.08	17.46	0.82	1.16e-37	IgG glycosylation;
UCEC	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.78	-0.37	4.16e-6	Multiple sclerosis;
UCEC	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.59	-5.97	-0.44	1.66e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.02	-0.55	3.07e-13	Total cholesterol levels;
UCEC	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-5.99	-0.44	1.54e-8	Hepatocellular carcinoma;
UCEC	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	1.1	10.09	0.64	1.61e-18	Mosquito bite size;
UCEC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.62	0.42	9.27e-8	Prudent dietary pattern;
UCEC	cis	rs59104589	0.617	rs73002170	chr2:242325980	G/A	cg19488206	chr2:242435732	STK25	0.54	4.87	0.37	2.83e-6	Fibrinogen levels;
UCEC	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.61	5.77	0.43	4.58e-8	Corneal astigmatism;
UCEC	cis	rs2708377	0.790	rs73051387	chr12:11314463	A/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.76	6.0	0.44	1.46e-8	Bitter taste perception;
UCEC	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg26718707	chr10:518370	DIP2C	-0.4	-4.53	-0.35	1.19e-5	Psychosis in Alzheimer's disease;
UCEC	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg18681998	chr4:17616180	MED28	0.68	7.55	0.53	4.15e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.91	10.55	0.66	9.88e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.6	7.35	0.52	1.27e-11	Multiple myeloma;
UCEC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.68	6.6	0.48	6.95e-10	Aortic root size;
UCEC	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.5	5.03	0.38	1.43e-6	Dupuytren's disease;
UCEC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.57	-8.33	-0.57	5.35e-14	Refractive error;
UCEC	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-7.49	-0.53	5.83e-12	Electrocardiographic conduction measures;
UCEC	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	17.62	0.82	4.64e-38	IgG glycosylation;
UCEC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs7088591	0.867	rs59474487	chr10:59788534	A/G	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.63	-7.02	-0.5	7.62e-11	Brugada syndrome;
UCEC	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.77	-6.13	-0.45	7.54e-9	Calcium levels;
UCEC	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg15534755	chr11:117069859	TAGLN	0.34	4.64	0.36	7.68e-6	Blood protein levels;
UCEC	cis	rs12980942	1.000	rs34945449	chr19:41819824	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.58	5.2	0.39	6.55e-7	Coronary artery disease;
UCEC	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.95	-11.12	-0.68	3.15e-21	Obesity-related traits;
UCEC	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.76	-8.56	-0.58	1.36e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.66	6.42	0.47	1.77e-9	Bladder cancer;
UCEC	cis	rs12980942	0.935	rs12980480	chr19:41804655	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.66	6.15	0.45	6.92e-9	Coronary artery disease;
UCEC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	4.54	0.35	1.16e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	0.9	9.13	0.6	4.92e-16	Heart rate;
UCEC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01380346	chr19:18557039	ELL	-0.49	-5.09	-0.39	1.09e-6	Breast cancer;
UCEC	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg01072550	chr1:21505969	NA	0.55	5.19	0.39	6.91e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9309473	0.500	rs10189578	chr2:73728609	C/A	cg20560298	chr2:73613845	ALMS1	-0.52	-5.1	-0.39	1.04e-6	Metabolite levels;
UCEC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.74	-0.63	1.32e-17	Height;
UCEC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.76	0.37	4.62e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.48	-5.79	-0.43	4.17e-8	Bipolar disorder;
UCEC	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.9	10.13	0.64	1.28e-18	Menarche (age at onset);
UCEC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.87	-0.49	1.72e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.53	0.62	4.73e-17	Platelet count;
UCEC	cis	rs2708977	0.637	rs583705	chr2:97068754	C/T	cg22654517	chr2:96458247	NA	0.45	5.72	0.43	5.67e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.7	6.5	0.47	1.17e-9	Bipolar disorder;
UCEC	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.63	7.06	0.5	5.99e-11	Pubertal anthropometrics;
UCEC	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg23950597	chr19:37808831	NA	-0.83	-5.56	-0.42	1.22e-7	Coronary artery calcification;
UCEC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18932078	chr1:2524107	MMEL1	0.35	5.98	0.44	1.6e-8	Ulcerative colitis;
UCEC	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.14	-11.66	-0.69	1.17e-22	Ulcerative colitis;
UCEC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.5	-5.38	-0.41	2.82e-7	Response to antineoplastic agents;
UCEC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.8	-0.49	2.46e-10	Schizophrenia;
UCEC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-5.34	-0.4	3.48e-7	Schizophrenia;
UCEC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.57	6.49	0.47	1.23e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.94	10.38	0.65	2.8e-19	Cognitive function;
UCEC	cis	rs6684428	0.536	rs6684599	chr1:56392558	G/T	cg11651538	chr1:56320950	NA	-0.44	-4.52	-0.35	1.27e-5	Airflow obstruction;
UCEC	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.62	-5.57	-0.42	1.16e-7	Alzheimer's disease;
UCEC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-6.18	-0.45	5.88e-9	Tonsillectomy;
UCEC	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.76	8.92	0.59	1.7e-15	Bone mineral density;
UCEC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.48	0.77	4.23e-30	Height;
UCEC	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg16751203	chr2:127950803	CYP27C1	0.4	5.4	0.41	2.62e-7	Protein C levels;
UCEC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg03859395	chr2:55845619	SMEK2	0.89	11.13	0.68	3.02e-21	Metabolic syndrome;
UCEC	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg03999872	chr20:62272968	STMN3	-0.48	-4.6	-0.36	8.88e-6	Atopic dermatitis;
UCEC	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.69	-0.36	6.22e-6	Parkinson's disease;
UCEC	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.64	-0.53	2.58e-12	Exhaled nitric oxide output;
UCEC	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7246967	0.932	rs62120788	chr19:23051012	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.63	-0.53	2.66e-12	Total cholesterol levels;
UCEC	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs61776719	0.840	rs35267671	chr1:38397369	C/T	cg18451016	chr1:38461880	NA	0.68	7.52	0.53	5.13e-12	Coronary artery disease;
UCEC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17600642	0.694	rs17600433	chr10:72445227	A/G	cg23422916	chr10:72218225	NA	0.58	4.87	0.37	2.79e-6	Bipolar disorder;
UCEC	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg26513180	chr16:89883248	FANCA	-0.47	-4.99	-0.38	1.66e-6	Vitiligo;
UCEC	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.63	6.15	0.45	7.02e-9	Sudden cardiac arrest;
UCEC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.47	5.32	0.4	3.86e-7	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.62	-0.36	8.22e-6	Blood metabolite levels;
UCEC	cis	rs2120243	0.874	rs2316708	chr3:157150299	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.67	0.36	6.71e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.74	8.44	0.57	2.82e-14	Ear protrusion;
UCEC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs11697848	0.867	rs118070805	chr20:48509409	A/G	cg17849948	chr20:48532315	SPATA2	1.03	4.98	0.38	1.73e-6	Systemic lupus erythematosus;
UCEC	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.67	-8.09	-0.55	2.09e-13	IgG glycosylation;
UCEC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-5.21	-0.39	6.29e-7	Prostate cancer;
UCEC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.5	-4.84	-0.37	3.31e-6	Resting heart rate;
UCEC	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	8.24	0.56	8.79e-14	Bipolar disorder;
UCEC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.64	7.1	0.51	4.96e-11	Homoarginine levels;
UCEC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg26441486	chr22:50317300	CRELD2	0.75	5.13	0.39	9e-7	Schizophrenia;
UCEC	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.74	7.7	0.54	1.82e-12	Sudden cardiac arrest;
UCEC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.68	-6.68	-0.48	4.56e-10	Blood metabolite levels;
UCEC	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.38	4.99	0.38	1.67e-6	Total body bone mineral density;
UCEC	cis	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg10524888	chr4:39529563	UGDH	-0.64	-4.78	-0.37	4.18e-6	Plasma amyloid beta peptide concentrations (ABx-40);
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.03	0.5	7.15e-11	Platelet count;
UCEC	cis	rs7781557	1.000	rs11496066	chr7:102486254	T/C	cg06322601	chr7:102330635	NA	0.67	5.6	0.42	1e-7	Colorectal adenoma (advanced);
UCEC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.59	-5.43	-0.41	2.24e-7	Coronary artery disease;
UCEC	cis	rs6684428	1.000	rs10888944	chr1:56341409	A/C	cg11651538	chr1:56320950	NA	-0.62	-5.91	-0.44	2.32e-8	Airflow obstruction;
UCEC	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.54	5.94	0.44	2.02e-8	Breast cancer;
UCEC	cis	rs7246967	0.551	rs7248993	chr19:22849152	G/C	cg24889512	chr19:22816950	ZNF492	0.58	6.29	0.46	3.52e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-6.84	-0.49	2e-10	Response to antipsychotic treatment;
UCEC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.4	4.74	0.36	5.08e-6	Blood protein levels;
UCEC	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.32	-0.4	3.73e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.68	8.01	0.55	3.24e-13	Prudent dietary pattern;
UCEC	cis	rs1007190	0.881	rs9914884	chr17:42955589	T/C	cg15406952	chr17:42872593	NA	0.7	5.52	0.41	1.51e-7	DNA methylation (variation);
UCEC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.17	16.05	0.8	4.03e-34	Cognitive function;
UCEC	cis	rs4448343	0.927	rs1355620	chr9:98270168	A/G	cg13456470	chr9:98266766	PTCH1	0.34	4.55	0.35	1.11e-5	Height;
UCEC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.67	0.36	6.77e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.41	4.59	0.35	9.34e-6	Eosinophil percentage of white cells;
UCEC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.49	4.65	0.36	7.24e-6	Menopause (age at onset);
UCEC	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	6.67	0.48	4.95e-10	Hemoglobin concentration;
UCEC	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	8.01	0.55	3.1400000000000003e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.6	5.13	0.39	8.9e-7	Phospholipid levels (plasma);
UCEC	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	0.67	8.61	0.58	1.03e-14	Gut microbiome composition (winter);
UCEC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg09491104	chr22:46646882	C22orf40	-0.58	-6.4	-0.47	2e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.93	-0.44	2.03e-8	Tonsillectomy;
UCEC	cis	rs7520050	0.843	rs1707334	chr1:46605728	A/C	cg15837086	chr1:46506065	PIK3R3	-0.36	-4.65	-0.36	7.4e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg24851651	chr11:66362959	CCS	-0.41	-5.15	-0.39	8.28e-7	Educational attainment (years of education);
UCEC	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.43	-4.65	-0.36	7.38e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs1483890	0.723	rs6419767	chr3:69412505	G/A	cg22125112	chr3:69402811	FRMD4B	0.46	4.77	0.37	4.42e-6	Resting heart rate;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.62	-6.5	-0.47	1.2e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg18721089	chr20:30220636	NA	-0.42	-5.46	-0.41	1.94e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg15513719	chr13:114904418	NA	0.5	4.95	0.38	2.03e-6	Schizophrenia;
UCEC	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.71	-6.15	-0.45	7.02e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg08266712	chr14:104979372	NA	-0.44	-4.62	-0.36	8.2e-6	Reticulocyte count;
UCEC	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-5.23	-0.4	5.72e-7	Response to antipsychotic treatment;
UCEC	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-1.01	-12.31	-0.71	2.24e-24	Obesity-related traits;
UCEC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.47	5.48	0.41	1.77e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	0.71	8.18	0.56	1.2e-13	Monocyte percentage of white cells;
UCEC	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-0.85	-11.72	-0.7	7.93e-23	Triglycerides;
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.57	0.58	1.29e-14	Platelet count;
UCEC	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	0.85	5.67	0.42	7.24e-8	Blood protein levels;
UCEC	cis	rs4615376	1.000	rs9473354	chr6:13059035	C/A	cg11378619	chr6:12164359	HIVEP1	-0.51	-4.84	-0.37	3.2e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06238570	chr21:40685208	BRWD1	-0.45	-4.5	-0.35	1.35e-5	Cognitive function;
UCEC	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.75	-0.54	1.42e-12	Total cholesterol levels;
UCEC	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.46	4.59	0.35	9.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.72	8.95	0.59	1.42e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs7246967	0.866	rs12984122	chr19:23030674	G/A	cg24889512	chr19:22816950	ZNF492	0.5	5.09	0.39	1.09e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.7	-5.51	-0.41	1.58e-7	Alcohol dependence;
UCEC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.7	6.05	0.45	1.12e-8	Cognitive function;
UCEC	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.96	-10.8	-0.67	2.2e-20	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg04553112	chr3:125709451	NA	-0.72	-5.05	-0.38	1.32e-6	Blood pressure (smoking interaction);
UCEC	cis	rs17123764	0.892	rs57342147	chr12:50129422	A/G	cg20471783	chr12:50157085	TMBIM6	0.62	4.91	0.38	2.43e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Cleft plate (environmental tobacco smoke interaction);
UCEC	trans	rs76228276	0.737	rs1021415	chr8:100389266	A/G	cg24113496	chr5:138725830	MGC29506	0.63	6.75	0.49	3.18e-10	Childhood ear infection;
UCEC	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.59	5.77	0.43	4.49e-8	Lung cancer;
UCEC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.55	5.08	0.39	1.15e-6	White matter hyperintensity burden;
UCEC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.47	4.99	0.38	1.68e-6	Schizophrenia;
UCEC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.65	5.67	0.42	7.46e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	5.05	0.38	1.3e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.66	-6.75	-0.49	3.12e-10	Hypospadias;
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.96	11.51	0.69	2.89e-22	Colorectal adenoma (advanced);
UCEC	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg01072550	chr1:21505969	NA	-0.63	-6.49	-0.47	1.22e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.57	-4.78	-0.37	4.28e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.45	5.18	0.39	7.11e-7	Blood metabolite ratios;
UCEC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.17	-0.39	7.47e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2242663	0.798	rs1945302	chr11:66337498	C/T	cg24851651	chr11:66362959	CCS	0.47	5.97	0.44	1.67e-8	Bipolar disorder;
UCEC	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs10432489	0.708	rs4613228	chr2:181725816	G/C	cg21995919	chr2:182322279	ITGA4	-0.89	-4.64	-0.36	7.58e-6	QT interval;
UCEC	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.52	4.68	0.36	6.54e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.57	7.22	0.51	2.63e-11	Anterior chamber depth;
UCEC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.4	-4.87	-0.37	2.8e-6	Height;
UCEC	cis	rs9931543	0.504	rs9922112	chr16:56314687	A/C	cg10482356	chr16:56328421	GNAO1	-0.38	-5.26	-0.4	4.98e-7	Subjective well-being;
UCEC	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.55e-7	Schizophrenia;
UCEC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg22868518	chr11:507468	RNH1	-0.69	-4.64	-0.36	7.52e-6	Body mass index;
UCEC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.59	5.27	0.4	4.8e-7	Menarche (age at onset);
UCEC	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.57	6.67	0.48	4.77e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.63	6.38	0.47	2.17e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.95e-6	Tonsillectomy;
UCEC	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-4.82	-0.37	3.51e-6	Total cholesterol levels;
UCEC	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.68	-7.63	-0.53	2.67e-12	Blood protein levels;
UCEC	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs11235843	0.571	rs12364069	chr11:73362259	G/A	cg23931323	chr11:73372278	PLEKHB1	0.62	4.85	0.37	3.17e-6	Hand grip strength;
UCEC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.55	-5.93	-0.44	2.1e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.58	6.33	0.46	2.74e-9	Cognitive function;
UCEC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.67	6.07	0.45	1.04e-8	Aortic root size;
UCEC	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.58	6.61	0.48	6.49e-10	Blood metabolite ratios;
UCEC	cis	rs7336933	0.932	rs9532947	chr13:42492215	T/C	cg18400088	chr13:41634674	WBP4	0.57	4.88	0.37	2.7e-6	Calcium levels;
UCEC	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.61	6.91	0.5	1.35e-10	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10924970	0.601	rs12024609	chr1:235452167	G/A	cg26050004	chr1:235667680	B3GALNT2	0.53	4.92	0.38	2.27e-6	Asthma;
UCEC	cis	rs78487399	0.808	rs78108161	chr2:43663848	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.6	-0.35	8.9e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.46	-0.41	2e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.56	-4.8	-0.37	3.81e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.72	-8.22	-0.56	9.95e-14	Menarche (age at onset);
UCEC	cis	rs9650657	0.711	rs7007318	chr8:10592278	C/G	cg14992524	chr8:10586135	SOX7	0.29	4.5	0.35	1.35e-5	Neuroticism;
UCEC	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.75	7.69	0.54	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.59	7.14	0.51	3.89e-11	Oral cavity cancer;
UCEC	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs17106184	1.000	rs72902726	chr1:51223500	T/C	cg07174182	chr1:51127561	FAF1	-0.82	-5.25	-0.4	5.23e-7	Type 2 diabetes;
UCEC	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.59	-6.55	-0.48	9.17e-10	Metabolite levels;
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.21	0.56	1.03e-13	Prudent dietary pattern;
UCEC	cis	rs6964587	0.758	rs7798233	chr7:91500083	G/A	cg17063962	chr7:91808500	NA	-0.73	-5.49	-0.41	1.72e-7	Breast cancer;
UCEC	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.55	-4.94	-0.38	2.07e-6	Pediatric autoimmune diseases;
UCEC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg08886695	chr4:3369023	RGS12	-0.48	-5.37	-0.4	3.08e-7	Serum sulfate level;
UCEC	cis	rs73416724	1.000	rs112472472	chr6:43279276	G/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	7.33	0.52	1.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.66	-8.12	-0.56	1.68e-13	Paraoxonase activity;
UCEC	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-6.63	-0.48	5.91e-10	Height;
UCEC	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.56	5.18	0.39	7.19e-7	Tonsillectomy;
UCEC	cis	rs4713118	0.506	rs9366697	chr6:27633018	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.45	-4.77	-0.37	4.48e-6	Parkinson's disease;
UCEC	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.7	-6.12	-0.45	8.07e-9	Diastolic blood pressure;
UCEC	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	6.33	0.46	2.79e-9	Body mass index;
UCEC	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.85	9.91	0.63	4.79e-18	Monocyte count;
UCEC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.08e-8	Breast cancer;
UCEC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.49	5.29	0.4	4.3e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.35	-0.46	2.5e-9	Cardiac Troponin-T levels;
UCEC	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg03342759	chr3:160939853	NMD3	0.53	4.87	0.37	2.86e-6	Morning vs. evening chronotype;
UCEC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.73	8.73	0.58	5.26e-15	Prudent dietary pattern;
UCEC	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.49	5.14	0.39	8.79e-7	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs2901381	0.701	rs12633440	chr3:168815209	C/T	cg21477417	chr3:169490753	MYNN	-0.55	-4.56	-0.35	1.07e-5	Plateletcrit;
UCEC	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.6	6.58	0.48	7.68e-10	Resting heart rate;
UCEC	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.84	-10.08	-0.64	1.71e-18	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg04871131	chr7:94954202	PON1	0.52	5.22	0.4	5.9e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.68	7.13	0.51	4.12e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4654899	0.865	rs3856173	chr1:21114833	C/T	cg01072550	chr1:21505969	NA	-0.48	-4.53	-0.35	1.2e-5	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.57	-6.2	-0.46	5.3300000000000004e-09	Menarche (age at onset);
UCEC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.47	-4.84	-0.37	3.18e-6	Aortic root size;
UCEC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.57	5.4	0.41	2.58e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.75	6.82	0.49	2.25e-10	Neutrophil percentage of white cells;
UCEC	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-0.77	-5.57	-0.42	1.21e-7	Post bronchodilator FEV1;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15553989	chr6:64346784	NA	0.67	6.77	0.49	2.82e-10	Migraine with aura;
UCEC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-5.73	-0.43	5.41e-8	Body mass index;
UCEC	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg27246729	chr12:121163418	ACADS	0.46	4.55	0.35	1.12e-5	Mean corpuscular volume;
UCEC	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.18	-0.45	5.86e-9	Morning vs. evening chronotype;
UCEC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs3743832	0.965	rs4305016	chr16:9207529	A/T	cg08831531	chr16:9218945	NA	-0.43	-4.64	-0.36	7.75e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.75	7.08	0.5	5.55e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg01217666	chr12:57472591	TMEM194A	0.7	6.75	0.49	3.11e-10	Migraine with aura;
UCEC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.56	4.86	0.37	3.04e-6	Response to diuretic therapy;
UCEC	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.62	6.1	0.45	8.9e-9	Coronary artery disease;
UCEC	cis	rs2224391	0.784	rs35048711	chr6:5262235	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-6.69	-0.48	4.39e-10	Height;
UCEC	cis	rs713477	1.000	rs10134905	chr14:55911792	G/A	cg13175173	chr14:55914753	NA	-0.4	-4.53	-0.35	1.23e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.6	6.93	0.5	1.2e-10	Hip circumference;
UCEC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26207909	chr14:103986467	CKB	0.54	6.03	0.45	1.26e-8	Body mass index;
UCEC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-5.12	-0.39	9.46e-7	Height;
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.68	-5.57	-0.42	1.19e-7	Platelet count;
UCEC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.61	5.99	0.44	1.58e-8	Post bronchodilator FEV1;
UCEC	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.53	5.25	0.4	5.24e-7	Blood metabolite levels;
UCEC	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.47	-5.15	-0.39	8.19e-7	Prostate cancer;
UCEC	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.64	6.5	0.47	1.17e-9	C-reactive protein levels;
UCEC	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.76	-6.98	-0.5	9.63e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	0.76	7.79	0.54	1.11e-12	Parkinson's disease;
UCEC	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.56	5.08	0.39	1.14e-6	Selective IgA deficiency;
UCEC	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg01072550	chr1:21505969	NA	-0.64	-6.49	-0.47	1.21e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.59	5.49	0.41	1.72e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg23978390	chr7:1156363	C7orf50	-0.47	-4.66	-0.36	6.9e-6	Longevity;Endometriosis;
UCEC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	1.06	12.09	0.71	8.66e-24	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs73157695	0.521	rs55918937	chr21:47184033	C/T	cg11214348	chr21:47283868	PCBP3	-0.37	-4.97	-0.38	1.87e-6	Myopia;
UCEC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.62	6.35	0.46	2.56e-9	Menopause (age at onset);
UCEC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.56	-5.06	-0.39	1.23e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.45	4.66	0.36	6.9e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7246967	1.000	rs7257127	chr19:23056699	A/G	cg24889512	chr19:22816950	ZNF492	0.49	5.16	0.39	7.71e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.42e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	0.92	9.44	0.61	7.75e-17	Height;
UCEC	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.35	-5.3	-0.4	4.17e-7	Schizophrenia;
UCEC	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg26781129	chr3:44753946	ZNF502	-0.5	-5.49	-0.41	1.72e-7	Depressive symptoms;
UCEC	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.64	-7.58	-0.53	3.56e-12	Prevalent atrial fibrillation;
UCEC	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg19041857	chr6:27730383	NA	-0.59	-4.69	-0.36	6.12e-6	Breast cancer;
UCEC	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	8.34	0.57	4.82e-14	Menopause (age at onset);
UCEC	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg08250081	chr4:10125330	NA	0.47	4.63	0.36	7.94e-6	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	trans	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg15509575	chr4:2286509	ZFYVE28	0.41	7.19	0.51	3.08e-11	Rheumatoid arthritis;
UCEC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	5.22	0.4	6.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	5.14	0.39	8.69e-7	Prudent dietary pattern;
UCEC	cis	rs17106184	1.000	rs72902722	chr1:51223002	T/C	cg07174182	chr1:51127561	FAF1	-0.88	-5.58	-0.42	1.12e-7	Type 2 diabetes;
UCEC	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.85	0.43	3.08e-8	Eosinophil percentage of white cells;
UCEC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.6	6.58	0.48	7.68e-10	Resting heart rate;
UCEC	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18854424	chr1:2615690	NA	0.36	5.28	0.4	4.62e-7	Ulcerative colitis;
UCEC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.52	-0.41	1.48e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	5.49	0.41	1.7e-7	Joint mobility (Beighton score);
UCEC	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-4.68	-0.36	6.45e-6	Bipolar disorder;
UCEC	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg24011408	chr12:48396354	COL2A1	0.56	4.9	0.37	2.47e-6	Lung cancer;
UCEC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.72	6.13	0.45	7.77e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg22852734	chr6:133119734	C6orf192	0.94	8.64	0.58	8.55e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs8105895	0.935	rs8110975	chr19:22240233	C/G	cg02912127	chr19:22235281	ZNF257	-0.62	-5.18	-0.39	7.3e-7	Body mass index (change over time);
UCEC	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.58	5.69	0.42	6.7e-8	Lung cancer;
UCEC	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg11189052	chr15:85197271	WDR73	0.57	4.55	0.35	1.1e-5	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.41	4.99	0.38	1.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg13147721	chr7:65941812	NA	-0.69	-5.11	-0.39	1.01e-6	Diabetic kidney disease;
UCEC	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.35	4.66	0.36	6.93e-6	Total body bone mineral density;
UCEC	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-6.18	-0.45	5.86e-9	Morning vs. evening chronotype;
UCEC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-4.75	-0.37	4.7e-6	Obesity-related traits;
UCEC	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.56	-5.46	-0.41	2.02e-7	Mortality in heart failure;
UCEC	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.71	8.24	0.56	8.87e-14	Immature fraction of reticulocytes;
UCEC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg23888215	chr10:79422304	NA	-0.99	-7.6	-0.53	3.24e-12	Bone mineral density;
UCEC	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.57	-5.08	-0.39	1.11e-6	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
UCEC	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.8	6.95	0.5	1.1e-10	Morning vs. evening chronotype;
UCEC	cis	rs7267005	0.661	rs17093095	chr20:34381123	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.67	5.32	0.4	3.71e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	4.67	0.36	6.77e-6	IgG glycosylation;
UCEC	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.85	7.94	0.55	4.91e-13	Prostate cancer;
UCEC	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-6.77	-0.49	2.88e-10	Platelet distribution width;
UCEC	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg20203395	chr5:56204925	C5orf35	0.65	4.95	0.38	2.04e-6	Initial pursuit acceleration;
UCEC	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.83	-10.87	-0.67	1.45e-20	White blood cell count (basophil);
UCEC	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.61	6.17	0.45	6.23e-9	Endometrial cancer;
UCEC	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.82	-6.56	-0.48	8.53e-10	Fibroblast growth factor basic levels;
UCEC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.38	-4.85	-0.37	3.17e-6	Body mass index;
UCEC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.43	6.21	0.46	5.08e-9	Schizophrenia;
UCEC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.18	0.64	9.47e-19	Electrocardiographic conduction measures;
UCEC	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.5	-4.92	-0.38	2.28e-6	Primary biliary cholangitis;
UCEC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.47	5.04	0.38	1.37e-6	Alcohol dependence;
UCEC	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.99	7.55	0.53	4.22e-12	Multiple sclerosis;
UCEC	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-11.71	-0.69	8.56e-23	Primary sclerosing cholangitis;
UCEC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.55	5.93	0.44	2.08e-8	Corneal astigmatism;
UCEC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.93	7.18	0.51	3.16e-11	Monobrow;
UCEC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs4755351	0.504	rs12225045	chr11:33346513	A/G	cg05567920	chr11:33183001	CSTF3	0.57	4.58	0.35	9.8200000000000008e-06	Lung cancer in ever smokers;
UCEC	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.99	7.94	0.55	4.83e-13	Multiple sclerosis;
UCEC	cis	rs9469578	0.579	rs7744811	chr6:33692368	T/C	cg18708504	chr6:33715942	IP6K3	0.54	5.15	0.39	8.2e-7	Phosphorus levels;
UCEC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	4.56	0.35	1.08e-5	Platelet count;
UCEC	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg24578937	chr1:2090814	PRKCZ	-0.42	-5.02	-0.38	1.46e-6	Height;
UCEC	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.47	-5.67	-0.42	7.27e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.74	0.58	4.99e-15	Platelet count;
UCEC	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs6893807	0.778	rs1501672	chr5:87963761	A/G	cg09002922	chr5:87956389	LOC645323	-0.6	-5.58	-0.42	1.15e-7	Body mass index;
UCEC	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.52	7.85	0.54	7.88e-13	Crohn's disease;
UCEC	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg20485758	chr6:26088446	HFE	0.69	4.5	0.35	1.36e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.3	0.52	1.66e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.62	6.73	0.49	3.54e-10	Colorectal cancer;
UCEC	cis	rs7095607	0.785	rs3956957	chr10:69919445	A/T	cg18986048	chr10:69913749	MYPN	0.52	6.17	0.45	6.33e-9	Lung function (FVC);
UCEC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg01072550	chr1:21505969	NA	-0.55	-5.11	-0.39	9.72e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1007190	0.881	rs71373521	chr17:42949442	C/T	cg15406952	chr17:42872593	NA	0.71	5.67	0.42	7.44e-8	DNA methylation (variation);
UCEC	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-5.17	-0.39	7.61e-7	Aortic root size;
UCEC	cis	rs10432489	0.708	rs10178270	chr2:181773395	G/C	cg21995919	chr2:182322279	ITGA4	-0.77	-5.16	-0.39	7.71e-7	QT interval;
UCEC	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-6.26	-0.46	3.94e-9	Morning vs. evening chronotype;
UCEC	cis	rs7474896	0.836	rs584630	chr10:38338699	G/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-4.68	-0.36	6.39e-6	Obesity (extreme);
UCEC	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg22166914	chr1:53195759	ZYG11B	0.79	8.28	0.56	7.08e-14	Monocyte count;
UCEC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-6.02	-0.44	1.33e-8	Tonsillectomy;
UCEC	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.42	-5.09	-0.39	1.07e-6	Neuroticism;
UCEC	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Schizophrenia;
UCEC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg16584290	chr5:462447	EXOC3	-0.49	-5.02	-0.38	1.48e-6	Cystic fibrosis severity;
UCEC	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.37	-4.74	-0.36	5.05e-6	Acylcarnitine levels;
UCEC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.43	-5.32	-0.4	3.87e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.84	-8.47	-0.57	2.35e-14	Obesity-related traits;
UCEC	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	5.9	0.44	2.36e-8	Myopia (pathological);
UCEC	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	0.79	5.25	0.4	5.28e-7	Diabetic retinopathy;
UCEC	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg13073564	chr4:8508604	NA	-0.46	-5.03	-0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.67	6.52	0.47	1.07e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg09165964	chr15:75287851	SCAMP5	-0.55	-5.71	-0.43	5.93e-8	Lung cancer;
UCEC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.89	-9.85	-0.63	6.78e-18	Cognitive function;
UCEC	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.55	-5.9	-0.44	2.37e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.07	0.5	5.71e-11	Coronary artery disease;
UCEC	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.62	6.59	0.48	7.24e-10	Motion sickness;
UCEC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	11.01	0.67	6.11e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.5	5.04	0.38	1.37e-6	Colorectal cancer;
UCEC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.53	5.2	0.39	6.67e-7	Menopause (age at onset);
UCEC	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.46	-5.26	-0.4	5.07e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1392935	0.620	rs9896174	chr17:49931598	A/C	cg08555112	chr17:48942811	TOB1	0.53	4.83	0.37	3.46e-6	Bacterial meningitis;
UCEC	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg22619376	chr5:1859849	NA	0.38	4.54	0.35	1.18e-5	Cardiovascular disease risk factors;
UCEC	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg04283868	chr2:201171347	SPATS2L	0.58	5.85	0.43	3.06e-8	Asthma (bronchodilator response);
UCEC	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	7.61	0.53	3.02e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.66	-5.63	-0.42	8.82e-8	Alcohol dependence;
UCEC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.41	-0.47	1.83e-9	Aortic root size;
UCEC	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.48	4.75	0.36	4.77e-6	Blood metabolite levels;
UCEC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg06238570	chr21:40685208	BRWD1	0.81	7.97	0.55	3.97e-13	Cognitive function;
UCEC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.9100000000000004e-06	Breast cancer;
UCEC	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-5.02	-0.38	1.47e-6	Bipolar disorder;
UCEC	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg21191810	chr6:118973309	C6orf204	0.35	4.92	0.38	2.34e-6	Electrocardiographic conduction measures;
UCEC	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.47	-4.91	-0.38	2.39e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg18402987	chr7:1209562	NA	0.47	5.0	0.38	1.62e-6	Longevity;Endometriosis;
UCEC	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg03342759	chr3:160939853	NMD3	-0.55	-5.43	-0.41	2.28e-7	Kawasaki disease;
UCEC	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.68	5.69	0.42	6.65e-8	IgG glycosylation;
UCEC	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.49	4.82	0.37	3.52e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.72	8.16	0.56	1.34e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs4851266	1.000	rs893246	chr2:100814917	T/C	cg14675211	chr2:100938903	LONRF2	0.67	6.35	0.46	2.51e-9	Educational attainment;
UCEC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.65	6.32	0.46	2.98e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.77	-8.81	-0.59	3.21e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg26138937	chr11:71823887	C11orf51	0.98	5.07	0.39	1.17e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs8105895	0.935	rs62110989	chr19:22260299	A/G	cg24072202	chr19:22235272	ZNF257	-0.59	-5.08	-0.39	1.12e-6	Body mass index (change over time);
UCEC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.36	-5.52	-0.41	1.49e-7	Ulcerative colitis;
UCEC	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	5.05	0.38	1.28e-6	Lung cancer in ever smokers;
UCEC	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.52	7.09	0.51	5.09e-11	Sitting height ratio;
UCEC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg04310649	chr10:35416472	CREM	0.49	4.75	0.36	4.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs2892463	0.551	rs9506231	chr13:30374227	A/G	cg10211454	chr13:31195985	USPL1	0.4	4.57	0.35	1.01e-5	Non-word repetition;
UCEC	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg08320659	chr6:26088202	HFE	0.77	4.6	0.36	8.86e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.31	0.46	3.04e-9	Hip circumference;
UCEC	cis	rs12363310	0.665	rs3920965	chr11:101676886	C/T	cg00202702	chr11:101918157	C11orf70	0.39	4.52	0.35	1.24e-5	Systemic sclerosis;
UCEC	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.57	5.48	0.41	1.84e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.59	-5.23	-0.4	5.79e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.99	13.55	0.75	1.2100000000000001e-27	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.49	5.57	0.42	1.18e-7	Testicular germ cell tumor;
UCEC	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.35	-0.4	3.37e-7	Menarche (age at onset);
UCEC	cis	rs7246967	0.673	rs7249685	chr19:22882379	C/T	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.84	-10.25	-0.65	6.15e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.5	4.96	0.38	1.91e-6	Diastolic blood pressure;
UCEC	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg17420585	chr12:42539391	GXYLT1	0.4	5.11	0.39	1e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.84	4.65	0.36	7.48e-6	Diabetic kidney disease;
UCEC	cis	rs883565	0.528	rs4676584	chr3:38965907	C/A	cg01426195	chr3:39028469	NA	0.58	6.86	0.49	1.76e-10	Handedness;
UCEC	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg06637938	chr14:75390232	RPS6KL1	0.71	7.0	0.5	8.63e-11	Caffeine consumption;
UCEC	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.68	5.96	0.44	1.76e-8	Subjective well-being;
UCEC	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.63	4.95	0.38	2.04e-6	Carotid intima media thickness;
UCEC	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs11235843	0.929	rs68128239	chr11:73420592	G/A	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.21	0.39	6.27e-7	Rheumatoid arthritis;
UCEC	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg24675658	chr1:53192096	ZYG11B	-0.79	-8.8	-0.59	3.43e-15	Monocyte count;
UCEC	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.56	-5.03	-0.38	1.38e-6	Post bronchodilator FEV1;
UCEC	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.88	5.17	0.39	7.65e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7113850	0.541	rs77227176	chr11:24208375	T/C	ch.11.24196551F	chr11:24239977	NA	0.67	4.92	0.38	2.29e-6	Bone fracture in osteoporosis;
UCEC	cis	rs466639	0.810	rs78785488	chr1:165387479	T/G	cg03421657	chr1:166039754	FAM78B	0.42	4.59	0.35	9.54e-6	Menarche (age at onset);
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg06818710	chr6:28411271	ZSCAN23	0.54	6.52	0.47	1.08e-9	Cardiac Troponin-T levels;
UCEC	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.26	-0.4	4.9e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9467773	1.000	rs9467802	chr6:26581168	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.61	6.71	0.48	3.92e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.69	0.36	6.08e-6	Breast cancer;
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.89e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4588572	0.643	rs10063319	chr5:77758425	T/C	cg11547950	chr5:77652471	NA	-0.49	-5.55	-0.42	1.3e-7	Triglycerides;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.42	-0.47	1.74e-9	Cardiac Troponin-T levels;
UCEC	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	0.9	6.27	0.46	3.74e-9	Iron status biomarkers;
UCEC	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg20485758	chr6:26088446	HFE	0.69	4.59	0.35	9.5e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-0.61	-5.48	-0.41	1.83e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.73	7.7	0.54	1.88e-12	Breast cancer;
UCEC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.57	-8.3	-0.56	6.26e-14	Refractive error;
UCEC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.27	-0.4	4.82e-7	Breast cancer;
UCEC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08805041	chr16:621841	PIGQ	-0.34	-5.18	-0.39	7.31e-7	Height;
UCEC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg23018236	chr17:30244563	NA	-0.64	-4.63	-0.36	8.01e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.99	-0.38	1.69e-6	Gut microbiome composition (summer);
UCEC	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg19678392	chr7:94953810	PON1	-0.58	-5.65	-0.42	7.97e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs12984634	chr19:22833744	C/T	cg24889512	chr19:22816950	ZNF492	0.58	6.19	0.45	5.82e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.46	-5.07	-0.39	1.17e-6	Mean corpuscular hemoglobin;
UCEC	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.93	5.9	0.44	2.39e-8	Plasma clusterin levels;
UCEC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.87	-9.46	-0.62	7.07e-17	Cognitive function;
UCEC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-4.9	-0.37	2.47e-6	Alzheimer's disease (late onset);
UCEC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg16497661	chr14:103986332	CKB	0.49	5.85	0.43	3.01e-8	Body mass index;
UCEC	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.54	5.14	0.39	8.54e-7	Cleft lip with or without cleft palate;
UCEC	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.85	-0.43	3.07e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg18681998	chr4:17616180	MED28	-0.84	-10.71	-0.66	3.76e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs79815064	0.850	rs74433128	chr3:46279933	T/G	cg19145607	chr3:45983792	CXCR6;FYCO1	0.71	4.69	0.36	6.16e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.8	8.18	0.56	1.2e-13	Parkinson's disease;
UCEC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.79	5.9	0.44	2.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.57	-6.2	-0.46	5.54e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg18681998	chr4:17616180	MED28	-0.57	-6.31	-0.46	3.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.21	0.51	2.76e-11	Bladder cancer;
UCEC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.76	8.25	0.56	8.04e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg20026190	chr17:76395443	PGS1	0.38	4.64	0.36	7.72e-6	HDL cholesterol levels;
UCEC	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.63	-5.53	-0.42	1.42e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.69e-7	Menarche (age at onset);
UCEC	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.44	-5.25	-0.4	5.16e-7	Metabolite levels;
UCEC	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.37	-5.36	-0.4	3.16e-7	Vitamin D levels;
UCEC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.69	6.37	0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.45	4.94	0.38	2.13e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.53	5.69	0.42	6.81e-8	Menarche (age at onset);
UCEC	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.76	-0.37	4.69e-6	Extrinsic epigenetic age acceleration;
UCEC	trans	rs12755164	0.771	rs6657082	chr1:73353328	A/T	cg17780956	chr4:156297616	MAP9	0.66	6.89	0.49	1.51e-10	Schizophrenia;
UCEC	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.51	4.81	0.37	3.71e-6	Temperament;
UCEC	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.71	6.7	0.48	4.22e-10	Crohn's disease;
UCEC	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.65	-5.8	-0.43	3.97e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12545109	0.723	rs2610045	chr8:57413439	A/G	cg07776626	chr8:57350775	NA	0.41	4.61	0.36	8.61e-6	Obesity-related traits;
UCEC	cis	rs12767760	0.714	rs1417408	chr10:99298476	T/C	cg17778955	chr10:99210596	ZDHHC16	-0.47	-4.81	-0.37	3.63e-6	Obesity-related traits;
UCEC	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.66	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	5.9	0.44	2.46e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs9463078	0.625	rs3799986	chr6:44900253	C/T	cg25276700	chr6:44698697	NA	0.41	4.53	0.35	1.2e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	6.55	0.48	8.94e-10	Bone mineral density;
UCEC	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs9463078	0.845	rs6458419	chr6:45085038	T/C	cg25276700	chr6:44698697	NA	-0.42	-4.53	-0.35	1.23e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.32	4.82	0.37	3.48e-6	Schizophrenia;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.48	-5.1	-0.39	1.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.59	-6.56	-0.48	8.44e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.63	9.22	0.61	2.95e-16	Prudent dietary pattern;
UCEC	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.64	-4.72	-0.36	5.43e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2302190	0.941	rs6503865	chr17:56549672	A/C	cg12560992	chr17:57184187	TRIM37	0.55	4.9	0.37	2.45e-6	Vitamin D levels;
UCEC	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.54	4.86	0.37	2.92e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07215822	chr6:158701037	NA	0.66	5.77	0.43	4.55e-8	Height;
UCEC	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.68	8.16	0.56	1.4e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.43	4.55	0.35	1.09e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.06	0.45	1.08e-8	Cognitive test performance;
UCEC	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.94	-10.6	-0.66	7.41e-20	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.54	-5.88	-0.44	2.61e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.47	-5.59	-0.42	1.06e-7	Dupuytren's disease;
UCEC	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.74	0.36	4.99e-6	Educational attainment;
UCEC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.17	0.51	3.31e-11	Bladder cancer;
UCEC	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.28	-0.51	1.85e-11	Coronary artery disease;
UCEC	cis	rs7975161	0.786	rs10861181	chr12:104651110	T/C	cg25273343	chr12:104657179	TXNRD1	-0.57	-5.27	-0.4	4.77e-7	Toenail selenium levels;
UCEC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.76	-7.98	-0.55	3.84e-13	Cognitive function;
UCEC	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.62	6.96	0.5	1.06e-10	Height;
UCEC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.77	-8.89	-0.59	1.99e-15	Immature fraction of reticulocytes;
UCEC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.5	-5.24	-0.4	5.38e-7	Blood metabolite levels;
UCEC	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg01256987	chr12:42539512	GXYLT1	0.42	4.92	0.38	2.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.67	-5.53	-0.41	1.44e-7	Alcohol dependence;
UCEC	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.59	-7.09	-0.5	5.13e-11	Oral cavity cancer;
UCEC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.59	0.42	1.05e-7	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg09655341	chr17:79618100	PDE6G	-0.31	-4.75	-0.36	4.8e-6	Eye color traits;
UCEC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg14517863	chr17:44321492	NA	-0.38	-5.09	-0.39	1.07e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.52	-5.18	-0.39	7.07e-7	Brugada syndrome;
UCEC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-7.74	-0.54	1.49e-12	Tonsillectomy;
UCEC	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	6.22	0.46	4.82e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg18681998	chr4:17616180	MED28	0.77	8.85	0.59	2.54e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg15837086	chr1:46506065	PIK3R3	-0.39	-4.94	-0.38	2.08e-6	Red blood cell count;Reticulocyte count;
UCEC	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.68	7.96	0.55	4.39e-13	Immature fraction of reticulocytes;
UCEC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.99	0.44	1.56e-8	Breast cancer;
UCEC	cis	rs7517126	1.000	rs7514704	chr1:196839991	A/G	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs7267005	0.661	rs17093099	chr20:34387463	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg23711669	chr6:146136114	FBXO30	-0.54	-6.09	-0.45	9.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.75	6.91	0.5	1.36e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	0.93	9.64	0.62	2.38e-17	Heart rate;
UCEC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.61	-7.63	-0.53	2.72e-12	Prostate cancer;
UCEC	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg02733842	chr7:1102375	C7orf50	-0.63	-5.78	-0.43	4.34e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.46	-0.47	1.41e-9	Blood metabolite levels;
UCEC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	Androgen levels;
UCEC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-6.87	-0.49	1.7e-10	Electrocardiographic conduction measures;
UCEC	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg08501292	chr6:25962987	TRIM38	0.99	4.62	0.36	8.46e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs2880058	0.521	rs6678610	chr1:162009345	A/T	cg19523287	chr12:49488311	DHH	-0.65	-6.71	-0.48	3.88e-10	QT interval;
UCEC	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.85	7.61	0.53	3.06e-12	Body mass index;
UCEC	cis	rs2455799	0.613	rs13071303	chr3:15958203	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-5.94	-0.44	1.99e-8	Mean platelet volume;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.85	-0.37	3.16e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-6.99	-0.5	8.77e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.42	6.73	0.49	3.63e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.57	6.33	0.46	2.87e-9	Sjögren's syndrome;
UCEC	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.65	-6.94	-0.5	1.15e-10	Blood trace element (Zn levels);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17371249	chr1:241682474	FH	0.6	7.16	0.51	3.57e-11	Warfarin maintenance dose;
UCEC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.67	7.61	0.53	3.06e-12	Menopause (age at onset);
UCEC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.58	-5.98	-0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	4.95	0.38	2.04e-6	Menarche (age at onset);
UCEC	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.24	-7.51	-0.53	5.14e-12	Diabetic kidney disease;
UCEC	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.63	6.85	0.49	1.87e-10	Glomerular filtration rate (creatinine);
UCEC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-10.61	-0.66	6.79e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs713477	0.901	rs7146306	chr14:55905853	C/T	cg13175173	chr14:55914753	NA	-0.41	-4.62	-0.36	8.18e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg05738196	chr6:26577821	NA	0.64	7.6	0.53	3.21e-12	Intelligence (multi-trait analysis);
UCEC	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.43	5.02	0.38	1.48e-6	Blood metabolite ratios;
UCEC	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	0.62	6.33	0.46	2.78e-9	Vitiligo;
UCEC	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.72	6.55	0.48	8.85e-10	Aortic root size;
UCEC	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.51	5.68	0.42	6.85e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9863	0.861	rs4765528	chr12:124462254	A/T	cg12597309	chr12:124393772	DNAH10	-0.33	-4.72	-0.36	5.36e-6	White blood cell count;
UCEC	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.63	5.49	0.41	1.7e-7	Uric acid levels;
UCEC	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.43	-4.95	-0.38	2.03e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.63	6.69	0.48	4.38e-10	QRS complex (12-leadsum);
UCEC	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.65	6.55	0.48	8.95e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs2901460	0.527	rs10167456	chr2:62112839	G/A	cg02183531	chr2:62113199	CCT4	-0.57	-4.82	-0.37	3.53e-6	Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25605045	chr2:97523931	ANKRD39	0.65	7.48	0.53	6.28e-12	Warfarin maintenance dose;
UCEC	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg13647831	chr13:111720013	NA	-0.73	-4.6	-0.35	9.15e-6	Obesity-related traits;
UCEC	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	0.94	13.89	0.75	1.51e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.54	-4.86	-0.37	2.97e-6	Hypospadias;
UCEC	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.45	-5.22	-0.4	5.98e-7	Birth weight;
UCEC	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg24848339	chr3:12840334	CAND2	-0.39	-4.85	-0.37	3.08e-6	QRS complex (12-leadsum);
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.36	-0.46	2.41e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.9	9.28	0.61	2.04e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.62	5.14	0.39	8.67e-7	Body mass index;
UCEC	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.62	-7.43	-0.52	8.05e-12	Prevalent atrial fibrillation;
UCEC	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.42	-5.78	-0.43	4.33e-8	Metabolite levels;
UCEC	cis	rs7709377	0.597	rs10079691	chr5:115472076	A/G	cg23108291	chr5:115420582	COMMD10	-0.51	-5.29	-0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.87	-0.37	2.84e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.51	5.53	0.42	1.41e-7	Platelet count;
UCEC	cis	rs9326248	0.530	rs10750100	chr11:116917244	T/C	cg13068653	chr11:117074303	TAGLN	0.54	4.74	0.36	4.93e-6	Blood protein levels;
UCEC	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.65	-7.35	-0.52	1.29e-11	Menarche (age at onset);
UCEC	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.81	8.2	0.56	1.12e-13	Colorectal cancer;
UCEC	cis	rs2603127	0.634	rs3100641	chr3:108294705	A/G	cg25456186	chr3:108837069	MORC1	0.71	4.72	0.36	5.56e-6	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.57	6.09	0.45	9.17e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs8020441	0.588	rs59096640	chr14:51186392	G/C	cg04730355	chr14:51134070	SAV1	0.65	5.73	0.43	5.5e-8	Cognitive performance;
UCEC	cis	rs10789491	0.767	rs4660359	chr1:47190019	C/G	cg15501359	chr1:47185051	KIAA0494	0.77	6.18	0.45	6.1e-9	Response to hepatitis C treatment;
UCEC	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg16583315	chr14:65563665	MAX	-0.41	-4.62	-0.36	8.31e-6	Obesity-related traits;
UCEC	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.03	0.5	7.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.69	8.71	0.58	5.7e-15	Menarche (age at onset);
UCEC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg12292205	chr6:26970375	C6orf41	0.59	5.22	0.4	5.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.66	6.3	0.46	3.33e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.54	5.41	0.41	2.45e-7	Menopause (age at onset);
UCEC	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	5.4	0.41	2.68e-7	Bipolar disorder;
UCEC	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.83	0.49	2.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs3736594	0.513	rs62138966	chr2:27819172	G/A	cg27432699	chr2:27873401	GPN1	0.51	4.65	0.36	7.27e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs6684428	0.536	rs11206686	chr1:56394673	A/G	cg11651538	chr1:56320950	NA	-0.44	-4.52	-0.35	1.27e-5	Airflow obstruction;
UCEC	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.62	5.09	0.39	1.06e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.35	-5.19	-0.39	6.98e-7	Alcohol dependence;
UCEC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg07596299	chr11:71824057	C11orf51	-0.92	-5.06	-0.39	1.24e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.37	5.5	0.41	1.66e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.57	4.59	0.35	9.35e-6	Longevity;
UCEC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg04154034	chr17:28927549	LRRC37B2	0.8	5.25	0.4	5.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.14e-6	Schizophrenia;
UCEC	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.48	-4.58	-0.35	9.98e-6	Personality dimensions;
UCEC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg27624424	chr6:160112604	SOD2	0.57	5.39	0.41	2.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg11859384	chr17:80120422	CCDC57	0.54	5.95	0.44	1.91e-8	Life satisfaction;
UCEC	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.8	8.4	0.57	3.43e-14	Caffeine consumption;
UCEC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	-0.53	-5.13	-0.39	8.95e-7	Lymphocyte counts;
UCEC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg19678392	chr7:94953810	PON1	-0.56	-5.12	-0.39	9.29e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.48	-5.34	-0.4	3.42e-7	Neuroticism;
UCEC	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.57	-6.09	-0.45	9.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.56	-5.43	-0.41	2.31e-7	Aortic root size;
UCEC	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.41	5.27	0.4	4.88e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg14851346	chr12:38532713	NA	0.52	5.02	0.38	1.47e-6	Heart rate;
UCEC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg18478394	chr8:109455254	TTC35	0.52	5.0	0.38	1.62e-6	Dupuytren's disease;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-4.91	-0.38	2.42e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.67	7.83	0.54	8.95e-13	Mean corpuscular volume;
UCEC	cis	rs2979489	0.945	rs2979472	chr8:30291704	G/C	cg26383811	chr8:30366931	RBPMS	0.66	5.03	0.38	1.41e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.12	18.43	0.84	4.85e-40	IgG glycosylation;
UCEC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	5.96	0.44	1.76e-8	Monocyte percentage of white cells;
UCEC	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg03342759	chr3:160939853	NMD3	0.51	4.75	0.36	4.77e-6	Morning vs. evening chronotype;
UCEC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg22654517	chr2:96458247	NA	0.43	4.79	0.37	4.01e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg04287289	chr16:89883240	FANCA	-0.5	-5.31	-0.4	3.91e-7	Vitiligo;
UCEC	cis	rs12318506	0.826	rs11180438	chr12:75668035	T/G	cg04728562	chr12:75699417	CAPS2	-0.8	-5.0	-0.38	1.6e-6	Coronary artery calcification;
UCEC	cis	rs7113850	0.541	rs79932281	chr11:24231839	T/G	ch.11.24196551F	chr11:24239977	NA	0.65	5.09	0.39	1.08e-6	Bone fracture in osteoporosis;
UCEC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.68	6.54	0.47	9.67e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs975730	0.966	rs10094878	chr8:129345261	A/G	cg14920061	chr8:129326392	NA	0.34	4.52	0.35	1.24e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	0.94	13.52	0.74	1.46e-27	Homoarginine levels;
UCEC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.54	5.31	0.4	3.97e-7	Menopause (age at onset);
UCEC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.79	-8.61	-0.58	1.04e-14	Immature fraction of reticulocytes;
UCEC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.73	7.44	0.52	7.8e-12	Blood protein levels;
UCEC	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.56	5.76	0.43	4.66e-8	IgG glycosylation;
UCEC	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.45	-0.41	2.1e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg11323433	chr13:111301576	CARS2	-0.78	-4.66	-0.36	6.91e-6	Obesity-related traits;
UCEC	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg09904177	chr6:26538194	HMGN4	-0.73	-5.03	-0.38	1.42e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs253959	0.842	rs10079037	chr5:115454221	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.48	-5.25	-0.4	5.15e-7	Menarche (age at onset);
UCEC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.54	0.58	1.59e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.45	4.8	0.37	3.81e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.67	-5.7	-0.43	6.47e-8	Schizophrenia;
UCEC	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg24562669	chr7:97807699	LMTK2	0.47	5.36	0.4	3.13e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.43	5.15	0.39	8.22e-7	Total body bone mineral density;
UCEC	trans	rs10091038	0.966	rs12679976	chr8:29365363	G/A	cg01832757	chr6:159547894	NA	0.42	6.67	0.48	4.81e-10	Response to statin therapy;
UCEC	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.5	4.94	0.38	2.12e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.54	5.33	0.4	3.6e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.71	-5.26	-0.4	5e-7	Narcolepsy;
UCEC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs6060717	0.536	rs17432470	chr20:34547763	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.76	-0.37	4.55e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.88	-8.56	-0.58	1.36e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs75804782	0.630	rs79693451	chr2:239296473	A/G	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-6.15	-0.45	7.1e-9	Tonsillectomy;
UCEC	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.43	5.39	0.41	2.72e-7	HIV-1 susceptibility;
UCEC	cis	rs10242455	0.867	rs2740558	chr7:99324743	T/C	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.73	6.33	0.46	2.76e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.69	7.59	0.53	3.34e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.54	-5.4	-0.41	2.62e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.49	-4.78	-0.37	4.29e-6	Body mass index;
UCEC	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg05527609	chr1:210001259	C1orf107	-0.52	-4.75	-0.36	4.89e-6	Red blood cell count;
UCEC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg13147721	chr7:65941812	NA	-0.84	-5.48	-0.41	1.81e-7	Diabetic kidney disease;
UCEC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg04043695	chr12:129287642	SLC15A4	-0.73	-7.14	-0.51	3.99e-11	Systemic lupus erythematosus;
UCEC	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs35934224	0.783	rs45465601	chr22:19868678	T/C	cg00936699	chr22:20101830	TRMT2A	-0.45	-4.79	-0.37	4.04e-6	Glaucoma (primary open-angle);
UCEC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.53	4.83	0.37	3.44e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.62	7.07	0.5	5.86e-11	Retinal vascular caliber;
UCEC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.65	-5.91	-0.44	2.25e-8	Aortic root size;
UCEC	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.62	7.29	0.52	1.73e-11	Obesity-related traits;
UCEC	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	0.96	10.47	0.65	1.65e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.92	-7.2	-0.51	2.93e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	6.18	0.45	6.12e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs8105895	1.000	rs17450788	chr19:22224755	T/C	cg02912127	chr19:22235281	ZNF257	-0.51	-4.55	-0.35	1.14e-5	Body mass index (change over time);
UCEC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.73	0.54	1.55e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg04450003	chr12:50355995	AQP5	0.81	5.58	0.42	1.12e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-0.96	-4.92	-0.38	2.27e-6	Mitochondrial DNA levels;
UCEC	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.21	-0.46	5.16e-9	Metabolite levels;
UCEC	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.57	-0.35	1.01e-5	Cardiac Troponin-T levels;
UCEC	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.78	0.54	1.16e-12	Eye color traits;
UCEC	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg08807892	chr2:162101083	NA	0.58	6.0	0.44	1.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.1	0.39	1.02e-6	Aortic root size;
UCEC	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	2.01e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs925228	0.793	rs11679459	chr2:24091908	A/T	cg16945982	chr2:25016118	CENPO;C2orf79	-0.51	-4.64	-0.36	7.74e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6565681	0.883	rs4523980	chr17:78347664	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.67	-4.66	-0.36	7.11e-6	Moyamoya disease;
UCEC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg05738196	chr6:26577821	NA	0.57	5.43	0.41	2.29e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11574514	1.000	rs1123072	chr16:67898797	G/A	cg23401756	chr16:68013981	DPEP3	-0.62	-4.52	-0.35	1.24e-5	Crohn's disease;
UCEC	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	0.99	5.76	0.43	4.86e-8	Schizophrenia;
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.7	8.17	0.56	1.32e-13	Menarche (age at onset);
UCEC	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-5.01	-0.38	1.51e-6	HDL cholesterol;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	6.74	0.49	3.36e-10	Platelet count;
UCEC	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg15837086	chr1:46506065	PIK3R3	0.44	4.73	0.36	5.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.39	4.91	0.38	2.36e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.54	-0.35	1.15e-5	Parkinson's disease;
UCEC	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.73	-5.68	-0.42	6.85e-8	Orofacial clefts;
UCEC	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2882667	0.929	rs17207828	chr5:138299835	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-4.55	-0.35	1.12e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg12024160	chr4:1254474	NA	0.61	7.13	0.51	4.32e-11	Obesity-related traits;
UCEC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.57	-4.99	-0.38	1.65e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.59	-6.92	-0.5	1.28e-10	Cardiac Troponin-T levels;
UCEC	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.66	7.0	0.5	8.43e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.42	-4.71	-0.36	5.59e-6	Alcoholic chronic pancreatitis;
UCEC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg04357082	chr16:980022	LMF1	0.45	4.7	0.36	6.04e-6	Non-glioblastoma glioma;Glioblastoma;Glioma;
UCEC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-6.6	-0.48	7.03e-10	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.53	5.42	0.41	2.36e-7	Post bronchodilator FEV1;
UCEC	cis	rs6832769	1.000	rs3805154	chr4:56363927	C/T	cg05960024	chr4:56376020	CLOCK	0.57	5.8	0.43	3.97e-8	Personality dimensions;
UCEC	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Electroencephalogram traits;
UCEC	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.77	-0.37	4.34e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.56	-4.96	-0.38	1.95e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs970548	0.954	rs7076198	chr10:45996309	C/T	cg15223267	chr10:46222474	FAM21C	0.54	5.15	0.39	8.09e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg23625390	chr15:77176239	SCAPER	0.46	5.22	0.4	5.91e-7	Blood metabolite levels;
UCEC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.62	-6.8	-0.49	2.46e-10	Longevity;
UCEC	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.44	-5.15	-0.39	8.15e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.66	-7.69	-0.54	1.93e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.69	-7.1	-0.51	4.96e-11	Cognitive function;
UCEC	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.73	-8.21	-0.56	1.04e-13	Waist circumference;Body mass index;
UCEC	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.67	7.55	0.53	4.22e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.59	6.42	0.47	1.73e-9	Prostate cancer;
UCEC	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.51	5.3	0.4	4.15e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg04756594	chr16:24857601	SLC5A11	-0.48	-4.7	-0.36	5.82e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.57	-5.45	-0.41	2.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.56	-6.34	-0.46	2.62e-9	Mean platelet volume;
UCEC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.6	-6.17	-0.45	6.21e-9	Blood trace element (Zn levels);
UCEC	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-5.14	-0.39	8.75e-7	Blood metabolite levels;
UCEC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.76	7.6	0.53	3.17e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-4.56	-0.35	1.05e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg23070574	chr3:14187308	XPC	0.46	5.19	0.39	6.97e-7	Ovarian reserve;
UCEC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.41	-4.83	-0.37	3.32e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.72	-5.85	-0.43	3.13e-8	Coronary artery calcification;
UCEC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg13695892	chr22:41940480	POLR3H	-0.7	-4.81	-0.37	3.75e-6	Vitiligo;
UCEC	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.74	-5.9	-0.44	2.41e-8	Alzheimer's disease (late onset);
UCEC	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.89	12.63	0.72	3.12e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.56	5.05	0.38	1.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.65	-4.92	-0.38	2.26e-6	Autism;
UCEC	cis	rs6540	1.000	rs6540	chr11:252649	C/T	cg19150467	chr11:489454	PTDSS2	-0.67	-4.72	-0.36	5.35e-6	Endometriosis;
UCEC	cis	rs4148689	1.000	rs4148686	chr7:117134517	C/G	cg21212505	chr7:117228958	CFTR	-0.42	-4.71	-0.36	5.75e-6	Gout;
UCEC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.36	-4.69	-0.36	6.09e-6	Monocyte count;
UCEC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.82	10.25	0.65	6.32e-19	IgG glycosylation;
UCEC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.6	-5.8	-0.43	3.9e-8	Blood metabolite levels;
UCEC	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.28e-10	Blood protein levels;
UCEC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs350251	0.934	rs350207	chr16:12212914	T/G	cg01282078	chr16:12139025	RUNDC2A	-0.47	-4.61	-0.36	8.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.57	5.51	0.41	1.6e-7	Retinal vascular caliber;
UCEC	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs9326726	0.844	rs4957755	chr5:107704203	T/C	cg17432647	chr5:107996819	NA	-0.54	-4.68	-0.36	6.54e-6	Resting heart rate;
UCEC	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.55	-0.53	4.31e-12	Hypospadias;
UCEC	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	0.71	5.69	0.42	6.8e-8	Blood protein levels;
UCEC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg00343986	chr7:65444356	GUSB	-0.53	-4.92	-0.38	2.34e-6	Aortic root size;
UCEC	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.68	5.73	0.43	5.5e-8	Menopause (age at onset);
UCEC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.66	-0.48	5.19e-10	Chronic sinus infection;
UCEC	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.57	5.57	0.42	1.19e-7	Eosinophil percentage of white cells;
UCEC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.68	5.64	0.42	8.58e-8	Corneal astigmatism;
UCEC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg00657871	chr1:85156634	SSX2IP	-0.55	-6.99	-0.5	9.01e-11	Iris heterochromicity;
UCEC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	9.47	0.62	6.58e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.83	4.72	0.36	5.37e-6	Diabetic retinopathy;
UCEC	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	11.83	0.7	4.15e-23	Prudent dietary pattern;
UCEC	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.52	5.9	0.44	2.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg24675658	chr1:53192096	ZYG11B	-0.77	-8.56	-0.58	1.36e-14	Monocyte count;
UCEC	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-7.78	-0.54	1.18e-12	Chronic sinus infection;
UCEC	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.41	4.99	0.38	1.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.54	-6.23	-0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg22166914	chr1:53195759	ZYG11B	0.66	7.01	0.5	7.83e-11	Monocyte count;
UCEC	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg14008862	chr17:28927542	LRRC37B2	0.73	4.64	0.36	7.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs600806	0.778	rs9661614	chr1:110021837	T/C	cg02175308	chr1:109941060	SORT1	0.29	4.64	0.36	7.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg14092571	chr14:90743983	NA	0.41	5.34	0.4	3.39e-7	Mortality in heart failure;
UCEC	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.74	-4.7	-0.36	5.94e-6	Night sleep phenotypes;
UCEC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.57	-4.58	-0.35	9.93e-6	Menopause (age at onset);
UCEC	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg26067569	chr2:200525129	NA	-0.53	-4.54	-0.35	1.17e-5	Schizophrenia;
UCEC	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-4.86	-0.37	2.94e-6	Gut microbiome composition (summer);
UCEC	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.09	8.74	0.58	4.8e-15	Uric acid levels;
UCEC	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.51	4.69	0.36	6.25e-6	Menopause (age at onset);
UCEC	cis	rs7246967	0.611	rs60021625	chr19:22829554	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg19567339	chr10:100142640	NA	0.54	6.44	0.47	1.56e-9	Metabolite levels;
UCEC	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24249390	chr15:90295951	MESP1	-0.41	-4.63	-0.36	7.87e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.39	4.52	0.35	1.24e-5	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	6.06	0.45	1.1e-8	Height;
UCEC	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg05963712	chr12:49373746	WNT1	0.46	4.51	0.35	1.3e-5	Longevity (90 years and older);
UCEC	cis	rs11958404	0.929	rs6890364	chr5:157380519	T/G	cg05962755	chr5:157440814	NA	0.77	4.64	0.36	7.49e-6	IgG glycosylation;
UCEC	cis	rs6460942	0.908	rs117451929	chr7:12265149	A/T	cg06484146	chr7:12443880	VWDE	-0.63	-4.58	-0.35	9.86e-6	Coronary artery disease;
UCEC	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg04730355	chr14:51134070	SAV1	-0.47	-4.81	-0.37	3.75e-6	Mean platelet volume;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.06	-0.45	1.07e-8	Pubertal anthropometrics;
UCEC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg19318889	chr4:1322082	MAEA	0.42	4.92	0.38	2.32e-6	Obesity-related traits;
UCEC	cis	rs4372836	0.964	rs2293553	chr2:28932284	C/T	cg09522027	chr2:28974177	PPP1CB	0.72	7.33	0.52	1.39e-11	Body mass index;
UCEC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-0.89	-11.68	-0.69	1.03e-22	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17665859	0.844	rs73175035	chr8:460615	A/C	cg17960703	chr8:356704	FBXO25	1.06	4.9	0.37	2.46e-6	Bilirubin levels;
UCEC	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg13147721	chr7:65941812	NA	-1.02	-5.29	-0.4	4.42e-7	Diabetic kidney disease;
UCEC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.13e-7	Aortic root size;
UCEC	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.88	-7.46	-0.52	7.01e-12	Coronary artery calcification;
UCEC	cis	rs7258465	1.000	rs10413237	chr19:18548249	A/C	cg01380346	chr19:18557039	ELL	-0.49	-4.88	-0.37	2.78e-6	Breast cancer;
UCEC	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg04154034	chr17:28927549	LRRC37B2	0.66	4.82	0.37	3.57e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg06096015	chr1:231504339	EGLN1	0.49	5.97	0.44	1.71e-8	Hemoglobin concentration;
UCEC	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-4.82	-0.37	3.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.03	-0.38	1.39e-6	Gut microbiome composition (summer);
UCEC	cis	rs9567349	0.541	rs7328408	chr13:44634989	C/T	cg17491360	chr13:45384268	NA	-0.51	-4.73	-0.36	5.28e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.65	6.72	0.48	3.65e-10	Body mass index;
UCEC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.81	4.56	0.35	1.06e-5	Diabetic retinopathy;
UCEC	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg05738196	chr6:26577821	NA	-0.54	-5.09	-0.39	1.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.49	-5.57	-0.42	1.17e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18854424	chr1:2615690	NA	0.46	6.42	0.47	1.77e-9	Ulcerative colitis;
UCEC	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.5	-5.05	-0.38	1.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.42	-5.54	-0.42	1.37e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.49	5.74	0.43	5.13e-8	Pulse pressure;
UCEC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg07153921	chr17:41440717	NA	-0.58	-6.94	-0.5	1.18e-10	Menopause (age at onset);
UCEC	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.67	-6.38	-0.47	2.2e-9	Strep throat;
UCEC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.42e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.58	-6.77	-0.49	2.9e-10	Prostate cancer;
UCEC	trans	rs6479901	0.895	rs7920159	chr10:64972176	C/G	cg12751693	chr12:62629162	NA	-0.54	-6.73	-0.49	3.49e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.49	-6.59	-0.48	7.22e-10	Body mass index;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.68	-0.48	4.54e-10	Cardiac Troponin-T levels;
UCEC	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-6.58	-0.48	7.9e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs9900062	0.586	rs6504249	chr17:62676149	A/G	cg02097616	chr17:62675921	NA	0.45	4.94	0.38	2.08e-6	QT interval;
UCEC	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.51	-5.05	-0.38	1.3e-6	Bone mineral density;
UCEC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.54	0.42	1.39e-7	Body mass index;
UCEC	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.56	5.16	0.39	7.74e-7	Morning vs. evening chronotype;
UCEC	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.63	7.51	0.53	5.33e-12	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg03714773	chr7:91764589	CYP51A1	0.43	5.21	0.39	6.23e-7	Breast cancer;
UCEC	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs17490626	0.568	rs12413529	chr10:71211644	G/T	cg12610070	chr10:71211762	TSPAN15	-0.39	-6.17	-0.45	6.39e-9	Thrombosis;
UCEC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.61	-4.83	-0.37	3.42e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.53	-4.94	-0.38	2.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.56	-4.93	-0.38	2.24e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.6	4.72	0.36	5.37e-6	Corneal astigmatism;
UCEC	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg27068330	chr11:65405492	SIPA1	-0.53	-4.71	-0.36	5.7e-6	Breast cancer;
UCEC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.63	7.1	0.51	4.9e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.77	0.43	4.48e-8	Breast cancer;
UCEC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg07169764	chr2:136633963	MCM6	-0.51	-4.62	-0.36	8.33e-6	Colorectal cancer;
UCEC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.74	-7.02	-0.5	7.74e-11	Menopause (age at onset);
UCEC	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.81	5.15	0.39	8.05e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs11760485	0.965	rs5021673	chr7:4399638	C/G	cg22450045	chr7:4839495	RADIL	0.41	4.86	0.37	2.94e-6	Early childhood aggressive behavior;
UCEC	cis	rs10242455	0.867	rs1818797	chr7:99296195	G/A	cg07715041	chr7:99302981	CYP3A7	-0.47	-4.83	-0.37	3.33e-6	Blood metabolite levels;
UCEC	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.45	-4.65	-0.36	7.2e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.56	6.12	0.45	8.19e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2213920	0.569	rs6478170	chr9:118246331	G/A	cg13918206	chr9:118159781	DEC1	0.73	4.91	0.38	2.4e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.88	0.44	2.61e-8	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.91	12.85	0.73	8.32e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	5.07	0.39	1.19e-6	Response to antipsychotic treatment;
UCEC	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg02693607	chr7:27150598	HOXA3	0.6	5.03	0.38	1.42e-6	Type 1 diabetes;
UCEC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.48	4.94	0.38	2.07e-6	Platelet count;
UCEC	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.18	9.82	0.63	8.37e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs34172651	1.000	rs34172651	chr16:24766841	T/C	cg04756594	chr16:24857601	SLC5A11	0.42	4.96	0.38	1.93e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs11881740	chr19:22843844	T/C	cg08271804	chr19:22816896	ZNF492	0.61	6.21	0.46	5.18e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.46	-5.03	-0.38	1.38e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	8.62	0.58	9.66e-15	Mean platelet volume;
UCEC	cis	rs11343	0.675	rs7359333	chr16:19262344	A/T	cg09635681	chr16:19729622	C16orf88;IQCK	-0.52	-4.6	-0.35	9.09e-6	Parkinson's disease;
UCEC	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.64	5.12	0.39	9.36e-7	Prostate cancer;
UCEC	cis	rs5167	0.504	rs66867801	chr19:45457293	C/T	cg13119609	chr19:45449297	APOC2	0.43	6.22	0.46	4.96e-9	Blood protein levels;
UCEC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.65	6.03	0.45	1.24e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg20821713	chr7:1055600	C7orf50	-0.45	-5.04	-0.38	1.36e-6	Longevity;Endometriosis;
UCEC	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.4	5.26	0.4	5.03e-7	Alcohol dependence;
UCEC	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	7.02	0.5	7.67e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs10137082	0.765	rs8014568	chr14:23843363	C/T	cg09353400	chr14:23504423	PSMB5	-0.52	-4.55	-0.35	1.1e-5	Type 1 diabetes;
UCEC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.56	0.48	8.79e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.73	8.91	0.59	1.79e-15	Monocyte count;
UCEC	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.64	-8.44	-0.57	2.83e-14	Alcohol dependence (age at onset);
UCEC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.59	5.59	0.42	1.1e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.21	0.51	2.79e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.08	0.39	1.11e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.97	6.6	0.48	7.1e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.44	-0.47	1.62e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	-0.57	-6.54	-0.47	9.6e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	6.12	0.45	7.97e-9	HDL cholesterol;
UCEC	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-5.35	-0.4	3.24e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-4.79	-0.37	4.07e-6	Hair shape;
UCEC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.68	-5.08	-0.39	1.11e-6	Autism;
UCEC	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.54	5.33	0.4	3.65e-7	Coronary artery disease;
UCEC	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.93	-0.38	2.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.17	-0.45	6.3e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg26114124	chr12:9217669	LOC144571	0.4	4.85	0.37	3.05e-6	Sjögren's syndrome;
UCEC	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7520050	0.872	rs1707308	chr1:46604315	G/A	cg15837086	chr1:46506065	PIK3R3	-0.35	-4.57	-0.35	1.01e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.95	0.44	1.84e-8	Breast cancer;
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg04871131	chr7:94954202	PON1	-0.52	-5.13	-0.39	9.07e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.54	-4.65	-0.36	7.37e-6	Colorectal cancer;
UCEC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.48	-6.13	-0.45	7.78e-9	Mean platelet volume;
UCEC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.41	4.67	0.36	6.82e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg21827317	chr3:136751795	NA	0.49	5.52	0.41	1.49e-7	Gestational age at birth (child effect);
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.9	11.24	0.68	1.53e-21	Prudent dietary pattern;
UCEC	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs731174	0.592	rs12121777	chr1:38188841	C/T	cg24088508	chr1:38156462	C1orf109	-0.63	-4.89	-0.37	2.6e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg00614314	chr15:82944287	LOC80154	0.52	4.85	0.37	3.14e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-8.82	-0.59	3.05e-15	Height;
UCEC	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.72	6.82	0.49	2.25e-10	Schizophrenia;
UCEC	cis	rs7295749	0.609	rs12229182	chr12:27263632	A/G	cg13639987	chr12:27397408	STK38L	-1.01	-4.65	-0.36	7.22e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg20129853	chr10:51489980	NA	0.41	5.08	0.39	1.11e-6	Prostate-specific antigen levels;
UCEC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	4.63	0.36	8.09e-6	Cognitive test performance;
UCEC	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.56	4.95	0.38	2.01e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg00105475	chr2:10696890	NA	0.51	7.2	0.51	2.83e-11	Prostate cancer;
UCEC	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg23782820	chr8:58130467	NA	0.49	4.86	0.37	2.99e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-5.16	-0.39	8.02e-7	Monocyte percentage of white cells;
UCEC	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.78	-7.97	-0.55	4.15e-13	Cholesterol, total;
UCEC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.83	0.37	3.41e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg05991184	chr2:219186017	PNKD	-0.44	-4.54	-0.35	1.17e-5	Colorectal cancer;
UCEC	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.55	-5.69	-0.42	6.65e-8	White matter hyperintensity burden;
UCEC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.31	-5.2	-0.39	6.57e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.76	7.89	0.55	6.18e-13	Tonsillectomy;
UCEC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.69	5.82	0.43	3.6e-8	Menopause (age at onset);
UCEC	cis	rs8105895	0.935	rs62110987	chr19:22257295	A/C	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.07e-7	Body mass index (change over time);
UCEC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-8.04	-0.55	2.75e-13	Chronic sinus infection;
UCEC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.55	-5.21	-0.4	6.17e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7870753	0.628	rs2406001	chr9:99188970	C/G	cg25260653	chr9:99212216	HABP4	0.54	4.93	0.38	2.19e-6	Height;
UCEC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.85	5.57	0.42	1.2e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg14008862	chr17:28927542	LRRC37B2	0.67	5.17	0.39	7.42e-7	Body mass index;
UCEC	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-6.37	-0.46	2.33e-9	Crohn's disease;
UCEC	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.03	6.81	0.49	2.36e-10	Lung disease severity in cystic fibrosis;
UCEC	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-12.43	-0.72	1.07e-24	Coronary artery disease;
UCEC	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	6.36	0.46	2.35e-9	Lung function (FEV1/FVC);
UCEC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-4.95	-0.38	1.97e-6	Tonsillectomy;
UCEC	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.67	-5.98	-0.44	1.66e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.45	-6.29	-0.46	3.45e-9	Eye color traits;
UCEC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04731861	chr2:219085781	ARPC2	0.41	4.63	0.36	8e-6	Colorectal cancer;
UCEC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg04154034	chr17:28927549	LRRC37B2	0.55	4.74	0.36	5.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-9.52	-0.62	4.89e-17	Morning vs. evening chronotype;
UCEC	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.67	6.8	0.49	2.39e-10	Smoking behavior;
UCEC	cis	rs11543198	0.826	rs7174305	chr15:74728998	C/G	cg12101586	chr15:75019203	CYP1A1	0.72	4.55	0.35	1.13e-5	Bladder cancer;
UCEC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.73	6.02	0.44	1.35e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs79815064	0.850	rs79539493	chr3:46302938	G/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.73	4.58	0.35	9.85e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.81	-0.37	3.73e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	9.89	0.63	5.52e-18	Multiple sclerosis;
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.8	8.85	0.59	2.63e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.57e-6	Colorectal cancer;
UCEC	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs7224668	0.647	rs9898133	chr17:79249997	C/T	cg15215033	chr17:79258732	SLC38A10	0.34	4.86	0.37	2.94e-6	IgG glycosylation;
UCEC	cis	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg00614314	chr15:82944287	LOC80154	0.53	4.89	0.37	2.62e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-5.75	-0.43	5.08e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.41	4.61	0.36	8.67e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	4.58	0.35	9.81e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7597155	0.935	rs4852988	chr2:69978290	A/C	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.41	-0.41	2.53e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.69	0.54	1.92e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.83	-8.48	-0.57	2.21e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	0.82	7.07	0.5	5.7e-11	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.05	8.91	0.59	1.79e-15	Opioid sensitivity;
UCEC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-4.59	-0.35	9.26e-6	Headache;
UCEC	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.52	-5.26	-0.4	4.93e-7	Schizophrenia;
UCEC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg05738196	chr6:26577821	NA	0.65	7.72	0.54	1.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.66	7.08	0.5	5.42e-11	Menopause (age at onset);
UCEC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.66	-6.09	-0.45	9.22e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg24069376	chr3:38537580	EXOG	-0.44	-5.28	-0.4	4.59e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.27	-0.4	4.72e-7	Blood metabolite levels;
UCEC	cis	rs644799	0.930	rs11021348	chr11:95655481	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	7.64	0.53	2.57e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg18681998	chr4:17616180	MED28	0.69	8.09	0.56	2.04e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.56	-5.18	-0.39	7.08e-7	Coronary artery disease;
UCEC	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.8	8.45	0.57	2.65e-14	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs4908768	0.906	rs10492965	chr1:8598127	G/A	cg13081009	chr1:8430745	RERE	0.42	4.57	0.35	1.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs244899	0.967	rs184957	chr5:167919623	T/A	cg06604206	chr5:167912465	RARS	-0.37	-4.64	-0.36	7.56e-6	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.96	6.41	0.47	1.89e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.56	5.17	0.39	7.48e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.34	-0.46	2.7e-9	Pancreatic cancer;
UCEC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.12	-17.27	-0.82	3.31e-37	IgG glycosylation;
UCEC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.39	-5.07	-0.39	1.18e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.52	-5.33	-0.4	3.66e-7	Parkinson's disease;
UCEC	cis	rs4654899	0.643	rs1408409	chr1:21089781	T/C	cg01072550	chr1:21505969	NA	-0.48	-4.75	-0.36	4.74e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg20307385	chr11:47447363	PSMC3	-0.63	-4.59	-0.35	9.54e-6	Intraocular pressure;
UCEC	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	5.83	0.43	3.31e-8	Bone mineral density;
UCEC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.5	-5.44	-0.41	2.18e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.86	-10.42	-0.65	2.23e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg04310649	chr10:35416472	CREM	-0.49	-4.88	-0.37	2.7e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.64	6.53	0.47	1.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	7.73	0.54	1.56e-12	Platelet count;
UCEC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-4.75	-0.36	4.72e-6	Aortic root size;
UCEC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.66	7.13	0.51	4.22e-11	Platelet count;
UCEC	cis	rs1816854	0.872	rs11182275	chr12:44206289	T/G	cg20956634	chr12:44200518	TWF1	0.5	5.08	0.39	1.1e-6	Inflammatory bowel disease;
UCEC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.68	7.43	0.52	8.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.71	6.24	0.46	4.53e-9	Coronary artery disease;
UCEC	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.68	7.78	0.54	1.2e-12	Mean corpuscular volume;
UCEC	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.59	-5.03	-0.38	1.44e-6	Reticulocyte count;
UCEC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs2165738	0.517	rs2119997	chr2:24692639	C/T	cg02313965	chr2:25016582	C2orf79;CENPO	0.52	5.09	0.39	1.09e-6	Type 1 diabetes;
UCEC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.65	4.97	0.38	1.87e-6	Mean platelet volume;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg07836142	chr6:28411423	ZSCAN23	0.42	4.66	0.36	7.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg03714773	chr7:91764589	CYP51A1	0.43	5.26	0.4	4.99e-7	Breast cancer;
UCEC	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.19	-9.01	-0.6	1e-15	Gut microbiome composition (summer);
UCEC	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-5.13	-0.39	8.85e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-4.5	-0.35	1.36e-5	Parkinson's disease;
UCEC	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.53	-5.83	-0.43	3.34e-8	IgG glycosylation;
UCEC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg03714773	chr7:91764589	CYP51A1	0.49	6.11	0.45	8.55e-9	Breast cancer;
UCEC	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.06	-12.38	-0.71	1.42e-24	Ulcerative colitis;
UCEC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.65	0.62	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.44	-4.52	-0.35	1.27e-5	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg01013738	chr7:1149705	C7orf50	-0.5	-4.78	-0.37	4.24e-6	Longevity;Endometriosis;
UCEC	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	4.87	0.37	2.81e-6	IgG glycosylation;
UCEC	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg04310649	chr10:35416472	CREM	-0.48	-4.92	-0.38	2.25e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.38	4.79	0.37	4.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.76	-0.43	4.84e-8	Birth weight;
UCEC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.47	4.71	0.36	5.74e-6	Blood metabolite levels;
UCEC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06462663	chr19:18546047	ISYNA1	0.44	5.59	0.42	1.1e-7	Breast cancer;
UCEC	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.58	-6.07	-0.45	1.05e-8	Breast cancer;
UCEC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg06784218	chr1:46089804	CCDC17	0.44	5.08	0.39	1.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.56	5.65	0.42	8.03e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.44	-5.28	-0.4	4.5e-7	Bone mineral density (spine);
UCEC	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.42	4.84	0.37	3.28e-6	Total body bone mineral density;
UCEC	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.42	4.93	0.38	2.19e-6	Total body bone mineral density;
UCEC	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.52	5.63	0.42	8.84e-8	Melanoma;
UCEC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg01689657	chr7:91764605	CYP51A1	0.42	5.46	0.41	1.97e-7	Breast cancer;
UCEC	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.53	-0.35	1.21e-5	Response to antipsychotic treatment;
UCEC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.43	0.41	2.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.47	5.14	0.39	8.52e-7	Oral cavity cancer;
UCEC	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18854424	chr1:2615690	NA	0.45	6.49	0.47	1.22e-9	Ulcerative colitis;
UCEC	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs16937	0.711	rs10900462	chr1:205153312	A/G	cg12580275	chr1:205744413	RAB7L1	-0.48	-5.17	-0.39	7.54e-7	Schizophrenia;
UCEC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.01	-0.38	1.56e-6	Joint mobility (Beighton score);
UCEC	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.8	0.37	3.85e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.29	0.4	4.43e-7	Platelet count;
UCEC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.48	0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.65	-7.43	-0.52	8.27e-12	Menarche (age at onset);
UCEC	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-4.93	-0.38	2.18e-6	Total cholesterol levels;
UCEC	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.53	-5.28	-0.4	4.47e-7	IgG glycosylation;
UCEC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg06238570	chr21:40685208	BRWD1	0.83	7.54	0.53	4.42e-12	Cognitive function;
UCEC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.61	-6.93	-0.5	1.25e-10	Body mass index;
UCEC	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.58	-5.85	-0.43	3.1e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-4.65	-0.36	7.26e-6	Schizophrenia;
UCEC	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	0.69	8.88	0.59	2.13e-15	Gut microbiome composition (winter);
UCEC	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.42	-0.52	8.45e-12	Hypospadias;
UCEC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.55	5.87	0.44	2.75e-8	Monocyte count;
UCEC	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.47	4.87	0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg22974920	chr21:40686053	BRWD1	-0.48	-4.69	-0.36	6.2e-6	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.65	6.89	0.49	1.51e-10	Menopause (age at onset);
UCEC	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.87	10.88	0.67	1.37e-20	IgG glycosylation;
UCEC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.87	-0.44	2.82e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.23	-15.21	-0.78	5.67e-32	Breast cancer;
UCEC	cis	rs7607369	0.574	rs12990478	chr2:219667463	T/A	cg02176678	chr2:219576539	TTLL4	-0.51	-5.15	-0.39	8.14e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs12618769	0.597	rs17502889	chr2:99031745	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.63	-0.36	7.86e-6	Bipolar disorder;
UCEC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.51	5.44	0.41	2.22e-7	Longevity;Endometriosis;
UCEC	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg22907277	chr7:1156413	C7orf50	0.76	7.95	0.55	4.57e-13	Longevity;Endometriosis;
UCEC	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.44	-5.81	-0.43	3.68e-8	Urinary metabolites;
UCEC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.45	-0.52	7.34e-12	Body mass index;
UCEC	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.62	7.01	0.5	7.95e-11	Tonsillectomy;
UCEC	cis	rs4965359	0.700	rs28831142	chr15:101574403	T/G	cg15200994	chr15:101606846	LRRK1	0.45	5.12	0.39	9.55e-7	Central corneal thickness;
UCEC	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-5.04	-0.38	1.35e-6	Alzheimer's disease (late onset);
UCEC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.64	-6.0	-0.44	1.44e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-4.9	-0.37	2.46e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg06238570	chr21:40685208	BRWD1	0.83	7.54	0.53	4.42e-12	Cognitive function;
UCEC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	9.12	0.6	5.39e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	4.61	0.36	8.54e-6	Obesity-related traits;
UCEC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	4.88	0.37	2.79e-6	Bipolar disorder;
UCEC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.51	-5.12	-0.39	9.58e-7	Breast cancer;
UCEC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.52	6.02	0.44	1.33e-8	Obesity-related traits;
UCEC	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg13683864	chr3:40499215	RPL14	0.72	8.03	0.55	2.96e-13	Renal cell carcinoma;
UCEC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Electroencephalogram traits;
UCEC	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.78	-6.81	-0.49	2.37e-10	Caudate activity during reward;
UCEC	trans	rs6919346	0.600	rs2174914	chr6:160863108	G/C	cg16588061	chr11:88070780	CTSC	0.75	6.73	0.49	3.49e-10	Lp (a) levels;
UCEC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.54	5.75	0.43	5.1e-8	Breast cancer;
UCEC	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-4.75	-0.36	4.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs732765	0.734	rs12323361	chr14:75171706	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.63	-0.36	8.04e-6	Non-small cell lung cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23300289	chr9:132146083	NA	0.54	7.1	0.51	4.99e-11	Warfarin maintenance dose;
UCEC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg21770322	chr7:97807741	LMTK2	0.85	14.84	0.77	4.96e-31	Breast cancer;
UCEC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg14092571	chr14:90743983	NA	-0.44	-5.97	-0.44	1.69e-8	Mortality in heart failure;
UCEC	cis	rs892864	0.685	rs11955447	chr5:127772210	T/C	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg18986330	chr14:100772766	SLC25A29;MIR345	0.43	4.57	0.35	1.03e-5	Alzheimer's disease (survival time);
UCEC	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.72	-7.11	-0.51	4.56e-11	Schizophrenia;
UCEC	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.63	7.52	0.53	5.1e-12	Obesity-related traits;
UCEC	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg08755490	chr11:65554678	OVOL1	0.52	5.3	0.4	4.18e-7	Acne (severe);
UCEC	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.54	-0.35	1.17e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs76419734	1.000	rs7676975	chr4:106763811	A/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.54	4.58	0.35	9.85e-6	Post bronchodilator FEV1;
UCEC	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg21419209	chr3:44054225	NA	-0.51	-5.47	-0.41	1.91e-7	Coronary artery disease;
UCEC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.59e-6	Aortic root size;
UCEC	cis	rs7246967	0.673	rs16999580	chr19:22923487	C/T	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.98e-6	Tonsillectomy;
UCEC	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg21770322	chr7:97807741	LMTK2	0.84	14.48	0.77	4.35e-30	Breast cancer;
UCEC	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.73	0.43	5.45e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs631288	0.793	rs41295831	chr1:146767490	G/A	cg25205988	chr1:146714368	CHD1L	0.89	4.57	0.35	1.01e-5	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs926938	0.783	rs10858053	chr1:115297374	A/G	cg12756093	chr1:115239321	AMPD1	-0.57	-5.88	-0.44	2.64e-8	Autism;
UCEC	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	5.18	0.39	7.11e-7	Mood instability;
UCEC	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs4662945	0.586	rs67836955	chr2:130177825	G/A	cg05962382	chr2:130345044	NA	-0.5	-5.51	-0.41	1.55e-7	Response to cytidine analogues (gemcitabine);
UCEC	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.63	-6.8	-0.49	2.44e-10	Resting heart rate;
UCEC	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.76	8.07	0.55	2.3e-13	Vitamin D levels;
UCEC	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.7	7.86	0.54	7.67e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7772486	0.875	rs2777482	chr6:146320341	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-4.87	-0.37	2.84e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	0.81	5.39	0.41	2.7e-7	Diabetic retinopathy;
UCEC	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.36	-0.52	1.18e-11	Prevalent atrial fibrillation;
UCEC	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg01072550	chr1:21505969	NA	0.47	4.74	0.36	4.94e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.64	6.87	0.49	1.72e-10	Homoarginine levels;
UCEC	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.17	-17.23	-0.82	4.31e-37	Exhaled nitric oxide output;
UCEC	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.56	0.53	4.02e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.52	-5.1	-0.39	1.02e-6	Coronary artery disease;
UCEC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg23307798	chr14:103986281	CKB	0.56	5.34	0.4	3.48e-7	Body mass index;
UCEC	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.51	-5.13	-0.39	8.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg04315214	chr1:2043799	PRKCZ	0.48	5.61	0.42	9.59e-8	Height;
UCEC	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg18681998	chr4:17616180	MED28	-0.67	-7.28	-0.51	1.82e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.7	8.82	0.59	2.97e-15	Vitiligo;
UCEC	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.46	-0.41	2.02e-7	Cardiac Troponin-T levels;
UCEC	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs16937	0.711	rs10751431	chr1:205128059	C/T	cg12580275	chr1:205744413	RAB7L1	0.45	5.05	0.38	1.28e-6	Schizophrenia;
UCEC	trans	rs10242455	0.557	rs45529541	chr7:99048143	C/A	cg09045935	chr12:6379348	NA	0.97	6.9	0.49	1.43e-10	Blood metabolite levels;
UCEC	cis	rs4478037	1.000	rs4074416	chr3:33161729	A/G	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg13683864	chr3:40499215	RPL14	-1.06	-14.57	-0.77	2.54e-30	Renal cell carcinoma;
UCEC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg13575925	chr12:9217583	LOC144571	0.42	4.98	0.38	1.77e-6	Sjögren's syndrome;
UCEC	cis	rs7246967	0.551	rs57775631	chr19:22814461	T/C	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.29e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg20007245	chr22:24372913	LOC391322	-0.72	-7.68	-0.54	2.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7095607	1.000	rs4746740	chr10:69960999	C/T	cg18986048	chr10:69913749	MYPN	0.42	4.61	0.36	8.68e-6	Lung function (FVC);
UCEC	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-8.78	-0.59	3.87e-15	Hip circumference;
UCEC	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	0.96	10.43	0.65	2.12e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.83	0.49	2.12e-10	Eye color traits;
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.97	0.44	1.67e-8	Platelet count;
UCEC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.17e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.93	10.88	0.67	1.36e-20	Subjective well-being;
UCEC	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.36	-0.46	2.39e-9	Response to antipsychotic treatment;
UCEC	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.02	0.38	1.5e-6	Lung cancer in ever smokers;
UCEC	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-5.55	-0.42	1.32e-7	Coffee consumption (cups per day);
UCEC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.84	7.75	0.54	1.42e-12	Testicular germ cell tumor;
UCEC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.94	10.38	0.65	2.8e-19	Cognitive function;
UCEC	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.35	-5.73	-0.43	5.4e-8	Cancer;
UCEC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.79	-4.61	-0.36	8.81e-6	Skin colour saturation;
UCEC	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-8.71	-0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.67	-6.66	-0.48	5.1e-10	Morning vs. evening chronotype;
UCEC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.17	15.97	0.8	6.24e-34	Cognitive function;
UCEC	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg13683864	chr3:40499215	RPL14	-1.01	-10.65	-0.66	5.51e-20	Renal cell carcinoma;
UCEC	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.52	5.76	0.43	4.83e-8	Menopause (age at onset);
UCEC	cis	rs7866350	0.604	rs1935389	chr9:100994470	A/G	cg16199381	chr9:100396477	TSTD2;NCBP1	-0.45	-4.53	-0.35	1.2e-5	Post-traumatic stress disorder;
UCEC	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.85	-0.37	3.06e-6	Breast cancer;
UCEC	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.76	7.58	0.53	3.64e-12	Itch intensity from mosquito bite;
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.36	4.67	0.36	6.66e-6	Total body bone mineral density;
UCEC	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg23972785	chr8:11611189	GATA4	-0.35	-4.51	-0.35	1.32e-5	Neuroticism;
UCEC	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.37	4.9	0.37	2.5e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	0.96	5.94	0.44	1.94e-8	Skin colour saturation;
UCEC	cis	rs13437751	0.649	rs60897208	chr7:63347718	T/C	cg00787055	chr7:63562162	NA	0.5	5.17	0.39	7.38e-7	QT interval (drug interaction);
UCEC	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.56	5.02	0.38	1.46e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg12923728	chr3:195709715	SDHAP1	-0.61	-4.58	-0.35	9.73e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.5	4.53	0.35	1.19e-5	Obesity-related traits;
UCEC	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.31	-0.46	3.18e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.42	5.2	0.39	6.69e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-0.77	-8.94	-0.59	1.48e-15	Obesity-related traits;
UCEC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg23217946	chr19:22817039	ZNF492	0.41	4.54	0.35	1.17e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.67	-7.32	-0.52	1.52e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg05991184	chr2:219186017	PNKD	0.42	4.54	0.35	1.15e-5	Ulcerative colitis;
UCEC	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	5.46	0.41	1.97e-7	Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.76	7.69	0.54	2e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	trans	rs78587638	0.790	rs9973476	chr2:119167440	C/A	cg09400194	chr10:81107848	PPIF	-0.61	-6.72	-0.48	3.79e-10	Mosquito bite size;
UCEC	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.61	0.53	3.01e-12	Ileal carcinoids;
UCEC	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.68	-6.75	-0.49	3.25e-10	Blood metabolite levels;
UCEC	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg22166914	chr1:53195759	ZYG11B	0.7	7.4	0.52	9.47e-12	Monocyte count;
UCEC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.48	-5.65	-0.42	8.14e-8	Aortic root size;
UCEC	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.53	0.41	1.43e-7	Birth weight;
UCEC	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	0.77	9.14	0.6	4.54e-16	Multiple myeloma;
UCEC	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.45	5.06	0.39	1.21e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg06521331	chr12:34319734	NA	-0.63	-5.0	-0.38	1.64e-6	Morning vs. evening chronotype;
UCEC	cis	rs9830388	0.584	rs778488	chr3:23437464	A/T	cg13266188	chr3:23522396	UBE2E2	0.39	4.51	0.35	1.32e-5	RR interval (tricyclic/tetracyclic antidepressant use interaction);
UCEC	cis	rs12786942	0.569	rs4255512	chr11:101313991	A/T	cg03942599	chr11:101341554	TRPC6	0.5	6.09	0.45	9.38e-9	Facial depth;
UCEC	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	6.6	0.48	7.14e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.6	5.8	0.43	3.86e-8	Bipolar disorder and schizophrenia;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg06168050	chr17:30677336	ZNF207	-0.8	-7.45	-0.52	7.16e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.54	-0.42	1.35e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.36	-0.46	2.35e-9	Metabolite levels;
UCEC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.34	0.57	4.85e-14	Chronic sinus infection;
UCEC	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg19715936	chr7:50634035	DDC	0.44	5.48	0.41	1.78e-7	Malaria;
UCEC	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.98	-0.38	1.73e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.32	-0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg09491104	chr22:46646882	C22orf40	-0.51	-5.04	-0.38	1.36e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.7	6.22	0.46	4.97e-9	Aortic root size;
UCEC	cis	rs340417	0.731	rs2279383	chr5:178804448	A/G	cg14126918	chr5:178622003	ADAMTS2	0.64	4.77	0.37	4.46e-6	Skin pigmentation;
UCEC	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg20965017	chr5:231967	SDHA	-0.59	-4.98	-0.38	1.8e-6	Breast cancer;
UCEC	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.43	5.01	0.38	1.56e-6	Blood metabolite ratios;
UCEC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-5.46	-0.41	2.02e-7	Initial pursuit acceleration;
UCEC	cis	rs9309473	0.500	rs11126402	chr2:73776582	G/C	cg20560298	chr2:73613845	ALMS1	-0.47	-4.74	-0.36	4.97e-6	Metabolite levels;
UCEC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg13695892	chr22:41940480	POLR3H	-0.75	-5.62	-0.42	9.13e-8	Vitiligo;
UCEC	cis	rs2242663	0.705	rs551708	chr11:66486143	T/C	cg24851651	chr11:66362959	CCS	-0.39	-4.63	-0.36	7.91e-6	Bipolar disorder;
UCEC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg22563815	chr15:78856949	CHRNA5	-0.35	-4.61	-0.36	8.7e-6	Sudden cardiac arrest;
UCEC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.92	0.59	1.68e-15	Alzheimer's disease;
UCEC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.67	0.36	6.63e-6	Diabetic retinopathy;
UCEC	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.73	4.56	0.35	1.09e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.48	4.73	0.36	5.15e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
UCEC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.5	-5.58	-0.42	1.12e-7	Diastolic blood pressure;
UCEC	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg05660106	chr1:15850417	CASP9	0.61	5.61	0.42	9.68e-8	Systolic blood pressure;
UCEC	cis	rs12363310	0.541	rs4548585	chr11:101685752	C/T	cg11843188	chr11:102322558	TMEM123	-0.49	-4.72	-0.36	5.43e-6	Systemic sclerosis;
UCEC	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.55	-4.73	-0.36	5.11e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg06238570	chr21:40685208	BRWD1	-0.7	-8.25	-0.56	8.22e-14	Menarche (age at onset);
UCEC	cis	rs17102423	0.623	rs2898862	chr14:65612144	G/A	cg11161011	chr14:65562177	MAX	-0.64	-5.76	-0.43	4.65e-8	Obesity-related traits;
UCEC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.46	5.2	0.39	6.61e-7	Obesity-related traits;
UCEC	cis	rs116095464	1.000	rs6863730	chr5:325003	G/T	cg22857025	chr5:266934	NA	-0.86	-7.41	-0.52	9.23e-12	Breast cancer;
UCEC	cis	rs7781557	0.640	rs73192025	chr7:102591489	T/C	cg06322601	chr7:102330635	NA	0.58	4.7	0.36	6.02e-6	Colorectal adenoma (advanced);
UCEC	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.66	0.53	2.26e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-5.66	-0.42	7.79e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19500275	chr17:80737654	TBCD	0.48	4.8	0.37	3.8e-6	Glycated hemoglobin levels;
UCEC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	4.85	0.37	3.14e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2270450	0.513	rs1421378	chr6:46703513	C/T	cg05947443	chr6:46703440	PLA2G7	0.36	4.77	0.37	4.41e-6	Hashimoto thyroiditis versus Graves' disease;
UCEC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.51	-5.18	-0.39	7.34e-7	Longevity;
UCEC	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.94	-7.94	-0.55	4.82e-13	Gut microbiome composition (summer);
UCEC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.54	5.94	0.44	1.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.19	-0.45	5.64e-9	Personality dimensions;
UCEC	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.69	-8.51	-0.57	1.87e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.87	0.49	1.71e-10	Bladder cancer;
UCEC	cis	rs9810089	0.843	rs11717954	chr3:136112109	A/G	cg21827317	chr3:136751795	NA	0.46	4.51	0.35	1.33e-5	Gestational age at birth (child effect);
UCEC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.72	6.6	0.48	7.16e-10	Alzheimer's disease;
UCEC	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.55	-5.28	-0.4	4.52e-7	Cognitive test performance;
UCEC	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.83	8.92	0.59	1.67e-15	Dental caries;
UCEC	cis	rs7113850	0.541	rs78737372	chr11:24233984	G/A	ch.11.24196551F	chr11:24239977	NA	0.7	4.86	0.37	3.04e-6	Bone fracture in osteoporosis;
UCEC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.68	-7.56	-0.53	4.07e-12	Menarche (age at onset);
UCEC	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-7.19	-0.51	3.04e-11	Urate levels in overweight individuals;
UCEC	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.72	-0.43	5.66e-8	Total cholesterol levels;
UCEC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.41	4.63	0.36	7.83e-6	Height;
UCEC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.6	-5.35	-0.4	3.29e-7	Mortality in heart failure;
UCEC	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.56	4.87	0.37	2.88e-6	HDL cholesterol levels;
UCEC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.41	-0.47	1.85e-9	Crohn's disease;
UCEC	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-5.38	-0.41	2.92e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg24851651	chr11:66362959	CCS	0.45	5.17	0.39	7.4e-7	Educational attainment (years of education);
UCEC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs73206853	0.764	rs55887805	chr12:110597246	T/C	cg12870014	chr12:110450643	ANKRD13A	0.67	5.56	0.42	1.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg13683864	chr3:40499215	RPL14	0.54	5.51	0.41	1.54e-7	Renal cell carcinoma;
UCEC	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.82	9.34	0.61	1.41e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06505273	chr16:24850292	NA	-0.46	-4.63	-0.36	7.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.53	5.7	0.43	6.26e-8	QRS complex (12-leadsum);
UCEC	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.1	0.45	8.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs753778	0.748	rs56767156	chr8:142216476	G/C	cg18755752	chr8:142205143	DENND3	-0.66	-7.52	-0.53	5.09e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.53	5.2	0.39	6.6e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.51	4.89	0.37	2.67e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.5	4.74	0.36	5.07e-6	HDL cholesterol;
UCEC	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.45	5.63	0.42	8.86e-8	Anterior chamber depth;
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.6	0.58	1.1e-14	Prudent dietary pattern;
UCEC	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.57	-0.42	1.17e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-5.66	-0.42	7.72e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.611	rs73030511	chr19:22826034	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.48	5.06	0.39	1.24e-6	Red blood cell count;
UCEC	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.71	-0.36	5.8e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg01256987	chr12:42539512	GXYLT1	-0.43	-4.84	-0.37	3.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.52	5.59	0.42	1.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.91	5.94	0.44	1.96e-8	Gut microbiome composition (summer);
UCEC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	-0.57	-6.54	-0.47	9.6e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7709377	0.570	rs10059455	chr5:115434739	A/G	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-6.34	-0.46	2.64e-9	Morning vs. evening chronotype;
UCEC	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs732765	0.734	rs12892937	chr14:75168927	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.63	-0.36	8.04e-6	Non-small cell lung cancer;
UCEC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.63	5.97	0.44	1.74e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.51	5.36	0.4	3.12e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.62	-4.5	-0.35	1.36e-5	Cognitive test performance;
UCEC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.64	6.03	0.45	1.28e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.94	9.24	0.61	2.64e-16	Initial pursuit acceleration;
UCEC	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg15764593	chr10:829463	NA	-0.62	-4.63	-0.36	8.04e-6	Uric acid levels;
UCEC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	9.46	0.62	6.92e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg09120320	chr17:61926383	NA	0.44	4.61	0.36	8.79e-6	Prudent dietary pattern;
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	9.3	0.61	1.83e-16	Platelet count;
UCEC	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.71	-5.74	-0.43	5.15e-8	Depression;
UCEC	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-6.96	-0.5	1.04e-10	HDL cholesterol;
UCEC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	4.97	0.38	1.86e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.97	-13.78	-0.75	3.01e-28	Homoarginine levels;
UCEC	cis	rs1784203	1.000	rs1784203	chr11:93450134	A/G	cg10353388	chr11:93474820	C11orf54;TAF1D	-0.92	-6.07	-0.45	1.03e-8	Waist circumference adjusted for body mass index;
UCEC	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.13	-0.45	7.76e-9	Inflammatory bowel disease;
UCEC	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.39	-5.54	-0.42	1.35e-7	Primary biliary cholangitis;
UCEC	cis	rs10095849	0.576	rs4376471	chr8:39458399	A/G	cg24581462	chr8:38759627	PLEKHA2	-0.37	-4.81	-0.37	3.63e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.8	-9.17	-0.6	4.01e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg17279458	chr3:44753948	ZNF502	-0.5	-5.47	-0.41	1.85e-7	Depressive symptoms;
UCEC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.56	-6.02	-0.44	1.31e-8	Prostate cancer;
UCEC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.78	7.83	0.54	9.08e-13	Vitiligo;
UCEC	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.3	-0.4	4.14e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.47	-4.64	-0.36	7.66e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.21e-6	Breast cancer;
UCEC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.55	5.44	0.41	2.19e-7	Response to diuretic therapy;
UCEC	cis	rs7246967	0.673	rs11881740	chr19:22843844	T/C	cg24889512	chr19:22816950	ZNF492	0.56	6.1	0.45	9.02e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg13777783	chr17:79615861	NA	-0.33	-4.77	-0.37	4.37e-6	Eye color traits;
UCEC	cis	rs4372836	0.930	rs7589860	chr2:28967648	A/T	cg09522027	chr2:28974177	PPP1CB	-0.79	-8.15	-0.56	1.5e-13	Body mass index;
UCEC	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.57	5.75	0.43	5.06e-8	Colorectal cancer;
UCEC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg03714773	chr7:91764589	CYP51A1	0.41	5.05	0.38	1.26e-6	Breast cancer;
UCEC	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.62	-5.01	-0.38	1.54e-6	Initial pursuit acceleration;
UCEC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg13683864	chr3:40499215	RPL14	0.72	8.12	0.56	1.76e-13	Renal cell carcinoma;
UCEC	cis	rs60311166	0.661	rs60611300	chr3:52569949	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.92	5.13	0.39	9.09e-7	CTACK levels;
UCEC	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg13683864	chr3:40499215	RPL14	-0.53	-5.3	-0.4	4.11e-7	Renal cell carcinoma;
UCEC	cis	rs2179367	0.959	rs4895789	chr6:149764654	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.39	-5.26	-0.4	4.94e-7	Dupuytren's disease;
UCEC	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.66	6.26	0.46	3.93e-9	Height;
UCEC	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01391022	chr12:122360665	WDR66	-0.44	-5.25	-0.4	5.16e-7	Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	12.33	0.71	2e-24	Post bronchodilator FEV1;
UCEC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.52	6.35	0.46	2.48e-9	Total body bone mineral density;
UCEC	cis	rs970548	0.908	rs10900229	chr10:46121046	C/T	cg15223267	chr10:46222474	FAM21C	0.58	5.15	0.39	8.3e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.5	-4.9	-0.38	2.45e-6	Schizophrenia;
UCEC	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.6	-4.96	-0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg18681998	chr4:17616180	MED28	0.65	7.65	0.53	2.43e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.73	6.42	0.47	1.78e-9	Cognitive function;
UCEC	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.62	4.89	0.37	2.62e-6	Breast cancer;
UCEC	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	8.05	0.55	2.53e-13	Total body bone mineral density;
UCEC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg05991184	chr2:219186017	PNKD	-0.43	-4.56	-0.35	1.07e-5	Colorectal cancer;
UCEC	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg14850604	chr14:76278056	TTLL5	-0.4	-4.55	-0.35	1.13e-5	Acute lymphoblastic leukemia (childhood);
UCEC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.52	4.91	0.38	2.44e-6	Mortality in heart failure;
UCEC	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.49	5.41	0.41	2.51e-7	Life satisfaction;
UCEC	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.56	4.91	0.38	2.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.35e-18	Height;
UCEC	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.49	5.34	0.4	3.48e-7	Platelet distribution width;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06957848	chr1:57286154	C1orf168	-0.7	-6.79	-0.49	2.6200000000000003e-10	Migraine with aura;
UCEC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.72	6.68	0.48	4.6e-10	Aortic root size;
UCEC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.48	-5.86	-0.44	2.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	6.3	0.46	3.32e-9	Platelet count;
UCEC	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.5	5.24	0.4	5.57e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.71	-5.87	-0.44	2.79e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-7.45	-0.52	7.43e-12	Menarche (age at onset);
UCEC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	trans	rs6479901	0.895	rs7082066	chr10:64998971	A/G	cg12751693	chr12:62629162	NA	-0.57	-7.19	-0.51	3.05e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.52	-0.41	1.48e-7	Obesity-related traits;
UCEC	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.05	-0.45	1.15e-8	Morning vs. evening chronotype;
UCEC	cis	rs10242455	1.000	rs10229552	chr7:99234899	T/A	cg07715041	chr7:99302981	CYP3A7	0.51	5.01	0.38	1.55e-6	Blood metabolite levels;
UCEC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.77	-7.98	-0.55	3.9e-13	Cognitive function;
UCEC	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.53	5.91	0.44	2.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.64	6.08	0.45	9.74e-9	Mortality in heart failure;
UCEC	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.74	-9.85	-0.63	7.01e-18	Gut microbiota (bacterial taxa);
UCEC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.79	7.87	0.54	7.04e-13	Smoking behavior;
UCEC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	5.77	0.43	4.57e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.79	-7.61	-0.53	3.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.61	4.86	0.37	3.04e-6	Serum parathyroid hormone levels;
UCEC	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg24069376	chr3:38537580	EXOG	-0.43	-5.23	-0.4	5.76e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.86	10.15	0.64	1.14e-18	Blood metabolite levels;
UCEC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-8.45	-0.57	2.66e-14	Bipolar disorder and schizophrenia;
UCEC	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg13147721	chr7:65941812	NA	0.86	6.23	0.46	4.73e-9	Diabetic kidney disease;
UCEC	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	4.9	0.37	2.52e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg13575925	chr12:9217583	LOC144571	0.41	4.66	0.36	7.01e-6	Sjögren's syndrome;
UCEC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg21853948	chr4:100867292	DNAJB14	0.45	4.66	0.36	6.88e-6	HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.62	5.91	0.44	2.34e-8	Schizophrenia;
UCEC	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-7.2	-0.51	2.94e-11	Parkinson's disease;
UCEC	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.6	5.91	0.44	2.24e-8	Diabetic kidney disease;
UCEC	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.61	-5.59	-0.42	1.07e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg21053147	chr12:120880522	NA	-0.54	-4.79	-0.37	4.06e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg25019722	chr6:37503610	NA	-0.3	-4.59	-0.35	9.52e-6	Cognitive performance;
UCEC	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.66	-6.24	-0.46	4.45e-9	Cocaine dependence;
UCEC	cis	rs539514	0.501	rs8000656	chr13:76400640	A/G	cg04757411	chr13:76259545	LMO7	0.47	5.26	0.4	5.07e-7	Type 1 diabetes;
UCEC	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	0.92	11.59	0.69	1.84e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.84	12.29	0.71	2.55e-24	Leprosy;
UCEC	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.93	12.43	0.72	1.08e-24	Metabolic syndrome;
UCEC	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.41	4.93	0.38	2.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.98	-0.5	9.46e-11	Tonsillectomy;
UCEC	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.39	4.61	0.36	8.66e-6	Systolic blood pressure;
UCEC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.5	4.6	0.35	9.1e-6	Post bronchodilator FEV1;
UCEC	cis	rs884366	0.964	rs11153164	chr6:109596309	G/A	cg01475377	chr6:109611718	NA	0.47	5.18	0.39	7.26e-7	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.63	5.47	0.41	1.93e-7	Heart rate;
UCEC	cis	rs78487399	0.808	rs78191305	chr2:43673978	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	8.78	0.59	3.88e-15	Alzheimer's disease;
UCEC	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.58	-5.0	-0.38	1.61e-6	Prudent dietary pattern;
UCEC	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.53	-5.91	-0.44	2.27e-8	IgG glycosylation;
UCEC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-5.73	-0.43	5.55e-8	Menarche (age at onset);
UCEC	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.69	0.48	4.39e-10	Coffee consumption (cups per day);
UCEC	cis	rs10924970	0.649	rs6673756	chr1:235412134	G/A	cg26050004	chr1:235667680	B3GALNT2	0.53	4.81	0.37	3.63e-6	Asthma;
UCEC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Bipolar disorder;
UCEC	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.64	8.37	0.57	4.04e-14	Mean platelet volume;
UCEC	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.58	4.83	0.37	3.32e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.65	0.42	7.96e-8	Breast cancer;
UCEC	cis	rs11697848	1.000	rs117878815	chr20:48432705	C/T	cg17849948	chr20:48532315	SPATA2	1.02	5.16	0.39	7.8e-7	Systemic lupus erythematosus;
UCEC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.84	5.09	0.39	1.1e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6460942	0.731	rs75994414	chr7:12307992	C/A	cg06484146	chr7:12443880	VWDE	-0.79	-5.88	-0.44	2.64e-8	Coronary artery disease;
UCEC	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.0	0.5	8.67e-11	Bipolar disorder;
UCEC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.82	6.93	0.5	1.26e-10	Initial pursuit acceleration;
UCEC	cis	rs925228	0.955	rs12471864	chr2:24110135	C/T	cg13272742	chr2:24272458	FKBP1B	0.59	5.03	0.38	1.4e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	17.69	0.82	3.14e-38	Schizophrenia;
UCEC	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.94	8.95	0.59	1.43e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs4400599	0.608	rs4845609	chr1:154181954	G/T	cg05139571	chr1:154127138	NUP210L	0.47	5.08	0.39	1.14e-6	Platelet distribution width;
UCEC	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-4.59	-0.35	9.58e-6	Blood metabolite levels;
UCEC	cis	rs9470794	1.000	rs11756902	chr6:38118638	G/C	cg03458162	chr6:37400668	FTSJD2	0.81	4.83	0.37	3.46e-6	Type 2 diabetes;
UCEC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-5.45	-0.41	2.03e-7	Platelet count;
UCEC	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.57	-4.98	-0.38	1.78e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	4.93	0.38	2.21e-6	Menarche (age at onset);
UCEC	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.08	-0.45	9.67e-9	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18252515	chr7:66147081	NA	0.58	5.41	0.41	2.51e-7	Aortic root size;
UCEC	cis	rs420259	0.516	rs460477	chr16:23601237	G/A	cg26562691	chr16:23850404	PRKCB	0.34	4.55	0.35	1.12e-5	Bipolar disorder;
UCEC	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-9.01	-0.6	1e-15	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg13319975	chr6:146136371	FBXO30	0.52	5.74	0.43	5.14e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	7.23	0.51	2.43e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.75	-0.63	1.27e-17	Monocyte count;
UCEC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.58	-0.35	9.65e-6	Breast cancer;
UCEC	cis	rs787274	0.850	rs10759603	chr9:115639581	C/G	cg13803584	chr9:115635662	SNX30	-0.69	-5.75	-0.43	5.08e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.38	5.77	0.43	4.49e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12516959	chr21:47718080	NA	-0.39	-4.52	-0.35	1.27e-5	Testicular germ cell tumor;
UCEC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.44	-4.88	-0.37	2.78e-6	Schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01490821	chr2:170684022	UBR3	0.55	7.03	0.5	7.32e-11	Warfarin maintenance dose;
UCEC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.57	-4.64	-0.36	7.65e-6	Gut microbiome composition (summer);
UCEC	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00612595	chr21:47717864	NA	-0.5	-5.57	-0.42	1.16e-7	Testicular germ cell tumor;
UCEC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.64	5.68	0.42	7.08e-8	Lung function (FEV1/FVC);
UCEC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.73	-7.5	-0.53	5.56e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-7.34	-0.52	1.31e-11	Ulcerative colitis;
UCEC	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.7	-7.49	-0.53	6.02e-12	Coronary artery disease;
UCEC	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.8	-8.88	-0.59	2.19e-15	Monocyte count;
UCEC	cis	rs12979813	1.000	rs10418759	chr19:11340242	A/G	cg00767042	chr19:11517436	RGL3	0.37	5.37	0.41	2.97e-7	HDL cholesterol;
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.73	-0.36	5.17e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	4.71	0.36	5.72e-6	Personality dimensions;
UCEC	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	0.97	8.16	0.56	1.4e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.69	6.07	0.45	1.03e-8	Bipolar disorder;
UCEC	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.37	4.68	0.36	6.4e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	8.03e-6	Bladder cancer;
UCEC	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.46	6.59	0.48	7.17e-10	Sense of smell;
UCEC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.87	-9.6	-0.62	2.96e-17	Cognitive function;
UCEC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.54	-7.58	-0.53	3.61e-12	Prostate cancer;
UCEC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.45	4.68	0.36	6.34e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2970992	0.764	rs2175792	chr2:101323275	T/C	cg01042948	chr2:101319752	NA	0.44	4.71	0.36	5.76e-6	Educational attainment;
UCEC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.19e-6	Breast cancer;
UCEC	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.67	0.48	4.89e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	0.82	4.54	0.35	1.15e-5	IgG glycosylation;
UCEC	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.31e-6	Coronary artery disease;
UCEC	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	0.96	8.72	0.58	5.39e-15	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.65	8.29	0.56	6.7e-14	Anterior chamber depth;
UCEC	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	6.31	0.46	3.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18932078	chr1:2524107	MMEL1	0.39	5.97	0.44	1.7e-8	Ulcerative colitis;
UCEC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.87	10.24	0.65	6.4e-19	Breast cancer;
UCEC	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg12292205	chr6:26970375	C6orf41	0.61	6.63	0.48	6.04e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.57	-5.56	-0.42	1.21e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.59	7.13	0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.93	0.59	1.57e-15	Platelet count;
UCEC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.54	5.28	0.4	4.46e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.04	-0.45	1.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.53	-5.48	-0.41	1.79e-7	Breast cancer;
UCEC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg13870426	chr17:30244630	NA	-0.63	-4.58	-0.35	9.78e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2901460	0.509	rs12463815	chr2:62087165	C/T	cg02183531	chr2:62113199	CCT4	-0.54	-4.54	-0.35	1.17e-5	Mean corpuscular volume;
UCEC	cis	rs10924970	0.935	rs6667150	chr1:235355244	A/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.61	0.36	8.85e-6	Asthma;
UCEC	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.53	-5.16	-0.39	7.99e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg23888215	chr10:79422304	NA	-1.1	-8.85	-0.59	2.52e-15	Bone mineral density;
UCEC	cis	rs12575480	0.744	rs73398059	chr11:2082990	C/T	cg20363586	chr11:1855286	SYT8	0.42	4.71	0.36	5.7e-6	Pursuit maintenance gain;
UCEC	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-12.73	-0.72	1.75e-25	Schizophrenia;
UCEC	cis	rs6431393	0.915	rs11693354	chr2:236533344	G/T	cg16844875	chr2:237476791	NA	-0.54	-5.13	-0.39	9.03e-7	Menarche (age at onset);
UCEC	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06223018	chr3:49557076	DAG1	0.34	4.86	0.37	2.92e-6	Parkinson's disease;
UCEC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.82	-9.78	-0.63	1.06e-17	Coronary artery disease;
UCEC	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.19	8.55	0.58	1.43e-14	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.59	-6.41	-0.47	1.84e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.64	-5.06	-0.38	1.26e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg13147721	chr7:65941812	NA	-0.67	-4.6	-0.35	9.05e-6	Diabetic kidney disease;
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.72	-7.85	-0.54	8.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg00071950	chr4:10020882	SLC2A9	0.49	5.2	0.39	6.63e-7	Blood metabolite levels;
UCEC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.7	-0.36	5.85e-6	Breast cancer;
UCEC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	0.95	12.43	0.72	1.08e-24	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg10092517	chr14:104682880	NA	0.37	4.66	0.36	7.13e-6	Body mass index;
UCEC	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.57	4.53	0.35	1.21e-5	Blood protein levels;
UCEC	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	19.67	0.85	5.22e-43	Schizophrenia;
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.87	0.59	2.31e-15	Platelet count;
UCEC	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.68	-6.04	-0.45	1.23e-8	Bipolar disorder;
UCEC	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.9	-0.37	2.46e-6	Aortic root size;
UCEC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.53	-5.07	-0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg26116260	chr4:7069785	GRPEL1	0.44	4.51	0.35	1.33e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-8.88	-0.59	2.2e-15	Coffee consumption (cups per day);
UCEC	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.87	9.92	0.63	4.42e-18	Dental caries;
UCEC	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg04310649	chr10:35416472	CREM	-0.47	-4.62	-0.36	8.17e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.5	4.74	0.36	4.94e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.68	4.83	0.37	3.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg07645718	chr20:61493192	TCFL5	0.79	5.69	0.43	6.57e-8	Obesity-related traits;
UCEC	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg13147721	chr7:65941812	NA	-0.84	-5.48	-0.41	1.81e-7	Diabetic kidney disease;
UCEC	cis	rs4400599	0.618	rs9943097	chr1:154205823	C/T	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	0.73	5.93	0.44	2.07e-8	Alzheimer's disease or small vessel stroke;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.59	-5.34	-0.4	3.47e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.62	-5.8	-0.43	3.93e-8	Parkinson's disease;
UCEC	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.44	5.16	0.39	7.78e-7	Bone mineral density;
UCEC	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	0.84	6.28	0.46	3.71e-9	Mitochondrial DNA levels;
UCEC	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.97	0.5	9.93e-11	Coronary artery disease;
UCEC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg21770322	chr7:97807741	LMTK2	0.5	6.32	0.46	2.96e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg19743168	chr1:23544995	NA	0.44	6.2	0.46	5.39e-9	Height;
UCEC	cis	rs7267005	0.661	rs75742093	chr20:34409737	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	11.09	0.67	3.83e-21	Leprosy;
UCEC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg12024160	chr4:1254474	NA	0.63	7.28	0.51	1.84e-11	Obesity-related traits;
UCEC	cis	rs7246967	0.673	rs2099341	chr19:22834360	A/G	cg24889512	chr19:22816950	ZNF492	0.58	6.19	0.45	5.82e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.89	-7.57	-0.53	3.71e-12	Coronary artery calcification;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg11697111	chr7:1126903	GPER;C7orf50	-0.48	-4.69	-0.36	6.24e-6	Longevity;Endometriosis;
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	7.62	0.53	2.92e-12	Platelet count;
UCEC	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.61	4.87	0.37	2.81e-6	Breast cancer;
UCEC	cis	rs7246967	0.611	rs7250964	chr19:22822494	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.59	5.3	0.4	4.19e-7	Corneal astigmatism;
UCEC	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.75	9.97	0.64	3.33e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.65	-7.59	-0.53	3.44e-12	Breast cancer;
UCEC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.69	6.06	0.45	1.1e-8	Adiposity;
UCEC	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.65	-7.42	-0.52	8.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.79	8.47	0.57	2.39e-14	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs12931792	0.687	rs8057425	chr16:30182541	T/C	cg06985993	chr16:30040055	FAM57B	0.39	5.04	0.38	1.32e-6	Tonsillectomy;
UCEC	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26002218	chr14:103986227	CKB	0.37	5.21	0.39	6.19e-7	Body mass index;
UCEC	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.59	-6.03	-0.45	1.24e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.65	-5.68	-0.42	6.95e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11760485	0.782	rs2107839	chr7:4406863	C/T	cg25842763	chr7:4870162	RADIL	-0.41	-4.7	-0.36	6.02e-6	Early childhood aggressive behavior;
UCEC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-4.98	-0.38	1.75e-6	Tonsillectomy;
UCEC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.64	-6.57	-0.48	8.16e-10	Diastolic blood pressure;
UCEC	cis	rs12051139	0.593	rs4843477	chr16:86904001	C/T	cg06599274	chr16:86589076	MTHFSD;FLJ30679	0.38	4.51	0.35	1.32e-5	Interleukin-2 levels;Interleukin-1-receptor antagonist levels;
UCEC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-1.08	-5.12	-0.39	9.34e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.71	0.36	5.7e-6	Personality dimensions;
UCEC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.56	-6.19	-0.45	5.82e-9	Refractive error;
UCEC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg14008862	chr17:28927542	LRRC37B2	0.63	4.95	0.38	2.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg11871910	chr12:69753446	YEATS4	0.89	10.31	0.65	4.27e-19	Blood protein levels;
UCEC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.58	0.42	1.14e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg20821713	chr7:1055600	C7orf50	-0.69	-6.36	-0.46	2.36e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg06671706	chr8:8559999	CLDN23	0.66	5.34	0.4	3.47e-7	Obesity-related traits;
UCEC	cis	rs7175404	0.527	rs78236986	chr15:94052865	G/A	cg25253948	chr15:93956996	NA	0.68	4.53	0.35	1.23e-5	Attention deficit hyperactivity disorder;
UCEC	cis	rs7246967	0.736	rs386119	chr19:23000818	G/A	cg08271804	chr19:22816896	ZNF492	0.63	5.67	0.42	7.35e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2970992	0.764	rs3112258	chr2:101328375	T/C	cg01042948	chr2:101319752	NA	0.56	5.99	0.44	1.56e-8	Educational attainment;
UCEC	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.51	-4.7	-0.36	6e-6	Corneal astigmatism;
UCEC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.67	7.35	0.52	1.27e-11	Menopause (age at onset);
UCEC	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.48	5.1	0.39	1.01e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.33	-0.46	2.76e-9	Aortic root size;
UCEC	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg06521331	chr12:34319734	NA	-0.59	-4.62	-0.36	8.16e-6	Morning vs. evening chronotype;
UCEC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.72	-5.46	-0.41	1.97e-7	White matter hyperintensity burden;
UCEC	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-4.6	-0.35	9.11e-6	Neuroticism;
UCEC	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.82	-0.49	2.21e-10	Mood instability;
UCEC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.86e-6	Body mass index;
UCEC	cis	rs7215564	0.730	rs1125587	chr17:78581696	A/G	cg01498832	chr17:78682934	RPTOR	0.59	5.05	0.38	1.3e-6	Myopia (pathological);
UCEC	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.49	4.89	0.37	2.62e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg03859395	chr2:55845619	SMEK2	0.97	12.69	0.72	2.22e-25	Metabolic syndrome;
UCEC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.72	-9.12	-0.6	5.15e-16	Vitiligo;
UCEC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg14078730	chr11:63896557	MACROD1	-0.43	-4.62	-0.36	8.33e-6	Platelet count;
UCEC	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.9	-9.65	-0.62	2.33e-17	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2058350	0.636	rs3759358	chr12:3940633	A/T	cg23794848	chr12:3563020	NA	0.49	4.51	0.35	1.29e-5	Cognitive performance;
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-6.4	-0.47	2e-9	Platelet count;
UCEC	cis	rs35934224	0.783	rs58195087	chr22:19858547	A/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.11	-0.39	1.01e-6	Glaucoma (primary open-angle);
UCEC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg19678392	chr7:94953810	PON1	-0.57	-5.57	-0.42	1.19e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.47	-6.07	-0.45	1.05e-8	IgG glycosylation;
UCEC	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.65	6.37	0.46	2.33e-9	Coronary artery disease;
UCEC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.84	7.7	0.54	1.83e-12	Cognitive function;
UCEC	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg22654517	chr2:96458247	NA	-0.41	-4.52	-0.35	1.25e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs253959	0.804	rs10054441	chr5:115703121	C/A	cg23108291	chr5:115420582	COMMD10	-0.48	-4.82	-0.37	3.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.67	-0.36	6.69e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-10.68	-0.66	4.54e-20	Cognitive function;
UCEC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.47	-4.96	-0.38	1.9e-6	Cardiac Troponin-T levels;
UCEC	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg15352829	chr14:105391018	PLD4	-0.44	-6.23	-0.46	4.74e-9	Rheumatoid arthritis;
UCEC	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg00277334	chr10:82204260	NA	-0.48	-4.75	-0.36	4.85e-6	Post bronchodilator FEV1;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.53	-5.89	-0.44	2.51e-8	Cardiac Troponin-T levels;
UCEC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18252515	chr7:66147081	NA	-0.46	-4.73	-0.36	5.23e-6	Aortic root size;
UCEC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg13695892	chr22:41940480	POLR3H	0.68	5.34	0.4	3.43e-7	Vitiligo;
UCEC	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs4851266	1.000	rs11689201	chr2:100820431	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.38	-0.41	2.82e-7	Resting heart rate;
UCEC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.26	0.4	5.08e-7	Hemoglobin concentration;
UCEC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg19318889	chr4:1322082	MAEA	0.42	4.98	0.38	1.73e-6	Obesity-related traits;
UCEC	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg00617691	chr10:743931	NA	0.32	4.65	0.36	7.37e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs1940013	0.846	rs11223031	chr11:132234745	G/T	cg11473001	chr11:131780499	NTM	-0.4	-4.77	-0.37	4.42e-6	Sleep-related phenotypes;
UCEC	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18854424	chr1:2615690	NA	0.47	7.15	0.51	3.78e-11	Ulcerative colitis;
UCEC	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg01072550	chr1:21505969	NA	0.59	5.99	0.44	1.54e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.75	0.54	1.38e-12	Heart rate;
UCEC	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.42	6.73	0.49	3.63e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.54	4.87	0.37	2.91e-6	Methadone dose in opioid dependence;
UCEC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.7	6.12	0.45	7.96e-9	Alzheimer's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10745802	chr3:128445504	RAB7A	0.58	6.82	0.49	2.23e-10	Warfarin maintenance dose;
UCEC	cis	rs9467773	1.000	rs12663894	chr6:26577370	C/T	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.19	0.39	7.01e-7	Blood protein levels;
UCEC	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.85	6.32	0.46	2.95e-9	Exhaled nitric oxide levels;
UCEC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg13092806	chr2:177043255	NA	0.58	5.48	0.41	1.79e-7	IgG glycosylation;
UCEC	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg19752551	chr11:57585705	CTNND1	0.52	4.72	0.36	5.53e-6	Schizophrenia;
UCEC	cis	rs9790314	0.613	rs2121718	chr3:160603511	C/T	cg03342759	chr3:160939853	NMD3	0.54	4.99	0.38	1.69e-6	Morning vs. evening chronotype;
UCEC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.15	-0.51	3.85e-11	Breast cancer;
UCEC	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-5.12	-0.39	9.57e-7	Total bilirubin levels in HIV-1 infection;
UCEC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.88	0.44	2.65e-8	HDL cholesterol;
UCEC	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.52	5.38	0.41	2.88e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg00074818	chr8:8560427	CLDN23	-0.39	-4.89	-0.37	2.56e-6	Neuroticism;
UCEC	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.69	-7.08	-0.5	5.63e-11	Blood pressure (smoking interaction);
UCEC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.62	4.56	0.35	1.07e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg20295408	chr7:1910781	MAD1L1	-0.48	-4.52	-0.35	1.25e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg04871131	chr7:94954202	PON1	-0.57	-5.51	-0.41	1.59e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10924970	0.967	rs10925192	chr1:235400826	T/C	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg15837086	chr1:46506065	PIK3R3	-0.39	-5.02	-0.38	1.47e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.46	5.23	0.4	5.68e-7	Bone mineral density;
UCEC	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.64	6.35	0.46	2.57e-9	Mean corpuscular volume;
UCEC	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.93	-8.85	-0.59	2.51e-15	Motion sickness;
UCEC	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.35	1.37e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.4	-4.84	-0.37	3.31e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.58	-8.24	-0.56	8.54e-14	Refractive error;
UCEC	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg04310649	chr10:35416472	CREM	-0.5	-4.87	-0.37	2.88e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg05072774	chr3:49840536	C3orf54	-0.52	-5.33	-0.4	3.6e-7	Resting heart rate;
UCEC	cis	rs10507349	0.632	rs532503	chr13:26817532	C/T	cg01600817	chr13:26797529	RNF6	0.46	4.92	0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.27	-7.19	-0.51	3.04e-11	Schizophrenia;
UCEC	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.63	5.16	0.39	7.77e-7	Crohn's disease;
UCEC	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.45	4.6	0.35	9.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.09e-6	Height;
UCEC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.42	4.98	0.38	1.75e-6	Birth weight;
UCEC	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg03959625	chr15:84868606	LOC388152	0.5	5.22	0.4	5.91e-7	Schizophrenia;
UCEC	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.47e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.47	4.78	0.37	4.26e-6	Prostate cancer;
UCEC	cis	rs7246967	0.673	rs7250620	chr19:22853126	A/T	cg08271804	chr19:22816896	ZNF492	0.64	6.39	0.47	2.09e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927997	0.623	rs4494327	chr11:76294836	A/T	cg17647271	chr11:76299819	NA	-0.57	-6.03	-0.45	1.29e-8	Gut microbiota (functional units);Crohn's disease;
UCEC	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.86	-0.44	2.88e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.69	-6.97	-0.5	9.94e-11	Tonsillectomy;
UCEC	cis	rs17532515	0.583	rs2874478	chr4:141404389	A/G	cg25428846	chr4:141107931	NA	-0.39	-4.71	-0.36	5.78e-6	Select biomarker traits;
UCEC	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.85	7.57	0.53	3.89e-12	Body mass index;
UCEC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-6.37	-0.47	2.31e-9	Gut microbiome composition (summer);
UCEC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg26898376	chr11:64110657	CCDC88B	0.38	4.51	0.35	1.3e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.37e-8	Orofacial clefts;
UCEC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	5.1	0.39	1.01e-6	Sudden cardiac arrest;
UCEC	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.5	5.22	0.4	5.96e-7	Schizophrenia;
UCEC	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.6	6.37	0.46	2.34e-9	Initial pursuit acceleration;
UCEC	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	6.54	0.47	9.66e-10	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.6	6.47	0.47	1.4e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2179367	0.887	rs2789492	chr6:149747379	A/G	cg16235748	chr6:149772707	ZC3H12D	0.35	4.73	0.36	5.3e-6	Dupuytren's disease;
UCEC	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.77	10.14	0.64	1.18e-18	Body mass index;
UCEC	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.77	8.71	0.58	5.75e-15	White blood cell count (basophil);
UCEC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.62	-6.11	-0.45	8.3e-9	Blood metabolite levels;
UCEC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.1	-0.39	1.03e-6	Mean platelet volume;
UCEC	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg23950597	chr19:37808831	NA	-0.92	-6.34	-0.46	2.73e-9	Coronary artery calcification;
UCEC	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	-0.37	-5.15	-0.39	8.35e-7	Coronary artery disease;
UCEC	cis	rs12786942	0.569	rs12276736	chr11:101315197	A/T	cg03942599	chr11:101341554	TRPC6	0.5	6.09	0.45	9.38e-9	Facial depth;
UCEC	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.67e-7	Aortic root size;
UCEC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.8	9.98	0.64	3.1e-18	Monocyte count;
UCEC	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg01874867	chr7:94954059	PON1	-0.54	-5.15	-0.39	8.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg21589460	chr7:45850481	NA	-0.6	-5.65	-0.42	7.91e-8	Subjective response to lithium treatment in bipolar disorder;
UCEC	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.69	-7.74	-0.54	1.46e-12	Breast cancer;
UCEC	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg03627880	chr6:151815985	C6orf97	0.68	4.51	0.35	1.31e-5	Menarche (age at onset);
UCEC	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	0.88	10.65	0.66	5.55e-20	Schizophrenia;
UCEC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg19318889	chr4:1322082	MAEA	0.54	5.7	0.43	6.48e-8	Obesity-related traits;
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg08461772	chr7:95026248	PON3	0.36	5.03	0.38	1.39e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg16616514	chr4:6324629	PPP2R2C	0.43	5.25	0.4	5.14e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.57e-13	Chronic sinus infection;
UCEC	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.51	-5.83	-0.43	3.31e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg12637676	chr8:11587161	GATA4	-0.38	-5.11	-0.39	9.72e-7	Retinal vascular caliber;
UCEC	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.87	0.49	1.67e-10	Ileal carcinoids;
UCEC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	0.89	5.57	0.42	1.21e-7	Skin colour saturation;
UCEC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.88	-8.92	-0.59	1.7e-15	Cognitive function;
UCEC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.5	5.21	0.39	6.21e-7	Schizophrenia;
UCEC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.83	8.95	0.59	1.41e-15	Longevity;
UCEC	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.12	-15.23	-0.78	4.81e-32	Myeloid white cell count;
UCEC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.68	5.68	0.42	6.94e-8	Cocaine dependence;
UCEC	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.71	-5.15	-0.39	8.2e-7	Mean platelet volume;
UCEC	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	1.1	9.55	0.62	4.03e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-9.28	-0.61	2.04e-16	Coffee consumption (cups per day);
UCEC	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	6.24	0.46	4.43e-9	Alzheimer's disease;
UCEC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.59	7.37	0.52	1.17e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg20045696	chr14:77926864	AHSA1	-0.68	-5.15	-0.39	8.41e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.55	5.23	0.4	5.7e-7	Lung cancer;
UCEC	cis	rs3935996	0.965	rs4589149	chr1:56315961	G/C	cg11959316	chr1:57001742	PPAP2B	0.36	4.62	0.36	8.43e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
UCEC	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg14092571	chr14:90743983	NA	-0.42	-5.52	-0.41	1.46e-7	Mortality in heart failure;
UCEC	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.59	4.61	0.36	8.6e-6	Corneal astigmatism;
UCEC	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.39	4.78	0.37	4.12e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs77926410	0.685	rs7135238	chr12:10631762	A/G	cg25023291	chr12:11339792	TAS2R42	-0.4	-5.05	-0.38	1.32e-6	Mean corpuscular volume;
UCEC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg19645103	chr12:69753606	YEATS4	-0.55	-4.99	-0.38	1.66e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs12545109	0.959	rs12546307	chr8:57314790	T/A	cg09654669	chr8:57350985	NA	-0.44	-4.57	-0.35	1.04e-5	Obesity-related traits;
UCEC	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	5.44	0.41	2.13e-7	Initial pursuit acceleration;
UCEC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.7	-4.89	-0.37	2.56e-6	Narcolepsy;
UCEC	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-4.72	-0.36	5.4e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.36	4.67	0.36	6.77e-6	Crohn's disease;
UCEC	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-5.76	-0.43	4.69e-8	Schizophrenia;
UCEC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.63	6.51	0.47	1.12e-9	Obesity-related traits;
UCEC	cis	rs925550	0.866	rs4833841	chr4:123584597	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.7	-6.36	-0.46	2.35e-9	Primary biliary cholangitis;
UCEC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.66	-4.96	-0.38	1.9e-6	Aortic root size;
UCEC	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.27	-0.56	7.22e-14	Headache;
UCEC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.8	-8.16	-0.56	1.35e-13	Cognitive function;
UCEC	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.72	-0.54	1.67e-12	Monocyte count;
UCEC	cis	rs7570971	0.500	rs13413101	chr2:135859371	A/T	cg07169764	chr2:136633963	MCM6	0.63	5.95	0.44	1.86e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	4.68	0.36	6.54e-6	Joint mobility (Beighton score);
UCEC	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.47	5.65	0.42	7.88e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	8.17	0.56	1.27e-13	Smoking behavior;
UCEC	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.47	4.73	0.36	5.24e-6	Dental caries;
UCEC	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-4.61	-0.36	8.61e-6	Mitochondrial DNA levels;
UCEC	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.54	4.97	0.38	1.85e-6	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.68	8.16	0.56	1.39e-13	Prudent dietary pattern;
UCEC	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.58	5.49	0.41	1.74e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	5.42	0.41	2.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg23795048	chr12:9217529	LOC144571	0.42	4.9	0.37	2.49e-6	Sjögren's syndrome;
UCEC	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.06	-7.08	-0.5	5.43e-11	Diabetic kidney disease;
UCEC	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.46	-0.72	8.76e-25	Ulcerative colitis;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.36	-0.4	3.11e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.54	0.53	4.52e-12	Bladder cancer;
UCEC	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2839627	0.608	rs2001521	chr21:44232180	T/A	cg03543861	chr21:44258195	NA	0.51	4.98	0.38	1.78e-6	Information processing speed;
UCEC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	5.42	0.41	2.4e-7	Monocyte percentage of white cells;
UCEC	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.35	-0.4	3.33e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7246967	0.932	rs35446354	chr19:23027324	A/G	cg05241461	chr19:22816980	ZNF492	0.48	5.12	0.39	9.3e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg19318889	chr4:1322082	MAEA	0.42	5.0	0.38	1.6e-6	Obesity-related traits;
UCEC	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.7	-8.42	-0.57	3.08e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7078219	0.505	rs10883367	chr10:101287990	A/G	cg09788492	chr10:101292477	NKX2-3	0.43	4.65	0.36	7.38e-6	Dental caries;
UCEC	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	9.59	0.62	3.31e-17	Post bronchodilator FEV1;
UCEC	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	4.53	0.35	1.2e-5	Protein C levels;
UCEC	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23422044	chr7:1970798	MAD1L1	-0.41	-4.58	-0.35	9.69e-6	Neuroticism;
UCEC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.91	11.49	0.69	3.36e-22	Breast cancer;
UCEC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg05802129	chr4:122689817	NA	-0.5	-5.26	-0.4	5.06e-7	Type 2 diabetes;
UCEC	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg14078730	chr11:63896557	MACROD1	-0.47	-5.19	-0.39	6.75e-7	Platelet count;
UCEC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.89	10.63	0.66	6.04e-20	Breast cancer;
UCEC	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.76	-7.15	-0.51	3.8e-11	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.48	-0.41	1.84e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.02	-0.44	1.35e-8	Response to antipsychotic treatment;
UCEC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.4	3.06e-7	Breast cancer;
UCEC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	trans	rs4389974	1.000	rs11784006	chr8:112382425	G/A	cg22736090	chr17:62339926	TEX2	0.66	7.05	0.5	6.3e-11	Body mass index;
UCEC	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs77988765	0.908	rs79664737	chr11:70020641	T/C	cg02486268	chr11:69682825	NA	0.48	4.51	0.35	1.3e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.65	-7.03	-0.5	7.19e-11	Hypospadias;
UCEC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8105895	0.935	rs75025987	chr19:22230669	T/A	cg20662725	chr19:22235022	ZNF257	-0.64	-5.31	-0.4	3.95e-7	Body mass index (change over time);
UCEC	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.57	6.25	0.46	4.16e-9	Resting heart rate;
UCEC	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.75	0.43	4.87e-8	Coffee consumption (cups per day);
UCEC	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.94	10.99	0.67	7.17e-21	Ulcerative colitis;
UCEC	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-25.56	-0.9	5.8e-56	Myeloid white cell count;
UCEC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.66	6.24	0.46	4.48e-9	Schizophrenia;
UCEC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-5.42	-0.41	2.39e-7	Aortic root size;
UCEC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.77	0.59	4.07e-15	Prudent dietary pattern;
UCEC	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.41	5.58	0.42	1.11e-7	Alcohol dependence;
UCEC	cis	rs4778581	0.643	rs939969	chr15:80391470	C/T	cg08257866	chr15:80351198	ZFAND6	0.4	4.62	0.36	8.31e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.56	0.48	8.79e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.6	4.8	0.37	3.93e-6	Iron status biomarkers;
UCEC	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.72	6.75	0.49	3.27e-10	Height;
UCEC	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.68	0.36	6.33e-6	Alzheimer's disease;
UCEC	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.7	6.5	0.47	1.17e-9	Bipolar disorder;
UCEC	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.66	7.12	0.51	4.52e-11	Lewy body disease;
UCEC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.51	-4.65	-0.36	7.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.7	-6.56	-0.48	8.54e-10	Aortic root size;
UCEC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1823913	0.549	rs4516458	chr2:192189903	C/T	cg15998761	chr2:191300784	MFSD6	0.43	4.77	0.37	4.33e-6	Obesity-related traits;
UCEC	cis	rs240764	0.579	rs9386233	chr6:101149540	C/T	cg09795085	chr6:101329169	ASCC3	0.44	4.7	0.36	5.93e-6	Neuroticism;
UCEC	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-5.41	-0.41	2.54e-7	Alcohol dependence;
UCEC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg00546932	chr16:1947055	NA	0.39	5.21	0.39	6.32e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg11150807	chr10:43354902	NA	0.84	6.73	0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.55	-5.52	-0.41	1.51e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	0.92	11.96	0.7	1.86e-23	Homoarginine levels;
UCEC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.44	6.3	0.46	3.2e-9	Vitamin D levels;
UCEC	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.66	-6.43	-0.47	1.64e-9	Metabolite levels;
UCEC	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg18681998	chr4:17616180	MED28	0.91	11.85	0.7	3.59e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg23972785	chr8:11611189	GATA4	-0.35	-4.51	-0.35	1.32e-5	Neuroticism;
UCEC	cis	rs4615376	0.950	rs13209107	chr6:13045071	A/G	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.74	-7.73	-0.54	1.57e-12	Cognitive function;
UCEC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.65	-5.66	-0.42	7.78e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.48	-4.67	-0.36	6.85e-6	Diastolic blood pressure;
UCEC	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.58	-6.87	-0.49	1.72e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg16797656	chr11:68205561	LRP5	0.48	5.44	0.41	2.2e-7	Total body bone mineral density;
UCEC	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.37	0.52	1.13e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.52	-5.57	-0.42	1.17e-7	Body mass index;
UCEC	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.76	9.15	0.6	4.43e-16	Monocyte count;
UCEC	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.66	-6.54	-0.47	9.58e-10	Coronary artery disease;
UCEC	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg06637938	chr14:75390232	RPS6KL1	0.73	6.14	0.45	7.33e-9	Height;
UCEC	cis	rs4500972	1	rs4500972	chr2:73767897	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.31	-0.4	3.94e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.54	6.03	0.45	1.3e-8	Life satisfaction;
UCEC	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.28	12.72	0.72	1.86e-25	Corneal structure;
UCEC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.77	-5.49	-0.41	1.7e-7	Narcolepsy;
UCEC	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg27153327	chr16:1920815	C16orf73	0.43	4.73	0.36	5.31e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.53	5.46	0.41	1.98e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.55	5.83	0.43	3.33e-8	Blood metabolite levels;
UCEC	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs2967951	0.822	rs2567581	chr5:10425182	A/G	cg19616316	chr5:10992684	CTNND2	0.63	4.51	0.35	1.32e-5	Body mass index;
UCEC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.67	-6.95	-0.5	1.1e-10	Body mass index;
UCEC	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.95	11.31	0.68	9.85e-22	Ulcerative colitis;
UCEC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg12035532	chr1:1886765	KIAA1751	0.44	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg11945507	chr8:142233382	SLC45A4	0.4	4.62	0.36	8.34e-6	Immature fraction of reticulocytes;
UCEC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18252515	chr7:66147081	NA	-0.64	-6.06	-0.45	1.09e-8	Aortic root size;
UCEC	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.53	-4.82	-0.37	3.47e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs34486957	0.600	rs35770198	chr14:60046150	A/G	cg12189551	chr14:60952945	C14orf39	0.36	4.52	0.35	1.27e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.54	6.4	0.47	1.99e-9	Breast cancer;
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.52	-5.82	-0.43	3.55e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.64	6.41	0.47	1.85e-9	Dental caries;
UCEC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.65	0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	9.21	0.6	3.13e-16	Monocyte count;
UCEC	cis	rs13401104	0.796	rs57900956	chr2:237119214	C/A	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg04202892	chr2:111875749	ACOXL	0.47	5.48	0.41	1.76e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg23018236	chr17:30244563	NA	-0.67	-4.64	-0.36	7.52e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1028488	0.511	rs6934743	chr6:170696385	A/G	cg20370364	chr6:170703943	FAM120B	-0.48	-4.74	-0.36	4.98e-6	Interferon alpha levels in systemic lupus erythematosus;
UCEC	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	8.83	0.59	2.92e-15	Coffee consumption (cups per day);
UCEC	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.68	5.65	0.42	7.99e-8	Alcohol dependence;
UCEC	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.52	-5.82	-0.43	3.48e-8	Total body bone mineral density;
UCEC	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.39	-4.73	-0.36	5.13e-6	Blood metabolite levels;
UCEC	cis	rs7246967	0.673	rs55638152	chr19:23055294	G/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs713477	0.967	rs6573029	chr14:55913550	A/C	cg13175173	chr14:55914753	NA	-0.41	-4.53	-0.35	1.21e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	9.43	0.61	8.41e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10940138	0.830	rs10447112	chr5:67219761	G/A	ch.5.1281357F	chr5:67228439	NA	0.57	4.66	0.36	7.17e-6	Menarche (age at onset);
UCEC	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.26	14.61	0.77	1.96e-30	Type 1 diabetes nephropathy;
UCEC	cis	rs9470794	0.790	rs11751630	chr6:38142318	A/T	cg01504030	chr6:38141879	BTBD9	-0.79	-5.7	-0.43	6.19e-8	Type 2 diabetes;
UCEC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg11569703	chr11:65557185	OVOL1	0.54	6.81	0.49	2.37e-10	Acne (severe);
UCEC	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.53	-5.27	-0.4	4.85e-7	Systemic lupus erythematosus;
UCEC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.59	5.48	0.41	1.81e-7	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.31	-13.85	-0.75	1.89e-28	Atopic dermatitis;
UCEC	cis	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26002218	chr14:103986227	CKB	0.36	5.15	0.39	8.15e-7	Body mass index;
UCEC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.65	-7.5	-0.53	5.7e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg09555818	chr19:45449301	APOC2	0.5	6.74	0.49	3.29e-10	Blood protein levels;
UCEC	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.84	-7.71	-0.54	1.75e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg22974920	chr21:40686053	BRWD1	-0.51	-4.64	-0.36	7.78e-6	Cognitive function;
UCEC	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.6	-5.35	-0.4	3.29e-7	Mortality in heart failure;
UCEC	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg25306006	chr11:71932630	FOLR2	-0.4	-4.7	-0.36	6.01e-6	Vitamin D levels;
UCEC	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.58	0.48	7.59e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.56	-5.3	-0.4	4.11e-7	Coronary artery disease;
UCEC	cis	rs953387	0.956	rs4954396	chr2:136927557	A/C	cg07169764	chr2:136633963	MCM6	0.51	5.04	0.38	1.32e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	8.04	0.55	2.65e-13	Coronary artery disease;
UCEC	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.47	7.23	0.51	2.45e-11	Airflow obstruction;
UCEC	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg21770322	chr7:97807741	LMTK2	-0.46	-5.17	-0.39	7.56e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.57e-13	Chronic sinus infection;
UCEC	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.68	7.04	0.5	6.84e-11	Coronary artery disease;
UCEC	cis	rs151997	1.000	rs152803	chr5:50212120	C/T	cg06027927	chr5:50259733	NA	0.53	4.83	0.37	3.41e-6	Callous-unemotional behaviour;
UCEC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.61	7.01	0.5	8.06e-11	Longevity;Endometriosis;
UCEC	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg24803719	chr17:45855879	NA	-0.47	-4.99	-0.38	1.69e-6	IgG glycosylation;
UCEC	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs953387	0.910	rs10928558	chr2:136926222	T/C	cg07169764	chr2:136633963	MCM6	0.51	4.8	0.37	3.9e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.43	-5.84	-0.43	3.28e-8	Prostate cancer;
UCEC	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg12292205	chr6:26970375	C6orf41	0.65	7.68	0.54	2.01e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg14530993	chr4:882597	GAK	0.77	4.87	0.37	2.82e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.6	-6.95	-0.5	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg12253828	chr6:101329408	ASCC3	0.46	4.71	0.36	5.73e-6	Neuroticism;
UCEC	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	8.08	0.55	2.2e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.77	-7.45	-0.52	7.29e-12	Lung cancer;
UCEC	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.7	7.36	0.52	1.24e-11	Primary sclerosing cholangitis;
UCEC	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs8005745	0.522	rs2301109	chr14:62197596	G/A	cg01748970	chr14:62088363	NA	-0.61	-5.69	-0.43	6.57e-8	Select biomarker traits;
UCEC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.58	4.84	0.37	3.32e-6	Longevity;
UCEC	cis	rs11021221	0.808	rs11021209	chr11:95283557	T/C	cg22049858	chr11:94884121	NA	0.66	4.68	0.36	6.55e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
UCEC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.47	4.83	0.37	3.33e-6	Red cell distribution width;
UCEC	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	8.01	0.55	3.24e-13	Electrocardiographic conduction measures;
UCEC	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.41	5.61	0.42	9.97e-8	Alcohol dependence;
UCEC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	9.49	0.62	5.86e-17	Coffee consumption (cups per day);
UCEC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg13147721	chr7:65941812	NA	0.94	6.91	0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.63	6.77	0.49	2.88e-10	Menopause (age at onset);
UCEC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-5.31	-0.4	4.02e-7	Platelet count;
UCEC	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.41	5.02	0.38	1.51e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.67	-4.79	-0.37	4.08e-6	Rheumatoid arthritis;
UCEC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.8	8.98	0.6	1.19e-15	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.85	10.25	0.65	6.2e-19	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.87	9.53	0.62	4.55e-17	Breast cancer;
UCEC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.87	0.37	2.79e-6	Aortic root size;
UCEC	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg15837086	chr1:46506065	PIK3R3	0.37	4.54	0.35	1.16e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.12	13.6	0.75	8.96e-28	Cognitive function;
UCEC	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.65	5.34	0.4	3.43e-7	Response to diuretic therapy;
UCEC	cis	rs10988449	1.000	rs10988449	chr9:132370360	C/T	cg18327994	chr9:132372705	NA	-0.54	-4.98	-0.38	1.79e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.71	0.43	5.91e-8	Prudent dietary pattern;
UCEC	cis	rs7246967	0.611	rs8107724	chr19:22867414	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.48	6.14	0.45	7.38e-9	HDL cholesterol levels;
UCEC	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.88	0.37	2.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.11	10.02	0.64	2.43e-18	Vitiligo;
UCEC	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg11697111	chr7:1126903	GPER;C7orf50	-0.49	-4.81	-0.37	3.74e-6	Longevity;Endometriosis;
UCEC	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.75	-8.11	-0.56	1.81e-13	Breast cancer;
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.19e-14	Prudent dietary pattern;
UCEC	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.78	-7.55	-0.53	4.27e-12	Initial pursuit acceleration;
UCEC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.69	-0.54	2e-12	IgG glycosylation;
UCEC	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-4.92	-0.38	2.27e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.72	-8.3	-0.56	6.26e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg05660106	chr1:15850417	CASP9	0.5	4.64	0.36	7.59e-6	Systolic blood pressure;
UCEC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.49	-4.65	-0.36	7.33e-6	Parkinson's disease;
UCEC	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	8.75	0.59	4.46e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg19875535	chr5:140030758	IK	0.43	4.8	0.37	3.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.47	4.85	0.37	3.07e-6	Smoking initiation;
UCEC	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg11859384	chr17:80120422	CCDC57	-0.44	-4.83	-0.37	3.41e-6	Life satisfaction;
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg20119798	chr7:94954144	PON1	-0.49	-4.62	-0.36	8.38e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.53	5.29	0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs968451	0.789	rs1569501	chr22:39683534	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.51	4.63	0.36	8.09e-6	Primary biliary cholangitis;
UCEC	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg25664220	chr3:72788482	NA	-0.62	-5.22	-0.4	6.08e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	4.74	0.36	4.96e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.13	-7.01	-0.5	8.19e-11	Diabetic kidney disease;
UCEC	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.65	6.53	0.47	1.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.43	4.84	0.37	3.22e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg17294928	chr15:75287854	SCAMP5	0.49	5.1	0.39	1.01e-6	Caffeine consumption;
UCEC	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs6728642	1.000	rs60608738	chr2:97608085	G/A	cg18463001	chr5:180611085	NA	-0.76	-6.82	-0.49	2.22e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.51	4.99	0.38	1.7e-6	Emphysema distribution in smoking;
UCEC	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.45	0.47	1.48e-9	Ileal carcinoids;
UCEC	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg02158880	chr13:53174818	NA	0.53	6.2	0.46	5.37e-9	Lewy body disease;
UCEC	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg03714773	chr7:91764589	CYP51A1	0.42	4.93	0.38	2.16e-6	Breast cancer;
UCEC	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.6	6.78	0.49	2.72e-10	Longevity;
UCEC	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.73	-6.44	-0.47	1.56e-9	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs970548	0.739	rs10793620	chr10:46087283	A/G	cg15223267	chr10:46222474	FAM21C	0.51	4.79	0.37	3.98e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.16	-12.9	-0.73	6.07e-26	Breast cancer;
UCEC	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-0.8	-8.36	-0.57	4.27e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.64	6.9	0.49	1.43e-10	Sudden cardiac arrest;
UCEC	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg16576597	chr16:28551801	NUPR1	0.32	4.71	0.36	5.75e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.11e-13	Prudent dietary pattern;
UCEC	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.47	-5.37	-0.4	3.06e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg09910674	chr16:89028015	CBFA2T3	0.6	4.54	0.35	1.16e-5	Skin colour saturation;
UCEC	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg03342759	chr3:160939853	NMD3	0.53	4.75	0.36	4.72e-6	Morning vs. evening chronotype;
UCEC	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	0.87	4.65	0.36	7.41e-6	IgG glycosylation;
UCEC	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	5.61	0.42	9.53e-8	Monocyte percentage of white cells;
UCEC	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs7766436	0.885	rs11759879	chr6:22587130	C/T	cg13666174	chr6:22585274	NA	-0.61	-6.13	-0.45	7.52e-9	Coronary artery disease;
UCEC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.58	7.0	0.5	8.6e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.51	5.38	0.41	2.82e-7	Type 2 diabetes;
UCEC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.02	-0.38	1.48e-6	Systemic lupus erythematosus;
UCEC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-4.93	-0.38	2.23e-6	Testicular germ cell tumor;
UCEC	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg15782153	chr7:917662	C7orf20	0.47	4.8	0.37	3.82e-6	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs61776719	0.905	rs17465420	chr1:38398588	T/C	cg17077180	chr1:38461687	NA	0.63	6.87	0.49	1.68e-10	Coronary artery disease;
UCEC	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-0.83	-8.33	-0.57	5.12e-14	Height;
UCEC	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	8.03	0.55	2.88e-13	Electrocardiographic conduction measures;
UCEC	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	0.85	5.2	0.39	6.49e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs2862064	0.872	rs1393209	chr5:156477540	G/A	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs11761441	0.602	rs6979396	chr7:93116	G/A	cg06458707	chr7:1083209	C7orf50	0.25	4.56	0.35	1.07e-5	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.29	-0.61	1.94e-16	Vitiligo;
UCEC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg03859395	chr2:55845619	SMEK2	0.96	12.54	0.72	5.58e-25	Metabolic syndrome;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.42	-0.47	1.77e-9	Platelet count;
UCEC	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.55	-4.93	-0.38	2.18e-6	Crohn's disease;
UCEC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.66	-0.48	5.15e-10	Crohn's disease;
UCEC	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-4.7	-0.36	5.81e-6	Colorectal cancer;
UCEC	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.48	-5.15	-0.39	8.16e-7	Menarche (age at onset);
UCEC	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.45	4.56	0.35	1.08e-5	Response to temozolomide;
UCEC	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.5	-5.07	-0.39	1.16e-6	P wave terminal force;
UCEC	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg00107782	chr1:151300621	NA	-0.67	-4.54	-0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.64	6.29	0.46	3.38e-9	Bladder cancer;
UCEC	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.89	12.58	0.72	4.37e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.75	5.52	0.41	1.47e-7	Bipolar disorder;
UCEC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.66	6.54	0.47	9.53e-10	Schizophrenia;
UCEC	cis	rs2998286	0.549	rs675678	chr10:28945329	A/G	cg07964848	chr10:28035894	MKX	0.66	5.29	0.4	4.41e-7	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
UCEC	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.55	-5.9	-0.44	2.44e-8	Sudden cardiac arrest;
UCEC	cis	rs7611694	0.501	rs6438140	chr3:113064394	A/C	cg11138929	chr3:113251189	SIDT1	-0.41	-4.91	-0.38	2.39e-6	Prostate cancer;
UCEC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.43	0.41	2.23e-7	Prudent dietary pattern;
UCEC	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.72	4.85	0.37	3.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.84	-7.75	-0.54	1.38e-12	Bladder cancer;
UCEC	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-5.4	-0.41	2.58e-7	Response to antipsychotic treatment;
UCEC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.49	4.93	0.38	2.22e-6	Dupuytren's disease;
UCEC	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.52	5.47	0.41	1.9e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14019695	chr9:139328340	INPP5E	0.46	5.81	0.43	3.72e-8	Monocyte percentage of white cells;
UCEC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.34	0.52	1.33e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	6.05e-9	Colorectal cancer;
UCEC	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.99	-11.98	-0.7	1.68e-23	Survival in pancreatic cancer;
UCEC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.61	-5.09	-0.39	1.08e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.36	4.85	0.37	3.05e-6	Eye color traits;
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg21856205	chr7:94953877	PON1	-0.55	-5.16	-0.39	7.96e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.9	11.81	0.7	4.62e-23	Metabolic syndrome;
UCEC	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.84	-6.88	-0.49	1.58e-10	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.7	7.74	0.54	1.49e-12	Menopause (age at onset);
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg04871131	chr7:94954202	PON1	0.55	5.57	0.42	1.18e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.7	-7.4	-0.52	9.76e-12	Hypospadias;
UCEC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.44	5.12	0.39	9.26e-7	Response to antineoplastic agents;
UCEC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.56	5.39	0.41	2.75e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.37	4.75	0.36	4.75e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg13870426	chr17:30244630	NA	-0.62	-4.52	-0.35	1.24e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.7	7.73	0.54	1.53e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.54	5.15	0.39	8.17e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.65	5.56	0.42	1.21e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-5.19	-0.39	6.79e-7	Monocyte percentage of white cells;
UCEC	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.44	5.19	0.39	6.97e-7	Alzheimer's disease (late onset);
UCEC	cis	rs2892463	0.796	rs9578139	chr13:30386310	T/C	cg18356743	chr13:30408050	UBL3	0.4	4.53	0.35	1.2e-5	Non-word repetition;
UCEC	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	0.82	7.3	0.52	1.66e-11	Blood protein levels;
UCEC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.65	6.33	0.46	2.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.75	-8.43	-0.57	2.98e-14	Primary sclerosing cholangitis;
UCEC	cis	rs6867032	0.527	rs4975790	chr5:2010376	C/T	cg26168224	chr5:2018326	NA	0.57	7.0	0.5	8.37e-11	Gut microbiome composition (winter);
UCEC	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.25	0.65	6.03e-19	Electrocardiographic conduction measures;
UCEC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.58	-5.95	-0.44	1.88e-8	Dental caries;
UCEC	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.45	4.77	0.37	4.44e-6	Alzheimer's disease;
UCEC	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg03959625	chr15:84868606	LOC388152	0.46	4.62	0.36	8.44e-6	Schizophrenia;
UCEC	cis	rs7246967	0.551	rs8103204	chr19:22936517	T/A	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-5.46	-0.41	2e-7	Total body bone mineral density;
UCEC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.7	7.4	0.52	9.89e-12	Breast cancer;
UCEC	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	0.69	9.21	0.6	3.12e-16	Gut microbiome composition (winter);
UCEC	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.49	5.52	0.41	1.49e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03352830	chr11:487213	PTDSS2	0.84	6.6	0.48	6.95e-10	Body mass index;
UCEC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.58	-6.1	-0.45	9.11e-9	Age at first birth;
UCEC	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg04374321	chr14:90722782	PSMC1	-0.56	-5.45	-0.41	2.05e-7	Mortality in heart failure;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.5	7.38	0.52	1.07e-11	Prudent dietary pattern;
UCEC	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.73	7.7	0.54	1.88e-12	Blood metabolite levels;
UCEC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.83	-0.43	3.45e-8	Mortality in heart failure;
UCEC	cis	rs17102423	0.558	rs11628664	chr14:65615651	C/T	cg11161011	chr14:65562177	MAX	-0.62	-5.38	-0.41	2.83e-7	Obesity-related traits;
UCEC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.77	-7.15	-0.51	3.71e-11	Response to antineoplastic agents;
UCEC	cis	rs2299682	0.826	rs6086901	chr20:9464148	C/G	cg11931762	chr20:9488920	NA	-0.64	-4.94	-0.38	2.11e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-9.95	-0.63	3.74e-18	Renal cell carcinoma;
UCEC	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs731174	0.559	rs10908376	chr1:38196026	G/A	cg24088508	chr1:38156462	C1orf109	-0.62	-4.52	-0.35	1.25e-5	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.08	8.21	0.56	1.04e-13	Alzheimer's disease (late onset);
UCEC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.27e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-5.36	-0.4	3.08e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-4.6	-0.36	8.87e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.96	-0.5	1.05e-10	Eye color traits;
UCEC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.58	5.25	0.4	5.28e-7	Uric acid levels;
UCEC	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.67	-0.36	6.83e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	7.06	0.5	6.12e-11	Platelet count;
UCEC	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.67	7.43	0.52	8.1e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	4.56e-18	Cognitive function;
UCEC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.6	7.68	0.54	2.07e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09491104	chr22:46646882	C22orf40	-0.48	-4.58	-0.35	9.71e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg13147721	chr7:65941812	NA	-0.91	-6.06	-0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.36	5.03	0.38	1.42e-6	Height;
UCEC	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.24	0.46	4.53e-9	Cognitive test performance;
UCEC	cis	rs7246967	1.000	rs11882498	chr19:23060012	C/T	cg08271804	chr19:22816896	ZNF492	0.55	4.95	0.38	2.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.02	-11.72	-0.7	8.03e-23	Schizophrenia;
UCEC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.86	-9.48	-0.62	6.3e-17	Cognitive function;
UCEC	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	7.92	0.55	5.44e-13	Mean platelet volume;
UCEC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.57	-5.53	-0.42	1.4e-7	Lymphocyte counts;
UCEC	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg21419209	chr3:44054225	NA	-0.49	-5.37	-0.41	2.95e-7	Coronary artery disease;
UCEC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.78	9.18	0.6	3.67e-16	Lymphocyte counts;
UCEC	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.56	5.52	0.41	1.52e-7	Large artery stroke;
UCEC	cis	rs9931543	0.504	rs4784651	chr16:56311774	A/G	cg10482356	chr16:56328421	GNAO1	0.34	4.75	0.36	4.75e-6	Subjective well-being;
UCEC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg15848620	chr12:58087721	OS9	-0.53	-5.09	-0.39	1.07e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-0.77	-7.3	-0.52	1.63e-11	Vitiligo;
UCEC	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	5.05	0.38	1.3e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs2245008	0.672	rs2245005	chr16:83983893	A/G	cg27171569	chr16:83987465	OSGIN1	0.54	5.18	0.39	7.12e-7	Pursuit maintenance gain;
UCEC	cis	rs2625529	0.775	rs2723342	chr15:72107699	G/C	cg08183300	chr15:72770749	ARIH1	0.61	4.55	0.35	1.13e-5	Red blood cell count;
UCEC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18252515	chr7:66147081	NA	0.51	4.95	0.38	2.04e-6	Aortic root size;
UCEC	cis	rs644799	0.930	rs11021348	chr11:95655481	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	6.47	0.47	1.35e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-5.24	-0.4	5.54e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg21466736	chr12:48725269	NA	0.38	4.59	0.35	9.31e-6	Glycated hemoglobin levels;
UCEC	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg14008862	chr17:28927542	LRRC37B2	0.52	4.51	0.35	1.29e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.06	-0.67	4.48e-21	Primary sclerosing cholangitis;
UCEC	cis	rs526231	0.543	rs72785717	chr5:102333105	C/T	cg23492399	chr5:102201601	PAM	-0.59	-4.74	-0.36	4.93e-6	Primary biliary cholangitis;
UCEC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.57	6.12	0.45	8.27e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10242455	0.867	rs2687086	chr7:99295450	C/T	cg18809830	chr7:99032528	PTCD1	0.53	4.56	0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg03711944	chr11:47377212	SPI1	-0.51	-4.57	-0.35	1.02e-5	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.97	12.6	0.72	3.88e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.49	4.66	0.36	7.17e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.45	-5.01	-0.38	1.53e-6	Blood metabolite ratios;
UCEC	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.59	-5.99	-0.44	1.55e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg11871910	chr12:69753446	YEATS4	0.89	10.33	0.65	3.83e-19	Blood protein levels;
UCEC	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-6.56	-0.48	8.65e-10	Platelet distribution width;
UCEC	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	6.9	0.49	1.42e-10	Coronary artery disease;
UCEC	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg04155231	chr12:9217510	LOC144571	0.41	4.84	0.37	3.23e-6	Sjögren's syndrome;
UCEC	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.54	4.63	0.36	8.1e-6	Methadone dose in opioid dependence;
UCEC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-6.43	-0.47	1.65e-9	Diastolic blood pressure;
UCEC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.66	6.92	0.5	1.28e-10	Motion sickness;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg04202892	chr2:111875749	ACOXL	0.44	4.89	0.37	2.57e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg13695892	chr22:41940480	POLR3H	-0.7	-5.77	-0.43	4.45e-8	Vitiligo;
UCEC	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.67	-7.83	-0.54	9.1e-13	Prevalent atrial fibrillation;
UCEC	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Bladder cancer;
UCEC	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.89	12.13	0.71	6.64e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Amyotrophic lateral sclerosis (age of onset);
UCEC	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg27068330	chr11:65405492	SIPA1	-0.54	-4.72	-0.36	5.54e-6	Breast cancer;
UCEC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.57	6.1	0.45	9.06e-9	Monocyte count;
UCEC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.62	6.0	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6546886	0.912	rs7560668	chr2:74300717	A/G	cg14702570	chr2:74259524	NA	-0.41	-5.25	-0.4	5.29e-7	Dialysis-related mortality;
UCEC	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.41	-0.47	1.91e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.58	6.4	0.47	2.01e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.74	6.6	0.48	7.12e-10	Coronary artery disease;
UCEC	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.8	-9.25	-0.61	2.42e-16	Height;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	6.0	0.44	1.46e-8	Platelet count;
UCEC	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg16558253	chr16:72132732	DHX38	-0.49	-5.2	-0.39	6.48e-7	Blood protein levels;
UCEC	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.6	5.12	0.39	9.51e-7	Alzheimer's disease;
UCEC	cis	rs11048434	1.000	rs1805719	chr12:9151467	A/G	cg26114124	chr12:9217669	LOC144571	0.45	5.08	0.39	1.14e-6	Sjögren's syndrome;
UCEC	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-10.0	-0.64	2.78e-18	Chronic sinus infection;
UCEC	cis	rs3087591	0.919	rs12603838	chr17:29408059	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	7.94	0.55	4.91e-13	Hip circumference;
UCEC	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-0.93	-12.07	-0.71	9.41e-24	Height;
UCEC	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.5	4.61	0.36	8.56e-6	Aortic root size;
UCEC	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.85	-5.98	-0.44	1.62e-8	Psoriasis;
UCEC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.6	-5.39	-0.41	2.74e-7	Type 2 diabetes;
UCEC	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.56	5.11	0.39	9.87e-7	Corneal astigmatism;
UCEC	trans	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg02022102	chr7:27168609	HOXA4	0.6	6.78	0.49	2.67e-10	Protein biomarker;
UCEC	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.48	5.65	0.42	7.9e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.47	4.66	0.36	6.99e-6	Gout;
UCEC	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.46	6.76	0.49	3.01e-10	Blood protein levels;
UCEC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg14092571	chr14:90743983	NA	-0.41	-5.52	-0.41	1.51e-7	Mortality in heart failure;
UCEC	cis	rs3008870	0.536	rs2815383	chr1:67516316	T/A	cg02640540	chr1:67518911	SLC35D1	0.57	4.81	0.37	3.77e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs2043599	1.000	rs61195059	chr19:56459458	C/T	cg12582959	chr19:56159199	CCDC106	0.65	4.58	0.35	1e-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.8	-10.05	-0.64	2.08e-18	Systemic sclerosis;
UCEC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.51	4.71	0.36	5.58e-6	Vitiligo;
UCEC	cis	rs1784581	0.761	rs6455791	chr6:162418533	G/A	cg17173639	chr6:162384350	PARK2	0.65	6.59	0.48	7.38e-10	Itch intensity from mosquito bite;
UCEC	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.6	-4.91	-0.38	2.44e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.52	6.1	0.45	9.06e-9	Mean corpuscular volume;
UCEC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.53	5.95	0.44	1.88e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.57	4.76	0.37	4.57e-6	Obesity-related traits;
UCEC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.65	5.04	0.38	1.33e-6	Corneal astigmatism;
UCEC	cis	rs7916852	0.717	rs3885634	chr10:28357366	T/C	cg01424281	chr10:28031091	MKX	-0.63	-4.54	-0.35	1.17e-5	Glaucoma (primary open-angle);
UCEC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg07930552	chr6:133119739	C6orf192	0.95	6.53	0.47	1.02e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.74	-8.92	-0.59	1.67e-15	Prudent dietary pattern;
UCEC	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	0.9	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.93	7.62	0.53	2.88e-12	Obesity-related traits;
UCEC	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.51	5.02	0.38	1.45e-6	Hemoglobin concentration;
UCEC	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.49	6.58	0.48	7.89e-10	Total body bone mineral density;
UCEC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	6.07	0.45	1.04e-8	Menarche (age at onset);
UCEC	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.58	-5.88	-0.44	2.65e-8	Vitiligo;
UCEC	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.41	5.23	0.4	5.76e-7	Fibrinogen levels;
UCEC	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.43	5.21	0.4	6.16e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg11871910	chr12:69753446	YEATS4	0.86	9.13	0.6	4.96e-16	Blood protein levels;
UCEC	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-7.68	-0.53	2.11e-12	Migraine;Coronary artery disease;
UCEC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.64	5.45	0.41	2.06e-7	High light scatter reticulocyte count;
UCEC	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.58	6.14	0.45	7.19e-9	Motion sickness;
UCEC	cis	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg00614314	chr15:82944287	LOC80154	0.53	4.86	0.37	3.01e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs7308134	0.891	rs68074245	chr12:1991830	A/G	cg16046261	chr12:1602312	ERC1	0.62	4.65	0.36	7.38e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.74	8.06	0.55	2.43e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.6	-4.64	-0.36	7.79e-6	Narcolepsy;
UCEC	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg20701182	chr2:24300061	SF3B14	0.54	4.54	0.35	1.14e-5	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs12980942	0.748	rs61459202	chr19:41833548	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.78	5.26	0.4	5.1e-7	Coronary artery disease;
UCEC	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.45	5.92	0.44	2.19e-8	Fibrinogen levels;
UCEC	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.43	-4.74	-0.36	5.03e-6	Asthma (sex interaction);
UCEC	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	7.04	0.5	6.65e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs7246967	0.673	rs7252925	chr19:22865808	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.69	8.27	0.56	7.44e-14	Testicular germ cell tumor;
UCEC	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg23070574	chr3:14187308	XPC	0.41	4.54	0.35	1.18e-5	Ovarian reserve;
UCEC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.57	5.56	0.42	1.21e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg18131467	chr2:239335373	ASB1	-0.48	-4.57	-0.35	1.03e-5	Lung function (FEV1/FVC);
UCEC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.55	-5.41	-0.41	2.45e-7	Aortic root size;
UCEC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.77	-4.58	-0.35	1e-5	Diabetic retinopathy;
UCEC	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg20965017	chr5:231967	SDHA	0.59	5.17	0.39	7.56e-7	Breast cancer;
UCEC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.86	9.09	0.6	6.3e-16	Parkinson's disease;
UCEC	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg18232548	chr7:50535776	DDC	-0.67	-7.53	-0.53	4.73e-12	Body mass index;
UCEC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.85	-9.3	-0.61	1.79e-16	Breast cancer;
UCEC	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.5	-4.95	-0.38	2.01e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.88	0.49	1.61e-10	Coronary artery disease;
UCEC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	0.87	12.39	0.71	1.38e-24	Leprosy;
UCEC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.01	-0.38	1.53e-6	Chronic sinus infection;
UCEC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-0.67	-5.35	-0.4	3.29e-7	Morning vs. evening chronotype;
UCEC	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg03342759	chr3:160939853	NMD3	0.52	4.72	0.36	5.54e-6	Morning vs. evening chronotype;
UCEC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.33	-5.4	-0.41	2.59e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.56	-5.16	-0.39	7.83e-7	Cognitive function;
UCEC	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.12e-18	Height;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.72	-8.14	-0.56	1.58e-13	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.38	0.52	1.07e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.55	-4.56	-0.35	1.05e-5	Initial pursuit acceleration;
UCEC	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.49	-6.11	-0.45	8.68e-9	Mean platelet volume;
UCEC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.1	17.82	0.83	1.45e-38	IgG glycosylation;
UCEC	cis	rs1324913	1.000	rs1324914	chr13:74634972	A/G	cg13696283	chr13:74707153	KLF12	-0.41	-4.68	-0.36	6.41e-6	Menarche (age at onset);
UCEC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.12	13.93	0.75	1.17e-28	Cognitive function;
UCEC	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.41	4.81	0.37	3.66e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.86	9.26	0.61	2.25e-16	Parkinson's disease;
UCEC	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.0	7.35	0.52	1.3e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.79	0.37	4.11e-6	Menopause (age at onset);
UCEC	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.64	-7.2	-0.51	2.88e-11	Body mass index;
UCEC	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.66	-5.15	-0.39	8.41e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg10932868	chr11:921992	NA	0.43	5.79	0.43	4.08e-8	Alzheimer's disease (late onset);
UCEC	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg19875535	chr5:140030758	IK	-0.45	-4.88	-0.37	2.74e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10256972	0.775	rs10259248	chr7:1018968	G/C	cg20821713	chr7:1055600	C7orf50	-0.54	-5.5	-0.41	1.64e-7	Longevity;Endometriosis;
UCEC	cis	rs4687718	0.528	rs62256967	chr3:53355645	C/T	cg12173409	chr3:54154746	NA	0.54	4.77	0.37	4.39e-6	QRS duration;
UCEC	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.56	-6.48	-0.47	1.29e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.93	0.38	2.17e-6	Bipolar disorder;
UCEC	cis	rs12973672	0.812	rs12984022	chr19:35754011	A/C	cg12095397	chr19:35769544	USF2	0.49	4.62	0.36	8.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.82	-0.49	2.24e-10	Aortic root size;
UCEC	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-4.63	-0.36	7.87e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs9637454	0.526	rs35792166	chr3:178271216	C/T	cg10634551	chr3:178254242	KCNMB2	-0.45	-5.28	-0.4	4.56e-7	Hippocampal sclerosis;
UCEC	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.32	0.4	3.85e-7	Total body bone mineral density;
UCEC	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.47	-5.86	-0.44	2.92e-8	Migraine;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.29	-0.46	3.36e-9	Pubertal anthropometrics;
UCEC	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.6e-9	Motion sickness;
UCEC	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.68	-5.6	-0.42	1.03e-7	Obesity-related traits;
UCEC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.46	-5.03	-0.38	1.43e-6	Blood protein levels;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.43	-4.54	-0.35	1.16e-5	Pubertal anthropometrics;
UCEC	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-8.54	-0.58	1.55e-14	Colorectal cancer;
UCEC	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-5.55	-0.42	1.28e-7	Asthma;
UCEC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.68	7.45	0.52	7.46e-12	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.7	7.74	0.54	1.49e-12	Menopause (age at onset);
UCEC	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7902334	1.000	rs7902334	chr10:12645941	A/C	cg26169081	chr10:12648338	CAMK1D	-0.8	-5.22	-0.4	6.09e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27286337	chr10:134555280	INPP5A	0.59	5.37	0.41	2.94e-7	Migraine;
UCEC	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.72	7.14	0.51	3.91e-11	Parkinson's disease;
UCEC	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-4.91	-0.38	2.42e-6	Hemoglobin concentration;
UCEC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.68	10.24	0.65	6.5e-19	Height;
UCEC	cis	rs4240897	0.935	rs4846082	chr1:12042443	C/T	cg13216073	chr1:12042593	MFN2	0.5	5.08	0.39	1.11e-6	Tuberculosis;
UCEC	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.07	8.12	0.56	1.75e-13	Sexual dysfunction (female);
UCEC	cis	rs9534288	0.619	rs6561290	chr13:46682460	A/G	cg15192986	chr13:46630673	CPB2	-0.5	-4.7	-0.36	5.81e-6	Blood protein levels;
UCEC	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.21	0.51	2.73e-11	Motion sickness;
UCEC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.88	-10.8	-0.67	2.19e-20	Blood metabolite levels;
UCEC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.67e-9	Rheumatoid arthritis;
UCEC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg22598563	chr5:131563921	P4HA2	-0.33	-4.57	-0.35	1.04e-5	Blood metabolite levels;
UCEC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg04154034	chr17:28927549	LRRC37B2	0.76	5.09	0.39	1.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.5	-5.26	-0.4	5.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6457821	1.000	rs73415612	chr6:35437650	A/G	cg06087101	chr6:35551932	FKBP5	0.53	4.51	0.35	1.34e-5	Height;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.55	-0.42	1.3e-7	Cardiac Troponin-T levels;
UCEC	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.55e-7	Schizophrenia;
UCEC	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.54	5.18	0.39	7.08e-7	Lung cancer;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.42	-0.41	2.37e-7	Pulmonary function;
UCEC	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.55	5.93	0.44	2.12e-8	Neuroticism;
UCEC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-0.62	-5.33	-0.4	3.57e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.62	0.42	9.27e-8	Prudent dietary pattern;
UCEC	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.55	-4.94	-0.38	2.07e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.5	0.41	1.67e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.57	-0.42	1.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.54	5.06	0.39	1.24e-6	Alcohol dependence;
UCEC	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-6.29	-0.46	3.43e-9	Blood protein levels;
UCEC	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg01181863	chr3:195395398	SDHAP2	0.52	4.86	0.37	3.04e-6	Pancreatic cancer;
UCEC	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.69	0.48	4.45e-10	Coffee consumption (cups per day);
UCEC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.59	-0.35	9.5e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.54	0.35	1.15e-5	Menopause (age at onset);
UCEC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.89	8.7	0.58	6.13e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.74	6.66	0.48	5.03e-10	Body mass index;
UCEC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-4.9	-0.37	2.55e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs867371	1.000	rs881308	chr15:82475797	A/G	cg00614314	chr15:82944287	LOC80154	0.53	4.86	0.37	3.01e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs4372836	1.000	rs6710959	chr2:28958603	C/T	cg09522027	chr2:28974177	PPP1CB	-0.75	-7.63	-0.53	2.76e-12	Body mass index;
UCEC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.77	-8.77	-0.59	4.04e-15	Menarche (age at onset);
UCEC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-4.54	-0.35	1.15e-5	Aortic root size;
UCEC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.64	-0.48	5.8e-10	Aortic root size;
UCEC	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs524281	0.731	rs3829937	chr11:65787666	G/A	cg25010124	chr11:64981596	SLC22A20	-0.41	-4.55	-0.35	1.11e-5	Electroencephalogram traits;
UCEC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.77	-8.25	-0.56	8.27e-14	Menarche (age at onset);
UCEC	cis	rs4356932	0.790	rs6532130	chr4:76969190	A/G	cg22252999	chr4:76996414	ART3	0.44	4.54	0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.54	4.97	0.38	1.86e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg26566898	chr11:117069891	TAGLN	0.37	4.81	0.37	3.74e-6	Blood protein levels;
UCEC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg11901034	chr3:128598214	ACAD9	0.64	7.24	0.51	2.31e-11	IgG glycosylation;
UCEC	cis	rs4265793	1.000	rs4265793	chr16:19028549	T/C	cg06773604	chr16:18995157	TMC7	0.74	5.12	0.39	9.51e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.47	4.88	0.37	2.76e-6	Schizophrenia;
UCEC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.61	6.05	0.45	1.15e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.55	-5.29	-0.4	4.31e-7	Post bronchodilator FEV1;
UCEC	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.49	5.44	0.41	2.13e-7	Emphysema distribution in smoking;
UCEC	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg14851346	chr12:38532713	NA	0.49	4.83	0.37	3.46e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.72	-0.54	1.61e-12	Monocyte count;
UCEC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.36	-0.46	2.47e-9	Parkinson's disease;
UCEC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.01	10.84	0.67	1.78e-20	Cognitive ability;
UCEC	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.57	6.04	0.45	1.18e-8	Neurofibrillary tangles;
UCEC	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.72	5.39	0.41	2.8e-7	Diabetic retinopathy;
UCEC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18854424	chr1:2615690	NA	0.47	7.15	0.51	3.78e-11	Ulcerative colitis;
UCEC	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	8.8	0.59	3.38e-15	Hip circumference;
UCEC	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.67	0.48	4.92e-10	Coronary artery disease;
UCEC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg04756594	chr16:24857601	SLC5A11	-0.44	-5.28	-0.4	4.6e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.48	-4.58	-0.35	9.98e-6	Personality dimensions;
UCEC	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.15	-0.39	8.2e-7	Mean platelet volume;
UCEC	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.0	-0.44	1.5e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg21770322	chr7:97807741	LMTK2	0.45	5.78	0.43	4.31e-8	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.13	7.93	0.55	5.04e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2812533	0.689	rs2812520	chr10:71430254	T/A	cg04292442	chr10:72124092	LRRC20	-0.43	-4.56	-0.35	1.06e-5	Type 2 diabetes;
UCEC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	7.04	0.5	6.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.47	4.6	0.35	9.02e-6	Colorectal cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01530797	chr7:139875863	LOC100134229;JHDM1D	0.58	6.74	0.49	3.36e-10	Warfarin maintenance dose;
UCEC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.41	4.78	0.37	4.3e-6	Height;
UCEC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.23	0.4	5.71e-7	Rheumatoid arthritis;
UCEC	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.52	4.62	0.36	8.21e-6	Protein C levels;
UCEC	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12292205	chr6:26970375	C6orf41	-0.6	-4.9	-0.38	2.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.66	6.92	0.5	1.3100000000000001e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs829661	0.947	rs829654	chr2:30714717	A/G	cg17749961	chr2:30669863	LCLAT1	0.51	4.76	0.37	4.67e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs11239544	1	rs11239544	chr10:46007533	C/T	cg15223267	chr10:46222474	FAM21C	0.55	5.26	0.4	5.01e-7	Cholesterol, total;
UCEC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.53	-0.35	1.19e-5	Parkinson's disease;
UCEC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.55	5.4	0.41	2.64e-7	Colorectal cancer;
UCEC	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg21782813	chr7:2030301	MAD1L1	0.52	5.66	0.42	7.56e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.82	7.51	0.53	5.38e-12	Obesity-related traits;
UCEC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.92	10.29	0.65	4.98e-19	Cognitive function;
UCEC	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs9517313	0.591	rs17574543	chr13:99172893	G/A	cg07423050	chr13:99094983	FARP1	-0.5	-5.08	-0.39	1.11e-6	Neuroticism;
UCEC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.24	0.46	4.35e-9	Cognitive test performance;
UCEC	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg01426195	chr3:39028469	NA	0.56	6.22	0.46	4.93e-9	Handedness;
UCEC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.6	5.87	0.44	2.8e-8	QRS complex (12-leadsum);
UCEC	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.69	6.51	0.47	1.14e-9	Height;
UCEC	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.55	5.84	0.43	3.22e-8	Autism;
UCEC	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9470794	0.748	rs11752863	chr6:37936506	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	9.79	0.63	9.91e-18	Blood protein levels;
UCEC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-8.17	-0.56	1.27e-13	Gut microbiome composition (summer);
UCEC	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.52	4.77	0.37	4.44e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-0.83	-8.11	-0.56	1.85e-13	Coronary artery disease;
UCEC	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.52	0.62	5.04e-17	Blood protein levels;
UCEC	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.61	6.46	0.47	1.45e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10208940	0.920	rs35002937	chr2:68753240	T/A	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.5	-4.84	-0.37	3.29e-6	Obesity-related traits;
UCEC	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.41	-5.16	-0.39	7.84e-7	Dilated cardiomyopathy;
UCEC	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg07460842	chr6:66804631	NA	0.65	5.43	0.41	2.26e-7	Metabolite levels;
UCEC	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.24	-0.51	2.32e-11	Heart rate;
UCEC	cis	rs1595825	0.891	rs60582020	chr2:198520555	A/C	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs7246967	0.611	rs12984903	chr19:22833881	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg06216157	chr17:7210363	EIF5A	0.76	4.52	0.35	1.29e-5	Androgen levels;
UCEC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-8.37	-0.57	4.05e-14	Migraine;Coronary artery disease;
UCEC	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.41	-4.63	-0.36	7.96e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.58	-5.45	-0.41	2.12e-7	Blood protein levels;
UCEC	cis	rs7246967	0.673	rs34726149	chr19:22952111	A/G	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6032067	0.929	rs2233895	chr20:43850143	T/A	cg00873616	chr20:43920241	NA	0.51	5.11	0.39	9.79e-7	Blood protein levels;
UCEC	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.7	-7.92	-0.55	5.37e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.3	7.55	0.53	4.26e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.53	5.52	0.41	1.5e-7	Dupuytren's disease;
UCEC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.6	5.76	0.43	4.78e-8	Corneal astigmatism;
UCEC	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.5	-5.01	-0.38	1.55e-6	Height;
UCEC	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.68	5.8	0.43	3.9e-8	Prostate cancer;
UCEC	cis	rs12216499	1.000	rs77446828	chr6:159414034	C/T	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.81	8.36	0.57	4.28e-14	Longevity;
UCEC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.61	-4.89	-0.37	2.64e-6	Initial pursuit acceleration;
UCEC	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.23e-9	Diabetic retinopathy;
UCEC	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg18279126	chr7:2041391	MAD1L1	0.45	5.46	0.41	1.95e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.19e-6	Vitamin D levels;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg05930166	chr1:222884917	AIDA;C1orf58	-0.63	-6.93	-0.5	1.23e-10	Breast cancer;
UCEC	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg09795085	chr6:101329169	ASCC3	0.58	4.52	0.35	1.24e-5	Economic and political preferences (immigration/crime);
UCEC	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.7	-5.09	-0.39	1.1e-6	Mean platelet volume;
UCEC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2455799	1.000	rs12488913	chr3:15847941	C/A	cg16303742	chr3:15540471	COLQ	-0.41	-4.74	-0.36	4.92e-6	Mean platelet volume;
UCEC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.69	5.31	0.4	4.04e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.72	6.98	0.5	9.39e-11	Schizophrenia;
UCEC	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.66	5.19	0.39	6.76e-7	HIV-1 control;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.8	-9.25	-0.61	2.41e-16	Longevity;Endometriosis;
UCEC	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.59	6.32	0.46	3e-9	Lifespan;
UCEC	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.55	6.11	0.45	8.65e-9	Breast cancer;
UCEC	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.62	5.82	0.43	3.63e-8	Crohn's disease;
UCEC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-11.14	-0.68	2.85e-21	Schizophrenia;
UCEC	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.5	-6.39	-0.47	2.05e-9	Height;
UCEC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.9	-0.37	2.51e-6	Testicular germ cell tumor;
UCEC	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.41	0.52	9.12e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.73	-7.67	-0.53	2.18e-12	Breast cancer;
UCEC	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg03999872	chr20:62272968	STMN3	-0.49	-4.68	-0.36	6.44e-6	Atopic dermatitis;
UCEC	cis	rs960450	0.826	rs2865799	chr4:98531675	C/G	cg11693424	chr4:99502614	TSPAN5	-0.32	-4.75	-0.36	4.81e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	4.56	0.35	1.08e-5	Coronary artery disease;
UCEC	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.58	-5.93	-0.44	2.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.75	8.41	0.57	3.23e-14	Coronary artery disease;
UCEC	cis	rs4265793	0.655	rs6497322	chr16:19093306	T/G	cg06773604	chr16:18995157	TMC7	0.75	5.34	0.4	3.41e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.77	-7.92	-0.55	5.44e-13	Parkinson's disease;
UCEC	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	6.97	0.5	9.67e-11	Leprosy;
UCEC	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.27	-10.14	-0.64	1.2e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg06238570	chr21:40685208	BRWD1	0.54	5.73	0.43	5.51e-8	Cognitive function;
UCEC	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.67	5.75	0.43	4.94e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	4.56	0.35	1.08e-5	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg07930552	chr6:133119739	C6orf192	0.94	8.73	0.58	5.04e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs9843304	0.868	rs4681516	chr3:149212125	G/C	cg08667024	chr3:149219783	TM4SF4	0.4	4.76	0.37	4.66e-6	Gallstone disease;
UCEC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg07537917	chr2:241836409	C2orf54	-0.5	-7.26	-0.51	2.07e-11	Urinary metabolites;
UCEC	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.54	5.73	0.43	5.45e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg17652424	chr22:38574118	PLA2G6	-0.41	-5.2	-0.39	6.52e-7	Cutaneous nevi;
UCEC	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.52	-0.41	1.49e-7	Life satisfaction;
UCEC	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.53	5.3	0.4	4.12e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.76	8.2	0.56	1.08e-13	Menopause (age at onset);
UCEC	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.59	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg14530993	chr4:882597	GAK	-0.64	-4.87	-0.37	2.87e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-0.92	-11.68	-0.69	1.03e-22	Height;
UCEC	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.45	-5.02	-0.38	1.47e-6	Recombination rate (males);
UCEC	cis	rs11760485	0.782	rs4720257	chr7:4407814	A/G	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.51	5.87	0.44	2.81e-8	Mean corpuscular volume;
UCEC	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.13	-0.45	7.73e-9	Pubertal anthropometrics;
UCEC	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	1.07	7.86	0.54	7.47e-13	Corneal structure;
UCEC	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.57	5.78	0.43	4.21e-8	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg03714773	chr7:91764589	CYP51A1	0.41	4.9	0.37	2.5e-6	Breast cancer;
UCEC	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.61	0.42	9.6e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.56	6.44	0.47	1.61e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.89	-6.73	-0.49	3.46e-10	Exhaled nitric oxide output;
UCEC	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	0.95	8.76	0.59	4.42e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg00086871	chr4:6988644	TBC1D14	-0.49	-4.59	-0.35	9.29e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-4.51	-0.35	1.31e-5	Developmental language disorder (linguistic errors);
UCEC	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.96	-14.46	-0.77	5.03e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.75	-6.07	-0.45	1.06e-8	Birth weight;
UCEC	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.7	6.75	0.49	3.11e-10	Aortic root size;
UCEC	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg23307798	chr14:103986281	CKB	-0.61	-7.33	-0.52	1.39e-11	Body mass index;
UCEC	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.57	5.02	0.38	1.44e-6	Crohn's disease;
UCEC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.54	-5.94	-0.44	1.97e-8	Diastolic blood pressure;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg07838603	chr6:28411030	ZSCAN23	0.52	6.54	0.48	9.31e-10	Pubertal anthropometrics;
UCEC	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.53	-4.69	-0.36	6.31e-6	Immature fraction of reticulocytes;
UCEC	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg22857025	chr5:266934	NA	-0.95	-8.83	-0.59	2.82e-15	Breast cancer;
UCEC	cis	rs8105895	1.000	rs2359820	chr19:22208114	G/T	cg24175803	chr19:22235144	ZNF257	-0.5	-4.61	-0.36	8.81e-6	Body mass index (change over time);
UCEC	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg08890418	chr1:21044141	KIF17	0.54	5.37	0.41	2.94e-7	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs7246967	0.673	rs8104564	chr19:22867207	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.8	0.43	4e-8	Height;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg09120320	chr17:61926383	NA	0.44	4.55	0.35	1.1e-5	Prudent dietary pattern;
UCEC	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.49	4.99	0.38	1.68e-6	Neuroticism;
UCEC	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg18721089	chr20:30220636	NA	-0.39	-4.86	-0.37	2.98e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.97	12.63	0.72	3.2e-25	Ulcerative colitis;
UCEC	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.56	6.68	0.48	4.56e-10	Longevity;
UCEC	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.63	5.85	0.43	3.09e-8	Tonsillectomy;
UCEC	cis	rs9467773	0.967	rs10223792	chr6:26579616	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg21280719	chr6:42927975	GNMT	0.38	4.53	0.35	1.22e-5	Blood protein levels;
UCEC	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg21770322	chr7:97807741	LMTK2	0.46	5.75	0.43	4.97e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	6.44	0.47	1.62e-9	Cognitive test performance;
UCEC	cis	rs11867410	0.744	rs73992167	chr17:63965866	C/T	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.57	5.05	0.38	1.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg03146154	chr1:46216737	IPP	-0.57	-5.67	-0.42	7.18e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.79	-6.13	-0.45	7.6e-9	Narcolepsy;
UCEC	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22117172	chr7:91764530	CYP51A1	0.44	5.73	0.43	5.6e-8	Breast cancer;
UCEC	cis	rs10509540	0.793	rs1035797	chr10:90051857	G/T	cg10205334	chr10:89622497	PTEN;KILLIN	0.46	4.65	0.36	7.47e-6	Type 1 diabetes;
UCEC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg19926144	chr10:661009	DIP2C	0.79	4.75	0.37	4.71e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.76	-5.44	-0.41	2.13e-7	Systemic lupus erythematosus;
UCEC	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg21770322	chr7:97807741	LMTK2	0.71	10.28	0.65	5.12e-19	Breast cancer;
UCEC	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg19926144	chr10:661009	DIP2C	0.79	4.7	0.36	5.81e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.74	-8.2	-0.56	1.12e-13	Ulcerative colitis;
UCEC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.57	6.1	0.45	8.99e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.14e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-4.67	-0.36	6.76e-6	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg15167202	chr5:149997153	SYNPO	-0.38	-4.86	-0.37	3.01e-6	HIV-1 control;
UCEC	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.27	0.51	2.01e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg23793686	chr15:68133972	NA	-0.44	-4.52	-0.35	1.24e-5	Restless legs syndrome;
UCEC	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.41	-0.41	2.49e-7	Height;
UCEC	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg20936604	chr3:58311152	NA	-0.59	-4.96	-0.38	1.89e-6	Cholesterol, total;
UCEC	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs11118844	0.793	rs4433402	chr1:221946172	A/G	cg04222084	chr1:221915650	DUSP10	-0.76	-7.21	-0.51	2.71e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs534126	0.885	rs10274425	chr7:143016166	A/G	cg04182207	chr7:143013161	CLCN1	0.36	4.72	0.36	5.34e-6	Cancer;
UCEC	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.77	-8.85	-0.59	2.54e-15	Facial morphology (factor 19);
UCEC	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	4.83	0.37	3.33e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.48	5.97	0.44	1.71e-8	HDL cholesterol levels;
UCEC	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.73	5.9	0.44	2.35e-8	Alzheimer's disease;
UCEC	cis	rs7246967	0.866	rs12981220	chr19:23021400	G/T	cg08271804	chr19:22816896	ZNF492	-0.58	-5.64	-0.42	8.29e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-6.59	-0.48	7.42e-10	Menarche (age at onset);
UCEC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-0.95	-5.72	-0.43	5.64e-8	Diabetic kidney disease;
UCEC	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.63	-7.53	-0.53	4.84e-12	Obesity-related traits;
UCEC	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg02106180	chr16:845767	CHTF18	0.47	5.13	0.39	8.85e-7	Mean corpuscular volume;
UCEC	cis	rs4372836	0.729	rs12714241	chr2:28969413	T/C	cg09522027	chr2:28974177	PPP1CB	-0.89	-9.8	-0.63	9.15e-18	Body mass index;
UCEC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.63	6.93	0.5	1.25e-10	Melanoma;
UCEC	cis	rs11693319	1.000	rs11693319	chr2:179738269	C/T	cg26389888	chr2:178973147	PDE11A	0.6	4.61	0.36	8.53e-6	Blood pressure measurement (cold pressor test);
UCEC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.33	-0.46	2.76e-9	Aortic root size;
UCEC	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.62	-0.36	8.42e-6	Breast cancer;
UCEC	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.42	4.76	0.37	4.55e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.28	0.51	1.88e-11	Ileal carcinoids;
UCEC	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.03	-12.38	-0.71	1.43e-24	Dilated cardiomyopathy;
UCEC	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.7	-0.43	6.33e-8	Hemoglobin concentration;
UCEC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.54	5.15	0.39	8.35e-7	Blood metabolite levels;
UCEC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.67	0.42	7.2e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg21253087	chr9:139290292	SNAPC4	0.41	4.72	0.36	5.44e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7212590	0.581	rs9901254	chr17:57832917	A/T	cg10252138	chr17:58120427	NA	-0.72	-5.81	-0.43	3.73e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	6.74	0.49	3.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.84	6.82	0.49	2.18e-10	Response to hepatitis C treatment;
UCEC	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.54	4.55	0.35	1.13e-5	Obesity-related traits;
UCEC	cis	rs6723108	0.627	rs2197579	chr2:135644978	C/T	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.47	7.19	0.51	2.98e-11	Primary biliary cholangitis;
UCEC	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2806864	1.000	rs943371	chr1:117467690	C/G	cg19765820	chr1:116518738	SLC22A15	0.63	4.79	0.37	4.05e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.69	7.74	0.54	1.44e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs4865169	1.000	rs4865169	chr4:57879792	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-5.25	-0.4	5.17e-7	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16691477	chr11:64889790	FAU;MRPL49	0.69	8.14	0.56	1.56e-13	Warfarin maintenance dose;
UCEC	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-4.98	-0.38	1.8e-6	Obesity-related traits;
UCEC	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	5.33	0.4	3.62e-7	Cognitive test performance;
UCEC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg01689657	chr7:91764605	CYP51A1	0.43	5.38	0.41	2.83e-7	Breast cancer;
UCEC	cis	rs295140	1.000	rs13028959	chr2:201185919	C/A	cg04283868	chr2:201171347	SPATS2L	0.53	5.16	0.39	7.71e-7	QT interval;
UCEC	cis	rs2455799	1.000	rs6773547	chr3:15882245	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-4.59	-0.35	9.29e-6	Mean platelet volume;
UCEC	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.59	0.62	3.15e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.63	-6.5	-0.47	1.19e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs600626	0.529	rs2004638	chr11:75471012	C/T	cg24262691	chr11:75473276	NA	0.38	4.83	0.37	3.4e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg20607287	chr7:12443886	VWDE	-0.62	-4.6	-0.35	9.18e-6	Coronary artery disease;
UCEC	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.67	-4.69	-0.36	6.18e-6	Aortic root size;
UCEC	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18252515	chr7:66147081	NA	0.46	4.72	0.36	5.33e-6	Aortic root size;
UCEC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.51	0.35	1.31e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.2e-7	Schizophrenia;
UCEC	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.82	7.28	0.51	1.87e-11	Longevity;
UCEC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.6	5.82	0.43	3.54e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg14664628	chr15:75095509	CSK	-0.52	-5.16	-0.39	7.71e-7	Caffeine consumption;
UCEC	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.57	-0.42	1.17e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	7.84	0.54	8.51e-13	Tonsillectomy;
UCEC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	7.57	0.53	3.82e-12	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.78	6.75	0.49	3.23e-10	Gastritis;
UCEC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.55	6.2	0.46	5.29e-9	Menarche (age at onset);
UCEC	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg23352942	chr3:46931381	PTH1R	-0.4	-5.21	-0.39	6.32e-7	Birth weight;
UCEC	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	7.39	0.52	1.01e-11	Schizophrenia;
UCEC	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.45	4.6	0.35	9e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs9815925	0.748	rs3821750	chr3:184766301	T/C	cg00151007	chr3:184769954	VPS8	0.58	5.55	0.42	1.27e-7	Heschl's gyrus morphology;
UCEC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.74	-6.62	-0.48	6.45e-10	Diastolic blood pressure;
UCEC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.42	-0.47	1.76e-9	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12980942	0.810	rs8105901	chr19:41792092	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.81	5.94	0.44	1.97e-8	Coronary artery disease;
UCEC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12516959	chr21:47718080	NA	-0.41	-4.66	-0.36	7.07e-6	Testicular germ cell tumor;
UCEC	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	1.0	9.44	0.61	7.75e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-0.96	-6.67	-0.48	4.81e-10	Sexual dysfunction (female);
UCEC	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.44	-4.58	-0.35	9.79e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.62	-5.67	-0.42	7.35e-8	Pulmonary function;
UCEC	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-23.58	-0.89	8.38e-52	Myeloid white cell count;
UCEC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.57	-0.42	1.19e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4865169	0.871	rs9918067	chr4:57870544	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-5.33	-0.4	3.67e-7	Breast cancer;
UCEC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.16	-0.45	6.61e-9	Blood metabolite levels;
UCEC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.54	6.0	0.44	1.46e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.58	7.64	0.53	2.61e-12	Gut microbiota (bacterial taxa);
UCEC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg23370820	chr17:17987590	NA	0.43	4.91	0.38	2.4e-6	Total body bone mineral density;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.91	11.07	0.67	4.37e-21	Menarche (age at onset);
UCEC	cis	rs4853036	0.716	rs10209551	chr2:69997995	A/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-4.51	-0.35	1.34e-5	Colorectal or endometrial cancer;
UCEC	cis	rs6919534	0.688	rs6457809	chr6:35154315	G/T	cg03355690	chr6:35265616	DEF6	0.52	4.55	0.35	1.11e-5	Height;
UCEC	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	7.4	0.52	9.47e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.69	6.02	0.44	1.32e-8	Adiposity;
UCEC	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.71	-5.68	-0.42	6.82e-8	Asthma;
UCEC	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg23950597	chr19:37808831	NA	0.6	4.73	0.36	5.21e-6	Coronary artery calcification;
UCEC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.81	0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-9.24	-0.61	2.59e-16	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg07817883	chr1:32538562	TMEM39B	1.2	9.65	0.62	2.27e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.55	5.77	0.43	4.53e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.83	-10.08	-0.64	1.75e-18	Coronary artery disease;
UCEC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg02160872	chr5:212506	CCDC127	-0.69	-7.12	-0.51	4.37e-11	Breast cancer;
UCEC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.72	6.52	0.47	1.06e-9	Red cell distribution width;
UCEC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs10924970	0.649	rs2093406	chr1:235371545	A/G	cg26050004	chr1:235667680	B3GALNT2	0.47	4.57	0.35	1.01e-5	Asthma;
UCEC	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.74	-9.22	-0.61	2.96e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.66	-6.71	-0.48	3.87e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.52	5.53	0.42	1.39e-7	Breast cancer;
UCEC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.67	7.14	0.51	4.05e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.6	6.54	0.47	9.46e-10	Retinal vascular caliber;
UCEC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.05	-0.38	1.29e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18252515	chr7:66147081	NA	0.55	5.3	0.4	4.17e-7	Aortic root size;
UCEC	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.73	-7.9	-0.55	5.89e-13	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17913451	chr14:58619030	C14orf37	0.66	8.0	0.55	3.49e-13	Warfarin maintenance dose;
UCEC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.67	-6.86	-0.49	1.75e-10	Neurofibrillary tangles;
UCEC	cis	rs1007190	0.881	rs12941832	chr17:42987482	G/T	cg15406952	chr17:42872593	NA	0.76	5.47	0.41	1.93e-7	DNA methylation (variation);
UCEC	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.73	8.57	0.58	1.28e-14	Extraversion;
UCEC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.96	0.59	1.34e-15	Alzheimer's disease;
UCEC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.81	6.48	0.47	1.33e-9	Testicular germ cell tumor;
UCEC	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.0	-8.16	-0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg00614314	chr15:82944287	LOC80154	0.67	6.48	0.47	1.33e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.57	-5.5	-0.41	1.68e-7	Corneal astigmatism;
UCEC	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.69	-6.59	-0.48	7.46e-10	Height;
UCEC	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-1.01	-7.39	-0.52	1.02e-11	Multiple sclerosis;
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.93	11.32	0.68	9.51e-22	Prudent dietary pattern;
UCEC	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-0.62	-4.69	-0.36	6.1e-6	Plateletcrit;
UCEC	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.71	-6.27	-0.46	3.84e-9	Adiposity;
UCEC	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.71	-6.44	-0.47	1.57e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.62	-5.74	-0.43	5.36e-8	Hypospadias;
UCEC	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.47	4.63	0.36	7.89e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	0.97	7.47	0.52	6.54e-12	Body mass index;
UCEC	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.51	-4.72	-0.36	5.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.22	-0.4	6.08e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-7.22	-0.51	2.55e-11	Platelet distribution width;
UCEC	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	10.28	0.65	5.16e-19	Bipolar disorder;
UCEC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg24375607	chr4:120327624	NA	0.49	4.99	0.38	1.65e-6	Corneal astigmatism;
UCEC	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg20026190	chr17:76395443	PGS1	0.38	4.52	0.35	1.28e-5	HDL cholesterol levels;
UCEC	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg07776626	chr8:57350775	NA	-0.42	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.67	-0.36	6.7e-6	Educational attainment (years of education);
UCEC	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg11632617	chr15:75315747	PPCDC	-0.63	-7.03	-0.5	7.32e-11	Lung cancer;
UCEC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs7246967	0.611	rs7250285	chr19:22837108	C/T	cg24889512	chr19:22816950	ZNF492	0.58	6.19	0.45	5.82e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg04176532	chr22:50317003	CRELD2	0.47	4.73	0.36	5.12e-6	Schizophrenia;
UCEC	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.72	6.99	0.5	8.87e-11	Refractive astigmatism;
UCEC	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.41	4.56	0.35	1.07e-5	Height;
UCEC	cis	rs7072216	0.621	rs11189595	chr10:100167322	C/T	cg19567339	chr10:100142640	NA	0.57	6.01	0.44	1.43e-8	Metabolite levels;
UCEC	cis	rs72906064	1.000	rs17244416	chr2:156916826	G/C	cg14040602	chr2:157557294	NA	0.64	4.66	0.36	7.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.67	6.84	0.49	1.94e-10	Body mass index;
UCEC	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg22166914	chr1:53195759	ZYG11B	0.7	7.4	0.52	9.47e-12	Monocyte count;
UCEC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.08	6.51	0.47	1.1e-9	Diabetic retinopathy;
UCEC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg03714773	chr7:91764589	CYP51A1	-0.38	-4.58	-0.35	9.71e-6	Breast cancer;
UCEC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.75	-8.14	-0.56	1.52e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.68	0.36	6.35e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs78487399	0.831	rs12469373	chr2:43829191	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.1	-0.45	8.86e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.13	0.45	7.82e-9	Motion sickness;
UCEC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	5.94	0.44	1.99e-8	Joint mobility (Beighton score);
UCEC	cis	rs11958404	0.932	rs6870420	chr5:157437166	T/C	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs78487399	0.808	rs17030967	chr2:43748983	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-4.63	-0.36	7.86e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg21053147	chr12:120880522	NA	-0.67	-5.52	-0.41	1.48e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-0.99	-14.01	-0.76	7.25e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.61	-6.81	-0.49	2.29e-10	Pubertal anthropometrics;
UCEC	cis	rs2280630	0.529	rs4342048	chr3:39012943	A/G	cg01426195	chr3:39028469	NA	-0.69	-8.57	-0.58	1.28e-14	Verbal declarative memory;
UCEC	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.52	5.04	0.38	1.36e-6	Resting heart rate;
UCEC	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.34	0.4	3.43e-7	Multiple sclerosis;
UCEC	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.39	-0.47	2.09e-9	Metabolite levels;
UCEC	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg06671706	chr8:8559999	CLDN23	0.56	4.67	0.36	6.86e-6	Obesity-related traits;
UCEC	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg01657329	chr11:68192670	LRP5	0.41	4.72	0.36	5.38e-6	Bone mineral density (spine);
UCEC	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg19912559	chr1:40204330	PPIE	0.48	4.66	0.36	7.15e-6	Blood protein levels;
UCEC	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.46	5.6	0.42	1.03e-7	Coronary artery disease;
UCEC	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.62	-6.63	-0.48	6.11e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.31	-7.9	-0.55	5.95e-13	Schizophrenia;
UCEC	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs600626	0.529	rs10899115	chr11:75471849	A/G	cg24262691	chr11:75473276	NA	0.38	4.69	0.36	6.18e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs11850957	0.563	rs11849156	chr14:25538909	A/C	cg11775837	chr14:25519611	STXBP6	0.53	4.57	0.35	1.03e-5	Subcutaneous adipose tissue;
UCEC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.52	-5.57	-0.42	1.19e-7	Electroencephalogram traits;
UCEC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg00815214	chr21:47717953	NA	-0.45	-5.38	-0.41	2.93e-7	Testicular germ cell tumor;
UCEC	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg18135206	chr14:102964638	TECPR2	0.96	11.42	0.69	5.18e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg13147721	chr7:65941812	NA	-0.75	-5.07	-0.39	1.19e-6	Diabetic kidney disease;
UCEC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.6	6.58	0.48	7.68e-10	Resting heart rate;
UCEC	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	1.08	5.22	0.4	6.1e-7	Thyroid stimulating hormone;
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.62	7.48	0.52	6.32e-12	Schizophrenia;
UCEC	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.7	7.79	0.54	1.11e-12	Ewing sarcoma;
UCEC	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.6	5.4	0.41	2.56e-7	Corneal astigmatism;
UCEC	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs9341808	0.500	rs806851	chr6:81030831	A/C	cg08355045	chr6:80787529	NA	-0.37	-5.09	-0.39	1.09e-6	Sitting height ratio;
UCEC	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.96	0.59	1.34e-15	Alzheimer's disease;
UCEC	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg13695892	chr22:41940480	POLR3H	-0.68	-4.61	-0.36	8.57e-6	Vitiligo;
UCEC	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.64	6.86	0.49	1.81e-10	Menopause (age at onset);
UCEC	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-6.39	-0.47	2.12e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs554111	0.685	rs113664832	chr1:21058655	G/A	cg08890418	chr1:21044141	KIF17	-0.54	-5.2	-0.39	6.52e-7	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.57	5.95	0.44	1.89e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4588572	0.643	rs13359053	chr5:77690224	T/C	cg11547950	chr5:77652471	NA	0.47	5.42	0.41	2.41e-7	Triglycerides;
UCEC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg24562669	chr7:97807699	LMTK2	0.44	5.3	0.4	4.14e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	6.14	0.45	7.2e-9	Personality dimensions;
UCEC	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg26116260	chr4:7069785	GRPEL1	-0.55	-4.72	-0.36	5.51e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.6	5.68	0.42	6.97e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.75	-8.68	-0.58	6.97e-15	Facial morphology (factor 19);
UCEC	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	0.92	8.9	0.59	1.92e-15	Post bronchodilator FEV1;
UCEC	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.47	-4.76	-0.37	4.5e-6	Dental caries;
UCEC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	0.94	8.99	0.6	1.1e-15	Cognitive function;
UCEC	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.52	-4.76	-0.37	4.63e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg22166914	chr1:53195759	ZYG11B	0.82	8.52	0.57	1.79e-14	Monocyte count;
UCEC	cis	rs3802344	0.590	rs34616588	chr9:133589309	A/G	cg01474677	chr9:133586259	NA	-0.99	-5.2	-0.39	6.49e-7	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.78	0.37	4.15e-6	Cognitive ability;
UCEC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg00105475	chr2:10696890	NA	0.4	4.82	0.37	3.58e-6	Prostate cancer;
UCEC	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.51	-5.45	-0.41	2.04e-7	Alcohol dependence;
UCEC	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.11	12.02	0.7	1.34e-23	Blood protein levels;
UCEC	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	6.34	0.46	2.68e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7246967	0.673	rs55932152	chr19:22873428	A/T	cg05241461	chr19:22816980	ZNF492	0.57	6.27	0.46	3.77e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.33	4.61	0.36	8.82e-6	Crohn's disease;
UCEC	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05890377	chr2:74357713	NA	0.66	6.02	0.44	1.34e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs829661	0.793	rs829639	chr2:30703247	A/G	cg17749961	chr2:30669863	LCLAT1	0.7	5.12	0.39	9.44e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.78	-8.01	-0.55	3.21e-13	Joint mobility (Beighton score);
UCEC	cis	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg14992524	chr8:10586135	SOX7	0.26	4.61	0.36	8.52e-6	Neuroticism;
UCEC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-0.76	-7.68	-0.54	2.02e-12	Urate levels;
UCEC	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.7	8.92	0.59	1.75e-15	Mean platelet volume;
UCEC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.34e-18	Height;
UCEC	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.83	-9.95	-0.63	3.73e-18	Primary sclerosing cholangitis;
UCEC	cis	rs2190422	0.551	rs2256517	chr7:103166261	G/T	cg18108683	chr7:102477205	FBXL13	0.54	4.65	0.36	7.32e-6	Morning vs. evening chronotype;
UCEC	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.64	-7.18	-0.51	3.21e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.77	-8.55	-0.58	1.42e-14	Ear protrusion;
UCEC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.57	-6.83	-0.49	2.14e-10	Menopause (age at onset);
UCEC	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.42	-4.98	-0.38	1.77e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.45	5.05	0.38	1.28e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.55	-5.74	-0.43	5.32e-8	Autism;
UCEC	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.08	11.34	0.68	8.18e-22	Corneal structure;
UCEC	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.01	5.85	0.43	3.02e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	0.88	5.61	0.42	9.57e-8	Arsenic metabolism;
UCEC	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.83	10.37	0.65	2.98e-19	Metabolic syndrome;
UCEC	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.66	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.6	5.64	0.42	8.37e-8	Corneal astigmatism;
UCEC	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.62	-5.06	-0.39	1.22e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-5.31	-0.4	4e-7	Chronic sinus infection;
UCEC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.74	8.58	0.58	1.2e-14	Menopause (age at onset);
UCEC	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.7	6.76	0.49	3.05e-10	Schizophrenia;
UCEC	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.68	7.49	0.53	5.99e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.71	7.93	0.55	5.16e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.76	7.51	0.53	5.16e-12	Lung cancer;
UCEC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.04	-0.38	1.34e-6	Breast cancer;
UCEC	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.56	4.89	0.37	2.62e-6	Crohn's disease;
UCEC	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.63	4.98	0.38	1.75e-6	Major depressive disorder;
UCEC	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	5.44	0.41	2.14e-7	Eosinophil percentage of white cells;
UCEC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-4.53	-0.35	1.22e-5	Mean platelet volume;
UCEC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.68	6.83	0.49	2.12e-10	Multiple myeloma (IgH translocation);
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg19743759	chr9:35072884	VCP	-0.74	-9.24	-0.61	2.64e-16	Breast cancer;
UCEC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.71	7.05	0.5	6.34e-11	Tonsillectomy;
UCEC	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.65	5.04	0.38	1.32e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.78	8.34	0.57	4.8e-14	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4851266	0.966	rs1160545	chr2:100832269	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.6	-6.43	-0.47	1.65e-9	Obesity-related traits;
UCEC	cis	rs7582720	0.832	rs116426890	chr2:204196618	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.86	4.74	0.36	4.95e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.14	6.41	0.47	1.85e-9	Eosinophil percentage of granulocytes;
UCEC	cis	rs8099014	0.816	rs8099343	chr18:56110071	C/T	cg19165390	chr18:56932082	NA	0.35	4.77	0.37	4.36e-6	Platelet count;
UCEC	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.7	6.76	0.49	3.05e-10	Schizophrenia;
UCEC	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.75	6.26	0.46	4.02e-9	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	5.33	0.4	3.63e-7	Lung cancer in ever smokers;
UCEC	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.77	-8.42	-0.57	3.13e-14	Ulcerative colitis;
UCEC	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs1978968	0.731	rs9605466	chr22:18461056	A/T	cg03078520	chr22:18463400	MICAL3	-0.55	-6.61	-0.48	6.56e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.63	0.42	8.82e-8	Breast cancer;
UCEC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.67	4.67	0.36	6.69e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.78	4.94	0.38	2.08e-6	Arsenic metabolism;
UCEC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.42	-4.57	-0.35	1.04e-5	Schizophrenia;
UCEC	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.6	-7.16	-0.51	3.54e-11	Prevalent atrial fibrillation;
UCEC	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.35	-0.52	1.25e-11	Blood trace element (Zn levels);
UCEC	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.42	0.41	2.39e-7	Aortic root size;
UCEC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05776053	chr2:74358815	NA	0.4	4.52	0.35	1.25e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.08	-10.95	-0.67	8.72e-21	Vitiligo;
UCEC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.86	-0.37	2.92e-6	Breast cancer;
UCEC	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg23625390	chr15:77176239	SCAPER	0.52	5.18	0.39	7.21e-7	Blood metabolite levels;
UCEC	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.55	-6.45	-0.47	1.52e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.68	6.04	0.45	1.21e-8	High light scatter reticulocyte count;
UCEC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.61	0.36	8.52e-6	Menopause (age at onset);
UCEC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg20965017	chr5:231967	SDHA	-0.62	-5.69	-0.42	6.61e-8	Breast cancer;
UCEC	cis	rs12332430	1.000	rs35337710	chr5:147559192	T/C	cg02292949	chr5:147648492	SPINK5L3	0.61	4.88	0.37	2.76e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.51	-5.13	-0.39	8.93e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs10242455	0.702	rs73713580	chr7:99241610	C/T	cg18809830	chr7:99032528	PTCD1	-0.75	-4.57	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.99	11.62	0.69	1.48e-22	Cognitive function;
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.51	5.32	0.4	3.87e-7	Schizophrenia;
UCEC	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-4.62	-0.36	8.41e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs7113850	0.541	rs74832028	chr11:24232359	A/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.42	-5.03	-0.38	1.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.58	5.84	0.43	3.21e-8	Platelet count;
UCEC	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg20825769	chr15:43991375	CKMT1A	-0.55	-4.52	-0.35	1.25e-5	Lung cancer in ever smokers;
UCEC	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.55	5.1	0.39	1.04e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.61	-5.81	-0.43	3.67e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.75	4.78	0.37	4.29e-6	Alzheimer's disease;
UCEC	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.56	6.19	0.45	5.79e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg04663916	chr13:50265991	EBPL	0.53	5.49	0.41	1.75e-7	Obesity-related traits;
UCEC	cis	rs7246967	0.551	rs7257333	chr19:22881149	C/T	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-6.31	-0.46	3.09e-9	Tonsillectomy;
UCEC	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.77	8.06	0.55	2.43e-13	Breast cancer;
UCEC	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.56	5.9	0.44	2.36e-8	Schizophrenia;
UCEC	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.38	4.52	0.35	1.27e-5	Multiple system atrophy;
UCEC	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.75	-0.36	4.89e-6	Parkinson's disease;
UCEC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.77	-8.52	-0.57	1.74e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.74	6.41	0.47	1.89e-9	Bipolar disorder;
UCEC	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.66	-7.23	-0.51	2.42e-11	Extraversion;
UCEC	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.44	4.62	0.36	8.24e-6	Alzheimer's disease;
UCEC	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg07527032	chr15:84868466	LOC388152	0.49	4.51	0.35	1.29e-5	Schizophrenia;
UCEC	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg20387954	chr3:183756860	HTR3D	0.51	6.11	0.45	8.3e-9	Anterior chamber depth;
UCEC	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.21	-0.39	6.41e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.94	-9.1	-0.6	5.8e-16	Dilated cardiomyopathy;
UCEC	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.59	-5.2	-0.39	6.48e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.59	7.44	0.52	7.86e-12	Obesity-related traits;
UCEC	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.74	5.03	0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.53	-4.69	-0.36	6.18e-6	Colorectal adenoma (advanced);
UCEC	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.89	0.37	2.59e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.8	-0.49	2.47e-10	Prostate cancer;
UCEC	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg13147721	chr7:65941812	NA	-0.68	-4.82	-0.37	3.53e-6	Diabetic kidney disease;
UCEC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg03161606	chr19:29218774	NA	0.54	4.63	0.36	8.1e-6	Methadone dose in opioid dependence;
UCEC	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.97	-0.59	1.28e-15	Exhaled nitric oxide output;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.54	-6.2	-0.46	5.5e-9	Pulmonary function;
UCEC	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-5.1	-0.39	1.04e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.49	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.65	5.32	0.4	3.82e-7	Corneal astigmatism;
UCEC	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.71	6.6	0.48	7.11e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.5	4.62	0.36	8.2e-6	Bone properties (heel);
UCEC	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs9463078	0.683	rs1342640	chr6:44743516	T/C	cg25276700	chr6:44698697	NA	0.44	4.82	0.37	3.49e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg19743168	chr1:23544995	NA	0.4	5.59	0.42	1.08e-7	Height;
UCEC	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	0.77	5.01	0.38	1.52e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs4146922	0.793	rs7601401	chr2:56004592	A/G	cg04324126	chr2:55277572	RTN4	-0.49	-4.65	-0.36	7.36e-6	Height;
UCEC	cis	rs6546886	0.957	rs4371381	chr2:74246613	T/C	cg14702570	chr2:74259524	NA	-0.44	-5.64	-0.42	8.36e-8	Dialysis-related mortality;
UCEC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.49	4.86	0.37	2.92e-6	Parkinson's disease;
UCEC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.14	0.39	8.63e-7	Bipolar disorder;
UCEC	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.66	7.45	0.52	7.45e-12	Resting heart rate;
UCEC	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg05660106	chr1:15850417	CASP9	0.51	5.15	0.39	8.19e-7	Systolic blood pressure;
UCEC	cis	rs7870753	0.628	rs7857610	chr9:99189953	C/T	cg25260653	chr9:99212216	HABP4	0.53	4.95	0.38	1.99e-6	Height;
UCEC	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.48	-4.73	-0.36	5.22e-6	Mortality in heart failure;
UCEC	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.69	0.36	6.29e-6	Rheumatoid arthritis;
UCEC	cis	rs1414896	1.000	rs1414896	chr1:95692310	G/A	cg17104959	chr1:95696376	NA	-0.31	-4.62	-0.36	8.23e-6	Non-alcoholic fatty liver disease histology (AST);
UCEC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.83	0.37	3.4e-6	Breast cancer;
UCEC	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.16	0.51	3.59e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.63	-7.2	-0.51	2.92e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.77	-7.66	-0.53	2.32e-12	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Smoking initiation;
UCEC	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.0	0.38	1.63e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.5	-5.96	-0.44	1.83e-8	Neuroticism;
UCEC	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.67	-0.36	6.76e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.52	5.74	0.43	5.15e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.54	-5.99	-0.44	1.51e-8	Cardiac Troponin-T levels;
UCEC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.58	-0.48	7.92e-10	Obesity-related traits;
UCEC	cis	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg00614314	chr15:82944287	LOC80154	-0.51	-6.1	-0.45	9.09e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.59	5.58	0.42	1.14e-7	Schizophrenia;
UCEC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.44	-5.88	-0.44	2.7e-8	IgG glycosylation;
UCEC	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.79	9.31	0.61	1.7e-16	Breast cancer;
UCEC	cis	rs2092319	0.649	rs2744784	chr1:26030613	A/G	cg26002253	chr1:26438845	PDIK1L	0.87	4.83	0.37	3.41e-6	Nose morphology;
UCEC	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-0.89	-5.54	-0.42	1.36e-7	Blood protein levels;
UCEC	cis	rs16957091	0.647	rs6493060	chr15:42977676	G/A	cg24196017	chr15:43021976	CDAN1	-0.62	-6.41	-0.47	1.9e-9	MGMT methylation in smokers;
UCEC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.86	10.81	0.67	2.03e-20	IgG glycosylation;
UCEC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-9.05	-0.6	7.71e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs713477	0.967	rs12431542	chr14:55913078	T/C	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.15e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg02820040	chr2:241836501	C2orf54	-0.37	-4.56	-0.35	1.09e-5	Urinary metabolites;
UCEC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg01689657	chr7:91764605	CYP51A1	0.47	5.91	0.44	2.27e-8	Breast cancer;
UCEC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.42	4.98	0.38	1.77e-6	QRS complex (12-leadsum);
UCEC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.61	-5.36	-0.4	3.19e-7	Systemic lupus erythematosus;
UCEC	cis	rs6437061	0.745	rs4297869	chr2:232835711	A/C	cg02061626	chr2:233274167	ALPPL2	0.47	4.7	0.36	5.86e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.64	6.37	0.46	2.33e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.611	rs7246424	chr19:22882185	A/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.7	8.01	0.55	3.19e-13	Metabolic syndrome;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.44	-5.27	-0.4	4.8e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.55	5.2	0.39	6.53e-7	Calcium levels;
UCEC	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.57	0.48	8.27e-10	Coffee consumption (cups per day);
UCEC	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.62	-7.06	-0.5	6.1e-11	Tonsillectomy;
UCEC	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg04682699	chr3:50248845	SLC38A3	-0.4	-4.8	-0.37	3.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	1.02	7.72	0.54	1.68e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg18755752	chr8:142205143	DENND3	-0.54	-4.94	-0.38	2.08e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.48	-5.92	-0.44	2.13e-8	Mean platelet volume;
UCEC	cis	rs713477	1.000	rs12888361	chr14:55906187	A/G	cg13175173	chr14:55914753	NA	-0.41	-4.63	-0.36	7.98e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.61e-6	Diabetic kidney disease;
UCEC	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Depression;
UCEC	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.74	7.74	0.54	1.47e-12	Breast cancer;
UCEC	cis	rs4074961	0.527	rs6704190	chr1:38010751	C/T	cg17933807	chr1:38061675	GNL2	0.88	10.81	0.67	2.08e-20	Axial length;
UCEC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-1.01	-4.68	-0.36	6.54e-6	Thyroid stimulating hormone;
UCEC	cis	rs6693882	0.967	rs6693553	chr1:96144984	C/T	cg12448539	chr1:95364293	CNN3	-0.51	-4.83	-0.37	3.42e-6	Pain;
UCEC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13683864	chr3:40499215	RPL14	-0.97	-9.61	-0.62	2.79e-17	Renal cell carcinoma;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.2	-0.39	6.6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Crohn's disease;
UCEC	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.77	11.09	0.67	3.83e-21	Leprosy;
UCEC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	0.93	9.64	0.62	2.38e-17	Heart rate;
UCEC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.73	8.71	0.58	5.86e-15	Prudent dietary pattern;
UCEC	cis	rs11675119	0.501	rs9751941	chr2:3494262	C/T	cg15541040	chr2:3486749	NA	-0.57	-5.0	-0.38	1.65e-6	Neurofibrillary tangles;
UCEC	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.55	4.95	0.38	2.05e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	0.96	6.56	0.48	8.61e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs17433710	0.929	rs16843630	chr1:162670043	A/G	cg19264028	chr1:162630153	DDR2	1.05	6.79	0.49	2.53e-10	Dupuytren's disease;
UCEC	cis	rs1852612	0.932	rs1852614	chr7:45404785	C/T	cg26127197	chr7:45030251	NA	-0.35	-4.52	-0.35	1.25e-5	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.46	6.37	0.47	2.27e-9	Alcohol dependence;
UCEC	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.9	9.08	0.6	6.71e-16	Height;
UCEC	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg03342759	chr3:160939853	NMD3	0.53	5.34	0.4	3.45e-7	Morning vs. evening chronotype;
UCEC	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.36	5.09	0.39	1.07e-6	Fat distribution (HIV);
UCEC	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.91	-0.44	2.24e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.87	-0.44	2.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.54	5.26	0.4	5.07e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7070678	0.638	rs3780844	chr10:29805595	T/C	cg07724896	chr10:29780678	SVIL	-0.59	-4.79	-0.37	4.07e-6	Platelet thrombus formation;
UCEC	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.51	5.04	0.38	1.35e-6	Aortic root size;
UCEC	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.59	5.25	0.4	5.27e-7	Crohn's disease;
UCEC	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.5	-5.18	-0.39	7.13e-7	Total body bone mineral density;
UCEC	trans	rs1459104	1.000	rs12577585	chr11:55302603	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	trans	rs7101446	0.545	rs537473	chr11:63172771	T/G	cg15769409	chr9:138372274	KIAA0649	-0.66	-6.79	-0.49	2.6e-10	Economic and political preferences;
UCEC	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.71	-6.86	-0.49	1.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.37	4.78	0.37	4.28e-6	Bone mineral density;
UCEC	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.79	-6.26	-0.46	4.07e-9	Corneal structure;
UCEC	cis	rs1712517	0.904	rs6584547	chr10:105065409	C/T	cg05636881	chr10:105038444	INA	0.38	4.73	0.36	5.14e-6	Migraine;
UCEC	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-4.66	-0.36	6.96e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7432375	0.579	rs10935199	chr3:136563535	G/C	cg21827317	chr3:136751795	NA	0.48	4.76	0.37	4.69e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6437061	0.745	rs3100612	chr2:232907292	A/C	cg02061626	chr2:233274167	ALPPL2	0.48	5.18	0.39	7.28e-7	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.13	-0.45	7.72e-9	Pubertal anthropometrics;
UCEC	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.65	6.53	0.47	1.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-6.09	-0.45	9.44e-9	Mean platelet volume;
UCEC	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.02	0.38	1.49e-6	Height;
UCEC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.82e-15	Blood protein levels;
UCEC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.69	0.48	4.47e-10	Cognitive test performance;
UCEC	cis	rs7680126	0.633	rs4697745	chr4:10305081	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-4.55	-0.35	1.11e-5	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
UCEC	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.07	-0.45	1.05e-8	Prudent dietary pattern;
UCEC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg19567339	chr10:100142640	NA	0.41	4.82	0.37	3.59e-6	Metabolite levels;
UCEC	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.54	5.33	0.4	3.71e-7	Coronary artery disease;
UCEC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11088226	0.692	rs28709516	chr21:33890366	G/A	cg03366312	chr21:34388564	NA	-0.34	-4.63	-0.36	7.98e-6	Gastritis;
UCEC	cis	rs2376682	1.000	rs2376682	chr5:118009472	T/C	cg17593721	chr5:118788746	HSD17B4	0.47	4.67	0.36	6.85e-6	Diisocyanate-induced asthma;
UCEC	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.99	0.5	8.9e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.93	-0.44	2.1e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.59	6.16	0.45	6.6e-9	Blood protein levels;
UCEC	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.27	12.66	0.72	2.64e-25	Corneal structure;
UCEC	cis	rs6882716	0.636	rs10043680	chr5:10804522	A/G	cg14521931	chr5:10832172	NA	0.64	5.61	0.42	9.56e-8	Alcohol consumption (maxi-drinks);
UCEC	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg06462663	chr19:18546047	ISYNA1	0.46	5.91	0.44	2.25e-8	Breast cancer;
UCEC	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.63	-5.14	-0.39	8.75e-7	Lymphocyte counts;
UCEC	cis	rs4389656	0.857	rs453536	chr5:6736458	T/G	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.64	5.46	0.41	1.97e-7	Graves' disease;
UCEC	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.47	1.11e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg05874882	chr4:1763078	NA	-0.61	-6.93	-0.5	1.23e-10	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.24	-0.46	4.51e-9	Total cholesterol levels;
UCEC	cis	rs12339094	0.591	rs9410969	chr9:90414334	T/A	cg14178383	chr9:91347716	NA	0.71	4.77	0.37	4.46e-6	Smoking quantity;
UCEC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.56	5.89	0.44	2.5e-8	Schizophrenia;
UCEC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg19812747	chr11:111475976	SIK2	-0.37	-4.64	-0.36	7.71e-6	Primary sclerosing cholangitis;
UCEC	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg04906043	chr13:21280425	IL17D	-0.47	-4.72	-0.36	5.5e-6	Schizophrenia, bipolar disorder and depression (combined);
UCEC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg00343986	chr7:65444356	GUSB	0.59	5.83	0.43	3.38e-8	Aortic root size;
UCEC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg20965017	chr5:231967	SDHA	-0.64	-6.03	-0.45	1.26e-8	Breast cancer;
UCEC	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.65	5.68	0.42	6.93e-8	Obesity (extreme);
UCEC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	4.86	0.37	2.97e-6	Menopause (age at onset);
UCEC	cis	rs514406	0.734	rs581118	chr1:53311324	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	9.27	0.61	2.14e-16	Monocyte count;
UCEC	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.62	-4.64	-0.36	7.6e-6	Obesity-related traits;
UCEC	cis	rs858239	0.932	rs1728320	chr7:23319789	T/G	cg27449745	chr7:23145252	KLHL7	-0.44	-4.52	-0.35	1.27e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.41	-4.97	-0.38	1.87e-6	Dupuytren's disease;
UCEC	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.64	5.05	0.38	1.3e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	4.52	0.35	1.29e-5	Height;
UCEC	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.59	8.77	0.59	4e-15	Prudent dietary pattern;
UCEC	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.57	4.92	0.38	2.34e-6	Corneal astigmatism;
UCEC	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs7215564	0.908	rs35112467	chr17:78677562	C/T	cg01369328	chr17:79479832	ACTG1	-0.56	-4.59	-0.35	9.36e-6	Myopia (pathological);
UCEC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg24881330	chr22:46731750	TRMU	0.73	7.35	0.52	1.3e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.54	-5.62	-0.42	9.32e-8	Glomerular filtration rate;
UCEC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	4.86	0.37	2.97e-6	Menopause (age at onset);
UCEC	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.64	5.49	0.41	1.69e-7	Cocaine dependence;
UCEC	cis	rs1109861	0.783	rs625315	chr10:11225337	G/T	cg23397013	chr10:10571132	NA	-0.38	-4.89	-0.37	2.66e-6	Urinary albumin-to-creatinine ratio;
UCEC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg23978390	chr7:1156363	C7orf50	0.46	4.54	0.35	1.16e-5	Longevity;Endometriosis;
UCEC	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	4.83	0.37	3.36e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg04731861	chr2:219085781	ARPC2	0.44	4.93	0.38	2.24e-6	Colorectal cancer;
UCEC	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.69	0.42	6.73e-8	Rheumatoid arthritis;
UCEC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.15	-10.71	-0.66	3.77e-20	Vitiligo;
UCEC	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.45	-5.26	-0.4	4.93e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.66	-5.94	-0.44	1.95e-8	Body mass index;
UCEC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	5.69	0.42	6.64e-8	Bone mineral density;
UCEC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.5	4.79	0.37	4.12e-6	Aortic root size;
UCEC	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.46	5.52	0.41	1.47e-7	Schizophrenia;
UCEC	cis	rs11958404	0.932	rs72818108	chr5:157437883	A/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.48	-5.04	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.65	8.37	0.57	4.11e-14	Menarche (age at onset);
UCEC	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg14851346	chr12:38532713	NA	-0.48	-4.56	-0.35	1.05e-5	Morning vs. evening chronotype;
UCEC	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.48	4.75	0.36	4.74e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.58	6.22	0.46	5.02e-9	Schizophrenia;
UCEC	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-8.84	-0.59	2.68e-15	Vitiligo;
UCEC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.53	-4.86	-0.37	3.03e-6	Cognitive function;
UCEC	trans	rs12216499	0.710	rs12212859	chr6:159343986	T/C	cg03103158	chr8:28748202	INTS9;HMBOX1	-1.0	-6.72	-0.48	3.68e-10	Bladder cancer (smoking interaction);
UCEC	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.75	0.36	4.83e-6	Personality dimensions;
UCEC	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246967	0.932	rs4932793	chr19:23036449	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	6.96	0.5	1.02e-10	Homoarginine levels;
UCEC	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	6.0	0.44	1.44e-8	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg16583315	chr14:65563665	MAX	-0.42	-4.85	-0.37	3.14e-6	Obesity-related traits;
UCEC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	7.25	0.51	2.2e-11	Homoarginine levels;
UCEC	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	4.77	0.37	4.42e-6	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.69	-7.64	-0.53	2.62e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.65	5.56	0.42	1.21e-7	Lymphocyte counts;
UCEC	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.66	-6.0	-0.44	1.46e-8	Metabolite levels;
UCEC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7894051	0.764	rs11101725	chr10:135194608	A/G	cg20534287	chr10:135191450	PAOX	-0.6	-6.51	-0.47	1.14e-9	Lifespan;
UCEC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.49	-5.38	-0.41	2.9e-7	Aortic root size;
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg13683864	chr3:40499215	RPL14	-0.53	-5.34	-0.4	3.46e-7	Renal cell carcinoma;
UCEC	cis	rs9470794	0.790	rs4336442	chr6:38146446	A/T	cg01504030	chr6:38141879	BTBD9	-0.79	-5.57	-0.42	1.17e-7	Type 2 diabetes;
UCEC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.1	13.63	0.75	7.24e-28	Cognitive function;
UCEC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg18681998	chr4:17616180	MED28	0.72	7.16	0.51	3.57e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4400599	0.572	rs7516809	chr1:154205501	T/C	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg15352829	chr14:105391018	PLD4	0.45	6.41	0.47	1.87e-9	Rheumatoid arthritis;
UCEC	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.55	5.66	0.42	7.69e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.65	6.79	0.49	2.65e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	6.0	0.44	1.47e-8	Myopia (pathological);
UCEC	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.49	-5.7	-0.43	6.41e-8	Gout;
UCEC	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.72	6.37	0.46	2.34e-9	Coronary artery disease;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.47	5.03	0.38	1.38e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.55	6.21	0.46	5.11e-9	Mean corpuscular volume;
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.74	-5.73	-0.43	5.58e-8	Platelet count;
UCEC	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.68	7.01	0.5	8.16e-11	Dilated cardiomyopathy;
UCEC	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.52	5.33	0.4	3.71e-7	Joint mobility (Beighton score);
UCEC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.47	4.68	0.36	6.56e-6	Gout;
UCEC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.57	5.29	0.4	4.39e-7	Blood protein levels;
UCEC	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.55	0.48	9.17e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-8.85	-0.59	2.57e-15	Blood metabolite levels;
UCEC	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.32e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.72	-0.43	5.68e-8	Alcohol dependence;
UCEC	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg21231944	chr12:82153410	PPFIA2	0.45	4.8	0.37	3.79e-6	Resting heart rate;
UCEC	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.49	5.7	0.43	6.47e-8	Aortic root size;
UCEC	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.51	4.72	0.36	5.56e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.7	7.3	0.52	1.67e-11	Primary sclerosing cholangitis;
UCEC	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.83	-0.43	3.36e-8	Mortality in heart failure;
UCEC	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.44	4.57	0.35	1.02e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.5	5.06	0.39	1.21e-6	Blood metabolite levels;
UCEC	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.14	8.11	0.56	1.83e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg06466757	chr4:1255808	NA	0.45	4.66	0.36	7.09e-6	Obesity-related traits;
UCEC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.62	5.98	0.44	1.64e-8	Sudden cardiac arrest;
UCEC	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.63	5.73	0.43	5.58e-8	Menarche (age at onset);
UCEC	cis	rs4713118	0.513	rs2294480	chr6:27583961	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.46	-4.75	-0.36	4.86e-6	Parkinson's disease;
UCEC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.69	5.6	0.42	1.01e-7	Corneal astigmatism;
UCEC	cis	rs7968440	0.966	rs7977742	chr12:51130207	C/T	cg20014596	chr12:50898483	DIP2B	0.46	4.54	0.35	1.18e-5	Fibrinogen;
UCEC	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.46	6.01	0.44	1.39e-8	Bone mineral density;
UCEC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.5	-0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	7.44	0.52	7.9e-12	Bone mineral density;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	5.7	0.43	6.36e-8	Prudent dietary pattern;
UCEC	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14019695	chr9:139328340	INPP5E	0.42	4.69	0.36	6.27e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2410182	0.586	rs460289	chr21:41187280	G/C	cg06560309	chr21:40720186	HMGN1	0.58	4.88	0.37	2.69e-6	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	0.93	9.48	0.62	6.08e-17	Heart rate;
UCEC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.85e-6	Testicular germ cell tumor;
UCEC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.85	9.18	0.6	3.75e-16	Parkinson's disease;
UCEC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.69	-6.91	-0.5	1.38e-10	Blood metabolite levels;
UCEC	cis	rs7078219	0.505	rs6584282	chr10:101286495	A/G	cg09788492	chr10:101292477	NKX2-3	0.43	4.58	0.35	9.99e-6	Dental caries;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05657792	chr17:6899758	ALOX12	-0.43	-5.26	-0.4	4.9e-7	Tonsillectomy;
UCEC	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.49	-5.42	-0.41	2.44e-7	Retinal vascular caliber;
UCEC	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.54	-5.44	-0.41	2.17e-7	Aortic root size;
UCEC	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.53	-4.82	-0.37	3.51e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs28530618	0.580	rs4607010	chr20:31255271	G/C	cg13636640	chr20:31349939	DNMT3B	-0.64	-5.45	-0.41	2.08e-7	Birth weight;
UCEC	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.63	6.51	0.47	1.11e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg12024160	chr4:1254474	NA	0.57	6.87	0.49	1.67e-10	Obesity-related traits;
UCEC	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.76	6.7	0.48	4.23e-10	Prostate cancer;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.52	5.59	0.42	1.08e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1150668	0.805	rs2859348	chr6:28359170	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.48	-5.0	-0.38	1.6e-6	Pubertal anthropometrics;
UCEC	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg18681998	chr4:17616180	MED28	0.77	8.44	0.57	2.72e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.93	5.93	0.44	2.1e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	0.94	8.99	0.6	1.1e-15	Cognitive function;
UCEC	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg16303742	chr3:15540471	COLQ	-0.41	-5.22	-0.4	6.02e-7	Mean platelet volume;
UCEC	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.31	0.46	3.13e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.57	-6.39	-0.47	2.09e-9	Pubertal anthropometrics;
UCEC	cis	rs12681287	0.927	rs2976177	chr8:87332332	A/T	cg27223183	chr8:87520930	FAM82B	-0.53	-4.64	-0.36	7.7e-6	Caudate activity during reward;
UCEC	cis	rs9326726	0.844	rs2416189	chr5:107712059	G/A	cg17432647	chr5:107996819	NA	-0.54	-4.68	-0.36	6.54e-6	Resting heart rate;
UCEC	cis	rs1298062	0.757	rs1673039	chr19:50977957	C/T	cg11430371	chr19:50961752	MYBPC2	0.39	4.53	0.35	1.2e-5	Age of smoking initiation;
UCEC	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.51	5.47	0.41	1.88e-7	Body mass index;
UCEC	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg13147721	chr7:65941812	NA	-0.74	-5.04	-0.38	1.37e-6	Diabetic kidney disease;
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.51	0.53	5.22e-12	Platelet count;
UCEC	trans	rs1459104	1.000	rs34382934	chr11:55315256	C/T	cg16096432	chr1:54776890	SSBP3	-1.0	-6.71	-0.48	3.85e-10	Body mass index;
UCEC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.85	-0.37	3.05e-6	Chronic sinus infection;
UCEC	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.52	4.8	0.37	3.92e-6	Type 2 diabetes;
UCEC	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.55	6.81	0.49	2.31e-10	Subjective well-being (multi-trait analysis);
UCEC	cis	rs6882716	0.534	rs7719906	chr5:10809586	G/A	cg14521931	chr5:10832172	NA	-0.66	-5.68	-0.42	6.84e-8	Alcohol consumption (maxi-drinks);
UCEC	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg21191810	chr6:118973309	C6orf204	0.39	5.33	0.4	3.65e-7	Electrocardiographic conduction measures;
UCEC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.39	-5.74	-0.43	5.14e-8	Crohn's disease;
UCEC	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg26002218	chr14:103986227	CKB	-0.39	-4.96	-0.38	1.93e-6	Coronary artery disease;
UCEC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.61	-5.86	-0.44	2.89e-8	Prostate cancer;
UCEC	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	0.95	13.53	0.74	1.35e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18252515	chr7:66147081	NA	0.6	5.72	0.43	5.86e-8	Aortic root size;
UCEC	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.61	0.42	9.55e-8	Heart rate;
UCEC	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.4	4.74	0.36	5.03e-6	Mean corpuscular volume;
UCEC	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg19099843	chr7:12443191	VWDE	0.66	4.51	0.35	1.33e-5	Coronary artery disease;
UCEC	cis	rs4851266	1.000	rs12619178	chr2:100838157	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs73206853	0.697	rs56084592	chr12:110577910	T/A	cg12870014	chr12:110450643	ANKRD13A	0.67	5.56	0.42	1.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.98	0.64	3.12e-18	Breast cancer;
UCEC	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	4.85	0.37	3.12e-6	Menarche (age at onset);
UCEC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.05	-0.45	1.16e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.5	4.56	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.69	7.65	0.53	2.38e-12	Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.63	-0.36	8.02e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.66	-7.09	-0.5	5.16e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	1.07	14.47	0.77	4.65e-30	Monocyte count;
UCEC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg20965017	chr5:231967	SDHA	-0.64	-6.03	-0.45	1.26e-8	Breast cancer;
UCEC	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	0.8	10.98	0.67	7.58e-21	Monocyte percentage of white cells;
UCEC	cis	rs7302981	0.809	rs66768395	chr12:50568265	G/T	cg20014596	chr12:50898483	DIP2B	0.43	4.53	0.35	1.22e-5	Systolic blood pressure;
UCEC	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.66	-6.24	-0.46	4.45e-9	Cocaine dependence;
UCEC	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-6.03	-0.45	1.28e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.12	-0.51	4.43e-11	Bone mineral density;
UCEC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg22974920	chr21:40686053	BRWD1	0.59	5.09	0.39	1.1e-6	Cognitive function;
UCEC	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.66	-6.39	-0.47	2.11e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg03711944	chr11:47377212	SPI1	-0.48	-4.62	-0.36	8.39e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.67	-6.96	-0.5	1.06e-10	Breast cancer;
UCEC	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.37	5.09	0.39	1.07e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.77	-8.15	-0.56	1.48e-13	Height;
UCEC	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.01	-0.38	1.56e-6	Educational attainment;
UCEC	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs7246967	0.673	rs8102172	chr19:22870019	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9931543	0.504	rs4784650	chr16:56306640	A/G	cg10482356	chr16:56328421	GNAO1	-0.36	-5.11	-0.39	9.86e-7	Subjective well-being;
UCEC	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.71	7.13	0.51	4.14e-11	Eotaxin levels;
UCEC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15716185	chr18:60190644	ZCCHC2	0.61	7.23	0.51	2.49e-11	Warfarin maintenance dose;
UCEC	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.39	-4.93	-0.38	2.2e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.38	-4.76	-0.37	4.61e-6	Neuroticism;
UCEC	cis	rs1468333	1.000	rs2967781	chr5:137557609	T/C	cg07848042	chr5:137667509	CDC25C	0.48	4.71	0.36	5.61e-6	Resting heart rate;
UCEC	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.4	4.84	0.37	3.22e-6	Subjective well-being;
UCEC	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	0.82	9.26	0.61	2.27e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.68	4.74	0.36	5.08e-6	Aortic root size;
UCEC	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	0.88	8.58	0.58	1.27e-14	Coronary artery disease;
UCEC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.64	7.13	0.51	4.12e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4789452	1.000	rs11658815	chr17:75375881	G/A	cg21830368	chr17:75373327	SEPT9	-0.31	-4.97	-0.38	1.84e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.93	-0.38	2.2e-6	Coronary artery disease;
UCEC	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.6	5.46	0.41	1.94e-7	Morning vs. evening chronotype;
UCEC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg01689657	chr7:91764605	CYP51A1	0.49	6.25	0.46	4.21e-9	Breast cancer;
UCEC	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.43	0.47	1.68e-9	Personality dimensions;
UCEC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Body mass index;
UCEC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.99	0.38	1.72e-6	Breast cancer;
UCEC	cis	rs1893767	1.000	rs12806671	chr11:123956887	C/T	cg15915129	chr11:124933008	SLC37A2	-0.55	-4.69	-0.36	6.22e-6	Obesity-related traits;
UCEC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg24789503	chr3:195384528	SDHAP2	0.65	4.83	0.37	3.35e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	0.59	6.51	0.47	1.13e-9	QRS complex (12-leadsum);
UCEC	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.64	-5.86	-0.44	2.94e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.64	6.75	0.49	3.25e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.76	8.25	0.56	8.25e-14	Immature fraction of reticulocytes;
UCEC	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.53	-6.76	-0.49	3.08e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs12086130	0.892	rs72904801	chr1:51442137	A/G	cg07174182	chr1:51127561	FAF1	-0.8	-5.04	-0.38	1.35e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.47	-4.9	-0.37	2.46e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.54	-6.2	-0.46	5.5e-9	Pulmonary function;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.43	-0.41	2.3e-7	Cardiac Troponin-T levels;
UCEC	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	4.8	0.37	3.79e-6	Bone mineral density;
UCEC	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs7709377	0.620	rs10066081	chr5:115488569	A/G	cg23108291	chr5:115420582	COMMD10	0.55	5.58	0.42	1.14e-7	Metabolite levels  (X-11787);
UCEC	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.49	-5.33	-0.4	3.64e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.9	-0.49	1.41e-10	Response to antipsychotic treatment;
UCEC	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.43	-5.2	-0.39	6.43e-7	Vitiligo;
UCEC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.56	-4.92	-0.38	2.29e-6	Longevity;
UCEC	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.81	-7.37	-0.52	1.13e-11	Blood protein levels;
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-5.57	-0.42	1.16e-7	Platelet count;
UCEC	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.46	4.67	0.36	6.64e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.74	-4.81	-0.37	3.76e-6	Hair shape;
UCEC	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.4	-5.56	-0.42	1.23e-7	Alcohol dependence;
UCEC	cis	rs35934224	0.783	rs7289343	chr22:19860990	G/T	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.8	-0.37	3.84e-6	Glaucoma (primary open-angle);
UCEC	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.65	6.69	0.48	4.46e-10	Breast cancer;
UCEC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg06784218	chr1:46089804	CCDC17	0.45	5.6	0.42	1.05e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10924970	0.649	rs12034913	chr1:235399332	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-4.51	-0.35	1.34e-5	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-9.44	-0.61	8.11e-17	Chronic sinus infection;
UCEC	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	5.31	0.4	3.93e-7	Mood instability;
UCEC	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg04310649	chr10:35416472	CREM	-0.47	-4.58	-0.35	9.83e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.28	-0.46	3.68e-9	Joint mobility (Beighton score);
UCEC	cis	rs2147959	0.883	rs10916314	chr1:228633332	A/T	cg00655913	chr1:228633920	NA	0.53	5.89	0.44	2.58e-8	Adult asthma;
UCEC	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg09120320	chr17:61926383	NA	0.44	4.65	0.36	7.21e-6	Prudent dietary pattern;
UCEC	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.95	12.06	0.71	1.04e-23	Ulcerative colitis;
UCEC	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.61	5.78	0.43	4.25e-8	Vitamin D levels;
UCEC	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.48	-6.78	-0.49	2.73e-10	Age-related hearing impairment;
UCEC	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.58	6.36	0.46	2.36e-9	Type 2 diabetes;
UCEC	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	6.75	0.49	3.12e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.39	5.81	0.43	3.76e-8	Ulcerative colitis;
UCEC	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.48	-5.64	-0.42	8.3e-8	Aortic root size;
UCEC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	6.59	0.48	7.21e-10	Total body bone mineral density;
UCEC	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg18099408	chr3:52552593	STAB1	0.43	4.81	0.37	3.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.47	4.86	0.37	2.97e-6	Smoking initiation;
UCEC	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.78	8.97	0.59	1.29e-15	Mortality in heart failure;
UCEC	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.43	4.84	0.37	3.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.99	13.01	0.73	3.06e-26	Monocyte count;
UCEC	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.61	5.72	0.43	5.71e-8	Brain structure;
UCEC	cis	rs7246967	0.673	rs34174596	chr19:22933519	G/A	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.59	6.99	0.5	8.96e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.65	5.76	0.43	4.73e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg09044154	chr16:88155775	NA	-0.57	-4.82	-0.37	3.55e-6	Menopause (age at onset);
UCEC	cis	rs17068510	0.688	rs73182059	chr8:3869745	G/C	cg10938233	chr8:4573688	CSMD1	-0.57	-4.62	-0.36	8.37e-6	Cerebrospinal fluid clusterin levels;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.76	8.55	0.58	1.47e-14	Menarche (age at onset);
UCEC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg14784868	chr12:69753453	YEATS4	0.57	4.87	0.37	2.8e-6	Response to diuretic therapy;
UCEC	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs1519814	1.000	rs4871041	chr8:121136584	C/T	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.88	0.37	2.68e-6	Diabetic retinopathy;
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.56	-5.11	-0.39	1e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.61	5.45	0.41	2.06e-7	Blood protein levels;
UCEC	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.93	-0.38	2.22e-6	Body mass index;
UCEC	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.47	6.01	0.44	1.42e-8	HDL cholesterol levels;
UCEC	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg24069376	chr3:38537580	EXOG	0.38	4.73	0.36	5.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.63	-7.2	-0.51	2.92e-11	Vitiligo;
UCEC	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24249390	chr15:90295951	MESP1	-0.47	-5.18	-0.39	7.28e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg14438399	chr17:27053147	TLCD1	-0.57	-4.76	-0.37	4.59e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.43	7.83	0.54	8.87e-13	Cognitive function;
UCEC	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.84	-10.13	-0.64	1.26e-18	Ulcerative colitis;
UCEC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.67	0.42	7.2e-8	Height;
UCEC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg11871910	chr12:69753446	YEATS4	0.86	9.11	0.6	5.55e-16	Blood protein levels;
UCEC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg14008862	chr17:28927542	LRRC37B2	0.65	4.7	0.36	5.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg19645103	chr12:69753606	YEATS4	-0.56	-5.06	-0.39	1.22e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.38	0.41	2.91e-7	HIV-1 control;
UCEC	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.54	5.61	0.42	9.94e-8	Breast cancer;
UCEC	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg15513719	chr13:114904418	NA	0.5	4.97	0.38	1.87e-6	Schizophrenia;
UCEC	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs2970992	0.764	rs925577	chr2:101324948	C/T	cg01042948	chr2:101319752	NA	-0.41	-4.58	-0.35	9.98e-6	Educational attainment;
UCEC	cis	rs10012307	1.000	rs60428487	chr4:137483670	C/T	cg12033966	chr4:138453416	PCDH18	-0.72	-5.01	-0.38	1.56e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.47	-4.52	-0.35	1.26e-5	Pancreatic cancer;
UCEC	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.51	-5.04	-0.38	1.37e-6	Refractive error;
UCEC	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	-0.58	-6.57	-0.48	8.09e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg16616514	chr4:6324629	PPP2R2C	0.44	5.29	0.4	4.34e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.51e-18	Height;
UCEC	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.62	-4.71	-0.36	5.57e-6	Facial morphology (factor 23);
UCEC	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.5	4.6	0.35	9.22e-6	Blood trace element (Cu levels);
UCEC	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg04202892	chr2:111875749	ACOXL	0.47	5.48	0.41	1.79e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.48	-5.98	-0.44	1.58e-8	Total body bone mineral density;
UCEC	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg19567339	chr10:100142640	NA	0.4	4.76	0.37	4.56e-6	Metabolite levels;
UCEC	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.59	6.35	0.46	2.49e-9	Neuroticism;
UCEC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18252515	chr7:66147081	NA	-0.54	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.67	0.62	2e-17	Menopause (age at onset);
UCEC	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg14851346	chr12:38532713	NA	-0.47	-4.56	-0.35	1.05e-5	Bladder cancer;
UCEC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Bone mineral density;
UCEC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-4.9	-0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.42	0.41	2.39e-7	IgG glycosylation;
UCEC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs7246967	0.611	rs73030511	chr19:22826034	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	5.61	0.42	9.59e-8	Eosinophil percentage of white cells;
UCEC	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg05991184	chr2:219186017	PNKD	-0.54	-5.94	-0.44	1.97e-8	Colorectal cancer;
UCEC	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs17106184	1.000	rs3827731	chr1:50987827	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7074356	0.688	rs7898558	chr10:82183505	G/T	cg27210863	chr10:82299606	SH2D4B	-0.32	-4.61	-0.36	8.68e-6	Borderline personality disorder;
UCEC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.7	5.22	0.4	5.87e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.58	4.72	0.36	5.52e-6	Psoriasis;
UCEC	cis	rs59918340	0.738	rs7007986	chr8:142217115	G/A	cg04804543	chr8:142233427	SLC45A4	-0.47	-5.48	-0.41	1.77e-7	Immature fraction of reticulocytes;
UCEC	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.49	4.82	0.37	3.49e-6	Menopause (age at onset);
UCEC	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.5	-4.98	-0.38	1.77e-6	Diastolic blood pressure;
UCEC	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-4.74	-0.36	5.07e-6	Obesity-related traits;
UCEC	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.53	-5.64	-0.42	8.41e-8	Brugada syndrome;
UCEC	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.77e-10	Chronic sinus infection;
UCEC	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg00343986	chr7:65444356	GUSB	-0.52	-4.93	-0.38	2.21e-6	Aortic root size;
UCEC	cis	rs7246967	0.673	rs8103430	chr19:22931498	A/G	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg05874882	chr4:1763078	NA	-0.67	-6.19	-0.45	5.8e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg16584290	chr5:462447	EXOC3	-0.46	-4.71	-0.36	5.78e-6	Cystic fibrosis severity;
UCEC	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-6.72	-0.48	3.67e-10	Platelet count;
UCEC	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg06456738	chr11:66361081	CCDC87;CCS	0.54	4.57	0.35	1.01e-5	Airway imaging phenotypes;
UCEC	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.13	-0.51	4.14e-11	Joint mobility (Beighton score);
UCEC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.92	0.63	4.53e-18	Heart rate;
UCEC	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.62	6.39	0.47	2.09e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.99	14.34	0.76	9.79e-30	Bone mineral density;
UCEC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.78	-7.51	-0.53	5.18e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12234571	0.793	rs59285626	chr7:77414160	C/T	cg20048109	chr7:78158112	MAGI2	-0.45	-4.68	-0.36	6.53e-6	Obesity-related traits;
UCEC	cis	rs10851411	0.559	rs56172155	chr15:42882182	C/T	cg21293051	chr15:42870591	STARD9	0.75	4.82	0.37	3.48e-6	Glucose homeostasis traits;
UCEC	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	10.2	0.64	8.12e-19	Exhaled nitric oxide output;
UCEC	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.27	-0.4	4.88e-7	Menarche (age at onset);
UCEC	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-4.57	-0.35	1.02e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg04043695	chr12:129287642	SLC15A4	0.63	5.8	0.43	3.99e-8	Systemic lupus erythematosus;
UCEC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg13695892	chr22:41940480	POLR3H	0.7	5.38	0.41	2.92e-7	Vitiligo;
UCEC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.61	6.45	0.47	1.51e-9	Motion sickness;
UCEC	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.52	5.65	0.42	7.99e-8	Melanoma;
UCEC	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.52	4.54	0.35	1.18e-5	Cholesterol, total;
UCEC	cis	rs925228	1.000	rs6545222	chr2:24235704	G/A	cg16945982	chr2:25016118	CENPO;C2orf79	0.57	4.94	0.38	2.11e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.97	-0.55	4.04e-13	Total cholesterol levels;
UCEC	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.51	5.22	0.4	5.88e-7	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg06784218	chr1:46089804	CCDC17	0.43	4.93	0.38	2.21e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.69	7.72	0.54	1.61e-12	Coronary artery disease;
UCEC	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	0.72	4.54	0.35	1.16e-5	Diabetic retinopathy;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.52	-6.04	-0.45	1.2e-8	Pubertal anthropometrics;
UCEC	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10503871	0.690	rs7812836	chr8:30352258	A/G	cg26383811	chr8:30366931	RBPMS	-0.5	-5.11	-0.39	9.74e-7	Metabolite levels  (X-11787);
UCEC	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.11	0.39	9.71e-7	Birth weight;
UCEC	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg13147721	chr7:65941812	NA	0.91	6.06	0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	1.05	13.58	0.75	9.92e-28	Testicular germ cell tumor;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.71	-0.43	5.98e-8	Pubertal anthropometrics;
UCEC	cis	rs6834538	0.862	rs7659503	chr4:113425304	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.45	-4.55	-0.35	1.12e-5	Free thyroxine concentration;
UCEC	cis	rs2474937	0.535	rs4141768	chr1:118924845	G/A	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	0.74	4.97	0.38	1.83e-6	Diabetic retinopathy;
UCEC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-0.63	-5.62	-0.42	9.18e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.9	-0.44	2.35e-8	Menarche (age at onset);
UCEC	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.46	5.02	0.38	1.5e-6	Dental caries;
UCEC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.59	5.49	0.41	1.7e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10507349	0.632	rs7983171	chr13:26818035	A/G	cg01600817	chr13:26797529	RNF6	0.46	4.92	0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.76	7.07	0.5	5.8e-11	Bladder cancer;
UCEC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.54	5.31	0.4	3.9e-7	Cognitive test performance;
UCEC	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.88	0.49	1.6e-10	Cognitive test performance;
UCEC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg14008862	chr17:28927542	LRRC37B2	-0.83	-4.91	-0.38	2.42e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3015497	0.753	rs4643225	chr14:51122205	G/C	cg04730355	chr14:51134070	SAV1	-0.53	-5.65	-0.42	8e-8	Mean platelet volume;
UCEC	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.87	0.54	6.96e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.58	-7.12	-0.51	4.39e-11	Pubertal anthropometrics;
UCEC	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.63	6.69	0.48	4.42e-10	Retinal vascular caliber;
UCEC	cis	rs60515486	0.702	rs11821917	chr11:47410166	T/A	cg20307385	chr11:47447363	PSMC3	-0.63	-4.59	-0.35	9.28e-6	Lymphocyte counts;
UCEC	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg07387570	chr22:46663686	TTC38	-0.47	-4.68	-0.36	6.42e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	1.0	9.69	0.62	1.75e-17	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg11871910	chr12:69753446	YEATS4	0.79	8.0	0.55	3.39e-13	Blood protein levels;
UCEC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.86	10.47	0.65	1.63e-19	Longevity;Endometriosis;
UCEC	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.65	6.85	0.49	1.83e-10	Menopause (age at onset);
UCEC	cis	rs2147959	0.941	rs12131962	chr1:228631641	G/A	cg25874119	chr1:228633904	NA	0.55	6.15	0.45	6.92e-9	Adult asthma;
UCEC	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.5	-5.34	-0.4	3.4e-7	Retinal vascular caliber;
UCEC	trans	rs66573146	1.000	rs28384174	chr4:6961107	G/T	cg07817883	chr1:32538562	TMEM39B	1.04	7.93	0.55	5.11e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs884366	0.724	rs4946960	chr6:109641677	A/G	cg01475377	chr6:109611718	NA	0.44	4.89	0.37	2.63e-6	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs3120667	0.720	rs6696556	chr1:152430842	A/C	cg03115048	chr1:152077402	NA	-0.54	-4.69	-0.36	6.18e-6	Eating disorders;
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.51	0.53	5.41e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	18.37	0.83	6.63e-40	Testicular germ cell tumor;
UCEC	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg13147721	chr7:65941812	NA	-0.92	-5.8	-0.43	3.91e-8	Diabetic kidney disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15884411	chr2:96932403	CIAO1;TMEM127	0.58	6.98	0.5	9.52e-11	Warfarin maintenance dose;
UCEC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg14008862	chr17:28927542	LRRC37B2	0.75	5.54	0.42	1.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	0.88	6.38	0.47	2.19e-9	Red blood cell traits;
UCEC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.48	4.81	0.37	3.63e-6	Prostate cancer;
UCEC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-4.56	-0.35	1.08e-5	Longevity;
UCEC	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.52	4.53	0.35	1.2e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9463078	0.605	rs4711799	chr6:44765780	A/T	cg25276700	chr6:44698697	NA	0.44	5.05	0.38	1.27e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-5.17	-0.39	7.47e-7	Response to antipsychotic treatment;
UCEC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg24826892	chr11:71159390	DHCR7	0.52	5.05	0.38	1.26e-6	Vitamin D levels;
UCEC	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.67	5.6	0.42	1.04e-7	Systolic blood pressure;
UCEC	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.7	9.58	0.62	3.42e-17	Coronary artery disease;
UCEC	cis	rs1712517	0.838	rs6584543	chr10:104997014	G/A	cg05636881	chr10:105038444	INA	-0.44	-5.6	-0.42	1.02e-7	Migraine;
UCEC	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-4.66	-0.36	7.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.48	-6.12	-0.45	8.08e-9	Total body bone mineral density;
UCEC	cis	rs11118844	0.843	rs4589119	chr1:221915967	G/A	cg04222084	chr1:221915650	DUSP10	-0.77	-6.84	-0.49	2.02e-10	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg01256987	chr12:42539512	GXYLT1	0.42	4.92	0.38	2.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.56	4.78	0.37	4.13e-6	Mammographic density (dense area);
UCEC	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.75	6.91	0.5	1.36e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	4.96	0.38	1.92e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-5.33	-0.4	3.67e-7	Morning vs. evening chronotype;
UCEC	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.98	13.78	0.75	2.86e-28	Bone mineral density;
UCEC	cis	rs7246967	0.932	rs4932799	chr19:23051581	C/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.91	0.5	1.37e-10	Personality dimensions;
UCEC	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.67	6.63	0.48	6.04e-10	Alcohol dependence;Nicotine use;
UCEC	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	6.25	0.46	4.16e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.69	-6.8	-0.49	2.51e-10	Blood metabolite levels;
UCEC	cis	rs8177876	0.731	rs77145371	chr16:81118660	A/G	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.0	-0.5	8.42e-11	Breast cancer;
UCEC	cis	rs2806864	1.000	rs2250729	chr1:117463353	C/A	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.69	-0.36	6.13e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	4.54	0.35	1.18e-5	Obesity-related traits;
UCEC	cis	rs1318937	0.510	rs78164273	chr3:15245132	C/T	cg08692541	chr3:14716288	C3orf20	0.68	4.78	0.37	4.2e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.62	-5.42	-0.41	2.38e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-6.1	-0.45	9.12e-9	Type 2 diabetes;
UCEC	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.08	-0.45	9.91e-9	Resting heart rate;
UCEC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-5.82	-0.43	3.57e-8	Colorectal cancer;
UCEC	cis	rs9682041	0.561	rs6790483	chr3:170154406	G/A	cg11886554	chr3:170076028	SKIL	0.74	5.05	0.38	1.3e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.59	-7.08	-0.5	5.5e-11	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.71	8.77	0.59	4.11e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.46	5.34	0.4	3.39e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.57	-5.73	-0.43	5.52e-8	Breast cancer;
UCEC	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	0.77	5.68	0.42	7.05e-8	Red blood cell traits;
UCEC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.72	7.53	0.53	4.82e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg23995753	chr2:160760732	LY75	-0.41	-4.81	-0.37	3.78e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.83	-9.66	-0.62	2.15e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.21e-6	Breast cancer;
UCEC	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.6	4.58	0.35	9.79e-6	Corneal astigmatism;
UCEC	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.41	4.67	0.36	6.64e-6	Height;
UCEC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg14092571	chr14:90743983	NA	0.43	5.14	0.39	8.74e-7	Mortality in heart failure;
UCEC	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.84	-9.79	-0.63	9.82e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.14	0.39	8.81e-7	Heart rate;
UCEC	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	0.77	6.31	0.46	3.16e-9	Testicular germ cell tumor;
UCEC	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-1.15	-5.03	-0.38	1.39e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.35	-5.03	-0.38	1.4e-6	Vitamin D levels;
UCEC	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.65	-5.53	-0.42	1.41e-7	Coronary artery calcification;
UCEC	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	12.77	0.73	1.34e-25	Height;
UCEC	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.69	5.91	0.44	2.32e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13866156	chr1:1669148	SLC35E2	-0.44	-4.51	-0.35	1.32e-5	Body mass index;
UCEC	cis	rs6670533	0.571	rs11801547	chr1:24861399	A/G	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs7246967	0.932	rs62120780	chr19:23043714	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11190179	1.000	rs11190172	chr10:101358381	T/C	cg14256752	chr10:102295592	HIF1AN	-0.74	-4.74	-0.36	4.9e-6	&beta2-Glycoprotein I (&beta;2-GPI) plasma levels;
UCEC	cis	rs7852296	0.541	rs77929287	chr9:126361605	T/C	cg13582060	chr9:127040032	NEK6	0.86	4.66	0.36	7.07e-6	Personality dimensions;
UCEC	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg12850546	chr22:42539477	CYP2D7P1	-0.43	-4.67	-0.36	6.87e-6	Schizophrenia;
UCEC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg04553112	chr3:125709451	NA	-0.67	-5.4	-0.41	2.6e-7	Blood pressure (smoking interaction);
UCEC	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.52	-5.12	-0.39	9.47e-7	Aortic root size;
UCEC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21178979	chr7:1889533	MAD1L1	0.38	5.17	0.39	7.51e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.83	9.09	0.6	6.09e-16	Dental caries;
UCEC	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.8	-5.1	-0.39	1.04e-6	Vitiligo;
UCEC	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-17.69	-0.82	3e-38	Exhaled nitric oxide output;
UCEC	cis	rs7709377	0.595	rs116024534	chr5:115440929	T/C	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.51	8.36	0.57	4.33e-14	Airflow obstruction;
UCEC	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg06265175	chr8:121136014	COL14A1	0.48	5.2	0.39	6.53e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.0	8.12	0.56	1.72e-13	Exhaled nitric oxide output;
UCEC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg26162295	chr17:38119207	GSDMA	-0.31	-4.58	-0.35	1e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs77861329	1.000	rs123681	chr3:52209320	A/G	cg08692210	chr3:52188851	WDR51A	0.84	6.59	0.48	7.36e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.9	-10.43	-0.65	2.1e-19	Prudent dietary pattern;
UCEC	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg13683864	chr3:40499215	RPL14	-0.54	-5.45	-0.41	2.06e-7	Renal cell carcinoma;
UCEC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.93	12.52	0.72	6.18e-25	Metabolic syndrome;
UCEC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.78	8.15	0.56	1.44e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.66	5.17	0.39	7.5e-7	Body mass index;
UCEC	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-4.84	-0.37	3.19e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-7.61	-0.53	3.06e-12	Parkinson's disease;
UCEC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs6934651	0.581	rs55634002	chr6:85833782	G/A	cg18860790	chr6:84937415	KIAA1009	-0.95	-4.95	-0.38	2e-6	Breast cancer;
UCEC	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.5	4.57	0.35	1.05e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg22166914	chr1:53195759	ZYG11B	0.82	8.52	0.57	1.79e-14	Monocyte count;
UCEC	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.15	-8.94	-0.59	1.48e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.96	-10.84	-0.67	1.76e-20	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.37	4.66	0.36	7.07e-6	Renal cell carcinoma;
UCEC	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.89	11.31	0.68	9.85e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-4.9	-0.37	2.54e-6	Personality dimensions;
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.62	5.17	0.39	7.43e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.69	7.52	0.53	4.95e-12	IgG glycosylation;
UCEC	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg00250761	chr1:31883323	NA	-0.43	-5.86	-0.44	2.88e-8	Alcohol dependence;
UCEC	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.62	6.39	0.47	2.09e-9	Body mass index;
UCEC	cis	rs6832769	0.890	rs1522107	chr4:56380773	A/T	cg05960024	chr4:56376020	CLOCK	0.55	5.99	0.44	1.52e-8	Personality dimensions;
UCEC	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg01072550	chr1:21505969	NA	-0.57	-5.6	-0.42	1.02e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	-0.72	-5.95	-0.44	1.92e-8	Bitter taste perception;
UCEC	cis	rs9341808	0.538	rs623048	chr6:80981916	C/T	cg08355045	chr6:80787529	NA	-0.34	-4.55	-0.35	1.11e-5	Sitting height ratio;
UCEC	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg04879645	chr16:947229	LMF1	0.37	4.57	0.35	1.03e-5	Coronary artery disease;
UCEC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.62	-6.22	-0.46	4.82e-9	Blood metabolite levels;
UCEC	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.51	5.02	0.38	1.5e-6	High light scatter reticulocyte count;
UCEC	cis	rs10254160	1.000	rs17159613	chr7:112062655	A/T	cg00851377	chr7:112726089	GPR85	-0.79	-4.55	-0.35	1.12e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs58521262	0.556	rs291769	chr19:23183941	T/C	cg08486875	chr19:23386892	NA	0.33	4.57	0.35	1.04e-5	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.68	7.9	0.55	5.99e-13	Prudent dietary pattern;
UCEC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.69	7.6	0.53	3.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg24803719	chr17:45855879	NA	-0.47	-5.22	-0.4	5.91e-7	IgG glycosylation;
UCEC	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.47	-6.34	-0.46	2.72e-9	Sense of smell;
UCEC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-6.13	-0.45	7.54e-9	Monocyte count;
UCEC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.7	-8.43	-0.57	3.01e-14	Prudent dietary pattern;
UCEC	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.65	-0.36	7.21e-6	Blood protein levels;
UCEC	cis	rs11675119	0.501	rs12994811	chr2:3494301	C/A	cg15506890	chr2:3487001	NA	-0.51	-4.57	-0.35	1.05e-5	Neurofibrillary tangles;
UCEC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.41	5.3	0.4	4.17e-7	Fibrinogen levels;
UCEC	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg04155231	chr12:9217510	LOC144571	0.4	4.96	0.38	1.89e-6	Sjögren's syndrome;
UCEC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg05738196	chr6:26577821	NA	-0.61	-6.85	-0.49	1.85e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22683308	chr4:1340831	KIAA1530	-0.46	-4.65	-0.36	7.38e-6	Longevity;
UCEC	cis	rs3015497	0.586	rs7144714	chr14:51078585	G/A	cg04730355	chr14:51134070	SAV1	-0.48	-5.03	-0.38	1.38e-6	Mean platelet volume;
UCEC	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-6.18	-0.45	5.92e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg05738196	chr6:26577821	NA	0.62	6.07	0.45	1.01e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.69	-7.71	-0.54	1.74e-12	Breast cancer;
UCEC	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-0.81	-5.03	-0.38	1.4e-6	Diabetic retinopathy;
UCEC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.57	5.99	0.44	1.57e-8	Initial pursuit acceleration;
UCEC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	0.92	12.81	0.73	1.07e-25	Homoarginine levels;
UCEC	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-5.64	-0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-12.77	-0.73	1.38e-25	Ulcerative colitis;
UCEC	cis	rs6746896	0.708	rs6727384	chr2:97400324	A/G	cg01950434	chr2:97203154	ARID5A	-0.47	-5.05	-0.38	1.27e-6	Bipolar disorder;
UCEC	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.1	-17.49	-0.82	9.8e-38	Myeloid white cell count;
UCEC	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.4	-0.41	2.66e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.41	-5.21	-0.39	6.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.48	-5.83	-0.43	3.43e-8	Bipolar disorder;
UCEC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.51	5.24	0.4	5.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10507349	1.000	rs10507349	chr13:26781528	A/G	cg01600817	chr13:26797529	RNF6	0.49	4.62	0.36	8.26e-6	Type 2 diabetes;
UCEC	cis	rs7975161	0.638	rs4592489	chr12:104619699	C/T	cg25273343	chr12:104657179	TXNRD1	-0.49	-4.89	-0.37	2.59e-6	Toenail selenium levels;
UCEC	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.97	-7.63	-0.53	2.7e-12	Dupuytren's disease;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.19	0.45	5.66e-9	Platelet count;
UCEC	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.68	-0.69	1.01e-22	Primary sclerosing cholangitis;
UCEC	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.67	6.42	0.47	1.79e-9	Cognitive ability;
UCEC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.94	10.2	0.64	8.28e-19	Cognitive function;
UCEC	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.5	4.82	0.37	3.6e-6	Coronary artery disease;
UCEC	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.49	-4.64	-0.36	7.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.53	-4.79	-0.37	4.03e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.53	5.29	0.4	4.35e-7	Blood protein levels;
UCEC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.46	4.71	0.36	5.7e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.64	5.07	0.39	1.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.48	-4.81	-0.37	3.77e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg08027265	chr7:2291960	NA	-0.41	-4.58	-0.35	9.73e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.91e-7	Hemoglobin concentration;
UCEC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07690219	chr3:49449608	TCTA;RHOA	0.52	4.76	0.37	4.5e-6	Menarche (age at onset);
UCEC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.65	4.82	0.37	3.62e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3768644	0.598	rs10174010	chr2:72387539	C/T	cg07678644	chr2:71558969	ZNF638	0.56	4.6	0.35	9.12e-6	Schizophrenia;
UCEC	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-1.03	-6.85	-0.49	1.84e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.27	0.4	4.81e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg06521331	chr12:34319734	NA	-0.63	-4.96	-0.38	1.88e-6	Morning vs. evening chronotype;
UCEC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg16616514	chr4:6324629	PPP2R2C	-0.42	-4.79	-0.37	4.05e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg04155231	chr12:9217510	LOC144571	0.42	5.21	0.4	6.16e-7	Sjögren's syndrome;
UCEC	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.47	5.08	0.39	1.13e-6	Headache;
UCEC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg05738196	chr6:26577821	NA	0.66	7.78	0.54	1.17e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg23070574	chr3:14187308	XPC	0.46	5.19	0.39	6.97e-7	Ovarian reserve;
UCEC	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg08890418	chr1:21044141	KIF17	0.71	7.69	0.54	1.95e-12	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.59	-5.76	-0.43	4.83e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg21905437	chr5:178450457	ZNF879	0.67	7.06	0.5	5.98e-11	Pubertal anthropometrics;
UCEC	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg14530993	chr4:882597	GAK	0.72	4.81	0.37	3.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs253959	0.883	rs6894046	chr5:115428439	T/A	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.59	5.79	0.43	4.13e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.45	6.09	0.45	9.46e-9	Electrocardiographic conduction measures;
UCEC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.47	-5.81	-0.43	3.76e-8	Neutrophil percentage of white cells;
UCEC	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.43	4.53	0.35	1.22e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.59	-6.57	-0.48	8.34e-10	Menarche (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10686375	chr16:67464878	HSD11B2	0.66	7.83	0.54	8.77e-13	Warfarin maintenance dose;
UCEC	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg09165964	chr15:75287851	SCAMP5	0.49	5.4	0.41	2.62e-7	Caffeine consumption;
UCEC	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	0.78	9.1	0.6	5.88e-16	Bone mineral density;
UCEC	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.63	-5.41	-0.41	2.47e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg07153921	chr17:41440717	NA	-0.48	-5.41	-0.41	2.5e-7	Menopause (age at onset);
UCEC	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.33	7.69	0.54	1.91e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.3	-0.4	4.2e-7	Resting heart rate;
UCEC	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg23791538	chr6:167370224	RNASET2	-0.58	-6.21	-0.46	5.1e-9	Crohn's disease;
UCEC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg21854759	chr1:92012499	NA	-0.47	-4.53	-0.35	1.21e-5	Breast cancer;
UCEC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg18827107	chr12:86230957	RASSF9	-0.43	-5.16	-0.39	7.78e-7	Major depressive disorder;
UCEC	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.68	6.56	0.48	8.72e-10	Crohn's disease;
UCEC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.71	7.82	0.54	9.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.64	8.44	0.57	2.81e-14	Anterior chamber depth;
UCEC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.64	-6.43	-0.47	1.7e-9	Pancreatic cancer;
UCEC	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Kawasaki disease;
UCEC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.46	4.72	0.36	5.49e-6	Aortic root size;
UCEC	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg01843034	chr6:37503916	NA	-0.33	-4.74	-0.36	4.95e-6	Cognitive performance;
UCEC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg01262667	chr19:19385393	TM6SF2	0.52	7.37	0.52	1.11e-11	Tonsillectomy;
UCEC	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.67	-6.49	-0.47	1.23e-9	Retinal vascular caliber;
UCEC	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.49	4.67	0.36	6.63e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-8.7	-0.58	6.14e-15	Extraversion;
UCEC	cis	rs6424115	0.594	rs7519640	chr1:24069637	G/C	cg15997130	chr1:24165203	NA	0.57	6.12	0.45	7.99e-9	Immature fraction of reticulocytes;
UCEC	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.67	0.62	1.99e-17	Blood protein levels;
UCEC	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.44	-4.53	-0.35	1.23e-5	Glomerular filtration rate;
UCEC	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.76	6.67	0.48	4.84e-10	Menopause (age at onset);
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.48	-4.75	-0.36	4.81e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.61	6.82	0.49	2.23e-10	Mean platelet volume;
UCEC	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.98	-11.0	-0.67	6.44e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.63	-5.19	-0.39	6.8e-7	Asthma;
UCEC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	3.98e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12635074	0.547	rs6786714	chr3:56231518	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.35	4.52	0.35	1.26e-5	Morning vs. evening chronotype;
UCEC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg22974920	chr21:40686053	BRWD1	0.61	5.38	0.41	2.81e-7	Cognitive function;
UCEC	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	6.54	0.48	9.3e-10	Ileal carcinoids;
UCEC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	6.16	0.45	6.46e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.51	5.03	0.38	1.44e-6	Resting heart rate;
UCEC	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.49	5.01	0.38	1.56e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg19554555	chr3:13937349	NA	-0.59	-5.91	-0.44	2.29e-8	Ovarian reserve;
UCEC	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg17515076	chr17:73810948	UNK	-0.52	-5.99	-0.44	1.53e-8	White matter hyperintensity burden;
UCEC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	4.84	0.37	3.3e-6	Monocyte percentage of white cells;
UCEC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.59	6.64	0.48	5.7e-10	Hemoglobin concentration;
UCEC	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-6.18	-0.45	5.92e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.79	7.39	0.52	1.02e-11	Menopause (age at onset);
UCEC	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.6	-0.35	9.01e-6	Alzheimer's disease (late onset);
UCEC	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	5.81	0.43	3.69e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-5.19	-0.39	6.73e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	16.03	0.8	4.31e-34	Colorectal cancer;
UCEC	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.82	-8.66	-0.58	7.85e-15	Itch intensity from mosquito bite;
UCEC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.46	5.1	0.39	1.05e-6	Emphysema distribution in smoking;
UCEC	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.73	-5.44	-0.41	2.2e-7	Huntington's disease progression;
UCEC	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.06e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.71	8.48	0.57	2.18e-14	Prudent dietary pattern;
UCEC	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs944990	0.765	rs10156602	chr9:96345328	A/G	cg13787134	chr9:96362102	PHF2	-0.34	-4.51	-0.35	1.34e-5	Body mass index;
UCEC	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.49	5.31	0.4	4.06e-7	Platelet distribution width;
UCEC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.53	-5.73	-0.43	5.36e-8	Menarche (age at onset);
UCEC	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.61	-4.56	-0.35	1.09e-5	Autism;
UCEC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg10295955	chr4:187884368	NA	-0.89	-11.68	-0.69	1.03e-22	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.75	-7.91	-0.55	5.69e-13	Tonsillectomy;
UCEC	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs72906064	0.614	rs72906035	chr2:156901905	A/G	cg14040602	chr2:157557294	NA	0.64	4.8	0.37	3.85e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	5.4	0.41	2.67e-7	Aortic root size;
UCEC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.59	5.68	0.42	7.11e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg12580275	chr1:205744413	RAB7L1	0.52	4.82	0.37	3.53e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg20999797	chr1:1681921	NA	0.36	4.94	0.38	2.11e-6	Body mass index;
UCEC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg11871910	chr12:69753446	YEATS4	0.66	7.42	0.52	8.61e-12	Blood protein levels;
UCEC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.47	-6.57	-0.48	8.04e-10	Sense of smell;
UCEC	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.48	4.76	0.37	4.66e-6	Lung cancer;
UCEC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg21466736	chr12:48725269	NA	0.35	4.75	0.36	4.87e-6	Plateletcrit;
UCEC	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.45	-4.74	-0.36	4.9100000000000004e-06	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg18721089	chr20:30220636	NA	-0.36	-4.5	-0.35	1.35e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.37	-4.72	-0.36	5.43e-6	Refractive error;
UCEC	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-10.08	-0.64	1.67e-18	Headache;
UCEC	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.63	6.9	0.49	1.45e-10	Monocyte count;
UCEC	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.02	-0.64	2.46e-18	Height;
UCEC	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.75	0.43	4.9e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-0.91	-5.36	-0.4	3.22e-7	Diabetic kidney disease;
UCEC	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.51	4.85	0.37	3.17e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-0.93	-6.4	-0.47	1.93e-9	Mitochondrial DNA levels;
UCEC	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-0.8	-5.21	-0.39	6.35e-7	Diabetic kidney disease;
UCEC	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	5.94	0.44	1.97e-8	Cognitive test performance;
UCEC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.45	0.57	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.61	-6.06	-0.45	1.07e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.65	4.72	0.36	5.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg02158880	chr13:53174818	NA	0.42	4.83	0.37	3.43e-6	Lewy body disease;
UCEC	cis	rs2970992	0.764	rs12712081	chr2:101329232	T/C	cg01042948	chr2:101319752	NA	0.56	5.99	0.44	1.56e-8	Educational attainment;
UCEC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.66	-6.31	-0.46	3.16e-9	Acne (severe);
UCEC	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-5.64	-0.42	8.34e-8	Vitiligo;
UCEC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.5e-16	Height;
UCEC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.62	6.2	0.46	5.39e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.59	-0.35	9.5e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.6	-0.42	1.04e-7	Pancreatic cancer;
UCEC	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg11632617	chr15:75315747	PPCDC	-0.55	-5.05	-0.38	1.3e-6	Lung cancer;
UCEC	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.5	-0.47	1.2e-9	Eye color traits;
UCEC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.62	6.02	0.44	1.33e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs67839313	0.541	rs10163076	chr15:40606484	C/T	cg07121488	chr15:40581105	PLCB2	0.71	5.15	0.39	8.11e-7	Type 2 diabetes;
UCEC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	6.23	0.46	4.7e-9	HDL cholesterol;
UCEC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.5	-6.06	-0.45	1.12e-8	Height;
UCEC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.16e-5	Lung cancer;
UCEC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg22974920	chr21:40686053	BRWD1	-0.53	-4.87	-0.37	2.82e-6	Cognitive function;
UCEC	cis	rs8020441	0.838	rs4901051	chr14:51164768	G/A	cg04730355	chr14:51134070	SAV1	0.56	5.22	0.4	5.99e-7	Cognitive performance;
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9532580	0.620	rs2701859	chr13:41141232	T/C	cg21288729	chr13:41239152	FOXO1	0.48	4.8	0.37	3.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7246967	0.673	rs2885221	chr19:22839387	A/G	cg03230154	chr19:22817176	ZNF492	0.45	4.56	0.35	1.06e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.28	-12.72	-0.72	1.86e-25	Corneal structure;
UCEC	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg01072550	chr1:21505969	NA	-0.57	-5.82	-0.43	3.48e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg06238570	chr21:40685208	BRWD1	0.73	6.76	0.49	2.98e-10	Cognitive function;
UCEC	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	ch.11.42038R	chr11:967971	AP2A2	0.43	4.84	0.37	3.26e-6	Alzheimer's disease (late onset);
UCEC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.5	5.66	0.42	7.58e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg21191810	chr6:118973309	C6orf204	0.44	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7246967	0.736	rs453723	chr19:22998489	C/T	cg08271804	chr19:22816896	ZNF492	0.57	5.05	0.38	1.3e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg01966129	chr22:22901880	PRAME;LOC648691	0.25	4.55	0.35	1.1e-5	Bone mineral density;
UCEC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.69	-7.09	-0.5	5.35e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs11867410	0.744	rs61710735	chr17:63939740	C/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	5.43	0.41	2.33e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.82e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs405956	0.769	rs9500032	chr6:105566414	C/T	cg22580625	chr6:105627791	POPDC3	-0.54	-5.07	-0.39	1.19e-6	QT interval;
UCEC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg08027265	chr7:2291960	NA	-0.46	-4.91	-0.38	2.4e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18252515	chr7:66147081	NA	-0.59	-5.47	-0.41	1.86e-7	Aortic root size;
UCEC	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs4478037	1.000	rs4074415	chr3:33161745	A/G	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg26061582	chr7:22766209	IL6	0.59	5.48	0.41	1.83e-7	Lung cancer;
UCEC	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-4.87	-0.37	2.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7651736	0.636	rs60985825	chr3:136755496	G/T	cg21827317	chr3:136751795	NA	-0.45	-4.63	-0.36	8.13e-6	Neuroticism;
UCEC	cis	rs28795989	0.795	rs4696778	chr4:7919308	C/G	cg00251875	chr4:7801337	AFAP1	-0.54	-5.89	-0.44	2.5e-8	Intraocular pressure;
UCEC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.72	6.96	0.5	1.03e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.71	8.98	0.6	1.19e-15	Testicular germ cell tumor;
UCEC	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	4.56e-18	Cognitive function;
UCEC	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg13683864	chr3:40499215	RPL14	0.58	6.38	0.47	2.18e-9	Renal cell carcinoma;
UCEC	cis	rs17122693	0.748	rs72681607	chr14:51115866	T/C	cg04730355	chr14:51134070	SAV1	0.96	10.1	0.64	1.57e-18	Cognitive performance;
UCEC	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.52	-7.31	-0.52	1.58e-11	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg21831649	chr1:16050377	PLEKHM2	-0.43	-4.52	-0.35	1.24e-5	Systolic blood pressure;
UCEC	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	4.88	0.37	2.76e-6	Blood metabolite levels;
UCEC	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.54	-5.22	-0.4	5.9e-7	Handedness;
UCEC	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.63	-0.36	8.09e-6	Bipolar disorder;
UCEC	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.9	0.55	5.93e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11958404	0.932	rs72816547	chr5:157417820	G/T	cg05962755	chr5:157440814	NA	0.76	4.92	0.38	2.25e-6	IgG glycosylation;
UCEC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg14008862	chr17:28927542	LRRC37B2	0.73	4.95	0.38	2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.85	-0.37	3.12e-6	Blood metabolite levels;
UCEC	cis	rs7870753	1.000	rs34304649	chr9:99247301	T/A	cg25260653	chr9:99212216	HABP4	0.48	4.84	0.37	3.3e-6	Height;
UCEC	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	0.85	8.82	0.59	3.09e-15	Primary sclerosing cholangitis;
UCEC	cis	rs7517126	1.000	rs6428367	chr1:196844192	C/T	cg07209298	chr1:196795943	CFHR1	-0.45	-4.56	-0.35	1.07e-5	Blood protein levels;
UCEC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg23093090	chr10:104574429	C10orf26	0.48	5.36	0.4	3.17e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.85	0.54	8.05e-13	Platelet count;
UCEC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg04871131	chr7:94954202	PON1	-0.52	-5.01	-0.38	1.51e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.45	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.49	4.9	0.37	2.56e-6	Morning vs. evening chronotype;
UCEC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-4.66	-0.36	6.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6832769	0.961	rs3805147	chr4:56306730	C/T	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg23978390	chr7:1156363	C7orf50	0.47	4.58	0.35	9.92e-6	Longevity;Endometriosis;
UCEC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg12596171	chr3:113251061	SIDT1	-0.46	-4.6	-0.35	9.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-6.31	-0.46	3.11e-9	Superior crus of antihelix expression;
UCEC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	6.1	0.45	9.04e-9	Tonsillectomy;
UCEC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.59	-5.73	-0.43	5.54e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.71	6.72	0.48	3.73e-10	Bladder cancer;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.5	-5.57	-0.42	1.18e-7	Depression;
UCEC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.36	4.81	0.37	3.68e-6	Eye color traits;
UCEC	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12912251	0.591	rs3104150	chr15:39003585	T/C	cg10631289	chr15:39006617	NA	-0.61	-5.01	-0.38	1.53e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg24687543	chr11:63912206	MACROD1	0.56	4.5	0.35	1.36e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-0.52	-5.34	-0.4	3.39e-7	Yeast infection;
UCEC	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg06238570	chr21:40685208	BRWD1	0.78	7.62	0.53	2.93e-12	Cognitive function;
UCEC	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.75	-7.82	-0.54	9.64e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.47	-5.04	-0.38	1.35e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2806864	1.000	rs2249984	chr1:117469322	T/A	cg19765820	chr1:116518738	SLC22A15	-0.6	-4.52	-0.35	1.25e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.63	5.97	0.44	1.71e-8	Aortic root size;
UCEC	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg14121845	chr20:25566513	NINL	0.4	4.78	0.37	4.29e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg20119798	chr7:94954144	PON1	-0.5	-4.75	-0.36	4.77e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9283706	0.608	rs13171572	chr5:66334552	T/A	cg11590213	chr5:66331682	MAST4	0.45	5.62	0.42	9.42e-8	Coronary artery disease;
UCEC	cis	rs7638995	0.878	rs1995665	chr3:69183140	A/C	cg26574240	chr3:69171822	LMOD3	-0.65	-5.86	-0.44	2.95e-8	Alzheimer's disease (late onset);
UCEC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.8	-7.04	-0.5	6.97e-11	Blood metabolite levels;
UCEC	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.65	-7.62	-0.53	2.85e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg27112062	chr3:48456733	PLXNB1	-0.52	-4.52	-0.35	1.27e-5	Cognitive function;
UCEC	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg21419209	chr3:44054225	NA	-0.52	-5.58	-0.42	1.15e-7	Coronary artery disease;
UCEC	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg06562184	chr8:19319451	CSGALNACT1	0.49	5.16	0.39	7.93e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.67	5.89	0.44	2.49e-8	Menopause (age at onset);
UCEC	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg07776626	chr8:57350775	NA	-0.48	-4.7	-0.36	6.05e-6	Obesity-related traits;
UCEC	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.47	5.89	0.44	2.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.51	5.21	0.39	6.32e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.56	-5.76	-0.43	4.7e-8	IgG glycosylation;
UCEC	cis	rs17123764	0.605	rs73305085	chr12:50056233	G/A	cg20471783	chr12:50157085	TMBIM6	0.69	5.11	0.39	9.9e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.73	0.49	3.49e-10	Eye color traits;
UCEC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg04287289	chr16:89883240	FANCA	0.44	4.92	0.38	2.29e-6	Vitiligo;
UCEC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.56	5.34	0.4	3.5e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.7	0.58	6.08e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg15513719	chr13:114904418	NA	0.46	4.54	0.35	1.16e-5	Schizophrenia;
UCEC	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.51	4.9	0.37	2.54e-6	Hemoglobin concentration;
UCEC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.47	5.13	0.39	9.16e-7	Aortic root size;
UCEC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.88	-9.76	-0.63	1.17e-17	Cognitive function;
UCEC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg03714773	chr7:91764589	CYP51A1	-0.46	-5.61	-0.42	9.6e-8	Breast cancer;
UCEC	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-5.15	-0.39	8.2e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.66	8.07	0.55	2.25e-13	Mean platelet volume;
UCEC	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.73	-5.42	-0.41	2.39e-7	Huntington's disease progression;
UCEC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.71	-7.51	-0.53	5.38e-12	Blood metabolite levels;
UCEC	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.48	-0.41	1.83e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.3	-8.53	-0.58	1.66e-14	Diabetic kidney disease;
UCEC	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.52	5.96	0.44	1.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.29	0.46	3.47e-9	Tonsillectomy;
UCEC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.89	0.49	1.55e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.5	5.89	0.44	2.47e-8	Total body bone mineral density;
UCEC	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.66	-4.59	-0.35	9.44e-6	Hair shape;
UCEC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg01262667	chr19:19385393	TM6SF2	-0.5	-7.02	-0.5	7.51e-11	Tonsillectomy;
UCEC	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.67	0.62	1.99e-17	Blood protein levels;
UCEC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.42	-4.95	-0.38	2e-6	Rheumatoid arthritis;
UCEC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.68	6.11	0.45	8.65e-9	Aortic root size;
UCEC	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.69	8.44	0.57	2.77e-14	Bone mineral density;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg00139056	chr1:8385396	SLC45A1	-0.71	-7.18	-0.51	3.24e-11	Migraine with aura;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.5	-5.21	-0.39	6.28e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.75	-5.43	-0.41	2.27e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs8105895	1.000	rs62112907	chr19:22209569	A/G	cg24175803	chr19:22235144	ZNF257	-0.5	-4.61	-0.36	8.81e-6	Body mass index (change over time);
UCEC	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg16497661	chr14:103986332	CKB	0.46	5.31	0.4	4e-7	Body mass index;
UCEC	cis	rs4372836	0.964	rs4408686	chr2:28940526	T/C	cg09522027	chr2:28974177	PPP1CB	0.73	7.28	0.51	1.86e-11	Body mass index;
UCEC	cis	rs80285556	1.000	rs76812330	chr19:50531860	C/T	cg11918822	chr19:50479865	VRK3	0.78	4.54	0.35	1.14e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
UCEC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.69	7.8	0.54	1.08e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.74	-8.44	-0.57	2.71e-14	Menarche (age at onset);
UCEC	cis	rs1318937	0.764	rs58837640	chr3:15240646	C/G	cg21849552	chr3:14597650	NA	0.49	4.78	0.37	4.17e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.47	4.96	0.38	1.95e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.83	-9.21	-0.6	3.17e-16	Cognitive function;
UCEC	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.32	-0.4	3.75e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4853036	0.951	rs13393656	chr2:70119255	C/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.67	-0.36	6.73e-6	Colorectal or endometrial cancer;
UCEC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.44	5.2	0.39	6.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-8.87	-0.59	2.25e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	8.15e-8	Diabetic kidney disease;
UCEC	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.91	8.62	0.58	9.52e-15	Colorectal adenoma (advanced);
UCEC	cis	rs151997	1.000	rs152690	chr5:50213584	A/T	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	4.9	0.37	2.51e-6	Mood instability;
UCEC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.75	0.43	4.87e-8	Breast cancer;
UCEC	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-0.57	-4.59	-0.35	9.37e-6	Blood pressure (smoking interaction);
UCEC	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.57	-5.23	-0.4	5.8e-7	Brain structure;
UCEC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.63	5.95	0.44	1.85e-8	Response to diuretic therapy;
UCEC	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg13695892	chr22:41940480	POLR3H	-0.65	-5.32	-0.4	3.75e-7	Vitiligo;
UCEC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.48	4.81	0.37	3.71e-6	Blood protein levels;
UCEC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.62	5.22	0.4	5.97e-7	RR interval (heart rate);
UCEC	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.09	16.3	0.8	9.01e-35	Schizophrenia;
UCEC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg19318889	chr4:1322082	MAEA	0.48	5.09	0.39	1.1e-6	Obesity-related traits;
UCEC	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs7101446	0.545	rs11231494	chr11:63214497	C/T	cg04056542	chr11:62495784	HNRNPUL2;TTC9C	0.49	4.54	0.35	1.19e-5	Economic and political preferences;
UCEC	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.55	5.59	0.42	1.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.53	-6.58	-0.48	7.95e-10	Total body bone mineral density;
UCEC	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.55	-5.44	-0.41	2.13e-7	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-8.22	-0.56	9.69e-14	Hip circumference;
UCEC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18099408	chr3:52552593	STAB1	-0.39	-4.52	-0.35	1.25e-5	Bipolar disorder;
UCEC	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	5.57	0.42	1.15e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.12	-0.45	8.15e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.47	-0.41	1.9e-7	Platelet count;
UCEC	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg04906043	chr13:21280425	IL17D	-0.45	-4.6	-0.35	8.98e-6	Dental caries;
UCEC	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14019695	chr9:139328340	INPP5E	0.47	5.07	0.39	1.16e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.56	5.62	0.42	9.51e-8	Neuroticism;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-1.1	-7.53	-0.53	4.79e-12	Bone mineral density;
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.82	-0.37	3.59e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.71	6.57	0.48	8.16e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.87	5.63	0.42	8.97e-8	Psoriasis;
UCEC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4747241	0.556	rs4495815	chr10:74068978	G/T	cg05988358	chr10:74082489	NA	0.38	4.76	0.37	4.61e-6	Heschl's gyrus morphology;
UCEC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-13.15	-0.74	1.31e-26	Height;
UCEC	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs295140	1.000	rs13026151	chr2:201164570	T/A	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.57	7.23	0.51	2.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.5	4.71	0.36	5.63e-6	Night sleep phenotypes;
UCEC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg14067834	chr17:29058358	SUZ12P	0.65	4.51	0.35	1.31e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.62	-4.95	-0.38	1.98e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-5.08	-0.39	1.11e-6	Total body bone mineral density;
UCEC	cis	rs8020441	0.541	rs8012745	chr14:51160753	G/A	cg04730355	chr14:51134070	SAV1	0.8	7.77	0.54	1.26e-12	Cognitive performance;
UCEC	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.45	6.15	0.45	6.94e-9	Superior crus of antihelix expression;
UCEC	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.36	-0.52	1.2e-11	Eye color traits;
UCEC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg26721908	chr21:47610096	LSS	0.45	5.97	0.44	1.71e-8	Testicular germ cell tumor;
UCEC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-5.66	-0.42	7.58e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs78487399	0.908	rs72868628	chr2:43833039	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.77	-0.43	4.63e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.63	5.79	0.43	4.18e-8	Itch intensity from mosquito bite;
UCEC	cis	rs876084	0.510	rs10096137	chr8:121101910	A/G	cg06265175	chr8:121136014	COL14A1	0.45	4.8	0.37	3.85e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10409785	chr4:100485006	RG9MTD2;MTTP	-0.48	-4.55	-0.35	1.13e-5	Gut microbiome composition (summer);
UCEC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-5.75	-0.43	5.01e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.67	5.73	0.43	5.45e-8	High light scatter reticulocyte count;
UCEC	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.62	6.53	0.47	9.92e-10	Bladder cancer;
UCEC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg13683864	chr3:40499215	RPL14	-0.53	-5.37	-0.41	3e-7	Renal cell carcinoma;
UCEC	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.55	-5.09	-0.39	1.08e-6	Menarche (age at onset);
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.71	-8.3	-0.56	6.3e-14	Prudent dietary pattern;
UCEC	cis	rs2742417	0.967	rs2742441	chr3:45748429	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.69	-4.97	-0.38	1.81e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	6.84	0.49	1.99e-10	Joint mobility (Beighton score);
UCEC	cis	rs7246967	0.673	rs7254097	chr19:22865900	T/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.84	7.93	0.55	5e-13	Bladder cancer;
UCEC	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.47	-6.49	-0.47	1.23e-9	Height;
UCEC	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.7	6.29	0.46	3.39e-9	Subjective well-being;
UCEC	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.88	0.44	2.61e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	0.53	5.98	0.44	1.6e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.81	-0.37	3.65e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg17724175	chr1:150552817	MCL1	-0.43	-4.72	-0.36	5.4e-6	Tonsillectomy;
UCEC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.6	6.22	0.46	4.82e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg05072774	chr3:49840536	C3orf54	-0.49	-4.57	-0.35	1.03e-5	Resting heart rate;
UCEC	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.41	-5.34	-0.4	3.44e-7	IgG glycosylation;
UCEC	cis	rs1425902	0.518	rs6473794	chr8:54127162	T/C	cg01281904	chr8:54164757	OPRK1	-0.38	-4.75	-0.37	4.72e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs4654899	0.571	rs34530426	chr1:21085204	C/T	cg01072550	chr1:21505969	NA	-0.48	-4.75	-0.36	4.74e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.51	6.3	0.46	3.25e-9	Subjective well-being (multi-trait analysis);
UCEC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.52	-5.53	-0.41	1.44e-7	Testicular germ cell tumor;
UCEC	cis	rs12681287	0.752	rs12675974	chr8:87247845	T/C	cg27223183	chr8:87520930	FAM82B	-0.63	-5.43	-0.41	2.32e-7	Caudate activity during reward;
UCEC	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-1.0	-12.13	-0.71	6.62e-24	Cognitive function;
UCEC	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg02158880	chr13:53174818	NA	0.55	6.53	0.47	1.01e-9	Lewy body disease;
UCEC	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg15837086	chr1:46506065	PIK3R3	0.37	4.52	0.35	1.28e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	6.06	0.45	1.1e-8	Height;
UCEC	cis	rs295140	1.000	rs67190025	chr2:201172086	C/T	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.87	-8.05	-0.55	2.63e-13	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	8.1	0.56	1.92e-13	Total body bone mineral density;
UCEC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.65	-5.22	-0.4	5.9e-7	Menopause (age at onset);
UCEC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-8.7	-0.58	6.17e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg22974920	chr21:40686053	BRWD1	0.61	5.36	0.4	3.1e-7	Cognitive function;
UCEC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.81	-9.08	-0.6	6.61e-16	Height;
UCEC	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.47	5.04	0.38	1.32e-6	Headache;
UCEC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.78	-6.49	-0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.65	-0.53	2.4e-12	Hypospadias;
UCEC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	6.27	0.46	3.84e-9	Menarche (age at onset);
UCEC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-4.71	-0.36	5.65e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.92	-10.16	-0.64	1.08e-18	Cognitive function;
UCEC	cis	rs4615376	0.951	rs9473427	chr6:13078644	T/C	cg23946962	chr6:12515937	NA	-0.43	-4.66	-0.36	6.95e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	4.85	0.37	3.11e-6	Schizophrenia;
UCEC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.9	9.65	0.62	2.3e-17	Cognitive function;
UCEC	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.67	4.97	0.38	1.83e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.34	-0.46	2.7e-9	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.47	0.41	1.88e-7	Breast cancer;
UCEC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.7	-7.65	-0.53	2.44e-12	Breast cancer;
UCEC	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.95	0.59	1.44e-15	Mean corpuscular hemoglobin;
UCEC	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	8.79	0.59	3.54e-15	Mean platelet volume;
UCEC	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-1.1	-7.03	-0.5	7.06e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Corneal astigmatism;
UCEC	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg13683864	chr3:40499215	RPL14	0.71	8.1	0.56	1.97e-13	Renal cell carcinoma;
UCEC	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7113850	0.541	rs4451727	chr11:24216855	G/C	ch.11.24196551F	chr11:24239977	NA	0.66	5.67	0.42	7.43e-8	Bone fracture in osteoporosis;
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs13401104	0.796	rs72620808	chr2:237114372	G/A	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg24088508	chr1:38156462	C1orf109	-0.56	-5.01	-0.38	1.54e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-9.25	-0.61	2.4e-16	Electrocardiographic conduction measures;
UCEC	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	10.41	0.65	2.3e-19	Post bronchodilator FEV1;
UCEC	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.51	-0.35	1.31e-5	Alzheimer's disease (late onset);
UCEC	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.48	4.58	0.35	9.74e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg05501817	chr11:14380813	RRAS2	-0.5	-4.77	-0.37	4.36e-6	Sense of smell;
UCEC	cis	rs9309473	0.528	rs6546820	chr2:73553397	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-5.17	-0.39	7.63e-7	Metabolite levels;
UCEC	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6460942	0.505	rs73055515	chr7:12328804	A/G	cg06484146	chr7:12443880	VWDE	-0.61	-4.82	-0.37	3.57e-6	Coronary artery disease;
UCEC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.96	-0.55	4.31e-13	Monocyte count;
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.63	4.82	0.37	3.55e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7246967	0.673	rs8103875	chr19:22866862	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg12586109	chr17:80790369	TBCD;ZNF750	0.45	4.81	0.37	3.63e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.66	-7.27	-0.51	2.02e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	7.17	0.51	3.3e-11	Lymphocyte counts;
UCEC	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	0.94	8.23	0.56	9.33e-14	Red blood cell traits;
UCEC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg18279126	chr7:2041391	MAD1L1	0.41	5.13	0.39	9.17e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg11569703	chr11:65557185	OVOL1	0.48	6.25	0.46	4.27e-9	Acne (severe);
UCEC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	7.72	0.54	1.65e-12	Monocyte count;
UCEC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-4.52	-0.35	1.27e-5	Electroencephalogram traits;
UCEC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.53	-5.62	-0.42	9.31e-8	Longevity;
UCEC	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.95	-0.44	1.92e-8	Parkinson's disease;
UCEC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-10.93	-0.67	1.02e-20	Vitiligo;
UCEC	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.12	0.39	9.58e-7	Blood protein levels;
UCEC	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.93	-7.23	-0.51	2.45e-11	Dupuytren's disease;
UCEC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.46	6.71	0.48	3.89e-10	Homoarginine levels;
UCEC	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.34	0.57	4.82e-14	Menopause (age at onset);
UCEC	cis	rs749052	0.561	rs3116190	chr2:233048921	C/T	cg23548455	chr2:233377587	NA	-0.69	-4.56	-0.35	1.05e-5	Height;
UCEC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.15	-9.34	-0.61	1.45e-16	Vitiligo;
UCEC	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.13	-7.24	-0.51	2.33e-11	Schizophrenia;
UCEC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.38	-0.47	2.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	0.82	6.29	0.46	3.42e-9	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg19784848	chr5:219127	SDHA;CCDC127	-0.57	-4.56	-0.35	1.08e-5	Breast cancer;
UCEC	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.61	5.38	0.41	2.88e-7	Alcohol dependence;
UCEC	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg24169773	chr3:122142474	KPNA1	-0.7	-5.05	-0.38	1.31e-6	LDL cholesterol levels;
UCEC	cis	rs72906064	0.731	rs17185142	chr2:156924303	T/C	cg14040602	chr2:157557294	NA	0.63	4.61	0.36	8.84e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.45	6.27	0.46	3.77e-9	Height;
UCEC	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.91	-0.44	2.29e-8	Depression;
UCEC	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg03354898	chr7:1950403	MAD1L1	0.47	4.59	0.35	9.63e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg02366345	chr4:152330872	FAM160A1	0.35	4.73	0.36	5.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.12	0.45	8.11e-9	Platelet count;
UCEC	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.6	6.16	0.45	6.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.75	-7.04	-0.5	6.79e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.5	-5.48	-0.41	1.79e-7	Facial morphology (factor 20);
UCEC	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg13683864	chr3:40499215	RPL14	-0.53	-5.37	-0.4	3.08e-7	Renal cell carcinoma;
UCEC	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.49	5.01	0.38	1.56e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.77	7.14	0.51	3.96e-11	Multiple sclerosis;
UCEC	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	5.9	0.44	2.36e-8	Coffee consumption (cups per day);
UCEC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.64	-5.83	-0.43	3.32e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-23.91	-0.89	1.59e-52	Myeloid white cell count;
UCEC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.5	6.06	0.45	1.09e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.57	-5.55	-0.42	1.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.65	0.36	7.46e-6	Breast cancer;
UCEC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.74	7.24	0.51	2.27e-11	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-6.61	-0.48	6.65e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.47	0.41	1.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-11.87	-0.7	3.2e-23	Chronic sinus infection;
UCEC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.49	5.17	0.39	7.37e-7	Cognitive test performance;
UCEC	cis	rs6893782	0.830	rs2897160	chr5:131741498	C/T	cg01022228	chr5:132202151	UQCRQ	0.47	4.5	0.35	1.36e-5	Acylcarnitine levels;
UCEC	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.58	-0.53	3.58e-12	Myopia;Myopia (pathological);
UCEC	trans	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg02900749	chr2:68251473	NA	-0.99	-7.46	-0.52	7.08e-12	Pursuit maintenance gain;
UCEC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.65	-6.32	-0.46	2.92e-9	Blood metabolite levels;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.51	-6.23	-0.46	4.69e-9	Pulmonary function;
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.44	-0.41	2.2e-7	Platelet count;
UCEC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.44	-6.37	-0.47	2.3e-9	Rheumatoid arthritis;
UCEC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.74	-6.72	-0.48	3.71e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg13683864	chr3:40499215	RPL14	-0.56	-6.01	-0.44	1.4e-8	Renal cell carcinoma;
UCEC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-5.98	-0.44	1.63e-8	Aortic root size;
UCEC	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.5	4.74	0.36	4.94e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.46	4.82	0.37	3.5e-6	Red blood cell count;
UCEC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.58	-8.34	-0.57	4.88e-14	Refractive error;
UCEC	cis	rs12618769	0.597	rs3754884	chr2:99125376	C/T	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.41	-0.47	1.86e-9	Metabolite levels;
UCEC	cis	rs57905270	1.000	rs57905270	chr2:228486714	G/T	cg12489444	chr2:228498029	C2orf83	-0.5	-4.52	-0.35	1.28e-5	Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction);
UCEC	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.72	8.03	0.55	2.92e-13	Coronary artery disease;
UCEC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs6921919	0.789	rs11970439	chr6:28303464	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.9	-0.37	2.48e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs84178	0.852	rs231889	chr11:2777192	C/T	cg26513837	chr11:3014269	NAP1L4	0.58	4.68	0.36	6.37e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.62	-6.7	-0.48	4.05e-10	Initial pursuit acceleration;
UCEC	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.61	5.52	0.41	1.47e-7	Lung function (FEV1/FVC);
UCEC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.53	6.42	0.47	1.76e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.61	4.56	0.35	1.07e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.66	-7.14	-0.51	3.92e-11	Extraversion;
UCEC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.56	5.68	0.42	7.08e-8	Monocyte percentage of white cells;
UCEC	cis	rs526231	0.578	rs2112886	chr5:102251382	C/T	cg23492399	chr5:102201601	PAM	0.57	4.92	0.38	2.25e-6	Primary biliary cholangitis;
UCEC	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.42	-5.39	-0.41	2.73e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs4654899	0.828	rs4654735	chr1:21432001	T/C	cg01072550	chr1:21505969	NA	-0.53	-5.21	-0.39	6.19e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg11632617	chr15:75315747	PPCDC	-0.63	-7.22	-0.51	2.63e-11	Blood trace element (Zn levels);
UCEC	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	0.95	8.21	0.56	1.03e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.72	0.36	5.52e-6	Colorectal cancer;
UCEC	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg24130564	chr14:104152367	KLC1	-0.54	-4.78	-0.37	4.22e-6	Reticulocyte count;
UCEC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.41	-4.76	-0.37	4.6e-6	Abdominal aortic aneurysm;
UCEC	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.94	10.2	0.64	8.28e-19	Cognitive function;
UCEC	cis	rs10887741	0.646	rs11202499	chr10:89433211	C/G	cg13926569	chr10:89418898	PAPSS2	0.41	4.79	0.37	4.06e-6	Exercise (leisure time);
UCEC	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.95	6.48	0.47	1.28e-9	Eosinophil percentage of granulocytes;
UCEC	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-4.82	-0.37	3.54e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg05874882	chr4:1763078	NA	0.63	6.04	0.45	1.18e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.6	6.19	0.45	5.58e-9	Red blood cell count;
UCEC	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-4.64	-0.36	7.49e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7246967	0.611	rs8104327	chr19:22867159	C/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13683864	chr3:40499215	RPL14	-0.97	-10.68	-0.66	4.61e-20	Renal cell carcinoma;
UCEC	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.54	5.22	0.4	5.92e-7	Aortic root size;
UCEC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.61	-4.7	-0.36	6.02e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-6.4	-0.47	1.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.56	-5.92	-0.44	2.19e-8	Blood protein levels;
UCEC	cis	rs240764	0.555	rs11967951	chr6:101231905	G/A	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg05695927	chr15:45694626	SPATA5L1	0.46	4.77	0.37	4.4e-6	Homoarginine levels;
UCEC	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs7246967	0.611	rs2885222	chr19:22839944	T/G	cg03230154	chr19:22817176	ZNF492	0.45	4.56	0.35	1.06e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.59	-5.32	-0.4	3.87e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg26114124	chr12:9217669	LOC144571	0.4	4.78	0.37	4.22e-6	Sjögren's syndrome;
UCEC	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.38	-0.41	2.87e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.74	-0.36	5.09e-6	Bone mineral density;
UCEC	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.64	-5.69	-0.42	6.64e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	0.89	7.21	0.51	2.75e-11	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.19	-0.39	6.95e-7	Resting heart rate;
UCEC	cis	rs4588572	0.601	rs6867673	chr5:77779125	A/G	cg11547950	chr5:77652471	NA	-0.45	-5.09	-0.39	1.1e-6	Triglycerides;
UCEC	cis	rs60311166	0.661	rs57298447	chr3:52659384	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	4.64	0.36	7.57e-6	CTACK levels;
UCEC	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.58	4.85	0.37	3.05e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.48	5.0	0.38	1.59e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.6	5.62	0.42	9.15e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01839850	chr22:38240395	ANKRD54;MIR658	0.6	7.3	0.52	1.66e-11	Warfarin maintenance dose;
UCEC	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg18016565	chr1:150552671	MCL1	0.63	7.6	0.53	3.23e-12	Tonsillectomy;
UCEC	cis	rs7781557	1.000	rs7790451	chr7:102465988	G/A	cg06322601	chr7:102330635	NA	0.62	5.65	0.42	8.2e-8	Colorectal adenoma (advanced);
UCEC	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.7	5.73	0.43	5.37e-8	Menopause (age at onset);
UCEC	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg00122941	chr17:4613640	ARRB2	0.65	5.05	0.38	1.31e-6	Lymphocyte counts;
UCEC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.06	0.5	6.03e-11	Chronic sinus infection;
UCEC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.77	-0.37	4.32e-6	Obesity-related traits;
UCEC	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-8.62	-0.58	1.01e-14	Colorectal cancer;
UCEC	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.51	4.74	0.36	4.94e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.44	5.4	0.41	2.58e-7	Height;
UCEC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.54	5.26	0.4	4.94e-7	Menopause (age at onset);
UCEC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.68	5.61	0.42	9.6e-8	Corneal astigmatism;
UCEC	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.73	7.23	0.51	2.45e-11	Schizophrenia;
UCEC	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg01426195	chr3:39028469	NA	-0.76	-10.34	-0.65	3.66e-19	Handedness;
UCEC	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.79	-0.37	4.02e-6	Parkinson's disease;
UCEC	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.33	4.59	0.35	9.43e-6	Menarche (age at onset);
UCEC	cis	rs875971	0.571	rs160647	chr7:65554352	C/T	cg11764359	chr7:65958608	NA	-0.64	-4.59	-0.35	9.41e-6	Aortic root size;
UCEC	cis	rs6832769	0.961	rs6817663	chr4:56447215	A/G	cg05960024	chr4:56376020	CLOCK	-0.57	-6.02	-0.44	1.35e-8	Personality dimensions;
UCEC	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.59	0.42	1.07e-7	Dupuytren's disease;
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.6	-6.61	-0.48	6.49e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3741798	1.000	rs77559638	chr12:12499909	T/A	cg08615371	chr12:12503544	MANSC1	1.07	5.96	0.44	1.83e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.73	0.36	5.11e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.57	6.6	0.48	6.87e-10	Prostate cancer;
UCEC	cis	rs12767760	0.714	rs1107517	chr10:99299991	G/C	cg17778955	chr10:99210596	ZDHHC16	-0.49	-4.97	-0.38	1.83e-6	Obesity-related traits;
UCEC	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-0.81	-8.38	-0.57	3.95e-14	Height;
UCEC	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.07	-11.38	-0.68	6.36e-22	Corneal structure;
UCEC	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.76	-8.43	-0.57	3.01e-14	Ulcerative colitis;
UCEC	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg13540341	chr19:49222985	MAMSTR	0.37	4.57	0.35	1.04e-5	Dietary macronutrient intake;
UCEC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg16381253	chr16:909593	LMF1	-0.48	-5.14	-0.39	8.78e-7	Insulin-like growth factors;
UCEC	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg15103426	chr22:29168792	CCDC117	-0.65	-6.1	-0.45	9.12e-9	Lymphocyte counts;
UCEC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg10503236	chr1:231470652	EXOC8	-0.41	-4.77	-0.37	4.38e-6	Hemoglobin concentration;
UCEC	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg12339802	chr1:38156545	C1orf109	-0.59	-4.91	-0.38	2.36e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12618769	0.597	rs55900716	chr2:99109132	G/A	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.12	13.93	0.75	1.17e-28	Cognitive function;
UCEC	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.62	6.8	0.49	2.49e-10	Blood metabolite ratios;
UCEC	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.66	-6.47	-0.47	1.38e-9	Mortality in heart failure;
UCEC	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.41	5.13	0.39	8.96e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.51	5.55	0.42	1.32e-7	Crohn's disease;
UCEC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.96	10.53	0.66	1.1e-19	Cognitive function;
UCEC	cis	rs6460942	1.000	rs75564554	chr7:12319362	A/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg19875535	chr5:140030758	IK	0.43	4.81	0.37	3.64e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.04	0.38	1.33e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-4.57	-0.35	1.03e-5	Parkinson's disease;
UCEC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.6	6.03	0.45	1.25e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.6	-5.05	-0.38	1.27e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg10263370	chr3:44754102	ZNF502	-0.5	-5.05	-0.38	1.3e-6	Depressive symptoms;
UCEC	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.88	-9.35	-0.61	1.38e-16	Prudent dietary pattern;
UCEC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.66	-6.0	-0.44	1.49e-8	Cardiac Troponin-T levels;
UCEC	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.64	4.85	0.37	3.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.81	0.37	3.68e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg18681998	chr4:17616180	MED28	0.77	9.51	0.62	5.17e-17	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.44	0.57	2.83e-14	Smoking behavior;
UCEC	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.56	5.36	0.4	3.12e-7	Systemic lupus erythematosus;
UCEC	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.48	6.44	0.47	1.64e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs3736594	0.513	rs62138968	chr2:27824485	C/G	cg27432699	chr2:27873401	GPN1	0.53	5.09	0.39	1.08e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.6	-6.71	-0.48	4e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.61	5.65	0.42	8.13e-8	Heart rate;
UCEC	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg24375607	chr4:120327624	NA	0.47	4.99	0.38	1.66e-6	Corneal astigmatism;
UCEC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.96	-8.97	-0.59	1.26e-15	Exhaled nitric oxide output;
UCEC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg03714773	chr7:91764589	CYP51A1	0.42	4.93	0.38	2.16e-6	Breast cancer;
UCEC	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.46	-4.62	-0.36	8.49e-6	Itch intensity from mosquito bite;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06665941	chr21:34602869	IFNAR2	0.63	7.82	0.54	9.34e-13	Warfarin maintenance dose;
UCEC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.61	0.36	8.6e-6	Bipolar disorder;
UCEC	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-6.85	-0.49	1.89e-10	Colorectal cancer;
UCEC	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg23793686	chr15:68133972	NA	-0.36	-4.63	-0.36	7.83e-6	Restless legs syndrome;
UCEC	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.65	6.7	0.48	4.11e-10	Eosinophil percentage of white cells;
UCEC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	8.98	0.6	1.21e-15	Chronic sinus infection;
UCEC	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg17933807	chr1:38061675	GNL2	0.88	10.34	0.65	3.56e-19	Axial length;
UCEC	cis	rs11697848	1.000	rs2284649	chr20:48526494	G/A	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg04709771	chr16:646395	RAB40C	0.42	4.9	0.37	2.54e-6	Height;
UCEC	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.47	0.47	1.38e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7246967	0.799	rs12983185	chr19:23030575	A/G	cg05241461	chr19:22816980	ZNF492	0.48	5.18	0.39	7.31e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-4.57	-0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.57	-5.56	-0.42	1.21e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7968440	0.808	rs1613835	chr12:51205066	C/T	cg00552387	chr12:51477546	CSRNP2	0.58	4.75	0.36	4.72e-6	Fibrinogen;
UCEC	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-0.96	-15.09	-0.78	1.16e-31	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18854424	chr1:2615690	NA	0.45	6.5	0.47	1.19e-9	Ulcerative colitis;
UCEC	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	7.98	0.55	3.73e-13	Alzheimer's disease;
UCEC	cis	rs17106184	1.000	rs72902744	chr1:51243642	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.22	-9.19	-0.6	3.48e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs7597155	0.935	rs7567400	chr2:69981295	A/G	cg02498382	chr2:70120550	SNRNP27	0.48	5.44	0.41	2.14e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6416877	0.885	rs9747682	chr17:1346407	A/G	cg09375892	chr17:708413	NXN	-0.61	-4.62	-0.36	8.16e-6	Myeloid white cell count;
UCEC	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.61	6.55	0.48	8.91e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg16303742	chr3:15540471	COLQ	-0.41	-5.18	-0.39	7.08e-7	Mean platelet volume;
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.74	-8.41	-0.57	3.26e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-6.19	-0.45	5.76e-9	Menarche (age at onset);
UCEC	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	8.39	0.57	3.59e-14	Post bronchodilator FEV1;
UCEC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-4.54	-0.35	1.14e-5	Longevity;
UCEC	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-5.55	-0.42	1.29e-7	Response to antipsychotic treatment;
UCEC	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg19680485	chr15:31195859	MTMR15	0.52	4.51	0.35	1.32e-5	Huntington's disease progression;
UCEC	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg08250081	chr4:10125330	NA	0.45	4.53	0.35	1.22e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.76	-9.04	-0.6	8.26e-16	Body mass index;
UCEC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-7.23	-0.51	2.51e-11	Cognitive function;
UCEC	cis	rs2882667	0.858	rs35812969	chr5:138377550	G/C	cg04439458	chr5:138467593	SIL1	-0.44	-4.68	-0.36	6.34e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.5	-0.41	1.61e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg08917208	chr2:24149416	ATAD2B	0.66	4.8	0.37	3.89e-6	Lymphocyte counts;
UCEC	cis	rs925550	0.800	rs6837455	chr4:123588942	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	-0.69	-6.29	-0.46	3.39e-9	Primary biliary cholangitis;
UCEC	cis	rs10242455	0.702	rs74347626	chr7:99206021	G/T	cg18809830	chr7:99032528	PTCD1	-0.81	-4.68	-0.36	6.51e-6	Blood metabolite levels;
UCEC	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.53	-5.09	-0.39	1.07e-6	Diastolic blood pressure;
UCEC	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.8	-7.16	-0.51	3.65e-11	Resting heart rate;
UCEC	cis	rs7095607	0.785	rs10997959	chr10:69916909	G/C	cg18986048	chr10:69913749	MYPN	0.55	6.32	0.46	3e-9	Lung function (FVC);
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-5.47	-0.41	1.85e-7	Prudent dietary pattern;
UCEC	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.6	-7.16	-0.51	3.54e-11	Prevalent atrial fibrillation;
UCEC	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.88	9.78	0.63	1.03e-17	Ulcerative colitis;
UCEC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.67	-4.77	-0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.49	-5.19	-0.39	6.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg03859395	chr2:55845619	SMEK2	0.91	11.57	0.69	2e-22	Metabolic syndrome;
UCEC	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	4.92	0.38	2.29e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg18681998	chr4:17616180	MED28	0.73	7.73	0.54	1.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.49	-0.41	1.71e-7	Pubertal anthropometrics;
UCEC	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-6.3	-0.46	3.24e-9	Obesity-related traits;
UCEC	cis	rs4478037	0.915	rs78193453	chr3:33141680	G/T	cg19404215	chr3:33155277	CRTAP	1.04	8.61	0.58	1.04e-14	Major depressive disorder;
UCEC	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	7.15	0.51	3.76e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.58	-6.61	-0.48	6.51e-10	Vitiligo;
UCEC	cis	rs7246967	0.800	rs4932794	chr19:23036556	G/A	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.68	-6.15	-0.45	6.83e-9	Neurofibrillary tangles;
UCEC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.49	-6.51	-0.47	1.13e-9	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.41	-4.98	-0.38	1.79e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.71	8.16	0.56	1.39e-13	Body mass index;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.52	-6.07	-0.45	1.03e-8	Pubertal anthropometrics;
UCEC	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.63	6.28	0.46	3.56e-9	Bladder cancer;
UCEC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg16497661	chr14:103986332	CKB	-0.44	-5.13	-0.39	9.11e-7	Body mass index;
UCEC	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09491104	chr22:46646882	C22orf40	-0.46	-4.5	-0.35	1.35e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg26721908	chr21:47610096	LSS	0.6	6.94	0.5	1.18e-10	Testicular germ cell tumor;
UCEC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18854424	chr1:2615690	NA	0.36	5.24	0.4	5.46e-7	Ulcerative colitis;
UCEC	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-0.84	-5.6	-0.42	1.01e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs7246967	0.611	rs12984903	chr19:22833881	A/G	cg05241461	chr19:22816980	ZNF492	0.56	6.03	0.45	1.25e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.85	-0.59	2.49e-15	Height;
UCEC	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.69	5.65	0.42	7.97e-8	Bipolar disorder;
UCEC	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg05991184	chr2:219186017	PNKD	-0.52	-5.73	-0.43	5.55e-8	Colorectal cancer;
UCEC	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.1e-7	Hemoglobin concentration;
UCEC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.54	-0.35	1.17e-5	Type 2 diabetes;
UCEC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.25	14.95	0.78	2.58e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06671706	chr8:8559999	CLDN23	0.51	4.67	0.36	6.66e-6	Obesity-related traits;
UCEC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg14008862	chr17:28927542	LRRC37B2	0.63	4.95	0.38	2.01e-6	Body mass index;
UCEC	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.68	-5.67	-0.42	7.21e-8	Lymphocyte counts;
UCEC	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.57	5.14	0.39	8.5e-7	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.61	5.6	0.42	1.04e-7	Morning vs. evening chronotype;
UCEC	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.62	5.32	0.4	3.75e-7	Subjective well-being;
UCEC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.36	-5.81	-0.43	3.81e-8	Plasma homocysteine levels (post-methionine load test);
UCEC	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.61	-4.96	-0.38	1.91e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	7.89	0.55	6.23e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs28530618	0.500	rs7268275	chr20:31224015	C/T	cg13636640	chr20:31349939	DNMT3B	-0.56	-5.27	-0.4	4.67e-7	Birth weight;
UCEC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.73	-6.13	-0.45	7.74e-9	Menopause (age at onset);
UCEC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.68	8.83	0.59	2.96e-15	Multiple system atrophy;
UCEC	cis	rs6832769	1.000	rs3736544	chr4:56309992	A/G	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04731861	chr2:219085781	ARPC2	0.41	4.6	0.36	8.88e-6	Colorectal cancer;
UCEC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.88	7.22	0.51	2.64e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg02146966	chr17:18967117	NA	-0.74	-6.91	-0.5	1.38e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.72	-4.82	-0.37	3.6e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.75	-0.59	4.6e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg17330251	chr7:94953956	PON1	-0.57	-5.16	-0.39	7.97e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg13683864	chr3:40499215	RPL14	-0.57	-6.16	-0.45	6.76e-9	Renal cell carcinoma;
UCEC	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	0.93	6.99	0.5	9e-11	Obesity-related traits;
UCEC	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.47	4.89	0.37	2.59e-6	Vitiligo;
UCEC	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7106204	0.514	rs2083753	chr11:24255896	A/G	ch.11.24196551F	chr11:24239977	NA	0.54	5.7	0.43	6.49e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7246967	0.932	rs11882432	chr19:23029703	A/G	cg08271804	chr19:22816896	ZNF492	0.54	5.29	0.4	4.43e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.673	rs7245540	chr19:22881504	C/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.45	-4.66	-0.36	7.12e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.49	0.47	1.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs12973672	0.812	rs13345192	chr19:35756155	A/C	cg12095397	chr19:35769544	USF2	-0.48	-4.64	-0.36	7.75e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9341808	0.558	rs2322635	chr6:80897210	A/G	cg08355045	chr6:80787529	NA	0.41	5.1	0.39	1.02e-6	Sitting height ratio;
UCEC	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	IgM levels;
UCEC	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.73	7.45	0.52	7.25e-12	Breast cancer;
UCEC	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-4.72	-0.36	5.34e-6	Bladder cancer;
UCEC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.09	0.39	1.1e-6	Rheumatoid arthritis;
UCEC	cis	rs4372836	0.681	rs9309664	chr2:28939626	A/G	cg09522027	chr2:28974177	PPP1CB	0.51	5.22	0.4	5.98e-7	Body mass index;
UCEC	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.42	4.59	0.35	9.56e-6	Mean corpuscular volume;
UCEC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.06	-15.87	-0.79	1.13e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.74	-0.36	4.9e-6	Response to antipsychotic treatment;
UCEC	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.65	4.67	0.36	6.69e-6	Breast cancer;
UCEC	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.65	-6.96	-0.5	1.02e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6600233	0.874	rs11248850	chr16:163598	C/T	cg02353723	chr16:163133	C16orf35	-0.59	-6.69	-0.48	4.47e-10	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg11871910	chr12:69753446	YEATS4	1.06	13.39	0.74	3.05e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.76	6.98	0.5	9.41e-11	Response to diuretic therapy;
UCEC	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.61	6.51	0.47	1.11e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.62	-5.61	-0.42	9.6e-8	Type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.45	-5.16	-0.39	7.82e-7	Response to temozolomide;
UCEC	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.68	5.22	0.4	5.89e-7	Nonalcoholic fatty liver disease;
UCEC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.66	6.21	0.46	5.08e-9	Corneal astigmatism;
UCEC	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.45	5.51	0.41	1.58e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg26816564	chr1:7831052	VAMP3	0.77	5.25	0.4	5.29e-7	Inflammatory bowel disease;
UCEC	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.89	0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.42	4.53	0.35	1.19e-5	Longevity;Endometriosis;
UCEC	cis	rs17122693	0.551	rs2934681	chr14:51061491	C/T	cg04730355	chr14:51134070	SAV1	0.73	8.33	0.57	5.2e-14	Cognitive performance;
UCEC	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg18681998	chr4:17616180	MED28	-0.57	-6.69	-0.48	4.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.6	0.42	1.01e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs12634933	0.737	rs56781999	chr3:169031716	A/T	cg03603669	chr3:169896616	PHC3	-0.47	-4.62	-0.36	8.31e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg14196790	chr5:131705035	SLC22A5	0.49	5.35	0.4	3.33e-7	Blood metabolite levels;
UCEC	cis	rs3780378	0.967	rs7863219	chr9:5046548	A/C	cg02405213	chr9:5042618	JAK2	-0.47	-4.55	-0.35	1.14e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.55	5.57	0.42	1.17e-7	Schizophrenia;
UCEC	cis	rs9321099	1.000	rs34509171	chr6:128205563	A/T	cg25012434	chr6:128842125	PTPRK	0.71	4.84	0.37	3.25e-6	Sense of smell;
UCEC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	8.11	0.56	1.78e-13	Bone mineral density;
UCEC	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.48	-0.41	1.77e-7	Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.71	7.53	0.53	4.61e-12	Lymphocyte counts;
UCEC	cis	rs713477	1.000	rs2185036	chr14:55907710	A/G	cg13175173	chr14:55914753	NA	-0.41	-4.63	-0.36	8.04e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.64	6.39	0.47	2.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.34	0.71	1.81e-24	Platelet count;
UCEC	cis	rs829661	1.000	rs829661	chr2:30726691	T/C	cg17749961	chr2:30669863	LCLAT1	0.52	4.83	0.37	3.45e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.42	-5.62	-0.42	9.19e-8	Alcohol dependence;
UCEC	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg17259809	chr10:104614391	C10orf32	-0.68	-4.58	-0.35	9.92e-6	Arsenic metabolism;
UCEC	cis	rs9650657	0.737	rs2116095	chr8:10635297	T/C	cg00629382	chr8:10268916	MSRA	-0.45	-4.59	-0.35	9.46e-6	Neuroticism;
UCEC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.08	-15.93	-0.8	7.73e-34	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.68	6.98	0.5	9.48e-11	Body mass index;
UCEC	cis	rs78487399	0.908	rs73925553	chr2:43810646	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.5	-4.61	-0.36	8.69e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs6684428	0.614	rs11206680	chr1:56364414	A/G	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.54	-5.64	-0.42	8.38e-8	Type 2 diabetes;
UCEC	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.66	6.24	0.46	4.51e-9	Aortic root size;
UCEC	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs11867410	0.744	rs73338694	chr17:63983654	T/A	cg06996976	chr17:64576105	PRKCA	-0.72	-4.55	-0.35	1.13e-5	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg24674445	chr1:156076363	NA	0.49	4.58	0.35	9.99e-6	Ischemic stroke;
UCEC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24308560	chr3:49941425	MST1R	-0.5	-5.43	-0.41	2.32e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.48	-5.17	-0.39	7.45e-7	Menarche (age at onset);
UCEC	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.52	5.86	0.44	2.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.63	-0.36	8.14e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	7.59	0.53	3.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2806864	1.000	rs2250855	chr1:117462800	C/T	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.64	-0.36	7.65e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.81	-7.11	-0.51	4.71e-11	Neurofibrillary tangles;
UCEC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.26	0.51	2.12e-11	Smoking behavior;
UCEC	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-7.42	-0.52	8.88e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs8064454	1.000	rs11651755	chr17:36099840	A/G	cg20090283	chr17:36718549	SRCIN1	0.31	4.83	0.37	3.37e-6	Prostate cancer;
UCEC	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	6.99e-7	Aortic root size;
UCEC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.56	-6.08	-0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12311346	chr5:56204834	C5orf35	-0.59	-5.36	-0.4	3.17e-7	Type 2 diabetes;
UCEC	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Depression;
UCEC	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.58	-5.88	-0.44	2.64e-8	White matter hyperintensity burden;
UCEC	cis	rs7011507	0.545	rs10216585	chr8:49071490	A/G	ch.8.1073630F	chr8:48637817	KIAA0146	-0.51	-4.7	-0.36	5.97e-6	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.52	4.65	0.36	7.46e-6	Optic nerve measurement (cup area);
UCEC	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.72	6.6	0.48	7.16e-10	Alzheimer's disease;
UCEC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.71	6.15	0.45	6.91e-9	Cognitive function;
UCEC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg23018236	chr17:30244563	NA	-0.65	-4.67	-0.36	6.67e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg23950597	chr19:37808831	NA	-0.86	-6.2	-0.46	5.29e-9	Coronary artery calcification;
UCEC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.48	5.25	0.4	5.34e-7	Aortic root size;
UCEC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.55	5.89	0.44	2.46e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.72	7.78	0.54	1.19e-12	Lymphocyte counts;
UCEC	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.67	0.42	7.31e-8	Cognitive test performance;
UCEC	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.73	-7.91	-0.55	5.75e-13	Menarche (age at onset);
UCEC	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.71	-5.65	-0.42	7.88e-8	Type 2 diabetes;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.51	-5.64	-0.42	8.38e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.21	-0.39	6.32e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg17744295	chr19:16178097	TPM4	-0.62	-4.51	-0.35	1.34e-5	Pulse pressure;
UCEC	cis	rs11063421	1.000	rs11063421	chr12:5058393	T/C	cg14976741	chr12:4872921	GALNT8	-0.7	-4.93	-0.38	2.22e-6	Schizophrenia;
UCEC	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.64	4.95	0.38	2.04e-6	Prostate cancer;
UCEC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg19318889	chr4:1322082	MAEA	0.41	4.93	0.38	2.18e-6	Obesity-related traits;
UCEC	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg05855489	chr10:104503620	C10orf26	0.79	9.53	0.62	4.55e-17	Waist circumference;Hip circumference;
UCEC	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.92	0.5	1.3100000000000001e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs28787949	chr19:22830356	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg04871131	chr7:94954202	PON1	-0.52	-5.13	-0.39	9.07e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	5.15	0.39	8.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg19926144	chr10:661009	DIP2C	0.76	4.61	0.36	8.67e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs55670112	0.935	rs10055971	chr5:114276746	A/G	cg05461448	chr5:114880715	FEM1C	-0.44	-4.59	-0.35	9.62e-6	Epilepsy;
UCEC	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.9	0.59	1.86e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.57	6.5	0.47	1.18e-9	Hip circumference;
UCEC	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg17515076	chr17:73810948	UNK	-0.51	-5.66	-0.42	7.73e-8	White matter hyperintensity burden;
UCEC	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.71	0.43	6.04e-8	Joint mobility (Beighton score);
UCEC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.8	-7.7	-0.54	1.88e-12	Initial pursuit acceleration;
UCEC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.46	5.67	0.42	7.27e-8	Prostate cancer;
UCEC	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg01072550	chr1:21505969	NA	-0.63	-6.67	-0.48	4.74e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.43	-4.54	-0.35	1.18e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.87	-9.8	-0.63	9.04e-18	Cognitive function;
UCEC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-6.34	-0.46	2.66e-9	Longevity;Endometriosis;
UCEC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.52	-5.6	-0.42	1.03e-7	Menarche (age at onset);
UCEC	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.74	-6.03	-0.45	1.26e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11190179	0.744	rs11190170	chr10:101357717	G/C	cg14256752	chr10:102295592	HIF1AN	-0.74	-4.74	-0.36	4.9e-6	&beta2-Glycoprotein I (&beta;2-GPI) plasma levels;
UCEC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	1.07	5.04	0.38	1.38e-6	IgG glycosylation;
UCEC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.51	-5.66	-0.42	7.71e-8	Tonsillectomy;
UCEC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	5.13	0.39	9.21e-7	Monocyte percentage of white cells;
UCEC	cis	rs6882076	0.961	rs55776147	chr5:156400808	A/G	cg12943317	chr5:156479607	HAVCR1	-0.53	-5.57	-0.42	1.16e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs7302981	0.741	rs4459386	chr12:50594947	A/G	cg20014596	chr12:50898483	DIP2B	-0.48	-4.83	-0.37	3.42e-6	Systolic blood pressure;
UCEC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg20965017	chr5:231967	SDHA	-0.67	-5.87	-0.44	2.82e-8	Breast cancer;
UCEC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.69	-6.19	-0.45	5.8e-9	Corneal astigmatism;
UCEC	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs36051895	0.664	rs10815154	chr9:5095538	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-4.8	-0.37	3.89e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.03	-0.45	1.29e-8	Blood metabolite levels;
UCEC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.55	5.71	0.43	6.1e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.66	7.92	0.55	5.36e-13	Hip circumference;
UCEC	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg13777783	chr17:79615861	NA	-0.34	-4.71	-0.36	5.75e-6	Eye color traits;
UCEC	cis	rs295140	1.000	rs1367856	chr2:201160739	T/A	cg04283868	chr2:201171347	SPATS2L	0.53	5.23	0.4	5.64e-7	QT interval;
UCEC	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.26	-0.4	5e-7	Coronary artery disease;
UCEC	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.41	5.28	0.4	4.54e-7	Alcohol dependence;
UCEC	cis	rs6437061	0.745	rs3116165	chr2:232983050	C/T	cg02061626	chr2:233274167	ALPPL2	0.57	6.43	0.47	1.65e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.49	4.92	0.38	2.28e-6	Dupuytren's disease;
UCEC	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.7	-8.18	-0.56	1.24e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg01072550	chr1:21505969	NA	-0.6	-5.79	-0.43	4.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.5	0.53	5.49e-12	Bipolar disorder;
UCEC	cis	rs6840360	0.642	rs7676493	chr4:152426765	C/T	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs847649	1.000	rs1100046	chr7:102549295	T/A	cg18108683	chr7:102477205	FBXL13	-0.61	-7.87	-0.54	7.03e-13	Morning vs. evening chronotype;
UCEC	cis	rs7902334	1.000	rs7902334	chr10:12645941	A/C	cg00115178	chr10:12648176	CAMK1D	-0.77	-4.64	-0.36	7.56e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-4.94	-0.38	2.07e-6	Morning vs. evening chronotype;
UCEC	cis	rs7870753	0.838	rs10122900	chr9:99207540	C/T	cg25260653	chr9:99212216	HABP4	0.58	5.64	0.42	8.35e-8	Height;
UCEC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg01493522	chr13:37497338	NA	-0.45	-4.96	-0.38	1.96e-6	Coronary artery disease;
UCEC	cis	rs7267005	0.661	rs17093119	chr20:34423392	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	10.47	0.65	1.65e-19	Cognitive ability;
UCEC	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs10743315	0.643	rs16915128	chr12:19304286	G/T	cg02471346	chr12:19282374	PLEKHA5	-0.67	-4.66	-0.36	7.1e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	0.92	8.58	0.58	1.21e-14	Cognitive function;
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Depression;
UCEC	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg23950597	chr19:37808831	NA	0.63	4.9	0.37	2.52e-6	Coronary artery calcification;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04447216	chr19:53290205	ZNF600	0.57	6.78	0.49	2.66e-10	Warfarin maintenance dose;
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.16	-0.45	6.74e-9	Cardiac Troponin-T levels;
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.52	0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.41	-4.66	-0.36	7.1e-6	Lung cancer;
UCEC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.71	-6.26	-0.46	4e-9	Initial pursuit acceleration;
UCEC	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.59	0.53	3.42e-12	Menopause (age at onset);
UCEC	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-4.99	-0.38	1.71e-6	Crohn's disease;
UCEC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.67	7.35	0.52	1.27e-11	Menopause (age at onset);
UCEC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.15	-0.45	7.05e-9	Chronic sinus infection;
UCEC	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs12980942	0.872	rs66724427	chr19:41776257	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.64	5.67	0.42	7.47e-8	Coronary artery disease;
UCEC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-4.6	-0.35	9.21e-6	Menarche (age at onset);
UCEC	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.47	-4.87	-0.37	2.8e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.41	0.52	9.12e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	0.87	8.32	0.57	5.49e-14	Breast cancer;
UCEC	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg18479299	chr3:125709523	NA	-0.65	-4.5	-0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	9.89e-16	Menopause (age at onset);
UCEC	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.87	7.28	0.51	1.83e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.14	-0.45	7.44e-9	Birth weight;
UCEC	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.24	0.65	6.66e-19	Electrocardiographic conduction measures;
UCEC	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.58	-5.02	-0.38	1.49e-6	Neuroticism;
UCEC	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9831754	0.704	rs9823412	chr3:78457646	T/C	cg06138941	chr3:78371609	NA	-0.68	-5.05	-0.38	1.31e-6	Calcium levels;
UCEC	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.62	-5.64	-0.42	8.35e-8	Response to zileuton treatment in asthma (FEV1 change interaction);
UCEC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg16989719	chr2:238392110	NA	-0.42	-5.9	-0.44	2.44e-8	Prostate cancer;
UCEC	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.27	-0.4	4.72e-7	Blood metabolite levels;
UCEC	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.58	5.98	0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs12365397	0.775	rs1874435	chr11:43246675	A/G	cg07515919	chr11:43391688	TTC17	-0.46	-4.67	-0.36	6.7e-6	Migraine;
UCEC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-9.56	-0.62	3.86e-17	Cognitive function;
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	4.7	0.36	6.02e-6	Obesity-related traits;
UCEC	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-5.08	-0.39	1.13e-6	Blood metabolite levels;
UCEC	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.51	4.77	0.37	4.43e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg13870426	chr17:30244630	NA	-0.64	-4.7	-0.36	5.85e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6793245	0.845	rs4073797	chr3:38590850	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-5.18	-0.39	7.23e-7	QT interval;
UCEC	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.8	8.0	0.55	3.42e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.5	5.22	0.4	5.92e-7	Schizophrenia;
UCEC	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.61	5.49	0.41	1.7e-7	Corneal astigmatism;
UCEC	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg17652424	chr22:38574118	PLA2G6	-0.42	-5.25	-0.4	5.29e-7	Cutaneous nevi;
UCEC	cis	rs892864	0.685	rs7720440	chr5:127767975	C/A	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-0.97	-4.61	-0.36	8.61e-6	Mitochondrial DNA levels;
UCEC	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.39	4.71	0.36	5.76e-6	Refractive error;
UCEC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.56	6.11	0.45	8.32e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.67	-7.53	-0.53	4.8e-12	Menarche (age at onset);
UCEC	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.44	4.57	0.35	1.03e-5	Endometrial cancer;
UCEC	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.46	6.52	0.47	1.04e-9	Metabolite levels;
UCEC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.54	5.15	0.39	8.35e-7	Blood metabolite levels;
UCEC	cis	rs7709377	0.570	rs4921063	chr5:115446146	G/T	cg23108291	chr5:115420582	COMMD10	0.51	5.27	0.4	4.86e-7	Metabolite levels  (X-11787);
UCEC	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.02	0.44	1.35e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.69	7.12	0.51	4.45e-11	Left atrial antero-posterior diameter;
UCEC	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.18	-0.39	7.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg09120320	chr17:61926383	NA	0.44	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.53	-5.88	-0.44	2.69e-8	Pubertal anthropometrics;
UCEC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18252515	chr7:66147081	NA	-0.55	-5.17	-0.39	7.38e-7	Aortic root size;
UCEC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.69	0.36	6.22e-6	Tonsillectomy;
UCEC	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.28	10.85	0.67	1.63e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.46	5.03	0.38	1.41e-6	Coronary artery disease;
UCEC	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs10242455	0.681	rs1851425	chr7:99300231	G/A	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.29e-6	Blood metabolite levels;
UCEC	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.73	-5.99	-0.44	1.52e-8	Coronary artery calcification;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.73	-0.43	5.55e-8	Pulmonary function;
UCEC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.55	5.72	0.43	5.76e-8	Prostate cancer;
UCEC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.43	5.02	0.38	1.48e-6	Prostate cancer;
UCEC	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.17	0.45	6.43e-9	Rheumatoid arthritis;
UCEC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.64	6.21	0.46	5.22e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.932	rs34897621	chr19:23027527	A/C	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs12410462	0.710	rs74140145	chr1:227423946	C/T	cg12615916	chr1:227505854	CDC42BPA	0.62	5.43	0.41	2.27e-7	Major depressive disorder;
UCEC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg01256987	chr12:42539512	GXYLT1	-0.43	-4.84	-0.37	3.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	0.94	5.75	0.43	4.97e-8	Skin colour saturation;
UCEC	cis	rs4588572	0.643	rs10942857	chr5:77760241	A/G	cg11547950	chr5:77652471	NA	-0.49	-5.55	-0.42	1.3e-7	Triglycerides;
UCEC	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.51	-5.45	-0.41	2.12e-7	Pulse pressure;
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.58	-5.95	-0.44	1.92e-8	Parkinson's disease;
UCEC	cis	rs3015497	0.789	rs3015500	chr14:51108877	C/T	cg04730355	chr14:51134070	SAV1	-0.55	-5.83	-0.43	3.35e-8	Mean platelet volume;
UCEC	cis	rs925228	1.000	rs2339938	chr2:24234974	C/T	cg16945982	chr2:25016118	CENPO;C2orf79	-0.58	-5.24	-0.4	5.5e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs17824620	0.548	rs79113984	chr12:113118535	G/A	cg26711794	chr12:112450906	ERP29;TMEM116	0.58	4.61	0.36	8.58e-6	Platelet count;
UCEC	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.34	-0.4	3.49e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg26061582	chr7:22766209	IL6	0.61	5.74	0.43	5.2e-8	Lung cancer;
UCEC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.55	0.62	4.18e-17	Menopause (age at onset);
UCEC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.86	0.44	2.88e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.82	-8.39	-0.57	3.78e-14	Caffeine consumption;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25018755	chr22:43506952	BIK	0.53	6.75	0.49	3.21e-10	Warfarin maintenance dose;
UCEC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.17	19.04	0.84	1.62e-41	Testicular germ cell tumor;
UCEC	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.25	0.56	8.05e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.53	4.99	0.38	1.7e-6	Menopause (age at onset);
UCEC	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg02980000	chr4:1222292	CTBP1	0.6	4.77	0.37	4.42e-6	Systolic blood pressure;
UCEC	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.55e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg11569703	chr11:65557185	OVOL1	-0.42	-5.99	-0.44	1.58e-8	Acne (severe);
UCEC	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.78	11.31	0.68	9.94e-22	Leprosy;
UCEC	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.73	-6.33	-0.46	2.79e-9	Adiposity;
UCEC	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.47	4.78	0.37	4.19e-6	Prostate cancer;
UCEC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.48	5.39	0.41	2.74e-7	Total body bone mineral density;
UCEC	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-0.51	-4.72	-0.36	5.38e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.9	-9.89	-0.63	5.5e-18	Obesity-related traits;
UCEC	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.27	-0.65	5.62e-19	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg04310649	chr10:35416472	CREM	-0.49	-4.9	-0.37	2.47e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.09e-17	Heart rate;
UCEC	cis	rs12753816	0.830	rs1830495	chr1:169147373	A/G	cg03848065	chr1:168212210	NA	0.37	4.63	0.36	8.01e-6	Coronary artery disease;
UCEC	cis	rs2120243	0.845	rs2316710	chr3:157150180	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.67	0.36	6.71e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18252515	chr7:66147081	NA	0.55	5.12	0.39	9.39e-7	Aortic root size;
UCEC	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.6	-6.45	-0.47	1.56e-9	Motion sickness;
UCEC	cis	rs7004769	0.554	rs922269	chr8:9169154	A/G	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26398333	chr1:153895721	GATAD2B	0.67	8.25	0.56	8.03e-14	Warfarin maintenance dose;
UCEC	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.5	-4.54	-0.35	1.18e-5	Diabetic retinopathy;
UCEC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg13092806	chr2:177043255	NA	0.57	5.38	0.41	2.89e-7	IgG glycosylation;
UCEC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-6.32	-0.46	2.98e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg22166914	chr1:53195759	ZYG11B	0.68	7.28	0.52	1.81e-11	Monocyte count;
UCEC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.71	-8.31	-0.57	5.69e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.71	6.37	0.47	2.3e-9	Subjective well-being;
UCEC	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7638909	0.512	rs11720166	chr3:38599812	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-4.9	-0.37	2.52e-6	Electrocardiographic conduction measures;
UCEC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.48	-4.81	-0.37	3.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.47	-5.5	-0.41	1.63e-7	Aortic root size;
UCEC	cis	rs420259	0.516	rs2106458	chr16:23531431	G/A	cg26562691	chr16:23850404	PRKCB	-0.34	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.14	0.45	7.24e-9	Platelet count;
UCEC	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.52	-4.79	-0.37	4.11e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs3862260	0.967	rs3862261	chr1:120160822	G/A	cg17939831	chr1:119836654	NA	-0.53	-5.26	-0.4	4.99e-7	Systemic lupus erythematosus;
UCEC	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-6.08	-0.45	9.87e-9	Rheumatoid arthritis;
UCEC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.7	-7.38	-0.52	1.06e-11	Immature fraction of reticulocytes;
UCEC	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.45	-0.47	1.56e-9	Crohn's disease;
UCEC	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.77	6.83	0.49	2.11e-10	Breast cancer;
UCEC	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.49	-7.13	-0.51	4.11e-11	Rheumatoid arthritis;
UCEC	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.68	7.18	0.51	3.16e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.18e-6	Vitiligo;
UCEC	cis	rs992037	0.641	rs6455737	chr6:162039061	C/T	cg10395920	chr6:161285175	NA	-0.45	-4.82	-0.37	3.55e-6	Metabolite levels;
UCEC	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg19920283	chr7:105172520	RINT1	0.51	4.54	0.35	1.16e-5	Bipolar disorder (body mass index interaction);
UCEC	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.6	5.65	0.42	8.05e-8	Corneal astigmatism;
UCEC	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg25019722	chr6:37503610	NA	-0.31	-4.75	-0.37	4.7e-6	Cognitive performance;
UCEC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.71	-5.86	-0.44	2.87e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg01262667	chr19:19385393	TM6SF2	0.5	6.97	0.5	9.7e-11	Tonsillectomy;
UCEC	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.51	-5.09	-0.39	1.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.64	-0.36	7.63e-6	Type 2 diabetes;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-4.53	-0.35	1.21e-5	Morning vs. evening chronotype;
UCEC	cis	rs7246967	0.932	rs62120772	chr19:23037151	G/C	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.51	-4.76	-0.37	4.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	6.5	0.47	1.15e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.45	-5.15	-0.39	8.16e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.62	4.96	0.38	1.89e-6	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.45	-5.01	-0.38	1.57e-6	Testicular germ cell tumor;
UCEC	cis	rs3790645	1.000	rs364977	chr1:26893836	G/A	cg17456097	chr1:26900765	RPS6KA1	0.48	4.57	0.35	1.03e-5	Glucose homeostasis traits;
UCEC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.56e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.41	-5.07	-0.39	1.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.59	0.42	1.07e-7	Birth weight;
UCEC	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.46	5.29	0.4	4.35e-7	Blood metabolite ratios;
UCEC	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg08886695	chr4:3369023	RGS12	-0.5	-5.39	-0.41	2.72e-7	Serum sulfate level;
UCEC	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.57	-5.36	-0.4	3.11e-7	High light scatter reticulocyte count;
UCEC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg00614314	chr15:82944287	LOC80154	0.54	4.91	0.38	2.41e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.69	-7.91	-0.55	5.64e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.65	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	6.96	0.5	1.03e-10	Initial pursuit acceleration;
UCEC	cis	rs7072216	0.770	rs7896828	chr10:100170507	A/T	cg19567339	chr10:100142640	NA	0.55	6.52	0.47	1.05e-9	Metabolite levels;
UCEC	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.74	7.78	0.54	1.17e-12	Breast cancer;
UCEC	cis	rs11088226	0.692	rs8127603	chr21:33886658	T/C	cg03366312	chr21:34388564	NA	-0.33	-4.61	-0.36	8.51e-6	Gastritis;
UCEC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.57	6.17	0.45	6.35e-9	Cognitive function;
UCEC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.78	-6.21	-0.46	5.26e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.75	8.41	0.57	3.38e-14	Coronary artery disease;
UCEC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.82	6.18	0.45	5.89e-9	White matter hyperintensity burden;
UCEC	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.84	-5.87	-0.44	2.76e-8	Coronary artery calcification;
UCEC	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.77	-9.1	-0.6	5.99e-16	Obesity-related traits;
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.8	11.33	0.68	8.62e-22	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-20.74	-0.86	1.68e-45	Myeloid white cell count;
UCEC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-6.16	-0.45	6.53e-9	Tonsillectomy;
UCEC	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06766273	chr11:62521983	ZBTB3	0.59	7.24	0.51	2.37e-11	Warfarin maintenance dose;
UCEC	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.26	-14.56	-0.77	2.74e-30	Type 1 diabetes nephropathy;
UCEC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.42e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9470794	1.000	rs56348433	chr6:38004992	T/C	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.59	-5.04	-0.38	1.32e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	0.86	6.28	0.46	3.67e-9	Left atrial antero-posterior diameter;
UCEC	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg11150807	chr10:43354902	NA	-0.75	-4.71	-0.36	5.68e-6	Blood protein levels;
UCEC	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg26114124	chr12:9217669	LOC144571	0.41	5.06	0.38	1.25e-6	Sjögren's syndrome;
UCEC	cis	rs4499344	0.657	rs259238	chr19:33140381	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	5.73	0.43	5.51e-8	Mean platelet volume;
UCEC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.61	-6.1	-0.45	8.83e-9	Blood metabolite levels;
UCEC	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.46	4.54	0.35	1.17e-5	Aortic root size;
UCEC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.52	-5.77	-0.43	4.56e-8	Refractive error;
UCEC	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.54	-5.5	-0.41	1.66e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.79	-9.75	-0.63	1.24e-17	White blood cell count (basophil);
UCEC	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-6.04	-0.45	1.21e-8	Monocyte percentage of white cells;
UCEC	cis	rs4499344	0.730	rs369859	chr19:33104305	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.96	0.44	1.75e-8	Mean platelet volume;
UCEC	cis	rs939574	0.512	rs908197	chr2:220144410	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.61	5.26	0.4	4.9e-7	Platelet distribution width;
UCEC	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.51	-4.63	-0.36	7.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.57	0.35	1.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7705819	0.955	rs11134802	chr5:172882963	T/G	cg14746387	chr5:172879299	NA	0.47	4.9	0.37	2.55e-6	Stroke;
UCEC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.84	-0.43	3.29e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg05874882	chr4:1763078	NA	-0.66	-6.25	-0.46	4.26e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.4	-4.73	-0.36	5.12e-6	Urinary metabolites;
UCEC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs2892463	0.796	rs6490429	chr13:30367047	G/A	cg18356743	chr13:30408050	UBL3	-0.41	-4.61	-0.36	8.85e-6	Non-word repetition;
UCEC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.47	4.86	0.37	2.96e-6	Blood protein levels;
UCEC	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.69	-6.71	-0.48	3.92e-10	Platelet distribution width;
UCEC	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.58	6.75	0.49	3.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-4.58	-0.35	9.87e-6	Headache;
UCEC	cis	rs2708977	0.637	rs687950	chr2:97069612	C/G	cg22654517	chr2:96458247	NA	-0.45	-5.75	-0.43	5.02e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.14	-14.6	-0.77	2.06e-30	Schizophrenia;
UCEC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg03539765	chr12:9217390	LOC144571	0.41	4.83	0.37	3.41e-6	Sjögren's syndrome;
UCEC	cis	rs13098911	0.540	rs17214952	chr3:46011436	A/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.64	5.78	0.43	4.41e-8	Platelet count;
UCEC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.62	7.01	0.5	7.95e-11	Tonsillectomy;
UCEC	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.38	4.58	0.35	9.64e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-13.35	-0.74	3.95e-27	Body mass index;
UCEC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.57	-4.73	-0.36	5.12e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg02160872	chr5:212506	CCDC127	-0.7	-6.88	-0.49	1.59e-10	Breast cancer;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.58	-0.35	9.86e-6	Pubertal anthropometrics;
UCEC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.89	-9.48	-0.62	6.41e-17	Homoarginine levels;
UCEC	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.7	-5.58	-0.42	1.11e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-5.44	-0.41	2.22e-7	Alcohol dependence;
UCEC	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs12428035	0.764	rs72637836	chr13:96738627	G/T	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs758129	0.501	rs2307449	chr15:89863928	G/T	cg23124613	chr15:89731485	ABHD2	0.41	4.73	0.36	5.24e-6	Schizophrenia;
UCEC	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.59	-5.95	-0.44	1.89e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.81	0.37	3.66e-6	Platelet count;
UCEC	cis	rs3772130	0.560	rs7649585	chr3:121562300	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.66	0.53	2.26e-12	Bipolar disorder;
UCEC	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.48	5.54	0.42	1.36e-7	QRS complex (12-leadsum);
UCEC	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.78	5.55	0.42	1.28e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.64	5.05	0.38	1.31e-6	Cocaine dependence;
UCEC	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.49	-4.7	-0.36	5.81e-6	Bipolar disorder;
UCEC	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.5	-6.97	-0.5	9.9e-11	Sense of smell;
UCEC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-0.76	-7.19	-0.51	3.09e-11	Breast cancer;
UCEC	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.55	-5.66	-0.42	7.52e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg06462663	chr19:18546047	ISYNA1	0.53	6.73	0.49	3.58e-10	Breast cancer;
UCEC	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.4	4.84	0.37	3.22e-6	Subjective well-being;
UCEC	cis	rs8177876	0.822	rs4306521	chr16:81114893	T/C	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	0.9	11.04	0.67	5.07e-21	Eosinophil percentage of white cells;
UCEC	cis	rs34486957	0.600	rs12897732	chr14:60046827	T/C	cg12189551	chr14:60952945	C14orf39	0.36	4.53	0.35	1.2e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-4.71	-0.36	5.76e-6	Joint mobility (Beighton score);
UCEC	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.13	0.39	9.04e-7	IgG glycosylation;
UCEC	cis	rs1576263	0.967	rs162282	chr6:8553033	T/A	cg21535247	chr6:8435926	SLC35B3	0.49	4.97	0.38	1.84e-6	Photic sneeze reflex;
UCEC	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.55	-4.93	-0.38	2.21e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.12	-7.58	-0.53	3.64e-12	Diabetic kidney disease;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.46	-5.05	-0.38	1.31e-6	Depression;
UCEC	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.6	-6.13	-0.45	7.71e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-4.59	-0.35	9.25e-6	Bipolar disorder;
UCEC	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.59	8.39	0.57	3.69e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.77	-7.97	-0.55	3.96e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	trans	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg15509575	chr4:2286509	ZFYVE28	0.43	7.64	0.53	2.52e-12	Rheumatoid arthritis;
UCEC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.84	11.67	0.69	1.11e-22	Vitiligo;
UCEC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.94	-10.78	-0.66	2.55e-20	Cognitive function;
UCEC	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17467752	chr17:38218738	THRA	-0.48	-4.81	-0.37	3.63e-6	Asthma and hay fever;
UCEC	cis	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg17469321	chr7:55412551	NA	0.68	5.98	0.44	1.65e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-12.7	-0.72	2.12e-25	Height;
UCEC	cis	rs2901381	0.701	rs13095581	chr3:168822752	C/T	cg21477417	chr3:169490753	MYNN	-0.56	-4.62	-0.36	8.17e-6	Plateletcrit;
UCEC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.53	0.47	9.92e-10	Menarche (age at onset);
UCEC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.45	6.11	0.45	8.46e-9	Bone mineral density;
UCEC	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.65	0.48	5.34e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.56	5.06	0.39	1.23e-6	Crohn's disease;
UCEC	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.17	0.45	6.3e-9	Aortic root size;
UCEC	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.66	-4.79	-0.37	4.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.87	-10.91	-0.67	1.11e-20	Brugada syndrome;
UCEC	cis	rs1595825	0.891	rs7584475	chr2:198577424	A/C	cg19156104	chr2:198669113	PLCL1	-0.63	-4.55	-0.35	1.12e-5	Ulcerative colitis;
UCEC	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.38	5.19	0.39	6.81e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.72	8.46	0.57	2.43e-14	Menarche (age at onset);
UCEC	cis	rs7072216	0.687	rs11189586	chr10:100154096	A/G	cg19567339	chr10:100142640	NA	0.57	7.32	0.52	1.5e-11	Metabolite levels;
UCEC	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-6.52	-0.47	1.07e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.44	5.29	0.4	4.29e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.21	-9.55	-0.62	4e-17	Hip circumference adjusted for BMI;
UCEC	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.92	7.2	0.51	2.95e-11	Gastritis;
UCEC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.92	-10.53	-0.66	1.11e-19	Cognitive function;
UCEC	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.48	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.68	6.02	0.44	1.34e-8	Schizophrenia;
UCEC	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.65	-6.82	-0.49	2.21e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.73	-7.74	-0.54	1.47e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.45	4.91	0.38	2.4e-6	HDL cholesterol;
UCEC	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.69	5.05	0.38	1.3e-6	Mean platelet volume;
UCEC	cis	rs10411936	1.000	rs11878602	chr19:16555153	A/C	cg08200625	chr19:17001002	F2RL3	0.34	4.55	0.35	1.1e-5	White blood cell count;Multiple sclerosis;
UCEC	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-0.77	-6.84	-0.49	2.03e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg14008862	chr17:28927542	LRRC37B2	0.61	5.05	0.38	1.32e-6	Body mass index;
UCEC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg04804543	chr8:142233427	SLC45A4	0.46	5.7	0.43	6.31e-8	Immature fraction of reticulocytes;
UCEC	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.54	5.53	0.41	1.42e-7	Bipolar disorder;
UCEC	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-1.0	-12.2	-0.71	4.4e-24	Obesity-related traits;
UCEC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.97	-0.38	1.82e-6	Immature fraction of reticulocytes;
UCEC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.33	0.46	2.84e-9	Aortic root size;
UCEC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.46	-5.07	-0.39	1.17e-6	Fibrinogen levels;
UCEC	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.01	0.5	7.99e-11	Morning vs. evening chronotype;
UCEC	cis	rs295140	0.805	rs11890234	chr2:201206706	C/T	cg04283868	chr2:201171347	SPATS2L	0.55	5.46	0.41	1.97e-7	QT interval;
UCEC	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg22166914	chr1:53195759	ZYG11B	0.63	6.67	0.48	4.88e-10	Monocyte count;
UCEC	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	5.05	0.38	1.3e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.43	-4.91	-0.38	2.37e-6	Bipolar disorder;
UCEC	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.51	-5.05	-0.38	1.29e-6	Total body bone mineral density;
UCEC	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg17063962	chr7:91808500	NA	0.77	7.69	0.54	1.99e-12	Breast cancer;
UCEC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.51	5.02	0.38	1.49e-6	Longevity;
UCEC	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg08493051	chr2:3487164	NA	-0.58	-5.7	-0.43	6.26e-8	Neurofibrillary tangles;
UCEC	cis	rs7246967	0.673	rs7250620	chr19:22853126	A/T	cg24889512	chr19:22816950	ZNF492	0.58	6.26	0.46	4.02e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg05991184	chr2:219186017	PNKD	0.53	5.86	0.43	2.98e-8	Colorectal cancer;
UCEC	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.69	6.7	0.48	4.15e-10	Schizophrenia;
UCEC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.81	7.9	0.55	6.17e-13	Cognitive function;
UCEC	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.39	-0.47	2.09e-9	Crohn's disease;
UCEC	cis	rs1866631	1.000	rs1866631	chr2:174075761	G/A	cg08754268	chr2:173809244	RAPGEF4	-0.38	-4.51	-0.35	1.33e-5	Lung cancer in ever smokers;
UCEC	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.74	-5.24	-0.4	5.54e-7	Body mass index;
UCEC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg00334056	chr6:33755658	LEMD2	-0.43	-4.64	-0.36	7.6e-6	Crohn's disease;
UCEC	cis	rs2998286	0.723	rs332190	chr10:28919828	C/T	cg07964848	chr10:28035894	MKX	0.59	4.5	0.35	1.36e-5	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
UCEC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg03609598	chr5:56110824	MAP3K1	-0.63	-5.33	-0.4	3.69e-7	Coronary artery disease;
UCEC	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg21191810	chr6:118973309	C6orf204	0.41	5.67	0.42	7.27e-8	Electrocardiographic conduction measures;
UCEC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.49	-4.72	-0.36	5.55e-6	Prudent dietary pattern;
UCEC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.47	-5.55	-0.42	1.32e-7	Bipolar disorder;
UCEC	cis	rs12618769	0.625	rs56232707	chr2:99032298	G/A	cg14361474	chr2:99058762	NA	-0.48	-4.77	-0.37	4.31e-6	Bipolar disorder;
UCEC	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.51	-4.78	-0.37	4.21e-6	Prostate cancer;
UCEC	cis	rs8005745	0.614	rs2301108	chr14:62197464	C/T	cg01748970	chr14:62088363	NA	0.61	5.69	0.43	6.57e-8	Select biomarker traits;
UCEC	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.72	-7.81	-0.54	9.81e-13	Facial morphology (factor 19);
UCEC	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-13.65	-0.75	6.44e-28	Schizophrenia;
UCEC	cis	rs11958404	0.789	rs72818145	chr5:157476552	G/C	cg05962755	chr5:157440814	NA	0.78	5.52	0.41	1.47e-7	IgG glycosylation;
UCEC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg06466757	chr4:1255808	NA	0.46	4.79	0.37	3.97e-6	Obesity-related traits;
UCEC	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	8.33	0.57	5.21e-14	Ulcerative colitis;
UCEC	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.49	-0.57	2.06e-14	Blood trace element (Zn levels);
UCEC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.66	0.36	7e-6	Schizophrenia;
UCEC	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg13206674	chr6:150067644	NUP43	0.53	5.22	0.4	6e-7	Lung cancer;
UCEC	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.5	0.62	5.51e-17	Alzheimer's disease;
UCEC	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.61	-5.3	-0.4	4.21e-7	Response to diuretic therapy;
UCEC	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg01112020	chr2:239008986	ESPNL	-0.36	-4.75	-0.36	4.8e-6	Prostate cancer;
UCEC	cis	rs2386661	0.826	rs2386651	chr10:5678031	C/A	cg17085576	chr10:5658249	NA	-0.49	-4.87	-0.37	2.91e-6	Breast cancer;
UCEC	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.26	9.82	0.63	8.27e-18	Uric acid levels;
UCEC	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.52	5.1	0.39	1.02e-6	Dilated cardiomyopathy;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg16130600	chr7:120590585	ING3	-0.75	-6.76	-0.49	3.09e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.34	-0.4	3.41e-7	Blood metabolite levels;
UCEC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.79	7.59	0.53	3.32e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg20399509	chr21:47717575	C21orf57	-0.46	-4.9	-0.37	2.47e-6	Testicular germ cell tumor;
UCEC	cis	rs4372836	1.000	rs7579277	chr2:28996295	G/A	cg09522027	chr2:28974177	PPP1CB	-0.61	-6.46	-0.47	1.41e-9	Body mass index;
UCEC	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.8	8.92	0.59	1.71e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg21419209	chr3:44054225	NA	-0.46	-4.81	-0.37	3.67e-6	Coronary artery disease;
UCEC	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.62	5.56	0.42	1.23e-7	Morning vs. evening chronotype;
UCEC	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg09165964	chr15:75287851	SCAMP5	-0.55	-5.68	-0.42	6.87e-8	Lung cancer;
UCEC	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.78	-6.81	-0.49	2.37e-10	Caudate activity during reward;
UCEC	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.54	0.42	1.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.52	4.75	0.36	4.75e-6	Uric acid levels;
UCEC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.26	0.51	2.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	7.01	0.5	7.98e-11	Platelet count;
UCEC	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18252515	chr7:66147081	NA	0.46	4.69	0.36	6.27e-6	Aortic root size;
UCEC	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	8.5	0.57	1.95e-14	Coffee consumption (cups per day);
UCEC	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.47	5.09	0.39	1.08e-6	Headache;
UCEC	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg17800788	chr1:21766015	NBPF3	0.37	5.34	0.4	3.44e-7	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-5.2	-0.39	6.68e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.5	-4.99	-0.38	1.65e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg18681998	chr4:17616180	MED28	0.52	5.89	0.44	2.58e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.46	-4.91	-0.38	2.36e-6	Longevity;
UCEC	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.72	0.36	5.53e-6	Myopia (pathological);
UCEC	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.51	-5.24	-0.4	5.57e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.57	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.45	5.01	0.38	1.54e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.56	0.35	1.06e-5	Breast cancer;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.65	7.22	0.51	2.62e-11	Menarche (age at onset);
UCEC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg14008862	chr17:28927542	LRRC37B2	0.88	4.71	0.36	5.74e-6	Body mass index;
UCEC	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.78	8.77	0.59	4.07e-15	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.67	7.65	0.53	2.38e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.17e-21	Breast cancer;
UCEC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.64	-5.88	-0.44	2.7e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.51	-4.65	-0.36	7.31e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg13575925	chr12:9217583	LOC144571	0.42	4.96	0.38	1.92e-6	Sjögren's syndrome;
UCEC	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	0.84	5.8	0.43	3.95e-8	Mitochondrial DNA levels;
UCEC	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg22563815	chr15:78856949	CHRNA5	0.38	4.83	0.37	3.37e-6	Sudden cardiac arrest;
UCEC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-5.08	-0.39	1.12e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.55	5.93	0.44	2.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.11	-20.13	-0.86	4.39e-44	IgG glycosylation;
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.59	6.81	0.49	2.31e-10	Menarche (age at onset);
UCEC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg26513180	chr16:89883248	FANCA	-0.45	-4.72	-0.36	5.46e-6	Vitiligo;
UCEC	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.36	4.59	0.35	9.35e-6	Renal cell carcinoma;
UCEC	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-4.68	-0.36	6.49e-6	Height;
UCEC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.3	4.55	0.35	1.09e-5	Schizophrenia;
UCEC	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg14092571	chr14:90743983	NA	0.38	4.83	0.37	3.43e-6	Mortality in heart failure;
UCEC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.57	-4.81	-0.37	3.63e-6	Menarche (age at onset);
UCEC	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.46	-0.52	6.88e-12	Resting heart rate;
UCEC	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.61	5.49	0.41	1.7e-7	Corneal astigmatism;
UCEC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.7	-0.43	6.35e-8	Breast cancer;
UCEC	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.48	5.31	0.4	3.92e-7	Response to temozolomide;
UCEC	cis	rs7246967	0.604	rs8107322	chr19:22897432	A/C	cg05241461	chr19:22816980	ZNF492	0.57	6.07	0.45	1.03e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	6.81e-9	Aortic root size;
UCEC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg04804543	chr8:142233427	SLC45A4	-0.5	-5.99	-0.44	1.58e-8	Immature fraction of reticulocytes;
UCEC	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.65	6.37	0.47	2.23e-9	Bladder cancer;
UCEC	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs7113850	0.541	rs7933381	chr11:24237534	T/C	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14159747	chr11:113255604	NA	0.7	9.37	0.61	1.22e-16	Neuroticism;
UCEC	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.85	0.49	1.87e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg06784218	chr1:46089804	CCDC17	0.42	4.68	0.36	6.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	1.000	rs9467802	chr6:26581168	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg01262667	chr19:19385393	TM6SF2	0.5	7.02	0.5	7.51e-11	Tonsillectomy;
UCEC	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.59	-5.29	-0.4	4.39e-7	Colorectal cancer;
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs2885221	chr19:22839387	A/G	cg08271804	chr19:22816896	ZNF492	0.66	6.54	0.47	9.68e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	6.97	0.5	9.86e-11	Chronic sinus infection;
UCEC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.83	8.14	0.56	1.5700000000000001e-13	Smoking behavior;
UCEC	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.75	-5.49	-0.41	1.71e-7	Narcolepsy;
UCEC	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.95	8.55	0.58	1.45e-14	Diastolic blood pressure;
UCEC	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.42	-4.57	-0.35	1.01e-5	C-reactive protein levels;
UCEC	cis	rs57709857	0.801	rs10105555	chr8:38104081	T/C	cg08167846	chr8:38212404	WHSC1L1	0.47	4.61	0.36	8.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.22	0.4	6e-7	Tonsillectomy;
UCEC	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.64	5.61	0.42	9.65e-8	Aortic root size;
UCEC	cis	rs7781557	0.640	rs6964296	chr7:102572942	C/T	cg06322601	chr7:102330635	NA	0.55	4.52	0.35	1.25e-5	Colorectal adenoma (advanced);
UCEC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg06096015	chr1:231504339	EGLN1	0.47	5.46	0.41	1.94e-7	Hemoglobin concentration;
UCEC	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg18016565	chr1:150552671	MCL1	-0.56	-5.99	-0.44	1.56e-8	Tonsillectomy;
UCEC	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.14e-7	Body mass index;
UCEC	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	0.97	7.86	0.54	7.35e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.67	-5.26	-0.4	5.04e-7	Chronic sinus infection;
UCEC	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg06157570	chr12:6886703	LAG3	0.51	5.12	0.39	9.63e-7	HDL cholesterol levels;
UCEC	cis	rs1978968	1.000	rs5992926	chr22:18449876	A/G	cg03078520	chr22:18463400	MICAL3	-0.52	-5.19	-0.39	6.99e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.42	-4.96	-0.38	1.94e-6	Lung cancer;
UCEC	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.48	-5.02	-0.38	1.49e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3752645	1.000	rs6960708	chr7:106777203	A/G	cg24384195	chr7:106505370	PIK3CG	-0.45	-4.55	-0.35	1.1e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.95	8.79	0.59	3.58e-15	Diastolic blood pressure;
UCEC	cis	rs7870753	0.838	rs7037607	chr9:99244798	G/A	cg25260653	chr9:99212216	HABP4	0.58	5.85	0.43	3.1e-8	Height;
UCEC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04476341	chr5:669733	TPPP	0.39	4.64	0.36	7.68e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.0	-0.44	1.43e-8	Blood metabolite levels;
UCEC	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-7.06	-0.5	6.18e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.56	-4.85	-0.37	3.14e-6	Obesity-related traits;
UCEC	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.63	7.61	0.53	3.08e-12	Mean platelet volume;
UCEC	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-5.37	-0.4	3.03e-7	Life satisfaction;
UCEC	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.81	-0.43	3.74e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.73	-4.81	-0.37	3.75e-6	LDL cholesterol levels;
UCEC	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.55	6.89	0.49	1.56e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7088591	0.867	rs73292706	chr10:59786967	T/G	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.29	-0.46	3.4e-9	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.66	-7.09	-0.5	5.16e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2200578	1.000	rs72961173	chr2:99886868	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.8	5.95	0.44	1.92e-8	IgG glycosylation;
UCEC	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.6	4.58	0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg10932868	chr11:921992	NA	0.45	5.91	0.44	2.35e-8	Alzheimer's disease (late onset);
UCEC	cis	rs12234571	1.000	rs59056139	chr7:77448671	T/C	cg20048109	chr7:78158112	MAGI2	-0.5	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs756777	0.878	rs7855899	chr9:136665308	C/T	cg14069709	chr9:136671979	VAV2	0.4	4.96	0.38	1.89e-6	IgG glycosylation;
UCEC	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.74	0.43	5.22e-8	Rheumatoid arthritis;
UCEC	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg04553112	chr3:125709451	NA	-0.64	-4.72	-0.36	5.53e-6	Blood pressure (smoking interaction);
UCEC	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.44	-4.95	-0.38	1.99e-6	Schizophrenia;
UCEC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.41	-5.02	-0.38	1.48e-6	Dupuytren's disease;
UCEC	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.49	5.23	0.4	5.72e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.59	-6.23	-0.46	4.63e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.34	5.18	0.39	7.27e-7	Schizophrenia;
UCEC	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	0.94	5.75	0.43	4.97e-8	Skin colour saturation;
UCEC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg24531977	chr5:56204891	C5orf35	-0.58	-5.77	-0.43	4.44e-8	Coronary artery disease;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.93	-0.38	2.19e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.61	6.71	0.48	3.93e-10	Cognitive function;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.58	6.54	0.47	9.5e-10	Menarche (age at onset);
UCEC	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.55	-4.82	-0.37	3.48e-6	Menarche (age at onset);
UCEC	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.7	-5.51	-0.41	1.58e-7	Alcohol dependence;
UCEC	cis	rs2415984	0.846	rs57096889	chr14:46832470	C/G	cg14871534	chr14:47121158	RPL10L	0.39	4.53	0.35	1.21e-5	Number of children ever born;
UCEC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg04155231	chr12:9217510	LOC144571	0.42	5.19	0.39	6.76e-7	Sjögren's syndrome;
UCEC	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.25	0.56	8.05e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.54	5.43	0.41	2.3e-7	Schizophrenia;
UCEC	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.51	5.53	0.41	1.44e-7	Platelet distribution width;
UCEC	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.55	-6.12	-0.45	8.15e-9	Crohn's disease;
UCEC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg04154034	chr17:28927549	LRRC37B2	0.57	4.89	0.37	2.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.67	-5.67	-0.42	7.47e-8	Schizophrenia;
UCEC	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg16099169	chr2:106886729	NA	-0.7	-4.87	-0.37	2.86e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs17106184	1.000	rs57095912	chr1:51356830	T/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	trans	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg02900749	chr2:68251473	NA	-0.96	-7.1	-0.51	4.94e-11	Pursuit maintenance gain;
UCEC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-5.89	-0.44	2.47e-8	Testicular germ cell tumor;
UCEC	cis	rs7246967	0.673	rs7247191	chr19:22899585	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.07	0.45	1.03e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.61	5.81	0.43	3.68e-8	Corneal astigmatism;
UCEC	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.63	6.46	0.47	1.43e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.49	-5.3	-0.4	4.25e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.1	0.39	1.05e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg10806820	chr3:48699090	CELSR3	0.71	4.61	0.36	8.71e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.57	-5.55	-0.42	1.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs2904967	0.852	rs488289	chr11:65039264	T/C	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.52	4.87	0.37	2.82e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.54	-0.42	1.37e-7	Life satisfaction;
UCEC	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg23950597	chr19:37808831	NA	0.63	4.9	0.37	2.52e-6	Coronary artery calcification;
UCEC	cis	rs78487399	0.908	rs6717791	chr2:43822006	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-5.17	-0.39	7.5e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.63	6.29	0.46	3.38e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg26373179	chr19:44306615	LYPD5	-0.42	-4.78	-0.37	4.14e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	7.12	0.51	4.37e-11	Coffee consumption (cups per day);
UCEC	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-6.38	-0.47	2.19e-9	Morning vs. evening chronotype;
UCEC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26002218	chr14:103986227	CKB	0.35	4.93	0.38	2.17e-6	Body mass index;
UCEC	cis	rs4708832	0.529	rs34355068	chr6:159904894	G/A	cg17154159	chr6:160401562	IGF2R	0.66	4.66	0.36	7.01e-6	QRS duration;
UCEC	cis	rs7246967	0.673	rs57027767	chr19:22876535	A/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2652822	0.571	rs62012880	chr15:63527162	A/G	cg02713581	chr15:63449717	RPS27L	0.5	4.67	0.36	6.61e-6	Metabolic traits;
UCEC	cis	rs4654899	0.931	rs4654887	chr1:21234923	A/G	cg01072550	chr1:21505969	NA	0.61	6.23	0.46	4.76e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.48	5.46	0.41	1.96e-7	Lung function (FEV1);
UCEC	cis	rs4588572	0.644	rs2115435	chr5:77723700	A/C	cg11547950	chr5:77652471	NA	-0.37	-4.81	-0.37	3.64e-6	Triglycerides;
UCEC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.67	5.93	0.44	2.04e-8	Aortic root size;
UCEC	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.63	-0.58	9.29e-15	Total cholesterol levels;
UCEC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14380408	chr9:140944087	CACNA1B	0.41	4.75	0.36	4.82e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2376682	1.000	rs6865449	chr5:118000174	A/G	cg17593721	chr5:118788746	HSD17B4	0.48	4.77	0.37	4.4e-6	Diisocyanate-induced asthma;
UCEC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.75	0.43	4.94e-8	Tonsillectomy;
UCEC	cis	rs871392	0.564	rs7295726	chr12:42150564	G/A	cg20693580	chr12:42326382	NA	0.53	4.88	0.37	2.74e-6	Biochemical measures;
UCEC	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.89	-9.7	-0.62	1.7e-17	Cognitive ability;
UCEC	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.75	-7.34	-0.52	1.35e-11	Schizophrenia;
UCEC	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-4.52	-0.35	1.28e-5	Skin colour saturation;
UCEC	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg21191810	chr6:118973309	C6orf204	0.4	5.48	0.41	1.77e-7	Electrocardiographic conduction measures;
UCEC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.69	-0.54	1.98e-12	Tonsillectomy;
UCEC	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.62	-5.89	-0.44	2.58e-8	Obesity-related traits;
UCEC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.61	6.35	0.46	2.55e-9	Neuroticism;
UCEC	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.57	-5.15	-0.39	8.27e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.64	-0.36	7.5e-6	Parkinson's disease;
UCEC	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.84	-0.43	3.15e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.61	6.61	0.48	6.69e-10	Obesity-related traits;
UCEC	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg01072550	chr1:21505969	NA	-0.55	-5.07	-0.39	1.18e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.82	6.53	0.47	1e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.7	6.87	0.49	1.71e-10	Bladder cancer;
UCEC	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.5	-6.11	-0.45	8.56e-9	Mean platelet volume;
UCEC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.91	5.94	0.44	1.96e-8	Gut microbiome composition (summer);
UCEC	cis	rs892864	0.685	rs11951921	chr5:127747855	C/T	cg17313118	chr5:127157258	NA	0.67	4.63	0.36	8.13e-6	Multiple system atrophy;
UCEC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.62	-6.91	-0.5	1.38e-10	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.46	-6.64	-0.48	5.68e-10	Urinary metabolites;
UCEC	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg03714773	chr7:91764589	CYP51A1	0.4	4.91	0.38	2.44e-6	Breast cancer;
UCEC	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.63	4.76	0.37	4.59e-6	Educational attainment;
UCEC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.52	-5.66	-0.42	7.61e-8	Blood metabolite levels;
UCEC	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24308560	chr3:49941425	MST1R	-0.5	-5.4	-0.41	2.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.82	-9.63	-0.62	2.61e-17	Mortality in heart failure;
UCEC	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.84	5.28	0.4	4.58e-7	Diisocyanate-induced asthma;
UCEC	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	5.53	0.41	1.45e-7	Coffee consumption (cups per day);
UCEC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	0.98	11.66	0.69	1.18e-22	Blood pressure (smoking interaction);
UCEC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.54	-6.01	-0.44	1.4e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg12024160	chr4:1254474	NA	-0.51	-5.5	-0.41	1.65e-7	Obesity-related traits;
UCEC	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.69	5.37	0.4	3.05e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.67	-6.53	-0.47	1.02e-9	Trans fatty acid levels;
UCEC	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.58	-4.93	-0.38	2.24e-6	Obesity-related traits;
UCEC	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	4.93	0.38	2.18e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
UCEC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg15837086	chr1:46506065	PIK3R3	0.37	4.54	0.35	1.18e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.69	7.84	0.54	8.45e-13	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.82e-25	Height;
UCEC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.41	-5.16	-0.39	7.87e-7	Dilated cardiomyopathy;
UCEC	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg09795085	chr6:101329169	ASCC3	0.59	4.56	0.35	1.09e-5	Economic and political preferences (immigration/crime);
UCEC	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.64	5.0	0.38	1.62e-6	Platelet distribution width;
UCEC	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	7.93e-6	Heart rate;
UCEC	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.49	4.83	0.37	3.38e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.39	0.47	2.11e-9	Menarche (age at onset);
UCEC	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.64	8.06	0.55	2.47e-13	Fibrinogen levels;
UCEC	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	6.44	0.47	1.62e-9	Cognitive test performance;
UCEC	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.46	4.82	0.37	3.57e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.67	5.7	0.43	6.39e-8	Mammographic density (dense area);
UCEC	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.63	6.3	0.46	3.33e-9	Lung cancer;
UCEC	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.84	-0.37	3.32e-6	Response to antipsychotic treatment;
UCEC	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.55	-6.22	-0.46	4.99e-9	Lung cancer;
UCEC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-0.92	-9.83	-0.63	7.77e-18	Urate levels;
UCEC	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.57	6.24	0.46	4.49e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11760485	0.965	rs7776529	chr7:4401820	A/G	cg15613991	chr7:5277080	NA	-0.39	-4.63	-0.36	7.91e-6	Early childhood aggressive behavior;
UCEC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.48	-4.97	-0.38	1.84e-6	Monocyte count;
UCEC	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg00122941	chr17:4613640	ARRB2	0.64	4.99	0.38	1.66e-6	Lymphocyte counts;
UCEC	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.81	0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg26781129	chr3:44753946	ZNF502	-0.44	-4.76	-0.37	4.55e-6	Depressive symptoms;
UCEC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.95	-0.38	2.03e-6	Breast cancer;
UCEC	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.59	7.55	0.53	4.23e-12	Corneal structure;
UCEC	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.83	8.91	0.59	1.76e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-6.63	-0.48	5.87e-10	Longevity;Endometriosis;
UCEC	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.62	6.39	0.47	2.04e-9	Dental caries;
UCEC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg23950597	chr19:37808831	NA	-0.79	-5.72	-0.43	5.79e-8	Coronary artery calcification;
UCEC	cis	rs7246967	0.611	rs62118823	chr19:22844066	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.24	0.46	4.43e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.61	-6.05	-0.45	1.16e-8	Blood metabolite levels;
UCEC	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.49	5.12	0.39	9.31e-7	Granulocyte percentage of myeloid white cells;
UCEC	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.08	9.15	0.6	4.36e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg13172905	chr8:30341765	RBPMS	0.49	4.53	0.35	1.22e-5	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.49	0.41	1.7e-7	HIV-1 control;
UCEC	cis	rs17027750	0.532	rs1672767	chr3:3198513	A/G	cg16797762	chr3:3221439	CRBN	-0.43	-4.51	-0.35	1.33e-5	Basophil percentage of granulocytes;Basophil percentage of white cells;
UCEC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg00684032	chr4:1343700	KIAA1530	0.44	4.54	0.35	1.18e-5	Obesity-related traits;
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg20821713	chr7:1055600	C7orf50	-0.53	-5.29	-0.4	4.43e-7	Longevity;Endometriosis;
UCEC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.69	7.7	0.54	1.85e-12	Menopause (age at onset);
UCEC	trans	rs808225	0.874	rs1950290	chr14:58389921	T/G	cg12462816	chr6:127836107	C6orf174	0.58	6.91	0.5	1.37e-10	Pulmonary function;
UCEC	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.72	6.64	0.48	5.63e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.96	0.38	1.95e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-4.54	-0.35	1.14e-5	Intraocular pressure;
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.67	0.53	2.21e-12	Platelet count;
UCEC	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.5	5.38	0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.58	-7.07	-0.5	5.84e-11	Total body bone mineral density;
UCEC	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.18	0.6	3.61e-16	Coffee consumption (cups per day);
UCEC	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.5	-4.78	-0.37	4.22e-6	Prostate cancer;
UCEC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	4.84	0.37	3.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg19318889	chr4:1322082	MAEA	0.41	4.7	0.36	5.99e-6	Longevity;
UCEC	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg04553112	chr3:125709451	NA	-0.74	-5.15	-0.39	8.37e-7	Blood pressure (smoking interaction);
UCEC	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-0.9	-6.74	-0.49	3.32e-10	Mitochondrial DNA levels;
UCEC	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.57	-6.01	-0.44	1.41e-8	Retinal vascular caliber;
UCEC	cis	rs4713118	0.662	rs4713120	chr6:27721835	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.65	-0.36	7.33e-6	Parkinson's disease;
UCEC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.67	4.59	0.35	9.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.61	0.36	8.75e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.92e-7	Body mass index;
UCEC	cis	rs847649	0.692	rs7800548	chr7:102481842	C/T	cg18108683	chr7:102477205	FBXL13	0.63	8.12	0.56	1.68e-13	Morning vs. evening chronotype;
UCEC	cis	rs7944735	0.817	rs7942031	chr11:47868474	T/C	cg08722104	chr11:47448306	PSMC3	-0.46	-4.51	-0.35	1.3e-5	Intraocular pressure;
UCEC	cis	rs17123764	1.000	rs2241418	chr12:49951232	T/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.43	0.41	2.27e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.16	19.75	0.85	3.37e-43	IgG glycosylation;
UCEC	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-8.21	-0.56	1.04e-13	Response to antipsychotic treatment;
UCEC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.4	-0.47	1.94e-9	Aortic root size;
UCEC	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.48	-4.56	-0.35	1.07e-5	Cardiac Troponin-T levels;
UCEC	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.0	-8.16	-0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.54	-5.88	-0.44	2.68e-8	Prostate cancer;
UCEC	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg13319975	chr6:146136371	FBXO30	0.43	4.58	0.35	9.89e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	0.81	9.91	0.63	4.78e-18	Bone mineral density;
UCEC	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.65	-0.42	7.98e-8	Body mass index;
UCEC	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-5.79	-0.43	4.11e-8	Response to antipsychotic treatment;
UCEC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.58	6.82	0.49	2.19e-10	Iron status biomarkers (transferrin levels);
UCEC	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.32	-0.4	3.73e-7	Morning vs. evening chronotype;
UCEC	cis	rs7072216	0.652	rs11189600	chr10:100179274	A/G	cg26618903	chr10:100175079	PYROXD2	0.4	5.26	0.4	4.96e-7	Metabolite levels;
UCEC	cis	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.73	-0.36	5.26e-6	Depression;
UCEC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs10924970	0.649	rs12032572	chr1:235389354	T/C	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	4.59	0.35	9.39e-6	Rheumatoid arthritis;
UCEC	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.53	-4.53	-0.35	1.19e-5	Pediatric autoimmune diseases;
UCEC	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-0.54	-5.41	-0.41	2.53e-7	Pediatric autoimmune diseases;
UCEC	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.86	-5.64	-0.42	8.45e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs295140	1.000	rs7599609	chr2:201177653	G/A	cg04283868	chr2:201171347	SPATS2L	0.52	5.18	0.39	7.23e-7	QT interval;
UCEC	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.56	-5.0	-0.38	1.59e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11697848	0.867	rs118126443	chr20:48532114	T/C	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.19	0.51	3.08e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6429082	0.508	rs4233473	chr1:235488052	C/G	cg26050004	chr1:235667680	B3GALNT2	0.49	5.19	0.39	6.94e-7	Adiposity;
UCEC	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.39	-4.91	-0.38	2.38e-6	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.37e-6	Breast cancer;
UCEC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg07653901	chr22:50250238	ZBED4	0.77	5.04	0.38	1.33e-6	Schizophrenia;
UCEC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.81	8.26	0.56	7.66e-14	Parkinson's disease;
UCEC	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.79	0.43	4.1e-8	Eosinophil percentage of white cells;
UCEC	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.36	-5.29	-0.4	4.41e-7	Ulcerative colitis;
UCEC	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.41	4.52	0.35	1.28e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.34	5.01	0.38	1.54e-6	Ulcerative colitis;
UCEC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg12024160	chr4:1254474	NA	0.49	4.59	0.35	9.49e-6	Longevity;
UCEC	cis	rs10924970	0.601	rs11804525	chr1:235470695	G/A	cg26050004	chr1:235667680	B3GALNT2	0.5	4.84	0.37	3.23e-6	Asthma;
UCEC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.52	5.39	0.41	2.8e-7	Schizophrenia;
UCEC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.61	-7.01	-0.5	8.16e-11	Prostate cancer;
UCEC	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg13334819	chr7:99746414	C7orf59	-0.56	-5.19	-0.39	6.85e-7	Coronary artery disease;
UCEC	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg11859384	chr17:80120422	CCDC57	-0.53	-5.83	-0.43	3.39e-8	Life satisfaction;
UCEC	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.0	0.44	1.47e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.67	-5.93	-0.44	2.11e-8	Breast cancer;
UCEC	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.64	-7.11	-0.51	4.75e-11	Menarche (age at onset);
UCEC	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg19743168	chr1:23544995	NA	-0.44	-6.15	-0.45	7.02e-9	Height;
UCEC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	6.34	0.46	2.6e-9	Personality dimensions;
UCEC	cis	rs11760485	0.965	rs57518719	chr7:4402398	T/A	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.65	4.64	0.36	7.65e-6	Breast cancer;
UCEC	cis	rs925228	0.869	rs2339929	chr2:24051245	C/T	cg13272742	chr2:24272458	FKBP1B	-0.57	-4.98	-0.38	1.78e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.47	4.78	0.37	4.19e-6	Prostate cancer;
UCEC	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.48	-5.45	-0.41	2.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.63	6.13	0.45	7.61e-9	Breast cancer;
UCEC	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	5.83	0.43	3.42e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.06	8.6	0.58	1.08e-14	Lymphocyte percentage of white cells;
UCEC	trans	rs2147959	0.714	rs1925721	chr1:228728841	G/C	cg17337874	chr7:2701641	TTYH3	0.62	6.7	0.48	4.16e-10	Adult asthma;
UCEC	cis	rs58722170	0.659	rs12023270	chr1:38086578	A/G	cg17933807	chr1:38061675	GNL2	0.6	5.12	0.39	9.27e-7	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05657792	chr17:6899758	ALOX12	0.45	5.66	0.42	7.6e-8	Tonsillectomy;
UCEC	cis	rs1519814	0.702	rs4871032	chr8:121042074	C/T	cg22335954	chr8:121166405	COL14A1	0.53	4.51	0.35	1.3e-5	Breast cancer;
UCEC	cis	rs7246967	0.611	rs12983761	chr19:22840597	C/A	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.5	-6.2	-0.46	5.43e-9	Total body bone mineral density;
UCEC	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.77	7.67	0.53	2.23e-12	Lung cancer;
UCEC	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.71	-5.06	-0.38	1.25e-6	Aortic root size;
UCEC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	7.72	0.54	1.62e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.48e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	6.7	0.48	4.18e-10	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.87	10.21	0.64	8e-19	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg22907277	chr7:1156413	C7orf50	-0.55	-5.07	-0.39	1.19e-6	Longevity;Endometriosis;
UCEC	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.69	-0.58	6.53e-15	Total cholesterol levels;
UCEC	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.58	-8.26	-0.56	7.77e-14	Total body bone mineral density;
UCEC	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg14438399	chr17:27053147	TLCD1	0.59	4.79	0.37	3.95e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.55	5.47	0.41	1.87e-7	Menopause (age at onset);
UCEC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18252515	chr7:66147081	NA	-0.46	-4.76	-0.37	4.67e-6	Aortic root size;
UCEC	cis	rs742614	0.533	rs2747536	chr20:32404128	C/G	cg06304546	chr20:32448765	NA	-0.71	-7.94	-0.55	4.72e-13	Stearic acid (18:0) levels;
UCEC	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg01072550	chr1:21505969	NA	-0.56	-5.28	-0.4	4.47e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.82	-8.87	-0.59	2.33e-15	Cognitive function;
UCEC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-5.75	-0.43	4.94e-8	Body mass index;
UCEC	cis	rs847649	0.699	rs10271157	chr7:102527591	A/G	cg18108683	chr7:102477205	FBXL13	-0.66	-8.41	-0.57	3.26e-14	Morning vs. evening chronotype;
UCEC	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg15513719	chr13:114904418	NA	0.47	4.6	0.35	8.93e-6	Schizophrenia;
UCEC	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.52	-5.06	-0.38	1.25e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.6	6.01	0.44	1.41e-8	Symmetrical dimethylarginine levels;
UCEC	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18854424	chr1:2615690	NA	0.47	7.0	0.5	8.46e-11	Ulcerative colitis;
UCEC	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg04310649	chr10:35416472	CREM	-0.47	-4.57	-0.35	1.02e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6925255	0.669	rs9352763	chr6:80466110	C/T	cg09116618	chr6:81233028	NA	-0.31	-4.53	-0.35	1.22e-5	Aging;
UCEC	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	0.99	9.27	0.61	2.13e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.92	-0.38	2.28e-6	Cardiac Troponin-T levels;
UCEC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.18	0.39	7.04e-7	Breast cancer;
UCEC	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg18681998	chr4:17616180	MED28	0.73	6.91	0.5	1.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.62	-5.52	-0.41	1.48e-7	Pulmonary function;
UCEC	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-0.99	-5.75	-0.43	4.99e-8	Mitochondrial DNA levels;
UCEC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.67e-7	Aortic root size;
UCEC	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.82	6.26	0.46	4.06e-9	Obesity (early onset extreme);
UCEC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.6	-7.68	-0.54	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.67	-0.42	7.3900000000000007e-08	Mood instability;
UCEC	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg26898376	chr11:64110657	CCDC88B	0.38	4.51	0.35	1.3e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs11686241	0.748	rs11892361	chr2:217288955	A/T	cg15830940	chr2:217278069	SMARCAL1	-0.45	-4.53	-0.35	1.23e-5	Cancer;
UCEC	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg18681998	chr4:17616180	MED28	0.91	11.86	0.7	3.39e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.67	7.11	0.51	4.78e-11	Menopause (age at onset);
UCEC	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg23324259	chr8:82754387	SNX16	-0.52	-4.51	-0.35	1.32e-5	Diastolic blood pressure;
UCEC	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg21854759	chr1:92012499	NA	-0.48	-4.62	-0.36	8.3e-6	Breast cancer;
UCEC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.67	-7.57	-0.53	3.75e-12	Monocyte count;
UCEC	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.11	-7.24	-0.51	2.28e-11	Diabetic kidney disease;
UCEC	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.88	-5.93	-0.44	2.1e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.63	5.06	0.39	1.22e-6	HIV-1 control;
UCEC	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg14456004	chr13:21872349	NA	-1.09	-8.75	-0.59	4.64e-15	White matter hyperintensity burden;
UCEC	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.91	11.4	0.69	5.59e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.78	-8.13	-0.56	1.59e-13	Cognitive function;
UCEC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg06238570	chr21:40685208	BRWD1	0.84	7.68	0.53	2.1e-12	Cognitive function;
UCEC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg05241461	chr19:22816980	ZNF492	0.58	6.36	0.46	2.37e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs295140	1.000	rs55677233	chr2:201168695	T/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs4687718	0.929	rs62255996	chr3:53279868	A/G	cg19378537	chr3:53290327	TKT	0.73	4.51	0.35	1.33e-5	QRS duration;
UCEC	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg06096015	chr1:231504339	EGLN1	-0.44	-4.77	-0.37	4.45e-6	Hemoglobin concentration;
UCEC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.79	7.95	0.55	4.53e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.44	6.39	0.47	2.11e-9	Rheumatoid arthritis;
UCEC	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.49	0.47	1.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-6.12	-0.45	8.23e-9	Platelet count;
UCEC	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.48	-5.25	-0.4	5.34e-7	Longevity;
UCEC	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg23307798	chr14:103986281	CKB	-0.49	-5.06	-0.39	1.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-4.75	-0.36	4.73e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.01	0.44	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.86	-8.86	-0.59	2.43e-15	Obesity-related traits;
UCEC	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.84	-0.54	8.26e-13	Blood protein levels;
UCEC	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-4.87	-0.37	2.91e-6	Pediatric autoimmune diseases;
UCEC	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.53	-5.33	-0.4	3.6e-7	Hepatocellular carcinoma;
UCEC	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.61	5.88	0.44	2.66e-8	Interstitial lung disease;
UCEC	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg13073564	chr4:8508604	NA	-0.46	-5.03	-0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1832871	0.599	rs1539312	chr6:158743188	G/A	cg07215822	chr6:158701037	NA	0.49	5.22	0.4	6.08e-7	Height;
UCEC	trans	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg07817883	chr1:32538562	TMEM39B	0.93	7.4	0.52	9.56e-12	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-5.24	-0.4	5.45e-7	Aortic root size;
UCEC	cis	rs295140	1.000	rs10931899	chr2:201176901	A/G	cg04283868	chr2:201171347	SPATS2L	-0.52	-5.18	-0.39	7.29e-7	QT interval;
UCEC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg18755752	chr8:142205143	DENND3	-0.57	-5.25	-0.4	5.35e-7	Immature fraction of reticulocytes;
UCEC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.52	4.75	0.36	4.8e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.53	4.81	0.37	3.74e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.55	0.35	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7212590	0.655	rs8072050	chr17:58010972	G/A	cg10252138	chr17:58120427	NA	-0.69	-4.56	-0.35	1.09e-5	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.58	5.6	0.42	1.04e-7	Blood metabolite levels;
UCEC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.87	9.46	0.61	7.21e-17	Dental caries;
UCEC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg12035532	chr1:1886765	KIAA1751	0.44	4.63	0.36	7.9e-6	Body mass index;
UCEC	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.62	6.97	0.5	1.02e-10	Longevity;
UCEC	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.93	10.94	0.67	9.44e-21	Subjective well-being;
UCEC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg24375607	chr4:120327624	NA	0.48	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.56	-6.16	-0.45	6.5e-9	Pubertal anthropometrics;
UCEC	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.69e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06873352	chr17:61820015	STRADA	-0.64	-6.88	-0.49	1.61e-10	Prudent dietary pattern;
UCEC	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.03	-0.55	2.93e-13	Breast cancer;
UCEC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.77	4.73	0.36	5.29e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.78	-7.9	-0.55	6.02e-13	Uric acid levels;
UCEC	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18932078	chr1:2524107	MMEL1	0.34	5.8	0.43	3.99e-8	Ulcerative colitis;
UCEC	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg00500100	chr5:140098250	VTRNA1-2	0.34	4.51	0.35	1.32e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.5	5.15	0.39	8.18e-7	Plateletcrit;Platelet count;
UCEC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.59	6.76	0.49	3e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.56	-5.46	-0.41	1.98e-7	Coronary artery disease;
UCEC	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.0	0.38	1.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-4.96	-0.38	1.92e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	5.03	0.38	1.4e-6	Bipolar disorder;
UCEC	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.84	8.64	0.58	8.55e-15	Mosquito bite size;
UCEC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.5	5.61	0.42	9.7e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.74	-0.43	5.22e-8	Alcohol dependence;
UCEC	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.74	0.49	3.28e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	4.98	0.38	1.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs61134957	1.000	rs73309657	chr8:92611516	C/T	cg26596161	chr8:92261459	SLC26A7	0.96	4.91	0.38	2.37e-6	Night sleep phenotypes;
UCEC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg01262667	chr19:19385393	TM6SF2	0.51	6.9	0.49	1.45e-10	Tonsillectomy;
UCEC	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-0.93	-10.0	-0.64	2.85e-18	Red cell distribution width;
UCEC	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.74	-0.36	4.97e-6	Breast cancer;
UCEC	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	5.57	0.42	1.17e-7	Menarche (age at onset);
UCEC	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-6.13	-0.45	7.79e-9	Crohn's disease;
UCEC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.61	6.62	0.48	6.21e-10	Prostate cancer;
UCEC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.61	-5.81	-0.43	3.67e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.94	-0.5	1.19e-10	Longevity;Endometriosis;
UCEC	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg20368463	chr18:77673604	PQLC1	0.71	5.38	0.41	2.88e-7	Opioid sensitivity;
UCEC	cis	rs6754311	0.589	rs11681659	chr2:136820960	C/T	cg07169764	chr2:136633963	MCM6	-0.68	-6.23	-0.46	4.64e-9	Mosquito bite size;
UCEC	cis	rs10949834	0.652	rs2269082	chr7:73519875	A/G	cg07137043	chr7:73588983	EIF4H	-0.64	-4.66	-0.36	6.98e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.52	4.78	0.37	4.14e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7611694	0.501	rs1906142	chr3:113154223	C/T	cg11138929	chr3:113251189	SIDT1	0.46	5.37	0.4	3.08e-7	Prostate cancer;
UCEC	cis	rs6446731	0.614	rs6446727	chr4:3274488	T/A	cg08886695	chr4:3369023	RGS12	-0.41	-4.85	-0.37	3.11e-6	Mean platelet volume;
UCEC	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.43	4.76	0.37	4.67e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg09165964	chr15:75287851	SCAMP5	0.53	5.99	0.44	1.57e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.57	5.77	0.43	4.54e-8	Birth weight;
UCEC	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	4.77	0.37	4.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg04013166	chr16:89971882	TCF25	0.58	6.58	0.48	7.63e-10	Skin colour saturation;
UCEC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg10503236	chr1:231470652	EXOC8	-0.39	-4.65	-0.36	7.21e-6	Hemoglobin concentration;
UCEC	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.72	-0.54	1.67e-12	Monocyte count;
UCEC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.51	-5.44	-0.41	2.22e-7	Alcohol dependence;
UCEC	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.58	5.55	0.42	1.33e-7	Uric acid levels;
UCEC	cis	rs7617773	0.823	rs9839447	chr3:48194667	T/C	cg11946769	chr3:48343235	NME6	-0.56	-4.81	-0.37	3.65e-6	Coronary artery disease;
UCEC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg22974920	chr21:40686053	BRWD1	-0.46	-4.59	-0.35	9.6e-6	Menarche (age at onset);
UCEC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.45	-6.27	-0.46	3.78e-9	Mortality in heart failure;
UCEC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg07836142	chr6:28411423	ZSCAN23	0.63	8.05	0.55	2.54e-13	Pubertal anthropometrics;
UCEC	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.62	-5.83	-0.43	3.35e-8	Mammographic density (dense area);
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.02	0.55	3.03e-13	Platelet count;
UCEC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.42	-5.11	-0.39	9.91e-7	Refractive error;
UCEC	cis	rs4074536	0.622	rs6668528	chr1:116314321	G/A	cg21648376	chr1:116311395	CASQ2	-0.61	-5.83	-0.43	3.31e-8	QRS duration;
UCEC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.59	-4.8	-0.37	3.88e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.76	6.76	0.49	3.09e-10	Caudate activity during reward;
UCEC	cis	rs763121	0.657	rs5995603	chr22:39040733	G/A	cg06022373	chr22:39101656	GTPBP1	0.77	7.44	0.52	7.94e-12	Menopause (age at onset);
UCEC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.05	-0.45	1.16e-8	Aortic root size;
UCEC	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg23995753	chr2:160760732	LY75	-0.38	-4.57	-0.35	1.01e-5	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	1.1	13.0	0.73	3.41e-26	Post bronchodilator FEV1;
UCEC	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.41	-4.52	-0.35	1.24e-5	Motion sickness;
UCEC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs59104589	0.569	rs4254498	chr2:242363611	G/C	cg19488206	chr2:242435732	STK25	0.53	4.55	0.35	1.11e-5	Fibrinogen levels;
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.58	-5.69	-0.42	6.67e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Bladder cancer;
UCEC	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.51	0.53	5.16e-12	Mosquito bite size;
UCEC	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg27083787	chr2:113543245	IL1A	-0.44	-4.51	-0.35	1.3e-5	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.42	-4.51	-0.35	1.31e-5	Height;
UCEC	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg05775895	chr3:12838266	CAND2	0.6	5.4	0.41	2.68e-7	QRS complex (12-leadsum);
UCEC	cis	rs239198	0.602	rs17672397	chr6:101288160	C/T	cg09795085	chr6:101329169	ASCC3	0.47	4.57	0.35	1e-5	Menarche (age at onset);
UCEC	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.47	5.32	0.4	3.82e-7	White matter hyperintensity burden;
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-6.22	-0.46	4.99e-9	Platelet count;
UCEC	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.68	-6.38	-0.47	2.14e-9	Blood pressure (smoking interaction);
UCEC	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.53	-6.37	-0.47	2.27e-9	Monocyte percentage of white cells;
UCEC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.93	0.38	2.22e-6	Tonsillectomy;
UCEC	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.01	0.5	8.2e-11	Menopause (age at onset);
UCEC	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.53	5.52	0.41	1.5e-7	Dupuytren's disease;
UCEC	cis	rs12365397	0.569	rs1353465	chr11:43242587	A/G	cg07515919	chr11:43391688	TTC17	-0.51	-5.94	-0.44	1.96e-8	Migraine;
UCEC	cis	rs4615376	0.950	rs34054185	chr6:13044393	T/C	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg16797656	chr11:68205561	LRP5	0.47	5.72	0.43	5.78e-8	Total body bone mineral density;
UCEC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.47	-4.59	-0.35	9.3e-6	Systemic lupus erythematosus;
UCEC	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.75	-6.05	-0.45	1.16e-8	Alzheimer's disease (late onset);
UCEC	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6842789	0.510	rs1996580	chr4:124871513	A/G	cg01723706	chr4:124814442	LOC285419	-0.47	-4.69	-0.36	6.08e-6	Neuroticism;
UCEC	cis	rs4372836	0.543	rs6742291	chr2:29007349	T/C	cg09522027	chr2:28974177	PPP1CB	-0.79	-8.71	-0.58	5.73e-15	Body mass index;
UCEC	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18032046	chr6:28092343	ZSCAN16	0.68	5.88	0.44	2.7e-8	Depression;
UCEC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.69	-9.01	-0.6	9.82e-16	Height;
UCEC	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.39	5.64	0.42	8.39e-8	Vitiligo;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-5.43	-0.41	2.32e-7	Depression;
UCEC	cis	rs13089785	0.788	rs2280422	chr3:123696930	C/T	cg23184556	chr3:123600215	MYLK	0.43	4.66	0.36	7.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.39	4.52	0.35	1.25e-5	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg24687543	chr11:63912206	MACROD1	0.39	4.52	0.35	1.25e-5	Platelet count;
UCEC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.6	6.36	0.46	2.4e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg04176532	chr22:50317003	CRELD2	0.47	4.73	0.36	5.12e-6	Schizophrenia;
UCEC	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.15	-0.51	3.83e-11	Chronic sinus infection;
UCEC	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.76	8.76	0.59	4.43e-15	Schizophrenia;
UCEC	cis	rs6763768	0.606	rs6795127	chr3:53376669	C/T	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.77	-8.22	-0.56	9.79e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs5167	0.504	rs73047641	chr19:45457377	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.08	0.45	1.01e-8	Blood protein levels;
UCEC	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg09165964	chr15:75287851	SCAMP5	0.54	6.34	0.46	2.62e-9	Breast cancer;
UCEC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18932078	chr1:2524107	MMEL1	-0.38	-6.02	-0.44	1.34e-8	Ulcerative colitis;
UCEC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-9.05	-0.6	8.12e-16	Schizophrenia;
UCEC	cis	rs829883	0.604	rs249841	chr12:98871743	A/G	cg25150519	chr12:98850993	NA	0.57	5.11	0.39	1e-6	Colorectal adenoma (advanced);
UCEC	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.66	-6.44	-0.47	1.59e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs57590327	0.528	rs7642112	chr3:81674927	C/T	cg07356753	chr3:81810745	GBE1	-0.77	-8.64	-0.58	8.69e-15	Extraversion;
UCEC	cis	rs6832769	1.000	rs4580704	chr4:56326707	C/G	cg05960024	chr4:56376020	CLOCK	-0.57	-5.9	-0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.56	-4.89	-0.37	2.57e-6	Major depressive disorder;
UCEC	cis	rs7709377	0.570	rs1396479	chr5:115454833	A/G	cg23108291	chr5:115420582	COMMD10	0.53	5.47	0.41	1.9e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	4.89	0.37	2.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17106184	1.000	rs72904718	chr1:51315456	T/C	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.91	7.82	0.54	9.24e-13	Body mass index;
UCEC	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg24375607	chr4:120327624	NA	0.53	5.51	0.41	1.56e-7	Corneal astigmatism;
UCEC	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.72	5.11	0.39	9.68e-7	Blood protein levels;
UCEC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg21681030	chr2:46777652	RHOQ	0.57	4.51	0.35	1.33e-5	Height;
UCEC	cis	rs4744901	0.915	rs62567254	chr9:72163175	C/A	cg14326805	chr9:71737756	TJP2	-0.6	-4.56	-0.35	1.06e-5	Schizophrenia;
UCEC	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.55	4.69	0.36	6.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.58	4.93	0.38	2.22e-6	Lung cancer;
UCEC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.86	-0.37	3.01e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.44	-5.24	-0.4	5.52e-7	Total body bone mineral density;
UCEC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.45	-5.09	-0.39	1.09e-6	Tonsillectomy;
UCEC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg12024160	chr4:1254474	NA	0.71	8.48	0.57	2.19e-14	Obesity-related traits;
UCEC	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.16	-0.45	6.75e-9	Personality dimensions;
UCEC	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.44	4.91	0.38	2.42e-6	Bipolar disorder;
UCEC	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	1.18	15.17	0.78	6.89e-32	Body mass index;
UCEC	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg11632617	chr15:75315747	PPCDC	-0.62	-7.21	-0.51	2.68e-11	Blood trace element (Zn levels);
UCEC	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.3	-0.4	4.23e-7	Breast cancer;
UCEC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.22	-0.4	6.04e-7	Joint mobility (Beighton score);
UCEC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg20965017	chr5:231967	SDHA	-0.63	-5.96	-0.44	1.8e-8	Breast cancer;
UCEC	cis	rs10242455	0.702	rs73403290	chr7:99157828	C/T	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.53	5.32	0.4	3.78e-7	Birth weight;
UCEC	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.62	9.02	0.6	9.26e-16	Prudent dietary pattern;
UCEC	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg04287289	chr16:89883240	FANCA	-0.51	-5.4	-0.41	2.56e-7	Vitiligo;
UCEC	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.56	-8.33	-0.57	5.32e-14	Height;
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-6.48	-0.47	1.32e-9	Platelet count;
UCEC	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-8.27	-0.56	7.21e-14	Resting heart rate;
UCEC	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.67	-5.53	-0.41	1.44e-7	Alcohol dependence;
UCEC	cis	rs8105895	1.000	rs11881224	chr19:22220340	G/A	cg20662725	chr19:22235022	ZNF257	-0.56	-4.99	-0.38	1.65e-6	Body mass index (change over time);
UCEC	cis	rs35934224	0.783	rs13053818	chr22:19859652	G/A	cg11182965	chr22:19864308	TXNRD2	-0.68	-6.13	-0.45	7.75e-9	Glaucoma (primary open-angle);
UCEC	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.45	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-9.42	-0.61	8.77e-17	Blood metabolite levels;
UCEC	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-4.88	-0.37	2.69e-6	Blood metabolite levels;
UCEC	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.58	-4.78	-0.37	4.15e-6	Corneal structure;
UCEC	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16346588	chr10:242978	ZMYND11	0.47	4.57	0.35	1.03e-5	Psychosis in Alzheimer's disease;
UCEC	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.53	-0.42	1.4e-7	Eye color traits;
UCEC	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg20560298	chr2:73613845	ALMS1	-0.58	-5.05	-0.38	1.28e-6	Metabolite levels;
UCEC	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.21	0.39	6.42e-7	Cognitive test performance;
UCEC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg17105886	chr17:28927953	LRRC37B2	0.64	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs7250620	chr19:22853126	A/T	cg05241461	chr19:22816980	ZNF492	0.56	6.11	0.45	8.62e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.63	-5.15	-0.39	8.26e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-0.75	-5.2	-0.39	6.61e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs926938	0.783	rs2144428	chr1:115269211	G/A	cg12756093	chr1:115239321	AMPD1	-0.56	-5.66	-0.42	7.72e-8	Autism;
UCEC	cis	rs73206853	0.841	rs7959516	chr12:110622224	A/C	cg12870014	chr12:110450643	ANKRD13A	0.81	4.89	0.37	2.64e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs953387	1.000	rs4954392	chr2:136901607	A/G	cg07169764	chr2:136633963	MCM6	0.51	5.07	0.39	1.15e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.66	5.71	0.43	6.03e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
UCEC	cis	rs3777722	0.688	rs2757045	chr6:167350963	C/T	cg12495975	chr6:166919189	RPS6KA2	0.49	4.66	0.36	7.12e-6	Spontaneous preterm birth (preterm birth);
UCEC	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg02158880	chr13:53174818	NA	0.44	5.04	0.38	1.32e-6	Lewy body disease;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.82	-7.8	-0.54	1.08e-12	Longevity;Endometriosis;
UCEC	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.57	6.46	0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.82	4.73	0.36	5.13e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg26875137	chr12:53738046	NA	0.5	5.64	0.42	8.56e-8	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.71	6.69	0.48	4.43e-10	High light scatter reticulocyte count;
UCEC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.8	8.83	0.59	2.92e-15	Smoking behavior;
UCEC	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.94	10.54	0.66	1.1e-19	Cognitive function;
UCEC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg04804543	chr8:142233427	SLC45A4	0.41	4.87	0.37	2.9e-6	Immature fraction of reticulocytes;
UCEC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.53	5.07	0.39	1.18e-6	Resting heart rate;
UCEC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg11632617	chr15:75315747	PPCDC	-0.63	-7.49	-0.53	5.78e-12	Blood trace element (Zn levels);
UCEC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg26031613	chr14:104095156	KLC1	0.59	5.63	0.42	8.75e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs4372836	0.504	rs7475	chr2:29023749	A/G	cg09522027	chr2:28974177	PPP1CB	-0.65	-6.59	-0.48	7.5e-10	Body mass index;
UCEC	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.77	0.37	4.38e-6	Rheumatoid arthritis;
UCEC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.62	-6.38	-0.47	2.13e-9	Initial pursuit acceleration;
UCEC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg23793686	chr15:68133972	NA	-0.36	-4.7	-0.36	5.9e-6	Restless legs syndrome;
UCEC	cis	rs7937127	0.744	rs72902715	chr11:43512780	C/T	cg16512570	chr11:44087867	ACCS	0.81	4.55	0.35	1.1e-5	Fibrinogen levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24872791	chr11:18034920	SERGEF	0.63	7.53	0.53	4.74e-12	Warfarin maintenance dose;
UCEC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	4.66	0.36	7.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.52	4.72	0.36	5.52e-6	Corneal astigmatism;
UCEC	cis	rs3802344	0.590	rs7875972	chr9:133589022	A/T	cg01474677	chr9:133586259	NA	-0.91	-4.61	-0.36	8.64e-6	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.52	5.41	0.41	2.55e-7	Testicular germ cell tumor;
UCEC	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.5	4.63	0.36	7.94e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg04756594	chr16:24857601	SLC5A11	-0.5	-6.03	-0.45	1.27e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	0.45	4.66	0.36	6.92e-6	QRS complex (12-leadsum);
UCEC	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	7.59	0.53	3.42e-12	Bipolar disorder;
UCEC	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg13319975	chr6:146136371	FBXO30	0.42	4.53	0.35	1.21e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2585417	0.743	rs6013925	chr20:52828077	A/G	cg14415559	chr20:52836060	PFDN4	0.46	5.8	0.43	3.99e-8	Obesity-related traits;
UCEC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.76	-6.82	-0.49	2.19e-10	Initial pursuit acceleration;
UCEC	cis	rs7725816	0.748	rs10060151	chr5:147502144	C/T	cg10994339	chr5:147443536	SPINK5	-0.5	-4.68	-0.36	6.51e-6	Yeast infection;
UCEC	cis	rs16944613	0.541	rs10852135	chr15:91106412	T/C	cg08919649	chr15:91565780	VPS33B	0.67	4.52	0.35	1.27e-5	Colorectal cancer;
UCEC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.89	10.4	0.65	2.44e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.82	-0.49	2.16e-10	Pubertal anthropometrics;
UCEC	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-7.28	-0.51	1.82e-11	Morning vs. evening chronotype;
UCEC	cis	rs3112255	0.597	rs2970991	chr2:101322193	C/G	cg01042948	chr2:101319752	NA	-0.44	-4.85	-0.37	3.05e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.58	-8.27	-0.56	7.52e-14	Total body bone mineral density;
UCEC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs2904967	0.929	rs592050	chr11:65030189	C/G	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs9326248	0.530	rs2000614	chr11:116915742	C/T	cg13068653	chr11:117074303	TAGLN	0.54	4.74	0.36	4.93e-6	Blood protein levels;
UCEC	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.63	-5.68	-0.42	6.87e-8	Resting heart rate;
UCEC	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.2	-0.39	6.58e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.46	6.37	0.47	2.27e-9	Alcohol dependence;
UCEC	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs7937612	0.965	rs7118391	chr11:120270709	C/T	cg12584626	chr11:120203529	NA	0.51	5.09	0.39	1.06e-6	Intraocular pressure;
UCEC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.75	8.32	0.57	5.62e-14	Menopause (age at onset);
UCEC	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.55	5.66	0.42	7.74e-8	Aortic root size;
UCEC	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10012307	1.000	rs72985937	chr4:137484998	A/G	cg12033966	chr4:138453416	PCDH18	-0.72	-4.98	-0.38	1.75e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.65	-5.84	-0.43	3.17e-8	Metabolite levels;
UCEC	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.61	-5.4	-0.41	2.64e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.55	-6.17	-0.45	6.37e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24249390	chr15:90295951	MESP1	-0.41	-4.73	-0.36	5.22e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.57	-5.78	-0.43	4.4e-8	Strep throat;
UCEC	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.6	5.77	0.43	4.42e-8	Monocyte count;
UCEC	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.58	-6.02	-0.44	1.33e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.63	-8.76	-0.59	4.22e-15	Cancer (pleiotropy);
UCEC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.59	5.6	0.42	1.02e-7	Schizophrenia;
UCEC	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.59	-6.09	-0.45	9.26e-9	Breast cancer;
UCEC	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-7.39	-0.52	9.96e-12	Resting heart rate;
UCEC	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-4.55	-0.35	1.1e-5	Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.31	-0.4	3.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.74	-7.86	-0.54	7.41e-13	Cognitive function;
UCEC	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg26929925	chr5:138714136	SLC23A1	-0.42	-4.51	-0.35	1.33e-5	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.52	-6.01	-0.44	1.39e-8	Pubertal anthropometrics;
UCEC	cis	rs7095607	0.813	rs7895737	chr10:69924146	A/G	cg18986048	chr10:69913749	MYPN	0.53	6.29	0.46	3.35e-9	Lung function (FVC);
UCEC	cis	rs35934224	0.783	rs56291622	chr22:19858734	C/T	cg11182965	chr22:19864308	TXNRD2	-0.36	-4.94	-0.38	2.08e-6	Glaucoma (primary open-angle);
UCEC	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	7.01	0.5	7.94e-11	Eye color traits;
UCEC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.62	-5.69	-0.43	6.52e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg14196790	chr5:131705035	SLC22A5	0.44	5.14	0.39	8.55e-7	Blood metabolite levels;
UCEC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.68	7.01	0.5	7.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.83	8.91	0.59	1.76e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	8.66	0.58	7.87e-15	Electrocardiographic conduction measures;
UCEC	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.01	-0.38	1.53e-6	Life satisfaction;
UCEC	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.75	-5.83	-0.43	3.44e-8	Birth weight;
UCEC	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.79	6.32	0.46	2.99e-9	Initial pursuit acceleration;
UCEC	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.54	-5.67	-0.42	7.3e-8	Breast cancer;
UCEC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.33	-5.4	-0.41	2.59e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.52	4.91	0.38	2.42e-6	Bone mineral density;
UCEC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.78	8.58	0.58	1.24e-14	Breast cancer;
UCEC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg03859395	chr2:55845619	SMEK2	1.0	13.75	0.75	3.61e-28	Metabolic syndrome;
UCEC	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.54	6.14	0.45	7.23e-9	Height;
UCEC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-7.03	-0.5	7.05e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs7246967	0.736	rs411131	chr19:22993439	G/A	cg24889512	chr19:22816950	ZNF492	0.53	5.03	0.38	1.43e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.55	5.13	0.39	9.1e-7	Coronary artery disease;
UCEC	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.4	5.5	0.41	1.65e-7	Obesity-related traits;
UCEC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.77	-8.74	-0.58	4.82e-15	Height;
UCEC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3956705	0.798	rs1045477	chr7:32908704	T/C	cg05721444	chr7:32995514	FKBP9	-0.45	-4.54	-0.35	1.18e-5	Red cell distribution width;
UCEC	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.58	5.62	0.42	9.5e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.71	7.05	0.5	6.41e-11	Aortic root size;
UCEC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.59	5.78	0.43	4.4e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9948	1.000	rs9948	chr2:97500800	C/G	cg26665480	chr2:98280029	ACTR1B	0.55	4.53	0.35	1.21e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.43	-5.59	-0.42	1.06e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.89	0.44	2.5e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-4.93	-0.38	2.2e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.45	5.94	0.44	1.96e-8	Total body bone mineral density;
UCEC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-7.44	-0.52	7.81e-12	Initial pursuit acceleration;
UCEC	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7267005	0.661	rs74768850	chr20:34419847	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.2e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg02160872	chr5:212506	CCDC127	-0.69	-7.19	-0.51	2.99e-11	Breast cancer;
UCEC	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Parkinson's disease;
UCEC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg18171715	chr4:852160	GAK	0.49	4.64	0.36	7.64e-6	Obesity-related traits;
UCEC	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03352830	chr11:487213	PTDSS2	-0.56	-4.62	-0.36	8.37e-6	Body mass index;
UCEC	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	Height;
UCEC	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.44	5.82	0.43	3.54e-8	Bone mineral density;
UCEC	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.39	4.93	0.38	2.15e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06671706	chr8:8559999	CLDN23	0.66	5.34	0.4	3.47e-7	Obesity-related traits;
UCEC	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.08	-0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-9.07	-0.6	7.22e-16	Gut microbiome composition (summer);
UCEC	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.58	6.23	0.46	4.65e-9	Pulmonary function decline;
UCEC	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg17052170	chr8:144099482	LY6E;LOC100133669	0.41	4.51	0.35	1.31e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.54	6.08	0.45	9.82e-9	Response to temozolomide;
UCEC	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.42	4.99	0.38	1.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.62	5.5	0.41	1.6e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.46	4.77	0.37	4.34e-6	HDL cholesterol;
UCEC	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs11581903	0.568	rs11590859	chr1:53073838	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.83	4.58	0.35	9.96e-6	Joint mobility (Beighton score);
UCEC	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.42	5.27	0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg11697111	chr7:1126903	GPER;C7orf50	-0.44	-4.54	-0.35	1.15e-5	Longevity;Endometriosis;
UCEC	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.81	9.51	0.62	5.06e-17	Menopause (age at onset);
UCEC	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg23795048	chr12:9217529	LOC144571	0.4	4.69	0.36	6.14e-6	Sjögren's syndrome;
UCEC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-5.93	-0.44	2.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.43	5.09	0.39	1.07e-6	HDL cholesterol levels;
UCEC	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.53	-5.05	-0.38	1.28e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-0.85	-11.29	-0.68	1.13e-21	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.48	-4.86	-0.37	3.01e-6	Menarche (age at onset);
UCEC	cis	rs7106204	0.514	rs1443044	chr11:24255575	C/G	ch.11.24196551F	chr11:24239977	NA	-0.55	-5.91	-0.44	2.27e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	6.74	0.49	3.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.54	6.1	0.45	8.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.22	0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	0.92	10.55	0.66	1.02e-19	Corneal structure;
UCEC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	7.72	0.54	1.69e-12	Total body bone mineral density;
UCEC	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg00105475	chr2:10696890	NA	-0.45	-5.67	-0.42	7.19e-8	Prostate cancer;
UCEC	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.71	7.42	0.52	8.49e-12	Obesity;Body mass index;
UCEC	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg23815491	chr16:72088622	HP	0.37	4.56	0.35	1.06e-5	Fibrinogen levels;
UCEC	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.73	-9.1	-0.6	5.83e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6684428	1.000	rs6693526	chr1:56349764	G/A	cg11651538	chr1:56320950	NA	-0.69	-6.19	-0.45	5.59e-9	Airflow obstruction;
UCEC	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg11301795	chr4:187892539	NA	-0.56	-7.11	-0.51	4.79e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.23	0.4	5.62e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13683864	chr3:40499215	RPL14	-0.67	-6.65	-0.48	5.45e-10	Renal cell carcinoma;
UCEC	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.36	-5.22	-0.4	6.13e-7	Vitamin D levels;
UCEC	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg13206674	chr6:150067644	NUP43	0.51	4.62	0.36	8.19e-6	Lung cancer;
UCEC	cis	rs10924970	0.649	rs3845565	chr1:235449647	G/C	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.48	-5.77	-0.43	4.46e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6582630	0.555	rs7956782	chr12:38603641	C/G	cg26384229	chr12:38710491	ALG10B	0.82	6.78	0.49	2.7e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.38	0.57	3.92e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.83	-0.37	3.38e-6	Blood metabolite levels;
UCEC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	0.96	7.33	0.52	1.39e-11	Economic and political preferences (immigration/crime);
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.78	-0.37	4.26e-6	Pubertal anthropometrics;
UCEC	cis	rs9650657	0.812	rs11250072	chr8:10632121	C/T	cg00629382	chr8:10268916	MSRA	-0.48	-4.75	-0.37	4.7e-6	Neuroticism;
UCEC	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.69	-0.54	2e-12	IgG glycosylation;
UCEC	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.56	-5.22	-0.4	5.9e-7	Testicular germ cell tumor;
UCEC	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.91	9.92	0.63	4.58e-18	Post bronchodilator FEV1;
UCEC	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.29	0.4	4.4e-7	IgG glycosylation;
UCEC	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.85	8.92	0.59	1.67e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.46	4.57	0.35	1.04e-5	Lung disease severity in cystic fibrosis;
UCEC	cis	rs644799	0.897	rs10831445	chr11:95660386	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	4.72	0.36	5.5e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	6.49	0.47	1.26e-9	Multiple sclerosis;
UCEC	cis	rs7870753	0.786	rs3802443	chr9:99263580	A/G	cg25260653	chr9:99212216	HABP4	0.56	5.5	0.41	1.62e-7	Height;
UCEC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.68	-5.19	-0.39	6.72e-7	Cerebrospinal P-tau181p levels;
UCEC	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg15358701	chr1:161410459	NA	-0.73	-5.0	-0.38	1.59e-6	Rheumatoid arthritis;
UCEC	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.72	-8.21	-0.56	1.01e-13	Coronary artery disease;
UCEC	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.61	6.38	0.47	2.15e-9	Autism;
UCEC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg06675538	chr2:114033490	PAX8;LOC440839	-0.52	-5.19	-0.39	6.75e-7	Lymphocyte counts;
UCEC	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7580658	0.509	rs12477653	chr2:127952081	C/T	cg16751203	chr2:127950803	CYP27C1	0.4	5.38	0.41	2.82e-7	Protein C levels;
UCEC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg24562669	chr7:97807699	LMTK2	0.44	5.3	0.4	4.14e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	4.89	0.37	2.56e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.67	6.25	0.46	4.15e-9	Aortic root size;
UCEC	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.79	-9.41	-0.61	9.58e-17	Morning vs. evening chronotype;
UCEC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.67	-4.79	-0.37	4.08e-6	Rheumatoid arthritis;
UCEC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.11	0.39	9.92e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.45	4.55	0.35	1.11e-5	Initial pursuit acceleration;
UCEC	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.98	-0.44	1.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-7.97	-0.55	3.94e-13	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg04025307	chr7:1156635	C7orf50	0.81	5.45	0.41	2.09e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9467773	0.836	rs1977198	chr6:26466225	A/C	cg09904177	chr6:26538194	HMGN4	0.52	4.68	0.36	6.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.52	-7.17	-0.51	3.37e-11	Refractive error;
UCEC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.37	5.0	0.38	1.64e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs4788439	1.000	rs112722093	chr16:24956456	A/G	cg04047827	chr16:24740859	TNRC6A	-0.51	-4.73	-0.36	5.27e-6	Blood metabolite levels;
UCEC	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24249390	chr15:90295951	MESP1	-0.44	-4.92	-0.38	2.29e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.6	-5.94	-0.44	1.99e-8	Schizophrenia;
UCEC	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.57	6.45	0.47	1.53e-9	Crohn's disease;
UCEC	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.42	4.58	0.35	9.86e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg24375607	chr4:120327624	NA	0.5	5.13	0.39	9.21e-7	Educational attainment;
UCEC	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	6.3	0.46	3.22e-9	LDL cholesterol;
UCEC	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-8.73	-0.58	5.16e-15	Total body bone mineral density;
UCEC	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.66	6.34	0.46	2.69e-9	Cognitive ability;
UCEC	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.3	0.52	1.66e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.87	-8.83	-0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.81	-8.83	-0.59	2.91e-15	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.83	-0.43	3.37e-8	Prudent dietary pattern;
UCEC	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.87	0.49	1.72e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.65	6.75	0.49	3.19e-10	Immature fraction of reticulocytes;
UCEC	cis	rs713477	1.000	rs12887846	chr14:55911139	T/C	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	trans	rs8130944	0.964	rs12626774	chr21:44139048	C/G	cg11475259	chr17:780898	NXN	-0.59	-6.78	-0.49	2.72e-10	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-0.68	-8.17	-0.56	1.33e-13	Obesity-related traits;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00164150	chr2:20101139	TTC32	0.6	7.08	0.5	5.47e-11	Warfarin maintenance dose;
UCEC	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg02461776	chr11:598696	PHRF1	0.55	5.36	0.4	3.23e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg14008862	chr17:28927542	LRRC37B2	0.62	4.87	0.37	2.81e-6	Body mass index;
UCEC	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.59	5.26	0.4	4.99e-7	Corneal astigmatism;
UCEC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.76	8.08	0.55	2.2e-13	Blood protein levels;
UCEC	cis	rs7709377	0.547	rs1090078	chr5:115674867	G/T	cg23108291	chr5:115420582	COMMD10	-0.47	-4.63	-0.36	7.9e-6	Metabolite levels  (X-11787);
UCEC	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.6	-4.75	-0.36	4.73e-6	Exhaled nitric oxide output;
UCEC	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	5.0	0.38	1.61e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.72	8.77	0.59	4.15e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	0.94	9.97	0.64	3.3e-18	Heart rate;
UCEC	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.63	-4.65	-0.36	7.48e-6	Multiple sclerosis;
UCEC	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.79	8.99	0.6	1.1e-15	Platelet distribution width;
UCEC	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.73	-7.36	-0.52	1.18e-11	Plateletcrit;Platelet count;
UCEC	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.48	-4.75	-0.36	4.85e-6	Obesity-related traits;
UCEC	cis	rs55692468	0.606	rs6759772	chr2:153322724	C/T	cg20171711	chr2:153307345	FMNL2	-0.49	-4.55	-0.35	1.11e-5	Intraocular pressure;
UCEC	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.12e-7	Life satisfaction;
UCEC	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.48	-4.56	-0.35	1.06e-5	Coronary artery disease;
UCEC	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.5	-4.82	-0.37	3.54e-6	Prostate cancer;
UCEC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg03078520	chr22:18463400	MICAL3	-0.54	-5.0	-0.38	1.61e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg16616514	chr4:6324629	PPP2R2C	0.43	5.25	0.4	5.14e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs295140	1.000	rs11696001	chr2:201162433	G/A	cg04283868	chr2:201171347	SPATS2L	0.53	5.18	0.39	7.14e-7	QT interval;
UCEC	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.94	-7.35	-0.52	1.24e-11	Multiple sclerosis;
UCEC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.51	-5.05	-0.38	1.27e-6	Longevity;Endometriosis;
UCEC	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.73	8.21	0.56	1.02e-13	Lymphocyte counts;
UCEC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.59	5.6	0.42	1.04e-7	Aortic root size;
UCEC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.65	4.64	0.36	7.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg04154034	chr17:28927549	LRRC37B2	0.69	5.14	0.39	8.66e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11958404	0.932	rs76228149	chr5:157434486	G/A	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg00750074	chr16:89608354	SPG7	-0.44	-4.6	-0.35	9.2e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs36715	0.953	rs36700	chr5:127551273	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	4.64	0.36	7.53e-6	Breast cancer;
UCEC	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.07	-10.94	-0.67	9.51e-21	Vitiligo;
UCEC	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.33	-5.55	-0.42	1.29e-7	Mean corpuscular volume;
UCEC	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg06970220	chr1:156163860	SLC25A44	0.47	5.61	0.42	9.88e-8	Testicular germ cell tumor;
UCEC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg23307798	chr14:103986281	CKB	0.64	7.56	0.53	3.92e-12	Body mass index;
UCEC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.87	8.39	0.57	3.75e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.46	4.59	0.35	9.47e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.55	-6.0	-0.44	1.46e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg13319975	chr6:146136371	FBXO30	-0.48	-5.22	-0.4	6e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.37	-4.93	-0.38	2.22e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6722750	0.716	rs6546057	chr2:64414165	A/G	cg22352474	chr2:64371530	PELI1	-0.48	-4.6	-0.35	8.98e-6	Neuroticism;
UCEC	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.23	-0.4	5.61e-7	Hemoglobin concentration;
UCEC	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.67	6.8	0.49	2.39e-10	Smoking behavior;
UCEC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06462663	chr19:18546047	ISYNA1	0.44	5.59	0.42	1.09e-7	Breast cancer;
UCEC	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.62	0.53	2.9e-12	Alzheimer's disease;
UCEC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.58	-0.42	1.13e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.38	-4.98	-0.38	1.8e-6	Sense of smell;
UCEC	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg05527609	chr1:210001259	C1orf107	-0.51	-4.6	-0.35	8.92e-6	Red blood cell count;
UCEC	cis	rs250585	0.736	rs250559	chr16:23452824	G/A	cg26562691	chr16:23850404	PRKCB	0.35	4.61	0.36	8.8e-6	Egg allergy;
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	5.99	0.44	1.57e-8	Platelet count;
UCEC	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.64	0.42	8.28e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.8	5.17	0.39	7.51e-7	Cognitive ability (multi-trait analysis);
UCEC	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg12311346	chr5:56204834	C5orf35	-0.6	-5.26	-0.4	5e-7	Type 2 diabetes;
UCEC	cis	rs11118844	0.843	rs7518806	chr1:221915633	T/A	cg04222084	chr1:221915650	DUSP10	-0.81	-7.03	-0.5	7.12e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.31	10.06	0.64	1.96e-18	Uric acid levels;
UCEC	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.61	-6.03	-0.45	1.25e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.86	5.87	0.44	2.79e-8	Psoriasis;
UCEC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg08222618	chr4:941054	TMEM175	0.56	6.17	0.45	6.18e-9	Sjögren's syndrome;
UCEC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.77	-8.77	-0.59	4.04e-15	Menarche (age at onset);
UCEC	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.75	8.3	0.57	6.04e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.49	-0.47	1.27e-9	Post bronchodilator FEV1;
UCEC	cis	rs708547	0.705	rs4355453	chr4:57727876	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-4.9	-0.37	2.48e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	6.58	0.48	7.56e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.36	5.17	0.39	7.5e-7	Coronary artery disease;
UCEC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg19622623	chr12:86230825	RASSF9	-0.39	-4.86	-0.37	3.03e-6	Major depressive disorder;
UCEC	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	6.02	0.44	1.33e-8	IgG glycosylation;
UCEC	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.95	0.38	1.98e-6	Rheumatoid arthritis;
UCEC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.62	6.05	0.45	1.15e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.61	-5.56	-0.42	1.24e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1575951	1.000	rs10764798	chr10:130436819	T/A	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs7095607	0.538	rs2673796	chr10:69917242	A/G	cg18986048	chr10:69913749	MYPN	0.43	4.58	0.35	9.7e-6	Lung function (FVC);
UCEC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg23791538	chr6:167370224	RNASET2	-0.5	-5.05	-0.38	1.28e-6	Primary biliary cholangitis;
UCEC	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-7.66	-0.53	2.27e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.92	-0.44	2.22e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.48	4.8	0.37	3.87e-6	Breast cancer;
UCEC	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg13683864	chr3:40499215	RPL14	-0.56	-5.9	-0.44	2.37e-8	Renal cell carcinoma;
UCEC	cis	rs6546886	1.000	rs4328662	chr2:74244037	A/C	cg14702570	chr2:74259524	NA	-0.38	-4.58	-0.35	9.71e-6	Dialysis-related mortality;
UCEC	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.09	0.5	5.17e-11	Coronary artery disease;
UCEC	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.19e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.7	-7.29	-0.52	1.75e-11	Blood metabolite levels;
UCEC	cis	rs12144044	0.701	rs2999159	chr1:113230758	A/G	cg22162597	chr1:113214053	CAPZA1	-0.83	-6.43	-0.47	1.64e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.54	-5.92	-0.44	2.23e-8	Prostate cancer;
UCEC	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-0.72	-7.8	-0.54	1.05e-12	Gut microbiome composition (winter);
UCEC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg12463550	chr7:65579703	CRCP	0.71	7.26	0.51	2.11e-11	Aortic root size;
UCEC	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg13401533	chr1:37979913	MEAF6	0.58	4.93	0.38	2.22e-6	Axial length;
UCEC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.58	5.49	0.41	1.76e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-4.54	-0.35	1.18e-5	Pediatric autoimmune diseases;
UCEC	cis	rs847649	0.692	rs10271184	chr7:102477176	A/G	cg18108683	chr7:102477205	FBXL13	-0.63	-8.12	-0.56	1.71e-13	Morning vs. evening chronotype;
UCEC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.79	6.87	0.49	1.68e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.5	-6.29	-0.46	3.51e-9	Homoarginine levels;
UCEC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-7.8	-0.54	1.03e-12	Cognitive function;
UCEC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.5	-4.77	-0.37	4.41e-6	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs8106215	chr19:22879446	G/A	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg19997662	chr15:101784653	CHSY1	-0.59	-7.59	-0.53	3.31e-12	Corneal structure;
UCEC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.93	-10.65	-0.66	5.43e-20	Chronic sinus infection;
UCEC	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.91	12.85	0.73	8.32e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	4.64	0.36	7.69e-6	Aortic root size;
UCEC	cis	rs7917772	0.690	rs11191369	chr10:104457456	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.48	4.92	0.38	2.27e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs883565	0.502	rs7427462	chr3:38963275	G/A	cg01426195	chr3:39028469	NA	0.58	6.86	0.49	1.76e-10	Handedness;
UCEC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	0.98	9.51	0.62	5.13e-17	Initial pursuit acceleration;
UCEC	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg02527881	chr3:46936655	PTH1R	-0.6	-8.37	-0.57	4.16e-14	Birth weight;
UCEC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.71	-7.91	-0.55	5.69e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.38	4.8	0.37	3.81e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	0.73	4.63	0.36	7.92e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.68	7.23	0.51	2.45e-11	Lymphocyte counts;
UCEC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg06784218	chr1:46089804	CCDC17	0.4	4.65	0.36	7.45e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	4.55	0.35	1.09e-5	Height;
UCEC	cis	rs11760485	0.965	rs11773381	chr7:4401128	C/T	cg22450045	chr7:4839495	RADIL	-0.41	-5.09	-0.39	1.08e-6	Early childhood aggressive behavior;
UCEC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg11569703	chr11:65557185	OVOL1	-0.42	-5.99	-0.44	1.58e-8	Acne (severe);
UCEC	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.85	-9.78	-0.63	1.07e-17	Tonsillectomy;
UCEC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.74	-9.41	-0.61	9.38e-17	Cancer (pleiotropy);
UCEC	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.74	-4.79	-0.37	4.07e-6	Hair shape;
UCEC	cis	rs7818345	0.512	rs4922028	chr8:19303771	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.52	5.4	0.41	2.59e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.47	-6.12	-0.45	8.11e-9	IgG glycosylation;
UCEC	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg04439458	chr5:138467593	SIL1	-0.47	-5.35	-0.4	3.26e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2475553	0.547	rs62437121	chr6:158650718	G/A	cg07215822	chr6:158701037	NA	-0.65	-4.94	-0.38	2.05e-6	Lipoprotein (a) - cholesterol levels;
UCEC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg17294928	chr15:75287854	SCAMP5	0.45	4.88	0.37	2.72e-6	Caffeine consumption;
UCEC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.03	-0.38	1.42e-6	Personality dimensions;
UCEC	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.55	-4.61	-0.36	8.58e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg24531977	chr5:56204891	C5orf35	-0.49	-4.88	-0.37	2.78e-6	Coronary artery disease;
UCEC	cis	rs734999	0.967	rs2495365	chr1:2498027	A/G	cg18854424	chr1:2615690	NA	0.45	6.21	0.46	5.22e-9	Ulcerative colitis;
UCEC	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.56	-0.42	1.23e-7	Blood metabolite levels;
UCEC	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.66	-7.31	-0.52	1.55e-11	Blood protein levels;
UCEC	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.96	8.46	0.57	2.5e-14	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	5.02	0.38	1.49e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-6.17	-0.45	6.37e-9	Blood metabolite levels;
UCEC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.59	-4.9	-0.37	2.5e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.52	-5.32	-0.4	3.71e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.84	8.76	0.59	4.38e-15	Heart rate;
UCEC	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.58	6.6	0.48	6.9e-10	Hip circumference;
UCEC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.47	5.88	0.44	2.59e-8	HDL cholesterol levels;
UCEC	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.35	-0.46	2.47e-9	Response to antipsychotic treatment;
UCEC	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.75	6.23	0.46	4.72e-9	Fibroblast growth factor basic levels;
UCEC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.73	-6.88	-0.49	1.63e-10	Aortic root size;
UCEC	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs10256972	0.810	rs10257195	chr7:1032554	T/C	cg22907277	chr7:1156413	C7orf50	0.53	4.68	0.36	6.5e-6	Longevity;Endometriosis;
UCEC	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.61	-7.22	-0.51	2.52e-11	Mean corpuscular volume;
UCEC	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.15	0.6	4.38e-16	Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.76	-7.84	-0.54	8.64e-13	Cognitive function;
UCEC	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	6.89	0.49	1.5e-10	Coronary artery disease;
UCEC	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg17420585	chr12:42539391	GXYLT1	-0.42	-5.19	-0.39	6.94e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.5	-4.9	-0.38	2.45e-6	Schizophrenia;
UCEC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs3750082	0.852	rs7786669	chr7:32898338	A/G	cg05721444	chr7:32995514	FKBP9	0.5	5.46	0.41	1.99e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2395528	1.000	rs4598621	chr10:80101868	A/G	cg03450842	chr10:80834947	ZMIZ1	-0.44	-4.75	-0.36	4.85e-6	Conduct disorder (maternal expressed emotions interaction);
UCEC	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.52	5.25	0.4	5.34e-7	Monocyte percentage of white cells;
UCEC	cis	rs7267005	0.661	rs17093097	chr20:34387006	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	0.82	5.95	0.44	1.92e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.53	5.04	0.38	1.38e-6	Refractive astigmatism;
UCEC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.96	10.54	0.66	1.06e-19	Cognitive function;
UCEC	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.7	-5.8	-0.43	3.85e-8	Depression;
UCEC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.82	11.19	0.68	2.08e-21	Headache;
UCEC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.62	7.42	0.52	8.68e-12	Vitiligo;
UCEC	cis	rs7597155	0.806	rs11126244	chr2:69974873	C/A	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.12	-0.39	9.49e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.39e-7	Aortic root size;
UCEC	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.36	4.54	0.35	1.15e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs151997	0.925	rs27270	chr5:50183712	A/G	cg06027927	chr5:50259733	NA	-0.55	-5.1	-0.39	1.01e-6	Callous-unemotional behaviour;
UCEC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	4.86	0.37	3.01e-6	Longevity;
UCEC	cis	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg00614314	chr15:82944287	LOC80154	0.54	5.02	0.38	1.48e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs5167	0.504	rs3760627	chr19:45457180	T/C	cg09555818	chr19:45449301	APOC2	0.45	5.89	0.44	2.48e-8	Blood protein levels;
UCEC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.48	-4.87	-0.37	2.87e-6	Coronary artery disease;
UCEC	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	6.3	0.46	3.22e-9	LDL cholesterol;
UCEC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.46	-7.14	-0.51	4e-11	Ulcerative colitis;
UCEC	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.52	5.57	0.42	1.17e-7	Coenzyme Q10 levels;
UCEC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.62	5.41	0.41	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.37	4.62	0.36	8.43e-6	Acylcarnitine levels;
UCEC	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.77	0.37	4.33e-6	Breast cancer;
UCEC	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.67	-5.17	-0.39	7.4e-7	Breast cancer;
UCEC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.11	-0.39	9.73e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg06818710	chr6:28411271	ZSCAN23	0.5	5.86	0.44	2.88e-8	Cardiac Troponin-T levels;
UCEC	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.82	10.91	0.67	1.15e-20	Body mass index;
UCEC	cis	rs6684428	1.000	rs10888947	chr1:56375280	C/T	cg11651538	chr1:56320950	NA	-0.65	-6.11	-0.45	8.54e-9	Airflow obstruction;
UCEC	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	8.85	0.59	2.61e-15	Mean platelet volume;
UCEC	cis	rs9467773	1.000	rs6918506	chr6:26577857	C/G	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.62	9.24	0.61	2.54e-16	Prudent dietary pattern;
UCEC	cis	rs9470794	1.000	rs11750950	chr6:37979180	T/C	cg03458162	chr6:37400668	FTSJD2	0.86	5.03	0.38	1.44e-6	Type 2 diabetes;
UCEC	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg13575925	chr12:9217583	LOC144571	0.41	4.77	0.37	4.49e-6	Sjögren's syndrome;
UCEC	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.58	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.68	7.53	0.53	4.82e-12	Ulcerative colitis;
UCEC	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.81	-0.37	3.69e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-0.55	-4.69	-0.36	6.16e-6	Post bronchodilator FEV1;
UCEC	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.51	5.93	0.44	2.04e-8	Alcohol dependence;
UCEC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg17740752	chr1:2529902	MMEL1	-0.31	-4.58	-0.35	9.84e-6	Ulcerative colitis;
UCEC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg09491104	chr22:46646882	C22orf40	0.59	6.58	0.48	7.57e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.6	-6.14	-0.45	7.32e-9	Myopia (pathological);
UCEC	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.69	-5.97	-0.44	1.68e-8	Adiposity;
UCEC	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.51	4.72	0.36	5.53e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg10820045	chr2:198174542	NA	-0.49	-6.19	-0.45	5.62e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.33	0.71	1.99e-24	Prudent dietary pattern;
UCEC	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.46	-5.42	-0.41	2.38e-7	Monocyte percentage of white cells;
UCEC	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.53	6.52	0.47	1.05e-9	Total body bone mineral density;
UCEC	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.17	9.57	0.62	3.63e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.63	5.56	0.42	1.22e-7	Blood trace element (Zn levels);
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-8.24	-0.56	8.92e-14	Colorectal cancer;
UCEC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	9.55	0.62	4.18e-17	Chronic sinus infection;
UCEC	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.77	8.41	0.57	3.26e-14	Blood protein levels;
UCEC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.29	-0.68	1.15e-21	Headache;
UCEC	cis	rs13065560	0.594	rs9858516	chr3:38891548	C/T	cg01426195	chr3:39028469	NA	-0.53	-5.61	-0.42	9.91e-8	Interleukin-18 levels;
UCEC	trans	rs66573146	0.803	rs60228659	chr4:7031704	G/A	cg07817883	chr1:32538562	TMEM39B	1.18	8.24	0.56	8.91e-14	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs12980942	1.000	rs8109167	chr19:41823167	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	5.37	0.4	3e-7	Coronary artery disease;
UCEC	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.55	5.07	0.39	1.2e-6	Bitter taste perception;
UCEC	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.28	0.56	6.81e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.38	0.41	2.87e-7	Hemoglobin concentration;
UCEC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.44	5.3	0.4	4.22e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-5.61	-0.42	9.86e-8	Menarche (age at onset);
UCEC	cis	rs9309711	0.518	rs9752314	chr2:3494322	A/G	cg15506890	chr2:3487001	NA	-0.53	-4.71	-0.36	5.61e-6	Neurofibrillary tangles;
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-6.69	-0.48	4.46e-10	Platelet count;
UCEC	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.63	5.65	0.42	8.1e-8	Corneal astigmatism;
UCEC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	5.24	0.4	5.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.88	-10.15	-0.64	1.11e-18	Cognitive function;
UCEC	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.72	6.36	0.46	2.42e-9	Caudate activity during reward;
UCEC	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.51	4.77	0.37	4.43e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.77	7.18	0.51	3.16e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.75	-0.43	4.99e-8	Alcohol dependence;
UCEC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.61	6.68	0.48	4.66e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	9.16e-11	Tonsillectomy;
UCEC	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg03576123	chr11:487126	PTDSS2	0.73	5.57	0.42	1.16e-7	Body mass index;
UCEC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.39	-4.52	-0.35	1.28e-5	Height;
UCEC	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg22852734	chr6:133119734	C6orf192	0.71	4.93	0.38	2.18e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.61	7.46	0.52	7.1e-12	Bone mineral density;
UCEC	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.63	-8.13	-0.56	1.63e-13	Anterior chamber depth;
UCEC	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.54	-5.69	-0.42	6.57e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.85	-0.37	3.06e-6	Breast cancer;
UCEC	cis	rs7581030	1.000	rs6753560	chr2:71593535	G/A	cg07678644	chr2:71558969	ZNF638	0.55	4.97	0.38	1.83e-6	Testicular germ cell tumor;
UCEC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.86	-0.37	3.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.87	-8.85	-0.59	2.58e-15	Itch intensity from mosquito bite;
UCEC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg17764715	chr19:33622953	WDR88	0.64	6.01	0.44	1.37e-8	Bone properties (heel);
UCEC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.66	6.71	0.48	3.93e-10	Menopause (age at onset);
UCEC	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	1.18	15.17	0.78	6.89e-32	Body mass index;
UCEC	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg19912559	chr1:40204330	PPIE	0.51	5.04	0.38	1.36e-6	Blood protein levels;
UCEC	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg21419209	chr3:44054225	NA	-0.47	-5.04	-0.38	1.36e-6	Coronary artery disease;
UCEC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.9e-15	Height;
UCEC	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.14	9.68	0.62	1.95e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs7308134	0.891	rs7980286	chr12:1992500	A/G	cg16046261	chr12:1602312	ERC1	0.62	4.65	0.36	7.38e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.79	6.11	0.45	8.68e-9	Gut microbiome composition (summer);
UCEC	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.46	5.23	0.4	5.71e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg07636037	chr3:49044803	WDR6	0.57	4.76	0.37	4.68e-6	Menarche (age at onset);
UCEC	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.49	-5.53	-0.41	1.43e-7	Gout;
UCEC	cis	rs2839627	0.638	rs7281701	chr21:44277296	C/T	cg03543861	chr21:44258195	NA	0.51	4.74	0.36	4.92e-6	Information processing speed;
UCEC	cis	rs7870753	0.628	rs10820604	chr9:99192494	A/G	cg25260653	chr9:99212216	HABP4	0.54	5.12	0.39	9.23e-7	Height;
UCEC	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.13	-0.51	4.13e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg04310649	chr10:35416472	CREM	-0.46	-4.55	-0.35	1.12e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.54	-4.66	-0.36	6.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Parkinson's disease;
UCEC	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-6.35	-0.46	2.57e-9	Morning vs. evening chronotype;
UCEC	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.86	5.23	0.4	5.64e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.58	6.94	0.5	1.19e-10	Menarche (age at onset);
UCEC	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.71	7.53	0.53	4.61e-12	Lymphocyte counts;
UCEC	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.49	5.29	0.4	4.35e-7	Systemic lupus erythematosus;
UCEC	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.51	4.82	0.37	3.54e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.5	-5.09	-0.39	1.09e-6	Idiopathic membranous nephropathy;
UCEC	cis	rs12367572	0.620	rs2643140	chr12:45418311	C/T	cg03114573	chr12:45410052	DBX2	-0.57	-6.73	-0.49	3.51e-10	Gut microbiome composition (summer);
UCEC	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-7.08	-0.5	5.64e-11	Response to antipsychotic treatment;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.11	0.39	9.81e-7	Platelet count;
UCEC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-0.61	-7.57	-0.53	3.82e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.14	-14.26	-0.76	1.61e-29	Cognitive function;
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.64	7.45	0.52	7.15e-12	Menarche (age at onset);
UCEC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.79	-8.3	-0.56	6.25e-14	Cognitive function;
UCEC	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.4	-4.82	-0.37	3.5e-6	Abdominal aortic aneurysm;
UCEC	cis	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg21775007	chr8:11205619	TDH	0.42	4.58	0.35	9.72e-6	Retinal vascular caliber;
UCEC	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.63	6.39	0.47	2.02e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg13683864	chr3:40499215	RPL14	0.98	10.26	0.65	5.81e-19	Renal cell carcinoma;
UCEC	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.49	5.7	0.43	6.29e-8	Bone mineral density;
UCEC	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.59	5.76	0.43	4.85e-8	Retinal vascular caliber;
UCEC	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.65	4.64	0.36	7.65e-6	Breast cancer;
UCEC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg07153921	chr17:41440717	NA	-0.58	-6.94	-0.5	1.18e-10	Menopause (age at onset);
UCEC	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-6.81	-0.49	2.29e-10	Menarche (age at onset);
UCEC	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.44	4.73	0.36	5.21e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10242455	0.867	rs13362853	chr7:99223147	T/C	cg18809830	chr7:99032528	PTCD1	-0.54	-4.63	-0.36	7.88e-6	Blood metabolite levels;
UCEC	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.73	-7.06	-0.5	6.04e-11	Body mass index;
UCEC	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg21770322	chr7:97807741	LMTK2	0.54	6.8	0.49	2.44e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	13.81	0.75	2.48e-28	Schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06157335	chr1:53164003	C1orf163	0.58	7.16	0.51	3.65e-11	Warfarin maintenance dose;
UCEC	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.61	0.53	3.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.53	-6.16	-0.45	6.71e-9	Pubertal anthropometrics;
UCEC	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.51	-5.14	-0.39	8.76e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.14	0.39	8.68e-7	Breast cancer;
UCEC	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.46	-5.44	-0.41	2.17e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.44	4.96	0.38	1.94e-6	Menarche (age at onset);
UCEC	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-10.89	-0.67	1.28e-20	Vitiligo;
UCEC	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.42	4.63	0.36	8.14e-6	Obesity-related traits;
UCEC	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-4.59	-0.35	9.38e-6	Self-reported allergy;
UCEC	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.7	-6.17	-0.45	6.22e-9	Prudent dietary pattern;
UCEC	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.4e-8	Height;
UCEC	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.37	4.57	0.35	1.03e-5	Type 2 diabetes;
UCEC	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.46	4.82	0.37	3.52e-6	Endometrial cancer;
UCEC	cis	rs34390795	1	rs34390795	chr12:133112394	CGT/C	cg07099606	chr12:133051136	NA	0.5	5.14	0.39	8.61e-7	Red blood cell count;
UCEC	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.5	5.69	0.42	6.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.46	0.41	2.01e-7	Platelet count;
UCEC	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-0.94	-6.81	-0.49	2.31e-10	Body mass index;
UCEC	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.12	0.51	4.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg21191810	chr6:118973309	C6orf204	0.42	5.8	0.43	3.85e-8	Electrocardiographic conduction measures;
UCEC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg24069376	chr3:38537580	EXOG	0.55	6.47	0.47	1.35e-9	Schizophrenia;
UCEC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	6.57	0.48	8.3e-10	Platelet count;
UCEC	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.79	9.6	0.62	3.02e-17	Mean corpuscular volume;
UCEC	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.87	-12.39	-0.71	1.33e-24	Urate levels in lean individuals;
UCEC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.6	0.42	1.03e-7	Breast cancer;
UCEC	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg13593689	chr9:129986794	NA	0.47	4.75	0.36	4.73e-6	Intraocular pressure;
UCEC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.54	5.82	0.43	3.48e-8	Schizophrenia;
UCEC	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.57	-5.09	-0.39	1.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	0.87	6.97	0.5	9.86e-11	Blood protein levels;
UCEC	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.59	-5.59	-0.42	1.07e-7	Coronary artery disease;
UCEC	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-0.64	-6.0	-0.44	1.47e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	5.8	0.43	3.92e-8	Body mass index;
UCEC	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.6	5.59	0.42	1.07e-7	Vitiligo;
UCEC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	0.93	9.91	0.63	4.9e-18	Breast cancer;
UCEC	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.88	7.86	0.54	7.54e-13	Body mass index;
UCEC	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.57	4.8	0.37	3.8e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.08	0.39	1.11e-6	Height;
UCEC	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-21.26	-0.87	1.07e-46	Myeloid white cell count;
UCEC	cis	rs295140	1.000	rs10931897	chr2:201162520	T/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.3	-0.4	4.18e-7	Hemoglobin concentration;
UCEC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg22974920	chr21:40686053	BRWD1	-0.53	-4.82	-0.37	3.52e-6	Cognitive function;
UCEC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.72	-7.12	-0.51	4.35e-11	Aortic root size;
UCEC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.88	11.34	0.68	8.17e-22	Metabolic syndrome;
UCEC	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.85	9.87	0.63	5.96e-18	Blood metabolite levels;
UCEC	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg14092571	chr14:90743983	NA	-0.43	-5.7	-0.43	6.3e-8	Mortality in heart failure;
UCEC	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	4.76	0.37	4.66e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.97	-6.88	-0.49	1.64e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.33	4.69	0.36	6.1e-6	Primary biliary cholangitis;
UCEC	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.59	-6.45	-0.47	1.49e-9	Lung cancer;
UCEC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.81	-0.37	3.65e-6	Type 2 diabetes;
UCEC	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.72	-7.86	-0.54	7.48e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.59	5.29	0.4	4.33e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg03689076	chr20:33865952	NA	0.56	4.72	0.36	5.43e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-0.96	-14.44	-0.77	5.37e-30	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg05493336	chr16:89469845	ANKRD11	-0.36	-4.56	-0.35	1.07e-5	Multiple myeloma (IgH translocation);
UCEC	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg06521331	chr12:34319734	NA	-0.52	-4.61	-0.36	8.56e-6	Morning vs. evening chronotype;
UCEC	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.44	5.1	0.39	1.01e-6	Mortality in heart failure;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg27470027	chr11:63684601	RCOR2	0.62	6.85	0.49	1.92e-10	Schizophrenia;
UCEC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg11871910	chr12:69753446	YEATS4	0.55	4.89	0.37	2.56e-6	Response to diuretic therapy;
UCEC	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg03711944	chr11:47377212	SPI1	0.55	5.46	0.41	1.99e-7	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.66	0.58	7.84e-15	Platelet count;
UCEC	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	1.15	7.97	0.55	4.01e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.52	4.53	0.35	1.23e-5	Alzheimer's disease;
UCEC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg13695892	chr22:41940480	POLR3H	0.66	5.18	0.39	7.34e-7	Vitiligo;
UCEC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.6	-5.21	-0.4	6.15e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg01493522	chr13:37497338	NA	-0.46	-4.91	-0.38	2.4e-6	Coronary artery disease;
UCEC	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-6.18	-0.45	5.98e-9	Prevalent atrial fibrillation;
UCEC	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-6.3	-0.46	3.2e-9	Bipolar disorder;
UCEC	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.56	5.97	0.44	1.69e-8	Obesity-related traits;
UCEC	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.6	-5.47	-0.41	1.92e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
UCEC	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.61	-0.48	6.78e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.68	-6.06	-0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg00646381	chr17:77835854	NA	0.44	5.04	0.38	1.32e-6	Glucocorticoid-induced osteonecrosis (age 10 years and older);
UCEC	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.65	-6.84	-0.49	1.98e-10	Diastolic blood pressure;
UCEC	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.96	-0.38	1.93e-6	Height;
UCEC	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg22598563	chr5:131563921	P4HA2	0.35	4.69	0.36	6.28e-6	Blood metabolite levels;
UCEC	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.52	4.73	0.36	5.12e-6	Coronary artery disease;
UCEC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.56	4.81	0.37	3.63e-6	Neutrophil percentage of white cells;
UCEC	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg08886695	chr4:3369023	RGS12	-0.49	-5.45	-0.41	2.08e-7	Serum sulfate level;
UCEC	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg18681998	chr4:17616180	MED28	0.75	8.93	0.59	1.56e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.79	7.03	0.5	7.06e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.5	-5.27	-0.4	4.67e-7	Coronary artery disease;
UCEC	cis	rs2131877	0.956	rs57750973	chr3:194870093	T/C	cg19760965	chr3:194868843	C3orf21	0.43	4.71	0.36	5.8e-6	Non-small cell lung cancer;
UCEC	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg20825769	chr15:43991375	CKMT1A	-0.6	-4.65	-0.36	7.24e-6	Lung cancer in ever smokers;
UCEC	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-0.95	-9.76	-0.63	1.16e-17	Height;
UCEC	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.69	7.2	0.51	2.96e-11	Resting heart rate;
UCEC	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.51	5.09	0.39	1.06e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.77	8.88	0.59	2.11e-15	Obesity-related traits;
UCEC	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg19554555	chr3:13937349	NA	-0.53	-5.58	-0.42	1.14e-7	Ovarian reserve;
UCEC	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.89	-0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.56	6.37	0.47	2.27e-9	Hip circumference;
UCEC	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.83	-0.7	4.16e-23	Primary sclerosing cholangitis;
UCEC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.67	5.15	0.39	8.34e-7	Mean platelet volume;
UCEC	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.86	10.17	0.64	1.03e-18	Blood protein levels;
UCEC	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.98	0.76	8.98e-29	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs460214	0.564	rs458465	chr21:40024644	A/T	cg05519781	chr21:40033154	ERG	-0.55	-5.51	-0.41	1.53e-7	Response to cognitive-behavioural therapy in anxiety disorder;
UCEC	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.89	0.37	2.6e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.65	7.38	0.52	1.08e-11	Body mass index;
UCEC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg22166914	chr1:53195759	ZYG11B	0.57	6.19	0.45	5.8e-9	Monocyte count;
UCEC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.64	0.53	2.54e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.37	-4.98	-0.38	1.75e-6	Longevity;
UCEC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.73	-6.48	-0.47	1.27e-9	Initial pursuit acceleration;
UCEC	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.61	-6.65	-0.48	5.31e-10	Height;
UCEC	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	trans	rs877282	0.731	rs67369760	chr10:791583	C/T	cg22713356	chr15:30763199	NA	1.23	9.78	0.63	1.04e-17	Uric acid levels;
UCEC	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	5.78	0.43	4.31e-8	Alzheimer's disease;
UCEC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.43	-4.85	-0.37	3.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1978968	1.000	rs5013012	chr22:18450149	A/G	cg03078520	chr22:18463400	MICAL3	-0.52	-5.19	-0.39	6.99e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.69	-7.56	-0.53	4.01e-12	Breast cancer;
UCEC	cis	rs7246967	0.932	rs34949383	chr19:23033858	G/C	cg24889512	chr19:22816950	ZNF492	0.49	5.28	0.4	4.5e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.18	0.39	7.33e-7	Cognitive test performance;
UCEC	cis	rs7095607	0.777	rs10762191	chr10:69920031	C/A	cg18986048	chr10:69913749	MYPN	0.54	6.36	0.46	2.43e-9	Lung function (FVC);
UCEC	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.57	5.54	0.42	1.35e-7	Coronary artery disease;
UCEC	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.64	5.61	0.42	9.81e-8	Asthma;
UCEC	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.6	6.45	0.47	1.51e-9	Noise-induced hearing loss;
UCEC	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.32	-0.57	5.54e-14	Exhaled nitric oxide output;
UCEC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.07	-0.39	1.16e-6	Breast cancer;
UCEC	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg01475377	chr6:109611718	NA	-0.4	-4.93	-0.38	2.15e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.37	-0.47	2.29e-9	Blood pressure (smoking interaction);
UCEC	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.55	-5.34	-0.4	3.52e-7	Post bronchodilator FEV1;
UCEC	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	0.81	4.55	0.35	1.1e-5	Major depressive disorder;
UCEC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.73	-4.86	-0.37	2.93e-6	Narcolepsy;
UCEC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg24889512	chr19:22816950	ZNF492	0.6	6.58	0.48	7.59e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.5	-0.35	1.35e-5	Blood protein levels;
UCEC	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.85	6.67	0.48	4.9e-10	Fibroblast growth factor basic levels;
UCEC	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg13334819	chr7:99746414	C7orf59	-0.6	-5.02	-0.38	1.5e-6	Coronary artery disease;
UCEC	cis	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg02356786	chr1:243265016	LOC731275	0.84	5.84	0.43	3.24e-8	Obesity (early onset extreme);
UCEC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg05738196	chr6:26577821	NA	0.59	6.59	0.48	7.5e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.49	0.41	1.7e-7	HIV-1 control;
UCEC	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.47	-5.09	-0.39	1.09e-6	Morning vs. evening chronotype;
UCEC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-0.57	-7.3	-0.52	1.71e-11	Cancer (pleiotropy);
UCEC	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.66	-0.36	7.02e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.2	0.39	6.6e-7	Breast cancer;
UCEC	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg03146154	chr1:46216737	IPP	0.45	4.7	0.36	5.82e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.68	-7.42	-0.52	8.87e-12	Coronary artery disease;
UCEC	cis	rs4372836	0.729	rs4638745	chr2:29093803	A/G	cg09522027	chr2:28974177	PPP1CB	0.79	8.33	0.57	5.15e-14	Body mass index;
UCEC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.73	-0.36	5.11e-6	Parkinson's disease;
UCEC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.69	6.16	0.45	6.57e-9	Aortic root size;
UCEC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.57	6.12	0.45	8.09e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg02776659	chr21:47717406	C21orf57	-0.41	-4.56	-0.35	1.07e-5	Testicular germ cell tumor;
UCEC	cis	rs2721195	0.719	rs4925812	chr8:145808035	C/T	cg15320075	chr8:145703422	NA	0.47	4.61	0.36	8.58e-6	Age at first birth;
UCEC	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.88	-9.8	-0.63	9.42e-18	Blood metabolite levels;
UCEC	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-4.53	-0.35	1.21e-5	Blood metabolite levels;
UCEC	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.64	6.2	0.46	5.42e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-5.63	-0.42	8.9e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17592292	chr4:967094	DGKQ	0.62	7.33	0.52	1.42e-11	Warfarin maintenance dose;
UCEC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.47	4.94	0.38	2.07e-6	Pulse pressure;
UCEC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg22868518	chr11:507468	RNH1	0.66	4.53	0.35	1.22e-5	Body mass index;
UCEC	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.72	6.98	0.5	9.39e-11	Schizophrenia;
UCEC	cis	rs4400599	0.805	rs12063830	chr1:154150911	A/G	cg05139571	chr1:154127138	NUP210L	0.44	4.69	0.36	6.07e-6	Platelet distribution width;
UCEC	cis	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs35934224	0.783	rs12159647	chr22:19860575	C/T	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.8	-0.37	3.84e-6	Glaucoma (primary open-angle);
UCEC	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.59	5.79	0.43	4.03e-8	Colorectal cancer;
UCEC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.55	-0.53	4.3e-12	Prevalent atrial fibrillation;
UCEC	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg26528668	chr16:1614120	IFT140	0.48	5.65	0.42	8.06e-8	Coronary artery disease;
UCEC	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.97	5.46	0.41	1.99e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.84	-8.88	-0.59	2.09e-15	Blood metabolite levels;
UCEC	cis	rs7072216	0.881	rs2147897	chr10:100147813	A/C	cg19567339	chr10:100142640	NA	-0.61	-8.31	-0.57	5.71e-14	Metabolite levels;
UCEC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.72	8.88	0.59	2.14e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8105895	0.935	rs8110289	chr19:22239717	A/G	cg02912127	chr19:22235281	ZNF257	-0.64	-5.35	-0.4	3.29e-7	Body mass index (change over time);
UCEC	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.58	7.44	0.52	7.64e-12	Bone mineral density;
UCEC	trans	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg15509575	chr4:2286509	ZFYVE28	0.4	6.96	0.5	1.02e-10	Rheumatoid arthritis;
UCEC	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24023618	chr6:114292459	HDAC2	0.59	7.4	0.52	9.49e-12	Warfarin maintenance dose;
UCEC	cis	rs4237845	0.611	rs9971722	chr12:58308383	G/T	cg02175503	chr12:58329896	NA	0.79	8.42	0.57	3.12e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.52	-4.7	-0.36	6.05e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs751837	1.000	rs10047845	chr14:103481677	G/C	cg02938407	chr14:103486904	CDC42BPB	0.69	4.51	0.35	1.34e-5	Large B-cell lymphoma;
UCEC	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	8.02	0.55	3.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.83	8.96	0.59	1.32e-15	Longevity;Endometriosis;
UCEC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.45	0.41	2.09e-7	Tonsillectomy;
UCEC	cis	rs1165668	1.000	rs1165669	chr12:104318172	C/T	cg21863207	chr12:104234989	NT5DC3	-0.53	-4.66	-0.36	6.9e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	0.78	5.42	0.41	2.35e-7	Red blood cell traits;
UCEC	cis	rs4372836	1.000	rs6547872	chr2:28978074	C/T	cg09522027	chr2:28974177	PPP1CB	-0.61	-6.46	-0.47	1.41e-9	Body mass index;
UCEC	cis	rs6437061	0.740	rs991396	chr2:232821041	A/T	cg02061626	chr2:233274167	ALPPL2	0.51	5.74	0.43	5.2e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.36	0.4	3.12e-7	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.8	-8.66	-0.58	7.95e-15	Height;
UCEC	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg18646521	chr2:111875858	NA	0.4	4.63	0.36	7.81e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.79	-0.49	2.55e-10	Total body bone mineral density;
UCEC	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.3	-8.53	-0.58	1.66e-14	Diabetic kidney disease;
UCEC	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.67	-8.93	-0.59	1.57e-15	Neuroticism;
UCEC	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.55	6.9	0.49	1.41e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.24	-7.51	-0.53	5.14e-12	Diabetic kidney disease;
UCEC	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs420259	0.516	rs2040573	chr16:23529732	C/T	cg26562691	chr16:23850404	PRKCB	-0.34	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.51	-0.53	5.19e-12	Colorectal cancer;
UCEC	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.46	5.26	0.4	5e-7	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.11	-0.39	1e-6	Resting heart rate;
UCEC	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.54	-4.84	-0.37	3.26e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	8.26	0.56	7.65e-14	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	0.62	7.75	0.54	1.39e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.92	-0.38	2.34e-6	Aortic root size;
UCEC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.43	4.66	0.36	7.03e-6	Total body bone mineral density;
UCEC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.43	4.86	0.37	2.94e-6	Erythrocyte sedimentation rate;
UCEC	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.58	-6.18	-0.45	6.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.66	5.16	0.39	7.74e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	0.85	6.56	0.48	8.48e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.61	6.34	0.46	2.67e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs10851411	0.697	rs17709867	chr15:42800767	C/T	cg21293051	chr15:42870591	STARD9	0.78	4.71	0.36	5.74e-6	Glucose homeostasis traits;
UCEC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg06784218	chr1:46089804	CCDC17	0.54	6.73	0.49	3.58e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.41	-5.05	-0.38	1.26e-6	Menarche (age at onset);
UCEC	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.34	-4.95	-0.38	2e-6	Vitamin D levels;
UCEC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	0.93	8.72	0.58	5.4e-15	Cognitive function;
UCEC	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.95	0.5	1.08e-10	Morning vs. evening chronotype;
UCEC	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.65	5.14	0.39	8.53e-7	Orofacial clefts;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg11913218	chr1:10754156	CASZ1	0.68	6.89	0.49	1.49e-10	Schizophrenia;
UCEC	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.48	5.07	0.39	1.17e-6	Obesity;
UCEC	cis	rs2455799	0.964	rs2654651	chr3:15781620	G/C	cg16303742	chr3:15540471	COLQ	-0.41	-4.78	-0.37	4.16e-6	Mean platelet volume;
UCEC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.43	5.23	0.4	5.78e-7	Information processing speed;
UCEC	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.69	-5.61	-0.42	9.86e-8	Cognitive test performance;
UCEC	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.19	-0.39	6.73e-7	Bipolar disorder;
UCEC	cis	rs4713118	0.615	rs57252182	chr6:27720249	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.45	-4.75	-0.36	4.87e-6	Parkinson's disease;
UCEC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg11871910	chr12:69753446	YEATS4	1.06	13.41	0.74	2.74e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.74	8.58	0.58	1.21e-14	Mean corpuscular volume;
UCEC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.88	-9.71	-0.63	1.56e-17	Cognitive function;
UCEC	cis	rs28795989	0.896	rs7441569	chr4:7887548	A/G	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs11235843	0.571	rs12364069	chr11:73362259	G/A	cg09185399	chr11:73372479	PLEKHB1	0.58	4.52	0.35	1.29e-5	Hand grip strength;
UCEC	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	0.93	9.64	0.62	2.38e-17	Heart rate;
UCEC	cis	rs787274	0.867	rs786978	chr9:115460239	A/G	cg13803584	chr9:115635662	SNX30	-0.64	-5.91	-0.44	2.31e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1892094	1.000	rs72706958	chr1:169097057	A/T	cg17859187	chr1:168147929	TIPRL	-0.44	-4.52	-0.35	1.27e-5	Coronary artery disease;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg21980954	chr13:111141868	COL4A2	0.98	5.31	0.4	4e-7	Obesity-related traits;
UCEC	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.56	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.68	-6.12	-0.45	8.14e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.72	0.36	5.52e-6	Colorectal cancer;
UCEC	cis	rs7307889	0.793	rs7489044	chr12:6009595	A/G	cg23245485	chr12:6484219	SCNN1A	0.52	4.76	0.37	4.52e-6	Obesity-related traits;
UCEC	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.56	5.19	0.39	6.92e-7	Coronary artery disease;
UCEC	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.78	8.21	0.56	1.02e-13	Caffeine consumption;
UCEC	cis	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg12524725	chr2:239427019	NA	-0.71	-4.52	-0.35	1.26e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.43	4.51	0.35	1.3e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.75	7.44	0.52	7.68e-12	Menarche (age at onset);
UCEC	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.89	-6.55	-0.48	8.84e-10	Coronary artery calcification;
UCEC	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.72	6.46	0.47	1.46e-9	Subjective well-being;
UCEC	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.62	6.16	0.45	6.64e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg00086871	chr4:6988644	TBC1D14	0.96	5.8	0.43	3.87e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.0	9.42	0.61	9.05e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	6.89	0.49	1.5e-10	Ileal carcinoids;
UCEC	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	0.82	6.0	0.44	1.5e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.58	-4.93	-0.38	2.22e-6	Type 2 diabetes;
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg19678392	chr7:94953810	PON1	-0.58	-5.63	-0.42	9.08e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.58	-6.06	-0.45	1.08e-8	Hepatocellular carcinoma;
UCEC	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.6	5.25	0.4	5.22e-7	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.31e-6	Breast cancer;
UCEC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.58e-6	Diabetic kidney disease;
UCEC	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg05110241	chr16:68378359	PRMT7	-0.52	-4.58	-0.35	1e-5	Schizophrenia;
UCEC	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.52	-5.6	-0.42	1.01e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.51	5.36	0.4	3.15e-7	Schizophrenia;
UCEC	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.76	7.96	0.55	4.33e-13	Post bronchodilator FEV1;
UCEC	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	trans	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg07817883	chr1:32538562	TMEM39B	1.35	9.64	0.62	2.34e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.54	4.72	0.36	5.37e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.68	-5.09	-0.39	1.09e-6	White matter hyperintensity burden;
UCEC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg00786635	chr1:25594202	NA	0.5	4.86	0.37	3e-6	Erythrocyte sedimentation rate;
UCEC	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.82	8.32	0.57	5.58e-14	Colorectal cancer;
UCEC	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg03714773	chr7:91764589	CYP51A1	-0.41	-4.85	-0.37	3.15e-6	Breast cancer;
UCEC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.5	-5.06	-0.39	1.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7172689	0.908	rs11072995	chr15:81527032	A/T	cg00110041	chr15:81142343	KIAA1199	-0.5	-4.86	-0.37	2.92e-6	Inattentive symptoms;
UCEC	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.82	4.8	0.37	3.91e-6	Alzheimer's disease (late onset);
UCEC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg13147721	chr7:65941812	NA	0.94	6.91	0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg15192986	chr13:46630673	CPB2	-0.55	-5.56	-0.42	1.25e-7	Blood protein levels;
UCEC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.53	5.3	0.4	4.08e-7	Menopause (age at onset);
UCEC	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	7.64	0.53	2.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.36	-0.57	4.36e-14	Coronary artery disease;
UCEC	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	0.88	8.07	0.55	2.31e-13	Cognitive function;
UCEC	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.55	-6.85	-0.49	1.86e-10	Total body bone mineral density;
UCEC	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.19	0.45	5.76e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.48	-0.47	1.29e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.7	-0.54	1.84e-12	Schizophrenia;
UCEC	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.81	11.0	0.67	6.55e-21	Headache;
UCEC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg05132306	chr1:1846340	CALML6	-0.37	-4.67	-0.36	6.66e-6	Body mass index;
UCEC	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.86	5.82	0.43	3.56e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	6.78	0.49	2.67e-10	Coffee consumption (cups per day);
UCEC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.18	-0.39	7.29e-7	Cotinine glucuronidation;
UCEC	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-4.62	-0.36	8.26e-6	Type 2 diabetes;
UCEC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.83	-8.48	-0.57	2.21e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-13.35	-0.74	3.95e-27	Body mass index;
UCEC	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	22.67	0.88	7.68e-50	Chronic sinus infection;
UCEC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.58	-0.42	1.15e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs2267681	0.508	rs4726815	chr7:139514460	C/G	cg14116596	chr7:139528673	TBXAS1	0.58	5.5	0.41	1.64e-7	Cervical cancer;
UCEC	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg09491104	chr22:46646882	C22orf40	-0.51	-5.04	-0.38	1.36e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.5	0.57	1.92e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg01072550	chr1:21505969	NA	-0.52	-4.87	-0.37	2.83e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.99	8.02	0.55	2.98e-13	Exhaled nitric oxide output;
UCEC	cis	rs3824488	0.920	rs28474857	chr9:98247204	C/T	cg14565164	chr9:98057177	FANCC	0.68	4.53	0.35	1.21e-5	Neuroticism;
UCEC	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-5.74	-0.43	5.36e-8	Total cholesterol levels;
UCEC	cis	rs8177876	0.822	rs8177959	chr16:81115687	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg20965017	chr5:231967	SDHA	-0.63	-5.78	-0.43	4.32e-8	Breast cancer;
UCEC	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-4.53	-0.35	1.23e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs17490626	0.568	rs12416520	chr10:71211945	A/G	cg12610070	chr10:71211762	TSPAN15	-0.39	-6.17	-0.45	6.39e-9	Thrombosis;
UCEC	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.67	-6.42	-0.47	1.81e-9	Vitamin D levels;
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.62	-7.76	-0.54	1.35e-12	Paraoxonase activity;
UCEC	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.48	0.77	4.23e-30	Height;
UCEC	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.63	-6.36	-0.46	2.41e-9	Blood metabolite levels;
UCEC	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.66	6.42	0.47	1.77e-9	Bladder cancer;
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.67	8.27	0.56	7.2e-14	Menarche (age at onset);
UCEC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.6	6.16	0.45	6.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.5	-5.62	-0.42	9.27e-8	Tonsillectomy;
UCEC	cis	rs6840360	0.607	rs1561918	chr4:152446832	T/A	cg02366345	chr4:152330872	FAM160A1	0.34	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg11632617	chr15:75315747	PPCDC	-0.59	-6.86	-0.49	1.82e-10	Blood trace element (Zn levels);
UCEC	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg22868518	chr11:507468	RNH1	-0.57	-5.68	-0.42	6.82e-8	Systemic lupus erythematosus;
UCEC	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.72	-6.54	-0.47	9.39e-10	Platelet distribution width;
UCEC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26002218	chr14:103986227	CKB	0.36	5.24	0.4	5.56e-7	Body mass index;
UCEC	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.41	-5.27	-0.4	4.68e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.69	0.42	6.76e-8	Lung cancer;
UCEC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.74	4.59	0.35	9.35e-6	Skin colour saturation;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg14547644	chr6:28411285	ZSCAN23	0.5	5.43	0.41	2.29e-7	Cardiac Troponin-T levels;
UCEC	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.61	7.18	0.51	3.23e-11	Menopause (age at onset);
UCEC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.26	-0.46	3.91e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.24	-7.74	-0.54	1.48e-12	Diabetic kidney disease;
UCEC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06505273	chr16:24850292	NA	-0.5	-4.86	-0.37	2.99e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs57027767	chr19:22876535	A/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg20575277	chr15:90728569	SEMA4B	0.44	4.62	0.36	8.15e-6	Rheumatoid arthritis;
UCEC	cis	rs970548	0.954	rs61854123	chr10:46065451	G/A	cg15223267	chr10:46222474	FAM21C	0.56	5.13	0.39	9e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg03714773	chr7:91764589	CYP51A1	0.46	5.45	0.41	2.03e-7	Breast cancer;
UCEC	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Corneal astigmatism;
UCEC	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg05660106	chr1:15850417	CASP9	0.62	5.73	0.43	5.57e-8	Systolic blood pressure;
UCEC	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg16060761	chr17:80687452	NA	0.53	5.4	0.41	2.66e-7	Glycated hemoglobin levels;
UCEC	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.41	-5.19	-0.39	6.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-4.55	-0.35	1.12e-5	Self-reported allergy;
UCEC	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.64	5.67	0.42	7.36e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.62	-6.09	-0.45	9.28e-9	Metabolite levels;
UCEC	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.46	4.71	0.36	5.78e-6	Response to temozolomide;
UCEC	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-24.41	-0.9	1.43e-53	Myeloid white cell count;
UCEC	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.81	0.37	3.66e-6	Platelet count;
UCEC	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04202892	chr2:111875749	ACOXL	0.46	5.41	0.41	2.52e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.66	5.58	0.42	1.13e-7	High light scatter reticulocyte count;
UCEC	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.87	-9.58	-0.62	3.47e-17	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.49	5.13	0.39	9.12e-7	Type 2 diabetes;
UCEC	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	4.63	0.36	7.83e-6	Ulcerative colitis;Inflammatory bowel disease;
UCEC	trans	rs6725041	0.967	rs13013744	chr2:213069327	T/C	cg19573490	chr17:79870317	PCYT2;SIRT7	0.58	6.8	0.49	2.43e-10	QT interval (ambient particulate matter interaction);
UCEC	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2041895	0.509	rs12368448	chr12:107316796	A/C	cg13944111	chr12:107296891	NA	-0.33	-4.54	-0.35	1.16e-5	Glaucoma (low intraocular pressure);
UCEC	cis	rs13095912	0.962	rs6785918	chr3:185330631	A/G	cg11274856	chr3:185301563	NA	0.56	7.56	0.53	3.97e-12	Systolic blood pressure;
UCEC	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.66	-0.36	6.99e-6	Type 2 diabetes;
UCEC	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.47	4.78	0.37	4.12e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg26721908	chr21:47610096	LSS	-0.37	-4.65	-0.36	7.39e-6	Testicular germ cell tumor;
UCEC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.83	9.23	0.61	2.71e-16	Breast cancer;
UCEC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg10978503	chr1:24200527	CNR2	0.34	4.96	0.38	1.93e-6	Immature fraction of reticulocytes;
UCEC	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.78	8.33	0.57	5.07e-14	Mood instability;
UCEC	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	6.29	0.46	3.42e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.54	6.27	0.46	3.83e-9	Breast cancer;
UCEC	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.54	5.46	0.41	1.94e-7	Homoarginine levels;
UCEC	cis	rs10924970	0.649	rs10925306	chr1:235442776	A/T	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.9	-0.49	1.41e-10	Response to antipsychotic treatment;
UCEC	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.33	0.4	3.69e-7	Coronary artery disease;
UCEC	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.46	-4.81	-0.37	3.66e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.68	-6.15	-0.45	6.86e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.58	-4.86	-0.37	2.98e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-5.92	-0.44	2.17e-8	Morning vs. evening chronotype;
UCEC	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	6.92	0.5	1.26e-10	Platelet distribution width;
UCEC	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg15833940	chr8:1526540	DLGAP2	0.3	4.59	0.35	9.29e-6	Lung cancer;
UCEC	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.28	0.51	1.82e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.94	0.5	1.17e-10	Mood instability;
UCEC	cis	rs6460942	0.555	rs7803268	chr7:12306793	G/A	cg20607287	chr7:12443886	VWDE	-0.65	-4.7	-0.36	5.89e-6	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.88	7.44	0.52	7.98e-12	Platelet count;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.58	-0.42	1.1e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.5	5.35	0.4	3.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-7.46	-0.52	6.8e-12	Morning vs. evening chronotype;
UCEC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg23324259	chr8:82754387	SNX16	0.56	4.89	0.37	2.59e-6	Diastolic blood pressure;
UCEC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg13683864	chr3:40499215	RPL14	-0.52	-5.28	-0.4	4.56e-7	Renal cell carcinoma;
UCEC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.69	6.37	0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs7246967	0.673	rs2915932	chr19:22843701	C/T	cg24889512	chr19:22816950	ZNF492	0.59	6.32	0.46	2.98e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.86	-7.06	-0.5	6.03e-11	Coronary artery calcification;
UCEC	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.52	-6.01	-0.44	1.38e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg03859395	chr2:55845619	SMEK2	1.04	15.26	0.78	4.08e-32	Metabolic syndrome;
UCEC	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.64	5.08	0.39	1.11e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03404566	chr17:6899310	ALOX12	0.47	5.51	0.41	1.55e-7	Tonsillectomy;
UCEC	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	0.88	6.19	0.45	5.65e-9	Red blood cell traits;
UCEC	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg06985993	chr16:30040055	FAM57B	0.39	5.04	0.38	1.32e-6	Tonsillectomy;
UCEC	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.58	-6.73	-0.49	3.6e-10	Menopause (age at onset);
UCEC	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg18721089	chr20:30220636	NA	0.35	4.54	0.35	1.15e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.64	7.89	0.55	6.22e-13	Mean platelet volume;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14893161	chr1:205819251	PM20D1	0.7	8.52	0.57	1.79e-14	Menarche (age at onset);
UCEC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	4.81	0.37	3.77e-6	Lung function (FEV1/FVC);
UCEC	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.56	-6.27	-0.46	3.76e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.29	10.84	0.67	1.74e-20	Uric acid levels;
UCEC	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-0.93	-9.45	-0.61	7.35e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs4774830	0.744	rs62046383	chr15:56303623	C/T	cg24530489	chr15:56299380	NA	-0.65	-4.58	-0.35	9.88e-6	Delta-5 desaturase activity;
UCEC	cis	rs7709377	0.620	rs11742938	chr5:115474074	T/G	cg23108291	chr5:115420582	COMMD10	0.53	5.47	0.41	1.9e-7	Metabolite levels  (X-11787);
UCEC	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.7	7.1	0.51	5.03e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.48	5.64	0.42	8.42e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.99	-0.64	2.94e-18	Ulcerative colitis;
UCEC	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.92	-7.84	-0.54	8.57e-13	Body mass index;
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-0.84	-9.65	-0.62	2.31e-17	Height;
UCEC	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.52	5.54	0.42	1.39e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.56	-5.92	-0.44	2.19e-8	Blood protein levels;
UCEC	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.35	0.52	1.3e-11	Coffee consumption (cups per day);
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.69	7.86	0.54	7.32e-13	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.78	5.77	0.43	4.53e-8	Exhaled nitric oxide output;
UCEC	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-6.23	-0.46	4.65e-9	Glomerular filtration rate;
UCEC	cis	rs4499344	0.730	rs2903755	chr19:33098870	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs782107	0.761	rs782105	chr12:58835719	G/A	cg19181132	chr12:59314527	LRIG3	0.48	5.1	0.39	1.01e-6	Interleukin-12p70 levels;
UCEC	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg20607287	chr7:12443886	VWDE	-0.62	-4.54	-0.35	1.18e-5	Coronary artery disease;
UCEC	cis	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg00047079	chr13:79188975	RNF219	-0.58	-6.28	-0.46	3.6e-9	Schizophrenia;
UCEC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.56	-5.27	-0.4	4.82e-7	Obesity-related traits;
UCEC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.51	-5.13	-0.39	9.21e-7	Refractive error;
UCEC	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.74	-0.43	5.18e-8	Bladder cancer;
UCEC	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.43	4.52	0.35	1.28e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.53	4.85	0.37	3.09e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs3790645	1.000	rs897641	chr1:26881806	C/A	cg23229016	chr1:26872525	RPS6KA1	0.34	6.32	0.46	2.89e-9	Glucose homeostasis traits;
UCEC	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.99	-0.38	1.65e-6	Crohn's disease;
UCEC	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg05738196	chr6:26577821	NA	0.48	4.96	0.38	1.95e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.66	7.01	0.5	8.16e-11	Obesity-related traits;
UCEC	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.41	-5.02	-0.38	1.48e-6	Bone mineral density (spine);
UCEC	cis	rs9970896	0.850	rs4660129	chr1:236094087	A/G	cg13719188	chr1:236445668	ERO1LB	0.72	5.27	0.4	4.82e-7	Monocyte percentage of white cells;
UCEC	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.22	0.56	9.56e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	0.92	12.97	0.73	4.05e-26	Homoarginine levels;
UCEC	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.54	-5.18	-0.39	7.28e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.58	-5.67	-0.42	7.17e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.12e-9	Tonsillectomy;
UCEC	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.91	10.18	0.64	9.37e-19	Post bronchodilator FEV1;
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.89e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg04871131	chr7:94954202	PON1	-0.53	-5.19	-0.39	6.74e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg20821713	chr7:1055600	C7orf50	0.69	6.75	0.49	3.15e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.55	-5.04	-0.38	1.35e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	6.94	0.5	1.14e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.7	-5.12	-0.39	9.4e-7	Narcolepsy;
UCEC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.2	14.93	0.78	2.91e-31	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.56	-0.42	1.24e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.62	-0.42	9.51e-8	Urate levels in overweight individuals;
UCEC	cis	rs17490626	0.568	rs12413523	chr10:71211664	C/G	cg12610070	chr10:71211762	TSPAN15	-0.39	-6.17	-0.45	6.39e-9	Thrombosis;
UCEC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-6.25	-0.46	4.28e-9	Response to antipsychotic treatment;
UCEC	cis	rs17594362	0.512	rs348247	chr13:42126614	C/T	cg24916177	chr13:42031761	C13orf15	0.52	4.68	0.36	6.41e-6	Multiple sclerosis;
UCEC	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.83	8.69	0.58	6.38e-15	Vitamin D levels;
UCEC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-4.62	-0.36	8.18e-6	Primary biliary cholangitis;
UCEC	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg00086871	chr4:6988644	TBC1D14	0.85	5.44	0.41	2.18e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.58	6.22	0.46	5e-9	Initial pursuit acceleration;
UCEC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-0.57	-6.63	-0.48	5.88e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.82	8.53	0.58	1.69e-14	Parkinson's disease;
UCEC	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.61	6.47	0.47	1.36e-9	Retinal vascular caliber;
UCEC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.61	-6.26	-0.46	4.07e-9	Prudent dietary pattern;
UCEC	cis	rs12367572	0.540	rs7954773	chr12:45455769	C/T	cg03114573	chr12:45410052	DBX2	0.55	6.66	0.48	5.18e-10	Gut microbiome composition (summer);
UCEC	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.68	0.42	7.12e-8	Rheumatoid arthritis;
UCEC	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.63	6.16	0.45	6.79e-9	Multiple myeloma (IgH translocation);
UCEC	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.43	-4.94	-0.38	2.11e-6	Obesity;
UCEC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-6.0	-0.44	1.44e-8	Electroencephalogram traits;
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.32	-0.46	2.9e-9	Prudent dietary pattern;
UCEC	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg22067481	chr19:53234126	ZNF611	-0.5	-5.33	-0.4	3.56e-7	Response to paliperidone in schizophrenia (PANSS score);
UCEC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.96	0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.54	-4.82	-0.37	3.55e-6	Coronary artery disease;
UCEC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.45	0.52	7.37e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg15848620	chr12:58087721	OS9	-0.53	-5.01	-0.38	1.55e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.77	-5.21	-0.39	6.37e-7	Blood pressure (smoking interaction);
UCEC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.58	-5.73	-0.43	5.42e-8	Prudent dietary pattern;
UCEC	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.86	-0.43	2.97e-8	Adiposity;
UCEC	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	0.83	5.92	0.44	2.23e-8	Red blood cell traits;
UCEC	cis	rs1007190	0.881	rs3744470	chr17:42983901	A/T	cg15406952	chr17:42872593	NA	0.73	5.7	0.43	6.28e-8	DNA methylation (variation);
UCEC	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-5.38	-0.41	2.85e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.53	-0.42	1.41e-7	Aortic root size;
UCEC	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.55	-5.09	-0.39	1.1e-6	Initial pursuit acceleration;
UCEC	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	0.81	5.03	0.38	1.4e-6	Diabetic retinopathy;
UCEC	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg05535760	chr7:792225	HEATR2	0.77	6.5	0.47	1.16e-9	Cerebrospinal P-tau181p levels;
UCEC	cis	rs3914502	0.550	rs73174729	chr3:174479811	G/T	cg21145449	chr3:174580620	NAALADL2	-0.39	-4.66	-0.36	7.12e-6	Autism spectrum disorder;
UCEC	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.39	-5.08	-0.39	1.14e-6	Eye color traits;
UCEC	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.05	-7.67	-0.53	2.21e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.37	-13.26	-0.74	6.98e-27	Type 1 diabetes nephropathy;
UCEC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.34	-4.78	-0.37	4.23e-6	Longevity;
UCEC	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.87	-7.1	-0.51	5.01e-11	Coronary artery calcification;
UCEC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.78	8.89	0.59	2e-15	Menarche (age at onset);
UCEC	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.49	6.56	0.48	8.6e-10	Neutrophil percentage of white cells;
UCEC	cis	rs12681287	0.752	rs10435564	chr8:87266239	T/C	cg27223183	chr8:87520930	FAM82B	-0.61	-5.08	-0.39	1.15e-6	Caudate activity during reward;
UCEC	cis	rs9715521	0.868	rs6848053	chr4:59839309	T/C	cg11281224	chr4:60001000	NA	-0.53	-5.29	-0.4	4.44e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	0.8	7.09	0.5	5.3e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs807029	0.577	rs11190787	chr10:102758625	G/T	cg04662943	chr10:102668895	NA	0.47	4.71	0.36	5.79e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-5.16	-0.39	7.86e-7	Personality dimensions;
UCEC	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.83	9.54	0.62	4.39e-17	Metabolite levels;
UCEC	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs7709377	0.595	rs11241360	chr5:115448187	A/G	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg03354898	chr7:1950403	MAD1L1	-0.56	-5.49	-0.41	1.7e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs10887741	0.606	rs3824722	chr10:89435723	C/G	cg13926569	chr10:89418898	PAPSS2	0.41	4.85	0.37	3.16e-6	Exercise (leisure time);
UCEC	cis	rs6733160	0.967	rs12614186	chr2:64368444	A/C	cg22352474	chr2:64371530	PELI1	0.42	4.51	0.35	1.29e-5	Allergic dermatitis (nickel);
UCEC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.53	5.69	0.42	6.59e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-4.92	-0.38	2.27e-6	Insulin-like growth factors;
UCEC	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.47	-4.91	-0.38	2.44e-6	Body mass index;
UCEC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.91	-4.7	-0.36	6.02e-6	Plasma clusterin levels;
UCEC	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.53	-5.09	-0.39	1.08e-6	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.96	11.99	0.7	1.61e-23	Multiple sclerosis;
UCEC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.63	-6.84	-0.49	2e-10	Menarche (age at onset);
UCEC	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	1.000	rs936525	chr19:23056189	C/T	cg08271804	chr19:22816896	ZNF492	0.53	5.12	0.39	9.4e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	8.07	0.55	2.23e-13	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs876084	0.505	rs7834024	chr8:121103053	T/C	cg06265175	chr8:121136014	COL14A1	0.46	5.01	0.38	1.56e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs883565	0.740	rs6780772	chr3:39087764	A/G	cg01426195	chr3:39028469	NA	-0.68	-8.52	-0.58	1.71e-14	Handedness;
UCEC	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.67	-7.2	-0.51	2.84e-11	Stearic acid (18:0) levels;
UCEC	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	0.8	6.02	0.44	1.32e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.63	7.51	0.53	5.19e-12	Obesity-related traits;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	-0.61	-6.74	-0.49	3.29e-10	Breast cancer;
UCEC	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg05991184	chr2:219186017	PNKD	0.52	5.48	0.41	1.81e-7	Colorectal cancer;
UCEC	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg01072550	chr1:21505969	NA	-0.52	-4.59	-0.35	9.48e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.45	6.27	0.46	3.77e-9	Height;
UCEC	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.85	-0.43	3.1e-8	Adiposity;
UCEC	cis	rs890835	1.000	rs890835	chr5:175956271	A/C	cg17652716	chr5:176910622	PDLIM7	-0.67	-4.77	-0.37	4.44e-6	Menopause (age at onset);
UCEC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.7	6.25	0.46	4.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.85	7.1	0.51	5.04e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.55	6.68	0.48	4.54e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4372836	0.636	rs4665434	chr2:28976403	A/G	cg09522027	chr2:28974177	PPP1CB	-0.55	-5.62	-0.42	9.2e-8	Body mass index;
UCEC	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg26781129	chr3:44753946	ZNF502	-0.41	-4.71	-0.36	5.58e-6	Depressive symptoms;
UCEC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.09	-0.39	1.06e-6	Breast cancer;
UCEC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.73	-5.9	-0.44	2.36e-8	Calcium levels;
UCEC	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	4.82	0.37	3.51e-6	Blood protein levels;
UCEC	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.8	0.37	3.82e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.59	4.51	0.35	1.34e-5	Corneal astigmatism;
UCEC	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	6.9	0.49	1.42e-10	Coronary artery disease;
UCEC	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	8.21	0.56	1.02e-13	Post bronchodilator FEV1;
UCEC	trans	rs78587638	0.790	rs961842	chr2:119173701	G/A	cg09400194	chr10:81107848	PPIF	-0.6	-6.7	-0.48	4.2e-10	Mosquito bite size;
UCEC	cis	rs60311166	1.000	rs61220667	chr3:52744436	T/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.83	4.64	0.36	7.71e-6	CTACK levels;
UCEC	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.65	-6.02	-0.44	1.35e-8	Coronary artery disease;
UCEC	cis	rs10924970	0.625	rs2789370	chr1:235503256	A/G	cg26050004	chr1:235667680	B3GALNT2	0.49	4.59	0.35	9.24e-6	Asthma;
UCEC	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg13695892	chr22:41940480	POLR3H	-0.63	-5.28	-0.4	4.47e-7	Vitiligo;
UCEC	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.55	5.09	0.39	1.08e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	5.9	0.44	2.36e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.48	-5.4	-0.41	2.63e-7	Total body bone mineral density;
UCEC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.83	7.59	0.53	3.46e-12	Cognitive function;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	7.07	0.5	5.9e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.93	-0.38	2.16e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11760485	0.799	rs4236353	chr7:4407330	T/C	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.85	-8.49	-0.57	2.07e-14	Resting heart rate;
UCEC	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.94	0.5	1.17e-10	Parkinson's disease;
UCEC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.6	5.89	0.44	2.57e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg11632617	chr15:75315747	PPCDC	0.6	5.92	0.44	2.2e-8	Blood trace element (Zn levels);
UCEC	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-4.9	-0.37	2.47e-6	Coronary artery disease;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.9	10.87	0.67	1.45e-20	Menarche (age at onset);
UCEC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.72	-8.36	-0.57	4.31e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.1	-7.03	-0.5	7.31e-11	Diabetic kidney disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04968835	chr1:143913847	FAM72D	0.54	6.8	0.49	2.49e-10	Warfarin maintenance dose;
UCEC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.99	-6.23	-0.46	4.71e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg06521331	chr12:34319734	NA	-0.62	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.5	-5.53	-0.42	1.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg05962950	chr11:130786565	SNX19	0.63	6.81	0.49	2.32e-10	Schizophrenia;
UCEC	cis	rs4919044	0.641	rs11187231	chr10:94736462	T/A	cg00519463	chr10:94352821	KIF11	0.87	4.65	0.36	7.48e-6	Coronary artery disease;
UCEC	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.85	-6.75	-0.49	3.19e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Bladder cancer;
UCEC	cis	rs2074193	0.951	rs215340	chr12:47732638	A/G	cg11844464	chr12:46931139	NA	0.66	4.88	0.37	2.76e-6	Migraine with aura;
UCEC	cis	rs73206853	0.764	rs28580853	chr12:110826209	C/G	cg12870014	chr12:110450643	ANKRD13A	0.57	5.24	0.4	5.46e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg05962950	chr11:130786565	SNX19	-0.5	-5.17	-0.39	7.42e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.6	0.48	7.05e-10	Coronary artery disease;
UCEC	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg04155231	chr12:9217510	LOC144571	0.42	5.21	0.39	6.31e-7	Sjögren's syndrome;
UCEC	cis	rs7246967	0.551	rs7257333	chr19:22881149	C/T	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.65	0.48	5.42e-10	Motion sickness;
UCEC	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246967	0.611	rs12973264	chr19:22867749	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.68	6.42	0.47	1.76e-9	Breast cancer;
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	8.62	0.58	9.76e-15	Platelet count;
UCEC	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.8	7.91	0.55	5.64e-13	Longevity;Endometriosis;
UCEC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.6	0.58	1.11e-14	Prudent dietary pattern;
UCEC	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.64	-6.97	-0.5	9.92e-11	Hypospadias;
UCEC	cis	rs731174	0.797	rs679742	chr1:38156190	C/G	cg12339802	chr1:38156545	C1orf109	-0.61	-5.13	-0.39	9.08e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.8	0.37	3.79e-6	Breast cancer;
UCEC	cis	rs944990	0.640	rs10739951	chr9:96361585	T/C	cg13787134	chr9:96362102	PHF2	-0.39	-5.3	-0.4	4.18e-7	Body mass index;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.29	-0.46	3.38e-9	Cardiac Troponin-T levels;
UCEC	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg04155231	chr12:9217510	LOC144571	0.43	5.09	0.39	1.1e-6	Sjögren's syndrome;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.73	-0.43	5.59e-8	Cardiac Troponin-T levels;
UCEC	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs944990	0.662	rs10114002	chr9:96358030	A/G	cg13787134	chr9:96362102	PHF2	0.33	4.58	0.35	1e-5	Body mass index;
UCEC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg18451016	chr1:38461880	NA	0.5	4.76	0.37	4.5e-6	Coronary artery disease;
UCEC	cis	rs2288912	0.808	rs35670684	chr19:45455985	A/C	cg13119609	chr19:45449297	APOC2	0.42	6.02	0.44	1.35e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.63	7.32	0.52	1.48e-11	Waist-hip ratio;
UCEC	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.64	6.87	0.49	1.69e-10	Mortality in heart failure;
UCEC	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.63	-4.52	-0.35	1.25e-5	Gut microbiome composition (summer);
UCEC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs7246967	0.673	rs57736314	chr19:22880272	T/G	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.66	-7.24	-0.51	2.36e-11	Ear protrusion;
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.86	-10.63	-0.66	6.03e-20	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.66	0.53	2.3e-12	Schizophrenia;
UCEC	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.96	-0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	0.74	4.76	0.37	4.67e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.74	0.43	5.23e-8	Rheumatoid arthritis;
UCEC	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.23e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.57	5.71	0.43	6.09e-8	Bipolar disorder;
UCEC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18252515	chr7:66147081	NA	0.52	4.91	0.38	2.35e-6	Aortic root size;
UCEC	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.56	0.48	8.64e-10	Cognitive test performance;
UCEC	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.5	5.73	0.43	5.6e-8	Neuroticism;
UCEC	cis	rs6723108	0.627	rs7589297	chr2:135652399	C/A	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05157120	chr14:69727352	GALNTL1	0.54	6.73	0.49	3.48e-10	Warfarin maintenance dose;
UCEC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg09521647	chr2:100722408	AFF3	-0.32	-4.88	-0.37	2.68e-6	Chronic sinus infection;
UCEC	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.68	0.42	7.07e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.41	4.93	0.38	2.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.52	-0.35	1.27e-5	Bipolar disorder;
UCEC	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg03060546	chr3:49711283	APEH	0.61	5.79	0.43	4.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.55	5.03	0.38	1.4e-6	Coronary artery disease;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.76	9.24	0.61	2.52e-16	Menarche (age at onset);
UCEC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg03714773	chr7:91764589	CYP51A1	0.47	5.77	0.43	4.44e-8	Breast cancer;
UCEC	cis	rs7088591	0.867	rs7099096	chr10:59778731	T/C	cg11142981	chr10:60273225	BICC1	0.59	4.53	0.35	1.22e-5	Blood pressure;
UCEC	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.43	4.56	0.35	1.05e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs34726149	chr19:22952111	A/G	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs1575951	1.000	rs7903071	chr10:130438541	G/A	cg27041381	chr10:131357203	MGMT	0.6	5.23	0.4	5.71e-7	Plasma clusterin levels;
UCEC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg11150807	chr10:43354902	NA	0.8	4.54	0.35	1.16e-5	Blood protein levels;
UCEC	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.3	10.07	0.64	1.79e-18	Uric acid levels;
UCEC	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.58	5.37	0.4	3.02e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.48	6.14	0.45	7.38e-9	HDL cholesterol levels;
UCEC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	4.82	0.37	3.52e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs335810	1.000	rs16942155	chr15:60418758	A/G	cg03059131	chr15:60296996	FOXB1	-0.71	-4.55	-0.35	1.09e-5	Type 2 diabetes;
UCEC	cis	rs3849046	0.817	rs6874487	chr5:137907006	A/G	cg18180673	chr5:137827632	NA	-0.45	-4.54	-0.35	1.16e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.96	6.69	0.48	4.4e-10	Type 2 diabetes;
UCEC	cis	rs6752107	0.935	rs10929326	chr2:234151045	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	6.53	0.47	1.02e-9	Crohn's disease;Inflammatory bowel disease;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg17168838	chr19:54663528	LENG1	-0.74	-6.7	-0.48	4.05e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	1.07	7.92	0.55	5.34e-13	Corneal structure;
UCEC	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.55	-6.08	-0.45	1.01e-8	Tonsillectomy;
UCEC	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.32	5.2	0.39	6.43e-7	Cancer;
UCEC	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Depression;
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.81	9.79	0.63	9.74e-18	Menarche (age at onset);
UCEC	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.55	5.77	0.43	4.51e-8	Longevity;
UCEC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.52	-4.93	-0.38	2.23e-6	Post bronchodilator FEV1;
UCEC	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	5.56	0.42	1.24e-7	Breast cancer;
UCEC	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.74	-7.15	-0.51	3.77e-11	Response to antineoplastic agents;
UCEC	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.52	-4.74	-0.36	5.09e-6	Diabetic retinopathy;
UCEC	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.63	5.63	0.42	8.91e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.61	5.57	0.42	1.17e-7	Corneal astigmatism;
UCEC	cis	rs7870753	0.838	rs7039472	chr9:99245574	C/T	cg25260653	chr9:99212216	HABP4	0.58	5.85	0.43	3.1e-8	Height;
UCEC	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.65	-7.02	-0.5	7.8e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.68	-0.42	6.9e-8	Hemoglobin concentration;
UCEC	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.25	5.96	0.44	1.82e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.45	4.57	0.35	1.02e-5	Menopause (age at onset);
UCEC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.67	-5.71	-0.43	6.16e-8	Aortic root size;
UCEC	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.6	5.39	0.41	2.71e-7	Subjective well-being;
UCEC	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.64	0.36	7.62e-6	Menopause (age at onset);
UCEC	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.51	4.75	0.37	4.69e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.82	8.88	0.59	2.19e-15	Blood protein levels;
UCEC	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.47	-4.97	-0.38	1.81e-6	Longevity;
UCEC	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg01072550	chr1:21505969	NA	-0.57	-5.58	-0.42	1.13e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	0.81	4.79	0.37	4.1e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.82	8.03	0.55	2.93e-13	Blood protein levels;
UCEC	cis	rs7597155	0.846	rs4852981	chr2:69963655	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.36	-0.4	3.2e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.19e-10	Aortic root size;
UCEC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.73	-6.24	-0.46	4.46e-9	Schizophrenia;
UCEC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.56	4.69	0.36	6.32e-6	Neutrophil percentage of white cells;
UCEC	cis	rs13401104	0.633	rs35055104	chr2:237108884	C/T	cg23897927	chr2:237117786	ASB18	-0.52	-4.6	-0.35	9.04e-6	Educational attainment;
UCEC	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-4.95	-0.38	2.04e-6	Hemoglobin concentration;
UCEC	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	7.24	0.51	2.34e-11	Ileal carcinoids;
UCEC	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.6	-4.53	-0.35	1.19e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.62	4.86	0.37	3.02e-6	Breast cancer;
UCEC	cis	rs7656342	0.866	rs6841397	chr4:9815402	G/A	cg00071950	chr4:10020882	SLC2A9	0.44	4.57	0.35	1.04e-5	Gut microbiota (bacterial taxa);
UCEC	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.18	0.39	7.14e-7	Breast cancer;
UCEC	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.71	6.66	0.48	5.16e-10	High light scatter reticulocyte count;
UCEC	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.67	7.86	0.54	7.43e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.25	-0.4	5.26e-7	Initial pursuit acceleration;
UCEC	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.68	-6.14	-0.45	7.16e-9	Pancreatic cancer;
UCEC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.73	7.17	0.51	3.38e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.35	0.4	3.23e-7	Prudent dietary pattern;
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg09682330	chr6:28411287	ZSCAN23	0.47	5.09	0.39	1.1e-6	Cardiac Troponin-T levels;
UCEC	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.38	4.52	0.35	1.27e-5	Multiple system atrophy;
UCEC	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.82	0.49	2.24e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	4.73	0.36	5.22e-6	Cognitive ability;
UCEC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	0.87	7.46	0.52	7.08e-12	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.5	-5.08	-0.39	1.11e-6	Dental caries;
UCEC	cis	rs78487399	0.908	rs12471686	chr2:43831083	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.1	-0.45	8.86e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.67	6.8	0.49	2.41e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.39	-4.84	-0.37	3.32e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.68	-7.76	-0.54	1.29e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-9.12	-0.6	5.21e-16	Blood metabolite levels;
UCEC	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.55	-5.63	-0.42	9.06e-8	Red cell distribution width;
UCEC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.8	7.95	0.55	4.48e-13	Cognitive function;
UCEC	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg14851346	chr12:38532713	NA	0.52	4.64	0.36	7.55e-6	Heart rate;
UCEC	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.44	-4.94	-0.38	2.07e-6	Pelvic organ prolapse;
UCEC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.98	-0.44	1.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24308560	chr3:49941425	MST1R	0.52	5.89	0.44	2.57e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.71	-7.06	-0.5	6.3e-11	Body mass index;
UCEC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.1	18.4	0.84	5.6e-40	IgG glycosylation;
UCEC	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg00612595	chr21:47717864	NA	-0.46	-5.02	-0.38	1.49e-6	Testicular germ cell tumor;
UCEC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg16235748	chr6:149772707	ZC3H12D	0.37	4.77	0.37	4.44e-6	Dupuytren's disease;
UCEC	cis	rs9814567	0.555	rs1498726	chr3:134167300	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	5.07	0.39	1.16e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7246967	1.000	rs62120832	chr19:23064264	A/G	cg08271804	chr19:22816896	ZNF492	0.57	4.91	0.38	2.37e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.71	6.22	0.46	4.91e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-8.1	-0.56	1.95e-13	Body mass index;
UCEC	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg01072550	chr1:21505969	NA	-0.53	-5.01	-0.38	1.51e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.76	-7.09	-0.5	5.16e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	0.839	rs7214098	chr17:57204632	C/T	cg12560992	chr17:57184187	TRIM37	0.88	10.28	0.65	5.01e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.51	-5.02	-0.38	1.5e-6	Prostate cancer;
UCEC	cis	rs7267005	0.661	rs78094716	chr20:34432958	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.49	-4.72	-0.36	5.43e-6	Neurofibrillary tangles;
UCEC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg22974920	chr21:40686053	BRWD1	0.59	5.28	0.4	4.49e-7	Cognitive function;
UCEC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.4	4.71	0.36	5.59e-6	Obesity-related traits;
UCEC	cis	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg17325771	chr7:75508891	RHBDD2	-0.53	-6.38	-0.47	2.16e-9	Eotaxin levels;
UCEC	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.51	-6.25	-0.46	4.31e-9	Neuroticism;
UCEC	cis	rs80226907	0.570	rs76278827	chr14:55908007	G/A	cg13175173	chr14:55914753	NA	0.75	4.91	0.38	2.39e-6	Mean platelet volume;
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	4.83	0.37	3.44e-6	Prudent dietary pattern;
UCEC	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	trans	rs9420907	0.636	rs4387287	chr10:105677897	A/C	cg06749524	chr10:111152929	NA	0.65	7.06	0.5	6.27e-11	Telomere length;
UCEC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg22974920	chr21:40686053	BRWD1	0.62	5.41	0.41	2.52e-7	Cognitive function;
UCEC	cis	rs732765	0.734	rs12882425	chr14:75189226	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.54	-4.88	-0.37	2.69e-6	Non-small cell lung cancer;
UCEC	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	0.9	5.56	0.42	1.23e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs76096589	0.557	rs12587721	chr14:51016600	A/G	cg18894781	chr14:51955716	FRMD6	-0.44	-4.52	-0.35	1.27e-5	Diisocyanate-induced asthma;
UCEC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.62	6.52	0.47	1.06e-9	Colorectal cancer;
UCEC	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.88	-7.19	-0.51	3.05e-11	Coronary artery calcification;
UCEC	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.61	6.33	0.46	2.78e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.49	-4.74	-0.36	5.04e-6	Cardiac Troponin-T levels;
UCEC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.72	8.77	0.59	4.15e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg23307798	chr14:103986281	CKB	0.62	7.48	0.52	6.34e-12	Body mass index;
UCEC	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.72	9.12	0.6	5.32e-16	Testicular germ cell tumor;
UCEC	cis	rs7527939	0.579	rs11119484	chr1:210574569	G/A	cg17589890	chr1:210857205	KCNH1	0.39	4.81	0.37	3.64e-6	Schizophrenia;
UCEC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.07	-11.48	-0.69	3.57e-22	Corneal structure;
UCEC	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.52	-5.34	-0.4	3.45e-7	Multiple sclerosis;
UCEC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.86	-8.85	-0.59	2.58e-15	Obesity-related traits;
UCEC	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg21191810	chr6:118973309	C6orf204	0.42	5.94	0.44	1.97e-8	Electrocardiographic conduction measures;
UCEC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.71	0.58	5.67e-15	Blood protein levels;
UCEC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.6	5.86	0.43	2.97e-8	Calcium levels;
UCEC	cis	rs1165472	0.708	rs3862237	chr1:56185027	C/T	cg11523071	chr1:56160889	NA	-0.61	-4.75	-0.37	4.71e-6	Paclitaxel-induced neuropathy;
UCEC	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.37e-18	Height;
UCEC	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-4.68	-0.36	6.54e-6	Colorectal cancer;
UCEC	cis	rs7582701	1.000	rs7582701	chr2:46550769	C/G	cg17518825	chr2:46523461	EPAS1	0.47	5.08	0.39	1.13e-6	IgG glycosylation;
UCEC	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-5.66	-0.42	7.72e-8	Metabolite levels;
UCEC	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg06096015	chr1:231504339	EGLN1	0.41	4.77	0.37	4.41e-6	Hemoglobin concentration;
UCEC	cis	rs259282	0.605	rs28615461	chr19:33110149	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.46	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	6.34	0.46	2.65e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.69	-7.21	-0.51	2.78e-11	Body mass index;
UCEC	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.6	-6.55	-0.48	8.95e-10	Glomerular filtration rate;
UCEC	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg06462663	chr19:18546047	ISYNA1	-0.46	-5.77	-0.43	4.6e-8	Breast cancer;
UCEC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg18478394	chr8:109455254	TTC35	0.51	4.93	0.38	2.24e-6	Dupuytren's disease;
UCEC	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.86	12.3	0.71	2.41e-24	Leprosy;
UCEC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.8	9.62	0.62	2.71e-17	Monocyte count;
UCEC	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.45	4.58	0.35	9.97e-6	Schizophrenia;
UCEC	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.54	-5.48	-0.41	1.8e-7	Retinal vascular caliber;
UCEC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26207909	chr14:103986467	CKB	0.52	5.59	0.42	1.08e-7	Body mass index;
UCEC	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-0.74	-7.23	-0.51	2.47e-11	Height;
UCEC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs10012307	1.000	rs17048742	chr4:137503673	C/T	cg12033966	chr4:138453416	PCDH18	-0.71	-5.08	-0.39	1.12e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	trans	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg02900749	chr2:68251473	NA	-0.99	-7.37	-0.52	1.16e-11	Pursuit maintenance gain;
UCEC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-7.47	-0.52	6.46e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg18681998	chr4:17616180	MED28	0.8	8.9	0.59	1.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.68	7.62	0.53	2.84e-12	Longevity;
UCEC	cis	rs713477	0.967	rs6573032	chr14:55913776	A/G	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.24e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs6728642	1.000	rs11900461	chr2:97615993	C/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-5.26	-0.4	5.1e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg26114124	chr12:9217669	LOC144571	-0.4	-4.7	-0.36	5.88e-6	Sjögren's syndrome;
UCEC	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.49	5.01	0.38	1.56e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10254160	1.000	rs4730545	chr7:112067070	A/G	cg14158407	chr7:112758954	LOC401397	-1.01	-4.51	-0.35	1.3e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.57	-5.59	-0.42	1.05e-7	Total body bone mineral density;
UCEC	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.32	-4.77	-0.37	4.37e-6	Schizophrenia;
UCEC	cis	rs6806528	0.722	rs4855301	chr3:69267578	A/T	cg15909737	chr3:69811645	MITF	0.64	4.79	0.37	4.07e-6	Celiac disease;
UCEC	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.63	-4.8	-0.37	3.85e-6	Type 2 diabetes;
UCEC	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.4	0.57	3.52e-14	Exhaled nitric oxide output;
UCEC	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg10412286	chr16:89977652	TCF25	0.63	4.68	0.36	6.37e-6	Skin colour saturation;
UCEC	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.67	-5.38	-0.41	2.81e-7	Smoking initiation;
UCEC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.36	-0.4	3.08e-7	Cardiac Troponin-T levels;
UCEC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.62	6.46	0.47	1.46e-9	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.77	7.48	0.53	6.2e-12	Smoking behavior;
UCEC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg01262667	chr19:19385393	TM6SF2	0.5	6.97	0.5	9.7e-11	Tonsillectomy;
UCEC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.76	5.18	0.39	7.31e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs1483890	0.642	rs9825849	chr3:69404575	C/T	cg22125112	chr3:69402811	FRMD4B	0.46	4.83	0.37	3.41e-6	Resting heart rate;
UCEC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.78	-5.25	-0.4	5.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.55	-0.42	1.3e-7	Chronic sinus infection;
UCEC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg14353649	chr10:135191496	PAOX	0.54	5.32	0.4	3.82e-7	Lifespan;
UCEC	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg19567339	chr10:100142640	NA	-0.52	-6.37	-0.47	2.26e-9	Metabolite levels;
UCEC	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-4.51	-0.35	1.32e-5	Electroencephalogram traits;
UCEC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg22974920	chr21:40686053	BRWD1	0.61	5.36	0.4	3.1e-7	Cognitive function;
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg14456004	chr13:21872349	NA	0.5	5.22	0.4	6.06e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	trans	rs7980799	0.621	rs7138393	chr12:33590787	G/C	cg12743970	chr17:64536520	PRKCA	-0.57	-6.87	-0.49	1.7e-10	Heart rate;Heart rate variability traits (RMSSD);
UCEC	cis	rs7201929	1.000	rs7201929	chr16:28871966	C/T	cg10436792	chr16:28889110	ATP2A1	-0.37	-4.6	-0.35	9.15e-6	QT interval;
UCEC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.61	5.64	0.42	8.49e-8	Refractive astigmatism;
UCEC	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.52	-5.23	-0.4	5.64e-7	Morning vs. evening chronotype;
UCEC	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.64	-6.17	-0.45	6.26e-9	Prostate cancer;
UCEC	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-9.57	-0.62	3.65e-17	Electrocardiographic conduction measures;
UCEC	cis	rs7070678	0.662	rs35517756	chr10:29796598	A/G	cg24350475	chr10:30316933	KIAA1462	0.52	5.04	0.38	1.34e-6	Platelet thrombus formation;
UCEC	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.56	5.77	0.43	4.6e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg01689657	chr7:91764605	CYP51A1	0.47	5.91	0.44	2.27e-8	Breast cancer;
UCEC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.89	11.4	0.68	5.9e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4372836	0.658	rs7579321	chr2:28983166	T/C	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.68	-0.53	2.09e-12	Body mass index;
UCEC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.48	-4.99	-0.38	1.71e-6	Lung cancer;
UCEC	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.49	5.34	0.4	3.48e-7	Platelet distribution width;
UCEC	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.64	6.29	0.46	3.38e-9	Bladder cancer;
UCEC	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.71	-6.97	-0.5	1.01e-10	Menopause (age at onset);
UCEC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.57	4.67	0.36	6.72e-6	Breast cancer;
UCEC	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.53	-6.6	-0.48	6.84e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.26	0.4	5.08e-7	Hemoglobin concentration;
UCEC	cis	rs2302190	0.882	rs8067183	chr17:56462023	G/A	cg12560992	chr17:57184187	TRIM37	0.54	4.88	0.37	2.68e-6	Vitamin D levels;
UCEC	cis	rs58502974	0.673	rs7728943	chr5:7796625	A/G	cg12187999	chr5:6845652	NA	-0.37	-4.52	-0.35	1.24e-5	Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder;Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.49	4.53	0.35	1.23e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18932078	chr1:2524107	MMEL1	-0.35	-6.02	-0.44	1.3e-8	Ulcerative colitis;
UCEC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg20965017	chr5:231967	SDHA	-0.62	-5.36	-0.4	3.17e-7	Breast cancer;
UCEC	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	4.61	0.36	8.59e-6	Hemoglobin concentration;
UCEC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.64	6.16	0.45	6.56e-9	Aortic root size;
UCEC	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg02158880	chr13:53174818	NA	0.42	4.56	0.35	1.07e-5	Lewy body disease;
UCEC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.49	-4.87	-0.37	2.81e-6	Blood protein levels;
UCEC	cis	rs7611694	0.501	rs9840124	chr3:113109100	C/T	cg12596171	chr3:113251061	SIDT1	-0.51	-5.08	-0.39	1.13e-6	Prostate cancer;
UCEC	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.57	6.47	0.47	1.39e-9	Red blood cell count;
UCEC	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.74	-8.54	-0.58	1.56e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.48	5.36	0.4	3.18e-7	Mean corpuscular volume;
UCEC	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	0.98	4.84	0.37	3.24e-6	Thyroid stimulating hormone;
UCEC	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.58	5.33	0.4	3.67e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.6	-4.95	-0.38	1.97e-6	Obesity-related traits;
UCEC	cis	rs12573330	1.000	rs12572297	chr10:98470371	T/C	cg10113589	chr10:98118853	OPALIN	0.47	4.57	0.35	1.01e-5	Monocyte percentage of white cells;
UCEC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.97	-12.45	-0.72	9.42e-25	Multiple sclerosis;
UCEC	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	5.4	0.41	2.66e-7	Cognitive test performance;
UCEC	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.69	8.26	0.56	7.92e-14	Hip circumference;
UCEC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg23018236	chr17:30244563	NA	-0.78	-5.95	-0.44	1.91e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs61332075	0.503	rs113377546	chr2:239303870	G/A	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Lung function (FEV1/FVC);
UCEC	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg08216368	chr11:237063	SIRT3;PSMD13	0.46	4.57	0.35	1.01e-5	Alzheimer's disease (late onset);
UCEC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.13	0.64	1.29e-18	Cognitive ability;
UCEC	cis	rs6761276	0.899	rs13398125	chr2:113834835	G/A	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-1.04	-7.62	-0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs8063160	0.935	rs73283869	chr16:90067184	G/A	cg07984980	chr16:89898383	SPIRE2	0.82	4.65	0.36	7.34e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
UCEC	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.52	5.18	0.39	7.03e-7	Mortality in heart failure;
UCEC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-10.42	-0.65	2.19e-19	Cognitive function;
UCEC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.55	6.11	0.45	8.44e-9	Calcium levels;
UCEC	cis	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg20307385	chr11:47447363	PSMC3	-0.63	-4.73	-0.36	5.11e-6	Intraocular pressure;
UCEC	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.57	-5.75	-0.43	4.94e-8	Eye color traits;
UCEC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg10412286	chr16:89977652	TCF25	0.63	4.68	0.36	6.37e-6	Skin colour saturation;
UCEC	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.47	-5.63	-0.42	8.66e-8	Mean platelet volume;
UCEC	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.36	-5.61	-0.42	9.9e-8	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs6604026	0.740	rs10874747	chr1:93352491	A/G	cg17283838	chr1:93427260	FAM69A	-0.45	-4.57	-0.35	1.01e-5	Multiple sclerosis;
UCEC	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	cg07049167	chr1:166818506	POGK	0.55	5.17	0.39	7.66e-7	Refractive astigmatism;
UCEC	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.58	-5.35	-0.4	3.27e-7	Mortality in heart failure;
UCEC	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs11867410	0.744	rs74007965	chr17:63928560	G/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.88	-0.37	2.74e-6	Alzheimer's disease (late onset);
UCEC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.43	4.73	0.36	5.21e-6	Response to antineoplastic agents;
UCEC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg14851346	chr12:38532713	NA	-0.51	-5.07	-0.39	1.17e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6893207	1.000	rs6878840	chr5:16377302	C/G	cg11584519	chr5:16175867	MARCH11	-0.64	-4.69	-0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.61	5.64	0.42	8.4e-8	Multiple sclerosis;
UCEC	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	1.04	14.11	0.76	4.07e-29	Ulcerative colitis;
UCEC	cis	rs4853036	1.000	rs13020991	chr2:70068642	A/G	cg02498382	chr2:70120550	SNRNP27	-0.47	-4.56	-0.35	1.06e-5	Colorectal or endometrial cancer;
UCEC	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.76	-8.56	-0.58	1.36e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	7.13	0.51	4.12e-11	Chronic sinus infection;
UCEC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg14008862	chr17:28927542	LRRC37B2	0.58	5.18	0.39	7.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	7.87	0.54	6.93e-13	Smoking behavior;
UCEC	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	5.36	0.4	3.14e-7	Cognitive test performance;
UCEC	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.6	-7.16	-0.51	3.56e-11	Prevalent atrial fibrillation;
UCEC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26207909	chr14:103986467	CKB	0.53	5.85	0.43	3.1e-8	Body mass index;
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg00993799	chr7:104653126	LOC100216545	-0.58	-6.85	-0.49	1.89e-10	Breast cancer;
UCEC	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	8.77	0.59	4.17e-15	Electrocardiographic conduction measures;
UCEC	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.37	4.57	0.35	1.03e-5	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-4.82	-0.37	3.52e-6	Blood metabolite levels;
UCEC	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.1	-14.51	-0.77	3.62e-30	Schizophrenia;
UCEC	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-12.16	-0.71	5.58e-24	Height;
UCEC	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.83	6.5	0.47	1.17e-9	Lymphocyte counts;
UCEC	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.5	-5.48	-0.41	1.78e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2932538	0.583	rs2932537	chr1:113230394	C/T	cg22162597	chr1:113214053	CAPZA1	0.73	6.06	0.45	1.11e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg11161011	chr14:65562177	MAX	-0.8	-7.45	-0.52	7.5e-12	Obesity-related traits;
UCEC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.45	5.93	0.44	2.06e-8	Coronary artery disease;
UCEC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	4.7	0.36	5.84e-6	Cognitive ability;
UCEC	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.37	-5.84	-0.43	3.19e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	0.71	5.27	0.4	4.72e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6834538	1.000	rs2171280	chr4:113472637	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.47	-4.52	-0.35	1.24e-5	Free thyroxine concentration;
UCEC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.79	-8.57	-0.58	1.28e-14	Breast cancer;
UCEC	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.84	-9.36	-0.61	1.29e-16	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Bladder cancer;
UCEC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-6.24	-0.46	4.51e-9	Menarche (age at onset);
UCEC	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.69	-0.36	6.22e-6	Parkinson's disease;
UCEC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.45	0.41	2.04e-7	Prudent dietary pattern;
UCEC	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.34	-0.4	3.5e-7	Bipolar disorder;
UCEC	cis	rs11867410	0.744	rs73992176	chr17:63967383	C/T	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	0.95	14.66	0.77	1.5e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.65	-6.08	-0.45	9.85e-9	Vitiligo;
UCEC	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.34	-4.55	-0.35	1.14e-5	Homoarginine levels;
UCEC	cis	rs6882076	1.000	rs12517431	chr5:156392248	C/T	cg12943317	chr5:156479607	HAVCR1	-0.5	-5.23	-0.4	5.83e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.51	4.83	0.37	3.37e-6	Coronary artery disease;
UCEC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.51	5.53	0.42	1.41e-7	Platelet count;
UCEC	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg06096015	chr1:231504339	EGLN1	0.47	5.24	0.4	5.58e-7	Hemoglobin concentration;
UCEC	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.54	-4.86	-0.37	2.97e-6	Hypospadias;
UCEC	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.64	4.51	0.35	1.34e-5	Breast cancer;
UCEC	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg00277334	chr10:82204260	NA	-0.55	-5.38	-0.41	2.81e-7	Post bronchodilator FEV1;
UCEC	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.6	4.74	0.36	4.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.57	0.42	1.16e-7	Prudent dietary pattern;
UCEC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.8	8.25	0.56	8.32e-14	Lung cancer;
UCEC	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.21	8.07	0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	0.45	4.63	0.36	7.99e-6	QRS complex (12-leadsum);
UCEC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg17279458	chr3:44753948	ZNF502	-0.42	-4.59	-0.35	9.57e-6	Depressive symptoms;
UCEC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-6.69	-0.48	4.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.75	0.36	4.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7307889	0.793	rs10161036	chr12:6005072	C/T	cg23245485	chr12:6484219	SCNN1A	0.53	4.76	0.37	4.55e-6	Obesity-related traits;
UCEC	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.46	-4.93	-0.38	2.22e-6	Schizophrenia;
UCEC	cis	rs7714670	0.736	rs2973545	chr5:73094209	G/T	cg00119811	chr5:73092353	RGNEF	-0.37	-4.52	-0.35	1.26e-5	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg03748352	chr10:182365	ZMYND11	0.56	4.55	0.35	1.12e-5	Uric acid levels;
UCEC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.63	5.54	0.42	1.39e-7	Response to diuretic therapy;
UCEC	cis	rs4646312	0.555	rs2020917	chr22:19928884	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	-0.52	-5.02	-0.38	1.46e-6	Schizophrenia;
UCEC	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.69	-5.27	-0.4	4.69e-7	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.49	5.07	0.39	1.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17718580	0.826	rs72679544	chr14:51031469	C/A	cg04730355	chr14:51134070	SAV1	1.16	5.38	0.41	2.9e-7	Cognitive performance;
UCEC	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.81	-9.22	-0.61	2.96e-16	Primary sclerosing cholangitis;
UCEC	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.53	4.87	0.37	2.81e-6	Night sleep phenotypes;
UCEC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.71	7.09	0.51	5.09e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7975161	0.630	rs6539128	chr12:104618454	A/G	cg25273343	chr12:104657179	TXNRD1	-0.74	-5.18	-0.39	7.08e-7	Toenail selenium levels;
UCEC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.56	5.96	0.44	1.75e-8	Electroencephalogram traits;
UCEC	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.88	-0.54	6.69e-13	Total cholesterol levels;
UCEC	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.44	-5.77	-0.43	4.44e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg02413938	chr2:239008929	ESPNL	-0.36	-4.63	-0.36	8.06e-6	Prostate cancer;
UCEC	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-5.99	-0.44	1.57e-8	Electroencephalogram traits;
UCEC	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.68	8.27	0.56	7.35e-14	Immature fraction of reticulocytes;
UCEC	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.17	0.64	9.99e-19	Electrocardiographic conduction measures;
UCEC	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg01072550	chr1:21505969	NA	-0.58	-5.68	-0.42	6.94e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.54	5.61	0.42	9.78e-8	Schizophrenia;
UCEC	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.77	7.66	0.53	2.34e-12	Schizophrenia;
UCEC	trans	rs6479901	0.895	rs10761728	chr10:64995568	C/T	cg12751693	chr12:62629162	NA	-0.55	-6.79	-0.49	2.6e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18932078	chr1:2524107	MMEL1	0.39	6.23	0.46	4.69e-9	Ulcerative colitis;
UCEC	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.63	-6.38	-0.47	2.22e-9	C-reactive protein levels;
UCEC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.61	4.71	0.36	5.78e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.49	-7.34	-0.52	1.36e-11	Diabetic kidney disease;
UCEC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.65	-0.42	7.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.62	6.61	0.48	6.58e-10	Menopause (age at onset);
UCEC	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg17294928	chr15:75287854	SCAMP5	-0.48	-4.61	-0.36	8.6e-6	Lung cancer;
UCEC	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.46	0.47	1.46e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg01426195	chr3:39028469	NA	-0.77	-10.31	-0.65	4.22e-19	Handedness;
UCEC	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.0	7.57	0.53	3.79e-12	Uric acid levels;
UCEC	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.71	7.31	0.52	1.6e-11	Alcohol dependence;
UCEC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	0.91	4.8	0.37	3.8e-6	IgG glycosylation;
UCEC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg26721908	chr21:47610096	LSS	-0.35	-4.52	-0.35	1.27e-5	Testicular germ cell tumor;
UCEC	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.59	-0.48	7.46e-10	Mood instability;
UCEC	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.56	5.46	0.41	1.99e-7	Blood metabolite levels;
UCEC	cis	rs4654899	0.931	rs3767241	chr1:21166144	C/T	cg01072550	chr1:21505969	NA	0.54	5.5	0.41	1.63e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.04	-0.38	1.37e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	4.94	0.38	2.12e-6	Lymphocyte counts;
UCEC	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.98	11.47	0.69	3.64e-22	Cognitive function;
UCEC	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.28	0.4	4.57e-7	Coronary artery disease;
UCEC	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.07	-0.39	1.19e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.56	4.65	0.36	7.43e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.19e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.41	4.61	0.36	8.79e-6	Chronic sinus infection;
UCEC	cis	rs4265793	1.000	rs8051547	chr16:19028869	T/C	cg06773604	chr16:18995157	TMC7	0.76	5.77	0.43	4.46e-8	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs17600642	0.694	rs72814530	chr10:72444745	A/G	cg23422916	chr10:72218225	NA	-0.55	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs7523273	0.526	rs1204706	chr1:208021060	G/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-4.88	-0.37	2.74e-6	Schizophrenia;
UCEC	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.8	-10.03	-0.64	2.28e-18	Systemic sclerosis;
UCEC	cis	rs1595825	0.836	rs79748557	chr2:198567912	G/T	cg19156104	chr2:198669113	PLCL1	-0.66	-4.74	-0.36	5.06e-6	Ulcerative colitis;
UCEC	cis	rs10266483	0.921	rs683510	chr7:63749361	A/C	cg23304165	chr7:63498798	NA	-0.44	-4.79	-0.37	4.11e-6	Response to statin therapy;
UCEC	cis	rs17824620	0.548	rs77885072	chr12:113120459	T/C	cg26711794	chr12:112450906	ERP29;TMEM116	0.6	4.9	0.37	2.47e-6	Platelet count;
UCEC	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg13683864	chr3:40499215	RPL14	0.54	5.51	0.41	1.56e-7	Renal cell carcinoma;
UCEC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.79	-0.37	4.02e-6	Parkinson's disease;
UCEC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg06027949	chr8:82754900	SNX16	-0.61	-5.13	-0.39	9.13e-7	Diastolic blood pressure;
UCEC	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.71	9.18	0.6	3.74e-16	Rheumatoid arthritis;
UCEC	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs75804782	0.625	rs59039294	chr2:239470654	G/A	cg12524725	chr2:239427019	NA	-0.67	-4.63	-0.36	7.93e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs4588572	0.643	rs1560197	chr5:77768302	T/C	cg11547950	chr5:77652471	NA	-0.47	-5.5	-0.41	1.64e-7	Triglycerides;
UCEC	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg05660106	chr1:15850417	CASP9	0.53	4.8	0.37	3.93e-6	Systolic blood pressure;
UCEC	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.44	-0.41	2.22e-7	Morning vs. evening chronotype;
UCEC	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.52	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.6	0.35	9.12e-6	Educational attainment;
UCEC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.8	0.49	2.47e-10	Motion sickness;
UCEC	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.37	-0.47	2.27e-9	Crohn's disease;
UCEC	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.74	-4.79	-0.37	4.07e-6	Hair shape;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-6.2	-0.46	5.55e-9	Response to antipsychotic treatment;
UCEC	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.95	8.47	0.57	2.32e-14	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.71	6.16	0.45	6.59e-9	Alzheimer's disease;
UCEC	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.63	-5.2	-0.39	6.7e-7	LDL cholesterol levels;
UCEC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg24163568	chr5:669837	TPPP	0.44	5.53	0.42	1.42e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.38	4.52	0.35	1.27e-5	Multiple system atrophy;
UCEC	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.47	-4.52	-0.35	1.29e-5	Waist circumference;Body mass index;
UCEC	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.45	-0.57	2.59e-14	Monocyte count;
UCEC	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.52	-0.69	2.74e-22	Monocyte count;
UCEC	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.57	-5.01	-0.38	1.57e-6	Birth weight;
UCEC	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.52	5.88	0.44	2.66e-8	Hip circumference;
UCEC	cis	rs8177876	0.822	rs74437879	chr16:81112592	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg23782820	chr8:58130467	NA	0.62	4.81	0.37	3.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.63	7.1	0.51	4.9e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3785574	0.650	rs2005132	chr17:62008232	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.39	-0.41	2.78e-7	Height;
UCEC	cis	rs66716358	0.552	rs11037948	chr11:44324907	G/C	cg02785814	chr11:44338707	NA	-0.51	-5.0	-0.38	1.59e-6	Monobrow;
UCEC	cis	rs10186876	0.728	rs4953034	chr2:44143216	T/A	cg10317145	chr2:44065680	ABCG8;ABCG5	-0.34	-4.56	-0.35	1.08e-5	Hand grip strength;
UCEC	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.78	4.69	0.36	6.21e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10899021	1.000	rs11236201	chr11:74375633	A/G	cg25880958	chr11:74394337	NA	-0.72	-4.64	-0.36	7.54e-6	Response to metformin (IC50);
UCEC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg20821713	chr7:1055600	C7orf50	-0.74	-7.03	-0.5	7.37e-11	Bronchopulmonary dysplasia;
UCEC	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.65	-0.36	7.22e-6	Morning vs. evening chronotype;
UCEC	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-9.23	-0.61	2.79e-16	Monocyte count;
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	Androgen levels;
UCEC	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	cis	rs4778214	1.000	rs4778214	chr15:28205564	A/G	cg08281084	chr15:28459700	HERC2	-0.52	-4.53	-0.35	1.21e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
UCEC	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.53	-5.64	-0.42	8.41e-8	Brugada syndrome;
UCEC	cis	rs10242455	0.702	rs73405247	chr7:99159174	C/G	cg18809830	chr7:99032528	PTCD1	-0.82	-4.58	-0.35	1e-5	Blood metabolite levels;
UCEC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.69	-6.8	-0.49	2.4e-10	Blood metabolite levels;
UCEC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg13870426	chr17:30244630	NA	-0.63	-4.56	-0.35	1.06e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs11697848	1.000	rs13433386	chr20:48507912	A/G	cg17849948	chr20:48532315	SPATA2	1.05	4.98	0.38	1.78e-6	Systemic lupus erythematosus;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs4654899	0.931	rs1152998	chr1:21124290	C/T	cg01072550	chr1:21505969	NA	-0.51	-5.07	-0.39	1.19e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.04	7.99	0.55	3.62e-13	Vitiligo;
UCEC	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg07645718	chr20:61493192	TCFL5	0.67	4.87	0.37	2.9e-6	Obesity-related traits;
UCEC	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.64	6.7	0.48	4.08e-10	QRS complex (12-leadsum);
UCEC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	9.25	0.61	2.43e-16	Alzheimer's disease;
UCEC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg06521331	chr12:34319734	NA	-0.54	-4.82	-0.37	3.61e-6	Morning vs. evening chronotype;
UCEC	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.51	-5.46	-0.41	1.98e-7	Hip circumference adjusted for BMI;Body mass index;
UCEC	trans	rs10242455	0.702	rs3528	chr7:99055940	T/C	cg09045935	chr12:6379348	NA	0.97	6.85	0.49	1.84e-10	Blood metabolite levels;
UCEC	cis	rs7766436	0.961	rs6922960	chr6:22570189	T/C	cg13666174	chr6:22585274	NA	-0.47	-5.14	-0.39	8.75e-7	Coronary artery disease;
UCEC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.83	-0.43	3.38e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-6.03	-0.45	1.25e-8	Longevity;
UCEC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.72	-8.36	-0.57	4.31e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1519814	1.000	rs10104973	chr8:121104385	C/T	cg22335954	chr8:121166405	COL14A1	-0.53	-4.93	-0.38	2.17e-6	Breast cancer;
UCEC	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.42	-5.09	-0.39	1.09e-6	Menopause (age at onset);
UCEC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg18721089	chr20:30220636	NA	-0.38	-5.03	-0.38	1.43e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.72	6.35	0.46	2.59e-9	Coronary artery disease;
UCEC	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.07	9.56	0.62	3.77e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.49	7.37	0.52	1.17e-11	Homoarginine levels;
UCEC	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.57	-5.49	-0.41	1.76e-7	Cocaine dependence;
UCEC	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.7	-0.48	4.15e-10	Coffee consumption (cups per day);
UCEC	cis	rs7968440	1.000	rs2250752	chr12:51106091	A/C	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs7007970	1.000	rs16892938	chr8:120684434	G/C	cg01975934	chr8:119970761	NA	-0.56	-4.62	-0.36	8.17e-6	Height;
UCEC	cis	rs4372836	1.000	rs7562170	chr2:28943516	T/C	cg09522027	chr2:28974177	PPP1CB	0.74	7.51	0.53	5.27e-12	Body mass index;
UCEC	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.52	-5.2	-0.39	6.71e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.83	-0.54	8.96e-13	Menarche (age at onset);
UCEC	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.61	7.62	0.53	2.81e-12	Bone mineral density;
UCEC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.52	5.34	0.4	3.39e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg04176532	chr22:50317003	CRELD2	0.47	4.7	0.36	5.82e-6	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.58	4.78	0.37	4.21e-6	Breast cancer;
UCEC	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.53	4.8	0.37	3.83e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.63	-6.11	-0.45	8.56e-9	Acne (severe);
UCEC	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.72	-0.43	5.63e-8	Breast cancer;
UCEC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.58	4.51	0.35	1.34e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-5.86	-0.44	2.94e-8	Platelet count;
UCEC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.64	5.82	0.43	3.54e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.39	4.56	0.35	1.05e-5	Systolic blood pressure;
UCEC	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.21	-0.46	5.12e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.54	-5.43	-0.41	2.3e-7	Longevity;Endometriosis;
UCEC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.47	5.56	0.42	1.21e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7088591	1.000	rs77243899	chr10:59786157	C/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg14547644	chr6:28411285	ZSCAN23	0.57	6.33	0.46	2.86e-9	Cardiac Troponin-T levels;
UCEC	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.96	-0.44	1.78e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.52	-4.86	-0.37	3.01e-6	Post bronchodilator FEV1;
UCEC	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.61	6.79	0.49	2.56e-10	Resting heart rate;
UCEC	cis	rs2882667	0.858	rs11949916	chr5:138396277	T/G	cg04439458	chr5:138467593	SIL1	-0.44	-4.66	-0.36	7.04e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1549118	0.595	rs7160485	chr14:78332734	C/G	cg18985109	chr14:78266276	ADCK1	-0.63	-5.17	-0.39	7.4e-7	Resting heart rate;
UCEC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06462663	chr19:18546047	ISYNA1	0.47	5.96	0.44	1.83e-8	Breast cancer;
UCEC	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.1	18.53	0.84	2.74e-40	IgG glycosylation;
UCEC	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	1.24	9.15	0.6	4.32e-16	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.63	-6.71	-0.48	3.97e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.41	-0.41	2.48e-7	Aortic root size;
UCEC	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.59	5.97	0.44	1.73e-8	Orofacial clefts;
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.72	9.21	0.6	3.08e-16	Menarche (age at onset);
UCEC	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.71	6.4	0.47	1.98e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.46	5.02	0.38	1.47e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs8105895	1.000	rs75167249	chr19:22128655	C/T	cg20662725	chr19:22235022	ZNF257	-0.65	-5.45	-0.41	2.04e-7	Body mass index (change over time);
UCEC	cis	rs11697848	1.000	rs34499196	chr20:48536152	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-0.98	-7.48	-0.53	6.22e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.91	11.4	0.69	5.59e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.85	10.85	0.67	1.64e-20	Metabolic syndrome;
UCEC	cis	rs6840360	0.608	rs6831644	chr4:152283746	A/G	cg25486957	chr4:152246857	NA	-0.47	-4.83	-0.37	3.46e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.45	4.94	0.38	2.13e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	0.87	6.46	0.47	1.47e-9	Lymphocyte counts;
UCEC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.54	4.54	0.35	1.19e-5	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg10553204	chr2:20871195	GDF7	-0.46	-5.54	-0.42	1.35e-7	Abdominal aortic aneurysm;
UCEC	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-5.08	-0.39	1.13e-6	Gut microbiome composition (summer);
UCEC	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg01072550	chr1:21505969	NA	-0.55	-5.07	-0.39	1.18e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Schizophrenia;
UCEC	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.69	7.39	0.52	1.05e-11	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.61	4.9	0.37	2.46e-6	RR interval (heart rate);
UCEC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.37	-5.28	-0.4	4.47e-7	Longevity;
UCEC	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	5.4	0.41	2.68e-7	Bipolar disorder;
UCEC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.74	-0.36	5.03e-6	Resting heart rate;
UCEC	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.25	-7.79	-0.54	1.09e-12	Diabetic kidney disease;
UCEC	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.73	-4.81	-0.37	3.75e-6	LDL cholesterol levels;
UCEC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.1	18.06	0.83	3.91e-39	Testicular germ cell tumor;
UCEC	cis	rs6441961	0.832	rs4683198	chr3:46329278	A/G	cg11126313	chr3:46284262	CCR3	0.45	4.5	0.35	1.35e-5	Celiac disease;
UCEC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.69	5.98	0.44	1.6e-8	Cognitive function;
UCEC	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.59	-5.65	-0.42	8.02e-8	Body mass index;
UCEC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.08	11.39	0.68	6.27e-22	Psoriasis vulgaris;
UCEC	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg24910161	chr17:38119198	GSDMA	-0.33	-4.7	-0.36	5.87e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.46e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs77861329	1.000	rs72964044	chr3:52092670	G/C	cg08692210	chr3:52188851	WDR51A	0.63	4.56	0.35	1.07e-5	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.81	6.79	0.49	2.6e-10	Exhaled nitric oxide levels;
UCEC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-5.98	-0.44	1.66e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.57	6.26	0.46	4.09e-9	Neutrophil percentage of white cells;
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg26114124	chr12:9217669	LOC144571	0.42	5.11	0.39	9.91e-7	Sjögren's syndrome;
UCEC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs3914502	0.935	rs2222447	chr3:174580826	A/C	cg21145449	chr3:174580620	NAALADL2	0.41	4.61	0.36	8.62e-6	Autism spectrum disorder;
UCEC	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg02158880	chr13:53174818	NA	0.42	4.83	0.37	3.43e-6	Lewy body disease;
UCEC	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs787274	0.681	rs787284	chr9:115538040	A/G	cg13803584	chr9:115635662	SNX30	-0.69	-5.64	-0.42	8.63e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.18	0.6	3.61e-16	Coffee consumption (cups per day);
UCEC	cis	rs8177876	0.908	rs80187824	chr16:81118680	T/C	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9309473	1.000	rs10175180	chr2:73673123	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-5.88	-0.44	2.67e-8	Metabolite levels;
UCEC	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.35	1.36e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12767760	0.681	rs11814566	chr10:99316063	T/C	cg17778955	chr10:99210596	ZDHHC16	-0.44	-4.54	-0.35	1.15e-5	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.79	0.43	4.17e-8	Breast cancer;
UCEC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.24	9.05	0.6	7.72e-16	Corneal structure;
UCEC	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.45	-6.41	-0.47	1.88e-9	Rheumatoid arthritis;
UCEC	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.84	-9.79	-0.63	9.82e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	5.93	0.44	2.06e-8	IgG glycosylation;
UCEC	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Bladder cancer;
UCEC	cis	rs11697848	1.000	rs79547786	chr20:48555820	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs394563	0.839	rs584916	chr6:149790319	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.4	-4.73	-0.36	5.17e-6	Dupuytren's disease;
UCEC	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-0.85	-8.26	-0.56	7.56e-14	Coronary artery disease;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.49	-5.19	-0.39	6.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9309473	1.000	rs6546839	chr2:73680508	G/C	cg20560298	chr2:73613845	ALMS1	-0.65	-5.87	-0.44	2.77e-8	Metabolite levels;
UCEC	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.62	-7.38	-0.52	1.06e-11	Urate levels;
UCEC	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.65	-7.25	-0.51	2.22e-11	Menarche (age at onset);
UCEC	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.29	-0.76	1.33e-29	Schizophrenia;
UCEC	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-7.54	-0.53	4.55e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4509693	0.882	rs7071427	chr10:102491832	T/C	cg24127310	chr10:102502104	NA	0.93	8.04	0.55	2.75e-13	Alzheimer's disease;
UCEC	cis	rs13279522	0.536	rs7824630	chr8:67003194	C/G	cg00269606	chr8:67090928	CRH	0.34	4.54	0.35	1.17e-5	Coronary heart disease event reduction (statin therapy interaction);
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.57	-0.42	1.21e-7	Pubertal anthropometrics;
UCEC	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.05e-11	Eye color traits;
UCEC	cis	rs13065560	0.594	rs4234134	chr3:38887970	A/T	cg01426195	chr3:39028469	NA	0.52	5.57	0.42	1.16e-7	Interleukin-18 levels;
UCEC	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.4	-4.56	-0.35	1.06e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg18681998	chr4:17616180	MED28	0.7	8.05	0.55	2.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9402633	0.938	rs1040804	chr6:135042768	T/A	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.5	5.21	0.39	6.26e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.55	-6.3	-0.46	3.25e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-0.76	-5.02	-0.38	1.49e-6	Diabetic retinopathy;
UCEC	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg07169764	chr2:136633963	MCM6	0.67	6.21	0.46	5.16e-9	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.64	-7.17	-0.51	3.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	8.1	0.56	1.92e-13	Total body bone mineral density;
UCEC	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Systemic lupus erythematosus;
UCEC	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.81	-0.43	3.72e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.52	4.86	0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.68	8.35	0.57	4.74e-14	Testicular germ cell tumor;
UCEC	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg10263370	chr3:44754102	ZNF502	-0.47	-4.76	-0.37	4.51e-6	Depressive symptoms;
UCEC	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.73	4.56	0.35	1.09e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.41	-5.55	-0.42	1.3e-7	Alcohol dependence;
UCEC	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.7	-7.05	-0.5	6.63e-11	Refractive astigmatism;
UCEC	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.65	-7.92	-0.55	5.29e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.53	4.94	0.38	2.11e-6	Tonsillectomy;
UCEC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.52	6.04	0.45	1.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.85	9.82	0.63	8.34e-18	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs7212590	0.748	rs9904374	chr17:57908096	T/C	cg10252138	chr17:58120427	NA	-0.68	-5.43	-0.41	2.33e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg18973586	chr4:963968	DGKQ	0.44	4.7	0.36	5.99e-6	Obesity-related traits;
UCEC	cis	rs883565	0.582	rs7623343	chr3:39146792	A/C	cg01426195	chr3:39028469	NA	-0.74	-9.36	-0.61	1.25e-16	Handedness;
UCEC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.36	-0.57	4.36e-14	Coronary artery disease;
UCEC	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.75	5.7	0.43	6.44e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg03037974	chr15:76606532	NA	0.32	4.53	0.35	1.21e-5	Blood metabolite levels;
UCEC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.74	7.56	0.53	3.95e-12	Multiple myeloma (IgH translocation);
UCEC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.89	10.79	0.66	2.34e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.44	4.62	0.36	8.4e-6	Schizophrenia;
UCEC	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.69	6.91	0.5	1.38e-10	Resting heart rate;
UCEC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	7.0	0.5	8.66e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.57	0.42	1.18e-7	Alzheimer's disease;
UCEC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12516959	chr21:47718080	NA	-0.43	-4.81	-0.37	3.65e-6	Testicular germ cell tumor;
UCEC	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.21	0.51	2.73e-11	Motion sickness;
UCEC	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.7	-7.88	-0.55	6.56e-13	Waist circumference;Body mass index;
UCEC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs7894051	1.000	rs11101723	chr10:135192139	C/A	cg12428399	chr10:135191333	PAOX	0.64	5.11	0.39	9.85e-7	Lifespan;
UCEC	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-5.77	-0.43	4.57e-8	Asthma;
UCEC	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg02413938	chr2:239008929	ESPNL	-0.38	-4.51	-0.35	1.34e-5	Prostate cancer;
UCEC	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.52	4.88	0.37	2.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9326726	0.844	rs2900122	chr5:107644170	G/A	cg17432647	chr5:107996819	NA	0.58	4.51	0.35	1.32e-5	Resting heart rate;
UCEC	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.63	5.18	0.39	7.17e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.56	5.64	0.42	8.28e-8	Motion sickness;
UCEC	cis	rs75804782	0.566	rs77693902	chr2:239260477	T/G	cg11815105	chr2:239148849	HES6	1.03	4.64	0.36	7.53e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.51	5.24	0.4	5.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.45	-5.03	-0.38	1.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	7.91	0.55	5.63e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-4.57	-0.35	1.01e-5	Schizophrenia;
UCEC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.95	12.09	0.71	8.78e-24	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	4.58	0.35	9.81e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.46e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.75	0.49	3.2e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.46	4.76	0.37	4.64e-6	Blood protein levels;
UCEC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.56	-5.96	-0.44	1.83e-8	Migraine;
UCEC	cis	rs10242455	0.867	rs1879859	chr7:99294762	C/T	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.29e-6	Blood metabolite levels;
UCEC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.91	-9.84	-0.63	7.18e-18	Post bronchodilator FEV1;
UCEC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.2	0.56	1.07e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.32	0.46	2.98e-9	Menarche (age at onset);
UCEC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.43	0.72	1.07e-24	Prudent dietary pattern;
UCEC	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg01973587	chr1:228161476	NA	0.38	5.03	0.38	1.39e-6	Diastolic blood pressure;
UCEC	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.59	0.35	9.25e-6	Breast cancer;
UCEC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.55	-4.54	-0.35	1.16e-5	Depression;
UCEC	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.52	4.74	0.36	4.9e-6	Resting heart rate;
UCEC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg05962950	chr11:130786565	SNX19	0.5	4.67	0.36	6.76e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11958404	0.932	rs72816581	chr5:157432591	T/A	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.87	-9.87	-0.63	6.07e-18	Cognitive function;
UCEC	cis	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg00614314	chr15:82944287	LOC80154	-0.57	-5.34	-0.4	3.42e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.65	7.06	0.5	6.14e-11	Age at first birth;
UCEC	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.66	8.74	0.58	4.99e-15	Anterior chamber depth;
UCEC	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.7	5.16	0.39	8.04e-7	Multiple sclerosis;
UCEC	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-7.75	-0.54	1.42e-12	Hip circumference;
UCEC	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.53	-4.91	-0.38	2.37e-6	Menarche (age at onset);
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg13903179	chr13:21900392	NA	0.42	4.82	0.37	3.6e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.56	5.67	0.42	7.22e-8	Longevity;Endometriosis;
UCEC	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-0.81	-5.25	-0.4	5.33e-7	Blood protein levels;
UCEC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.19	-0.45	5.77e-9	Tonsillectomy;
UCEC	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg16060761	chr17:80687452	NA	-0.52	-4.8	-0.37	3.88e-6	Glycated hemoglobin levels;
UCEC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	0.74	4.97	0.38	1.88e-6	Diabetic retinopathy;
UCEC	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-5.44	-0.41	2.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.59	-6.5	-0.47	1.18e-9	Refractive error;
UCEC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	6.59	0.48	7.5e-10	Total body bone mineral density;
UCEC	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.67	-5.42	-0.41	2.39e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.94	-0.38	2.13e-6	Bipolar disorder;
UCEC	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg18232548	chr7:50535776	DDC	-0.67	-7.53	-0.53	4.73e-12	Body mass index;
UCEC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg01256987	chr12:42539512	GXYLT1	0.41	4.72	0.36	5.42e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.55	0.35	1.1e-5	Menopause (age at onset);
UCEC	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24249390	chr15:90295951	MESP1	-0.42	-4.76	-0.37	4.64e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.77	-5.76	-0.43	4.79e-8	Narcolepsy;
UCEC	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-4.86	-0.37	3.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg02573091	chr5:74908125	NA	0.61	4.51	0.35	1.34e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9364220	0.646	rs2029489	chr6:168496038	A/G	cg09046490	chr6:168390201	NA	0.47	5.0	0.38	1.61e-6	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
UCEC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg14078730	chr11:63896557	MACROD1	0.54	6.22	0.46	4.81e-9	Platelet count;
UCEC	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg14851346	chr12:38532713	NA	-0.48	-4.57	-0.35	1.01e-5	Bladder cancer;
UCEC	cis	rs7246967	0.673	rs12985495	chr19:22930378	A/G	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2970992	0.624	rs2309905	chr2:101328575	T/A	cg01042948	chr2:101319752	NA	0.56	5.99	0.44	1.56e-8	Educational attainment;
UCEC	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg17632214	chr22:31556050	RNF185	0.54	5.01	0.38	1.53e-6	Colorectal cancer;
UCEC	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.59	6.92	0.5	1.32e-10	Mean corpuscular volume;
UCEC	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.67	0.42	7.47e-8	Psoriasis;
UCEC	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.68	0.36	6.48e-6	Response to antipsychotic treatment;
UCEC	cis	rs4615376	0.951	rs9473370	chr6:13065071	A/C	cg11378619	chr6:12164359	HIVEP1	-0.53	-4.51	-0.35	1.31e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.74	7.85	0.54	7.74e-13	Menopause (age at onset);
UCEC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Diabetic kidney disease;
UCEC	cis	rs12540874	0.518	rs12718674	chr7:50627130	T/C	cg18232548	chr7:50535776	DDC	-0.48	-4.85	-0.37	3.11e-6	Systemic sclerosis;
UCEC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.12	0.39	9.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg06818710	chr6:28411271	ZSCAN23	0.55	6.63	0.48	5.83e-10	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.58	8.69	0.58	6.55e-15	Prudent dietary pattern;
UCEC	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.09	-0.45	9.34e-9	Metabolite levels;
UCEC	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.43	4.8	0.37	3.79e-6	Bone mineral density;
UCEC	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.71	8.3	0.56	6.17e-14	Lung cancer in ever smokers;
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.6	6.92	0.5	1.27e-10	Menarche (age at onset);
UCEC	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.65	-5.93	-0.44	2.05e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.24	0.61	2.58e-16	Post bronchodilator FEV1;
UCEC	cis	rs7374004	1.000	rs7374004	chr3:38625709	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-5.5	-0.41	1.62e-7	PR interval;
UCEC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg23815491	chr16:72088622	HP	0.37	4.71	0.36	5.79e-6	Fibrinogen levels;
UCEC	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.9	-10.78	-0.66	2.56e-20	Blood metabolite levels;
UCEC	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2386661	0.826	rs1132293	chr10:5681038	C/T	cg17085576	chr10:5658249	NA	-0.47	-4.7	-0.36	5.81e-6	Breast cancer;
UCEC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg21856205	chr7:94953877	PON1	-0.54	-4.87	-0.37	2.84e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg20119798	chr7:94954144	PON1	-0.56	-5.67	-0.42	7.45e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.6	-4.54	-0.35	1.14e-5	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.6	5.62	0.42	9.42e-8	Uric acid levels;
UCEC	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	0.98	7.38	0.52	1.08e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.63	5.3	0.4	4.09e-7	Cocaine dependence;
UCEC	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.32	5.0	0.38	1.59e-6	Cancer;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg13525197	chr6:28411240	ZSCAN23	0.54	6.14	0.45	7.16e-9	Pubertal anthropometrics;
UCEC	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.87	-0.63	6.02e-18	Leprosy;
UCEC	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-0.65	-6.22	-0.46	4.85e-9	Acne (severe);
UCEC	cis	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg12524725	chr2:239427019	NA	-0.72	-4.64	-0.36	7.67e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.62	-7.09	-0.5	5.16e-11	Cardiac Troponin-T levels;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg14547644	chr6:28411285	ZSCAN23	-0.55	-5.97	-0.44	1.69e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2412819	0.571	rs66903736	chr15:43911633	C/T	cg24361265	chr15:44068668	ELL3	0.55	4.62	0.36	8.49e-6	Lung cancer;
UCEC	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs7870753	0.838	rs7871404	chr9:99262296	A/G	cg25260653	chr9:99212216	HABP4	0.54	5.46	0.41	1.97e-7	Height;
UCEC	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.9	-10.73	-0.66	3.4e-20	Blood metabolite levels;
UCEC	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.42	5.09	0.39	1.07e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-10.96	-0.67	8.59e-21	Cognitive function;
UCEC	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.67	7.02	0.5	7.8e-11	Tonsillectomy;
UCEC	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18854424	chr1:2615690	NA	0.47	7.15	0.51	3.78e-11	Ulcerative colitis;
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.45	-4.81	-0.37	3.65e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.62	4.69	0.36	6.31e-6	Lung cancer;
UCEC	cis	rs259282	0.524	rs11878322	chr19:33122886	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	7.14	0.51	4.05e-11	Schizophrenia;
UCEC	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg07041428	chr4:1763019	NA	-0.41	-4.8	-0.37	3.92e-6	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-4.5	-0.35	1.36e-5	Coronary artery disease;
UCEC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg14784868	chr12:69753453	YEATS4	0.55	4.68	0.36	6.37e-6	Response to diuretic therapy;
UCEC	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	0.87	10.26	0.65	5.75e-19	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg14067834	chr17:29058358	SUZ12P	0.65	4.51	0.35	1.31e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.63	-0.42	8.87e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24308560	chr3:49941425	MST1R	-0.47	-5.08	-0.39	1.14e-6	Body mass index;
UCEC	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.86	-9.6	-0.62	3.05e-17	Cognitive function;
UCEC	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	1.11	6.54	0.47	9.41e-10	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.56	-6.44	-0.47	1.6e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.4	4.68	0.36	6.35e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.25	-7.72	-0.54	1.61e-12	Schizophrenia;
UCEC	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.61	-6.16	-0.45	6.56e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7580658	0.545	rs885275	chr2:127951095	T/C	cg16751203	chr2:127950803	CYP27C1	0.39	5.09	0.39	1.09e-6	Protein C levels;
UCEC	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.43	5.06	0.38	1.25e-6	Blood metabolite ratios;
UCEC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.72	6.64	0.48	5.57e-10	Aortic root size;
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg19678392	chr7:94953810	PON1	-0.58	-5.65	-0.42	7.97e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg22598563	chr5:131563921	P4HA2	-0.36	-4.72	-0.36	5.39e-6	Blood metabolite levels;
UCEC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg26898376	chr11:64110657	CCDC88B	0.45	5.23	0.4	5.79e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg05660106	chr1:15850417	CASP9	0.55	4.87	0.37	2.88e-6	Systolic blood pressure;
UCEC	cis	rs58722170	0.659	rs55852308	chr1:38078630	A/T	cg17933807	chr1:38061675	GNL2	-0.62	-5.14	-0.39	8.47e-7	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.13	0.64	1.29e-18	Cognitive ability;
UCEC	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.67	4.65	0.36	7.18e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg05528280	chr10:464225	DIP2C	-0.5	-4.62	-0.36	8.32e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-0.82	-5.26	-0.4	5.01e-7	Plateletcrit;
UCEC	cis	rs10208940	0.920	rs11894861	chr2:68706723	C/G	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.17	15.02	0.78	1.73e-31	Cognitive function;
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	8.93	0.59	1.57e-15	Platelet count;
UCEC	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg12463550	chr7:65579703	CRCP	-0.52	-5.3	-0.4	4.11e-7	Aortic root size;
UCEC	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.54	6.28	0.46	3.67e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.37	-4.64	-0.36	7.56e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg20965017	chr5:231967	SDHA	-0.63	-5.87	-0.44	2.78e-8	Breast cancer;
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.62	0.58	9.98e-15	Prudent dietary pattern;
UCEC	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.73	-8.39	-0.57	3.75e-14	Menopause (age at onset);
UCEC	cis	rs6684428	0.901	rs11206681	chr1:56364528	T/C	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.88	-0.59	2.12e-15	Electrocardiographic conduction measures;
UCEC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.44	-4.95	-0.38	1.98e-6	Response to antineoplastic agents;
UCEC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.66	6.01	0.44	1.38e-8	Aortic root size;
UCEC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg21770322	chr7:97807741	LMTK2	0.52	6.07	0.45	1.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2224391	0.822	rs2773321	chr6:5262220	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.62	-6.69	-0.48	4.39e-10	Height;
UCEC	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.56	-5.27	-0.4	4.82e-7	Obesity-related traits;
UCEC	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg11189052	chr15:85197271	WDR73	0.6	4.69	0.36	6.27e-6	Schizophrenia;
UCEC	cis	rs6838801	0.765	rs17002161	chr4:77598673	C/G	cg17476223	chr4:77663285	SHROOM3	0.47	4.5	0.35	1.35e-5	Cleft lip with or without cleft palate;
UCEC	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	7.04	0.5	6.95e-11	Alzheimer's disease;
UCEC	cis	rs7088591	0.867	rs2159855	chr10:59780998	A/G	cg11142981	chr10:60273225	BICC1	0.66	4.82	0.37	3.51e-6	Blood pressure;
UCEC	cis	rs4654899	0.629	rs2320590	chr1:21155195	C/T	cg01072550	chr1:21505969	NA	0.53	5.23	0.4	5.62e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.85	-9.82	-0.63	8.38e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-5.11	-0.39	1e-6	Metabolite levels;
UCEC	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1008126	0.840	rs2535760	chr7:103176955	G/A	cg03942871	chr7:102574105	LRRC17;FBXL13	-0.32	-4.52	-0.35	1.28e-5	Metabolite levels (Pyroglutamine);
UCEC	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.53	-5.34	-0.4	3.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs892864	0.685	rs10063393	chr5:127745955	A/T	cg17313118	chr5:127157258	NA	0.67	4.82	0.37	3.52e-6	Multiple system atrophy;
UCEC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg00083072	chr11:65415190	SIPA1	0.45	5.02	0.38	1.46e-6	Acne (severe);
UCEC	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.68	5.29	0.4	4.29e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg22852734	chr6:133119734	C6orf192	0.94	8.64	0.58	8.55e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.67	7.98	0.55	3.9e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	5.02	0.38	1.46e-6	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.03	0.5	7.08e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	trans	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg06410510	chr2:107458059	ST6GAL2	0.76	6.93	0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.53	5.96	0.44	1.81e-8	Mean corpuscular volume;
UCEC	cis	rs6704644	0.511	rs55983182	chr2:234277769	T/C	cg16719865	chr2:234394478	USP40	-0.52	-4.54	-0.35	1.16e-5	Bilirubin levels;
UCEC	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg08890418	chr1:21044141	KIF17	-0.45	-4.52	-0.35	1.28e-5	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.6	-0.42	1e-7	Kawasaki disease;
UCEC	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.59	5.7	0.43	6.47e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.73	6.01	0.44	1.43e-8	Cerebrospinal P-tau181p levels;
UCEC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg18827107	chr12:86230957	RASSF9	-0.42	-4.64	-0.36	7.6e-6	Major depressive disorder;
UCEC	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.08	-0.45	1e-8	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.71	-6.91	-0.5	1.35e-10	Aortic root size;
UCEC	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.85	-12.02	-0.7	1.31e-23	Post bronchodilator FEV1;
UCEC	cis	rs860295	0.557	rs7534795	chr1:155275553	C/T	cg02153340	chr1:155202674	NA	-0.47	-5.27	-0.4	4.84e-7	Body mass index;
UCEC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	7.08	0.5	5.64e-11	Initial pursuit acceleration;
UCEC	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg18681998	chr4:17616180	MED28	0.67	6.45	0.47	1.51e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.72e-6	Aortic root size;
UCEC	cis	rs16937	0.521	rs78176224	chr1:205178609	G/A	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	7.57	0.53	3.73e-12	Exhaled nitric oxide output;
UCEC	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.69	-4.81	-0.37	3.71e-6	LDL cholesterol levels;
UCEC	cis	rs405956	1.000	rs9322831	chr6:105558337	G/A	cg22580625	chr6:105627791	POPDC3	-0.7	-6.5	-0.47	1.17e-9	QT interval;
UCEC	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg05660106	chr1:15850417	CASP9	0.85	9.76	0.63	1.18e-17	Systolic blood pressure;
UCEC	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg01072550	chr1:21505969	NA	-0.54	-5.02	-0.38	1.5e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.53	-4.88	-0.37	2.7e-6	Coronary artery disease;
UCEC	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.44	-0.52	7.77e-12	Resting heart rate;
UCEC	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.97	10.56	0.66	9.35e-20	Cognitive function;
UCEC	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.51	5.83	0.43	3.32e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.69	5.17	0.39	7.37e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.4	5.08	0.39	1.13e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg09491104	chr22:46646882	C22orf40	-0.65	-7.72	-0.54	1.69e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.55	-5.34	-0.4	3.52e-7	Post bronchodilator FEV1;
UCEC	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	0.85	8.82	0.59	3.09e-15	Primary sclerosing cholangitis;
UCEC	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.44	4.98	0.38	1.78e-6	Aortic root size;
UCEC	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-4.63	-0.36	8.06e-6	Cognitive test performance;
UCEC	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.66	0.42	7.77e-8	Height;
UCEC	cis	rs4687718	0.528	rs79550721	chr3:53349364	C/G	cg12173409	chr3:54154746	NA	0.54	4.83	0.37	3.41e-6	QRS duration;
UCEC	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.36e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6934651	0.581	rs62420828	chr6:85827970	A/G	cg18860790	chr6:84937415	KIAA1009	-0.88	-4.62	-0.36	8.21e-6	Breast cancer;
UCEC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.67	-5.51	-0.41	1.56e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg24375607	chr4:120327624	NA	0.48	5.05	0.38	1.32e-6	Corneal astigmatism;
UCEC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.69	-7.9	-0.55	5.86e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.49	5.14	0.39	8.79e-7	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.72	6.96	0.5	1.03e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.72	6.4	0.47	1.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05776053	chr2:74358815	NA	0.45	5.55	0.42	1.31e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg17330251	chr7:94953956	PON1	-0.58	-5.52	-0.41	1.5e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.33	0.46	2.78e-9	Menarche (age at onset);
UCEC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.5	4.56	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-5.86	-0.44	2.89e-8	Hepatocellular carcinoma;
UCEC	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	6.93	0.5	1.25e-10	Platelet distribution width;
UCEC	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.86	7.67	0.53	2.19e-12	Dupuytren's disease;
UCEC	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.53	5.63	0.42	8.99e-8	Monocyte count;
UCEC	cis	rs7070678	0.662	rs11817300	chr10:29798785	A/T	cg24350475	chr10:30316933	KIAA1462	0.48	4.65	0.36	7.36e-6	Platelet thrombus formation;
UCEC	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg23018236	chr17:30244563	NA	-0.68	-4.67	-0.36	6.62e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.49	-5.34	-0.4	3.46e-7	Alcohol dependence;
UCEC	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.92	10.71	0.66	3.87e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.99	-10.83	-0.67	1.86e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg19318889	chr4:1322082	MAEA	0.44	5.28	0.4	4.64e-7	Obesity-related traits;
UCEC	cis	rs1451882	0.698	rs1376786	chr8:1061074	A/G	cg00776166	chr8:613548	NA	-0.75	-4.6	-0.35	8.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg21191810	chr6:118973309	C6orf204	0.41	5.67	0.42	7.43e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg03146154	chr1:46216737	IPP	0.44	4.61	0.36	8.53e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.61	-0.36	8.56e-6	Parkinson's disease;
UCEC	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.74	-8.32	-0.57	5.38e-14	Sudden cardiac arrest;
UCEC	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.49	-0.41	1.75e-7	Mean corpuscular volume;
UCEC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.53	-5.57	-0.42	1.17e-7	Educational attainment;
UCEC	cis	rs1978968	0.731	rs9617648	chr22:18460059	G/T	cg03078520	chr22:18463400	MICAL3	-0.54	-6.59	-0.48	7.51e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.66	6.15	0.45	6.86e-9	Aortic root size;
UCEC	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6893207	1.000	rs77450575	chr5:16391380	T/C	cg11584519	chr5:16175867	MARCH11	0.74	4.53	0.35	1.19e-5	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.49	-4.76	-0.37	4.52e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.46	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs1575951	1.000	rs1575951	chr10:130442181	G/A	cg27041381	chr10:131357203	MGMT	0.6	4.97	0.38	1.84e-6	Plasma clusterin levels;
UCEC	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	8.56	0.58	1.38e-14	Mean platelet volume;
UCEC	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.47	4.7	0.36	5.87e-6	Blood protein levels;
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.54	6.59	0.48	7.47e-10	Menarche (age at onset);
UCEC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.66	5.64	0.42	8.56e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.96	-13.42	-0.74	2.61e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.66	6.71	0.48	3.93e-10	Menopause (age at onset);
UCEC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-6.2	-0.46	5.44e-9	Dental caries;
UCEC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.63	0.42	8.88e-8	Breast cancer;
UCEC	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.27	-0.4	4.72e-7	Blood metabolite levels;
UCEC	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.73	6.09	0.45	9.53e-9	Colorectal adenoma (advanced);
UCEC	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.72e-25	Height;
UCEC	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.69	6.89	0.49	1.49e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-6.18	-0.45	6.08e-9	Chronic sinus infection;
UCEC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.64	6.35	0.46	2.55e-9	Dental caries;
UCEC	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	4.54	0.35	1.16e-5	Lung function (FEV1/FVC);
UCEC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.69	6.16	0.45	6.57e-9	Aortic root size;
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	5.67	0.42	7.21e-8	Platelet count;
UCEC	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.72	6.17	0.45	6.22e-9	Alzheimer's disease;
UCEC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.39	-4.79	-0.37	3.97e-6	Menarche (age at onset);
UCEC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.64	6.97	0.5	9.78e-11	Neuroticism;
UCEC	cis	rs1468333	1.000	rs4835671	chr5:137511801	C/T	cg07848042	chr5:137667509	CDC25C	0.48	4.78	0.37	4.3e-6	Resting heart rate;
UCEC	trans	rs1459104	1.000	rs12797013	chr11:55318288	T/G	cg16096432	chr1:54776890	SSBP3	-1.0	-6.71	-0.48	3.85e-10	Body mass index;
UCEC	cis	rs968451	0.865	rs5757610	chr22:39707979	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	5.23	0.4	5.66e-7	Primary biliary cholangitis;
UCEC	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.54	-4.93	-0.38	2.2e-6	Educational attainment;
UCEC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.63	6.93	0.5	1.25e-10	Tonsillectomy;
UCEC	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.51	-5.12	-0.39	9.26e-7	Red cell distribution width;
UCEC	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.97	0.44	1.71e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg17105886	chr17:28927953	LRRC37B2	0.64	4.7	0.36	5.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-8.76	-0.59	4.29e-15	Coffee consumption (cups per day);
UCEC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.79	-7.78	-0.54	1.17e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.67	5.37	0.4	3.05e-7	Corneal astigmatism;
UCEC	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.33	5.04	0.38	1.34e-6	Cancer;
UCEC	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.73	-8.5	-0.57	1.99e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg22974920	chr21:40686053	BRWD1	0.61	5.35	0.4	3.37e-7	Cognitive function;
UCEC	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-1.05	-6.99	-0.5	8.98e-11	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7326068	0.510	rs4432108	chr13:21342151	G/A	cg04906043	chr13:21280425	IL17D	-0.48	-4.74	-0.36	4.93e-6	Schizophrenia, bipolar disorder and depression (combined);
UCEC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.69	6.89	0.49	1.49e-10	Menopause (age at onset);
UCEC	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.78	10.22	0.64	7.28e-19	Body mass index;
UCEC	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.51	5.56	0.42	1.25e-7	Body mass index;
UCEC	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.46	-6.11	-0.45	8.68e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs7210990	0.661	rs1079534	chr17:15949133	T/A	cg00380437	chr17:16342463	NCRNA00188;SNORD49B;SNORD49A	0.43	4.67	0.36	6.67e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
UCEC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.49	0.41	1.73e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.98	0.64	3.12e-18	Breast cancer;
UCEC	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg02461776	chr11:598696	PHRF1	0.44	4.64	0.36	7.73e-6	Systemic lupus erythematosus;
UCEC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg18681998	chr4:17616180	MED28	0.73	6.97	0.5	9.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.79	-7.29	-0.52	1.73e-11	Resting heart rate;
UCEC	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.83	7.84	0.54	8.47e-13	Blood protein levels;
UCEC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-4.74	-0.36	4.97e-6	Aortic root size;
UCEC	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.56	5.22	0.4	6e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.61	-6.13	-0.45	7.71e-9	Bipolar disorder;
UCEC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg01112020	chr2:239008986	ESPNL	-0.34	-4.51	-0.35	1.32e-5	Prostate cancer;
UCEC	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.55	6.44	0.47	1.62e-9	Mean corpuscular volume;
UCEC	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.47	-4.51	-0.35	1.34e-5	Hemoglobin concentration;
UCEC	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg05991184	chr2:219186017	PNKD	0.52	5.63	0.42	8.66e-8	Colorectal cancer;
UCEC	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.06	6.29	0.46	3.49e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	0.88	8.34	0.57	4.94e-14	Breast cancer;
UCEC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.48	-4.64	-0.36	7.8e-6	Aortic root size;
UCEC	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.84	-7.7	-0.54	1.89e-12	Bronchopulmonary dysplasia;
UCEC	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg13575925	chr12:9217583	LOC144571	0.4	4.58	0.35	9.75e-6	Sjögren's syndrome;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.56	0.58	1.41e-14	Prudent dietary pattern;
UCEC	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.68	-7.84	-0.54	8.26e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs78487399	0.710	rs17031000	chr2:43758625	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-4.91	-0.38	2.4e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.53	6.53	0.47	1.02e-9	Total body bone mineral density;
UCEC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.85	0.43	3.1e-8	Breast cancer;
UCEC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.61	-6.31	-0.46	3.18e-9	Coronary artery disease;
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.53	5.96	0.44	1.81e-8	Mean corpuscular volume;
UCEC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18252515	chr7:66147081	NA	-0.51	-4.9	-0.37	2.51e-6	Aortic root size;
UCEC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.05	-0.38	1.3e-6	Aortic root size;
UCEC	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg01262667	chr19:19385393	TM6SF2	0.5	6.97	0.5	9.7e-11	Tonsillectomy;
UCEC	cis	rs12644436	0.896	rs12641897	chr4:88785770	T/C	cg27179352	chr4:88029472	AFF1	0.41	4.51	0.35	1.32e-5	HIV-1 viral setpoint;
UCEC	cis	rs6832769	1.000	rs6554286	chr4:56400304	T/G	cg05960024	chr4:56376020	CLOCK	-0.54	-5.47	-0.41	1.88e-7	Personality dimensions;
UCEC	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-5.99	-0.44	1.57e-8	Electroencephalogram traits;
UCEC	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.17	11.24	0.68	1.54e-21	Corneal structure;
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.78	9.3	0.61	1.85e-16	Prudent dietary pattern;
UCEC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.79	-0.37	4.02e-6	Parkinson's disease;
UCEC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18854424	chr1:2615690	NA	0.5	7.29	0.52	1.75e-11	Ulcerative colitis;
UCEC	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22509189	chr2:225307070	NA	-0.57	-4.73	-0.36	5.12e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.73	7.56	0.53	4.02e-12	Vitamin D levels;
UCEC	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.68e-16	Breast cancer;
UCEC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.51	4.61	0.36	8.73e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg25482853	chr8:67687455	SGK3	1.07	7.81	0.54	1e-12	Obesity-related traits;
UCEC	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	5.42	0.41	2.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.81	10.11	0.64	1.46e-18	Longevity;Endometriosis;
UCEC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.6	6.23	0.46	4.56e-9	Diastolic blood pressure;
UCEC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.65	6.95	0.5	1.12e-10	Menopause (age at onset);
UCEC	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-11.7	-0.69	9.16e-23	Ulcerative colitis;
UCEC	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.79	-6.91	-0.5	1.36e-10	Longevity;
UCEC	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.76	-0.37	4.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg24562669	chr7:97807699	LMTK2	0.73	10.79	0.66	2.38e-20	Breast cancer;
UCEC	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.45	4.7	0.36	5.88e-6	Schizophrenia;
UCEC	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg01380346	chr19:18557039	ELL	-0.44	-4.56	-0.35	1.08e-5	Breast cancer;
UCEC	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.51	4.86	0.37	2.97e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.9	0.44	2.41e-8	Menarche (age at onset);
UCEC	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg16023434	chr1:11395635	NA	0.36	4.73	0.36	5.29e-6	Body mass index;
UCEC	cis	rs11760485	0.893	rs4723685	chr7:4400870	C/A	cg22450045	chr7:4839495	RADIL	-0.4	-5.0	-0.38	1.64e-6	Early childhood aggressive behavior;
UCEC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.78	8.25	0.56	8.25e-14	Menarche (age at onset);
UCEC	cis	rs8177876	0.642	rs8052490	chr16:81111856	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.18	-6.53	-0.47	1.01e-9	Diabetic kidney disease;
UCEC	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.95	0.38	2.05e-6	Bipolar disorder;
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs925228	0.635	rs2194410	chr2:23945663	T/G	cg16901991	chr2:24272451	FKBP1B	0.53	5.02	0.38	1.46e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4722166	0.532	rs6461662	chr7:22757089	C/T	cg05472934	chr7:22766657	IL6	0.54	5.17	0.39	7.51e-7	Lung cancer;
UCEC	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.63	5.88	0.44	2.6e-8	Refractive astigmatism;
UCEC	cis	rs12618769	0.652	rs4851145	chr2:99222916	A/G	cg10123293	chr2:99228465	UNC50	-0.47	-5.36	-0.4	3.12e-7	Bipolar disorder;
UCEC	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.44	-5.1	-0.39	1.02e-6	Subjective well-being;
UCEC	cis	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	6.15	0.45	7.11e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg13683864	chr3:40499215	RPL14	1.15	16.85	0.81	3.7e-36	Renal cell carcinoma;
UCEC	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	0.89	7.79	0.54	1.12e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07215822	chr6:158701037	NA	-0.67	-5.7	-0.43	6.43e-8	Height;
UCEC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg06935464	chr4:38784597	TLR10	0.64	4.58	0.35	9.69e-6	Breast cancer;
UCEC	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-8.68	-0.58	7.08e-15	Exhaled nitric oxide output;
UCEC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.5	-4.84	-0.37	3.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-1.0	-12.18	-0.71	4.99e-24	Obesity-related traits;
UCEC	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	5.43	0.41	2.24e-7	Electrocardiographic conduction measures;
UCEC	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.83	-9.12	-0.6	5.19e-16	Breast cancer;
UCEC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.37	0.52	1.17e-11	Tonsillectomy;
UCEC	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs847649	0.842	rs4729860	chr7:102625567	C/T	cg18108683	chr7:102477205	FBXL13	0.56	6.8	0.49	2.4e-10	Morning vs. evening chronotype;
UCEC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.39	-0.52	1.02e-11	Breast cancer;
UCEC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs7267005	0.661	rs112742250	chr20:34410597	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg14078730	chr11:63896557	MACROD1	0.66	5.16	0.39	8.04e-7	Mean platelet volume;
UCEC	cis	rs41271951	0.512	rs7537292	chr1:151071038	C/G	cg00107782	chr1:151300621	NA	-0.68	-4.58	-0.35	9.72e-6	Blood protein levels;
UCEC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg18279126	chr7:2041391	MAD1L1	0.48	5.77	0.43	4.6e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.58	-5.24	-0.4	5.4e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg04510874	chr15:91427884	FES	0.44	5.16	0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg22563815	chr15:78856949	CHRNA5	-0.38	-5.07	-0.39	1.17e-6	Sudden cardiac arrest;
UCEC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-7.31	-0.52	1.56e-11	Breast cancer;
UCEC	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.62	-7.12	-0.51	4.4e-11	Skin colour saturation;
UCEC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.84	-10.34	-0.65	3.57e-19	Coronary artery disease;
UCEC	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg24375607	chr4:120327624	NA	0.47	5.06	0.38	1.26e-6	Educational attainment;
UCEC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.71	-6.86	-0.49	1.81e-10	Multiple sclerosis;
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.7	-0.48	4.13e-10	Platelet count;
UCEC	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg04154034	chr17:28927549	LRRC37B2	0.65	4.76	0.37	4.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4478037	1.000	rs61433006	chr3:33162363	T/A	cg19404215	chr3:33155277	CRTAP	0.7	5.58	0.42	1.1e-7	Major depressive disorder;
UCEC	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg05072774	chr3:49840536	C3orf54	-0.5	-4.71	-0.36	5.59e-6	Resting heart rate;
UCEC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.35	-4.87	-0.37	2.9e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.23	-0.46	4.68e-9	Prudent dietary pattern;
UCEC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	5.13	0.39	8.82e-7	Diabetic retinopathy;
UCEC	cis	rs10242455	0.867	rs2687087	chr7:99294472	G/A	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	6.74e-7	Blood metabolite levels;
UCEC	cis	rs290268	0.817	rs291006	chr9:93540244	A/C	cg02608019	chr9:93564028	SYK	0.53	5.97	0.44	1.69e-8	Platelet count;
UCEC	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.78	6.49	0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	cis	rs1165668	0.755	rs2583283	chr12:104313643	G/A	cg21863207	chr12:104234989	NT5DC3	0.6	5.5	0.41	1.62e-7	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-4.53	-0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.49	-5.01	-0.38	1.57e-6	Longevity;Endometriosis;
UCEC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.89	-9.18	-0.6	3.73e-16	Heart rate;
UCEC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.87	10.53	0.66	1.12e-19	Breast cancer;
UCEC	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.88	0.44	2.68e-8	Cognitive function;
UCEC	cis	rs2964802	0.505	rs4410623	chr5:10832271	A/C	cg14521931	chr5:10832172	NA	0.46	4.74	0.36	5.06e-6	Major depressive disorder;Recurrent major depressive disorder;
UCEC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.68	7.24	0.51	2.27e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.52	-5.04	-0.38	1.35e-6	Platelet count;
UCEC	cis	rs2882667	0.858	rs11951899	chr5:138374310	A/G	cg04439458	chr5:138467593	SIL1	-0.43	-4.54	-0.35	1.14e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	0.53	5.98	0.44	1.6e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	7.49	0.53	5.9e-12	Lymphocyte counts;
UCEC	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg13575925	chr12:9217583	LOC144571	0.4	4.75	0.37	4.7e-6	Sjögren's syndrome;
UCEC	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg18681998	chr4:17616180	MED28	0.77	9.04	0.6	8.29e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg06671706	chr8:8559999	CLDN23	0.66	5.4	0.41	2.64e-7	Obesity-related traits;
UCEC	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg11150807	chr10:43354902	NA	0.84	6.73	0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.53	5.53	0.42	1.42e-7	Dupuytren's disease;
UCEC	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg00122941	chr17:4613640	ARRB2	0.65	5.05	0.38	1.31e-6	Lymphocyte counts;
UCEC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg09521647	chr2:100722408	AFF3	-0.32	-4.85	-0.37	3.05e-6	Chronic sinus infection;
UCEC	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg12024160	chr4:1254474	NA	-0.56	-7.19	-0.51	3.01e-11	Obesity-related traits;
UCEC	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03517284	chr6:25882590	NA	-0.49	-4.62	-0.36	8.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.54	-6.3	-0.46	3.24e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.53	-0.35	1.22e-5	Aortic root size;
UCEC	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.52	4.87	0.37	2.85e-6	Corneal astigmatism;
UCEC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.43	-0.41	2.29e-7	Obesity-related traits;
UCEC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg15837086	chr1:46506065	PIK3R3	0.36	4.52	0.35	1.27e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg16583315	chr14:65563665	MAX	-0.45	-5.73	-0.43	5.37e-8	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.72	8.92	0.59	1.66e-15	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.64	-4.63	-0.36	7.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.23	-15.21	-0.78	5.67e-32	Breast cancer;
UCEC	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.73	5.54	0.42	1.34e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.76	-8.62	-0.58	9.97e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.67	-6.95	-0.5	1.09e-10	Longevity;Endometriosis;
UCEC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.66	7.38	0.52	1.07e-11	Lymphocyte counts;
UCEC	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.31	4.51	0.35	1.3e-5	Cancer;
UCEC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.68	0.42	6.95e-8	Breast cancer;
UCEC	cis	rs925228	0.955	rs6729507	chr2:24163121	T/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.65	-0.42	8.11e-8	Neutrophil percentage of white cells;
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.22	-0.46	5e-9	Pubertal anthropometrics;
UCEC	cis	rs11675119	0.501	rs12994811	chr2:3494301	C/A	cg10845886	chr2:3471009	TTC15	-0.54	-4.73	-0.36	5.27e-6	Neurofibrillary tangles;
UCEC	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.88	0.37	2.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6060717	0.536	rs6060666	chr20:34478954	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.54	-0.35	1.19e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs847649	0.767	rs11972261	chr7:102641244	T/G	cg18108683	chr7:102477205	FBXL13	0.61	7.41	0.52	9.32e-12	Morning vs. evening chronotype;
UCEC	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.18	-0.45	5.84e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg03859395	chr2:55845619	SMEK2	0.89	10.9	0.67	1.17e-20	Metabolic syndrome;
UCEC	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.76	-8.62	-0.58	9.97e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.66	-5.55	-0.42	1.32e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs72906064	0.614	rs114924621	chr2:156900702	T/C	cg14040602	chr2:157557294	NA	0.63	4.74	0.36	4.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.5	4.78	0.37	4.2e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.45	5.09	0.39	1.1e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.39	-5.03	-0.38	1.43e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.37	4.67	0.36	6.77e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1937680	0.572	rs7082269	chr10:53650963	A/G	cg20114739	chr10:53459604	PRKG1;CSTF2T	0.58	4.5	0.35	1.36e-5	Breast cancer;
UCEC	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Bladder cancer;
UCEC	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg15764593	chr10:829463	NA	-0.68	-5.56	-0.42	1.25e-7	Uric acid levels;
UCEC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.49	-5.05	-0.38	1.3e-6	Pulse pressure;
UCEC	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.85	-8.36	-0.57	4.39e-14	Obesity-related traits;
UCEC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.65	4.66	0.36	7.16e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.27	0.4	4.69e-7	Breast cancer;
UCEC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.67	6.04	0.45	1.19e-8	Aortic root size;
UCEC	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.39	5.33	0.4	3.55e-7	Superior crus of antihelix expression;
UCEC	cis	rs17068510	0.688	rs73182060	chr8:3869803	T/C	cg10938233	chr8:4573688	CSMD1	-0.57	-4.62	-0.36	8.37e-6	Cerebrospinal fluid clusterin levels;
UCEC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.55	7.02	0.5	7.63e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.98	-0.44	1.64e-8	Response to antipsychotic treatment;
UCEC	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.79	-0.37	3.98e-6	Tonsillectomy;
UCEC	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.43	4.67	0.36	6.78e-6	Height;
UCEC	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.95	-0.5	1.09e-10	Urate levels in overweight individuals;
UCEC	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.5	-4.7	-0.36	5.81e-6	Longevity;
UCEC	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	5.16	0.39	7.78e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg18016565	chr1:150552671	MCL1	0.58	6.42	0.47	1.75e-9	Tonsillectomy;
UCEC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.76	7.69	0.54	2e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	11.5	0.69	3.21e-22	Prudent dietary pattern;
UCEC	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18932078	chr1:2524107	MMEL1	0.33	5.49	0.41	1.74e-7	Ulcerative colitis;
UCEC	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Bladder cancer;
UCEC	cis	rs59104589	0.617	rs16843671	chr2:242374358	T/C	cg19488206	chr2:242435732	STK25	0.51	4.54	0.35	1.17e-5	Fibrinogen levels;
UCEC	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.66	4.82	0.37	3.53e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.16	16.38	0.8	5.65e-35	Exhaled nitric oxide output;
UCEC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg11569703	chr11:65557185	OVOL1	0.51	6.66	0.48	4.99e-10	Acne (severe);
UCEC	cis	rs2734839	0.964	rs2734831	chr11:113293596	G/T	cg14159747	chr11:113255604	NA	-0.51	-6.09	-0.45	9.36e-9	Information processing speed;
UCEC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.67	6.74	0.49	3.41e-10	Breast cancer;
UCEC	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg17420585	chr12:42539391	GXYLT1	0.42	5.27	0.4	4.74e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg00614314	chr15:82944287	LOC80154	0.52	4.85	0.37	3.14e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-0.6	-6.99	-0.5	8.83e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.67	-4.7	-0.36	5.92e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.09	0.39	1.1e-6	Breast cancer;
UCEC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.94	10.94	0.67	9.16e-21	Breast cancer;
UCEC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg03611598	chr17:48586076	MYCBPAP	-0.47	-5.14	-0.39	8.77e-7	Visceral fat;
UCEC	cis	rs7725337	0.931	rs919184	chr5:88283736	A/T	cg26650655	chr5:88178400	MEF2C	0.44	4.85	0.37	3.15e-6	Total body bone mineral density;
UCEC	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.68	-0.58	6.9e-15	Total cholesterol levels;
UCEC	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.54	6.08	0.45	9.76e-9	Hip circumference;
UCEC	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg09904177	chr6:26538194	HMGN4	-0.74	-5.18	-0.39	7.05e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.54	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.64	-4.79	-0.37	3.95e-6	Autism;
UCEC	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Educational attainment;
UCEC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.83	-8.84	-0.59	2.7e-15	Cognitive function;
UCEC	cis	rs17824620	0.548	rs56278638	chr12:113122464	A/T	cg26711794	chr12:112450906	ERP29;TMEM116	0.6	4.9	0.37	2.47e-6	Platelet count;
UCEC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg22907277	chr7:1156413	C7orf50	0.53	4.71	0.36	5.63e-6	Longevity;Endometriosis;
UCEC	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg04058563	chr4:185651563	MLF1IP	-0.38	-4.57	-0.35	1.03e-5	Kawasaki disease;
UCEC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.25	-0.4	5.19e-7	Aortic root size;
UCEC	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg18681998	chr4:17616180	MED28	0.66	7.67	0.53	2.22e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.7	-6.98	-0.5	9.25e-11	Tonsillectomy;
UCEC	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.13	-0.45	7.68e-9	Aortic root size;
UCEC	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.45	-4.81	-0.37	3.68e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	0.85	10.24	0.65	6.58e-19	Blood protein levels;
UCEC	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.66	5.57	0.42	1.2e-7	Triglycerides;
UCEC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg05241461	chr19:22816980	ZNF492	0.58	6.36	0.46	2.37e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.64	-6.87	-0.49	1.7e-10	Platelet distribution width;
UCEC	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.34	-0.4	3.43e-7	Bipolar disorder;
UCEC	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg12463550	chr7:65579703	CRCP	0.49	4.65	0.36	7.28e-6	Calcium levels;
UCEC	trans	rs4823173	0.509	rs2073080	chr22:44394402	C/T	cg24663798	chr18:76639743	NA	0.56	7.03	0.5	7.15e-11	Hepatic lipid content in extreme obesity;
UCEC	cis	rs6460942	0.591	rs6942551	chr7:12338356	C/T	cg06484146	chr7:12443880	VWDE	-0.54	-4.5	-0.35	1.36e-5	Coronary artery disease;
UCEC	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.75	7.12	0.51	4.39e-11	Response to bleomycin (chromatid breaks);
UCEC	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.33	5.05	0.38	1.31e-6	Cancer;
UCEC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.49	7.39	0.52	9.97e-12	Homoarginine levels;
UCEC	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.59	6.28	0.46	3.53e-9	Retinal vascular caliber;
UCEC	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg14008862	chr17:28927542	LRRC37B2	0.61	4.93	0.38	2.18e-6	Body mass index;
UCEC	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.01	0.55	3.25e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.5	4.7	0.36	5.88e-6	Monocyte count;
UCEC	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.5	5.21	0.39	6.21e-7	Schizophrenia;
UCEC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg15147215	chr3:52552868	STAB1	-0.46	-5.07	-0.39	1.19e-6	Bipolar disorder;
UCEC	cis	rs10916082	1	rs10916082	chr1:227252626	A/G	cg24747565	chr1:227506021	CDC42BPA	-0.52	-4.6	-0.35	9.08e-6	Diastolic blood pressure;
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.54	-0.84	2.53e-40	Exhaled nitric oxide output;
UCEC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs10503871	0.625	rs13250304	chr8:30346587	G/A	cg26383811	chr8:30366931	RBPMS	0.5	5.05	0.38	1.3e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.52	6.01	0.44	1.38e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.45	-4.79	-0.37	4.03e-6	Autism;
UCEC	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.92	-8.0	-0.55	3.45e-13	Platelet count;
UCEC	cis	rs79815064	0.850	rs79539493	chr3:46302938	G/A	cg19145607	chr3:45983792	CXCR6;FYCO1	0.71	4.6	0.35	9.22e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.74	7.42	0.52	8.83e-12	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.79	-0.49	2.56e-10	Chronic sinus infection;
UCEC	cis	rs7246967	0.604	rs58536761	chr19:22880331	G/C	cg24889512	chr19:22816950	ZNF492	0.57	5.81	0.43	3.78e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.68	-6.44	-0.47	1.59e-9	Cocaine dependence;
UCEC	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg07435449	chr11:120005650	TRIM29	0.53	5.55	0.42	1.32e-7	Stroke (pediatric);
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.47	0.72	8.44e-25	Prudent dietary pattern;
UCEC	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.69	7.75	0.54	1.42e-12	Age at first birth;
UCEC	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg19468946	chr17:37922297	IKZF3	-0.48	-5.28	-0.4	4.52e-7	Self-reported allergy;
UCEC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	6.98	0.5	9.32e-11	Chronic sinus infection;
UCEC	cis	rs7582720	1.000	rs72932767	chr2:203679306	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	4.99	0.38	1.72e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11697848	1.000	rs2284646	chr20:48526776	T/G	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.0	0.44	1.48e-8	Platelet count;
UCEC	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.97	0.38	1.84e-6	Monocyte percentage of white cells;
UCEC	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.57	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.72	-6.6	-0.48	6.89e-10	Diastolic blood pressure;
UCEC	cis	rs2892463	0.592	rs7320474	chr13:30374487	G/C	cg10211454	chr13:31195985	USPL1	0.4	4.57	0.35	1.01e-5	Non-word repetition;
UCEC	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Corneal astigmatism;
UCEC	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.51	-5.2	-0.39	6.68e-7	Crohn's disease;
UCEC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.95	-0.5	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.6	-5.63	-0.42	9.03e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.68	4.71	0.36	5.72e-6	Inflammatory biomarkers;
UCEC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.52	5.3	0.4	4.22e-7	Diastolic blood pressure;
UCEC	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.76	-8.81	-0.59	3.28e-15	Menarche (age at onset);
UCEC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.18	0.45	6.03e-9	Platelet count;
UCEC	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-0.94	-6.98	-0.5	9.53e-11	Body mass index;
UCEC	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.58	6.52	0.47	1.05e-9	Longevity;
UCEC	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.61	7.01	0.5	7.81e-11	Hip circumference;
UCEC	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-0.85	-10.74	-0.66	3.24e-20	Height;
UCEC	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.82	12.27	0.71	2.76e-24	Leprosy;
UCEC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.78	9.34	0.61	1.43e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1451375	0.698	rs10899748	chr7:50646089	G/A	cg19715936	chr7:50634035	DDC	0.51	5.85	0.43	3e-8	Malaria;
UCEC	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.63	-0.36	7.97e-6	Pulmonary function;
UCEC	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg24562669	chr7:97807699	LMTK2	-0.42	-5.16	-0.39	7.75e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.5	5.78	0.43	4.29e-8	Alcohol dependence;
UCEC	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.53	-4.82	-0.37	3.51e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.11	-0.39	9.76e-7	Colorectal cancer;
UCEC	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	4.88	0.37	2.72e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.39	-4.71	-0.36	5.65e-6	Subjective well-being;
UCEC	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.44	-4.59	-0.35	9.31e-6	Height;
UCEC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.63	-8.76	-0.59	4.43e-15	Cancer (pleiotropy);
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg01594214	chr6:123110554	SMPDL3A	0.67	7.2	0.51	2.82e-11	Schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05147328	chr17:79849438	ANAPC11;THOC4	0.64	7.77	0.54	1.24e-12	Warfarin maintenance dose;
UCEC	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.76	-10.18	-0.64	9.54e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	4.55	0.35	1.1e-5	Response to antipsychotic treatment;
UCEC	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.52	4.51	0.35	1.3e-5	Corneal astigmatism;
UCEC	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	5.37	0.4	3.04e-7	Mood instability;
UCEC	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-0.71	-7.79	-0.54	1.12e-12	Trans fatty acid levels;
UCEC	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.95	-7.41	-0.52	9.05e-12	Multiple sclerosis;
UCEC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.69	0.69	1e-22	Platelet count;
UCEC	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg16139770	chr10:63661496	ARID5B	-0.45	-4.69	-0.36	6.07e-6	Night sleep phenotypes;
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.82	0.59	3.13e-15	Platelet count;
UCEC	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.83	-0.37	3.39e-6	Alzheimer's disease (late onset);
UCEC	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	0.88	6.36	0.46	2.38e-9	Red blood cell traits;
UCEC	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg11569703	chr11:65557185	OVOL1	-0.44	-6.13	-0.45	7.73e-9	Acne (severe);
UCEC	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.3	-0.4	4.15e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2281845	0.507	rs11589642	chr1:201100748	A/G	cg06714761	chr1:201096289	NA	-0.45	-5.02	-0.38	1.46e-6	Permanent tooth development;
UCEC	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.43	-5.81	-0.43	3.64e-8	IgG glycosylation;
UCEC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-13.31	-0.74	5.15e-27	Chronic sinus infection;
UCEC	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.71	-6.13	-0.45	7.81e-9	Adiposity;
UCEC	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	0.88	10.18	0.64	9.44e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.56	-6.4	-0.47	1.92e-9	Refractive error;
UCEC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-5.56	-0.42	1.26e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.49	-5.52	-0.41	1.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-4.58	-0.35	9.71e-6	QRS complex (12-leadsum);
UCEC	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.62	-0.48	6.2e-10	HDL cholesterol;
UCEC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00802000	chr16:706648	WDR90	-0.49	-5.58	-0.42	1.11e-7	Height;
UCEC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	0.97	10.09	0.64	1.59e-18	Cognitive function;
UCEC	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.57	5.22	0.4	6.06e-7	Coronary artery disease;
UCEC	cis	rs11693319	1.000	rs2130221	chr2:179750087	T/C	cg26389888	chr2:178973147	PDE11A	0.59	4.88	0.37	2.75e-6	Blood pressure measurement (cold pressor test);
UCEC	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs7072216	0.691	rs10786419	chr10:100180940	T/C	cg19567339	chr10:100142640	NA	0.53	6.16	0.45	6.71e-9	Metabolite levels;
UCEC	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.48	-4.87	-0.37	2.81e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.5	-5.0	-0.38	1.59e-6	P wave terminal force;
UCEC	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-7.88	-0.54	6.7e-13	Body mass index;
UCEC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.98	-0.5	9.24e-11	Coronary artery disease;
UCEC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.52	5.2	0.39	6.5e-7	Breast cancer;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.62	7.12	0.51	4.47e-11	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.56	-4.99	-0.38	1.7e-6	Colorectal cancer;
UCEC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg01072550	chr1:21505969	NA	-0.55	-5.07	-0.39	1.18e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg23795048	chr12:9217529	LOC144571	-0.4	-4.81	-0.37	3.63e-6	Sjögren's syndrome;
UCEC	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.42	-5.09	-0.39	1.09e-6	Menopause (age at onset);
UCEC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22117172	chr7:91764530	CYP51A1	0.42	5.24	0.4	5.41e-7	Breast cancer;
UCEC	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.07	-0.64	1.85e-18	Height;
UCEC	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	5.47	0.41	1.92e-7	Coronary artery disease;
UCEC	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.58	6.07	0.45	1.04e-8	Bone mineral density;
UCEC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg22166914	chr1:53195759	ZYG11B	0.61	6.27	0.46	3.87e-9	Monocyte count;
UCEC	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.72	-7.61	-0.53	3.11e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.5	-4.9	-0.38	2.45e-6	Schizophrenia;
UCEC	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.49	-5.37	-0.4	3.03e-7	Longevity;
UCEC	cis	rs9843304	0.585	rs9847009	chr3:149208167	A/G	cg08667024	chr3:149219783	TM4SF4	0.5	6.22	0.46	4.8e-9	Gallstone disease;
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.55	5.97	0.44	1.69e-8	Menarche (age at onset);
UCEC	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg08493051	chr2:3487164	NA	-0.59	-5.71	-0.43	6.04e-8	Neurofibrillary tangles;
UCEC	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.68	5.46	0.41	1.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.08	0.39	1.14e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-7.6	-0.53	3.13e-12	Hypospadias;
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-5.97	-0.44	1.67e-8	Platelet count;
UCEC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.28	0.56	7.07e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg06157570	chr12:6886703	LAG3	0.51	5.12	0.39	9.63e-7	HDL cholesterol levels;
UCEC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg01689657	chr7:91764605	CYP51A1	0.46	5.59	0.42	1.09e-7	Breast cancer;
UCEC	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.86	10.88	0.67	1.39e-20	Mortality in heart failure;
UCEC	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	0.73	4.73	0.36	5.21e-6	Mitochondrial DNA levels;
UCEC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.54	5.74	0.43	5.16e-8	Pulse pressure;
UCEC	cis	rs864537	0.691	rs9662048	chr1:167412947	A/T	cg24449463	chr1:168025552	DCAF6	0.44	4.5	0.35	1.36e-5	Celiac disease or Rheumatoid arthritis;Celiac disease;
UCEC	cis	rs7968440	0.808	rs1659387	chr12:51205067	A/T	cg01096478	chr12:50898751	DIP2B	0.55	4.62	0.36	8.35e-6	Fibrinogen;
UCEC	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.8	5.18	0.39	7.24e-7	Body mass index;
UCEC	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.75	-6.74	-0.49	3.27e-10	Platelet distribution width;
UCEC	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6832769	0.961	rs6824955	chr4:56317136	A/C	cg05960024	chr4:56376020	CLOCK	0.54	5.15	0.39	8.35e-7	Personality dimensions;
UCEC	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	5.0	0.38	1.63e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.57	-0.35	1.04e-5	Response to antipsychotic treatment;
UCEC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.87	-9.6	-0.62	2.96e-17	Cognitive function;
UCEC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-10.95	-0.67	8.97e-21	Vitiligo;
UCEC	cis	rs17220352	0.502	rs62574193	chr9:119477732	C/T	cg13412550	chr9:120177700	ASTN2	-0.82	-5.47	-0.41	1.9e-7	Headache;
UCEC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.84	0.43	3.15e-8	Height;
UCEC	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg19567339	chr10:100142640	NA	0.55	6.53	0.47	9.99e-10	Metabolite levels;
UCEC	cis	rs10242455	0.867	rs776742	chr7:99292755	C/T	cg18809830	chr7:99032528	PTCD1	-0.53	-4.56	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.21	0.51	2.73e-11	Motion sickness;
UCEC	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg23018236	chr17:30244563	NA	-0.61	-4.72	-0.36	5.54e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.53	0.62	4.52e-17	Bipolar disorder;
UCEC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg06134567	chr22:46658398	PKDREJ	0.47	4.73	0.36	5.28e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.22	10.74	0.66	3.18e-20	Corneal structure;
UCEC	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.63	6.67	0.48	4.95e-10	Blood metabolite ratios;
UCEC	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.49	-5.12	-0.39	9.27e-7	Asthma;
UCEC	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.49	-5.57	-0.42	1.17e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.71	-6.4	-0.47	1.94e-9	Aortic root size;
UCEC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs425277	0.876	rs74747369	chr1:2055850	G/A	cg24578937	chr1:2090814	PRKCZ	0.53	5.71	0.43	5.98e-8	Height;
UCEC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.55	-5.73	-0.43	5.54e-8	Prostate cancer;
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg23791538	chr6:167370224	RNASET2	-0.5	-4.9	-0.37	2.47e-6	Crohn's disease;
UCEC	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.73	-8.51	-0.57	1.8e-14	White blood cell count (basophil);
UCEC	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg04439458	chr5:138467593	SIL1	-0.46	-5.22	-0.4	5.93e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg24910161	chr17:38119198	GSDMA	-0.34	-4.72	-0.36	5.51e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.53	5.09	0.39	1.1e-6	Menopause (age at onset);
UCEC	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg01851573	chr8:8652454	MFHAS1	-0.39	-4.7	-0.36	5.88e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs4588572	0.643	rs11744479	chr5:77729220	T/G	cg11547950	chr5:77652471	NA	-0.46	-4.82	-0.37	3.58e-6	Triglycerides;
UCEC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg21770322	chr7:97807741	LMTK2	0.45	5.59	0.42	1.06e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.47	-0.47	1.38e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.62	-7.12	-0.51	4.37e-11	Extrinsic epigenetic age acceleration;
UCEC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26002218	chr14:103986227	CKB	-0.33	-4.75	-0.37	4.69e-6	Body mass index;
UCEC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.53	-5.52	-0.41	1.49e-7	Cardiac Troponin-T levels;
UCEC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.7	7.48	0.53	6.11e-12	Breast cancer;
UCEC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.88	9.77	0.63	1.1e-17	Breast cancer;
UCEC	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.36	-0.4	3.18e-7	Hemoglobin concentration;
UCEC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg07636037	chr3:49044803	WDR6	0.56	4.54	0.35	1.15e-5	Menarche (age at onset);
UCEC	cis	rs7267005	1.000	rs113733573	chr20:34385136	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.41	-4.58	-0.35	9.76e-6	Smoking behavior;
UCEC	cis	rs10924970	0.649	rs2382568	chr1:235468880	G/A	cg26050004	chr1:235667680	B3GALNT2	0.5	4.8	0.37	3.85e-6	Asthma;
UCEC	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.53	-5.48	-0.41	1.79e-7	Sudden cardiac arrest;
UCEC	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.78	-7.38	-0.52	1.08e-11	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.75	0.36	4.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg11200568	chr7:226540	FAM20C	-0.47	-4.52	-0.35	1.25e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.9	10.84	0.67	1.74e-20	Breast cancer;
UCEC	cis	rs6684428	0.536	rs12119831	chr1:56392010	A/G	cg11651538	chr1:56320950	NA	0.44	4.73	0.36	5.11e-6	Airflow obstruction;
UCEC	cis	rs1550115	0.614	rs11884143	chr2:24712930	C/G	cg16406212	chr2:24163862	UBXN2A	0.51	4.69	0.36	6.12e-6	Coronary artery disease;
UCEC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg13695892	chr22:41940480	POLR3H	0.68	5.31	0.4	3.94e-7	Vitiligo;
UCEC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.59	6.38	0.47	2.17e-9	Blood metabolite levels;
UCEC	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.67	-4.88	-0.37	2.75e-6	Diabetic retinopathy;
UCEC	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.61	6.97	0.5	1.01e-10	Skin colour saturation;
UCEC	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.39	-5.33	-0.4	3.63e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.51	5.47	0.41	1.86e-7	Tumor biomarkers;
UCEC	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg19805062	chr22:46654627	PKDREJ	0.46	4.57	0.35	1.02e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.15	0.39	8.32e-7	HDL cholesterol;
UCEC	cis	rs4908768	0.579	rs55840223	chr1:8862787	G/C	cg13081009	chr1:8430745	RERE	0.45	5.06	0.39	1.22e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.44	-0.41	2.18e-7	Pulmonary function;
UCEC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-5.04	-0.38	1.35e-6	Bipolar disorder;
UCEC	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.32	4.54	0.35	1.18e-5	Iron status biomarkers;
UCEC	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.6	4.88	0.37	2.68e-6	Corneal astigmatism;
UCEC	cis	rs7715256	0.791	rs1346482	chr5:153535857	G/A	cg27295185	chr5:154320610	MRPL22	0.42	4.7	0.36	5.95e-6	BMI (adjusted for smoking behaviour);Body mass index;Childhood body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.57	8.38	0.57	3.93e-14	Height;
UCEC	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-8.81	-0.59	3.19e-15	Vitiligo;
UCEC	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg14438399	chr17:27053147	TLCD1	0.6	4.87	0.37	2.85e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.63	5.11	0.39	9.95e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.19	8.04	0.55	2.74e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.67	-7.68	-0.54	2.08e-12	Menarche (age at onset);
UCEC	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	8.7	0.58	6.14e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.35	4.85	0.37	3.16e-6	Eye color traits;
UCEC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.58	-4.84	-0.37	3.21e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Body mass index;
UCEC	cis	rs427691	0.625	rs845740	chr5:109018902	C/T	cg17395555	chr5:108820864	NA	0.59	4.51	0.35	1.31e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg13844804	chr7:814759	HEATR2	0.6	4.62	0.36	8.18e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg13147721	chr7:65941812	NA	-0.73	-4.87	-0.37	2.9e-6	Diabetic kidney disease;
UCEC	cis	rs55665837	0.539	rs10832310	chr11:14878442	C/G	cg19336497	chr11:14380999	RRAS2	-0.31	-4.53	-0.35	1.22e-5	Vitamin D levels;
UCEC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.48	5.24	0.4	5.46e-7	Pulse pressure;
UCEC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.62	-7.32	-0.52	1.52e-11	Prostate cancer;
UCEC	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.27e-13	Parkinson's disease;
UCEC	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.65	-7.64	-0.53	2.58e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.83	7.76	0.54	1.34e-12	Diastolic blood pressure;
UCEC	cis	rs2062225	0.735	rs7594735	chr2:111746856	A/G	cg23782758	chr2:111737646	ACOXL	-0.56	-4.58	-0.35	1e-5	Monocyte count;
UCEC	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	5.27	0.4	4.7e-7	Monocyte percentage of white cells;
UCEC	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.67	-6.65	-0.48	5.39e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-5.11	-0.39	9.94e-7	Aortic root size;
UCEC	cis	rs9463078	0.739	rs6910749	chr6:44773892	A/G	cg25276700	chr6:44698697	NA	-0.44	-5.07	-0.39	1.17e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.62	-6.71	-0.48	4.03e-10	Longevity;Endometriosis;
UCEC	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	5.63	0.42	8.97e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.49	5.0	0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg04553112	chr3:125709451	NA	-0.72	-5.05	-0.38	1.32e-6	Blood pressure (smoking interaction);
UCEC	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-1.06	-6.95	-0.5	1.08e-10	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.53	-5.26	-0.4	4.9e-7	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs35934224	0.891	rs33997573	chr22:19868951	C/T	cg11182965	chr22:19864308	TXNRD2	-0.57	-7.13	-0.51	4.11e-11	Glaucoma (primary open-angle);
UCEC	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.53	4.74	0.36	4.93e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.54	0.47	9.35e-10	Cognitive test performance;
UCEC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.72	-4.65	-0.36	7.38e-6	Psoriasis;
UCEC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	6.36	0.46	2.44e-9	Blood metabolite levels;
UCEC	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-4.88	-0.37	2.77e-6	Total cholesterol levels;
UCEC	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.99	13.63	0.75	7.05e-28	Bone mineral density;
UCEC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.59	-0.42	1.05e-7	Monocyte percentage of white cells;
UCEC	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.69	6.4	0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs11586313	0.649	rs61815701	chr1:152887412	G/A	cg07796016	chr1:152779584	LCE1C	-0.59	-5.74	-0.43	5.31e-8	Vitamin D levels;
UCEC	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.63	-5.39	-0.41	2.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	4.67	0.36	6.67e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.52	5.63	0.42	9.01e-8	Tonsillectomy;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.33	0.61	1.5e-16	Platelet count;
UCEC	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.74	5.05	0.38	1.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.68	-6.06	-0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.56	4.6	0.35	9.15e-6	Obesity-related traits;
UCEC	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.54	4.9	0.37	2.46e-6	Lung cancer;
UCEC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26002218	chr14:103986227	CKB	0.36	5.14	0.39	8.75e-7	Body mass index;
UCEC	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.49	5.05	0.38	1.27e-6	Migraine;
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg20999797	chr1:1681921	NA	-0.36	-4.93	-0.38	2.16e-6	Body mass index;
UCEC	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg03859395	chr2:55845619	SMEK2	1.07	15.94	0.8	7.71e-34	Metabolic syndrome;
UCEC	cis	rs1635	0.655	rs9368532	chr6:27782010	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.73	-4.93	-0.38	2.22e-6	Schizophrenia;
UCEC	cis	rs3914502	0.615	rs9290517	chr3:174523771	G/C	cg21145449	chr3:174580620	NAALADL2	0.44	5.01	0.38	1.51e-6	Autism spectrum disorder;
UCEC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg20965017	chr5:231967	SDHA	-0.65	-5.79	-0.43	4.1e-8	Breast cancer;
UCEC	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	1.23	6.38	0.47	2.16e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg07153921	chr17:41440717	NA	-0.57	-6.58	-0.48	7.55e-10	Menopause (age at onset);
UCEC	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.7	0.43	6.22e-8	Height;
UCEC	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.78	-0.37	4.16e-6	Multiple sclerosis;
UCEC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.3	0.4	4.21e-7	Rheumatoid arthritis;
UCEC	cis	rs2474937	0.561	rs10802025	chr1:118927673	T/A	cg10572355	chr1:119549145	NA	0.43	4.53	0.35	1.21e-5	Congenital heart malformation;
UCEC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.65	0.62	2.23e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.54	5.13	0.39	8.99e-7	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.54	5.72	0.43	5.63e-8	Red blood cell count;
UCEC	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.31	0.4	3.96e-7	Total body bone mineral density;
UCEC	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.61	-0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-0.57	-5.39	-0.41	2.72e-7	Monocyte percentage of white cells;
UCEC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg22974920	chr21:40686053	BRWD1	0.61	5.37	0.41	2.99e-7	Cognitive function;
UCEC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg15133208	chr4:90757351	SNCA	0.35	4.72	0.36	5.45e-6	Dementia with Lewy bodies;
UCEC	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.58	-6.55	-0.48	9.11e-10	Lung cancer;
UCEC	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.22	-0.4	6.03e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.42	5.43	0.41	2.32e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.47	-4.77	-0.37	4.38e-6	Neuroticism;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.64	-6.17	-0.45	6.26e-9	Prostate cancer;
UCEC	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.97	0.5	9.79e-11	Alzheimer's disease;
UCEC	cis	rs7937612	1.000	rs10892582	chr11:120347715	C/T	cg12584626	chr11:120203529	NA	0.5	4.94	0.38	2.08e-6	Intraocular pressure;
UCEC	cis	rs7611694	0.532	rs7650538	chr3:113180678	C/T	cg11138929	chr3:113251189	SIDT1	-0.42	-4.95	-0.38	1.98e-6	Prostate cancer;
UCEC	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg24562669	chr7:97807699	LMTK2	0.47	5.76	0.43	4.64e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	-0.57	-4.59	-0.35	9.55e-6	Bitter taste perception;
UCEC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	0.7	4.93	0.38	2.17e-6	Iron status biomarkers;
UCEC	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.23	-0.46	4.68e-9	Prudent dietary pattern;
UCEC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.33	0.4	3.61e-7	Rheumatoid arthritis;
UCEC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.56	-5.83	-0.43	3.35e-8	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.46	5.61	0.42	9.91e-8	Bone mineral density;
UCEC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.69	-6.59	-0.48	7.43e-10	Parkinson's disease;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.51	-6.0	-0.44	1.45e-8	Pubertal anthropometrics;
UCEC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.54	-4.62	-0.36	8.16e-6	Menarche (age at onset);
UCEC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.73	7.41	0.52	9.29e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.19e-6	Multiple sclerosis;
UCEC	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.75	-7.28	-0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.7	9.13	0.6	5.02e-16	Mean platelet volume;
UCEC	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.6	5.07	0.39	1.2e-6	Coronary artery disease;
UCEC	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.88	0.37	2.68e-6	Diabetic retinopathy;
UCEC	cis	rs7246967	0.673	rs36029703	chr19:22906188	C/A	cg05241461	chr19:22816980	ZNF492	0.56	5.87	0.44	2.8e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.24	0.46	4.42e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.19e-7	QRS complex (12-leadsum);
UCEC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg23795048	chr12:9217529	LOC144571	0.41	5.09	0.39	1.1e-6	Sjögren's syndrome;
UCEC	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.71	-8.76	-0.59	4.35e-15	Hip circumference;
UCEC	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.76	8.88	0.59	2.21e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.12e-7	Life satisfaction;
UCEC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	0.73	5.15	0.39	8.33e-7	Body mass index;
UCEC	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12292205	chr6:26970375	C6orf41	-0.67	-4.8	-0.37	3.88e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.43	5.06	0.38	1.26e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg09491104	chr22:46646882	C22orf40	0.6	6.81	0.49	2.38e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2676071	0.617	rs2676074	chr15:33600119	T/A	cg17732372	chr15:33604133	RYR3	-0.33	-5.03	-0.38	1.42e-6	Periodontitis (Mean PAL);
UCEC	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	9.51	0.62	5.18e-17	Coffee consumption (cups per day);
UCEC	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg21191810	chr6:118973309	C6orf204	0.41	5.67	0.42	7.28e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.0	-0.5	8.47e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.93	-0.5	1.25e-10	Breast cancer;
UCEC	cis	rs12643440	0.960	rs16894651	chr4:17208345	C/T	cg27207796	chr4:17783322	FAM184B	-0.53	-4.61	-0.36	8.77e-6	Metabolite levels (Pyroglutamine);
UCEC	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.66	0.42	7.63e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	9.51	0.62	5.18e-17	Coffee consumption (cups per day);
UCEC	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	7.63	0.53	2.71e-12	Post bronchodilator FEV1;
UCEC	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs7246967	0.673	rs12985495	chr19:22930378	A/G	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg00614314	chr15:82944287	LOC80154	0.53	4.86	0.37	3.01e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05360402	chr5:110848191	STARD4	0.59	7.05	0.5	6.59e-11	Warfarin maintenance dose;
UCEC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg21231944	chr12:82153410	PPFIA2	0.45	4.74	0.36	5.03e-6	Resting heart rate;
UCEC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	10.01	0.64	2.59e-18	Cognitive ability;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.49	4.7	0.36	5.97e-6	Menarche (age at onset);
UCEC	cis	rs10129255	0.528	rs17113214	chr14:107107969	A/T	cg03031183	chr14:106916953	NA	-0.43	-4.63	-0.36	8.06e-6	Kawasaki disease;
UCEC	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-4.92	-0.38	2.25e-6	Metabolite levels;
UCEC	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.54	5.82	0.43	3.55e-8	Prostate cancer;
UCEC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg12463550	chr7:65579703	CRCP	0.5	4.62	0.36	8.26e-6	Calcium levels;
UCEC	cis	rs10924970	0.967	rs7553200	chr1:235467940	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	4.84	0.37	3.21e-6	Asthma;
UCEC	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	5.36	0.4	3.19e-7	Height;
UCEC	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.96	10.35	0.65	3.32e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-4.99	-0.38	1.65e-6	Morning vs. evening chronotype;
UCEC	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg23791538	chr6:167370224	RNASET2	-0.56	-6.1	-0.45	8.87e-9	Crohn's disease;
UCEC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.62	-6.65	-0.48	5.35e-10	Bipolar disorder;
UCEC	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-10.38	-0.65	2.85e-19	Blood metabolite levels;
UCEC	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg01689657	chr7:91764605	CYP51A1	0.47	5.95	0.44	1.86e-8	Breast cancer;
UCEC	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.72	-5.99	-0.44	1.54e-8	Tonometry;
UCEC	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-5.21	-0.39	6.23e-7	Kawasaki disease;
UCEC	cis	rs28795989	0.830	rs1320074	chr4:7904111	T/G	cg00251875	chr4:7801337	AFAP1	0.5	5.71	0.43	6.04e-8	Intraocular pressure;
UCEC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	4.76	0.37	4.53e-6	Platelet count;
UCEC	cis	rs4662945	0.688	rs34713181	chr2:130212385	G/A	cg05962382	chr2:130345044	NA	-0.41	-4.55	-0.35	1.13e-5	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.66	5.44	0.41	2.16e-7	Blood metabolite levels;
UCEC	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs9463078	0.817	rs2145826	chr6:44763781	G/A	cg25276700	chr6:44698697	NA	0.45	4.52	0.35	1.29e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.51	4.7	0.36	5.91e-6	Uric acid levels;
UCEC	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-0.42	-4.54	-0.35	1.18e-5	IgG glycosylation;
UCEC	cis	rs7149337	0.773	rs3007067	chr14:51596420	G/A	cg23942311	chr14:51606299	NA	0.36	6.05	0.45	1.17e-8	Cancer;
UCEC	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.62	5.58	0.42	1.11e-7	Coronary heart disease;
UCEC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.52	-4.91	-0.38	2.41e-6	Coronary artery disease;
UCEC	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.16	0.56	1.39e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.89	0.44	2.5e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.92	0.38	2.3e-6	Schizophrenia;
UCEC	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.43	-5.58	-0.42	1.12e-7	Monocyte count;
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg08461772	chr7:95026248	PON3	-0.34	-4.73	-0.36	5.28e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-7.49	-0.53	5.89e-12	Cognitive function;
UCEC	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg23950597	chr19:37808831	NA	-0.86	-5.72	-0.43	5.69e-8	Coronary artery calcification;
UCEC	cis	rs7909670	0.836	rs1888666	chr10:12933952	A/T	cg18678121	chr10:12170807	SEC61A2	0.45	4.7	0.36	5.83e-6	Height;
UCEC	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.62	-5.34	-0.4	3.42e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17034641	1.000	rs10495929	chr2:46372174	A/G	cg12428440	chr2:46370979	PRKCE	-0.6	-5.12	-0.39	9.55e-7	Hemoglobin;Hematocrit;
UCEC	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-4.56	-0.35	1.07e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12635074	0.547	rs73080547	chr3:56258688	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.37	4.69	0.36	6.18e-6	Morning vs. evening chronotype;
UCEC	cis	rs1595825	0.891	rs79845692	chr2:198523541	T/C	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-6.37	-0.47	2.24e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	7.84	0.54	8.24e-13	Alzheimer's disease;
UCEC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.82	-8.29	-0.56	6.64e-14	Resting heart rate;
UCEC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.63	5.85	0.43	3.07e-8	Aortic root size;
UCEC	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.68	5.47	0.41	1.87e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	5.13	0.39	9.18e-7	Cognitive test performance;
UCEC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.61	-5.88	-0.44	2.6e-8	Resting heart rate;
UCEC	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.56	-5.06	-0.39	1.22e-6	Metabolite levels;
UCEC	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.0	-6.46	-0.47	1.41e-9	Diabetic kidney disease;
UCEC	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.55	-4.57	-0.35	1.02e-5	Menarche (age at onset);
UCEC	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.13	0.51	4.18e-11	Coffee consumption (cups per day);
UCEC	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.57	0.48	8.01e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-0.98	-7.42	-0.52	8.88e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18252515	chr7:66147081	NA	0.55	5.05	0.38	1.28e-6	Aortic root size;
UCEC	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.66	-6.91	-0.49	1.4e-10	Itch intensity from mosquito bite;
UCEC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.71	8.94	0.59	1.51e-15	Mean platelet volume;
UCEC	cis	rs4499344	0.556	rs259217	chr19:33138368	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg18230493	chr5:56204884	C5orf35	-0.63	-6.44	-0.47	1.63e-9	Coronary artery disease;
UCEC	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.42	-5.77	-0.43	4.5e-8	Sitting height ratio;
UCEC	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg21905437	chr5:178450457	ZNF879	0.67	7.2	0.51	2.94e-11	Pubertal anthropometrics;
UCEC	cis	rs17639063	0.737	rs62243506	chr3:62526876	G/T	cg04329977	chr3:61546343	PTPRG	-0.89	-4.78	-0.37	4.2e-6	QT interval (sulfonylurea treatment interaction);
UCEC	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.6	5.83	0.43	3.41e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.49	5.0	0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.71	8.91	0.59	1.85e-15	Hip circumference;
UCEC	cis	rs6763768	0.606	rs13062474	chr3:53331547	C/T	cg10956333	chr3:53294961	NA	0.41	4.83	0.37	3.33e-6	Bacterial meningitis;
UCEC	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	0.89	8.54	0.58	1.59e-14	Corneal structure;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.7	-7.52	-0.53	4.99e-12	Paraoxonase activity;
UCEC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.42	-4.58	-0.35	9.87e-6	Longevity;
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.68	-8.0	-0.55	3.35e-13	Menarche (age at onset);
UCEC	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.69	6.61	0.48	6.53e-10	Vitamin D levels;
UCEC	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-6.62	-0.48	6.43e-10	Fibrinogen levels;
UCEC	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-6.57	-0.48	8.26e-10	Coffee consumption (cups per day);
UCEC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-4.76	-0.37	4.65e-6	Aortic root size;
UCEC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg24069376	chr3:38537580	EXOG	-0.39	-4.88	-0.37	2.76e-6	Electrocardiographic conduction measures;
UCEC	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.47	-4.63	-0.36	8.05e-6	Dental caries;
UCEC	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.74	-7.79	-0.54	1.13e-12	Menarche (age at onset);
UCEC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	5.95	0.44	1.88e-8	Menarche (age at onset);
UCEC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	10.11	0.64	1.4e-18	Chronic sinus infection;
UCEC	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.69	-5.63	-0.42	8.95e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg20203395	chr5:56204925	C5orf35	-0.61	-4.55	-0.35	1.11e-5	Type 2 diabetes;
UCEC	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.58	-5.03	-0.38	1.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg18681998	chr4:17616180	MED28	0.64	7.28	0.51	1.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs539514	0.556	rs1108412	chr13:76321497	G/A	cg04757411	chr13:76259545	LMO7	-0.38	-4.6	-0.35	9.22e-6	Type 1 diabetes;
UCEC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.68	7.05	0.5	6.36e-11	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs34486957	0.600	rs8003052	chr14:60043053	C/T	cg12189551	chr14:60952945	C14orf39	0.36	4.52	0.35	1.27e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.53	5.98	0.44	1.66e-8	Mean corpuscular volume;
UCEC	cis	rs4871297	0.729	rs17284115	chr8:123699206	C/A	cg17213048	chr8:124332861	ATAD2	0.41	4.59	0.35	9.34e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.59	0.35	9.58e-6	Menopause (age at onset);
UCEC	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	6.06	0.45	1.09e-8	Response to bleomycin (chromatid breaks);
UCEC	cis	rs12049351	0.665	rs970103	chr1:229570135	G/A	cg23647989	chr1:229125535	NA	0.46	4.58	0.35	9.99e-6	Circulating myeloperoxidase levels (plasma);
UCEC	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg11871910	chr12:69753446	YEATS4	0.55	4.88	0.37	2.76e-6	Response to diuretic therapy;
UCEC	cis	rs611744	0.781	rs75534351	chr8:109118714	A/T	cg18478394	chr8:109455254	TTC35	0.52	5.59	0.42	1.1e-7	Dupuytren's disease;
UCEC	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.83	0.37	3.33e-6	Multiple sclerosis;
UCEC	cis	rs1415259	0.889	rs12406484	chr1:162072429	C/G	cg19130550	chr1:161994277	OLFML2B	0.43	4.52	0.35	1.28e-5	Electrocardiographic traits;
UCEC	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.12	10.7	0.66	4.08e-20	Ulcerative colitis;
UCEC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.61	0.53	3.07e-12	Platelet count;
UCEC	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-4.99	-0.38	1.67e-6	Type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03157738	chr19:11308118	KANK2	0.65	8.05	0.55	2.58e-13	Warfarin maintenance dose;
UCEC	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.49	-4.83	-0.37	3.43e-6	Morning vs. evening chronotype;
UCEC	cis	rs3813359	0.668	rs4895875	chr6:130608293	T/C	cg10100811	chr6:131116068	NA	0.6	4.56	0.35	1.08e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs17106184	0.892	rs3789581	chr1:51019450	T/C	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.22	-0.4	6.13e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	0.86	5.47	0.41	1.91e-7	Arsenic metabolism;
UCEC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg18721089	chr20:30220636	NA	-0.41	-5.21	-0.4	6.18e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg16616514	chr4:6324629	PPP2R2C	0.41	4.98	0.38	1.77e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2386661	0.826	rs1317517	chr10:5672580	T/G	cg17085576	chr10:5658249	NA	-0.5	-5.1	-0.39	1.04e-6	Breast cancer;
UCEC	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg14851346	chr12:38532713	NA	0.52	5.02	0.38	1.47e-6	Heart rate;
UCEC	cis	rs59104589	0.617	rs60132543	chr2:242344599	T/C	cg19488206	chr2:242435732	STK25	0.49	5.06	0.38	1.25e-6	Fibrinogen levels;
UCEC	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	1.03	8.84	0.59	2.71e-15	Dupuytren's disease;
UCEC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg08807892	chr2:162101083	NA	0.58	6.05	0.45	1.15e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.6	5.56	0.42	1.23e-7	Mosquito bite size;
UCEC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	7.52	0.53	4.98e-12	Bone mineral density;
UCEC	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg03859395	chr2:55845619	SMEK2	0.85	9.54	0.62	4.48e-17	Metabolic syndrome;
UCEC	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg18681998	chr4:17616180	MED28	0.65	6.66	0.48	5.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.33	4.8	0.37	3.79e-6	Schizophrenia;
UCEC	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.76	-6.99	-0.5	8.77e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-4.73	-0.36	5.22e-6	Waist circumference adjusted for body mass index;
UCEC	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.08e-8	Breast cancer;
UCEC	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.06	-0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.65	-4.55	-0.35	1.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.9	9.01	0.6	1.01e-15	Testicular germ cell tumor;
UCEC	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-0.86	-7.57	-0.53	3.8e-12	Post bronchodilator FEV1;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg00280220	chr17:61926910	NA	-0.43	-4.71	-0.36	5.72e-6	Prudent dietary pattern;
UCEC	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.74	-8.17	-0.56	1.3e-13	White blood cell count (basophil);
UCEC	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.75	6.69	0.48	4.27e-10	Coronary artery disease;
UCEC	cis	rs55670112	0.935	rs4395625	chr5:114277883	A/G	cg05461448	chr5:114880715	FEM1C	-0.44	-4.58	-0.35	9.96e-6	Epilepsy;
UCEC	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-5.22	-0.4	6.13e-7	Morning vs. evening chronotype;
UCEC	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.48	5.13	0.39	9.04e-7	Headache;
UCEC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg24562669	chr7:97807699	LMTK2	0.5	6.12	0.45	7.99e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9843304	0.528	rs11919764	chr3:149187235	C/T	cg08667024	chr3:149219783	TM4SF4	-0.49	-5.65	-0.42	8.1e-8	Gallstone disease;
UCEC	cis	rs3790645	0.645	rs3790644	chr1:26884676	G/A	cg23229016	chr1:26872525	RPS6KA1	0.28	4.74	0.36	5.07e-6	Glucose homeostasis traits;
UCEC	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21178979	chr7:1889533	MAD1L1	0.36	4.69	0.36	6.23e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	5.72	0.43	5.88e-8	Monocyte percentage of white cells;
UCEC	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.59	4.56	0.35	1.09e-5	Bipolar disorder (body mass index interaction);
UCEC	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.47	5.65	0.42	7.88e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.58	5.14	0.39	8.69e-7	Obesity (extreme);
UCEC	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.62	5.5	0.41	1.65e-7	Phospholipid levels (plasma);
UCEC	cis	rs539096	0.830	rs2842183	chr1:44020394	T/C	cg11851915	chr1:44060116	PTPRF	-0.43	-4.51	-0.35	1.33e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.91	11.32	0.68	9.49e-22	Ulcerative colitis;
UCEC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01380346	chr19:18557039	ELL	-0.46	-4.85	-0.37	3.14e-6	Breast cancer;
UCEC	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.06	0.55	2.44e-13	Prudent dietary pattern;
UCEC	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg21118186	chr11:28129915	METT5D1;KIF18A	0.53	4.81	0.37	3.78e-6	Bipolar disorder;
UCEC	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-6.63	-0.48	6.11e-10	Fibrinogen levels;
UCEC	cis	rs7246967	0.608	rs2569728	chr19:23014004	C/T	cg08271804	chr19:22816896	ZNF492	0.5	4.63	0.36	7.99e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.76	-5.91	-0.44	2.27e-8	Corneal structure;
UCEC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.45	-5.15	-0.39	8.2e-7	Longevity;Endometriosis;
UCEC	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	18.83	0.84	5.07e-41	IgG glycosylation;
UCEC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-0.76	-7.68	-0.54	2.02e-12	Urate levels;
UCEC	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg27246729	chr12:121163418	ACADS	0.46	4.53	0.35	1.2e-5	Mean corpuscular volume;
UCEC	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.67	5.66	0.42	7.65e-8	Blood metabolite levels;
UCEC	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.51	-0.47	1.1e-9	Caudate activity during reward;
UCEC	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.53	-4.83	-0.37	3.42e-6	Longevity;
UCEC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.69	8.08	0.55	2.23e-13	Menarche (age at onset);
UCEC	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	7.79	0.54	1.08e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg05132306	chr1:1846340	CALML6	-0.38	-4.78	-0.37	4.2e-6	Body mass index;
UCEC	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg01236616	chr12:121019343	POP5	0.58	4.66	0.36	6.91e-6	High light scatter reticulocyte count;
UCEC	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-10.34	-0.65	3.65e-19	Ulcerative colitis;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.61	-8.73	-0.58	5.28e-15	Prudent dietary pattern;
UCEC	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.48	0.62	6.36e-17	Electrocardiographic conduction measures;
UCEC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-5.55	-0.42	1.29e-7	Blood trace element (Zn levels);
UCEC	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.36	5.03	0.38	1.42e-6	Height;
UCEC	cis	rs4852324	1.000	rs4852324	chr2:74202578	A/G	cg00753399	chr2:74404556	MOBKL1B	-0.56	-4.63	-0.36	7.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg21770322	chr7:97807741	LMTK2	0.82	13.77	0.75	3.17e-28	Breast cancer;
UCEC	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.34	0.46	2.63e-9	Diabetic retinopathy;
UCEC	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	5.86	0.43	2.97e-8	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	0.94	5.77	0.43	4.53e-8	Skin colour saturation;
UCEC	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg20560298	chr2:73613845	ALMS1	0.52	4.95	0.38	1.99e-6	Metabolite levels;
UCEC	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.57	0.42	1.18e-7	Alzheimer's disease;
UCEC	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg18232548	chr7:50535776	DDC	-0.62	-6.72	-0.48	3.7e-10	Body mass index;
UCEC	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.54	6.19	0.45	5.62e-9	Blood metabolite levels;
UCEC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg16616514	chr4:6324629	PPP2R2C	-0.43	-5.26	-0.4	4.91e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	1.13	8.34	0.57	4.94e-14	Vitiligo;
UCEC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.5	5.59	0.42	1.05e-7	Response to antineoplastic agents;
UCEC	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.3	-0.57	6.04e-14	Acylcarnitine levels;
UCEC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.24	0.4	5.55e-7	Height;
UCEC	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.51	5.12	0.39	9.44e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.82	4.91	0.38	2.44e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.65	8.07	0.55	2.23e-13	Bone mineral density;
UCEC	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	1.06	10.42	0.65	2.26e-19	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	5.36	0.4	3.17e-7	Ileal carcinoids;
UCEC	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.69	-6.92	-0.5	1.28e-10	Tonsillectomy;
UCEC	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg07596299	chr11:71824057	C11orf51	0.76	4.57	0.35	1.04e-5	Severe influenza A (H1N1) infection;
UCEC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.38	-0.47	2.17e-9	Tonsillectomy;
UCEC	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.59	-0.42	1.09e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2041895	0.527	rs10861678	chr12:107319661	C/T	cg13944111	chr12:107296891	NA	0.38	4.99	0.38	1.66e-6	Glaucoma (low intraocular pressure);
UCEC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.56	5.06	0.39	1.25e-6	Corneal astigmatism;
UCEC	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.54	6.39	0.47	2.05e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12363310	0.633	rs11225014	chr11:101675358	A/G	cg00202702	chr11:101918157	C11orf70	0.39	4.52	0.35	1.24e-5	Systemic sclerosis;
UCEC	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.77	6.7	0.48	4.06e-10	Breast cancer;
UCEC	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.44	4.59	0.35	9.4e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.57	6.69	0.48	4.33e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg03146154	chr1:46216737	IPP	0.46	4.85	0.37	3.07e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.56	-5.06	-0.38	1.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.65	5.44	0.41	2.2e-7	Smoking initiation;
UCEC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.19	-0.39	6.99e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.48	4.65	0.36	7.25e-6	Primary sclerosing cholangitis;
UCEC	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-5.98	-0.44	1.59e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-0.81	-5.0	-0.38	1.6e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg21770322	chr7:97807741	LMTK2	0.53	6.88	0.49	1.6e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.58	-0.42	1.11e-7	Adiposity;
UCEC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.73	-6.58	-0.48	7.64e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.48	-4.73	-0.36	5.22e-6	Mortality in heart failure;
UCEC	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg03078520	chr22:18463400	MICAL3	0.49	4.82	0.37	3.58e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs6893207	1.000	rs114018714	chr5:16379920	A/T	cg11584519	chr5:16175867	MARCH11	0.78	4.92	0.38	2.3e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05347473	chr6:146136440	FBXO30	0.53	6.06	0.45	1.08e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07690219	chr3:49449608	TCTA;RHOA	0.52	4.76	0.37	4.5e-6	Menarche (age at onset);
UCEC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg15445000	chr17:37608096	MED1	-0.5	-5.05	-0.38	1.29e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	6.4	0.47	1.92e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.8	0.43	3.83e-8	Response to antipsychotic treatment;
UCEC	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.67	7.09	0.5	5.32e-11	Dilated cardiomyopathy;
UCEC	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.06	-9.07	-0.6	7.04e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.4	4.86	0.37	3.02e-6	Tonsillectomy;
UCEC	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.19	-9.51	-0.62	5.14e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.9e-9	Prudent dietary pattern;
UCEC	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.64	6.96	0.5	1.04e-10	Eye color traits;
UCEC	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.5	-4.82	-0.37	3.53e-6	QRS complex (12-leadsum);
UCEC	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.51	5.83	0.43	3.44e-8	Testicular germ cell tumor;
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	8.89	0.59	2.02e-15	Platelet count;
UCEC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.61	-5.71	-0.43	6.17e-8	Acne (severe);
UCEC	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg18016565	chr1:150552671	MCL1	-0.48	-5.05	-0.38	1.28e-6	Melanoma;
UCEC	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.57	-5.05	-0.38	1.29e-6	Carotid intima media thickness;
UCEC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.66	-7.77	-0.54	1.22e-12	Menarche (age at onset);
UCEC	cis	rs10242455	0.702	rs73713507	chr7:99138603	G/A	cg18809830	chr7:99032528	PTCD1	-0.92	-5.26	-0.4	4.95e-7	Blood metabolite levels;
UCEC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22117172	chr7:91764530	CYP51A1	0.43	5.43	0.41	2.26e-7	Breast cancer;
UCEC	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.68	8.83	0.59	2.94e-15	Vitiligo;
UCEC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.33	0.4	3.61e-7	Rheumatoid arthritis;
UCEC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg26061582	chr7:22766209	IL6	0.61	5.68	0.42	6.86e-8	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
UCEC	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg02175308	chr1:109941060	SORT1	0.31	4.71	0.36	5.71e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg21905437	chr5:178450457	ZNF879	0.64	7.1	0.51	4.95e-11	Pubertal anthropometrics;
UCEC	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.57	4.53	0.35	1.21e-5	Exhaled nitric oxide output;
UCEC	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.67	0.36	6.7e-6	Schizophrenia;
UCEC	cis	rs73416724	0.925	rs79641366	chr6:43279144	T/C	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.43	-5.78	-0.43	4.27e-8	Prostate cancer;
UCEC	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-5.49	-0.41	1.68e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	10.41	0.65	2.34e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.7	-7.8	-0.54	1.03e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.08	-8.51	-0.57	1.82e-14	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	0.97	9.68	0.62	1.85e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.47	1.11e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.17	0.45	6.43e-9	Rheumatoid arthritis;
UCEC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.84	9.27	0.61	2.21e-16	Breast cancer;
UCEC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.68	7.31	0.52	1.55e-11	Lymphocyte counts;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.54	-5.76	-0.43	4.83e-8	Pubertal anthropometrics;
UCEC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs12618769	0.652	rs3754878	chr2:99179384	G/A	cg10123293	chr2:99228465	UNC50	0.48	5.27	0.4	4.85e-7	Bipolar disorder;
UCEC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.53	6.74	0.49	3.27e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-5.64	-0.42	8.37e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	5.83	0.43	3.32e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-5.45	-0.41	2.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2694528	0.686	rs7723165	chr5:59876715	A/G	cg11474532	chr5:59995715	DEPDC1B	0.61	4.6	0.35	9.17e-6	Parkinson's disease;
UCEC	cis	rs970548	0.721	rs57491883	chr10:46100101	T/C	cg15223267	chr10:46222474	FAM21C	0.55	5.27	0.4	4.88e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-8.13	-0.56	1.64e-13	Menarche (age at onset);
UCEC	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.69	-7.64	-0.53	2.62e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.43	-4.87	-0.37	2.84e-6	Pelvic organ prolapse;
UCEC	cis	rs4879656	0.564	rs7864363	chr9:33022000	C/G	cg09633881	chr9:33002021	APTX	0.37	4.63	0.36	7.92e-6	Menopause (age at onset);
UCEC	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.5	-5.03	-0.38	1.43e-6	Itch intensity from mosquito bite;
UCEC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.54	6.24	0.46	4.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2200578	1.000	rs72954221	chr2:99899445	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.8	5.95	0.44	1.92e-8	IgG glycosylation;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	6.95	0.5	1.08e-10	Platelet count;
UCEC	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg18681998	chr4:17616180	MED28	0.67	7.11	0.51	4.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg20573242	chr4:122745356	CCNA2	0.46	4.53	0.35	1.19e-5	Type 2 diabetes;
UCEC	cis	rs10012307	1.000	rs12644210	chr4:137516319	A/G	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.66	0.36	7.16e-6	Bipolar disorder;
UCEC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.56	-6.62	-0.48	6.22e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2386661	0.826	rs1317516	chr10:5672720	A/G	cg17085576	chr10:5658249	NA	0.51	5.16	0.39	8.03e-7	Breast cancer;
UCEC	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-6.37	-0.47	2.3e-9	Morning vs. evening chronotype;
UCEC	cis	rs7072216	0.687	rs10883085	chr10:100155613	A/T	cg19567339	chr10:100142640	NA	0.41	4.7	0.36	5.99e-6	Metabolite levels;
UCEC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18252515	chr7:66147081	NA	0.56	5.14	0.39	8.49e-7	Aortic root size;
UCEC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.33	0.57	5.11e-14	Menopause (age at onset);
UCEC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg19743168	chr1:23544995	NA	0.44	6.3	0.46	3.25e-9	Height;
UCEC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.75	8.35	0.57	4.73e-14	Chronic sinus infection;
UCEC	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg05660106	chr1:15850417	CASP9	1.04	11.84	0.7	3.92e-23	Systolic blood pressure;
UCEC	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.8	-0.37	3.85e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.64	6.21	0.46	5.2e-9	Breast cancer;
UCEC	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.22	-0.51	2.54e-11	Educational attainment (years of education);
UCEC	cis	rs13098911	0.540	rs34849862	chr3:46001367	C/A	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06836181	chr2:64995545	NA	0.56	6.74	0.49	3.42e-10	Warfarin maintenance dose;
UCEC	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg26207909	chr14:103986467	CKB	-0.45	-4.51	-0.35	1.34e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg19622623	chr12:86230825	RASSF9	-0.38	-4.68	-0.36	6.47e-6	Major depressive disorder;
UCEC	cis	rs8105895	0.935	rs62110988	chr19:22259956	C/T	cg24072202	chr19:22235272	ZNF257	-0.61	-5.31	-0.4	3.93e-7	Body mass index (change over time);
UCEC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.54	5.42	0.41	2.44e-7	Platelet count;
UCEC	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.68	-6.15	-0.45	6.86e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg08027265	chr7:2291960	NA	-0.46	-4.94	-0.38	2.13e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246967	0.673	rs8106215	chr19:22879446	G/A	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.67	6.98	0.5	9.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	7.66	0.53	2.32e-12	Total body bone mineral density;
UCEC	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.51	-0.57	1.87e-14	Total body bone mineral density;
UCEC	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.59	5.11	0.39	9.86e-7	Heart rate;
UCEC	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.5	-5.02	-0.38	1.48e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg22139774	chr2:100720529	AFF3	-0.37	-4.7	-0.36	5.88e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.87	-0.37	2.88e-6	Pulmonary function;
UCEC	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg19041857	chr6:27730383	NA	-0.58	-4.88	-0.37	2.76e-6	Breast cancer;
UCEC	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg12637676	chr8:11587161	GATA4	-0.36	-4.61	-0.36	8.65e-6	Retinal vascular caliber;
UCEC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg20203395	chr5:56204925	C5orf35	-0.54	-5.29	-0.4	4.27e-7	Coronary artery disease;
UCEC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.55	5.88	0.44	2.59e-8	Corneal astigmatism;
UCEC	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13939156	chr17:80058883	NA	-0.36	-4.58	-0.35	9.72e-6	Life satisfaction;
UCEC	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.2	-0.51	2.9e-11	Monocyte count;
UCEC	cis	rs1351696	1	rs1351696	chr11:48382471	A/G	cg20307385	chr11:47447363	PSMC3	0.65	4.68	0.36	6.58e-6	D-dimer levels;
UCEC	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.53	5.39	0.41	2.8e-7	Sudden cardiac arrest;
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	8.26	0.56	7.84e-14	Prudent dietary pattern;
UCEC	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.18	-0.45	5.9e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.76	8.25	0.56	8.04e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2376682	1.000	rs12658945	chr5:118001567	A/G	cg17593721	chr5:118788746	HSD17B4	0.48	4.77	0.37	4.4e-6	Diisocyanate-induced asthma;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.88	10.0	0.64	2.74e-18	Menarche (age at onset);
UCEC	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.49	5.6	0.42	1.01e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg26061582	chr7:22766209	IL6	0.63	5.65	0.42	8.22e-8	Lung cancer;
UCEC	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.57	6.49	0.47	1.22e-9	Crohn's disease;
UCEC	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg14121845	chr20:25566513	NINL	0.4	4.78	0.37	4.29e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.54	-0.42	1.36e-7	Superior crus of antihelix expression;
UCEC	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.71	-7.91	-0.55	5.58e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.52	6.37	0.46	2.34e-9	Total body bone mineral density;
UCEC	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg10932868	chr11:921992	NA	0.41	5.24	0.4	5.4e-7	Alzheimer's disease (late onset);
UCEC	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.55	-5.75	-0.43	5.02e-8	Bipolar disorder;
UCEC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.54	-5.11	-0.39	9.99e-7	Cognitive function;
UCEC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.7	-6.5	-0.47	1.18e-9	Aortic root size;
UCEC	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs12681287	0.752	rs10435563	chr8:87266060	C/T	cg27223183	chr8:87520930	FAM82B	-0.61	-5.08	-0.39	1.15e-6	Caudate activity during reward;
UCEC	cis	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg20560298	chr2:73613845	ALMS1	0.55	5.48	0.41	1.84e-7	Schizophrenia;
UCEC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	12.77	0.73	1.31e-25	Chronic sinus infection;
UCEC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg07153921	chr17:41440717	NA	-0.61	-7.22	-0.51	2.53e-11	Menopause (age at onset);
UCEC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg09654669	chr8:57350985	NA	-0.54	-6.04	-0.45	1.19e-8	Obesity-related traits;
UCEC	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.68	-0.69	1.01e-22	Primary sclerosing cholangitis;
UCEC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg20607287	chr7:12443886	VWDE	-0.62	-4.6	-0.35	9.18e-6	Coronary artery disease;
UCEC	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	6.72	0.48	3.81e-10	Ileal carcinoids;
UCEC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.5	-5.48	-0.41	1.8e-7	Aortic root size;
UCEC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.77	-0.43	4.45e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3015497	0.789	rs11621971	chr14:51124527	C/T	cg04730355	chr14:51134070	SAV1	0.49	5.02	0.38	1.5e-6	Mean platelet volume;
UCEC	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.46	5.01	0.38	1.53e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.96	0.5	1.03e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.55	-5.07	-0.39	1.18e-6	Multiple sclerosis;
UCEC	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg18681998	chr4:17616180	MED28	0.56	6.31	0.46	3.09e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	0.673	rs12984634	chr19:22833744	C/T	cg23217946	chr19:22817039	ZNF492	0.41	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.59	8.69	0.58	6.69e-15	Prudent dietary pattern;
UCEC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.44	-4.55	-0.35	1.11e-5	Monocyte count;
UCEC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.56	0.35	1.08e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.55	-6.15	-0.45	6.92e-9	Pulmonary function;
UCEC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg13575925	chr12:9217583	LOC144571	-0.4	-4.95	-0.38	2.05e-6	Sjögren's syndrome;
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	6.22	0.46	4.78e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.54	-5.55	-0.42	1.32e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.37	-0.4	3.05e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs13437751	0.649	rs28646219	chr7:63351777	G/C	cg00787055	chr7:63562162	NA	0.44	4.61	0.36	8.82e-6	QT interval (drug interaction);
UCEC	cis	rs9302690	1.000	rs41351945	chr16:57446809	C/T	cg27017172	chr16:57497170	POLR2C	1.3	6.3	0.46	3.27e-9	Blood protein levels;
UCEC	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.83	-8.29	-0.56	6.41e-14	Resting heart rate;
UCEC	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.61	-0.53	2.96e-12	Neuroticism;
UCEC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg14008862	chr17:28927542	LRRC37B2	0.62	5.61	0.42	9.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.62	6.05	0.45	1.17e-8	Vitamin D levels;
UCEC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.42	-4.91	-0.38	2.42e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.68	6.74	0.49	3.4e-10	Menopause (age at onset);
UCEC	cis	rs57994353	0.508	rs7874956	chr9:139336813	T/G	cg14019695	chr9:139328340	INPP5E	0.48	5.9	0.44	2.43e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
UCEC	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg17652424	chr22:38574118	PLA2G6	-0.39	-4.72	-0.36	5.39e-6	Cutaneous nevi;
UCEC	cis	rs4499344	0.556	rs259227	chr19:33134791	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	5.71	0.43	5.95e-8	Mean platelet volume;
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.74	-0.36	5.02e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.51	5.98	0.44	1.6e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs847649	0.804	rs4729866	chr7:102685561	A/C	cg18108683	chr7:102477205	FBXL13	0.55	6.77	0.49	2.88e-10	Morning vs. evening chronotype;
UCEC	cis	rs7246967	0.673	rs4446014	chr19:22897758	T/G	cg08271804	chr19:22816896	ZNF492	0.7	4.68	0.36	6.56e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12481680	0.834	rs6099810	chr20:56443634	G/T	cg00626515	chr20:56287004	PMEPA1	0.42	4.8	0.37	3.91e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs7766436	0.885	rs7773749	chr6:22587190	C/G	cg13666174	chr6:22585274	NA	-0.5	-5.27	-0.4	4.77e-7	Coronary artery disease;
UCEC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.45	4.69	0.36	6.13e-6	Sjögren's syndrome;
UCEC	cis	rs2729354	0.817	rs2649667	chr11:57270509	A/C	cg24343310	chr11:57249947	NA	0.42	4.75	0.36	4.8e-6	Blood protein levels;
UCEC	cis	rs17106184	1.000	rs3789588	chr1:51266523	G/A	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.56	6.58	0.48	7.65e-10	Lewy body disease;
UCEC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.88	-9.81	-0.63	8.53e-18	Cognitive function;
UCEC	cis	rs13095912	0.927	rs4686683	chr3:185307363	A/C	cg11274856	chr3:185301563	NA	0.47	6.05	0.45	1.12e-8	Systolic blood pressure;
UCEC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.51	0.41	1.6e-7	Breast cancer;
UCEC	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.39	-5.28	-0.4	4.59e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg21204522	chr6:27730016	NA	-0.57	-4.73	-0.36	5.32e-6	Depression;
UCEC	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.54	5.64	0.42	8.35e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.5	-5.22	-0.4	6.06e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg13683864	chr3:40499215	RPL14	-0.53	-5.37	-0.4	3.08e-7	Renal cell carcinoma;
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.48	-4.86	-0.37	3e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.59	-6.2	-0.46	5.44e-9	Testicular germ cell tumor;
UCEC	cis	rs72906064	1.000	rs1526903	chr2:156910857	A/G	cg14040602	chr2:157557294	NA	0.65	4.72	0.36	5.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.65	-6.35	-0.46	2.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7968440	0.736	rs7978559	chr12:51188638	G/A	cg00552387	chr12:51477546	CSRNP2	0.55	4.63	0.36	7.89e-6	Fibrinogen;
UCEC	cis	rs4148689	1.000	rs4148692	chr7:117150129	C/T	cg21212505	chr7:117228958	CFTR	-0.41	-4.62	-0.36	8.24e-6	Gout;
UCEC	trans	rs10242455	0.702	rs55927283	chr7:99057191	G/C	cg09045935	chr12:6379348	NA	0.97	6.85	0.49	1.84e-10	Blood metabolite levels;
UCEC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg08755490	chr11:65554678	OVOL1	0.5	5.31	0.4	3.89e-7	Acne (severe);
UCEC	cis	rs713477	0.967	rs6573028	chr14:55913397	C/T	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.23e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-6.32	-0.46	2.94e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-5.06	-0.38	1.26e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7766436	0.885	rs13211957	chr6:22573415	C/T	cg13666174	chr6:22585274	NA	-0.61	-6.25	-0.46	4.21e-9	Coronary artery disease;
UCEC	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.33	0.4	3.64e-7	Cognitive test performance;
UCEC	cis	rs11153730	0.503	rs283040	chr6:118631934	A/G	cg21191810	chr6:118973309	C6orf204	0.4	5.11	0.39	9.71e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.66	6.73	0.49	3.54e-10	Eosinophil percentage of white cells;
UCEC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.82	0.75	2.28e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg06784218	chr1:46089804	CCDC17	0.54	6.32	0.46	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.42	0.41	2.39e-7	IgG glycosylation;
UCEC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.38	0.41	2.9e-7	Alzheimer's disease;
UCEC	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-4.75	-0.37	4.71e-6	Colorectal cancer;
UCEC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	4.98e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.5	5.27	0.4	4.74e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg12463550	chr7:65579703	CRCP	-0.5	-5.07	-0.39	1.17e-6	Aortic root size;
UCEC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	10.01	0.64	2.66e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs4534959	0.546	rs9963324	chr18:62062517	G/A	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.57	5.07	0.39	1.2e-6	Mean corpuscular volume;
UCEC	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.62	7.18	0.51	3.19e-11	Pulmonary function decline;
UCEC	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.42	-5.02	-0.38	1.49e-6	Refractive error;
UCEC	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-1.0	-7.4	-0.52	9.69e-12	Body mass index;
UCEC	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.63	-5.14	-0.39	8.67e-7	LDL cholesterol levels;
UCEC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.46	-5.53	-0.41	1.45e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.58	7.41	0.52	9.38e-12	Warfarin maintenance dose;
UCEC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg00083072	chr11:65415190	SIPA1	0.52	5.66	0.42	7.79e-8	Systemic lupus erythematosus;
UCEC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg06660395	chr4:1396306	NA	0.39	4.87	0.37	2.83e-6	Obesity-related traits;
UCEC	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.61	5.27	0.4	4.67e-7	Heart rate;
UCEC	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	7.57	0.53	3.79e-12	Coronary artery disease;
UCEC	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.47	5.58	0.42	1.13e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.58	6.61	0.48	6.51e-10	Mean corpuscular volume;
UCEC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	6.19	0.45	5.61e-9	Platelet count;
UCEC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.65	0.48	5.39e-10	Cognitive test performance;
UCEC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.54	5.0	0.38	1.59e-6	Birth weight;
UCEC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.2	0.39	6.55e-7	Breast cancer;
UCEC	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-4.53	-0.35	1.23e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	0.94	14.47	0.77	4.73e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.8	9.41	0.61	9.31e-17	Mortality in heart failure;
UCEC	cis	rs4747241	0.739	rs7081608	chr10:74073037	A/G	cg05988358	chr10:74082489	NA	0.37	4.59	0.35	9.29e-6	Heschl's gyrus morphology;
UCEC	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.14	-0.39	8.66e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs10140922	0.567	rs2415263	chr14:35630319	A/C	cg03549618	chr14:35838977	NA	0.33	4.63	0.36	7.93e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg24562669	chr7:97807699	LMTK2	-0.46	-5.36	-0.4	3.1e-7	Breast cancer;
UCEC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.6	-5.74	-0.43	5.31e-8	Schizophrenia;
UCEC	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.64	6.06	0.45	1.08e-8	Prostate cancer;
UCEC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.5	-5.74	-0.43	5.16e-8	Aortic root size;
UCEC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.95	0.55	4.44e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg17105886	chr17:28927953	LRRC37B2	0.64	4.7	0.36	5.98e-6	Body mass index;
UCEC	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.51	-0.35	1.31e-5	Menopause (age at onset);
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg12262378	chr17:6899522	ALOX12	0.4	4.69	0.36	6.1e-6	Tonsillectomy;
UCEC	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg14851346	chr12:38532713	NA	-0.46	-4.51	-0.35	1.32e-5	Bladder cancer;
UCEC	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.01	6.25	0.46	4.25e-9	Skin colour saturation;
UCEC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18932078	chr1:2524107	MMEL1	0.4	6.26	0.46	4.03e-9	Ulcerative colitis;
UCEC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.87	8.82	0.59	2.98e-15	Smoking behavior;
UCEC	cis	rs7307889	0.546	rs10160866	chr12:6014627	G/T	cg26215727	chr12:6485537	SCNN1A	0.49	4.5	0.35	1.35e-5	Obesity-related traits;
UCEC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg22974920	chr21:40686053	BRWD1	0.57	4.71	0.36	5.57e-6	Cognitive function;
UCEC	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.09	-0.39	1.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.19	7.69	0.54	1.98e-12	Diabetic kidney disease;
UCEC	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.47	-4.86	-0.37	3.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.63	-0.42	8.86e-8	Life satisfaction;
UCEC	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg06521331	chr12:34319734	NA	-0.52	-4.61	-0.36	8.56e-6	Morning vs. evening chronotype;
UCEC	cis	rs11867410	1.000	rs73338606	chr17:63965613	G/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.87	-0.37	2.81e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.47	4.96	0.38	1.96e-6	Pulse pressure;
UCEC	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15541040	chr2:3486749	NA	-0.71	-6.85	-0.49	1.86e-10	Neurofibrillary tangles;
UCEC	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg19338460	chr6:170058176	WDR27	-0.55	-4.53	-0.35	1.22e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.28e-9	Platelet count;
UCEC	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	7.91	0.55	5.76e-13	Tonsillectomy;
UCEC	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.35	1.11e-5	Bladder cancer;
UCEC	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.49	5.04	0.38	1.35e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1372520	0.506	rs356198	chr4:90682504	C/T	cg15133208	chr4:90757351	SNCA	0.55	6.23	0.46	4.68e-9	Neuroticism;
UCEC	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.87	0.44	2.77e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	8.93	0.59	1.6e-15	Coffee consumption (cups per day);
UCEC	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.3	-0.4	4.1e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	0.8	7.9	0.55	6.1e-13	Testicular germ cell tumor;
UCEC	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.64	-0.42	8.58e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-4.57	-0.35	1.02e-5	Parkinson's disease;
UCEC	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.36	-0.46	2.37e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.02	-8.13	-0.56	1.62e-13	Exhaled nitric oxide output;
UCEC	cis	rs2957692	0.528	rs11042731	chr11:10340423	C/T	cg08691479	chr11:9595265	WEE1	-0.62	-4.55	-0.35	1.12e-5	Circulating vasoactive peptide levels;
UCEC	cis	rs11235843	0.571	rs10898929	chr11:73365695	C/T	cg23931323	chr11:73372278	PLEKHB1	0.62	5.03	0.38	1.39e-6	Hand grip strength;
UCEC	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.82	11.16	0.68	2.46e-21	Headache;
UCEC	trans	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg02022102	chr7:27168609	HOXA4	0.6	6.8	0.49	2.5e-10	Protein biomarker;
UCEC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.72	6.16	0.45	6.53e-9	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	0.82	5.49	0.41	1.71e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.78	5.85	0.43	3.02e-8	Body mass index;
UCEC	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.09	0.45	9.63e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.41	-4.58	-0.35	9.93e-6	Pelvic organ prolapse;
UCEC	cis	rs7246967	0.673	rs34682021	chr19:22826728	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	7.41	0.52	8.92e-12	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.61	6.98	0.5	9.2e-11	Skin colour saturation;
UCEC	cis	rs28530618	0.603	rs11697988	chr20:31248176	C/G	cg13636640	chr20:31349939	DNMT3B	-0.56	-5.16	-0.39	7.99e-7	Birth weight;
UCEC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.6	-5.8	-0.43	3.9e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.77	8.08	0.55	2.19e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.95	7.43	0.52	8.17e-12	Vitiligo;
UCEC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.87	9.18	0.6	3.74e-16	Longevity;Endometriosis;
UCEC	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.07	-0.39	1.15e-6	Life satisfaction;
UCEC	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.51	-5.1	-0.39	1.03e-6	Menarche (age at onset);
UCEC	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg13695892	chr22:41940480	POLR3H	0.52	4.79	0.37	3.97e-6	Vitiligo;
UCEC	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg22166914	chr1:53195759	ZYG11B	0.7	7.43	0.52	8.07e-12	Monocyte count;
UCEC	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.84	9.32	0.61	1.59e-16	Breast cancer;
UCEC	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.79	8.29	0.56	6.55e-14	Cognitive function;
UCEC	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.54	5.79	0.43	4.02e-8	Response to temozolomide;
UCEC	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg09910674	chr16:89028015	CBFA2T3	0.6	4.61	0.36	8.71e-6	Skin colour saturation;
UCEC	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg14530993	chr4:882597	GAK	0.68	4.54	0.35	1.16e-5	Parkinson's disease;
UCEC	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.5	4.77	0.37	4.42e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.02	-0.38	1.46e-6	Bladder cancer;
UCEC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.52	-4.77	-0.37	4.46e-6	Refractive error;
UCEC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.49	-6.0	-0.44	1.47e-8	Total body bone mineral density;
UCEC	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.52	-5.09	-0.39	1.06e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6728642	1.000	rs57035274	chr2:97608124	C/A	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.1	-0.51	5.02e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	0.93	5.5	0.41	1.64e-7	Gut microbiota (bacterial taxa);
UCEC	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.05	8.79	0.59	3.7e-15	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-5.17	-0.39	7.51e-7	HDL cholesterol;
UCEC	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.53	-5.68	-0.42	7.12e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	7.87	0.54	6.99e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.59	-6.07	-0.45	1.03e-8	Systemic lupus erythematosus;
UCEC	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.63	-6.9	-0.49	1.43e-10	Brugada syndrome;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg05874882	chr4:1763078	NA	0.71	5.12	0.39	9.5e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.52	-5.94	-0.44	1.98e-8	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.8	-9.34	-0.61	1.4e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.57	-5.79	-0.43	4.01e-8	Systemic lupus erythematosus;
UCEC	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.76	7.77	0.54	1.22e-12	Tonsillectomy;
UCEC	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.6	-5.69	-0.42	6.73e-8	Red cell distribution width;
UCEC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	0.76	8.52	0.57	1.74e-14	Cognitive test performance;
UCEC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.55	6.93	0.5	1.24e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg05501817	chr11:14380813	RRAS2	-0.5	-4.68	-0.36	6.39e-6	Sense of smell;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.66	-0.36	7.15e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.47	4.54	0.35	1.15e-5	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.94	10.99	0.67	7.17e-21	Ulcerative colitis;
UCEC	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.14	-0.45	7.48e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.7	7.14	0.51	4e-11	Caffeine consumption;
UCEC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-4.87	-0.37	2.87e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-5.02	-0.38	1.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.68	9.25	0.61	2.47e-16	Systolic blood pressure;
UCEC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-5.02	-0.38	1.49e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17489649	1.000	rs3797681	chr5:109159824	A/G	cg17436293	chr5:109223084	NA	-0.36	-4.69	-0.36	6.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.54	-5.5	-0.41	1.61e-7	Height;
UCEC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.84	8.89	0.59	1.97e-15	Breast cancer;
UCEC	cis	rs4499344	0.730	rs10410888	chr19:33103328	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.41e-9	Mean platelet volume;
UCEC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg05855489	chr10:104503620	C10orf26	-0.61	-6.44	-0.47	1.56e-9	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04025307	chr7:1156635	C7orf50	0.64	6.98	0.5	9.26e-11	Longevity;Endometriosis;
UCEC	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.45	4.91	0.38	2.37e-6	HDL cholesterol;
UCEC	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.29	4.52	0.35	1.26e-5	Diastolic blood pressure;
UCEC	cis	rs1635	0.655	rs9368532	chr6:27782010	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.79	-5.49	-0.41	1.7e-7	Schizophrenia;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg11871910	chr12:69753446	YEATS4	0.71	7.5	0.53	5.5e-12	Blood protein levels;
UCEC	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg26781129	chr3:44753946	ZNF502	-0.43	-4.68	-0.36	6.55e-6	Depressive symptoms;
UCEC	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.44	-4.63	-0.36	8.07e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.02	-8.13	-0.56	1.62e-13	Exhaled nitric oxide output;
UCEC	cis	rs12681287	0.752	rs13255058	chr8:87287445	G/A	cg27223183	chr8:87520930	FAM82B	-0.62	-5.32	-0.4	3.75e-7	Caudate activity during reward;
UCEC	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg04879645	chr16:947229	LMF1	0.37	4.57	0.35	1.03e-5	Coronary artery disease;
UCEC	cis	rs11235843	0.853	rs66556722	chr11:73403039	A/G	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.62	6.51	0.47	1.09e-9	Longevity;Endometriosis;
UCEC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.14	-15.38	-0.79	2.04e-32	Cognitive function;
UCEC	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	0.98	8.45	0.57	2.68e-14	Red blood cell traits;
UCEC	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.13	-7.01	-0.5	8.19e-11	Diabetic kidney disease;
UCEC	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.11	14.38	0.76	7.8e-30	Schizophrenia;
UCEC	cis	rs6437061	0.717	rs3100611	chr2:232850486	C/A	cg02061626	chr2:233274167	ALPPL2	-0.5	-5.37	-0.41	2.99e-7	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.92	9.0	0.6	1.04e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.88	-9.71	-0.62	1.61e-17	Cognitive function;
UCEC	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.53	-4.88	-0.37	2.72e-6	Smoking behavior;
UCEC	cis	rs16944613	0.541	rs6496688	chr15:91090381	G/A	cg08919649	chr15:91565780	VPS33B	0.65	4.56	0.35	1.08e-5	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.15	-7.31	-0.52	1.56e-11	Breast cancer;
UCEC	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.56	5.94	0.44	2e-8	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.43	5.33	0.4	3.6e-7	Height;
UCEC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.45	4.94	0.38	2.07e-6	Prostate cancer;
UCEC	cis	rs1519814	0.956	rs4369033	chr8:121138921	C/A	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg14438399	chr17:27053147	TLCD1	-0.55	-4.67	-0.36	6.72e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg13683864	chr3:40499215	RPL14	-0.95	-10.97	-0.67	7.89e-21	Renal cell carcinoma;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.65	6.71	0.48	3.95e-10	Obesity-related traits;
UCEC	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.5	-5.32	-0.4	3.74e-7	Obesity-related traits;
UCEC	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg04154034	chr17:28927549	LRRC37B2	0.91	5.19	0.39	7.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.77	-7.98	-0.55	3.9e-13	Cognitive function;
UCEC	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.62	6.44	0.47	1.64e-9	Blood protein levels;
UCEC	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg13401533	chr1:37979913	MEAF6	0.55	4.72	0.36	5.49e-6	Axial length;
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs9463078	0.764	rs10948187	chr6:44921320	A/G	cg25276700	chr6:44698697	NA	0.45	5.28	0.4	4.63e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.05	5.8	0.43	3.93e-8	Skin colour saturation;
UCEC	cis	rs7088591	0.867	rs4586101	chr10:59780084	G/C	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.49	-0.41	1.76e-7	Pubertal anthropometrics;
UCEC	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.56	5.55	0.42	1.3e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg07755735	chr2:20870362	GDF7	-0.48	-5.73	-0.43	5.5e-8	Abdominal aortic aneurysm;
UCEC	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.03	-0.45	1.28e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.94	0.44	2.02e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9470794	1.000	rs73421439	chr6:37938271	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg05962950	chr11:130786565	SNX19	0.46	4.55	0.35	1.1e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	7.9	0.55	5.84e-13	Smoking behavior;
UCEC	cis	rs79815064	0.850	rs75994669	chr3:46300863	T/G	cg19145607	chr3:45983792	CXCR6;FYCO1	0.71	4.6	0.35	9.22e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.22	0.46	4.96e-9	Rheumatoid arthritis;
UCEC	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.7	-0.43	6.34e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.08	-6.74	-0.49	3.41e-10	Diabetic kidney disease;
UCEC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.19	-0.39	6.74e-7	Sudden cardiac arrest;
UCEC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-12.97	-0.73	3.93e-26	Height;
UCEC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg12559939	chr2:27858050	GPN1	0.45	4.71	0.36	5.73e-6	Oral cavity cancer;
UCEC	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	4.6	0.35	9.01e-6	Lung cancer in ever smokers;
UCEC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.85	0.37	3.16e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.37	-0.61	1.2e-16	Blood metabolite levels;
UCEC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.73	8.23	0.56	9.04e-14	Longevity;Endometriosis;
UCEC	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg01072550	chr1:21505969	NA	-0.56	-5.28	-0.4	4.47e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-6.82	-0.49	2.24e-10	Prostate cancer;
UCEC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.48	-4.59	-0.35	9.29e-6	Red blood cell count;
UCEC	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.63	-6.09	-0.45	9.26e-9	Metabolite levels;
UCEC	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg06917450	chr1:38156652	C1orf109	-0.54	-5.09	-0.39	1.07e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs73206853	0.841	rs55754138	chr12:110869335	G/T	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13265914	chr8:21999630	REEP4	0.57	7.13	0.51	4.21e-11	Warfarin maintenance dose;
UCEC	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-4.73	-0.36	5.12e-6	Aortic root size;
UCEC	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg18681998	chr4:17616180	MED28	0.7	8.04	0.55	2.78e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg13319975	chr6:146136371	FBXO30	0.44	4.73	0.36	5.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.69	-6.76	-0.49	2.97e-10	Blood metabolite levels;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.22	-0.46	5e-9	Pubertal anthropometrics;
UCEC	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.52	4.76	0.37	4.51e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs243088	1.000	rs243021	chr2:60584819	G/A	cg16665442	chr2:60585866	NA	-0.39	-4.7	-0.36	5.98e-6	Type 2 diabetes;
UCEC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08822215	chr16:89438651	ANKRD11	0.5	5.17	0.39	7.38e-7	Multiple myeloma (IgH translocation);
UCEC	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	8.23	0.56	9.22e-14	Colorectal cancer;
UCEC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.5	-5.08	-0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-6.02	-0.44	1.33e-8	Electroencephalogram traits;
UCEC	cis	rs12982903	0.915	rs7259761	chr19:5952713	A/G	cg27649253	chr19:5245891	PTPRS	0.62	4.59	0.35	9.54e-6	Heart rate variability traits (SDNN);
UCEC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg07527032	chr15:84868466	LOC388152	0.51	4.72	0.36	5.36e-6	Schizophrenia;
UCEC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.48	-4.99	-0.38	1.71e-6	Lung cancer;
UCEC	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	5.76	0.43	4.84e-8	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.57	-6.12	-0.45	8.29e-9	Monocyte count;
UCEC	cis	rs6919346	0.652	rs4709441	chr6:160936231	A/T	cg03221100	chr6:160147693	WTAP	0.52	4.72	0.36	5.52e-6	Lp (a) levels;
UCEC	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg18827107	chr12:86230957	RASSF9	-0.4	-4.52	-0.35	1.24e-5	Major depressive disorder;
UCEC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.46	-4.55	-0.35	1.13e-5	Parkinson's disease;
UCEC	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg06784218	chr1:46089804	CCDC17	0.54	6.73	0.49	3.58e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.58	6.04	0.45	1.22e-8	Radiation response;
UCEC	cis	rs713477	0.967	rs61976571	chr14:55908774	T/C	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg05132306	chr1:1846340	CALML6	-0.37	-4.67	-0.36	6.65e-6	Body mass index;
UCEC	cis	rs828999	1.000	rs828999	chr1:108744934	A/G	cg11967332	chr1:108735228	SLC25A24	-0.46	-5.39	-0.41	2.78e-7	Monocyte percentage of white cells;
UCEC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.3	0.61	1.84e-16	Menopause (age at onset);
UCEC	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg06784218	chr1:46089804	CCDC17	0.52	6.32	0.46	2.91e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.34	0.46	2.72e-9	Blood protein levels;
UCEC	cis	rs731174	0.802	rs504518	chr1:38182333	G/T	cg06917450	chr1:38156652	C1orf109	-0.57	-5.29	-0.4	4.38e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.38	-0.47	2.19e-9	Cardiac Troponin-T levels;
UCEC	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.46	5.22	0.4	6.08e-7	Prostate cancer;
UCEC	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.87	-7.18	-0.51	3.26e-11	Coronary artery calcification;
UCEC	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.19	-0.45	5.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6437061	0.774	rs3103258	chr2:233000699	C/T	cg20569070	chr2:232597279	PDE6D	0.4	4.62	0.36	8.44e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg05695927	chr15:45694626	SPATA5L1	0.52	5.2	0.39	6.63e-7	Homoarginine levels;
UCEC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.7	0.36	5.99e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.57	7.21	0.51	2.68e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg04155231	chr12:9217510	LOC144571	0.41	5.09	0.39	1.09e-6	Sjögren's syndrome;
UCEC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg04310649	chr10:35416472	CREM	-0.49	-4.76	-0.37	4.61e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.66	-4.67	-0.36	6.67e-6	Red blood cell traits;
UCEC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.8	7.76	0.54	1.33e-12	Cognitive function;
UCEC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.51	-4.94	-0.38	2.06e-6	Coronary artery disease;
UCEC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg19318889	chr4:1322082	MAEA	0.4	4.86	0.37	2.92e-6	Obesity-related traits;
UCEC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	0.96	9.89	0.63	5.35e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg22166914	chr1:53195759	ZYG11B	0.78	8.19	0.56	1.14e-13	Monocyte count;
UCEC	cis	rs1832871	0.505	rs11757895	chr6:158812456	G/T	cg07215822	chr6:158701037	NA	-0.61	-4.94	-0.38	2.13e-6	Height;
UCEC	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.61	7.05	0.5	6.4e-11	Dialysis-related mortality;
UCEC	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.56	5.35	0.4	3.27e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.18	0.39	7.26e-7	Rheumatoid arthritis;
UCEC	cis	rs8032158	1.000	rs8024944	chr15:56125135	C/A	cg10433327	chr15:56209506	NEDD4	-0.3	-4.98	-0.38	1.73e-6	Keloid;
UCEC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06223018	chr3:49557076	DAG1	0.34	4.86	0.37	2.92e-6	Parkinson's disease;
UCEC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.55	5.48	0.41	1.79e-7	Schizophrenia;
UCEC	cis	rs9823506	1	rs9823506	chr3:100476713	C/T	cg10343442	chr3:100428642	TFG	1.27	5.58	0.42	1.11e-7	Asthma (childhood onset);
UCEC	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	7.26	0.51	2.09e-11	Colorectal cancer;
UCEC	cis	rs6684428	0.706	rs61774839	chr1:56336609	G/A	cg11651538	chr1:56320950	NA	-0.77	-6.81	-0.49	2.33e-10	Airflow obstruction;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg00280220	chr17:61926910	NA	0.43	4.7	0.36	5.91e-6	Prudent dietary pattern;
UCEC	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.03	15.16	0.78	7.3e-32	Myeloid white cell count;
UCEC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.03	10.95	0.67	8.74e-21	Vitiligo;
UCEC	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.73	0.43	5.45e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.67	-0.69	1.12e-22	Primary sclerosing cholangitis;
UCEC	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-1.15	-7.25	-0.51	2.19e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-7.11	-0.51	4.63e-11	Morning vs. evening chronotype;
UCEC	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.75	-0.63	1.27e-17	Monocyte count;
UCEC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg00339695	chr16:24857497	SLC5A11	0.55	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.54	-6.79	-0.49	2.54e-10	Coronary artery disease;
UCEC	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg01262667	chr19:19385393	TM6SF2	0.48	6.61	0.48	6.66e-10	Tonsillectomy;
UCEC	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.65	-6.08	-0.45	9.85e-9	Vitiligo;
UCEC	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.49	-4.92	-0.38	2.25e-6	Longevity;Endometriosis;
UCEC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg06462663	chr19:18546047	ISYNA1	0.48	6.08	0.45	9.88e-9	Breast cancer;
UCEC	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.64	4.64	0.36	7.55e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-6.98	-0.5	9.26e-11	Breast cancer;
UCEC	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.62	4.85	0.37	3.12e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg19715936	chr7:50634035	DDC	0.45	5.56	0.42	1.21e-7	Malaria;
UCEC	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-6.93	-0.5	1.24e-10	Vitiligo;
UCEC	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.46	-4.63	-0.36	8.08e-6	Schizophrenia;
UCEC	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg00500100	chr5:140098250	VTRNA1-2	0.34	4.56	0.35	1.07e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg25922239	chr6:33757077	LEMD2	0.63	5.17	0.39	7.36e-7	Crohn's disease;
UCEC	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.85	-0.37	3.09e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.42	-4.77	-0.37	4.36e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg23795048	chr12:9217529	LOC144571	0.44	5.13	0.39	8.84e-7	Sjögren's syndrome;
UCEC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-7.57	-0.53	3.72e-12	Joint mobility (Beighton score);
UCEC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg17986701	chr20:44574422	PCIF1	0.47	4.79	0.37	4.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.52	5.43	0.41	2.28e-7	Schizophrenia;
UCEC	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-6.49	-0.47	1.23e-9	IgG glycosylation;
UCEC	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg00105475	chr2:10696890	NA	-0.46	-5.4	-0.41	2.62e-7	Prostate cancer;
UCEC	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.65	5.68	0.42	6.85e-8	Bipolar disorder;
UCEC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-9.07	-0.6	7.22e-16	Gut microbiome composition (summer);
UCEC	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	9.94	0.63	3.98e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	4.69	0.36	6.32e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	5.43	0.41	2.32e-7	HDL cholesterol;
UCEC	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.6	5.49	0.41	1.69e-7	Uric acid levels;
UCEC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg24687543	chr11:63912206	MACROD1	0.57	4.8	0.37	3.81e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg22166914	chr1:53195759	ZYG11B	-0.86	-9.7	-0.62	1.72e-17	Monocyte count;
UCEC	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	0.94	10.19	0.64	9.08e-19	Primary sclerosing cholangitis;
UCEC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.76	8.55	0.58	1.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs6722750	0.783	rs11125991	chr2:64387765	A/G	cg22352474	chr2:64371530	PELI1	0.5	4.63	0.36	8.13e-6	Neuroticism;
UCEC	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg16989719	chr2:238392110	NA	-0.42	-5.83	-0.43	3.44e-8	Prostate cancer;
UCEC	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05472934	chr7:22766657	IL6	0.8	7.8	0.54	1.05e-12	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-5.13	-0.39	8.89e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg17833184	chr10:135191291	PAOX	0.58	4.88	0.37	2.72e-6	Lifespan;
UCEC	cis	rs56235845	0.796	rs13153019	chr5:176782218	T/C	cg17509989	chr5:176798049	RGS14	0.56	4.9	0.37	2.55e-6	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg26721908	chr21:47610096	LSS	0.42	5.33	0.4	3.58e-7	Testicular germ cell tumor;
UCEC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg21132104	chr15:45694354	SPATA5L1	-0.64	-5.95	-0.44	1.91e-8	Homoarginine levels;
UCEC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	0.92	9.74	0.63	1.31e-17	Breast cancer;
UCEC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.51	-5.53	-0.41	1.46e-7	Diastolic blood pressure;
UCEC	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.69	7.8	0.54	1.08e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7870753	0.786	rs10739886	chr9:99201983	A/G	cg25260653	chr9:99212216	HABP4	0.58	5.7	0.43	6.48e-8	Height;
UCEC	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg14121845	chr20:25566513	NINL	0.4	4.74	0.36	5e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.55	4.82	0.37	3.56e-6	Menarche (age at onset);
UCEC	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.49	-5.06	-0.39	1.22e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.51	5.53	0.42	1.41e-7	Platelet count;
UCEC	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.76	6.76	0.49	3.09e-10	Caudate activity during reward;
UCEC	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.25	-0.56	8.03e-14	Blood metabolite levels;
UCEC	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.88	5.88	0.44	2.71e-8	Arsenic metabolism;
UCEC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.64	-7.03	-0.5	7.23e-11	Coronary artery disease;
UCEC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	8.62	0.58	9.72e-15	Prudent dietary pattern;
UCEC	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-5.89	-0.44	2.58e-8	Menarche (age at onset);
UCEC	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.61	-0.42	9.89e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6670533	0.571	rs61358817	chr1:24864789	G/A	cg07475527	chr1:24864545	NA	-0.74	-4.98	-0.38	1.8e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.62	5.9	0.44	2.43e-8	Aortic root size;
UCEC	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg12379764	chr21:47803548	PCNT	0.6	4.85	0.37	3.08e-6	Lymphocyte counts;
UCEC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.64	-5.54	-0.42	1.35e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg24910161	chr17:38119198	GSDMA	-0.33	-4.61	-0.36	8.63e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs787274	1.000	rs787297	chr9:115542133	G/T	cg13803584	chr9:115635662	SNX30	-0.72	-5.95	-0.44	1.89e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.62	-7.11	-0.51	4.8e-11	Menarche (age at onset);
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.74	8.37	0.57	4.05e-14	Menarche (age at onset);
UCEC	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18252515	chr7:66147081	NA	-0.5	-4.61	-0.36	8.79e-6	Aortic root size;
UCEC	cis	rs7870753	0.838	rs7849634	chr9:99256215	T/C	cg25260653	chr9:99212216	HABP4	0.52	5.11	0.39	1e-6	Height;
UCEC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.99	8.48	0.57	2.2e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.53	-5.44	-0.41	2.22e-7	Testicular germ cell tumor;
UCEC	cis	rs1536827	0.686	rs6537610	chr10:135323318	G/T	cg24678803	chr10:135378570	SYCE1	-0.59	-4.5	-0.35	1.36e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs139371	0.713	rs139315	chr22:39499653	C/T	cg15548613	chr22:38610795	MAFF	0.44	4.62	0.36	8.3e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-6.71	-0.48	3.92e-10	Platelet distribution width;
UCEC	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.58	6.56	0.48	8.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.6	0.48	7.02e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	4.96	0.38	1.94e-6	Personality dimensions;
UCEC	cis	rs10254160	1.000	rs1014725	chr7:112050858	G/A	cg14158407	chr7:112758954	LOC401397	-1.02	-4.54	-0.35	1.15e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.57	-5.1	-0.39	1.03e-6	Neuroticism;
UCEC	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.55	-5.9	-0.44	2.43e-8	Red blood cell count;
UCEC	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg20368463	chr18:77673604	PQLC1	0.72	5.27	0.4	4.75e-7	Opioid sensitivity;
UCEC	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.53	5.37	0.41	3e-7	Prostate cancer;
UCEC	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.57	-0.48	7.98e-10	Adiposity;
UCEC	cis	rs732765	0.734	rs10130425	chr14:75185394	C/T	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.49	-4.97	-0.38	1.87e-6	Total body bone mineral density;
UCEC	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.73	0.36	5.12e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.44	4.56	0.35	1.05e-5	Alzheimer's disease (late onset);
UCEC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg14008862	chr17:28927542	LRRC37B2	0.62	4.78	0.37	4.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.37	-0.47	2.29e-9	Blood pressure (smoking interaction);
UCEC	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg16511985	chr3:153974050	SGEF	-0.67	-6.35	-0.46	2.49e-9	Coronary artery disease;
UCEC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.4	-4.83	-0.37	3.42e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg06562184	chr8:19319451	CSGALNACT1	0.45	4.64	0.36	7.56e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.01e-5	Type 2 diabetes;
UCEC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.56	5.83	0.43	3.4e-8	Motion sickness;
UCEC	cis	rs60311166	1.000	rs60823713	chr3:52573101	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.82	4.65	0.36	7.2e-6	CTACK levels;
UCEC	cis	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.68	7.07	0.5	5.8200000000000003e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9863	0.827	rs12823740	chr12:124458002	C/A	cg03785426	chr12:124419970	DNAH10	0.36	4.5	0.35	1.36e-5	White blood cell count;
UCEC	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.56	-5.33	-0.4	3.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	0.931	rs11673604	chr19:18540988	T/C	cg06462663	chr19:18546047	ISYNA1	0.53	6.75	0.49	3.16e-10	Breast cancer;
UCEC	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.69	5.81	0.43	3.81e-8	Initial pursuit acceleration;
UCEC	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.44	-6.28	-0.46	3.62e-9	Rheumatoid arthritis;
UCEC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.59	-5.93	-0.44	2.05e-8	Acne (severe);
UCEC	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg22654517	chr2:96458247	NA	0.44	4.67	0.36	6.6e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.63	-6.24	-0.46	4.34e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.43	4.52	0.35	1.24e-5	Response to temozolomide;
UCEC	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.72	7.13	0.51	4.25e-11	Calcium levels;
UCEC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg20965017	chr5:231967	SDHA	-0.66	-5.19	-0.39	6.79e-7	Asthma (childhood onset);
UCEC	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-0.85	-8.25	-0.56	8.41e-14	Coronary artery disease;
UCEC	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg19318889	chr4:1322082	MAEA	0.49	5.28	0.4	4.52e-7	Obesity-related traits;
UCEC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	0.99	13.43	0.74	2.4e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.55	5.79	0.43	4.03e-8	Blood metabolite levels;
UCEC	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg01072550	chr1:21505969	NA	-0.57	-5.61	-0.42	9.88e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg04315214	chr1:2043799	PRKCZ	0.48	5.61	0.42	9.59e-8	Height;
UCEC	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.56	5.65	0.42	8.03e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.21	-0.39	6.41e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs7088591	0.867	rs2159856	chr10:59780913	A/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs2172802	0.599	rs2088462	chr4:62512727	G/C	cg04118610	chr4:62707027	LPHN3	-0.42	-4.74	-0.36	5.09e-6	Partial epilepsies;
UCEC	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.74	9.17	0.6	3.89e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.84	-0.37	3.32e-6	Response to antipsychotic treatment;
UCEC	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-5.56	-0.42	1.22e-7	Schizophrenia;
UCEC	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.56	-6.31	-0.46	3.06e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.37	6.33	0.46	2.86e-9	Cancer;
UCEC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs150268548	1	rs150268548	chr19:19494483	G/A	cg03709012	chr19:19516395	GATAD2A	1.11	5.35	0.4	3.29e-7	LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;Response to fenofibrate (LDL cholesterol levels);
UCEC	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.43	4.66	0.36	7.07e-6	Longevity;
UCEC	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.57	6.66	0.48	5.01e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs1712517	0.771	rs11191654	chr10:105077124	C/A	cg05636881	chr10:105038444	INA	0.43	5.36	0.4	3.16e-7	Migraine;
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.71	0.43	5.91e-8	Prudent dietary pattern;
UCEC	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.13	0.45	7.66e-9	IgG glycosylation;
UCEC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.94	0.44	1.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg24687543	chr11:63912206	MACROD1	0.41	5.12	0.39	9.22e-7	Platelet count;
UCEC	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-7.14	-0.51	4.04e-11	Parkinson's disease;
UCEC	cis	rs10012307	0.786	rs59318752	chr4:137481820	C/G	cg12033966	chr4:138453416	PCDH18	-0.72	-5.04	-0.38	1.36e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.59	6.67	0.48	4.96e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.5	4.61	0.36	8.8e-6	Corneal astigmatism;
UCEC	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.64	5.36	0.4	3.09e-7	Obesity (extreme);
UCEC	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.71	6.23	0.46	4.76e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-0.97	-6.31	-0.46	3.06e-9	Diabetic kidney disease;
UCEC	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.94	9.29	0.61	1.9e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs3750082	0.754	rs35110377	chr7:32971770	C/G	cg05721444	chr7:32995514	FKBP9	-0.53	-6.43	-0.47	1.7e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs8105895	0.935	rs62110986	chr19:22256771	G/A	cg24072202	chr19:22235272	ZNF257	-0.61	-5.31	-0.4	3.93e-7	Body mass index (change over time);
UCEC	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.74	7.0	0.5	8.28e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.46	5.25	0.4	5.24e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.64	8.25	0.56	8.2e-14	Menarche (age at onset);
UCEC	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg00105475	chr2:10696890	NA	0.49	5.87	0.44	2.81e-8	Prostate cancer;
UCEC	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.7	7.98	0.55	3.9e-13	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	5.16	0.39	7.96e-7	Breast cancer;
UCEC	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.67	6.42	0.47	1.8e-9	Lymphocyte counts;
UCEC	cis	rs6429082	0.511	rs12748957	chr1:235426133	T/A	cg26050004	chr1:235667680	B3GALNT2	0.45	4.76	0.37	4.58e-6	Adiposity;
UCEC	cis	rs6460942	0.591	rs4721078	chr7:12334657	T/A	cg06484146	chr7:12443880	VWDE	-0.62	-4.9	-0.37	2.49e-6	Coronary artery disease;
UCEC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.38	-0.41	2.88e-7	Initial pursuit acceleration;
UCEC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.53	-6.54	-0.47	9.66e-10	Fibrinogen levels;
UCEC	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.79	6.92	0.5	1.33e-10	Breast cancer;
UCEC	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.67	-7.31	-0.52	1.6e-11	Coronary artery disease;
UCEC	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.5	-6.91	-0.5	1.38e-10	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.47	7.15	0.51	3.76e-11	Blood protein levels;
UCEC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.08	-0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.77	6.27	0.46	3.74e-9	Lymphocyte counts;
UCEC	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.41	-5.32	-0.4	3.8e-7	Prostate cancer;
UCEC	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	8.82	0.59	3.11e-15	Alzheimer's disease;
UCEC	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg26721908	chr21:47610096	LSS	0.36	4.55	0.35	1.13e-5	Testicular germ cell tumor;
UCEC	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg05855489	chr10:104503620	C10orf26	0.53	4.77	0.37	4.49e-6	Arsenic metabolism;
UCEC	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg17469321	chr7:55412551	NA	0.69	6.35	0.46	2.59e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2062225	0.696	rs11896172	chr2:111768652	T/C	cg23782758	chr2:111737646	ACOXL	-0.48	-4.61	-0.36	8.85e-6	Monocyte count;
UCEC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.88	12.1	0.71	7.96e-24	Metabolic syndrome;
UCEC	cis	rs7772486	0.558	rs2142980	chr6:146080679	G/A	cg23711669	chr6:146136114	FBXO30	-0.65	-5.85	-0.43	3.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.43	4.82	0.37	3.55e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.55	-5.69	-0.42	6.65e-8	White matter hyperintensity burden;
UCEC	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.48	5.43	0.41	2.31e-7	Tonsillectomy;
UCEC	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.79	-0.54	1.1e-12	Diastolic blood pressure;
UCEC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg13695892	chr22:41940480	POLR3H	-0.69	-5.31	-0.4	3.91e-7	Vitiligo;
UCEC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.59	-0.35	9.27e-6	Alzheimer's disease (late onset);
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.51	-5.21	-0.39	6.2e-7	Depression;
UCEC	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.12	12.36	0.71	1.65e-24	Blood protein levels;
UCEC	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	7.26	0.51	2.12e-11	Coronary artery disease;
UCEC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.2	6.68	0.48	4.6e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	6.85	0.49	1.93e-10	Platelet count;
UCEC	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.54	-0.47	9.57e-10	Response to antipsychotic treatment;
UCEC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.5	5.23	0.4	5.66e-7	Schizophrenia;
UCEC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.47	-4.85	-0.37	3.07e-6	Bipolar disorder;
UCEC	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.61	6.37	0.47	2.24e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.62	6.76	0.49	3.03e-10	Monocyte count;
UCEC	cis	rs12618769	0.625	rs4850880	chr2:99212417	C/T	cg10123293	chr2:99228465	UNC50	0.49	5.51	0.41	1.58e-7	Bipolar disorder;
UCEC	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	0.99	8.72	0.58	5.55e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.55	5.57	0.42	1.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs7246967	0.608	rs396440	chr19:23002966	A/G	cg24889512	chr19:22816950	ZNF492	0.49	4.72	0.36	5.53e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6032067	0.759	rs6032043	chr20:43817897	A/C	cg00873616	chr20:43920241	NA	0.4	4.52	0.35	1.27e-5	Blood protein levels;
UCEC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	0.93	9.93	0.63	4.27e-18	Breast cancer;
UCEC	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg23972785	chr8:11611189	GATA4	-0.36	-4.6	-0.35	8.98e-6	Neuroticism;
UCEC	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.66	-7.01	-0.5	7.91e-11	Stearic acid (18:0) levels;
UCEC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.72	8.71	0.58	5.69e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg19090574	chr1:205240910	TMCC2	-0.44	-4.62	-0.36	8.49e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.57	5.08	0.39	1.15e-6	Response to diuretic therapy;
UCEC	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.34	-0.46	2.7e-9	Pancreatic cancer;
UCEC	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.58	-6.39	-0.47	2.06e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.64	5.67	0.42	7.36e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6763768	0.600	rs11705809	chr3:53363940	T/C	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs7309	0.967	rs3754970	chr2:162091836	T/C	cg16506815	chr2:162101123	NA	0.53	5.5	0.41	1.67e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	2.01e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg04896959	chr15:78267971	NA	-0.59	-6.16	-0.45	6.54e-9	Coronary artery disease or large artery stroke;
UCEC	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg16023434	chr1:11395635	NA	-0.37	-4.86	-0.37	3e-6	Body mass index;
UCEC	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06925236	chr11:68039653	C11orf24	0.61	7.74	0.54	1.48e-12	Warfarin maintenance dose;
UCEC	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.22	0.56	9.83e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.53	6.52	0.47	1.05e-9	Total body bone mineral density;
UCEC	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	0.86	7.28	0.51	1.83e-11	Alzheimer's disease;
UCEC	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.97	7.28	0.51	1.91e-11	Exhaled nitric oxide levels;
UCEC	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.67	5.15	0.39	8.13e-7	Diabetic retinopathy;
UCEC	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.77	0.59	4.14e-15	Prudent dietary pattern;
UCEC	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-6.19	-0.45	5.79e-9	Homoarginine levels;
UCEC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.53	-5.2	-0.39	6.55e-7	Systemic lupus erythematosus;
UCEC	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-0.63	-6.01	-0.44	1.43e-8	Acne (severe);
UCEC	cis	rs2473248	1.000	rs2473248	chr1:22536643	T/C	cg22683154	chr1:23345188	KDM1A	0.5	5.15	0.39	8.29e-7	Birth weight;
UCEC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.58	-6.62	-0.48	6.18e-10	Electroencephalogram traits;
UCEC	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.89	-0.44	2.56e-8	Mortality in heart failure;
UCEC	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.58	5.11	0.39	9.95e-7	Corneal astigmatism;
UCEC	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.54	-6.02	-0.44	1.33e-8	Brugada syndrome;
UCEC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg03859395	chr2:55845619	SMEK2	1.0	14.54	0.77	3.04e-30	Metabolic syndrome;
UCEC	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.57	-5.6	-0.42	1.02e-7	Aortic root size;
UCEC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-5.17	-0.39	7.52e-7	Personality dimensions;
UCEC	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg06784218	chr1:46089804	CCDC17	0.47	5.75	0.43	5e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg00738113	chr16:70207722	CLEC18C	0.39	4.54	0.35	1.17e-5	Sjögren's syndrome;
UCEC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs9467773	0.967	rs1321482	chr6:26575154	T/C	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.69	-7.19	-0.51	3.01e-11	Blood metabolite levels;
UCEC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.58	7.92	0.55	5.34e-13	Total body bone mineral density;
UCEC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.56	5.04	0.38	1.35e-6	Selective IgA deficiency;
UCEC	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.73	-7.05	-0.5	6.48e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.46	4.64	0.36	7.72e-6	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.5	4.76	0.37	4.5e-6	Menopause (age at onset);
UCEC	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-4.62	-0.36	8.44e-6	Bipolar disorder;
UCEC	cis	rs354033	0.959	rs354041	chr7:149297035	A/C	cg24335155	chr7:149193227	ZNF746	0.37	4.57	0.35	1.01e-5	Multiple sclerosis;
UCEC	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7766436	0.848	rs6931450	chr6:22582076	T/C	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.48	5.87	0.44	2.8e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg19678392	chr7:94953810	PON1	-0.58	-5.7	-0.43	6.45e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.48	-4.97	-0.38	1.81e-6	Aortic root size;
UCEC	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.86	0.49	1.8e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Body mass index;
UCEC	cis	rs17122693	0.748	rs76141309	chr14:51110947	A/C	cg04730355	chr14:51134070	SAV1	1.08	6.32	0.46	2.96e-9	Cognitive performance;
UCEC	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.72	7.07	0.5	5.97e-11	Bladder cancer;
UCEC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.67	7.6	0.53	3.2e-12	Menopause (age at onset);
UCEC	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.85	-0.43	3.1e-8	Adiposity;
UCEC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.82	8.61	0.58	1.06e-14	Longevity;Endometriosis;
UCEC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.63	4.66	0.36	6.89e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.35e-7	Breast cancer;
UCEC	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.42	-5.26	-0.4	5.11e-7	Colorectal cancer;
UCEC	cis	rs7246967	0.611	rs2885222	chr19:22839944	T/G	cg08271804	chr19:22816896	ZNF492	0.66	6.54	0.47	9.68e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.92	-0.38	2.31e-6	Gut microbiome composition (summer);
UCEC	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.69	-7.42	-0.52	8.5e-12	Bone mineral density;
UCEC	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.4	5.04	0.38	1.35e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.58	-5.03	-0.38	1.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.52	-0.41	1.49e-7	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.71	0.36	5.78e-6	Breast cancer;
UCEC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	5.79	0.43	4.02e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-10.82	-0.67	1.97e-20	Body mass index;
UCEC	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.55	4.75	0.37	4.7e-6	Red blood cell count;
UCEC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-5.12	-0.39	9.52e-7	Type 2 diabetes;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.67	-0.36	6.76e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.69	7.57	0.53	3.89e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg03859395	chr2:55845619	SMEK2	1.0	13.93	0.75	1.16e-28	Metabolic syndrome;
UCEC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg12024160	chr4:1254474	NA	0.71	7.77	0.54	1.23e-12	Obesity-related traits;
UCEC	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.16	0.45	6.65e-9	Menarche (age at onset);
UCEC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.39	4.99	0.38	1.66e-6	Fibrinogen levels;
UCEC	cis	rs5167	0.504	rs66771331	chr19:45457319	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.08	0.45	1.01e-8	Blood protein levels;
UCEC	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.46	-5.04	-0.38	1.32e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.46	-4.95	-0.38	1.98e-6	Vitiligo;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.9	-0.37	2.52e-6	Depression;
UCEC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12618769	0.597	rs4851142	chr2:99133611	A/C	cg14361474	chr2:99058762	NA	-0.47	-4.62	-0.36	8.44e-6	Bipolar disorder;
UCEC	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.54	4.87	0.37	2.84e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.69	7.54	0.53	4.38e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs58799304	0.618	rs35997354	chr1:156071806	G/A	cg24674445	chr1:156076363	NA	0.51	4.5	0.35	1.35e-5	Ischemic stroke;
UCEC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	4.79	0.37	4.11e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.68	-7.72	-0.54	1.64e-12	Magnesium levels;
UCEC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.09	-0.39	1.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.64	6.6	0.48	7.07e-10	Longevity;Endometriosis;
UCEC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg21053147	chr12:120880522	NA	-0.65	-5.46	-0.41	1.98e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.61	6.06	0.45	1.09e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg01391022	chr12:122360665	WDR66	-0.41	-4.86	-0.37	2.93e-6	Mean corpuscular volume;
UCEC	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-6.27	-0.46	3.81e-9	Total cholesterol levels;
UCEC	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.49	-4.61	-0.36	8.7e-6	Corneal astigmatism;
UCEC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.52	4.86	0.37	2.98e-6	Obesity-related traits;
UCEC	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	5.01	0.38	1.51e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.48	4.58	0.35	9.91e-6	Coronary artery disease;
UCEC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.45	4.56	0.35	1.06e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-6.31	-0.46	3.05e-9	Dental caries;
UCEC	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.47	-6.57	-0.48	8.04e-10	Vitamin D levels;
UCEC	cis	rs9815925	0.748	rs1080745	chr3:184771440	G/A	cg00151007	chr3:184769954	VPS8	0.58	5.55	0.42	1.27e-7	Heschl's gyrus morphology;
UCEC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.59	5.44	0.41	2.14e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.53	-5.26	-0.4	4.9e-7	IgG glycosylation;
UCEC	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.5	6.16	0.45	6.47e-9	Subjective well-being (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs34676724	chr19:22918473	A/C	cg05241461	chr19:22816980	ZNF492	0.56	5.85	0.43	3.02e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.42	0.57	3.02e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-6.79	-0.49	2.64e-10	Obesity-related traits;
UCEC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg18493069	chr6:108582623	SNX3	-0.54	-6.8	-0.49	2.44e-10	Iris heterochromicity;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.75	8.48	0.57	2.21e-14	Menarche (age at onset);
UCEC	cis	rs7088591	0.867	rs115297070	chr10:59791505	A/G	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.47	-4.73	-0.36	5.31e-6	Cardiac Troponin-T levels;
UCEC	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg05991184	chr2:219186017	PNKD	0.43	4.76	0.37	4.59e-6	Ulcerative colitis;
UCEC	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.55	5.95	0.44	1.91e-8	Monocyte percentage of white cells;
UCEC	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.49	6.78	0.49	2.75e-10	Height;
UCEC	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg01657329	chr11:68192670	LRP5	0.45	5.44	0.41	2.15e-7	Total body bone mineral density;
UCEC	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg20387954	chr3:183756860	HTR3D	0.47	5.67	0.42	7.4e-8	Anterior chamber depth;
UCEC	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.46	4.88	0.37	2.68e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	6.92	0.5	1.26e-10	Platelet distribution width;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.43	-4.78	-0.37	4.21e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.59	5.7	0.43	6.47e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.54	-5.37	-0.4	3.04e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7246967	0.611	rs73022711	chr19:22875404	G/A	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.78	5.05	0.38	1.29e-6	Platelet count;
UCEC	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	0.97	8.84	0.59	2.73e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.57	6.4	0.47	1.98e-9	Mean platelet volume;
UCEC	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	5.83	0.43	3.43e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.57	3.4e-14	Parkinson's disease;
UCEC	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg06166341	chr4:1223170	CTBP1	0.6	5.24	0.4	5.41e-7	Systolic blood pressure;
UCEC	cis	rs7246967	1.000	rs7246967	chr19:23056346	T/G	cg08271804	chr19:22816896	ZNF492	0.55	5.15	0.39	8.38e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.55	-5.02	-0.38	1.49e-6	Menarche (age at onset);
UCEC	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg16060761	chr17:80687452	NA	-0.53	-4.99	-0.38	1.66e-6	Glycated hemoglobin levels;
UCEC	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg02503808	chr4:7069936	GRPEL1	0.41	4.7	0.36	5.84e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.51	8.36	0.57	4.33e-14	Airflow obstruction;
UCEC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.68	-6.75	-0.49	3.25e-10	Blood metabolite levels;
UCEC	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.46	5.15	0.39	8.38e-7	Longevity;
UCEC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg18755752	chr8:142205143	DENND3	-0.59	-5.48	-0.41	1.78e-7	Immature fraction of reticulocytes;
UCEC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg08461772	chr7:95026248	PON3	0.45	6.01	0.44	1.41e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.57	5.11	0.39	9.98e-7	Corneal astigmatism;
UCEC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24308560	chr3:49941425	MST1R	-0.48	-5.07	-0.39	1.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	4.57	0.35	1.02e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.53	5.09	0.39	1.06e-6	Neutrophil percentage of white cells;
UCEC	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.54	-0.47	9.57e-10	Response to antipsychotic treatment;
UCEC	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg15167202	chr5:149997153	SYNPO	-0.38	-4.77	-0.37	4.33e-6	HIV-1 control;
UCEC	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.68	-4.53	-0.35	1.22e-5	Red blood cell traits;
UCEC	cis	rs295140	1.000	rs3739121	chr2:201171014	G/C	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.66	-6.49	-0.47	1.21e-9	Malaria;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.52	-6.49	-0.47	1.24e-9	Pubertal anthropometrics;
UCEC	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.86	-0.37	3.03e-6	Height;
UCEC	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.07	-0.5	5.67e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg21642963	chr15:78858002	CHRNA5	0.5	4.7	0.36	5.94e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1712517	0.771	rs2292807	chr10:105155645	T/C	cg05636881	chr10:105038444	INA	0.45	5.23	0.4	5.68e-7	Migraine;
UCEC	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.47	4.97	0.38	1.86e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.86e-15	Blood protein levels;
UCEC	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.43	4.73	0.36	5.12e-6	Blood metabolite levels;
UCEC	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.46	4.85	0.37	3.07e-6	Coronary heart disease;
UCEC	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.63	6.48	0.47	1.3e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
UCEC	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	4.81	0.37	3.63e-6	Refractive astigmatism;
UCEC	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.42	-5.28	-0.4	4.52e-7	Urinary tract infection frequency;
UCEC	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.83	6.77	0.49	2.92e-10	Corneal structure;
UCEC	cis	rs8020441	1.000	rs8018822	chr14:51170609	C/T	cg04730355	chr14:51134070	SAV1	0.56	5.27	0.4	4.78e-7	Cognitive performance;
UCEC	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.63	5.17	0.39	7.69e-7	Height;
UCEC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.43	4.73	0.36	5.15e-6	Alcohol dependence;
UCEC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg11569703	chr11:65557185	OVOL1	-0.42	-5.99	-0.44	1.58e-8	Acne (severe);
UCEC	cis	rs2742417	0.967	rs2742419	chr3:45731929	G/A	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.22	-0.4	5.99e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-4.58	-0.35	1e-5	Bipolar disorder and schizophrenia;
UCEC	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.62	-6.09	-0.45	9.28e-9	Metabolite levels;
UCEC	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.75	0.43	5.11e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.38	-4.98	-0.38	1.75e-6	Dupuytren's disease;
UCEC	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.69	5.41	0.41	2.45e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.48	-4.87	-0.37	2.87e-6	Blood metabolite levels;
UCEC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.49	-5.54	-0.42	1.35e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.89	0.59	2.07e-15	Prudent dietary pattern;
UCEC	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	9.81	0.63	8.81e-18	Bipolar disorder;
UCEC	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	0.64	6.76	0.49	3.06e-10	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.81	10.42	0.65	2.17e-19	Vitiligo;
UCEC	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.6e-7	Aortic root size;
UCEC	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-4.93	-0.38	2.19e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.62	6.39	0.47	2.09e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.86	0.54	7.35e-13	Bone mineral density;
UCEC	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.63	6.67	0.48	4.96e-10	Body mass index;
UCEC	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	0.93	8.44	0.57	2.75e-14	Nonalcoholic fatty liver disease;
UCEC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	5.29	0.4	4.37e-7	Personality dimensions;
UCEC	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06223018	chr3:49557076	DAG1	0.34	4.86	0.37	2.93e-6	Parkinson's disease;
UCEC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.55	6.37	0.47	2.29e-9	Breast cancer;
UCEC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.95	0.5	1.08e-10	Menarche (age at onset);
UCEC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.13	-13.23	-0.74	8.41e-27	Breast cancer;
UCEC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.58	-5.63	-0.42	8.92e-8	IgG glycosylation;
UCEC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.49	4.55	0.35	1.13e-5	Breast cancer;
UCEC	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.79	-9.62	-0.62	2.68e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	5.11	0.39	9.85e-7	Myopia (pathological);
UCEC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.65	4.55	0.35	1.1e-5	Aortic root size;
UCEC	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	6.5	0.47	1.16e-9	Alzheimer's disease;
UCEC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.53	4.64	0.36	7.51e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.49	-4.96	-0.38	1.91e-6	Depression;
UCEC	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.53	5.35	0.4	3.35e-7	Testicular germ cell tumor;
UCEC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.66	-6.57	-0.48	8.33e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.29	0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs4845459	0.933	rs6700181	chr1:152593087	A/G	cg07796016	chr1:152779584	LCE1C	-0.42	-4.71	-0.36	5.75e-6	Psoriasis;
UCEC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.73	6.47	0.47	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg03230154	chr19:22817176	ZNF492	0.44	4.54	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.19	-10.59	-0.66	7.81e-20	Vitiligo;
UCEC	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-6.98	-0.5	9.52e-11	Menarche (age at onset);
UCEC	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.64	7.59	0.53	3.34e-12	Breast cancer;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs2944755	1.000	rs2944755	chr8:141574194	A/G	cg08444833	chr8:141574162	EIF2C2	0.71	5.04	0.38	1.35e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.42	5.23	0.4	5.8e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.53	-6.72	-0.48	3.72e-10	Mean platelet volume;
UCEC	cis	rs6790433	0.595	rs13081062	chr3:14470545	C/T	cg00625653	chr3:13921227	WNT7A	-0.39	-4.65	-0.36	7.33e-6	Response to taxane treatment (docetaxel);
UCEC	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-1.01	-11.99	-0.7	1.55e-23	Dilated cardiomyopathy;
UCEC	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.2	20.74	0.86	1.64e-45	Myeloid white cell count;
UCEC	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.72	6.76	0.49	3.09e-10	Schizophrenia;
UCEC	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-1.05	-9.42	-0.61	9.11e-17	Blood pressure (smoking interaction);
UCEC	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.22	-6.97	-0.5	9.87e-11	Diabetic kidney disease;
UCEC	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.52	4.73	0.36	5.13e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg20007245	chr22:24372913	LOC391322	-0.55	-5.94	-0.44	1.96e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.75	7.51	0.53	5.16e-12	Mosquito bite size;
UCEC	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.53	4.53	0.35	1.2e-5	Alzheimer's disease;
UCEC	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.51	4.64	0.36	7.7e-6	Menopause (age at onset);
UCEC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.69	6.07	0.45	1.04e-8	Aortic root size;
UCEC	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.16	-0.45	6.67e-9	Personality dimensions;
UCEC	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.68	0.36	6.36e-6	Schizophrenia;
UCEC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.57	7.02	0.5	7.59e-11	Fibrinogen levels;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.26	-0.4	4.93e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.56	-6.4	-0.47	2.01e-9	Type 2 diabetes;
UCEC	cis	rs16937	0.662	rs11240376	chr1:205146460	A/G	cg12580275	chr1:205744413	RAB7L1	0.53	5.57	0.42	1.21e-7	Schizophrenia;
UCEC	cis	rs11048434	0.932	rs12817960	chr12:9153127	C/T	cg23795048	chr12:9217529	LOC144571	0.49	5.56	0.42	1.26e-7	Sjögren's syndrome;
UCEC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00802000	chr16:706648	WDR90	-0.49	-5.6	-0.42	1.02e-7	Height;
UCEC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg13147721	chr7:65941812	NA	-0.92	-5.8	-0.43	3.91e-8	Diabetic kidney disease;
UCEC	cis	rs13253111	0.624	rs7012030	chr8:28096346	C/T	cg26534493	chr8:28060551	NA	0.48	5.31	0.4	4.05e-7	Childhood body mass index;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15607618	chr20:2854069	PTPRA	0.59	6.83	0.49	2.1e-10	Warfarin maintenance dose;
UCEC	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.52	5.21	0.4	6.14e-7	Testicular germ cell tumor;
UCEC	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.45	-4.65	-0.36	7.3e-6	Facial morphology (factor 20);
UCEC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.48	4.68	0.36	6.47e-6	Blood protein levels;
UCEC	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg00852783	chr1:26633632	UBXN11	0.51	4.89	0.37	2.61e-6	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.72	6.55	0.48	8.85e-10	Aortic root size;
UCEC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-8.77	-0.59	4.2e-15	Colorectal cancer;
UCEC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.1	0.51	4.81e-11	Motion sickness;
UCEC	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.52	-5.85	-0.43	3.09e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.39	-4.53	-0.35	1.19e-5	Iron status biomarkers;
UCEC	cis	rs931127	0.505	rs746429	chr11:65417434	G/A	cg27068330	chr11:65405492	SIPA1	-0.64	-6.59	-0.48	7.21e-10	Systemic lupus erythematosus;
UCEC	cis	rs78487399	0.908	rs73925552	chr2:43810564	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.92	-0.38	2.28e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-8.99	-0.6	1.12e-15	Blood metabolite levels;
UCEC	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.51	0.35	1.3e-5	Menopause (age at onset);
UCEC	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.67	5.26	0.4	4.91e-7	Neutrophil percentage of white cells;
UCEC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.4	0.57	3.53e-14	Prudent dietary pattern;
UCEC	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-6.08	-0.45	9.87e-9	Rheumatoid arthritis;
UCEC	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.56	5.05	0.38	1.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	6e-6	Cardiac Troponin-T levels;
UCEC	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.89	0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.45	-0.41	2.04e-7	Blood metabolite levels;
UCEC	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs2299682	0.826	rs2092360	chr20:9473899	G/A	cg11931762	chr20:9488920	NA	-0.75	-5.39	-0.41	2.75e-7	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs1570989	0.543	rs6458035	chr6:12015296	A/G	cg17804551	chr6:12015979	HIVEP1	0.45	5.26	0.4	4.96e-7	Alcohol and nicotine co-dependence;
UCEC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.72	8.42	0.57	3.18e-14	Menopause (age at onset);
UCEC	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.77	4.8	0.37	3.81e-6	Prostate cancer;
UCEC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.87	0.37	2.79e-6	Aortic root size;
UCEC	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.51	7.11	0.51	4.64e-11	Total body bone mineral density;
UCEC	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	5.79	0.43	4.13e-8	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg16616514	chr4:6324629	PPP2R2C	0.44	5.4	0.41	2.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs6921919	0.638	rs7772827	chr6:28301143	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.28	-0.4	4.58e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg03609598	chr5:56110824	MAP3K1	-0.57	-4.92	-0.38	2.27e-6	Type 2 diabetes;
UCEC	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.49	-5.18	-0.39	7.34e-7	Pulse pressure;
UCEC	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.46	4.98	0.38	1.74e-6	Alcoholic chronic pancreatitis;
UCEC	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.05	-7.81	-0.54	1.01e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg05695927	chr15:45694626	SPATA5L1	0.46	4.77	0.37	4.4e-6	Homoarginine levels;
UCEC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.35	-4.95	-0.38	2.05e-6	Longevity;
UCEC	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	11.01	0.67	6.11e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9402633	0.818	rs9389212	chr6:135051407	C/T	cg16239184	chr6:135079577	NA	-0.5	-4.53	-0.35	1.23e-5	Platelet count;
UCEC	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.58	-4.98	-0.38	1.74e-6	Serum thyroid-stimulating hormone levels;
UCEC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg02160872	chr5:212506	CCDC127	-0.68	-7.06	-0.5	6.24e-11	Breast cancer;
UCEC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-8.61	-0.58	1.05e-14	Menarche (age at onset);
UCEC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	0.94	9.1	0.6	5.76e-16	Cognitive function;
UCEC	cis	rs13063635	0.915	rs17714228	chr3:45945132	A/C	cg16320329	chr3:45981161	FYCO1	-0.82	-4.68	-0.36	6.38e-6	Eosinophil percentage of granulocytes;
UCEC	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.57	5.2	0.39	6.65e-7	Resting heart rate;
UCEC	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.48	5.24	0.4	5.49e-7	Systemic lupus erythematosus;
UCEC	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.47	4.78	0.37	4.12e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-6.67	-0.48	4.76e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.03e-5	Type 2 diabetes;
UCEC	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs250585	0.736	rs3096175	chr16:23457583	C/T	cg26562691	chr16:23850404	PRKCB	0.35	4.71	0.36	5.62e-6	Egg allergy;
UCEC	cis	rs151997	0.571	rs13340385	chr5:50318847	T/G	cg06027927	chr5:50259733	NA	0.57	4.95	0.38	1.99e-6	Callous-unemotional behaviour;
UCEC	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg26441486	chr22:50317300	CRELD2	0.75	5.12	0.39	9.25e-7	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.7	7.93	0.55	4.99e-13	Menopause (age at onset);
UCEC	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-5.62	-0.42	9.1e-8	HDL cholesterol;
UCEC	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.43	4.88	0.37	2.75e-6	Rheumatoid arthritis;
UCEC	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg05962950	chr11:130786565	SNX19	0.5	4.67	0.36	6.76e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.85	-10.84	-0.67	1.77e-20	Height;
UCEC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg05738196	chr6:26577821	NA	0.66	7.97	0.55	4.12e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-5.82	-0.43	3.49e-8	Menarche (age at onset);
UCEC	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	17.69	0.82	3.12e-38	Chronic sinus infection;
UCEC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.57	-4.7	-0.36	5.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4950937	0.830	rs3766541	chr1:203193049	C/T	cg20961782	chr1:203452697	PRELP	0.51	4.86	0.37	2.97e-6	Blood protein levels;
UCEC	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.66	-0.36	6.9e-6	Type 2 diabetes;
UCEC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	5.28	0.4	4.63e-7	Personality dimensions;
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.25	0.71	3.21e-24	Platelet count;
UCEC	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg26721908	chr21:47610096	LSS	-0.43	-5.71	-0.43	6.07e-8	Testicular germ cell tumor;
UCEC	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-1.04	-8.31	-0.57	5.72e-14	Exhaled nitric oxide output;
UCEC	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.56	6.14e-14	Prudent dietary pattern;
UCEC	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.51	-5.04	-0.38	1.34e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg00738919	chr7:1100172	C7orf50	0.75	4.57	0.35	1.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.55	-5.15	-0.39	8.14e-7	Huntington's disease progression;
UCEC	cis	rs1823913	0.503	rs35282329	chr2:192208651	G/A	cg15998761	chr2:191300784	MFSD6	0.41	4.74	0.36	4.94e-6	Obesity-related traits;
UCEC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.68	6.11	0.45	8.65e-9	Aortic root size;
UCEC	cis	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg14777817	chr13:80055594	NDFIP2	0.56	5.46	0.41	2.02e-7	Schizophrenia;
UCEC	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.0	-0.44	1.47e-8	Parkinson's disease;
UCEC	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.75	-5.71	-0.43	5.98e-8	Fibroblast growth factor basic levels;
UCEC	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.87	10.88	0.67	1.37e-20	IgG glycosylation;
UCEC	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.13	-7.01	-0.5	8.19e-11	Diabetic kidney disease;
UCEC	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	0.95	9.67	0.62	2.02e-17	Height;
UCEC	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18252515	chr7:66147081	NA	0.52	5.12	0.39	9.53e-7	Aortic root size;
UCEC	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.55	5.6	0.42	1.02e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.58	-5.48	-0.41	1.82e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs6761276	0.868	rs12468224	chr2:113834434	G/C	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.46	5.14	0.39	8.69e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.6	6.76	0.49	3.1e-10	Height;
UCEC	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	4.54	0.35	1.17e-5	Height;
UCEC	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.79	0.49	2.61e-10	Motion sickness;
UCEC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.53	5.55	0.42	1.28e-7	Breast cancer;
UCEC	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.22	-0.56	9.71e-14	Hemoglobin concentration;
UCEC	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg27565417	chr10:70588208	STOX1	0.47	4.87	0.37	2.86e-6	Left atrial antero-posterior diameter;
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg20119798	chr7:94954144	PON1	-0.49	-4.62	-0.36	8.38e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Alcohol dependence;
UCEC	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.77e-10	Chronic sinus infection;
UCEC	cis	rs713477	1.000	rs7142204	chr14:55908436	G/T	cg13175173	chr14:55914753	NA	0.4	4.55	0.35	1.1e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.43	-4.91	-0.38	2.41e-6	Response to antineoplastic agents;
UCEC	cis	rs17681684	0.505	rs62064492	chr17:9803713	G/A	cg26853458	chr17:9805074	RCVRN	0.46	5.37	0.41	2.99e-7	GIP levels in response to oral glucose tolerance test (fasting);
UCEC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.67	-0.42	7.33e-8	Breast cancer;
UCEC	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg00617691	chr10:743931	NA	0.32	4.72	0.36	5.55e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.77	0.37	4.33e-6	Blood metabolite levels;
UCEC	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.57	5.46	0.41	1.99e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg08738300	chr3:44038990	NA	0.59	4.93	0.38	2.2e-6	Coronary artery disease;
UCEC	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg04374321	chr14:90722782	PSMC1	0.71	7.94	0.55	4.81e-13	Mortality in heart failure;
UCEC	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	6.76	0.49	2.96e-10	Bipolar disorder;
UCEC	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.66	-5.54	-0.42	1.37e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.8	-11.04	-0.67	5.25e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.48	4.77	0.37	4.39e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.28	-0.46	3.63e-9	Aortic root size;
UCEC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.88	0.44	2.65e-8	HDL cholesterol;
UCEC	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg07796016	chr1:152779584	LCE1C	-0.41	-4.59	-0.35	9.54e-6	Psoriasis;
UCEC	cis	rs7611694	0.501	rs6438148	chr3:113138080	A/G	cg11138929	chr3:113251189	SIDT1	-0.4	-4.66	-0.36	7.04e-6	Prostate cancer;
UCEC	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.5	-4.98	-0.38	1.74e-6	Breast size;
UCEC	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.7	7.57	0.53	3.78e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-16.75	-0.81	6.56e-36	Colorectal cancer;
UCEC	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.52	-0.41	1.49e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	4.91	0.38	2.38e-6	Menopause (age at onset);
UCEC	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.52	5.13	0.39	8.97e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg18478394	chr8:109455254	TTC35	0.51	4.93	0.38	2.24e-6	Dupuytren's disease;
UCEC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg05738196	chr6:26577821	NA	0.66	7.97	0.55	4.12e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs6670533	0.571	rs11799673	chr1:24861471	G/A	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	5.49	0.41	1.71e-7	LDL cholesterol;
UCEC	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg05991184	chr2:219186017	PNKD	0.44	4.91	0.38	2.41e-6	Ulcerative colitis;
UCEC	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.18	-17.26	-0.82	3.54e-37	Exhaled nitric oxide output;
UCEC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.63	0.42	8.97e-8	Prudent dietary pattern;
UCEC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.37	-5.31	-0.4	3.9e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.51	5.98	0.44	1.6e-8	Nonalcoholic fatty liver disease;
UCEC	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.47	-4.78	-0.37	4.27e-6	Coronary artery disease;
UCEC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.63	-4.74	-0.36	5.01e-6	Narcolepsy;
UCEC	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.89	0.37	2.57e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.64	5.28	0.4	4.62e-7	Menarche (age at onset);
UCEC	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg17420585	chr12:42539391	GXYLT1	-0.42	-5.19	-0.39	6.94e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg18681998	chr4:17616180	MED28	0.52	5.75	0.43	4.9e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.57	-6.69	-0.48	4.36e-10	Prostate cancer;
UCEC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.83	8.55	0.58	1.46e-14	Longevity;Endometriosis;
UCEC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.11	11.66	0.69	1.17e-22	White matter hyperintensity burden;
UCEC	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.91	-0.49	1.4e-10	Diabetic kidney disease;
UCEC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.73	-0.36	5.23e-6	Obesity-related traits;
UCEC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.2e-5	Parkinson's disease;
UCEC	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.54	4.63	0.36	7.88e-6	Obesity-related traits;
UCEC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.69	-7.36	-0.52	1.2e-11	Height;
UCEC	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.3	-0.46	3.28e-9	Response to antipsychotic treatment;
UCEC	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.53	5.31	0.4	3.92e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.67e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.86	0.44	2.92e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11048434	1.000	rs7971932	chr12:9157346	G/A	cg04155231	chr12:9217510	LOC144571	0.45	4.87	0.37	2.89e-6	Sjögren's syndrome;
UCEC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.99	11.0	0.67	6.49e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18252515	chr7:66147081	NA	0.46	4.72	0.36	5.52e-6	Aortic root size;
UCEC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.53	-4.55	-0.35	1.1e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg24851651	chr11:66362959	CCS	0.46	5.5	0.41	1.61e-7	Educational attainment (years of education);
UCEC	cis	rs4687718	0.929	rs73840299	chr3:53277063	C/T	cg19378537	chr3:53290327	TKT	0.61	4.62	0.36	8.16e-6	QRS duration;
UCEC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.67	-6.7	-0.48	4.19e-10	Blood metabolite levels;
UCEC	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.78	5.03	0.38	1.43e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.69	6.13	0.45	7.8e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.71	7.34	0.52	1.37e-11	Lymphocyte counts;
UCEC	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.43	-0.52	8.25e-12	Total cholesterol levels;
UCEC	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	1.01	7.38	0.52	1.1e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9393813	0.529	rs73395360	chr6:27457317	A/C	cg27490387	chr6:26520793	HCG11	-0.4	-4.63	-0.36	8.07e-6	Bipolar disorder;
UCEC	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.67	-6.41	-0.47	1.87e-9	Blood pressure (smoking interaction);
UCEC	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.31	-0.4	4.03e-7	Breast cancer;
UCEC	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.67	7.43	0.52	8.34e-12	Crohn's disease;
UCEC	cis	rs925228	0.910	rs4665249	chr2:24174616	T/C	cg13272742	chr2:24272458	FKBP1B	0.6	5.18	0.39	7.31e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.77	8.67	0.58	7.45e-15	Primary sclerosing cholangitis;
UCEC	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.72	-0.48	3.82e-10	Response to antipsychotic treatment;
UCEC	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.12	-0.51	4.45e-11	Prevalent atrial fibrillation;
UCEC	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	1.12	14.32	0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs308403	0.532	rs309386	chr4:123665991	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.87	12.96	0.73	4.3e-26	Blood protein levels;
UCEC	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.66	-6.92	-0.5	1.29e-10	Menarche (age at onset);
UCEC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.64	0.42	8.27e-8	Cognitive test performance;
UCEC	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	4.59	0.35	9.37e-6	Height;
UCEC	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.14	-0.45	7.31e-9	Aortic root size;
UCEC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.76	7.69	0.54	1.99e-12	Cognitive function;
UCEC	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.68	-4.63	-0.36	8.13e-6	Hair shape;
UCEC	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-5.49	-0.41	1.72e-7	Large artery stroke;
UCEC	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.85	-10.52	-0.66	1.24e-19	Coronary artery disease;
UCEC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	7.04	0.5	6.93e-11	Platelet count;
UCEC	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.78	5.84	0.43	3.19e-8	Lymphocyte counts;
UCEC	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.71	9.19	0.6	3.47e-16	Testicular germ cell tumor;
UCEC	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg23950597	chr19:37808831	NA	0.6	4.69	0.36	6.17e-6	Coronary artery calcification;
UCEC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.43	-0.41	2.23e-7	Longevity;
UCEC	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.51	-5.14	-0.39	8.44e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.48	4.71	0.36	5.77e-6	Mean platelet volume;
UCEC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.54	-6.1	-0.45	8.84e-9	Type 2 diabetes;
UCEC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.52	-4.93	-0.38	2.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	6.53	0.47	1e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.5	0.41	1.62e-7	Rheumatoid arthritis;
UCEC	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-6.26	-0.46	4.03e-9	Crohn's disease;
UCEC	cis	rs2268983	0.538	rs8016977	chr14:69417003	T/C	cg11064738	chr14:68985557	RAD51L1	-0.48	-4.6	-0.36	8.87e-6	Smoking behavior;
UCEC	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.6	6.71	0.48	4.02e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.95	11.18	0.68	2.22e-21	Chronic sinus infection;
UCEC	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2904967	0.929	rs554122	chr11:65033874	T/C	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.75	6.68	0.48	4.56e-10	Cognitive function;
UCEC	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-4.82	-0.37	3.62e-6	Life satisfaction;
UCEC	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.55	-4.94	-0.38	2.07e-6	Pediatric autoimmune diseases;
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	4.51	0.35	1.33e-5	Obesity-related traits;
UCEC	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	4.96	0.38	1.89e-6	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	0.91	6.32	0.46	2.99e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.65	0.53	2.41e-12	Ileal carcinoids;
UCEC	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18932078	chr1:2524107	MMEL1	0.39	6.23	0.46	4.56e-9	Ulcerative colitis;
UCEC	cis	rs427941	0.521	rs55752209	chr7:101886661	A/G	cg08135718	chr7:101819329	CUX1	0.56	5.71	0.43	5.93e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs77861329	0.748	rs6786592	chr3:52196241	T/C	cg08692210	chr3:52188851	WDR51A	0.63	5.81	0.43	3.78e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-6.58	-0.48	7.7e-10	Prudent dietary pattern;
UCEC	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.67	6.75	0.49	3.22e-10	Coronary artery disease;
UCEC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	8.09	0.56	2.03e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.66	-7.45	-0.52	7.48e-12	Motion sickness;
UCEC	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.58	-5.65	-0.42	8.22e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg18016565	chr1:150552671	MCL1	0.45	4.53	0.35	1.19e-5	Melanoma;
UCEC	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.14	0.39	8.59e-7	Rheumatoid arthritis;
UCEC	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg20488157	chr14:104394430	TDRD9	-0.65	-4.57	-0.35	1.02e-5	Bipolar disorder;
UCEC	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.99	11.06	0.67	4.42e-21	Alcohol dependence;
UCEC	cis	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Intraocular pressure;
UCEC	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs10012307	1.000	rs57344125	chr4:137504133	A/T	cg12033966	chr4:138453416	PCDH18	-0.71	-5.08	-0.39	1.12e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg05695927	chr15:45694626	SPATA5L1	0.47	4.7	0.36	5.83e-6	Homoarginine levels;
UCEC	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.58	5.19	0.39	6.74e-7	Corneal astigmatism;
UCEC	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.61	-0.36	8.69e-6	Hemoglobin concentration;
UCEC	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.65	-5.9	-0.44	2.37e-8	Metabolite levels;
UCEC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg23950597	chr19:37808831	NA	0.6	4.69	0.36	6.17e-6	Coronary artery calcification;
UCEC	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.56	4.76	0.37	4.63e-6	Dental caries;
UCEC	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.43	4.72	0.36	5.42e-6	Renal cell carcinoma;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.45	-5.06	-0.39	1.22e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.64	5.59	0.42	1.06e-7	Coronary artery disease;
UCEC	cis	rs2180233	0.753	rs12732380	chr1:30676733	C/T	cg00108524	chr1:30559124	NA	-0.51	-4.61	-0.36	8.76e-6	Attention deficit hyperactivity disorder and conduct disorder;
UCEC	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.71	7.81	0.54	1.02e-12	IgG glycosylation;
UCEC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	7.61	0.53	3.02e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.48	5.03	0.38	1.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.4	-4.87	-0.37	2.83e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.73	-9.1	-0.6	6.03e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.72	9.17	0.6	4e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.09e-14	Prudent dietary pattern;
UCEC	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.86	0.44	2.95e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7106204	0.800	rs6484026	chr11:24214633	G/A	ch.11.24196551F	chr11:24239977	NA	0.53	5.48	0.41	1.83e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs11622475	0.911	rs55908053	chr14:104386173	T/C	cg20488157	chr14:104394430	TDRD9	0.66	4.63	0.36	7.9e-6	Bipolar disorder;
UCEC	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	4.86	0.37	2.96e-6	Monocyte count;
UCEC	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.38	7.19	0.51	3.11e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.03	0.45	1.25e-8	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs11867410	0.744	rs73992156	chr17:63961199	T/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.63	4.67	0.36	6.61e-6	Lymphocyte counts;
UCEC	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.76	7.87	0.54	7.23e-13	Breast cancer;
UCEC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.9	-9.89	-0.63	5.5e-18	Obesity-related traits;
UCEC	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg19610905	chr11:61596333	FADS2	-0.73	-7.3	-0.52	1.64e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.34	-5.57	-0.42	1.19e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-4.67	-0.36	6.59e-6	Blood metabolite levels;
UCEC	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.46	-5.6	-0.42	1.01e-7	Prevalent atrial fibrillation;
UCEC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg03037974	chr15:76606532	NA	0.32	4.53	0.35	1.21e-5	Blood metabolite levels;
UCEC	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	5.27	0.4	4.87e-7	Mood instability;
UCEC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.16	-6.86	-0.49	1.82e-10	Breast cancer;
UCEC	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs10012307	1.000	rs17048768	chr4:137511441	C/T	cg12033966	chr4:138453416	PCDH18	0.65	4.61	0.36	8.63e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7095607	0.606	rs7095492	chr10:69957375	C/T	cg18986048	chr10:69913749	MYPN	0.43	4.52	0.35	1.27e-5	Lung function (FVC);
UCEC	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-1.03	-7.78	-0.54	1.19e-12	Bone mineral density;
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-0.99	-11.37	-0.68	6.7e-22	Blood pressure (smoking interaction);
UCEC	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.54	7.73	0.54	1.52e-12	Multiple system atrophy;
UCEC	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.4	4.91	0.38	2.36e-6	Blood metabolite levels;
UCEC	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.48	-4.62	-0.36	8.4e-6	Coronary artery disease;
UCEC	cis	rs1678443	1	rs1678443	chr3:138097534	C/A	cg18030038	chr3:137905877	ARMC8	-0.9	-5.13	-0.39	9.04e-7	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.78	-7.55	-0.53	4.27e-12	Initial pursuit acceleration;
UCEC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.5	-5.61	-0.42	9.54e-8	Fibrinogen levels;
UCEC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-4.54	-0.35	1.15e-5	Headache;
UCEC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.5	-4.77	-0.37	4.41e-6	Schizophrenia;
UCEC	cis	rs9309473	0.519	rs2421583	chr2:73898785	C/G	cg20560298	chr2:73613845	ALMS1	0.51	4.78	0.37	4.16e-6	Metabolite levels;
UCEC	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.51	-5.65	-0.42	7.94e-8	Vitiligo;
UCEC	cis	rs999943	0.774	rs12212284	chr6:33640874	T/A	cg14003231	chr6:33640908	ITPR3	0.7	5.88	0.44	2.68e-8	Obesity (extreme);
UCEC	cis	rs4654899	0.931	rs10799669	chr1:21172501	T/C	cg01072550	chr1:21505969	NA	0.48	4.64	0.36	7.63e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7246967	0.673	rs60675447	chr19:22810892	G/A	cg24889512	chr19:22816950	ZNF492	0.54	5.62	0.42	9.39e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg01072550	chr1:21505969	NA	0.62	6.35	0.46	2.53e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11867410	0.744	rs11867289	chr17:63939218	T/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.4	-4.69	-0.36	6.15e-6	Multiple myeloma;
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.35	5.04	0.38	1.34e-6	Coronary artery disease;
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.53	0.62	4.73e-17	Platelet count;
UCEC	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.62	5.95	0.44	1.84e-8	Coronary artery disease;
UCEC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.56	4.68	0.36	6.43e-6	Neutrophil percentage of white cells;
UCEC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.31	-4.56	-0.35	1.09e-5	Body mass index;
UCEC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-4.73	-0.36	5.18e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.47	4.77	0.37	4.34e-6	Vitiligo;
UCEC	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.48	5.37	0.4	3.06e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.82	-11.43	-0.69	4.74e-22	Post bronchodilator FEV1;
UCEC	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.61	5.9	0.44	2.4e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.84	0.37	3.27e-6	Rheumatoid arthritis;
UCEC	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs4588572	0.645	rs10059940	chr5:77680873	T/C	cg11547950	chr5:77652471	NA	0.48	5.35	0.4	3.34e-7	Triglycerides;
UCEC	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg21770322	chr7:97807741	LMTK2	0.52	6.59	0.48	7.43e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-5.44	-0.41	2.14e-7	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.58	5.43	0.41	2.27e-7	Corneal astigmatism;
UCEC	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.61	-6.46	-0.47	1.47e-9	Type 2 diabetes;
UCEC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.91	11.23	0.68	1.6e-21	Longevity;Endometriosis;
UCEC	cis	rs1519814	1.000	rs10087151	chr8:121172261	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-5.31	-0.4	3.93e-7	Breast cancer;
UCEC	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.58	-4.87	-0.37	2.87e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs8105895	0.867	rs116220423	chr19:22237041	G/A	cg02912127	chr19:22235281	ZNF257	-0.59	-5.05	-0.38	1.31e-6	Body mass index (change over time);
UCEC	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg19318889	chr4:1322082	MAEA	0.5	5.5	0.41	1.63e-7	Obesity-related traits;
UCEC	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg24069376	chr3:38537580	EXOG	-0.43	-5.23	-0.4	5.76e-7	Electrocardiographic conduction measures;
UCEC	cis	rs13098911	0.540	rs4388012	chr3:45996501	A/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.57	5.05	0.38	1.27e-6	Menarche (age at onset);
UCEC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg02160872	chr5:212506	CCDC127	-0.7	-7.38	-0.52	1.07e-11	Breast cancer;
UCEC	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	8.21	0.56	1.05e-13	Menarche (age at onset);
UCEC	cis	rs2474937	0.561	rs4642877	chr1:118925655	C/T	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.64	6.17	0.45	6.24e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.74	-8.1	-0.56	1.98e-13	Height;
UCEC	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg26781129	chr3:44753946	ZNF502	-0.47	-5.16	-0.39	7.9e-7	Depressive symptoms;
UCEC	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.68	7.46	0.52	7.07e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-5.16	-0.39	7.91e-7	Schizophrenia;
UCEC	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg18479299	chr3:125709523	NA	-0.61	-4.88	-0.37	2.78e-6	Blood pressure (smoking interaction);
UCEC	cis	rs9463078	0.715	rs9357459	chr6:44782562	C/T	cg25276700	chr6:44698697	NA	-0.47	-5.2	-0.39	6.5e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.93	5.89	0.44	2.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.55	5.8	0.43	3.98e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs80130819	0.515	rs917055	chr12:48385576	A/G	cg05342945	chr12:48394962	COL2A1	-0.71	-4.9	-0.37	2.48e-6	Prostate cancer;
UCEC	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg14829360	chr17:73884958	NA	-0.56	-5.7	-0.43	6.31e-8	Psoriasis;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg20119798	chr7:94954144	PON1	-0.49	-4.64	-0.36	7.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.47	-5.3	-0.4	4.2e-7	Neuroticism;
UCEC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.38	0.52	1.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.8	8.36	0.57	4.39e-14	Primary sclerosing cholangitis;
UCEC	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg12580275	chr1:205744413	RAB7L1	0.51	4.74	0.36	5.07e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg24130564	chr14:104152367	KLC1	-0.55	-4.94	-0.38	2.06e-6	Reticulocyte count;
UCEC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.54	0.35	1.18e-5	Menopause (age at onset);
UCEC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-4.75	-0.36	4.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.79	-8.5	-0.57	1.94e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	0.87	9.74	0.63	1.32e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg21231944	chr12:82153410	PPFIA2	-0.44	-5.07	-0.39	1.17e-6	Resting heart rate;
UCEC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.66	6.77	0.49	2.84e-10	Systemic lupus erythematosus;
UCEC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.72	-6.94	-0.5	1.18e-10	Aortic root size;
UCEC	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.8	-0.63	9.46e-18	Leprosy;
UCEC	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18252515	chr7:66147081	NA	0.47	4.76	0.37	4.55e-6	Aortic root size;
UCEC	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.41	5.12	0.39	9.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.52	4.54	0.35	1.15e-5	Schizophrenia;
UCEC	cis	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg20307385	chr11:47447363	PSMC3	0.5	4.57	0.35	1.01e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.42	-4.79	-0.37	4.06e-6	Blood metabolite levels;
UCEC	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.7	6.6	0.48	6.88e-10	Bladder cancer;
UCEC	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.84	-8.14	-0.56	1.51e-13	Parkinson's disease;
UCEC	trans	rs12755164	0.771	rs11210085	chr1:73362466	T/G	cg17780956	chr4:156297616	MAP9	-0.65	-6.93	-0.5	1.26e-10	Schizophrenia;
UCEC	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs151997	0.962	rs32482	chr5:50207118	T/C	cg06027927	chr5:50259733	NA	0.54	4.85	0.37	3.06e-6	Callous-unemotional behaviour;
UCEC	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	8.81	0.59	3.28e-15	Electrocardiographic conduction measures;
UCEC	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.38	-4.67	-0.36	6.63e-6	Mean platelet volume;
UCEC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.68	7.82	0.54	9.45e-13	Mean corpuscular volume;
UCEC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	8.5	0.57	2.01e-14	Prudent dietary pattern;
UCEC	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.54	5.32	0.4	3.72e-7	Coronary artery disease;
UCEC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg21856205	chr7:94953877	PON1	-0.53	-4.55	-0.35	1.13e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20386705	chr6:38607295	BTBD9	0.57	6.72	0.48	3.72e-10	Warfarin maintenance dose;
UCEC	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg18099408	chr3:52552593	STAB1	0.47	5.28	0.4	4.46e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.67	-0.36	6.86e-6	Type 2 diabetes;
UCEC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.69	-6.25	-0.46	4.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.68	5.2	0.39	6.66e-7	Corneal astigmatism;
UCEC	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs539514	0.563	rs7983875	chr13:76329245	T/C	cg04757411	chr13:76259545	LMO7	-0.48	-5.66	-0.42	7.58e-8	Type 1 diabetes;
UCEC	cis	rs7197653	0.519	rs55757091	chr16:68323654	G/A	cg05110241	chr16:68378359	PRMT7	-0.46	-4.71	-0.36	5.62e-6	Magnesium levels;
UCEC	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.59	4.78	0.37	4.27e-6	Corneal astigmatism;
UCEC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg02160872	chr5:212506	CCDC127	-0.67	-7.08	-0.5	5.4e-11	Breast cancer;
UCEC	cis	rs6882076	0.961	rs58198139	chr5:156399039	C/T	cg12943317	chr5:156479607	HAVCR1	-0.49	-5.09	-0.39	1.09e-6	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.86	0.54	7.44e-13	Alzheimer's disease;
UCEC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg02304201	chr16:2564839	ATP6V0C	0.45	4.65	0.36	7.22e-6	Insulin-like growth factors;
UCEC	cis	rs3813359	0.841	rs716301	chr6:130756349	C/T	cg18932809	chr6:130686826	NA	-0.66	-4.61	-0.36	8.73e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs580809	0.700	rs4742741	chr9:101539601	G/A	cg14451115	chr9:101050633	GABBR2	0.41	4.56	0.35	1.09e-5	Body mass index;
UCEC	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.61	5.81	0.43	3.68e-8	Corneal astigmatism;
UCEC	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.66	5.88	0.44	2.59e-8	Corneal astigmatism;
UCEC	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg15764593	chr10:829463	NA	0.55	4.69	0.36	6.09e-6	Uric acid levels;
UCEC	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	0.82	5.23	0.4	5.64e-7	Arsenic metabolism;
UCEC	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg15659132	chr6:26577336	NA	0.48	4.55	0.35	1.11e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs13092825	0.794	rs34627996	chr3:113276381	G/C	cg12596171	chr3:113251061	SIDT1	-0.55	-4.61	-0.36	8.71e-6	Dental caries;
UCEC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg11644478	chr21:40555479	PSMG1	-0.53	-5.7	-0.43	6.45e-8	Menarche (age at onset);
UCEC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg20534287	chr10:135191450	PAOX	0.68	6.63	0.48	5.84e-10	Lifespan;
UCEC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.61	-7.37	-0.52	1.14e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg06238570	chr21:40685208	BRWD1	0.83	8.21	0.56	1.04e-13	Cognitive function;
UCEC	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.36	4.87	0.37	2.84e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg20307385	chr11:47447363	PSMC3	0.56	5.19	0.39	7.01e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.37	5.47	0.41	1.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs6832769	1.000	rs726967	chr4:56421713	A/T	cg05960024	chr4:56376020	CLOCK	-0.49	-4.57	-0.35	1.04e-5	Personality dimensions;
UCEC	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18252515	chr7:66147081	NA	-0.54	-5.24	-0.4	5.45e-7	Aortic root size;
UCEC	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.49	0.41	1.73e-7	Heart rate;
UCEC	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.63	-0.48	6.13e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24308560	chr3:49941425	MST1R	-0.46	-4.98	-0.38	1.74e-6	Body mass index;
UCEC	cis	rs17102423	0.615	rs7147987	chr14:65538131	A/G	cg11161011	chr14:65562177	MAX	-0.54	-4.95	-0.38	1.98e-6	Obesity-related traits;
UCEC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.57	6.74	0.49	3.35e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.51	4.73	0.36	5.21e-6	Night sleep phenotypes;
UCEC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.57	0.42	1.18e-7	Monocyte percentage of white cells;
UCEC	cis	rs7766436	0.845	rs1342207	chr6:22587762	G/A	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-6.1	-0.45	8.85e-9	Morning vs. evening chronotype;
UCEC	trans	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg26043149	chr18:55253948	FECH	-0.83	-8.35	-0.57	4.61e-14	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.42	-0.47	1.76e-9	Schizophrenia;
UCEC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs76439304	1.000	rs77430005	chr12:27087009	C/A	cg19407459	chr12:26986763	ITPR2	0.99	5.49	0.41	1.7e-7	Mean corpuscular volume;
UCEC	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.67	7.01	0.5	7.93e-11	Lymphocyte counts;
UCEC	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.89	10.69	0.66	4.24e-20	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	4.61	0.36	8.61e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.67	-7.84	-0.54	8.59e-13	Obesity-related traits;
UCEC	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.47	-5.3	-0.4	4.2e-7	Retinal vascular caliber;
UCEC	cis	rs860295	0.580	rs6672284	chr1:155277963	C/T	cg02153340	chr1:155202674	NA	-0.47	-5.27	-0.4	4.84e-7	Body mass index;
UCEC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.83	9.96	0.63	3.62e-18	Menopause (age at onset);
UCEC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.6	0.53	3.18e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6723108	0.603	rs3769023	chr2:135713703	G/A	cg07169764	chr2:136633963	MCM6	0.51	5.0	0.38	1.62e-6	Type 2 diabetes;
UCEC	cis	rs13065560	0.659	rs4676476	chr3:38882009	C/T	cg01426195	chr3:39028469	NA	-0.53	-5.72	-0.43	5.88e-8	Interleukin-18 levels;
UCEC	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg01072550	chr1:21505969	NA	-0.59	-5.62	-0.42	9.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	4.76	0.37	4.57e-6	Lung function (FEV1/FVC);
UCEC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.83	9.23	0.61	2.71e-16	Breast cancer;
UCEC	cis	rs7766436	0.885	rs6908600	chr6:22582002	C/T	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	4.58	0.35	9.83e-6	Lung cancer in ever smokers;
UCEC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.9	0.37	2.54e-6	Rheumatoid arthritis;
UCEC	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-6.03	-0.45	1.28e-8	Morning vs. evening chronotype;
UCEC	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.8	-7.51	-0.53	5.39e-12	Strep throat;
UCEC	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg16164276	chr3:11034345	SLC6A1	-0.48	-4.55	-0.35	1.1e-5	Alzheimer's disease;
UCEC	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-4.98	-0.38	1.77e-6	Neuroticism;
UCEC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.61	-6.53	-0.47	9.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg03714773	chr7:91764589	CYP51A1	0.45	5.43	0.41	2.23e-7	Breast cancer;
UCEC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.67	7.34	0.52	1.36e-11	Monocyte count;
UCEC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.66	-6.06	-0.45	1.11e-8	Body mass index;
UCEC	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.9	-9.65	-0.62	2.33e-17	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.59	4.63	0.36	8.14e-6	Body mass index;
UCEC	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-5.27	-0.4	4.75e-7	Crohn's disease;
UCEC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.98	-0.5	9.24e-11	Coronary artery disease;
UCEC	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.56	0.35	1.08e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.68	-7.06	-0.5	6.13e-11	Neurofibrillary tangles;
UCEC	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-8.92	-0.59	1.66e-15	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg13385521	chr17:29058706	SUZ12P	-0.58	-4.58	-0.35	9.85e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.71	-7.77	-0.54	1.24e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.3	0.4	4.13e-7	Rheumatoid arthritis;
UCEC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg05855489	chr10:104503620	C10orf26	-0.63	-6.84	-0.49	1.99e-10	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.59	6.8	0.49	2.48e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.09	-0.39	1.09e-6	Pubertal anthropometrics;
UCEC	cis	rs10924970	0.578	rs12031118	chr1:235463887	T/G	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.79	-0.49	2.59e-10	Prostate cancer;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.53	-6.22	-0.46	5e-9	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.5e-16	Height;
UCEC	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	0.98	12.36	0.71	1.67e-24	Coronary artery disease;
UCEC	cis	rs1568889	0.877	rs12786351	chr11:28271122	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.6	5.34	0.4	3.48e-7	Bipolar disorder;
UCEC	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.59	4.92	0.38	2.29e-6	Lung cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05821866	chr1:167905319	DCAF6;BRP44	0.54	6.78	0.49	2.74e-10	Warfarin maintenance dose;
UCEC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.71	-5.06	-0.38	1.25e-6	Aortic root size;
UCEC	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.34	5.1	0.39	1.02e-6	Ulcerative colitis;
UCEC	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.77	-5.94	-0.44	2e-8	Multiple system atrophy;
UCEC	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.05	-0.38	1.27e-6	Bone mineral density;
UCEC	cis	rs7611694	0.501	rs4682486	chr3:113109346	T/C	cg11138929	chr3:113251189	SIDT1	-0.42	-4.93	-0.38	2.22e-6	Prostate cancer;
UCEC	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg24851651	chr11:66362959	CCS	-0.41	-5.08	-0.39	1.15e-6	Educational attainment (years of education);
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg08461772	chr7:95026248	PON3	0.32	4.62	0.36	8.48e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.32	4.98	0.38	1.74e-6	Cancer;
UCEC	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.41	-5.21	-0.39	6.33e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs3816788	0.792	rs13257744	chr8:21872853	T/C	cg17168535	chr8:21777572	XPO7	0.73	7.79	0.54	1.09e-12	Lung cancer in ever smokers;
UCEC	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.54e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.61	6.1	0.45	8.91e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.13	-0.45	7.64e-9	Aortic root size;
UCEC	cis	rs36051895	0.632	rs10974984	chr9:5150427	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-4.77	-0.37	4.39e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.7	6.88	0.49	1.64e-10	Bipolar disorder;
UCEC	cis	rs3770752	0.897	rs13015451	chr2:37551085	T/C	cg20091297	chr2:37572423	QPCT	0.47	4.56	0.35	1.09e-5	Schizophrenia;
UCEC	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.42	-4.69	-0.36	6.26e-6	Response to antineoplastic agents;
UCEC	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.47	-5.84	-0.43	3.3e-8	Prevalent atrial fibrillation;
UCEC	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.57	8.37	0.57	4.24e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	0.94	9.34	0.61	1.45e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.52	-5.2	-0.39	6.71e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.62	5.33	0.4	3.68e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7088591	0.867	rs4606437	chr10:59779976	G/T	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.77	6.18	0.45	6.1e-9	Response to hepatitis C treatment;
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.46	-4.77	-0.37	4.39e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.44	5.03	0.38	1.43e-6	Mortality in heart failure;
UCEC	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.43	5.19	0.39	6.95e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.8	6.79	0.49	2.54e-10	Menopause (age at onset);
UCEC	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg10631289	chr15:39006617	NA	-0.62	-5.32	-0.4	3.85e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.68	-7.06	-0.5	6.13e-11	Neurofibrillary tangles;
UCEC	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.61	-6.11	-0.45	8.5e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.42	0.61	9.11e-17	Blood protein levels;
UCEC	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.16	14.9	0.78	3.46e-31	Cognitive function;
UCEC	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.83	-9.37	-0.61	1.22e-16	Homoarginine levels;
UCEC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.96	-0.55	4.31e-13	Monocyte count;
UCEC	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.35	5.75	0.43	5.06e-8	Cancer;
UCEC	cis	rs16912285	0.748	rs58504811	chr11:24252020	T/G	ch.11.24196551F	chr11:24239977	NA	0.51	4.8	0.37	3.86e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.24	0.4	5.44e-7	Mean platelet volume;
UCEC	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.73	5.11	0.39	1e-6	Inflammatory bowel disease;
UCEC	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.34	-4.61	-0.36	8.8e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg00857998	chr1:205179979	DSTYK	0.47	4.65	0.36	7.36e-6	Red blood cell count;
UCEC	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.6	-4.96	-0.38	1.89e-6	Obesity-related traits;
UCEC	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.51	4.54	0.35	1.16e-5	Height;
UCEC	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.59	-5.12	-0.39	9.39e-7	Reticulocyte count;
UCEC	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.46	4.52	0.35	1.27e-5	Coronary artery disease;
UCEC	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.78	-8.85	-0.59	2.49e-15	Height;
UCEC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.52	5.08	0.39	1.13e-6	Obesity-related traits;
UCEC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.7	-6.9	-0.49	1.41e-10	Response to antineoplastic agents;
UCEC	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-7.06	-0.5	6.17e-11	Obesity-related traits;
UCEC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.58	4.7	0.36	5.98e-6	Longevity;
UCEC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.94	10.98	0.67	7.45e-21	Breast cancer;
UCEC	cis	rs970821	0.868	rs7820881	chr8:124739709	G/A	cg23359983	chr8:125486969	RNF139	0.57	4.53	0.35	1.23e-5	Breast cancer;
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.5	0.41	1.66e-7	Rheumatoid arthritis;
UCEC	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg00873616	chr20:43920241	NA	-0.49	-4.63	-0.36	8.02e-6	Blood protein levels;
UCEC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg04837898	chr3:45731254	SACM1L	-0.42	-4.68	-0.36	6.36e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg08461772	chr7:95026248	PON3	0.36	4.92	0.38	2.3e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.65	6.03	0.45	1.24e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.72e-7	Heart rate;
UCEC	cis	rs2280630	0.529	rs784495	chr3:39178899	C/T	cg01426195	chr3:39028469	NA	0.68	8.43	0.57	2.91e-14	Verbal declarative memory;
UCEC	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.78	7.11	0.51	4.76e-11	Morning vs. evening chronotype;
UCEC	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.64	5.39	0.41	2.81e-7	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.5	5.0	0.38	1.59e-6	Menopause (age at onset);
UCEC	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.74	7.63	0.53	2.66e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.53	5.98	0.44	1.63e-8	Mean corpuscular volume;
UCEC	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.52	-4.95	-0.38	2.01e-6	Coronary artery disease;
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.56	6.14	0.45	7.39e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7215564	0.908	rs35253080	chr17:78700167	G/A	cg01498832	chr17:78682934	RPTOR	0.57	4.7	0.36	5.88e-6	Myopia (pathological);
UCEC	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg00277334	chr10:82204260	NA	-0.48	-4.76	-0.37	4.49e-6	Post bronchodilator FEV1;
UCEC	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.39	-4.67	-0.36	6.86e-6	Menopause (age at onset);
UCEC	cis	rs4615376	0.951	rs13218974	chr6:13023935	T/C	cg11378619	chr6:12164359	HIVEP1	-0.57	-4.53	-0.35	1.19e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg20936604	chr3:58311152	NA	-0.56	-4.77	-0.37	4.32e-6	Cholesterol, total;
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.43	-0.41	2.3e-7	Cardiac Troponin-T levels;
UCEC	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-6.19	-0.45	5.58e-9	Hemoglobin concentration;
UCEC	cis	rs77861329	1.000	rs9857878	chr3:52109668	A/G	cg08692210	chr3:52188851	WDR51A	-0.73	-5.14	-0.39	8.7e-7	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg06521331	chr12:34319734	NA	-0.63	-5.0	-0.38	1.64e-6	Morning vs. evening chronotype;
UCEC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg04545659	chr9:139973827	UAP1L1	-0.37	-4.8	-0.37	3.9e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.92	9.8	0.63	9.37e-18	Cognitive function;
UCEC	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.98	0.5	9.49e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs10216189	0.785	rs4352753	chr7:5527223	A/C	cg11800390	chr7:5515995	FBXL18	0.62	7.5	0.53	5.63e-12	Relative hand skill in reading disability;
UCEC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.55	6.34	0.46	2.71e-9	Calcium levels;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07509464	chr2:106359129	NA	-0.65	-6.68	-0.48	4.53e-10	Migraine with aura;
UCEC	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg07905965	chr19:39260460	NA	0.4	4.72	0.36	5.41e-6	Heart rate;
UCEC	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.68	7.41	0.52	9.09e-12	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.66	-7.01	-0.5	7.98e-11	Parkinson's disease;
UCEC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.81	-7.93	-0.55	5.02e-13	Obesity-related traits;
UCEC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.49	5.29	0.4	4.42e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Amyotrophic lateral sclerosis (age of onset);
UCEC	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.46	-5.55	-0.42	1.31e-7	Subjective well-being;
UCEC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.58	5.86	0.44	2.88e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.85	8.02	0.55	3.11e-13	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg05991184	chr2:219186017	PNKD	0.52	5.69	0.43	6.56e-8	Colorectal cancer;
UCEC	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg21053147	chr12:120880522	NA	0.68	4.87	0.37	2.91e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.27	-0.4	4.69e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6893207	1.000	rs75901284	chr5:16371750	T/C	cg11584519	chr5:16175867	MARCH11	0.74	4.55	0.35	1.1e-5	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.49	4.65	0.36	7.24e-6	Menopause (age at onset);
UCEC	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-5.44	-0.41	2.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg05660106	chr1:15850417	CASP9	0.55	4.87	0.37	2.88e-6	Systolic blood pressure;
UCEC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs6137726	0.652	rs6082779	chr20:22655695	C/T	cg08244522	chr20:23030533	THBD	0.44	4.56	0.35	1.06e-5	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.52	-5.73	-0.43	5.52e-8	Gut microbiome composition (summer);
UCEC	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg19413350	chr8:57351067	NA	-0.41	-4.85	-0.37	3.15e-6	Obesity-related traits;
UCEC	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.54	2e-12	IgG glycosylation;
UCEC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.71	7.19	0.51	3.09e-11	Type 2 diabetes;
UCEC	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg13683864	chr3:40499215	RPL14	-0.53	-5.3	-0.4	4.11e-7	Renal cell carcinoma;
UCEC	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.55	5.3	0.4	4.13e-7	Eosinophil percentage of white cells;
UCEC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg20821713	chr7:1055600	C7orf50	-0.74	-6.98	-0.5	9.55e-11	Bronchopulmonary dysplasia;
UCEC	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-5.78	-0.43	4.35e-8	Monocyte percentage of white cells;
UCEC	cis	rs7582720	1.000	rs72932725	chr2:203649341	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.7	0.36	6.02e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.76	6.89	0.49	1.55e-10	Post bronchodilator FEV1;
UCEC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.53	5.48	0.41	1.83e-7	Birth weight;
UCEC	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs7246967	0.673	rs597906	chr19:22868205	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.88	-0.44	2.6e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.55	-6.15	-0.45	6.85e-9	Lung cancer;
UCEC	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-9.79	-0.63	9.98e-18	Coronary artery disease;
UCEC	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.44e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.42	5.43	0.41	2.27e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	5.96	0.44	1.78e-8	Breast cancer;
UCEC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.59	-6.43	-0.47	1.7e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs72949976	0.707	rs62186571	chr2:214038673	C/G	cg08319019	chr2:214017104	IKZF2	-0.73	-5.8	-0.43	3.9e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.78	-4.78	-0.37	4.26e-6	Platelet count;
UCEC	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.58	-5.35	-0.4	3.32e-7	Metabolite levels;
UCEC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.5	-5.18	-0.39	7.13e-7	Total body bone mineral density;
UCEC	cis	rs860295	1.000	rs822490	chr1:155822971	A/G	cg06221963	chr1:154839813	KCNN3	0.43	4.57	0.35	1.04e-5	Body mass index;
UCEC	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg23260525	chr10:116636907	FAM160B1	0.33	4.53	0.35	1.23e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	trans	rs925228	0.869	rs2339853	chr2:23958164	C/T	cg02894226	chr20:3190561	ITPA	0.65	6.69	0.48	4.48e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg07153921	chr17:41440717	NA	-0.47	-4.69	-0.36	6.23e-6	Menopause (age at onset);
UCEC	cis	rs7246967	0.799	rs12983185	chr19:23030575	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.39	0.41	2.8e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.66	6.76	0.49	2.99e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.65	-4.67	-0.36	6.77e-6	Multiple sclerosis;
UCEC	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.53	7.59	0.53	3.45e-12	Height;
UCEC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.01	-6.55	-0.48	8.96e-10	Diabetic kidney disease;
UCEC	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.36	-0.4	3.15e-7	Chronic sinus infection;
UCEC	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.69	-6.3	-0.46	3.28e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg13147721	chr7:65941812	NA	-0.94	-6.91	-0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.73	-0.43	5.6e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2742417	0.967	rs1969625	chr3:45734975	A/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs62344088	1.000	rs7716917	chr5:93387	A/C	cg02160872	chr5:212506	CCDC127	-0.58	-4.58	-0.35	9.93e-6	Asthma (childhood onset);
UCEC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg22974920	chr21:40686053	BRWD1	0.53	4.87	0.37	2.82e-6	Cognitive function;
UCEC	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-1.04	-11.28	-0.68	1.17e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.63	6.63	0.48	6.08e-10	Diastolic blood pressure;
UCEC	cis	rs12799172	0.566	rs2741741	chr11:6817499	A/C	cg11333968	chr11:7569641	PPFIBP2	0.46	4.55	0.35	1.09e-5	Periodontal disease-related phenotypes;
UCEC	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-6.3	-0.46	3.27e-9	Morning vs. evening chronotype;
UCEC	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg03609598	chr5:56110824	MAP3K1	-0.62	-5.05	-0.38	1.3e-6	Type 2 diabetes;
UCEC	cis	rs35934224	0.783	rs7290770	chr22:19861161	C/T	cg11182965	chr22:19864308	TXNRD2	-0.63	-6.05	-0.45	1.12e-8	Glaucoma (primary open-angle);
UCEC	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg14019695	chr9:139328340	INPP5E	0.47	5.12	0.39	9.28e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.73	7.98	0.55	3.91e-13	Mortality in heart failure;
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg20821713	chr7:1055600	C7orf50	-0.45	-4.66	-0.36	7.12e-6	Longevity;Endometriosis;
UCEC	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg05991184	chr2:219186017	PNKD	0.52	5.65	0.42	7.87e-8	Colorectal cancer;
UCEC	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.62	9.09	0.6	6.26e-16	Total body bone mineral density;
UCEC	cis	rs17123764	0.818	rs7953911	chr12:49948500	T/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.22	0.4	5.91e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.54	-5.68	-0.42	6.92e-8	Parkinson's disease;
UCEC	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.73	-4.81	-0.37	3.75e-6	LDL cholesterol levels;
UCEC	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg21214455	chr15:72412075	SENP8	0.49	4.64	0.36	7.55e-6	Red blood cell count;
UCEC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10743315	0.908	rs7297169	chr12:19466956	G/T	cg26259627	chr12:19592630	AEBP2	0.67	4.61	0.36	8.65e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg19318889	chr4:1322082	MAEA	0.5	5.43	0.41	2.32e-7	Obesity-related traits;
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	8.8	0.59	3.51e-15	Platelet count;
UCEC	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg18002602	chr11:66138449	SLC29A2	-0.41	-4.77	-0.37	4.36e-6	Educational attainment (years of education);
UCEC	cis	rs11760485	0.965	rs10233780	chr7:4404058	C/G	cg22450045	chr7:4839495	RADIL	-0.38	-4.73	-0.36	5.17e-6	Early childhood aggressive behavior;
UCEC	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg10104451	chr8:143696006	ARC	-0.54	-5.09	-0.39	1.1e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7475343	0.818	rs17399879	chr10:5332298	T/G	cg20587968	chr10:5406423	UCN3	0.55	4.56	0.35	1.07e-5	Intelligence;
UCEC	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg14664628	chr15:75095509	CSK	-0.51	-4.8	-0.37	3.94e-6	Caffeine consumption;
UCEC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4851266	1.000	rs1122231	chr2:100834546	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs554111	0.509	rs495522	chr1:21105994	C/T	cg08890418	chr1:21044141	KIF17	0.54	5.27	0.4	4.84e-7	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.59	-5.11	-0.39	9.69e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.74	-0.49	3.31e-10	Caudate activity during reward;
UCEC	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.45	-4.55	-0.35	1.13e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.35	4.71	0.36	5.59e-6	Age of smoking initiation;
UCEC	cis	rs731174	0.797	rs539585	chr1:38148123	T/G	cg12339802	chr1:38156545	C1orf109	-0.61	-5.34	-0.4	3.47e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs883565	0.502	rs9839582	chr3:38943120	G/A	cg01426195	chr3:39028469	NA	0.48	5.36	0.4	3.22e-7	Handedness;
UCEC	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.74	-7.43	-0.52	8.25e-12	Plateletcrit;Platelet count;
UCEC	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.77	0.43	4.48e-8	Breast cancer;
UCEC	cis	rs253959	0.881	rs2416427	chr5:115437676	G/A	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Depression;
UCEC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.82	10.16	0.64	1.04e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg17105886	chr17:28927953	LRRC37B2	0.64	4.7	0.36	5.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8032158	0.702	rs11630780	chr15:56128445	G/T	cg10433327	chr15:56209506	NEDD4	0.3	4.58	0.35	9.85e-6	Keloid;
UCEC	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	4.93	0.38	2.18e-6	Joint mobility (Beighton score);
UCEC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.82	11.12	0.68	3.1e-21	Headache;
UCEC	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.79	6.04	0.45	1.19e-8	Body mass index;
UCEC	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.06	-0.39	1.22e-6	Dilated cardiomyopathy;
UCEC	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.5	5.11	0.39	1.01e-6	Glaucoma;
UCEC	cis	rs9831754	0.704	rs6774325	chr3:78458727	G/A	cg06138941	chr3:78371609	NA	-0.68	-5.05	-0.38	1.31e-6	Calcium levels;
UCEC	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg07169764	chr2:136633963	MCM6	-0.51	-4.62	-0.36	8.33e-6	Colorectal cancer;
UCEC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.91	4.76	0.37	4.6e-6	Diabetic retinopathy;
UCEC	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.07	0.39	1.19e-6	Height;
UCEC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.68	-8.21	-0.56	1.04e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.51	5.52	0.41	1.49e-7	Alcohol dependence;
UCEC	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.6	5.99	0.44	1.53e-8	Lung cancer;
UCEC	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.48	5.63	0.42	9.01e-8	Aortic root size;
UCEC	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.95	-14.71	-0.77	1.09e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.73	-7.07	-0.5	5.71e-11	Ulcerative colitis;
UCEC	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.63	6.93	0.5	1.23e-10	Neuroticism;
UCEC	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg22166914	chr1:53195759	ZYG11B	0.78	8.35	0.57	4.7e-14	Monocyte count;
UCEC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.64	6.27	0.46	3.73e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs4478037	1.000	rs58864038	chr3:33161355	G/A	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs11169225	1.000	rs7299924	chr12:50348961	A/G	cg04450003	chr12:50355995	AQP5	0.85	5.95	0.44	1.89e-8	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-1.03	-6.54	-0.47	9.59e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg16576597	chr16:28551801	NUPR1	0.35	4.99	0.38	1.68e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs72700829	0.507	rs11204766	chr1:151018060	G/C	cg00107782	chr1:151300621	NA	-0.69	-4.57	-0.35	1.01e-5	Schizophrenia;
UCEC	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.35	4.52	0.35	1.27e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.96	12.05	0.7	1.07e-23	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.68	5.76	0.43	4.77e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.79	-7.7	-0.54	1.82e-12	Parkinson's disease;
UCEC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg09381666	chr16:88757816	NA	-0.47	-4.58	-0.35	9.98e-6	Autism spectrum disorder-related traits;
UCEC	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.4	-0.41	2.62e-7	Morning vs. evening chronotype;
UCEC	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.08	0.5	5.48e-11	Motion sickness;
UCEC	cis	rs7607369	0.559	rs4674342	chr2:219660064	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-5.09	-0.39	1.06e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg22563815	chr15:78856949	CHRNA5	-0.36	-4.87	-0.37	2.8e-6	Sudden cardiac arrest;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg07838603	chr6:28411030	ZSCAN23	0.51	5.96	0.44	1.77e-8	Pubertal anthropometrics;
UCEC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.65	0.36	7.34e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg18490616	chr2:88469792	THNSL2	-0.9	-4.83	-0.37	3.38e-6	Plasma clusterin levels;
UCEC	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.71	-6.26	-0.46	4e-9	Initial pursuit acceleration;
UCEC	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.63	5.7	0.43	6.41e-8	Obesity (extreme);
UCEC	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.71	-0.36	5.73e-6	Bipolar disorder;
UCEC	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.82	-0.37	3.52e-6	Mood instability;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.36	-0.46	2.42e-9	Pubertal anthropometrics;
UCEC	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.49	-5.0	-0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.519	rs7606947	chr2:73909818	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-4.71	-0.36	5.61e-6	Metabolite levels;
UCEC	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.82	0.37	3.6e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs10242455	0.764	rs2740564	chr7:99295693	T/C	cg07715041	chr7:99302981	CYP3A7	-0.47	-4.83	-0.37	3.33e-6	Blood metabolite levels;
UCEC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.8	-0.37	3.94e-6	Joint mobility (Beighton score);
UCEC	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.71	0.43	6.13e-8	Rheumatoid arthritis;
UCEC	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24308560	chr3:49941425	MST1R	0.54	6.2	0.46	5.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.5	8.05	0.55	2.64e-13	Airflow obstruction;
UCEC	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.42	0.41	2.42e-7	Neutrophil percentage of white cells;
UCEC	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.64	-5.82	-0.43	3.61e-8	Corneal astigmatism;
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg01874867	chr7:94954059	PON1	-0.55	-5.19	-0.39	6.97e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.53	-0.41	1.45e-7	Hemoglobin concentration;
UCEC	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg14353649	chr10:135191496	PAOX	0.53	5.24	0.4	5.57e-7	Lifespan;
UCEC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	18.22	0.83	1.57e-39	IgG glycosylation;
UCEC	cis	rs60311166	1.000	rs34173244	chr3:52668776	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	4.71	0.36	5.76e-6	CTACK levels;
UCEC	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.59	5.64	0.42	8.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs631288	0.793	rs6681716	chr1:146707824	A/C	cg25205988	chr1:146714368	CHD1L	0.63	4.98	0.38	1.77e-6	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	6.15	0.45	6.95e-9	Personality dimensions;
UCEC	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.87	-6.85	-0.49	1.85e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg03146154	chr1:46216737	IPP	-0.51	-5.42	-0.41	2.42e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.85	9.11	0.6	5.68e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.932	rs4932800	chr19:23051648	G/A	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.673	rs407989	chr19:22991586	C/G	cg24889512	chr19:22816950	ZNF492	-0.54	-5.11	-0.39	9.9e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg09120320	chr17:61926383	NA	0.44	4.59	0.35	9.52e-6	Prudent dietary pattern;
UCEC	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.7	7.34	0.52	1.33e-11	Schizophrenia;
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg21856205	chr7:94953877	PON1	0.54	5.2	0.39	6.49e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.52	-0.47	1.05e-9	Total cholesterol levels;
UCEC	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.5	-6.73	-0.49	3.46e-10	Eye color traits;
UCEC	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	4.68	0.36	6.33e-6	Educational attainment;
UCEC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-7.49	-0.53	5.94e-12	Initial pursuit acceleration;
UCEC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.72	8.77	0.59	4.15e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6666258	1.000	rs34106427	chr1:154813988	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	0.62	4.81	0.37	3.68e-6	Atrial fibrillation;
UCEC	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.59	-5.94	-0.44	1.96e-8	Testicular germ cell tumor;
UCEC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.71	-7.32	-0.52	1.54e-11	Tonsillectomy;
UCEC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.88	9.7	0.62	1.63e-17	Cognitive function;
UCEC	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.74	7.37	0.52	1.13e-11	Caffeine consumption;
UCEC	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg23752985	chr2:85803571	VAMP8	0.43	4.64	0.36	7.78e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.5	4.94	0.38	2.12e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.79	-0.43	4.02e-8	Breast cancer;
UCEC	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.41	4.7	0.36	5.94e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.9	-0.37	2.48e-6	Breast cancer;
UCEC	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.75	-5.17	-0.39	7.36e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg00266579	chr16:28619858	SULT1A1	0.63	4.57	0.35	1.05e-5	Platelet distribution width;
UCEC	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg19610905	chr11:61596333	FADS2	-0.75	-7.52	-0.53	5.06e-12	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	5.01	0.38	1.56e-6	Breast cancer;
UCEC	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.82	-8.96	-0.59	1.36e-15	Homoarginine levels;
UCEC	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.47	4.59	0.35	9.5e-6	Motion sickness;
UCEC	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	13.03	0.73	2.72e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.59	5.69	0.43	6.56e-8	Type 2 diabetes;
UCEC	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.59	-6.7	-0.48	4.16e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.86	-0.44	2.93e-8	Platelet count;
UCEC	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg15229765	chr7:158739774	NA	0.66	4.59	0.35	9.4e-6	Height;
UCEC	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.41	-4.69	-0.36	6.15e-6	Post bronchodilator FEV1;
UCEC	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.6	5.97	0.44	1.69e-8	Orofacial clefts;
UCEC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.77	-6.78	-0.49	2.68e-10	Initial pursuit acceleration;
UCEC	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs3026445	0.832	rs7975364	chr12:110602275	A/T	cg12870014	chr12:110450643	ANKRD13A	0.44	4.67	0.36	6.65e-6	QT interval;
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.49	5.08	0.39	1.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.7	7.89	0.55	6.5e-13	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs847649	0.961	rs7456502	chr7:102596022	C/A	cg18108683	chr7:102477205	FBXL13	0.63	8.01	0.55	3.2e-13	Morning vs. evening chronotype;
UCEC	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs6893207	1.000	rs80326742	chr5:16405647	A/C	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs34486957	0.600	rs7141565	chr14:60043572	G/C	cg12189551	chr14:60952945	C14orf39	0.36	4.52	0.35	1.27e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg10503236	chr1:231470652	EXOC8	-0.39	-4.6	-0.35	8.92e-6	Hemoglobin concentration;
UCEC	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg21770322	chr7:97807741	LMTK2	0.54	6.77	0.49	2.82e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.49	-4.63	-0.36	8e-6	Schizophrenia;
UCEC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.78e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	0.53	5.98	0.44	1.6e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-6.83	-0.49	2.07e-10	IgG glycosylation;
UCEC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg26441486	chr22:50317300	CRELD2	0.75	5.13	0.39	9e-7	Schizophrenia;
UCEC	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.58e-8	Electrocardiographic conduction measures;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.76	8.52	0.58	1.72e-14	Menarche (age at onset);
UCEC	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.45	-0.41	2.04e-7	Bipolar disorder;
UCEC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.55	-5.06	-0.39	1.24e-6	Serum sulfate level;
UCEC	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.65	-0.36	7.2e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.17	0.45	6.23e-9	Menarche (age at onset);
UCEC	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-7.49	-0.53	5.88e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.6	-4.6	-0.35	8.97e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.42	5.02	0.38	1.49e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.6	6.48	0.47	1.33e-9	Post bronchodilator FEV1;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.45	-4.93	-0.38	2.23e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.52	-5.86	-0.44	2.95e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	1.15	5.9	0.44	2.35e-8	LDL cholesterol;
UCEC	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26002218	chr14:103986227	CKB	-0.33	-4.66	-0.36	6.94e-6	Body mass index;
UCEC	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-4.56	-0.35	1.08e-5	Homocysteine levels;
UCEC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12516959	chr21:47718080	NA	-0.41	-4.66	-0.36	7.07e-6	Testicular germ cell tumor;
UCEC	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.57	5.27	0.4	4.85e-7	Multiple sclerosis;
UCEC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.79	8.77	0.59	4.15e-15	Body mass index (adult);
UCEC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.43	5.12	0.39	9.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.65	0.36	7.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg02160872	chr5:212506	CCDC127	-0.7	-7.17	-0.51	3.38e-11	Breast cancer;
UCEC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg20965017	chr5:231967	SDHA	-0.62	-5.64	-0.42	8.48e-8	Breast cancer;
UCEC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.93	-0.44	2.03e-8	Tonsillectomy;
UCEC	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	10.18	0.64	9.29e-19	Electrocardiographic conduction measures;
UCEC	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.36	-0.76	9.02e-30	Schizophrenia;
UCEC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg05738196	chr6:26577821	NA	0.58	6.27	0.46	3.89e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	0.97	6.9	0.49	1.44e-10	Mean corpuscular volume;
UCEC	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.29	0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.38	4.63	0.36	8.08e-6	Refractive error;
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg00035636	chr13:21900591	NA	0.41	4.54	0.35	1.15e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.57	0.77	2.48e-30	Height;
UCEC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.99	14.85	0.77	4.68e-31	Bone mineral density;
UCEC	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs11671007	1	rs11671007	chr19:2893405	A/G	cg08634464	chr19:2901147	ZNF57	-1.16	-9.1	-0.6	6.04e-16	Daytime sleep phenotypes;
UCEC	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.28	12.07	0.71	9.43e-24	Corneal structure;
UCEC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg03146154	chr1:46216737	IPP	0.5	5.42	0.41	2.42e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.43	-4.64	-0.36	7.75e-6	Cardiac Troponin-T levels;
UCEC	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.99	-0.76	8.29e-29	Schizophrenia;
UCEC	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.48	-5.26	-0.4	4.94e-7	Longevity;
UCEC	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-0.95	-6.94	-0.5	1.18e-10	Alzheimer's disease (late onset);
UCEC	cis	rs13095912	1.000	rs36066570	chr3:185314454	C/A	cg11274856	chr3:185301563	NA	0.55	7.29	0.52	1.77e-11	Systolic blood pressure;
UCEC	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg24903633	chr5:55946094	NA	-0.45	-4.67	-0.36	6.76e-6	Coronary artery disease;
UCEC	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.7	-7.36	-0.52	1.18e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs10503871	0.761	rs2979531	chr8:30383013	A/G	cg26383811	chr8:30366931	RBPMS	-0.49	-5.06	-0.39	1.21e-6	Metabolite levels  (X-11787);
UCEC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.45	-0.47	1.49e-9	Aortic root size;
UCEC	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.71	7.97	0.55	4.06e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.6	5.13	0.39	8.9e-7	Phospholipid levels (plasma);
UCEC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-8.21	-0.56	1.06e-13	Heart rate;
UCEC	cis	rs11133665	1.000	rs11133665	chr5:1188285	G/A	cg16624210	chr5:671434	TPPP	-0.47	-4.69	-0.36	6.08e-6	Urinary metabolites;
UCEC	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.42	5.96	0.44	1.82e-8	Superior crus of antihelix expression;
UCEC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.57	-5.79	-0.43	4.16e-8	Bipolar disorder;
UCEC	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.6	6.67	0.48	4.87e-10	QRS complex (12-leadsum);
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	7.64	0.53	2.62e-12	Platelet count;
UCEC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.82	0.49	2.17e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.7	6.37	0.46	2.34e-9	Breast cancer;
UCEC	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.82	8.85	0.59	2.61e-15	Dental caries;
UCEC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.65	5.71	0.43	6.01e-8	Cognitive function;
UCEC	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.62	6.44	0.47	1.61e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.29	-0.4	4.29e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.41	4.78	0.37	4.26e-6	Homocysteine levels;
UCEC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.64	-6.2	-0.46	5.49e-9	Aortic root size;
UCEC	cis	rs8105895	0.935	rs8110975	chr19:22240233	C/G	cg24072202	chr19:22235272	ZNF257	-0.59	-5.06	-0.39	1.22e-6	Body mass index (change over time);
UCEC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-6.23	-0.46	4.77e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg01179851	chr18:76746274	SALL3	-0.5	-4.55	-0.35	1.1e-5	Opioid sensitivity;
UCEC	cis	rs17789174	0.855	rs62049872	chr16:85090257	C/T	cg02758499	chr16:85682440	KIAA0182	0.51	4.63	0.36	8.02e-6	Dysphagia;
UCEC	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.57	6.27	0.46	3.81e-9	Crohn's disease;
UCEC	cis	rs7215564	0.908	rs34710385	chr17:78676494	G/A	cg01369328	chr17:79479832	ACTG1	-0.56	-4.59	-0.35	9.36e-6	Myopia (pathological);
UCEC	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.86	-11.04	-0.67	5e-21	White blood cell count (basophil);
UCEC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.49	4.67	0.36	6.76e-6	Menopause (age at onset);
UCEC	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-10.38	-0.65	2.85e-19	Blood metabolite levels;
UCEC	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-7.27	-0.51	1.97e-11	Eye color traits;
UCEC	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.63	5.65	0.42	8.21e-8	Parkinson's disease;
UCEC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.66	4.94	0.38	2.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg20965017	chr5:231967	SDHA	-0.58	-5.16	-0.39	7.98e-7	Breast cancer;
UCEC	cis	rs6446731	0.517	rs2798221	chr4:3270488	T/C	cg08886695	chr4:3369023	RGS12	0.43	4.93	0.38	2.22e-6	Mean platelet volume;
UCEC	cis	rs17122693	0.748	rs72681609	chr14:51117376	A/G	cg04730355	chr14:51134070	SAV1	0.99	10.13	0.64	1.25e-18	Cognitive performance;
UCEC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.75	8.07	0.55	2.26e-13	Sudden cardiac arrest;
UCEC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.86e-15	Blood protein levels;
UCEC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.52	4.8	0.37	3.8e-6	Menopause (age at onset);
UCEC	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.55	-0.42	1.31e-7	Body mass index;
UCEC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.98	-0.44	1.65e-8	Breast cancer;
UCEC	cis	rs394563	0.775	rs399673	chr6:149783221	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.41	-5.02	-0.38	1.48e-6	Dupuytren's disease;
UCEC	cis	rs6684428	0.706	rs10493187	chr1:56320969	C/T	cg11651538	chr1:56320950	NA	-0.76	-6.66	-0.48	5.2e-10	Airflow obstruction;
UCEC	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.12	0.68	3.14e-21	Corneal structure;
UCEC	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	5.52	0.41	1.48e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg03060546	chr3:49711283	APEH	-0.57	-5.33	-0.4	3.64e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.55	6.12	0.45	8.28e-9	Aortic root size;
UCEC	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-4.82	-0.37	3.52e-6	Blood metabolite levels;
UCEC	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.57	7.23	0.51	2.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.66	6.73	0.49	3.63e-10	Coronary artery disease;
UCEC	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg24130564	chr14:104152367	KLC1	-0.53	-4.53	-0.35	1.2e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.54	-4.52	-0.35	1.27e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg19743168	chr1:23544995	NA	0.44	6.3	0.46	3.31e-9	Height;
UCEC	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.56	0.42	1.21e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.17e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.5	0.41	1.61e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg16797656	chr11:68205561	LRP5	0.48	5.45	0.41	2.03e-7	Total body bone mineral density;
UCEC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.6	-5.74	-0.43	5.31e-8	Schizophrenia;
UCEC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-4.95	-0.38	1.99e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13401104	0.786	rs11677411	chr2:237110028	T/C	cg23897927	chr2:237117786	ASB18	-0.51	-4.54	-0.35	1.14e-5	Educational attainment;
UCEC	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.57	6.18	0.45	6.12e-9	Red blood cell count;
UCEC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.08	13.47	0.74	1.88e-27	Cognitive function;
UCEC	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.66	-7.66	-0.53	2.33e-12	Headache;
UCEC	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.24e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12618769	0.597	rs1587835	chr2:99041269	A/C	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.36	5.05	0.38	1.26e-6	Fat distribution (HIV);
UCEC	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.54	-4.61	-0.36	8.6e-6	Schizophrenia;
UCEC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.75	8.33	0.57	5.16e-14	Coronary artery disease;
UCEC	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	17.83	0.83	1.43e-38	Schizophrenia;
UCEC	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg18681998	chr4:17616180	MED28	0.66	6.0	0.44	1.44e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg06157570	chr12:6886703	LAG3	-0.53	-5.33	-0.4	3.56e-7	HDL cholesterol levels;
UCEC	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-6.25	-0.46	4.17e-9	Hemoglobin concentration;
UCEC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.66	6.03	0.45	1.24e-8	Menarche (age at onset);
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.58	-0.48	7.8e-10	Cardiac Troponin-T levels;
UCEC	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-6.36	-0.46	2.37e-9	Morning vs. evening chronotype;
UCEC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs9309473	0.950	rs13391258	chr2:73848933	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-4.84	-0.37	3.26e-6	Metabolite levels;
UCEC	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.47	4.6	0.35	9.02e-6	Colorectal cancer;
UCEC	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.62	5.02	0.38	1.49e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.57	4.81	0.37	3.68e-6	Neutrophil percentage of white cells;
UCEC	trans	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg02022102	chr7:27168609	HOXA4	0.6	6.79	0.49	2.6200000000000003e-10	Protein biomarker;
UCEC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.51	5.47	0.41	1.91e-7	Schizophrenia;
UCEC	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.42	-4.8	-0.37	3.9e-6	Schizophrenia;
UCEC	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.7	-0.43	6.3e-8	Mortality in heart failure;
UCEC	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11584989	chr19:19387371	SF4	0.58	6.67	0.48	4.78e-10	Bipolar disorder;
UCEC	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.25	-0.4	5.19e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.58	-6.17	-0.45	6.44e-9	Prostate cancer;
UCEC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.33	4.62	0.36	8.27e-6	Crohn's disease;
UCEC	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs4588572	0.643	rs1529499	chr5:77721431	T/C	cg11547950	chr5:77652471	NA	-0.44	-4.97	-0.38	1.87e-6	Triglycerides;
UCEC	cis	rs953387	0.910	rs16833335	chr2:136949744	C/T	cg07169764	chr2:136633963	MCM6	0.51	5.06	0.39	1.21e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.65	7.3	0.52	1.68e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.43	4.88	0.37	2.76e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.66	-6.43	-0.47	1.64e-9	Metabolite levels;
UCEC	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-7.91	-0.55	5.7e-13	Colorectal cancer;
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.89	0.59	2.07e-15	Prudent dietary pattern;
UCEC	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.77	7.77	0.54	1.28e-12	Ulcerative colitis;
UCEC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	10.63	0.66	6.27e-20	Colorectal cancer;
UCEC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.44	6.11	0.45	8.62e-9	Electrocardiographic conduction measures;
UCEC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg02413938	chr2:239008929	ESPNL	-0.36	-4.64	-0.36	7.64e-6	Prostate cancer;
UCEC	cis	rs7246967	0.673	rs2361260	chr19:22914144	C/T	cg08271804	chr19:22816896	ZNF492	-0.66	-6.44	-0.47	1.59e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg03711944	chr11:47377212	SPI1	0.51	4.58	0.35	9.8200000000000008e-06	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg08222913	chr3:52553049	STAB1	-0.45	-5.24	-0.4	5.42e-7	Cognitive function;
UCEC	cis	rs2629540	0.586	rs10794183	chr10:126536609	G/C	cg08799069	chr10:126477246	METTL10	-0.69	-6.27	-0.46	3.88e-9	Cocaine dependence;
UCEC	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.87	-0.44	2.75e-8	Hemoglobin concentration;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.46	-5.4	-0.41	2.63e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.78	7.31	0.52	1.54e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.5	5.3	0.4	4.18e-7	Aortic root size;
UCEC	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.63	-6.57	-0.48	8.3e-10	Sudden cardiac arrest;
UCEC	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg04374321	chr14:90722782	PSMC1	0.56	4.76	0.37	4.66e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.52	7.99	0.55	3.65e-13	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg18230493	chr5:56204884	C5orf35	-0.52	-4.59	-0.35	9.43e-6	Coronary artery disease;
UCEC	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.49	-5.2	-0.39	6.43e-7	Crohn's disease;
UCEC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg10965384	chr11:64119977	CCDC88B	0.37	4.52	0.35	1.28e-5	Platelet count;
UCEC	cis	rs7709377	0.595	rs13179593	chr5:115440772	A/G	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.62	-7.88	-0.55	6.65e-13	Fibrinogen levels;
UCEC	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	1.04	11.72	0.69	8.32e-23	Alcohol dependence;
UCEC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.7	0.36	5.93e-6	Breast cancer;
UCEC	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.37	4.84	0.37	3.27e-6	Dupuytren's disease;
UCEC	cis	rs12681287	0.711	rs28506490	chr8:87246118	T/C	cg27223183	chr8:87520930	FAM82B	-0.56	-4.73	-0.36	5.13e-6	Caudate activity during reward;
UCEC	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12516959	chr21:47718080	NA	-0.49	-5.14	-0.39	8.63e-7	Testicular germ cell tumor;
UCEC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.48	5.26	0.4	5e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs17639063	0.737	rs9853256	chr3:62529509	G/A	cg04329977	chr3:61546343	PTPRG	-0.96	-5.26	-0.4	5e-7	QT interval (sulfonylurea treatment interaction);
UCEC	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-6.41	-0.47	1.86e-9	Platelet count;
UCEC	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.5	0.62	5.4e-17	Coffee consumption (cups per day);
UCEC	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.2	-0.6	3.34e-16	Lung cancer;
UCEC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	0.93	10.14	0.64	1.2e-18	IgG glycosylation;
UCEC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.55	-5.46	-0.41	1.99e-7	Aortic root size;
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	4.98e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg14289826	chr9:140003911	NA	0.4	5.46	0.41	1.99e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.74	0.58	4.85e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.71	-7.91	-0.55	5.58e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.68	5.65	0.42	7.99e-8	Alcohol dependence;
UCEC	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.4	4.87	0.37	2.8e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.87	9.9	0.63	5.12e-18	Monocyte count;
UCEC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.69	-6.92	-0.5	1.28e-10	Tonsillectomy;
UCEC	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg01451880	chr3:45801044	SLC6A20	-0.37	-4.53	-0.35	1.19e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg03859395	chr2:55845619	SMEK2	0.97	13.95	0.75	1.04e-28	Metabolic syndrome;
UCEC	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.79	7.9	0.55	5.88e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg19554555	chr3:13937349	NA	-0.51	-5.25	-0.4	5.11e-7	Ovarian reserve;
UCEC	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.42	5.11	0.39	9.81e-7	Sitting height ratio;
UCEC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs1441264	1.000	rs1441264	chr13:79580919	C/T	cg08278487	chr13:79177773	POU4F1	0.49	4.73	0.36	5.18e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs72823319	0.606	rs9914342	chr17:37190141	A/G	cg27330720	chr17:37558981	FBXL20	-0.5	-4.54	-0.35	1.14e-5	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.61	0.62	2.9e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg12740337	chr6:28058973	ZSCAN12L1	-0.31	-4.57	-0.35	1.02e-5	Depression;
UCEC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg12253828	chr6:101329408	ASCC3	0.47	4.78	0.37	4.24e-6	Neuroticism;
UCEC	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.08	-0.39	1.14e-6	Depression;
UCEC	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	6.58	0.48	7.74e-10	Electrocardiographic conduction measures;
UCEC	cis	rs7949566	0.535	rs4935965	chr11:126278522	C/T	cg09760666	chr11:125775128	DDX25	0.42	4.55	0.35	1.1e-5	Platelet distribution width;Mean platelet volume;
UCEC	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.37	4.71	0.36	5.7e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.97	0.55	3.99e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.68	-5.62	-0.42	9.08e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.13	-7.33	-0.52	1.39e-11	Diabetic kidney disease;
UCEC	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.77	5.76	0.43	4.69e-8	Exhaled nitric oxide levels;
UCEC	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.57	6.47	0.47	1.34e-9	Vitiligo;
UCEC	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.65	5.31	0.4	3.97e-7	Initial pursuit acceleration;
UCEC	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg10902566	chr4:727664	PCGF3	-0.6	-4.99	-0.38	1.67e-6	Systolic blood pressure;
UCEC	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.56	5.15	0.39	8.42e-7	Metabolite levels;
UCEC	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.71	7.73	0.54	1.58e-12	Paraoxonase activity;
UCEC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Bone mineral density;
UCEC	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg08461772	chr7:95026248	PON3	0.34	4.79	0.37	4.1e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.41	-4.89	-0.37	2.63e-6	Menarche (age at onset);
UCEC	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg17467752	chr17:38218738	THRA	0.71	8.11	0.56	1.83e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg19715936	chr7:50634035	DDC	-0.51	-6.14	-0.45	7.14e-9	Malaria;
UCEC	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg05738196	chr6:26577821	NA	-0.52	-4.71	-0.36	5.71e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.87	-9.62	-0.62	2.75e-17	Menopause (age at onset);
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg01874867	chr7:94954059	PON1	-0.54	-5.1	-0.39	1.03e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	0.97	5.56	0.42	1.22e-7	IgG glycosylation;
UCEC	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg25358565	chr5:93447407	FAM172A	1.05	5.44	0.41	2.2e-7	Diabetic retinopathy;
UCEC	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.7	-5.33	-0.4	3.65e-7	HIV-1 control;
UCEC	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.73	0.43	5.62e-8	Coffee consumption (cups per day);
UCEC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.69	5.93	0.44	2.12e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.65	7.1	0.51	4.95e-11	Homoarginine levels;
UCEC	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.41	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.47	-4.6	-0.35	9.02e-6	Blood protein levels;
UCEC	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	5.96	0.44	1.79e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.72	6.64	0.48	5.57e-10	Aortic root size;
UCEC	cis	rs7246967	0.604	rs8107322	chr19:22897432	A/C	cg24889512	chr19:22816950	ZNF492	0.62	6.68	0.48	4.67e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4588572	0.686	rs10078289	chr5:77670793	T/G	cg11547950	chr5:77652471	NA	0.5	5.08	0.39	1.15e-6	Triglycerides;
UCEC	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.47	5.26	0.4	5.05e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1712517	0.740	rs11191663	chr10:105118462	C/T	cg05636881	chr10:105038444	INA	0.43	5.09	0.39	1.08e-6	Migraine;
UCEC	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.62	4.94	0.38	2.1e-6	Bladder cancer;
UCEC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-4.88	-0.37	2.77e-6	Total cholesterol levels;
UCEC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.73	7.86	0.54	7.46e-13	Lymphocyte counts;
UCEC	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	7.08	0.5	5.43e-11	Coffee consumption (cups per day);
UCEC	cis	rs10849689	1	rs10849689	chr12:110493222	A/G	cg12870014	chr12:110450643	ANKRD13A	0.75	8.34	0.57	4.95e-14	Schizophrenia;
UCEC	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.54	-6.02	-0.44	1.32e-8	Blood metabolite levels;
UCEC	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.68	-7.28	-0.51	1.87e-11	Pubertal anthropometrics;
UCEC	cis	rs970548	0.954	rs72796498	chr10:45982219	C/T	cg15223267	chr10:46222474	FAM21C	0.54	5.15	0.39	8.09e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg02160872	chr5:212506	CCDC127	-0.74	-6.69	-0.48	4.4e-10	Breast cancer;
UCEC	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.75	-8.57	-0.58	1.3e-14	Extraversion;
UCEC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.6	-7.58	-0.53	3.65e-12	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg24069376	chr3:38537580	EXOG	0.49	6.07	0.45	1.05e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11673344	0.864	rs826322	chr19:37504596	A/G	cg08692348	chr19:37642883	ZNF585A	0.43	4.63	0.36	7.9e-6	Obesity-related traits;
UCEC	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg01256987	chr12:42539512	GXYLT1	-0.43	-4.9	-0.37	2.51e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.57	5.55	0.42	1.29e-7	Lymphocyte counts;
UCEC	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.55	5.97	0.44	1.69e-8	P wave terminal force;
UCEC	cis	rs2998286	0.541	rs332180	chr10:28910095	C/T	cg08815081	chr10:28035731	MKX	0.66	4.79	0.37	3.99e-6	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
UCEC	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18932078	chr1:2524107	MMEL1	-0.35	-6.04	-0.45	1.2e-8	Ulcerative colitis;
UCEC	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.61	-4.98	-0.38	1.73e-6	Depression;
UCEC	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg14530993	chr4:882597	GAK	0.7	4.76	0.37	4.51e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg01072550	chr1:21505969	NA	-0.47	-4.6	-0.36	8.87e-6	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.38	-0.41	2.89e-7	Pubertal anthropometrics;
UCEC	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.55	-5.31	-0.4	3.9e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01973587	chr1:228161476	NA	0.36	4.78	0.37	4.27e-6	Diastolic blood pressure;
UCEC	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.63e-7	Life satisfaction;
UCEC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	0.81	6.89	0.49	1.52e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-5.07	-0.39	1.15e-6	Bipolar disorder;
UCEC	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.09	6.29	0.46	3.48e-9	Diabetic retinopathy;
UCEC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.65	6.89	0.49	1.51e-10	Menopause (age at onset);
UCEC	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.52	-5.28	-0.4	4.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg24562669	chr7:97807699	LMTK2	0.47	5.32	0.4	3.84e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.63	-6.24	-0.46	4.4e-9	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.37	5.22	0.4	6.06e-7	Coronary artery disease;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.46	-5.07	-0.39	1.19e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-4.64	-0.36	7.53e-6	Extraversion;
UCEC	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	5.8	0.43	3.88e-8	Personality dimensions;
UCEC	cis	rs10924970	0.649	rs10495361	chr1:235389548	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs75804782	0.630	rs55762325	chr2:239250723	A/G	cg11815105	chr2:239148849	HES6	1.03	4.64	0.36	7.53e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.49	5.66	0.42	7.6e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.17e-14	Prudent dietary pattern;
UCEC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.4	4.71	0.36	5.59e-6	Obesity-related traits;
UCEC	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.56	-5.56	-0.42	1.23e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.6	6.93	0.5	1.2e-10	Hip circumference;
UCEC	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	0.85	5.65	0.42	7.96e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.51	4.99	0.38	1.7e-6	Emphysema distribution in smoking;
UCEC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.7	7.25	0.51	2.19e-11	Menopause (age at onset);
UCEC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg22907277	chr7:1156413	C7orf50	0.55	5.42	0.41	2.35e-7	Longevity;Endometriosis;
UCEC	cis	rs732765	0.734	rs7152804	chr14:75164008	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.7	-0.36	6.04e-6	Non-small cell lung cancer;
UCEC	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.83	-5.37	-0.41	2.97e-7	Putamen volume;
UCEC	cis	rs7560272	0.538	rs12052539	chr2:73937153	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-4.56	-0.35	1.08e-5	Schizophrenia;
UCEC	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.68	6.8	0.49	2.51e-10	Type 2 diabetes;
UCEC	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01391022	chr12:122360665	WDR66	-0.45	-4.64	-0.36	7.76e-6	Mean corpuscular volume;
UCEC	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.57	5.37	0.41	2.94e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.05	0.5	6.39e-11	Eye color traits;
UCEC	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.68	6.94	0.5	1.16e-10	Resting heart rate;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.93	-0.38	2.19e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.45	-4.94	-0.38	2.08e-6	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.54	-5.99	-0.44	1.51e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7870753	0.628	rs10820597	chr9:99188347	C/A	cg25260653	chr9:99212216	HABP4	0.53	4.95	0.38	1.99e-6	Height;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.72	-0.43	5.68e-8	Pubertal anthropometrics;
UCEC	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4499344	0.556	rs259231	chr19:33129067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	6.85	0.49	1.84e-10	Mean platelet volume;
UCEC	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.5	-4.72	-0.36	5.41e-6	Diastolic blood pressure;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg20119798	chr7:94954144	PON1	-0.51	-4.51	-0.35	1.33e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg14254433	chr6:34482411	PACSIN1	-0.64	-4.51	-0.35	1.34e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.47	-5.32	-0.4	3.81e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg14092571	chr14:90743983	NA	-0.43	-5.83	-0.43	3.45e-8	Mortality in heart failure;
UCEC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.28	0.4	4.64e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.64	0.58	8.67e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.64	6.07	0.45	1.04e-8	Selective IgA deficiency;
UCEC	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.49	4.67	0.36	6.63e-6	Vitiligo;
UCEC	cis	rs13191362	0.688	rs73025321	chr6:162974896	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	4.56	0.35	1.08e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.51	-5.56	-0.42	1.21e-7	Aortic root size;
UCEC	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.87	8.76	0.59	4.39e-15	Post bronchodilator FEV1;
UCEC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.6	6.32	0.46	2.91e-9	Initial pursuit acceleration;
UCEC	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.18	0.51	3.23e-11	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs12681287	0.752	rs1436628	chr8:87313345	C/G	cg27223183	chr8:87520930	FAM82B	0.78	6.39	0.47	2.04e-9	Caudate activity during reward;
UCEC	cis	rs7709377	0.595	rs153594	chr5:115635788	T/C	cg23108291	chr5:115420582	COMMD10	-0.53	-5.31	-0.4	4.04e-7	Metabolite levels  (X-11787);
UCEC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg23888215	chr10:79422304	NA	-0.94	-7.51	-0.53	5.4e-12	Bone mineral density;
UCEC	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.88	-12.58	-0.72	4.25e-25	Urate levels in lean individuals;
UCEC	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.44	5.41	0.41	2.54e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.83	8.86	0.59	2.43e-15	Breast cancer;
UCEC	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.58	5.27	0.4	4.76e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	8.47	0.57	2.34e-14	Bipolar disorder;
UCEC	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.79	-9.12	-0.6	5.25e-16	Obesity-related traits;
UCEC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.25e-7	Systemic lupus erythematosus;
UCEC	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.92	-0.59	1.69e-15	Height;
UCEC	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	0.94	7.93	0.55	5.13e-13	Type 2 diabetes nephropathy;
UCEC	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.59	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.07	0.45	1.05e-8	Cognitive test performance;
UCEC	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg03342759	chr3:160939853	NMD3	-0.5	-4.84	-0.37	3.23e-6	Kawasaki disease;
UCEC	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.61	-5.33	-0.4	3.62e-7	Heart rate;
UCEC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg22974920	chr21:40686053	BRWD1	0.56	4.75	0.36	4.78e-6	Cognitive function;
UCEC	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.13	11.05	0.67	4.9e-21	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.64	-7.35	-0.52	1.24e-11	Menarche (age at onset);
UCEC	cis	rs35934224	0.783	rs34675706	chr22:19847618	G/A	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.02	-0.38	1.49e-6	Glaucoma (primary open-angle);
UCEC	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.09	-10.57	-0.66	8.95e-20	Vitiligo;
UCEC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.64	-7.16	-0.51	3.65e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.48	5.29	0.4	4.4e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2075165	0.901	rs2025577	chr1:156314104	T/C	cg20302342	chr1:156215951	PAQR6	0.51	5.2	0.39	6.72e-7	Tonsillectomy;
UCEC	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.88	11.19	0.68	2.1e-21	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-4.73	-0.36	5.11e-6	Hemoglobin concentration;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.45	-5.22	-0.4	5.89e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4372836	0.553	rs6706858	chr2:28992607	C/G	cg09522027	chr2:28974177	PPP1CB	-0.76	-8.39	-0.57	3.63e-14	Body mass index;
UCEC	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg13683864	chr3:40499215	RPL14	1.15	16.85	0.81	3.7e-36	Renal cell carcinoma;
UCEC	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.57	-0.35	1.03e-5	Blood protein levels;
UCEC	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.51	5.11	0.39	9.87e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg07153921	chr17:41440717	NA	0.46	5.14	0.39	8.58e-7	Menopause (age at onset);
UCEC	cis	rs10952927	1.000	rs34884256	chr7:88346154	T/C	cg05683227	chr7:87850031	SRI	-0.53	-4.66	-0.36	7.02e-6	Restless legs syndrome;
UCEC	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.78	0.37	4.21e-6	Bladder cancer;
UCEC	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg03934865	chr2:198174659	NA	-0.41	-5.15	-0.39	8.23e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27286337	chr10:134555280	INPP5A	0.61	5.2	0.39	6.52e-7	Migraine;
UCEC	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.7	8.15	0.56	1.44e-13	Immature fraction of reticulocytes;
UCEC	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg06521331	chr12:34319734	NA	-0.63	-5.0	-0.38	1.64e-6	Morning vs. evening chronotype;
UCEC	cis	rs7633770	0.841	rs6774048	chr3:46702202	C/G	cg11219411	chr3:46661640	NA	0.45	5.41	0.41	2.45e-7	Coronary artery disease;
UCEC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	0.92	6.32	0.46	2.91e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.56	-5.34	-0.4	3.39e-7	Neurofibrillary tangles;
UCEC	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.82	11.19	0.68	2.1e-21	Headache;
UCEC	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.63	-5.22	-0.4	5.9e-7	Blood metabolite levels;
UCEC	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.67	-7.86	-0.54	7.32e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs12973672	1.000	rs8101606	chr19:35774556	A/C	cg12095397	chr19:35769544	USF2	0.45	4.89	0.37	2.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.46	4.62	0.36	8.34e-6	Menarche (age at onset);
UCEC	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.46	-4.6	-0.35	9.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.99	-7.23	-0.51	2.47e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7246967	0.673	rs34376806	chr19:22900861	A/G	cg08271804	chr19:22816896	ZNF492	0.67	6.5	0.47	1.18e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.59	6.41	0.47	1.91e-9	Multiple sclerosis;
UCEC	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.48	5.38	0.41	2.91e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.0	-0.64	2.71e-18	Monocyte count;
UCEC	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs1519814	0.696	rs2326434	chr8:121047798	A/C	cg22335954	chr8:121166405	COL14A1	-0.58	-4.53	-0.35	1.22e-5	Breast cancer;
UCEC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.69	-0.48	4.43e-10	Aortic root size;
UCEC	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg13073564	chr4:8508604	NA	-0.49	-5.34	-0.4	3.5e-7	Response to antineoplastic agents;
UCEC	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg14664628	chr15:75095509	CSK	-0.53	-5.1	-0.39	1.05e-6	Caffeine consumption;
UCEC	cis	rs11697848	1.000	rs2284647	chr20:48526749	A/C	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.54	-5.36	-0.4	3.12e-7	Large artery stroke;
UCEC	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg07636037	chr3:49044803	WDR6	-0.61	-4.82	-0.37	3.61e-6	Menarche (age at onset);
UCEC	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.99	10.99	0.67	6.94e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.08	-0.39	1.11e-6	Colorectal cancer;
UCEC	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.45	-0.47	1.51e-9	Response to antipsychotic treatment;
UCEC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.72	8.39	0.57	3.64e-14	Menopause (age at onset);
UCEC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.72	-4.86	-0.37	2.98e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	5.83	0.43	3.37e-8	Breast cancer;
UCEC	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.69e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-0.92	-8.63	-0.58	9.08e-15	Dilated cardiomyopathy;
UCEC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.42	-4.87	-0.37	2.86e-6	Schizophrenia;
UCEC	cis	rs66573146	1.000	rs73088528	chr4:6967747	G/C	cg00086871	chr4:6988644	TBC1D14	0.75	4.96	0.38	1.93e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg24060327	chr5:131705240	SLC22A5	0.5	4.74	0.36	4.96e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.61	5.7	0.43	6.37e-8	Type 2 diabetes;
UCEC	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs16937	0.711	rs10900470	chr1:205168614	C/T	cg12580275	chr1:205744413	RAB7L1	0.48	5.1	0.39	1.03e-6	Schizophrenia;
UCEC	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.54	-5.39	-0.41	2.8e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg01874867	chr7:94954059	PON1	-0.54	-5.1	-0.39	1.03e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs55670112	0.935	rs1453018	chr5:114270145	C/T	cg05461448	chr5:114880715	FEM1C	-0.45	-4.63	-0.36	7.9e-6	Epilepsy;
UCEC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	6.21	0.46	5.08e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.62	-0.36	8.37e-6	Blood metabolite levels;
UCEC	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.74	6.18	0.45	6.06e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs12618769	0.625	rs113342082	chr2:99034198	G/A	cg14361474	chr2:99058762	NA	-0.48	-4.77	-0.37	4.31e-6	Bipolar disorder;
UCEC	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg15513719	chr13:114904418	NA	0.49	4.97	0.38	1.87e-6	Schizophrenia;
UCEC	cis	rs10924970	0.649	rs10925099	chr1:235366902	C/A	cg26050004	chr1:235667680	B3GALNT2	0.51	4.78	0.37	4.3e-6	Asthma;
UCEC	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.43	-4.53	-0.35	1.19e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.7	-6.65	-0.48	5.29e-10	HDL cholesterol;
UCEC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg23782820	chr8:58130467	NA	0.5	4.69	0.36	6.07e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg14092571	chr14:90743983	NA	0.44	5.23	0.4	5.74e-7	Mortality in heart failure;
UCEC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.98	-0.5	9.46e-11	Tonsillectomy;
UCEC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	7.99	0.55	3.64e-13	Prudent dietary pattern;
UCEC	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.6	-5.25	-0.4	5.23e-7	Metabolite levels;
UCEC	cis	rs6761276	0.899	rs11693750	chr2:113835602	C/T	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs10924970	0.649	rs4659676	chr1:235396577	A/C	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.59	-5.78	-0.43	4.24e-8	White matter hyperintensity burden;
UCEC	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.47	-5.66	-0.42	7.76e-8	Subjective well-being;
UCEC	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.69	7.95	0.55	4.5e-13	Breast cancer;
UCEC	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg13695892	chr22:41940480	POLR3H	-0.66	-5.15	-0.39	8.25e-7	Vitiligo;
UCEC	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.85	-0.37	3.06e-6	Breast cancer;
UCEC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.65	-0.48	5.37e-10	Aortic root size;
UCEC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.62	-6.54	-0.47	9.45e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08822215	chr16:89438651	ANKRD11	0.46	4.64	0.36	7.57e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.01	-6.55	-0.48	8.96e-10	Diabetic kidney disease;
UCEC	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs7302981	0.667	rs7308692	chr12:50627654	C/T	cg20014596	chr12:50898483	DIP2B	-0.46	-4.72	-0.36	5.41e-6	Systolic blood pressure;
UCEC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg18681998	chr4:17616180	MED28	0.67	6.45	0.47	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs36051895	0.664	rs9695933	chr9:5153104	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-5.02	-0.38	1.46e-6	Pediatric autoimmune diseases;
UCEC	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.41	0.47	1.88e-9	Coffee consumption (cups per day);
UCEC	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-0.84	-4.72	-0.36	5.34e-6	Inflammatory biomarkers;
UCEC	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.53	5.96	0.44	1.81e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.75	0.43	5.04e-8	Breast cancer;
UCEC	cis	rs9400271	0.527	rs11759230	chr6:109640321	A/C	cg01475377	chr6:109611718	NA	0.45	5.0	0.38	1.6e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.65	8.02	0.55	3.07e-13	Bone mineral density;
UCEC	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.02	0.38	1.46e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07741184	chr6:167504864	NA	-0.32	-4.59	-0.35	9.31e-6	Primary biliary cholangitis;
UCEC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg23950597	chr19:37808831	NA	0.6	4.69	0.36	6.17e-6	Coronary artery calcification;
UCEC	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.69	-8.21	-0.56	1.05e-13	Blood trace element (Zn levels);
UCEC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.63	0.36	8.1e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg05738196	chr6:26577821	NA	0.59	5.91	0.44	2.34e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	5.95	0.44	1.88e-8	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.61	7.39	0.52	1.04e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.56	5.19	0.39	7e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.93	10.1	0.64	1.5e-18	Cognitive function;
UCEC	cis	rs12681963	0.748	rs10088714	chr8:29892151	C/T	cg07899425	chr8:30585046	GSR	0.57	5.08	0.39	1.15e-6	Migraine;
UCEC	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.99	0.84	2.16e-41	Schizophrenia;
UCEC	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.67	6.47	0.47	1.37e-9	Obesity;Body mass index;
UCEC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.23e-7	Prudent dietary pattern;
UCEC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.54	-5.54	-0.42	1.37e-7	Schizophrenia;
UCEC	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.52	4.63	0.36	7.96e-6	Protein C levels;
UCEC	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.55	5.67	0.42	7.27e-8	Pediatric autoimmune diseases;
UCEC	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-0.79	-8.54	-0.58	1.53e-14	Height;
UCEC	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.56	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.56	4.93	0.38	2.16e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.72	7.45	0.52	7.16e-12	Parkinson's disease;
UCEC	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.71	5.0	0.38	1.62e-6	Lymphocyte counts;
UCEC	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.67	6.36	0.46	2.41e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.63	5.79	0.43	4.12e-8	Major depressive disorder;
UCEC	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg01072550	chr1:21505969	NA	-0.51	-5.01	-0.38	1.51e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.52	5.71	0.43	5.95e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	18.39	0.83	5.87e-40	Colorectal cancer;
UCEC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.54	4.8	0.37	3.78e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-6.89	-0.49	1.49e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.61	0.36	8.76e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	9.42	0.61	8.67e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs1324913	1.000	rs9573345	chr13:74640009	C/G	cg13696283	chr13:74707153	KLF12	-0.43	-4.84	-0.37	3.19e-6	Menarche (age at onset);
UCEC	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.14	0.71	6.4e-24	Prudent dietary pattern;
UCEC	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.69	6.81	0.49	2.31e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	0.73	7.59	0.53	3.34e-12	Breast cancer;
UCEC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-4.73	-0.36	5.18e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.51	4.79	0.37	3.98e-6	Intelligence;Intelligence (multi-trait analysis);
UCEC	cis	rs6546886	0.912	rs10200470	chr2:74284687	A/G	cg14702570	chr2:74259524	NA	-0.42	-5.23	-0.4	5.83e-7	Dialysis-related mortality;
UCEC	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.48	5.32	0.4	3.73e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs151997	1.000	rs32483	chr5:50205230	C/T	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	5.22	0.4	6.12e-7	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.23	0.61	2.82e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	4.85	0.37	3.12e-6	Menarche (age at onset);
UCEC	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.6	5.23	0.4	5.8e-7	Corneal astigmatism;
UCEC	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	0.88	5.76	0.43	4.79e-8	Arsenic metabolism;
UCEC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg18653534	chr16:772142	FAM173A	-0.47	-5.57	-0.42	1.19e-7	Height;
UCEC	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.57	4.73	0.36	5.14e-6	Lung cancer;
UCEC	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.61	5.59	0.42	1.1e-7	Major depressive disorder;
UCEC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.55	0.35	1.1e-5	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.96	-0.38	1.9e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.76	8.02	0.55	3.09e-13	Breast cancer;
UCEC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.14	-0.39	8.7e-7	Dupuytren's disease;
UCEC	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.32	4.95	0.38	2.03e-6	Cancer;
UCEC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.53	-5.68	-0.42	6.94e-8	Vitiligo;
UCEC	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.22	6.5	0.47	1.15e-9	Schizophrenia;
UCEC	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg23260525	chr10:116636907	FAM160B1	0.33	4.53	0.35	1.23e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg24011408	chr12:48396354	COL2A1	0.53	4.67	0.36	6.85e-6	Lung cancer;
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.09	17.42	0.82	1.41e-37	Schizophrenia;
UCEC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg03146154	chr1:46216737	IPP	0.46	4.81	0.37	3.65e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.54	4.61	0.36	8.75e-6	Response to diuretic therapy;
UCEC	cis	rs4889855	0.614	rs6565694	chr17:78501101	T/C	cg16591659	chr17:78472290	NA	-0.43	-4.51	-0.35	1.33e-5	Fractional excretion of uric acid;
UCEC	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.62	5.59	0.42	1.07e-7	Coronary artery disease;
UCEC	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg19197139	chr17:4613644	ARRB2	0.81	6.1	0.45	8.9e-9	Lymphocyte counts;
UCEC	cis	rs4588572	0.686	rs67689570	chr5:77676843	T/C	cg11547950	chr5:77652471	NA	0.49	5.25	0.4	5.14e-7	Triglycerides;
UCEC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.65	-6.27	-0.46	3.77e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.57	-4.89	-0.37	2.6e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7937612	1.000	rs1373270	chr11:120324080	G/A	cg12584626	chr11:120203529	NA	0.49	4.75	0.36	4.82e-6	Intraocular pressure;
UCEC	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg21191810	chr6:118973309	C6orf204	0.38	5.33	0.4	3.61e-7	Electrocardiographic conduction measures;
UCEC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.59	0.42	1.05e-7	Monocyte percentage of white cells;
UCEC	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.19	0.45	5.56e-9	Rheumatoid arthritis;
UCEC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.14	18.7	0.84	1.07e-40	Testicular germ cell tumor;
UCEC	cis	rs11811982	0.793	rs11803919	chr1:227228955	G/A	cg12615916	chr1:227505854	CDC42BPA	0.8	5.71	0.43	6.19e-8	Optic disc area;
UCEC	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.87	-10.91	-0.67	1.11e-20	Brugada syndrome;
UCEC	cis	rs9467773	1.000	rs1570061	chr6:26575986	T/C	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2302190	0.882	rs6503859	chr17:56460852	C/G	cg12560992	chr17:57184187	TRIM37	0.54	4.88	0.37	2.68e-6	Vitamin D levels;
UCEC	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg05673287	chr15:77411982	SGK269	-0.44	-4.54	-0.35	1.18e-5	Type 2 diabetes;
UCEC	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	8.21	0.56	1.02e-13	Caffeine consumption;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.46	-4.71	-0.36	5.66e-6	Parkinson's disease;
UCEC	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.37	-4.64	-0.36	7.74e-6	Bone mineral density (spine);
UCEC	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg00325661	chr8:49890786	NA	0.57	5.94	0.44	1.95e-8	Sudden cardiac arrest;
UCEC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg00339695	chr16:24857497	SLC5A11	-0.45	-5.5	-0.41	1.66e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.25	0.51	2.18e-11	Response to antipsychotic treatment;
UCEC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.81	7.9	0.55	6.17e-13	Cognitive function;
UCEC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg23307798	chr14:103986281	CKB	0.65	7.94	0.55	4.86e-13	Body mass index;
UCEC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Bipolar disorder;
UCEC	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg19500275	chr17:80737654	TBCD	0.48	4.86	0.37	2.95e-6	Glycated hemoglobin levels;
UCEC	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg20387954	chr3:183756860	HTR3D	0.48	5.74	0.43	5.2e-8	Anterior chamber depth;
UCEC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.3	-4.52	-0.35	1.26e-5	Ulcerative colitis;
UCEC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.6	0.48	7.02e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.12	11.87	0.7	3.29e-23	Opioid sensitivity;
UCEC	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.42	4.63	0.36	7.91e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.46	4.79	0.37	4.07e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs692916	0.740	rs599881	chr18:60548877	A/G	cg07187971	chr18:60481018	PHLPP1	-0.38	-4.66	-0.36	7.05e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.24	-7.74	-0.54	1.48e-12	Diabetic kidney disease;
UCEC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.49	4.81	0.37	3.71e-6	Blood protein levels;
UCEC	cis	rs731174	0.797	rs678511	chr1:38156427	T/C	cg12339802	chr1:38156545	C1orf109	-0.61	-5.35	-0.4	3.32e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs17123764	0.605	rs55812050	chr12:50088540	C/A	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2319125	0.683	rs5015874	chr17:63966658	A/T	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	&beta2-Glycoprotein I (&beta;2-GPI) plasma levels;
UCEC	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg23782820	chr8:58130467	NA	0.51	4.76	0.37	4.5e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7709377	0.570	rs1129494	chr5:115428334	G/T	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg02503808	chr4:7069936	GRPEL1	-0.51	-4.54	-0.35	1.17e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.48	-5.14	-0.39	8.7e-7	Cardiac Troponin-T levels;
UCEC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg06096015	chr1:231504339	EGLN1	-0.45	-5.32	-0.4	3.86e-7	Hemoglobin concentration;
UCEC	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.5	-6.79	-0.49	2.63e-10	Eye color traits;
UCEC	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.45	-5.33	-0.4	3.63e-7	Dementia with Lewy bodies;
UCEC	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6493487	0.512	rs17521789	chr15:51271177	G/A	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.57	-5.86	-0.44	2.87e-8	Parkinson's disease;
UCEC	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.76	-6.06	-0.45	1.07e-8	Educational attainment;
UCEC	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.34	-0.9	1.95e-53	Myeloid white cell count;
UCEC	cis	rs256277	0.507	rs2047070	chr5:111302127	T/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-5.33	-0.4	3.63e-7	Coronary artery disease;
UCEC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.43	-5.19	-0.39	6.99e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.65	6.27	0.46	3.84e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4869931	1.000	rs4869930	chr6:151009835	T/C	cg06471296	chr6:150259601	NA	0.35	4.57	0.35	1.01e-5	Systolic blood pressure in sickle cell anemia;
UCEC	cis	rs7709377	0.547	rs1677415	chr5:115683658	T/G	cg23108291	chr5:115420582	COMMD10	-0.49	-4.81	-0.37	3.68e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7581030	0.917	rs10865384	chr2:71522017	C/T	cg07678644	chr2:71558969	ZNF638	0.58	5.35	0.4	3.35e-7	Testicular germ cell tumor;
UCEC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Body mass index;
UCEC	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg26898376	chr11:64110657	CCDC88B	-0.5	-4.75	-0.36	4.8e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18986713	chr8:29953064	LEPROTL1	0.61	7.15	0.51	3.86e-11	Warfarin maintenance dose;
UCEC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.55	-5.28	-0.4	4.65e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.59	7.65	0.53	2.42e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.78	8.8	0.59	3.5e-15	Mortality in heart failure;
UCEC	cis	rs17106184	0.786	rs56985406	chr1:50999695	G/A	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	8.17	0.56	1.27e-13	Smoking behavior;
UCEC	cis	rs1497406	1.000	rs1497406	chr1:16505320	A/G	cg15135617	chr1:17231562	NA	0.49	5.02	0.38	1.45e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.48	-4.94	-0.38	2.1e-6	Schizophrenia;
UCEC	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.85	-0.37	3.09e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.78	-9.04	-0.6	8.43e-16	Primary sclerosing cholangitis;
UCEC	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.67	-5.67	-0.42	7.47e-8	Schizophrenia;
UCEC	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.59	5.63	0.42	8.66e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.54	5.41	0.41	2.45e-7	Menopause (age at onset);
UCEC	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg05660106	chr1:15850417	CASP9	0.93	10.44	0.65	1.95e-19	Systolic blood pressure;
UCEC	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.0	7.64	0.53	2.58e-12	Economic and political preferences (immigration/crime);
UCEC	cis	rs11867410	0.744	rs73349086	chr17:63941281	C/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg01528321	chr10:82214614	TSPAN14	0.58	4.56	0.35	1.05e-5	Borderline personality disorder;
UCEC	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.51	6.17	0.45	6.43e-9	Oral cavity cancer;
UCEC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg24562669	chr7:97807699	LMTK2	0.4	4.93	0.38	2.19e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.79	-8.04	-0.55	2.73e-13	Mosquito bite size;
UCEC	cis	rs8105895	0.935	rs62110981	chr19:22246013	A/G	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.06e-7	Body mass index (change over time);
UCEC	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.41	4.7	0.36	5.94e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.27	0.61	2.11e-16	Bipolar disorder;
UCEC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.58	-0.42	1.1e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs1267303	0.682	rs1886117	chr1:46964909	T/A	cg25110126	chr1:46999211	NA	-0.5	-4.81	-0.37	3.68e-6	Monobrow;
UCEC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.46	-5.11	-0.39	9.83e-7	Alcohol dependence;
UCEC	cis	rs847577	0.588	rs6946915	chr7:97711340	C/G	cg24562669	chr7:97807699	LMTK2	0.7	9.98	0.64	3.21e-18	Breast cancer;
UCEC	cis	rs11673344	0.864	rs703530	chr19:37500918	G/A	cg08692348	chr19:37642883	ZNF585A	0.43	4.61	0.36	8.77e-6	Obesity-related traits;
UCEC	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.38	0.57	3.92e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.83	-9.18	-0.6	3.69e-16	Lung cancer;
UCEC	cis	rs953387	1.000	rs4954569	chr2:136913375	C/T	cg07169764	chr2:136633963	MCM6	0.54	5.37	0.41	3e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	6.64	0.48	5.68e-10	Menarche (age at onset);
UCEC	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg18232548	chr7:50535776	DDC	-0.64	-7.18	-0.51	3.15e-11	Body mass index;
UCEC	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.47	-5.65	-0.42	8.1e-8	Fibrinogen levels;
UCEC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.82	8.9	0.59	1.87e-15	Cognitive function;
UCEC	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17123764	0.818	rs7977389	chr12:49981722	T/C	cg20471783	chr12:50157085	TMBIM6	0.67	5.39	0.41	2.77e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	0.91	6.29	0.46	3.36e-9	Body mass index;
UCEC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.78	7.54	0.53	4.45e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	4.52	0.35	1.25e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.58	-6.6	-0.48	7.04e-10	Educational attainment;
UCEC	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg21053147	chr12:120880522	NA	0.67	4.75	0.36	4.79e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	6.04	0.45	1.21e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.65	4.72	0.36	5.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.49	6.79	0.49	2.63e-10	Homoarginine levels;
UCEC	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.27	0.4	4.67e-7	Cognitive test performance;
UCEC	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.42	4.93	0.38	2.18e-6	Response to antineoplastic agents;
UCEC	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.49	-4.98	-0.38	1.79e-6	Blood metabolite levels;
UCEC	cis	rs290268	0.845	rs290266	chr9:93537952	T/A	cg02608019	chr9:93564028	SYK	0.53	5.92	0.44	2.18e-8	Platelet count;
UCEC	cis	rs10256972	0.810	rs10257195	chr7:1032554	T/C	cg23978390	chr7:1156363	C7orf50	0.47	4.52	0.35	1.28e-5	Longevity;Endometriosis;
UCEC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.48	-5.22	-0.4	6.08e-7	Alcohol dependence;
UCEC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-0.95	-12.99	-0.73	3.48e-26	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.96	-0.5	1.04e-10	Coronary artery disease;
UCEC	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg24733560	chr20:60626293	TAF4	0.4	4.64	0.36	7.79e-6	Body mass index;
UCEC	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg24687543	chr11:63912206	MACROD1	0.56	4.5	0.35	1.36e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.48	5.31	0.4	3.92e-7	Response to temozolomide;
UCEC	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24308560	chr3:49941425	MST1R	-0.44	-4.76	-0.37	4.67e-6	Body mass index;
UCEC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.17	14.25	0.76	1.73e-29	Breast cancer;
UCEC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	0.56	5.61	0.42	9.56e-8	Total cholesterol levels;
UCEC	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.19e-7	QRS complex (12-leadsum);
UCEC	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs1545257	0.505	rs13016195	chr2:24634942	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-5.13	-0.39	9.05e-7	Sjögren's syndrome;
UCEC	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-5.77	-0.43	4.47e-8	Educational attainment (years of education);
UCEC	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.16	0.39	7.77e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.47	5.2	0.39	6.69e-7	Menarche (age at onset);
UCEC	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.45	-0.47	1.52e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9341808	0.538	rs7747327	chr6:81035774	G/T	cg08355045	chr6:80787529	NA	-0.35	-4.68	-0.36	6.43e-6	Sitting height ratio;
UCEC	cis	rs78487399	0.908	rs12475503	chr2:43831319	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.1	-0.45	8.86e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.62	7.1	0.51	4.97e-11	Blood metabolite ratios;
UCEC	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.62	-5.81	-0.43	3.77e-8	Alzheimer's disease;
UCEC	cis	rs7709377	0.595	rs253952	chr5:115633670	A/G	cg23108291	chr5:115420582	COMMD10	-0.57	-5.9	-0.44	2.43e-8	Metabolite levels  (X-11787);
UCEC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.52	6.04	0.45	1.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-6.73	-0.49	3.51e-10	Coffee consumption (cups per day);
UCEC	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-7.56	-0.53	3.93e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.9	-0.37	2.46e-6	Extrinsic epigenetic age acceleration;
UCEC	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	7.18	0.51	3.29e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.48	-5.3	-0.4	4.21e-7	Life satisfaction;
UCEC	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.4	-4.52	-0.35	1.27e-5	Schizophrenia;
UCEC	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg10978503	chr1:24200527	CNR2	0.37	5.03	0.38	1.43e-6	Immature fraction of reticulocytes;
UCEC	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.49	4.99	0.38	1.65e-6	Schizophrenia;
UCEC	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.53	-5.45	-0.41	2.03e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.48	-4.87	-0.37	2.81e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.66	0.48	5.2e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16097330	chr5:171615472	STK10	0.59	6.85	0.49	1.89e-10	Warfarin maintenance dose;
UCEC	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.47	-4.83	-0.37	3.35e-6	Body mass index;
UCEC	cis	rs3750082	0.889	rs6963831	chr7:32934827	G/T	cg05721444	chr7:32995514	FKBP9	0.53	5.87	0.44	2.81e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.7	6.21	0.46	5.21e-9	Mammographic density (dense area);
UCEC	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.51	-4.5	-0.35	1.36e-5	Systemic lupus erythematosus;
UCEC	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.64	0.58	8.67e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	0.77	4.67	0.36	6.75e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg07606381	chr6:8435919	SLC35B3	-0.56	-4.86	-0.37	3.04e-6	Motion sickness;
UCEC	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.87	-9.73	-0.63	1.39e-17	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.33	0.52	1.44e-11	Obesity-related traits;
UCEC	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.81	9.44	0.61	7.71e-17	Metabolite levels;
UCEC	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.76	-6.37	-0.47	2.28e-9	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7070678	0.625	rs2025855	chr10:29789738	G/A	cg07724896	chr10:29780678	SVIL	-0.56	-4.54	-0.35	1.16e-5	Platelet thrombus formation;
UCEC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg01689657	chr7:91764605	CYP51A1	0.48	6.06	0.45	1.07e-8	Breast cancer;
UCEC	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.61	-5.54	-0.42	1.35e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs174601	0.721	rs174530	chr11:61546592	A/G	cg19610905	chr11:61596333	FADS2	-0.76	-8.32	-0.57	5.4e-14	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.85	0.49	1.91e-10	Motion sickness;
UCEC	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.55	6.31	0.46	3.13e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.86	5.28	0.4	4.47e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs7072216	0.687	rs7924209	chr10:100155927	T/C	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg23625390	chr15:77176239	SCAPER	0.48	4.69	0.36	6.12e-6	Blood metabolite levels;
UCEC	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.14	-18.5	-0.84	3.28e-40	IgG glycosylation;
UCEC	cis	rs4588572	0.643	rs2012562	chr5:77768088	T/A	cg11547950	chr5:77652471	NA	-0.48	-5.58	-0.42	1.12e-7	Triglycerides;
UCEC	cis	rs17123764	1.000	rs73305012	chr12:49962637	A/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.19	0.39	6.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8099014	0.834	rs4940699	chr18:56109007	A/C	cg19165390	chr18:56932082	NA	0.35	4.77	0.37	4.36e-6	Platelet count;
UCEC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	9.88	0.63	5.79e-18	Chronic sinus infection;
UCEC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.5	4.98	0.38	1.75e-6	Longevity;Endometriosis;
UCEC	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg16023434	chr1:11395635	NA	0.38	4.71	0.36	5.78e-6	Body mass index;
UCEC	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.45	4.65	0.36	7.26e-6	Vitiligo;
UCEC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.08	-0.39	1.13e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs858239	0.932	rs858272	chr7:23276785	A/G	cg17274742	chr7:23286539	GPNMB	0.39	4.58	0.35	9.75e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs59104589	0.617	rs62193220	chr2:242353493	G/A	cg19488206	chr2:242435732	STK25	0.5	5.17	0.39	7.53e-7	Fibrinogen levels;
UCEC	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.69	-6.75	-0.49	3.22e-10	Cocaine dependence;
UCEC	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	10.01	0.64	2.59e-18	Cognitive ability;
UCEC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	7.25	0.51	2.25e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs7595037	0.552	rs11126184	chr2:68652174	C/A	cg12452813	chr2:68675892	NA	-0.47	-4.68	-0.36	6.4e-6	Multiple sclerosis;
UCEC	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.14	-0.76	3.42e-29	Schizophrenia;
UCEC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg03714773	chr7:91764589	CYP51A1	0.48	5.87	0.44	2.76e-8	Breast cancer;
UCEC	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.59	-4.96	-0.38	1.95e-6	Corneal structure;
UCEC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.7	-8.08	-0.55	2.14e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.96	-7.52	-0.53	5.07e-12	Multiple sclerosis;
UCEC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-1.0	-9.3	-0.61	1.81e-16	Bronchopulmonary dysplasia;
UCEC	cis	rs28735056	0.565	rs2012687	chr18:77711127	G/T	cg20368463	chr18:77673604	PQLC1	-0.73	-6.54	-0.47	9.75e-10	Schizophrenia;
UCEC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs3743102	0.591	rs12148608	chr15:83382102	A/G	cg00614314	chr15:82944287	LOC80154	0.88	4.82	0.37	3.5e-6	Colorectal adenoma (advanced);
UCEC	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.21	0.46	5.26e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	10.53	0.66	1.16e-19	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg05660106	chr1:15850417	CASP9	0.95	8.78	0.59	3.84e-15	Systolic blood pressure;
UCEC	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.56	-4.76	-0.37	4.54e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	7.57	0.53	3.73e-12	Exhaled nitric oxide output;
UCEC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.79	7.0	0.5	8.33e-11	Longevity;
UCEC	cis	rs151997	0.924	rs32480	chr5:50208099	G/A	cg06027927	chr5:50259733	NA	0.54	4.85	0.37	3.06e-6	Callous-unemotional behaviour;
UCEC	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.75	-7.71	-0.54	1.72e-12	Body mass index;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.74	9.03	0.6	9.17e-16	Menarche (age at onset);
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg09120320	chr17:61926383	NA	0.43	4.66	0.36	7.08e-6	Prudent dietary pattern;
UCEC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.55	5.8	0.43	3.98e-8	Primary sclerosing cholangitis;
UCEC	cis	rs6460942	0.908	rs78682952	chr7:12284886	C/A	cg06484146	chr7:12443880	VWDE	-0.64	-4.6	-0.35	9.23e-6	Coronary artery disease;
UCEC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.66	-7.6	-0.53	3.15e-12	Body mass index;
UCEC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.51	4.65	0.36	7.32e-6	Calcium levels;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.43	-5.08	-0.39	1.12e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.9	11.28	0.68	1.16e-21	Metabolic syndrome;
UCEC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.79	4.95	0.38	1.98e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.38	0.52	1.09e-11	Ileal carcinoids;
UCEC	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg05802129	chr4:122689817	NA	-0.42	-4.53	-0.35	1.22e-5	Type 2 diabetes;
UCEC	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.43	-5.99	-0.44	1.58e-8	Height;
UCEC	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	6.58	0.48	7.65e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs1823913	0.503	rs35868016	chr2:192208808	C/T	cg15998761	chr2:191300784	MFSD6	0.39	4.71	0.36	5.64e-6	Obesity-related traits;
UCEC	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26207909	chr14:103986467	CKB	0.48	4.66	0.36	6.93e-6	Body mass index;
UCEC	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.99	7.98	0.55	3.79e-13	Exhaled nitric oxide output;
UCEC	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.67	8.04	0.55	2.71e-13	Breast cancer;
UCEC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg11569703	chr11:65557185	OVOL1	0.51	6.66	0.48	4.99e-10	Acne (severe);
UCEC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.73	9.18	0.6	3.76e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.5	4.7	0.36	5.87e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.5	5.14	0.39	8.57e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.67	4.85	0.37	3.15e-6	Multiple sclerosis;
UCEC	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg24069376	chr3:38537580	EXOG	0.46	5.56	0.42	1.25e-7	Electrocardiographic conduction measures;
UCEC	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	5.95	0.44	1.84e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.65	-6.97	-0.5	1e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.96	-0.38	1.93e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.6	-0.69	1.67e-22	Height;
UCEC	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.51	5.37	0.41	2.96e-7	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs4244915	chr19:22854138	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-0.77	-6.84	-0.49	2.03e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.36	0.68	7.21e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.48	5.44	0.41	2.14e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs11867410	0.744	rs7207859	chr17:63948647	T/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-5.92	-0.44	2.15e-8	Glomerular filtration rate;
UCEC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-6.48	-0.47	1.28e-9	Menarche (age at onset);
UCEC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.82	7.38	0.52	1.07e-11	Resting heart rate;
UCEC	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-9.33	-0.61	1.48e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06762426	chr11:62420836	INTS5	0.94	5.39	0.41	2.8e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.54	-5.81	-0.43	3.72e-8	Blood metabolite levels;
UCEC	cis	rs2200578	1.000	rs62153845	chr2:99887162	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.83	5.4	0.41	2.59e-7	IgG glycosylation;
UCEC	cis	rs295140	1.000	rs7559005	chr2:201161371	C/T	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9921338	0.561	rs11859280	chr16:11470372	A/C	cg04583000	chr16:11888783	NA	-0.69	-4.96	-0.38	1.96e-6	Vein graft stenosis in coronary artery bypass grafting;
UCEC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.58	-6.51	-0.47	1.1e-9	Menopause (age at onset);
UCEC	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg01072550	chr1:21505969	NA	-0.6	-5.79	-0.43	4.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg11437231	chr11:47291487	MADD	0.51	5.0	0.38	1.59e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs638882	0.695	rs2155271	chr11:115733690	C/T	cg04087571	chr11:116723030	SIK3	0.27	4.52	0.35	1.24e-5	Hip geometry;
UCEC	cis	rs36051895	0.589	rs6476945	chr9:5191793	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.3	-0.4	4.15e-7	Pediatric autoimmune diseases;
UCEC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.58	5.28	0.4	4.63e-7	Corneal astigmatism;
UCEC	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg15133208	chr4:90757351	SNCA	-0.34	-4.53	-0.35	1.21e-5	Dementia with Lewy bodies;
UCEC	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg19805062	chr22:46654627	PKDREJ	0.43	4.58	0.35	9.71e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4074536	0.622	rs10737736	chr1:116315536	G/A	cg21648376	chr1:116311395	CASQ2	-0.6	-5.78	-0.43	4.23e-8	QRS duration;
UCEC	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.49	4.87	0.37	2.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg01262667	chr19:19385393	TM6SF2	0.43	5.41	0.41	2.51e-7	Tonsillectomy;
UCEC	cis	rs9470794	1.000	rs57591988	chr6:37943292	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.51	-4.57	-0.35	1.01e-5	Initial pursuit acceleration;
UCEC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.68	-6.13	-0.45	7.6e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.55	-6.95	-0.5	1.08e-10	Corneal structure;
UCEC	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg27631724	chr1:11040367	C1orf127	0.33	4.61	0.36	8.81e-6	Ewing sarcoma;
UCEC	cis	rs7404928	0.609	rs56213545	chr16:23936910	G/A	cg21745164	chr16:23765304	CHP2	-0.48	-4.54	-0.35	1.17e-5	Primary biliary cholangitis;Rheumatoid arthritis;
UCEC	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.84	-10.11	-0.64	1.47e-18	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.8	0.49	2.44e-10	Homoarginine levels;
UCEC	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	0.7	5.45	0.41	2.09e-7	Blood protein levels;
UCEC	cis	rs11867410	0.744	rs57195681	chr17:63966093	G/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs11129176	0.959	rs4564927	chr3:25051556	C/T	cg02506578	chr3:25824554	NGLY1	0.6	4.72	0.36	5.4e-6	Optic disc area;
UCEC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg01262667	chr19:19385393	TM6SF2	0.52	7.25	0.51	2.21e-11	Tonsillectomy;
UCEC	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg00612595	chr21:47717864	NA	-0.5	-5.41	-0.41	2.45e-7	Testicular germ cell tumor;
UCEC	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg09491104	chr22:46646882	C22orf40	-0.67	-7.6	-0.53	3.22e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10256972	0.810	rs10257195	chr7:1032554	T/C	cg20821713	chr7:1055600	C7orf50	-0.55	-5.62	-0.42	9.42e-8	Longevity;Endometriosis;
UCEC	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.75	6.26	0.46	4.02e-9	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg13147721	chr7:65941812	NA	-0.75	-5.07	-0.39	1.19e-6	Diabetic kidney disease;
UCEC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.68	7.59	0.53	3.45e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9400271	0.527	rs9400274	chr6:109639876	G/A	cg01475377	chr6:109611718	NA	0.45	5.0	0.38	1.6e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg08886695	chr4:3369023	RGS12	-0.51	-5.09	-0.39	1.09e-6	Serum sulfate level;
UCEC	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	8.1	0.56	1.99e-13	Post bronchodilator FEV1;
UCEC	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.44	4.74	0.36	5.01e-6	Life satisfaction;
UCEC	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.65	-0.48	5.43e-10	Total cholesterol levels;
UCEC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.2e-5	Chronic sinus infection;
UCEC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg19318889	chr4:1322082	MAEA	0.46	4.91	0.38	2.41e-6	Obesity-related traits;
UCEC	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	6.22	0.46	4.98e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.69	-0.43	6.5e-8	Cardiac Troponin-T levels;
UCEC	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.57	7.95	0.55	4.51e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.64	5.27	0.4	4.87e-7	Systolic blood pressure;
UCEC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.5	-4.77	-0.37	4.46e-6	Renal cell carcinoma;
UCEC	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-5.24	-0.4	5.36e-7	Primary biliary cholangitis;
UCEC	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.75	-8.4	-0.57	3.51e-14	Extraversion;
UCEC	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg13593689	chr9:129986794	NA	0.48	4.9	0.37	2.54e-6	Intraocular pressure;
UCEC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-7.48	-0.52	6.36e-12	Menarche (age at onset);
UCEC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.49	5.19	0.39	6.98e-7	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs7088591	0.867	rs74402014	chr10:59784008	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	0.86	5.46	0.41	2e-7	Diabetic retinopathy;
UCEC	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	0.99	10.04	0.64	2.13e-18	Caffeine consumption;
UCEC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg12024160	chr4:1254474	NA	0.5	6.51	0.47	1.11e-9	Obesity-related traits;
UCEC	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.65	6.0	0.44	1.46e-8	Menarche (age at onset);
UCEC	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.52	5.75	0.43	4.96e-8	Menopause (age at onset);
UCEC	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.64	-6.53	-0.47	9.99e-10	Systemic lupus erythematosus;
UCEC	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.52	-0.69	2.74e-22	Monocyte count;
UCEC	cis	rs4534636	0.812	rs28485567	chr12:8664719	T/C	cg00911551	chr12:8234647	NECAP1	-0.49	-4.64	-0.36	7.75e-6	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
UCEC	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.56	5.62	0.42	9.51e-8	Neuroticism;
UCEC	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.68	-7.11	-0.51	4.8e-11	Response to temozolomide;
UCEC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.53	-6.25	-0.46	4.15e-9	Type 2 diabetes;
UCEC	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	6.45	0.47	1.51e-9	Motion sickness;
UCEC	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	0.98	7.46	0.52	7.14e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg02461776	chr11:598696	PHRF1	0.47	5.24	0.4	5.55e-7	Systemic lupus erythematosus;
UCEC	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs59104589	0.517	rs15129	chr2:242168976	T/C	cg12761732	chr2:242547234	THAP4	0.58	4.64	0.36	7.53e-6	Fibrinogen levels;
UCEC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.84	-7.93	-0.55	5.1e-13	Initial pursuit acceleration;
UCEC	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.65	6.05	0.45	1.12e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg11979743	chr20:814510	FAM110A	0.57	6.73	0.49	3.53e-10	N-glycan levels;
UCEC	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-0.7	-6.51	-0.47	1.12e-9	Breast cancer;
UCEC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.81	-9.06	-0.6	7.44e-16	Lung cancer;
UCEC	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.68	-6.8	-0.49	2.5e-10	Itch intensity from mosquito bite;
UCEC	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.4	5.42	0.41	2.44e-7	Birth weight;
UCEC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.55	5.93	0.44	2.02e-8	Schizophrenia;
UCEC	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.24	-0.4	5.36e-7	Resting heart rate;
UCEC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.34	5.13	0.39	9.17e-7	Ulcerative colitis;
UCEC	cis	rs10432489	0.708	rs4531892	chr2:181746482	T/A	cg21995919	chr2:182322279	ITGA4	0.77	5.7	0.43	6.26e-8	QT interval;
UCEC	cis	rs9470794	1.000	rs58332635	chr6:38029056	A/G	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.7	6.1	0.45	9.11e-9	Alzheimer's disease;
UCEC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-6.51	-0.47	1.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.58	5.18	0.39	7.29e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg13147721	chr7:65941812	NA	-0.75	-5.06	-0.38	1.26e-6	Diabetic kidney disease;
UCEC	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.94	9.42	0.61	8.73e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.55	0.42	1.31e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg00105475	chr2:10696890	NA	-0.41	-5.05	-0.38	1.32e-6	Prostate cancer;
UCEC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.63	0.36	8.13e-6	Breast cancer;
UCEC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg00343986	chr7:65444356	GUSB	0.52	4.99	0.38	1.69e-6	Aortic root size;
UCEC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg06238570	chr21:40685208	BRWD1	0.83	8.11	0.56	1.81e-13	Cognitive function;
UCEC	cis	rs7959452	1.000	rs7959452	chr12:69735492	A/G	cg20891283	chr12:69753455	YEATS4	0.73	7.51	0.53	5.34e-12	Blood protein levels;
UCEC	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.64	-6.51	-0.47	1.09e-9	Body mass index;
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.17	-0.39	7.61e-7	Platelet count;
UCEC	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.96	-7.63	-0.53	2.66e-12	Dupuytren's disease;
UCEC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	7.23	0.51	2.39e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg00343986	chr7:65444356	GUSB	-0.49	-4.61	-0.36	8.69e-6	Aortic root size;
UCEC	cis	rs74542309	0.947	rs34190156	chr10:72544084	T/A	cg15763670	chr10:73473235	C10orf105;CDH23	-0.6	-4.66	-0.36	6.89e-6	Pursuit maintenance gain;
UCEC	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-8.62	-0.58	1.01e-14	Vitiligo;
UCEC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.97	0.38	1.83e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.92	0.44	2.23e-8	Monocyte percentage of white cells;
UCEC	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.56	6.25	0.46	4.27e-9	Height;
UCEC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs8177876	0.642	rs4324143	chr16:81114988	G/C	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	5.85	0.43	3.11e-8	Platelet count;
UCEC	cis	rs7007970	1.000	rs10955934	chr8:120676929	C/T	cg01975934	chr8:119970761	NA	-0.56	-4.57	-0.35	1.03e-5	Height;
UCEC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.71	7.05	0.5	6.41e-11	Aortic root size;
UCEC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.55	5.51	0.41	1.58e-7	Colorectal cancer;
UCEC	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg03859395	chr2:55845619	SMEK2	0.99	13.59	0.75	9.11e-28	Metabolic syndrome;
UCEC	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.26	-0.46	4.08e-9	Crohn's disease;
UCEC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.36	-0.4	3.09e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927997	0.708	rs2155219	chr11:76299194	G/T	cg17647271	chr11:76299819	NA	-0.57	-6.09	-0.45	9.4e-9	Gut microbiota (functional units);Crohn's disease;
UCEC	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.3	0.4	4.23e-7	Breast cancer;
UCEC	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	9.03	0.6	9.01e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.66	5.44	0.41	2.2e-7	Metabolite levels;
UCEC	cis	rs7095607	0.785	rs10762190	chr10:69919905	C/A	cg18986048	chr10:69913749	MYPN	0.54	6.36	0.46	2.43e-9	Lung function (FVC);
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.58	-6.48	-0.47	1.33e-9	Pubertal anthropometrics;
UCEC	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg24851651	chr11:66362959	CCS	-0.4	-5.1	-0.39	1.02e-6	Educational attainment (years of education);
UCEC	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.6	4.99	0.38	1.67e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.45	-4.59	-0.35	9.47e-6	Aortic root size;
UCEC	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.64	6.09	0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	0.97	7.3	0.52	1.67e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.58	-5.73	-0.43	5.57e-8	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	1.18	14.71	0.77	1.1e-30	Body mass index;
UCEC	cis	rs2551802	0.615	rs17395735	chr2:177067780	C/T	cg13092806	chr2:177043255	NA	0.68	6.32	0.46	2.97e-9	Motion sickness;
UCEC	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.47	4.9	0.37	2.46e-6	Schizophrenia;
UCEC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.42	0.41	2.42e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.53	-5.12	-0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.82	10.91	0.67	1.12e-20	Body mass index;
UCEC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.61	-6.89	-0.49	1.51e-10	Longevity;
UCEC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	0.86	10.07	0.64	1.8e-18	Breast cancer;
UCEC	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	15.84	0.79	1.36e-33	Colorectal cancer;
UCEC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.58e-6	Diabetic kidney disease;
UCEC	cis	rs6840360	0.642	rs56301462	chr4:152452128	T/G	cg02366345	chr4:152330872	FAM160A1	0.35	4.69	0.36	6.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.4	-5.96	-0.44	1.81e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	0.82	6.99	0.5	8.86e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-4.55	-0.35	1.14e-5	Blood pressure (smoking interaction);
UCEC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.66	4.73	0.36	5.16e-6	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.7	5.04	0.38	1.35e-6	Multiple sclerosis;
UCEC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.94	-0.5	1.17e-10	Total body bone mineral density;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.57	0.58	1.29e-14	Platelet count;
UCEC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.82	9.2	0.6	3.3e-16	Monocyte count;
UCEC	cis	rs11958404	0.860	rs72816577	chr5:157431806	A/G	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.65	5.17	0.39	7.58e-7	Bladder cancer;
UCEC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg00083072	chr11:65415190	SIPA1	0.42	4.56	0.35	1.05e-5	Acne (severe);
UCEC	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.48	-6.32	-0.46	2.99e-9	Neutrophil percentage of white cells;
UCEC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.43	5.12	0.39	9.28e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg01072550	chr1:21505969	NA	-0.61	-6.48	-0.47	1.32e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	0.88	10.42	0.65	2.16e-19	Schizophrenia;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg12410154	chr3:57261551	APPL1	-0.64	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs1575951	1.000	rs10829457	chr10:130437323	G/C	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg04310649	chr10:35416472	CREM	-0.49	-4.53	-0.35	1.19e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.04e-6	Schizophrenia;
UCEC	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.45	4.92	0.38	2.31e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.33e-8	Lung cancer;
UCEC	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-4.53	-0.35	1.19e-5	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.82	8.11	0.56	1.8e-13	Selective IgA deficiency;
UCEC	cis	rs17123764	0.710	rs12317646	chr12:50084470	C/T	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.69	-6.23	-0.46	4.54e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.71	5.1	0.39	1.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.59	6.49	0.47	1.27e-9	Red blood cell count;
UCEC	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg18681998	chr4:17616180	MED28	0.9	11.82	0.7	4.49e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.76	7.55	0.53	4.32e-12	Response to diuretic therapy;
UCEC	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.76	8.34	0.57	5.05e-14	Itch intensity from mosquito bite;
UCEC	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.48	-5.16	-0.39	7.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.57	-8.18	-0.56	1.25e-13	Sense of smell;
UCEC	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.74	-6.71	-0.48	4e-10	Platelet distribution width;
UCEC	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.73	5.21	0.39	6.33e-7	LDL cholesterol;
UCEC	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.79	9.94	0.63	3.92e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.74	-8.18	-0.56	1.25e-13	Sudden cardiac arrest;
UCEC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.37	0.41	2.95e-7	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.57	7.96	0.55	4.2e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.61	6.91	0.5	1.35e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.37	-0.4	3.02e-7	Bipolar disorder;
UCEC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.51	5.16	0.39	8.03e-7	Cognitive test performance;
UCEC	cis	rs2062225	0.696	rs11123295	chr2:111768373	G/A	cg23782758	chr2:111737646	ACOXL	-0.48	-4.61	-0.36	8.85e-6	Monocyte count;
UCEC	cis	rs1595825	0.891	rs4491721	chr2:198521407	C/G	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.56	-6.21	-0.46	5.25e-9	Crohn's disease;
UCEC	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.74	7.7	0.54	1.82e-12	Sudden cardiac arrest;
UCEC	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	0.86	4.98	0.38	1.78e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.7	6.36	0.46	2.45e-9	Morning vs. evening chronotype;
UCEC	cis	rs838147	0.733	rs12975781	chr19:49249698	A/G	cg13540341	chr19:49222985	MAMSTR	-0.44	-5.52	-0.41	1.49e-7	Dietary macronutrient intake;
UCEC	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.06	0.39	1.23e-6	Aortic root size;
UCEC	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.74	-5.19	-0.39	6.75e-7	Body mass index;
UCEC	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.54	-5.25	-0.4	5.26e-7	Prostate cancer;
UCEC	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.53	6.24	0.46	4.43e-9	Type 2 diabetes;
UCEC	trans	rs66573146	1.000	rs7686168	chr4:6986057	C/A	cg07817883	chr1:32538562	TMEM39B	1.13	9.6	0.62	3.04e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.48	-4.91	-0.38	2.39e-6	Height;
UCEC	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.7	7.86	0.54	7.5e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.7	6.22	0.46	4.97e-9	Aortic root size;
UCEC	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.74	6.75	0.49	3.19e-10	Parkinson's disease;
UCEC	cis	rs2267137	0.903	rs715494	chr22:29782433	G/T	cg07256473	chr22:29710276	RASL10A	-0.55	-6.08	-0.45	9.97e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.43	5.61	0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.59	8.39	0.57	3.64e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.81	-6.29	-0.46	3.37e-9	Exhaled nitric oxide output;
UCEC	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.07	0.5	5.86e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.14	-7.42	-0.52	8.44e-12	Diabetic kidney disease;
UCEC	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.83	8.82	0.59	3.14e-15	Blood protein levels;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.59	-0.42	1.05e-7	Pubertal anthropometrics;
UCEC	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.61	6.24	0.46	4.45e-9	Asthma (sex interaction);
UCEC	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.85	10.62	0.66	6.61e-20	Mortality in heart failure;
UCEC	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg04756594	chr16:24857601	SLC5A11	0.45	5.43	0.41	2.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.06	0.39	1.24e-6	Rheumatoid arthritis;
UCEC	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg11632617	chr15:75315747	PPCDC	-0.53	-4.82	-0.37	3.57e-6	Lung cancer;
UCEC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg14008862	chr17:28927542	LRRC37B2	-0.65	-6.11	-0.45	8.51e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.44	4.9	0.37	2.49e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.8	-7.47	-0.52	6.54e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg20387954	chr3:183756860	HTR3D	0.49	5.86	0.44	2.88e-8	Anterior chamber depth;
UCEC	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.11	9.62	0.62	2.73e-17	Opioid sensitivity;
UCEC	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg08493051	chr2:3487164	NA	0.69	7.01	0.5	8.03e-11	Neurofibrillary tangles;
UCEC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.83	0.43	3.41e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg23093090	chr10:104574429	C10orf26	0.44	4.77	0.37	4.37e-6	Waist circumference;Hip circumference;
UCEC	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	0.88	7.25	0.51	2.25e-11	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9309473	1.000	rs6546836	chr2:73677833	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-5.53	-0.41	1.46e-7	Metabolite levels;
UCEC	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.48	5.59	0.42	1.1e-7	Menarche (age at onset);
UCEC	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs4880487	0.888	rs4880788	chr10:1254141	C/T	cg03183215	chr10:1252341	ADARB2	-0.44	-5.21	-0.39	6.34e-7	Migraine;
UCEC	cis	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-6.03	-0.45	1.27e-8	Schizophrenia;
UCEC	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg23950597	chr19:37808831	NA	-0.81	-5.62	-0.42	9.3e-8	Coronary artery calcification;
UCEC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.55	5.22	0.4	5.97e-7	Calcium levels;
UCEC	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.89	-10.14	-0.64	1.2e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.46	5.89	0.44	2.49e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.18	6.29	0.46	3.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	6.07	0.45	1.03e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.12	-0.39	9.58e-7	Aortic root size;
UCEC	cis	rs4700695	0.841	rs706681	chr5:65317913	G/T	cg21114390	chr5:65439923	SFRS12	0.56	4.65	0.36	7.29e-6	Facial morphology (factor 19);
UCEC	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg04756594	chr16:24857601	SLC5A11	-0.43	-5.26	-0.4	4.94e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.31	0.52	1.59e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.62	5.71	0.43	6.1e-8	Coronary artery disease;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.68	-0.42	6.85e-8	Pubertal anthropometrics;
UCEC	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-6.83	-0.49	2.05e-10	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.6	-6.44	-0.47	1.58e-9	Glomerular filtration rate;
UCEC	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.46	5.11	0.39	9.98e-7	Blood metabolite levels;
UCEC	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg23370820	chr17:17987590	NA	0.37	4.68	0.36	6.46e-6	Total body bone mineral density;
UCEC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.17	6.11	0.45	8.68e-9	Diabetic kidney disease;
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.18	0.45	6.11e-9	Platelet count;
UCEC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.81	9.08	0.6	6.81e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.63	-0.42	8.99e-8	Mood instability;
UCEC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.77	-8.8	-0.59	3.48e-15	Longevity;Endometriosis;
UCEC	trans	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02355339	chr19:35517344	GRAMD1A	-0.68	-6.99	-0.5	8.88e-11	Smoking behavior;
UCEC	cis	rs4499344	0.664	rs4286210	chr19:33101221	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg05962950	chr11:130786565	SNX19	0.75	6.94	0.5	1.17e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.82	5.66	0.42	7.85e-8	Psoriasis;
UCEC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.32	0.57	5.56e-14	Smoking behavior;
UCEC	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.98	-0.44	1.6e-8	Platelet count;
UCEC	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-8.24	-0.56	8.88e-14	Colorectal cancer;
UCEC	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.56	6.4	0.47	1.95e-9	Type 2 diabetes;
UCEC	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.52	-5.33	-0.4	3.55e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.36	4.55	0.35	1.1e-5	Multiple system atrophy;
UCEC	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg24562669	chr7:97807699	LMTK2	0.45	5.46	0.41	1.94e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.83	8.97	0.59	1.27e-15	Longevity;
UCEC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.51	4.63	0.36	7.94e-6	Corneal astigmatism;
UCEC	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.9	5.79	0.43	4.07e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.53	0.41	1.43e-7	Rheumatoid arthritis;
UCEC	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.85	8.53	0.58	1.65e-14	Post bronchodilator FEV1;
UCEC	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.7	-6.95	-0.5	1.11e-10	Blood metabolite levels;
UCEC	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-6.61	-0.48	6.55e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.47	-4.56	-0.35	1.06e-5	Total body bone mineral density;
UCEC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.71	7.87	0.54	7.21e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.81	10.68	0.66	4.49e-20	Vitiligo;
UCEC	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg03959625	chr15:84868606	LOC388152	0.46	4.84	0.37	3.21e-6	Schizophrenia;
UCEC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	5.21	0.39	6.26e-7	Prostate cancer;
UCEC	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.51	-5.01	-0.38	1.52e-6	Brugada syndrome;
UCEC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.69	7.15	0.51	3.87e-11	Dental caries;
UCEC	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.93	0.44	2.07e-8	Breast cancer;
UCEC	cis	rs925228	0.824	rs2675351	chr2:24083573	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.28e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7106204	0.514	rs1596280	chr11:24250853	T/C	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.54	-5.26	-0.4	4.94e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg20999797	chr1:1681921	NA	0.37	4.95	0.38	2e-6	Body mass index;
UCEC	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.47	-0.41	1.91e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	5.95	0.44	1.87e-8	Cognitive test performance;
UCEC	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.51	5.11	0.39	9.83e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg16797656	chr11:68205561	LRP5	0.64	8.98	0.6	1.17e-15	Total body bone mineral density;
UCEC	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-6.66	-0.48	5e-10	Oral cavity cancer;
UCEC	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	4.86	0.37	2.94e-6	Rheumatoid arthritis;
UCEC	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.29	0.52	1.72e-11	Response to antipsychotic treatment;
UCEC	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.41	5.52	0.41	1.53e-7	Alcohol dependence;
UCEC	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.06	0.39	1.22e-6	Lung cancer in ever smokers;
UCEC	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.08	-8.51	-0.57	1.82e-14	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.7	7.76	0.54	1.3e-12	Blood metabolite levels;
UCEC	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg02158880	chr13:53174818	NA	0.45	4.97	0.38	1.82e-6	Lewy body disease;
UCEC	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-5.79	-0.43	4.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4789452	1.000	rs7216382	chr17:75374578	T/C	cg21830368	chr17:75373327	SEPT9	-0.32	-5.0	-0.38	1.64e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	6.16	0.45	6.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.45	4.6	0.35	9.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.6	5.69	0.42	6.67e-8	Uric acid levels;
UCEC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	5.72	0.43	5.85e-8	Parkinson's disease;
UCEC	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.2e-7	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.07	-0.5	5.94e-11	Breast cancer;
UCEC	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.62	-7.43	-0.52	8.05e-12	Prevalent atrial fibrillation;
UCEC	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.66	-4.57	-0.35	1.04e-5	Lung function (FEV1/FVC);
UCEC	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.46	0.57	2.45e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg23034840	chr1:205782522	SLC41A1	0.51	5.08	0.39	1.14e-6	Menarche (age at onset);
UCEC	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.69	5.85	0.43	3.12e-8	Coronary artery disease;
UCEC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.58	5.57	0.42	1.21e-7	Calcium levels;
UCEC	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	5.52	0.41	1.51e-7	Bipolar disorder;
UCEC	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.67	6.22	0.46	4.82e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.73	0.43	5.45e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg18230493	chr5:56204884	C5orf35	0.48	4.6	0.35	9.19e-6	Coronary artery disease;
UCEC	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	5.67	0.42	7.33e-8	Iron status biomarkers;
UCEC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	0.89	12.12	0.71	7.04e-24	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg06466757	chr4:1255808	NA	0.46	4.79	0.37	3.97e-6	Obesity-related traits;
UCEC	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.68	8.09	0.56	2.03e-13	Mean corpuscular volume;
UCEC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs12980942	0.810	rs16958999	chr19:41825186	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.61	5.58	0.42	1.1e-7	Coronary artery disease;
UCEC	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.74	-8.94	-0.59	1.53e-15	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.08	0.39	1.15e-6	Obesity-related traits;
UCEC	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.93	0.38	2.17e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.68	7.07	0.5	5.83e-11	Blood protein levels;
UCEC	cis	rs2455799	1.000	rs11921219	chr3:15865369	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-4.8	-0.37	3.89e-6	Mean platelet volume;
UCEC	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs7894051	1.000	rs11101723	chr10:135192139	C/A	cg14353649	chr10:135191496	PAOX	0.49	4.63	0.36	7.92e-6	Lifespan;
UCEC	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-1.04	-7.62	-0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg05279229	chr7:1896384	MAD1L1	-0.45	-4.58	-0.35	9.65e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg04176532	chr22:50317003	CRELD2	0.5	5.11	0.39	9.72e-7	Schizophrenia;
UCEC	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.58	-5.93	-0.44	2.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs919433	0.963	rs1429417	chr2:198158171	T/G	cg03934865	chr2:198174659	NA	-0.39	-4.87	-0.37	2.8e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs9402633	0.938	rs9402630	chr6:135037925	C/T	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.61	-4.89	-0.37	2.64e-6	Initial pursuit acceleration;
UCEC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg16989719	chr2:238392110	NA	-0.42	-5.9	-0.44	2.44e-8	Prostate cancer;
UCEC	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg14008862	chr17:28927542	LRRC37B2	0.67	4.97	0.38	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.4	4.54	0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.04	8.54	0.58	1.55e-14	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.52	-4.76	-0.37	4.56e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.81	7.82	0.54	9.27e-13	Colorectal adenoma (advanced);
UCEC	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.58	-5.28	-0.4	4.49e-7	Metabolite levels;
UCEC	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.81	0.63	8.71e-18	Blood protein levels;
UCEC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.74	7.26	0.51	2.11e-11	Psoriasis;
UCEC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-5.95	-0.44	1.91e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Bipolar disorder;
UCEC	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.45	-5.0	-0.38	1.58e-6	Longevity;Endometriosis;
UCEC	cis	rs6840360	0.573	rs7692939	chr4:152258455	C/T	cg25486957	chr4:152246857	NA	-0.45	-4.95	-0.38	2.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs9715521	0.775	rs62301191	chr4:59842587	T/G	cg11281224	chr4:60001000	NA	-0.61	-5.88	-0.44	2.71e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg01072550	chr1:21505969	NA	-0.59	-5.62	-0.42	9.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.24	-0.65	6.48e-19	Monocyte count;
UCEC	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg23260525	chr10:116636907	FAM160B1	0.33	4.51	0.35	1.32e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.45	4.83	0.37	3.37e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.61	5.42	0.41	2.34e-7	Longevity;
UCEC	cis	rs12545109	0.959	rs12547974	chr8:57314785	G/T	cg09654669	chr8:57350985	NA	-0.44	-4.52	-0.35	1.27e-5	Obesity-related traits;
UCEC	cis	rs7651039	0.641	rs2455827	chr3:15662906	C/G	cg16303742	chr3:15540471	COLQ	0.56	7.01	0.5	8.13e-11	Coronary heart disease;
UCEC	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.11e-7	Body mass index;
UCEC	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg10503236	chr1:231470652	EXOC8	0.39	4.54	0.35	1.15e-5	Hemoglobin concentration;
UCEC	cis	rs6921919	0.789	rs6456814	chr6:28305812	C/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.45	-4.62	-0.36	8.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	1.000	rs12980225	chr19:23026745	G/C	cg24889512	chr19:22816950	ZNF492	0.5	5.32	0.4	3.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.65	-0.42	8.11e-8	Neutrophil percentage of white cells;
UCEC	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.65	9.02	0.6	9.68e-16	Systolic blood pressure;
UCEC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.61	-0.42	9.61e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg00105475	chr2:10696890	NA	0.42	5.14	0.39	8.62e-7	Prostate cancer;
UCEC	cis	rs11958404	0.932	rs72816592	chr5:157435246	A/G	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.83	5.19	0.39	7.01e-7	Rheumatoid arthritis;
UCEC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg15147215	chr3:52552868	STAB1	0.48	5.42	0.41	2.34e-7	Electroencephalogram traits;
UCEC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg13395646	chr4:1353034	KIAA1530	-0.8	-8.13	-0.56	1.65e-13	Obesity-related traits;
UCEC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.27	0.4	4.85e-7	Rheumatoid arthritis;
UCEC	cis	rs7937612	1.000	rs7948928	chr11:120273224	C/G	cg12584626	chr11:120203529	NA	-0.5	-5.0	-0.38	1.65e-6	Intraocular pressure;
UCEC	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.55	5.93	0.44	2.02e-8	Schizophrenia;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	4.92	0.38	2.25e-6	Lymphocyte counts;
UCEC	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.56	4.71	0.36	5.63e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.63	6.51	0.47	1.12e-9	Obesity-related traits;
UCEC	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.08	-0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	1.2	8.95	0.59	1.46e-15	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg02160872	chr5:212506	CCDC127	-0.64	-4.95	-0.38	2.02e-6	Asthma (childhood onset);
UCEC	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg13147721	chr7:65941812	NA	-0.93	-5.86	-0.44	2.86e-8	Diabetic kidney disease;
UCEC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.52	5.36	0.4	3.17e-7	Monocyte count;
UCEC	cis	rs16957091	0.866	rs7166775	chr15:43042690	A/G	cg24196017	chr15:43021976	CDAN1	0.59	6.07	0.45	1.05e-8	MGMT methylation in smokers;
UCEC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.8	8.82	0.59	3.13e-15	Immature fraction of reticulocytes;
UCEC	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.67	7.5	0.53	5.51e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.47	4.69	0.36	6.26e-6	Blood metabolite levels;
UCEC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.68	8.26	0.56	7.9e-14	Monocyte percentage of white cells;
UCEC	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.52	-4.66	-0.36	7.03e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.51	4.68	0.36	6.46e-6	Bone properties (heel);
UCEC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.48	4.75	0.36	4.82e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.56	-6.0	-0.44	1.44e-8	Electroencephalogram traits;
UCEC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.76	7.93	0.55	5.07e-13	Lymphocyte counts;
UCEC	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg14438399	chr17:27053147	TLCD1	0.58	4.67	0.36	6.84e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs62344088	1.000	rs56315075	chr5:103904	G/A	cg22857025	chr5:266934	NA	-0.79	-5.29	-0.4	4.37e-7	Asthma (childhood onset);
UCEC	cis	rs12618769	0.652	rs3769698	chr2:99233894	T/C	cg10123293	chr2:99228465	UNC50	0.49	5.48	0.41	1.78e-7	Bipolar disorder;
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg21856205	chr7:94953877	PON1	-0.54	-5.19	-0.39	6.72e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-0.91	-11.46	-0.69	4.05e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.75	-7.87	-0.54	7.19e-13	Mosquito bite size;
UCEC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg19318889	chr4:1322082	MAEA	0.63	7.13	0.51	4.11e-11	Longevity;
UCEC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.64	6.83	0.49	2.14e-10	Homoarginine levels;
UCEC	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.61	-6.7	-0.48	4.04e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.44	-5.54	-0.42	1.39e-7	Dupuytren's disease;
UCEC	cis	rs847577	0.630	rs6967926	chr7:97715088	C/T	cg21770322	chr7:97807741	LMTK2	0.84	14.28	0.76	1.46e-29	Breast cancer;
UCEC	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.79	5.11	0.39	9.85e-7	Body mass index;
UCEC	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.72	6.95	0.5	1.1e-10	Crohn's disease;
UCEC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	13.91	0.75	1.32e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.74	-6.46	-0.47	1.47e-9	Asthma;
UCEC	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg01072550	chr1:21505969	NA	-0.57	-5.63	-0.42	8.87e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-5.5	-0.41	1.6e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	6.3	0.46	3.32e-9	Platelet count;
UCEC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.42	4.71	0.36	5.79e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg01689657	chr7:91764605	CYP51A1	0.47	6.17	0.45	6.34e-9	Breast cancer;
UCEC	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg21191810	chr6:118973309	C6orf204	-0.44	-5.95	-0.44	1.92e-8	Electrocardiographic conduction measures;
UCEC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.84	0.37	3.23e-6	Tonsillectomy;
UCEC	cis	rs9596863	1.000	rs1545659	chr13:54433788	G/A	ch.13.53330881F	chr13:54432880	NA	-0.53	-4.56	-0.35	1.07e-5	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.51	5.73	0.43	5.41e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs4148689	0.904	rs6466613	chr7:117136858	T/G	cg21212505	chr7:117228958	CFTR	-0.42	-4.71	-0.36	5.75e-6	Gout;
UCEC	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-1.08	-9.49	-0.62	5.79e-17	Dupuytren's disease;
UCEC	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.52	-5.59	-0.42	1.09e-7	Schizophrenia;
UCEC	cis	rs2425143	1.000	rs73905926	chr20:34251982	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.57	-0.35	1.02e-5	Blood protein levels;
UCEC	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18932078	chr1:2524107	MMEL1	0.4	6.27	0.46	3.74e-9	Ulcerative colitis;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg21957174	chr11:64511624	RASGRP2	-0.58	-6.71	-0.48	4e-10	N-glycan levels;
UCEC	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.46	-4.77	-0.37	4.41e-6	Schizophrenia;
UCEC	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg05962950	chr11:130786565	SNX19	-0.76	-7.11	-0.51	4.7e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg20307385	chr11:47447363	PSMC3	-0.63	-4.59	-0.35	9.54e-6	Axial length;
UCEC	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.63	6.16	0.45	6.79e-9	Multiple myeloma (IgH translocation);
UCEC	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.6	4.55	0.35	1.1e-5	Menarche (age at onset);
UCEC	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.73	4.58	0.35	9.9e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs12086130	0.892	rs3176447	chr1:51433687	T/A	cg07174182	chr1:51127561	FAF1	-0.73	-4.97	-0.38	1.81e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	4.95	0.38	2.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg06627628	chr2:24431161	ITSN2	-0.52	-5.28	-0.4	4.51e-7	Sjögren's syndrome;
UCEC	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg04202892	chr2:111875749	ACOXL	0.41	4.54	0.35	1.15e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.61	7.16	0.51	3.61e-11	Hip circumference;
UCEC	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-0.97	-14.47	-0.77	4.68e-30	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg26721908	chr21:47610096	LSS	-0.36	-4.54	-0.35	1.17e-5	Testicular germ cell tumor;
UCEC	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	0.76	5.23	0.4	5.63e-7	Blood protein levels;
UCEC	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.78	-6.13	-0.45	7.6e-9	Calcium levels;
UCEC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg05738196	chr6:26577821	NA	0.65	7.72	0.54	1.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.86	-0.37	2.92e-6	Breast cancer;
UCEC	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg04155231	chr12:9217510	LOC144571	0.42	4.97	0.38	1.86e-6	Sjögren's syndrome;
UCEC	cis	rs13095912	1.000	rs35497918	chr3:185310312	C/T	cg11274856	chr3:185301563	NA	0.55	7.29	0.52	1.77e-11	Systolic blood pressure;
UCEC	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.5	-5.53	-0.41	1.43e-7	Facial morphology (factor 20);
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg24095088	chr6:160210874	MRPL18;TCP1	0.66	6.87	0.49	1.71e-10	Triglyceride levels;
UCEC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.44	5.28	0.4	4.63e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.61	5.75	0.43	4.94e-8	Lung cancer;
UCEC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg01689657	chr7:91764605	CYP51A1	0.46	5.96	0.44	1.79e-8	Breast cancer;
UCEC	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.58	5.1	0.39	1.03e-6	Alcohol dependence;
UCEC	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.22	6.5	0.47	1.15e-9	Schizophrenia;
UCEC	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.05	-0.38	1.26e-6	Acylcarnitine levels;
UCEC	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	8.9	0.59	1.89e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	0.69	8.88	0.59	2.13e-15	Gut microbiome composition (winter);
UCEC	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.73	7.47	0.52	6.43e-12	Parkinson's disease;
UCEC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg00815214	chr21:47717953	NA	-0.39	-4.56	-0.35	1.09e-5	Testicular germ cell tumor;
UCEC	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.54	4.65	0.36	7.45e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg09132178	chr16:78079569	NA	0.49	5.53	0.42	1.42e-7	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.46	-4.68	-0.36	6.41e-6	Body mass index;
UCEC	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.75	5.57	0.42	1.18e-7	Major depressive disorder;
UCEC	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.43	-4.66	-0.36	7.04e-6	Total body bone mineral density;
UCEC	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.53	-5.02	-0.38	1.46e-6	Morning vs. evening chronotype;
UCEC	cis	rs4950937	0.830	rs946258	chr1:203190240	A/G	cg20961782	chr1:203452697	PRELP	0.51	4.87	0.37	2.87e-6	Blood protein levels;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.54	-6.53	-0.47	1.03e-9	Pubertal anthropometrics;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.72	8.25	0.56	8.07e-14	Menarche (age at onset);
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.55	-6.77	-0.49	2.9e-10	Monocyte percentage of white cells;
UCEC	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.56	-4.89	-0.37	2.57e-6	Major depressive disorder;
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.37	-5.2	-0.39	6.63e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.59	6.74	0.49	3.37e-10	Longevity;
UCEC	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	5.84	0.43	3.22e-8	Coffee consumption (cups per day);
UCEC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.43	4.56	0.35	1.05e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.12e-10	Chronic sinus infection;
UCEC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.46	5.19	0.39	6.77e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.46	-4.58	-0.35	9.86e-6	Depression;
UCEC	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.61	-6.0	-0.44	1.5e-8	Bipolar disorder;
UCEC	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	10.83	0.67	1.85e-20	Colorectal cancer;
UCEC	cis	rs2307449	0.929	rs7162771	chr15:89853468	T/C	cg23124613	chr15:89731485	ABHD2	-0.42	-4.9	-0.37	2.5e-6	Menopause (age at onset);
UCEC	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.93	4.5	0.35	1.36e-5	Thyroid stimulating hormone;
UCEC	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-0.8	-7.12	-0.51	4.46e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	5.52	0.41	1.51e-7	Mood instability;
UCEC	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.72	6.17	0.45	6.39e-9	Coronary artery disease;
UCEC	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.67	0.48	4.84e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.24	-0.65	6.48e-19	Monocyte count;
UCEC	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.51	5.4	0.41	2.65e-7	Type 2 diabetes;
UCEC	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.5	4.75	0.36	4.87e-6	Uric acid levels;
UCEC	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg08886695	chr4:3369023	RGS12	-0.51	-5.15	-0.39	8.4e-7	Serum sulfate level;
UCEC	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs151997	0.925	rs27287	chr5:50195567	C/A	cg06027927	chr5:50259733	NA	0.55	5.03	0.38	1.42e-6	Callous-unemotional behaviour;
UCEC	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.56	4.73	0.36	5.21e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-6.81	-0.49	2.28e-10	Mood instability;
UCEC	cis	rs9309473	0.607	rs58962779	chr2:73555801	T/C	cg20560298	chr2:73613845	ALMS1	-0.6	-5.54	-0.42	1.35e-7	Metabolite levels;
UCEC	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.53	-5.0	-0.38	1.59e-6	Breast size;
UCEC	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	5.08	0.39	1.15e-6	Aortic root size;
UCEC	cis	rs16932667	0.823	rs11063476	chr12:5140982	A/G	cg18770669	chr12:5541220	NTF3	0.42	4.68	0.36	6.47e-6	Intelligence (childhood);
UCEC	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.52	6.44	0.47	1.61e-9	Total body bone mineral density;
UCEC	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.88	0.37	2.73e-6	Rheumatoid arthritis;
UCEC	cis	rs16937	0.711	rs11240390	chr1:205179457	A/G	cg00857998	chr1:205179979	DSTYK	0.51	4.6	0.35	9.08e-6	Schizophrenia;
UCEC	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.65	-6.97	-0.5	1.02e-10	Hypospadias;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.56	-6.3	-0.46	3.24e-9	Pubertal anthropometrics;
UCEC	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs4851266	1.000	rs11686280	chr2:100827718	C/A	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg13147721	chr7:65941812	NA	-0.75	-5.06	-0.38	1.26e-6	Diabetic kidney disease;
UCEC	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.58	-5.04	-0.38	1.33e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg12024160	chr4:1254474	NA	-0.54	-7.11	-0.51	4.75e-11	Obesity-related traits;
UCEC	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	8.55	0.58	1.43e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.43	-4.77	-0.37	4.31e-6	Schizophrenia;
UCEC	cis	rs7336933	0.866	rs7318484	chr13:42463010	C/T	cg18400088	chr13:41634674	WBP4	0.54	4.58	0.35	1e-5	Calcium levels;
UCEC	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.18	-0.39	7.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8105895	0.935	rs62110981	chr19:22246013	A/G	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.64e-7	Body mass index (change over time);
UCEC	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.75	8.05	0.55	2.53e-13	Itch intensity from mosquito bite;
UCEC	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.77e-10	Chronic sinus infection;
UCEC	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	0.84	5.35	0.4	3.27e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.95	-6.75	-0.49	3.27e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.54	5.13	0.39	9.17e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs4372836	1.000	rs6707848	chr2:28988083	T/C	cg09522027	chr2:28974177	PPP1CB	-0.61	-6.46	-0.47	1.41e-9	Body mass index;
UCEC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.6	-6.87	-0.49	1.73e-10	Electrocardiographic conduction measures;
UCEC	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg24069376	chr3:38537580	EXOG	0.46	5.62	0.42	9.36e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.0	-0.5	8.47e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.78	7.74	0.54	1.44e-12	Lung cancer;
UCEC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg10820045	chr2:198174542	NA	-0.49	-6.07	-0.45	1.04e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	4.66	0.36	6.98e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.49	-6.25	-0.46	4.2e-9	Mean platelet volume;
UCEC	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg11150807	chr10:43354902	NA	-0.76	-4.69	-0.36	6.07e-6	Blood protein levels;
UCEC	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.73	-6.17	-0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg16583315	chr14:65563665	MAX	-0.43	-5.39	-0.41	2.72e-7	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.27e-30	Chronic sinus infection;
UCEC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.65	5.91	0.44	2.3e-8	Aortic root size;
UCEC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg18230493	chr5:56204884	C5orf35	-0.51	-4.56	-0.35	1.07e-5	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.65	0.36	7.3e-6	Menopause (age at onset);
UCEC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg23888215	chr10:79422304	NA	-1.14	-8.84	-0.59	2.74e-15	Bone mineral density;
UCEC	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.52	4.55	0.35	1.14e-5	Cholesterol, total;
UCEC	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8105895	1.000	rs57912102	chr19:22136043	T/C	cg20662725	chr19:22235022	ZNF257	-0.65	-5.44	-0.41	2.22e-7	Body mass index (change over time);
UCEC	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.79	8.65	0.58	8.08e-15	Blood protein levels;
UCEC	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.42	6.0	0.44	1.45e-8	Ulcerative colitis;
UCEC	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg13172905	chr8:30341765	RBPMS	-0.49	-4.53	-0.35	1.22e-5	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg22907277	chr7:1156413	C7orf50	0.6	5.47	0.41	1.91e-7	Longevity;Endometriosis;
UCEC	cis	rs6709815	0.841	rs12694442	chr2:219663599	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-5.07	-0.39	1.18e-6	Reticulocyte count;High light scatter reticulocyte count;
UCEC	cis	rs9039	1.000	rs9921107	chr16:9219845	G/T	cg08831531	chr16:9218945	NA	-0.43	-4.58	-0.35	9.84e-6	Menopause (age at onset);
UCEC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-9.07	-0.6	7.22e-16	Gut microbiome composition (summer);
UCEC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-4.99	-0.38	1.67e-6	Blood metabolite levels;
UCEC	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.63	-6.12	-0.45	8.25e-9	White matter hyperintensity burden;
UCEC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg22974920	chr21:40686053	BRWD1	0.63	5.12	0.39	9.5e-7	Cognitive function;
UCEC	cis	rs6840360	0.573	rs2407171	chr4:152256782	A/G	cg25486957	chr4:152246857	NA	-0.45	-4.92	-0.38	2.27e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.49	-5.65	-0.42	8.11e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.73	-9.18	-0.6	3.76e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	4.8	0.37	3.84e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.44	-4.84	-0.37	3.21e-6	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs9400271	0.527	rs11759269	chr6:109640488	C/T	cg01475377	chr6:109611718	NA	-0.46	-5.12	-0.39	9.31e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.65	6.49	0.47	1.25e-9	Coronary artery disease;
UCEC	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.53	-5.22	-0.4	5.94e-7	Diastolic blood pressure;
UCEC	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.55	7.87	0.54	7.31e-13	Height;
UCEC	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.67e-9	Rheumatoid arthritis;
UCEC	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.52	-4.9	-0.37	2.52e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg11859384	chr17:80120422	CCDC57	-0.49	-5.37	-0.41	2.98e-7	Life satisfaction;
UCEC	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.32	-0.52	1.53e-11	Caffeine consumption;
UCEC	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18932078	chr1:2524107	MMEL1	0.35	6.05	0.45	1.13e-8	Ulcerative colitis;
UCEC	cis	rs7246967	0.673	rs57027767	chr19:22876535	A/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg07506560	chr2:240697449	NA	0.41	4.7	0.36	5.84e-6	Obesity-related traits;
UCEC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg03354898	chr7:1950403	MAD1L1	0.47	5.59	0.42	1.07e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-8.23	-0.56	8.97e-14	Resting heart rate;
UCEC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.46	4.83	0.37	3.36e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.44	-4.61	-0.36	8.57e-6	Aortic root size;
UCEC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	0.69	6.55	0.48	9.16e-10	Breast cancer;
UCEC	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs925228	0.869	rs2712070	chr2:23985329	A/T	cg08744769	chr2:70142523	MXD1	0.66	6.68	0.48	4.63e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.81	0.59	3.26e-15	Longevity;Endometriosis;
UCEC	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-1.1	-7.03	-0.5	7.06e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.54	4.62	0.36	8.16e-6	Menarche (age at onset);
UCEC	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.55	6.15	0.45	6.85e-9	Neuroticism;
UCEC	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.65	-6.07	-0.45	1.05e-8	Platelet distribution width;
UCEC	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.57	7.02	0.5	7.49e-11	Subjective well-being (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	5.68	0.42	6.92e-8	Prudent dietary pattern;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.45	-0.41	2.08e-7	Pubertal anthropometrics;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.65	-0.36	7.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.21	-0.46	5.27e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg09307838	chr4:120376055	NA	0.6	5.31	0.4	3.97e-7	Educational attainment;
UCEC	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg17534202	chr9:96721102	NA	0.42	4.57	0.35	1.02e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.57	5.51	0.41	1.57e-7	Migraine;Coronary artery disease;
UCEC	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.65	-5.53	-0.42	1.4e-7	Multiple sclerosis;
UCEC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.59	-6.37	-0.47	2.24e-9	Prostate cancer;
UCEC	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.57	5.6	0.42	1.05e-7	Orofacial clefts;
UCEC	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg23307798	chr14:103986281	CKB	-0.44	-4.54	-0.35	1.17e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.49	5.55	0.42	1.28e-7	Blood metabolite ratios;
UCEC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.69	4.81	0.37	3.74e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg13683864	chr3:40499215	RPL14	0.7	7.47	0.52	6.46e-12	Renal cell carcinoma;
UCEC	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-7.71	-0.54	1.73e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.59	-6.42	-0.47	1.77e-9	Obesity-related traits;
UCEC	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.85	10.94	0.67	9.61e-21	Obesity-related traits;
UCEC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.67	0.42	7.31e-8	Cognitive test performance;
UCEC	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.73	7.17	0.51	3.38e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.52	-4.86	-0.37	2.96e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs6723108	0.603	rs3814354	chr2:135711657	G/A	cg07169764	chr2:136633963	MCM6	0.51	5.0	0.38	1.59e-6	Type 2 diabetes;
UCEC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.96	-0.38	1.92e-6	Breast cancer;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.52	-6.54	-0.47	9.33e-10	Pubertal anthropometrics;
UCEC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-7.56	-0.53	3.93e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.53	5.28	0.4	4.64e-7	Lung cancer;
UCEC	cis	rs251253	0.601	rs251241	chr5:172498259	A/G	cg08386832	chr5:172482807	C5orf41	-0.52	-4.77	-0.37	4.36e-6	PR interval;
UCEC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.6	-5.79	-0.43	4.07e-8	Blood metabolite levels;
UCEC	cis	rs2892463	0.565	rs9506226	chr13:30359329	C/A	cg10211454	chr13:31195985	USPL1	0.41	4.59	0.35	9.36e-6	Non-word repetition;
UCEC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9649465	0.551	rs10255400	chr7:123388036	G/A	cg03229431	chr7:123269106	ASB15	-0.57	-5.65	-0.42	7.98e-8	Migraine;
UCEC	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.44	-4.81	-0.37	3.68e-6	Longevity;
UCEC	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs2256039	0.736	rs2245980	chr9:86789462	A/G	cg06138027	chr9:86596281	HNRNPK;RMI1	0.51	4.53	0.35	1.22e-5	Multiple system atrophy;
UCEC	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg04154034	chr17:28927549	LRRC37B2	0.56	4.51	0.35	1.33e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs61776719	0.875	rs28683126	chr1:38402459	G/A	cg17077180	chr1:38461687	NA	0.6	6.48	0.47	1.29e-9	Coronary artery disease;
UCEC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	5.7	0.43	6.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.34	5.09	0.39	1.07e-6	Vitiligo;
UCEC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg17420585	chr12:42539391	GXYLT1	-0.42	-4.98	-0.38	1.74e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-0.97	-6.31	-0.46	3.06e-9	Diabetic kidney disease;
UCEC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.75	8.72	0.58	5.4e-15	Cognitive function;
UCEC	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg15133208	chr4:90757351	SNCA	-0.34	-4.59	-0.35	9.53e-6	Dementia with Lewy bodies;
UCEC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.53	-5.76	-0.43	4.75e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.44	4.66	0.36	7.12e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.45	-4.81	-0.37	3.65e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs17012589	0.910	rs7311887	chr12:85625315	G/C	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.59	-0.35	9.26e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg24069376	chr3:38537580	EXOG	0.47	5.73	0.43	5.44e-8	Electrocardiographic conduction measures;
UCEC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg00343986	chr7:65444356	GUSB	-0.51	-4.9	-0.37	2.54e-6	Calcium levels;
UCEC	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.51	0.35	1.32e-5	Prudent dietary pattern;
UCEC	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	7.28	0.52	1.82e-11	Migraine;Coronary artery disease;
UCEC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg19926144	chr10:661009	DIP2C	0.82	4.87	0.37	2.84e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.62	-7.16	-0.51	3.52e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.1	9.09	0.6	6.17e-16	Vitiligo;
UCEC	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.51	4.97	0.38	1.8e-6	High light scatter reticulocyte count;
UCEC	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.57	-5.31	-0.4	3.98e-7	Lupus nephritis in systemic lupus erythematosus;
UCEC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg00343986	chr7:65444356	GUSB	-0.52	-4.59	-0.35	9.47e-6	Aortic root size;
UCEC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg00339695	chr16:24857497	SLC5A11	0.5	5.62	0.42	9.31e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7870753	0.838	rs10761035	chr9:99236092	G/A	cg25260653	chr9:99212216	HABP4	0.58	5.85	0.43	3.1e-8	Height;
UCEC	cis	rs7004769	0.554	rs77515954	chr8:9172687	G/C	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.62	-0.36	8.42e-6	Breast cancer;
UCEC	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.11	9.61	0.62	2.86e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.42	-4.79	-0.37	3.95e-6	Response to antineoplastic agents;
UCEC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg13660082	chr14:53194042	PSMC6	-0.75	-6.32	-0.46	2.94e-9	Alzheimer's disease (late onset);
UCEC	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-11.22	-0.68	1.73e-21	Schizophrenia;
UCEC	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.74	0.49	3.41e-10	Breast cancer;
UCEC	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.42	4.93	0.38	2.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.48	4.72	0.36	5.36e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.5	-4.54	-0.35	1.18e-5	Diabetic retinopathy;
UCEC	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.78	-9.59	-0.62	3.33e-17	White blood cell count (basophil);
UCEC	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-6.06	-0.45	1.12e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	7.27	0.51	1.92e-11	Total cholesterol levels;
UCEC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-5.61	-0.42	9.74e-8	Total body bone mineral density;
UCEC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.75	-6.98	-0.5	9.21e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-1.07	-9.48	-0.62	6.14e-17	Dupuytren's disease;
UCEC	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.63	-7.36	-0.52	1.19e-11	Hemoglobin concentration;
UCEC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.83	7.25	0.51	2.23e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg03714773	chr7:91764589	CYP51A1	0.42	4.96	0.38	1.95e-6	Breast cancer;
UCEC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.9	8.27	0.56	7.28e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg18681998	chr4:17616180	MED28	0.87	9.63	0.62	2.51e-17	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	5.28	0.4	4.53e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.56	0.48	8.66e-10	Aortic root size;
UCEC	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.6	-5.47	-0.41	1.9e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.54	-6.55	-0.48	8.83e-10	Total body bone mineral density;
UCEC	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.95	7.43	0.52	8.17e-12	Vitiligo;
UCEC	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	4.84	0.37	3.22e-6	Joint mobility (Beighton score);
UCEC	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.6	6.94	0.5	1.14e-10	Obesity-related traits;
UCEC	cis	rs12681287	0.752	rs9297861	chr8:87254730	G/C	cg27223183	chr8:87520930	FAM82B	-0.64	-5.34	-0.4	3.48e-7	Caudate activity during reward;
UCEC	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.44	4.77	0.37	4.32e-6	Coronary artery disease;
UCEC	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.49	4.71	0.36	5.57e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-5.45	-0.41	2.03e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg06462663	chr19:18546047	ISYNA1	0.43	5.43	0.41	2.26e-7	Breast cancer;
UCEC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.79	-7.33	-0.52	1.45e-11	Diastolic blood pressure;
UCEC	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.71	7.85	0.54	8.06e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.94	-0.44	1.99e-8	Parkinson's disease;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.14	-0.45	7.48e-9	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.5	5.7	0.43	6.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.18	-0.45	6.07e-9	Superior crus of antihelix expression;
UCEC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.7	-7.65	-0.53	2.5e-12	Menopause (age at onset);
UCEC	cis	rs7101446	0.704	rs7112909	chr11:63181782	A/T	cg21706343	chr11:62521476	ZBTB3	0.53	4.65	0.36	7.47e-6	Economic and political preferences;
UCEC	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.43	4.54	0.35	1.18e-5	Eye color traits;
UCEC	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-6.69	-0.48	4.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.88	11.52	0.69	2.75e-22	Bone mineral density;
UCEC	cis	rs4972806	0.775	rs2857534	chr2:177035676	G/T	cg13092806	chr2:177043255	NA	0.56	5.29	0.4	4.41e-7	IgG glycosylation;
UCEC	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.48	5.0	0.38	1.61e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.73	-6.9	-0.49	1.42e-10	Aortic root size;
UCEC	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.77	-0.37	4.35e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.73	7.87	0.54	7.1e-13	Lymphocyte counts;
UCEC	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-5.44	-0.41	2.13e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg25767906	chr1:53392781	SCP2	-0.45	-4.71	-0.36	5.74e-6	Monocyte count;
UCEC	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs782107	0.674	rs3858563	chr12:58802776	C/T	cg19181132	chr12:59314527	LRIG3	0.42	4.61	0.36	8.66e-6	Interleukin-12p70 levels;
UCEC	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	0.68	4.84	0.37	3.3e-6	Diabetic retinopathy;
UCEC	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.59	-5.98	-0.44	1.63e-8	Hepatocellular carcinoma;
UCEC	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg00343986	chr7:65444356	GUSB	0.5	4.57	0.35	1.02e-5	Aortic root size;
UCEC	cis	rs970548	0.721	rs11239541	chr10:46001866	C/T	cg15223267	chr10:46222474	FAM21C	0.5	4.85	0.37	3.05e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.81	-10.07	-0.64	1.81e-18	White blood cell count (basophil);
UCEC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-5.26	-0.4	4.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-7.25	-0.51	2.14e-11	Glomerular filtration rate (creatinine);
UCEC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.12	0.39	9.26e-7	Bladder cancer;
UCEC	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.56	6.96	0.5	1.03e-10	Neuroticism;
UCEC	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	6.1	0.45	9.01e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.74	7.97	0.55	4.13e-13	Breast cancer;
UCEC	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.01	-0.38	1.53e-6	Joint mobility (Beighton score);
UCEC	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.58	6.29	0.46	3.51e-9	Joint mobility (Beighton score);
UCEC	cis	rs7709377	0.595	rs1382344	chr5:115616350	G/A	cg23108291	chr5:115420582	COMMD10	0.49	5.01	0.38	1.55e-6	Metabolite levels  (X-11787);
UCEC	cis	rs2242663	0.798	rs1791679	chr11:66337874	C/A	cg24851651	chr11:66362959	CCS	0.47	5.97	0.44	1.67e-8	Bipolar disorder;
UCEC	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.66	-8.26	-0.56	7.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.84	-8.46	-0.57	2.42e-14	Obesity-related traits;
UCEC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.13e-11	Schizophrenia;
UCEC	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.46	-4.67	-0.36	6.61e-6	Blood protein levels;
UCEC	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs2075165	0.901	rs7542045	chr1:156246473	G/C	cg20302342	chr1:156215951	PAQR6	0.53	5.45	0.41	2.03e-7	Tonsillectomy;
UCEC	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.69	8.38	0.57	3.91e-14	Immature fraction of reticulocytes;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.78	-0.49	2.7e-10	Cardiac Troponin-T levels;
UCEC	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg05660106	chr1:15850417	CASP9	0.99	11.32	0.68	9.48e-22	Systolic blood pressure;
UCEC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.62	5.45	0.41	2.09e-7	Aortic root size;
UCEC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg03711944	chr11:47377212	SPI1	-0.51	-4.59	-0.35	9.48e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	trans	rs66573146	1.000	rs66573146	chr4:6984464	C/G	cg07817883	chr1:32538562	TMEM39B	1.16	9.43	0.61	8.15e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.7	7.73	0.54	1.55e-12	Prudent dietary pattern;
UCEC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.34	4.62	0.36	8.39e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.58	-5.18	-0.39	7.18e-7	Reticulocyte count;
UCEC	cis	rs17106184	1.000	rs72902763	chr1:51255320	T/C	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.45	5.01	0.38	1.54e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg20007245	chr22:24372913	LOC391322	-0.57	-6.14	-0.45	7.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.61	5.81	0.43	3.68e-8	Corneal astigmatism;
UCEC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.5	-5.65	-0.42	8.01e-8	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg11871910	chr12:69753446	YEATS4	0.73	7.75	0.54	1.41e-12	Blood protein levels;
UCEC	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.68	7.14	0.51	3.98e-11	Blood metabolite levels;
UCEC	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.5	-5.09	-0.39	1.08e-6	Schizophrenia;
UCEC	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.87	-9.46	-0.62	7.07e-17	Cognitive function;
UCEC	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.44	-4.75	-0.37	4.71e-6	Response to temozolomide;
UCEC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.43	-4.55	-0.35	1.11e-5	Aortic root size;
UCEC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.49	-5.39	-0.41	2.79e-7	Prostate cancer;
UCEC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.61	5.13	0.39	9.1e-7	Blood metabolite levels;
UCEC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.68	6.1	0.45	8.81e-9	Lymphocyte percentage of white cells;
UCEC	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.78	-6.13	-0.45	7.6e-9	Calcium levels;
UCEC	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.83	9.18	0.6	3.66e-16	Breast cancer;
UCEC	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-20.81	-0.86	1.13e-45	Myeloid white cell count;
UCEC	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.13	-0.51	4.11e-11	Colorectal cancer;
UCEC	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.57	-0.48	7.98e-10	Adiposity;
UCEC	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.67	0.48	4.84e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.73	-6.0	-0.44	1.44e-8	Cisplatin-induced ototoxicity;
UCEC	cis	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14521931	chr5:10832172	NA	-0.59	-5.36	-0.4	3.11e-7	Alcohol consumption (maxi-drinks);
UCEC	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.18e-6	Vitiligo;
UCEC	cis	rs3816063	0.925	rs35212078	chr8:142160829	T/G	cg04124606	chr8:142095021	NA	0.42	4.55	0.35	1.09e-5	Obesity-related traits;
UCEC	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.5	0.53	5.66e-12	Schizophrenia;
UCEC	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.49	5.0	0.38	1.65e-6	Colorectal cancer;
UCEC	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.57	6.28	0.46	3.65e-9	Blood metabolite levels;
UCEC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg12559939	chr2:27858050	GPN1	0.45	4.65	0.36	7.22e-6	Oral cavity cancer;
UCEC	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.61	-6.26	-0.46	4e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.89	7.48	0.53	6.13e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg27246729	chr12:121163418	ACADS	0.5	4.68	0.36	6.53e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.54	-5.5	-0.41	1.61e-7	Hepatocellular carcinoma;
UCEC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.75	8.26	0.56	7.83e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.71	5.73	0.43	5.4e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.6	-0.42	1e-7	Fear of minor pain;
UCEC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-6.35	-0.46	2.51e-9	Tonsillectomy;
UCEC	cis	rs3015497	0.587	rs1353204	chr14:51081515	C/T	cg04730355	chr14:51134070	SAV1	-0.52	-5.5	-0.41	1.66e-7	Mean platelet volume;
UCEC	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-13.35	-0.74	3.95e-27	Body mass index;
UCEC	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.5	-5.06	-0.38	1.26e-6	Breast cancer;
UCEC	cis	rs354033	1.000	rs354031	chr7:149285921	A/G	cg24335155	chr7:149193227	ZNF746	0.39	4.74	0.36	4.98e-6	Multiple sclerosis;
UCEC	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05962382	chr2:130345044	NA	-0.49	-5.85	-0.43	3.09e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs1576263	0.967	rs9328489	chr6:8562117	G/T	cg21535247	chr6:8435926	SLC35B3	-0.48	-5.02	-0.38	1.48e-6	Photic sneeze reflex;
UCEC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.04	6.46	0.47	1.45e-9	Diabetic retinopathy;
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.27	-0.4	4.86e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9999118	0.744	rs304676	chr4:124145289	T/G	cg17338352	chr4:123653805	LOC729338;BBS12	-0.61	-4.7	-0.36	6.05e-6	Irritable bowel syndrome;
UCEC	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.74	-7.67	-0.53	2.16e-12	Bipolar disorder and schizophrenia;
UCEC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.46	-5.54	-0.42	1.38e-7	Height;
UCEC	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	0.69	4.76	0.37	4.66e-6	Iron status biomarkers;
UCEC	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.48	7.5	0.53	5.54e-12	Airflow obstruction;
UCEC	cis	rs8016620	1.000	rs8016620	chr14:97393685	A/G	cg00912449	chr14:97431137	NA	-0.85	-4.75	-0.36	4.82e-6	Obesity-related traits;
UCEC	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.84	10.58	0.66	8.47e-20	Metabolic syndrome;
UCEC	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-0.89	-7.5	-0.53	5.62e-12	Blood pressure (smoking interaction);
UCEC	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.6	5.01	0.38	1.53e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg11150807	chr10:43354902	NA	-0.74	-4.63	-0.36	7.83e-6	Blood protein levels;
UCEC	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg26898376	chr11:64110657	CCDC88B	0.38	4.51	0.35	1.3e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	1.06	12.09	0.71	8.66e-24	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.7	-7.37	-0.52	1.12e-11	Longevity;Endometriosis;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.52	4.88	0.37	2.75e-6	Intelligence;Intelligence (multi-trait analysis);
UCEC	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.55	-6.37	-0.47	2.23e-9	Type 2 diabetes;
UCEC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.58	-6.88	-0.49	1.63e-10	Multiple myeloma;
UCEC	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.77	-0.49	2.85e-10	Obesity-related traits;
UCEC	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.56	-4.91	-0.38	2.36e-6	Carotid intima media thickness;
UCEC	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.4	4.87	0.37	2.8e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs2892463	0.796	rs4265673	chr13:30365439	G/T	cg18356743	chr13:30408050	UBL3	-0.4	-4.51	-0.35	1.34e-5	Non-word repetition;
UCEC	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.41	-5.27	-0.4	4.68e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.77	-6.78	-0.49	2.68e-10	Initial pursuit acceleration;
UCEC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	0.88	5.21	0.39	6.24e-7	Skin colour saturation;
UCEC	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.75	9.05	0.6	7.88e-16	Bone mineral density;
UCEC	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.97	7.28	0.51	1.91e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13470333	chr7:1908714	MAD1L1	0.34	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.57	6.44	0.47	1.62e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs66573146	1.000	rs56178503	chr4:6961748	C/T	cg00086871	chr4:6988644	TBC1D14	0.77	4.95	0.38	2e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg19539664	chr3:44753367	ZNF502	-0.45	-4.78	-0.37	4.26e-6	Depressive symptoms;
UCEC	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-0.97	-7.03	-0.5	7.13e-11	Body mass index;
UCEC	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.63	7.52	0.53	4.98e-12	Obesity-related traits;
UCEC	cis	rs7968440	1.000	rs11609231	chr12:50932430	A/G	cg20014596	chr12:50898483	DIP2B	0.49	4.85	0.37	3.18e-6	Fibrinogen;
UCEC	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.82	-9.47	-0.62	6.72e-17	Coronary artery disease;
UCEC	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg04374321	chr14:90722782	PSMC1	0.58	5.13	0.39	8.98e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.49	4.53	0.35	1.19e-5	Lung cancer;
UCEC	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-6.7	-0.48	4.23e-10	Heart rate;
UCEC	trans	rs4534959	0.546	rs7241119	chr18:62059495	A/G	cg18966047	chr5:180480456	BTNL9	1.31	6.98	0.5	9.49e-11	Airflow obstruction;
UCEC	cis	rs7088591	0.867	rs11815071	chr10:59783588	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18252515	chr7:66147081	NA	-0.54	-5.1	-0.39	1.05e-6	Aortic root size;
UCEC	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.52	-0.69	2.74e-22	Monocyte count;
UCEC	cis	rs6493487	0.512	rs7162325	chr15:51121400	A/T	cg20651644	chr15:50170642	ATP8B4	0.51	4.64	0.36	7.55e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs7095607	0.704	rs6480309	chr10:69953066	G/A	cg18986048	chr10:69913749	MYPN	0.52	5.79	0.43	4.2e-8	Lung function (FVC);
UCEC	cis	rs11760485	0.824	rs73051240	chr7:4400400	T/C	cg15613991	chr7:5277080	NA	-0.4	-4.65	-0.36	7.44e-6	Early childhood aggressive behavior;
UCEC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.58	-0.48	7.59e-10	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24249390	chr15:90295951	MESP1	-0.43	-4.97	-0.38	1.87e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg11742103	chr11:62369870	EML3;MTA2	-0.35	-4.64	-0.36	7.72e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg20119798	chr7:94954144	PON1	-0.52	-4.62	-0.36	8.39e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.66	5.77	0.43	4.55e-8	Aortic root size;
UCEC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	0.7	5.6	0.42	1e-7	Alzheimer's disease;
UCEC	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.69	-8.62	-0.58	9.74e-15	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.57	-7.44	-0.52	7.9e-12	Prudent dietary pattern;
UCEC	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.5	5.96	0.44	1.82e-8	Total cholesterol levels;
UCEC	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg19041857	chr6:27730383	NA	-0.7	-5.46	-0.41	1.94e-7	Depression;
UCEC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg12463550	chr7:65579703	CRCP	-0.54	-5.41	-0.41	2.56e-7	Aortic root size;
UCEC	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.54	-6.22	-0.46	4.97e-9	Lung cancer;
UCEC	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.63	0.42	8.9e-8	Height;
UCEC	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-0.84	-4.72	-0.36	5.34e-6	Inflammatory biomarkers;
UCEC	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.45	4.62	0.36	8.42e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	2.01e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.87	-9.83	-0.63	7.84e-18	Cognitive function;
UCEC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-0.99	-14.73	-0.77	9.43e-31	Homoarginine levels;
UCEC	cis	rs7607369	0.536	rs12990447	chr2:219667413	T/C	cg02176678	chr2:219576539	TTLL4	-0.51	-5.15	-0.39	8.14e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.94	9.98	0.64	3.14e-18	Cognitive function;
UCEC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.0	-0.44	1.49e-8	Aortic root size;
UCEC	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.65	-7.42	-0.52	8.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.03	-12.56	-0.72	4.71e-25	Dilated cardiomyopathy;
UCEC	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.6	4.67	0.36	6.62e-6	Orofacial clefts;
UCEC	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.97	6.02	0.44	1.32e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.61	5.43	0.41	2.28e-7	HDL cholesterol;
UCEC	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.81	0.49	2.33e-10	Motion sickness;
UCEC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.48	4.86	0.37	3e-6	Prostate cancer;
UCEC	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	0.74	5.5	0.41	1.64e-7	Post bronchodilator FEV1;
UCEC	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	0.54	5.47	0.41	1.9e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.68	-6.11	-0.45	8.45e-9	Prudent dietary pattern;
UCEC	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.56	-7.28	-0.51	1.91e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.97	0.5	9.86e-11	Coronary artery disease;
UCEC	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.68	7.14	0.51	4.03e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.59	6.29	0.46	3.49e-9	IgG glycosylation;
UCEC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.66	6.78	0.49	2.69e-10	Tonsillectomy;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.47	-0.47	1.38e-9	Pubertal anthropometrics;
UCEC	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.96e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg15541040	chr2:3486749	NA	-0.61	-5.42	-0.41	2.4e-7	Neurofibrillary tangles;
UCEC	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg04851639	chr8:1020857	NA	-0.42	-5.75	-0.43	5.07e-8	Schizophrenia;
UCEC	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg17800788	chr1:21766015	NBPF3	0.4	5.77	0.43	4.58e-8	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs73206853	0.925	rs28670753	chr12:110826463	C/T	cg12870014	chr12:110450643	ANKRD13A	0.57	5.24	0.4	5.46e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-13.29	-0.74	5.88e-27	Height;
UCEC	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.33	0.52	1.44e-11	Obesity-related traits;
UCEC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.39	-4.59	-0.35	9.49e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.53	4.86	0.37	2.94e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.78	7.14	0.51	4.08e-11	Educational attainment;
UCEC	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.88	12.32	0.71	2.05e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4849887	1.000	rs7575067	chr2:121241958	T/C	cg00421221	chr2:121106091	INHBB	0.43	4.52	0.35	1.26e-5	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.58	-0.35	9.74e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg13147721	chr7:65941812	NA	-0.97	-6.48	-0.47	1.29e-9	Diabetic kidney disease;
UCEC	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.45	4.64	0.36	7.56e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.57	-8.33	-0.57	5.35e-14	Refractive error;
UCEC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.49	-4.81	-0.37	3.76e-6	Dental caries;
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.47	-4.73	-0.36	5.24e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.673	rs8104564	chr19:22867207	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.69	-7.76	-0.54	1.32e-12	Bone mineral density;
UCEC	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.04	0.45	1.19e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.48	-4.83	-0.37	3.34e-6	Parkinson's disease;
UCEC	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.67	6.2	0.46	5.41e-9	Schizophrenia;
UCEC	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.48	-5.02	-0.38	1.49e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	7.3	0.52	1.63e-11	Platelet count;
UCEC	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.91	-0.38	2.45e-6	Aortic root size;
UCEC	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg19413350	chr8:57351067	NA	-0.39	-4.63	-0.36	7.91e-6	Obesity-related traits;
UCEC	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.68	9.04	0.6	8.62e-16	Coronary artery disease;
UCEC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	6.18	0.45	5.92e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	6.01	0.44	1.4e-8	Menarche (age at onset);
UCEC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.64	-6.01	-0.44	1.37e-8	Aortic root size;
UCEC	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg18512352	chr11:47633146	NA	-0.38	-4.59	-0.35	9.43e-6	Subjective well-being;
UCEC	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.76	8.6	0.58	1.09e-14	Mortality in heart failure;
UCEC	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.56	5.19	0.39	6.92e-7	Coronary artery disease;
UCEC	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-4.63	-0.36	8.11e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg16743903	chr16:89593216	SPG7	-0.48	-4.8	-0.37	3.89e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.61	-6.02	-0.44	1.33e-8	Dental caries;
UCEC	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.35	-4.75	-0.37	4.71e-6	Breast cancer;
UCEC	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.59	7.17	0.51	3.4e-11	Inhibitory control;
UCEC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.73	-6.86	-0.49	1.81e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.38	-4.52	-0.35	1.24e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.59	-5.74	-0.43	5.14e-8	White matter hyperintensity burden;
UCEC	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.66	-6.08	-0.45	1.01e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.65	6.81	0.49	2.3e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg16744186	chr7:2138722	MAD1L1	-0.43	-4.94	-0.38	2.07e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg14092571	chr14:90743983	NA	0.38	4.75	0.37	4.71e-6	Mortality in heart failure;
UCEC	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.23	12.11	0.71	7.57e-24	Corneal structure;
UCEC	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg03859395	chr2:55845619	SMEK2	1.0	14.11	0.76	3.97e-29	Metabolic syndrome;
UCEC	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	0.93	13.85	0.75	1.96e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	0.92	12.78	0.73	1.25e-25	Homoarginine levels;
UCEC	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.55	8.47	0.57	2.28e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-6.42	-0.47	1.81e-9	Asthma;
UCEC	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg07930192	chr7:1003750	NA	0.46	4.82	0.37	3.47e-6	Longevity;Endometriosis;
UCEC	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg05660106	chr1:15850417	CASP9	0.51	5.11	0.39	9.81e-7	Systolic blood pressure;
UCEC	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.53	-4.67	-0.36	6.79e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.59	5.55	0.42	1.3e-7	Skin colour saturation;
UCEC	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Morning vs. evening chronotype;
UCEC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.69	-6.76	-0.49	2.97e-10	Blood metabolite levels;
UCEC	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-5.64	-0.42	8.29e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs787274	1.000	rs787298	chr9:115542206	C/T	cg13803584	chr9:115635662	SNX30	-0.69	-5.64	-0.42	8.63e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.46	-4.59	-0.35	9.33e-6	Menopause (age at onset);
UCEC	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.78	-6.81	-0.49	2.37e-10	Caudate activity during reward;
UCEC	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.71	9.18	0.6	3.59e-16	Rheumatoid arthritis;
UCEC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	0.69	5.06	0.38	1.26e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg22974920	chr21:40686053	BRWD1	0.64	5.55	0.42	1.27e-7	Cognitive function;
UCEC	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-5.84	-0.43	3.15e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.64	9.28	0.61	2e-16	Prudent dietary pattern;
UCEC	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	5.28	0.4	4.46e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.55	-0.35	1.12e-5	Breast cancer;
UCEC	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.49	-4.66	-0.36	7.05e-6	Cystic fibrosis severity;
UCEC	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.76	-7.31	-0.52	1.57e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg13575925	chr12:9217583	LOC144571	0.42	5.14	0.39	8.48e-7	Sjögren's syndrome;
UCEC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.49	-6.6	-0.48	7.09e-10	Prostate cancer;
UCEC	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.99	0.5	8.94e-11	Mood instability;
UCEC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.5	-5.32	-0.4	3.74e-7	Bipolar disorder;
UCEC	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.79	6.41	0.47	1.9e-9	Coronary artery disease;
UCEC	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.63	6.92	0.5	1.28e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.32	4.51	0.35	1.32e-5	Alzheimer's disease (late onset);
UCEC	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.5	-0.41	1.61e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.42	-4.57	-0.35	1.01e-5	Prostate cancer;
UCEC	cis	rs17433710	0.778	rs61811980	chr1:162674489	C/T	cg19264028	chr1:162630153	DDR2	1.07	4.65	0.36	7.3e-6	Dupuytren's disease;
UCEC	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.68	-6.24	-0.46	4.39e-9	Asthma;
UCEC	cis	rs877282	0.853	rs4579862	chr10:753298	A/C	cg17470449	chr10:769945	NA	0.52	4.76	0.37	4.65e-6	Uric acid levels;
UCEC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.68	6.06	0.45	1.08e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.1	8.11	0.56	1.87e-13	Alzheimer's disease (late onset);
UCEC	cis	rs6539267	0.885	rs12579099	chr12:106765727	A/G	cg02476566	chr12:106696527	TCP11L2	0.61	5.0	0.38	1.59e-6	Tourette syndrome;
UCEC	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.59	-5.03	-0.38	1.44e-6	Reticulocyte count;
UCEC	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.49	4.96	0.38	1.95e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg16616514	chr4:6324629	PPP2R2C	0.39	4.81	0.37	3.64e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-5.85	-0.43	3e-8	Menarche (age at onset);
UCEC	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	7.04	0.5	6.77e-11	Coffee consumption (cups per day);
UCEC	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.43	-4.52	-0.35	1.28e-5	White matter hyperintensity burden;
UCEC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	7.08	0.5	5.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg03114573	chr12:45410052	DBX2	0.45	4.52	0.35	1.26e-5	Gut microbiome composition (summer);
UCEC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	0.99	6.29	0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg04553112	chr3:125709451	NA	-0.64	-4.72	-0.36	5.53e-6	Blood pressure (smoking interaction);
UCEC	cis	rs6684428	1.000	rs12141873	chr1:56374311	G/T	cg11651538	chr1:56320950	NA	-0.75	-6.44	-0.47	1.6e-9	Airflow obstruction;
UCEC	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.56	5.56	0.42	1.22e-7	Adiposity;
UCEC	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.66	-5.55	-0.42	1.31e-7	Alcohol dependence;
UCEC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg14078730	chr11:63896557	MACROD1	0.62	4.85	0.37	3.14e-6	Mean platelet volume;
UCEC	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24308560	chr3:49941425	MST1R	-0.44	-4.76	-0.37	4.67e-6	Body mass index;
UCEC	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg08886695	chr4:3369023	RGS12	-0.56	-5.54	-0.42	1.36e-7	Serum sulfate level;
UCEC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg05738196	chr6:26577821	NA	0.58	6.27	0.46	3.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.75	-0.37	4.69e-6	Obesity-related traits;
UCEC	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg16558253	chr16:72132732	DHX38	-0.48	-5.13	-0.39	9.13e-7	Blood protein levels;
UCEC	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg01262667	chr19:19385393	TM6SF2	0.5	7.14	0.51	3.93e-11	Tonsillectomy;
UCEC	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.49	4.83	0.37	3.4e-6	Height;
UCEC	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.88	-9.39	-0.61	1.06e-16	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg15147215	chr3:52552868	STAB1	-0.58	-6.6	-0.48	7.12e-10	Bipolar disorder;
UCEC	cis	rs9470794	1.000	rs79287562	chr6:38095957	A/G	cg03458162	chr6:37400668	FTSJD2	0.81	4.8	0.37	3.94e-6	Type 2 diabetes;
UCEC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.97	12.38	0.71	1.43e-24	Breast cancer;
UCEC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs2167364	0.746	rs1817074	chr7:50574012	T/C	cg18232548	chr7:50535776	DDC	0.52	5.67	0.42	7.48e-8	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.49	4.9	0.37	2.56e-6	Morning vs. evening chronotype;
UCEC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	4.71	0.36	5.66e-6	Neuroticism;
UCEC	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.09	7.63	0.53	2.68e-12	Sexual dysfunction (female);
UCEC	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg03711944	chr11:47377212	SPI1	-0.51	-4.81	-0.37	3.63e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-5.4	-0.41	2.66e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14019695	chr9:139328340	INPP5E	-0.51	-5.55	-0.42	1.29e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.54	7.64	0.53	2.64e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-10.12	-0.64	1.33e-18	Schizophrenia;
UCEC	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg19041857	chr6:27730383	NA	-0.64	-5.07	-0.39	1.19e-6	Lung cancer in ever smokers;
UCEC	cis	rs7015263	0.572	rs11787036	chr8:87375876	A/C	cg27223183	chr8:87520930	FAM82B	0.46	4.67	0.36	6.82e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.47	4.75	0.36	4.74e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.67	-7.32	-0.52	1.52e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.08	-8.51	-0.57	1.82e-14	Vitiligo;
UCEC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.57	0.35	1.04e-5	Height;
UCEC	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-4.86	-0.37	2.97e-6	Hypospadias;
UCEC	cis	rs9463078	0.764	rs9367211	chr6:44885305	T/C	cg25276700	chr6:44698697	NA	-0.42	-4.72	-0.36	5.37e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.64	-6.87	-0.49	1.68e-10	Homoarginine levels;
UCEC	cis	rs6893807	1.000	rs1422192	chr5:87959023	G/A	cg09002922	chr5:87956389	LOC645323	-0.58	-5.76	-0.43	4.72e-8	Body mass index;
UCEC	cis	rs8105895	1.000	rs79846980	chr19:22141343	T/C	cg02912127	chr19:22235281	ZNF257	-0.61	-4.87	-0.37	2.86e-6	Body mass index (change over time);
UCEC	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg15848620	chr12:58087721	OS9	-0.53	-5.0	-0.38	1.62e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.73	-5.82	-0.43	3.56e-8	Corneal structure;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.71	-0.43	6.13e-8	Pubertal anthropometrics;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.68	-0.42	6.93e-8	Longevity;Endometriosis;
UCEC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.81	0.59	3.25e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-10.4	-0.65	2.44e-19	Intelligence (multi-trait analysis);
UCEC	trans	rs6581612	0.683	rs2047486	chr12:65625091	C/T	cg12591315	chr12:10022688	CLEC2B	-0.65	-6.68	-0.48	4.66e-10	Hippocampal volume;
UCEC	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.0	-8.14	-0.56	1.56e-13	Exhaled nitric oxide output;
UCEC	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	10.3	0.65	4.64e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7611694	0.501	rs7623122	chr3:113136418	C/T	cg12596171	chr3:113251061	SIDT1	-0.54	-5.37	-0.4	3.08e-7	Prostate cancer;
UCEC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16164276	chr3:11034345	SLC6A1	0.5	4.65	0.36	7.2e-6	Alzheimer's disease;
UCEC	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.91	8.7	0.58	6.3e-15	Colorectal adenoma (advanced);
UCEC	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg17547346	chr11:68671486	IGHMBP2;MRPL21	-0.47	-4.5	-0.35	1.36e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.38	4.52	0.35	1.27e-5	Multiple system atrophy;
UCEC	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg13256891	chr4:100009986	ADH5	-0.71	-5.3	-0.4	4.09e-7	Alcohol dependence;
UCEC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.73	5.32	0.4	3.72e-7	Body mass index;
UCEC	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.63	5.09	0.39	1.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.59	-5.69	-0.43	6.52e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.62	5.95	0.44	1.89e-8	Lymphocyte counts;
UCEC	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.46	-4.63	-0.36	8.08e-6	Schizophrenia;
UCEC	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg19041857	chr6:27730383	NA	-0.64	-5.09	-0.39	1.06e-6	Lung cancer in ever smokers;
UCEC	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.5	5.43	0.41	2.23e-7	QRS complex (12-leadsum);
UCEC	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.66	0.36	6.93e-6	Menarche (age at onset);
UCEC	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.43	5.56	0.42	1.21e-7	Schizophrenia;
UCEC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.75	8.25	0.56	8.34e-14	Menopause (age at onset);
UCEC	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.32	-0.4	3.75e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-4.9	-0.37	2.52e-6	Aortic root size;
UCEC	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs711830	1.000	rs1549334	chr2:177039197	G/A	cg13092806	chr2:177043255	NA	0.94	9.46	0.62	6.82e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.48	-4.71	-0.36	5.59e-6	Total body bone mineral density;
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.17e-14	Prudent dietary pattern;
UCEC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.69	7.87	0.54	7.25e-13	Menarche (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15459742	chr9:111775564	CTNNAL1	0.6	6.99	0.5	8.71e-11	Warfarin maintenance dose;
UCEC	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.51	-4.54	-0.35	1.18e-5	Colorectal cancer;
UCEC	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	1.02	10.4	0.65	2.46e-19	Post bronchodilator FEV1;
UCEC	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.66	-7.5	-0.53	5.7e-12	Extraversion;
UCEC	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.7	4.55	0.35	1.11e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.66	0.58	7.7e-15	Prudent dietary pattern;
UCEC	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.74	-6.68	-0.48	4.68e-10	Caudate activity during reward;
UCEC	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	6.41	0.47	1.82e-9	Platelet count;
UCEC	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.73	-0.43	5.62e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.48	-6.3	-0.46	3.22e-9	Refractive error;
UCEC	cis	rs7246967	0.611	rs3853652	chr19:22871913	C/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.52	6.05	0.45	1.17e-8	Mean corpuscular volume;
UCEC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-5.52	-0.41	1.5e-7	Mean platelet volume;
UCEC	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.49	-5.27	-0.4	4.7e-7	QRS complex (12-leadsum);
UCEC	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.86	-0.37	3.01e-6	Breast cancer;
UCEC	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.63	-5.65	-0.42	8.01e-8	Pulmonary function;
UCEC	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-8.24	-0.56	8.89e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	1.12	13.32	0.74	4.78e-27	Post bronchodilator FEV1;
UCEC	cis	rs7633770	0.735	rs877680	chr3:46702471	A/G	cg11219411	chr3:46661640	NA	0.5	5.81	0.43	3.65e-8	Coronary artery disease;
UCEC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-5.76	-0.43	4.86e-8	Monocyte percentage of white cells;
UCEC	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-7.87	-0.54	7.09e-13	Vitiligo;
UCEC	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.38	-0.52	1.1e-11	Chronic sinus infection;
UCEC	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.55	-5.21	-0.4	6.14e-7	High light scatter reticulocyte count;
UCEC	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.67	-7.65	-0.53	2.38e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.52	-0.47	1.05e-9	Total cholesterol levels;
UCEC	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	5.13	0.39	9e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.43	-5.43	-0.41	2.27e-7	Urinary tract infection frequency;
UCEC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	5.54	0.42	1.34e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg10932868	chr11:921992	NA	0.43	5.62	0.42	9.47e-8	Alzheimer's disease (late onset);
UCEC	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	6.81	0.49	2.31e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg05855489	chr10:104503620	C10orf26	-0.51	-5.2	-0.39	6.6e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.64	-5.76	-0.43	4.75e-8	Menarche (age at onset);
UCEC	cis	rs370915	0.542	rs1000060	chr4:187839499	G/A	cg19519643	chr4:187840862	NA	-0.49	-5.35	-0.4	3.27e-7	Gout;
UCEC	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs10540	0.686	rs12806099	chr11:531572	G/A	cg03576123	chr11:487126	PTDSS2	-0.96	-7.01	-0.5	8.17e-11	Body mass index;
UCEC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.54	-5.06	-0.39	1.21e-6	Blood protein levels;
UCEC	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.97	0.38	1.84e-6	Monocyte percentage of white cells;
UCEC	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.71	-0.43	5.96e-8	Fear of minor pain;
UCEC	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.86	0.49	1.79e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.91	-0.38	2.42e-6	Bipolar disorder;
UCEC	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.92	9.0	0.6	1.08e-15	Post bronchodilator FEV1;
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.84	-10.15	-0.64	1.13e-18	Paraoxonase activity;
UCEC	cis	rs6820391	0.748	rs7675771	chr4:54447002	G/C	cg04173182	chr4:54446035	LNX1	0.36	4.54	0.35	1.16e-5	Cervical artery dissection;
UCEC	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.74	-7.38	-0.52	1.08e-11	Caffeine consumption;
UCEC	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.88	0.37	2.72e-6	Diabetic retinopathy;
UCEC	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.52	-5.39	-0.41	2.73e-7	Body mass index;
UCEC	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.64	-4.62	-0.36	8.43e-6	Gut microbiome composition (summer);
UCEC	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.66	-7.81	-0.54	1e-12	Monocyte count;
UCEC	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.85	-8.82	-0.59	3.03e-15	Itch intensity from mosquito bite;
UCEC	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	13.79	0.75	2.77e-28	Height;
UCEC	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-13.45	-0.74	2.19e-27	Schizophrenia;
UCEC	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	0.75	4.79	0.37	3.98e-6	Diabetic retinopathy;
UCEC	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.78	-8.22	-0.56	9.73e-14	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.96	7.01	0.5	8.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs61776719	0.875	rs28683126	chr1:38402459	G/A	cg18451016	chr1:38461880	NA	0.66	7.14	0.51	3.91e-11	Coronary artery disease;
UCEC	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.46	-4.75	-0.36	4.73e-6	Personality dimensions;
UCEC	cis	rs10924970	0.649	rs3795250	chr1:235383351	T/C	cg26050004	chr1:235667680	B3GALNT2	0.47	4.6	0.35	9.17e-6	Asthma;
UCEC	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-0.95	-9.46	-0.62	7e-17	Dilated cardiomyopathy;
UCEC	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.76	-6.82	-0.49	2.17e-10	Inflammatory bowel disease;
UCEC	cis	rs427691	0.625	rs845735	chr5:109023871	C/G	cg17395555	chr5:108820864	NA	-0.63	-4.82	-0.37	3.59e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.56	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs4722166	0.532	rs4719713	chr7:22758811	G/A	cg05472934	chr7:22766657	IL6	0.54	5.15	0.39	8.4e-7	Lung cancer;
UCEC	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.2	-0.46	5.37e-9	Resting heart rate;
UCEC	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.92	0.38	2.31e-6	Diabetic retinopathy;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.53	-0.35	1.22e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.43	0.47	1.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg06466757	chr4:1255808	NA	0.46	4.83	0.37	3.39e-6	Obesity-related traits;
UCEC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.44	-5.81	-0.43	3.71e-8	Urinary metabolites;
UCEC	cis	rs14403	1.000	rs55655818	chr1:243661222	G/T	cg21452805	chr1:244014465	NA	0.57	4.8	0.37	3.81e-6	Schizophrenia;
UCEC	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg05539622	chr2:73298971	SFXN5	0.47	4.52	0.35	1.27e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs78487399	0.808	rs113377695	chr2:43835359	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.52	-0.35	1.24e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6756513	0.520	rs7569566	chr2:70174030	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.51	-0.35	1.31e-5	Breast cancer;Platelet count;
UCEC	cis	rs4615376	1.000	rs4711909	chr6:13060214	C/A	cg11378619	chr6:12164359	HIVEP1	-0.5	-4.81	-0.37	3.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg04154034	chr17:28927549	LRRC37B2	0.65	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg22166914	chr1:53195759	ZYG11B	0.58	6.03	0.45	1.26e-8	Monocyte count;
UCEC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.59	0.42	1.05e-7	Rheumatoid arthritis;
UCEC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg13395646	chr4:1353034	KIAA1530	0.6	5.84	0.43	3.24e-8	Obesity-related traits;
UCEC	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs2473248	1.000	rs2744726	chr1:22539571	C/A	cg22683154	chr1:23345188	KDM1A	0.46	4.84	0.37	3.28e-6	Birth weight;
UCEC	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.58	-5.74	-0.43	5.28e-8	White matter hyperintensity burden;
UCEC	cis	rs2299682	0.826	rs6077553	chr20:9474529	A/G	cg11931762	chr20:9488920	NA	-0.75	-5.46	-0.41	1.98e-7	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	5.72	0.43	5.88e-8	Monocyte percentage of white cells;
UCEC	cis	rs7611694	0.501	rs6438144	chr3:113123328	A/G	cg12596171	chr3:113251061	SIDT1	0.56	5.56	0.42	1.25e-7	Prostate cancer;
UCEC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	5.09	0.39	1.06e-6	Bipolar disorder;
UCEC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.5	5.67	0.42	7.25e-8	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.62	-5.35	-0.4	3.31e-7	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs7709377	0.597	rs11739600	chr5:115474214	C/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs4233802	0.619	rs1441970	chr2:151164771	C/T	cg25300694	chr2:151184358	NA	-0.69	-4.75	-0.37	4.72e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
UCEC	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.69	7.65	0.53	2.37e-12	Coronary artery disease;
UCEC	cis	rs76878669	0.538	rs12785651	chr11:66179063	T/C	cg24851651	chr11:66362959	CCS	-0.39	-4.88	-0.37	2.78e-6	Educational attainment (years of education);
UCEC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg01689657	chr7:91764605	CYP51A1	0.49	6.28	0.46	3.57e-9	Breast cancer;
UCEC	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17012589	0.823	rs11608487	chr12:85688680	A/G	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.46	-4.55	-0.35	1.12e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.44	-4.6	-0.35	9.03e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg01072550	chr1:21505969	NA	-0.59	-6.22	-0.46	4.97e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.67	5.15	0.39	8.27e-7	Nonalcoholic fatty liver disease;
UCEC	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.62	-0.42	9.45e-8	Fear of minor pain;
UCEC	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.52	6.85	0.49	1.89e-10	Gut microbiota (bacterial taxa);
UCEC	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	8.26	0.56	7.79e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.96	-0.38	1.93e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.62	-6.4	-0.47	1.93e-9	Blood trace element (Zn levels);
UCEC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	6.4	0.47	1.91e-9	Systolic blood pressure;
UCEC	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.62	-0.48	6.23e-10	Joint mobility (Beighton score);
UCEC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.46	-4.66	-0.36	7.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-7.56	-0.53	4.03e-12	Blood protein levels;
UCEC	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg05775895	chr3:12838266	CAND2	-0.45	-4.52	-0.35	1.25e-5	QRS complex (12-leadsum);
UCEC	cis	rs7336933	0.866	rs7328609	chr13:42461189	C/A	cg18400088	chr13:41634674	WBP4	0.55	4.71	0.36	5.74e-6	Calcium levels;
UCEC	cis	rs334147	1.000	rs777550	chr2:128278475	C/T	cg14478610	chr2:127864964	BIN1	-0.5	-4.9	-0.37	2.48e-6	Educational attainment;
UCEC	cis	rs925550	0.932	rs6811007	chr4:123585362	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.75	6.21	0.46	5.06e-9	Primary biliary cholangitis;
UCEC	cis	rs2742417	1.000	rs1877934	chr3:45753295	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.72	5.06	0.38	1.25e-6	Obsessive-compulsive symptoms;
UCEC	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	0.87	5.6	0.42	1.04e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.79	7.73	0.54	1.54e-12	Menopause (age at onset);
UCEC	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.51	5.33	0.4	3.58e-7	Autism;
UCEC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.47	-0.52	6.41e-12	Breast cancer;
UCEC	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg12310025	chr6:25882481	NA	-0.51	-4.53	-0.35	1.21e-5	Educational attainment;
UCEC	cis	rs1463104	0.508	rs1381952	chr4:88788738	C/T	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	Bone mineral density;
UCEC	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.36	-0.46	2.47e-9	Parkinson's disease;
UCEC	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.63	7.99	0.55	3.6e-13	Anterior chamber depth;
UCEC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg13683864	chr3:40499215	RPL14	0.83	9.48	0.62	6.37e-17	Renal cell carcinoma;
UCEC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.73	-8.03	-0.55	2.84e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.53	-4.94	-0.38	2.09e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.58	6.05	0.45	1.13e-8	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg00343986	chr7:65444356	GUSB	-0.51	-4.51	-0.35	1.3e-5	Aortic root size;
UCEC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg06238570	chr21:40685208	BRWD1	0.78	7.71	0.54	1.73e-12	Cognitive function;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.15	-0.45	7.03e-9	Pubertal anthropometrics;
UCEC	cis	rs1832871	0.965	rs705953	chr6:158775332	A/G	cg07215822	chr6:158701037	NA	0.48	4.9	0.38	2.45e-6	Height;
UCEC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg23625390	chr15:77176239	SCAPER	0.51	5.05	0.38	1.27e-6	Blood metabolite levels;
UCEC	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.9	9.28	0.61	2.01e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	0.87	5.19	0.39	6.86e-7	Arsenic metabolism;
UCEC	cis	rs17123764	0.605	rs73306808	chr12:50078632	G/T	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs71736125	1	rs71736125	chr6:135051318	TCC/T	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Plateletcrit;
UCEC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	7.05e-9	Aortic root size;
UCEC	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg27446573	chr6:127587934	RNF146	0.67	6.62	0.48	6.3e-10	Breast cancer;
UCEC	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.61	6.08	0.45	9.85e-9	Lung cancer;
UCEC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg00343986	chr7:65444356	GUSB	0.52	4.75	0.37	4.72e-6	Aortic root size;
UCEC	cis	rs256277	0.507	rs9326846	chr5:111301546	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-5.14	-0.39	8.61e-7	Coronary artery disease;
UCEC	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.72	6.36	0.46	2.42e-9	Caudate activity during reward;
UCEC	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2172802	0.560	rs1497913	chr4:62559086	C/T	cg04118610	chr4:62707027	LPHN3	-0.41	-4.6	-0.35	9.02e-6	Partial epilepsies;
UCEC	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.7	10.05	0.64	2.09e-18	Neuroticism;
UCEC	cis	rs7709377	0.597	rs11241374	chr5:115519754	T/C	cg23108291	chr5:115420582	COMMD10	0.52	5.48	0.41	1.77e-7	Metabolite levels  (X-11787);
UCEC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	5.78	0.43	4.28e-8	Platelet count;
UCEC	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-5.12	-0.39	9.52e-7	Colorectal cancer;
UCEC	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.74	6.59	0.48	7.53e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	0.99	9.57	0.62	3.59e-17	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg04043695	chr12:129287642	SLC15A4	-0.61	-5.96	-0.44	1.82e-8	Systemic lupus erythematosus;
UCEC	cis	rs2074193	0.906	rs215339	chr12:47732594	T/G	cg11844464	chr12:46931139	NA	0.67	4.98	0.38	1.78e-6	Migraine with aura;
UCEC	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.59	-6.29	-0.46	3.43e-9	Blood protein levels;
UCEC	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	5.54	0.42	1.34e-7	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs308403	0.608	rs309362	chr4:123658154	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.68	6.14	0.45	7.25e-9	Blood protein levels;
UCEC	cis	rs787274	1.000	rs787274	chr9:115550363	A/C	cg13803584	chr9:115635662	SNX30	-0.69	-5.21	-0.39	6.36e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4448343	0.927	rs1355619	chr9:98270171	A/G	cg13456470	chr9:98266766	PTCH1	0.41	5.56	0.42	1.22e-7	Height;
UCEC	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.67	-5.66	-0.42	7.83e-8	Obesity-related traits;
UCEC	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg00944541	chr22:43045525	CYB5R3	0.59	6.68	0.48	4.52e-10	Parental longevity (mother's age at death);
UCEC	cis	rs9467773	1.000	rs6913462	chr6:26577530	A/G	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs200880	0.525	rs6135962	chr20:1759791	C/T	cg11784305	chr20:1757812	NA	-0.62	-4.91	-0.38	2.38e-6	Mean platelet volume;
UCEC	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.38	5.56	0.42	1.21e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.79	9.6	0.62	3.04e-17	Monocyte count;
UCEC	cis	rs17316633	0.901	rs62327602	chr4:110826015	G/T	cg06981781	chr4:110842888	EGF	-0.53	-4.9	-0.37	2.5e-6	Hair morphology;
UCEC	cis	rs17162190	0.698	rs6693662	chr1:26821230	A/G	cg23229016	chr1:26872525	RPS6KA1	0.26	4.58	0.35	9.66e-6	Mean corpuscular volume;
UCEC	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.63	6.38	0.47	2.22e-9	C-reactive protein levels;
UCEC	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.7	-4.89	-0.37	2.56e-6	Narcolepsy;
UCEC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-7.48	-0.53	6.14e-12	Chronic sinus infection;
UCEC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.73	8.14	0.56	1.51e-13	Mortality in heart failure;
UCEC	cis	rs6901250	0.632	rs688961	chr6:117089080	A/T	cg12892004	chr6:117198278	RFX6	0.42	4.54	0.35	1.15e-5	C-reactive protein levels;
UCEC	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.59	5.5	0.41	1.63e-7	Migraine;
UCEC	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	8.76	0.59	4.43e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.78	7.54	0.53	4.45e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.51	4.68	0.36	6.54e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.79	-0.37	4.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.14	-13.91	-0.75	1.38e-28	Breast cancer;
UCEC	cis	rs7715256	0.904	rs815610	chr5:153517178	C/G	cg27295185	chr5:154320610	MRPL22	0.42	4.52	0.35	1.24e-5	BMI (adjusted for smoking behaviour);Body mass index;Childhood body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.21	-0.46	5.09e-9	Cardiac Troponin-T levels;
UCEC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.77	-0.37	4.46e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs890835	1.000	rs4868646	chr5:175947142	C/T	cg17652716	chr5:176910622	PDLIM7	0.61	4.94	0.38	2.14e-6	Menopause (age at onset);
UCEC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.06	-6.58	-0.48	7.56e-10	Diabetic kidney disease;
UCEC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.43	-0.41	2.32e-7	Hemoglobin concentration;
UCEC	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Kawasaki disease;
UCEC	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg01493522	chr13:37497338	NA	-0.46	-4.95	-0.38	2.03e-6	Coronary artery disease;
UCEC	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.56	5.29	0.4	4.32e-7	Multiple sclerosis;
UCEC	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.76	7.09	0.5	5.16e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg11569703	chr11:65557185	OVOL1	0.51	6.66	0.48	4.99e-10	Acne (severe);
UCEC	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.48	4.92	0.38	2.25e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.51	-5.72	-0.43	5.79e-8	Tonsillectomy;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.73	-5.23	-0.4	5.86e-7	Platelet count;
UCEC	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg26721908	chr21:47610096	LSS	0.43	5.6	0.42	1.04e-7	Testicular germ cell tumor;
UCEC	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.48	4.71	0.36	5.77e-6	Mean platelet volume;
UCEC	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg00083072	chr11:65415190	SIPA1	0.44	4.95	0.38	2.01e-6	Acne (severe);
UCEC	cis	rs36051895	0.559	rs1590268	chr9:5209433	T/A	cg02405213	chr9:5042618	JAK2	-0.54	-4.95	-0.38	2.05e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1978968	0.763	rs5992137	chr22:18457986	T/C	cg03078520	chr22:18463400	MICAL3	-0.49	-6.08	-0.45	9.65e-9	Presence of antiphospholipid antibodies;
UCEC	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.98	13.48	0.74	1.85e-27	Bone mineral density;
UCEC	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.55	0.42	1.27e-7	Bipolar disorder and schizophrenia;
UCEC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-13.44	-0.74	2.27e-27	Height;
UCEC	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.78	7.31	0.52	1.56e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.37	0.47	2.24e-9	Tonsillectomy;
UCEC	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.76	-6.03	-0.45	1.27e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	5.79	0.43	4.02e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.3	-0.46	3.33e-9	Chronic sinus infection;
UCEC	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	6.26	0.46	4.1e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.62	5.33	0.4	3.56e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.45	4.75	0.36	4.76e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs28669119	0.778	rs80043958	chr5:88179575	A/G	cg18498987	chr5:88179539	MEF2C	0.69	4.77	0.37	4.42e-6	Schizophrenia;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg02776659	chr21:47717406	C21orf57	-0.41	-4.57	-0.35	1.01e-5	Testicular germ cell tumor;
UCEC	cis	rs9715521	0.935	rs34361458	chr4:59838192	C/A	cg11281224	chr4:60001000	NA	-0.52	-5.2	-0.39	6.59e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-4.78	-0.37	4.14e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.21	11.12	0.68	3.14e-21	Corneal structure;
UCEC	cis	rs7246967	0.551	rs56968124	chr19:22814449	T/C	cg24889512	chr19:22816950	ZNF492	0.59	6.47	0.47	1.38e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.55	-5.26	-0.4	4.89e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.66	-7.09	-0.5	5.16e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.72	-6.69	-0.48	4.43e-10	Body mass index;
UCEC	cis	rs78487399	0.634	rs77881454	chr2:43757293	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-4.69	-0.36	6.21e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.84	-5.49	-0.41	1.74e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.59	5.27	0.4	4.78e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.8	-8.62	-0.58	9.83e-15	Homoarginine levels;
UCEC	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.47	5.22	0.4	6.05e-7	Rheumatoid arthritis;
UCEC	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-4.99	-0.38	1.69e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg16576597	chr16:28551801	NUPR1	0.32	4.85	0.37	3.15e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs8010715	0.771	rs2277481	chr14:24587545	A/G	cg20933586	chr14:24608199	FAM158A	0.37	4.68	0.36	6.54e-6	IgG glycosylation;
UCEC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.68	-6.1	-0.45	9e-9	Pancreatic cancer;
UCEC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	5.31	0.4	3.98e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.5	4.74	0.36	4.98e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs12618769	0.597	rs3754893	chr2:99063149	T/A	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg04154034	chr17:28927549	LRRC37B2	0.57	5.18	0.39	7.21e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.55	5.68	0.42	7.11e-8	Blood protein levels;
UCEC	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.42	-4.95	-0.38	1.99e-6	Schizophrenia;
UCEC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.59	6.53	0.47	9.92e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg10224037	chr5:178157518	ZNF354A	0.72	5.6	0.42	1.02e-7	Neutrophil percentage of white cells;
UCEC	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.4	5.1	0.39	1.05e-6	Neuroticism;
UCEC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.51	5.84	0.43	3.18e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.79	0.43	4.17e-8	Lymphocyte percentage of white cells;
UCEC	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.63	6.75	0.49	3.16e-10	Adiponectin levels;
UCEC	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-5.61	-0.42	9.86e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7546668	1.000	rs4233534	chr1:15842329	C/T	cg05660106	chr1:15850417	CASP9	-0.46	-4.87	-0.37	2.88e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2415984	0.846	rs11625752	chr14:46834341	G/A	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.49	-5.05	-0.38	1.31e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg04202892	chr2:111875749	ACOXL	0.45	5.25	0.4	5.13e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.8	-0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs11800820	0.647	rs4654279	chr1:246686111	C/T	cg16700716	chr1:246684329	NA	0.6	5.52	0.41	1.47e-7	Obesity-related traits;
UCEC	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.54	6.67	0.48	4.89e-10	Total body bone mineral density;
UCEC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg11871910	chr12:69753446	YEATS4	0.55	4.91	0.38	2.36e-6	Response to diuretic therapy;
UCEC	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.74	0.43	5.23e-8	Rheumatoid arthritis;
UCEC	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	5.0	0.38	1.59e-6	Joint mobility (Beighton score);
UCEC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg13575925	chr12:9217583	LOC144571	0.39	4.53	0.35	1.2e-5	Sjögren's syndrome;
UCEC	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.52	-4.81	-0.37	3.63e-6	Longevity;
UCEC	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.59	4.56	0.35	1.09e-5	Bipolar disorder (body mass index interaction);
UCEC	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.53	4.86	0.37	3.01e-6	Lung cancer;
UCEC	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.84	0.43	3.15e-8	Height;
UCEC	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.44	-5.33	-0.4	3.67e-7	Dupuytren's disease;
UCEC	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.62	5.91	0.44	2.34e-8	Schizophrenia;
UCEC	cis	rs7517126	1.000	rs13374399	chr1:196842006	G/A	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg01689657	chr7:91764605	CYP51A1	0.51	6.57	0.48	8.11e-10	Breast cancer;
UCEC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.57	4.88	0.37	2.71e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.3	0.4	4.21e-7	Response to antipsychotic treatment;
UCEC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.67	-7.53	-0.53	4.72e-12	Menarche (age at onset);
UCEC	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.75	0.75	3.48e-28	Height;
UCEC	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	6.95	0.5	1.1e-10	Chronic sinus infection;
UCEC	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.6	5.17	0.39	7.69e-7	HDL cholesterol levels;
UCEC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.16	-0.39	8.01e-7	Chronic sinus infection;
UCEC	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.51	4.89	0.37	2.67e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.18	0.39	7.34e-7	Hemoglobin concentration;
UCEC	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs995000	0.931	rs626787	chr1:62901243	C/G	cg04278597	chr1:63154320	DOCK7	0.46	4.56	0.35	1.06e-5	Triglyceride levels;
UCEC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg20368463	chr18:77673604	PQLC1	0.55	5.1	0.39	1.01e-6	Opioid sensitivity;
UCEC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.68	-7.06	-0.5	6.13e-11	Neurofibrillary tangles;
UCEC	cis	rs116095464	0.619	rs28731093	chr5:241028	T/C	cg22496380	chr5:211416	CCDC127	-0.7	-6.24	-0.46	4.41e-9	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08825816	chr14:58666796	ACTR10	0.6	6.96	0.5	1.04e-10	Warfarin maintenance dose;
UCEC	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.75	-5.7	-0.43	6.48e-8	Schizophrenia;
UCEC	cis	rs259282	0.524	rs731674	chr19:33132395	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.66	6.39	0.47	2.11e-9	Schizophrenia;
UCEC	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg02344993	chr17:57696989	CLTC	0.49	4.73	0.36	5.29e-6	Hemoglobin concentration;
UCEC	cis	rs7607369	0.536	rs4674345	chr2:219671598	A/G	cg02176678	chr2:219576539	TTLL4	-0.57	-5.97	-0.44	1.71e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg18279126	chr7:2041391	MAD1L1	0.39	4.79	0.37	4.05e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.76	-8.89	-0.59	2.08e-15	Obesity-related traits;
UCEC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.49	-7.34	-0.52	1.36e-11	Gout;
UCEC	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.52	5.51	0.41	1.54e-7	Type 2 diabetes;
UCEC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.3	-0.4	4.18e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.6	5.95	0.44	1.87e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.75	-6.2	-0.46	5.29e-9	Schizophrenia;
UCEC	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.42	4.61	0.36	8.61e-6	Obesity-related traits;
UCEC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.8	-8.53	-0.58	1.66e-14	Longevity;
UCEC	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg21770322	chr7:97807741	LMTK2	0.5	6.32	0.46	2.96e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs6761276	0.727	rs6743376	chr2:113832333	C/A	cg09040174	chr2:113837401	NA	0.48	4.83	0.37	3.35e-6	Protein quantitative trait loci;
UCEC	cis	rs10924970	0.649	rs4659763	chr1:235447779	T/C	cg26050004	chr1:235667680	B3GALNT2	0.53	4.81	0.37	3.63e-6	Asthma;
UCEC	cis	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg03999872	chr20:62272968	STMN3	0.49	4.65	0.36	7.45e-6	Atopic dermatitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25460059	chr11:9595544	WEE1	0.58	6.76	0.49	2.96e-10	Warfarin maintenance dose;
UCEC	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.76	8.02	0.55	3.02e-13	Eosinophil percentage of white cells;
UCEC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.45	4.96	0.38	1.9e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg19645103	chr12:69753606	YEATS4	-0.55	-5.0	-0.38	1.62e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03611598	chr17:48586076	MYCBPAP	-0.43	-5.2	-0.39	6.59e-7	Visceral fat;
UCEC	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.58	5.25	0.4	5.34e-7	Corneal astigmatism;
UCEC	cis	rs7246967	0.866	rs4932694	chr19:23032707	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.52	5.96	0.44	1.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.74	-9.36	-0.61	1.26e-16	Leprosy;
UCEC	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-4.54	-0.35	1.14e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.51	-5.11	-0.39	9.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.69	4.92	0.38	2.32e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12428035	1.000	rs77930391	chr13:96297821	G/A	cg07859753	chr13:96300257	NA	0.65	5.48	0.41	1.82e-7	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg12463550	chr7:65579703	CRCP	0.49	4.6	0.36	8.88e-6	Aortic root size;
UCEC	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs731174	0.797	rs501252	chr1:38154170	A/G	cg06917450	chr1:38156652	C1orf109	-0.61	-5.66	-0.42	7.71e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs514475	1.000	rs514475	chr6:138038905	A/C	cg15962969	chr6:138866887	NHSL1	0.71	4.78	0.37	4.17e-6	Inflammatory skin disease;
UCEC	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.51	4.56	0.35	1.07e-5	Triglycerides;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.49	-5.67	-0.42	7.3900000000000007e-08	Testicular germ cell tumor;
UCEC	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.5	-5.11	-0.39	9.72e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.39	5.82	0.43	3.6e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.28e-21	Breast cancer;
UCEC	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.45	4.7	0.36	5.82e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.55	-4.8	-0.37	3.83e-6	Menarche (age at onset);
UCEC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-6.63	-0.48	5.96e-10	Cognitive function;
UCEC	cis	rs9715521	0.718	rs62301190	chr4:59842351	A/G	cg11281224	chr4:60001000	NA	-0.61	-5.88	-0.44	2.71e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg12292205	chr6:26970375	C6orf41	0.6	5.17	0.39	7.49e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.64	-5.07	-0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.05	-9.44	-0.61	8.11e-17	Vitiligo;
UCEC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.42	0.41	2.39e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-7.55	-0.53	4.34e-12	Electrocardiographic conduction measures;
UCEC	cis	rs7246967	0.673	rs12975767	chr19:22862809	A/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	6.86	0.49	1.77e-10	Platelet count;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg06818710	chr6:28411271	ZSCAN23	0.44	5.29	0.4	4.36e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.75	-7.93	-0.55	5.01e-13	Lung cancer;
UCEC	cis	rs7246967	0.611	rs4933024	chr19:22867063	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.59	6.17	0.45	6.4e-9	Ulcerative colitis;
UCEC	cis	rs9535020	0.520	rs111410327	chr13:49143341	A/C	cg05840412	chr13:49145436	NA	-0.76	-4.8	-0.37	3.82e-6	Chronic kidney disease;
UCEC	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-0.83	-6.58	-0.48	7.65e-10	Corneal structure;
UCEC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.51	-4.69	-0.36	6.21e-6	Corneal astigmatism;
UCEC	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.73	4.92	0.38	2.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg06784218	chr1:46089804	CCDC17	-0.42	-4.77	-0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.76	-0.49	3.07e-10	Coffee consumption (cups per day);
UCEC	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.42	-4.79	-0.37	3.96e-6	Menopause (age at onset);
UCEC	cis	rs12481680	1.000	rs4810105	chr20:56414438	A/T	cg00626515	chr20:56287004	PMEPA1	0.4	4.59	0.35	9.28e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18252515	chr7:66147081	NA	0.56	5.19	0.39	6.86e-7	Aortic root size;
UCEC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.7	8.85	0.59	2.55e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-5.63	-0.42	9.06e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg06238570	chr21:40685208	BRWD1	-0.49	-4.54	-0.35	1.16e-5	Menarche (age at onset);
UCEC	cis	rs10012307	1.000	rs12650445	chr4:137507822	T/A	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs12980942	0.872	rs16958994	chr19:41824981	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	5.37	0.4	3e-7	Coronary artery disease;
UCEC	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.4	-5.35	-0.4	3.23e-7	Alcohol dependence;
UCEC	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg11211951	chr8:145729740	GPT	-0.42	-4.81	-0.37	3.62e-6	Age at first birth;
UCEC	cis	rs2242663	0.529	rs1785640	chr11:66223158	C/T	cg24851651	chr11:66362959	CCS	0.39	4.56	0.35	1.06e-5	Bipolar disorder;
UCEC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	0.99	8.74	0.58	4.73e-15	Vitiligo;
UCEC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg11569703	chr11:65557185	OVOL1	0.51	6.6	0.48	6.88e-10	Acne (severe);
UCEC	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	0.82	4.59	0.35	9.24e-6	Major depressive disorder;
UCEC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.56	-6.46	-0.47	1.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.59	6.86	0.49	1.82e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.14	13.95	0.75	1.06e-28	Cognitive function;
UCEC	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-6.85	-0.49	1.85e-10	Resting heart rate;
UCEC	cis	rs7937612	1.000	rs10892574	chr11:120288944	G/C	cg12584626	chr11:120203529	NA	0.54	5.29	0.4	4.34e-7	Intraocular pressure;
UCEC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	6.97	0.5	1e-10	Eye color traits;
UCEC	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.93	-0.38	2.15e-6	Bipolar disorder;
UCEC	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.51	6.04	0.45	1.21e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg05147244	chr20:61493195	TCFL5	0.93	5.24	0.4	5.58e-7	Obesity-related traits;
UCEC	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	7.44	0.52	7.9e-12	Bone mineral density;
UCEC	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.79	8.96	0.59	1.32e-15	Blood metabolite levels;
UCEC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg19318889	chr4:1322082	MAEA	0.47	5.11	0.39	9.9e-7	Obesity-related traits;
UCEC	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.74	-4.51	-0.35	1.34e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	0.98	9.9	0.63	5.21e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.78	6.37	0.46	2.34e-9	Lymphocyte counts;
UCEC	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.14	-14.88	-0.78	4e-31	Schizophrenia;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.33	-0.4	3.69e-7	Cardiac Troponin-T levels;
UCEC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.63	5.93	0.44	2.03e-8	Response to diuretic therapy;
UCEC	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.5	-5.31	-0.4	3.94e-7	Dilated cardiomyopathy;
UCEC	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.47	-6.71	-0.48	3.94e-10	Urinary metabolites;
UCEC	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.76	8.03	0.55	2.85e-13	Breast cancer;
UCEC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.63	5.66	0.42	7.65e-8	Breast cancer;
UCEC	cis	rs2839627	0.638	rs60342559	chr21:44310051	T/C	cg03543861	chr21:44258195	NA	0.52	5.16	0.39	7.86e-7	Information processing speed;
UCEC	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg04756594	chr16:24857601	SLC5A11	0.41	4.97	0.38	1.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.0	0.38	1.6e-6	Rheumatoid arthritis;
UCEC	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	5.29	0.4	4.37e-7	Personality dimensions;
UCEC	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.65	5.98	0.44	1.59e-8	Corneal astigmatism;
UCEC	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.4	-5.2	-0.39	6.64e-7	Sense of smell;
UCEC	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.33	4.6	0.35	9.05e-6	Crohn's disease;
UCEC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.673	rs34342502	chr19:22881428	C/A	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.44	5.3	0.4	4.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs735860	0.700	rs209524	chr6:53213226	G/C	cg10236188	chr6:53219634	NA	0.45	4.62	0.36	8.46e-6	Glaucoma;
UCEC	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	5.01	0.38	1.56e-6	Breast cancer;
UCEC	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-5.53	-0.41	1.44e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg02454025	chr1:11042201	C1orf127	0.72	7.94	0.55	4.82e-13	Ewing sarcoma;
UCEC	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.68	10.39	0.65	2.6e-19	Total body bone mineral density;
UCEC	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.79	5.87	0.44	2.8e-8	Exhaled nitric oxide output;
UCEC	cis	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	0.92	9.15	0.6	4.51e-16	Post bronchodilator FEV1;
UCEC	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.67	-7.3	-0.52	1.65e-11	Cognitive test performance;
UCEC	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.45	4.62	0.36	8.49e-6	Blood metabolite levels;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg11965913	chr1:205819406	PM20D1	0.74	8.72	0.58	5.43e-15	Menarche (age at onset);
UCEC	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.62	5.35	0.4	3.37e-7	Ulcerative colitis;
UCEC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.1	7.99	0.55	3.58e-13	Alzheimer's disease (late onset);
UCEC	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.7	9.37	0.61	1.22e-16	Neuroticism;
UCEC	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.84	9.57	0.62	3.69e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22509189	chr2:225307070	NA	-0.58	-5.24	-0.4	5.43e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg07424592	chr7:64974309	NA	0.81	4.8	0.37	3.9e-6	Diabetic kidney disease;
UCEC	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.88	0.49	1.62e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-5.63	-0.42	8.81e-8	Aortic root size;
UCEC	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.81	-8.56	-0.58	1.38e-14	Lung cancer;
UCEC	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.77	0.54	1.23e-12	Smoking behavior;
UCEC	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.96	-10.8	-0.67	2.2e-20	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-0.91	-11.76	-0.7	6.53e-23	Height;
UCEC	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.56	6.76	0.49	2.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.59	-5.27	-0.4	4.85e-7	Metabolite levels;
UCEC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.62	-5.24	-0.4	5.42e-7	Corneal astigmatism;
UCEC	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.51	5.45	0.41	2.07e-7	Tuberculosis;
UCEC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.37	-4.59	-0.35	9.37e-6	Body mass index;
UCEC	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.76	8.03	0.55	2.85e-13	Breast cancer;
UCEC	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.45	5.28	0.4	4.52e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.68	-7.01	-0.5	7.89e-11	Breast cancer;
UCEC	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.74	6.92	0.5	1.28e-10	Red cell distribution width;
UCEC	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.64	5.23	0.4	5.63e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg18016565	chr1:150552671	MCL1	0.64	7.35	0.52	1.25e-11	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2200578	1.000	rs2200578	chr2:99876244	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.83	5.4	0.41	2.59e-7	IgG glycosylation;
UCEC	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.78	0.49	2.78e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.77	-6.64	-0.48	5.62e-10	Menopause (age at onset);
UCEC	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg20825769	chr15:43991375	CKMT1A	-0.48	-4.58	-0.35	9.74e-6	Lung cancer in ever smokers;
UCEC	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	7.95	0.55	4.49e-13	Schizophrenia;
UCEC	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.43	-5.96	-0.44	1.75e-8	IgG glycosylation;
UCEC	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.78	0.37	4.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.56	6.26	0.46	3.91e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-1.04	-8.0	-0.55	3.46e-13	White matter hyperintensity burden;
UCEC	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.58	-5.5	-0.41	1.64e-7	Coronary artery disease;
UCEC	cis	rs10012307	1.000	rs2406013	chr4:137493428	G/A	cg12033966	chr4:138453416	PCDH18	-0.74	-5.07	-0.39	1.19e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs2415984	0.846	rs12185004	chr14:46833895	C/T	cg14871534	chr14:47121158	RPL10L	0.41	4.77	0.37	4.45e-6	Number of children ever born;
UCEC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-5.2	-0.39	6.64e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.49	5.68	0.42	6.85e-8	Bone mineral density;
UCEC	cis	rs9326726	0.699	rs158605	chr5:107526098	C/A	cg17432647	chr5:107996819	NA	0.52	4.6	0.35	9.05e-6	Resting heart rate;
UCEC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.53	-0.41	1.44e-7	Gut microbiome composition (summer);
UCEC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.54	6.37	0.47	2.3e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.39	0.71	1.34e-24	Prudent dietary pattern;
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg01874867	chr7:94954059	PON1	-0.54	-5.15	-0.39	8.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	0.95	10.04	0.64	2.18e-18	Red blood cell traits;
UCEC	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.66	4.75e-20	Body mass index;
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.57	6.46	0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs7975161	0.580	rs4246270	chr12:104728530	G/A	cg25273343	chr12:104657179	TXNRD1	-0.81	-5.11	-0.39	9.85e-7	Toenail selenium levels;
UCEC	cis	rs10121009	0.587	rs2281999	chr9:35381504	C/T	cg26315493	chr9:35071724	VCP	-0.49	-4.58	-0.35	9.73e-6	Parkinson's disease;
UCEC	cis	rs58722170	0.627	rs12039431	chr1:38082122	G/A	cg17933807	chr1:38061675	GNL2	-0.62	-5.15	-0.39	8.33e-7	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.85	-7.2	-0.51	2.86e-11	Coronary artery calcification;
UCEC	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-4.93	-0.38	2.18e-6	Menarche (age at onset);
UCEC	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.66	6.43	0.47	1.64e-9	Smoking behavior;
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg07404485	chr7:94953653	PON1	-0.45	-4.52	-0.35	1.29e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg10902566	chr4:727664	PCGF3	-0.56	-4.73	-0.36	5.26e-6	Systolic blood pressure;
UCEC	cis	rs17106184	1.000	rs76852824	chr1:51121526	T/C	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg24703168	chr6:28411309	ZSCAN23	-0.46	-5.0	-0.38	1.64e-6	Pulmonary function;
UCEC	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	0.81	5.03	0.38	1.4e-6	Diabetic retinopathy;
UCEC	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.53	-5.21	-0.39	6.31e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg14547644	chr6:28411285	ZSCAN23	0.53	6.15	0.45	7.01e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.64	7.04	0.5	7.01e-11	Longevity;Endometriosis;
UCEC	cis	rs2075165	0.838	rs12072638	chr1:156267480	T/G	cg20302342	chr1:156215951	PAQR6	0.52	5.37	0.4	3.06e-7	Tonsillectomy;
UCEC	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.63	6.01	0.44	1.42e-8	Lymphocyte counts;
UCEC	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.61	-5.21	-0.39	6.37e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6594713	0.504	rs11956139	chr5:112624552	A/G	cg24145369	chr5:112930120	YTHDC2	-0.44	-4.52	-0.35	1.27e-5	Brain cytoarchitecture;
UCEC	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.94	-11.71	-0.69	8.92e-23	Multiple sclerosis;
UCEC	cis	rs7404928	0.651	rs28734145	chr16:23949343	C/T	cg01062539	chr16:23765258	CHP2	-0.36	-4.71	-0.36	5.65e-6	Primary biliary cholangitis;Rheumatoid arthritis;
UCEC	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg04837898	chr3:45731254	SACM1L	-0.41	-4.62	-0.36	8.31e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs4908768	0.639	rs4908512	chr1:8830366	A/T	cg13081009	chr1:8430745	RERE	0.42	4.56	0.35	1.07e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.7	7.04	0.5	6.66e-11	Body mass index;
UCEC	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.13	-0.51	4.17e-11	Eye color traits;
UCEC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.99	11.04	0.67	5.1e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.64	8.42	0.57	3.17e-14	Anterior chamber depth;
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs12216499	1.000	rs16889320	chr6:159414899	T/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.45	4.62	0.36	8.49e-6	Blood metabolite levels;
UCEC	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg23018236	chr17:30244563	NA	-0.67	-4.64	-0.36	7.72e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.32	0.4	3.8e-7	Diabetic retinopathy;
UCEC	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.55	4.92	0.38	2.27e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.64	6.07	0.45	1.04e-8	Selective IgA deficiency;
UCEC	cis	rs10242455	0.764	rs2687084	chr7:99298132	C/A	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.13	-0.39	9.04e-7	Blood metabolite levels;
UCEC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg22974920	chr21:40686053	BRWD1	-0.52	-4.64	-0.36	7.51e-6	Cognitive function;
UCEC	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.51	4.8	0.37	3.94e-6	Corneal astigmatism;
UCEC	cis	rs2425143	0.818	rs35448195	chr20:34542365	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.62	-0.36	8.41e-6	Blood protein levels;
UCEC	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.72	0.36	5.47e-6	Breast cancer;
UCEC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg06238570	chr21:40685208	BRWD1	0.8	7.38	0.52	1.05e-11	Cognitive function;
UCEC	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.76	0.43	4.68e-8	Coffee consumption (cups per day);
UCEC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.45	-5.35	-0.4	3.24e-7	Alcohol dependence;
UCEC	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.81	-6.09	-0.45	9.26e-9	Body mass index;
UCEC	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.74	0.49	3.4e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs10121009	0.565	rs4498642	chr9:35436662	C/G	cg14286155	chr9:34620395	DCTN3	-0.48	-4.53	-0.35	1.23e-5	Parkinson's disease;
UCEC	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.68	5.16	0.39	7.81e-7	Mean platelet volume;
UCEC	cis	rs7219021	0.886	rs9915337	chr17:46857421	T/A	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.53	6.27	0.46	3.86e-9	Breast cancer;
UCEC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.5	-4.98	-0.38	1.76e-6	Hemoglobin concentration;
UCEC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.58	5.61	0.42	9.93e-8	Calcium levels;
UCEC	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.62	7.09	0.5	5.31e-11	Skin colour saturation;
UCEC	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg05501817	chr11:14380813	RRAS2	-0.52	-4.92	-0.38	2.34e-6	Sense of smell;
UCEC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.74	0.43	5.32e-8	Tonsillectomy;
UCEC	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg20293894	chr10:134779328	NA	-0.6	-4.53	-0.35	1.22e-5	Lifespan;
UCEC	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.47	-6.01	-0.44	1.37e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	6.29	0.46	3.42e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.87	7.22	0.51	2.61e-11	Gastritis;
UCEC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.52	-5.04	-0.38	1.33e-6	Cognitive test performance;
UCEC	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13683864	chr3:40499215	RPL14	-0.98	-10.28	-0.65	5.15e-19	Renal cell carcinoma;
UCEC	cis	rs939574	0.722	rs55951006	chr2:220132151	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.93	6.48	0.47	1.3e-9	Platelet distribution width;
UCEC	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.76	-8.64	-0.58	8.81e-15	Waist circumference;Body mass index;
UCEC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.65	-0.53	2.49e-12	Tonsillectomy;
UCEC	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.72	5.5	0.41	1.68e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.66	6.68	0.48	4.61e-10	Breast cancer;
UCEC	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.53	4.63	0.36	7.98e-6	Menarche (age at onset);
UCEC	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.99	-11.5	-0.69	3.14e-22	Cognitive function;
UCEC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.76e-7	Hemoglobin concentration;
UCEC	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.72	-4.87	-0.37	2.84e-6	Bipolar disorder;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-20.74	-0.86	1.68e-45	Myeloid white cell count;
UCEC	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.09	16.07	0.8	3.58e-34	IgG glycosylation;
UCEC	cis	rs17106184	1.000	rs59390962	chr1:51314531	C/T	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07167872	chr1:205819463	PM20D1	0.74	8.1	0.56	1.93e-13	Menarche (age at onset);
UCEC	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.57	6.39	0.47	2.09e-9	Bipolar disorder;
UCEC	cis	rs13401104	0.786	rs56257332	chr2:237107405	G/A	cg23897927	chr2:237117786	ASB18	-0.51	-4.59	-0.35	9.3e-6	Educational attainment;
UCEC	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.47	-4.52	-0.35	1.26e-5	Total body bone mineral density;
UCEC	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.6	5.1	0.39	1.04e-6	Lung cancer;
UCEC	cis	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg17469321	chr7:55412551	NA	0.74	5.72	0.43	5.83e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg01426195	chr3:39028469	NA	-0.46	-5.16	-0.39	7.89e-7	Handedness;
UCEC	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.32	0.46	2.94e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.8	-9.88	-0.63	5.62e-18	White blood cell count (basophil);
UCEC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.72	-0.43	5.63e-8	Breast cancer;
UCEC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.54	-0.66	1.05e-19	Schizophrenia;
UCEC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.62	-6.53	-0.47	1.02e-9	Neurofibrillary tangles;
UCEC	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.71	7.21	0.51	2.8e-11	Aortic root size;
UCEC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.52	5.32	0.4	3.82e-7	Dupuytren's disease;
UCEC	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-7.73	-0.54	1.57e-12	Coronary artery disease;
UCEC	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.51	0.47	1.12e-9	Aortic root size;
UCEC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.49	-4.97	-0.38	1.88e-6	Parkinson's disease;
UCEC	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.65	6.7	0.48	4.16e-10	Sudden cardiac arrest;
UCEC	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.91	9.92	0.63	4.58e-18	Post bronchodilator FEV1;
UCEC	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-7.06	-0.5	6.17e-11	Exhaled nitric oxide output;
UCEC	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.76	6.42	0.47	1.73e-9	Menopause (age at onset);
UCEC	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.57	6.6	0.48	6.97e-10	NT-proBNP levels in acute coronary syndrome;
UCEC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.2	-14.88	-0.78	4.07e-31	Breast cancer;
UCEC	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs10012307	1.000	rs12641453	chr4:137516593	T/C	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.82	7.9	0.55	5.92e-13	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.51	4.64	0.36	7.7e-6	Menopause (age at onset);
UCEC	cis	rs3015497	0.616	rs3825571	chr14:51052118	A/G	cg04730355	chr14:51134070	SAV1	-0.45	-4.84	-0.37	3.2e-6	Mean platelet volume;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.83	-0.43	3.37e-8	Prudent dietary pattern;
UCEC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	5.02	0.38	1.45e-6	Cognitive test performance;
UCEC	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.49	4.93	0.38	2.2e-6	Triglycerides;
UCEC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.51	5.03	0.38	1.39e-6	Hemoglobin concentration;
UCEC	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.55	5.87	0.44	2.78e-8	Corneal astigmatism;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg11368578	chr7:150754936	CDK5	-0.6	-6.87	-0.49	1.7e-10	Breast cancer;
UCEC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	0.9	9.9	0.63	5.04e-18	Breast cancer;
UCEC	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	0.9	12.03	0.7	1.26e-23	Ewing sarcoma;
UCEC	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.46	4.65	0.36	7.25e-6	Blood metabolite levels;
UCEC	cis	rs4356932	0.934	rs4859603	chr4:76965747	A/G	cg22252999	chr4:76996414	ART3	0.44	4.54	0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.56	-8.17	-0.56	1.31e-13	Sense of smell;
UCEC	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	trans	rs11748684	1.000	rs10051948	chr5:42316584	C/A	cg23982445	chr2:394333	NA	0.88	6.69	0.48	4.41e-10	Response to taxane treatment (docetaxel);
UCEC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-1.03	-15.24	-0.78	4.68e-32	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	4.52	0.35	1.27e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.61	5.27	0.4	4.67e-7	Heart rate;
UCEC	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg05132306	chr1:1846340	CALML6	-0.37	-4.72	-0.36	5.51e-6	Body mass index;
UCEC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.72	8.49	0.57	2.11e-14	Prudent dietary pattern;
UCEC	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg05962950	chr11:130786565	SNX19	0.5	4.66	0.36	6.96e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.83	-10.33	-0.65	3.76e-19	White blood cell count (basophil);
UCEC	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.58	5.8	0.43	3.84e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1572072	0.545	rs7338268	chr13:24129798	C/T	cg24350296	chr13:24144486	TNFRSF19	-0.38	-4.73	-0.36	5.23e-6	Nasopharyngeal carcinoma;
UCEC	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.48	5.4	0.41	2.68e-7	Response to temozolomide;
UCEC	cis	rs4851266	1.000	rs11691409	chr2:100826165	T/A	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.44	-5.25	-0.4	5.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	-0.55	-6.32	-0.46	3.01e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.43	4.56	0.35	1.06e-5	Uric acid clearance;
UCEC	cis	rs731174	0.797	rs678511	chr1:38156427	T/C	cg06917450	chr1:38156652	C1orf109	-0.63	-6.1	-0.45	9.02e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.64	5.92	0.44	2.17e-8	Menarche (age at onset);
UCEC	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.54	6.16	0.45	6.7e-9	Height;
UCEC	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg06781209	chr11:61594997	FADS2	-0.51	-4.79	-0.37	4.1e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs17034641	0.938	rs12990701	chr2:46372472	C/G	cg12428440	chr2:46370979	PRKCE	0.61	4.93	0.38	2.2e-6	Hemoglobin;Hematocrit;
UCEC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg17145862	chr1:211918768	LPGAT1	0.63	7.01	0.5	7.97e-11	Leprosy;
UCEC	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.49	4.76	0.37	4.62e-6	Emphysema distribution in smoking;
UCEC	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.33	4.87	0.37	2.81e-6	Schizophrenia;
UCEC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg23018236	chr17:30244563	NA	-0.73	-5.14	-0.39	8.67e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs2425143	1.000	rs6058304	chr20:34299851	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.57	-0.35	1.03e-5	Blood protein levels;
UCEC	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.63	-6.21	-0.46	5.11e-9	Ileal carcinoids;
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.3	0.61	1.78e-16	Platelet count;
UCEC	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.55e-9	Lung cancer;
UCEC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.94	10.43	0.65	2.06e-19	Cognitive function;
UCEC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg05991184	chr2:219186017	PNKD	0.52	5.69	0.43	6.56e-8	Colorectal cancer;
UCEC	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	6.01	0.44	1.37e-8	Schizophrenia;
UCEC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg12024160	chr4:1254474	NA	0.55	7.01	0.5	7.83e-11	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.37e-6	Breast cancer;
UCEC	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.55	6.93	0.5	1.2e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.44	4.63	0.36	8.03e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.71	-6.59	-0.48	7.52e-10	Platelet distribution width;
UCEC	cis	rs7246967	1.000	rs34629498	chr19:23060720	C/T	cg08271804	chr19:22816896	ZNF492	0.55	4.95	0.38	2.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.53	5.68	0.42	7.04e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.39	-5.12	-0.39	9.5e-7	Dupuytren's disease;
UCEC	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	6.96	0.5	1.04e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.48	4.85	0.37	3.18e-6	Blood metabolite levels;
UCEC	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1318937	0.588	rs112820857	chr3:15250000	C/T	cg08692541	chr3:14716288	C3orf20	0.68	4.78	0.37	4.2e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.55	5.22	0.4	5.97e-7	Calcium levels;
UCEC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.47	-6.57	-0.48	8.23e-10	Sense of smell;
UCEC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg11508081	chr17:41442227	NA	0.39	4.53	0.35	1.22e-5	Menopause (age at onset);
UCEC	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.95	-6.75	-0.49	3.27e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs17122693	0.748	rs72681630	chr14:51141250	A/G	cg04730355	chr14:51134070	SAV1	0.95	9.94	0.63	3.95e-18	Cognitive performance;
UCEC	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.44	5.68	0.42	7.13e-8	Fibrinogen levels;
UCEC	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.88	11.34	0.68	8.17e-22	Metabolic syndrome;
UCEC	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.57	-5.36	-0.4	3.11e-7	High light scatter reticulocyte count;
UCEC	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg04043695	chr12:129287642	SLC15A4	0.67	6.66	0.48	5.22e-10	Systemic lupus erythematosus;
UCEC	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.53	-4.7	-0.36	5.92e-6	Obesity-related traits;
UCEC	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.44	-5.07	-0.39	1.2e-6	Smoking behavior;
UCEC	cis	rs2801405	0.604	rs610603	chr10:100387552	A/G	cg25214158	chr10:101289600	NA	-0.37	-4.56	-0.35	1.08e-5	Obesity-related traits;
UCEC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg19318889	chr4:1322082	MAEA	0.45	4.82	0.37	3.5e-6	Obesity-related traits;
UCEC	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	0.99	6.02	0.44	1.32e-8	Skin colour saturation;
UCEC	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.5	4.95	0.38	2.04e-6	Emphysema distribution in smoking;
UCEC	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg01072550	chr1:21505969	NA	-0.5	-4.51	-0.35	1.32e-5	Superior frontal gyrus grey matter volume;
UCEC	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.85	10.71	0.66	3.86e-20	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.38	0.47	2.14e-9	Rheumatoid arthritis;
UCEC	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.46	5.37	0.41	2.97e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12826209	chr6:26865740	GUSBL1	0.51	4.9	0.37	2.48e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.88	-7.56	-0.53	3.93e-12	Alzheimer's disease;
UCEC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.8	-7.04	-0.5	6.88e-11	Blood metabolite levels;
UCEC	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg03714773	chr7:91764589	CYP51A1	0.43	5.43	0.41	2.31e-7	Breast cancer;
UCEC	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.87	-9.46	-0.62	7.07e-17	Cognitive function;
UCEC	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg13777783	chr17:79615861	NA	-0.33	-4.77	-0.37	4.37e-6	Eye color traits;
UCEC	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.55	4.9	0.37	2.54e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs12980942	0.935	rs12985162	chr19:41831507	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.72	5.38	0.41	2.83e-7	Coronary artery disease;
UCEC	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.73	5.96	0.44	1.79e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7088591	0.867	rs79906959	chr10:59787996	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-7.52	-0.53	5.1e-12	Coronary artery disease;
UCEC	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg26721908	chr21:47610096	LSS	-0.37	-4.64	-0.36	7.6e-6	Testicular germ cell tumor;
UCEC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4372836	0.504	rs62131973	chr2:29044437	T/G	cg09522027	chr2:28974177	PPP1CB	-0.68	-7.05	-0.5	6.48e-11	Body mass index;
UCEC	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.77	-4.99	-0.38	1.69e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.52	-6.71	-0.48	3.9e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-0.59	-6.92	-0.5	1.27e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	0.9	8.46	0.57	2.51e-14	Cognitive function;
UCEC	cis	rs7937612	0.931	rs12806740	chr11:120203628	G/A	cg12584626	chr11:120203529	NA	0.44	4.55	0.35	1.12e-5	Intraocular pressure;
UCEC	cis	rs6684428	1.000	rs61774843	chr1:56367384	C/T	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-6.89	-0.49	1.55e-10	Heart rate;
UCEC	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg23752985	chr2:85803571	VAMP8	0.43	4.64	0.36	7.78e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs1425902	0.554	rs55738135	chr8:54131931	G/T	cg01281904	chr8:54164757	OPRK1	-0.4	-4.87	-0.37	2.85e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.72	7.21	0.51	2.79e-11	Primary sclerosing cholangitis;
UCEC	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	cis	rs6715284	0.579	rs57855620	chr2:202445638	A/C	cg20169521	chr2:202563587	MPP4	-0.59	-4.59	-0.35	9.29e-6	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.59	6.09	0.45	9.5e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg18681998	chr4:17616180	MED28	0.84	10.82	0.67	1.93e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.68	6.78	0.49	2.78e-10	Lymphocyte counts;
UCEC	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.73	8.31	0.57	5.7e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-8.0	-0.55	3.45e-13	Response to antipsychotic treatment;
UCEC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-6.41	-0.47	1.86e-9	Platelet count;
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.78	9.12	0.6	5.39e-16	Longevity;Endometriosis;
UCEC	cis	rs10924970	0.649	rs4412584	chr1:235418146	T/C	cg26050004	chr1:235667680	B3GALNT2	0.53	4.79	0.37	4.1e-6	Asthma;
UCEC	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-5.11	-0.39	9.98e-7	Total cholesterol levels;
UCEC	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.73	5.93	0.44	2.08e-8	Menopause (age at onset);
UCEC	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-22.5	-0.88	1.87e-49	Myeloid white cell count;
UCEC	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.42	-4.64	-0.36	7.58e-6	Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs8103875	chr19:22866862	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.63	-4.55	-0.35	1.11e-5	Gut microbiome composition (summer);
UCEC	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-5.17	-0.39	7.51e-7	Waist circumference adjusted for body mass index;
UCEC	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.36	-0.76	9.02e-30	Schizophrenia;
UCEC	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.88	6.8	0.49	2.45e-10	Multiple sclerosis;
UCEC	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	6.34	0.46	2.6e-9	Bone mineral density;
UCEC	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	0.94	5.99	0.44	1.58e-8	Type 2 diabetes nephropathy;
UCEC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.21	7.09	0.5	5.34e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg02454025	chr1:11042201	C1orf127	0.72	7.94	0.55	4.82e-13	Ewing sarcoma;
UCEC	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.94	0.38	2.08e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.84	-9.18	-0.6	3.77e-16	Cognitive function;
UCEC	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.51	-4.81	-0.37	3.7e-6	Schizophrenia;
UCEC	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	6.02	0.44	1.32e-8	Response to antipsychotic treatment;
UCEC	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.47	-6.25	-0.46	4.26e-9	Neuroticism;
UCEC	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.11	-0.39	9.9e-7	Mood instability;
UCEC	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.6	4.65	0.36	7.33e-6	Obesity-related traits;
UCEC	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.34	4.71	0.36	5.62e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.68	-6.19	-0.45	5.72e-9	Aortic root size;
UCEC	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg23460707	chr10:133558971	NA	0.37	4.91	0.38	2.36e-6	Survival in rectal cancer;
UCEC	cis	rs35934224	0.724	rs16984286	chr22:19858114	A/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.11	-0.39	1.01e-6	Glaucoma (primary open-angle);
UCEC	cis	rs7095607	1.000	rs7094885	chr10:69953817	T/C	cg18986048	chr10:69913749	MYPN	0.46	4.97	0.38	1.84e-6	Lung function (FVC);
UCEC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.39	-4.59	-0.35	9.56e-6	Body mass index;
UCEC	cis	rs4026608	0.965	rs10878359	chr12:66404624	C/T	cg16292773	chr12:66211550	RPSAP52	0.45	4.59	0.35	9.53e-6	Aortic root size;
UCEC	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	6.02	0.44	1.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.57	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	trans	rs6581612	0.587	rs67478364	chr12:65646004	T/G	cg12591315	chr12:10022688	CLEC2B	-0.65	-6.68	-0.48	4.66e-10	Hippocampal volume;
UCEC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg26721908	chr21:47610096	LSS	-0.41	-5.35	-0.4	3.25e-7	Testicular germ cell tumor;
UCEC	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.68	7.74	0.54	1.49e-12	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg02160872	chr5:212506	CCDC127	0.71	7.14	0.51	4.03e-11	Breast cancer;
UCEC	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs9467773	0.967	rs6913877	chr6:26577488	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.49	-4.74	-0.36	5.08e-6	Cardiac Troponin-T levels;
UCEC	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.71	-8.57	-0.58	1.27e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.71	-6.46	-0.47	1.42e-9	High light scatter reticulocyte count;
UCEC	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.76e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg11871910	chr12:69753446	YEATS4	0.92	11.29	0.68	1.11e-21	Blood protein levels;
UCEC	cis	rs9650657	0.812	rs7834466	chr8:10634805	G/T	cg00629382	chr8:10268916	MSRA	-0.48	-4.73	-0.36	5.31e-6	Neuroticism;
UCEC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.45	4.9	0.37	2.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.49	5.05	0.38	1.27e-6	Migraine;
UCEC	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.09	-0.45	9.34e-9	Blood metabolite levels;
UCEC	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.49	5.59	0.42	1.09e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg16583315	chr14:65563665	MAX	-0.4	-4.62	-0.36	8.22e-6	Obesity-related traits;
UCEC	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.51	-0.35	1.33e-5	Joint mobility (Beighton score);
UCEC	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4687718	0.528	rs62256051	chr3:53311775	C/T	cg12173409	chr3:54154746	NA	0.6	4.83	0.37	3.35e-6	QRS duration;
UCEC	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	1.02	10.22	0.64	7.26e-19	Alcohol dependence;
UCEC	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.54	-4.83	-0.37	3.4e-6	Carotid intima media thickness;
UCEC	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.64	6.46	0.47	1.46e-9	Cognitive ability;
UCEC	cis	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg20560298	chr2:73613845	ALMS1	0.52	5.08	0.39	1.14e-6	Schizophrenia;
UCEC	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-25.18	-0.9	3.61e-55	Myeloid white cell count;
UCEC	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.58	5.03	0.38	1.43e-6	Hemoglobin concentration;Hematocrit;
UCEC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.14	18.22	0.83	1.57e-39	IgG glycosylation;
UCEC	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.64	7.2	0.51	2.93e-11	Eye color traits;
UCEC	cis	rs11686241	0.688	rs6739813	chr2:217370675	T/C	cg15830940	chr2:217278069	SMARCAL1	0.46	4.54	0.35	1.14e-5	Cancer;
UCEC	cis	rs16937	0.662	rs11240376	chr1:205146460	A/G	cg00857998	chr1:205179979	DSTYK	0.52	4.54	0.35	1.15e-5	Schizophrenia;
UCEC	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.51	5.41	0.41	2.49e-7	Tumor biomarkers;
UCEC	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.43	4.52	0.35	1.28e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.63	0.53	2.75e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg23625390	chr15:77176239	SCAPER	-0.81	-7.53	-0.53	4.62e-12	Blood metabolite levels;
UCEC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg23018236	chr17:30244563	NA	-0.65	-4.83	-0.37	3.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.67	0.36	6.85e-6	Bipolar disorder;
UCEC	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg24687543	chr11:63912206	MACROD1	0.57	4.8	0.37	3.81e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg23796481	chr11:64053134	BAD;GPR137	0.68	6.41	0.47	1.84e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.68	-4.73	-0.36	5.16e-6	LDL cholesterol levels;
UCEC	cis	rs11958404	0.932	rs72816564	chr5:157427484	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-5.21	-0.39	6.28e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.07	0.5	5.86e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.43	-0.41	2.25e-7	Obesity-related traits;
UCEC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.68	8.18	0.56	1.21e-13	Neuroticism;
UCEC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.53	5.12	0.39	9.33e-7	Menopause (age at onset);
UCEC	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.82	-10.07	-0.64	1.83e-18	Coronary artery disease;
UCEC	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.66	6.19	0.45	5.8e-9	Bladder cancer;
UCEC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-5.88	-0.44	2.62e-8	Platelet count;
UCEC	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.0	13.22	0.74	8.7e-27	Testicular germ cell tumor;
UCEC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-6.18	-0.45	6.01e-9	Prostate cancer;
UCEC	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.59	-5.94	-0.44	1.95e-8	White matter hyperintensity burden;
UCEC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg06671706	chr8:8559999	CLDN23	0.53	4.88	0.37	2.68e-6	Obesity-related traits;
UCEC	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.18	0.45	5.9e-9	Cognitive ability;
UCEC	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	7.36	0.52	1.21e-11	Exhaled nitric oxide levels;
UCEC	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.1	0.56	1.89e-13	Alzheimer's disease;
UCEC	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg00738919	chr7:1100172	C7orf50	0.75	4.57	0.35	1.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg02344993	chr17:57696989	CLTC	-0.51	-4.84	-0.37	3.29e-6	Obesity-related traits;
UCEC	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.7	6.34	0.46	2.65e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	8.12	0.56	1.7e-13	Alzheimer's disease;
UCEC	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.76	-7.07	-0.5	5.66e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.42	4.82	0.37	3.49e-6	Lung cancer;
UCEC	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.55	6.85	0.49	1.88e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.45	-5.46	-0.41	1.95e-7	Subjective well-being;
UCEC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.55	-6.09	-0.45	9.28e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg06562184	chr8:19319451	CSGALNACT1	0.44	4.87	0.37	2.85e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2120243	0.874	rs2316709	chr3:157150247	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.67	0.36	6.71e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	4.87	0.37	2.81e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.6	6.6	0.48	6.95e-10	Resting heart rate;
UCEC	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.75	-0.36	4.81e-6	Alzheimer's disease (late onset);
UCEC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.33	-4.67	-0.36	6.77e-6	Iron status biomarkers;
UCEC	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	0.81	5.03	0.38	1.4e-6	Diabetic retinopathy;
UCEC	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-6.24	-0.46	4.33e-9	Coronary artery disease;
UCEC	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.55	-5.66	-0.42	7.85e-8	Hepatocellular carcinoma;
UCEC	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-5.84	-0.43	3.2e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.85	8.63	0.58	9.13e-15	Mosquito bite size;
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.51	5.01	0.38	1.54e-6	Dilated cardiomyopathy;
UCEC	cis	rs5997397	0.583	rs5752793	chr22:29160314	A/G	cg15103426	chr22:29168792	CCDC117	0.48	4.52	0.35	1.25e-5	Red cell distribution width;
UCEC	trans	rs6581612	0.587	rs1498789	chr12:65600908	C/T	cg12591315	chr12:10022688	CLEC2B	-0.67	-6.73	-0.49	3.54e-10	Hippocampal volume;
UCEC	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.56	-6.53	-0.47	1e-9	Educational attainment;
UCEC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18252515	chr7:66147081	NA	0.49	4.89	0.37	2.61e-6	Aortic root size;
UCEC	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg23625390	chr15:77176239	SCAPER	0.46	4.53	0.35	1.24e-5	Blood metabolite levels;
UCEC	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.66	-5.83	-0.43	3.32e-8	Systolic blood pressure;
UCEC	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-9.6	-0.62	2.97e-17	Blood metabolite levels;
UCEC	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg01072550	chr1:21505969	NA	0.58	6.06	0.45	1.07e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-5.01	-0.38	1.53e-6	Morning vs. evening chronotype;
UCEC	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-1.02	-8.38	-0.57	3.87e-14	White matter hyperintensity burden;
UCEC	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.37	-0.46	2.33e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg05660106	chr1:15850417	CASP9	0.55	4.91	0.38	2.44e-6	Systolic blood pressure;
UCEC	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.55	5.65	0.42	8.11e-8	Prostate cancer;
UCEC	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.58	-5.9	-0.44	2.45e-8	Glomerular filtration rate;
UCEC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18252515	chr7:66147081	NA	-0.46	-4.7	-0.36	5.89e-6	Aortic root size;
UCEC	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.02	18.29	0.83	1.08e-39	Colorectal cancer;
UCEC	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-0.72	-9.76	-0.63	1.15e-17	Gut microbiome composition (winter);
UCEC	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.78	-0.37	4.16e-6	Blood metabolite levels;
UCEC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00995209	chr8:144881704	SCRIB	-0.57	-6.69	-0.48	4.39e-10	N-glycan levels;
UCEC	cis	rs12573330	1.000	rs57710486	chr10:98470865	T/C	cg10113589	chr10:98118853	OPALIN	0.47	4.57	0.35	1.01e-5	Monocyte percentage of white cells;
UCEC	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.88	12.61	0.72	3.51e-25	Leprosy;
UCEC	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.68	-4.85	-0.37	3.17e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.67	7.98	0.55	3.9e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12292205	chr6:26970375	C6orf41	-0.65	-4.6	-0.35	8.97e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-0.87	-8.96	-0.59	1.36e-15	Heart rate;
UCEC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.02	-0.44	1.33e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	4.99	0.38	1.65e-6	Bone mineral density;
UCEC	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	6.39	0.47	2.11e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg19715936	chr7:50634035	DDC	0.43	5.16	0.39	7.71e-7	Malaria;
UCEC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.93	10.12	0.64	1.38e-18	Cognitive function;
UCEC	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-4.77	-0.37	4.36e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs6583826	0.538	rs11187076	chr10:94336963	G/A	cg00519463	chr10:94352821	KIF11	-0.43	-4.64	-0.36	7.77e-6	Type 2 diabetes;
UCEC	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.7	5.62	0.42	9.13e-8	Corneal astigmatism;
UCEC	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.92	8.72	0.58	5.42e-15	Morning vs. evening chronotype;
UCEC	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.38	5.62	0.42	9.48e-8	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg19567339	chr10:100142640	NA	0.69	9.41	0.61	9.25e-17	Metabolite levels;
UCEC	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg05962950	chr11:130786565	SNX19	0.74	6.31	0.46	3.09e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.61	7.25	0.51	2.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6763768	0.606	rs60287116	chr3:53388457	C/T	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.9	0.59	1.86e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.66	5.91	0.44	2.28e-8	Lymphocyte counts;
UCEC	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.71	6.81	0.49	2.35e-10	Refractive astigmatism;
UCEC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.82	8.77	0.59	4.19e-15	Cognitive function;
UCEC	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg03609598	chr5:56110824	MAP3K1	0.54	5.16	0.39	7.81e-7	Coronary artery disease;
UCEC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.7	7.74	0.54	1.49e-12	Menopause (age at onset);
UCEC	cis	rs9309711	0.518	rs9752314	chr2:3494322	A/G	cg15541040	chr2:3486749	NA	-0.6	-5.22	-0.4	6e-7	Neurofibrillary tangles;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.75	9.37	0.61	1.17e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.76	0.63	1.16e-17	Platelet count;
UCEC	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.73	4.92	0.38	2.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg05874882	chr4:1763078	NA	-0.66	-6.32	-0.46	3.02e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.43	-5.24	-0.4	5.49e-7	Refractive error;
UCEC	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.62	-6.18	-0.45	5.86e-9	Morning vs. evening chronotype;
UCEC	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg18016565	chr1:150552671	MCL1	-0.52	-5.77	-0.43	4.45e-8	Tonsillectomy;
UCEC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.71	8.44	0.57	2.84e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.68	-0.58	6.9e-15	Total cholesterol levels;
UCEC	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg14438399	chr17:27053147	TLCD1	0.63	5.14	0.39	8.75e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.55	-5.5	-0.41	1.65e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg00250761	chr1:31883323	NA	-0.39	-5.07	-0.39	1.19e-6	Alcohol dependence;
UCEC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.46	-4.73	-0.36	5.33e-6	Dental caries;
UCEC	cis	rs806321	0.755	rs2740520	chr13:50786363	G/T	cg12964420	chr13:50975679	NA	0.37	4.55	0.35	1.13e-5	Multiple sclerosis;
UCEC	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg03188948	chr7:1209495	NA	0.42	4.51	0.35	1.3e-5	Longevity;Endometriosis;
UCEC	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.71	-0.54	1.75e-12	Monocyte count;
UCEC	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	8.17	0.56	1.27e-13	Smoking behavior;
UCEC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.49	5.13	0.39	9.15e-7	Vitiligo;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.91	11.99	0.7	1.58e-23	Menarche (age at onset);
UCEC	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9467773	1.000	rs9467802	chr6:26581168	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.55	6.2	0.46	5.48e-9	Crohn's disease;
UCEC	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.55	5.01	0.38	1.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.58	-6.13	-0.45	7.69e-9	Testicular germ cell tumor;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.48	5.59	0.42	1.1e-7	Menarche (age at onset);
UCEC	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.65	-6.32	-0.46	2.91e-9	Coronary artery disease;
UCEC	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.63	-5.39	-0.41	2.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Diabetic kidney disease;
UCEC	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	Bipolar disorder;
UCEC	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	0.9	8.46	0.57	2.51e-14	Cognitive function;
UCEC	cis	rs9309473	0.519	rs6730785	chr2:73642403	A/C	cg20560298	chr2:73613845	ALMS1	0.54	5.36	0.4	3.18e-7	Metabolite levels;
UCEC	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.06	0.5	6.28e-11	Motion sickness;
UCEC	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Body mass index;
UCEC	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.39	5.79	0.43	4.18e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.78	-6.46	-0.47	1.42e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.7	6.62	0.48	6.29e-10	Ovarian reserve;
UCEC	cis	rs7546668	1.000	rs9298	chr1:15897020	C/T	cg05660106	chr1:15850417	CASP9	-0.45	-4.58	-0.35	9.94e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg05738196	chr6:26577821	NA	-0.59	-6.47	-0.47	1.39e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2733954	1.000	rs2733954	chr16:85836256	C/T	cg04419883	chr16:85607562	NA	0.33	4.58	0.35	9.97e-6	Leprosy;
UCEC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.53	6.56	0.48	8.71e-10	Total body bone mineral density;
UCEC	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-4.73	-0.36	5.22e-6	Waist circumference adjusted for body mass index;
UCEC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.74	7.24	0.51	2.27e-11	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.73	8.12	0.56	1.71e-13	Menarche (age at onset);
UCEC	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	4.52	0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	7.59	0.53	3.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-1.01	-7.34	-0.52	1.35e-11	Multiple sclerosis;
UCEC	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.67	-5.47	-0.41	1.93e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.49	-5.91	-0.44	2.28e-8	Neuroticism;
UCEC	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.65	-5.74	-0.43	5.25e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.45	-6.12	-0.45	8.03e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.5	-5.01	-0.38	1.55e-6	P wave terminal force;
UCEC	cis	rs8032158	1.000	rs28660477	chr15:56145267	T/C	cg10433327	chr15:56209506	NEDD4	-0.31	-4.97	-0.38	1.84e-6	Keloid;
UCEC	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.79	0.37	4.11e-6	Menopause (age at onset);
UCEC	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.09	0.39	1.07e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.75	-8.24	-0.56	8.61e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.27	0.4	4.67e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.55	5.21	0.39	6.33e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs240764	0.659	rs1006398	chr6:101037718	T/A	cg09795085	chr6:101329169	ASCC3	0.48	5.25	0.4	5.23e-7	Neuroticism;
UCEC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg02461776	chr11:598696	PHRF1	0.47	5.09	0.39	1.08e-6	Systemic lupus erythematosus;
UCEC	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	0.8	9.82	0.63	8.38e-18	Bone mineral density;
UCEC	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg19438565	chr8:143695827	ARC	-0.46	-4.64	-0.36	7.78e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.67	-5.96	-0.44	1.8e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.32	4.53	0.35	1.21e-5	Primary biliary cholangitis;
UCEC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.01	-7.96	-0.55	4.33e-13	White matter hyperintensity burden;
UCEC	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.94	9.48	0.62	6.1e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.51e-7	Hemoglobin concentration;
UCEC	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.59	6.76	0.49	3e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.4	5.93	0.44	2.08e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.62	-6.13	-0.45	7.79e-9	Metabolite levels;
UCEC	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg14019695	chr9:139328340	INPP5E	0.41	4.59	0.35	9.4e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.73	6.63	0.48	5.97e-10	Aortic root size;
UCEC	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg18681998	chr4:17616180	MED28	-0.64	-7.03	-0.5	7.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.36	0.61	1.24e-16	Platelet count;
UCEC	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	0.81	9.36	0.61	1.28e-16	Bone mineral density;
UCEC	cis	rs2979489	0.891	rs17552243	chr8:30362627	T/C	cg26383811	chr8:30366931	RBPMS	-0.73	-6.15	-0.45	7.12e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.91	-0.38	2.42e-6	Bipolar disorder;
UCEC	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.65	-7.64	-0.53	2.56e-12	Vitiligo;
UCEC	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	trans	rs9313296	0.661	rs2545513	chr5:165522065	G/A	cg03539051	chr19:56418660	NLRP13	1.11	6.93	0.5	1.23e-10	Weight;Waist circumference;
UCEC	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.51	-5.63	-0.42	8.8e-8	HDL cholesterol;
UCEC	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.63	6.91	0.49	1.39e-10	Tonsillectomy;
UCEC	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.55	-5.46	-0.41	1.97e-7	Breast size;
UCEC	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.46	-4.9	-0.37	2.54e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.46	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs12980942	0.872	rs12327659	chr19:41796472	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.62	5.51	0.41	1.54e-7	Coronary artery disease;
UCEC	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.52	7.51	0.53	5.18e-12	Height;
UCEC	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.79	-8.57	-0.58	1.28e-14	Breast cancer;
UCEC	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.52	5.72	0.43	5.8e-8	Retinal vascular caliber;
UCEC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.8	-8.94	-0.59	1.5e-15	Breast cancer;
UCEC	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.64	-6.11	-0.45	8.6e-9	Brugada syndrome;
UCEC	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.69	-4.76	-0.37	4.57e-6	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
UCEC	cis	rs797973	0.584	rs9913225	chr17:27570622	C/T	cg03378797	chr17:27493467	MYO18A	-0.39	-4.52	-0.35	1.26e-5	Type 2 diabetes;
UCEC	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.82	-0.37	3.61e-6	Blood metabolite levels;
UCEC	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-5.86	-0.44	2.89e-8	Bone mineral density;
UCEC	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.98	-7.66	-0.53	2.25e-12	Dupuytren's disease;
UCEC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	7.28	0.51	1.83e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.77	0.43	4.47e-8	Breast cancer;
UCEC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.34	0.57	4.85e-14	Chronic sinus infection;
UCEC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg19318889	chr4:1322082	MAEA	0.45	4.78	0.37	4.28e-6	Obesity-related traits;
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.67	-7.27	-0.51	1.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.63	4.88	0.37	2.69e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.64	-5.39	-0.41	2.76e-7	Insulin-like growth factors;
UCEC	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.72	-6.43	-0.47	1.72e-9	Bipolar disorder;
UCEC	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg24531977	chr5:56204891	C5orf35	-0.66	-4.6	-0.35	8.97e-6	Type 2 diabetes;
UCEC	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg23260525	chr10:116636907	FAM160B1	0.33	4.51	0.35	1.32e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.52	5.07	0.39	1.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.78	-5.57	-0.42	1.18e-7	Body mass index;
UCEC	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg04154034	chr17:28927549	LRRC37B2	0.83	5.26	0.4	5.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg20607287	chr7:12443886	VWDE	-0.64	-4.69	-0.36	6.11e-6	Coronary artery disease;
UCEC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.62	-0.42	9.31e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg13683864	chr3:40499215	RPL14	-0.55	-5.59	-0.42	1.05e-7	Renal cell carcinoma;
UCEC	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.64	6.27	0.46	3.82e-9	Aortic root size;
UCEC	cis	rs12681288	0.963	rs35220148	chr8:1027602	G/A	cg04851639	chr8:1020857	NA	-0.34	-4.96	-0.38	1.89e-6	Schizophrenia;
UCEC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg08755490	chr11:65554678	OVOL1	0.49	5.11	0.39	9.7e-7	Acne (severe);
UCEC	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.93	-0.38	2.17e-6	Coronary artery disease;
UCEC	cis	rs7088591	0.867	rs35707322	chr10:59778109	A/G	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-6.17	-0.45	6.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.49	5.32	0.4	3.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg07664667	chr16:778351	HAGHL	-0.62	-6.73	-0.49	3.57e-10	Neuroticism;
UCEC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.56	-4.69	-0.36	6.31e-6	Initial pursuit acceleration;
UCEC	cis	rs847649	0.731	rs2298854	chr7:102729631	T/G	cg18108683	chr7:102477205	FBXL13	0.53	6.31	0.46	3.18e-9	Morning vs. evening chronotype;
UCEC	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.59	-5.3	-0.4	4.22e-7	Corneal astigmatism;
UCEC	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.03	15.59	0.79	5.99e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg07838603	chr6:28411030	ZSCAN23	0.43	4.51	0.35	1.3e-5	Parkinson's disease;
UCEC	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-5.67	-0.42	7.42e-8	Initial pursuit acceleration;
UCEC	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.44	5.12	0.39	9.4e-7	Obesity;
UCEC	cis	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg20307385	chr11:47447363	PSMC3	0.53	5.09	0.39	1.06e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	0.81	5.41	0.41	2.48e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.38	0.41	2.82e-7	Response to antipsychotic treatment;
UCEC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.5	4.94	0.38	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.4	5.12	0.39	9.42e-7	Migraine;
UCEC	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	5.9	0.44	2.41e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs639436	0.681	rs639047	chr19:56032666	G/A	cg04438519	chr19:56133084	ZNF784	0.44	4.53	0.35	1.2e-5	Lung adenocarcinoma;
UCEC	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg03959625	chr15:84868606	LOC388152	0.46	4.72	0.36	5.44e-6	Schizophrenia;
UCEC	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.71	-0.43	5.94e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.5	4.76	0.37	4.56e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.74	-4.61	-0.36	8.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	7.74	0.54	1.46e-12	Hip circumference;
UCEC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.38	0.47	2.12e-9	Diabetic retinopathy;
UCEC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg05802129	chr4:122689817	NA	-0.55	-5.54	-0.42	1.33e-7	Type 2 diabetes;
UCEC	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.63	-4.5	-0.35	1.35e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.71	0.36	5.79e-6	Menopause (age at onset);
UCEC	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.58	-0.66	8.26e-20	Blood metabolite levels;
UCEC	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-8.33	-0.57	5.08e-14	Electrocardiographic conduction measures;
UCEC	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.54	5.66	0.42	7.76e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.49	-5.64	-0.42	8.56e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.5	5.82	0.43	3.62e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	0.9	11.98	0.7	1.72e-23	Ewing sarcoma;
UCEC	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs12431410	0.536	rs1957998	chr14:60148800	C/G	cg10397765	chr14:61113109	SIX1	-0.45	-4.87	-0.37	2.83e-6	Schizophrenia;
UCEC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18252515	chr7:66147081	NA	0.49	4.92	0.38	2.34e-6	Aortic root size;
UCEC	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.69	5.64	0.42	8.55e-8	Alcohol dependence;
UCEC	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg16797656	chr11:68205561	LRP5	0.64	9.25	0.61	2.38e-16	Total body bone mineral density;
UCEC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.46	0.47	1.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.03	-16.07	-0.8	3.43e-34	IgG glycosylation;
UCEC	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.48	-5.18	-0.39	7.26e-7	Morning vs. evening chronotype;
UCEC	cis	rs11969893	0.850	rs9390713	chr6:101424262	G/A	cg12253828	chr6:101329408	ASCC3	0.98	5.63	0.42	8.79e-8	Economic and political preferences (immigration/crime);
UCEC	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.79	8.08	0.55	2.13e-13	Caffeine consumption;
UCEC	cis	rs716804	0.740	rs7118500	chr11:10284762	C/A	cg23875677	chr11:10229755	SBF2	-0.46	-4.64	-0.36	7.77e-6	Neuroticism;
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.46	-5.0	-0.38	1.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7246967	0.611	rs7250285	chr19:22837108	C/T	cg23217946	chr19:22817039	ZNF492	0.41	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs16937	0.711	rs10751429	chr1:205107478	C/T	cg12580275	chr1:205744413	RAB7L1	0.49	5.69	0.42	6.64e-8	Schizophrenia;
UCEC	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.67	4.66	0.36	7.13e-6	Psoriasis;
UCEC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg24375607	chr4:120327624	NA	0.48	5.04	0.38	1.34e-6	Corneal astigmatism;
UCEC	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.03	6.81	0.49	2.36e-10	Lung disease severity in cystic fibrosis;
UCEC	cis	rs35934224	0.831	rs1044732	chr22:19863142	T/C	cg11182965	chr22:19864308	TXNRD2	-0.63	-6.04	-0.45	1.18e-8	Glaucoma (primary open-angle);
UCEC	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.69	-6.15	-0.45	6.9e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs944990	0.618	rs2398847	chr9:96365758	A/G	cg13787134	chr9:96362102	PHF2	-0.37	-4.85	-0.37	3.14e-6	Body mass index;
UCEC	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	0.77	4.95	0.38	2e-6	Iron status biomarkers;
UCEC	cis	rs7766436	0.848	rs13200143	chr6:22586212	T/G	cg13666174	chr6:22585274	NA	-0.61	-6.13	-0.45	7.52e-9	Coronary artery disease;
UCEC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.79	0.37	4.12e-6	Breast cancer;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.48	-5.77	-0.43	4.46e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.79	-9.21	-0.6	3.11e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg03354898	chr7:1950403	MAD1L1	-0.59	-5.88	-0.44	2.67e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg22166914	chr1:53195759	ZYG11B	0.66	7.01	0.5	7.83e-11	Monocyte count;
UCEC	cis	rs4499344	0.589	rs259233	chr19:33127000	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	6.85	0.49	1.84e-10	Mean platelet volume;
UCEC	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.64	-6.87	-0.49	1.72e-10	Prostate cancer;
UCEC	cis	rs60311166	1.000	rs60770874	chr3:52750199	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.79	5.34	0.4	3.41e-7	CTACK levels;
UCEC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg04154034	chr17:28927549	LRRC37B2	0.56	4.51	0.35	1.33e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.32	-5.24	-0.4	5.44e-7	Mean corpuscular volume;
UCEC	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.44	-5.44	-0.41	2.15e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	1.08	9.71	0.63	1.6e-17	Dupuytren's disease;
UCEC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.62	6.73	0.49	3.55e-10	Colorectal cancer;
UCEC	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	9.99	0.64	2.88e-18	Electrocardiographic conduction measures;
UCEC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.61	9.01	0.6	9.92e-16	Prudent dietary pattern;
UCEC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9309473	0.500	rs2421668	chr2:73885096	G/A	cg20560298	chr2:73613845	ALMS1	0.52	4.96	0.38	1.94e-6	Metabolite levels;
UCEC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.65	-7.34	-0.52	1.32e-11	Menarche (age at onset);
UCEC	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.73	8.37	0.57	4.2e-14	IgG glycosylation;
UCEC	cis	rs3744061	0.505	rs9907915	chr17:74651236	A/G	cg02128979	chr17:74682217	MXRA7	0.44	4.78	0.37	4.27e-6	Retinal arteriolar caliber;
UCEC	cis	rs11133613	0.546	rs28676354	chr5:947272	A/G	cg23377852	chr5:1339812	CLPTM1L	-0.68	-5.03	-0.38	1.41e-6	Red cell distribution width;
UCEC	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.46	-4.84	-0.37	3.19e-6	Body mass index;
UCEC	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.5	5.26	0.4	4.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.35	-5.18	-0.39	7.3e-7	Vitamin D levels;
UCEC	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.5	5.57	0.42	1.17e-7	Platelet distribution width;
UCEC	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs1079204	1.000	rs13423003	chr2:219111341	G/C	cg05728596	chr2:219128475	GPBAR1	0.75	5.94	0.44	1.97e-8	Smooth-surface caries;
UCEC	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.59	4.85	0.37	3.06e-6	Corneal astigmatism;
UCEC	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.67	4.77	0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg09655341	chr17:79618100	PDE6G	0.31	4.53	0.35	1.21e-5	Eye color traits;
UCEC	cis	rs6717918	0.564	rs6742242	chr2:233066190	T/C	cg02061626	chr2:233274167	ALPPL2	0.51	5.37	0.4	3.06e-7	Height;
UCEC	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.55	-5.48	-0.41	1.8e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7045138	1	rs7045138	chr9:100591463	C/T	cg13688889	chr9:100608707	NA	-0.53	-5.51	-0.41	1.58e-7	Thyroid hormone levels;
UCEC	cis	rs9470794	1.000	rs77474124	chr6:38044915	T/G	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.66	5.09	0.39	1.09e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08822215	chr16:89438651	ANKRD11	0.53	5.39	0.41	2.74e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.67	-6.64	-0.48	5.7e-10	Blood metabolite levels;
UCEC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.69	0.42	6.71e-8	Height;
UCEC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg06027949	chr8:82754900	SNX16	0.62	5.22	0.4	5.98e-7	Diastolic blood pressure;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09428623	chr2:68480128	PPP3R1	0.56	6.71	0.48	3.93e-10	Warfarin maintenance dose;
UCEC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.74	-8.4	-0.57	3.56e-14	Menarche (age at onset);
UCEC	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.41	4.9	0.37	2.56e-6	Plateletcrit;
UCEC	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.19e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs11153730	0.503	rs12212582	chr6:118626480	A/G	cg21191810	chr6:118973309	C6orf204	0.39	4.92	0.38	2.28e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.73	7.17	0.51	3.38e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	4.56	0.35	1.05e-5	Personality dimensions;
UCEC	cis	rs12644436	1.000	rs1564148	chr4:88789479	T/C	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	HIV-1 viral setpoint;
UCEC	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.24	9.49	0.62	5.83e-17	Uric acid levels;
UCEC	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg10978503	chr1:24200527	CNR2	0.37	4.89	0.37	2.6e-6	Immature fraction of reticulocytes;
UCEC	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-7.93	-0.55	5.03e-13	Resting heart rate;
UCEC	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.62	6.51	0.47	1.11e-9	Colorectal cancer;
UCEC	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg21191810	chr6:118973309	C6orf204	0.44	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs3818285	0.505	rs71479284	chr10:111746437	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.46	-5.14	-0.39	8.61e-7	Superior crus of antihelix expression;
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.53	6.54	0.47	9.75e-10	Menarche (age at onset);
UCEC	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.47	4.83	0.37	3.44e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.56	-5.09	-0.39	1.06e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.49	0.53	5.76e-12	Ileal carcinoids;
UCEC	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.17	-9.57	-0.62	3.63e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg23018236	chr17:30244563	NA	-0.67	-4.64	-0.36	7.52e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.41	4.57	0.35	1.03e-5	Mean corpuscular volume;
UCEC	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.46	6.27	0.46	3.84e-9	Alcohol dependence;
UCEC	cis	rs12318506	0.793	rs11180432	chr12:75661314	C/T	cg04728562	chr12:75699417	CAPS2	-0.8	-5.0	-0.38	1.6e-6	Coronary artery calcification;
UCEC	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.59	5.69	0.43	6.53e-8	Bone properties (heel);
UCEC	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-4.51	-0.35	1.31e-5	Type 2 diabetes;
UCEC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg22974920	chr21:40686053	BRWD1	0.57	5.0	0.38	1.58e-6	Cognitive function;
UCEC	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.5	5.14	0.39	8.66e-7	Primary sclerosing cholangitis;
UCEC	cis	rs12681287	0.752	rs10092651	chr8:87247678	A/C	cg27223183	chr8:87520930	FAM82B	-0.56	-4.73	-0.36	5.13e-6	Caudate activity during reward;
UCEC	cis	rs354033	1.000	rs11766910	chr7:149279620	C/T	cg24335155	chr7:149193227	ZNF746	0.39	4.69	0.36	6.31e-6	Multiple sclerosis;
UCEC	cis	rs11072089	0.579	rs7182493	chr15:69684050	C/T	cg21828345	chr15:68724752	ITGA11	0.63	4.85	0.37	3.16e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.51	4.88	0.37	2.73e-6	Blood metabolite levels;
UCEC	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg23950597	chr19:37808831	NA	-0.64	-5.0	-0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.53	5.15	0.39	8.32e-7	Colorectal cancer;
UCEC	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.48e-16	Vitiligo;
UCEC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.54	-5.9	-0.44	2.38e-8	Prostate cancer;
UCEC	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.64	6.7	0.48	4.08e-10	QRS complex (12-leadsum);
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	8.92e-6	Prudent dietary pattern;
UCEC	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.65	5.25	0.4	5.29e-7	Systolic blood pressure;
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.61	6.09	0.45	9.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.63	5.53	0.41	1.45e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg14078730	chr11:63896557	MACROD1	0.66	5.16	0.39	8.04e-7	Mean platelet volume;
UCEC	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg16388896	chr14:106116875	NA	0.35	4.74	0.36	4.9100000000000004e-06	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.82	8.89	0.59	2.03e-15	Breast cancer;
UCEC	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg18681998	chr4:17616180	MED28	0.79	9.2	0.6	3.25e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	11.61	0.69	1.63e-22	Platelet count;
UCEC	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.5	5.36	0.4	3.16e-7	Alcohol dependence;
UCEC	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.61	-5.96	-0.44	1.81e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.52	4.96	0.38	1.88e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.72	-6.71	-0.48	3.96e-10	Prudent dietary pattern;
UCEC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.74	-7.82	-0.54	9.63e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.66	-7.26	-0.51	2.12e-11	Hypospadias;
UCEC	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-6.67	-0.48	4.89e-10	Primary biliary cholangitis;
UCEC	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.83	9.45	0.61	7.28e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.45	-6.27	-0.46	3.78e-9	Mortality in heart failure;
UCEC	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg13683864	chr3:40499215	RPL14	0.69	7.31	0.52	1.62e-11	Renal cell carcinoma;
UCEC	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-0.98	-7.42	-0.52	8.88e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.51	4.82	0.37	3.58e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.56	0.35	1.07e-5	Breast cancer;
UCEC	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.49	-6.04	-0.45	1.23e-8	Mean platelet volume;
UCEC	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-14.22	-0.76	2.08e-29	Schizophrenia;
UCEC	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.46	5.0	0.38	1.64e-6	Metabolic traits;
UCEC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-0.56	-7.26	-0.51	2.13e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.22	10.58	0.66	8.64e-20	Corneal structure;
UCEC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg22117172	chr7:91764530	CYP51A1	0.4	5.25	0.4	5.12e-7	Breast cancer;
UCEC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12516959	chr21:47718080	NA	0.42	4.88	0.37	2.76e-6	Testicular germ cell tumor;
UCEC	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.09	16.96	0.81	1.98e-36	Primary sclerosing cholangitis;
UCEC	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.27	0.4	4.8e-7	Personality dimensions;
UCEC	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.69	-7.32	-0.52	1.47e-11	Height;
UCEC	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.89	7.12	0.51	4.47e-11	Exhaled nitric oxide output;
UCEC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18252515	chr7:66147081	NA	0.52	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.38	0.57	3.92e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs394563	0.775	rs412894	chr6:149781175	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.4	-4.88	-0.37	2.79e-6	Dupuytren's disease;
UCEC	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.41	-6.62	-0.48	6.16e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.54	-0.84	2.53e-40	Exhaled nitric oxide output;
UCEC	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.69	-5.05	-0.38	1.31e-6	Calcium levels;
UCEC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.54	0.42	1.34e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.89	-0.37	2.62e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg09682330	chr6:28411287	ZSCAN23	0.47	5.0	0.38	1.59e-6	Cardiac Troponin-T levels;
UCEC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.94e-7	Aortic root size;
UCEC	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.7	-8.39	-0.57	3.62e-14	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.51	5.4	0.41	2.65e-7	Type 2 diabetes;
UCEC	cis	rs16937	0.711	rs6682229	chr1:205152932	T/C	cg12580275	chr1:205744413	RAB7L1	0.48	5.2	0.39	6.47e-7	Schizophrenia;
UCEC	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.63	-0.36	7.94e-6	Educational attainment (years of education);
UCEC	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg18681998	chr4:17616180	MED28	-0.7	-7.51	-0.53	5.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	9.23	0.61	2.72e-16	Coffee consumption (cups per day);
UCEC	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.89	-12.68	-0.72	2.34e-25	Urate levels in lean individuals;
UCEC	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.56	5.19	0.39	6.96e-7	Lung cancer;
UCEC	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.78	9.31	0.61	1.7e-16	Breast cancer;
UCEC	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-0.98	-11.06	-0.67	4.42e-21	Blood pressure (smoking interaction);
UCEC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-8.61	-0.58	1.05e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.09	-0.39	1.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs10946940	1.000	rs10946940	chr6:27560587	A/G	cg07836142	chr6:28411423	ZSCAN23	0.44	4.72	0.36	5.48e-6	Systemic lupus erythematosus;
UCEC	cis	rs6684428	1.000	rs4130692	chr1:56345824	C/A	cg11651538	chr1:56320950	NA	-0.69	-6.29	-0.46	3.51e-9	Airflow obstruction;
UCEC	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.46	-4.85	-0.37	3.12e-6	Acylcarnitine levels;
UCEC	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	7.73	0.54	1.57e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.45	-5.0	-0.38	1.6e-6	Schizophrenia;
UCEC	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.69	-8.31	-0.57	5.77e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	1.0	11.54	0.69	2.37e-22	Cognitive function;
UCEC	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.48	4.93	0.38	2.16e-6	Dupuytren's disease;
UCEC	cis	rs3862260	1.000	rs3862260	chr1:120160789	G/A	cg17939831	chr1:119836654	NA	-0.53	-5.26	-0.4	4.99e-7	Systemic lupus erythematosus;
UCEC	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.9	11.41	0.69	5.43e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.78	-5.09	-0.39	1.06e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.94	0.5	1.16e-10	Eye color traits;
UCEC	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.83	-9.09	-0.6	6.26e-16	Breast cancer;
UCEC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.69	-0.36	6.22e-6	Breast cancer;
UCEC	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg27608806	chr12:125509780	BRI3BP	-0.6	-7.27	-0.51	1.94e-11	N-glycan levels;
UCEC	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg23793686	chr15:68133972	NA	0.4	4.56	0.35	1.07e-5	Restless legs syndrome;
UCEC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.57	0.35	1.04e-5	Height;
UCEC	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.25	10.08	0.64	1.76e-18	Uric acid levels;
UCEC	cis	rs9831754	0.526	rs6548551	chr3:78342292	C/T	cg06138941	chr3:78371609	NA	0.49	4.78	0.37	4.17e-6	Calcium levels;
UCEC	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.74	6.46	0.47	1.46e-9	Bipolar disorder;
UCEC	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.67	-5.16	-0.39	7.93e-7	Huntington's disease progression;
UCEC	cis	rs2806864	1.000	rs2806861	chr1:117463895	A/G	cg19765820	chr1:116518738	SLC22A15	-0.62	-4.65	-0.36	7.37e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs1996152	0.543	rs11077747	chr17:72385894	G/C	cg23221732	chr17:72383708	NA	-0.42	-4.8	-0.37	3.94e-6	Interleukin-12p70 levels;
UCEC	trans	rs6579967	0.655	rs6878700	chr5:152130343	A/G	cg24115593	chr5:169010705	CCDC99	-1.04	-6.84	-0.49	2e-10	Facial morphology (factor 1, breadth of lateral portion of upper face);
UCEC	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.34e-6	Hemoglobin concentration;
UCEC	cis	rs4074536	0.559	rs3810997	chr1:116312614	T/C	cg21648376	chr1:116311395	CASQ2	-0.62	-5.9	-0.44	2.36e-8	QRS duration;
UCEC	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.5	5.04	0.38	1.37e-6	Diastolic blood pressure;
UCEC	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-5.12	-0.39	9.32e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.47	5.69	0.42	6.72e-8	Prudent dietary pattern;
UCEC	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	7.57	0.53	3.79e-12	Coronary artery disease;
UCEC	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.77	7.53	0.53	4.85e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.57	-4.55	-0.35	1.09e-5	Corneal structure;
UCEC	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.35	1.2e-5	Menarche (age at onset);
UCEC	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.71	-8.1	-0.56	1.88e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.99	0.38	1.66e-6	Platelet count;
UCEC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.53	-5.8	-0.43	3.98e-8	Longevity;
UCEC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.49	-4.97	-0.38	1.87e-6	Total body bone mineral density;
UCEC	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg11859384	chr17:80120422	CCDC57	-0.49	-5.42	-0.41	2.43e-7	Life satisfaction;
UCEC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.8	8.31	0.57	5.72e-14	Breast cancer;
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-5.66	-0.42	7.51e-8	Platelet count;
UCEC	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.26	0.46	3.94e-9	Coffee consumption (cups per day);
UCEC	cis	rs11697848	1.000	rs11697848	chr20:48575315	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.34	4.78	0.37	4.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Body mass index;
UCEC	cis	rs4372836	0.504	rs13009357	chr2:29041877	T/C	cg09522027	chr2:28974177	PPP1CB	-0.68	-7.05	-0.5	6.48e-11	Body mass index;
UCEC	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	5.72	0.43	5.68e-8	Myopia (pathological);
UCEC	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.72	-6.02	-0.44	1.33e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.91	9.28	0.61	2.06e-16	Post bronchodilator FEV1;
UCEC	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.69	7.6	0.53	3.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6820391	0.663	rs4864474	chr4:54450380	G/A	cg04173182	chr4:54446035	LNX1	0.36	4.68	0.36	6.43e-6	Cervical artery dissection;
UCEC	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.5	5.69	0.42	6.64e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.78	-0.43	4.37e-8	Breast cancer;
UCEC	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg00614314	chr15:82944287	LOC80154	-0.56	-5.32	-0.4	3.88e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	14.69	0.77	1.2e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.37	-4.78	-0.37	4.26e-6	Alcohol dependence;
UCEC	cis	rs2708377	0.656	rs73066852	chr12:11276541	A/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.75	6.25	0.46	4.25e-9	Bitter taste perception;
UCEC	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.45	-6.16	-0.45	6.73e-9	Prostate cancer;
UCEC	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg05738196	chr6:26577821	NA	0.56	5.87	0.44	2.75e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18252515	chr7:66147081	NA	0.5	4.62	0.36	8.2e-6	Aortic root size;
UCEC	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.4	4.63	0.36	7.9e-6	Alcoholic chronic pancreatitis;
UCEC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.83	7.33	0.52	1.42e-11	Longevity;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg08798685	chr6:27730294	NA	-0.45	-4.62	-0.36	8.33e-6	Myopia;
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg01013738	chr7:1149705	C7orf50	-0.5	-4.72	-0.36	5.51e-6	Longevity;Endometriosis;
UCEC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.66	-0.48	5.15e-10	Resting heart rate;
UCEC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.58	-5.95	-0.44	1.88e-8	Dental caries;
UCEC	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	6.13	0.45	7.78e-9	Coffee consumption (cups per day);
UCEC	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg11697111	chr7:1126903	GPER;C7orf50	-0.52	-5.16	-0.39	7.72e-7	Longevity;Endometriosis;
UCEC	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	1.12	5.69	0.43	6.51e-8	Systolic blood pressure response to hydrochlorothiazide in hypertension;
UCEC	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.42	-4.59	-0.35	9.25e-6	Schizophrenia;
UCEC	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-5.44	-0.41	2.17e-7	Body mass index;
UCEC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.48	-5.07	-0.39	1.16e-6	Aortic root size;
UCEC	cis	rs970548	0.690	rs1982796	chr10:46042573	G/A	cg15223267	chr10:46222474	FAM21C	0.48	4.54	0.35	1.15e-5	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg00316803	chr15:76480434	C15orf27	-0.44	-5.08	-0.39	1.14e-6	Blood metabolite levels;
UCEC	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg04283868	chr2:201171347	SPATS2L	-0.54	-5.38	-0.41	2.83e-7	QT interval;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.77	0.59	4.14e-15	Prudent dietary pattern;
UCEC	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.69	8.39	0.57	3.71e-14	Immature fraction of reticulocytes;
UCEC	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg24562669	chr7:97807699	LMTK2	0.48	5.86	0.43	2.98e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06156847	chr2:113672199	IL1F7	-0.33	-4.53	-0.35	1.19e-5	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.41	-4.58	-0.35	9.71e-6	Schizophrenia;
UCEC	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg06096015	chr1:231504339	EGLN1	0.4	4.6	0.35	9.09e-6	Hemoglobin concentration;
UCEC	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.43	4.66	0.36	6.9e-6	Mean platelet volume;
UCEC	trans	rs925228	1.000	rs2339938	chr2:24234974	C/T	cg25491145	chr3:194304769	NA	-0.75	-6.72	-0.48	3.82e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.69	5.81	0.43	3.74e-8	Alzheimer's disease;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.71	-7.65	-0.53	2.49e-12	Paraoxonase activity;
UCEC	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22857025	chr5:266934	NA	-0.87	-7.14	-0.51	3.96e-11	Asthma (childhood onset);
UCEC	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg13181385	chr13:112874202	NA	0.37	4.52	0.35	1.25e-5	Platelet distribution width;
UCEC	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	trans	rs4389974	0.932	rs1573937	chr8:112404802	A/G	cg22736090	chr17:62339926	TEX2	0.68	6.98	0.5	9.48e-11	Body mass index;
UCEC	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.68	-6.06	-0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-0.79	-6.25	-0.46	4.25e-9	Blood pressure (smoking interaction);
UCEC	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.8	-6.29	-0.46	3.49e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	0.94	9.97	0.64	3.3e-18	Heart rate;
UCEC	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg17674042	chr6:34482479	PACSIN1	-0.65	-4.7	-0.36	6.04e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.63	-6.43	-0.47	1.72e-9	Blood protein levels;
UCEC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05863683	chr7:1912471	MAD1L1	0.43	4.54	0.35	1.15e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.65	5.64	0.42	8.3e-8	Uric acid levels;
UCEC	cis	rs17122693	1.000	rs3015444	chr14:51085116	T/C	cg04730355	chr14:51134070	SAV1	0.72	7.28	0.51	1.83e-11	Cognitive performance;
UCEC	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.67	4.97	0.38	1.83e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs253959	0.662	rs13190269	chr5:115465523	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.63	-7.33	-0.52	1.46e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.74	0.36	5.09e-6	Diabetic retinopathy;
UCEC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.41	4.78	0.37	4.2e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12379764	chr21:47803548	PCNT	0.44	4.85	0.37	3.13e-6	Testicular germ cell tumor;
UCEC	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.97	-0.55	4.1e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg06562184	chr8:19319451	CSGALNACT1	0.44	4.61	0.36	8.81e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg00083072	chr11:65415190	SIPA1	0.45	5.06	0.39	1.23e-6	Acne (severe);
UCEC	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	cg07049167	chr1:166818506	POGK	0.74	6.75	0.49	3.16e-10	Refractive astigmatism;
UCEC	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.76	-9.24	-0.61	2.54e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.8	0.43	4e-8	Height;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20442586	chr15:45444606	DUOX1	-0.56	-6.78	-0.49	2.75e-10	Warfarin maintenance dose;
UCEC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg24687543	chr11:63912206	MACROD1	0.42	5.18	0.39	7.31e-7	Platelet count;
UCEC	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.77	-5.61	-0.42	9.54e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs1576263	0.934	rs330111	chr6:8546711	A/G	cg21535247	chr6:8435926	SLC35B3	0.51	5.34	0.4	3.44e-7	Photic sneeze reflex;
UCEC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	6.14	0.45	7.45e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.53	6.04	0.45	1.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	6.57	0.48	8.06e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.53	-0.77	3.29e-30	Schizophrenia;
UCEC	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-5.0	-0.38	1.63e-6	Vitiligo;
UCEC	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-9.68	-0.62	1.93e-17	Exhaled nitric oxide output;
UCEC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-10.64	-0.66	5.72e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs8105895	0.733	rs62110979	chr19:22245152	T/C	cg02912127	chr19:22235281	ZNF257	-0.64	-5.35	-0.4	3.29e-7	Body mass index (change over time);
UCEC	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-7.07	-0.5	5.72e-11	Coronary artery disease;
UCEC	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.07	-0.45	1.04e-8	Parkinson's disease;
UCEC	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.04e-6	Schizophrenia;
UCEC	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	0.64	6.74	0.49	3.44e-10	Homoarginine levels;
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg13395646	chr4:1353034	KIAA1530	-0.71	-6.65	-0.48	5.5e-10	Obesity-related traits;
UCEC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.57	5.82	0.43	3.54e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.61	6.33	0.46	2.85e-9	Initial pursuit acceleration;
UCEC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs847649	0.731	rs13222980	chr7:102703898	A/G	cg18108683	chr7:102477205	FBXL13	0.53	6.32	0.46	2.95e-9	Morning vs. evening chronotype;
UCEC	cis	rs17106184	1.000	rs72904749	chr1:51367420	C/T	cg07174182	chr1:51127561	FAF1	-0.61	-4.79	-0.37	4.02e-6	Type 2 diabetes;
UCEC	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.13	-7.01	-0.5	8.19e-11	Diabetic kidney disease;
UCEC	trans	rs66573146	1.000	rs66519732	chr4:6990569	C/G	cg07817883	chr1:32538562	TMEM39B	1.08	8.77	0.59	4.19e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.92	5.81	0.43	3.78e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7246967	0.673	rs34676724	chr19:22918473	A/C	cg08271804	chr19:22816896	ZNF492	0.68	6.57	0.48	8.04e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg03859395	chr2:55845619	SMEK2	0.99	14.0	0.76	7.95e-29	Metabolic syndrome;
UCEC	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.6	-7.45	-0.52	7.46e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg19318889	chr4:1322082	MAEA	0.59	7.1	0.51	4.92e-11	Longevity;
UCEC	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-5.41	-0.41	2.45e-7	Calcium levels;
UCEC	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg20936604	chr3:58311152	NA	-0.6	-4.86	-0.37	3.03e-6	Cholesterol, total;
UCEC	cis	rs4662945	0.724	rs4427966	chr2:130221148	G/A	cg05962382	chr2:130345044	NA	-0.39	-4.77	-0.37	4.42e-6	Response to cytidine analogues (gemcitabine);
UCEC	trans	rs4784256	0.713	rs9934917	chr16:52805899	A/G	cg00925156	chr12:7917828	LOC360030	0.58	6.76	0.49	3.03e-10	Morning vs. evening chronotype;
UCEC	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg10263370	chr3:44754102	ZNF502	-0.62	-4.88	-0.37	2.71e-6	IgG glycosylation;
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-5.72	-0.43	5.7e-8	Platelet count;
UCEC	cis	rs2862064	0.929	rs2088917	chr5:156432215	A/G	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.73	-0.43	5.52e-8	Platelet count;
UCEC	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.38	-4.54	-0.35	1.14e-5	Educational attainment (years of education);
UCEC	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.42	-4.62	-0.36	8.27e-6	Schizophrenia;
UCEC	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.51	-0.47	1.14e-9	Tonsillectomy;
UCEC	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.52	4.76	0.37	4.49e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg19743168	chr1:23544995	NA	0.44	6.17	0.45	6.2e-9	Height;
UCEC	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.79	7.26	0.51	2.14e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.62	5.42	0.41	2.35e-7	Longevity;
UCEC	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	0.94	10.34	0.65	3.55e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	0.6	5.4	0.41	2.68e-7	Blood trace element (Cu levels);
UCEC	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12826209	chr6:26865740	GUSBL1	0.5	4.8	0.37	3.83e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.68	6.66	0.48	5.02e-10	Aortic root size;
UCEC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.74	-7.02	-0.5	7.67e-11	Aortic root size;
UCEC	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg05660106	chr1:15850417	CASP9	0.55	4.91	0.38	2.44e-6	Systolic blood pressure;
UCEC	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	6.43	0.47	1.68e-9	Schizophrenia;
UCEC	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24308560	chr3:49941425	MST1R	0.43	4.53	0.35	1.21e-5	Menarche (age at onset);
UCEC	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	7.89	0.55	6.23e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.7	7.03	0.5	7.17e-11	Aortic root size;
UCEC	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg01677386	chr11:118938358	VPS11	-0.52	-4.63	-0.36	7.82e-6	Coronary artery disease;
UCEC	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.28e-9	Platelet count;
UCEC	cis	rs12365397	0.698	rs12577356	chr11:43278262	C/A	cg07515919	chr11:43391688	TTC17	0.45	4.68	0.36	6.37e-6	Migraine;
UCEC	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg01256987	chr12:42539512	GXYLT1	-0.46	-5.39	-0.41	2.71e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-0.85	-11.72	-0.7	7.93e-23	Triglycerides;
UCEC	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.51	0.47	1.09e-9	Menarche (age at onset);
UCEC	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.81	9.71	0.63	1.55e-17	Mortality in heart failure;
UCEC	cis	rs10012307	1.000	rs12640919	chr4:137510817	T/C	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.65	6.96	0.5	1.07e-10	IgG glycosylation;
UCEC	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.63	4.78	0.37	4.16e-6	Carotid intima media thickness;
UCEC	cis	rs534126	0.961	rs6464541	chr7:143013171	T/G	cg04182207	chr7:143013161	CLCN1	-0.39	-5.15	-0.39	8.3e-7	Cancer;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.5	-5.34	-0.4	3.47e-7	Cardiac Troponin-T levels;
UCEC	cis	rs77861329	0.748	rs735768	chr3:52174970	A/C	cg08692210	chr3:52188851	WDR51A	0.62	5.84	0.43	3.23e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg25664220	chr3:72788482	NA	-0.63	-5.33	-0.4	3.69e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.79	8.15	0.56	1.43e-13	Height;
UCEC	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.53	0.62	4.57e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.64	-6.59	-0.48	7.21e-10	Sudden cardiac arrest;
UCEC	cis	rs36051895	0.632	rs7849717	chr9:5170080	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.11	-0.39	9.68e-7	Pediatric autoimmune diseases;
UCEC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	4.55	0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.64	4.94	0.38	2.12e-6	Pediatric areal bone mineral density (radius);
UCEC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Urate levels;
UCEC	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.95	-0.38	1.99e-6	Response to antipsychotic treatment;
UCEC	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.76	7.09	0.5	5.16e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.85	-0.49	1.91e-10	Personality dimensions;
UCEC	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.51	4.96	0.38	1.94e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.81	0.37	3.66e-6	Platelet count;
UCEC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg03230154	chr19:22817176	ZNF492	0.44	4.54	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg12637676	chr8:11587161	GATA4	-0.35	-4.65	-0.36	7.29e-6	Retinal vascular caliber;
UCEC	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	1.1	5.32	0.4	3.78e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6832769	1.000	rs28448438	chr4:56416665	C/T	cg05960024	chr4:56376020	CLOCK	-0.57	-5.79	-0.43	4.16e-8	Personality dimensions;
UCEC	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.56	5.61	0.42	9.73e-8	Colorectal cancer;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	8.91	0.59	1.77e-15	Platelet count;
UCEC	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.53	-5.17	-0.39	7.49e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs356992	0.915	rs356977	chr2:60748758	A/G	cg08426369	chr2:60753602	BCL11A	0.42	4.51	0.35	1.32e-5	Educational attainment (years of education);
UCEC	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.53	-5.01	-0.38	1.52e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.66	-4.67	-0.36	6.77e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.15	-8.94	-0.59	1.48e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs4448343	0.736	rs2297086	chr9:98240120	C/T	cg13456470	chr9:98266766	PTCH1	0.37	4.57	0.35	1.03e-5	Height;
UCEC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.68	5.2	0.39	6.65e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg22974920	chr21:40686053	BRWD1	0.61	5.38	0.41	2.81e-7	Cognitive function;
UCEC	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.16	-0.39	8.03e-7	Mood instability;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs10507349	0.584	rs7981748	chr13:26818317	G/A	cg01600817	chr13:26797529	RNF6	-0.46	-4.92	-0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.48	0.57	2.22e-14	Prudent dietary pattern;
UCEC	cis	rs10412972	1.000	rs10401507	chr19:52156867	A/G	cg13729816	chr19:52954722	NA	-0.44	-4.73	-0.36	5.24e-6	Plasma plasminogen levels;
UCEC	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	0.53	5.34	0.4	3.44e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg04837898	chr3:45731254	SACM1L	-0.4	-4.53	-0.35	1.21e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg09457645	chr17:33443370	RAD51L3	0.61	4.63	0.36	8.11e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	0.86	6.86	0.49	1.81e-10	Blood protein levels;
UCEC	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.35	-5.47	-0.41	1.9e-7	Ulcerative colitis;
UCEC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.65	-6.31	-0.46	3.07e-9	Breast cancer;
UCEC	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.54	4.57	0.35	1.02e-5	Lymphocyte counts;
UCEC	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg04673462	chr1:38461896	NA	0.63	5.84	0.43	3.28e-8	Coronary artery disease;
UCEC	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.27e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	4.86	0.37	3.03e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.84	-9.78	-0.63	1.02e-17	Paraoxonase activity;
UCEC	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-4.82	-0.37	3.49e-6	Primary biliary cholangitis;
UCEC	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.67	-6.8	-0.49	2.42e-10	Eosinophil percentage of white cells;
UCEC	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg12850546	chr22:42539477	CYP2D7P1	-0.68	-5.23	-0.4	5.76e-7	Birth weight;
UCEC	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.64	5.1	0.39	1.02e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs12474201	0.887	rs35158352	chr2:46953763	C/T	cg06386533	chr2:46925753	SOCS5	0.67	6.16	0.45	6.5e-9	Height;
UCEC	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.58	5.25	0.4	5.34e-7	Corneal astigmatism;
UCEC	cis	rs9815925	0.702	rs6762956	chr3:184617051	G/T	cg00151007	chr3:184769954	VPS8	-0.5	-4.9	-0.37	2.54e-6	Heschl's gyrus morphology;
UCEC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.88	-0.37	2.74e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.65	-5.94	-0.44	1.98e-8	Aortic root size;
UCEC	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.68	5.75	0.43	5.1e-8	Blood metabolite levels;
UCEC	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.49	5.24	0.4	5.46e-7	Lung cancer;
UCEC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	trans	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg02900749	chr2:68251473	NA	-0.83	-6.88	-0.49	1.64e-10	Pursuit maintenance gain;
UCEC	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	6.13	0.45	7.78e-9	Coffee consumption (cups per day);
UCEC	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.69	5.93	0.44	2.12e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-10.85	-0.67	1.64e-20	Exhaled nitric oxide output;
UCEC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg24163568	chr5:669837	TPPP	0.4	5.08	0.39	1.13e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.37	-0.47	2.24e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6662386	0.557	rs34198408	chr1:88223604	C/T	cg10042178	chr1:87794589	LMO4	0.49	4.72	0.36	5.56e-6	Prostate-specific antigen levels;
UCEC	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg05991184	chr2:219186017	PNKD	0.52	5.64	0.42	8.51e-8	Colorectal cancer;
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.62	-6.19	-0.45	5.57e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.81	-0.37	3.7e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.72	0.48	3.76e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs4499344	0.730	rs380320	chr19:33105904	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	7.77	0.54	1.22e-12	Mean platelet volume;
UCEC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg06238570	chr21:40685208	BRWD1	0.83	8.11	0.56	1.81e-13	Cognitive function;
UCEC	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	7.35	0.52	1.3e-11	Hip circumference;
UCEC	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.83	6.67	0.48	4.9e-10	Exhaled nitric oxide levels;
UCEC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.5	4.86	0.37	2.94e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.85	-10.0	-0.64	2.79e-18	Blood metabolite levels;
UCEC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.37	0.4	3.06e-7	Breast cancer;
UCEC	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.48	-5.2	-0.39	6.43e-7	Life satisfaction;
UCEC	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.51	5.26	0.4	4.99e-7	QT interval;
UCEC	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9463078	0.727	rs9463054	chr6:44917197	T/C	cg25276700	chr6:44698697	NA	-0.41	-4.62	-0.36	8.36e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.64	-6.0	-0.44	1.46e-8	Coronary artery disease;
UCEC	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.65	6.64	0.48	5.8e-10	Systemic lupus erythematosus;
UCEC	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.44	-4.88	-0.37	2.68e-6	Schizophrenia;
UCEC	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.69	-4.81	-0.37	3.71e-6	LDL cholesterol levels;
UCEC	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg21253087	chr9:139290292	SNAPC4	0.43	4.75	0.36	4.89e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	9.46	0.62	6.85e-17	Systemic lupus erythematosus;
UCEC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.0	0.5	8.28e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7246967	0.673	rs2885221	chr19:22839387	A/G	cg01485075	chr19:22817371	ZNF492	0.41	4.53	0.35	1.21e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.551	rs75360744	chr19:22857956	G/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.38	-4.81	-0.37	3.62e-6	Body mass index;
UCEC	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.61	5.72	0.43	5.78e-8	Aortic root size;
UCEC	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg01072550	chr1:21505969	NA	-0.51	-4.7	-0.36	5.95e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.44	5.29	0.4	4.29e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.52	6.39	0.47	2.06e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.73	5.72	0.43	5.86e-8	Small cell lung carcinoma;
UCEC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1832871	0.619	rs262826	chr6:158680567	C/T	cg07215822	chr6:158701037	NA	-0.53	-5.77	-0.43	4.55e-8	Height;
UCEC	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.86	0.54	7.6e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.73	7.12	0.51	4.5e-11	Parkinson's disease;
UCEC	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	5.2	0.39	6.7e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg13683864	chr3:40499215	RPL14	0.89	10.42	0.65	2.23e-19	Renal cell carcinoma;
UCEC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.64	5.12	0.39	9.26e-7	Bladder cancer;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg03119028	chr1:89458849	CCBL2;RBMXL1	0.68	6.93	0.5	1.24e-10	Migraine with aura;
UCEC	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.46	-6.44	-0.47	1.64e-9	Vitamin D levels;
UCEC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.48	4.93	0.38	2.17e-6	Schizophrenia;
UCEC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.79	0.37	3.96e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.48	0.53	6.08e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.46	-4.96	-0.38	1.91e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Morning vs. evening chronotype;
UCEC	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.85	-10.42	-0.65	2.17e-19	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22117172	chr7:91764530	CYP51A1	0.4	4.86	0.37	2.98e-6	Breast cancer;
UCEC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.55	0.35	1.11e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.68	-7.03	-0.5	7.12e-11	Initial pursuit acceleration;
UCEC	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg19404215	chr3:33155277	CRTAP	0.81	4.55	0.35	1.1e-5	Major depressive disorder;
UCEC	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.66	6.77	0.49	2.84e-10	Systemic lupus erythematosus;
UCEC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	20.35	0.86	1.36e-44	Chronic sinus infection;
UCEC	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.7	-7.17	-0.51	3.47e-11	Sudden cardiac arrest;
UCEC	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.52	-0.35	1.27e-5	Breast cancer;
UCEC	cis	rs17106184	0.681	rs72902706	chr1:51212796	A/C	cg07174182	chr1:51127561	FAF1	-0.82	-5.25	-0.4	5.23e-7	Type 2 diabetes;
UCEC	cis	rs4588572	0.644	rs10942856	chr5:77746199	A/G	cg11547950	chr5:77652471	NA	0.38	4.68	0.36	6.53e-6	Triglycerides;
UCEC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.57	4.84	0.37	3.24e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.59	-6.82	-0.49	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.5	6.82	0.49	2.25e-10	Pursuit maintenance gain;
UCEC	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg18016565	chr1:150552671	MCL1	0.46	4.62	0.36	8.3e-6	Melanoma;
UCEC	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.49	4.95	0.38	2.04e-6	Blood metabolite levels;
UCEC	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.75	7.16	0.51	3.53e-11	Schizophrenia;
UCEC	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg03714773	chr7:91764589	CYP51A1	0.43	5.45	0.41	2.09e-7	Breast cancer;
UCEC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.64	-0.42	8.28e-8	Pancreatic cancer;
UCEC	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.51	0.47	1.11e-9	Menarche (age at onset);
UCEC	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.44	-4.73	-0.36	5.11e-6	Platelet distribution width;
UCEC	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.65	6.81	0.49	2.27e-10	Morning vs. evening chronotype;
UCEC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.86	-0.37	2.94e-6	Bipolar disorder;
UCEC	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.56	6.08	0.45	1.01e-8	Total cholesterol levels;
UCEC	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg12870014	chr12:110450643	ANKRD13A	0.58	4.89	0.37	2.6e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Corneal astigmatism;
UCEC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.63	6.96	0.5	1.07e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246657	0.507	rs8107654	chr19:37453534	C/T	cg23950597	chr19:37808831	NA	-1.04	-6.71	-0.48	3.91e-10	Coronary artery calcification;
UCEC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.29	0.46	3.47e-9	Tonsillectomy;
UCEC	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.6	-4.84	-0.37	3.2e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.89	-5.58	-0.42	1.13e-7	Rheumatoid arthritis;
UCEC	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.14	0.45	7.36e-9	Lung cancer;
UCEC	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.65	6.52	0.47	1.06e-9	Coronary artery disease;
UCEC	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.54	-5.55	-0.42	1.32e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.05	-0.38	1.3e-6	Pubertal anthropometrics;
UCEC	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.76	6.76	0.49	3.09e-10	Caudate activity during reward;
UCEC	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-5.73	-0.43	5.52e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.63	-7.27	-0.51	1.99e-11	Prudent dietary pattern;
UCEC	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.69	-0.36	6.3e-6	Menarche (age at onset);
UCEC	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.62	7.12	0.51	4.41e-11	Pulmonary function decline;
UCEC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.65	0.36	7.23e-6	Tonsillectomy;
UCEC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.7	-6.76	-0.49	2.97e-10	Aortic root size;
UCEC	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.48	4.79	0.37	3.98e-6	Corneal astigmatism;
UCEC	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.51	5.0	0.38	1.6e-6	Itch intensity from mosquito bite;
UCEC	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg16060761	chr17:80687452	NA	-0.54	-4.78	-0.37	4.25e-6	Glycated hemoglobin levels;
UCEC	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-5.61	-0.42	9.74e-8	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.48	-5.76	-0.43	4.86e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.93	0.44	2.03e-8	Breast cancer;
UCEC	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	4.51	0.35	1.31e-5	Systolic blood pressure;
UCEC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg11569703	chr11:65557185	OVOL1	-0.42	-6.08	-0.45	9.66e-9	Acne (severe);
UCEC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	7.72	0.54	1.64e-12	Smoking behavior;
UCEC	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg19041857	chr6:27730383	NA	-0.68	-4.94	-0.38	2.08e-6	Breast cancer;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.89	-0.44	2.49e-8	Platelet count;
UCEC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.74	0.63	1.3e-17	Menopause (age at onset);
UCEC	cis	rs259282	0.524	rs4805006	chr19:33124136	G/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	7.19	0.51	3.08e-11	Schizophrenia;
UCEC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.53	-5.37	-0.4	3.07e-7	Aortic root size;
UCEC	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg21419209	chr3:44054225	NA	-0.47	-5.04	-0.38	1.36e-6	Coronary artery disease;
UCEC	cis	rs11688237	1.000	rs11688237	chr2:144560021	G/A	cg12646452	chr2:144560348	NA	0.37	4.9	0.37	2.51e-6	Chin dimples;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.67	-5.41	-0.41	2.53e-7	Height;
UCEC	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.67	5.75	0.43	5.01e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg06784218	chr1:46089804	CCDC17	-0.42	-4.76	-0.37	4.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	5.97	0.44	1.66e-8	Platelet count;
UCEC	cis	rs1007190	0.881	rs16939676	chr17:42976347	C/A	cg15406952	chr17:42872593	NA	0.73	5.7	0.43	6.28e-8	DNA methylation (variation);
UCEC	cis	rs6684428	0.536	rs7538008	chr1:56396084	A/G	cg11651538	chr1:56320950	NA	-0.45	-4.6	-0.35	9.24e-6	Airflow obstruction;
UCEC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.01	14.05	0.76	5.58e-29	Height;
UCEC	cis	rs1712517	0.771	rs10883858	chr10:105127708	G/A	cg05636881	chr10:105038444	INA	0.43	5.05	0.38	1.3e-6	Migraine;
UCEC	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	4.7	0.36	5.85e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs10924970	0.967	rs2152954	chr1:235417780	A/G	cg26050004	chr1:235667680	B3GALNT2	0.46	4.8	0.37	3.85e-6	Asthma;
UCEC	cis	rs2147959	0.941	rs4653960	chr1:228631719	T/C	cg25874119	chr1:228633904	NA	0.51	5.22	0.4	5.88e-7	Adult asthma;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.75	-0.36	4.88e-6	Pulmonary function;
UCEC	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.6	-6.39	-0.47	2.07e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.58e-6	Diabetic kidney disease;
UCEC	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	4.7	0.36	5.86e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	0.94	6.19	0.45	5.83e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs1832871	0.965	rs861179	chr6:158712720	A/G	cg07215822	chr6:158701037	NA	-0.5	-4.96	-0.38	1.89e-6	Height;
UCEC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg19318889	chr4:1322082	MAEA	-0.43	-4.84	-0.37	3.27e-6	Obesity-related traits;
UCEC	cis	rs2502731	0.584	rs3003578	chr9:130994179	C/T	cg13642260	chr9:130955380	CIZ1	0.52	5.79	0.43	4.1e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.84	10.25	0.65	6.11e-19	Menopause (age at onset);
UCEC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.57e-13	Chronic sinus infection;
UCEC	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg11621586	chr10:70884670	VPS26A	0.97	9.67	0.62	2e-17	Left atrial antero-posterior diameter;
UCEC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg13695892	chr22:41940480	POLR3H	-0.67	-5.26	-0.4	5.01e-7	Vitiligo;
UCEC	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.49	-5.7	-0.43	6.37e-8	Prostate cancer;
UCEC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	7.67	0.53	2.16e-12	Menarche (age at onset);
UCEC	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4727027	0.769	rs2140957	chr7:148758885	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.83	0.37	3.44e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.57	0.35	1.02e-5	Parkinson's disease;
UCEC	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	7.4	0.52	9.69e-12	Total body bone mineral density;
UCEC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.48	4.95	0.38	1.98e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.500	rs3823631	chr7:2190100	A/G	cg02951883	chr7:2050386	MAD1L1	-0.55	-5.05	-0.38	1.26e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.1	0.51	5.05e-11	Coffee consumption (cups per day);
UCEC	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg16325326	chr1:53192061	ZYG11B	-0.82	-9.23	-0.61	2.79e-16	Monocyte count;
UCEC	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.51	-4.53	-0.35	1.22e-5	Diabetic retinopathy;
UCEC	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.59	-6.34	-0.46	2.63e-9	Breast size;
UCEC	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg02158880	chr13:53174818	NA	0.42	4.83	0.37	3.43e-6	Lewy body disease;
UCEC	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.54	6.38	0.47	2.13e-9	Bone mineral density;
UCEC	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24308560	chr3:49941425	MST1R	0.46	5.01	0.38	1.56e-6	Body mass index;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.9	10.87	0.67	1.45e-20	Menarche (age at onset);
UCEC	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	6.93	0.5	1.21e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-5.53	-0.42	1.4e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.61	6.44	0.47	1.59e-9	Motion sickness;
UCEC	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.54	-5.27	-0.4	4.85e-7	Schizophrenia;
UCEC	cis	rs2262909	0.962	rs439574	chr19:22232024	A/C	cg11619707	chr19:22235551	ZNF257	-0.38	-5.0	-0.38	1.63e-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
UCEC	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.53	5.03	0.38	1.44e-6	Coronary artery disease;
UCEC	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.58	5.46	0.41	2e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.83	8.97	0.59	1.25e-15	Breast cancer;
UCEC	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.55	5.94	0.44	1.94e-8	HDL cholesterol;
UCEC	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.14	-0.45	7.21e-9	Parkinson's disease;
UCEC	cis	rs7246967	0.673	rs1433085	chr19:22811099	T/A	cg05241461	chr19:22816980	ZNF492	0.52	5.46	0.41	1.98e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-6.71	-0.48	3.84e-10	Response to antipsychotic treatment;
UCEC	cis	rs244899	0.967	rs2432642	chr5:167921047	C/G	cg06604206	chr5:167912465	RARS	-0.37	-4.56	-0.35	1.09e-5	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.4	5.19	0.39	6.94e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.45	5.09	0.39	1.08e-6	Testicular germ cell tumor;
UCEC	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.79	-7.72	-0.54	1.68e-12	Colorectal cancer;
UCEC	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.51	4.58	0.35	9.84e-6	Menarche (age at onset);
UCEC	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	0.84	9.79	0.63	9.85e-18	Breast cancer;
UCEC	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.45	-4.84	-0.37	3.25e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.84	-10.03	-0.64	2.38e-18	Brugada syndrome;
UCEC	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.48	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg19926144	chr10:661009	DIP2C	0.85	4.95	0.38	2.02e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.58	6.58	0.48	7.75e-10	Red blood cell count;
UCEC	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-5.42	-0.41	2.39e-7	Metabolite levels;
UCEC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs9309473	0.898	rs9807961	chr2:73694043	A/G	cg20560298	chr2:73613845	ALMS1	-0.63	-5.69	-0.42	6.79e-8	Metabolite levels;
UCEC	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.29	0.4	4.43e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10012307	1.000	rs17048714	chr4:137486174	A/C	cg12033966	chr4:138453416	PCDH18	-0.71	-4.92	-0.38	2.29e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs36051895	0.589	rs10283734	chr9:5217139	A/T	cg02405213	chr9:5042618	JAK2	-0.52	-4.98	-0.38	1.77e-6	Pediatric autoimmune diseases;
UCEC	cis	rs17106184	1.000	rs72902765	chr1:51256698	T/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.46	4.63	0.36	7.86e-6	Schizophrenia;
UCEC	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.93	0.63	4.12e-18	Blood protein levels;
UCEC	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg04202892	chr2:111875749	ACOXL	0.46	5.41	0.41	2.52e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.52	4.75	0.36	4.75e-6	Bone properties (heel);
UCEC	cis	rs7246967	0.673	rs12979173	chr19:22820681	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg24562669	chr7:97807699	LMTK2	0.48	5.87	0.44	2.84e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.62	0.48	6.43e-10	Aortic root size;
UCEC	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.47	-5.03	-0.38	1.41e-6	Response to temozolomide;
UCEC	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.58	-5.93	-0.44	2.09e-8	White matter hyperintensity burden;
UCEC	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	9.39	0.61	1.08e-16	Bipolar disorder;
UCEC	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.47	4.76	0.37	4.51e-6	Breast cancer;
UCEC	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.67	6.33	0.46	2.85e-9	Ovarian reserve;
UCEC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-5.43	-0.41	2.28e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.57	5.98	0.44	1.66e-8	Asthma (sex interaction);
UCEC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.71	6.49	0.47	1.25e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.57	6.06	0.45	1.11e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-4.88	-0.37	2.78e-6	Colorectal cancer;
UCEC	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg09655341	chr17:79618100	PDE6G	-0.32	-4.6	-0.35	8.94e-6	Eye color traits;
UCEC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.87	9.53	0.62	4.72e-17	Cognitive function;
UCEC	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.7	7.99	0.55	3.68e-13	Monocyte percentage of white cells;
UCEC	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.65	-5.38	-0.41	2.9e-7	Schizophrenia;
UCEC	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.52	5.44	0.41	2.13e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Diabetic kidney disease;
UCEC	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	0.76	6.17	0.45	6.24e-9	Blood protein levels;
UCEC	cis	rs4077515	0.967	rs4075760	chr9:139266697	A/G	cg14019695	chr9:139328340	INPP5E	0.47	5.06	0.39	1.23e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.72	8.39	0.57	3.64e-14	Menopause (age at onset);
UCEC	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.25	0.46	4.16e-9	Coffee consumption (cups per day);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05886006	chr1:161359784	NA	0.55	6.89	0.49	1.53e-10	Warfarin maintenance dose;
UCEC	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.82	-0.37	3.51e-6	Joint mobility (Beighton score);
UCEC	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.43	5.01	0.38	1.54e-6	HDL cholesterol;
UCEC	cis	rs1483890	0.723	rs13075664	chr3:69411365	G/A	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	0.98	8.19	0.56	1.14e-13	Pediatric areal bone mineral density (radius);
UCEC	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.66	7.06	0.5	6.17e-11	Mean platelet volume;
UCEC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.7	-0.36	5.94e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg01657329	chr11:68192670	LRP5	0.42	4.74	0.36	5.04e-6	Bone mineral density (spine);
UCEC	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	5.81	0.43	3.77e-8	Caffeine consumption;
UCEC	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs17106184	1.000	rs113611257	chr1:51221103	G/A	cg07174182	chr1:51127561	FAF1	-0.88	-5.58	-0.42	1.12e-7	Type 2 diabetes;
UCEC	cis	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg18809830	chr7:99032528	PTCD1	-0.91	-4.65	-0.36	7.24e-6	Blood metabolite levels;
UCEC	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.56	5.59	0.42	1.08e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.68	6.65	0.48	5.32e-10	Mood instability;
UCEC	cis	rs10887741	0.546	rs7903516	chr10:89441102	T/C	cg13926569	chr10:89418898	PAPSS2	0.4	4.62	0.36	8.48e-6	Exercise (leisure time);
UCEC	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.44	-4.77	-0.37	4.49e-6	Prostate cancer;
UCEC	cis	rs3780378	0.875	rs10115312	chr9:5003973	G/T	cg02405213	chr9:5042618	JAK2	-0.48	-4.7	-0.36	6.05e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.0	-0.38	1.58e-6	Breast cancer;
UCEC	cis	rs7113850	0.541	rs76874215	chr11:24235158	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs250585	0.736	rs193937	chr16:23436358	C/T	cg26562691	chr16:23850404	PRKCB	0.36	4.75	0.36	4.81e-6	Egg allergy;
UCEC	cis	rs78487399	0.764	rs12473987	chr2:43812180	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.13	-0.39	9.12e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg22467129	chr15:76604101	ETFA	-0.49	-5.11	-0.39	9.87e-7	Blood metabolite levels;
UCEC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.53	-4.99	-0.38	1.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.32	0.61	1.62e-16	Electrocardiographic conduction measures;
UCEC	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.65	7.92	0.55	5.44e-13	Mean platelet volume;
UCEC	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.6	6.47	0.47	1.38e-9	Lung cancer;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	5.98	0.44	1.64e-8	Prudent dietary pattern;
UCEC	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13683864	chr3:40499215	RPL14	-0.94	-9.64	-0.62	2.42e-17	Renal cell carcinoma;
UCEC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.69	-5.98	-0.44	1.63e-8	Aortic root size;
UCEC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg04871131	chr7:94954202	PON1	-0.51	-4.99	-0.38	1.65e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg22907277	chr7:1156413	C7orf50	0.54	5.05	0.38	1.32e-6	Longevity;Endometriosis;
UCEC	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.66	-7.23	-0.51	2.42e-11	Extraversion;
UCEC	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg26898376	chr11:64110657	CCDC88B	0.38	4.51	0.35	1.3e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.67	0.48	4.85e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	5.02	0.38	1.47e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6723108	0.627	rs766270	chr2:135666926	G/C	cg07169764	chr2:136633963	MCM6	0.48	4.62	0.36	8.23e-6	Type 2 diabetes;
UCEC	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.49	-5.25	-0.4	5.22e-7	Diastolic blood pressure;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.59	-6.2	-0.46	5.4e-9	Parkinson's disease;
UCEC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.94	10.32	0.65	4.01e-19	Cognitive function;
UCEC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.77	0.43	4.48e-8	Breast cancer;
UCEC	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.4	-5.76	-0.43	4.76e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.74	-5.24	-0.4	5.54e-7	Body mass index;
UCEC	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.39	-4.67	-0.36	6.6e-6	Menopause (age at onset);
UCEC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.56	-6.51	-0.47	1.12e-9	Prostate cancer;
UCEC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.59	0.72	4.13e-25	Chronic sinus infection;
UCEC	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	5.11	0.39	9.92e-7	Myopia (pathological);
UCEC	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs9467773	1.000	rs6913462	chr6:26577530	A/G	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg24505687	chr6:33548425	BAK1	0.51	5.86	0.44	2.95e-8	Platelet count;
UCEC	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.66	6.74	0.49	3.37e-10	Colorectal cancer;
UCEC	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.1	9.58	0.62	3.45e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.55	4.98	0.38	1.74e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.06	-12.96	-0.73	4.21e-26	Body mass index;
UCEC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg04154034	chr17:28927549	LRRC37B2	-0.78	-5.07	-0.39	1.16e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	0.92	5.65	0.42	8.1e-8	Skin colour saturation;
UCEC	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.36	5.29	0.4	4.41e-7	Ulcerative colitis;
UCEC	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg23795048	chr12:9217529	LOC144571	0.41	5.14	0.39	8.54e-7	Sjögren's syndrome;
UCEC	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg16583315	chr14:65563665	MAX	-0.44	-5.82	-0.43	3.55e-8	Obesity-related traits;
UCEC	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Smoking initiation;
UCEC	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg14121845	chr20:25566513	NINL	0.41	4.84	0.37	3.24e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.76	-8.11	-0.56	1.88e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.8	-9.37	-0.61	1.18e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.51	5.17	0.39	7.49e-7	Vitiligo;
UCEC	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.62	9.09	0.6	6.26e-16	Total body bone mineral density;
UCEC	trans	rs12216499	0.642	rs4709245	chr6:159343152	T/C	cg03103158	chr8:28748202	INTS9;HMBOX1	-1.0	-6.72	-0.48	3.68e-10	Bladder cancer (smoking interaction);
UCEC	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.57	-4.85	-0.37	3.16e-6	Blood pressure (smoking interaction);
UCEC	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg18681998	chr4:17616180	MED28	0.78	8.56	0.58	1.35e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.61	-6.05	-0.45	1.16e-8	Blood metabolite levels;
UCEC	cis	rs10208940	1.000	rs10208940	chr2:68733389	C/T	cg12452813	chr2:68675892	NA	-0.48	-4.57	-0.35	1.03e-5	Urate levels in lean individuals;
UCEC	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg22166914	chr1:53195759	ZYG11B	0.77	7.99	0.55	3.66e-13	Monocyte count;
UCEC	cis	rs9309473	1.000	rs10186501	chr2:73697844	C/T	cg20560298	chr2:73613845	ALMS1	-0.6	-5.44	-0.41	2.17e-7	Metabolite levels;
UCEC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.85	-0.37	3.09e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.86	9.21	0.61	3.02e-16	Parkinson's disease;
UCEC	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.46	-5.76	-0.43	4.84e-8	Prostate cancer;
UCEC	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg13683864	chr3:40499215	RPL14	1.03	13.2	0.74	9.6800000000000007e-27	Renal cell carcinoma;
UCEC	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg11632617	chr15:75315747	PPCDC	-0.53	-4.55	-0.35	1.1e-5	Lung cancer;
UCEC	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg06784218	chr1:46089804	CCDC17	0.54	6.34	0.46	2.63e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.41	5.08	0.39	1.14e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.47	-4.55	-0.35	1.13e-5	Gut microbiome composition (summer);
UCEC	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.6	-6.33	-0.46	2.87e-9	Breast cancer;
UCEC	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.19	-0.39	6.73e-7	Bipolar disorder;
UCEC	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.82	-0.54	9.67e-13	Total cholesterol levels;
UCEC	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.21	-0.51	2.69e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.63	-6.71	-0.48	3.88e-10	Neurofibrillary tangles;
UCEC	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22455342	chr2:225449267	CUL3	0.52	5.45	0.41	2.06e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.5	5.59	0.42	1.06e-7	Longevity;
UCEC	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-4.73	-0.36	5.16e-6	Menarche (age at onset);
UCEC	cis	rs7766436	0.885	rs4711020	chr6:22582920	A/G	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01380346	chr19:18557039	ELL	0.45	4.59	0.35	9.37e-6	Breast cancer;
UCEC	cis	rs2386661	0.523	rs7896088	chr10:5652286	C/T	cg17085576	chr10:5658249	NA	-0.45	-5.17	-0.39	7.63e-7	Breast cancer;
UCEC	cis	rs256277	0.507	rs1493453	chr5:111295084	G/A	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.53	-5.01	-0.38	1.56e-6	Coronary artery disease;
UCEC	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.52	-5.32	-0.4	3.76e-7	Refractive error;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.14	-0.45	7.27e-9	Pubertal anthropometrics;
UCEC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg01262667	chr19:19385393	TM6SF2	0.43	5.39	0.41	2.7e-7	Tonsillectomy;
UCEC	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.0	0.38	1.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg04470557	chr5:131630995	SLC22A4	-0.75	-4.53	-0.35	1.21e-5	Rheumatoid arthritis;
UCEC	cis	rs925228	0.793	rs4665248	chr2:24167751	C/A	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.78	-7.9	-0.55	5.88e-13	Parkinson's disease;
UCEC	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.48	-5.32	-0.4	3.87e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.61	5.7	0.43	6.47e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg11871910	chr12:69753446	YEATS4	0.88	10.22	0.64	7.61e-19	Blood protein levels;
UCEC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.74	-7.07	-0.5	5.76e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.72	0.36	5.34e-6	Cognitive ability;
UCEC	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	6.58	0.48	7.65e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.39	0.71	1.34e-24	Prudent dietary pattern;
UCEC	cis	rs17401966	0.838	rs35257796	chr1:10267390	T/A	cg19773385	chr1:10388646	KIF1B	-0.53	-5.28	-0.4	4.62e-7	Hepatocellular carcinoma;
UCEC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.41	4.62	0.36	8.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2288327	0.818	rs16866365	chr2:179385852	A/G	cg09915519	chr2:179397513	TTN;MIR548N	-0.68	-4.65	-0.36	7.26e-6	Atrial fibrillation;
UCEC	cis	rs7870753	1.000	rs7870753	chr9:99201585	A/G	cg25260653	chr9:99212216	HABP4	0.48	4.58	0.35	9.98e-6	Height;
UCEC	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.64	7.1	0.51	4.97e-11	Monocyte count;
UCEC	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.82	10.16	0.64	1.04e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.6	0.58	1.11e-14	Prudent dietary pattern;
UCEC	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.41	4.69	0.36	6.17e-6	Blood metabolite ratios;
UCEC	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.6	-0.48	7.07e-10	Neutrophil percentage of white cells;
UCEC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.69	8.74	0.58	4.81e-15	Rheumatoid arthritis;
UCEC	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	1.12	14.32	0.76	1.12e-29	Schizophrenia;
UCEC	cis	rs427941	0.740	rs67531258	chr7:101829087	G/A	cg01723606	chr7:101944275	SH2B2	0.42	4.56	0.35	1.09e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg19715936	chr7:50634035	DDC	-0.45	-4.68	-0.36	6.34e-6	Malaria;
UCEC	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.4	5.32	0.4	3.81e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.74	6.28	0.46	3.64e-9	Corneal structure;
UCEC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.54	-5.4	-0.41	2.68e-7	Cotinine glucuronidation;
UCEC	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.5	-0.35	1.35e-5	Blood protein levels;
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg02158880	chr13:53174818	NA	0.74	8.22	0.56	9.66e-14	Lewy body disease;
UCEC	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.57	-6.15	-0.45	6.86e-9	Refractive error;
UCEC	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	0.67	8.65	0.58	8.06e-15	Gut microbiome composition (winter);
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg23139173	chr13:111589973	NA	0.77	4.82	0.37	3.49e-6	Obesity-related traits;
UCEC	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.7	7.98	0.55	3.9e-13	Menopause (age at onset);
UCEC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.52	5.91	0.44	2.33e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.37	0.47	2.24e-9	Tonsillectomy;
UCEC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.86	-9.47	-0.62	6.42e-17	Blood protein levels;
UCEC	cis	rs3736594	0.513	rs62138964	chr2:27814438	C/T	cg27432699	chr2:27873401	GPN1	0.53	5.09	0.39	1.08e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.02e-5	Type 2 diabetes;
UCEC	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	0.68	7.45	0.52	7.3e-12	Homoarginine levels;
UCEC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg05072774	chr3:49840536	C3orf54	0.52	4.96	0.38	1.95e-6	Resting heart rate;
UCEC	cis	rs7580658	0.545	rs13006847	chr2:127952263	C/T	cg16751203	chr2:127950803	CYP27C1	-0.4	-5.38	-0.41	2.82e-7	Protein C levels;
UCEC	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.82	0.43	3.49e-8	Life satisfaction;
UCEC	cis	rs9470794	1.000	rs12662940	chr6:38110935	C/T	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.51	5.15	0.39	8.21e-7	IgG glycosylation;
UCEC	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg18681998	chr4:17616180	MED28	0.89	11.36	0.68	7.14e-22	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg26031613	chr14:104095156	KLC1	0.96	6.55	0.48	8.95e-10	Body mass index;
UCEC	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg13593689	chr9:129986794	NA	0.47	4.76	0.37	4.65e-6	Intraocular pressure;
UCEC	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.74	0.43	5.26e-8	Alcohol dependence;
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.61	-5.1	-0.39	1.04e-6	Platelet count;
UCEC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.7	7.74	0.54	1.49e-12	Menopause (age at onset);
UCEC	cis	rs1335645	0.570	rs12403848	chr1:111627231	C/T	cg00321911	chr1:111669324	DRAM2	-0.67	-5.01	-0.38	1.55e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6471393	0.964	rs10504930	chr8:94744813	A/G	cg14028520	chr8:94909876	NA	0.45	4.59	0.35	9.58e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg23070574	chr3:14187308	XPC	0.42	4.58	0.35	9.99e-6	Ovarian reserve;
UCEC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.61	7.48	0.52	6.28e-12	Blood protein levels;
UCEC	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-0.86	-6.58	-0.48	7.73e-10	Lymphocyte counts;
UCEC	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.52	5.57	0.42	1.17e-7	Body mass index;
UCEC	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.54	5.55	0.42	1.31e-7	Systolic blood pressure;
UCEC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.43	5.27	0.4	4.73e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.64	5.34	0.4	3.52e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs10242455	0.702	rs76840929	chr7:98945858	T/C	cg18809830	chr7:99032528	PTCD1	-0.9	-4.76	-0.37	4.53e-6	Blood metabolite levels;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.29	-0.4	4.38e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg00105475	chr2:10696890	NA	0.39	4.71	0.36	5.76e-6	Prostate cancer;
UCEC	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24308560	chr3:49941425	MST1R	-0.5	-5.4	-0.41	2.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.58	6.06	0.45	1.08e-8	Hepatocellular carcinoma;
UCEC	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18854424	chr1:2615690	NA	0.36	5.27	0.4	4.85e-7	Ulcerative colitis;
UCEC	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.47	-5.01	-0.38	1.55e-6	Lymphocyte counts;
UCEC	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.41	4.53	0.35	1.21e-5	Menarche (age at onset);
UCEC	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.65	6.43	0.47	1.67e-9	Aortic root size;
UCEC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-4.63	-0.36	7.81e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.71	6.16	0.45	6.54e-9	Coronary artery disease;
UCEC	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.66	8.76	0.59	4.38e-15	Anterior chamber depth;
UCEC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.35	4.59	0.35	9.46e-6	Monocyte count;
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.56	0.53	3.94e-12	Platelet count;
UCEC	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg08890418	chr1:21044141	KIF17	0.71	7.69	0.54	1.95e-12	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.72	7.22	0.51	2.52e-11	Itch intensity from mosquito bite;
UCEC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.53	5.34	0.4	3.42e-7	Menopause (age at onset);
UCEC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg22974920	chr21:40686053	BRWD1	0.63	5.5	0.41	1.68e-7	Cognitive function;
UCEC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.12	-0.39	9.58e-7	Aortic root size;
UCEC	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.9	8.73	0.58	5.28e-15	Cognitive ability;
UCEC	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg27153327	chr16:1920815	C16orf73	0.44	4.9	0.37	2.52e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.57	6.45	0.47	1.53e-9	Crohn's disease;
UCEC	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.77	-0.37	4.35e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-4.66	-0.36	7.17e-6	Joint mobility (Beighton score);
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.96	-0.38	1.91e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.54	5.66	0.42	7.76e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.02	-14.21	-0.76	2.25e-29	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.61	6.04	0.45	1.21e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs36051895	0.659	rs7025540	chr9:5043152	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-4.81	-0.37	3.75e-6	Pediatric autoimmune diseases;
UCEC	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	0.88	5.8	0.43	3.98e-8	Arsenic metabolism;
UCEC	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.88	5.7	0.43	6.31e-8	LDL cholesterol;
UCEC	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.62	0.48	6.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1390897	0.645	rs4888595	chr16:77122965	G/A	cg09454613	chr16:77233327	SYCE1L;MON1B	-0.4	-4.58	-0.35	9.79e-6	beta-nerve growth factor levels;
UCEC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.91	9.89	0.63	5.5e-18	Cognitive function;
UCEC	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.58	-0.42	1.1e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.46	5.23	0.4	5.61e-7	Colorectal cancer;
UCEC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-7.38	-0.52	1.06e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	0.64	5.01	0.38	1.55e-6	Orofacial clefts;
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.53	-5.7	-0.43	6.34e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.95	10.87	0.67	1.45e-20	Breast cancer;
UCEC	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.76	-5.34	-0.4	3.45e-7	Blood protein levels;
UCEC	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-7.3	-0.52	1.65e-11	Coronary artery disease;
UCEC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.51	5.59	0.42	1.09e-7	Menopause (age at onset);
UCEC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg03714773	chr7:91764589	CYP51A1	0.38	4.63	0.36	8.01e-6	Breast cancer;
UCEC	cis	rs7246967	0.932	rs35948178	chr19:23028519	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-1.09	-14.15	-0.76	3.1e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg13147721	chr7:65941812	NA	0.88	6.17	0.45	6.38e-9	Diabetic kidney disease;
UCEC	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.47	0.41	1.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.64	-4.52	-0.35	1.29e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	8.88	0.59	2.1e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.56	6.12	0.45	8.19e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.62	-6.63	-0.48	5.9e-10	Prostate cancer;
UCEC	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-5.17	-0.39	7.48e-7	Gut microbiome composition (summer);
UCEC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.57	-0.69	2.04e-22	Height;
UCEC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.59	5.0	0.38	1.64e-6	Response to diuretic therapy;
UCEC	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.98	8.49	0.57	2.03e-14	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg05738196	chr6:26577821	NA	0.62	7.28	0.51	1.91e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs17818399	0.620	rs3087822	chr2:46852033	C/T	cg26688816	chr2:46740690	ATP6V1E2	0.5	4.58	0.35	9.74e-6	Height;
UCEC	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.6	-6.43	-0.47	1.67e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.49e-6	Hemoglobin concentration;
UCEC	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.62	5.98	0.44	1.64e-8	Sudden cardiac arrest;
UCEC	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.62	7.46	0.52	7.02e-12	Oral cavity cancer;
UCEC	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.47	5.01	0.38	1.53e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs7374004	1.000	rs7374004	chr3:38625709	A/T	cg24069376	chr3:38537580	EXOG	-0.43	-4.5	-0.35	1.35e-5	PR interval;
UCEC	cis	rs7246967	0.673	rs55638152	chr19:23055294	G/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.83	8.91	0.59	1.76e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-5.41	-0.41	2.48e-7	Platelet count;
UCEC	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.86	7.15	0.51	3.75e-11	Prostate cancer;
UCEC	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.73	-7.43	-0.52	8.24e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.44	-4.67	-0.36	6.65e-6	Schizophrenia;
UCEC	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	4.9	0.37	2.55e-6	Bipolar disorder;
UCEC	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg03728395	chr2:85555865	TGOLN2	-0.34	-4.55	-0.35	1.11e-5	Ear protrusion;
UCEC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs877674	1.000	rs1889571	chr1:32195819	T/G	cg07656362	chr1:32688117	C1orf91;EIF3I	0.83	4.64	0.36	7.67e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.51	5.68	0.42	6.87e-8	Blood metabolite ratios;
UCEC	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg02158880	chr13:53174818	NA	0.43	4.86	0.37	2.95e-6	Lewy body disease;
UCEC	cis	rs7095607	1.000	rs7094660	chr10:69956912	A/G	cg18986048	chr10:69913749	MYPN	0.46	5.03	0.38	1.42e-6	Lung function (FVC);
UCEC	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg26114124	chr12:9217669	LOC144571	0.42	4.73	0.36	5.26e-6	Sjögren's syndrome;
UCEC	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg00325661	chr8:49890786	NA	-0.54	-5.38	-0.41	2.84e-7	Sudden cardiac arrest;
UCEC	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.66	-6.04	-0.45	1.2e-8	Systemic lupus erythematosus;
UCEC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.54	-6.13	-0.45	7.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs66573146	1.000	rs59683609	chr4:6964910	C/G	cg07817883	chr1:32538562	TMEM39B	1.23	9.45	0.61	7.4e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.0	-0.38	1.58e-6	Personality dimensions;
UCEC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.71	5.28	0.4	4.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7246967	0.673	rs34174596	chr19:22933519	G/A	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.2e-7	Systemic lupus erythematosus;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg06818710	chr6:28411271	ZSCAN23	0.54	6.31	0.46	3.05e-9	Pubertal anthropometrics;
UCEC	cis	rs7072216	1.000	rs7072216	chr10:100156853	A/G	cg19567339	chr10:100142640	NA	0.53	6.59	0.48	7.19e-10	Metabolite levels;
UCEC	cis	rs4615376	0.906	rs9473285	chr6:13049347	G/C	cg11378619	chr6:12164359	HIVEP1	-0.44	-4.68	-0.36	6.33e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.27	-0.51	1.97e-11	Monocyte count;
UCEC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.97	12.05	0.7	1.1e-23	Breast cancer;
UCEC	cis	rs405956	0.769	rs4946657	chr6:105582076	C/T	cg22580625	chr6:105627791	POPDC3	-0.55	-5.17	-0.39	7.64e-7	QT interval;
UCEC	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02097616	chr17:62675921	NA	0.44	4.86	0.37	3e-6	Joint mobility (Beighton score);
UCEC	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.48	5.53	0.41	1.45e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.63	-6.95	-0.5	1.1e-10	Prostate cancer;
UCEC	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.54	-4.86	-0.37	2.97e-6	Hypospadias;
UCEC	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg07796016	chr1:152779584	LCE1C	-0.42	-4.71	-0.36	5.75e-6	Psoriasis;
UCEC	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.66	-0.36	6.93e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20011983	chr2:74347215	NA	-0.61	-4.73	-0.36	5.25e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.4	-0.47	1.94e-9	Aortic root size;
UCEC	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	6.22	0.46	4.97e-9	Personality dimensions;
UCEC	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.07	-15.87	-0.79	1.15e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.59	-5.69	-0.43	6.52e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.48	5.4	0.41	2.58e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-0.76	-7.19	-0.51	3.09e-11	Breast cancer;
UCEC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg13147721	chr7:65941812	NA	-0.91	-6.06	-0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg03078520	chr22:18463400	MICAL3	-0.49	-4.93	-0.38	2.17e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.76	0.49	3.05e-10	Coffee consumption (cups per day);
UCEC	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	7.76	0.54	1.35e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg01072550	chr1:21505969	NA	-0.5	-4.68	-0.36	6.55e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-4.81	-0.37	3.66e-6	Bipolar disorder;
UCEC	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	1.02	7.64	0.53	2.56e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	1.15	6.21	0.46	5.27e-9	Type 2 diabetes;
UCEC	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.86	-5.82	-0.43	3.56e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.41	-0.41	2.5e-7	Aortic root size;
UCEC	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.2	-17.61	-0.82	4.9e-38	Exhaled nitric oxide output;
UCEC	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg07776626	chr8:57350775	NA	-0.48	-5.39	-0.41	2.71e-7	Obesity-related traits;
UCEC	cis	rs12618769	0.597	rs2278213	chr2:99136059	A/G	cg14361474	chr2:99058762	NA	-0.5	-4.98	-0.38	1.79e-6	Bipolar disorder;
UCEC	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.66	6.14	0.45	7.34e-9	Schizophrenia;
UCEC	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.5	4.79	0.37	3.98e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	0.79	7.57	0.53	3.8e-12	Vitamin D levels;
UCEC	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	5.86	0.43	2.98e-8	Menarche (age at onset);
UCEC	cis	rs7165102	1.000	rs2414884	chr15:66075872	C/T	cg11164506	chr15:66649558	TIPIN	-0.33	-4.65	-0.36	7.18e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.12	14.94	0.78	2.77e-31	Cognitive function;
UCEC	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-4.8	-0.37	3.87e-6	Neuroticism;
UCEC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.72	7.26	0.51	2.09e-11	Breast cancer;
UCEC	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.71	8.0	0.55	3.35e-13	Bone mineral density;
UCEC	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	6.16	0.45	6.56e-9	High light scatter reticulocyte count;
UCEC	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.76	8.44	0.57	2.8e-14	Primary sclerosing cholangitis;
UCEC	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.64	4.69	0.36	6.11e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.56	5.73	0.43	5.52e-8	Lung cancer;
UCEC	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.59	-6.23	-0.46	4.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.92	-11.51	-0.69	2.91e-22	Monocyte count;
UCEC	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.36	5.75	0.43	5.04e-8	Cancer;
UCEC	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.86	-0.37	3.01e-6	Depression;
UCEC	cis	rs308403	0.568	rs13101575	chr4:123617561	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.6	4.5	0.35	1.36e-5	Blood protein levels;
UCEC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.6	5.76	0.43	4.7e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.56	-5.88	-0.44	2.63e-8	Parkinson's disease;
UCEC	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.34	4.88	0.37	2.7e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.43	-5.15	-0.39	8.1e-7	Tonsillectomy;
UCEC	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.5	5.41	0.41	2.52e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.8	0.59	3.41e-15	Platelet count;
UCEC	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.75	0.43	4.91e-8	Tonsillectomy;
UCEC	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.51	5.98	0.44	1.6e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.37	-0.47	2.23e-9	Aortic root size;
UCEC	cis	rs72655828	1.000	rs72655828	chr13:112008727	C/T	cg25759064	chr13:111805337	ARHGEF7	-0.87	-4.65	-0.36	7.26e-6	Initial pursuit acceleration;
UCEC	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.58	4.81	0.37	3.68e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.57	6.08	0.45	1e-8	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.63	6.68	0.48	4.5e-10	Menopause (age at onset);
UCEC	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	0.73	5.82	0.43	3.55e-8	Post bronchodilator FEV1;
UCEC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.67	-6.62	-0.48	6.2e-10	Blood metabolite levels;
UCEC	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	5.6	0.42	1.01e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-13.05	-0.73	2.45e-26	Ulcerative colitis;
UCEC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.43	-4.77	-0.37	4.41e-6	Blood metabolite levels;
UCEC	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg22868518	chr11:507468	RNH1	-0.52	-5.04	-0.38	1.33e-6	Systemic lupus erythematosus;
UCEC	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.71	-0.43	6.01e-8	Tonsillectomy;
UCEC	cis	rs11958404	0.932	rs6859470	chr5:157429505	T/G	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.41	4.69	0.36	6.17e-6	Blood metabolite ratios;
UCEC	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg24851651	chr11:66362959	CCS	0.42	5.05	0.38	1.31e-6	Educational attainment (years of education);
UCEC	cis	rs7975161	0.579	rs7962423	chr12:104710910	G/A	cg25273343	chr12:104657179	TXNRD1	-0.81	-5.11	-0.39	9.85e-7	Toenail selenium levels;
UCEC	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg05991184	chr2:219186017	PNKD	0.47	5.23	0.4	5.77e-7	Colorectal cancer;
UCEC	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.44	-4.97	-0.38	1.82e-6	Neuroticism;
UCEC	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg03078520	chr22:18463400	MICAL3	-0.56	-5.4	-0.41	2.65e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.63	5.62	0.42	9.37e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.54	4.51	0.35	1.31e-5	Obesity-related traits;
UCEC	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.23	-19.17	-0.85	7.79e-42	Exhaled nitric oxide output;
UCEC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.36	-5.3	-0.4	4.15e-7	Multiple sclerosis;
UCEC	cis	rs9309473	0.898	rs6546861	chr2:73849861	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-4.84	-0.37	3.26e-6	Metabolite levels;
UCEC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg27068330	chr11:65405492	SIPA1	-0.59	-5.79	-0.43	4.14e-8	Acne (severe);
UCEC	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.74	0.43	5.23e-8	Rheumatoid arthritis;
UCEC	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg27033923	chr15:41106683	ZFYVE19	-0.52	-5.33	-0.4	3.64e-7	Ulcerative colitis;
UCEC	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-13.11	-0.73	1.74e-26	Primary sclerosing cholangitis;
UCEC	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-4.6	-0.35	9.11e-6	Metabolite levels;
UCEC	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.75	-7.86	-0.54	7.67e-13	Blood protein levels;
UCEC	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.57	-5.36	-0.4	3.2e-7	Initial pursuit acceleration;
UCEC	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg13695892	chr22:41940480	POLR3H	0.55	4.72	0.36	5.55e-6	Vitiligo;
UCEC	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-11.87	-0.7	3.2e-23	Chronic sinus infection;
UCEC	cis	rs7246967	0.673	rs7247191	chr19:22899585	C/T	cg24889512	chr19:22816950	ZNF492	0.62	6.68	0.48	4.67e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.58	5.16	0.39	7.83e-7	Corneal astigmatism;
UCEC	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.45	4.57	0.35	1.01e-5	Blood metabolite levels;
UCEC	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.65	6.26	0.46	4.07e-9	Height;
UCEC	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg20575277	chr15:90728569	SEMA4B	0.45	4.64	0.36	7.65e-6	Rheumatoid arthritis;
UCEC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.0	-0.44	1.46e-8	Prudent dietary pattern;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.5	-5.84	-0.43	3.15e-8	Cardiac Troponin-T levels;
UCEC	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.36	-5.58	-0.42	1.14e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.58	5.43	0.41	2.29e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	10.44	0.65	1.99e-19	Platelet count;
UCEC	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.46	4.81	0.37	3.64e-6	Menopause (age at onset);
UCEC	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.68	-7.73	-0.54	1.58e-12	Paraoxonase activity;
UCEC	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.46	-5.16	-0.39	7.96e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10266483	0.739	rs2692099	chr7:63767762	G/C	cg23304165	chr7:63498798	NA	-0.5	-5.41	-0.41	2.49e-7	Response to statin therapy;
UCEC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	0.92	8.67	0.58	7.37e-15	Cognitive function;
UCEC	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.53	4.65	0.36	7.23e-6	Monobrow;
UCEC	cis	rs10096908	0.892	rs10103618	chr8:41663896	A/G	cg01513060	chr8:40802449	NA	0.67	4.51	0.35	1.3e-5	Hypertension;Blood pressure traits (multi-trait analysis);Systolic blood pressure;
UCEC	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	5.64	0.42	8.63e-8	Response to bleomycin (chromatid breaks);
UCEC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.69	7.86	0.54	7.66e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.77	-0.37	4.44e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.85	-10.62	-0.66	6.63e-20	Brugada syndrome;
UCEC	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.66	7.63	0.53	2.77e-12	Post bronchodilator FEV1;
UCEC	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	0.88	12.11	0.71	7.41e-24	Triglycerides;
UCEC	cis	rs12635074	0.558	rs17235452	chr3:56277184	T/C	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.39	4.8	0.37	3.94e-6	Morning vs. evening chronotype;
UCEC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.81	-0.43	3.66e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.7	0.36	5.83e-6	Alzheimer's disease;
UCEC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26207909	chr14:103986467	CKB	0.49	5.5	0.41	1.67e-7	Body mass index;
UCEC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.72e-25	Height;
UCEC	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	0.91	9.1	0.6	5.79e-16	Heart rate;
UCEC	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg23793686	chr15:68133972	NA	-0.36	-4.67	-0.36	6.82e-6	Restless legs syndrome;
UCEC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	0.9	12.21	0.71	3.99e-24	Bone mineral density;
UCEC	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	4.53	0.35	1.21e-5	Breast cancer;
UCEC	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-4.86	-0.37	3.04e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.65	5.44	0.41	2.16e-7	Blood metabolite levels;
UCEC	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.5	5.94	0.44	1.94e-8	Breast cancer;
UCEC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7015263	0.714	rs7822494	chr8:87476439	C/T	cg27223183	chr8:87520930	FAM82B	-0.48	-4.59	-0.35	9.51e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	0.54	5.47	0.41	1.9e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.69	-6.8	-0.49	2.51e-10	Blood metabolite levels;
UCEC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.69	-8.69	-0.58	6.6e-15	Prudent dietary pattern;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.66	-7.57	-0.53	3.69e-12	Paraoxonase activity;
UCEC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg13385521	chr17:29058706	SUZ12P	0.59	4.51	0.35	1.32e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.79	-7.64	-0.53	2.58e-12	Menopause (age at onset);
UCEC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs735860	0.712	rs2294864	chr6:53140928	T/A	cg10236188	chr6:53219634	NA	-0.48	-5.11	-0.39	9.95e-7	Glaucoma;
UCEC	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.64	8.34	0.57	4.85e-14	Testicular germ cell tumor;
UCEC	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.09	9.05	0.6	8.14e-16	Vitiligo;
UCEC	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg21905437	chr5:178450457	ZNF879	0.66	7.27	0.51	2.01e-11	Pubertal anthropometrics;
UCEC	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.81	-0.43	3.74e-8	Prudent dietary pattern;
UCEC	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.62	6.33	0.46	2.84e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.49	-4.64	-0.36	7.74e-6	Morning vs. evening chronotype;
UCEC	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.5	4.9	0.37	2.51e-6	High light scatter reticulocyte count;
UCEC	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-4.55	-0.35	1.13e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.8	-0.63	9.46e-18	Leprosy;
UCEC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.63	-6.65	-0.48	5.38e-10	Longevity;Endometriosis;
UCEC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.52	5.21	0.39	6.34e-7	Homoarginine levels;
UCEC	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg12035532	chr1:1886765	KIAA1751	0.44	4.69	0.36	6.18e-6	Body mass index;
UCEC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.46	5.11	0.39	9.68e-7	Response to temozolomide;
UCEC	trans	rs4389974	0.966	rs55874510	chr8:112381048	G/A	cg22736090	chr17:62339926	TEX2	0.66	7.05	0.5	6.3e-11	Body mass index;
UCEC	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.92	0.59	1.68e-15	Alzheimer's disease;
UCEC	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	5.34	0.4	3.47e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs59918340	0.738	rs7007986	chr8:142217115	G/A	cg23750338	chr8:142222470	SLC45A4	0.75	7.85	0.54	7.88e-13	Immature fraction of reticulocytes;
UCEC	cis	rs4332037	0.715	rs57234495	chr7:1906466	G/A	cg23422044	chr7:1970798	MAD1L1	-0.63	-5.67	-0.42	7.26e-8	Bipolar disorder;
UCEC	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.61	4.67	0.36	6.86e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.53	-5.46	-0.41	2.02e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4146922	0.793	rs7601401	chr2:56004592	A/G	cg00879447	chr2:56412077	CCDC85A	-0.48	-4.87	-0.37	2.81e-6	Height;
UCEC	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.65	-5.96	-0.44	1.78e-8	Cognitive ability;
UCEC	cis	rs1978968	0.833	rs5992941	chr22:18463747	T/C	cg03078520	chr22:18463400	MICAL3	-0.5	-6.34	-0.46	2.68e-9	Presence of antiphospholipid antibodies;
UCEC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.55	6.4	0.47	1.98e-9	Monocyte percentage of white cells;
UCEC	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.62	-5.77	-0.43	4.47e-8	Educational attainment (years of education);
UCEC	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.53	-5.64	-0.42	8.41e-8	Brugada syndrome;
UCEC	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.54	5.28	0.4	4.65e-7	Lung cancer;
UCEC	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.47	4.9	0.37	2.49e-6	Smoking initiation;
UCEC	cis	rs7246967	0.673	rs34425596	chr19:22899779	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.07	0.45	1.03e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.97	-11.5	-0.69	3.12e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.65	7.54	0.53	4.38e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6693882	0.967	rs6690439	chr1:96144899	A/C	cg12448539	chr1:95364293	CNN3	0.49	4.59	0.35	9.57e-6	Pain;
UCEC	cis	rs6832769	1.000	rs35767091	chr4:56346723	G/A	cg05960024	chr4:56376020	CLOCK	0.56	5.84	0.43	3.22e-8	Personality dimensions;
UCEC	cis	rs600806	0.742	rs12753439	chr1:110015519	G/A	cg02175308	chr1:109941060	SORT1	-0.29	-4.58	-0.35	9.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-4.56	-0.35	1.07e-5	Electroencephalogram traits;
UCEC	cis	rs3087591	0.659	rs2525570	chr17:29681245	A/G	cg24425628	chr17:29625626	OMG;NF1	0.52	5.65	0.42	8.22e-8	Hip circumference;
UCEC	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.79	-9.07	-0.6	7.08e-16	Primary sclerosing cholangitis;
UCEC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.65	-6.16	-0.45	6.56e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.65	7.22	0.51	2.55e-11	Body mass index;
UCEC	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg14689365	chr7:158441557	NCAPG2	-0.48	-4.53	-0.35	1.22e-5	Height;
UCEC	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.39	0.41	2.75e-7	Breast cancer;
UCEC	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.35	-8.8	-0.59	3.44e-15	Diabetic kidney disease;
UCEC	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.1	6.82	0.49	2.2e-10	Night sleep phenotypes;
UCEC	cis	rs6754311	0.637	rs12185712	chr2:136456642	A/G	cg07169764	chr2:136633963	MCM6	-0.69	-6.5	-0.47	1.2e-9	Mosquito bite size;
UCEC	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.49	-4.91	-0.38	2.36e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.47	-0.47	1.39e-9	Crohn's disease;
UCEC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	6.05	0.45	1.13e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4281086	0.965	rs35483889	chr8:10378256	G/A	cg01072821	chr8:10382165	T-SP1	0.32	4.54	0.35	1.18e-5	Obesity-related traits;
UCEC	cis	rs2806864	1.000	rs2250951	chr1:117462050	G/T	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.7	-0.36	6.06e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs4148689	0.951	rs34683806	chr7:117165147	A/G	cg21212505	chr7:117228958	CFTR	-0.4	-4.6	-0.35	9.23e-6	Gout;
UCEC	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.66	6.69	0.48	4.33e-10	Breast cancer;
UCEC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.81	9.45	0.61	7.28e-17	Menopause (age at onset);
UCEC	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.54	-6.26	-0.46	4.09e-9	Type 2 diabetes;
UCEC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.61	6.76	0.49	3.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.16	0.45	6.48e-9	Cognitive ability;
UCEC	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.35	-0.4	3.34e-7	Mood instability;
UCEC	cis	rs7818345	0.763	rs4431609	chr8:19293565	A/C	cg06562184	chr8:19319451	CSGALNACT1	-0.51	-5.31	-0.4	4.02e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg14438399	chr17:27053147	TLCD1	0.6	4.76	0.37	4.56e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	4.72	0.36	5.53e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs12618769	0.597	rs3754879	chr2:99164541	G/T	cg10123293	chr2:99228465	UNC50	0.44	4.68	0.36	6.59e-6	Bipolar disorder;
UCEC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg21770322	chr7:97807741	LMTK2	0.54	6.77	0.49	2.82e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.51	-4.66	-0.36	7.06e-6	Body mass index;
UCEC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.68	6.16	0.45	6.59e-9	Aortic root size;
UCEC	cis	rs782107	0.761	rs782106	chr12:58834349	T/C	cg19181132	chr12:59314527	LRIG3	0.48	5.1	0.39	1.01e-6	Interleukin-12p70 levels;
UCEC	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg17420585	chr12:42539391	GXYLT1	0.4	5.14	0.39	8.8e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.75	7.3	0.52	1.69e-11	Mosquito bite size;
UCEC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.83	9.44	0.61	7.87e-17	Monocyte count;
UCEC	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.78	-9.25	-0.61	2.43e-16	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7246967	0.673	rs7250343	chr19:22822845	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg05738196	chr6:26577821	NA	0.59	6.46	0.47	1.47e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	4.54	0.35	1.15e-5	Obesity-related traits;
UCEC	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.73	-4.86	-0.37	2.93e-6	Narcolepsy;
UCEC	cis	rs9467773	1.000	rs1570061	chr6:26575986	T/C	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.51	-5.93	-0.44	2.12e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-5.34	-0.4	3.44e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.71	-6.91	-0.5	1.35e-10	Aortic root size;
UCEC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.76	-8.43	-0.57	2.99e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	5.17	0.39	7.37e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-0.75	-7.53	-0.53	4.68e-12	Urate levels;
UCEC	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.59	0.48	7.46e-10	Tonsillectomy;
UCEC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs77861329	0.920	rs9860982	chr3:52096432	T/C	cg08692210	chr3:52188851	WDR51A	0.69	5.06	0.39	1.22e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.51	0.57	1.87e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg16060761	chr17:80687452	NA	-0.41	-4.65	-0.36	7.47e-6	Breast cancer;
UCEC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.52	4.98	0.38	1.78e-6	Coronary artery disease;
UCEC	cis	rs2190422	0.551	rs11971743	chr7:103160158	T/G	cg18108683	chr7:102477205	FBXL13	-0.54	-4.66	-0.36	7.06e-6	Morning vs. evening chronotype;
UCEC	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.26	0.51	2.07e-11	Tonsillectomy;
UCEC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.87	0.54	7.12e-13	Smoking behavior;
UCEC	cis	rs2862064	0.649	rs1995377	chr5:156436679	T/A	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.73	-0.43	5.52e-8	Platelet count;
UCEC	cis	rs970548	0.954	rs11239528	chr10:45955036	A/G	cg15223267	chr10:46222474	FAM21C	0.51	4.62	0.36	8.48e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.6	-6.07	-0.45	1.04e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.76	-0.37	4.67e-6	Breast cancer;
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.86	7.14	0.51	3.9e-11	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	11.81	0.7	4.69e-23	Platelet count;
UCEC	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.68	5.23	0.4	5.67e-7	Mean platelet volume;
UCEC	cis	rs172166	0.561	rs149974	chr6:27985096	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.36	-0.4	3.11e-7	Cardiac Troponin-T levels;
UCEC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	7.6	0.53	3.26e-12	Total body bone mineral density;
UCEC	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	0.83	5.91	0.44	2.34e-8	Left atrial antero-posterior diameter;
UCEC	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.46	-4.74	-0.36	5.08e-6	IgG glycosylation;
UCEC	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.7	6.52	0.47	1.08e-9	Migraine;Coronary artery disease;
UCEC	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.79	-8.14	-0.56	1.5e-13	Mosquito bite size;
UCEC	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg19715936	chr7:50634035	DDC	0.45	5.57	0.42	1.21e-7	Malaria;
UCEC	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	5.9	0.44	2.36e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.75	7.31	0.52	1.62e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.49	4.67	0.36	6.83e-6	Menopause (age at onset);
UCEC	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.79	5.17	0.39	7.5e-7	Psoriasis;
UCEC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.79	-8.42	-0.57	3.06e-14	Blood protein levels;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.62	-7.79	-0.54	1.11e-12	Pubertal anthropometrics;
UCEC	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.56	0.42	1.24e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.48	5.2	0.39	6.66e-7	Aortic root size;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.46	5.44	0.41	2.2e-7	Menarche (age at onset);
UCEC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.74	-7.77	-0.54	1.22e-12	Tonsillectomy;
UCEC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.56	-6.15	-0.45	6.82e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg04310649	chr10:35416472	CREM	-0.48	-4.67	-0.36	6.76e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg06660395	chr4:1396306	NA	0.34	4.57	0.35	1.04e-5	Obesity-related traits;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.45	0.41	2.11e-7	Platelet count;
UCEC	cis	rs10743315	0.778	rs965861	chr12:19360719	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.51	-4.96	-0.38	1.94e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.62	5.45	0.41	2.07e-7	Uric acid levels;
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg04871131	chr7:94954202	PON1	-0.53	-5.27	-0.4	4.86e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.41	5.15	0.39	8.28e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.62	4.8	0.37	3.84e-6	Bladder cancer;
UCEC	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-4.84	-0.37	3.26e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.49	-0.41	1.69e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	0.96	5.25	0.4	5.22e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg22117172	chr7:91764530	CYP51A1	-0.4	-5.15	-0.39	8.37e-7	Breast cancer;
UCEC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246967	0.611	rs62118770	chr19:22824029	A/G	cg08271804	chr19:22816896	ZNF492	0.68	4.72	0.36	5.55e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10924970	0.649	rs11801073	chr1:235458109	G/A	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.71	-4.75	-0.36	4.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	4.93	0.38	2.22e-6	Bipolar disorder;
UCEC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.55	5.06	0.39	1.21e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.52	-4.55	-0.35	1.1e-5	Cognitive ability;
UCEC	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.61	6.77	0.49	2.91e-10	Hip circumference;
UCEC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.54	0.47	9.49e-10	Coffee consumption (cups per day);
UCEC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.59	5.75	0.43	4.92e-8	Tonsillectomy;
UCEC	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.6	5.49	0.41	1.71e-7	Initial pursuit acceleration;
UCEC	cis	rs4460629	0.742	rs7366355	chr1:155076734	C/T	cg02153340	chr1:155202674	NA	-0.4	-4.58	-0.35	1e-5	Serum magnesium levels;
UCEC	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.46	-4.91	-0.38	2.38e-6	Schizophrenia;
UCEC	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	7.44	0.52	7.96e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs10242455	0.717	rs2741872	chr7:99339776	A/T	cg18809830	chr7:99032528	PTCD1	0.55	4.52	0.35	1.25e-5	Blood metabolite levels;
UCEC	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.41	5.17	0.39	7.58e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-20.88	-0.86	8.01e-46	Myeloid white cell count;
UCEC	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.85	5.89	0.44	2.51e-8	Type 2 diabetes;
UCEC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg22974920	chr21:40686053	BRWD1	0.56	4.76	0.37	4.57e-6	Cognitive function;
UCEC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.51	-0.47	1.12e-9	Platelet count;
UCEC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.65	-7.21	-0.51	2.68e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.41	-4.79	-0.37	3.98e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.41	-4.88	-0.37	2.69e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.66	-5.88	-0.44	2.65e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4615376	0.906	rs13219842	chr6:13041502	G/A	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.12e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.56	4.92	0.38	2.25e-6	Reticulocyte count;
UCEC	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.33e-8	Lung cancer;
UCEC	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.58	-7.12	-0.51	4.5e-11	Total body bone mineral density;
UCEC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg19645103	chr12:69753606	YEATS4	0.53	4.83	0.37	3.46e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.66	-6.31	-0.46	3.16e-9	Acne (severe);
UCEC	cis	rs12618769	0.652	rs17034171	chr2:99221095	A/G	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.46e-7	Bipolar disorder;
UCEC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg00277334	chr10:82204260	NA	0.46	4.58	0.35	9.74e-6	Post bronchodilator FEV1;
UCEC	cis	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg03999872	chr20:62272968	STMN3	-0.48	-4.6	-0.36	8.88e-6	Atopic dermatitis;
UCEC	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg23018236	chr17:30244563	NA	-0.67	-4.64	-0.36	7.52e-6	Hip circumference adjusted for BMI;
UCEC	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.08	-0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.45	-4.65	-0.36	7.34e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	6.96	0.5	1.06e-10	Chronic sinus infection;
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg08461772	chr7:95026248	PON3	0.4	5.32	0.4	3.83e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.11e-13	Prudent dietary pattern;
UCEC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg22974920	chr21:40686053	BRWD1	0.54	4.91	0.38	2.42e-6	Cognitive function;
UCEC	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.84	-4.81	-0.37	3.78e-6	Inflammatory biomarkers;
UCEC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.21	-0.39	6.25e-7	Breast cancer;
UCEC	cis	rs10448044	0.536	rs7000109	chr8:80062983	C/T	cg19598189	chr8:79513961	PKIA	0.37	4.51	0.35	1.34e-5	Suicide in bipolar disorder;
UCEC	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-4.9	-0.37	2.48e-6	Joint mobility (Beighton score);
UCEC	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.41	4.54	0.35	1.15e-5	Sjögren's syndrome;
UCEC	cis	rs36051895	0.587	rs11999802	chr9:5189773	T/G	cg02405213	chr9:5042618	JAK2	-0.51	-4.7	-0.36	6.04e-6	Pediatric autoimmune diseases;
UCEC	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.51	5.09	0.39	1.08e-6	Colorectal cancer;
UCEC	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.62	-7.49	-0.53	5.77e-12	Multiple myeloma;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.6	8.4	0.57	3.57e-14	Prudent dietary pattern;
UCEC	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.35	4.72	0.36	5.51e-6	Blood protein levels;
UCEC	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	8.01	0.55	3.17e-13	Lymphocyte percentage of white cells;
UCEC	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.7	5.58	0.42	1.11e-7	Neutrophil percentage of white cells;
UCEC	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.52	-4.95	-0.38	1.97e-6	Schizophrenia;
UCEC	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.58	-6.02	-0.44	1.32e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7432375	0.523	rs12486911	chr3:136558953	C/G	cg21827317	chr3:136751795	NA	0.48	4.76	0.37	4.61e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg00614314	chr15:82944287	LOC80154	0.54	4.91	0.38	2.41e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.46	-4.74	-0.36	5.02e-6	Height;
UCEC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.73	7.61	0.53	3.12e-12	Breast cancer;
UCEC	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.55	-5.55	-0.42	1.29e-7	Schizophrenia;
UCEC	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg14092571	chr14:90743983	NA	-0.46	-6.33	-0.46	2.85e-9	Mortality in heart failure;
UCEC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.72	6.54	0.47	9.46e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.31	-0.46	3.16e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg01262667	chr19:19385393	TM6SF2	0.49	6.54	0.47	9.5e-10	Tonsillectomy;
UCEC	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.52	4.61	0.36	8.64e-6	Ileal carcinoids;
UCEC	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg13147721	chr7:65941812	NA	-0.75	-5.07	-0.39	1.19e-6	Diabetic kidney disease;
UCEC	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-9.78	-0.63	1.04e-17	Electrocardiographic conduction measures;
UCEC	cis	rs10503871	0.761	rs6997010	chr8:30365489	T/A	cg26383811	chr8:30366931	RBPMS	0.48	4.84	0.37	3.26e-6	Metabolite levels  (X-11787);
UCEC	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.63e-7	Life satisfaction;
UCEC	cis	rs2585417	1.000	rs2585417	chr20:52843799	C/T	cg14415559	chr20:52836060	PFDN4	-0.4	-4.65	-0.36	7.43e-6	Obesity-related traits;
UCEC	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg22493117	chr19:13227649	TRMT1;NACC1	-0.48	-4.64	-0.36	7.8e-6	Bipolar disorder;
UCEC	cis	rs9320282	0.587	rs1546721	chr6:109625796	T/C	cg01475377	chr6:109611718	NA	-0.37	-4.62	-0.36	8.27e-6	White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.9	-6.79	-0.49	2.59e-10	Exhaled nitric oxide output;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07000514	chr7:1090232	C7orf50	0.45	4.59	0.35	9.5e-6	Longevity;Endometriosis;
UCEC	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg10820045	chr2:198174542	NA	0.5	6.3	0.46	3.34e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.65	7.38	0.52	1.09e-11	Ulcerative colitis;
UCEC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.8	9.09	0.6	6.15e-16	Coronary artery disease;
UCEC	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.62	-6.91	-0.5	1.37e-10	Red blood cell count;
UCEC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	15.41	0.79	1.73e-32	Chronic sinus infection;
UCEC	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.75	-7.16	-0.51	3.64e-11	Initial pursuit acceleration;
UCEC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg06466757	chr4:1255808	NA	0.47	4.96	0.38	1.9e-6	Obesity-related traits;
UCEC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.7	-6.73	-0.49	3.63e-10	Aortic root size;
UCEC	cis	rs10007810	0.760	rs11729552	chr4:41594774	A/G	cg24722073	chr4:41882163	NA	-0.41	-4.89	-0.37	2.64e-6	Longevity (90 years and older);
UCEC	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg08886695	chr4:3369023	RGS12	-0.49	-5.13	-0.39	9.07e-7	Serum sulfate level;
UCEC	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg27391334	chr7:1352002	NA	0.38	4.7	0.36	5.82e-6	Longevity;Endometriosis;
UCEC	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.63	-5.95	-0.44	1.86e-8	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	0.71	5.7	0.43	6.22e-8	Blood protein levels;
UCEC	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.77	8.79	0.59	3.59e-15	Coronary artery disease;
UCEC	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.43	-5.31	-0.4	3.97e-7	Mortality in heart failure;
UCEC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.78	8.1	0.56	1.94e-13	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-7.59	-0.53	3.48e-12	Hip circumference;
UCEC	cis	rs7004769	0.554	rs74323363	chr8:9173789	A/C	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg03714773	chr7:91764589	CYP51A1	0.43	4.98	0.38	1.75e-6	Breast cancer;
UCEC	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.6	0.42	1.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs8105895	0.935	rs62112921	chr19:22227577	T/C	cg24175803	chr19:22235144	ZNF257	-0.64	-5.51	-0.41	1.59e-7	Body mass index (change over time);
UCEC	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg05855489	chr10:104503620	C10orf26	-0.74	-8.51	-0.57	1.81e-14	Waist circumference;Hip circumference;
UCEC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg21770322	chr7:97807741	LMTK2	0.84	14.48	0.77	4.35e-30	Breast cancer;
UCEC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-4.98	-0.38	1.78e-6	Blood metabolite levels;
UCEC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.58	6.56	0.48	8.64e-10	Red blood cell count;
UCEC	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.61	-9.06	-0.6	7.36e-16	Total body bone mineral density;
UCEC	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.65	-5.49	-0.41	1.74e-7	Coronary artery calcification;
UCEC	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg08886695	chr4:3369023	RGS12	-0.5	-5.04	-0.38	1.37e-6	Serum sulfate level;
UCEC	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.44	-4.59	-0.35	9.48e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.62	6.43	0.47	1.65e-9	Breast cancer;
UCEC	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.45	4.77	0.37	4.4e-6	Retinal vascular caliber;
UCEC	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.47	-5.21	-0.39	6.28e-7	Longevity;
UCEC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.24	-0.56	8.48e-14	Total body bone mineral density;
UCEC	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	0.86	11.52	0.69	2.78e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.78	0.59	3.82e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.36	-5.81	-0.43	3.81e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Body mass index;
UCEC	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.54	5.13	0.39	9.19e-7	Coronary artery disease;
UCEC	cis	rs6728642	0.831	rs10496325	chr2:97683329	C/T	cg26665480	chr2:98280029	ACTR1B	0.61	6.16	0.45	6.66e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.43	-4.74	-0.36	4.96e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.11	0.39	9.68e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.1	0.51	4.82e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.66	-4.86	-0.37	3e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg07153921	chr17:41440717	NA	-0.47	-4.69	-0.36	6.08e-6	Menopause (age at onset);
UCEC	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.65	-5.52	-0.41	1.52e-7	Blood pressure (smoking interaction);
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg01060016	chr13:111720031	NA	-0.89	-4.96	-0.38	1.92e-6	Obesity-related traits;
UCEC	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg15837086	chr1:46506065	PIK3R3	-0.38	-4.7	-0.36	5.95e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.27	-0.51	1.97e-11	Coronary artery disease;
UCEC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg22974920	chr21:40686053	BRWD1	0.57	5.01	0.38	1.53e-6	Cognitive function;
UCEC	cis	rs151997	0.777	rs6870880	chr5:50256207	G/A	cg06027927	chr5:50259733	NA	0.57	5.35	0.4	3.29e-7	Callous-unemotional behaviour;
UCEC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-0.96	-6.06	-0.45	1.11e-8	Diabetic kidney disease;
UCEC	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.04	14.79	0.77	6.88e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.45	4.79	0.37	4.1e-6	Corneal astigmatism;
UCEC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-10.68	-0.66	4.54e-20	Cognitive function;
UCEC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.99	12.52	0.72	6.1e-25	Multiple sclerosis;
UCEC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.62	5.55	0.42	1.28e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.51	-4.56	-0.35	1.06e-5	Response to antineoplastic agents;
UCEC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.09	9.99	0.64	3.03e-18	Vitiligo;
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.42	-4.71	-0.36	5.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1318772	0.932	rs7705255	chr5:112950169	C/A	cg12552261	chr5:112820674	MCC	0.8	5.12	0.39	9.57e-7	F-cell distribution;
UCEC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.33	0.4	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg27246729	chr12:121163418	ACADS	0.51	4.67	0.36	6.72e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.68	-8.08	-0.55	2.18e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.53	-5.22	-0.4	5.94e-7	Diastolic blood pressure;
UCEC	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.49	-5.43	-0.41	2.31e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.79	-8.49	-0.57	2.1e-14	Morning vs. evening chronotype;
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.6	4.69	0.36	6.06e-6	Corneal astigmatism;
UCEC	cis	rs4372836	0.504	rs13382966	chr2:29068882	T/C	cg09522027	chr2:28974177	PPP1CB	-0.68	-7.09	-0.5	5.25e-11	Body mass index;
UCEC	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	6.3	0.46	3.19e-9	Neuroticism;
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg04871131	chr7:94954202	PON1	-0.5	-4.69	-0.36	6.27e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.89e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs8020441	1.000	rs68120925	chr14:51169258	C/A	cg04730355	chr14:51134070	SAV1	0.57	5.32	0.4	3.85e-7	Cognitive performance;
UCEC	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7799006	0.895	rs3800938	chr7:2267442	C/G	cg08027265	chr7:2291960	NA	-0.53	-5.51	-0.41	1.57e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.37	-5.18	-0.39	7.17e-7	Crohn's disease;
UCEC	cis	rs3914502	0.615	rs1399805	chr3:174527103	G/A	cg21145449	chr3:174580620	NAALADL2	0.46	5.1	0.39	1.05e-6	Autism spectrum disorder;
UCEC	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	1.04	11.99	0.7	1.6e-23	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs17106184	1.000	rs12071359	chr1:51388895	G/A	cg07174182	chr1:51127561	FAF1	-0.61	-4.79	-0.37	4.02e-6	Type 2 diabetes;
UCEC	cis	rs7204230	1.000	rs62049783	chr16:53298567	C/T	cg10109421	chr16:52641824	NA	0.4	4.59	0.35	9.25e-6	Fibrinogen;
UCEC	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.83	-9.86	-0.63	6.55e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg13401533	chr1:37979913	MEAF6	0.58	4.92	0.38	2.27e-6	Axial length;
UCEC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.78	6.52	0.47	1.08e-9	Gut microbiome composition (summer);
UCEC	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01973587	chr1:228161476	NA	0.37	4.94	0.38	2.1e-6	Diastolic blood pressure;
UCEC	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18932078	chr1:2524107	MMEL1	0.37	5.86	0.43	2.99e-8	Ulcerative colitis;
UCEC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg19761014	chr17:28927070	LRRC37B2	0.64	4.69	0.36	6.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.7	0.43	6.41e-8	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24249390	chr15:90295951	MESP1	-0.44	-4.87	-0.37	2.83e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.5	-5.07	-0.39	1.19e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.48	4.86	0.37	3e-6	Prostate cancer;
UCEC	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.77	-4.63	-0.36	7.99e-6	Putamen volume;
UCEC	cis	rs3750082	0.855	rs12536402	chr7:32936419	C/G	cg05721444	chr7:32995514	FKBP9	-0.53	-5.94	-0.44	2.01e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs732505	0.618	rs1337057	chr19:5676950	G/A	cg26242866	chr19:5711310	LONP1	0.79	4.64	0.36	7.69e-6	vWF and FVIII levels;
UCEC	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.5	-4.54	-0.35	1.14e-5	Refractive error;
UCEC	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.6	-6.2	-0.46	5.3300000000000004e-09	Myopia (pathological);
UCEC	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg23855989	chr12:50355821	AQP5	0.74	5.89	0.44	2.47e-8	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.56	-6.25	-0.46	4.31e-9	Inflammatory bowel disease;
UCEC	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.7	-5.29	-0.4	4.4e-7	Body mass index;
UCEC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs12681287	0.752	rs13256500	chr8:87247063	G/A	cg27223183	chr8:87520930	FAM82B	-0.63	-5.37	-0.41	2.98e-7	Caudate activity during reward;
UCEC	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg05962950	chr11:130786565	SNX19	0.61	6.52	0.47	1.04e-9	Schizophrenia;
UCEC	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.55	-6.08	-0.45	1.01e-8	Tonsillectomy;
UCEC	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.01	-12.37	-0.71	1.51e-24	Dilated cardiomyopathy;
UCEC	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.78	-8.43	-0.57	2.94e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.42	-5.32	-0.4	3.87e-7	Monocyte count;
UCEC	cis	rs5167	0.504	rs10426750	chr19:45457684	G/C	cg13119609	chr19:45449297	APOC2	0.42	5.97	0.44	1.72e-8	Blood protein levels;
UCEC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.48	0.77	4.23e-30	Height;
UCEC	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	5.61	0.42	9.69e-8	Platelet count;
UCEC	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.89	-9.36	-0.61	1.26e-16	Blood metabolite levels;
UCEC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs13065560	0.562	rs6786732	chr3:38920203	C/T	cg01426195	chr3:39028469	NA	-0.47	-4.89	-0.37	2.66e-6	Interleukin-18 levels;
UCEC	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.83	-0.49	2.1e-10	Diabetic kidney disease;
UCEC	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.67	6.81	0.49	2.34e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.85	0.43	3.11e-8	Monocyte percentage of white cells;
UCEC	trans	rs1459104	0.929	rs12794656	chr11:55289878	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.63	-5.13	-0.39	8.9e-7	Menarche (age at onset);
UCEC	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.78	7.31	0.52	1.6e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.47	5.09	0.39	1.09e-6	Systemic lupus erythematosus;
UCEC	cis	rs9470794	1.000	rs11758095	chr6:38085449	C/G	cg03458162	chr6:37400668	FTSJD2	0.81	4.8	0.37	3.94e-6	Type 2 diabetes;
UCEC	cis	rs1572438	0.640	rs10498652	chr6:875493	A/G	cg16431787	chr6:1082220	LOC285768	-0.41	-4.54	-0.35	1.17e-5	Aging;
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.62	4.6	0.35	9.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg22974920	chr21:40686053	BRWD1	-0.54	-4.95	-0.38	1.99e-6	Cognitive function;
UCEC	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-8.03	-0.55	2.91e-13	Hip circumference;
UCEC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.76	-7.35	-0.52	1.3e-11	Breast cancer;
UCEC	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-6.72	-0.48	3.67e-10	Platelet count;
UCEC	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.69	7.31	0.52	1.61e-11	Breast cancer;
UCEC	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.5	-4.62	-0.36	8.37e-6	Platelet count;
UCEC	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.57	-6.61	-0.48	6.5e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg10914120	chr13:113893660	CUL4A	0.47	4.6	0.35	9.13e-6	Platelet distribution width;
UCEC	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg13256891	chr4:100009986	ADH5	-0.69	-5.15	-0.39	8.11e-7	Alcohol dependence;
UCEC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-6.21	-0.46	5.1e-9	Crohn's disease;
UCEC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg01112020	chr2:239008986	ESPNL	-0.36	-4.94	-0.38	2.11e-6	Prostate cancer;
UCEC	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.69	-8.55	-0.58	1.44e-14	Response to temozolomide;
UCEC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	5.37	0.4	3.04e-7	Lung cancer in ever smokers;
UCEC	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg21419209	chr3:44054225	NA	-0.49	-5.36	-0.4	3.16e-7	Coronary artery disease;
UCEC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.66	-0.36	6.91e-6	Bipolar disorder;
UCEC	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.68	-8.06	-0.55	2.46e-13	Waist-hip ratio;
UCEC	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.6	-6.74	-0.49	3.38e-10	Cardiac Troponin-T levels;
UCEC	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.65	-6.81	-0.49	2.27e-10	IgG glycosylation;
UCEC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	0.83	7.16	0.51	3.56e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.63	5.87	0.44	2.79e-8	Menopause (age at onset);
UCEC	cis	rs787274	0.867	rs786977	chr9:115459708	A/G	cg13803584	chr9:115635662	SNX30	0.65	4.71	0.36	5.61e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.58	-5.03	-0.38	1.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.56	-0.66	9.36e-20	Primary sclerosing cholangitis;
UCEC	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg18681998	chr4:17616180	MED28	0.67	7.11	0.51	4.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.86	-8.92	-0.59	1.75e-15	Type 2 diabetes;
UCEC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.55	5.47	0.41	1.89e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.66	6.51	0.47	1.1e-9	Lymphocyte counts;
UCEC	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	4.9	0.37	2.52e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg20387954	chr3:183756860	HTR3D	-0.41	-4.99	-0.38	1.68e-6	Anterior chamber depth;
UCEC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.61	-5.55	-0.42	1.29e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.11	0.51	4.64e-11	Tonsillectomy;
UCEC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-7.56	-0.53	3.93e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.9	-9.45	-0.61	7.51e-17	Urate levels;
UCEC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.77	-7.42	-0.52	8.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-4.58	-0.35	9.8200000000000008e-06	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg04607235	chr12:12878440	APOLD1	-0.98	-9.72	-0.63	1.51e-17	Lymphocyte counts;
UCEC	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.59	5.26	0.4	4.99e-7	Corneal astigmatism;
UCEC	cis	rs7611694	0.501	rs2895413	chr3:113037942	C/T	cg11138929	chr3:113251189	SIDT1	0.44	5.18	0.39	7.32e-7	Prostate cancer;
UCEC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.59	5.44	0.41	2.14e-7	Type 2 diabetes;
UCEC	cis	rs8010715	0.816	rs8015168	chr14:24599872	A/T	cg20933586	chr14:24608199	FAM158A	0.38	4.79	0.37	3.97e-6	IgG glycosylation;
UCEC	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.12e-18	Height;
UCEC	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.46	-4.83	-0.37	3.43e-6	Schizophrenia;
UCEC	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	0.96	8.05	0.55	2.64e-13	Opioid sensitivity;
UCEC	cis	rs7246967	0.866	rs438972	chr19:23019827	A/G	cg24889512	chr19:22816950	ZNF492	0.49	5.07	0.39	1.17e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.89	9.21	0.61	3.02e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-4.51	-0.35	1.31e-5	Longevity;
UCEC	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.76	-0.37	4.54e-6	Parkinson's disease;
UCEC	cis	rs3762637	0.943	rs9841897	chr3:122282569	T/C	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.51	-4.94	-0.38	2.08e-6	Coronary artery disease;
UCEC	cis	rs787274	0.543	rs10759590	chr9:115610567	G/C	cg13803584	chr9:115635662	SNX30	-0.71	-4.61	-0.36	8.78e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg04756594	chr16:24857601	SLC5A11	0.63	4.85	0.37	3.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg24163568	chr5:669837	TPPP	-0.44	-5.64	-0.42	8.28e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.21	-0.39	6.25e-7	Depression;
UCEC	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	6.02	0.44	1.31e-8	Monocyte percentage of white cells;
UCEC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.59	4.89	0.37	2.65e-6	Mean platelet volume;
UCEC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.75	-9.97	-0.64	3.4e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.89	11.57	0.69	2.08e-22	Metabolic syndrome;
UCEC	cis	rs4774899	0.869	rs2733174	chr15:57331666	C/T	cg04891611	chr15:57618705	NA	0.36	4.63	0.36	7.92e-6	Urinary tract infection frequency;
UCEC	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.31	-0.4	3.92e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.66	6.85	0.49	1.9e-10	Response to diuretic therapy;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg09682330	chr6:28411287	ZSCAN23	0.52	6.22	0.46	4.93e-9	Pubertal anthropometrics;
UCEC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.38	-0.41	2.82e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.69	-5.71	-0.43	6.06e-8	Menopause (age at onset);
UCEC	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.28	0.46	3.7e-9	Coffee consumption (cups per day);
UCEC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.63	5.66	0.42	7.63e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.74	0.7	7.26e-23	Chronic sinus infection;
UCEC	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg09654669	chr8:57350985	NA	-0.43	-4.62	-0.36	8.41e-6	Obesity-related traits;
UCEC	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.65	6.2	0.46	5.36e-9	Vitiligo;
UCEC	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.47	-5.71	-0.43	6.16e-8	Subjective well-being;
UCEC	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.81	6.4	0.47	1.92e-9	Lymphocyte counts;
UCEC	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.8	9.41	0.61	9.31e-17	Mortality in heart failure;
UCEC	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.65	7.3	0.52	1.64e-11	Resting heart rate;
UCEC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg24375607	chr4:120327624	NA	0.48	5.04	0.38	1.34e-6	Corneal astigmatism;
UCEC	cis	rs4713118	0.513	rs6915987	chr6:27515776	G/A	cg07836142	chr6:28411423	ZSCAN23	0.47	4.73	0.36	5.25e-6	Parkinson's disease;
UCEC	cis	rs4789452	1.000	rs35825162	chr17:75373188	G/A	cg21830368	chr17:75373327	SEPT9	-0.31	-4.85	-0.37	3.06e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-8.77	-0.59	4.06e-15	Vitiligo;
UCEC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.14	0.51	3.99e-11	Tonsillectomy;
UCEC	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.64	6.27	0.46	3.87e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.48	4.67	0.36	6.81e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.63	-6.08	-0.45	9.7e-9	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.46	4.89	0.37	2.66e-6	Total body bone mineral density;
UCEC	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-1.0	-12.18	-0.71	4.99e-24	Obesity-related traits;
UCEC	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	0.51	4.59	0.35	9.62e-6	Pulmonary function decline;
UCEC	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg04310649	chr10:35416472	CREM	-0.49	-4.88	-0.37	2.7e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg26781129	chr3:44753946	ZNF502	0.5	5.52	0.41	1.51e-7	Depressive symptoms;
UCEC	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.57	-6.61	-0.48	6.5e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2288327	0.778	rs6755456	chr2:179562140	T/C	cg09915519	chr2:179397513	TTN;MIR548N	-0.64	-4.63	-0.36	7.92e-6	Atrial fibrillation;
UCEC	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.51	5.09	0.39	1.08e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.77	10.69	0.66	4.4e-20	Vitiligo;
UCEC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.63	4.53	0.35	1.19e-5	Gut microbiome composition (summer);
UCEC	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg01083584	chr19:14629193	DNAJB1	0.66	7.01	0.5	7.99e-11	Schizophrenia;
UCEC	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-22.92	-0.88	2.24e-50	Myeloid white cell count;
UCEC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.81	-0.37	3.75e-6	Parkinson's disease;
UCEC	cis	rs1372436	0.557	rs115324377	chr2:151187070	T/C	cg25300694	chr2:151184358	NA	-0.69	-4.74	-0.36	5.02e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
UCEC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.63	-0.36	8.13e-6	Breast cancer;
UCEC	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.85	-0.43	3.02e-8	Response to antipsychotic treatment;
UCEC	cis	rs514475	1.000	rs514475	chr6:138038905	A/C	cg24324628	chr6:138866882	NHSL1	0.75	4.68	0.36	6.55e-6	Inflammatory skin disease;
UCEC	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.57	0.42	1.18e-7	Monocyte percentage of white cells;
UCEC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.67	-6.81	-0.49	2.35e-10	Lymphocyte counts;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg21795699	chr17:15903687	ZSWIM7;TTC19	0.65	6.7	0.48	4.11e-10	Triglyceride levels;
UCEC	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg21419209	chr3:44054225	NA	-0.48	-5.09	-0.39	1.08e-6	Coronary artery disease;
UCEC	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.4	-5.25	-0.4	5.35e-7	Monocyte count;
UCEC	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.76	8.94	0.59	1.52e-15	Crohn's disease;
UCEC	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.52	-4.79	-0.37	4.04e-6	Morning vs. evening chronotype;
UCEC	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg14210321	chr2:106509881	NCK2	-0.47	-4.54	-0.35	1.17e-5	Addiction;
UCEC	cis	rs28735056	0.596	rs4799106	chr18:77671112	G/A	cg20368463	chr18:77673604	PQLC1	-0.74	-7.08	-0.5	5.59e-11	Schizophrenia;
UCEC	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.54	6.96	0.5	1.02e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.74	5.03	0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.72	-7.85	-0.54	8.14e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg14067834	chr17:29058358	SUZ12P	0.64	4.6	0.35	9.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg08250081	chr4:10125330	NA	0.47	4.62	0.36	8.15e-6	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs6876348	0.564	rs2577427	chr5:128311818	C/T	cg02841155	chr5:128301328	SLC27A6	-0.35	-4.54	-0.35	1.17e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-5.02	-0.38	1.45e-6	Prostate cancer;
UCEC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.47	-5.32	-0.4	3.86e-7	Rheumatoid arthritis;
UCEC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.87	9.73	0.63	1.44e-17	Cognitive function;
UCEC	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs9467773	1.000	rs12663883	chr6:26577326	C/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.58	7.05	0.5	6.56e-11	Menopause (age at onset);
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg25202407	chr1:205417560	MIR135B	0.38	4.77	0.37	4.35e-6	Menarche (age at onset);
UCEC	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.67	6.54	0.47	9.56e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs78487399	0.808	rs12105786	chr2:43676433	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg06238570	chr21:40685208	BRWD1	-0.65	-7.28	-0.51	1.86e-11	Menarche (age at onset);
UCEC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.55	6.18	0.45	5.87e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.56	-5.04	-0.38	1.37e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.6	-4.85	-0.37	3.09e-6	Coronary artery calcification;
UCEC	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg26781129	chr3:44753946	ZNF502	-0.41	-4.53	-0.35	1.21e-5	Depressive symptoms;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.5	4.62	0.36	8.15e-6	Gestational age at birth (maternal effect);
UCEC	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.91	-11.79	-0.7	5.2e-23	Height;
UCEC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs7246967	0.611	rs7250285	chr19:22837108	C/T	cg05241461	chr19:22816980	ZNF492	0.56	6.03	0.45	1.25e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.89	-10.88	-0.67	1.4e-20	Schizophrenia;
UCEC	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-4.51	-0.35	1.3e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18932078	chr1:2524107	MMEL1	0.34	5.57	0.42	1.16e-7	Multiple sclerosis;
UCEC	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.67	-7.3	-0.52	1.71e-11	Coronary artery disease;
UCEC	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.27	0.56	7.48e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.69	5.72	0.43	5.74e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.53	-5.73	-0.43	5.48e-8	Coronary artery disease;
UCEC	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg20387954	chr3:183756860	HTR3D	0.5	6.02	0.44	1.31e-8	Anterior chamber depth;
UCEC	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.6	0.48	6.88e-10	Bladder cancer;
UCEC	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.43	4.82	0.37	3.49e-6	Electroencephalogram traits;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.34	-0.4	3.49e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg23625390	chr15:77176239	SCAPER	-0.67	-5.82	-0.43	3.62e-8	Blood metabolite levels;
UCEC	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.45	5.06	0.39	1.23e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.51	-4.65	-0.36	7.31e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.68	-8.02	-0.55	3.13e-13	Headache;
UCEC	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.6	4.77	0.37	4.35e-6	Corneal astigmatism;
UCEC	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.9	-6.75	-0.49	3.2e-10	Exhaled nitric oxide output;
UCEC	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18932078	chr1:2524107	MMEL1	-0.35	-6.13	-0.45	7.85e-9	Ulcerative colitis;
UCEC	cis	rs731174	0.802	rs504518	chr1:38182333	G/T	cg12339802	chr1:38156545	C1orf109	-0.57	-4.83	-0.37	3.46e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs2147959	0.941	rs4653960	chr1:228631719	T/C	cg00655913	chr1:228633920	NA	0.49	4.99	0.38	1.7e-6	Adult asthma;
UCEC	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg12310025	chr6:25882481	NA	-0.59	-4.64	-0.36	7.69e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.94	0.44	1.99e-8	Coffee consumption (cups per day);
UCEC	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.49	-5.3	-0.4	4.18e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg17470449	chr10:769945	NA	-0.47	-4.65	-0.36	7.25e-6	Uric acid levels;
UCEC	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	4.76	0.37	4.6e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.56	6.36	0.46	2.41e-9	Aortic root size;
UCEC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-5.46	-0.41	1.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg03146154	chr1:46216737	IPP	0.44	4.61	0.36	8.5e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	8.46	0.57	2.4e-14	Post bronchodilator FEV1;
UCEC	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.67	5.96	0.44	1.75e-8	Coronary artery disease;
UCEC	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.8	8.56	0.58	1.38e-14	Blood protein levels;
UCEC	cis	rs10924970	0.649	rs1933247	chr1:235432767	A/G	cg26050004	chr1:235667680	B3GALNT2	0.54	4.88	0.37	2.75e-6	Asthma;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11668638	chr6:42952412	PPP2R5D	0.58	7.35	0.52	1.28e-11	Warfarin maintenance dose;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.58	-6.1	-0.45	8.95e-9	Parkinson's disease;
UCEC	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.46	4.78	0.37	4.27e-6	Total body bone mineral density;
UCEC	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	5.75	0.43	4.88e-8	Colorectal cancer;
UCEC	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.59	4.62	0.36	8.29e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.51	4.92	0.38	2.33e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg00280220	chr17:61926910	NA	0.38	4.51	0.35	1.31e-5	Prudent dietary pattern;
UCEC	cis	rs2410182	0.615	rs463943	chr21:41188003	T/C	cg06560309	chr21:40720186	HMGN1	0.58	4.88	0.37	2.69e-6	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs7211029	1.000	rs9907432	chr17:77140372	G/A	cg14870271	chr17:76976010	LGALS3BP	-0.43	-4.62	-0.36	8.34e-6	Sleep latency;
UCEC	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.53	-4.98	-0.38	1.77e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.5	4.75	0.36	4.83e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg00339695	chr16:24857497	SLC5A11	-0.52	-5.96	-0.44	1.77e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.9	-8.8	-0.59	3.51e-15	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.57	-6.44	-0.47	1.61e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg19784848	chr5:219127	SDHA;CCDC127	-0.6	-4.95	-0.38	1.98e-6	Breast cancer;
UCEC	cis	rs9463078	0.764	rs2396370	chr6:44946472	A/G	cg25276700	chr6:44698697	NA	-0.45	-5.08	-0.39	1.1e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg19678392	chr7:94953810	PON1	-0.58	-5.7	-0.43	6.45e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-5.82	-0.43	3.52e-8	Longevity;
UCEC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.95	10.87	0.67	1.41e-20	Breast cancer;
UCEC	cis	rs10242455	0.557	rs73401516	chr7:99068351	C/A	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.85e-6	Blood metabolite levels;
UCEC	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.03	0.38	1.4e-6	Rheumatoid arthritis;
UCEC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.56	-0.35	1.07e-5	Parkinson's disease;
UCEC	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.48	4.75	0.36	4.77e-6	Blood metabolite levels;
UCEC	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.5	5.15	0.39	8.16e-7	Coronary heart disease;
UCEC	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.72	7.43	0.52	8.25e-12	Post bronchodilator FEV1;
UCEC	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.1	0.39	1.01e-6	Personality dimensions;
UCEC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.45	-5.51	-0.41	1.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.5	-4.54	-0.35	1.17e-5	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.71e-6	Breast cancer;
UCEC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.51	4.69	0.36	6.25e-6	Menopause (age at onset);
UCEC	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.71	7.4	0.52	9.9e-12	Breast cancer;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.54	-6.02	-0.44	1.35e-8	Pubertal anthropometrics;
UCEC	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg04025307	chr7:1156635	C7orf50	0.8	5.34	0.4	3.52e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.84	-9.49	-0.62	5.88e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg23625390	chr15:77176239	SCAPER	-0.67	-7.54	-0.53	4.58e-12	Blood metabolite levels;
UCEC	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs12681287	0.752	rs4288357	chr8:87251833	C/T	cg27223183	chr8:87520930	FAM82B	-0.57	-4.64	-0.36	7.72e-6	Caudate activity during reward;
UCEC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.82	8.07	0.55	2.29e-13	Cognitive function;
UCEC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.64	6.32	0.46	2.99e-9	Sudden cardiac arrest;
UCEC	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-9.4	-0.61	1.02e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-7.04	-0.5	7e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-6.0	-0.44	1.49e-8	Prudent dietary pattern;
UCEC	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.57	-5.12	-0.39	9.56e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.67	-4.78	-0.37	4.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.58	5.94	0.44	1.96e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.66	-7.71	-0.54	1.73e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg20701182	chr2:24300061	SF3B14	0.54	4.6	0.35	9.1e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.85	-8.92	-0.59	1.68e-15	Prudent dietary pattern;
UCEC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg02527881	chr3:46936655	PTH1R	-0.38	-4.77	-0.37	4.4e-6	Colorectal cancer;
UCEC	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.53	5.13	0.39	9.16e-7	Uric acid levels;
UCEC	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	6.37	0.47	2.27e-9	Multiple sclerosis;
UCEC	cis	rs117623576	0.941	rs16932939	chr10:32407862	T/C	cg03047570	chr10:32398778	NA	-0.57	-5.16	-0.39	7.79e-7	Anti-saccade response;
UCEC	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.69	5.74	0.43	5.3e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs4713118	0.666	rs4140646	chr6:27738801	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-4.52	-0.35	1.28e-5	Parkinson's disease;
UCEC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.66	6.1	0.45	8.81e-9	Menarche (age at onset);
UCEC	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.7	-8.11	-0.56	1.86e-13	Lung cancer;
UCEC	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg04154034	chr17:28927549	LRRC37B2	0.97	5.06	0.39	1.24e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.48	4.85	0.37	3.1e-6	Monocyte count;
UCEC	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg01689657	chr7:91764605	CYP51A1	0.46	5.77	0.43	4.48e-8	Breast cancer;
UCEC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.87	9.52	0.62	4.93e-17	Psoriasis;
UCEC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.79	0.43	4.18e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs36051895	0.587	rs7019418	chr9:5259847	G/C	cg02405213	chr9:5042618	JAK2	-0.46	-4.53	-0.35	1.21e-5	Pediatric autoimmune diseases;
UCEC	cis	rs6893807	0.778	rs1501673	chr5:87963600	G/A	cg09002922	chr5:87956389	LOC645323	-0.59	-5.65	-0.42	8.2e-8	Body mass index;
UCEC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.18	0.45	6.01e-9	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.03	0.38	1.4e-6	Breast cancer;
UCEC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg22907277	chr7:1156413	C7orf50	0.87	5.03	0.38	1.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6446731	0.593	rs7656026	chr4:3273625	G/C	cg08886695	chr4:3369023	RGS12	-0.47	-5.46	-0.41	2.03e-7	Mean platelet volume;
UCEC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-6.78	-0.49	2.76e-10	Fibrinogen levels;
UCEC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg00083072	chr11:65415190	SIPA1	0.49	5.12	0.39	9.55e-7	Acne (severe);
UCEC	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	4.63	0.36	8.08e-6	Educational attainment;
UCEC	cis	rs7597155	0.819	rs6750104	chr2:69970120	C/T	cg02498382	chr2:70120550	SNRNP27	-0.51	-5.4	-0.41	2.67e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.73	0.36	5.12e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.48	5.57	0.42	1.17e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg23795048	chr12:9217529	LOC144571	0.39	4.82	0.37	3.52e-6	Sjögren's syndrome;
UCEC	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.27	-0.4	4.82e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7074356	0.522	rs1591958	chr10:82062661	G/A	cg01528321	chr10:82214614	TSPAN14	0.5	4.58	0.35	9.98e-6	Borderline personality disorder;
UCEC	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.1	9.19	0.6	3.4e-16	Vitiligo;
UCEC	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.68	-7.4	-0.52	9.5e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.38	0.76	7.94e-30	Homoarginine levels;
UCEC	cis	rs7633770	0.931	rs12637421	chr3:46695074	T/C	cg11219411	chr3:46661640	NA	0.54	6.21	0.46	5.25e-9	Coronary artery disease;
UCEC	cis	rs12086130	0.881	rs77603669	chr1:51423779	G/T	cg07174182	chr1:51127561	FAF1	-0.83	-5.26	-0.4	4.96e-7	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.53	5.49	0.41	1.7e-7	Diastolic blood pressure;
UCEC	trans	rs925228	0.793	rs6545184	chr2:24175914	A/T	cg18674340	chr17:45867686	NA	0.71	6.68	0.48	4.58e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7336933	0.866	rs7332372	chr13:42465490	C/T	cg18400088	chr13:41634674	WBP4	0.55	4.71	0.36	5.74e-6	Calcium levels;
UCEC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	ch.11.42038R	chr11:967971	AP2A2	0.39	4.56	0.35	1.08e-5	Alzheimer's disease (late onset);
UCEC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg18279126	chr7:2041391	MAD1L1	-0.43	-5.27	-0.4	4.82e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.67	-5.72	-0.43	5.65e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-8.55	-0.58	1.47e-14	Menarche (age at onset);
UCEC	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg22598563	chr5:131563921	P4HA2	0.34	4.53	0.35	1.23e-5	Blood metabolite levels;
UCEC	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.06	8.15	0.56	1.47e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg06784218	chr1:46089804	CCDC17	-0.53	-6.18	-0.45	6.02e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.55	4.85	0.37	3.05e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	8.36	0.57	4.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.51	-5.44	-0.41	2.22e-7	Alcohol dependence;
UCEC	cis	rs17433710	0.500	rs10494374	chr1:162630958	A/C	cg19264028	chr1:162630153	DDR2	-0.75	-5.98	-0.44	1.66e-8	Dupuytren's disease;
UCEC	cis	rs59104589	0.617	rs73002114	chr2:242280924	G/A	cg19488206	chr2:242435732	STK25	0.53	4.76	0.37	4.53e-6	Fibrinogen levels;
UCEC	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.23	0.46	4.74e-9	Coffee consumption (cups per day);
UCEC	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.68	-7.39	-0.52	1e-11	Waist circumference;Body mass index;
UCEC	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.53	6.17	0.45	6.28e-9	Platelet count;
UCEC	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg19926144	chr10:661009	DIP2C	0.81	4.77	0.37	4.32e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg23793686	chr15:68133972	NA	-0.43	-4.57	-0.35	1.02e-5	Restless legs syndrome;
UCEC	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-7.46	-0.52	6.9e-12	Personality dimensions;
UCEC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.49	5.56	0.42	1.21e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.69	7.78	0.54	1.15e-12	Mortality in heart failure;
UCEC	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.69	-7.9	-0.55	5.86e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg12024160	chr4:1254474	NA	0.71	8.9	0.59	1.93e-15	Obesity-related traits;
UCEC	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.64	5.88	0.44	2.7e-8	Schizophrenia;
UCEC	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.73	-7.36	-0.52	1.18e-11	Plateletcrit;Platelet count;
UCEC	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13939156	chr17:80058883	NA	-0.36	-4.6	-0.35	9.18e-6	Life satisfaction;
UCEC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg03146154	chr1:46216737	IPP	0.44	4.61	0.36	8.53e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	8.13	0.56	1.66e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.52	5.77	0.43	4.46e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.51	-5.11	-0.39	1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.83	7.76	0.54	1.34e-12	Diastolic blood pressure;
UCEC	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	5.04	0.38	1.36e-6	Neuroticism;
UCEC	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.99	-0.44	1.54e-8	Mood instability;
UCEC	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.52	-5.37	-0.4	3.02e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.6	-4.75	-0.36	4.73e-6	Exhaled nitric oxide output;
UCEC	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	8.08	0.55	2.12e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg21053147	chr12:120880522	NA	-0.66	-5.45	-0.41	2.11e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg09910674	chr16:89028015	CBFA2T3	0.6	4.61	0.36	8.71e-6	Skin colour saturation;
UCEC	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.72	-8.3	-0.57	6.1e-14	Waist circumference;Body mass index;
UCEC	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.66	-4.57	-0.35	1.03e-5	Mean platelet volume;
UCEC	cis	rs834603	0.965	rs834601	chr7:47445812	T/C	cg23694490	chr7:47445681	TNS3	-0.33	-5.19	-0.39	7e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.75	-0.49	3.15e-10	Pubertal anthropometrics;
UCEC	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.72	6.25	0.46	4.28e-9	Coronary artery disease;
UCEC	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs10924970	0.649	rs12760850	chr1:235405245	C/G	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.64	5.87	0.44	2.83e-8	Corneal astigmatism;
UCEC	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.42	-4.65	-0.36	7.46e-6	Height;
UCEC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg03354898	chr7:1950403	MAD1L1	-0.55	-5.33	-0.4	3.58e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.75	-7.69	-0.54	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs853679	0.567	rs6905380	chr6:28374902	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.72	-0.36	5.51e-6	Depression;
UCEC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.67	-6.29	-0.46	3.47e-9	Aortic root size;
UCEC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.83	5.38	0.41	2.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.57	-5.86	-0.44	2.96e-8	Blood protein levels;
UCEC	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.43	4.76	0.37	4.51e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.41	-4.97	-0.38	1.84e-6	Eotaxin levels;
UCEC	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.44	-5.29	-0.4	4.29e-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.77	-7.37	-0.52	1.12e-11	Schizophrenia;
UCEC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg00105475	chr2:10696890	NA	0.45	5.5	0.41	1.64e-7	Prostate cancer;
UCEC	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.51	-0.35	1.32e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs787274	1.000	rs787280	chr9:115539085	C/T	cg13803584	chr9:115635662	SNX30	-0.68	-5.48	-0.41	1.79e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.49	5.01	0.38	1.56e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	5.92	0.44	2.17e-8	Initial pursuit acceleration;
UCEC	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.6	6.68	0.48	4.65e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6876348	0.598	rs1898550	chr5:128285661	C/T	cg02841155	chr5:128301328	SLC27A6	-0.38	-5.3	-0.4	4.18e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.01	-0.44	1.39e-8	Response to antipsychotic treatment;
UCEC	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.66	9.48	0.62	6.07e-17	Total body bone mineral density;
UCEC	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.48	5.58	0.42	1.11e-7	Caffeine consumption;
UCEC	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.73	7.1	0.51	4.86e-11	Smoking behavior;
UCEC	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.74	-0.43	5.34e-8	Blood metabolite levels;
UCEC	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.58	-5.12	-0.39	9.24e-7	Metabolite levels;
UCEC	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.79	-7.58	-0.53	3.51e-12	Blood metabolite levels;
UCEC	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.66	-7.04	-0.5	6.99e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.5	5.0	0.38	1.64e-6	Vitamin D levels;
UCEC	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.64	7.04	0.5	7.01e-11	Longevity;Endometriosis;
UCEC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.49	4.9	0.37	2.51e-6	Vitiligo;
UCEC	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.21	-0.46	5.1e-9	Crohn's disease;
UCEC	cis	rs7246967	0.673	rs12980342	chr19:22849357	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg18279126	chr7:2041391	MAD1L1	0.38	4.53	0.35	1.22e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.7	-0.54	1.88e-12	Acylcarnitine levels;
UCEC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg26061582	chr7:22766209	IL6	-0.54	-5.36	-0.4	3.09e-7	Lung cancer;
UCEC	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-4.73	-0.36	5.22e-6	Type 2 diabetes;
UCEC	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.51	6.75	0.49	3.11e-10	Bone mineral density;
UCEC	cis	rs7246967	0.673	rs9677019	chr19:22912659	T/C	cg08271804	chr19:22816896	ZNF492	0.66	6.39	0.47	2.08e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12980942	0.872	rs12974420	chr19:41798660	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.82	6.43	0.47	1.64e-9	Coronary artery disease;
UCEC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg18755752	chr8:142205143	DENND3	-0.57	-5.14	-0.39	8.49e-7	Immature fraction of reticulocytes;
UCEC	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.54	-4.93	-0.38	2.18e-6	Menarche (age at onset);
UCEC	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg05072774	chr3:49840536	C3orf54	-0.54	-5.59	-0.42	1.09e-7	Resting heart rate;
UCEC	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.69	-5.21	-0.4	6.17e-7	Initial pursuit acceleration;
UCEC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg00815214	chr21:47717953	NA	-0.41	-4.64	-0.36	7.62e-6	Testicular germ cell tumor;
UCEC	cis	rs73416724	1.000	rs112870457	chr6:43280714	T/G	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs259282	0.605	rs35728696	chr19:33108096	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.55	5.03	0.38	1.41e-6	Schizophrenia;
UCEC	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.53	4.97	0.38	1.84e-6	Systemic lupus erythematosus;
UCEC	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.73	-7.76	-0.54	1.28e-12	Blood protein levels;
UCEC	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg04837898	chr3:45731254	SACM1L	-0.4	-4.53	-0.35	1.19e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs12681287	0.752	rs10085920	chr8:87252666	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-5.34	-0.4	3.48e-7	Caudate activity during reward;
UCEC	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.85	-9.24	-0.61	2.61e-16	Ulcerative colitis;
UCEC	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.69	7.89	0.55	6.33e-13	Menopause (age at onset);
UCEC	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4499344	0.730	rs434020	chr19:33104070	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.41e-9	Mean platelet volume;
UCEC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.98	12.64	0.72	2.92e-25	Breast cancer;
UCEC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.82	7.28	0.51	1.87e-11	Longevity;
UCEC	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.61	-5.13	-0.39	9.21e-7	Coronary artery calcification;
UCEC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.49	4.51	0.35	1.34e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.77	-7.04	-0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs732765	0.734	rs28470774	chr14:75186907	C/T	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs10242455	0.702	rs116671616	chr7:98954558	C/T	cg18809830	chr7:99032528	PTCD1	-0.88	-4.64	-0.36	7.53e-6	Blood metabolite levels;
UCEC	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.59	6.59	0.48	7.25e-10	Crohn's disease;
UCEC	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-1.09	-9.55	-0.62	4.07e-17	Dupuytren's disease;
UCEC	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.57	6.49	0.47	1.22e-9	Crohn's disease;
UCEC	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.68	-0.36	6.51e-6	Monocyte percentage of white cells;
UCEC	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.84	8.12	0.56	1.74e-13	Blood protein levels;
UCEC	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.65	8.12	0.56	1.75e-13	Bone mineral density;
UCEC	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.67	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg04141460	chr1:224302109	FBXO28	0.59	6.69	0.48	4.3e-10	N-glycan levels;
UCEC	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.44	-5.11	-0.39	9.67e-7	Subjective well-being;
UCEC	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.72	-9.53	-0.62	4.57e-17	Height;
UCEC	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg10978503	chr1:24200527	CNR2	0.37	4.89	0.37	2.6e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.15	14.53	0.77	3.22e-30	Cognitive function;
UCEC	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.33	-0.46	2.81e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.52	5.4	0.41	2.57e-7	Height;
UCEC	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-7.95	-0.55	4.57e-13	Total cholesterol levels;
UCEC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.36	-5.81	-0.43	3.81e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.62	-0.42	9.24e-8	Fear of minor pain;
UCEC	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.51	4.61	0.36	8.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.78	-8.96	-0.59	1.35e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	4.95	0.38	1.99e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.33	-5.4	-0.41	2.61e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.29	-0.46	3.42e-9	Pulmonary function;
UCEC	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.48	4.67	0.36	6.64e-6	Diastolic blood pressure;
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.57	-6.73	-0.49	3.58e-10	Monocyte percentage of white cells;
UCEC	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.55	6.15	0.45	7.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.95	-7.32	-0.52	1.5e-11	Exhaled nitric oxide output;
UCEC	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.57	-4.68	-0.36	6.57e-6	Menopause (age at onset);
UCEC	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.47	-4.68	-0.36	6.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.47	4.93	0.38	2.21e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	1.11	13.13	0.73	1.47e-26	Post bronchodilator FEV1;
UCEC	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.52	-0.41	1.47e-7	Fear of minor pain;
UCEC	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.83	-10.87	-0.67	1.45e-20	White blood cell count (basophil);
UCEC	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	5.01	0.38	1.51e-6	Response to antipsychotic treatment;
UCEC	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.53	-6.06	-0.45	1.08e-8	Educational attainment;
UCEC	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.83	-0.37	3.42e-6	Fear of minor pain;
UCEC	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.52	-5.19	-0.39	6.8e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg03342759	chr3:160939853	NMD3	-0.6	-5.83	-0.43	3.46e-8	Kawasaki disease;
UCEC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg13395646	chr4:1353034	KIAA1530	-0.78	-6.91	-0.5	1.37e-10	Obesity-related traits;
UCEC	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-4.73	-0.36	5.32e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.44	-4.88	-0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10431058	0.930	rs7948142	chr11:107478703	T/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.49	4.81	0.37	3.75e-6	Common traits (Other);
UCEC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.2	0.56	1.07e-13	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.0	0.5	8.45e-11	Morning vs. evening chronotype;
UCEC	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-4.7	-0.36	5.96e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs12039431	0.746	rs61776184	chr1:38008523	C/T	cg17933807	chr1:38061675	GNL2	-0.53	-4.65	-0.36	7.27e-6	Epithelial ovarian cancer;
UCEC	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.96	-0.44	1.83e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-5.26	-0.4	5.1e-7	Life satisfaction;
UCEC	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	5.98	0.44	1.61e-8	Alzheimer's disease;
UCEC	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.47	-4.77	-0.37	4.38e-6	Neuroticism;
UCEC	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.85	-10.37	-0.65	2.93e-19	Coronary artery disease;
UCEC	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.62	-5.05	-0.38	1.27e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs4615376	0.950	rs4379290	chr6:13045015	G/T	cg11378619	chr6:12164359	HIVEP1	0.59	4.57	0.35	1.03e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs829661	1.000	rs829672	chr2:30712016	C/T	cg17749961	chr2:30669863	LCLAT1	0.51	4.76	0.37	4.67e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.73	7.93	0.55	5.14e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg03146154	chr1:46216737	IPP	-0.48	-5.09	-0.39	1.09e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.94	9.29	0.61	1.9e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.8	7.78	0.54	1.19e-12	Selective IgA deficiency;
UCEC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.59	4.95	0.38	2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.53	5.2	0.39	6.61e-7	Lymphocyte counts;
UCEC	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.53	-5.25	-0.4	5.22e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.45	5.79	0.43	4.19e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg14092571	chr14:90743983	NA	-0.42	-5.65	-0.42	8.07e-8	Mortality in heart failure;
UCEC	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.49	4.54	0.35	1.18e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg24851651	chr11:66362959	CCS	-0.41	-5.17	-0.39	7.5e-7	Educational attainment (years of education);
UCEC	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.69	0.42	6.59e-8	Colorectal cancer;
UCEC	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.76	7.28	0.51	1.91e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.88	9.67	0.62	2.01e-17	Breast cancer;
UCEC	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.52	-5.77	-0.43	4.47e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	0.68	7.45	0.52	7.3e-12	Homoarginine levels;
UCEC	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.41	5.33	0.4	3.65e-7	Blood protein levels;
UCEC	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs9309473	0.950	rs10206899	chr2:73900900	T/C	cg20560298	chr2:73613845	ALMS1	-0.52	-4.62	-0.36	8.2e-6	Metabolite levels;
UCEC	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.51	5.32	0.4	3.87e-7	Mean corpuscular hemoglobin;
UCEC	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.74	8.25	0.56	8.45e-14	Coronary artery disease;
UCEC	cis	rs7709377	0.553	rs12332433	chr5:115465930	C/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	6.44	0.47	1.62e-9	Cognitive test performance;
UCEC	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.61	5.82	0.43	3.54e-8	Coronary artery disease;
UCEC	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7336933	0.866	rs9315872	chr13:42490008	T/C	cg18400088	chr13:41634674	WBP4	0.57	4.88	0.37	2.7e-6	Calcium levels;
UCEC	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg04662943	chr10:102668895	NA	0.48	4.74	0.36	4.9e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.79	-8.49	-0.57	2.11e-14	Morning vs. evening chronotype;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.68	8.31	0.57	5.7e-14	Menarche (age at onset);
UCEC	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg00105475	chr2:10696890	NA	0.42	5.17	0.39	7.53e-7	Prostate cancer;
UCEC	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.71	-5.43	-0.41	2.33e-7	White matter hyperintensity burden;
UCEC	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.76	8.73	0.58	5.01e-15	Menarche (age at onset);
UCEC	cis	rs7072216	0.881	rs755126	chr10:100148951	G/A	cg19567339	chr10:100142640	NA	0.62	8.8	0.59	3.46e-15	Metabolite levels;
UCEC	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.37	-0.4	3.02e-7	Bipolar disorder;
UCEC	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.51	4.81	0.37	3.68e-6	Coronary artery disease;
UCEC	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.78	0.49	2.67e-10	Cognitive ability;
UCEC	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.69	-6.78	-0.49	2.69e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.65	6.02	0.44	1.35e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	4.91	0.38	2.35e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.84	-9.16	-0.6	4.1e-16	Blood metabolite levels;
UCEC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.52	4.7	0.36	6.03e-6	Type 2 diabetes;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.67	8.03	0.55	2.87e-13	Menarche (age at onset);
UCEC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg09521647	chr2:100722408	AFF3	-0.33	-5.11	-0.39	9.72e-7	Chronic sinus infection;
UCEC	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.89	7.22	0.51	2.53e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs67145503	0.769	rs913987	chr9:130629139	G/T	cg11973688	chr9:130564956	FPGS	-0.51	-4.53	-0.35	1.19e-5	Hematocrit;Hemoglobin concentration;Red blood cell count;
UCEC	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.62	-5.35	-0.4	3.37e-7	Ulcerative colitis;
UCEC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07837209	chr13:79184101	NA	0.49	4.54	0.35	1.14e-5	Large artery stroke;
UCEC	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.48	-5.98	-0.44	1.6e-8	Mean platelet volume;
UCEC	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-4.73	-0.36	5.27e-6	Gut microbiome composition (summer);
UCEC	cis	rs953387	1.000	rs950176	chr2:136898078	A/G	cg07169764	chr2:136633963	MCM6	0.55	5.54	0.42	1.34e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.44	0.47	1.57e-9	Platelet count;
UCEC	cis	rs10127852	0.702	rs77881471	chr1:85319053	T/C	cg21422605	chr1:85313514	LPAR3	0.39	4.66	0.36	7.17e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.57	5.03	0.38	1.41e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg09165964	chr15:75287851	SCAMP5	0.49	5.4	0.41	2.62e-7	Caffeine consumption;
UCEC	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.55	5.23	0.4	5.79e-7	Lung cancer;
UCEC	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	0.92	12.97	0.73	4.05e-26	Homoarginine levels;
UCEC	cis	rs2892463	0.565	rs4297554	chr13:30370452	C/A	cg10211454	chr13:31195985	USPL1	0.4	4.59	0.35	9.58e-6	Non-word repetition;
UCEC	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg07153921	chr17:41440717	NA	0.57	6.34	0.46	2.61e-9	Menopause (age at onset);
UCEC	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.65	4.8	0.37	3.94e-6	Multiple sclerosis;
UCEC	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.65	0.36	7.34e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	6.03	0.45	1.28e-8	Response to antipsychotic treatment;
UCEC	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.6	5.59	0.42	1.08e-7	Corneal astigmatism;
UCEC	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.14	5.99	0.44	1.57e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.62	0.48	6.39e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.43	6.37	0.47	2.3e-9	Crohn's disease;
UCEC	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg12560992	chr17:57184187	TRIM37	-0.72	-7.75	-0.54	1.36e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.46	-5.01	-0.38	1.51e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.11	14.03	0.76	6.67e-29	Cognitive function;
UCEC	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg12870014	chr12:110450643	ANKRD13A	0.67	5.56	0.42	1.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	0.87	7.63	0.53	2.72e-12	Nonalcoholic fatty liver disease;
UCEC	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.53	0.41	1.43e-7	Rheumatoid arthritis;
UCEC	cis	rs735860	0.726	rs209500	chr6:53188137	A/C	cg10236188	chr6:53219634	NA	-0.46	-4.72	-0.36	5.44e-6	Glaucoma;
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	8.63	0.58	9.3e-15	Platelet count;
UCEC	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg01551729	chr5:1099476	SLC12A7	0.51	4.72	0.36	5.41e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.38	-0.41	2.94e-7	Bipolar disorder;
UCEC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.09	9.99	0.64	3.03e-18	Vitiligo;
UCEC	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.51	5.94	0.44	1.96e-8	Aortic root size;
UCEC	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.74	7.13	0.51	4.1e-11	Menopause (age at onset);
UCEC	cis	rs782107	0.614	rs1729790	chr12:58750741	C/G	cg19181132	chr12:59314527	LRIG3	0.47	4.98	0.38	1.73e-6	Interleukin-12p70 levels;
UCEC	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.1	18.4	0.84	5.6e-40	IgG glycosylation;
UCEC	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.75	-7.85	-0.54	7.83e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.67	-5.94	-0.44	1.99e-8	Neuroticism;
UCEC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.51	-4.69	-0.36	6.2e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.51	-5.26	-0.4	5e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs925550	0.932	rs6821165	chr4:123609808	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.74	-6.61	-0.48	6.6e-10	Primary biliary cholangitis;
UCEC	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.7	6.71	0.48	3.97e-10	Vitamin D levels;
UCEC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.69	-8.59	-0.58	1.15e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	4.89	0.37	2.67e-6	Systolic blood pressure;
UCEC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs73206853	0.614	rs57154770	chr12:110814415	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	4.73	0.36	5.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs6437061	0.745	rs3116222	chr2:232873590	G/C	cg02061626	chr2:233274167	ALPPL2	-0.52	-5.69	-0.42	6.62e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.57	-5.74	-0.43	5.11e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg05991184	chr2:219186017	PNKD	0.5	5.41	0.41	2.45e-7	Colorectal cancer;
UCEC	cis	rs7307889	0.793	rs73047610	chr12:5996698	T/C	cg10294363	chr12:6480192	SCNN1A	0.6	4.65	0.36	7.32e-6	Obesity-related traits;
UCEC	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.51	5.83	0.43	3.35e-8	Dialysis-related mortality;
UCEC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg04154034	chr17:28927549	LRRC37B2	0.58	5.2	0.39	6.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.51	5.48	0.41	1.77e-7	Neuroticism;
UCEC	cis	rs223116	0.515	rs1555413	chr14:23964548	A/G	cg15440973	chr14:24610792	FAM158A	0.54	4.65	0.36	7.26e-6	Resting heart rate;
UCEC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg00083072	chr11:65415190	SIPA1	0.4	4.86	0.37	2.98e-6	Non-alcoholic fatty liver disease histology (lobular);
UCEC	cis	rs11697848	1.000	rs79598075	chr20:48562116	T/C	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs7267005	0.661	rs17093129	chr20:34427797	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-4.51	-0.35	1.3e-5	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.77	-6.13	-0.45	7.54e-9	Calcium levels;
UCEC	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.37	4.67	0.36	6.83e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26207909	chr14:103986467	CKB	-0.49	-5.27	-0.4	4.67e-7	Body mass index;
UCEC	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.48	-5.14	-0.39	8.47e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-4.91	-0.38	2.44e-6	Alzheimer's disease (late onset);
UCEC	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.64	7.06	0.5	6.25e-11	Menarche (age at onset);
UCEC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.71	7.96	0.55	4.32e-13	Menopause (age at onset);
UCEC	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.53	5.49	0.41	1.75e-7	Lymphocyte counts;
UCEC	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.38	-4.64	-0.36	7.75e-6	Longevity;
UCEC	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.68	-4.92	-0.38	2.29e-6	Prostate cancer;
UCEC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.74	-7.38	-0.52	1.08e-11	Caffeine consumption;
UCEC	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.74	7.78	0.54	1.17e-12	Breast cancer;
UCEC	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg07796016	chr1:152779584	LCE1C	-0.42	-4.71	-0.36	5.75e-6	Psoriasis;
UCEC	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg16797656	chr11:68205561	LRP5	0.48	5.31	0.4	3.96e-7	Total body bone mineral density;
UCEC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.13	0.64	1.29e-18	Cognitive ability;
UCEC	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg06970220	chr1:156163860	SLC25A44	0.46	4.84	0.37	3.2e-6	Testicular germ cell tumor;
UCEC	cis	rs12681287	0.752	rs10104242	chr8:87247714	G/C	cg27223183	chr8:87520930	FAM82B	-0.56	-4.73	-0.36	5.13e-6	Caudate activity during reward;
UCEC	cis	rs2708377	0.929	rs73053785	chr12:11162411	T/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.76	6.23	0.46	4.7e-9	Bitter taste perception;
UCEC	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg04553112	chr3:125709451	NA	-0.73	-5.09	-0.39	1.07e-6	Blood pressure (smoking interaction);
UCEC	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.75	-0.37	4.72e-6	Blood metabolite levels;
UCEC	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.59	-6.46	-0.47	1.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg14210321	chr2:106509881	NCK2	-0.48	-4.69	-0.36	6.3e-6	Addiction;
UCEC	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.69	-6.23	-0.46	4.66e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg24304712	chr1:244624785	C1orf101	-0.48	-4.5	-0.35	1.36e-5	RR interval (heart rate);
UCEC	cis	rs12928939	0.911	rs7202840	chr16:71824714	C/T	cg03805757	chr16:71968109	PKD1L3	-0.46	-4.67	-0.36	6.71e-6	Post bronchodilator FEV1;
UCEC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.53	5.01	0.38	1.57e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.62	7.04	0.5	6.73e-11	Metabolite levels;
UCEC	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.71	6.21	0.46	5.11e-9	Menopause (age at onset);
UCEC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	5.99	0.44	1.55e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.52	-5.15	-0.39	8.13e-7	Breast cancer;
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg01874867	chr7:94954059	PON1	-0.58	-5.35	-0.4	3.25e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	6.49	0.47	1.25e-9	Tonsillectomy;
UCEC	cis	rs4880487	0.924	rs10903404	chr10:1248591	C/A	cg03183215	chr10:1252341	ADARB2	-0.46	-5.39	-0.41	2.79e-7	Migraine;
UCEC	cis	rs858239	0.932	rs858275	chr7:23294144	T/C	cg25635316	chr7:23637023	CCDC126	-0.41	-4.55	-0.35	1.11e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.45	5.05	0.38	1.28e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	0.86	9.12	0.6	5.4e-16	Parkinson's disease;
UCEC	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.66	-4.67	-0.36	6.73e-6	LDL cholesterol levels;
UCEC	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg17085576	chr10:5658249	NA	-0.55	-5.68	-0.42	6.86e-8	Breast cancer;
UCEC	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.82	-8.15	-0.56	1.46e-13	Obesity-related traits;
UCEC	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.56	5.65	0.42	8.13e-8	Vitiligo;
UCEC	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-5.04	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.63	7.06	0.5	6.19e-11	Resting heart rate;
UCEC	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.61	7.12	0.51	4.54e-11	Hip circumference;
UCEC	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg22563815	chr15:78856949	CHRNA5	0.39	5.05	0.38	1.29e-6	Sudden cardiac arrest;
UCEC	cis	rs2075165	0.870	rs12128955	chr1:156243821	C/T	cg20302342	chr1:156215951	PAQR6	0.52	5.34	0.4	3.53e-7	Tonsillectomy;
UCEC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.37	-5.05	-0.38	1.28e-6	Prostate cancer;
UCEC	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg24562669	chr7:97807699	LMTK2	0.48	5.92	0.44	2.23e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg18099408	chr3:52552593	STAB1	0.42	4.88	0.37	2.76e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.65	0.36	7.19e-6	Breast cancer;
UCEC	cis	rs7709377	0.595	rs42959	chr5:115593966	C/G	cg23108291	chr5:115420582	COMMD10	0.47	4.54	0.35	1.15e-5	Metabolite levels  (X-11787);
UCEC	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.59	-6.05	-0.45	1.17e-8	White matter hyperintensity burden;
UCEC	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.86	-0.37	2.93e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.82	-0.37	3.48e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.69	4.87	0.37	2.9e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.64	5.91	0.44	2.31e-8	Corneal astigmatism;
UCEC	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.69	4.79	0.37	3.98e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg08501292	chr6:25962987	TRIM38	0.98	4.76	0.37	4.56e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg04682699	chr3:50248845	SLC38A3	0.41	4.65	0.36	7.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9470794	1.000	rs57995712	chr6:37988632	T/G	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg04310649	chr10:35416472	CREM	-0.48	-4.85	-0.37	3.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10924970	0.625	rs12044028	chr1:235492972	T/G	cg26050004	chr1:235667680	B3GALNT2	0.49	4.52	0.35	1.28e-5	Asthma;
UCEC	cis	rs9868873	1.000	rs7629297	chr3:122737178	A/T	cg02041593	chr3:122741233	SEMA5B	0.5	5.23	0.4	5.72e-7	Esophageal cancer;
UCEC	cis	rs7246967	0.673	rs34174596	chr19:22933519	G/A	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.62	6.41	0.47	1.84e-9	Retinal vascular caliber;
UCEC	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	0.88	5.43	0.41	2.23e-7	Blood protein levels;
UCEC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg04871131	chr7:94954202	PON1	-0.48	-4.53	-0.35	1.21e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.03	-5.52	-0.41	1.49e-7	Plateletcrit;
UCEC	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.52	-4.67	-0.36	6.67e-6	Colorectal cancer;
UCEC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.5	4.78	0.37	4.17e-6	Corneal astigmatism;
UCEC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.61	-5.53	-0.42	1.41e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg21231944	chr12:82153410	PPFIA2	-0.46	-5.32	-0.4	3.87e-7	Resting heart rate;
UCEC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	6.72	0.48	3.75e-10	Homoarginine levels;
UCEC	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.56	4.79	0.37	3.96e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.73	0.36	5.16e-6	Diabetic retinopathy;
UCEC	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg18099408	chr3:52552593	STAB1	0.44	4.94	0.38	2.07e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg19536664	chr17:6899085	ALOX12	0.4	4.95	0.38	2e-6	Tonsillectomy;
UCEC	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-4.87	-0.37	2.81e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12681287	0.752	rs4389908	chr8:87274852	A/G	cg27223183	chr8:87520930	FAM82B	-0.64	-5.38	-0.41	2.93e-7	Caudate activity during reward;
UCEC	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.64	7.01	0.5	7.81e-11	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg19760965	chr3:194868843	C3orf21	0.4	4.57	0.35	1.04e-5	Non-small cell lung cancer;
UCEC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.5	6.87	0.49	1.65e-10	Homoarginine levels;
UCEC	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	4.92	0.38	2.29e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg22974920	chr21:40686053	BRWD1	0.55	4.82	0.37	3.47e-6	Cognitive function;
UCEC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.67	5.42	0.41	2.38e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.68	-6.27	-0.46	3.86e-9	Colorectal cancer;
UCEC	cis	rs7246967	0.932	rs35968517	chr19:23027040	T/C	cg24889512	chr19:22816950	ZNF492	0.5	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	6.84	0.49	2.01e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3762637	0.943	rs7629285	chr3:122265739	A/G	cg24169773	chr3:122142474	KPNA1	0.65	4.63	0.36	8.02e-6	LDL cholesterol levels;
UCEC	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.79	8.22	0.56	9.7e-14	Caffeine consumption;
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-0.97	-5.15	-0.39	8.4e-7	Plateletcrit;
UCEC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.18	-0.39	7.23e-7	Bone mineral density;
UCEC	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs925228	0.955	rs2339886	chr2:24160642	G/T	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs77216612	0.877	rs66561220	chr12:12878765	T/C	cg04607235	chr12:12878440	APOLD1	-0.98	-9.9	-0.63	5.09e-18	Lymphocyte counts;
UCEC	cis	rs6446731	0.517	rs2858086	chr4:3270611	A/G	cg08886695	chr4:3369023	RGS12	0.43	4.91	0.38	2.4e-6	Mean platelet volume;
UCEC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg09655341	chr17:79618100	PDE6G	-0.32	-4.94	-0.38	2.1e-6	Eye color traits;
UCEC	cis	rs4588572	0.686	rs4352584	chr5:77682948	C/G	cg11547950	chr5:77652471	NA	0.49	5.38	0.41	2.86e-7	Triglycerides;
UCEC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	5.74	0.43	5.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	8.02	0.55	3.03e-13	Platelet count;
UCEC	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-0.97	-11.05	-0.67	4.71e-21	Blood pressure (smoking interaction);
UCEC	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg03342759	chr3:160939853	NMD3	0.52	4.8	0.37	3.85e-6	Morning vs. evening chronotype;
UCEC	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.76	-6.05	-0.45	1.13e-8	Schizophrenia;
UCEC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.34	0.46	2.72e-9	Tonsillectomy;
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.73	-8.25	-0.56	8.45e-14	Coronary artery disease;
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-5.03	-0.38	1.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.58	-7.68	-0.54	2.03e-12	Diabetic kidney disease;
UCEC	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg21905437	chr5:178450457	ZNF879	0.64	7.1	0.51	4.95e-11	Pubertal anthropometrics;
UCEC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.54	-0.35	1.19e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs713477	0.967	rs7146170	chr14:55914054	G/C	cg13175173	chr14:55914753	NA	-0.43	-4.78	-0.37	4.24e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.13	0.45	7.56e-9	Platelet count;
UCEC	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-5.65	-0.42	8.19e-8	Bipolar disorder;
UCEC	cis	rs7246967	0.673	rs16999580	chr19:22923487	C/T	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg07838603	chr6:28411030	ZSCAN23	0.47	5.33	0.4	3.68e-7	Cardiac Troponin-T levels;
UCEC	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	0.9	7.31	0.52	1.57e-11	Blood protein levels;
UCEC	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.47e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs17122693	0.748	rs61607560	chr14:51143649	C/T	cg04730355	chr14:51134070	SAV1	0.95	9.85	0.63	6.97e-18	Cognitive performance;
UCEC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.66	6.48	0.47	1.27e-9	Aortic root size;
UCEC	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg18681998	chr4:17616180	MED28	0.69	8.08	0.55	2.2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.44	4.51	0.35	1.34e-5	Brugada syndrome;
UCEC	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.44	4.8	0.37	3.94e-6	Mean corpuscular volume;
UCEC	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.53	4.63	0.36	7.89e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs829661	0.948	rs829662	chr2:30726551	G/C	cg17749961	chr2:30669863	LCLAT1	0.52	4.83	0.37	3.45e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.87	-10.91	-0.67	1.11e-20	Brugada syndrome;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.53	-6.29	-0.46	3.44e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1712517	0.771	rs11191666	chr10:105127278	A/G	cg05636881	chr10:105038444	INA	0.44	5.12	0.39	9.53e-7	Migraine;
UCEC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.0	0.44	1.48e-8	Menarche (age at onset);
UCEC	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	0.61	4.67	0.36	6.8e-6	Parkinson's disease;
UCEC	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.5	-5.27	-0.4	4.88e-7	Menarche (age at onset);
UCEC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.67	7.22	0.51	2.64e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.56	5.08	0.39	1.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.71	9.09	0.6	6.32e-16	Testicular germ cell tumor;
UCEC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.68	-6.6	-0.48	6.9e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09015484	chr9:96929106	NA	0.65	7.89	0.55	6.34e-13	Warfarin maintenance dose;
UCEC	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.5	5.97	0.44	1.73e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.33	-5.73	-0.43	5.46e-8	Mean corpuscular volume;
UCEC	cis	rs9456883	0.511	rs4709019	chr6:164220590	A/T	cg03034180	chr6:163721894	PACRG	0.36	4.75	0.37	4.71e-6	Sepsis in extremely premature infants;
UCEC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.73	-6.63	-0.48	5.89e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs787274	1.000	rs10759584	chr9:115554736	T/G	cg13803584	chr9:115635662	SNX30	-0.69	-5.58	-0.42	1.13e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.65	4.72	0.36	5.45e-6	Smoking behavior;
UCEC	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.67	-5.56	-0.42	1.25e-7	Platelet count;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.58	-6.68	-0.48	4.49e-10	Depression;
UCEC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	9.78	0.63	1.03e-17	Ulcerative colitis;
UCEC	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	12.63	0.72	3.12e-25	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7937612	0.897	rs1893261	chr11:120198093	A/G	cg12584626	chr11:120203529	NA	-0.46	-4.87	-0.37	2.86e-6	Intraocular pressure;
UCEC	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-5.35	-0.4	3.3e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	0.56	5.49	0.41	1.76e-7	QRS complex (12-leadsum);
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.78	10.52	0.66	1.24e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg24375607	chr4:120327624	NA	0.48	4.98	0.38	1.74e-6	Educational attainment;
UCEC	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.83	-10.99	-0.67	7.04e-21	Height;
UCEC	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.6	-5.36	-0.4	3.08e-7	Metabolite levels;
UCEC	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.56	5.39	0.41	2.68e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg00325661	chr8:49890786	NA	0.51	5.42	0.41	2.41e-7	Sudden cardiac arrest;
UCEC	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.53	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.45	5.05	0.38	1.28e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.69	5.49	0.41	1.73e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.58	5.89	0.44	2.5e-8	Lung cancer;
UCEC	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg25767906	chr1:53392781	SCP2	-0.44	-4.59	-0.35	9.46e-6	Monocyte count;
UCEC	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg12024160	chr4:1254474	NA	0.68	8.01	0.55	3.17e-13	Obesity-related traits;
UCEC	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg02158880	chr13:53174818	NA	0.55	6.37	0.46	2.32e-9	Lewy body disease;
UCEC	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.56	-0.42	1.23e-7	Life satisfaction;
UCEC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.81	7.09	0.5	5.29e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.64	-4.99	-0.38	1.69e-6	HIV-1 control;
UCEC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	7.05	0.5	6.47e-11	Alzheimer's disease;
UCEC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.67	6.28	0.46	3.54e-9	Schizophrenia;
UCEC	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.73	-6.94	-0.5	1.14e-10	Prostate cancer;
UCEC	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-6.43	-0.47	1.64e-9	Morning vs. evening chronotype;
UCEC	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg14121845	chr20:25566513	NINL	0.4	4.74	0.36	4.9e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg18681998	chr4:17616180	MED28	0.68	7.8	0.54	1.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.75	5.68	0.42	7.07e-8	Type 2 diabetes;
UCEC	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg18681998	chr4:17616180	MED28	0.87	11.43	0.69	4.85e-22	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.67	-5.53	-0.41	1.44e-7	Alcohol dependence;
UCEC	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.61	-7.33	-0.52	1.43e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.57	-0.35	1.02e-5	Lung cancer in ever smokers;
UCEC	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-5.67	-0.42	7.16e-8	Platelet count;
UCEC	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.59	4.92	0.38	2.29e-6	Lung cancer;
UCEC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.7	-5.48	-0.41	1.8e-7	Birth weight;
UCEC	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-4.73	-0.36	5.22e-6	Waist circumference adjusted for body mass index;
UCEC	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg24531977	chr5:56204891	C5orf35	-0.45	-4.74	-0.36	4.98e-6	Coronary artery disease;
UCEC	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.57	-7.21	-0.51	2.68e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7072216	0.922	rs2296438	chr10:100146895	T/C	cg19567339	chr10:100142640	NA	0.59	7.9	0.55	6.08e-13	Metabolite levels;
UCEC	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg02413938	chr2:239008929	ESPNL	-0.36	-4.66	-0.36	7.08e-6	Prostate cancer;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04155289	chr7:94953770	PON1	0.71	7.81	0.54	1.01e-12	Paraoxonase activity;
UCEC	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18252515	chr7:66147081	NA	0.46	4.69	0.36	6.18e-6	Aortic root size;
UCEC	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.66	-5.38	-0.41	2.88e-7	Schizophrenia;
UCEC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.66	-8.14	-0.56	1.55e-13	Height;
UCEC	cis	rs7246967	0.673	rs67631531	chr19:22830466	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.71	6.98	0.5	9.32e-11	Schizophrenia;
UCEC	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.74	-8.41	-0.57	3.35e-14	Diastolic blood pressure;
UCEC	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.71	6.52	0.47	1.07e-9	Response to antineoplastic agents;
UCEC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg10978503	chr1:24200527	CNR2	0.37	5.0	0.38	1.61e-6	Immature fraction of reticulocytes;
UCEC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.52	0.35	1.26e-5	Menopause (age at onset);
UCEC	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.71	-8.33	-0.57	5.08e-14	Electrocardiographic conduction measures;
UCEC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-4.56	-0.35	1.07e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs10012307	1.000	rs7670546	chr4:137523572	G/T	cg12033966	chr4:138453416	PCDH18	-0.68	-4.67	-0.36	6.67e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.46	4.5	0.35	1.36e-5	Type 2 diabetes;
UCEC	cis	rs1029966	0.697	rs2908662	chr16:4982013	A/G	cg02568374	chr16:4588917	C16orf5	-0.48	-4.68	-0.36	6.45e-6	Cancer;
UCEC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs883565	0.569	rs704959	chr3:39180263	G/A	cg01426195	chr3:39028469	NA	0.62	7.57	0.53	3.89e-12	Handedness;
UCEC	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg15837086	chr1:46506065	PIK3R3	-0.37	-4.58	-0.35	9.68e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.49	-4.51	-0.35	1.34e-5	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.8	-6.79	-0.49	2.58e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	1.000	rs12665431	chr6:26577308	T/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1850744	0.536	rs13131004	chr4:9612911	C/A	cg15442990	chr4:9534313	NA	0.66	5.0	0.38	1.65e-6	Economic and political preferences;
UCEC	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg27068330	chr11:65405492	SIPA1	-0.53	-4.71	-0.36	5.7e-6	Breast cancer;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.74	8.15	0.56	1.43e-13	Prudent dietary pattern;
UCEC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg09654669	chr8:57350985	NA	-0.57	-6.41	-0.47	1.87e-9	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.65	7.79	0.54	1.09e-12	Menarche (age at onset);
UCEC	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.61	4.65	0.36	7.42e-6	Lung cancer;
UCEC	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.74	-5.18	-0.39	7.08e-7	Toenail selenium levels;
UCEC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg07424592	chr7:64974309	NA	0.77	4.77	0.37	4.39e-6	Diabetic kidney disease;
UCEC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.51	6.61	0.48	6.79e-10	Breast cancer;
UCEC	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg03714773	chr7:91764589	CYP51A1	0.46	5.67	0.42	7.37e-8	Breast cancer;
UCEC	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-4.82	-0.37	3.57e-6	Colorectal cancer;
UCEC	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg15358701	chr1:161410459	NA	-0.81	-5.06	-0.39	1.21e-6	Rheumatoid arthritis;
UCEC	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.43	6.19	0.45	5.71e-9	Crohn's disease;
UCEC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.98e-7	Aortic root size;
UCEC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.5	5.09	0.39	1.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13063635	0.915	rs75928798	chr3:45962603	A/G	cg16320329	chr3:45981161	FYCO1	-0.83	-4.74	-0.36	4.95e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.61e-6	Diabetic kidney disease;
UCEC	cis	rs9470794	1.000	rs34370874	chr6:37994586	A/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg24562669	chr7:97807699	LMTK2	0.41	5.09	0.39	1.08e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.36	0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7246967	0.800	rs7256135	chr19:23039121	A/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg03714773	chr7:91764589	CYP51A1	-0.43	-5.2	-0.39	6.49e-7	Breast cancer;
UCEC	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.31	-0.4	3.94e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg14008862	chr17:28927542	LRRC37B2	0.61	5.09	0.39	1.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.56	0.53	3.95e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg04871131	chr7:94954202	PON1	-0.53	-5.27	-0.4	4.86e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs66573146	1.000	rs67067921	chr4:6984341	A/T	cg00086871	chr4:6988644	TBC1D14	0.83	5.68	0.42	7.12e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg18681998	chr4:17616180	MED28	0.58	6.63	0.48	6.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	5.78	0.43	4.35e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs350251	0.934	rs1704112	chr16:12211425	C/G	cg01282078	chr16:12139025	RUNDC2A	-0.47	-4.7	-0.36	6.03e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg16558253	chr16:72132732	DHX38	-0.43	-5.13	-0.39	8.86e-7	Fibrinogen levels;
UCEC	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.5	0.53	5.48e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.56	5.53	0.41	1.45e-7	Eosinophil percentage of white cells;
UCEC	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg23795048	chr12:9217529	LOC144571	0.4	4.95	0.38	1.99e-6	Sjögren's syndrome;
UCEC	cis	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg00614314	chr15:82944287	LOC80154	0.53	4.94	0.38	2.07e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.69	7.45	0.52	7.32e-12	Diastolic blood pressure;
UCEC	cis	rs713477	1.000	rs28478984	chr14:55911326	C/A	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.55	-5.15	-0.39	8.18e-7	Cognitive function;
UCEC	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg23260525	chr10:116636907	FAM160B1	0.34	4.59	0.35	9.63e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.42	-0.47	1.81e-9	Tonsillectomy;
UCEC	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg05519781	chr21:40033154	ERG	0.53	5.62	0.42	9.22e-8	Coronary artery disease;
UCEC	cis	rs16879308	1.000	rs73097974	chr5:51237597	C/A	cg10599735	chr5:52096100	ITGA1;PELO	0.97	4.83	0.37	3.46e-6	Migraine without aura;
UCEC	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.54	-5.57	-0.42	1.16e-7	Sudden cardiac arrest;
UCEC	cis	rs7095607	0.842	rs2130097	chr10:69919422	A/T	cg18986048	chr10:69913749	MYPN	0.52	6.17	0.45	6.33e-9	Lung function (FVC);
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.51	5.83	0.43	3.46e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	5.08	0.39	1.12e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	0.58	4.85	0.37	3.17e-6	Neutrophil percentage of white cells;
UCEC	cis	rs17106184	1.000	rs72902772	chr1:51265368	C/T	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.53	-5.27	-0.4	4.81e-7	Longevity;Endometriosis;
UCEC	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.78	8.31	0.57	5.97e-14	Caffeine consumption;
UCEC	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg01874867	chr7:94954059	PON1	-0.53	-4.7	-0.36	5.89e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10256972	0.775	rs10259248	chr7:1018968	G/C	cg22907277	chr7:1156413	C7orf50	0.54	4.8	0.37	3.89e-6	Longevity;Endometriosis;
UCEC	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg11150807	chr10:43354902	NA	0.82	6.41	0.47	1.83e-9	Blood protein levels;
UCEC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg13147721	chr7:65941812	NA	-0.69	-4.77	-0.37	4.32e-6	Diabetic kidney disease;
UCEC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.77	-8.73	-0.58	5.09e-15	Height;
UCEC	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.46	4.71	0.36	5.75e-6	Prostate cancer;
UCEC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	6.11	0.45	8.57e-9	Schizophrenia;
UCEC	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg01072550	chr1:21505969	NA	-0.5	-4.7	-0.36	5.98e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.9	0.55	5.98e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg21770322	chr7:97807741	LMTK2	0.49	6.15	0.45	7.12e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs16957091	0.647	rs35838915	chr15:43357124	C/A	cg15904908	chr15:43213022	TTBK2	0.48	4.72	0.36	5.47e-6	MGMT methylation in smokers;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09844983	chr1:28240714	RPA2	0.63	7.42	0.52	8.49e-12	Warfarin maintenance dose;
UCEC	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.56	-5.22	-0.4	6.03e-7	Migraine;Coronary artery disease;
UCEC	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.54	-5.3	-0.4	4.25e-7	Asthma (sex interaction);
UCEC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.06	0.45	1.08e-8	Alzheimer's disease;
UCEC	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.78	5.43	0.41	2.28e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-5.12	-0.39	9.23e-7	Metabolite levels;
UCEC	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.69	8.44	0.57	2.85e-14	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-1.0	-8.84	-0.59	2.66e-15	Dupuytren's disease;
UCEC	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.41	0.47	1.84e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs787274	0.850	rs7873289	chr9:115638386	G/A	cg13803584	chr9:115635662	SNX30	-0.69	-5.75	-0.43	5.08e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.69	5.53	0.41	1.45e-7	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.16	-0.39	7.86e-7	Aortic root size;
UCEC	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.54	0.42	1.33e-7	Cognitive test performance;
UCEC	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.49	4.99	0.38	1.72e-6	Migraine;
UCEC	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg12923728	chr3:195709715	SDHAP1	-0.62	-4.59	-0.35	9.46e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.4	-5.14	-0.39	8.52e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.93	9.11	0.6	5.72e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	5.2	0.39	6.7e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.42	-9.32	-0.61	1.58e-16	Gout;
UCEC	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.52	-5.24	-0.4	5.36e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12545109	0.571	rs7002482	chr8:57295200	C/T	cg07776626	chr8:57350775	NA	-0.51	-5.34	-0.4	3.44e-7	Obesity-related traits;
UCEC	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.6	-5.4	-0.41	2.57e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.66	-5.63	-0.42	8.82e-8	Alcohol dependence;
UCEC	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.41	0.52	8.93e-12	Eye color traits;
UCEC	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-4.97	-0.38	1.87e-6	Type 2 diabetes;
UCEC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg00083072	chr11:65415190	SIPA1	0.43	4.65	0.36	7.41e-6	Acne (severe);
UCEC	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.35	-4.51	-0.35	1.32e-5	Refractive error;
UCEC	cis	rs6144337	1	rs6144337	chr11:47284302	TCCATGTGCCTCA/T	cg19229622	chr11:47291485	MADD	-0.47	-4.57	-0.35	1.03e-5	Lymphocyte percentage of white cells;
UCEC	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	14.69	0.77	1.2e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.62	-0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs9868873	1.000	rs9864897	chr3:122730715	G/T	cg02041593	chr3:122741233	SEMA5B	0.52	5.13	0.39	8.97e-7	Esophageal cancer;
UCEC	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.68	-6.75	-0.49	3.25e-10	Blood metabolite levels;
UCEC	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg16797656	chr11:68205561	LRP5	0.45	5.02	0.38	1.45e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.47	4.89	0.37	2.62e-6	Schizophrenia;
UCEC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.64	-4.68	-0.36	6.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.67	-5.41	-0.41	2.49e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs76419734	0.558	rs4235415	chr4:106593850	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	8.01	0.55	3.16e-13	Post bronchodilator FEV1;
UCEC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.87	5.5	0.41	1.62e-7	Psoriasis;
UCEC	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.61	6.34	0.46	2.67e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.34	-0.46	2.61e-9	Parkinson's disease;
UCEC	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.47	4.79	0.37	4.01e-6	Insulin-like growth factors;
UCEC	cis	rs10185178	1.000	rs10185178	chr2:171356274	A/G	cg21128415	chr2:171359116	MYO3B	-1.12	-9.52	-0.62	4.78e-17	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-4.98	-0.38	1.79e-6	Blood metabolite levels;
UCEC	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.64	-5.01	-0.38	1.55e-6	Corneal astigmatism;
UCEC	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.47	4.7	0.36	5.87e-6	Blood protein levels;
UCEC	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.69	5.78	0.43	4.29e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.0	-0.38	1.65e-6	Aortic root size;
UCEC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.67	6.54	0.47	9.65e-10	Vitamin D levels;
UCEC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	4.8	0.37	3.92e-6	Cognitive test performance;
UCEC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.673	rs7253063	chr19:22865897	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.64	-6.29	-0.46	3.48e-9	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.38	0.41	2.86e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12086130	0.892	rs1043141	chr1:51439777	C/T	cg07174182	chr1:51127561	FAF1	-0.83	-5.02	-0.38	1.47e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.61	-0.36	8.75e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.35	-0.46	2.47e-9	Response to antipsychotic treatment;
UCEC	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.43	6.37	0.47	2.3e-9	Rheumatoid arthritis;
UCEC	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-4.9	-0.37	2.51e-6	Life satisfaction;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23142935	chr16:22385308	CDR2	0.61	7.19	0.51	2.99e-11	Warfarin maintenance dose;
UCEC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.42	-5.0	-0.38	1.6e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.44	4.77	0.37	4.41e-6	Mean corpuscular volume;
UCEC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg20007245	chr22:24372913	LOC391322	-0.57	-6.14	-0.45	7.33e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.68	0.36	6.48e-6	Response to antipsychotic treatment;
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.18	0.51	3.16e-11	Platelet count;
UCEC	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg23791538	chr6:167370224	RNASET2	-0.48	-4.77	-0.37	4.4e-6	Primary biliary cholangitis;
UCEC	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs12216499	0.579	rs79459275	chr6:159428366	T/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.73	-4.58	-0.35	1e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs116095464	0.619	rs28731093	chr5:241028	T/C	cg22857025	chr5:266934	NA	-1.15	-12.4	-0.71	1.29e-24	Breast cancer;
UCEC	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.38	0.52	1.1e-11	Total body bone mineral density;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs11958404	0.789	rs7736318	chr5:157477593	A/G	cg05962755	chr5:157440814	NA	0.78	5.52	0.41	1.47e-7	IgG glycosylation;
UCEC	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.65	7.38	0.52	1.09e-11	Ulcerative colitis;
UCEC	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.46	5.15	0.39	8.39e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.77	0.59	4.14e-15	Prudent dietary pattern;
UCEC	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.49	-5.43	-0.41	2.27e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.66	8.01	0.55	3.26e-13	Testicular germ cell tumor;
UCEC	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.48	-5.0	-0.38	1.6e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.62	4.94	0.38	2.14e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.44	5.69	0.43	6.56e-8	Monocyte count;
UCEC	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Alcohol dependence;
UCEC	cis	rs9811216	1.000	rs9866776	chr3:169487651	C/A	cg16622863	chr3:169387280	NA	-0.44	-4.55	-0.35	1.12e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs9290065	0.519	rs6774203	chr3:160705217	G/T	cg03342759	chr3:160939853	NMD3	-0.58	-5.63	-0.42	8.71e-8	Kawasaki disease;
UCEC	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.48	5.93	0.44	2.09e-8	Electrocardiographic conduction measures;
UCEC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.48	-5.06	-0.39	1.22e-6	Aortic root size;
UCEC	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.95	0.5	1.13e-10	Alzheimer's disease;
UCEC	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.24e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.67	7.22	0.51	2.62e-11	Age at first birth;
UCEC	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.03	-0.38	1.39e-6	Chronic sinus infection;
UCEC	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.72	-7.63	-0.53	2.7e-12	Body mass index;
UCEC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18854424	chr1:2615690	NA	0.5	7.3	0.52	1.66e-11	Ulcerative colitis;
UCEC	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.5	4.55	0.35	1.13e-5	Obesity-related traits;
UCEC	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.52	-5.18	-0.39	7.11e-7	Multiple sclerosis;
UCEC	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24249390	chr15:90295951	MESP1	-0.44	-4.83	-0.37	3.4e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.46	5.03	0.38	1.4e-6	Platelet count;
UCEC	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24249390	chr15:90295951	MESP1	-0.46	-5.14	-0.39	8.48e-7	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12292205	chr6:26970375	C6orf41	0.57	5.05	0.38	1.31e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.1	17.82	0.83	1.45e-38	IgG glycosylation;
UCEC	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.63	6.93	0.5	1.24e-10	Tonsillectomy;
UCEC	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	0.81	6.45	0.47	1.53e-9	Response to hepatitis C treatment;
UCEC	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg13683864	chr3:40499215	RPL14	0.48	4.55	0.35	1.09e-5	Renal cell carcinoma;
UCEC	cis	rs10012307	1.000	rs17048753	chr4:137508393	T/A	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg27529037	chr20:44575021	PCIF1	0.39	4.63	0.36	7.87e-6	Metabolite levels;
UCEC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg15147215	chr3:52552868	STAB1	-0.44	-4.86	-0.37	2.94e-6	Bipolar disorder;
UCEC	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.82	-0.54	9.19e-13	Body mass index;
UCEC	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.5	5.38	0.41	2.88e-7	Neuroticism;
UCEC	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.06	0.45	1.11e-8	Coronary artery disease;
UCEC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.47	5.14	0.39	8.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.57	5.62	0.42	9.41e-8	Platelet count;
UCEC	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.54	-5.64	-0.42	8.28e-8	Coronary artery disease;
UCEC	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs75804782	0.630	rs56304316	chr2:239253266	C/A	cg11815105	chr2:239148849	HES6	1.03	5.0	0.38	1.6e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.55	-5.21	-0.4	6.17e-7	Uric acid levels;
UCEC	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	5.5	0.41	1.68e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg14178214	chr9:98491799	NA	-0.51	-4.82	-0.37	3.48e-6	Neuroticism;
UCEC	cis	rs732765	0.734	rs9323602	chr14:75182008	A/G	cg11740921	chr14:74946960	NPC2	-0.45	-4.67	-0.36	6.84e-6	Non-small cell lung cancer;
UCEC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.5	-5.24	-0.4	5.38e-7	Blood metabolite levels;
UCEC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17600642	0.694	rs72814533	chr10:72444918	G/C	cg23422916	chr10:72218225	NA	-0.55	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg09737314	chr17:6899359	ALOX12	0.47	5.55	0.42	1.32e-7	Tonsillectomy;
UCEC	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.61	-6.66	-0.48	5.15e-10	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	5.68	0.42	7.12e-8	Rheumatoid arthritis;
UCEC	cis	rs10089	0.552	rs56718459	chr5:127546214	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	5.5	0.41	1.61e-7	Ileal carcinoids;
UCEC	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.76	-6.64	-0.48	5.59e-10	Caudate activity during reward;
UCEC	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.53	5.85	0.43	3.08e-8	QRS complex (12-leadsum);
UCEC	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.53	5.2	0.39	6.67e-7	Menopause (age at onset);
UCEC	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.67	5.69	0.42	6.66e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs12618769	0.625	rs3820945	chr2:99105156	G/A	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.66	-6.99	-0.5	8.95e-11	Sudden cardiac arrest;
UCEC	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-4.81	-0.37	3.73e-6	Body mass index;
UCEC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-5.9	-0.44	2.42e-8	Total body bone mineral density;
UCEC	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18932078	chr1:2524107	MMEL1	0.4	6.53	0.47	1e-9	Ulcerative colitis;
UCEC	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.15	-0.39	8.1e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg11632617	chr15:75315747	PPCDC	-0.49	-4.96	-0.38	1.89e-6	Blood trace element (Zn levels);
UCEC	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	0.81	9.99	0.64	3.02e-18	Bone mineral density;
UCEC	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	4.84	0.37	3.19e-6	Response to antipsychotic treatment;
UCEC	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.08	5.72	0.43	5.66e-8	Diabetic retinopathy;
UCEC	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg07493874	chr5:1342172	CLPTM1L	0.46	5.16	0.39	7.7300000000000005e-07	Lung cancer;
UCEC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg11508081	chr17:41442227	NA	0.43	4.52	0.35	1.27e-5	Menopause (age at onset);
UCEC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.61	-6.01	-0.44	1.4e-8	Blood metabolite levels;
UCEC	cis	rs9911578	0.839	rs56360354	chr17:57202927	A/G	cg12560992	chr17:57184187	TRIM37	0.89	10.28	0.65	5.17e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.25	-0.46	4.29e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.52	-4.81	-0.37	3.64e-6	Platelet count;
UCEC	cis	rs4372836	0.504	rs12714249	chr2:29055916	G/A	cg09522027	chr2:28974177	PPP1CB	-0.68	-7.05	-0.5	6.48e-11	Body mass index;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs35934224	0.783	rs12106549	chr22:19846987	G/T	cg11182965	chr22:19864308	TXNRD2	-0.34	-4.57	-0.35	1.04e-5	Glaucoma (primary open-angle);
UCEC	cis	rs295140	0.903	rs56326533	chr2:201168758	T/C	cg04283868	chr2:201171347	SPATS2L	0.48	4.58	0.35	1e-5	QT interval;
UCEC	cis	rs2307449	0.929	rs1061316	chr15:89860350	A/C	cg23124613	chr15:89731485	ABHD2	-0.43	-5.08	-0.39	1.11e-6	Menopause (age at onset);
UCEC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.58	-5.41	-0.41	2.49e-7	Childhood ear infection;
UCEC	cis	rs7656342	0.897	rs7685396	chr4:9794724	C/A	cg00071950	chr4:10020882	SLC2A9	0.48	5.04	0.38	1.33e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg14008862	chr17:28927542	LRRC37B2	0.83	5.44	0.41	2.16e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.65	6.36	0.46	2.4e-9	Aortic root size;
UCEC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg09491104	chr22:46646882	C22orf40	-0.53	-5.76	-0.43	4.86e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.15	9.34	0.61	1.45e-16	Vitiligo;
UCEC	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24308560	chr3:49941425	MST1R	0.52	5.92	0.44	2.16e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.47	5.83	0.43	3.41e-8	Refractive error;
UCEC	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-6.26	-0.46	3.94e-9	Morning vs. evening chronotype;
UCEC	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.66	-4.64	-0.36	7.54e-6	Aortic root size;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.63	-5.2	-0.39	6.7e-7	LDL cholesterol levels;
UCEC	cis	rs4074536	0.796	rs10801990	chr1:116309183	G/A	cg21648376	chr1:116311395	CASQ2	-0.5	-4.89	-0.37	2.59e-6	QRS duration;
UCEC	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.3	-0.46	3.28e-9	Response to antipsychotic treatment;
UCEC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.21	0.39	6.32e-7	Personality dimensions;
UCEC	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.57	6.43	0.47	1.66e-9	Red blood cell count;
UCEC	cis	rs7246967	0.932	rs62120772	chr19:23037151	G/C	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1355223	0.833	rs11032804	chr11:34680598	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.42	-0.41	2.43e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.52	-5.26	-0.4	4.98e-7	Bipolar disorder;
UCEC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.43	0.41	2.29e-7	Cognitive function;
UCEC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.63	-5.14	-0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.92	9.83	0.63	7.92e-18	Cognitive function;
UCEC	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.82	0.43	3.53e-8	Monocyte percentage of white cells;
UCEC	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.56	-6.83	-0.49	2.09e-10	Height;
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.72	0.58	5.56e-15	Platelet count;
UCEC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.63	6.95	0.5	1.11e-10	Pubertal anthropometrics;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.45	-4.67	-0.36	6.63e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.53	-5.94	-0.44	1.99e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg18230493	chr5:56204884	C5orf35	-0.51	-4.58	-0.35	9.76e-6	Coronary artery disease;
UCEC	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.55	5.29	0.4	4.42e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg12035532	chr1:1886765	KIAA1751	0.44	4.69	0.36	6.18e-6	Body mass index;
UCEC	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.11	17.63	0.82	4.35e-38	Testicular germ cell tumor;
UCEC	cis	rs9831754	0.715	rs9840902	chr3:78369573	G/A	cg06138941	chr3:78371609	NA	-0.71	-5.22	-0.4	5.99e-7	Calcium levels;
UCEC	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.89	7.22	0.51	2.53e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.43	-5.02	-0.38	1.47e-6	Tonsillectomy;
UCEC	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.25	-0.46	4.28e-9	Resting heart rate;
UCEC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.55	6.74	0.49	3.45e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10503871	0.690	rs4147357	chr8:30344444	T/C	cg26383811	chr8:30366931	RBPMS	0.48	4.8	0.37	3.94e-6	Metabolite levels  (X-11787);
UCEC	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.86	9.79	0.63	9.91e-18	Blood protein levels;
UCEC	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	0.87	5.29	0.4	4.37e-7	Blood protein levels;
UCEC	cis	rs1545257	0.505	rs7583687	chr2:24634003	C/G	cg06627628	chr2:24431161	ITSN2	-0.51	-5.19	-0.39	6.77e-7	Sjögren's syndrome;
UCEC	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg22166914	chr1:53195759	ZYG11B	0.57	5.67	0.42	7.43e-8	Monocyte count;
UCEC	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg22974920	chr21:40686053	BRWD1	0.54	4.93	0.38	2.16e-6	Cognitive function;
UCEC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	4.57	0.35	1.02e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.55	7.72	0.54	1.66e-12	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg24308560	chr3:49941425	MST1R	-0.51	-4.64	-0.36	7.73e-6	Resting heart rate;
UCEC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.68	0.36	6.36e-6	Schizophrenia;
UCEC	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-6.18	-0.45	5.86e-9	Morning vs. evening chronotype;
UCEC	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.52	-5.92	-0.44	2.23e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.75	8.07	0.55	2.26e-13	Sudden cardiac arrest;
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg19318889	chr4:1322082	MAEA	0.52	5.7	0.43	6.2e-8	Obesity-related traits;
UCEC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs4388249	0.696	rs31600	chr5:109006376	A/C	cg17395555	chr5:108820864	NA	-0.52	-4.54	-0.35	1.17e-5	Schizophrenia;
UCEC	cis	rs883565	0.696	rs6599007	chr3:39114445	A/C	cg01426195	chr3:39028469	NA	-0.68	-8.51	-0.57	1.83e-14	Handedness;
UCEC	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg13926569	chr10:89418898	PAPSS2	-0.63	-7.34	-0.52	1.35e-11	Magnesium levels;
UCEC	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.63	0.42	9.07e-8	Psoriasis;
UCEC	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.48	-5.33	-0.4	3.56e-7	Lung cancer;
UCEC	cis	rs7937612	0.931	rs10892562	chr11:120221618	A/G	cg12584626	chr11:120203529	NA	0.49	5.15	0.39	8.35e-7	Intraocular pressure;
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs6788895	1.000	rs34771595	chr3:150517939	T/G	cg19584864	chr3:150127772	TSC22D2	-0.75	-4.69	-0.36	6.23e-6	Breast cancer;
UCEC	cis	rs9637454	0.526	rs35792166	chr3:178271216	C/T	cg08812936	chr3:178254213	KCNMB2	-0.39	-4.8	-0.37	3.79e-6	Hippocampal sclerosis;
UCEC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	4.95	0.38	1.99e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.51	5.4	0.41	2.65e-7	Type 2 diabetes;
UCEC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-7.38	-0.52	1.08e-11	Chronic sinus infection;
UCEC	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs12234571	1.000	rs73374135	chr7:77383255	A/G	cg20048109	chr7:78158112	MAGI2	-0.53	-4.81	-0.37	3.76e-6	Obesity-related traits;
UCEC	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	5.05	0.38	1.27e-6	Bone mineral density;
UCEC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.48	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-10.12	-0.64	1.33e-18	Schizophrenia;
UCEC	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.46	4.8	0.37	3.81e-6	Schizophrenia;
UCEC	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	0.77	9.29	0.61	1.94e-16	Multiple myeloma;
UCEC	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01065977	chr19:18549689	ISYNA1	-0.36	-5.04	-0.38	1.36e-6	Breast cancer;
UCEC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.73	7.86	0.54	7.67e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.42	-4.66	-0.36	6.95e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.85	9.14	0.6	4.55e-16	Blood metabolite levels;
UCEC	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.41	-5.43	-0.41	2.24e-7	Blood protein levels;
UCEC	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-4.58	-0.35	9.88e-6	Morning vs. evening chronotype;
UCEC	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.58	-5.16	-0.39	7.92e-7	Hypospadias;
UCEC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.6	0.42	1.03e-7	Cognitive test performance;
UCEC	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Blood protein levels;
UCEC	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.67	-6.62	-0.48	6.2e-10	Blood metabolite levels;
UCEC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	4.8	0.37	3.87e-6	Colorectal cancer;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04871131	chr7:94954202	PON1	-0.56	-6.29	-0.46	3.41e-9	Paraoxonase activity;
UCEC	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.59	-5.77	-0.43	4.54e-8	Bipolar disorder;
UCEC	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.55	5.29	0.4	4.42e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.5	-4.59	-0.35	9.57e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-0.72	-6.46	-0.47	1.48e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg18973586	chr4:963968	DGKQ	0.46	4.79	0.37	4.1e-6	Obesity-related traits;
UCEC	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.67e-9	Crohn's disease;
UCEC	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg16583315	chr14:65563665	MAX	-0.47	-6.1	-0.45	8.92e-9	Obesity-related traits;
UCEC	cis	rs7309	0.967	rs3754970	chr2:162091836	T/C	cg21518248	chr2:162101506	NA	0.55	5.78	0.43	4.41e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.13e-9	Tonsillectomy;
UCEC	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.44	-6.28	-0.46	3.68e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-5.02	-0.38	1.5e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	4.63	0.36	7.96e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-1.01	-11.14	-0.68	2.83e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs912062	1.000	rs912062	chr9:841152	C/A	cg14267263	chr9:841436	DMRT1	-0.79	-5.54	-0.42	1.36e-7	Obesity-related traits;
UCEC	cis	rs7246967	0.541	rs74169641	chr19:22830576	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	9.49	0.62	5.74e-17	Alzheimer's disease;
UCEC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.52	6.12	0.45	8.19e-9	Testicular germ cell tumor;
UCEC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	4.53	0.35	1.19e-5	Calcium levels;
UCEC	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.59	4.74	0.36	4.93e-6	Longevity;
UCEC	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-11.5	-0.69	3.08e-22	Coronary artery disease;
UCEC	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.7	-6.79	-0.49	2.63e-10	Mosquito bite size;
UCEC	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.18	-0.45	5.84e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.69	0.36	6.25e-6	Schizophrenia;
UCEC	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	5.83	0.43	3.31e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.45	4.6	0.35	9.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg03714773	chr7:91764589	CYP51A1	-0.43	-5.24	-0.4	5.56e-7	Breast cancer;
UCEC	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-8.52	-0.57	1.74e-14	Vitiligo;
UCEC	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg20302342	chr1:156215951	PAQR6	0.51	5.52	0.41	1.47e-7	Tonsillectomy;
UCEC	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.56	-5.71	-0.43	6.19e-8	Hepatocellular carcinoma;
UCEC	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg08027265	chr7:2291960	NA	-0.49	-5.22	-0.4	6.04e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.64	6.6	0.48	7.13e-10	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07157834	chr1:205819609	PM20D1	0.67	7.45	0.52	7.35e-12	Menarche (age at onset);
UCEC	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.71	6.88	0.49	1.62e-10	Crohn's disease;
UCEC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.48	4.81	0.37	3.63e-6	Prostate cancer;
UCEC	cis	rs7968440	0.591	rs6580732	chr12:50646279	T/G	cg20014596	chr12:50898483	DIP2B	-0.47	-4.66	-0.36	7.06e-6	Fibrinogen;
UCEC	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.65	-0.53	2.46e-12	Coronary artery disease;
UCEC	cis	rs36051895	0.632	rs10116823	chr9:5171944	T/A	cg02405213	chr9:5042618	JAK2	-0.52	-5.26	-0.4	5.1e-7	Pediatric autoimmune diseases;
UCEC	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg01426195	chr3:39028469	NA	-0.77	-10.31	-0.65	4.22e-19	Handedness;
UCEC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.89	-0.44	2.48e-8	Prudent dietary pattern;
UCEC	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg06784218	chr1:46089804	CCDC17	0.4	4.58	0.35	9.79e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.94	0.44	1.94e-8	Mood instability;
UCEC	cis	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.53e-7	Bipolar disorder;
UCEC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	5.9	0.44	2.42e-8	Menarche (age at onset);
UCEC	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.69	6.23	0.46	4.55e-9	Obesity-related traits;
UCEC	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.78	0.49	2.68e-10	Motion sickness;
UCEC	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.66	-5.0	-0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg07256473	chr22:29710276	RASL10A	-0.63	-6.99	-0.5	8.98e-11	Immature fraction of reticulocytes;
UCEC	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.59	6.59	0.48	7.25e-10	Crohn's disease;
UCEC	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-4.86	-0.37	3.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17789174	0.953	rs11149708	chr16:85104919	T/G	cg02758499	chr16:85682440	KIAA0182	0.5	4.71	0.36	5.7e-6	Dysphagia;
UCEC	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Cognitive function;
UCEC	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs10924970	0.649	rs12743844	chr1:235389233	T/C	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.72	8.67	0.58	7.41e-15	Monocyte count;
UCEC	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.46	5.31	0.4	4.02e-7	Blood metabolite levels;
UCEC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	0.79	5.25	0.4	5.28e-7	Diabetic retinopathy;
UCEC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.71	-6.56	-0.48	8.47e-10	Aortic root size;
UCEC	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs77861329	1.000	rs164638	chr3:52207886	T/G	cg08692210	chr3:52188851	WDR51A	0.83	6.68	0.48	4.72e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs4074536	0.622	rs10923440	chr1:116317441	G/A	cg21648376	chr1:116311395	CASQ2	-0.6	-5.74	-0.43	5.36e-8	QRS duration;
UCEC	cis	rs3770752	0.836	rs34819784	chr2:37491032	G/C	cg20091297	chr2:37572423	QPCT	0.49	4.93	0.38	2.18e-6	Schizophrenia;
UCEC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.75e-9	Blood metabolite levels;
UCEC	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.7	-6.19	-0.45	5.64e-9	Bipolar disorder;
UCEC	cis	rs11761441	0.602	rs9642262	chr7:91782	T/C	cg06458707	chr7:1083209	C7orf50	0.26	4.69	0.36	6.13e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	5.96	0.44	1.81e-8	Personality dimensions;
UCEC	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-4.82	-0.37	3.61e-6	Blood metabolite levels;
UCEC	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.5	-5.13	-0.39	9.03e-7	Body mass index;
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4234798	1.000	rs4689088	chr4:7222253	G/A	cg18431297	chr4:7219810	SORCS2	0.4	4.97	0.38	1.86e-6	Insulin-like growth factors;
UCEC	cis	rs8020441	1.000	rs72681673	chr14:51171922	G/A	cg04730355	chr14:51134070	SAV1	0.7	6.3	0.46	3.23e-9	Cognitive performance;
UCEC	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.56	5.24	0.4	5.45e-7	Dental caries;
UCEC	cis	rs2302190	0.769	rs7211294	chr17:56462783	G/A	cg12560992	chr17:57184187	TRIM37	0.56	4.73	0.36	5.12e-6	Vitamin D levels;
UCEC	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg03342759	chr3:160939853	NMD3	0.52	4.66	0.36	6.88e-6	Morning vs. evening chronotype;
UCEC	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.5	5.32	0.4	3.74e-7	Cognitive test performance;
UCEC	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.64	0.48	5.65e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.64	5.45	0.41	2.06e-7	High light scatter reticulocyte count;
UCEC	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24375607	chr4:120327624	NA	0.5	4.53	0.35	1.19e-5	Corneal astigmatism;
UCEC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg00343986	chr7:65444356	GUSB	-0.52	-4.66	-0.36	6.9e-6	Aortic root size;
UCEC	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.46	-5.09	-0.39	1.1e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.61	-5.55	-0.42	1.27e-7	Response to antipsychotic treatment;
UCEC	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.51	5.26	0.4	4.97e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11584989	chr19:19387371	SF4	0.57	6.51	0.47	1.14e-9	Bipolar disorder;
UCEC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-6.12	-0.45	8.17e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7246967	0.932	rs4932799	chr19:23051581	C/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg04176532	chr22:50317003	CRELD2	0.47	4.73	0.36	5.12e-6	Schizophrenia;
UCEC	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.51	-7.02	-0.5	7.44e-11	Refractive error;
UCEC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.64	-4.59	-0.35	9.41e-6	Aortic root size;
UCEC	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.51	-5.12	-0.39	9.26e-7	Red cell distribution width;
UCEC	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.62	-5.87	-0.44	2.8e-8	Breast size;
UCEC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.66	5.86	0.44	2.91e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6663390	0.510	rs73072979	chr1:208072057	G/A	cg03990033	chr1:208084030	CD34	0.57	5.48	0.41	1.84e-7	Facial morphology (factor 18);
UCEC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.92	-0.44	2.22e-8	Mood instability;
UCEC	cis	rs13098911	0.540	rs71325098	chr3:46012391	A/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.25	-7.8	-0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	8.31	0.57	5.84e-14	Chronic sinus infection;
UCEC	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	4.75	0.36	4.83e-6	Personality dimensions;
UCEC	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.98	-11.18	-0.68	2.17e-21	Obesity-related traits;
UCEC	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.96	-0.38	1.92e-6	Breast cancer;
UCEC	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.79	9.48	0.62	6.24e-17	Monocyte count;
UCEC	cis	rs7246967	0.673	rs8103012	chr19:22879285	C/T	cg08271804	chr19:22816896	ZNF492	0.58	5.75	0.43	4.89e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.02	-6.63	-0.48	6.11e-10	Diabetic kidney disease;
UCEC	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.8	-0.37	3.79e-6	Resting heart rate;
UCEC	cis	rs17102884	0.587	rs10162454	chr14:75144618	T/C	cg16124934	chr14:75389480	RPS6KL1	-0.51	-5.0	-0.38	1.58e-6	Neuroticism;
UCEC	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.48	-5.43	-0.41	2.23e-7	Anterior chamber depth;
UCEC	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.54	4.7	0.36	5.81e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.73	6.27	0.46	3.73e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.48	5.38	0.41	2.89e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.58	-6.24	-0.46	4.43e-9	Menarche (age at onset);
UCEC	cis	rs4953318	0.894	rs10495928	chr2:46353166	A/G	cg12428440	chr2:46370979	PRKCE	0.43	4.63	0.36	7.82e-6	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs59104589	0.617	rs3771561	chr2:242353704	A/G	cg19488206	chr2:242435732	STK25	-0.51	-5.24	-0.4	5.55e-7	Fibrinogen levels;
UCEC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-0.56	-6.37	-0.47	2.26e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-0.73	-7.06	-0.5	6.28e-11	Post bronchodilator FEV1;
UCEC	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	14.66	0.77	1.5e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg04896959	chr15:78267971	NA	0.56	5.79	0.43	4.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg08250081	chr4:10125330	NA	0.45	4.53	0.35	1.22e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.53	0.74	1.33e-27	Homoarginine levels;
UCEC	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.89	11.03	0.67	5.52e-21	Primary sclerosing cholangitis;
UCEC	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.29	10.03	0.64	2.35e-18	Uric acid levels;
UCEC	cis	rs11668163	0.602	rs2967726	chr19:8771771	A/G	cg13544883	chr19:7852051	CLEC4GP1	-0.34	-4.52	-0.35	1.25e-5	Resting metabolic rate;
UCEC	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg18681998	chr4:17616180	MED28	-0.71	-7.66	-0.53	2.29e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.81	10.39	0.65	2.63e-19	Mean corpuscular volume;
UCEC	cis	rs6416877	0.819	rs6502708	chr17:1353766	C/A	cg09375892	chr17:708413	NXN	-0.61	-4.62	-0.36	8.16e-6	Myeloid white cell count;
UCEC	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.71	6.96	0.5	1.06e-10	Bladder cancer;
UCEC	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-5.68	-0.42	6.97e-8	Morning vs. evening chronotype;
UCEC	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-6.79	-0.49	2.64e-10	Personality dimensions;
UCEC	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.41	4.93	0.38	2.16e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.8	-0.37	3.88e-6	Depression;
UCEC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-0.78	-8.07	-0.55	2.25e-13	Urate levels;
UCEC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.27	-10.7	-0.66	3.95e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.78	6.12	0.45	8.16e-9	Body mass index;
UCEC	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.87	0.44	2.77e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.44	-4.93	-0.38	2.18e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs953387	0.744	rs115224560	chr2:136896041	T/A	cg07169764	chr2:136633963	MCM6	0.53	5.25	0.4	5.35e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs9911578	0.839	rs11658694	chr17:57205174	T/C	cg12560992	chr17:57184187	TRIM37	0.88	10.28	0.65	5.01e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.59	-0.35	9.27e-6	Alzheimer's disease (late onset);
UCEC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.45	-4.93	-0.38	2.18e-6	Calcium levels;
UCEC	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg06462663	chr19:18546047	ISYNA1	0.43	5.28	0.4	4.65e-7	Breast cancer;
UCEC	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.39	0.47	2.02e-9	Educational attainment;
UCEC	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.73	-7.36	-0.52	1.18e-11	Plateletcrit;Platelet count;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.44	-0.41	2.18e-7	Pulmonary function;
UCEC	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.75	-8.38	-0.57	4.02e-14	Height;
UCEC	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg21214455	chr15:72412075	SENP8	0.51	4.76	0.37	4.66e-6	Red blood cell count;
UCEC	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.33e-8	Lung cancer;
UCEC	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.72	4.56	0.35	1.06e-5	LDL cholesterol;
UCEC	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.59	4.93	0.38	2.19e-6	Blood metabolite levels;
UCEC	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.02	-14.1	-0.76	4.26e-29	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	6.36	0.46	2.41e-9	Personality dimensions;
UCEC	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg20129853	chr10:51489980	NA	0.41	4.97	0.38	1.88e-6	Prostate-specific antigen levels;
UCEC	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2473967	1.000	rs9398330	chr6:113393990	C/T	cg15417249	chr6:114131273	NA	-0.68	-4.56	-0.35	1.08e-5	Asthma (childhood onset);
UCEC	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.41	5.59	0.42	1.06e-7	Alcohol dependence;
UCEC	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg21521518	chr4:53727714	RASL11B	0.69	4.75	0.36	4.75e-6	Optic nerve measurement (cup area);
UCEC	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.57	5.56	0.42	1.25e-7	Blood protein levels;
UCEC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.68	6.5	0.47	1.17e-9	Menarche (age at onset);
UCEC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg21770322	chr7:97807741	LMTK2	0.5	6.27	0.46	3.84e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18252515	chr7:66147081	NA	0.52	5.44	0.41	2.14e-7	Aortic root size;
UCEC	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.59	-6.05	-0.45	1.16e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.66	-0.42	7.63e-8	Pubertal anthropometrics;
UCEC	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	0.74	4.97	0.38	1.88e-6	Diabetic retinopathy;
UCEC	cis	rs10895987	1.000	rs11227126	chr11:64908062	A/T	cg02030452	chr11:65589615	NA	-0.47	-4.51	-0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.75	7.76	0.54	1.35e-12	Lymphocyte counts;
UCEC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	8.06	0.55	2.38e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.58	6.36	0.46	2.37e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.42	0.41	2.39e-7	IgG glycosylation;
UCEC	cis	rs732765	0.734	rs4899530	chr14:75165825	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.53	-4.68	-0.36	6.35e-6	Non-small cell lung cancer;
UCEC	trans	rs1552172	0.853	rs11587821	chr1:145599038	G/T	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.66	-7.08	-0.5	5.47e-11	Breast cancer;
UCEC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	0.74	9.33	0.61	1.53e-16	Obesity-related traits;
UCEC	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.84	-7.94	-0.55	4.66e-13	Initial pursuit acceleration;
UCEC	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-5.11	-0.39	9.87e-7	Bipolar disorder;
UCEC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	5.23	0.4	5.7e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.9	11.19	0.68	2.01e-21	Menarche (age at onset);
UCEC	cis	rs7246967	0.673	rs597906	chr19:22868205	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs4654899	0.897	rs710311	chr1:21062001	T/C	cg01072550	chr1:21505969	NA	-0.49	-4.75	-0.36	4.86e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-4.55	-0.35	1.11e-5	Monocyte count;
UCEC	cis	rs12982903	0.915	rs626000	chr19:5961848	C/A	cg27649253	chr19:5245891	PTPRS	-0.64	-4.66	-0.36	6.94e-6	Heart rate variability traits (SDNN);
UCEC	cis	rs7246967	0.551	rs8103204	chr19:22936517	T/A	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	8.17	0.56	1.32e-13	Mean corpuscular hemoglobin;
UCEC	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.7	5.59	0.42	1.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg00612595	chr21:47717864	NA	-0.49	-5.37	-0.4	3.07e-7	Testicular germ cell tumor;
UCEC	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.69	-8.5	-0.57	1.96e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.75	6.69	0.48	4.29e-10	Coronary artery disease;
UCEC	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg14067834	chr17:29058358	SUZ12P	0.65	4.51	0.35	1.31e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6832769	0.922	rs28665088	chr4:56251080	A/G	cg05960024	chr4:56376020	CLOCK	0.51	4.83	0.37	3.37e-6	Personality dimensions;
UCEC	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg12024160	chr4:1254474	NA	-0.55	-6.73	-0.49	3.62e-10	Obesity-related traits;
UCEC	cis	rs7474896	0.725	rs11011405	chr10:38215601	G/A	cg00409905	chr10:38381863	ZNF37A	-0.65	-4.8	-0.37	3.91e-6	Obesity (extreme);
UCEC	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.85	5.42	0.41	2.42e-7	Psoriasis;
UCEC	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.44	-4.53	-0.35	1.23e-5	Schizophrenia;
UCEC	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.8	-0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.76	-7.48	-0.53	6.07e-12	Lung cancer;
UCEC	cis	rs10242455	0.867	rs15524	chr7:99245914	A/G	cg07715041	chr7:99302981	CYP3A7	0.49	4.93	0.38	2.18e-6	Blood metabolite levels;
UCEC	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.79	0.43	4.18e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12039431	0.746	rs10908354	chr1:38014601	A/G	cg17933807	chr1:38061675	GNL2	-0.52	-4.55	-0.35	1.1e-5	Epithelial ovarian cancer;
UCEC	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.63	7.5	0.53	5.47e-12	Metabolite levels;
UCEC	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.33	-0.52	1.39e-11	Eye color traits;
UCEC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.77	-7.32	-0.52	1.53e-11	Initial pursuit acceleration;
UCEC	cis	rs9949291	0.958	rs12968491	chr18:61252096	C/T	cg15422147	chr18:61144339	SERPINB5	0.29	4.66	0.36	7.03e-6	Eosinophil percentage of white cells;
UCEC	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg05962950	chr11:130786565	SNX19	-0.47	-4.87	-0.37	2.9e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	4.66	0.36	7.13e-6	Breast cancer;
UCEC	cis	rs1978968	0.763	rs9605474	chr22:18463297	A/G	cg03078520	chr22:18463400	MICAL3	-0.55	-6.95	-0.5	1.08e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.59	-6.71	-0.48	3.84e-10	Cancer (pleiotropy);
UCEC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.94	0.44	1.98e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.76	8.02	0.55	3.09e-13	Breast cancer;
UCEC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.7	6.69	0.48	4.29e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg13575925	chr12:9217583	LOC144571	0.42	5.05	0.38	1.31e-6	Sjögren's syndrome;
UCEC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg20387954	chr3:183756860	HTR3D	0.5	6.15	0.45	7.09e-9	Anterior chamber depth;
UCEC	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.42	-4.68	-0.36	6.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.56	0.35	1.08e-5	Breast cancer;
UCEC	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	0.86	5.47	0.41	1.91e-7	Arsenic metabolism;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg19041857	chr6:27730383	NA	-0.49	-4.76	-0.37	4.63e-6	Pubertal anthropometrics;
UCEC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-6.97	-0.5	9.76e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.67	-4.87	-0.37	2.84e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.54	-5.02	-0.38	1.5e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7106204	0.514	rs1443043	chr11:24251991	A/G	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-7.25	-0.51	2.18e-11	Response to antipsychotic treatment;
UCEC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.97	-0.38	1.82e-6	Immature fraction of reticulocytes;
UCEC	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg15848620	chr12:58087721	OS9	-0.51	-4.86	-0.37	2.95e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs11958404	0.932	rs72816600	chr5:157436349	T/C	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs10242455	0.867	rs2687077	chr7:99306566	C/T	cg07715041	chr7:99302981	CYP3A7	-0.49	-4.99	-0.38	1.68e-6	Blood metabolite levels;
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.6	8.76	0.59	4.24e-15	Prudent dietary pattern;
UCEC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	1.0	12.13	0.71	6.62e-24	Cognitive function;
UCEC	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.5	-0.47	1.17e-9	Tonsillectomy;
UCEC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.59	5.76	0.43	4.82e-8	Tonsillectomy;
UCEC	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg21856205	chr7:94953877	PON1	-0.52	-4.81	-0.37	3.7e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.93	-0.44	2.08e-8	Response to antipsychotic treatment;
UCEC	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.82	10.15	0.64	1.15e-18	Mortality in heart failure;
UCEC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.34	-0.46	2.69e-9	Prudent dietary pattern;
UCEC	cis	rs7638909	0.512	rs7645178	chr3:38597558	A/G	cg24069376	chr3:38537580	EXOG	-0.38	-4.57	-0.35	1.01e-5	Electrocardiographic conduction measures;
UCEC	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.7	6.96	0.5	1.07e-10	Primary sclerosing cholangitis;
UCEC	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg04155231	chr12:9217510	LOC144571	0.4	4.96	0.38	1.89e-6	Sjögren's syndrome;
UCEC	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.73	-7.49	-0.53	5.89e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.41	-4.85	-0.37	3.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.92	11.67	0.69	1.13e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.7	0.36	5.82e-6	Menopause (age at onset);
UCEC	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.62	-7.19	-0.51	3e-11	Prostate cancer;
UCEC	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.62	6.0	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.63	-0.48	5.97e-10	Platelet count;
UCEC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.49	-4.51	-0.35	1.31e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	9.9	0.63	5.09e-18	Chronic sinus infection;
UCEC	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg05855489	chr10:104503620	C10orf26	0.55	4.65	0.36	7.3e-6	Waist circumference;Hip circumference;
UCEC	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.07	0.5	5.71e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg06238570	chr21:40685208	BRWD1	0.75	7.17	0.51	3.34e-11	Cognitive function;
UCEC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.86	7.62	0.53	2.95e-12	Blood metabolite levels;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.1	-0.39	1.05e-6	Pulmonary function;
UCEC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Bipolar disorder;
UCEC	cis	rs35934224	0.831	rs8141610	chr22:19870147	A/G	cg11182965	chr22:19864308	TXNRD2	0.54	6.71	0.48	3.84e-10	Glaucoma (primary open-angle);
UCEC	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.34	-0.57	4.9e-14	Chronic sinus infection;
UCEC	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-1.04	-9.56	-0.62	3.82e-17	Dupuytren's disease;
UCEC	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-4.58	-0.35	9.71e-6	Mood instability;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23628684	chr21:30446052	CCT8	0.65	8.03	0.55	2.84e-13	Warfarin maintenance dose;
UCEC	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.74	7.5	0.53	5.45e-12	Schizophrenia;
UCEC	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.76	7.3	0.52	1.71e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12617721	0.874	rs3754890	chr2:99088624	C/T	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder with mood-incongruent psychosis;
UCEC	cis	rs9463078	0.683	rs6458412	chr6:44735834	A/G	cg25276700	chr6:44698697	NA	0.44	4.88	0.37	2.75e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.53	5.25	0.4	5.26e-7	Lung cancer;
UCEC	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.54	-0.42	1.37e-7	Total cholesterol levels;
UCEC	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.5	5.01	0.38	1.54e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.46	4.57	0.35	1.01e-5	Aortic root size;
UCEC	cis	rs7714670	0.706	rs2973549	chr5:73091126	T/A	cg00119811	chr5:73092353	RGNEF	-0.38	-4.66	-0.36	7e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.63	5.02	0.38	1.48e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	7.68	0.53	2.1e-12	Tonsillectomy;
UCEC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.53	-5.28	-0.4	4.55e-7	Blood metabolite levels;
UCEC	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.79	-9.62	-0.62	2.68e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.49	5.28	0.4	4.59e-7	Schizophrenia;
UCEC	cis	rs9470794	1.000	rs11757072	chr6:38018628	C/T	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg23307798	chr14:103986281	CKB	0.52	4.77	0.37	4.31e-6	Body mass index;
UCEC	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.56	-4.98	-0.38	1.76e-6	Carotid intima media thickness;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.51	-5.8	-0.43	3.95e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.66	-5.48	-0.41	1.78e-7	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.0	-7.54	-0.53	4.5e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.19	0.39	6.81e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.64	5.98	0.44	1.6e-8	Aortic root size;
UCEC	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.72	6.75	0.49	3.27e-10	Height;
UCEC	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.43	4.98	0.38	1.8e-6	Alcohol dependence;
UCEC	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	1.25	5.71	0.43	6.02e-8	Parkinson's disease;
UCEC	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.45	-6.16	-0.45	6.73e-9	Prostate cancer;
UCEC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.04	11.93	0.7	2.28e-23	Cognitive ability;
UCEC	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.53	-6.25	-0.46	4.15e-9	Type 2 diabetes;
UCEC	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	0.85	5.37	0.4	3.02e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.69	-7.45	-0.52	7.4e-12	Immature fraction of reticulocytes;
UCEC	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg18681998	chr4:17616180	MED28	-0.61	-6.43	-0.47	1.65e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg05991184	chr2:219186017	PNKD	0.53	5.86	0.43	2.98e-8	Colorectal cancer;
UCEC	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-4.88	-0.37	2.7e-6	Monocyte percentage of white cells;
UCEC	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg03711944	chr11:47377212	SPI1	-0.48	-4.62	-0.36	8.39e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg13683864	chr3:40499215	RPL14	-0.59	-6.12	-0.45	7.95e-9	Renal cell carcinoma;
UCEC	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.08	7.02	0.5	7.65e-11	Schizophrenia;
UCEC	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg05660106	chr1:15850417	CASP9	0.53	5.16	0.39	7.7e-7	Systolic blood pressure;
UCEC	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.62	5.63	0.42	9.04e-8	Pancreatic cancer;
UCEC	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.97	-9.04	-0.6	8.37e-16	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.78	7.3	0.52	1.68e-11	Menopause (age at onset);
UCEC	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.07e-11	Eye color traits;
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.46	-4.96	-0.38	1.91e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-5.37	-0.4	3e-7	Morning vs. evening chronotype;
UCEC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.67	7.35	0.52	1.27e-11	Menopause (age at onset);
UCEC	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-6.36	-0.46	2.36e-9	Morning vs. evening chronotype;
UCEC	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg13683864	chr3:40499215	RPL14	0.72	8.54	0.58	1.57e-14	Renal cell carcinoma;
UCEC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.49	0.41	1.73e-7	Heart rate;
UCEC	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	6.22	0.46	4.83e-9	Migraine;
UCEC	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg21419209	chr3:44054225	NA	-0.49	-5.31	-0.4	3.94e-7	Coronary artery disease;
UCEC	cis	rs731174	0.797	rs670692	chr1:38148124	G/A	cg12339802	chr1:38156545	C1orf109	-0.61	-5.34	-0.4	3.47e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6457821	1.000	rs77934702	chr6:35376775	G/C	cg06087101	chr6:35551932	FKBP5	0.71	4.59	0.35	9.29e-6	Height;
UCEC	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.37	5.4	0.41	2.66e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.87e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1823913	0.599	rs17414109	chr2:192175401	T/A	cg15998761	chr2:191300784	MFSD6	0.39	4.56	0.35	1.08e-5	Obesity-related traits;
UCEC	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.63	7.08	0.5	5.61e-11	Tonsillectomy;
UCEC	cis	rs1940013	0.960	rs12417610	chr11:132291036	C/T	cg27370013	chr11:131780276	NTM	-0.37	-4.52	-0.35	1.26e-5	Sleep-related phenotypes;
UCEC	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.84	0.54	8.33e-13	Coffee consumption (cups per day);
UCEC	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.63	6.17	0.45	6.19e-9	Lung cancer;
UCEC	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.76	0.63	1.16e-17	Platelet count;
UCEC	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	0.72	9.71	0.63	1.59e-17	Monocyte percentage of white cells;
UCEC	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.73	-4.86	-0.37	2.93e-6	Narcolepsy;
UCEC	cis	rs7088591	0.867	rs79061453	chr10:59784487	C/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.56	-6.79	-0.49	2.57e-10	Total body bone mineral density;
UCEC	cis	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg07636037	chr3:49044803	WDR6	0.56	4.54	0.35	1.15e-5	Menarche (age at onset);
UCEC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.83	4.72	0.36	5.37e-6	Diabetic retinopathy;
UCEC	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	18.41	0.84	5.47e-40	Schizophrenia;
UCEC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.48	5.45	0.41	2.04e-7	Dental caries;
UCEC	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.37	0.52	1.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg16423285	chr20:60520624	NA	0.52	4.81	0.37	3.76e-6	Obesity-related traits;
UCEC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.44	-5.41	-0.41	2.54e-7	Blood protein levels;
UCEC	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.88	11.34	0.68	8.17e-22	Metabolic syndrome;
UCEC	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg25664220	chr3:72788482	NA	-0.63	-5.39	-0.41	2.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11568819	1.000	rs11568819	chr11:102401633	C/T	cg01813071	chr11:102401616	MMP7	1.01	5.29	0.4	4.43e-7	Blood protein levels;
UCEC	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg07537917	chr2:241836409	C2orf54	-0.32	-4.87	-0.37	2.86e-6	Urinary metabolites;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.29	-0.4	4.45e-7	Cardiac Troponin-T levels;
UCEC	cis	rs2882667	0.654	rs7709770	chr5:138149339	A/G	cg05839636	chr5:137878905	ETF1	-0.55	-4.59	-0.35	9.38e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.71	0.36	5.75e-6	Breast cancer;
UCEC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.7	6.65	0.48	5.4e-10	Aortic root size;
UCEC	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	6.6	0.48	7.04e-10	Menarche (age at onset);
UCEC	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.69	6.3	0.46	3.23e-9	Breast cancer;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.53	-0.41	1.43e-7	Pubertal anthropometrics;
UCEC	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.4	5.39	0.41	2.68e-7	Longevity;
UCEC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.43	4.62	0.36	8.31e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg17469321	chr7:55412551	NA	0.68	5.98	0.44	1.65e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.13	9.15	0.6	4.36e-16	Vitiligo;
UCEC	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.6	-7.07	-0.5	5.93e-11	Bipolar disorder and schizophrenia;
UCEC	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12826209	chr6:26865740	GUSBL1	0.51	4.88	0.37	2.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.54	6.08	0.45	9.93e-9	Attention deficit hyperactivity disorder;
UCEC	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.7	-7.62	-0.53	2.91e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs2376682	1.000	rs10065812	chr5:118033746	G/A	cg17593721	chr5:118788746	HSD17B4	0.5	4.61	0.36	8.57e-6	Diisocyanate-induced asthma;
UCEC	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg05738196	chr6:26577821	NA	0.6	6.51	0.47	1.1e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.54	6.03	0.45	1.24e-8	Mean corpuscular volume;
UCEC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	7.28	0.51	1.83e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6684428	0.706	rs10888942	chr1:56335432	C/G	cg11651538	chr1:56320950	NA	-0.76	-6.77	-0.49	2.86e-10	Airflow obstruction;
UCEC	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs17106184	0.901	rs59600829	chr1:51405667	C/T	cg07174182	chr1:51127561	FAF1	-0.77	-4.95	-0.38	1.97e-6	Type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-0.76	-7.31	-0.52	1.59e-11	Breast cancer;
UCEC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18252515	chr7:66147081	NA	0.49	4.89	0.37	2.6e-6	Aortic root size;
UCEC	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.55	5.88	0.44	2.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7246967	0.544	rs420861	chr19:23005904	G/T	cg05241461	chr19:22816980	ZNF492	0.49	4.69	0.36	6.13e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.55	5.42	0.41	2.35e-7	Menopause (age at onset);
UCEC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.71	6.9	0.49	1.47e-10	Aortic root size;
UCEC	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.48	5.29	0.4	4.33e-7	Type 2 diabetes;
UCEC	cis	rs1293940	1.000	rs1293940	chr6:151999091	T/C	cg20627916	chr6:152128328	ESR1	-0.39	-4.57	-0.35	1.01e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);
UCEC	cis	rs8080784	0.545	rs12950432	chr17:58832117	G/A	cg22641952	chr17:58219985	NA	-0.51	-4.81	-0.37	3.67e-6	Coronary artery disease;
UCEC	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	5.98	0.44	1.63e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg08222913	chr3:52553049	STAB1	0.41	4.82	0.37	3.51e-6	Electroencephalogram traits;
UCEC	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.45	4.71	0.36	5.74e-6	Gout;
UCEC	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	0.8	4.94	0.38	2.09e-6	Arsenic metabolism;
UCEC	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.53	5.0	0.38	1.59e-6	Blood metabolite levels;
UCEC	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.73	7.86	0.54	7.56e-13	Multiple system atrophy;
UCEC	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-14.02	-0.76	7.02e-29	Schizophrenia;
UCEC	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.61	-5.8	-0.43	3.85e-8	Acne (severe);
UCEC	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.67	-7.41	-0.52	9.34e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-6.14	-0.45	7.43e-9	Hemoglobin concentration;
UCEC	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.49	-5.21	-0.39	6.27e-7	Body mass index;
UCEC	trans	rs4841134	0.625	rs12235038	chr8:9237403	G/T	cg02929982	chr14:63872285	PPP2R5E	-0.58	-6.72	-0.48	3.7e-10	Age-related disease endophenotypes;
UCEC	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.47	-5.01	-0.38	1.53e-6	Platelet count;
UCEC	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.6	6.53	0.47	9.82e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.68	-6.75	-0.49	3.15e-10	Dilated cardiomyopathy;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.4	-4.52	-0.35	1.27e-5	Myopia;
UCEC	cis	rs12634933	0.737	rs16853481	chr3:169031754	C/T	cg03603669	chr3:169896616	PHC3	-0.47	-4.62	-0.36	8.31e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.73	-8.88	-0.59	2.1e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.5	4.98	0.38	1.76e-6	QRS complex (12-leadsum);
UCEC	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.65	6.65	0.48	5.35e-10	Chronic sinus infection;
UCEC	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.54	4.95	0.38	2.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.74	-4.81	-0.37	3.76e-6	Hair shape;
UCEC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.51	5.28	0.4	4.6e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.83	-11.45	-0.69	4.28e-22	Urate levels in lean individuals;
UCEC	cis	rs4499344	0.768	rs10411319	chr19:33102805	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.74	0.43	5.27e-8	Mean platelet volume;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.4	-4.74	-0.36	4.92e-6	Depression;
UCEC	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg17933807	chr1:38061675	GNL2	0.96	11.71	0.69	8.87e-23	Axial length;
UCEC	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.48	6.3	0.46	3.26e-9	Coronary heart disease;
UCEC	cis	rs944990	0.640	rs2398846	chr9:96365743	A/T	cg13787134	chr9:96362102	PHF2	-0.37	-4.85	-0.37	3.14e-6	Body mass index;
UCEC	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.57	-6.4	-0.47	2e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.81	8.3	0.56	6.16e-14	Longevity;Endometriosis;
UCEC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.62	-7.19	-0.51	3e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6437061	0.805	rs1078093	chr2:233087245	G/A	cg02061626	chr2:233274167	ALPPL2	0.48	5.23	0.4	5.77e-7	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	8.04e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs883565	0.696	rs7620304	chr3:39079623	T/A	cg01426195	chr3:39028469	NA	-0.68	-8.52	-0.58	1.71e-14	Handedness;
UCEC	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	4.93	0.38	2.21e-6	Response to antipsychotic treatment;
UCEC	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.53	5.53	0.42	1.42e-7	Dupuytren's disease;
UCEC	cis	rs7307889	0.793	rs56201315	chr12:6013379	G/C	cg10294363	chr12:6480192	SCNN1A	0.65	4.65	0.36	7.23e-6	Obesity-related traits;
UCEC	cis	rs2336384	1.000	rs6672267	chr1:12054911	A/G	cg13216073	chr1:12042593	MFN2	0.46	4.59	0.35	9.41e-6	Platelet count;
UCEC	cis	rs6688613	0.685	rs11579987	chr1:166889364	C/G	cg07049167	chr1:166818506	POGK	-0.56	-5.13	-0.39	8.84e-7	Refractive astigmatism;
UCEC	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.15	0.45	7.04e-9	Motion sickness;
UCEC	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.54	5.07	0.39	1.18e-6	Coronary artery disease;
UCEC	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs7246967	0.932	rs35948178	chr19:23028519	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-5.26	-0.4	5.1e-7	Life satisfaction;
UCEC	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.8	-0.37	3.83e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.72	6.21	0.46	5.03e-9	Mammographic density (dense area);
UCEC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.66	-5.46	-0.41	1.96e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg18099408	chr3:52552593	STAB1	-0.44	-5.2	-0.39	6.48e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.38	0.41	2.94e-7	Hemoglobin concentration;
UCEC	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.71	0.58	5.94e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg01072550	chr1:21505969	NA	-0.59	-5.62	-0.42	9.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.53	-5.12	-0.39	9.28e-7	IgG glycosylation;
UCEC	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.68	6.27	0.46	3.79e-9	Multiple sclerosis;
UCEC	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.63	-6.17	-0.45	6.39e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs66686620	1.000	rs6724990	chr2:69247789	C/T	cg12800200	chr2:69260302	ANTXR1	0.54	5.21	0.39	6.22e-7	Breast cancer;
UCEC	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.42	4.98	0.38	1.77e-6	QRS complex (12-leadsum);
UCEC	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.56	5.04	0.38	1.37e-6	Corneal astigmatism;
UCEC	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.63	-5.12	-0.39	9.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.56	5.03	0.38	1.42e-6	Selective IgA deficiency;
UCEC	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg20026190	chr17:76395443	PGS1	0.4	4.81	0.37	3.73e-6	HDL cholesterol levels;
UCEC	cis	rs17122693	1.000	rs2934682	chr14:51061207	A/T	cg04730355	chr14:51134070	SAV1	0.64	6.45	0.47	1.48e-9	Cognitive performance;
UCEC	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.85	7.13	0.51	4.17e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.65	-5.88	-0.44	2.72e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-4.6	-0.36	8.87e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.64	-5.81	-0.43	3.74e-8	Subjective well-being;
UCEC	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	5.01	0.38	1.55e-6	Breast cancer;
UCEC	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg09021430	chr5:549028	NA	-0.57	-5.26	-0.4	5.05e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.49	4.7	0.36	6.01e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg20026190	chr17:76395443	PGS1	0.38	4.63	0.36	8.14e-6	HDL cholesterol levels;
UCEC	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.7	-7.91	-0.55	5.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.51	-5.74	-0.43	5.2100000000000003e-08	Crohn's disease;
UCEC	trans	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg02900749	chr2:68251473	NA	-1.0	-7.7	-0.54	1.85e-12	Pursuit maintenance gain;
UCEC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.57	4.65	0.36	7.4e-6	Initial pursuit acceleration;
UCEC	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4713118	0.666	rs2893930	chr6:27738806	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-4.52	-0.35	1.28e-5	Parkinson's disease;
UCEC	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.66	-4.64	-0.36	7.54e-6	Aortic root size;
UCEC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.53	-5.64	-0.42	8.56e-8	Monocyte count;
UCEC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	17.69	0.82	3.12e-38	Chronic sinus infection;
UCEC	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg16511985	chr3:153974050	SGEF	0.59	5.34	0.4	3.44e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.86	9.57	0.62	3.6e-17	Breast cancer;
UCEC	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg14675211	chr2:100938903	LONRF2	0.47	4.84	0.37	3.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg04871131	chr7:94954202	PON1	-0.53	-5.19	-0.39	6.74e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	0.92	6.86	0.49	1.82e-10	Alzheimer's disease (late onset);
UCEC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	4.6	0.35	9.16e-6	Response to antipsychotic treatment;
UCEC	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.59	-0.42	1.05e-7	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.75	5.68	0.42	7.04e-8	Exhaled nitric oxide output;
UCEC	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.12e-18	Height;
UCEC	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.82	5.49	0.41	1.71e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-7.46	-0.52	6.96e-12	Total body bone mineral density;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.88	-0.37	2.77e-6	Depression;
UCEC	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.62	7.46	0.52	7.02e-12	Oral cavity cancer;
UCEC	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.78	0.37	4.21e-6	Bladder cancer;
UCEC	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg16584290	chr5:462447	EXOC3	-0.44	-4.57	-0.35	1.03e-5	Cystic fibrosis severity;
UCEC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg05991184	chr2:219186017	PNKD	-0.45	-4.79	-0.37	4.1e-6	Colorectal cancer;
UCEC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.42	-4.85	-0.37	3.07e-6	Age at first birth;
UCEC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-6.13	-0.45	7.53e-9	Tonsillectomy;
UCEC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.37	-5.44	-0.41	2.19e-7	Ulcerative colitis;
UCEC	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.91	8.62	0.58	9.52e-15	Colorectal adenoma (advanced);
UCEC	cis	rs12681287	0.752	rs4310184	chr8:87245253	T/C	cg27223183	chr8:87520930	FAM82B	-0.63	-5.4	-0.41	2.67e-7	Caudate activity during reward;
UCEC	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.69	5.56	0.42	1.24e-7	Type 2 diabetes;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.74	-8.31	-0.57	5.9e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.55	-5.43	-0.41	2.29e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.18e-6	Vitiligo;
UCEC	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.61	7.92	0.55	5.49e-13	Weight;
UCEC	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06671706	chr8:8559999	CLDN23	0.66	5.34	0.4	3.47e-7	Obesity-related traits;
UCEC	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.53	4.92	0.38	2.25e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-4.71	-0.36	5.76e-6	Height;
UCEC	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg26513180	chr16:89883248	FANCA	-0.44	-4.67	-0.36	6.64e-6	Vitiligo;
UCEC	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg05991184	chr2:219186017	PNKD	0.46	5.11	0.39	9.82e-7	Ulcerative colitis;
UCEC	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs4908768	0.906	rs12145445	chr1:8604370	C/G	cg13081009	chr1:8430745	RERE	0.42	4.57	0.35	1.01e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.75	-8.51	-0.57	1.81e-14	Extraversion;
UCEC	cis	rs11239537	1	rs11239537	chr10:45982508	T/C	cg15223267	chr10:46222474	FAM21C	0.49	4.83	0.37	3.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.96	10.54	0.66	1.06e-19	Cognitive function;
UCEC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.64	-7.2	-0.51	2.88e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18252515	chr7:66147081	NA	-0.54	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.57	6.41	0.47	1.83e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.68	5.89	0.44	2.58e-8	Platelet count;
UCEC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.51	0.41	1.57e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.6	0.42	1.03e-7	Cognitive test performance;
UCEC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.53	4.73	0.36	5.29e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg22868518	chr11:507468	RNH1	-0.57	-5.68	-0.42	6.82e-8	Systemic lupus erythematosus;
UCEC	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	8.57	0.58	1.32e-14	Nonalcoholic fatty liver disease;
UCEC	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.57	5.93	0.44	2.06e-8	Breast cancer;
UCEC	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	0.86	8.22	0.56	9.65e-14	Cognitive function;
UCEC	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7246967	0.673	rs3853649	chr19:22880460	C/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	11.61	0.69	1.56e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.5	5.54	0.42	1.34e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg24375607	chr4:120327624	NA	0.47	4.93	0.38	2.24e-6	Corneal astigmatism;
UCEC	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-0.91	-6.44	-0.47	1.59e-9	Coronary artery disease;
UCEC	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.25	-7.8	-0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	5.65	0.42	8.06e-8	Platelet count;
UCEC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.06	0.5	6.09e-11	Multiple sclerosis;
UCEC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	5.9	0.44	2.41e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.31	-10.38	-0.65	2.78e-19	Hip circumference adjusted for BMI;
UCEC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.94	9.77	0.63	1.09e-17	Cognitive ability;
UCEC	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg08890418	chr1:21044141	KIF17	0.53	5.11	0.39	9.79e-7	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs11958404	0.858	rs72818142	chr5:157474934	C/T	cg05962755	chr5:157440814	NA	0.78	5.52	0.41	1.47e-7	IgG glycosylation;
UCEC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg16497661	chr14:103986332	CKB	0.5	5.82	0.43	3.61e-8	Body mass index;
UCEC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.46	-4.69	-0.36	6.07e-6	Pulse pressure;
UCEC	cis	rs1978968	0.869	rs35035092	chr22:18463274	G/T	cg03078520	chr22:18463400	MICAL3	-0.56	-5.53	-0.42	1.41e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.59	0.48	7.32e-10	Coffee consumption (cups per day);
UCEC	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.81	7.27	0.51	1.98e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.67	5.59	0.42	1.06e-7	Body mass index;
UCEC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23156509	chr2:114033830	PAX8;LOC440839	-0.53	-5.13	-0.39	8.95e-7	Lymphocyte counts;
UCEC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.74	-5.63	-0.42	9e-8	Birth weight;
UCEC	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.47	-5.66	-0.42	7.76e-8	Subjective well-being;
UCEC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.34	-4.71	-0.36	5.71e-6	Menopause (age at onset);
UCEC	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.15e-6	Primary biliary cholangitis;
UCEC	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.88	12.34	0.71	1.89e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-0.58	-5.81	-0.43	3.7e-8	Pediatric autoimmune diseases;
UCEC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.86	9.34	0.61	1.41e-16	Dental caries;
UCEC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.63	-6.85	-0.49	1.91e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.38	4.79	0.37	4.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.62e-7	Bipolar disorder;
UCEC	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.71	6.41	0.47	1.86e-9	Response to antineoplastic agents;
UCEC	trans	rs12476592	0.602	rs11125977	chr2:63809549	C/T	cg20689730	chr22:20072653	MIR1306;DGCR8	-0.69	-6.69	-0.48	4.43e-10	Childhood ear infection;
UCEC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.72	9.14	0.6	4.72e-16	Rheumatoid arthritis;
UCEC	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-6.22	-0.46	4.79e-9	Tonsillectomy;
UCEC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs4713118	0.669	rs200997	chr6:27811815	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.52	-5.19	-0.39	6.91e-7	Parkinson's disease;
UCEC	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-6.25	-0.46	4.22e-9	Personality dimensions;
UCEC	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg20560298	chr2:73613845	ALMS1	0.53	5.16	0.39	7.87e-7	Schizophrenia;
UCEC	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.85	-7.04	-0.5	6.96e-11	Body mass index;
UCEC	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.68	-7.75	-0.54	1.43e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-7.32	-0.52	1.46e-11	Menarche (age at onset);
UCEC	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.54	-6.0	-0.44	1.45e-8	Diastolic blood pressure;
UCEC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.51	4.83	0.37	3.4e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3736594	0.546	rs6734059	chr2:27808154	C/T	cg27432699	chr2:27873401	GPN1	-0.51	-4.84	-0.37	3.21e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg05738196	chr6:26577821	NA	0.61	6.78	0.49	2.72e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.55	-6.37	-0.47	2.23e-9	Type 2 diabetes;
UCEC	cis	rs4919044	0.866	rs55661575	chr10:94825108	C/T	cg00519463	chr10:94352821	KIF11	0.96	5.36	0.4	3.11e-7	Coronary artery disease;
UCEC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg07387570	chr22:46663686	TTC38	-0.47	-4.63	-0.36	7.91e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.79	0.37	4.01e-6	Breast cancer;
UCEC	cis	rs1355223	0.752	rs896856	chr11:34676842	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-4.71	-0.36	5.72e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.76	-6.89	-0.49	1.53e-10	Initial pursuit acceleration;
UCEC	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.63	-5.08	-0.39	1.12e-6	Menarche (age at onset);
UCEC	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.15	-9.34	-0.61	1.45e-16	Vitiligo;
UCEC	cis	rs7246967	0.866	rs7250801	chr19:23035957	G/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.63	-5.65	-0.42	8.08e-8	Pulmonary function;
UCEC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.46	-5.1	-0.39	1.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg05962950	chr11:130786565	SNX19	-0.64	-6.85	-0.49	1.9e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.55	0.53	4.29e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	0.83	6.4	0.47	1.95e-9	Corneal structure;
UCEC	cis	rs7826222	0.589	rs4509327	chr8:9862937	C/G	cg00629382	chr8:10268916	MSRA	-0.65	-4.56	-0.35	1.09e-5	Adiposity;
UCEC	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg19567339	chr10:100142640	NA	-0.52	-5.88	-0.44	2.7e-8	Metabolite levels;
UCEC	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.99	14.8	0.77	6.32e-31	Bone mineral density;
UCEC	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.08	13.06	0.73	2.36e-26	Ulcerative colitis;
UCEC	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg19197139	chr17:4613644	ARRB2	0.82	6.18	0.45	5.92e-9	Lymphocyte counts;
UCEC	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.5	6.21	0.46	5.1e-9	Information processing speed;
UCEC	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.88	8.55	0.58	1.44e-14	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-4.88	-0.37	2.78e-6	Gut microbiome composition (summer);
UCEC	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-4.84	-0.37	3.19e-6	Non-small cell lung cancer;
UCEC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.49	-5.52	-0.41	1.5e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg20387954	chr3:183756860	HTR3D	0.5	6.02	0.44	1.32e-8	Anterior chamber depth;
UCEC	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.69	6.09	0.45	9.44e-9	Alzheimer's disease;
UCEC	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	7.3	0.52	1.65e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	4.6	0.35	9.24e-6	Bipolar disorder;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.56	-6.64	-0.48	5.61e-10	Pubertal anthropometrics;
UCEC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs7072216	0.881	rs11189591	chr10:100155296	T/G	cg19567339	chr10:100142640	NA	0.64	9.26	0.61	2.27e-16	Metabolite levels;
UCEC	cis	rs526231	0.543	rs34804	chr5:102428239	G/A	cg23492399	chr5:102201601	PAM	-0.57	-4.65	-0.36	7.39e-6	Primary biliary cholangitis;
UCEC	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg08916839	chr5:415575	AHRR	0.49	4.51	0.35	1.33e-5	Cystic fibrosis severity;
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.83	9.52	0.62	4.98e-17	Menarche (age at onset);
UCEC	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.73	-8.34	-0.57	5.06e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-4.81	-0.37	3.66e-6	Pediatric autoimmune diseases;
UCEC	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg03859395	chr2:55845619	SMEK2	1.02	14.34	0.76	1.01e-29	Metabolic syndrome;
UCEC	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-5.96	-0.44	1.75e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg03037974	chr15:76606532	NA	0.32	4.55	0.35	1.13e-5	Blood metabolite levels;
UCEC	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.68	-9.71	-0.63	1.57e-17	Neuroticism;
UCEC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.59	6.36	0.46	2.39e-9	Schizophrenia;
UCEC	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.61	-4.83	-0.37	3.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11760485	0.965	rs4723684	chr7:4400850	A/G	cg15613991	chr7:5277080	NA	-0.4	-4.73	-0.36	5.11e-6	Early childhood aggressive behavior;
UCEC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.32	0.52	1.5e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg26721908	chr21:47610096	LSS	-0.43	-5.61	-0.42	9.9e-8	Testicular germ cell tumor;
UCEC	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.5	6.06	0.45	1.09e-8	Coronary artery disease;
UCEC	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.73	-4.73	-0.36	5.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.05	-0.38	1.28e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.92	0.38	2.31e-6	Diabetic retinopathy;
UCEC	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.47	5.26	0.4	5.07e-7	Facial morphology (factor 20);
UCEC	cis	rs239198	0.521	rs9377241	chr6:101334265	C/T	cg09795085	chr6:101329169	ASCC3	0.47	4.53	0.35	1.22e-5	Menarche (age at onset);
UCEC	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-5.17	-0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.73	-4.81	-0.37	3.75e-6	LDL cholesterol levels;
UCEC	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg12850546	chr22:42539477	CYP2D7P1	-0.75	-5.76	-0.43	4.85e-8	Birth weight;
UCEC	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.61	-6.94	-0.5	1.14e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.23	0.56	9.47e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.67	-7.33	-0.52	1.41e-11	Ear protrusion;
UCEC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg19413350	chr8:57351067	NA	-0.44	-4.84	-0.37	3.23e-6	Obesity-related traits;
UCEC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.43	0.41	2.3e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.62	5.41	0.41	2.48e-7	Coronary artery disease;
UCEC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-8.61	-0.58	1.06e-14	Bipolar disorder and schizophrenia;
UCEC	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.48	-5.36	-0.4	3.19e-7	Colorectal cancer;
UCEC	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.26	-6.87	-0.49	1.72e-10	Atopic dermatitis;
UCEC	cis	rs7959452	1.000	rs2168029	chr12:69734641	A/C	cg20891283	chr12:69753455	YEATS4	0.73	7.51	0.53	5.34e-12	Blood protein levels;
UCEC	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	5.94	0.44	1.99e-8	Coffee consumption (cups per day);
UCEC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.35	-4.54	-0.35	1.17e-5	Monocyte count;
UCEC	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.9	-0.37	2.47e-6	Aortic root size;
UCEC	cis	rs2280630	0.529	rs6599010	chr3:39153222	C/T	cg01426195	chr3:39028469	NA	-0.69	-8.31	-0.57	5.85e-14	Verbal declarative memory;
UCEC	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg00639195	chr15:79103007	ADAMTS7	-0.53	-4.66	-0.36	7.13e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg06238570	chr21:40685208	BRWD1	0.7	6.7	0.48	4.25e-10	Cognitive function;
UCEC	cis	rs6832769	1.000	rs9684708	chr4:56430381	G/A	cg05960024	chr4:56376020	CLOCK	-0.57	-5.74	-0.43	5.25e-8	Personality dimensions;
UCEC	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	0.9	5.4	0.41	2.61e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.53	-4.58	-0.35	9.96e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-5.76	-0.43	4.86e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.58	6.23	0.46	4.67e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.59	-6.6	-0.48	7.09e-10	Menarche (age at onset);
UCEC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.77	-8.8	-0.59	3.45e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs3956705	1.000	rs3956705	chr7:32953295	C/T	cg05721444	chr7:32995514	FKBP9	-0.47	-4.72	-0.36	5.53e-6	Red cell distribution width;
UCEC	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.41e-8	Height;
UCEC	cis	rs56330463	0.967	rs2082395	chr5:148200600	A/G	cg16699715	chr5:148961007	FLJ41603	-0.43	-4.52	-0.35	1.25e-5	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;Eosinophil percentage of white cells;Monocyte percentage of white cells;Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;
UCEC	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.46	-0.52	6.88e-12	Resting heart rate;
UCEC	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-4.97	-0.38	1.85e-6	Bipolar disorder;
UCEC	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.78	-9.37	-0.61	1.22e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.57e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.82	11.12	0.68	3.1e-21	Headache;
UCEC	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.03	-8.47	-0.57	2.35e-14	Exhaled nitric oxide output;
UCEC	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.37	-4.78	-0.37	4.27e-6	Body mass index;
UCEC	cis	rs7560272	0.538	rs7599453	chr2:73937901	T/G	cg20560298	chr2:73613845	ALMS1	0.48	4.56	0.35	1.08e-5	Schizophrenia;
UCEC	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-5.37	-0.4	3.05e-7	QT interval;
UCEC	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg24851651	chr11:66362959	CCS	-0.39	-4.91	-0.38	2.35e-6	Educational attainment (years of education);
UCEC	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	0.88	6.38	0.47	2.22e-9	Red blood cell traits;
UCEC	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.47	6.11	0.45	8.39e-9	Sitting height ratio;
UCEC	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.65	-6.95	-0.5	1.09e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg11498726	chr8:26250323	BNIP3L	-0.54	-5.16	-0.39	7.99e-7	Red cell distribution width;
UCEC	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.71	7.19	0.51	3.11e-11	Primary sclerosing cholangitis;
UCEC	cis	rs10242455	0.867	rs10211	chr7:99302994	C/T	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	6.74e-7	Blood metabolite levels;
UCEC	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg17515076	chr17:73810948	UNK	0.46	4.99	0.38	1.7e-6	White matter hyperintensity burden;
UCEC	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg11569703	chr11:65557185	OVOL1	0.48	6.25	0.46	4.27e-9	Acne (severe);
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg21856205	chr7:94953877	PON1	-0.57	-5.07	-0.39	1.2e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs36051895	0.589	rs10122037	chr9:5192874	A/G	cg02405213	chr9:5042618	JAK2	0.53	5.14	0.39	8.6e-7	Pediatric autoimmune diseases;
UCEC	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.53	-5.07	-0.39	1.19e-6	Pediatric autoimmune diseases;
UCEC	cis	rs6684428	0.706	rs12138137	chr1:56325176	C/T	cg11651538	chr1:56320950	NA	-0.75	-6.56	-0.48	8.79e-10	Airflow obstruction;
UCEC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	1.01	12.88	0.73	6.94e-26	Monocyte count;
UCEC	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs8042680	0.554	rs1867226	chr15:91523713	C/G	cg14398957	chr15:91536180	PRC1	-0.44	-4.67	-0.36	6.77e-6	Type 2 diabetes;
UCEC	trans	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg26043149	chr18:55253948	FECH	-0.84	-8.49	-0.57	2.11e-14	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18252515	chr7:66147081	NA	0.53	4.97	0.38	1.81e-6	Aortic root size;
UCEC	cis	rs7246967	0.673	rs2361245	chr19:22834530	A/G	cg05241461	chr19:22816980	ZNF492	0.56	6.03	0.45	1.25e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12506899	0.934	rs714825	chr4:74208199	A/G	cg19660515	chr4:74285329	ALB	0.32	4.57	0.35	1.01e-5	Tumor biomarkers;
UCEC	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg21466736	chr12:48725269	NA	0.38	4.59	0.35	9.31e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.68	4.75	0.37	4.7e-6	Menopause (age at onset);
UCEC	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.66	5.51	0.41	1.58e-7	Body mass index;
UCEC	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg01689657	chr7:91764605	CYP51A1	0.5	6.48	0.47	1.29e-9	Breast cancer;
UCEC	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	4.8	0.37	3.79e-6	HDL cholesterol;
UCEC	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg18099408	chr3:52552593	STAB1	-0.42	-4.51	-0.35	1.34e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-7.09	-0.5	5.35e-11	Parkinson's disease;
UCEC	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.52	5.41	0.41	2.52e-7	Schizophrenia;
UCEC	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19500275	chr17:80737654	TBCD	0.47	4.6	0.35	9.03e-6	Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	0.78	7.4	0.52	9.88e-12	Breast cancer;
UCEC	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	0.67	4.87	0.37	2.9e-6	Diabetic retinopathy;
UCEC	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.52e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.82	-7.02	-0.5	7.67e-11	Initial pursuit acceleration;
UCEC	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-4.69	-0.36	6.12e-6	Heart rate;
UCEC	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.74	6.6	0.48	7.12e-10	Coronary artery disease;
UCEC	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg19041857	chr6:27730383	NA	-0.64	-5.05	-0.38	1.3e-6	Lung cancer in ever smokers;
UCEC	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg17259809	chr10:104614391	C10orf32	-0.71	-4.67	-0.36	6.62e-6	Arsenic metabolism;
UCEC	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.58	5.01	0.38	1.57e-6	Multiple sclerosis;
UCEC	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.63	6.78	0.49	2.73e-10	Lung cancer in ever smokers;
UCEC	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.57	5.09	0.39	1.08e-6	Corneal astigmatism;
UCEC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.83	6.5	0.47	1.17e-9	Lymphocyte counts;
UCEC	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.44	-5.05	-0.38	1.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18252515	chr7:66147081	NA	-0.52	-5.11	-0.39	9.78e-7	Aortic root size;
UCEC	cis	rs13401104	0.732	rs11692797	chr2:237110032	C/A	cg23897927	chr2:237117786	ASB18	-0.51	-4.54	-0.35	1.14e-5	Educational attainment;
UCEC	cis	rs2950163	0.947	rs751052	chr2:6177539	A/G	cg04174211	chr2:7058432	RNF144A	-0.51	-4.56	-0.35	1.07e-5	Response to metformin (IC50);
UCEC	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.81	-0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.63	-5.64	-0.42	8.46e-8	Pulmonary function;
UCEC	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg06462663	chr19:18546047	ISYNA1	-0.48	-5.98	-0.44	1.66e-8	Breast cancer;
UCEC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	4.99	0.38	1.66e-6	Bipolar disorder;
UCEC	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.8	-8.13	-0.56	1.63e-13	Blood metabolite levels;
UCEC	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.7	0.36	5.92e-6	Breast cancer;
UCEC	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-1.08	-6.94	-0.5	1.17e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg22815214	chr1:201083145	CACNA1S	-0.43	-4.77	-0.37	4.41e-6	Permanent tooth development;
UCEC	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.52	-5.21	-0.4	6.14e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.07	-6.82	-0.49	2.2e-10	Breast cancer;
UCEC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.56	6.0	0.44	1.44e-8	Menarche (age at onset);
UCEC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg00343986	chr7:65444356	GUSB	-0.52	-4.85	-0.37	3.16e-6	Aortic root size;
UCEC	cis	rs10208940	0.920	rs7576303	chr2:68838019	G/A	cg12452813	chr2:68675892	NA	0.48	4.63	0.36	7.91e-6	Urate levels in lean individuals;
UCEC	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.45	4.92	0.38	2.27e-6	Emphysema distribution in smoking;
UCEC	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.59	-6.48	-0.47	1.33e-9	Crohn's disease;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.41	4.78	0.37	4.12e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.68	5.74	0.43	5.22e-8	Alcohol dependence;
UCEC	cis	rs7597155	0.846	rs6546545	chr2:69961847	T/C	cg02498382	chr2:70120550	SNRNP27	-0.52	-5.68	-0.42	7.07e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.48	-5.07	-0.39	1.2e-6	Bipolar disorder;
UCEC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-4.59	-0.35	9.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	0.95	13.11	0.73	1.67e-26	Homoarginine levels;
UCEC	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg15764593	chr10:829463	NA	-0.56	-4.68	-0.36	6.45e-6	Uric acid levels;
UCEC	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-0.97	-6.31	-0.46	3.06e-9	Diabetic kidney disease;
UCEC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.47	5.5	0.41	1.6e-7	Aortic root size;
UCEC	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.76	6.78	0.49	2.69e-10	Caudate activity during reward;
UCEC	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.9	12.1	0.71	8e-24	Metabolic syndrome;
UCEC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-6.16	-0.45	6.75e-9	Personality dimensions;
UCEC	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.44	4.55	0.35	1.12e-5	Hypertriglyceridemia;
UCEC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.63	6.52	0.47	1.08e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg06784218	chr1:46089804	CCDC17	0.42	4.99	0.38	1.7e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg07636037	chr3:49044803	WDR6	-0.59	-4.7	-0.36	5.97e-6	Menarche (age at onset);
UCEC	cis	rs9463078	0.739	rs1041333	chr6:44945206	A/T	cg25276700	chr6:44698697	NA	-0.45	-5.08	-0.39	1.1e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.09	-7.01	-0.5	8.04e-11	Schizophrenia;
UCEC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg06154544	chr16:764854	METRN	-0.44	-5.04	-0.38	1.34e-6	Height;
UCEC	cis	rs2892463	0.796	rs6490430	chr13:30378701	T/C	cg18356743	chr13:30408050	UBL3	0.4	4.53	0.35	1.2e-5	Non-word repetition;
UCEC	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.58	-4.61	-0.36	8.61e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.08	-0.45	1e-8	Morning vs. evening chronotype;
UCEC	cis	rs12681287	0.752	rs10111095	chr8:87250984	T/C	cg27223183	chr8:87520930	FAM82B	-0.57	-4.64	-0.36	7.72e-6	Caudate activity during reward;
UCEC	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg21191810	chr6:118973309	C6orf204	0.44	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.66	0.48	5.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.59	5.47	0.41	1.88e-7	Schizophrenia;
UCEC	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.71	-0.43	5.98e-8	Hemoglobin concentration;
UCEC	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.57	-4.62	-0.36	8.32e-6	Menopause (age at onset);
UCEC	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg21770322	chr7:97807741	LMTK2	0.47	5.93	0.44	2.04e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.58	-4.63	-0.36	8.01e-6	Menopause (age at onset);
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.83	0.59	2.82e-15	Platelet count;
UCEC	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg11494091	chr17:61959527	GH2	-0.59	-7.46	-0.52	6.91e-12	Prudent dietary pattern;
UCEC	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.09	-0.39	1.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.63	-5.45	-0.41	2.05e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.51	4.99	0.38	1.7e-6	Emphysema distribution in smoking;
UCEC	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.45	-0.52	7.34e-12	Body mass index;
UCEC	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.61	0.42	9.98e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg03711944	chr11:47377212	SPI1	-0.51	-4.71	-0.36	5.77e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1712517	0.836	rs7093039	chr10:105149547	A/G	cg05636881	chr10:105038444	INA	0.42	5.0	0.38	1.6e-6	Migraine;
UCEC	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg02160872	chr5:212506	CCDC127	-0.79	-8.14	-0.56	1.52e-13	Breast cancer;
UCEC	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.19	-0.45	5.58e-9	Response to antipsychotic treatment;
UCEC	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.88	-9.82	-0.63	8.01e-18	Blood metabolite levels;
UCEC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.57	0.42	1.18e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg04154034	chr17:28927549	LRRC37B2	0.83	4.95	0.38	1.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.74	-4.78	-0.37	4.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.58	8.24	0.56	8.63e-14	Total body bone mineral density;
UCEC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.5	-4.52	-0.35	1.29e-5	Tuberculosis;
UCEC	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg18681998	chr4:17616180	MED28	0.79	9.2	0.6	3.25e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	9.03	0.6	8.72e-16	Chronic sinus infection;
UCEC	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.09	8.7	0.58	6.28e-15	Uric acid levels;
UCEC	cis	rs539096	0.789	rs10890253	chr1:44021456	C/G	cg11851915	chr1:44060116	PTPRF	0.43	4.54	0.35	1.14e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs34390795	1	rs34390795	chr12:133112394	CGT/C	cg06183872	chr12:133049993	NA	0.67	6.93	0.5	1.2e-10	Red blood cell count;
UCEC	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.53	-5.4	-0.41	2.57e-7	Monocyte count;
UCEC	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg26769984	chr7:1090371	C7orf50	0.48	4.62	0.36	8.47e-6	Longevity;Endometriosis;
UCEC	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.01	-7.61	-0.53	2.98e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.97	4.8	0.37	3.82e-6	Thyroid stimulating hormone;
UCEC	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.61	-0.48	6.56e-10	Depression;
UCEC	cis	rs877674	1.000	rs4949222	chr1:32220915	G/T	cg07656362	chr1:32688117	C1orf91;EIF3I	0.84	4.88	0.37	2.71e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.27	-0.46	3.72e-9	Personality dimensions;
UCEC	cis	rs10242455	0.571	rs45532337	chr7:99310319	A/G	cg18809830	chr7:99032528	PTCD1	-0.71	-4.7	-0.36	5.97e-6	Blood metabolite levels;
UCEC	cis	rs6670533	0.571	rs11801912	chr1:24861373	T/C	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg07836142	chr6:28411423	ZSCAN23	0.53	6.34	0.46	2.65e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg14851346	chr12:38532713	NA	-0.47	-4.59	-0.35	9.36e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.52	5.39	0.41	2.69e-7	Dupuytren's disease;
UCEC	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.72	-8.3	-0.57	6.1e-14	Waist circumference;Body mass index;
UCEC	cis	rs1868673	0.679	rs6414375	chr3:150139360	A/G	cg24290546	chr3:150134309	TSC22D2	-0.49	-4.58	-0.35	9.83e-6	Waist circumference;
UCEC	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.5	5.13	0.39	8.96e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.5	4.79	0.37	3.97e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11697848	1.000	rs79590385	chr20:48580964	T/A	cg17849948	chr20:48532315	SPATA2	0.87	4.68	0.36	6.44e-6	Systemic lupus erythematosus;
UCEC	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.78	6.37	0.46	2.34e-9	Lymphocyte counts;
UCEC	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.52	6.04	0.45	1.18e-8	Calcium levels;
UCEC	cis	rs11679564	0.714	rs4670638	chr2:37164911	C/G	cg14987922	chr2:37194071	STRN	0.56	4.64	0.36	7.5e-6	Immature fraction of reticulocytes;
UCEC	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.55	6.93	0.5	1.25e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.47	-6.08	-0.45	9.74e-9	Mean platelet volume;
UCEC	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.75	-0.43	4.97e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg08461772	chr7:95026248	PON3	0.41	5.34	0.4	3.39e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.14	10.57	0.66	8.74e-20	Vitiligo;
UCEC	cis	rs7781557	1.000	rs17474893	chr7:102480757	C/T	cg06322601	chr7:102330635	NA	0.76	6.66	0.48	5.23e-10	Colorectal adenoma (advanced);
UCEC	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.49	4.56	0.35	1.09e-5	Retinal vascular caliber;
UCEC	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs75804782	0.581	rs55931535	chr2:239372632	A/G	cg12524725	chr2:239427019	NA	-0.69	-4.7	-0.36	5.89e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.31	0.52	1.62e-11	Bladder cancer;
UCEC	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.62	-6.44	-0.47	1.59e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg21253087	chr9:139290292	SNAPC4	0.45	5.13	0.39	9.15e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.7	-8.79	-0.59	3.62e-15	Monocyte count;
UCEC	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.56	-5.87	-0.44	2.78e-8	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-13.35	-0.74	3.95e-27	Body mass index;
UCEC	cis	rs9356171	0.572	rs2281406	chr6:164325848	C/T	cg25752492	chr6:164341247	NA	-0.59	-5.89	-0.44	2.47e-8	Diisocyanate-induced asthma;
UCEC	cis	rs7246967	0.551	rs75360744	chr19:22857956	G/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.65	4.57	0.35	1.04e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.62	-6.6	-0.48	6.96e-10	Motion sickness;
UCEC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.63	-0.42	8.99e-8	Metabolite levels;
UCEC	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.41	5.29	0.4	4.39e-7	Metabolite levels;
UCEC	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg04155231	chr12:9217510	LOC144571	0.43	5.03	0.38	1.38e-6	Sjögren's syndrome;
UCEC	cis	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs17106184	0.892	rs72900922	chr1:51095195	G/A	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.64	6.15	0.45	6.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.65	-6.35	-0.46	2.57e-9	Mortality in heart failure;
UCEC	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.56	-5.33	-0.4	3.62e-7	Pediatric autoimmune diseases;
UCEC	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.55	4.66	0.36	7.09e-6	Systolic blood pressure;
UCEC	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.63	6.45	0.47	1.52e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.59	8.01	0.55	3.29e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.88	0.37	2.68e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg06238570	chr21:40685208	BRWD1	0.73	7.07	0.5	5.67e-11	Cognitive function;
UCEC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.93	5.98	0.44	1.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.44	5.55	0.42	1.3e-7	Fibrinogen levels;
UCEC	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.47	5.16	0.39	7.82e-7	Response to temozolomide;
UCEC	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg18223379	chr20:31619647	BPIL3	-0.38	-4.72	-0.36	5.51e-6	Ulcerative colitis;
UCEC	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.22	-0.4	6.13e-7	Neutrophil percentage of white cells;
UCEC	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.63	-5.21	-0.39	6.37e-7	Platelet distribution width;
UCEC	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.69	-0.42	6.8e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.1	19.13	0.84	9.78e-42	Schizophrenia;
UCEC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.05	-0.45	1.16e-8	Aortic root size;
UCEC	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.5	4.97	0.38	1.86e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.58	-6.13	-0.45	7.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	1.11	13.21	0.74	9.4e-27	Post bronchodilator FEV1;
UCEC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.59	-6.44	-0.47	1.63e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg13695892	chr22:41940480	POLR3H	-0.65	-5.32	-0.4	3.75e-7	Vitiligo;
UCEC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg06462663	chr19:18546047	ISYNA1	0.51	6.41	0.47	1.82e-9	Breast cancer;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.55	-6.34	-0.46	2.6e-9	Pulmonary function;
UCEC	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg06784218	chr1:46089804	CCDC17	0.44	5.0	0.38	1.6e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.63	-6.23	-0.46	4.69e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.63	-5.81	-0.43	3.69e-8	Systemic lupus erythematosus;
UCEC	cis	rs8005745	0.614	rs1957757	chr14:62196948	T/C	cg01748970	chr14:62088363	NA	-0.74	-6.99	-0.5	8.76e-11	Select biomarker traits;
UCEC	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.66	6.13	0.45	7.55e-9	Subjective well-being;
UCEC	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.89	0.44	2.5e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.84	-9.36	-0.61	1.26e-16	Cognitive function;
UCEC	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	0.72	4.89	0.37	2.66e-6	Diabetic retinopathy;
UCEC	cis	rs9469578	1.000	rs16869464	chr6:33715127	A/G	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.58	4.82	0.37	3.49e-6	IgG glycosylation;
UCEC	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg08493051	chr2:3487164	NA	-0.6	-6.37	-0.47	2.24e-9	Neurofibrillary tangles;
UCEC	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg19567339	chr10:100142640	NA	0.41	4.89	0.37	2.57e-6	Metabolite levels;
UCEC	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.51	5.93	0.44	2.04e-8	Alcohol dependence;
UCEC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-5.0	-0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.85	10.18	0.64	9.46e-19	Coronary artery disease;
UCEC	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.72	-9.25	-0.61	2.46e-16	Prevalent atrial fibrillation;
UCEC	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.65	-6.22	-0.46	4.85e-9	Acne (severe);
UCEC	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.12	6.66	0.48	5.23e-10	Type 2 diabetes;
UCEC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.64	-5.89	-0.44	2.47e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.71	-6.45	-0.47	1.54e-9	Coronary artery disease;
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg21419209	chr3:44054225	NA	-0.51	-5.1	-0.39	1.01e-6	Coronary artery disease;
UCEC	cis	rs1575951	1.000	rs10764799	chr10:130436939	T/C	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-8.17	-0.56	1.31e-13	Colorectal cancer;
UCEC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.01	-0.44	1.41e-8	Blood metabolite levels;
UCEC	cis	rs12318506	0.826	rs11180434	chr12:75662128	T/C	cg04728562	chr12:75699417	CAPS2	-0.8	-5.0	-0.38	1.6e-6	Coronary artery calcification;
UCEC	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.71	8.25	0.56	8.13e-14	Mean corpuscular volume;
UCEC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.83	5.5	0.41	1.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs1981331	0.609	rs117296583	chr21:48053238	C/T	cg23283320	chr21:48055893	PRMT2	1.61	7.21	0.51	2.76e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.72	8.69	0.58	6.46e-15	Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25883402	chr1:173837173	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.6	6.89	0.49	1.53e-10	Warfarin maintenance dose;
UCEC	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	6.51	0.47	1.13e-9	Alzheimer's disease;
UCEC	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-7.34	-0.52	1.35e-11	Parkinson's disease;
UCEC	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg13683864	chr3:40499215	RPL14	-0.65	-6.88	-0.49	1.56e-10	Renal cell carcinoma;
UCEC	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.1	0.56	1.99e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.39	5.26	0.4	5.08e-7	Bipolar disorder;
UCEC	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.88	0.37	2.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.79	-8.74	-0.58	4.77e-15	Height;
UCEC	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.07	-0.45	1.04e-8	Parkinson's disease;
UCEC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	-0.54	-6.15	-0.45	7.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.91	7.16	0.51	3.56e-11	Exhaled nitric oxide output;
UCEC	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.58	5.48	0.41	1.79e-7	Corneal astigmatism;
UCEC	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	7.28	0.51	1.88e-11	Ileal carcinoids;
UCEC	cis	rs12136530	0.774	rs4912097	chr1:19784410	C/G	cg25599739	chr1:19403133	UBR4	-0.58	-4.84	-0.37	3.31e-6	Lead levels in blood;
UCEC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.79	-8.29	-0.56	6.68e-14	Diastolic blood pressure;
UCEC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg06096015	chr1:231504339	EGLN1	0.48	5.58	0.42	1.13e-7	Hemoglobin concentration;
UCEC	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	6.08	0.45	9.92e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.21	-22.92	-0.88	2.24e-50	Myeloid white cell count;
UCEC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg00343986	chr7:65444356	GUSB	0.49	4.59	0.35	9.31e-6	Aortic root size;
UCEC	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.68	8.14	0.56	1.56e-13	Testicular germ cell tumor;
UCEC	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.89	-12.76	-0.72	1.42e-25	Urate levels in lean individuals;
UCEC	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg21191810	chr6:118973309	C6orf204	0.42	5.82	0.43	3.59e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	0.86	4.98	0.38	1.78e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7870753	0.838	rs10991352	chr9:99249548	A/T	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.64	6.67	0.48	4.95e-10	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.16	-0.56	1.37e-13	Total cholesterol levels;
UCEC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6921919	0.697	rs758398	chr6:28320674	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.4	-4.64	-0.36	7.71e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.65	0.36	7.19e-6	Breast cancer;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg17436946	chr4:39699568	UBE2K	0.68	7.02	0.5	7.72e-11	Schizophrenia;
UCEC	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.57	-5.2	-0.39	6.57e-7	Reticulocyte count;
UCEC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg16497661	chr14:103986332	CKB	0.49	5.85	0.43	3.01e-8	Body mass index;
UCEC	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.82	7.38	0.52	1.1e-11	Bladder cancer;
UCEC	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.54	6.22	0.46	4.82e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.54	-6.93	-0.5	1.26e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4853525	0.884	rs34303278	chr2:191731470	G/C	cg10560079	chr2:191398806	TMEM194B	-0.5	-5.07	-0.39	1.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.47	-5.01	-0.38	1.57e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.82	-6.77	-0.49	2.9e-10	Vitiligo;
UCEC	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg14092571	chr14:90743983	NA	-0.41	-5.14	-0.39	8.71e-7	Mortality in heart failure;
UCEC	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.5	-6.2	-0.46	5.38e-9	Total body bone mineral density;
UCEC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg03354898	chr7:1950403	MAD1L1	0.47	4.7	0.36	5.92e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.62	4.82	0.37	3.58e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7246967	0.604	rs12981846	chr19:23021359	G/A	cg08271804	chr19:22816896	ZNF492	0.52	5.01	0.38	1.56e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-5.24	-0.4	5.49e-7	Hemoglobin concentration;
UCEC	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.88	-9.61	-0.62	2.79e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.41	4.58	0.35	9.83e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.75e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.73	7.42	0.52	8.68e-12	Longevity;Endometriosis;
UCEC	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.16	9.5	0.62	5.46e-17	Uric acid levels;
UCEC	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.6	4.67	0.36	6.78e-6	Lung cancer;
UCEC	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.33	-0.46	2.79e-9	Coffee consumption (cups per day);
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.53	0.42	1.42e-7	Platelet count;
UCEC	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-7.98	-0.55	3.82e-13	Exhaled nitric oxide output;
UCEC	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.55	6.36	0.46	2.45e-9	Blood metabolite ratios;
UCEC	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12644436	0.832	rs6854753	chr4:88777093	C/T	cg27179352	chr4:88029472	AFF1	0.41	4.8	0.37	3.94e-6	HIV-1 viral setpoint;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-0.57	-7.12	-0.51	4.4e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg01256987	chr12:42539512	GXYLT1	0.42	4.92	0.38	2.31e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.5	-5.79	-0.43	4.06e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.61	-7.63	-0.53	2.7e-12	Obesity-related traits;
UCEC	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.9	6.97	0.5	9.76e-11	Vitiligo;
UCEC	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.44	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10114577	chr22:36697021	MYH9	-0.63	-7.35	-0.52	1.29e-11	Warfarin maintenance dose;
UCEC	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.57	4.62	0.36	8.32e-6	Menopause (age at onset);
UCEC	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.2	-0.46	5.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg05991184	chr2:219186017	PNKD	0.45	4.76	0.37	4.53e-6	Colorectal cancer;
UCEC	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.47	4.99	0.38	1.68e-6	Blood metabolite levels;
UCEC	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.52	5.7	0.43	6.42e-8	Atrioventricular conduction;
UCEC	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg24562669	chr7:97807699	LMTK2	0.5	6.2	0.46	5.32e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.64	-6.96	-0.5	1.05e-10	Multiple myeloma (IgH translocation);
UCEC	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.77	-8.87	-0.59	2.24e-15	Height;
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg22974920	chr21:40686053	BRWD1	0.54	4.92	0.38	2.33e-6	Cognitive function;
UCEC	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg19318889	chr4:1322082	MAEA	0.46	4.91	0.38	2.4e-6	Obesity-related traits;
UCEC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	1.0	11.14	0.68	2.83e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.72	-0.63	1.52e-17	Monocyte count;
UCEC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg04013166	chr16:89971882	TCF25	0.73	4.59	0.35	9.44e-6	Skin colour saturation;
UCEC	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.7	-7.29	-0.52	1.73e-11	Cognitive function;
UCEC	cis	rs6838801	0.765	rs3943037	chr4:77600874	A/G	cg17476223	chr4:77663285	SHROOM3	0.47	4.55	0.35	1.12e-5	Cleft lip with or without cleft palate;
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg14078730	chr11:63896557	MACROD1	0.45	4.69	0.36	6.27e-6	Platelet count;
UCEC	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.0	-0.44	1.5e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.53	6.04	0.45	1.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg24069376	chr3:38537580	EXOG	0.38	4.73	0.36	5.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.06	0.39	1.24e-6	Rheumatoid arthritis;
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.54	-0.47	9.71e-10	Platelet count;
UCEC	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg18367735	chr17:79674897	NA	0.57	4.54	0.35	1.16e-5	Dental caries;
UCEC	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.88	0.37	2.69e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.33	4.89	0.37	2.59e-6	Schizophrenia;
UCEC	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.65	-4.79	-0.37	3.97e-6	Coronary artery disease;
UCEC	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-0.62	-7.51	-0.53	5.15e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.58	6.52	0.47	1.05e-9	Red blood cell count;
UCEC	cis	rs1545257	0.505	rs958352	chr2:24634240	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-5.19	-0.39	6.77e-7	Sjögren's syndrome;
UCEC	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	8.39	0.57	3.78e-14	Blood protein levels;
UCEC	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.65	-5.25	-0.4	5.27e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-5.11	-0.39	9.97e-7	Diabetic retinopathy;
UCEC	cis	rs10242455	0.702	rs6956305	chr7:99241310	A/G	cg18809830	chr7:99032528	PTCD1	-0.75	-4.57	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	7.7	0.54	1.81e-12	Smoking behavior;
UCEC	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg16023434	chr1:11395635	NA	0.36	4.54	0.35	1.18e-5	Body mass index;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg20119798	chr7:94954144	PON1	-0.51	-4.83	-0.37	3.33e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg00651523	chr6:28411279	ZSCAN23	0.54	6.12	0.45	7.91e-9	Pubertal anthropometrics;
UCEC	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.69	6.4	0.47	1.95e-9	High light scatter reticulocyte count;
UCEC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.78	0.59	3.81e-15	Prudent dietary pattern;
UCEC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.33	4.57	0.35	1.01e-5	Alzheimer's disease (late onset);
UCEC	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.24	0.71	3.51e-24	Prudent dietary pattern;
UCEC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.54	5.91	0.44	2.27e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6445967	0.832	rs1055973	chr3:58308960	T/C	cg23715586	chr3:58305044	RPP14	0.37	4.6	0.35	9.09e-6	Platelet count;
UCEC	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.93	9.72	0.63	1.49e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.51	4.78	0.37	4.17e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg05660106	chr1:15850417	CASP9	0.61	5.61	0.42	9.68e-8	Systolic blood pressure;
UCEC	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.0	-8.16	-0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.66	0.36	7.02e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7534824	0.543	rs6693339	chr1:101424431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.53	-4.62	-0.36	8.27e-6	Refractive astigmatism;
UCEC	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg23795048	chr12:9217529	LOC144571	0.4	4.69	0.36	6.14e-6	Sjögren's syndrome;
UCEC	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.6	-4.52	-0.35	1.28e-5	Waist circumference adjusted for body mass index;
UCEC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.08	-0.39	1.15e-6	Chronic sinus infection;
UCEC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.7	-7.38	-0.52	1.07e-11	Cognitive function;
UCEC	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.58	6.2	0.46	5.45e-9	Motion sickness;
UCEC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.41	0.41	2.45e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.59	6.6	0.48	7.14e-10	Height;
UCEC	cis	rs7582720	1.000	rs78128841	chr2:203663975	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.82	4.74	0.36	5.01e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.41	0.52	9.12e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs10095849	0.576	rs4733917	chr8:39476978	T/C	cg24581462	chr8:38759627	PLEKHA2	0.36	4.63	0.36	7.85e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg00786635	chr1:25594202	NA	0.57	5.71	0.43	6.17e-8	Erythrocyte sedimentation rate;
UCEC	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg24130564	chr14:104152367	KLC1	-0.58	-4.82	-0.37	3.61e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.45	-5.14	-0.39	8.48e-7	White matter hyperintensity burden;
UCEC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26002218	chr14:103986227	CKB	0.36	5.16	0.39	7.75e-7	Body mass index;
UCEC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.88	-0.44	2.63e-8	Chronic sinus infection;
UCEC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01973587	chr1:228161476	NA	0.38	4.99	0.38	1.65e-6	Diastolic blood pressure;
UCEC	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-4.94	-0.38	2.09e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.78	-8.58	-0.58	1.24e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.57	-4.53	-0.35	1.2e-5	Corneal astigmatism;
UCEC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.54	-5.44	-0.41	2.17e-7	Aortic root size;
UCEC	cis	rs2415984	0.846	rs2899976	chr14:46823487	C/T	cg14871534	chr14:47121158	RPL10L	0.4	4.54	0.35	1.15e-5	Number of children ever born;
UCEC	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.64	5.56	0.42	1.22e-7	Schizophrenia;
UCEC	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.51	4.84	0.37	3.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07677032	chr17:61819896	STRADA	-0.49	-4.5	-0.35	1.36e-5	Prudent dietary pattern;
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.76	-0.43	4.8e-8	Primary biliary cholangitis;
UCEC	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.63	5.05	0.38	1.27e-6	Resting heart rate;
UCEC	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.6e-7	Breast cancer;
UCEC	cis	rs1165668	0.785	rs2583223	chr12:104316841	G/A	cg21863207	chr12:104234989	NT5DC3	0.6	5.57	0.42	1.19e-7	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.71	9.3	0.61	1.86e-16	Mean platelet volume;
UCEC	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.59	6.99	0.5	9.06e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg23307798	chr14:103986281	CKB	0.65	8.0	0.55	3.42e-13	Body mass index;
UCEC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg04166393	chr7:2884313	GNA12	0.6	4.56	0.35	1.05e-5	Height;
UCEC	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.6	6.29	0.46	3.38e-9	Colorectal cancer;
UCEC	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.34	-4.54	-0.35	1.16e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.64	5.48	0.41	1.81e-7	Alzheimer's disease;
UCEC	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.85	7.74	0.54	1.48e-12	Body mass index;
UCEC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.52	6.04	0.45	1.19e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs74225573	1	rs74225573	chr1:11280994	T/C	cg26230245	chr1:11322756	MTOR	-0.89	-5.45	-0.41	2.03e-7	Corneal curvature;
UCEC	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	5.85	0.43	3.01e-8	Monocyte percentage of white cells;
UCEC	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.63	-4.91	-0.38	2.38e-6	Gut microbiome composition (summer);
UCEC	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.61	-6.03	-0.45	1.29e-8	Blood metabolite levels;
UCEC	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.62	-7.09	-0.5	5.23e-11	Vitiligo;
UCEC	cis	rs6832769	1.000	rs7670225	chr4:56368018	C/T	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs925228	0.869	rs6545121	chr2:24044501	T/A	cg16945982	chr2:25016118	CENPO;C2orf79	-0.55	-4.95	-0.38	2.02e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.44	4.8	0.37	3.81e-6	Response to temozolomide;
UCEC	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.89	-9.92	-0.63	4.46e-18	Blood metabolite levels;
UCEC	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	0.82	7.51	0.53	5.39e-12	Testicular germ cell tumor;
UCEC	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.83	-8.73	-0.58	5.09e-15	Ulcerative colitis;
UCEC	cis	rs7246967	0.736	rs2617779	chr19:22998321	G/A	cg24889512	chr19:22816950	ZNF492	0.54	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg21770322	chr7:97807741	LMTK2	0.44	5.5	0.41	1.63e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-4.79	-0.37	3.98e-6	Metabolite levels;
UCEC	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.75	7.98	0.55	3.72e-13	Itch intensity from mosquito bite;
UCEC	cis	rs7725816	0.710	rs9325072	chr5:147497540	C/T	cg10994339	chr5:147443536	SPINK5	-0.54	-4.57	-0.35	1.03e-5	Yeast infection;
UCEC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-5.95	-0.44	1.87e-8	Menarche (age at onset);
UCEC	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.57	0.42	1.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.68	7.04	0.5	6.77e-11	Adiposity;
UCEC	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	1.12	13.32	0.74	4.78e-27	Post bronchodilator FEV1;
UCEC	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.47	-5.24	-0.4	5.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-8.5	-0.57	1.97e-14	Headache;
UCEC	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.86	-0.49	1.8e-10	Menarche (age at onset);
UCEC	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.48	4.91	0.38	2.38e-6	Blood metabolite levels;
UCEC	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	4.89	0.37	2.58e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.19	-19.34	-0.85	3.16e-42	Chronic sinus infection;
UCEC	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10509540	0.551	rs643431	chr10:90027875	G/A	cg10205334	chr10:89622497	PTEN;KILLIN	-0.48	-4.72	-0.36	5.45e-6	Type 1 diabetes;
UCEC	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.52	-4.86	-0.37	3.02e-6	Longevity;
UCEC	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.6	-4.65	-0.36	7.22e-6	Gut microbiome composition (summer);
UCEC	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg04154034	chr17:28927549	LRRC37B2	0.75	4.61	0.36	8.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02547747	chr22:24667267	CYTSA	0.65	7.29	0.52	1.79e-11	Warfarin maintenance dose;
UCEC	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.48	-4.83	-0.37	3.44e-6	Blood metabolite levels;
UCEC	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg19743168	chr1:23544995	NA	-0.43	-5.41	-0.41	2.53e-7	Height;
UCEC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.54	4.61	0.36	8.75e-6	Response to diuretic therapy;
UCEC	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.79	9.14	0.6	4.65e-16	Lymphocyte counts;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg00651523	chr6:28411279	ZSCAN23	0.54	6.61	0.48	6.7e-10	Pubertal anthropometrics;
UCEC	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg16751203	chr2:127950803	CYP27C1	0.35	4.56	0.35	1.08e-5	Protein C levels;
UCEC	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.52	7.59	0.53	3.39e-12	Coronary artery disease or large artery stroke;
UCEC	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-6.18	-0.45	6.12e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs4499344	0.693	rs8106944	chr19:33097783	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.74	0.43	5.16e-8	Mean platelet volume;
UCEC	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg06323624	chr16:30642532	NA	0.36	4.63	0.36	7.84e-6	Dementia with Lewy bodies;
UCEC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.26	14.93	0.78	2.86e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-6.49	-0.47	1.21e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.9	-0.37	2.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.79	-0.63	9.7e-18	Leprosy;
UCEC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.72	8.06	0.55	2.45e-13	Bone mineral density;
UCEC	cis	rs11958404	0.860	rs6868830	chr5:157442187	T/C	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	8.83	0.59	2.96e-15	Platelet count;
UCEC	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg06521331	chr12:34319734	NA	0.66	5.03	0.38	1.41e-6	Morning vs. evening chronotype;
UCEC	cis	rs7246967	0.608	rs437859	chr19:23007349	A/G	cg08271804	chr19:22816896	ZNF492	-0.51	-4.79	-0.37	4.06e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.73	-5.47	-0.41	1.85e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.37	-4.7	-0.36	5.92e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.42	-4.74	-0.36	5.02e-6	Total body bone mineral density;
UCEC	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	4.8	0.37	3.8e-6	Diabetic retinopathy;
UCEC	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.6	5.44	0.41	2.15e-7	Mammographic density (dense area);
UCEC	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg23950597	chr19:37808831	NA	-0.64	-5.1	-0.39	1.03e-6	Coronary artery calcification;
UCEC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.68	6.79	0.49	2.53e-10	Menopause (age at onset);
UCEC	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	0.75	7.65	0.53	2.47e-12	Height;
UCEC	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg05991184	chr2:219186017	PNKD	0.48	5.31	0.4	4.02e-7	Colorectal cancer;
UCEC	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.43	-0.47	1.65e-9	Personality dimensions;
UCEC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.57	5.47	0.41	1.9e-7	Lung cancer;
UCEC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg11871910	chr12:69753446	YEATS4	0.59	5.85	0.43	3.03e-8	Blood protein levels;
UCEC	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.08	-8.04	-0.55	2.72e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-5.0	-0.38	1.65e-6	Response to antipsychotic treatment;
UCEC	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.67	6.99	0.5	8.82e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs3790645	1.000	rs383913	chr1:26893306	A/G	cg23229016	chr1:26872525	RPS6KA1	0.31	5.74	0.43	5.29e-8	Glucose homeostasis traits;
UCEC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.65	-5.79	-0.43	4.07e-8	Aortic root size;
UCEC	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs11697848	1.000	rs11698676	chr20:48536585	G/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.57	-7.0	-0.5	8.59e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.52	5.54	0.42	1.39e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.82	-0.37	3.58e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.55	5.05	0.38	1.3e-6	Corneal astigmatism;
UCEC	cis	rs6600233	0.874	rs11865131	chr16:163667	G/A	cg02353723	chr16:163133	C16orf35	-0.58	-6.47	-0.47	1.35e-9	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.57	5.5	0.41	1.63e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.62	5.87	0.44	2.73e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-1.12	-6.89	-0.49	1.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.99	-0.38	1.69e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg02160872	chr5:212506	CCDC127	-0.67	-6.44	-0.47	1.59e-9	Breast cancer;
UCEC	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.05	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg11871910	chr12:69753446	YEATS4	0.55	4.89	0.37	2.56e-6	Response to diuretic therapy;
UCEC	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.08	8.7	0.58	6.13e-15	Uric acid levels;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.09	0.51	5.11e-11	Platelet count;
UCEC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.73	6.61	0.48	6.75e-10	Cognitive function;
UCEC	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.82	9.49	0.62	5.77e-17	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.93	0.38	2.17e-6	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg09904177	chr6:26538194	HMGN4	-0.74	-5.18	-0.39	7.05e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8105895	0.935	rs62110989	chr19:22260299	A/G	cg24175803	chr19:22235144	ZNF257	-0.62	-5.4	-0.41	2.62e-7	Body mass index (change over time);
UCEC	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.74	8.02	0.55	3.09e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.37e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.52	5.39	0.41	2.69e-7	Dupuytren's disease;
UCEC	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.41	4.62	0.36	8.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01391022	chr12:122360665	WDR66	-0.42	-5.02	-0.38	1.46e-6	Mean corpuscular volume;
UCEC	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.38	4.78	0.37	4.26e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4849887	1.000	rs1534100	chr2:121241907	A/G	cg00421221	chr2:121106091	INHBB	0.42	4.62	0.36	8.33e-6	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs7246967	0.932	rs66737024	chr19:23031686	C/T	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg13575925	chr12:9217583	LOC144571	0.4	4.63	0.36	8.11e-6	Sjögren's syndrome;
UCEC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.43	5.02	0.38	1.5e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg09904177	chr6:26538194	HMGN4	-0.62	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs692916	0.704	rs636316	chr18:60569223	A/G	cg07187971	chr18:60481018	PHLPP1	-0.37	-4.6	-0.35	9.02e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.62	5.18	0.39	7.03e-7	Breast cancer;
UCEC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.69	6.16	0.45	6.57e-9	Aortic root size;
UCEC	cis	rs7246967	0.932	rs1478457	chr19:23065269	C/T	cg08271804	chr19:22816896	ZNF492	0.55	4.94	0.38	2.1e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11118844	0.744	rs10779456	chr1:221953057	A/G	cg04222084	chr1:221915650	DUSP10	0.63	4.54	0.35	1.18e-5	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.72	-0.36	5.51e-6	Parkinson's disease;
UCEC	cis	rs2062225	0.735	rs11679060	chr2:111769205	G/A	cg23782758	chr2:111737646	ACOXL	-0.48	-4.61	-0.36	8.85e-6	Monocyte count;
UCEC	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.52	4.94	0.38	2.13e-6	Height;
UCEC	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.51	5.32	0.4	3.87e-7	Intraocular pressure;
UCEC	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg24562669	chr7:97807699	LMTK2	0.4	4.96	0.38	1.96e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.53	-5.86	-0.43	2.97e-8	Tonsillectomy;
UCEC	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.03	11.53	0.69	2.56e-22	Exhaled nitric oxide output;
UCEC	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-10.29	-0.65	4.73e-19	Cognitive function;
UCEC	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	4.8	0.37	3.79e-6	Schizophrenia;
UCEC	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.86	7.86	0.54	7.31e-13	Prostate cancer;
UCEC	cis	rs10924970	0.649	rs4659480	chr1:235435172	G/A	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-5.61	-0.42	9.91e-8	Platelet count;
UCEC	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	5.28	0.4	4.48e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg21827317	chr3:136751795	NA	0.49	5.52	0.41	1.49e-7	Gestational age at birth (child effect);
UCEC	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg00105475	chr2:10696890	NA	-0.39	-4.86	-0.37	2.96e-6	Prostate cancer;
UCEC	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.94	0.5	1.17e-10	Mood instability;
UCEC	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	0.81	9.4	0.61	9.88e-17	Blood pressure (smoking interaction);
UCEC	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.66	5.84	0.43	3.3e-8	Platelet count;
UCEC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg26898376	chr11:64110657	CCDC88B	0.5	6.11	0.45	8.46e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.9	10.35	0.65	3.38e-19	Menarche (age at onset);
UCEC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.53	5.02	0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs76878669	0.561	rs7948058	chr11:66148111	T/A	cg24851651	chr11:66362959	CCS	0.5	6.0	0.44	1.44e-8	Educational attainment (years of education);
UCEC	cis	rs10012307	1.000	rs12639873	chr4:137518286	C/T	cg12033966	chr4:138453416	PCDH18	-0.8	-4.66	-0.36	7.14e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg05775895	chr3:12838266	CAND2	0.59	5.39	0.41	2.74e-7	QRS complex (12-leadsum);
UCEC	cis	rs4074536	0.796	rs10801991	chr1:116309438	T/G	cg21648376	chr1:116311395	CASQ2	-0.5	-4.89	-0.37	2.59e-6	QRS duration;
UCEC	cis	rs16937	0.711	rs6682400	chr1:205173519	T/G	cg00857998	chr1:205179979	DSTYK	0.51	4.6	0.35	9.08e-6	Schizophrenia;
UCEC	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.18	0.51	3.16e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7165102	1.000	rs7181333	chr15:66039826	C/T	cg11164506	chr15:66649558	TIPIN	0.33	4.62	0.36	8.4e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	6.27	0.46	3.77e-9	Total body bone mineral density;
UCEC	cis	rs921968	0.679	rs7607369	chr2:219279097	A/G	cg02176678	chr2:219576539	TTLL4	0.53	5.51	0.41	1.58e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.4	6.12	0.45	8.11e-9	Body mass index;
UCEC	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.54	-5.32	-0.4	3.77e-7	Schizophrenia;
UCEC	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.67	6.99	0.5	8.82e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.89	-9.87	-0.63	6.12e-18	Cognitive function;
UCEC	cis	rs6732160	0.574	rs1991612	chr2:73480501	G/C	cg05539622	chr2:73298971	SFXN5	0.49	4.69	0.36	6.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.53	-5.46	-0.41	1.94e-7	Crohn's disease;
UCEC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	7.76	0.54	1.35e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.66	-7.54	-0.53	4.4e-12	Menarche (age at onset);
UCEC	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.05	-0.55	2.52e-13	Total cholesterol levels;
UCEC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs60515486	0.702	rs11827106	chr11:47402615	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-4.54	-0.35	1.15e-5	Lymphocyte counts;
UCEC	cis	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg14329783	chr7:75779857	NA	-0.59	-4.54	-0.35	1.16e-5	Eotaxin levels;
UCEC	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.55	-5.82	-0.43	3.55e-8	Type 2 diabetes;
UCEC	cis	rs12644436	0.896	rs12641894	chr4:88785760	T/C	cg27179352	chr4:88029472	AFF1	0.41	4.51	0.35	1.32e-5	HIV-1 viral setpoint;
UCEC	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.72	-8.79	-0.59	3.7e-15	Prevalent atrial fibrillation;
UCEC	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg21053147	chr12:120880522	NA	0.67	4.78	0.37	4.19e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.14	-0.39	8.46e-7	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.71	5.23	0.4	5.63e-7	Aortic root size;
UCEC	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg13250285	chr3:50228871	GNAT1	-0.34	-4.99	-0.38	1.7e-6	Menarche (age at onset);
UCEC	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.64	4.84	0.37	3.22e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.88	7.86	0.54	7.54e-13	Body mass index;
UCEC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs7246967	0.932	rs34897621	chr19:23027527	A/C	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-12.78	-0.73	1.27e-25	Height;
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	8.42	0.57	3.05e-14	Prudent dietary pattern;
UCEC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.58	4.65	0.36	7.31e-6	Skin colour saturation;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs17664267	0.954	rs8096164	chr18:40876883	T/G	cg22039287	chr18:40696075	RIT2	0.41	4.71	0.36	5.74e-6	Conduct disorder (maternal expressed emotions interaction);
UCEC	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs4372836	0.828	rs6728459	chr2:28999336	A/G	cg09522027	chr2:28974177	PPP1CB	-0.77	-7.69	-0.54	1.92e-12	Body mass index;
UCEC	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs4819052	0.645	rs2838817	chr21:46631698	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	4.64	0.36	7.61e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg13073564	chr4:8508604	NA	-0.46	-5.03	-0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.63	-6.2	-0.46	5.39e-9	Platelet distribution width;
UCEC	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.42	-5.54	-0.42	1.37e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.65	-6.44	-0.47	1.57e-9	Prostate cancer;
UCEC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	1.0	11.14	0.68	2.83e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.79	7.97	0.55	3.96e-13	Smoking behavior;
UCEC	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.4	5.17	0.39	7.51e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.68	-0.36	6.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.54	4.75	0.37	4.72e-6	Corneal astigmatism;
UCEC	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	4.8	0.37	3.88e-6	Lung function (FEV1/FVC);
UCEC	cis	rs9595066	1.000	rs7981575	chr13:44710947	C/T	cg02577989	chr13:44716179	NA	0.52	4.54	0.35	1.15e-5	Schizophrenia;
UCEC	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.55	5.87	0.44	2.78e-8	Corneal astigmatism;
UCEC	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.74	5.58	0.42	1.12e-7	LDL cholesterol;
UCEC	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg08886695	chr4:3369023	RGS12	-0.55	-5.44	-0.41	2.22e-7	Serum sulfate level;
UCEC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg05695927	chr15:45694626	SPATA5L1	0.52	5.18	0.39	7.35e-7	Homoarginine levels;
UCEC	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.82e-6	Gut microbiome composition (summer);
UCEC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg09521647	chr2:100722408	AFF3	-0.32	-4.85	-0.37	3.05e-6	Chronic sinus infection;
UCEC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.01	-0.38	1.54e-6	Breast cancer;
UCEC	cis	rs7246967	0.673	rs12971914	chr19:22888898	A/T	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.05e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6684514	0.542	rs11264472	chr1:156292366	A/G	cg20302342	chr1:156215951	PAQR6	0.52	5.45	0.41	2.07e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
UCEC	cis	rs3736757	0.870	rs10797987	chr1:184651822	T/C	cg05045817	chr1:184633523	NA	0.38	4.55	0.35	1.09e-5	Obesity-related traits;
UCEC	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.69	7.98	0.55	3.75e-13	Mean corpuscular volume;
UCEC	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.85	7.72	0.54	1.62e-12	Body mass index;
UCEC	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	0.94	11.84	0.7	3.99e-23	Platelet distribution width;
UCEC	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg16797656	chr11:68205561	LRP5	0.64	8.98	0.6	1.17e-15	Total body bone mineral density;
UCEC	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.56	5.05	0.38	1.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.6	0.42	1e-7	Prudent dietary pattern;
UCEC	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.44	4.68	0.36	6.36e-6	Schizophrenia;
UCEC	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	0.99	8.76	0.59	4.35e-15	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.74	-0.54	1.46e-12	Body mass index;
UCEC	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.6	6.4	0.47	1.91e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.47	-5.04	-0.38	1.35e-6	Menarche (age at onset);
UCEC	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-6.35	-0.46	2.5e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.58	6.27	0.46	3.85e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.5	-4.93	-0.38	2.15e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.45	-6.15	-0.45	6.9e-9	Mortality in heart failure;
UCEC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.59	5.45	0.41	2.03e-7	Type 2 diabetes;
UCEC	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.83	8.21	0.56	1.04e-13	Cognitive function;
UCEC	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.54	-5.57	-0.42	1.16e-7	Sudden cardiac arrest;
UCEC	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs6460942	1.000	rs77010200	chr7:12290724	G/A	cg06484146	chr7:12443880	VWDE	-0.77	-5.5	-0.41	1.63e-7	Coronary artery disease;
UCEC	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-5.11	-0.39	9.93e-7	Metabolite levels;
UCEC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	1.0	14.62	0.77	1.89e-30	Bone mineral density;
UCEC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.65	8.1	0.56	1.88e-13	Vitiligo;
UCEC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.59	5.49	0.41	1.72e-7	Schizophrenia;
UCEC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01973587	chr1:228161476	NA	0.37	4.94	0.38	2.1e-6	Diastolic blood pressure;
UCEC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.68	6.04	0.45	1.2e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.74	-6.59	-0.48	7.46e-10	Initial pursuit acceleration;
UCEC	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-4.75	-0.36	4.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.81	-6.04	-0.45	1.18e-8	Lymphocyte counts;
UCEC	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.76	-7.86	-0.54	7.31e-13	Lymphocyte counts;
UCEC	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.88	-9.79	-0.63	9.62e-18	Breast cancer;
UCEC	cis	rs6952808	0.898	rs7799807	chr7:1868092	A/G	cg19097150	chr7:2500200	NA	0.32	4.62	0.36	8.27e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg19926144	chr10:661009	DIP2C	0.76	4.61	0.36	8.67e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs7944735	0.508	rs1872167	chr11:47901269	C/T	cg08722104	chr11:47448306	PSMC3	-0.49	-4.54	-0.35	1.16e-5	Intraocular pressure;
UCEC	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Body mass index;
UCEC	cis	rs7219021	0.926	rs7208848	chr17:46855295	C/T	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg13844804	chr7:814759	HEATR2	0.68	5.01	0.38	1.55e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-5.15	-0.39	8.09e-7	Personality dimensions;
UCEC	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg21770322	chr7:97807741	LMTK2	0.53	6.6	0.48	7.11e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg03714773	chr7:91764589	CYP51A1	-0.42	-5.07	-0.39	1.16e-6	Breast cancer;
UCEC	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.72	7.83	0.54	8.93e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	5.66	0.42	7.59e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg13683864	chr3:40499215	RPL14	0.66	6.99	0.5	9.02e-11	Renal cell carcinoma;
UCEC	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg09654669	chr8:57350985	NA	-0.54	-6.08	-0.45	1.01e-8	Obesity-related traits;
UCEC	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.78	-8.22	-0.56	9.89e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1816854	0.938	rs3764004	chr12:44201451	T/C	cg20956634	chr12:44200518	TWF1	0.5	5.03	0.38	1.41e-6	Inflammatory bowel disease;
UCEC	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.68	-5.37	-0.41	2.99e-7	Gut microbiome composition (summer);
UCEC	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.56	-6.07	-0.45	1.05e-8	Menarche (age at onset);
UCEC	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.89	-7.39	-0.52	1.05e-11	Coronary artery calcification;
UCEC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.82	8.83	0.59	2.81e-15	Blood protein levels;
UCEC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.65	-5.22	-0.4	5.9e-7	Menopause (age at onset);
UCEC	cis	rs10242455	0.867	rs2687139	chr7:99323074	A/C	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg03321784	chr17:37729644	NA	-0.36	-4.55	-0.35	1.11e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-6.69	-0.48	4.26e-10	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.77	10.52	0.66	1.22e-19	Vitiligo;
UCEC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg04155231	chr12:9217510	LOC144571	0.45	5.63	0.42	8.95e-8	Sjögren's syndrome;
UCEC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.84	-8.97	-0.59	1.26e-15	Breast cancer;
UCEC	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.71	-5.16	-0.39	7.71e-7	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg24889512	chr19:22816950	ZNF492	0.61	6.28	0.46	3.59e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.64	6.72	0.48	3.75e-10	Obesity-related traits;
UCEC	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.51	4.73	0.36	5.21e-6	Night sleep phenotypes;
UCEC	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg19041857	chr6:27730383	NA	-0.54	-4.54	-0.35	1.15e-5	Lung cancer in ever smokers;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15028047	chr2:242607778	ATG4B	-0.57	-6.77	-0.49	2.83e-10	Warfarin maintenance dose;
UCEC	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.73	6.69	0.48	4.27e-10	Body mass index;
UCEC	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.52	5.43	0.41	2.32e-7	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg14008862	chr17:28927542	LRRC37B2	0.68	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg09165964	chr15:75287851	SCAMP5	-0.55	-5.71	-0.43	5.93e-8	Lung cancer;
UCEC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	9.03	0.6	8.72e-16	Chronic sinus infection;
UCEC	cis	rs17122693	0.515	rs10148593	chr14:51201829	A/G	cg04730355	chr14:51134070	SAV1	-0.59	-5.15	-0.39	8.17e-7	Cognitive performance;
UCEC	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg11153328	chr22:36877737	TXN2	-0.53	-4.72	-0.36	5.44e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10405744	0.744	rs8112652	chr19:20183808	G/A	cg19204924	chr19:20576478	ZNF826	0.54	4.95	0.38	1.97e-6	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);
UCEC	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.6	-6.62	-0.48	6.22e-10	Refractive error;
UCEC	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.35	-4.66	-0.36	7.07e-6	Panic disorder;
UCEC	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg14008862	chr17:28927542	LRRC37B2	0.63	5.0	0.38	1.59e-6	Body mass index;
UCEC	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.95	7.24	0.51	2.3e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	6.09	0.45	9.19e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.69	-6.37	-0.47	2.31e-9	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs12980942	0.810	rs35812313	chr19:41789178	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.85	6.57	0.48	7.97e-10	Coronary artery disease;
UCEC	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.78	-7.15	-0.51	3.76e-11	Parkinson's disease;
UCEC	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.55	-0.42	1.28e-7	Body mass index;
UCEC	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.61	6.76	0.49	3.05e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg11632617	chr15:75315747	PPCDC	-0.67	-7.71	-0.54	1.75e-12	Lung cancer;
UCEC	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.57	6.05	0.45	1.15e-8	Red blood cell count;
UCEC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.51	5.8	0.43	3.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.5	6.1	0.45	8.95e-9	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs883565	0.654	rs6779880	chr3:39022926	G/T	cg01426195	chr3:39028469	NA	0.69	8.39	0.57	3.61e-14	Handedness;
UCEC	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.73	-6.55	-0.48	8.88e-10	Platelet distribution width;
UCEC	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.8	-6.73	-0.49	3.54e-10	Blood pressure (smoking interaction);
UCEC	cis	rs12618769	0.597	rs3769716	chr2:99133305	G/A	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	17.82	0.83	1.5e-38	Schizophrenia;
UCEC	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	1.15	5.9	0.44	2.35e-8	LDL cholesterol;
UCEC	cis	rs7212590	0.748	rs8074176	chr17:57861995	G/A	cg10252138	chr17:58120427	NA	-0.69	-5.52	-0.41	1.51e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg12024160	chr4:1254474	NA	0.56	6.8	0.49	2.44e-10	Obesity-related traits;
UCEC	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg14092571	chr14:90743983	NA	-0.66	-9.15	-0.6	4.47e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.42	4.54	0.35	1.18e-5	HDL cholesterol;
UCEC	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.03	-8.74	-0.58	4.99e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.57	-0.48	7.96e-10	Pubertal anthropometrics;
UCEC	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.01	0.5	7.87e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.72	-0.36	5.54e-6	Major depressive disorder;
UCEC	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.61	-5.18	-0.39	7.24e-7	Obesity-related traits;
UCEC	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.5	-0.35	1.34e-5	Parkinson's disease;
UCEC	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.78	-6.11	-0.45	8.48e-9	Calcium levels;
UCEC	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.08	-0.45	9.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs7252925	chr19:22865808	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.69	-0.42	6.8e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.2	0.39	6.59e-7	Life satisfaction;
UCEC	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.3	0.52	1.66e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs8105895	0.935	rs62112918	chr19:22227079	C/T	cg02912127	chr19:22235281	ZNF257	-0.58	-4.69	-0.36	6.25e-6	Body mass index (change over time);
UCEC	cis	rs6893207	1.000	rs59939724	chr5:16403887	C/T	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	9.03	0.6	8.84e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg19041857	chr6:27730383	NA	-0.65	-5.04	-0.38	1.32e-6	Breast cancer;
UCEC	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.89	-0.44	2.56e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.85	-7.2	-0.51	2.86e-11	Coronary artery calcification;
UCEC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.58	6.44	0.47	1.57e-9	Prostate cancer;
UCEC	cis	rs12980942	0.872	rs7256416	chr19:41787931	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.63	5.65	0.42	8.15e-8	Coronary artery disease;
UCEC	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.49	0.47	1.24e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.41	-4.62	-0.36	8.48e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.67	0.58	7.46e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.42	-0.41	2.36e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	5.98	0.44	1.62e-8	Platelet count;
UCEC	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.61	6.47	0.47	1.38e-9	Motion sickness;
UCEC	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.48	5.22	0.4	6.06e-7	Blood metabolite levels;
UCEC	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.48	-6.04	-0.45	1.22e-8	Mean platelet volume;
UCEC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	5.28	0.4	4.59e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg04202892	chr2:111875749	ACOXL	0.47	5.48	0.41	1.79e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	6.27	0.46	3.84e-9	Menarche (age at onset);
UCEC	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg11569703	chr11:65557185	OVOL1	0.51	6.6	0.48	6.88e-10	Acne (severe);
UCEC	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.61	6.59	0.48	7.32e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg01072550	chr1:21505969	NA	-0.63	-6.54	-0.47	9.5e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.54	-6.13	-0.45	7.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.47	5.06	0.39	1.23e-6	Aortic root size;
UCEC	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.28	0.4	4.59e-7	Colorectal cancer;
UCEC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.11	10.06	0.64	1.94e-18	Vitiligo;
UCEC	cis	rs58521262	0.556	rs290578	chr19:23221489	T/G	cg08486875	chr19:23386892	NA	0.33	4.51	0.35	1.32e-5	Testicular germ cell tumor;
UCEC	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.53	5.88	0.44	2.72e-8	Retinal vascular caliber;
UCEC	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.54	4.88	0.37	2.69e-6	Alzheimer's disease;
UCEC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.59	5.86	0.44	2.91e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.94	-0.38	2.09e-6	Pubertal anthropometrics;
UCEC	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg04154034	chr17:28927549	LRRC37B2	0.91	5.19	0.39	7.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg02160872	chr5:212506	CCDC127	-0.77	-8.1	-0.56	1.89e-13	Breast cancer;
UCEC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg04155231	chr12:9217510	LOC144571	0.43	5.53	0.42	1.39e-7	Sjögren's syndrome;
UCEC	cis	rs4908768	0.596	rs4908516	chr1:8879610	G/C	cg13081009	chr1:8430745	RERE	0.47	4.71	0.36	5.59e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-1.03	-4.57	-0.35	1.02e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.45	-5.14	-0.39	8.49e-7	Birth weight;
UCEC	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.82	7.84	0.54	8.42e-13	Schizophrenia;
UCEC	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg00339695	chr16:24857497	SLC5A11	0.54	6.23	0.46	4.61e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4757319	0.515	rs10832437	chr11:15433225	C/T	cg03245590	chr11:15329459	NA	0.41	4.55	0.35	1.13e-5	Breast cancer;
UCEC	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.52	5.36	0.4	3.08e-7	Dupuytren's disease;
UCEC	cis	rs7246967	0.673	rs2361023	chr19:22816867	C/T	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.29e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-5.09	-0.39	1.09e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.7	7.67	0.53	2.2e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs405956	1.000	rs9404601	chr6:105568685	G/A	cg22580625	chr6:105627791	POPDC3	-0.71	-6.69	-0.48	4.38e-10	QT interval;
UCEC	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.66	6.36	0.46	2.4e-9	Metabolite levels;
UCEC	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	7.42	0.52	8.56e-12	LDL cholesterol;
UCEC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg22907277	chr7:1156413	C7orf50	0.55	5.11	0.39	9.73e-7	Longevity;Endometriosis;
UCEC	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	5.85	0.43	3.02e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs12428035	0.764	rs4547219	chr13:96741656	A/G	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.96	0.44	1.77e-8	Platelet count;
UCEC	cis	rs17433710	0.543	rs11577330	chr1:162651672	A/T	cg04915463	chr1:162039957	NOS1AP	0.53	5.42	0.41	2.44e-7	Dupuytren's disease;
UCEC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.62	-5.17	-0.39	7.54e-7	Initial pursuit acceleration;
UCEC	cis	rs12118280	0.522	rs519129	chr1:108731906	T/C	cg11967332	chr1:108735228	SLC25A24	-0.7	-6.74	-0.49	3.34e-10	Myeloid white cell count;
UCEC	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg03859395	chr2:55845619	SMEK2	1.04	15.32	0.78	2.94e-32	Metabolic syndrome;
UCEC	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.63	4.78	0.37	4.16e-6	Carotid intima media thickness;
UCEC	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.6	-5.37	-0.41	2.99e-7	Metabolite levels;
UCEC	cis	rs17123764	0.786	rs58446833	chr12:50116733	T/C	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.43	0.65	2.06e-19	Chronic sinus infection;
UCEC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg22166914	chr1:53195759	ZYG11B	0.78	8.12	0.56	1.73e-13	Monocyte count;
UCEC	cis	rs864537	0.691	rs9662048	chr1:167412947	A/T	cg13426340	chr1:167131977	NA	0.43	4.59	0.35	9.31e-6	Celiac disease or Rheumatoid arthritis;Celiac disease;
UCEC	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-9.15	-0.6	4.35e-16	Blood metabolite levels;
UCEC	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	trans	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.76	-6.57	-0.48	8.1e-10	Longevity;
UCEC	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-0.97	-5.51	-0.41	1.58e-7	Mitochondrial DNA levels;
UCEC	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg03078520	chr22:18463400	MICAL3	0.5	5.0	0.38	1.65e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-9.34	-0.61	1.45e-16	Vitiligo;
UCEC	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.68	6.89	0.49	1.49e-10	Caffeine consumption;
UCEC	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg11632617	chr15:75315747	PPCDC	-0.58	-5.19	-0.39	6.93e-7	Lung cancer;
UCEC	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-4.88	-0.37	2.79e-6	Depression;
UCEC	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.79	8.96	0.59	1.35e-15	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.61	-5.41	-0.41	2.52e-7	HDL cholesterol levels;
UCEC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg04155231	chr12:9217510	LOC144571	0.41	4.99	0.38	1.7e-6	Sjögren's syndrome;
UCEC	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.83	-10.29	-0.65	4.77e-19	Brugada syndrome;
UCEC	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.06	9.54	0.62	4.26e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.39	4.56	0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs78487399	0.908	rs12469695	chr2:43833258	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-4.57	-0.35	1.02e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg24977027	chr2:88469347	THNSL2	-0.64	-6.36	-0.46	2.35e-9	Response to metformin (IC50);
UCEC	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.4	5.6	0.42	1e-7	Crohn's disease;
UCEC	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.09	6.27	0.46	3.74e-9	Diabetic retinopathy;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24049990	chr10:91011593	LIPA	0.58	6.72	0.48	3.81e-10	Warfarin maintenance dose;
UCEC	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.85	-10.42	-0.65	2.17e-19	Brugada syndrome;
UCEC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs8105895	0.736	rs2359835	chr19:22242690	A/G	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.64e-7	Body mass index (change over time);
UCEC	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.52	-5.34	-0.4	3.53e-7	Schizophrenia;
UCEC	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-0.99	-7.56	-0.53	3.92e-12	Economic and political preferences (immigration/crime);
UCEC	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.51	-4.79	-0.37	4.04e-6	Hepatocellular carcinoma;
UCEC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.38	-0.41	2.82e-7	Breast cancer;
UCEC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.36	-0.4	3.12e-7	Neutrophil percentage of white cells;
UCEC	cis	rs11264213	0.901	rs663163	chr1:36390527	A/G	cg27506609	chr1:36549197	TEKT2	0.48	4.62	0.36	8.31e-6	Schizophrenia;
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.45	0.41	2.11e-7	Platelet count;
UCEC	cis	rs4713118	0.539	rs200967	chr6:27862127	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.52	-5.34	-0.4	3.48e-7	Parkinson's disease;
UCEC	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	4.72	0.36	5.46e-6	IgG glycosylation;
UCEC	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg23795048	chr12:9217529	LOC144571	0.43	4.98	0.38	1.78e-6	Sjögren's syndrome;
UCEC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.6	6.23	0.46	4.65e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.46	5.16	0.39	7.87e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-0.91	-9.15	-0.6	4.52e-16	Height;
UCEC	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.41	4.91	0.38	2.35e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.82	4.91	0.38	2.44e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	6.14	0.45	7.44e-9	Cognitive test performance;
UCEC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.75	8.24	0.56	8.66e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.6	5.52	0.41	1.47e-7	Aortic root size;
UCEC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18932078	chr1:2524107	MMEL1	0.33	5.37	0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.99	7.33	0.52	1.43e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.78	5.82	0.43	3.52e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	4.82	0.37	3.52e-6	Breast cancer;
UCEC	cis	rs7611694	0.501	rs4682486	chr3:113109346	T/C	cg12596171	chr3:113251061	SIDT1	-0.54	-5.5	-0.41	1.61e-7	Prostate cancer;
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.81	-0.37	3.77e-6	Testicular germ cell tumor;
UCEC	trans	rs9972711	0.536	rs2272552	chr16:15917321	A/G	cg14428146	chr8:23563925	NKX2-6	-0.44	-6.78	-0.49	2.66e-10	Coronary artery disease;
UCEC	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14019695	chr9:139328340	INPP5E	0.41	4.61	0.36	8.73e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg19875535	chr5:140030758	IK	0.44	4.87	0.37	2.91e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.14	-0.45	7.21e-9	Parkinson's disease;
UCEC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.7	-7.3	-0.52	1.65e-11	Blood metabolite levels;
UCEC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.78	6.49	0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	5.1	0.39	1.04e-6	Coronary heart disease;
UCEC	cis	rs7611694	0.501	rs6768117	chr3:113151841	A/G	cg12596171	chr3:113251061	SIDT1	-0.54	-5.37	-0.4	3.08e-7	Prostate cancer;
UCEC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.71	-7.47	-0.52	6.47e-12	Mean platelet volume;
UCEC	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg06758158	chr16:89114156	NA	-0.71	-4.7	-0.36	5.82e-6	Red blood cell count;
UCEC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	5.25	0.4	5.11e-7	Total cholesterol levels;
UCEC	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.5	-4.64	-0.36	7.56e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.25	-0.61	2.38e-16	Height;
UCEC	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.28	12.96	0.73	4.17e-26	Corneal structure;
UCEC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.46	4.76	0.37	4.64e-6	Blood protein levels;
UCEC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg14092571	chr14:90743983	NA	-0.42	-5.7	-0.43	6.47e-8	Mortality in heart failure;
UCEC	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.48	4.97	0.38	1.84e-6	Retinal vascular caliber;
UCEC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.62	0.42	9.27e-8	Prudent dietary pattern;
UCEC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-10.8	-0.67	2.2e-20	Cognitive function;
UCEC	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.42	5.47	0.41	1.85e-7	Fibrinogen levels;
UCEC	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.85	6.98	0.5	9.46e-11	Prostate cancer;
UCEC	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.42	-0.47	1.76e-9	Schizophrenia;
UCEC	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.92	9.28	0.61	2.06e-16	Cognitive ability;
UCEC	cis	rs13095912	0.889	rs35917986	chr3:185310041	G/A	cg11274856	chr3:185301563	NA	0.55	7.29	0.52	1.77e-11	Systolic blood pressure;
UCEC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.41	-4.6	-0.35	9.19e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs713477	1.000	rs12888234	chr14:55911352	T/A	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.46	-4.68	-0.36	6.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg12637676	chr8:11587161	GATA4	-0.35	-4.65	-0.36	7.29e-6	Retinal vascular caliber;
UCEC	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.63	-6.85	-0.49	1.87e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.62	-5.25	-0.4	5.12e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-0.96	-11.74	-0.7	7.03e-23	Dilated cardiomyopathy;
UCEC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.55	5.93	0.44	2.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs883565	0.740	rs6763016	chr3:39098964	G/A	cg01426195	chr3:39028469	NA	-0.68	-8.5	-0.57	1.94e-14	Handedness;
UCEC	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.83	-0.49	2.05e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.55	-5.63	-0.42	8.87e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.75	-7.53	-0.53	4.85e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.54	-0.47	9.73e-10	Mood instability;
UCEC	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.55	-5.47	-0.41	1.89e-7	Prostate cancer;
UCEC	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.97	5.44	0.41	2.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg15837086	chr1:46506065	PIK3R3	0.37	4.52	0.35	1.27e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.41	-4.81	-0.37	3.74e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.69	7.05	0.5	6.31e-11	Resting heart rate;
UCEC	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg05962950	chr11:130786565	SNX19	0.47	4.76	0.37	4.5e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.59	5.75	0.43	5e-8	Bladder cancer;
UCEC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	6.0	0.44	1.44e-8	Breast cancer;
UCEC	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg16583315	chr14:65563665	MAX	-0.48	-5.24	-0.4	5.36e-7	Obesity-related traits;
UCEC	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	6.05	0.45	1.16e-8	Menarche (age at onset);
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.44	-4.77	-0.37	4.39e-6	Parkinson's disease;
UCEC	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.45	-5.14	-0.39	8.53e-7	Prudent dietary pattern;
UCEC	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg27153327	chr16:1920815	C16orf73	0.61	5.89	0.44	2.53e-8	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.34	4.51	0.35	1.29e-5	Mean corpuscular volume;
UCEC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.57	-5.44	-0.41	2.2e-7	Lupus nephritis in systemic lupus erythematosus;
UCEC	cis	rs7072216	0.770	rs7896828	chr10:100170507	A/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.79	-0.37	4.03e-6	Metabolite levels;
UCEC	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.21	8.07	0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg15358701	chr1:161410459	NA	-0.83	-4.95	-0.38	2.02e-6	Rheumatoid arthritis;
UCEC	cis	rs925228	0.779	rs13035058	chr2:24172771	T/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.74	4.64	0.36	7.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.23	0.46	4.71e-9	Coffee consumption (cups per day);
UCEC	trans	rs4841134	0.513	rs12155833	chr8:9234847	A/T	cg02929982	chr14:63872285	PPP2R5E	-0.6	-6.98	-0.5	9.23e-11	Age-related disease endophenotypes;
UCEC	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs9341808	0.622	rs684283	chr6:80967317	T/G	cg08355045	chr6:80787529	NA	-0.36	-4.67	-0.36	6.79e-6	Sitting height ratio;
UCEC	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	6.22	0.46	4.98e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.63	4.95	0.38	2.04e-6	Carotid intima media thickness;
UCEC	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg21204522	chr6:27730016	NA	-0.57	-4.73	-0.36	5.32e-6	Depression;
UCEC	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs6677604	1.000	rs12144939	chr1:196698945	G/T	cg07209298	chr1:196795943	CFHR1	0.43	4.52	0.35	1.29e-5	IgA nephropathy;Nephropathy;Blood protein levels;
UCEC	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.74	0.36	4.9100000000000004e-06	Personality dimensions;
UCEC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.36	-0.4	3.15e-7	Initial pursuit acceleration;
UCEC	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.6	-5.37	-0.4	3.04e-7	Toenail selenium levels;
UCEC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.53	-5.54	-0.42	1.39e-7	Monocyte percentage of white cells;
UCEC	cis	rs787274	1.000	rs4979148	chr9:115553399	C/T	cg13803584	chr9:115635662	SNX30	-0.69	-5.58	-0.42	1.13e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg04473437	chr5:205334	CCDC127	-0.58	-4.64	-0.36	7.6e-6	Breast cancer;
UCEC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.71	-8.67	-0.58	7.18e-15	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.4	-5.56	-0.42	1.22e-7	Alcohol dependence;
UCEC	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.76	-0.37	4.67e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.22	10.63	0.66	6.11e-20	Corneal structure;
UCEC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-1.11	-9.86	-0.63	6.55e-18	Dupuytren's disease;
UCEC	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg19743168	chr1:23544995	NA	0.46	5.97	0.44	1.69e-8	Height;
UCEC	cis	rs11697848	1.000	rs76488652	chr20:48510918	T/C	cg17849948	chr20:48532315	SPATA2	1.06	5.14	0.39	8.75e-7	Systemic lupus erythematosus;
UCEC	cis	rs9900062	0.586	rs6504250	chr17:62680553	T/C	cg02097616	chr17:62675921	NA	0.45	4.94	0.38	2.08e-6	QT interval;
UCEC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg20387954	chr3:183756860	HTR3D	0.48	5.36	0.4	3.17e-7	Anterior chamber depth;
UCEC	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.76	5.28	0.4	4.59e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs9283706	0.608	rs10065036	chr5:66338084	G/A	cg11590213	chr5:66331682	MAST4	0.45	5.41	0.41	2.45e-7	Coronary artery disease;
UCEC	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.5	-5.43	-0.41	2.28e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.65	-0.36	7.36e-6	Alzheimer's disease (late onset);
UCEC	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.44	5.32	0.4	3.86e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.7	-5.51	-0.41	1.58e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.72	-10.47	-0.65	1.6e-19	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.65	7.41	0.52	9.11e-12	Body mass index;
UCEC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.52	4.76	0.37	4.5e-6	Menarche (age at onset);
UCEC	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	6.48	0.47	1.3e-9	Hip circumference;
UCEC	cis	rs12644436	0.864	rs7680187	chr4:88777547	T/C	cg27179352	chr4:88029472	AFF1	0.4	4.63	0.36	7.85e-6	HIV-1 viral setpoint;
UCEC	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	0.86	5.21	0.39	6.41e-7	Arsenic metabolism;
UCEC	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.67	-6.7	-0.48	4.11e-10	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.63	-5.79	-0.43	4.03e-8	Coronary artery disease;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.83	-0.37	3.44e-6	Pulmonary function;
UCEC	cis	rs1468333	1.000	rs17171770	chr5:137514815	C/T	cg07848042	chr5:137667509	CDC25C	0.48	4.72	0.36	5.43e-6	Resting heart rate;
UCEC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.72	-0.43	5.69e-8	Mean corpuscular volume;
UCEC	cis	rs4400599	0.642	rs4364874	chr1:154167788	C/A	cg05139571	chr1:154127138	NUP210L	0.44	4.76	0.37	4.63e-6	Platelet distribution width;
UCEC	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-4.56	-0.35	1.08e-5	Blood pressure (smoking interaction);
UCEC	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.51	-5.58	-0.42	1.12e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.62	-6.57	-0.48	8.35e-10	Sudden cardiac arrest;
UCEC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg01262667	chr19:19385393	TM6SF2	0.5	7.14	0.51	3.93e-11	Tonsillectomy;
UCEC	cis	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg20368463	chr18:77673604	PQLC1	0.65	4.76	0.37	4.54e-6	Opioid sensitivity;
UCEC	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.56	5.42	0.41	2.41e-7	Radiation response;
UCEC	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs7570971	1.000	rs1375131	chr2:135954797	T/C	cg07169764	chr2:136633963	MCM6	0.63	5.72	0.43	5.8e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg08461772	chr7:95026248	PON3	0.4	5.51	0.41	1.53e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.5	7.18	0.51	3.28e-11	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4908768	0.906	rs56163601	chr1:8751897	G/A	cg13081009	chr1:8430745	RERE	0.47	4.77	0.37	4.42e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs7709377	0.597	rs12657249	chr5:115520736	A/C	cg23108291	chr5:115420582	COMMD10	0.52	5.47	0.41	1.88e-7	Metabolite levels  (X-11787);
UCEC	cis	rs58521262	0.556	rs435715	chr19:23126086	G/C	cg08486875	chr19:23386892	NA	-0.33	-4.6	-0.35	8.96e-6	Testicular germ cell tumor;
UCEC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-5.7	-0.43	6.37e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-8.05	-0.55	2.6e-13	Body mass index;
UCEC	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.98	-11.22	-0.68	1.75e-21	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.42	-5.07	-0.39	1.19e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07483432	chr12:72079704	TMEM19	0.66	7.93	0.55	5.08e-13	Warfarin maintenance dose;
UCEC	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.6	-4.72	-0.36	5.53e-6	Coronary artery calcification;
UCEC	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.45	5.19	0.39	6.95e-7	Aortic root size;
UCEC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.62	6.6	0.48	6.98e-10	IgG glycosylation;
UCEC	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.69	-5.98	-0.44	1.63e-8	Aortic root size;
UCEC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.64	-5.8	-0.43	3.92e-8	Menarche (age at onset);
UCEC	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg05660106	chr1:15850417	CASP9	0.49	4.75	0.36	4.8e-6	Systolic blood pressure;
UCEC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.78	-9.38	-0.61	1.12e-16	Platelet count;
UCEC	cis	rs12618769	0.597	rs72821951	chr2:99157009	A/C	cg10123293	chr2:99228465	UNC50	0.44	4.78	0.37	4.29e-6	Bipolar disorder;
UCEC	cis	rs11760485	0.858	rs11767003	chr7:4401503	G/A	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs1978968	0.826	rs5992946	chr22:18466111	G/T	cg03078520	chr22:18463400	MICAL3	-0.48	-4.8	-0.37	3.89e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs4240897	0.935	rs2236055	chr1:12042261	A/G	cg13216073	chr1:12042593	MFN2	0.52	5.52	0.41	1.52e-7	Tuberculosis;
UCEC	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.56	6.19	0.45	5.79e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg06784218	chr1:46089804	CCDC17	0.55	6.49	0.47	1.25e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs253959	0.883	rs27368	chr5:115693892	G/A	cg23108291	chr5:115420582	COMMD10	-0.5	-4.99	-0.38	1.66e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.62	5.59	0.42	1.07e-7	Graves' disease;
UCEC	cis	rs12618769	0.625	rs3769717	chr2:99124817	G/A	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.69	-0.36	6.22e-6	Parkinson's disease;
UCEC	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.28	-0.4	4.48e-7	Total cholesterol levels;
UCEC	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.55	5.1	0.39	1.03e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	4.54	0.35	1.17e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.49	6.39	0.47	2.05e-9	Platelet count;
UCEC	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg21770322	chr7:97807741	LMTK2	0.52	6.52	0.47	1.04e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg03959625	chr15:84868606	LOC388152	0.43	4.64	0.36	7.69e-6	Schizophrenia;
UCEC	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.52	-5.73	-0.43	5.57e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.61	-6.12	-0.45	7.93e-9	Blood metabolite levels;
UCEC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg02733842	chr7:1102375	C7orf50	-0.61	-5.68	-0.42	7.14e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.47	4.52	0.35	1.25e-5	Response to antipsychotic treatment;
UCEC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.85	-0.37	3.06e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg27153327	chr16:1920815	C16orf73	0.42	4.78	0.37	4.22e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.22	-0.51	2.59e-11	Resting heart rate;
UCEC	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.35	4.59	0.35	9.39e-6	Schizophrenia;
UCEC	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.97	-12.16	-0.71	5.72e-24	Breast cancer;
UCEC	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.15	-0.39	8.39e-7	Schizophrenia;
UCEC	cis	rs6890610	0.657	rs816747	chr5:154275962	G/A	cg02687067	chr5:153784852	GALNT10	-0.49	-4.57	-0.35	1.03e-5	Breast cancer;
UCEC	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.67	-7.99	-0.55	3.69e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-8.53	-0.58	1.63e-14	Colorectal cancer;
UCEC	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	0.74	4.76	0.37	4.67e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs34486957	0.600	rs12896208	chr14:60046646	C/G	cg12189551	chr14:60952945	C14orf39	0.37	4.58	0.35	9.92e-6	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs1595825	0.838	rs58576043	chr2:198524149	C/T	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.72	6.25	0.46	4.25e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.32	-0.46	2.98e-9	Parkinson's disease;
UCEC	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-12.51	-0.72	6.75e-25	Ulcerative colitis;
UCEC	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.58	5.78	0.43	4.23e-8	Colorectal cancer;
UCEC	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-0.94	-5.91	-0.44	2.33e-8	Mitochondrial DNA levels;
UCEC	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22857025	chr5:266934	NA	-1.01	-9.83	-0.63	7.64e-18	Breast cancer;
UCEC	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	4.66	0.36	7.01e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3790645	0.958	rs2290589	chr1:26880288	C/T	cg23229016	chr1:26872525	RPS6KA1	0.31	5.47	0.41	1.85e-7	Glucose homeostasis traits;
UCEC	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.82	-4.88	-0.37	2.69e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.59	5.69	0.43	6.56e-8	Type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	5.05	0.38	1.26e-6	Breast cancer;
UCEC	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.94	-0.5	1.17e-10	Morning vs. evening chronotype;
UCEC	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.63	6.83	0.49	2.08e-10	Immature fraction of reticulocytes;
UCEC	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.03	-8.28	-0.56	7.04e-14	Exhaled nitric oxide output;
UCEC	trans	rs6579967	0.826	rs115185629	chr5:152121541	G/A	cg10205403	chr12:95867231	METAP2	-1.2	-6.96	-0.5	1.04e-10	Facial morphology (factor 1, breadth of lateral portion of upper face);
UCEC	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-5.19	-0.39	6.76e-7	Body mass index;
UCEC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.5	-5.95	-0.44	1.92e-8	Electroencephalogram traits;
UCEC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.74	-0.43	5.22e-8	Alcohol dependence;
UCEC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.73	7.61	0.53	3.01e-12	Sudden cardiac arrest;
UCEC	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.73	8.43	0.57	3e-14	Cognitive function;
UCEC	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.69	8.55	0.58	1.43e-14	Mean platelet volume;
UCEC	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.72	6.13	0.45	7.7e-9	Lung function (FEV1/FVC);
UCEC	cis	rs1595825	0.891	rs7580003	chr2:198517893	C/T	cg19156104	chr2:198669113	PLCL1	-0.62	-4.66	-0.36	6.88e-6	Ulcerative colitis;
UCEC	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg13777783	chr17:79615861	NA	0.33	4.59	0.35	9.57e-6	Eye color traits;
UCEC	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.51	-5.44	-0.41	2.14e-7	Monocyte count;
UCEC	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.8	-9.18	-0.6	3.65e-16	Coronary artery disease;
UCEC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg27624424	chr6:160112604	SOD2	0.57	5.38	0.41	2.91e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.51	5.81	0.43	3.78e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.57	-6.74	-0.49	3.42e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.62	-0.48	6.2e-10	HDL cholesterol;
UCEC	trans	rs9527419	0.722	rs3098267	chr13:55906337	T/C	cg14957718	chr3:50243260	SLC38A3	0.75	6.71	0.48	3.92e-10	Response to platinum-based chemotherapy (cisplatin);
UCEC	cis	rs151997	0.925	rs27570	chr5:50191974	G/A	cg06027927	chr5:50259733	NA	0.52	4.83	0.37	3.42e-6	Callous-unemotional behaviour;
UCEC	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.68	-6.08	-0.45	1.01e-8	Initial pursuit acceleration;
UCEC	cis	rs1996152	0.543	rs9906415	chr17:72389282	A/G	cg23221732	chr17:72383708	NA	0.42	5.0	0.38	1.63e-6	Interleukin-12p70 levels;
UCEC	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs4845459	0.933	rs11205044	chr1:152593437	T/C	cg07796016	chr1:152779584	LCE1C	-0.44	-4.85	-0.37	3.09e-6	Psoriasis;
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.45	-4.9	-0.37	2.51e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg13695892	chr22:41940480	POLR3H	-0.68	-4.61	-0.36	8.57e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.55	6.23	0.46	4.57e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.68	-5.82	-0.43	3.49e-8	Longevity;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.48	0.57	2.18e-14	Prudent dietary pattern;
UCEC	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	0.83	5.26	0.4	5.06e-7	Diabetic retinopathy;
UCEC	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.51	-5.19	-0.39	6.98e-7	Height;
UCEC	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.65	6.05	0.45	1.12e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg23307798	chr14:103986281	CKB	0.56	5.33	0.4	3.63e-7	Body mass index;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.65	-0.42	7.89e-8	Platelet count;
UCEC	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.5	0.41	1.62e-7	Rheumatoid arthritis;
UCEC	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.46	4.77	0.37	4.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.54	-5.9	-0.44	2.43e-8	Parkinson's disease;
UCEC	cis	rs11850957	0.563	rs10132327	chr14:25540222	T/C	cg11775837	chr14:25519611	STXBP6	0.52	4.53	0.35	1.23e-5	Subcutaneous adipose tissue;
UCEC	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.44	4.68	0.36	6.36e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.91	11.38	0.68	6.45e-22	Breast cancer;
UCEC	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg12024160	chr4:1254474	NA	0.47	4.97	0.38	1.84e-6	Longevity;
UCEC	cis	rs2071426	0.959	rs1592037	chr10:96792328	A/G	cg09036531	chr10:96991505	NA	0.54	4.73	0.36	5.24e-6	Blood metabolite levels;
UCEC	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.74	4.83	0.37	3.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9715521	0.900	rs62301182	chr4:59834267	A/G	cg11281224	chr4:60001000	NA	-0.58	-5.91	-0.44	2.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.92	10.51	0.65	1.31e-19	Breast cancer;
UCEC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13683864	chr3:40499215	RPL14	-1.0	-10.24	-0.65	6.75e-19	Renal cell carcinoma;
UCEC	cis	rs36051895	0.632	rs7047795	chr9:5181467	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.42	-0.41	2.38e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.56	5.84	0.43	3.16e-8	Diastolic blood pressure;
UCEC	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.64	7.28	0.51	1.83e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.72	8.95	0.59	1.4e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.64	6.32	0.46	3e-9	Longevity;Endometriosis;
UCEC	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.66	-7.23	-0.51	2.42e-11	Extraversion;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.52	-6.49	-0.47	1.26e-9	Pubertal anthropometrics;
UCEC	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.11	7.26	0.51	2.05e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.09	0.39	1.1e-6	Personality dimensions;
UCEC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.27e-30	Chronic sinus infection;
UCEC	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.5	-4.76	-0.37	4.66e-6	QRS complex (12-leadsum);
UCEC	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.55	4.8	0.37	3.83e-6	Menarche (age at onset);
UCEC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.54	7.54	0.53	4.51e-12	Total body bone mineral density;
UCEC	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.54	-0.35	1.15e-5	Educational attainment;
UCEC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.59	6.47	0.47	1.38e-9	Monocyte count;
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.8	0.43	3.91e-8	Platelet count;
UCEC	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	0.95	8.76	0.59	4.42e-15	Granulocyte percentage of myeloid white cells;
UCEC	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-9.37	-0.61	1.21e-16	Height;
UCEC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.61	-5.44	-0.41	2.14e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	9.23	0.61	2.72e-16	Coffee consumption (cups per day);
UCEC	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg18230493	chr5:56204884	C5orf35	-0.64	-6.34	-0.46	2.65e-9	Coronary artery disease;
UCEC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.86	0.44	2.88e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.88	-0.67	1.32e-20	Headache;
UCEC	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.63	6.53	0.47	1e-9	Retinal vascular caliber;
UCEC	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs6763768	0.606	rs2029213	chr3:53378245	C/T	cg10956333	chr3:53294961	NA	0.4	4.67	0.36	6.82e-6	Bacterial meningitis;
UCEC	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg19678392	chr7:94953810	PON1	-0.54	-4.77	-0.37	4.47e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg15135617	chr1:17231562	NA	0.47	4.76	0.37	4.6e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg05132306	chr1:1846340	CALML6	-0.37	-4.75	-0.36	4.86e-6	Body mass index;
UCEC	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg24555468	chr13:114820315	RASA3	0.52	4.59	0.35	9.56e-6	Facial morphology (factor 14, intercanthal width);
UCEC	cis	rs4845570	1.000	rs6681093	chr1:151755284	C/G	cg07092448	chr1:151763213	TDRKH	-0.79	-8.62	-0.58	9.83e-15	Coronary artery disease;
UCEC	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.71	0.36	5.77e-6	Calcium levels;
UCEC	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.55	5.11	0.39	9.78e-7	Corneal astigmatism;
UCEC	cis	rs6540731	1.000	rs6540731	chr1:212392163	A/G	cg01168776	chr1:212002499	LPGAT1	0.37	4.73	0.36	5.23e-6	Intelligence (childhood);
UCEC	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	5.55	0.42	1.29e-7	Rheumatoid arthritis;
UCEC	cis	rs2425143	0.818	rs7272684	chr20:34424692	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.53	-0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07677856	chr17:61926188	NA	-0.43	-4.5	-0.35	1.35e-5	Prudent dietary pattern;
UCEC	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.44	0.41	2.19e-7	Total body bone mineral density;
UCEC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.55	6.11	0.45	8.51e-9	Calcium levels;
UCEC	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.74	-10.38	-0.65	2.88e-19	Leprosy;
UCEC	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27286337	chr10:134555280	INPP5A	0.62	5.47	0.41	1.91e-7	Migraine;
UCEC	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	0.59	5.27	0.4	4.81e-7	Left atrial antero-posterior diameter;
UCEC	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg05501817	chr11:14380813	RRAS2	-0.51	-4.81	-0.37	3.66e-6	Vitamin D levels;
UCEC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs12618769	0.597	rs4599165	chr2:99144483	G/A	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg14008862	chr17:28927542	LRRC37B2	0.83	5.44	0.41	2.16e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2051090	0.762	rs4941823	chr13:36453926	C/T	cg19508437	chr13:35517410	NBEA	0.35	4.64	0.36	7.52e-6	Pediatric non-alcoholic fatty liver disease activity score;
UCEC	cis	rs11048434	0.932	rs12816518	chr12:9153132	G/A	cg13575925	chr12:9217583	LOC144571	0.42	4.62	0.36	8.17e-6	Sjögren's syndrome;
UCEC	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.75	-8.45	-0.57	2.55e-14	Extraversion;
UCEC	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.67	5.1	0.39	1.03e-6	Prostate cancer;
UCEC	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.71	6.35	0.46	2.53e-9	Aortic root size;
UCEC	cis	rs925228	0.793	rs11679459	chr2:24091908	A/T	cg13272742	chr2:24272458	FKBP1B	-0.53	-4.65	-0.36	7.33e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.45	-4.65	-0.36	7.26e-6	Pancreatic cancer;
UCEC	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	8.17	0.56	1.27e-13	Smoking behavior;
UCEC	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.43	4.55	0.35	1.1e-5	Response to antineoplastic agents;
UCEC	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg18681998	chr4:17616180	MED28	0.9	11.5	0.69	3.14e-22	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	0.77	4.73	0.36	5.17e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	5.53	0.41	1.46e-7	Coffee consumption (cups per day);
UCEC	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.5	-4.94	-0.38	2.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.28	-0.4	4.61e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs12428035	1.000	rs75192006	chr13:96303624	C/T	cg07859753	chr13:96300257	NA	0.65	5.48	0.41	1.79e-7	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg04202892	chr2:111875749	ACOXL	0.41	4.76	0.37	4.63e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg01557791	chr16:72042693	DHODH	-0.43	-4.7	-0.36	6.02e-6	Fibrinogen levels;
UCEC	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	0.94	13.02	0.73	2.92e-26	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.76	-8.7	-0.58	6.04e-15	Facial morphology (factor 19);
UCEC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.64	5.96	0.44	1.82e-8	Homoarginine levels;
UCEC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.77	-8.7	-0.58	6.11e-15	Longevity;Endometriosis;
UCEC	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg03627880	chr6:151815985	C6orf97	-0.77	-5.03	-0.38	1.4e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.71	-0.36	5.69e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.59	6.67	0.48	4.96e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.76	-8.29	-0.56	6.37e-14	Monocyte count;
UCEC	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.61	7.44	0.52	7.9e-12	Bone mineral density;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26059219	chr3:4508837	SUMF1	0.54	6.67	0.48	4.89e-10	Warfarin maintenance dose;
UCEC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13683864	chr3:40499215	RPL14	-1.0	-10.24	-0.65	6.75e-19	Renal cell carcinoma;
UCEC	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg00791764	chr4:53727839	RASL11B	-0.65	-5.19	-0.39	6.76e-7	Optic nerve measurement (cup area);
UCEC	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg12850546	chr22:42539477	CYP2D7P1	0.44	4.88	0.37	2.73e-6	Schizophrenia;
UCEC	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.64	-5.81	-0.43	3.69e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg05660106	chr1:15850417	CASP9	0.89	10.27	0.65	5.36e-19	Systolic blood pressure;
UCEC	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Parkinson's disease;
UCEC	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.1	9.77	0.63	1.11e-17	Vitiligo;
UCEC	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.61	6.21	0.46	5.03e-9	Blood metabolite levels;
UCEC	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.57	-5.7	-0.43	6.42e-8	Breast cancer;
UCEC	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.9	-0.37	2.47e-6	Height;
UCEC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg02160872	chr5:212506	CCDC127	-0.7	-7.37	-0.52	1.16e-11	Breast cancer;
UCEC	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.54	0.35	1.18e-5	Menopause (age at onset);
UCEC	cis	rs4654899	0.606	rs651085	chr1:21097783	A/G	cg01072550	chr1:21505969	NA	0.49	4.93	0.38	2.24e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.58	6.54	0.47	9.61e-10	Crohn's disease;
UCEC	cis	rs7709377	0.595	rs11241359	chr5:115448150	G/T	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg26898376	chr11:64110657	CCDC88B	0.41	4.78	0.37	4.13e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.21	-13.64	-0.75	6.96e-28	Type 1 diabetes nephropathy;
UCEC	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.64	-6.52	-0.47	1.08e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3914502	0.935	rs2293204	chr3:174558364	C/T	cg21145449	chr3:174580620	NAALADL2	0.44	5.01	0.38	1.55e-6	Autism spectrum disorder;
UCEC	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg01256987	chr12:42539512	GXYLT1	-0.5	-5.72	-0.43	5.66e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.7	-6.95	-0.5	1.09e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.46	-4.62	-0.36	8.18e-6	Aortic root size;
UCEC	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.64	7.22	0.51	2.57e-11	Prostate-specific antigen levels;
UCEC	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg10932868	chr11:921992	NA	0.43	5.58	0.42	1.12e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9911578	0.839	rs11658694	chr17:57205174	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-7.26	-0.51	2.09e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.61	-6.53	-0.47	9.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	1.0	7.08	0.5	5.52e-11	Obesity-related traits;
UCEC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.11	-0.39	9.75e-7	Parkinson's disease;
UCEC	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg21533262	chr7:107110551	COG5;GPR22	-0.42	-4.52	-0.35	1.28e-5	Coronary artery disease;
UCEC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.84	9.53	0.62	4.72e-17	Post bronchodilator FEV1;
UCEC	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.45	-4.68	-0.36	6.38e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	0.87	8.48	0.57	2.15e-14	Coronary artery disease;
UCEC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	7.89	0.55	6.18e-13	Tonsillectomy;
UCEC	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg21466736	chr12:48725269	NA	0.36	4.76	0.37	4.61e-6	Plateletcrit;
UCEC	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.87	-0.37	2.81e-6	Breast cancer;
UCEC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.61	0.36	8.61e-6	Menopause (age at onset);
UCEC	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg08886695	chr4:3369023	RGS12	0.48	5.02	0.38	1.49e-6	Parental longevity (mother's age at death);
UCEC	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.4	-5.4	-0.41	2.66e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.82e-15	Blood protein levels;
UCEC	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.69	8.09	0.55	2.08e-13	Longevity;
UCEC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg20821713	chr7:1055600	C7orf50	-0.59	-6.2	-0.46	5.45e-9	Longevity;Endometriosis;
UCEC	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.51	4.82	0.37	3.59e-6	Bipolar disorder;
UCEC	cis	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg20307385	chr11:47447363	PSMC3	0.57	5.12	0.39	9.6e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.56	5.64	0.42	8.29e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.8	8.58	0.58	1.21e-14	Eosinophil percentage of white cells;
UCEC	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	4.5	0.35	1.35e-5	Lung function (FEV1/FVC);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08052428	chr9:135996421	RALGDS	0.57	7.0	0.5	8.34e-11	Warfarin maintenance dose;
UCEC	cis	rs8177876	0.642	rs76909932	chr16:81119054	A/C	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	5.8	0.43	3.92e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.39	0.41	2.76e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4499344	0.730	rs12460624	chr19:33098042	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.93	0.44	2.05e-8	Mean platelet volume;
UCEC	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.43	0.47	1.67e-9	Aortic root size;
UCEC	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-5.33	-0.4	3.62e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs10887741	0.646	rs7903568	chr10:89433931	T/A	cg13926569	chr10:89418898	PAPSS2	0.41	4.85	0.37	3.16e-6	Exercise (leisure time);
UCEC	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.51	5.0	0.38	1.61e-6	Mood instability;
UCEC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.92e-6	Breast cancer;
UCEC	cis	rs7580658	0.545	rs59318157	chr2:127950074	G/C	cg16751203	chr2:127950803	CYP27C1	0.38	5.13	0.39	8.92e-7	Protein C levels;
UCEC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	cis	rs7246967	0.673	rs16994997	chr19:22879610	T/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7246967	0.611	rs7246424	chr19:22882185	A/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.54	-5.5	-0.41	1.61e-7	Hepatocellular carcinoma;
UCEC	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.33	4.65	0.36	7.31e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.63	-8.78	-0.59	3.97e-15	Cancer (pleiotropy);
UCEC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.15	-14.91	-0.78	3.22e-31	Cognitive function;
UCEC	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.31	4.62	0.36	8.22e-6	Schizophrenia;
UCEC	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-0.77	-6.82	-0.49	2.15e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs12617721	0.645	rs114544871	chr2:99045485	T/G	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder with mood-incongruent psychosis;
UCEC	cis	rs2267681	0.583	rs10256282	chr7:139528444	C/T	cg14116596	chr7:139528673	TBXAS1	0.51	5.08	0.39	1.15e-6	Cervical cancer;
UCEC	cis	rs8020441	0.541	rs67026579	chr14:51155207	A/G	cg04730355	chr14:51134070	SAV1	0.77	7.04	0.5	6.86e-11	Cognitive performance;
UCEC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg11569703	chr11:65557185	OVOL1	-0.45	-6.43	-0.47	1.67e-9	Acne (severe);
UCEC	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.85	-9.04	-0.6	8.2e-16	Blood protein levels;
UCEC	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg03859395	chr2:55845619	SMEK2	0.97	13.95	0.75	1.04e-28	Metabolic syndrome;
UCEC	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.45	4.63	0.36	8.07e-6	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.52	0.41	1.48e-7	Breast cancer;
UCEC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.69	-6.79	-0.49	2.56e-10	Blood metabolite levels;
UCEC	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg04310649	chr10:35416472	CREM	-0.48	-4.92	-0.38	2.25e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.38	-4.65	-0.36	7.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9309473	0.500	rs6757996	chr2:73772251	G/A	cg20560298	chr2:73613845	ALMS1	-0.55	-5.48	-0.41	1.77e-7	Metabolite levels;
UCEC	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg01072550	chr1:21505969	NA	-0.59	-5.62	-0.42	9.13e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg22166914	chr1:53195759	ZYG11B	0.75	7.72	0.54	1.62e-12	Monocyte count;
UCEC	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg13092806	chr2:177043255	NA	0.56	5.24	0.4	5.47e-7	IgG glycosylation;
UCEC	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	0.81	6.89	0.49	1.52e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.77	8.89	0.59	2.02e-15	Menopause (age at onset);
UCEC	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.76	-6.89	-0.49	1.53e-10	Initial pursuit acceleration;
UCEC	cis	rs9283706	0.595	rs6866433	chr5:66324152	A/G	cg11590213	chr5:66331682	MAST4	0.42	5.29	0.4	4.33e-7	Coronary artery disease;
UCEC	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.02	-0.5	7.59e-11	Colorectal cancer;
UCEC	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-4.66	-0.36	6.96e-6	Alzheimer's disease (late onset);
UCEC	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.74e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-5.85	-0.43	3.1e-8	Menarche (age at onset);
UCEC	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.59	-5.9	-0.44	2.36e-8	Schizophrenia;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.36	-0.46	2.44e-9	Depression;
UCEC	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24308560	chr3:49941425	MST1R	0.52	5.87	0.44	2.79e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg22532475	chr10:104410764	TRIM8	-0.49	-5.56	-0.42	1.26e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.1	-13.11	-0.73	1.71e-26	Breast cancer;
UCEC	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-4.85	-0.37	3.1e-6	Metabolite levels;
UCEC	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	0.75	7.69	0.54	1.94e-12	Parkinson's disease;
UCEC	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.5	5.21	0.39	6.26e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg23018236	chr17:30244563	NA	-0.67	-4.65	-0.36	7.34e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.42	5.32	0.4	3.76e-7	Eotaxin levels;
UCEC	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.34	4.79	0.37	4.09e-6	Childhood ear infection;
UCEC	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg01072550	chr1:21505969	NA	-0.53	-5.01	-0.38	1.51e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.19	-0.39	6.74e-7	Sudden cardiac arrest;
UCEC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.47	-5.24	-0.4	5.42e-7	Response to antineoplastic agents;
UCEC	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.6	6.92	0.5	1.3100000000000001e-10	Vitiligo;
UCEC	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.71	6.43	0.47	1.66e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs78487399	0.808	rs7581586	chr2:43668176	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg06671706	chr8:8559999	CLDN23	0.54	4.92	0.38	2.3e-6	Obesity-related traits;
UCEC	cis	rs7246967	0.611	rs7246424	chr19:22882185	A/G	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.57	-0.42	1.18e-7	Obesity-related traits;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.61	-0.48	6.56e-10	Pulmonary function;
UCEC	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	5.59	0.42	1.05e-7	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.05	0.45	1.13e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg01262667	chr19:19385393	TM6SF2	-0.51	-7.2	-0.51	2.84e-11	Tonsillectomy;
UCEC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.66	5.32	0.4	3.75e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg01851573	chr8:8652454	MFHAS1	0.4	4.59	0.35	9.57e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.53	-0.41	1.45e-7	Hemoglobin concentration;
UCEC	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	6.22	0.46	4.82e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.41	5.4	0.41	2.66e-7	Blood protein levels;
UCEC	cis	rs12428035	1.000	rs115779493	chr13:96300448	T/A	cg07859753	chr13:96300257	NA	0.66	5.51	0.41	1.56e-7	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.09	0.39	1.08e-6	Homocysteine levels;
UCEC	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	0.9	7.84	0.54	8.5e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.05	-0.45	1.12e-8	Parkinson's disease;
UCEC	cis	rs7246967	0.673	rs937078	chr19:22811667	G/A	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18252515	chr7:66147081	NA	0.57	5.33	0.4	3.64e-7	Aortic root size;
UCEC	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.86	-0.37	2.92e-6	Response to antipsychotic treatment;
UCEC	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.07	7.89	0.55	6.47e-13	Sexual dysfunction (female);
UCEC	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg13575925	chr12:9217583	LOC144571	0.39	4.51	0.35	1.33e-5	Sjögren's syndrome;
UCEC	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.89	-0.44	2.58e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.6	5.69	0.42	6.66e-8	Uric acid levels;
UCEC	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	IgM levels;
UCEC	cis	rs3772130	0.583	rs6767409	chr3:121564989	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs7246967	0.611	rs57013651	chr19:22863027	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.53	5.2	0.39	6.61e-7	Lymphocyte counts;
UCEC	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg21770322	chr7:97807741	LMTK2	0.84	14.48	0.77	4.35e-30	Breast cancer;
UCEC	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.24	0.65	6.66e-19	Electrocardiographic conduction measures;
UCEC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.75	-5.64	-0.42	8.41e-8	Mean platelet volume;
UCEC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.67	-6.22	-0.46	4.9e-9	Aortic root size;
UCEC	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.16	-0.6	4.23e-16	Coffee consumption (cups per day);
UCEC	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg15133208	chr4:90757351	SNCA	-0.37	-4.9	-0.37	2.52e-6	Dementia with Lewy bodies;
UCEC	cis	rs883565	0.740	rs2293312	chr3:39111140	C/A	cg01426195	chr3:39028469	NA	-0.68	-8.51	-0.57	1.83e-14	Handedness;
UCEC	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg19805062	chr22:46654627	PKDREJ	-0.44	-4.71	-0.36	5.76e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.5	-4.9	-0.37	2.49e-6	Neuroticism;
UCEC	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.81	-8.35	-0.57	4.64e-14	Mosquito bite size;
UCEC	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.55	5.91	0.44	2.31e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg21191810	chr6:118973309	C6orf204	0.39	5.33	0.4	3.65e-7	Electrocardiographic conduction measures;
UCEC	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.64	5.6	0.42	1.02e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.51	-5.24	-0.4	5.39e-7	Height;
UCEC	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.45	4.59	0.35	9.39e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.5	5.28	0.4	4.59e-7	Initial pursuit acceleration;
UCEC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg12035532	chr1:1886765	KIAA1751	0.44	4.56	0.35	1.07e-5	Body mass index;
UCEC	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.53	6.52	0.47	1.05e-9	Total body bone mineral density;
UCEC	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.6	6.77	0.49	2.89e-10	Red blood cell count;
UCEC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.39	5.51	0.41	1.59e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg21856205	chr7:94953877	PON1	-0.56	-5.32	-0.4	3.8e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg06238570	chr21:40685208	BRWD1	0.76	7.39	0.52	1.03e-11	Cognitive function;
UCEC	cis	rs6670533	0.571	rs16829805	chr1:24860590	C/T	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-5.66	-0.42	7.86e-8	Chronic sinus infection;
UCEC	cis	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-5.82	-0.43	3.5e-8	Educational attainment (years of education);
UCEC	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	7.07	0.5	5.71e-11	Coronary artery disease;
UCEC	cis	rs7219021	0.926	rs9912856	chr17:46861667	C/T	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.54	-5.93	-0.44	2.03e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg07537917	chr2:241836409	C2orf54	-0.32	-4.92	-0.38	2.29e-6	Urinary metabolites;
UCEC	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.81	8.6	0.58	1.12e-14	Blood protein levels;
UCEC	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-4.85	-0.37	3.12e-6	Acylcarnitine levels;
UCEC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.54	0.42	1.34e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	0.89	9.19	0.6	3.53e-16	Left atrial antero-posterior diameter;
UCEC	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.52	-4.58	-0.35	9.7e-6	Diabetic retinopathy;
UCEC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-7.86	-0.54	7.36e-13	Menarche (age at onset);
UCEC	cis	rs10507349	0.632	rs534195	chr13:26817679	G/T	cg01600817	chr13:26797529	RNF6	0.42	4.62	0.36	8.44e-6	Type 2 diabetes;
UCEC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg01874867	chr7:94954059	PON1	-0.52	-4.65	-0.36	7.42e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-1.03	-7.23	-0.51	2.5e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.78	7.31	0.52	1.6e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.12	-0.39	9.24e-7	Morning vs. evening chronotype;
UCEC	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	0.9	7.69	0.54	1.95e-12	Red blood cell traits;
UCEC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg07387570	chr22:46663686	TTC38	-0.47	-4.62	-0.36	8.32e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.42	-4.59	-0.35	9.62e-6	Hip circumference;
UCEC	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.6	5.56	0.42	1.27e-7	Coronary artery disease;
UCEC	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg19197139	chr17:4613644	ARRB2	0.82	6.18	0.45	5.92e-9	Lymphocyte counts;
UCEC	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.58	6.31	0.46	3.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg01380346	chr19:18557039	ELL	-0.47	-4.73	-0.36	5.28e-6	Breast cancer;
UCEC	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg11569703	chr11:65557185	OVOL1	-0.42	-6.01	-0.44	1.38e-8	Acne (severe);
UCEC	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	4.8	0.37	3.92e-6	Cognitive test performance;
UCEC	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.67	8.83	0.59	2.91e-15	Bipolar disorder;
UCEC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.54	4.89	0.37	2.6e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg00614314	chr15:82944287	LOC80154	0.54	4.97	0.38	1.85e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-6.61	-0.48	6.55e-10	Morning vs. evening chronotype;
UCEC	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.5	4.85	0.37	3.16e-6	Vitiligo;
UCEC	cis	rs28425639	0.569	rs7425132	chr2:100561563	A/G	cg22139774	chr2:100720529	AFF3	-0.43	-4.51	-0.35	1.33e-5	Response to paliperidone in schizophrenia (negative Marder score);
UCEC	cis	rs10127852	0.702	rs10127586	chr1:85318919	A/T	cg21422605	chr1:85313514	LPAR3	0.39	4.67	0.36	6.84e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.85e-8	Red blood cell count;
UCEC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.63	-0.48	6.08e-10	Tonsillectomy;
UCEC	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	1.0	11.82	0.7	4.54e-23	Cognitive function;
UCEC	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.33	0.52	1.39e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.71	6.69	0.48	4.43e-10	High light scatter reticulocyte count;
UCEC	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.15	8.44	0.57	2.75e-14	Exhaled nitric oxide output;
UCEC	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	5.24	0.4	5.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.25	7.8	0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.55	5.94	0.44	1.96e-8	Schizophrenia;
UCEC	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.06	-0.45	1.09e-8	Metabolite levels;
UCEC	cis	rs17123764	0.818	rs12311839	chr12:49963405	A/G	cg20471783	chr12:50157085	TMBIM6	0.63	5.19	0.39	6.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-8.2	-0.56	1.12e-13	Gut microbiome composition (summer);
UCEC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-7.96	-0.55	4.37e-13	Menarche (age at onset);
UCEC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.54	-5.99	-0.44	1.56e-8	Blood metabolite levels;
UCEC	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.5	5.38	0.41	2.92e-7	Alcohol dependence;
UCEC	trans	rs9313296	0.661	rs2431312	chr5:165522039	G/A	cg03539051	chr19:56418660	NLRP13	1.11	6.93	0.5	1.23e-10	Weight;Waist circumference;
UCEC	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs7246967	1.000	rs7257127	chr19:23056699	A/G	cg05241461	chr19:22816980	ZNF492	0.47	4.93	0.38	2.18e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18252515	chr7:66147081	NA	0.54	5.25	0.4	5.27e-7	Aortic root size;
UCEC	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.65	7.93	0.55	5.21e-13	Hip circumference;
UCEC	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	7.11	0.51	4.7e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.46	4.87	0.37	2.9e-6	Menopause (age at onset);
UCEC	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.53	5.28	0.4	4.52e-7	Blood trace element (Zn levels);
UCEC	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.55	-6.32	-0.46	3e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.65	7.54	0.53	4.42e-12	Schizophrenia;
UCEC	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.58	7.09	0.5	5.14e-11	Oral cavity cancer;
UCEC	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.67	-0.42	7.23e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.93	-0.38	2.22e-6	Body mass index;
UCEC	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.85	-6.4	-0.47	1.97e-9	Vitiligo;
UCEC	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.44	-5.29	-0.4	4.26e-7	Rheumatoid arthritis;
UCEC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg17724175	chr1:150552817	MCL1	-0.41	-4.57	-0.35	1.04e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.58	6.4	0.47	1.96e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.16	5.94	0.44	1.95e-8	Diabetic retinopathy;
UCEC	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	4.91	0.38	2.43e-6	Bipolar disorder;
UCEC	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.74	9.3	0.61	1.76e-16	Menarche (age at onset);
UCEC	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.7	-7.52	-0.53	5.09e-12	Waist circumference;Body mass index;
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg07404485	chr7:94953653	PON1	-0.5	-5.54	-0.42	1.38e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.31	0.52	1.63e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg24631222	chr15:78858424	CHRNA5	0.48	4.61	0.36	8.56e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12216499	0.786	rs12199084	chr6:159421904	A/G	cg10634217	chr6:160211790	TCP1;MRPL18	-0.69	-4.63	-0.36	7.89e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.86	-8.76	-0.59	4.32e-15	Obesity-related traits;
UCEC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.86	-0.49	1.8e-10	Menarche (age at onset);
UCEC	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg20026190	chr17:76395443	PGS1	0.47	5.87	0.44	2.74e-8	HDL cholesterol levels;
UCEC	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-6.16	-0.45	6.58e-9	Diastolic blood pressure;
UCEC	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.55	6.33	0.46	2.77e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9864370	1.000	rs1011599	chr3:168912578	G/A	cg18504196	chr3:168331449	C3orf50	0.53	4.52	0.35	1.26e-5	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.52	6.83	0.49	2.1e-10	Osteoporosis;
UCEC	cis	rs17122693	0.688	rs72681637	chr14:51152761	C/A	cg04730355	chr14:51134070	SAV1	0.94	9.67	0.62	1.96e-17	Cognitive performance;
UCEC	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.62	-6.85	-0.49	1.86e-10	Blood trace element (Zn levels);
UCEC	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	5.06	0.39	1.24e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	6.37	0.47	2.29e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg18973586	chr4:963968	DGKQ	-0.42	-4.52	-0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.73	5.42	0.41	2.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.52	4.7	0.36	5.82e-6	Coronary artery disease;
UCEC	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.71	7.12	0.51	4.54e-11	Opioid sensitivity;
UCEC	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.46	4.65	0.36	7.28e-6	Schizophrenia;
UCEC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.43	-5.97	-0.44	1.71e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg17674042	chr6:34482479	PACSIN1	-0.65	-4.7	-0.36	6.04e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.46	4.53	0.35	1.23e-5	Pediatric autoimmune diseases;
UCEC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.7	5.9	0.44	2.4e-8	Smoking initiation;
UCEC	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.77e-9	Blood metabolite levels;
UCEC	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.54	-5.36	-0.4	3.17e-7	Systemic lupus erythematosus;
UCEC	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.44	5.22	0.4	6.01e-7	Fibrinogen levels;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg00417742	chr7:112580528	C7orf60	-0.58	-6.91	-0.5	1.38e-10	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.57	0.42	1.16e-7	Prudent dietary pattern;
UCEC	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.42	4.61	0.36	8.79e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.95	9.03	0.6	9.17e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.79	9.74	0.63	1.3e-17	Bone mineral density;
UCEC	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	6.5	0.47	1.14e-9	Bone mineral density;
UCEC	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.78	-6.67	-0.48	4.77e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.71	7.07	0.5	5.74e-11	Diastolic blood pressure;
UCEC	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.56	0.53	4.04e-12	Bipolar disorder;
UCEC	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.57	-4.97	-0.38	1.83e-6	QT interval (drug interaction);
UCEC	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg18099408	chr3:52552593	STAB1	0.42	4.78	0.37	4.28e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg05775895	chr3:12838266	CAND2	0.49	4.83	0.37	3.39e-6	P wave duration;
UCEC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg24881330	chr22:46731750	TRMU	-0.62	-5.82	-0.43	3.63e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.66	6.85	0.49	1.9e-10	Response to diuretic therapy;
UCEC	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.65	6.88	0.49	1.62e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg15358701	chr1:161410459	NA	-0.74	-5.07	-0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.61	5.31	0.4	3.89e-7	Heart rate;
UCEC	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.34	4.54	0.35	1.15e-5	Childhood ear infection;
UCEC	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-0.98	-10.11	-0.64	1.43e-18	Blood pressure (smoking interaction);
UCEC	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.66	-6.76	-0.49	3.04e-10	Body mass index;
UCEC	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.89	-0.49	1.49e-10	Total cholesterol levels;
UCEC	cis	rs10924970	0.967	rs2891015	chr1:235459509	T/C	cg26050004	chr1:235667680	B3GALNT2	0.47	4.9	0.37	2.47e-6	Asthma;
UCEC	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	0.89	5.57	0.42	1.21e-7	Skin colour saturation;
UCEC	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.12	-13.15	-0.74	1.36e-26	Breast cancer;
UCEC	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.58	5.68	0.42	6.83e-8	Lung cancer;
UCEC	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.56	5.76	0.43	4.65e-8	Hepatocellular carcinoma;
UCEC	cis	rs925228	0.779	rs13035058	chr2:24172771	T/C	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-7.18	-0.51	3.18e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-4.85	-0.37	3.17e-6	HDL cholesterol;
UCEC	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg23631578	chr16:74455140	CLEC18B	0.3	4.6	0.35	8.95e-6	Breast cancer;
UCEC	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.54	5.07	0.39	1.17e-6	Pancreatic cancer;
UCEC	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.54	5.94	0.44	1.96e-8	Monocyte percentage of white cells;
UCEC	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.52	4.9	0.37	2.55e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg01874867	chr7:94954059	PON1	-0.54	-5.1	-0.39	1.03e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.06	10.0	0.64	2.74e-18	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	0.81	7.19	0.51	3.05e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.58	-5.96	-0.44	1.75e-8	Breast cancer;
UCEC	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.31e-5	Dementia with Lewy bodies;
UCEC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.58	-8.4	-0.57	3.56e-14	Sense of smell;
UCEC	cis	rs5770917	0.522	rs5770916	chr22:51016098	C/T	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	0.49	4.84	0.37	3.23e-6	Narcolepsy;
UCEC	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.51	5.47	0.41	1.85e-7	Schizophrenia;
UCEC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.64	-8.74	-0.58	4.77e-15	Prudent dietary pattern;
UCEC	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.74	-5.18	-0.39	7.29e-7	Bipolar disorder;
UCEC	cis	rs1978968	0.763	rs9605472	chr22:18463216	A/G	cg03078520	chr22:18463400	MICAL3	-0.55	-6.98	-0.5	9.62e-11	Presence of antiphospholipid antibodies;
UCEC	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.52	-6.22	-0.46	4.94e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.74	-8.32	-0.57	5.62e-14	Sudden cardiac arrest;
UCEC	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.36	-4.9	-0.37	2.46e-6	Eye color traits;
UCEC	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg19438565	chr8:143695827	ARC	-0.46	-4.66	-0.36	6.88e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.6	6.1	0.45	8.96e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22117172	chr7:91764530	CYP51A1	0.38	4.98	0.38	1.78e-6	Breast cancer;
UCEC	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.55	5.85	0.43	3.12e-8	Autism;
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-5.91	-0.44	2.23e-8	Platelet count;
UCEC	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg10932868	chr11:921992	NA	0.41	5.4	0.41	2.57e-7	Alzheimer's disease (late onset);
UCEC	cis	rs7246967	0.673	rs35007247	chr19:22822923	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-0.98	-11.06	-0.67	4.42e-21	Blood pressure (smoking interaction);
UCEC	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.43	-5.43	-0.41	2.27e-7	Urinary tract infection frequency;
UCEC	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg04310649	chr10:35416472	CREM	-0.49	-4.67	-0.36	6.82e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.94	-0.38	2.06e-6	Joint mobility (Beighton score);
UCEC	cis	rs10507349	0.632	rs7988894	chr13:26818637	T/C	cg01600817	chr13:26797529	RNF6	-0.46	-4.92	-0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.11	-0.39	9.65e-7	Metabolite levels;
UCEC	cis	rs4730268	0.950	rs2051953	chr7:107440936	G/C	cg18560240	chr7:107437656	SLC26A3	-0.74	-6.16	-0.45	6.72e-9	IgG glycosylation;
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.19	-0.45	5.74e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.72	9.21	0.6	3.08e-16	Menarche (age at onset);
UCEC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-11.79	-0.7	5.19e-23	Primary sclerosing cholangitis;
UCEC	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.34	4.83	0.37	3.35e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg13256891	chr4:100009986	ADH5	-0.7	-5.4	-0.41	2.65e-7	Alcohol dependence;
UCEC	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-0.99	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.58	6.49	0.47	1.25e-9	Red blood cell count;
UCEC	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.41	-5.36	-0.4	3.13e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.5	4.9	0.37	2.55e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg05660106	chr1:15850417	CASP9	0.85	9.76	0.63	1.18e-17	Systolic blood pressure;
UCEC	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.54	4.69	0.36	6.21e-6	Response to diuretic therapy;
UCEC	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.12e-18	Height;
UCEC	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.77	-9.54	-0.62	4.34e-17	Leprosy;
UCEC	cis	rs6832769	0.826	rs10462035	chr4:56379178	G/A	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.45e-8	Personality dimensions;
UCEC	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.62	4.55	0.35	1.12e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg01851573	chr8:8652454	MFHAS1	0.4	4.69	0.36	6.24e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.56	-4.5	-0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.51	5.62	0.42	9.38e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg03859395	chr2:55845619	SMEK2	1.05	15.19	0.78	6.32e-32	Metabolic syndrome;
UCEC	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.79	-7.05	-0.5	6.38e-11	Alzheimer's disease;
UCEC	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg09491104	chr22:46646882	C22orf40	-0.54	-5.72	-0.43	5.82e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.41	4.91	0.38	2.39e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg03342759	chr3:160939853	NMD3	-0.56	-5.29	-0.4	4.39e-7	Morning vs. evening chronotype;
UCEC	cis	rs1595825	0.838	rs7603283	chr2:198517592	A/G	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg05805236	chr11:65401703	PCNXL3	-0.46	-4.86	-0.37	2.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.73	8.26	0.56	7.92e-14	Mortality in heart failure;
UCEC	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.79	8.29	0.56	6.55e-14	Cognitive function;
UCEC	cis	rs7246967	0.673	rs8102006	chr19:22870103	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7307889	0.793	rs73047640	chr12:6008290	C/T	cg23245485	chr12:6484219	SCNN1A	0.59	4.68	0.36	6.4e-6	Obesity-related traits;
UCEC	cis	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.68	8.49	0.57	2.1e-14	Menarche (age at onset);
UCEC	cis	rs5770917	0.522	rs3752393	chr22:51015557	C/T	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.58	-5.01	-0.38	1.57e-6	Narcolepsy;
UCEC	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.46	5.58	0.42	1.11e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg05962950	chr11:130786565	SNX19	0.53	4.67	0.36	6.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.09	-0.45	9.34e-9	Blood metabolite levels;
UCEC	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.64	-0.42	8.58e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.51	4.58	0.35	9.85e-6	Coronary artery disease;
UCEC	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg18099408	chr3:52552593	STAB1	0.37	4.51	0.35	1.32e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg04310649	chr10:35416472	CREM	-0.47	-4.66	-0.36	7.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.61	5.53	0.41	1.45e-7	Corneal astigmatism;
UCEC	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.35	5.8	0.43	3.94e-8	Cancer;
UCEC	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.54	5.45	0.41	2.09e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.22	-0.4	5.94e-7	Bipolar disorder;
UCEC	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.78	-4.74	-0.36	4.9e-6	Mosquito bite size;
UCEC	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.02	-8.36	-0.57	4.5e-14	Exhaled nitric oxide output;
UCEC	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-5.24	-0.4	5.55e-7	Educational attainment (years of education);
UCEC	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.71	5.79	0.43	4.02e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.93	9.66	0.62	2.08e-17	Cognitive ability;
UCEC	cis	rs12216499	0.892	rs2235824	chr6:159393101	A/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.54	-0.35	1.15e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.72	6.77	0.49	2.91e-10	Selective IgA deficiency;
UCEC	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg09910674	chr16:89028015	CBFA2T3	0.6	4.54	0.35	1.16e-5	Skin colour saturation;
UCEC	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.54	6.4	0.47	1.97e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.62	5.76	0.43	4.67e-8	Menarche (age at onset);
UCEC	cis	rs12086130	0.892	rs59225836	chr1:51485912	A/C	cg07174182	chr1:51127561	FAF1	-0.81	-4.93	-0.38	2.21e-6	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.77	-4.86	-0.37	2.98e-6	Psoriasis;
UCEC	trans	rs66573146	0.803	rs59809420	chr4:6969928	G/T	cg07817883	chr1:32538562	TMEM39B	1.44	9.79	0.63	9.68e-18	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.49	-7.34	-0.52	1.31e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-5.28	-0.4	4.58e-7	Colorectal cancer;
UCEC	cis	rs76878669	0.538	rs4930368	chr11:66179358	T/C	cg24851651	chr11:66362959	CCS	-0.39	-4.88	-0.37	2.78e-6	Educational attainment (years of education);
UCEC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.75	7.11	0.51	4.8e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs7215564	0.818	rs4890055	chr17:78587225	A/C	cg01498832	chr17:78682934	RPTOR	0.66	5.06	0.39	1.21e-6	Myopia (pathological);
UCEC	cis	rs8010715	0.520	rs12435994	chr14:24589461	A/C	cg20933586	chr14:24608199	FAM158A	0.43	5.42	0.41	2.42e-7	IgG glycosylation;
UCEC	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.49	4.92	0.38	2.33e-6	Monocyte percentage of white cells;
UCEC	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.69	-0.42	6.69e-8	Fear of minor pain;
UCEC	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.42	4.93	0.38	2.24e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.7	0.36	5.93e-6	Menopause (age at onset);
UCEC	cis	rs61134957	1.000	rs73309653	chr8:92610231	G/A	cg26596161	chr8:92261459	SLC26A7	0.96	4.91	0.38	2.37e-6	Night sleep phenotypes;
UCEC	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.12	-0.56	1.72e-13	Schizophrenia;
UCEC	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg05527609	chr1:210001259	C1orf107	-0.59	-4.92	-0.38	2.27e-6	Red blood cell count;
UCEC	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.72	6.17	0.45	6.21e-9	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.73	-0.43	5.41e-8	Fear of minor pain;
UCEC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg20387954	chr3:183756860	HTR3D	0.47	5.62	0.42	9.52e-8	Anterior chamber depth;
UCEC	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg04871131	chr7:94954202	PON1	-0.52	-5.15	-0.39	8.14e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.67	0.42	7.24e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.71	-5.83	-0.43	3.36e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-5.66	-0.42	7.83e-8	Colorectal cancer;
UCEC	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg05991184	chr2:219186017	PNKD	-0.43	-4.56	-0.35	1.07e-5	Colorectal cancer;
UCEC	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.76	6.15	0.45	7.01e-9	Menopause (age at onset);
UCEC	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg07169764	chr2:136633963	MCM6	-0.51	-4.62	-0.36	8.33e-6	Colorectal cancer;
UCEC	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.72	6.17	0.45	6.21e-9	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.81	9.71	0.63	1.57e-17	Monocyte count;
UCEC	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.6	8.68	0.58	6.81e-15	Prudent dietary pattern;
UCEC	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.77	4.73	0.36	5.29e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg21486944	chr6:28411378	ZSCAN23	0.46	4.96	0.38	1.96e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.56	-6.14	-0.45	7.37e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg23283320	chr21:48055893	PRMT2	0.9	5.71	0.43	5.95e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.49	-6.65	-0.48	5.51e-10	Body mass index;
UCEC	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.54	6.3	0.46	3.31e-9	Iron status biomarkers (transferrin levels);
UCEC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.6	0.53	3.22e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.56	5.24	0.4	5.38e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg16797656	chr11:68205561	LRP5	0.49	5.41	0.41	2.52e-7	Total body bone mineral density;
UCEC	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg21231944	chr12:82153410	PPFIA2	-0.46	-4.8	-0.37	3.89e-6	Resting heart rate;
UCEC	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.73	-0.43	5.49e-8	Initial pursuit acceleration;
UCEC	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.6	6.94	0.5	1.16e-10	Obesity-related traits;
UCEC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.98	11.72	0.69	8.32e-23	Cognitive function;
UCEC	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.14	0.39	8.66e-7	Diabetic retinopathy;
UCEC	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.46	0.47	1.48e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.6	6.04	0.45	1.23e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg06096015	chr1:231504339	EGLN1	-0.44	-4.77	-0.37	4.45e-6	Hemoglobin concentration;
UCEC	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.55	5.75	0.43	5.07e-8	Corneal astigmatism;
UCEC	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.33	-4.54	-0.35	1.15e-5	Alzheimer's disease (late onset);
UCEC	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.56	-6.44	-0.47	1.61e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.43	0.47	1.68e-9	Menarche (age at onset);
UCEC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.68	7.48	0.52	6.3e-12	Menopause (age at onset);
UCEC	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.94	-0.44	1.94e-8	Hypospadias;
UCEC	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.27e-7	Life satisfaction;
UCEC	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	6.14	0.45	7.43e-9	Cognitive test performance;
UCEC	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.38	4.68	0.36	6.48e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg08027265	chr7:2291960	NA	-0.52	-5.21	-0.4	6.15e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.49	5.49	0.41	1.75e-7	Tonsillectomy;
UCEC	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	9.51	0.62	5.18e-17	Coffee consumption (cups per day);
UCEC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.65	-0.36	7.19e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.66	0.36	6.94e-6	Rheumatoid arthritis;
UCEC	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.39	5.63	0.42	8.88e-8	Ulcerative colitis;
UCEC	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs77926410	1.000	rs7980470	chr12:10553888	A/G	cg25023291	chr12:11339792	TAS2R42	0.41	4.66	0.36	7.13e-6	Mean corpuscular volume;
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	5.55	0.42	1.27e-7	Platelet count;
UCEC	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs787274	0.850	rs7862183	chr9:115529696	C/T	cg13803584	chr9:115635662	SNX30	-0.71	-5.71	-0.43	6.1e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.64	6.98	0.5	9.64e-11	Homoarginine levels;
UCEC	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg06784218	chr1:46089804	CCDC17	0.55	6.62	0.48	6.19e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.96	0.5	1.03e-10	Motion sickness;
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-7.4	-0.52	9.51e-12	Waist circumference;Body mass index;
UCEC	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.63	7.11	0.51	4.75e-11	Longevity;Endometriosis;
UCEC	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg14092571	chr14:90743983	NA	-0.43	-5.68	-0.42	7.02e-8	Mortality in heart failure;
UCEC	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	0.79	4.54	0.35	1.18e-5	Height;
UCEC	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.19e-7	QRS complex (12-leadsum);
UCEC	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15312298	chr8:127570908	FAM84B	0.52	6.73	0.49	3.54e-10	Warfarin maintenance dose;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.87	-11.25	-0.68	1.45e-21	Longevity;Endometriosis;
UCEC	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.27	0.46	3.81e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.63	-0.36	7.9e-6	Type 2 diabetes;
UCEC	cis	rs151997	1.000	rs42415	chr5:50207442	T/A	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.55	4.88	0.37	2.79e-6	Interstitial lung disease;
UCEC	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	9.91	0.63	4.76e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.14	-0.45	7.38e-9	Cardiac Troponin-T levels;
UCEC	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.59	-6.45	-0.47	1.56e-9	Crohn's disease;
UCEC	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg22166914	chr1:53195759	ZYG11B	-0.82	-9.07	-0.6	7.02e-16	Monocyte count;
UCEC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs1832871	1.000	rs827864	chr6:158711023	A/G	cg07215822	chr6:158701037	NA	-0.5	-4.96	-0.38	1.89e-6	Height;
UCEC	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.8	9.03	0.6	8.91e-16	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs17106184	0.892	rs72902768	chr1:51261965	C/T	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.78	9.79	0.63	1.01e-17	Leprosy;
UCEC	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.89	10.41	0.65	2.39e-19	Blood metabolite levels;
UCEC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.55	6.11	0.45	8.65e-9	Breast cancer;
UCEC	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.56	-0.35	1.06e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.44	-4.9	-0.37	2.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02711652	chr17:63555717	AXIN2	-0.53	-4.97	-0.38	1.82e-6	QT interval;
UCEC	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	5.04	0.38	1.33e-6	IgG glycosylation;
UCEC	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.45	4.67	0.36	6.77e-6	Prostate cancer;
UCEC	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg26025557	chr3:42842344	HIGD1A	-0.44	-4.55	-0.35	1.11e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.57	-8.54	-0.58	1.56e-14	Beta-trace protein levels;
UCEC	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.48	-5.74	-0.43	5.24e-8	Bipolar disorder;
UCEC	cis	rs7246967	0.932	rs35446354	chr19:23027324	A/G	cg24889512	chr19:22816950	ZNF492	0.5	5.32	0.4	3.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-0.74	-5.77	-0.43	4.52e-8	Red blood cell traits;
UCEC	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg13695892	chr22:41940480	POLR3H	-0.59	-4.83	-0.37	3.45e-6	Vitiligo;
UCEC	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.72	7.34	0.52	1.37e-11	Type 2 diabetes;
UCEC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.66	6.32	0.46	2.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.82	7.96	0.55	4.23e-13	Cognitive function;
UCEC	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.58	4.96	0.38	1.9e-6	Alzheimer's disease;
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12318506	0.826	rs35933860	chr12:75731821	A/G	cg04728562	chr12:75699417	CAPS2	-0.84	-4.79	-0.37	4.06e-6	Coronary artery calcification;
UCEC	cis	rs8105895	0.800	rs62112872	chr19:22192425	T/C	cg02912127	chr19:22235281	ZNF257	-0.54	-4.68	-0.36	6.36e-6	Body mass index (change over time);
UCEC	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-6.73	-0.49	3.59e-10	Total cholesterol levels;
UCEC	cis	rs2386661	1.000	rs4749853	chr10:5674758	T/A	cg17085576	chr10:5658249	NA	0.46	4.56	0.35	1.05e-5	Breast cancer;
UCEC	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.53	-5.73	-0.43	5.4e-8	Parkinson's disease;
UCEC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.36	-4.9	-0.37	2.46e-6	Eye color traits;
UCEC	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg15147215	chr3:52552868	STAB1	-0.48	-5.34	-0.4	3.47e-7	Bipolar disorder;
UCEC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.76	-0.37	4.5e-6	Hemoglobin concentration;
UCEC	cis	rs970548	0.690	rs11239535	chr10:45978387	C/T	cg15223267	chr10:46222474	FAM21C	0.49	4.86	0.37	2.99e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.51	5.16	0.39	7.92e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1165668	0.816	rs1866072	chr12:104310706	C/G	cg21863207	chr12:104234989	NT5DC3	0.56	5.26	0.4	5.04e-7	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs17135859	0.514	rs10055089	chr5:112626272	T/C	cg24145369	chr5:112930120	YTHDC2	-0.46	-4.55	-0.35	1.13e-5	F-cell distribution;
UCEC	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	0.9	11.6	0.69	1.66e-22	Schizophrenia;
UCEC	cis	rs6893807	0.778	rs13174131	chr5:87959538	T/G	cg09002922	chr5:87956389	LOC645323	-0.57	-5.26	-0.4	4.94e-7	Body mass index;
UCEC	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.51	5.05	0.38	1.29e-6	High light scatter reticulocyte count;
UCEC	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg00105475	chr2:10696890	NA	0.4	4.78	0.37	4.28e-6	Prostate cancer;
UCEC	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg04154034	chr17:28927549	LRRC37B2	0.53	4.72	0.36	5.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	5.81	0.43	3.75e-8	LDL cholesterol;
UCEC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg04824913	chr4:887549	GAK	0.48	4.53	0.35	1.22e-5	Sjögren's syndrome;
UCEC	cis	rs7088591	0.867	rs35991269	chr10:59778227	A/T	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-4.51	-0.35	1.3e-5	Airway imaging phenotypes;
UCEC	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg19500275	chr17:80737654	TBCD	0.48	4.8	0.37	3.86e-6	Glycated hemoglobin levels;
UCEC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.41	4.73	0.36	5.32e-6	Pulse pressure;
UCEC	cis	rs12216499	1.000	rs79357647	chr6:159402432	A/G	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.52	-0.35	1.28e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg04310649	chr10:35416472	CREM	-0.49	-4.51	-0.35	1.34e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.48	-4.83	-0.37	3.35e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg02160872	chr5:212506	CCDC127	-0.59	-5.03	-0.38	1.42e-6	Asthma (childhood onset);
UCEC	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.63	5.7	0.43	6.25e-8	Lung cancer (smoking interaction);
UCEC	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-1.11	-5.49	-0.41	1.68e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	5.96	0.44	1.76e-8	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.72	-6.6	-0.48	6.83e-10	Aortic root size;
UCEC	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.93	-0.38	2.22e-6	Body mass index;
UCEC	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.48	4.62	0.36	8.49e-6	HDL cholesterol;
UCEC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.08	0.39	1.15e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-7.93	-0.55	4.95e-13	Cognitive function;
UCEC	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.57	5.71	0.43	5.92e-8	Smoking behavior;
UCEC	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.39	4.55	0.35	1.1e-5	Survival in rectal cancer;
UCEC	cis	rs139371	0.713	rs139309	chr22:39499006	C/G	cg15548613	chr22:38610795	MAFF	0.44	4.58	0.35	9.74e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs78487399	0.710	rs6759383	chr2:43805228	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.91	-0.38	2.36e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.27	-23.46	-0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs4747241	0.626	rs4300326	chr10:74068696	A/G	cg05988358	chr10:74082489	NA	-0.37	-4.57	-0.35	1.03e-5	Heschl's gyrus morphology;
UCEC	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.2	0.39	6.58e-7	Alzheimer's disease;
UCEC	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.88	-11.46	-0.69	3.89e-22	Height;
UCEC	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.91	12.89	0.73	6.68e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.8	7.76	0.54	1.34e-12	Chronic sinus infection;
UCEC	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.49	5.55	0.42	1.31e-7	Lung cancer;
UCEC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.89	11.99	0.7	1.6e-23	Menopause (age at onset);
UCEC	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.6	6.23	0.46	4.69e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.65	5.55	0.42	1.33e-7	High light scatter reticulocyte count;
UCEC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	0.92	8.83	0.59	2.96e-15	Cognitive function;
UCEC	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.45	6.14	0.45	7.35e-9	Height;
UCEC	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg13319975	chr6:146136371	FBXO30	0.66	5.82	0.43	3.47e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-5.27	-0.4	4.7e-7	Breast cancer;
UCEC	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.58	5.27	0.4	4.71e-7	Crohn's disease;
UCEC	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg04756594	chr16:24857601	SLC5A11	0.42	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2708977	0.667	rs772156	chr2:97029830	G/A	cg22654517	chr2:96458247	NA	0.45	5.57	0.42	1.16e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.78	-6.22	-0.46	4.78e-9	Neuroticism;
UCEC	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg13695892	chr22:41940480	POLR3H	-0.61	-5.25	-0.4	5.29e-7	Vitiligo;
UCEC	cis	rs7246967	0.673	rs2361260	chr19:22914144	C/T	cg24889512	chr19:22816950	ZNF492	-0.62	-6.55	-0.48	9.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.72	-5.84	-0.43	3.2e-8	Asthma;
UCEC	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.48	5.22	0.4	5.86e-7	Nonalcoholic fatty liver disease;
UCEC	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.43	-0.74	2.46e-27	Height;
UCEC	cis	rs9467773	1.000	rs12663883	chr6:26577326	C/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg01689657	chr7:91764605	CYP51A1	0.47	6.3	0.46	3.28e-9	Breast cancer;
UCEC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	6.6	0.48	6.81e-10	Post bronchodilator FEV1;
UCEC	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.65	-6.28	-0.46	3.59e-9	Morning vs. evening chronotype;
UCEC	cis	rs12367572	0.601	rs10880730	chr12:45422443	G/A	cg03114573	chr12:45410052	DBX2	-0.53	-6.48	-0.47	1.29e-9	Gut microbiome composition (summer);
UCEC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg03859395	chr2:55845619	SMEK2	-0.86	-9.69	-0.62	1.8e-17	Metabolic syndrome;
UCEC	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-7.89	-0.55	6.4e-13	Total body bone mineral density;
UCEC	cis	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.37	0.4	3.04e-7	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg08886695	chr4:3369023	RGS12	0.48	5.09	0.39	1.08e-6	Parental longevity (mother's age at death);
UCEC	cis	rs9596863	1.000	rs1379831	chr13:54418506	C/G	ch.13.53330881F	chr13:54432880	NA	0.51	4.73	0.36	5.26e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.61	5.21	0.39	6.39e-7	Obesity-related traits;
UCEC	cis	rs77861329	1.000	rs352150	chr3:52209995	A/G	cg08692210	chr3:52188851	WDR51A	0.84	6.53	0.47	1.02e-9	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.62	0.42	9.47e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.93	12.01	0.7	1.39e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11697848	1.000	rs77310132	chr20:48510630	A/G	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.73	0.36	5.12e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs4900538	0.827	rs1046651	chr14:102971016	T/C	cg18135206	chr14:102964638	TECPR2	0.98	12.15	0.71	5.94e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.57	-5.37	-0.4	3.05e-7	Asthma (sex interaction);
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19536664	chr17:6899085	ALOX12	0.42	5.12	0.39	9.46e-7	Tonsillectomy;
UCEC	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.88	0.44	2.71e-8	Electrocardiographic conduction measures;
UCEC	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg21772509	chr8:41503840	NKX6-3	0.51	5.72	0.43	5.9e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.56	-4.92	-0.38	2.28e-6	Lung cancer;
UCEC	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg05874882	chr4:1763078	NA	0.67	6.45	0.47	1.56e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7070678	0.615	rs7909079	chr10:29799335	T/C	cg24350475	chr10:30316933	KIAA1462	0.51	4.63	0.36	8.11e-6	Platelet thrombus formation;
UCEC	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	7.78	0.54	1.21e-12	Coronary artery disease;
UCEC	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.6	-6.06	-0.45	1.12e-8	Aortic root size;
UCEC	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.8	-8.74	-0.58	4.77e-15	Myeloid white cell count;
UCEC	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.57	6.03	0.45	1.26e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2862064	0.685	rs2862066	chr5:156447395	T/G	cg12943317	chr5:156479607	HAVCR1	-0.67	-5.12	-0.39	9.44e-7	Platelet count;
UCEC	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.66	-5.77	-0.43	4.61e-8	Obesity-related traits;
UCEC	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg22117172	chr7:91764530	CYP51A1	0.39	4.77	0.37	4.4e-6	Breast cancer;
UCEC	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg01072550	chr1:21505969	NA	0.61	6.36	0.46	2.41e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	7.57	0.53	3.73e-12	Exhaled nitric oxide output;
UCEC	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.87	9.96	0.63	3.63e-18	Menopause (age at onset);
UCEC	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-5.09	-0.39	1.1e-6	Acylcarnitine levels;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.62	6.67	0.48	4.78e-10	Menarche (age at onset);
UCEC	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.69	-6.52	-0.47	1.04e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	0.99	13.47	0.74	1.92e-27	Eosinophil percentage of white cells;
UCEC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.45	-6.55	-0.48	8.89e-10	Urinary metabolites;
UCEC	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.22	-6.97	-0.5	9.87e-11	Diabetic kidney disease;
UCEC	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-7.18	-0.51	3.24e-11	Parkinson's disease;
UCEC	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg04149295	chr10:70884716	VPS26A	0.53	4.6	0.35	8.97e-6	Left atrial antero-posterior diameter;
UCEC	cis	rs7197653	0.667	rs7190070	chr16:68353983	C/T	cg05110241	chr16:68378359	PRMT7	-0.52	-4.55	-0.35	1.1e-5	Magnesium levels;
UCEC	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.71	-8.54	-0.58	1.59e-14	Extrinsic epigenetic age acceleration;
UCEC	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.42	-5.19	-0.39	6.98e-7	Congenital heart disease (maternal effect);
UCEC	cis	rs7072216	0.770	rs1739	chr10:100176339	A/G	cg26618903	chr10:100175079	PYROXD2	-0.43	-5.99	-0.44	1.53e-8	Metabolite levels;
UCEC	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg22868518	chr11:507468	RNH1	-0.57	-5.68	-0.42	6.82e-8	Systemic lupus erythematosus;
UCEC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.57	-6.21	-0.46	5.21e-9	Menarche (age at onset);
UCEC	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	5.16	0.39	7.72e-7	Ileal carcinoids;
UCEC	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.97	-11.8	-0.7	5.08e-23	Body mass index;
UCEC	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.53	-5.51	-0.41	1.58e-7	Breast cancer;
UCEC	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.52	-5.87	-0.44	2.82e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg03714773	chr7:91764589	CYP51A1	0.39	4.55	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs77216612	0.840	rs11055030	chr12:12878349	G/C	cg09462578	chr12:12878428	APOLD1	-1.1	-11.1	-0.68	3.46e-21	Lymphocyte counts;
UCEC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-5.76	-0.43	4.76e-8	Chronic sinus infection;
UCEC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.83	0.49	2.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.17	-0.39	7.45e-7	Parkinson's disease;
UCEC	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.52	5.04	0.38	1.36e-6	Resting heart rate;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.37	-0.41	2.99e-7	Parkinson's disease;
UCEC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.65	-6.05	-0.45	1.13e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	4.92	0.38	2.31e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.51	5.59	0.42	1.08e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.58	-5.77	-0.43	4.56e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.5	5.48	0.41	1.84e-7	Tonsillectomy;
UCEC	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.53e-13	Total cholesterol levels;
UCEC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.62	6.01	0.44	1.37e-8	Schizophrenia;
UCEC	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg01874867	chr7:94954059	PON1	-0.52	-4.6	-0.35	9.21e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs4820803	1.000	rs4820803	chr22:29669648	C/G	cg07256473	chr22:29710276	RASL10A	-0.59	-4.81	-0.37	3.66e-6	Breast cancer;
UCEC	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.58	5.16	0.39	8.02e-7	Metabolite levels;
UCEC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.53	5.85	0.43	3.08e-8	Menopause (age at onset);
UCEC	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	6.05e-9	Colorectal cancer;
UCEC	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-4.82	-0.37	3.59e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.53	-4.69	-0.36	6.2e-6	Gut microbiome composition (summer);
UCEC	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18854424	chr1:2615690	NA	0.46	6.7	0.48	4.24e-10	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.11	-0.51	4.66e-11	Parkinson's disease;
UCEC	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs735860	0.712	rs6909592	chr6:53163090	C/G	cg10236188	chr6:53219634	NA	0.47	4.89	0.37	2.58e-6	Glaucoma;
UCEC	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.71	6.59	0.48	7.26e-10	Menarche (age at onset);
UCEC	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.66	-6.5	-0.47	1.18e-9	Diastolic blood pressure;
UCEC	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.77	-0.37	4.35e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.5	-5.31	-0.4	3.92e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.07	-0.39	1.19e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24308560	chr3:49941425	MST1R	0.44	4.74	0.36	4.93e-6	Body mass index;
UCEC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-10.36	-0.65	3.16e-19	IgG glycosylation;
UCEC	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.45	-4.78	-0.37	4.13e-6	Coronary artery disease;
UCEC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	0.84	7.21	0.51	2.77e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.73	7.16	0.51	3.65e-11	Psoriasis;
UCEC	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.57	-5.83	-0.43	3.41e-8	Corneal astigmatism;
UCEC	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg02461776	chr11:598696	PHRF1	0.53	5.16	0.39	7.98e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.42	5.15	0.39	8.33e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.82	-8.77	-0.59	4.19e-15	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.51	5.09	0.39	1.06e-6	Mood instability;
UCEC	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.11	14.36	0.76	8.69e-30	Schizophrenia;
UCEC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-10.68	-0.66	4.61e-20	Renal cell carcinoma;
UCEC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.67	-6.12	-0.45	8.1e-9	Aortic root size;
UCEC	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.31	4.99	0.38	1.69e-6	Cancer;
UCEC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.59	0.35	9.42e-6	Menopause (age at onset);
UCEC	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.09	-6.98	-0.5	9.35e-11	Breast cancer;
UCEC	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg25019722	chr6:37503610	NA	-0.3	-4.73	-0.36	5.21e-6	Cognitive performance;
UCEC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.9	0.37	2.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg24375607	chr4:120327624	NA	0.53	5.01	0.38	1.54e-6	Corneal astigmatism;
UCEC	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.5	4.57	0.35	1.01e-5	Lupus nephritis in systemic lupus erythematosus;
UCEC	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.6	7.22	0.51	2.63e-11	Lewy body disease;
UCEC	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	7.89	0.55	6.23e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.37	0.4	3.02e-7	Response to antipsychotic treatment;
UCEC	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.74	7.94	0.55	4.78e-13	Breast cancer;
UCEC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.71	8.73	0.58	5.09e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.6	-5.49	-0.41	1.75e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.03	-9.03	-0.6	9.05e-16	Blood pressure (smoking interaction);
UCEC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg01262667	chr19:19385393	TM6SF2	0.52	7.25	0.51	2.21e-11	Tonsillectomy;
UCEC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-6.27	-0.46	3.88e-9	Dental caries;
UCEC	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.9	0.44	2.44e-8	Life satisfaction;
UCEC	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	4.8	0.37	3.8e-6	Diabetic retinopathy;
UCEC	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg11871910	chr12:69753446	YEATS4	0.89	10.58	0.66	8.49e-20	Blood protein levels;
UCEC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.65	6.85	0.49	1.83e-10	Menopause (age at onset);
UCEC	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.36	-0.76	8.71e-30	Schizophrenia;
UCEC	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.67	-0.36	6.79e-6	Breast cancer;
UCEC	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-5.27	-0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	0.78	7.35	0.52	1.25e-11	Testicular germ cell tumor;
UCEC	cis	rs17106184	1.000	rs72896994	chr1:50891117	C/A	cg07174182	chr1:51127561	FAF1	-0.78	-4.71	-0.36	5.72e-6	Type 2 diabetes;
UCEC	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg20368463	chr18:77673604	PQLC1	0.71	4.81	0.37	3.72e-6	Opioid sensitivity;
UCEC	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.02	7.54	0.53	4.45e-12	Corneal structure;
UCEC	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.05	-0.55	2.52e-13	Total cholesterol levels;
UCEC	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.59	-7.37	-0.52	1.14e-11	Inhibitory control;
UCEC	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.09	-18.1	-0.83	3.06e-39	Testicular germ cell tumor;
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09220393	chr16:1703475	CRAMP1L	-0.44	-4.52	-0.35	1.25e-5	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.88	0.49	1.6e-10	Cognitive test performance;
UCEC	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10147044	chr15:75230572	COX5A	0.59	6.73	0.49	3.59e-10	Warfarin maintenance dose;
UCEC	cis	rs9463078	0.764	rs976699	chr6:44952852	G/T	cg25276700	chr6:44698697	NA	-0.44	-4.93	-0.38	2.19e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg19678392	chr7:94953810	PON1	-0.59	-5.72	-0.43	5.82e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-5.91	-0.44	2.34e-8	Menarche (age at onset);
UCEC	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.4	-0.52	9.5e-12	Total cholesterol levels;
UCEC	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg11150807	chr10:43354902	NA	0.81	5.31	0.4	3.98e-7	Blood protein levels;
UCEC	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.59	5.84	0.43	3.25e-8	Uric acid levels;
UCEC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.54	4.79	0.37	4.03e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg00800038	chr16:89945340	TCF25	-0.79	-4.61	-0.36	8.81e-6	Skin colour saturation;
UCEC	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg04058563	chr4:185651563	MLF1IP	0.65	5.09	0.39	1.08e-6	Blood protein levels;
UCEC	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-6.88	-0.49	1.6e-10	Caffeine consumption;
UCEC	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.18	9.12	0.6	5.36e-16	Mean corpuscular hemoglobin;
UCEC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs6558174	0.714	rs17674754	chr8:22533388	A/G	cg03733263	chr8:22462867	KIAA1967	0.67	5.18	0.39	7.06e-7	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg06096015	chr1:231504339	EGLN1	0.45	5.24	0.4	5.4e-7	Hemoglobin concentration;
UCEC	cis	rs11760485	0.965	rs9655027	chr7:4402672	C/T	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg17330251	chr7:94953956	PON1	-0.58	-5.52	-0.41	1.5e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg06238570	chr21:40685208	BRWD1	-0.74	-7.22	-0.51	2.64e-11	Cognitive function;
UCEC	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.34	-4.64	-0.36	7.62e-6	Blood protein levels;
UCEC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-5.3	-0.4	4.14e-7	Prostate cancer;
UCEC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.54	5.17	0.39	7.43e-7	Calcium levels;
UCEC	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.49	-5.31	-0.4	3.96e-7	Response to temozolomide;
UCEC	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.86	10.02	0.64	2.41e-18	Breast cancer;
UCEC	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.55	6.0	0.44	1.48e-8	Height;
UCEC	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.67	8.13	0.56	1.65e-13	Multiple myeloma;
UCEC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.7	-5.09	-0.39	1.1e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.12	-0.51	4.5e-11	Breast cancer;
UCEC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24308560	chr3:49941425	MST1R	0.54	6.2	0.46	5.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.54	5.25	0.4	5.3e-7	Cleft lip with or without cleft palate;
UCEC	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.55	5.26	0.4	5.03e-7	Coronary artery disease;
UCEC	cis	rs7709377	0.620	rs10051302	chr5:115488698	G/C	cg23108291	chr5:115420582	COMMD10	0.6	6.27	0.46	3.73e-9	Metabolite levels  (X-11787);
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.46	-5.27	-0.4	4.82e-7	Monocyte percentage of white cells;
UCEC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg00343986	chr7:65444356	GUSB	-0.49	-4.61	-0.36	8.69e-6	Aortic root size;
UCEC	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.46	4.79	0.37	4.12e-6	Schizophrenia;
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg07387570	chr22:46663686	TTC38	0.5	5.06	0.38	1.25e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg04013166	chr16:89971882	TCF25	0.72	5.52	0.41	1.47e-7	Skin colour saturation;
UCEC	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-4.83	-0.37	3.33e-6	HDL cholesterol;
UCEC	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.48	-4.83	-0.37	3.37e-6	Dental caries;
UCEC	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-6.66	-0.48	5.15e-10	Platelet distribution width;
UCEC	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.69	-5.76	-0.43	4.73e-8	Lung disease severity in cystic fibrosis;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg15921012	chr3:15919793	NA	-0.6	-7.01	-0.5	8.07e-11	Schizophrenia;
UCEC	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	8.43	0.57	2.9e-14	Alzheimer's disease;
UCEC	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.58	-5.22	-0.4	5.88e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.15	19.58	0.85	8.52e-43	IgG glycosylation;
UCEC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-5.1	-0.39	1.04e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.69	6.02	0.44	1.32e-8	Adiposity;
UCEC	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.55	-0.35	1.13e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.611	rs62118771	chr19:22824298	C/T	cg08271804	chr19:22816896	ZNF492	0.68	4.72	0.36	5.55e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.75	-0.37	4.69e-6	Breast cancer;
UCEC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.47	-6.12	-0.45	8.11e-9	IgG glycosylation;
UCEC	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.55	5.26	0.4	4.91e-7	Obesity-related traits;
UCEC	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg23782820	chr8:58130467	NA	0.51	4.78	0.37	4.2e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	4.96	0.38	1.94e-6	Rheumatoid arthritis;
UCEC	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.72	-6.11	-0.45	8.46e-9	Colorectal adenoma (advanced);
UCEC	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.58	5.95	0.44	1.91e-8	Longevity;Endometriosis;
UCEC	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg11871910	chr12:69753446	YEATS4	0.88	10.24	0.65	6.52e-19	Blood protein levels;
UCEC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg01256987	chr12:42539512	GXYLT1	-0.5	-5.72	-0.43	5.66e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7709377	0.597	rs11241352	chr5:115412283	G/A	cg23108291	chr5:115420582	COMMD10	0.49	4.79	0.37	3.98e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs1545257	0.537	rs2702088	chr2:24642535	G/C	cg06627628	chr2:24431161	ITSN2	-0.55	-5.6	-0.42	1.04e-7	Sjögren's syndrome;
UCEC	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.71	-7.22	-0.51	2.52e-11	Aortic root size;
UCEC	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.68	8.09	0.56	2.02e-13	Testicular germ cell tumor;
UCEC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.67	-6.0	-0.44	1.48e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.57	8.1	0.56	1.99e-13	Prudent dietary pattern;
UCEC	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs1519814	0.915	rs6992410	chr8:121113566	T/G	cg22335954	chr8:121166405	COL14A1	-0.67	-5.39	-0.41	2.79e-7	Breast cancer;
UCEC	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	6.62	0.48	6.24e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1980946	1.000	rs66865647	chr20:48347101	A/G	cg01159004	chr20:48330681	B4GALT5	-0.57	-4.53	-0.35	1.22e-5	Palmitic acid (16:0) levels;
UCEC	cis	rs1414896	1.000	rs10874910	chr1:95707567	C/T	cg17104959	chr1:95696376	NA	-0.31	-4.52	-0.35	1.24e-5	Non-alcoholic fatty liver disease histology (AST);
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.4	0.61	9.75e-17	Platelet count;
UCEC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg14078730	chr11:63896557	MACROD1	0.51	5.79	0.43	4.05e-8	Platelet count;
UCEC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg02344993	chr17:57696989	CLTC	0.49	4.74	0.36	4.95e-6	Hemoglobin concentration;
UCEC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	5.31	0.4	3.98e-7	Mood instability;
UCEC	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs372883	0.530	rs55921835	chr21:30544623	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-5.07	-0.39	1.16e-6	Pancreatic cancer;
UCEC	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.69	6.93	0.5	1.25e-10	Multiple sclerosis;
UCEC	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7709377	0.597	rs10066026	chr5:115518568	A/G	cg23108291	chr5:115420582	COMMD10	0.52	5.48	0.41	1.77e-7	Metabolite levels  (X-11787);
UCEC	cis	rs77861329	1.000	rs17051957	chr3:52099441	A/G	cg08692210	chr3:52188851	WDR51A	0.68	5.3	0.4	4.13e-7	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9309473	1.000	rs2140195	chr2:73702344	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-5.53	-0.41	1.45e-7	Metabolite levels;
UCEC	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg22654517	chr2:96458247	NA	0.41	4.57	0.35	1.04e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.62	6.76	0.49	3.03e-10	Monocyte count;
UCEC	cis	rs2970992	0.817	rs2137670	chr2:101330834	G/T	cg01042948	chr2:101319752	NA	0.56	6.02	0.44	1.33e-8	Educational attainment;
UCEC	cis	rs2376682	0.959	rs11740424	chr5:117986967	A/G	cg17593721	chr5:118788746	HSD17B4	0.57	5.36	0.4	3.18e-7	Diisocyanate-induced asthma;
UCEC	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg07930552	chr6:133119739	C6orf192	0.92	8.54	0.58	1.59e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-5.91	-0.44	2.27e-8	Response to antipsychotic treatment;
UCEC	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg04025307	chr7:1156635	C7orf50	0.79	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4356932	0.703	rs71629034	chr4:76964953	A/G	cg22252999	chr4:76996414	ART3	0.44	4.54	0.35	1.15e-5	Blood protein levels;
UCEC	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.41	-4.6	-0.35	9.21e-6	Colorectal cancer;
UCEC	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.64e-7	Life satisfaction;
UCEC	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.73	-6.44	-0.47	1.61e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2970992	1.000	rs2970992	chr2:101322309	C/A	cg01042948	chr2:101319752	NA	0.51	5.41	0.41	2.55e-7	Educational attainment;
UCEC	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.56	5.89	0.44	2.58e-8	Age at first birth;
UCEC	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg01689657	chr7:91764605	CYP51A1	-0.43	-5.32	-0.4	3.87e-7	Breast cancer;
UCEC	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	4.52	0.35	1.27e-5	Diabetic retinopathy;
UCEC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.61	-6.13	-0.45	7.6e-9	Monocyte percentage of white cells;
UCEC	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.66	-6.29	-0.46	3.44e-9	Cocaine dependence;
UCEC	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.49	-0.41	1.69e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6684428	1.000	rs10789010	chr1:56353295	C/G	cg11651538	chr1:56320950	NA	-0.69	-6.19	-0.45	5.59e-9	Airflow obstruction;
UCEC	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.52	6.08	0.45	9.89e-9	Multiple myeloma;
UCEC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.67	5.15	0.39	8.13e-7	Diabetic retinopathy;
UCEC	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.86	5.56	0.42	1.26e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.77	-6.84	-0.49	1.94e-10	Resting heart rate;
UCEC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.82	8.73	0.58	5.22e-15	Blood protein levels;
UCEC	cis	rs7474896	0.778	rs11011431	chr10:38335263	T/C	cg00409905	chr10:38381863	ZNF37A	-0.67	-4.94	-0.38	2.12e-6	Obesity (extreme);
UCEC	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.43	4.96	0.38	1.91e-6	Alzheimer's disease (late onset);
UCEC	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.54	6.17	0.45	6.28e-9	Menopause (age at onset);
UCEC	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs7709377	0.574	rs1508875	chr5:115496470	C/T	cg23108291	chr5:115420582	COMMD10	-0.51	-5.1	-0.39	1.02e-6	Metabolite levels  (X-11787);
UCEC	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.52	5.59	0.42	1.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg15764593	chr10:829463	NA	-0.62	-4.63	-0.36	8.04e-6	Uric acid levels;
UCEC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.65	7.47	0.52	6.43e-12	Obesity-related traits;
UCEC	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.44	-4.92	-0.38	2.31e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-6.18	-0.45	5.85e-9	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-0.81	-4.6	-0.35	9.11e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg26114124	chr12:9217669	LOC144571	0.4	4.74	0.36	5.05e-6	Sjögren's syndrome;
UCEC	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.54	4.8	0.37	3.79e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.6	-0.42	1e-7	Fear of minor pain;
UCEC	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.72	5.73	0.43	5.46e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.44	-0.47	1.62e-9	Aortic root size;
UCEC	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.84	-0.49	1.98e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.53	5.5	0.41	1.67e-7	Dupuytren's disease;
UCEC	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.82	-5.57	-0.42	1.2e-7	Multiple sclerosis;
UCEC	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg09910674	chr16:89028015	CBFA2T3	0.6	4.62	0.36	8.41e-6	Skin colour saturation;
UCEC	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-20.98	-0.87	4.65e-46	Myeloid white cell count;
UCEC	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.73	0.49	3.63e-10	Tonsillectomy;
UCEC	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.78	-0.37	4.16e-6	Multiple sclerosis;
UCEC	cis	rs7246967	0.611	rs1835993	chr19:22833037	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01380346	chr19:18557039	ELL	-0.5	-5.11	-0.39	9.82e-7	Breast cancer;
UCEC	cis	rs1978968	0.731	rs9605462	chr22:18459859	C/T	cg03078520	chr22:18463400	MICAL3	-0.54	-6.59	-0.48	7.51e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.63	-6.57	-0.48	8.07e-10	Dental caries;
UCEC	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.49	5.53	0.41	1.44e-7	White matter hyperintensity burden;
UCEC	cis	rs6882076	1.000	rs1501908	chr5:156398169	C/G	cg12943317	chr5:156479607	HAVCR1	0.5	5.28	0.4	4.61e-7	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.97	-0.44	1.71e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.61	-0.58	1.01e-14	Total cholesterol levels;
UCEC	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.66	-7.56	-0.53	4.02e-12	Body mass index;
UCEC	cis	rs11761441	0.595	rs35457587	chr7:86193	C/T	cg06458707	chr7:1083209	C7orf50	0.26	4.71	0.36	5.78e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.83	8.5	0.57	1.92e-14	Breast cancer;
UCEC	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.61	-8.76	-0.59	4.27e-15	Prudent dietary pattern;
UCEC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.13e-7	Aortic root size;
UCEC	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246967	0.551	rs8102812	chr19:22879243	A/T	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	0.64	6.94	0.5	1.17e-10	Yeast infection;
UCEC	cis	rs9469578	0.792	rs73743329	chr6:33713943	T/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	0.78	5.14	0.39	8.67e-7	Diabetic retinopathy;
UCEC	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.43	-4.69	-0.36	6.12e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.56	-5.27	-0.4	4.82e-7	Obesity-related traits;
UCEC	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.74	-7.9	-0.55	6.07e-13	Lung cancer;
UCEC	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.59	6.01	0.44	1.42e-8	Total body bone mineral density;
UCEC	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.98	-8.27	-0.56	7.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg03354898	chr7:1950403	MAD1L1	-0.45	-5.23	-0.4	5.83e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg11871910	chr12:69753446	YEATS4	0.88	10.24	0.65	6.52e-19	Blood protein levels;
UCEC	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.61	-6.26	-0.46	4.07e-9	Prudent dietary pattern;
UCEC	cis	rs73017364	0.688	rs16857964	chr1:162149593	A/G	cg19130550	chr1:161994277	OLFML2B	-0.48	-4.57	-0.35	1.01e-5	QT interval;
UCEC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	5.05	0.38	1.28e-6	Aortic root size;
UCEC	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs174775	0.513	rs2071578	chr22:29725893	T/C	cg07256473	chr22:29710276	RASL10A	0.64	6.16	0.45	6.76e-9	Immature fraction of reticulocytes;
UCEC	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.48	5.03	0.38	1.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg03999872	chr20:62272968	STMN3	-0.48	-4.6	-0.36	8.88e-6	Atopic dermatitis;
UCEC	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-12.58	-0.72	4.23e-25	Body mass index;
UCEC	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.04	-8.42	-0.57	3.15e-14	White matter hyperintensity burden;
UCEC	cis	rs2172802	0.599	rs11131341	chr4:62547726	A/G	cg04118610	chr4:62707027	LPHN3	-0.42	-4.72	-0.36	5.53e-6	Partial epilepsies;
UCEC	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.42	6.01	0.44	1.42e-8	Crohn's disease;
UCEC	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.56	-4.93	-0.38	2.23e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	5.12	0.39	9.51e-7	Lung cancer in ever smokers;
UCEC	cis	rs9341808	0.667	rs806783	chr6:80942943	A/C	cg08355045	chr6:80787529	NA	-0.39	-4.96	-0.38	1.96e-6	Sitting height ratio;
UCEC	cis	rs834603	1.000	rs834603	chr7:47447921	A/G	cg23694490	chr7:47445681	TNS3	-0.33	-5.25	-0.4	5.32e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.87	-7.18	-0.51	3.26e-11	Coronary artery calcification;
UCEC	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.49	-4.75	-0.36	4.75e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.73	0.43	5.42e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.87	10.02	0.64	2.43e-18	Blood protein levels;
UCEC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.91	-0.49	1.4e-10	Joint mobility (Beighton score);
UCEC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.76	9.61	0.62	2.84e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.24	-0.4	5.54e-7	Pulmonary function;
UCEC	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.63	-6.53	-0.47	1.02e-9	Survival in pancreatic cancer;
UCEC	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.55	-5.37	-0.41	2.96e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	0.9	6.88	0.49	1.64e-10	Alzheimer's disease (late onset);
UCEC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.64	0.42	8.27e-8	Cognitive test performance;
UCEC	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	0.89	7.88	0.54	6.78e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.74	-6.62	-0.48	6.39e-10	Diastolic blood pressure;
UCEC	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg16797656	chr11:68205561	LRP5	0.49	5.81	0.43	3.72e-8	Total body bone mineral density;
UCEC	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.74	7.65	0.53	2.41e-12	Tonsillectomy;
UCEC	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	5.93	0.44	2.08e-8	IgG glycosylation;
UCEC	trans	rs4841134	0.513	rs12155833	chr8:9234847	A/T	cg12069736	chr14:102288479	PPP2R5C	-0.59	-6.68	-0.48	4.69e-10	Age-related disease endophenotypes;
UCEC	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	0.77	9.15	0.6	4.32e-16	Multiple myeloma;
UCEC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg21770322	chr7:97807741	LMTK2	0.53	6.66	0.48	5.14e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6832769	1.000	rs6837710	chr4:56374455	C/T	cg05960024	chr4:56376020	CLOCK	0.54	5.06	0.39	1.25e-6	Personality dimensions;
UCEC	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg05501817	chr11:14380813	RRAS2	-0.52	-5.06	-0.39	1.23e-6	Sense of smell;
UCEC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.78e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.86	-9.33	-0.61	1.51e-16	Ulcerative colitis;
UCEC	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg22974920	chr21:40686053	BRWD1	0.54	4.87	0.37	2.86e-6	Cognitive function;
UCEC	trans	rs2613514	0.667	rs72894055	chr17:76040582	A/G	cg09848947	chr16:88798826	FAM38A	1.01	6.8	0.49	2.47e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	6.18	0.45	6.13e-9	Bipolar disorder;
UCEC	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg21214455	chr15:72412075	SENP8	-0.5	-4.55	-0.35	1.13e-5	Red blood cell count;
UCEC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.75	7.98	0.55	3.85e-13	Menopause (age at onset);
UCEC	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg12884169	chr21:40033163	ERG	0.45	5.96	0.44	1.83e-8	Coronary artery disease;
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.78	7.11	0.51	4.76e-11	Morning vs. evening chronotype;
UCEC	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg13683864	chr3:40499215	RPL14	-0.57	-6.16	-0.45	6.76e-9	Renal cell carcinoma;
UCEC	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.66	8.63	0.58	9.45e-15	Anterior chamber depth;
UCEC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.58	-0.35	9.96e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Morning vs. evening chronotype;
UCEC	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.75	6.69	0.48	4.27e-10	Coronary artery disease;
UCEC	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg06238570	chr21:40685208	BRWD1	-0.63	-7.16	-0.51	3.63e-11	Menarche (age at onset);
UCEC	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.72	-7.94	-0.55	4.92e-13	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.21	-10.04	-0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	0.91	5.02	0.38	1.45e-6	IgG glycosylation;
UCEC	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.5	4.92	0.38	2.3e-6	High light scatter reticulocyte count;
UCEC	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.37	-4.78	-0.37	4.19e-6	HIV-1 control;
UCEC	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.31e-5	Dementia with Lewy bodies;
UCEC	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg05623727	chr3:50126028	RBM5	0.34	5.14	0.39	8.69e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.19	-0.56	1.19e-13	Total cholesterol levels;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg06642177	chr6:134496341	SGK1	-0.61	-6.74	-0.49	3.39e-10	Breast cancer;
UCEC	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg14500267	chr11:67383377	NA	0.32	4.55	0.35	1.13e-5	Mean corpuscular volume;
UCEC	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.64	5.91	0.44	2.31e-8	Corneal astigmatism;
UCEC	cis	rs6832720	1.000	rs62313006	chr4:58199007	T/C	cg24819475	chr4:57397423	NA	-0.67	-4.97	-0.38	1.87e-6	Cotinine glucuronidation;
UCEC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05347473	chr6:146136440	FBXO30	0.52	5.65	0.42	8.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.66	0.42	7.77e-8	Height;
UCEC	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.55	4.97	0.38	1.86e-6	Menarche (age at onset);
UCEC	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.66	4.87	0.37	2.82e-6	Lung cancer;
UCEC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.51	-0.35	1.32e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg06466757	chr4:1255808	NA	0.47	4.96	0.38	1.9e-6	Obesity-related traits;
UCEC	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg21770322	chr7:97807741	LMTK2	0.85	14.96	0.78	2.41e-31	Breast cancer;
UCEC	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg01072550	chr1:21505969	NA	-0.57	-5.21	-0.39	6.2e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.4	5.25	0.4	5.19e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	6.98	0.5	9.4e-11	Platelet count;
UCEC	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.54	4.86	0.37	3.01e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.54	5.48	0.41	1.83e-7	Age at first birth;
UCEC	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.67	6.03	0.45	1.29e-8	Alzheimer's disease;
UCEC	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.22	-9.72	-0.63	1.48e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg02158880	chr13:53174818	NA	-0.53	-6.18	-0.45	5.97e-9	Lewy body disease;
UCEC	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg07905965	chr19:39260460	NA	0.39	4.61	0.36	8.51e-6	Heart rate;
UCEC	cis	rs9283706	0.594	rs1366338	chr5:66344307	A/G	cg11590213	chr5:66331682	MAST4	-0.42	-4.74	-0.36	5.01e-6	Coronary artery disease;
UCEC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.71	0.43	5.97e-8	Menarche (age at onset);
UCEC	cis	rs17600642	0.642	rs72814531	chr10:72444857	G/A	cg23422916	chr10:72218225	NA	-0.55	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.58	-6.02	-0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.43	-5.31	-0.4	4.04e-7	Refractive error;
UCEC	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.25	-0.4	5.26e-7	Initial pursuit acceleration;
UCEC	cis	rs59104589	0.569	rs62190378	chr2:242397237	C/T	cg12761732	chr2:242547234	THAP4	0.68	4.53	0.35	1.22e-5	Fibrinogen levels;
UCEC	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-0.69	-6.39	-0.47	2.02e-9	Post bronchodilator FEV1;
UCEC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.9	9.45	0.61	7.57e-17	Cognitive function;
UCEC	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.35	-5.25	-0.4	5.18e-7	Ulcerative colitis;
UCEC	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-6.19	-0.45	5.58e-9	Hemoglobin concentration;
UCEC	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg15145296	chr3:125709740	NA	-0.56	-4.51	-0.35	1.33e-5	Blood pressure (smoking interaction);
UCEC	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.31	-0.4	4.03e-7	Dupuytren's disease;
UCEC	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg15167202	chr5:149997153	SYNPO	-0.37	-4.6	-0.35	9.05e-6	HIV-1 control;
UCEC	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4722166	0.599	rs7776857	chr7:22754768	G/T	cg05472934	chr7:22766657	IL6	0.63	5.29	0.4	4.44e-7	Lung cancer;
UCEC	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-0.91	-6.47	-0.47	1.35e-9	Left atrial antero-posterior diameter;
UCEC	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.72	-0.43	5.73e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs6460942	0.591	rs62448728	chr7:12332915	A/T	cg06484146	chr7:12443880	VWDE	-0.62	-4.9	-0.37	2.49e-6	Coronary artery disease;
UCEC	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-5.25	-0.4	5.23e-7	Personality dimensions;
UCEC	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	0.87	9.71	0.63	1.57e-17	Breast cancer;
UCEC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg03859395	chr2:55845619	SMEK2	1.02	14.97	0.78	2.27e-31	Metabolic syndrome;
UCEC	cis	rs1468333	1.000	rs7735635	chr5:137508336	G/A	cg07848042	chr5:137667509	CDC25C	-0.47	-4.6	-0.35	8.9e-6	Resting heart rate;
UCEC	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.91	-0.44	2.26e-8	Personality dimensions;
UCEC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	5.42	0.41	2.34e-7	Breast cancer;
UCEC	cis	rs13437751	0.649	rs9654806	chr7:63339807	C/G	cg00787055	chr7:63562162	NA	-0.48	-4.78	-0.37	4.27e-6	QT interval (drug interaction);
UCEC	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.69	-6.1	-0.45	8.94e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg21641573	chr4:1210478	CTBP1	0.81	4.67	0.36	6.83e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg05738196	chr6:26577821	NA	0.59	6.5	0.47	1.16e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.5	6.02	0.44	1.31e-8	Oral cavity cancer;
UCEC	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs6060717	0.536	rs6060669	chr20:34480557	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-4.51	-0.35	1.31e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	0.83	4.75	0.36	4.85e-6	Arsenic metabolism;
UCEC	cis	rs953387	1.000	rs10803550	chr2:136907790	C/T	cg07169764	chr2:136633963	MCM6	0.53	5.26	0.4	4.94e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.51	5.21	0.39	6.19e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg21231944	chr12:82153410	PPFIA2	-0.45	-5.12	-0.39	9.57e-7	Resting heart rate;
UCEC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.36	-4.53	-0.35	1.2e-5	Lung cancer;
UCEC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.54	4.95	0.38	1.97e-6	Diabetic retinopathy;
UCEC	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.42	7.6	0.53	3.25e-12	Cognitive function;
UCEC	cis	rs6437061	0.737	rs3103296	chr2:233034495	C/T	cg20569070	chr2:232597279	PDE6D	-0.42	-4.81	-0.37	3.64e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg05802129	chr4:122689817	NA	-0.42	-4.53	-0.35	1.22e-5	Type 2 diabetes;
UCEC	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.64	-6.0	-0.44	1.5e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.59	0.48	7.22e-10	Cognitive test performance;
UCEC	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.64	-6.13	-0.45	7.84e-9	Vitiligo;
UCEC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.65	-0.53	2.49e-12	Tonsillectomy;
UCEC	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-0.99	-11.94	-0.7	2.17e-23	Body mass index;
UCEC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.57	6.41	0.47	1.85e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-0.49	-4.66	-0.36	7.06e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.48	5.11	0.39	9.95e-7	Diastolic blood pressure;
UCEC	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.54	-5.42	-0.41	2.44e-7	Blood metabolite levels;
UCEC	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.61	7.06	0.5	6.01e-11	Blood metabolite ratios;
UCEC	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg15147215	chr3:52552868	STAB1	-0.41	-4.55	-0.35	1.14e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-0.61	-6.93	-0.5	1.26e-10	Trans fatty acid levels;
UCEC	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.63	6.14	0.45	7.4e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18932078	chr1:2524107	MMEL1	-0.35	-6.14	-0.45	7.34e-9	Ulcerative colitis;
UCEC	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.75	5.63	0.42	8.81e-8	Type 2 diabetes;
UCEC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.58	-0.35	1e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.38	0.61	1.13e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10924970	0.534	rs10925362	chr1:235464380	G/A	cg26050004	chr1:235667680	B3GALNT2	0.54	4.94	0.38	2.07e-6	Asthma;
UCEC	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.67	-6.57	-0.48	8.14e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6496932	0.770	rs4843040	chr15:85838636	C/T	cg05329798	chr15:85176641	SCAND2	-0.39	-4.54	-0.35	1.15e-5	Central corneal thickness;Corneal structure;
UCEC	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	17.84	0.83	1.3e-38	Schizophrenia;
UCEC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs17123764	0.818	rs7970241	chr12:49948759	C/T	cg20471783	chr12:50157085	TMBIM6	0.65	5.43	0.41	2.27e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.57	6.56	0.48	8.8e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	0.81	5.02	0.38	1.47e-6	Diabetic retinopathy;
UCEC	cis	rs6984449	0.516	rs4921645	chr8:19303736	A/C	cg06562184	chr8:19319451	CSGALNACT1	-0.43	-4.53	-0.35	1.23e-5	Educational attainment;
UCEC	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	5.17	0.39	7.42e-7	Response to antipsychotic treatment;
UCEC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg00500100	chr5:140098250	VTRNA1-2	0.34	4.51	0.35	1.32e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg08027265	chr7:2291960	NA	-0.46	-4.91	-0.38	2.4e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.6	8.9	0.59	1.91e-15	Prudent dietary pattern;
UCEC	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.82	-8.44	-0.57	2.74e-14	Mosquito bite size;
UCEC	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.57	-4.86	-0.37	2.99e-6	Mortality in heart failure;
UCEC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg03934865	chr2:198174659	NA	-0.44	-5.59	-0.42	1.07e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22496380	chr5:211416	CCDC127	-1.08	-4.55	-0.35	1.13e-5	Breast cancer;
UCEC	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg14851346	chr12:38532713	NA	-0.48	-4.61	-0.36	8.71e-6	Bladder cancer;
UCEC	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.66	6.5	0.47	1.18e-9	Refractive astigmatism;
UCEC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.63	5.59	0.42	1.06e-7	Chronic sinus infection;
UCEC	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg22974920	chr21:40686053	BRWD1	-0.58	-5.15	-0.39	8.16e-7	Cognitive function;
UCEC	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.64	-5.99	-0.44	1.56e-8	Refractive astigmatism;
UCEC	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.74	-8.52	-0.57	1.73e-14	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg14283194	chr7:91763737	CYP51A1	-0.48	-5.18	-0.39	7.14e-7	Breast cancer;
UCEC	cis	rs12753920	0.697	rs4623754	chr1:92575278	A/G	cg06442199	chr1:92414344	BRDT	0.42	4.55	0.35	1.1e-5	Systemic lupus erythematosus;
UCEC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.49	-5.3	-0.4	4.25e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.37	-0.4	3.07e-7	Response to antipsychotic treatment;
UCEC	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.7	-0.36	5.96e-6	Hemoglobin concentration;
UCEC	cis	rs1568889	0.592	rs11828877	chr11:28384030	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	5.21	0.39	6.39e-7	Bipolar disorder;
UCEC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.76	6.96	0.5	1.07e-10	White matter hyperintensity burden;
UCEC	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.54	-4.96	-0.38	1.92e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.38	0.47	2.2e-9	Menarche (age at onset);
UCEC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-4.98	-0.38	1.77e-6	Personality dimensions;
UCEC	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.8	9.13	0.6	4.86e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.52	-4.99	-0.38	1.68e-6	Diastolic blood pressure;
UCEC	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-6.75	-0.49	3.2e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.66	6.93	0.5	1.23e-10	Dental caries;
UCEC	cis	rs41271951	0.512	rs115968379	chr1:151050087	A/C	cg00107782	chr1:151300621	NA	-0.7	-4.75	-0.36	4.81e-6	Blood protein levels;
UCEC	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.89	10.63	0.66	6.04e-20	Breast cancer;
UCEC	cis	rs7106204	0.764	rs7933686	chr11:24246790	G/C	ch.11.24196551F	chr11:24239977	NA	0.71	4.84	0.37	3.24e-6	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs13065560	0.594	rs4234133	chr3:38888021	T/C	cg01426195	chr3:39028469	NA	-0.53	-5.67	-0.42	7.27e-8	Interleukin-18 levels;
UCEC	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.53	-5.69	-0.42	6.72e-8	Blood metabolite levels;
UCEC	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.5	5.44	0.41	2.19e-7	QRS complex (12-leadsum);
UCEC	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg14851346	chr12:38532713	NA	0.52	5.02	0.38	1.47e-6	Heart rate;
UCEC	cis	rs8177876	0.822	rs9926174	chr16:81111436	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.44	-0.52	7.77e-12	Resting heart rate;
UCEC	cis	rs6754311	0.906	rs4954387	chr2:136784344	A/G	cg07169764	chr2:136633963	MCM6	0.71	7.14	0.51	4.04e-11	Mosquito bite size;
UCEC	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.52	-5.21	-0.39	6.28e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg01065977	chr19:18549689	ISYNA1	-0.35	-4.86	-0.37	3.01e-6	Breast cancer;
UCEC	cis	rs7581030	0.958	rs1804020	chr2:71654175	G/A	cg07678644	chr2:71558969	ZNF638	-0.55	-4.96	-0.38	1.89e-6	Testicular germ cell tumor;
UCEC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	0.84	9.12	0.6	5.24e-16	Homoarginine levels;
UCEC	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.94	-9.69	-0.62	1.76e-17	Obesity-related traits;
UCEC	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.85	-10.79	-0.66	2.38e-20	Height;
UCEC	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.6	5.23	0.4	5.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.65	-6.38	-0.47	2.19e-9	Aortic root size;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg01021488	chr15:99395581	IGF1R	0.65	6.79	0.49	2.57e-10	Schizophrenia;
UCEC	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg01072550	chr1:21505969	NA	-0.55	-5.07	-0.39	1.18e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.23	-0.4	5.86e-7	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs8105895	1.000	rs117638181	chr19:22163014	C/G	cg02912127	chr19:22235281	ZNF257	-0.57	-4.95	-0.38	2.03e-6	Body mass index (change over time);
UCEC	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.39	-0.41	2.75e-7	Aortic root size;
UCEC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.53	-6.61	-0.48	6.8e-10	Total body bone mineral density;
UCEC	cis	rs13401104	0.796	rs1466207	chr2:237121350	C/T	cg23897927	chr2:237117786	ASB18	-0.5	-4.52	-0.35	1.28e-5	Educational attainment;
UCEC	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.85	-11.06	-0.67	4.52e-21	White blood cell count (basophil);
UCEC	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.68	7.4	0.52	9.44e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9790314	0.613	rs56665329	chr3:160590858	T/A	cg03342759	chr3:160939853	NMD3	0.56	5.23	0.4	5.7e-7	Morning vs. evening chronotype;
UCEC	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.53	-5.85	-0.43	3.02e-8	Diastolic blood pressure;
UCEC	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.22	0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-5.41	-0.41	2.48e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg17420585	chr12:42539391	GXYLT1	0.41	4.69	0.36	6.23e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.69	6.73	0.49	3.5e-10	Multiple sclerosis;
UCEC	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.28	-0.4	4.61e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.53	-4.85	-0.37	3.05e-6	Pancreatic cancer;
UCEC	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg01689657	chr7:91764605	CYP51A1	0.48	6.18	0.45	6.1e-9	Breast cancer;
UCEC	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.58	6.21	0.46	5.24e-9	Breast cancer;
UCEC	cis	rs73206853	0.925	rs12318836	chr12:110642190	A/C	cg12870014	chr12:110450643	ANKRD13A	0.61	5.74	0.43	5.18e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.5	-5.29	-0.4	4.28e-7	Longevity;
UCEC	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.55	-5.94	-0.44	2.02e-8	P wave terminal force;
UCEC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg22166914	chr1:53195759	ZYG11B	0.68	7.14	0.51	4.02e-11	Monocyte count;
UCEC	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg11901034	chr3:128598214	ACAD9	-0.69	-8.25	-0.56	8.23e-14	IgG glycosylation;
UCEC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.7	8.0	0.55	3.44e-13	Longevity;Endometriosis;
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg04154034	chr17:28927549	LRRC37B2	0.82	5.36	0.4	3.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Primary biliary cholangitis;
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.99	-0.44	1.54e-8	Platelet count;
UCEC	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg21419209	chr3:44054225	NA	-0.5	-5.04	-0.38	1.34e-6	Coronary artery disease;
UCEC	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.54	-5.26	-0.4	4.94e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.62	6.4	0.47	1.98e-9	Immature fraction of reticulocytes;
UCEC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg06917634	chr15:78832804	PSMA4	0.48	4.53	0.35	1.21e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-4.75	-0.36	4.73e-6	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.7	0.36	5.93e-6	Breast cancer;
UCEC	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.66	0.53	2.29e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.65	-6.45	-0.47	1.55e-9	Blood metabolite levels;
UCEC	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg25664220	chr3:72788482	NA	-0.5	-4.61	-0.36	8.71e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-4.91	-0.38	2.34e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs174479	0.647	rs174454	chr11:61650747	A/G	cg01500311	chr11:61656094	FADS3	-0.44	-5.06	-0.39	1.22e-6	Sphingolipid levels;
UCEC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-6.45	-0.47	1.52e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.66	-6.87	-0.49	1.7e-10	Blood pressure (smoking interaction);
UCEC	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg19104757	chr7:226563	FAM20C	-0.51	-4.59	-0.35	9.6e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.53	5.31	0.4	3.99e-7	Total body bone mineral density;
UCEC	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg20129853	chr10:51489980	NA	0.42	5.03	0.38	1.44e-6	Prostate-specific antigen levels;
UCEC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.76	9.0	0.6	1.08e-15	Cognitive function;
UCEC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg24069376	chr3:38537580	EXOG	0.38	4.73	0.36	5.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs36051895	0.664	rs7851455	chr9:5100501	G/C	cg02405213	chr9:5042618	JAK2	-0.53	-5.29	-0.4	4.44e-7	Pediatric autoimmune diseases;
UCEC	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.37	-0.52	1.16e-11	Pursuit maintenance gain;
UCEC	cis	rs116175783	0.557	rs62188123	chr2:162241846	T/C	cg06347928	chr2:163175126	IFIH1	-0.58	-4.54	-0.35	1.15e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.5	5.41	0.41	2.55e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.6	-7.13	-0.51	4.2e-11	Gut microbiome composition (winter);
UCEC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	0.94	9.66	0.62	2.1e-17	Heart rate;
UCEC	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-6.91	-0.5	1.36e-10	Colorectal cancer;
UCEC	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.0	10.71	0.66	3.79e-20	Corneal structure;
UCEC	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.47	6.4	0.47	1.92e-9	Sense of smell;
UCEC	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg11569703	chr11:65557185	OVOL1	-0.43	-6.06	-0.45	1.09e-8	Acne (severe);
UCEC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.73	8.26	0.56	7.92e-14	Mortality in heart failure;
UCEC	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg05673287	chr15:77411982	SGK269	-0.45	-4.64	-0.36	7.55e-6	Type 2 diabetes;
UCEC	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.73	-8.69	-0.58	6.57e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.37	5.47	0.41	1.88e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.7	0.48	4.07e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.62	-6.71	-0.48	4.02e-10	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg08755490	chr11:65554678	OVOL1	0.5	5.3	0.4	4.07e-7	Acne (severe);
UCEC	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.64	5.59	0.42	1.06e-7	Coronary artery disease;
UCEC	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.62	6.78	0.49	2.77e-10	Bipolar disorder;
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg19678392	chr7:94953810	PON1	-0.58	-5.63	-0.42	9.08e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6832769	1.000	rs9312662	chr4:56386371	A/G	cg05960024	chr4:56376020	CLOCK	-0.56	-5.85	-0.43	3.01e-8	Personality dimensions;
UCEC	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.99	-0.76	8.29e-29	Schizophrenia;
UCEC	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.66	-6.67	-0.48	4.87e-10	Cognitive function;
UCEC	cis	rs7246967	0.866	rs4932695	chr19:23036377	T/C	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.83e-7	Bronchopulmonary dysplasia;
UCEC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.86	0.49	1.81e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.8	8.62	0.58	9.81e-15	Menopause (age at onset);
UCEC	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.53	4.8	0.37	3.88e-6	Alzheimer's disease;
UCEC	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	5.01	0.38	1.54e-6	IgG glycosylation;
UCEC	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.66	6.07	0.45	1.05e-8	Resting heart rate;
UCEC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg06562184	chr8:19319451	CSGALNACT1	0.52	5.58	0.42	1.14e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2970992	0.817	rs10197891	chr2:101334579	C/T	cg01042948	chr2:101319752	NA	0.57	6.04	0.45	1.2e-8	Educational attainment;
UCEC	cis	rs9309473	1.000	rs2901438	chr2:73665656	G/A	cg20560298	chr2:73613845	ALMS1	-0.65	-5.95	-0.44	1.89e-8	Metabolite levels;
UCEC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.71	5.65	0.42	8.01e-8	Gut microbiome composition (summer);
UCEC	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg04310649	chr10:35416472	CREM	-0.49	-4.58	-0.35	1e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg14067834	chr17:29058358	SUZ12P	0.58	4.84	0.37	3.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs61528732	0.590	rs9633948	chr11:119731210	C/T	cg21943376	chr11:118800953	NA	-0.66	-4.51	-0.35	1.33e-5	Intraocular pressure;
UCEC	cis	rs7246967	0.611	rs73022711	chr19:22875404	G/A	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg11871910	chr12:69753446	YEATS4	0.6	5.98	0.44	1.64e-8	Blood protein levels;
UCEC	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.56	-5.88	-0.44	2.69e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs17102884	0.587	rs6574190	chr14:75167015	G/A	cg16124934	chr14:75389480	RPS6KL1	-0.48	-4.7	-0.36	5.91e-6	Neuroticism;
UCEC	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.42	-4.51	-0.35	1.34e-5	Platelet count;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.64	8.05	0.55	2.59e-13	Menarche (age at onset);
UCEC	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.58	5.62	0.42	9.3e-8	Bone properties (heel);
UCEC	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.41	5.05	0.38	1.26e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.55	6.22	0.46	4.87e-9	Hip circumference;
UCEC	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.47	-6.17	-0.45	6.45e-9	IgG glycosylation;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.73	-8.42	-0.57	3.13e-14	Menarche (age at onset);
UCEC	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.54	-0.84	2.53e-40	Exhaled nitric oxide output;
UCEC	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.2e-5	Parkinson's disease;
UCEC	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.5	4.71	0.36	5.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	0.74	9.87	0.63	5.98e-18	Monocyte percentage of white cells;
UCEC	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.61	6.47	0.47	1.39e-9	Ulcerative colitis;
UCEC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.31e-5	Dementia with Lewy bodies;
UCEC	cis	rs16937	0.686	rs3851285	chr1:205155753	C/T	cg12580275	chr1:205744413	RAB7L1	0.49	5.33	0.4	3.61e-7	Schizophrenia;
UCEC	cis	rs10242455	1.000	rs7808022	chr7:99220083	A/C	cg07715041	chr7:99302981	CYP3A7	0.46	4.67	0.36	6.87e-6	Blood metabolite levels;
UCEC	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.69	6.16	0.45	6.57e-9	Aortic root size;
UCEC	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.62	5.86	0.44	2.88e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg13147721	chr7:65941812	NA	-1.1	-5.91	-0.44	2.32e-8	Diabetic kidney disease;
UCEC	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg00071950	chr4:10020882	SLC2A9	0.51	5.32	0.4	3.72e-7	Blood metabolite levels;
UCEC	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.71	7.17	0.51	3.45e-11	Menarche (age at onset);
UCEC	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.57	5.18	0.39	7.29e-7	Corneal astigmatism;
UCEC	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.57e-13	Chronic sinus infection;
UCEC	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg13575925	chr12:9217583	LOC144571	0.4	4.75	0.37	4.7e-6	Sjögren's syndrome;
UCEC	cis	rs7975161	0.882	rs4406890	chr12:104638773	A/C	cg25273343	chr12:104657179	TXNRD1	-0.55	-5.15	-0.39	8.06e-7	Toenail selenium levels;
UCEC	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.1	-0.39	1.04e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	4.56	0.35	1.07e-5	Fibroblast growth factor basic levels;
UCEC	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-5.06	-0.39	1.21e-6	Headache;
UCEC	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg11789530	chr4:8429930	ACOX3	0.65	6.56	0.48	8.59e-10	Response to antineoplastic agents;
UCEC	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	0.53	5.91	0.44	2.28e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.71	6.49	0.47	1.25e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.34	-0.4	3.44e-7	Parkinson's disease;
UCEC	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04731861	chr2:219085781	ARPC2	0.41	4.55	0.35	1.1e-5	Colorectal cancer;
UCEC	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg05991184	chr2:219186017	PNKD	-0.43	-4.56	-0.35	1.07e-5	Colorectal cancer;
UCEC	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	6.18	0.45	5.97e-9	Bone mineral density;
UCEC	cis	rs11235843	0.571	rs10898927	chr11:73364750	G/A	cg09185399	chr11:73372479	PLEKHB1	0.6	4.64	0.36	7.69e-6	Hand grip strength;
UCEC	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg03999872	chr20:62272968	STMN3	-0.49	-4.65	-0.36	7.45e-6	Atopic dermatitis;
UCEC	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-6.11	-0.45	8.56e-9	Electroencephalogram traits;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg00267373	chr16:2024786	TBL3	-0.57	-7.12	-0.51	4.35e-11	N-glycan levels;
UCEC	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.63	-5.76	-0.43	4.77e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.83	-10.21	-0.64	7.68e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-5.94	-0.44	1.93e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.61	5.93	0.44	2.11e-8	Bladder cancer;
UCEC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg17986701	chr20:44574422	PCIF1	0.47	4.74	0.36	4.9100000000000004e-06	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.84	-10.34	-0.65	3.53e-19	Height;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	14.11	0.76	3.99e-29	Prudent dietary pattern;
UCEC	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.92	-0.38	2.34e-6	Aortic root size;
UCEC	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06223018	chr3:49557076	DAG1	0.33	4.83	0.37	3.47e-6	Parkinson's disease;
UCEC	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.78	-9.59	-0.62	3.33e-17	White blood cell count (basophil);
UCEC	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.52	-5.92	-0.44	2.18e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.65	7.97	0.55	4.05e-13	Developmental language disorder (linguistic errors);
UCEC	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	10.41	0.65	2.3e-19	Post bronchodilator FEV1;
UCEC	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.53	0.53	4.75e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.14	0.45	7.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-5.01	-0.38	1.54e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.45	4.66	0.36	7.13e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg09928842	chr8:135845050	NA	-0.54	-6.77	-0.49	2.81e-10	Iris heterochromicity;
UCEC	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.72	-8.56	-0.58	1.4e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs13063635	0.915	rs1994492	chr3:45960646	T/C	cg16320329	chr3:45981161	FYCO1	-0.83	-4.76	-0.37	4.5e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.75	7.44	0.52	7.68e-12	Menarche (age at onset);
UCEC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.81	-11.07	-0.67	4.41e-21	Post bronchodilator FEV1;
UCEC	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	7.92e-8	Resting heart rate;
UCEC	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.53	-4.99	-0.38	1.66e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs12980942	0.630	rs7256856	chr19:41788352	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.63	5.65	0.42	8.15e-8	Coronary artery disease;
UCEC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs228437	0.565	rs7754115	chr6:134938220	A/G	cg20986996	chr6:134210159	TCF21	0.38	4.51	0.35	1.33e-5	Melanoma;
UCEC	cis	rs1981331	0.609	rs117296583	chr21:48053238	C/T	cg17243659	chr21:48055224	PRMT2	1.06	4.51	0.35	1.29e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.56	4.75	0.36	4.83e-6	Height;
UCEC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.76e-17	Menopause (age at onset);
UCEC	cis	rs9463078	0.764	rs3799971	chr6:44819319	G/C	cg25276700	chr6:44698697	NA	-0.43	-4.72	-0.36	5.44e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.86	10.76	0.66	2.89e-20	Primary sclerosing cholangitis;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg19041857	chr6:27730383	NA	-0.45	-4.58	-0.35	9.85e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7404928	0.645	rs67922443	chr16:23929583	G/A	cg01062539	chr16:23765258	CHP2	-0.52	-4.51	-0.35	1.32e-5	Primary biliary cholangitis;Rheumatoid arthritis;
UCEC	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg04553112	chr3:125709451	NA	-0.71	-4.91	-0.38	2.4e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg09997546	chr11:8931473	C11orf17;ST5	-0.38	-4.87	-0.37	2.85e-6	Hemoglobin concentration;
UCEC	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.35e-18	Height;
UCEC	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.69	5.95	0.44	1.92e-8	Morning vs. evening chronotype;
UCEC	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg06562184	chr8:19319451	CSGALNACT1	-0.53	-5.77	-0.43	4.56e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	trans	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg02022102	chr7:27168609	HOXA4	-0.59	-6.77	-0.49	2.91e-10	Protein biomarker;
UCEC	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.85	-7.2	-0.51	2.86e-11	Coronary artery calcification;
UCEC	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-11.11	-0.68	3.36e-21	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.72e-7	Heart rate;
UCEC	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg14092571	chr14:90743983	NA	-0.45	-6.21	-0.46	5.26e-9	Mortality in heart failure;
UCEC	cis	rs4400599	0.600	rs12095767	chr1:154188028	T/C	cg05139571	chr1:154127138	NUP210L	0.47	5.08	0.39	1.14e-6	Platelet distribution width;
UCEC	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.16	0.39	7.99e-7	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.8	7.44	0.52	7.68e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg19318889	chr4:1322082	MAEA	0.51	5.52	0.41	1.48e-7	Obesity-related traits;
UCEC	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.58	6.73	0.49	3.51e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	0.89	9.53	0.62	4.66e-17	Homoarginine levels;
UCEC	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.67	6.33	0.46	2.85e-9	Ovarian reserve;
UCEC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.68	-7.69	-0.54	1.89e-12	Monocyte count;
UCEC	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.73	7.85	0.54	7.8e-13	Menopause (age at onset);
UCEC	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.28	0.4	4.62e-7	Menarche (age at onset);
UCEC	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-8.46	-0.57	2.49e-14	Colorectal cancer;
UCEC	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.51	-5.24	-0.4	5.51e-7	Vitiligo;
UCEC	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.55	5.77	0.43	4.51e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg04155231	chr12:9217510	LOC144571	0.41	4.74	0.36	5.01e-6	Sjögren's syndrome;
UCEC	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.79	-9.45	-0.61	7.33e-17	Breast cancer;
UCEC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06505273	chr16:24850292	NA	-0.47	-4.56	-0.35	1.07e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.46	-4.76	-0.37	4.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21178979	chr7:1889533	MAD1L1	0.38	5.08	0.39	1.13e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	0.95	6.16	0.45	6.63e-9	Skin colour saturation;
UCEC	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.44	-5.14	-0.39	8.43e-7	Resting heart rate;
UCEC	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.41	4.52	0.35	1.28e-5	Diastolic blood pressure;
UCEC	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg18681998	chr4:17616180	MED28	-0.6	-6.36	-0.46	2.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.86	9.68	0.62	1.84e-17	Breast cancer;
UCEC	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg13695892	chr22:41940480	POLR3H	-0.63	-4.61	-0.36	8.71e-6	Vitiligo;
UCEC	cis	rs172166	0.516	rs2021826	chr6:28132756	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.58	-6.49	-0.47	1.26e-9	Cardiac Troponin-T levels;
UCEC	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04733989	chr22:42467013	NAGA	-0.48	-4.94	-0.38	2.06e-6	Cognitive function;
UCEC	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.57	-4.8	-0.37	3.89e-6	Systemic lupus erythematosus;
UCEC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18252515	chr7:66147081	NA	0.51	5.34	0.4	3.51e-7	Aortic root size;
UCEC	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.75	-8.18	-0.56	1.2e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.41	4.55	0.35	1.09e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.67	8.27	0.56	7.2e-14	Menarche (age at onset);
UCEC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.57	-6.39	-0.47	2.09e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.88	12.36	0.71	1.63e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.56	-5.26	-0.4	5e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.54	-5.04	-0.38	1.37e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6493487	0.512	rs35114758	chr15:51371419	C/G	cg17676096	chr15:52263839	LEO1	-0.78	-4.73	-0.36	5.22e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg13334819	chr7:99746414	C7orf59	-0.56	-5.42	-0.41	2.34e-7	Coronary artery disease;
UCEC	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-4.66	-0.36	6.89e-6	Coronary artery disease;
UCEC	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg13147721	chr7:65941812	NA	-0.99	-5.41	-0.41	2.51e-7	Diabetic kidney disease;
UCEC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg22974920	chr21:40686053	BRWD1	0.57	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	5.56	0.42	1.25e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.89	-12.68	-0.72	2.34e-25	Urate levels in lean individuals;
UCEC	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.46	-0.41	2e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs10242455	0.702	rs6976017	chr7:99249999	G/A	cg18809830	chr7:99032528	PTCD1	-0.75	-4.57	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg24851651	chr11:66362959	CCS	-0.4	-4.93	-0.38	2.2e-6	Educational attainment (years of education);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07491357	chr18:9914943	VAPA	0.59	6.94	0.5	1.13e-10	Warfarin maintenance dose;
UCEC	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	0.81	7.02	0.5	7.74e-11	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	0.95	14.69	0.77	1.2e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.48	5.17	0.39	7.68e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs4400599	0.606	rs7542975	chr1:154204813	G/A	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08077726	chr17:74734280	SFRS2;MFSD11	0.62	7.23	0.51	2.49e-11	Warfarin maintenance dose;
UCEC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.79	7.95	0.55	4.53e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg22974920	chr21:40686053	BRWD1	0.53	4.77	0.37	4.31e-6	Cognitive function;
UCEC	cis	rs8020441	0.541	rs59857560	chr14:51158851	G/A	cg04730355	chr14:51134070	SAV1	0.87	8.22	0.56	9.63e-14	Cognitive performance;
UCEC	cis	rs9469578	0.901	rs16869459	chr6:33714908	G/A	cg18708504	chr6:33715942	IP6K3	0.51	4.96	0.38	1.96e-6	Phosphorus levels;
UCEC	cis	rs73206853	0.841	rs57726737	chr12:110843701	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9309473	0.607	rs1522927	chr2:73556155	T/G	cg20560298	chr2:73613845	ALMS1	-0.6	-5.54	-0.42	1.34e-7	Metabolite levels;
UCEC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.4	-0.47	1.98e-9	Platelet count;
UCEC	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg08459430	chr5:81571289	RPS23	0.48	4.65	0.36	7.25e-6	Breast cancer;
UCEC	cis	rs17106184	1.000	rs80326064	chr1:51240851	C/T	cg07174182	chr1:51127561	FAF1	-0.89	-5.66	-0.42	7.66e-8	Type 2 diabetes;
UCEC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.57	-4.61	-0.36	8.73e-6	Menopause (age at onset);
UCEC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg13525197	chr6:28411240	ZSCAN23	-0.43	-4.63	-0.36	7.91e-6	Parkinson's disease;
UCEC	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg26721908	chr21:47610096	LSS	0.41	5.25	0.4	5.22e-7	Testicular germ cell tumor;
UCEC	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.76	7.77	0.54	1.26e-12	Smoking behavior;
UCEC	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.68	7.46	0.52	7.07e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04013166	chr16:89971882	TCF25	0.69	6.32	0.46	3.02e-9	Skin colour saturation;
UCEC	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.58	-6.23	-0.46	4.7e-9	Breast cancer;
UCEC	cis	rs12145833	0.596	rs3926866	chr1:243437632	G/C	cg02356786	chr1:243265016	LOC731275	0.81	5.15	0.39	8.39e-7	Obesity (early onset extreme);
UCEC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.73	5.48	0.41	1.8e-7	Diabetic retinopathy;
UCEC	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.2	-0.46	5.37e-9	Resting heart rate;
UCEC	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.47	-5.49	-0.41	1.75e-7	HDL cholesterol levels;
UCEC	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.73	5.54	0.42	1.34e-7	Bipolar disorder;
UCEC	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg01426195	chr3:39028469	NA	-0.55	-6.33	-0.46	2.81e-9	Handedness;
UCEC	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.61	5.35	0.4	3.28e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.45	-5.14	-0.39	8.72e-7	Oral cavity cancer;
UCEC	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.71	0.54	1.72e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	5.78	0.43	4.34e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.69	6.26	0.46	3.99e-9	Migraine;
UCEC	cis	rs1957429	1.000	rs1957431	chr14:65353187	A/G	cg23373153	chr14:65346875	NA	0.94	7.46	0.52	6.89e-12	Pediatric areal bone mineral density (radius);
UCEC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.37	0.57	4.24e-14	Prudent dietary pattern;
UCEC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg26721908	chr21:47610096	LSS	-0.37	-4.66	-0.36	7.04e-6	Testicular germ cell tumor;
UCEC	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.05	14.35	0.76	9.58e-30	Schizophrenia;
UCEC	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.68	0.54	2.08e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	7.08	0.5	5.49e-11	Chronic sinus infection;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.76	-0.37	4.54e-6	Depression;
UCEC	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg26410121	chr1:144521081	LOC728875	-0.66	-7.32	-0.52	1.48e-11	Amyotrophic lateral sclerosis (sporadic);
UCEC	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.66	6.78	0.49	2.77e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4615376	0.950	rs13193716	chr6:13045208	C/T	cg11378619	chr6:12164359	HIVEP1	-0.58	-4.59	-0.35	9.31e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.56	5.16	0.39	7.75e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.32	-0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg26061582	chr7:22766209	IL6	0.58	5.47	0.41	1.93e-7	Lung cancer;
UCEC	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-12.81	-0.73	1.08e-25	Body mass index;
UCEC	cis	rs611744	0.837	rs422847	chr8:109103274	C/T	cg18478394	chr8:109455254	TTC35	-0.43	-4.54	-0.35	1.16e-5	Dupuytren's disease;
UCEC	cis	rs4615376	1.000	rs9463377	chr6:13033576	A/C	cg11378619	chr6:12164359	HIVEP1	0.49	4.72	0.36	5.41e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.71	-6.27	-0.46	3.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg06784218	chr1:46089804	CCDC17	-0.58	-7.29	-0.52	1.75e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06762426	chr11:62420836	INTS5	0.94	5.39	0.41	2.8e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.66	5.92	0.44	2.2e-8	Menarche (age at onset);
UCEC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.63	4.88	0.37	2.69e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.59	5.37	0.4	3.08e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.64	7.17	0.51	3.43e-11	Menarche (age at onset);
UCEC	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg22166914	chr1:53195759	ZYG11B	0.55	5.51	0.41	1.56e-7	Monocyte count;
UCEC	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.52	5.34	0.4	3.46e-7	Testicular germ cell tumor;
UCEC	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.79	-9.85	-0.63	6.7e-18	White blood cell count (basophil);
UCEC	cis	rs7937612	0.965	rs4938799	chr11:120208257	T/G	cg12584626	chr11:120203529	NA	0.48	5.02	0.38	1.45e-6	Intraocular pressure;
UCEC	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.7	7.74	0.54	1.46e-12	Mortality in heart failure;
UCEC	cis	rs4074536	0.622	rs3827736	chr1:116313263	C/G	cg21648376	chr1:116311395	CASQ2	-0.61	-6.14	-0.45	7.34e-9	QRS duration;
UCEC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg23795048	chr12:9217529	LOC144571	0.41	4.98	0.38	1.76e-6	Sjögren's syndrome;
UCEC	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.46	4.83	0.37	3.36e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg26850624	chr5:429559	AHRR	-0.48	-4.57	-0.35	1.01e-5	Cystic fibrosis severity;
UCEC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	0.91	13.23	0.74	8.08e-27	Multiple system atrophy;
UCEC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-4.91	-0.38	2.4e-6	Personality dimensions;
UCEC	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.58	-6.26	-0.46	3.91e-9	Bipolar disorder;
UCEC	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.35	-5.15	-0.39	8.08e-7	Vitamin D levels;
UCEC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg22974920	chr21:40686053	BRWD1	-0.53	-4.87	-0.37	2.82e-6	Cognitive function;
UCEC	cis	rs2398893	1.000	rs1411861	chr9:96763614	A/G	cg07076509	chr9:96720819	NA	0.47	4.81	0.37	3.65e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1519814	1.000	rs7826920	chr8:121121010	T/C	cg22335954	chr8:121166405	COL14A1	-0.57	-5.15	-0.39	8.16e-7	Breast cancer;
UCEC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	7.22	0.51	2.65e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg07153921	chr17:41440717	NA	-0.55	-5.73	-0.43	5.61e-8	Menopause (age at onset);
UCEC	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg14078730	chr11:63896557	MACROD1	0.67	5.21	0.39	6.28e-7	Mean platelet volume;
UCEC	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.38	0.52	1.07e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.51	5.95	0.44	1.93e-8	Prostate cancer;
UCEC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg04312967	chr16:1597521	IFT140;TMEM204	-0.48	-4.94	-0.38	2.14e-6	Insulin-like growth factors;
UCEC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.63	-5.14	-0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.56	6.08	0.45	9.73e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.66	5.6	0.42	1.04e-7	Schizophrenia;
UCEC	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-4.99	-0.38	1.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.65	5.47	0.41	1.91e-7	Asthma;
UCEC	cis	rs7937612	0.965	rs4539328	chr11:120218243	T/C	cg12584626	chr11:120203529	NA	0.49	5.15	0.39	8.35e-7	Intraocular pressure;
UCEC	cis	rs3112255	1.000	rs3112255	chr2:101317260	C/A	cg01042948	chr2:101319752	NA	0.47	4.93	0.38	2.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.44	4.5	0.35	1.35e-5	Alzheimer's disease;
UCEC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.48	0.77	4.23e-30	Height;
UCEC	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.51	5.3	0.4	4.15e-7	Breast cancer;
UCEC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.84	8.36	0.57	4.44e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg15147215	chr3:52552868	STAB1	-0.44	-4.86	-0.37	2.94e-6	Bipolar disorder;
UCEC	cis	rs999943	0.739	rs62407633	chr6:33609244	C/T	cg14003231	chr6:33640908	ITPR3	0.7	5.85	0.43	3.08e-8	Obesity (extreme);
UCEC	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	8.71	0.58	5.95e-15	Coffee consumption (cups per day);
UCEC	cis	rs858239	0.730	rs858279	chr7:23251005	T/C	cg08455073	chr7:23286463	GPNMB	0.41	4.57	0.35	1.01e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg24375607	chr4:120327624	NA	0.52	5.47	0.41	1.87e-7	Corneal astigmatism;
UCEC	cis	rs1635	0.655	rs9380024	chr6:27830354	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.72	-4.99	-0.38	1.71e-6	Schizophrenia;
UCEC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	0.99	11.11	0.68	3.31e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.5	5.3	0.4	4.18e-7	Aortic root size;
UCEC	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.53	-5.18	-0.39	7.15e-7	Cocaine dependence;
UCEC	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.87	7.65	0.53	2.37e-12	Prostate cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03705947	chr1:68152081	GADD45A	0.57	7.53	0.53	4.81e-12	Warfarin maintenance dose;
UCEC	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.43	6.31	0.46	3.08e-9	Primary biliary cholangitis;
UCEC	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.51	-5.44	-0.41	2.22e-7	Alcohol dependence;
UCEC	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.66	-7.23	-0.51	2.42e-11	Extraversion;
UCEC	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.43	-5.22	-0.4	6.09e-7	Refractive error;
UCEC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.86	9.74	0.63	1.3e-17	Dental caries;
UCEC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.23	7.17	0.51	3.44e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-4.55	-0.35	1.12e-5	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.09	9.83	0.63	7.55e-18	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.45	-4.78	-0.37	4.3e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.73	-5.64	-0.42	8.37e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.47	-5.04	-0.38	1.37e-6	Retinal vascular caliber;
UCEC	cis	rs17123764	1.000	rs7301209	chr12:49946051	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.27	0.4	4.69e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4372836	0.754	rs6709674	chr2:28989667	A/G	cg09522027	chr2:28974177	PPP1CB	-0.83	-9.37	-0.61	1.21e-16	Body mass index;
UCEC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.56	-7.26	-0.51	2.13e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.43	4.61	0.36	8.66e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.62	6.39	0.47	2.07e-9	Blood metabolite levels;
UCEC	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.59	-4.56	-0.35	1.08e-5	Blood pressure (smoking interaction);
UCEC	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.38	0.41	2.82e-7	Response to antipsychotic treatment;
UCEC	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.55	4.93	0.38	2.17e-6	Lung cancer;
UCEC	cis	rs6546550	0.743	rs6731941	chr2:70018496	A/G	cg02498382	chr2:70120550	SNRNP27	-0.58	-6.22	-0.46	4.97e-9	Prevalent atrial fibrillation;
UCEC	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22857025	chr5:266934	NA	-0.98	-9.67	-0.62	1.97e-17	Breast cancer;
UCEC	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-8.87	-0.59	2.22e-15	Hip circumference;
UCEC	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg00339695	chr16:24857497	SLC5A11	0.76	5.69	0.42	6.58e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg20368463	chr18:77673604	PQLC1	0.71	5.36	0.4	3.1e-7	Opioid sensitivity;
UCEC	cis	rs77880822	0.562	rs6078405	chr20:1247246	T/C	cg16922058	chr20:1206700	RAD21L1	0.75	4.73	0.36	5.22e-6	Angiotensin-converting enzyme inhibitor intolerance;
UCEC	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.78	5.55	0.42	1.28e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg23018236	chr17:30244563	NA	-0.57	-5.49	-0.41	1.74e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs2299682	0.826	rs6086902	chr20:9464150	C/G	cg11931762	chr20:9488920	NA	-0.64	-4.94	-0.38	2.11e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs2302190	0.882	rs8072873	chr17:56669049	G/C	cg12560992	chr17:57184187	TRIM37	0.53	4.69	0.36	6.08e-6	Vitamin D levels;
UCEC	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg23070574	chr3:14187308	XPC	0.48	5.51	0.41	1.59e-7	Ovarian reserve;
UCEC	cis	rs10743315	0.643	rs4077883	chr12:19333359	C/A	cg02471346	chr12:19282374	PLEKHA5	0.69	4.78	0.37	4.21e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.99	-0.5	9.02e-11	Tonsillectomy;
UCEC	cis	rs12644436	1.000	rs1903797	chr4:88790203	C/T	cg27179352	chr4:88029472	AFF1	0.41	4.52	0.35	1.27e-5	HIV-1 viral setpoint;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.54	-5.78	-0.43	4.41e-8	Pubertal anthropometrics;
UCEC	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.25	-0.4	5.2e-7	Acylcarnitine levels;
UCEC	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.78	-0.43	4.38e-8	Initial pursuit acceleration;
UCEC	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.4	4.67	0.36	6.69e-6	Hemoglobin concentration;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.78	-0.37	4.14e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8010715	0.816	rs2332224	chr14:24598544	C/G	cg20933586	chr14:24608199	FAM158A	0.37	4.78	0.37	4.16e-6	IgG glycosylation;
UCEC	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.51	-4.54	-0.35	1.18e-5	Colorectal cancer;
UCEC	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.47	4.68	0.36	6.57e-6	Height;
UCEC	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.58	5.28	0.4	4.56e-7	Coronary artery disease;
UCEC	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.82	-0.37	3.54e-6	Breast cancer;
UCEC	cis	rs12980942	1.000	rs12984160	chr19:41815713	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.95	0.44	1.87e-8	Coronary artery disease;
UCEC	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.67	8.76	0.59	4.33e-15	Anterior chamber depth;
UCEC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.2	0.56	1.07e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg18827107	chr12:86230957	RASSF9	-0.4	-4.54	-0.35	1.15e-5	Major depressive disorder;
UCEC	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg01380346	chr19:18557039	ELL	-0.44	-4.6	-0.35	9.21e-6	Breast cancer;
UCEC	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg05709478	chr1:6581295	PLEKHG5	0.72	5.53	0.42	1.42e-7	Body mass index;
UCEC	cis	rs1355223	0.872	rs913204	chr11:34706224	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	4.52	0.35	1.25e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg21770322	chr7:97807741	LMTK2	-0.54	-6.5	-0.47	1.16e-9	Breast cancer;
UCEC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.65	5.51	0.41	1.55e-7	High light scatter reticulocyte count;
UCEC	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	11.56	0.69	2.14e-22	Prudent dietary pattern;
UCEC	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	6.73	0.49	3.49e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.47	5.5	0.41	1.6e-7	Aortic root size;
UCEC	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.11e-7	Body mass index;
UCEC	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.81	-9.22	-0.61	2.96e-16	Primary sclerosing cholangitis;
UCEC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs1007190	0.881	rs9909048	chr17:42973517	G/C	cg15406952	chr17:42872593	NA	0.73	5.7	0.43	6.28e-8	DNA methylation (variation);
UCEC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05776053	chr2:74358815	NA	0.42	5.22	0.4	5.96e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.75	6.75	0.49	3.21e-10	Cognitive function;
UCEC	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.51	5.43	0.41	2.24e-7	Schizophrenia;
UCEC	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.71	8.97	0.59	1.24e-15	Testicular germ cell tumor;
UCEC	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-13.15	-0.74	1.31e-26	Height;
UCEC	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	7.04	0.5	7e-11	Chronic sinus infection;
UCEC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.78	-10.25	-0.65	6.34e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg04202892	chr2:111875749	ACOXL	0.42	4.62	0.36	8.34e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.56	4.82	0.37	3.56e-6	Alzheimer's disease;
UCEC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg08994789	chr17:28903642	LRRC37B2	0.42	4.97	0.38	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.46	-4.88	-0.37	2.7e-6	Body mass index;
UCEC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	-0.54	-6.15	-0.45	7.11e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg04896959	chr15:78267971	NA	-0.46	-5.56	-0.42	1.21e-7	Coronary artery disease or large artery stroke;
UCEC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.6	0.48	7.02e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.92	9.78	0.63	1.03e-17	Cognitive function;
UCEC	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.95	8.55	0.58	1.43e-14	Alcohol dependence;
UCEC	cis	rs10929956	0.593	rs61010155	chr2:160699166	C/A	cg23995753	chr2:160760732	LY75	-0.39	-4.72	-0.36	5.49e-6	Crohn's disease-related phenotypes;
UCEC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg24375607	chr4:120327624	NA	0.45	4.75	0.36	4.75e-6	Corneal astigmatism;
UCEC	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg03354898	chr7:1950403	MAD1L1	-0.46	-4.53	-0.35	1.22e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.24e-8	Systemic lupus erythematosus;
UCEC	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.76	-8.17	-0.56	1.3e-13	Height;
UCEC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.53	5.24	0.4	5.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.64	-0.53	2.6e-12	Total cholesterol levels;
UCEC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg19318889	chr4:1322082	MAEA	-0.44	-5.4	-0.41	2.66e-7	Obesity-related traits;
UCEC	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.53	-5.47	-0.41	1.86e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12516959	chr21:47718080	NA	-0.49	-5.72	-0.43	5.76e-8	Testicular germ cell tumor;
UCEC	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg18478394	chr8:109455254	TTC35	0.46	4.58	0.35	1e-5	Dupuytren's disease;
UCEC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.8	-0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.43	-4.54	-0.35	1.14e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.44	4.95	0.38	2.03e-6	Alzheimer's disease (late onset);
UCEC	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-10.49	-0.65	1.49e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.88	0.54	6.81e-13	Platelet count;
UCEC	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.5	4.8	0.37	3.84e-6	Height;
UCEC	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	6.22	0.46	4.86e-9	Homoarginine levels;
UCEC	cis	rs1776883	0.502	rs4713758	chr6:34145361	A/G	cg10661734	chr6:34122502	NA	-0.48	-5.06	-0.39	1.21e-6	Asthma;Asthma (childhood onset);
UCEC	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.36	-4.9	-0.37	2.46e-6	Eye color traits;
UCEC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	5.41	0.41	2.46e-7	Obesity-related traits;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.62	6.91	0.49	1.39e-10	Menarche (age at onset);
UCEC	cis	rs11118844	0.843	rs12144586	chr1:221919378	A/G	cg04222084	chr1:221915650	DUSP10	-0.75	-6.76	-0.49	3.1e-10	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.59	5.3	0.4	4.24e-7	Lupus nephritis in systemic lupus erythematosus;
UCEC	cis	rs12365397	0.569	rs7926780	chr11:43236755	A/G	cg07515919	chr11:43391688	TTC17	-0.51	-5.97	-0.44	1.7e-8	Migraine;
UCEC	cis	rs8177876	0.822	rs8177950	chr16:81116895	A/G	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.72	0.36	5.43e-6	Tonsillectomy;
UCEC	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.6	5.71	0.43	5.99e-8	Lung cancer;
UCEC	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-0.56	-7.2	-0.51	2.86e-11	Cancer (pleiotropy);
UCEC	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.51	-4.86	-0.37	3.04e-6	Diabetic retinopathy;
UCEC	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-6.75	-0.49	3.16e-10	Response to antipsychotic treatment;
UCEC	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.98	0.44	1.63e-8	Height;
UCEC	cis	rs427941	0.732	rs55961409	chr7:101846699	G/A	cg08135718	chr7:101819329	CUX1	0.44	5.19	0.39	6.98e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14813019	chr8:90996956	NBN	0.58	6.75	0.49	3.27e-10	Warfarin maintenance dose;
UCEC	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.76	-7.61	-0.53	2.97e-12	Caffeine consumption;
UCEC	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs884366	1.000	rs4946962	chr6:109646840	T/C	cg01475377	chr6:109611718	NA	0.46	5.24	0.4	5.52e-7	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.38	-4.52	-0.35	1.29e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.7	6.1	0.45	8.93e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Parkinson's disease;
UCEC	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13683864	chr3:40499215	RPL14	-0.96	-10.04	-0.64	2.14e-18	Renal cell carcinoma;
UCEC	cis	rs10242455	0.681	rs1851425	chr7:99300231	G/A	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	6.74e-7	Blood metabolite levels;
UCEC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.64	6.09	0.45	9.33e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.75	-0.43	4.96e-8	Life satisfaction;
UCEC	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.7	-0.54	1.87e-12	IgG glycosylation;
UCEC	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.69	-7.12	-0.51	4.34e-11	Dental caries;
UCEC	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.0	0.38	1.6e-6	Rheumatoid arthritis;
UCEC	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.46	-5.13	-0.39	8.93e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.37	4.66	0.36	6.92e-6	Social autistic-like traits;
UCEC	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.52	5.51	0.41	1.54e-7	Red blood cell count;
UCEC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.46	0.41	2.01e-7	Prudent dietary pattern;
UCEC	cis	rs8032158	1.000	rs11633313	chr15:56135709	A/G	cg10433327	chr15:56209506	NEDD4	-0.31	-5.08	-0.39	1.14e-6	Keloid;
UCEC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.48	-4.84	-0.37	3.18e-6	Aortic root size;
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.62	7.54	0.53	4.39e-12	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs2267137	0.747	rs1963292	chr22:29805867	T/C	cg07256473	chr22:29710276	RASL10A	0.49	4.76	0.37	4.6e-6	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.79	-6.36	-0.46	2.38e-9	Lymphocyte percentage of white cells;
UCEC	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.64	5.12	0.39	9.47e-7	HIV-1 control;
UCEC	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg04155231	chr12:9217510	LOC144571	0.4	4.85	0.37	3.18e-6	Sjögren's syndrome;
UCEC	cis	rs1298062	0.861	rs2431821	chr19:50995098	G/A	cg11430371	chr19:50961752	MYBPC2	0.39	4.72	0.36	5.35e-6	Age of smoking initiation;
UCEC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.49	-6.64	-0.48	5.82e-10	Body mass index;
UCEC	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg07615347	chr10:60278583	BICC1	-0.44	-4.74	-0.36	4.92e-6	Refractive error;
UCEC	cis	rs10012307	1.000	rs8180218	chr4:137524050	C/A	cg12033966	chr4:138453416	PCDH18	-0.68	-4.67	-0.36	6.67e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	1.19	9.63	0.62	2.5e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-8.24	-0.56	8.76e-14	Height;
UCEC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg18584368	chr5:314553	AHRR;PDCD6	0.58	4.58	0.35	9.92e-6	Asthma (childhood onset);
UCEC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.73	7.17	0.51	3.38e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg00409905	chr10:38381863	ZNF37A	0.48	4.63	0.36	8.05e-6	Obesity (extreme);
UCEC	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-8.46	-0.57	2.45e-14	Longevity;Endometriosis;
UCEC	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.91	11.03	0.67	5.4e-21	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12234571	1.000	rs73375848	chr7:77515190	T/C	cg20048109	chr7:78158112	MAGI2	-0.51	-4.53	-0.35	1.21e-5	Obesity-related traits;
UCEC	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.55	0.62	4.01e-17	Bipolar disorder;
UCEC	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.97	0.38	1.85e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	0.99	5.66	0.42	7.79e-8	Diabetic retinopathy;
UCEC	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-7.32	-0.52	1.46e-11	Menarche (age at onset);
UCEC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs970548	0.955	rs10900223	chr10:46021631	T/C	cg15223267	chr10:46222474	FAM21C	0.53	4.72	0.36	5.44e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs56161922	1.000	rs57587123	chr1:207825415	A/G	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.56	-6.08	-0.45	9.7e-9	Gut microbiome composition (summer);
UCEC	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.09	0.39	1.09e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.54	5.37	0.41	2.94e-7	Bipolar disorder;
UCEC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.13	13.97	0.76	9.28e-29	Cognitive function;
UCEC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.1	0.51	4.81e-11	Motion sickness;
UCEC	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.66	-7.01	-0.5	8.18e-11	Mean platelet volume;
UCEC	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.8	8.18	0.56	1.25e-13	Primary sclerosing cholangitis;
UCEC	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.65	6.98	0.5	9.49e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.49	5.61	0.42	9.96e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.49	4.55	0.35	1.13e-5	Coronary artery disease;
UCEC	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg16558253	chr16:72132732	DHX38	-0.49	-5.2	-0.39	6.48e-7	Blood protein levels;
UCEC	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.49	-4.81	-0.37	3.76e-6	Multiple sclerosis;
UCEC	cis	rs16857609	0.628	rs35856653	chr2:218350206	C/A	cg23340935	chr2:218354150	DIRC3	0.48	4.65	0.36	7.43e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg05991184	chr2:219186017	PNKD	-0.45	-4.76	-0.37	4.64e-6	Colorectal cancer;
UCEC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg23217946	chr19:22817039	ZNF492	0.41	4.54	0.35	1.17e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.62	7.99	0.55	3.55e-13	Anterior chamber depth;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.91	-0.49	1.4e-10	Depression;
UCEC	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.68	6.46	0.47	1.46e-9	Aortic root size;
UCEC	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.72	-6.96	-0.5	1.03e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9283706	0.562	rs10471697	chr5:66328555	A/T	cg11590213	chr5:66331682	MAST4	0.46	5.81	0.43	3.72e-8	Coronary artery disease;
UCEC	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.53	5.1	0.39	1.02e-6	Neutrophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.63	7.51	0.53	5.18e-12	Obesity-related traits;
UCEC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.51	5.93	0.44	2.04e-8	Alcohol dependence;
UCEC	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.47	4.92	0.38	2.31e-6	Vitiligo;
UCEC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.47	-4.55	-0.35	1.11e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs731174	0.802	rs6426030	chr1:38188195	A/G	cg06917450	chr1:38156652	C1orf109	-0.54	-4.77	-0.37	4.39e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-12.46	-0.72	8.76e-25	Ulcerative colitis;
UCEC	cis	rs16932667	0.857	rs12424672	chr12:5140168	G/A	cg03854198	chr12:5541311	NTF3	0.47	5.25	0.4	5.15e-7	Intelligence (childhood);
UCEC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.72	-6.31	-0.46	3.14e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.75	-0.36	4.88e-6	Pulmonary function;
UCEC	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.65	-7.01	-0.5	8.18e-11	Coronary artery disease;
UCEC	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg22166914	chr1:53195759	ZYG11B	0.53	5.3	0.4	4.2e-7	Monocyte count;
UCEC	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.35	4.95	0.38	2.05e-6	Coronary artery disease;
UCEC	cis	rs354033	0.959	rs735120	chr7:149313811	C/T	cg24335155	chr7:149193227	ZNF746	0.37	4.58	0.35	9.65e-6	Multiple sclerosis;
UCEC	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.46	-5.89	-0.44	2.51e-8	Mean platelet volume;
UCEC	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.27e-13	Parkinson's disease;
UCEC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.9	-0.37	2.47e-6	Aortic root size;
UCEC	cis	rs7597155	0.846	rs2312550	chr2:69959005	G/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.36	-0.4	3.2e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7937612	1.000	rs10750173	chr11:120288368	T/C	cg12584626	chr11:120203529	NA	0.54	5.3	0.4	4.12e-7	Intraocular pressure;
UCEC	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.57	5.38	0.41	2.92e-7	Blood metabolite levels;
UCEC	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg24562669	chr7:97807699	LMTK2	0.47	5.71	0.43	6.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.62	-6.75	-0.49	3.2e-10	Urinary metabolites;
UCEC	trans	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg09872104	chr7:134855509	C7orf49	-1.05	-6.99	-0.5	8.84e-11	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.69	5.49	0.41	1.73e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg18721089	chr20:30220636	NA	-0.42	-5.33	-0.4	3.54e-7	Mean corpuscular hemoglobin;
UCEC	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.92	10.07	0.64	1.78e-18	Post bronchodilator FEV1;
UCEC	cis	rs8105895	0.736	rs2359835	chr19:22242690	A/G	cg24072202	chr19:22235272	ZNF257	-0.61	-5.33	-0.4	3.64e-7	Body mass index (change over time);
UCEC	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.36	-0.4	3.12e-7	Neutrophil percentage of white cells;
UCEC	cis	rs847649	1.000	rs847649	chr7:102556011	C/T	cg18108683	chr7:102477205	FBXL13	-0.62	-7.75	-0.54	1.42e-12	Morning vs. evening chronotype;
UCEC	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.49	5.59	0.42	1.08e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs758129	0.632	rs2238296	chr15:89875329	A/G	cg23124613	chr15:89731485	ABHD2	-0.4	-4.59	-0.35	9.51e-6	Schizophrenia;
UCEC	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	7.31	0.52	1.56e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg00612595	chr21:47717864	NA	-0.48	-5.16	-0.39	8.01e-7	Testicular germ cell tumor;
UCEC	cis	rs3015497	0.616	rs34061700	chr14:51084860	G/A	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.37e-6	Mean platelet volume;
UCEC	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.37	-0.52	1.15e-11	Eye color traits;
UCEC	cis	rs2120019	0.638	rs34492112	chr15:75294917	G/A	cg11632617	chr15:75315747	PPCDC	0.54	5.95	0.44	1.89e-8	Blood trace element (Zn levels);
UCEC	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg19554555	chr3:13937349	NA	-0.59	-5.81	-0.43	3.73e-8	Ovarian reserve;
UCEC	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.5	-4.98	-0.38	1.74e-6	Breast size;
UCEC	cis	rs7246967	0.551	rs7351072	chr19:23044529	C/T	cg08271804	chr19:22816896	ZNF492	0.59	5.57	0.42	1.16e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.01e-5	Type 2 diabetes;
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.92	10.32	0.65	4.03e-19	Menarche (age at onset);
UCEC	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.86	-12.23	-0.71	3.61e-24	Urate levels in lean individuals;
UCEC	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.36	4.86	0.37	2.99e-6	Prostate cancer;
UCEC	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg04553112	chr3:125709451	NA	0.72	5.05	0.38	1.32e-6	Blood pressure (smoking interaction);
UCEC	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	6.49	0.47	1.25e-9	Tonsillectomy;
UCEC	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.57	4.83	0.37	3.36e-6	Bipolar disorder;
UCEC	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9469578	1.000	rs73743336	chr6:33715391	G/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.77	7.67	0.53	2.23e-12	Lung cancer;
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.21	0.56	1.03e-13	Prudent dietary pattern;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.9	-0.37	2.52e-6	Depression;
UCEC	cis	rs3015497	0.789	rs3015502	chr14:51108427	T/C	cg04730355	chr14:51134070	SAV1	-0.55	-5.83	-0.43	3.35e-8	Mean platelet volume;
UCEC	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.54	5.45	0.41	2.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4851266	1.000	rs12990462	chr2:100827216	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg05660106	chr1:15850417	CASP9	1.02	11.66	0.69	1.15e-22	Systolic blood pressure;
UCEC	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.63	-7.24	-0.51	2.35e-11	Vitiligo;
UCEC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.62	6.35	0.46	2.56e-9	Menopause (age at onset);
UCEC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg22598563	chr5:131563921	P4HA2	-0.34	-4.56	-0.35	1.05e-5	Blood metabolite levels;
UCEC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg06096015	chr1:231504339	EGLN1	0.41	4.83	0.37	3.39e-6	Hemoglobin concentration;
UCEC	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.63	-5.42	-0.41	2.34e-7	Alcohol dependence;
UCEC	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.54	-6.26	-0.46	3.98e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.84	-10.42	-0.65	2.15e-19	Longevity;Endometriosis;
UCEC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.01	-13.64	-0.75	7.01e-28	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.02	-0.5	7.58e-11	Parkinson's disease;
UCEC	cis	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg02356786	chr1:243265016	LOC731275	0.84	5.84	0.43	3.24e-8	Obesity (early onset extreme);
UCEC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.81	5.61	0.42	9.82e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.66	7.48	0.53	6.25e-12	Obesity-related traits;
UCEC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs4372836	0.504	rs7597048	chr2:29066756	A/G	cg09522027	chr2:28974177	PPP1CB	0.57	5.94	0.44	2e-8	Body mass index;
UCEC	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg03999872	chr20:62272968	STMN3	-0.48	-4.56	-0.35	1.08e-5	Atopic dermatitis;
UCEC	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.64	-5.69	-0.42	6.64e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	0.94	8.02	0.55	2.97e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.54	4.8	0.37	3.88e-6	Lung function (FEV1/FVC);
UCEC	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.57	-4.55	-0.35	1.13e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.54	5.14	0.39	8.81e-7	Coronary artery disease;
UCEC	cis	rs743757	0.762	rs12491425	chr3:50575312	A/G	cg07638105	chr3:50605146	C3orf18	0.51	4.61	0.36	8.6e-6	Diastolic blood pressure;
UCEC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.57	5.17	0.39	7.59e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	5.66	0.42	7.76e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs10242455	0.702	rs78218664	chr7:99154381	C/A	cg18809830	chr7:99032528	PTCD1	-0.92	-5.26	-0.4	4.95e-7	Blood metabolite levels;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.61	7.13	0.51	4.09e-11	Menarche (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09610735	chr10:22609918	BMI1	0.57	6.97	0.5	9.83e-11	Warfarin maintenance dose;
UCEC	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.51	-5.16	-0.39	7.93e-7	Refractive error;
UCEC	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg17294928	chr15:75287854	SCAMP5	0.44	4.73	0.36	5.26e-6	Caffeine consumption;
UCEC	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	8.66	0.58	7.87e-15	Electrocardiographic conduction measures;
UCEC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.82	8.1	0.56	1.9e-13	Selective IgA deficiency;
UCEC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12516959	chr21:47718080	NA	-0.4	-4.6	-0.35	9.23e-6	Testicular germ cell tumor;
UCEC	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.66	5.58	0.42	1.11e-7	Gut microbiome composition (summer);
UCEC	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.56	6.07	0.45	1.06e-8	Dupuytren's disease;
UCEC	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.62	6.51	0.47	1.11e-9	Colorectal cancer;
UCEC	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-7.87	-0.54	7.23e-13	Monocyte count;
UCEC	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.66	-6.44	-0.47	1.59e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.75	6.51	0.47	1.11e-9	Platelet count;
UCEC	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.36	0.46	2.45e-9	Morning vs. evening chronotype;
UCEC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.45	6.26	0.46	4.08e-9	Urinary metabolites;
UCEC	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg07684019	chr5:139174529	PSD2	0.31	4.62	0.36	8.18e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	5.62	0.42	9.35e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.59	5.83	0.43	3.35e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.74	6.58	0.48	7.65e-10	Mean corpuscular volume;
UCEC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.71	0.54	1.73e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.72	6.77	0.49	2.8e-10	Reticulocyte fraction of red cells;
UCEC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-4.61	-0.36	8.69e-6	Aortic root size;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05577945	chr13:78271874	SLAIN1	0.62	7.45	0.52	7.29e-12	Warfarin maintenance dose;
UCEC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.51	4.65	0.36	7.41e-6	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
UCEC	cis	rs3008870	0.536	rs2815383	chr1:67516316	T/A	cg08660285	chr1:67390436	MIER1;WDR78	0.54	4.68	0.36	6.38e-6	Lymphocyte percentage of white cells;
UCEC	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.77	8.23	0.56	9.09e-14	Metabolite levels;
UCEC	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.55	-5.53	-0.42	1.41e-7	Aortic root size;
UCEC	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.47	5.23	0.4	5.63e-7	Emphysema distribution in smoking;
UCEC	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.72	8.06	0.55	2.38e-13	Mortality in heart failure;
UCEC	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.93	0.38	2.17e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.86	5.63	0.42	8.93e-8	Psoriasis;
UCEC	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.45	-0.41	2.09e-7	Birth weight;
UCEC	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.58	-7.14	-0.51	3.97e-11	Total body bone mineral density;
UCEC	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.73	-8.37	-0.57	4.06e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01261044	chr14:35451962	SRP54	0.57	7.06	0.5	5.97e-11	Warfarin maintenance dose;
UCEC	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	7.96	0.55	4.24e-13	Platelet count;
UCEC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.65	5.0	0.38	1.6e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.53	-5.97	-0.44	1.7e-8	Pubertal anthropometrics;
UCEC	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.55	6.0	0.44	1.44e-8	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.11	-6.97	-0.5	9.87e-11	Alzheimer's disease (late onset);
UCEC	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.14e-7	Body mass index;
UCEC	cis	rs11958404	0.932	rs72816583	chr5:157432647	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg12850546	chr22:42539477	CYP2D7P1	-1.17	-8.22	-0.56	1e-13	Birth weight;
UCEC	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.52	5.0	0.38	1.58e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.88	-9.54	-0.62	4.25e-17	Blood metabolite levels;
UCEC	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	0.91	9.18	0.6	3.7e-16	Heart rate;
UCEC	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.66	7.87	0.54	6.98e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	0.94	10.73	0.66	3.34e-20	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg24889512	chr19:22816950	ZNF492	0.6	6.58	0.48	7.59e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.41	-4.79	-0.37	4.07e-6	Menarche (age at onset);
UCEC	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.56	4.97	0.38	1.87e-6	High light scatter reticulocyte count;
UCEC	cis	rs78487399	0.710	rs6731998	chr2:43677273	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6763768	0.606	rs9812118	chr3:53380053	T/C	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg02851062	chr11:122848983	BSX	-0.37	-4.7	-0.36	6.05e-6	Menarche (age at onset);
UCEC	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg19715936	chr7:50634035	DDC	0.44	5.52	0.41	1.52e-7	Malaria;
UCEC	cis	rs1165668	1.000	rs1165670	chr12:104318406	G/A	cg21863207	chr12:104234989	NT5DC3	0.53	4.66	0.36	6.9e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg10415171	chr14:77413900	NA	0.46	4.86	0.37	2.99e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.53	-5.63	-0.42	8.82e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.58	-6.19	-0.45	5.73e-9	Primary sclerosing cholangitis;
UCEC	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.5	-0.47	1.16e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.71	6.16	0.45	6.59e-9	Alzheimer's disease;
UCEC	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.83	12.2	0.71	4.31e-24	Leprosy;
UCEC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.45	0.52	7.27e-12	Total body bone mineral density;
UCEC	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.61	-0.42	9.95e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-1.03	-12.24	-0.71	3.38e-24	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg19752551	chr11:57585705	CTNND1	0.44	4.6	0.35	9.07e-6	Schizophrenia;
UCEC	cis	rs7072216	0.881	rs10883084	chr10:100151189	T/C	cg19567339	chr10:100142640	NA	0.61	8.57	0.58	1.32e-14	Metabolite levels;
UCEC	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.59	4.51	0.35	1.34e-5	Corneal astigmatism;
UCEC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	0.93	9.51	0.62	5.16e-17	Heart rate;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.45	-5.15	-0.39	8.2e-7	Longevity;Endometriosis;
UCEC	cis	rs4141404	0.561	rs5994376	chr22:31563555	A/C	cg20786683	chr22:31477247	SMTN	-0.54	-5.16	-0.39	7.7e-7	Paclitaxel-induced neuropathy;
UCEC	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg18681998	chr4:17616180	MED28	0.51	5.67	0.42	7.3900000000000007e-08	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	5.1	0.39	1.01e-6	Parkinson's disease;
UCEC	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg09144964	chr7:27150262	HOXA3	-0.56	-4.69	-0.36	6.28e-6	Type 1 diabetes;
UCEC	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	0.77	4.85	0.37	3.09e-6	Height;
UCEC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.27	-0.46	3.71e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.52	6.44	0.47	1.64e-9	Cisplatin-induced ototoxicity;
UCEC	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.61	-5.7	-0.43	6.28e-8	Mortality in heart failure;
UCEC	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-0.85	-6.59	-0.48	7.36e-10	Coronary artery disease;
UCEC	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	5.59	0.42	1.1e-7	Prudent dietary pattern;
UCEC	cis	rs77861329	1.000	rs352153	chr3:52211184	A/T	cg08692210	chr3:52188851	WDR51A	0.79	6.0	0.44	1.5e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.45	-5.05	-0.38	1.32e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.57	0.42	1.19e-7	Cognitive test performance;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg07236798	chr8:131455818	NA	0.64	6.83	0.49	2.08e-10	Schizophrenia;
UCEC	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.69	6.86	0.49	1.76e-10	Breast cancer;
UCEC	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.46	5.04	0.38	1.35e-6	IgG glycosylation;
UCEC	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-5.68	-0.42	6.88e-8	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.62	0.48	6.35e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.64	-6.62	-0.48	6.42e-10	Mean platelet volume;
UCEC	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.68	-7.7	-0.54	1.85e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.49	5.78	0.43	4.31e-8	Oral cavity cancer;
UCEC	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg13683864	chr3:40499215	RPL14	-0.53	-5.37	-0.4	3.08e-7	Renal cell carcinoma;
UCEC	cis	rs7737355	0.812	rs2108870	chr5:131088486	C/T	cg23943829	chr5:132009111	IL4	0.36	4.56	0.35	1.07e-5	Life satisfaction;
UCEC	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-4.6	-0.35	9.16e-6	Self-reported allergy;
UCEC	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.81	-10.01	-0.64	2.56e-18	White blood cell count (basophil);
UCEC	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.66	7.41	0.52	8.98e-12	Menarche (age at onset);
UCEC	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.43	-4.87	-0.37	2.84e-6	Total body bone mineral density;
UCEC	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-0.85	-10.72	-0.66	3.68e-20	Height;
UCEC	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-6.27	-0.46	3.85e-9	Primary biliary cholangitis;
UCEC	cis	rs2554380	0.891	rs2585055	chr15:84281488	A/G	cg25130800	chr15:85143846	ZSCAN2	-0.6	-4.75	-0.36	4.82e-6	Height;
UCEC	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.91	10.73	0.66	3.3e-20	Subjective well-being;
UCEC	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	0.71	5.71	0.43	5.98e-8	Alzheimer's disease;
UCEC	cis	rs1572072	0.545	rs1572073	chr13:24127240	C/T	cg24350296	chr13:24144486	TNFRSF19	-0.37	-4.52	-0.35	1.29e-5	Nasopharyngeal carcinoma;
UCEC	cis	rs2179367	0.919	rs4897124	chr6:149763209	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.37	-4.7	-0.36	5.86e-6	Dupuytren's disease;
UCEC	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.72	7.13	0.51	4.23e-11	Smoking behavior;
UCEC	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.35	-0.46	2.47e-9	Response to antipsychotic treatment;
UCEC	cis	rs7336933	0.866	rs9532943	chr13:42443355	C/A	cg18400088	chr13:41634674	WBP4	0.54	4.58	0.35	1e-5	Calcium levels;
UCEC	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg10802521	chr3:52805072	NEK4	-0.49	-4.85	-0.37	3.11e-6	Electroencephalogram traits;
UCEC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	6.51	0.47	1.11e-9	Platelet count;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.6	8.66	0.58	7.59e-15	Prudent dietary pattern;
UCEC	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.48e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.75	7.15	0.51	3.78e-11	Schizophrenia;
UCEC	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.25	-7.6	-0.53	3.14e-12	Schizophrenia;
UCEC	cis	rs10887741	0.646	rs12413510	chr10:89436979	T/C	cg13926569	chr10:89418898	PAPSS2	0.41	4.85	0.37	3.16e-6	Exercise (leisure time);
UCEC	cis	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg17469321	chr7:55412551	NA	0.71	5.7	0.43	6.36e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs4345220	0.553	rs4860999	chr4:41649717	G/C	cg15232654	chr4:41643107	LIMCH1	0.59	6.36	0.46	2.44e-9	Migraine with aura;
UCEC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-0.83	-9.49	-0.62	5.87e-17	Height;
UCEC	cis	rs10096908	0.786	rs12676896	chr8:41655690	G/C	cg01513060	chr8:40802449	NA	0.68	4.53	0.35	1.23e-5	Hypertension;Blood pressure traits (multi-trait analysis);Systolic blood pressure;
UCEC	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg11871910	chr12:69753446	YEATS4	0.7	6.49	0.47	1.25e-9	Response to diuretic therapy;
UCEC	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	9.03	0.6	8.82e-16	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.72	6.84	0.49	1.98e-10	Schizophrenia;
UCEC	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-0.88	-6.38	-0.47	2.15e-9	Body mass index;
UCEC	cis	rs7011507	0.545	rs6993968	chr8:49081038	A/G	ch.8.1073630F	chr8:48637817	KIAA0146	-0.49	-4.62	-0.36	8.28e-6	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.47	-5.44	-0.41	2.2e-7	Lung cancer;
UCEC	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.93	7.71	0.54	1.79e-12	Monobrow;
UCEC	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.65	-6.68	-0.48	4.57e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.69	0.48	4.39e-10	Coffee consumption (cups per day);
UCEC	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.56	7.13	0.51	4.29e-11	Anterior chamber depth;
UCEC	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.54	4.55	0.35	1.13e-5	Obesity-related traits;
UCEC	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.6	-0.42	1.04e-7	Blood metabolite levels;
UCEC	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg05855489	chr10:104503620	C10orf26	-0.6	-6.38	-0.47	2.13e-9	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.91	-0.5	1.35e-10	Chronic sinus infection;
UCEC	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.57	-5.18	-0.39	7.13e-7	Hypospadias;
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg19678392	chr7:94953810	PON1	0.59	5.81	0.43	3.73e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.58	6.17	0.45	6.28e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-0.65	-8.63	-0.58	9.45e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.65	-7.19	-0.51	2.97e-11	Waist circumference;Body mass index;
UCEC	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.57	6.03	0.45	1.29e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.14	-0.45	7.5e-9	Birth weight;
UCEC	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.88	12.97	0.73	3.93e-26	Leprosy;
UCEC	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	5.23	0.4	5.69e-7	Personality dimensions;
UCEC	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg02366345	chr4:152330872	FAM160A1	0.34	4.61	0.36	8.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.5	-4.96	-0.38	1.94e-6	Cocaine dependence;
UCEC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg14078730	chr11:63896557	MACROD1	0.68	5.33	0.4	3.56e-7	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs2082445	chr19:22834587	A/G	cg08271804	chr19:22816896	ZNF492	0.63	6.25	0.46	4.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs565229	0.714	rs497879	chr11:122148259	G/A	cg14126608	chr11:122846540	NA	-0.6	-4.67	-0.36	6.77e-6	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.09	0.39	1.08e-6	Rheumatoid arthritis;
UCEC	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.6	4.53	0.35	1.19e-5	Corneal astigmatism;
UCEC	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.62	-6.3	-0.46	3.25e-9	Diastolic blood pressure;
UCEC	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	4.65	0.36	7.41e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.59	6.86	0.49	1.82e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.56	0.35	1.08e-5	Height;
UCEC	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg14092571	chr14:90743983	NA	-0.45	-6.21	-0.46	5.26e-9	Mortality in heart failure;
UCEC	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	6.06	0.45	1.08e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9309473	1.000	rs10189574	chr2:73698518	C/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.44	-0.41	2.17e-7	Metabolite levels;
UCEC	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.86e-6	Testicular germ cell tumor;
UCEC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.65	5.83	0.43	3.32e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.41	4.72	0.36	5.49e-6	Blood metabolite ratios;
UCEC	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.6	8.83	0.59	2.88e-15	Prudent dietary pattern;
UCEC	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.68	5.89	0.44	2.52e-8	Adiposity;
UCEC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.37	-4.84	-0.37	3.29e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.52	0.53	4.87e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.48	-9.65	-0.62	2.21e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs6838801	0.765	rs1826526	chr4:77607479	T/A	cg17476223	chr4:77663285	SHROOM3	0.47	4.53	0.35	1.23e-5	Cleft lip with or without cleft palate;
UCEC	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.52	-6.43	-0.47	1.7e-9	Total body bone mineral density;
UCEC	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.91	-0.44	2.26e-8	Personality dimensions;
UCEC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	5.04	0.38	1.37e-6	Obesity-related traits;
UCEC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.56	-6.35	-0.46	2.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.61	-0.36	8.57e-6	Breast cancer;
UCEC	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	5.99	0.44	1.55e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1056265	0.500	rs2027024	chr9:71449346	A/T	cg00794837	chr9:72287772	APBA1	0.52	4.66	0.36	7.06e-6	Angiotensin-converting enzyme inhibitor intolerance;
UCEC	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.71	7.11	0.51	4.68e-11	Vitamin D levels;
UCEC	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-5.44	-0.41	2.21e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.5	-4.91	-0.38	2.34e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.58	-5.32	-0.4	3.84e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs12786942	0.569	rs10082588	chr11:101315000	A/G	cg03942599	chr11:101341554	TRPC6	0.5	6.09	0.45	9.38e-9	Facial depth;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04579211	chr15:41221939	DLL4	0.61	7.57	0.53	3.83e-12	Warfarin maintenance dose;
UCEC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	4.63	0.36	7.89e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.7	-8.02	-0.55	3.11e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.76	-8.31	-0.57	5.81e-14	Itch intensity from mosquito bite;
UCEC	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.58	6.53	0.47	1.01e-9	Breast cancer;
UCEC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg02733842	chr7:1102375	C7orf50	-0.61	-5.61	-0.42	9.92e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg12024160	chr4:1254474	NA	0.53	4.86	0.37	2.93e-6	Longevity;
UCEC	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18932078	chr1:2524107	MMEL1	-0.33	-5.37	-0.41	2.94e-7	Ulcerative colitis;
UCEC	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-5.2	-0.39	6.66e-7	Morning vs. evening chronotype;
UCEC	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.5	5.67	0.42	7.46e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.49	-5.39	-0.41	2.73e-7	Life satisfaction;
UCEC	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.46	4.53	0.35	1.2e-5	Prostate cancer;
UCEC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.65	5.49	0.41	1.7e-7	Longevity;
UCEC	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.91	7.06	0.5	6.27e-11	Cerebrospinal P-tau181p levels;
UCEC	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.82	-8.37	-0.57	4.14e-14	Caffeine consumption;
UCEC	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.54	6.56	0.48	8.58e-10	Menarche (age at onset);
UCEC	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.67	-6.28	-0.46	3.57e-9	Parkinson's disease;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.44	5.28	0.4	4.55e-7	Tonsillectomy;
UCEC	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.4	5.1	0.39	1.04e-6	Breast cancer;
UCEC	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.69	7.25	0.51	2.16e-11	Urate levels in obese individuals;
UCEC	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.6	4.53	0.35	1.19e-5	Corneal astigmatism;
UCEC	cis	rs7523273	1.000	rs7523273	chr1:207977083	A/G	cg22525895	chr1:207977042	MIR29B2	-0.58	-5.54	-0.42	1.38e-7	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs8103430	chr19:22931498	A/G	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.54	0.35	1.15e-5	Lymphocyte counts;
UCEC	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-0.54	-6.63	-0.48	5.93e-10	Total body bone mineral density;
UCEC	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg08890418	chr1:21044141	KIF17	0.69	7.61	0.53	3.07e-12	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-6.76	-0.49	3.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.5	-5.53	-0.41	1.45e-7	Aortic root size;
UCEC	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.45	4.74	0.36	4.98e-6	Autism;
UCEC	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.72	-5.84	-0.43	3.2e-8	Asthma;
UCEC	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg08755490	chr11:65554678	OVOL1	0.5	5.31	0.4	3.89e-7	Acne (severe);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.57	7.09	0.5	5.31e-11	Warfarin maintenance dose;
UCEC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg04154034	chr17:28927549	LRRC37B2	0.77	4.76	0.37	4.62e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.2	-22.37	-0.88	3.56e-49	Myeloid white cell count;
UCEC	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg18681998	chr4:17616180	MED28	0.65	6.63	0.48	5.96e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	7.31	0.52	1.6e-11	Platelet count;
UCEC	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.94	0.5	1.19e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.57	5.65	0.42	7.95e-8	Ulcerative colitis;
UCEC	cis	rs7095607	0.785	rs4746731	chr10:69920924	C/A	cg18986048	chr10:69913749	MYPN	0.54	6.36	0.46	2.43e-9	Lung function (FVC);
UCEC	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg04756594	chr16:24857601	SLC5A11	0.45	5.11	0.39	1.01e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	0.87	8.29	0.56	6.42e-14	Breast cancer;
UCEC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.63	-6.48	-0.47	1.3e-9	Mean platelet volume;
UCEC	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.89	-5.62	-0.42	9.2e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.56	5.64	0.42	8.41e-8	Blood protein levels;
UCEC	cis	rs10877840	0.506	rs34714539	chr12:40322527	C/T	cg00686022	chr12:40020078	C12orf40	0.63	4.56	0.35	1.06e-5	Parkinson's disease;
UCEC	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg03859395	chr2:55845619	SMEK2	0.97	12.66	0.72	2.65e-25	Metabolic syndrome;
UCEC	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg04662943	chr10:102668895	NA	0.46	4.59	0.35	9.48e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-4.8	-0.37	3.87e-6	Neuroticism;
UCEC	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.86	-9.99	-0.64	2.89e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.51	5.82	0.43	3.48e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.21	8.07	0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.88e-8	Red blood cell count;
UCEC	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.51	-0.47	1.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg03999872	chr20:62272968	STMN3	-0.49	-4.65	-0.36	7.45e-6	Atopic dermatitis;
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg16381253	chr16:909593	LMF1	-0.45	-4.67	-0.36	6.66e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7246967	0.551	rs56968124	chr19:22814449	T/C	cg08271804	chr19:22816896	ZNF492	0.64	6.53	0.47	1.01e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.58	-0.35	9.68e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.86	9.35	0.61	1.39e-16	Breast cancer;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg03456512	chr7:107531689	DLD	-0.61	-6.69	-0.48	4.35e-10	Breast cancer;
UCEC	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	5.33	0.4	3.68e-7	Aortic root size;
UCEC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.64	6.09	0.45	9.17e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.4	4.86	0.37	3.04e-6	Refractive error;
UCEC	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.76	7.01	0.5	8.13e-11	Selective IgA deficiency;
UCEC	cis	rs876084	0.505	rs6469899	chr8:121102762	C/T	cg06265175	chr8:121136014	COL14A1	0.46	4.88	0.37	2.77e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-13.03	-0.73	2.71e-26	Height;
UCEC	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.5	6.06	0.45	1.09e-8	Coronary artery disease;
UCEC	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg08886695	chr4:3369023	RGS12	-0.6	-5.85	-0.43	3.01e-8	Serum sulfate level;
UCEC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg24375607	chr4:120327624	NA	0.47	4.96	0.38	1.92e-6	Corneal astigmatism;
UCEC	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.56	-5.15	-0.39	8.23e-7	Malaria;
UCEC	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.66	-7.59	-0.53	3.48e-12	Prevalent atrial fibrillation;
UCEC	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.13	11.93	0.7	2.31e-23	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg22166914	chr1:53195759	ZYG11B	0.77	7.8	0.54	1.07e-12	Monocyte count;
UCEC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg14078730	chr11:63896557	MACROD1	0.46	4.51	0.35	1.3e-5	Platelet count;
UCEC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg19805062	chr22:46654627	PKDREJ	-0.44	-4.64	-0.36	7.68e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.55	5.4	0.41	2.68e-7	Pediatric autoimmune diseases;
UCEC	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.55	5.1	0.39	1.01e-6	Response to antineoplastic agents;
UCEC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg11200568	chr7:226540	FAM20C	0.48	4.6	0.35	8.9e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.45	-5.16	-0.39	7.75e-7	Aortic root size;
UCEC	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.57	-4.53	-0.35	1.2e-5	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.46	4.64	0.36	7.72e-6	Coronary artery disease;
UCEC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.71	-6.26	-0.46	4.09e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.73	-5.35	-0.4	3.33e-7	Mean platelet volume;
UCEC	cis	rs77861329	1.000	rs9817653	chr3:52148233	T/G	cg08692210	chr3:52188851	WDR51A	0.86	6.67	0.48	4.91e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7246967	0.551	rs6511367	chr19:22821270	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.673	rs4932784	chr19:22874251	A/C	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	0.97	10.93	0.67	1.01e-20	Corneal structure;
UCEC	trans	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg02900749	chr2:68251473	NA	-0.96	-7.1	-0.51	4.94e-11	Pursuit maintenance gain;
UCEC	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-7.22	-0.51	2.65e-11	Parkinson's disease;
UCEC	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.55	5.08	0.39	1.12e-6	Corneal astigmatism;
UCEC	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg14159672	chr1:205819179	PM20D1	0.44	4.53	0.35	1.22e-5	Parkinson's disease;
UCEC	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.06	-0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.66	6.71	0.48	3.93e-10	Menopause (age at onset);
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07589254	chr7:1705402	NA	-0.54	-4.76	-0.37	4.67e-6	Longevity;Endometriosis;
UCEC	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.61	0.48	6.79e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.05	14.81	0.77	6.15e-31	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs10924970	1.000	rs12095653	chr1:235327138	T/C	cg26050004	chr1:235667680	B3GALNT2	0.43	4.69	0.36	6.17e-6	Asthma;
UCEC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg27624424	chr6:160112604	SOD2	0.56	4.55	0.35	1.1e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.59	-5.3	-0.4	4.18e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.7	5.68	0.42	7.09e-8	Type 2 diabetes;
UCEC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12826209	chr6:26865740	GUSBL1	0.51	4.88	0.37	2.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-6.36	-0.46	2.39e-9	Coffee consumption (cups per day);
UCEC	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.59	5.61	0.42	9.96e-8	Parkinson's disease;
UCEC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.72	-5.93	-0.44	2.06e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.28	0.4	4.61e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg02160872	chr5:212506	CCDC127	-0.8	-8.22	-0.56	9.67e-14	Breast cancer;
UCEC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6893807	0.778	rs13162708	chr5:87943345	C/T	cg09002922	chr5:87956389	LOC645323	-0.58	-5.34	-0.4	3.5e-7	Body mass index;
UCEC	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.61	-6.16	-0.45	6.61e-9	Blood metabolite levels;
UCEC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.49	6.1	0.45	9.05e-9	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	0.47	5.14	0.39	8.59e-7	Longevity;
UCEC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg15848620	chr12:58087721	OS9	-0.51	-4.82	-0.37	3.51e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	7.32	0.52	1.53e-11	Platelet count;
UCEC	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.73	-0.49	3.51e-10	Joint mobility (Beighton score);
UCEC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.57e-13	Chronic sinus infection;
UCEC	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	1.04	7.33	0.52	1.44e-11	Obesity-related traits;
UCEC	cis	rs7113850	0.541	rs11820983	chr11:24211705	T/C	ch.11.24196551F	chr11:24239977	NA	0.66	5.69	0.43	6.53e-8	Bone fracture in osteoporosis;
UCEC	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.69	-6.8	-0.49	2.51e-10	Blood metabolite levels;
UCEC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-4.8	-0.37	3.81e-6	Lymphocyte counts;
UCEC	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	1.03	9.44	0.61	7.96e-17	Dupuytren's disease;
UCEC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.5	-5.39	-0.41	2.8e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.48	5.24	0.4	5.49e-7	Systemic lupus erythematosus;
UCEC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	0.9	4.76	0.37	4.65e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-4.93	-0.38	2.17e-6	Gut microbiome composition (summer);
UCEC	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.64	6.39	0.47	2.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26314531	chr2:26401878	FAM59B	0.66	4.9	0.37	2.49e-6	Gut microbiome composition (summer);
UCEC	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.65	5.9	0.44	2.36e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.68	5.82	0.43	3.55e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg13683864	chr3:40499215	RPL14	-0.65	-6.89	-0.49	1.48e-10	Renal cell carcinoma;
UCEC	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.67	5.35	0.4	3.27e-7	Coronary artery disease;
UCEC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg23324259	chr8:82754387	SNX16	0.6	5.31	0.4	3.92e-7	Diastolic blood pressure;
UCEC	cis	rs8020441	0.891	rs61362797	chr14:51167752	A/T	cg04730355	chr14:51134070	SAV1	0.56	5.22	0.4	5.99e-7	Cognitive performance;
UCEC	cis	rs4345220	0.585	rs6831658	chr4:41642581	T/C	cg15232654	chr4:41643107	LIMCH1	0.43	4.63	0.36	8.1e-6	Migraine with aura;
UCEC	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	6.35	0.46	2.58e-9	Personality dimensions;
UCEC	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.79	-0.43	4.14e-8	Fear of minor pain;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.57	-5.56	-0.42	1.21e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9843304	0.528	rs1317213	chr3:149191150	C/T	cg08667024	chr3:149219783	TM4SF4	0.5	5.62	0.42	9.47e-8	Gallstone disease;
UCEC	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.58	-5.62	-0.42	9.35e-8	Blood protein levels;
UCEC	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.73	-0.49	3.46e-10	HDL cholesterol;
UCEC	cis	rs56341938	0.769	rs9836733	chr3:168704860	T/G	cg21477417	chr3:169490753	MYNN	0.44	4.59	0.35	9.45e-6	Lung function (FEV1/FVC);
UCEC	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.53	-5.26	-0.4	4.9e-7	IgG glycosylation;
UCEC	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.7	-8.28	-0.56	6.85e-14	Monocyte count;
UCEC	cis	rs8032158	0.702	rs35040841	chr15:56124149	A/G	cg10433327	chr15:56209506	NEDD4	-0.32	-4.99	-0.38	1.66e-6	Keloid;
UCEC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.47	-5.38	-0.41	2.9e-7	Lung cancer;
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.51	-5.8	-0.43	3.95e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg19622623	chr12:86230825	RASSF9	-0.38	-4.69	-0.36	6.19e-6	Major depressive disorder;
UCEC	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.58	-5.81	-0.43	3.7e-8	Breast size;
UCEC	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6764050	1.000	rs9851627	chr3:187520398	C/T	cg04952622	chr3:188067331	LPP	0.68	5.11	0.39	9.94e-7	Response to citalopram treatment;
UCEC	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Heart rate;
UCEC	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.01	-0.38	1.57e-6	Huntington's disease progression;
UCEC	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	18.05	0.83	4e-39	Schizophrenia;
UCEC	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg24687543	chr11:63912206	MACROD1	0.47	5.63	0.42	9.03e-8	Platelet count;
UCEC	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	9.18	0.6	3.7e-16	Chronic sinus infection;
UCEC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.5	-5.54	-0.42	1.33e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.66	-7.03	-0.5	7.21e-11	Dental caries;
UCEC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18854424	chr1:2615690	NA	-0.36	-5.18	-0.39	7.19e-7	Ulcerative colitis;
UCEC	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.67	8.07	0.55	2.32e-13	Testicular germ cell tumor;
UCEC	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.07	-11.48	-0.69	3.57e-22	Corneal structure;
UCEC	cis	rs11858159	0.676	rs12916923	chr15:24424270	C/G	cg22159025	chr15:25201020	SNRPN;SNURF	-0.47	-4.7	-0.36	6.06e-6	Platelet thrombus formation;
UCEC	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	0.92	12.81	0.73	1.07e-25	Homoarginine levels;
UCEC	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	5.16	0.39	7.85e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs11048434	0.932	rs12817960	chr12:9153127	C/T	cg04155231	chr12:9217510	LOC144571	0.48	5.54	0.42	1.36e-7	Sjögren's syndrome;
UCEC	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.83	8.69	0.58	6.38e-15	Vitamin D levels;
UCEC	cis	rs11048434	0.932	rs12816518	chr12:9153132	G/A	cg26114124	chr12:9217669	LOC144571	0.45	5.08	0.39	1.14e-6	Sjögren's syndrome;
UCEC	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	7.91	0.55	5.76e-13	Tonsillectomy;
UCEC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.61	5.81	0.43	3.76e-8	Aortic root size;
UCEC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg14456004	chr13:21872349	NA	1.09	10.87	0.67	1.41e-20	White matter hyperintensity burden;
UCEC	cis	rs8177876	0.822	rs9923732	chr16:81110903	A/G	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-7.01	-0.5	8.01e-11	Breast cancer;
UCEC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg19318889	chr4:1322082	MAEA	0.42	5.09	0.39	1.06e-6	Obesity-related traits;
UCEC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	10.2	0.64	8.4e-19	Monocyte count;
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.6	0.42	1.04e-7	Platelet count;
UCEC	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg23950597	chr19:37808831	NA	-0.81	-5.89	-0.44	2.49e-8	Coronary artery calcification;
UCEC	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg26408565	chr15:76604113	ETFA	-0.44	-4.5	-0.35	1.35e-5	Blood metabolite levels;
UCEC	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg03714773	chr7:91764589	CYP51A1	0.39	4.58	0.35	1e-5	Breast cancer;
UCEC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	4.64	0.36	7.7e-6	Tonsillectomy;
UCEC	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg11150807	chr10:43354902	NA	0.78	6.42	0.47	1.78e-9	Blood protein levels;
UCEC	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.59	6.1	0.45	8.73e-9	Immature fraction of reticulocytes;
UCEC	cis	rs4713118	0.568	rs9468213	chr6:27706180	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.48	-4.93	-0.38	2.21e-6	Parkinson's disease;
UCEC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	6.49	0.47	1.21e-9	Bone mineral density;
UCEC	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.29	0.4	4.32e-7	Coronary artery disease;
UCEC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.16	14.9	0.78	3.46e-31	Cognitive function;
UCEC	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-7.06	-0.5	6.18e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.55e-9	Lung cancer;
UCEC	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg26818010	chr10:134567672	INPP5A	-0.61	-6.17	-0.45	6.16e-9	Migraine;
UCEC	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.22	0.4	5.99e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.66	-4.86	-0.37	2.94e-6	Coronary artery disease;
UCEC	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.0	0.38	1.63e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.49	-4.83	-0.37	3.33e-6	Post bronchodilator FEV1;
UCEC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.58	-4.63	-0.36	8.01e-6	Menopause (age at onset);
UCEC	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.57	-5.71	-0.43	6.1e-8	Glomerular filtration rate;
UCEC	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg03342759	chr3:160939853	NMD3	0.53	4.86	0.37	3.04e-6	Morning vs. evening chronotype;
UCEC	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-7.06	-0.5	6.17e-11	Exhaled nitric oxide output;
UCEC	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.69	-6.84	-0.49	1.97e-10	Itch intensity from mosquito bite;
UCEC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg17105886	chr17:28927953	LRRC37B2	0.51	4.52	0.35	1.27e-5	Body mass index;
UCEC	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-4.89	-0.37	2.56e-6	Joint mobility (Beighton score);
UCEC	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.43	-4.72	-0.36	5.48e-6	Mean corpuscular volume;
UCEC	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.42	4.78	0.37	4.18e-6	Height;
UCEC	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg11871910	chr12:69753446	YEATS4	-0.62	-6.64	-0.48	5.78e-10	Blood protein levels;
UCEC	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.58	-0.35	9.68e-6	Pulmonary function;
UCEC	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18932078	chr1:2524107	MMEL1	0.42	6.6	0.48	7.1e-10	Ulcerative colitis;
UCEC	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.53	-4.7	-0.36	5.92e-6	Obesity-related traits;
UCEC	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.8	9.31	0.61	1.75e-16	Schizophrenia;
UCEC	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.7	-7.24	-0.51	2.34e-11	Blood metabolite levels;
UCEC	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.76	8.31	0.57	5.83e-14	Menopause (age at onset);
UCEC	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg23324259	chr8:82754387	SNX16	0.56	4.89	0.37	2.59e-6	Diastolic blood pressure;
UCEC	cis	rs13279522	0.536	rs4262310	chr8:67000607	T/G	cg00269606	chr8:67090928	CRH	0.34	4.54	0.35	1.17e-5	Coronary heart disease event reduction (statin therapy interaction);
UCEC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg00612595	chr21:47717864	NA	-0.49	-5.34	-0.4	3.46e-7	Testicular germ cell tumor;
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.47	4.98	0.38	1.76e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg20387954	chr3:183756860	HTR3D	0.52	6.3	0.46	3.19e-9	Anterior chamber depth;
UCEC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.68	7.7	0.54	1.89e-12	Prostate cancer;
UCEC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg03354898	chr7:1950403	MAD1L1	-0.48	-4.63	-0.36	8.14e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.6	5.76	0.43	4.7e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7307889	1.000	rs73047647	chr12:6011088	A/G	cg10294363	chr12:6480192	SCNN1A	0.61	4.85	0.37	3.09e-6	Obesity-related traits;
UCEC	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.6	-6.45	-0.47	1.54e-9	Glomerular filtration rate;
UCEC	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs11250464	0.794	rs11250487	chr10:1434168	C/A	cg08668359	chr10:1443807	ADARB2	0.53	5.05	0.38	1.3e-6	Radiation response;
UCEC	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.07e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.43	-5.14	-0.39	8.51e-7	Congenital heart disease (maternal effect);
UCEC	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.58	-6.25	-0.46	4.26e-9	IgG glycosylation;
UCEC	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.46	-5.3	-0.4	4.1e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6684428	1.000	rs6684428	chr1:56359813	T/A	cg11651538	chr1:56320950	NA	-0.69	-6.19	-0.45	5.59e-9	Airflow obstruction;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg24703168	chr6:28411309	ZSCAN23	-0.52	-5.78	-0.43	4.25e-8	Pubertal anthropometrics;
UCEC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.61	6.71	0.48	4.01e-10	Cognitive function;
UCEC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.57	5.53	0.41	1.45e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-0.93	-6.4	-0.47	1.93e-9	Mitochondrial DNA levels;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.12	-0.45	8.25e-9	Pubertal anthropometrics;
UCEC	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg10123293	chr2:99228465	UNC50	0.51	5.53	0.41	1.44e-7	Bipolar disorder;
UCEC	cis	rs4654899	0.643	rs589755	chr1:21099846	A/G	cg01072550	chr1:21505969	NA	-0.51	-5.22	-0.4	6e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.62	5.81	0.43	3.81e-8	Vitamin D levels;
UCEC	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs17433710	0.602	rs10737486	chr1:162665075	G/A	cg19264028	chr1:162630153	DDR2	-0.61	-5.3	-0.4	4.13e-7	Dupuytren's disease;
UCEC	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.69e-11	Eye color traits;
UCEC	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg17515076	chr17:73810948	UNK	-0.51	-5.73	-0.43	5.43e-8	White matter hyperintensity burden;
UCEC	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.74	4.88	0.37	2.72e-6	Neuroticism;
UCEC	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.61	7.44	0.52	7.9e-12	Bone mineral density;
UCEC	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg07636037	chr3:49044803	WDR6	0.56	4.53	0.35	1.23e-5	Menarche (age at onset);
UCEC	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.66	-5.54	-0.42	1.37e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6677604	1.000	rs35253683	chr1:196704039	G/A	cg07209298	chr1:196795943	CFHR1	0.43	4.55	0.35	1.14e-5	IgA nephropathy;Nephropathy;Blood protein levels;
UCEC	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.5	-5.37	-0.4	3.02e-7	Platelet count;
UCEC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.72	6.13	0.45	7.7e-9	Lung function (FEV1/FVC);
UCEC	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.46	5.29	0.4	4.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg21770322	chr7:97807741	LMTK2	0.8	12.43	0.72	1.06e-24	Breast cancer;
UCEC	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	7.7	0.54	1.88e-12	Breast cancer;
UCEC	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg03354898	chr7:1950403	MAD1L1	0.6	6.41	0.47	1.9e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	5.06	0.39	1.21e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-5.15	-0.39	8.42e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7937890	0.559	rs6486193	chr11:14437607	C/G	cg24299074	chr11:15133087	INSC	-0.39	-4.77	-0.37	4.48e-6	Mitochondrial DNA levels;
UCEC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18252515	chr7:66147081	NA	0.57	5.54	0.42	1.38e-7	Aortic root size;
UCEC	cis	rs9467773	1.000	rs1001687	chr6:26573218	C/G	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	15.52	0.79	8.84e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.51	-0.57	1.87e-14	Total body bone mineral density;
UCEC	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	4.73	0.36	5.31e-6	Myopia (pathological);
UCEC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18252515	chr7:66147081	NA	0.56	5.14	0.39	8.49e-7	Aortic root size;
UCEC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.74	-7.02	-0.5	7.45e-11	Bone mineral density;
UCEC	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.64	5.97	0.44	1.7e-8	Vitiligo;
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.96	0.44	1.77e-8	Platelet count;
UCEC	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg20630560	chr1:228395858	OBSCN	-0.33	-4.82	-0.37	3.57e-6	Diastolic blood pressure;
UCEC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg20965017	chr5:231967	SDHA	-0.65	-5.95	-0.44	1.9e-8	Breast cancer;
UCEC	cis	rs2041840	0.538	rs4670692	chr2:37573246	G/A	cg25727520	chr2:37576821	QPCT	-0.51	-6.0	-0.44	1.48e-8	Chronic lymphocytic leukemia;
UCEC	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.85	-0.43	3.09e-8	Depression;
UCEC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.55	-4.86	-0.37	2.95e-6	Coronary artery disease;
UCEC	cis	rs782107	0.637	rs1845468	chr12:58767204	A/G	cg19181132	chr12:59314527	LRIG3	-0.46	-4.87	-0.37	2.82e-6	Interleukin-12p70 levels;
UCEC	cis	rs782107	0.614	rs1494519	chr12:58766949	G/C	cg19181132	chr12:59314527	LRIG3	-0.45	-4.84	-0.37	3.2e-6	Interleukin-12p70 levels;
UCEC	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs2224391	0.628	rs2753222	chr6:5242075	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-4.53	-0.35	1.23e-5	Height;
UCEC	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.38	-4.7	-0.36	6.04e-6	Menarche (age at onset);
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg08461772	chr7:95026248	PON3	0.35	4.77	0.37	4.48e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.89	7.72	0.54	1.65e-12	Bladder cancer;
UCEC	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-4.59	-0.35	9.34e-6	Hemoglobin concentration;
UCEC	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs17106184	1.000	rs72900956	chr1:51143665	G/T	cg07174182	chr1:51127561	FAF1	-0.72	-4.6	-0.35	9.22e-6	Type 2 diabetes;
UCEC	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.64	5.59	0.42	1.06e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs6663390	0.510	rs1932818	chr1:208078257	C/T	cg03990033	chr1:208084030	CD34	0.48	4.76	0.37	4.63e-6	Facial morphology (factor 18);
UCEC	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	4.83	0.37	3.4e-6	Educational attainment;
UCEC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.67	0.42	7.31e-8	Cognitive test performance;
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-4.6	-0.35	9.1e-6	Electroencephalogram traits;
UCEC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.84	0.59	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs62027291	0.898	rs17465755	chr15:77307752	G/T	cg26408565	chr15:76604113	ETFA	0.55	4.62	0.36	8.28e-6	Plateletcrit;
UCEC	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.46	6.71	0.48	3.89e-10	Homoarginine levels;
UCEC	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-0.93	-12.33	-0.71	2.02e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.57	-5.16	-0.39	7.98e-7	Platelet count;
UCEC	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.6	4.65	0.36	7.47e-6	Lung cancer;
UCEC	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.71	0.36	5.79e-6	Menopause (age at onset);
UCEC	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg06238570	chr21:40685208	BRWD1	0.63	6.63	0.48	5.85e-10	Cognitive function;
UCEC	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg16497661	chr14:103986332	CKB	0.45	4.65	0.36	7.31e-6	Body mass index;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.34	0.71	1.81e-24	Platelet count;
UCEC	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg13683864	chr3:40499215	RPL14	-0.69	-6.66	-0.48	5.01e-10	Renal cell carcinoma;
UCEC	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.64	7.08	0.5	5.52e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.67	5.9	0.44	2.44e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg06238570	chr21:40685208	BRWD1	0.78	7.71	0.54	1.73e-12	Cognitive function;
UCEC	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.55	5.57	0.42	1.2e-7	Orofacial clefts;
UCEC	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.75e-9	Blood metabolite levels;
UCEC	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs2806864	1.000	rs2250096	chr1:117468983	C/T	cg19765820	chr1:116518738	SLC22A15	-0.6	-4.52	-0.35	1.25e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs8099014	0.861	rs6566969	chr18:56118999	A/G	cg19165390	chr18:56932082	NA	0.37	4.76	0.37	4.63e-6	Platelet count;
UCEC	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	0.82	6.26	0.46	4.07e-9	Red blood cell traits;
UCEC	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.64	6.03	0.45	1.28e-8	Corneal astigmatism;
UCEC	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.78	7.48	0.52	6.39e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg20387954	chr3:183756860	HTR3D	0.42	5.03	0.38	1.4e-6	Anterior chamber depth;
UCEC	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg09132178	chr16:78079569	NA	-0.48	-5.11	-0.39	9.69e-7	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.38	-4.65	-0.36	7.31e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.21e-5	Parkinson's disease;
UCEC	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-5.03	-0.38	1.39e-6	Height;
UCEC	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.54	-6.18	-0.45	5.86e-9	Type 2 diabetes;
UCEC	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.53	5.84	0.43	3.3e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.43	-4.53	-0.35	1.22e-5	Resting heart rate;
UCEC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.96	-0.44	1.78e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg05963712	chr12:49373746	WNT1	0.46	4.56	0.35	1.06e-5	Longevity (90 years and older);
UCEC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg03146154	chr1:46216737	IPP	-0.46	-4.95	-0.38	1.97e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg07776626	chr8:57350775	NA	-0.47	-5.33	-0.4	3.61e-7	Obesity-related traits;
UCEC	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.45	-4.66	-0.36	6.99e-6	Pancreatic cancer;
UCEC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.66	6.24	0.46	4.51e-9	Aortic root size;
UCEC	cis	rs7246967	0.673	rs4932782	chr19:22812801	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.76	5.15	0.39	8.33e-7	Gut microbiome composition (summer);
UCEC	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.59	-7.67	-0.53	2.22e-12	Coronary artery disease or large artery stroke;
UCEC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.56	-5.16	-0.39	7.74e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs6761276	0.899	rs11678375	chr2:113835691	T/C	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.53	5.29	0.4	4.35e-7	Neutrophil percentage of white cells;
UCEC	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.59	6.36	0.46	2.35e-9	Platelet count;
UCEC	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.45	-4.85	-0.37	3.16e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.34	-0.52	1.36e-11	Parkinson's disease;
UCEC	cis	rs60311166	1.000	rs6780005	chr3:52636615	C/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.83	4.64	0.36	7.71e-6	CTACK levels;
UCEC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.56	0.48	8.79e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.7	-7.41	-0.52	9.23e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg12024160	chr4:1254474	NA	0.53	6.96	0.5	1.02e-10	Obesity-related traits;
UCEC	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg10978503	chr1:24200527	CNR2	0.37	5.01	0.38	1.56e-6	Immature fraction of reticulocytes;
UCEC	cis	rs7246967	0.736	rs411131	chr19:22993439	G/A	cg08271804	chr19:22816896	ZNF492	0.59	5.21	0.4	6.16e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg03078520	chr22:18463400	MICAL3	-0.49	-4.93	-0.38	2.17e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.65	6.57	0.48	8.08e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-0.85	-7.48	-0.52	6.31e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Subjective well-being;
UCEC	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	0.74	7.44	0.52	7.75e-12	Parkinson's disease;
UCEC	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.54	-5.06	-0.38	1.26e-6	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.69	-6.78	-0.49	2.72e-10	Prudent dietary pattern;
UCEC	cis	rs77106637	1.000	rs77106637	chr11:72478320	G/A	cg03713592	chr11:72463424	ARAP1	1.06	5.84	0.43	3.26e-8	Type 2 diabetes;
UCEC	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.83	7.78	0.54	1.17e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.55	-6.03	-0.45	1.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.63	7.04	0.5	6.95e-11	Longevity;
UCEC	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg12463550	chr7:65579703	CRCP	-0.53	-5.42	-0.41	2.39e-7	Aortic root size;
UCEC	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-4.67	-0.36	6.79e-6	Life satisfaction;
UCEC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.43	4.9	0.37	2.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.71	-9.28	-0.61	2.06e-16	Oral cavity cancer;
UCEC	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.5	5.84	0.43	3.29e-8	Longevity;
UCEC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg11569703	chr11:65557185	OVOL1	0.48	5.87	0.44	2.79e-8	Acne (severe);
UCEC	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.57	4.81	0.37	3.75e-6	Neutrophil percentage of white cells;
UCEC	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.61	-6.1	-0.45	8.88e-9	Itch intensity from mosquito bite;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23099347	chr16:29827497	C16orf53	0.68	7.65	0.53	2.42e-12	Warfarin maintenance dose;
UCEC	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-6.36	-0.46	2.39e-9	Response to antipsychotic treatment;
UCEC	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg11632617	chr15:75315747	PPCDC	-0.58	-5.19	-0.39	6.93e-7	Lung cancer;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.46	-4.76	-0.37	4.64e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.8	8.67	0.58	7.13e-15	Menopause (age at onset);
UCEC	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.16	0.45	6.75e-9	Motion sickness;
UCEC	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.64	5.77	0.43	4.54e-8	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.02	-0.38	1.5e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.83	8.9	0.59	1.87e-15	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.62	-7.93	-0.55	5e-13	Fibrinogen levels;
UCEC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26207909	chr14:103986467	CKB	0.53	5.77	0.43	4.59e-8	Body mass index;
UCEC	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.45	5.18	0.39	7.11e-7	Blood metabolite ratios;
UCEC	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.77	-8.77	-0.59	3.98e-15	Coronary artery disease;
UCEC	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.61	-7.05	-0.5	6.44e-11	Prostate cancer;
UCEC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg24826892	chr11:71159390	DHCR7	0.52	5.06	0.39	1.22e-6	Vitamin D levels;
UCEC	cis	rs829661	0.947	rs4952147	chr2:30776270	G/A	cg17749961	chr2:30669863	LCLAT1	0.52	4.88	0.37	2.68e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg12751644	chr20:60527061	NA	-0.36	-4.71	-0.36	5.65e-6	Body mass index;
UCEC	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.56e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.75	8.16	0.56	1.35e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.85	-0.43	3.09e-8	Parkinson's disease;
UCEC	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg06637938	chr14:75390232	RPS6KL1	0.52	4.83	0.37	3.34e-6	Height;
UCEC	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.66	7.33	0.52	1.43e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.72	6.82	0.49	2.26e-10	Aortic root size;
UCEC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-0.94	-6.98	-0.5	9.53e-11	Body mass index;
UCEC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	4.54	0.35	1.16e-5	Obesity-related traits;
UCEC	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.53	6.06	0.45	1.08e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg24851651	chr11:66362959	CCS	0.46	5.47	0.41	1.92e-7	Educational attainment (years of education);
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs7246967	0.736	rs446058	chr19:23000061	G/A	cg24889512	chr19:22816950	ZNF492	0.57	5.61	0.42	9.94e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg24060327	chr5:131705240	SLC22A5	0.5	4.74	0.36	4.96e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-5.13	-0.39	8.84e-7	Bladder cancer;
UCEC	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.5	-5.07	-0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs7560272	0.588	rs4852965	chr2:73911169	T/C	cg20560298	chr2:73613845	ALMS1	0.51	4.79	0.37	4.02e-6	Schizophrenia;
UCEC	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.6	-6.51	-0.47	1.14e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs8177876	0.822	rs76948085	chr16:81112804	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.66	6.32	0.46	2.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-6.41	-0.47	1.88e-9	Hemoglobin concentration;
UCEC	cis	rs8105895	0.932	rs60548522	chr19:22214874	G/A	cg24175803	chr19:22235144	ZNF257	-0.5	-4.61	-0.36	8.81e-6	Body mass index (change over time);
UCEC	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.95	-6.78	-0.49	2.74e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.69	0.36	6.22e-6	Tonsillectomy;
UCEC	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.4	-5.32	-0.4	3.81e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs240764	0.567	rs12528607	chr6:101260131	A/G	cg09795085	chr6:101329169	ASCC3	0.52	4.84	0.37	3.3e-6	Neuroticism;
UCEC	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.53	5.59	0.42	1.07e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.13	-0.39	9.18e-7	Body mass index;
UCEC	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8105895	0.935	rs62112920	chr19:22227149	A/G	cg24175803	chr19:22235144	ZNF257	-0.64	-5.51	-0.41	1.59e-7	Body mass index (change over time);
UCEC	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg03354898	chr7:1950403	MAD1L1	-0.73	-8.22	-0.56	9.77e-14	Bipolar disorder and schizophrenia;
UCEC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg05855489	chr10:104503620	C10orf26	0.7	8.1	0.56	1.94e-13	Waist circumference;Hip circumference;
UCEC	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg21253087	chr9:139290292	SNAPC4	0.39	4.57	0.35	1.05e-5	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs539096	0.830	rs2842176	chr1:44022534	C/T	cg11851915	chr1:44060116	PTPRF	-0.43	-4.51	-0.35	1.33e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.66	6.15	0.45	6.86e-9	Aortic root size;
UCEC	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.68	-5.95	-0.44	1.92e-8	Prudent dietary pattern;
UCEC	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	5.4	0.41	2.66e-7	Coronary artery disease;
UCEC	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.8	5.17	0.39	7.51e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.46	-5.95	-0.44	1.87e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs17135859	0.817	rs6889348	chr5:112965145	A/G	cg15956794	chr5:112312232	DCP2	-0.54	-4.61	-0.36	8.54e-6	F-cell distribution;
UCEC	cis	rs8049040	0.564	rs310335	chr16:71573918	T/A	cg08717414	chr16:71523259	ZNF19	-0.59	-5.79	-0.43	4.06e-8	Blood protein levels;
UCEC	cis	rs7582720	1.000	rs72932746	chr2:203663498	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.7	0.36	5.88e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	0.97	9.3	0.61	1.78e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.7	6.15	0.45	7.1e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7968440	0.808	rs1659387	chr12:51205067	A/T	cg00552387	chr12:51477546	CSRNP2	0.58	4.75	0.36	4.72e-6	Fibrinogen;
UCEC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.01	-6.53	-0.47	1.02e-9	Diabetic kidney disease;
UCEC	cis	rs4234798	0.585	rs13121616	chr4:7212389	A/G	cg18431297	chr4:7219810	SORCS2	0.41	4.76	0.37	4.62e-6	Insulin-like growth factors;
UCEC	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.58	0.35	9.64e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.47	-5.46	-0.41	2e-7	Longevity;Endometriosis;
UCEC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg03859395	chr2:55845619	SMEK2	-1.01	-13.4	-0.74	2.93e-27	Metabolic syndrome;
UCEC	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.38e-16	Breast cancer;
UCEC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	8.5	0.57	2e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.82	7.79	0.54	1.11e-12	Initial pursuit acceleration;
UCEC	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg24069376	chr3:38537580	EXOG	0.38	4.73	0.36	5.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.61	-5.18	-0.39	7.24e-7	Obesity-related traits;
UCEC	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.73	-7.28	-0.51	1.84e-11	Plateletcrit;Platelet count;
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.67	-7.21	-0.51	2.67e-11	Prudent dietary pattern;
UCEC	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10276303	0.929	rs4236325	chr7:3374848	A/C	cg25507518	chr7:2405875	EIF3B	-0.47	-5.1	-0.39	1.02e-6	Dupuytren's disease;
UCEC	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.87	10.07	0.64	1.85e-18	Height;
UCEC	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-1.03	-6.85	-0.49	1.84e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.59	-6.42	-0.47	1.79e-9	Retinal vascular caliber;
UCEC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.87	9.52	0.62	4.93e-17	Psoriasis;
UCEC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.65	6.33	0.46	2.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7870753	1.000	rs10820633	chr9:99214796	G/A	cg25260653	chr9:99212216	HABP4	0.49	4.75	0.36	4.89e-6	Height;
UCEC	cis	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg18451256	chr2:128284158	IWS1	-0.51	-4.56	-0.35	1.08e-5	Protein C levels;
UCEC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg14067834	chr17:29058358	SUZ12P	0.61	4.76	0.37	4.6e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.92	0.5	1.28e-10	Chronic sinus infection;
UCEC	cis	rs7095944	0.552	rs12764568	chr10:126544646	A/T	cg08799069	chr10:126477246	METTL10	-0.53	-5.46	-0.41	1.97e-7	Asthma;
UCEC	cis	rs13098911	0.540	rs71325100	chr3:46013832	C/T	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.62	6.19	0.45	5.67e-9	Vitamin D levels;
UCEC	cis	rs17433710	0.500	rs7415775	chr1:162626791	C/G	cg19264028	chr1:162630153	DDR2	-0.89	-6.22	-0.46	4.93e-9	Dupuytren's disease;
UCEC	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.0	-11.3	-0.68	1.05e-21	Exhaled nitric oxide output;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg09682330	chr6:28411287	ZSCAN23	-0.47	-4.99	-0.38	1.65e-6	Cardiac Troponin-T levels;
UCEC	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-6.02	-0.44	1.33e-8	Dental caries;
UCEC	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.63	6.96	0.5	1.03e-10	Tonsillectomy;
UCEC	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.73	7.06	0.5	6.11e-11	Schizophrenia;
UCEC	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.59	4.59	0.35	9.34e-6	Obesity-related traits;
UCEC	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.83	9.11	0.6	5.65e-16	Itch intensity from mosquito bite;
UCEC	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg04311557	chr16:71523289	ZNF19	-0.67	-5.61	-0.42	9.64e-8	Post bronchodilator FEV1;
UCEC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.6	5.59	0.42	1.07e-7	Type 2 diabetes;
UCEC	cis	rs8105895	1.000	rs1849004	chr19:22142455	A/C	cg20662725	chr19:22235022	ZNF257	-0.66	-5.5	-0.41	1.61e-7	Body mass index (change over time);
UCEC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg06027949	chr8:82754900	SNX16	0.62	5.78	0.43	4.41e-8	Diastolic blood pressure;
UCEC	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.52	-0.41	1.49e-7	Neutrophil percentage of white cells;
UCEC	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.56	4.71	0.36	5.78e-6	Obesity-related traits;
UCEC	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.93	12.01	0.7	1.39e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.69	0.48	4.3e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg17294928	chr15:75287854	SCAMP5	0.51	5.68	0.42	6.99e-8	Breast cancer;
UCEC	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-5.07	-0.39	1.17e-6	Morning vs. evening chronotype;
UCEC	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg08316699	chr6:150357289	NA	0.29	4.53	0.35	1.19e-5	Alopecia areata;
UCEC	cis	rs12980942	1.000	rs2241719	chr19:41829581	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.75	5.88	0.44	2.68e-8	Coronary artery disease;
UCEC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.88	0.44	2.61e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.72	8.54	0.58	1.52e-14	Prudent dietary pattern;
UCEC	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.58	5.5	0.41	1.66e-7	Vitamin D levels;
UCEC	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.59	4.72	0.36	5.41e-6	Resting heart rate;
UCEC	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.72	5.5	0.41	1.68e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.68	7.46	0.52	7.07e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg23320987	chr13:114192810	TMCO3	0.56	4.55	0.35	1.1e-5	Facial morphology (factor 14, intercanthal width);
UCEC	cis	rs3914502	0.615	rs1515620	chr3:174527494	A/G	cg21145449	chr3:174580620	NAALADL2	0.46	5.15	0.39	8.15e-7	Autism spectrum disorder;
UCEC	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.61	0.42	9.67e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.62	7.59	0.53	3.43e-12	Mean platelet volume;
UCEC	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.53	-0.41	1.43e-7	Hemoglobin concentration;
UCEC	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.65	-6.5	-0.47	1.2e-9	Acne (severe);
UCEC	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.71	-7.08	-0.5	5.47e-11	Diastolic blood pressure;
UCEC	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg21681030	chr2:46777652	RHOQ	0.58	4.63	0.36	7.84e-6	Height;
UCEC	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	4.94	0.38	2.08e-6	Homocysteine levels;
UCEC	cis	rs829883	0.646	rs249836	chr12:98878342	T/C	cg25150519	chr12:98850993	NA	0.62	5.51	0.41	1.59e-7	Colorectal adenoma (advanced);
UCEC	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.74	-8.51	-0.57	1.88e-14	Facial morphology (factor 19);
UCEC	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.73	8.25	0.56	8.24e-14	Lymphocyte counts;
UCEC	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.02	-8.46	-0.57	2.5e-14	Exhaled nitric oxide output;
UCEC	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.51	-5.09	-0.39	1.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	0.48	5.03	0.38	1.44e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.58	-5.56	-0.42	1.26e-7	Migraine;Coronary artery disease;
UCEC	cis	rs159572	0.651	rs42919	chr5:55502645	A/G	cg04607372	chr5:54523900	NA	0.32	5.1	0.39	1.03e-6	Post-traumatic stress disorder;
UCEC	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg14817848	chr12:12715558	DUSP16	0.51	5.34	0.4	3.42e-7	Coronary artery calcification;
UCEC	cis	rs4372836	0.729	rs4611608	chr2:29064536	A/G	cg09522027	chr2:28974177	PPP1CB	0.7	7.91	0.55	5.59e-13	Body mass index;
UCEC	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.53	5.18	0.39	7.1e-7	Immature fraction of reticulocytes;
UCEC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg20965017	chr5:231967	SDHA	-0.6	-5.15	-0.39	8.34e-7	Breast cancer;
UCEC	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.85	-0.43	3.14e-8	Response to antipsychotic treatment;
UCEC	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.59	6.54	0.47	9.58e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3743832	0.897	rs8049976	chr16:9182268	T/C	cg08831531	chr16:9218945	NA	-0.43	-4.53	-0.35	1.19e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.4	4.86	0.37	3.04e-6	Refractive error;
UCEC	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.57	-5.69	-0.42	6.76e-8	White matter hyperintensity burden;
UCEC	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26002218	chr14:103986227	CKB	0.37	5.2	0.39	6.49e-7	Body mass index;
UCEC	cis	rs884366	1.000	rs1006081	chr6:109625550	C/T	cg01475377	chr6:109611718	NA	-0.47	-5.27	-0.4	4.7e-7	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg02820040	chr2:241836501	C2orf54	-0.39	-4.76	-0.37	4.6e-6	Urinary metabolites;
UCEC	cis	rs4713118	0.615	rs9295747	chr6:27736993	G/T	cg07836142	chr6:28411423	ZSCAN23	0.48	4.93	0.38	2.22e-6	Parkinson's disease;
UCEC	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.55	6.12	0.45	8.08e-9	Height;
UCEC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.67	6.07	0.45	1.05e-8	Aortic root size;
UCEC	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.61	-5.16	-0.39	7.89e-7	LDL cholesterol levels;
UCEC	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.63	-5.64	-0.42	8.46e-8	Pulmonary function;
UCEC	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.7	-6.94	-0.5	1.18e-10	Tonsillectomy;
UCEC	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	6.86	0.49	1.78e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.65	6.74	0.49	3.28e-10	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.43	5.1	0.39	1.01e-6	Tonsillectomy;
UCEC	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16346588	chr10:242978	ZMYND11	0.47	4.5	0.35	1.35e-5	Psychosis in Alzheimer's disease;
UCEC	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.44	6.82	0.49	2.23e-10	Primary biliary cholangitis;
UCEC	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.54	-4.63	-0.36	7.86e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11077815	0.708	rs4789296	chr17:74440550	C/T	cg06840243	chr17:74442338	UBE2O	-0.39	-5.24	-0.4	5.46e-7	Lymphocyte counts;
UCEC	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg22974920	chr21:40686053	BRWD1	-0.59	-5.14	-0.39	8.51e-7	Cognitive function;
UCEC	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg05090351	chr10:126851162	NA	0.43	4.97	0.38	1.82e-6	Menarche (age at onset);
UCEC	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg16616514	chr4:6324629	PPP2R2C	0.4	4.86	0.37	3.01e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.45	-0.41	2.04e-7	Bipolar disorder;
UCEC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.48	4.61	0.36	8.55e-6	Menopause (age at onset);
UCEC	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.51	-0.35	1.31e-5	Alzheimer's disease (late onset);
UCEC	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg12586109	chr17:80790369	TBCD;ZNF750	-0.43	-4.68	-0.36	6.32e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.59	8.69	0.58	6.69e-15	Prudent dietary pattern;
UCEC	cis	rs172166	0.538	rs1150686	chr6:28161271	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.13	-0.45	7.86e-9	Cardiac Troponin-T levels;
UCEC	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-0.61	-6.82	-0.49	2.25e-10	Gut microbiome composition (winter);
UCEC	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.67	9.02	0.6	9.25e-16	Systolic blood pressure;
UCEC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.85	-10.51	-0.66	1.32e-19	Height;
UCEC	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.52	0.53	5.05e-12	Total body bone mineral density;
UCEC	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.45	4.81	0.37	3.65e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.35	-4.51	-0.35	1.3e-5	Monocyte percentage of white cells;
UCEC	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg05660106	chr1:15850417	CASP9	-0.96	-9.02	-0.6	9.21e-16	Systolic blood pressure;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.9e-9	Prudent dietary pattern;
UCEC	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-0.97	-6.31	-0.46	3.06e-9	Diabetic kidney disease;
UCEC	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg03342759	chr3:160939853	NMD3	0.54	4.88	0.37	2.75e-6	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.7	-0.36	5.85e-6	Breast cancer;
UCEC	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.51	5.62	0.42	9.48e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.7	6.13	0.45	7.83e-9	Mitochondrial DNA levels;
UCEC	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.55	7.95	0.55	4.63e-13	Total body bone mineral density;
UCEC	cis	rs7968440	0.808	rs1613835	chr12:51205066	C/T	cg01096478	chr12:50898751	DIP2B	0.55	4.62	0.36	8.35e-6	Fibrinogen;
UCEC	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.75	-8.71	-0.58	5.63e-15	Extraversion;
UCEC	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.34	4.66	0.36	7.14e-6	Eye color traits;
UCEC	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.51	-5.38	-0.41	2.82e-7	Autism;
UCEC	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.38	5.62	0.42	9.1e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.84	-9.77	-0.63	1.13e-17	Tonsillectomy;
UCEC	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.69	7.22	0.51	2.54e-11	Longevity;Endometriosis;
UCEC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg04154034	chr17:28927549	LRRC37B2	0.78	4.89	0.37	2.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.47	4.92	0.38	2.29e-6	Pulse pressure;
UCEC	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg14582100	chr15:45693742	SPATA5L1	0.45	6.18	0.45	6.14e-9	Homoarginine levels;
UCEC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.67	-5.98	-0.44	1.66e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg03661428	chr13:111589040	NA	0.86	4.95	0.38	2.04e-6	Obesity-related traits;
UCEC	cis	rs17123764	0.818	rs11169082	chr12:49985408	G/A	cg20471783	chr12:50157085	TMBIM6	0.65	5.34	0.4	3.53e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg04310649	chr10:35416472	CREM	-0.51	-4.83	-0.37	3.35e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg00316803	chr15:76480434	C15orf27	-0.46	-5.24	-0.4	5.53e-7	Blood metabolite levels;
UCEC	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-0.91	-7.72	-0.54	1.61e-12	Blood protein levels;
UCEC	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.64	7.31	0.52	1.61e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.39	-8.83	-0.59	2.95e-15	Gout;
UCEC	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-1.01	-12.31	-0.71	2.24e-24	Obesity-related traits;
UCEC	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.57	6.75	0.49	3.21e-10	Prevalent atrial fibrillation;
UCEC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg17105886	chr17:28927953	LRRC37B2	0.54	5.09	0.39	1.1e-6	Body mass index;
UCEC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.37	5.5	0.41	1.64e-7	Vitiligo;
UCEC	cis	rs117623576	0.941	rs211424	chr10:32398895	A/G	cg03047570	chr10:32398778	NA	0.54	5.0	0.38	1.64e-6	Anti-saccade response;
UCEC	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.64	4.93	0.38	2.18e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.55	5.2	0.39	6.63e-7	Aortic root size;
UCEC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg22974920	chr21:40686053	BRWD1	-0.51	-4.61	-0.36	8.71e-6	Cognitive function;
UCEC	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.26	-0.4	4.91e-7	Joint mobility (Beighton score);
UCEC	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.43	4.71	0.36	5.73e-6	Pulse pressure;
UCEC	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg19318889	chr4:1322082	MAEA	0.4	4.93	0.38	2.21e-6	Obesity-related traits;
UCEC	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.18	-0.45	5.89e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.48	-4.81	-0.37	3.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.82	8.73	0.58	5.22e-15	Blood protein levels;
UCEC	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg07076509	chr9:96720819	NA	0.44	5.09	0.39	1.06e-6	Esophageal adenocarcinoma;
UCEC	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.49	-5.02	-0.38	1.46e-6	Asthma;
UCEC	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.62	7.93	0.55	5.04e-13	Anterior chamber depth;
UCEC	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.43	-6.27	-0.46	3.84e-9	Rheumatoid arthritis;
UCEC	trans	rs11169552	0.510	rs10876043	chr12:50904144	C/T	cg18451256	chr2:128284158	IWS1	-0.7	-7.5	-0.53	5.52e-12	Colorectal cancer;
UCEC	cis	rs9470794	0.790	rs9462399	chr6:38141322	G/T	cg01504030	chr6:38141879	BTBD9	0.81	5.32	0.4	3.86e-7	Type 2 diabetes;
UCEC	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.78	11.41	0.69	5.33e-22	Leprosy;
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.52	-0.41	1.53e-7	Platelet count;
UCEC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.39	4.58	0.35	9.75e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.59	-6.94	-0.5	1.18e-10	Prevalent atrial fibrillation;
UCEC	cis	rs13253111	0.624	rs13277389	chr8:28100234	G/T	cg26534493	chr8:28060551	NA	0.49	5.29	0.4	4.28e-7	Childhood body mass index;
UCEC	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg24375607	chr4:120327624	NA	0.51	5.27	0.4	4.72e-7	Corneal astigmatism;
UCEC	cis	rs12644436	0.794	rs17013343	chr4:88779331	G/A	cg27179352	chr4:88029472	AFF1	0.41	4.56	0.35	1.08e-5	HIV-1 viral setpoint;
UCEC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.26	-0.51	2.12e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.63	-6.31	-0.46	3.14e-9	Blood metabolite levels;
UCEC	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg25258258	chr7:157415380	PTPRN2	0.45	4.84	0.37	3.3e-6	Colorectal cancer;
UCEC	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs7709377	0.595	rs11952043	chr5:115445009	A/G	cg23108291	chr5:115420582	COMMD10	0.5	5.16	0.39	7.99e-7	Metabolite levels  (X-11787);
UCEC	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg23795048	chr12:9217529	LOC144571	0.42	5.01	0.38	1.55e-6	Sjögren's syndrome;
UCEC	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.6	5.96	0.44	1.76e-8	Monocyte percentage of white cells;
UCEC	cis	rs2398893	0.774	rs35271736	chr9:96888786	A/G	cg07076509	chr9:96720819	NA	0.49	4.91	0.38	2.44e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.42	-6.03	-0.45	1.29e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs3812049	0.532	rs251389	chr5:127541877	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	5.48	0.41	1.78e-7	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.67	7.45	0.52	7.38e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.52	4.9	0.37	2.54e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.63	7.52	0.53	4.98e-12	Obesity-related traits;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7937612	0.931	rs61898351	chr11:120199924	T/C	cg12584626	chr11:120203529	NA	0.47	4.81	0.37	3.63e-6	Intraocular pressure;
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	6.45	0.47	1.51e-9	Platelet count;
UCEC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.89	8.46	0.57	2.49e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.59	5.15	0.39	8.06e-7	Migraine;
UCEC	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.68	5.82	0.43	3.64e-8	Coronary artery disease;
UCEC	cis	rs1355223	0.867	rs3818514	chr11:34680053	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-5.42	-0.41	2.43e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs7937612	1.000	rs10892576	chr11:120294423	C/T	cg12584626	chr11:120203529	NA	0.54	5.3	0.4	4.12e-7	Intraocular pressure;
UCEC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	5.08	0.39	1.13e-6	Obesity-related traits;
UCEC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.59	6.86	0.49	1.82e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs55665837	0.539	rs10832311	chr11:14881926	T/G	cg19336497	chr11:14380999	RRAS2	-0.31	-4.53	-0.35	1.22e-5	Vitamin D levels;
UCEC	cis	rs10007810	0.760	rs7692048	chr4:41584929	C/T	cg24722073	chr4:41882163	NA	-0.39	-4.64	-0.36	7.74e-6	Longevity (90 years and older);
UCEC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.65	-6.4	-0.47	1.98e-9	Diastolic blood pressure;
UCEC	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg18681998	chr4:17616180	MED28	0.47	5.42	0.41	2.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg13683864	chr3:40499215	RPL14	0.71	8.02	0.55	3.01e-13	Renal cell carcinoma;
UCEC	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-5.37	-0.41	2.96e-7	Total cholesterol levels;
UCEC	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.54	5.07	0.39	1.18e-6	Coronary artery disease;
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	8.63	0.58	9.3e-15	Platelet count;
UCEC	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.35	-0.4	3.33e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg08459430	chr5:81571289	RPS23	0.46	4.51	0.35	1.33e-5	Breast cancer;
UCEC	cis	rs7781557	0.638	rs55781834	chr7:102572433	A/C	cg06322601	chr7:102330635	NA	0.57	4.61	0.36	8.69e-6	Colorectal adenoma (advanced);
UCEC	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.71e-16	Vitiligo;
UCEC	cis	rs9486594	0.597	rs2500575	chr6:107654373	C/T	cg16950012	chr6:106773140	ATG5	0.51	4.67	0.36	6.75e-6	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.49	5.56	0.42	1.21e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.07	17.07	0.82	1.04e-36	Testicular germ cell tumor;
UCEC	cis	rs10864302	0.747	rs7524314	chr1:7449971	A/G	cg22507406	chr1:7867939	PER3	-0.62	-5.17	-0.39	7.42e-7	Photic sneeze reflex;
UCEC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.67	6.44	0.47	1.61e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs8005745	0.522	rs3783752	chr14:62185692	A/G	cg01748970	chr14:62088363	NA	-0.58	-4.66	-0.36	6.9e-6	Select biomarker traits;
UCEC	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.62	-5.33	-0.4	3.6e-7	Lung cancer;
UCEC	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.61	-6.0	-0.44	1.48e-8	Bipolar disorder;
UCEC	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.85	7.03	0.5	7.37e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.46	-4.57	-0.35	1.01e-5	Pubertal anthropometrics;
UCEC	cis	rs10949834	0.793	rs810532	chr7:73505188	A/G	cg07137043	chr7:73588983	EIF4H	-0.66	-4.6	-0.35	8.95e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.68	0.58	6.96e-15	Platelet count;
UCEC	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-4.78	-0.37	4.25e-6	Menarche (age at onset);
UCEC	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.56	5.07	0.39	1.2e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs2172802	0.570	rs6820960	chr4:62518033	A/T	cg04118610	chr4:62707027	LPHN3	-0.42	-4.63	-0.36	8.02e-6	Partial epilepsies;
UCEC	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.19	0.45	5.63e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	3.14e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.57	-4.8	-0.37	3.89e-6	Systemic lupus erythematosus;
UCEC	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.54	-5.55	-0.42	1.32e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.55	5.12	0.39	9.59e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	5.82	0.43	3.48e-8	Rheumatoid arthritis;
UCEC	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg02820040	chr2:241836501	C2orf54	-0.41	-5.07	-0.39	1.18e-6	Urinary metabolites;
UCEC	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.53	5.65	0.42	7.92e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs3015497	0.616	rs11157759	chr14:51087263	A/G	cg04730355	chr14:51134070	SAV1	-0.48	-4.75	-0.36	4.8e-6	Mean platelet volume;
UCEC	cis	rs10256972	0.810	rs10257195	chr7:1032554	T/C	cg07308232	chr7:1071921	C7orf50	-0.45	-4.5	-0.35	1.34e-5	Longevity;Endometriosis;
UCEC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.46	4.54	0.35	1.16e-5	Aortic root size;
UCEC	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.47	5.22	0.4	5.93e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	0.77	4.76	0.37	4.57e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	7.8	0.54	1.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs16957091	0.647	rs7176957	chr15:43336802	C/T	cg15904908	chr15:43213022	TTBK2	0.49	4.77	0.37	4.33e-6	MGMT methylation in smokers;
UCEC	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.98	11.89	0.7	2.94e-23	Colorectal adenoma (advanced);
UCEC	cis	rs4523957	0.690	rs7213715	chr17:2093511	A/T	cg16513277	chr17:2031491	SMG6	-0.58	-6.24	-0.46	4.49e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7088591	0.867	rs11814091	chr10:59788937	T/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	7.28	0.51	1.89e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.76	-8.77	-0.59	3.99e-15	Extraversion;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.51	0.53	5.22e-12	Platelet count;
UCEC	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4345220	0.585	rs28459824	chr4:41643508	A/G	cg15232654	chr4:41643107	LIMCH1	0.46	5.0	0.38	1.64e-6	Migraine with aura;
UCEC	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.61	-5.53	-0.42	1.41e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.42	4.65	0.36	7.21e-6	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	trans	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg15509575	chr4:2286509	ZFYVE28	0.39	6.78	0.49	2.72e-10	Rheumatoid arthritis;
UCEC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.73	-4.82	-0.37	3.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.11	-0.39	9.84e-7	Response to antipsychotic treatment;
UCEC	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	0.81	4.94	0.38	2.05e-6	Diabetic retinopathy;
UCEC	cis	rs7246967	0.673	rs2885221	chr19:22839387	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.46	0.47	1.46e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg18478394	chr8:109455254	TTC35	0.5	5.14	0.39	8.47e-7	Dupuytren's disease;
UCEC	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg11569703	chr11:65557185	OVOL1	-0.42	-6.08	-0.45	9.66e-9	Acne (severe);
UCEC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14008862	chr17:28927542	LRRC37B2	0.56	5.44	0.41	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.5	0.41	1.63e-7	Tonsillectomy;
UCEC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.56	0.42	1.22e-7	Breast cancer;
UCEC	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.32	-4.76	-0.37	4.5e-6	Schizophrenia;
UCEC	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.04	0.45	1.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.66	5.91	0.44	2.26e-8	Corneal astigmatism;
UCEC	cis	rs4265793	0.655	rs7193124	chr16:19098371	C/T	cg06773604	chr16:18995157	TMC7	0.76	5.19	0.39	6.72e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.61	4.77	0.37	4.46e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.15	-0.64	1.12e-18	Hemostatic factors and hematological phenotypes;
UCEC	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-1.07	-9.49	-0.62	5.71e-17	Blood pressure (smoking interaction);
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	8.11	0.56	1.81e-13	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg09521647	chr2:100722408	AFF3	-0.32	-4.86	-0.37	3.03e-6	Chronic sinus infection;
UCEC	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.33	0.4	3.68e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17672112	0.607	rs705588	chr6:101275792	A/C	cg17769771	chr6:100952856	NA	0.41	4.6	0.35	9.15e-6	Putamen volume;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg27502791	chr1:65886279	LEPR;LEPROT	0.68	6.86	0.49	1.79e-10	Schizophrenia;
UCEC	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.58	-5.78	-0.43	4.29e-8	Bipolar disorder;
UCEC	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.46	6.34	0.46	2.62e-9	Thyroid hormone levels;
UCEC	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg24375607	chr4:120327624	NA	0.52	5.41	0.41	2.54e-7	Corneal astigmatism;
UCEC	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.36	-4.55	-0.35	1.1e-5	Dupuytren's disease;
UCEC	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.76	-8.7	-0.58	6.04e-15	Facial morphology (factor 19);
UCEC	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.56	6.12	0.45	8.18e-9	Blood metabolite levels;
UCEC	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.07e-11	Eye color traits;
UCEC	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.59	6.76	0.49	3e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.21	0.39	6.27e-7	Rheumatoid arthritis;
UCEC	cis	rs892864	0.803	rs74582270	chr5:127829522	T/C	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Multiple system atrophy;
UCEC	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	5.7	0.43	6.27e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.53	-5.26	-0.4	4.9e-7	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.7	6.96	0.5	1.07e-10	Primary sclerosing cholangitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16140913	chr4:8430389	ACOX3	0.66	7.79	0.54	1.11e-12	Warfarin maintenance dose;
UCEC	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.17	-11.1	-0.68	3.56e-21	Vitiligo;
UCEC	cis	rs7246967	0.673	rs3844578	chr19:22880610	G/C	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.62	5.68	0.42	6.88e-8	Mortality in heart failure;
UCEC	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-5.04	-0.38	1.35e-6	Colorectal cancer;
UCEC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg05991184	chr2:219186017	PNKD	0.53	5.86	0.43	2.98e-8	Colorectal cancer;
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	8.84	0.59	2.65e-15	Platelet count;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.47	-5.21	-0.39	6.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg04851639	chr8:1020857	NA	-0.37	-5.03	-0.38	1.39e-6	Schizophrenia;
UCEC	trans	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg22466653	chr17:56232357	OR4D1	0.48	6.72	0.48	3.78e-10	Obesity-related traits;
UCEC	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.27	0.46	3.79e-9	Tonsillectomy;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01083340	chr11:66176265	NA	0.58	7.19	0.51	3e-11	Warfarin maintenance dose;
UCEC	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg24069376	chr3:38537580	EXOG	0.43	5.31	0.4	3.91e-7	Electrocardiographic conduction measures;
UCEC	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.84	6.37	0.46	2.34e-9	Multiple sclerosis;
UCEC	cis	rs9650657	0.741	rs10100333	chr8:10584288	C/T	cg14992524	chr8:10586135	SOX7	0.28	4.54	0.35	1.17e-5	Neuroticism;
UCEC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.66	-5.54	-0.42	1.36e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.86	-5.82	-0.43	3.56e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.36	-5.83	-0.43	3.37e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.56	7.09	0.5	5.12e-11	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2415984	0.818	rs12185003	chr14:46833927	A/G	cg14871534	chr14:47121158	RPL10L	0.41	4.77	0.37	4.45e-6	Number of children ever born;
UCEC	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-8.65	-0.58	8.31e-15	Headache;
UCEC	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs4389974	0.966	rs62520633	chr8:112388245	A/G	cg22736090	chr17:62339926	TEX2	0.65	6.82	0.49	2.2e-10	Body mass index;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.77	-0.43	4.5e-8	Pubertal anthropometrics;
UCEC	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg21191810	chr6:118973309	C6orf204	0.43	6.01	0.44	1.42e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg03808351	chr9:123631620	PHF19	0.46	5.21	0.39	6.2e-7	Birth weight;
UCEC	cis	rs7656342	0.866	rs6841397	chr4:9815402	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	4.57	0.35	1.02e-5	Gut microbiota (bacterial taxa);
UCEC	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.77	6.44	0.47	1.59e-9	Morning vs. evening chronotype;
UCEC	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.82	8.19	0.56	1.18e-13	Breast cancer;
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.24	0.71	3.51e-24	Prudent dietary pattern;
UCEC	cis	rs7634260	0.730	rs79832786	chr3:9668982	G/C	cg02053257	chr3:10353648	SEC13	-0.5	-4.69	-0.36	6.21e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Delta-6 desaturase activity;Delta-5 desaturase activity;
UCEC	cis	rs7625357	0.651	rs12631412	chr3:169262998	C/T	cg03603669	chr3:169896616	PHC3	-0.42	-4.59	-0.35	9.45e-6	Childhood and early adolescence aggressive behavior;
UCEC	cis	rs1324913	1.000	rs7335812	chr13:74633384	C/T	cg13696283	chr13:74707153	KLF12	0.42	5.14	0.39	8.58e-7	Menarche (age at onset);
UCEC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26207909	chr14:103986467	CKB	0.54	6.03	0.45	1.26e-8	Body mass index;
UCEC	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.53	5.51	0.41	1.6e-7	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs73022713	chr19:22876222	G/C	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg22166914	chr1:53195759	ZYG11B	0.59	6.18	0.45	6.1e-9	Monocyte count;
UCEC	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.84	-7.18	-0.51	3.15e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg20607287	chr7:12443886	VWDE	-0.63	-4.63	-0.36	7.93e-6	Coronary artery disease;
UCEC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.5	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.53	-4.82	-0.37	3.51e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4615376	1.000	rs4711908	chr6:13060208	A/G	cg11378619	chr6:12164359	HIVEP1	-0.5	-4.81	-0.37	3.67e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.55	6.26	0.46	3.96e-9	Retinal vascular caliber;
UCEC	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs2836974	0.799	rs8129303	chr21:40711959	G/A	cg11890956	chr21:40555474	PSMG1	1.01	11.7	0.69	9.32e-23	Cognitive function;
UCEC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.71	6.12	0.45	8.18e-9	Menopause (age at onset);
UCEC	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.91	-13.18	-0.74	1.1e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.74	9.12	0.6	5.24e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.76	6.67	0.48	4.84e-10	Menopause (age at onset);
UCEC	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	0.97	14.16	0.76	2.91e-29	Homoarginine levels;
UCEC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	6.27	0.46	3.88e-9	Personality dimensions;
UCEC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg11764359	chr7:65958608	NA	0.72	7.23	0.51	2.51e-11	Aortic root size;
UCEC	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-4.71	-0.36	5.77e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	0.91	6.32	0.46	2.99e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.57	-6.74	-0.49	3.42e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.32	0.4	3.85e-7	Breast cancer;
UCEC	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg03714773	chr7:91764589	CYP51A1	0.46	5.45	0.41	2.03e-7	Breast cancer;
UCEC	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.9	9.45	0.61	7.57e-17	Cognitive function;
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.48	6.87	0.49	1.73e-10	Prudent dietary pattern;
UCEC	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg01112020	chr2:239008986	ESPNL	-0.34	-4.51	-0.35	1.32e-5	Prostate cancer;
UCEC	cis	rs9912468	1.000	rs4577128	chr17:64308473	A/G	cg19474267	chr17:64306194	PRKCA	-0.43	-6.06	-0.45	1.08e-8	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
UCEC	cis	rs3956705	0.798	rs1045530	chr7:32908135	C/G	cg05721444	chr7:32995514	FKBP9	-0.45	-4.54	-0.35	1.18e-5	Red cell distribution width;
UCEC	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-4.94	-0.38	2.08e-6	Morning vs. evening chronotype;
UCEC	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.61	6.01	0.44	1.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.14	-10.66	-0.66	5.25e-20	Vitiligo;
UCEC	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-4.82	-0.37	3.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.59	-5.92	-0.44	2.15e-8	Urate levels in obese individuals;
UCEC	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-9.33	-0.61	1.48e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.16	-0.56	1.37e-13	Total cholesterol levels;
UCEC	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.61	6.37	0.47	2.28e-9	Motion sickness;
UCEC	cis	rs10208940	0.920	rs13417100	chr2:68821725	C/T	cg12452813	chr2:68675892	NA	-0.48	-4.63	-0.36	7.91e-6	Urate levels in lean individuals;
UCEC	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-4.55	-0.35	1.13e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.43	4.76	0.37	4.58e-6	Anxiety disorder;
UCEC	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.43	-4.65	-0.36	7.27e-6	Cardiac Troponin-T levels;
UCEC	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.6	8.85	0.59	2.56e-15	Prudent dietary pattern;
UCEC	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.51	-0.57	1.87e-14	Total body bone mineral density;
UCEC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg22974920	chr21:40686053	BRWD1	0.56	4.76	0.37	4.57e-6	Cognitive function;
UCEC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26002218	chr14:103986227	CKB	0.36	4.54	0.35	1.14e-5	Body mass index;
UCEC	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.53	-6.57	-0.48	8.09e-10	Total body bone mineral density;
UCEC	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	0.92	11.6	0.69	1.66e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.33	-0.46	2.76e-9	Aortic root size;
UCEC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg24562669	chr7:97807699	LMTK2	0.42	5.06	0.39	1.24e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.66	0.85	5.55e-43	Chronic sinus infection;
UCEC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.66	-5.9	-0.44	2.43e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.49	5.08	0.39	1.11e-6	Autism spectrum disorder-related traits;
UCEC	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg03528137	chr13:111589969	NA	0.73	4.83	0.37	3.44e-6	Obesity-related traits;
UCEC	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg01256987	chr12:42539512	GXYLT1	0.41	4.75	0.36	4.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.09	8.69	0.58	6.66e-15	Uric acid levels;
UCEC	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.6	-5.8	-0.43	3.9e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	6.39	0.47	2.05e-9	Response to antipsychotic treatment;
UCEC	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	-0.64	-7.03	-0.5	7.06e-11	IgG glycosylation;
UCEC	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.86	9.3	0.61	1.76e-16	Mean corpuscular hemoglobin;
UCEC	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.67	7.5	0.53	5.55e-12	Crohn's disease;
UCEC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs72906064	1.000	rs72906064	chr2:156911600	G/T	cg14040602	chr2:157557294	NA	0.64	4.66	0.36	6.94e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.86	-0.37	2.99e-6	Testicular germ cell tumor;
UCEC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.27	0.68	1.3e-21	Chronic sinus infection;
UCEC	cis	rs7246967	0.673	rs7250343	chr19:22822845	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	0.87	5.43	0.41	2.32e-7	Skin colour saturation;
UCEC	cis	rs16937	0.662	rs10900468	chr1:205163057	A/G	cg00857998	chr1:205179979	DSTYK	0.52	4.61	0.36	8.62e-6	Schizophrenia;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.65	7.49	0.53	5.84e-12	Menarche (age at onset);
UCEC	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.51	5.39	0.41	2.69e-7	Retinal vascular caliber;
UCEC	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.09	17.32	0.82	2.6e-37	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.12	-6.76	-0.49	2.95e-10	Breast cancer;
UCEC	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.65	-4.77	-0.37	4.31e-6	Psoriasis;
UCEC	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.72	5.22	0.4	5.93e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg20368463	chr18:77673604	PQLC1	0.72	5.27	0.4	4.75e-7	Opioid sensitivity;
UCEC	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.75	7.3	0.52	1.64e-11	Vitamin D levels;
UCEC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.49	4.95	0.38	2e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.56	-5.72	-0.43	5.73e-8	Longevity;Endometriosis;
UCEC	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.91	6.44	0.47	1.58e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.48	-5.17	-0.39	7.56e-7	Information processing speed;
UCEC	cis	rs1387221	0.904	rs8180998	chr8:59614999	A/G	cg24495373	chr8:59337659	UBXN2B	0.38	4.56	0.35	1.07e-5	Clozapine-induced cytotoxicity;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.93	12.66	0.72	2.67e-25	Menarche (age at onset);
UCEC	cis	rs11867410	0.744	rs74631703	chr17:63967279	T/G	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2806864	1.000	rs2250865	chr1:117462691	A/G	cg19765820	chr1:116518738	SLC22A15	0.65	4.53	0.35	1.2e-5	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.67	6.22	0.46	4.82e-9	Nonalcoholic fatty liver disease;
UCEC	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.03	-8.28	-0.56	7.04e-14	Exhaled nitric oxide output;
UCEC	cis	rs1978968	0.763	rs9605473	chr22:18463266	C/T	cg03078520	chr22:18463400	MICAL3	0.53	7.04	0.5	6.94e-11	Presence of antiphospholipid antibodies;
UCEC	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-5.1	-0.39	1.02e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.69	-6.33	-0.46	2.87e-9	Diastolic blood pressure;
UCEC	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	0.94	6.54	0.47	9.46e-10	Skin colour saturation;
UCEC	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	4.84	0.37	3.26e-6	Response to antipsychotic treatment;
UCEC	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.65	4.64	0.36	7.65e-6	Breast cancer;
UCEC	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg13147721	chr7:65941812	NA	0.69	4.83	0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg01072550	chr1:21505969	NA	-0.57	-5.44	-0.41	2.21e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.85	0.43	3.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2892463	0.796	rs9551744	chr13:30384052	T/C	cg18356743	chr13:30408050	UBL3	0.41	4.58	0.35	9.74e-6	Non-word repetition;
UCEC	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg14092571	chr14:90743983	NA	0.45	6.07	0.45	1.05e-8	Mortality in heart failure;
UCEC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.85	10.76	0.66	2.79e-20	Menopause (age at onset);
UCEC	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.69	4.9	0.37	2.49e-6	Aortic root size;
UCEC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.45	-4.51	-0.35	1.32e-5	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg19678392	chr7:94953810	PON1	0.57	5.59	0.42	1.08e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.84	-8.74	-0.58	4.87e-15	Itch intensity from mosquito bite;
UCEC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.46	-6.35	-0.46	2.54e-9	Mortality in heart failure;
UCEC	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.47	5.04	0.38	1.38e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.63	-6.46	-0.47	1.46e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.46	-5.49	-0.41	1.69e-7	Subjective well-being;
UCEC	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	1.0	11.7	0.69	9.03e-23	Cognitive function;
UCEC	cis	rs9470794	1.000	rs876818	chr6:38120660	C/T	cg03458162	chr6:37400668	FTSJD2	0.78	4.74	0.36	5.1e-6	Type 2 diabetes;
UCEC	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg04374321	chr14:90722782	PSMC1	0.64	6.87	0.49	1.67e-10	Mortality in heart failure;
UCEC	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.63	-6.35	-0.46	2.5e-9	Body mass index;
UCEC	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.02	8.33	0.57	5.12e-14	Uric acid levels;
UCEC	cis	rs6663390	0.510	rs6540445	chr1:208081467	A/G	cg03990033	chr1:208084030	CD34	-0.55	-5.41	-0.41	2.53e-7	Facial morphology (factor 18);
UCEC	cis	rs16857609	0.628	rs874839	chr2:218354087	T/G	cg23340935	chr2:218354150	DIRC3	0.52	5.02	0.38	1.49e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.54	-6.17	-0.45	6.25e-9	Menopause (age at onset);
UCEC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.83	0.43	3.41e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.58	-6.74	-0.49	3.39e-10	Height;
UCEC	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.56	5.69	0.43	6.52e-8	Systemic lupus erythematosus;
UCEC	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.36	-0.46	2.39e-9	Response to antipsychotic treatment;
UCEC	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.41	-4.82	-0.37	3.47e-6	Lung cancer;
UCEC	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg07153921	chr17:41440717	NA	-0.56	-5.93	-0.44	2.1e-8	Menopause (age at onset);
UCEC	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	4.88	0.37	2.76e-6	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.05	7.91	0.55	5.72e-13	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.93	0.63	4.19e-18	Breast cancer;
UCEC	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.58	5.51	0.41	1.56e-7	Migraine;Coronary artery disease;
UCEC	trans	rs890835	1.000	rs1978604	chr5:175949049	G/A	cg07418892	chr6:52150456	MCM3	0.68	6.81	0.49	2.35e-10	Menopause (age at onset);
UCEC	cis	rs73206853	0.764	rs7960988	chr12:110749918	G/A	cg12870014	chr12:110450643	ANKRD13A	0.6	4.91	0.38	2.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg22974920	chr21:40686053	BRWD1	0.61	5.36	0.4	3.1e-7	Cognitive function;
UCEC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg00083072	chr11:65415190	SIPA1	0.45	5.03	0.38	1.43e-6	Acne (severe);
UCEC	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.55	5.88	0.44	2.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.53	0.41	1.43e-7	Rheumatoid arthritis;
UCEC	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.54	4.51	0.35	1.34e-5	Bladder cancer;
UCEC	cis	rs4448343	0.736	rs2236407	chr9:98237796	A/G	cg13456470	chr9:98266766	PTCH1	0.38	4.95	0.38	2.01e-6	Height;
UCEC	cis	rs6840360	0.573	rs10024721	chr4:152265331	G/A	cg25486957	chr4:152246857	NA	-0.44	-4.84	-0.37	3.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.5	-4.68	-0.36	6.4e-6	Platelet count;
UCEC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.48	5.62	0.42	9.17e-8	Bone mineral density;
UCEC	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg13683864	chr3:40499215	RPL14	0.77	8.34	0.57	4.93e-14	Renal cell carcinoma;
UCEC	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.57	-5.09	-0.39	1.08e-6	Corneal astigmatism;
UCEC	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.76	7.66	0.53	2.36e-12	Mosquito bite size;
UCEC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.5	-7.54	-0.53	4.44e-12	Primary biliary cholangitis;
UCEC	cis	rs7112925	0.932	rs2282502	chr11:66834252	C/T	cg06012016	chr11:67219631	GPR152	-0.42	-4.76	-0.37	4.55e-6	Height;
UCEC	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.57	-5.61	-0.42	9.55e-8	White matter hyperintensity burden;
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03760483	chr17:6899297	ALOX12	0.47	5.6	0.42	1.03e-7	Tonsillectomy;
UCEC	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg14008862	chr17:28927542	LRRC37B2	0.82	4.81	0.37	3.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg16060761	chr17:80687452	NA	-0.41	-4.65	-0.36	7.47e-6	Breast cancer;
UCEC	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.91	-11.08	-0.67	3.98e-21	Blood metabolite levels;
UCEC	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	6.75	0.49	3.11e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.52	-0.41	1.49e-7	Neutrophil percentage of white cells;
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.75	-8.44	-0.57	2.72e-14	Paraoxonase activity;
UCEC	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	0.71	5.38	0.41	2.83e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs735860	0.726	rs209518	chr6:53208016	C/A	cg10236188	chr6:53219634	NA	0.46	4.72	0.36	5.44e-6	Glaucoma;
UCEC	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg23070574	chr3:14187308	XPC	0.42	4.87	0.37	2.86e-6	Ovarian reserve;
UCEC	cis	rs7088591	0.867	rs35419144	chr10:59778244	T/A	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.67	-5.06	-0.39	1.21e-6	Blood protein levels;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.62	4.54	0.35	1.18e-5	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.68	5.7	0.43	6.24e-8	Systolic blood pressure;
UCEC	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.54	-5.02	-0.38	1.51e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.48	0.47	1.33e-9	Cognitive test performance;
UCEC	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.79	9.14	0.6	4.65e-16	Lymphocyte counts;
UCEC	cis	rs11760485	0.782	rs2107840	chr7:4406993	C/G	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs4687718	0.929	rs62255992	chr3:53277790	A/C	cg19378537	chr3:53290327	TKT	0.61	4.62	0.36	8.16e-6	QRS duration;
UCEC	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.47	5.89	0.44	2.54e-8	HDL cholesterol levels;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.87	11.31	0.68	9.95e-22	Menarche (age at onset);
UCEC	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.54	-5.37	-0.41	2.95e-7	Breast size;
UCEC	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.55	4.66	0.36	7.09e-6	Systolic blood pressure;
UCEC	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-0.43	-4.56	-0.35	1.08e-5	IgG glycosylation;
UCEC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-13.15	-0.74	1.31e-26	Height;
UCEC	cis	rs975730	1.000	rs3922390	chr8:129328343	G/T	cg14920061	chr8:129326392	NA	0.36	4.54	0.35	1.19e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.55	5.0	0.38	1.62e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-5.28	-0.4	4.61e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-5.04	-0.38	1.33e-6	Testicular germ cell tumor;
UCEC	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6724465	0.866	rs12185751	chr2:219904908	G/A	cg18013012	chr2:220119233	TUBA4B;TUBA4A	0.73	4.78	0.37	4.3e-6	Height;
UCEC	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.89	-0.44	2.55e-8	Prudent dietary pattern;
UCEC	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.5	-4.88	-0.37	2.78e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.6	-5.62	-0.42	9.51e-8	Pancreatic cancer;
UCEC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.07	-14.99	-0.78	2.1e-31	Schizophrenia;
UCEC	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.75	8.43	0.57	2.85e-14	Blood protein levels;
UCEC	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg06671706	chr8:8559999	CLDN23	0.65	5.24	0.4	5.54e-7	Obesity-related traits;
UCEC	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.54	-5.15	-0.39	8.34e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg13334819	chr7:99746414	C7orf59	-0.56	-5.42	-0.41	2.34e-7	Coronary artery disease;
UCEC	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18854424	chr1:2615690	NA	0.48	6.97	0.5	9.81e-11	Ulcerative colitis;
UCEC	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg16583315	chr14:65563665	MAX	-0.43	-5.77	-0.43	4.61e-8	Obesity-related traits;
UCEC	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs13095912	0.962	rs12374077	chr3:185317674	G/C	cg11274856	chr3:185301563	NA	0.55	7.23	0.51	2.48e-11	Systolic blood pressure;
UCEC	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg20368463	chr18:77673604	PQLC1	0.74	5.31	0.4	3.94e-7	Opioid sensitivity;
UCEC	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.39	0.47	2.02e-9	Motion sickness;
UCEC	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.34	-5.1	-0.39	1.03e-6	Schizophrenia;
UCEC	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.43	5.19	0.39	7e-7	Lung cancer;
UCEC	cis	rs8099014	0.954	rs9961522	chr18:56107279	T/C	cg19165390	chr18:56932082	NA	0.34	4.65	0.36	7.28e-6	Platelet count;
UCEC	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg04154034	chr17:28927549	LRRC37B2	0.83	5.26	0.4	5.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.51	5.39	0.41	2.76e-7	Breast cancer;
UCEC	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg13147721	chr7:65941812	NA	-0.81	-6.01	-0.44	1.4e-8	Diabetic kidney disease;
UCEC	cis	rs4865169	0.791	rs11731868	chr4:57895214	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.46	-4.73	-0.36	5.2e-6	Breast cancer;
UCEC	cis	rs9831754	0.756	rs13084140	chr3:78426004	G/A	cg06138941	chr3:78371609	NA	-0.71	-5.52	-0.41	1.5e-7	Calcium levels;
UCEC	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.79	8.37	0.57	4.19e-14	Caffeine consumption;
UCEC	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.34	4.67	0.36	6.76e-6	Obesity-related traits;
UCEC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg21853948	chr4:100867292	DNAJB14	0.44	4.54	0.35	1.16e-5	Alcohol dependence;
UCEC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.99	-0.44	1.52e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.63	6.15	0.45	6.87e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.44	4.53	0.35	1.23e-5	Aortic root size;
UCEC	cis	rs829661	0.947	rs1252646	chr2:30741913	C/T	cg17749961	chr2:30669863	LCLAT1	-0.51	-4.86	-0.37	3.03e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.97	12.14	0.71	6.26e-24	Breast cancer;
UCEC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg13683864	chr3:40499215	RPL14	-0.68	-6.79	-0.49	2.59e-10	Renal cell carcinoma;
UCEC	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.71	7.8	0.54	1.02e-12	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.98	12.53	0.72	5.88e-25	Breast cancer;
UCEC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg13575925	chr12:9217583	LOC144571	0.4	4.96	0.38	1.89e-6	Sjögren's syndrome;
UCEC	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.64	6.21	0.46	5.2e-9	Breast cancer;
UCEC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.56	-4.69	-0.36	6.09e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg16497661	chr14:103986332	CKB	0.44	4.51	0.35	1.32e-5	Body mass index;
UCEC	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.51	5.75	0.43	4.9e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6728642	1.000	rs7580504	chr2:97605597	C/G	cg26665480	chr2:98280029	ACTR1B	-0.66	-4.87	-0.37	2.82e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs6460942	1.000	rs73053527	chr7:12313008	C/A	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg12637676	chr8:11587161	GATA4	-0.35	-4.65	-0.36	7.29e-6	Neuroticism;
UCEC	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.71	6.96	0.5	1.06e-10	Bladder cancer;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.58	-5.2	-0.39	6.71e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4849887	0.881	rs7575205	chr2:121242087	T/C	cg00421221	chr2:121106091	INHBB	0.46	4.81	0.37	3.76e-6	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.2	-0.39	6.43e-7	Pediatric autoimmune diseases;
UCEC	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.73	0.36	5.27e-6	Tonsillectomy;
UCEC	cis	rs883565	0.543	rs784488	chr3:39173135	C/G	cg01426195	chr3:39028469	NA	0.65	7.97	0.55	4.1e-13	Handedness;
UCEC	cis	rs75229567	0.717	rs74527680	chr12:70235392	A/G	cg10114359	chr12:70132523	RAB3IP	1.11	4.93	0.38	2.15e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
UCEC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs2167364	0.773	rs4947584	chr7:50572709	A/T	cg18232548	chr7:50535776	DDC	-0.48	-5.33	-0.4	3.59e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.38	-0.47	2.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.79	6.87	0.49	1.71e-10	Bladder cancer;
UCEC	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	0.85	10.06	0.64	1.92e-18	Schizophrenia;
UCEC	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	0.97	6.98	0.5	9.19e-11	Vitiligo;
UCEC	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs7246967	0.551	rs7249473	chr19:22906694	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.59	0.48	7.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.61	-5.16	-0.39	7.81e-7	Platelet count;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg02203542	chr20:305175	SOX12	0.59	6.84	0.49	1.99e-10	N-glycan levels;
UCEC	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.54	5.43	0.41	2.32e-7	Lung cancer;
UCEC	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.87	9.41	0.61	9.19e-17	Mean corpuscular hemoglobin;
UCEC	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-0.97	-13.18	-0.74	1.14e-26	Height;
UCEC	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.66	7.88	0.54	6.71e-13	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg17294928	chr15:75287854	SCAMP5	0.47	4.8	0.37	3.83e-6	Caffeine consumption;
UCEC	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-5.52	-0.41	1.51e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.7	6.88	0.49	1.64e-10	Bipolar disorder;
UCEC	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.75	7.31	0.52	1.61e-11	Vitamin D levels;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs9313296	0.661	rs2644725	chr5:165522270	C/T	cg03539051	chr19:56418660	NLRP13	1.11	6.93	0.5	1.23e-10	Weight;Waist circumference;
UCEC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.71	-0.43	6.19e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.58	-6.4	-0.47	1.96e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.54	-5.46	-0.41	1.95e-7	Aortic root size;
UCEC	cis	rs11760485	0.858	rs5021671	chr7:4399800	A/G	cg15613991	chr7:5277080	NA	-0.4	-4.69	-0.36	6.21e-6	Early childhood aggressive behavior;
UCEC	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg05072774	chr3:49840536	C3orf54	-0.54	-5.59	-0.42	1.09e-7	Resting heart rate;
UCEC	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs138249	1.000	rs138249	chr22:50569790	C/T	cg05988158	chr22:51021418	CHKB-CPT1B;CHKB;LOC100144603	0.44	4.58	0.35	9.87e-6	Gestational age at birth in labor-initiated deliveries (child effect);
UCEC	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.44	4.85	0.37	3.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.82	6.96	0.5	1.06e-10	Initial pursuit acceleration;
UCEC	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.68	6.24	0.46	4.34e-9	Aortic root size;
UCEC	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.69	-7.64	-0.53	2.62e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg00105475	chr2:10696890	NA	0.45	5.6	0.42	1.01e-7	Prostate cancer;
UCEC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.5	-0.47	1.17e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs853679	0.657	rs1778482	chr6:28240992	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.43	-4.83	-0.37	3.41e-6	Depression;
UCEC	cis	rs7714670	0.736	rs2973547	chr5:73092415	C/G	cg00119811	chr5:73092353	RGNEF	-0.38	-4.66	-0.36	7.12e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.56	4.79	0.37	4.1e-6	Alzheimer's disease;
UCEC	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.75	0.43	4.87e-8	Coffee consumption (cups per day);
UCEC	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7709377	0.597	rs35941525	chr5:115464237	G/T	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg05660106	chr1:15850417	CASP9	0.85	9.73	0.63	1.41e-17	Systolic blood pressure;
UCEC	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs10242455	0.614	rs2687072	chr7:99316926	A/G	cg07715041	chr7:99302981	CYP3A7	-0.51	-5.23	-0.4	5.68e-7	Blood metabolite levels;
UCEC	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	0.95	13.14	0.73	1.43e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs1335645	0.502	rs618089	chr1:111625277	T/C	cg00321911	chr1:111669324	DRAM2	0.55	4.66	0.36	7.16e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.56	-4.85	-0.37	3.08e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg11508081	chr17:41442227	NA	0.4	4.51	0.35	1.34e-5	Menopause (age at onset);
UCEC	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.73	-0.36	5.11e-6	Parkinson's disease;
UCEC	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.51	-5.03	-0.38	1.4e-6	Endometrial cancer;
UCEC	cis	rs7709377	0.595	rs27125	chr5:115637755	A/T	cg23108291	chr5:115420582	COMMD10	0.52	5.29	0.4	4.27e-7	Metabolite levels  (X-11787);
UCEC	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg18681998	chr4:17616180	MED28	0.79	9.26	0.61	2.32e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg05695927	chr15:45694626	SPATA5L1	0.47	4.85	0.37	3.08e-6	Homoarginine levels;
UCEC	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.55	0.42	1.28e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.5	4.75	0.36	4.72e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.9	-0.37	2.48e-6	Dupuytren's disease;
UCEC	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-5.49	-0.41	1.74e-7	Educational attainment (years of education);
UCEC	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg23370820	chr17:17987590	NA	0.39	4.97	0.38	1.85e-6	Total body bone mineral density;
UCEC	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg18827107	chr12:86230957	RASSF9	-0.44	-4.73	-0.36	5.29e-6	Major depressive disorder;
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.67	6.02	0.44	1.34e-8	Platelet count;
UCEC	cis	rs59104589	0.583	rs28386824	chr2:242349893	A/G	cg19488206	chr2:242435732	STK25	0.49	5.06	0.38	1.25e-6	Fibrinogen levels;
UCEC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.03	-8.51	-0.57	1.86e-14	White matter hyperintensity burden;
UCEC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.8	-8.94	-0.59	1.53e-15	Cognitive function;
UCEC	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.59	-5.72	-0.43	5.83e-8	Dental caries;
UCEC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.43	4.63	0.36	8.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.59	5.53	0.41	1.44e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.72	-8.28	-0.56	6.93e-14	Headache;
UCEC	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.76	-0.37	4.62e-6	Coronary artery disease;
UCEC	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.63	6.5	0.47	1.2e-9	Migraine;
UCEC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.42	4.8	0.37	3.81e-6	Height;
UCEC	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.5	5.66	0.42	7.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.51	5.7	0.43	6.45e-8	Blood metabolite levels;
UCEC	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg04043695	chr12:129287642	SLC15A4	-0.68	-6.51	-0.47	1.11e-9	Systemic lupus erythematosus;
UCEC	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	5.57	0.42	1.16e-7	Response to antipsychotic treatment;
UCEC	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.5	-6.0	-0.44	1.46e-8	Mean platelet volume;
UCEC	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.84	9.37	0.61	1.2e-16	Bone mineral density;
UCEC	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.1	6.72	0.48	3.8e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	1.07	5.04	0.38	1.38e-6	IgG glycosylation;
UCEC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.42	-5.03	-0.38	1.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1712517	0.873	rs1163086	chr10:105039579	A/G	cg05636881	chr10:105038444	INA	0.46	5.27	0.4	4.76e-7	Migraine;
UCEC	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-0.78	-6.11	-0.45	8.39e-9	Body mass index;
UCEC	cis	rs1940013	0.680	rs4937695	chr11:132244573	A/G	cg11473001	chr11:131780499	NTM	-0.42	-4.93	-0.38	2.23e-6	Sleep-related phenotypes;
UCEC	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.58	5.54	0.42	1.37e-7	Asthma (sex interaction);
UCEC	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-5.3	-0.4	4.24e-7	Extrinsic epigenetic age acceleration;
UCEC	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.79	-9.79	-0.63	9.7e-18	Leprosy;
UCEC	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.3	0.52	1.68e-11	Eye color traits;
UCEC	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.71	7.95	0.55	4.62e-13	Mortality in heart failure;
UCEC	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg24611264	chr11:120008944	TRIM29	-0.34	-5.27	-0.4	4.69e-7	Stroke (pediatric);
UCEC	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.53	5.28	0.4	4.46e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.72	7.46	0.52	6.97e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.83	-0.37	3.35e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.67	6.96	0.5	1.05e-10	Longevity;Endometriosis;
UCEC	cis	rs10242455	0.702	rs59574285	chr7:99236151	C/T	cg18809830	chr7:99032528	PTCD1	-0.77	-4.68	-0.36	6.55e-6	Blood metabolite levels;
UCEC	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.54e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.43	4.8	0.37	3.89e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1981331	0.609	rs73907584	chr21:48079678	A/G	cg23283320	chr21:48055893	PRMT2	0.85	5.4	0.41	2.63e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.52	-4.68	-0.36	6.58e-6	Colorectal cancer;
UCEC	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.77	-8.71	-0.58	5.67e-15	Height;
UCEC	cis	rs6728642	1.000	rs60608738	chr2:97608085	G/A	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.1	-0.51	5.02e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg21905437	chr5:178450457	ZNF879	0.66	7.27	0.51	2.01e-11	Pubertal anthropometrics;
UCEC	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.73	-7.28	-0.51	1.84e-11	Plateletcrit;Platelet count;
UCEC	cis	rs2468677	0.553	rs7010465	chr8:140583772	G/T	cg17476951	chr8:141053896	TRAPPC9	-0.39	-4.53	-0.35	1.2e-5	Adiponectin levels;
UCEC	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.54	-5.57	-0.42	1.17e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs2075165	0.901	rs949464	chr1:156272271	C/T	cg20302342	chr1:156215951	PAQR6	0.52	5.37	0.4	3.06e-7	Tonsillectomy;
UCEC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.08	-18.06	-0.83	3.76e-39	Testicular germ cell tumor;
UCEC	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.69	5.98	0.44	1.64e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.85	8.74	0.58	4.85e-15	Cognitive function;
UCEC	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	cis	rs8177876	0.822	rs10514514	chr16:81115273	A/G	cg08591886	chr16:81111003	C16orf46	-0.83	-5.02	-0.38	1.49e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	0.72	5.63	0.42	8.85e-8	Post bronchodilator FEV1;
UCEC	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.39	4.88	0.37	2.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7106204	0.920	rs7946615	chr11:24221036	T/C	ch.11.24196551F	chr11:24239977	NA	0.66	5.73	0.43	5.56e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7088591	0.867	rs60106619	chr10:59788233	T/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg03999872	chr20:62272968	STMN3	-0.48	-4.6	-0.36	8.88e-6	Atopic dermatitis;
UCEC	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.53	5.2	0.39	6.6e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs11958404	0.932	rs72816579	chr5:157431877	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13683864	chr3:40499215	RPL14	-0.68	-6.78	-0.49	2.73e-10	Renal cell carcinoma;
UCEC	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	12.61	0.72	3.61e-25	Height;
UCEC	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.79	9.06	0.6	7.44e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs4716602	0.513	rs13237220	chr7:156169727	G/A	cg04090468	chr7:156181990	NA	-0.7	-5.79	-0.43	4.19e-8	Anti-saccade response;
UCEC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	0.99	6.02	0.44	1.32e-8	Skin colour saturation;
UCEC	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.69	-6.73	-0.49	3.6e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	4.58	0.35	9.8200000000000008e-06	Urate levels;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.67	-0.36	6.76e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs539096	0.697	rs11210887	chr1:44076019	G/A	cg23963351	chr1:43834180	ELOVL1	0.45	4.56	0.35	1.07e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-6.18	-0.45	5.92e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-7.04	-0.5	6.92e-11	Response to antipsychotic treatment;
UCEC	cis	rs713477	0.935	rs7147968	chr14:55909040	G/A	cg13175173	chr14:55914753	NA	-0.4	-4.55	-0.35	1.09e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.72	6.72	0.48	3.78e-10	Height;
UCEC	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.46	-0.41	1.99e-7	Longevity;
UCEC	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.8	8.82	0.59	3.04e-15	Smoking behavior;
UCEC	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.65	0.36	7.39e-6	Tonsillectomy;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg25202407	chr1:205417560	MIR135B	0.38	4.77	0.37	4.35e-6	Menarche (age at onset);
UCEC	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.8	-10.24	-0.65	6.67e-19	Menarche (age at onset);
UCEC	cis	rs953387	0.910	rs1123848	chr2:136945029	C/T	cg07169764	chr2:136633963	MCM6	0.49	4.78	0.37	4.2e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.61	-5.19	-0.39	6.82e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.63	6.29	0.46	3.38e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-4.62	-0.36	8.4e-6	Type 2 diabetes;
UCEC	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.1	0.39	1.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.85	11.04	0.67	5.07e-21	Prudent dietary pattern;
UCEC	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.26	0.61	2.35e-16	Bipolar disorder;
UCEC	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.85	-5.83	-0.43	3.42e-8	Exhaled nitric oxide output;
UCEC	cis	rs9649213	0.574	rs7794187	chr7:97889758	A/C	cg24562669	chr7:97807699	LMTK2	0.58	6.68	0.48	4.48e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs953387	0.869	rs1519525	chr2:136965117	C/T	cg07169764	chr2:136633963	MCM6	0.51	4.94	0.38	2.1e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg05991184	chr2:219186017	PNKD	0.51	5.37	0.41	2.97e-7	Colorectal cancer;
UCEC	cis	rs2242663	0.581	rs2511224	chr11:66262606	T/C	cg24851651	chr11:66362959	CCS	-0.39	-4.9	-0.37	2.53e-6	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	4.72	0.36	5.46e-6	Breast cancer;
UCEC	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.97	-0.44	1.73e-8	Menarche (age at onset);
UCEC	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.58	6.22	0.46	4.91e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.94	-0.38	2.11e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs894344	0.584	rs2028556	chr8:135648040	T/C	cg07888246	chr8:135877498	NA	-0.45	-4.79	-0.37	4.01e-6	Systolic blood pressure;
UCEC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.6	6.17	0.45	6.44e-9	Longevity;Endometriosis;
UCEC	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.67	-7.44	-0.52	7.62e-12	HDL cholesterol;
UCEC	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.8	6.57	0.48	8.15e-10	Body mass index;
UCEC	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.8	-8.49	-0.57	2.09e-14	Parkinson's disease;
UCEC	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-5.03	-0.38	1.39e-6	Chronic sinus infection;
UCEC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.57	8.09	0.55	2.09e-13	Total body bone mineral density;
UCEC	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.66	-6.44	-0.47	1.59e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.45	6.27	0.46	3.77e-9	Height;
UCEC	cis	rs11867410	0.744	rs7225618	chr17:63948398	C/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs11153730	0.503	rs283066	chr6:118620064	A/G	cg21191810	chr6:118973309	C6orf204	0.39	5.05	0.38	1.27e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.7	8.43	0.57	3.02e-14	Ulcerative colitis;
UCEC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	5.42	0.41	2.38e-7	Body mass index;
UCEC	cis	rs17123764	0.792	rs11169073	chr12:49968426	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.19	0.39	6.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.46	-4.76	-0.37	4.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg06636001	chr8:8085503	FLJ10661	0.83	8.68	0.58	6.92e-15	Neuroticism;
UCEC	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.84	-10.13	-0.64	1.26e-18	Ulcerative colitis;
UCEC	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.42	-4.87	-0.37	2.9e-6	Pelvic organ prolapse;
UCEC	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.53	5.33	0.4	3.7e-7	Corneal astigmatism;
UCEC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg18681998	chr4:17616180	MED28	0.65	7.53	0.53	4.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg13695892	chr22:41940480	POLR3H	-0.61	-5.25	-0.4	5.29e-7	Vitiligo;
UCEC	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.5	5.89	0.44	2.57e-8	Total body bone mineral density;
UCEC	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.63	6.42	0.47	1.78e-9	Lung cancer;
UCEC	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.83	10.35	0.65	3.4e-19	Mortality in heart failure;
UCEC	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.43	4.82	0.37	3.55e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.56	-5.09	-0.39	1.06e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.55	-5.15	-0.39	8.18e-7	Coronary artery disease;
UCEC	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7246967	0.551	rs35740274	chr19:22831413	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.43	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.71	7.02	0.5	7.59e-11	Menarche (age at onset);
UCEC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs11760485	0.838	rs4236350	chr7:4407241	A/G	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.75	-8.7	-0.58	6.14e-15	Extraversion;
UCEC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06223018	chr3:49557076	DAG1	0.31	4.51	0.35	1.33e-5	Parkinson's disease;
UCEC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	5.0	0.38	1.64e-6	Rheumatoid arthritis;
UCEC	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.68	7.96	0.55	4.39e-13	Metabolite levels;
UCEC	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs36715	0.909	rs152906	chr5:127551840	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.05	0.38	1.29e-6	Breast cancer;
UCEC	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg26116260	chr4:7069785	GRPEL1	-0.64	-5.69	-0.42	6.6e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.85	-0.37	3.05e-6	Aortic root size;
UCEC	cis	rs6456156	0.904	rs2023305	chr6:167524898	A/G	cg01526474	chr6:167834866	NA	-0.4	-4.6	-0.35	9.01e-6	Primary biliary cholangitis;
UCEC	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg19875535	chr5:140030758	IK	0.44	4.91	0.38	2.35e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.62	6.86	0.49	1.79e-10	Longevity;Endometriosis;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6493487	0.512	rs17521919	chr15:51291056	A/C	cg17676096	chr15:52263839	LEO1	-0.78	-4.79	-0.37	4e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg16576597	chr16:28551801	NUPR1	0.34	4.85	0.37	3.13e-6	Mosquito bite size;
UCEC	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.56	-4.63	-0.36	7.93e-6	Bladder cancer;
UCEC	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.54	5.6	0.42	1e-7	Type 2 diabetes;
UCEC	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.4	-0.52	9.87e-12	Educational attainment (years of education);
UCEC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.86	-0.44	2.87e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.96e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg08501292	chr6:25962987	TRIM38	0.89	4.64	0.36	7.56e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.9	11.95	0.7	2.03e-23	Height;
UCEC	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.59	-6.08	-0.45	9.69e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.48	5.81	0.43	3.81e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg07636037	chr3:49044803	WDR6	0.57	4.66	0.36	7.14e-6	Menarche (age at onset);
UCEC	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.68	6.73	0.49	3.47e-10	Plateletcrit;Platelet count;
UCEC	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs8105895	1.000	rs75167249	chr19:22128655	C/T	cg02912127	chr19:22235281	ZNF257	-0.59	-4.91	-0.38	2.37e-6	Body mass index (change over time);
UCEC	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg23950597	chr19:37808831	NA	0.65	5.28	0.4	4.6e-7	Coronary artery calcification;
UCEC	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.5	-5.76	-0.43	4.86e-8	Aortic root size;
UCEC	cis	rs36051895	0.587	rs7848872	chr9:5197027	T/A	cg02405213	chr9:5042618	JAK2	-0.56	-4.61	-0.36	8.52e-6	Pediatric autoimmune diseases;
UCEC	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.73	4.53	0.35	1.19e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs11693319	1.000	rs67113930	chr2:179741348	A/G	cg26389888	chr2:178973147	PDE11A	0.61	4.67	0.36	6.87e-6	Blood pressure measurement (cold pressor test);
UCEC	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.53	4.97	0.38	1.87e-6	Menarche (age at onset);
UCEC	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg05962950	chr11:130786565	SNX19	-0.68	-5.7	-0.43	6.35e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.57	-5.48	-0.41	1.84e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.08	-8.01	-0.55	3.24e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.73	-7.98	-0.55	3.73e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.81	-8.54	-0.58	1.53e-14	Breast cancer;
UCEC	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg19318889	chr4:1322082	MAEA	0.46	4.94	0.38	2.14e-6	Obesity-related traits;
UCEC	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg12024160	chr4:1254474	NA	0.65	7.46	0.52	7.04e-12	Obesity-related traits;
UCEC	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.44	-4.95	-0.38	2.05e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg06521331	chr12:34319734	NA	-0.58	-4.54	-0.35	1.15e-5	Morning vs. evening chronotype;
UCEC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.19	9.49	0.62	5.91e-17	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.23	12.11	0.71	7.57e-24	Corneal structure;
UCEC	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg26721908	chr21:47610096	LSS	-0.44	-5.18	-0.39	7.03e-7	Testicular germ cell tumor;
UCEC	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg08222913	chr3:52553049	STAB1	-0.44	-5.13	-0.39	8.97e-7	Bipolar disorder;
UCEC	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.57	6.14	0.45	7.45e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.57	4.5	0.35	1.36e-5	Menopause (age at onset);
UCEC	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.48	0.47	1.29e-9	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.62	5.11	0.39	9.97e-7	Obesity-related traits;
UCEC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	5.74	0.43	5.12e-8	Menarche (age at onset);
UCEC	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.63	-4.94	-0.38	2.11e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.82	-7.65	-0.53	2.38e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.78	6.13	0.45	7.6e-9	Calcium levels;
UCEC	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg07636037	chr3:49044803	WDR6	0.57	4.66	0.36	6.99e-6	Menarche (age at onset);
UCEC	cis	rs17034641	0.744	rs2053797	chr2:46370892	C/T	cg12428440	chr2:46370979	PRKCE	0.6	5.2	0.39	6.56e-7	Hemoglobin;Hematocrit;
UCEC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18252515	chr7:66147081	NA	0.52	5.44	0.41	2.14e-7	Aortic root size;
UCEC	cis	rs35934224	0.891	rs5993850	chr22:19869703	C/T	cg11182965	chr22:19864308	TXNRD2	-0.48	-5.95	-0.44	1.87e-8	Glaucoma (primary open-angle);
UCEC	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg16616514	chr4:6324629	PPP2R2C	0.4	4.92	0.38	2.31e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs256277	0.544	rs26540	chr5:111349320	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.56	-5.45	-0.41	2.03e-7	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.74	-7.45	-0.52	7.53e-12	Aortic root size;
UCEC	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.59	6.85	0.49	1.9e-10	Iron status biomarkers;
UCEC	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.49	-5.35	-0.4	3.26e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg02022102	chr7:27168609	HOXA4	0.6	6.78	0.49	2.67e-10	Protein biomarker;
UCEC	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-0.94	-6.23	-0.46	4.55e-9	Corneal structure;
UCEC	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.73	7.32	0.52	1.51e-11	Coronary artery disease;
UCEC	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-5.5	-0.41	1.65e-7	HDL cholesterol;
UCEC	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg00852783	chr1:26633632	UBXN11	0.64	7.73	0.54	1.53e-12	Obesity-related traits;
UCEC	cis	rs295140	0.647	rs295129	chr2:201229473	G/A	cg04283868	chr2:201171347	SPATS2L	-0.47	-4.54	-0.35	1.15e-5	QT interval;
UCEC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.79	7.31	0.52	1.56e-11	Diastolic blood pressure;
UCEC	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.63	-5.71	-0.43	6.17e-8	Aortic root size;
UCEC	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-0.76	-6.75	-0.49	3.21e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16164276	chr3:11034345	SLC6A1	-0.48	-4.55	-0.35	1.1e-5	Alzheimer's disease;
UCEC	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.63	-7.38	-0.52	1.05e-11	Electrocardiographic conduction measures;
UCEC	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg26898376	chr11:64110657	CCDC88B	0.48	5.89	0.44	2.52e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.28	0.46	3.65e-9	Platelet count;
UCEC	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.46	4.77	0.37	4.43e-6	Schizophrenia;
UCEC	cis	rs7870753	0.838	rs1057687	chr9:99252464	A/G	cg25260653	chr9:99212216	HABP4	0.52	5.11	0.39	1e-6	Height;
UCEC	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.62	6.24	0.46	4.52e-9	Symmetrical dimethylarginine levels;
UCEC	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	10.01	0.64	2.57e-18	Bipolar disorder;
UCEC	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.79	-8.04	-0.55	2.72e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	0.98	4.69	0.36	6.21e-6	Thyroid stimulating hormone;
UCEC	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Electroencephalogram traits;
UCEC	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.42	5.11	0.39	9.68e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs13098911	0.540	rs13071283	chr3:46010007	T/C	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.11	14.66	0.77	1.44e-30	Schizophrenia;
UCEC	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.51	6.41	0.47	1.85e-9	Osteoporosis;
UCEC	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.62	-7.02	-0.5	7.51e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs1552172	0.811	rs12402787	chr1:145609971	T/C	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.66	-7.17	-0.51	3.4e-11	Breast cancer;
UCEC	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.57	5.28	0.4	4.5e-7	Vitiligo;
UCEC	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg06521331	chr12:34319734	NA	-0.59	-4.62	-0.36	8.16e-6	Morning vs. evening chronotype;
UCEC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.92	0.38	2.34e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	0.97	13.96	0.75	1.01e-28	Homoarginine levels;
UCEC	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg13460858	chr9:96720652	NA	-0.41	-4.64	-0.36	7.5e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.58	5.04	0.38	1.35e-6	Lung cancer;
UCEC	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.78	-6.83	-0.49	2.12e-10	Platelet distribution width;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg06175036	chr4:846732	GAK	-0.55	-6.72	-0.48	3.64e-10	N-glycan levels;
UCEC	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.48	4.92	0.38	2.3e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs17433710	1.000	rs17433710	chr1:162672011	T/C	cg19264028	chr1:162630153	DDR2	1.06	5.19	0.39	6.89e-7	Dupuytren's disease;
UCEC	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.84	0.54	8.29e-13	Total body bone mineral density;
UCEC	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-0.95	-9.76	-0.63	1.16e-17	Height;
UCEC	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg06818710	chr6:28411271	ZSCAN23	-0.43	-4.59	-0.35	9.57e-6	Cardiac Troponin-T levels;
UCEC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.64	-6.55	-0.48	9.06e-10	Longevity;Endometriosis;
UCEC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.46	5.08	0.39	1.11e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.7	6.6	0.48	6.88e-10	Bladder cancer;
UCEC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg21770322	chr7:97807741	LMTK2	0.46	5.83	0.43	3.35e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.63	6.98	0.5	9.4e-11	Pulmonary function decline;
UCEC	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg03146154	chr1:46216737	IPP	-0.59	-5.81	-0.43	3.68e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12618769	0.625	rs56240302	chr2:99148970	C/T	cg14361474	chr2:99058762	NA	-0.47	-4.56	-0.35	1.07e-5	Bipolar disorder;
UCEC	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	6.97	0.5	9.77e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	4.68	0.36	6.51e-6	Lung cancer in ever smokers;
UCEC	cis	rs73206853	0.841	rs56184938	chr12:110817193	T/C	cg12870014	chr12:110450643	ANKRD13A	0.61	4.73	0.36	5.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.5	-4.9	-0.37	2.54e-6	Cardiac Troponin-T levels;
UCEC	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.58	5.88	0.44	2.67e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.54	5.15	0.39	8.08e-7	Schizophrenia;
UCEC	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.73	7.69	0.54	1.98e-12	Tonsillectomy;
UCEC	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.72	8.07	0.55	2.26e-13	Ulcerative colitis;
UCEC	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.58	5.36	0.4	3.19e-7	Lung cancer;
UCEC	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.56	-5.03	-0.38	1.43e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.65	0.36	7.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg14008862	chr17:28927542	LRRC37B2	0.67	4.76	0.37	4.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs55684269	chr19:22924547	C/T	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.21	9.1	0.6	5.98e-16	Uric acid levels;
UCEC	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	7.26	0.51	2.07e-11	Type 2 diabetes;
UCEC	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-0.65	-6.22	-0.46	4.85e-9	Acne (severe);
UCEC	cis	rs2070997	0.591	rs10901294	chr9:133732752	A/G	cg12998491	chr9:134152531	FAM78A	0.78	4.95	0.38	2.05e-6	Response to amphetamines;
UCEC	cis	rs7374004	0.601	rs13062931	chr3:38637160	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.67	6.06	0.45	1.07e-8	PR interval;
UCEC	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg12586109	chr17:80790369	TBCD;ZNF750	-0.46	-5.03	-0.38	1.41e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg05660106	chr1:15850417	CASP9	0.52	4.98	0.38	1.78e-6	Systolic blood pressure;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.5	-4.8	-0.37	3.93e-6	Pubertal anthropometrics;
UCEC	cis	rs883565	0.771	rs3736573	chr3:39129742	A/C	cg01426195	chr3:39028469	NA	-0.73	-9.25	-0.61	2.5e-16	Handedness;
UCEC	cis	rs6060717	0.536	rs6060664	chr20:34478884	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.54	-0.35	1.19e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs73157695	0.521	rs55918937	chr21:47184033	C/T	cg07529122	chr21:47054539	NA	0.41	4.88	0.37	2.67e-6	Myopia;
UCEC	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.81	-6.29	-0.46	3.37e-9	Exhaled nitric oxide output;
UCEC	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg14008862	chr17:28927542	LRRC37B2	-0.73	-4.89	-0.37	2.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.4	-4.69	-0.36	6.08e-6	Hepatitis;
UCEC	cis	rs6832769	1.000	rs11133399	chr4:56413831	A/G	cg05960024	chr4:56376020	CLOCK	-0.52	-4.94	-0.38	2.13e-6	Personality dimensions;
UCEC	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg18681998	chr4:17616180	MED28	-0.71	-7.67	-0.53	2.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.73	6.88	0.49	1.6e-10	Aortic root size;
UCEC	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.48	-5.22	-0.4	5.99e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.58	-6.78	-0.49	2.73e-10	Pubertal anthropometrics;
UCEC	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.51	4.99	0.38	1.7e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.72	6.04	0.45	1.22e-8	Ulcerative colitis;
UCEC	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.94	0.44	1.93e-8	Tonsillectomy;
UCEC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.59	0.35	9.29e-6	Menopause (age at onset);
UCEC	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.42	-6.09	-0.45	9.23e-9	Longevity;
UCEC	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	5.76	0.43	4.84e-8	LDL cholesterol;
UCEC	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-5.37	-0.4	3.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.63	-5.2	-0.39	6.7e-7	LDL cholesterol levels;
UCEC	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.63	-5.74	-0.43	5.16e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.77	7.99	0.55	3.67e-13	Parkinson's disease;
UCEC	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg23260525	chr10:116636907	FAM160B1	0.33	4.51	0.35	1.32e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.73	0.36	5.16e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg13683864	chr3:40499215	RPL14	-0.59	-5.64	-0.42	8.59e-8	Renal cell carcinoma;
UCEC	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg24910161	chr17:38119198	GSDMA	-0.34	-4.76	-0.37	4.61e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.51	4.75	0.36	4.74e-6	Longevity;
UCEC	cis	rs4687718	0.528	rs62256006	chr3:53289634	G/A	cg12173409	chr3:54154746	NA	0.61	4.85	0.37	3.06e-6	QRS duration;
UCEC	cis	rs782590	0.840	rs10181648	chr2:55725948	A/G	cg03859395	chr2:55845619	SMEK2	0.79	8.73	0.58	5.15e-15	Metabolic syndrome;
UCEC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.78	-5.82	-0.43	3.47e-8	Initial pursuit acceleration;
UCEC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7517126	1.000	rs35445694	chr1:196838865	A/T	cg07209298	chr1:196795943	CFHR1	0.52	5.04	0.38	1.33e-6	Blood protein levels;
UCEC	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg26031613	chr14:104095156	KLC1	0.58	5.6	0.42	1.03e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.8	-8.77	-0.59	3.98e-15	Breast cancer;
UCEC	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.55	5.17	0.39	7.53e-7	Blood trace element (Cu levels);
UCEC	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs117623576	0.618	rs211413	chr10:32396902	C/A	cg03047570	chr10:32398778	NA	0.56	5.17	0.39	7.56e-7	Anti-saccade response;
UCEC	cis	rs1940013	0.680	rs4937696	chr11:132244630	T/C	cg11473001	chr11:131780499	NTM	-0.42	-4.93	-0.38	2.23e-6	Sleep-related phenotypes;
UCEC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs2708377	0.656	rs116607079	chr12:11262044	C/T	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.75	6.25	0.46	4.25e-9	Bitter taste perception;
UCEC	cis	rs10266483	0.705	rs599522	chr7:63758482	A/G	cg23304165	chr7:63498798	NA	-0.58	-6.13	-0.45	7.73e-9	Response to statin therapy;
UCEC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.62	6.5	0.47	1.17e-9	Colorectal cancer;
UCEC	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-0.58	-5.83	-0.43	3.41e-8	Pediatric autoimmune diseases;
UCEC	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg03924805	chr2:242211663	HDLBP	-0.45	-4.59	-0.35	9.44e-6	Joint mobility (Beighton score);
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg25202407	chr1:205417560	MIR135B	0.41	5.0	0.38	1.64e-6	Menarche (age at onset);
UCEC	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.42	4.56	0.35	1.08e-5	Response to antineoplastic agents;
UCEC	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs12644436	1.000	rs1564149	chr4:88789715	T/C	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	HIV-1 viral setpoint;
UCEC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.76	7.7	0.54	1.82e-12	Longevity;Endometriosis;
UCEC	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.94	0.55	4.92e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-5.57	-0.42	1.18e-7	Response to antipsychotic treatment;
UCEC	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.6	5.29	0.4	4.34e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg04043695	chr12:129287642	SLC15A4	0.7	7.0	0.5	8.35e-11	Systemic lupus erythematosus;
UCEC	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg16616514	chr4:6324629	PPP2R2C	0.42	5.09	0.39	1.06e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg24127310	chr10:102502104	NA	1.14	11.22	0.68	1.72e-21	Alzheimer's disease;
UCEC	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.88	0.37	2.72e-6	Diabetic retinopathy;
UCEC	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-0.72	-4.83	-0.37	3.46e-6	Diabetic kidney disease;
UCEC	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-5.44	-0.41	2.19e-7	Menarche (age at onset);
UCEC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg26061582	chr7:22766209	IL6	0.59	5.48	0.41	1.77e-7	Lung cancer;
UCEC	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.65	6.05	0.45	1.12e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg26618903	chr10:100175079	PYROXD2	-0.39	-5.17	-0.39	7.48e-7	Metabolite levels;
UCEC	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	4.66	0.36	6.98e-6	Height;
UCEC	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.82	9.2	0.6	3.24e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.91	6.1	0.45	8.83e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg16558253	chr16:72132732	DHX38	-0.42	-5.2	-0.39	6.64e-7	Prostate cancer;
UCEC	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.59	5.61	0.42	9.76e-8	Corneal astigmatism;
UCEC	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.33	5.04	0.38	1.34e-6	Cancer;
UCEC	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg05855489	chr10:104503620	C10orf26	-0.49	-5.21	-0.39	6.3e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs7175404	0.591	rs57685087	chr15:94060306	G/A	cg25253948	chr15:93956996	NA	0.63	4.65	0.36	7.24e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.11	-0.51	4.64e-11	Prevalent atrial fibrillation;
UCEC	cis	rs2179367	1.000	rs2179367	chr6:149762537	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.43	-5.69	-0.42	6.58e-8	Dupuytren's disease;
UCEC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg19645103	chr12:69753606	YEATS4	-0.49	-4.54	-0.35	1.16e-5	Response to diuretic therapy;
UCEC	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.42	4.52	0.35	1.28e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.54	-5.53	-0.41	1.45e-7	Aortic root size;
UCEC	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.91	9.96	0.63	3.6e-18	Post bronchodilator FEV1;
UCEC	cis	rs13098911	0.540	rs17215008	chr3:46012279	T/C	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.64	6.84	0.49	2.03e-10	Longevity;Endometriosis;
UCEC	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg13482628	chr17:19912719	NA	0.45	5.41	0.41	2.51e-7	Schizophrenia;
UCEC	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1893767	1.000	rs7111239	chr11:123958449	T/C	cg15915129	chr11:124933008	SLC37A2	-0.55	-4.69	-0.36	6.22e-6	Obesity-related traits;
UCEC	cis	rs253959	0.734	rs1421847	chr5:115701098	T/C	cg23108291	chr5:115420582	COMMD10	-0.47	-4.84	-0.37	3.28e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.04	-0.38	1.36e-6	Personality dimensions;
UCEC	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.72	-7.81	-0.54	1.02e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg03714773	chr7:91764589	CYP51A1	0.41	5.12	0.39	9.28e-7	Breast cancer;
UCEC	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.62	5.16	0.39	7.95e-7	Dental caries;
UCEC	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.68	-7.68	-0.54	2.11e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2274471	0.645	rs12237834	chr9:5093646	C/T	cg03390472	chr9:5043263	JAK2	-0.48	-4.59	-0.35	9.44e-6	Crohn's disease;
UCEC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.66	-7.43	-0.52	8.03e-12	Menarche (age at onset);
UCEC	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	0.89	9.0	0.6	1.05e-15	Heart rate;
UCEC	cis	rs405956	0.932	rs9654624	chr6:105584895	G/C	cg22580625	chr6:105627791	POPDC3	-0.69	-6.3	-0.46	3.26e-9	QT interval;
UCEC	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.55	5.94	0.44	1.97e-8	Platelet count;
UCEC	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs6460942	0.591	rs62448726	chr7:12330881	A/G	cg06484146	chr7:12443880	VWDE	-0.62	-4.9	-0.37	2.49e-6	Coronary artery disease;
UCEC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.08	0.39	1.15e-6	Rheumatoid arthritis;
UCEC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg24881330	chr22:46731750	TRMU	0.73	7.36	0.52	1.18e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs259282	0.652	rs2161458	chr19:33129038	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	7.19	0.51	3.08e-11	Schizophrenia;
UCEC	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.71	-6.83	-0.49	2.11e-10	Aortic root size;
UCEC	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.72	-8.36	-0.57	4.31e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.58	-6.39	-0.47	2.02e-9	Blood metabolite levels;
UCEC	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg21419209	chr3:44054225	NA	-0.46	-4.72	-0.36	5.53e-6	Coronary artery disease;
UCEC	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.25	7.8	0.54	1.05e-12	Diabetic kidney disease;
UCEC	cis	rs7517126	0.858	rs12726401	chr1:196660729	T/C	cg07209298	chr1:196795943	CFHR1	0.48	4.55	0.35	1.1e-5	Blood protein levels;
UCEC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg20203395	chr5:56204925	C5orf35	-0.71	-6.37	-0.46	2.32e-9	Type 2 diabetes;
UCEC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.5	5.46	0.41	2.01e-7	Body mass index;
UCEC	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.79	5.07	0.39	1.18e-6	Major depressive disorder;
UCEC	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.68	5.51	0.41	1.55e-7	Gut microbiome composition (summer);
UCEC	cis	rs6669919	0.967	rs6678844	chr1:211674774	G/T	cg10512769	chr1:211675356	NA	-0.32	-4.79	-0.37	4.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.6	6.19	0.45	5.78e-9	Gestational age at birth (maternal effect);
UCEC	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.7	4.96	0.38	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.73	-7.72	-0.54	1.66e-12	Lung cancer;
UCEC	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.66	7.09	0.5	5.36e-11	Coronary artery disease;
UCEC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.61	7.11	0.51	4.75e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10786436	0.605	rs7923631	chr10:100284148	T/C	cg24343515	chr10:99400468	PI4K2A	-0.46	-4.6	-0.35	9e-6	Type 1 diabetes;
UCEC	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.48	-4.7	-0.36	6.04e-6	Dental caries;
UCEC	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.46	-0.41	1.96e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.11e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.55	4.92	0.38	2.27e-6	Lung cancer;
UCEC	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg06462663	chr19:18546047	ISYNA1	0.51	6.46	0.47	1.42e-9	Breast cancer;
UCEC	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.87	-9.18	-0.6	3.65e-16	Blood metabolite levels;
UCEC	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.4	-4.51	-0.35	1.33e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2862064	1.000	rs2862064	chr5:156445827	C/G	cg12943317	chr5:156479607	HAVCR1	-0.67	-5.12	-0.39	9.49e-7	Platelet count;
UCEC	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-0.99	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	4.88	0.37	2.73e-6	IgG glycosylation;
UCEC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.73	6.42	0.47	1.78e-9	Cognitive function;
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg05132306	chr1:1846340	CALML6	-0.37	-4.72	-0.36	5.51e-6	Body mass index;
UCEC	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.86	9.79	0.63	9.54e-18	Menopause (age at onset);
UCEC	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.03	7.15	0.51	3.77e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg03859395	chr2:55845619	SMEK2	-0.88	-10.53	-0.66	1.14e-19	Metabolic syndrome;
UCEC	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.52	5.27	0.4	4.76e-7	Corneal astigmatism;
UCEC	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-7.81	-0.54	1.01e-12	Blood metabolite levels;
UCEC	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.62	5.92	0.44	2.15e-8	Breast size;
UCEC	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.57	6.99	0.5	8.75e-11	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.41	5.04	0.38	1.35e-6	Age-related hearing impairment;
UCEC	cis	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg20307385	chr11:47447363	PSMC3	0.66	4.57	0.35	1.04e-5	Intraocular pressure;
UCEC	cis	rs7115242	0.800	rs7931770	chr11:116866290	C/T	cg13068653	chr11:117074303	TAGLN	0.53	4.65	0.36	7.36e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
UCEC	cis	rs16957091	0.607	rs7182650	chr15:43342878	T/A	cg15904908	chr15:43213022	TTBK2	0.49	4.81	0.37	3.72e-6	MGMT methylation in smokers;
UCEC	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg14008862	chr17:28927542	LRRC37B2	0.76	5.31	0.4	3.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-8.07	-0.55	2.25e-13	Menarche (age at onset);
UCEC	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.34	0.4	3.48e-7	Birth weight;
UCEC	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg19318889	chr4:1322082	MAEA	0.42	4.84	0.37	3.22e-6	Obesity-related traits;
UCEC	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg10902566	chr4:727664	PCGF3	-0.57	-4.84	-0.37	3.23e-6	Systolic blood pressure;
UCEC	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs3785574	0.650	rs2320125	chr17:62008318	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-5.4	-0.41	2.66e-7	Height;
UCEC	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg19031565	chr17:72978794	NA	-0.38	-5.05	-0.38	1.29e-6	Systemic lupus erythematosus;
UCEC	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10946940	0.930	rs12215012	chr6:27507494	C/G	cg07836142	chr6:28411423	ZSCAN23	0.44	4.62	0.36	8.16e-6	Systemic lupus erythematosus;
UCEC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.14	13.32	0.74	4.76e-27	Cognitive function;
UCEC	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	1.09	6.99	0.5	9.12e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.41	-4.5	-0.35	1.36e-5	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg00612595	chr21:47717864	NA	0.48	5.3	0.4	4.22e-7	Testicular germ cell tumor;
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.71	-5.21	-0.39	6.2e-7	Narcolepsy;
UCEC	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.63	-0.48	5.88e-10	Response to antipsychotic treatment;
UCEC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-4.52	-0.35	1.29e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs12618769	0.597	rs11888595	chr2:99084708	T/G	cg14361474	chr2:99058762	NA	-0.47	-4.63	-0.36	8.06e-6	Bipolar disorder;
UCEC	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.56	4.9	0.37	2.54e-6	Bipolar disorder;
UCEC	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.7	-7.61	-0.53	3.02e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.97	7.02	0.5	7.49e-11	Obesity-related traits;
UCEC	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.56	6.25	0.46	4.16e-9	Menarche (age at onset);
UCEC	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.55	5.48	0.41	1.76e-7	Hemoglobin concentration;
UCEC	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	Androgen levels;
UCEC	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.56	-0.42	1.26e-7	Pubertal anthropometrics;
UCEC	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.58	-4.51	-0.35	1.3e-5	Blood pressure (smoking interaction);
UCEC	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.38	-4.74	-0.36	4.93e-6	Dupuytren's disease;
UCEC	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.84	0.37	3.32e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.54	-5.39	-0.41	2.7e-7	IgG glycosylation;
UCEC	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg05802129	chr4:122689817	NA	-0.54	-5.53	-0.41	1.45e-7	Type 2 diabetes;
UCEC	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.03e-8	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs12545109	0.800	rs2576591	chr8:57423606	A/G	cg07776626	chr8:57350775	NA	-0.49	-4.71	-0.36	5.6e-6	Obesity-related traits;
UCEC	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.72	-7.11	-0.51	4.72e-11	Monocyte count;
UCEC	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg21531300	chr14:75988800	BATF	-0.45	-4.7	-0.36	5.82e-6	IgG glycosylation;
UCEC	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12826209	chr6:26865740	GUSBL1	0.5	4.86	0.37	2.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs892864	0.685	rs6881856	chr5:127732536	C/T	cg17313118	chr5:127157258	NA	0.7	4.85	0.37	3.05e-6	Multiple system atrophy;
UCEC	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg16583315	chr14:65563665	MAX	-0.4	-4.59	-0.35	9.34e-6	Obesity-related traits;
UCEC	cis	rs2081015	0.701	rs890793	chr5:153573938	C/T	cg11921908	chr5:153825219	SAP30L	-0.45	-4.84	-0.37	3.2e-6	Carotid artery intima media thickness (sex interaction);
UCEC	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.2	0.39	6.44e-7	Breast cancer;
UCEC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.57	-0.42	1.15e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-9.78	-0.63	1.04e-17	Electrocardiographic conduction measures;
UCEC	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg18451016	chr1:38461880	NA	0.59	5.55	0.42	1.28e-7	Coronary artery disease;
UCEC	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.12	9.6	0.62	3.07e-17	Uric acid levels;
UCEC	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs12623288	0.510	rs7589861	chr2:46610479	A/G	cg04518274	chr2:46525028	EPAS1	-0.61	-4.52	-0.35	1.25e-5	Hair morphology;
UCEC	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-4.68	-0.36	6.42e-6	Metabolite levels;
UCEC	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.24	0.46	4.36e-9	Aortic root size;
UCEC	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.58	-5.21	-0.39	6.22e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.74	-0.36	5e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.38	-4.88	-0.37	2.75e-6	Body mass index;
UCEC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.63	5.92	0.44	2.21e-8	Response to diuretic therapy;
UCEC	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg21191810	chr6:118973309	C6orf204	0.44	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.12	14.73	0.77	9.75e-31	Schizophrenia;
UCEC	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.24	14.68	0.77	1.34e-30	Type 1 diabetes nephropathy;
UCEC	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg14558114	chr2:88469736	THNSL2	0.67	4.56	0.35	1.06e-5	Plasma clusterin levels;
UCEC	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.74	0.58	4.99e-15	Total body bone mineral density;
UCEC	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg23625390	chr15:77176239	SCAPER	0.44	4.5	0.35	1.35e-5	Blood metabolite levels;
UCEC	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.52	-5.25	-0.4	5.27e-7	Dupuytren's disease;
UCEC	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg13395646	chr4:1353034	KIAA1530	-0.7	-6.5	-0.47	1.18e-9	Obesity-related traits;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.8	8.78	0.59	3.8e-15	Longevity;Endometriosis;
UCEC	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.7	7.16	0.51	3.58e-11	Menopause (age at onset);
UCEC	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.15	0.39	8.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.52	-5.28	-0.4	4.55e-7	Breast cancer;
UCEC	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg20307385	chr11:47447363	PSMC3	0.63	4.59	0.35	9.54e-6	Axial length;
UCEC	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.65	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.91	9.23	0.61	2.82e-16	Post bronchodilator FEV1;
UCEC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24308560	chr3:49941425	MST1R	0.54	6.2	0.46	5.36e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12753920	0.724	rs981583	chr1:92571295	T/A	cg06442199	chr1:92414344	BRDT	0.43	4.69	0.36	6.08e-6	Systemic lupus erythematosus;
UCEC	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg03934865	chr2:198174659	NA	-0.45	-5.77	-0.43	4.54e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.9	8.57	0.58	1.32e-14	Colorectal adenoma (advanced);
UCEC	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-6.11	-0.45	8.43e-9	Chronic sinus infection;
UCEC	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.78	7.11	0.51	4.81e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	0.91	5.02	0.38	1.45e-6	IgG glycosylation;
UCEC	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.96	9.43	0.61	8.49e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.47	4.59	0.35	9.48e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.98	0.38	1.74e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.8	-0.37	3.79e-6	Resting heart rate;
UCEC	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.7	-8.02	-0.55	3.05e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.6	-6.44	-0.47	1.59e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg15848620	chr12:58087721	OS9	-0.51	-4.88	-0.37	2.79e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.16	15.53	0.79	8.36e-33	Cognitive function;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg12035532	chr1:1886765	KIAA1751	0.43	4.56	0.35	1.06e-5	Body mass index;
UCEC	cis	rs308447	0.516	rs6815982	chr4:123677472	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.59	-5.14	-0.39	8.64e-7	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg02158880	chr13:53174818	NA	0.49	5.9	0.44	2.35e-8	Lewy body disease;
UCEC	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-5.23	-0.4	5.72e-7	Response to antipsychotic treatment;
UCEC	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.58	-5.55	-0.42	1.27e-7	Large artery stroke;
UCEC	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.51	4.95	0.38	2e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs10507349	0.632	rs610475	chr13:26817813	C/T	cg01600817	chr13:26797529	RNF6	0.46	4.92	0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs139371	0.742	rs139318	chr22:39500932	G/A	cg15548613	chr22:38610795	MAFF	0.45	4.74	0.36	4.97e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.07	0.39	1.16e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs7874142	0.601	rs10776910	chr9:137708960	A/C	cg02902969	chr10:409431	DIP2C	-0.62	-6.7	-0.48	4.14e-10	Longevity;
UCEC	cis	rs6137726	0.508	rs2145058	chr20:22640770	T/C	cg08244522	chr20:23030533	THBD	-0.46	-4.57	-0.35	1.04e-5	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg27391334	chr7:1352002	NA	0.36	4.53	0.35	1.22e-5	Longevity;Endometriosis;
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	7.8	0.54	1.08e-12	Platelet count;
UCEC	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	4.96	0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs6546886	0.912	rs7589915	chr2:74282130	G/C	cg14702570	chr2:74259524	NA	-0.42	-5.06	-0.39	1.22e-6	Dialysis-related mortality;
UCEC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.89	-0.44	2.58e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs13401104	0.796	rs56338351	chr2:237119104	G/A	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.63	5.31	0.4	3.97e-7	Menopause (age at onset);
UCEC	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.88	-0.37	2.74e-6	Alzheimer's disease (late onset);
UCEC	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg20965017	chr5:231967	SDHA	-0.63	-5.92	-0.44	2.14e-8	Breast cancer;
UCEC	cis	rs713477	0.967	rs4243600	chr14:55910679	A/G	cg13175173	chr14:55914753	NA	-0.4	-4.56	-0.35	1.06e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.67	6.52	0.47	1.08e-9	Bladder cancer;
UCEC	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg00325661	chr8:49890786	NA	-0.59	-6.18	-0.45	5.97e-9	Sudden cardiac arrest;
UCEC	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs12365397	0.698	rs4755702	chr11:43272262	A/G	cg07515919	chr11:43391688	TTC17	-0.44	-4.57	-0.35	1.03e-5	Migraine;
UCEC	cis	rs7246967	0.673	rs7254097	chr19:22865900	T/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.5	5.19	0.39	6.8e-7	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.59	0.62	3.15e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.65	4.57	0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6437061	0.614	rs3116152	chr2:232950147	C/G	cg02061626	chr2:233274167	ALPPL2	-0.42	-4.57	-0.35	1.01e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.48	5.03	0.38	1.4e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg05874882	chr4:1763078	NA	-0.67	-6.3	-0.46	3.33e-9	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7246967	0.611	rs56271774	chr19:22831327	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg05501817	chr11:14380813	RRAS2	-0.49	-4.67	-0.36	6.76e-6	Sense of smell;
UCEC	cis	rs7937612	0.965	rs4381380	chr11:120273316	A/G	cg12584626	chr11:120203529	NA	-0.49	-4.93	-0.38	2.15e-6	Intraocular pressure;
UCEC	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.5	7.33	0.52	1.39e-11	Crohn's disease;
UCEC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg03959625	chr15:84868606	LOC388152	-0.47	-4.97	-0.38	1.86e-6	Schizophrenia;
UCEC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.58	5.9	0.44	2.35e-8	Dental caries;
UCEC	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.12	-8.65	-0.58	8.14e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.59	-6.37	-0.47	2.24e-9	Prostate cancer;
UCEC	cis	rs17122693	0.748	rs17122714	chr14:51104741	C/T	cg04730355	chr14:51134070	SAV1	0.98	10.27	0.65	5.57e-19	Cognitive performance;
UCEC	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.43	4.59	0.35	9.27e-6	Schizophrenia;
UCEC	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.94	-0.55	4.83e-13	Menarche (age at onset);
UCEC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.46	-4.82	-0.37	3.55e-6	Alcohol dependence;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.86	-0.37	3.04e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg09491104	chr22:46646882	C22orf40	-0.68	-7.77	-0.54	1.26e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12311346	chr5:56204834	C5orf35	0.61	5.93	0.44	2.03e-8	Type 2 diabetes;
UCEC	cis	rs758324	0.891	rs4425498	chr5:131220010	C/G	cg17578380	chr5:130847962	RAPGEF6	0.68	4.62	0.36	8.37e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-8.68	-0.58	6.8e-15	Morning vs. evening chronotype;
UCEC	cis	rs77861329	1.000	rs9868101	chr3:52138377	T/C	cg08692210	chr3:52188851	WDR51A	0.75	5.88	0.44	2.68e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	8.89	0.59	2.02e-15	Platelet count;
UCEC	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg13695892	chr22:41940480	POLR3H	-0.65	-5.31	-0.4	4.03e-7	Vitiligo;
UCEC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.47	5.07	0.39	1.17e-6	Headache;
UCEC	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg03859395	chr2:55845619	SMEK2	1.03	14.88	0.78	3.97e-31	Metabolic syndrome;
UCEC	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.73	-7.65	-0.53	2.49e-12	Tonsillectomy;
UCEC	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.66	6.24	0.46	4.51e-9	Aortic root size;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg19041857	chr6:27730383	NA	-0.48	-4.8	-0.37	3.83e-6	Pubertal anthropometrics;
UCEC	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-8.86	-0.59	2.45e-15	Exhaled nitric oxide output;
UCEC	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.01	-12.16	-0.71	5.61e-24	Dilated cardiomyopathy;
UCEC	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg01072550	chr1:21505969	NA	-0.53	-4.93	-0.38	2.23e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg22563815	chr15:78856949	CHRNA5	0.39	4.86	0.37	3.02e-6	Sudden cardiac arrest;
UCEC	cis	rs7246967	0.736	rs386119	chr19:23000818	G/A	cg05241461	chr19:22816980	ZNF492	0.52	5.06	0.39	1.24e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg17105886	chr17:28927953	LRRC37B2	0.5	4.53	0.35	1.2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.19e-6	Cannabis dependence symptom count;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg24703168	chr6:28411309	ZSCAN23	-0.52	-6.24	-0.46	4.33e-9	Pubertal anthropometrics;
UCEC	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.52	-5.18	-0.39	7.11e-7	Multiple sclerosis;
UCEC	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs791888	1.000	rs2762521	chr10:89414923	T/A	cg13926569	chr10:89418898	PAPSS2	-0.53	-6.43	-0.47	1.64e-9	Magnesium levels;
UCEC	cis	rs6461992	0.850	rs2023843	chr7:27243221	C/T	cg12455363	chr7:27200671	NA	0.95	4.6	0.35	8.93e-6	Systolic blood pressure;
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.9	9.45	0.61	7.57e-17	Cognitive function;
UCEC	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.64	5.41	0.41	2.49e-7	Alzheimer's disease;
UCEC	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.71	-7.68	-0.54	2.05e-12	Breast cancer;
UCEC	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.81	-5.8	-0.43	3.96e-8	Pediatric areal bone mineral density (radius);
UCEC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	7.31	0.52	1.55e-11	Platelet count;
UCEC	cis	rs7072216	0.687	rs11597428	chr10:100154247	G/C	cg19567339	chr10:100142640	NA	0.57	7.32	0.52	1.5e-11	Metabolite levels;
UCEC	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.62	6.27	0.46	3.8e-9	Glomerular filtration rate;
UCEC	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg13683864	chr3:40499215	RPL14	-0.65	-6.47	-0.47	1.39e-9	Renal cell carcinoma;
UCEC	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.62	5.05	0.38	1.28e-6	Corneal astigmatism;
UCEC	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.81	-5.19	-0.39	6.81e-7	Major depressive disorder;
UCEC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg00815214	chr21:47717953	NA	-0.4	-4.66	-0.36	7e-6	Testicular germ cell tumor;
UCEC	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg10932868	chr11:921992	NA	0.39	4.66	0.36	6.89e-6	Alzheimer's disease (late onset);
UCEC	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	1.0	13.26	0.74	6.7399999999999993e-27	Monocyte count;
UCEC	cis	rs4372836	0.504	rs7601413	chr2:29032238	C/T	cg09522027	chr2:28974177	PPP1CB	-0.71	-7.4	-0.52	9.8e-12	Body mass index;
UCEC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.66	-8.14	-0.56	1.55e-13	Height;
UCEC	cis	rs13401104	0.796	rs10929167	chr2:237115248	G/A	cg23897927	chr2:237117786	ASB18	-0.52	-4.51	-0.35	1.34e-5	Educational attainment;
UCEC	cis	rs13063635	0.915	rs17714101	chr3:45939802	G/A	cg16320329	chr3:45981161	FYCO1	-0.82	-4.68	-0.36	6.38e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9341808	0.667	rs2476826	chr6:80876064	C/T	cg08355045	chr6:80787529	NA	0.42	5.06	0.39	1.22e-6	Sitting height ratio;
UCEC	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	0.97	7.35	0.52	1.26e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18252515	chr7:66147081	NA	0.55	5.12	0.39	9.39e-7	Aortic root size;
UCEC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.64	0.36	7.75e-6	Menopause (age at onset);
UCEC	cis	rs847649	0.731	rs1829957	chr7:102687010	T/A	cg18108683	chr7:102477205	FBXL13	0.46	5.25	0.4	5.34e-7	Morning vs. evening chronotype;
UCEC	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.51	5.39	0.41	2.76e-7	Breast cancer;
UCEC	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.32	0.46	2.98e-9	Menarche (age at onset);
UCEC	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg22598563	chr5:131563921	P4HA2	-0.34	-4.56	-0.35	1.06e-5	Blood metabolite levels;
UCEC	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.49	4.51	0.35	1.3e-5	Alcohol dependence;
UCEC	cis	rs8020441	0.945	rs4259956	chr14:51170177	T/G	cg04730355	chr14:51134070	SAV1	0.71	6.41	0.47	1.84e-9	Cognitive performance;
UCEC	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.67	-5.8	-0.43	3.99e-8	Obesity-related traits;
UCEC	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.41	-4.96	-0.38	1.89e-6	Subjective well-being;
UCEC	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	0.83	5.26	0.4	5.06e-7	Diabetic retinopathy;
UCEC	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.51	-5.16	-0.39	7.85e-7	Schizophrenia;
UCEC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.45	5.93	0.44	2.06e-8	Coronary artery disease;
UCEC	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.75	-0.43	4.97e-8	Cardiac Troponin-T levels;
UCEC	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	4.52	0.35	1.27e-5	Diabetic retinopathy;
UCEC	cis	rs4372836	0.504	rs7601934	chr2:29032673	A/C	cg09522027	chr2:28974177	PPP1CB	0.72	7.32	0.52	1.52e-11	Body mass index;
UCEC	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg13695892	chr22:41940480	POLR3H	0.7	5.52	0.41	1.53e-7	Vitiligo;
UCEC	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.94	10.92	0.67	1.04e-20	Breast cancer;
UCEC	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg01072550	chr1:21505969	NA	-0.52	-5.01	-0.38	1.53e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.5	-5.72	-0.43	5.67e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-9.37	-0.61	1.17e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-8.6	-0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	4.94	0.38	2.07e-6	Response to antipsychotic treatment;
UCEC	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-6.54	-0.47	9.49e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.52	-6.07	-0.45	1.04e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg13147721	chr7:65941812	NA	-0.94	-6.91	-0.5	1.35e-10	Diabetic kidney disease;
UCEC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.12	-0.45	7.9e-9	Aortic root size;
UCEC	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs2200578	1.000	rs7566277	chr2:99916242	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.8	5.76	0.43	4.67e-8	IgG glycosylation;
UCEC	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.38	-0.47	2.14e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.59	5.48	0.41	1.77e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.56	-4.89	-0.37	2.58e-6	Metabolite levels;
UCEC	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg11871910	chr12:69753446	YEATS4	0.62	5.98	0.44	1.64e-8	Response to diuretic therapy;
UCEC	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.53	-5.88	-0.44	2.62e-8	IgG glycosylation;
UCEC	cis	rs7246967	0.736	rs423687	chr19:23000745	C/T	cg05241461	chr19:22816980	ZNF492	0.52	5.06	0.39	1.24e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	1.08	7.59	0.53	3.45e-12	Obesity-related traits;
UCEC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	7.77	0.54	1.24e-12	Alzheimer's disease;
UCEC	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.71	-5.06	-0.38	1.25e-6	Aortic root size;
UCEC	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.08	0.45	1e-8	Rheumatoid arthritis;
UCEC	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg23070574	chr3:14187308	XPC	0.41	4.54	0.35	1.18e-5	Ovarian reserve;
UCEC	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	7.36	0.52	1.21e-11	Exhaled nitric oxide levels;
UCEC	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg24069376	chr3:38537580	EXOG	-0.36	-4.69	-0.36	6.24e-6	Electrocardiographic conduction measures;
UCEC	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.51	4.9	0.37	2.54e-6	Hemoglobin concentration;
UCEC	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.59	4.98	0.38	1.74e-6	Migraine;
UCEC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.56	-6.0	-0.44	1.44e-8	Electroencephalogram traits;
UCEC	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.65	7.65	0.53	2.5e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg21770322	chr7:97807741	LMTK2	0.82	13.93	0.75	1.2e-28	Breast cancer;
UCEC	cis	rs12644436	0.896	rs7655253	chr4:88777396	A/C	cg27179352	chr4:88029472	AFF1	-0.42	-4.95	-0.38	1.98e-6	HIV-1 viral setpoint;
UCEC	cis	rs7945071	0.507	rs4753892	chr11:110302643	C/T	cg26763524	chr11:110300429	FDX1	-0.39	-4.63	-0.36	8.05e-6	Cognitive function;
UCEC	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.49	-5.04	-0.38	1.33e-6	IgG glycosylation;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	trans	rs1923243	0.649	rs7523396	chr1:73371702	T/C	cg17780956	chr4:156297616	MAP9	-0.65	-6.88	-0.49	1.6e-10	Migraine;
UCEC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.48	4.77	0.37	4.39e-6	Menopause (age at onset);
UCEC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.9	9.11	0.6	5.47e-16	Heart rate;
UCEC	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.04	8.46	0.57	2.53e-14	Exhaled nitric oxide output;
UCEC	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-4.5	-0.35	1.37e-5	Schizophrenia;
UCEC	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13939156	chr17:80058883	NA	-0.37	-4.65	-0.36	7.21e-6	Life satisfaction;
UCEC	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.21	-10.04	-0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs17433710	0.516	rs10737487	chr1:162667331	G/A	cg04915463	chr1:162039957	NOS1AP	0.48	4.79	0.37	4.1e-6	Dupuytren's disease;
UCEC	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	0.92	8.97	0.59	1.25e-15	Heart rate;
UCEC	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	0.8	6.02	0.44	1.32e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.8	-6.23	-0.46	4.73e-9	White matter hyperintensity burden;
UCEC	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg18099408	chr3:52552593	STAB1	-0.42	-4.83	-0.37	3.42e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg20007245	chr22:24372913	LOC391322	-0.58	-6.27	-0.46	3.74e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.37	4.93	0.38	2.24e-6	Crohn's disease;
UCEC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs7246967	0.800	rs2061774	chr19:23025775	C/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.66	-7.23	-0.51	2.42e-11	Extraversion;
UCEC	cis	rs6893807	1.000	rs2304608	chr5:87962298	C/A	cg09002922	chr5:87956389	LOC645323	-0.6	-6.08	-0.45	9.79e-9	Body mass index;
UCEC	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.0	0.44	1.47e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg10130564	chr11:117069849	TAGLN	-0.35	-4.52	-0.35	1.28e-5	Blood protein levels;
UCEC	cis	rs1635	0.655	rs9380024	chr6:27830354	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.74	-5.27	-0.4	4.72e-7	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg06784218	chr1:46089804	CCDC17	0.44	4.91	0.38	2.35e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.26	-0.46	3.92e-9	Post bronchodilator FEV1;
UCEC	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg08755490	chr11:65554678	OVOL1	0.51	5.41	0.41	2.53e-7	Acne (severe);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09698166	chr20:21106763	PLK1S1	0.64	7.93	0.55	5.14e-13	Warfarin maintenance dose;
UCEC	cis	rs10208940	0.841	rs7598760	chr2:68837054	A/G	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg23324259	chr8:82754387	SNX16	0.58	5.1	0.39	1.02e-6	Diastolic blood pressure;
UCEC	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.68	-8.08	-0.55	2.18e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs731174	0.802	rs776052	chr1:38179143	C/T	cg06917450	chr1:38156652	C1orf109	-0.59	-5.35	-0.4	3.34e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.56	-5.42	-0.41	2.37e-7	Asthma (sex interaction);
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg01013738	chr7:1149705	C7orf50	-0.49	-4.55	-0.35	1.1e-5	Longevity;Endometriosis;
UCEC	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.46	4.81	0.37	3.63e-6	Metabolic syndrome;
UCEC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.67	6.9	0.49	1.43e-10	Body mass index;
UCEC	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.49	-5.45	-0.41	2.08e-7	Prostate cancer;
UCEC	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg21770322	chr7:97807741	LMTK2	0.53	6.5	0.47	1.15e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.48	-4.61	-0.36	8.55e-6	Alcohol dependence;
UCEC	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.55	-5.43	-0.41	2.26e-7	Asthma (sex interaction);
UCEC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg23978390	chr7:1156363	C7orf50	0.46	4.75	0.36	4.73e-6	Longevity;Endometriosis;
UCEC	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.66	-6.12	-0.45	8.17e-9	Aortic root size;
UCEC	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.66	-7.72	-0.54	1.64e-12	Monocyte count;
UCEC	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-9.82	-0.63	7.96e-18	Ulcerative colitis;
UCEC	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg20026190	chr17:76395443	PGS1	0.38	4.59	0.35	9.53e-6	HDL cholesterol levels;
UCEC	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg17279458	chr3:44753948	ZNF502	-0.43	-4.71	-0.36	5.63e-6	Depressive symptoms;
UCEC	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg13683864	chr3:40499215	RPL14	-0.56	-5.82	-0.43	3.5e-8	Renal cell carcinoma;
UCEC	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.22	11.92	0.7	2.38e-23	Corneal structure;
UCEC	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.71	8.48	0.57	2.18e-14	Prudent dietary pattern;
UCEC	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.88	-9.51	-0.62	5.24e-17	Parkinson's disease;
UCEC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.54	-5.22	-0.4	6.06e-7	Lymphocyte counts;
UCEC	cis	rs17106184	0.582	rs60848584	chr1:51010143	C/T	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg06214220	chr9:36400252	RNF38	-0.59	-6.72	-0.48	3.69e-10	Breast cancer;
UCEC	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.55	5.95	0.44	1.88e-8	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.62	-6.83	-0.49	2.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs59104589	0.517	rs3821281	chr2:242385340	A/G	cg19488206	chr2:242435732	STK25	0.52	4.61	0.36	8.7e-6	Fibrinogen levels;
UCEC	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg08890418	chr1:21044141	KIF17	0.69	6.55	0.48	9.04e-10	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.86	-0.44	2.85e-8	Joint mobility (Beighton score);
UCEC	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.56	5.06	0.39	1.25e-6	Corneal astigmatism;
UCEC	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.0	-0.38	1.58e-6	Breast cancer;
UCEC	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05776053	chr2:74358815	NA	0.41	5.07	0.39	1.17e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.58	5.19	0.39	6.74e-7	Corneal astigmatism;
UCEC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.23	-15.21	-0.78	5.67e-32	Breast cancer;
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.86	-0.49	1.77e-10	Depression;
UCEC	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.5	4.76	0.37	4.68e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.54e-12	Intelligence (multi-trait analysis);
UCEC	trans	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02355339	chr19:35517344	GRAMD1A	-0.68	-6.99	-0.5	8.88e-11	Smoking behavior;
UCEC	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.69	6.29	0.46	3.49e-9	Aortic root size;
UCEC	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg18681998	chr4:17616180	MED28	0.63	6.82	0.49	2.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	4.73	0.36	5.24e-6	Lung cancer in ever smokers;
UCEC	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.52	5.29	0.4	4.45e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs12618769	0.656	rs3820943	chr2:99123177	G/C	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.24	-0.46	4.34e-9	Response to antipsychotic treatment;
UCEC	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg19743168	chr1:23544995	NA	0.44	6.29	0.46	3.37e-9	Height;
UCEC	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.79	-0.37	3.99e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.48	-5.03	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	7.79	0.54	1.08e-12	Tonsillectomy;
UCEC	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.47	4.89	0.37	2.59e-6	Vitiligo;
UCEC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	4.69	0.36	6.09e-6	Bipolar disorder;
UCEC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg05802129	chr4:122689817	NA	-0.54	-5.54	-0.42	1.36e-7	Type 2 diabetes;
UCEC	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.47	-5.45	-0.41	2.07e-7	Attention deficit hyperactivity disorder;
UCEC	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.55	5.82	0.43	3.49e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs7212590	0.581	rs8064505	chr17:57838831	G/A	cg10252138	chr17:58120427	NA	-0.67	-4.59	-0.35	9.5e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.65	5.78	0.43	4.3e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	0.76	6.17	0.45	6.24e-9	Blood protein levels;
UCEC	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg05501817	chr11:14380813	RRAS2	-0.51	-4.78	-0.37	4.15e-6	Sense of smell;
UCEC	cis	rs6952808	0.698	rs11765639	chr7:1986738	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	5.83	0.43	3.39e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.55	5.72	0.43	5.76e-8	Prostate cancer;
UCEC	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	0.93	9.49	0.62	5.91e-17	Heart rate;
UCEC	cis	rs7246967	0.542	rs56355379	chr19:22900455	C/T	cg05241461	chr19:22816980	ZNF492	0.56	5.96	0.44	1.82e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg01072550	chr1:21505969	NA	-0.62	-6.6	-0.48	7.11e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg05660106	chr1:15850417	CASP9	1.04	11.84	0.7	3.92e-23	Systolic blood pressure;
UCEC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.68	5.55	0.42	1.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs758324	0.755	rs2221674	chr5:131242218	T/A	cg23943829	chr5:132009111	IL4	-0.35	-4.53	-0.35	1.19e-5	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg24631222	chr15:78858424	CHRNA5	0.8	7.06	0.5	6.28e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.92	8.85	0.59	2.55e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.39	5.64	0.42	8.39e-8	Vitiligo;
UCEC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.89e-7	Hemoglobin concentration;
UCEC	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.58	6.79	0.49	2.53e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.34	-0.4	3.49e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.15	0.39	8.15e-7	Breast cancer;
UCEC	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.41	-5.55	-0.42	1.3e-7	Alcohol dependence;
UCEC	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.97	7.43	0.52	8.11e-12	Monobrow;
UCEC	cis	rs6446731	0.517	rs2071668	chr4:3269905	A/G	cg08886695	chr4:3369023	RGS12	0.43	4.91	0.38	2.4e-6	Mean platelet volume;
UCEC	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.51	5.39	0.41	2.73e-7	Schizophrenia;
UCEC	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.34	4.57	0.35	1.01e-5	Prostate cancer;
UCEC	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.18	0.51	3.16e-11	Platelet count;
UCEC	cis	rs11235843	0.929	rs112650783	chr11:73389928	G/A	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	5.71	0.43	6.09e-8	Cognitive test performance;
UCEC	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg02158880	chr13:53174818	NA	0.42	4.63	0.36	7.89e-6	Lewy body disease;
UCEC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.61	0.36	8.75e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs925550	0.867	rs309389	chr4:123610706	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.56	-5.24	-0.4	5.52e-7	Primary biliary cholangitis;
UCEC	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	4.53	0.35	1.2e-5	Depressive episodes in bipolar disorder;
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs1940013	0.639	rs4937694	chr11:132243518	C/T	cg11473001	chr11:131780499	NTM	0.42	4.74	0.36	5.06e-6	Sleep-related phenotypes;
UCEC	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg26781129	chr3:44753946	ZNF502	-0.49	-5.36	-0.4	3.14e-7	Depressive symptoms;
UCEC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg04450456	chr4:17643702	FAM184B	-0.41	-4.57	-0.35	1.03e-5	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.82	11.07	0.67	4.27e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.79	-0.43	4.1e-8	Breast cancer;
UCEC	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg12610070	chr10:71211762	TSPAN15	-0.33	-4.55	-0.35	1.11e-5	Venous thromboembolism;
UCEC	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.53	5.13	0.39	9.16e-7	Uric acid levels;
UCEC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg05962950	chr11:130786565	SNX19	0.76	6.99	0.5	8.94e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.64	8.34	0.57	4.81e-14	Anterior chamber depth;
UCEC	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.7	7.22	0.51	2.53e-11	Menopause (age at onset);
UCEC	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.54	5.78	0.43	4.22e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg05775895	chr3:12838266	CAND2	0.55	4.82	0.37	3.51e-6	QRS complex (12-leadsum);
UCEC	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.6	-4.59	-0.35	9.6e-6	Initial pursuit acceleration;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.39	-0.47	2.04e-9	Cardiac Troponin-T levels;
UCEC	cis	rs7965445	0.614	rs73156178	chr12:132008021	C/T	cg17175626	chr12:132445368	EP400	-0.4	-4.69	-0.36	6.06e-6	Mortality in heart failure;
UCEC	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-6.89	-0.49	1.49e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.48	-4.77	-0.37	4.43e-6	Schizophrenia;
UCEC	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.56	6.54	0.47	9.54e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11958404	0.932	rs72816542	chr5:157416402	C/T	cg05962755	chr5:157440814	NA	0.76	4.92	0.38	2.25e-6	IgG glycosylation;
UCEC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	4.99	0.38	1.67e-6	Obesity-related traits;
UCEC	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.22	-0.4	5.94e-7	Bipolar disorder;
UCEC	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	4.95	0.38	1.97e-6	Cognitive test performance;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15057251	chr18:32621312	MAPRE2	0.59	7.17	0.51	3.42e-11	Warfarin maintenance dose;
UCEC	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.51	4.92	0.38	2.25e-6	Corneal astigmatism;
UCEC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg05347473	chr6:146136440	FBXO30	-0.42	-4.67	-0.36	6.8e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg25025879	chr12:53359317	NA	-0.59	-6.67	-0.48	4.75e-10	Cancer (pleiotropy);
UCEC	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.38	5.08	0.39	1.14e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.1	-0.45	9.08e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.11	9.68	0.62	1.89e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.58	-6.06	-0.45	1.08e-8	Hepatocellular carcinoma;
UCEC	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.6	-7.43	-0.52	8.35e-12	Inhibitory control;
UCEC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.72	8.42	0.57	3.18e-14	Menopause (age at onset);
UCEC	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03576123	chr11:487126	PTDSS2	-0.96	-7.01	-0.5	8.17e-11	Body mass index;
UCEC	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13939156	chr17:80058883	NA	-0.36	-4.55	-0.35	1.12e-5	Life satisfaction;
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.81	8.33	0.57	5.24e-14	Prudent dietary pattern;
UCEC	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.6	0.42	1.03e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9942416	0.533	rs12109685	chr5:75024066	A/G	cg19683494	chr5:74908142	NA	0.64	4.56	0.35	1.07e-5	Age-related disease endophenotypes;
UCEC	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.8	4.91	0.38	2.37e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg20007245	chr22:24372913	LOC391322	0.65	6.9	0.49	1.41e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg12596171	chr3:113251061	SIDT1	-0.54	-4.85	-0.37	3.17e-6	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.44	4.68	0.36	6.36e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.78	-6.22	-0.46	4.78e-9	Neuroticism;
UCEC	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg27535305	chr1:53392650	SCP2	-0.44	-5.68	-0.42	6.85e-8	Monocyte count;
UCEC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.5	4.72	0.36	5.34e-6	High light scatter reticulocyte count;
UCEC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.92	4.75	0.37	4.69e-6	Plasma clusterin levels;
UCEC	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-4.76	-0.37	4.67e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.99	-11.68	-0.69	1.03e-22	Cognitive function;
UCEC	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.63	-7.29	-0.52	1.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.15	14.93	0.78	2.99e-31	Cognitive function;
UCEC	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.52	4.64	0.36	7.69e-6	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
UCEC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.64	0.36	7.54e-6	Breast cancer;
UCEC	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.2e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.74	-0.36	5.1e-6	Pubertal anthropometrics;
UCEC	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	1.0	9.8	0.63	9.25e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.57	-4.93	-0.38	2.22e-6	Coronary artery disease;
UCEC	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.95	-7.11	-0.51	4.69e-11	Exhaled nitric oxide levels;
UCEC	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.76	8.67	0.58	7.34e-15	Waist circumference;Body mass index;
UCEC	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	5.4	0.41	2.65e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.35	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.45	4.73	0.36	5.19e-6	Schizophrenia;
UCEC	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.42	5.58	0.42	1.15e-7	Blood protein levels;
UCEC	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.62	-0.42	9.43e-8	Neutrophil percentage of white cells;
UCEC	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.72	6.53	0.47	1.02e-9	Height;
UCEC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg06027949	chr8:82754900	SNX16	-0.6	-4.96	-0.38	1.88e-6	Diastolic blood pressure;
UCEC	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs17106184	1.000	rs72904719	chr1:51324546	G/T	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.72	7.47	0.52	6.45e-12	Primary sclerosing cholangitis;
UCEC	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.52	4.7	0.36	5.83e-6	Coronary artery disease;
UCEC	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.64	6.1	0.45	8.85e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.93	-13.44	-0.74	2.36e-27	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	cg07049167	chr1:166818506	POGK	-0.76	-7.0	-0.5	8.42e-11	Refractive astigmatism;
UCEC	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.85	-0.43	3.07e-8	Aortic root size;
UCEC	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.83	0.37	3.46e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.85	10.84	0.67	1.72e-20	IgG glycosylation;
UCEC	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.43	4.96	0.38	1.88e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.89	-7.6	-0.53	3.13e-12	Coronary artery calcification;
UCEC	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.21	-0.51	2.69e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg25011176	chr20:3776985	CDC25B	0.54	5.09	0.39	1.06e-6	Bipolar disorder;
UCEC	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-5.35	-0.4	3.27e-7	Homoarginine levels;
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.86	9.11	0.6	5.68e-16	Menarche (age at onset);
UCEC	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.65	-6.02	-0.44	1.35e-8	Blood protein levels;
UCEC	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.44	-4.59	-0.35	9.48e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.6	-5.54	-0.42	1.38e-7	Neurofibrillary tangles;
UCEC	cis	rs4851266	1.000	rs6750097	chr2:100836885	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.6	7.35	0.52	1.29e-11	Multiple myeloma;
UCEC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.56	-4.95	-0.38	2e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.52	4.77	0.37	4.46e-6	Coronary artery disease;
UCEC	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.72	-8.17	-0.56	1.3e-13	Waist circumference;Body mass index;
UCEC	cis	rs10503871	0.625	rs4292648	chr8:30324803	C/T	cg26383811	chr8:30366931	RBPMS	0.5	5.28	0.4	4.5e-7	Metabolite levels  (X-11787);
UCEC	cis	rs4448343	0.963	rs28457763	chr9:98260514	G/A	cg13456470	chr9:98266766	PTCH1	0.36	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.84	-5.54	-0.42	1.34e-7	Bipolar disorder;
UCEC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.51	-4.84	-0.37	3.26e-6	Diastolic blood pressure;
UCEC	cis	rs2136093	0.506	rs12137705	chr1:90851025	C/T	cg01786362	chr1:90274359	NA	-0.38	-4.69	-0.36	6.08e-6	Response to antidepressants;
UCEC	cis	rs7937612	1.000	rs7104639	chr11:120239456	C/G	cg12584626	chr11:120203529	NA	0.54	5.47	0.41	1.89e-7	Intraocular pressure;
UCEC	cis	rs7646881	0.544	rs28856044	chr3:158302759	T/C	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.43e-6	Tetralogy of Fallot;
UCEC	cis	rs692916	0.704	rs1701767	chr18:60571079	G/A	cg07187971	chr18:60481018	PHLPP1	-0.37	-4.6	-0.35	9.02e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.52	-5.78	-0.43	4.27e-8	Prostate cancer;
UCEC	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.38	-4.98	-0.38	1.76e-6	Body mass index;
UCEC	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg17515076	chr17:73810948	UNK	-0.53	-5.93	-0.44	2.1e-8	White matter hyperintensity burden;
UCEC	trans	rs9821348	0.929	rs76892996	chr3:106784363	C/T	cg22693702	chr11:62105635	ASRGL1	-1.04	-6.68	-0.48	4.51e-10	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.53	2.09e-12	IgG glycosylation;
UCEC	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	Bipolar disorder;
UCEC	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	0.54	5.39	0.41	2.73e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24308560	chr3:49941425	MST1R	0.53	6.03	0.45	1.26e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.85	-9.3	-0.61	1.79e-16	Breast cancer;
UCEC	cis	rs6546886	0.912	rs7601526	chr2:74278481	A/G	cg14702570	chr2:74259524	NA	-0.43	-5.26	-0.4	5.03e-7	Dialysis-related mortality;
UCEC	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.73	7.71	0.54	1.73e-12	Testicular germ cell tumor;
UCEC	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg06238570	chr21:40685208	BRWD1	0.81	7.4	0.52	9.8e-12	Cognitive function;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.52	-5.98	-0.44	1.63e-8	Pulmonary function;
UCEC	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.66	-7.53	-0.53	4.73e-12	Systemic sclerosis;
UCEC	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.62	6.05	0.45	1.17e-8	Vitamin D levels;
UCEC	cis	rs12644436	1.000	rs12644725	chr4:88785815	A/G	cg27179352	chr4:88029472	AFF1	0.42	4.59	0.35	9.47e-6	HIV-1 viral setpoint;
UCEC	cis	rs925228	0.869	rs2339929	chr2:24051245	C/T	cg16945982	chr2:25016118	CENPO;C2orf79	-0.55	-4.95	-0.38	2.02e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg07930552	chr6:133119739	C6orf192	0.94	8.59	0.58	1.17e-14	Type 2 diabetes nephropathy;
UCEC	cis	rs12635074	0.521	rs17825368	chr3:56306140	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.34	4.77	0.37	4.4e-6	Morning vs. evening chronotype;
UCEC	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.79	-8.13	-0.56	1.63e-13	Mosquito bite size;
UCEC	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.73	-7.01	-0.5	7.83e-11	Ulcerative colitis;
UCEC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg09655341	chr17:79618100	PDE6G	-0.3	-4.55	-0.35	1.12e-5	Eye color traits;
UCEC	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.31	-7.9	-0.55	5.95e-13	Schizophrenia;
UCEC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	5.45	0.41	2.08e-7	Menarche (age at onset);
UCEC	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg05527609	chr1:210001259	C1orf107	-0.74	-5.23	-0.4	5.69e-7	Red blood cell count;
UCEC	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.49	4.7	0.36	6.01e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.38	0.41	2.94e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.96	0.5	1.03e-10	Coronary artery disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25441200	chr7:156742235	NOM1	0.59	7.1	0.51	4.82e-11	Warfarin maintenance dose;
UCEC	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg17420585	chr12:42539391	GXYLT1	0.39	4.98	0.38	1.75e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.65	-6.3	-0.46	3.23e-9	Metabolite levels;
UCEC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.64	0.42	8.33e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg23018236	chr17:30244563	NA	-0.69	-4.69	-0.36	6.13e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	1.12	6.12	0.45	7.97e-9	Skin colour saturation;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.6	0.58	1.12e-14	Platelet count;
UCEC	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	0.77	9.33	0.61	1.56e-16	Triglycerides;
UCEC	cis	rs8105895	1.000	rs8100042	chr19:22127841	T/A	cg20662725	chr19:22235022	ZNF257	-0.65	-5.45	-0.41	2.04e-7	Body mass index (change over time);
UCEC	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.8	-5.95	-0.44	1.91e-8	Verbal memory performance (residualized delayed recall change);
UCEC	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-0.99	-8.38	-0.57	3.98e-14	Blood pressure (smoking interaction);
UCEC	trans	rs17685	0.767	rs10954732	chr7:75611149	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.71	-8.3	-0.56	6.17e-14	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	6.06	0.45	1.1e-8	Height;
UCEC	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.65	5.97	0.44	1.7e-8	Schizophrenia;
UCEC	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg13695892	chr22:41940480	POLR3H	-0.7	-5.47	-0.41	1.92e-7	Vitiligo;
UCEC	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-1.07	-9.49	-0.62	5.71e-17	Blood pressure (smoking interaction);
UCEC	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg12317470	chr15:67143691	NA	-0.59	-5.12	-0.39	9.62e-7	Lung cancer (smoking interaction);
UCEC	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.72	6.02	0.44	1.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-6.42	-0.47	1.75e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.49	6.46	0.47	1.45e-9	Total body bone mineral density;
UCEC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.65	-6.4	-0.47	1.98e-9	Diastolic blood pressure;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.47	-4.89	-0.37	2.57e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.12	7.3	0.52	1.63e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg00747619	chr16:12897686	CPPED1	-0.73	-5.29	-0.4	4.27e-7	Testicular germ cell tumor;
UCEC	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	4.58	0.35	9.76e-6	Multiple sclerosis;
UCEC	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg00250761	chr1:31883323	NA	-0.39	-5.14	-0.39	8.44e-7	Alcohol dependence;
UCEC	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.65	7.47	0.52	6.46e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.19	-0.39	6.73e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.46	6.75	0.49	3.24e-10	HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs6684428	0.536	rs11583130	chr1:56400111	A/G	cg11651538	chr1:56320950	NA	-0.44	-4.63	-0.36	7.82e-6	Airflow obstruction;
UCEC	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.54	4.95	0.38	2.04e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.44	-4.64	-0.36	7.49e-6	Homocysteine levels;
UCEC	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg21770322	chr7:97807741	LMTK2	0.52	6.07	0.45	1.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.86	0.37	3.03e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.46	-4.56	-0.35	1.08e-5	Schizophrenia;
UCEC	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.68	7.61	0.53	3.05e-12	Menopause (age at onset);
UCEC	cis	rs372883	0.530	rs11088110	chr21:30543373	G/A	cg24692254	chr21:30365293	RNF160	-0.56	-4.96	-0.38	1.95e-6	Pancreatic cancer;
UCEC	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.79	-6.23	-0.46	4.6e-9	Corneal structure;
UCEC	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.45	-4.51	-0.35	1.3e-5	Obesity-related traits;
UCEC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.71	6.02	0.44	1.33e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.72	6.39	0.47	2.11e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.6	-4.72	-0.36	5.53e-6	Coronary artery calcification;
UCEC	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.55	5.31	0.4	4.06e-7	Platelet count;
UCEC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	0.45	4.74	0.36	5.04e-6	Lymphocyte counts;
UCEC	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.62	-6.32	-0.46	2.91e-9	Diastolic blood pressure;
UCEC	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	6.33	0.46	2.87e-9	Total body bone mineral density;
UCEC	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.63	5.35	0.4	3.24e-7	High light scatter reticulocyte count;
UCEC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-7.09	-0.5	5.26e-11	Initial pursuit acceleration;
UCEC	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.11	-0.39	9.66e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.67	5.58	0.42	1.12e-7	Smoking initiation;
UCEC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg14092571	chr14:90743983	NA	-0.44	-5.83	-0.43	3.4e-8	Mortality in heart failure;
UCEC	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg26781129	chr3:44753946	ZNF502	-0.41	-4.56	-0.35	1.05e-5	Depressive symptoms;
UCEC	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.92	8.3	0.57	6.02e-14	Bladder cancer;
UCEC	cis	rs17106184	1.000	rs72904732	chr1:51342809	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.5	4.55	0.35	1.11e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs492146	0.740	rs1032418	chr6:52834957	A/T	cg24393602	chr6:52860404	GSTA4	0.55	4.74	0.36	5.1e-6	Epilepsy (remission after treatment);
UCEC	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.46	-4.83	-0.37	3.4e-6	Schizophrenia;
UCEC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg13777783	chr17:79615861	NA	-0.34	-4.68	-0.36	6.47e-6	Eye color traits;
UCEC	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.72	6.89	0.49	1.52e-10	Crohn's disease;
UCEC	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.53	5.85	0.43	3.01e-8	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs883115	1.000	rs6658957	chr1:224814053	A/G	cg01808320	chr1:224927238	CNIH3	-0.41	-4.91	-0.38	2.35e-6	Cancer;
UCEC	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.86	0.37	2.94e-6	Schizophrenia;
UCEC	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.63	-4.86	-0.37	2.92e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.47	6.36	0.46	2.38e-9	Alcohol dependence;
UCEC	cis	rs7004769	0.554	rs79352655	chr8:9175228	G/T	cg27598956	chr8:9758788	LOC157627	-0.47	-4.53	-0.35	1.21e-5	Fibrinogen levels;
UCEC	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg06521331	chr12:34319734	NA	-0.53	-4.68	-0.36	6.32e-6	Morning vs. evening chronotype;
UCEC	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.54	5.61	0.42	9.78e-8	Schizophrenia;
UCEC	cis	rs7113850	0.541	rs80243979	chr11:24231811	A/C	ch.11.24196551F	chr11:24239977	NA	0.65	5.09	0.39	1.08e-6	Bone fracture in osteoporosis;
UCEC	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-0.89	-11.57	-0.69	2.04e-22	Height;
UCEC	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.42	-4.68	-0.36	6.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg24687543	chr11:63912206	MACROD1	0.4	5.03	0.38	1.42e-6	Platelet count;
UCEC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.59	5.45	0.41	2.03e-7	Type 2 diabetes;
UCEC	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg04733989	chr22:42467013	NAGA	-0.48	-4.94	-0.38	2.06e-6	Cognitive function;
UCEC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.5	4.56	0.35	1.09e-5	Breast cancer;
UCEC	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.8	7.3	0.52	1.64e-11	Bladder cancer;
UCEC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.8	-0.37	3.92e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.66	-7.09	-0.51	5.08e-11	Itch intensity from mosquito bite;
UCEC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	5.21	0.39	6.31e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.44	4.66	0.36	6.89e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs4478037	0.915	rs60206069	chr3:33152508	C/A	cg19404215	chr3:33155277	CRTAP	1.03	8.53	0.58	1.61e-14	Major depressive disorder;
UCEC	cis	rs13095912	1.000	rs13340181	chr3:185325612	T/C	cg11274856	chr3:185301563	NA	0.55	7.38	0.52	1.05e-11	Systolic blood pressure;
UCEC	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.38	0.61	1.13e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg07169764	chr2:136633963	MCM6	0.67	6.71	0.48	3.91e-10	Mosquito bite size;
UCEC	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.7	-9.43	-0.61	8.43e-17	Itch intensity from mosquito bite;
UCEC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	0.98	6.48	0.47	1.33e-9	Skin colour saturation;
UCEC	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.56	-5.04	-0.38	1.37e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.44	5.29	0.4	4.29e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17106184	1.000	rs115072809	chr1:51023860	C/T	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.21	-0.39	6.25e-7	Breast cancer;
UCEC	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-0.99	-13.53	-0.74	1.3e-27	Height;
UCEC	cis	rs6677604	0.909	rs16840522	chr1:196710916	T/C	cg07209298	chr1:196795943	CFHR1	0.44	4.59	0.35	9.47e-6	IgA nephropathy;Nephropathy;Blood protein levels;
UCEC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg01689657	chr7:91764605	CYP51A1	-0.43	-5.48	-0.41	1.79e-7	Breast cancer;
UCEC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.42	-5.03	-0.38	1.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11355319	chr5:89825117	LYSMD3	0.55	6.83	0.49	2.08e-10	Warfarin maintenance dose;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.51	0.65	1.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	9.97	0.64	3.33e-18	Menopause (age at onset);
UCEC	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.47	4.71	0.36	5.62e-6	Obesity-related traits;
UCEC	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.6	5.64	0.42	8.39e-8	Birth weight;
UCEC	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg14078730	chr11:63896557	MACROD1	0.63	4.87	0.37	2.79e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg03714773	chr7:91764589	CYP51A1	0.4	4.89	0.37	2.65e-6	Breast cancer;
UCEC	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg06784218	chr1:46089804	CCDC17	0.53	6.65	0.48	5.46e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.58	8.26	0.56	7.64e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.73	-7.59	-0.53	3.46e-12	Menarche (age at onset);
UCEC	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.52	5.82	0.43	3.62e-8	Life satisfaction;
UCEC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg24687543	chr11:63912206	MACROD1	0.39	4.8	0.37	3.87e-6	Platelet count;
UCEC	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.76e-17	Menopause (age at onset);
UCEC	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg14008862	chr17:28927542	LRRC37B2	0.78	5.05	0.38	1.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7106204	0.562	rs7109606	chr11:24251314	G/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg24703168	chr6:28411309	ZSCAN23	-0.46	-5.0	-0.38	1.64e-6	Pulmonary function;
UCEC	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.75	-0.43	4.97e-8	Cardiac Troponin-T levels;
UCEC	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-5.62	-0.42	9.24e-8	Pediatric autoimmune diseases;
UCEC	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.52e-9	Lung cancer;
UCEC	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18252515	chr7:66147081	NA	0.47	4.81	0.37	3.78e-6	Aortic root size;
UCEC	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg06768213	chr1:227963296	SNAP47	0.4	4.93	0.38	2.17e-6	Diastolic blood pressure;
UCEC	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg11569703	chr11:65557185	OVOL1	0.41	5.23	0.4	5.8e-7	Acne (severe);
UCEC	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	-0.57	-6.54	-0.47	9.37e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.97	6.16	0.45	6.5e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.78	0.59	3.88e-15	Smoking behavior;
UCEC	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.89	7.52	0.53	4.92e-12	Platelet count;
UCEC	cis	rs2585417	0.742	rs6127138	chr20:52828384	A/G	cg14415559	chr20:52836060	PFDN4	-0.46	-5.3	-0.4	4.15e-7	Obesity-related traits;
UCEC	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.55	7.62	0.53	2.85e-12	Total body bone mineral density;
UCEC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.59	5.28	0.4	4.46e-7	Corneal astigmatism;
UCEC	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.61	0.42	9.55e-8	Heart rate;
UCEC	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.73	-7.36	-0.52	1.18e-11	Plateletcrit;Platelet count;
UCEC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.55	6.38	0.47	2.22e-9	Obesity-related traits;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03315687	chr19:40932206	SERTAD1	0.58	7.21	0.51	2.79e-11	Warfarin maintenance dose;
UCEC	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg03146154	chr1:46216737	IPP	-0.49	-4.65	-0.36	7.21e-6	High light scatter reticulocyte count;
UCEC	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.54	-4.68	-0.36	6.57e-6	Gut microbiome composition (summer);
UCEC	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.5	-6.37	-0.47	2.29e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
UCEC	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.43	6.47	0.47	1.39e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg08461772	chr7:95026248	PON3	0.36	4.76	0.37	4.67e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.55	4.78	0.37	4.24e-6	Initial pursuit acceleration;
UCEC	cis	rs11760485	0.824	rs73051242	chr7:4400401	G/A	cg22450045	chr7:4839495	RADIL	-0.39	-4.71	-0.36	5.7e-6	Early childhood aggressive behavior;
UCEC	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.61	6.08	0.45	9.81e-9	Colorectal cancer;
UCEC	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7106204	0.513	rs7131112	chr11:24249402	A/G	ch.11.24196551F	chr11:24239977	NA	0.64	6.73	0.49	3.52e-10	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.66	-4.81	-0.37	3.64e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7246967	0.673	rs3951783	chr19:22839264	T/A	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.95e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.56	6.7	0.48	4.07e-10	Longevity;
UCEC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.43	-0.52	8.19e-12	Breast cancer;
UCEC	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.68	6.51	0.47	1.11e-9	Height;
UCEC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.73	0.36	5.27e-6	Menopause (age at onset);
UCEC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.71	-0.48	3.9e-10	Total body bone mineral density;
UCEC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg04154034	chr17:28927549	LRRC37B2	0.56	4.55	0.35	1.11e-5	Body mass index;
UCEC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	6.23	0.46	4.74e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.79	7.44	0.52	7.78e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.55	5.01	0.38	1.52e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.65	0.48	5.51e-10	Motion sickness;
UCEC	cis	rs2708977	0.637	rs676007	chr2:97075052	G/A	cg22654517	chr2:96458247	NA	0.45	5.75	0.43	5.06e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.74	-5.51	-0.41	1.53e-7	Narcolepsy;
UCEC	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.26	-0.4	5.05e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.68	6.11	0.45	8.65e-9	Aortic root size;
UCEC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.78	-0.43	4.37e-8	Breast cancer;
UCEC	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.0	0.38	1.6e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs9976767	0.932	rs11910048	chr21:43822576	C/T	cg00134539	chr21:43824071	UBASH3A	0.29	4.56	0.35	1.08e-5	Type 1 diabetes;
UCEC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.6	-6.39	-0.47	2.11e-9	Psoriasis;
UCEC	cis	rs7560272	0.538	rs3980695	chr2:73939552	A/G	cg20560298	chr2:73613845	ALMS1	0.48	4.56	0.35	1.08e-5	Schizophrenia;
UCEC	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.73	6.56	0.48	8.66e-10	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.7	8.4	0.57	3.53e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.66	5.98	0.44	1.66e-8	Corneal astigmatism;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.48	-4.85	-0.37	3.15e-6	Parkinson's disease;
UCEC	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	7.06	0.5	6.17e-11	Exhaled nitric oxide output;
UCEC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.45	4.7	0.36	5.88e-6	Schizophrenia;
UCEC	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.6	-0.48	7.07e-10	Neutrophil percentage of white cells;
UCEC	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.71	6.16	0.45	6.59e-9	Alzheimer's disease;
UCEC	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.53	5.22	0.4	5.91e-7	Neuroticism;
UCEC	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs427941	0.732	rs11760331	chr7:101840903	G/A	cg08135718	chr7:101819329	CUX1	0.45	5.26	0.4	4.99e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.4	5.1	0.39	1.04e-6	Breast cancer;
UCEC	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-0.64	-5.77	-0.43	4.45e-8	Alzheimer's disease or small vessel stroke;
UCEC	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.62	6.51	0.47	1.11e-9	Colorectal cancer;
UCEC	cis	rs785830	0.717	rs617453	chr9:223339	A/G	cg14500300	chr9:211689	NA	0.35	4.53	0.35	1.23e-5	Platelet distribution width;
UCEC	cis	rs117623576	0.618	rs211416	chr10:32397591	T/A	cg03047570	chr10:32398778	NA	0.56	5.14	0.39	8.58e-7	Anti-saccade response;
UCEC	cis	rs7715256	0.791	rs1632065	chr5:153525007	T/C	cg27295185	chr5:154320610	MRPL22	0.41	4.56	0.35	1.06e-5	BMI (adjusted for smoking behaviour);Body mass index;Childhood body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	8.64	0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.68	6.23	0.46	4.56e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg05802129	chr4:122689817	NA	-0.53	-5.32	-0.4	3.72e-7	Type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg20965017	chr5:231967	SDHA	-0.59	-5.31	-0.4	4.04e-7	Breast cancer;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.39	-4.97	-0.38	1.87e-6	Body mass index;
UCEC	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.6	5.65	0.42	8.14e-8	Coronary artery disease;
UCEC	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.6	5.34	0.4	3.51e-7	Neuroticism;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17317280	chr5:41871189	OXCT1	-0.63	-6.69	-0.48	4.44e-10	Migraine with aura;
UCEC	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.76	0.37	4.6e-6	Cognitive ability;
UCEC	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.51	-4.68	-0.36	6.51e-6	Gut microbiome composition (summer);
UCEC	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.56	5.59	0.42	1.08e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-6.18	-0.45	5.86e-9	Morning vs. evening chronotype;
UCEC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	14.59	0.77	2.25e-30	Birth weight;
UCEC	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.59	-4.85	-0.37	3.12e-6	Body mass index;
UCEC	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.54	-0.58	1.56e-14	Monocyte count;
UCEC	cis	rs7246967	0.611	rs8108452	chr19:22853618	G/A	cg08271804	chr19:22816896	ZNF492	0.67	4.53	0.35	1.2e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg08493051	chr2:3487164	NA	-0.61	-6.59	-0.48	7.47e-10	Neurofibrillary tangles;
UCEC	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.56	5.04	0.38	1.37e-6	Corneal astigmatism;
UCEC	cis	rs782107	0.637	rs782089	chr12:58781303	C/T	cg19181132	chr12:59314527	LRIG3	0.45	4.77	0.37	4.45e-6	Interleukin-12p70 levels;
UCEC	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Crohn's disease;
UCEC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.67	-0.36	6.79e-6	Breast cancer;
UCEC	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.56	5.64	0.42	8.35e-8	Bipolar disorder;
UCEC	cis	rs11760485	0.965	rs4723682	chr7:4400669	T/C	cg15613991	chr7:5277080	NA	-0.41	-4.89	-0.37	2.66e-6	Early childhood aggressive behavior;
UCEC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg08461772	chr7:95026248	PON3	0.35	4.93	0.38	2.17e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.46	-5.47	-0.41	1.87e-7	Prudent dietary pattern;
UCEC	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.41	5.4	0.41	2.58e-7	Alcohol dependence;
UCEC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg08493051	chr2:3487164	NA	-0.69	-7.32	-0.52	1.51e-11	Neurofibrillary tangles;
UCEC	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.68	5.05	0.38	1.31e-6	Calcium levels;
UCEC	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.63	-0.36	8.13e-6	Breast cancer;
UCEC	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-0.6	-7.59	-0.53	3.33e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs858239	0.899	rs858271	chr7:23278283	G/T	cg08455073	chr7:23286463	GPNMB	0.4	4.58	0.35	9.97e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.55	-0.69	2.35e-22	Chronic sinus infection;
UCEC	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.46	-5.43	-0.41	2.24e-7	Prostate cancer;
UCEC	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16346588	chr10:242978	ZMYND11	0.48	4.73	0.36	5.29e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.64	5.29	0.4	4.39e-7	Extraversion;
UCEC	cis	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg20368463	chr18:77673604	PQLC1	0.53	4.88	0.37	2.75e-6	Opioid sensitivity;
UCEC	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.89	-4.8	-0.37	3.94e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7095607	0.813	rs4584466	chr10:69933132	C/G	cg18986048	chr10:69913749	MYPN	0.49	5.91	0.44	2.26e-8	Lung function (FVC);
UCEC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg14092571	chr14:90743983	NA	-0.44	-5.85	-0.43	3.07e-8	Mortality in heart failure;
UCEC	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.56	-5.16	-0.39	7.81e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-5.79	-0.43	4.02e-8	Chronic sinus infection;
UCEC	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.04	8.52	0.57	1.76e-14	Uric acid levels;
UCEC	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.66	5.01	0.38	1.51e-6	Corneal astigmatism;
UCEC	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.59	6.01	0.44	1.4e-8	Colorectal cancer;
UCEC	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.43	-4.92	-0.38	2.32e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	6.1	0.45	8.98e-9	Schizophrenia;
UCEC	cis	rs4924935	0.669	rs7221935	chr17:18760399	G/C	cg11293112	chr17:17809020	TOM1L2	-0.39	-4.53	-0.35	1.2e-5	Pancreatic cancer;
UCEC	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.38	-4.81	-0.37	3.62e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs11586313	0.571	rs11583382	chr1:152874096	G/A	cg07796016	chr1:152779584	LCE1C	-0.5	-4.64	-0.36	7.49e-6	Vitamin D levels;
UCEC	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.64	5.32	0.4	3.8e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.77	7.29	0.52	1.76e-11	Lung function (FEV1/FVC);
UCEC	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg14092571	chr14:90743983	NA	0.44	5.32	0.4	3.85e-7	Mortality in heart failure;
UCEC	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.41	4.8	0.37	3.88e-6	Total body bone mineral density;
UCEC	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.7	5.26	0.4	4.97e-7	Bipolar disorder;
UCEC	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.79	9.15	0.6	4.42e-16	Adiposity;
UCEC	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.5	0.47	1.18e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg03609598	chr5:56110824	MAP3K1	0.66	5.3	0.4	4.24e-7	Initial pursuit acceleration;
UCEC	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.69	5.31	0.4	4.04e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-0.93	-6.6	-0.48	7.07e-10	Left atrial antero-posterior diameter;
UCEC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.56	5.06	0.39	1.23e-6	Crohn's disease;
UCEC	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.55	-0.35	1.1e-5	Tonsillectomy;
UCEC	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-0.92	-5.79	-0.43	4.08e-8	Mitochondrial DNA levels;
UCEC	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.56	-6.23	-0.46	4.67e-9	Iron status biomarkers (transferrin levels);
UCEC	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg10503236	chr1:231470652	EXOC8	-0.4	-4.58	-0.35	9.76e-6	Hemoglobin concentration;
UCEC	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.43	-5.38	-0.41	2.86e-7	Urinary tract infection frequency;
UCEC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.86	6.78	0.49	2.75e-10	Body mass index;
UCEC	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg23307798	chr14:103986281	CKB	-0.6	-7.23	-0.51	2.42e-11	Body mass index;
UCEC	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.48	-5.41	-0.41	2.56e-7	Gut microbiome composition (winter);
UCEC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.59	6.04	0.45	1.23e-8	Initial pursuit acceleration;
UCEC	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.1	-0.45	8.89e-9	Blood metabolite levels;
UCEC	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs9961915	1.000	rs8099541	chr18:24664890	G/A	cg25983544	chr18:23713626	PSMA8	-0.36	-4.64	-0.36	7.7e-6	Dental caries;
UCEC	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-0.76	-7.19	-0.51	3.09e-11	Breast cancer;
UCEC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg12024160	chr4:1254474	NA	-0.56	-5.92	-0.44	2.15e-8	Longevity;
UCEC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg13147721	chr7:65941812	NA	-0.74	-5.07	-0.39	1.17e-6	Diabetic kidney disease;
UCEC	cis	rs61134957	1.000	rs56318259	chr8:92620358	C/T	cg26596161	chr8:92261459	SLC26A7	0.94	4.71	0.36	5.75e-6	Night sleep phenotypes;
UCEC	cis	rs78761021	0.720	rs55735457	chr17:9796710	C/T	cg26853458	chr17:9805074	RCVRN	0.38	4.66	0.36	7.07e-6	Type 2 diabetes;
UCEC	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.95	-7.31	-0.52	1.61e-11	Exhaled nitric oxide output;
UCEC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-6.37	-0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.68	-5.42	-0.41	2.41e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.25	0.4	5.16e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.23	0.4	5.73e-7	Birth weight;
UCEC	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.63	-6.34	-0.46	2.7e-9	Pancreatic cancer;
UCEC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.55	-5.0	-0.38	1.59e-6	Schizophrenia;
UCEC	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07146103	chr1:1170069	B3GALT6	0.72	6.7	0.48	4.16e-10	Plasma amyloid beta peptide concentrations (ABx-40);
UCEC	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.54	5.72	0.43	5.67e-8	Diastolic blood pressure;
UCEC	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	0.92	6.32	0.46	2.91e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs17106184	1.000	rs12064411	chr1:51220291	A/G	cg07174182	chr1:51127561	FAF1	-0.62	-4.54	-0.35	1.16e-5	Type 2 diabetes;
UCEC	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.59	-6.11	-0.45	8.49e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.71	7.1	0.51	4.96e-11	Eotaxin levels;
UCEC	cis	rs78487399	0.908	rs72868636	chr2:43838516	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.92	-0.38	2.32e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-4.86	-0.37	3.02e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg16797656	chr11:68205561	LRP5	-0.51	-6.73	-0.49	3.48e-10	Bone mineral density (spine);
UCEC	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.56	-5.81	-0.43	3.76e-8	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.57	-7.44	-0.52	7.9e-12	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.86	9.16	0.6	4.27e-16	Prudent dietary pattern;
UCEC	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.53e-15	Airflow obstruction;
UCEC	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.5	-4.93	-0.38	2.15e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.79	-6.28	-0.46	3.65e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.45	5.39	0.41	2.76e-7	Coronary artery disease;
UCEC	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.03	-0.38	1.42e-6	Personality dimensions;
UCEC	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	5.12	0.39	9.63e-7	Myopia (pathological);
UCEC	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-0.87	-6.9	-0.49	1.47e-10	Pediatric areal bone mineral density (radius);
UCEC	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.19	-7.33	-0.52	1.45e-11	Diabetic kidney disease;
UCEC	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.69	-5.78	-0.43	4.41e-8	Alcohol dependence;
UCEC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg22907277	chr7:1156413	C7orf50	0.77	7.28	0.51	1.86e-11	Longevity;Endometriosis;
UCEC	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.58	5.33	0.4	3.67e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg14851346	chr12:38532713	NA	0.51	4.93	0.38	2.21e-6	Heart rate;
UCEC	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.55	-5.09	-0.39	1.06e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.44	-4.95	-0.38	2.03e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.69	8.44	0.57	2.85e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	8.14	0.56	1.55e-13	Bone mineral density;
UCEC	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg23795048	chr12:9217529	LOC144571	0.42	5.0	0.38	1.62e-6	Sjögren's syndrome;
UCEC	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.57	0.35	1.01e-5	Response to antipsychotic treatment;
UCEC	cis	rs17123764	0.605	rs7956181	chr12:50056339	T/C	cg20471783	chr12:50157085	TMBIM6	0.66	5.05	0.38	1.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs36051895	0.593	rs2094619	chr9:5167712	G/C	cg02405213	chr9:5042618	JAK2	-0.51	-4.8	-0.37	3.82e-6	Pediatric autoimmune diseases;
UCEC	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.77	-4.59	-0.35	9.58e-6	Inflammatory biomarkers;
UCEC	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.73	7.36	0.52	1.22e-11	Coronary artery disease;
UCEC	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.73	5.18	0.39	7.09e-7	Inflammatory bowel disease;
UCEC	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.55	-6.17	-0.45	6.37e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.43	5.14	0.39	8.55e-7	Kawasaki disease;
UCEC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.47	5.34	0.4	3.42e-7	Prudent dietary pattern;
UCEC	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg19197139	chr17:4613644	ARRB2	0.81	6.1	0.45	8.9e-9	Lymphocyte counts;
UCEC	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.63	4.66	0.36	6.97e-6	Cognitive test performance;
UCEC	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-4.56	-0.35	1.08e-5	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.22	-15.61	-0.79	5.2e-33	Breast cancer;
UCEC	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg06462663	chr19:18546047	ISYNA1	0.43	5.43	0.41	2.29e-7	Breast cancer;
UCEC	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.5	-5.36	-0.4	3.08e-7	Metabolic traits;
UCEC	cis	rs889312	0.923	rs12697152	chr5:56025716	A/G	cg20203395	chr5:56204925	C5orf35	0.47	4.56	0.35	1.07e-5	Breast cancer;Breast cancer (early onset);
UCEC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg24562669	chr7:97807699	LMTK2	0.73	10.6	0.66	7.61e-20	Breast cancer;
UCEC	cis	rs73001065	0.901	rs17217098	chr19:19702384	G/A	cg03709012	chr19:19516395	GATAD2A	1.24	5.8	0.43	3.87e-8	LDL cholesterol;
UCEC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg12024160	chr4:1254474	NA	0.7	8.37	0.57	4.08e-14	Obesity-related traits;
UCEC	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-4.85	-0.37	3.16e-6	Morning vs. evening chronotype;
UCEC	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.84	6.01	0.44	1.41e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	7.16	0.51	3.63e-11	Lymphocyte counts;
UCEC	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.63	8.33	0.57	5.16e-14	Mean platelet volume;
UCEC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-7.91	-0.55	5.7e-13	Colorectal cancer;
UCEC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.2	0.56	1.07e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.38	0.47	2.19e-9	Personality dimensions;
UCEC	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	6.78	0.49	2.68e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs73206853	0.925	rs61106808	chr12:110876009	C/G	cg12870014	chr12:110450643	ANKRD13A	0.64	5.62	0.42	9.28e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18252515	chr7:66147081	NA	-0.56	-5.18	-0.39	7.35e-7	Aortic root size;
UCEC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg00815214	chr21:47717953	NA	-0.42	-4.86	-0.37	3.01e-6	Testicular germ cell tumor;
UCEC	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg14196790	chr5:131705035	SLC22A5	0.44	4.68	0.36	6.59e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.6	-6.35	-0.46	2.49e-9	Total cholesterol levels;
UCEC	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.8	5.17	0.39	7.51e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-6.15	-0.45	6.98e-9	Schizophrenia;
UCEC	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg13575925	chr12:9217583	LOC144571	0.43	4.65	0.36	7.26e-6	Sjögren's syndrome;
UCEC	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.66	6.93	0.5	1.23e-10	Dental caries;
UCEC	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.54	4.84	0.37	3.24e-6	Lung cancer;
UCEC	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg12205435	chr5:138714322	SLC23A1	-0.46	-4.72	-0.36	5.51e-6	Esophageal squamous cell carcinoma;
UCEC	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.66	-0.36	7.07e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.75	8.04	0.55	2.79e-13	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg08461772	chr7:95026248	PON3	-0.43	-5.23	-0.4	5.82e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.63	5.92	0.44	2.15e-8	Coronary artery disease;
UCEC	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.61	-5.34	-0.4	3.54e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7870753	0.838	rs1590971	chr9:99246217	C/T	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs7264396	1.000	rs224424	chr20:34147998	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-4.59	-0.35	9.48e-6	Total cholesterol levels;
UCEC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.49	-4.83	-0.37	3.33e-6	Post bronchodilator FEV1;
UCEC	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg19554555	chr3:13937349	NA	-0.6	-5.99	-0.44	1.56e-8	Ovarian reserve;
UCEC	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.75	7.98	0.55	3.85e-13	Menopause (age at onset);
UCEC	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg01112020	chr2:239008986	ESPNL	-0.34	-4.55	-0.35	1.1e-5	Prostate cancer;
UCEC	cis	rs9715521	0.900	rs72634620	chr4:59822396	C/T	cg11281224	chr4:60001000	NA	-0.59	-5.88	-0.44	2.61e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.27	0.61	2.22e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg17330251	chr7:94953956	PON1	-0.54	-4.96	-0.38	1.96e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.52	-5.06	-0.38	1.25e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs12481680	1.000	rs7273940	chr20:56419323	G/A	cg00626515	chr20:56287004	PMEPA1	0.44	4.72	0.36	5.55e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.64	-6.32	-0.46	2.91e-9	Metabolite levels;
UCEC	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.55	5.13	0.39	8.88e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.65	7.57	0.53	3.74e-12	Mean corpuscular volume;
UCEC	cis	rs600626	0.529	rs59913369	chr11:75473265	A/G	cg24262691	chr11:75473276	NA	0.39	4.81	0.37	3.71e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-4.94	-0.38	2.1e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg00677455	chr12:58241039	CTDSP2	0.56	5.63	0.42	8.68e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.71	6.44	0.47	1.57e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs12367572	0.580	rs1495034	chr12:45414203	C/T	cg03114573	chr12:45410052	DBX2	-0.53	-6.43	-0.47	1.67e-9	Gut microbiome composition (summer);
UCEC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.47	-4.86	-0.37	3.04e-6	Aortic root size;
UCEC	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.71	-6.75	-0.49	3.18e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	4.98	0.38	1.74e-6	Height;
UCEC	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.61	-4.76	-0.37	4.63e-6	Huntington's disease progression;
UCEC	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.75	-8.68	-0.58	6.97e-15	Facial morphology (factor 19);
UCEC	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg02158880	chr13:53174818	NA	0.43	4.77	0.37	4.32e-6	Lewy body disease;
UCEC	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.69	5.59	0.42	1.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.47	4.98	0.38	1.73e-6	Schizophrenia;
UCEC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-7.05	-0.5	6.42e-11	Breast cancer;
UCEC	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg21770322	chr7:97807741	LMTK2	0.52	6.47	0.47	1.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.93	-10.7	-0.66	3.99e-20	Height;
UCEC	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg22166914	chr1:53195759	ZYG11B	-0.82	-9.07	-0.6	7.02e-16	Monocyte count;
UCEC	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg06935464	chr4:38784597	TLR10	0.64	4.51	0.35	1.32e-5	Breast cancer;
UCEC	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.85	7.57	0.53	3.89e-12	Body mass index;
UCEC	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	6.01	0.44	1.41e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg18681998	chr4:17616180	MED28	0.84	10.12	0.64	1.37e-18	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg14092571	chr14:90743983	NA	-0.42	-5.65	-0.42	8.07e-8	Mortality in heart failure;
UCEC	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg13575925	chr12:9217583	LOC144571	0.4	4.58	0.35	9.75e-6	Sjögren's syndrome;
UCEC	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg08271804	chr19:22816896	ZNF492	0.64	6.53	0.47	1.01e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg13081009	chr1:8430745	RERE	0.43	4.62	0.36	8.18e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg23950597	chr19:37808831	NA	-0.64	-5.1	-0.39	1.03e-6	Coronary artery calcification;
UCEC	cis	rs240764	0.594	rs9403997	chr6:101163433	A/C	cg09795085	chr6:101329169	ASCC3	0.45	4.85	0.37	3.11e-6	Neuroticism;
UCEC	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.63	4.93	0.38	2.23e-6	Breast cancer;
UCEC	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs8105895	0.935	rs62110987	chr19:22257295	A/C	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.63e-7	Body mass index (change over time);
UCEC	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg13147721	chr7:65941812	NA	-0.94	-6.81	-0.49	2.37e-10	Diabetic kidney disease;
UCEC	cis	rs9463078	0.764	rs9395051	chr6:44825715	C/A	cg25276700	chr6:44698697	NA	-0.43	-4.72	-0.36	5.44e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.53	-5.34	-0.4	3.51e-7	Lymphocyte counts;
UCEC	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.52	-0.35	1.25e-5	Homocysteine levels;
UCEC	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.62	6.19	0.45	5.65e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-7.48	-0.53	6.14e-12	Crohn's disease;
UCEC	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg13206674	chr6:150067644	NUP43	0.57	5.72	0.43	5.73e-8	Lung cancer;
UCEC	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.84	-6.08	-0.45	9.82e-9	Orofacial clefts;
UCEC	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg00800038	chr16:89945340	TCF25	-0.79	-4.52	-0.35	1.28e-5	Skin colour saturation;
UCEC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg10130564	chr11:117069849	TAGLN	0.34	4.74	0.36	4.99e-6	Blood protein levels;
UCEC	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs72700829	0.593	rs77209899	chr1:150992019	G/A	cg00107782	chr1:151300621	NA	-0.67	-4.57	-0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg20821713	chr7:1055600	C7orf50	-0.53	-5.27	-0.4	4.7e-7	Longevity;Endometriosis;
UCEC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.15	19.27	0.85	4.53e-42	IgG glycosylation;
UCEC	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-6.63	-0.48	5.91e-10	Height;
UCEC	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.55	6.68	0.48	4.54e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg20119798	chr7:94954144	PON1	-0.54	-5.04	-0.38	1.37e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.5	7.0	0.5	8.29e-11	Homoarginine levels;
UCEC	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.94	9.98	0.64	3.14e-18	Cognitive function;
UCEC	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.46	4.51	0.35	1.32e-5	Emphysema distribution in smoking;
UCEC	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.53	5.82	0.43	3.49e-8	Life satisfaction;
UCEC	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.01	6.98	0.5	9.2e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.68	7.22	0.51	2.59e-11	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.58	-5.83	-0.43	3.37e-8	Hepatocellular carcinoma;
UCEC	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.53	0.62	4.52e-17	Bipolar disorder;
UCEC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.69	0.58	6.34e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs1892094	0.935	rs10919068	chr1:169097056	A/T	cg17859187	chr1:168147929	TIPRL	-0.44	-4.52	-0.35	1.27e-5	Coronary artery disease;
UCEC	cis	rs4788439	0.901	rs7200552	chr16:24954408	G/A	cg04047827	chr16:24740859	TNRC6A	-0.53	-4.98	-0.38	1.76e-6	Blood metabolite levels;
UCEC	cis	rs3956705	1.000	rs12701265	chr7:32971236	G/A	cg05721444	chr7:32995514	FKBP9	-0.49	-4.9	-0.37	2.52e-6	Red cell distribution width;
UCEC	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.64	6.31	0.46	3.04e-9	Lung cancer;
UCEC	cis	rs7113850	0.541	rs114370606	chr11:24232247	C/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.29	0.4	4.35e-7	Coronary artery disease;
UCEC	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	7.65	0.53	2.4e-12	Schizophrenia;
UCEC	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.62	5.59	0.42	1.07e-7	Graves' disease;
UCEC	cis	rs9393294	1.000	rs9393304	chr6:22502304	A/G	cg15541384	chr6:21886458	FLJ22536	-0.69	-4.64	-0.36	7.69e-6	Mean platelet volume;
UCEC	cis	rs12216499	1.000	rs10455836	chr6:159394754	C/T	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.38	-4.95	-0.38	1.99e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs17123764	0.710	rs2278069	chr12:49944508	A/G	cg20471783	chr12:50157085	TMBIM6	0.67	5.54	0.42	1.33e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2131877	0.956	rs60023213	chr3:194870505	A/T	cg19760965	chr3:194868843	C3orf21	0.43	4.71	0.36	5.8e-6	Non-small cell lung cancer;
UCEC	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-5.01	-0.38	1.57e-6	Longevity;
UCEC	cis	rs77861329	1.000	rs2304505	chr3:52184760	T/C	cg08692210	chr3:52188851	WDR51A	0.74	6.01	0.44	1.39e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	4.98	0.38	1.75e-6	Breast cancer;
UCEC	cis	rs4074536	0.622	rs10802001	chr1:116315610	A/T	cg21648376	chr1:116311395	CASQ2	-0.62	-6.12	-0.45	8.02e-9	QRS duration;
UCEC	cis	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg14992524	chr8:10586135	SOX7	0.31	4.87	0.37	2.87e-6	Neuroticism;
UCEC	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.45	-4.56	-0.35	1.08e-5	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
UCEC	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.66	5.78	0.43	4.4e-8	Adiposity;
UCEC	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg13073564	chr4:8508604	NA	-0.46	-5.03	-0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs12039431	0.748	rs6692773	chr1:38025407	G/A	cg17933807	chr1:38061675	GNL2	-0.53	-4.66	-0.36	6.96e-6	Epithelial ovarian cancer;
UCEC	cis	rs138171347	1	rs138171347	chr17:5183203	AAAAT/A	cg24500398	chr17:5266808	RABEP1	-0.43	-4.88	-0.37	2.76e-6	White blood cell count;
UCEC	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	7.04	0.5	6.84e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs8177876	0.822	rs59685942	chr16:81115139	A/G	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.46	5.08	0.39	1.14e-6	Metabolic traits;
UCEC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.62	-6.22	-0.46	4.94e-9	Lymphocyte counts;
UCEC	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.53	5.92	0.44	2.17e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.44	6.08	0.45	9.88e-9	Metabolite levels;
UCEC	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.65	6.75	0.49	3.11e-10	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
UCEC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.86	-9.79	-0.63	9.7e-18	Breast cancer;
UCEC	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.4	5.8	0.43	3.99e-8	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.77	-7.89	-0.55	6.25e-13	Parkinson's disease;
UCEC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.16	-14.37	-0.76	8.54e-30	Breast cancer;
UCEC	cis	rs7246967	0.611	rs12978511	chr19:22819216	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.58	0.48	7.59e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10924970	0.649	rs12409696	chr1:235423607	T/C	cg26050004	chr1:235667680	B3GALNT2	0.53	4.79	0.37	4.1e-6	Asthma;
UCEC	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.52	-4.79	-0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.58	4.52	0.35	1.27e-5	Major depressive disorder;
UCEC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg07817648	chr10:79422355	NA	-0.73	-5.87	-0.44	2.79e-8	Bone mineral density;
UCEC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.61	-5.87	-0.44	2.82e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs6728642	1.000	rs7593754	chr2:97607544	C/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-6.78	-0.49	2.66e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.51	5.89	0.44	2.49e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.52	5.55	0.42	1.32e-7	Schizophrenia;
UCEC	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-7.3	-0.52	1.72e-11	Exhaled nitric oxide levels;
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	7.86	0.54	7.61e-13	Platelet count;
UCEC	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg23950597	chr19:37808831	NA	0.6	4.83	0.37	3.38e-6	Coronary artery calcification;
UCEC	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.59	-5.89	-0.44	2.51e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg11569703	chr11:65557185	OVOL1	-0.43	-6.06	-0.45	1.09e-8	Acne (severe);
UCEC	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg23719950	chr11:63933701	MACROD1	-0.66	-4.54	-0.35	1.14e-5	Mean platelet volume;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03762994	chr17:6899332	ALOX12	0.45	5.27	0.4	4.69e-7	Tonsillectomy;
UCEC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.53	5.06	0.39	1.21e-6	Menopause (age at onset);
UCEC	cis	rs36051895	0.658	rs11999928	chr9:5006743	T/G	cg02405213	chr9:5042618	JAK2	-0.45	-4.51	-0.35	1.3e-5	Pediatric autoimmune diseases;
UCEC	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.5	-4.58	-0.35	9.7e-6	Huntington's disease progression;
UCEC	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.44	-4.51	-0.35	1.33e-5	Schizophrenia;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.86	-0.37	2.97e-6	Pulmonary function;
UCEC	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	0.71	4.53	0.35	1.21e-5	Height;
UCEC	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.47	-4.95	-0.38	2.02e-6	Large artery stroke;
UCEC	cis	rs4654899	0.931	rs4654727	chr1:21214735	C/T	cg01072550	chr1:21505969	NA	0.56	5.86	0.44	2.87e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.77	-5.96	-0.44	1.81e-8	Red blood cell count;
UCEC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg02160872	chr5:212506	CCDC127	-0.7	-7.45	-0.52	7.41e-12	Breast cancer;
UCEC	cis	rs11760485	0.782	rs10273709	chr7:4406094	A/G	cg25842763	chr7:4870162	RADIL	-0.42	-4.78	-0.37	4.28e-6	Early childhood aggressive behavior;
UCEC	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.8	9.46	0.62	7.12e-17	Breast cancer;
UCEC	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.51	5.21	0.39	6.32e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.52	5.04	0.38	1.35e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	4.7	0.36	5.81e-6	Menarche (age at onset);
UCEC	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.85	-10.42	-0.65	2.16e-19	Brugada syndrome;
UCEC	cis	rs9326726	0.844	rs17452232	chr5:107606255	C/G	cg17432647	chr5:107996819	NA	0.49	4.51	0.35	1.33e-5	Resting heart rate;
UCEC	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.21	0.46	5.19e-9	Cognitive ability;
UCEC	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.65	-5.85	-0.43	3.14e-8	Pancreatic cancer;
UCEC	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.58	-5.37	-0.4	3.07e-7	Longevity;
UCEC	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.55	5.73	0.43	5.43e-8	Red blood cell count;
UCEC	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.4	-4.55	-0.35	1.11e-5	Homocysteine levels;
UCEC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7894051	1.000	rs11101723	chr10:135192139	C/A	cg20534287	chr10:135191450	PAOX	0.67	6.22	0.46	4.83e-9	Lifespan;
UCEC	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg13147721	chr7:65941812	NA	0.97	6.38	0.47	2.15e-9	Diabetic kidney disease;
UCEC	cis	rs7307889	0.793	rs73047652	chr12:6015033	T/G	cg23245485	chr12:6484219	SCNN1A	0.54	4.71	0.36	5.61e-6	Obesity-related traits;
UCEC	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.65	6.35	0.46	2.54e-9	Lymphocyte counts;
UCEC	cis	rs731174	0.797	rs539585	chr1:38148123	T/G	cg06917450	chr1:38156652	C1orf109	-0.64	-6.11	-0.45	8.36e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg16576597	chr16:28551801	NUPR1	0.31	4.6	0.35	8.91e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.52	-5.02	-0.38	1.49e-6	Total body bone mineral density;
UCEC	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg15659132	chr6:26577336	NA	0.43	4.61	0.36	8.67e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.62	6.54	0.47	9.35e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.67	5.63	0.42	8.81e-8	Smoking initiation;
UCEC	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.0	0.44	1.47e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs67839313	0.541	rs10163093	chr15:40606918	C/T	cg07121488	chr15:40581105	PLCB2	0.8	5.32	0.4	3.85e-7	Type 2 diabetes;
UCEC	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg12310025	chr6:25882481	NA	-0.51	-4.58	-0.35	9.71e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.5	5.56	0.42	1.24e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg23782820	chr8:58130467	NA	0.51	4.83	0.37	3.46e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	0.74	4.97	0.38	1.88e-6	Diabetic retinopathy;
UCEC	cis	rs3744061	0.505	rs9915915	chr17:74652274	A/G	cg02128979	chr17:74682217	MXRA7	0.46	5.01	0.38	1.51e-6	Retinal arteriolar caliber;
UCEC	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg13147721	chr7:65941812	NA	0.91	6.06	0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.47	5.18	0.39	7.24e-7	Platelet distribution width;
UCEC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.43	-5.97	-0.44	1.72e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-7.13	-0.51	4.27e-11	Heart rate;
UCEC	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.41	-4.59	-0.35	9.33e-6	Mean corpuscular volume;
UCEC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.51	5.43	0.41	2.25e-7	Electroencephalogram traits;
UCEC	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.63	5.89	0.44	2.5e-8	Coronary artery disease;
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.35	-5.33	-0.4	3.67e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-6.44	-0.47	1.58e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.54	5.26	0.4	4.92e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.45	4.66	0.36	7.13e-6	Schizophrenia;
UCEC	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.51	5.02	0.38	1.47e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.46	7.74	0.54	1.48e-12	Cognitive function;
UCEC	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-5.51	-0.41	1.58e-7	Mitochondrial DNA levels;
UCEC	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.45	4.51	0.35	1.31e-5	Colorectal cancer;
UCEC	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg08027265	chr7:2291960	NA	-0.47	-5.47	-0.41	1.91e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.4	0.52	9.91e-12	Ileal carcinoids;
UCEC	trans	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg25482853	chr8:67687455	SGK3	1.18	7.74	0.54	1.45e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg14664628	chr15:75095509	CSK	-0.51	-4.82	-0.37	3.5e-6	Caffeine consumption;
UCEC	cis	rs4280164	0.945	rs4374085	chr14:24771080	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-4.7	-0.36	6.03e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs4074536	0.796	rs10157905	chr1:116308511	C/T	cg21648376	chr1:116311395	CASQ2	-0.51	-4.94	-0.38	2.08e-6	QRS duration;
UCEC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.39	0.47	2.1e-9	Aortic root size;
UCEC	cis	rs7870753	0.838	rs7021496	chr9:99263497	T/C	cg25260653	chr9:99212216	HABP4	0.56	5.5	0.41	1.62e-7	Height;
UCEC	cis	rs9810890	0.764	rs9831652	chr3:128561127	G/A	cg24249734	chr3:127872125	EEFSEC	-0.59	-4.87	-0.37	2.8e-6	Dental caries;
UCEC	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs4713118	0.911	rs9295746	chr6:27730064	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.56	-4.57	-0.35	1.03e-5	Parkinson's disease;
UCEC	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.41	-4.9	-0.37	2.51e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg10840864	chr17:61903314	PSMC5;FTSJ3	-0.39	-5.38	-0.41	2.9e-7	Prudent dietary pattern;
UCEC	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.5	-4.91	-0.38	2.45e-6	Coronary artery disease;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07589254	chr7:1705402	NA	-0.54	-4.76	-0.37	4.67e-6	Longevity;Endometriosis;
UCEC	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.62	5.33	0.4	3.68e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-4.9	-0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.46	4.91	0.38	2.4e-6	Vitiligo;
UCEC	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-5.83	-0.43	3.39e-8	Body mass index;
UCEC	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.83	6.56	0.48	8.76e-10	Lymphocyte counts;
UCEC	cis	rs7570971	0.652	rs17261772	chr2:135911422	T/C	cg07169764	chr2:136633963	MCM6	0.67	6.38	0.47	2.15e-9	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg21419209	chr3:44054225	NA	-0.5	-5.14	-0.39	8.57e-7	Coronary artery disease;
UCEC	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg20387954	chr3:183756860	HTR3D	0.47	5.56	0.42	1.21e-7	Anterior chamber depth;
UCEC	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg11871910	chr12:69753446	YEATS4	1.07	13.47	0.74	1.87e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.73	-9.09	-0.6	6.28e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs752045	0.525	rs11991398	chr8:5931095	G/T	cg10761351	chr8:6637965	NA	0.52	4.72	0.36	5.42e-6	Hand grip strength;
UCEC	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.68	-5.61	-0.42	9.98e-8	Psoriasis vulgaris;
UCEC	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	0.98	7.48	0.53	6.22e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.73	6.92	0.5	1.29e-10	High light scatter reticulocyte count;
UCEC	cis	rs7804356	0.953	rs73069539	chr7:26903661	C/T	cg02693607	chr7:27150598	HOXA3	0.57	4.79	0.37	4.07e-6	Type 1 diabetes;
UCEC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.51	4.66	0.36	7.12e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.91	11.49	0.69	3.36e-22	Breast cancer;
UCEC	cis	rs11760485	0.965	rs56098795	chr7:4402225	G/A	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.62	6.98	0.5	9.23e-11	Pubertal anthropometrics;
UCEC	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.85	12.3	0.71	2.38e-24	Leprosy;
UCEC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.54	-5.57	-0.42	1.16e-7	Sudden cardiac arrest;
UCEC	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.65	-6.01	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg13147721	chr7:65941812	NA	-0.69	-4.85	-0.37	3.1e-6	Diabetic kidney disease;
UCEC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg12024160	chr4:1254474	NA	-0.51	-5.5	-0.41	1.65e-7	Obesity-related traits;
UCEC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.64	-4.59	-0.35	9.41e-6	Aortic root size;
UCEC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs10095849	0.576	rs10088799	chr8:39468849	G/T	cg24581462	chr8:38759627	PLEKHA2	0.36	4.7	0.36	5.98e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.56	-4.99	-0.38	1.68e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	7.16	0.51	3.5e-11	Gastritis;
UCEC	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.49	5.66	0.42	7.61e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg18755752	chr8:142205143	DENND3	0.54	5.1	0.39	1.03e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.55	6.49	0.47	1.21e-9	Blood metabolite levels;
UCEC	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.48	-5.34	-0.4	3.51e-7	Longevity;
UCEC	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.46	6.71	0.48	3.89e-10	Homoarginine levels;
UCEC	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.58	-5.86	-0.44	2.94e-8	Pancreatic cancer;
UCEC	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg27535305	chr1:53392650	SCP2	0.41	5.0	0.38	1.62e-6	Monocyte count;
UCEC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.55	-5.21	-0.4	6.17e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.89	-6.28	-0.46	3.55e-9	Multiple sclerosis;
UCEC	cis	rs11958404	0.932	rs72816588	chr5:157434390	C/T	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg14121845	chr20:25566513	NINL	-0.41	-4.79	-0.37	3.99e-6	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.72	8.21	0.56	1.02e-13	Monocyte count;
UCEC	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.38	-5.05	-0.38	1.27e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg07776626	chr8:57350775	NA	-0.44	-4.72	-0.36	5.56e-6	Obesity-related traits;
UCEC	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg03627880	chr6:151815985	C6orf97	-0.76	-4.97	-0.38	1.87e-6	Menarche (age at onset);
UCEC	cis	rs17123764	0.892	rs12304796	chr12:50123466	T/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg22974920	chr21:40686053	BRWD1	0.57	4.99	0.38	1.66e-6	Cognitive function;
UCEC	cis	rs4499344	0.730	rs259285	chr19:33164697	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.17	0.39	7.69e-7	Mean platelet volume;
UCEC	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.86	12.3	0.71	2.41e-24	Leprosy;
UCEC	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.28	0.76	1.47e-29	Chronic sinus infection;
UCEC	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg14092571	chr14:90743983	NA	0.44	5.29	0.4	4.29e-7	Mortality in heart failure;
UCEC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.07	0.39	1.17e-6	Bipolar disorder;
UCEC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg26031613	chr14:104095156	KLC1	0.59	5.7	0.43	6.48e-8	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
UCEC	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.51	-5.01	-0.38	1.52e-6	Brugada syndrome;
UCEC	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg06818710	chr6:28411271	ZSCAN23	0.55	6.63	0.48	5.83e-10	Pubertal anthropometrics;
UCEC	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.46	-4.69	-0.36	6.15e-6	Emphysema distribution in smoking;
UCEC	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.22	0.4	5.87e-7	Personality dimensions;
UCEC	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.5	5.13	0.39	8.87e-7	Initial pursuit acceleration;
UCEC	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.5	-5.15	-0.39	8.41e-7	Height;
UCEC	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs10946940	0.965	rs62401383	chr6:27564547	C/T	cg07836142	chr6:28411423	ZSCAN23	0.44	4.71	0.36	5.68e-6	Systemic lupus erythematosus;
UCEC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.6	-7.91	-0.55	5.53e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.91	0.55	5.64e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	6.04	0.45	1.2e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.69	-6.38	-0.47	2.18e-9	Aortic root size;
UCEC	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.6	4.63	0.36	8.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.63	5.88	0.44	2.59e-8	Platelet count;
UCEC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.27	0.4	4.85e-7	Personality dimensions;
UCEC	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.46	-5.46	-0.41	1.98e-7	Bipolar disorder;
UCEC	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	0.85	7.08	0.5	5.57e-11	Opioid sensitivity;
UCEC	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg19678392	chr7:94953810	PON1	-0.58	-5.23	-0.4	5.62e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.65	7.37	0.52	1.17e-11	Leprosy;
UCEC	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.1	0.45	8.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.63	7.06	0.5	5.99e-11	Pubertal anthropometrics;
UCEC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.7e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.69	-7.46	-0.52	6.9e-12	Lymphocyte counts;
UCEC	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-7.69	-0.54	1.95e-12	IgG glycosylation;
UCEC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg14008862	chr17:28927542	LRRC37B2	0.82	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.52	5.24	0.4	5.58e-7	Diastolic blood pressure;
UCEC	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.83	8.95	0.59	1.41e-15	Longevity;
UCEC	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.81	7.32	0.52	1.52e-11	Bladder cancer;
UCEC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.68	-0.36	6.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg07537917	chr2:241836409	C2orf54	-0.33	-5.12	-0.39	9.62e-7	Urinary metabolites;
UCEC	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg05501817	chr11:14380813	RRAS2	-0.49	-4.67	-0.36	6.76e-6	Sense of smell;
UCEC	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.18	0.45	6.02e-9	Breast cancer;
UCEC	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.5	4.78	0.37	4.2e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.93	0.38	2.18e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8105895	0.935	rs62110987	chr19:22257295	A/C	cg02912127	chr19:22235281	ZNF257	-0.63	-5.33	-0.4	3.6e-7	Body mass index (change over time);
UCEC	cis	rs1519814	1.000	rs7000103	chr8:121166200	A/C	cg22335954	chr8:121166405	COL14A1	-0.69	-5.61	-0.42	9.74e-8	Breast cancer;
UCEC	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg04202892	chr2:111875749	ACOXL	0.45	5.21	0.39	6.4e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs9283706	0.608	rs1428408	chr5:66331203	T/C	cg11590213	chr5:66331682	MAST4	0.46	5.81	0.43	3.72e-8	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-6.27	-0.46	3.8e-9	Platelet count;
UCEC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.71	6.39	0.47	2.1e-9	Neutrophil percentage of white cells;
UCEC	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg23950597	chr19:37808831	NA	-0.81	-5.62	-0.42	9.3e-8	Coronary artery calcification;
UCEC	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-4.55	-0.35	1.12e-5	Joint mobility (Beighton score);
UCEC	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.84	-9.1	-0.6	5.87e-16	Lung cancer;
UCEC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg02160872	chr5:212506	CCDC127	-0.7	-7.3	-0.52	1.64e-11	Breast cancer;
UCEC	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.47	-5.5	-0.41	1.6e-7	Aortic root size;
UCEC	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-5.02	-0.38	1.47e-6	Response to antipsychotic treatment;
UCEC	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.55	-0.58	1.48e-14	Mean platelet volume;
UCEC	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.91	10.26	0.65	5.98e-19	Cognitive function;
UCEC	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.55	5.98	0.44	1.59e-8	Platelet distribution width;
UCEC	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg18099408	chr3:52552593	STAB1	0.44	4.99	0.38	1.67e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.51	5.07	0.39	1.16e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg03859395	chr2:55845619	SMEK2	1.01	14.66	0.77	1.47e-30	Metabolic syndrome;
UCEC	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.9	0.37	2.48e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.53	-5.61	-0.42	9.86e-8	Menarche (age at onset);
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.71	7.97	0.55	3.97e-13	Menarche (age at onset);
UCEC	trans	rs1117324	0.510	rs72898281	chr2:21898339	T/C	cg20672981	chr7:27242161	NA	0.54	6.81	0.49	2.38e-10	Response to antipsychotic treatment;
UCEC	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg12024160	chr4:1254474	NA	0.55	6.67	0.48	4.74e-10	Obesity-related traits;
UCEC	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.89	8.42	0.57	3.1e-14	Prostate cancer;
UCEC	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.68	-5.95	-0.44	1.92e-8	Prudent dietary pattern;
UCEC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.55	-5.98	-0.44	1.66e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.63	7.13	0.51	4.23e-11	Urate levels;
UCEC	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.44	5.07	0.39	1.2e-6	Mortality in heart failure;
UCEC	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.52	5.98	0.44	1.64e-8	Fibrinogen levels;
UCEC	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.68	-5.67	-0.42	7.36e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg05132306	chr1:1846340	CALML6	-0.36	-4.57	-0.35	1.05e-5	Body mass index;
UCEC	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	9.41	0.61	9.31e-17	Bipolar disorder;
UCEC	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	4.67	0.36	6.77e-6	IgG glycosylation;
UCEC	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.27	9.82	0.63	8.39e-18	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.67	6.57	0.48	8.19e-10	Prostate cancer;
UCEC	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.2	-9.07	-0.6	7.22e-16	Gut microbiome composition (summer);
UCEC	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.8	6.43	0.47	1.71e-9	Response to hepatitis C treatment;
UCEC	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.53	-4.96	-0.38	1.89e-6	Renal cell carcinoma;
UCEC	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg10381502	chr11:71823885	C11orf51	-1.02	-4.88	-0.37	2.72e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.79	9.04	0.6	8.58e-16	Menarche (age at onset);
UCEC	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.64	-0.36	7.61e-6	Height;
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.37	-0.4	3.02e-7	Cardiac Troponin-T levels;
UCEC	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.84	5.91	0.44	2.27e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg18032046	chr6:28092343	ZSCAN16	0.69	5.77	0.43	4.45e-8	Depression;
UCEC	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.63	6.53	0.47	1.02e-9	Menopause (age at onset);
UCEC	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.78	-6.41	-0.47	1.85e-9	Corneal structure;
UCEC	cis	rs7611694	0.501	rs6438143	chr3:113117829	T/C	cg12596171	chr3:113251061	SIDT1	-0.54	-5.5	-0.41	1.61e-7	Prostate cancer;
UCEC	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.77	4.73	0.36	5.29e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg02851062	chr11:122848983	BSX	-0.36	-4.55	-0.35	1.09e-5	Menarche (age at onset);
UCEC	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.51	-5.37	-0.4	3.06e-7	Vitiligo;
UCEC	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-0.93	-12.07	-0.71	9.83e-24	Coronary artery disease;
UCEC	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg05660106	chr1:15850417	CASP9	0.87	9.75	0.63	1.22e-17	Systolic blood pressure;
UCEC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg02160872	chr5:212506	CCDC127	-0.72	-7.35	-0.52	1.29e-11	Breast cancer;
UCEC	cis	rs13401104	0.796	rs1466206	chr2:237121221	G/C	cg23897927	chr2:237117786	ASB18	-0.5	-4.52	-0.35	1.28e-5	Educational attainment;
UCEC	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg07386859	chr16:1872102	HAGH	0.43	4.79	0.37	4.01e-6	Insulin-like growth factors;
UCEC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	5.92	0.44	2.14e-8	Cognitive test performance;
UCEC	cis	rs925228	1.000	rs1044277	chr2:24225621	T/C	cg13272742	chr2:24272458	FKBP1B	0.57	4.68	0.36	6.36e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.37	-4.9	-0.37	2.49e-6	Dupuytren's disease;
UCEC	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.66	7.54	0.53	4.48e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.73	5.11	0.39	1e-6	Inflammatory bowel disease;
UCEC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.7	6.66	0.48	5.08e-10	Chronic sinus infection;
UCEC	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg01072550	chr1:21505969	NA	-0.59	-6.0	-0.44	1.47e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3956705	0.798	rs35443929	chr7:32935434	C/A	cg05721444	chr7:32995514	FKBP9	-0.45	-4.54	-0.35	1.18e-5	Red cell distribution width;
UCEC	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg18681998	chr4:17616180	MED28	0.73	8.48	0.57	2.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.65	7.85	0.54	7.8e-13	Prevalent atrial fibrillation;
UCEC	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.17	0.39	7.68e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs58799304	0.531	rs74965833	chr1:156054119	C/T	cg24674445	chr1:156076363	NA	0.54	4.72	0.36	5.55e-6	Ischemic stroke;
UCEC	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1056265	0.544	rs7851399	chr9:71443705	A/G	cg00794837	chr9:72287772	APBA1	0.49	4.71	0.36	5.62e-6	Angiotensin-converting enzyme inhibitor intolerance;
UCEC	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.52	5.63	0.42	8.97e-8	Tonsillectomy;
UCEC	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.82	9.53	0.62	4.73e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.59	5.47	0.41	1.88e-7	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs34795935	chr19:22865188	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg04935436	chr20:30431758	NA	0.36	4.52	0.35	1.25e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.65	6.21	0.46	5.27e-9	Response to diuretic therapy;
UCEC	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.61	6.97	0.5	9.87e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.54	-5.84	-0.43	3.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.54	4.69	0.36	6.09e-6	Dental caries;
UCEC	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.61	5.74	0.43	5.34e-8	Vitamin D levels;
UCEC	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.57	5.55	0.42	1.3e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-5.46	-0.41	1.94e-7	Longevity;Endometriosis;
UCEC	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.42	-4.7	-0.36	5.93e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg07645718	chr20:61493192	TCFL5	-0.71	-5.18	-0.39	7.24e-7	Obesity-related traits;
UCEC	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg12580275	chr1:205744413	RAB7L1	0.44	4.93	0.38	2.22e-6	Schizophrenia;
UCEC	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.91	-0.55	5.73e-13	Total cholesterol levels;
UCEC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg03354898	chr7:1950403	MAD1L1	-0.74	-9.19	-0.6	3.5e-16	Bipolar disorder and schizophrenia;
UCEC	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.39	-0.41	2.69e-7	Alcohol dependence;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07589254	chr7:1705402	NA	0.56	4.83	0.37	3.33e-6	Longevity;Endometriosis;
UCEC	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg24889512	chr19:22816950	ZNF492	0.62	6.44	0.47	1.58e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	6.8	0.49	2.5e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.7	-5.81	-0.43	3.79e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg05660106	chr1:15850417	CASP9	0.63	5.77	0.43	4.44e-8	Systolic blood pressure;
UCEC	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg25922239	chr6:33757077	LEMD2	0.63	5.17	0.39	7.36e-7	Crohn's disease;
UCEC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg10553204	chr2:20871195	GDF7	-0.42	-5.18	-0.39	7.13e-7	Abdominal aortic aneurysm;
UCEC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.62	-5.59	-0.42	1.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs8177876	0.731	rs8177948	chr16:81116920	C/G	cg08591886	chr16:81111003	C16orf46	-0.8	-4.7	-0.36	5.94e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.72	6.95	0.5	1.1e-10	Crohn's disease;
UCEC	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg11632617	chr15:75315747	PPCDC	-0.6	-6.44	-0.47	1.6e-9	Lung cancer;
UCEC	cis	rs7072216	0.687	rs7908310	chr10:100156227	G/A	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-8.66	-0.58	7.71e-15	Coronary artery disease;
UCEC	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.48	-5.16	-0.39	7.88e-7	IgG glycosylation;
UCEC	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.1	0.39	1.01e-6	Personality dimensions;
UCEC	cis	rs2084898	0.550	rs470941	chr11:119999755	C/T	cg07435449	chr11:120005650	TRIM29	0.49	5.02	0.38	1.49e-6	Stroke (pediatric);
UCEC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.71	0.43	6.16e-8	Blood metabolite levels;
UCEC	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.44	-5.88	-0.44	2.7e-8	IgG glycosylation;
UCEC	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg23782820	chr8:58130467	NA	0.51	4.88	0.37	2.73e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4820803	1.000	rs879580	chr22:29659960	C/T	cg07256473	chr22:29710276	RASL10A	-0.65	-5.08	-0.39	1.14e-6	Breast cancer;
UCEC	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.79	-9.72	-0.63	1.47e-17	Obesity-related traits;
UCEC	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.39	-4.77	-0.37	4.36e-6	Type 2 diabetes;
UCEC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.74	0.36	5.07e-6	Height;
UCEC	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg20821713	chr7:1055600	C7orf50	-0.73	-7.17	-0.51	3.41e-11	Bronchopulmonary dysplasia;
UCEC	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	0.82	9.07	0.6	7.12e-16	Breast cancer;
UCEC	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg12463550	chr7:65579703	CRCP	-0.53	-5.38	-0.41	2.91e-7	Aortic root size;
UCEC	cis	rs877674	0.872	rs2271931	chr1:32203163	C/G	cg07656362	chr1:32688117	C1orf91;EIF3I	0.89	4.94	0.38	2.08e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg13575925	chr12:9217583	LOC144571	0.4	4.73	0.36	5.2e-6	Sjögren's syndrome;
UCEC	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg22166914	chr1:53195759	ZYG11B	-0.75	-7.75	-0.54	1.4e-12	Monocyte count;
UCEC	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.47	5.03	0.38	1.42e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.77	7.53	0.53	4.78e-12	Parkinson's disease;
UCEC	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.82e-15	Blood protein levels;
UCEC	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.91	-10.16	-0.64	1.04e-18	Obesity-related traits;
UCEC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.37	5.54	0.42	1.39e-7	Vitiligo;
UCEC	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.58	-5.21	-0.39	6.32e-7	Morning vs. evening chronotype;
UCEC	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.53	4.82	0.37	3.55e-6	Uric acid levels;
UCEC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.4	5.37	0.41	2.94e-7	Monocyte count;
UCEC	cis	rs285406	0.506	rs285402	chr8:87041727	C/T	cg22106623	chr8:87082205	PSKH2	-0.55	-5.77	-0.43	4.49e-8	Adverse response to lamotrigine and phenytoin;
UCEC	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg11871910	chr12:69753446	YEATS4	1.06	13.41	0.74	2.74e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.17	0.45	6.17e-9	Platelet count;
UCEC	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.46	-5.57	-0.42	1.2e-7	Subjective well-being;
UCEC	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.2e-7	Systemic lupus erythematosus;
UCEC	trans	rs10496288	0.529	rs4852696	chr2:83151641	G/C	cg02863237	chr10:6131472	RBM17	0.71	7.27	0.51	1.98e-11	Hypertension (SNP x SNP interaction);
UCEC	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.34	4.71	0.36	5.75e-6	Primary biliary cholangitis;
UCEC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg26721908	chr21:47610096	LSS	0.36	4.62	0.36	8.32e-6	Testicular germ cell tumor;
UCEC	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg24687543	chr11:63912206	MACROD1	0.56	4.57	0.35	1.02e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.77	-8.92	-0.59	1.66e-15	Menarche (age at onset);
UCEC	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.46	-4.8	-0.37	3.78e-6	Body mass index;
UCEC	cis	rs1318772	1.000	rs182988	chr5:112813566	T/A	cg12552261	chr5:112820674	MCC	-0.87	-6.46	-0.47	1.42e-9	F-cell distribution;
UCEC	cis	rs2262909	0.962	rs401424	chr19:22232023	A/G	cg11619707	chr19:22235551	ZNF257	-0.38	-4.94	-0.38	2.14e-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
UCEC	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.47	-5.55	-0.42	1.3e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.76	0.49	3.09e-10	Coffee consumption (cups per day);
UCEC	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.07	-0.39	1.15e-6	Life satisfaction;
UCEC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.21	-0.51	2.71e-11	Multiple sclerosis;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.46	-4.84	-0.37	3.23e-6	Parkinson's disease;
UCEC	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.72	-6.43	-0.47	1.72e-9	Bipolar disorder;
UCEC	cis	rs9649213	0.593	rs6967576	chr7:98016373	A/G	cg24562669	chr7:97807699	LMTK2	-0.37	-4.58	-0.35	9.72e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.61	5.96	0.44	1.76e-8	Lymphocyte counts;
UCEC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.52	5.08	0.39	1.13e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.68	5.07	0.39	1.17e-6	Multiple sclerosis;
UCEC	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.08	5.98	0.44	1.65e-8	Type 2 diabetes;
UCEC	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg20560298	chr2:73613845	ALMS1	0.52	5.08	0.39	1.12e-6	Metabolite levels;
UCEC	cis	rs2629540	0.508	rs12217633	chr10:126533872	A/G	cg08799069	chr10:126477246	METTL10	-0.69	-6.27	-0.46	3.88e-9	Cocaine dependence;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.57	-6.38	-0.47	2.12e-9	Pubertal anthropometrics;
UCEC	cis	rs740160	0.558	rs73395508	chr7:98901894	A/C	cg18809830	chr7:99032528	PTCD1	-0.55	-4.53	-0.35	1.23e-5	Dehydroepiandrosterone sulphate levels;
UCEC	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01973587	chr1:228161476	NA	0.38	4.98	0.38	1.79e-6	Diastolic blood pressure;
UCEC	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.67	-5.96	-0.44	1.8e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.69	7.79	0.54	1.12e-12	Menarche (age at onset);
UCEC	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg23782820	chr8:58130467	NA	0.51	4.78	0.37	4.2e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.5	-5.24	-0.4	5.36e-7	Type 2 diabetes;
UCEC	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.78	-6.16	-0.45	6.64e-9	Calcium levels;
UCEC	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.56	6.35	0.46	2.59e-9	Calcium levels;
UCEC	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.76	-8.7	-0.58	6.04e-15	Facial morphology (factor 19);
UCEC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-5.51	-0.41	1.54e-7	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.54	-6.91	-0.5	1.37e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.26	-0.4	4.96e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.28	-0.4	4.61e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.52	5.45	0.41	2.09e-7	Dupuytren's disease;
UCEC	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-5.93	-0.44	2.1e-8	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	6.86	0.49	1.81e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.876	rs4738494	chr8:57327438	G/T	cg09654669	chr8:57350985	NA	-0.46	-4.76	-0.37	4.69e-6	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.67	-5.43	-0.41	2.25e-7	Menopause (age at onset);
UCEC	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs11235843	0.853	rs1043234	chr11:73471761	C/A	cg09185399	chr11:73372479	PLEKHB1	0.67	4.62	0.36	8.19e-6	Hand grip strength;
UCEC	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.62	-5.8	-0.43	3.84e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.58	-6.77	-0.49	2.9e-10	Prostate cancer;
UCEC	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.74	8.04	0.55	2.74e-13	Lymphocyte counts;
UCEC	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg11271282	chr2:238384023	NA	0.5	4.74	0.36	5.02e-6	Prostate cancer;
UCEC	cis	rs1981331	0.609	rs7279368	chr21:48065999	A/G	cg17243659	chr21:48055224	PRMT2	1.04	4.51	0.35	1.32e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.29	0.4	4.27e-7	Cognitive test performance;
UCEC	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg00343986	chr7:65444356	GUSB	-0.52	-4.86	-0.37	2.99e-6	Aortic root size;
UCEC	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.76	-6.93	-0.5	1.22e-10	Morning vs. evening chronotype;
UCEC	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.33	4.75	0.36	4.83e-6	Crohn's disease;
UCEC	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.88	0.49	1.59e-10	Coronary artery disease;
UCEC	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.68	-5.05	-0.38	1.31e-6	Calcium levels;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.52	-5.77	-0.43	4.57e-8	Pubertal anthropometrics;
UCEC	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.71	-7.32	-0.52	1.54e-11	Tonsillectomy;
UCEC	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.5	4.55	0.35	1.14e-5	Interstitial lung disease;
UCEC	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.15	-0.51	3.85e-11	Breast cancer;
UCEC	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.46	-5.16	-0.39	8.03e-7	Blood protein levels;
UCEC	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg21452805	chr1:244014465	NA	0.51	4.67	0.36	6.74e-6	RR interval (heart rate);
UCEC	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.66	7.63	0.53	2.78e-12	Prudent dietary pattern;
UCEC	cis	rs10507349	0.584	rs9507689	chr13:26819041	A/G	cg01600817	chr13:26797529	RNF6	-0.46	-4.92	-0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg06784218	chr1:46089804	CCDC17	0.54	6.74	0.49	3.41e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg05991184	chr2:219186017	PNKD	0.46	4.99	0.38	1.68e-6	Ulcerative colitis;
UCEC	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.77	8.47	0.57	2.38e-14	Intelligence (multi-trait analysis);
UCEC	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.16	11.97	0.7	1.76e-23	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.54	6.32	0.46	3.01e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	5.35	0.4	3.24e-7	Calcium levels;
UCEC	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-7.73	-0.54	1.58e-12	Colorectal cancer;
UCEC	cis	rs10242455	0.702	rs73403286	chr7:99154865	A/C	cg18809830	chr7:99032528	PTCD1	-0.81	-4.65	-0.36	7.32e-6	Blood metabolite levels;
UCEC	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	1.03	11.99	0.7	1.54e-23	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	2.01e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.61	6.12	0.45	8.27e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg05695927	chr15:45694626	SPATA5L1	0.53	5.19	0.39	6.73e-7	Homoarginine levels;
UCEC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.62	7.82	0.54	9.15e-13	Sjögren's syndrome;
UCEC	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.84	9.2	0.6	3.32e-16	Cognitive function;
UCEC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.77	-8.01	-0.55	3.28e-13	Cognitive function;
UCEC	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	4.68	0.36	6.59e-6	Personality dimensions;
UCEC	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg09654669	chr8:57350985	NA	-0.45	-4.79	-0.37	4.1e-6	Obesity-related traits;
UCEC	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.58	-5.93	-0.44	2.09e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.87	11.18	0.68	2.14e-21	Obesity-related traits;
UCEC	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg13844804	chr7:814759	HEATR2	0.67	4.9	0.37	2.5e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6670533	0.571	rs72884445	chr1:24868592	C/T	cg07475527	chr1:24864545	NA	-0.69	-4.88	-0.37	2.67e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.64	6.87	0.49	1.71e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg19318889	chr4:1322082	MAEA	0.5	5.46	0.41	1.95e-7	Obesity-related traits;
UCEC	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	0.44	4.75	0.36	4.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs13401104	0.796	rs11894118	chr2:237119192	C/A	cg23897927	chr2:237117786	ASB18	-0.52	-4.62	-0.36	8.16e-6	Educational attainment;
UCEC	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.74	-5.7	-0.43	6.33e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg03733263	chr8:22462867	KIAA1967	0.85	10.97	0.67	7.82e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.76	-0.37	4.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.7	-6.73	-0.49	3.63e-10	Aortic root size;
UCEC	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	8.33	0.57	5.26e-14	Post bronchodilator FEV1;
UCEC	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-0.9	-11.27	-0.68	1.3e-21	Height;
UCEC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.34	0.61	1.41e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg15848620	chr12:58087721	OS9	-0.52	-4.86	-0.37	3.03e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.56	5.2	0.39	6.53e-7	Brain structure;
UCEC	cis	rs16847609	1.000	rs79642202	chr3:137695045	A/G	cg10731507	chr3:138067853	MRAS	-0.57	-5.06	-0.38	1.25e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg06562184	chr8:19319451	CSGALNACT1	0.58	5.85	0.43	3.12e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.56	-5.46	-0.41	2.02e-7	Mortality in heart failure;
UCEC	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.65	7.35	0.52	1.3e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.56	-6.96	-0.5	1.02e-10	Total body bone mineral density;
UCEC	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.11	9.47	0.62	6.77e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.33e-8	Lung cancer;
UCEC	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.94	0.5	1.15e-10	Nonalcoholic fatty liver disease;
UCEC	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs9341808	0.628	rs9294172	chr6:80918561	G/A	cg08355045	chr6:80787529	NA	0.41	5.15	0.39	8.25e-7	Sitting height ratio;
UCEC	cis	rs16912285	0.688	rs12284649	chr11:24316260	T/A	ch.11.24196551F	chr11:24239977	NA	0.45	4.53	0.35	1.23e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.47	-6.21	-0.46	5.09e-9	Urinary metabolites;
UCEC	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.83	-10.57	-0.66	8.75e-20	White blood cell count (basophil);
UCEC	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	0.53	5.28	0.4	4.47e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.87	0.44	2.78e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.56	8.05	0.55	2.58e-13	Height;
UCEC	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-8.29	-0.56	6.57e-14	Ulcerative colitis;
UCEC	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	4.52	0.35	1.25e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.63	9.75	0.63	1.28e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg26067569	chr2:200525129	NA	0.54	4.57	0.35	1.04e-5	Schizophrenia;
UCEC	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg21204522	chr6:27730016	NA	-0.58	-4.53	-0.35	1.19e-5	Depression;
UCEC	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.03	14.72	0.77	1.06e-30	Schizophrenia;
UCEC	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg02158880	chr13:53174818	NA	0.46	5.47	0.41	1.86e-7	Lewy body disease;
UCEC	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.04	12.95	0.73	4.39e-26	Dilated cardiomyopathy;
UCEC	cis	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg20307385	chr11:47447363	PSMC3	0.52	4.75	0.36	4.83e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.7	6.65	0.48	5.52e-10	Height;
UCEC	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-1.0	-10.51	-0.66	1.28e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.57	-5.26	-0.4	4.94e-7	Metabolite levels;
UCEC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.59	5.83	0.43	3.35e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs9993696	1	rs9993696	chr4:2187377	T/G	cg04300684	chr4:1523326	NA	-0.37	-5.31	-0.4	3.88e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.39	9.01	0.6	9.98e-16	Diabetic kidney disease;
UCEC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.68	-7.68	-0.54	2.11e-12	Intelligence (multi-trait analysis);
UCEC	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-0.77	-6.84	-0.49	2.03e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.51	5.13	0.39	9.21e-7	QRS complex (12-leadsum);
UCEC	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs60311166	1.000	rs72965177	chr3:52635064	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.8	4.54	0.35	1.16e-5	CTACK levels;
UCEC	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	0.98	4.53	0.35	1.19e-5	IgG glycosylation;
UCEC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg19413350	chr8:57351067	NA	-0.41	-4.85	-0.37	3.15e-6	Obesity-related traits;
UCEC	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14019695	chr9:139328340	INPP5E	0.48	5.11	0.39	9.82e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.73	4.95	0.38	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16346588	chr10:242978	ZMYND11	0.47	4.6	0.35	9.06e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.44	-5.85	-0.43	3.06e-8	IgG glycosylation;
UCEC	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.66	-4.54	-0.35	1.14e-5	Mean platelet volume;
UCEC	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.54	-4.61	-0.36	8.85e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs239198	0.555	rs9399695	chr6:101290415	A/C	cg09795085	chr6:101329169	ASCC3	0.49	4.54	0.35	1.15e-5	Menarche (age at onset);
UCEC	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.74	9.04	0.6	8.3e-16	Mean corpuscular volume;
UCEC	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.46	-5.03	-0.38	1.43e-6	Rheumatoid arthritis;
UCEC	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	4.81	0.37	3.67e-6	Lung cancer in ever smokers;
UCEC	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.85	-6.09	-0.45	9.58e-9	LDL cholesterol;
UCEC	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.76	7.74	0.54	1.44e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.81	7.66	0.53	2.32e-12	Diastolic blood pressure;
UCEC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.46	6.78	0.49	2.7e-10	Homoarginine levels;
UCEC	cis	rs17824620	0.504	rs74237650	chr12:113117520	C/T	cg26711794	chr12:112450906	ERP29;TMEM116	0.6	4.65	0.36	7.39e-6	Platelet count;
UCEC	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.56	5.89	0.44	2.51e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.43	-0.41	2.27e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.59	-7.19	-0.51	3.05e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs10012307	1.000	rs72990061	chr4:137512805	C/A	cg12033966	chr4:138453416	PCDH18	-0.71	-5.01	-0.38	1.54e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.66	5.63	0.42	8.72e-8	Aortic root size;
UCEC	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-1.21	-8.94	-0.59	1.51e-15	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg20007245	chr22:24372913	LOC391322	-0.53	-5.77	-0.43	4.58e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	4.76	0.37	4.68e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.55	-0.58	1.48e-14	Mean platelet volume;
UCEC	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.34	-0.4	3.49e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	6.98	0.5	9.25e-11	Ileal carcinoids;
UCEC	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.55	-5.44	-0.41	2.13e-7	Mortality in heart failure;
UCEC	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg19743168	chr1:23544995	NA	0.45	5.88	0.44	2.66e-8	Height;
UCEC	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.53	5.65	0.42	7.95e-8	Schizophrenia;
UCEC	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.42	-5.11	-0.39	9.67e-7	Refractive error;
UCEC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.35	4.86	0.37	3e-6	Crohn's disease;
UCEC	cis	rs9899728	0.520	rs12936866	chr17:73052050	A/G	cg27626185	chr17:73056755	KCTD2	-0.65	-5.72	-0.43	5.8e-8	Alzheimer's disease or small vessel stroke;
UCEC	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.87	-7.06	-0.5	6.2e-11	Coronary artery calcification;
UCEC	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.77	-6.26	-0.46	4.04e-9	Red blood cell count;
UCEC	cis	rs4851251	1.000	rs62150284	chr2:100784118	T/C	cg22139774	chr2:100720529	AFF3	0.45	4.67	0.36	6.71e-6	Educational attainment (years of education);
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.67	0.53	2.21e-12	Platelet count;
UCEC	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06462663	chr19:18546047	ISYNA1	0.47	5.94	0.44	1.94e-8	Breast cancer;
UCEC	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.94	9.94	0.63	3.91e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.78	7.44	0.52	7.9e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg24562669	chr7:97807699	LMTK2	0.62	8.14	0.56	1.55e-13	Breast cancer;
UCEC	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.79	-7.6	-0.53	3.18e-12	Initial pursuit acceleration;
UCEC	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.44	5.04	0.38	1.32e-6	Blood protein levels;
UCEC	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.39	-5.29	-0.4	4.26e-7	IgG glycosylation;
UCEC	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg09120320	chr17:61926383	NA	0.44	4.59	0.35	9.52e-6	Prudent dietary pattern;
UCEC	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg04756594	chr16:24857601	SLC5A11	0.5	5.93	0.44	2.06e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.56	4.53	0.35	1.23e-5	Bladder cancer;
UCEC	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.44	5.09	0.39	1.08e-6	Blood metabolite ratios;
UCEC	cis	rs7246967	0.611	rs62118823	chr19:22844066	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.52	0.47	1.04e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.91	-10.78	-0.66	2.57e-20	Cognitive function;
UCEC	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg13683864	chr3:40499215	RPL14	-0.62	-6.18	-0.45	5.96e-9	Renal cell carcinoma;
UCEC	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.96	-0.44	1.78e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.62	5.28	0.4	4.61e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.76	8.2	0.56	1.08e-13	Menopause (age at onset);
UCEC	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.64	7.33	0.52	1.4e-11	Prostate-specific antigen levels;
UCEC	cis	rs4516970	0.655	rs73781666	chr6:160206106	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	-0.89	-4.61	-0.36	8.71e-6	Iron status biomarkers;
UCEC	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	7.16	0.51	3.58e-11	Platelet count;
UCEC	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.64	0.53	2.64e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.56	-5.52	-0.41	1.52e-7	Large artery stroke;
UCEC	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.44	4.81	0.37	3.78e-6	Alcohol dependence;
UCEC	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.11	-0.39	9.68e-7	Life satisfaction;
UCEC	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg12292205	chr6:26970375	C6orf41	0.61	6.61	0.48	6.7e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.6	5.82	0.43	3.6e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.7	-6.56	-0.48	8.46e-10	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.67	-5.47	-0.41	1.93e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs17824620	1.000	rs17824620	chr12:113100994	G/T	cg26711794	chr12:112450906	ERP29;TMEM116	0.6	4.82	0.37	3.59e-6	Platelet count;
UCEC	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.5	-0.47	1.19e-9	Eye color traits;
UCEC	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.67	7.32	0.52	1.53e-11	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.63	-5.73	-0.43	5.42e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11844464	chr12:46931139	NA	-0.52	-4.81	-0.37	3.73e-6	Migraine with aura;
UCEC	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg12559939	chr2:27858050	GPN1	0.44	4.58	0.35	9.71e-6	Oral cavity cancer;
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	7.01	0.5	7.98e-11	Platelet count;
UCEC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg13695892	chr22:41940480	POLR3H	0.62	4.9	0.37	2.5e-6	Vitiligo;
UCEC	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.39	-0.41	2.72e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg24562669	chr7:97807699	LMTK2	0.47	5.93	0.44	2.1e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.65	-5.4	-0.41	2.68e-7	Initial pursuit acceleration;
UCEC	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.02	-7.4	-0.52	9.84e-12	Body mass index;
UCEC	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.52	-0.47	1.08e-9	Depression;
UCEC	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.3	4.55	0.35	1.09e-5	Schizophrenia;
UCEC	cis	rs7560272	0.564	rs4852939	chr2:73856769	C/G	cg20560298	chr2:73613845	ALMS1	-0.53	-5.14	-0.39	8.53e-7	Schizophrenia;
UCEC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.57	6.26	0.46	3.92e-9	Cognitive function;
UCEC	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg14582100	chr15:45693742	SPATA5L1	0.34	4.62	0.36	8.46e-6	Homoarginine levels;
UCEC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.66	-6.34	-0.46	2.71e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4975616	0.686	rs37009	chr5:1350339	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.74	-7.9	-0.55	6.13e-13	Lung cancer;
UCEC	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg18681998	chr4:17616180	MED28	-0.56	-6.1	-0.45	8.78e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.22	14.78	0.77	7.3e-31	Body mass index;
UCEC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg19500275	chr17:80737654	TBCD	0.38	4.58	0.35	9.69e-6	Glycated hemoglobin levels;
UCEC	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	10.72	0.66	3.69e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.72	8.42	0.57	3.18e-14	Menopause (age at onset);
UCEC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.93	0.38	2.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7246967	0.932	rs35007403	chr19:23037447	T/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.5	0.47	1.19e-9	Personality dimensions;
UCEC	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg19413350	chr8:57351067	NA	-0.41	-4.83	-0.37	3.41e-6	Obesity-related traits;
UCEC	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg22524514	chr11:65779676	CST6	0.53	4.97	0.38	1.87e-6	Crohn's disease;
UCEC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.6	6.52	0.47	1.08e-9	Total body bone mineral density;
UCEC	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.83	9.2	0.6	3.35e-16	Breast cancer;
UCEC	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.53	-6.22	-0.46	5.02e-9	Prostate cancer;
UCEC	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-10.89	-0.67	1.28e-20	Vitiligo;
UCEC	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.69	-7.86	-0.54	7.36e-13	Menarche (age at onset);
UCEC	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	12.0	0.7	1.47e-23	Ulcerative colitis;
UCEC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.59	5.88	0.44	2.65e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.65	-6.01	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg00122941	chr17:4613640	ARRB2	-0.56	-4.99	-0.38	1.66e-6	Lymphocyte counts;
UCEC	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.63	4.84	0.37	3.3e-6	Itch intensity from mosquito bite;
UCEC	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.54	5.29	0.4	4.3e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg15147215	chr3:52552868	STAB1	-0.44	-4.87	-0.37	2.82e-6	Electroencephalogram traits;
UCEC	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.68	0.36	6.42e-6	Cognitive ability;
UCEC	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg15133208	chr4:90757351	SNCA	-0.33	-4.53	-0.35	1.19e-5	Dementia with Lewy bodies;
UCEC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.65	8.15	0.56	1.44e-13	Obesity-related traits;
UCEC	cis	rs7246967	0.932	rs35735434	chr19:23039477	T/C	cg24889512	chr19:22816950	ZNF492	0.5	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	4.71	0.36	5.69e-6	Lung cancer in ever smokers;
UCEC	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.55	-6.24	-0.46	4.49e-9	Inflammatory bowel disease;
UCEC	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg04553112	chr3:125709451	NA	-0.64	-4.72	-0.36	5.53e-6	Blood pressure (smoking interaction);
UCEC	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.52	5.86	0.43	2.99e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2554380	0.628	rs4473150	chr15:84482831	C/G	cg18393722	chr15:85113863	UBE2QP1	0.5	4.55	0.35	1.12e-5	Height;
UCEC	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.75	-6.69	-0.48	4.3e-10	Smoking behavior;
UCEC	cis	rs9549260	0.564	rs12184871	chr13:41291928	C/A	cg21288729	chr13:41239152	FOXO1	0.56	5.9	0.44	2.35e-8	Red blood cell count;
UCEC	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.48	5.92	0.44	2.16e-8	Anterior chamber depth;
UCEC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg05738196	chr6:26577821	NA	0.59	5.77	0.43	4.56e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs883565	0.792	rs1274958	chr3:39184959	C/T	cg01426195	chr3:39028469	NA	0.53	5.02	0.38	1.51e-6	Handedness;
UCEC	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.55	4.54	0.35	1.17e-5	HDL cholesterol levels;
UCEC	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.04	6.35	0.46	2.48e-9	Skin colour saturation;
UCEC	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.6	4.69	0.36	6.06e-6	Corneal astigmatism;
UCEC	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.38	4.94	0.38	2.07e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.82	0.49	2.24e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.7	-0.54	1.88e-12	Breast cancer;
UCEC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.23	-0.4	5.82e-7	Breast cancer;
UCEC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.82	8.9	0.59	1.87e-15	Cognitive function;
UCEC	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.4	4.57	0.35	1.04e-5	Smoking behavior;
UCEC	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.51	-5.09	-0.39	1.07e-6	Neuroticism;
UCEC	cis	rs847649	0.618	rs6465880	chr7:102515237	T/C	cg18108683	chr7:102477205	FBXL13	-0.65	-8.15	-0.56	1.44e-13	Morning vs. evening chronotype;
UCEC	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.71	-0.63	1.54e-17	Monocyte count;
UCEC	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.74	7.86	0.54	7.31e-13	Blood protein levels;
UCEC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.27	0.56	7.34e-14	Smoking behavior;
UCEC	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.37	4.75	0.36	4.78e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg13683864	chr3:40499215	RPL14	-0.58	-6.07	-0.45	1.01e-8	Renal cell carcinoma;
UCEC	cis	rs4345220	0.585	rs4861124	chr4:41642889	A/G	cg15232654	chr4:41643107	LIMCH1	0.43	4.6	0.35	9.09e-6	Migraine with aura;
UCEC	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.56	5.48	0.41	1.78e-7	Blood metabolite levels;
UCEC	cis	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg17469321	chr7:55412551	NA	0.72	6.42	0.47	1.74e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs17106184	1.000	rs72902729	chr1:51231935	A/G	cg07174182	chr1:51127561	FAF1	-0.89	-5.66	-0.42	7.66e-8	Type 2 diabetes;
UCEC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	5.12	0.39	9.45e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs151997	0.962	rs56170692	chr5:50247928	G/A	cg06027927	chr5:50259733	NA	0.56	5.16	0.39	8e-7	Callous-unemotional behaviour;
UCEC	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-5.08	-0.39	1.14e-6	Menarche (age at onset);
UCEC	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-11.76	-0.7	6.55e-23	Ulcerative colitis;
UCEC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.53	5.01	0.38	1.53e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.6	-6.6	-0.48	7.12e-10	Asthma;
UCEC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg04155231	chr12:9217510	LOC144571	0.41	5.02	0.38	1.48e-6	Sjögren's syndrome;
UCEC	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-5.05	-0.38	1.3e-6	Schizophrenia;
UCEC	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	0.86	4.92	0.38	2.25e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	5.88	0.44	2.63e-8	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs7246967	0.673	rs3853650	chr19:22880490	A/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.85	-10.43	-0.65	2.13e-19	Brugada syndrome;
UCEC	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.97	0.44	1.7e-8	HDL cholesterol;
UCEC	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg10123293	chr2:99228465	UNC50	0.49	5.51	0.41	1.58e-7	Bipolar disorder;
UCEC	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-5.0	-0.38	1.64e-6	Diabetic retinopathy;
UCEC	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	0.93	9.98	0.64	3.22e-18	Corneal structure;
UCEC	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.37	5.64	0.42	8.65e-8	Body mass index;
UCEC	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.48	0.52	6.39e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs4879656	0.564	rs4879657	chr9:33012465	C/T	cg09633881	chr9:33002021	APTX	-0.36	-4.58	-0.35	9.86e-6	Menopause (age at onset);
UCEC	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.83	-0.37	3.38e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.66	6.45	0.47	1.52e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11871801	0.750	rs7216927	chr17:40651497	T/A	cg20099018	chr17:40169396	DNAJC7;NKIRAS2	0.47	4.55	0.35	1.1e-5	Crohn's disease;
UCEC	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.52	-0.47	1.05e-9	Platelet count;
UCEC	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg01426195	chr3:39028469	NA	-0.75	-9.83	-0.63	7.69e-18	Handedness;
UCEC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.81	-7.47	-0.52	6.61e-12	Diastolic blood pressure;
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.46	-4.99	-0.38	1.7e-6	Pulmonary function;
UCEC	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.28	12.72	0.72	1.86e-25	Corneal structure;
UCEC	cis	rs6832769	1.000	rs28572116	chr4:56424344	A/T	cg05960024	chr4:56376020	CLOCK	-0.55	-5.57	-0.42	1.2e-7	Personality dimensions;
UCEC	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg14078730	chr11:63896557	MACROD1	0.67	5.26	0.4	5.04e-7	Mean platelet volume;
UCEC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.95	9.33	0.61	1.56e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.52	-5.33	-0.4	3.57e-7	Schizophrenia;
UCEC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg04756594	chr16:24857601	SLC5A11	-0.39	-4.96	-0.38	1.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01973587	chr1:228161476	NA	0.36	4.82	0.37	3.59e-6	Diastolic blood pressure;
UCEC	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.66	7.44	0.52	7.76e-12	Body mass index;
UCEC	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg13695892	chr22:41940480	POLR3H	0.68	5.34	0.4	3.43e-7	Vitiligo;
UCEC	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.63	-0.36	8.06e-6	LDL cholesterol levels;
UCEC	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg27299712	chr1:6550532	PLEKHG5	0.51	4.82	0.37	3.61e-6	Body mass index;
UCEC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg20965017	chr5:231967	SDHA	-0.62	-5.64	-0.42	8.44e-8	Breast cancer;
UCEC	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg13683864	chr3:40499215	RPL14	-0.57	-6.13	-0.45	7.8e-9	Renal cell carcinoma;
UCEC	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg12473912	chr3:136751656	NA	0.43	4.98	0.38	1.77e-6	Gestational age at birth (child effect);
UCEC	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg13593689	chr9:129986794	NA	0.45	4.74	0.36	4.97e-6	Intraocular pressure;
UCEC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.96	10.54	0.66	1.06e-19	Cognitive function;
UCEC	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg11632617	chr15:75315747	PPCDC	-0.66	-7.68	-0.54	2.07e-12	Lung cancer;
UCEC	cis	rs8105895	0.935	rs8110289	chr19:22239717	A/G	cg24072202	chr19:22235272	ZNF257	-0.61	-5.33	-0.4	3.64e-7	Body mass index (change over time);
UCEC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.59	-0.35	9.5e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9467773	0.967	rs1321482	chr6:26575154	T/C	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg08027265	chr7:2291960	NA	0.43	5.01	0.38	1.57e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.66	-5.82	-0.43	3.51e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.51	5.32	0.4	3.87e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.95	-0.44	1.9e-8	Depression;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.74	8.78	0.59	3.9e-15	Menarche (age at onset);
UCEC	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.48	5.56	0.42	1.24e-7	Oral cavity cancer;
UCEC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.54	-0.47	9.58e-10	Joint mobility (Beighton score);
UCEC	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.59	5.29	0.4	4.44e-7	Corneal astigmatism;
UCEC	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg05539622	chr2:73298971	SFXN5	0.5	4.62	0.36	8.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1832871	0.599	rs661857	chr6:158658788	T/C	cg07215822	chr6:158701037	NA	-0.54	-5.69	-0.43	6.57e-8	Height;
UCEC	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-7.21	-0.51	2.77e-11	Hypospadias;
UCEC	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg20965017	chr5:231967	SDHA	-0.63	-5.87	-0.44	2.78e-8	Breast cancer;
UCEC	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	0.88	6.36	0.46	2.41e-9	Red blood cell traits;
UCEC	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.15	-13.01	-0.73	3.09e-26	Breast cancer;
UCEC	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg05738196	chr6:26577821	NA	-0.63	-7.79	-0.54	1.14e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6594713	0.759	rs13181944	chr5:112687535	T/A	cg06062378	chr5:112387002	MCC	-0.43	-4.88	-0.37	2.76e-6	Brain cytoarchitecture;
UCEC	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.79	9.15	0.6	4.48e-16	Schizophrenia;
UCEC	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.55	5.57	0.42	1.19e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.77	-9.2	-0.6	3.26e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.65	6.23	0.46	4.58e-9	Breast cancer;
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.48	-4.76	-0.37	4.65e-6	Parkinson's disease;
UCEC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.17e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.34	-4.54	-0.35	1.18e-5	Monocyte count;
UCEC	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg13264159	chr8:625131	ERICH1	-0.91	-4.71	-0.36	5.61e-6	IgG glycosylation;
UCEC	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	0.77	4.86	0.37	3e-6	Height;
UCEC	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.5	4.75	0.36	4.75e-6	Blood protein levels;
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.77	8.11	0.56	1.86e-13	Menarche (age at onset);
UCEC	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.28	10.73	0.66	3.45e-20	Uric acid levels;
UCEC	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg22166914	chr1:53195759	ZYG11B	-0.75	-7.75	-0.54	1.4e-12	Monocyte count;
UCEC	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg19743168	chr1:23544995	NA	-0.43	-5.41	-0.41	2.53e-7	Height;
UCEC	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-4.66	-0.36	7.03e-6	Bipolar disorder;
UCEC	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.84	7.93	0.55	5e-13	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.42	4.52	0.35	1.28e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.74	8.53	0.58	1.69e-14	Menopause (age at onset);
UCEC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg18279126	chr7:2041391	MAD1L1	0.37	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.07	-0.39	1.18e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-5.08	-0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.64	-4.68	-0.36	6.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.78	0.43	4.33e-8	Colorectal cancer;
UCEC	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg05660106	chr1:15850417	CASP9	0.66	7.14	0.51	3.9e-11	Systolic blood pressure;
UCEC	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.69	-6.28	-0.46	3.56e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.88	-9.25	-0.61	2.5e-16	Blood metabolite levels;
UCEC	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.53	-0.35	1.21e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.54	4.54	0.35	1.19e-5	Obesity-related traits;
UCEC	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.65	0.36	7.34e-6	Parkinson's disease;
UCEC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.87	10.88	0.67	1.38e-20	Longevity;Endometriosis;
UCEC	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.46	0.47	1.46e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs953387	0.910	rs4954573	chr2:136927094	T/G	cg07169764	chr2:136633963	MCM6	0.49	4.61	0.36	8.58e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.62	6.9	0.49	1.47e-10	Pubertal anthropometrics;
UCEC	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.51	-5.82	-0.43	3.6e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.26	-0.4	4.96e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg13695892	chr22:41940480	POLR3H	-0.7	-5.45	-0.41	2.1e-7	Vitiligo;
UCEC	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.56	5.28	0.4	4.66e-7	Birth weight;
UCEC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.53	-4.73	-0.36	5.24e-6	Serum sulfate level;
UCEC	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.78	7.44	0.52	7.71e-12	Response to antipsychotic treatment;
UCEC	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.39	-4.64	-0.36	7.51e-6	Type 2 diabetes;
UCEC	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.48	-5.98	-0.44	1.58e-8	Total body bone mineral density;
UCEC	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.14	6.92	0.5	1.26e-10	Eosinophil percentage of granulocytes;
UCEC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-0.85	-10.73	-0.66	3.37e-20	Height;
UCEC	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg20821713	chr7:1055600	C7orf50	-0.74	-6.97	-0.5	1.02e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.02	-0.38	1.45e-6	Blood metabolite levels;
UCEC	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.36	-4.91	-0.38	2.37e-6	Primary biliary cholangitis;
UCEC	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	10.9	0.67	1.23e-20	Electrocardiographic conduction measures;
UCEC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg18827107	chr12:86230957	RASSF9	-0.44	-4.78	-0.37	4.14e-6	Major depressive disorder;
UCEC	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.65	6.58	0.48	7.62e-10	C-reactive protein levels;
UCEC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg06466757	chr4:1255808	NA	0.45	4.74	0.36	5.08e-6	Obesity-related traits;
UCEC	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg18479299	chr3:125709523	NA	-0.67	-4.59	-0.35	9.33e-6	Blood pressure (smoking interaction);
UCEC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg02160872	chr5:212506	CCDC127	-0.69	-7.12	-0.51	4.46e-11	Breast cancer;
UCEC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	7.7	0.54	1.85e-12	Chronic sinus infection;
UCEC	trans	rs7246760	1.000	rs67507476	chr19:9852948	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.48	-0.53	6.1e-12	Pursuit maintenance gain;
UCEC	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.62	6.09	0.45	9.63e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.52	4.84	0.37	3.2e-6	Platelet count;
UCEC	cis	rs5167	0.504	rs66867801	chr19:45457293	C/T	cg09555818	chr19:45449301	APOC2	0.48	6.35	0.46	2.58e-9	Blood protein levels;
UCEC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.63	7.53	0.53	4.83e-12	Obesity-related traits;
UCEC	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg05963712	chr12:49373746	WNT1	0.46	4.51	0.35	1.3e-5	Longevity (90 years and older);
UCEC	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg00815214	chr21:47717953	NA	0.39	4.69	0.36	6.2e-6	Testicular germ cell tumor;
UCEC	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg04202892	chr2:111875749	ACOXL	0.42	4.67	0.36	6.85e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs28735056	0.935	rs552957	chr18:77595748	G/A	cg20368463	chr18:77673604	PQLC1	-0.63	-4.85	-0.37	3.13e-6	Schizophrenia;
UCEC	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.61	5.9	0.44	2.46e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg18681998	chr4:17616180	MED28	-0.7	-7.51	-0.53	5.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.03e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13065560	0.515	rs4676660	chr3:39059192	G/A	cg01426195	chr3:39028469	NA	-0.54	-4.99	-0.38	1.71e-6	Interleukin-18 levels;
UCEC	cis	rs6684428	0.536	rs11804906	chr1:56394231	A/G	cg11651538	chr1:56320950	NA	-0.44	-4.52	-0.35	1.27e-5	Airflow obstruction;
UCEC	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.16	0.39	7.77e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.9	0.44	2.44e-8	HDL cholesterol;
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs782107	0.614	rs1729791	chr12:58765453	T/C	cg19181132	chr12:59314527	LRIG3	-0.46	-4.87	-0.37	2.82e-6	Interleukin-12p70 levels;
UCEC	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.68	5.16	0.39	7.76e-7	Height;
UCEC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.42e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.21e-6	Breast cancer;
UCEC	cis	rs970548	0.672	rs56005617	chr10:46056127	C/T	cg15223267	chr10:46222474	FAM21C	0.49	4.67	0.36	6.83e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.59	5.73	0.43	5.38e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.64	-0.36	7.79e-6	Resting heart rate;
UCEC	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.63	7.04	0.5	6.65e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	0.86	9.75	0.63	1.22e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.66	6.21	0.46	5.13e-9	Subjective well-being;
UCEC	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.85	10.6	0.66	7.61e-20	IgG glycosylation;
UCEC	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.47	-5.55	-0.42	1.3e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.1	9.62	0.62	2.76e-17	Corneal structure;
UCEC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg01689657	chr7:91764605	CYP51A1	0.48	5.99	0.44	1.56e-8	Breast cancer;
UCEC	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-4.5	-0.35	1.35e-5	Blood metabolite levels;
UCEC	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.55	5.13	0.39	9.1e-7	Coronary artery disease;
UCEC	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-0.7	-6.1	-0.45	8.84e-9	Diastolic blood pressure;
UCEC	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.66	5.4	0.41	2.62e-7	Systolic blood pressure;
UCEC	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.51	-6.15	-0.45	7.03e-9	Electrocardiographic conduction measures;
UCEC	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.73	-5.27	-0.4	4.79e-7	Mean platelet volume;
UCEC	cis	rs2742417	0.967	rs2742427	chr3:45736423	C/T	cg09251680	chr3:45801144	SLC6A20	0.37	4.52	0.35	1.24e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	0.51	5.25	0.4	5.21e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	1.0	11.0	0.67	6.53e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-0.94	-7.02	-0.5	7.77e-11	Body mass index;
UCEC	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.6	7.22	0.51	2.63e-11	Lewy body disease;
UCEC	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.53	-5.06	-0.39	1.24e-6	Homoarginine levels;
UCEC	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg21856205	chr7:94953877	PON1	-0.54	-5.15	-0.39	8.38e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg01072550	chr1:21505969	NA	-0.57	-6.01	-0.44	1.43e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg22166914	chr1:53195759	ZYG11B	0.8	8.6	0.58	1.11e-14	Monocyte count;
UCEC	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.66	-7.57	-0.53	3.77e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	0.85	6.91	0.5	1.35e-10	Response to hepatitis C treatment;
UCEC	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.97	0.44	1.68e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.55	6.49	0.47	1.25e-9	Menarche (age at onset);
UCEC	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.08	-15.93	-0.8	7.73e-34	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.72	-5.56	-0.42	1.21e-7	Orofacial clefts;
UCEC	cis	rs2070997	0.591	rs2515714	chr9:133706244	A/C	cg12998491	chr9:134152531	FAM78A	-0.86	-5.28	-0.4	4.49e-7	Response to amphetamines;
UCEC	trans	rs76693355	0.512	rs10790381	chr11:120257495	C/T	cg07699613	chr5:150603746	CCDC69	0.83	6.81	0.49	2.27e-10	Intraocular pressure;
UCEC	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.48	-5.28	-0.4	4.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.58	6.36	0.46	2.44e-9	Blood metabolite levels;
UCEC	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.72	-0.48	3.81e-10	Eye color traits;
UCEC	cis	rs6460942	0.591	rs7804805	chr7:12332066	C/G	cg06484146	chr7:12443880	VWDE	-0.62	-4.9	-0.37	2.49e-6	Coronary artery disease;
UCEC	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg08886695	chr4:3369023	RGS12	0.5	4.78	0.37	4.18e-6	Parental longevity (mother's age at death);
UCEC	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	6.69	0.48	4.3e-10	Neuroticism;
UCEC	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.74	7.17	0.51	3.44e-11	Orofacial clefts;
UCEC	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	1.01	9.5	0.62	5.47e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs4345220	0.585	rs4861125	chr4:41642969	T/G	cg15232654	chr4:41643107	LIMCH1	0.43	4.6	0.35	9.09e-6	Migraine with aura;
UCEC	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-0.61	-7.11	-0.51	4.75e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.58	-6.62	-0.48	6.27e-10	Pubertal anthropometrics;
UCEC	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.6	5.13	0.39	9e-7	Multiple sclerosis;
UCEC	cis	rs7246967	0.932	rs35446354	chr19:23027324	A/G	cg08271804	chr19:22816896	ZNF492	0.54	5.29	0.4	4.43e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg23271606	chr7:92464891	CDK6	-0.48	-5.23	-0.4	5.72e-7	Breast cancer;
UCEC	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.43	4.84	0.37	3.2e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	6.02	0.44	1.33e-8	IgG glycosylation;
UCEC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.55	5.93	0.44	2.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs7246967	0.736	rs2617779	chr19:22998321	G/A	cg05241461	chr19:22816980	ZNF492	0.52	4.84	0.37	3.25e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.1e-10	Tonsillectomy;
UCEC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.72	-7.12	-0.51	4.35e-11	Aortic root size;
UCEC	cis	rs9467773	1.000	rs12663894	chr6:26577370	C/T	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.78	11.31	0.68	9.94e-22	Leprosy;
UCEC	cis	rs7246967	0.932	rs4932798	chr19:23051507	G/A	cg08271804	chr19:22816896	ZNF492	0.59	5.6	0.42	1.03e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.43	5.19	0.39	6.95e-7	Neuroticism;
UCEC	cis	rs61776719	0.520	rs11485595	chr1:38411350	C/T	cg17077180	chr1:38461687	NA	0.65	6.42	0.47	1.79e-9	Coronary artery disease;
UCEC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.49	0.41	1.73e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.65	6.83	0.49	2.05e-10	Pubertal anthropometrics;
UCEC	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.44	0.47	1.64e-9	Menarche (age at onset);
UCEC	cis	rs7088591	0.867	rs61351365	chr10:59788633	G/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.39	-5.18	-0.39	7.19e-7	Dupuytren's disease;
UCEC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.19e-10	Aortic root size;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02382073	chr4:106067967	TET2	0.6	6.79	0.49	2.56e-10	Warfarin maintenance dose;
UCEC	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	0.98	14.29	0.76	1.32e-29	Homoarginine levels;
UCEC	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.96	0.38	1.92e-6	Monocyte percentage of white cells;
UCEC	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-8.47	-0.57	2.37e-14	Coffee consumption (cups per day);
UCEC	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.82	4.91	0.38	2.44e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.76	8.42	0.57	3.09e-14	Blood protein levels;
UCEC	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.88	-9.67	-0.62	1.96e-17	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2267137	0.903	rs5752903	chr22:29769306	G/T	cg07256473	chr22:29710276	RASL10A	0.53	5.29	0.4	4.35e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.91	9.56	0.62	3.93e-17	Cognitive function;
UCEC	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.73	6.59	0.48	7.38e-10	Coronary artery disease;
UCEC	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs13401104	0.680	rs11894606	chr2:237114834	T/G	cg23897927	chr2:237117786	ASB18	-0.53	-4.74	-0.36	5e-6	Educational attainment;
UCEC	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.53	-5.23	-0.4	5.79e-7	Ileal carcinoids;
UCEC	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	0.98	10.14	0.64	1.18e-18	Left atrial antero-posterior diameter;
UCEC	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.91	-0.38	2.35e-6	Height;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.6	-6.81	-0.49	2.33e-10	Cardiac Troponin-T levels;
UCEC	cis	rs11958404	0.860	rs6868839	chr5:157442196	T/G	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-5.49	-0.41	1.75e-7	Morning vs. evening chronotype;
UCEC	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-1.01	-8.12	-0.56	1.72e-13	White matter hyperintensity burden;
UCEC	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.57	6.46	0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.54	5.56	0.42	1.24e-7	Corneal astigmatism;
UCEC	cis	rs7246967	1.000	rs8113312	chr19:23061182	G/C	cg24889512	chr19:22816950	ZNF492	0.49	4.99	0.38	1.68e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Subjective well-being;
UCEC	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.96	-0.38	1.9e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.5	-4.74	-0.36	4.92e-6	Diabetic retinopathy;
UCEC	cis	rs78761021	0.720	rs874306	chr17:9797994	G/A	cg26853458	chr17:9805074	RCVRN	0.39	4.93	0.38	2.19e-6	Type 2 diabetes;
UCEC	cis	rs17123764	0.818	rs73305008	chr12:49958911	G/A	cg20471783	chr12:50157085	TMBIM6	0.63	5.19	0.39	6.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-6.4	-0.47	1.96e-9	Mood instability;
UCEC	cis	rs7781557	0.640	rs55681588	chr7:102577338	C/G	cg06322601	chr7:102330635	NA	0.57	4.61	0.36	8.64e-6	Colorectal adenoma (advanced);
UCEC	cis	rs883565	0.740	rs2037655	chr3:39072754	T/C	cg01426195	chr3:39028469	NA	-0.67	-8.21	-0.56	1.04e-13	Handedness;
UCEC	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.5	4.76	0.37	4.62e-6	Coronary artery disease;
UCEC	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.59	5.54	0.42	1.37e-7	Schizophrenia;
UCEC	cis	rs4789452	1.000	rs4789452	chr17:75372850	G/A	cg21830368	chr17:75373327	SEPT9	-0.31	-4.84	-0.37	3.24e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	0.92	5.68	0.42	7.02e-8	Skin colour saturation;
UCEC	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	4.68	0.36	6.52e-6	Personality dimensions;
UCEC	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.57	-4.5	-0.35	1.36e-5	Coronary artery calcification;
UCEC	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.59	-5.43	-0.41	2.33e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.66	-5.38	-0.41	2.85e-7	Primary biliary cholangitis;
UCEC	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.52	4.84	0.37	3.2e-6	Menopause (age at onset);
UCEC	cis	rs2882667	0.515	rs13161286	chr5:138484105	A/G	cg04439458	chr5:138467593	SIL1	-0.48	-5.19	-0.39	6.79e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.4	4.67	0.36	6.68e-6	HDL cholesterol;
UCEC	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg04871131	chr7:94954202	PON1	-0.53	-5.16	-0.39	8.03e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg03078520	chr22:18463400	MICAL3	-0.56	-5.63	-0.42	8.88e-8	Presence of antiphospholipid antibodies;
UCEC	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.48	4.54	0.35	1.16e-5	Multiple myeloma (IgH translocation);
UCEC	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.37	-5.71	-0.43	5.92e-8	Schizophrenia;
UCEC	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg10978503	chr1:24200527	CNR2	0.36	4.76	0.37	4.57e-6	Immature fraction of reticulocytes;
UCEC	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg10820045	chr2:198174542	NA	-0.44	-5.48	-0.41	1.81e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.58	-5.37	-0.4	3.06e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	4.98	0.38	1.75e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.55	4.73	0.36	5.28e-6	Cognitive ability;
UCEC	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.36	5.09	0.39	1.09e-6	Coronary artery disease;
UCEC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.31	-0.4	4.03e-7	Breast cancer;
UCEC	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.85	-7.2	-0.51	2.86e-11	Coronary artery calcification;
UCEC	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.12	-0.39	9.58e-7	Breast cancer;
UCEC	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.53	-0.47	1.03e-9	Tonsillectomy;
UCEC	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg24069376	chr3:38537580	EXOG	-0.42	-5.19	-0.39	6.77e-7	Electrocardiographic conduction measures;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.47	-5.0	-0.38	1.64e-6	Pubertal anthropometrics;
UCEC	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.64	-0.36	7.74e-6	Aortic root size;
UCEC	cis	rs250585	0.736	rs30012	chr16:23420943	A/G	cg26562691	chr16:23850404	PRKCB	0.35	4.68	0.36	6.39e-6	Egg allergy;
UCEC	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.08	16.93	0.81	2.33e-36	IgG glycosylation;
UCEC	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.59	5.25	0.4	5.22e-7	Corneal astigmatism;
UCEC	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.66	-7.25	-0.51	2.16e-11	Ear protrusion;
UCEC	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.59	-8.08	-0.55	2.16e-13	Proinsulin levels;
UCEC	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.48	-7.09	-0.5	5.32e-11	Primary biliary cholangitis;
UCEC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.49	4.77	0.37	4.31e-6	Blood protein levels;
UCEC	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs4891159	0.548	rs948646	chr18:74118168	G/A	cg24786174	chr18:74118243	ZNF516	0.56	6.53	0.47	9.82e-10	Longevity;
UCEC	cis	rs256277	0.657	rs468300	chr5:111366222	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-4.54	-0.35	1.15e-5	Coronary artery disease;
UCEC	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.63	6.39	0.47	2.07e-9	Homoarginine levels;
UCEC	cis	rs17639063	0.737	rs11915020	chr3:62531699	T/C	cg04329977	chr3:61546343	PTPRG	-0.92	-4.89	-0.37	2.59e-6	QT interval (sulfonylurea treatment interaction);
UCEC	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg00546932	chr16:1947055	NA	-0.37	-5.0	-0.38	1.58e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs1318937	0.516	rs73023424	chr3:15243502	G/C	cg21849552	chr3:14597650	NA	0.49	4.76	0.37	4.5e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.68	0.36	6.58e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.85	7.72	0.54	1.62e-12	Body mass index;
UCEC	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-6.17	-0.45	6.36e-9	Rheumatoid arthritis;
UCEC	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.5	5.5	0.41	1.65e-7	Mean corpuscular volume;
UCEC	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.68	6.69	0.48	4.36e-10	Large artery stroke;
UCEC	cis	rs4676380	0.855	rs1583261	chr2:241644740	T/C	cg25428929	chr2:242606353	ATG4B	-0.45	-4.53	-0.35	1.2e-5	Response to metformin (IC50);
UCEC	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.43	4.55	0.35	1.14e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg00677455	chr12:58241039	CTDSP2	0.53	4.95	0.38	1.97e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.61	-4.51	-0.35	1.29e-5	Gut microbiome composition (summer);
UCEC	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.22	-0.4	5.87e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.66	-6.01	-0.44	1.37e-8	Serum sulfate level;
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.74	7.47	0.52	6.44e-12	Longevity;Endometriosis;
UCEC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.72	-9.01	-0.6	1.02e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.48	-4.84	-0.37	3.3e-6	Parkinson's disease;
UCEC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg24687543	chr11:63912206	MACROD1	0.57	4.8	0.37	3.81e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.57	6.2	0.46	5.34e-9	Neuroticism;
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.57	6.5	0.47	1.19e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs735860	0.763	rs1346603	chr6:53149262	C/T	cg10236188	chr6:53219634	NA	0.44	4.64	0.36	7.54e-6	Glaucoma;
UCEC	cis	rs2062225	0.696	rs10183208	chr2:111761291	A/C	cg23782758	chr2:111737646	ACOXL	-0.48	-4.61	-0.36	8.85e-6	Monocyte count;
UCEC	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.63	6.32	0.46	2.9e-9	Lung cancer;
UCEC	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.08	-0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.41	-4.9	-0.37	2.51e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.85	7.59	0.53	3.32e-12	Body mass index;
UCEC	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.91	11.4	0.69	5.59e-22	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.18e-8	Neuroticism;
UCEC	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	5.6	0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-8.54	-0.58	1.58e-14	Cognitive function;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.49	-5.47	-0.41	1.85e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg22868518	chr11:507468	RNH1	-0.48	-4.58	-0.35	9.98e-6	Systemic lupus erythematosus;
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.74	5.24	0.4	5.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs2319125	0.770	rs9904229	chr17:64037278	A/C	cg06996976	chr17:64576105	PRKCA	-0.43	-4.85	-0.37	3.16e-6	&beta2-Glycoprotein I (&beta;2-GPI) plasma levels;
UCEC	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	7.9	0.55	5.99e-13	Joint mobility (Beighton score);
UCEC	cis	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.5	5.51	0.41	1.59e-7	Life satisfaction;
UCEC	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-7.7	-0.54	1.87e-12	Heart rate;
UCEC	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg10263370	chr3:44754102	ZNF502	-0.47	-4.76	-0.37	4.51e-6	Depressive symptoms;
UCEC	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg07148914	chr20:33460835	GGT7	-0.45	-4.61	-0.36	8.73e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-4.91	-0.38	2.42e-6	Monocyte percentage of white cells;
UCEC	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg00339695	chr16:24857497	SLC5A11	0.52	5.86	0.44	2.96e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11118844	0.843	rs11118847	chr1:221922614	A/G	cg04222084	chr1:221915650	DUSP10	-0.77	-7.1	-0.51	4.9e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-4.99	-0.38	1.67e-6	Mean platelet volume;
UCEC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.53	-0.47	1e-9	Initial pursuit acceleration;
UCEC	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.46	4.84	0.37	3.24e-6	HDL cholesterol;
UCEC	cis	rs8105895	0.935	rs78646027	chr19:22257410	C/T	cg24175803	chr19:22235144	ZNF257	-0.48	-5.11	-0.39	9.82e-7	Body mass index (change over time);
UCEC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.57	6.56	0.48	8.68e-10	Aortic root size;
UCEC	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.62	5.36	0.4	3.21e-7	RR interval (heart rate);
UCEC	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.69	8.2	0.56	1.09e-13	Immature fraction of reticulocytes;
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg09120320	chr17:61926383	NA	0.47	5.47	0.41	1.87e-7	Prudent dietary pattern;
UCEC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg19318889	chr4:1322082	MAEA	0.4	4.93	0.38	2.21e-6	Obesity-related traits;
UCEC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.6	5.62	0.42	9.45e-8	Aortic root size;
UCEC	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg03543861	chr21:44258195	NA	0.47	4.82	0.37	3.52e-6	Information processing speed;
UCEC	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.74	-7.89	-0.55	6.2800000000000005e-13	Body mass index;
UCEC	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-5.17	-0.39	7.48e-7	Gut microbiome composition (summer);
UCEC	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.51	4.61	0.36	8.65e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6921919	1.000	rs6922111	chr6:28325308	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.47	-4.83	-0.37	3.38e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.37	0.46	2.31e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.49	-5.72	-0.43	5.66e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.47	4.89	0.37	2.65e-6	Alcohol dependence;
UCEC	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.54	0.62	4.29e-17	Bipolar disorder;
UCEC	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.5	-5.22	-0.4	5.88e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8105265	1	rs8105265	chr19:2920705	A/G	cg08634464	chr19:2901147	ZNF57	0.96	8.12	0.56	1.71e-13	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7246967	0.673	rs2082445	chr19:22834587	A/G	cg24889512	chr19:22816950	ZNF492	0.58	6.19	0.45	5.82e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.8	6.11	0.45	8.66e-9	Initial pursuit acceleration;
UCEC	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg05962950	chr11:130786565	SNX19	0.46	4.56	0.35	1.09e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg11632617	chr15:75315747	PPCDC	-0.66	-7.58	-0.53	3.55e-12	Lung cancer;
UCEC	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg05072774	chr3:49840536	C3orf54	-0.55	-4.78	-0.37	4.17e-6	Resting heart rate;
UCEC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Smoking initiation;
UCEC	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-4.69	-0.36	6.1e-6	Type 2 diabetes;
UCEC	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.73	0.49	3.58e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.68	-6.06	-0.45	1.09e-8	Pancreatic cancer;
UCEC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.08	0.39	1.12e-6	Breast cancer;
UCEC	cis	rs1595825	0.891	rs76637837	chr2:198529496	G/A	cg19156104	chr2:198669113	PLCL1	-0.61	-4.56	-0.35	1.05e-5	Ulcerative colitis;
UCEC	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.61	6.97	0.5	1.01e-10	Red blood cell count;
UCEC	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.71	8.37	0.57	4.26e-14	Prudent dietary pattern;
UCEC	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.65	6.17	0.45	6.24e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.5e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.57	-6.55	-0.48	9.15e-10	Response to temozolomide;
UCEC	cis	rs4615376	1.000	rs9463410	chr6:13064274	A/G	cg11378619	chr6:12164359	HIVEP1	-0.49	-4.69	-0.36	6.32e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.56	5.78	0.43	4.27e-8	Lymphocyte counts;
UCEC	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Bipolar disorder;
UCEC	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.94	-6.12	-0.45	8.18e-9	Arsenic metabolism;
UCEC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.6	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs77861329	0.748	rs749995	chr3:52176701	C/T	cg08692210	chr3:52188851	WDR51A	0.63	5.79	0.43	4.15e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	5.67	0.42	7.25e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	8.71	0.58	5.81e-15	Platelet count;
UCEC	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.73	5.17	0.39	7.4e-7	Aortic root size;
UCEC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-8.82	-0.59	3.06e-15	Chronic sinus infection;
UCEC	cis	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.59	-0.35	9.44e-6	Depression;
UCEC	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.03	-0.55	2.93e-13	Breast cancer;
UCEC	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.06	-0.39	1.21e-6	Breast cancer;
UCEC	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg18366169	chr5:1948875	NA	-0.39	-4.59	-0.35	9.51e-6	Gut microbiome composition (winter);
UCEC	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.68	-7.75	-0.54	1.37e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.57	5.44	0.41	2.17e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	0.83	6.53	0.47	1.01e-9	Corneal structure;
UCEC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	4.71	0.36	5.8e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs10242455	0.681	rs2687140	chr7:99322342	T/C	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.36	-0.4	3.12e-7	Blood metabolite levels;
UCEC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.5	4.67	0.36	6.71e-6	Resting heart rate;
UCEC	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.69	5.96	0.44	1.83e-8	Coronary artery disease;
UCEC	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.62	5.4	0.41	2.67e-7	Sudden cardiac arrest;
UCEC	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.52	5.1	0.39	1.02e-6	Dilated cardiomyopathy;
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.63	6.21	0.46	5.25e-9	Longevity;Endometriosis;
UCEC	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.67	7.64	0.53	2.55e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs7951870	0.504	rs3740973	chr11:46422237	G/A	cg23542274	chr11:45718455	NA	-0.32	-4.53	-0.35	1.2e-5	Schizophrenia;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.62	6.67	0.48	4.78e-10	Menarche (age at onset);
UCEC	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.49	-4.83	-0.37	3.41e-6	Pediatric autoimmune diseases;
UCEC	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.68	-5.71	-0.43	5.97e-8	Metabolite levels;
UCEC	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.61	-6.18	-0.45	6.13e-9	Body mass index;
UCEC	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.52	-4.85	-0.37	3.14e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.28	-0.4	4.61e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg06238570	chr21:40685208	BRWD1	0.83	8.11	0.56	1.81e-13	Cognitive function;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.65	6.58	0.48	7.95e-10	Longevity;Endometriosis;
UCEC	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.7	-5.32	-0.4	3.74e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	0.7	4.93	0.38	2.17e-6	Iron status biomarkers;
UCEC	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg21419209	chr3:44054225	NA	-0.49	-5.2	-0.39	6.71e-7	Coronary artery disease;
UCEC	cis	rs1712517	0.773	rs1063461	chr10:105049105	C/G	cg05636881	chr10:105038444	INA	0.47	5.37	0.4	3e-7	Migraine;
UCEC	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg18240653	chr6:144019428	PHACTR2	-0.62	-4.64	-0.36	7.6e-6	Obesity-related traits;
UCEC	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-7.68	-0.54	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg01262667	chr19:19385393	TM6SF2	0.38	4.61	0.36	8.79e-6	Bipolar disorder;
UCEC	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.38	0.57	3.92e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.5	4.76	0.37	4.5e-6	Menopause (age at onset);
UCEC	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg12586109	chr17:80790369	TBCD;ZNF750	0.42	4.6	0.35	9.12e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.14	0.39	8.59e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg01475377	chr6:109611718	NA	-0.38	-4.71	-0.36	5.58e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1892094	1.000	rs1892094	chr1:169094459	A/G	cg17859187	chr1:168147929	TIPRL	0.47	4.89	0.37	2.57e-6	Coronary artery disease;
UCEC	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.34e-6	Hemoglobin concentration;
UCEC	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg05962950	chr11:130786565	SNX19	0.5	5.08	0.39	1.14e-6	Schizophrenia;
UCEC	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.43	4.58	0.35	9.74e-6	HDL cholesterol;
UCEC	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.86e-7	Hemoglobin concentration;
UCEC	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-8.08	-0.55	2.15e-13	Gut microbiome composition (summer);
UCEC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.53	4.99	0.38	1.66e-6	Menopause (age at onset);
UCEC	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.5	5.95	0.44	1.84e-8	Total body bone mineral density;
UCEC	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.6	-5.99	-0.44	1.58e-8	Post bronchodilator FEV1;
UCEC	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.81	0.49	2.27e-10	Coffee consumption (cups per day);
UCEC	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg02344993	chr17:57696989	CLTC	0.49	4.74	0.36	4.95e-6	Hemoglobin concentration;
UCEC	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	6.12	0.45	8.04e-9	Coffee consumption (cups per day);
UCEC	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.49	-5.61	-0.42	9.53e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.64	7.01	0.5	8.14e-11	Homoarginine levels;
UCEC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.63	7.05	0.5	6.63e-11	Homoarginine levels;
UCEC	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.16	-0.45	6.67e-9	Personality dimensions;
UCEC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.59	0.66	7.93e-20	Cognitive ability;
UCEC	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.53	5.28	0.4	4.46e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.55	5.85	0.43	3.12e-8	Autism;
UCEC	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.62	6.0	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.81	8.73	0.58	5.04e-15	Blood protein levels;
UCEC	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.51	-4.65	-0.36	7.31e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg09491104	chr22:46646882	C22orf40	-0.66	-7.64	-0.53	2.55e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.47	5.5	0.41	1.6e-7	Aortic root size;
UCEC	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.53	6.24	0.46	4.43e-9	Type 2 diabetes;
UCEC	cis	rs73206853	0.764	rs56127909	chr12:110833763	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.63	6.05	0.45	1.17e-8	Aortic root size;
UCEC	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.69	6.12	0.45	8.25e-9	Schizophrenia;
UCEC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.55	4.52	0.35	1.24e-5	Bladder cancer;
UCEC	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.88e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-6.31	-0.46	3.17e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.01	0.5	7.95e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6460942	1.000	rs17191008	chr7:12417690	T/G	cg06484146	chr7:12443880	VWDE	-0.72	-4.91	-0.38	2.39e-6	Coronary artery disease;
UCEC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.87	-4.72	-0.36	5.39e-6	Diabetic retinopathy;
UCEC	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.6	-7.68	-0.54	2.04e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.72	-7.63	-0.53	2.74e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.66	-7.93	-0.55	5.02e-13	IgG glycosylation;
UCEC	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg23719950	chr11:63933701	MACROD1	-0.66	-4.56	-0.35	1.05e-5	Mean platelet volume;
UCEC	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.81	-0.37	3.71e-6	Type 2 diabetes;
UCEC	cis	rs9402633	0.818	rs78154983	chr6:135077427	A/G	cg16239184	chr6:135079577	NA	0.52	4.57	0.35	1.01e-5	Platelet count;
UCEC	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.53	-0.35	1.19e-5	Total body bone mineral density;
UCEC	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.62	4.94	0.38	2.06e-6	Menarche (age at onset);
UCEC	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	6.39	0.47	2.04e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	7.61	0.53	3.12e-12	Monocyte count;
UCEC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg20965017	chr5:231967	SDHA	-0.63	-5.88	-0.44	2.62e-8	Breast cancer;
UCEC	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.36	-0.4	3.2e-7	Adiposity;
UCEC	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.75	-7.62	-0.53	2.82e-12	Lymphocyte counts;
UCEC	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.09	9.99	0.64	3.03e-18	Vitiligo;
UCEC	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg19318889	chr4:1322082	MAEA	0.48	5.09	0.39	1.1e-6	Obesity-related traits;
UCEC	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.88	5.5	0.41	1.64e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs1519814	1.000	rs12678023	chr8:121123494	G/A	cg22335954	chr8:121166405	COL14A1	-0.57	-5.15	-0.39	8.16e-7	Breast cancer;
UCEC	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.67	6.57	0.48	8.19e-10	Prostate cancer;
UCEC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg06158985	chr3:52099285	C3orf74	-0.34	-4.61	-0.36	8.79e-6	Schizophrenia;
UCEC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.7	5.04	0.38	1.37e-6	Gut microbiome composition (summer);
UCEC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.61	0.36	8.61e-6	Menopause (age at onset);
UCEC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs1816854	0.938	rs10506231	chr12:44206027	C/T	cg20956634	chr12:44200518	TWF1	0.5	5.08	0.39	1.1e-6	Inflammatory bowel disease;
UCEC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.9	9.45	0.61	7.57e-17	Cognitive function;
UCEC	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.72	-8.89	-0.59	2.06e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.52	4.98	0.38	1.79e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg09184832	chr6:79620586	NA	-0.49	-4.81	-0.37	3.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-9.34	-0.61	1.47e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs7246967	0.932	rs34373479	chr19:23043862	A/G	cg24889512	chr19:22816950	ZNF492	0.5	5.05	0.38	1.28e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	4.66	0.36	6.98e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.57	-5.41	-0.41	2.45e-7	Blood protein levels;
UCEC	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg24375607	chr4:120327624	NA	0.51	4.81	0.37	3.73e-6	Corneal astigmatism;
UCEC	cis	rs539514	0.664	rs1323712	chr13:76300085	C/G	cg04757411	chr13:76259545	LMO7	-0.39	-4.77	-0.37	4.38e-6	Type 1 diabetes;
UCEC	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg06671706	chr8:8559999	CLDN23	-0.46	-4.52	-0.35	1.26e-5	Obesity-related traits;
UCEC	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.52	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.51	4.84	0.37	3.23e-6	Coronary artery disease;
UCEC	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	0.67	5.35	0.4	3.29e-7	Left atrial antero-posterior diameter;
UCEC	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.64	-7.26	-0.51	2.07e-11	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg19678392	chr7:94953810	PON1	-0.59	-5.38	-0.41	2.87e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.36	0.52	1.23e-11	Bipolar disorder;
UCEC	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.38	-0.47	2.19e-9	Response to antipsychotic treatment;
UCEC	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.45	-5.95	-0.44	1.89e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.96	11.05	0.67	4.95e-21	Cognitive function;
UCEC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg26781129	chr3:44753946	ZNF502	-0.42	-4.66	-0.36	6.96e-6	Depressive symptoms;
UCEC	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg00815214	chr21:47717953	NA	-0.39	-4.55	-0.35	1.1e-5	Testicular germ cell tumor;
UCEC	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg11871910	chr12:69753446	YEATS4	0.73	7.79	0.54	1.1e-12	Blood protein levels;
UCEC	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg14675211	chr2:100938903	LONRF2	0.47	4.84	0.37	3.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-5.55	-0.42	1.31e-7	Life satisfaction;
UCEC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg12463550	chr7:65579703	CRCP	0.52	5.23	0.4	5.72e-7	Aortic root size;
UCEC	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.83	-7.61	-0.53	3.1e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.4	-0.41	2.59e-7	Homoarginine levels;
UCEC	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg14582100	chr15:45693742	SPATA5L1	0.35	4.67	0.36	6.68e-6	Homoarginine levels;
UCEC	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg03714773	chr7:91764589	CYP51A1	-0.41	-4.69	-0.36	6.12e-6	Breast cancer;
UCEC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	7.57	0.53	3.89e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs12365397	0.748	rs1496222	chr11:43264509	A/G	cg07515919	chr11:43391688	TTC17	0.47	4.91	0.38	2.39e-6	Migraine;
UCEC	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg15147215	chr3:52552868	STAB1	-0.41	-4.54	-0.35	1.15e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24375607	chr4:120327624	NA	-0.51	-5.2	-0.39	6.62e-7	Corneal astigmatism;
UCEC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.53	7.24	0.51	2.35e-11	Height;
UCEC	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18252515	chr7:66147081	NA	-0.55	-5.37	-0.4	3.02e-7	Aortic root size;
UCEC	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.76	-8.43	-0.57	3.01e-14	Ulcerative colitis;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06396496	chr3:53289970	TKT	0.6	7.08	0.5	5.4e-11	Warfarin maintenance dose;
UCEC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.79	-8.56	-0.58	1.4e-14	Height;
UCEC	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	0.55	6.91	0.5	1.34e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.33	-0.4	3.7e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.63	-6.02	-0.44	1.34e-8	Menopause (age at onset);
UCEC	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.57	-6.15	-0.45	7.12e-9	Heart rate;
UCEC	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg04871131	chr7:94954202	PON1	-0.53	-5.27	-0.4	4.86e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.66	5.49	0.41	1.75e-7	Menopause (age at onset);
UCEC	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg00105475	chr2:10696890	NA	0.45	5.6	0.42	1.01e-7	Prostate cancer;
UCEC	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.6	5.28	0.4	4.64e-7	Major depressive disorder;
UCEC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.41	4.57	0.35	1.04e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.54	-5.9	-0.44	2.37e-8	Tonsillectomy;
UCEC	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-5.32	-0.4	3.84e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs17106184	1.000	rs72904726	chr1:51339332	T/C	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.48	-5.25	-0.4	5.33e-7	Height;
UCEC	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.79	-8.73	-0.58	5.13e-15	Cognitive function;
UCEC	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	9.63	0.62	2.62e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.66	5.94	0.44	1.95e-8	Body mass index;
UCEC	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg13147721	chr7:65941812	NA	0.91	6.06	0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg13695892	chr22:41940480	POLR3H	-0.68	-4.61	-0.36	8.57e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.18	8.71	0.58	5.94e-15	Night sleep phenotypes;
UCEC	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.94	9.47	0.62	6.78e-17	Dilated cardiomyopathy;
UCEC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.45	-4.59	-0.35	9.53e-6	Non-alcoholic fatty liver disease histology (lobular);
UCEC	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	6.5	0.47	1.14e-9	Bone mineral density;
UCEC	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.39	-5.61	-0.42	9.78e-8	Schizophrenia;
UCEC	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.51	5.13	0.39	9.21e-7	QRS complex (12-leadsum);
UCEC	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.52	4.85	0.37	3.09e-6	Corneal astigmatism;
UCEC	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13683864	chr3:40499215	RPL14	-0.99	-10.44	-0.65	1.93e-19	Renal cell carcinoma;
UCEC	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.56	7.6	0.53	3.3e-12	Total body bone mineral density;
UCEC	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.73	-6.44	-0.47	1.56e-9	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.86	-6.26	-0.46	3.94e-9	Hip circumference adjusted for BMI;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20087221	chr10:98135160	TLL2	0.63	7.87	0.54	6.97e-13	Warfarin maintenance dose;
UCEC	cis	rs10992471	0.598	rs2398751	chr9:95206240	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.45	4.58	0.35	9.94e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg18478394	chr8:109455254	TTC35	0.48	4.76	0.37	4.54e-6	Dupuytren's disease;
UCEC	cis	rs4074961	0.527	rs10908355	chr1:38035286	G/T	cg17933807	chr1:38061675	GNL2	0.88	11.22	0.68	1.71e-21	Axial length;
UCEC	trans	rs1552172	0.887	rs1471629	chr1:145707240	C/A	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.81	-0.49	2.36e-10	Breast cancer;
UCEC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-4.84	-0.37	3.29e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.05	-0.45	1.15e-8	Response to antipsychotic treatment;
UCEC	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	5.58	0.42	1.12e-7	HIV-1 control;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-5.68	-0.42	7.08e-8	Morning vs. evening chronotype;
UCEC	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs11760485	0.928	rs4723687	chr7:4400977	C/T	cg22450045	chr7:4839495	RADIL	-0.4	-4.99	-0.38	1.66e-6	Early childhood aggressive behavior;
UCEC	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.67	-0.42	7.3900000000000007e-08	Mood instability;
UCEC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg11477892	chr4:106580295	NA	-0.46	-4.72	-0.36	5.46e-6	Post bronchodilator FEV1;
UCEC	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.89	0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg05991184	chr2:219186017	PNKD	0.45	4.73	0.36	5.33e-6	Ulcerative colitis;
UCEC	cis	rs7072216	0.687	rs11189589	chr10:100154565	A/G	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs8177876	0.642	rs56032321	chr16:81117906	A/C	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.5	5.66	0.42	7.67e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	9.9	0.63	4.95e-18	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.22	18.5	0.84	3.25e-40	Exhaled nitric oxide output;
UCEC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.06	-0.39	1.24e-6	Response to antipsychotic treatment;
UCEC	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	5.58	0.42	1.14e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs883565	0.543	rs784496	chr3:39179536	A/G	cg01426195	chr3:39028469	NA	0.59	7.0	0.5	8.42e-11	Handedness;
UCEC	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.91	5.11	0.39	1e-6	Fat distribution (HIV);
UCEC	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.67	-7.84	-0.54	8.59e-13	Obesity-related traits;
UCEC	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.64	6.25	0.46	4.18e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs17106184	1.000	rs58574309	chr1:50960180	C/T	cg07174182	chr1:51127561	FAF1	-0.84	-5.34	-0.4	3.4e-7	Type 2 diabetes;
UCEC	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.86	0.43	2.98e-8	Breast cancer;
UCEC	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.49	5.4	0.41	2.67e-7	Pulse pressure;
UCEC	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg07776626	chr8:57350775	NA	-0.47	-5.32	-0.4	3.71e-7	Obesity-related traits;
UCEC	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg22166914	chr1:53195759	ZYG11B	-0.64	-7.01	-0.5	8.17e-11	Monocyte count;
UCEC	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.7	-4.72	-0.36	5.47e-6	Blood protein levels;
UCEC	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.23	0.46	4.67e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs17433710	0.543	rs10753585	chr1:162669006	C/T	cg06409308	chr1:161719417	DUSP12	0.51	4.52	0.35	1.25e-5	Dupuytren's disease;
UCEC	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.61	-5.76	-0.43	4.85e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.19	0.39	6.87e-7	Cognitive test performance;
UCEC	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.72	0.43	5.78e-8	Breast cancer;
UCEC	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg15687855	chr3:44754131	ZNF502	-0.56	-4.51	-0.35	1.34e-5	IgG glycosylation;
UCEC	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.74	0.63	1.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.73	9.11	0.6	5.58e-16	Neuroticism;
UCEC	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.32	0.4	3.78e-7	Breast cancer;
UCEC	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg12394014	chr15:79171566	MORF4L1	0.45	4.53	0.35	1.2e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26359510	chr1:8075137	ERRFI1	0.9	4.57	0.35	1.03e-5	Inflammatory bowel disease;
UCEC	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.65	-5.03	-0.38	1.4e-6	Skin colour saturation;
UCEC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.67	6.92	0.5	1.28e-10	Smoking behavior;
UCEC	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02711652	chr17:63555717	AXIN2	0.49	4.57	0.35	1.02e-5	QT interval;
UCEC	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.6	5.67	0.42	7.44e-8	Corneal astigmatism;
UCEC	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.6	5.41	0.41	2.53e-7	Lung cancer;
UCEC	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	4.7	0.36	5.86e-6	Body mass index;
UCEC	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.6	5.75	0.43	4.94e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.0	0.38	1.62e-6	Sudden cardiac arrest;
UCEC	cis	rs7975161	0.832	rs11111955	chr12:104650735	T/C	cg25273343	chr12:104657179	TXNRD1	-0.68	-5.53	-0.42	1.42e-7	Toenail selenium levels;
UCEC	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.79	-8.6	-0.58	1.11e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.78	-5.84	-0.43	3.29e-8	Red blood cell traits;
UCEC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg26031613	chr14:104095156	KLC1	0.58	5.63	0.42	8.84e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs7245540	chr19:22881504	C/G	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.57	5.24	0.4	5.48e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs3777722	0.688	rs2757045	chr6:167350963	C/T	cg23869232	chr6:167175937	RPS6KA2	0.42	4.51	0.35	1.32e-5	Spontaneous preterm birth (preterm birth);
UCEC	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg06784218	chr1:46089804	CCDC17	0.44	5.01	0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	5.28	0.4	4.47e-7	Bone mineral density;
UCEC	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.03	0.5	7.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.61	-6.63	-0.48	6.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.52	5.66	0.42	7.8e-8	HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs17106184	0.786	rs72898974	chr1:50975971	C/T	cg07174182	chr1:51127561	FAF1	-0.79	-5.0	-0.38	1.6e-6	Type 2 diabetes;
UCEC	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.7	6.12	0.45	8.14e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.67	-0.36	6.66e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.69	-7.54	-0.53	4.55e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.42	-5.28	-0.4	4.58e-7	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-0.8	-7.42	-0.52	8.89e-12	Breast cancer;
UCEC	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.78	6.16	0.45	6.73e-9	Educational attainment;
UCEC	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.6	-0.48	7.07e-10	Schizophrenia;
UCEC	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.67	-6.22	-0.46	4.9e-9	Aortic root size;
UCEC	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.16	18.0	0.83	5.4e-39	Testicular germ cell tumor;
UCEC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.72	5.53	0.41	1.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.55	5.16	0.39	7.86e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg01874867	chr7:94954059	PON1	-0.55	-5.12	-0.39	9.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-5.62	-0.42	9.21e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	9.16	0.6	4.19e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs73017364	0.688	rs7550191	chr1:162135465	A/C	cg19130550	chr1:161994277	OLFML2B	-0.53	-4.56	-0.35	1.09e-5	QT interval;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.92	12.1	0.71	7.97e-24	Menarche (age at onset);
UCEC	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.63	7.54	0.53	4.44e-12	Obesity-related traits;
UCEC	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.42	4.63	0.36	8.01e-6	Schizophrenia;
UCEC	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	1.04	14.68	0.77	1.33e-30	Ulcerative colitis;
UCEC	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-7.44	-0.52	7.9e-12	Motion sickness;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs60311166	1.000	rs57560655	chr3:52577334	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.82	4.65	0.36	7.2e-6	CTACK levels;
UCEC	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg04662943	chr10:102668895	NA	0.5	4.95	0.38	1.97e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2041840	0.538	rs3770755	chr2:37574134	G/C	cg25727520	chr2:37576821	QPCT	-0.51	-6.0	-0.44	1.48e-8	Chronic lymphocytic leukemia;
UCEC	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.68	7.01	0.5	8.11e-11	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg20307385	chr11:47447363	PSMC3	-0.63	-4.53	-0.35	1.19e-5	Intraocular pressure;
UCEC	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg00852783	chr1:26633632	UBXN11	0.5	4.84	0.37	3.32e-6	Obesity-related traits;
UCEC	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-6.39	-0.47	2.11e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9999118	0.744	rs216100	chr4:124135781	A/G	cg17338352	chr4:123653805	LOC729338;BBS12	-0.6	-4.72	-0.36	5.46e-6	Irritable bowel syndrome;
UCEC	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.69	6.93	0.5	1.26e-10	White blood cell count (basophil);
UCEC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg02160872	chr5:212506	CCDC127	-0.7	-7.19	-0.51	2.97e-11	Breast cancer;
UCEC	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.51	0.47	1.11e-9	Menarche (age at onset);
UCEC	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.45	4.92	0.38	2.27e-6	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.15	8.08	0.55	2.15e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.65	-5.57	-0.42	1.16e-7	Birth weight;
UCEC	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.64	-5.78	-0.43	4.3e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.54	-0.42	1.34e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.3	0.52	1.66e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.63	5.59	0.42	1.09e-7	Breast cancer;
UCEC	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.54	5.3	0.4	4.2e-7	Menopause (age at onset);
UCEC	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg12982090	chr3:42733453	KBTBD5	0.48	4.82	0.37	3.61e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.62	5.23	0.4	5.68e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.43	-6.27	-0.46	3.84e-9	Rheumatoid arthritis;
UCEC	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.52	-4.77	-0.37	4.46e-6	Coronary artery disease;
UCEC	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.78	-9.04	-0.6	8.43e-16	Primary sclerosing cholangitis;
UCEC	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-5.4	-0.41	2.63e-7	HDL cholesterol;
UCEC	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.61	4.7	0.36	5.84e-6	Lymphocyte counts;
UCEC	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg04013166	chr16:89971882	TCF25	0.69	6.32	0.46	3.02e-9	Skin colour saturation;
UCEC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.81	-8.91	-0.59	1.83e-15	Obesity-related traits;
UCEC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.53	-5.31	-0.4	4.01e-7	Aortic root size;
UCEC	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.47	-6.12	-0.45	8.11e-9	IgG glycosylation;
UCEC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.95	0.55	4.54e-13	Chronic sinus infection;
UCEC	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.69	7.2	0.51	2.96e-11	Resting heart rate;
UCEC	cis	rs2806864	1.000	rs2250884	chr1:117462113	T/A	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.7	-0.36	6.06e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.83	-9.65	-0.62	2.23e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.47	0.41	1.89e-7	Birth weight;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.2	-0.46	5.31e-9	Pubertal anthropometrics;
UCEC	cis	rs2932538	0.583	rs2279500	chr1:113244433	T/C	cg22162597	chr1:113214053	CAPZA1	-0.8	-6.17	-0.45	6.44e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.62	6.8	0.49	2.49e-10	Blood metabolite ratios;
UCEC	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.59	-6.71	-0.48	3.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.56	-5.12	-0.39	9.4e-7	Systemic lupus erythematosus;
UCEC	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	1.03	6.84	0.49	1.93e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg24687543	chr11:63912206	MACROD1	0.57	4.87	0.37	2.87e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.83	9.45	0.61	7.28e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.65	6.33	0.46	2.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.59	-5.95	-0.44	1.84e-8	Hepatocellular carcinoma;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.34	-0.46	2.72e-9	Pubertal anthropometrics;
UCEC	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg14078730	chr11:63896557	MACROD1	-0.44	-4.72	-0.36	5.34e-6	Platelet count;
UCEC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7517126	1.000	rs7517126	chr1:196840272	A/G	cg07209298	chr1:196795943	CFHR1	0.46	4.6	0.36	8.88e-6	Blood protein levels;
UCEC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-0.6	-6.96	-0.5	1.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg13250285	chr3:50228871	GNAT1	-0.39	-5.61	-0.42	9.82e-8	Menarche (age at onset);
UCEC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg01689657	chr7:91764605	CYP51A1	0.39	4.75	0.36	4.79e-6	Breast cancer;
UCEC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.1	0.39	1.03e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.48	5.3	0.4	4.15e-7	Tonsillectomy;
UCEC	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.75	6.23	0.46	4.72e-9	Fibroblast growth factor basic levels;
UCEC	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.65	5.17	0.39	7.58e-7	Bladder cancer;
UCEC	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.34	4.74	0.36	5.01e-6	Ewing sarcoma;
UCEC	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.74	0.63	1.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.5	-7.23	-0.51	2.48e-11	Urinary metabolites;
UCEC	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.11	9.47	0.62	6.77e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.67	-7.3	-0.52	1.71e-11	Coronary artery disease;
UCEC	cis	rs10924970	0.649	rs12036412	chr1:235398812	T/C	cg26050004	chr1:235667680	B3GALNT2	0.53	4.81	0.37	3.63e-6	Asthma;
UCEC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.58	-0.48	7.92e-10	Obesity-related traits;
UCEC	cis	rs6909279	0.933	rs6557149	chr6:151876413	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.47	-4.54	-0.35	1.17e-5	Bone mineral density;
UCEC	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg03859395	chr2:55845619	SMEK2	1.0	13.75	0.75	3.61e-28	Metabolic syndrome;
UCEC	cis	rs6723108	0.603	rs62168891	chr2:135672187	C/T	cg07169764	chr2:136633963	MCM6	0.48	4.56	0.35	1.07e-5	Type 2 diabetes;
UCEC	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.5	5.27	0.4	4.68e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.49	-4.88	-0.37	2.71e-6	Electroencephalogram traits;
UCEC	cis	rs12194062	0.659	rs117516727	chr6:128248673	T/C	cg25012434	chr6:128842125	PTPRK	-0.56	-4.62	-0.36	8.42e-6	QRS duration;
UCEC	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-0.98	-11.06	-0.67	4.42e-21	Blood pressure (smoking interaction);
UCEC	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg13399274	chr11:65370826	MAP3K11	-0.69	-4.57	-0.35	1.04e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	5.72	0.43	5.89e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.52	-4.51	-0.35	1.3e-5	Systemic lupus erythematosus;
UCEC	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.55	6.39	0.47	2.04e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.68	5.73	0.43	5.5e-8	Menopause (age at onset);
UCEC	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	5.0	0.38	1.63e-6	IgG glycosylation;
UCEC	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg05660106	chr1:15850417	CASP9	0.59	5.39	0.41	2.75e-7	Systolic blood pressure;
UCEC	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.69	8.82	0.59	3.06e-15	Mean platelet volume;
UCEC	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.5	5.52	0.41	1.49e-7	Blood metabolite levels;
UCEC	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.79	-8.07	-0.55	2.26e-13	Multiple sclerosis;
UCEC	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg06784218	chr1:46089804	CCDC17	0.55	6.88	0.49	1.64e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.48	5.23	0.4	5.62e-7	Longevity;Endometriosis;
UCEC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.57	-7.87	-0.54	7.07e-13	Prudent dietary pattern;
UCEC	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg13147721	chr7:65941812	NA	-0.86	-5.79	-0.43	4.1e-8	Diabetic kidney disease;
UCEC	cis	rs7246967	0.611	rs57013651	chr19:22863027	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.33	4.73	0.36	5.17e-6	Crohn's disease;
UCEC	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.56	-5.72	-0.43	5.68e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.41	4.63	0.36	8e-6	Monocyte count;
UCEC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	5.73	0.43	5.61e-8	Rheumatoid arthritis;
UCEC	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg14851346	chr12:38532713	NA	-0.51	-4.91	-0.38	2.35e-6	Heart rate;
UCEC	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.5	-5.61	-0.42	9.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg03543861	chr21:44258195	NA	0.47	4.93	0.38	2.18e-6	Information processing speed;
UCEC	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.56	-5.06	-0.39	1.22e-6	Metabolite levels;
UCEC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.44	-4.62	-0.36	8.23e-6	Dilated cardiomyopathy;
UCEC	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.46	6.37	0.47	2.27e-9	Alcohol dependence;
UCEC	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-8.13	-0.56	1.63e-13	Headache;
UCEC	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg05991184	chr2:219186017	PNKD	0.51	5.59	0.42	1.06e-7	Colorectal cancer;
UCEC	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Bladder cancer;
UCEC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.55	-4.84	-0.37	3.22e-6	Menarche (age at onset);
UCEC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-4.71	-0.36	5.77e-6	Aortic root size;
UCEC	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.43	4.58	0.35	9.85e-6	Iron status biomarkers;
UCEC	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.42	5.13	0.39	9.12e-7	Refractive error;
UCEC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.48	4.61	0.36	8.55e-6	Menopause (age at onset);
UCEC	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.62	6.91	0.5	1.34e-10	IgG glycosylation;
UCEC	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.57	-6.29	-0.46	3.37e-9	Height;
UCEC	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.800	rs12985313	chr19:23037780	T/C	cg24889512	chr19:22816950	ZNF492	0.5	5.32	0.4	3.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6684428	1.000	rs55693755	chr1:56369906	T/A	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.68	0.36	6.44e-6	Menopause (age at onset);
UCEC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg22974920	chr21:40686053	BRWD1	0.58	5.06	0.39	1.22e-6	Cognitive function;
UCEC	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-4.51	-0.35	1.34e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.29	0.52	1.75e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.87	9.06	0.6	7.67e-16	Longevity;Endometriosis;
UCEC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg13695892	chr22:41940480	POLR3H	-0.61	-4.91	-0.38	2.45e-6	Vitiligo;
UCEC	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.19e-10	Aortic root size;
UCEC	cis	rs7945071	0.507	rs11213398	chr11:110301799	A/G	cg26763524	chr11:110300429	FDX1	-0.4	-4.73	-0.36	5.26e-6	Cognitive function;
UCEC	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg24069376	chr3:38537580	EXOG	-0.39	-5.0	-0.38	1.61e-6	Electrocardiographic conduction measures;
UCEC	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.66	4.71	0.36	5.7e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.65e-10	Motion sickness;
UCEC	cis	rs3015497	0.526	rs10136630	chr14:51046474	G/A	cg04730355	chr14:51134070	SAV1	-0.47	-5.01	-0.38	1.53e-6	Mean platelet volume;
UCEC	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.44	5.14	0.39	8.49e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.53	5.12	0.39	9.52e-7	Endometrial cancer;
UCEC	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.85	-10.42	-0.65	2.17e-19	Brugada syndrome;
UCEC	cis	rs7088591	0.867	rs73290941	chr10:59784819	T/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.12	-0.56	1.71e-13	Monocyte count;
UCEC	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.47	4.99	0.38	1.65e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01391022	chr12:122360665	WDR66	-0.47	-4.58	-0.35	9.84e-6	Mean corpuscular volume;
UCEC	cis	rs1519814	0.876	rs10955954	chr8:121108052	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-4.99	-0.38	1.68e-6	Breast cancer;
UCEC	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.77	8.85	0.59	2.61e-15	Lymphocyte counts;
UCEC	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.45	4.6	0.35	9e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs807669	0.500	rs5746668	chr22:19149151	T/G	cg02655711	chr22:19163373	SLC25A1	0.56	4.91	0.38	2.42e-6	Metabolite levels;
UCEC	cis	rs2708377	0.858	rs73051630	chr12:11147188	G/A	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.78	6.4	0.47	1.94e-9	Bitter taste perception;
UCEC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg20616779	chr7:157276406	NA	-0.33	-4.6	-0.35	9.15e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
UCEC	cis	rs2288327	0.818	rs3829747	chr2:179397561	C/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.7	-4.78	-0.37	4.28e-6	Atrial fibrillation;
UCEC	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-1.15	-7.25	-0.51	2.19e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.55	5.18	0.39	7.32e-7	Migraine;Coronary artery disease;
UCEC	cis	rs2862064	0.932	rs1553317	chr5:156479424	A/C	cg12943317	chr5:156479607	HAVCR1	-0.65	-4.96	-0.38	1.94e-6	Platelet count;
UCEC	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	1.25	5.71	0.43	6.02e-8	Parkinson's disease;
UCEC	cis	rs7088591	1.000	rs73292716	chr10:59787727	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg18016565	chr1:150552671	MCL1	0.6	6.83	0.49	2.05e-10	Tonsillectomy;
UCEC	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	8.38	0.57	3.92e-14	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg24703168	chr6:28411309	ZSCAN23	0.5	5.56	0.42	1.25e-7	Pubertal anthropometrics;
UCEC	cis	rs17122693	1.000	rs72679592	chr14:51094047	T/C	cg04730355	chr14:51134070	SAV1	0.89	8.53	0.58	1.69e-14	Cognitive performance;
UCEC	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.59	4.59	0.35	9.34e-6	Obesity-related traits;
UCEC	cis	rs7937612	1.000	rs7117321	chr11:120239051	T/C	cg12584626	chr11:120203529	NA	0.54	5.47	0.41	1.89e-7	Intraocular pressure;
UCEC	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.59	7.16	0.51	3.53e-11	Oral cavity cancer;
UCEC	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18252515	chr7:66147081	NA	0.54	5.25	0.4	5.27e-7	Aortic root size;
UCEC	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.76	8.02	0.55	3.09e-13	Breast cancer;
UCEC	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg20387954	chr3:183756860	HTR3D	0.51	6.24	0.46	4.35e-9	Anterior chamber depth;
UCEC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.57	-5.5	-0.41	1.6e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.62	7.44	0.52	7.83e-12	Oral cavity cancer;
UCEC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.07	-0.45	1.06e-8	Prudent dietary pattern;
UCEC	cis	rs7246967	0.673	rs9676498	chr19:22910510	A/G	cg05241461	chr19:22816980	ZNF492	0.56	5.89	0.44	2.55e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs11697848	1.000	rs77480041	chr20:48429020	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.28	0.4	4.56e-7	Systemic lupus erythematosus;
UCEC	cis	rs756777	0.878	rs56683818	chr9:136664457	T/C	cg14069709	chr9:136671979	VAV2	-0.42	-5.17	-0.39	7.39e-7	IgG glycosylation;
UCEC	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.71	6.61	0.48	6.48e-10	Asthma;
UCEC	cis	rs13315871	0.929	rs9842917	chr3:58244800	C/T	cg20936604	chr3:58311152	NA	-0.57	-4.73	-0.36	5.26e-6	Cholesterol, total;
UCEC	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg05072774	chr3:49840536	C3orf54	-0.54	-5.59	-0.42	1.09e-7	Resting heart rate;
UCEC	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.19	-0.45	5.72e-9	Blood protein levels;
UCEC	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.25	-6.95	-0.5	1.12e-10	Atopic dermatitis;
UCEC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.4	0.52	9.93e-12	Homoarginine levels;
UCEC	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.73	8.73	0.58	5.25e-15	Mean corpuscular volume;
UCEC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.6	5.9	0.44	2.44e-8	Calcium levels;
UCEC	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.42	5.97	0.44	1.67e-8	Alcohol dependence;
UCEC	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.49	5.53	0.41	1.44e-7	White matter hyperintensity burden;
UCEC	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs10940138	0.779	rs62370675	chr5:67247975	G/A	ch.5.1281357F	chr5:67228439	NA	0.55	4.73	0.36	5.19e-6	Menarche (age at onset);
UCEC	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.55	-4.94	-0.38	2.07e-6	Pediatric autoimmune diseases;
UCEC	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.74	-8.32	-0.57	5.38e-14	Sudden cardiac arrest;
UCEC	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.77	9.4	0.61	1.02e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.95	0.38	1.97e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.71	0.54	1.72e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg23791538	chr6:167370224	RNASET2	-0.56	-5.89	-0.44	2.48e-8	Primary biliary cholangitis;
UCEC	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.63	5.15	0.39	8.41e-7	Resting heart rate;
UCEC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs9402633	0.938	rs9376055	chr6:135043731	C/T	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	14.78	0.77	7.17e-31	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg00083072	chr11:65415190	SIPA1	0.42	5.2	0.39	6.61e-7	Non-alcoholic fatty liver disease histology (lobular);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03333267	chr4:6577084	MAN2B2	0.58	7.03	0.5	7.15e-11	Warfarin maintenance dose;
UCEC	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg19743168	chr1:23544995	NA	0.43	5.97	0.44	1.69e-8	Height;
UCEC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.45	4.78	0.37	4.14e-6	Total body bone mineral density;
UCEC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg24375607	chr4:120327624	NA	0.47	4.74	0.36	5.01e-6	Corneal astigmatism;
UCEC	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	6.59	0.48	7.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-6.13	-0.45	7.68e-9	Heart rate;
UCEC	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.88e-7	Parkinson's disease;
UCEC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.79	0.37	4.12e-6	Breast cancer;
UCEC	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.57	-5.35	-0.4	3.33e-7	Red cell distribution width;
UCEC	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.06	-0.45	1.07e-8	Depression;
UCEC	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.68	5.87	0.44	2.82e-8	Cognitive function;
UCEC	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-7.52	-0.53	4.87e-12	Total cholesterol levels;
UCEC	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-0.92	-11.27	-0.68	1.24e-21	Blood pressure (smoking interaction);
UCEC	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-0.94	-12.89	-0.73	6.44e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs8042680	0.554	rs8036115	chr15:91528961	G/A	cg14398957	chr15:91536180	PRC1	-0.45	-4.64	-0.36	7.79e-6	Type 2 diabetes;
UCEC	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.57	-4.99	-0.38	1.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.47	4.7	0.36	5.87e-6	Blood protein levels;
UCEC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.67	-6.94	-0.5	1.15e-10	Longevity;Endometriosis;
UCEC	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	9.94	0.63	4.04e-18	Electrocardiographic conduction measures;
UCEC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	5.47	0.41	1.87e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	5.97	0.44	1.67e-8	Platelet count;
UCEC	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.47	-4.68	-0.36	6.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.19	8.77	0.59	4.18e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.61	6.11	0.45	8.54e-9	Lung cancer;
UCEC	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.67	5.96	0.44	1.78e-8	Adiposity;
UCEC	cis	rs7589342	0.894	rs3820890	chr2:106496293	G/A	cg14210321	chr2:106509881	NCK2	-0.51	-4.9	-0.37	2.54e-6	Addiction;
UCEC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.63	5.44	0.41	2.18e-7	Gut microbiome composition (summer);
UCEC	cis	rs9843304	0.900	rs6774253	chr3:149211897	G/C	cg08667024	chr3:149219783	TM4SF4	0.42	5.02	0.38	1.45e-6	Gallstone disease;
UCEC	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.8	7.64	0.53	2.63e-12	Selective IgA deficiency;
UCEC	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.79	10.1	0.64	1.5e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs6546550	0.658	rs10186725	chr2:70015491	A/G	cg02498382	chr2:70120550	SNRNP27	-0.44	-4.79	-0.37	4.04e-6	Prevalent atrial fibrillation;
UCEC	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.45	-6.92	-0.5	1.28e-10	Primary biliary cholangitis;
UCEC	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.7	0.54	1.83e-12	Ileal carcinoids;
UCEC	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18252515	chr7:66147081	NA	-0.54	-5.25	-0.4	5.19e-7	Aortic root size;
UCEC	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.87	0.37	2.83e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg05501817	chr11:14380813	RRAS2	-0.48	-4.86	-0.37	2.95e-6	Vitamin D levels;
UCEC	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.63	5.13	0.39	9.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs151997	0.925	rs27847	chr5:50176197	G/T	cg06027927	chr5:50259733	NA	0.53	4.87	0.37	2.84e-6	Callous-unemotional behaviour;
UCEC	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.5	5.13	0.39	8.95e-7	Bipolar disorder;
UCEC	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.72	8.76	0.59	4.42e-15	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.58	-0.42	1.14e-7	Monocyte percentage of white cells;
UCEC	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.75	7.7	0.54	1.87e-12	Caffeine consumption;
UCEC	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.85	-0.37	3.05e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg11871910	chr12:69753446	YEATS4	1.07	13.31	0.74	5.04e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs78761021	0.688	rs55811931	chr17:9796537	G/A	cg26853458	chr17:9805074	RCVRN	0.39	4.76	0.37	4.62e-6	Type 2 diabetes;
UCEC	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-5.3	-0.4	4.14e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.63	-5.54	-0.42	1.34e-7	Breast cancer;
UCEC	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.63	-6.64	-0.48	5.76e-10	Adiposity;
UCEC	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg26114124	chr12:9217669	LOC144571	0.4	4.6	0.35	9.19e-6	Sjögren's syndrome;
UCEC	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.66	-6.01	-0.44	1.37e-8	Psoriasis vulgaris;
UCEC	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg02175308	chr1:109941060	SORT1	-0.32	-4.62	-0.36	8.15e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg18721089	chr20:30220636	NA	-0.41	-5.21	-0.4	6.18e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs6809441	0.527	rs6794510	chr3:41494431	A/G	cg17545383	chr3:40566228	ZNF621	0.47	4.73	0.36	5.17e-6	Alcohol dependence;
UCEC	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs9546434	0.841	rs7330329	chr13:36644724	A/C	cg20704442	chr13:36052768	MIR548F5;NBEA	0.47	4.9	0.37	2.47e-6	Optic cup area;
UCEC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg15759873	chr2:46746934	ATP6V1E2	-0.37	-4.73	-0.36	5.29e-6	HDL cholesterol;
UCEC	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.73	6.38	0.47	2.12e-9	Neurofibrillary tangles;
UCEC	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-0.73	-8.49	-0.57	2.1e-14	Blood trace element (Zn levels);
UCEC	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.46	5.16	0.39	7.97e-7	Emphysema distribution in smoking;
UCEC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.65	-6.33	-0.46	2.76e-9	Aortic root size;
UCEC	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.35	5.86	0.44	2.88e-8	Cancer;
UCEC	cis	rs4853525	0.923	rs2355575	chr2:191728404	T/G	cg10560079	chr2:191398806	TMEM194B	-0.49	-4.89	-0.37	2.64e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.71	5.81	0.43	3.75e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.32	-0.46	2.9e-9	Prudent dietary pattern;
UCEC	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	1.15	5.9	0.44	2.35e-8	LDL cholesterol;
UCEC	cis	rs953387	0.866	rs4954577	chr2:136948711	A/G	cg07169764	chr2:136633963	MCM6	0.51	5.06	0.39	1.21e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-0.97	-4.61	-0.36	8.64e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.64	6.2	0.46	5.42e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3112255	0.512	rs11123843	chr2:101338023	A/T	cg01042948	chr2:101319752	NA	0.48	4.91	0.38	2.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-1.06	-8.07	-0.55	2.29e-13	Multiple sclerosis;
UCEC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	6.81	0.49	2.29e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	7.94	0.55	4.7e-13	Post bronchodilator FEV1;
UCEC	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.48	-4.65	-0.36	7.31e-6	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-11.54	-0.69	2.43e-22	Cognitive function;
UCEC	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.82	-5.45	-0.41	2.04e-7	Bipolar disorder;
UCEC	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.68	-7.17	-0.51	3.39e-11	Height;
UCEC	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.49	-4.64	-0.36	7.5e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.72	-7.22	-0.51	2.64e-11	Aortic root size;
UCEC	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.96	0.44	1.78e-8	Body mass index;
UCEC	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.65	-6.16	-0.45	6.68e-9	Platelet distribution width;
UCEC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg04310649	chr10:35416472	CREM	-0.48	-4.65	-0.36	7.38e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.5	5.13	0.39	9.13e-7	Monocyte count;
UCEC	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.49	-4.56	-0.35	1.07e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.69	-7.87	-0.54	7.13e-13	Menarche (age at onset);
UCEC	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.74	-8.42	-0.57	3.15e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9486594	0.597	rs2430461	chr6:107650309	G/A	cg16950012	chr6:106773140	ATG5	0.53	4.86	0.37	2.94e-6	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.52	-5.06	-0.39	1.24e-6	Diastolic blood pressure;
UCEC	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.6	5.12	0.39	9.63e-7	RR interval (heart rate);
UCEC	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.74	0.49	3.41e-10	Breast cancer;
UCEC	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.54	5.66	0.42	7.71e-8	Red blood cell count;
UCEC	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.56	5.06	0.39	1.25e-6	Corneal astigmatism;
UCEC	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.63	-6.26	-0.46	3.94e-9	Morning vs. evening chronotype;
UCEC	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.39	6.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.6	-6.78	-0.49	2.69e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.15	-0.45	7.05e-9	Chronic sinus infection;
UCEC	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.59	6.08	0.45	1e-8	Retinal vascular caliber;
UCEC	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg11861562	chr11:117069780	TAGLN	-0.38	-4.68	-0.36	6.49e-6	Blood protein levels;
UCEC	cis	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg23307798	chr14:103986281	CKB	-0.48	-4.99	-0.38	1.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs74542309	1.000	rs35957062	chr10:72551878	G/A	cg15763670	chr10:73473235	C10orf105;CDH23	-0.61	-4.74	-0.36	4.98e-6	Pursuit maintenance gain;
UCEC	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11235843	0.853	rs1043234	chr11:73471761	C/A	cg23931323	chr11:73372278	PLEKHB1	0.69	4.69	0.36	6.07e-6	Hand grip strength;
UCEC	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.82	7.43	0.52	8.15e-12	Vitiligo;
UCEC	cis	rs1355223	0.867	rs7943755	chr11:34691451	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-4.88	-0.37	2.76e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.52	-0.41	1.49e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.66	5.88	0.44	2.69e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.2e-9	Blood protein levels;
UCEC	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.66	7.5	0.53	5.67e-12	Resting heart rate;
UCEC	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-5.83	-0.43	3.32e-8	Response to antipsychotic treatment;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20538819	chr1:214724805	PTPN14	0.61	7.39	0.52	1.04e-11	Warfarin maintenance dose;
UCEC	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg18755752	chr8:142205143	DENND3	0.58	5.56	0.42	1.25e-7	Immature fraction of reticulocytes;
UCEC	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.78	-8.68	-0.58	7.07e-15	Monocyte count;
UCEC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.72	-7.22	-0.51	2.64e-11	Aortic root size;
UCEC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.61	6.5	0.47	1.15e-9	Crohn's disease;
UCEC	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg10202436	chr5:138733726	SPATA24	-0.3	-4.52	-0.35	1.28e-5	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg24069376	chr3:38537580	EXOG	0.43	5.3	0.4	4.19e-7	Electrocardiographic conduction measures;
UCEC	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	6.23	0.46	4.6e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.82	7.37	0.52	1.16e-11	Bladder cancer;
UCEC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	5.13	0.39	8.82e-7	Diabetic retinopathy;
UCEC	cis	rs975730	0.966	rs35695271	chr8:129361995	T/G	cg14920061	chr8:129326392	NA	0.36	4.56	0.35	1.06e-5	Celiac disease or Rheumatoid arthritis;
UCEC	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-7.98	-0.55	3.82e-13	Exhaled nitric oxide output;
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.45	0.61	7.28e-17	Platelet count;
UCEC	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.77	6.64	0.48	5.59e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg04025307	chr7:1156635	C7orf50	0.8	5.41	0.41	2.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg23752985	chr2:85803571	VAMP8	0.44	4.67	0.36	6.71e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.15	0.51	3.8e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg04154034	chr17:28927549	LRRC37B2	0.57	5.31	0.4	4.01e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-5.69	-0.42	6.8e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg05738196	chr6:26577821	NA	0.63	7.19	0.51	3.06e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.36	0.52	1.23e-11	Bipolar disorder;
UCEC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.78	-9.12	-0.6	5.26e-16	Age at first birth;
UCEC	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs12216499	0.892	rs2235823	chr6:159393211	G/A	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.54	-0.35	1.15e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.95	0.55	4.44e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.71	7.37	0.52	1.13e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.84	0.37	3.26e-6	Prostate-specific antigen levels;
UCEC	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.57e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.6	-6.0	-0.44	1.49e-8	Bipolar disorder;
UCEC	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.72e-7	Heart rate;
UCEC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.4	-4.61	-0.36	8.54e-6	Total body bone mineral density;
UCEC	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.8	-4.82	-0.37	3.47e-6	IgG glycosylation;
UCEC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-5.13	-0.39	8.86e-7	Aortic root size;
UCEC	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.52	4.84	0.37	3.2e-6	Menopause (age at onset);
UCEC	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg04155231	chr12:9217510	LOC144571	0.44	5.18	0.39	7.04e-7	Sjögren's syndrome;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg02594498	chr15:22893147	CYFIP1	-0.62	-6.73	-0.49	3.62e-10	Breast cancer;
UCEC	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-6.44	-0.47	1.57e-9	Fibrinogen levels;
UCEC	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.15	-10.75	-0.66	3.01e-20	Vitiligo;
UCEC	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.01	6.29	0.46	3.51e-9	Skin colour saturation;
UCEC	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.44	-6.03	-0.45	1.25e-8	Life satisfaction;
UCEC	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg14196790	chr5:131705035	SLC22A5	-0.42	-4.57	-0.35	1.02e-5	Breast cancer;Mosquito bite size;
UCEC	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	0.62	6.46	0.47	1.47e-9	Cannabis dependence symptom count;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.26	-0.46	3.92e-9	Pubertal anthropometrics;
UCEC	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-1.07	-9.63	-0.62	2.54e-17	Dupuytren's disease;
UCEC	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.63	6.74	0.49	3.4e-10	Retinal vascular caliber;
UCEC	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.73	-7.37	-0.52	1.16e-11	Plateletcrit;Platelet count;
UCEC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.8	5.53	0.41	1.45e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.82	0.75	2.28e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs7826222	0.632	rs1962448	chr8:9871971	G/A	cg00629382	chr8:10268916	MSRA	-0.68	-4.6	-0.35	9.05e-6	Adiposity;
UCEC	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	1.01	7.6	0.53	3.27e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.7	6.1	0.45	8.93e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	12.33	0.71	2e-24	Post bronchodilator FEV1;
UCEC	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.12	-0.51	4.45e-11	Prevalent atrial fibrillation;
UCEC	cis	rs73206853	0.843	rs12320025	chr12:110742991	A/G	cg12870014	chr12:110450643	ANKRD13A	0.6	5.74	0.43	5.29e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.33	4.73	0.36	5.17e-6	Crohn's disease;
UCEC	cis	rs12216499	0.892	rs12193306	chr6:159400479	G/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.66	-4.63	-0.36	7.97e-6	Bladder cancer (smoking interaction);
UCEC	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.52	5.35	0.4	3.28e-7	LDL cholesterol levels;LDL cholesterol;
UCEC	cis	rs9326726	0.844	rs6896653	chr5:107704881	G/T	cg17432647	chr5:107996819	NA	-0.51	-4.58	-0.35	9.85e-6	Resting heart rate;
UCEC	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.54	-5.92	-0.44	2.23e-8	Prostate cancer;
UCEC	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.71	-6.93	-0.5	1.26e-10	Cocaine dependence;
UCEC	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg10902566	chr4:727664	PCGF3	-0.58	-4.88	-0.37	2.78e-6	Systolic blood pressure;
UCEC	trans	rs4389974	1.000	rs12681048	chr8:112383093	G/A	cg22736090	chr17:62339926	TEX2	0.67	7.15	0.51	3.71e-11	Body mass index;
UCEC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs2280630	0.529	rs784518	chr3:39186038	C/G	cg01426195	chr3:39028469	NA	0.69	8.55	0.58	1.49e-14	Verbal declarative memory;
UCEC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.7	-7.98	-0.55	3.82e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.73	7.06	0.5	6.11e-11	Schizophrenia;
UCEC	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.71	-9.21	-0.61	3.03e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	0.81	9.47	0.62	6.65e-17	Male-pattern baldness;
UCEC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.97	10.64	0.66	5.95e-20	Cognitive function;
UCEC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.98	12.57	0.72	4.46e-25	Breast cancer;
UCEC	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.98	-7.66	-0.53	2.25e-12	Dupuytren's disease;
UCEC	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.72	6.22	0.46	4.82e-9	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.93	5.89	0.44	2.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-4.68	-0.36	6.38e-6	Chronic sinus infection;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.43	-4.95	-0.38	2.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.59	-6.71	-0.48	3.87e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.15	0.51	3.77e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg24703168	chr6:28411309	ZSCAN23	0.41	4.62	0.36	8.4e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg13147721	chr7:65941812	NA	-0.85	-5.54	-0.42	1.38e-7	Diabetic kidney disease;
UCEC	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-6.02	-0.44	1.33e-8	Dental caries;
UCEC	cis	rs7106204	0.514	rs12293105	chr11:24256048	T/C	ch.11.24196551F	chr11:24239977	NA	0.55	5.83	0.43	3.41e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg06238570	chr21:40685208	BRWD1	0.83	8.21	0.56	1.04e-13	Cognitive function;
UCEC	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg19468946	chr17:37922297	IKZF3	-0.44	-4.85	-0.37	3.17e-6	Self-reported allergy;
UCEC	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-4.51	-0.35	1.29e-5	Height;
UCEC	cis	rs6599222	0.530	rs3924120	chr3:38636155	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.44	4.53	0.35	1.21e-5	PR interval;
UCEC	cis	rs7937612	0.931	rs7115714	chr11:120294861	G/A	cg12584626	chr11:120203529	NA	0.53	5.25	0.4	5.12e-7	Intraocular pressure;
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.88	0.54	6.81e-13	Platelet count;
UCEC	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.97	7.28	0.51	1.91e-11	Exhaled nitric oxide levels;
UCEC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.59	5.48	0.41	1.81e-7	Schizophrenia;
UCEC	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.61	4.66	0.36	7.01e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs7070678	0.662	rs12775779	chr10:29801848	A/G	cg07724896	chr10:29780678	SVIL	0.53	4.56	0.35	1.08e-5	Platelet thrombus formation;
UCEC	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.52	-5.0	-0.38	1.58e-6	Metabolite levels;
UCEC	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg01426195	chr3:39028469	NA	-0.68	-8.61	-0.58	1.06e-14	Handedness;
UCEC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.56	-6.59	-0.48	7.4e-10	Educational attainment;
UCEC	cis	rs11169225	1.000	rs7299924	chr12:50348961	A/G	cg23855989	chr12:50355821	AQP5	0.96	6.63	0.48	5.98e-10	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg10932868	chr11:921992	NA	-0.42	-5.47	-0.41	1.91e-7	Alzheimer's disease (late onset);
UCEC	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.05	-0.45	1.13e-8	Metabolite levels;
UCEC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.93	10.23	0.64	6.83e-19	Cognitive function;
UCEC	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.62	6.56	0.48	8.61e-10	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.64	-0.42	8.51e-8	Neutrophil percentage of white cells;
UCEC	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	5.69	0.43	6.56e-8	Joint mobility (Beighton score);
UCEC	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.97	-11.3	-0.68	1.03e-21	Obesity-related traits;
UCEC	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.57	-4.93	-0.38	2.19e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.89	-0.59	2.01e-15	Exhaled nitric oxide output;
UCEC	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-0.99	-6.24	-0.46	4.44e-9	Diabetic kidney disease;
UCEC	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.11	0.51	4.78e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.42	7.6	0.53	3.25e-12	Cognitive function;
UCEC	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	6.81	0.49	2.31e-10	Alzheimer's disease;
UCEC	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.77	8.47	0.57	2.28e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg06466757	chr4:1255808	NA	0.44	4.62	0.36	8.43e-6	Obesity-related traits;
UCEC	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.49	-4.81	-0.37	3.69e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	0.48	5.91	0.44	2.26e-8	Prudent dietary pattern;
UCEC	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.14e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	9.76	0.63	1.15e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg23217946	chr19:22817039	ZNF492	0.41	4.54	0.35	1.17e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.27	0.71	2.77e-24	Platelet count;
UCEC	cis	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg03342759	chr3:160939853	NMD3	0.56	5.22	0.4	5.95e-7	Morning vs. evening chronotype;
UCEC	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	5.45	0.41	2.07e-7	Metabolite levels;
UCEC	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.86e-7	Morning vs. evening chronotype;
UCEC	cis	rs7070678	0.638	rs61849287	chr10:29795756	C/T	cg24350475	chr10:30316933	KIAA1462	0.48	4.66	0.36	6.93e-6	Platelet thrombus formation;
UCEC	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-1.23	-6.46	-0.47	1.47e-9	Schizophrenia;
UCEC	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.42	-5.54	-0.42	1.37e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg00651523	chr6:28411279	ZSCAN23	-0.52	-5.73	-0.43	5.55e-8	Pulmonary function;
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.58	6.58	0.48	7.84e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-6.2	-0.46	5.55e-9	Response to antipsychotic treatment;
UCEC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.6	4.98	0.38	1.72e-6	Body mass index;
UCEC	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.49	-0.53	5.8e-12	Educational attainment (years of education);
UCEC	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-5.64	-0.42	8.37e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.51	5.82	0.43	3.48e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35681285	1.000	rs4721494	chr7:16404615	C/T	cg18753594	chr7:16793736	TSPAN13	-0.64	-4.75	-0.36	4.79e-6	Serum tamsulosin hydrochloride concentration;
UCEC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg20203395	chr5:56204925	C5orf35	-0.55	-4.93	-0.38	2.22e-6	Coronary artery disease;
UCEC	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	0.73	9.93	0.63	4.11e-18	Gut microbiome composition (winter);
UCEC	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.65	5.29	0.4	4.43e-7	Systolic blood pressure;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.65	-0.42	7.89e-8	Platelet count;
UCEC	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-0.91	-9.15	-0.6	4.52e-16	Height;
UCEC	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.6	5.64	0.42	8.37e-8	Corneal astigmatism;
UCEC	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.72	8.92	0.59	1.67e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg03539765	chr12:9217390	LOC144571	-0.4	-4.56	-0.35	1.08e-5	Sjögren's syndrome;
UCEC	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.69	0.36	6.27e-6	Breast cancer;
UCEC	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.7	6.86	0.49	1.74e-10	Vitamin D levels;
UCEC	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.62	5.44	0.41	2.17e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.5	5.1	0.39	1.01e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs159572	0.666	rs160012	chr5:55504226	T/C	cg04607372	chr5:54523900	NA	0.32	4.72	0.36	5.48e-6	Post-traumatic stress disorder;
UCEC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Alcohol dependence;
UCEC	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.58	5.19	0.39	6.74e-7	Corneal astigmatism;
UCEC	cis	rs9470004	1	rs9470004	chr6:35341850	C/T	cg00237391	chr6:35265643	DEF6	1.04	4.78	0.37	4.16e-6	Height;
UCEC	cis	rs12568771	0.781	rs12037558	chr1:17608353	G/A	cg13381844	chr1:17973557	ARHGEF10L	0.35	4.54	0.35	1.15e-5	IgA nephropathy;
UCEC	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.54	4.9	0.37	2.54e-6	Refractive astigmatism;
UCEC	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.42	5.26	0.4	5.02e-7	Fat distribution (HIV);
UCEC	cis	rs10242455	0.702	rs58348977	chr7:99188014	G/A	cg18809830	chr7:99032528	PTCD1	-0.81	-4.55	-0.35	1.14e-5	Blood metabolite levels;
UCEC	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.43	4.64	0.36	7.79e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.74	-6.46	-0.47	1.44e-9	Obesity-related traits;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg19041857	chr6:27730383	NA	-0.44	-4.82	-0.37	3.53e-6	Depression;
UCEC	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.64	5.13	0.39	9e-7	Obesity-related traits;
UCEC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.33	-0.65	3.91e-19	Cognitive function;
UCEC	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-7.67	-0.53	2.2e-12	Body mass index;
UCEC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.57	-6.67	-0.48	4.76e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.58	-4.63	-0.36	8.01e-6	Menopause (age at onset);
UCEC	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.64	-5.67	-0.42	7.3e-8	Aortic root size;
UCEC	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg13073564	chr4:8508604	NA	-0.51	-6.07	-0.45	1.02e-8	Response to antineoplastic agents;
UCEC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.55	5.68	0.42	7.05e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.67	-0.36	6.76e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg21253087	chr9:139290292	SNAPC4	-0.44	-5.05	-0.38	1.32e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.79	0.49	2.52e-10	Platelet count;
UCEC	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	15.41	0.79	1.73e-32	Chronic sinus infection;
UCEC	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.67	7.87	0.54	7.15e-13	Colorectal cancer;
UCEC	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.86	-0.59	2.44e-15	Exhaled nitric oxide output;
UCEC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg22974920	chr21:40686053	BRWD1	0.58	4.74	0.36	5.02e-6	Cognitive function;
UCEC	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.66	-6.13	-0.45	7.56e-9	Systemic lupus erythematosus;
UCEC	cis	rs711830	0.587	rs10188827	chr2:177007664	C/T	cg13092806	chr2:177043255	NA	0.76	5.45	0.41	2.1e-7	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg14008862	chr17:28927542	LRRC37B2	0.67	5.16	0.39	7.78e-7	Body mass index;
UCEC	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.51	4.67	0.36	6.74e-6	Menarche (age at onset);
UCEC	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg18681998	chr4:17616180	MED28	0.83	10.84	0.67	1.7e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg03859395	chr2:55845619	SMEK2	0.97	13.95	0.75	1.04e-28	Metabolic syndrome;
UCEC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12450239	0.514	rs7217700	chr17:77452372	C/T	cg24331786	chr17:76895244	TIMP2	0.41	4.61	0.36	8.51e-6	Body mass index;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.54	6.43	0.47	1.67e-9	Menarche (age at onset);
UCEC	cis	rs7709377	0.597	rs11241371	chr5:115493530	C/T	cg23108291	chr5:115420582	COMMD10	0.53	5.39	0.41	2.72e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.42	5.22	0.4	6.11e-7	Urinary metabolites;
UCEC	cis	rs892864	0.685	rs59535791	chr5:127760820	C/A	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg04896959	chr15:78267971	NA	-0.66	-6.72	-0.48	3.66e-10	Coronary artery disease or large artery stroke;
UCEC	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg08027265	chr7:2291960	NA	-0.42	-4.72	-0.36	5.56e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.55	5.19	0.39	6.97e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs11054731	1.000	rs10845501	chr12:12415697	A/G	cg15213114	chr10:74927623	ECD;FAM149B1	0.66	7.19	0.51	3.1e-11	Coronary artery calcification;
UCEC	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs1519814	1.000	rs6983133	chr8:121166682	T/G	cg22335954	chr8:121166405	COL14A1	-0.69	-5.61	-0.42	9.74e-8	Breast cancer;
UCEC	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.84	0.37	3.21e-6	Aortic root size;
UCEC	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.63	4.57	0.35	1.02e-5	Pre-treatment pain in head and neck squamous cell carcinoma;
UCEC	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.65	8.21	0.56	1.01e-13	Endometriosis;
UCEC	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.16	-0.45	6.77e-9	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.49	4.85	0.37	3.06e-6	Gout;
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.64	-5.88	-0.44	2.6e-8	Menarche (age at onset);
UCEC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.64	6.85	0.49	1.88e-10	Menopause (age at onset);
UCEC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.53	6.11	0.45	8.55e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs36051895	0.659	rs1322224	chr9:5267889	C/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.7	-0.36	5.97e-6	Pediatric autoimmune diseases;
UCEC	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.63	-6.69	-0.48	4.32e-10	Sudden cardiac arrest;
UCEC	cis	rs7246967	0.866	rs34752785	chr19:23044573	T/A	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.81	-0.54	9.99e-13	Total cholesterol levels;
UCEC	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.58	6.93	0.5	1.25e-10	Oral cavity cancer;
UCEC	trans	rs4389974	1.000	rs4604474	chr8:112381405	T/A	cg22736090	chr17:62339926	TEX2	0.66	7.05	0.5	6.3e-11	Body mass index;
UCEC	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.5	-5.24	-0.4	5.36e-7	Schizophrenia;
UCEC	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.66	7.71	0.54	1.77e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.83e-6	Gut microbiome composition (summer);
UCEC	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.53	5.24	0.4	5.37e-7	Radiation response;
UCEC	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	trans	rs1552172	0.887	rs12725120	chr1:145661313	C/T	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.64	-6.96	-0.5	1.04e-10	Breast cancer;
UCEC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.67	-6.12	-0.45	8.1e-9	Aortic root size;
UCEC	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg01426195	chr3:39028469	NA	-0.46	-4.84	-0.37	3.26e-6	Handedness;
UCEC	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.54	-6.26	-0.46	4.09e-9	Type 2 diabetes;
UCEC	cis	rs7959452	0.836	rs12827594	chr12:69729434	G/A	cg14784868	chr12:69753453	YEATS4	0.65	6.36	0.46	2.42e-9	Blood protein levels;
UCEC	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.82	9.74	0.63	1.29e-17	Adiposity;
UCEC	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.43	-0.9	1.26e-53	Myeloid white cell count;
UCEC	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4448343	1.000	rs28629854	chr9:98262833	A/G	cg13456470	chr9:98266766	PTCH1	0.36	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.66	6.23	0.46	4.72e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs1355223	0.867	rs11821793	chr11:34681462	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.58	-0.35	9.75e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg11569703	chr11:65557185	OVOL1	-0.42	-5.99	-0.44	1.58e-8	Acne (severe);
UCEC	cis	rs7088591	1.000	rs16911648	chr10:59782764	A/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg13525197	chr6:28411240	ZSCAN23	0.55	6.08	0.45	9.75e-9	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-0.7	-6.96	-0.5	1.03e-10	Breast cancer;
UCEC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg17105886	chr17:28927953	LRRC37B2	0.51	4.8	0.37	3.79e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.98	11.46	0.69	4e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg04682699	chr3:50248845	SLC38A3	-0.4	-4.94	-0.38	2.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	1.07	6.59	0.48	7.49e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.43	4.76	0.37	4.62e-6	Tuberculosis;
UCEC	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg12024160	chr4:1254474	NA	0.63	7.59	0.53	3.45e-12	Obesity-related traits;
UCEC	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-8.09	-0.55	2.1e-13	Hemoglobin concentration;
UCEC	cis	rs4713118	0.539	rs510987	chr6:27847517	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.55	-5.97	-0.44	1.69e-8	Parkinson's disease;
UCEC	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.32	0.46	2.88e-9	Personality dimensions;
UCEC	cis	rs11625487	0.915	rs11845826	chr14:77966145	C/A	cg10415171	chr14:77413900	NA	0.44	4.51	0.35	1.31e-5	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg19413350	chr8:57351067	NA	-0.41	-4.87	-0.37	2.84e-6	Obesity-related traits;
UCEC	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-7.82	-0.54	9.36e-13	Ileal carcinoids;
UCEC	cis	rs12912251	0.591	rs12912235	chr15:39000074	C/T	cg10631289	chr15:39006617	NA	0.52	4.75	0.36	4.86e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
UCEC	cis	rs7617773	0.963	rs6771787	chr3:48194242	C/T	cg11946769	chr3:48343235	NME6	-0.55	-4.81	-0.37	3.77e-6	Coronary artery disease;
UCEC	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.63	7.2	0.51	2.92e-11	Post bronchodilator FEV1;
UCEC	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.85	-10.42	-0.65	2.17e-19	Brugada syndrome;
UCEC	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.72	-5.84	-0.43	3.2e-8	Asthma;
UCEC	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	5.0	0.38	1.64e-6	IgG glycosylation;
UCEC	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.49	5.0	0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg16497661	chr14:103986332	CKB	0.45	4.73	0.36	5.24e-6	Body mass index;
UCEC	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.48	-4.74	-0.36	4.89e-6	Multiple sclerosis;
UCEC	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	0.65	6.4	0.47	1.97e-9	Vitiligo;
UCEC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.67	5.9	0.44	2.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg23795048	chr12:9217529	LOC144571	0.42	5.01	0.38	1.55e-6	Sjögren's syndrome;
UCEC	cis	rs2288327	0.818	rs2857265	chr2:179398823	G/A	cg09915519	chr2:179397513	TTN;MIR548N	-0.68	-4.69	-0.36	6.25e-6	Atrial fibrillation;
UCEC	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.26	-10.85	-0.67	1.59e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs55670112	0.935	rs55944000	chr5:114269926	T/C	cg05461448	chr5:114880715	FEM1C	-0.45	-4.63	-0.36	7.9e-6	Epilepsy;
UCEC	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.71	7.88	0.54	6.79e-13	Monocyte count;
UCEC	cis	rs6137726	0.508	rs4815131	chr20:22639632	T/C	cg08244522	chr20:23030533	THBD	-0.47	-4.77	-0.37	4.31e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg18681998	chr4:17616180	MED28	0.89	11.57	0.69	1.98e-22	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg21053147	chr12:120880522	NA	-0.65	-5.46	-0.41	1.98e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs10924970	0.649	rs10802583	chr1:235438687	C/T	cg26050004	chr1:235667680	B3GALNT2	0.49	4.68	0.36	6.5e-6	Asthma;
UCEC	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-7.65	-0.53	2.42e-12	Blood metabolite levels;
UCEC	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.62	5.74	0.43	5.35e-8	Type 2 diabetes;
UCEC	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.37	5.64	0.42	8.65e-8	Body mass index;
UCEC	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-6.31	-0.46	3.15e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg20002381	chr19:39279703	LGALS7B	-0.34	-4.51	-0.35	1.3e-5	Heart rate;
UCEC	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-0.94	-10.35	-0.65	3.39e-19	Urate levels;
UCEC	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.94	10.98	0.67	7.45e-21	Breast cancer;
UCEC	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.68	5.6	0.42	1e-7	Major depressive disorder;
UCEC	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.61	-4.96	-0.38	1.95e-6	Coronary artery calcification;
UCEC	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.58	5.42	0.41	2.33e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.78	-6.13	-0.45	7.6e-9	Calcium levels;
UCEC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Bipolar disorder;
UCEC	cis	rs2288327	0.818	rs2288325	chr2:179404786	A/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.65	-4.51	-0.35	1.33e-5	Atrial fibrillation;
UCEC	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.58	6.0	0.44	1.46e-8	Schizophrenia;
UCEC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.41	4.56	0.35	1.05e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-10.76	-0.66	2.83e-20	Schizophrenia;
UCEC	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	1.04	5.74	0.43	5.14e-8	Skin colour saturation;
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg01993413	chr14:21979151	METTL3	-0.74	-6.7	-0.48	4.05e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-0.92	-6.82	-0.49	2.24e-10	Body mass index;
UCEC	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.72	-5.28	-0.4	4.6e-7	Fibroblast growth factor basic levels;
UCEC	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.69	-7.56	-0.53	4.01e-12	Breast cancer;
UCEC	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg06157570	chr12:6886703	LAG3	0.54	5.32	0.4	3.73e-7	HDL cholesterol levels;
UCEC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	5.61	0.42	9.69e-8	Platelet count;
UCEC	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.59	-6.29	-0.46	3.39e-9	Obesity-related traits;
UCEC	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.54	6.32	0.46	2.91e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.46	-4.7	-0.36	5.87e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.52	5.76	0.43	4.72e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.68	-6.37	-0.47	2.29e-9	Blood pressure (smoking interaction);
UCEC	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	4.99	0.38	1.66e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs3914502	0.615	rs1515619	chr3:174527160	A/G	cg21145449	chr3:174580620	NAALADL2	0.46	5.1	0.39	1.05e-6	Autism spectrum disorder;
UCEC	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.74	-4.69	-0.36	6.13e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.49	-5.03	-0.38	1.4e-6	Blood metabolite levels;
UCEC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.53	5.68	0.42	6.9e-8	HDL cholesterol;
UCEC	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.92	10.18	0.64	9.15e-19	Colorectal adenoma (advanced);
UCEC	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg08574758	chr4:666278	ATP5I	-0.69	-4.52	-0.35	1.24e-5	Recombination rate (females);
UCEC	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-6.29	-0.46	3.43e-9	Blood protein levels;
UCEC	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.47	4.65	0.36	7.24e-6	High light scatter reticulocyte count;
UCEC	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.39	-0.76	7.59e-30	Schizophrenia;
UCEC	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.74	7.58	0.53	3.5e-12	Blood protein levels;
UCEC	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.73	-7.04	-0.5	6.82e-11	Metabolite levels;
UCEC	cis	rs7709377	0.570	rs10036669	chr5:115444743	G/T	cg23108291	chr5:115420582	COMMD10	0.49	5.04	0.38	1.36e-6	Metabolite levels  (X-11787);
UCEC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-5.83	-0.43	3.31e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.5	-0.72	6.83e-25	Primary sclerosing cholangitis;
UCEC	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7302981	0.809	rs1044370	chr12:50570610	T/C	cg20014596	chr12:50898483	DIP2B	0.43	4.53	0.35	1.22e-5	Systolic blood pressure;
UCEC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-6.72	-0.48	3.69e-10	Longevity;
UCEC	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg09555818	chr19:45449301	APOC2	0.47	6.24	0.46	4.33e-9	Blood protein levels;
UCEC	cis	rs2224391	0.540	rs112849053	chr6:5255733	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-4.89	-0.37	2.63e-6	Height;
UCEC	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-6.04	-0.45	1.2e-8	Dental caries;
UCEC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.96	10.49	0.65	1.47e-19	Cognitive function;
UCEC	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	8.87	0.59	2.32e-15	Mean platelet volume;
UCEC	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.87	-10.78	-0.66	2.45e-20	Primary sclerosing cholangitis;
UCEC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.49	-5.9	-0.44	2.35e-8	Height;
UCEC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.6	-6.43	-0.47	1.69e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg01851573	chr8:8652454	MFHAS1	0.43	5.15	0.39	8.24e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.46	4.76	0.37	4.5e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs10031466	1.000	rs2279550	chr4:189012728	G/C	cg03652810	chr4:189026682	TRIML2	-0.47	-5.71	-0.43	5.9e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.64	0.48	5.54e-10	High light scatter reticulocyte count;
UCEC	cis	rs250585	0.736	rs30010	chr16:23422658	G/C	cg26562691	chr16:23850404	PRKCB	0.36	4.65	0.36	7.37e-6	Egg allergy;
UCEC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg08271804	chr19:22816896	ZNF492	0.64	6.48	0.47	1.33e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.54	-5.93	-0.44	2.03e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1832871	0.578	rs262820	chr6:158663101	G/T	cg07215822	chr6:158701037	NA	-0.53	-5.68	-0.42	6.93e-8	Height;
UCEC	cis	rs7781557	0.640	rs7779854	chr7:102551582	G/A	cg06322601	chr7:102330635	NA	0.57	4.58	0.35	9.97e-6	Colorectal adenoma (advanced);
UCEC	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg22598563	chr5:131563921	P4HA2	0.34	4.68	0.36	6.5e-6	Blood metabolite levels;
UCEC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.69	-6.91	-0.5	1.38e-10	Blood metabolite levels;
UCEC	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.96	-13.81	-0.75	2.47e-28	Bone mineral density;
UCEC	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.86	6.77	0.49	2.92e-10	Body mass index;
UCEC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.83	9.59	0.62	3.23e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	0.81	10.87	0.67	1.43e-20	Gut microbiome composition (winter);
UCEC	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.65	-7.1	-0.51	4.87e-11	Homoarginine levels;
UCEC	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-6.42	-0.47	1.8e-9	Morning vs. evening chronotype;
UCEC	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.65	7.38	0.52	1.08e-11	Body mass index;
UCEC	cis	rs253959	0.814	rs2221676	chr5:115458887	C/T	cg23108291	chr5:115420582	COMMD10	0.52	5.44	0.41	2.21e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs10242455	0.867	rs2740562	chr7:99319157	G/A	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg21521518	chr4:53727714	RASL11B	0.53	4.69	0.36	6.19e-6	Optic nerve measurement (cup area);
UCEC	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.54	-5.72	-0.43	5.72e-8	Refractive error;
UCEC	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.62	-6.42	-0.47	1.77e-9	Sudden cardiac arrest;
UCEC	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-9.25	-0.61	2.5e-16	Blood metabolite levels;
UCEC	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.43	0.47	1.65e-9	Cognitive test performance;
UCEC	cis	rs6954274	0.609	rs62445701	chr7:9862998	G/T	cg27477025	chr7:9765726	NA	-0.43	-4.56	-0.35	1.09e-5	Subjective well-being;
UCEC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.45	5.29	0.4	4.43e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg08459430	chr5:81571289	RPS23	-0.52	-4.97	-0.38	1.84e-6	Breast cancer;
UCEC	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.7	-0.36	5.86e-6	Bipolar disorder;
UCEC	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.37	-0.46	2.33e-9	Crohn's disease;
UCEC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.63	-5.78	-0.43	4.31e-8	Coronary artery disease;
UCEC	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	7.97	0.55	3.93e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.6	5.49	0.41	1.69e-7	Uric acid levels;
UCEC	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-8.12	-0.56	1.73e-13	Colorectal cancer;
UCEC	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.78	-0.37	4.19e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.54	5.74	0.43	5.16e-8	Pulse pressure;
UCEC	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.49	4.73	0.36	5.23e-6	Obesity-related traits;
UCEC	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.76	8.19	0.56	1.14e-13	Itch intensity from mosquito bite;
UCEC	cis	rs4234798	0.605	rs4689637	chr4:7211197	A/G	cg18431297	chr4:7219810	SORCS2	0.41	4.69	0.36	6.25e-6	Insulin-like growth factors;
UCEC	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.65	-5.07	-0.39	1.16e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.57	-0.35	1.01e-5	Breast cancer;
UCEC	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.9	5.77	0.43	4.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.78	-9.96	-0.63	3.51e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg22166914	chr1:53195759	ZYG11B	0.67	7.07	0.5	5.8200000000000003e-11	Monocyte count;
UCEC	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	trans	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg19318889	chr4:1322082	MAEA	0.42	4.73	0.36	5.16e-6	Longevity;
UCEC	cis	rs4400599	0.805	rs10908739	chr1:154160655	T/C	cg05139571	chr1:154127138	NUP210L	0.44	4.77	0.37	4.49e-6	Platelet distribution width;
UCEC	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs10242455	0.702	rs115279860	chr7:98994492	C/T	cg18809830	chr7:99032528	PTCD1	-0.91	-4.65	-0.36	7.24e-6	Blood metabolite levels;
UCEC	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.68	-6.85	-0.49	1.91e-10	Dental caries;
UCEC	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.85	-0.43	3.07e-8	Aortic root size;
UCEC	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-6.45	-0.47	1.49e-9	Initial pursuit acceleration;
UCEC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.11	0.71	7.71e-24	Prudent dietary pattern;
UCEC	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.78	5.04	0.38	1.33e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg01072550	chr1:21505969	NA	-0.53	-5.05	-0.38	1.29e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.9e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.57	5.99	0.44	1.57e-8	Initial pursuit acceleration;
UCEC	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.56	-0.66	9.36e-20	Primary sclerosing cholangitis;
UCEC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.65	0.36	7.31e-6	Height;
UCEC	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.93	10.12	0.64	1.38e-18	Cognitive function;
UCEC	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-8.05	-0.55	2.6e-13	Body mass index;
UCEC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.09e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.34	5.72	0.43	5.81e-8	Cancer;
UCEC	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.66	-7.93	-0.55	5.02e-13	IgG glycosylation;
UCEC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.87	11.44	0.69	4.38e-22	Menopause (age at onset);
UCEC	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.75	7.06	0.5	6.27e-11	Bladder cancer;
UCEC	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.58	5.02	0.38	1.45e-6	Response to diuretic therapy;
UCEC	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.58	6.73	0.49	3.62e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs7709377	0.620	rs1396482	chr5:115475502	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg01851573	chr8:8652454	MFHAS1	0.54	4.7	0.36	5.81e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.7	-6.25	-0.46	4.3e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.76	7.47	0.52	6.75e-12	Aortic root size;
UCEC	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.37	-0.4	3.07e-7	Response to antipsychotic treatment;
UCEC	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.12	-0.51	4.33e-11	Response to antipsychotic treatment;
UCEC	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.57	0.42	1.19e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7578199	0.576	rs2074774	chr2:242396087	A/T	cg02201132	chr2:242212884	HDLBP	-0.43	-4.85	-0.37	3.15e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg14008862	chr17:28927542	LRRC37B2	0.74	5.36	0.4	3.17e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.7	9.13	0.6	5.05e-16	Rheumatoid arthritis;
UCEC	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg07796016	chr1:152779584	LCE1C	-0.54	-5.22	-0.4	6.04e-7	Vitamin D levels;
UCEC	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg03859395	chr2:55845619	SMEK2	-0.74	-7.22	-0.51	2.63e-11	Metabolic syndrome;
UCEC	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg27068330	chr11:65405492	SIPA1	-0.56	-5.5	-0.41	1.67e-7	Acne (severe);
UCEC	cis	rs7246967	0.935	rs8112754	chr19:23060870	C/T	cg24889512	chr19:22816950	ZNF492	0.49	4.99	0.38	1.68e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.56	-6.65	-0.48	5.27e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.41	-4.89	-0.37	2.65e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.73	-0.43	5.49e-8	Initial pursuit acceleration;
UCEC	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.52	4.92	0.38	2.32e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.23	-0.4	5.71e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.56	-5.69	-0.43	6.51e-8	White matter hyperintensity burden;
UCEC	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.31	-0.46	3.18e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.41	5.17	0.39	7.53e-7	Bone mineral density;
UCEC	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-0.76	-7.19	-0.51	3.09e-11	Breast cancer;
UCEC	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.7	0.43	6.22e-8	Height;
UCEC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.53	5.1	0.39	1.04e-6	Obesity-related traits;
UCEC	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.17	0.51	3.36e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg20007245	chr22:24372913	LOC391322	-0.55	-5.94	-0.44	1.96e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.68	5.65	0.42	8.04e-8	Corneal astigmatism;
UCEC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.01	-11.03	-0.67	5.33e-21	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.66	5.38	0.41	2.87e-7	Corneal astigmatism;
UCEC	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	7.57	0.53	3.79e-12	Coronary artery disease;
UCEC	cis	rs17123764	0.605	rs7954994	chr12:50068089	C/T	cg20471783	chr12:50157085	TMBIM6	0.65	5.49	0.41	1.7e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.65	-7.47	-0.52	6.66e-12	Hip circumference;
UCEC	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.64	5.91	0.44	2.31e-8	Corneal astigmatism;
UCEC	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.64	-5.67	-0.42	7.49e-8	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg12024160	chr4:1254474	NA	-0.53	-5.62	-0.42	9.14e-8	Obesity-related traits;
UCEC	cis	rs17490626	0.533	rs5030925	chr10:71211150	A/C	cg12610070	chr10:71211762	TSPAN15	-0.4	-6.44	-0.47	1.6e-9	Thrombosis;
UCEC	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.47	-5.23	-0.4	5.83e-7	Rheumatoid arthritis;
UCEC	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.64	0.42	8.28e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg24069376	chr3:38537580	EXOG	0.47	5.89	0.44	2.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.63	5.05	0.38	1.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.29	0.46	3.48e-9	Coronary artery disease;
UCEC	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.78	7.85	0.54	8.07e-13	Lung cancer;
UCEC	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-4.83	-0.37	3.41e-6	Life satisfaction;
UCEC	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.51	-5.82	-0.43	3.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.6	-4.95	-0.38	1.97e-6	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.13	0.45	7.56e-9	Platelet count;
UCEC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg02820040	chr2:241836501	C2orf54	-0.4	-4.98	-0.38	1.76e-6	Urinary metabolites;
UCEC	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.45	-4.92	-0.38	2.34e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6670533	0.571	rs10489444	chr1:24863530	A/G	cg07475527	chr1:24864545	NA	0.82	4.64	0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.47	0.41	1.92e-7	HIV-1 control;
UCEC	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-0.96	-7.23	-0.51	2.42e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.49	-4.77	-0.37	4.36e-6	Obesity-related traits;
UCEC	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.5	-4.89	-0.37	2.59e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.55	-0.35	1.1e-5	Tonsillectomy;
UCEC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg18681998	chr4:17616180	MED28	0.67	6.42	0.47	1.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.75	7.99	0.55	3.59e-13	Multiple myeloma (IgH translocation);
UCEC	cis	rs73069940	0.744	rs730831	chr4:1240299	T/G	cg07110949	chr4:1309878	MAEA	-0.66	-4.56	-0.35	1.08e-5	Type 2 diabetes;
UCEC	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.63	5.84	0.43	3.24e-8	Mammographic density (dense area);
UCEC	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg20560298	chr2:73613845	ALMS1	0.56	5.45	0.41	2.03e-7	Metabolite levels;
UCEC	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg01973587	chr1:228161476	NA	0.39	5.18	0.39	7.16e-7	Diastolic blood pressure;
UCEC	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.61	-5.24	-0.4	5.43e-7	Mortality in heart failure;
UCEC	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.67	6.49	0.47	1.24e-9	Crohn's disease;
UCEC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.55	-5.35	-0.4	3.26e-7	Platelet count;
UCEC	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg04287289	chr16:89883240	FANCA	-0.51	-5.4	-0.41	2.56e-7	Vitiligo;
UCEC	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04731861	chr2:219085781	ARPC2	0.41	4.55	0.35	1.1e-5	Colorectal cancer;
UCEC	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg05738196	chr6:26577821	NA	0.66	7.97	0.55	4.12e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg01493522	chr13:37497338	NA	-0.46	-4.96	-0.38	1.9e-6	Coronary artery disease;
UCEC	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	4.96	0.38	1.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.49	-4.72	-0.36	5.51e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg15326795	chr6:26217500	HIST1H2BG;HIST1H2AE	-0.6	-4.63	-0.36	7.85e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1519814	1.000	rs4871045	chr8:121167814	T/C	cg22335954	chr8:121166405	COL14A1	-0.68	-5.53	-0.42	1.42e-7	Breast cancer;
UCEC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.85	8.81	0.59	3.28e-15	Cognitive function;
UCEC	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.53	-4.58	-0.35	9.64e-6	Strep throat;
UCEC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg19760965	chr3:194868843	C3orf21	0.4	4.57	0.35	1.04e-5	Non-small cell lung cancer;
UCEC	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.51	-4.76	-0.37	4.68e-6	Body mass index;
UCEC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.79	7.91	0.55	5.79e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg01112020	chr2:239008986	ESPNL	-0.36	-4.77	-0.37	4.43e-6	Prostate cancer;
UCEC	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.51	5.04	0.38	1.36e-6	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg01380346	chr19:18557039	ELL	-0.44	-4.56	-0.35	1.07e-5	Breast cancer;
UCEC	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.58	-7.02	-0.5	7.75e-11	Menarche (age at onset);
UCEC	cis	rs72823319	0.645	rs9896717	chr17:37244233	A/G	cg27330720	chr17:37558981	FBXL20	0.51	4.54	0.35	1.18e-5	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	4.64	0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.41	4.61	0.36	8.6e-6	Hypertriglyceridemia;
UCEC	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18252515	chr7:66147081	NA	0.46	4.67	0.36	6.82e-6	Aortic root size;
UCEC	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.75	-0.36	4.81e-6	Alzheimer's disease (late onset);
UCEC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.23	-14.5	-0.77	3.92e-30	Breast cancer;
UCEC	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.56	-5.79	-0.43	4.11e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.83	7.18	0.51	3.21e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.81	9.25	0.61	2.37e-16	Menopause (age at onset);
UCEC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.24e-10	Aortic root size;
UCEC	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.52	5.37	0.41	2.99e-7	Testicular germ cell tumor;
UCEC	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.54	6.4	0.47	2.01e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-0.82	-9.47	-0.62	6.77e-17	Blood pressure (smoking interaction);
UCEC	cis	rs11958404	0.860	rs56090852	chr5:157431120	A/G	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg11161011	chr14:65562177	MAX	-0.8	-7.45	-0.52	7.3e-12	Obesity-related traits;
UCEC	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	7.04	0.5	6.93e-11	Platelet count;
UCEC	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.56	-4.77	-0.37	4.31e-6	Type 2 diabetes;
UCEC	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.86e-7	Morning vs. evening chronotype;
UCEC	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.96	-0.38	1.96e-6	Late-onset Alzheimer's disease;
UCEC	trans	rs7246760	0.867	rs8107594	chr19:9835957	G/C	cg02900749	chr2:68251473	NA	-1.01	-7.61	-0.53	2.98e-12	Pursuit maintenance gain;
UCEC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	4.98	0.38	1.77e-6	Lung cancer in ever smokers;
UCEC	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.81	7.81	0.54	9.83e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg12024160	chr4:1254474	NA	0.52	6.24	0.46	4.33e-9	Obesity-related traits;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.79	7.55	0.53	4.27e-12	Longevity;Endometriosis;
UCEC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.73	-6.88	-0.49	1.63e-10	Aortic root size;
UCEC	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg11519256	chr10:5708881	ASB13	0.46	4.72	0.36	5.39e-6	Menopause (age at onset);
UCEC	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-5.97	-0.44	1.7e-8	Total body bone mineral density;
UCEC	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.73	6.52	0.47	1.03e-9	Parkinson's disease;
UCEC	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.45	-5.18	-0.39	7.17e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.62	-5.6	-0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.92	0.55	5.41e-13	Menopause (age at onset);
UCEC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.62	4.54	0.35	1.14e-5	Gestational age at birth (maternal effect);
UCEC	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.51	-4.69	-0.36	6.08e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg08890418	chr1:21044141	KIF17	-0.46	-4.58	-0.35	9.76e-6	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg21247757	chr5:134228918	TXNDC15	-0.7	-6.67	-0.48	4.75e-10	Migraine with aura;
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.64	7.01	0.5	8.22e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.78	-6.17	-0.45	6.34e-9	Birth weight;
UCEC	cis	rs9302690	1.000	rs16957051	chr16:57468408	C/T	cg27017172	chr16:57497170	POLR2C	-1.26	-6.72	-0.48	3.77e-10	Blood protein levels;
UCEC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	1.0	11.82	0.7	4.54e-23	Cognitive function;
UCEC	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs829661	0.947	rs829660	chr2:30726765	A/C	cg17749961	chr2:30669863	LCLAT1	0.71	5.85	0.43	3.08e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.66	-5.66	-0.42	7.51e-8	Platelet count;
UCEC	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg09654669	chr8:57350985	NA	-0.54	-6.05	-0.45	1.14e-8	Obesity-related traits;
UCEC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg16497661	chr14:103986332	CKB	0.49	5.85	0.43	3.01e-8	Body mass index;
UCEC	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-12.06	-0.71	1.01e-23	Ulcerative colitis;
UCEC	cis	rs17106184	0.892	rs57400675	chr1:51068657	C/T	cg07174182	chr1:51127561	FAF1	-0.73	-4.67	-0.36	6.73e-6	Type 2 diabetes;
UCEC	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.46	-5.4	-0.41	2.56e-7	Aortic root size;
UCEC	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.79	-8.14	-0.56	1.5e-13	Mosquito bite size;
UCEC	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.49	6.53	0.47	9.95e-10	Total body bone mineral density;
UCEC	cis	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg20368463	chr18:77673604	PQLC1	0.57	4.56	0.35	1.08e-5	Opioid sensitivity;
UCEC	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.78	7.75	0.54	1.39e-12	Lung cancer;
UCEC	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.52	-5.38	-0.41	2.92e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.68	6.21	0.46	5.14e-9	Aortic root size;
UCEC	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.61	-0.36	8.81e-6	Type 2 diabetes;
UCEC	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.6	-5.73	-0.43	5.37e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg11901034	chr3:128598214	ACAD9	0.52	4.57	0.35	1.03e-5	IgG glycosylation;
UCEC	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.63	-6.17	-0.45	6.41e-9	Diastolic blood pressure;
UCEC	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.15	-0.51	3.85e-11	Breast cancer;
UCEC	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.61	6.94	0.5	1.14e-10	Obesity-related traits;
UCEC	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs17718580	0.609	rs59767247	chr14:51044774	C/A	cg04730355	chr14:51134070	SAV1	0.8	7.82	0.54	9.34e-13	Cognitive performance;
UCEC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg22974920	chr21:40686053	BRWD1	0.56	4.76	0.37	4.57e-6	Cognitive function;
UCEC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg22907277	chr7:1156413	C7orf50	0.6	5.56	0.42	1.22e-7	Longevity;Endometriosis;
UCEC	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.61	0.58	1.02e-14	Menopause (age at onset);
UCEC	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-12.23	-0.71	3.65e-24	Primary sclerosing cholangitis;
UCEC	cis	rs11867410	0.744	rs8067452	chr17:63946212	A/G	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs3743832	0.931	rs12443681	chr16:9181690	T/C	cg08831531	chr16:9218945	NA	-0.43	-4.57	-0.35	1.02e-5	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.75	4.78	0.37	4.27e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg08501292	chr6:25962987	TRIM38	0.92	5.0	0.38	1.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.17	14.23	0.76	1.89e-29	Body mass index;
UCEC	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.47	5.39	0.41	2.74e-7	White matter hyperintensity burden;
UCEC	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.66	-6.91	-0.5	1.37e-10	Hypospadias;
UCEC	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.52	-5.66	-0.42	7.61e-8	Blood metabolite levels;
UCEC	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.81	-8.69	-0.58	6.64e-15	Cognitive function;
UCEC	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.59	5.7	0.43	6.47e-8	Bladder cancer;
UCEC	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.78	11.31	0.68	9.94e-22	Leprosy;
UCEC	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs7246967	1.000	rs62120832	chr19:23064264	A/G	cg24889512	chr19:22816950	ZNF492	0.52	4.85	0.37	3.16e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.56	-6.25	-0.46	4.25e-9	Lung cancer;
UCEC	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg21672276	chr3:44754072	ZNF502	0.43	4.62	0.36	8.32e-6	Depressive symptoms;
UCEC	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-1.0	-10.51	-0.66	1.28e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.52	5.02	0.38	1.47e-6	Pediatric autoimmune diseases;
UCEC	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-8.0	-0.55	3.33e-13	Schizophrenia;
UCEC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.48	-4.7	-0.36	6.04e-6	Dental caries;
UCEC	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.5	5.84	0.43	3.25e-8	Longevity;
UCEC	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.5	-5.65	-0.42	8.24e-8	Longevity;
UCEC	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg02980000	chr4:1222292	CTBP1	0.63	5.27	0.4	4.71e-7	Systolic blood pressure;
UCEC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg20203395	chr5:56204925	C5orf35	0.66	5.26	0.4	5.09e-7	Initial pursuit acceleration;
UCEC	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.51	-5.01	-0.38	1.56e-6	Asthma (sex interaction);
UCEC	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	6.1	0.45	8.87e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.55	-0.69	2.35e-22	Chronic sinus infection;
UCEC	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.92	-0.44	2.13e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs77926410	0.649	rs7310149	chr12:10621215	G/T	cg25023291	chr12:11339792	TAS2R42	-0.42	-5.23	-0.4	5.61e-7	Mean corpuscular volume;
UCEC	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.57	-5.03	-0.38	1.42e-6	Metabolite levels;
UCEC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.56	5.67	0.42	7.49e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.53	-5.95	-0.44	1.87e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg22771759	chr13:24902376	NA	0.45	4.82	0.37	3.54e-6	Obesity-related traits;
UCEC	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.54	5.95	0.44	1.91e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.52	-5.65	-0.42	8.01e-8	Aortic root size;
UCEC	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.7	5.58	0.42	1.11e-7	Neutrophil percentage of white cells;
UCEC	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	20.35	0.86	1.36e-44	Chronic sinus infection;
UCEC	cis	rs7004769	0.554	rs17716095	chr8:9180023	A/G	cg27598956	chr8:9758788	LOC157627	-0.48	-4.6	-0.35	9.19e-6	Fibrinogen levels;
UCEC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.48	4.59	0.35	9.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.11	-0.51	4.74e-11	Coffee consumption (cups per day);
UCEC	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.33	-4.77	-0.37	4.38e-6	Vitamin D levels;
UCEC	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	9.16	0.6	4.03e-16	Bipolar disorder;
UCEC	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	5.03	0.38	1.42e-6	Headache;
UCEC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.38	-4.88	-0.37	2.72e-6	Dupuytren's disease;
UCEC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg11632617	chr15:75315747	PPCDC	-0.63	-7.21	-0.51	2.75e-11	Blood trace element (Zn levels);
UCEC	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.81	8.14	0.56	1.5e-13	Schizophrenia;
UCEC	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-5.26	-0.4	5.03e-7	Obesity-related traits;
UCEC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-0.61	-7.58	-0.53	3.52e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.56	-5.48	-0.41	1.83e-7	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.11	-0.45	8.63e-9	Prudent dietary pattern;
UCEC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-4.55	-0.35	1.11e-5	Monocyte count;
UCEC	cis	rs8105895	0.935	rs62112918	chr19:22227079	C/T	cg24175803	chr19:22235144	ZNF257	-0.64	-5.51	-0.41	1.59e-7	Body mass index (change over time);
UCEC	cis	rs12545109	0.732	rs1973629	chr8:57429583	A/G	cg09654669	chr8:57350985	NA	-0.48	-4.54	-0.35	1.16e-5	Obesity-related traits;
UCEC	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-0.91	-5.62	-0.42	9.23e-8	Mitochondrial DNA levels;
UCEC	cis	rs6534441	0.727	rs77517452	chr4:125457244	G/A	cg21609808	chr4:125404261	NA	0.42	4.94	0.38	2.08e-6	Major depressive disorder;
UCEC	cis	rs7766436	0.553	rs6939284	chr6:22556885	C/G	cg13666174	chr6:22585274	NA	0.45	4.55	0.35	1.13e-5	Coronary artery disease;
UCEC	cis	rs405956	0.932	rs9391266	chr6:105558047	G/A	cg22580625	chr6:105627791	POPDC3	-0.7	-6.5	-0.47	1.17e-9	QT interval;
UCEC	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.91	-0.5	1.38e-10	Coffee consumption (cups per day);
UCEC	cis	rs2136093	0.506	rs61770071	chr1:90857375	C/A	cg01786362	chr1:90274359	NA	-0.43	-4.81	-0.37	3.76e-6	Response to antidepressants;
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.67	-5.51	-0.41	1.6e-7	Platelet count;
UCEC	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.71	-6.63	-0.48	6.03e-10	Resting heart rate;
UCEC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg24375607	chr4:120327624	NA	0.48	5.17	0.39	7.64e-7	Corneal astigmatism;
UCEC	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.58	-5.9	-0.44	2.43e-8	Glomerular filtration rate;
UCEC	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	6.86	0.49	1.74e-10	Alzheimer's disease;
UCEC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.61	6.37	0.46	2.34e-9	Breast cancer;
UCEC	cis	rs797973	0.627	rs797975	chr17:27618627	C/G	cg04532153	chr17:27046900	SNORD42B;RPL23A	-0.45	-4.76	-0.37	4.58e-6	Type 2 diabetes;
UCEC	cis	rs4074536	0.796	rs12563940	chr1:116309865	T/C	cg21648376	chr1:116311395	CASQ2	-0.51	-5.08	-0.39	1.11e-6	QRS duration;
UCEC	cis	rs4908768	0.906	rs11121223	chr1:8772845	T/A	cg13081009	chr1:8430745	RERE	0.52	5.16	0.39	7.75e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6446731	0.593	rs2157090	chr4:3273110	C/T	cg08886695	chr4:3369023	RGS12	-0.44	-4.92	-0.38	2.24e-6	Mean platelet volume;
UCEC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg22857025	chr5:266934	NA	-0.91	-8.64	-0.58	8.56e-15	Breast cancer;
UCEC	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.91	5.0	0.38	1.64e-6	Inflammatory bowel disease;
UCEC	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.49	-5.12	-0.39	9.46e-7	Height;
UCEC	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.71	6.65	0.48	5.42e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.66	-6.32	-0.46	2.88e-9	Resting heart rate;
UCEC	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.57	5.46	0.41	1.99e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg05738196	chr6:26577821	NA	0.48	4.87	0.37	2.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.71	6.74	0.49	3.3e-10	Menopause (age at onset);
UCEC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.54	-6.27	-0.46	3.82e-9	Prostate cancer;
UCEC	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg08027265	chr7:2291960	NA	-0.44	-4.71	-0.36	5.64e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.71	6.45	0.47	1.48e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.5	-5.73	-0.43	5.37e-8	Parkinson's disease;
UCEC	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	8.19	0.56	1.17e-13	Neuroticism;
UCEC	cis	rs2270676	0.659	rs55940411	chr11:74181308	A/T	cg13271206	chr11:75109830	RPS3	0.77	4.8	0.37	3.82e-6	Corneal astigmatism;
UCEC	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.45	6.25	0.46	4.22e-9	Height;
UCEC	cis	rs9467773	0.901	rs10223789	chr6:26579609	C/T	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.73	-5.25	-0.4	5.13e-7	Aortic root size;
UCEC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.64	5.43	0.41	2.33e-7	Aortic root size;
UCEC	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.67	5.82	0.43	3.52e-8	Response to antineoplastic agents;
UCEC	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.72	5.84	0.43	3.24e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	8.06	0.55	2.38e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.76	10.9	0.67	1.24e-20	Monocyte percentage of white cells;
UCEC	cis	rs7336933	0.688	rs9532942	chr13:42443077	C/T	cg18400088	chr13:41634674	WBP4	0.54	4.58	0.35	1e-5	Calcium levels;
UCEC	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs12545109	0.800	rs2670028	chr8:57423673	G/A	cg09654669	chr8:57350985	NA	-0.47	-5.0	-0.38	1.59e-6	Obesity-related traits;
UCEC	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.66	5.53	0.41	1.42e-7	Systolic blood pressure;
UCEC	cis	rs139371	0.742	rs139324	chr22:39501823	C/T	cg15548613	chr22:38610795	MAFF	0.45	4.74	0.36	5.08e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.03	-8.74	-0.58	4.99e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.68	-7.14	-0.51	3.91e-11	Breast cancer;
UCEC	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.54	5.92	0.44	2.22e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9402633	0.938	rs72986475	chr6:135033083	A/G	cg16239184	chr6:135079577	NA	0.51	4.65	0.36	7.44e-6	Platelet count;
UCEC	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.57	6.04	0.45	1.19e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg00612595	chr21:47717864	NA	-0.48	-5.2	-0.39	6.53e-7	Testicular germ cell tumor;
UCEC	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.53	2.09e-12	IgG glycosylation;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg20821713	chr7:1055600	C7orf50	-0.57	-5.76	-0.43	4.83e-8	Longevity;Endometriosis;
UCEC	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.65	-5.84	-0.43	3.26e-8	Serum sulfate level;
UCEC	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.62	-6.01	-0.44	1.41e-8	Diastolic blood pressure;
UCEC	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.71	5.8	0.43	3.92e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.82	-6.61	-0.48	6.62e-10	Alzheimer's disease (late onset);
UCEC	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.21	7.45	0.52	7.56e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.59	6.76	0.49	3e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.59	4.99	0.38	1.67e-6	Huntington's disease progression;
UCEC	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg07424592	chr7:64974309	NA	0.77	4.77	0.37	4.39e-6	Diabetic kidney disease;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg13129662	chr17:48227708	PPP1R9B	0.64	6.76	0.49	3.09e-10	Triglyceride levels;
UCEC	cis	rs3736594	0.513	rs6704596	chr2:27796927	A/G	cg27432699	chr2:27873401	GPN1	0.53	5.12	0.39	9.4e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.57	5.37	0.4	3.04e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.54	5.35	0.4	3.27e-7	Colorectal cancer;
UCEC	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.73	-0.43	5.62e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg06917450	chr1:38156652	C1orf109	-0.54	-5.48	-0.41	1.78e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.68	-6.16	-0.45	6.5e-9	Response to metformin (IC50);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16627807	chr19:40596541	ZNF780A	0.6	7.59	0.53	3.34e-12	Warfarin maintenance dose;
UCEC	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg06784218	chr1:46089804	CCDC17	0.54	6.32	0.46	3e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12705054	0.520	rs10281195	chr7:98861915	C/T	cg24650262	chr7:98904301	NA	-0.48	-4.69	-0.36	6.31e-6	Facial emotion recognition (sad faces);
UCEC	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-0.81	-4.6	-0.35	9.11e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.33	-5.59	-0.42	1.07e-7	Mean corpuscular volume;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.53	-6.06	-0.45	1.08e-8	Pubertal anthropometrics;
UCEC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-6.61	-0.48	6.7e-10	Menarche (age at onset);
UCEC	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-1.07	-9.56	-0.62	3.79e-17	Dupuytren's disease;
UCEC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.52	-5.38	-0.41	2.92e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.61	6.83	0.49	2.11e-10	Pubertal anthropometrics;
UCEC	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg18973586	chr4:963968	DGKQ	0.46	4.79	0.37	4.1e-6	Obesity-related traits;
UCEC	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.76	8.21	0.56	1.03e-13	Menopause (age at onset);
UCEC	cis	rs17012589	0.869	rs35388734	chr12:85681153	T/A	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.45	-4.51	-0.35	1.33e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs308447	0.576	rs10005301	chr4:123715055	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.64	-7.66	-0.53	2.35e-12	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs7095607	0.813	rs1873111	chr10:69922446	T/C	cg18986048	chr10:69913749	MYPN	0.53	6.29	0.46	3.35e-9	Lung function (FVC);
UCEC	cis	rs7011049	0.915	rs11997706	chr8:53833202	T/G	cg26025543	chr8:53854495	NA	0.63	4.69	0.36	6.16e-6	Systolic blood pressure;
UCEC	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.52	5.39	0.41	2.69e-7	Dupuytren's disease;
UCEC	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.73	-6.93	-0.5	1.23e-10	Inflammatory bowel disease;
UCEC	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.24e-8	Systemic lupus erythematosus;
UCEC	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.59	-5.25	-0.4	5.29e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.48	5.05	0.38	1.29e-6	Longevity;Endometriosis;
UCEC	cis	rs896543	1.000	rs896543	chr2:237509207	A/G	cg25295825	chr2:237489920	CXCR7	-0.58	-7.3	-0.52	1.66e-11	Alcohol dependence (age at onset);
UCEC	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.6	4.91	0.38	2.36e-6	Menopause (age at onset);
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg09120320	chr17:61926383	NA	0.46	4.76	0.37	4.63e-6	Prudent dietary pattern;
UCEC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.41	-4.98	-0.38	1.77e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.56	0.42	1.26e-7	Hemoglobin concentration;
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg26769984	chr7:1090371	C7orf50	0.47	4.59	0.35	9.52e-6	Longevity;Endometriosis;
UCEC	cis	rs117623576	0.680	rs11008756	chr10:32363137	A/G	cg09476325	chr10:33189322	ITGB1	0.67	4.59	0.35	9.24e-6	Anti-saccade response;
UCEC	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	0.54	5.98	0.44	1.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs425277	0.958	rs17372341	chr1:2042350	G/A	cg24578937	chr1:2090814	PRKCZ	0.56	5.41	0.41	2.48e-7	Height;
UCEC	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	4.77	0.37	4.37e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.87	-0.37	2.82e-6	Coronary artery disease;
UCEC	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.65	-5.23	-0.4	5.76e-7	Corneal astigmatism;
UCEC	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.35	-4.87	-0.37	2.9e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg24562669	chr7:97807699	LMTK2	0.4	4.93	0.38	2.19e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4499344	0.730	rs7246338	chr19:33099504	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.08	0.45	9.82e-9	Mean platelet volume;
UCEC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	0.72	4.71	0.36	5.66e-6	Diabetic retinopathy;
UCEC	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.4	-0.47	1.93e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg21419209	chr3:44054225	NA	-0.53	-5.47	-0.41	1.9e-7	Coronary artery disease;
UCEC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-4.7	-0.36	5.94e-6	Blood metabolite levels;
UCEC	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.17	0.39	7.68e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.6	6.76	0.49	3.06e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.72	-7.23	-0.51	2.51e-11	Aortic root size;
UCEC	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	-0.59	-6.74	-0.49	3.32e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-5.77	-0.43	4.55e-8	Monocyte percentage of white cells;
UCEC	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.43	-4.85	-0.37	3.05e-6	Prostate cancer;
UCEC	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.59	5.9	0.44	2.44e-8	Colorectal cancer;
UCEC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg07387570	chr22:46663686	TTC38	-0.47	-4.62	-0.36	8.32e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg24851651	chr11:66362959	CCS	-0.46	-5.39	-0.41	2.79e-7	Educational attainment (years of education);
UCEC	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg07386859	chr16:1872102	HAGH	-0.46	-4.93	-0.38	2.23e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs6032067	0.929	rs55726011	chr20:43855229	C/T	cg00873616	chr20:43920241	NA	0.52	5.21	0.39	6.37e-7	Blood protein levels;
UCEC	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.67	6.82	0.49	2.17e-10	Multiple sclerosis;
UCEC	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.66	-6.81	-0.49	2.37e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.72	-0.43	5.78e-8	Parkinson's disease;
UCEC	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg06096015	chr1:231504339	EGLN1	0.42	4.59	0.35	9.32e-6	Hemoglobin concentration;
UCEC	cis	rs308403	0.533	rs12644866	chr4:123667604	T/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	8.7	0.58	6.12e-15	Blood protein levels;
UCEC	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.51	4.91	0.38	2.35e-6	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg13147721	chr7:65941812	NA	0.87	6.66	0.48	5.2e-10	Diabetic kidney disease;
UCEC	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.68	0.36	6.5e-6	Monocyte percentage of white cells;
UCEC	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06508976	chr9:131940586	IER5L	0.62	7.7	0.54	1.79e-12	Warfarin maintenance dose;
UCEC	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.7	7.08	0.5	5.59e-11	Primary sclerosing cholangitis;
UCEC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-4.58	-0.35	9.96e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.36	4.52	0.35	1.29e-5	Obesity-related traits;
UCEC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	6.37	0.47	2.3e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.19e-14	Prudent dietary pattern;
UCEC	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.6	-6.13	-0.45	7.73e-9	Breast size;
UCEC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.7	9.13	0.6	5.05e-16	Rheumatoid arthritis;
UCEC	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.62	6.56	0.48	8.8e-10	Colorectal cancer;
UCEC	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.67	-0.36	6.75e-6	Response to antipsychotic treatment;
UCEC	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.76	7.36	0.52	1.18e-11	Menopause (age at onset);
UCEC	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-7.23	-0.51	2.4e-11	Blood trace element (Cu levels);
UCEC	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.56	-0.42	1.21e-7	Systolic blood pressure;
UCEC	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-6.37	-0.46	2.33e-9	Crohn's disease;
UCEC	cis	rs970548	0.954	rs11239571	chr10:46087892	A/G	cg15223267	chr10:46222474	FAM21C	-0.57	-5.28	-0.4	4.49e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs3914502	0.530	rs476190	chr3:174477549	G/A	cg21145449	chr3:174580620	NAALADL2	-0.4	-4.56	-0.35	1.07e-5	Autism spectrum disorder;
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.51	-4.94	-0.38	2.11e-6	Height;
UCEC	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.63	7.1	0.51	4.87e-11	Menarche (age at onset);
UCEC	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	6.03	0.45	1.29e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.5	5.7	0.43	6.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16369786	chr1:63153804	DOCK7	0.57	6.72	0.48	3.83e-10	Warfarin maintenance dose;
UCEC	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg21419209	chr3:44054225	NA	-0.51	-5.26	-0.4	5.02e-7	Coronary artery disease;
UCEC	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.96	10.01	0.64	2.59e-18	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	6.97	0.5	9.86e-11	Chronic sinus infection;
UCEC	cis	rs17123764	0.710	rs4584654	chr12:50103546	C/T	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.46	-4.54	-0.35	1.15e-5	Mortality in heart failure;
UCEC	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	4.82	0.37	3.61e-6	Alzheimer's disease (late onset);
UCEC	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.5	5.38	0.41	2.89e-7	Total body bone mineral density;
UCEC	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.72	-8.81	-0.59	3.28e-15	Prevalent atrial fibrillation;
UCEC	cis	rs7246967	0.736	rs446058	chr19:23000061	G/A	cg05241461	chr19:22816980	ZNF492	0.52	5.06	0.39	1.24e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs16912285	0.535	rs7109619	chr11:24251339	G/A	ch.11.24196551F	chr11:24239977	NA	0.54	5.38	0.41	2.9e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg23307798	chr14:103986281	CKB	0.65	7.86	0.54	7.4e-13	Body mass index;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg00651523	chr6:28411279	ZSCAN23	0.42	4.71	0.36	5.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15309264	chr2:58274034	VRK2	0.6	7.18	0.51	3.25e-11	Warfarin maintenance dose;
UCEC	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg21191810	chr6:118973309	C6orf204	0.39	5.33	0.4	3.65e-7	Electrocardiographic conduction measures;
UCEC	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	7.51	0.53	5.17e-12	Alzheimer's disease;
UCEC	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.63	5.17	0.39	7.69e-7	Height;
UCEC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.87	13.16	0.74	1.28e-26	Birth weight;
UCEC	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	8.15	0.56	1.46e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.01	-0.38	1.54e-6	Pediatric autoimmune diseases;
UCEC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs749052	0.561	rs3116189	chr2:233048622	T/G	cg23548455	chr2:233377587	NA	-0.72	-4.65	-0.36	7.45e-6	Height;
UCEC	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.64	6.0	0.44	1.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8105895	1.000	rs8104559	chr19:22205167	T/C	cg20662725	chr19:22235022	ZNF257	-0.52	-4.66	-0.36	6.99e-6	Body mass index (change over time);
UCEC	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.45	-6.49	-0.47	1.21e-9	Ulcerative colitis;
UCEC	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg24910161	chr17:38119198	GSDMA	-0.33	-4.72	-0.36	5.55e-6	Self-reported allergy;
UCEC	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.58	4.6	0.35	9.16e-6	Schizophrenia;
UCEC	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.04e-14	Menarche (age at onset);
UCEC	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.82	10.03	0.64	2.36e-18	Metabolic syndrome;
UCEC	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.66	-5.52	-0.41	1.46e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.56	-4.64	-0.36	7.6e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.67	7.51	0.53	5.22e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.52	4.81	0.37	3.76e-6	Alzheimer's disease;
UCEC	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.2e-6	Uric acid levels;
UCEC	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg23793686	chr15:68133972	NA	-0.42	-4.53	-0.35	1.19e-5	Restless legs syndrome;
UCEC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg05072774	chr3:49840536	C3orf54	-0.53	-5.39	-0.41	2.78e-7	Resting heart rate;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg16763192	chr16:12897684	CPPED1	-0.71	-4.94	-0.38	2.11e-6	Testicular germ cell tumor;
UCEC	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg00266579	chr16:28619858	SULT1A1	0.63	4.66	0.36	6.98e-6	Platelet distribution width;
UCEC	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	4.53	0.35	1.23e-5	Response to antipsychotic treatment;
UCEC	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.59	5.59	0.42	1.06e-7	Cognitive test performance;
UCEC	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.48	5.56	0.42	1.24e-7	Aortic root size;
UCEC	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-7.32	-0.52	1.46e-11	Neuroticism;
UCEC	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg03342759	chr3:160939853	NMD3	-0.5	-4.84	-0.37	3.23e-6	Educational attainment (years of education);
UCEC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.7	9.01	0.6	1.02e-15	Vitiligo;
UCEC	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18932078	chr1:2524107	MMEL1	0.33	5.43	0.41	2.32e-7	Ulcerative colitis;
UCEC	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.72	0.48	3.68e-10	Coffee consumption (cups per day);
UCEC	cis	rs1912528	0.783	rs6536588	chr4:140862671	C/T	cg01641771	chr4:140476319	SETD7	-0.42	-4.83	-0.37	3.45e-6	Educational attainment (years of education);
UCEC	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg18681998	chr4:17616180	MED28	0.77	9.33	0.61	1.52e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18932078	chr1:2524107	MMEL1	0.39	6.33	0.46	2.81e-9	Ulcerative colitis;
UCEC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.52	4.97	0.38	1.85e-6	Alcohol dependence;
UCEC	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg20119798	chr7:94954144	PON1	-0.5	-4.75	-0.36	4.77e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18252515	chr7:66147081	NA	0.59	5.52	0.41	1.52e-7	Aortic root size;
UCEC	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.74	-0.43	5.29e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.69	7.47	0.52	6.43e-12	Cognitive test performance;
UCEC	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.24	-0.4	5.56e-7	Breast cancer;
UCEC	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg18827107	chr12:86230957	RASSF9	-0.44	-4.73	-0.36	5.29e-6	Major depressive disorder;
UCEC	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg27124370	chr19:33622961	WDR88	0.54	4.8	0.37	3.78e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2425143	0.908	rs12480111	chr20:34423186	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.76	-0.37	4.59e-6	Blood protein levels;
UCEC	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-4.57	-0.35	1.02e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.56	-4.89	-0.37	2.57e-6	Major depressive disorder;
UCEC	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.08	-0.39	1.11e-6	Colorectal cancer;
UCEC	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.54	5.72	0.43	5.86e-8	Red blood cell count;
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.65	-5.01	-0.38	1.54e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg11569703	chr11:65557185	OVOL1	-0.46	-6.56	-0.48	8.6e-10	Acne (severe);
UCEC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.71	-7.0	-0.5	8.61e-11	Acne (severe);
UCEC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.63	-6.26	-0.46	4.04e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg09120320	chr17:61926383	NA	0.42	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.68	6.5	0.47	1.19e-9	Crohn's disease;
UCEC	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.92e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg21100191	chr22:23484243	RTDR1	0.72	7.94	0.55	4.75e-13	Bone mineral density;
UCEC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.45	-5.35	-0.4	3.31e-7	Body mass index;
UCEC	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg05527609	chr1:210001259	C1orf107	-0.53	-4.98	-0.38	1.76e-6	Red blood cell count;
UCEC	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.39e-7	Aortic root size;
UCEC	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.66	6.66	0.48	5.1e-10	Breast cancer;
UCEC	cis	rs17123764	0.605	rs7967624	chr12:50159519	A/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.02	0.38	1.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11867410	0.744	rs73349030	chr17:63929638	G/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.24	-0.4	5.47e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg24375607	chr4:120327624	NA	0.48	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.77	9.65	0.62	2.25e-17	Bipolar disorder and schizophrenia;
UCEC	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs4372836	1.000	rs4666119	chr2:28975690	C/G	cg09522027	chr2:28974177	PPP1CB	-0.76	-8.01	-0.55	3.23e-13	Body mass index;
UCEC	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg17294928	chr15:75287854	SCAMP5	-0.47	-4.52	-0.35	1.26e-5	Lung cancer;
UCEC	cis	rs883565	0.528	rs4428122	chr3:38972603	C/A	cg01426195	chr3:39028469	NA	0.58	6.86	0.49	1.76e-10	Handedness;
UCEC	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg06166341	chr4:1223170	CTBP1	0.47	4.81	0.37	3.76e-6	Systolic blood pressure;
UCEC	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1483890	0.723	rs900670	chr3:69406781	G/A	cg22125112	chr3:69402811	FRMD4B	0.44	4.69	0.36	6.18e-6	Resting heart rate;
UCEC	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.74	0.36	5.09e-6	Diabetic retinopathy;
UCEC	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg17469321	chr7:55412551	NA	0.68	5.6	0.42	1.01e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.82	8.93	0.59	1.65e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs12663883	chr6:26577326	C/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg05501817	chr11:14380813	RRAS2	-0.52	-4.92	-0.38	2.34e-6	Sense of smell;
UCEC	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.56	5.52	0.41	1.47e-7	Vitiligo;
UCEC	cis	rs7766436	0.885	rs6935379	chr6:22581462	A/G	cg13666174	chr6:22585274	NA	-0.52	-5.46	-0.41	2e-7	Coronary artery disease;
UCEC	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg00343986	chr7:65444356	GUSB	-0.52	-4.93	-0.38	2.21e-6	Aortic root size;
UCEC	cis	rs4345220	0.585	rs4861126	chr4:41643057	C/G	cg15232654	chr4:41643107	LIMCH1	0.48	5.33	0.4	3.55e-7	Migraine with aura;
UCEC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-13.38	-0.74	3.33e-27	Height;
UCEC	cis	rs6460942	1.000	rs117657017	chr7:12318891	T/C	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.71	7.24	0.51	2.38e-11	Height;
UCEC	cis	rs9463078	0.547	rs1342370	chr6:44747732	A/G	cg25276700	chr6:44698697	NA	-0.38	-4.57	-0.35	1.01e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg01831904	chr17:28903510	LRRC37B2	0.44	4.6	0.35	9.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00815214	chr21:47717953	NA	-0.49	-5.36	-0.4	3.16e-7	Testicular germ cell tumor;
UCEC	cis	rs4950937	0.750	rs946257	chr1:203189908	C/G	cg20961782	chr1:203452697	PRELP	0.52	5.0	0.38	1.63e-6	Blood protein levels;
UCEC	cis	rs7165102	1.000	rs10431765	chr15:66044551	G/A	cg11164506	chr15:66649558	TIPIN	-0.33	-4.67	-0.36	6.63e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs8105895	0.935	rs7252380	chr19:22245715	G/A	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.06e-7	Body mass index (change over time);
UCEC	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg22868518	chr11:507468	RNH1	-0.47	-4.53	-0.35	1.19e-5	Systemic lupus erythematosus;
UCEC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg16497661	chr14:103986332	CKB	0.48	5.55	0.42	1.27e-7	Body mass index;
UCEC	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-1.0	-12.22	-0.71	3.78e-24	Obesity-related traits;
UCEC	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.0	8.12	0.56	1.7e-13	Exhaled nitric oxide output;
UCEC	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.67	6.51	0.47	1.1e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.49	6.48	0.47	1.29e-9	Bone mineral density;
UCEC	cis	rs2283228	0.867	rs2237892	chr11:2839751	C/T	cg23617121	chr11:3121460	OSBPL5	0.64	4.7	0.36	6.01e-6	Type 2 diabetes;
UCEC	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.66	-4.86	-0.37	2.95e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.73	0.36	5.16e-6	Diabetic retinopathy;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.39	-0.41	2.7e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.49	4.53	0.35	1.2e-5	Height;
UCEC	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.58	5.34	0.4	3.46e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.81	0.49	2.29e-10	Bipolar disorder;
UCEC	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.64	-6.95	-0.5	1.1e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.64	6.35	0.46	2.57e-9	Mean corpuscular volume;
UCEC	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.95	0.38	2.01e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2415984	0.846	rs8014836	chr14:46839015	T/C	cg14871534	chr14:47121158	RPL10L	0.4	4.62	0.36	8.23e-6	Number of children ever born;
UCEC	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg11569703	chr11:65557185	OVOL1	0.54	6.81	0.49	2.37e-10	Acne (severe);
UCEC	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.5	4.74	0.36	4.9100000000000004e-06	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.46e-16	Height;
UCEC	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg20203395	chr5:56204925	C5orf35	-0.55	-5.11	-0.39	9.85e-7	Coronary artery disease;
UCEC	cis	rs7246967	0.866	rs35177997	chr19:23060227	T/C	cg08271804	chr19:22816896	ZNF492	0.54	5.02	0.38	1.48e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	0.87	5.38	0.41	2.81e-7	Skin colour saturation;
UCEC	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.59	-5.76	-0.43	4.83e-8	Platelet count;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.67	-0.42	7.46e-8	Breast cancer;
UCEC	cis	rs4789294	0.806	rs9896887	chr17:74444059	G/A	cg06840243	chr17:74442338	UBE2O	0.4	4.53	0.35	1.2e-5	Lymphocyte percentage of white cells;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.81	8.05	0.55	2.64e-13	Longevity;Endometriosis;
UCEC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.56	-4.62	-0.36	8.46e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.79	-9.06	-0.6	7.44e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg11477892	chr4:106580295	NA	-0.44	-4.64	-0.36	7.59e-6	Post bronchodilator FEV1;
UCEC	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.34e-8	Lung cancer;
UCEC	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.55	-5.76	-0.43	4.78e-8	Blood metabolite levels;
UCEC	cis	rs11867410	0.744	rs8069807	chr17:63950056	A/G	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.77	8.85	0.59	2.49e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.54	-6.14	-0.45	7.38e-9	Pulmonary function;
UCEC	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-0.99	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.64	7.14	0.51	4.06e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-11.27	-0.68	1.25e-21	Vitiligo;
UCEC	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.52	-0.47	1.05e-9	Total cholesterol levels;
UCEC	cis	rs13253111	0.624	rs28372101	chr8:28099384	G/T	cg26534493	chr8:28060551	NA	0.48	5.3	0.4	4.14e-7	Childhood body mass index;
UCEC	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.6	-0.48	7.12e-10	Eye color traits;
UCEC	cis	rs56804039	0.524	rs66989459	chr8:8367911	C/G	cg09615915	chr8:7625446	FAM90A10	-0.38	-4.5	-0.35	1.35e-5	Cervical cancer;
UCEC	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.64	-6.36	-0.46	2.35e-9	Morning vs. evening chronotype;
UCEC	cis	rs10924970	0.967	rs1933251	chr1:235451172	G/T	cg26050004	chr1:235667680	B3GALNT2	0.46	4.81	0.37	3.69e-6	Asthma;
UCEC	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.12e-7	Life satisfaction;
UCEC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.61	-5.6	-0.42	1.02e-7	Selective IgA deficiency;
UCEC	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.69	7.61	0.53	2.97e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.68	6.77	0.49	2.88e-10	Neurofibrillary tangles;
UCEC	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.69	-7.49	-0.53	5.9e-12	Eye color traits;
UCEC	cis	rs16944613	0.588	rs8042497	chr15:91110331	T/A	cg08919649	chr15:91565780	VPS33B	0.74	4.93	0.38	2.17e-6	Colorectal cancer;
UCEC	trans	rs7243110	0.954	rs4142939	chr18:52520149	C/G	cg22094205	chr11:74109076	PGM2L1	0.68	6.76	0.49	2.96e-10	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	0.99	8.77	0.59	4.15e-15	Vitiligo;
UCEC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.13	18.33	0.83	8.57e-40	Testicular germ cell tumor;
UCEC	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.61	5.7	0.43	6.37e-8	Type 2 diabetes;
UCEC	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.59	5.43	0.41	2.27e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.27	15.25	0.78	4.31e-32	Corneal structure;
UCEC	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.61	-4.8	-0.37	3.89e-6	Autism;
UCEC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.51	5.51	0.41	1.54e-7	Ulcerative colitis;
UCEC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.2	0.39	6.6e-7	Breast cancer;
UCEC	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.84	4.9	0.37	2.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.58	5.02	0.38	1.44e-6	Longevity;
UCEC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.47	5.28	0.4	4.52e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4372836	1.000	rs11690423	chr2:28951537	G/C	cg09522027	chr2:28974177	PPP1CB	0.79	8.15	0.56	1.5e-13	Body mass index;
UCEC	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.07	-0.39	1.17e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.02	-7.03	-0.5	7.09e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	12.06	0.71	1.01e-23	Prudent dietary pattern;
UCEC	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.63	6.13	0.45	7.57e-9	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.51	5.5	0.41	1.64e-7	Alcohol dependence;
UCEC	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.62	4.55	0.35	1.12e-5	Fibroblast growth factor basic levels;
UCEC	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	5.08	0.39	1.12e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg01874867	chr7:94954059	PON1	-0.54	-5.0	-0.38	1.63e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs3736594	0.643	rs2384655	chr2:27952235	A/T	cg27432699	chr2:27873401	GPN1	-0.53	-6.11	-0.45	8.39e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.37	4.75	0.36	4.79e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.84	-0.43	3.17e-8	Pubertal anthropometrics;
UCEC	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Lung disease severity in cystic fibrosis;
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs41271951	0.512	rs41266632	chr1:151042980	C/T	cg00107782	chr1:151300621	NA	-0.7	-4.75	-0.36	4.81e-6	Blood protein levels;
UCEC	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.2	0.56	1.12e-13	Smoking behavior;
UCEC	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg06521331	chr12:34319734	NA	-0.62	-4.94	-0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.63	-6.51	-0.47	1.14e-9	Metabolic syndrome;
UCEC	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.52	4.84	0.37	3.2e-6	Platelet count;
UCEC	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.63	-7.35	-0.52	1.29e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-6.32	-0.46	2.91e-9	Metabolite levels;
UCEC	trans	rs11917787	0.571	rs3934035	chr3:306714	C/T	cg05703009	chr11:5841688	OR52N2	0.7	6.7	0.48	4.04e-10	QT interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs35934224	0.843	rs1139795	chr22:19867771	C/T	cg11182965	chr22:19864308	TXNRD2	-0.41	-5.23	-0.4	5.68e-7	Glaucoma (primary open-angle);
UCEC	cis	rs7818345	1.000	rs4392916	chr8:19309355	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.49	4.78	0.37	4.28e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.48	5.44	0.41	2.16e-7	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.67	-6.03	-0.45	1.28e-8	Systolic blood pressure;
UCEC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-4.54	-0.35	1.15e-5	Aortic root size;
UCEC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23978390	chr7:1156363	C7orf50	0.68	7.21	0.51	2.68e-11	Longevity;Endometriosis;
UCEC	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-4.63	-0.36	8e-6	Coronary artery disease;
UCEC	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.63	-5.93	-0.44	2.09e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9469578	1.000	rs9469580	chr6:33715837	A/G	cg18708504	chr6:33715942	IP6K3	-0.52	-5.16	-0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg19678392	chr7:94953810	PON1	-0.56	-5.18	-0.39	7.32e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.98	-0.44	1.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.88e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.54	-6.11	-0.45	8.64e-9	Electroencephalogram traits;
UCEC	cis	rs7709377	0.595	rs173813	chr5:115632671	A/C	cg23108291	chr5:115420582	COMMD10	-0.44	-4.5	-0.35	1.36e-5	Metabolite levels  (X-11787);
UCEC	cis	rs76419734	1.000	rs28488297	chr4:106767226	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.54	4.58	0.35	9.85e-6	Post bronchodilator FEV1;
UCEC	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.62	-5.44	-0.41	2.22e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.14	19.25	0.85	5.06e-42	Schizophrenia;
UCEC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	6.88	0.49	1.64e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.65	7.18	0.51	3.2e-11	Homoarginine levels;
UCEC	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.09	-0.39	1.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.48	-0.41	1.84e-7	Platelet count;
UCEC	cis	rs9879864	0.746	rs6782394	chr3:107399129	A/G	cg14141331	chr3:107646658	LOC285205	0.58	4.9	0.37	2.47e-6	Measles;
UCEC	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg23950597	chr19:37808831	NA	-0.68	-5.27	-0.4	4.75e-7	Coronary artery calcification;
UCEC	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.21	-0.56	1.01e-13	Coronary artery disease;
UCEC	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg05991184	chr2:219186017	PNKD	0.49	5.56	0.42	1.24e-7	Colorectal cancer;
UCEC	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.02	7.23	0.51	2.45e-11	Gut microbiome composition (summer);
UCEC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.04	7.05	0.5	6.61e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg05962950	chr11:130786565	SNX19	0.45	4.58	0.35	9.76e-6	Schizophrenia;
UCEC	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.48	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.61	6.39	0.47	2.05e-9	QRS complex (12-leadsum);
UCEC	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg16797656	chr11:68205561	LRP5	0.46	5.44	0.41	2.21e-7	Total body bone mineral density;
UCEC	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	1.1	13.39	0.74	3.13e-27	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.79	8.25	0.56	8.06e-14	Prudent dietary pattern;
UCEC	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	5.2	0.39	6.68e-7	Menarche (age at onset);
UCEC	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.51	-5.12	-0.39	9.34e-7	Total body bone mineral density;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg04871131	chr7:94954202	PON1	-0.52	-4.76	-0.37	4.67e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.63	7.04	0.5	6.65e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.57	5.05	0.38	1.27e-6	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.73	0.36	5.27e-6	Menopause (age at onset);
UCEC	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.71	7.82	0.54	9.23e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.55	-4.93	-0.38	2.24e-6	Colorectal cancer;
UCEC	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.53	-5.3	-0.4	4.1e-7	Schizophrenia;
UCEC	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18932078	chr1:2524107	MMEL1	-0.39	-6.5	-0.47	1.17e-9	Ulcerative colitis;
UCEC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.66	-7.75	-0.54	1.42e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs7246967	0.551	rs34897132	chr19:22826891	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.63	5.58	0.42	1.14e-7	Ulcerative colitis;
UCEC	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.64	7.24	0.51	2.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg13926569	chr10:89418898	PAPSS2	0.59	7.15	0.51	3.84e-11	Magnesium levels;
UCEC	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg22598563	chr5:131563921	P4HA2	0.34	4.56	0.35	1.09e-5	Blood metabolite levels;
UCEC	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.79	6.77	0.49	2.89e-10	Gastritis;
UCEC	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.74	-0.75	3.67e-28	Schizophrenia;
UCEC	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg23625390	chr15:77176239	SCAPER	0.45	4.66	0.36	6.9e-6	Blood metabolite levels;
UCEC	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.65	5.28	0.4	4.47e-7	Corneal astigmatism;
UCEC	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.04	7.99	0.55	3.62e-13	Vitiligo;
UCEC	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.89	-0.49	1.55e-10	Neuroticism;
UCEC	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg06238570	chr21:40685208	BRWD1	0.53	5.53	0.41	1.44e-7	Cognitive function;
UCEC	cis	rs11760485	1.000	rs11760485	chr7:4401550	C/T	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Morning vs. evening chronotype;
UCEC	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.7	0.36	6.01e-6	Tonsillectomy;
UCEC	cis	rs11910985	0.546	rs113970410	chr21:48080896	C/G	cg23283320	chr21:48055893	PRMT2	1.65	7.68	0.54	2.04e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg22974920	chr21:40686053	BRWD1	0.59	4.77	0.37	4.46e-6	Cognitive function;
UCEC	cis	rs9039	1.000	rs11862745	chr16:9218887	C/T	cg08831531	chr16:9218945	NA	0.46	5.13	0.39	8.97e-7	Menopause (age at onset);
UCEC	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.41	6.0	0.44	1.45e-8	Rheumatoid arthritis;
UCEC	cis	rs7246967	0.673	rs4932784	chr19:22874251	A/C	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.51	-6.24	-0.46	4.53e-9	Menarche (age at onset);
UCEC	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg05802129	chr4:122689817	NA	-0.56	-5.75	-0.43	4.99e-8	Type 2 diabetes;
UCEC	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.54	6.24	0.46	4.51e-9	Sjögren's syndrome;
UCEC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.47	4.56	0.35	1.06e-5	Menopause (age at onset);
UCEC	cis	rs12644436	0.896	rs12650750	chr4:88785547	G/C	cg27179352	chr4:88029472	AFF1	0.41	4.51	0.35	1.32e-5	HIV-1 viral setpoint;
UCEC	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.74e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.77	4.73	0.36	5.29e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg18681998	chr4:17616180	MED28	0.81	10.14	0.64	1.18e-18	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.73	-6.57	-0.48	8.29e-10	Lymphocyte percentage of white cells;
UCEC	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.26	0.56	7.97e-14	Chronic sinus infection;
UCEC	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.82	8.04	0.55	2.71e-13	Blood protein levels;
UCEC	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.57	4.76	0.37	4.63e-6	Obesity-related traits;
UCEC	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7212590	0.581	rs8081710	chr17:57838040	G/A	cg10252138	chr17:58120427	NA	-0.67	-4.59	-0.35	9.5e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13683864	chr3:40499215	RPL14	-0.94	-9.66	-0.62	2.17e-17	Renal cell carcinoma;
UCEC	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.07	-15.49	-0.79	1.03e-32	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	4.54	0.35	1.15e-5	Cognitive test performance;
UCEC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.73	8.95	0.59	1.44e-15	Headache;
UCEC	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.59	5.5	0.41	1.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg24163568	chr5:669837	TPPP	0.42	5.32	0.4	3.77e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs11264213	0.515	rs9660657	chr1:36548941	C/T	cg27506609	chr1:36549197	TEKT2	-0.63	-6.47	-0.47	1.38e-9	Schizophrenia;
UCEC	cis	rs9715521	0.775	rs12646141	chr4:59846130	G/C	cg11281224	chr4:60001000	NA	-0.61	-5.88	-0.44	2.71e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg20490015	chr17:62336680	TEX2	0.47	4.81	0.37	3.7e-6	Prudent dietary pattern;
UCEC	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg05527609	chr1:210001259	C1orf107	-0.52	-4.83	-0.37	3.46e-6	Red blood cell count;
UCEC	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.69	6.62	0.48	6.39e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.7	-0.36	5.85e-6	Type 2 diabetes;
UCEC	cis	rs7246967	0.608	rs433579	chr19:23003127	T/C	cg24889512	chr19:22816950	ZNF492	0.49	4.72	0.36	5.53e-6	Bronchopulmonary dysplasia;
UCEC	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.05	9.13	0.6	4.84e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg20965017	chr5:231967	SDHA	-0.6	-5.15	-0.39	8.32e-7	Breast cancer;
UCEC	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg23995753	chr2:160760732	LY75	-0.39	-4.65	-0.36	7.32e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs8177876	0.822	rs8056972	chr16:81112422	C/A	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.87	5.56	0.42	1.24e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.52	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	5.71	0.43	6.08e-8	Bipolar disorder;
UCEC	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.6	-5.95	-0.44	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs151997	0.962	rs27273	chr5:50181074	G/A	cg06027927	chr5:50259733	NA	0.53	4.86	0.37	3.01e-6	Callous-unemotional behaviour;
UCEC	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	5.81	0.43	3.75e-8	LDL cholesterol;
UCEC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.62	6.2	0.46	5.49e-9	Cognitive function;
UCEC	cis	rs6832769	1.000	rs4864998	chr4:56332606	A/G	cg05960024	chr4:56376020	CLOCK	0.49	4.51	0.35	1.34e-5	Personality dimensions;
UCEC	cis	rs59918340	0.738	rs7007986	chr8:142217115	G/A	cg11945507	chr8:142233382	SLC45A4	-0.43	-4.65	-0.36	7.36e-6	Immature fraction of reticulocytes;
UCEC	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-11.7	-0.69	9.29e-23	Coronary artery disease;
UCEC	cis	rs10924970	0.967	rs10754589	chr1:235439755	T/C	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.74e-6	Asthma;
UCEC	cis	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.56	5.08	0.39	1.14e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg14078730	chr11:63896557	MACROD1	0.65	5.06	0.39	1.22e-6	Mean platelet volume;
UCEC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.5	6.77	0.49	2.85e-10	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	0.88	12.62	0.72	3.26e-25	Leprosy;
UCEC	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.66	-4.79	-0.37	4.08e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7709377	0.620	rs13180407	chr5:115478988	T/C	cg23108291	chr5:115420582	COMMD10	0.53	5.47	0.41	1.9e-7	Metabolite levels  (X-11787);
UCEC	cis	rs7113850	0.541	rs78363992	chr11:24232126	C/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.91	8.31	0.57	5.68e-14	Bladder cancer;
UCEC	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.29	-0.46	3.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.47	-5.46	-0.41	2e-7	Lung cancer;
UCEC	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.5	6.37	0.46	2.34e-9	Cystic fibrosis severity;
UCEC	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg19318889	chr4:1322082	MAEA	0.41	5.01	0.38	1.55e-6	Obesity-related traits;
UCEC	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	5.9	0.44	2.46e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.95	-0.44	1.89e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.81	10.96	0.67	8.39e-21	Headache;
UCEC	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg23939001	chr4:940644	TMEM175	0.54	6.05	0.45	1.15e-8	Sjögren's syndrome;
UCEC	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-0.73	-4.81	-0.37	3.78e-6	Diabetic retinopathy;
UCEC	cis	rs9672608	1.000	rs9672608	chr15:78797463	T/A	cg24631222	chr15:78858424	CHRNA5	0.76	6.7	0.48	4.08e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-4.56	-0.35	1.08e-5	Gut microbiome composition (summer);
UCEC	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	7.93e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.55	5.35	0.4	3.3e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.51	-7.14	-0.51	3.93e-11	Refractive error;
UCEC	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-5.53	-0.41	1.43e-7	Height;
UCEC	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.49	5.6	0.42	1.04e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.23	0.4	5.62e-7	Electroencephalogram traits;
UCEC	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.27	9.33	0.61	1.53e-16	Uric acid levels;
UCEC	cis	rs4706831	0.647	rs627240	chr6:80985885	C/A	cg08355045	chr6:80787529	NA	-0.33	-4.52	-0.35	1.28e-5	Joint mobility (Beighton score);
UCEC	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.99	0.38	1.69e-6	Rheumatoid arthritis;
UCEC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.6	6.16	0.45	6.58e-9	Diastolic blood pressure;
UCEC	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs10506710	0.791	rs7961559	chr12:73442724	T/C	cg13663218	chr12:72666976	LOC283392;TRHDE	-0.33	-4.85	-0.37	3.08e-6	Systolic blood pressure;
UCEC	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.63	6.92	0.5	1.28e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.89	-7.45	-0.52	7.26e-12	Coronary artery calcification;
UCEC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg01874867	chr7:94954059	PON1	-0.52	-4.64	-0.36	7.64e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg14008862	chr17:28927542	LRRC37B2	-0.7	-4.73	-0.36	5.12e-6	Body mass index;
UCEC	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.48	5.13	0.39	8.95e-7	Pulse pressure;
UCEC	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg23018236	chr17:30244563	NA	-0.78	-5.95	-0.44	1.91e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg00977110	chr5:151150581	G3BP1	0.55	4.6	0.35	8.92e-6	Preschool internalizing problems;
UCEC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.6	4.62	0.36	8.48e-6	Corneal astigmatism;
UCEC	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.61	6.01	0.44	1.38e-8	Lung cancer;
UCEC	cis	rs7095607	1.000	rs4745948	chr10:69937987	G/A	cg18986048	chr10:69913749	MYPN	0.42	4.53	0.35	1.19e-5	Lung function (FVC);
UCEC	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.91	-9.9	-0.63	5.07e-18	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6761276	0.899	rs6759676	chr2:113836348	A/G	cg09040174	chr2:113837401	NA	-0.51	-5.66	-0.42	7.79e-8	Protein quantitative trait loci;
UCEC	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg23793686	chr15:68133972	NA	-0.36	-4.7	-0.36	5.9e-6	Restless legs syndrome;
UCEC	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.7	4.8	0.37	3.88e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg24562669	chr7:97807699	LMTK2	-0.44	-5.23	-0.4	5.8e-7	Breast cancer;
UCEC	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg23625390	chr15:77176239	SCAPER	0.5	4.95	0.38	1.98e-6	Blood metabolite levels;
UCEC	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-0.59	-6.92	-0.5	1.27e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.5	-4.54	-0.35	1.18e-5	Diabetic retinopathy;
UCEC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg13147721	chr7:65941812	NA	0.95	5.56	0.42	1.23e-7	Diabetic kidney disease;
UCEC	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.63	-5.41	-0.41	2.51e-7	Longevity;
UCEC	cis	rs78487399	0.808	rs17030946	chr2:43733509	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-4.98	-0.38	1.8e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.69	6.17	0.45	6.29e-9	Aortic root size;
UCEC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.63	-6.35	-0.46	2.55e-9	Blood metabolite levels;
UCEC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs151997	0.962	rs152687	chr5:50208563	A/G	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.86	7.67	0.53	2.19e-12	Dupuytren's disease;
UCEC	cis	rs13063635	0.915	rs1994491	chr3:45960420	G/C	cg16320329	chr3:45981161	FYCO1	-0.83	-4.76	-0.37	4.5e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.51	5.02	0.38	1.49e-6	Longevity;
UCEC	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.59	-6.51	-0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.36	6.17	0.45	6.3e-9	Cancer;
UCEC	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg24851651	chr11:66362959	CCS	-0.44	-5.41	-0.41	2.51e-7	Educational attainment (years of education);
UCEC	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.44	4.55	0.35	1.11e-5	Endometrial cancer;
UCEC	cis	rs9868873	0.915	rs7626808	chr3:122736795	A/G	cg02041593	chr3:122741233	SEMA5B	0.5	5.23	0.4	5.72e-7	Esophageal cancer;
UCEC	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-12.4	-0.71	1.29e-24	Ulcerative colitis;
UCEC	cis	rs2882667	0.756	rs11957953	chr5:138479377	G/T	cg04439458	chr5:138467593	SIL1	-0.45	-5.04	-0.38	1.36e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.58	5.92	0.44	2.18e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.84	-0.37	3.23e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg06410510	chr2:107458059	ST6GAL2	-0.75	-6.89	-0.49	1.53e-10	Prostate cancer;
UCEC	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg17085576	chr10:5658249	NA	-0.51	-5.05	-0.38	1.29e-6	Breast cancer;
UCEC	cis	rs3914502	0.615	rs9841418	chr3:174518452	T/C	cg21145449	chr3:174580620	NAALADL2	0.44	5.05	0.38	1.28e-6	Autism spectrum disorder;
UCEC	cis	rs1846974	1	rs1846974	chr5:87969927	G/A	cg09002922	chr5:87956389	LOC645323	-0.59	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs12428035	0.764	rs11616724	chr13:96741670	C/A	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.76	-7.96	-0.55	4.33e-13	Menarche (age at onset);
UCEC	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg02820040	chr2:241836501	C2orf54	-0.4	-5.1	-0.39	1.03e-6	Urinary metabolites;
UCEC	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.48	-5.1	-0.39	1.03e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.63	5.22	0.4	6.02e-7	Inflammatory bowel disease;
UCEC	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.54	-5.06	-0.39	1.21e-6	High light scatter reticulocyte count;
UCEC	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-5.42	-0.41	2.4e-7	Fear of minor pain;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.01	-0.44	1.38e-8	Pubertal anthropometrics;
UCEC	cis	rs7124681	0.505	rs7126378	chr11:47585348	G/T	cg20307385	chr11:47447363	PSMC3	0.68	5.66	0.42	7.58e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.65	-4.56	-0.35	1.08e-5	Gut microbiome composition (summer);
UCEC	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.41	-5.07	-0.39	1.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.46	0.62	7e-17	Alzheimer's disease;
UCEC	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.11	12.5	0.72	6.82e-25	White matter hyperintensity burden;
UCEC	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.51	4.84	0.37	3.29e-6	Hemoglobin concentration;
UCEC	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.65	5.29	0.4	4.38e-7	Cognitive test performance;
UCEC	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg00983440	chr10:79422392	NA	0.94	7.58	0.53	3.59e-12	Bone mineral density;
UCEC	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.81	5.36	0.4	3.09e-7	Body mass index;
UCEC	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg06886374	chr16:1844152	IGFALS	-0.42	-4.75	-0.36	4.79e-6	Blood protein levels;
UCEC	cis	rs4780355	0.619	rs918737	chr16:11439639	T/C	cg00044050	chr16:11439710	C16orf75	-0.45	-4.72	-0.36	5.46e-6	Crohn's disease and psoriasis;
UCEC	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	5.98	0.44	1.6e-8	Cognitive test performance;
UCEC	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.26	0.46	3.96e-9	Coffee consumption (cups per day);
UCEC	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.85	10.26	0.65	5.9e-19	Monocyte count;
UCEC	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.56	-4.84	-0.37	3.28e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.64	-7.55	-0.53	4.12e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.46	-6.06	-0.45	1.09e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.41	4.68	0.36	6.32e-6	Prostate cancer;
UCEC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.86	9.56	0.62	3.76e-17	Blood protein levels;
UCEC	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-5.33	-0.4	3.68e-7	Body mass index;
UCEC	cis	rs72949976	0.707	rs10932473	chr2:214039057	C/T	cg08319019	chr2:214017104	IKZF2	-0.75	-6.01	-0.44	1.4e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.2	6.79	0.49	2.58e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.25e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.46	-4.67	-0.36	6.61e-6	Blood protein levels;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg07836142	chr6:28411423	ZSCAN23	0.6	6.91	0.5	1.34e-10	Pubertal anthropometrics;
UCEC	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.56	-5.07	-0.39	1.2e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg12292205	chr6:26970375	C6orf41	0.57	4.97	0.38	1.84e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-6.13	-0.45	7.51e-9	Coffee consumption (cups per day);
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs9039	1.000	rs9932208	chr16:9218267	T/C	cg08831531	chr16:9218945	NA	-0.47	-5.05	-0.38	1.32e-6	Menopause (age at onset);
UCEC	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.36	5.3	0.4	4.13e-7	Ulcerative colitis;
UCEC	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-0.98	-11.04	-0.67	5.08e-21	Blood pressure (smoking interaction);
UCEC	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06762426	chr11:62420836	INTS5	0.9	5.07	0.39	1.16e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.58	-6.8	-0.49	2.51e-10	Total body bone mineral density;
UCEC	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.63	-5.04	-0.38	1.37e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.83	-7.98	-0.55	3.75e-13	Alzheimer's disease;
UCEC	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs6832769	1.000	rs6811520	chr4:56315178	T/C	cg05960024	chr4:56376020	CLOCK	0.48	4.51	0.35	1.33e-5	Personality dimensions;
UCEC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg13147721	chr7:65941812	NA	0.95	6.46	0.47	1.43e-9	Gout;
UCEC	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	5.47	0.41	1.91e-7	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.37	-4.76	-0.37	4.65e-6	Mean platelet volume;
UCEC	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.15	-0.39	8.07e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.63	6.67	0.48	4.95e-10	QRS complex (12-leadsum);
UCEC	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.81	-7.11	-0.51	4.71e-11	Neurofibrillary tangles;
UCEC	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	7.17	0.51	3.3e-11	Lymphocyte counts;
UCEC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	0.87	7.29	0.52	1.78e-11	White matter hyperintensity burden;
UCEC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.8e-6	Breast cancer;
UCEC	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.34	-4.58	-0.35	9.92e-6	Total body bone mineral density;
UCEC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.8	7.94	0.55	4.84e-13	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	0.93	9.6	0.62	3.04e-17	Heart rate;
UCEC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.6	-7.7	-0.54	1.82e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.57	4.88	0.37	2.68e-6	Response to diuretic therapy;
UCEC	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.51	4.87	0.37	2.84e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.65	7.26	0.51	2.09e-11	Body mass index;
UCEC	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.47	-4.77	-0.37	4.38e-6	Neuroticism;
UCEC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.76	0.43	4.75e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.58	0.35	9.95e-6	Schizophrenia;
UCEC	cis	rs8177876	0.822	rs80315956	chr16:81112859	G/A	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.39	4.97	0.38	1.86e-6	Insulin-like growth factors;
UCEC	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.65	-7.25	-0.51	2.14e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	-0.57	-6.54	-0.47	9.37e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12039431	0.589	rs61776186	chr1:38011993	G/C	cg17933807	chr1:38061675	GNL2	-0.52	-4.55	-0.35	1.1e-5	Epithelial ovarian cancer;
UCEC	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg06456738	chr11:66361081	CCDC87;CCS	0.55	4.59	0.35	9.27e-6	Airway imaging phenotypes;
UCEC	cis	rs1007190	0.881	rs34854300	chr17:42969013	T/C	cg15406952	chr17:42872593	NA	0.73	5.7	0.43	6.28e-8	DNA methylation (variation);
UCEC	cis	rs2862064	1.000	rs6896499	chr5:156431325	A/G	cg12943317	chr5:156479607	HAVCR1	-0.74	-5.57	-0.42	1.2e-7	Platelet count;
UCEC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.39	-4.74	-0.36	4.93e-6	Prudent dietary pattern;
UCEC	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.48	-4.87	-0.37	2.85e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.95	5.98	0.44	1.62e-8	Plasma clusterin levels;
UCEC	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.54	5.55	0.42	1.27e-7	Coronary artery disease;
UCEC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg19645103	chr12:69753606	YEATS4	-0.49	-4.55	-0.35	1.12e-5	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.86	4.66	0.36	7.08e-6	Inflammatory bowel disease;
UCEC	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.58	5.38	0.41	2.88e-7	Corneal astigmatism;
UCEC	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.83	0.59	2.8e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-7.2	-0.51	2.81e-11	Blood protein levels;
UCEC	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.55	7.89	0.55	6.32e-13	Total body bone mineral density;
UCEC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.38e-17	Height;
UCEC	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.61	6.02	0.44	1.33e-8	Lung cancer;
UCEC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.68	7.43	0.52	8.39e-12	Monocyte count;
UCEC	cis	rs56313388	0.793	rs9937815	chr16:56330832	C/T	cg10482356	chr16:56328421	GNAO1	0.35	4.66	0.36	7.1e-6	Pulse pressure;
UCEC	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.89	0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.12	-0.39	9.64e-7	Aortic root size;
UCEC	cis	rs8177876	0.822	rs56119129	chr16:81118266	C/T	cg08591886	chr16:81111003	C16orf46	-0.78	-4.51	-0.35	1.32e-5	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.56	0.53	4.04e-12	Bipolar disorder;
UCEC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg08222913	chr3:52553049	STAB1	-0.42	-4.67	-0.36	6.7e-6	Electroencephalogram traits;
UCEC	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.54	-5.15	-0.39	8.08e-7	Schizophrenia;
UCEC	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.54	4.63	0.36	7.88e-6	Obesity-related traits;
UCEC	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.46	-4.6	-0.35	9.11e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	4.61	0.36	8.69e-6	Platelet count;
UCEC	cis	rs925228	0.955	rs10182357	chr2:24153132	T/A	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.23e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.72	-6.02	-0.44	1.33e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.53	5.1	0.39	1.03e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.6	0.35	9e-6	Parkinson's disease;
UCEC	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.56	5.1	0.39	1.02e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.79	11.5	0.69	3.1e-22	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.62	6.17	0.45	6.18e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.33	-0.57	5.2e-14	Total cholesterol levels;
UCEC	cis	rs6717918	0.564	rs6437052	chr2:233064080	G/A	cg02061626	chr2:233274167	ALPPL2	0.5	5.25	0.4	5.15e-7	Height;
UCEC	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg14456004	chr13:21872349	NA	0.5	5.33	0.4	3.61e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg24675658	chr1:53192096	ZYG11B	0.87	9.85	0.63	6.65e-18	Monocyte count;
UCEC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.84	-7.94	-0.55	4.66e-13	Initial pursuit acceleration;
UCEC	cis	rs2901460	0.509	rs12470090	chr2:62094367	T/C	cg02183531	chr2:62113199	CCT4	-0.54	-4.54	-0.35	1.17e-5	Mean corpuscular volume;
UCEC	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.59	6.92	0.5	1.32e-10	Mean corpuscular volume;
UCEC	cis	rs7246967	0.932	rs8105614	chr19:23038023	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.63	5.12	0.39	9.61e-7	Initial pursuit acceleration;
UCEC	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.94	-7.35	-0.52	1.24e-11	Multiple sclerosis;
UCEC	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.63	5.82	0.43	3.63e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.86e-6	Body mass index;
UCEC	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	4.78	0.37	4.26e-6	IgG glycosylation;
UCEC	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg21770322	chr7:97807741	LMTK2	0.5	6.33	0.46	2.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.84	-4.65	-0.36	7.47e-6	Diabetic retinopathy;
UCEC	cis	rs4077515	1.000	rs11145763	chr9:139263596	A/C	cg14019695	chr9:139328340	INPP5E	0.48	5.1	0.39	1.05e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6446731	0.517	rs2157093	chr4:3270913	C/G	cg08886695	chr4:3369023	RGS12	0.44	4.98	0.38	1.75e-6	Mean platelet volume;
UCEC	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.72	5.04	0.38	1.35e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs12618769	0.652	rs11537554	chr2:99216531	A/G	cg10123293	chr2:99228465	UNC50	0.5	5.46	0.41	1.94e-7	Bipolar disorder;
UCEC	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.63	5.48	0.41	1.82e-7	Cocaine dependence;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.36	-0.46	2.38e-9	Pubertal anthropometrics;
UCEC	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.63	-5.52	-0.41	1.53e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg07838603	chr6:28411030	ZSCAN23	-0.45	-4.63	-0.36	7.81e-6	Cardiac Troponin-T levels;
UCEC	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs405956	1.000	rs413806	chr6:105555395	G/A	cg22580625	chr6:105627791	POPDC3	-0.7	-6.5	-0.47	1.17e-9	QT interval;
UCEC	cis	rs8105895	0.935	rs62111038	chr19:22286614	A/G	cg20662725	chr19:22235022	ZNF257	-0.57	-4.85	-0.37	3.16e-6	Body mass index (change over time);
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.62	6.78	0.49	2.78e-10	Menarche (age at onset);
UCEC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.4	4.93	0.38	2.18e-6	Homoarginine levels;
UCEC	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	4.86	0.37	2.98e-6	Obesity-related traits;
UCEC	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg17294928	chr15:75287854	SCAMP5	-0.48	-4.61	-0.36	8.6e-6	Lung cancer;
UCEC	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-4.78	-0.37	4.27e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	0.49	4.79	0.37	4.04e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.73	7.89	0.55	6.36e-13	Lymphocyte counts;
UCEC	cis	rs7534537	1.000	rs7527089	chr1:204274516	C/A	cg17158762	chr1:204518670	MDM4	0.65	4.96	0.38	1.93e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.76	0.37	4.6e-6	Cognitive ability;
UCEC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.67	6.99	0.5	8.8e-11	Neutrophil percentage of white cells;
UCEC	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9402633	0.938	rs9389211	chr6:135040237	C/T	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.42	4.61	0.36	8.79e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.55	-5.77	-0.43	4.58e-8	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs35934224	0.891	rs8141451	chr22:19870036	C/G	cg11182965	chr22:19864308	TXNRD2	-0.48	-6.01	-0.44	1.42e-8	Glaucoma (primary open-angle);
UCEC	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-6.85	-0.49	1.89e-10	Colorectal cancer;
UCEC	cis	rs420259	0.516	rs9931842	chr16:23524558	T/A	cg26562691	chr16:23850404	PRKCB	-0.34	-4.55	-0.35	1.12e-5	Bipolar disorder;
UCEC	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg13385521	chr17:29058706	SUZ12P	0.67	4.66	0.36	7.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.61	6.69	0.48	4.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.57	5.7	0.43	6.28e-8	Colorectal cancer;
UCEC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.64	6.09	0.45	9.33e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg02820040	chr2:241836501	C2orf54	-0.4	-5.18	-0.39	7.24e-7	Urinary metabolites;
UCEC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.9	8.65	0.58	8.25e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.68	-5.99	-0.44	1.55e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.69	7.41	0.52	9e-12	Bone mineral density;
UCEC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.56	4.61	0.36	8.56e-6	Corneal astigmatism;
UCEC	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg06970220	chr1:156163860	SLC25A44	0.46	4.84	0.37	3.2e-6	Testicular germ cell tumor;
UCEC	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.03	-0.5	7.15e-11	Urate levels in overweight individuals;
UCEC	cis	rs201260	0.606	rs9396778	chr6:9976215	A/G	cg00405198	chr6:10419885	TFAP2A	0.49	4.51	0.35	1.31e-5	Electroencephalogram traits;
UCEC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.49	-4.98	-0.38	1.72e-6	Coronary artery disease;
UCEC	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.61	5.59	0.42	1.05e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg18279126	chr7:2041391	MAD1L1	0.46	5.8	0.43	3.99e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.69	8.2	0.56	1.12e-13	Metabolite levels;
UCEC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.56	6.14e-14	Prudent dietary pattern;
UCEC	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg22166914	chr1:53195759	ZYG11B	0.78	8.18	0.56	1.24e-13	Monocyte count;
UCEC	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg19404215	chr3:33155277	CRTAP	0.82	4.73	0.36	5.27e-6	Major depressive disorder;
UCEC	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.93	5.89	0.44	2.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.38	0.57	3.83e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.79	-6.65	-0.48	5.31e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs36051895	0.589	rs7850294	chr9:5191128	C/T	cg02405213	chr9:5042618	JAK2	0.56	5.42	0.41	2.36e-7	Pediatric autoimmune diseases;
UCEC	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.09	-0.45	9.61e-9	Systemic lupus erythematosus;
UCEC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.23	-14.63	-0.77	1.8e-30	Breast cancer;
UCEC	cis	rs7474896	0.778	rs12571785	chr10:38211399	A/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-4.8	-0.37	3.91e-6	Obesity (extreme);
UCEC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.71	-6.52	-0.47	1.07e-9	Aortic root size;
UCEC	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.5	-5.19	-0.39	6.98e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.43	-4.67	-0.36	6.82e-6	Obesity-related traits;
UCEC	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-10.75	-0.66	2.97e-20	Primary sclerosing cholangitis;
UCEC	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg11632617	chr15:75315747	PPCDC	0.66	7.47	0.52	6.71e-12	Lung cancer;
UCEC	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.65	6.89	0.49	1.51e-10	Menopause (age at onset);
UCEC	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.59	6.86	0.49	1.82e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.66	7.94	0.55	4.87e-13	Hip circumference;
UCEC	cis	rs75804782	0.572	rs56330821	chr2:239273949	C/T	cg11815105	chr2:239148849	HES6	0.99	4.63	0.36	8e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg05962950	chr11:130786565	SNX19	0.55	5.43	0.41	2.25e-7	Schizophrenia;
UCEC	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.69	7.57	0.53	3.79e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg01262667	chr19:19385393	TM6SF2	-0.51	-7.2	-0.51	2.84e-11	Tonsillectomy;
UCEC	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.69	8.09	0.55	2.08e-13	Longevity;
UCEC	cis	rs6446731	0.593	rs2530601	chr4:3272378	C/G	cg08886695	chr4:3369023	RGS12	-0.4	-4.64	-0.36	7.59e-6	Mean platelet volume;
UCEC	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg08216368	chr11:237063	SIRT3;PSMD13	0.46	4.57	0.35	1.01e-5	Alzheimer's disease (late onset);
UCEC	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.73	-5.68	-0.42	6.85e-8	Orofacial clefts;
UCEC	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-0.74	-8.11	-0.56	1.79e-13	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
UCEC	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.39	-5.35	-0.4	3.37e-7	Prostate cancer;
UCEC	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.38	-5.71	-0.43	5.91e-8	Body mass index;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.35	-0.4	3.29e-7	Pubertal anthropometrics;
UCEC	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.69	-6.92	-0.5	1.28e-10	Tonsillectomy;
UCEC	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-5.12	-0.39	9.5e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg05991184	chr2:219186017	PNKD	-0.49	-5.26	-0.4	4.94e-7	Colorectal cancer;
UCEC	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.04	7.99	0.55	3.62e-13	Vitiligo;
UCEC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.65	0.36	7.44e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.62	-7.26	-0.51	2.08e-11	Prostate cancer;
UCEC	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	8.33	0.57	5.27e-14	Total body bone mineral density;
UCEC	trans	rs10496288	0.529	rs4852696	chr2:83151641	G/C	cg11455018	chr16:30709778	SRCAP	0.61	6.87	0.49	1.7e-10	Hypertension (SNP x SNP interaction);
UCEC	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.54	-4.53	-0.35	1.23e-5	Initial pursuit acceleration;
UCEC	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.67	5.45	0.41	2.09e-7	Obesity-related traits;
UCEC	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.71	6.78	0.49	2.7e-10	Schizophrenia;
UCEC	cis	rs7246967	0.673	rs7252925	chr19:22865808	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.82	7.96	0.55	4.23e-13	Cognitive function;
UCEC	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.62	5.17	0.39	7.41e-7	High light scatter reticulocyte count;
UCEC	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-9.28	-0.61	1.99e-16	Coffee consumption (cups per day);
UCEC	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.75	-7.75	-0.54	1.36e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.58	6.39	0.47	2.04e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.42	4.83	0.37	3.46e-6	HDL cholesterol levels;
UCEC	cis	rs17106184	1.000	rs3789577	chr1:50954128	A/G	cg07174182	chr1:51127561	FAF1	0.84	5.35	0.4	3.33e-7	Type 2 diabetes;
UCEC	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg01262667	chr19:19385393	TM6SF2	0.5	6.97	0.5	9.7e-11	Tonsillectomy;
UCEC	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg11871910	chr12:69753446	YEATS4	0.56	5.03	0.38	1.38e-6	Response to diuretic therapy;
UCEC	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.54	5.45	0.41	2.1e-7	Schizophrenia;
UCEC	cis	rs17162190	0.590	rs10902748	chr1:26817825	G/A	cg23229016	chr1:26872525	RPS6KA1	0.27	4.63	0.36	8.09e-6	Mean corpuscular volume;
UCEC	cis	rs16937	0.574	rs10900455	chr1:205123534	T/C	cg12580275	chr1:205744413	RAB7L1	0.45	5.05	0.38	1.28e-6	Schizophrenia;
UCEC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.81	8.06	0.55	2.42e-13	Smoking behavior;
UCEC	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg08000102	chr2:233561755	GIGYF2	-0.57	-4.81	-0.37	3.62e-6	Coronary artery disease;
UCEC	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.71	-0.36	5.57e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-8.36	-0.57	4.26e-14	Coronary artery disease;
UCEC	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.67	-0.36	6.83e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.51	4.93	0.38	2.2e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4372836	0.543	rs3768665	chr2:29005602	G/A	cg09522027	chr2:28974177	PPP1CB	-0.77	-8.31	-0.57	5.8e-14	Body mass index;
UCEC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg09491104	chr22:46646882	C22orf40	0.55	5.96	0.44	1.75e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-5.4	-0.41	2.66e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.83	0.49	2.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.65	-6.16	-0.45	6.68e-9	Platelet distribution width;
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg07404485	chr7:94953653	PON1	0.44	4.55	0.35	1.11e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-8.92	-0.59	1.69e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	0.86	11.81	0.7	4.68e-23	Monocyte percentage of white cells;
UCEC	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.39	-5.09	-0.39	1.08e-6	Dupuytren's disease;
UCEC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.7	-6.73	-0.49	3.57e-10	Aortic root size;
UCEC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg09655341	chr17:79618100	PDE6G	-0.3	-4.55	-0.35	1.12e-5	Eye color traits;
UCEC	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.68	5.74	0.43	5.27e-8	Menopause (age at onset);
UCEC	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs925550	0.932	rs17005992	chr4:123583615	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.61	-5.82	-0.43	3.52e-8	Primary biliary cholangitis;
UCEC	cis	rs2051090	1.000	rs4941822	chr13:36453613	C/A	cg19508437	chr13:35517410	NBEA	-0.35	-4.59	-0.35	9.44e-6	Pediatric non-alcoholic fatty liver disease activity score;
UCEC	cis	rs151997	1.000	rs251043	chr5:50215997	A/G	cg06027927	chr5:50259733	NA	0.54	4.86	0.37	2.98e-6	Callous-unemotional behaviour;
UCEC	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12516959	chr21:47718080	NA	-0.4	-4.58	-0.35	9.85e-6	Testicular germ cell tumor;
UCEC	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.12	-9.14	-0.6	4.69e-16	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs9467773	0.967	rs1321482	chr6:26575154	T/C	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.44	5.39	0.41	2.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1459104	1.000	rs35218816	chr11:55087104	C/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.16e-10	Body mass index;
UCEC	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.34	0.76	1.01e-29	Chronic sinus infection;
UCEC	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-6.11	-0.45	8.41e-9	Morning vs. evening chronotype;
UCEC	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg01072550	chr1:21505969	NA	0.59	6.27	0.46	3.84e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.1	-0.39	1.05e-6	Pulmonary function;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.67	6.56	0.48	8.8e-10	Longevity;Endometriosis;
UCEC	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	7.93e-6	Heart rate;
UCEC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.62	-6.7	-0.48	4.16e-10	Menarche (age at onset);
UCEC	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.64	6.68	0.48	4.59e-10	Immature fraction of reticulocytes;
UCEC	cis	rs9650657	0.836	rs11250067	chr8:10606954	T/C	cg14992524	chr8:10586135	SOX7	0.32	5.22	0.4	5.9e-7	Neuroticism;
UCEC	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.5	-4.7	-0.36	5.83e-6	Gut microbiome composition (summer);
UCEC	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg23260525	chr10:116636907	FAM160B1	0.33	4.53	0.35	1.23e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-5.03	-0.38	1.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg09997546	chr11:8931473	C11orf17;ST5	-0.41	-4.83	-0.37	3.39e-6	Hemoglobin concentration;
UCEC	cis	rs73206853	0.697	rs16934006	chr12:110527907	T/A	cg12870014	chr12:110450643	ANKRD13A	0.76	6.1	0.45	8.95e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg14008862	chr17:28927542	LRRC37B2	0.6	4.8	0.37	3.8e-6	Body mass index;
UCEC	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.05	-0.38	1.28e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.52	0.53	5.13e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg11519256	chr10:5708881	ASB13	0.5	5.0	0.38	1.63e-6	Menopause (age at onset);
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-5.97	-0.44	1.67e-8	Platelet count;
UCEC	cis	rs4233949	0.832	rs6734097	chr2:54651933	C/T	cg17376041	chr2:54856335	SPTBN1	0.51	4.86	0.37	2.95e-6	Bone mineral density;
UCEC	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg03859395	chr2:55845619	SMEK2	1.03	15.04	0.78	1.49e-31	Metabolic syndrome;
UCEC	cis	rs7246967	0.800	rs2362131	chr19:23022436	T/C	cg24889512	chr19:22816950	ZNF492	0.48	5.06	0.38	1.25e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.81	9.14	0.6	4.62e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.04	0.38	1.36e-6	Rheumatoid arthritis;
UCEC	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.45	6.24	0.46	4.39e-9	Alcohol dependence;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.72	-0.43	5.68e-8	Pubertal anthropometrics;
UCEC	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.72	-7.7	-0.54	1.83e-12	Blood protein levels;
UCEC	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	11.35	0.68	7.76e-22	Leprosy;
UCEC	cis	rs7611694	0.501	rs6438145	chr3:113125211	C/T	cg11138929	chr3:113251189	SIDT1	-0.4	-4.58	-0.35	1e-5	Prostate cancer;
UCEC	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.76	8.03	0.55	2.85e-13	Breast cancer;
UCEC	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.54e-18	Height;
UCEC	cis	rs10949834	0.824	rs2285025	chr7:73529976	T/C	cg07137043	chr7:73588983	EIF4H	-0.77	-4.57	-0.35	1.03e-5	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-4.68	-0.36	6.59e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.57	4.8	0.37	3.79e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs9463078	0.547	rs4714819	chr6:44735285	G/C	cg25276700	chr6:44698697	NA	0.46	5.47	0.41	1.92e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6546550	0.694	rs12467361	chr2:70019127	G/A	cg02498382	chr2:70120550	SNRNP27	-0.55	-5.9	-0.44	2.36e-8	Prevalent atrial fibrillation;
UCEC	cis	rs13098911	0.540	rs76597151	chr3:46001227	G/A	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.31	-0.4	3.94e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.39	-4.93	-0.38	2.16e-6	Educational attainment (years of education);
UCEC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.61	6.03	0.45	1.27e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.81	7.9	0.55	6.17e-13	Cognitive function;
UCEC	cis	rs11958404	0.932	rs56065211	chr5:157439386	C/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.46	0.62	7e-17	Alzheimer's disease;
UCEC	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.12	0.39	9.55e-7	Rheumatoid arthritis;
UCEC	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg04154034	chr17:28927549	LRRC37B2	0.73	5.07	0.39	1.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.54e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.65	5.49	0.41	1.75e-7	High light scatter reticulocyte count;
UCEC	cis	rs7246967	0.932	rs4932793	chr19:23036449	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.31	0.61	1.69e-16	Platelet count;
UCEC	cis	rs71636213	0.527	rs9293816	chr5:79664437	A/T	cg09571630	chr5:80437492	RASGRF2	-0.45	-4.56	-0.35	1.07e-5	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.53	5.51	0.41	1.6e-7	Schizophrenia;
UCEC	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.66	-0.42	7.82e-8	Fear of minor pain;
UCEC	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.42	5.96	0.44	1.82e-8	Superior crus of antihelix expression;
UCEC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.66	5.23	0.4	5.74e-7	Initial pursuit acceleration;
UCEC	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.18	-0.39	7.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.56	-5.02	-0.38	1.46e-6	Pediatric autoimmune diseases;
UCEC	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.93	11.38	0.68	6.57e-22	Homoarginine levels;
UCEC	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	0.93	5.93	0.44	2.1e-8	Type 2 diabetes nephropathy;
UCEC	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.62	7.11	0.51	4.57e-11	Leprosy;
UCEC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.58	-4.72	-0.36	5.52e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	5.02	0.38	1.47e-6	Breast cancer;
UCEC	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	0.93	9.8	0.63	9.51e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.98	-11.32	-0.68	9.62e-22	Obesity-related traits;
UCEC	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.57	6.45	0.47	1.53e-9	Crohn's disease;
UCEC	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	6.73	0.49	3.54e-10	Menopause (age at onset);
UCEC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg01689657	chr7:91764605	CYP51A1	-0.44	-5.67	-0.42	7.46e-8	Breast cancer;
UCEC	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg23791538	chr6:167370224	RNASET2	0.49	4.87	0.37	2.86e-6	Primary biliary cholangitis;
UCEC	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg22654517	chr2:96458247	NA	0.43	4.61	0.36	8.77e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.33	0.4	3.68e-7	Colorectal cancer;
UCEC	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg03543861	chr21:44258195	NA	0.46	4.99	0.38	1.67e-6	Information processing speed;
UCEC	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.62	5.79	0.43	4.03e-8	Aortic root size;
UCEC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	4.86	0.37	2.97e-6	Lung function (FEV1/FVC);
UCEC	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-8.18	-0.56	1.23e-13	Body mass index;
UCEC	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.68	5.67	0.42	7.38e-8	Prostate cancer;
UCEC	cis	rs9810089	0.843	rs838202	chr3:136035217	G/A	cg21827317	chr3:136751795	NA	0.46	4.63	0.36	8.1e-6	Gestational age at birth (child effect);
UCEC	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.8	-9.25	-0.61	2.41e-16	Longevity;Endometriosis;
UCEC	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.57	6.43	0.47	1.67e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.83	8.8	0.59	3.49e-15	Blood protein levels;
UCEC	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-6.19	-0.45	5.76e-9	Menarche (age at onset);
UCEC	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.65	-7.74	-0.54	1.46e-12	Hip circumference;
UCEC	cis	rs28795989	0.862	rs35661042	chr4:7887427	G/C	cg00251875	chr4:7801337	AFAP1	0.48	5.71	0.43	5.98e-8	Intraocular pressure;
UCEC	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.65	6.65	0.48	5.26e-10	Adiposity;
UCEC	cis	rs6788895	1.000	rs34348847	chr3:150501389	C/G	cg09723797	chr3:150481914	SIAH2	0.66	4.55	0.35	1.12e-5	Breast cancer;
UCEC	cis	rs7560272	0.589	rs34874205	chr2:73875458	G/A	cg20560298	chr2:73613845	ALMS1	0.53	4.89	0.37	2.67e-6	Schizophrenia;
UCEC	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.03	-12.95	-0.73	4.59e-26	Body mass index;
UCEC	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-4.87	-0.37	2.8e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.73	-9.18	-0.6	3.76e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9309473	0.519	rs2178154	chr2:73661738	C/T	cg20560298	chr2:73613845	ALMS1	0.49	4.86	0.37	3.02e-6	Metabolite levels;
UCEC	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14019695	chr9:139328340	INPP5E	0.59	6.39	0.47	2.01e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.67	-5.97	-0.44	1.67e-8	Metabolite levels;
UCEC	cis	rs870825	0.655	rs6844929	chr4:185653809	C/G	cg04058563	chr4:185651563	MLF1IP	-0.63	-6.75	-0.49	3.23e-10	Blood protein levels;
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.81	9.72	0.63	1.47e-17	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.51	5.4	0.41	2.65e-7	Type 2 diabetes;
UCEC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07589254	chr7:1705402	NA	-0.55	-4.74	-0.36	4.95e-6	Longevity;Endometriosis;
UCEC	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.6	4.74	0.36	4.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.06	-0.45	1.09e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs36715	1.000	rs181850	chr5:127547487	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.47	0.41	1.89e-7	Breast cancer;
UCEC	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.65	0.48	5.35e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.77	7.72	0.54	1.64e-12	Smoking behavior;
UCEC	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-0.8	-8.78	-0.59	3.87e-15	Monocyte percentage of white cells;
UCEC	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-6.84	-0.49	2.03e-10	Plateletcrit;Platelet count;
UCEC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.69	6.26	0.46	4.07e-9	Aortic root size;
UCEC	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg24562669	chr7:97807699	LMTK2	0.48	5.86	0.43	2.98e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.62	-6.09	-0.45	9.25e-9	Metabolite levels;
UCEC	cis	rs6460942	1.000	rs73053531	chr7:12317474	T/C	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg19760965	chr3:194868843	C3orf21	0.4	4.57	0.35	1.04e-5	Non-small cell lung cancer;
UCEC	cis	rs4778581	0.604	rs7169038	chr15:80418756	G/A	cg08257866	chr15:80351198	ZFAND6	0.41	4.76	0.37	4.55e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.55	4.86	0.37	2.93e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs13401104	0.796	rs72620806	chr2:237113736	C/T	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.41	10.47	0.65	1.63e-19	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.91	8.7	0.58	6.3e-15	Colorectal adenoma (advanced);
UCEC	cis	rs9467773	0.967	rs9461272	chr6:26579648	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.75	-8.99	-0.6	1.12e-15	Ulcerative colitis;
UCEC	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.62	-5.79	-0.43	4.03e-8	Metabolite levels;
UCEC	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.59	-5.85	-0.43	3.13e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg22166914	chr1:53195759	ZYG11B	-0.64	-6.49	-0.47	1.21e-9	Monocyte count;
UCEC	cis	rs925228	0.955	rs1156797	chr2:24117541	A/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.74	7.57	0.53	3.83e-12	Breast cancer;
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.79	0.49	2.52e-10	Platelet count;
UCEC	cis	rs8020441	1.000	rs8020441	chr14:51170879	T/G	cg04730355	chr14:51134070	SAV1	0.64	5.99	0.44	1.51e-8	Cognitive performance;
UCEC	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-7.51	-0.53	5.32e-12	Exhaled nitric oxide output;
UCEC	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.73	-7.25	-0.51	2.15e-11	Lymphocyte counts;
UCEC	cis	rs41271951	0.512	rs76649628	chr1:151041851	A/G	cg00107782	chr1:151300621	NA	-0.68	-4.58	-0.35	9.72e-6	Blood protein levels;
UCEC	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	5.24	0.4	5.36e-7	Response to antipsychotic treatment;
UCEC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.5	5.86	0.44	2.94e-8	Alcohol dependence;
UCEC	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.54	5.22	0.4	5.92e-7	Calcium levels;
UCEC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-4.9	-0.37	2.46e-6	Joint mobility (Beighton score);
UCEC	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg26061582	chr7:22766209	IL6	0.58	5.41	0.41	2.5e-7	Lung cancer;
UCEC	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.16	0.56	1.36e-13	Chronic sinus infection;
UCEC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	6.78	0.49	2.77e-10	Platelet count;
UCEC	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.43	4.95	0.38	2.02e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.48	5.17	0.39	7.64e-7	Corneal astigmatism;
UCEC	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	1.09	13.54	0.75	1.24e-27	Schizophrenia;
UCEC	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg24687543	chr11:63912206	MACROD1	0.52	4.93	0.38	2.17e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-6.69	-0.48	4.31e-10	Fibrinogen levels;
UCEC	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.41	0.52	9.12e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7975161	0.572	rs7957725	chr12:104574749	A/T	cg25273343	chr12:104657179	TXNRD1	-0.72	-5.15	-0.39	8.08e-7	Toenail selenium levels;
UCEC	cis	rs7246967	0.551	rs1835994	chr19:22833045	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1575951	1.000	rs10829455	chr10:130435783	A/G	cg27041381	chr10:131357203	MGMT	-0.54	-4.59	-0.35	9.59e-6	Plasma clusterin levels;
UCEC	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.52	5.15	0.39	8.33e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.08	9.05	0.6	7.94e-16	Vitiligo;
UCEC	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	6.96	0.5	1.05e-10	Menopause (age at onset);
UCEC	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-9.21	-0.6	3.12e-16	Renal cell carcinoma;
UCEC	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.42	5.15	0.39	8.08e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.78	-6.49	-0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22117172	chr7:91764530	CYP51A1	0.43	5.41	0.41	2.48e-7	Breast cancer;
UCEC	cis	rs56281245	0.793	rs7733723	chr5:145041065	C/T	cg14510905	chr5:145040858	NA	0.54	5.03	0.38	1.39e-6	Hepcidin levels;
UCEC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg22166914	chr1:53195759	ZYG11B	0.7	7.5	0.53	5.47e-12	Monocyte count;
UCEC	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	5.9	0.44	2.46e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs3015497	0.586	rs12587842	chr14:51092562	A/G	cg04730355	chr14:51134070	SAV1	-0.47	-5.04	-0.38	1.37e-6	Mean platelet volume;
UCEC	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.47	-0.52	6.41e-12	Personality dimensions;
UCEC	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.66	6.5	0.47	1.19e-9	Vitamin D levels;
UCEC	cis	rs4345220	0.546	rs12511338	chr4:41644585	T/G	cg15232654	chr4:41643107	LIMCH1	0.45	4.82	0.37	3.48e-6	Migraine with aura;
UCEC	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.78	-0.37	4.19e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.79	-8.11	-0.56	1.83e-13	Uric acid levels;
UCEC	cis	rs17106184	0.818	rs112095647	chr1:51237302	C/G	cg07174182	chr1:51127561	FAF1	-0.63	-4.63	-0.36	8.01e-6	Type 2 diabetes;
UCEC	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.23e-6	Morning vs. evening chronotype;
UCEC	cis	rs6748734	0.857	rs10933641	chr2:241813788	T/C	cg04034577	chr2:241836375	C2orf54	-0.42	-5.53	-0.42	1.41e-7	Urinary metabolites;
UCEC	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.63	-7.13	-0.51	4.28e-11	Menarche (age at onset);
UCEC	cis	rs847649	0.699	rs7794668	chr7:102510416	C/T	cg18108683	chr7:102477205	FBXL13	0.65	8.15	0.56	1.47e-13	Morning vs. evening chronotype;
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.62	-4.91	-0.38	2.44e-6	Autism;
UCEC	cis	rs28714278	0.857	rs12164905	chr15:40300691	A/C	cg10505819	chr15:40309387	EIF2AK4	-0.42	-4.99	-0.38	1.71e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17467752	chr17:38218738	THRA	-0.57	-6.53	-0.47	1.01e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.66	-7.09	-0.5	5.16e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.52	5.38	0.41	2.92e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.45	0.61	7.27e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.48	-4.58	-0.35	9.68e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	0.77	9.23	0.61	2.76e-16	Multiple myeloma;
UCEC	cis	rs9715521	0.775	rs62301195	chr4:59846934	G/T	cg11281224	chr4:60001000	NA	-0.61	-5.88	-0.44	2.71e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg04310649	chr10:35416472	CREM	-0.48	-4.92	-0.38	2.25e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.52	6.83	0.49	2.1e-10	Osteoporosis;
UCEC	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.45	-5.41	-0.41	2.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-7.07	-0.5	5.87e-11	Total body bone mineral density;
UCEC	cis	rs2299682	0.826	rs6086918	chr20:9478096	C/A	cg11931762	chr20:9488920	NA	-0.61	-4.67	-0.36	6.85e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.6	5.99	0.44	1.53e-8	Lung cancer;
UCEC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.69	-6.9	-0.49	1.45e-10	Cognitive function;
UCEC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	5.35	0.4	3.25e-7	Platelet count;
UCEC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.97	10.87	0.67	1.42e-20	Cognitive function;
UCEC	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg17425144	chr1:10567563	PEX14	0.45	5.2	0.39	6.5e-7	Prostate cancer;
UCEC	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg13575925	chr12:9217583	LOC144571	0.39	4.55	0.35	1.1e-5	Sjögren's syndrome;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07273675	chr19:14183752	LOC113230	0.6	6.84	0.49	2.03e-10	Warfarin maintenance dose;
UCEC	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.42	-5.15	-0.39	8.25e-7	Mean platelet volume;
UCEC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.53	-0.42	1.41e-7	Aortic root size;
UCEC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.98	-10.61	-0.66	7.02e-20	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.58	5.51	0.41	1.58e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6893207	1.000	rs7725999	chr5:16403651	C/A	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.84	-0.49	1.98e-10	Total cholesterol levels;
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.72	-0.43	5.65e-8	Pubertal anthropometrics;
UCEC	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg13385521	chr17:29058706	SUZ12P	0.73	5.22	0.4	6.09e-7	Body mass index;
UCEC	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-6.8	-0.49	2.48e-10	Mean platelet volume;
UCEC	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.58	-5.14	-0.39	8.52e-7	Coronary artery disease;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.76	-0.49	3.09e-10	Pulmonary function;
UCEC	cis	rs10242455	0.867	rs2687143	chr7:99320469	C/T	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs10242455	0.717	rs2687134	chr7:99331042	T/G	cg07715041	chr7:99302981	CYP3A7	-0.5	-4.97	-0.38	1.85e-6	Blood metabolite levels;
UCEC	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg26114124	chr12:9217669	LOC144571	0.4	4.65	0.36	7.42e-6	Sjögren's syndrome;
UCEC	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.48	0.62	6.28e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.69	6.02	0.44	1.32e-8	Adiposity;
UCEC	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.96	10.54	0.66	1.06e-19	Cognitive function;
UCEC	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.7	-5.59	-0.42	1.05e-7	Schizophrenia;
UCEC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.49	-5.12	-0.39	9.36e-7	Monocyte count;
UCEC	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.45	-0.41	2.1e-7	Obesity-related traits;
UCEC	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.49	4.53	0.35	1.22e-5	Multiple myeloma (IgH translocation);
UCEC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.74	-0.43	5.24e-8	Chronic sinus infection;
UCEC	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.76	8.03	0.55	2.85e-13	Breast cancer;
UCEC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.75	-0.36	4.77e-6	Breast cancer;
UCEC	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.78	8.27	0.56	7.41e-14	Menopause (age at onset);
UCEC	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.49	4.54	0.35	1.15e-5	Alcohol dependence;
UCEC	trans	rs9821642	0.659	rs2197839	chr3:103246058	G/A	cg14521134	chr3:44162215	NA	-0.47	-6.71	-0.48	4e-10	Economic and political preferences (environmentalism);
UCEC	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-4.89	-0.37	2.6e-6	Morning vs. evening chronotype;
UCEC	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg15837086	chr1:46506065	PIK3R3	-0.39	-4.68	-0.36	6.51e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg06096015	chr1:231504339	EGLN1	0.48	5.57	0.42	1.17e-7	Hemoglobin concentration;
UCEC	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.64	6.37	0.46	2.33e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	6.48	0.47	1.3e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.56	-0.35	1.09e-5	Bone mineral density;
UCEC	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.83	7.57	0.53	3.73e-12	Bladder cancer;
UCEC	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	0.83	4.97	0.38	1.87e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg22166914	chr1:53195759	ZYG11B	0.54	5.52	0.41	1.5e-7	Monocyte count;
UCEC	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg20560298	chr2:73613845	ALMS1	0.52	4.99	0.38	1.68e-6	Schizophrenia;
UCEC	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.64	6.98	0.5	9.64e-11	Homoarginine levels;
UCEC	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2307449	0.894	rs12592258	chr15:89844849	C/T	cg23124613	chr15:89731485	ABHD2	-0.4	-4.6	-0.35	8.98e-6	Menopause (age at onset);
UCEC	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.66	6.24	0.46	4.48e-9	Schizophrenia;
UCEC	cis	rs6763768	0.606	rs1001222	chr3:53352099	G/A	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg09074113	chr2:20870087	GDF7	-0.45	-5.83	-0.43	3.37e-8	Abdominal aortic aneurysm;
UCEC	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.63	-6.31	-0.46	3.14e-9	Blood metabolite levels;
UCEC	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg21521518	chr4:53727714	RASL11B	0.67	4.77	0.37	4.32e-6	Optic nerve measurement (cup area);
UCEC	cis	rs11969893	0.737	rs9386262	chr6:101427687	G/T	cg12253828	chr6:101329408	ASCC3	1.03	5.67	0.42	7.2e-8	Economic and political preferences (immigration/crime);
UCEC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.48	-6.08	-0.45	9.94e-9	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9283706	0.608	rs12522430	chr5:66339522	T/C	cg11590213	chr5:66331682	MAST4	0.45	5.02	0.38	1.45e-6	Coronary artery disease;
UCEC	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.62	5.59	0.42	1.07e-7	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.57	0.58	1.29e-14	Platelet count;
UCEC	cis	rs7165102	0.965	rs28599929	chr15:66036868	T/C	cg11164506	chr15:66649558	TIPIN	-0.33	-4.56	-0.35	1.09e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.68	-0.36	6.55e-6	Mood instability;
UCEC	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg04439458	chr5:138467593	SIL1	0.41	4.75	0.36	4.81e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	0.92	9.37	0.61	1.19e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6688613	0.685	rs10918600	chr1:166919342	C/T	cg07049167	chr1:166818506	POGK	-0.55	-5.3	-0.4	4.14e-7	Refractive astigmatism;
UCEC	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.96	11.17	0.68	2.27e-21	Ulcerative colitis;
UCEC	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.52	5.65	0.42	7.99e-8	Tonsillectomy;
UCEC	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.82	11.16	0.68	2.46e-21	Headache;
UCEC	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-4.67	-0.36	6.76e-6	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs2302190	1.000	rs7207286	chr17:56514458	A/C	cg12560992	chr17:57184187	TRIM37	-0.53	-5.33	-0.4	3.66e-7	Vitamin D levels;
UCEC	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg21214455	chr15:72412075	SENP8	0.53	4.91	0.38	2.43e-6	Red blood cell count;
UCEC	cis	rs7246967	0.611	rs8104327	chr19:22867159	C/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.9	9.11	0.6	5.47e-16	Heart rate;
UCEC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.57	-6.05	-0.45	1.15e-8	Bipolar disorder;
UCEC	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg04545659	chr9:139973827	UAP1L1	0.38	4.93	0.38	2.24e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10129255	0.528	rs8008320	chr14:107108139	C/A	cg03031183	chr14:106916953	NA	-0.43	-4.63	-0.36	8.06e-6	Kawasaki disease;
UCEC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.42	-4.78	-0.37	4.2e-6	Prostate cancer;
UCEC	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.08	-0.39	1.13e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg12024160	chr4:1254474	NA	0.45	4.85	0.37	3.06e-6	Longevity;
UCEC	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	0.89	10.26	0.65	5.98e-19	Schizophrenia;
UCEC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg15534755	chr11:117069859	TAGLN	0.34	4.64	0.36	7.68e-6	Blood protein levels;
UCEC	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.48	-5.74	-0.43	5.29e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.69	8.82	0.59	3.06e-15	Mean platelet volume;
UCEC	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg05991184	chr2:219186017	PNKD	0.44	4.96	0.38	1.89e-6	Ulcerative colitis;
UCEC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.52	-5.08	-0.39	1.14e-6	Aortic root size;
UCEC	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.47	5.33	0.4	3.56e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg10902566	chr4:727664	PCGF3	-0.57	-5.02	-0.38	1.45e-6	Systolic blood pressure;
UCEC	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.43	-4.71	-0.36	5.72e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.68	-6.43	-0.47	1.71e-9	Prudent dietary pattern;
UCEC	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12826209	chr6:26865740	GUSBL1	0.52	5.04	0.38	1.32e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	1.000	rs35332070	chr19:23034266	G/A	cg08271804	chr19:22816896	ZNF492	0.59	5.57	0.42	1.16e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.75	0.43	4.95e-8	Breast cancer;
UCEC	cis	rs7204230	1.000	rs2287077	chr16:53322120	T/C	cg10109421	chr16:52641824	NA	0.42	4.66	0.36	7.14e-6	Fibrinogen;
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.6	0.58	1.12e-14	Platelet count;
UCEC	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.62	7.33	0.52	1.4e-11	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-0.76	-7.19	-0.51	3.09e-11	Breast cancer;
UCEC	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg16583315	chr14:65563665	MAX	-0.42	-5.6	-0.42	1e-7	Obesity-related traits;
UCEC	cis	rs7095607	0.538	rs2634708	chr10:69920013	C/A	cg18986048	chr10:69913749	MYPN	0.63	6.95	0.5	1.1e-10	Lung function (FVC);
UCEC	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	0.77	5.99	0.44	1.51e-8	Blood protein levels;
UCEC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.57	5.99	0.44	1.55e-8	Monocyte count;
UCEC	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.3	0.4	4.24e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.45	-5.23	-0.4	5.79e-7	Obesity;
UCEC	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.51	-5.09	-0.39	1.08e-6	Large artery stroke;
UCEC	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg16583315	chr14:65563665	MAX	-0.4	-4.59	-0.35	9.58e-6	Obesity-related traits;
UCEC	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.66	5.42	0.41	2.37e-7	Metabolite levels;
UCEC	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.54	5.22	0.4	5.93e-7	Calcium levels;
UCEC	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.92	9.79	0.63	9.91e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.93	8.75	0.59	4.67e-15	Type 2 diabetes nephropathy;
UCEC	trans	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.75	7.83	0.54	8.83e-13	Breast cancer;
UCEC	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18252515	chr7:66147081	NA	0.51	5.34	0.4	3.51e-7	Aortic root size;
UCEC	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.47	4.77	0.37	4.45e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.68	-7.61	-0.53	3.07e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.6	-0.42	1e-7	Pubertal anthropometrics;
UCEC	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	6.14	0.45	7.43e-9	Cognitive test performance;
UCEC	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.6	-4.86	-0.37	2.94e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	0.93	6.46	0.47	1.41e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg11271282	chr2:238384023	NA	0.48	4.58	0.35	9.77e-6	Prostate cancer;
UCEC	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.59	9.03	0.6	9.12e-16	Prudent dietary pattern;
UCEC	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.53	-0.47	9.89e-10	Blood metabolite levels;
UCEC	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg14438399	chr17:27053147	TLCD1	-0.56	-4.55	-0.35	1.1e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	7.36	0.52	1.21e-11	Exhaled nitric oxide levels;
UCEC	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.7	6.99	0.5	8.7e-11	Mosquito bite size;
UCEC	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.86	7.58	0.53	3.68e-12	Obesity-related traits;
UCEC	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg06238570	chr21:40685208	BRWD1	0.86	7.89	0.55	6.34e-13	Cognitive function;
UCEC	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.6	-4.95	-0.38	1.97e-6	Obesity-related traits;
UCEC	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18099408	chr3:52552593	STAB1	-0.46	-5.01	-0.38	1.54e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.72	6.86	0.49	1.75e-10	Crohn's disease;
UCEC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.79	-0.49	2.56e-10	Chronic sinus infection;
UCEC	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg01689657	chr7:91764605	CYP51A1	0.46	6.18	0.45	6.02e-9	Breast cancer;
UCEC	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg03078520	chr22:18463400	MICAL3	-0.41	-4.63	-0.36	8.04e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.56	4.5	0.35	1.36e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7705819	1.000	rs34674270	chr5:172872959	G/C	cg14746387	chr5:172879299	NA	0.48	5.16	0.39	7.79e-7	Stroke;
UCEC	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.51	5.88	0.44	2.71e-8	Mean corpuscular volume;
UCEC	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.47	4.91	0.38	2.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.73	7.77	0.54	1.24e-12	Primary sclerosing cholangitis;
UCEC	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.86	-11.54	-0.69	2.4e-22	Metabolic syndrome;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17919570	chr2:234763381	HJURP	0.57	6.99	0.5	8.81e-11	Warfarin maintenance dose;
UCEC	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.51	5.05	0.38	1.29e-6	High light scatter reticulocyte count;
UCEC	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg05754148	chr16:3507555	NAT15	0.45	4.58	0.35	9.87e-6	Tuberculosis;
UCEC	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.69	6.56	0.48	8.64e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9326726	0.844	rs13190222	chr5:107562301	C/A	cg17432647	chr5:107996819	NA	0.49	4.51	0.35	1.3e-5	Resting heart rate;
UCEC	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.61	6.19	0.45	5.63e-9	Retinal vascular caliber;
UCEC	cis	rs6540556	0.723	rs12086634	chr1:209880259	T/G	cg05527609	chr1:210001259	C1orf107	-0.6	-4.65	-0.36	7.42e-6	Red blood cell count;
UCEC	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-0.95	-9.76	-0.63	1.16e-17	Height;
UCEC	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.7	6.01	0.44	1.37e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.2e-9	Blood protein levels;
UCEC	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-0.85	-4.74	-0.36	5.1e-6	IgG glycosylation;
UCEC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.87	0.44	2.72e-8	Menarche (age at onset);
UCEC	cis	rs66573146	0.901	rs7668802	chr4:6986236	T/A	cg16571794	chr4:7648627	SORCS2	0.6	4.54	0.35	1.14e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg07838603	chr6:28411030	ZSCAN23	0.47	5.33	0.4	3.66e-7	Cardiac Troponin-T levels;
UCEC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.79	4.98	0.38	1.8e-6	Gut microbiome composition (summer);
UCEC	cis	rs11675119	0.513	rs9752321	chr2:3494374	A/G	cg10845886	chr2:3471009	TTC15	-0.53	-4.66	-0.36	7.11e-6	Neurofibrillary tangles;
UCEC	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg17259809	chr10:104614391	C10orf32	-0.68	-4.57	-0.35	1.04e-5	Arsenic metabolism;
UCEC	cis	rs78487399	0.808	rs7587268	chr2:43673892	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.65	0.42	7.9e-8	Breast cancer;
UCEC	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg18681998	chr4:17616180	MED28	0.77	9.33	0.61	1.52e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.64	5.6	0.42	1.03e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6832769	0.961	rs13138697	chr4:56363309	G/A	cg05960024	chr4:56376020	CLOCK	0.49	4.51	0.35	1.34e-5	Personality dimensions;
UCEC	cis	rs7558233	0.614	rs6544858	chr2:23676071	C/T	cg00747342	chr2:23700632	KLHL29	-0.52	-4.51	-0.35	1.33e-5	Cannabis use (initiation);
UCEC	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-13.23	-0.74	8.38e-27	Schizophrenia;
UCEC	cis	rs1445130	0.688	rs4832444	chr2:18835760	T/C	cg27104604	chr2:18833621	NA	-0.46	-4.55	-0.35	1.13e-5	Bulimia nervosa;
UCEC	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-5.93	-0.44	2.03e-8	Tonsillectomy;
UCEC	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.48	5.38	0.41	2.85e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg04154034	chr17:28927549	LRRC37B2	-0.92	-5.28	-0.4	4.58e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07698384	chr15:25684465	UBE3A	0.6	7.43	0.52	8.26e-12	Warfarin maintenance dose;
UCEC	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.52	-4.77	-0.37	4.46e-6	Coronary artery disease;
UCEC	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.78	-7.86	-0.54	7.53e-13	Prudent dietary pattern;
UCEC	cis	rs7106204	0.688	rs4462347	chr11:24218865	G/A	ch.11.24196551F	chr11:24239977	NA	0.61	5.0	0.38	1.64e-6	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg08493051	chr2:3487164	NA	-0.6	-6.34	-0.46	2.72e-9	Neurofibrillary tangles;
UCEC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.36	-5.81	-0.43	3.81e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.61	-6.32	-0.46	2.99e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.64	5.81	0.43	3.65e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	5.68	0.42	7.04e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.7	8.37	0.57	4.07e-14	Breast cancer;
UCEC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-6.11	-0.45	8.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.05	-13.4	-0.74	2.85e-27	Prudent dietary pattern;
UCEC	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.38	0.41	2.88e-7	Personality dimensions;
UCEC	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg19338460	chr6:170058176	WDR27	-0.92	-6.32	-0.46	2.96e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.55	7.08	0.5	5.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.28	0.4	4.57e-7	Rheumatoid arthritis;
UCEC	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.36	-0.52	1.2e-11	Eye color traits;
UCEC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg07653901	chr22:50250238	ZBED4	0.52	4.8	0.37	3.89e-6	Schizophrenia;
UCEC	cis	rs8105895	0.799	rs62112922	chr19:22228340	C/T	cg24072202	chr19:22235272	ZNF257	-0.56	-4.66	-0.36	6.89e-6	Body mass index (change over time);
UCEC	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.63	6.3	0.46	3.19e-9	Mean corpuscular volume;
UCEC	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.68	-4.54	-0.35	1.15e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2302190	0.882	rs7209650	chr17:56674905	C/T	cg12560992	chr17:57184187	TRIM37	0.53	4.61	0.36	8.63e-6	Vitamin D levels;
UCEC	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.17	0.39	7.58e-7	Bladder cancer;
UCEC	cis	rs6662386	0.557	rs10801904	chr1:88222493	G/A	cg10042178	chr1:87794589	LMO4	0.49	4.72	0.36	5.56e-6	Prostate-specific antigen levels;
UCEC	cis	rs2892463	0.765	rs4238128	chr13:30357943	C/T	cg18356743	chr13:30408050	UBL3	-0.41	-4.55	-0.35	1.12e-5	Non-word repetition;
UCEC	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.62	-6.1	-0.45	8.98e-9	IgG glycosylation;
UCEC	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.46	5.67	0.42	7.27e-8	Prostate cancer;
UCEC	cis	rs7072216	0.652	rs11189600	chr10:100179274	A/G	cg19567339	chr10:100142640	NA	-0.48	-5.64	-0.42	8.59e-8	Metabolite levels;
UCEC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg07424592	chr7:64974309	NA	0.76	4.71	0.36	5.58e-6	Diabetic kidney disease;
UCEC	cis	rs7095607	0.654	rs7081017	chr10:69954451	A/G	cg18986048	chr10:69913749	MYPN	0.52	5.68	0.42	6.97e-8	Lung function (FVC);
UCEC	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.8	8.87	0.59	2.28e-15	Blood metabolite levels;
UCEC	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg13926569	chr10:89418898	PAPSS2	-0.57	-6.57	-0.48	8.14e-10	Magnesium levels;
UCEC	cis	rs7088591	0.867	rs75056761	chr10:59784862	A/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg07589254	chr7:1705402	NA	-0.54	-4.71	-0.36	5.78e-6	Longevity;Endometriosis;
UCEC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.07	-15.87	-0.79	1.16e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	0.99	5.76	0.43	4.86e-8	Schizophrenia;
UCEC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.82	-8.88	-0.59	2.13e-15	Cognitive function;
UCEC	cis	rs61776719	0.875	rs28683126	chr1:38402459	G/A	cg04673462	chr1:38461896	NA	0.56	5.7	0.43	6.41e-8	Coronary artery disease;
UCEC	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7264396	1.000	rs224429	chr20:34152018	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-4.5	-0.35	1.35e-5	Total cholesterol levels;
UCEC	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.45	0.41	2.1e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.65	5.68	0.42	6.85e-8	Bipolar disorder;
UCEC	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.56	4.96	0.38	1.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.55	5.43	0.41	2.32e-7	Morning vs. evening chronotype;
UCEC	cis	rs12635074	0.547	rs11707901	chr3:56244163	T/C	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.37	4.67	0.36	6.71e-6	Morning vs. evening chronotype;
UCEC	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.9	-0.44	2.35e-8	Menarche (age at onset);
UCEC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.74	6.49	0.47	1.21e-9	Cognitive function;
UCEC	cis	rs9356171	0.572	rs11756250	chr6:164325686	A/G	cg25752492	chr6:164341247	NA	-0.59	-5.89	-0.44	2.47e-8	Diisocyanate-induced asthma;
UCEC	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg04374321	chr14:90722782	PSMC1	0.55	4.65	0.36	7.37e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg03714773	chr7:91764589	CYP51A1	-0.39	-4.71	-0.36	5.57e-6	Breast cancer;
UCEC	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.47	-6.57	-0.48	8.26e-10	Height;
UCEC	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.55	5.96	0.44	1.82e-8	Schizophrenia;
UCEC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.57	5.18	0.39	7.29e-7	Corneal astigmatism;
UCEC	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg27299712	chr1:6550532	PLEKHG5	0.53	4.9	0.37	2.51e-6	Body mass index;
UCEC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	7.12	0.51	4.53e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.63	7.1	0.51	4.9e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg21253087	chr9:139290292	SNAPC4	0.42	4.68	0.36	6.33e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11958404	1.000	rs72816529	chr5:157411454	G/C	cg05962755	chr5:157440814	NA	0.76	4.92	0.38	2.25e-6	IgG glycosylation;
UCEC	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.49	4.83	0.37	3.36e-6	Blood metabolite levels;
UCEC	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.59	-5.78	-0.43	4.24e-8	QRS complex (12-leadsum);
UCEC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.55	-0.35	1.1e-5	Tonsillectomy;
UCEC	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.37	-5.47	-0.41	1.92e-7	Schizophrenia;
UCEC	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18932078	chr1:2524107	MMEL1	0.35	5.99	0.44	1.58e-8	Ulcerative colitis;
UCEC	cis	rs2267137	0.868	rs5763178	chr22:29773869	A/G	cg07256473	chr22:29710276	RASL10A	0.54	5.94	0.44	2.01e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-4.88	-0.37	2.69e-6	Kawasaki disease;
UCEC	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.58	-0.35	9.66e-6	Mood instability;
UCEC	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.72	8.23	0.56	9.15e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.82	10.15	0.64	1.15e-18	Mortality in heart failure;
UCEC	cis	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.34	-0.46	2.73e-9	Pubertal anthropometrics;
UCEC	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	6.39	0.47	2.02e-9	Coronary artery disease;
UCEC	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg22598563	chr5:131563921	P4HA2	0.34	4.56	0.35	1.09e-5	Blood metabolite levels;
UCEC	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2281845	0.507	rs12025414	chr1:201100496	A/G	cg06714761	chr1:201096289	NA	0.47	5.08	0.39	1.12e-6	Permanent tooth development;
UCEC	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg06466757	chr4:1255808	NA	0.46	4.77	0.37	4.33e-6	Obesity-related traits;
UCEC	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.31e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs10242455	0.867	rs1357319	chr7:99310181	G/T	cg07715041	chr7:99302981	CYP3A7	0.5	5.04	0.38	1.37e-6	Blood metabolite levels;
UCEC	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.59	-5.03	-0.38	1.44e-6	Reticulocyte count;
UCEC	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.91	8.74	0.58	4.75e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.69	7.03	0.5	7.32e-11	Itch intensity from mosquito bite;
UCEC	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.43	4.58	0.35	9.89e-6	IgG glycosylation;
UCEC	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00791764	chr4:53727839	RASL11B	0.67	4.67	0.36	6.81e-6	Optic nerve measurement (cup area);
UCEC	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.43	-5.22	-0.4	6.08e-7	Refractive error;
UCEC	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs11867410	0.744	rs73349089	chr17:63941673	G/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.52	-5.07	-0.39	1.18e-6	Pediatric autoimmune diseases;
UCEC	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg24687543	chr11:63912206	MACROD1	0.54	4.71	0.36	5.65e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	4.69	0.36	6.32e-6	Adiposity;
UCEC	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.42	4.51	0.35	1.34e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.51	4.85	0.37	3.09e-6	Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs1570060	chr6:26573562	A/G	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs847577	0.506	rs7808528	chr7:97721425	G/T	cg21770322	chr7:97807741	LMTK2	0.82	13.77	0.75	3.17e-28	Breast cancer;
UCEC	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	6.52	0.47	1.07e-9	Menopause (age at onset);
UCEC	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.44	0.47	1.61e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg23625390	chr15:77176239	SCAPER	0.48	4.76	0.37	4.59e-6	Blood metabolite levels;
UCEC	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.6	4.89	0.37	2.59e-6	Corneal astigmatism;
UCEC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg11366901	chr6:160182831	ACAT2	0.82	7.17	0.51	3.31e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg23782820	chr8:58130467	NA	0.51	4.78	0.37	4.2e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.43	5.45	0.41	2.11e-7	Fibrinogen levels;
UCEC	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-0.95	-7.97	-0.55	4.13e-13	White matter hyperintensity burden;
UCEC	trans	rs12755164	0.771	rs6679116	chr1:73348889	C/A	cg17780956	chr4:156297616	MAP9	-0.65	-6.93	-0.5	1.26e-10	Schizophrenia;
UCEC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.81	-0.37	3.75e-6	Parkinson's disease;
UCEC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.61	-5.56	-0.42	1.24e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11697848	1.000	rs56366827	chr20:48543851	C/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	0.84	10.56	0.66	9.21e-20	Bone mineral density;
UCEC	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.84	-9.13	-0.6	5.01e-16	Blood metabolite levels;
UCEC	cis	rs7267005	0.661	rs111433174	chr20:34378058	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.75	7.5	0.53	5.73e-12	Post bronchodilator FEV1;
UCEC	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg06637938	chr14:75390232	RPS6KL1	0.71	5.94	0.44	1.96e-8	Height;
UCEC	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.78	7.8	0.54	1.04e-12	Lung cancer;
UCEC	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.03	0.38	1.43e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs76878669	0.561	rs7940980	chr11:66172910	C/T	cg24851651	chr11:66362959	CCS	0.47	5.23	0.4	5.72e-7	Educational attainment (years of education);
UCEC	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg27246729	chr12:121163418	ACADS	0.49	4.52	0.35	1.25e-5	Urinary metabolites (H-NMR features);
UCEC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg12024160	chr4:1254474	NA	0.51	4.73	0.36	5.11e-6	Longevity;
UCEC	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.85	-0.49	1.91e-10	Coronary artery disease;
UCEC	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.57	4.54	0.35	1.18e-5	Height;
UCEC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.4	4.68	0.36	6.35e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21178979	chr7:1889533	MAD1L1	0.39	5.24	0.4	5.5e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.41	6.01	0.44	1.4e-8	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.37	-0.47	2.27e-9	Pulmonary function;
UCEC	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	6.55	0.48	8.94e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	4.65	0.36	7.36e-6	Colorectal cancer;
UCEC	cis	rs4448343	0.927	rs1355619	chr9:98270171	A/G	cg00638945	chr9:98266643	PTCH1	0.31	4.58	0.35	9.84e-6	Height;
UCEC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.49	-5.43	-0.41	2.24e-7	Prostate cancer;
UCEC	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.57	-6.74	-0.49	3.35e-10	Prostate cancer;
UCEC	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg05180856	chr15:91428056	FES	0.43	5.46	0.41	1.96e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.62	6.56	0.48	8.62e-10	Motion sickness;
UCEC	cis	rs7246967	0.551	rs59127381	chr19:22885035	T/A	cg08271804	chr19:22816896	ZNF492	0.69	4.65	0.36	7.26e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.55	-6.17	-0.45	6.34e-9	Depression;
UCEC	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.65	5.53	0.41	1.44e-7	Uric acid levels;
UCEC	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.54	5.63	0.42	8.77e-8	Corneal astigmatism;
UCEC	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.42	-4.68	-0.36	6.36e-6	Blood protein levels;
UCEC	cis	rs1318937	0.588	rs80123042	chr3:15283464	G/T	cg08692541	chr3:14716288	C3orf20	0.68	4.78	0.37	4.2e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	11.5	0.69	3.03e-22	Ulcerative colitis;
UCEC	cis	rs7072216	0.853	rs6584194	chr10:100160399	T/C	cg19567339	chr10:100142640	NA	0.55	6.37	0.46	2.31e-9	Metabolite levels;
UCEC	cis	rs2944755	0.959	rs2977491	chr8:141574277	A/G	cg08444833	chr8:141574162	EIF2C2	-0.68	-4.94	-0.38	2.13e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.58	-5.38	-0.41	2.81e-7	Blood trace element (Cu levels);
UCEC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.03	10.0	0.64	2.77e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.33	-0.4	3.55e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.56e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.0	0.38	1.64e-6	Bladder cancer;
UCEC	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.49	4.71	0.36	5.72e-6	Menopause (age at onset);
UCEC	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.65	6.72	0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.26	-0.4	4.94e-7	Neutrophil percentage of white cells;
UCEC	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.64	-6.74	-0.49	3.36e-10	IgG glycosylation;
UCEC	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.56	5.67	0.42	7.33e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	7.9	0.55	5.95e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.5	-5.09	-0.39	1.06e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.47	-4.89	-0.37	2.59e-6	Coronary artery disease;
UCEC	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.62	-5.21	-0.39	6.3e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.48	-5.23	-0.4	5.66e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.56	-5.79	-0.43	4.09e-8	Breast cancer;
UCEC	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.5	-4.98	-0.38	1.74e-6	Breast size;
UCEC	cis	rs2657888	0.628	rs2638285	chr12:56886361	A/G	cg23002907	chr12:56915593	RBMS2	0.43	5.6	0.42	1.04e-7	Adiponectin levels;
UCEC	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg27525446	chr1:17019810	ESPNP	-0.51	-4.96	-0.38	1.95e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	7.05e-9	Aortic root size;
UCEC	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.94	5.78	0.43	4.29e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.56	-4.88	-0.37	2.71e-6	Pediatric autoimmune diseases;
UCEC	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-4.64	-0.36	7.6e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.52	5.85	0.43	3e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.69	-5.03	-0.38	1.43e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.69	4.76	0.37	4.6e-6	Mean platelet volume;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.5	-0.41	1.65e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.8	-7.63	-0.53	2.75e-12	Multiple sclerosis;
UCEC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.39	-4.52	-0.35	1.25e-5	Bipolar disorder;
UCEC	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.68	-7.89	-0.55	6.52e-13	Monocyte count;
UCEC	cis	rs4853525	0.923	rs7582941	chr2:191728900	A/T	cg10560079	chr2:191398806	TMEM194B	-0.46	-4.55	-0.35	1.11e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7246967	0.541	rs16999009	chr19:22909658	A/G	cg08271804	chr19:22816896	ZNF492	-0.66	-6.24	-0.46	4.53e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.54	-6.23	-0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs883565	0.527	rs11715262	chr3:39003853	A/T	cg01426195	chr3:39028469	NA	-0.59	-7.04	-0.5	7.01e-11	Handedness;
UCEC	cis	rs7611694	0.501	rs4682138	chr3:113150806	C/T	cg12596171	chr3:113251061	SIDT1	-0.5	-5.13	-0.39	9.06e-7	Prostate cancer;
UCEC	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.5	-4.8	-0.37	3.91e-6	Blood protein levels;
UCEC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-5.89	-0.44	2.57e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-5.86	-0.43	2.96e-8	Mean platelet volume;
UCEC	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg21466736	chr12:48725269	NA	0.35	4.75	0.36	4.84e-6	Plateletcrit;
UCEC	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.49	4.89	0.37	2.66e-6	Testicular germ cell tumor;
UCEC	cis	rs4722166	0.532	rs1880242	chr7:22759607	A/C	cg05472934	chr7:22766657	IL6	-0.55	-5.19	-0.39	6.93e-7	Lung cancer;
UCEC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg07653901	chr22:50250238	ZBED4	0.92	5.32	0.4	3.84e-7	Schizophrenia;
UCEC	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.08	-15.68	-0.79	3.4e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.63	-4.79	-0.37	3.98e-6	Narcolepsy;
UCEC	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-7.88	-0.54	6.82e-13	Response to antipsychotic treatment;
UCEC	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.61	5.74	0.43	5.34e-8	Vitamin D levels;
UCEC	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-4.67	-0.36	6.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.45	-4.86	-0.37	3.01e-6	Schizophrenia;
UCEC	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.8	8.68	0.58	6.98e-15	Metabolite levels;
UCEC	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg05991184	chr2:219186017	PNKD	-0.5	-5.58	-0.42	1.14e-7	Colorectal cancer;
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.59	0.72	4.09e-25	Prudent dietary pattern;
UCEC	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.78	6.48	0.47	1.32e-9	Morning vs. evening chronotype;
UCEC	cis	rs2862064	0.932	rs6870977	chr5:156446249	T/C	cg12943317	chr5:156479607	HAVCR1	-0.75	-5.56	-0.42	1.22e-7	Platelet count;
UCEC	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-0.98	-11.06	-0.67	4.42e-21	Blood pressure (smoking interaction);
UCEC	trans	rs9527419	0.506	rs7338142	chr13:56264562	G/C	cg14957718	chr3:50243260	SLC38A3	0.72	6.83	0.49	2.12e-10	Response to platinum-based chemotherapy (cisplatin);
UCEC	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	6.01	0.44	1.41e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	6.0	0.44	1.43e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.51	4.91	0.38	2.39e-6	Corneal astigmatism;
UCEC	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-4.66	-0.36	6.9e-6	Type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg20965017	chr5:231967	SDHA	0.6	5.56	0.42	1.24e-7	Breast cancer;
UCEC	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.05	0.55	2.58e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.49	-5.41	-0.41	2.54e-7	Alcohol dependence;
UCEC	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.3	4.72	0.36	5.4e-6	Cancer;
UCEC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg14078730	chr11:63896557	MACROD1	0.66	5.16	0.39	8.04e-7	Mean platelet volume;
UCEC	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.85	6.78	0.49	2.75e-10	Fibroblast growth factor basic levels;
UCEC	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	6.15	0.45	6.81e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.54	6.23	0.46	4.6e-9	Platelet count;
UCEC	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.77	-5.64	-0.42	8.35e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.91	0.38	2.4e-6	Aortic root size;
UCEC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg04154034	chr17:28927549	LRRC37B2	0.58	5.19	0.39	6.85e-7	Body mass index;
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.74	8.77	0.59	4.07e-15	Menarche (age at onset);
UCEC	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg05660106	chr1:15850417	CASP9	0.93	10.44	0.65	1.95e-19	Systolic blood pressure;
UCEC	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.18	-0.71	4.78e-24	Primary sclerosing cholangitis;
UCEC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.52	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs8105895	0.866	rs62112908	chr19:22213956	A/G	cg20662725	chr19:22235022	ZNF257	-0.53	-4.8	-0.37	3.78e-6	Body mass index (change over time);
UCEC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg03354898	chr7:1950403	MAD1L1	-0.74	-9.19	-0.6	3.5e-16	Bipolar disorder and schizophrenia;
UCEC	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.51	-5.34	-0.4	3.5e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg03714773	chr7:91764589	CYP51A1	0.46	5.62	0.42	9.39e-8	Breast cancer;
UCEC	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	9.37	0.61	1.2e-16	Platelet count;
UCEC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	9.05	0.6	7.86e-16	Hip circumference;
UCEC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg07817648	chr10:79422355	NA	-0.65	-5.26	-0.4	4.91e-7	Bone mineral density;
UCEC	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.78	6.48	0.47	1.32e-9	Morning vs. evening chronotype;
UCEC	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.57	4.97	0.38	1.86e-6	Uric acid levels;
UCEC	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg22598563	chr5:131563921	P4HA2	-0.37	-5.02	-0.38	1.47e-6	Blood metabolite levels;
UCEC	cis	rs60311166	1.000	rs58100002	chr3:52589840	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.82	4.65	0.36	7.2e-6	CTACK levels;
UCEC	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.37	-4.59	-0.35	9.44e-6	Body mass index;
UCEC	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.6	-5.18	-0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.84	-10.76	-0.66	2.78e-20	Metabolic syndrome;
UCEC	cis	rs7011049	0.908	rs11986701	chr8:53833480	G/T	cg26025543	chr8:53854495	NA	0.61	4.52	0.35	1.29e-5	Systolic blood pressure;
UCEC	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.61	7.99	0.55	3.66e-13	Bone mineral density;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.73	8.67	0.58	7.27e-15	Menarche (age at onset);
UCEC	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.62	7.11	0.51	4.67e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2708377	0.656	rs73066852	chr12:11276541	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.59	4.72	0.36	5.36e-6	Bitter taste perception;
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.46	-0.47	1.48e-9	Cardiac Troponin-T levels;
UCEC	cis	rs16957091	0.647	rs28374998	chr15:43289177	C/G	cg15904908	chr15:43213022	TTBK2	0.48	4.71	0.36	5.7e-6	MGMT methylation in smokers;
UCEC	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-6.51	-0.47	1.11e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg13695892	chr22:41940480	POLR3H	-0.68	-5.28	-0.4	4.52e-7	Vitiligo;
UCEC	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.23	-19.12	-0.84	1.07e-41	Exhaled nitric oxide output;
UCEC	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.59	5.85	0.43	3.08e-8	Diabetic kidney disease;
UCEC	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	9.0	0.6	1.06e-15	Hip circumference;
UCEC	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg22598563	chr5:131563921	P4HA2	0.33	4.53	0.35	1.19e-5	Blood metabolite levels;
UCEC	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	6.07	0.45	1.05e-8	Response to antipsychotic treatment;
UCEC	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.85	0.43	3.07e-8	Cognitive test performance;
UCEC	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg00800038	chr16:89945340	TCF25	-0.79	-4.52	-0.35	1.28e-5	Skin colour saturation;
UCEC	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg13683864	chr3:40499215	RPL14	-0.65	-6.88	-0.49	1.59e-10	Renal cell carcinoma;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20566420	chr12:122327043	PSMD9	0.57	6.8	0.49	2.44e-10	Warfarin maintenance dose;
UCEC	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.49	-5.56	-0.42	1.22e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.77	-0.37	4.44e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.89e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	5.08	0.39	1.1e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs785830	0.717	rs542669	chr9:224367	G/C	cg14500300	chr9:211689	NA	0.36	4.61	0.36	8.64e-6	Platelet distribution width;
UCEC	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.38	-5.71	-0.43	5.91e-8	Body mass index;
UCEC	cis	rs6754311	0.684	rs11681248	chr2:136820076	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-6.01	-0.44	1.37e-8	Mosquito bite size;
UCEC	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.73	7.52	0.53	5.07e-12	Breast cancer;
UCEC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.83	9.52	0.62	4.94e-17	Monocyte count;
UCEC	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	0.8	6.37	0.46	2.32e-9	Corneal structure;
UCEC	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.51	4.67	0.36	6.86e-6	Pancreatic cancer;
UCEC	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.92	12.8	0.73	1.14e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4954585	0.762	rs12986776	chr2:136991517	C/G	cg07169764	chr2:136633963	MCM6	-0.5	-4.51	-0.35	1.3e-5	Colorectal cancer;
UCEC	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.32	-5.56	-0.42	1.25e-7	Mean corpuscular volume;
UCEC	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.68	-6.86	-0.49	1.78e-10	Blood metabolite levels;
UCEC	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.86	-6.6	-0.48	6.9e-10	Exhaled nitric oxide output;
UCEC	cis	rs7106204	0.748	rs2403891	chr11:24213130	C/T	ch.11.24196551F	chr11:24239977	NA	0.53	5.48	0.41	1.83e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.67	-4.85	-0.37	3.17e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	0.81	4.79	0.37	4.1e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs7816613	0.573	rs16868276	chr8:102745351	C/G	cg15001633	chr8:103265981	UBR5	0.49	5.09	0.39	1.09e-6	Age-related hearing impairment;
UCEC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg22974920	chr21:40686053	BRWD1	0.59	5.09	0.39	1.1e-6	Cognitive function;
UCEC	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.54	0.35	1.19e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg13575925	chr12:9217583	LOC144571	0.4	4.75	0.37	4.7e-6	Sjögren's syndrome;
UCEC	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.49	-4.86	-0.37	3.01e-6	Obesity-related traits;
UCEC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg05775895	chr3:12838266	CAND2	0.6	5.98	0.44	1.62e-8	QRS complex (12-leadsum);
UCEC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.7	-7.29	-0.52	1.73e-11	Cognitive function;
UCEC	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.47	-5.16	-0.39	7.8e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.61	5.02	0.38	1.48e-6	Eosinophilic esophagitis;
UCEC	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.5	5.8	0.43	3.93e-8	Testicular germ cell tumor;
UCEC	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	1.09	9.98	0.64	3.07e-18	Corneal structure;
UCEC	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.07	-0.39	1.18e-6	Total cholesterol levels;
UCEC	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.62	-5.85	-0.43	3.13e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg19413350	chr8:57351067	NA	-0.4	-4.64	-0.36	7.54e-6	Obesity-related traits;
UCEC	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	trans	rs1552172	0.887	rs12729321	chr1:145645820	G/T	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.62	-6.87	-0.49	1.7e-10	Breast cancer;
UCEC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.87	10.88	0.67	1.37e-20	IgG glycosylation;
UCEC	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.2	0.39	6.43e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.4	0.47	1.97e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.54	-6.12	-0.45	8.28e-9	Pubertal anthropometrics;
UCEC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.66	-6.26	-0.46	4.03e-9	Aortic root size;
UCEC	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.69	6.66	0.48	5.09e-10	Schizophrenia;
UCEC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.94	10.3	0.65	4.68e-19	Cognitive function;
UCEC	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.63	6.28	0.46	3.56e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.78	7.84	0.54	8.33e-13	Multiple myeloma (IgH translocation);
UCEC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg07636037	chr3:49044803	WDR6	0.57	4.76	0.37	4.68e-6	Menarche (age at onset);
UCEC	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.79	7.87	0.54	7.04e-13	Smoking behavior;
UCEC	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-4.84	-0.37	3.23e-6	Menarche (age at onset);
UCEC	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg05347473	chr6:146136440	FBXO30	0.4	4.64	0.36	7.63e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	8.62	0.58	1e-14	Chronic sinus infection;
UCEC	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	4.82	0.37	3.58e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.53	0.77	3.12e-30	Height;
UCEC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.86	0.43	2.98e-8	Breast cancer;
UCEC	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	0.55	5.82	0.43	3.51e-8	QRS complex (12-leadsum);
UCEC	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg06096015	chr1:231504339	EGLN1	0.41	4.57	0.35	1.02e-5	Hemoglobin concentration;
UCEC	cis	rs10924970	0.967	rs2185021	chr1:235452744	G/A	cg26050004	chr1:235667680	B3GALNT2	0.46	4.81	0.37	3.69e-6	Asthma;
UCEC	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.85	-8.48	-0.57	2.23e-14	Schizophrenia;
UCEC	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	5.33	0.4	3.69e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.81	10.06	0.64	1.98e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.47	4.84	0.37	3.28e-6	Breast cancer;
UCEC	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.51	4.63	0.36	7.94e-6	Corneal astigmatism;
UCEC	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.48	4.9	0.37	2.51e-6	Red blood cell count;
UCEC	cis	rs76878669	0.538	rs12785321	chr11:66179736	A/C	cg24851651	chr11:66362959	CCS	-0.39	-4.94	-0.38	2.07e-6	Educational attainment (years of education);
UCEC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg07424592	chr7:64974309	NA	0.77	4.77	0.37	4.39e-6	Diabetic kidney disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg15239874	chr12:121148841	UNC119B	0.57	6.74	0.49	3.3e-10	Warfarin maintenance dose;
UCEC	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.63	5.49	0.41	1.7e-7	Uric acid levels;
UCEC	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg19318889	chr4:1322082	MAEA	0.52	5.69	0.42	6.7e-8	Obesity-related traits;
UCEC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg24881330	chr22:46731750	TRMU	0.73	7.36	0.52	1.18e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.97	11.47	0.69	3.68e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.05	7.53	0.53	4.74e-12	Sexual dysfunction (female);
UCEC	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg08027265	chr7:2291960	NA	-0.42	-4.54	-0.35	1.14e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.66	4.75e-20	Body mass index;
UCEC	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.21	9.88	0.63	5.65e-18	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg26752003	chr8:145688521	CYHR1	-0.63	-6.22	-0.46	4.82e-9	Age at first birth;
UCEC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.39	4.54	0.35	1.14e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-4.73	-0.36	5.17e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.34	0.4	3.53e-7	Rheumatoid arthritis;
UCEC	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.49	5.37	0.41	2.98e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg10932868	chr11:921992	NA	-0.42	-5.37	-0.4	3.02e-7	Alzheimer's disease (late onset);
UCEC	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.63	6.09	0.45	9.33e-9	Lymphocyte counts;
UCEC	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.44	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	5.03	0.38	1.41e-6	Cognitive function;
UCEC	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.68	-6.85	-0.49	1.89e-10	Plateletcrit;Platelet count;
UCEC	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.25	-0.56	8.41e-14	Total cholesterol levels;
UCEC	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.65	4.82	0.37	3.52e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.63	-6.31	-0.46	3.08e-9	C-reactive protein levels;
UCEC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg11131117	chr7:1891496	MAD1L1	-0.34	-4.68	-0.36	6.55e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.35	1.2e-5	Menarche (age at onset);
UCEC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.68	5.65	0.42	8.04e-8	Corneal astigmatism;
UCEC	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.73	9.16	0.6	4.11e-16	Menarche (age at onset);
UCEC	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.58	6.4	0.47	1.96e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.85	-0.37	3.05e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.66	-5.86	-0.44	2.95e-8	Alzheimer's disease;
UCEC	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.86	9.25	0.61	2.42e-16	Migraine;Coronary artery disease;
UCEC	cis	rs8112909	0.843	rs1422627	chr19:46416738	C/T	cg03208830	chr19:45909395	PPP1R13L;CD3EAP	0.56	4.59	0.35	9.44e-6	Interferon gamma-induced protein 10 levels;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg00651523	chr6:28411279	ZSCAN23	0.47	5.44	0.41	2.18e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.46	4.59	0.35	9.45e-6	Motion sickness;
UCEC	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.54	0.47	9.35e-10	Cognitive test performance;
UCEC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.51	5.02	0.38	1.5e-6	Menopause (age at onset);
UCEC	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.62	6.98	0.5	9.23e-11	Pubertal anthropometrics;
UCEC	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg22974920	chr21:40686053	BRWD1	-0.54	-4.86	-0.37	2.99e-6	Cognitive function;
UCEC	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.62	5.91	0.44	2.34e-8	Schizophrenia;
UCEC	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.52	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.47	-5.04	-0.38	1.37e-6	Retinal vascular caliber;
UCEC	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.56	5.16	0.39	7.8e-7	Corneal astigmatism;
UCEC	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.48	4.79	0.37	4.06e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.61	-5.28	-0.4	4.52e-7	Metabolite levels;
UCEC	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.36	-0.4	3.12e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.61	5.84	0.43	3.18e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg27153327	chr16:1920815	C16orf73	0.44	4.9	0.37	2.52e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.88	-0.44	2.65e-8	Depression;
UCEC	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.26e-9	Prudent dietary pattern;
UCEC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.6	5.34	0.4	3.5e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.69	8.47	0.57	2.34e-14	Prudent dietary pattern;
UCEC	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.41	4.8	0.37	3.9e-6	Menarche (age at onset);
UCEC	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-13.31	-0.74	4.94e-27	Schizophrenia;
UCEC	cis	rs78487399	0.908	rs17031088	chr2:43807090	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.99	-0.38	1.69e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg01426195	chr3:39028469	NA	0.76	9.75	0.63	1.25e-17	Handedness;
UCEC	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.52	-5.08	-0.39	1.13e-6	Multiple sclerosis;
UCEC	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	5.94	0.44	1.96e-8	Bone mineral density;
UCEC	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.59	-6.46	-0.47	1.48e-9	Bipolar disorder;
UCEC	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	1.07	13.96	0.76	9.85e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg14664628	chr15:75095509	CSK	-0.51	-4.8	-0.37	3.94e-6	Caffeine consumption;
UCEC	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.49	4.54	0.35	1.17e-5	Lung cancer;
UCEC	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.7	6.87	0.49	1.73e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs13136331	0.642	rs1319917	chr4:88628808	G/C	cg01170486	chr4:88020856	AFF1	0.58	4.72	0.36	5.52e-6	Sitting height ratio;
UCEC	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.52	-5.19	-0.39	6.73e-7	Bipolar disorder;
UCEC	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.54	-5.39	-0.41	2.71e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg08576658	chr19:56098601	NA	0.67	7.22	0.51	2.52e-11	Triglyceride levels;
UCEC	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.44	4.83	0.37	3.41e-6	Life satisfaction;
UCEC	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg14254433	chr6:34482411	PACSIN1	-0.64	-4.51	-0.35	1.34e-5	Chronic lymphocytic leukemia;
UCEC	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs151997	0.853	rs3846498	chr5:50253625	A/C	cg06027927	chr5:50259733	NA	-0.56	-5.25	-0.4	5.18e-7	Callous-unemotional behaviour;
UCEC	cis	rs6906287	0.669	rs2356491	chr6:118806564	A/G	cg21191810	chr6:118973309	C6orf204	0.39	5.25	0.4	5.14e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.45	4.73	0.36	5.23e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.44	-4.59	-0.35	9.49e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.5	-5.47	-0.41	1.89e-7	Aortic root size;
UCEC	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.67	-7.0	-0.5	8.52e-11	Height;
UCEC	cis	rs10896135	0.531	rs597626	chr11:66316557	T/C	cg24851651	chr11:66362959	CCS	-0.42	-5.15	-0.39	8.37e-7	Bipolar disorder;
UCEC	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.41	7.67	0.53	2.23e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg14092571	chr14:90743983	NA	-0.43	-5.69	-0.43	6.56e-8	Mortality in heart failure;
UCEC	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-4.54	-0.35	1.15e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.49	4.52	0.35	1.26e-5	Handedness;
UCEC	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.71	9.2	0.6	3.32e-16	Rheumatoid arthritis;
UCEC	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.57	-5.37	-0.4	3.03e-7	High light scatter reticulocyte count;
UCEC	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg27535305	chr1:53392650	SCP2	-0.43	-5.49	-0.41	1.76e-7	Monocyte count;
UCEC	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.58	5.21	0.39	6.4e-7	Acne (severe);
UCEC	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.54	5.82	0.43	3.63e-8	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.51	0.47	1.11e-9	Menarche (age at onset);
UCEC	cis	rs712046	0.901	rs712045	chr17:34358452	C/T	cg10009297	chr17:34890195	MYO19;PIGW	0.45	4.6	0.35	9.01e-6	Pulmonary function;
UCEC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.59	0.35	9.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9467773	1.000	rs1977201	chr6:26573674	T/C	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs36051895	0.632	rs7032616	chr9:5180996	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-5.24	-0.4	5.41e-7	Pediatric autoimmune diseases;
UCEC	cis	rs6761276	0.899	rs11677043	chr2:113835520	A/G	cg09040174	chr2:113837401	NA	0.52	5.72	0.43	5.72e-8	Protein quantitative trait loci;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.47	-5.05	-0.38	1.3e-6	Pubertal anthropometrics;
UCEC	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01391022	chr12:122360665	WDR66	-0.42	-4.83	-0.37	3.36e-6	Mean corpuscular volume;
UCEC	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.52	5.22	0.4	6.05e-7	Blood protein levels;
UCEC	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.82	0.49	2.15e-10	Motion sickness;
UCEC	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg01072550	chr1:21505969	NA	-0.58	-6.14	-0.45	7.38e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2302190	0.882	rs8068135	chr17:56654210	A/C	cg12560992	chr17:57184187	TRIM37	0.53	4.69	0.36	6.08e-6	Vitamin D levels;
UCEC	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.52	5.08	0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.66	-4.53	-0.35	1.23e-5	Hair shape;
UCEC	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.63	7.19	0.51	2.99e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9987289	0.667	rs11781511	chr8:9192423	A/G	cg24185864	chr8:9762057	MIR124-1;LOC157627	0.49	4.59	0.35	9.43e-6	HDL Cholesterol - Triglycerides (HDLC-TG);C-reactive protein levels or LDL-cholesterol levels (pleiotropy);C-reactive protein levels or triglyceride levels (pleiotropy);LDL cholesterol;HDL cholesterol;Cholesterol, total;C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Metabolic syndrome (bivariate traits);Total cholesterol levels;Plasma lactate levels;C-reactive protein levels;LDL cholesterol levels;
UCEC	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.22	11.23	0.68	1.66e-21	Corneal structure;
UCEC	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.96	0.5	1.03e-10	Mood instability;
UCEC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.54	4.87	0.37	2.9e-6	Corneal astigmatism;
UCEC	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.87	-5.25	-0.4	5.11e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg05738196	chr6:26577821	NA	0.49	4.56	0.35	1.06e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.74	8.91	0.59	1.83e-15	Menarche (age at onset);
UCEC	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.72	8.77	0.59	4.15e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.72	-7.49	-0.53	6.02e-12	Vitamin D levels;
UCEC	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-6.71	-0.48	3.92e-10	Platelet distribution width;
UCEC	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.47	5.61	0.42	9.88e-8	Prostate cancer;
UCEC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.39	-5.56	-0.42	1.22e-7	Longevity;
UCEC	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.55	5.19	0.39	6.85e-7	Lung cancer;
UCEC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.67	7.0	0.5	8.38e-11	Body mass index;
UCEC	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.68	-6.41	-0.47	1.83e-9	HDL cholesterol;
UCEC	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.73	-4.88	-0.37	2.78e-6	LDL cholesterol levels;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg26268016	chr7:112580305	C7orf60	-0.62	-7.18	-0.51	3.14e-11	Breast cancer;
UCEC	cis	rs9402633	0.938	rs6902798	chr6:135036003	C/T	cg16239184	chr6:135079577	NA	-0.5	-4.73	-0.36	5.15e-6	Platelet count;
UCEC	cis	rs9469578	0.901	rs57303110	chr6:33706159	G/A	cg18708504	chr6:33715942	IP6K3	0.55	5.31	0.4	3.92e-7	Phosphorus levels;
UCEC	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg19554555	chr3:13937349	NA	0.58	5.79	0.43	4.1e-8	Ovarian reserve;
UCEC	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	8.95	0.59	1.4e-15	Mean platelet volume;
UCEC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.5	4.96	0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.44	4.54	0.35	1.18e-5	Metabolic traits;
UCEC	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.14	0.6	4.62e-16	Alzheimer's disease;
UCEC	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.57	5.26	0.4	5.06e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.43	-0.41	2.27e-7	Platelet count;
UCEC	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18932078	chr1:2524107	MMEL1	-0.33	-5.43	-0.41	2.25e-7	Ulcerative colitis;
UCEC	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.62	-4.65	-0.36	7.28e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.15	0.39	8.42e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.53	4.7	0.36	6.05e-6	Cholesterol, total;
UCEC	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.45	-4.75	-0.37	4.7e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.59	6.91	0.5	1.35e-10	Vitiligo;
UCEC	cis	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg17469321	chr7:55412551	NA	0.7	6.36	0.46	2.38e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-5.04	-0.38	1.34e-6	Morning vs. evening chronotype;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27261837	chr1:146714163	CHD1L	0.54	6.76	0.49	2.96e-10	Warfarin maintenance dose;
UCEC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.66	-4.6	-0.35	9.19e-6	Aortic root size;
UCEC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.53	5.25	0.4	5.32e-7	Vitiligo;
UCEC	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.6	5.25	0.4	5.3e-7	White matter hyperintensity burden;
UCEC	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.69	7.47	0.52	6.69e-12	Breast cancer;
UCEC	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.6	7.14	0.51	4.01e-11	Oral cavity cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24727182	chr4:109684250	AGXT2L1	0.54	6.86	0.49	1.83e-10	Warfarin maintenance dose;
UCEC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-0.63	-7.36	-0.52	1.18e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg19041857	chr6:27730383	NA	-0.43	-4.57	-0.35	1.01e-5	Myopia;
UCEC	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.53	0.35	1.22e-5	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.96	9.35	0.61	1.37e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.85	-0.43	3.01e-8	Obesity-related traits;
UCEC	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg13147721	chr7:65941812	NA	-0.85	-5.74	-0.43	5.3e-8	Diabetic kidney disease;
UCEC	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.4	4.99	0.38	1.7e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.85	-8.49	-0.57	2.07e-14	Resting heart rate;
UCEC	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.44	6.09	0.45	9.36e-9	Vitamin D levels;
UCEC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.49	-5.29	-0.4	4.37e-7	Menopause (age at onset);
UCEC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.73	7.39	0.52	9.97e-12	Blood protein levels;
UCEC	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.75	-0.49	3.15e-10	Pubertal anthropometrics;
UCEC	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.41	5.15	0.39	8.28e-7	Electrocardiographic conduction measures;
UCEC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.47	5.5	0.41	1.6e-7	Aortic root size;
UCEC	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.56	4.72	0.36	5.49e-6	Body mass index;
UCEC	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04731861	chr2:219085781	ARPC2	0.41	4.55	0.35	1.1e-5	Colorectal cancer;
UCEC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.61	0.42	9.69e-8	Breast cancer;
UCEC	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.53	5.29	0.4	4.31e-7	Menopause (age at onset);
UCEC	cis	rs3772130	0.540	rs11717089	chr3:121563271	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.8	6.04	0.45	1.18e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.56	4.55	0.35	1.13e-5	Bladder cancer;
UCEC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.59	5.29	0.4	4.44e-7	Corneal astigmatism;
UCEC	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	10.38	0.65	2.87e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.55	-5.56	-0.42	1.21e-7	Obesity-related traits;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.66	7.21	0.51	2.7e-11	Longevity;Endometriosis;
UCEC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg17105886	chr17:28927953	LRRC37B2	0.64	4.56	0.35	1.06e-5	Body mass index;
UCEC	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.5	-4.98	-0.38	1.74e-6	Breast size;
UCEC	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.71	8.66	0.58	7.58e-15	Monocyte count;
UCEC	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.82	8.73	0.58	5.22e-15	Blood protein levels;
UCEC	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg18827107	chr12:86230957	RASSF9	-0.43	-4.8	-0.37	3.83e-6	Major depressive disorder;
UCEC	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	0.85	5.3	0.4	4.13e-7	Arsenic metabolism;
UCEC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.57	5.05	0.38	1.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.55	-0.48	8.89e-10	Cardiac Troponin-T levels;
UCEC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-5.22	-0.4	5.88e-7	Longevity;Endometriosis;
UCEC	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.65	6.07	0.45	1.03e-8	Height;
UCEC	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.03	-0.38	1.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg22974920	chr21:40686053	BRWD1	0.59	5.09	0.39	1.1e-6	Cognitive function;
UCEC	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg00105475	chr2:10696890	NA	0.4	4.78	0.37	4.28e-6	Prostate cancer;
UCEC	cis	rs308403	0.600	rs309361	chr4:123657978	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.8	8.42	0.57	3.18e-14	Blood protein levels;
UCEC	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.79	5.13	0.39	8.82e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	0.68	7.44	0.52	7.65e-12	Homoarginine levels;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.83	9.89	0.63	5.3e-18	Menarche (age at onset);
UCEC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.53	4.64	0.36	7.51e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.64	5.47	0.41	1.88e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg13147721	chr7:65941812	NA	-0.7	-5.0	-0.38	1.58e-6	Diabetic kidney disease;
UCEC	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.51	5.88	0.44	2.71e-8	Mean corpuscular volume;
UCEC	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs4708832	0.529	rs240862	chr6:159916242	T/C	cg24100167	chr6:160221433	PNLDC1	-0.54	-4.51	-0.35	1.29e-5	QRS duration;
UCEC	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.41	0.47	1.91e-9	Coffee consumption (cups per day);
UCEC	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.8	-0.37	3.8e-6	Blood metabolite levels;
UCEC	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.55	4.86	0.37	3e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.57	5.68	0.42	7.03e-8	Bladder cancer;
UCEC	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.47	6.73	0.49	3.56e-10	Homoarginine levels;
UCEC	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg22974920	chr21:40686053	BRWD1	-0.55	-4.97	-0.38	1.81e-6	Cognitive function;
UCEC	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.97e-6	Body mass index;
UCEC	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.47	-5.91	-0.44	2.25e-8	Mean platelet volume;
UCEC	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.94	-0.38	2.05e-6	Testicular germ cell tumor;
UCEC	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.32	-0.57	5.65e-14	Exhaled nitric oxide output;
UCEC	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	cis	rs243088	1.000	rs243020	chr2:60585028	A/G	cg16665442	chr2:60585866	NA	-0.41	-4.93	-0.38	2.15e-6	Type 2 diabetes;
UCEC	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg00105475	chr2:10696890	NA	-0.44	-5.52	-0.41	1.48e-7	Prostate cancer;
UCEC	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.57	5.11	0.39	9.9e-7	Corneal astigmatism;
UCEC	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02650964	chr4:1222621	CTBP1	0.5	4.71	0.36	5.8e-6	Systolic blood pressure;
UCEC	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg04154034	chr17:28927549	LRRC37B2	0.55	5.21	0.39	6.42e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-6.13	-0.45	7.54e-9	Monocyte count;
UCEC	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	9.49	0.62	5.97e-17	Platelet count;
UCEC	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.69	-7.9	-0.55	5.86e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg02158880	chr13:53174818	NA	0.56	6.58	0.48	7.65e-10	Lewy body disease;
UCEC	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg17764715	chr19:33622953	WDR88	0.64	6.01	0.44	1.37e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg12024160	chr4:1254474	NA	0.64	7.3	0.52	1.63e-11	Obesity-related traits;
UCEC	cis	rs580809	1.000	rs72735324	chr9:101525489	A/G	cg14451115	chr9:101050633	GABBR2	-0.46	-4.56	-0.35	1.06e-5	Body mass index;
UCEC	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg12463550	chr7:65579703	CRCP	0.53	5.42	0.41	2.39e-7	Aortic root size;
UCEC	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.88	7.78	0.54	1.17e-12	Blood metabolite levels;
UCEC	cis	rs925550	0.526	rs62322204	chr4:123629089	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.71	-7.49	-0.53	5.75e-12	Primary biliary cholangitis;
UCEC	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.49	-5.16	-0.39	7.7300000000000005e-07	Systolic blood pressure;
UCEC	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.03	-0.38	1.41e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.78	7.31	0.52	1.6e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.42	5.3	0.4	4.06e-7	Alcohol dependence;
UCEC	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.6	7.52	0.53	5.14e-12	Testicular germ cell tumor;
UCEC	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.94	10.92	0.67	1.04e-20	Breast cancer;
UCEC	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-7.22	-0.51	2.54e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.71	6.77	0.49	2.84e-10	Platelet distribution width;
UCEC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.64	-5.88	-0.44	2.6e-8	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	0.82	11.57	0.69	2.06e-22	Monocyte percentage of white cells;
UCEC	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	0.83	5.25	0.4	5.22e-7	Arsenic metabolism;
UCEC	cis	rs17401966	0.894	rs61778406	chr1:10435816	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-5.43	-0.41	2.25e-7	Hepatocellular carcinoma;
UCEC	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.49	-4.95	-0.38	2.05e-6	Breast cancer;
UCEC	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.52	4.88	0.37	2.76e-6	Coronary artery disease;
UCEC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs742614	0.533	rs2626547	chr20:32404921	G/A	cg06304546	chr20:32448765	NA	-0.45	-4.79	-0.37	4.05e-6	Stearic acid (18:0) levels;
UCEC	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.76	-8.27	-0.56	7.38e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.84	10.68	0.66	4.65e-20	Metabolic syndrome;
UCEC	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.43	-4.73	-0.36	5.29e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-5.16	-0.39	8.02e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.56	5.93	0.44	2.07e-8	Schizophrenia;
UCEC	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.64	6.24	0.46	4.4e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-7.39	-0.52	1e-11	Ulcerative colitis;
UCEC	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.52	5.15	0.39	8.27e-7	Pediatric autoimmune diseases;
UCEC	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.39	-9.01	-0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.59	5.47	0.41	1.88e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.76	7.51	0.53	5.36e-12	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
UCEC	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.99	-12.0	-0.7	1.46e-23	Obesity-related traits;
UCEC	cis	rs554111	0.660	rs658851	chr1:21079425	T/C	cg08890418	chr1:21044141	KIF17	0.55	5.45	0.41	2.08e-7	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.48	-5.18	-0.39	7.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.84	9.68	0.62	1.87e-17	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.47	-5.75	-0.43	5.04e-8	Subjective well-being;
UCEC	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.08	7.7	0.54	1.86e-12	Sexual dysfunction (female);
UCEC	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.38	4.58	0.35	9.99e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
UCEC	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.52	-0.41	1.49e-7	Mortality in heart failure;
UCEC	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg22974920	chr21:40686053	BRWD1	0.58	5.06	0.39	1.22e-6	Cognitive function;
UCEC	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.9	10.65	0.66	5.36e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg24158363	chr17:73401717	GRB2	0.65	6.79	0.49	2.57e-10	Schizophrenia;
UCEC	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg23795048	chr12:9217529	LOC144571	0.39	5.01	0.38	1.53e-6	Sjögren's syndrome;
UCEC	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-4.6	-0.36	8.86e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.7	6.9	0.49	1.48e-10	Parkinson's disease;
UCEC	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.51	-6.2	-0.46	5.48e-9	Mean platelet volume;
UCEC	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs7095607	0.813	rs7903493	chr10:69931156	C/A	cg18986048	chr10:69913749	MYPN	0.54	6.26	0.46	4.09e-9	Lung function (FVC);
UCEC	cis	rs7725816	0.748	rs6580523	chr5:147499426	A/C	cg10994339	chr5:147443536	SPINK5	-0.5	-4.68	-0.36	6.51e-6	Yeast infection;
UCEC	cis	rs4851266	1.000	rs4851264	chr2:100810188	T/C	cg14675211	chr2:100938903	LONRF2	0.66	6.44	0.47	1.59e-9	Educational attainment;
UCEC	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.61	6.98	0.5	9.32e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.64	5.42	0.41	2.4e-7	Cocaine dependence;
UCEC	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.67	5.66	0.42	7.85e-8	Coronary artery disease;
UCEC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs308447	0.516	rs6853540	chr4:123679848	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.61	5.07	0.39	1.18e-6	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.72	8.44	0.57	2.8e-14	Body mass index;
UCEC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.3	0.56	6.26e-14	Sudden cardiac arrest;
UCEC	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg07169764	chr2:136633963	MCM6	-0.75	-7.28	-0.51	1.82e-11	Mosquito bite size;
UCEC	cis	rs7264396	0.836	rs6120995	chr20:34185726	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-4.96	-0.38	1.92e-6	Total cholesterol levels;
UCEC	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.63	-6.03	-0.45	1.3e-8	Urate levels in obese individuals;
UCEC	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06223018	chr3:49557076	DAG1	0.33	4.76	0.37	4.66e-6	Parkinson's disease;
UCEC	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.67	5.85	0.43	3.1e-8	Platelet count;
UCEC	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.91	-8.85	-0.59	2.6e-15	Blood metabolite levels;
UCEC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.82	8.62	0.58	9.5e-15	Breast cancer;
UCEC	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.49	5.51	0.41	1.59e-7	Response to temozolomide;
UCEC	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.63	5.67	0.42	7.19e-8	Platelet count;
UCEC	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12826209	chr6:26865740	GUSBL1	0.51	5.0	0.38	1.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12039431	0.746	rs61776185	chr1:38010651	G/A	cg17933807	chr1:38061675	GNL2	-0.55	-4.7	-0.36	6.01e-6	Epithelial ovarian cancer;
UCEC	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.48	6.14	0.45	7.38e-9	HDL cholesterol levels;
UCEC	cis	rs970548	1.000	rs58865519	chr10:46010891	C/A	cg15223267	chr10:46222474	FAM21C	0.54	5.18	0.39	7.09e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.44	-4.62	-0.36	8.38e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.36	4.67	0.36	6.66e-6	Total body bone mineral density;
UCEC	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.81	-8.44	-0.57	2.7e-14	Mosquito bite size;
UCEC	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.77	-4.63	-0.36	7.99e-6	Putamen volume;
UCEC	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.57	6.36	0.46	2.42e-9	Bipolar disorder;
UCEC	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.8	7.76	0.54	1.31e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.5	-5.03	-0.38	1.38e-6	Prostate cancer;
UCEC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg03711944	chr11:47377212	SPI1	-0.5	-4.62	-0.36	8.25e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.85	5.05	0.38	1.27e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.46	6.86	0.49	1.78e-10	Primary biliary cholangitis;
UCEC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg21770322	chr7:97807741	LMTK2	-0.48	-5.84	-0.43	3.25e-8	Breast cancer;
UCEC	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.36	-0.4	3.09e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7646881	0.500	rs2082838	chr3:158305894	A/G	cg05743054	chr3:158288903	MLF1	0.51	4.74	0.36	4.93e-6	Tetralogy of Fallot;
UCEC	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg16616514	chr4:6324629	PPP2R2C	0.4	4.89	0.37	2.63e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	5.08	0.39	1.13e-6	Electrocardiographic conduction measures;
UCEC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-6.37	-0.47	2.23e-9	Aortic root size;
UCEC	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.47	-5.33	-0.4	3.59e-7	Obesity-related traits;
UCEC	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg12923728	chr3:195709715	SDHAP1	0.63	4.66	0.36	6.99e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg07435449	chr11:120005650	TRIM29	0.51	5.07	0.39	1.17e-6	Stroke (pediatric);
UCEC	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	1.0	5.88	0.44	2.71e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.83	9.99	0.64	2.95e-18	Menopause (age at onset);
UCEC	cis	rs308447	0.543	rs13130243	chr4:123708911	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.59	6.61	0.48	6.71e-10	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.48	5.39	0.41	2.73e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	0.72	5.34	0.4	3.52e-7	Blood protein levels;
UCEC	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.89	-0.49	1.49e-10	Total cholesterol levels;
UCEC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.54	4.87	0.37	2.85e-6	Skin colour saturation;
UCEC	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.59	5.69	0.43	6.56e-8	Type 2 diabetes;
UCEC	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.69	-7.07	-0.5	5.72e-11	Blood metabolite levels;
UCEC	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.71	-0.48	3.92e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7246967	0.551	rs3925175	chr19:22880958	G/A	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.63	7.08	0.5	5.61e-11	Crohn's disease;
UCEC	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg24375607	chr4:120327624	NA	0.46	4.76	0.37	4.68e-6	Corneal astigmatism;
UCEC	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg14008862	chr17:28927542	LRRC37B2	0.83	5.44	0.41	2.16e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	0.69	5.85	0.43	3.04e-8	Type 2 diabetes nephropathy;
UCEC	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.79	-8.77	-0.59	4.1e-15	Cognitive function;
UCEC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg23307798	chr14:103986281	CKB	0.63	6.59	0.48	7.32e-10	Body mass index;
UCEC	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg15848620	chr12:58087721	OS9	-0.51	-4.82	-0.37	3.51e-6	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.71	8.97	0.59	1.24e-15	Testicular germ cell tumor;
UCEC	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	5.05	0.38	1.28e-6	Height;
UCEC	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.33	0.4	3.56e-7	Diabetic retinopathy;
UCEC	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-5.13	-0.39	8.86e-7	Aortic root size;
UCEC	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs7246967	0.673	rs8103875	chr19:22866862	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18932078	chr1:2524107	MMEL1	-0.33	-5.32	-0.4	3.73e-7	Multiple sclerosis;
UCEC	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.55	-5.68	-0.42	6.85e-8	Dental caries;
UCEC	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.63	7.85	0.54	8.1e-13	Bone mineral density;
UCEC	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg06562184	chr8:19319451	CSGALNACT1	0.43	4.75	0.36	4.79e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg05738196	chr6:26577821	NA	-0.53	-4.83	-0.37	3.4e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11118844	0.793	rs10218652	chr1:221947406	T/C	cg04222084	chr1:221915650	DUSP10	-0.77	-7.19	-0.51	3.1e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs7215564	0.730	rs7214653	chr17:78581450	A/G	cg01498832	chr17:78682934	RPTOR	-0.62	-5.16	-0.39	7.89e-7	Myopia (pathological);
UCEC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg11871910	chr12:69753446	YEATS4	0.64	7.11	0.51	4.69e-11	Blood protein levels;
UCEC	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.49	-0.47	1.24e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.47	-6.1	-0.45	9.08e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.35	-5.09	-0.39	1.07e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.49	5.13	0.39	9.14e-7	Testicular germ cell tumor;
UCEC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg03354898	chr7:1950403	MAD1L1	-0.6	-5.96	-0.44	1.77e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.1	-0.45	9.13e-9	Coffee consumption (cups per day);
UCEC	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.47	5.48	0.41	1.79e-7	Aortic root size;
UCEC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg14582100	chr15:45693742	SPATA5L1	-0.5	-6.27	-0.46	3.81e-9	Homoarginine levels;
UCEC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.49	5.16	0.39	7.92e-7	Longevity;Endometriosis;
UCEC	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.75	-0.36	4.8e-6	Response to antipsychotic treatment;
UCEC	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg23791538	chr6:167370224	RNASET2	-0.52	-5.33	-0.4	3.67e-7	Crohn's disease;
UCEC	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.14	0.45	7.48e-9	Personality dimensions;
UCEC	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.71	8.86	0.59	2.47e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	6.78	0.49	2.68e-10	Motion sickness;
UCEC	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.63	-5.61	-0.42	9.97e-8	Mortality in heart failure;
UCEC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg08461772	chr7:95026248	PON3	0.4	5.51	0.41	1.53e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.64	-4.62	-0.36	8.43e-6	Gut microbiome composition (summer);
UCEC	cis	rs73416724	1.000	rs78567061	chr6:43293446	G/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.07	4.9	0.37	2.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.9	-0.37	2.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.65	-6.76	-0.49	2.98e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg16023434	chr1:11395635	NA	0.37	4.69	0.36	6.29e-6	Body mass index;
UCEC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg02160872	chr5:212506	CCDC127	-0.83	-7.44	-0.52	7.74e-12	Asthma (childhood onset);
UCEC	trans	rs2699783	0.636	rs13427967	chr2:66210538	A/C	cg04646674	chr19:13113482	NFIX	0.68	6.7	0.48	4.08e-10	Bipolar disorder (body mass index interaction);
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.8	-8.44	-0.57	2.83e-14	Prudent dietary pattern;
UCEC	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.43	5.66	0.42	7.79e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.69	-7.47	-0.52	6.64e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg12024160	chr4:1254474	NA	0.68	8.04	0.55	2.71e-13	Obesity-related traits;
UCEC	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg18232548	chr7:50535776	DDC	-0.67	-7.54	-0.53	4.49e-12	Body mass index;
UCEC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.0	-0.44	1.46e-8	Prudent dietary pattern;
UCEC	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.58	-5.03	-0.38	1.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs1483890	0.638	rs1564756	chr3:69402489	T/G	cg22125112	chr3:69402811	FRMD4B	-0.44	-4.54	-0.35	1.15e-5	Resting heart rate;
UCEC	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.4	-0.41	2.6e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	0.99	11.08	0.67	3.98e-21	Exhaled nitric oxide output;
UCEC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.6e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg17306686	chr7:157230923	NA	0.39	4.86	0.37	2.92e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
UCEC	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.66	-6.32	-0.46	2.98e-9	Aortic root size;
UCEC	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.54	5.3	0.4	4.18e-7	Vitiligo;
UCEC	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-0.78	-9.23	-0.61	2.7e-16	Multiple myeloma;
UCEC	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.48	4.61	0.36	8.55e-6	Menopause (age at onset);
UCEC	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.5	5.09	0.39	1.1e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	0.99	9.59	0.62	3.16e-17	Initial pursuit acceleration;
UCEC	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	6.79	0.49	2.52e-10	Platelet count;
UCEC	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg09149842	chr20:31351091	DNMT3B	-0.42	-4.58	-0.35	9.71e-6	Ulcerative colitis;
UCEC	cis	rs17106184	1.000	rs72902755	chr1:51250908	G/T	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.94	9.83	0.63	7.66e-18	Prudent dietary pattern;
UCEC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg14008862	chr17:28927542	LRRC37B2	0.6	5.78	0.43	4.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.65	5.98	0.44	1.63e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg11859384	chr17:80120422	CCDC57	-0.53	-5.88	-0.44	2.66e-8	Life satisfaction;
UCEC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.54	-4.54	-0.35	1.16e-5	Menarche (age at onset);
UCEC	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.09	8.69	0.58	6.66e-15	Uric acid levels;
UCEC	cis	rs9815925	0.702	rs9832304	chr3:184686285	A/G	cg00151007	chr3:184769954	VPS8	-0.44	-4.66	-0.36	7.02e-6	Heschl's gyrus morphology;
UCEC	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.51	5.79	0.43	4.04e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg19678392	chr7:94953810	PON1	-0.6	-5.39	-0.41	2.77e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.41	-4.81	-0.37	3.74e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-5.47	-0.41	1.89e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-0.72	-7.45	-0.52	7.28e-12	Height;
UCEC	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-5.57	-0.42	1.2e-7	Colorectal cancer;
UCEC	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg16060761	chr17:80687452	NA	-0.42	-4.75	-0.37	4.7e-6	Breast cancer;
UCEC	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg23307798	chr14:103986281	CKB	-0.59	-6.3	-0.46	3.35e-9	Body mass index;
UCEC	cis	rs4400599	0.618	rs10908751	chr1:154187305	C/T	cg05139571	chr1:154127138	NUP210L	0.47	5.08	0.39	1.14e-6	Platelet distribution width;
UCEC	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.96	-0.5	1.05e-10	Eye color traits;
UCEC	cis	rs12579753	0.667	rs7487640	chr12:82286681	A/G	cg07988820	chr12:82153109	PPFIA2	0.52	4.59	0.35	9.55e-6	Resting heart rate;
UCEC	cis	rs73562014	0.529	rs7939476	chr11:110342986	A/T	cg26763524	chr11:110300429	FDX1	0.41	5.14	0.39	8.7e-7	Coronary artery disease;
UCEC	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.57	6.07	0.45	1.02e-8	Schizophrenia;
UCEC	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.71	6.92	0.5	1.29e-10	Bladder cancer;
UCEC	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.57	7.05	0.5	6.44e-11	Testicular germ cell tumor;
UCEC	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-1.11	-5.49	-0.41	1.68e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.42	5.97	0.44	1.75e-8	Crohn's disease;
UCEC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.61	-5.53	-0.42	1.4e-7	Coronary artery disease;
UCEC	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	5.81	0.43	3.8e-8	Gut microbiome composition (summer);
UCEC	cis	rs12980942	1.000	rs1865053	chr19:41814412	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	5.04	0.38	1.37e-6	Coronary artery disease;
UCEC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.58	5.31	0.4	3.98e-7	Corneal astigmatism;
UCEC	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg22166914	chr1:53195759	ZYG11B	-0.67	-7.19	-0.51	3.09e-11	Monocyte count;
UCEC	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-5.01	-0.38	1.56e-6	Non-small cell lung cancer;
UCEC	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	0.75	4.99	0.38	1.68e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	8.64	0.58	8.66e-15	Blood protein levels;
UCEC	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.71	7.4	0.52	9.9e-12	Breast cancer;
UCEC	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.73	5.15	0.39	8.36e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg12334488	chr2:20871173	GDF7	-0.37	-4.55	-0.35	1.1e-5	Abdominal aortic aneurysm;
UCEC	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	11.27	0.68	1.3e-21	Chronic sinus infection;
UCEC	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.97	10.57	0.66	9.1e-20	Cognitive function;
UCEC	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.5	-0.35	1.35e-5	Aortic root size;
UCEC	cis	rs6669919	0.967	rs7513031	chr1:211671900	C/T	cg10512769	chr1:211675356	NA	0.32	4.75	0.37	4.71e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.2	-0.39	6.62e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.54	-4.57	-0.35	1.01e-5	Colorectal cancer;
UCEC	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.65	-6.01	-0.44	1.4e-8	Neuroticism;
UCEC	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.52	5.54	0.42	1.39e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.57	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.23	-0.4	5.83e-7	Breast cancer;
UCEC	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.6	6.39	0.47	2.02e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	7.69	0.54	1.97e-12	Bone mineral density;
UCEC	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.64	6.98	0.5	9.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.95e-6	Tonsillectomy;
UCEC	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.52	5.27	0.4	4.76e-7	Corneal astigmatism;
UCEC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.6	6.14	0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.95	-6.83	-0.49	2.08e-10	Platelet count;
UCEC	cis	rs7204230	1.000	rs62049781	chr16:53283009	T/C	cg10109421	chr16:52641824	NA	0.4	4.58	0.35	9.66e-6	Fibrinogen;
UCEC	cis	rs10242455	0.867	rs2687078	chr7:99304712	C/T	cg07715041	chr7:99302981	CYP3A7	-0.5	-5.19	-0.39	7e-7	Blood metabolite levels;
UCEC	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.72	-7.86	-0.54	7.65e-13	White blood cell count (basophil);
UCEC	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.11	-0.45	8.61e-9	Parkinson's disease;
UCEC	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg18016565	chr1:150552671	MCL1	-0.54	-5.83	-0.43	3.4e-8	Tonsillectomy;
UCEC	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.75	6.84	0.49	1.99e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs117623576	0.941	rs60146023	chr10:32411515	G/A	cg03047570	chr10:32398778	NA	-0.53	-4.85	-0.37	3.11e-6	Anti-saccade response;
UCEC	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.86	-9.21	-0.61	3.04e-16	Lung cancer;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.54	-6.16	-0.45	6.71e-9	Pubertal anthropometrics;
UCEC	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg03911494	chr16:71660463	MARVELD3	0.45	4.53	0.35	1.23e-5	Blood protein levels;
UCEC	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.69	-0.42	6.68e-8	Depression;
UCEC	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg13525197	chr6:28411240	ZSCAN23	0.44	5.14	0.39	8.47e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.46	-0.41	1.98e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.46	5.15	0.39	8.15e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.52	5.1	0.39	1.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs692916	1.000	rs692916	chr18:60525392	C/T	cg07187971	chr18:60481018	PHLPP1	-0.41	-5.49	-0.41	1.71e-7	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.69	5.76	0.43	4.76e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.07	-9.39	-0.61	1.09e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg13695892	chr22:41940480	POLR3H	0.67	5.17	0.39	7.44e-7	Vitiligo;
UCEC	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-5.57	-0.42	1.16e-7	Platelet count;
UCEC	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.69	6.65	0.48	5.52e-10	Height;
UCEC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.48e-6	Hemoglobin concentration;
UCEC	cis	rs7611694	0.531	rs66524865	chr3:113043206	T/A	cg12596171	chr3:113251061	SIDT1	0.59	5.93	0.44	2.09e-8	Prostate cancer;
UCEC	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.86	5.62	0.42	9.09e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-0.57	-6.61	-0.48	6.58e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.48	-4.86	-0.37	3e-6	Headache;
UCEC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-0.97	-7.21	-0.51	2.72e-11	Body mass index;
UCEC	cis	rs3015497	0.653	rs2356456	chr14:51093216	A/T	cg04730355	chr14:51134070	SAV1	-0.46	-5.02	-0.38	1.45e-6	Mean platelet volume;
UCEC	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.44	5.2	0.39	6.5e-7	Height;
UCEC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	0.97	10.99	0.67	7.04e-21	IgG glycosylation;
UCEC	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg17294928	chr15:75287854	SCAMP5	0.5	5.21	0.39	6.37e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs883565	0.569	rs1274968	chr3:39170090	A/G	cg01426195	chr3:39028469	NA	-0.61	-7.24	-0.51	2.29e-11	Handedness;
UCEC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.65	6.78	0.49	2.77e-10	Coronary artery disease;
UCEC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	18.36	0.83	6.96e-40	Chronic sinus infection;
UCEC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.63	-6.7	-0.48	4.14e-10	Neurofibrillary tangles;
UCEC	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.36	-5.2	-0.39	6.43e-7	Vitamin D levels;
UCEC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	6.31	0.46	3.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.91	8.21	0.56	1.06e-13	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg21770322	chr7:97807741	LMTK2	-0.51	-6.37	-0.46	2.33e-9	Breast cancer;
UCEC	cis	rs2019216	0.500	rs12450390	chr17:21910636	G/T	cg22648282	chr17:21454238	C17orf51	-0.45	-5.08	-0.39	1.13e-6	Pelvic organ prolapse;
UCEC	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg14008862	chr17:28927542	LRRC37B2	0.65	5.24	0.4	5.37e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg17105886	chr17:28927953	LRRC37B2	0.65	4.61	0.36	8.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.66	5.33	0.4	3.63e-7	Chronic sinus infection;
UCEC	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.63	-9.17	-0.6	3.86e-16	Coronary artery disease or large artery stroke;
UCEC	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg16583315	chr14:65563665	MAX	-0.44	-5.84	-0.43	3.26e-8	Obesity-related traits;
UCEC	cis	rs17433710	0.500	rs6694717	chr1:162623404	G/T	cg19264028	chr1:162630153	DDR2	-0.84	-5.55	-0.42	1.31e-7	Dupuytren's disease;
UCEC	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.43	-0.52	8.25e-12	Total cholesterol levels;
UCEC	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.6	0.48	6.99e-10	Eye color traits;
UCEC	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs9815925	0.545	rs6779667	chr3:184589984	G/T	cg00151007	chr3:184769954	VPS8	0.55	5.16	0.39	7.8e-7	Heschl's gyrus morphology;
UCEC	cis	rs12145833	1.000	rs10926986	chr1:243467611	A/C	cg02356786	chr1:243265016	LOC731275	-0.73	-4.93	-0.38	2.24e-6	Obesity (early onset extreme);
UCEC	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.93	9.21	0.6	3.14e-16	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.97	7.02	0.5	7.49e-11	Obesity-related traits;
UCEC	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.76	-8.41	-0.57	3.38e-14	Trans fatty acid levels;
UCEC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.49	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.45	-4.51	-0.35	1.29e-5	Parkinson's disease;
UCEC	cis	rs728616	0.510	rs12416084	chr10:81749215	A/G	cg05935833	chr10:81318306	SFTPA2	-0.37	-4.55	-0.35	1.1e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.42	4.93	0.38	2.24e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg01256987	chr12:42539512	GXYLT1	0.41	4.75	0.36	4.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg19041857	chr6:27730383	NA	-0.71	-5.42	-0.41	2.44e-7	Depression;
UCEC	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.5	-6.2	-0.46	5.43e-9	Total body bone mineral density;
UCEC	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.54	5.45	0.41	2.12e-7	Aortic root size;
UCEC	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-5.62	-0.42	9.24e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.7	-6.51	-0.47	1.12e-9	Prostate cancer;
UCEC	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.19e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs4146922	0.793	rs62167688	chr2:56009382	C/A	cg00879447	chr2:56412077	CCDC85A	0.47	4.7	0.36	6.04e-6	Height;
UCEC	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	0.81	6.39	0.47	2.1e-9	Corneal structure;
UCEC	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.66	5.95	0.44	1.92e-8	Nonalcoholic fatty liver disease;
UCEC	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.87	0.44	2.77e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Bone mineral density;
UCEC	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.73	0.54	1.57e-12	Ileal carcinoids;
UCEC	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg18681998	chr4:17616180	MED28	0.56	6.11	0.45	8.68e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg11945507	chr8:142233382	SLC45A4	0.43	4.79	0.37	4.07e-6	Immature fraction of reticulocytes;
UCEC	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.79	8.18	0.56	1.26e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.5	4.67	0.36	6.63e-6	Methadone dose in opioid dependence;
UCEC	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-0.8	-7.07	-0.5	5.72e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.61	5.38	0.41	2.88e-7	Alcohol dependence;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24013618	chr4:870925	GAK	0.57	6.8	0.49	2.39e-10	Warfarin maintenance dose;
UCEC	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg04155231	chr12:9217510	LOC144571	0.4	4.85	0.37	3.18e-6	Sjögren's syndrome;
UCEC	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	0.97	13.6	0.75	8.93e-28	Bone mineral density;
UCEC	trans	rs11989744	0.500	rs1438456	chr8:23566909	T/C	cg03492747	chr16:86543808	FOXF1	-0.66	-7.68	-0.54	2.01e-12	Waist-hip ratio;
UCEC	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.69	6.03	0.45	1.25e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg14067834	chr17:29058358	SUZ12P	0.65	4.51	0.35	1.31e-5	Body mass index;
UCEC	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.37	4.67	0.36	6.77e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.53	5.2	0.39	6.67e-7	Menopause (age at onset);
UCEC	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.21	10.62	0.66	6.53e-20	Corneal structure;
UCEC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.67	-7.65	-0.53	2.42e-12	Menarche (age at onset);
UCEC	cis	rs78761021	0.720	rs7220089	chr17:9796985	G/A	cg26853458	chr17:9805074	RCVRN	0.38	4.66	0.36	7.07e-6	Type 2 diabetes;
UCEC	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.58	-6.35	-0.46	2.48e-9	Crohn's disease;
UCEC	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg22117172	chr7:91764530	CYP51A1	0.4	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs10256972	0.900	rs4388364	chr7:1033045	T/G	cg20821713	chr7:1055600	C7orf50	-0.54	-5.61	-0.42	9.87e-8	Longevity;Endometriosis;
UCEC	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.56	5.89	0.44	2.55e-8	Blood protein levels;
UCEC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg03859395	chr2:55845619	SMEK2	0.97	13.49	0.74	1.74e-27	Metabolic syndrome;
UCEC	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.76	-0.49	3.07e-10	Coffee consumption (cups per day);
UCEC	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.05	-17.57	-0.82	6.05e-38	IgG glycosylation;
UCEC	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.47	4.84	0.37	3.24e-6	Dental caries;
UCEC	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg26528668	chr16:1614120	IFT140	0.45	5.36	0.4	3.18e-7	Coronary artery disease;
UCEC	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1575951	1.000	rs11016397	chr10:130431317	A/G	cg27041381	chr10:131357203	MGMT	-0.53	-4.82	-0.37	3.56e-6	Plasma clusterin levels;
UCEC	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.78	-6.98	-0.5	9.36e-11	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.64	-4.93	-0.38	2.2e-6	Orofacial clefts;
UCEC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg11871910	chr12:69753446	YEATS4	0.72	7.35	0.52	1.29e-11	Blood protein levels;
UCEC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.62	5.79	0.43	4.03e-8	Aortic root size;
UCEC	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg20821713	chr7:1055600	C7orf50	-0.69	-6.74	-0.49	3.37e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4265793	1.000	rs4426336	chr16:19027262	A/G	cg06773604	chr16:18995157	TMC7	0.74	5.64	0.42	8.37e-8	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.54	-5.29	-0.4	4.37e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.12	9.58	0.62	3.53e-17	Uric acid levels;
UCEC	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg17330251	chr7:94953956	PON1	-0.6	-5.32	-0.4	3.88e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.94	0.5	1.15e-10	Nonalcoholic fatty liver disease;
UCEC	trans	rs1552172	0.853	rs1471630	chr1:145707297	A/G	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.81	-0.49	2.36e-10	Breast cancer;
UCEC	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg10914120	chr13:113893660	CUL4A	-0.54	-5.31	-0.4	3.91e-7	Platelet distribution width;
UCEC	cis	rs151997	1.000	rs42736	chr5:50244838	G/C	cg06027927	chr5:50259733	NA	0.54	4.96	0.38	1.96e-6	Callous-unemotional behaviour;
UCEC	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	14.66	0.77	1.5e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.59	6.91	0.5	1.35e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.62	-6.38	-0.47	2.13e-9	Initial pursuit acceleration;
UCEC	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg11189052	chr15:85197271	WDR73	0.57	4.6	0.36	8.87e-6	Schizophrenia;
UCEC	cis	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg17412351	chr7:75678396	MDH2;STYXL1	-0.43	-4.62	-0.36	8.19e-6	Eotaxin levels;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.92	-0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.34	4.66	0.36	6.91e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.64	-6.25	-0.46	4.3e-9	Pancreatic cancer;
UCEC	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg19610905	chr11:61596333	FADS2	-0.63	-5.44	-0.41	2.18e-7	Red cell distribution width;Mean platelet volume;
UCEC	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.8	9.14	0.6	4.64e-16	Monocyte count;
UCEC	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.53	4.92	0.38	2.25e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.06	-0.45	1.09e-8	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.67	7.28	0.51	1.88e-11	Mortality in heart failure;
UCEC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.15	0.51	3.71e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.74	-6.69	-0.48	4.47e-10	Intelligence (multi-trait analysis);
UCEC	trans	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02355339	chr19:35517344	GRAMD1A	-0.68	-6.99	-0.5	8.88e-11	Smoking behavior;
UCEC	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.45	-4.53	-0.35	1.22e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.65	6.08	0.45	9.96e-9	Platelet distribution width;
UCEC	trans	rs1923243	0.649	rs4579707	chr1:73396527	C/T	cg17780956	chr4:156297616	MAP9	-0.64	-6.69	-0.48	4.34e-10	Migraine;
UCEC	cis	rs6437061	0.591	rs3100619	chr2:232919261	T/C	cg20569070	chr2:232597279	PDE6D	0.4	4.59	0.35	9.59e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg04155231	chr12:9217510	LOC144571	0.42	5.17	0.39	7.58e-7	Sjögren's syndrome;
UCEC	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.07	16.92	0.81	2.59e-36	IgG glycosylation;
UCEC	cis	rs9463078	0.803	rs2396380	chr6:45043557	T/A	cg25276700	chr6:44698697	NA	-0.47	-5.01	-0.38	1.55e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.07	-0.45	1.04e-8	Bipolar disorder;
UCEC	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg18681998	chr4:17616180	MED28	0.58	6.57	0.48	8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.58	-5.87	-0.44	2.75e-8	Hepatocellular carcinoma;
UCEC	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.59	-6.42	-0.47	1.74e-9	Motion sickness;
UCEC	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.64	-7.12	-0.51	4.55e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg13147721	chr7:65941812	NA	-0.84	-5.48	-0.41	1.81e-7	Diabetic kidney disease;
UCEC	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg01072550	chr1:21505969	NA	-0.58	-6.32	-0.46	2.91e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.92	12.22	0.71	3.88e-24	Metabolic syndrome;
UCEC	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	5.92	0.44	2.21e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.7	-7.39	-0.52	1.04e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9961915	1.000	rs8099553	chr18:24680562	C/G	cg25983544	chr18:23713626	PSMA8	-0.35	-4.59	-0.35	9.43e-6	Dental caries;
UCEC	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg22563815	chr15:78856949	CHRNA5	-0.39	-5.19	-0.39	6.74e-7	Sudden cardiac arrest;
UCEC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.64	-6.65	-0.48	5.33e-10	Body mass index;
UCEC	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.4e-6	Homoarginine levels;
UCEC	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs8105895	0.867	rs116220423	chr19:22237041	G/A	cg24072202	chr19:22235272	ZNF257	-0.57	-5.07	-0.39	1.19e-6	Body mass index (change over time);
UCEC	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.41	5.24	0.4	5.56e-7	Carotid intima media thickness;
UCEC	cis	rs11623869	0.553	rs11627567	chr14:103851775	C/T	cg26031613	chr14:104095156	KLC1	0.99	6.6	0.48	6.87e-10	Bone mineral density;
UCEC	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	0.77	5.03	0.38	1.43e-6	Diabetic retinopathy;
UCEC	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.58	6.25	0.46	4.25e-9	HDL cholesterol;
UCEC	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.34	5.04	0.38	1.38e-6	Schizophrenia;
UCEC	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg03114573	chr12:45410052	DBX2	-0.43	-5.08	-0.39	1.11e-6	Gut microbiome composition (summer);
UCEC	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg09491104	chr22:46646882	C22orf40	-0.54	-5.96	-0.44	1.79e-8	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.45	6.14	0.45	7.32e-9	Life satisfaction;
UCEC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.58	5.98	0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-5.69	-0.42	6.8e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.54	-5.93	-0.44	2.03e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	7.01	0.5	8.02e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.75	-6.18	-0.45	5.9e-9	Colorectal adenoma (advanced);
UCEC	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg13683864	chr3:40499215	RPL14	-0.53	-5.36	-0.4	3.18e-7	Renal cell carcinoma;
UCEC	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.05	12.82	0.73	9.86e-26	Exhaled nitric oxide output;
UCEC	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.38	4.52	0.35	1.24e-5	Iron status biomarkers;
UCEC	cis	rs1324913	1.000	rs1324912	chr13:74635907	C/T	cg13696283	chr13:74707153	KLF12	0.44	5.21	0.4	6.14e-7	Menarche (age at onset);
UCEC	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.77	7.07	0.5	5.71e-11	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.91	9.92	0.63	4.58e-18	Post bronchodilator FEV1;
UCEC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.81	8.06	0.55	2.42e-13	Smoking behavior;
UCEC	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-7.11	-0.51	4.63e-11	Morning vs. evening chronotype;
UCEC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.5	-4.78	-0.37	4.25e-6	Cardiac Troponin-T levels;
UCEC	cis	rs10242455	0.571	rs73713594	chr7:99326498	A/G	cg18809830	chr7:99032528	PTCD1	-0.69	-4.54	-0.35	1.17e-5	Blood metabolite levels;
UCEC	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.56	-5.33	-0.4	3.7e-7	Obesity-related traits;
UCEC	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs4849887	1.000	rs4848601	chr2:121243011	G/C	cg00421221	chr2:121106091	INHBB	0.43	4.52	0.35	1.26e-5	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-0.98	-7.48	-0.53	6.22e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.51	-4.72	-0.36	5.34e-6	Colorectal adenoma (advanced);
UCEC	cis	rs2302190	1.000	rs8065388	chr17:56562132	C/T	cg12560992	chr17:57184187	TRIM37	0.53	5.07	0.39	1.18e-6	Vitamin D levels;
UCEC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	4.92e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.75	-8.41	-0.57	3.25e-14	Sudden cardiac arrest;
UCEC	trans	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg18288967	chr1:45987694	PRDX1	0.74	6.8	0.49	2.48e-10	Obesity-related traits;
UCEC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.91	-10.23	-0.64	7.17e-19	Cognitive function;
UCEC	cis	rs1143633	1.000	rs1143633	chr2:113590467	A/G	cg12858261	chr2:113808755	IL1F8	0.5	4.67	0.36	6.87e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18932078	chr1:2524107	MMEL1	-0.35	-6.12	-0.45	8.27e-9	Ulcerative colitis;
UCEC	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.67	4.77	0.37	4.42e-6	Small cell lung carcinoma;
UCEC	cis	rs7095607	0.785	rs10997957	chr10:69916441	G/A	cg18986048	chr10:69913749	MYPN	0.52	6.06	0.45	1.1e-8	Lung function (FVC);
UCEC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.6e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs3829109	0.564	rs11789379	chr9:139285260	T/C	cg14086826	chr9:138757010	CAMSAP1	0.54	4.53	0.35	1.22e-5	Peak insulin response;Acute insulin response;
UCEC	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.66	6.88	0.49	1.58e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg00277334	chr10:82204260	NA	-0.42	-4.55	-0.35	1.09e-5	Post bronchodilator FEV1;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.53	5.69	0.42	6.81e-8	Menarche (age at onset);
UCEC	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.15	-0.39	8.39e-7	Response to antipsychotic treatment;
UCEC	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.47	4.69	0.36	6.23e-6	Bladder cancer;
UCEC	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.6	-5.75	-0.43	4.88e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.51	4.85	0.37	3.12e-6	Menarche (age at onset);
UCEC	cis	rs867371	0.656	rs2665103	chr15:82432715	A/G	cg00614314	chr15:82944287	LOC80154	-0.5	-5.65	-0.42	8e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-6.58	-0.48	7.67e-10	Metabolite levels;
UCEC	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	7.88	0.54	6.71e-13	Smoking behavior;
UCEC	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.57	5.6	0.42	1.04e-7	Blood protein levels;
UCEC	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.52	-4.77	-0.37	4.46e-6	Coronary artery disease;
UCEC	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-6.91	-0.49	1.39e-10	Chronic sinus infection;
UCEC	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.85	-0.37	3.12e-6	Blood metabolite levels;
UCEC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg14078730	chr11:63896557	MACROD1	0.59	5.03	0.38	1.43e-6	Mean platelet volume;
UCEC	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.51	0.35	1.33e-5	Depression;
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.53	-5.89	-0.44	2.51e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.82	4.73	0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg23970785	chr16:11036526	DEXI	0.41	4.55	0.35	1.13e-5	Testicular germ cell tumor;
UCEC	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg06462663	chr19:18546047	ISYNA1	0.39	4.79	0.37	4.04e-6	Breast cancer;
UCEC	cis	rs56161922	1.000	rs74184055	chr1:207852226	G/A	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg05738196	chr6:26577821	NA	0.65	7.89	0.55	6.52e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.54	-5.73	-0.43	5.45e-8	Retinal vascular caliber;
UCEC	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.52	-5.2	-0.39	6.71e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18854424	chr1:2615690	NA	0.47	7.15	0.51	3.78e-11	Ulcerative colitis;
UCEC	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.65	-0.42	7.91e-8	Pancreatic cancer;
UCEC	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.5	-0.41	1.65e-7	Platelet count;
UCEC	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.47	4.77	0.37	4.46e-6	Prostate cancer;
UCEC	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-6.41	-0.47	1.82e-9	Rheumatoid arthritis;
UCEC	cis	rs10924970	0.967	rs7518225	chr1:235394541	A/C	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.82	9.32	0.61	1.61e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.64	5.38	0.41	2.84e-7	High light scatter reticulocyte count;
UCEC	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.45	-4.8	-0.37	3.89e-6	Blood protein levels;
UCEC	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.54	-4.73	-0.36	5.33e-6	Coronary artery disease;
UCEC	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.78	-7.51	-0.53	5.18e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7709377	0.546	rs13181756	chr5:115493736	C/T	cg23108291	chr5:115420582	COMMD10	0.53	5.39	0.41	2.72e-7	Metabolite levels  (X-11787);
UCEC	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-5.64	-0.42	8.37e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs12719740	0.638	rs8043332	chr15:99073306	C/T	cg18585722	chr15:99091410	NA	-0.46	-4.69	-0.36	6.3e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs12363310	0.541	rs4754803	chr11:101679800	A/G	cg11843188	chr11:102322558	TMEM123	-0.52	-4.54	-0.35	1.18e-5	Systemic sclerosis;
UCEC	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.7	5.13	0.39	8.95e-7	Alcohol dependence;
UCEC	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.66	6.88	0.49	1.58e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg19678392	chr7:94953810	PON1	-0.58	-5.65	-0.42	7.97e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.34	4.68	0.36	6.33e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs172166	0.543	rs1150691	chr6:28168033	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.08	-0.39	1.13e-6	Cardiac Troponin-T levels;
UCEC	cis	rs2708977	0.609	rs611943	chr2:97067074	T/C	cg22654517	chr2:96458247	NA	0.42	5.45	0.41	2.07e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.5	-5.08	-0.39	1.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg04154034	chr17:28927549	LRRC37B2	0.76	5.35	0.4	3.27e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.61	5.42	0.41	2.35e-7	Height;
UCEC	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	9.13	0.6	5.02e-16	Mean platelet volume;
UCEC	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-7.01	-0.5	8.13e-11	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg13695892	chr22:41940480	POLR3H	-0.68	-4.75	-0.36	4.89e-6	Vitiligo;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.74	-0.36	5e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.68	5.47	0.41	1.89e-7	Smoking initiation;
UCEC	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.54	5.52	0.41	1.47e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-6.34	-0.46	2.62e-9	Joint mobility (Beighton score);
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.77	8.74	0.58	4.87e-15	Menarche (age at onset);
UCEC	cis	rs8042680	0.554	rs3803563	chr15:91531352	C/A	cg14398957	chr15:91536180	PRC1	-0.44	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.35	-4.58	-0.35	9.68e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-5.15	-0.39	8.14e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg20965017	chr5:231967	SDHA	-0.62	-5.54	-0.42	1.37e-7	Breast cancer;
UCEC	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg17294928	chr15:75287854	SCAMP5	0.5	5.13	0.39	8.99e-7	Caffeine consumption;
UCEC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.57	-4.79	-0.37	4.11e-6	Initial pursuit acceleration;
UCEC	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.8	-0.37	3.83e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-5.9	-0.44	2.43e-8	Neuroticism;
UCEC	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.92	-13.29	-0.74	5.63e-27	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-4.59	-0.35	9.33e-6	Monocyte percentage of white cells;
UCEC	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.58	-5.6	-0.42	1.03e-7	White matter hyperintensity burden;
UCEC	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.5e-7	Tonsillectomy;
UCEC	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.52	-0.41	1.51e-7	Blood metabolite levels;
UCEC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.79	0.37	4.11e-6	Menopause (age at onset);
UCEC	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.76	-0.37	4.5e-6	Hemoglobin concentration;
UCEC	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.9	12.22	0.71	3.93e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1712517	0.844	rs1163081	chr10:105029840	G/C	cg05636881	chr10:105038444	INA	0.46	5.47	0.41	1.88e-7	Migraine;
UCEC	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg22166914	chr1:53195759	ZYG11B	0.76	7.97	0.55	4.06e-13	Monocyte count;
UCEC	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.6	0.42	1.01e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.73	5.61	0.42	9.94e-8	Platelet count;
UCEC	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	7.74	0.54	1.5e-12	Menopause (age at onset);
UCEC	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	5.02	0.38	1.44e-6	Monocyte percentage of white cells;
UCEC	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.63	6.28	0.46	3.56e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7246967	0.673	rs55684269	chr19:22924547	C/T	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-4.96	-0.38	1.95e-6	Migraine;Coronary artery disease;
UCEC	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.4	5.16	0.39	7.74e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.99	9.43	0.61	8.36e-17	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.58	-4.74	-0.36	5.07e-6	Menopause (age at onset);
UCEC	cis	rs73206853	0.925	rs12310834	chr12:110762756	A/G	cg12870014	chr12:110450643	ANKRD13A	0.61	5.86	0.43	2.99e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	6.07	0.45	1.04e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.9	0.44	2.41e-8	Menarche (age at onset);
UCEC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.53	5.87	0.44	2.73e-8	Monocyte percentage of white cells;
UCEC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg03714773	chr7:91764589	CYP51A1	-0.43	-5.16	-0.39	8.04e-7	Breast cancer;
UCEC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.9	0.37	2.55e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14893161	chr1:205819251	PM20D1	0.85	10.09	0.64	1.63e-18	Menarche (age at onset);
UCEC	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.76	4.88	0.37	2.72e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.77e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.55	5.72	0.43	5.76e-8	Prostate cancer;
UCEC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.68	-5.91	-0.44	2.25e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg07250515	chr12:56618133	OBFC2B	-0.59	-5.23	-0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.97	11.37	0.68	6.97e-22	Cognitive function;
UCEC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.08	-15.93	-0.8	7.73e-34	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2267681	0.603	rs12534299	chr7:139538522	A/G	cg14116596	chr7:139528673	TBXAS1	-0.51	-5.23	-0.4	5.69e-7	Cervical cancer;
UCEC	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	trans	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg02022102	chr7:27168609	HOXA4	0.6	6.8	0.49	2.5e-10	Protein biomarker;
UCEC	cis	rs883565	0.740	rs6599003	chr3:39093326	A/G	cg01426195	chr3:39028469	NA	0.7	8.68	0.58	6.78e-15	Handedness;
UCEC	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.39	9.01	0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.75	6.83	0.49	2.08e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	8.36	0.57	4.43e-14	Platelet count;
UCEC	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg01689657	chr7:91764605	CYP51A1	0.5	6.44	0.47	1.57e-9	Breast cancer;
UCEC	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.48	5.61	0.42	9.83e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs13117816	0.545	rs7686039	chr4:37008671	A/G	cg18778608	chr19:3761698	MRPL54;APBA3	-0.73	-6.7	-0.48	4.18e-10	Multiple sclerosis--Brain Glutamate Levels;
UCEC	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.1	13.41	0.74	2.72e-27	Cognitive function;
UCEC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	11.01	0.67	6.11e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.67	6.59	0.48	7.38e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-4.55	-0.35	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg17259809	chr10:104614391	C10orf32	-0.68	-4.57	-0.35	1.04e-5	Arsenic metabolism;
UCEC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.65	6.32	0.46	2.98e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2070997	0.591	rs2855189	chr9:133702511	G/A	cg12998491	chr9:134152531	FAM78A	-0.86	-5.32	-0.4	3.78e-7	Response to amphetamines;
UCEC	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.62	-6.32	-0.46	2.95e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg13147721	chr7:65941812	NA	-0.93	-6.85	-0.49	1.88e-10	Diabetic kidney disease;
UCEC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.68	-6.99	-0.5	8.92e-11	Neurofibrillary tangles;
UCEC	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.56	5.42	0.41	2.41e-7	Radiation response;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	ch.1.1168472R	chr1:36766063	THRAP3	0.71	6.87	0.49	1.69e-10	Migraine with aura;
UCEC	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.5	5.73	0.43	5.41e-8	Total body bone mineral density;
UCEC	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-6.4	-0.47	1.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	0.65	7.05	0.5	6.34e-11	Homoarginine levels;
UCEC	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.48	-5.92	-0.44	2.13e-8	Mean platelet volume;
UCEC	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.55	-5.07	-0.39	1.19e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg18681998	chr4:17616180	MED28	0.72	6.64	0.48	5.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	7.56	0.53	3.95e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.53	-5.09	-0.39	1.07e-6	Bipolar disorder;
UCEC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.32	0.4	3.85e-7	Rheumatoid arthritis;
UCEC	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.7	5.38	0.41	2.88e-7	Breast cancer;
UCEC	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.84	10.58	0.66	8.47e-20	Metabolic syndrome;
UCEC	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.34	5.94	0.44	1.96e-8	Cancer;
UCEC	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.63	-0.42	9.01e-8	Fear of minor pain;
UCEC	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.49	6.7	0.48	4.16e-10	Total body bone mineral density;
UCEC	cis	rs7011049	1.000	rs11997538	chr8:53832663	A/C	cg26025543	chr8:53854495	NA	0.6	4.54	0.35	1.18e-5	Systolic blood pressure;
UCEC	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.45	-5.01	-0.38	1.51e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.71	0.36	5.77e-6	Aortic root size;
UCEC	cis	rs7714670	0.704	rs12653477	chr5:73090089	A/C	cg00119811	chr5:73092353	RGNEF	-0.38	-4.77	-0.37	4.31e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.65	7.24	0.51	2.37e-11	Monocyte count;
UCEC	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.51	4.86	0.37	3.01e-6	Bone mineral density;
UCEC	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.46	5.75	0.43	5.05e-8	Monocyte count;
UCEC	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs713477	0.935	rs12888181	chr14:55906082	A/C	cg13175173	chr14:55914753	NA	-0.41	-4.62	-0.36	8.18e-6	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs11958404	0.932	rs72816571	chr5:157429759	C/T	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.14	0.39	8.63e-7	Bipolar disorder;
UCEC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.63	5.97	0.44	1.71e-8	Aortic root size;
UCEC	cis	rs7560272	0.512	rs13015885	chr2:73920482	G/T	cg20560298	chr2:73613845	ALMS1	0.47	4.5	0.35	1.37e-5	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.68	6.15	0.45	7.01e-9	Corneal astigmatism;
UCEC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.71	-7.03	-0.5	7.03e-11	Adiposity;
UCEC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.57	6.24	0.46	4.49e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.66	-5.67	-0.42	7.16e-8	Platelet count;
UCEC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.6	5.03	0.38	1.44e-6	High light scatter reticulocyte count;
UCEC	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg13926569	chr10:89418898	PAPSS2	-0.57	-6.57	-0.48	8.14e-10	Magnesium levels;
UCEC	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.95	-0.38	1.97e-6	Mood instability;
UCEC	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.51	5.77	0.43	4.45e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.7	-6.12	-0.45	7.94e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.41	4.84	0.37	3.24e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.81	7.88	0.55	6.54e-13	Cognitive function;
UCEC	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14019695	chr9:139328340	INPP5E	0.49	5.59	0.42	1.1e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg21856205	chr7:94953877	PON1	0.6	4.9	0.38	2.45e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.53	4.99	0.38	1.67e-6	Lung cancer;
UCEC	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg22166914	chr1:53195759	ZYG11B	0.59	6.18	0.45	6.1e-9	Monocyte count;
UCEC	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.53	5.96	0.44	1.78e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.84	7.53	0.53	4.62e-12	Bladder cancer;
UCEC	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.56	-4.71	-0.36	5.65e-6	Platelet distribution width;
UCEC	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.78	8.9	0.59	1.91e-15	Menarche (age at onset);
UCEC	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.41	4.79	0.37	3.97e-6	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.46	-5.13	-0.39	8.99e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.89	8.18	0.56	1.2e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	9.97	0.64	3.39e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.34	0.4	3.49e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	6.06	0.45	1.09e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.62	-6.11	-0.45	8.3e-9	Blood metabolite levels;
UCEC	cis	rs1575951	1.000	rs7916893	chr10:130438354	A/G	cg27041381	chr10:131357203	MGMT	0.6	5.23	0.4	5.71e-7	Plasma clusterin levels;
UCEC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.44	4.9	0.37	2.53e-6	Blood metabolite levels;
UCEC	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.47	5.03	0.38	1.4e-6	Menopause (age at onset);
UCEC	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-6.01	-0.44	1.37e-8	Personality dimensions;
UCEC	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-0.97	-11.05	-0.67	4.71e-21	Blood pressure (smoking interaction);
UCEC	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	0.92	9.92	0.63	4.54e-18	Height;
UCEC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.6	-6.92	-0.5	1.28e-10	Menopause (age at onset);
UCEC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.63	-8.03	-0.55	2.83e-13	Obesity-related traits;
UCEC	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.57	-6.21	-0.46	5.1e-9	Prudent dietary pattern;
UCEC	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg17306686	chr7:157230923	NA	0.37	4.67	0.36	6.85e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
UCEC	cis	rs17433710	0.778	rs61811983	chr1:162675139	T/G	cg19264028	chr1:162630153	DDR2	1.07	4.65	0.36	7.3e-6	Dupuytren's disease;
UCEC	cis	rs58365266	1.000	rs58365266	chr3:195813757	C/T	cg01181863	chr3:195395398	SDHAP2	-0.71	-4.84	-0.37	3.29e-6	Red cell distribution width;
UCEC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.71	-6.4	-0.47	1.94e-9	Aortic root size;
UCEC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8067354	0.914	rs9900133	chr17:57802047	G/T	cg02344993	chr17:57696989	CLTC	0.46	4.57	0.35	1.04e-5	Hemoglobin concentration;
UCEC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.66	-5.7	-0.43	6.25e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.74	6.41	0.47	1.89e-9	Bipolar disorder;
UCEC	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.59	6.16	0.45	6.7e-9	Colorectal cancer;
UCEC	cis	rs11958404	0.932	rs72818113	chr5:157439825	G/T	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-1.12	-10.15	-0.64	1.11e-18	Dupuytren's disease;
UCEC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.77	0.37	4.45e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.59	4.76	0.37	4.59e-6	Initial pursuit acceleration;
UCEC	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.0	-0.67	6.69e-21	Chronic sinus infection;
UCEC	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.62	6.42	0.47	1.79e-9	Dental caries;
UCEC	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-4.94	-0.38	2.12e-6	Personality dimensions;
UCEC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-5.07	-0.39	1.2e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-7.3	-0.52	1.64e-11	Parkinson's disease;
UCEC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	0.56	6.32	0.46	2.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.78	0.37	4.27e-6	Breast cancer;
UCEC	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	cis	rs4851266	0.966	rs10496345	chr2:100817619	T/G	cg14675211	chr2:100938903	LONRF2	0.68	6.32	0.46	2.96e-9	Educational attainment;
UCEC	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.21	-0.46	5.06e-9	Blood protein levels;
UCEC	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg23782820	chr8:58130467	NA	0.51	4.83	0.37	3.46e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.83	6.56	0.48	8.58e-10	Body mass index;
UCEC	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.58	-5.66	-0.42	7.75e-8	Hypospadias;
UCEC	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.12	-0.51	4.5e-11	Breast cancer;
UCEC	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	0.81	5.09	0.39	1.06e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs1832871	0.672	rs62437399	chr6:158784251	C/A	cg07215822	chr6:158701037	NA	-0.69	-6.02	-0.44	1.33e-8	Height;
UCEC	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.73	0.36	5.23e-6	Diabetic retinopathy;
UCEC	cis	rs7582720	0.887	rs72932755	chr2:203673563	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	4.99	0.38	1.72e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.55	5.57	0.42	1.16e-7	Coronary artery disease;
UCEC	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.4	-0.41	2.59e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.56	5.08	0.39	1.13e-6	Recalcitrant atopic dermatitis;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.08	-0.39	1.12e-6	Pubertal anthropometrics;
UCEC	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	0.82	6.63	0.48	6e-10	Alzheimer's disease;
UCEC	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs871392	0.564	rs1532451	chr12:42141172	A/G	cg20693580	chr12:42326382	NA	-0.54	-5.07	-0.39	1.18e-6	Biochemical measures;
UCEC	cis	rs8177876	0.822	rs4324141	chr16:81114825	A/G	cg08591886	chr16:81111003	C16orf46	0.78	4.8	0.37	3.86e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg20825769	chr15:43991375	CKMT1A	-0.56	-4.57	-0.35	1.02e-5	Lung cancer in ever smokers;
UCEC	cis	rs10095849	0.608	rs72641297	chr8:39472233	C/T	cg24581462	chr8:38759627	PLEKHA2	0.36	4.64	0.36	7.56e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08822215	chr16:89438651	ANKRD11	-0.51	-5.07	-0.39	1.18e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	0.8	8.56	0.58	1.39e-14	Height;
UCEC	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	0.76	4.85	0.37	3.15e-6	Mitochondrial DNA levels;
UCEC	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-5.02	-0.38	1.5e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	0.71	4.55	0.35	1.14e-5	Mitochondrial DNA levels;
UCEC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg03859395	chr2:55845619	SMEK2	1.04	15.3	0.78	3.24e-32	Metabolic syndrome;
UCEC	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg18478394	chr8:109455254	TTC35	0.51	4.93	0.38	2.24e-6	Dupuytren's disease;
UCEC	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.71	-0.36	5.69e-6	Total body bone mineral density;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	6.24	0.46	4.54e-9	Platelet count;
UCEC	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.09	-0.67	3.8e-21	Primary sclerosing cholangitis;
UCEC	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.63	0.36	8.14e-6	Breast cancer;
UCEC	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.87	0.37	2.86e-6	Lymphocyte counts;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.93	0.55	5.01e-13	Platelet count;
UCEC	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs4615376	1.000	rs35776201	chr6:13030350	G/A	cg11378619	chr6:12164359	HIVEP1	-0.61	-4.86	-0.37	2.94e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	1.12	14.04	0.76	5.95e-29	Body mass index;
UCEC	cis	rs514475	0.759	rs6924473	chr6:138066687	G/A	cg15962969	chr6:138866887	NHSL1	0.67	4.95	0.38	1.99e-6	Inflammatory skin disease;
UCEC	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg13147721	chr7:65941812	NA	-0.7	-4.97	-0.38	1.84e-6	Diabetic kidney disease;
UCEC	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.51	-5.1	-0.39	1.01e-6	Cognitive function;
UCEC	cis	rs7553864	0.605	rs7531038	chr1:87605049	C/G	cg17420885	chr1:87600446	LOC339524	-0.4	-4.51	-0.35	1.32e-5	Smoking behavior;
UCEC	cis	rs58521262	0.530	rs381403	chr19:23126236	C/T	cg08486875	chr19:23386892	NA	-0.33	-4.63	-0.36	8.06e-6	Testicular germ cell tumor;
UCEC	cis	rs12286929	0.898	rs117569901	chr11:115018509	T/G	cg04055981	chr11:115044050	NA	0.48	4.79	0.37	4.05e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg20965017	chr5:231967	SDHA	0.52	4.66	0.36	7.05e-6	Breast cancer;
UCEC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-6.03	-0.45	1.25e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7106204	0.688	rs7131103	chr11:24219299	A/G	ch.11.24196551F	chr11:24239977	NA	0.63	5.21	0.39	6.29e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.18	0.56	1.24e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs6670533	0.571	rs11801548	chr1:24861448	A/G	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.46e-6	QRS complex (12-leadsum);
UCEC	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.6	-5.95	-0.44	1.9e-8	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs944990	0.640	rs10117225	chr9:96367345	A/G	cg13787134	chr9:96362102	PHF2	0.36	4.68	0.36	6.41e-6	Body mass index;
UCEC	cis	rs6820391	0.816	rs6826933	chr4:54445715	C/T	cg04173182	chr4:54446035	LNX1	0.36	4.53	0.35	1.19e-5	Cervical artery dissection;
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs10507349	0.913	rs9319280	chr13:26778961	T/G	cg19792403	chr13:26796018	RNF6	0.54	4.57	0.35	1.05e-5	Type 2 diabetes;
UCEC	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.53	-0.47	1.03e-9	Mood instability;
UCEC	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-5.11	-0.39	9.87e-7	Bipolar disorder;
UCEC	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg03711944	chr11:47377212	SPI1	-0.5	-4.69	-0.36	6.3e-6	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.52	-5.05	-0.38	1.27e-6	Non-substance related behavioral disinhibition;
UCEC	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.95e-6	Tonsillectomy;
UCEC	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.81	9.5	0.62	5.4e-17	Ewing sarcoma;
UCEC	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.13	17.67	0.82	3.42e-38	IgG glycosylation;
UCEC	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.7	-6.56	-0.48	8.54e-10	Aortic root size;
UCEC	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.78	-8.22	-0.56	9.93e-14	Menarche (age at onset);
UCEC	cis	rs116095464	0.718	rs62331563	chr5:355286	T/C	cg22857025	chr5:266934	NA	-1.07	-4.53	-0.35	1.22e-5	Breast cancer;
UCEC	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg26721908	chr21:47610096	LSS	0.36	4.54	0.35	1.15e-5	Testicular germ cell tumor;
UCEC	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.85	-0.54	7.89e-13	Menarche (age at onset);
UCEC	cis	rs6893807	1.000	rs3814424	chr5:87968953	C/T	cg09002922	chr5:87956389	LOC645323	-0.61	-6.18	-0.45	5.92e-9	Body mass index;
UCEC	cis	rs78487399	0.808	rs75097983	chr2:43725624	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-4.63	-0.36	7.86e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg18016565	chr1:150552671	MCL1	-0.54	-5.83	-0.43	3.4e-8	Tonsillectomy;
UCEC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.34e-18	Height;
UCEC	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	0.87	5.43	0.41	2.32e-7	Skin colour saturation;
UCEC	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.64	-6.06	-0.45	1.12e-8	Lymphocyte counts;
UCEC	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13569146	chr6:26330589	NA	-0.55	-4.75	-0.37	4.7e-6	Educational attainment;
UCEC	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg22166914	chr1:53195759	ZYG11B	0.6	6.3	0.46	3.33e-9	Monocyte count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23629415	chr14:54955474	GMFB	0.64	7.61	0.53	3.03e-12	Warfarin maintenance dose;
UCEC	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-8.86	-0.59	2.45e-15	Exhaled nitric oxide output;
UCEC	cis	rs4588572	0.643	rs1560196	chr5:77701982	G/C	cg11547950	chr5:77652471	NA	0.44	4.78	0.37	4.19e-6	Triglycerides;
UCEC	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.5	4.86	0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs75804782	0.572	rs55764347	chr2:239253529	G/A	cg11815105	chr2:239148849	HES6	1.03	5.0	0.38	1.6e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9463078	0.683	rs12215252	chr6:44736265	C/T	cg25276700	chr6:44698697	NA	0.44	4.88	0.37	2.75e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs4879656	0.564	rs2183870	chr9:32994500	T/G	cg09633881	chr9:33002021	APTX	0.37	4.75	0.37	4.71e-6	Menopause (age at onset);
UCEC	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.5	-5.72	-0.43	5.67e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs883565	0.569	rs784514	chr3:39164622	A/G	cg01426195	chr3:39028469	NA	0.62	7.39	0.52	1.01e-11	Handedness;
UCEC	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg12596171	chr3:113251061	SIDT1	-0.52	-4.54	-0.35	1.14e-5	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs11697848	1.000	rs2235621	chr20:48473731	G/A	cg17849948	chr20:48532315	SPATA2	1.03	5.1	0.39	1.01e-6	Systemic lupus erythematosus;
UCEC	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.84	6.32	0.46	2.92e-9	Multiple sclerosis;
UCEC	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg23260525	chr10:116636907	FAM160B1	-0.34	-4.58	-0.35	9.74e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.79	-6.86	-0.49	1.83e-10	Blood metabolite levels;
UCEC	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.8	7.23	0.51	2.51e-11	Coronary artery calcification;
UCEC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.47	5.44	0.41	2.19e-7	Breast cancer;
UCEC	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.68	7.01	0.5	7.86e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.53	-4.67	-0.36	6.83e-6	Pulmonary function decline;
UCEC	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.63	6.13	0.45	7.79e-9	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg20965017	chr5:231967	SDHA	-0.62	-5.52	-0.41	1.5e-7	Breast cancer;
UCEC	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg16299576	chr8:10872819	XKR6	-0.63	-4.53	-0.35	1.22e-5	Alcohol dependence;Nicotine use;
UCEC	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.91	-0.44	2.23e-8	Myopia (pathological);
UCEC	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.21	-0.46	5.18e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11867410	0.744	rs73992157	chr17:63961200	C/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.63	5.63	0.42	8.91e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.69	6.58	0.48	7.61e-10	Neurofibrillary tangles;
UCEC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.88	9.65	0.62	2.32e-17	Breast cancer;
UCEC	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg22467129	chr15:76604101	ETFA	-0.49	-5.11	-0.39	9.87e-7	Blood metabolite levels;
UCEC	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.52	6.05	0.45	1.12e-8	Breast cancer;
UCEC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.59	4.56	0.35	1.09e-5	Corneal astigmatism;
UCEC	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	0.967	rs10223792	chr6:26579616	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.79	9.62	0.62	2.69e-17	Mean corpuscular volume;
UCEC	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg20821713	chr7:1055600	C7orf50	-0.66	-6.34	-0.46	2.68e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.67	-7.34	-0.52	1.36e-11	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.44	4.67	0.36	6.82e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.74	-8.09	-0.56	2.06e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09870606	chr16:74641419	GLG1	-0.53	-4.92	-0.38	2.27e-6	Energy expenditure (24h);
UCEC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.8	-8.94	-0.59	1.53e-15	Cognitive function;
UCEC	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg21782813	chr7:2030301	MAD1L1	0.59	6.57	0.48	8.06e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg26031613	chr14:104095156	KLC1	1.25	15.78	0.79	1.92e-33	Body mass index;
UCEC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg23782820	chr8:58130467	NA	0.51	4.83	0.37	3.35e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.63	7.27	0.51	1.95e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.63	-6.2	-0.46	5.42e-9	Corneal structure;
UCEC	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.42	-5.62	-0.42	9.19e-8	Alcohol dependence;
UCEC	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-5.58	-0.42	1.12e-7	Morning vs. evening chronotype;
UCEC	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-5.12	-0.39	9.26e-7	Platelet distribution width;
UCEC	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.94	10.08	0.64	1.67e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs6903823	0.508	rs1150724	chr6:28250236	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.53	-6.3	-0.46	3.22e-9	Pulmonary function;
UCEC	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.17	0.64	9.99e-19	Electrocardiographic conduction measures;
UCEC	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.09	6.27	0.46	3.74e-9	Diabetic retinopathy;
UCEC	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.8	0.37	3.82e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22857025	chr5:266934	NA	-1.13	-13.14	-0.73	1.41e-26	Breast cancer;
UCEC	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg03934865	chr2:198174659	NA	-0.42	-5.25	-0.4	5.33e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-1.09	-14.03	-0.76	6.38e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs7611694	0.501	rs9869141	chr3:113116059	A/G	cg11138929	chr3:113251189	SIDT1	-0.42	-5.13	-0.39	8.93e-7	Prostate cancer;
UCEC	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.61	6.15	0.45	7.03e-9	Colorectal cancer;
UCEC	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg03714773	chr7:91764589	CYP51A1	0.41	4.83	0.37	3.4e-6	Breast cancer;
UCEC	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.44	-4.59	-0.35	9.31e-6	Response to antipsychotic treatment;
UCEC	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.67	5.75	0.43	4.91e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs174479	0.743	rs174464	chr11:61657926	A/G	cg01500311	chr11:61656094	FADS3	0.51	6.43	0.47	1.69e-9	Sphingolipid levels;
UCEC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.63	-5.96	-0.44	1.81e-8	Aortic root size;
UCEC	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.53	-4.76	-0.37	4.63e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.61	-0.42	9.8e-8	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.75	9.67	0.62	2e-17	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	1.02	13.54	0.75	1.24e-27	Monocyte count;
UCEC	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.91	-10.81	-0.67	2.04e-20	Blood metabolite levels;
UCEC	cis	rs17122693	0.551	rs2934685	chr14:51050865	C/G	cg04730355	chr14:51134070	SAV1	0.73	8.71	0.58	5.66e-15	Cognitive performance;
UCEC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.49	5.07	0.39	1.2e-6	Breast cancer;
UCEC	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.53	5.04	0.38	1.36e-6	Menarche (age at onset);
UCEC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.55	-4.84	-0.37	3.27e-6	Longevity;
UCEC	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.58	6.18	0.45	6.02e-9	Mean platelet volume;
UCEC	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.09	-0.39	1.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.5	4.84	0.37	3.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	6.07	0.45	1.04e-8	Myopia (pathological);
UCEC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg20999797	chr1:1681921	NA	0.39	5.28	0.4	4.53e-7	Body mass index;
UCEC	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-0.93	-10.78	-0.66	2.43e-20	Corneal structure;
UCEC	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.41	-5.06	-0.39	1.24e-6	HIV-1 susceptibility;
UCEC	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.47	-4.68	-0.36	6.49e-6	Body mass index;
UCEC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.71	6.06	0.45	1.11e-8	Alzheimer's disease;
UCEC	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs78487399	0.808	rs28700209	chr2:43667465	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.55	-0.35	1.13e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.57	-4.58	-0.35	9.64e-6	Initial pursuit acceleration;
UCEC	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg13695892	chr22:41940480	POLR3H	-0.66	-5.15	-0.39	8.25e-7	Vitiligo;
UCEC	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.63	4.8	0.37	3.89e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	0.77	4.76	0.37	4.57e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18854424	chr1:2615690	NA	0.5	7.29	0.52	1.75e-11	Ulcerative colitis;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg03722871	chr13:111527030	NA	-1.02	-5.68	-0.42	6.82e-8	Obesity-related traits;
UCEC	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-0.87	-6.9	-0.49	1.47e-10	Pediatric areal bone mineral density (radius);
UCEC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.87	-10.99	-0.67	6.78e-21	Height;
UCEC	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.09	9.05	0.6	8.14e-16	Vitiligo;
UCEC	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.63	-6.96	-0.5	1.06e-10	Facial morphology (factor 23);
UCEC	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-6.0	-0.44	1.44e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	7.93	0.55	5.21e-13	Hip circumference;
UCEC	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.87	-0.49	1.72e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs8032158	0.963	rs1912398	chr15:56159103	T/G	cg10433327	chr15:56209506	NEDD4	-0.3	-4.86	-0.37	3.01e-6	Keloid;
UCEC	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	0.95	5.76	0.43	4.85e-8	Gut microbiota (bacterial taxa);
UCEC	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.58	6.42	0.47	1.75e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4788815	0.691	rs4788808	chr16:71615613	A/G	cg00732059	chr16:71740210	PHLPP2	-0.43	-4.63	-0.36	7.88e-6	Metabolite levels;
UCEC	cis	rs6546886	0.957	rs4853005	chr2:74258049	G/C	cg14702570	chr2:74259524	NA	-0.42	-5.44	-0.41	2.15e-7	Dialysis-related mortality;
UCEC	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.72	-6.27	-0.46	3.83e-9	Parkinson's disease;
UCEC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg16497661	chr14:103986332	CKB	0.49	5.81	0.43	3.74e-8	Body mass index;
UCEC	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.46	-4.76	-0.37	4.51e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.01	0.5	8.1e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.47	-4.87	-0.37	2.91e-6	Aortic root size;
UCEC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18932078	chr1:2524107	MMEL1	0.35	5.99	0.44	1.58e-8	Ulcerative colitis;
UCEC	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg16576083	chr14:105354267	KIAA0284	0.85	8.81	0.59	3.16e-15	IgG glycosylation;
UCEC	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.14e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-6.33	-0.46	2.77e-9	Multiple sclerosis;
UCEC	cis	rs117623576	0.941	rs211409	chr10:32393213	T/C	cg03047570	chr10:32398778	NA	0.59	5.39	0.41	2.79e-7	Anti-saccade response;
UCEC	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg12024160	chr4:1254474	NA	0.56	6.85	0.49	1.9e-10	Obesity-related traits;
UCEC	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.32	4.64	0.36	7.81e-6	Schizophrenia;
UCEC	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.51	4.88	0.37	2.76e-6	Coronary artery disease;
UCEC	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-6.09	-0.45	9.43e-9	Hepatocellular carcinoma;
UCEC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.34	-0.46	2.63e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs239198	0.602	rs9377240	chr6:101323752	C/T	cg09795085	chr6:101329169	ASCC3	0.49	4.76	0.37	4.61e-6	Menarche (age at onset);
UCEC	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg03354898	chr7:1950403	MAD1L1	-0.49	-5.12	-0.39	9.28e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.3	0.61	1.86e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.55	-6.09	-0.45	9.19e-9	Lung cancer;
UCEC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6832769	1.000	rs28463765	chr4:56412434	C/T	cg05960024	chr4:56376020	CLOCK	-0.54	-5.12	-0.39	9.47e-7	Personality dimensions;
UCEC	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	0.92	6.97	0.5	1.01e-10	Mean corpuscular volume;
UCEC	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs7246967	0.673	rs1433085	chr19:22811099	T/A	cg08271804	chr19:22816896	ZNF492	0.6	5.81	0.43	3.7e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.68	7.56	0.53	3.95e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.47	-4.87	-0.37	2.86e-6	Alzheimer's disease;
UCEC	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.52	-5.34	-0.4	3.5e-7	Hepatocellular carcinoma;
UCEC	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.02	-11.72	-0.7	8.03e-23	Schizophrenia;
UCEC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.75	7.81	0.54	1.01e-12	Breast cancer;
UCEC	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-6.4	-0.47	2e-9	Urinary metabolites;
UCEC	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg05502283	chr19:13203715	NFIX	-0.35	-4.79	-0.37	4.1e-6	Breast cancer;
UCEC	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.73	7.16	0.51	3.6e-11	Monocyte count;
UCEC	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.58	6.35	0.46	2.56e-9	Mean platelet volume;
UCEC	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.45	-4.69	-0.36	6.19e-6	Vitiligo;
UCEC	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.66	-5.06	-0.38	1.26e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.02	-8.17	-0.56	1.33e-13	Exhaled nitric oxide output;
UCEC	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.43	0.41	2.28e-7	Height;
UCEC	cis	rs12644436	0.899	rs1381953	chr4:88788792	C/T	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	HIV-1 viral setpoint;
UCEC	cis	rs9463078	0.845	rs9369514	chr6:44797271	C/A	cg25276700	chr6:44698697	NA	-0.42	-4.66	-0.36	7.05e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.54	-5.46	-0.41	1.98e-7	Aortic root size;
UCEC	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.48	5.06	0.39	1.24e-6	Red blood cell count;
UCEC	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg01013738	chr7:1149705	C7orf50	-0.49	-4.57	-0.35	1.03e-5	Longevity;Endometriosis;
UCEC	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.5	5.19	0.39	6.74e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-6.29	-0.46	3.46e-9	Heart rate;
UCEC	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.72	7.33	0.52	1.44e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.58	-5.8	-0.43	3.93e-8	White matter hyperintensity burden;
UCEC	cis	rs2882667	0.822	rs11738376	chr5:138398172	G/A	cg04439458	chr5:138467593	SIL1	-0.45	-4.87	-0.37	2.79e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2299682	0.826	rs16995976	chr20:9482637	C/T	cg11931762	chr20:9488920	NA	0.69	4.72	0.36	5.48e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.77	-7.78	-0.54	1.21e-12	Body mass index;
UCEC	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg21214455	chr15:72412075	SENP8	0.48	4.58	0.35	9.78e-6	Red blood cell count;
UCEC	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg11871910	chr12:69753446	YEATS4	0.66	6.38	0.47	2.17e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg04310649	chr10:35416472	CREM	-0.51	-4.84	-0.37	3.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg18681998	chr4:17616180	MED28	-0.67	-7.43	-0.52	8.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.54	-5.72	-0.43	5.84e-8	Pubertal anthropometrics;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg18992706	chr13:44453352	CCDC122;C13orf31	0.67	6.67	0.48	4.88e-10	Schizophrenia;
UCEC	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.75	6.69	0.48	4.27e-10	Coronary artery disease;
UCEC	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.66	-6.48	-0.47	1.28e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg16558253	chr16:72132732	DHX38	0.41	4.89	0.37	2.63e-6	Prostate cancer;
UCEC	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18932078	chr1:2524107	MMEL1	0.34	5.44	0.41	2.15e-7	Ulcerative colitis;
UCEC	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.39e-7	Body mass index;
UCEC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.69	-6.34	-0.46	2.71e-9	Aortic root size;
UCEC	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg22166914	chr1:53195759	ZYG11B	0.63	6.54	0.47	9.65e-10	Monocyte count;
UCEC	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.54	5.72	0.43	5.86e-8	Red blood cell count;
UCEC	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-4.71	-0.36	5.64e-6	Alzheimer's disease (late onset);
UCEC	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.59	5.66	0.42	7.74e-8	Uric acid levels;
UCEC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.62	5.57	0.42	1.2e-7	Corneal astigmatism;
UCEC	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.86	-9.19	-0.6	3.58e-16	Schizophrenia;
UCEC	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-8.41	-0.57	3.28e-14	Extraversion;
UCEC	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.59	6.15	0.45	7.09e-9	Initial pursuit acceleration;
UCEC	cis	rs4372836	0.504	rs7601720	chr2:29032478	G/A	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.33	-0.52	1.38e-11	Body mass index;
UCEC	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.54	4.86	0.37	2.96e-6	Birth weight;
UCEC	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.02	6.92	0.5	1.26e-10	Platelet distribution width;
UCEC	cis	rs9603616	0.719	rs4598779	chr13:40235373	A/G	cg20659195	chr13:40746648	NA	-0.39	-4.6	-0.35	9.08e-6	Rheumatoid arthritis;
UCEC	cis	rs731174	0.559	rs10908375	chr1:38194094	G/C	cg24088508	chr1:38156462	C1orf109	-0.58	-4.59	-0.35	9.32e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.75	8.15	0.56	1.49e-13	Menopause (age at onset);
UCEC	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg11569703	chr11:65557185	OVOL1	-0.5	-6.79	-0.49	2.64e-10	Acne (severe);
UCEC	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.52	-5.2	-0.39	6.48e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.58	-6.03	-0.45	1.24e-8	Ulcerative colitis;
UCEC	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg23307798	chr14:103986281	CKB	0.64	7.74	0.54	1.46e-12	Body mass index;
UCEC	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01973587	chr1:228161476	NA	0.37	4.79	0.37	3.97e-6	Diastolic blood pressure;
UCEC	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg21017887	chr14:105400489	NA	-0.63	-7.41	-0.52	8.97e-12	Rheumatoid arthritis;
UCEC	cis	rs12367572	0.663	rs1118481	chr12:45354469	C/G	cg03114573	chr12:45410052	DBX2	-0.42	-4.56	-0.35	1.08e-5	Gut microbiome composition (summer);
UCEC	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.68	5.82	0.43	3.55e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.68	-7.33	-0.52	1.41e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4499344	0.556	rs259228	chr19:33134635	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	5.45	0.41	2.04e-7	Mean platelet volume;
UCEC	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg24253500	chr15:84953950	NA	-0.43	-4.51	-0.35	1.31e-5	Schizophrenia;
UCEC	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg16303742	chr3:15540471	COLQ	-0.48	-6.01	-0.44	1.39e-8	Mean platelet volume;
UCEC	cis	rs10746514	0.841	rs9725652	chr1:232245997	T/A	cg09506761	chr1:232265262	NA	0.53	5.4	0.41	2.67e-7	Response to statin therapy;
UCEC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	6.9	0.49	1.45e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.41	14.99	0.78	2.08e-31	Atopic dermatitis;
UCEC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.51	5.12	0.39	9.32e-7	Vitiligo;
UCEC	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.43	4.8	0.37	3.79e-6	Bone mineral density;
UCEC	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.63	5.94	0.44	1.98e-8	Crohn's disease;
UCEC	cis	rs7246967	0.611	rs66620859	chr19:22837230	G/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-6.53	-0.47	1.01e-9	Chronic sinus infection;
UCEC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.7	6.36	0.46	2.35e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	7.94	0.55	4.67e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg18451016	chr1:38461880	NA	0.57	5.45	0.41	2.09e-7	Red cell distribution width;
UCEC	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.54	-5.94	-0.44	1.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.7	-6.4	-0.47	2e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg00651523	chr6:28411279	ZSCAN23	0.53	5.88	0.44	2.68e-8	Cardiac Troponin-T levels;
UCEC	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.02	-7.79	-0.54	1.08e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.73	8.45	0.57	2.57e-14	Menopause (age at onset);
UCEC	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.51	5.83	0.43	3.44e-8	Testicular germ cell tumor;
UCEC	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.49	0.41	1.7e-7	HIV-1 control;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.58	-6.87	-0.49	1.68e-10	Cardiac Troponin-T levels;
UCEC	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg25393495	chr8:12034317	NA	0.33	4.57	0.35	1.04e-5	Retinal vascular caliber;
UCEC	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.8	0.49	2.47e-10	Motion sickness;
UCEC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18252515	chr7:66147081	NA	-0.51	-4.8	-0.37	3.88e-6	Aortic root size;
UCEC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg03859395	chr2:55845619	SMEK2	-0.75	-7.4	-0.52	9.45e-12	Metabolic syndrome;
UCEC	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.51	7.16	0.51	3.57e-11	Coronary artery disease or large artery stroke;
UCEC	cis	rs4869931	1.000	rs6929743	chr6:151007388	C/G	cg06471296	chr6:150259601	NA	0.35	4.54	0.35	1.14e-5	Systolic blood pressure in sickle cell anemia;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.58	-6.49	-0.47	1.26e-9	Cardiac Troponin-T levels;
UCEC	cis	rs11077815	0.733	rs7219524	chr17:74442440	C/G	cg06840243	chr17:74442338	UBE2O	-0.42	-5.77	-0.43	4.47e-8	Lymphocyte counts;
UCEC	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg16583315	chr14:65563665	MAX	-0.47	-6.11	-0.45	8.46e-9	Obesity-related traits;
UCEC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.74	0.36	4.94e-6	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg06096015	chr1:231504339	EGLN1	0.4	4.6	0.35	9.22e-6	Hemoglobin concentration;
UCEC	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.53	5.66	0.42	7.57e-8	Multiple myeloma;
UCEC	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.83	8.1	0.56	1.99e-13	Post bronchodilator FEV1;
UCEC	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.69	6.21	0.46	5.12e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-7.2	-0.51	2.89e-11	Parkinson's disease;
UCEC	cis	rs7088591	0.867	rs11819316	chr10:59788942	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.68	4.73	0.36	5.29e-6	Aortic root size;
UCEC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01065977	chr19:18549689	ISYNA1	-0.36	-5.14	-0.39	8.57e-7	Breast cancer;
UCEC	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg21770322	chr7:97807741	LMTK2	0.86	14.92	0.78	3.1e-31	Breast cancer;
UCEC	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg17420585	chr12:42539391	GXYLT1	-0.42	-5.19	-0.39	6.94e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.54	4.9	0.38	2.45e-6	Corneal astigmatism;
UCEC	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.45	-4.58	-0.35	9.71e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.54	4.57	0.35	1.02e-5	Colorectal cancer;
UCEC	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.63	-0.42	8.93e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-5.18	-0.39	7.32e-7	Multiple sclerosis;
UCEC	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.74	6.6	0.48	7.12e-10	Coronary artery disease;
UCEC	cis	rs998584	1.000	rs11967262	chr6:43760327	C/G	cg24804436	chr6:42955017	PPP2R5D	0.39	4.53	0.35	1.23e-5	Waist circumference adjusted for BMI in inactive individuals;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Triglycerides;HDL cholesterol;Waist circumference adjusted for BMI in non-smokers;Body mass index;White blood cell count;Adiponectin levels;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist circumference adjusted for BMI in active individuals;Reticulocyte count;
UCEC	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.67	6.87	0.49	1.7e-10	Multiple sclerosis;
UCEC	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.52	0.35	1.26e-5	Height;
UCEC	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.8	9.2	0.6	3.33e-16	Coronary artery disease;
UCEC	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	5.25	0.4	5.29e-7	IgG glycosylation;
UCEC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.48	4.74	0.36	5.08e-6	Menarche (age at onset);
UCEC	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.56	4.96	0.38	1.89e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs75804782	0.630	rs57033609	chr2:239228512	C/T	cg11815105	chr2:239148849	HES6	1.0	4.68	0.36	6.57e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.67	5.85	0.43	3.13e-8	Bipolar disorder;
UCEC	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.8	-0.63	9.01e-18	Monocyte count;
UCEC	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg07387570	chr22:46663686	TTC38	-0.47	-4.62	-0.36	8.32e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.74	-6.14	-0.45	7.23e-9	Body mass index;
UCEC	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.58	6.04	0.45	1.18e-8	Neuroticism;
UCEC	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs4523957	0.788	rs11078865	chr17:2109109	T/A	cg16513277	chr17:2031491	SMG6	-0.45	-4.97	-0.38	1.83e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1355223	0.867	rs7925421	chr11:34681677	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.58	-0.35	9.75e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs4880487	0.888	rs10903405	chr10:1249498	C/G	cg03183215	chr10:1252341	ADARB2	-0.46	-5.39	-0.41	2.79e-7	Migraine;
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.69	8.52	0.58	1.71e-14	Menarche (age at onset);
UCEC	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.52	5.09	0.39	1.07e-6	Platelet count;
UCEC	cis	rs9467773	1.000	rs12663894	chr6:26577370	C/T	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	7.19	0.51	3.09e-11	Motion sickness;
UCEC	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.91	-0.49	1.4e-10	Longevity;Endometriosis;
UCEC	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	0.89	8.46	0.57	2.49e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs1079204	1.000	rs1567869	chr2:219126735	C/T	cg05728596	chr2:219128475	GPBAR1	-0.92	-10.39	-0.65	2.68e-19	Smooth-surface caries;
UCEC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs4265793	1.000	rs7190066	chr16:19032780	G/T	cg06773604	chr16:18995157	TMC7	0.73	5.45	0.41	2.09e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg00343986	chr7:65444356	GUSB	-0.52	-4.85	-0.37	3.16e-6	Aortic root size;
UCEC	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg04154034	chr17:28927549	LRRC37B2	0.76	5.35	0.4	3.27e-7	Body mass index;
UCEC	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.41	-4.75	-0.36	4.87e-6	Bipolar disorder;
UCEC	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.24	-0.51	2.3e-11	Breast cancer;
UCEC	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.22	-0.46	4.87e-9	Aortic root size;
UCEC	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.58	4.55	0.35	1.13e-5	Menopause (age at onset);
UCEC	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.56	4.58	0.35	9.8200000000000008e-06	Heart rate;
UCEC	cis	rs7581030	1.000	rs2013708	chr2:71600354	A/G	cg07678644	chr2:71558969	ZNF638	0.56	5.14	0.39	8.6e-7	Testicular germ cell tumor;
UCEC	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.69	7.75	0.54	1.42e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7709377	0.570	rs4921062	chr5:115445812	T/A	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.44	-5.15	-0.39	8.12e-7	Prostate cancer;
UCEC	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-5.27	-0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	5.44	0.41	2.17e-7	Rheumatoid arthritis;
UCEC	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg16386697	chr22:51017162	CPT1B;CHKB-CPT1B	-0.73	-5.48	-0.41	1.76e-7	Narcolepsy;
UCEC	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.25	-0.46	4.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.51	-5.54	-0.42	1.35e-7	Menopause (age at onset);
UCEC	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs2811893	0.546	rs10489540	chr1:59159954	T/C	cg19813884	chr1:59043370	TACSTD2	0.39	4.71	0.36	5.65e-6	Diabetic retinopathy;
UCEC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.66	5.23	0.4	5.74e-7	Initial pursuit acceleration;
UCEC	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.8	-7.32	-0.52	1.52e-11	Resting heart rate;
UCEC	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.51	4.63	0.36	7.93e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-5.07	-0.39	1.18e-6	Hemoglobin concentration;
UCEC	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.4	0.41	2.59e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.15	0.51	3.8e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg26114124	chr12:9217669	LOC144571	0.41	4.84	0.37	3.29e-6	Sjögren's syndrome;
UCEC	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	5.48	0.41	1.8e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs847649	0.621	rs2222539	chr7:102674786	G/A	cg18108683	chr7:102477205	FBXL13	0.45	5.15	0.39	8.24e-7	Morning vs. evening chronotype;
UCEC	cis	rs4372836	0.681	rs13025377	chr2:28953556	G/A	cg09522027	chr2:28974177	PPP1CB	-0.54	-5.47	-0.41	1.91e-7	Body mass index;
UCEC	cis	rs7572644	0.640	rs11127126	chr2:28023284	C/T	cg27432699	chr2:27873401	GPN1	0.45	4.51	0.35	1.32e-5	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
UCEC	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.29	-0.4	4.44e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg11871910	chr12:69753446	YEATS4	0.62	5.49	0.41	1.7e-7	Response to diuretic therapy;
UCEC	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.07	0.5	5.71e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.55	-5.51	-0.41	1.54e-7	Morning vs. evening chronotype;
UCEC	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.42	12.82	0.73	1.02e-25	Atopic dermatitis;
UCEC	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg27391334	chr7:1352002	NA	0.37	4.62	0.36	8.31e-6	Longevity;Endometriosis;
UCEC	cis	rs77861329	0.748	rs4687810	chr3:52169095	T/C	cg08692210	chr3:52188851	WDR51A	0.65	5.97	0.44	1.71e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs986417	0.818	rs8014133	chr14:61104738	A/C	cg17336400	chr14:61201680	MNAT1	-0.94	-4.7	-0.36	6.05e-6	Gut microbiota (bacterial taxa);
UCEC	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.05	-7.64	-0.53	2.59e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg23229016	chr1:26872525	RPS6KA1	0.3	5.59	0.42	1.08e-7	Glucose homeostasis traits;
UCEC	cis	rs2267137	0.843	rs570731	chr22:29758817	A/G	cg07256473	chr22:29710276	RASL10A	-0.55	-6.29	-0.46	3.38e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs3015497	0.789	rs8003372	chr14:51102351	G/A	cg04730355	chr14:51134070	SAV1	-0.51	-5.11	-0.39	9.94e-7	Mean platelet volume;
UCEC	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.49	-4.7	-0.36	5.98e-6	Dental caries;
UCEC	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18854424	chr1:2615690	NA	-0.46	-7.14	-0.51	4e-11	Ulcerative colitis;
UCEC	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	8.81	0.59	3.18e-15	Coffee consumption (cups per day);
UCEC	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-4.55	-0.35	1.12e-5	Blood metabolite levels;
UCEC	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.57	-4.86	-0.37	2.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg11871910	chr12:69753446	YEATS4	0.62	5.49	0.41	1.7e-7	Response to diuretic therapy;
UCEC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.73	-0.43	5.6e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6060717	0.536	rs3787173	chr20:34472105	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.56	-0.35	1.05e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.55	-5.94	-0.44	1.95e-8	Bipolar disorder;
UCEC	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.47	4.64	0.36	7.5e-6	Coronary artery disease;
UCEC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.53	-5.32	-0.4	3.71e-7	Prostate cancer;
UCEC	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-5.09	-0.39	1.09e-6	Menarche (age at onset);
UCEC	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.43	-5.4	-0.41	2.6e-7	Urinary tract infection frequency;
UCEC	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.49	4.77	0.37	4.47e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28795989	0.613	rs2385900	chr4:7921777	G/A	cg12632249	chr4:7449638	SORCS2	-0.35	-4.53	-0.35	1.19e-5	Intraocular pressure;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.78	0.59	3.81e-15	Prudent dietary pattern;
UCEC	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.5	4.94	0.38	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1250259	0.519	rs34255697	chr2:216266225	G/T	cg17325911	chr2:216976926	XRCC5	0.44	4.87	0.37	2.86e-6	Coronary artery disease;Pulse pressure;
UCEC	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.17	0.45	6.36e-9	Platelet count;
UCEC	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg05072774	chr3:49840536	C3orf54	-0.51	-5.26	-0.4	4.9e-7	Resting heart rate;
UCEC	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.48	-5.49	-0.41	1.72e-7	White matter hyperintensity burden;
UCEC	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	1.18	9.48	0.62	6.42e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg20999797	chr1:1681921	NA	0.36	4.81	0.37	3.69e-6	Body mass index;
UCEC	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg04756594	chr16:24857601	SLC5A11	-0.49	-4.73	-0.36	5.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.93	0.5	1.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22117172	chr7:91764530	CYP51A1	0.41	5.15	0.39	8.15e-7	Breast cancer;
UCEC	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.7	5.68	0.42	7.09e-8	Type 2 diabetes;
UCEC	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-5.61	-0.42	9.55e-8	Heart rate;
UCEC	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.71	5.82	0.43	3.5e-8	Alzheimer's disease;
UCEC	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.15	8.08	0.55	2.15e-13	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.52	-5.98	-0.44	1.64e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.47	5.5	0.41	1.6e-7	Aortic root size;
UCEC	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.53	-5.28	-0.4	4.47e-7	IgG glycosylation;
UCEC	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.82	11.11	0.68	3.41e-21	Body mass index;
UCEC	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.49	-5.43	-0.41	2.27e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.44	-5.44	-0.41	2.22e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg03342759	chr3:160939853	NMD3	0.54	5.08	0.39	1.12e-6	Morning vs. evening chronotype;
UCEC	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.67	6.19	0.45	5.83e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.84	5.5	0.41	1.65e-7	Psoriasis;
UCEC	cis	rs4372836	0.929	rs55883854	chr2:28929541	C/T	cg09522027	chr2:28974177	PPP1CB	0.74	7.52	0.53	5.09e-12	Body mass index;
UCEC	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.4	0.41	2.57e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.57	-5.49	-0.41	1.75e-7	Asthma (sex interaction);
UCEC	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg13319975	chr6:146136371	FBXO30	0.47	4.96	0.38	1.88e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.72	8.31	0.57	5.97e-14	IgG glycosylation;
UCEC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.82	6.96	0.5	1.06e-10	Initial pursuit acceleration;
UCEC	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg17105886	chr17:28927953	LRRC37B2	0.47	4.55	0.35	1.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	8.37	0.57	4.23e-14	Lymphocyte percentage of white cells;
UCEC	cis	rs643472	0.514	rs2341674	chr8:29198256	A/G	cg03603593	chr8:29442834	NA	-0.57	-4.7	-0.36	6.04e-6	Corticobasal degeneration;
UCEC	cis	rs4646312	0.555	rs1800706	chr22:19928022	G/A	cg07194846	chr22:19930177	COMT;TXNRD2	-0.52	-4.97	-0.38	1.8e-6	Schizophrenia;
UCEC	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg16583315	chr14:65563665	MAX	-0.43	-5.73	-0.43	5.44e-8	Obesity-related traits;
UCEC	cis	rs8105895	0.935	rs62110988	chr19:22259956	C/T	cg02912127	chr19:22235281	ZNF257	-0.63	-5.33	-0.4	3.6e-7	Body mass index (change over time);
UCEC	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13683864	chr3:40499215	RPL14	-1.01	-10.69	-0.66	4.38e-20	Renal cell carcinoma;
UCEC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.25	0.65	6.03e-19	Electrocardiographic conduction measures;
UCEC	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	7.82	0.54	9.53e-13	Ileal carcinoids;
UCEC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg17330251	chr7:94953956	PON1	-0.56	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.39	-5.24	-0.4	5.4e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-4.5	-0.35	1.35e-5	Blood protein levels;
UCEC	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-0.9	-5.96	-0.44	1.77e-8	Mitochondrial DNA levels;
UCEC	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.31	10.75	0.66	2.96e-20	Uric acid levels;
UCEC	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.54	5.93	0.44	2.13e-8	Bipolar disorder;
UCEC	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01391022	chr12:122360665	WDR66	-0.47	-4.54	-0.35	1.14e-5	Mean corpuscular volume;
UCEC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-4.57	-0.35	1.01e-5	Multiple myeloma (IgH translocation);
UCEC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.47	5.05	0.38	1.28e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.85	10.85	0.67	1.64e-20	Metabolic syndrome;
UCEC	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg10902566	chr4:727664	PCGF3	-0.56	-4.73	-0.36	5.26e-6	Systolic blood pressure;
UCEC	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.94	0.5	1.14e-10	Coronary artery disease;
UCEC	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.63	4.98	0.38	1.79e-6	Body mass index;
UCEC	trans	rs4534959	0.546	rs7242686	chr18:62059400	A/T	cg18966047	chr5:180480456	BTNL9	-1.23	-7.08	-0.5	5.44e-11	Airflow obstruction;
UCEC	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.79	-5.89	-0.44	2.5e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	1.08	6.16	0.45	6.52e-9	Skin colour saturation;
UCEC	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.37	4.71	0.36	5.69e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2708377	0.929	rs73066828	chr12:11270654	A/C	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.75	6.25	0.46	4.25e-9	Bitter taste perception;
UCEC	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.39	-4.67	-0.36	6.86e-6	Menopause (age at onset);
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.71	-0.43	6.01e-8	Pubertal anthropometrics;
UCEC	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.74	-8.58	-0.58	1.23e-14	Menarche (age at onset);
UCEC	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.47	5.55	0.42	1.32e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.81	-10.4	-0.65	2.42e-19	White blood cell count (basophil);
UCEC	cis	rs6684428	0.610	rs10493189	chr1:56315657	A/G	cg11651538	chr1:56320950	NA	-0.66	-4.85	-0.37	3.17e-6	Airflow obstruction;
UCEC	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.39	5.37	0.41	3e-7	Sitting height ratio;
UCEC	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg25600027	chr14:23388339	RBM23	-0.45	-4.64	-0.36	7.62e-6	Cognitive ability (multi-trait analysis);
UCEC	cis	rs2474937	0.561	rs6428745	chr1:118925454	A/C	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.68	-6.37	-0.47	2.23e-9	Aortic root size;
UCEC	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.57	-5.5	-0.41	1.6e-7	Dental caries;
UCEC	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.34	-0.4	3.5e-7	Bipolar disorder;
UCEC	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.44	-0.41	2.22e-7	Body mass index;
UCEC	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs308403	0.509	rs1849430	chr4:123674701	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.72	9.23	0.61	2.82e-16	Blood protein levels;
UCEC	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.2	-0.39	6.71e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.47	-5.02	-0.38	1.46e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.61	4.9	0.37	2.46e-6	RR interval (heart rate);
UCEC	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.84	0.37	3.21e-6	Aortic root size;
UCEC	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.78	10.7	0.66	4.16e-20	Vitiligo;
UCEC	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.51	4.66	0.36	6.99e-6	Menopause (age at onset);
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg15133208	chr4:90757351	SNCA	-0.33	-4.51	-0.35	1.34e-5	Dementia with Lewy bodies;
UCEC	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg23307798	chr14:103986281	CKB	0.56	5.28	0.4	4.61e-7	Body mass index;
UCEC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.73	-6.92	-0.5	1.29e-10	Pancreatic cancer;
UCEC	cis	rs2081015	0.701	rs890793	chr5:153573938	C/T	cg11307618	chr5:153990559	NA	-0.53	-5.98	-0.44	1.66e-8	Carotid artery intima media thickness (sex interaction);
UCEC	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	5.13	0.39	9.12e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.51	-4.89	-0.37	2.66e-6	Longevity;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.45	-5.18	-0.39	7.12e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	5.68	0.42	7.01e-8	Rheumatoid arthritis;
UCEC	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.53	-6.39	-0.47	2.09e-9	Fibrinogen levels;
UCEC	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.67	6.29	0.46	3.49e-9	Response to antineoplastic agents;
UCEC	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-5.18	-0.39	7.29e-7	Hepatocellular carcinoma;
UCEC	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-6.97	-0.5	1.02e-10	Mean platelet volume;
UCEC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg10503236	chr1:231470652	EXOC8	-0.4	-4.58	-0.35	9.76e-6	Hemoglobin concentration;
UCEC	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-10.37	-0.65	2.94e-19	Cognitive function;
UCEC	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.65	8.66	0.58	7.68e-15	Neuroticism;
UCEC	cis	rs367615	0.918	rs115145487	chr5:108888146	A/G	cg17395555	chr5:108820864	NA	0.53	4.97	0.38	1.88e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.63	-5.14	-0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.77	7.45	0.52	7.48e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.55	-5.93	-0.44	2.12e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.65	4.62	0.36	8.2e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.87	-0.44	2.77e-8	Hemoglobin concentration;
UCEC	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.49	-4.64	-0.36	7.7e-6	Bipolar disorder;
UCEC	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.48	-6.68	-0.48	4.66e-10	Height;
UCEC	cis	rs57709857	0.801	rs28867132	chr8:38101724	T/C	cg08167846	chr8:38212404	WHSC1L1	0.47	4.61	0.36	8.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg10932868	chr11:921992	NA	0.37	4.51	0.35	1.3e-5	Alzheimer's disease (late onset);
UCEC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg04310649	chr10:35416472	CREM	-0.49	-4.88	-0.37	2.7e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.05	-0.45	1.15e-8	Aortic root size;
UCEC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	4.72	0.36	5.48e-6	Personality dimensions;
UCEC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg01689657	chr7:91764605	CYP51A1	0.49	6.27	0.46	3.79e-9	Breast cancer;
UCEC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.97	0.44	1.7e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	0.82	7.05	0.5	6.3e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2806974	0.675	rs12860317	chr13:53827237	A/G	cg16114640	chr13:52980000	THSD1	-0.47	-4.53	-0.35	1.22e-5	Trans fatty acid levels;
UCEC	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.6	5.67	0.42	7.28e-8	High light scatter reticulocyte count;
UCEC	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.73	6.27	0.46	3.86e-9	Cognitive test performance;
UCEC	cis	rs4919044	0.756	rs2478239	chr10:94806370	A/T	cg18197594	chr10:94334836	IDE	-0.53	-4.52	-0.35	1.25e-5	Coronary artery disease;
UCEC	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg04662943	chr10:102668895	NA	0.46	4.59	0.35	9.48e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg05695927	chr15:45694626	SPATA5L1	-0.52	-4.7	-0.36	5.89e-6	Homoarginine levels;
UCEC	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.05	-0.38	1.3e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.8	-0.49	2.48e-10	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.49	4.5	0.35	1.35e-5	Prudent dietary pattern;
UCEC	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-4.52	-0.35	1.26e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.47	-0.52	6.55e-12	Total cholesterol levels;
UCEC	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg13147721	chr7:65941812	NA	-0.92	-5.8	-0.43	3.91e-8	Diabetic kidney disease;
UCEC	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.54	5.82	0.43	3.55e-8	Prostate cancer;
UCEC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs12644436	0.827	rs6854478	chr4:88776726	G/A	cg27179352	chr4:88029472	AFF1	0.41	4.8	0.37	3.94e-6	HIV-1 viral setpoint;
UCEC	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg23950597	chr19:37808831	NA	-0.81	-5.89	-0.44	2.49e-8	Coronary artery calcification;
UCEC	cis	rs6437061	0.737	rs3103295	chr2:233034472	T/C	cg02061626	chr2:233274167	ALPPL2	-0.45	-4.91	-0.38	2.42e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs117623576	0.680	rs72777120	chr10:32367608	A/G	cg09476325	chr10:33189322	ITGB1	0.66	4.52	0.35	1.26e-5	Anti-saccade response;
UCEC	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg05539622	chr2:73298971	SFXN5	0.48	4.57	0.35	1.02e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs787274	0.867	rs787269	chr9:115548676	T/C	cg13803584	chr9:115635662	SNX30	-0.69	-5.21	-0.39	6.36e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs7204230	1.000	rs8043931	chr16:53300014	C/T	cg10109421	chr16:52641824	NA	0.4	4.59	0.35	9.25e-6	Fibrinogen;
UCEC	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.44	5.28	0.4	4.63e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.61	-6.1	-0.45	8.72e-9	Prudent dietary pattern;
UCEC	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06762426	chr11:62420836	INTS5	0.86	4.73	0.36	5.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.63	7.9	0.55	5.88e-13	Mean platelet volume;
UCEC	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.45	0.61	7.27e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.53	5.19	0.39	6.84e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.55	4.98	0.38	1.76e-6	Corneal astigmatism;
UCEC	trans	rs925228	0.910	rs4665249	chr2:24174616	T/C	cg18674340	chr17:45867686	NA	0.71	6.68	0.48	4.58e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.49	4.67	0.36	6.76e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg05874882	chr4:1763078	NA	-0.55	-5.8	-0.43	3.99e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg00983440	chr10:79422392	NA	-1.12	-8.67	-0.58	7.17e-15	Bone mineral density;
UCEC	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.78	-6.45	-0.47	1.54e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.38	-4.7	-0.36	6.06e-6	Monocyte percentage of white cells;
UCEC	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg10978503	chr1:24200527	CNR2	-0.35	-4.61	-0.36	8.81e-6	Immature fraction of reticulocytes;
UCEC	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.52	5.3	0.4	4.19e-7	Schizophrenia;
UCEC	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.38	4.53	0.35	1.21e-5	Systolic blood pressure;
UCEC	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.57	0.35	1.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1318937	0.764	rs9864422	chr3:15227252	C/T	cg21849552	chr3:14597650	NA	0.43	4.61	0.36	8.51e-6	Alcohol and nicotine co-dependence;Alcohol dependence;
UCEC	cis	rs847577	0.630	rs13221758	chr7:97719806	A/C	cg21770322	chr7:97807741	LMTK2	0.83	13.84	0.75	2.09e-28	Breast cancer;
UCEC	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.63	-6.71	-0.48	3.97e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg17469321	chr7:55412551	NA	-0.68	-6.39	-0.47	2.05e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.5	4.54	0.35	1.14e-5	Preschool internalizing problems;
UCEC	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-7.17	-0.51	3.39e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.57	6.46	0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs7246967	0.611	rs3931771	chr19:22896820	A/G	cg24889512	chr19:22816950	ZNF492	0.62	6.68	0.48	4.67e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6832769	0.925	rs4371676	chr4:56329008	G/A	cg05960024	chr4:56376020	CLOCK	0.49	4.51	0.35	1.34e-5	Personality dimensions;
UCEC	cis	rs7560272	0.501	rs11894953	chr2:73964631	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-4.78	-0.37	4.27e-6	Schizophrenia;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg00280220	chr17:61926910	NA	0.43	4.65	0.36	7.43e-6	Prudent dietary pattern;
UCEC	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.75	-0.37	4.72e-6	Blood metabolite levels;
UCEC	cis	rs8177876	0.642	rs10514513	chr16:81114183	C/T	cg08591886	chr16:81111003	C16orf46	-0.81	-4.94	-0.38	2.08e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg19678392	chr7:94953810	PON1	-0.58	-5.7	-0.43	6.45e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.47	0.72	8.44e-25	Prudent dietary pattern;
UCEC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18252515	chr7:66147081	NA	0.53	5.02	0.38	1.49e-6	Aortic root size;
UCEC	cis	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg20307385	chr11:47447363	PSMC3	-0.65	-4.68	-0.36	6.58e-6	Intraocular pressure;
UCEC	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.51	-5.09	-0.39	1.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.7	7.3	0.52	1.64e-11	Menopause (age at onset);
UCEC	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.95	-9.21	-0.6	3.08e-16	Dilated cardiomyopathy;
UCEC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.69	0.48	4.28e-10	Homoarginine levels;
UCEC	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg13683864	chr3:40499215	RPL14	-0.56	-6.11	-0.45	8.39e-9	Renal cell carcinoma;
UCEC	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.82	10.45	0.65	1.9e-19	White blood cell count (basophil);
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.76	0.63	1.16e-17	Platelet count;
UCEC	cis	rs9302690	1.000	rs62037143	chr16:57486583	T/C	cg27017172	chr16:57497170	POLR2C	1.2	7.0	0.5	8.41e-11	Blood protein levels;
UCEC	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg08798685	chr6:27730294	NA	-0.63	-4.58	-0.35	9.87e-6	Depression;
UCEC	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.55	4.96	0.38	1.95e-6	Coronary artery disease;
UCEC	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.14	9.94	0.63	3.91e-18	Corneal structure;
UCEC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg15358701	chr1:161410459	NA	-0.74	-5.07	-0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.69	-7.72	-0.54	1.65e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.69	9.09	0.6	6.31e-16	Alcohol dependence (age at onset);
UCEC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.48	-4.58	-0.35	9.92e-6	Parkinson's disease;
UCEC	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	5.03	0.38	1.44e-6	IgG glycosylation;
UCEC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg11871910	chr12:69753446	YEATS4	0.73	7.77	0.54	1.28e-12	Blood protein levels;
UCEC	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.69	-5.94	-0.44	1.94e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.54	6.07	0.45	1.04e-8	Prostate cancer;
UCEC	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.36	-0.46	2.46e-9	Resting heart rate;
UCEC	cis	rs10208940	0.777	rs4513330	chr2:68850921	C/T	cg12452813	chr2:68675892	NA	-0.47	-4.54	-0.35	1.16e-5	Urate levels in lean individuals;
UCEC	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-0.71	-4.73	-0.36	5.22e-6	Blood protein levels;
UCEC	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.81	10.4	0.65	2.42e-19	White blood cell count (basophil);
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg06818710	chr6:28411271	ZSCAN23	0.53	6.82	0.49	2.19e-10	Pubertal anthropometrics;
UCEC	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.41	-4.98	-0.38	1.73e-6	Neuroticism;
UCEC	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.81	-6.83	-0.49	2.11e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.89	-9.8	-0.63	9.27e-18	Cognitive function;
UCEC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg03609598	chr5:56110824	MAP3K1	-0.55	-4.68	-0.36	6.36e-6	Coronary artery disease;
UCEC	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-9.66	-0.62	2.16e-17	Electrocardiographic conduction measures;
UCEC	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.55	-4.54	-0.35	1.16e-5	Depression;
UCEC	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16346588	chr10:242978	ZMYND11	0.47	4.55	0.35	1.12e-5	Psychosis in Alzheimer's disease;
UCEC	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.51	-4.62	-0.36	8.45e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs28530618	0.580	rs11167174	chr20:31248879	G/A	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.11	-0.39	9.76e-7	Birth weight;
UCEC	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.53	5.42	0.41	2.42e-7	Neutrophil percentage of white cells;
UCEC	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.06	0.39	1.21e-6	Bipolar disorder;
UCEC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg12463550	chr7:65579703	CRCP	0.52	5.19	0.39	6.87e-7	Aortic root size;
UCEC	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg27068330	chr11:65405492	SIPA1	-0.53	-4.71	-0.36	5.7e-6	Breast cancer;
UCEC	cis	rs28386778	0.669	rs4968674	chr17:62015048	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-5.75	-0.43	4.94e-8	Prudent dietary pattern;
UCEC	cis	rs3116162	0.605	rs2129778	chr2:233031983	C/T	cg23548455	chr2:233377587	NA	-0.69	-4.53	-0.35	1.23e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
UCEC	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.59	5.54	0.42	1.35e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	0.84	10.56	0.66	9.21e-20	Bone mineral density;
UCEC	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg01391022	chr12:122360665	WDR66	-0.43	-4.93	-0.38	2.17e-6	Mean corpuscular volume;
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.85	-0.49	1.9e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.59	0.53	3.42e-12	Menopause (age at onset);
UCEC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	5.74	0.43	5.31e-8	Tonsillectomy;
UCEC	cis	rs7937612	1.000	rs2305008	chr11:120319064	A/C	cg12584626	chr11:120203529	NA	0.55	5.36	0.4	3.18e-7	Intraocular pressure;
UCEC	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.64	6.25	0.46	4.17e-9	Lymphocyte counts;
UCEC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.48	-4.52	-0.35	1.26e-5	Aortic root size;
UCEC	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.24	-0.61	2.54e-16	Coffee consumption (cups per day);
UCEC	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.57	-7.0	-0.5	8.55e-11	Rheumatoid arthritis;
UCEC	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.64	-6.62	-0.48	6.42e-10	Mean platelet volume;
UCEC	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.63	5.79	0.43	4.03e-8	Menarche (age at onset);
UCEC	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.57	7.23	0.51	2.46e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	5.25	0.4	5.11e-7	Lung cancer in ever smokers;
UCEC	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.67	0.62	1.99e-17	Blood protein levels;
UCEC	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.07e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7975161	0.630	rs7138317	chr12:104650271	G/A	cg25273343	chr12:104657179	TXNRD1	-0.82	-4.99	-0.38	1.69e-6	Toenail selenium levels;
UCEC	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-4.56	-0.35	1.08e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.59	4.74	0.36	4.93e-6	Longevity;
UCEC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.5e-16	Vitiligo;
UCEC	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	7.36	0.52	1.22e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.33	4.59	0.35	9.52e-6	Primary biliary cholangitis;
UCEC	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	7.94	0.55	4.87e-13	Exhaled nitric oxide levels;
UCEC	cis	rs9356171	0.540	rs2207441	chr6:164325217	G/A	cg25752492	chr6:164341247	NA	-0.59	-5.96	-0.44	1.81e-8	Diisocyanate-induced asthma;
UCEC	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	5.2	0.39	6.51e-7	Personality dimensions;
UCEC	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.83	-11.45	-0.69	4.28e-22	Urate levels in lean individuals;
UCEC	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.8	-0.49	2.46e-10	Coffee consumption (cups per day);
UCEC	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.36	5.29	0.4	4.41e-7	Ulcerative colitis;
UCEC	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.63	5.49	0.41	1.7e-7	Uric acid levels;
UCEC	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.58	6.59	0.48	7.5e-10	Longevity;
UCEC	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.52	4.53	0.35	1.22e-5	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.57	6.59	0.48	7.53e-10	Menarche (age at onset);
UCEC	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg20399509	chr21:47717575	C21orf57	-0.5	-5.38	-0.41	2.85e-7	Testicular germ cell tumor;
UCEC	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.56	-5.17	-0.39	7.54e-7	Morning vs. evening chronotype;
UCEC	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.57	6.46	0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs4499344	0.730	rs614370	chr19:33106390	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.39e-9	Mean platelet volume;
UCEC	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.47	4.67	0.36	6.87e-6	Height;
UCEC	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg11632617	chr15:75315747	PPCDC	-0.62	-7.21	-0.51	2.68e-11	Blood trace element (Zn levels);
UCEC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.65	-0.36	7.19e-6	Breast cancer;
UCEC	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg25600027	chr14:23388339	RBM23	-0.43	-4.53	-0.35	1.2e-5	Cognitive ability (multi-trait analysis);
UCEC	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg18230493	chr5:56204884	C5orf35	-0.52	-4.52	-0.35	1.27e-5	Coronary artery disease;
UCEC	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg23950597	chr19:37808831	NA	-0.77	-5.38	-0.41	2.9e-7	Coronary artery calcification;
UCEC	cis	rs308403	0.608	rs309368	chr4:123662997	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.39	0.47	2.05e-9	Blood protein levels;
UCEC	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg15133208	chr4:90757351	SNCA	-0.45	-5.3	-0.4	4.07e-7	Neuroticism;
UCEC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-6.91	-0.49	1.4e-10	Joint mobility (Beighton score);
UCEC	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs60594510	1	rs60594510	chr12:110594503	C/T	cg12870014	chr12:110450643	ANKRD13A	0.67	5.56	0.42	1.25e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.551	rs7250608	chr19:22853056	C/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-0.73	-6.92	-0.5	1.28e-10	Systemic lupus erythematosus;
UCEC	cis	rs9400271	0.527	rs4946959	chr6:109641563	A/G	cg01475377	chr6:109611718	NA	0.44	4.88	0.37	2.76e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12264333	chr10:105209552	CALHM2	-0.52	-6.89	-0.49	1.53e-10	Warfarin maintenance dose;
UCEC	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.11	-0.39	9.76e-7	Colorectal cancer;
UCEC	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg07387570	chr22:46663686	TTC38	-0.49	-4.89	-0.37	2.59e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.1	-6.76	-0.49	3.08e-10	Breast cancer;
UCEC	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.1	-7.03	-0.5	7.31e-11	Diabetic kidney disease;
UCEC	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg18016565	chr1:150552671	MCL1	0.64	7.32	0.52	1.52e-11	Tonsillectomy;
UCEC	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.56	-4.76	-0.37	4.51e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg00529422	chr1:16285251	ZBTB17	-0.44	-4.97	-0.38	1.81e-6	Dilated cardiomyopathy;
UCEC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.5	4.92	0.38	2.32e-6	Lymphocyte counts;
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.6	-7.19	-0.51	3.08e-11	Pubertal anthropometrics;
UCEC	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.3e-11	Breast cancer;
UCEC	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.44	0.41	2.14e-7	Blood protein levels;
UCEC	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.62	5.1	0.39	1.02e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.71	-0.36	5.59e-6	Menopause (age at onset);
UCEC	cis	rs66573146	1.000	rs9942188	chr4:6984181	C/T	cg00086871	chr4:6988644	TBC1D14	0.82	5.6	0.42	1.04e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.43	5.36	0.4	3.12e-7	Neutrophil percentage of white cells;
UCEC	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.55	5.1	0.39	1.02e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.61	6.11	0.45	8.49e-9	Lung cancer;
UCEC	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.56	5.36	0.4	3.11e-7	Hepatocellular carcinoma;
UCEC	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg05775895	chr3:12838266	CAND2	0.6	5.4	0.41	2.68e-7	QRS complex (12-leadsum);
UCEC	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	7.91	0.55	5.55e-13	Smoking behavior;
UCEC	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.59	5.03	0.38	1.41e-6	Corneal astigmatism;
UCEC	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.35	-4.71	-0.36	5.66e-6	Schizophrenia;
UCEC	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	8.02	0.55	2.97e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs9868873	1.000	rs9821665	chr3:122729779	A/G	cg02041593	chr3:122741233	SEMA5B	0.51	5.31	0.4	4.03e-7	Esophageal cancer;
UCEC	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg03078520	chr22:18463400	MICAL3	-0.41	-4.63	-0.36	8.04e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.55e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2708377	0.858	rs117212341	chr12:11282556	C/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.59	4.72	0.36	5.36e-6	Bitter taste perception;
UCEC	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.81	-9.01	-0.6	1.02e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.4	-5.56	-0.42	1.23e-7	Alcohol dependence;
UCEC	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.62	4.9	0.37	2.53e-6	Type 2 diabetes;
UCEC	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.55	5.72	0.43	5.86e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.44	4.62	0.36	8.2e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.11	8.78	0.59	3.95e-15	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.45	0.52	7.36e-12	Ileal carcinoids;
UCEC	cis	rs7374004	0.840	rs62242766	chr3:38636826	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.56	5.16	0.39	7.85e-7	PR interval;
UCEC	cis	rs11958404	0.932	rs72816585	chr5:157433901	A/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.53	5.3	0.4	4.18e-7	Dupuytren's disease;
UCEC	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.71	6.72	0.48	3.72e-10	Monocyte count;
UCEC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg06238570	chr21:40685208	BRWD1	0.76	7.5	0.53	5.6e-12	Cognitive function;
UCEC	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-4.72	-0.36	5.46e-6	Monocyte percentage of white cells;
UCEC	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg26014689	chr19:7917955	EVI5L	-0.44	-4.7	-0.36	5.86e-6	Menarche (age at onset);
UCEC	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-4.73	-0.36	5.12e-6	Educational attainment;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.47	-4.59	-0.35	9.42e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7246967	0.673	rs4244915	chr19:22854138	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.54	0.47	9.41e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.65	6.04	0.45	1.21e-8	Subjective well-being;
UCEC	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.23	0.4	5.62e-7	Electroencephalogram traits;
UCEC	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg26354017	chr1:205819088	PM20D1	0.64	8.07	0.55	2.35e-13	Menarche (age at onset);
UCEC	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.53	-5.44	-0.41	2.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.55	-5.54	-0.42	1.33e-7	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.63	5.76	0.43	4.64e-8	Coronary artery disease;
UCEC	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.55	5.45	0.41	2.05e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg14092571	chr14:90743983	NA	-0.43	-5.73	-0.43	5.57e-8	Mortality in heart failure;
UCEC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.79	-9.55	-0.62	4.21e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-7.43	-0.52	8.12e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.52	5.01	0.38	1.57e-6	Menopause (age at onset);
UCEC	cis	rs1575951	1.000	rs10829454	chr10:130435621	C/G	cg27041381	chr10:131357203	MGMT	0.6	5.2	0.39	6.6e-7	Plasma clusterin levels;
UCEC	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.44	-5.01	-0.38	1.54e-6	Total body bone mineral density;
UCEC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg24562669	chr7:97807699	LMTK2	0.48	5.87	0.44	2.84e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	7.37	0.52	1.17e-11	Homoarginine levels;
UCEC	cis	rs11021221	0.628	rs11021219	chr11:95301957	C/T	cg22049858	chr11:94884121	NA	0.74	4.68	0.36	6.42e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
UCEC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	0.83	7.16	0.51	3.56e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.4	-4.76	-0.37	4.63e-6	Menopause (age at onset);
UCEC	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs1816854	0.938	rs11182273	chr12:44202901	C/G	cg00106942	chr12:44200524	TWF1	0.58	6.17	0.45	6.33e-9	Inflammatory bowel disease;
UCEC	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.1	9.87	0.63	6.03e-18	Corneal structure;
UCEC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01380346	chr19:18557039	ELL	-0.5	-5.21	-0.39	6.19e-7	Breast cancer;
UCEC	cis	rs7709377	0.595	rs785375	chr5:115659452	A/T	cg23108291	chr5:115420582	COMMD10	-0.45	-4.56	-0.35	1.09e-5	Metabolite levels  (X-11787);
UCEC	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.54	4.51	0.35	1.34e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.16	0.39	7.92e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27286337	chr10:134555280	INPP5A	0.55	4.97	0.38	1.87e-6	Migraine;
UCEC	cis	rs1981331	0.609	rs77725404	chr21:48080376	C/T	cg17243659	chr21:48055224	PRMT2	1.04	4.51	0.35	1.32e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs8105895	1.000	rs79846980	chr19:22141343	T/C	cg20662725	chr19:22235022	ZNF257	-0.69	-5.64	-0.42	8.56e-8	Body mass index (change over time);
UCEC	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.35	-4.53	-0.35	1.22e-5	Refractive error;
UCEC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.64	9.25	0.61	2.46e-16	Prudent dietary pattern;
UCEC	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.46	-0.41	1.96e-7	Response to antipsychotic treatment;
UCEC	cis	rs6670533	0.571	rs80091715	chr1:24860343	G/A	cg07475527	chr1:24864545	NA	-0.82	-4.64	-0.36	7.54e-6	Fasting blood insulin (BMI interaction);
UCEC	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.61	6.0	0.44	1.44e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.54	6.12	0.45	7.91e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	1.000	rs9467799	chr6:26578364	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.91	6.09	0.45	9.47e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.49	4.94	0.38	2.06e-6	Dupuytren's disease;
UCEC	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13683864	chr3:40499215	RPL14	-0.87	-8.86	-0.59	2.38e-15	Renal cell carcinoma;
UCEC	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.67	7.6	0.53	3.14e-12	Mean corpuscular volume;
UCEC	cis	rs1575951	1.000	rs10829464	chr10:130445500	C/T	cg09154334	chr10:131341043	MGMT	0.54	4.56	0.35	1.06e-5	Plasma clusterin levels;
UCEC	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.68	0.36	6.48e-6	Response to antipsychotic treatment;
UCEC	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg16797656	chr11:68205561	LRP5	0.47	5.34	0.4	3.48e-7	Total body bone mineral density;
UCEC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs334147	1.000	rs334140	chr2:128235148	A/G	cg14478610	chr2:127864964	BIN1	0.58	5.14	0.39	8.5e-7	Educational attainment;
UCEC	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg06238570	chr21:40685208	BRWD1	0.76	7.46	0.52	6.88e-12	Cognitive function;
UCEC	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.64	-6.92	-0.5	1.3100000000000001e-10	Hypospadias;
UCEC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.49	5.22	0.4	5.9e-7	Red cell distribution width;
UCEC	cis	rs8105895	1.000	rs11881224	chr19:22220340	G/A	cg02912127	chr19:22235281	ZNF257	-0.52	-4.59	-0.35	9.61e-6	Body mass index (change over time);
UCEC	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.47	4.57	0.35	1.04e-5	Verbal declarative memory;
UCEC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.67	6.81	0.49	2.26e-10	Body mass index;
UCEC	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg19926144	chr10:661009	DIP2C	0.82	4.87	0.37	2.84e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.16	0.45	6.78e-9	Motion sickness;
UCEC	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.49	4.93	0.38	2.22e-6	Dupuytren's disease;
UCEC	cis	rs73206853	0.764	rs6606685	chr12:110881986	C/G	cg12870014	chr12:110450643	ANKRD13A	0.64	5.62	0.42	9.28e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.73	-7.9	-0.55	5.92e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.66	5.5	0.41	1.67e-7	Smoking initiation;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg04871131	chr7:94954202	PON1	-0.55	-5.47	-0.41	1.93e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.41	-4.55	-0.35	1.09e-5	Growth-regulated protein alpha levels;
UCEC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.52	5.87	0.44	2.73e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.38	4.79	0.37	4.05e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg07424592	chr7:64974309	NA	0.78	4.75	0.36	4.81e-6	Diabetic kidney disease;
UCEC	trans	rs2270927	0.790	rs6874435	chr5:75574855	A/G	cg13563193	chr19:33072644	PDCD5	0.9	7.09	0.5	5.24e-11	Mean corpuscular volume;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.62	-7.86	-0.54	7.67e-13	Pubertal anthropometrics;
UCEC	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.6	-0.53	3.13e-12	Hypospadias;
UCEC	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.61	5.94	0.44	1.95e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.06	-0.5	6.23e-11	Colorectal cancer;
UCEC	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.41	-5.29	-0.4	4.34e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.56	5.23	0.4	5.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.54	5.61	0.42	9.94e-8	Breast cancer;
UCEC	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.53	6.67	0.48	4.94e-10	Total body bone mineral density;
UCEC	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.55	5.53	0.41	1.44e-7	Menopause (age at onset);
UCEC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.56	-6.37	-0.47	2.24e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.52	4.83	0.37	3.38e-6	Coronary artery disease;
UCEC	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.58	-4.89	-0.37	2.62e-6	Corneal structure;
UCEC	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.63	5.7	0.43	6.25e-8	Morning vs. evening chronotype;
UCEC	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg01262667	chr19:19385393	TM6SF2	0.5	7.02	0.5	7.51e-11	Tonsillectomy;
UCEC	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg24375607	chr4:120327624	NA	-0.45	-4.79	-0.37	4.07e-6	Corneal astigmatism;
UCEC	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.5	-4.99	-0.38	1.69e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.34	4.86	0.37	3.02e-6	Coronary artery disease;
UCEC	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.57	-5.34	-0.4	3.5e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.12	-0.6	5.33e-16	Height;
UCEC	cis	rs5754227	0.895	rs11913403	chr22:33106737	T/G	cg12003043	chr22:32341402	C22orf24;YWHAH	-0.55	-4.88	-0.37	2.68e-6	Advanced age-related macular degeneration;
UCEC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.54	0.35	1.16e-5	Breast cancer;
UCEC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.75	0.36	4.75e-6	Birth weight;
UCEC	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.6	6.59	0.48	7.4e-10	Eye color traits;
UCEC	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.92	0.59	1.68e-15	Alzheimer's disease;
UCEC	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.65	6.31	0.46	3.04e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg05072774	chr3:49840536	C3orf54	-0.54	-5.59	-0.42	1.09e-7	Resting heart rate;
UCEC	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.4	4.91	0.38	2.38e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-10.64	-0.66	5.91e-20	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.74	0.36	4.92e-6	Breast cancer;
UCEC	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14019695	chr9:139328340	INPP5E	0.47	5.0	0.38	1.6e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.5	0.47	1.19e-9	Personality dimensions;
UCEC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.63	5.27	0.4	4.71e-7	Systolic blood pressure;
UCEC	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.64	-7.15	-0.51	3.77e-11	Ulcerative colitis;
UCEC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.69	6.59	0.48	7.34e-10	Aortic root size;
UCEC	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.37	0.41	2.97e-7	Total body bone mineral density;
UCEC	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.65	5.83	0.43	3.37e-8	Menopause (age at onset);
UCEC	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg13143389	chr11:8680333	TRIM66	0.35	4.53	0.35	1.23e-5	Hemoglobin concentration;
UCEC	cis	rs6761276	0.780	rs12477867	chr2:113835919	C/A	cg09040174	chr2:113837401	NA	0.52	5.78	0.43	4.38e-8	Protein quantitative trait loci;
UCEC	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.53	-7.13	-0.51	4.14e-11	Coronary artery disease or large artery stroke;
UCEC	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.63	-6.27	-0.46	3.89e-9	C-reactive protein levels;
UCEC	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.86	7.25	0.51	2.17e-11	Type 2 diabetes;
UCEC	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg20891283	chr12:69753455	YEATS4	0.58	4.97	0.38	1.84e-6	Response to diuretic therapy;
UCEC	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.49	5.26	0.4	4.95e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13683864	chr3:40499215	RPL14	-0.78	-8.38	-0.57	3.98e-14	Renal cell carcinoma;
UCEC	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg26441486	chr22:50317300	CRELD2	0.76	4.51	0.35	1.32e-5	Schizophrenia;
UCEC	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.53	5.87	0.44	2.83e-8	Retinal vascular caliber;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	9.2	0.6	3.22e-16	Platelet count;
UCEC	cis	rs2299682	0.826	rs6086897	chr20:9463254	G/T	cg11931762	chr20:9488920	NA	-0.72	-4.76	-0.37	4.59e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs11697848	1.000	rs77146093	chr20:48482352	C/T	cg17849948	chr20:48532315	SPATA2	1.03	5.08	0.39	1.13e-6	Systemic lupus erythematosus;
UCEC	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg17674042	chr6:34482479	PACSIN1	-0.65	-4.7	-0.36	6.04e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg16583315	chr14:65563665	MAX	-0.42	-4.72	-0.36	5.36e-6	Obesity-related traits;
UCEC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-6.82	-0.49	2.19e-10	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.72	-7.45	-0.52	7.35e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg18681998	chr4:17616180	MED28	0.77	8.6	0.58	1.1e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7804356	1.000	rs73069533	chr7:26892325	G/A	cg03456212	chr7:26904342	SKAP2	-0.61	-4.67	-0.36	6.63e-6	Type 1 diabetes;
UCEC	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.62	6.67	0.48	4.78e-10	Neuroticism;
UCEC	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg18755752	chr8:142205143	DENND3	0.59	5.47	0.41	1.86e-7	Immature fraction of reticulocytes;
UCEC	cis	rs6060717	0.536	rs11699815	chr20:34543125	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.62	-0.36	8.41e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.65	5.06	0.39	1.23e-6	Corneal astigmatism;
UCEC	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	6.06	0.45	1.08e-8	Cognitive test performance;
UCEC	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.54	6.77	0.49	2.84e-10	Weight;
UCEC	cis	rs3750082	0.889	rs4437549	chr7:32914965	C/T	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.25e-9	Skin colour saturation;
UCEC	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.02	-0.44	1.36e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.59	4.6	0.35	9.02e-6	Obesity-related traits;
UCEC	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg07838603	chr6:28411030	ZSCAN23	-0.54	-6.69	-0.48	4.47e-10	Pubertal anthropometrics;
UCEC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.6	6.89	0.49	1.53e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg17279458	chr3:44753948	ZNF502	-0.57	-4.7	-0.36	5.81e-6	IgG glycosylation;
UCEC	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg04756594	chr16:24857601	SLC5A11	0.42	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.1	8.78	0.59	3.82e-15	Uric acid levels;
UCEC	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	0.79	5.95	0.44	1.92e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs77861329	0.660	rs6778442	chr3:52148483	T/C	cg08692210	chr3:52188851	WDR51A	0.62	5.5	0.41	1.66e-7	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg09021430	chr5:549028	NA	-0.59	-4.89	-0.37	2.56e-6	Obesity-related traits;
UCEC	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs9864370	1.000	rs1011598	chr3:168913181	G/A	cg18504196	chr3:168331449	C3orf50	0.53	4.52	0.35	1.26e-5	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-8.71	-0.58	5.63e-15	Extraversion;
UCEC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18252515	chr7:66147081	NA	-0.51	-4.79	-0.37	3.95e-6	Aortic root size;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-7.54	-0.53	4.45e-12	Cognitive function;
UCEC	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.52	4.87	0.37	2.85e-6	Corneal astigmatism;
UCEC	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	0.65	5.09	0.39	1.08e-6	Systemic lupus erythematosus;
UCEC	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.96	-0.55	4.18e-13	Total cholesterol levels;
UCEC	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.59	-4.91	-0.38	2.37e-6	Corneal structure;
UCEC	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-0.58	-7.47	-0.52	6.53e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg01072550	chr1:21505969	NA	-0.52	-4.91	-0.38	2.39e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.81	6.9	0.49	1.46e-10	Bladder cancer;
UCEC	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg23417306	chr2:180868811	CWC22	-0.5	-4.57	-0.35	1.02e-5	Schizophrenia;
UCEC	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.61	-5.65	-0.42	7.94e-8	Resting heart rate;
UCEC	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.37	-4.65	-0.36	7.23e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9577729	1.000	rs75161416	chr13:113024898	C/T	cg14666946	chr13:112249733	NA	0.69	4.59	0.35	9.46e-6	Diisocyanate-induced asthma;
UCEC	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26207909	chr14:103986467	CKB	0.54	5.9	0.44	2.38e-8	Body mass index;
UCEC	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.72	7.15	0.51	3.82e-11	Chronic sinus infection;
UCEC	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	0.91	9.1	0.6	5.79e-16	Heart rate;
UCEC	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.61	5.2	0.39	6.48e-7	RR interval (heart rate);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05522046	chr3:52931664	TMEM110	0.68	8.11	0.56	1.8e-13	Warfarin maintenance dose;
UCEC	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18252515	chr7:66147081	NA	-0.46	-4.71	-0.36	5.67e-6	Aortic root size;
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.01	-0.38	1.54e-6	Cardiac Troponin-T levels;
UCEC	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.68	7.0	0.5	8.5e-11	Adiposity;
UCEC	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.0	-0.38	1.58e-6	Coronary artery disease;
UCEC	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.96	-9.91	-0.63	4.89e-18	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg13147721	chr7:65941812	NA	-0.69	-4.83	-0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs36051895	0.658	rs7030260	chr9:5008070	C/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.02	-0.38	1.47e-6	Pediatric autoimmune diseases;
UCEC	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.58	-6.08	-0.45	9.87e-9	Rheumatoid arthritis;
UCEC	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.97	7.28	0.51	1.91e-11	Exhaled nitric oxide levels;
UCEC	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.53	-5.08	-0.39	1.14e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.15	0.39	8.21e-7	Breast cancer;
UCEC	cis	rs883565	0.569	rs6599273	chr3:38998552	T/G	cg01426195	chr3:39028469	NA	-0.58	-6.86	-0.49	1.76e-10	Handedness;
UCEC	cis	rs1549118	0.595	rs17106478	chr14:78328310	A/G	cg18985109	chr14:78266276	ADCK1	0.63	5.17	0.39	7.4e-7	Resting heart rate;
UCEC	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	0.68	6.51	0.47	1.13e-9	Vitiligo;
UCEC	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.65	5.86	0.44	2.87e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.95	-9.37	-0.61	1.21e-16	Cognitive ability;
UCEC	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.56	-7.06	-0.5	6.16e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.64	7.13	0.51	4.1e-11	Body mass index;
UCEC	cis	rs6437061	0.717	rs3116161	chr2:232963797	C/G	cg02061626	chr2:233274167	ALPPL2	-0.54	-6.03	-0.45	1.28e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-0.8	-7.42	-0.52	8.89e-12	Breast cancer;
UCEC	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.56	4.76	0.37	4.57e-6	Systolic blood pressure;
UCEC	cis	rs7246967	0.866	rs4932694	chr19:23032707	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.22	-0.4	6.08e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	6.92	0.5	1.28e-10	Initial pursuit acceleration;
UCEC	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg18016565	chr1:150552671	MCL1	-0.54	-5.87	-0.44	2.79e-8	Tonsillectomy;
UCEC	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.52	-4.9	-0.37	2.52e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1165668	0.785	rs2439624	chr12:104313715	T/C	cg21863207	chr12:104234989	NT5DC3	0.55	4.73	0.36	5.26e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs2172802	0.576	rs13122170	chr4:62416200	T/C	cg18242907	chr4:62067393	NA	0.46	4.51	0.35	1.32e-5	Partial epilepsies;
UCEC	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	4.77	0.37	4.45e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg24578937	chr1:2090814	PRKCZ	-0.39	-4.82	-0.37	3.49e-6	Height;
UCEC	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.59	4.69	0.36	6.19e-6	Corneal astigmatism;
UCEC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.58	5.27	0.4	4.76e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.16	0.45	6.75e-9	Motion sickness;
UCEC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.63	-7.14	-0.51	4.07e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg23950597	chr19:37808831	NA	-0.71	-5.18	-0.39	7.11e-7	Coronary artery calcification;
UCEC	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.44	-4.98	-0.38	1.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.8	5.11	0.39	9.89e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.63	4.9	0.38	2.45e-6	Platelet distribution width;
UCEC	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg22067481	chr19:53234126	ZNF611	-0.5	-5.33	-0.4	3.56e-7	Response to paliperidone in schizophrenia (PANSS score);
UCEC	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg21191810	chr6:118973309	C6orf204	0.42	5.92	0.44	2.22e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.57	-4.53	-0.35	1.19e-5	Menarche (age at onset);
UCEC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.57	-0.42	1.16e-7	Personality dimensions;
UCEC	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.54	-0.42	1.38e-7	Initial pursuit acceleration;
UCEC	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.54	4.9	0.37	2.52e-6	Lymphocyte counts;
UCEC	cis	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg17325771	chr7:75508891	RHBDD2	-0.46	-5.43	-0.41	2.29e-7	Eotaxin levels;
UCEC	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs11235843	0.853	rs12365044	chr11:73452511	C/A	cg23931323	chr11:73372278	PLEKHB1	0.66	4.53	0.35	1.23e-5	Hand grip strength;
UCEC	cis	rs7156960	0.898	rs12884039	chr14:76717953	A/G	cg14850604	chr14:76278056	TTLL5	0.37	4.54	0.35	1.14e-5	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.78	8.01	0.55	3.27e-13	Parkinson's disease;
UCEC	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg23307798	chr14:103986281	CKB	-0.56	-5.87	-0.44	2.79e-8	Body mass index;
UCEC	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.85	0.43	3.14e-8	Breast cancer;
UCEC	cis	rs4774899	0.869	rs2962993	chr15:57344066	A/C	cg04891611	chr15:57618705	NA	-0.36	-4.53	-0.35	1.19e-5	Urinary tract infection frequency;
UCEC	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.63	5.79	0.43	4.08e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.38	0.47	2.16e-9	Coffee consumption (cups per day);
UCEC	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg03711944	chr11:47377212	SPI1	-0.49	-4.5	-0.35	1.35e-5	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg24069376	chr3:38537580	EXOG	-0.38	-4.75	-0.36	4.87e-6	Electrocardiographic conduction measures;
UCEC	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.21	0.46	5.19e-9	Cognitive ability;
UCEC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-7.05	-0.5	6.42e-11	Breast cancer;
UCEC	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.79	7.71	0.54	1.76e-12	Migraine;Coronary artery disease;
UCEC	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg26781129	chr3:44753946	ZNF502	-0.57	-4.74	-0.36	5.09e-6	IgG glycosylation;
UCEC	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.85	7.55	0.53	4.19e-12	Blood metabolite levels;
UCEC	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg14008862	chr17:28927542	LRRC37B2	0.63	6.0	0.44	1.43e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04476341	chr5:669733	TPPP	0.41	4.9	0.37	2.54e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-0.92	-12.57	-0.72	4.47e-25	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.69	-7.88	-0.54	6.85e-13	Blood protein levels;
UCEC	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.38	4.66	0.36	7.03e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	11.68	0.69	1.06e-22	Platelet count;
UCEC	cis	rs7611694	0.501	rs2171293	chr3:113100342	A/G	cg12596171	chr3:113251061	SIDT1	-0.5	-5.11	-0.39	9.98e-7	Prostate cancer;
UCEC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.64	7.09	0.5	5.2e-11	Age at first birth;
UCEC	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg05775895	chr3:12838266	CAND2	0.58	5.13	0.39	8.89e-7	QRS complex (12-leadsum);
UCEC	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.54	4.9	0.38	2.45e-6	Educational attainment;
UCEC	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.72	9.05	0.6	7.75e-16	Testicular germ cell tumor;
UCEC	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.5	5.7	0.43	6.45e-8	Blood metabolite ratios;
UCEC	cis	rs253959	0.711	rs10077013	chr5:115516926	G/A	cg23108291	chr5:115420582	COMMD10	0.5	5.18	0.39	7.13e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.75	-6.73	-0.49	3.58e-10	Initial pursuit acceleration;
UCEC	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.66	-0.36	6.93e-6	LDL cholesterol levels;
UCEC	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.65	-6.82	-0.49	2.16e-10	Colorectal cancer;
UCEC	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg22524514	chr11:65779676	CST6	0.49	4.79	0.37	3.99e-6	Crohn's disease;
UCEC	cis	rs8105895	0.935	rs62110987	chr19:22257295	A/C	cg24072202	chr19:22235272	ZNF257	-0.61	-5.31	-0.4	3.93e-7	Body mass index (change over time);
UCEC	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.57	0.48	8.18e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-5.56	-0.42	1.26e-7	Platelet count;
UCEC	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.87	-9.97	-0.64	3.24e-18	Blood protein levels;
UCEC	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.83	8.87	0.59	2.29e-15	Blood protein levels;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	0.89	10.88	0.67	1.36e-20	Menarche (age at onset);
UCEC	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.61	-0.36	8.69e-6	Hemoglobin concentration;
UCEC	cis	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg00086871	chr4:6988644	TBC1D14	0.85	5.17	0.39	7.61e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.63	0.58	9.46e-15	Prudent dietary pattern;
UCEC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	0.54	6.13	0.45	7.64e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.5	5.44	0.41	2.2e-7	Body mass index;
UCEC	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs1046896	0.521	rs3859206	chr17:80693128	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.42	4.84	0.37	3.26e-6	Glycated hemoglobin levels;
UCEC	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.48e-16	Vitiligo;
UCEC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	1.24	5.98	0.44	1.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.45	6.27	0.46	3.77e-9	Height;
UCEC	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.63	5.85	0.43	3.06e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg07836142	chr6:28411423	ZSCAN23	-0.62	-6.99	-0.5	8.78e-11	Cardiac Troponin-T levels;
UCEC	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.92	9.75	0.63	1.28e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.66	-6.0	-0.44	1.49e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.91	-10.59	-0.66	7.94e-20	Blood metabolite levels;
UCEC	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg18864497	chr6:7313384	SSR1	-0.74	-6.84	-0.49	2.02e-10	Neuroticism;
UCEC	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.71	6.57	0.48	8.21e-10	Schizophrenia;
UCEC	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg01072550	chr1:21505969	NA	-0.52	-4.89	-0.37	2.65e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.53	5.98	0.44	1.63e-8	Hip circumference;
UCEC	cis	rs6546550	0.901	rs12475412	chr2:70167197	C/T	cg02498382	chr2:70120550	SNRNP27	-0.65	-7.78	-0.54	1.18e-12	Prevalent atrial fibrillation;
UCEC	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.77	0.37	4.4e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.63	0.58	9.46e-15	Prudent dietary pattern;
UCEC	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg19610905	chr11:61596333	FADS2	-0.51	-5.09	-0.39	1.09e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg06238570	chr21:40685208	BRWD1	0.76	7.47	0.52	6.52e-12	Cognitive function;
UCEC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.02	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.48	5.45	0.41	2.06e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.6	5.5	0.41	1.62e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.56	-5.57	-0.42	1.16e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.2	9.2	0.6	3.3e-16	Gut microbiome composition (summer);
UCEC	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.66	7.44	0.52	7.76e-12	Body mass index;
UCEC	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg05855489	chr10:104503620	C10orf26	-0.52	-4.53	-0.35	1.23e-5	Arsenic metabolism;
UCEC	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg19187155	chr2:232395269	NMUR1	0.72	6.9	0.49	1.47e-10	Height;
UCEC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.41	-9.25	-0.61	2.49e-16	Gout;
UCEC	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.53	-5.27	-0.4	4.87e-7	Height;
UCEC	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.65	4.86	0.37	3.01e-6	Inflammatory bowel disease;
UCEC	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.49	4.94	0.38	2.13e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.75	-7.17	-0.51	3.37e-11	Parkinson's disease;
UCEC	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.55	-5.72	-0.43	5.83e-8	Eye color traits;
UCEC	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.75	-7.69	-0.54	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.86	-0.37	3.03e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	7.45	0.52	7.49e-12	Bone mineral density;
UCEC	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.54	5.16	0.39	7.74e-7	Chronic sinus infection;
UCEC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.84	-0.43	3.16e-8	Breast cancer;
UCEC	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.1	9.45	0.61	7.27e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.72	5.29	0.4	4.31e-7	Type 2 diabetes nephropathy;
UCEC	cis	rs11241936	0.513	rs2408998	chr5:126975808	C/A	cg04241501	chr5:126853924	PRRC1	-0.5	-4.6	-0.35	9.04e-6	Plasma amyloid beta peptide concentrations (ABx-42);
UCEC	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.41	4.57	0.35	1.02e-5	Menopause (age at onset);
UCEC	cis	rs7870753	0.853	rs10761022	chr9:99224746	A/T	cg25260653	chr9:99212216	HABP4	0.49	4.89	0.37	2.62e-6	Height;
UCEC	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg20936604	chr3:58311152	NA	-0.6	-4.86	-0.37	3.03e-6	Cholesterol, total;
UCEC	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.91	8.29	0.56	6.7e-14	Bladder cancer;
UCEC	trans	rs4146922	0.793	rs7590753	chr2:55996131	C/G	cg03313676	chr20:62526047	DNAJC5	0.72	7.4	0.52	9.5e-12	Height;
UCEC	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.73	7.98	0.55	3.91e-13	Mortality in heart failure;
UCEC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-6.27	-0.46	3.79e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	4.97	0.38	1.84e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg11985680	chr1:76251867	SNORD45C;RABGGTB	0.53	4.53	0.35	1.2e-5	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	1.07	9.47	0.62	6.77e-17	Dupuytren's disease;
UCEC	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.75	4.88	0.37	2.73e-6	Platelet count;
UCEC	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg14438399	chr17:27053147	TLCD1	-0.58	-4.81	-0.37	3.74e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg01072550	chr1:21505969	NA	-0.61	-6.34	-0.46	2.71e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.64	-6.14	-0.45	7.2e-9	Aortic root size;
UCEC	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.74	6.44	0.47	1.62e-9	Cognitive function;
UCEC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.56	0.35	1.07e-5	Electroencephalogram traits;
UCEC	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	-0.55	-6.32	-0.46	3.01e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	13.44	0.74	2.33e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7709377	0.570	rs9326987	chr5:115436407	A/G	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg24634471	chr8:143751801	JRK	0.5	5.29	0.4	4.26e-7	Schizophrenia;
UCEC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs59918340	0.627	rs1865249	chr8:142215982	A/C	cg04804543	chr8:142233427	SLC45A4	-0.47	-5.4	-0.41	2.61e-7	Immature fraction of reticulocytes;
UCEC	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.34e-6	Hemoglobin concentration;
UCEC	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.57	-6.75	-0.49	3.13e-10	Total body bone mineral density;
UCEC	cis	rs9469578	0.681	rs78748610	chr6:33714412	T/C	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	5.29	0.4	4.32e-7	IgG glycosylation;
UCEC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.81	8.6	0.58	1.12e-14	Parkinson's disease;
UCEC	cis	rs8063160	0.666	rs12918773	chr16:89741403	G/A	cg02226192	chr16:89461734	ANKRD11	-0.73	-4.64	-0.36	7.64e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
UCEC	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.75	-8.4	-0.57	3.51e-14	Extraversion;
UCEC	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.36	5.02	0.38	1.48e-6	Fat distribution (HIV);
UCEC	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.7	6.39	0.47	2.05e-9	Coronary artery disease;
UCEC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.63	7.54	0.53	4.44e-12	Obesity-related traits;
UCEC	cis	rs7607369	0.527	rs72966038	chr2:219656190	G/A	cg02176678	chr2:219576539	TTLL4	-0.69	-7.54	-0.53	4.55e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.49	-4.85	-0.37	3.07e-6	Post bronchodilator FEV1;
UCEC	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-6.52	-0.47	1.08e-9	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	1.07	14.29	0.76	1.38e-29	Monocyte count;
UCEC	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-5.22	-0.4	5.99e-7	Schizophrenia;
UCEC	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.55	-4.67	-0.36	6.86e-6	Pulmonary function decline;
UCEC	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.7	-6.85	-0.49	1.85e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.25	-0.51	2.19e-11	Eye color traits;
UCEC	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg19743168	chr1:23544995	NA	0.49	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.62	-6.56	-0.48	8.57e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.49	5.77	0.43	4.52e-8	Monocyte percentage of white cells;
UCEC	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	6.59	0.48	7.55e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-5.95	-0.44	1.84e-8	Platelet count;
UCEC	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.8	8.82	0.59	3.13e-15	Immature fraction of reticulocytes;
UCEC	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg10503236	chr1:231470652	EXOC8	0.42	5.07	0.39	1.18e-6	Hemoglobin concentration;
UCEC	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.01	8.54	0.58	1.53e-14	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	5.25	0.4	5.32e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg12463550	chr7:65579703	CRCP	0.49	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.51	-0.35	1.34e-5	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg09120320	chr17:61926383	NA	0.44	4.57	0.35	1.03e-5	Prudent dietary pattern;
UCEC	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-12.23	-0.71	3.65e-24	Schizophrenia;
UCEC	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg06935464	chr4:38784597	TLR10	0.64	4.51	0.35	1.32e-5	Breast cancer;
UCEC	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.51	-4.54	-0.35	1.18e-5	Colorectal cancer;
UCEC	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-6.55	-0.48	8.88e-10	Height;
UCEC	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.73	7.29	0.52	1.79e-11	Menarche (age at onset);
UCEC	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg24977027	chr2:88469347	THNSL2	0.81	5.72	0.43	5.67e-8	Plasma clusterin levels;
UCEC	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.75	-8.72	-0.58	5.55e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs787274	0.850	rs7047914	chr9:115620773	A/C	cg13803584	chr9:115635662	SNX30	-0.74	-4.63	-0.36	8e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.27e-7	Life satisfaction;
UCEC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg14008862	chr17:28927542	LRRC37B2	0.63	4.5	0.35	1.36e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg18755752	chr8:142205143	DENND3	0.58	5.25	0.4	5.16e-7	Immature fraction of reticulocytes;
UCEC	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg18016565	chr1:150552671	MCL1	-0.52	-5.77	-0.43	4.45e-8	Tonsillectomy;
UCEC	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.56	-6.08	-0.45	9.64e-9	Blood metabolite levels;
UCEC	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-6.5	-0.47	1.18e-9	Personality dimensions;
UCEC	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Urate levels;
UCEC	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.57	5.26	0.4	5.11e-7	Morning vs. evening chronotype;
UCEC	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg19500275	chr17:80737654	TBCD	0.59	5.61	0.42	9.92e-8	Glycated hemoglobin levels;
UCEC	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg12024160	chr4:1254474	NA	0.64	7.5	0.53	5.73e-12	Obesity-related traits;
UCEC	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg01426195	chr3:39028469	NA	0.58	6.86	0.49	1.76e-10	Handedness;
UCEC	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg11161011	chr14:65562177	MAX	-0.79	-7.29	-0.52	1.81e-11	Obesity-related traits;
UCEC	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.65	-6.95	-0.5	1.11e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.75	-8.16	-0.56	1.41e-13	Waist circumference;Body mass index;
UCEC	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.56	-6.36	-0.46	2.46e-9	Electroencephalogram traits;
UCEC	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.58	4.78	0.37	4.15e-6	Migraine;
UCEC	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.57	-6.81	-0.49	2.3e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.1	13.49	0.74	1.68e-27	Cognitive function;
UCEC	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.45	5.61	0.42	9.77e-8	Coronary heart disease;
UCEC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.69	0.36	6.14e-6	Tonsillectomy;
UCEC	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg04906043	chr13:21280425	IL17D	-0.47	-4.74	-0.36	5.04e-6	Schizophrenia, bipolar disorder and depression (combined);
UCEC	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-5.06	-0.39	1.24e-6	Systolic blood pressure;
UCEC	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.54	-5.94	-0.44	1.97e-8	Electrocardiographic conduction measures;
UCEC	cis	rs11760485	0.929	rs11764749	chr7:4401547	T/C	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg05072774	chr3:49840536	C3orf54	-0.56	-5.16	-0.39	8.03e-7	Resting heart rate;
UCEC	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.59	-5.98	-0.44	1.65e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg20368463	chr18:77673604	PQLC1	-0.5	-4.62	-0.36	8.35e-6	Opioid sensitivity;
UCEC	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.07	-0.39	1.19e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-9.47	-0.62	6.48e-17	Coffee consumption (cups per day);
UCEC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg18279126	chr7:2041391	MAD1L1	0.43	5.24	0.4	5.49e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	4.8	0.37	3.8e-6	Diabetic retinopathy;
UCEC	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.5	4.54	0.35	1.14e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg03757805	chr13:111521981	C13orf29	-0.46	-4.51	-0.35	1.29e-5	Sitting height ratio;
UCEC	cis	rs9467773	1.000	rs9467800	chr6:26578525	A/C	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.5	-5.7	-0.43	6.24e-8	Rheumatoid arthritis;
UCEC	cis	rs4372836	0.664	rs4233729	chr2:29092679	T/C	cg09522027	chr2:28974177	PPP1CB	0.79	8.33	0.57	5.15e-14	Body mass index;
UCEC	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.51	-5.43	-0.41	2.3e-7	Monocyte count;
UCEC	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.47	0.41	1.85e-7	Platelet count;
UCEC	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.54	6.12	0.45	7.98e-9	Calcium levels;
UCEC	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	5.47	0.41	1.93e-7	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.49	5.29	0.4	4.3e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.71	5.72	0.43	5.62e-8	Cognitive test performance;
UCEC	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.59	-5.48	-0.41	1.76e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.85	0.54	7.81e-13	Alzheimer's disease;
UCEC	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-5.74	-0.43	5.16e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs76439304	1.000	rs76439304	chr12:27033470	G/T	cg19407459	chr12:26986763	ITPR2	0.98	5.43	0.41	2.27e-7	Mean corpuscular volume;
UCEC	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.22e-10	Motion sickness;
UCEC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg24531977	chr5:56204891	C5orf35	-0.51	-4.59	-0.35	9.26e-6	Coronary artery disease;
UCEC	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-4.93	-0.38	2.2e-6	Pubertal anthropometrics;
UCEC	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg01256987	chr12:42539512	GXYLT1	0.41	4.88	0.37	2.71e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.98	0.5	9.31e-11	Motion sickness;
UCEC	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.58	5.48	0.41	1.79e-7	Corneal astigmatism;
UCEC	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.67	6.7	0.48	4.2e-10	Dilated cardiomyopathy;
UCEC	cis	rs56341938	0.679	rs4645171	chr3:168823124	C/T	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.69	7.88	0.55	6.56e-13	Menopause (age at onset);
UCEC	cis	rs7246967	0.866	rs7250801	chr19:23035957	G/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.92	0.38	2.31e-6	Diabetic retinopathy;
UCEC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.11	0.45	8.33e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg05623727	chr3:50126028	RBM5	0.35	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.07	-0.39	1.18e-6	Total cholesterol levels;
UCEC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.47	-0.47	1.36e-9	Aortic root size;
UCEC	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.47	5.31	0.4	4.02e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.52	4.92	0.38	2.33e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.45	-5.09	-0.39	1.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.3e-7	Hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg01689657	chr7:91764605	CYP51A1	0.49	6.27	0.46	3.79e-9	Breast cancer;
UCEC	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-6.08	-0.45	9.77e-9	Prevalent atrial fibrillation;
UCEC	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.11	-0.39	9.68e-7	Life satisfaction;
UCEC	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.49	5.56	0.42	1.25e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.45	0.41	2.12e-7	Hemoglobin concentration;
UCEC	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.76	-8.62	-0.58	9.97e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg13385521	chr17:29058706	SUZ12P	0.59	4.51	0.35	1.32e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.51	5.67	0.42	7.42e-8	Prostate cancer;
UCEC	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs11235843	0.714	rs7128512	chr11:73372299	A/G	cg27005935	chr11:73371801	PLEKHB1	-0.47	-4.55	-0.35	1.13e-5	Hand grip strength;
UCEC	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-4.55	-0.35	1.13e-5	Hemoglobin concentration;
UCEC	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg14092571	chr14:90743983	NA	-0.42	-5.65	-0.42	7.97e-8	Mortality in heart failure;
UCEC	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-5.41	-0.41	2.48e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.72	-6.71	-0.48	4.03e-10	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.16	-9.26	-0.61	2.27e-16	Vitiligo;
UCEC	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.46e-16	Height;
UCEC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.42	-4.92	-0.38	2.27e-6	Height;
UCEC	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg11871910	chr12:69753446	YEATS4	0.53	5.6	0.42	1.04e-7	Blood protein levels;
UCEC	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.5	5.18	0.39	7.2e-7	Type 2 diabetes;
UCEC	cis	rs26868	0.712	rs26832	chr16:2238337	A/G	cg02248941	chr16:2239361	CASKIN1	0.41	5.02	0.38	1.47e-6	Height;
UCEC	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.51	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg27033923	chr15:41106683	ZFYVE19	-0.56	-4.76	-0.37	4.61e-6	Ulcerative colitis;
UCEC	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.51	5.0	0.38	1.62e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg13844804	chr7:814759	HEATR2	0.61	4.68	0.36	6.49e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.7	6.6	0.48	6.88e-10	Bladder cancer;
UCEC	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg18681998	chr4:17616180	MED28	0.78	7.8	0.54	1.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.74	8.61	0.58	1.05e-14	Monocyte count;
UCEC	cis	rs773506	0.628	rs10733740	chr9:93933158	G/T	cg03243796	chr9:93920768	NA	0.4	5.05	0.38	1.29e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.77	8.57	0.58	1.28e-14	Primary sclerosing cholangitis;
UCEC	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-13.43	-0.74	2.46e-27	Height;
UCEC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.36	0.4	3.15e-7	Rheumatoid arthritis;
UCEC	cis	rs7246967	1.000	rs35332070	chr19:23034266	G/A	cg05241461	chr19:22816980	ZNF492	0.5	5.14	0.39	8.65e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.67	-5.37	-0.4	3.06e-7	Schizophrenia;
UCEC	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.49	-5.24	-0.4	5.37e-7	Blood metabolite levels;
UCEC	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.32	4.58	0.35	9.99e-6	Bipolar disorder and schizophrenia;
UCEC	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.77	10.13	0.64	1.25e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.61	7.58	0.53	3.5e-12	Prudent dietary pattern;
UCEC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.0	0.38	1.58e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7246967	0.673	rs7248107	chr19:22878529	G/T	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4853525	0.923	rs2204859	chr2:191736873	C/A	cg10560079	chr2:191398806	TMEM194B	-0.46	-4.79	-0.37	3.96e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-0.75	-4.82	-0.37	3.51e-6	Skin colour saturation;
UCEC	cis	rs12980942	1.000	rs3826714	chr19:41825776	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.61	5.58	0.42	1.1e-7	Coronary artery disease;
UCEC	cis	rs847649	0.692	rs1541519	chr7:102466741	G/T	cg18108683	chr7:102477205	FBXL13	-0.62	-7.7	-0.54	1.88e-12	Morning vs. evening chronotype;
UCEC	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.58	-6.82	-0.49	2.25e-10	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.23	-0.4	5.83e-7	Breast cancer;
UCEC	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.78	-5.93	-0.44	2.05e-8	Gut microbiome composition (summer);
UCEC	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.61	-5.9	-0.44	2.36e-8	Pulmonary function;
UCEC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.85	7.61	0.53	3.06e-12	Body mass index;
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.48	-5.22	-0.4	6.09e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.85	5.98	0.44	1.63e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg23307798	chr14:103986281	CKB	-0.6	-7.23	-0.51	2.42e-11	Body mass index;
UCEC	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-9.71	-0.63	1.6e-17	Vitiligo;
UCEC	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	6.61	0.48	6.47e-10	Total body bone mineral density;
UCEC	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.55	6.29	0.46	3.45e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12311346	chr5:56204834	C5orf35	-0.44	-4.61	-0.36	8.82e-6	Breast cancer;Breast cancer (early onset);
UCEC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.53	-0.41	1.44e-7	Body mass index;
UCEC	cis	rs13098911	0.540	rs13079869	chr3:46008087	G/A	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs12428035	0.764	rs72638024	chr13:96769760	T/C	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg00546932	chr16:1947055	NA	0.37	5.18	0.39	7.16e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.79	-8.15	-0.56	1.44e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.55	5.34	0.4	3.39e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.6	5.43	0.41	2.32e-7	Response to antineoplastic agents;
UCEC	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.36	-0.52	1.2e-11	Eye color traits;
UCEC	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg18755752	chr8:142205143	DENND3	0.53	5.13	0.39	9.16e-7	Immature fraction of reticulocytes;
UCEC	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.71	7.88	0.54	6.72e-13	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.5	0.41	1.63e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	5.48	0.41	1.77e-7	Breast cancer;
UCEC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26207909	chr14:103986467	CKB	-0.51	-5.64	-0.42	8.39e-8	Body mass index;
UCEC	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.54e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.68	-6.08	-0.45	9.97e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg13683864	chr3:40499215	RPL14	-0.52	-5.32	-0.4	3.84e-7	Renal cell carcinoma;
UCEC	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.68	5.7	0.43	6.24e-8	Systolic blood pressure;
UCEC	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-5.69	-0.42	6.68e-8	Schizophrenia;
UCEC	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.8	9.26	0.61	2.35e-16	Bone mineral density;
UCEC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.75	9.67	0.62	2e-17	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.06	-0.5	6.25e-11	Breast cancer;
UCEC	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.66	-0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.62	-6.62	-0.48	6.33e-10	Parkinson's disease;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg16060761	chr17:80687452	NA	-0.49	-4.74	-0.36	5.09e-6	Breast cancer;
UCEC	cis	rs28714278	0.857	rs35602605	chr15:40308859	G/T	cg10505819	chr15:40309387	EIF2AK4	0.57	5.51	0.41	1.59e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.54	0.53	4.58e-12	Alzheimer's disease;
UCEC	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.74	-8.2	-0.56	1.07e-13	Ulcerative colitis;
UCEC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.8	7.95	0.55	4.55e-13	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.58	6.6	0.48	6.9e-10	Hip circumference;
UCEC	cis	rs9467773	0.901	rs10223789	chr6:26579609	C/T	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.43	-0.41	2.26e-7	Metabolite levels;
UCEC	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.41	-5.19	-0.39	6.75e-7	Menarche (age at onset);
UCEC	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.42	4.52	0.35	1.26e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.69	7.0	0.5	8.3e-11	Primary sclerosing cholangitis;
UCEC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.68	-5.93	-0.44	2.06e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.45	-4.77	-0.37	4.43e-6	Height;
UCEC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.27e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.82	0.49	2.24e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7246967	0.673	rs36029703	chr19:22906188	C/A	cg24889512	chr19:22816950	ZNF492	0.62	6.59	0.48	7.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.4	-5.26	-0.4	5.01e-7	Urate levels in overweight individuals;
UCEC	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg23307798	chr14:103986281	CKB	0.64	7.67	0.53	2.14e-12	Body mass index;
UCEC	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.38	-4.91	-0.38	2.43e-6	Cutaneous nevi;
UCEC	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg23795048	chr12:9217529	LOC144571	0.43	5.35	0.4	3.37e-7	Sjögren's syndrome;
UCEC	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.69	7.85	0.54	8e-13	Menopause (age at onset);
UCEC	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.31	0.4	3.98e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.23	-0.4	5.83e-7	Breast cancer;
UCEC	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.5	6.33	0.46	2.82e-9	IgG glycosylation;
UCEC	cis	rs17123764	1.000	rs11169069	chr12:49966534	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.19	0.39	6.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.59	-4.75	-0.36	4.82e-6	LDL cholesterol levels;
UCEC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.29	-0.56	6.44e-14	Chronic sinus infection;
UCEC	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.37	-4.84	-0.37	3.29e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.43	4.55	0.35	1.09e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.48	0.41	1.84e-7	Breast cancer;
UCEC	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-5.96	-0.44	1.78e-8	Birth weight;
UCEC	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.72	7.14	0.51	3.99e-11	Parkinson's disease;
UCEC	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.64	4.77	0.37	4.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.41	1.99e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg13770691	chr19:1021866	C19orf6	0.5	5.45	0.41	2.11e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	9.96	0.63	3.63e-18	Menopause (age at onset);
UCEC	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	5.85	0.43	3.1e-8	Menarche (age at onset);
UCEC	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.66	5.31	0.4	4.01e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs17012589	0.639	rs10779155	chr12:85697921	T/C	cg02569458	chr12:86230093	RASSF9	0.39	4.51	0.35	1.3e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.66	8.82	0.59	2.97e-15	Anterior chamber depth;
UCEC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.61	-5.24	-0.4	5.46e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs12711979	1.000	rs6542655	chr2:3872434	T/C	cg17052675	chr2:3827356	NA	-0.36	-4.57	-0.35	1.03e-5	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.94	0.38	2.13e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg21269758	chr1:25870003	LDLRAP1	0.64	6.79	0.49	2.57e-10	Schizophrenia;
UCEC	cis	rs4280164	0.887	rs11158634	chr14:24776457	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-4.66	-0.36	6.91e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-9.65	-0.62	2.23e-17	Blood metabolite levels;
UCEC	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-6.69	-0.48	4.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.69	-6.91	-0.5	1.38e-10	Blood metabolite levels;
UCEC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.55	5.41	0.41	2.53e-7	Methadone dose in opioid dependence;
UCEC	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.76	5.64	0.42	8.53e-8	Body mass index;
UCEC	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg05660106	chr1:15850417	CASP9	0.85	9.76	0.63	1.18e-17	Systolic blood pressure;
UCEC	cis	rs925228	0.955	rs11687065	chr2:24132701	G/T	cg13272742	chr2:24272458	FKBP1B	-0.55	-4.64	-0.36	7.51e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.51	5.55	0.42	1.3e-7	Blood metabolite levels;
UCEC	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs2882667	0.824	rs11748097	chr5:138479887	C/A	cg04439458	chr5:138467593	SIL1	-0.49	-5.6	-0.42	1.01e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9864370	1.000	rs13326508	chr3:168922096	C/T	cg18504196	chr3:168331449	C3orf50	0.64	4.78	0.37	4.28e-6	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.44	4.51	0.35	1.31e-5	Response to temozolomide;
UCEC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.83	8.8	0.59	3.49e-15	Blood protein levels;
UCEC	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.48	5.44	0.41	2.17e-7	Rheumatoid arthritis;
UCEC	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.82	8.38	0.57	3.82e-14	Lung cancer;
UCEC	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.65	-7.24	-0.51	2.31e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.66	-6.3	-0.46	3.21e-9	Prudent dietary pattern;
UCEC	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.96	0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs8080784	0.673	rs8072558	chr17:58834724	A/T	cg22641952	chr17:58219985	NA	0.53	4.62	0.36	8.37e-6	Coronary artery disease;
UCEC	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.73	7.7	0.54	1.88e-12	Breast cancer;
UCEC	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.65	6.03	0.45	1.24e-8	Aortic root size;
UCEC	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-5.52	-0.41	1.51e-7	Metabolite levels;
UCEC	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	8.64	0.58	8.83e-15	Gut microbiome composition (summer);
UCEC	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	1.06	7.33	0.52	1.44e-11	Mean corpuscular volume;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.54	-6.08	-0.45	1e-8	Depression;
UCEC	cis	rs1355223	0.867	rs1377495	chr11:34682962	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.55	5.25	0.4	5.29e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.85	-9.3	-0.61	1.79e-16	Breast cancer;
UCEC	cis	rs9467773	1.000	rs6456735	chr6:26574149	G/A	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18252515	chr7:66147081	NA	0.58	5.41	0.41	2.51e-7	Aortic root size;
UCEC	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.56	5.73	0.43	5.39e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg11803278	chr7:157951799	PTPRN2	0.35	5.9	0.44	2.42e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11118844	0.744	rs4623704	chr1:221953846	G/A	cg04222084	chr1:221915650	DUSP10	-0.81	-5.67	-0.42	7.28e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs711830	1.000	rs6433571	chr2:177039578	G/T	cg13092806	chr2:177043255	NA	0.94	9.45	0.61	7.62e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs2996428	0.709	rs6667255	chr1:3711689	T/C	cg13057898	chr1:3703894	LRRC47	0.53	5.07	0.39	1.19e-6	Red cell distribution width;
UCEC	cis	rs925228	0.668	rs3795945	chr2:23920632	C/G	cg16901991	chr2:24272451	FKBP1B	0.53	5.02	0.38	1.47e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	5.96e-6	Parkinson's disease;
UCEC	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.45	-5.19	-0.39	6.96e-7	Osteoporosis;
UCEC	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.53	5.59	0.42	1.07e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs9309473	0.948	rs6719753	chr2:73749054	T/G	cg20560298	chr2:73613845	ALMS1	-0.59	-5.32	-0.4	3.82e-7	Metabolite levels;
UCEC	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.9	-0.44	2.4e-8	Platelet count;
UCEC	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg13147721	chr7:65941812	NA	-0.91	-5.58	-0.42	1.13e-7	Diabetic kidney disease;
UCEC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.59	7.13	0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.59	-5.75	-0.43	4.88e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs59104589	0.617	rs61615527	chr2:242342768	T/A	cg19488206	chr2:242435732	STK25	0.49	5.06	0.38	1.25e-6	Fibrinogen levels;
UCEC	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg25393495	chr8:12034317	NA	-0.32	-4.75	-0.36	4.74e-6	Triglycerides;
UCEC	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.46	-5.26	-0.4	4.97e-7	Aortic root size;
UCEC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg16558253	chr16:72132732	DHX38	-0.48	-5.92	-0.44	2.19e-8	Fibrinogen levels;
UCEC	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.48	-6.32	-0.46	2.99e-9	Neutrophil percentage of white cells;
UCEC	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.97	-0.59	1.28e-15	Exhaled nitric oxide output;
UCEC	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.59	-4.94	-0.38	2.09e-6	Corneal structure;
UCEC	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg26513180	chr16:89883248	FANCA	0.59	6.81	0.49	2.32e-10	Vitiligo;
UCEC	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.64	-6.49	-0.47	1.26e-9	Mean platelet volume;
UCEC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs7219021	0.926	rs7209437	chr17:46855267	A/G	cg16584676	chr17:46985605	UBE2Z	-0.49	-4.76	-0.37	4.53e-6	Schizophrenia or bipolar disorder;
UCEC	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.68	5.46	0.41	1.99e-7	Body mass index;
UCEC	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-6.76	-0.49	2.97e-10	Coffee consumption (cups per day);
UCEC	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.59	5.92	0.44	2.15e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg04154034	chr17:28927549	LRRC37B2	0.97	5.06	0.39	1.24e-6	Body mass index;
UCEC	cis	rs3780378	1.000	rs10815158	chr9:5112844	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-5.06	-0.38	1.25e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.69	-7.11	-0.51	4.77e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.7	8.58	0.58	1.23e-14	Hip circumference;
UCEC	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.87	10.97	0.67	8.05e-21	Metabolic syndrome;
UCEC	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-4.54	-0.35	1.17e-5	Alzheimer's disease (late onset);
UCEC	cis	rs8020441	0.891	rs112124522	chr14:51167502	G/A	cg04730355	chr14:51134070	SAV1	0.56	5.22	0.4	5.99e-7	Cognitive performance;
UCEC	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.59	5.12	0.39	9.49e-7	Lung cancer;
UCEC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.82	-11.43	-0.69	4.73e-22	Post bronchodilator FEV1;
UCEC	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.38	5.62	0.42	9.1e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.57	6.36	0.46	2.42e-9	Bipolar disorder;
UCEC	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.63	-7.0	-0.5	8.66e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg02022102	chr7:27168609	HOXA4	0.6	6.79	0.49	2.6200000000000003e-10	Protein biomarker;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.42	-0.41	2.39e-7	Pubertal anthropometrics;
UCEC	cis	rs79243044	0.786	rs16932549	chr11:5560909	C/T	cg19741704	chr11:6440456	APBB1	-0.54	-4.74	-0.36	4.94e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.57	-0.35	1.04e-5	Type 2 diabetes;
UCEC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.52	4.7	0.36	5.9e-6	Lung cancer;
UCEC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg09165964	chr15:75287851	SCAMP5	0.54	6.4	0.47	1.99e-9	Breast cancer;
UCEC	cis	rs7246967	0.866	rs438972	chr19:23019827	A/G	cg05241461	chr19:22816980	ZNF492	0.46	4.8	0.37	3.86e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.68	8.21	0.56	1.01e-13	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.72	7.46	0.52	6.96e-12	Tonsillectomy;
UCEC	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.71	-4.91	-0.38	2.37e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.61	0.62	2.8e-17	Coffee consumption (cups per day);
UCEC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.1	17.87	0.83	1.09e-38	IgG glycosylation;
UCEC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.65	0.36	7.23e-6	Diabetic retinopathy;
UCEC	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.85	-10.28	-0.65	5.03e-19	Brugada syndrome;
UCEC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05472934	chr7:22766657	IL6	0.77	7.69	0.54	1.94e-12	Lung cancer;
UCEC	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg18016565	chr1:150552671	MCL1	0.61	6.7	0.48	4.14e-10	Tonsillectomy;
UCEC	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.53	6.16	0.45	6.65e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs7246967	0.800	rs2362131	chr19:23022436	T/C	cg05241461	chr19:22816980	ZNF492	0.46	4.81	0.37	3.75e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.42	-4.81	-0.37	3.65e-6	Blood protein levels;
UCEC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Bipolar disorder;
UCEC	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg05991184	chr2:219186017	PNKD	0.52	5.63	0.42	8.66e-8	Colorectal cancer;
UCEC	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.58	-5.9	-0.44	2.45e-8	Glomerular filtration rate;
UCEC	cis	rs828999	0.654	rs9325363	chr1:108713557	G/T	cg11967332	chr1:108735228	SLC25A24	0.39	4.55	0.35	1.1e-5	Monocyte percentage of white cells;
UCEC	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.64	5.93	0.44	2.13e-8	Schizophrenia;
UCEC	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.94	9.42	0.61	8.73e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg05738196	chr6:26577821	NA	0.6	6.51	0.47	1.1e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg18827107	chr12:86230957	RASSF9	-0.45	-4.91	-0.38	2.43e-6	Major depressive disorder;
UCEC	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg20387954	chr3:183756860	HTR3D	0.5	5.93	0.44	2.09e-8	Anterior chamber depth;
UCEC	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.63	6.02	0.44	1.33e-8	Schizophrenia;
UCEC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-6.17	-0.45	6.36e-9	Tonsillectomy;
UCEC	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.71	-7.12	-0.51	4.41e-11	Coronary artery disease;
UCEC	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-8.21	-0.56	1.02e-13	Monocyte count;
UCEC	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.03	-0.55	2.93e-13	Acylcarnitine levels;
UCEC	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg14008862	chr17:28927542	LRRC37B2	0.75	5.54	0.42	1.39e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-9.36	-0.61	1.28e-16	Chronic sinus infection;
UCEC	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg13147721	chr7:65941812	NA	-0.7	-4.98	-0.38	1.76e-6	Diabetic kidney disease;
UCEC	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.6	-4.96	-0.38	1.95e-6	Depression;
UCEC	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.74	7.41	0.52	9e-12	Lung cancer;
UCEC	cis	rs7312774	0.609	rs2374655	chr12:107380162	T/C	cg02128625	chr12:107312370	NA	0.66	4.58	0.35	1e-5	Severe influenza A (H1N1) infection;
UCEC	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.59	-6.43	-0.47	1.71e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.41	4.57	0.35	1.03e-5	Mean corpuscular volume;
UCEC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	0.8	7.09	0.5	5.3e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.68	5.34	0.4	3.44e-7	Smoking behavior;
UCEC	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.95	-10.19	-0.64	8.83e-19	Schizophrenia;
UCEC	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.68	-4.7	-0.36	5.88e-6	Red blood cell traits;
UCEC	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.43	4.77	0.37	4.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.53	5.52	0.41	1.52e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06028605	chr16:24865363	SLC5A11	-0.35	-4.54	-0.35	1.19e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg20307385	chr11:47447363	PSMC3	0.56	4.88	0.37	2.74e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.54	6.15	0.45	6.81e-9	Mean platelet volume;
UCEC	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.78	6.75	0.49	3.23e-10	Gastritis;
UCEC	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	5.41	0.41	2.46e-7	Prudent dietary pattern;
UCEC	cis	rs1567532	0.617	rs12993886	chr2:79934600	A/T	cg11074070	chr2:80557293	CTNNA2	-0.59	-4.63	-0.36	7.95e-6	Survival in pancreatic cancer;
UCEC	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.17	12.19	0.71	4.63e-24	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.97	7.31	0.52	1.59e-11	Obesity-related traits;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.49	-6.59	-0.48	7.22e-10	Body mass index;
UCEC	cis	rs6437061	0.614	rs3100583	chr2:232944860	G/A	cg20569070	chr2:232597279	PDE6D	0.41	4.82	0.37	3.61e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs6684428	0.610	rs10888940	chr1:56315779	C/T	cg11651538	chr1:56320950	NA	-0.66	-4.85	-0.37	3.17e-6	Airflow obstruction;
UCEC	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.81	9.44	0.61	7.71e-17	Metabolite levels;
UCEC	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.77	8.52	0.57	1.79e-14	Menopause (age at onset);
UCEC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.22	-0.4	6.06e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.58	-8.13	-0.56	1.68e-13	Total body bone mineral density;
UCEC	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.44	-4.65	-0.36	7.37e-6	Vitiligo;
UCEC	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.59	5.48	0.41	1.79e-7	Coronary artery disease;
UCEC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.69	6.8	0.49	2.51e-10	Blood protein levels;
UCEC	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.45	4.85	0.37	3.13e-6	Smoking initiation;
UCEC	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.67	-8.15	-0.56	1.44e-13	IgG glycosylation;
UCEC	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.99	-0.5	9.1e-11	Neuroticism;
UCEC	cis	rs9463078	0.764	rs6923519	chr6:44864152	A/G	cg25276700	chr6:44698697	NA	-0.41	-4.54	-0.35	1.14e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.39	-5.21	-0.4	6.15e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01391022	chr12:122360665	WDR66	-0.41	-4.81	-0.37	3.63e-6	Mean corpuscular volume;
UCEC	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.24	-0.4	5.54e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-6.22	-0.46	4.87e-9	Morning vs. evening chronotype;
UCEC	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-11.1	-0.68	3.65e-21	Cognitive function;
UCEC	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.67	6.99	0.5	8.82e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.43	5.07	0.39	1.18e-6	Schizophrenia;
UCEC	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.61	0.42	9.55e-8	Heart rate;
UCEC	trans	rs7101446	0.568	rs629907	chr11:63176534	T/C	cg15769409	chr9:138372274	KIAA0649	-0.67	-6.99	-0.5	8.92e-11	Economic and political preferences;
UCEC	cis	rs7072216	0.922	rs7097824	chr10:100151799	A/T	cg19567339	chr10:100142640	NA	0.61	8.57	0.58	1.32e-14	Metabolite levels;
UCEC	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg14008862	chr17:28927542	LRRC37B2	0.82	4.81	0.37	3.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.69	7.6	0.53	3.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26002218	chr14:103986227	CKB	-0.33	-4.66	-0.36	6.94e-6	Body mass index;
UCEC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.51	-4.86	-0.37	3e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7072216	0.881	rs4345897	chr10:100147060	A/G	cg19567339	chr10:100142640	NA	0.59	7.7	0.54	1.82e-12	Metabolite levels;
UCEC	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.73	0.36	5.21e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg02573091	chr5:74908125	NA	0.61	4.51	0.35	1.34e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-6.35	-0.46	2.47e-9	Response to antipsychotic treatment;
UCEC	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg20488157	chr14:104394430	TDRD9	0.67	4.74	0.36	5e-6	Bipolar disorder;
UCEC	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.44	-0.47	1.62e-9	Eye color traits;
UCEC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg22166914	chr1:53195759	ZYG11B	-0.48	-4.56	-0.35	1.09e-5	Monocyte count;
UCEC	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.76	5.2	0.39	6.54e-7	Type 2 diabetes nephropathy;
UCEC	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg00122941	chr17:4613640	ARRB2	0.65	5.05	0.38	1.31e-6	Lymphocyte counts;
UCEC	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12379764	chr21:47803548	PCNT	-0.45	-4.88	-0.37	2.68e-6	Testicular germ cell tumor;
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg07836142	chr6:28411423	ZSCAN23	-0.61	-7.7	-0.54	1.84e-12	Depression;
UCEC	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-8.02	-0.55	3.12e-13	Electrocardiographic conduction measures;
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.59	-6.21	-0.46	5.2e-9	Blood protein levels;
UCEC	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-5.57	-0.42	1.18e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12379764	chr21:47803548	PCNT	0.44	4.87	0.37	2.85e-6	Testicular germ cell tumor;
UCEC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg11871910	chr12:69753446	YEATS4	0.74	7.74	0.54	1.48e-12	Blood protein levels;
UCEC	cis	rs10743315	0.778	rs9805106	chr12:19372357	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.5	-4.94	-0.38	2.1e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.67	-5.67	-0.42	7.38e-8	Aortic root size;
UCEC	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.51	5.48	0.41	1.82e-7	Platelet distribution width;
UCEC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.38	1.91e-6	Bladder cancer;
UCEC	cis	rs3746446	0.678	rs6120777	chr20:33560172	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	4.62	0.36	8.29e-6	Congenital left-sided heart lesions;
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.56	5.48	0.41	1.77e-7	Blood protein levels;
UCEC	cis	rs201260	0.544	rs17621335	chr6:9979424	T/C	cg00405198	chr6:10419885	TFAP2A	-0.51	-4.65	-0.36	7.42e-6	Electroencephalogram traits;
UCEC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.72	6.64	0.48	5.57e-10	Aortic root size;
UCEC	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	7.36	0.52	1.23e-11	Mood instability;
UCEC	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.53	4.67	0.36	6.74e-6	Cholesterol, total;
UCEC	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.01	6.29	0.46	3.51e-9	Skin colour saturation;
UCEC	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.56	7.9	0.55	6.03e-13	Height;
UCEC	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.64	6.4	0.47	1.96e-9	Dental caries;
UCEC	cis	rs4879656	0.525	rs7852206	chr9:33017381	T/C	cg09633881	chr9:33002021	APTX	-0.38	-4.78	-0.37	4.28e-6	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.73	7.42	0.52	8.5e-12	Breast cancer;
UCEC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-0.94	-12.69	-0.72	2.21e-25	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6669919	1.000	rs6669919	chr1:211674383	T/C	cg10512769	chr1:211675356	NA	-0.31	-4.67	-0.36	6.82e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.55	5.76	0.43	4.68e-8	Schizophrenia;
UCEC	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.35	-5.09	-0.39	1.07e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.32	0.4	3.73e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.29	0.4	4.38e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.74	-8.11	-0.56	1.8e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg18809830	chr7:99032528	PTCD1	-0.81	-4.65	-0.36	7.32e-6	Blood metabolite levels;
UCEC	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.84	9.12	0.6	5.31e-16	Dental caries;
UCEC	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.03	-0.55	2.93e-13	Breast cancer;
UCEC	cis	rs7246967	0.611	rs4933024	chr19:22867063	A/G	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg00316803	chr15:76480434	C15orf27	-0.39	-4.55	-0.35	1.12e-5	Blood metabolite levels;
UCEC	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.78	-9.97	-0.64	3.37e-18	Systemic sclerosis;
UCEC	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.16	0.39	7.77e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.6	-6.79	-0.49	2.53e-10	Tonsillectomy;
UCEC	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.53	-5.35	-0.4	3.28e-7	Prostate cancer;
UCEC	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	0.9	11.58	0.69	1.93e-22	Menarche (age at onset);
UCEC	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	8.03e-6	Bladder cancer;
UCEC	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.49	-4.54	-0.35	1.16e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.48	6.27	0.46	3.84e-9	Total body bone mineral density;
UCEC	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.85	-9.24	-0.61	2.53e-16	Cognitive function;
UCEC	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg10902566	chr4:727664	PCGF3	-0.6	-5.02	-0.38	1.48e-6	Systolic blood pressure;
UCEC	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs6722750	0.846	rs34923691	chr2:64395183	C/T	cg22352474	chr2:64371530	PELI1	0.56	5.38	0.41	2.94e-7	Neuroticism;
UCEC	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.8	4.78	0.37	4.26e-6	Platelet count;
UCEC	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.47e-6	QRS complex (12-leadsum);
UCEC	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13683864	chr3:40499215	RPL14	0.59	6.13	0.45	7.87e-9	Renal cell carcinoma;
UCEC	cis	rs7975161	0.521	rs4447242	chr12:104720708	T/G	cg25273343	chr12:104657179	TXNRD1	-0.81	-5.11	-0.39	9.85e-7	Toenail selenium levels;
UCEC	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.47	-4.7	-0.36	6.02e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.93	9.29	0.61	1.93e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.37	-0.52	1.15e-11	Mean corpuscular volume;
UCEC	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.49	4.73	0.36	5.27e-6	Type 2 diabetes;
UCEC	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg21419209	chr3:44054225	NA	0.51	5.34	0.4	3.42e-7	Coronary artery disease;
UCEC	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.74	-7.96	-0.55	4.19e-13	Height;
UCEC	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Electroencephalogram traits;
UCEC	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.76	-7.93	-0.55	5.12e-13	Plateletcrit;Platelet count;
UCEC	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.47	-5.1	-0.39	1.05e-6	Pubertal anthropometrics;
UCEC	cis	rs12318506	0.826	rs13377894	chr12:75661825	A/G	cg04728562	chr12:75699417	CAPS2	-0.8	-5.0	-0.38	1.6e-6	Coronary artery calcification;
UCEC	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.75	-7.28	-0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs17106184	0.892	rs112717424	chr1:51228799	A/G	cg07174182	chr1:51127561	FAF1	-0.82	-5.25	-0.4	5.23e-7	Type 2 diabetes;
UCEC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg14092571	chr14:90743983	NA	-0.42	-5.65	-0.42	8.07e-8	Mortality in heart failure;
UCEC	cis	rs17123764	0.605	rs4133070	chr12:50078124	A/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.39	0.41	2.72e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.54	-4.56	-0.35	1.06e-5	Carotid intima media thickness;
UCEC	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.5	-5.61	-0.42	9.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	5.57	0.42	1.18e-7	Alzheimer's disease;
UCEC	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.34	4.62	0.36	8.36e-6	Blood protein levels;
UCEC	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.54	-0.48	9.3e-10	Coffee consumption (cups per day);
UCEC	cis	rs61776719	0.817	rs2170169	chr1:38408164	G/A	cg17077180	chr1:38461687	NA	0.52	5.24	0.4	5.58e-7	Coronary artery disease;
UCEC	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	5.41	0.41	2.47e-7	Cognitive test performance;
UCEC	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	1.12	14.29	0.76	1.33e-29	Schizophrenia;
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg12262378	chr17:6899522	ALOX12	0.45	5.36	0.4	3.09e-7	Tonsillectomy;
UCEC	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.72	5.06	0.39	1.22e-6	Bipolar disorder;
UCEC	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg24268161	chr22:39747459	SYNGR1	-0.46	-5.14	-0.39	8.77e-7	Rheumatoid arthritis;
UCEC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.64	5.54	0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08805041	chr16:621841	PIGQ	-0.31	-4.57	-0.35	1.02e-5	Height;
UCEC	cis	rs2734839	0.896	rs11608109	chr11:113303448	G/C	cg14159747	chr11:113255604	NA	0.57	7.09	0.5	5.16e-11	Information processing speed;
UCEC	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.77	8.39	0.57	3.78e-14	Blood protein levels;
UCEC	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.58	5.98	0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs17122693	0.539	rs72681610	chr14:51117773	T/C	cg04730355	chr14:51134070	SAV1	1.08	6.32	0.46	2.96e-9	Cognitive performance;
UCEC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg04176532	chr22:50317003	CRELD2	0.51	4.99	0.38	1.69e-6	Schizophrenia;
UCEC	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.48	4.93	0.38	2.15e-6	Prostate cancer;
UCEC	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.74	-7.02	-0.5	7.67e-11	Aortic root size;
UCEC	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	5.26	0.4	5.02e-7	Response to antipsychotic treatment;
UCEC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-0.72	-7.1	-0.51	4.83e-11	Breast cancer;
UCEC	cis	rs6761276	0.837	rs11887823	chr2:113835311	T/A	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs6684428	1.000	rs17113073	chr1:56355353	A/T	cg11651538	chr1:56320950	NA	-0.74	-5.52	-0.41	1.48e-7	Airflow obstruction;
UCEC	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg13119609	chr19:45449297	APOC2	0.43	6.33	0.46	2.78e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs11697848	1.000	rs56309244	chr20:48491207	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.8	8.58	0.58	1.21e-14	Menarche (age at onset);
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.55	-6.06	-0.45	1.11e-8	Pubertal anthropometrics;
UCEC	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.17	0.6	3.94e-16	Coffee consumption (cups per day);
UCEC	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg18721089	chr20:30220636	NA	-0.39	-4.86	-0.37	2.98e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.24e-10	Aortic root size;
UCEC	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	0.71	5.64	0.42	8.32e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.67	7.6	0.53	3.2e-12	Menopause (age at onset);
UCEC	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.51	-0.35	1.32e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.48	5.43	0.41	2.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.64	8.39	0.57	3.64e-14	Anterior chamber depth;
UCEC	cis	rs11675119	0.501	rs12994811	chr2:3494301	C/A	cg08493051	chr2:3487164	NA	-0.54	-4.9	-0.37	2.5e-6	Neurofibrillary tangles;
UCEC	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-4.68	-0.36	6.57e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg03396347	chr1:1875803	NA	-0.36	-4.55	-0.35	1.1e-5	Body mass index;
UCEC	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.57	6.05	0.45	1.13e-8	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs7106204	1.000	rs7925633	chr11:24214815	A/G	ch.11.24196551F	chr11:24239977	NA	0.68	6.19	0.45	5.73e-9	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg00815214	chr21:47717953	NA	-0.49	-5.9	-0.44	2.38e-8	Testicular germ cell tumor;
UCEC	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-5.38	-0.41	2.9e-7	Morning vs. evening chronotype;
UCEC	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg07460842	chr6:66804631	NA	0.7	5.57	0.42	1.17e-7	Type 2 diabetes;
UCEC	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	4.95	0.38	1.97e-6	Monocyte percentage of white cells;
UCEC	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.69	6.35	0.46	2.6e-9	Aortic root size;
UCEC	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.78	0.43	4.34e-8	Cognitive test performance;
UCEC	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.17	-0.39	7.68e-7	Life satisfaction;
UCEC	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-5.75	-0.43	5.07e-8	Coffee consumption (cups per day);
UCEC	cis	rs6954274	0.609	rs62445702	chr7:9863005	G/A	cg27477025	chr7:9765726	NA	-0.45	-4.85	-0.37	3.16e-6	Subjective well-being;
UCEC	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.58	5.24	0.4	5.44e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6546886	0.912	rs7584777	chr2:74317747	T/C	cg14702570	chr2:74259524	NA	-0.43	-5.53	-0.41	1.43e-7	Dialysis-related mortality;
UCEC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg13844804	chr7:814759	HEATR2	-0.66	-4.61	-0.36	8.82e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-0.96	-6.69	-0.48	4.27e-10	Body mass index;
UCEC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.85	-9.04	-0.6	8.2e-16	Blood protein levels;
UCEC	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-6.66	-0.48	5.15e-10	Platelet distribution width;
UCEC	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.66	-7.54	-0.53	4.46e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.56	6.05	0.45	1.15e-8	Mosquito bite size;
UCEC	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.6	-5.1	-0.39	1.05e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.49	-5.76	-0.43	4.65e-8	Alcoholic chronic pancreatitis;
UCEC	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.6	-5.99	-0.44	1.52e-8	Urate levels in obese individuals;
UCEC	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.1	9.4	0.61	1.02e-16	Opioid sensitivity;
UCEC	cis	rs7553864	0.667	rs6576866	chr1:87601471	T/C	cg17420885	chr1:87600446	LOC339524	-0.42	-4.66	-0.36	6.94e-6	Smoking behavior;
UCEC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.67	-7.84	-0.54	8.59e-13	Obesity-related traits;
UCEC	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg19715936	chr7:50634035	DDC	0.45	5.56	0.42	1.21e-7	Malaria;
UCEC	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.65	-5.53	-0.42	1.39e-7	Breast cancer;
UCEC	cis	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.0	-0.38	1.63e-6	Schizophrenia;
UCEC	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.54	4.97	0.38	1.83e-6	Corneal astigmatism;
UCEC	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.68	0.42	6.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.51	-5.83	-0.43	3.31e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg20257096	chr14:21851954	SUPT16H	-0.59	-6.67	-0.48	4.72e-10	Breast cancer;
UCEC	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	0.63	7.03	0.5	7.35e-11	QRS complex (12-leadsum);
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.5	-5.22	-0.4	6.07e-7	Pubertal anthropometrics;
UCEC	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	5.83	0.43	3.43e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.45	5.05	0.38	1.28e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.59	6.49	0.47	1.21e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.71	6.33	0.46	2.8e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs2298450	0.563	rs55801841	chr21:37630745	G/A	cg02919814	chr21:37666008	DOPEY2	-0.61	-4.78	-0.37	4.23e-6	Schizophrenia;
UCEC	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.61	7.69	0.54	1.97e-12	Menopause (age at onset);
UCEC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg11871910	chr12:69753446	YEATS4	0.74	7.87	0.54	6.97e-13	Blood protein levels;
UCEC	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.53	-5.37	-0.4	3.04e-7	Height;
UCEC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-10.49	-0.65	1.42e-19	Schizophrenia;
UCEC	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.45	4.73	0.36	5.23e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.84	5.09	0.39	1.1e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.48	4.61	0.36	8.74e-6	Mean platelet volume;
UCEC	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.0	0.38	1.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-6.07	-0.45	1.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.78	9.59	0.62	3.31e-17	Bone mineral density;
UCEC	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.65	6.16	0.45	6.71e-9	Lymphocyte counts;
UCEC	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.83	-9.31	-0.61	1.74e-16	Blood protein levels;
UCEC	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	0.9	9.07	0.6	6.89e-16	Total cholesterol levels;
UCEC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.44	4.7	0.36	5.85e-6	Lymphocyte counts;
UCEC	cis	rs686320	0.667	rs666834	chr11:65183815	A/G	cg20713639	chr11:65185684	NA	-0.5	-4.53	-0.35	1.2e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.7	6.54	0.47	9.75e-10	Aortic root size;
UCEC	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.88	9.65	0.62	2.32e-17	Breast cancer;
UCEC	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg21419209	chr3:44054225	NA	-0.45	-4.57	-0.35	1.03e-5	Coronary artery disease;
UCEC	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg00612595	chr21:47717864	NA	-0.45	-4.9	-0.37	2.51e-6	Testicular germ cell tumor;
UCEC	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.53	0.42	1.41e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg01072550	chr1:21505969	NA	-0.63	-6.67	-0.48	4.84e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.56	6.09	0.45	9.24e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	1.0	13.26	0.74	6.7399999999999993e-27	Monocyte count;
UCEC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	4.88	0.37	2.7e-6	Monocyte percentage of white cells;
UCEC	cis	rs72792324	1.000	rs68033444	chr5:140767989	C/T	cg17023770	chr5:140624874	PCDHB15	-0.57	-4.55	-0.35	1.1e-5	Mean platelet volume;
UCEC	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.46	0.47	1.44e-9	Personality dimensions;
UCEC	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.7	7.16	0.51	3.65e-11	Mood instability;
UCEC	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.79	7.55	0.53	4.27e-12	Longevity;Endometriosis;
UCEC	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.53	6.13	0.45	7.51e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg04310649	chr10:35416472	CREM	-0.49	-4.76	-0.37	4.61e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.45	-4.59	-0.35	9.35e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.51	-4.86	-0.37	2.94e-6	Renal cell carcinoma;
UCEC	cis	rs925228	0.668	rs10779936	chr2:23950200	G/A	cg16901991	chr2:24272451	FKBP1B	0.53	4.79	0.37	3.97e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	5.34	0.4	3.47e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.41	4.81	0.37	3.68e-6	IgG glycosylation;
UCEC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.83	0.43	3.41e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.7	4.91	0.38	2.39e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg12024160	chr4:1254474	NA	0.48	4.51	0.35	1.29e-5	Longevity;
UCEC	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.41	0.52	8.96e-12	Eye color traits;
UCEC	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg14067834	chr17:29058358	SUZ12P	0.6	4.69	0.36	6.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.84	-6.77	-0.49	2.93e-10	Response to hepatitis C treatment;
UCEC	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-0.86	-9.17	-0.6	3.81e-16	Height;
UCEC	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.96	0.5	1.03e-10	Coronary artery disease;
UCEC	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.16	-0.45	6.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs8105895	1.000	rs57912102	chr19:22136043	T/C	cg02912127	chr19:22235281	ZNF257	-0.6	-4.87	-0.37	2.8e-6	Body mass index (change over time);
UCEC	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	0.88	6.29	0.46	3.41e-9	Pediatric areal bone mineral density (radius);
UCEC	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg24803719	chr17:45855879	NA	0.41	4.99	0.38	1.71e-6	IgG glycosylation;
UCEC	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.79	-6.5	-0.47	1.17e-9	Alzheimer's disease (late onset);
UCEC	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.75	-0.43	4.89e-8	Hemoglobin concentration;
UCEC	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.59	-5.15	-0.39	8.18e-7	Metabolite levels;
UCEC	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.85	-0.37	3.12e-6	Electroencephalogram traits;
UCEC	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.72	-6.38	-0.47	2.21e-9	Menopause (age at onset);
UCEC	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.47	4.93	0.38	2.22e-6	Longevity;
UCEC	cis	rs7872515	0.887	rs7029539	chr9:94864322	A/G	cg01248375	chr9:94877805	SPTLC1	0.44	4.68	0.36	6.34e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg09682330	chr6:28411287	ZSCAN23	0.51	5.49	0.41	1.71e-7	Pubertal anthropometrics;
UCEC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.53	-4.69	-0.36	6.23e-6	Blood pressure (smoking interaction);
UCEC	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg13264159	chr8:625131	ERICH1	-0.86	-4.84	-0.37	3.2e-6	IgG glycosylation;
UCEC	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.5	5.87	0.44	2.72e-8	Subjective well-being (multi-trait analysis);
UCEC	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	8.15	0.56	1.43e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.79	5.87	0.44	2.77e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs4778581	1.000	rs12911387	chr15:80403126	A/C	cg08257866	chr15:80351198	ZFAND6	-0.4	-4.67	-0.36	6.88e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	12.18	0.71	4.85e-24	Platelet count;
UCEC	cis	rs4919044	0.866	rs11187264	chr10:94824024	C/A	cg00519463	chr10:94352821	KIF11	0.96	5.36	0.4	3.11e-7	Coronary artery disease;
UCEC	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.58	-6.02	-0.44	1.33e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg01262667	chr19:19385393	TM6SF2	0.49	6.54	0.47	9.5e-10	Tonsillectomy;
UCEC	cis	rs9463078	0.715	rs1557143	chr6:44756415	T/C	cg25276700	chr6:44698697	NA	0.47	5.35	0.4	3.25e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.48	-4.6	-0.35	9e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.79	9.28	0.61	1.99e-16	Breast cancer;
UCEC	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg24011408	chr12:48396354	COL2A1	0.56	4.9	0.37	2.47e-6	Lung cancer;
UCEC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-5.28	-0.4	4.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.47	-5.17	-0.39	7.67e-7	Life satisfaction;
UCEC	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	1.07	9.64	0.62	2.45e-17	Mosquito bite size;
UCEC	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.65	0.62	2.27e-17	Blood protein levels;
UCEC	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.68	5.47	0.41	1.86e-7	Corneal astigmatism;
UCEC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	6.85	0.49	1.9e-10	Homoarginine levels;
UCEC	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.85	0.43	3.02e-8	Response to antipsychotic treatment;
UCEC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.76	6.82	0.49	2.18e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.68	-6.13	-0.45	7.6e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.6	-7.32	-0.52	1.54e-11	Total body bone mineral density;
UCEC	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.47	-4.92	-0.38	2.25e-6	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.45	5.18	0.39	7.17e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	1.01	9.43	0.61	8.14e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs9816784	0.525	rs422772	chr3:195806472	C/T	cg12923728	chr3:195709715	SDHAP1	-0.49	-4.51	-0.35	1.34e-5	Mean corpuscular hemoglobin;
UCEC	cis	rs60311166	1.000	rs72950430	chr3:52695061	A/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	4.64	0.36	7.57e-6	CTACK levels;
UCEC	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.56	-7.9	-0.55	5.91e-13	Prudent dietary pattern;
UCEC	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg00677455	chr12:58241039	CTDSP2	0.5	4.86	0.37	2.98e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.48e-16	Vitiligo;
UCEC	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg16584290	chr5:462447	EXOC3	-0.4	-4.66	-0.36	7.18e-6	Cystic fibrosis severity;
UCEC	cis	rs7088591	0.867	rs1930487	chr10:59782253	C/T	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-5.46	-0.41	1.96e-7	Height;
UCEC	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.5	4.59	0.35	9.58e-6	Body mass index;
UCEC	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	0.95	5.49	0.41	1.7e-7	Diabetic retinopathy;
UCEC	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg21770322	chr7:97807741	LMTK2	-0.5	-6.16	-0.45	6.54e-9	Breast cancer;
UCEC	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.49	0.47	1.26e-9	Personality dimensions;
UCEC	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.82	9.37	0.61	1.2e-16	Intelligence (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18863837	chr10:94352819	KIF11	0.65	7.74	0.54	1.46e-12	Warfarin maintenance dose;
UCEC	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	5.94	0.44	1.99e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.79	-5.92	-0.44	2.15e-8	Fibroblast growth factor basic levels;
UCEC	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	0.65	4.57	0.35	1.04e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs11697848	1.000	rs55713402	chr20:48529477	A/C	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-5.83	-0.43	3.46e-8	Platelet count;
UCEC	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg05660106	chr1:15850417	CASP9	0.85	9.76	0.63	1.18e-17	Systolic blood pressure;
UCEC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.5	-0.35	1.35e-5	Aortic root size;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	9.15	0.6	4.47e-16	Platelet count;
UCEC	cis	rs172166	0.515	rs2622320	chr6:28115336	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.55	-0.48	9.09e-10	Cardiac Troponin-T levels;
UCEC	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.54	4.9	0.37	2.54e-6	Refractive astigmatism;
UCEC	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	6.16	0.45	6.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg19513890	chr22:42538836	CYP2D7P1	-0.45	-5.08	-0.39	1.15e-6	Schizophrenia;
UCEC	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs1318772	0.932	rs1035409	chr5:112850963	G/A	cg12552261	chr5:112820674	MCC	0.69	4.54	0.35	1.15e-5	F-cell distribution;
UCEC	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18252515	chr7:66147081	NA	0.52	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	7.34	0.52	1.38e-11	Coffee consumption (cups per day);
UCEC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.54	4.74	0.36	5.07e-6	Response to diuretic therapy;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg05342682	chr7:94953680	PON1	0.58	6.97	0.5	9.93e-11	Paraoxonase activity;
UCEC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.53	-6.0	-0.44	1.44e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26002218	chr14:103986227	CKB	0.35	4.94	0.38	2.12e-6	Body mass index;
UCEC	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.2	-0.56	1.07e-13	Hemoglobin concentration;
UCEC	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.46	-4.99	-0.38	1.65e-6	Amyotrophic lateral sclerosis (age of onset);
UCEC	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-4.85	-0.37	3.12e-6	Acylcarnitine levels;
UCEC	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.79	-8.46	-0.57	2.44e-14	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.43	-4.86	-0.37	2.99e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	2.02e-7	Aortic root size;
UCEC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.56	-6.46	-0.47	1.41e-9	Electroencephalogram traits;
UCEC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.52	-0.69	2.74e-22	Monocyte count;
UCEC	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg18099408	chr3:52552593	STAB1	0.42	4.88	0.37	2.76e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3770752	0.860	rs11689794	chr2:37550196	T/C	cg20091297	chr2:37572423	QPCT	0.47	4.6	0.35	9.21e-6	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7246967	0.800	rs2061774	chr19:23025775	C/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9931543	0.678	rs876245	chr16:56291212	A/G	cg10482356	chr16:56328421	GNAO1	-0.35	-4.57	-0.35	1.02e-5	Subjective well-being;
UCEC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg21178979	chr7:1889533	MAD1L1	0.34	4.6	0.35	9.23e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.71	-9.23	-0.61	2.74e-16	Oral cavity cancer;
UCEC	cis	rs960450	1.000	rs1911792	chr4:98506463	A/G	cg05340658	chr4:99064831	C4orf37	-0.4	-4.51	-0.35	1.33e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg13695892	chr22:41940480	POLR3H	0.7	5.49	0.41	1.71e-7	Vitiligo;
UCEC	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.99	11.4	0.69	5.61e-22	Cognitive function;
UCEC	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.57	5.21	0.39	6.41e-7	Urinary electrolytes (magnesium/calcium ratio);
UCEC	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.66	-5.77	-0.43	4.62e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7246967	0.673	rs9676498	chr19:22910510	A/G	cg24889512	chr19:22816950	ZNF492	0.61	6.49	0.47	1.25e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.39	-0.41	2.68e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2036402	0.531	rs9790967	chr5:156434655	A/C	cg24526056	chr5:156479556	HAVCR1	0.46	4.75	0.36	4.84e-6	Hypertriglyceridemia;
UCEC	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg11569703	chr11:65557185	OVOL1	0.51	6.66	0.48	4.99e-10	Acne (severe);
UCEC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.13	-0.51	4.21e-11	Bipolar disorder and schizophrenia;
UCEC	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.68	6.52	0.47	1.04e-9	Bladder cancer;
UCEC	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.56	-4.57	-0.35	1.02e-5	Breast cancer;
UCEC	cis	rs4499344	0.730	rs10413061	chr19:33103278	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.41e-9	Mean platelet volume;
UCEC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.44	-4.65	-0.36	7.19e-6	Platelet count;
UCEC	cis	rs7937612	1.000	rs7101415	chr11:120239088	G/A	cg12584626	chr11:120203529	NA	0.47	4.63	0.36	7.84e-6	Intraocular pressure;
UCEC	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.58	5.88	0.44	2.67e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.13e-6	Childhood ear infection;
UCEC	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	0.82	4.69	0.36	6.21e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.66	6.12	0.45	8.07e-9	Aortic root size;
UCEC	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	0.54	5.47	0.41	1.9e-7	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18252515	chr7:66147081	NA	-0.46	-4.65	-0.36	7.24e-6	Aortic root size;
UCEC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.32e-6	Breast cancer;
UCEC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.8	4.91	0.38	2.37e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.47	4.94	0.38	2.07e-6	Pulse pressure;
UCEC	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.73	7.62	0.53	2.93e-12	Primary sclerosing cholangitis;
UCEC	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.63	7.63	0.53	2.66e-12	Mean platelet volume;
UCEC	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs9828933	0.882	rs3733127	chr3:63988174	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.66	-5.67	-0.42	7.4e-8	Type 2 diabetes;
UCEC	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.12	-0.56	1.71e-13	Monocyte count;
UCEC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.46	4.54	0.35	1.15e-5	Blood metabolite levels;
UCEC	cis	rs240764	0.619	rs9399652	chr6:101120006	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-4.79	-0.37	4.1e-6	Neuroticism;
UCEC	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.88	0.37	2.72e-6	Multiple sclerosis;
UCEC	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	5.8	0.43	3.99e-8	IgG glycosylation;
UCEC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	6.77	0.49	2.81e-10	Platelet count;
UCEC	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg18681998	chr4:17616180	MED28	0.58	6.53	0.47	1.02e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.72	7.33	0.52	1.44e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-5.68	-0.42	7.03e-8	Bipolar disorder;
UCEC	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.56	-0.42	1.23e-7	Life satisfaction;
UCEC	cis	rs7975161	0.624	rs11111943	chr12:104632418	T/C	cg25273343	chr12:104657179	TXNRD1	-0.79	-4.91	-0.38	2.43e-6	Toenail selenium levels;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg26769984	chr7:1090371	C7orf50	0.48	4.62	0.36	8.36e-6	Longevity;Endometriosis;
UCEC	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-5.68	-0.42	6.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.51	5.43	0.41	2.29e-7	Longevity;
UCEC	cis	rs56341938	0.679	rs6768432	chr3:168815374	A/C	cg21477417	chr3:169490753	MYNN	-0.51	-4.99	-0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg14008862	chr17:28927542	LRRC37B2	0.52	4.51	0.35	1.29e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.82	9.19	0.6	3.38e-16	Body mass index (adult);
UCEC	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.63	4.81	0.37	3.77e-6	Carotid intima media thickness;
UCEC	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.51	-5.53	-0.42	1.39e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.52	-7.22	-0.51	2.63e-11	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.55	-5.12	-0.39	9.59e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12643440	1.000	rs35915791	chr4:17217890	C/T	cg02108033	chr4:17783294	FAM184B	-0.52	-4.53	-0.35	1.23e-5	Metabolite levels (Pyroglutamine);
UCEC	cis	rs7095607	0.785	rs10823142	chr10:69921335	T/A	cg18986048	chr10:69913749	MYPN	0.54	6.39	0.47	2.08e-9	Lung function (FVC);
UCEC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg19715936	chr7:50634035	DDC	0.41	5.07	0.39	1.2e-6	Malaria;
UCEC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg23307798	chr14:103986281	CKB	0.64	7.76	0.54	1.33e-12	Body mass index;
UCEC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	8.32	0.57	5.56e-14	Smoking behavior;
UCEC	cis	rs7611694	0.531	rs66524865	chr3:113043206	T/A	cg11138929	chr3:113251189	SIDT1	0.44	5.18	0.39	7.32e-7	Prostate cancer;
UCEC	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.88	9.74	0.63	1.31e-17	Breast cancer;
UCEC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.7	-7.37	-0.52	1.12e-11	Longevity;Endometriosis;
UCEC	cis	rs17034641	1.000	rs17034641	chr2:46372644	G/A	cg12428440	chr2:46370979	PRKCE	0.6	4.87	0.37	2.8e-6	Hemoglobin;Hematocrit;
UCEC	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.37	4.61	0.36	8.5e-6	Obesity-related traits;
UCEC	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.92	6.97	0.5	9.96e-11	Exhaled nitric oxide levels;
UCEC	cis	rs79839061	0.764	rs12646225	chr4:696848	C/T	cg08937613	chr4:881914	GAK	0.59	4.7	0.36	5.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.67	7.68	0.54	2.04e-12	Mean corpuscular volume;
UCEC	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	0.82	8.68	0.58	6.89e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.52	5.63	0.42	8.76e-8	Response to temozolomide;
UCEC	cis	rs6716963	0.743	rs11695748	chr2:194639832	T/G	cg21560241	chr2:193640765	PCGEM1	-0.32	-4.66	-0.36	7.05e-6	Schizophrenia;
UCEC	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.38	-0.47	2.23e-9	Metabolite levels;
UCEC	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.72	6.35	0.46	2.59e-9	Coronary artery disease;
UCEC	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.45	-4.77	-0.37	4.43e-6	Height;
UCEC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	4.79	0.37	4.03e-6	Breast cancer;
UCEC	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg04310649	chr10:35416472	CREM	-0.51	-4.88	-0.37	2.78e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11958404	0.932	rs111802867	chr5:157424971	G/A	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-6.86	-0.49	1.8e-10	Developmental language disorder (linguistic errors);
UCEC	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.46	4.98	0.38	1.76e-6	Pulse pressure;
UCEC	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	0.86	4.97	0.38	1.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.54	5.14	0.39	8.69e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	1.02	10.59	0.66	7.88e-20	Caffeine consumption;
UCEC	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.57	0.35	1.01e-5	Menopause (age at onset);
UCEC	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.57	-5.6	-0.42	9.99e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.47	-4.64	-0.36	7.79e-6	Cardiac Troponin-T levels;
UCEC	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.21	12.02	0.7	1.31e-23	Corneal structure;
UCEC	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-6.0	-0.44	1.46e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.08	8.21	0.56	1.04e-13	Alzheimer's disease (late onset);
UCEC	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg12463550	chr7:65579703	CRCP	0.51	5.14	0.39	8.59e-7	Aortic root size;
UCEC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg12024160	chr4:1254474	NA	0.66	8.11	0.56	1.78e-13	Obesity-related traits;
UCEC	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.67	-7.3	-0.52	1.7e-11	Coronary artery disease;
UCEC	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04202892	chr2:111875749	ACOXL	0.44	5.21	0.39	6.21e-7	Chronic lymphocytic leukemia;
UCEC	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.44	4.89	0.37	2.59e-6	Mosquito bite size;
UCEC	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	0.72	4.88	0.37	2.68e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.48	7.26	0.51	2.13e-11	Primary biliary cholangitis;
UCEC	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-9.74	-0.63	1.3e-17	Blood metabolite levels;
UCEC	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.18	0.45	6.06e-9	Coffee consumption (cups per day);
UCEC	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.58	-0.35	9.75e-6	Response to antipsychotic treatment;
UCEC	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7582720	1.000	rs72932772	chr2:203682304	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.96	0.38	1.89e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.51	5.15	0.39	8.27e-7	Blood protein levels;
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-5.77	-0.43	4.45e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.02	11.38	0.68	6.67e-22	IgG glycosylation;
UCEC	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	8.02	0.55	3.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-8.23	-0.56	9.5e-14	Morning vs. evening chronotype;
UCEC	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.84	7.06	0.5	5.99e-11	Myopia (pathological);
UCEC	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.48	4.61	0.36	8.74e-6	Mean platelet volume;
UCEC	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.18	-0.56	1.24e-13	Breast cancer;
UCEC	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.11	0.39	9.82e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.83	9.75	0.63	1.24e-17	Menopause (age at onset);
UCEC	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.43	-5.86	-0.44	2.94e-8	IgG glycosylation;
UCEC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.66	6.12	0.45	8.15e-9	Schizophrenia;
UCEC	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.81	-9.14	-0.6	4.55e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.57	-5.45	-0.41	2.05e-7	Pediatric autoimmune diseases;
UCEC	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.48	-0.84	3.68e-40	Exhaled nitric oxide output;
UCEC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	5.07	0.39	1.17e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg14851346	chr12:38532713	NA	0.52	5.02	0.38	1.47e-6	Heart rate;
UCEC	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	0.92	9.84	0.63	7.28e-18	IgG glycosylation;
UCEC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.53	4.99	0.38	1.66e-6	Menopause (age at onset);
UCEC	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.72	7.86	0.54	7.67e-13	Blood pressure (smoking interaction);
UCEC	cis	rs73416724	1.000	rs70953686	chr6:43269516	G/A	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.63	5.14	0.39	8.66e-7	Gut microbiome composition (summer);
UCEC	cis	rs66686620	0.943	rs6546472	chr2:69260300	A/G	cg12800200	chr2:69260302	ANTXR1	-0.55	-5.33	-0.4	3.55e-7	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-9.41	-0.61	9.58e-17	Morning vs. evening chronotype;
UCEC	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.74	-6.25	-0.46	4.17e-9	Neurofibrillary tangles;
UCEC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.82	-0.49	2.26e-10	Prostate cancer;
UCEC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.64	5.54	0.42	1.33e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.82	9.75	0.63	1.28e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.1	-0.56	1.97e-13	Total cholesterol levels;
UCEC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.78	7.8	0.54	1.04e-12	Lung cancer;
UCEC	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.54	4.97	0.38	1.86e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.58	6.58	0.48	7.8e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs539514	0.587	rs9530466	chr13:76323774	T/C	cg04757411	chr13:76259545	LMO7	-0.48	-5.66	-0.42	7.58e-8	Type 1 diabetes;
UCEC	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.59	-5.69	-0.42	6.71e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.5	4.99	0.38	1.71e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.81	0.37	3.65e-6	Breast cancer;
UCEC	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	7.05	0.5	6.47e-11	Alzheimer's disease;
UCEC	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.32	4.7	0.36	5.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.44	5.2	0.39	6.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7004769	0.554	rs6982301	chr8:9183024	A/G	cg27598956	chr8:9758788	LOC157627	-0.48	-4.59	-0.35	9.58e-6	Fibrinogen levels;
UCEC	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.61	-0.62	2.81e-17	Primary sclerosing cholangitis;
UCEC	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18932078	chr1:2524107	MMEL1	0.34	5.71	0.43	6.11e-8	Ulcerative colitis;
UCEC	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg05802129	chr4:122689817	NA	-0.5	-5.26	-0.4	5.06e-7	Type 2 diabetes;
UCEC	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg24375607	chr4:120327624	NA	0.5	5.13	0.39	9.21e-7	Educational attainment;
UCEC	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.68	7.53	0.53	4.64e-12	Coronary artery disease;
UCEC	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.42	-5.12	-0.39	9.35e-7	Subjective well-being;
UCEC	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.49	4.76	0.37	4.68e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12365397	0.630	rs7948403	chr11:43222608	A/G	cg07515919	chr11:43391688	TTC17	-0.46	-5.56	-0.42	1.25e-7	Migraine;
UCEC	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.15	15.36	0.78	2.33e-32	Cognitive function;
UCEC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg06660395	chr4:1396306	NA	0.36	4.6	0.36	8.88e-6	Obesity-related traits;
UCEC	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.5	-5.58	-0.42	1.11e-7	Longevity;
UCEC	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg06166341	chr4:1223170	CTBP1	0.58	5.29	0.4	4.4e-7	Systolic blood pressure;
UCEC	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.87	-0.37	2.89e-6	Tonsillectomy;
UCEC	cis	rs7106204	0.514	rs7117803	chr11:24253214	A/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	5.28	0.4	4.63e-7	Bipolar disorder;
UCEC	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.67	-7.48	-0.52	6.34e-12	Morning vs. evening chronotype;
UCEC	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.65	-7.3	-0.52	1.71e-11	Blood trace element (Zn levels);
UCEC	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.44	5.17	0.39	7.39e-7	Metabolite levels;
UCEC	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	4.82	0.37	3.55e-6	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.45	0.41	2.06e-7	Breast cancer;
UCEC	cis	rs4148689	1.000	rs12673260	chr7:117137400	A/C	cg21212505	chr7:117228958	CFTR	-0.42	-4.71	-0.36	5.75e-6	Gout;
UCEC	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.57	5.63	0.42	8.99e-8	Blood protein levels;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.78	-0.37	4.14e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4372836	0.729	rs67410623	chr2:29057440	G/A	cg09522027	chr2:28974177	PPP1CB	0.84	8.78	0.59	3.82e-15	Body mass index;
UCEC	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.63	7.1	0.51	4.81e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	5.08	0.39	1.13e-6	Educational attainment;
UCEC	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.54	5.86	0.44	2.9e-8	Response to temozolomide;
UCEC	cis	rs4926298	0.890	rs1017180	chr19:13194772	C/T	cg11758861	chr19:13135514	NFIX	-0.48	-4.88	-0.37	2.7e-6	Bipolar disorder;
UCEC	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.58	0.42	1.12e-7	Coffee consumption (cups per day);
UCEC	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	4.88	0.37	2.67e-6	Monocyte count;
UCEC	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.34	4.78	0.37	4.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs12618769	0.652	rs1062847	chr2:99226173	T/A	cg10123293	chr2:99228465	UNC50	0.49	5.58	0.42	1.11e-7	Bipolar disorder;
UCEC	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.42	-4.98	-0.38	1.73e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs4865875	0.892	rs7728418	chr5:54101579	T/A	cg22421804	chr5:54100067	NA	0.37	4.72	0.36	5.33e-6	Sense of smell;
UCEC	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.66	-0.36	7.11e-6	Breast cancer;
UCEC	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.83	-9.68	-0.62	1.9e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.11	14.38	0.76	7.8e-30	Schizophrenia;
UCEC	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.35	5.76	0.43	4.72e-8	Cancer;
UCEC	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.84	4.59	0.35	9.49e-6	Alzheimer's disease (late onset);
UCEC	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.67	-4.77	-0.37	4.33e-6	Gut microbiome composition (summer);
UCEC	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg01689657	chr7:91764605	CYP51A1	0.45	5.68	0.42	6.95e-8	Breast cancer;
UCEC	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.71	-6.08	-0.45	9.63e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg10596483	chr8:143751796	JRK	0.46	4.84	0.37	3.21e-6	Schizophrenia;
UCEC	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg03859395	chr2:55845619	SMEK2	-0.97	-13.72	-0.75	4.32e-28	Metabolic syndrome;
UCEC	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg26067569	chr2:200525129	NA	0.52	4.56	0.35	1.05e-5	Schizophrenia;
UCEC	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg19197139	chr17:4613644	ARRB2	0.82	6.18	0.45	5.92e-9	Lymphocyte counts;
UCEC	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.89	-6.97	-0.5	9.81e-11	Exhaled nitric oxide output;
UCEC	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs8105895	0.935	rs7252220	chr19:22245564	G/A	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.64e-7	Body mass index (change over time);
UCEC	cis	rs554111	0.686	rs519209	chr1:21043790	C/T	cg08890418	chr1:21044141	KIF17	-0.71	-6.98	-0.5	9.42e-11	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.65	-0.42	7.91e-8	Pancreatic cancer;
UCEC	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg08807101	chr21:30365312	RNF160	0.57	5.02	0.38	1.46e-6	Selective IgA deficiency;
UCEC	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg00786635	chr1:25594202	NA	0.5	5.0	0.38	1.61e-6	Erythrocyte sedimentation rate;
UCEC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	0.99	11.34	0.68	8.41e-22	Cognitive function;
UCEC	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg20368463	chr18:77673604	PQLC1	-0.51	-4.59	-0.35	9.58e-6	Opioid sensitivity;
UCEC	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	6.87	0.49	1.67e-10	Alzheimer's disease;
UCEC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	cis	rs1150668	0.965	rs1654774	chr6:28096280	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.52	-5.84	-0.43	3.2e-8	Pubertal anthropometrics;
UCEC	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.83	6.42	0.47	1.73e-9	Body mass index;
UCEC	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg11519256	chr10:5708881	ASB13	0.52	5.18	0.39	7.2e-7	Childhood ear infection;
UCEC	cis	rs9900062	0.586	rs11653958	chr17:62686730	G/A	cg02097616	chr17:62675921	NA	0.47	5.11	0.39	9.78e-7	QT interval;
UCEC	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.49	5.6	0.42	1.04e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.91	-11.79	-0.7	5.2e-23	Height;
UCEC	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	6.21	0.46	5.09e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.62	6.65	0.48	5.37e-10	Neuroticism;
UCEC	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.93	10.45	0.65	1.89e-19	Cognitive function;
UCEC	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg04756594	chr16:24857601	SLC5A11	0.43	4.96	0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.35	4.75	0.36	4.85e-6	Blood protein levels;
UCEC	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.01	-0.38	1.57e-6	Huntington's disease progression;
UCEC	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-5.44	-0.41	2.15e-7	Obesity-related traits;
UCEC	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.9	-0.37	2.46e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.41	-4.87	-0.37	2.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7350721	0.752	rs949453	chr14:56319234	T/C	cg23678254	chr14:55647471	DLGAP5	0.33	4.61	0.36	8.76e-6	Body mass index (ever vs never smoking interaction);Body mass index  (smoking years interaction);
UCEC	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.43	4.71	0.36	5.73e-6	Recombination rate (males);
UCEC	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.44	-5.14	-0.39	8.44e-7	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.49	-0.57	2.06e-14	Blood trace element (Zn levels);
UCEC	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.34	0.61	1.45e-16	Blood protein levels;
UCEC	cis	rs2708977	0.637	rs654224	chr2:97080123	A/C	cg22654517	chr2:96458247	NA	0.42	4.95	0.38	1.99e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg06917634	chr15:78832804	PSMA4	0.55	5.44	0.41	2.18e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4345220	0.585	rs4861123	chr4:41642833	A/G	cg15232654	chr4:41643107	LIMCH1	0.49	5.16	0.39	7.94e-7	Migraine with aura;
UCEC	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.1	0.51	5.07e-11	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.53	-5.8	-0.43	3.99e-8	Longevity;
UCEC	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	7.02	0.5	7.79e-11	Coffee consumption (cups per day);
UCEC	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg00316803	chr15:76480434	C15orf27	0.4	4.88	0.37	2.76e-6	Blood metabolite levels;
UCEC	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.69	-8.51	-0.57	1.87e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-5.87	-0.44	2.76e-8	Menarche (age at onset);
UCEC	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.53	5.01	0.38	1.57e-6	Blood trace element (Cu levels);
UCEC	cis	rs7246967	1.000	rs11879853	chr19:23029434	C/T	cg08271804	chr19:22816896	ZNF492	-0.55	-5.34	-0.4	3.47e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	6.27	0.46	3.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.31	4.69	0.36	6.1e-6	Schizophrenia;
UCEC	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06671706	chr8:8559999	CLDN23	0.66	5.34	0.4	3.47e-7	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.23e-7	Breast cancer;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.46	-5.39	-0.41	2.79e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.6	5.78	0.43	4.38e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.61	4.6	0.36	8.88e-6	Multiple sclerosis;
UCEC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.44	-0.47	1.62e-9	Aortic root size;
UCEC	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.78	-8.92	-0.59	1.72e-15	Mortality in heart failure;
UCEC	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg24163568	chr5:669837	TPPP	-0.43	-5.47	-0.41	1.93e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-5.81	-0.43	3.68e-8	Urinary metabolites;
UCEC	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.98	-0.44	1.62e-8	Total cholesterol levels;
UCEC	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.04e-14	Menarche (age at onset);
UCEC	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.6	5.53	0.42	1.4e-7	Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.75	8.26	0.56	7.83e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	5.03	0.38	1.44e-6	Eosinophil percentage of white cells;
UCEC	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.58	-6.14	-0.45	7.29e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg10978503	chr1:24200527	CNR2	-0.39	-5.18	-0.39	7.26e-7	Immature fraction of reticulocytes;
UCEC	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg09655341	chr17:79618100	PDE6G	0.3	4.54	0.35	1.14e-5	Eye color traits;
UCEC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.52	0.35	1.28e-5	Diabetic retinopathy;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg24460917	chr20:18269097	ZNF133	0.72	7.01	0.5	8.07e-11	Schizophrenia;
UCEC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.52	6.65	0.48	5.45e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.51	5.41	0.41	2.52e-7	Height;
UCEC	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	5.47	0.41	1.87e-7	Monocyte percentage of white cells;
UCEC	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.84	-7.7	-0.54	1.81e-12	Neurofibrillary tangles;
UCEC	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.55	-6.74	-0.49	3.34e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	4.74	0.36	5.1e-6	Protein C levels;
UCEC	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.5	-5.67	-0.42	7.18e-8	Lung cancer;
UCEC	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.62	-0.42	9.51e-8	Urate levels in overweight individuals;
UCEC	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.68	-0.62	1.85e-17	Primary sclerosing cholangitis;
UCEC	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.55	6.59	0.48	7.31e-10	Mean corpuscular volume;
UCEC	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.06	-7.74	-0.54	1.48e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	5.19	0.39	6.73e-7	Cognitive test performance;
UCEC	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.69	-6.65	-0.48	5.47e-10	Blood pressure (smoking interaction);
UCEC	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs295140	0.967	rs4673906	chr2:201163812	G/T	cg04283868	chr2:201171347	SPATS2L	0.52	5.19	0.39	6.76e-7	QT interval;
UCEC	cis	rs6546550	0.713	rs6718517	chr2:70018462	T/C	cg02498382	chr2:70120550	SNRNP27	-0.55	-5.9	-0.44	2.36e-8	Prevalent atrial fibrillation;
UCEC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.04	-7.8	-0.54	1.08e-12	Body mass index;
UCEC	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.43	-5.61	-0.42	9.8e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs75804782	0.521	rs55988884	chr2:239396930	G/A	cg12524725	chr2:239427019	NA	-0.67	-4.57	-0.35	1.03e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.66	-6.9	-0.49	1.42e-10	Lung cancer;
UCEC	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.6	-5.25	-0.4	5.16e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-0.56	-4.64	-0.36	7.69e-6	Breast cancer (early onset);
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	7.67	0.53	2.21e-12	Platelet count;
UCEC	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg19318889	chr4:1322082	MAEA	0.5	5.46	0.41	1.95e-7	Obesity-related traits;
UCEC	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.02	-7.79	-0.54	1.08e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.88	0.49	1.62e-10	Bipolar disorder;
UCEC	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.71	6.39	0.47	2.02e-9	Parkinson's disease;
UCEC	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.45	4.63	0.36	8.07e-6	Schizophrenia;
UCEC	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	6.54	0.47	9.55e-10	Motion sickness;
UCEC	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.29	4.51	0.35	1.31e-5	Diastolic blood pressure;
UCEC	cis	rs1008126	0.918	rs2075040	chr7:103162847	T/C	cg18108683	chr7:102477205	FBXL13	0.44	4.66	0.36	6.93e-6	Metabolite levels (Pyroglutamine);
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg02594498	chr15:22893147	CYFIP1	0.69	6.96	0.5	1.03e-10	Triglyceride levels;
UCEC	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg16797656	chr11:68205561	LRP5	-0.59	-4.74	-0.36	5.08e-6	Total body bone mineral density (age 45-60);
UCEC	cis	rs6136489	1.000	rs4814776	chr20:1921523	G/T	cg08074820	chr20:2733358	EBF4	-0.4	-4.62	-0.36	8.28e-6	Platelet distribution width;Mean platelet volume;
UCEC	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs692804	0.818	rs540857	chr11:120078890	G/A	cg16775289	chr11:120081497	OAF	1.0	4.72	0.36	5.38e-6	Blood protein levels;
UCEC	cis	rs9469578	1.000	rs73743326	chr6:33709980	C/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14019695	chr9:139328340	INPP5E	-0.47	-4.87	-0.37	2.9e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	0.93	7.17	0.51	3.34e-11	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04476341	chr5:669733	TPPP	0.43	4.99	0.38	1.69e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.72	5.93	0.44	2.11e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.75	7.98	0.55	3.85e-13	Menopause (age at onset);
UCEC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.66	-6.78	-0.49	2.78e-10	Blood metabolite levels;
UCEC	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.56	-6.25	-0.46	4.31e-9	Inflammatory bowel disease;
UCEC	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.62	6.2	0.46	5.39e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.01	-0.38	1.56e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.56	4.96	0.38	1.93e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.68	-7.66	-0.53	2.29e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg05660106	chr1:15850417	CASP9	0.51	4.81	0.37	3.75e-6	Systolic blood pressure;
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.5	-0.47	1.16e-9	Platelet count;
UCEC	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.48	5.5	0.41	1.67e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-5.34	-0.4	3.46e-7	Alcohol dependence;
UCEC	cis	rs17106184	0.892	rs17106175	chr1:50904241	G/A	cg07174182	chr1:51127561	FAF1	-0.84	-5.36	-0.4	3.12e-7	Type 2 diabetes;
UCEC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.66	5.92	0.44	2.18e-8	Cognitive function;
UCEC	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg08890418	chr1:21044141	KIF17	-0.59	-6.04	-0.45	1.19e-8	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs10242455	0.764	rs2740561	chr7:99321441	G/A	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.62	-7.0	-0.5	8.66e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7617773	1.000	rs6771889	chr3:48194326	C/T	cg11946769	chr3:48343235	NME6	-0.55	-4.81	-0.37	3.77e-6	Coronary artery disease;
UCEC	cis	rs3743102	0.591	rs10520565	chr15:83255074	C/T	cg00614314	chr15:82944287	LOC80154	-0.89	-5.11	-0.39	9.93e-7	Colorectal adenoma (advanced);
UCEC	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.46	4.51	0.35	1.29e-5	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs2041840	0.538	rs10196818	chr2:37576852	A/G	cg25727520	chr2:37576821	QPCT	-0.44	-4.97	-0.38	1.85e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.5	4.77	0.37	4.36e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
UCEC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.49	0.41	1.75e-7	Hemoglobin concentration;
UCEC	trans	rs1552172	0.922	rs12755149	chr1:145704918	T/A	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.81	-0.49	2.36e-10	Breast cancer;
UCEC	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.51	0.47	1.12e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg20749916	chr13:111767003	ARHGEF7	-0.83	-4.53	-0.35	1.23e-5	Obesity-related traits;
UCEC	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.52	-5.71	-0.43	6.04e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-7.87	-0.54	7.13e-13	Menarche (age at onset);
UCEC	cis	rs892864	0.685	rs1848501	chr5:127771987	G/A	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg06466757	chr4:1255808	NA	0.47	4.86	0.37	2.98e-6	Obesity-related traits;
UCEC	cis	rs115344852	0.598	rs2531815	chr6:28436060	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.53	-5.68	-0.42	7.04e-8	Epithelial ovarian cancer;
UCEC	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg11632617	chr15:75315747	PPCDC	-0.67	-7.71	-0.54	1.75e-12	Lung cancer;
UCEC	cis	rs17012589	0.639	rs1512735	chr12:85716764	C/T	cg02569458	chr12:86230093	RASSF9	0.39	4.53	0.35	1.23e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.74	-0.43	5.26e-8	Hypospadias;
UCEC	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.69	-6.79	-0.49	2.59e-10	Tonsillectomy;
UCEC	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-0.53	-5.24	-0.4	5.51e-7	Blood trace element (Zn levels);
UCEC	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.41	4.8	0.37	3.9e-6	Menarche (age at onset);
UCEC	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.57	5.12	0.39	9.51e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4851266	1.000	rs11687241	chr2:100824595	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	0.98	9.9	0.63	5.21e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.49	4.72	0.36	5.47e-6	High light scatter reticulocyte count;
UCEC	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg14008862	chr17:28927542	LRRC37B2	0.82	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.49	-4.9	-0.37	2.51e-6	Monocyte count;
UCEC	cis	rs638882	0.695	rs2512587	chr11:115738921	C/T	cg04087571	chr11:116723030	SIK3	-0.27	-4.51	-0.35	1.32e-5	Hip geometry;
UCEC	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.36	0.52	1.23e-11	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg19743168	chr1:23544995	NA	0.44	6.23	0.46	4.74e-9	Height;
UCEC	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg24703168	chr6:28411309	ZSCAN23	0.51	6.24	0.46	4.49e-9	Pubertal anthropometrics;
UCEC	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.61	-7.54	-0.53	4.45e-12	Hip circumference;
UCEC	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.58	4.51	0.35	1.32e-5	Major depressive disorder;
UCEC	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.54	-5.04	-0.38	1.34e-6	Metabolic syndrome;
UCEC	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.53	-5.28	-0.4	4.65e-7	Asthma (sex interaction);
UCEC	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-0.91	-11.76	-0.7	6.53e-23	Height;
UCEC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.71	-5.33	-0.4	3.54e-7	White matter hyperintensity burden;
UCEC	cis	rs1978968	0.956	rs8135939	chr22:18434284	A/G	cg03078520	chr22:18463400	MICAL3	-0.41	-4.6	-0.35	8.9e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.47	-5.46	-0.41	1.99e-7	Aortic root size;
UCEC	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	0.97	7.02	0.5	7.6e-11	Chin dimples;
UCEC	cis	rs7246967	0.611	rs3951785	chr19:22851928	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	6.57	0.48	8.06e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.35	-4.53	-0.35	1.22e-5	Coronary artery disease;
UCEC	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-11.73	-0.7	7.47e-23	Primary sclerosing cholangitis;
UCEC	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg04154034	chr17:28927549	LRRC37B2	0.82	5.2	0.39	6.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.32	0.46	2.9e-9	Bone mineral density;
UCEC	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.58	5.7	0.43	6.48e-8	Post bronchodilator FEV1;
UCEC	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.61	-7.39	-0.52	1.04e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.67	-0.48	4.88e-10	Aortic root size;
UCEC	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg18016565	chr1:150552671	MCL1	-0.45	-4.55	-0.35	1.1e-5	Melanoma;
UCEC	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg07522913	chr7:27150403	HOXA3	-0.59	-4.57	-0.35	1.02e-5	Type 1 diabetes;
UCEC	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg23795048	chr12:9217529	LOC144571	-0.4	-5.12	-0.39	9.43e-7	Sjögren's syndrome;
UCEC	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7246967	0.611	rs62118780	chr19:22831114	C/G	cg08271804	chr19:22816896	ZNF492	0.68	4.72	0.36	5.55e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Bladder cancer;
UCEC	cis	rs756777	0.702	rs62576516	chr9:136681103	G/T	cg14069709	chr9:136671979	VAV2	-0.39	-4.78	-0.37	4.25e-6	IgG glycosylation;
UCEC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs9470794	0.915	rs57630694	chr6:38012681	T/A	cg03458162	chr6:37400668	FTSJD2	0.88	5.24	0.4	5.49e-7	Type 2 diabetes;
UCEC	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	1.01	10.13	0.64	1.24e-18	Alcohol dependence;
UCEC	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.72	-6.58	-0.48	7.67e-10	Initial pursuit acceleration;
UCEC	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.77	7.69	0.54	1.97e-12	Ulcerative colitis;
UCEC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg22974920	chr21:40686053	BRWD1	0.59	4.77	0.37	4.46e-6	Cognitive function;
UCEC	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.64	0.48	5.77e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.85	9.05	0.6	7.86e-16	Mean corpuscular hemoglobin;
UCEC	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	6.84	0.49	2.03e-10	Gastritis;
UCEC	cis	rs17641971	0.684	rs11785391	chr8:49930203	G/T	cg00325661	chr8:49890786	NA	0.42	4.9	0.37	2.52e-6	Blood metabolite levels;
UCEC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-4.72	-0.36	5.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.59	6.04	0.45	1.23e-8	Initial pursuit acceleration;
UCEC	cis	rs8020441	0.945	rs57182174	chr14:51167938	A/T	cg04730355	chr14:51134070	SAV1	0.55	5.19	0.39	7.03e-7	Cognitive performance;
UCEC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.13	13.97	0.76	9.28e-29	Cognitive function;
UCEC	cis	rs7695597	0.708	rs7680050	chr4:185181276	C/T	cg12654155	chr4:185238627	NA	-0.44	-4.53	-0.35	1.22e-5	Night sleep phenotypes;
UCEC	cis	rs968451	0.865	rs2076125	chr22:39711351	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	5.09	0.39	1.09e-6	Primary biliary cholangitis;
UCEC	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.73	-9.18	-0.6	3.76e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.43	6.04	0.45	1.18e-8	Schizophrenia;
UCEC	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.03	0.45	1.25e-8	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg18479299	chr3:125709523	NA	-0.67	-4.59	-0.35	9.33e-6	Blood pressure (smoking interaction);
UCEC	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg24881330	chr22:46731750	TRMU	0.73	7.36	0.52	1.18e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg15513719	chr13:114904418	NA	0.49	4.86	0.37	2.92e-6	Schizophrenia;
UCEC	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.12	-0.6	5.33e-16	Height;
UCEC	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	7.7	0.54	1.89e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	6.52	0.47	1.04e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs9467773	0.967	rs9461272	chr6:26579648	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3750082	0.817	rs3750078	chr7:32969489	G/A	cg05721444	chr7:32995514	FKBP9	-0.54	-6.16	-0.45	6.55e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.68	-6.04	-0.45	1.23e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-4.74	-0.36	4.9e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg16616514	chr4:6324629	PPP2R2C	0.42	5.09	0.39	1.06e-6	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg23815491	chr16:72088622	HP	-0.38	-4.71	-0.36	5.58e-6	Fibrinogen levels;
UCEC	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.63	-6.55	-0.48	8.96e-10	Dental caries;
UCEC	cis	rs7204230	0.921	rs62049782	chr16:53298383	G/C	cg10109421	chr16:52641824	NA	0.4	4.59	0.35	9.25e-6	Fibrinogen;
UCEC	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-0.58	-7.13	-0.51	4.29e-11	Total body bone mineral density;
UCEC	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.54e-7	Life satisfaction;
UCEC	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.57	4.72	0.36	5.53e-6	Gut microbiome composition (summer);
UCEC	cis	rs16937	0.711	rs11240390	chr1:205179457	A/G	cg12580275	chr1:205744413	RAB7L1	0.48	5.15	0.39	8.09e-7	Schizophrenia;
UCEC	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.67	6.72	0.48	3.69e-10	Caffeine consumption;
UCEC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.72	-8.15	-0.56	1.5e-13	Menarche (age at onset);
UCEC	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg19318889	chr4:1322082	MAEA	0.5	5.46	0.41	1.95e-7	Obesity-related traits;
UCEC	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.53	-5.4	-0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	0.76	4.9	0.37	2.54e-6	Diabetic kidney disease;
UCEC	cis	rs11697848	1.000	rs117447227	chr20:48552370	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.5	5.29	0.4	4.31e-7	Initial pursuit acceleration;
UCEC	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.46	-5.36	-0.4	3.13e-7	Bipolar disorder;
UCEC	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.59	6.3	0.46	3.2e-9	Noise-induced hearing loss;
UCEC	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg17294928	chr15:75287854	SCAMP5	0.55	6.14	0.45	7.34e-9	Breast cancer;
UCEC	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.57	4.62	0.36	8.45e-6	Initial pursuit acceleration;
UCEC	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.09	0.39	1.09e-6	Body mass index;
UCEC	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-4.93	-0.38	2.17e-6	Morning vs. evening chronotype;
UCEC	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg06671706	chr8:8559999	CLDN23	0.66	5.32	0.4	3.8e-7	Obesity-related traits;
UCEC	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.57	5.72	0.43	5.83e-8	Colorectal cancer;
UCEC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.62	7.41	0.52	9.36e-12	Prudent dietary pattern;
UCEC	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.82	-8.93	-0.59	1.58e-15	Menopause (age at onset);
UCEC	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.48	-4.69	-0.36	6.21e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.74	-7.59	-0.53	3.46e-12	Mosquito bite size;
UCEC	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.66	7.08	0.5	5.54e-11	Blood protein levels;
UCEC	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.47	-0.41	1.86e-7	Morning vs. evening chronotype;
UCEC	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.23	-9.95	-0.63	3.8e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg04310649	chr10:35416472	CREM	-0.49	-4.62	-0.36	8.35e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.44	-4.64	-0.36	7.73e-6	Aortic root size;
UCEC	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg00343986	chr7:65444356	GUSB	-0.51	-4.5	-0.35	1.36e-5	Aortic root size;
UCEC	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.56	5.03	0.38	1.43e-6	Corneal astigmatism;
UCEC	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.62	-0.48	6.32e-10	Aortic root size;
UCEC	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.72	7.83	0.54	8.93e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.76	7.41	0.52	9.23e-12	Cognitive function;
UCEC	trans	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg15509575	chr4:2286509	ZFYVE28	-0.4	-6.88	-0.49	1.62e-10	Rheumatoid arthritis;
UCEC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.67	8.33	0.57	5.26e-14	Vitiligo;
UCEC	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.11	9.45	0.61	7.25e-17	Lymphocyte percentage of white cells;
UCEC	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.69	0.58	6.52e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.21	10.62	0.66	6.53e-20	Corneal structure;
UCEC	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	5.79	0.43	4.02e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.76	-6.85	-0.49	1.91e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.61	-5.35	-0.4	3.33e-7	Alcohol dependence;
UCEC	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg02160872	chr5:212506	CCDC127	-0.78	-7.94	-0.55	4.8e-13	Breast cancer;
UCEC	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.88	-10.7	-0.66	4.11e-20	Blood metabolite levels;
UCEC	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.77	4.83	0.37	3.41e-6	Glioblastoma;
UCEC	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.97	-11.15	-0.68	2.6e-21	Height;
UCEC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.73	7.51	0.53	5.27e-12	Lymphocyte counts;
UCEC	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg01072550	chr1:21505969	NA	-0.57	-5.58	-0.42	1.13e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.42	-6.04	-0.45	1.18e-8	Rheumatoid arthritis;
UCEC	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-5.71	-0.43	6.16e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.42	-4.99	-0.38	1.67e-6	Refractive error;
UCEC	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.38	-4.61	-0.36	8.61e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	0.77	5.11	0.39	1.01e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	0.82	5.85	0.43	3.1e-8	Iron status biomarkers;
UCEC	cis	rs10924970	0.870	rs12095886	chr1:235432249	A/G	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.74e-6	Asthma;
UCEC	cis	rs514475	1.000	rs514475	chr6:138038905	A/C	cg26287741	chr6:138867125	NHSL1	0.75	4.71	0.36	5.67e-6	Inflammatory skin disease;
UCEC	cis	rs10506710	0.791	rs7974733	chr12:73442704	C/T	cg13663218	chr12:72666976	LOC283392;TRHDE	0.34	4.99	0.38	1.67e-6	Systolic blood pressure;
UCEC	trans	rs1459104	0.925	rs67465952	chr11:55194045	T/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg07404485	chr7:94953653	PON1	-0.45	-4.57	-0.35	1.02e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.58	-5.08	-0.39	1.14e-6	Metabolite levels;
UCEC	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.16	-0.51	3.52e-11	Breast cancer;
UCEC	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.47	5.25	0.4	5.2e-7	Systemic lupus erythematosus;
UCEC	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.36	-4.76	-0.37	4.59e-6	Total body bone mineral density;
UCEC	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.42	5.59	0.42	1.08e-7	Blood protein levels;
UCEC	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.42	4.53	0.35	1.22e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.62	7.08	0.5	5.56e-11	Heart rate;
UCEC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg15358701	chr1:161410459	NA	-0.81	-5.06	-0.39	1.21e-6	Rheumatoid arthritis;
UCEC	cis	rs953387	1.000	rs1401687	chr2:136908062	G/C	cg07169764	chr2:136633963	MCM6	0.53	5.45	0.41	2.06e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg16583315	chr14:65563665	MAX	-0.47	-5.02	-0.38	1.51e-6	Obesity-related traits;
UCEC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg24881330	chr22:46731750	TRMU	0.75	7.51	0.53	5.23e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.6	6.24	0.46	4.49e-9	Ulcerative colitis;
UCEC	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	3.14e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246967	0.673	rs67631531	chr19:22830466	A/G	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.57	5.11	0.39	9.98e-7	Corneal astigmatism;
UCEC	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.48	-5.55	-0.42	1.32e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.84	-0.37	3.32e-6	Response to antipsychotic treatment;
UCEC	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.65	6.61	0.48	6.79e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg07250515	chr12:56618133	OBFC2B	-0.63	-5.69	-0.42	6.78e-8	Psoriasis vulgaris;
UCEC	cis	rs6761276	0.932	rs10186133	chr2:113836944	G/T	cg09040174	chr2:113837401	NA	0.5	5.24	0.4	5.36e-7	Protein quantitative trait loci;
UCEC	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.73	7.03	0.5	7.05e-11	Menopause (age at onset);
UCEC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.82	8.89	0.59	2.06e-15	Cognitive function;
UCEC	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.56	5.16	0.39	7.75e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.59	-6.27	-0.46	3.72e-9	Longevity;Endometriosis;
UCEC	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-4.9	-0.37	2.5e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.72	5.42	0.41	2.43e-7	Response to hepatitis C treatment;
UCEC	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.67	7.98	0.55	3.9e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs7246967	0.544	rs391308	chr19:23009560	T/C	cg08271804	chr19:22816896	ZNF492	0.49	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.68	6.04	0.45	1.21e-8	High light scatter reticulocyte count;
UCEC	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.45	4.54	0.35	1.16e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-6.39	-0.47	2.07e-9	Response to antipsychotic treatment;
UCEC	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg20965017	chr5:231967	SDHA	-0.62	-5.25	-0.4	5.25e-7	Breast cancer;
UCEC	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg10932868	chr11:921992	NA	0.42	5.53	0.41	1.45e-7	Alzheimer's disease (late onset);
UCEC	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg21770322	chr7:97807741	LMTK2	0.53	6.71	0.48	3.97e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4713118	0.614	rs9380007	chr6:27660508	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.49	-5.0	-0.38	1.62e-6	Parkinson's disease;
UCEC	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.68	7.51	0.53	5.3e-12	IgG glycosylation;
UCEC	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg09998033	chr7:158218633	PTPRN2	-0.46	-4.6	-0.35	9.2e-6	Obesity-related traits;
UCEC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.52	4.7	0.36	5.84e-6	Cognitive ability;
UCEC	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.7	6.9	0.49	1.41e-10	Response to antineoplastic agents;
UCEC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08822215	chr16:89438651	ANKRD11	-0.6	-5.8	-0.43	3.88e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg21191810	chr6:118973309	C6orf204	0.42	5.82	0.43	3.49e-8	Electrocardiographic conduction measures;
UCEC	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.49	5.33	0.4	3.6e-7	Monocyte count;
UCEC	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.5	4.69	0.36	6.3e-6	Handedness;
UCEC	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.99	10.13	0.64	1.29e-18	Cognitive ability;
UCEC	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg11131117	chr7:1891496	MAD1L1	-0.37	-5.08	-0.39	1.12e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg09120320	chr17:61926383	NA	0.41	4.57	0.35	1.04e-5	Prudent dietary pattern;
UCEC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.72	-0.54	1.61e-12	Diastolic blood pressure;
UCEC	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	0.69	8.88	0.59	2.13e-15	Gut microbiome composition (winter);
UCEC	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.75	-6.41	-0.47	1.85e-9	Longevity;
UCEC	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.52	-5.63	-0.42	8.87e-8	Menarche (age at onset);
UCEC	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	4.74	0.36	4.98e-6	Hemoglobin concentration;
UCEC	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.81	8.58	0.58	1.21e-14	Neuroticism;
UCEC	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg24112000	chr20:60950667	NA	0.38	4.58	0.35	9.65e-6	Colorectal cancer;
UCEC	cis	rs7517126	1.000	rs35155714	chr1:196838929	C/A	cg07209298	chr1:196795943	CFHR1	0.51	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.71	-7.62	-0.53	2.8e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.52	-0.35	1.25e-5	Homocysteine levels;
UCEC	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.18	9.82	0.63	8.37e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.37	-5.2	-0.39	6.47e-7	Melanoma;
UCEC	cis	rs8099014	0.861	rs4940703	chr18:56115386	A/G	cg19165390	chr18:56932082	NA	0.38	4.78	0.37	4.18e-6	Platelet count;
UCEC	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.38	-0.41	2.85e-7	Response to antipsychotic treatment;
UCEC	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.64	6.06	0.45	1.1e-8	Coronary artery disease;
UCEC	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.56	5.77	0.43	4.58e-8	Monocyte count;
UCEC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.79	-9.17	-0.6	4.01e-16	Menarche (age at onset);
UCEC	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-0.77	-6.84	-0.49	2.03e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.32	0.4	3.8e-7	Diabetic retinopathy;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.63	-7.93	-0.55	5.03e-13	Pubertal anthropometrics;
UCEC	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg17526145	chr2:23869158	KLHL29	0.42	4.64	0.36	7.71e-6	Asthma;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.4	4.59	0.35	9.32e-6	Pulse pressure;
UCEC	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.64	6.26	0.46	3.99e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.54	4.7	0.36	6e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.35	-0.4	3.33e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.7	8.01	0.55	3.29e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	0.82	7.11	0.51	4.68e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg11437231	chr11:47291487	MADD	0.51	5.3	0.4	4.14e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs2289700	1.000	rs16970287	chr15:79228257	A/G	cg25744700	chr15:79237217	CTSH	-0.73	-4.6	-0.35	9.09e-6	Bipolar disorder;
UCEC	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.62	-5.54	-0.42	1.34e-7	Metabolite levels;
UCEC	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg06758158	chr16:89114156	NA	-0.72	-5.05	-0.38	1.31e-6	Red blood cell count;
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.99	-8.99	-0.6	1.11e-15	Platelet count;
UCEC	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.63	-6.03	-0.45	1.3e-8	Urate levels in obese individuals;
UCEC	cis	rs4372836	0.729	rs10166861	chr2:29061111	A/G	cg09522027	chr2:28974177	PPP1CB	-0.72	-8.15	-0.56	1.5e-13	Body mass index;
UCEC	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.36	-4.65	-0.36	7.23e-6	Refractive error;
UCEC	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg11189052	chr15:85197271	WDR73	0.57	4.55	0.35	1.13e-5	Schizophrenia;
UCEC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.56	0.48	8.66e-10	Aortic root size;
UCEC	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.62	6.98	0.5	9.23e-11	Pubertal anthropometrics;
UCEC	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	6.5	0.47	1.16e-9	Bone mineral density;
UCEC	cis	rs11867410	0.744	rs73349012	chr17:63927666	C/T	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.55	-0.48	8.89e-10	Pubertal anthropometrics;
UCEC	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.97	9.86	0.63	6.57e-18	IgG glycosylation;
UCEC	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg18681998	chr4:17616180	MED28	0.79	9.26	0.61	2.27e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4792901	0.959	rs9899005	chr17:41642868	C/T	cg04503457	chr17:41445688	NA	0.49	4.59	0.35	9.47e-6	Dupuytren's disease;
UCEC	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.44	4.78	0.37	4.13e-6	HDL cholesterol;
UCEC	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.47	4.68	0.36	6.56e-6	Gout;
UCEC	cis	rs1425902	0.554	rs1425905	chr8:54131001	C/T	cg01281904	chr8:54164757	OPRK1	-0.39	-4.82	-0.37	3.53e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.48	4.67	0.36	6.7e-6	Cognitive function;
UCEC	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.54	-5.42	-0.41	2.43e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.45	6.68	0.48	4.53e-10	Ulcerative colitis;
UCEC	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.66	0.36	7.06e-6	Multiple sclerosis;
UCEC	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.39	5.47	0.41	1.91e-7	Crohn's disease;
UCEC	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.5	5.08	0.39	1.14e-6	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.56	-7.16	-0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.35	5.81	0.43	3.81e-8	Cancer;
UCEC	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.56	0.35	1.06e-5	Breast cancer;
UCEC	cis	rs7246967	0.866	rs12972095	chr19:23034510	C/A	cg05241461	chr19:22816980	ZNF492	0.5	5.14	0.39	8.65e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.47	-5.58	-0.42	1.14e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.38	4.76	0.37	4.56e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.61	5.27	0.4	4.67e-7	Heart rate;
UCEC	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.58	-0.42	1.11e-7	Bipolar disorder;
UCEC	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.68	6.98	0.5	9.48e-11	Body mass index;
UCEC	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.99	11.0	0.67	6.49e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg22974920	chr21:40686053	BRWD1	0.6	5.3	0.4	4.13e-7	Cognitive function;
UCEC	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.6	5.52	0.41	1.5e-7	Menarche (age at onset);
UCEC	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-5.62	-0.42	9.37e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.75	-8.79	-0.59	3.64e-15	Obesity-related traits;
UCEC	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg23093090	chr10:104574429	C10orf26	-0.45	-5.05	-0.38	1.31e-6	Waist circumference;Hip circumference;
UCEC	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg18479299	chr3:125709523	NA	-0.65	-4.5	-0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.56	7.7	0.54	1.88e-12	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
UCEC	cis	rs56341938	0.679	rs6772430	chr3:168824165	T/C	cg21477417	chr3:169490753	MYNN	0.51	4.99	0.38	1.68e-6	Lung function (FEV1/FVC);
UCEC	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.61	-6.14	-0.45	7.32e-9	C-reactive protein levels;
UCEC	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9825420	1.000	rs17828523	chr3:37606770	A/G	cg15682617	chr3:38589863	SCN5A	-0.65	-4.55	-0.35	1.14e-5	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.61	5.53	0.42	1.42e-7	Corneal astigmatism;
UCEC	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.84	7.84	0.54	8.65e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.85	5.28	0.4	4.59e-7	Diisocyanate-induced asthma;
UCEC	cis	rs10786436	0.642	rs4919233	chr10:100283151	T/G	cg24343515	chr10:99400468	PI4K2A	-0.46	-4.67	-0.36	6.68e-6	Type 1 diabetes;
UCEC	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.69	6.89	0.49	1.49e-10	Menopause (age at onset);
UCEC	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.71	-6.45	-0.47	1.52e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1165472	0.755	rs12566150	chr1:56160904	C/G	cg11523071	chr1:56160889	NA	-0.51	-4.91	-0.38	2.41e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.73	6.86	0.49	1.76e-10	Selective IgA deficiency;
UCEC	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.43	4.59	0.35	9.57e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg26114124	chr12:9217669	LOC144571	0.41	4.74	0.36	4.98e-6	Sjögren's syndrome;
UCEC	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.47	-5.61	-0.42	9.66e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.19	0.39	6.84e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.44	-4.62	-0.36	8.32e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.57	-5.35	-0.4	3.36e-7	Coronary artery disease;
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.42	0.72	1.17e-24	Platelet count;
UCEC	cis	rs12980942	0.935	rs11880564	chr19:41831196	C/A	cg25627403	chr19:41769009	HNRNPUL1	0.75	5.88	0.44	2.68e-8	Coronary artery disease;
UCEC	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-5.17	-0.39	7.68e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.02	7.94	0.55	4.83e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	0.8	6.16	0.45	6.53e-9	Corneal structure;
UCEC	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.73	-6.0	-0.44	1.46e-8	Coronary artery disease;
UCEC	cis	rs970548	0.954	rs10466245	chr10:46031747	G/A	cg15223267	chr10:46222474	FAM21C	0.57	5.18	0.39	7.26e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	5.23	0.4	5.68e-7	Platelet count;
UCEC	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.46	5.13	0.39	9.11e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-4.62	-0.36	8.26e-6	Aortic root size;
UCEC	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.15	-12.07	-0.71	9.69e-24	Ulcerative colitis;
UCEC	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg07615347	chr10:60278583	BICC1	0.4	4.55	0.35	1.12e-5	Refractive error;
UCEC	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.15	-0.45	7.06e-9	Pulmonary function;
UCEC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.77	9.09	0.6	6.13e-16	Menarche (age at onset);
UCEC	cis	rs74542309	1.000	rs34232710	chr10:72555361	C/A	cg15763670	chr10:73473235	C10orf105;CDH23	-0.62	-4.89	-0.37	2.62e-6	Pursuit maintenance gain;
UCEC	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.6	7.0	0.5	8.33e-11	Blood metabolite ratios;
UCEC	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.59	-5.11	-0.39	9.69e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.39	-5.26	-0.4	5.1e-7	Mean corpuscular volume;
UCEC	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.41	4.59	0.35	9.45e-6	Monocyte count;
UCEC	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.51	5.45	0.41	2.1e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-10.38	-0.65	2.74e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.59	-5.3	-0.4	4.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.54	5.45	0.41	2.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.53	-4.88	-0.37	2.75e-6	Diastolic blood pressure;
UCEC	cis	rs17123764	0.892	rs11169097	chr12:50052596	A/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.32	0.4	3.85e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.87	9.15	0.6	4.45e-16	Cognitive function;
UCEC	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.49	4.82	0.37	3.49e-6	Menopause (age at onset);
UCEC	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.53	-5.64	-0.42	8.41e-8	Brugada syndrome;
UCEC	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.87	0.49	1.69e-10	Coronary artery disease;
UCEC	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.58	-6.02	-0.44	1.32e-8	Morning vs. evening chronotype;
UCEC	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs6540731	1.000	rs951623	chr1:212399062	T/C	cg07569918	chr1:212002970	LPGAT1	-0.41	-5.18	-0.39	7.29e-7	Intelligence (childhood);
UCEC	cis	rs1318772	0.866	rs13161969	chr5:112865809	A/C	cg12552261	chr5:112820674	MCC	0.82	5.34	0.4	3.52e-7	F-cell distribution;
UCEC	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg06521331	chr12:34319734	NA	-0.63	-5.0	-0.38	1.64e-6	Morning vs. evening chronotype;
UCEC	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	5.05	0.38	1.27e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.8	9.63	0.62	2.59e-17	Menarche (age at onset);
UCEC	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.79	9.82	0.63	8.29e-18	Body mass index;
UCEC	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.81	7.86	0.54	7.33e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.64	6.94	0.5	1.18e-10	Mortality in heart failure;
UCEC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.55	5.44	0.41	2.19e-7	Response to diuretic therapy;
UCEC	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-4.5	-0.35	1.36e-5	Life satisfaction;
UCEC	cis	rs3743832	0.966	rs6498426	chr16:9182577	C/T	cg08831531	chr16:9218945	NA	-0.45	-4.9	-0.37	2.49e-6	Non-substance related behavioral disinhibition;Behavioural disinhibition (generation interaction);
UCEC	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.99	-12.1	-0.71	8.2e-24	Cognitive function;
UCEC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.54	-4.78	-0.37	4.19e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs36051895	0.626	rs7870694	chr9:5100628	T/C	cg02405213	chr9:5042618	JAK2	-0.53	-5.25	-0.4	5.32e-7	Pediatric autoimmune diseases;
UCEC	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg17420585	chr12:42539391	GXYLT1	-0.45	-5.6	-0.42	1.01e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	5.91	0.44	2.28e-8	Response to antipsychotic treatment;
UCEC	cis	rs17123764	0.892	rs7136052	chr12:50110736	A/T	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.62	6.81	0.49	2.33e-10	Bipolar disorder;
UCEC	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.98	0.7	1.65e-23	Prudent dietary pattern;
UCEC	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24308560	chr3:49941425	MST1R	0.45	4.83	0.37	3.41e-6	Body mass index;
UCEC	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.66	6.2	0.46	5.32e-9	Corneal astigmatism;
UCEC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg19743168	chr1:23544995	NA	0.48	6.44	0.47	1.61e-9	Height;
UCEC	cis	rs17034641	1.000	rs12990867	chr2:46372411	G/A	cg12428440	chr2:46370979	PRKCE	0.6	4.84	0.37	3.21e-6	Hemoglobin;Hematocrit;
UCEC	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03576123	chr11:487126	PTDSS2	-0.96	-7.01	-0.5	8.17e-11	Body mass index;
UCEC	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.67	8.49	0.57	2.11e-14	Menopause (age at onset);
UCEC	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3015497	0.789	rs10133849	chr14:51121700	A/G	cg04730355	chr14:51134070	SAV1	-0.48	-4.9	-0.37	2.46e-6	Mean platelet volume;
UCEC	cis	rs7766436	0.770	rs11751669	chr6:22571037	A/G	cg13666174	chr6:22585274	NA	-0.59	-6.22	-0.46	4.85e-9	Coronary artery disease;
UCEC	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.88	9.96	0.63	3.57e-18	Ulcerative colitis;
UCEC	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19500275	chr17:80737654	TBCD	-0.49	-4.87	-0.37	2.84e-6	Glycated hemoglobin levels;
UCEC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg00316803	chr15:76480434	C15orf27	-0.45	-5.41	-0.41	2.51e-7	Blood metabolite levels;
UCEC	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.57	-4.62	-0.36	8.32e-6	Menopause (age at onset);
UCEC	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-4.55	-0.35	1.1e-5	Tonsillectomy;
UCEC	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.16	-0.39	7.88e-7	Pediatric autoimmune diseases;
UCEC	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg00500100	chr5:140098250	VTRNA1-2	0.33	4.51	0.35	1.34e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.39	-0.41	2.72e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.84	0.49	1.99e-10	Coffee consumption (cups per day);
UCEC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.49	5.56	0.42	1.21e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.55	-5.47	-0.41	1.88e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.34	-0.4	3.45e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13880726	chr7:1868755	MAD1L1	0.46	4.59	0.35	9.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs250585	0.736	rs30014	chr16:23415898	C/T	cg26562691	chr16:23850404	PRKCB	0.37	4.77	0.37	4.38e-6	Egg allergy;
UCEC	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.59	4.54	0.35	1.17e-5	Mean platelet volume;
UCEC	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07988820	chr12:82153109	PPFIA2	0.58	5.0	0.38	1.58e-6	Resting heart rate;
UCEC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.7	8.7	0.58	6.21e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.24e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.61	-6.71	-0.48	4.02e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-0.64	-5.76	-0.43	4.8e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg22563815	chr15:78856949	CHRNA5	0.39	4.76	0.37	4.64e-6	Sudden cardiac arrest;
UCEC	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.72	-7.67	-0.53	2.18e-12	Breast cancer;
UCEC	cis	rs7570971	1.000	rs7570971	chr2:135837906	C/A	cg07169764	chr2:136633963	MCM6	0.59	5.36	0.4	3.09e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
UCEC	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg13206674	chr6:150067644	NUP43	0.51	4.7	0.36	5.94e-6	Testicular germ cell tumor;
UCEC	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.4	4.54	0.35	1.17e-5	Mean platelet volume;
UCEC	trans	rs2131877	0.529	rs4677813	chr3:194863860	T/C	cg08834050	chr6:43022109	CUL7;MRPL2	0.61	6.74	0.49	3.37e-10	Non-small cell lung cancer;
UCEC	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.77e-9	Blood metabolite levels;
UCEC	cis	rs12644436	0.896	rs13144147	chr4:88785315	G/C	cg27179352	chr4:88029472	AFF1	0.41	4.51	0.35	1.32e-5	HIV-1 viral setpoint;
UCEC	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-6.55	-0.48	9.06e-10	Parkinson's disease;
UCEC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-6.7	-0.48	4.06e-10	Platelet count;
UCEC	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-5.35	-0.4	3.3e-7	Recalcitrant atopic dermatitis;
UCEC	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-7.35	-0.52	1.25e-11	Exhaled nitric oxide output;
UCEC	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06156847	chr2:113672199	IL1F7	0.33	4.76	0.37	4.54e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.6	6.77	0.49	2.94e-10	Red blood cell count;
UCEC	cis	rs9393813	0.516	rs4713098	chr6:27403605	C/T	cg27490387	chr6:26520793	HCG11	-0.42	-4.78	-0.37	4.14e-6	Bipolar disorder;
UCEC	cis	rs7582720	0.943	rs76122535	chr2:203664929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.9	0.37	2.51e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs16937	0.711	rs3851289	chr1:205149657	G/T	cg12580275	chr1:205744413	RAB7L1	0.49	5.33	0.4	3.66e-7	Schizophrenia;
UCEC	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg11813489	chr14:105363835	NA	0.36	4.8	0.37	3.88e-6	IgG glycosylation;
UCEC	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18099408	chr3:52552593	STAB1	-0.49	-5.74	-0.43	5.13e-8	Electroencephalogram traits;
UCEC	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-6.04	-0.45	1.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26002218	chr14:103986227	CKB	-0.33	-4.69	-0.36	6.26e-6	Body mass index;
UCEC	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.63	-5.39	-0.41	2.74e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg25306006	chr11:71932630	FOLR2	-0.4	-4.57	-0.35	1.04e-5	Vitamin D levels;
UCEC	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.85	12.3	0.71	2.38e-24	Leprosy;
UCEC	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.51	5.01	0.38	1.52e-6	Bladder cancer;
UCEC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.7	0.48	4.07e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.6	5.64	0.42	8.61e-8	Tourette syndrome;
UCEC	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs12618769	0.625	rs3769733	chr2:99100716	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.58	-0.35	1e-5	Bipolar disorder;
UCEC	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.5	4.92	0.38	2.26e-6	Emphysema distribution in smoking;
UCEC	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	4.95	0.38	2.04e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.89	5.82	0.43	3.49e-8	Platelet count;
UCEC	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.63	-5.45	-0.41	2.05e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.21	-0.51	2.69e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs256277	0.657	rs168873	chr5:111369219	A/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-4.51	-0.35	1.32e-5	Coronary artery disease;
UCEC	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.48e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.43	0.41	2.29e-7	Cognitive function;
UCEC	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.54	5.1	0.39	1.01e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs17106184	1.000	rs80297338	chr1:51255677	C/A	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.56	-5.57	-0.42	1.18e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.67	-8.53	-0.58	1.69e-14	Menopause (age at onset);
UCEC	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.67	-4.79	-0.37	4.08e-6	Rheumatoid arthritis;
UCEC	cis	rs17102884	0.541	rs8004430	chr14:75171683	C/T	cg16124934	chr14:75389480	RPS6KL1	-0.48	-4.73	-0.36	5.13e-6	Neuroticism;
UCEC	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.53	-5.1	-0.39	1.02e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2200578	1.000	rs116648076	chr2:99882347	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.77	5.38	0.41	2.94e-7	IgG glycosylation;
UCEC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.75	8.38	0.57	4.02e-14	Lymphocyte counts;
UCEC	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.61	-0.62	2.81e-17	Primary sclerosing cholangitis;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.03	-0.45	1.25e-8	Pubertal anthropometrics;
UCEC	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.56	5.22	0.4	6.02e-7	Menarche (age at onset);
UCEC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.55	5.41	0.41	2.47e-7	Menopause (age at onset);
UCEC	cis	rs7101446	0.704	rs7937356	chr11:63186494	C/A	cg21706343	chr11:62521476	ZBTB3	-0.53	-4.62	-0.36	8.38e-6	Economic and political preferences;
UCEC	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.77	7.67	0.53	2.23e-12	Lung cancer;
UCEC	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.78	-4.73	-0.36	5.25e-6	Skin colour saturation;
UCEC	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg13147721	chr7:65941812	NA	-0.91	-5.58	-0.42	1.13e-7	Diabetic kidney disease;
UCEC	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.69	6.07	0.45	1.03e-8	Bipolar disorder;
UCEC	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg22563815	chr15:78856949	CHRNA5	0.41	5.1	0.39	1.01e-6	Sudden cardiac arrest;
UCEC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.45	-0.41	2.09e-7	Birth weight;
UCEC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.68	6.35	0.46	2.56e-9	Menarche (age at onset);
UCEC	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-5.16	-0.39	7.86e-7	Personality dimensions;
UCEC	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.53	5.78	0.43	4.31e-8	White blood cell count (basophil);
UCEC	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.2	-0.46	5.32e-9	Height;
UCEC	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.47	-4.68	-0.36	6.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.52	5.53	0.42	1.42e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.43	0.41	2.27e-7	Cognitive test performance;
UCEC	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.41	5.2	0.39	6.6e-7	QRS complex (12-leadsum);
UCEC	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg19743168	chr1:23544995	NA	0.45	6.28	0.46	3.58e-9	Height;
UCEC	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.54	-5.43	-0.41	2.3e-7	Longevity;Endometriosis;
UCEC	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg24531977	chr5:56204891	C5orf35	0.5	5.08	0.39	1.15e-6	Coronary artery disease;
UCEC	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.62	0.42	9.13e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.68	-6.78	-0.49	2.66e-10	Diastolic blood pressure;
UCEC	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.64	5.41	0.41	2.49e-7	Alzheimer's disease;
UCEC	cis	rs4654899	0.680	rs10799670	chr1:21179445	T/C	cg01072550	chr1:21505969	NA	0.55	5.73	0.43	5.42e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg11871910	chr12:69753446	YEATS4	-1.07	-13.56	-0.75	1.11e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.12	-0.39	9.32e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-5.4	-0.41	2.68e-7	Response to antipsychotic treatment;
UCEC	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Alcohol dependence;
UCEC	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.52	-4.98	-0.38	1.76e-6	Addiction;
UCEC	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	6.03	0.45	1.24e-8	Response to bleomycin (chromatid breaks);
UCEC	cis	rs259282	0.524	rs1559180	chr19:33127443	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	7.19	0.51	3.08e-11	Schizophrenia;
UCEC	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	1.02	5.21	0.39	6.2e-7	Age-related hearing impairment;
UCEC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg24851651	chr11:66362959	CCS	-0.47	-5.38	-0.41	2.92e-7	Educational attainment (years of education);
UCEC	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.45	-5.09	-0.39	1.1e-6	Obesity-related traits;
UCEC	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.46	4.74	0.36	4.99e-6	Prostate cancer;
UCEC	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	8.38	0.57	3.94e-14	Schizophrenia;
UCEC	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.55	5.31	0.4	4.06e-7	Platelet count;
UCEC	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.52	5.8	0.43	3.95e-8	Height;
UCEC	cis	rs9467773	1.000	rs1570059	chr6:26573325	C/T	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2221651	0.588	rs112999871	chr6:131014797	A/G	cg16963127	chr6:131336044	EPB41L2	-0.59	-4.98	-0.38	1.73e-6	Monocyte percentage of white cells;
UCEC	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.87	0.44	2.72e-8	Menarche (age at onset);
UCEC	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-6.44	-0.47	1.58e-9	Gut microbiome composition (summer);
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.52	5.79	0.43	4.2e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs4654899	0.680	rs6692553	chr1:21221497	C/T	cg01072550	chr1:21505969	NA	0.55	5.84	0.43	3.29e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.83	9.16	0.6	4.24e-16	Metabolite levels;
UCEC	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.91	8.82	0.59	3.13e-15	Platelet count;
UCEC	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg11189052	chr15:85197271	WDR73	0.58	4.57	0.35	1.01e-5	Schizophrenia;
UCEC	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg00873616	chr20:43920241	NA	0.51	5.0	0.38	1.62e-6	Blood protein levels;
UCEC	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.47	-5.49	-0.41	1.69e-7	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs73129298	0.551	rs12624963	chr20:48592847	G/A	cg25655593	chr20:48599521	SNAI1	0.6	4.55	0.35	1.14e-5	Inflammatory skin disease;
UCEC	cis	rs6137726	0.508	rs975525	chr20:22640412	G/A	cg08244522	chr20:23030533	THBD	-0.46	-4.6	-0.35	9.13e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.62	0.42	9.43e-8	Psoriasis;
UCEC	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.81	-9.22	-0.61	2.96e-16	Primary sclerosing cholangitis;
UCEC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.65	-7.58	-0.53	3.67e-12	Body mass index;
UCEC	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg23307798	chr14:103986281	CKB	0.56	5.38	0.41	2.89e-7	Body mass index;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.53	-5.76	-0.43	4.7e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.67	-5.91	-0.44	2.31e-8	QRS complex (12-leadsum);
UCEC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.12	13.93	0.75	1.17e-28	Cognitive function;
UCEC	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.0	0.38	1.58e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs3770752	0.823	rs10190959	chr2:37539576	A/T	cg20091297	chr2:37572423	QPCT	0.48	4.85	0.37	3.18e-6	Schizophrenia;
UCEC	cis	rs12618769	0.597	rs72821920	chr2:99111591	A/G	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs2213920	0.679	rs4979534	chr9:118211159	T/C	cg13918206	chr9:118159781	DEC1	0.81	5.49	0.41	1.69e-7	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.32	-0.4	3.81e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.61	-6.81	-0.49	2.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7911264	0.628	rs6583833	chr10:94409800	C/T	cg00519463	chr10:94352821	KIF11	-0.51	-5.07	-0.39	1.2e-6	Inflammatory bowel disease;
UCEC	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg06784218	chr1:46089804	CCDC17	0.44	5.07	0.39	1.2e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs970548	0.908	rs11239538	chr10:45994596	G/C	cg15223267	chr10:46222474	FAM21C	0.54	5.15	0.39	8.09e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg22857025	chr5:266934	NA	-0.99	-9.3	-0.61	1.82e-16	Breast cancer;
UCEC	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg02269571	chr22:50332266	NA	-0.52	-5.03	-0.38	1.43e-6	Schizophrenia;
UCEC	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.51	2.57e-11	Coronary artery disease;
UCEC	cis	rs13401104	0.796	rs11887959	chr2:237114894	C/T	cg23897927	chr2:237117786	ASB18	-0.52	-4.67	-0.36	6.7e-6	Educational attainment;
UCEC	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	0.89	9.25	0.61	2.49e-16	Left atrial antero-posterior diameter;
UCEC	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.86	12.3	0.71	2.41e-24	Leprosy;
UCEC	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg02158880	chr13:53174818	NA	0.56	6.46	0.47	1.45e-9	Lewy body disease;
UCEC	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg18681998	chr4:17616180	MED28	0.78	9.14	0.6	4.73e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.62	-6.21	-0.46	5.17e-9	Breast cancer;
UCEC	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg17031739	chr1:67600172	NA	0.46	4.87	0.37	2.86e-6	Psoriasis;
UCEC	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg05991184	chr2:219186017	PNKD	0.49	5.13	0.39	9.11e-7	Colorectal cancer;
UCEC	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.91	9.56	0.62	3.93e-17	Cognitive function;
UCEC	cis	rs17854409	0.764	rs8114722	chr20:61478492	G/A	cg05147244	chr20:61493195	TCFL5	1.01	5.65	0.42	7.96e-8	Obesity-related traits;
UCEC	cis	rs2425143	1.000	rs17093026	chr20:34318911	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	4.96	0.38	1.9e-6	Blood protein levels;
UCEC	cis	rs12339094	1.000	rs12339094	chr9:90410222	A/C	cg14178383	chr9:91347716	NA	0.55	4.86	0.37	3.02e-6	Smoking quantity;
UCEC	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg23791538	chr6:167370224	RNASET2	-0.51	-4.98	-0.38	1.72e-6	Crohn's disease;
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.99	0.64	2.95e-18	Platelet count;
UCEC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg20891283	chr12:69753455	YEATS4	0.6	5.13	0.39	8.98e-7	Response to diuretic therapy;
UCEC	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.58	6.54	0.47	9.5e-10	Menarche (age at onset);
UCEC	cis	rs2376682	0.918	rs6891349	chr5:118015506	A/G	cg17593721	chr5:118788746	HSD17B4	-0.51	-4.64	-0.36	7.73e-6	Diisocyanate-induced asthma;
UCEC	cis	rs1823913	0.503	rs35672076	chr2:192208633	C/T	cg15998761	chr2:191300784	MFSD6	0.41	4.74	0.36	4.94e-6	Obesity-related traits;
UCEC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.77	8.56	0.58	1.35e-14	Immature fraction of reticulocytes;
UCEC	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.21	0.56	1.05e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.51e-7	Hemoglobin concentration;
UCEC	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg05802129	chr4:122689817	NA	-0.54	-5.56	-0.42	1.22e-7	Type 2 diabetes;
UCEC	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg22166914	chr1:53195759	ZYG11B	-0.75	-7.75	-0.54	1.4e-12	Monocyte count;
UCEC	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg13695892	chr22:41940480	POLR3H	-0.52	-5.2	-0.39	6.5e-7	Vitiligo;
UCEC	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg03354898	chr7:1950403	MAD1L1	-0.56	-5.49	-0.41	1.7e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.84	0.43	3.15e-8	Height;
UCEC	cis	rs172166	0.561	rs149973	chr6:27983613	G/T	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.96	-0.44	1.82e-8	Cardiac Troponin-T levels;
UCEC	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg09555818	chr19:45449301	APOC2	0.47	6.25	0.46	4.3e-9	Blood protein levels;
UCEC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.8e-6	Tonsillectomy;
UCEC	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg09521647	chr2:100722408	AFF3	-0.31	-4.81	-0.37	3.77e-6	Chronic sinus infection;
UCEC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.63	-9.23	-0.61	2.78e-16	Prudent dietary pattern;
UCEC	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.49	-4.86	-0.37	2.96e-6	Obesity-related traits;
UCEC	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.58	6.01	0.44	1.42e-8	Pulse pressure;
UCEC	cis	rs17824620	0.548	rs2158241	chr12:113124351	G/A	cg26711794	chr12:112450906	ERP29;TMEM116	0.6	4.85	0.37	3.18e-6	Platelet count;
UCEC	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg13319975	chr6:146136371	FBXO30	-0.45	-4.58	-0.35	9.96e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7088591	0.867	rs76314630	chr10:59784853	A/G	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs2172802	0.570	rs2036199	chr4:62540857	A/C	cg04118610	chr4:62707027	LPHN3	0.42	4.86	0.37	3e-6	Partial epilepsies;
UCEC	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.85	-0.37	3.06e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.86	6.11	0.45	8.58e-9	Exhaled nitric oxide output;
UCEC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg17105886	chr17:28927953	LRRC37B2	0.5	4.86	0.37	3.02e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11048434	1.000	rs11048434	chr12:9153932	G/A	cg23795048	chr12:9217529	LOC144571	0.47	5.16	0.39	8.04e-7	Sjögren's syndrome;
UCEC	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.03	-0.5	7.06e-11	Breast cancer;
UCEC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg19318889	chr4:1322082	MAEA	0.46	4.91	0.38	2.4e-6	Obesity-related traits;
UCEC	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.85	6.88	0.49	1.61e-10	Initial pursuit acceleration;
UCEC	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.53	-5.4	-0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.78	-6.55	-0.48	9.09e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2062225	0.735	rs4849327	chr2:111754146	A/T	cg23782758	chr2:111737646	ACOXL	-0.5	-4.75	-0.36	4.79e-6	Monocyte count;
UCEC	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.7	-5.87	-0.44	2.8e-8	Neurofibrillary tangles;
UCEC	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg21204522	chr6:27730016	NA	-0.59	-4.76	-0.37	4.51e-6	Depression;
UCEC	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	0.55	6.94	0.5	1.19e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	6.62	0.48	6.3e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.66	6.12	0.45	8.15e-9	Schizophrenia;
UCEC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.66	4.87	0.37	2.89e-6	Aortic root size;
UCEC	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg05991184	chr2:219186017	PNKD	-0.49	-5.26	-0.4	4.94e-7	Colorectal cancer;
UCEC	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.45	4.9	0.37	2.55e-6	Migraine;
UCEC	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.54	5.14	0.39	8.7e-7	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.66	6.24	0.46	4.51e-9	Aortic root size;
UCEC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.94e-7	Aortic root size;
UCEC	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.64	5.42	0.41	2.43e-7	Systolic blood pressure;
UCEC	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	0.86	7.28	0.51	1.83e-11	Alzheimer's disease;
UCEC	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg09998033	chr7:158218633	PTPRN2	-0.46	-4.68	-0.36	6.41e-6	Obesity-related traits;
UCEC	cis	rs12980942	0.872	rs3816052	chr19:41773797	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.57	5.31	0.4	3.97e-7	Coronary artery disease;
UCEC	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.33	4.57	0.35	1.03e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
UCEC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.54	4.86	0.37	3.01e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs2742417	0.935	rs2742442	chr3:45748599	T/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-5.09	-0.39	1.07e-6	Fear of minor pain;
UCEC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg20965017	chr5:231967	SDHA	-0.63	-5.69	-0.42	6.64e-8	Breast cancer;
UCEC	cis	rs4972806	0.814	rs2113560	chr2:177030986	T/C	cg14324370	chr2:177042789	NA	0.55	5.65	0.42	8.14e-8	IgG glycosylation;
UCEC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-0.6	-6.7	-0.48	4.14e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.35	0.4	3.36e-7	Rheumatoid arthritis;
UCEC	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.66	-7.66	-0.53	2.33e-12	Headache;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.79	9.76	0.63	1.15e-17	Menarche (age at onset);
UCEC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-5.82	-0.43	3.52e-8	Longevity;
UCEC	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.54	5.58	0.42	1.15e-7	Schizophrenia;
UCEC	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.7	7.87	0.54	7.21e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg22563815	chr15:78856949	CHRNA5	0.36	4.76	0.37	4.57e-6	Sudden cardiac arrest;
UCEC	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.33	5.06	0.39	1.21e-6	Vitiligo;
UCEC	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	14.67	0.77	1.42e-30	Birth weight;
UCEC	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18932078	chr1:2524107	MMEL1	0.4	6.3	0.46	3.21e-9	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.74	-8.54	-0.58	1.59e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11264213	0.591	rs4653158	chr1:36556187	G/A	cg27506609	chr1:36549197	TEKT2	-0.59	-5.97	-0.44	1.68e-8	Schizophrenia;
UCEC	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg23307798	chr14:103986281	CKB	0.53	4.9	0.37	2.46e-6	Body mass index;
UCEC	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.54	6.0	0.44	1.46e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.58	-5.95	-0.44	1.88e-8	Dental caries;
UCEC	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.63	5.58	0.42	1.11e-7	Heart rate;
UCEC	cis	rs2862064	1.000	rs6867207	chr5:156450106	G/A	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.77	-0.43	4.57e-8	Platelet count;
UCEC	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.26e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-6.63	-0.48	5.88e-10	Response to antipsychotic treatment;
UCEC	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.51	5.05	0.38	1.28e-6	Height;
UCEC	cis	rs2041840	0.538	rs2372998	chr2:37573556	G/A	cg25727520	chr2:37576821	QPCT	-0.51	-5.75	-0.43	5.03e-8	Chronic lymphocytic leukemia;
UCEC	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.51	5.0	0.38	1.64e-6	High light scatter reticulocyte count;
UCEC	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	5.49	0.41	1.74e-7	Cognitive test performance;
UCEC	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	5.64	0.42	8.35e-8	Ileal carcinoids;
UCEC	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.54	5.52	0.41	1.51e-7	IgG glycosylation;
UCEC	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.7	-6.32	-0.46	2.93e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.87	-0.49	1.68e-10	Colorectal cancer;
UCEC	cis	rs259282	0.584	rs10416758	chr19:33107716	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	5.16	0.39	7.7300000000000005e-07	Schizophrenia;
UCEC	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg13683864	chr3:40499215	RPL14	0.72	8.46	0.57	2.5e-14	Renal cell carcinoma;
UCEC	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.5	-5.17	-0.39	7.39e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4345220	0.585	rs6848577	chr4:41642617	C/T	cg15232654	chr4:41643107	LIMCH1	0.53	5.54	0.42	1.38e-7	Migraine with aura;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.59	-5.81	-0.43	3.8e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.69	0.43	6.52e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17012589	0.910	rs12827426	chr12:85648473	A/G	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	-0.48	-4.7	-0.36	5.9e-6	Bone mineral density (Ward's triangle area);
UCEC	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.67	-7.81	-0.54	9.69e-13	Vitiligo;
UCEC	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.55	-5.94	-0.44	1.94e-8	HDL cholesterol;
UCEC	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.51	-4.63	-0.36	8.08e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-0.95	-13.14	-0.73	1.43e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg01380346	chr19:18557039	ELL	-0.45	-4.77	-0.37	4.42e-6	Breast cancer;
UCEC	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20011983	chr2:74347215	NA	-0.63	-5.01	-0.38	1.56e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg20368463	chr18:77673604	PQLC1	0.54	5.0	0.38	1.61e-6	Opioid sensitivity;
UCEC	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.93	0.38	2.22e-6	Tonsillectomy;
UCEC	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.52	5.54	0.42	1.39e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-6.7	-0.48	4.14e-10	Calcium levels;
UCEC	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.61	7.07	0.5	5.86e-11	Menopause (age at onset);
UCEC	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.49	6.09	0.45	9.39e-9	Anterior chamber depth;
UCEC	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.62	6.21	0.46	5.17e-9	Lung cancer;
UCEC	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.52	4.61	0.36	8.66e-6	Pancreatic cancer;
UCEC	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.98	11.41	0.69	5.46e-22	Cognitive function;
UCEC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.41	4.58	0.35	9.88e-6	Chronic sinus infection;
UCEC	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.34	-0.46	2.63e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.89	10.7	0.66	4.18e-20	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.77	-0.49	2.8e-10	Coffee consumption (cups per day);
UCEC	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.7	6.88	0.49	1.64e-10	Bipolar disorder;
UCEC	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg16583315	chr14:65563665	MAX	-0.4	-4.59	-0.35	9.58e-6	Obesity-related traits;
UCEC	cis	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg08722104	chr11:47448306	PSMC3	0.49	5.28	0.4	4.46e-7	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.62	-7.43	-0.52	8.05e-12	Prevalent atrial fibrillation;
UCEC	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg05539622	chr2:73298971	SFXN5	0.47	4.55	0.35	1.11e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.75	7.3	0.52	1.64e-11	Vitamin D levels;
UCEC	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg15764593	chr10:829463	NA	-0.56	-4.98	-0.38	1.75e-6	Uric acid levels;
UCEC	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.91	8.52	0.58	1.73e-14	Alzheimer's disease;
UCEC	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg03609598	chr5:56110824	MAP3K1	-0.56	-5.04	-0.38	1.34e-6	Coronary artery disease;
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.27	-0.46	3.8e-9	Platelet count;
UCEC	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.88	0.37	2.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.64	6.26	0.46	3.97e-9	Bladder cancer;
UCEC	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.59	-4.63	-0.36	8.14e-6	Cholesterol, total;
UCEC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg16558253	chr16:72132732	DHX38	-0.44	-5.16	-0.39	7.82e-7	Fibrinogen levels;
UCEC	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.66	6.61	0.48	6.6e-10	Acne (severe);
UCEC	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.61	5.18	0.39	7.12e-7	High light scatter reticulocyte count;
UCEC	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Body mass index;
UCEC	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs2839627	0.638	rs9974287	chr21:44317003	T/G	cg03543861	chr21:44258195	NA	0.52	5.16	0.39	7.86e-7	Information processing speed;
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.7	0.58	6.31e-15	Platelet count;
UCEC	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.89	-0.55	6.26e-13	Breast cancer;
UCEC	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-6.61	-0.48	6.55e-10	Morning vs. evening chronotype;
UCEC	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.54	5.63	0.42	8.83e-8	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
UCEC	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.66	5.47	0.41	1.85e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.45	4.72	0.36	5.38e-6	Smoking initiation;
UCEC	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-4.74	-0.36	4.94e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.61	-6.2	-0.46	5.44e-9	Dental caries;
UCEC	cis	rs2799081	1	rs2799081	chr6:28270584	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.45	-5.16	-0.39	7.77e-7	Myopia;
UCEC	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-6.88	-0.49	1.62e-10	Morning vs. evening chronotype;
UCEC	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg23950597	chr19:37808831	NA	0.6	4.69	0.36	6.17e-6	Coronary artery calcification;
UCEC	cis	rs12973672	0.812	rs12979058	chr19:35750684	G/A	cg12095397	chr19:35769544	USF2	0.49	4.68	0.36	6.53e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg05738196	chr6:26577821	NA	0.65	7.72	0.54	1.65e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.62	-4.96	-0.38	1.93e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.49	-4.74	-0.36	5.1e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.66	5.7	0.43	6.24e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.13	-0.45	7.64e-9	Aortic root size;
UCEC	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.7	-8.62	-0.58	9.54e-15	Ulcerative colitis;
UCEC	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-6.14	-0.45	7.17e-9	Platelet count;
UCEC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-0.98	-12.41	-0.72	1.23e-24	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1858037	0.867	rs61226353	chr2:65590771	G/A	cg08085232	chr2:65598271	SPRED2	-0.52	-4.53	-0.35	1.19e-5	Rheumatoid arthritis;
UCEC	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	0.83	5.91	0.44	2.31e-8	Red blood cell traits;
UCEC	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg09795085	chr6:101329169	ASCC3	0.58	4.51	0.35	1.32e-5	Economic and political preferences (immigration/crime);
UCEC	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.69	-5.1	-0.39	1.01e-6	Calcium levels;
UCEC	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.44	-4.75	-0.36	4.76e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.61	-4.58	-0.35	9.66e-6	Mean platelet volume;
UCEC	trans	rs1552172	0.845	rs35880546	chr1:145713071	T/C	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.64	-6.88	-0.49	1.65e-10	Breast cancer;
UCEC	cis	rs6565681	1.000	rs6565681	chr17:78348494	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.67	-4.66	-0.36	7.11e-6	Moyamoya disease;
UCEC	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.06	7.69	0.54	1.99e-12	Alzheimer's disease (late onset);
UCEC	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.57	6.25	0.46	4.3e-9	Platelet count;
UCEC	cis	rs7246967	0.611	rs73030508	chr19:22826032	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg04804543	chr8:142233427	SLC45A4	0.47	5.82	0.43	3.62e-8	Immature fraction of reticulocytes;
UCEC	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.64	-6.17	-0.45	6.26e-9	Prostate cancer;
UCEC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.71	0.58	5.65e-15	Smoking behavior;
UCEC	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg19567339	chr10:100142640	NA	0.42	4.75	0.36	4.82e-6	Metabolite levels;
UCEC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-10.49	-0.65	1.42e-19	Schizophrenia;
UCEC	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg14067834	chr17:29058358	SUZ12P	-0.66	-5.33	-0.4	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.69	5.22	0.4	6.07e-7	Bipolar disorder;
UCEC	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-0.98	-12.5	-0.72	6.99e-25	Platelet distribution width;
UCEC	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-5.82	-0.43	3.55e-8	Bladder cancer;
UCEC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.24	0.4	5.59e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg23307798	chr14:103986281	CKB	0.56	5.34	0.4	3.48e-7	Body mass index;
UCEC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.66	4.73	0.36	5.16e-6	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg20129853	chr10:51489980	NA	-0.43	-4.74	-0.36	4.95e-6	Prostate-specific antigen levels;
UCEC	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.41	-0.47	1.83e-9	Blood metabolite levels;
UCEC	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg14004847	chr7:1930337	MAD1L1	0.64	5.29	0.4	4.4e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-7.47	-0.52	6.52e-12	Hip circumference;
UCEC	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-6.4	-0.47	1.97e-9	Menarche (age at onset);
UCEC	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs10924970	0.625	rs10925287	chr1:235434470	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg24375607	chr4:120327624	NA	0.52	4.85	0.37	3.09e-6	Corneal astigmatism;
UCEC	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.9	5.77	0.43	4.52e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.45	-5.16	-0.39	7.82e-7	Tonsillectomy;
UCEC	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.78	7.84	0.54	8.41e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs8112909	0.843	rs8111011	chr19:46416647	G/A	cg08831348	chr19:46142212	EML2	0.58	4.62	0.36	8.38e-6	Interferon gamma-induced protein 10 levels;
UCEC	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.65	-4.72	-0.36	5.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.12	9.33	0.61	1.48e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Depression;
UCEC	cis	rs17106184	0.892	rs76589723	chr1:51208574	G/A	cg07174182	chr1:51127561	FAF1	-0.82	-5.25	-0.4	5.23e-7	Type 2 diabetes;
UCEC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.38	4.72	0.36	5.44e-6	Renal cell carcinoma;
UCEC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.62	-5.98	-0.44	1.66e-8	Acne (severe);
UCEC	cis	rs9402633	0.877	rs9389217	chr6:135060306	C/T	cg16239184	chr6:135079577	NA	0.48	4.52	0.35	1.28e-5	Platelet count;
UCEC	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.44	-5.1	-0.39	1.01e-6	Response to antineoplastic agents;
UCEC	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg07169764	chr2:136633963	MCM6	-0.54	-4.81	-0.37	3.76e-6	Colorectal cancer;
UCEC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.79	7.61	0.53	3.02e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.54	-4.86	-0.37	3.04e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg11150807	chr10:43354902	NA	-0.84	-6.71	-0.48	3.97e-10	Blood protein levels;
UCEC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.16	-14.08	-0.76	4.67e-29	Breast cancer;
UCEC	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.53	-4.68	-0.36	6.51e-6	Colorectal adenoma (advanced);
UCEC	cis	rs6832769	0.925	rs3817444	chr4:56375981	A/C	cg05960024	chr4:56376020	CLOCK	0.57	5.74	0.43	5.25e-8	Personality dimensions;
UCEC	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	7.32	0.52	1.51e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg13695892	chr22:41940480	POLR3H	0.62	4.86	0.37	2.97e-6	Vitiligo;
UCEC	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.53	-5.27	-0.4	4.8e-7	Aortic root size;
UCEC	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs3736594	0.513	rs59876138	chr2:27792323	A/C	cg27432699	chr2:27873401	GPN1	0.53	5.12	0.39	9.4e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg25451120	chr17:47287444	ABI3;GNGT2	-0.48	-4.69	-0.36	6.3e-6	Prostate cancer;
UCEC	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04871131	chr7:94954202	PON1	-0.69	-7.79	-0.54	1.11e-12	Paraoxonase activity;
UCEC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.67	-8.2	-0.56	1.07e-13	Height;
UCEC	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg18016565	chr1:150552671	MCL1	-0.62	-7.05	-0.5	6.48e-11	Tonsillectomy;
UCEC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg26162295	chr17:38119207	GSDMA	-0.3	-4.51	-0.35	1.33e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.06	-0.67	4.56e-21	Chronic sinus infection;
UCEC	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.53	-5.23	-0.4	5.77e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.63	4.79	0.37	4.05e-6	Mean platelet volume;
UCEC	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.09	-0.5	5.21e-11	Breast cancer;
UCEC	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06462663	chr19:18546047	ISYNA1	0.47	5.96	0.44	1.83e-8	Breast cancer;
UCEC	cis	rs9326726	0.844	rs988437	chr5:107680687	C/T	cg17432647	chr5:107996819	NA	-0.53	-4.65	-0.36	7.25e-6	Resting heart rate;
UCEC	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Visceral adipose tissue adjusted for BMI;
UCEC	cis	rs172166	0.516	rs2791333	chr6:28111114	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.69	-0.42	6.73e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12379764	chr21:47803548	PCNT	-0.43	-4.58	-0.35	9.89e-6	Testicular germ cell tumor;
UCEC	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.76	7.84	0.54	8.56e-13	Caffeine consumption;
UCEC	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.41	-0.41	2.49e-7	Resting heart rate;
UCEC	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.55	-5.28	-0.4	4.52e-7	Cognitive test performance;
UCEC	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.1	0.45	8.76e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg16235748	chr6:149772707	ZC3H12D	0.47	5.56	0.42	1.23e-7	Dupuytren's disease;
UCEC	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.58	-0.69	1.92e-22	Height;
UCEC	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.57	-6.11	-0.45	8.31e-9	Blood protein levels;
UCEC	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.51	-5.29	-0.4	4.35e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.6	-6.51	-0.47	1.09e-9	Prostate cancer;
UCEC	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg22907277	chr7:1156413	C7orf50	0.88	9.46	0.62	6.91e-17	Longevity;Endometriosis;
UCEC	cis	rs7843479	0.828	rs4357289	chr8:21777476	G/A	cg17168535	chr8:21777572	XPO7	0.61	6.99	0.5	8.95e-11	Mean corpuscular volume;
UCEC	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.75	-6.33	-0.46	2.75e-9	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.61	-4.72	-0.36	5.44e-6	Coronary artery disease;
UCEC	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.6	6.92	0.5	1.3100000000000001e-10	Vitiligo;
UCEC	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.9	12.09	0.71	8.77e-24	Metabolic syndrome;
UCEC	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.48	-4.84	-0.37	3.21e-6	Non-alcoholic fatty liver disease histology (lobular);
UCEC	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg13575925	chr12:9217583	LOC144571	0.39	4.55	0.35	1.1e-5	Sjögren's syndrome;
UCEC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.16	-14.09	-0.76	4.64e-29	Breast cancer;
UCEC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-6.87	-0.49	1.73e-10	Eye color traits;
UCEC	cis	rs883565	0.740	rs10510698	chr3:39107993	A/C	cg01426195	chr3:39028469	NA	-0.7	-9.43	-0.61	8.3e-17	Handedness;
UCEC	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	5.55	0.42	1.31e-7	Cognitive test performance;
UCEC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-6.15	-0.45	7.05e-9	Platelet count;
UCEC	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.96	0.38	1.91e-6	Breast cancer;
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg20007245	chr22:24372913	LOC391322	0.58	5.93	0.44	2.09e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg01874867	chr7:94954059	PON1	0.56	5.31	0.4	3.97e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.44	5.21	0.39	6.4e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.54	5.73	0.43	5.6e-8	Diastolic blood pressure;
UCEC	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg19622623	chr12:86230825	RASSF9	-0.36	-4.8	-0.37	3.87e-6	Major depressive disorder;
UCEC	cis	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg21775007	chr8:11205619	TDH	0.39	4.53	0.35	1.22e-5	Retinal vascular caliber;
UCEC	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.67	7.64	0.53	2.55e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs7597155	0.512	rs6721715	chr2:69910110	A/G	cg02498382	chr2:70120550	SNRNP27	-0.46	-4.67	-0.36	6.79e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7070678	0.662	rs11007634	chr10:29803432	A/G	cg07724896	chr10:29780678	SVIL	-0.56	-4.64	-0.36	7.51e-6	Platelet thrombus formation;
UCEC	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.78	7.87	0.54	6.95e-13	Smoking behavior;
UCEC	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	4.86	0.37	2.98e-6	Obesity-related traits;
UCEC	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.59	0.62	3.18e-17	Blood protein levels;
UCEC	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.44	0.41	2.13e-7	Height;
UCEC	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.04	8.52	0.57	1.76e-14	Uric acid levels;
UCEC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.88	-0.37	2.73e-6	Aortic root size;
UCEC	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.65	4.86	0.37	3.01e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	7.37	0.52	1.14e-11	Tonsillectomy;
UCEC	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.49	-5.54	-0.42	1.35e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	1.04	7.31	0.52	1.56e-11	Obesity-related traits;
UCEC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.73	8.67	0.58	7.15e-15	Prudent dietary pattern;
UCEC	cis	rs1570989	0.571	rs6916066	chr6:12016009	G/C	cg17804551	chr6:12015979	HIVEP1	0.46	5.61	0.42	9.72e-8	Alcohol and nicotine co-dependence;
UCEC	cis	rs3762637	0.941	rs75344200	chr3:122073421	C/T	cg24169773	chr3:122142474	KPNA1	-0.65	-4.6	-0.35	9.18e-6	LDL cholesterol levels;
UCEC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-4.79	-0.37	4.08e-6	Lymphocyte counts;
UCEC	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04731861	chr2:219085781	ARPC2	0.41	4.63	0.36	8e-6	Colorectal cancer;
UCEC	cis	rs17789174	0.855	rs62049874	chr16:85090984	T/C	cg02758499	chr16:85682440	KIAA0182	0.51	4.63	0.36	8.02e-6	Dysphagia;
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	0.73	5.82	0.43	3.55e-8	Post bronchodilator FEV1;
UCEC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	4.76	0.37	4.66e-6	Bipolar disorder;
UCEC	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-0.43	-4.68	-0.36	6.51e-6	IgG glycosylation;
UCEC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	6.8	0.49	2.5e-10	Type 2 diabetes;
UCEC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.94	-10.73	-0.66	3.31e-20	Cognitive function;
UCEC	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.67	-4.79	-0.37	4.08e-6	Rheumatoid arthritis;
UCEC	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	0.9	7.01	0.5	8.23e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.49	-5.43	-0.41	2.32e-7	Longevity;
UCEC	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.73	-5.68	-0.42	6.85e-8	Orofacial clefts;
UCEC	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-5.04	-0.38	1.32e-6	Morning vs. evening chronotype;
UCEC	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg18478394	chr8:109455254	TTC35	0.47	4.63	0.36	7.87e-6	Dupuytren's disease;
UCEC	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.63	5.81	0.43	3.82e-8	Parkinson's disease;
UCEC	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	6.5	0.47	1.18e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg04439458	chr5:138467593	SIL1	-0.47	-5.35	-0.4	3.26e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.98	-13.76	-0.75	3.34e-28	Homoarginine levels;
UCEC	cis	rs11697848	0.748	rs2281221	chr20:48488686	A/C	cg17849948	chr20:48532315	SPATA2	1.03	5.1	0.39	1.01e-6	Systemic lupus erythematosus;
UCEC	cis	rs243088	1.000	rs243019	chr2:60585806	C/T	cg16665442	chr2:60585866	NA	0.39	4.67	0.36	6.87e-6	Type 2 diabetes;
UCEC	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.71	6.72	0.48	3.72e-10	Bladder cancer;
UCEC	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg13319975	chr6:146136371	FBXO30	0.56	6.18	0.45	6.05e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.72	8.59	0.58	1.17e-14	Menarche (age at onset);
UCEC	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	0.72	5.63	0.42	8.85e-8	Post bronchodilator FEV1;
UCEC	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-5.08	-0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17433710	0.778	rs61811982	chr1:162674747	A/G	cg19264028	chr1:162630153	DDR2	1.07	4.65	0.36	7.3e-6	Dupuytren's disease;
UCEC	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg00684032	chr4:1343700	KIAA1530	0.63	6.67	0.48	4.74e-10	Obesity-related traits;
UCEC	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-4.66	-0.36	7.16e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.8	8.68	0.58	6.98e-15	Metabolite levels;
UCEC	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.44	5.01	0.38	1.52e-6	Mortality in heart failure;
UCEC	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-4.96	-0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.68	6.13	0.45	7.68e-9	Adiposity;
UCEC	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	0.91	9.25	0.61	2.46e-16	Mitochondrial DNA levels;
UCEC	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.59	-6.0	-0.44	1.49e-8	Longevity;Endometriosis;
UCEC	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.6	-4.72	-0.36	5.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-6.71	-0.48	3.95e-10	Personality dimensions;
UCEC	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.69	5.59	0.42	1.07e-7	Body mass index;
UCEC	cis	rs6876348	0.598	rs2526252	chr5:128310259	C/G	cg02841155	chr5:128301328	SLC27A6	-0.36	-4.6	-0.35	9.16e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg22166914	chr1:53195759	ZYG11B	0.77	8.89	0.59	2e-15	Monocyte count;
UCEC	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg06096015	chr1:231504339	EGLN1	0.42	4.77	0.37	4.32e-6	Hemoglobin concentration;
UCEC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.32	-4.52	-0.35	1.24e-5	Alzheimer's disease (late onset);
UCEC	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	6.91	0.5	1.35e-10	Coffee consumption (cups per day);
UCEC	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.66	7.42	0.52	8.56e-12	Resting heart rate;
UCEC	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.48	4.61	0.36	8.55e-6	Menopause (age at onset);
UCEC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg21770322	chr7:97807741	LMTK2	0.47	5.91	0.44	2.25e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg17294928	chr15:75287854	SCAMP5	0.54	5.97	0.44	1.7e-8	Breast cancer;
UCEC	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.8	-8.5	-0.57	1.92e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.52	7.6	0.53	3.14e-12	Crohn's disease;
UCEC	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.63	5.48	0.41	1.82e-7	Uric acid levels;
UCEC	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.47	5.09	0.39	1.08e-6	Headache;
UCEC	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.46	5.08	0.39	1.11e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg09297252	chr8:7631214	NA	0.4	5.02	0.38	1.48e-6	Red cell distribution width;
UCEC	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.45	4.67	0.36	6.77e-6	Prostate cancer;
UCEC	cis	rs853679	0.527	rs853690	chr6:28285482	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.53	-5.9	-0.44	2.46e-8	Depression;
UCEC	cis	rs11697848	1.000	rs117045390	chr20:48588290	C/T	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	cis	rs883565	0.792	rs813669	chr3:39181723	C/T	cg01426195	chr3:39028469	NA	0.62	6.2	0.46	5.35e-9	Handedness;
UCEC	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.48	4.95	0.38	2.04e-6	Total body bone mineral density;
UCEC	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.91	-0.44	2.34e-8	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-7.47	-0.52	6.57e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.03	6.87	0.49	1.67e-10	Schizophrenia;
UCEC	cis	rs201260	0.544	rs17621335	chr6:9979424	T/C	cg17697633	chr6:10420079	TFAP2A	-0.55	-4.88	-0.37	2.73e-6	Electroencephalogram traits;
UCEC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.29	0.46	3.47e-9	Tonsillectomy;
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.5	0.35	1.36e-5	Prudent dietary pattern;
UCEC	cis	rs4499344	0.664	rs7258278	chr19:33099523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.07	0.45	1.03e-8	Mean platelet volume;
UCEC	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.72	-6.71	-0.48	3.96e-10	Prudent dietary pattern;
UCEC	cis	rs7072216	0.587	rs3814141	chr10:100171028	G/A	cg26618903	chr10:100175079	PYROXD2	-0.38	-4.6	-0.35	8.97e-6	Metabolite levels;
UCEC	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.12	0.68	3.14e-21	Corneal structure;
UCEC	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.54	4.64	0.36	7.77e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2455799	0.573	rs2455793	chr3:15743844	A/G	cg16303742	chr3:15540471	COLQ	-0.37	-4.55	-0.35	1.1e-5	Mean platelet volume;
UCEC	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.79e-6	Blood metabolite levels;
UCEC	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	0.9	9.15	0.6	4.3e-16	Heart rate;
UCEC	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg09469691	chr10:81107165	PPIF	0.51	4.56	0.35	1.06e-5	Height;
UCEC	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.46	-5.24	-0.4	5.58e-7	Facial morphology (factor 20);
UCEC	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.49	4.88	0.37	2.69e-6	Migraine;
UCEC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.8	7.35	0.52	1.25e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.61	5.53	0.41	1.45e-7	Corneal astigmatism;
UCEC	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.43	-4.65	-0.36	7.3e-6	Total body bone mineral density;
UCEC	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.56	5.49	0.41	1.73e-7	Height;
UCEC	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg26114124	chr12:9217669	LOC144571	0.41	4.87	0.37	2.89e-6	Sjögren's syndrome;
UCEC	cis	rs9341808	0.667	rs3805913	chr6:80927322	A/G	cg08355045	chr6:80787529	NA	0.42	5.18	0.39	7.29e-7	Sitting height ratio;
UCEC	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.7	-6.73	-0.49	3.57e-10	Aortic root size;
UCEC	cis	rs10896135	0.531	rs544021	chr11:66315661	C/G	cg24851651	chr11:66362959	CCS	0.42	5.15	0.39	8.37e-7	Bipolar disorder;
UCEC	cis	rs4668356	0.881	rs60396936	chr2:171993586	A/T	cg13882835	chr2:172017928	TLK1	0.66	4.51	0.35	1.32e-5	Cognitive performance;
UCEC	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.31	-0.46	3.11e-9	Developmental language disorder (linguistic errors);
UCEC	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.09	8.7	0.58	6.28e-15	Uric acid levels;
UCEC	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg22563815	chr15:78856949	CHRNA5	0.38	4.83	0.37	3.37e-6	Sudden cardiac arrest;
UCEC	cis	rs883565	0.612	rs784512	chr3:39165110	G/T	cg01426195	chr3:39028469	NA	0.62	7.39	0.52	1.01e-11	Handedness;
UCEC	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.69	6.65	0.48	5.2400000000000005e-10	Aortic root size;
UCEC	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.45	-5.15	-0.39	8.31e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs10924970	0.625	rs10802624	chr1:235494971	A/G	cg26050004	chr1:235667680	B3GALNT2	0.52	4.7	0.36	5.84e-6	Asthma;
UCEC	cis	rs11718455	0.526	rs11720884	chr3:43941406	A/G	cg08738300	chr3:44038990	NA	0.53	4.61	0.36	8.77e-6	Coronary artery disease;
UCEC	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.89	-7.57	-0.53	3.71e-12	Coronary artery calcification;
UCEC	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-5.17	-0.39	7.54e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.02	-0.44	1.33e-8	Parkinson's disease;
UCEC	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs4687718	0.528	rs77413676	chr3:53358117	T/C	cg12173409	chr3:54154746	NA	0.54	4.83	0.37	3.41e-6	QRS duration;
UCEC	cis	rs1978968	0.717	rs5992934	chr22:18457119	C/T	cg03078520	chr22:18463400	MICAL3	-0.49	-6.19	-0.45	5.67e-9	Presence of antiphospholipid antibodies;
UCEC	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.61	-6.38	-0.47	2.16e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.64	-6.45	-0.47	1.55e-9	Body mass index;
UCEC	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.49	-5.07	-0.39	1.2e-6	Vitiligo;
UCEC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.64	8.42	0.57	3.17e-14	Anterior chamber depth;
UCEC	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-5.3	-0.4	4.21e-7	Life satisfaction;
UCEC	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.65	4.87	0.37	2.82e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.12	7.93	0.55	5.04e-13	Sexual dysfunction (female);
UCEC	cis	rs7246967	0.611	rs1835993	chr19:22833037	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6815464	1	rs6815464	chr4:1309901	C/G	cg07110949	chr4:1309878	MAEA	-0.75	-5.35	-0.4	3.35e-7	Type 2 diabetes;
UCEC	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg20503657	chr10:835505	NA	1.19	6.21	0.46	5.17e-9	Eosinophil percentage of granulocytes;
UCEC	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg12850546	chr22:42539477	CYP2D7P1	-0.44	-4.66	-0.36	7.17e-6	Schizophrenia;
UCEC	cis	rs9810890	0.764	rs9846589	chr3:128560355	T/C	cg11901034	chr3:128598214	ACAD9	-0.6	-5.48	-0.41	1.78e-7	Dental caries;
UCEC	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.48	-4.71	-0.36	5.74e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs77861329	0.920	rs808787	chr3:52203249	G/A	cg08692210	chr3:52188851	WDR51A	0.84	6.55	0.48	8.84e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg03264133	chr6:25882463	NA	-0.58	-4.62	-0.36	8.22e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg20399509	chr21:47717575	C21orf57	-0.46	-4.96	-0.38	1.95e-6	Testicular germ cell tumor;
UCEC	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.68	-6.69	-0.48	4.39e-10	Tonsillectomy;
UCEC	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg23793686	chr15:68133972	NA	-0.44	-4.82	-0.37	3.54e-6	Restless legs syndrome;
UCEC	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.51	5.67	0.42	7.49e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.59	5.95	0.44	1.85e-8	Red cell distribution width;
UCEC	cis	rs884366	1.000	rs884366	chr6:109574095	G/A	cg01475377	chr6:109611718	NA	0.44	4.92	0.38	2.34e-6	HDL cholesterol levels;HDL cholesterol;
UCEC	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.95	-9.47	-0.62	6.7e-17	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.61	-6.23	-0.46	4.67e-9	Bipolar disorder;
UCEC	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.48	4.86	0.37	2.98e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.72	-7.02	-0.5	7.58e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg23307798	chr14:103986281	CKB	-0.48	-4.98	-0.38	1.77e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.5	-0.53	5.51e-12	Exhaled nitric oxide output;
UCEC	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.05	-0.45	1.13e-8	Metabolite levels;
UCEC	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg06238570	chr21:40685208	BRWD1	0.81	7.6	0.53	3.15e-12	Cognitive function;
UCEC	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.82	11.26	0.68	1.32e-21	Headache;
UCEC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.56	5.55	0.42	1.27e-7	Blood protein levels;
UCEC	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.75	6.22	0.46	4.96e-9	Menopause (age at onset);
UCEC	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.89	8.0	0.55	3.41e-13	Bladder cancer;
UCEC	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.95	-0.5	1.09e-10	Urate levels in overweight individuals;
UCEC	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs7072216	0.687	rs11189587	chr10:100154545	G/A	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs7870753	0.838	rs10820626	chr9:99204180	G/T	cg25260653	chr9:99212216	HABP4	0.58	5.7	0.43	6.48e-8	Height;
UCEC	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.58	-6.6	-0.48	7.08e-10	Body mass index;
UCEC	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-1.0	-11.9	-0.7	2.72e-23	Obesity-related traits;
UCEC	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01391022	chr12:122360665	WDR66	-0.46	-4.69	-0.36	6.19e-6	Mean corpuscular volume;
UCEC	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.61	5.6	0.42	1.04e-7	Morning vs. evening chronotype;
UCEC	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.76	-8.7	-0.58	6.04e-15	Facial morphology (factor 19);
UCEC	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg04492858	chr10:133558786	NA	0.39	4.53	0.35	1.23e-5	Survival in rectal cancer;
UCEC	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.5	-4.77	-0.37	4.41e-6	Schizophrenia;
UCEC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.57	-5.41	-0.41	2.45e-7	Blood protein levels;
UCEC	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.75	-7.53	-0.53	4.71e-12	Type 2 diabetes;
UCEC	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.673	rs2361021	chr19:22816324	T/G	cg24889512	chr19:22816950	ZNF492	0.59	6.47	0.47	1.38e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.54	5.98	0.44	1.65e-8	Mean corpuscular volume;
UCEC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg00612595	chr21:47717864	NA	-0.49	-5.38	-0.41	2.92e-7	Testicular germ cell tumor;
UCEC	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.71	-5.87	-0.44	2.8e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	4.66	0.36	6.95e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.69	-0.36	6.22e-6	Parkinson's disease;
UCEC	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	7.76	0.54	1.29e-12	Mean corpuscular hemoglobin;
UCEC	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.62	6.77	0.49	2.86e-10	Monocyte count;
UCEC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Body mass index;
UCEC	cis	rs334147	1.000	rs334162	chr2:128264431	C/T	cg14478610	chr2:127864964	BIN1	-0.55	-5.09	-0.39	1.08e-6	Educational attainment;
UCEC	cis	rs308403	0.600	rs13135445	chr4:123664457	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.55	4.63	0.36	8.01e-6	Blood protein levels;
UCEC	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.75	-7.24	-0.51	2.27e-11	Aortic root size;
UCEC	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.37	0.47	2.23e-9	Coffee consumption (cups per day);
UCEC	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.67	5.72	0.43	5.86e-8	Breast cancer;
UCEC	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.26	9.93	0.63	4.26e-18	Uric acid levels;
UCEC	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.54	-7.43	-0.52	8.28e-12	Total body bone mineral density;
UCEC	cis	rs4880487	0.888	rs35341304	chr10:1252526	T/C	cg03183215	chr10:1252341	ADARB2	-0.46	-5.43	-0.41	2.3e-7	Migraine;
UCEC	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-5.73	-0.43	5.46e-8	Colorectal cancer;
UCEC	cis	rs4588572	0.643	rs10474554	chr5:77799158	C/T	cg11547950	chr5:77652471	NA	-0.44	-4.82	-0.37	3.58e-6	Triglycerides;
UCEC	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.45	4.76	0.37	4.55e-6	Vitiligo;
UCEC	cis	rs2120991	1.000	rs11170737	chr12:54279604	A/G	cg07927839	chr12:53491483	IGFBP6	0.44	4.65	0.36	7.48e-6	Biliary atresia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.57	6.81	0.49	2.31e-10	Warfarin maintenance dose;
UCEC	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.72	7.48	0.53	6.15e-12	Colorectal cancer;
UCEC	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.8	-9.07	-0.6	7.1e-16	Height;
UCEC	cis	rs7088591	0.867	rs113703900	chr10:59792112	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.58	-5.23	-0.4	5.83e-7	Metabolite levels;
UCEC	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.47	4.54	0.35	1.16e-5	Lung cancer;
UCEC	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-6.42	-0.47	1.78e-9	Response to antipsychotic treatment;
UCEC	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs2172802	0.570	rs1497899	chr4:62545911	T/C	cg04118610	chr4:62707027	LPHN3	-0.44	-4.82	-0.37	3.48e-6	Partial epilepsies;
UCEC	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.42	-0.52	8.68e-12	Body mass index;
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.66	-7.32	-0.52	1.46e-11	Paraoxonase activity;
UCEC	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.9	-0.37	2.48e-6	Dupuytren's disease;
UCEC	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg07636037	chr3:49044803	WDR6	-0.62	-4.92	-0.38	2.28e-6	Menarche (age at onset);
UCEC	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.57	-0.53	3.73e-12	Hypospadias;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.61	-7.63	-0.53	2.76e-12	Pubertal anthropometrics;
UCEC	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg26781129	chr3:44753946	ZNF502	-0.42	-4.52	-0.35	1.27e-5	Depressive symptoms;
UCEC	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs6032067	0.929	rs6032063	chr20:43854475	C/T	cg00873616	chr20:43920241	NA	0.51	5.11	0.39	9.79e-7	Blood protein levels;
UCEC	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.49	-5.0	-0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.52	-5.69	-0.42	6.73e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01380346	chr19:18557039	ELL	-0.49	-5.09	-0.39	1.1e-6	Breast cancer;
UCEC	cis	rs244899	0.967	rs244898	chr5:167918926	T/C	cg06604206	chr5:167912465	RARS	-0.36	-4.58	-0.35	9.84e-6	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.66	6.32	0.46	2.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.84	9.55	0.62	4.23e-17	Menarche (age at onset);
UCEC	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.6	5.51	0.41	1.54e-7	Pancreatic cancer;
UCEC	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg23307798	chr14:103986281	CKB	0.55	5.28	0.4	4.61e-7	Body mass index;
UCEC	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.67	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.72	8.6	0.58	1.13e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.7	6.06	0.45	1.1e-8	Alzheimer's disease;
UCEC	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg04155231	chr12:9217510	LOC144571	0.39	4.57	0.35	1.02e-5	Sjögren's syndrome;
UCEC	cis	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg17469321	chr7:55412551	NA	0.69	6.35	0.46	2.47e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg19513890	chr22:42538836	CYP2D7P1	-0.43	-4.84	-0.37	3.24e-6	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.85	9.54	0.62	4.49e-17	Breast cancer;
UCEC	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.5	-5.48	-0.41	1.8e-7	Aortic root size;
UCEC	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.52	5.31	0.4	4.06e-7	Corneal astigmatism;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-5.76	-0.43	4.85e-8	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg18809830	chr7:99032528	PTCD1	-0.81	-4.65	-0.36	7.32e-6	Blood metabolite levels;
UCEC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22117172	chr7:91764530	CYP51A1	0.4	5.02	0.38	1.5e-6	Breast cancer;
UCEC	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.4	-5.4	-0.41	2.66e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.57	5.7	0.43	6.41e-8	Retinal vascular caliber;
UCEC	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg22598563	chr5:131563921	P4HA2	-0.34	-4.58	-0.35	9.85e-6	Blood metabolite levels;
UCEC	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg06521331	chr12:34319734	NA	-0.64	-5.31	-0.4	4.03e-7	Morning vs. evening chronotype;
UCEC	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.72	-6.65	-0.48	5.34e-10	Prostate cancer;
UCEC	cis	rs11760485	0.664	rs4412277	chr7:4405138	A/G	cg25842763	chr7:4870162	RADIL	-0.43	-4.87	-0.37	2.87e-6	Early childhood aggressive behavior;
UCEC	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.59	-6.61	-0.48	6.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.57	4.74	0.36	5e-6	Alzheimer's disease;
UCEC	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg17294928	chr15:75287854	SCAMP5	0.51	5.56	0.42	1.22e-7	Breast cancer;
UCEC	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.43	5.29	0.4	4.32e-7	Anterior chamber depth;
UCEC	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.73	7.04	0.5	6.97e-11	Monocyte count;
UCEC	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.85	-7.86	-0.54	7.42e-13	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	6.81	0.49	2.31e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1572072	0.545	rs9510776	chr13:24129450	T/G	cg24350296	chr13:24144486	TNFRSF19	-0.38	-4.72	-0.36	5.46e-6	Nasopharyngeal carcinoma;
UCEC	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.7	6.95	0.5	1.13e-10	Menarche (age at onset);
UCEC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.63	-7.14	-0.51	4.01e-11	Menarche (age at onset);
UCEC	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.51	-4.72	-0.36	5.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24249390	chr15:90295951	MESP1	-0.45	-5.02	-0.38	1.5e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.69	6.89	0.49	1.49e-10	Menopause (age at onset);
UCEC	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg22654517	chr2:96458247	NA	0.45	5.28	0.4	4.52e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-8.24	-0.56	8.96e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg19997662	chr15:101784653	CHSY1	-0.61	-8.1	-0.56	1.9e-13	Corneal structure;
UCEC	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.55	5.11	0.39	9.78e-7	Corneal astigmatism;
UCEC	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.74	-5.88	-0.44	2.59e-8	Schizophrenia;
UCEC	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	10.25	0.65	6.29e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.81	-7.59	-0.53	3.46e-12	Parkinson's disease;
UCEC	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg16751203	chr2:127950803	CYP27C1	-0.38	-4.54	-0.35	1.18e-5	Protein C levels;
UCEC	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	Bipolar disorder;
UCEC	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	7.7	0.54	1.85e-12	Chronic sinus infection;
UCEC	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	0.99	8.77	0.59	4.15e-15	Vitiligo;
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4074536	0.714	rs12023881	chr1:116304301	G/T	cg21648376	chr1:116311395	CASQ2	-0.51	-5.02	-0.38	1.51e-6	QRS duration;
UCEC	cis	rs7872515	0.887	rs58129324	chr9:94839105	T/C	cg01248375	chr9:94877805	SPTLC1	0.44	4.68	0.36	6.4e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.96	12.22	0.71	3.93e-24	Breast cancer;
UCEC	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.75	7.39	0.52	1e-11	Tonsillectomy;
UCEC	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.46	4.65	0.36	7.29e-6	Blood metabolite levels;
UCEC	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	7.64	0.53	2.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.6	5.84	0.43	3.26e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.47	-6.57	-0.48	8.25e-10	Urinary metabolites;
UCEC	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.86	-5.82	-0.43	3.56e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.49	5.23	0.4	5.72e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg06410510	chr2:107458059	ST6GAL2	-0.76	-6.93	-0.5	1.25e-10	Prostate cancer;
UCEC	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.21	0.51	2.8e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	0.77	4.73	0.36	5.17e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg26195577	chr20:24973756	C20orf3	-1.03	-5.52	-0.41	1.47e-7	Blood protein levels;
UCEC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.63	-6.92	-0.5	1.26e-10	Crohn's disease;
UCEC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.47	5.3	0.4	4.21e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1459104	1.000	rs12802877	chr11:55270032	C/T	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.64	-6.39	-0.47	2.11e-9	Blood metabolite levels;
UCEC	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.67	9.77	0.63	1.12e-17	Height;
UCEC	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.64	4.72	0.36	5.44e-6	Body mass index;
UCEC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.34	0.52	1.31e-11	Homoarginine levels;
UCEC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12516959	chr21:47718080	NA	-0.41	-4.62	-0.36	8.4e-6	Testicular germ cell tumor;
UCEC	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.6	-6.6	-0.48	7.12e-10	Asthma;
UCEC	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.75	6.99	0.5	9.16e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg11945507	chr8:142233382	SLC45A4	-0.42	-4.77	-0.37	4.43e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.62	7.41	0.52	9.06e-12	Oral cavity cancer;
UCEC	cis	rs534126	0.961	rs7810486	chr7:143007111	G/A	cg04182207	chr7:143013161	CLCN1	-0.4	-5.15	-0.39	8.33e-7	Cancer;
UCEC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.14	19.25	0.85	5.06e-42	Schizophrenia;
UCEC	cis	rs9283706	0.594	rs1428405	chr5:66327193	A/T	cg11590213	chr5:66331682	MAST4	0.45	5.21	0.39	6.39e-7	Coronary artery disease;
UCEC	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.62	6.55	0.48	9e-10	Immature fraction of reticulocytes;
UCEC	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.72	8.81	0.59	3.3e-15	Vitiligo;
UCEC	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg18681998	chr4:17616180	MED28	0.51	5.94	0.44	1.98e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.62	0.36	8.27e-6	Menopause (age at onset);
UCEC	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg13683864	chr3:40499215	RPL14	-0.67	-6.77	-0.49	2.82e-10	Renal cell carcinoma;
UCEC	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-4.51	-0.35	1.31e-5	Glomerular filtration rate (creatinine);
UCEC	cis	rs16937	0.597	rs3862949	chr1:205103070	A/T	cg12580275	chr1:205744413	RAB7L1	0.45	5.26	0.4	4.94e-7	Schizophrenia;
UCEC	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.6	4.53	0.35	1.19e-5	Corneal astigmatism;
UCEC	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-6.35	-0.46	2.52e-9	Platelet distribution width;
UCEC	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.12	-0.39	9.39e-7	Metabolite levels;
UCEC	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg01689657	chr7:91764605	CYP51A1	0.43	5.52	0.41	1.51e-7	Breast cancer;
UCEC	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.8	-8.83	-0.59	2.89e-15	Height;
UCEC	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.5	-5.13	-0.39	8.91e-7	Dental caries;
UCEC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.5	4.72	0.36	5.35e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs59918340	0.627	rs1865249	chr8:142215982	A/C	cg23750338	chr8:142222470	SLC45A4	0.74	7.72	0.54	1.61e-12	Immature fraction of reticulocytes;
UCEC	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg04439458	chr5:138467593	SIL1	-0.39	-4.69	-0.36	6.06e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.61	0.36	8.65e-6	Tonsillectomy;
UCEC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.65	5.42	0.41	2.36e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-7.37	-0.52	1.16e-11	Coronary artery disease;
UCEC	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-6.63	-0.48	6.13e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.64	4.55	0.35	1.14e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.7	8.36	0.57	4.33e-14	Prudent dietary pattern;
UCEC	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.72	-5.84	-0.43	3.2e-8	Asthma;
UCEC	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.85	-0.37	3.09e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.45	5.36	0.4	3.2e-7	Tonsillectomy;
UCEC	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-0.94	-6.77	-0.49	2.86e-10	Blood pressure (smoking interaction);
UCEC	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-7.93	-0.55	5.03e-13	Resting heart rate;
UCEC	cis	rs1426153	0.736	rs12288809	chr11:125169343	G/A	cg06074774	chr11:126138802	SRPR;FOXRED1	-0.91	-4.52	-0.35	1.26e-5	Alcohol and nicotine co-dependence;
UCEC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	cis	rs308403	0.509	rs309382	chr4:123669772	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.89	13.46	0.74	2e-27	Blood protein levels;
UCEC	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.09	-13.52	-0.74	1.43e-27	Schizophrenia;
UCEC	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.54	5.7	0.43	6.43e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.73	5.31	0.4	3.95e-7	Exhaled nitric oxide output;
UCEC	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.48	-5.92	-0.44	2.17e-8	Anterior chamber depth;
UCEC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.61	5.82	0.43	3.47e-8	Blood protein levels;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.53	-5.83	-0.43	3.4e-8	Cardiac Troponin-T levels;
UCEC	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.15	0.45	7.06e-9	IgG glycosylation;
UCEC	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.41	-4.53	-0.35	1.23e-5	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs1575951	1.000	rs11016407	chr10:130438202	T/G	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.57	0.35	1.04e-5	Height;
UCEC	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-6.37	-0.46	2.33e-9	Crohn's disease;
UCEC	cis	rs4372836	0.729	rs6547873	chr2:28981983	G/A	cg09522027	chr2:28974177	PPP1CB	-0.7	-7.68	-0.53	2.09e-12	Body mass index;
UCEC	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.86	11.2	0.68	1.95e-21	Brugada syndrome;
UCEC	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.34	-4.58	-0.35	9.92e-6	Total body bone mineral density;
UCEC	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.62	6.0	0.44	1.47e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.73	4.52	0.35	1.28e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.69	6.56	0.48	8.74e-10	Bladder cancer;
UCEC	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-12.59	-0.72	4.03e-25	Primary sclerosing cholangitis;
UCEC	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.61	-7.14	-0.51	3.97e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	0.77	4.95	0.38	2e-6	Iron status biomarkers;
UCEC	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.6	5.4	0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs10924970	0.935	rs7530147	chr1:235325570	G/T	cg26050004	chr1:235667680	B3GALNT2	0.43	4.79	0.37	4.05e-6	Asthma;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg25202407	chr1:205417560	MIR135B	0.37	4.74	0.36	5.09e-6	Menarche (age at onset);
UCEC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg04155231	chr12:9217510	LOC144571	0.41	4.84	0.37	3.23e-6	Sjögren's syndrome;
UCEC	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg09904177	chr6:26538194	HMGN4	-0.63	-4.68	-0.36	6.49e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.7	6.73	0.49	3.45e-10	Multiple sclerosis;
UCEC	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg15358701	chr1:161410459	NA	-0.81	-5.41	-0.41	2.52e-7	Rheumatoid arthritis;
UCEC	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg08493051	chr2:3487164	NA	-0.61	-6.59	-0.48	7.47e-10	Neurofibrillary tangles;
UCEC	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.56	-6.51	-0.47	1.1e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.5	-6.6	-0.48	7.07e-10	Neutrophil percentage of white cells;
UCEC	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.6	0.35	9.07e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18252515	chr7:66147081	NA	0.52	4.81	0.37	3.77e-6	Aortic root size;
UCEC	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.5	5.6	0.42	1.04e-7	Life satisfaction;
UCEC	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.14	0.45	7.5e-9	Rheumatoid arthritis;
UCEC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.98	0.44	1.63e-8	Monocyte percentage of white cells;
UCEC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg14906510	chr12:7781169	NA	0.56	4.69	0.36	6.16e-6	HDL cholesterol levels;
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.85	9.12	0.6	5.28e-16	Prudent dietary pattern;
UCEC	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.53	4.69	0.36	6.09e-6	Menarche (age at onset);
UCEC	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Bipolar disorder;
UCEC	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg16584290	chr5:462447	EXOC3	-0.48	-4.8	-0.37	3.87e-6	Cystic fibrosis severity;
UCEC	cis	rs554111	0.891	rs531044	chr1:21057011	T/C	cg08890418	chr1:21044141	KIF17	0.62	6.51	0.47	1.09e-9	Facial morphology (factor 17, height of vermillion upper lip);
UCEC	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.68	5.74	0.43	5.27e-8	Menopause (age at onset);
UCEC	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg10902566	chr4:727664	PCGF3	-0.57	-5.02	-0.38	1.45e-6	Systolic blood pressure;
UCEC	cis	rs240764	0.554	rs723742	chr6:101237174	T/A	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg05279229	chr7:1896384	MAD1L1	-0.48	-4.92	-0.38	2.3e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22117172	chr7:91764530	CYP51A1	0.42	5.28	0.4	4.52e-7	Breast cancer;
UCEC	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.96	-0.5	1.04e-10	Personality dimensions;
UCEC	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	1.01	7.68	0.54	2.06e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.41	-9.25	-0.61	2.49e-16	Gout;
UCEC	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.99	7.44	0.52	7.74e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.69	7.08	0.5	5.61e-11	Menopause (age at onset);
UCEC	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.0	-11.17	-0.68	2.28e-21	Schizophrenia;
UCEC	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.6	4.82	0.37	3.5e-6	Longevity;
UCEC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.84	10.67	0.66	4.76e-20	Metabolic syndrome;
UCEC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.9	-0.44	2.45e-8	Bipolar disorder;
UCEC	cis	rs713477	0.901	rs1572612	chr14:55909939	C/T	cg13175173	chr14:55914753	NA	-0.4	-4.55	-0.35	1.09e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-9.41	-0.61	9.58e-17	Morning vs. evening chronotype;
UCEC	cis	rs4499344	0.730	rs35098593	chr19:33103939	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	6.09	0.45	9.41e-9	Mean platelet volume;
UCEC	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg19567339	chr10:100142640	NA	0.51	5.91	0.44	2.24e-8	Metabolite levels;
UCEC	cis	rs1832871	0.965	rs1832872	chr6:158721813	G/A	cg07215822	chr6:158701037	NA	0.51	5.15	0.39	8.36e-7	Height;
UCEC	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.89	-0.44	2.55e-8	Prudent dietary pattern;
UCEC	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	0.82	10.7	0.66	4.12e-20	Multiple myeloma;
UCEC	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-6.3	-0.46	3.26e-9	Crohn's disease;
UCEC	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg06873352	chr17:61820015	STRADA	-0.61	-6.24	-0.46	4.4e-9	Prudent dietary pattern;
UCEC	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.38	5.25	0.4	5.3e-7	Obesity-related traits;
UCEC	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.66	7.45	0.52	7.48e-12	Motion sickness;
UCEC	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-4.6	-0.35	9e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.64	-6.56	-0.48	8.78e-10	Longevity;Endometriosis;
UCEC	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.77	-7.34	-0.52	1.35e-11	Parkinson's disease;
UCEC	cis	rs80226907	0.634	rs1959443	chr14:55901321	A/G	cg13175173	chr14:55914753	NA	0.71	4.66	0.36	7.08e-6	Mean platelet volume;
UCEC	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg13593689	chr9:129986794	NA	0.45	4.52	0.35	1.29e-5	Intraocular pressure;
UCEC	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg13683864	chr3:40499215	RPL14	1.11	16.0	0.8	5.29e-34	Renal cell carcinoma;
UCEC	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-0.84	-6.25	-0.46	4.23e-9	Coronary artery disease;
UCEC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg06401019	chr5:92957098	FAM172A;MIR2277	0.66	5.02	0.38	1.5e-6	Diabetic retinopathy;
UCEC	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	13.62	0.75	7.55e-28	Chronic sinus infection;
UCEC	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.03	0.38	1.4e-6	Rheumatoid arthritis;
UCEC	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg08755490	chr11:65554678	OVOL1	0.52	5.41	0.41	2.47e-7	Acne (severe);
UCEC	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg07153921	chr17:41440717	NA	-0.56	-5.9	-0.44	2.41e-8	Menopause (age at onset);
UCEC	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg11569703	chr11:65557185	OVOL1	0.4	5.74	0.43	5.22e-8	Acne (severe);
UCEC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.28	-0.4	4.62e-7	Hemoglobin concentration;
UCEC	cis	rs2425143	0.818	rs2378414	chr20:34534374	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-4.6	-0.35	9.03e-6	Blood protein levels;
UCEC	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg05539622	chr2:73298971	SFXN5	0.48	4.56	0.35	1.07e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.51	5.02	0.38	1.5e-6	Menopause (age at onset);
UCEC	cis	rs11235843	0.571	rs10898928	chr11:73364847	G/A	cg09185399	chr11:73372479	PLEKHB1	0.59	4.61	0.36	8.76e-6	Hand grip strength;
UCEC	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.6	-6.43	-0.47	1.67e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-4.72	-0.36	5.43e-6	Tonsillectomy;
UCEC	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg22974920	chr21:40686053	BRWD1	0.61	5.31	0.4	3.96e-7	Cognitive function;
UCEC	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.85	7.72	0.54	1.62e-12	Body mass index;
UCEC	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.8	5.33	0.4	3.57e-7	Psoriasis;
UCEC	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.11	0.56	1.8e-13	Smoking behavior;
UCEC	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs1572072	0.545	rs9550983	chr13:24123397	A/G	cg24350296	chr13:24144486	TNFRSF19	-0.4	-4.96	-0.38	1.96e-6	Nasopharyngeal carcinoma;
UCEC	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.71	7.87	0.54	6.97e-13	Breast cancer;
UCEC	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.41	4.91	0.38	2.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7394339	1	rs7394339	chr10:85120682	A/G	cg27352715	chr10:85985222	LRIT2	0.61	4.61	0.36	8.55e-6	Obsessive-compulsive symptoms;
UCEC	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg22598563	chr5:131563921	P4HA2	0.34	4.55	0.35	1.11e-5	Blood metabolite levels;
UCEC	cis	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg20307385	chr11:47447363	PSMC3	0.52	5.03	0.38	1.39e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.54	5.03	0.38	1.44e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9470794	0.790	rs9369034	chr6:38146232	C/T	cg01504030	chr6:38141879	BTBD9	-0.79	-5.03	-0.38	1.38e-6	Type 2 diabetes;
UCEC	cis	rs7300001	0.504	rs12318462	chr12:110504717	C/A	cg13234997	chr12:110011138	MVK;MMAB	-0.96	-4.61	-0.36	8.62e-6	Headache;
UCEC	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg04833646	chr19:10679720	CDKN2D	0.94	9.47	0.62	6.56e-17	Red cell distribution width;
UCEC	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13683864	chr3:40499215	RPL14	-1.01	-10.69	-0.66	4.38e-20	Renal cell carcinoma;
UCEC	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.82	-0.37	3.53e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.77	-8.73	-0.58	5.09e-15	Height;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg21204522	chr6:27730016	NA	-0.57	-4.73	-0.36	5.32e-6	Depression;
UCEC	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-6.46	-0.47	1.44e-9	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs1165668	0.816	rs1866069	chr12:104310545	G/T	cg21863207	chr12:104234989	NT5DC3	-0.48	-4.6	-0.35	9.1e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg00857998	chr1:205179979	DSTYK	0.47	4.67	0.36	6.87e-6	Red blood cell count;
UCEC	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	0.91	9.18	0.6	3.72e-16	Coronary artery disease;
UCEC	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg24562669	chr7:97807699	LMTK2	0.49	5.8	0.43	4e-8	Breast cancer;
UCEC	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.63	-5.43	-0.41	2.29e-7	Initial pursuit acceleration;
UCEC	cis	rs7246967	0.673	rs7248107	chr19:22878529	G/T	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg05660106	chr1:15850417	CASP9	-0.5	-4.82	-0.37	3.49e-6	Systolic blood pressure;
UCEC	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.6	5.76	0.43	4.78e-8	Corneal astigmatism;
UCEC	cis	rs1568889	0.712	rs4567438	chr11:28380051	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	5.92	0.44	2.15e-8	Bipolar disorder;
UCEC	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.69	6.75	0.49	3.12e-10	Bladder cancer;
UCEC	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.57	-6.67	-0.48	4.76e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	9.77	0.63	1.09e-17	Cognitive ability;
UCEC	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg26114124	chr12:9217669	LOC144571	0.39	4.87	0.37	2.83e-6	Sjögren's syndrome;
UCEC	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.54	-5.3	-0.4	4.21e-7	Morning vs. evening chronotype;
UCEC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg21772509	chr8:41503840	NKX6-3	0.51	5.72	0.43	5.9e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.14	15.04	0.78	1.52e-31	Cognitive function;
UCEC	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-6.23	-0.46	4.76e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.6	8.83	0.59	2.88e-15	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.47	0.41	1.93e-7	Breast cancer;
UCEC	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.7	0.36	5.93e-6	Breast cancer;
UCEC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.53	5.53	0.41	1.43e-7	Bipolar disorder;
UCEC	cis	rs10506710	0.791	rs17808669	chr12:73443445	C/T	cg13663218	chr12:72666976	LOC283392;TRHDE	-0.33	-4.91	-0.38	2.41e-6	Systolic blood pressure;
UCEC	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.45	4.56	0.35	1.06e-5	Tuberculosis;
UCEC	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	0.78	7.15	0.51	3.85e-11	Testicular germ cell tumor;
UCEC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.5	-5.24	-0.4	5.38e-7	Blood metabolite levels;
UCEC	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	1.06	9.81	0.63	8.82e-18	Corneal structure;
UCEC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg14664628	chr15:75095509	CSK	-0.52	-5.19	-0.39	6.84e-7	Breast cancer;
UCEC	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.57	4.61	0.36	8.66e-6	Orofacial clefts;
UCEC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.65	6.33	0.46	2.81e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.42	0.52	8.49e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.98	-0.44	1.66e-8	Breast cancer;
UCEC	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg07169764	chr2:136633963	MCM6	0.75	7.11	0.51	4.56e-11	Corneal structure;
UCEC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs13437751	0.649	rs10235050	chr7:63348783	T/C	cg00787055	chr7:63562162	NA	0.49	5.1	0.39	1.01e-6	QT interval (drug interaction);
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.02	-0.44	1.36e-8	Pulmonary function;
UCEC	cis	rs11958404	0.929	rs79656592	chr5:157430291	G/A	cg05962755	chr5:157440814	NA	0.75	5.27	0.4	4.79e-7	IgG glycosylation;
UCEC	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg23793686	chr15:68133972	NA	-0.35	-4.59	-0.35	9.63e-6	Restless legs syndrome;
UCEC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.55	5.67	0.42	7.16e-8	Corneal astigmatism;
UCEC	cis	rs2147959	0.883	rs10916314	chr1:228633332	A/T	cg25874119	chr1:228633904	NA	0.53	5.95	0.44	1.87e-8	Adult asthma;
UCEC	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg17420585	chr12:42539391	GXYLT1	0.39	5.01	0.38	1.57e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-5.38	-0.41	2.89e-7	Alcohol dependence;
UCEC	cis	rs1816854	0.938	rs11182273	chr12:44202901	C/G	cg20956634	chr12:44200518	TWF1	0.54	5.6	0.42	1.03e-7	Inflammatory bowel disease;
UCEC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.52	5.21	0.39	6.23e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.79	-8.88	-0.59	2.12e-15	Height;
UCEC	cis	rs78487399	0.808	rs75934770	chr2:43659694	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-4.67	-0.36	6.82e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg16797656	chr11:68205561	LRP5	0.49	5.68	0.42	6.93e-8	Total body bone mineral density;
UCEC	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	4.69	0.36	6.18e-6	Colorectal cancer;
UCEC	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.25	-0.4	5.19e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg00599163	chr2:162100495	NA	0.37	4.53	0.35	1.23e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.25	0.46	4.3e-9	Coffee consumption (cups per day);
UCEC	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg13777783	chr17:79615861	NA	0.33	4.62	0.36	8.39e-6	Eye color traits;
UCEC	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg03959625	chr15:84868606	LOC388152	0.45	4.59	0.35	9.41e-6	Schizophrenia;
UCEC	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.58	-5.46	-0.41	1.97e-7	Blood protein levels;
UCEC	cis	rs1483890	0.723	rs6549207	chr3:69412018	T/G	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	7.37	0.52	1.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.65	0.48	5.51e-10	Motion sickness;
UCEC	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.65	6.22	0.46	4.98e-9	Menarche (age at onset);
UCEC	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.74	7.58	0.53	3.5e-12	Blood protein levels;
UCEC	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.34	4.78	0.37	4.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg09997546	chr11:8931473	C11orf17;ST5	-0.39	-4.91	-0.38	2.4e-6	Hemoglobin concentration;
UCEC	cis	rs73206853	0.764	rs57033697	chr12:110550992	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	5.56	0.42	1.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.53	6.02	0.44	1.34e-8	Anterior chamber depth;
UCEC	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg19743168	chr1:23544995	NA	0.42	5.87	0.44	2.77e-8	Height;
UCEC	cis	rs7004769	0.554	rs74995105	chr8:9168567	T/C	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.98	6.3	0.46	3.32e-9	Platelet count;
UCEC	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.673	rs56663398	chr19:22820200	C/T	cg08271804	chr19:22816896	ZNF492	0.66	6.62	0.48	6.39e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.48	-5.98	-0.44	1.6e-8	Mean platelet volume;
UCEC	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.81	7.81	0.54	9.83e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.47	5.43	0.41	2.28e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7766436	0.885	rs13210010	chr6:22585075	C/T	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.69	6.21	0.46	5.12e-9	Plasma homocysteine levels (post-methionine load test);
UCEC	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.54	-5.49	-0.41	1.76e-7	Hepatocellular carcinoma;
UCEC	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.64	5.61	0.42	9.65e-8	Aortic root size;
UCEC	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg18681998	chr4:17616180	MED28	0.61	7.06	0.5	6.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.68	5.78	0.43	4.26e-8	Smoking initiation;
UCEC	cis	rs4434872	0.536	rs34665499	chr1:153892136	A/G	cg00151906	chr1:154548273	CHRNB2	0.56	4.55	0.35	1.1e-5	Conduct disorder (symptom count);
UCEC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-9.03	-0.6	9.07e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.1	0.56	1.9e-13	Electrocardiographic conduction measures;
UCEC	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg04374321	chr14:90722782	PSMC1	0.55	4.99	0.38	1.71e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	5.97	0.44	1.68e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.65	8.01	0.55	3.24e-13	Mean platelet volume;
UCEC	cis	rs8177876	0.822	rs9938965	chr16:81113163	G/C	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs6840360	0.607	rs6815320	chr4:152432500	T/C	cg02366345	chr4:152330872	FAM160A1	0.34	4.62	0.36	8.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.58	5.77	0.43	4.52e-8	Lung cancer;
UCEC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.47	-4.8	-0.37	3.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1981331	0.609	rs76937225	chr21:48069682	C/T	cg17243659	chr21:48055224	PRMT2	1.04	4.51	0.35	1.32e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21643547	chr1:205240462	TMCC2	-0.35	-5.09	-0.39	1.07e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs362296	0.698	rs3095080	chr4:3264418	C/T	cg08886695	chr4:3369023	RGS12	0.49	5.07	0.39	1.18e-6	Parental longevity (mother's age at death);
UCEC	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.28	-0.4	4.65e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7187365	0.671	rs36111922	chr16:86495235	C/G	cg02260710	chr16:85730584	NA	-0.41	-5.43	-0.41	2.33e-7	Obesity (early onset extreme);
UCEC	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg17425144	chr1:10567563	PEX14	0.45	5.2	0.39	6.5e-7	Prostate cancer;
UCEC	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.67	5.07	0.39	1.19e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.07	-9.39	-0.61	1.09e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.43	-5.63	-0.42	8.87e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs17123764	0.710	rs12315224	chr12:50109517	T/C	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.64	6.0	0.44	1.5e-8	Aortic root size;
UCEC	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.67	6.19	0.45	5.83e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.63	-6.16	-0.45	6.69e-9	Huntington's disease progression;
UCEC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.09	-0.45	9.34e-9	Metabolite levels;
UCEC	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.41	4.71	0.36	5.76e-6	Total body bone mineral density;
UCEC	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg04043695	chr12:129287642	SLC15A4	-0.71	-6.81	-0.49	2.35e-10	Systemic lupus erythematosus;
UCEC	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	0.64	6.74	0.49	3.44e-10	Homoarginine levels;
UCEC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.89	0.49	1.55e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.69	6.91	0.49	1.4e-10	Multiple sclerosis;
UCEC	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.63	-5.75	-0.43	4.97e-8	Cardiac Troponin-T levels;
UCEC	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.63	6.35	0.46	2.55e-9	Adiposity;
UCEC	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10432489	0.708	rs6730421	chr2:181755815	A/G	cg21995919	chr2:182322279	ITGA4	0.69	5.39	0.41	2.79e-7	QT interval;
UCEC	cis	rs222458	0.534	rs6911850	chr6:52857697	A/G	cg24393602	chr6:52860404	GSTA4	0.6	5.13	0.39	9.06e-7	Staphylococcus aureus nasal carriage (intermittent);
UCEC	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	5.74	0.43	5.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.36	-4.66	-0.36	7.1e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs7165102	1.000	rs6494537	chr15:66051345	C/T	cg11164506	chr15:66649558	TIPIN	-0.33	-4.62	-0.36	8.36e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg12253828	chr6:101329408	ASCC3	0.76	5.59	0.42	1.07e-7	Economic and political preferences (immigration/crime);
UCEC	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg00852783	chr1:26633632	UBXN11	-0.5	-5.53	-0.42	1.39e-7	Obesity-related traits;
UCEC	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.61	5.71	0.43	5.9e-8	Schizophrenia;
UCEC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.39	-5.13	-0.39	8.89e-7	Alcohol dependence;
UCEC	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs11048434	1.000	rs7971932	chr12:9157346	G/A	cg23795048	chr12:9217529	LOC144571	0.49	5.26	0.4	4.98e-7	Sjögren's syndrome;
UCEC	cis	rs7246967	0.673	rs12985495	chr19:22930378	A/G	cg05241461	chr19:22816980	ZNF492	0.56	5.88	0.44	2.62e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs253959	0.696	rs1421846	chr5:115701137	A/G	cg23108291	chr5:115420582	COMMD10	0.46	4.69	0.36	6.26e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2816062	0.786	rs2816059	chr1:18902977	G/A	cg18795169	chr1:18902165	NA	-0.86	-12.44	-0.72	9.87e-25	Urate levels in lean individuals;
UCEC	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg19468946	chr17:37922297	IKZF3	-0.43	-4.55	-0.35	1.12e-5	Self-reported allergy;
UCEC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	7.11	0.51	4.7e-11	Platelet count;
UCEC	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.62	-5.07	-0.39	1.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg03146154	chr1:46216737	IPP	-0.54	-5.81	-0.43	3.73e-8	Red blood cell count;Reticulocyte count;
UCEC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg02160872	chr5:212506	CCDC127	-0.72	-7.48	-0.52	6.37e-12	Breast cancer;
UCEC	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	5.38	0.41	2.86e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.06e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg12302875	chr7:2499975	NA	-0.34	-4.52	-0.35	1.26e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.73	5.02	0.38	1.5e-6	Gut microbiome composition (summer);
UCEC	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.43	-4.88	-0.37	2.79e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	6.15	0.45	6.81e-9	Alzheimer's disease;
UCEC	cis	rs11235843	0.929	rs66481935	chr11:73380323	A/T	cg23931323	chr11:73372278	PLEKHB1	0.67	4.64	0.36	7.79e-6	Hand grip strength;
UCEC	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.79	-9.75	-0.63	1.24e-17	White blood cell count (basophil);
UCEC	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.5	4.75	0.36	4.72e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.65	-7.47	-0.52	6.46e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.83	7.19	0.51	3.12e-11	Longevity;
UCEC	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.49	5.22	0.4	6.05e-7	Aortic root size;
UCEC	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.81	-7.93	-0.55	5.02e-13	Obesity-related traits;
UCEC	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.98e-6	Tonsillectomy;
UCEC	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.58	4.97	0.38	1.85e-6	Obesity-related traits;
UCEC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg22974920	chr21:40686053	BRWD1	0.63	5.17	0.39	7.62e-7	Cognitive function;
UCEC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.76	5.03	0.38	1.39e-6	Major depressive disorder;
UCEC	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.79	7.42	0.52	8.74e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg04553112	chr3:125709451	NA	-0.66	-4.8	-0.37	3.79e-6	Blood pressure (smoking interaction);
UCEC	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg21827317	chr3:136751795	NA	-0.45	-4.61	-0.36	8.76e-6	Neuroticism;
UCEC	cis	rs7870753	0.838	rs10820666	chr9:99234997	G/T	cg25260653	chr9:99212216	HABP4	0.58	5.85	0.43	3.1e-8	Height;
UCEC	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg02344993	chr17:57696989	CLTC	0.49	4.73	0.36	5.29e-6	Hemoglobin concentration;
UCEC	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.61	5.51	0.41	1.55e-7	Morning vs. evening chronotype;
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	9.61	0.62	2.92e-17	Platelet count;
UCEC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg06238570	chr21:40685208	BRWD1	0.79	7.72	0.54	1.67e-12	Cognitive function;
UCEC	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.58	-5.57	-0.42	1.17e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs6717918	0.520	rs3103264	chr2:232990738	A/G	cg02061626	chr2:233274167	ALPPL2	-0.51	-5.52	-0.41	1.51e-7	Height;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg21486944	chr6:28411378	ZSCAN23	0.48	4.95	0.38	2.04e-6	Cardiac Troponin-T levels;
UCEC	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.72e-25	Height;
UCEC	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18932078	chr1:2524107	MMEL1	0.39	6.3	0.46	3.28e-9	Ulcerative colitis;
UCEC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.49	4.87	0.37	2.83e-6	Diastolic blood pressure;
UCEC	cis	rs425277	1.000	rs56383911	chr1:2068714	G/A	cg24578937	chr1:2090814	PRKCZ	0.54	4.72	0.36	5.37e-6	Height;
UCEC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg06238570	chr21:40685208	BRWD1	0.81	7.88	0.54	6.89e-13	Cognitive function;
UCEC	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	8.78	0.59	3.93e-15	Platelet count;
UCEC	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.78	7.54	0.53	4.45e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.63	6.43	0.47	1.71e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg19875535	chr5:140030758	IK	0.44	4.91	0.38	2.35e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-7.49	-0.53	5.97e-12	Menarche (age at onset);
UCEC	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.53	-5.28	-0.4	4.46e-7	Hip circumference;
UCEC	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-1.06	-7.22	-0.51	2.59e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.27e-7	Life satisfaction;
UCEC	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.65	-6.71	-0.48	3.96e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg06521331	chr12:34319734	NA	0.62	4.79	0.37	4.05e-6	Morning vs. evening chronotype;
UCEC	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21877473	chr15:44617767	CASC4	0.44	4.53	0.35	1.23e-5	Lung cancer in ever smokers;
UCEC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg11632617	chr15:75315747	PPCDC	-0.62	-7.21	-0.51	2.68e-11	Blood trace element (Zn levels);
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.54	-6.29	-0.46	3.44e-9	Depression;
UCEC	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.51	-5.69	-0.42	6.67e-8	Brugada syndrome;
UCEC	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.66	6.49	0.47	1.26e-9	Breast cancer;
UCEC	cis	rs13253111	0.624	rs7832318	chr8:28110414	A/G	cg26534493	chr8:28060551	NA	0.45	4.85	0.37	3.1e-6	Childhood body mass index;
UCEC	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.51	6.46	0.47	1.45e-9	Cystic fibrosis severity;
UCEC	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.78	-0.37	4.16e-6	Multiple sclerosis;
UCEC	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.46	4.51	0.35	1.32e-5	Breast cancer;
UCEC	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.68	6.06	0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.85	12.0	0.7	1.44e-23	Urate levels in lean individuals;
UCEC	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	6.57	0.48	8.37e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.28	-0.46	3.69e-9	Pulmonary function;
UCEC	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg13147721	chr7:65941812	NA	0.91	6.06	0.45	1.07e-8	Diabetic kidney disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05694870	chr2:157190958	NA	0.56	7.06	0.5	5.98e-11	Warfarin maintenance dose;
UCEC	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.24	-24.64	-0.9	4.76e-54	Myeloid white cell count;
UCEC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.56	5.53	0.42	1.39e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7070678	0.662	rs11007634	chr10:29803432	A/G	cg24350475	chr10:30316933	KIAA1462	0.51	4.58	0.35	9.91e-6	Platelet thrombus formation;
UCEC	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.48	5.06	0.39	1.21e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg19743168	chr1:23544995	NA	0.44	6.27	0.46	3.84e-9	Height;
UCEC	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.83	4.95	0.38	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg01831904	chr17:28903510	LRRC37B2	0.48	5.1	0.39	1.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs3769124	0.513	rs78011982	chr2:239487105	C/T	cg17833746	chr17:40489785	STAT3	0.62	6.92	0.5	1.32e-10	Pulmonary function;
UCEC	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.12	-0.71	6.91e-24	Primary sclerosing cholangitis;
UCEC	cis	rs9463078	0.625	rs1891412	chr6:44760642	T/C	cg25276700	chr6:44698697	NA	0.47	5.39	0.41	2.77e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6903823	0.527	rs4713158	chr6:28277771	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.38	-0.41	2.9e-7	Pulmonary function;
UCEC	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.59	5.11	0.39	9.86e-7	Heart rate;
UCEC	cis	rs2120243	0.874	rs9868133	chr3:157151461	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.47	4.67	0.36	6.71e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg19680485	chr15:31195859	MTMR15	-0.62	-4.92	-0.38	2.32e-6	Huntington's disease progression;
UCEC	cis	rs7308134	0.891	rs12298882	chr12:1993258	T/C	cg16046261	chr12:1602312	ERC1	0.64	4.78	0.37	4.23e-6	QRS duration in Tripanosoma cruzi seropositivity;
UCEC	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.54	4.6	0.35	9.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs56281245	0.793	rs11948853	chr5:145062940	G/A	cg14510905	chr5:145040858	NA	0.5	4.52	0.35	1.27e-5	Hepcidin levels;
UCEC	cis	rs1519814	1.000	rs4271006	chr8:121146640	T/G	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.71	-6.45	-0.47	1.51e-9	Coronary artery disease;
UCEC	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.72	-8.91	-0.59	1.81e-15	Menarche (age at onset);
UCEC	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.6	5.92	0.44	2.23e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.32	-4.52	-0.35	1.24e-5	Alzheimer's disease (late onset);
UCEC	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.54	5.14	0.39	8.55e-7	Tonsillectomy;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.93	9.49	0.62	5.74e-17	Platelet count;
UCEC	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.84	0.49	1.98e-10	Cognitive test performance;
UCEC	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg24687543	chr11:63912206	MACROD1	0.57	4.87	0.37	2.87e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.66	-5.7	-0.43	6.25e-8	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.36	-0.46	2.47e-9	Parkinson's disease;
UCEC	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg08027265	chr7:2291960	NA	0.44	4.66	0.36	6.99e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-4.86	-0.37	2.97e-6	Hypospadias;
UCEC	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.8	8.93	0.59	1.61e-15	Immature fraction of reticulocytes;
UCEC	cis	rs256277	0.544	rs26556	chr5:111328992	A/G	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-5.03	-0.38	1.41e-6	Coronary artery disease;
UCEC	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.47	7.19	0.51	2.98e-11	Primary biliary cholangitis;
UCEC	cis	rs12428035	0.764	rs2170813	chr13:96739321	C/G	cg07859753	chr13:96300257	NA	0.59	4.65	0.36	7.3e-6	Response to statins (LDL cholesterol change);Glomerular filtration rate (cystatin C);
UCEC	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.77	-8.92	-0.59	1.66e-15	Menarche (age at onset);
UCEC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.59	-6.39	-0.47	2.1e-9	Obesity-related traits;
UCEC	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg14078730	chr11:63896557	MACROD1	0.52	5.73	0.43	5.46e-8	Platelet count;
UCEC	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg06784218	chr1:46089804	CCDC17	0.61	7.87	0.54	7.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	8.0	0.55	3.41e-13	Platelet count;
UCEC	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	12.6	0.72	3.9e-25	Prudent dietary pattern;
UCEC	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.46	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.58	6.41	0.47	1.9e-9	Monocyte percentage of white cells;
UCEC	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.84	-8.65	-0.58	8.25e-15	Blood metabolite levels;
UCEC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.94	-0.44	1.95e-8	Menarche (age at onset);
UCEC	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.7	-7.13	-0.51	4.16e-11	Vitamin D levels;
UCEC	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg05855489	chr10:104503620	C10orf26	-0.49	-4.84	-0.37	3.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.59	0.35	9.63e-6	Parkinson's disease;
UCEC	cis	rs10140922	0.567	rs8015470	chr14:35635209	C/T	cg20478089	chr14:35099711	SNX6	-0.43	-4.84	-0.37	3.26e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.8	-0.37	3.79e-6	Resting heart rate;
UCEC	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.51	7.15	0.51	3.73e-11	Multiple system atrophy;
UCEC	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22455342	chr2:225449267	CUL3	0.54	5.54	0.42	1.39e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	4.99	0.38	1.68e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.46	4.56	0.35	1.09e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.93	9.03	0.6	8.73e-16	Cognitive function;
UCEC	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.66	7.34	0.52	1.31e-11	Breast cancer;
UCEC	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.57	5.63	0.42	8.92e-8	Hemoglobin concentration;
UCEC	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.31	-0.4	3.94e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	13.3	0.74	5.27e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7595037	0.663	rs7421075	chr2:68656342	T/C	cg12452813	chr2:68675892	NA	-0.48	-4.57	-0.35	1.01e-5	Multiple sclerosis;
UCEC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg13695892	chr22:41940480	POLR3H	-0.7	-5.49	-0.41	1.71e-7	Vitiligo;
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.0	11.49	0.69	3.3e-22	Height;
UCEC	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.48	-6.32	-0.46	2.99e-9	Neutrophil percentage of white cells;
UCEC	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.39	4.52	0.35	1.24e-5	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.7	8.18	0.56	1.26e-13	Breast cancer;
UCEC	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg02160872	chr5:212506	CCDC127	-0.82	-8.38	-0.57	4e-14	Breast cancer;
UCEC	cis	rs9467773	1.000	rs1570059	chr6:26573325	C/T	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07905965	chr19:39260460	NA	0.41	4.67	0.36	6.69e-6	Heart rate;
UCEC	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.51	-5.45	-0.41	2.12e-7	Pulse pressure;
UCEC	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg12637676	chr8:11587161	GATA4	-0.36	-4.61	-0.36	8.65e-6	Retinal vascular caliber;
UCEC	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg21419209	chr3:44054225	NA	-0.52	-5.16	-0.39	7.95e-7	Coronary artery disease;
UCEC	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-5.23	-0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.64	5.02	0.38	1.44e-6	Resting heart rate;
UCEC	cis	rs4851266	0.898	rs12614880	chr2:100849341	A/G	cg14675211	chr2:100938903	LONRF2	0.65	6.27	0.46	3.78e-9	Educational attainment;
UCEC	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.49	-4.94	-0.38	2.1e-6	Body mass index;
UCEC	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.57	-0.35	1.02e-5	Bipolar disorder;
UCEC	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.52	4.64	0.36	7.54e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.26	0.4	5.07e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.7	-6.29	-0.46	3.43e-9	Parkinson's disease;
UCEC	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg04310649	chr10:35416472	CREM	-0.5	-4.76	-0.37	4.66e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.68	-0.36	6.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.65	6.14	0.45	7.5e-9	Lymphocyte counts;
UCEC	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.49	-4.75	-0.37	4.69e-6	Obesity-related traits;
UCEC	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg00343986	chr7:65444356	GUSB	-0.5	-4.62	-0.36	8.35e-6	Aortic root size;
UCEC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.15	-0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.09	0.39	1.09e-6	Birth weight;
UCEC	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.65	6.95	0.5	1.09e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-4.77	-0.37	4.37e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
UCEC	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.62	6.05	0.45	1.13e-8	Lymphocyte counts;
UCEC	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.87	0.37	2.79e-6	Aortic root size;
UCEC	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.02	8.27	0.56	7.34e-14	Exhaled nitric oxide output;
UCEC	cis	rs6546550	0.526	rs6546561	chr2:70174691	C/T	cg02498382	chr2:70120550	SNRNP27	-0.48	-4.95	-0.38	2e-6	Prevalent atrial fibrillation;
UCEC	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.05	-0.38	1.28e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.52	5.58	0.42	1.12e-7	Malaria;
UCEC	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.21	0.39	6.42e-7	Cognitive test performance;
UCEC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.5	-0.47	1.16e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.84	-8.46	-0.57	2.42e-14	Obesity-related traits;
UCEC	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.47	4.9	0.37	2.49e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg19875535	chr5:140030758	IK	-0.45	-4.62	-0.36	8.41e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.59	0.48	7.49e-10	Aortic root size;
UCEC	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.65	-5.31	-0.4	3.9e-7	Height;
UCEC	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.72	8.1	0.56	1.96e-13	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg01689657	chr7:91764605	CYP51A1	0.48	5.97	0.44	1.74e-8	Breast cancer;
UCEC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg06784218	chr1:46089804	CCDC17	0.54	6.29	0.46	3.36e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg01072550	chr1:21505969	NA	-0.66	-6.76	-0.49	3.1e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg11890956	chr21:40555474	PSMG1	1.03	11.99	0.7	1.57e-23	Cognitive function;
UCEC	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.51	5.12	0.39	9.56e-7	Cleft lip with or without cleft palate;
UCEC	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.6	4.97	0.38	1.83e-6	Eosinophilic esophagitis;
UCEC	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg11632617	chr15:75315747	PPCDC	-0.58	-5.19	-0.39	6.93e-7	Lung cancer;
UCEC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg01380346	chr19:18557039	ELL	-0.5	-5.22	-0.4	6.1e-7	Breast cancer;
UCEC	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg03924805	chr2:242211663	HDLBP	-0.45	-4.59	-0.35	9.44e-6	Joint mobility (Beighton score);
UCEC	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.4	4.54	0.35	1.18e-5	Menopause (age at onset);
UCEC	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.66	-7.01	-0.5	7.91e-11	Stearic acid (18:0) levels;
UCEC	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg16497661	chr14:103986332	CKB	0.48	5.55	0.42	1.29e-7	Body mass index;
UCEC	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.75	8.7	0.58	6.31e-15	IgG glycosylation;
UCEC	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.71	-0.36	5.74e-6	Total body bone mineral density;
UCEC	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.85	9.17	0.6	3.8e-16	Obesity-related traits;
UCEC	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg08461772	chr7:95026248	PON3	0.35	4.87	0.37	2.79e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg04310649	chr10:35416472	CREM	-0.49	-4.55	-0.35	1.14e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg01689657	chr7:91764605	CYP51A1	0.41	4.9	0.38	2.45e-6	Breast cancer;
UCEC	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.08	-0.39	1.11e-6	Colorectal cancer;
UCEC	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.57	7.27	0.51	1.95e-11	Anterior chamber depth;
UCEC	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs6565180	0.525	rs1132812	chr16:30198151	A/G	cg17640201	chr16:30407289	ZNF48	0.57	5.39	0.41	2.8e-7	Tonsillectomy;
UCEC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg13844804	chr7:814759	HEATR2	0.63	4.68	0.36	6.52e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs10819083	0.758	rs10819096	chr9:128742328	A/G	cg14916924	chr9:129433969	LMX1B	0.38	4.59	0.35	9.48e-6	Squamous cell lung carcinoma;
UCEC	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	5.06	0.39	1.22e-6	Lung cancer in ever smokers;
UCEC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg09491104	chr22:46646882	C22orf40	-0.67	-7.71	-0.54	1.74e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.46	0.47	1.44e-9	Personality dimensions;
UCEC	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	5.85	0.43	3.13e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.88	9.66	0.62	2.15e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.56	4.67	0.36	6.69e-6	Pulmonary function decline;
UCEC	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.72	0.58	5.61e-15	Total body bone mineral density;
UCEC	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs55670112	0.904	rs1453019	chr5:114271860	T/C	cg05461448	chr5:114880715	FEM1C	-0.43	-4.51	-0.35	1.34e-5	Epilepsy;
UCEC	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.56	6.13	0.45	7.73e-9	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
UCEC	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.85	10.77	0.66	2.64e-20	IgG glycosylation;
UCEC	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.37	4.53	0.35	1.21e-5	Educational attainment (years of education);
UCEC	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-4.83	-0.37	3.44e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	0.88	6.88	0.49	1.62e-10	Uric acid levels;
UCEC	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.52	-6.48	-0.47	1.27e-9	Total body bone mineral density;
UCEC	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.6	5.8	0.43	3.99e-8	Multiple myeloma (IgH translocation);
UCEC	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.38	-0.52	1.07e-11	Resting heart rate;
UCEC	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.65	6.12	0.45	7.96e-9	Coronary artery disease;
UCEC	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	0.82	7.1	0.51	4.83e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.56	5.3	0.4	4.16e-7	Coronary artery disease;
UCEC	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.74	5.57	0.42	1.19e-7	Pediatric areal bone mineral density (radius);
UCEC	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs36715	1.000	rs251213	chr5:127545605	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.47	0.41	1.89e-7	Breast cancer;
UCEC	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.65	5.97	0.44	1.7e-8	Schizophrenia;
UCEC	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7246967	0.673	rs4933027	chr19:22903972	A/C	cg24889512	chr19:22816950	ZNF492	-0.59	-6.22	-0.46	4.94e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.82	7.38	0.52	1.06e-11	Cognitive function;
UCEC	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.57	6.38	0.47	2.12e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs2194112	chr19:22926189	A/C	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg16164276	chr3:11034345	SLC6A1	-0.49	-4.65	-0.36	7.4e-6	Alzheimer's disease;
UCEC	cis	rs3956705	1.000	rs2392158	chr7:32980203	G/A	cg05721444	chr7:32995514	FKBP9	-0.5	-4.95	-0.38	2.01e-6	Red cell distribution width;
UCEC	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.15	0.51	3.8e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.43	4.52	0.35	1.26e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18252515	chr7:66147081	NA	-0.63	-5.49	-0.41	1.69e-7	Aortic root size;
UCEC	cis	rs7597155	0.811	rs4852319	chr2:69971429	G/A	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.37	-0.4	3e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs3825214	0.581	rs6489952	chr12:114758773	A/G	cg03104083	chr12:114887847	NA	-0.55	-4.75	-0.37	4.69e-6	Electrocardiographic traits;QRS duration;
UCEC	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.71	-0.36	5.75e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs17433710	0.500	rs10799857	chr1:162628852	A/G	cg19264028	chr1:162630153	DDR2	-0.89	-6.22	-0.46	4.93e-9	Dupuytren's disease;
UCEC	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.59	-6.1	-0.45	9.13e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-6.26	-0.46	4.05e-9	Lymphocyte counts;
UCEC	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs58521262	0.556	rs390911	chr19:23124745	A/C	cg08486875	chr19:23386892	NA	-0.33	-4.6	-0.35	8.96e-6	Testicular germ cell tumor;
UCEC	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg18232548	chr7:50535776	DDC	-0.71	-8.29	-0.56	6.58e-14	Body mass index;
UCEC	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.63	7.11	0.51	4.73e-11	Body mass index;
UCEC	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.52	-5.58	-0.42	1.14e-7	Body mass index;
UCEC	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.57	5.42	0.41	2.41e-7	Bladder cancer;
UCEC	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.69	6.07	0.45	1.03e-8	Bipolar disorder;
UCEC	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.68	6.74	0.49	3.31e-10	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.97	11.94	0.7	2.1e-23	Prudent dietary pattern;
UCEC	cis	rs2694528	0.686	rs7729781	chr5:59872406	C/T	cg11474532	chr5:59995715	DEPDC1B	0.61	4.6	0.35	9.17e-6	Parkinson's disease;
UCEC	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.72	5.13	0.39	9.03e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3772130	0.583	rs7618041	chr3:121566481	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.83	-8.57	-0.58	1.34e-14	Joint mobility (Beighton score);
UCEC	cis	rs1712517	0.771	rs10883857	chr10:105127587	A/C	cg05636881	chr10:105038444	INA	-0.47	-5.38	-0.41	2.86e-7	Migraine;
UCEC	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.32	4.6	0.35	9.07e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.61	-4.82	-0.37	3.59e-6	Schizophrenia;
UCEC	cis	rs4654899	0.680	rs2305463	chr1:21180181	C/T	cg01072550	chr1:21505969	NA	0.55	5.68	0.42	6.87e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7172971	0.688	rs7180420	chr15:42372872	A/G	cg27501645	chr15:41795087	ITPKA	0.63	4.56	0.35	1.08e-5	3-hydroxypropylmercapturic acid levels in smokers;
UCEC	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.67	-5.42	-0.41	2.39e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.83	0.59	2.84e-15	Chronic sinus infection;
UCEC	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.53	0.79	8.56e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-6.32	-0.46	3.01e-9	Menarche (age at onset);
UCEC	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.61	5.38	0.41	2.82e-7	Longevity;
UCEC	cis	rs56281245	1.000	rs9324986	chr5:145049595	C/T	cg14510905	chr5:145040858	NA	0.53	5.32	0.4	3.85e-7	Hepcidin levels;
UCEC	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	14.69	0.77	1.2e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.74	6.57	0.48	8.03e-10	Cognitive function;
UCEC	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.43	4.74	0.36	5e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg18681998	chr4:17616180	MED28	0.62	7.23	0.51	2.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.54	-6.5	-0.47	1.14e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	7.29	0.52	1.81e-11	Platelet count;
UCEC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.43	-4.6	-0.35	8.91e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs11867410	0.744	rs11872067	chr17:63938367	T/C	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6460942	1.000	rs79964328	chr7:12319392	A/C	cg06484146	chr7:12443880	VWDE	-0.84	-6.24	-0.46	4.49e-9	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-1.02	-11.5	-0.69	3.07e-22	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.42	-4.76	-0.37	4.61e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg13683864	chr3:40499215	RPL14	0.87	10.22	0.64	7.56e-19	Renal cell carcinoma;
UCEC	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.52	-4.89	-0.37	2.64e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg24375607	chr4:120327624	NA	0.48	4.61	0.36	8.73e-6	Corneal astigmatism;
UCEC	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg13147721	chr7:65941812	NA	-1.1	-5.91	-0.44	2.32e-8	Gout;
UCEC	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg19715936	chr7:50634035	DDC	0.43	4.59	0.35	9.37e-6	Malaria;
UCEC	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.54	-0.35	1.16e-5	Alzheimer's disease (late onset);
UCEC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs73206853	0.841	rs67974983	chr12:110519237	T/G	cg12870014	chr12:110450643	ANKRD13A	0.59	4.93	0.38	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.8	-0.37	3.88e-6	Testicular germ cell tumor;
UCEC	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg27299712	chr1:6550532	PLEKHG5	0.52	4.86	0.37	2.98e-6	Body mass index;
UCEC	cis	rs1335645	0.570	rs1591456	chr1:111632335	G/A	cg00321911	chr1:111669324	DRAM2	-0.67	-4.99	-0.38	1.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs11048434	0.966	rs1805677	chr12:9153559	C/G	cg23795048	chr12:9217529	LOC144571	-0.46	-4.92	-0.38	2.31e-6	Sjögren's syndrome;
UCEC	cis	rs2862064	0.872	rs2902132	chr5:156445525	C/T	cg12943317	chr5:156479607	HAVCR1	-0.75	-5.56	-0.42	1.22e-7	Platelet count;
UCEC	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.74	-7.86	-0.54	7.41e-13	Cognitive function;
UCEC	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.5	6.06	0.45	1.09e-8	Coronary artery disease;
UCEC	cis	rs117623576	0.680	rs211415	chr10:32397358	C/T	cg03047570	chr10:32398778	NA	0.56	5.14	0.39	8.58e-7	Anti-saccade response;
UCEC	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.67	6.88	0.49	1.62e-10	Chronic sinus infection;
UCEC	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.69	7.24	0.51	2.38e-11	Menarche (age at onset);
UCEC	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg13206674	chr6:150067644	NUP43	0.62	5.88	0.44	2.71e-8	Lung cancer;
UCEC	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.64	-0.36	7.59e-6	Breast cancer;
UCEC	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.8	8.27	0.56	7.23e-14	Menopause (age at onset);
UCEC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.81	8.37	0.57	4.16e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg00500100	chr5:140098250	VTRNA1-2	0.33	4.51	0.35	1.34e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.54	-0.42	1.36e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	5.08	0.39	1.13e-6	Electrocardiographic conduction measures;
UCEC	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.44	-4.88	-0.37	2.75e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.9	10.24	0.65	6.71e-19	Dental caries;
UCEC	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.77	-8.12	-0.56	1.72e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.51	5.29	0.4	4.31e-7	Breast cancer;
UCEC	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.39	0.47	2.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.7	-6.82	-0.49	2.24e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg03999872	chr20:62272968	STMN3	-0.48	-4.6	-0.36	8.88e-6	Atopic dermatitis;
UCEC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg22974920	chr21:40686053	BRWD1	0.56	4.89	0.37	2.57e-6	Cognitive function;
UCEC	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.63	5.61	0.42	9.55e-8	Heart rate;
UCEC	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.68	6.74	0.49	3.28e-10	Coronary artery disease;
UCEC	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-4.98	-0.38	1.78e-6	Mean platelet volume;
UCEC	cis	rs36715	0.953	rs36706	chr5:127556698	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	4.59	0.35	9.55e-6	Breast cancer;
UCEC	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.73	6.54	0.47	9.78e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	7.57	0.53	3.79e-12	Coronary artery disease;
UCEC	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg26114124	chr12:9217669	LOC144571	0.4	4.54	0.35	1.16e-5	Sjögren's syndrome;
UCEC	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.87	9.44	0.61	7.78e-17	Post bronchodilator FEV1;
UCEC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.85	-9.67	-0.62	2.02e-17	Cognitive function;
UCEC	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg11150807	chr10:43354902	NA	0.78	6.42	0.47	1.78e-9	Blood protein levels;
UCEC	cis	rs17106184	0.892	rs72900940	chr1:51124579	C/T	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-4.61	-0.36	8.7e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs12618769	0.652	rs3769701	chr2:99195111	A/C	cg10123293	chr2:99228465	UNC50	0.47	5.34	0.4	3.48e-7	Bipolar disorder;
UCEC	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg09904177	chr6:26538194	HMGN4	-0.75	-4.75	-0.36	4.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4778581	1.000	rs10851925	chr15:80398898	C/A	cg08257866	chr15:80351198	ZFAND6	0.4	4.58	0.35	9.67e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.22	0.56	9.95e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	8.91	0.59	1.77e-15	Platelet count;
UCEC	cis	rs12618769	0.652	rs17506535	chr2:99222834	G/C	cg10123293	chr2:99228465	UNC50	0.5	5.46	0.41	1.94e-7	Bipolar disorder;
UCEC	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.81	-8.27	-0.56	7.31e-14	Resting heart rate;
UCEC	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13569146	chr6:26330589	NA	-0.55	-4.75	-0.37	4.7e-6	Educational attainment;
UCEC	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.52	-5.64	-0.42	8.44e-8	Educational attainment;
UCEC	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-7.39	-0.52	1.03e-11	Educational attainment (years of education);
UCEC	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.75	-0.36	4.89e-6	Menopause (age at onset);
UCEC	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	5.6	0.42	1.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg25987502	chr17:6899865	ALOX12	0.35	4.55	0.35	1.12e-5	Tonsillectomy;
UCEC	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.82	0.63	8.37e-18	Blood protein levels;
UCEC	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.61	5.09	0.39	1.08e-6	Cardiac Troponin-T levels;
UCEC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.72	6.66	0.48	5.22e-10	Aortic root size;
UCEC	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-6.93	-0.5	1.21e-10	Ulcerative colitis;
UCEC	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg18681998	chr4:17616180	MED28	0.67	7.72	0.54	1.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-12.41	-0.72	1.2e-24	Primary sclerosing cholangitis;
UCEC	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.12	-0.45	8.25e-9	Pubertal anthropometrics;
UCEC	cis	rs782107	0.614	rs2643716	chr12:58768986	G/C	cg19181132	chr12:59314527	LRIG3	0.45	4.84	0.37	3.2e-6	Interleukin-12p70 levels;
UCEC	cis	rs4478037	1.000	rs75576169	chr3:33167801	G/A	cg19404215	chr3:33155277	CRTAP	0.86	6.59	0.48	7.28e-10	Major depressive disorder;
UCEC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	0.79	6.23	0.46	4.6e-9	Corneal structure;
UCEC	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg11871910	chr12:69753446	YEATS4	0.7	7.34	0.52	1.34e-11	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	6.9	0.49	1.44e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	11.53	0.69	2.67e-22	Chronic sinus infection;
UCEC	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.75	-8.46	-0.57	2.47e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.72	-0.66	3.56e-20	Schizophrenia;
UCEC	cis	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg08271804	chr19:22816896	ZNF492	0.67	6.48	0.47	1.28e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg21214455	chr15:72412075	SENP8	0.48	4.52	0.35	1.26e-5	Red blood cell count;
UCEC	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.54	5.31	0.4	4.06e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg09165964	chr15:75287851	SCAMP5	-0.55	-5.68	-0.42	6.87e-8	Lung cancer;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg20999797	chr1:1681921	NA	0.37	4.95	0.38	2e-6	Body mass index;
UCEC	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.12	-0.39	9.58e-7	Breast cancer;
UCEC	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-5.2	-0.39	6.43e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg06096015	chr1:231504339	EGLN1	0.41	4.83	0.37	3.39e-6	Hemoglobin concentration;
UCEC	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.61	7.3	0.52	1.71e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	8.79	0.59	3.62e-15	Hip circumference;
UCEC	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg05660106	chr1:15850417	CASP9	0.97	10.89	0.67	1.28e-20	Systolic blood pressure;
UCEC	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.83	-10.87	-0.67	1.45e-20	White blood cell count (basophil);
UCEC	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.73	-5.13	-0.39	9e-7	Mean platelet volume;
UCEC	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.39	4.65	0.36	7.18e-6	Response to anti-TNF therapy in rheumatoid arthritis;
UCEC	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.66	-7.93	-0.55	5.02e-13	IgG glycosylation;
UCEC	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.86	-11.22	-0.68	1.75e-21	Height;
UCEC	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.53	8.95	0.59	1.44e-15	Airflow obstruction;
UCEC	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18252515	chr7:66147081	NA	-0.55	-5.39	-0.41	2.79e-7	Aortic root size;
UCEC	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.69	6.54	0.47	9.63e-10	Menarche (age at onset);
UCEC	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.71	6.12	0.45	8.18e-9	Menopause (age at onset);
UCEC	cis	rs7309	0.967	rs3754970	chr2:162091836	T/C	cg00599163	chr2:162100495	NA	0.42	5.09	0.39	1.1e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.5	-6.23	-0.46	4.75e-9	Neuroticism;
UCEC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg01451880	chr3:45801044	SLC6A20	0.41	5.33	0.4	3.56e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7937612	0.965	rs10750172	chr11:120270253	A/G	cg12584626	chr11:120203529	NA	0.5	4.95	0.38	1.99e-6	Intraocular pressure;
UCEC	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg12310025	chr6:25882481	NA	-0.53	-4.84	-0.37	3.29e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.56	4.57	0.35	1.03e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.52	-5.18	-0.39	7.07e-7	Brugada syndrome;
UCEC	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg08351019	chr7:90893462	FZD1	-0.5	-5.32	-0.4	3.86e-7	Breast cancer;
UCEC	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	9.07	0.6	7.12e-16	Platelet count;
UCEC	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg07653901	chr22:50250238	ZBED4	0.77	5.0	0.38	1.59e-6	Schizophrenia;
UCEC	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg12558012	chr19:19281197	LOC729991-MEF2B;MEF2B	0.68	7.5	0.53	5.52e-12	IgG glycosylation;
UCEC	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.6	4.53	0.35	1.22e-5	Type 2 diabetes;
UCEC	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	5.56	0.42	1.23e-7	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.68	-6.11	-0.45	8.61e-9	Aortic root size;
UCEC	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.51	5.03	0.38	1.44e-6	Resting heart rate;
UCEC	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg19743168	chr1:23544995	NA	-0.43	-5.72	-0.43	5.64e-8	Height;
UCEC	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.16	0.39	7.74e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-4.75	-0.36	4.8e-6	Response to antipsychotic treatment;
UCEC	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.23	0.4	5.75e-7	HDL cholesterol;
UCEC	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.73	-5.35	-0.4	3.37e-7	Initial pursuit acceleration;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg21856205	chr7:94953877	PON1	-0.57	-5.07	-0.39	1.2e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.56	-6.36	-0.46	2.39e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.67	0.42	7.31e-8	Cognitive test performance;
UCEC	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16473166	chr22:50639996	SELO	-0.56	-5.39	-0.41	2.73e-7	Obesity-related traits;
UCEC	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg16583315	chr14:65563665	MAX	-0.44	-5.82	-0.43	3.55e-8	Obesity-related traits;
UCEC	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.82	-9.71	-0.63	1.56e-17	Paraoxonase activity;
UCEC	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.55	-0.42	1.31e-7	Response to antipsychotic treatment;
UCEC	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.24	-0.46	4.37e-9	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.59	8.59	0.58	1.19e-14	Prudent dietary pattern;
UCEC	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.46	4.54	0.35	1.16e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.28	0.4	4.63e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.73	4.58	0.35	9.9e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.51	4.93	0.38	2.15e-6	Blood protein levels;
UCEC	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.72	6.64	0.48	5.57e-10	Aortic root size;
UCEC	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.83	0.37	3.35e-6	Bipolar disorder;
UCEC	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.47	0.47	1.4e-9	Ileal carcinoids;
UCEC	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.58	5.05	0.38	1.27e-6	Parkinson's disease;
UCEC	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.7	6.55	0.48	8.92e-10	Height;
UCEC	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.83	-9.08	-0.6	6.81e-16	Cognitive function;
UCEC	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.55	5.97	0.44	1.69e-8	Brugada syndrome;
UCEC	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.65	7.54	0.53	4.38e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.59	5.64	0.42	8.59e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.43	-4.83	-0.37	3.46e-6	Prostate cancer;
UCEC	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-4.54	-0.35	1.17e-5	Alzheimer's disease (survival time);
UCEC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.31	-0.4	4.04e-7	Hemoglobin concentration;
UCEC	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.57	-5.18	-0.39	7.13e-7	Hypospadias;
UCEC	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.93	-13.26	-0.74	6.68e-27	Homoarginine levels;
UCEC	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.48	-5.25	-0.4	5.2e-7	Headache;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg06462703	chr12:133430564	CHFR	-0.54	-6.71	-0.48	3.91e-10	N-glycan levels;
UCEC	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.41	5.78	0.43	4.34e-8	Crohn's disease;
UCEC	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.27e-7	Life satisfaction;
UCEC	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.58	-6.02	-0.44	1.33e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3750082	0.889	rs11766608	chr7:32940086	C/T	cg05721444	chr7:32995514	FKBP9	0.56	6.2	0.46	5.31e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg17469321	chr7:55412551	NA	0.7	6.24	0.46	4.34e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.25	-0.4	5.22e-7	Headache;
UCEC	cis	rs7656342	0.653	rs11726221	chr4:9853863	C/A	cg11266682	chr4:10021025	SLC2A9	0.38	4.52	0.35	1.25e-5	Gut microbiota (bacterial taxa);
UCEC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-4.88	-0.37	2.68e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.54	0.58	1.52e-14	Exhaled nitric oxide output;
UCEC	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg09654669	chr8:57350985	NA	-0.55	-6.21	-0.46	5.24e-9	Obesity-related traits;
UCEC	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg18681998	chr4:17616180	MED28	0.84	10.12	0.64	1.37e-18	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.53	5.43	0.41	2.25e-7	Neutrophil percentage of white cells;
UCEC	cis	rs10507349	0.913	rs9581588	chr13:26777299	C/G	cg19792403	chr13:26796018	RNF6	0.54	4.57	0.35	1.05e-5	Type 2 diabetes;
UCEC	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.48	5.49	0.41	1.7e-7	White matter hyperintensity burden;
UCEC	cis	rs2288327	0.673	rs6723399	chr2:179381715	G/C	cg09915519	chr2:179397513	TTN;MIR548N	-0.59	-4.73	-0.36	5.25e-6	Atrial fibrillation;
UCEC	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg06462663	chr19:18546047	ISYNA1	0.51	6.45	0.47	1.52e-9	Breast cancer;
UCEC	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.45	5.74	0.43	5.34e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-9.51	-0.62	5.11e-17	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-6.6	-0.48	7e-10	Morning vs. evening chronotype;
UCEC	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.79	-7.15	-0.51	3.71e-11	Vitiligo;
UCEC	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.8	6.23	0.46	4.66e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.68	8.66	0.58	7.82e-15	Vitiligo;
UCEC	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.57	4.88	0.37	2.71e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs72720396	0.803	rs114993052	chr1:91190855	T/A	cg13456504	chr1:91191583	NA	0.58	4.83	0.37	3.36e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.58	-6.17	-0.45	6.44e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs4933027	chr19:22903972	A/C	cg08271804	chr19:22816896	ZNF492	-0.64	-6.21	-0.46	5.21e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.74	-6.38	-0.47	2.22e-9	Bipolar disorder;
UCEC	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-4.79	-0.37	4.08e-6	Platelet distribution width;
UCEC	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.08	0.55	2.12e-13	Sudden cardiac arrest;
UCEC	cis	rs9400271	0.504	rs9784763	chr6:109624937	A/G	cg01475377	chr6:109611718	NA	0.36	4.5	0.35	1.35e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg19041857	chr6:27730383	NA	-0.5	-4.93	-0.38	2.17e-6	Breast cancer;
UCEC	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.29	-0.4	4.44e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs6921919	0.638	rs1416920	chr6:28302784	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.87	-0.37	2.9e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.72	-4.61	-0.36	8.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs80226907	0.634	rs59169706	chr14:55913082	G/A	cg13175173	chr14:55914753	NA	0.73	4.68	0.36	6.55e-6	Mean platelet volume;
UCEC	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.53	5.3	0.4	4.18e-7	Dupuytren's disease;
UCEC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg19318889	chr4:1322082	MAEA	0.57	6.94	0.5	1.17e-10	Longevity;
UCEC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.75	-7.01	-0.5	8e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs78707713	0.891	rs17490626	chr10:71218646	G/C	cg00210249	chr10:71135679	HK1	-0.82	-4.53	-0.35	1.19e-5	Venous thromboembolism;
UCEC	cis	rs9341808	0.644	rs76102095	chr6:80942026	G/C	cg08355045	chr6:80787529	NA	-0.4	-5.02	-0.38	1.46e-6	Sitting height ratio;
UCEC	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.8	9.0	0.6	1.06e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg23972785	chr8:11611189	GATA4	-0.35	-4.51	-0.35	1.32e-5	Neuroticism;
UCEC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-6.33	-0.46	2.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.43	5.02	0.38	1.48e-6	Blood protein levels;
UCEC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.75	8.58	0.58	1.2e-14	Longevity;Endometriosis;
UCEC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.71	0.54	1.72e-12	Alzheimer's disease;
UCEC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.58	-0.58	1.25e-14	Mean platelet volume;
UCEC	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.57e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.44	-5.19	-0.39	6.93e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-5.03	-0.38	1.41e-6	Diabetic retinopathy;
UCEC	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg09654669	chr8:57350985	NA	-0.55	-6.23	-0.46	4.61e-9	Obesity-related traits;
UCEC	cis	rs4851266	0.765	rs11123821	chr2:100871189	A/C	cg14675211	chr2:100938903	LONRF2	0.66	6.54	0.47	9.54e-10	Educational attainment;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13412395	chr9:102583693	NR4A3	0.7	8.73	0.58	5.27e-15	Warfarin maintenance dose;
UCEC	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.66	7.62	0.53	2.85e-12	Monocyte count;
UCEC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg07424592	chr7:64974309	NA	0.77	4.77	0.37	4.39e-6	Diabetic kidney disease;
UCEC	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg05660106	chr1:15850417	CASP9	0.85	9.76	0.63	1.18e-17	Systolic blood pressure;
UCEC	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.67	5.86	0.44	2.92e-8	Cognitive function;
UCEC	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.47	-5.26	-0.4	5.02e-7	Coronary artery disease;
UCEC	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.6	4.91	0.38	2.36e-6	Menopause (age at onset);
UCEC	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg08471335	chr22:46685653	TTC38	0.43	4.5	0.35	1.35e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg06166341	chr4:1223170	CTBP1	0.58	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg14851346	chr12:38532713	NA	0.52	5.02	0.38	1.47e-6	Heart rate;
UCEC	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.54	-5.99	-0.44	1.53e-8	Diastolic blood pressure;
UCEC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg06238570	chr21:40685208	BRWD1	0.81	8.07	0.55	2.33e-13	Cognitive function;
UCEC	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.53	5.12	0.39	9.23e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.29	-0.56	6.37e-14	Total cholesterol levels;
UCEC	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.73	-4.51	-0.35	1.33e-5	Osteoarthritis;
UCEC	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.7	8.21	0.56	1.05e-13	Menarche (age at onset);
UCEC	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.65	6.64	0.48	5.55e-10	Itch intensity from mosquito bite;
UCEC	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.28e-21	Breast cancer;
UCEC	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg23307798	chr14:103986281	CKB	0.52	4.77	0.37	4.31e-6	Body mass index;
UCEC	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	1.03	13.74	0.75	3.75e-28	Ulcerative colitis;
UCEC	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg23070574	chr3:14187308	XPC	0.43	4.93	0.38	2.15e-6	Ovarian reserve;
UCEC	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg24069376	chr3:38537580	EXOG	0.46	5.55	0.42	1.28e-7	Electrocardiographic conduction measures;
UCEC	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-0.88	-11.14	-0.68	2.84e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg17515076	chr17:73810948	UNK	-0.52	-5.97	-0.44	1.72e-8	White matter hyperintensity burden;
UCEC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.67	6.87	0.49	1.7e-10	Multiple sclerosis;
UCEC	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg23791538	chr6:167370224	RNASET2	-0.47	-4.82	-0.37	3.49e-6	Primary biliary cholangitis;
UCEC	cis	rs16957091	0.738	rs8030587	chr15:42981806	C/T	cg24196017	chr15:43021976	CDAN1	-0.63	-6.57	-0.48	8.24e-10	MGMT methylation in smokers;
UCEC	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	6.41	0.47	1.82e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.74	7.97	0.55	4.04e-13	Lymphocyte counts;
UCEC	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.37	-5.85	-0.43	3.1e-8	Schizophrenia;
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.6	6.44	0.47	1.6e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.43	6.36	0.46	2.44e-9	Crohn's disease;
UCEC	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.61	-4.96	-0.38	1.88e-6	Gut microbiome composition (summer);
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.54	6.37	0.47	2.3e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.23	-0.4	5.64e-7	Hemoglobin concentration;
UCEC	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.42	4.75	0.36	4.86e-6	Alzheimer's disease (late onset);
UCEC	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.45	4.52	0.35	1.24e-5	Body mass index;
UCEC	cis	rs1483890	0.642	rs1843050	chr3:69403918	C/T	cg22125112	chr3:69402811	FRMD4B	-0.46	-4.91	-0.38	2.39e-6	Resting heart rate;
UCEC	cis	rs4372836	0.893	rs745645	chr2:28931571	G/T	cg09522027	chr2:28974177	PPP1CB	0.77	7.8	0.54	1.06e-12	Body mass index;
UCEC	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.5	5.5	0.41	1.61e-7	Alcohol dependence;
UCEC	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.81	10.62	0.66	6.49e-20	Developmental language disorder (linguistic errors);
UCEC	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg13147721	chr7:65941812	NA	-0.69	-4.83	-0.37	3.33e-6	Diabetic kidney disease;
UCEC	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.58	5.95	0.44	1.84e-8	Bipolar disorder;
UCEC	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.62	6.39	0.47	2.04e-9	Dental caries;
UCEC	cis	rs10507349	0.632	rs5028060	chr13:26819698	T/C	cg01600817	chr13:26797529	RNF6	-0.42	-4.62	-0.36	8.44e-6	Type 2 diabetes;
UCEC	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg03146154	chr1:46216737	IPP	-0.42	-4.54	-0.35	1.14e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7944735	0.508	rs111228939	chr11:47456067	T/C	cg20307385	chr11:47447363	PSMC3	-0.75	-4.81	-0.37	3.68e-6	Intraocular pressure;
UCEC	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.88	0.37	2.72e-6	Schizophrenia;
UCEC	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-0.82	-7.36	-0.52	1.19e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.68	6.86	0.49	1.76e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.97	-0.44	1.71e-8	Parkinson's disease;
UCEC	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg22532475	chr10:104410764	TRIM8	-0.45	-5.09	-0.39	1.09e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.61	6.07	0.45	1.06e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.7	4.52	0.35	1.27e-5	Mammographic density (dense area);
UCEC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.5	-5.99	-0.44	1.53e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.6	-5.65	-0.42	7.91e-8	Pancreatic cancer;
UCEC	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.58	5.55	0.42	1.33e-7	Uric acid levels;
UCEC	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.56	5.96	0.44	1.8e-8	Platelet count;
UCEC	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-1.0	-12.22	-0.71	3.84e-24	Obesity-related traits;
UCEC	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg17279458	chr3:44753948	ZNF502	-0.44	-4.6	-0.36	8.89e-6	Depressive symptoms;
UCEC	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.43	4.75	0.37	4.72e-6	Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs28795989	0.931	rs34317049	chr4:7898044	C/T	cg00251875	chr4:7801337	AFAP1	0.5	6.05	0.45	1.16e-8	Intraocular pressure;
UCEC	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.74	-0.43	5.29e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.49	5.3	0.4	4.08e-7	Aortic root size;
UCEC	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg01072550	chr1:21505969	NA	-0.63	-6.67	-0.48	4.84e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-5.99	-0.44	1.56e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4372836	0.543	rs11686412	chr2:28992405	A/G	cg09522027	chr2:28974177	PPP1CB	-0.76	-8.39	-0.57	3.63e-14	Body mass index;
UCEC	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg13777783	chr17:79615861	NA	-0.33	-4.66	-0.36	7.14e-6	Eye color traits;
UCEC	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.6	5.01	0.38	1.53e-6	Heart rate;
UCEC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.67	6.01	0.44	1.43e-8	Aortic root size;
UCEC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-7.01	-0.5	8.19e-11	Mean platelet volume;
UCEC	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.54	5.9	0.44	2.38e-8	Mood instability;
UCEC	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.6	5.48	0.41	1.78e-7	Type 2 diabetes;
UCEC	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.73	6.95	0.5	1.13e-10	Aortic root size;
UCEC	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.7	-7.25	-0.51	2.22e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs8177876	0.642	rs16954572	chr16:81112904	T/C	cg08591886	chr16:81111003	C16orf46	-0.79	-4.92	-0.38	2.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs9456883	0.511	rs9347792	chr6:164236262	C/T	cg03034180	chr6:163721894	PACRG	-0.36	-4.73	-0.36	5.17e-6	Sepsis in extremely premature infants;
UCEC	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg03342759	chr3:160939853	NMD3	-0.55	-5.29	-0.4	4.34e-7	Educational attainment (years of education);
UCEC	cis	rs4372836	1.000	rs34409160	chr2:28943865	C/T	cg09522027	chr2:28974177	PPP1CB	0.7	7.18	0.51	3.25e-11	Body mass index;
UCEC	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg17085576	chr10:5658249	NA	-0.5	-4.85	-0.37	3.11e-6	Breast cancer;
UCEC	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg18681998	chr4:17616180	MED28	0.79	9.2	0.6	3.25e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.62	7.02	0.5	7.56e-11	Mean platelet volume;
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.41	-0.47	1.88e-9	Prudent dietary pattern;
UCEC	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	4.66	0.36	7e-6	Response to antipsychotic treatment;
UCEC	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.73	6.51	0.47	1.11e-9	Coronary artery disease;
UCEC	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	8.08	0.55	2.19e-13	Tonsillectomy;
UCEC	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.81	9.25	0.61	2.37e-16	Menopause (age at onset);
UCEC	cis	rs731174	0.802	rs631102	chr1:38178836	C/T	cg06917450	chr1:38156652	C1orf109	-0.59	-5.35	-0.4	3.34e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.59	-0.35	9.48e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.58	5.55	0.42	1.33e-7	Uric acid levels;
UCEC	cis	rs36051895	0.632	rs10815165	chr9:5149138	T/C	cg02405213	chr9:5042618	JAK2	-0.48	-4.77	-0.37	4.39e-6	Pediatric autoimmune diseases;
UCEC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg12024160	chr4:1254474	NA	0.59	7.07	0.5	5.68e-11	Obesity-related traits;
UCEC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	4.95	0.38	1.98e-6	Rheumatoid arthritis;
UCEC	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.46	4.68	0.36	6.36e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.57	-5.58	-0.42	1.15e-7	Prudent dietary pattern;
UCEC	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.43e-9	Skin colour saturation;
UCEC	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.57	0.58	1.27e-14	Total body bone mineral density;
UCEC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.64	-5.15	-0.39	8.16e-7	Initial pursuit acceleration;
UCEC	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg05991184	chr2:219186017	PNKD	-0.47	-5.05	-0.38	1.28e-6	Colorectal cancer;
UCEC	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg15147215	chr3:52552868	STAB1	0.42	4.54	0.35	1.16e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.72	0.43	5.7e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-5.38	-0.41	2.87e-7	Chronic sinus infection;
UCEC	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	7.16	0.51	3.48e-11	Ileal carcinoids;
UCEC	cis	rs12980942	1.000	rs6957	chr19:41830606	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.6	5.37	0.41	2.97e-7	Coronary artery disease;
UCEC	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.0	0.38	1.63e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg06410510	chr2:107458059	ST6GAL2	-0.75	-6.89	-0.49	1.53e-10	Prostate cancer;
UCEC	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.14	0.45	7.46e-9	Tonsillectomy;
UCEC	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.44	-4.57	-0.35	1.03e-5	Asthma;
UCEC	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg02344993	chr17:57696989	CLTC	0.49	4.73	0.36	5.29e-6	Hemoglobin concentration;
UCEC	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.49	-4.86	-0.37	2.96e-6	Obesity-related traits;
UCEC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.55	-4.61	-0.36	8.56e-6	Initial pursuit acceleration;
UCEC	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg16532529	chr3:122101951	CCDC58;FAM162A	0.7	4.94	0.38	2.1e-6	Multiple sclerosis;
UCEC	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.58	6.22	0.46	5e-9	Initial pursuit acceleration;
UCEC	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.77	9.96	0.63	3.63e-18	Vitiligo;
UCEC	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs12019136	1	rs12019136	chr19:5835677	G/A	cg25387410	chr19:5844109	FUT3	-0.93	-9.08	-0.6	6.5e-16	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
UCEC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.59	5.26	0.4	4.97e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg18681998	chr4:17616180	MED28	0.66	6.35	0.46	2.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11931598	0.783	rs28385900	chr4:7050836	C/T	cg26116260	chr4:7069785	GRPEL1	0.44	4.51	0.35	1.29e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs9467773	1.000	rs6456735	chr6:26574149	G/A	cg05738196	chr6:26577821	NA	0.7	8.35	0.57	4.72e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs17718580	0.536	rs2047150	chr14:51086387	A/G	cg04730355	chr14:51134070	SAV1	0.72	7.27	0.51	1.98e-11	Cognitive performance;
UCEC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.61	5.38	0.41	2.82e-7	Longevity;
UCEC	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.4	-5.32	-0.4	3.81e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs3750082	0.889	rs1817050	chr7:32931906	T/G	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.84e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.44	5.25	0.4	5.15e-7	Tonsillectomy;
UCEC	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.7	-6.32	-0.46	2.94e-9	Neurofibrillary tangles;
UCEC	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.1	19.13	0.84	9.78e-42	Schizophrenia;
UCEC	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22455342	chr2:225449267	CUL3	0.52	5.45	0.41	2.06e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.68	-0.53	2.09e-12	IgG glycosylation;
UCEC	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg04726090	chr17:41856008	DUSP3	0.47	4.55	0.35	1.1e-5	Triglycerides;
UCEC	trans	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg15509575	chr4:2286509	ZFYVE28	0.42	7.38	0.52	1.07e-11	Rheumatoid arthritis;
UCEC	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	0.95	9.68	0.62	1.91e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.45	-0.47	1.56e-9	Crohn's disease;
UCEC	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.59	-5.67	-0.42	7.27e-8	Immature fraction of reticulocytes;
UCEC	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.53	5.3	0.4	4.08e-7	Menopause (age at onset);
UCEC	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	7.03	0.5	7.08e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6832769	1.000	rs3805152	chr4:56359658	C/T	cg05960024	chr4:56376020	CLOCK	0.54	5.06	0.39	1.25e-6	Personality dimensions;
UCEC	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.58	-5.85	-0.43	3.09e-8	Hepatocellular carcinoma;
UCEC	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.62	-5.2	-0.39	6.46e-7	Platelet distribution width;
UCEC	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg20387954	chr3:183756860	HTR3D	0.44	4.89	0.37	2.58e-6	Anterior chamber depth;
UCEC	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg13575925	chr12:9217583	LOC144571	0.4	4.52	0.35	1.26e-5	Sjögren's syndrome;
UCEC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.28	-0.51	1.89e-11	Blood trace element (Zn levels);
UCEC	cis	rs77861329	0.748	rs352152	chr3:52210700	A/C	cg08692210	chr3:52188851	WDR51A	-0.67	-6.02	-0.44	1.33e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.07	-6.82	-0.49	2.2e-10	Breast cancer;
UCEC	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg21053147	chr12:120880522	NA	-0.67	-5.52	-0.41	1.48e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs7517126	1.000	rs2336536	chr1:196839514	T/C	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.54	-6.62	-0.48	6.43e-10	Fibrinogen levels;
UCEC	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14019695	chr9:139328340	INPP5E	0.48	4.97	0.38	1.8e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.56	0.42	1.22e-7	Breast cancer;
UCEC	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg00298065	chr19:58715577	ZNF274	0.38	4.59	0.35	9.52e-6	Mean platelet volume;
UCEC	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	7.87e-8	Resting heart rate;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.76	8.08	0.55	2.12e-13	Menarche (age at onset);
UCEC	cis	rs6686929	1.000	rs1890787	chr1:18244913	T/C	cg03861428	chr1:17380702	SDHB	0.4	4.54	0.35	1.15e-5	Obesity-related traits;
UCEC	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	5.57	0.42	1.18e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.92	-0.38	2.34e-6	Aortic root size;
UCEC	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg12024160	chr4:1254474	NA	0.44	4.9	0.37	2.55e-6	Longevity;
UCEC	cis	rs6728642	0.519	rs6721921	chr2:97566501	G/A	cg26665480	chr2:98280029	ACTR1B	-0.59	-4.86	-0.37	3.03e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg05072774	chr3:49840536	C3orf54	-0.54	-5.64	-0.42	8.39e-8	Resting heart rate;
UCEC	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg21772509	chr8:41503840	NKX6-3	0.52	5.87	0.44	2.72e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
UCEC	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg01072550	chr1:21505969	NA	-0.63	-6.67	-0.48	4.84e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs12365397	0.698	rs10838081	chr11:43274207	A/T	cg07515919	chr11:43391688	TTC17	0.45	4.68	0.36	6.37e-6	Migraine;
UCEC	cis	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg08722104	chr11:47448306	PSMC3	-0.55	-4.83	-0.37	3.33e-6	Intraocular pressure;
UCEC	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg03748352	chr10:182365	ZMYND11	-0.54	-4.56	-0.35	1.06e-5	Uric acid levels;
UCEC	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg18681998	chr4:17616180	MED28	0.61	6.76	0.49	3.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.71	-6.35	-0.46	2.48e-9	Cognitive test performance;
UCEC	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.34	-0.4	3.5e-7	Bipolar disorder;
UCEC	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg21856205	chr7:94953877	PON1	-0.54	-5.2	-0.39	6.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.97e-8	Breast cancer;
UCEC	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	13.89	0.75	1.51e-28	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs883565	0.792	rs784501	chr3:39183895	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.54	-4.61	-0.36	8.83e-6	Handedness;
UCEC	cis	rs12145833	1.000	rs12145833	chr1:243483754	G/T	cg02356786	chr1:243265016	LOC731275	-0.65	-4.59	-0.35	9.28e-6	Obesity (early onset extreme);
UCEC	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.48	-0.41	1.83e-7	Mean corpuscular volume;
UCEC	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg18681998	chr4:17616180	MED28	0.91	12.13	0.71	6.85e-24	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg01843034	chr6:37503916	NA	-0.33	-4.74	-0.36	4.95e-6	Cognitive performance;
UCEC	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg15167202	chr5:149997153	SYNPO	-0.36	-4.61	-0.36	8.52e-6	HIV-1 control;
UCEC	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.55	-7.83	-0.54	8.81e-13	Total body bone mineral density;
UCEC	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	0.78	5.3	0.4	4.09e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
UCEC	cis	rs2307449	0.894	rs12592110	chr15:89844860	G/A	cg23124613	chr15:89731485	ABHD2	-0.4	-4.59	-0.35	9.4e-6	Menopause (age at onset);
UCEC	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.53	-5.26	-0.4	4.9e-7	IgG glycosylation;
UCEC	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.5	-5.29	-0.4	4.38e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.64	0.42	8.28e-8	Rheumatoid arthritis;
UCEC	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.51	-5.02	-0.38	1.48e-6	Menopause (age at onset);
UCEC	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-5.15	-0.39	8.1e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10924970	0.601	rs34636135	chr1:235465300	G/A	cg26050004	chr1:235667680	B3GALNT2	0.52	4.84	0.37	3.25e-6	Asthma;
UCEC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22117172	chr7:91764530	CYP51A1	0.4	5.12	0.39	9.33e-7	Breast cancer;
UCEC	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.25	9.53	0.62	4.71e-17	Uric acid levels;
UCEC	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.8	-4.66	-0.36	6.89e-6	Putamen volume;
UCEC	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg06027949	chr8:82754900	SNX16	0.6	5.07	0.39	1.18e-6	Diastolic blood pressure;
UCEC	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg18681998	chr4:17616180	MED28	0.58	6.56	0.48	8.45e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.78	7.4	0.52	9.65e-12	Bladder cancer;
UCEC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.72	-0.36	5.51e-6	Parkinson's disease;
UCEC	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg03146154	chr1:46216737	IPP	-0.45	-4.74	-0.36	4.94e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4865169	0.967	rs10023088	chr4:57884435	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.49	5.3	0.4	4.16e-7	Breast cancer;
UCEC	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.63	0.42	9.08e-8	Tonsillectomy;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.58	-6.4	-0.47	1.96e-9	Pubertal anthropometrics;
UCEC	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg12024160	chr4:1254474	NA	0.5	6.51	0.47	1.11e-9	Obesity-related traits;
UCEC	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	8.59	0.58	1.14e-14	Alzheimer's disease;
UCEC	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.6	0.53	3.2e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.39	4.58	0.35	9.71e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	7.89	0.55	6.18e-13	Tonsillectomy;
UCEC	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	0.83	5.25	0.4	5.22e-7	Arsenic metabolism;
UCEC	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.41	4.74	0.36	5.01e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs731174	0.797	rs501252	chr1:38154170	A/G	cg12339802	chr1:38156545	C1orf109	-0.61	-5.13	-0.39	9.08e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4478037	0.556	rs55680612	chr3:33100948	C/T	cg19404215	chr3:33155277	CRTAP	0.89	5.59	0.42	1.09e-7	Major depressive disorder;
UCEC	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg17259809	chr10:104614391	C10orf32	-0.71	-4.67	-0.36	6.62e-6	Arsenic metabolism;
UCEC	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg04756594	chr16:24857601	SLC5A11	0.48	4.65	0.36	7.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.79	8.78	0.59	3.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.44	5.34	0.4	3.41e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg07387570	chr22:46663686	TTC38	-0.47	-4.62	-0.36	8.32e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9715521	0.746	rs62301192	chr4:59843340	T/C	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.51	4.52	0.35	1.26e-5	Bipolar disorder;
UCEC	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.42	5.33	0.4	3.58e-7	Refractive error;
UCEC	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg04510874	chr15:91427884	FES	0.41	4.89	0.37	2.66e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.66	-0.42	7.8e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg27068330	chr11:65405492	SIPA1	-0.53	-4.71	-0.36	5.7e-6	Breast cancer;
UCEC	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	0.9	7.31	0.52	1.57e-11	Blood protein levels;
UCEC	cis	rs7246967	0.736	rs398945	chr19:22997116	A/T	cg24889512	chr19:22816950	ZNF492	-0.47	-4.68	-0.36	6.32e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.5	5.14	0.39	8.51e-7	Longevity;Endometriosis;
UCEC	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs4148689	0.951	rs1896888	chr7:117190598	T/C	cg21212505	chr7:117228958	CFTR	-0.41	-4.66	-0.36	7.08e-6	Gout;
UCEC	cis	rs7937612	0.802	rs36011588	chr11:120196433	C/G	cg12584626	chr11:120203529	NA	0.46	4.74	0.36	4.98e-6	Intraocular pressure;
UCEC	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.8	-9.96	-0.63	3.59e-18	White blood cell count (basophil);
UCEC	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-7.27	-0.51	1.93e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg26818010	chr10:134567672	INPP5A	-0.61	-6.17	-0.45	6.16e-9	Migraine;
UCEC	cis	rs8112909	0.843	rs1422627	chr19:46416738	C/T	cg08831348	chr19:46142212	EML2	0.58	4.62	0.36	8.38e-6	Interferon gamma-induced protein 10 levels;
UCEC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.74	-9.25	-0.61	2.42e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.66	5.79	0.43	4.02e-8	Alzheimer's disease;
UCEC	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.83	9.88	0.63	5.64e-18	Mortality in heart failure;
UCEC	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg07578070	chr6:150326732	RAET1K	0.43	4.58	0.35	9.84e-6	Alopecia areata;
UCEC	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.57	4.84	0.37	3.24e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Bipolar disorder;
UCEC	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.51	5.59	0.42	1.08e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9309473	1.000	rs10184268	chr2:73627044	C/T	cg20560298	chr2:73613845	ALMS1	-0.6	-5.44	-0.41	2.21e-7	Metabolite levels;
UCEC	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.65	6.07	0.45	1.02e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	7.07	0.5	5.93e-11	Cognitive test performance;
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.49	-6.64	-0.48	5.58e-10	Body mass index;
UCEC	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg09120320	chr17:61926383	NA	0.44	4.65	0.36	7.21e-6	Prudent dietary pattern;
UCEC	cis	rs10924970	0.649	rs4659656	chr1:235384114	A/G	cg26050004	chr1:235667680	B3GALNT2	0.5	5.01	0.38	1.55e-6	Asthma;
UCEC	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.52	5.06	0.39	1.24e-6	Response to antipsychotic treatment;
UCEC	cis	rs6722750	0.818	rs13411753	chr2:64394417	A/G	cg22352474	chr2:64371530	PELI1	0.5	4.73	0.36	5.18e-6	Neuroticism;
UCEC	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	5.43	0.41	2.33e-7	Menarche (age at onset);
UCEC	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg23791538	chr6:167370224	RNASET2	-0.55	-5.55	-0.42	1.28e-7	Crohn's disease;
UCEC	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.71	7.52	0.53	5.04e-12	Lymphocyte counts;
UCEC	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.71	6.29	0.46	3.51e-9	Subjective well-being;
UCEC	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.05	-6.79	-0.49	2.57e-10	Breast cancer;
UCEC	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.51	-4.98	-0.38	1.77e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.85	-8.36	-0.57	4.39e-14	Obesity-related traits;
UCEC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg03396347	chr1:1875803	NA	-0.36	-4.55	-0.35	1.1e-5	Body mass index;
UCEC	trans	rs925228	0.955	rs1400218	chr2:24145253	C/A	cg18674340	chr17:45867686	NA	0.73	6.75	0.49	3.24e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	7.87	0.54	7.23e-13	Response to antipsychotic treatment;
UCEC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.04e-6	Schizophrenia;
UCEC	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	1.18	7.1	0.51	5.06e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.68	-6.21	-0.46	5.06e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.71	-7.14	-0.51	4.02e-11	Blood metabolite levels;
UCEC	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.63	7.1	0.51	4.83e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	0.88	8.8	0.59	3.41e-15	Heart rate;
UCEC	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.53	4.92	0.38	2.31e-6	Diabetic retinopathy;
UCEC	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.54	-5.32	-0.4	3.85e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.75	-0.36	4.81e-6	Type 2 diabetes;
UCEC	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.69	6.72	0.48	3.71e-10	Menarche (age at onset);
UCEC	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	0.72	4.71	0.36	5.66e-6	Diabetic retinopathy;
UCEC	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.69	-0.42	6.77e-8	Fear of minor pain;
UCEC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg13695892	chr22:41940480	POLR3H	-0.66	-4.62	-0.36	8.3e-6	Vitiligo;
UCEC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.35	0.52	1.28e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg24687543	chr11:63912206	MACROD1	0.57	4.8	0.37	3.81e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	6.48	0.47	1.3e-9	Personality dimensions;
UCEC	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.65	4.65	0.36	7.3e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-6.0	-0.44	1.5e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg07386859	chr16:1872102	HAGH	-0.45	-4.81	-0.37	3.77e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	0.96	14.41	0.77	6.56e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg17279458	chr3:44753948	ZNF502	-0.43	-4.73	-0.36	5.12e-6	Depressive symptoms;
UCEC	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg18016565	chr1:150552671	MCL1	0.6	6.63	0.48	6.1e-10	Tonsillectomy;
UCEC	cis	rs4654899	0.680	rs4654874	chr1:21156667	C/T	cg01072550	chr1:21505969	NA	-0.55	-5.68	-0.42	7.02e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.65	5.55	0.42	1.29e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.5	4.96	0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	7.92	0.55	5.44e-13	Mean platelet volume;
UCEC	cis	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.91	9.65	0.62	2.21e-17	Cognitive function;
UCEC	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg14092571	chr14:90743983	NA	0.45	5.23	0.4	5.79e-7	Mortality in heart failure;
UCEC	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.83	-0.54	8.96e-13	Menarche (age at onset);
UCEC	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.77	-8.81	-0.59	3.15e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg04871131	chr7:94954202	PON1	-0.53	-5.27	-0.4	4.86e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.14	-0.45	7.31e-9	Crohn's disease;
UCEC	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.57	5.89	0.44	2.58e-8	Schizophrenia;
UCEC	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.45	-4.63	-0.36	7.87e-6	Schizophrenia;
UCEC	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg07537917	chr2:241836409	C2orf54	0.33	5.15	0.39	8.27e-7	Urinary metabolites;
UCEC	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.68	6.55	0.48	9.02e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg02160872	chr5:212506	CCDC127	-0.69	-7.43	-0.52	8.11e-12	Breast cancer;
UCEC	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-1.03	-6.85	-0.49	1.84e-10	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.78	-9.96	-0.63	3.6e-18	Blood protein levels;
UCEC	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg24687543	chr11:63912206	MACROD1	0.56	4.57	0.35	1.02e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.736	rs411131	chr19:22993439	G/A	cg05241461	chr19:22816980	ZNF492	0.48	4.52	0.35	1.25e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs77861329	1.000	rs352149	chr3:52209530	C/A	cg08692210	chr3:52188851	WDR51A	0.84	6.59	0.48	7.36e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.61	7.44	0.52	7.9e-12	Bone mineral density;
UCEC	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.66	5.72	0.43	5.9e-8	Schizophrenia;
UCEC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.55	5.18	0.39	7.11e-7	Homoarginine levels;
UCEC	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	5.35	0.4	3.29e-7	Coronary artery disease;
UCEC	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	4.82	0.37	3.47e-6	Multiple sclerosis;
UCEC	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.71	-8.43	-0.57	3.01e-14	Ulcerative colitis;
UCEC	cis	rs1519814	1.000	rs4504680	chr8:121132175	T/C	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs3849046	0.817	rs13160755	chr5:137885631	A/G	cg18180673	chr5:137827632	NA	-0.45	-4.52	-0.35	1.25e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9463078	0.702	rs929614	chr6:44771934	C/A	cg25276700	chr6:44698697	NA	-0.46	-5.34	-0.4	3.47e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18252515	chr7:66147081	NA	0.49	4.75	0.36	4.88e-6	Calcium levels;
UCEC	cis	rs295140	1.000	rs11888462	chr2:201160499	G/T	cg04283868	chr2:201171347	SPATS2L	0.53	5.25	0.4	5.2e-7	QT interval;
UCEC	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.83	-6.07	-0.45	1.02e-8	Pediatric areal bone mineral density (radius);
UCEC	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.84	9.57	0.62	3.69e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs4372836	0.677	rs4632298	chr2:29076282	T/C	cg09522027	chr2:28974177	PPP1CB	0.85	9.15	0.6	4.28e-16	Body mass index;
UCEC	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	6.19	0.45	5.75e-9	Tonsillectomy;
UCEC	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.58	5.91	0.44	2.3e-8	Tonsillectomy;
UCEC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.47	5.18	0.39	7.26e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.39	0.52	9.99e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-5.44	-0.41	2.16e-7	Obesity-related traits;
UCEC	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg20399509	chr21:47717575	C21orf57	-0.49	-5.38	-0.41	2.82e-7	Testicular germ cell tumor;
UCEC	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.64	5.0	0.38	1.62e-6	Platelet distribution width;
UCEC	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	0.99	14.62	0.77	1.84e-30	Homoarginine levels;
UCEC	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.69	8.27	0.56	7.24e-14	Neuroticism;
UCEC	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg24060327	chr5:131705240	SLC22A5	0.53	5.02	0.38	1.44e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.35	4.91	0.38	2.43e-6	Crohn's disease;
UCEC	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-0.84	-8.42	-0.57	3.12e-14	Breast cancer;
UCEC	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.44	-6.18	-0.45	6.06e-9	Rheumatoid arthritis;
UCEC	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.58	-5.24	-0.4	5.56e-7	Menopause (age at onset);
UCEC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.72	7.45	0.52	7.48e-12	Breast cancer;
UCEC	cis	rs427941	0.521	rs73187850	chr7:101867824	A/T	cg08135718	chr7:101819329	CUX1	0.54	5.53	0.41	1.44e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs10242455	0.867	rs10282706	chr7:99217424	G/A	cg18809830	chr7:99032528	PTCD1	-0.53	-4.52	-0.35	1.26e-5	Blood metabolite levels;
UCEC	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.62	-7.14	-0.51	3.93e-11	IgG glycosylation;
UCEC	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.47	4.89	0.37	2.64e-6	Blood metabolite levels;
UCEC	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg01256987	chr12:42539512	GXYLT1	-0.48	-5.42	-0.41	2.36e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.42	4.92	0.38	2.25e-6	Kawasaki disease;
UCEC	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg07250515	chr12:56618133	OBFC2B	0.62	5.28	0.4	4.53e-7	Psoriasis vulgaris;
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18402987	chr7:1209562	NA	0.49	5.11	0.39	1.01e-6	Longevity;Endometriosis;
UCEC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.55	4.82	0.37	3.56e-6	Menarche (age at onset);
UCEC	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.79	10.1	0.64	1.5e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2041895	0.509	rs1035236	chr12:107310797	C/T	cg13944111	chr12:107296891	NA	0.34	4.53	0.35	1.23e-5	Glaucoma (low intraocular pressure);
UCEC	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.7	-6.53	-0.47	1.02e-9	Body mass index;
UCEC	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-5.6	-0.42	1.04e-7	Morning vs. evening chronotype;
UCEC	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.59	-5.03	-0.38	1.44e-6	Reticulocyte count;
UCEC	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg16584290	chr5:462447	EXOC3	-0.47	-4.82	-0.37	3.52e-6	Cystic fibrosis severity;
UCEC	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.45	-5.95	-0.44	1.86e-8	IgG glycosylation;
UCEC	cis	rs72634258	0.503	rs71637401	chr1:7837012	G/A	cg26816564	chr1:7831052	VAMP3	0.92	4.98	0.38	1.78e-6	Inflammatory bowel disease;
UCEC	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.74	9.07	0.6	7.2e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.82	-9.42	-0.61	8.99e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-1.02	-12.33	-0.71	1.97e-24	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-4.97	-0.38	1.83e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.6	5.89	0.44	2.54e-8	Post bronchodilator FEV1;
UCEC	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.5	4.76	0.37	4.6e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.61	-5.55	-0.42	1.29e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.54	4.86	0.37	3.01e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.5	4.95	0.38	2.04e-6	Emphysema distribution in smoking;
UCEC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.85	10.61	0.66	7.02e-20	Mortality in heart failure;
UCEC	cis	rs1335645	0.570	rs12406191	chr1:111639491	C/G	cg00321911	chr1:111669324	DRAM2	-0.61	-4.53	-0.35	1.23e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00802000	chr16:706648	WDR90	-0.49	-5.66	-0.42	7.67e-8	Height;
UCEC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg11871910	chr12:69753446	YEATS4	1.07	13.42	0.74	2.54e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.53	-0.35	1.2e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.61	-6.46	-0.47	1.44e-9	Coronary artery disease;
UCEC	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.43	5.27	0.4	4.73e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-4.7	-0.36	5.92e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs10786436	0.609	rs4919234	chr10:100286047	A/C	cg24343515	chr10:99400468	PI4K2A	0.48	4.95	0.38	2.01e-6	Type 1 diabetes;
UCEC	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.63	6.4	0.47	1.96e-9	C-reactive protein levels;
UCEC	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.69	-5.89	-0.44	2.56e-8	Chronic sinus infection;
UCEC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.65	6.87	0.49	1.68e-10	Menopause (age at onset);
UCEC	cis	rs7581030	1.000	rs6760748	chr2:71600924	C/T	cg07678644	chr2:71558969	ZNF638	0.56	5.14	0.39	8.6e-7	Testicular germ cell tumor;
UCEC	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.45	-4.63	-0.36	8.01e-6	Alzheimer's disease (late onset);
UCEC	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.57	-5.78	-0.43	4.41e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.54	5.22	0.4	6.01e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs12367572	0.601	rs1495036	chr12:45410643	T/C	cg03114573	chr12:45410052	DBX2	-0.52	-6.04	-0.45	1.2e-8	Gut microbiome composition (summer);
UCEC	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.5	-0.41	1.62e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.58	-5.2	-0.39	6.64e-7	Hemoglobin concentration;Hematocrit;
UCEC	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg05874882	chr4:1763078	NA	-0.52	-4.78	-0.37	4.23e-6	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.9	8.16	0.56	1.4e-13	Bladder cancer;
UCEC	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	0.96	7.27	0.51	1.93e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.65	9.02	0.6	9.68e-16	Systolic blood pressure;
UCEC	trans	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg15509575	chr4:2286509	ZFYVE28	0.43	7.64	0.53	2.52e-12	Rheumatoid arthritis;
UCEC	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.73	7.59	0.53	3.44e-12	Caffeine consumption;
UCEC	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs78487399	0.908	rs17031095	chr2:43819139	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-5.08	-0.39	1.12e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.87	9.58	0.62	3.39e-17	Blood protein levels;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg15324453	chr15:40075013	FSIP1	0.62	6.98	0.5	9.42e-11	N-glycan levels;
UCEC	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.64	6.5	0.47	1.17e-9	C-reactive protein levels;
UCEC	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg04733989	chr22:42467013	NAGA	-0.48	-4.94	-0.38	2.06e-6	Cognitive function;
UCEC	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg07169764	chr2:136633963	MCM6	-0.51	-4.62	-0.36	8.33e-6	Colorectal cancer;
UCEC	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.64	6.84	0.49	1.99e-10	Longevity;Endometriosis;
UCEC	cis	rs4356932	0.688	rs59291856	chr4:76970801	T/C	cg22252999	chr4:76996414	ART3	0.45	4.61	0.36	8.74e-6	Blood protein levels;
UCEC	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.5	-4.9	-0.37	2.51e-6	Electroencephalogram traits;
UCEC	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.48	-6.38	-0.47	2.13e-9	Urinary metabolites;
UCEC	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg05110241	chr16:68378359	PRMT7	-0.54	-4.5	-0.35	1.36e-5	Magnesium levels;
UCEC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-5.19	-0.39	6.79e-7	Initial pursuit acceleration;
UCEC	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.46	-5.87	-0.44	2.77e-8	Prudent dietary pattern;
UCEC	cis	rs7246967	0.932	rs4932798	chr19:23051507	G/A	cg24889512	chr19:22816950	ZNF492	0.5	5.09	0.39	1.09e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.47	-6.39	-0.47	2.03e-9	Body mass index;
UCEC	cis	rs533123	0.816	rs569356	chr1:29136686	A/G	cg08366446	chr1:29138936	OPRD1	-0.8	-4.97	-0.38	1.82e-6	Schizophrenia;
UCEC	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-6.58	-0.48	7.75e-10	Platelet count;
UCEC	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.69	4.94	0.38	2.14e-6	Body mass index;
UCEC	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.24	-0.46	4.4e-9	Platelet count;
UCEC	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg23795048	chr12:9217529	LOC144571	0.42	5.02	0.38	1.5e-6	Sjögren's syndrome;
UCEC	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.68	-6.9	-0.49	1.48e-10	Cognitive function;
UCEC	cis	rs747782	0.527	rs1044269	chr11:47487740	G/A	cg08722104	chr11:47448306	PSMC3	0.44	4.54	0.35	1.18e-5	Intraocular pressure;
UCEC	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.22	0.56	9.83e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg02413938	chr2:239008929	ESPNL	-0.36	-4.57	-0.35	1.04e-5	Prostate cancer;
UCEC	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg23625390	chr15:77176239	SCAPER	0.46	4.52	0.35	1.29e-5	Blood metabolite levels;
UCEC	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg24375607	chr4:120327624	NA	0.65	5.63	0.42	8.78e-8	Corneal astigmatism;
UCEC	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.59	-5.95	-0.44	1.91e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.48	-5.15	-0.39	8.16e-7	Menarche (age at onset);
UCEC	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.36	10.93	0.67	9.95e-21	Night sleep phenotypes;
UCEC	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg18681998	chr4:17616180	MED28	0.7	8.09	0.55	2.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg13695892	chr22:41940480	POLR3H	0.68	5.34	0.4	3.43e-7	Vitiligo;
UCEC	cis	rs8112909	0.843	rs10414420	chr19:46415010	C/T	cg03208830	chr19:45909395	PPP1R13L;CD3EAP	-0.54	-4.52	-0.35	1.28e-5	Interferon gamma-induced protein 10 levels;
UCEC	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg00105475	chr2:10696890	NA	0.42	5.27	0.4	4.67e-7	Prostate cancer;
UCEC	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	5.58	0.42	1.13e-7	Menarche (age at onset);
UCEC	cis	rs6546886	0.957	rs11886928	chr2:74258529	T/G	cg14702570	chr2:74259524	NA	-0.43	-5.63	-0.42	8.67e-8	Dialysis-related mortality;
UCEC	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.74	-6.09	-0.45	9.51e-9	Caudate activity during reward;
UCEC	trans	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.7	-6.5	-0.47	1.18e-9	Aortic root size;
UCEC	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.54	5.77	0.43	4.55e-8	Schizophrenia;
UCEC	cis	rs2302190	0.882	rs3803751	chr17:56650356	A/G	cg12560992	chr17:57184187	TRIM37	0.53	4.69	0.36	6.08e-6	Vitamin D levels;
UCEC	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.74	4.88	0.37	2.72e-6	Neuroticism;
UCEC	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.32	-0.52	1.52e-11	Resting heart rate;
UCEC	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.46	6.34	0.46	2.66e-9	Plasma amyloid beta peptide concentrations (ABx-42);
UCEC	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	5.99	0.44	1.53e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.66	-4.86	-0.37	2.94e-6	Coronary artery disease;
UCEC	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs10851411	0.559	rs79044457	chr15:42895208	G/T	cg21293051	chr15:42870591	STARD9	0.78	5.01	0.38	1.55e-6	Glucose homeostasis traits;
UCEC	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.16	14.2	0.76	2.32e-29	Body mass index;
UCEC	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.84	5.98	0.44	1.65e-8	Orofacial clefts;
UCEC	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.11	-7.27	-0.51	1.92e-11	Diabetic kidney disease;
UCEC	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.65	-4.68	-0.36	6.53e-6	Aortic root size;
UCEC	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg14008862	chr17:28927542	LRRC37B2	0.62	4.87	0.37	2.81e-6	Body mass index;
UCEC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.7	7.12	0.51	4.47e-11	Menopause (age at onset);
UCEC	cis	rs17106184	1.000	rs1015085	chr1:51260668	C/A	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.62	5.99	0.44	1.52e-8	Lymphocyte counts;
UCEC	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.01	-0.67	6.03e-21	Chronic sinus infection;
UCEC	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg03609598	chr5:56110824	MAP3K1	0.66	5.3	0.4	4.24e-7	Initial pursuit acceleration;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.52	-0.41	1.52e-7	Alcohol dependence;
UCEC	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-0.9	-6.95	-0.5	1.09e-10	Mitochondrial DNA levels;
UCEC	cis	rs75804782	0.630	rs75921156	chr2:239279633	C/T	cg11815105	chr2:239148849	HES6	0.99	4.63	0.36	8e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg22771759	chr13:24902376	NA	0.45	4.73	0.36	5.25e-6	Obesity-related traits;
UCEC	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-6.04	-0.45	1.22e-8	Mean platelet volume;
UCEC	cis	rs10924970	0.601	rs12751195	chr1:235449195	T/C	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs7246967	0.551	rs8112442	chr19:22893369	C/T	cg08271804	chr19:22816896	ZNF492	0.67	6.57	0.48	8.11e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.58	7.0	0.5	8.66e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.71	8.02	0.55	3.05e-13	Menopause (age at onset);
UCEC	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	9.87	0.63	5.98e-18	Chronic sinus infection;
UCEC	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-6.08	-0.45	9.97e-9	Birth weight;
UCEC	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg01426195	chr3:39028469	NA	-0.75	-9.83	-0.63	7.69e-18	Handedness;
UCEC	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg19554555	chr3:13937349	NA	-0.53	-5.71	-0.43	6.08e-8	Ovarian reserve;
UCEC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.47e-8	Prostate cancer;
UCEC	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.62	4.8	0.37	3.82e-6	Prostate cancer;
UCEC	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.44	4.64	0.36	7.72e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg23034840	chr1:205782522	SLC41A1	0.52	4.73	0.36	5.33e-6	Menarche (age at onset);
UCEC	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.82	0.54	9.42e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.58	0.42	1.14e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.02	-8.39	-0.57	3.59e-14	White matter hyperintensity burden;
UCEC	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg16584290	chr5:462447	EXOC3	-0.48	-4.88	-0.37	2.72e-6	Cystic fibrosis severity;
UCEC	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg03859395	chr2:55845619	SMEK2	1.0	13.75	0.75	3.61e-28	Metabolic syndrome;
UCEC	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	0.88	5.21	0.39	6.24e-7	Skin colour saturation;
UCEC	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.69	0.36	6.29e-6	Rheumatoid arthritis;
UCEC	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.71	8.47	0.57	2.3e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	0.87	9.9	0.63	4.93e-18	Breast cancer;
UCEC	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.66	-6.08	-0.45	1.01e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.78	-0.49	2.76e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg02158880	chr13:53174818	NA	0.42	4.51	0.35	1.33e-5	Lewy body disease;
UCEC	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg13777783	chr17:79615861	NA	0.32	4.64	0.36	7.5e-6	Eye color traits;
UCEC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	4.8	0.37	3.8e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs847649	1.000	rs28856331	chr7:102543763	T/G	cg18108683	chr7:102477205	FBXL13	-0.61	-7.87	-0.54	7.03e-13	Morning vs. evening chronotype;
UCEC	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	7.09	0.5	5.19e-11	Motion sickness;
UCEC	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.72	-7.39	-0.52	1.01e-11	Body mass index;
UCEC	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.58	-6.3	-0.46	3.21e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.47	-5.21	-0.39	6.2e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg11459648	chr5:138714337	SLC23A1	-0.43	-4.61	-0.36	8.59e-6	Immune reponse to smallpox (secreted IFN-alpha);
UCEC	cis	rs12711979	0.509	rs882418	chr2:3820113	A/G	cg17052675	chr2:3827356	NA	-0.7	-9.87	-0.63	6.05e-18	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.61	-4.66	-0.36	6.92e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.51	5.1	0.39	1.03e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7004769	0.554	rs75975494	chr8:9169650	C/G	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	0.92	9.51	0.62	5.22e-17	Heart rate;
UCEC	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs8105895	0.935	rs62110986	chr19:22256771	G/A	cg24175803	chr19:22235144	ZNF257	-0.63	-5.5	-0.41	1.63e-7	Body mass index (change over time);
UCEC	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.69	6.07	0.45	1.03e-8	Bipolar disorder;
UCEC	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.53	5.02	0.38	1.45e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.49	-5.07	-0.39	1.19e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.61	-6.42	-0.47	1.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18252515	chr7:66147081	NA	-0.46	-4.7	-0.36	5.89e-6	Aortic root size;
UCEC	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.67	0.62	2e-17	Menopause (age at onset);
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	6.19	0.45	5.79e-9	Platelet count;
UCEC	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.72	0.36	5.36e-6	Personality dimensions;
UCEC	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.52	-5.18	-0.39	7.11e-7	Multiple sclerosis;
UCEC	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-10.02	-0.64	2.46e-18	Ulcerative colitis;
UCEC	cis	rs118105804	1.000	rs10765621	chr11:93402693	A/G	cg10353388	chr11:93474820	C11orf54;TAF1D	-1.05	-6.42	-0.47	1.8e-9	Scarlet fever;
UCEC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.38	0.76	8e-30	Height;
UCEC	cis	rs853679	0.657	rs1778483	chr6:28240991	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.86	-0.37	3.01e-6	Depression;
UCEC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.7	-5.73	-0.43	5.54e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg09796886	chr4:39640558	C4orf34	-0.63	-4.71	-0.36	5.78e-6	Plasma amyloid beta peptide concentrations (ABx-40);
UCEC	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.69	-0.36	6.14e-6	Monocyte percentage of white cells;
UCEC	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.81	-10.38	-0.65	2.74e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	7.5	0.53	5.51e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.73	6.6	0.48	6.97e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.92	10.18	0.64	9.59e-19	Cognitive function;
UCEC	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.82	8.56	0.58	1.37e-14	Longevity;Endometriosis;
UCEC	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.71	-6.25	-0.46	4.13e-9	Asthma;
UCEC	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.27	0.46	3.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.69	6.33	0.46	2.78e-9	Aortic root size;
UCEC	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.81	-8.35	-0.57	4.52e-14	Corneal structure;
UCEC	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.68	-0.36	6.43e-6	Total body bone mineral density;
UCEC	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.42	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.52	-5.18	-0.39	7.07e-7	Brugada syndrome;
UCEC	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.49	4.99	0.38	1.65e-6	Total body bone mineral density;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg10284592	chr11:57434942	ZDHHC5	0.66	7.05	0.5	6.35e-11	Triglyceride levels;
UCEC	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.57	-6.01	-0.44	1.37e-8	Coronary artery disease;
UCEC	cis	rs6704644	0.518	rs6750618	chr2:234369554	A/C	cg16719865	chr2:234394478	USP40	-0.59	-4.51	-0.35	1.3e-5	Bilirubin levels;
UCEC	cis	rs4654899	0.802	rs61781104	chr1:21257235	T/A	cg01072550	chr1:21505969	NA	-0.52	-4.66	-0.36	6.96e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-4.83	-0.37	3.42e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
UCEC	cis	rs731174	0.797	rs586252	chr1:38155265	G/C	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.29e-6	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.77	-9.58	-0.62	3.43e-17	Leprosy;
UCEC	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.86	-0.44	2.87e-8	Hemoglobin concentration;
UCEC	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg20129853	chr10:51489980	NA	0.39	4.75	0.36	4.77e-6	Prostate-specific antigen levels;
UCEC	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	6.78	0.49	2.79e-10	Schizophrenia;
UCEC	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg13695892	chr22:41940480	POLR3H	0.6	4.77	0.37	4.44e-6	Vitiligo;
UCEC	cis	rs10242455	0.867	rs2687144	chr7:99318808	C/T	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.66	5.42	0.41	2.37e-7	Metabolite levels;
UCEC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	0.96	7.38	0.52	1.06e-11	Obesity-related traits;
UCEC	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-12.94	-0.73	4.91e-26	Height;
UCEC	cis	rs4815879	0.764	rs4815880	chr20:5970053	C/T	cg25325723	chr20:6104886	FERMT1	-1.07	-4.89	-0.37	2.57e-6	Preeclampsia;
UCEC	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs17012589	0.639	rs10862968	chr12:85714770	C/T	cg02569458	chr12:86230093	RASSF9	0.39	4.53	0.35	1.23e-5	Bone mineral density (Ward's triangle area);
UCEC	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.42	-0.47	1.77e-9	Metabolite levels;
UCEC	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs73206853	0.841	rs4131850	chr12:110812553	G/A	cg12870014	chr12:110450643	ANKRD13A	0.61	4.73	0.36	5.26e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.54	-6.4	-0.47	1.93e-9	Testicular germ cell tumor;
UCEC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.62	5.43	0.41	2.26e-7	Response to diuretic therapy;
UCEC	cis	rs117623576	0.941	rs67225815	chr10:32408946	C/T	cg03047570	chr10:32398778	NA	-0.54	-4.87	-0.37	2.8e-6	Anti-saccade response;
UCEC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.49	5.67	0.42	7.18e-8	Total body bone mineral density;
UCEC	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18252515	chr7:66147081	NA	-0.59	-5.49	-0.41	1.71e-7	Aortic root size;
UCEC	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.62	5.85	0.43	3.02e-8	Response to diuretic therapy;
UCEC	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.69	8.58	0.58	1.21e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg12463550	chr7:65579703	CRCP	0.52	5.23	0.4	5.72e-7	Aortic root size;
UCEC	trans	rs4389974	0.966	rs62520632	chr8:112387930	C/T	cg22736090	chr17:62339926	TEX2	0.65	6.82	0.49	2.2e-10	Body mass index;
UCEC	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.56	-5.69	-0.42	6.71e-8	Pulse pressure;
UCEC	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.99	12.99	0.73	3.64e-26	Prudent dietary pattern;
UCEC	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.32	0.57	5.62e-14	Exhaled nitric oxide output;
UCEC	cis	rs8005745	0.614	rs71423444	chr14:62196197	C/A	cg01748970	chr14:62088363	NA	-0.72	-6.64	-0.48	5.6e-10	Select biomarker traits;
UCEC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08805041	chr16:621841	PIGQ	-0.32	-4.72	-0.36	5.45e-6	Height;
UCEC	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg03959625	chr15:84868606	LOC388152	0.46	4.57	0.35	1.02e-5	Schizophrenia;
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.21	0.56	1.03e-13	Prudent dietary pattern;
UCEC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg19678392	chr7:94953810	PON1	-0.55	-5.08	-0.39	1.12e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4851266	0.966	rs1465800	chr2:100834777	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.3	0.46	3.24e-9	Educational attainment;
UCEC	cis	rs7937612	1.000	rs7924963	chr11:120233536	G/A	cg12584626	chr11:120203529	NA	0.51	5.24	0.4	5.39e-7	Intraocular pressure;
UCEC	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.84	8.99	0.6	1.12e-15	Dental caries;
UCEC	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.56	-5.59	-0.42	1.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.16	-0.39	7.81e-7	Coronary artery disease;
UCEC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg19645103	chr12:69753606	YEATS4	0.55	5.0	0.38	1.62e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg19645103	chr12:69753606	YEATS4	-0.55	-4.99	-0.38	1.66e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.55	5.63	0.42	8.83e-8	Testicular germ cell tumor;
UCEC	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.1	9.17	0.6	3.88e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs2172802	0.576	rs10866121	chr4:62412747	G/A	cg18242907	chr4:62067393	NA	0.45	4.51	0.35	1.34e-5	Partial epilepsies;
UCEC	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg16060761	chr17:80687452	NA	-0.7	-9.22	-0.61	2.9e-16	Glycated hemoglobin levels;
UCEC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.74	-6.62	-0.48	6.45e-10	Diastolic blood pressure;
UCEC	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.71	-7.16	-0.51	3.53e-11	Blood metabolite levels;
UCEC	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.22	6.5	0.47	1.15e-9	Schizophrenia;
UCEC	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg26067569	chr2:200525129	NA	0.54	4.57	0.35	1.04e-5	Schizophrenia;
UCEC	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg13593689	chr9:129986794	NA	0.49	4.96	0.38	1.92e-6	Intraocular pressure;
UCEC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.54	4.89	0.37	2.6e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg02820040	chr2:241836501	C2orf54	-0.39	-4.86	-0.37	2.99e-6	Urinary metabolites;
UCEC	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.78	-10.71	-0.66	3.93e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs10121009	0.565	rs10972468	chr9:35431471	T/C	cg14286155	chr9:34620395	DCTN3	-0.48	-4.53	-0.35	1.23e-5	Parkinson's disease;
UCEC	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.54	-0.35	1.18e-5	Height;
UCEC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.56	6.32	0.46	2.91e-9	Vitiligo;
UCEC	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.64	0.48	5.57e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6903823	0.508	rs1150718	chr6:28256947	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.54	-6.2	-0.46	5.5e-9	Pulmonary function;
UCEC	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.69	0.36	6.14e-6	Tonsillectomy;
UCEC	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.51	-5.24	-0.4	5.49e-7	Asthma;
UCEC	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg26114124	chr12:9217669	LOC144571	0.39	4.66	0.36	7.07e-6	Sjögren's syndrome;
UCEC	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-5.71	-0.43	6.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.56	6.04	0.45	1.22e-8	Ulcerative colitis;
UCEC	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg17534202	chr9:96721102	NA	0.46	5.23	0.4	5.81e-7	Esophageal adenocarcinoma;
UCEC	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg05855489	chr10:104503620	C10orf26	0.46	4.74	0.36	4.98e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-7.06	-0.5	6.18e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7072216	0.922	rs6584191	chr10:100152055	C/G	cg19567339	chr10:100142640	NA	0.54	6.44	0.47	1.56e-9	Metabolite levels;
UCEC	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.67	5.48	0.41	1.79e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22857025	chr5:266934	NA	-0.91	-7.14	-0.51	4.01e-11	Asthma (childhood onset);
UCEC	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg14008862	chr17:28927542	LRRC37B2	0.64	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.51	5.8	0.43	3.97e-8	Mean corpuscular volume;
UCEC	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.51	5.65	0.42	8.06e-8	Platelet count;
UCEC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-5.23	-0.4	5.65e-7	Aortic root size;
UCEC	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.27e-30	Chronic sinus infection;
UCEC	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.69	-4.76	-0.37	4.65e-6	Body mass index;
UCEC	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.48	5.25	0.4	5.34e-7	Aortic root size;
UCEC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.65	7.35	0.52	1.3e-11	Platelet count;
UCEC	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-8.88	-0.59	2.16e-15	Exhaled nitric oxide output;
UCEC	cis	rs6840360	0.518	rs4696082	chr4:152286935	T/A	cg25486957	chr4:152246857	NA	-0.47	-4.73	-0.36	5.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.34	0.4	3.47e-7	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-5.69	-0.43	6.5e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg20368463	chr18:77673604	PQLC1	0.72	5.25	0.4	5.16e-7	Opioid sensitivity;
UCEC	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	5.19	0.39	6.73e-7	Cognitive test performance;
UCEC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs8105895	0.935	rs62110985	chr19:22256077	A/G	cg20662725	chr19:22235022	ZNF257	-0.66	-5.59	-0.42	1.07e-7	Body mass index (change over time);
UCEC	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.74	7.98	0.55	3.87e-13	Menopause (age at onset);
UCEC	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.04	-8.35	-0.57	4.54e-14	Exhaled nitric oxide output;
UCEC	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.75	6.67	0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.59	5.31	0.4	4.01e-7	Corneal astigmatism;
UCEC	cis	rs1008126	0.840	rs2237627	chr7:103177342	C/T	cg03942871	chr7:102574105	LRRC17;FBXL13	-0.32	-4.5	-0.35	1.35e-5	Metabolite levels (Pyroglutamine);
UCEC	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2302190	0.882	rs7221205	chr17:56485799	G/A	cg12560992	chr17:57184187	TRIM37	0.51	4.85	0.37	3.15e-6	Vitamin D levels;
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-6.14	-0.45	7.17e-9	Platelet count;
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg08461772	chr7:95026248	PON3	-0.35	-4.89	-0.37	2.65e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.51	5.47	0.41	1.88e-7	Body mass index;
UCEC	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg18721089	chr20:30220636	NA	-0.36	-4.94	-0.38	2.1e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs853679	0.527	rs1997660	chr6:28269663	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.91	-0.49	1.4e-10	Depression;
UCEC	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.16	-0.45	6.56e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg26721908	chr21:47610096	LSS	0.53	6.44	0.47	1.62e-9	Testicular germ cell tumor;
UCEC	cis	rs10940138	0.774	rs16897196	chr5:67228478	G/C	ch.5.1281357F	chr5:67228439	NA	0.64	6.01	0.44	1.42e-8	Menarche (age at onset);
UCEC	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.46	5.85	0.43	3.12e-8	Bone mineral density;
UCEC	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.68	-0.42	7.02e-8	Mortality in heart failure;
UCEC	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.31	-0.4	3.96e-7	Personality dimensions;
UCEC	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.7	-8.3	-0.56	6.13e-14	Urate levels in lean individuals;
UCEC	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.75	6.22	0.46	4.96e-9	Menopause (age at onset);
UCEC	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.46e-9	Crohn's disease;
UCEC	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.77	0.37	4.33e-6	Blood metabolite levels;
UCEC	cis	rs3762637	0.943	rs10222564	chr3:122266336	T/C	cg24169773	chr3:122142474	KPNA1	-0.65	-4.63	-0.36	8.02e-6	LDL cholesterol levels;
UCEC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.65	0.36	7.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.96	-13.46	-0.74	2.02e-27	Prudent dietary pattern;
UCEC	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs4851266	1.000	rs1465801	chr2:100836060	C/T	cg14675211	chr2:100938903	LONRF2	0.64	6.24	0.46	4.48e-9	Educational attainment;
UCEC	cis	rs62064224	0.703	rs4287613	chr17:30827688	C/T	cg18200150	chr17:30822561	MYO1D	0.42	5.12	0.39	9.63e-7	Schizophrenia;
UCEC	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.88	0.49	1.56e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6733160	0.967	rs6730262	chr2:64367694	C/T	cg22352474	chr2:64371530	PELI1	0.43	4.56	0.35	1.06e-5	Allergic dermatitis (nickel);
UCEC	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.64	-0.36	7.71e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.01	-0.38	1.56e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.79	-8.44	-0.57	2.81e-14	Parkinson's disease;
UCEC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.69	-9.28	-0.61	2.03e-16	Gut microbiota (bacterial taxa);
UCEC	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.68	6.6	0.48	6.82e-10	Blood trace element (Zn levels);
UCEC	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.93	-10.98	-0.67	7.52e-21	Personality dimensions;
UCEC	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg18681998	chr4:17616180	MED28	0.77	9.51	0.62	5.17e-17	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.96	10.5	0.65	1.4e-19	Cognitive function;
UCEC	cis	rs7246657	0.551	rs62108899	chr19:37595183	C/T	cg23950597	chr19:37808831	NA	-0.99	-5.63	-0.42	8.97e-8	Coronary artery calcification;
UCEC	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.04	-10.95	-0.67	8.97e-21	Vitiligo;
UCEC	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-4.83	-0.37	3.46e-6	Gut microbiome composition (summer);
UCEC	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.08	-10.96	-0.67	8.45e-21	Vitiligo;
UCEC	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg21770322	chr7:97807741	LMTK2	0.71	10.28	0.65	5.12e-19	Breast cancer;
UCEC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg05695927	chr15:45694626	SPATA5L1	-0.52	-4.69	-0.36	6.08e-6	Homoarginine levels;
UCEC	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg21214455	chr15:72412075	SENP8	0.47	4.73	0.36	5.22e-6	Red blood cell count;
UCEC	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.64	4.88	0.37	2.73e-6	Platelet distribution width;
UCEC	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg24562669	chr7:97807699	LMTK2	0.41	5.08	0.39	1.13e-6	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	8.33	0.57	5.1e-14	Exhaled nitric oxide output;
UCEC	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.51	-5.55	-0.42	1.31e-7	Body mass index;
UCEC	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.55	4.52	0.35	1.24e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg14092571	chr14:90743983	NA	-0.43	-5.78	-0.43	4.27e-8	Mortality in heart failure;
UCEC	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.85	9.71	0.62	1.63e-17	Post bronchodilator FEV1;
UCEC	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-4.76	-0.37	4.66e-6	Skin colour saturation;
UCEC	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.55	-0.42	1.3e-7	Alcohol dependence;
UCEC	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg15837086	chr1:46506065	PIK3R3	0.38	4.59	0.35	9.25e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.69	-7.9	-0.55	5.86e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.14	-0.45	7.44e-9	Birth weight;
UCEC	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.71	-6.91	-0.5	1.35e-10	Aortic root size;
UCEC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.64	-0.48	5.56e-10	Chronic sinus infection;
UCEC	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.55	-5.27	-0.4	4.71e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.76	7.0	0.5	8.25e-11	Platelet distribution width;
UCEC	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.54	4.79	0.37	4.12e-6	Corneal astigmatism;
UCEC	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.74	-5.44	-0.41	2.21e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg04176532	chr22:50317003	CRELD2	0.51	4.99	0.38	1.69e-6	Schizophrenia;
UCEC	cis	rs2657888	0.628	rs3809122	chr12:56882710	A/T	cg23002907	chr12:56915593	RBMS2	-0.35	-4.62	-0.36	8.49e-6	Adiponectin levels;
UCEC	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.84	-11.89	-0.7	2.87e-23	Vitiligo;
UCEC	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-5.01	-0.38	1.57e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.57	-6.01	-0.44	1.42e-8	Personality dimensions;
UCEC	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg07256473	chr22:29710276	RASL10A	-0.63	-7.02	-0.5	7.61e-11	Immature fraction of reticulocytes;
UCEC	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.75	-4.96	-0.38	1.92e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.69	6.38	0.47	2.13e-9	Aortic root size;
UCEC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.85	-7.46	-0.52	7.05e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.15	10.59	0.66	7.8500000000000006e-20	Corneal structure;
UCEC	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-0.94	-5.69	-0.42	6.71e-8	Diabetic retinopathy;
UCEC	cis	rs4851266	0.901	rs4851271	chr2:100833058	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.66	-7.6	-0.53	3.29e-12	Morning vs. evening chronotype;
UCEC	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.53	-5.39	-0.41	2.71e-7	Hepatocellular carcinoma;
UCEC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.87	9.6	0.62	2.96e-17	Cognitive function;
UCEC	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.89	0.49	1.55e-10	Bipolar disorder;
UCEC	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	5.11	0.39	9.91e-7	Myopia (pathological);
UCEC	cis	rs4400599	0.618	rs4393149	chr1:154195753	G/A	cg05139571	chr1:154127138	NUP210L	0.45	4.66	0.36	7.11e-6	Platelet distribution width;
UCEC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.47	-5.27	-0.4	4.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs308447	0.522	rs309363	chr4:123658169	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.8	8.42	0.57	3.18e-14	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	5.13	0.39	9.21e-7	Monocyte percentage of white cells;
UCEC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.17	6.85	0.49	1.93e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs3802344	0.590	rs116621198	chr9:133598041	C/T	cg01474677	chr9:133586259	NA	-0.95	-4.68	-0.36	6.33e-6	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.72	-6.79	-0.49	2.65e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs4880487	0.888	rs67456501	chr10:1252400	G/A	cg03183215	chr10:1252341	ADARB2	-0.48	-5.64	-0.42	8.58e-8	Migraine;
UCEC	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.85	7.72	0.54	1.62e-12	Body mass index;
UCEC	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.64	-6.05	-0.45	1.15e-8	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.75	7.96	0.55	4.24e-13	Facial morphology (factor 23);
UCEC	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.63	5.63	0.42	8.91e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12216499	1.000	rs77225875	chr6:159418145	A/C	cg10634217	chr6:160211790	TCP1;MRPL18	-0.65	-4.54	-0.35	1.15e-5	Bladder cancer (smoking interaction);
UCEC	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.65	-6.22	-0.46	4.85e-9	Acne (severe);
UCEC	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.5	5.73	0.43	5.46e-8	Blood metabolite ratios;
UCEC	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.54	-6.11	-0.45	8.33e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.27e-30	Chronic sinus infection;
UCEC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22117172	chr7:91764530	CYP51A1	0.38	4.94	0.38	2.13e-6	Breast cancer;
UCEC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.61	6.79	0.49	2.56e-10	Resting heart rate;
UCEC	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-10.05	-0.64	2.05e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg05241461	chr19:22816980	ZNF492	0.57	5.91	0.44	2.32e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.95	0.5	1.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg05132306	chr1:1846340	CALML6	-0.37	-4.67	-0.36	6.66e-6	Body mass index;
UCEC	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg17971929	chr21:40555470	PSMG1	0.88	9.25	0.61	2.48e-16	Cognitive function;
UCEC	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.57	5.46	0.41	1.99e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.56	-5.59	-0.42	1.05e-7	Morning vs. evening chronotype;
UCEC	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.58	5.34	0.4	3.4e-7	Lung cancer;
UCEC	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.91	-4.56	-0.35	1.08e-5	Type 2 diabetes;
UCEC	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.79	6.58	0.48	7.68e-10	Prostate cancer;
UCEC	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.48	-4.51	-0.35	1.32e-5	Blood trace element (Cu levels);
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.18	-9.42	-0.61	9.06e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.63	-6.71	-0.48	3.88e-10	Neurofibrillary tangles;
UCEC	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.64	6.01	0.44	1.37e-8	Schizophrenia;
UCEC	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg11150807	chr10:43354902	NA	-0.82	-6.82	-0.49	2.15e-10	Blood protein levels;
UCEC	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.34	-4.6	-0.35	8.92e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg24851651	chr11:66362959	CCS	0.44	5.06	0.39	1.21e-6	Educational attainment (years of education);
UCEC	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.37	-4.7	-0.36	5.95e-6	Educational attainment (years of education);
UCEC	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs11858159	0.532	rs12898466	chr15:24424834	C/G	cg18506672	chr15:25200253	SNRPN;SNURF	0.45	4.71	0.36	5.75e-6	Platelet thrombus formation;
UCEC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.68	5.51	0.41	1.57e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.4	5.05	0.38	1.31e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.6	7.07	0.5	5.71e-11	Lewy body disease;
UCEC	cis	rs3736594	0.546	rs6719960	chr2:27830067	C/T	cg27432699	chr2:27873401	GPN1	-0.5	-5.87	-0.44	2.79e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	0.81	6.98	0.5	9.25e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.57	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.02	-0.44	1.35e-8	Birth weight;
UCEC	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.63	7.53	0.53	4.84e-12	Obesity-related traits;
UCEC	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	0.85	9.98	0.64	3.12e-18	Breast cancer;
UCEC	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.74	-8.21	-0.56	1.03e-13	Blood pressure (smoking interaction);
UCEC	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.59	5.29	0.4	4.37e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs71281886	1	rs71281886	chr3:48352568	C/CA	cg11946769	chr3:48343235	NME6	0.66	6.06	0.45	1.09e-8	Breast cancer;
UCEC	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	7.03	0.5	7.04e-11	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.89	-9.36	-0.61	1.3e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.7	6.15	0.45	6.87e-9	Adiposity;
UCEC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg03354898	chr7:1950403	MAD1L1	-0.62	-5.99	-0.44	1.52e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	4.51	0.35	1.31e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.66	5.35	0.4	3.23e-7	Corneal astigmatism;
UCEC	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07741184	chr6:167504864	NA	-0.32	-4.51	-0.35	1.31e-5	Primary biliary cholangitis;
UCEC	cis	rs36051895	0.589	rs6476950	chr9:5218416	A/T	cg02405213	chr9:5042618	JAK2	-0.51	-4.83	-0.37	3.47e-6	Pediatric autoimmune diseases;
UCEC	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.65	0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs4265793	0.655	rs4531717	chr16:19079095	T/G	cg06773604	chr16:18995157	TMC7	0.75	5.43	0.41	2.32e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11764359	chr7:65958608	NA	-0.7	-6.71	-0.48	3.87e-10	Aortic root size;
UCEC	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-7.32	-0.52	1.52e-11	Response to antipsychotic treatment;
UCEC	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg21231944	chr12:82153410	PPFIA2	-0.46	-4.8	-0.37	3.89e-6	Resting heart rate;
UCEC	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.76	0.37	4.5e-6	Breast cancer;
UCEC	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg21770322	chr7:97807741	LMTK2	0.52	6.49	0.47	1.22e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.57	-5.43	-0.41	2.29e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.44	-4.87	-0.37	2.9e-6	Asthma;
UCEC	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.54	-5.49	-0.41	1.71e-7	Systemic lupus erythematosus;
UCEC	cis	rs60311166	1.000	rs7643568	chr3:52578474	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.78	5.2	0.39	6.6e-7	CTACK levels;
UCEC	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	4.55	0.35	1.1e-5	Response to antipsychotic treatment;
UCEC	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.82	7.96	0.55	4.23e-13	Cognitive function;
UCEC	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg18681998	chr4:17616180	MED28	0.55	6.11	0.45	8.68e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-0.59	-6.91	-0.5	1.37e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.87	-8.82	-0.59	3.09e-15	Obesity-related traits;
UCEC	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.55	5.72	0.43	5.76e-8	Prostate cancer;
UCEC	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.64	5.6	0.42	1.03e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2302190	0.882	rs9911609	chr17:56673087	T/C	cg12560992	chr17:57184187	TRIM37	0.52	4.68	0.36	6.48e-6	Vitamin D levels;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg01534423	chr17:18965556	NA	0.73	8.15	0.56	1.47e-13	Triglyceride levels;
UCEC	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.26	-0.4	5.02e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg07153921	chr17:41440717	NA	-0.51	-5.21	-0.39	6.25e-7	Menopause (age at onset);
UCEC	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.79	-9.39	-0.61	1.03e-16	Facial morphology (factor 19);
UCEC	cis	rs77861329	1.000	rs9811707	chr3:52190657	G/A	cg08692210	chr3:52188851	WDR51A	0.82	6.55	0.48	9e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg15468180	chr1:107600409	PRMT6	0.48	4.68	0.36	6.33e-6	Facial morphology (factor 21, depth of nasal alae);
UCEC	cis	rs7246967	0.673	rs8106215	chr19:22879446	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.76	9.1	0.6	5.85e-16	Breast cancer;
UCEC	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.53	-5.12	-0.39	9.28e-7	IgG glycosylation;
UCEC	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.53	-4.8	-0.37	3.93e-6	Coronary artery disease;
UCEC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg12712729	chr8:7886076	NA	0.42	5.0	0.38	1.6e-6	Red cell distribution width;
UCEC	cis	rs7683537	0.692	rs56317358	chr4:185659470	G/A	cg04058563	chr4:185651563	MLF1IP	0.65	5.09	0.39	1.08e-6	Systemic lupus erythematosus;
UCEC	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.57	-0.42	1.18e-7	Life satisfaction;
UCEC	cis	rs11761441	0.602	rs11771409	chr7:88730	A/G	cg06458707	chr7:1083209	C7orf50	0.25	4.63	0.36	7.9e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg21419209	chr3:44054225	NA	-0.52	-5.6	-0.42	1.01e-7	Coronary artery disease;
UCEC	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg00105475	chr2:10696890	NA	-0.37	-4.68	-0.36	6.54e-6	Prostate cancer;
UCEC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.53	5.09	0.39	1.06e-6	Menopause (age at onset);
UCEC	cis	rs80285556	1.000	rs55914901	chr19:50528346	C/G	cg11918822	chr19:50479865	VRK3	0.78	4.54	0.35	1.14e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
UCEC	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.52	-4.65	-0.36	7.26e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.61	-4.82	-0.37	3.59e-6	Schizophrenia;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg06818710	chr6:28411271	ZSCAN23	-0.57	-6.82	-0.49	2.2e-10	Pubertal anthropometrics;
UCEC	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg05738196	chr6:26577821	NA	0.51	4.98	0.38	1.74e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2708377	0.858	rs117212341	chr12:11282556	C/G	cg20188490	chr12:11080457	PRH2;PRR4;PRH1	0.75	6.25	0.46	4.25e-9	Bitter taste perception;
UCEC	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-5.93	-0.44	2.04e-8	Migraine;
UCEC	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg04043695	chr12:129287642	SLC15A4	0.67	6.66	0.48	5.22e-10	Systemic lupus erythematosus;
UCEC	cis	rs7870753	0.945	rs7870253	chr9:99231096	T/A	cg25260653	chr9:99212216	HABP4	0.47	4.77	0.37	4.47e-6	Height;
UCEC	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.42	4.93	0.38	2.19e-6	Total body bone mineral density;
UCEC	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-7.7	-0.54	1.88e-12	Breast cancer;
UCEC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.59	-6.87	-0.49	1.72e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.76	-5.2	-0.39	6.48e-7	Rheumatoid arthritis;
UCEC	cis	rs73416724	1.000	rs113163694	chr6:43283410	C/T	cg24109273	chr6:43484729	YIPF3;POLR1C	1.13	5.19	0.39	6.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.82	0.75	2.28e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.3	-0.4	4.18e-7	Personality dimensions;
UCEC	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.44	4.99	0.38	1.72e-6	Alzheimer's disease (late onset);
UCEC	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.48	4.67	0.36	6.82e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-8.3	-0.57	6.04e-14	Breast cancer;
UCEC	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	0.97	8.17	0.56	1.32e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	9.33	0.61	1.48e-16	Platelet count;
UCEC	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.46	5.29	0.4	4.43e-7	Bone mineral density;
UCEC	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.7	-7.96	-0.55	4.23e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs9393777	0.547	rs2893910	chr6:27283254	A/T	cg22548220	chr6:27277996	POM121L2	0.49	4.81	0.37	3.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.42	0.52	8.88e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	0.99	6.02	0.44	1.32e-8	Skin colour saturation;
UCEC	cis	rs4372836	0.504	rs6760186	chr2:29087274	T/C	cg09522027	chr2:28974177	PPP1CB	-0.64	-6.75	-0.49	3.17e-10	Body mass index;
UCEC	cis	rs377070	0.934	rs309407	chr4:123619335	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.54	4.61	0.36	8.55e-6	Mosquito bite size;
UCEC	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.58	6.8	0.49	2.4e-10	Iron status biomarkers (transferrin levels);
UCEC	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg19318889	chr4:1322082	MAEA	0.5	5.41	0.41	2.45e-7	Obesity-related traits;
UCEC	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg17800788	chr1:21766015	NBPF3	0.36	5.21	0.39	6.31e-7	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.99	-9.75	-0.63	1.27e-17	Alcohol dependence;
UCEC	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg13147721	chr7:65941812	NA	-0.74	-5.01	-0.38	1.54e-6	Diabetic kidney disease;
UCEC	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg18681998	chr4:17616180	MED28	0.69	7.51	0.53	5.43e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-10.42	-0.65	2.19e-19	Cognitive function;
UCEC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.46	-4.55	-0.35	1.1e-5	Prostate cancer;
UCEC	cis	rs4730268	0.861	rs4730264	chr7:107438561	C/T	cg18560240	chr7:107437656	SLC26A3	-0.61	-5.12	-0.39	9.27e-7	IgG glycosylation;
UCEC	cis	rs6921919	0.789	rs6912584	chr6:28309590	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.44	-4.59	-0.35	9.54e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.83	12.17	0.71	5.12e-24	Leprosy;
UCEC	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg03714773	chr7:91764589	CYP51A1	-0.43	-5.26	-0.4	4.93e-7	Breast cancer;
UCEC	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.4	4.93	0.38	2.19e-6	Tonsillectomy;
UCEC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.67	4.53	0.35	1.2e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs6743226	0.548	rs886811	chr2:242397292	G/A	cg10021735	chr2:242295487	FARP2	0.52	5.26	0.4	4.96e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
UCEC	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.65	-6.81	-0.49	2.35e-10	Lung cancer (smoking interaction);
UCEC	cis	rs1298062	0.663	rs1274685	chr19:50997828	G/A	cg11430371	chr19:50961752	MYBPC2	0.39	4.56	0.35	1.08e-5	Age of smoking initiation;
UCEC	cis	rs7937612	0.965	rs10892564	chr11:120224650	A/G	cg12584626	chr11:120203529	NA	0.48	4.97	0.38	1.87e-6	Intraocular pressure;
UCEC	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.42	-0.47	1.73e-9	Longevity;
UCEC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.65	-4.88	-0.37	2.73e-6	Mean platelet volume;
UCEC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.36	4.91	0.38	2.4e-6	Eye color traits;
UCEC	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.49	5.11	0.39	9.93e-7	Platelet count;
UCEC	cis	rs16937	0.711	rs6675633	chr1:205100480	G/A	cg12580275	chr1:205744413	RAB7L1	0.45	5.2	0.39	6.68e-7	Schizophrenia;
UCEC	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg18490616	chr2:88469792	THNSL2	0.91	4.88	0.37	2.68e-6	Plasma clusterin levels;
UCEC	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.0	-7.45	-0.52	7.34e-12	Body mass index;
UCEC	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.9	8.21	0.56	1.06e-13	Bladder cancer;
UCEC	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	7.22	0.51	2.57e-11	Coronary artery disease;
UCEC	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.48	5.23	0.4	5.67e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg08222913	chr3:52553049	STAB1	-0.4	-4.51	-0.35	1.34e-5	Bipolar disorder;
UCEC	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.78	8.97	0.59	1.27e-15	Lymphocyte counts;
UCEC	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	7.59	0.53	3.44e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg10806820	chr3:48699090	CELSR3	0.36	4.78	0.37	4.14e-6	Menarche (age at onset);
UCEC	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg20965017	chr5:231967	SDHA	-0.6	-5.15	-0.39	8.34e-7	Breast cancer;
UCEC	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg03934865	chr2:198174659	NA	-0.41	-5.21	-0.39	6.23e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.65	-5.42	-0.41	2.39e-7	Alcohol dependence;
UCEC	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.94	-8.69	-0.58	6.6e-15	Dilated cardiomyopathy;
UCEC	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg16423285	chr20:60520624	NA	-0.56	-4.87	-0.37	2.86e-6	Obesity-related traits;
UCEC	cis	rs2722425	0.708	rs1823643	chr8:40515088	A/G	cg12565636	chr8:39797497	IDO2	-0.59	-4.6	-0.35	8.9e-6	Fasting plasma glucose;
UCEC	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.58	5.11	0.39	9.98e-7	Corneal astigmatism;
UCEC	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg09491104	chr22:46646882	C22orf40	-0.51	-5.04	-0.38	1.36e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.68	-7.0	-0.5	8.54e-11	Primary tooth development (time to first tooth eruption);
UCEC	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.73	-7.6	-0.53	3.16e-12	Breast cancer;
UCEC	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.55	5.59	0.42	1.08e-7	Testicular germ cell tumor;
UCEC	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.44	6.11	0.45	8.7e-9	Electrocardiographic conduction measures;
UCEC	cis	rs7267005	0.661	rs74763238	chr20:34386034	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.48	-5.06	-0.39	1.24e-6	Aortic root size;
UCEC	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	12.25	0.71	3.21e-24	Platelet count;
UCEC	cis	rs78487399	0.908	rs12467420	chr2:43831150	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.1	-0.45	8.86e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.51	-5.58	-0.42	1.12e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.83	8.86	0.59	2.36e-15	Cognitive function;
UCEC	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.64	-5.99	-0.44	1.53e-8	Aortic root size;
UCEC	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.78	-0.43	4.32e-8	Height;
UCEC	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.53	4.84	0.37	3.29e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.77	-7.41	-0.52	9.34e-12	Lung cancer;
UCEC	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.17	-9.14	-0.6	4.75e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.14	8.68	0.58	7.09e-15	Vitiligo;
UCEC	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.18	0.6	3.61e-16	Coffee consumption (cups per day);
UCEC	cis	rs8105895	0.935	rs62112921	chr19:22227577	T/C	cg02912127	chr19:22235281	ZNF257	-0.58	-4.69	-0.36	6.25e-6	Body mass index (change over time);
UCEC	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.84	-0.37	3.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.8	0.37	3.9e-6	Parkinson's disease;
UCEC	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.63	6.71	0.48	3.92e-10	Longevity;
UCEC	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-10.93	-0.67	1.02e-20	Vitiligo;
UCEC	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg13695892	chr22:41940480	POLR3H	0.67	5.16	0.39	7.91e-7	Vitiligo;
UCEC	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.62	5.66	0.42	7.83e-8	Corneal astigmatism;
UCEC	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.5	4.9	0.37	2.51e-6	High light scatter reticulocyte count;
UCEC	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg12292205	chr6:26970375	C6orf41	0.61	5.41	0.41	2.5e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-1.0	-12.02	-0.7	1.32e-23	Cognitive function;
UCEC	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.01	8.16	0.56	1.4e-13	Vitiligo;
UCEC	cis	rs7267005	0.661	rs80015686	chr20:34388820	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg07460842	chr6:66804631	NA	-0.67	-5.47	-0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	6.37	0.47	2.28e-9	Motion sickness;
UCEC	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg27624424	chr6:160112604	SOD2	0.56	5.18	0.39	7.2e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg06784218	chr1:46089804	CCDC17	0.42	4.75	0.36	4.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs75804782	0.521	rs66477197	chr2:239403832	C/T	cg12524725	chr2:239427019	NA	-0.67	-4.54	-0.35	1.14e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.67	6.19	0.45	5.83e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.71	6.4	0.47	1.92e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.56	8.23	0.56	9.28e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg22974920	chr21:40686053	BRWD1	0.56	4.7	0.36	6.02e-6	Cognitive function;
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	5.11	0.39	1e-6	Obesity-related traits;
UCEC	cis	rs7804356	0.906	rs73069540	chr7:26904770	C/T	cg03456212	chr7:26904342	SKAP2	-0.62	-4.69	-0.36	6.21e-6	Type 1 diabetes;
UCEC	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.31	0.46	3.12e-9	Tonsillectomy;
UCEC	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg01689657	chr7:91764605	CYP51A1	0.44	5.67	0.42	7.34e-8	Breast cancer;
UCEC	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.37	5.21	0.39	6.3e-7	Fat distribution (HIV);
UCEC	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.67	5.91	0.44	2.25e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg01451880	chr3:45801044	SLC6A20	-0.36	-4.71	-0.36	5.79e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.91	-8.55	-0.58	1.49e-14	Blood metabolite levels;
UCEC	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.51	5.54	0.42	1.35e-7	Asthma (sex interaction);
UCEC	cis	rs4851266	1.000	rs4851266	chr2:100818479	C/T	cg14675211	chr2:100938903	LONRF2	0.64	5.89	0.44	2.54e-8	Educational attainment;
UCEC	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.48	-6.92	-0.5	1.3100000000000001e-10	Rheumatoid arthritis;
UCEC	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg24826892	chr11:71159390	DHCR7	0.49	4.51	0.35	1.34e-5	Vitamin D levels;
UCEC	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.87	-0.49	1.7e-10	Response to antipsychotic treatment;
UCEC	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-6.35	-0.46	2.51e-9	Morning vs. evening chronotype;
UCEC	cis	rs1893767	1.000	rs3741109	chr11:123952693	T/G	cg05468346	chr11:124823826	CCDC15	-0.82	-4.84	-0.37	3.19e-6	Obesity-related traits;
UCEC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg07424592	chr7:64974309	NA	0.77	4.77	0.37	4.39e-6	Diabetic kidney disease;
UCEC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg13777783	chr17:79615861	NA	0.32	4.64	0.36	7.5e-6	Eye color traits;
UCEC	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.74	-7.97	-0.55	3.98e-13	Breast cancer;
UCEC	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.98	7.26	0.51	2.13e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.54	5.94	0.44	1.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.49	0.41	1.72e-7	Platelet count;
UCEC	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.34	-4.51	-0.35	1.33e-5	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
UCEC	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.94	0.38	2.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.54	-5.78	-0.43	4.41e-8	Pubertal anthropometrics;
UCEC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg05738196	chr6:26577821	NA	0.58	6.27	0.46	3.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	9.18	0.6	3.75e-16	Menarche (age at onset);
UCEC	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.07	-0.6	7.06e-16	Coffee consumption (cups per day);
UCEC	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.68	6.17	0.45	6.3e-9	Aortic root size;
UCEC	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.47	4.94	0.38	2.1e-6	Total body bone mineral density;
UCEC	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.73	-4.86	-0.37	2.93e-6	Narcolepsy;
UCEC	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.73	-8.02	-0.55	3.09e-13	Sudden cardiac arrest;
UCEC	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.23	-19.12	-0.84	1.07e-41	Exhaled nitric oxide output;
UCEC	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.82e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-10.95	-0.67	8.97e-21	Vitiligo;
UCEC	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.77	5.34	0.4	3.47e-7	Exhaled nitric oxide output;
UCEC	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.65	-7.32	-0.52	1.52e-11	Systemic sclerosis;
UCEC	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	5.93	0.44	2.08e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg00983440	chr10:79422392	NA	-1.16	-8.76	-0.59	4.36e-15	Bone mineral density;
UCEC	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.73	0.36	5.11e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.54	6.0	0.44	1.46e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs4880487	0.888	rs4880789	chr10:1254393	G/T	cg03183215	chr10:1252341	ADARB2	-0.46	-5.45	-0.41	2.03e-7	Migraine;
UCEC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg13575925	chr12:9217583	LOC144571	0.4	4.64	0.36	7.49e-6	Sjögren's syndrome;
UCEC	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.58	-7.68	-0.54	2.03e-12	Diabetic kidney disease;
UCEC	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.46	-4.76	-0.37	4.57e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg04310649	chr10:35416472	CREM	-0.49	-4.51	-0.35	1.34e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg03342759	chr3:160939853	NMD3	-0.55	-4.94	-0.38	2.07e-6	Morning vs. evening chronotype;
UCEC	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.41	4.59	0.35	9.37e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.7	7.81	0.54	9.89e-13	Coronary artery disease;
UCEC	cis	rs11697848	0.881	rs75950318	chr20:48547448	A/G	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs4372836	0.504	rs3768666	chr2:29005870	C/T	cg09522027	chr2:28974177	PPP1CB	-0.71	-7.53	-0.53	4.81e-12	Body mass index;
UCEC	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg13870426	chr17:30244630	NA	-0.62	-4.52	-0.35	1.24e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.47	5.16	0.39	7.93e-7	Blood metabolite levels;
UCEC	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.48	-5.01	-0.38	1.53e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.83	0.49	2.12e-10	Eye color traits;
UCEC	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.55	-6.75	-0.49	3.22e-10	Total body bone mineral density;
UCEC	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.88	-10.58	-0.66	8.26e-20	Blood metabolite levels;
UCEC	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7015263	1.000	rs7817738	chr8:87503132	C/A	cg27223183	chr8:87520930	FAM82B	-0.46	-4.57	-0.35	1.01e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.44	5.19	0.39	6.97e-7	Alzheimer's disease (late onset);
UCEC	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.61	5.49	0.41	1.69e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-4.59	-0.35	9.41e-6	Hepatocellular carcinoma;
UCEC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg23791538	chr6:167370224	RNASET2	-0.5	-4.9	-0.37	2.47e-6	Crohn's disease;
UCEC	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.75	-4.6	-0.35	8.96e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.03e-5	Type 2 diabetes;
UCEC	cis	rs17106184	1.000	rs60483827	chr1:51301657	G/A	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.57	-5.68	-0.42	7.14e-8	Breast cancer;
UCEC	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg07153921	chr17:41440717	NA	0.57	6.0	0.44	1.46e-8	Menopause (age at onset);
UCEC	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.51	6.39	0.47	2.05e-9	Coronary artery disease;
UCEC	cis	rs912062	1.000	rs7037561	chr9:832711	C/T	cg14267263	chr9:841436	DMRT1	0.83	5.96	0.44	1.75e-8	Obesity-related traits;
UCEC	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.49	5.13	0.39	8.82e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs2415984	0.846	rs8018403	chr14:46836326	T/C	cg14871534	chr14:47121158	RPL10L	0.4	4.68	0.36	6.48e-6	Number of children ever born;
UCEC	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.09	16.3	0.8	9.01e-35	Schizophrenia;
UCEC	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg14092571	chr14:90743983	NA	-0.45	-6.15	-0.45	6.89e-9	Mortality in heart failure;
UCEC	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.57	6.48	0.47	1.3e-9	Hip circumference;
UCEC	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.56	6.18	0.45	6.05e-9	Brugada syndrome;
UCEC	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.98	10.96	0.67	8.14e-21	Cognitive function;
UCEC	cis	rs2742417	1.000	rs938363	chr3:45746364	T/G	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	1.02	8.68	0.58	6.97e-15	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg19622623	chr12:86230825	RASSF9	-0.38	-4.69	-0.36	6.19e-6	Major depressive disorder;
UCEC	cis	rs7267005	0.661	rs77779232	chr20:34400409	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.81	-4.61	-0.36	8.52e-6	Response to paliperidone in schizophrenia (Multivariate);
UCEC	cis	rs1519814	1.000	rs4871037	chr8:121124042	A/G	cg22335954	chr8:121166405	COL14A1	-0.68	-5.58	-0.42	1.11e-7	Breast cancer;
UCEC	cis	rs16939046	0.915	rs72656152	chr8:76087994	G/A	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-5.46	-0.41	1.96e-7	Response to antipsychotic treatment;
UCEC	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg01391022	chr12:122360665	WDR66	-0.45	-4.82	-0.37	3.54e-6	Mean corpuscular volume;
UCEC	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.57	5.3	0.4	4.1e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.89	0.37	2.57e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12286929	0.610	rs11606838	chr11:115042859	C/A	cg04055981	chr11:115044050	NA	0.49	5.71	0.43	6.11e-8	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1823913	0.927	rs35339956	chr2:192126394	C/T	cg15998761	chr2:191300784	MFSD6	0.4	4.6	0.35	9.13e-6	Obesity-related traits;
UCEC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22117172	chr7:91764530	CYP51A1	0.45	5.83	0.43	3.37e-8	Breast cancer;
UCEC	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.62	4.91	0.38	2.37e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.53	4.97	0.38	1.86e-6	Corneal astigmatism;
UCEC	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg20129853	chr10:51489980	NA	0.41	5.06	0.39	1.24e-6	Prostate-specific antigen levels;
UCEC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18252515	chr7:66147081	NA	0.46	4.71	0.36	5.67e-6	Aortic root size;
UCEC	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.14	6.57	0.48	8.34e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg19610905	chr11:61596333	FADS2	-0.73	-7.3	-0.52	1.64e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.48	5.48	0.41	1.84e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-10.45	-0.65	1.8e-19	Renal cell carcinoma;
UCEC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.42	-4.64	-0.36	7.56e-6	Prostate cancer;
UCEC	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.86	-9.8	-0.63	9.35e-18	Breast cancer;
UCEC	cis	rs9976767	0.828	rs3788013	chr21:43841328	C/A	cg00134539	chr21:43824071	UBASH3A	0.29	4.5	0.35	1.35e-5	Type 1 diabetes;
UCEC	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg20560298	chr2:73613845	ALMS1	0.52	5.08	0.39	1.14e-6	Metabolite levels;
UCEC	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg04837898	chr3:45731254	SACM1L	-0.4	-4.54	-0.35	1.15e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.7	6.57	0.48	8.26e-10	High light scatter reticulocyte count;
UCEC	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.08	14.03	0.76	6.47e-29	Chronic sinus infection;
UCEC	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.22	-0.46	5e-9	Pubertal anthropometrics;
UCEC	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	5.21	0.39	6.38e-7	Menarche (age at onset);
UCEC	cis	rs7246967	0.541	rs16999009	chr19:22909658	A/G	cg24889512	chr19:22816950	ZNF492	-0.63	-6.56	-0.48	8.76e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-4.74	-0.36	4.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13859212	chr4:99580143	TSPAN5	-0.44	-4.53	-0.35	1.22e-5	Gut microbiome composition (summer);
UCEC	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.66	5.42	0.41	2.37e-7	Metabolite levels;
UCEC	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.82	8.5	0.57	2.01e-14	Parkinson's disease;
UCEC	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg03934865	chr2:198174659	NA	-0.44	-5.62	-0.42	9.46e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs6934651	0.581	rs62420829	chr6:85829995	C/T	cg18860790	chr6:84937415	KIAA1009	-0.94	-4.9	-0.38	2.45e-6	Breast cancer;
UCEC	cis	rs4713118	0.527	rs36042294	chr6:27720712	C/G	cg07836142	chr6:28411423	ZSCAN23	-0.47	-4.88	-0.37	2.77e-6	Parkinson's disease;
UCEC	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.83	6.3	0.46	3.24e-9	Major depressive disorder;
UCEC	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg19743168	chr1:23544995	NA	-0.44	-6.38	-0.47	2.14e-9	Height;
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.63	-7.82	-0.54	9.21e-13	Pubertal anthropometrics;
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.59	8.61	0.58	1.03e-14	Prudent dietary pattern;
UCEC	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.85	-8.96	-0.59	1.38e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-6.35	-0.46	2.5e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.49	4.78	0.37	4.17e-6	Diastolic blood pressure;
UCEC	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-0.88	-7.75	-0.54	1.4e-12	Post bronchodilator FEV1;
UCEC	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg15147215	chr3:52552868	STAB1	-0.43	-4.93	-0.38	2.17e-6	Bipolar disorder;
UCEC	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg05501817	chr11:14380813	RRAS2	-0.52	-4.84	-0.37	3.3e-6	Sense of smell;
UCEC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg11632617	chr15:75315747	PPCDC	-0.6	-6.76	-0.49	3.02e-10	Lung cancer;
UCEC	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg08271804	chr19:22816896	ZNF492	0.68	6.53	0.47	9.95e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-5.09	-0.39	1.09e-6	Platelet distribution width;
UCEC	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.5	4.82	0.37	3.52e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17106184	1.000	rs60048959	chr1:51403897	C/T	cg07174182	chr1:51127561	FAF1	-0.77	-4.95	-0.38	1.97e-6	Type 2 diabetes;
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.55	0.58	1.47e-14	Prudent dietary pattern;
UCEC	cis	rs4668356	1.000	rs73017249	chr2:172018995	C/T	cg13882835	chr2:172017928	TLK1	0.67	4.54	0.35	1.14e-5	Cognitive performance;
UCEC	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg18478394	chr8:109455254	TTC35	0.47	4.63	0.36	7.87e-6	Dupuytren's disease;
UCEC	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	4.57	0.35	1.04e-5	Longevity;
UCEC	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg19318889	chr4:1322082	MAEA	0.45	5.34	0.4	3.46e-7	Longevity;
UCEC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.72	-6.78	-0.49	2.68e-10	Aortic root size;
UCEC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01973587	chr1:228161476	NA	0.38	4.95	0.38	2.03e-6	Diastolic blood pressure;
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.59	8.6	0.58	1.12e-14	Prudent dietary pattern;
UCEC	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.59	6.13	0.45	7.53e-9	Mood instability;
UCEC	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.68	-7.4	-0.52	9.51e-12	Waist circumference;Body mass index;
UCEC	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.82	-0.63	8.01e-18	Blood metabolite levels;
UCEC	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.42	-4.64	-0.36	7.64e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.02	-0.38	1.45e-6	Huntington's disease progression;
UCEC	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg21856205	chr7:94953877	PON1	0.56	5.4	0.41	2.58e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg20825769	chr15:43991375	CKMT1A	0.5	4.68	0.36	6.51e-6	Lung cancer in ever smokers;
UCEC	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.44e-9	Mean platelet volume;
UCEC	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg11871910	chr12:69753446	YEATS4	0.57	5.18	0.39	7.21e-7	Response to diuretic therapy;
UCEC	cis	rs11757661	0.609	rs74623888	chr6:89268867	G/A	cg27561949	chr6:88411006	NCRNA00120;AKIRIN2	-0.79	-4.69	-0.36	6.21e-6	Subcutaneous adipose tissue;
UCEC	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4448343	0.963	rs3758302	chr9:98272630	G/C	cg00638945	chr9:98266643	PTCH1	0.31	4.58	0.35	9.84e-6	Height;
UCEC	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-8.59	-0.58	1.18e-14	Extraversion;
UCEC	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.43	4.54	0.35	1.18e-5	Eye color traits;
UCEC	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.76	0.37	4.66e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.4	-4.83	-0.37	3.41e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.09	11.13	0.68	2.89e-21	Corneal structure;
UCEC	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Obesity-related traits;
UCEC	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.68	-8.08	-0.55	2.18e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.1	0.39	1.04e-6	Bipolar disorder;
UCEC	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-1.08	-9.28	-0.61	2.02e-16	Dupuytren's disease;
UCEC	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-6.52	-0.47	1.05e-9	Total cholesterol levels;
UCEC	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	11.41	0.69	5.52e-22	Chronic sinus infection;
UCEC	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.69	-7.5	-0.53	5.56e-12	Waist circumference;Body mass index;
UCEC	cis	rs17102884	0.600	rs9671386	chr14:75151047	G/A	cg16124934	chr14:75389480	RPS6KL1	-0.48	-4.58	-0.35	9.78e-6	Neuroticism;
UCEC	cis	rs12464624	0.554	rs4350773	chr2:71754430	C/T	cg14689456	chr2:71754492	DYSF	-0.32	-4.56	-0.35	1.09e-5	Urate levels in overweight individuals;
UCEC	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.74	-4.84	-0.37	3.25e-6	Hair shape;
UCEC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.6	6.99	0.5	9.02e-11	Rheumatoid arthritis;
UCEC	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.82	9.23	0.61	2.79e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs9470794	1.000	rs56914148	chr6:38048673	A/C	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.7	8.5	0.57	1.96e-14	Longevity;
UCEC	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.79	0.59	3.71e-15	Mean corpuscular hemoglobin;
UCEC	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.65	6.9	0.49	1.43e-10	Menopause (age at onset);
UCEC	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.45	-4.81	-0.37	3.73e-6	Lymphocyte counts;
UCEC	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.24	0.4	5.4e-7	Mean platelet volume;
UCEC	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-4.91	-0.38	2.44e-6	Mean corpuscular hemoglobin concentration;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00704288	chr1:44172956	ST3GAL3	0.59	7.05	0.5	6.32e-11	Warfarin maintenance dose;
UCEC	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.72	8.25	0.56	8.08e-14	Longevity;Endometriosis;
UCEC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.54	5.78	0.43	4.35e-8	Prostate cancer;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.6	-0.48	6.98e-10	Pubertal anthropometrics;
UCEC	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.5	-0.62	5.51e-17	Height;
UCEC	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg23795048	chr12:9217529	LOC144571	0.44	5.06	0.38	1.25e-6	Sjögren's syndrome;
UCEC	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.89	10.11	0.64	1.47e-18	Ulcerative colitis;
UCEC	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.58	-5.91	-0.44	2.33e-8	Dental caries;
UCEC	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg15468180	chr1:107600409	PRMT6	-0.44	-4.67	-0.36	6.72e-6	Facial morphology (factor 21, depth of nasal alae);
UCEC	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.71	6.8	0.49	2.44e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.49	5.32	0.4	3.76e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg01262667	chr19:19385393	TM6SF2	0.46	6.15	0.45	7.06e-9	Tonsillectomy;
UCEC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg06784218	chr1:46089804	CCDC17	0.55	6.49	0.47	1.25e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.67	7.17	0.51	3.44e-11	Longevity;Endometriosis;
UCEC	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.42	8.72	0.58	5.41e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.51	4.84	0.37	3.18e-6	Blood metabolite levels;
UCEC	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg13256891	chr4:100009986	ADH5	-0.7	-5.4	-0.41	2.65e-7	Alcohol dependence;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg14547644	chr6:28411285	ZSCAN23	0.59	6.68	0.48	4.68e-10	Pubertal anthropometrics;
UCEC	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	6.72	0.48	3.78e-10	Electrocardiographic conduction measures;
UCEC	cis	rs6437061	0.740	rs2679163	chr2:232816237	A/C	cg02061626	chr2:233274167	ALPPL2	-0.51	-5.64	-0.42	8.64e-8	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg16060761	chr17:80687452	NA	-0.52	-5.23	-0.4	5.74e-7	Glycated hemoglobin levels;
UCEC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.55	-5.2	-0.39	6.43e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.58	-6.89	-0.49	1.54e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.55	7.04	0.5	6.69e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.46	-4.54	-0.35	1.17e-5	Schizophrenia;
UCEC	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg03354898	chr7:1950403	MAD1L1	-0.57	-5.61	-0.42	9.98e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.4	5.2	0.39	6.56e-7	Sudden cardiac arrest;
UCEC	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.78	-7.01	-0.5	7.86e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	9.08	0.6	6.71e-16	Mean platelet volume;
UCEC	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg14008862	chr17:28927542	LRRC37B2	0.67	5.16	0.39	7.78e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.5	-0.35	1.35e-5	Aortic root size;
UCEC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg06784218	chr1:46089804	CCDC17	0.41	4.65	0.36	7.21e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.6	-4.61	-0.36	8.59e-6	Gut microbiome composition (summer);
UCEC	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-6.9	-0.49	1.44e-10	Coffee consumption (cups per day);
UCEC	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18932078	chr1:2524107	MMEL1	-0.33	-5.18	-0.39	7.18e-7	Ulcerative colitis;
UCEC	cis	rs9469578	1.000	rs16869466	chr6:33715265	A/G	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.74	-6.62	-0.48	6.45e-10	Diastolic blood pressure;
UCEC	cis	rs747782	0.528	rs624348	chr11:48400795	G/A	cg20307385	chr11:47447363	PSMC3	0.65	4.68	0.36	6.58e-6	Intraocular pressure;
UCEC	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.55	0.77	2.79e-30	Homoarginine levels;
UCEC	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.36	5.05	0.38	1.26e-6	Fat distribution (HIV);
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.62	0.42	9.36e-8	Prudent dietary pattern;
UCEC	cis	rs1355223	0.902	rs286858	chr11:34717357	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.46	4.62	0.36	8.37e-6	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.49	5.06	0.39	1.21e-6	Platelet distribution width;
UCEC	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.46	-4.82	-0.37	3.61e-6	Blood metabolite levels;
UCEC	cis	rs2280630	1.000	rs2280630	chr3:39195964	C/T	cg01426195	chr3:39028469	NA	-0.49	-5.11	-0.39	9.68e-7	Verbal declarative memory;
UCEC	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.06	-0.6	7.6e-16	Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.12	14.35	0.76	9.19e-30	Cognitive function;
UCEC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs11697848	1.000	rs3210879	chr20:48506190	T/C	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.54	5.49	0.41	1.73e-7	Blood protein levels;
UCEC	cis	rs6838801	0.588	rs344140	chr4:77660162	G/C	cg17476223	chr4:77663285	SHROOM3	-0.48	-4.51	-0.35	1.33e-5	Cleft lip with or without cleft palate;
UCEC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	9.57	0.62	3.67e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.76	7.19	0.51	3.05e-11	Menopause (age at onset);
UCEC	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-5.95	-0.44	1.88e-8	Blood metabolite levels;
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.55	-6.57	-0.48	8.01e-10	Pubertal anthropometrics;
UCEC	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	7.57	0.53	3.86e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg00614314	chr15:82944287	LOC80154	0.56	5.12	0.39	9.5e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs1545257	0.560	rs7561752	chr2:24643834	A/G	cg06627628	chr2:24431161	ITSN2	0.53	5.41	0.41	2.54e-7	Sjögren's syndrome;
UCEC	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.58	5.24	0.4	5.6e-7	Morning vs. evening chronotype;
UCEC	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.86	6.82	0.49	2.2e-10	Body mass index;
UCEC	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-0.74	-7.21	-0.51	2.67e-11	Breast cancer;
UCEC	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.32	-0.4	3.81e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg24375607	chr4:120327624	NA	-0.5	-5.29	-0.4	4.44e-7	Corneal astigmatism;
UCEC	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14019695	chr9:139328340	INPP5E	0.51	6.34	0.46	2.61e-9	Monocyte percentage of white cells;
UCEC	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.49	4.58	0.35	9.94e-6	Breast cancer;
UCEC	cis	rs9616064	0.710	rs12053764	chr22:46999703	C/T	cg05621596	chr22:47072043	GRAMD4	-0.56	-5.43	-0.41	2.3e-7	Urate levels in obese individuals;
UCEC	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-5.92	-0.44	2.15e-8	Prostate cancer;
UCEC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg11764359	chr7:65958608	NA	-0.71	-6.66	-0.48	5.19e-10	Aortic root size;
UCEC	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.74	6.6	0.48	7.12e-10	Coronary artery disease;
UCEC	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.52	5.04	0.38	1.34e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.74	-9.92	-0.63	4.6e-18	Gut microbiota (bacterial taxa);
UCEC	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg26067569	chr2:200525129	NA	0.54	4.57	0.35	1.04e-5	Schizophrenia;
UCEC	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.8	8.67	0.58	7.43e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.93	-0.38	2.2e-6	Coronary artery disease;
UCEC	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	5.19	0.39	6.73e-7	Cognitive test performance;
UCEC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg19805062	chr22:46654627	PKDREJ	-0.44	-4.71	-0.36	5.76e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.28e-5	Aortic root size;
UCEC	cis	rs7512898	0.545	rs6427850	chr1:200672410	T/G	cg19099833	chr1:201476290	CSRP1	-0.51	-5.18	-0.39	7.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.61	6.44	0.47	1.56e-9	Homoarginine levels;
UCEC	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.52	4.77	0.37	4.49e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.7	0.48	4.21e-10	Cognitive test performance;
UCEC	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	0.72	5.6	0.42	1.02e-7	Neutrophil percentage of white cells;
UCEC	cis	rs10924970	0.649	rs12729988	chr1:235372580	G/A	cg26050004	chr1:235667680	B3GALNT2	0.48	4.7	0.36	5.98e-6	Asthma;
UCEC	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.86	9.94	0.63	3.93e-18	Menarche (age at onset);
UCEC	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18252515	chr7:66147081	NA	-0.46	-4.7	-0.36	5.89e-6	Aortic root size;
UCEC	cis	rs4853036	0.951	rs6738783	chr2:70120608	A/G	cg02498382	chr2:70120550	SNRNP27	-0.49	-4.65	-0.36	7.21e-6	Colorectal or endometrial cancer;
UCEC	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.5	4.99	0.38	1.69e-6	Dupuytren's disease;
UCEC	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.67	-4.79	-0.37	4.08e-6	Rheumatoid arthritis;
UCEC	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.44	4.73	0.36	5.22e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs2970992	0.764	rs13024200	chr2:101329338	T/G	cg01042948	chr2:101319752	NA	0.56	5.99	0.44	1.56e-8	Educational attainment;
UCEC	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.53	5.31	0.4	3.94e-7	Schizophrenia;
UCEC	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.89	-7.22	-0.51	2.53e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.63	4.53	0.35	1.2e-5	Body mass index;
UCEC	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.5	-5.29	-0.4	4.37e-7	IgG glycosylation;
UCEC	cis	rs829883	1.000	rs249819	chr12:98897265	T/A	cg25150519	chr12:98850993	NA	0.76	6.74	0.49	3.29e-10	Colorectal adenoma (advanced);
UCEC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.55	5.05	0.38	1.27e-6	Menopause (age at onset);
UCEC	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.76	7.02	0.5	7.79e-11	Mean corpuscular hemoglobin;
UCEC	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.62	5.77	0.43	4.61e-8	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.54	-6.36	-0.46	2.38e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.59	-5.43	-0.41	2.25e-7	Pancreatic cancer;
UCEC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.63	-6.09	-0.45	9.59e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg18099408	chr3:52552593	STAB1	0.43	5.08	0.39	1.13e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.54	4.59	0.35	9.58e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg23791538	chr6:167370224	RNASET2	-0.59	-6.28	-0.46	3.67e-9	Crohn's disease;
UCEC	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-0.78	-6.75	-0.49	3.12e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6060717	0.610	rs1891154	chr20:34617129	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.47	-5.11	-0.39	1e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.8	7.11	0.51	4.73e-11	Bladder cancer;
UCEC	cis	rs10924970	0.967	rs2382616	chr1:235454237	C/T	cg26050004	chr1:235667680	B3GALNT2	0.45	4.74	0.36	5.03e-6	Asthma;
UCEC	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	9.89e-16	Menopause (age at onset);
UCEC	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.64	-6.21	-0.46	5.1e-9	Lymphocyte counts;
UCEC	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.78	6.11	0.45	8.51e-9	Body mass index;
UCEC	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.97	10.74	0.66	3.15e-20	Cognitive function;
UCEC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.46	-6.64	-0.48	5.67e-10	Urinary metabolites;
UCEC	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.94	-0.55	4.92e-13	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.59	8.49	0.57	2.12e-14	Prudent dietary pattern;
UCEC	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.58	-4.65	-0.36	7.41e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs1476670	0.683	rs813642	chr1:44506420	A/C	cg09470012	chr1:44509516	NA	0.42	5.24	0.4	5.57e-7	Eotaxin levels;
UCEC	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18252515	chr7:66147081	NA	0.59	5.49	0.41	1.71e-7	Aortic root size;
UCEC	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.8	-9.08	-0.6	6.46e-16	Height;
UCEC	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.54	5.33	0.4	3.69e-7	Menopause (age at onset);
UCEC	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	5.24	0.4	5.55e-7	Colorectal cancer;
UCEC	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.17	0.45	6.24e-9	IgG glycosylation;
UCEC	cis	rs77861329	1.000	rs9809977	chr3:52166147	T/C	cg08692210	chr3:52188851	WDR51A	0.86	6.58	0.48	7.74e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.11	-0.39	9.68e-7	Life satisfaction;
UCEC	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.06	9.15	0.6	4.43e-16	Platelet distribution width;
UCEC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg07250515	chr12:56618133	OBFC2B	-0.62	-5.5	-0.41	1.64e-7	Psoriasis vulgaris;
UCEC	cis	rs1980946	1.000	rs111841437	chr20:48345673	T/C	cg01159004	chr20:48330681	B4GALT5	-0.57	-4.5	-0.35	1.36e-5	Palmitic acid (16:0) levels;
UCEC	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.54	5.94	0.44	1.97e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg27068330	chr11:65405492	SIPA1	-0.51	-4.62	-0.36	8.4e-6	Breast cancer;
UCEC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.65	-7.45	-0.52	7.22e-12	Prudent dietary pattern;
UCEC	cis	rs9469578	0.892	rs73743333	chr6:33714042	G/A	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.69	7.59	0.53	3.44e-12	Menarche (age at onset);
UCEC	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.58	-5.92	-0.44	2.23e-8	Eye color traits;
UCEC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.67	-7.81	-0.54	1.01e-12	Menarche (age at onset);
UCEC	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg20007245	chr22:24372913	LOC391322	0.58	6.35	0.46	2.49e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-5.23	-0.4	5.77e-7	Gut microbiome composition (summer);
UCEC	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg21466736	chr12:48725269	NA	0.37	4.51	0.35	1.32e-5	Glycated hemoglobin levels;
UCEC	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-6.45	-0.47	1.49e-9	Hemoglobin concentration;
UCEC	cis	rs13063635	0.915	rs34068335	chr3:45954339	C/T	cg16320329	chr3:45981161	FYCO1	-0.83	-4.74	-0.36	4.96e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9321099	1.000	rs9388601	chr6:128233158	A/T	cg25012434	chr6:128842125	PTPRK	0.71	4.65	0.36	7.29e-6	Sense of smell;
UCEC	cis	rs6921919	0.697	rs12180820	chr6:28316478	A/G	cg06818710	chr6:28411271	ZSCAN23	0.46	5.53	0.41	1.45e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.58	5.33	0.4	3.67e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.44	-4.94	-0.38	2.14e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.27	-0.4	4.87e-7	Aortic root size;
UCEC	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.73	7.7	0.54	1.88e-12	Blood metabolite levels;
UCEC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.6	6.54	0.47	9.47e-10	Crohn's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25804860	chr16:47178250	NETO2	0.53	6.92	0.5	1.32e-10	Warfarin maintenance dose;
UCEC	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-5.01	-0.38	1.56e-6	Non-small cell lung cancer;
UCEC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.41	0.41	2.52e-7	Cognitive function;
UCEC	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	7.95e-8	Diabetic kidney disease;
UCEC	cis	rs7187365	0.671	rs36111922	chr16:86495235	C/G	cg16563187	chr16:85730606	NA	-0.36	-4.71	-0.36	5.63e-6	Obesity (early onset extreme);
UCEC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05776053	chr2:74358815	NA	0.41	5.07	0.39	1.17e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs4366490	0.534	rs4405319	chr11:62913644	G/T	cg06798491	chr11:62538386	TAF6L	-0.57	-4.82	-0.37	3.56e-6	Conotruncal heart defects;
UCEC	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	9.52	0.62	5.03e-17	Platelet count;
UCEC	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06156847	chr2:113672199	IL1F7	0.34	4.61	0.36	8.58e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.5	-0.41	1.64e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.57	6.45	0.47	1.53e-9	Crohn's disease;
UCEC	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18252515	chr7:66147081	NA	0.45	4.61	0.36	8.64e-6	Aortic root size;
UCEC	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	0.81	6.58	0.48	7.9e-10	Alzheimer's disease;
UCEC	trans	rs925228	0.955	rs12478037	chr2:24141469	T/C	cg18674340	chr17:45867686	NA	0.73	6.75	0.49	3.24e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.65	-7.7	-0.54	1.87e-12	IgG glycosylation;
UCEC	cis	rs6416877	0.921	rs8082128	chr17:1344184	A/C	cg09375892	chr17:708413	NXN	-0.61	-4.62	-0.36	8.16e-6	Myeloid white cell count;
UCEC	cis	rs7709377	0.597	rs1396481	chr5:115475187	A/G	cg23108291	chr5:115420582	COMMD10	0.51	5.29	0.4	4.28e-7	Metabolite levels  (X-11787);
UCEC	cis	rs73001065	1.000	rs73001065	chr19:19460541	G/C	cg03709012	chr19:19516395	GATAD2A	1.08	4.88	0.37	2.7e-6	LDL cholesterol;
UCEC	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.78	6.26	0.46	4.04e-9	Neuroticism;
UCEC	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.71	7.97	0.55	3.96e-13	Coronary artery disease;
UCEC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	0.61	6.63	0.48	5.9e-10	Monocyte percentage of white cells;
UCEC	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.58	6.54	0.47	9.37e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg11150807	chr10:43354902	NA	0.86	6.74	0.49	3.39e-10	Blood protein levels;
UCEC	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.46	-4.57	-0.35	1.01e-5	Blood metabolite levels;
UCEC	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.51e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.52	-4.85	-0.37	3.12e-6	Menarche (age at onset);
UCEC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.68	-7.24	-0.51	2.27e-11	Breast cancer;
UCEC	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-4.83	-0.37	3.37e-6	Blood metabolite levels;
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.49	-6.57	-0.48	8.16e-10	Body mass index;
UCEC	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.38	5.44	0.41	2.18e-7	Schizophrenia;
UCEC	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.87	-12.32	-0.71	2.1e-24	Post bronchodilator FEV1;
UCEC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.31	-5.18	-0.39	7.13e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.96	-0.44	1.79e-8	Bipolar disorder;
UCEC	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	4.86	0.37	2.96e-6	Breast cancer;
UCEC	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	9.15	0.6	4.42e-16	Coffee consumption (cups per day);
UCEC	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.82	7.97	0.55	4.15e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-5.04	-0.38	1.37e-6	Height;
UCEC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.42	4.82	0.37	3.55e-6	Platelet count;
UCEC	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	5.84	0.43	3.26e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg19926144	chr10:661009	DIP2C	0.76	4.61	0.36	8.67e-6	Eosinophil percentage of granulocytes;
UCEC	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs4265793	0.655	rs6497319	chr16:19043183	C/T	cg06773604	chr16:18995157	TMC7	0.72	5.51	0.41	1.54e-7	Response to angiotensin II receptor blocker therapy;
UCEC	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.46	-5.07	-0.39	1.2e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs16939046	1.000	rs72656159	chr8:76100145	C/T	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	0.89	11.96	0.7	1.84e-23	Blood protein levels;
UCEC	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg14851346	chr12:38532713	NA	-0.46	-4.51	-0.35	1.32e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.72	-5.78	-0.43	4.31e-8	Schizophrenia;
UCEC	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.23	12.27	0.71	2.87e-24	Corneal structure;
UCEC	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg08250081	chr4:10125330	NA	0.46	4.51	0.35	1.3e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.67	7.6	0.53	3.15e-12	Vitiligo;
UCEC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.49	-4.61	-0.36	8.69e-6	Vitiligo;
UCEC	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.51	-7.06	-0.5	6.14e-11	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.59	-7.64	-0.53	2.51e-12	Corneal structure;
UCEC	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.61	5.99	0.44	1.57e-8	Lung cancer;
UCEC	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg18681998	chr4:17616180	MED28	-0.71	-6.6	-0.48	7.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.24	-0.4	5.39e-7	Mood instability;
UCEC	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.65	6.2	0.46	5.36e-9	Vitiligo;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.53	-5.92	-0.44	2.17e-8	Pubertal anthropometrics;
UCEC	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg21770322	chr7:97807741	LMTK2	0.54	6.74	0.49	3.37e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.52	5.59	0.42	1.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11169552	0.510	rs10876043	chr12:50904144	C/T	cg14754491	chr12:50677585	LIMA1	-0.51	-4.77	-0.37	4.39e-6	Colorectal cancer;
UCEC	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.16	0.56	1.36e-13	Chronic sinus infection;
UCEC	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.8	-9.96	-0.63	3.59e-18	White blood cell count (basophil);
UCEC	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.71	5.07	0.39	1.2e-6	Body mass index;
UCEC	cis	rs9549260	0.564	rs6563845	chr13:41318907	A/G	cg21288729	chr13:41239152	FOXO1	0.55	5.64	0.42	8.44e-8	Red blood cell count;
UCEC	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-0.99	-9.39	-0.61	1.09e-16	Initial pursuit acceleration;
UCEC	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.54	5.57	0.42	1.18e-7	Post bronchodilator FEV1;
UCEC	cis	rs7307889	0.793	rs55712234	chr12:6006618	G/T	cg23245485	chr12:6484219	SCNN1A	0.6	4.78	0.37	4.24e-6	Obesity-related traits;
UCEC	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.17	-0.68	2.38e-21	Primary sclerosing cholangitis;
UCEC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg07836142	chr6:28411423	ZSCAN23	0.47	5.06	0.39	1.23e-6	Cardiac Troponin-T levels;
UCEC	cis	rs4853036	0.904	rs2278934	chr2:70121197	T/C	cg02498382	chr2:70120550	SNRNP27	-0.44	-4.72	-0.36	5.47e-6	Colorectal or endometrial cancer;
UCEC	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg13575925	chr12:9217583	LOC144571	0.39	4.74	0.36	5.07e-6	Sjögren's syndrome;
UCEC	cis	rs76734026	0.681	rs17181388	chr14:66118012	A/G	cg08164191	chr14:65623632	NA	-0.59	-4.53	-0.35	1.22e-5	Pediatric areal bone mineral density (radius);
UCEC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.57	5.4	0.41	2.58e-7	Aortic root size;
UCEC	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.71	5.26	0.4	4.9e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.53	5.3	0.4	4.18e-7	Dupuytren's disease;
UCEC	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg05660106	chr1:15850417	CASP9	0.55	4.91	0.38	2.37e-6	Systolic blood pressure;
UCEC	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg13683864	chr3:40499215	RPL14	-0.66	-6.55	-0.48	9.05e-10	Renal cell carcinoma;
UCEC	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.55	-4.85	-0.37	3.09e-6	Corneal astigmatism;
UCEC	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.53	-5.36	-0.4	3.14e-7	Hepatocellular carcinoma;
UCEC	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg22974920	chr21:40686053	BRWD1	0.62	5.45	0.41	2.03e-7	Cognitive function;
UCEC	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg08798685	chr6:27730294	NA	-0.63	-4.58	-0.35	9.87e-6	Depression;
UCEC	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg01072550	chr1:21505969	NA	-0.6	-6.23	-0.46	4.74e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.94	0.78	2.82e-31	Homoarginine levels;
UCEC	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.66	-0.42	7.62e-8	Alcohol dependence;
UCEC	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	9.26	0.61	2.25e-16	Bipolar disorder;
UCEC	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	7.15	0.51	3.71e-11	Motion sickness;
UCEC	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.58	-5.03	-0.38	1.38e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.46	4.74	0.36	4.99e-6	Prostate cancer;
UCEC	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg19645103	chr12:69753606	YEATS4	-0.55	-5.0	-0.38	1.62e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9918079	0.884	rs11728037	chr4:15594898	C/T	cg24513071	chr4:15006760	CPEB2	-0.74	-4.52	-0.35	1.27e-5	Obesity-related traits;
UCEC	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.27	-9.55	-0.62	4.2e-17	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.91	9.71	0.63	1.61e-17	Cognitive function;
UCEC	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg09795085	chr6:101329169	ASCC3	0.59	4.57	0.35	1.01e-5	Economic and political preferences (immigration/crime);
UCEC	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg01380346	chr19:18557039	ELL	-0.45	-4.56	-0.35	1.09e-5	Breast cancer;
UCEC	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.69	-7.25	-0.51	2.21e-11	Coronary artery disease;
UCEC	trans	rs17594526	0.826	rs75461791	chr18:53142328	T/C	cg12963529	chr20:43540202	PABPC1L	1.28	6.83	0.49	2.1e-10	Schizophrenia;
UCEC	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.7	6.51	0.47	1.13e-9	Menopause (age at onset);
UCEC	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.51	-4.62	-0.36	8.45e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7870753	0.838	rs754560	chr9:99212930	T/G	cg25260653	chr9:99212216	HABP4	0.48	4.76	0.37	4.57e-6	Height;
UCEC	cis	rs7617773	1.000	rs6442108	chr3:48192959	G/C	cg11946769	chr3:48343235	NME6	-0.56	-4.81	-0.37	3.65e-6	Coronary artery disease;
UCEC	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.25	-7.15	-0.51	3.67e-11	Schizophrenia;
UCEC	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.86	9.61	0.62	2.9e-17	Ulcerative colitis;
UCEC	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg19041857	chr6:27730383	NA	-0.67	-4.97	-0.38	1.86e-6	Breast cancer;
UCEC	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.48	6.82	0.49	2.19e-10	Homoarginine levels;
UCEC	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-6.03	-0.45	1.27e-8	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.6	8.83	0.59	2.88e-15	Prudent dietary pattern;
UCEC	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.53	5.98	0.44	1.6e-8	Menarche (age at onset);
UCEC	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.59	5.01	0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.55	-4.54	-0.35	1.19e-5	Bladder cancer;
UCEC	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-4.9	-0.38	2.45e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	5.81	0.43	3.67e-8	Initial pursuit acceleration;
UCEC	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.61	5.34	0.4	3.53e-7	Heart rate;
UCEC	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.53	5.17	0.39	7.49e-7	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	8.04	0.55	2.79e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.47	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	10.01	0.64	2.59e-18	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.55	6.16	0.45	6.5e-9	Mean corpuscular volume;
UCEC	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.18	0.39	7.04e-7	Breast cancer;
UCEC	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg07387570	chr22:46663686	TTC38	-0.49	-4.83	-0.37	3.41e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-5.24	-0.4	5.57e-7	Longevity;Endometriosis;
UCEC	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.44	5.15	0.39	8.07e-7	Breast cancer;
UCEC	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.72	8.59	0.58	1.17e-14	Menarche (age at onset);
UCEC	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg18479299	chr3:125709523	NA	-0.67	-4.59	-0.35	9.33e-6	Blood pressure (smoking interaction);
UCEC	trans	rs56184986	0.520	rs55655144	chr11:131719147	A/C	cg10599035	chr6:42981724	MEA1;KLHDC3	-1.23	-7.61	-0.53	3.1e-12	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	7.61	0.53	2.99e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.06	0.5	6.28e-11	Motion sickness;
UCEC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.54	-5.93	-0.44	2.09e-8	Blood metabolite levels;
UCEC	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-7.01	-0.5	8.13e-11	Chronic sinus infection;
UCEC	cis	rs7246967	0.932	rs58238799	chr19:23040182	G/T	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.79	-0.37	4.07e-6	Parkinson's disease;
UCEC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.59	5.73	0.43	5.43e-8	Tonsillectomy;
UCEC	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.52	-6.51	-0.47	1.11e-9	Information processing speed;
UCEC	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.64	5.56	0.42	1.21e-7	Subjective well-being;
UCEC	cis	rs6663390	0.510	rs2267897	chr1:208075378	C/T	cg03990033	chr1:208084030	CD34	0.53	5.04	0.38	1.33e-6	Facial morphology (factor 18);
UCEC	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.48	0.57	2.21e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.83	-9.82	-0.63	8.07e-18	Primary sclerosing cholangitis;
UCEC	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.5	-0.41	1.64e-7	Life satisfaction;
UCEC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.58	6.46	0.47	1.47e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.55	-6.17	-0.45	6.37e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.57	6.29	0.46	3.52e-9	Blood metabolite levels;
UCEC	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.58	-5.62	-0.42	9.1e-8	Systemic sclerosis;
UCEC	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.15	14.66	0.77	1.48e-30	Cognitive function;
UCEC	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg04553112	chr3:125709451	NA	-0.59	-4.55	-0.35	1.12e-5	Blood pressure (smoking interaction);
UCEC	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	5.39	0.41	2.78e-7	Metabolite levels;
UCEC	cis	rs7546668	1.000	rs1467513	chr1:15894959	T/C	cg05660106	chr1:15850417	CASP9	-0.47	-4.79	-0.37	3.95e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.51	-0.57	1.88e-14	Mean platelet volume;
UCEC	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.18	0.6	3.61e-16	Coffee consumption (cups per day);
UCEC	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-11.92	-0.7	2.34e-23	Coronary artery disease;
UCEC	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg13695892	chr22:41940480	POLR3H	0.68	5.34	0.4	3.43e-7	Vitiligo;
UCEC	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.58	6.82	0.49	2.21e-10	Iron status biomarkers (transferrin levels);
UCEC	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	0.97	15.48	0.79	1.11e-32	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.6	4.84	0.37	3.27e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg12024160	chr4:1254474	NA	0.51	6.31	0.46	3.1e-9	Obesity-related traits;
UCEC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg08493051	chr2:3487164	NA	-0.61	-6.43	-0.47	1.69e-9	Neurofibrillary tangles;
UCEC	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.53	-5.83	-0.43	3.34e-8	IgG glycosylation;
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg20999797	chr1:1681921	NA	0.37	4.95	0.38	2e-6	Body mass index;
UCEC	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.81	-8.51	-0.57	1.88e-14	Multiple sclerosis;
UCEC	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.57	6.56	0.48	8.38e-10	Calcium levels;
UCEC	cis	rs7246967	0.673	rs2361245	chr19:22834530	A/G	cg24889512	chr19:22816950	ZNF492	0.58	6.19	0.45	5.82e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.71	-8.91	-0.59	1.82e-15	Hip circumference;
UCEC	cis	rs2062225	1.000	rs3789093	chr2:111750549	C/T	cg23782758	chr2:111737646	ACOXL	-0.64	-4.63	-0.36	8.14e-6	Monocyte count;
UCEC	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.5	-6.61	-0.48	6.79e-10	Eye color traits;
UCEC	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.6	-5.63	-0.42	9.03e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.7	-6.07	-0.45	1.03e-8	Diastolic blood pressure;
UCEC	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.44	-4.66	-0.36	6.94e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.7	-5.34	-0.4	3.5e-7	Alzheimer's disease (late onset);
UCEC	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	6.78	0.49	2.69e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.47	0.47	1.37e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.56	5.69	0.42	6.58e-8	Primary sclerosing cholangitis;
UCEC	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.04	-8.35	-0.57	4.54e-14	Exhaled nitric oxide output;
UCEC	cis	rs6437061	0.835	rs2853361	chr2:233120923	A/G	cg02061626	chr2:233274167	ALPPL2	0.49	5.01	0.38	1.54e-6	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7226229	0.950	rs1038109	chr17:20923291	A/G	cg01666600	chr17:21279561	KCNJ12	0.44	4.57	0.35	1.01e-5	Blood trace element (Se levels);
UCEC	cis	rs731174	0.797	rs510208	chr1:38147166	A/G	cg12339802	chr1:38156545	C1orf109	-0.54	-4.51	-0.35	1.32e-5	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.8	0.37	3.86e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.53	5.45	0.41	2.09e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12784848	chr8:23081957	TNFRSF10A	0.71	8.69	0.58	6.43e-15	Warfarin maintenance dose;
UCEC	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.43	-4.77	-0.37	4.44e-6	Late-onset Alzheimer's disease;
UCEC	cis	rs13401104	0.796	rs11894483	chr2:237114619	T/C	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.54	-5.37	-0.4	3.02e-7	Breast cancer;
UCEC	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4588572	0.643	rs10063742	chr5:77759362	A/G	cg11547950	chr5:77652471	NA	-0.49	-5.55	-0.42	1.3e-7	Triglycerides;
UCEC	trans	rs7914735	0.604	rs11194230	chr10:110459019	C/T	cg00544901	chr19:49999417	RPS11	-0.56	-7.17	-0.51	3.32e-11	Iris heterochromicity;
UCEC	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs3750082	0.889	rs3750081	chr7:32930876	T/G	cg05721444	chr7:32995514	FKBP9	0.52	5.76	0.43	4.71e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	14.94	0.78	2.82e-31	Homoarginine levels;
UCEC	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.06	6.96	0.5	1.04e-10	Gut microbiome composition (summer);
UCEC	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg21856205	chr7:94953877	PON1	-0.55	-5.28	-0.4	4.57e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.74	-9.92	-0.63	4.6e-18	Gut microbiota (bacterial taxa);
UCEC	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.57	-5.78	-0.43	4.21e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs28673728	0.897	rs28391281	chr1:38408974	T/C	cg04673462	chr1:38461896	NA	0.63	5.97	0.44	1.67e-8	Red cell distribution width;
UCEC	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg24375607	chr4:120327624	NA	0.47	4.93	0.38	2.24e-6	Corneal astigmatism;
UCEC	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.86	0.44	2.95e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.5	5.55	0.42	1.31e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.47	-4.87	-0.37	2.84e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg03714773	chr7:91764589	CYP51A1	0.46	5.53	0.42	1.4e-7	Breast cancer;
UCEC	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.59	6.36	0.46	2.39e-9	Neutrophil percentage of white cells;
UCEC	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.54	5.62	0.42	9.15e-8	Systolic blood pressure;
UCEC	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.53	5.25	0.4	5.19e-7	Homoarginine levels;
UCEC	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.68	7.13	0.51	4.12e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	1.1	9.76	0.63	1.15e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg20119798	chr7:94954144	PON1	-0.49	-4.65	-0.36	7.31e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.58	-5.45	-0.41	2.12e-7	Blood protein levels;
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	11.24	0.68	1.56e-21	Prudent dietary pattern;
UCEC	trans	rs56184986	0.520	rs61901684	chr11:131728581	T/C	cg10599035	chr6:42981724	MEA1;KLHDC3	-1.23	-7.61	-0.53	3.1e-12	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.51	-5.9	-0.44	2.38e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.57	-4.56	-0.35	1.05e-5	Narcolepsy;
UCEC	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.09	-0.39	1.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.69	-4.89	-0.37	2.62e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.19	0.51	3.08e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg10503236	chr1:231470652	EXOC8	-0.41	-4.96	-0.38	1.94e-6	Hemoglobin concentration;
UCEC	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.7	6.16	0.45	6.66e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12618769	0.597	rs4851136	chr2:99060873	A/T	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.59	7.31	0.52	1.63e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.76	6.39	0.47	2.05e-9	Cognitive test performance;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12386336	chr1:222988474	NA	0.58	6.68	0.48	4.55e-10	Warfarin maintenance dose;
UCEC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg13844804	chr7:814759	HEATR2	0.68	5.01	0.38	1.51e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs11235843	0.503	rs11601905	chr11:73358923	C/T	cg09185399	chr11:73372479	PLEKHB1	0.58	4.52	0.35	1.29e-5	Hand grip strength;
UCEC	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.64	6.41	0.47	1.85e-9	Dental caries;
UCEC	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	8.36	0.57	4.35e-14	Post bronchodilator FEV1;
UCEC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.09	-0.45	9.34e-9	Metabolite levels;
UCEC	cis	rs36715	1.000	rs251212	chr5:127545910	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.47	0.41	1.89e-7	Breast cancer;
UCEC	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg08975724	chr8:8085496	FLJ10661	0.55	4.79	0.37	4.07e-6	Red cell distribution width;
UCEC	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg01262667	chr19:19385393	TM6SF2	-0.4	-4.6	-0.35	9.18e-6	Bipolar disorder;
UCEC	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12311346	chr5:56204834	C5orf35	0.48	4.69	0.36	6.29e-6	Coronary artery disease;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.76	8.89	0.59	2.08e-15	Menarche (age at onset);
UCEC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.65	-5.22	-0.4	5.9e-7	Menopause (age at onset);
UCEC	trans	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.53	-0.42	1.42e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg12637676	chr8:11587161	GATA4	-0.36	-4.61	-0.36	8.65e-6	Retinal vascular caliber;
UCEC	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-6.84	-0.49	1.98e-10	Blood pressure (smoking interaction);
UCEC	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg13575925	chr12:9217583	LOC144571	0.4	4.58	0.35	9.75e-6	Sjögren's syndrome;
UCEC	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg03146154	chr1:46216737	IPP	-0.61	-6.03	-0.45	1.28e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.46	-4.52	-0.35	1.28e-5	Coronary artery disease;
UCEC	cis	rs6460942	0.511	rs60387403	chr7:12083133	G/T	cg02514794	chr7:12446327	NA	0.68	4.84	0.37	3.27e-6	Coronary artery disease;
UCEC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg09033563	chr22:24373618	LOC391322	0.51	4.77	0.37	4.35e-6	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.65	6.73	0.49	3.62e-10	Body mass index;
UCEC	cis	rs7246967	0.673	rs12978964	chr19:22819244	G/A	cg05241461	chr19:22816980	ZNF492	0.58	6.36	0.46	2.37e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg12024160	chr4:1254474	NA	0.53	4.86	0.37	2.93e-6	Longevity;
UCEC	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.59	6.31	0.46	3.09e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.74	-5.13	-0.39	8.94e-7	Toenail selenium levels;
UCEC	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.7	8.26	0.56	7.61e-14	Metabolite levels;
UCEC	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-4.83	-0.37	3.37e-6	Acylcarnitine levels;
UCEC	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg06562184	chr8:19319451	CSGALNACT1	0.41	4.52	0.35	1.28e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.68	5.87	0.44	2.82e-8	Prostate cancer;
UCEC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-4.56	-0.35	1.08e-5	Gut microbiome composition (summer);
UCEC	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.47	4.6	0.35	9.11e-6	Breast cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25947998	chr8:42948467	SGK196	0.54	6.7	0.48	4.04e-10	Warfarin maintenance dose;
UCEC	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.68	-6.68	-0.48	4.56e-10	Blood metabolite levels;
UCEC	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	5.65	0.42	8.18e-8	Personality dimensions;
UCEC	cis	rs7246967	0.673	rs35335083	chr19:22869592	A/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.64	-7.26	-0.51	2.04e-11	Headache;
UCEC	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.67	-5.21	-0.4	6.18e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05776053	chr2:74358815	NA	0.44	5.09	0.39	1.08e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg00791764	chr4:53727839	RASL11B	0.67	4.93	0.38	2.16e-6	Optic nerve measurement (cup area);
UCEC	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg23950597	chr19:37808831	NA	-0.83	-5.56	-0.42	1.22e-7	Coronary artery calcification;
UCEC	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.69	0.36	6.14e-6	Tonsillectomy;
UCEC	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.48	4.78	0.37	4.13e-6	Monocyte percentage of white cells;
UCEC	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	0.92	10.9	0.67	1.24e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.22	9.43	0.61	8.31e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-6.99	-0.5	9e-11	Total body bone mineral density;
UCEC	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.69	-6.4	-0.47	1.99e-9	Inflammatory bowel disease;
UCEC	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.57	7.21	0.51	2.68e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.79	8.16	0.56	1.38e-13	Colorectal cancer;
UCEC	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.76	-7.22	-0.51	2.59e-11	Alzheimer's disease;
UCEC	cis	rs539514	0.612	rs1830760	chr13:76296625	G/A	cg04757411	chr13:76259545	LMO7	-0.41	-4.62	-0.36	8.38e-6	Type 1 diabetes;
UCEC	cis	rs12234571	1.000	rs73372287	chr7:77342585	T/C	cg20048109	chr7:78158112	MAGI2	-0.53	-4.81	-0.37	3.76e-6	Obesity-related traits;
UCEC	cis	rs7474896	0.832	rs2799499	chr10:38246545	A/G	cg00409905	chr10:38381863	ZNF37A	0.6	4.6	0.35	9.01e-6	Obesity (extreme);
UCEC	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.42	5.36	0.4	3.13e-7	Coronary artery disease;
UCEC	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.75	6.62	0.48	6.27e-10	Coronary artery disease;
UCEC	cis	rs7307889	1.000	rs7307889	chr12:5981353	A/G	cg10294363	chr12:6480192	SCNN1A	-0.59	-4.69	-0.36	6.14e-6	Obesity-related traits;
UCEC	cis	rs6663390	0.510	rs2300055	chr1:208065380	C/T	cg00387621	chr1:208086895	NA	0.59	4.52	0.35	1.25e-5	Facial morphology (factor 18);
UCEC	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.54	-5.05	-0.38	1.31e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.94	9.92	0.63	4.56e-18	Cognitive function;
UCEC	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	1.01	9.96	0.63	3.63e-18	Alcohol dependence;
UCEC	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.98e-7	Aortic root size;
UCEC	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.48	-5.04	-0.38	1.38e-6	Vitiligo;
UCEC	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.82	8.64	0.58	8.86e-15	Blood protein levels;
UCEC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.87	-9.52	-0.62	4.95e-17	Cognitive function;
UCEC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg19743168	chr1:23544995	NA	0.44	6.2	0.46	5.39e-9	Height;
UCEC	cis	rs7578199	0.576	rs2271030	chr2:242432704	G/C	cg02201132	chr2:242212884	HDLBP	-0.42	-4.61	-0.36	8.84e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.32	-0.52	1.52e-11	Resting heart rate;
UCEC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24308560	chr3:49941425	MST1R	-0.49	-5.16	-0.39	7.89e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.49	5.75	0.43	4.92e-8	Aortic root size;
UCEC	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.54	-4.79	-0.37	4.06e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-7.52	-0.53	5.1e-12	Coronary artery disease;
UCEC	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.69	-5.44	-0.41	2.14e-7	Type 2 diabetes;
UCEC	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.7	7.08	0.5	5.59e-11	Primary sclerosing cholangitis;
UCEC	cis	rs925228	0.955	rs963726	chr2:24148538	A/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.51	-4.8	-0.37	3.89e-6	Corneal astigmatism;
UCEC	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.78	6.49	0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-4.99	-0.38	1.72e-6	Gut microbiome composition (summer);
UCEC	cis	rs1712517	0.844	rs1163075	chr10:105021263	A/G	cg05636881	chr10:105038444	INA	-0.45	-5.43	-0.41	2.26e-7	Migraine;
UCEC	cis	rs4713118	0.523	rs2179096	chr6:27665920	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.49	-4.99	-0.38	1.67e-6	Parkinson's disease;
UCEC	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.74	8.34	0.57	4.78e-14	Coronary artery disease;
UCEC	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.3	0.46	3.23e-9	Coffee consumption (cups per day);
UCEC	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-5.37	-0.4	3.03e-7	Colorectal cancer;
UCEC	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.46	-5.16	-0.39	7.91e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.64	-4.59	-0.35	9.41e-6	Aortic root size;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg01874867	chr7:94954059	PON1	0.72	7.64	0.53	2.62e-12	Paraoxonase activity;
UCEC	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.52	-5.11	-0.39	9.77e-7	Pediatric autoimmune diseases;
UCEC	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.76	7.99	0.55	3.7e-13	Tonsillectomy;
UCEC	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.43	5.23	0.4	5.78e-7	Information processing speed;
UCEC	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.68	5.96	0.44	1.76e-8	Subjective well-being;
UCEC	cis	rs9931543	0.638	rs12448100	chr16:56292043	C/A	cg10482356	chr16:56328421	GNAO1	-0.35	-4.59	-0.35	9.35e-6	Subjective well-being;
UCEC	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg21905437	chr5:178450457	ZNF879	0.64	7.19	0.51	3e-11	Pubertal anthropometrics;
UCEC	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg03549618	chr14:35838977	NA	-0.35	-4.6	-0.35	9.23e-6	Psoriasis;
UCEC	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.62	-4.99	-0.38	1.72e-6	Initial pursuit acceleration;
UCEC	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-4.89	-0.37	2.62e-6	Aortic root size;
UCEC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.48	5.63	0.42	9.01e-8	Aortic root size;
UCEC	cis	rs11867410	0.744	rs73992149	chr17:63955729	T/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.65	-0.36	7.3e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.35	4.75	0.36	4.85e-6	Adiponectin levels;
UCEC	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.7	-0.36	5.92e-6	Alzheimer's disease (late onset);
UCEC	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.51	4.91	0.38	2.36e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	0.89	5.57	0.42	1.21e-7	Skin colour saturation;
UCEC	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	4.75	0.36	4.74e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg11871910	chr12:69753446	YEATS4	1.06	13.47	0.74	1.92e-27	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.62	-4.99	-0.38	1.66e-6	Initial pursuit acceleration;
UCEC	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.36	-6.22	-0.46	4.86e-9	Mean corpuscular volume;
UCEC	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.72	7.43	0.52	8.42e-12	Breast cancer;
UCEC	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg18230493	chr5:56204884	C5orf35	-0.52	-4.5	-0.35	1.36e-5	Coronary artery disease;
UCEC	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.15	6.96	0.5	1.06e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs970548	0.506	rs11239548	chr10:46018168	T/A	cg15223267	chr10:46222474	FAM21C	0.48	4.58	0.35	9.84e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.59	-6.05	-0.45	1.14e-8	Age at first birth;
UCEC	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.78	8.97	0.59	1.29e-15	Mortality in heart failure;
UCEC	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.62	6.48	0.47	1.31e-9	Motion sickness;
UCEC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.83	8.87	0.59	2.29e-15	Blood protein levels;
UCEC	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.82	9.34	0.61	1.45e-16	Blood protein levels;
UCEC	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.64	6.7	0.48	4.08e-10	QRS complex (12-leadsum);
UCEC	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.56	4.92	0.38	2.31e-6	Corneal astigmatism;
UCEC	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.56	6.12	0.45	8e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.42	5.3	0.4	4.06e-7	Alcohol dependence;
UCEC	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.59	6.01	0.44	1.43e-8	Asthma (sex interaction);
UCEC	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.85	-0.43	3.1e-8	Adiposity;
UCEC	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.34	4.75	0.37	4.7e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.46	-4.76	-0.37	4.51e-6	Gut microbiome composition (summer);
UCEC	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.52	-5.91	-0.44	2.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10242455	0.681	rs2740559	chr7:99324515	G/C	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17492891	chr22:41843204	TOB2	0.55	6.87	0.49	1.69e-10	Warfarin maintenance dose;
UCEC	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.76	-8.69	-0.58	6.46e-15	Menarche (age at onset);
UCEC	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	0.94	9.81	0.63	8.45e-18	Breast cancer;
UCEC	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg13575925	chr12:9217583	LOC144571	-0.42	-5.14	-0.39	8.48e-7	Sjögren's syndrome;
UCEC	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	5.39	0.41	2.79e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4077515	1.000	rs10870077	chr9:139263891	C/G	cg14019695	chr9:139328340	INPP5E	0.48	5.1	0.39	1.05e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.12	-0.6	5.33e-16	Height;
UCEC	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.59	7.14	0.51	3.89e-11	Oral cavity cancer;
UCEC	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg05925327	chr15:68127851	NA	-0.49	-5.59	-0.42	1.09e-7	Restless legs syndrome;
UCEC	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.55	-5.71	-0.43	5.94e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.58	5.06	0.39	1.23e-6	Crohn's disease;
UCEC	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.04	-0.45	1.23e-8	Resting heart rate;
UCEC	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.22	10.72	0.66	3.69e-20	Corneal structure;
UCEC	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-6.66	-0.48	5.15e-10	Platelet distribution width;
UCEC	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.5	5.4	0.41	2.61e-7	Total body bone mineral density;
UCEC	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg00639195	chr15:79103007	ADAMTS7	-0.58	-5.01	-0.38	1.54e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
UCEC	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.58	5.1	0.39	1.05e-6	Major depressive disorder;
UCEC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.55	-5.44	-0.41	2.16e-7	Total body bone mineral density;
UCEC	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.78	-8.84	-0.59	2.67e-15	Longevity;Endometriosis;
UCEC	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg21770322	chr7:97807741	LMTK2	0.85	15.2	0.78	5.91e-32	Breast cancer;
UCEC	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.59	5.35	0.4	3.26e-7	Menarche (age at onset);
UCEC	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg05660106	chr1:15850417	CASP9	0.57	5.25	0.4	5.11e-7	Systolic blood pressure;
UCEC	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-6.48	-0.47	1.28e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.67	6.55	0.48	9.23e-10	Vitamin D levels;
UCEC	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg14530993	chr4:882597	GAK	0.65	4.69	0.36	6.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	1.02	8.21	0.56	1.02e-13	Vitiligo;
UCEC	cis	rs28795989	0.931	rs7686202	chr4:7898577	C/T	cg00251875	chr4:7801337	AFAP1	0.46	5.58	0.42	1.11e-7	Intraocular pressure;
UCEC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.17	0.39	7.45e-7	Aortic root size;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg07838603	chr6:28411030	ZSCAN23	0.48	5.46	0.41	1.94e-7	Cardiac Troponin-T levels;
UCEC	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.54	5.39	0.41	2.78e-7	Menopause (age at onset);
UCEC	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.92	9.79	0.63	9.91e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.67	5.41	0.41	2.55e-7	Corneal astigmatism;
UCEC	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.48	-0.47	1.29e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.47	4.82	0.37	3.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.79	5.83	0.43	3.41e-8	Initial pursuit acceleration;
UCEC	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.69	-7.86	-0.54	7.36e-13	Menarche (age at onset);
UCEC	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg19760965	chr3:194868843	C3orf21	0.4	4.61	0.36	8.59e-6	Non-small cell lung cancer;
UCEC	cis	rs7968440	1.000	rs2731440	chr12:51057627	T/A	cg20014596	chr12:50898483	DIP2B	0.47	4.62	0.36	8.16e-6	Fibrinogen;
UCEC	cis	rs7517126	1.000	rs7517587	chr1:196840765	A/G	cg07209298	chr1:196795943	CFHR1	0.5	5.05	0.38	1.28e-6	Blood protein levels;
UCEC	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	0.9	9.45	0.61	7.5e-17	Left atrial antero-posterior diameter;
UCEC	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.67	7.17	0.51	3.32e-11	Coronary artery disease;
UCEC	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-9.78	-0.63	1.04e-17	Electrocardiographic conduction measures;
UCEC	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.88	10.0	0.64	2.84e-18	Blood metabolite levels;
UCEC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.86	-0.37	3.01e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.91	-0.44	2.25e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.46	-5.09	-0.39	1.09e-6	Platelet distribution width;
UCEC	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.59	4.9	0.38	2.45e-6	Gut microbiome composition (summer);
UCEC	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg24130564	chr14:104152367	KLC1	-0.56	-4.68	-0.36	6.43e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs151997	0.671	rs152926	chr5:50201787	G/A	cg06027927	chr5:50259733	NA	-0.65	-6.01	-0.44	1.41e-8	Callous-unemotional behaviour;
UCEC	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.62	5.52	0.41	1.53e-7	Alcohol dependence;
UCEC	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.65	-0.36	7.2e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.06	-15.86	-0.79	1.18e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg00339695	chr16:24857497	SLC5A11	0.52	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	trans	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg02900749	chr2:68251473	NA	-0.93	-7.39	-0.52	1.02e-11	Pursuit maintenance gain;
UCEC	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.42	-4.75	-0.36	4.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.59	5.7	0.43	6.47e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.43	-6.27	-0.46	3.84e-9	Rheumatoid arthritis;
UCEC	cis	rs7246967	0.611	rs8104052	chr19:22857804	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.25	-0.4	5.26e-7	Initial pursuit acceleration;
UCEC	cis	rs4851266	0.966	rs2309838	chr2:100838455	T/C	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.6	6.18	0.45	6.05e-9	Colorectal cancer;
UCEC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg05695927	chr15:45694626	SPATA5L1	0.51	4.98	0.38	1.74e-6	Homoarginine levels;
UCEC	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.89	7.22	0.51	2.53e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg18827107	chr12:86230957	RASSF9	0.4	4.5	0.35	1.35e-5	Major depressive disorder;
UCEC	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.41	-4.9	-0.37	2.5e-6	Menopause (age at onset);
UCEC	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.59	5.48	0.41	1.79e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.65	0.42	7.9e-8	Breast cancer;
UCEC	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.74	7.87	0.54	7.1e-13	Heart rate;
UCEC	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.09e-6	Height;
UCEC	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	14.59	0.77	2.27e-30	Chronic sinus infection;
UCEC	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.85	-10.84	-0.67	1.77e-20	Height;
UCEC	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.49	-4.7	-0.36	5.84e-6	Hepatocellular carcinoma;
UCEC	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.44	0.74	2.27e-27	Homoarginine levels;
UCEC	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg17534202	chr9:96721102	NA	0.51	5.42	0.41	2.38e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	5.5	0.41	1.63e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4730268	0.768	rs79139176	chr7:107438298	C/G	cg18560240	chr7:107437656	SLC26A3	-0.74	-6.23	-0.46	4.71e-9	IgG glycosylation;
UCEC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.54	5.31	0.4	4.04e-7	Menopause (age at onset);
UCEC	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-0.79	-8.15	-0.56	1.42e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.58	-5.29	-0.4	4.35e-7	Metabolite levels;
UCEC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.61	-4.83	-0.37	3.45e-6	Initial pursuit acceleration;
UCEC	cis	rs6686929	1.000	rs7534142	chr1:18242820	C/G	cg03861428	chr1:17380702	SDHB	0.41	4.6	0.35	8.96e-6	Obesity-related traits;
UCEC	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.07	0.5	5.71e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.59	-4.81	-0.37	3.74e-6	Coronary artery calcification;
UCEC	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.62	5.86	0.44	2.91e-8	Selective IgA deficiency;
UCEC	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.64	5.67	0.42	7.31e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg22563815	chr15:78856949	CHRNA5	-0.41	-5.3	-0.4	4.14e-7	Sudden cardiac arrest;
UCEC	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg22907277	chr7:1156413	C7orf50	1.0	6.3	0.46	3.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11958404	0.860	rs72818136	chr5:157462866	C/T	cg05962755	chr5:157440814	NA	0.75	5.5	0.41	1.64e-7	IgG glycosylation;
UCEC	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.69	6.29	0.46	3.49e-9	Aortic root size;
UCEC	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg15432903	chr11:17409602	KCNJ11	0.53	4.82	0.37	3.47e-6	Type 2 diabetes;
UCEC	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	5.51	0.41	1.59e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg16797656	chr11:68205561	LRP5	0.45	5.55	0.42	1.3e-7	Total body bone mineral density (age 45-60);
UCEC	cis	rs7246967	0.551	rs7250608	chr19:22853056	C/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7113850	0.541	rs76166238	chr11:24235418	G/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg19500275	chr17:80737654	TBCD	0.61	5.89	0.44	2.54e-8	Glycated hemoglobin levels;
UCEC	cis	rs11958404	0.789	rs72818150	chr5:157484121	A/G	cg05962755	chr5:157440814	NA	0.72	5.06	0.38	1.25e-6	IgG glycosylation;
UCEC	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.63	-6.19	-0.45	5.63e-9	Metabolite levels;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.53	0.35	1.19e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg25609507	chr10:50821597	CHAT	0.38	4.54	0.35	1.15e-5	Prostate-specific antigen levels;
UCEC	cis	rs4705962	0.917	rs10066660	chr5:132020990	G/A	cg27309611	chr5:132113725	SEPT8	0.38	4.99	0.38	1.68e-6	Atopic dermatitis;
UCEC	cis	rs6964587	0.507	rs12539439	chr7:91917365	A/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.38	0.41	2.82e-7	Breast cancer;
UCEC	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs529866	0.500	rs918739	chr16:11439733	G/T	cg00044050	chr16:11439710	C16orf75	-0.45	-4.72	-0.36	5.46e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.63	-4.74	-0.36	5.05e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.48	5.38	0.41	2.94e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.89	7.22	0.51	2.53e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg02160872	chr5:212506	CCDC127	-0.79	-8.15	-0.56	1.47e-13	Breast cancer;
UCEC	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.49	-5.49	-0.41	1.68e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.31	5.34	0.4	3.41e-7	Mean corpuscular volume;
UCEC	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.53	6.41	0.47	1.82e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	6.86	0.49	1.76e-10	Response to antipsychotic treatment;
UCEC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg00316803	chr15:76480434	C15orf27	0.4	4.53	0.35	1.19e-5	Blood metabolite levels;
UCEC	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.03e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17123764	0.818	rs12321819	chr12:49941997	T/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.3	0.4	4.09e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.57	-0.48	7.98e-10	Adiposity;
UCEC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.92	9.62	0.62	2.74e-17	Cognitive function;
UCEC	cis	rs7246967	0.673	rs34342502	chr19:22881428	C/A	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.45	-6.61	-0.48	6.7e-10	Rheumatoid arthritis;
UCEC	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg18681998	chr4:17616180	MED28	0.78	9.16	0.6	4.21e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.61	5.8	0.43	3.84e-8	Sudden cardiac arrest;
UCEC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.3	-10.61	-0.66	6.79e-20	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs4499344	0.730	rs406470	chr19:33104472	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.96	0.44	1.75e-8	Mean platelet volume;
UCEC	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.61	5.49	0.41	1.73e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg18681998	chr4:17616180	MED28	-0.58	-6.78	-0.49	2.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg06521331	chr12:34319734	NA	-0.58	-4.54	-0.35	1.15e-5	Morning vs. evening chronotype;
UCEC	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg21770322	chr7:97807741	LMTK2	0.53	6.5	0.47	1.15e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.03	0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.94	0.59	1.54e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg24375607	chr4:120327624	NA	-0.46	-5.06	-0.38	1.26e-6	Corneal astigmatism;
UCEC	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-7.88	-0.55	6.65e-13	Morning vs. evening chronotype;
UCEC	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.78	5.0	0.38	1.61e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.21	-0.39	6.24e-7	Superior crus of antihelix expression;
UCEC	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.55	5.21	0.39	6.39e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	1.12	6.14	0.45	7.25e-9	Skin colour saturation;
UCEC	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.56	-6.22	-0.46	4.78e-9	Menarche (age at onset);
UCEC	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.46	0.47	1.45e-9	Coffee consumption (cups per day);
UCEC	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.29	-0.4	4.28e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	0.99	10.1	0.64	1.48e-18	Corneal structure;
UCEC	cis	rs1575951	1.000	rs10829464	chr10:130445500	C/T	cg27041381	chr10:131357203	MGMT	0.63	5.51	0.41	1.53e-7	Plasma clusterin levels;
UCEC	cis	rs6893807	1.000	rs13163336	chr5:87943710	C/A	cg09002922	chr5:87956389	LOC645323	-0.59	-5.99	-0.44	1.58e-8	Body mass index;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg00651523	chr6:28411279	ZSCAN23	0.54	6.12	0.45	7.91e-9	Pubertal anthropometrics;
UCEC	cis	rs1150668	0.796	rs1150694	chr6:28175153	G/T	cg14547644	chr6:28411285	ZSCAN23	-0.56	-6.03	-0.45	1.26e-8	Pubertal anthropometrics;
UCEC	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.45	-4.53	-0.35	1.23e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.83	8.18	0.56	1.23e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23619332	chr11:27722060	BDNF	0.62	7.14	0.51	3.99e-11	Warfarin maintenance dose;
UCEC	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-10.09	-0.64	1.64e-18	Electrocardiographic conduction measures;
UCEC	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg18681998	chr4:17616180	MED28	0.78	9.19	0.6	3.38e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg24060327	chr5:131705240	SLC22A5	0.53	5.01	0.38	1.56e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs151997	0.962	rs27844	chr5:50190680	T/G	cg06027927	chr5:50259733	NA	0.51	4.74	0.36	5.01e-6	Callous-unemotional behaviour;
UCEC	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.73	6.85	0.49	1.91e-10	High light scatter reticulocyte count;
UCEC	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.66	-0.42	7.83e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.69	5.53	0.42	1.42e-7	Major depressive disorder;
UCEC	cis	rs6688613	0.840	rs6660048	chr1:166954186	C/T	cg07049167	chr1:166818506	POGK	-0.53	-5.4	-0.41	2.65e-7	Refractive astigmatism;
UCEC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.55	0.35	1.1e-5	Breast cancer;
UCEC	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.48	4.86	0.37	2.98e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.66	-7.85	-0.54	7.94e-13	Hip circumference;
UCEC	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.07	0.6	7.03e-16	Platelet count;
UCEC	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.62	6.51	0.47	1.11e-9	Colorectal cancer;
UCEC	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.7	6.98	0.5	9.52e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.44	-6.16	-0.45	6.76e-9	Urinary metabolites;
UCEC	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.55	4.72	0.36	5.48e-6	Alzheimer's disease;
UCEC	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.6	4.6	0.35	9.23e-6	Gut microbiome composition (summer);
UCEC	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-4.68	-0.36	6.59e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.78	-11.35	-0.68	7.8e-22	Leprosy;
UCEC	cis	rs440932	0.757	rs330943	chr8:9021026	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	4.95	0.38	2.04e-6	High light scatter reticulocyte percentage of red cells;
UCEC	cis	rs9976767	0.792	rs883869	chr21:43844840	T/C	cg00134539	chr21:43824071	UBASH3A	0.31	4.98	0.38	1.78e-6	Type 1 diabetes;
UCEC	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.61	0.36	8.53e-6	Parkinson's disease;
UCEC	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg16558253	chr16:72132732	DHX38	-0.48	-5.73	-0.43	5.4e-8	Fibrinogen levels;
UCEC	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	0.68	7.44	0.52	7.65e-12	Homoarginine levels;
UCEC	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.57	-4.61	-0.36	8.59e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.53	-4.67	-0.36	6.75e-6	Pediatric autoimmune diseases;
UCEC	cis	rs8080784	0.604	rs7503356	chr17:58837549	A/T	cg22641952	chr17:58219985	NA	-0.51	-4.81	-0.37	3.67e-6	Coronary artery disease;
UCEC	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.8	0.49	2.44e-10	Coffee consumption (cups per day);
UCEC	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg11859384	chr17:80120422	CCDC57	0.53	5.74	0.43	5.24e-8	Life satisfaction;
UCEC	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.74	6.86	0.49	1.79e-10	Morning vs. evening chronotype;
UCEC	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg21466736	chr12:48725269	NA	0.34	4.52	0.35	1.29e-5	Plateletcrit;
UCEC	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.87	10.42	0.65	2.27e-19	Monocyte count;
UCEC	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg22166914	chr1:53195759	ZYG11B	0.78	8.12	0.56	1.73e-13	Monocyte count;
UCEC	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	1.03	5.25	0.4	5.2e-7	Thyroid stimulating hormone;
UCEC	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.71	7.03	0.5	7.2e-11	Type 2 diabetes;
UCEC	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.74	5.68	0.42	7.06e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.96	-0.63	3.62e-18	Blood metabolite levels;
UCEC	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.69	6.49	0.47	1.22e-9	Aortic root size;
UCEC	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.53	4.72	0.36	5.44e-6	Methadone dose in opioid dependence;
UCEC	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg24163568	chr5:669837	TPPP	-0.41	-5.18	-0.39	7.15e-7	Obesity-related traits;
UCEC	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.6	-4.96	-0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.66	-7.54	-0.53	4.46e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.51	5.06	0.38	1.25e-6	QRS complex (12-leadsum);
UCEC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.38	4.96	0.38	1.9e-6	Bone mineral density;
UCEC	cis	rs10924970	0.870	rs7531130	chr1:235440556	C/G	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.74e-6	Asthma;
UCEC	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.66	-7.23	-0.51	2.42e-11	Extraversion;
UCEC	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg11945507	chr8:142233382	SLC45A4	-0.44	-4.91	-0.38	2.42e-6	Immature fraction of reticulocytes;
UCEC	cis	rs2806864	1.000	rs2250882	chr1:117462152	C/T	cg19765820	chr1:116518738	SLC22A15	-0.64	-4.7	-0.36	6.06e-6	Erectile dysfunction and prostate cancer treatment;
UCEC	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.43	6.23	0.46	4.67e-9	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.8	-7.62	-0.53	2.94e-12	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.29e-6	Corneal astigmatism;
UCEC	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg18877361	chr14:105973846	NA	-0.38	-4.54	-0.35	1.16e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.47	4.77	0.37	4.32e-6	Prudent dietary pattern;
UCEC	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.4	4.53	0.35	1.2e-5	Chronic sinus infection;
UCEC	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.67	-6.22	-0.46	4.87e-9	Aortic root size;
UCEC	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.65	6.12	0.45	8.03e-9	Aortic root size;
UCEC	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.02	-12.89	-0.73	6.41e-26	Body mass index;
UCEC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18252515	chr7:66147081	NA	-0.46	-4.73	-0.36	5.23e-6	Aortic root size;
UCEC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.49	-4.57	-0.35	1.01e-5	Response to diuretic therapy;
UCEC	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.41	4.88	0.37	2.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.96e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.67	7.01	0.5	8.21e-11	Paraoxonase activity;
UCEC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	0.72	4.89	0.37	2.66e-6	Diabetic retinopathy;
UCEC	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs12618769	0.652	rs72821965	chr2:99188783	T/C	cg10123293	chr2:99228465	UNC50	0.47	5.34	0.4	3.48e-7	Bipolar disorder;
UCEC	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	0.98	6.51	0.47	1.1e-9	Skin colour saturation;
UCEC	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg19318889	chr4:1322082	MAEA	0.45	5.64	0.42	8.26e-8	Obesity-related traits;
UCEC	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.41	-4.57	-0.35	1.02e-5	Depression;
UCEC	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.48	4.84	0.37	3.28e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.0	-0.44	1.46e-8	Prudent dietary pattern;
UCEC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.34	4.66	0.36	7.09e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.95	8.89	0.59	1.98e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs12980942	0.872	rs3752705	chr19:41798111	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.64	5.74	0.43	5.33e-8	Coronary artery disease;
UCEC	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.54	5.01	0.38	1.54e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.08	9.15	0.6	4.36e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.24	22.67	0.88	7.68e-50	Chronic sinus infection;
UCEC	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-6.37	-0.46	2.33e-9	Crohn's disease;
UCEC	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg13683864	chr3:40499215	RPL14	-1.03	-13.03	-0.73	2.72e-26	Renal cell carcinoma;
UCEC	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.43	-4.79	-0.37	4.06e-6	Mean corpuscular volume;
UCEC	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.01	6.98	0.5	9.2e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.69	7.57	0.53	3.79e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg01072550	chr1:21505969	NA	-0.54	-5.19	-0.39	6.96e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-4.88	-0.37	2.71e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg22089800	chr15:90895588	ZNF774	0.58	5.8	0.43	3.82e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.21	11.12	0.68	3.14e-21	Corneal structure;
UCEC	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.47	-5.39	-0.41	2.75e-7	Aortic root size;
UCEC	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.82	9.34	0.61	1.41e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg03714773	chr7:91764589	CYP51A1	0.41	4.8	0.37	3.8e-6	Breast cancer;
UCEC	cis	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg00614314	chr15:82944287	LOC80154	0.52	4.8	0.37	3.85e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.43	4.67	0.36	6.82e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.62	5.26	0.4	4.99e-7	Lymphocyte counts;
UCEC	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.81	8.14	0.56	1.5e-13	Schizophrenia;
UCEC	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	7.79e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.52	4.71	0.36	5.62e-6	Cognitive ability;
UCEC	cis	rs1239947	1.000	rs1239947	chr13:51106555	A/G	cg07121900	chr13:50706912	NA	-0.3	-4.7	-0.36	5.98e-6	Height;
UCEC	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg03342759	chr3:160939853	NMD3	-0.58	-5.74	-0.43	5.2100000000000003e-08	Educational attainment (years of education);
UCEC	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.68	-7.89	-0.55	6.52e-13	Monocyte count;
UCEC	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.51	-7.11	-0.51	4.59e-11	Refractive error;
UCEC	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.6	0.48	6.88e-10	Bladder cancer;
UCEC	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg01072550	chr1:21505969	NA	-0.51	-4.82	-0.37	3.51e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg02158880	chr13:53174818	NA	0.52	6.2	0.46	5.34e-9	Lewy body disease;
UCEC	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.38	0.61	1.13e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.51	4.81	0.37	3.71e-6	Alcohol dependence;
UCEC	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.47	-4.77	-0.37	4.39e-6	Parkinson's disease;
UCEC	cis	rs13098911	0.540	rs13059238	chr3:46007825	T/C	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg22598563	chr5:131563921	P4HA2	-0.35	-4.68	-0.36	6.39e-6	Blood metabolite levels;
UCEC	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.56	-6.36	-0.46	2.39e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Visceral adipose tissue adjusted for BMI;
UCEC	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-5.01	-0.38	1.56e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs12680875	0.872	rs7462676	chr8:54509681	G/A	cg01911395	chr8:55014377	LYPLA1	-0.74	-5.56	-0.42	1.21e-7	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.43	0.41	2.24e-7	Mood instability;
UCEC	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.53	-5.8	-0.43	3.97e-8	Diastolic blood pressure;
UCEC	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.85	10.18	0.64	9.46e-19	Coronary artery disease;
UCEC	cis	rs11931598	0.783	rs28385900	chr4:7050836	C/T	cg02503808	chr4:7069936	GRPEL1	0.51	5.62	0.42	9.47e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	8.74	0.58	4.99e-15	Platelet count;
UCEC	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.64	0.36	7.69e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.49	5.06	0.39	1.24e-6	Schizophrenia;
UCEC	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	-0.51	-4.8	-0.37	3.88e-6	Diabetic retinopathy;
UCEC	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Diabetic kidney disease;
UCEC	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.14	0.39	8.59e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.89	9.21	0.61	3.02e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.5	6.55	0.48	8.94e-10	Bone mineral density;
UCEC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.61	-9.09	-0.6	6.26e-16	Prudent dietary pattern;
UCEC	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.2	-0.51	2.9e-11	Monocyte count;
UCEC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.64	6.16	0.45	6.56e-9	Aortic root size;
UCEC	cis	rs9324268	0.851	rs9577310	chr13:112849594	G/T	cg15059558	chr13:112729515	NA	-0.52	-4.8	-0.37	3.94e-6	Renal transplant outcome;
UCEC	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.43	6.34	0.46	2.71e-9	Crohn's disease;
UCEC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.58	-5.16	-0.39	7.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.67	-4.79	-0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.66	7.28	0.51	1.82e-11	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg04202892	chr2:111875749	ACOXL	0.45	4.94	0.38	2.08e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	5.41	0.41	2.47e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.98e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-4.81	-0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.51	-4.78	-0.37	4.21e-6	Prostate cancer;
UCEC	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.66	-6.62	-0.48	6.35e-10	Morning vs. evening chronotype;
UCEC	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg13695892	chr22:41940480	POLR3H	-0.6	-4.95	-0.38	2.03e-6	Vitiligo;
UCEC	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.54	-5.38	-0.41	2.85e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26207909	chr14:103986467	CKB	0.53	5.76	0.43	4.64e-8	Body mass index;
UCEC	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.71	0.36	5.56e-6	Height;
UCEC	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg15133208	chr4:90757351	SNCA	-0.33	-4.52	-0.35	1.25e-5	Dementia with Lewy bodies;
UCEC	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.84	-10.27	-0.65	5.47e-19	Brugada syndrome;
UCEC	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	5.27	0.4	4.85e-7	Rheumatoid arthritis;
UCEC	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.36	6.18	0.45	5.91e-9	Cancer;
UCEC	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24308560	chr3:49941425	MST1R	-0.47	-4.96	-0.38	1.94e-6	Body mass index;
UCEC	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.53	5.06	0.38	1.26e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.63	-5.9	-0.44	2.41e-8	Aortic root size;
UCEC	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.46	-0.52	6.88e-12	Resting heart rate;
UCEC	cis	rs7113850	0.541	rs7131336	chr11:24219418	C/T	ch.11.24196551F	chr11:24239977	NA	0.63	5.21	0.39	6.29e-7	Bone fracture in osteoporosis;
UCEC	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.62	-6.01	-0.44	1.41e-8	Diastolic blood pressure;
UCEC	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Blood protein levels;
UCEC	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.66	7.77	0.54	1.22e-12	Menarche (age at onset);
UCEC	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.5	-5.53	-0.41	1.45e-7	Aortic root size;
UCEC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.81	7.19	0.51	3.05e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs28530618	0.603	rs750401	chr20:31246638	G/C	cg13636640	chr20:31349939	DNMT3B	-0.56	-5.16	-0.39	7.99e-7	Birth weight;
UCEC	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.58	6.48	0.47	1.28e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.43	4.79	0.37	4e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.76	-0.49	2.97e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.7	6.98	0.5	9.23e-11	Blood protein levels;
UCEC	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.69	5.83	0.43	3.42e-8	Alcohol dependence;
UCEC	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg06096015	chr1:231504339	EGLN1	0.44	4.85	0.37	3.11e-6	Hemoglobin concentration;
UCEC	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.42	4.57	0.35	1.03e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-5.74	-0.43	5.13e-8	Platelet count;
UCEC	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.45	-4.77	-0.37	4.34e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.15	11.18	0.68	2.13e-21	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg24889512	chr19:22816950	ZNF492	0.62	6.56	0.48	8.79e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-5.31	-0.4	4.01e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.63	6.53	0.47	1e-9	Retinal vascular caliber;
UCEC	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-6.9	-0.49	1.41e-10	Response to antipsychotic treatment;
UCEC	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.11	19.27	0.85	4.55e-42	Schizophrenia;
UCEC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.63	-0.36	7.82e-6	Alzheimer's disease (late onset);
UCEC	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.63	4.87	0.37	2.87e-6	Lymphocyte counts;
UCEC	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.59	-7.54	-0.53	4.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18854424	chr1:2615690	NA	0.45	6.73	0.49	3.63e-10	Ulcerative colitis;
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	8.57	0.58	1.29e-14	Platelet count;
UCEC	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-0.9	-7.61	-0.53	3e-12	Blood pressure (smoking interaction);
UCEC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-10.76	-0.66	2.83e-20	Schizophrenia;
UCEC	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.38	4.57	0.35	1.01e-5	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.91	7.79	0.54	1.1e-12	Platelet count;
UCEC	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.76	-7.92	-0.55	5.45e-13	Breast cancer;
UCEC	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.73	0.43	5.45e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.88	-10.65	-0.66	5.61e-20	Personality dimensions;
UCEC	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.42	-4.51	-0.35	1.33e-5	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg10297430	chr16:11272440	CLEC16A	0.69	4.56	0.35	1.08e-5	Testicular germ cell tumor;
UCEC	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.7	-7.49	-0.53	5.77e-12	Breast cancer;
UCEC	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg09997546	chr11:8931473	C11orf17;ST5	0.41	4.86	0.37	3.04e-6	Hemoglobin concentration;
UCEC	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.73	0.58	5.17e-15	Alzheimer's disease;
UCEC	cis	rs12618769	0.625	rs3769709	chr2:99187433	A/T	cg10123293	chr2:99228465	UNC50	0.48	5.27	0.4	4.85e-7	Bipolar disorder;
UCEC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.59	-5.81	-0.43	3.79e-8	Platelet count;
UCEC	cis	rs6834538	1.000	rs6816676	chr4:113483843	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.49	4.8	0.37	3.86e-6	Free thyroxine concentration;
UCEC	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.36	6.17	0.45	6.3e-9	Cancer;
UCEC	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-5.87	-0.44	2.73e-8	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.77	-9.72	-0.63	1.52e-17	Menarche (age at onset);
UCEC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.6	4.88	0.37	2.69e-6	Breast cancer;
UCEC	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.88	0.37	2.68e-6	Rheumatoid arthritis;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg11697111	chr7:1126903	GPER;C7orf50	0.48	4.66	0.36	7.18e-6	Longevity;Endometriosis;
UCEC	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.64	4.56	0.35	1.07e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.05	6.0	0.44	1.5e-8	Diabetic retinopathy;
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.86	7.77	0.54	1.27e-12	Platelet count;
UCEC	cis	rs7307889	1.000	rs73047647	chr12:6011088	A/G	cg23245485	chr12:6484219	SCNN1A	0.56	5.03	0.38	1.41e-6	Obesity-related traits;
UCEC	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg16616514	chr4:6324629	PPP2R2C	-0.36	-4.51	-0.35	1.3e-5	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1018836	0.923	rs12545726	chr8:91532087	T/A	cg16814680	chr8:91681699	NA	-0.69	-7.26	-0.51	2.1e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg05501817	chr11:14380813	RRAS2	-0.49	-4.67	-0.36	6.76e-6	Sense of smell;
UCEC	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.58	-4.95	-0.38	1.99e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.54	0.58	1.54e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4615376	1.000	rs4361612	chr6:13036642	A/G	cg11378619	chr6:12164359	HIVEP1	-0.59	-4.65	-0.36	7.48e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
UCEC	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.61	6.25	0.46	4.13e-9	Blood metabolite levels;
UCEC	cis	rs7709377	0.570	rs13184073	chr5:115437906	T/C	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs223116	0.564	rs12886508	chr14:23964080	A/C	cg15440973	chr14:24610792	FAM158A	0.53	4.57	0.35	1.04e-5	Resting heart rate;
UCEC	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13880726	chr7:1868755	MAD1L1	0.51	5.02	0.38	1.49e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.81	-11.28	-0.68	1.2e-21	Post bronchodilator FEV1;
UCEC	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.32	4.6	0.35	9.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.52	-6.22	-0.46	4.95e-9	Total body bone mineral density;
UCEC	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.84	-0.43	3.27e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg19041857	chr6:27730383	NA	-0.68	-4.94	-0.38	2.08e-6	Breast cancer;
UCEC	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.09	9.99	0.64	3.03e-18	Vitiligo;
UCEC	cis	rs12545109	0.917	rs10098993	chr8:57323116	T/C	cg09654669	chr8:57350985	NA	-0.45	-4.53	-0.35	1.21e-5	Obesity-related traits;
UCEC	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.57	5.09	0.39	1.08e-6	Corneal astigmatism;
UCEC	cis	rs17106184	1.000	rs59029934	chr1:50992756	C/T	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs302972	0.826	rs79738691	chr6:25148560	A/G	cg12449049	chr6:25088999	CMAH	0.78	4.51	0.35	1.3e-5	Creatinine levels in ischemic stroke;
UCEC	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	0.71	5.56	0.42	1.24e-7	Alzheimer's disease;
UCEC	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.54	-4.96	-0.38	1.96e-6	Blood protein levels;
UCEC	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.59	6.08	0.45	9.66e-9	Mean corpuscular volume;
UCEC	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.68	-7.42	-0.52	8.45e-12	Hypospadias;
UCEC	cis	rs2734839	0.964	rs12808482	chr11:113294998	T/A	cg14159747	chr11:113255604	NA	0.57	7.31	0.52	1.54e-11	Information processing speed;
UCEC	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	5.91	0.44	2.34e-8	Schizophrenia;
UCEC	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.08	7.18	0.51	3.17e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.31	-0.46	3.16e-9	Coffee consumption (cups per day);
UCEC	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.47	4.99	0.38	1.65e-6	Smoking initiation;
UCEC	cis	rs1364705	1.000	rs12677951	chr8:120226900	C/G	cg09273054	chr8:120220131	MAL2	0.54	4.69	0.36	6.23e-6	Hippocampal atrophy;
UCEC	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.45	-4.94	-0.38	2.08e-6	Schizophrenia;
UCEC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.77	10.4	0.65	2.54e-19	Vitiligo;
UCEC	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	0.94	10.04	0.64	2.23e-18	Corneal structure;
UCEC	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-6.46	-0.47	1.42e-9	Morning vs. evening chronotype;
UCEC	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.5	5.11	0.39	9.99e-7	Monocyte count;
UCEC	cis	rs7870753	0.838	rs10820634	chr9:99215104	T/C	cg25260653	chr9:99212216	HABP4	0.55	5.25	0.4	5.34e-7	Height;
UCEC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.55	7.0	0.5	8.34e-11	Sjögren's syndrome;
UCEC	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-11.47	-0.69	3.75e-22	Ulcerative colitis;
UCEC	cis	rs12545109	0.571	rs1370306	chr8:57299137	C/G	cg07776626	chr8:57350775	NA	-0.51	-5.34	-0.4	3.44e-7	Obesity-related traits;
UCEC	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	0.67	8.65	0.58	8.06e-15	Gut microbiome composition (winter);
UCEC	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg19773385	chr1:10388646	KIF1B	-0.56	-5.9	-0.44	2.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs7095607	0.538	rs2255027	chr10:69920911	T/C	cg18986048	chr10:69913749	MYPN	0.63	6.95	0.5	1.1e-10	Lung function (FVC);
UCEC	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.52	5.08	0.39	1.11e-6	Emphysema distribution in smoking;
UCEC	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.69	-5.91	-0.44	2.3e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.59	-5.93	-0.44	2.11e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-4.58	-0.35	1e-5	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.66	7.6	0.53	3.17e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.5	-5.65	-0.42	8.24e-8	Cardiac Troponin-T levels;
UCEC	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.48	-5.38	-0.41	2.82e-7	Retinal vascular caliber;
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.55	-5.97	-0.44	1.69e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04731861	chr2:219085781	ARPC2	0.43	4.68	0.36	6.34e-6	Colorectal cancer;
UCEC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.5	-5.22	-0.4	6.1e-7	Blood protein levels;
UCEC	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-5.48	-0.41	1.77e-7	Mean corpuscular volume;
UCEC	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.89	-11.26	-0.68	1.39e-21	Primary sclerosing cholangitis;
UCEC	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.78	-5.81	-0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.54	4.83	0.37	3.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7809799	0.826	rs73157602	chr7:98855617	T/C	cg24555656	chr7:99717359	TAF6;CNPY4	-0.93	-4.76	-0.37	4.6e-6	Ulcerative colitis;
UCEC	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.85	-10.54	-0.66	1.05e-19	Metabolic syndrome;
UCEC	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg14092571	chr14:90743983	NA	-0.43	-5.89	-0.44	2.56e-8	Mortality in heart failure;
UCEC	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg13206674	chr6:150067644	NUP43	0.52	4.74	0.36	5.07e-6	Testicular germ cell tumor;
UCEC	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.64	6.9	0.49	1.41e-10	Coronary artery disease;
UCEC	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18932078	chr1:2524107	MMEL1	0.35	5.99	0.44	1.58e-8	Ulcerative colitis;
UCEC	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.62	0.58	9.98e-15	Prudent dietary pattern;
UCEC	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.53	-5.09	-0.39	1.06e-6	Coronary artery disease;
UCEC	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.8	-7.97	-0.55	4.08e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7520050	0.902	rs1355642	chr1:46598903	A/G	cg15837086	chr1:46506065	PIK3R3	-0.36	-4.65	-0.36	7.38e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg22907277	chr7:1156413	C7orf50	0.88	9.46	0.62	6.91e-17	Longevity;Endometriosis;
UCEC	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	0.93	6.99	0.5	9e-11	Obesity-related traits;
UCEC	cis	rs4789452	0.902	rs4789454	chr17:75375199	C/T	cg21830368	chr17:75373327	SEPT9	-0.31	-4.97	-0.38	1.84e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-0.63	-6.02	-0.44	1.35e-8	Vitiligo;
UCEC	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.63	5.41	0.41	2.49e-7	Uric acid levels;
UCEC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.95	0.7	2.01e-23	Prudent dietary pattern;
UCEC	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	7.73	0.54	1.57e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.54e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg25174290	chr11:3078921	CARS	0.53	4.83	0.37	3.38e-6	Longevity;
UCEC	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.38	4.81	0.37	3.7e-6	Total body bone mineral density;
UCEC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg20399509	chr21:47717575	C21orf57	-0.42	-4.58	-0.35	9.96e-6	Testicular germ cell tumor;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19545348	chr1:211434133	RCOR3	0.59	7.33	0.52	1.44e-11	Warfarin maintenance dose;
UCEC	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.58	5.39	0.41	2.8e-7	Response to antineoplastic agents;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19310740	chr8:103424477	UBR5	0.61	6.84	0.49	1.98e-10	Warfarin maintenance dose;
UCEC	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.54	5.43	0.41	2.3e-7	Schizophrenia;
UCEC	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg07836142	chr6:28411423	ZSCAN23	0.56	6.36	0.46	2.35e-9	Cardiac Troponin-T levels;
UCEC	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg08755490	chr11:65554678	OVOL1	0.5	5.3	0.4	4.07e-7	Acne (severe);
UCEC	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.52	5.97	0.44	1.69e-8	Mean corpuscular volume;
UCEC	cis	rs253959	0.921	rs785377	chr5:115663974	G/A	cg23108291	chr5:115420582	COMMD10	-0.55	-5.52	-0.41	1.49e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.78e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-5.76	-0.43	4.83e-8	Response to antipsychotic treatment;
UCEC	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.67	7.74	0.54	1.46e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-9.54	-0.62	4.32e-17	Chronic sinus infection;
UCEC	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-5.71	-0.43	6.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21178979	chr7:1889533	MAD1L1	0.39	4.9	0.37	2.49e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg13777783	chr17:79615861	NA	-0.32	-4.64	-0.36	7.5e-6	Eye color traits;
UCEC	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.77	7.68	0.53	2.11e-12	Parkinson's disease;
UCEC	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	1.11	13.21	0.74	9.4e-27	Post bronchodilator FEV1;
UCEC	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.22	-0.4	6.13e-7	Morning vs. evening chronotype;
UCEC	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.56	6.25	0.46	4.27e-9	Height;
UCEC	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.8	8.11	0.56	1.81e-13	Schizophrenia;
UCEC	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.56	-5.16	-0.39	7.74e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1576263	0.967	rs7755191	chr6:8558640	A/C	cg21535247	chr6:8435926	SLC35B3	0.48	4.91	0.38	2.38e-6	Photic sneeze reflex;
UCEC	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.7	-0.43	6.46e-8	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18252515	chr7:66147081	NA	0.56	5.23	0.4	5.61e-7	Aortic root size;
UCEC	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.71	6.84	0.49	1.93e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.22	-15.07	-0.78	1.27e-31	Breast cancer;
UCEC	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.23	-0.46	4.73e-9	Response to antipsychotic treatment;
UCEC	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.46	-4.88	-0.37	2.78e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.54	6.2	0.46	5.52e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg07052010	chr16:12009989	GSPT1	-0.71	-4.89	-0.37	2.61e-6	Testicular germ cell tumor;
UCEC	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.69	-7.88	-0.54	6.85e-13	Blood protein levels;
UCEC	cis	rs4372836	1.000	rs72782294	chr2:28953390	C/G	cg09522027	chr2:28974177	PPP1CB	0.75	7.63	0.53	2.76e-12	Body mass index;
UCEC	cis	rs17106184	1.000	rs72902789	chr1:51293606	G/C	cg07174182	chr1:51127561	FAF1	-0.77	-4.98	-0.38	1.8e-6	Type 2 diabetes;
UCEC	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg11871910	chr12:69753446	YEATS4	0.57	5.07	0.39	1.18e-6	Response to diuretic therapy;
UCEC	cis	rs6693882	0.903	rs11165465	chr1:96144482	G/C	cg12448539	chr1:95364293	CNN3	0.49	4.66	0.36	7.04e-6	Pain;
UCEC	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.71	0.43	6.13e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.87	9.73	0.63	1.44e-17	Cognitive function;
UCEC	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.54	-5.36	-0.4	3.14e-7	Asthma (sex interaction);
UCEC	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.52	-5.19	-0.39	6.77e-7	Red cell distribution width;
UCEC	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.78	-9.59	-0.62	3.33e-17	White blood cell count (basophil);
UCEC	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.36	4.52	0.35	1.25e-5	Mean platelet volume;
UCEC	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg16558253	chr16:72132732	DHX38	0.45	5.35	0.4	3.26e-7	Prostate cancer;
UCEC	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.57	4.81	0.37	3.75e-6	Neutrophil percentage of white cells;
UCEC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.52	5.78	0.43	4.35e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	0.82	7.17	0.51	3.31e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.55	5.31	0.4	4.06e-7	Platelet count;
UCEC	trans	rs1459104	1.000	rs35726021	chr11:55191206	G/A	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.45	5.1	0.39	1.05e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	0.77	4.73	0.36	5.17e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.96	-12.53	-0.72	5.7e-25	Primary sclerosing cholangitis;
UCEC	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg07153921	chr17:41440717	NA	-0.56	-6.32	-0.46	3.01e-9	Menopause (age at onset);
UCEC	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.12	-13.41	-0.74	2.68e-27	Schizophrenia;
UCEC	cis	rs944990	0.640	rs10992804	chr9:96380352	G/T	cg13787134	chr9:96362102	PHF2	-0.38	-5.21	-0.39	6.28e-7	Body mass index;
UCEC	cis	rs2979489	0.945	rs13250272	chr8:30294942	A/G	cg26383811	chr8:30366931	RBPMS	0.66	5.03	0.38	1.4e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs3750082	0.852	rs2392152	chr7:32900549	A/G	cg05721444	chr7:32995514	FKBP9	-0.5	-5.62	-0.42	9.29e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.68	-7.24	-0.51	2.27e-11	Breast cancer;
UCEC	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.65	4.99	0.38	1.71e-6	Orofacial clefts;
UCEC	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg12292205	chr6:26970375	C6orf41	0.57	5.09	0.39	1.06e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.56	-5.65	-0.42	7.98e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.3	-0.46	3.27e-9	Prudent dietary pattern;
UCEC	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs12096438	1.000	rs12096438	chr1:25889422	C/T	cg21452808	chr1:25900135	NA	-0.3	-4.6	-0.35	8.95e-6	Platelet count;Mean platelet volume;
UCEC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.47	4.75	0.36	4.77e-6	Longevity;Endometriosis;
UCEC	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.75	9.64	0.62	2.37e-17	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs925228	0.869	rs2339853	chr2:23958164	C/T	cg17592292	chr4:967094	DGKQ	0.68	6.74	0.49	3.43e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.66	-7.51	-0.53	5.28e-12	Type 2 diabetes;
UCEC	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.66	7.88	0.54	6.71e-13	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.73	7.12	0.51	4.37e-11	Parkinson's disease;
UCEC	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg01380346	chr19:18557039	ELL	-0.47	-4.67	-0.36	6.75e-6	Breast cancer;
UCEC	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.4	-4.92	-0.38	2.32e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.53	6.07	0.45	1.06e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.82	8.55	0.58	1.43e-14	Mean corpuscular hemoglobin;
UCEC	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.52	4.86	0.37	2.98e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6893207	0.661	rs74521042	chr5:16384561	A/T	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.76	0.37	4.66e-6	Electroencephalogram traits;
UCEC	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg14008862	chr17:28927542	LRRC37B2	0.58	4.94	0.38	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17123764	0.710	rs2336058	chr12:50090880	C/G	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	4.84	0.37	3.29e-6	Homocysteine levels;
UCEC	cis	rs10864907	0.553	rs7578034	chr2:113718077	C/T	cg06156847	chr2:113672199	IL1F7	-0.31	-4.61	-0.36	8.5e-6	Pulmonary function;
UCEC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-5.52	-0.41	1.47e-7	Crohn's disease;
UCEC	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.06	-9.49	-0.62	5.98e-17	Vitiligo;
UCEC	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.9	8.57	0.58	1.32e-14	Colorectal adenoma (advanced);
UCEC	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.25	9.53	0.62	4.71e-17	Uric acid levels;
UCEC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.33	-4.54	-0.35	1.16e-5	Primary biliary cholangitis;
UCEC	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.83	0.43	3.41e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.36	0.46	2.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs674424	1.000	rs674424	chr11:119030752	C/T	cg20110707	chr11:118481992	PHLDB1	0.41	4.76	0.37	4.66e-6	Neutrophil percentage of white cells;
UCEC	cis	rs9341808	0.519	rs684251	chr6:80967337	G/A	cg08355045	chr6:80787529	NA	-0.36	-4.62	-0.36	8.38e-6	Sitting height ratio;
UCEC	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg22166914	chr1:53195759	ZYG11B	0.85	9.73	0.63	1.4e-17	Monocyte count;
UCEC	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.55	-5.1	-0.39	1.02e-6	Longevity;
UCEC	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.54	4.79	0.37	4.12e-6	Corneal astigmatism;
UCEC	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg24562669	chr7:97807699	LMTK2	0.43	5.29	0.4	4.42e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.81	9.45	0.61	7.35e-17	Bone mineral density;
UCEC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.7	-7.25	-0.51	2.22e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg04871131	chr7:94954202	PON1	-0.53	-5.19	-0.39	6.74e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.72	-0.66	3.56e-20	Schizophrenia;
UCEC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.44	0.41	2.15e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.69	-6.69	-0.48	4.35e-10	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.51	5.93	0.44	2.04e-8	Alcohol dependence;
UCEC	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.62	4.96	0.38	1.91e-6	Bladder cancer;
UCEC	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	6.93	0.5	1.26e-10	Body mass index (adult);
UCEC	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.75	8.1	0.56	1.91e-13	Menopause (age at onset);
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.49	-0.47	1.25e-9	Longevity;Endometriosis;
UCEC	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27467552	chr22:50353597	PIM3	-0.38	-4.65	-0.36	7.34e-6	Ulcerative colitis;
UCEC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.81	11.19	0.68	2.05e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.58	-5.09	-0.39	1.1e-6	Initial pursuit acceleration;
UCEC	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.89	11.95	0.7	2.01e-23	Menopause (age at onset);
UCEC	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.77	-9.0	-0.6	1.05e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.66	9.63	0.62	2.53e-17	Height;
UCEC	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	1.0	7.49	0.53	5.97e-12	Obesity-related traits;
UCEC	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg18230493	chr5:56204884	C5orf35	-0.55	-5.03	-0.38	1.38e-6	Coronary artery disease;
UCEC	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg03146154	chr1:46216737	IPP	-0.5	-4.93	-0.38	2.17e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg17178900	chr1:205818956	PM20D1	0.65	7.46	0.52	6.84e-12	Menarche (age at onset);
UCEC	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg23815491	chr16:72088622	HP	0.36	4.51	0.35	1.32e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
UCEC	cis	rs17122693	0.551	rs1812181	chr14:51052669	C/T	cg04730355	chr14:51134070	SAV1	0.75	8.88	0.59	2.14e-15	Cognitive performance;
UCEC	cis	rs798766	1.000	rs4865467	chr4:1745500	G/T	cg05874882	chr4:1763078	NA	0.54	5.41	0.41	2.51e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.57	-5.55	-0.42	1.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.81	0.37	3.66e-6	Platelet count;
UCEC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.57	-6.18	-0.45	5.92e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.53	5.34	0.4	3.41e-7	Blood protein levels;
UCEC	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.6	6.75	0.49	3.25e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6690583	0.623	rs61770879	chr1:85504938	A/C	cg11262906	chr1:85462892	MCOLN2	0.76	4.78	0.37	4.12e-6	Serum sulfate level;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.52	-0.41	1.53e-7	Platelet count;
UCEC	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-0.89	-11.57	-0.69	2.04e-22	Height;
UCEC	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.88	7.15	0.51	3.7e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.48	-4.9	-0.37	2.55e-6	Parkinson's disease;
UCEC	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.53	-5.68	-0.42	7.04e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs10129255	0.528	rs8008831	chr14:107108305	G/A	cg03031183	chr14:106916953	NA	-0.44	-4.66	-0.36	7.12e-6	Kawasaki disease;
UCEC	cis	rs3780378	0.840	rs10119004	chr9:5071049	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-5.14	-0.39	8.47e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.68	-7.75	-0.54	1.42e-12	Prudent dietary pattern;
UCEC	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg03859395	chr2:55845619	SMEK2	1.0	14.11	0.76	3.97e-29	Metabolic syndrome;
UCEC	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.32	-0.52	1.49e-11	Schizophrenia;
UCEC	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.51	-4.6	-0.35	8.95e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.92	-11.75	-0.7	6.85e-23	Ulcerative colitis;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.87	-0.37	2.9e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-0.78	-7.42	-0.52	8.78e-12	Breast cancer;
UCEC	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg21231944	chr12:82153410	PPFIA2	-0.47	-5.33	-0.4	3.67e-7	Resting heart rate;
UCEC	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.65	6.12	0.45	8.14e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.51	-5.4	-0.41	2.66e-7	Glaucoma;
UCEC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.64	-6.53	-0.47	1.01e-9	Body mass index;
UCEC	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.66	7.82	0.54	9.43e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.44	-4.87	-0.37	2.85e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs78761021	0.755	rs75458334	chr17:9795535	C/T	cg26853458	chr17:9805074	RCVRN	0.37	4.58	0.35	9.7e-6	Type 2 diabetes;
UCEC	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06762426	chr11:62420836	INTS5	0.93	5.36	0.4	3.12e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg21521518	chr4:53727714	RASL11B	0.74	5.12	0.39	9.44e-7	Optic nerve measurement (cup area);
UCEC	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.73	-11.14	-0.68	2.88e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-0.95	-6.75	-0.49	3.27e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.46	4.71	0.36	5.79e-6	Blood metabolite levels;
UCEC	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg06096015	chr1:231504339	EGLN1	0.43	4.9	0.37	2.53e-6	Hemoglobin concentration;
UCEC	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.46	5.67	0.42	7.27e-8	Prostate cancer;
UCEC	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	7.25	0.51	2.2e-11	Homoarginine levels;
UCEC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.6	-6.47	-0.47	1.39e-9	Menarche (age at onset);
UCEC	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.09	7.63	0.53	2.67e-12	Platelet count;
UCEC	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.61	-5.91	-0.44	2.34e-8	Colorectal cancer;
UCEC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.7	7.12	0.51	4.47e-11	Menopause (age at onset);
UCEC	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.76	-0.43	4.76e-8	Fear of minor pain;
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.39	-4.97	-0.38	1.87e-6	Body mass index;
UCEC	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.49	5.41	0.41	2.54e-7	Life satisfaction;
UCEC	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.69	5.84	0.43	3.15e-8	Smoking initiation;
UCEC	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.64	-0.42	8.62e-8	Body mass index;
UCEC	cis	rs6921919	0.848	rs9468350	chr6:28319107	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.8	-0.37	3.83e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-0.82	-7.36	-0.52	1.19e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.47	-4.77	-0.37	4.38e-6	Neuroticism;
UCEC	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.61	-5.72	-0.43	5.79e-8	Body mass index;
UCEC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.52	-6.44	-0.47	1.56e-9	Total body bone mineral density;
UCEC	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.65	7.12	0.51	4.53e-11	Mortality in heart failure;
UCEC	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.71	9.09	0.6	6.32e-16	Testicular germ cell tumor;
UCEC	cis	rs1893767	1.000	rs35035279	chr11:123957179	T/C	cg15915129	chr11:124933008	SLC37A2	-0.55	-4.69	-0.36	6.22e-6	Obesity-related traits;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg17823230	chr13:111141841	COL4A2	1.13	6.45	0.47	1.54e-9	Obesity-related traits;
UCEC	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.68	-0.62	1.85e-17	Primary sclerosing cholangitis;
UCEC	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.57	5.78	0.43	4.33e-8	Orofacial clefts;
UCEC	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.42	5.32	0.4	3.82e-7	Coronary artery disease;
UCEC	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-4.66	-0.36	7.11e-6	Pediatric autoimmune diseases;
UCEC	cis	rs4654899	0.865	rs6426658	chr1:21361176	G/A	cg01072550	chr1:21505969	NA	-0.5	-4.6	-0.35	9.16e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg22907277	chr7:1156413	C7orf50	0.55	5.09	0.39	1.1e-6	Longevity;Endometriosis;
UCEC	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.63	5.79	0.43	4.12e-8	Major depressive disorder;
UCEC	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg07988820	chr12:82153109	PPFIA2	-0.77	-7.55	-0.53	4.24e-12	Resting heart rate;
UCEC	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.45	4.87	0.37	2.8e-6	Emphysema distribution in smoking;
UCEC	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.49	-5.55	-0.42	1.3e-7	Height;
UCEC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.77	-0.49	2.85e-10	Obesity-related traits;
UCEC	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.57	-5.44	-0.41	2.22e-7	Body mass index;
UCEC	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg13753209	chr17:57696993	CLTC	0.48	4.7	0.36	5.87e-6	Hemoglobin concentration;
UCEC	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.47	4.73	0.36	5.18e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg05660106	chr1:15850417	CASP9	1.04	11.6	0.69	1.67e-22	Systolic blood pressure;
UCEC	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg18681998	chr4:17616180	MED28	0.74	7.48	0.52	6.28e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	2.96e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.69	-5.76	-0.43	4.81e-8	Birth weight;
UCEC	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.62	6.96	0.5	1.06e-10	Height;
UCEC	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.59	5.65	0.42	8.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.938	rs9626814	chr22:46637254	C/T	cg27079726	chr22:46659317	PKDREJ	0.49	5.07	0.39	1.18e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.56	-5.4	-0.41	2.67e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-7.91	-0.55	5.7e-13	Colorectal cancer;
UCEC	cis	rs11048434	1.000	rs12824212	chr12:9153417	A/G	cg04155231	chr12:9217510	LOC144571	0.46	5.63	0.42	8.97e-8	Sjögren's syndrome;
UCEC	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.12	-0.51	4.45e-11	Prevalent atrial fibrillation;
UCEC	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.9e-15	Height;
UCEC	cis	rs78487399	0.908	rs12463527	chr2:43815945	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-4.55	-0.35	1.09e-5	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs10129255	0.544	rs61997583	chr14:107110367	T/G	cg03031183	chr14:106916953	NA	-0.43	-4.63	-0.36	8.06e-6	Kawasaki disease;
UCEC	cis	rs7113850	0.541	rs76671714	chr11:24231278	C/G	ch.11.24196551F	chr11:24239977	NA	0.68	4.62	0.36	8.18e-6	Bone fracture in osteoporosis;
UCEC	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs4778581	0.750	rs7168791	chr15:80399687	A/C	cg08257866	chr15:80351198	ZFAND6	0.4	4.8	0.37	3.82e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7581030	0.958	rs6761251	chr2:71521191	T/G	cg07678644	chr2:71558969	ZNF638	0.57	5.12	0.39	9.6e-7	Testicular germ cell tumor;
UCEC	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.54	4.57	0.35	1.02e-5	Response to diuretic therapy;
UCEC	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.35	-0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.68	5.54	0.42	1.37e-7	Smoking initiation;
UCEC	cis	rs41271951	0.512	rs116666233	chr1:151056058	C/T	cg00107782	chr1:151300621	NA	-0.7	-4.75	-0.36	4.81e-6	Blood protein levels;
UCEC	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.44	-4.79	-0.37	4.09e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.8	-9.41	-0.61	9.7e-17	Blood protein levels;
UCEC	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg00612595	chr21:47717864	NA	-0.44	-4.76	-0.37	4.55e-6	Testicular germ cell tumor;
UCEC	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.44	-0.52	7.77e-12	Resting heart rate;
UCEC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg26061582	chr7:22766209	IL6	0.56	5.27	0.4	4.73e-7	Lung cancer;
UCEC	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.54	0.42	1.35e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.57	4.79	0.37	4.04e-6	Alzheimer's disease;
UCEC	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.65	-6.07	-0.45	1.03e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs6662386	0.557	rs4655986	chr1:88229627	A/G	cg10042178	chr1:87794589	LMO4	0.52	4.55	0.35	1.12e-5	Prostate-specific antigen levels;
UCEC	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-4.84	-0.37	3.3e-6	Heart rate;
UCEC	cis	rs9469578	1.000	rs6942022	chr6:33710284	C/T	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24308560	chr3:49941425	MST1R	-0.56	-6.36	-0.46	2.35e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg03354898	chr7:1950403	MAD1L1	-0.56	-5.53	-0.42	1.42e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg05962950	chr11:130786565	SNX19	0.79	8.06	0.55	2.36e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.21	-10.49	-0.65	1.46e-19	Uric acid levels;
UCEC	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.62	6.71	0.48	3.99e-10	Blood protein levels;
UCEC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.77	-9.25	-0.61	2.49e-16	Vitiligo;
UCEC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.66	-7.52	-0.53	5.13e-12	Menarche (age at onset);
UCEC	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg01081346	chr22:51017151	CPT1B;CHKB-CPT1B	-0.76	-5.96	-0.44	1.81e-8	Narcolepsy;
UCEC	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	5.18	0.39	7.29e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.69	0.54	1.98e-12	Alzheimer's disease;
UCEC	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.53	5.5	0.41	1.63e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs10924970	0.967	rs12030186	chr1:235397477	G/A	cg26050004	chr1:235667680	B3GALNT2	0.43	4.51	0.35	1.32e-5	Asthma;
UCEC	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.63	-6.99	-0.5	8.87e-11	Type 2 diabetes;
UCEC	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg04826882	chr13:114838756	RASA3	-0.61	-4.74	-0.36	5.01e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.54	5.18	0.39	7.08e-7	Lung cancer;
UCEC	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.64	0.36	7.6e-6	Diabetic retinopathy;
UCEC	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg15837086	chr1:46506065	PIK3R3	0.38	4.59	0.35	9.25e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.78	-6.49	-0.47	1.25e-9	Gut microbiome composition (summer);
UCEC	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-7.12	-0.51	4.55e-11	Prostate cancer;
UCEC	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.51	4.61	0.36	8.65e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.97	0.38	1.86e-6	Bipolar disorder;
UCEC	cis	rs9356171	0.572	rs2322175	chr6:164328086	G/C	cg25752492	chr6:164341247	NA	-0.59	-5.89	-0.44	2.47e-8	Diisocyanate-induced asthma;
UCEC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg09521647	chr2:100722408	AFF3	-0.32	-4.96	-0.38	1.95e-6	Chronic sinus infection;
UCEC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.8	5.31	0.4	4.02e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.52	4.67	0.36	6.79e-6	Longevity;
UCEC	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.24	-0.61	2.54e-16	Coffee consumption (cups per day);
UCEC	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.43	4.72	0.36	5.46e-6	Menarche (age at onset);
UCEC	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.67	-7.42	-0.52	8.81e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	5.94	0.44	1.95e-8	Cognitive test performance;
UCEC	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg16751203	chr2:127950803	CYP27C1	0.39	5.13	0.39	8.87e-7	Protein C levels;
UCEC	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.65	-5.21	-0.39	6.38e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.3	4.55	0.35	1.09e-5	Schizophrenia;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.48	-4.71	-0.36	5.69e-6	Pubertal anthropometrics;
UCEC	cis	rs9864370	0.688	rs784290	chr3:168931550	A/G	cg18504196	chr3:168331449	C3orf50	-0.6	-4.68	-0.36	6.52e-6	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.57	6.88	0.49	1.57e-10	Kawasaki disease;
UCEC	cis	rs7781557	0.702	rs7809047	chr7:102496061	T/G	cg06322601	chr7:102330635	NA	0.81	5.28	0.4	4.51e-7	Colorectal adenoma (advanced);
UCEC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg03714773	chr7:91764589	CYP51A1	0.43	5.39	0.41	2.8e-7	Breast cancer;
UCEC	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg06166341	chr4:1223170	CTBP1	-0.56	-4.59	-0.35	9.45e-6	Systolic blood pressure;
UCEC	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Blood protein levels;
UCEC	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.48	5.46	0.41	1.99e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.54	-5.31	-0.4	4.05e-7	Blood protein levels;
UCEC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.55	5.18	0.39	7.09e-7	Birth weight;
UCEC	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.57	6.49	0.47	1.25e-9	Monocyte percentage of white cells;
UCEC	cis	rs7582720	1.000	rs72932745	chr2:203662888	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	4.7	0.36	5.88e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.11	0.39	9.93e-7	Parkinson's disease;
UCEC	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.5	5.64	0.42	8.61e-8	Response to temozolomide;
UCEC	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.69	-5.46	-0.41	1.99e-7	Response to hepatitis C treatment;
UCEC	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs514406	0.536	rs878957	chr1:53197559	C/T	cg24675658	chr1:53192096	ZYG11B	0.48	4.74	0.36	4.97e-6	Monocyte count;
UCEC	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg09165964	chr15:75287851	SCAMP5	-0.54	-5.61	-0.42	9.9e-8	Lung cancer;
UCEC	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs1635	0.655	rs9368532	chr6:27782010	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.66	-4.63	-0.36	7.82e-6	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	10.11	0.64	1.4e-18	Chronic sinus infection;
UCEC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.68	6.04	0.45	1.2e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs240764	0.659	rs240772	chr6:101007895	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-5.34	-0.4	3.52e-7	Neuroticism;
UCEC	cis	rs9393813	0.529	rs12526864	chr6:27456242	C/T	cg27490387	chr6:26520793	HCG11	0.41	4.66	0.36	6.94e-6	Bipolar disorder;
UCEC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg01262667	chr19:19385393	TM6SF2	0.51	6.85	0.49	1.91e-10	Tonsillectomy;
UCEC	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.56	5.05	0.38	1.26e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.86	9.34	0.61	1.41e-16	Dental caries;
UCEC	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg03342759	chr3:160939853	NMD3	-0.59	-5.68	-0.42	7.08e-8	Morning vs. evening chronotype;
UCEC	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg18681998	chr4:17616180	MED28	0.54	6.1	0.45	9.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	1.0	5.6	0.42	1.01e-7	Skin colour saturation;
UCEC	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00967121	chr5:153418461	MFAP3;FAM114A2	-0.69	-6.85	-0.49	1.91e-10	Gut microbiome composition (summer);
UCEC	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.52	0.35	1.24e-5	Parkinson's disease;
UCEC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	4.74	0.36	4.93e-6	Electroencephalogram traits;
UCEC	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.62	-7.43	-0.52	8.05e-12	Prevalent atrial fibrillation;
UCEC	cis	rs12618769	0.652	rs3754875	chr2:99202747	C/G	cg10123293	chr2:99228465	UNC50	0.45	5.18	0.39	7.09e-7	Bipolar disorder;
UCEC	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.51	5.71	0.43	5.94e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
UCEC	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg03714773	chr7:91764589	CYP51A1	0.41	5.16	0.39	7.96e-7	Breast cancer;
UCEC	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs10254160	1.000	rs17159615	chr7:112062821	A/G	cg00851377	chr7:112726089	GPR85	-0.79	-4.55	-0.35	1.12e-5	Parental extreme longevity (95 years and older);
UCEC	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg17526145	chr2:23869158	KLHL29	0.46	5.05	0.38	1.31e-6	Asthma;
UCEC	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.96	-0.59	1.34e-15	Exhaled nitric oxide output;
UCEC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.83	5.65	0.42	8.24e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	8.12	0.56	1.71e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.74	8.11	0.56	1.86e-13	Sudden cardiac arrest;
UCEC	cis	rs9810890	0.764	rs59037701	chr3:128562299	A/G	cg03982443	chr3:128968543	COPG	-0.6	-4.69	-0.36	6.16e-6	Dental caries;
UCEC	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.9	9.31	0.61	1.73e-16	Cognitive function;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-5.74	-0.43	5.13e-8	Platelet count;
UCEC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.5	-5.53	-0.41	1.43e-7	Facial morphology (factor 20);
UCEC	cis	rs17824620	0.548	rs4766648	chr12:113119813	C/T	cg26711794	chr12:112450906	ERP29;TMEM116	0.61	5.02	0.38	1.48e-6	Platelet count;
UCEC	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.92	-0.44	2.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	0.97	15.52	0.79	8.84e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.57	6.26	0.46	4.05e-9	Breast cancer;
UCEC	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.55	5.65	0.42	7.98e-8	Tonsillectomy;
UCEC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.07	16.92	0.81	2.59e-36	IgG glycosylation;
UCEC	cis	rs10924970	0.625	rs12757645	chr1:235497804	T/C	cg26050004	chr1:235667680	B3GALNT2	0.49	4.55	0.35	1.12e-5	Asthma;
UCEC	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.57	5.63	0.42	8.99e-8	Blood protein levels;
UCEC	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	8.35	0.57	4.77e-14	Hip circumference;
UCEC	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.15	-6.98	-0.5	9.47e-11	Breast cancer;
UCEC	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.07e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg13147721	chr7:65941812	NA	-0.68	-4.73	-0.36	5.22e-6	Diabetic kidney disease;
UCEC	cis	rs58521262	0.556	rs465933	chr19:23128203	T/C	cg08486875	chr19:23386892	NA	-0.33	-4.6	-0.35	8.96e-6	Testicular germ cell tumor;
UCEC	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg05072774	chr3:49840536	C3orf54	-0.52	-5.32	-0.4	3.75e-7	Resting heart rate;
UCEC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.9	-0.44	2.35e-8	Menarche (age at onset);
UCEC	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06558623	chr16:89946397	TCF25	0.93	5.67	0.42	7.42e-8	Skin colour saturation;
UCEC	cis	rs7597155	0.846	rs1472950	chr2:69957212	A/C	cg02498382	chr2:70120550	SNRNP27	-0.49	-5.36	-0.4	3.09e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs847649	0.842	rs1608651	chr7:102624192	C/T	cg18108683	chr7:102477205	FBXL13	0.6	7.35	0.52	1.25e-11	Morning vs. evening chronotype;
UCEC	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6540731	1.000	rs3816912	chr1:212399849	A/G	cg07569918	chr1:212002970	LPGAT1	0.41	5.18	0.39	7.03e-7	Intelligence (childhood);
UCEC	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.79	-7.9	-0.55	5.84e-13	Mosquito bite size;
UCEC	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg24562669	chr7:97807699	LMTK2	0.49	5.98	0.44	1.58e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.49	-4.82	-0.37	3.55e-6	Cardiac Troponin-T levels;
UCEC	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	5.95	0.44	1.92e-8	Bipolar disorder;
UCEC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.58	6.63	0.48	5.94e-10	Total body bone mineral density;
UCEC	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	5.77	0.43	4.42e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg23950597	chr19:37808831	NA	-0.65	-5.07	-0.39	1.2e-6	Coronary artery calcification;
UCEC	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg06768213	chr1:227963296	SNAP47	0.38	4.67	0.36	6.85e-6	Diastolic blood pressure;
UCEC	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.28	-7.93	-0.55	4.96e-13	Diabetic kidney disease;
UCEC	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.58	-6.39	-0.47	2.02e-9	Blood metabolite levels;
UCEC	cis	rs894344	0.584	rs7012866	chr8:135616959	T/G	cg07888246	chr8:135877498	NA	-0.42	-4.62	-0.36	8.44e-6	Systolic blood pressure;
UCEC	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.64	-5.75	-0.43	4.97e-8	Metabolite levels;
UCEC	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.53	5.32	0.4	3.87e-7	Menopause (age at onset);
UCEC	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.55	5.07	0.39	1.19e-6	Lung cancer;
UCEC	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.64	-6.94	-0.5	1.14e-10	Morning vs. evening chronotype;
UCEC	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.04e-6	Schizophrenia;
UCEC	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.68	7.43	0.52	8.41e-12	Menopause (age at onset);
UCEC	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.6	-4.88	-0.37	2.78e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.88	-0.37	2.74e-6	Alzheimer's disease (late onset);
UCEC	cis	rs4654899	0.897	rs611658	chr1:21089133	T/G	cg01072550	chr1:21505969	NA	-0.5	-4.89	-0.37	2.64e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.68	0.48	4.64e-10	Coffee consumption (cups per day);
UCEC	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-0.67	-5.4	-0.41	2.64e-7	Morning vs. evening chronotype;
UCEC	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	4.52	0.35	1.24e-5	Refractive astigmatism;
UCEC	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg06521331	chr12:34319734	NA	-0.63	-4.86	-0.37	2.95e-6	Morning vs. evening chronotype;
UCEC	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17467752	chr17:38218738	THRA	-0.88	-9.9	-0.63	5.11e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.42	-5.28	-0.4	4.58e-7	Colorectal cancer;
UCEC	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg05925327	chr15:68127851	NA	-0.54	-6.02	-0.44	1.3e-8	Restless legs syndrome;
UCEC	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.34	4.68	0.36	6.34e-6	Acute lymphoblastic leukemia (childhood);
UCEC	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg13385521	chr17:29058706	SUZ12P	0.6	4.52	0.35	1.25e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	0.98	13.58	0.75	1.01e-27	Bone mineral density;
UCEC	cis	rs9467773	0.967	rs10223792	chr6:26579616	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs12971914	chr19:22888898	A/T	cg08271804	chr19:22816896	ZNF492	0.67	6.51	0.47	1.1e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.1	18.83	0.84	5.21e-41	Schizophrenia;
UCEC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg14008862	chr17:28927542	LRRC37B2	0.62	4.87	0.37	2.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	1.03	11.33	0.68	9.04e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-6.06	-0.45	1.12e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-5.13	-0.39	8.92e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-5.13	-0.39	8.86e-7	Aortic root size;
UCEC	cis	rs2280630	0.529	rs6599274	chr3:39013948	T/C	cg01426195	chr3:39028469	NA	-0.69	-8.58	-0.58	1.22e-14	Verbal declarative memory;
UCEC	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg16583315	chr14:65563665	MAX	0.43	5.7	0.43	6.39e-8	Obesity-related traits;
UCEC	cis	rs9650657	0.812	rs4240669	chr8:10629987	C/T	cg00629382	chr8:10268916	MSRA	-0.45	-4.59	-0.35	9.55e-6	Neuroticism;
UCEC	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.37	5.54	0.42	1.33e-7	Multiple sclerosis;
UCEC	cis	rs1165668	1.000	rs2583282	chr12:104313579	A/G	cg21863207	chr12:104234989	NT5DC3	0.55	4.73	0.36	5.26e-6	Coronary heart disease (SNP X SNP interaction);
UCEC	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg07424592	chr7:64974309	NA	0.79	4.74	0.36	4.98e-6	Diabetic kidney disease;
UCEC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.05	9.13	0.6	4.84e-16	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.65	-0.36	7.19e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22117172	chr7:91764530	CYP51A1	-0.38	-4.74	-0.36	4.96e-6	Breast cancer;
UCEC	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.46	-4.7	-0.36	5.87e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg01262667	chr19:19385393	TM6SF2	0.49	6.8	0.49	2.47e-10	Tonsillectomy;
UCEC	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.4	-5.16	-0.39	7.7300000000000005e-07	HIV-1 susceptibility;
UCEC	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.42	6.73	0.49	3.63e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg06238570	chr21:40685208	BRWD1	0.82	8.07	0.55	2.29e-13	Cognitive function;
UCEC	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.78	8.01	0.55	3.1400000000000003e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg24578937	chr1:2090814	PRKCZ	-0.42	-5.02	-0.38	1.46e-6	Height;
UCEC	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-9.83	-0.63	7.65e-18	Electrocardiographic conduction measures;
UCEC	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.7	0.36	5.93e-6	Menopause (age at onset);
UCEC	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-8.86	-0.59	2.45e-15	Exhaled nitric oxide output;
UCEC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.55	5.54	0.42	1.34e-7	Obesity-related traits;
UCEC	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg01072550	chr1:21505969	NA	-0.62	-6.6	-0.48	7.11e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.5	-5.48	-0.41	1.8e-7	Aortic root size;
UCEC	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.47	-5.16	-0.39	8e-7	Neuroticism;
UCEC	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.49	4.73	0.36	5.23e-6	Coronary artery disease;
UCEC	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.61	5.65	0.42	7.92e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs11677416	1.000	rs11677416	chr2:113529240	A/G	cg27083787	chr2:113543245	IL1A	0.54	5.25	0.4	5.21e-7	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.14	0.51	4.02e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.46	4.77	0.37	4.42e-6	Headache;
UCEC	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.46	-4.58	-0.35	9.75e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.46	4.58	0.35	9.68e-6	Aortic root size;
UCEC	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg05874882	chr4:1763078	NA	-0.53	-5.43	-0.41	2.25e-7	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg04287289	chr16:89883240	FANCA	-0.47	-5.07	-0.39	1.2e-6	Vitiligo;
UCEC	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-5.22	-0.4	6.01e-7	Gut microbiome composition (summer);
UCEC	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg09626299	chr10:82213104	TSPAN14	-0.41	-6.67	-0.48	4.93e-10	Post bronchodilator FEV1;
UCEC	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.68	-7.72	-0.54	1.63e-12	Monocyte count;
UCEC	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24249390	chr15:90295951	MESP1	-0.39	-4.58	-0.35	9.94e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.79	8.09	0.55	2.08e-13	Blood protein levels;
UCEC	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-4.61	-0.36	8.8e-6	Coronary artery disease;
UCEC	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.49	4.95	0.38	2.03e-6	Obesity-related traits;
UCEC	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-5.87	-0.44	2.74e-8	Multiple sclerosis;
UCEC	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.62	6.48	0.47	1.32e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs17123764	0.710	rs7688	chr12:50157071	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	4.98	0.38	1.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.59	-5.76	-0.43	4.8e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.72	-6.64	-0.48	5.61e-10	Initial pursuit acceleration;
UCEC	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-0.61	-7.57	-0.53	3.82e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-0.59	-9.87	-0.63	6.07e-18	Diastolic blood pressure;
UCEC	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.76	0.43	4.77e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.62	5.46	0.41	2.01e-7	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.58	4.54	0.35	1.15e-5	Gut microbiome composition (summer);
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.42	-4.75	-0.36	4.73e-6	Monocyte percentage of white cells;
UCEC	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.75	8.17	0.56	1.33e-13	Menopause (age at onset);
UCEC	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg11871910	chr12:69753446	YEATS4	0.89	10.31	0.65	4.27e-19	Blood protein levels;
UCEC	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.69	7.5	0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2147959	0.941	rs12131962	chr1:228631641	G/A	cg00655913	chr1:228633920	NA	0.54	5.99	0.44	1.51e-8	Adult asthma;
UCEC	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.86	0.59	2.35e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg00343986	chr7:65444356	GUSB	-0.54	-4.7	-0.36	5.92e-6	Aortic root size;
UCEC	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.19	-0.39	7e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.45	4.55	0.35	1.12e-5	Longevity;Endometriosis;
UCEC	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg13695892	chr22:41940480	POLR3H	-0.6	-5.06	-0.39	1.22e-6	Vitiligo;
UCEC	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-0.85	-9.21	-0.6	3.13e-16	Height;
UCEC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.53	-0.42	1.42e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.51	5.02	0.38	1.44e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
UCEC	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg24977027	chr2:88469347	THNSL2	0.83	5.78	0.43	4.37e-8	Plasma clusterin levels;
UCEC	cis	rs10988449	0.891	rs10988454	chr9:132390131	C/G	cg18327994	chr9:132372705	NA	0.51	5.01	0.38	1.57e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs66686620	1.000	rs13420940	chr2:69250234	C/T	cg12800200	chr2:69260302	ANTXR1	0.57	5.56	0.42	1.21e-7	Breast cancer;
UCEC	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.43	4.91	0.38	2.4e-6	Menarche (age at onset);
UCEC	cis	rs7709377	0.597	rs10478280	chr5:115481662	A/C	cg23108291	chr5:115420582	COMMD10	0.53	5.47	0.41	1.9e-7	Metabolite levels  (X-11787);
UCEC	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.55	6.12	0.45	8.08e-9	Height;
UCEC	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.71	-7.96	-0.55	4.39e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg21191810	chr6:118973309	C6orf204	0.43	6.09	0.45	9.59e-9	Electrocardiographic conduction measures;
UCEC	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.83	9.81	0.63	8.58e-18	Monocyte count;
UCEC	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.48	5.38	0.41	2.9e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg03354898	chr7:1950403	MAD1L1	-0.56	-5.37	-0.4	3.05e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.59	-6.41	-0.47	1.89e-9	Obesity-related traits;
UCEC	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.48	5.68	0.42	7.12e-8	Rheumatoid arthritis;
UCEC	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg06521331	chr12:34319734	NA	-0.63	-5.0	-0.38	1.64e-6	Morning vs. evening chronotype;
UCEC	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg18478394	chr8:109455254	TTC35	0.51	5.18	0.39	7.21e-7	Dupuytren's disease;
UCEC	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.69	5.69	0.43	6.53e-8	Menopause (age at onset);
UCEC	cis	rs13382862	1.000	rs13382862	chr2:20882449	A/G	cg07021052	chr2:20871279	NA	-0.39	-4.58	-0.35	9.86e-6	Abdominal aortic aneurysm;
UCEC	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.63	-5.55	-0.42	1.3e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg08459430	chr5:81571289	RPS23	-0.48	-4.64	-0.36	7.52e-6	Breast cancer;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.73	8.95	0.59	1.43e-15	Menarche (age at onset);
UCEC	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.7	7.46	0.52	6.78e-12	Coronary artery disease;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.79	8.76	0.59	4.22e-15	Longevity;Endometriosis;
UCEC	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.1	18.72	0.84	9.4e-41	IgG glycosylation;
UCEC	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-5.01	-0.38	1.56e-6	Non-small cell lung cancer;
UCEC	cis	rs2694917	0.671	rs2638301	chr12:56928814	A/G	cg02665130	chr12:57640672	STAC3	0.76	4.68	0.36	6.44e-6	Blood metabolite ratios;
UCEC	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-1.01	-7.35	-0.52	1.29e-11	Multiple sclerosis;
UCEC	cis	rs11958404	0.932	rs72818104	chr5:157437632	T/C	cg05962755	chr5:157440814	NA	0.71	5.18	0.39	7.06e-7	IgG glycosylation;
UCEC	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-4.86	-0.37	2.96e-6	Opioid sensitivity;
UCEC	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.59	0.35	9.54e-6	Bipolar disorder;
UCEC	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.62	6.78	0.49	2.69e-10	Motion sickness;
UCEC	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg18135206	chr14:102964638	TECPR2	1.05	13.23	0.74	8.15e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.78	7.13	0.51	4.13e-11	Morning vs. evening chronotype;
UCEC	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	0.75	9.28	0.61	2.02e-16	Obesity-related traits;
UCEC	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.65	6.49	0.47	1.25e-9	Coronary artery disease;
UCEC	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.54	0.35	1.16e-5	Prudent dietary pattern;
UCEC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.7	6.16	0.45	6.66e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.25	-0.4	5.19e-7	Aortic root size;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg17365369	chr19:52773256	ZNF766	0.65	6.86	0.49	1.78e-10	Schizophrenia;
UCEC	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.63	-6.09	-0.45	9.47e-9	Metabolite levels;
UCEC	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.85	-9.64	-0.62	2.34e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.73	7.12	0.51	4.37e-11	Parkinson's disease;
UCEC	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg08717414	chr16:71523259	ZNF19	-0.7	-4.72	-0.36	5.42e-6	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
UCEC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.57	-5.77	-0.43	4.52e-8	Breast cancer;
UCEC	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.62	-8.99	-0.6	1.1e-15	Prudent dietary pattern;
UCEC	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.47	-4.64	-0.36	7.6e-6	Mortality in heart failure;
UCEC	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-5.11	-0.39	9.75e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.59	-0.35	9.44e-6	Depression;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg07836142	chr6:28411423	ZSCAN23	-0.49	-5.54	-0.42	1.39e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg06562184	chr8:19319451	CSGALNACT1	0.52	5.61	0.42	9.63e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs8105895	0.935	rs8110975	chr19:22240233	C/G	cg24175803	chr19:22235144	ZNF257	-0.62	-5.37	-0.41	2.98e-7	Body mass index (change over time);
UCEC	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.95	-7.43	-0.52	8.03e-12	Multiple sclerosis;
UCEC	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-1.01	-5.86	-0.43	2.99e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.77	-9.53	-0.62	4.67e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.46	5.15	0.39	8.39e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs926938	0.543	rs360600	chr1:115388116	T/C	cg12756093	chr1:115239321	AMPD1	0.52	5.44	0.41	2.19e-7	Autism;
UCEC	cis	rs295140	1.000	rs3769476	chr2:201181428	T/C	cg04283868	chr2:201171347	SPATS2L	0.53	5.17	0.39	7.66e-7	QT interval;
UCEC	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg23791538	chr6:167370224	RNASET2	-0.55	-5.86	-0.44	2.87e-8	Primary biliary cholangitis;
UCEC	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.52	5.27	0.4	4.74e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Systolic blood pressure;
UCEC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.29	-0.56	6.44e-14	Chronic sinus infection;
UCEC	cis	rs73017364	0.688	rs56153955	chr1:162150870	G/A	cg19130550	chr1:161994277	OLFML2B	-0.53	-4.72	-0.36	5.47e-6	QT interval;
UCEC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.59	4.93	0.38	2.19e-6	Blood metabolite levels;
UCEC	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Psoriasis vulgaris;
UCEC	cis	rs4789452	1.000	rs34596832	chr17:75373170	C/T	cg21830368	chr17:75373327	SEPT9	-0.31	-4.85	-0.37	3.06e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.43	-4.5	-0.35	1.36e-5	Obesity-related traits;
UCEC	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.52	-6.28	-0.46	3.67e-9	Pubertal anthropometrics;
UCEC	cis	rs10872587	0.598	rs10457057	chr6:146542320	G/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.35	-0.4	3.23e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg27153327	chr16:1920815	C16orf73	0.52	5.08	0.39	1.11e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.51	-4.71	-0.36	5.77e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.89	9.09	0.6	6.26e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.87	12.39	0.71	1.33e-24	Urate levels in lean individuals;
UCEC	cis	rs9815925	0.590	rs1011147	chr3:184760449	C/T	cg00151007	chr3:184769954	VPS8	-0.49	-5.05	-0.38	1.27e-6	Heschl's gyrus morphology;
UCEC	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.49	5.0	0.38	1.61e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.91	-11.79	-0.7	5.2e-23	Height;
UCEC	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.57	5.72	0.43	5.83e-8	Colorectal cancer;
UCEC	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.18	13.85	0.75	1.96e-28	Breast cancer;
UCEC	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.61	5.09	0.39	1.09e-6	Blood metabolite levels;
UCEC	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.5	4.54	0.35	1.14e-5	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-6.08	-0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9283706	0.608	rs10060497	chr5:66332406	A/G	cg11590213	chr5:66331682	MAST4	0.45	5.83	0.43	3.31e-8	Coronary artery disease;
UCEC	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.48	-5.46	-0.41	2.01e-7	Height;
UCEC	cis	rs10121009	0.587	rs10738942	chr9:35439202	C/T	cg14286155	chr9:34620395	DCTN3	-0.48	-4.53	-0.35	1.23e-5	Parkinson's disease;
UCEC	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	7.91	0.55	5.55e-13	Smoking behavior;
UCEC	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.6	5.4	0.41	2.59e-7	Response to antineoplastic agents;
UCEC	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.48	-4.71	-0.36	5.74e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	5.21	0.39	6.31e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.42	4.67	0.36	6.81e-6	Renal cell carcinoma;
UCEC	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.56	6.01	0.44	1.4e-8	Platelet count;
UCEC	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.66	6.37	0.47	2.28e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg23795048	chr12:9217529	LOC144571	0.4	4.91	0.38	2.42e-6	Sjögren's syndrome;
UCEC	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	4.98	0.38	1.74e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.65	6.03	0.45	1.29e-8	Tourette syndrome;
UCEC	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs2592394	0.626	rs711828	chr2:177000363	A/G	cg13092806	chr2:177043255	NA	0.77	5.21	0.39	6.39e-7	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.5	-4.69	-0.36	6.08e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.68	-0.36	6.47e-6	Breast cancer;
UCEC	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg03354898	chr7:1950403	MAD1L1	-0.57	-5.56	-0.42	1.24e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-1.05	-7.95	-0.55	4.61e-13	Multiple sclerosis;
UCEC	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.08	-0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.57	6.04	0.45	1.19e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg14582100	chr15:45693742	SPATA5L1	0.34	4.62	0.36	8.46e-6	Homoarginine levels;
UCEC	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.52	4.9	0.37	2.46e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.7	-7.06	-0.5	6.23e-11	Coronary artery disease;
UCEC	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-6.6	-0.48	6.97e-10	Total body bone mineral density;
UCEC	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.52	5.14	0.39	8.48e-7	Immature fraction of reticulocytes;
UCEC	cis	rs883565	0.528	rs4504116	chr3:38953768	A/G	cg01426195	chr3:39028469	NA	0.46	5.11	0.39	9.73e-7	Handedness;
UCEC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.52	5.01	0.38	1.54e-6	Menopause (age at onset);
UCEC	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-6.58	-0.48	7.84e-10	Blood protein levels;
UCEC	cis	rs2862064	0.932	rs1553319	chr5:156479001	T/A	cg12943317	chr5:156479607	HAVCR1	-0.63	-4.9	-0.37	2.54e-6	Platelet count;
UCEC	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.53	6.34	0.46	2.6e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7178375	0.607	rs71474639	chr15:31213257	A/G	cg06792044	chr15:31234080	MTMR10;MTMR15	-0.57	-5.07	-0.39	1.2e-6	Hypertriglyceridemia;
UCEC	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.58	5.01	0.38	1.55e-6	Heart rate;
UCEC	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg26781129	chr3:44753946	ZNF502	-0.43	-4.62	-0.36	8.15e-6	Depressive symptoms;
UCEC	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.73	5.01	0.38	1.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18932078	chr1:2524107	MMEL1	-0.39	-6.5	-0.47	1.17e-9	Ulcerative colitis;
UCEC	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.35	-0.46	2.51e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.49	0.62	5.83e-17	Platelet count;
UCEC	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg25306006	chr11:71932630	FOLR2	-0.4	-4.57	-0.35	1.04e-5	Vitamin D levels;
UCEC	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.76	-6.93	-0.5	1.22e-10	Response to metformin (IC50);
UCEC	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.89	7.33	0.52	1.41e-11	Type 2 diabetes nephropathy;
UCEC	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26031613	chr14:104095156	KLC1	1.17	14.07	0.76	5.18e-29	Body mass index;
UCEC	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.17	0.51	3.31e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-5.04	-0.38	1.36e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18252515	chr7:66147081	NA	0.46	4.7	0.36	5.89e-6	Aortic root size;
UCEC	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs11958404	0.932	rs72816572	chr5:157429818	T/C	cg05962755	chr5:157440814	NA	0.71	5.11	0.39	9.73e-7	IgG glycosylation;
UCEC	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.1	-0.51	5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg24416660	chr17:73865998	NA	-0.34	-4.93	-0.38	2.15e-6	Psoriasis;
UCEC	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-9.01	-0.6	1e-15	Exhaled nitric oxide output;
UCEC	cis	rs62103177	0.733	rs80114941	chr18:77671740	G/A	cg20368463	chr18:77673604	PQLC1	0.68	4.69	0.36	6.12e-6	Opioid sensitivity;
UCEC	cis	rs6728642	1.000	rs59178801	chr2:97604455	C/T	cg26665480	chr2:98280029	ACTR1B	-0.72	-7.27	-0.51	1.93e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.57	6.7	0.48	4.07e-10	Prostate cancer;
UCEC	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.16	0.39	7.96e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs151997	0.962	rs39955	chr5:50187501	C/A	cg06027927	chr5:50259733	NA	0.54	4.97	0.38	1.81e-6	Callous-unemotional behaviour;
UCEC	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.7	-6.97	-0.5	9.85e-11	Response to antineoplastic agents;
UCEC	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.58	-6.26	-0.46	4.1e-9	Obesity-related traits;
UCEC	cis	rs6869841	0.542	rs67919143	chr5:172960956	C/T	cg17560677	chr5:172191082	NA	0.52	4.76	0.37	4.66e-6	Prostate cancer;
UCEC	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.24e-5	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs10242455	0.764	rs2037497	chr7:99315904	G/A	cg07715041	chr7:99302981	CYP3A7	-0.51	-5.23	-0.4	5.68e-7	Blood metabolite levels;
UCEC	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg18032046	chr6:28092343	ZSCAN16	0.68	5.67	0.42	7.49e-8	Depression;
UCEC	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.68	6.06	0.45	1.08e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	4.82	0.37	3.57e-6	Eosinophil percentage of white cells;
UCEC	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.82	-7.72	-0.54	1.61e-12	Diastolic blood pressure;
UCEC	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.7	6.65	0.48	5.4e-10	Aortic root size;
UCEC	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	6.78	0.49	2.69e-10	Motion sickness;
UCEC	cis	rs7246967	0.673	rs59567211	chr19:22829882	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.58	-5.09	-0.39	1.06e-6	Reticulocyte count;
UCEC	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-9.64	-0.62	2.35e-17	Blood metabolite levels;
UCEC	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.63	5.95	0.44	1.87e-8	Response to diuretic therapy;
UCEC	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.74	-0.43	5.3e-8	Mood instability;
UCEC	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.74	7.01	0.5	7.92e-11	Smoking behavior;
UCEC	cis	rs7246967	1.000	rs936526	chr19:23055987	A/C	cg05241461	chr19:22816980	ZNF492	0.45	4.61	0.36	8.65e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs12545109	0.836	rs2196586	chr8:57347126	C/T	cg09654669	chr8:57350985	NA	0.46	4.85	0.37	3.14e-6	Obesity-related traits;
UCEC	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.06	-0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.59	-5.66	-0.42	7.71e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg13695892	chr22:41940480	POLR3H	-0.59	-4.87	-0.37	2.83e-6	Vitiligo;
UCEC	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.43	-4.95	-0.38	2.01e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.75	8.19	0.56	1.13e-13	Menopause (age at onset);
UCEC	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.49	4.51	0.35	1.31e-5	Coronary artery disease;
UCEC	cis	rs8105895	0.736	rs2359835	chr19:22242690	A/G	cg02912127	chr19:22235281	ZNF257	-0.64	-5.35	-0.4	3.29e-7	Body mass index (change over time);
UCEC	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg12024160	chr4:1254474	NA	0.55	7.15	0.51	3.8e-11	Obesity-related traits;
UCEC	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.46	-0.62	6.94e-17	Coffee consumption (cups per day);
UCEC	cis	rs7546668	1.000	rs6695562	chr1:15842842	C/T	cg05660106	chr1:15850417	CASP9	-0.46	-4.87	-0.37	2.88e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.24	12.55	0.72	5.2e-25	Corneal structure;
UCEC	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-7.03	-0.5	7.19e-11	Hypospadias;
UCEC	cis	rs4908768	0.629	rs4908517	chr1:8887005	T/A	cg13081009	chr1:8430745	RERE	0.44	4.78	0.37	4.22e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.86	9.57	0.62	3.6e-17	Blood protein levels;
UCEC	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.47	-5.55	-0.42	1.3e-7	Age at first birth;
UCEC	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.13	0.39	8.82e-7	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.72	-6.91	-0.49	1.4e-10	Metabolite levels;
UCEC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.67	-6.42	-0.47	1.81e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.22	0.46	4.91e-9	Platelet count;
UCEC	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-7.45	-0.52	7.53e-12	Longevity;Endometriosis;
UCEC	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.72	6.55	0.48	9.17e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.62	7.98	0.55	3.75e-13	Bone mineral density;
UCEC	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.42	-5.12	-0.39	9.35e-7	Subjective well-being;
UCEC	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.83	-5.54	-0.42	1.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.72	-6.73	-0.49	3.58e-10	Aortic root size;
UCEC	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.62	-5.96	-0.44	1.77e-8	Schizophrenia;
UCEC	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.51	-0.35	1.29e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.86	6.89	0.49	1.5e-10	Body mass index;
UCEC	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.05	-0.38	1.3e-6	Pubertal anthropometrics;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.58	-0.48	7.8e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg06462663	chr19:18546047	ISYNA1	0.47	5.99	0.44	1.56e-8	Breast cancer;
UCEC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.53	-0.47	1.03e-9	Tonsillectomy;
UCEC	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	6.29	0.46	3.42e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.82	8.73	0.58	5.22e-15	Blood protein levels;
UCEC	trans	rs7246760	0.867	rs34648216	chr19:9850690	T/A	cg02900749	chr2:68251473	NA	-0.99	-7.48	-0.53	6.1e-12	Pursuit maintenance gain;
UCEC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.87	10.58	0.66	8.37e-20	Longevity;Endometriosis;
UCEC	cis	rs2172802	0.560	rs12510774	chr4:62563504	C/T	cg04118610	chr4:62707027	LPHN3	0.41	4.63	0.36	7.95e-6	Partial epilepsies;
UCEC	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-6.52	-0.47	1.03e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.58	-5.59	-0.42	1.05e-7	Morning vs. evening chronotype;
UCEC	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	5.43	0.41	2.28e-7	Monocyte percentage of white cells;
UCEC	cis	rs6893207	1.000	rs12188926	chr5:16390994	G/T	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.5	-5.69	-0.42	6.6e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs58521262	0.556	rs290579	chr19:23221067	T/C	cg08486875	chr19:23386892	NA	0.33	4.54	0.35	1.18e-5	Testicular germ cell tumor;
UCEC	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.5	-5.02	-0.38	1.48e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.14e-6	Schizophrenia;
UCEC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.55	-5.28	-0.4	4.63e-7	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.59	5.03	0.38	1.41e-6	Corneal astigmatism;
UCEC	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.54	5.1	0.39	1.05e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.44	-5.43	-0.41	2.3e-7	Blood metabolite levels;
UCEC	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.61	5.32	0.4	3.82e-7	Obesity-related traits;
UCEC	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6696846	0.515	rs6593924	chr1:205110452	A/G	cg12580275	chr1:205744413	RAB7L1	0.42	4.78	0.37	4.2e-6	Red blood cell count;
UCEC	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.53	5.62	0.42	9.45e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.7	7.71	0.54	1.69e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6921919	0.638	rs6456815	chr6:28306137	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.46	-4.86	-0.37	3.03e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18099408	chr3:52552593	STAB1	-0.44	-4.53	-0.35	1.23e-5	Bipolar disorder;
UCEC	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.5	5.19	0.39	6.78e-7	Monocyte percentage of white cells;
UCEC	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.58	-6.34	-0.46	2.7e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	7.07	0.5	5.74e-11	Ileal carcinoids;
UCEC	cis	rs405956	1.000	rs9486037	chr6:105561560	C/A	cg22580625	chr6:105627791	POPDC3	-0.7	-6.5	-0.47	1.17e-9	QT interval;
UCEC	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.71	8.02	0.55	3.05e-13	Menopause (age at onset);
UCEC	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.55	-5.47	-0.41	1.92e-7	Aortic root size;
UCEC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.68	7.12	0.51	4.38e-11	Longevity;Endometriosis;
UCEC	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.58	6.15	0.45	7.09e-9	Bipolar disorder;
UCEC	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	0.84	6.14	0.45	7.48e-9	Iron status biomarkers;
UCEC	cis	rs7246967	0.673	rs2099341	chr19:22834360	A/G	cg05241461	chr19:22816980	ZNF492	0.56	6.03	0.45	1.25e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.53	-6.08	-0.45	9.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.54	-5.46	-0.41	1.95e-7	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18932078	chr1:2524107	MMEL1	0.34	5.51	0.41	1.55e-7	Ulcerative colitis;
UCEC	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.51	4.8	0.37	3.86e-6	Bipolar disorder;
UCEC	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg20821713	chr7:1055600	C7orf50	-0.69	-6.18	-0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs13092825	0.794	rs35452897	chr3:113282075	C/T	cg12596171	chr3:113251061	SIDT1	-0.55	-4.7	-0.36	5.89e-6	Dental caries;
UCEC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.66	5.56	0.42	1.26e-7	High light scatter reticulocyte count;
UCEC	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg16584290	chr5:462447	EXOC3	-0.47	-4.78	-0.37	4.23e-6	Cystic fibrosis severity;
UCEC	cis	rs17490626	0.568	rs12413525	chr10:71211721	C/A	cg12610070	chr10:71211762	TSPAN15	-0.39	-6.17	-0.45	6.39e-9	Thrombosis;
UCEC	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	5.45	0.41	2.07e-7	Metabolite levels;
UCEC	cis	rs12618769	0.597	rs17505326	chr2:99156807	T/A	cg10123293	chr2:99228465	UNC50	0.45	4.52	0.35	1.27e-5	Bipolar disorder;
UCEC	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg03354898	chr7:1950403	MAD1L1	-0.5	-5.05	-0.38	1.29e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.09	-0.39	1.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.65	6.57	0.48	7.98e-10	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg20399509	chr21:47717575	C21orf57	-0.46	-5.01	-0.38	1.56e-6	Testicular germ cell tumor;
UCEC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.74	5.51	0.41	1.6e-7	Initial pursuit acceleration;
UCEC	cis	rs7766436	0.922	rs13217043	chr6:22612831	T/A	cg13666174	chr6:22585274	NA	-0.58	-5.74	-0.43	5.16e-8	Coronary artery disease;
UCEC	cis	rs11054731	0.807	rs4763794	chr12:12437418	A/G	cg15883249	chr12:13028664	RPL13AP20	0.4	4.59	0.35	9.4e-6	Coronary artery calcification;
UCEC	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.81	-5.82	-0.43	3.54e-8	Narcolepsy;
UCEC	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.63	4.83	0.37	3.42e-6	Corneal astigmatism;
UCEC	cis	rs2970992	0.764	rs4850949	chr2:101324382	A/T	cg01042948	chr2:101319752	NA	-0.42	-4.71	-0.36	5.73e-6	Educational attainment;
UCEC	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.45	4.91	0.38	2.38e-6	Self-reported allergy;
UCEC	cis	rs883565	0.528	rs9311200	chr3:38953896	C/T	cg01426195	chr3:39028469	NA	-0.45	-4.95	-0.38	2e-6	Handedness;
UCEC	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.43	-5.64	-0.42	8.58e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.49	4.83	0.37	3.42e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg21770322	chr7:97807741	LMTK2	0.52	6.49	0.47	1.22e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	5.92	0.44	2.22e-8	Response to antipsychotic treatment;
UCEC	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg18099408	chr3:52552593	STAB1	-0.43	-4.67	-0.36	6.74e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg23260525	chr10:116636907	FAM160B1	0.33	4.56	0.35	1.09e-5	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs2721195	0.967	rs4925809	chr8:145686313	C/T	cg15320075	chr8:145703422	NA	0.58	5.59	0.42	1.06e-7	Age at first birth;
UCEC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.65	0.36	7.25e-6	Menarche (age at onset);
UCEC	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4499344	0.730	rs410616	chr19:33106109	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.69	0.42	6.76e-8	Mean platelet volume;
UCEC	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03517284	chr6:25882590	NA	0.5	4.86	0.37	3.03e-6	Blood metabolite levels;
UCEC	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.08e-8	Breast cancer;
UCEC	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-0.96	-5.81	-0.43	3.7e-8	Diabetic kidney disease;
UCEC	cis	rs1575951	1.000	rs7098205	chr10:130439482	A/G	cg09154334	chr10:131341043	MGMT	0.55	4.67	0.36	6.69e-6	Plasma clusterin levels;
UCEC	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs7709377	0.570	rs10065178	chr5:115435148	G/A	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	0.74	5.03	0.38	1.42e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg24803719	chr17:45855879	NA	-0.51	-5.21	-0.39	6.22e-7	IgG glycosylation;
UCEC	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.45	-0.47	1.55e-9	Aortic root size;
UCEC	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.56	-6.46	-0.47	1.41e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-6.62	-0.48	6.21e-10	Morning vs. evening chronotype;
UCEC	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	0.88	5.61	0.42	9.89e-8	Diabetic retinopathy;
UCEC	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.73	5.25	0.4	5.17e-7	Aortic root size;
UCEC	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.65	-6.97	-0.5	1.02e-10	Hypospadias;
UCEC	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.09	-7.01	-0.5	8.04e-11	Schizophrenia;
UCEC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.67	-0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-7.41	-0.52	9.33e-12	Body mass index (adult);
UCEC	cis	rs10924970	0.687	rs4433382	chr1:235364993	C/A	cg26050004	chr1:235667680	B3GALNT2	0.49	4.55	0.35	1.1e-5	Asthma;
UCEC	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.63	6.65	0.48	5.48e-10	Neutrophil percentage of white cells;
UCEC	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.59	6.15	0.45	6.95e-9	Personality dimensions;
UCEC	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	7.11	0.51	4.65e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg16577123	chr5:140027231	NDUFA2;IK	0.46	4.83	0.37	3.41e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs8105895	0.935	rs62110986	chr19:22256771	G/A	cg02912127	chr19:22235281	ZNF257	-0.63	-5.33	-0.4	3.6e-7	Body mass index (change over time);
UCEC	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.53	-6.39	-0.47	2.12e-9	Total body bone mineral density;
UCEC	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg05695927	chr15:45694626	SPATA5L1	0.51	4.98	0.38	1.74e-6	Homoarginine levels;
UCEC	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.73	6.29	0.46	3.43e-9	Coronary artery disease;
UCEC	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-6.52	-0.47	1.07e-9	Hemoglobin concentration;
UCEC	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.86	4.66	0.36	7.08e-6	Inflammatory bowel disease;
UCEC	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg04374321	chr14:90722782	PSMC1	0.62	5.61	0.42	9.98e-8	Gut microbiota (bacterial taxa);
UCEC	trans	rs337161	0.719	rs337148	chr1:220940873	A/G	cg07378013	chr16:90088605	GAS8	-0.65	-7.12	-0.51	4.44e-11	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg13695892	chr22:41940480	POLR3H	-0.57	-4.72	-0.36	5.41e-6	Vitiligo;
UCEC	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg03078520	chr22:18463400	MICAL3	-0.47	-4.81	-0.37	3.73e-6	Presence of antiphospholipid antibodies;
UCEC	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.83	12.26	0.71	2.99e-24	Leprosy;
UCEC	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-7.12	-0.51	4.51e-11	Morning vs. evening chronotype;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg02773889	chr13:42615649	NA	-0.59	-6.89	-0.49	1.54e-10	Breast cancer;
UCEC	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg26031613	chr14:104095156	KLC1	1.25	15.78	0.79	1.92e-33	Body mass index;
UCEC	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.81	-8.44	-0.57	2.7e-14	Mosquito bite size;
UCEC	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	0.8	6.25	0.46	4.24e-9	Corneal structure;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04138181	chr16:23690918	PLK1	0.71	6.7	0.48	4.09e-10	Migraine with aura;
UCEC	cis	rs9467773	1.000	rs1001687	chr6:26573218	C/G	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.61	6.38	0.47	2.22e-9	Longevity;Endometriosis;
UCEC	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-6.86	-0.49	1.77e-10	Coffee consumption (cups per day);
UCEC	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	0.97	5.49	0.41	1.73e-7	Arsenic metabolism;
UCEC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.46	5.44	0.41	2.14e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs16937	0.711	rs11240382	chr1:205168569	A/G	cg12580275	chr1:205744413	RAB7L1	0.47	5.07	0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg13777783	chr17:79615861	NA	-0.33	-4.77	-0.37	4.49e-6	Eye color traits;
UCEC	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.72	-7.12	-0.51	4.33e-11	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg03714773	chr7:91764589	CYP51A1	0.43	5.19	0.39	6.77e-7	Breast cancer;
UCEC	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	5.41	0.41	2.46e-7	Alzheimer's disease;
UCEC	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.57	7.01	0.5	7.83e-11	Oral cavity cancer;
UCEC	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-7.05	-0.5	6.5500000000000006e-11	Blood trace element (Zn levels);
UCEC	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	5.86	0.44	2.88e-8	Platelet count;
UCEC	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.85	-9.08	-0.6	6.72e-16	Body mass index;
UCEC	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg15133208	chr4:90757351	SNCA	-0.45	-5.3	-0.4	4.07e-7	Neuroticism;
UCEC	cis	rs1978968	0.731	rs9605467	chr22:18461166	A/G	cg03078520	chr22:18463400	MICAL3	-0.55	-6.61	-0.48	6.56e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.61	-5.27	-0.4	4.79e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
UCEC	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.67	-5.47	-0.41	1.93e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	5.26	0.4	5.08e-7	Coronary artery disease;
UCEC	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.84	-0.54	8.4e-13	Total cholesterol levels;
UCEC	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.92	6.59	0.48	7.37e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs7560272	0.682	rs2421546	chr2:73641077	A/C	cg20560298	chr2:73613845	ALMS1	0.54	5.39	0.41	2.72e-7	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	1.0	11.02	0.67	5.67e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.57	-6.13	-0.45	7.76e-9	Red blood cell count;
UCEC	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.56	-5.78	-0.43	4.24e-8	Bipolar disorder;
UCEC	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.71	6.69	0.48	4.43e-10	High light scatter reticulocyte count;
UCEC	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.53	4.69	0.36	6.28e-6	Corneal astigmatism;
UCEC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.98	-0.38	1.76e-6	Aortic root size;
UCEC	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.47	-4.99	-0.38	1.69e-6	Height;
UCEC	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	20.35	0.86	1.36e-44	Chronic sinus infection;
UCEC	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-4.62	-0.36	8.35e-6	Type 2 diabetes;
UCEC	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.99	-10.42	-0.65	2.2e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs12118280	0.921	rs61799378	chr1:108742130	T/C	cg11967332	chr1:108735228	SLC25A24	0.99	9.35	0.61	1.37e-16	Myeloid white cell count;
UCEC	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.48	-0.41	1.78e-7	Blood metabolite levels;
UCEC	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.88	-0.49	1.58e-10	Eye color traits;
UCEC	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.76	7.01	0.5	7.99e-11	Morning vs. evening chronotype;
UCEC	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg10902566	chr4:727664	PCGF3	-0.61	-5.17	-0.39	7.67e-7	Systolic blood pressure;
UCEC	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.13	-7.33	-0.52	1.39e-11	Diabetic kidney disease;
UCEC	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.89	0.59	2.07e-15	Prudent dietary pattern;
UCEC	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg11569703	chr11:65557185	OVOL1	0.42	6.08	0.45	9.66e-9	Acne (severe);
UCEC	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	5.87	0.44	2.77e-8	Response to antipsychotic treatment;
UCEC	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-0.61	-5.91	-0.44	2.29e-8	Pediatric autoimmune diseases;
UCEC	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.82	8.67	0.58	7.43e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-4.73	-0.36	5.16e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.52	4.95	0.38	1.98e-6	Multiple myeloma (IgH translocation);
UCEC	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.78	0.49	2.67e-10	Cognitive ability;
UCEC	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.91	8.31	0.57	5.68e-14	Bladder cancer;
UCEC	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg23978390	chr7:1156363	C7orf50	0.61	6.01	0.44	1.43e-8	Longevity;Endometriosis;
UCEC	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.7	5.34	0.4	3.38e-7	Platelet count;
UCEC	cis	rs17106184	1.000	rs57412341	chr1:51310327	A/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.4	-4.81	-0.37	3.63e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg16325326	chr1:53192061	ZYG11B	-0.57	-5.63	-0.42	9.04e-8	Monocyte count;
UCEC	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.66	5.42	0.41	2.37e-7	Metabolite levels;
UCEC	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	1.02	14.58	0.77	2.45e-30	Bone mineral density;
UCEC	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.61	5.57	0.42	1.17e-7	Morning vs. evening chronotype;
UCEC	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.08	-0.64	1.71e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.56	-5.63	-0.42	8.89e-8	Breast cancer;
UCEC	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.52	-5.18	-0.39	7.11e-7	Multiple sclerosis;
UCEC	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.61	-0.36	8.57e-6	Pubertal anthropometrics;
UCEC	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.6	6.78	0.49	2.71e-10	Height;
UCEC	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.17	16.05	0.8	4.03e-34	Cognitive function;
UCEC	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.76	7.36	0.52	1.18e-11	Menopause (age at onset);
UCEC	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.86	-0.44	2.87e-8	Hemoglobin concentration;
UCEC	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.7	7.25	0.51	2.16e-11	Smoking behavior;
UCEC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.67	-5.71	-0.43	6.16e-8	Aortic root size;
UCEC	cis	rs7246967	0.866	rs35105042	chr19:23048352	A/C	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07169764	chr2:136633963	MCM6	-0.65	-6.12	-0.45	8.03e-9	Mosquito bite size;
UCEC	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg23791538	chr6:167370224	RNASET2	-0.53	-5.73	-0.43	5.49e-8	Primary biliary cholangitis;
UCEC	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9463078	0.753	rs10948186	chr6:44903248	C/T	cg25276700	chr6:44698697	NA	-0.42	-4.7	-0.36	5.86e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.45	-4.99	-0.38	1.71e-6	White matter hyperintensity burden;
UCEC	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	4.54	0.35	1.14e-5	Lung function (FEV1/FVC);
UCEC	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.07	17.23	0.82	4.25e-37	Testicular germ cell tumor;
UCEC	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	10.23	0.65	6.81e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.37	5.64	0.42	8.65e-8	Body mass index;
UCEC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18252515	chr7:66147081	NA	-0.54	-5.08	-0.39	1.14e-6	Aortic root size;
UCEC	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg07404485	chr7:94953653	PON1	-0.48	-4.65	-0.36	7.47e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg26769984	chr7:1090371	C7orf50	-0.45	-4.64	-0.36	7.78e-6	Longevity;Endometriosis;
UCEC	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs7246967	0.736	rs398945	chr19:22997116	A/T	cg08271804	chr19:22816896	ZNF492	-0.53	-4.84	-0.37	3.18e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11153730	0.503	rs283049	chr6:118635122	G/C	cg21191810	chr6:118973309	C6orf204	0.41	5.26	0.4	5.04e-7	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
UCEC	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg09654669	chr8:57350985	NA	-0.54	-6.05	-0.45	1.14e-8	Obesity-related traits;
UCEC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.71	-7.19	-0.51	2.97e-11	Breast cancer;
UCEC	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	0.85	9.86	0.63	6.57e-18	Breast cancer;
UCEC	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06762426	chr11:62420836	INTS5	0.86	4.73	0.36	5.21e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	9.15	0.6	4.29e-16	Electrocardiographic conduction measures;
UCEC	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg22974920	chr21:40686053	BRWD1	0.53	4.87	0.37	2.82e-6	Cognitive function;
UCEC	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.43	-5.97	-0.44	1.67e-8	Rheumatoid arthritis;
UCEC	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.67	5.32	0.4	3.81e-7	Huntington's disease progression;
UCEC	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.44	-4.6	-0.35	9.19e-6	Coronary heart disease;
UCEC	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.43	4.94	0.38	2.09e-6	HDL cholesterol levels;
UCEC	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.59	-6.42	-0.47	1.77e-9	Obesity-related traits;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.41	-0.41	2.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.57	5.84	0.43	3.21e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.78	-0.37	4.21e-6	Tonsillectomy;
UCEC	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.52	-5.63	-0.42	8.74e-8	Menarche (age at onset);
UCEC	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.43	4.8	0.37	3.79e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.43	-4.86	-0.37	2.99e-6	Prostate cancer;
UCEC	cis	rs4372836	1.000	rs7598876	chr2:28974466	T/C	cg09522027	chr2:28974177	PPP1CB	-0.76	-7.89	-0.55	6.19e-13	Body mass index;
UCEC	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg11161011	chr14:65562177	MAX	-0.73	-7.36	-0.52	1.21e-11	Obesity-related traits;
UCEC	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.77	-10.31	-0.65	4.23e-19	Blood protein levels;
UCEC	cis	rs12980942	0.810	rs3745295	chr19:41785282	T/G	cg25627403	chr19:41769009	HNRNPUL1	0.62	5.51	0.41	1.54e-7	Coronary artery disease;
UCEC	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg09165964	chr15:75287851	SCAMP5	0.48	5.26	0.4	4.95e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.43	4.64	0.36	7.65e-6	Pulse pressure;
UCEC	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs6460942	0.591	rs62448733	chr7:12350526	C/T	cg06484146	chr7:12443880	VWDE	-0.6	-4.69	-0.36	6.23e-6	Coronary artery disease;
UCEC	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	5.49	0.41	1.73e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.86	0.49	1.79e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.69	7.37	0.52	1.17e-11	Breast cancer;
UCEC	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.46	-0.47	1.43e-9	Gout;
UCEC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.36	-5.22	-0.4	6.13e-7	Vitamin D levels;
UCEC	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.76	9.07	0.6	7.19e-16	Ulcerative colitis;
UCEC	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.8	8.68	0.58	6.98e-15	Metabolite levels;
UCEC	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	7.0	0.5	8.65e-11	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.62	6.02	0.44	1.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs4448343	1.000	rs4448343	chr9:98266370	A/G	cg13456470	chr9:98266766	PTCH1	0.34	4.56	0.35	1.08e-5	Height;
UCEC	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.58	5.58	0.42	1.15e-7	Retinal vascular caliber;
UCEC	cis	rs7088591	1.000	rs11816094	chr10:59785405	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg01874867	chr7:94954059	PON1	-0.55	-5.12	-0.39	9.28e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.47	-4.61	-0.36	8.74e-6	Parkinson's disease;
UCEC	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.47	-4.77	-0.37	4.38e-6	Neuroticism;
UCEC	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.65	6.32	0.46	2.98e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.53	5.39	0.41	2.7e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.58	4.96	0.38	1.9e-6	Alzheimer's disease;
UCEC	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18932078	chr1:2524107	MMEL1	-0.38	-6.07	-0.45	1.03e-8	Ulcerative colitis;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.51	-5.14	-0.39	8.73e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-4.79	-0.37	4.08e-6	Lymphocyte counts;
UCEC	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-4.99	-0.38	1.67e-6	Blood metabolite levels;
UCEC	cis	rs2425143	0.908	rs11697087	chr20:34427583	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.53	-0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18252515	chr7:66147081	NA	-0.48	-4.96	-0.38	1.88e-6	Aortic root size;
UCEC	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.85	9.15	0.6	4.5e-16	Cognitive function;
UCEC	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.66	-6.43	-0.47	1.64e-9	Metabolite levels;
UCEC	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.61	-4.74	-0.36	5.08e-6	Schizophrenia;
UCEC	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg20129853	chr10:51489980	NA	0.42	5.03	0.38	1.44e-6	Prostate-specific antigen levels;
UCEC	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg00105475	chr2:10696890	NA	0.45	5.61	0.42	9.89e-8	Prostate cancer;
UCEC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.78	7.32	0.52	1.51e-11	Initial pursuit acceleration;
UCEC	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.9	12.22	0.71	3.91e-24	Metabolic syndrome;
UCEC	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.59	4.98	0.38	1.74e-6	Migraine;
UCEC	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.94	-0.38	2.14e-6	Pubertal anthropometrics;
UCEC	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs6761276	0.899	rs12711750	chr2:113835380	C/A	cg09040174	chr2:113837401	NA	0.52	5.77	0.43	4.43e-8	Protein quantitative trait loci;
UCEC	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.88	9.3	0.61	1.84e-16	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs2862064	0.932	rs1393208	chr5:156477725	G/A	cg12943317	chr5:156479607	HAVCR1	-0.63	-4.9	-0.37	2.54e-6	Platelet count;
UCEC	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.1	8.65	0.58	8.04e-15	Uric acid levels;
UCEC	cis	rs7710178	0.756	rs72803019	chr5:156144844	A/T	cg12943317	chr5:156479607	HAVCR1	0.74	4.51	0.35	1.29e-5	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs13401104	0.531	rs12469569	chr2:237113376	T/C	cg23897927	chr2:237117786	ASB18	-0.53	-4.72	-0.36	5.34e-6	Educational attainment;
UCEC	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-6.12	-0.45	8.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.23	7.17	0.51	3.44e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	5.54	0.42	1.38e-7	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg01689657	chr7:91764605	CYP51A1	0.4	5.24	0.4	5.47e-7	Breast cancer;
UCEC	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.35	4.81	0.37	3.64e-6	Multiple system atrophy;
UCEC	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.26	14.87	0.78	4.24e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.42	5.16	0.39	7.99e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.77	-7.9	-0.55	6.12e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg20999797	chr1:1681921	NA	0.38	5.04	0.38	1.33e-6	Body mass index;
UCEC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.46	6.78	0.49	2.7e-10	Homoarginine levels;
UCEC	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-1.03	-7.23	-0.51	2.5e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg24851651	chr11:66362959	CCS	0.45	5.17	0.39	7.4e-7	Educational attainment (years of education);
UCEC	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg13147721	chr7:65941812	NA	-0.85	-5.65	-0.42	8.15e-8	Diabetic kidney disease;
UCEC	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	4.52	0.35	1.24e-5	Bipolar disorder;
UCEC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg09910674	chr16:89028015	CBFA2T3	0.6	4.61	0.36	8.71e-6	Skin colour saturation;
UCEC	cis	rs10872587	0.598	rs10457057	chr6:146542320	G/T	cg23711669	chr6:146136114	FBXO30	0.56	4.7	0.36	5.82e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03404566	chr17:6899310	ALOX12	0.48	5.65	0.42	8.22e-8	Tonsillectomy;
UCEC	cis	rs9283706	0.594	rs7735834	chr5:66337444	A/G	cg11590213	chr5:66331682	MAST4	-0.46	-5.61	-0.42	9.61e-8	Coronary artery disease;
UCEC	cis	rs56161922	1.000	rs55821028	chr1:207843000	G/A	cg09557387	chr1:207818395	CR1L	0.87	4.66	0.36	7.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs1079204	1.000	rs2292549	chr2:219128506	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.63	4.88	0.37	2.7e-6	Smooth-surface caries;
UCEC	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg24851651	chr11:66362959	CCS	0.4	5.13	0.39	9.1e-7	Educational attainment (years of education);
UCEC	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.62	7.13	0.51	4.16e-11	Red blood cell count;
UCEC	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.48	5.97	0.44	1.68e-8	Migraine;
UCEC	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.7	6.52	0.47	1.07e-9	High light scatter reticulocyte count;
UCEC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.53	-6.58	-0.48	7.95e-10	Total body bone mineral density;
UCEC	cis	rs4849887	1.000	rs7598664	chr2:121243526	C/T	cg00421221	chr2:121106091	INHBB	0.43	4.52	0.35	1.26e-5	Breast size;Breast cancer (estrogen-receptor negative);Breast cancer;
UCEC	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.54e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7175404	0.591	rs74379684	chr15:94050205	C/T	cg06054272	chr15:93956988	NA	0.73	4.84	0.37	3.19e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.69	-7.98	-0.55	3.91e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.62	6.99	0.5	9.15e-11	Longevity;Endometriosis;
UCEC	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg09682330	chr6:28411287	ZSCAN23	0.5	5.5	0.41	1.66e-7	Pubertal anthropometrics;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.58	-6.34	-0.46	2.66e-9	Cardiac Troponin-T levels;
UCEC	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	0.97	12.61	0.72	3.65e-25	Platelet distribution width;
UCEC	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-18.54	-0.84	2.53e-40	Exhaled nitric oxide output;
UCEC	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.74	-6.65	-0.48	5.34e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1816854	0.938	rs11182280	chr12:44209584	T/C	cg20956634	chr12:44200518	TWF1	0.49	4.84	0.37	3.21e-6	Inflammatory bowel disease;
UCEC	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg21770322	chr7:97807741	LMTK2	0.45	5.65	0.42	8.23e-8	Prostate cancer (SNP x SNP interaction);
UCEC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.68	-7.69	-0.54	1.91e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.51	6.47	0.47	1.39e-9	Cystic fibrosis severity;
UCEC	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-4.72	-0.36	5.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-0.84	-9.62	-0.62	2.68e-17	Height;
UCEC	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.72	8.45	0.57	2.6e-14	Body mass index;
UCEC	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-10.68	-0.66	4.48e-20	Schizophrenia;
UCEC	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.89	-6.74	-0.49	3.37e-10	Exhaled nitric oxide output;
UCEC	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.85	-9.24	-0.61	2.53e-16	Cognitive function;
UCEC	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg04871131	chr7:94954202	PON1	-0.5	-4.66	-0.36	7.05e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.12	-0.39	9.54e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.89	8.11	0.56	1.8e-13	Bladder cancer;
UCEC	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg09491104	chr22:46646882	C22orf40	-0.48	-4.58	-0.35	9.71e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.88	0.44	2.61e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.45	5.18	0.39	7.11e-7	Blood metabolite ratios;
UCEC	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.85	9.91	0.63	4.71e-18	Blood protein levels;
UCEC	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.55	7.14	0.51	4.02e-11	Bipolar disorder and schizophrenia;
UCEC	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg00339695	chr16:24857497	SLC5A11	0.52	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9283706	0.689	rs1030231	chr5:66317265	A/G	cg11590213	chr5:66331682	MAST4	0.46	4.61	0.36	8.66e-6	Coronary artery disease;
UCEC	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.35	5.29	0.4	4.42e-7	Ulcerative colitis;
UCEC	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.92	9.79	0.63	9.91e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.25	-0.4	5.17e-7	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.6	-5.13	-0.39	8.95e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-5.77	-0.43	4.55e-8	Glomerular filtration rate;
UCEC	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.58	6.85	0.49	1.92e-10	Inhibitory control;
UCEC	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	0.78	4.55	0.35	1.11e-5	IgG glycosylation;
UCEC	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.73	-0.58	5.04e-15	Prevalent atrial fibrillation;
UCEC	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01391022	chr12:122360665	WDR66	-0.39	-4.59	-0.35	9.42e-6	Mean corpuscular volume;
UCEC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-0.65	-8.89	-0.59	2.07e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	1.0	10.91	0.67	1.12e-20	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.62	4.68	0.36	6.41e-6	Cognitive test performance;
UCEC	cis	rs6457821	1.000	rs74413192	chr6:35409168	C/T	cg06087101	chr6:35551932	FKBP5	0.8	5.33	0.4	3.54e-7	Height;
UCEC	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-1.07	-10.78	-0.66	2.52e-20	Lymphocyte counts;
UCEC	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.41	5.94	0.44	1.93e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.5	-4.69	-0.36	6.08e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	11.57	0.69	1.99e-22	Prudent dietary pattern;
UCEC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg26513180	chr16:89883248	FANCA	0.5	4.61	0.36	8.64e-6	Vitiligo;
UCEC	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.03	-12.56	-0.72	4.71e-25	Dilated cardiomyopathy;
UCEC	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-0.65	-8.63	-0.58	9.45e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.78	-8.86	-0.59	2.43e-15	Extraversion;
UCEC	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.16	-14.34	-0.76	1.03e-29	Breast cancer;
UCEC	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg05991184	chr2:219186017	PNKD	0.55	5.93	0.44	2.09e-8	Colorectal cancer;
UCEC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-10.72	-0.66	3.56e-20	Schizophrenia;
UCEC	cis	rs12680875	0.729	rs59631012	chr8:54508563	G/A	cg01911395	chr8:55014377	LYPLA1	-0.76	-5.83	-0.43	3.44e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.94	9.42	0.61	8.73e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs6763768	0.606	rs4687576	chr3:53385418	T/C	cg10956333	chr3:53294961	NA	0.41	4.88	0.37	2.75e-6	Bacterial meningitis;
UCEC	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.09	0.51	5.1e-11	Coffee consumption (cups per day);
UCEC	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.67	-6.67	-0.48	4.8e-10	Coronary artery disease;
UCEC	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.43	-4.92	-0.38	2.27e-6	Prostate cancer;
UCEC	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.52	-4.76	-0.37	4.56e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.47	5.32	0.4	3.78e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.49	6.7	0.48	4.05e-10	Body mass index;
UCEC	cis	rs4588572	0.686	rs4470742	chr5:77657957	T/G	cg11547950	chr5:77652471	NA	0.5	5.08	0.39	1.15e-6	Triglycerides;
UCEC	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.65	-5.8	-0.43	3.97e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg18659153	chr22:29710531	RASL10A	0.41	4.53	0.35	1.22e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.0	-7.43	-0.52	8.18e-12	Body mass index;
UCEC	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.45	4.52	0.35	1.28e-5	Aortic root size;
UCEC	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.62	6.68	0.48	4.61e-10	Platelet count;
UCEC	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.51	6.04	0.45	1.22e-8	Anterior chamber depth;
UCEC	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-5.2	-0.39	6.45e-7	Morning vs. evening chronotype;
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	7.6	0.53	3.14e-12	Platelet count;
UCEC	cis	rs57709857	0.757	rs10103315	chr8:38096587	G/A	cg08167846	chr8:38212404	WHSC1L1	0.47	4.54	0.35	1.17e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.7	8.31	0.57	5.75e-14	Menarche (age at onset);
UCEC	cis	rs10129255	0.560	rs61997579	chr14:107107770	T/A	cg03031183	chr14:106916953	NA	-0.43	-4.63	-0.36	8.06e-6	Kawasaki disease;
UCEC	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	6.27	0.46	3.85e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.44	5.17	0.39	7.43e-7	Alzheimer's disease (late onset);
UCEC	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg23782820	chr8:58130467	NA	0.49	4.57	0.35	1.04e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.64	4.87	0.37	2.83e-6	Gut microbiome composition (summer);
UCEC	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.09	-0.39	1.08e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs253959	0.729	rs1567335	chr5:115501792	C/T	cg23108291	chr5:115420582	COMMD10	-0.47	-4.69	-0.36	6.2e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-10.23	-0.65	6.78e-19	Mortality in heart failure;
UCEC	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg26898376	chr11:64110657	CCDC88B	0.44	5.6	0.42	9.99e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.58	4.65	0.36	7.31e-6	Skin colour saturation;
UCEC	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.55	5.7	0.43	6.34e-8	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	0.88	5.35	0.4	3.37e-7	Skin colour saturation;
UCEC	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.0	-8.34	-0.57	4.85e-14	White matter hyperintensity burden;
UCEC	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.7	7.08	0.5	5.45e-11	Type 2 diabetes;
UCEC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-6.63	-0.48	5.98e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-5.07	-0.39	1.2e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.6	5.23	0.4	5.63e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-7.69	-0.54	1.95e-12	Parkinson's disease;
UCEC	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.72	-0.43	5.66e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.52	-5.66	-0.42	7.53e-8	Menarche (age at onset);
UCEC	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg24892309	chr3:52724568	GNL3;SNORD19B	0.42	4.7	0.36	6.03e-6	Body mass index;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.43	4.64	0.36	7.63e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs10949834	0.529	rs150861	chr7:73524901	T/C	cg07137043	chr7:73588983	EIF4H	0.59	4.8	0.37	3.91e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs3015497	0.616	rs1494181	chr14:51056600	C/T	cg04730355	chr14:51134070	SAV1	-0.45	-4.67	-0.36	6.62e-6	Mean platelet volume;
UCEC	cis	rs1978968	0.763	rs34364976	chr22:18462027	C/T	cg03078520	chr22:18463400	MICAL3	-0.55	-6.61	-0.48	6.56e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.9	8.67	0.58	7.15e-15	Testicular germ cell tumor;
UCEC	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.31	4.7	0.36	6e-6	Blood metabolite levels;
UCEC	cis	rs10743315	0.547	rs7310796	chr12:19362390	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.54	-5.25	-0.4	5.32e-7	Gut microbiota (bacterial taxa);
UCEC	cis	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg12524725	chr2:239427019	NA	-0.67	-4.53	-0.35	1.21e-5	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs17764205	0.778	rs4807430	chr19:3244216	C/T	cg09528496	chr19:3881225	ATCAY	-0.62	-4.74	-0.36	4.89e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-5.66	-0.42	7.85e-8	Hepatocellular carcinoma;
UCEC	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.76	0.37	4.6e-6	Cognitive ability;
UCEC	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg10596483	chr8:143751796	JRK	-0.45	-4.64	-0.36	7.58e-6	Schizophrenia;
UCEC	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.57	-5.5	-0.41	1.6e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs732765	0.734	rs12323528	chr14:75152068	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.56	-4.93	-0.38	2.24e-6	Non-small cell lung cancer;
UCEC	cis	rs10016947	1.000	rs6837313	chr4:104303518	A/C	cg05605371	chr4:103940876	NHEDC1	-0.77	-4.56	-0.35	1.08e-5	Breast cancer;
UCEC	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.99	6.7	0.48	4.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.47	4.56	0.35	1.08e-5	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.38	5.53	0.41	1.44e-7	Rheumatoid arthritis;
UCEC	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-5.35	-0.4	3.32e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7432375	0.519	rs34799319	chr3:136586618	G/A	cg21827317	chr3:136751795	NA	0.47	4.66	0.36	7.03e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg02951883	chr7:2050386	MAD1L1	-0.5	-4.54	-0.35	1.17e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.48	5.24	0.4	5.45e-7	Tonsillectomy;
UCEC	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.16	-12.07	-0.71	9.84e-24	Ulcerative colitis;
UCEC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.48	5.54	0.42	1.33e-7	Vitiligo;
UCEC	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.52	4.64	0.36	7.51e-6	Cholesterol, total;
UCEC	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.77	7.65	0.53	2.37e-12	Menopause (age at onset);
UCEC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.44	0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.9	9.45	0.61	7.57e-17	Cognitive function;
UCEC	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.29	0.56	6.6e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	4.53	0.35	1.22e-5	Height;
UCEC	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-7.43	-0.52	8.09e-12	Morning vs. evening chronotype;
UCEC	cis	rs9467773	1.000	rs9467800	chr6:26578525	A/C	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs4372836	0.658	rs10178852	chr2:28997835	C/T	cg09522027	chr2:28974177	PPP1CB	-0.55	-5.62	-0.42	9.2e-8	Body mass index;
UCEC	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.76	-7.0	-0.5	8.31e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.54	7.75	0.54	1.4e-12	Multiple system atrophy;
UCEC	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.48	5.4	0.41	2.66e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7517126	1.000	rs56300393	chr1:196841394	G/A	cg07209298	chr1:196795943	CFHR1	0.5	5.07	0.39	1.18e-6	Blood protein levels;
UCEC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	6.6	0.48	6.98e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.64	-5.89	-0.44	2.56e-8	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
UCEC	cis	rs6717918	0.509	rs3116173	chr2:233006046	C/T	cg02061626	chr2:233274167	ALPPL2	-0.52	-5.71	-0.43	6.12e-8	Height;
UCEC	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.47	4.52	0.35	1.28e-5	Resting heart rate;
UCEC	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	0.98	14.29	0.76	1.32e-29	Homoarginine levels;
UCEC	cis	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.71	6.81	0.49	2.31e-10	Alzheimer's disease;
UCEC	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.61	-6.27	-0.46	3.84e-9	Dilated cardiomyopathy;
UCEC	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.7	6.56	0.48	8.52e-10	Migraine;Coronary artery disease;
UCEC	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.57	-4.61	-0.36	8.73e-6	Menopause (age at onset);
UCEC	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg11871910	chr12:69753446	YEATS4	-0.66	-5.51	-0.41	1.54e-7	Response to diuretic therapy;
UCEC	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.56	-6.52	-0.47	1.08e-9	Educational attainment;
UCEC	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.52	5.01	0.38	1.57e-6	Menopause (age at onset);
UCEC	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.36	4.62	0.36	8.16e-6	Depression;
UCEC	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	0.87	7.53	0.53	4.65e-12	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	trans	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg25482853	chr8:67687455	SGK3	1.04	7.33	0.52	1.45e-11	Obesity-related traits;
UCEC	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	5.78	0.43	4.33e-8	Colorectal cancer;
UCEC	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg18681998	chr4:17616180	MED28	0.79	9.26	0.61	2.32e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.64	-5.01	-0.38	1.52e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.16	-13.75	-0.75	3.6e-28	Breast cancer;
UCEC	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.79	-0.37	3.97e-6	Height;
UCEC	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.55	4.82	0.37	3.56e-6	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg11839771	chr15:80205821	ST20	-0.44	-4.68	-0.36	6.36e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-5.47	-0.41	1.9e-7	Multiple sclerosis;
UCEC	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.56	4.87	0.37	2.81e-6	Bipolar disorder;
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	6.24	0.46	4.5e-9	Platelet count;
UCEC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.45	4.52	0.35	1.27e-5	Vitiligo;
UCEC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.71	-7.15	-0.51	3.72e-11	Aortic root size;
UCEC	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.69	-8.67	-0.58	7.17e-15	Body mass index;
UCEC	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.75	9.12	0.6	5.28e-16	Menarche (age at onset);
UCEC	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	4.53	0.35	1.22e-5	Height;
UCEC	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.56	6.61	0.48	6.64e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.39	-4.99	-0.38	1.65e-6	Dilated cardiomyopathy;
UCEC	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg21770322	chr7:97807741	LMTK2	0.46	5.79	0.43	4.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	0.79	5.24	0.4	5.56e-7	Diabetic retinopathy;
UCEC	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.51	4.61	0.36	8.84e-6	Lymphocyte counts;
UCEC	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg23791538	chr6:167370224	RNASET2	0.57	5.93	0.44	2.06e-8	Primary biliary cholangitis;
UCEC	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	8.05	0.55	2.51e-13	Bone mineral density;
UCEC	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg10806820	chr3:48699090	CELSR3	0.76	4.89	0.37	2.63e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.6	4.85	0.37	3.07e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.54	5.71	0.43	5.94e-8	Pulse pressure;
UCEC	cis	rs4851266	1.000	rs2871344	chr2:100839430	A/G	cg14675211	chr2:100938903	LONRF2	0.57	5.53	0.42	1.41e-7	Educational attainment;
UCEC	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.81	-5.39	-0.41	2.7e-7	Rheumatoid arthritis;
UCEC	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.75	-7.6	-0.53	3.22e-12	Body mass index;
UCEC	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.52	-5.98	-0.44	1.62e-8	Lung cancer;
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-6.21	-0.46	5.16e-9	Platelet count;
UCEC	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.03	-8.28	-0.56	7.04e-14	Exhaled nitric oxide output;
UCEC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.71	7.49	0.53	5.83e-12	Breast cancer;
UCEC	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	1.02	5.51	0.41	1.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.67	5.04	0.38	1.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.45	-4.55	-0.35	1.09e-5	Platelet count;
UCEC	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.81	7.65	0.53	2.44e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.45	5.71	0.43	5.93e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.9	10.69	0.66	4.36e-20	Menarche (age at onset);
UCEC	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg01395667	chr1:17020878	ESPNP	-0.42	-4.51	-0.35	1.32e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.62	6.76	0.49	3.1e-10	Neuroticism;
UCEC	cis	rs2299682	0.826	rs6086908	chr20:9468661	G/A	cg11931762	chr20:9488920	NA	-0.73	-5.86	-0.43	2.97e-8	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.7	5.69	0.42	6.74e-8	Major depressive disorder;
UCEC	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg04043695	chr12:129287642	SLC15A4	0.66	6.52	0.47	1.08e-9	Systemic lupus erythematosus;
UCEC	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.82	-0.63	8.01e-18	Blood metabolite levels;
UCEC	cis	rs12643440	0.960	rs16894651	chr4:17208345	C/T	cg02108033	chr4:17783294	FAM184B	-0.55	-4.7	-0.36	6e-6	Metabolite levels (Pyroglutamine);
UCEC	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg03714773	chr7:91764589	CYP51A1	0.42	4.9	0.37	2.5e-6	Breast cancer;
UCEC	cis	rs7830371	0.545	rs2978508	chr8:62108954	C/T	cg06554036	chr8:61834534	NA	-0.4	-4.84	-0.37	3.2e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	6.07	0.45	1.01e-8	Lymphocyte percentage of white cells;
UCEC	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.06	-8.18	-0.56	1.24e-13	Hip circumference adjusted for BMI;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.48	-4.87	-0.37	2.87e-6	Pubertal anthropometrics;
UCEC	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg13683864	chr3:40499215	RPL14	-0.67	-6.8	-0.49	2.45e-10	Renal cell carcinoma;
UCEC	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg00651523	chr6:28411279	ZSCAN23	-0.54	-5.97	-0.44	1.71e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12379764	chr21:47803548	PCNT	0.44	4.87	0.37	2.85e-6	Testicular germ cell tumor;
UCEC	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.43	4.83	0.37	3.36e-6	Mean corpuscular volume;
UCEC	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.4	4.55	0.35	1.11e-5	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.77	-8.73	-0.58	5.09e-15	Height;
UCEC	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.69	-0.58	6.53e-15	Total cholesterol levels;
UCEC	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.21	7.55	0.53	4.22e-12	Atopic dermatitis;
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg09120320	chr17:61926383	NA	0.45	4.7	0.36	5.95e-6	Prudent dietary pattern;
UCEC	cis	rs4879656	0.564	rs20583	chr9:33026572	T/C	cg09633881	chr9:33002021	APTX	-0.38	-4.66	-0.36	6.97e-6	Menopause (age at onset);
UCEC	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg24069376	chr3:38537580	EXOG	-0.39	-4.88	-0.37	2.73e-6	Electrocardiographic conduction measures;
UCEC	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-0.99	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	7.77	0.54	1.23e-12	Smoking behavior;
UCEC	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-12.79	-0.73	1.19e-25	Exhaled nitric oxide levels;
UCEC	cis	rs2288327	0.818	rs3829748	chr2:179396354	G/A	cg09915519	chr2:179397513	TTN;MIR548N	-0.68	-4.69	-0.36	6.25e-6	Atrial fibrillation;
UCEC	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.88	0.49	1.6e-10	Cognitive test performance;
UCEC	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.64	0.42	8.27e-8	Cognitive test performance;
UCEC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.71	7.16	0.51	3.61e-11	Aortic root size;
UCEC	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg11632617	chr15:75315747	PPCDC	-0.67	-7.72	-0.54	1.62e-12	Lung cancer;
UCEC	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg08886695	chr4:3369023	RGS12	0.51	5.57	0.42	1.2e-7	Parental longevity (mother's age at death);
UCEC	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.66	5.81	0.43	3.74e-8	Coronary artery disease;
UCEC	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg01112020	chr2:239008986	ESPNL	-0.36	-4.75	-0.36	4.8e-6	Prostate cancer;
UCEC	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-10.9	-0.67	1.24e-20	Headache;
UCEC	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.65	4.61	0.36	8.66e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg12253828	chr6:101329408	ASCC3	0.47	4.67	0.36	6.74e-6	Neuroticism;
UCEC	cis	rs72774609	0.619	rs4925747	chr1:248036554	A/G	cg04309258	chr1:247267873	ZNF669	0.45	4.63	0.36	8.14e-6	Red cell distribution width;
UCEC	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.75	4.81	0.37	3.78e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	5.63	0.42	8.73e-8	Cognitive test performance;
UCEC	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.4	6.03	0.45	1.29e-8	Body mass index;
UCEC	cis	rs11867410	0.744	rs8077072	chr17:63931665	G/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	0.95	6.37	0.46	2.31e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.9	9.11	0.6	5.47e-16	Heart rate;
UCEC	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg05855489	chr10:104503620	C10orf26	0.54	4.53	0.35	1.19e-5	Waist circumference;Hip circumference;
UCEC	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg20821713	chr7:1055600	C7orf50	-0.73	-7.17	-0.51	3.41e-11	Bronchopulmonary dysplasia;
UCEC	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.54	4.84	0.37	3.24e-6	Lung cancer;
UCEC	cis	rs4654899	0.865	rs6673455	chr1:21361048	T/C	cg01072550	chr1:21505969	NA	-0.52	-4.86	-0.37	2.92e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.61	8.56	0.58	1.34e-14	Prudent dietary pattern;
UCEC	cis	rs2862064	1.000	rs7706978	chr5:156432566	T/C	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.73	-0.43	5.52e-8	Platelet count;
UCEC	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.99	-11.91	-0.7	2.6e-23	Cognitive function;
UCEC	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg11150807	chr10:43354902	NA	0.78	6.42	0.47	1.78e-9	Blood protein levels;
UCEC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.64	-0.36	7.75e-6	Blood protein levels;
UCEC	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.79e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.64	5.53	0.42	1.4e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.93	10.77	0.66	2.6e-20	Breast cancer;
UCEC	trans	rs3769124	0.513	rs6755460	chr2:239490760	G/A	cg17833746	chr17:40489785	STAT3	0.61	6.84	0.49	1.98e-10	Pulmonary function;
UCEC	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-6.33	-0.46	2.81e-9	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.57	-5.5	-0.41	1.6e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg05090351	chr10:126851162	NA	0.43	4.97	0.38	1.81e-6	Menarche (age at onset);
UCEC	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.6	-5.42	-0.41	2.34e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.66	-6.51	-0.47	1.09e-9	Aortic root size;
UCEC	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.57	6.19	0.45	5.68e-9	Height;
UCEC	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.4	5.77	0.43	4.53e-8	Crohn's disease;
UCEC	trans	rs4389974	0.932	rs1896862	chr8:112408023	C/T	cg22736090	chr17:62339926	TEX2	0.66	6.84	0.49	1.93e-10	Body mass index;
UCEC	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.44	-4.76	-0.37	4.67e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6882716	0.591	rs10044607	chr5:10806058	G/A	cg14521931	chr5:10832172	NA	-0.64	-5.42	-0.41	2.38e-7	Alcohol consumption (maxi-drinks);
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.27	-0.46	3.83e-9	Prudent dietary pattern;
UCEC	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Bladder cancer;
UCEC	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.81	-9.14	-0.6	4.6e-16	Blood protein levels;
UCEC	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.76	7.68	0.53	2.1e-12	Cognitive function;
UCEC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	4.51	0.35	1.3e-5	Height;
UCEC	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.56	5.07	0.39	1.2e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg09120320	chr17:61926383	NA	0.44	4.63	0.36	7.88e-6	Prudent dietary pattern;
UCEC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.64	-6.7	-0.48	4.15e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.0	-0.44	1.43e-8	Blood metabolite levels;
UCEC	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg19041857	chr6:27730383	NA	-0.68	-4.94	-0.38	2.08e-6	Breast cancer;
UCEC	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg04374321	chr14:90722782	PSMC1	-0.63	-5.82	-0.43	3.64e-8	Mortality in heart failure;
UCEC	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.43	6.37	0.47	2.3e-9	Crohn's disease;
UCEC	cis	rs600806	0.745	rs12136063	chr1:110014170	A/G	cg23032129	chr1:109941072	SORT1	0.31	4.54	0.35	1.15e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.56	-5.65	-0.42	8.22e-8	Hepatocellular carcinoma;
UCEC	cis	rs4523957	0.786	rs28524880	chr17:2125444	C/A	cg16513277	chr17:2031491	SMG6	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.52	4.69	0.36	6.13e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.42	-0.47	1.76e-9	Schizophrenia;
UCEC	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.06	-0.45	1.09e-8	Metabolite levels;
UCEC	cis	rs9341808	0.644	rs59371711	chr6:80942027	G/T	cg08355045	chr6:80787529	NA	-0.4	-5.02	-0.38	1.46e-6	Sitting height ratio;
UCEC	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.5	4.97	0.38	1.87e-6	Dupuytren's disease;
UCEC	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.62	6.26	0.46	4.1e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg10503236	chr1:231470652	EXOC8	0.37	4.57	0.35	1.03e-5	Hemoglobin concentration;
UCEC	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg03354898	chr7:1950403	MAD1L1	-0.53	-6.31	-0.46	3.18e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.68	-6.34	-0.46	2.65e-9	Aortic root size;
UCEC	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	1.0	8.01	0.55	3.21e-13	Pediatric areal bone mineral density (radius);
UCEC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.42	-5.17	-0.39	7.59e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-0.84	-9.62	-0.62	2.68e-17	Height;
UCEC	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	1.02	11.56	0.69	2.21e-22	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-6.02	-0.44	1.36e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg19743168	chr1:23544995	NA	0.47	6.1	0.45	8.74e-9	Height;
UCEC	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.82	-11.43	-0.69	4.74e-22	Post bronchodilator FEV1;
UCEC	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.54	5.04	0.38	1.35e-6	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg22563815	chr15:78856949	CHRNA5	-0.37	-4.9	-0.37	2.48e-6	Sudden cardiac arrest;
UCEC	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.8	-7.51	-0.53	5.39e-12	Strep throat;
UCEC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.4	-4.67	-0.36	6.82e-6	Bipolar disorder;
UCEC	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-13.17	-0.74	1.19e-26	Height;
UCEC	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.85	-12.09	-0.71	8.58e-24	Urate levels in lean individuals;
UCEC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.64	0.36	7.57e-6	Breast cancer;
UCEC	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.53	-6.6	-0.48	6.84e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg07386859	chr16:1872102	HAGH	-0.46	-5.01	-0.38	1.56e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.34	-8.75	-0.59	4.66e-15	Diabetic kidney disease;
UCEC	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	0.83	10.43	0.65	2.02e-19	Bone mineral density;
UCEC	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.73	8.63	0.58	9.01e-15	Prudent dietary pattern;
UCEC	cis	rs7175404	0.536	rs61557432	chr15:94053938	A/G	cg06054272	chr15:93956988	NA	0.67	4.8	0.37	3.9e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.7	-6.81	-0.49	2.34e-10	Ovarian reserve;
UCEC	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.58	-5.31	-0.4	3.98e-7	Metabolite levels;
UCEC	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-4.87	-0.37	2.84e-6	Bipolar disorder;
UCEC	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-6.22	-0.46	4.98e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.55	5.93	0.44	2.11e-8	Neuroticism;
UCEC	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24308560	chr3:49941425	MST1R	0.45	4.85	0.37	3.13e-6	Body mass index;
UCEC	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.63	-5.04	-0.38	1.37e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs4654899	0.802	rs12137203	chr1:21109088	T/A	cg01072550	chr1:21505969	NA	-0.5	-4.79	-0.37	3.95e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.68	-6.91	-0.5	1.37e-10	Colorectal cancer;
UCEC	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.11	10.02	0.64	2.43e-18	Vitiligo;
UCEC	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg08213375	chr14:104286397	PPP1R13B	0.33	4.78	0.37	4.18e-6	Schizophrenia;
UCEC	cis	rs7246967	0.604	rs8111899	chr19:22898871	C/T	cg08271804	chr19:22816896	ZNF492	0.71	4.74	0.36	5.07e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-7.54	-0.53	4.41e-12	Menarche (age at onset);
UCEC	trans	rs9313296	0.661	rs2644723	chr5:165522554	C/G	cg03539051	chr19:56418660	NLRP13	-1.08	-6.85	-0.49	1.86e-10	Weight;Waist circumference;
UCEC	cis	rs77926410	0.685	rs1851072	chr12:10633958	A/C	cg25023291	chr12:11339792	TAS2R42	-0.41	-5.05	-0.38	1.27e-6	Mean corpuscular volume;
UCEC	cis	rs1949733	1.000	rs6858542	chr4:8511547	C/G	cg11789530	chr4:8429930	ACOX3	-0.79	-7.62	-0.53	2.95e-12	Response to antineoplastic agents;
UCEC	cis	rs11958404	0.932	rs72816543	chr5:157416464	A/G	cg05962755	chr5:157440814	NA	0.64	4.76	0.37	4.68e-6	IgG glycosylation;
UCEC	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.72	-6.66	-0.48	5.22e-10	Aortic root size;
UCEC	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg24308560	chr3:49941425	MST1R	0.44	4.75	0.37	4.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.34	4.71	0.36	5.62e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs883565	0.569	rs784513	chr3:39164915	G/A	cg01426195	chr3:39028469	NA	0.62	7.39	0.52	1.01e-11	Handedness;
UCEC	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.52	5.36	0.4	3.21e-7	Blood metabolite levels;
UCEC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.7	-7.66	-0.53	2.32e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-7.0	-0.5	8.56e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg20113888	chr7:100732273	TRIM56	-0.57	-6.92	-0.5	1.32e-10	N-glycan levels;
UCEC	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	8.82	0.59	3.06e-15	Coffee consumption (cups per day);
UCEC	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.38	4.65	0.36	7.31e-6	Menarche (age at onset);
UCEC	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg00815214	chr21:47717953	NA	-0.4	-4.66	-0.36	7e-6	Testicular germ cell tumor;
UCEC	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg02158880	chr13:53174818	NA	-0.5	-5.79	-0.43	4.08e-8	Lewy body disease;
UCEC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.94	10.92	0.67	1.04e-20	Breast cancer;
UCEC	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg16164276	chr3:11034345	SLC6A1	-0.48	-4.61	-0.36	8.75e-6	Alzheimer's disease;
UCEC	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.6	-6.09	-0.45	9.52e-9	Endometrial cancer;
UCEC	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg18827107	chr12:86230957	RASSF9	0.41	4.62	0.36	8.36e-6	Major depressive disorder;
UCEC	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.53	5.22	0.4	5.91e-7	Neuroticism;
UCEC	cis	rs10256972	0.657	rs4311576	chr7:1010285	C/G	cg04102894	chr7:1000210	NA	-0.31	-4.51	-0.35	1.3e-5	Longevity;Endometriosis;
UCEC	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.67	0.36	6.87e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg23950597	chr19:37808831	NA	-0.65	-5.06	-0.39	1.22e-6	Coronary artery calcification;
UCEC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.88	-10.06	-0.64	1.89e-18	Cognitive function;
UCEC	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	6.37	0.47	2.27e-9	Hip circumference;
UCEC	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.57	5.07	0.39	1.19e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.62	6.99	0.5	8.98e-11	Tonsillectomy;
UCEC	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.83	-8.06	-0.55	2.49e-13	Acne (severe);
UCEC	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.44	5.25	0.4	5.32e-7	Metabolite levels;
UCEC	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-0.91	-11.49	-0.69	3.23e-22	Coronary artery disease;
UCEC	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg24562669	chr7:97807699	LMTK2	-0.45	-5.31	-0.4	4.01e-7	Breast cancer;
UCEC	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.43	5.83	0.43	3.47e-8	Alcohol dependence;
UCEC	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.67	5.8	0.43	3.89e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.0	-0.38	1.58e-6	Resting heart rate;
UCEC	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg10845886	chr2:3471009	TTC15	-0.53	-4.66	-0.36	7.11e-6	Neurofibrillary tangles;
UCEC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	0.97	5.32	0.4	3.83e-7	IgG glycosylation;
UCEC	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg21214455	chr15:72412075	SENP8	0.47	4.73	0.36	5.22e-6	Red blood cell count;
UCEC	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-9.05	-0.6	8.1e-16	Chronic sinus infection;
UCEC	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs10899021	1.000	rs11236202	chr11:74376692	A/G	cg25880958	chr11:74394337	NA	-0.72	-4.64	-0.36	7.54e-6	Response to metformin (IC50);
UCEC	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.79	-7.99	-0.55	3.54e-13	Parkinson's disease;
UCEC	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg01451880	chr3:45801044	SLC6A20	0.41	5.44	0.41	2.19e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.74	7.93	0.55	5.09e-13	Mood instability;
UCEC	cis	rs4588572	0.601	rs4305631	chr5:77668698	G/T	cg11547950	chr5:77652471	NA	0.5	5.08	0.39	1.15e-6	Triglycerides;
UCEC	cis	rs12086130	0.892	rs72904788	chr1:51415247	T/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.26	-0.4	4.96e-7	Hip circumference adjusted for BMI;Hip circumference;
UCEC	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.54	-6.87	-0.49	1.69e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	1.08	13.99	0.76	8.42e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
UCEC	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.83	-7.2	-0.51	2.83e-11	Vitiligo;
UCEC	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg21856205	chr7:94953877	PON1	-0.53	-4.76	-0.37	4.68e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.65	-4.69	-0.36	6.14e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.49	4.8	0.37	3.92e-6	Lung cancer (smoking interaction);
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.76	-0.43	4.79e-8	Depression;
UCEC	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.69	6.8	0.49	2.51e-10	Blood protein levels;
UCEC	cis	rs1150668	0.799	rs1736891	chr6:28187101	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.57	-6.42	-0.47	1.74e-9	Pubertal anthropometrics;
UCEC	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.67	6.73	0.49	3.47e-10	Morning vs. evening chronotype;
UCEC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg01256987	chr12:42539512	GXYLT1	-0.49	-5.66	-0.42	7.83e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9715521	0.868	rs62301181	chr4:59834246	A/G	cg11281224	chr4:60001000	NA	-0.58	-5.91	-0.44	2.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs925550	1.000	rs9685849	chr4:123588318	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.57	-5.1	-0.39	1.04e-6	Primary biliary cholangitis;
UCEC	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.48	-4.97	-0.38	1.88e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.72	0.43	5.66e-8	Breast cancer;
UCEC	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg24562669	chr7:97807699	LMTK2	-0.42	-5.03	-0.38	1.42e-6	Breast cancer;
UCEC	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.6	7.03	0.5	7.1e-11	Total cholesterol levels;
UCEC	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	7.65	0.53	2.41e-12	Tonsillectomy;
UCEC	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.75	-9.12	-0.6	5.37e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.52	-5.96	-0.44	1.83e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.58	-4.96	-0.38	1.89e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.47	4.65	0.36	7.28e-6	Aortic root size;
UCEC	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.8	-0.37	3.83e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.58	6.43	0.47	1.68e-9	Prostate cancer;
UCEC	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.49	-4.6	-0.36	8.88e-6	Blood trace element (Cu levels);
UCEC	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg21419209	chr3:44054225	NA	-0.5	-5.34	-0.4	3.43e-7	Coronary artery disease;
UCEC	cis	rs6704644	0.510	rs10153744	chr2:234280729	A/G	cg16719865	chr2:234394478	USP40	-0.53	-4.54	-0.35	1.16e-5	Bilirubin levels;
UCEC	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.75	9.16	0.6	4.22e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.65	6.98	0.5	9.43e-11	Menopause (age at onset);
UCEC	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg23093090	chr10:104574429	C10orf26	0.5	5.51	0.41	1.56e-7	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.29	0.4	4.44e-7	Breast cancer;
UCEC	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.64	-5.3	-0.4	4.14e-7	Alopecia areata;
UCEC	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.82	7.31	0.52	1.57e-11	Bladder cancer;
UCEC	cis	rs787274	1.000	rs787275	chr9:115550523	C/G	cg13803584	chr9:115635662	SNX30	-0.69	-5.21	-0.39	6.36e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.0	-8.21	-0.56	1.03e-13	White matter hyperintensity burden;
UCEC	trans	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg15509575	chr4:2286509	ZFYVE28	0.41	7.19	0.51	3.08e-11	Rheumatoid arthritis;
UCEC	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.78	4.55	0.35	1.12e-5	Cognitive function;
UCEC	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.6	5.59	0.42	1.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs41271951	0.512	rs114222784	chr1:151084781	C/T	cg00107782	chr1:151300621	NA	-0.68	-4.58	-0.35	9.72e-6	Blood protein levels;
UCEC	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.5	4.81	0.37	3.7e-6	Endometrial cancer;
UCEC	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.53	-5.68	-0.42	7.12e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.5	4.61	0.36	8.5e-6	Menarche (age at onset);
UCEC	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.59	0.62	3.21e-17	Gut microbiome composition (summer);
UCEC	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-4.51	-0.35	1.32e-5	Mood instability;
UCEC	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-5.98	-0.44	1.64e-8	Prostate cancer;
UCEC	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg14008862	chr17:28927542	LRRC37B2	0.69	5.12	0.39	9.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.64	6.39	0.47	2.01e-9	Itch intensity from mosquito bite;
UCEC	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.77	-7.32	-0.52	1.53e-11	Initial pursuit acceleration;
UCEC	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.56	-4.94	-0.38	2.14e-6	Lung disease severity in cystic fibrosis;
UCEC	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	1.15	11.56	0.69	2.15e-22	Body mass index;
UCEC	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.52	0.41	1.49e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.59	-5.97	-0.44	1.71e-8	Strep throat;
UCEC	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.51	4.88	0.37	2.69e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4757319	0.515	rs7109366	chr11:15438964	T/C	cg03245590	chr11:15329459	NA	0.42	4.7	0.36	5.81e-6	Breast cancer;
UCEC	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	6.0	0.44	1.47e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6893207	1.000	rs80145286	chr5:16404550	G/A	cg11584519	chr5:16175867	MARCH11	0.64	4.69	0.36	6.1e-6	Attention function in attention deficit hyperactive disorder;
UCEC	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06505273	chr16:24850292	NA	0.5	4.64	0.36	7.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.68	-6.67	-0.48	4.77e-10	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	5.37	0.41	2.97e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.51	-5.0	-0.38	1.59e-6	Red cell distribution width;
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.67	8.41	0.57	3.24e-14	Menarche (age at onset);
UCEC	cis	rs12618769	0.652	rs3769708	chr2:99187650	T/C	cg10123293	chr2:99228465	UNC50	0.47	5.34	0.4	3.48e-7	Bipolar disorder;
UCEC	cis	rs4654899	0.655	rs4654883	chr1:21213708	C/T	cg01072550	chr1:21505969	NA	0.55	5.91	0.44	2.28e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.3	-0.46	3.27e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.59	5.49	0.41	1.7e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	0.83	5.67	0.42	7.33e-8	Iron status biomarkers;
UCEC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.54	5.45	0.41	2.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4687718	0.929	rs62255995	chr3:53279830	A/G	cg19378537	chr3:53290327	TKT	0.73	4.51	0.35	1.33e-5	QRS duration;
UCEC	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.59	6.21	0.46	5.16e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12680875	0.872	rs66523251	chr8:54509117	C/G	cg01911395	chr8:55014377	LYPLA1	-0.77	-5.91	-0.44	2.26e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	8.09	0.56	2.04e-13	Ileal carcinoids;
UCEC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg14078730	chr11:63896557	MACROD1	0.67	5.21	0.39	6.28e-7	Mean platelet volume;
UCEC	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg18681998	chr4:17616180	MED28	0.53	5.87	0.44	2.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.59	5.48	0.41	1.79e-7	Coronary artery disease;
UCEC	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.49	5.62	0.42	9.46e-8	Eosinophil percentage of white cells;
UCEC	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.19	0.39	6.87e-7	Cognitive test performance;
UCEC	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.2e-7	Schizophrenia;
UCEC	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-8.54	-0.58	1.58e-14	Vitiligo;
UCEC	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.68	6.87	0.49	1.73e-10	Coronary artery disease;
UCEC	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.74	6.6	0.48	7.12e-10	Coronary artery disease;
UCEC	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg24562669	chr7:97807699	LMTK2	0.5	6.08	0.45	9.94e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg17077180	chr1:38461687	NA	-0.45	-4.54	-0.35	1.17e-5	Coronary artery disease;
UCEC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.53	6.04	0.45	1.22e-8	Alcohol dependence;
UCEC	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-5.92	-0.44	2.13e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg11153328	chr22:36877737	TXN2	-0.55	-4.97	-0.38	1.84e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17106184	1.000	rs72904723	chr1:51334304	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.47	-4.76	-0.37	4.5e-6	Dental caries;
UCEC	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.48	5.43	0.41	2.27e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7766436	0.885	rs5010014	chr6:22587299	A/G	cg13666174	chr6:22585274	NA	-0.5	-5.33	-0.4	3.6e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.88	9.75	0.63	1.28e-17	Breast cancer;
UCEC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.42	4.89	0.37	2.57e-6	Height;
UCEC	cis	rs4919044	0.641	rs7905234	chr10:94719384	A/G	cg00519463	chr10:94352821	KIF11	0.8	4.53	0.35	1.2e-5	Coronary artery disease;
UCEC	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-5.3	-0.4	4.17e-7	Initial pursuit acceleration;
UCEC	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	0.97	10.71	0.66	3.89e-20	Corneal structure;
UCEC	cis	rs1483890	0.723	rs34184121	chr3:69411426	A/T	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.46	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-8.33	-0.57	5.29e-14	Colorectal cancer;
UCEC	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.53	-6.39	-0.47	2.09e-9	Fibrinogen levels;
UCEC	cis	rs4448343	0.963	rs10512248	chr9:98259703	A/C	cg13456470	chr9:98266766	PTCH1	0.35	4.96	0.38	1.92e-6	Height;
UCEC	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.66	6.08	0.45	9.97e-9	Aortic root size;
UCEC	cis	rs256277	0.790	rs1494585	chr5:111294346	A/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.44	-4.7	-0.36	6e-6	Coronary artery disease;
UCEC	cis	rs11118844	0.744	rs6655994	chr1:221933888	A/G	cg04222084	chr1:221915650	DUSP10	-0.68	-5.84	-0.43	3.16e-8	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.84	-5.59	-0.42	1.08e-7	Metabolite levels (HVA/5-HIAA ratio);
UCEC	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg24505687	chr6:33548425	BAK1	0.51	5.87	0.44	2.77e-8	Platelet count;
UCEC	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.63	9.25	0.61	2.4e-16	Prudent dietary pattern;
UCEC	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.47	4.63	0.36	7.98e-6	Colorectal cancer;
UCEC	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.58	5.92	0.44	2.18e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs7246967	0.611	rs56276210	chr19:22899643	A/G	cg08271804	chr19:22816896	ZNF492	0.71	4.69	0.36	6.09e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg14992524	chr8:10586135	SOX7	0.3	4.63	0.36	7.94e-6	Neuroticism;
UCEC	cis	rs12481680	0.834	rs6099810	chr20:56443634	G/T	cg02468966	chr20:56287198	PMEPA1	0.42	4.61	0.36	8.51e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs829661	0.901	rs829663	chr2:30726536	T/A	cg17749961	chr2:30669863	LCLAT1	0.52	4.83	0.37	3.45e-6	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7095607	1.000	rs7095607	chr10:69957350	G/A	cg18986048	chr10:69913749	MYPN	0.46	5.03	0.38	1.42e-6	Lung function (FVC);
UCEC	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.14	-0.45	7.44e-9	Birth weight;
UCEC	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.51	-4.98	-0.38	1.74e-6	Refractive error;
UCEC	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.67	10.01	0.64	2.55e-18	Height;
UCEC	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.63	6.0	0.44	1.46e-8	Aortic root size;
UCEC	cis	rs5770917	1.000	rs2269384	chr22:51011115	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.73	-4.86	-0.37	2.93e-6	Narcolepsy;
UCEC	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg24375607	chr4:120327624	NA	0.48	5.35	0.4	3.36e-7	Educational attainment;
UCEC	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.54	6.04	0.45	1.2e-8	Hip circumference;
UCEC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18252515	chr7:66147081	NA	0.55	5.3	0.4	4.17e-7	Aortic root size;
UCEC	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.47	4.59	0.35	9.38e-6	Motion sickness;
UCEC	cis	rs925550	1.000	rs991290	chr4:123592856	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	-0.57	-5.07	-0.39	1.16e-6	Primary biliary cholangitis;
UCEC	cis	rs17106184	1.000	rs72904709	chr1:51306002	A/G	cg07174182	chr1:51127561	FAF1	-0.78	-5.0	-0.38	1.64e-6	Type 2 diabetes;
UCEC	cis	rs7246967	0.611	rs12984903	chr19:22833881	A/G	cg24889512	chr19:22816950	ZNF492	0.58	6.19	0.45	5.82e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.68	5.85	0.43	3.09e-8	Blood metabolite levels;
UCEC	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	12.52	0.72	6.35e-25	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg02851062	chr11:122848983	BSX	0.36	4.71	0.36	5.8e-6	Menarche (age at onset);
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.89	10.54	0.66	1.06e-19	Menarche (age at onset);
UCEC	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	8.22	0.56	9.74e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.12	9.6	0.62	3.07e-17	Uric acid levels;
UCEC	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg13334819	chr7:99746414	C7orf59	-0.54	-5.34	-0.4	3.49e-7	Coronary artery disease;
UCEC	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.7	-8.69	-0.58	6.39e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg21231944	chr12:82153410	PPFIA2	-0.44	-4.58	-0.35	9.93e-6	Resting heart rate;
UCEC	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.9	8.28	0.56	7e-14	Morning vs. evening chronotype;
UCEC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.04	-0.7	1.19e-23	Ulcerative colitis;
UCEC	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg00083072	chr11:65415190	SIPA1	0.42	4.56	0.35	1.05e-5	Acne (severe);
UCEC	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.56	-6.43	-0.47	1.65e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.66	-7.21	-0.51	2.77e-11	Hypospadias;
UCEC	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.81	0.54	9.68e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs78707713	0.524	rs10823377	chr10:71213327	G/A	cg12610070	chr10:71211762	TSPAN15	-0.32	-5.73	-0.43	5.46e-8	Venous thromboembolism;
UCEC	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs925228	0.824	rs2675351	chr2:24083573	A/G	cg13272742	chr2:24272458	FKBP1B	0.59	5.06	0.39	1.21e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	0.73	4.55	0.35	1.13e-5	Mitochondrial DNA levels;
UCEC	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	6.86	0.49	1.8e-10	Personality dimensions;
UCEC	cis	rs6460942	0.630	rs62448731	chr7:12341174	G/A	cg06484146	chr7:12443880	VWDE	-0.58	-4.7	-0.36	5.85e-6	Coronary artery disease;
UCEC	cis	rs4774830	0.744	rs62046389	chr15:56307688	T/G	cg24530489	chr15:56299380	NA	-0.65	-4.55	-0.35	1.14e-5	Delta-5 desaturase activity;
UCEC	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.79	-7.33	-0.52	1.45e-11	Diastolic blood pressure;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg24829313	chr11:63684597	RCOR2	0.71	7.63	0.53	2.79e-12	Schizophrenia;
UCEC	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg13334819	chr7:99746414	C7orf59	0.53	5.16	0.39	7.93e-7	Coronary artery disease;
UCEC	cis	rs4975616	0.686	rs40182	chr5:1350397	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.75	-8.09	-0.55	2.1e-13	Lung cancer;
UCEC	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-10.36	-0.65	3.13e-19	Blood metabolite levels;
UCEC	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	4.77	0.37	4.4e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.46	6.76	0.49	3.01e-10	Blood protein levels;
UCEC	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	4.72	0.36	5.42e-6	Refractive astigmatism;
UCEC	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.81	9.97	0.64	3.37e-18	Metabolic syndrome;
UCEC	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg09144964	chr7:27150262	HOXA3	0.56	4.69	0.36	6.28e-6	Type 1 diabetes;
UCEC	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.69	6.91	0.5	1.35e-10	Aortic root size;
UCEC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9733	1.000	rs9733	chr1:150618961	A/C	cg13175981	chr1:150552382	MCL1	0.55	5.72	0.43	5.89e-8	Tonsillectomy;
UCEC	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.51	-5.26	-0.4	4.92e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23422044	chr7:1970798	MAD1L1	-0.42	-4.67	-0.36	6.87e-6	Neuroticism;
UCEC	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.48	5.34	0.4	3.46e-7	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs4784256	0.713	rs34078005	chr16:52805881	C/G	cg00925156	chr12:7917828	LOC360030	0.59	6.89	0.49	1.54e-10	Morning vs. evening chronotype;
UCEC	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.67	0.42	7.24e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.49	-5.25	-0.4	5.15e-7	QRS complex (12-leadsum);
UCEC	cis	rs7264396	0.666	rs1536147	chr20:34173046	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.47	6.04	0.45	1.18e-8	Total cholesterol levels;
UCEC	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.04	6.4	0.47	1.98e-9	Diabetic retinopathy;
UCEC	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.73	9.87	0.63	6.07e-18	Vitiligo;
UCEC	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	4.6	0.35	8.96e-6	Lung cancer in ever smokers;
UCEC	cis	rs1524976	0.600	rs1949843	chr3:65453008	C/G	cg16238336	chr3:65465873	MAGI1	0.5	4.92	0.38	2.34e-6	PR interval;
UCEC	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg10932868	chr11:921992	NA	0.44	5.79	0.43	4.1e-8	Alzheimer's disease (late onset);
UCEC	cis	rs10786436	0.605	rs11594030	chr10:100280492	C/T	cg24343515	chr10:99400468	PI4K2A	-0.47	-4.78	-0.37	4.14e-6	Type 1 diabetes;
UCEC	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs8064299	0.655	rs11655219	chr17:72771293	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.48	4.55	0.35	1.12e-5	Monocyte count;
UCEC	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.49	-7.1	-0.51	4.88e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.74	7.46	0.52	7.09e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.68	-5.62	-0.42	9.08e-8	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs10256972	0.804	rs10275585	chr7:1017339	T/C	cg04025307	chr7:1156635	C7orf50	0.58	5.87	0.44	2.81e-8	Longevity;Endometriosis;
UCEC	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg18032046	chr6:28092343	ZSCAN16	0.62	5.15	0.39	8.16e-7	Depression;
UCEC	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.39	4.78	0.37	4.17e-6	Renal cell carcinoma;
UCEC	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-10.89	-0.67	1.28e-20	Ulcerative colitis;
UCEC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg13143389	chr11:8680333	TRIM66	0.37	4.74	0.36	4.93e-6	Hemoglobin concentration;
UCEC	cis	rs17123764	1.000	rs11833411	chr12:50000387	T/C	cg20471783	chr12:50157085	TMBIM6	0.63	5.42	0.41	2.42e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.57	4.63	0.36	8.06e-6	Heart rate;
UCEC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.5	5.28	0.4	4.55e-7	Schizophrenia;
UCEC	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg24562669	chr7:97807699	LMTK2	0.49	5.85	0.43	3.12e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	0.65	7.04	0.5	6.68e-11	Blood protein levels;
UCEC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.56	5.61	0.42	9.64e-8	Aortic root size;
UCEC	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg13575925	chr12:9217583	LOC144571	0.42	4.82	0.37	3.5e-6	Sjögren's syndrome;
UCEC	cis	rs9463078	0.753	rs3778507	chr6:44896803	G/A	cg25276700	chr6:44698697	NA	-0.42	-4.7	-0.36	5.86e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg18223379	chr20:31619647	BPIL3	0.39	4.6	0.35	9.23e-6	Ulcerative colitis;
UCEC	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2502731	0.539	rs3003614	chr9:130994736	G/A	cg09976142	chr9:130955436	CIZ1	0.47	5.41	0.41	2.5e-7	Attention deficit hyperactivity disorder;
UCEC	cis	rs12634933	0.737	rs12631188	chr3:169032125	C/G	cg03603669	chr3:169896616	PHC3	-0.47	-4.62	-0.36	8.31e-6	Blood pressure (smoking interaction);
UCEC	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.6	5.37	0.41	2.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	5.0	0.38	1.64e-6	Menarche (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27294431	chr1:186344717	TPR;C1orf27;MIR548F1	0.57	6.72	0.48	3.7e-10	Warfarin maintenance dose;
UCEC	cis	rs240764	0.604	rs9377234	chr6:101263035	C/T	cg09795085	chr6:101329169	ASCC3	0.52	4.84	0.37	3.3e-6	Neuroticism;
UCEC	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.62	4.82	0.37	3.61e-6	Body mass index;
UCEC	cis	rs732765	0.734	rs1057500	chr14:75205116	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.54	-4.88	-0.37	2.69e-6	Non-small cell lung cancer;
UCEC	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.96	8.46	0.57	2.5e-14	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.0	6.85	0.49	1.93e-10	Sexual dysfunction (female);
UCEC	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-0.91	-8.67	-0.58	7.26e-15	Dilated cardiomyopathy;
UCEC	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg06238570	chr21:40685208	BRWD1	0.51	5.23	0.4	5.63e-7	Cognitive function;
UCEC	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-7.13	-0.51	4.17e-11	Coronary artery disease;
UCEC	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.55	-5.96	-0.44	1.77e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.43	4.61	0.36	8.54e-6	Mean platelet volume;
UCEC	cis	rs7246967	0.673	rs73022713	chr19:22876222	G/C	cg05241461	chr19:22816980	ZNF492	0.58	6.18	0.45	5.91e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2734839	0.964	rs1116313	chr11:113296107	A/G	cg14159747	chr11:113255604	NA	0.57	7.31	0.52	1.54e-11	Information processing speed;
UCEC	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	5.51	0.41	1.53e-7	Ileal carcinoids;
UCEC	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	5.26	0.4	4.89e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.72	-7.39	-0.52	1.01e-11	Ear protrusion;
UCEC	cis	rs13401104	0.796	rs10929173	chr2:237116777	C/T	cg23897927	chr2:237117786	ASB18	-0.53	-4.57	-0.35	1.05e-5	Educational attainment;
UCEC	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2693698	0.679	rs4905809	chr14:99692739	C/T	cg20500854	chr14:99707650	BCL11B	0.54	5.09	0.39	1.08e-6	Schizophrenia;
UCEC	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.33e-8	Skin colour saturation;
UCEC	cis	rs11867410	0.744	rs8081345	chr17:63991329	C/T	cg06996976	chr17:64576105	PRKCA	-0.72	-4.55	-0.35	1.13e-5	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs11760485	0.782	rs2107835	chr7:4404630	T/C	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.46	-5.1	-0.39	1.04e-6	Longevity;
UCEC	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.25	-0.4	5.16e-7	Hemoglobin concentration;
UCEC	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.51	-4.84	-0.37	3.23e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7975161	1.000	rs7975161	chr12:104645405	C/T	cg25273343	chr12:104657179	TXNRD1	0.69	5.71	0.43	6.17e-8	Toenail selenium levels;
UCEC	cis	rs2625529	0.526	rs10851850	chr15:72486509	A/G	cg00334370	chr15:72668350	HEXA;C15orf34	0.52	5.11	0.39	9.99e-7	Red blood cell count;
UCEC	cis	rs4713118	0.505	rs156740	chr6:27960435	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.52	-5.6	-0.42	1.01e-7	Parkinson's disease;
UCEC	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs4499344	0.730	rs28402742	chr19:33099734	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Alcohol dependence;
UCEC	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.74	7.85	0.54	7.74e-13	Menopause (age at onset);
UCEC	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg15358701	chr1:161410459	NA	-0.88	-5.2	-0.39	6.6e-7	Rheumatoid arthritis;
UCEC	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg21231944	chr12:82153410	PPFIA2	-0.45	-4.77	-0.37	4.41e-6	Resting heart rate;
UCEC	cis	rs28530618	0.603	rs13043743	chr20:31257083	C/T	cg13636640	chr20:31349939	DNMT3B	-0.57	-5.19	-0.39	6.78e-7	Birth weight;
UCEC	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.59	5.32	0.4	3.82e-7	Uric acid levels;
UCEC	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg00280220	chr17:61926910	NA	0.43	4.7	0.36	5.91e-6	Prudent dietary pattern;
UCEC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.78	7.47	0.52	6.52e-12	Menopause (age at onset);
UCEC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg04310649	chr10:35416472	CREM	-0.52	-5.12	-0.39	9.64e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.59	-6.41	-0.47	1.89e-9	Obesity-related traits;
UCEC	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg04043695	chr12:129287642	SLC15A4	0.63	6.2	0.46	5.4e-9	Systemic lupus erythematosus;
UCEC	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.69	5.59	0.42	1.07e-7	Body mass index;
UCEC	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.67	-7.48	-0.53	6.18e-12	Prostate cancer;
UCEC	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.49	4.53	0.35	1.19e-5	Lung cancer;
UCEC	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg17646820	chr3:66848679	NA	-0.54	-4.74	-0.36	5.02e-6	Type 2 diabetes;
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.64	-7.37	-0.52	1.14e-11	Body mass index;
UCEC	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg23229016	chr1:26872525	RPS6KA1	0.34	6.45	0.47	1.49e-9	Glucose homeostasis traits;
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.64	-6.86	-0.49	1.83e-10	Survival in pancreatic cancer;
UCEC	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg19197139	chr17:4613644	ARRB2	0.82	6.18	0.45	5.92e-9	Lymphocyte counts;
UCEC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	0.87	9.9	0.63	4.93e-18	Breast cancer;
UCEC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.56	-5.19	-0.39	7.01e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.11	0.64	1.41e-18	Electrocardiographic conduction measures;
UCEC	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg13844804	chr7:814759	HEATR2	0.61	4.71	0.36	5.79e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.71	0.36	5.76e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.51	5.17	0.39	7.39e-7	Dupuytren's disease;
UCEC	cis	rs139371	0.713	rs139316	chr22:39499763	C/T	cg15548613	chr22:38610795	MAFF	-0.44	-4.57	-0.35	1.03e-5	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.07	-6.68	-0.48	4.54e-10	Diabetic kidney disease;
UCEC	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg10820045	chr2:198174542	NA	-0.49	-6.02	-0.44	1.3e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.97	-0.5	1.01e-10	Chronic sinus infection;
UCEC	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.55	7.58	0.53	3.63e-12	Total body bone mineral density;
UCEC	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.52	5.9	0.44	2.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.85	-0.37	3.14e-6	Testicular germ cell tumor;
UCEC	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.7	-5.44	-0.41	2.21e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs7072216	0.770	rs1737	chr10:100176366	T/C	cg26618903	chr10:100175079	PYROXD2	-0.44	-6.11	-0.45	8.4e-9	Metabolite levels;
UCEC	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs7646881	0.544	rs9881679	chr3:158298432	A/G	cg05743054	chr3:158288903	MLF1	-0.53	-4.72	-0.36	5.43e-6	Tetralogy of Fallot;
UCEC	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-0.96	-9.27	-0.61	2.18e-16	Lymphocyte counts;
UCEC	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg23888215	chr10:79422304	NA	-1.14	-9.0	-0.6	1.05e-15	Bone mineral density;
UCEC	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.44e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.5	-4.87	-0.37	2.91e-6	Obesity-related traits;
UCEC	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-0.94	-12.25	-0.71	3.19e-24	Height;
UCEC	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs11235843	0.571	rs4944850	chr11:73356096	A/C	cg09185399	chr11:73372479	PLEKHB1	0.58	4.53	0.35	1.22e-5	Hand grip strength;
UCEC	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-6.12	-0.45	8.02e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.65	-5.9	-0.44	2.46e-8	Menarche (age at onset);
UCEC	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.69	7.18	0.51	3.26e-11	Menopause (age at onset);
UCEC	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg23795048	chr12:9217529	LOC144571	0.4	4.95	0.38	1.99e-6	Sjögren's syndrome;
UCEC	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.6	-5.18	-0.39	7.28e-7	Platelet count;
UCEC	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	6.74	0.49	3.27e-10	Alzheimer's disease;
UCEC	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-4.91	-0.38	2.4e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.6	-4.52	-0.35	1.28e-5	Waist circumference adjusted for body mass index;
UCEC	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18932078	chr1:2524107	MMEL1	0.35	6.05	0.45	1.13e-8	Ulcerative colitis;
UCEC	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	6.95	0.5	1.12e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.96	10.54	0.66	1.06e-19	Cognitive function;
UCEC	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.52	-6.42	-0.47	1.79e-9	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.86	9.64	0.62	2.4e-17	Breast cancer;
UCEC	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	1.24	8.92	0.59	1.7e-15	Blood protein levels;
UCEC	cis	rs17102423	0.603	rs10873184	chr14:65605854	T/C	cg11161011	chr14:65562177	MAX	-0.86	-9.03	-0.6	9.09e-16	Obesity-related traits;
UCEC	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.14	0.6	4.79e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs8105895	1.000	rs117638181	chr19:22163014	C/G	cg24175803	chr19:22235144	ZNF257	-0.54	-4.8	-0.37	3.9e-6	Body mass index (change over time);
UCEC	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.68	-7.02	-0.5	7.56e-11	Mean platelet volume;
UCEC	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg23387056	chr11:14280742	SPON1	-0.39	-4.61	-0.36	8.52e-6	Mitochondrial DNA levels;
UCEC	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-14.05	-0.76	5.6e-29	Schizophrenia;
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.72	8.15	0.56	1.49e-13	Menarche (age at onset);
UCEC	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg10932868	chr11:921992	NA	0.41	5.34	0.4	3.47e-7	Alzheimer's disease (late onset);
UCEC	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.63	-6.26	-0.46	3.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.5	-0.41	1.63e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.11	9.56	0.62	3.87e-17	Uric acid levels;
UCEC	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.72	7.13	0.51	4.23e-11	Smoking behavior;
UCEC	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.2	0.51	2.83e-11	Coffee consumption (cups per day);
UCEC	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.66	7.91	0.55	5.65e-13	Hip circumference;
UCEC	cis	rs12618769	0.543	rs72819971	chr2:99034846	T/G	cg14361474	chr2:99058762	NA	-0.49	-4.84	-0.37	3.25e-6	Bipolar disorder;
UCEC	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.48	5.15	0.39	8.13e-7	Aortic root size;
UCEC	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.45	-6.16	-0.45	6.69e-9	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs2386661	0.704	rs2386650	chr10:5678058	G/A	cg17085576	chr10:5658249	NA	-0.48	-4.79	-0.37	3.97e-6	Breast cancer;
UCEC	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.77	7.53	0.53	4.85e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs59104589	0.617	rs3771550	chr2:242302811	A/G	cg19488206	chr2:242435732	STK25	0.5	5.13	0.39	9.01e-7	Fibrinogen levels;
UCEC	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-4.65	-0.36	7.45e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs7781557	1.000	rs7790451	chr7:102465988	G/A	cg18108683	chr7:102477205	FBXL13	-0.52	-4.7	-0.36	5.91e-6	Colorectal adenoma (advanced);
UCEC	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.69	6.21	0.46	5.12e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.69	5.31	0.4	3.94e-7	Mean platelet volume;
UCEC	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.55	-5.54	-0.42	1.35e-7	Polycystic ovary syndrome;
UCEC	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.52	5.38	0.41	2.87e-7	Testicular germ cell tumor;
UCEC	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	1.01	11.03	0.67	5.59e-21	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.66	5.43	0.41	2.32e-7	LDL cholesterol;
UCEC	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg07636037	chr3:49044803	WDR6	-0.57	-4.62	-0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg05072774	chr3:49840536	C3orf54	-0.54	-5.62	-0.42	9.37e-8	Resting heart rate;
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg01013738	chr7:1149705	C7orf50	0.51	4.75	0.37	4.71e-6	Longevity;Endometriosis;
UCEC	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg05962950	chr11:130786565	SNX19	0.63	6.69	0.48	4.26e-10	Schizophrenia;
UCEC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.6	7.03	0.5	7.09e-11	Menopause (age at onset);
UCEC	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	0.82	7.01	0.5	8.13e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg18827107	chr12:86230957	RASSF9	-0.41	-4.51	-0.35	1.33e-5	Major depressive disorder;
UCEC	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg23625390	chr15:77176239	SCAPER	0.47	4.62	0.36	8.33e-6	Blood metabolite levels;
UCEC	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.61	-5.45	-0.41	2.08e-7	Mortality in heart failure;
UCEC	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	4.51	0.35	1.32e-5	Obesity-related traits;
UCEC	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.54	-5.39	-0.41	2.8e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.44	-5.81	-0.43	3.68e-8	Urinary metabolites;
UCEC	cis	rs847649	1.000	rs13233521	chr7:102593794	C/T	cg18108683	chr7:102477205	FBXL13	0.63	7.88	0.54	6.81e-13	Morning vs. evening chronotype;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12366118	chr12:62860687	MON2	0.62	7.58	0.53	3.64e-12	Warfarin maintenance dose;
UCEC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	5.7	0.43	6.27e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs17106184	0.892	rs12098132	chr1:51127524	C/A	cg07174182	chr1:51127561	FAF1	-0.64	-4.51	-0.35	1.34e-5	Type 2 diabetes;
UCEC	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-7.63	-0.53	2.76e-12	Hip circumference;
UCEC	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.51	4.89	0.37	2.67e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs7804356	0.859	rs2391362	chr7:26907123	T/C	cg02693607	chr7:27150598	HOXA3	0.57	4.71	0.36	5.72e-6	Type 1 diabetes;
UCEC	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.73	6.18	0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg23307798	chr14:103986281	CKB	0.65	8.04	0.55	2.71e-13	Bone mineral density;
UCEC	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.65	-6.32	-0.46	2.89e-9	Blood metabolite levels;
UCEC	cis	rs116095464	0.681	rs1574220	chr5:314518	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.61	4.81	0.37	3.68e-6	Breast cancer;
UCEC	cis	rs6662386	0.557	rs919964	chr1:88219885	G/A	cg10042178	chr1:87794589	LMO4	0.49	4.72	0.36	5.56e-6	Prostate-specific antigen levels;
UCEC	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg14196790	chr5:131705035	SLC22A5	-0.42	-4.58	-0.35	9.83e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.26	10.91	0.67	1.15e-20	Corneal structure;
UCEC	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.05	-0.45	1.16e-8	Aortic root size;
UCEC	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.65	-4.81	-0.37	3.69e-6	Coronary artery disease;
UCEC	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg00343986	chr7:65444356	GUSB	0.52	5.04	0.38	1.35e-6	Aortic root size;
UCEC	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.72	6.14	0.45	7.39e-9	Platelet count;
UCEC	cis	rs16939046	1.000	rs72656141	chr8:76072337	T/A	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.79	-8.9	-0.59	1.91e-15	Height;
UCEC	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-5.21	-0.39	6.31e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07589254	chr7:1705402	NA	-0.55	-4.84	-0.37	3.24e-6	Longevity;Endometriosis;
UCEC	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.77	7.49	0.53	5.93e-12	Schizophrenia;
UCEC	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs4450131	0.569	rs3824801	chr10:126356840	T/G	cg08799069	chr10:126477246	METTL10	-0.43	-4.58	-0.35	9.81e-6	White blood cell count (basophil);
UCEC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-4.6	-0.35	9.21e-6	Menarche (age at onset);
UCEC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.49	-4.86	-0.37	2.94e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8099014	0.954	rs4245271	chr18:56114063	A/G	cg19165390	chr18:56932082	NA	0.35	4.74	0.36	4.95e-6	Platelet count;
UCEC	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.75	9.18	0.6	3.66e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.95	-0.59	1.4e-15	Exhaled nitric oxide output;
UCEC	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-9.55	-0.62	4e-17	Electrocardiographic conduction measures;
UCEC	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.6	6.24	0.46	4.44e-9	Retinal vascular caliber;
UCEC	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.39e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9463078	0.764	rs10948194	chr6:44951990	A/C	cg25276700	chr6:44698697	NA	-0.45	-5.08	-0.39	1.1e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.55	5.61	0.42	9.76e-8	Motion sickness;
UCEC	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg20399509	chr21:47717575	C21orf57	-0.44	-4.73	-0.36	5.24e-6	Testicular germ cell tumor;
UCEC	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.18	-0.39	7.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.47	4.84	0.37	3.2e-6	Schizophrenia;
UCEC	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.76	6.68	0.48	4.49e-10	Breast cancer;
UCEC	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.74	8.77	0.59	4.11e-15	Prudent dietary pattern;
UCEC	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.76	-8.79	-0.59	3.62e-15	Obesity-related traits;
UCEC	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.48	4.54	0.35	1.15e-5	Menopause (age at onset);
UCEC	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.68	-6.86	-0.49	1.83e-10	Longevity;Endometriosis;
UCEC	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-4.72	-0.36	5.47e-6	Type 2 diabetes;
UCEC	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.81	0.49	2.3e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.53	-4.81	-0.37	3.63e-6	Coronary artery disease;
UCEC	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg10978503	chr1:24200527	CNR2	0.36	4.81	0.37	3.72e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.59	-5.05	-0.38	1.31e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs13401104	0.796	rs10929170	chr2:237115591	A/G	cg23897927	chr2:237117786	ASB18	-0.52	-4.51	-0.35	1.34e-5	Educational attainment;
UCEC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg04473437	chr5:205334	CCDC127	-0.6	-4.64	-0.36	7.53e-6	Breast cancer;
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.46	0.72	8.88e-25	Prudent dietary pattern;
UCEC	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-5.84	-0.43	3.15e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg04871131	chr7:94954202	PON1	-0.52	-5.15	-0.39	8.14e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg10932868	chr11:921992	NA	0.44	5.86	0.43	2.97e-8	Alzheimer's disease (late onset);
UCEC	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.78	-10.57	-0.66	8.83e-20	Urate levels in lean individuals;
UCEC	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.65	0.36	7.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.65	6.36	0.46	2.4e-9	Aortic root size;
UCEC	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.08	-0.45	9.78e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24308560	chr3:49941425	MST1R	0.53	6.03	0.45	1.26e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg24163568	chr5:669837	TPPP	-0.36	-4.58	-0.35	9.8200000000000008e-06	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.71	4.6	0.35	8.94e-6	Obsessive-compulsive symptoms;
UCEC	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.42	5.69	0.42	6.67e-8	Life satisfaction;
UCEC	cis	rs427941	0.773	rs56235745	chr7:101828769	A/G	cg01723606	chr7:101944275	SH2B2	0.43	4.67	0.36	6.74e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs10129255	0.557	rs72622064	chr14:107107799	T/C	cg03031183	chr14:106916953	NA	-0.43	-4.62	-0.36	8.41e-6	Kawasaki disease;
UCEC	cis	rs10924970	0.934	rs6666023	chr1:235480068	G/A	cg26050004	chr1:235667680	B3GALNT2	0.46	4.95	0.38	2e-6	Asthma;
UCEC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.62	5.95	0.44	1.85e-8	Calcium levels;
UCEC	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg15837086	chr1:46506065	PIK3R3	-0.37	-4.5	-0.35	1.36e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.67	-8.05	-0.55	2.52e-13	IgG glycosylation;
UCEC	cis	rs3956705	0.830	rs7811609	chr7:32930597	A/G	cg05721444	chr7:32995514	FKBP9	0.45	4.54	0.35	1.18e-5	Red cell distribution width;
UCEC	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg07828340	chr4:882639	GAK	1.12	6.74	0.49	3.4e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs740160	0.558	rs12538893	chr7:98908497	G/A	cg18809830	chr7:99032528	PTCD1	-0.59	-5.03	-0.38	1.39e-6	Dehydroepiandrosterone sulphate levels;
UCEC	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.44	4.57	0.35	1.02e-5	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.64	7.47	0.52	6.74e-12	Hip circumference;
UCEC	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.63	7.49	0.53	6.03e-12	Schizophrenia;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.49	-5.44	-0.41	2.2e-7	Cardiac Troponin-T levels;
UCEC	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	7.87	0.54	7.02e-13	Alzheimer's disease;
UCEC	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-0.67	-5.35	-0.4	3.24e-7	Morning vs. evening chronotype;
UCEC	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg01072550	chr1:21505969	NA	-0.55	-5.13	-0.39	8.84e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs3770752	1.000	rs3770752	chr2:37576136	C/T	cg20091297	chr2:37572423	QPCT	-0.52	-5.05	-0.38	1.3e-6	Schizophrenia;
UCEC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.57	5.63	0.42	8.99e-8	Blood protein levels;
UCEC	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.49	4.59	0.35	9.55e-6	HDL cholesterol;
UCEC	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	8.1	0.56	1.99e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.54	-5.42	-0.41	2.43e-7	IgG glycosylation;
UCEC	cis	rs6709815	0.902	rs13020432	chr2:219668211	C/T	cg02176678	chr2:219576539	TTLL4	-0.5	-5.0	-0.38	1.6e-6	Reticulocyte count;High light scatter reticulocyte count;
UCEC	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg07645718	chr20:61493192	TCFL5	0.72	5.22	0.4	5.98e-7	Obesity-related traits;
UCEC	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg10560079	chr2:191398806	TMEM194B	-0.46	-4.54	-0.35	1.18e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.67	-7.67	-0.53	2.2e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	6.81	0.49	2.37e-10	Coffee consumption (cups per day);
UCEC	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.5	5.12	0.39	9.6e-7	Coronary heart disease;
UCEC	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.57	4.78	0.37	4.25e-6	Lymphocyte counts;
UCEC	cis	rs3088050	0.775	rs1966265	chr5:176516631	G/A	cg27139941	chr5:176894950	DBN1	0.62	4.51	0.35	1.34e-5	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
UCEC	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-0.99	-10.82	-0.67	1.92e-20	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.14	0.51	4.06e-11	Coffee consumption (cups per day);
UCEC	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.87	13.22	0.74	8.93e-27	Birth weight;
UCEC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.7	-7.68	-0.53	2.09e-12	Menarche (age at onset);
UCEC	cis	rs3772130	0.583	rs4296627	chr3:121567684	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.85	0.37	3.1e-6	Cognitive performance;
UCEC	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.51	-0.35	1.3e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.39	-0.41	2.73e-7	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.66	5.82	0.43	3.51e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs4778581	0.868	rs2103043	chr15:80426083	G/A	cg08257866	chr15:80351198	ZFAND6	0.4	4.59	0.35	9.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.58	5.29	0.4	4.33e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs7212590	0.581	rs8070961	chr17:57813168	A/G	cg10252138	chr17:58120427	NA	-0.71	-5.63	-0.42	9.02e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	0.97	6.51	0.47	1.09e-9	PR interval in Tripanosoma cruzi seropositivity;
UCEC	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg10820045	chr2:198174542	NA	-0.48	-5.88	-0.44	2.68e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.68	7.83	0.54	8.67e-13	Mean corpuscular volume;
UCEC	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.65	-5.51	-0.41	1.54e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.45	4.6	0.35	9e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.03	-0.38	1.4e-6	Joint mobility (Beighton score);
UCEC	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg20203395	chr5:56204925	C5orf35	0.5	4.64	0.36	7.53e-6	Coronary artery disease;
UCEC	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.75	7.93	0.55	5.11e-13	Primary sclerosing cholangitis;
UCEC	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.63	5.61	0.42	9.55e-8	Heart rate;
UCEC	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.69	-7.72	-0.54	1.64e-12	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs34486957	0.600	rs12896175	chr14:60046581	C/T	cg12189551	chr14:60952945	C14orf39	0.36	4.5	0.35	1.35e-5	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.53	-5.26	-0.4	4.9e-7	IgG glycosylation;
UCEC	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.51	-5.04	-0.38	1.37e-6	Refractive error;
UCEC	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	0.88	8.73	0.58	5.14e-15	Red cell distribution width;
UCEC	cis	rs7582720	1.000	rs72932752	chr2:203667526	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	4.99	0.38	1.72e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-4.66	-0.36	6.98e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.64	5.88	0.44	2.61e-8	Platelet distribution width;
UCEC	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.84	-9.21	-0.6	3.11e-16	Height;
UCEC	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.41	-5.05	-0.38	1.32e-6	Subjective well-being;
UCEC	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-4.99	-0.38	1.7e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs256277	0.782	rs1493454	chr5:111293403	T/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.44	-4.58	-0.35	9.79e-6	Coronary artery disease;
UCEC	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.7	-7.52	-0.53	5.04e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.58	5.38	0.41	2.82e-7	Corneal astigmatism;
UCEC	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.59	5.65	0.42	8.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg22974920	chr21:40686053	BRWD1	-0.47	-4.52	-0.35	1.26e-5	Menarche (age at onset);
UCEC	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.55	-4.57	-0.35	1.01e-5	Initial pursuit acceleration;
UCEC	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg18721089	chr20:30220636	NA	-0.39	-4.91	-0.38	2.44e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.48	5.65	0.42	7.97e-8	Aortic root size;
UCEC	cis	rs11235843	0.714	rs7128512	chr11:73372299	A/G	cg23931323	chr11:73372278	PLEKHB1	-0.56	-4.81	-0.37	3.64e-6	Hand grip strength;
UCEC	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-4.88	-0.37	2.7e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs28386778	0.669	rs4968674	chr17:62015048	G/T	cg11494091	chr17:61959527	GH2	-0.59	-7.42	-0.52	8.84e-12	Prudent dietary pattern;
UCEC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.57	6.56	0.48	8.39e-10	Aortic root size;
UCEC	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.65	6.63	0.48	5.9e-10	Longevity;Endometriosis;
UCEC	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-1.01	-7.39	-0.52	1.02e-11	Multiple sclerosis;
UCEC	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.58	5.58	0.42	1.13e-7	Aortic root size;
UCEC	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.41	-4.64	-0.36	7.74e-6	Longevity;
UCEC	trans	rs1552172	0.887	rs2040086	chr1:145651876	C/A	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.92	-0.5	1.32e-10	Breast cancer;
UCEC	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.55	-7.43	-0.52	8.12e-12	Height;
UCEC	cis	rs7937612	0.897	rs11217821	chr11:120202099	T/C	cg12584626	chr11:120203529	NA	0.48	4.97	0.38	1.84e-6	Intraocular pressure;
UCEC	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg05539622	chr2:73298971	SFXN5	0.52	4.74	0.36	4.9e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg12024160	chr4:1254474	NA	0.71	8.9	0.59	1.93e-15	Obesity-related traits;
UCEC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.44	-5.12	-0.39	9.58e-7	Aortic root size;
UCEC	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.76	7.36	0.52	1.18e-11	Menopause (age at onset);
UCEC	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	0.85	8.25	0.56	8.47e-14	Cognitive function;
UCEC	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.48	-4.93	-0.38	2.24e-6	Blood protein levels;
UCEC	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg13206674	chr6:150067644	NUP43	0.51	4.71	0.36	5.75e-6	Testicular germ cell tumor;
UCEC	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.64	6.11	0.45	8.71e-9	Selective IgA deficiency;
UCEC	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.61	7.26	0.51	2.11e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7945071	0.507	rs4753891	chr11:110298547	A/G	cg26763524	chr11:110300429	FDX1	0.4	4.62	0.36	8.3e-6	Cognitive function;
UCEC	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.23	8.99	0.6	1.1e-15	Atopic dermatitis;
UCEC	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.45	5.23	0.4	5.6e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	18.14	0.83	2.41e-39	IgG glycosylation;
UCEC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12516959	chr21:47718080	NA	-0.43	-4.8	-0.37	3.88e-6	Testicular germ cell tumor;
UCEC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.83	10.57	0.66	8.78e-20	Longevity;Endometriosis;
UCEC	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.64	4.85	0.37	3.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.57	-8.33	-0.57	5.35e-14	Refractive error;
UCEC	cis	rs12410462	0.551	rs2819502	chr1:227712652	T/C	cg13693136	chr1:228666638	NA	-0.35	-4.59	-0.35	9.43e-6	Major depressive disorder;
UCEC	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs12980942	0.872	rs11879562	chr19:41804976	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.65	6.01	0.44	1.38e-8	Coronary artery disease;
UCEC	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.64	5.99	0.44	1.55e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-4.6	-0.35	9e-6	Alzheimer's disease (late onset);
UCEC	cis	rs35934224	0.783	rs7285948	chr22:19861127	T/C	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.8	-0.37	3.84e-6	Glaucoma (primary open-angle);
UCEC	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.52	-5.56	-0.42	1.25e-7	Electroencephalogram traits;
UCEC	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg26162295	chr17:38119207	GSDMA	0.3	4.69	0.36	6.07e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.57	-6.64	-0.48	5.67e-10	Aortic root size;
UCEC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.49	-4.83	-0.37	3.33e-6	Post bronchodilator FEV1;
UCEC	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg13683864	chr3:40499215	RPL14	0.7	8.44	0.57	2.78e-14	Renal cell carcinoma;
UCEC	cis	rs829661	0.793	rs829681	chr2:30708932	A/C	cg17749961	chr2:30669863	LCLAT1	0.69	5.99	0.44	1.57e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.57	-6.45	-0.47	1.53e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2120243	0.538	rs4680360	chr3:157094479	C/T	cg24825693	chr3:157122686	VEPH1	0.45	4.52	0.35	1.25e-5	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg05991184	chr2:219186017	PNKD	-0.55	-6.22	-0.46	4.96e-9	Colorectal cancer;
UCEC	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg10932868	chr11:921992	NA	-0.45	-6.06	-0.45	1.07e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.72	-7.39	-0.52	1.01e-11	Ear protrusion;
UCEC	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.56	6.12	0.45	8.26e-9	Bipolar disorder;
UCEC	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg14851346	chr12:38532713	NA	0.51	4.93	0.38	2.21e-6	Heart rate;
UCEC	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg19554555	chr3:13937349	NA	-0.54	-5.58	-0.42	1.11e-7	Ovarian reserve;
UCEC	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.69	0.36	6.29e-6	Rheumatoid arthritis;
UCEC	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.37	3.11e-6	Breast cancer;
UCEC	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.42	-4.64	-0.36	7.62e-6	Metabolic traits;
UCEC	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	7.24	0.51	2.26e-11	Fibroblast growth factor basic levels;
UCEC	cis	rs7246967	0.608	rs437859	chr19:23007349	A/G	cg05241461	chr19:22816980	ZNF492	-0.46	-4.73	-0.36	5.31e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg18681998	chr4:17616180	MED28	0.82	9.93	0.63	4.25e-18	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.66	-6.42	-0.47	1.75e-9	Blood metabolite levels;
UCEC	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.82	7.44	0.52	7.94e-12	Bladder cancer;
UCEC	cis	rs11697848	1.000	rs75406401	chr20:48528509	T/G	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs1575951	1.000	rs11016404	chr10:130435919	G/A	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg06238570	chr21:40685208	BRWD1	-0.65	-7.28	-0.51	1.86e-11	Menarche (age at onset);
UCEC	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.63	-6.55	-0.48	9.11e-10	Mean platelet volume;
UCEC	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.63	6.75	0.49	3.19e-10	Platelet count;
UCEC	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.42	-4.68	-0.36	6.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8112909	0.655	rs9967617	chr19:46415584	A/G	cg03208830	chr19:45909395	PPP1R13L;CD3EAP	0.55	4.52	0.35	1.27e-5	Interferon gamma-induced protein 10 levels;
UCEC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-6.12	-0.45	8.29e-9	Monocyte count;
UCEC	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	0.74	6.2	0.46	5.41e-9	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	9.18	0.6	3.61e-16	Coffee consumption (cups per day);
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	5.02	0.38	1.48e-6	Platelet count;
UCEC	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.7	-8.35	-0.57	4.73e-14	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg03728395	chr2:85555865	TGOLN2	-0.36	-4.82	-0.37	3.6e-6	Ear protrusion;
UCEC	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.54	4.87	0.37	2.83e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.86	8.59	0.58	1.18e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg14019695	chr9:139328340	INPP5E	0.41	4.59	0.35	9.4e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.53	-5.35	-0.4	3.26e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-5.96	-0.44	1.76e-8	Morning vs. evening chronotype;
UCEC	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.91	4.96	0.38	1.89e-6	Diisocyanate-induced asthma;
UCEC	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.6	7.11	0.51	4.65e-11	Prevalent atrial fibrillation;
UCEC	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.72	6.85	0.49	1.93e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.63	-6.04	-0.45	1.19e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.77	7.07	0.5	5.68e-11	Morning vs. evening chronotype;
UCEC	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	5.32	0.4	3.8e-7	Lung cancer in ever smokers;
UCEC	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.97	10.64	0.66	5.95e-20	Cognitive function;
UCEC	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.18	9.31	0.61	1.74e-16	Uric acid levels;
UCEC	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.75	7.16	0.51	3.53e-11	Schizophrenia;
UCEC	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg05964544	chr11:70165517	PPFIA1	-0.53	-4.89	-0.37	2.6e-6	Coronary artery disease;
UCEC	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.79	-8.94	-0.59	1.53e-15	Longevity;Endometriosis;
UCEC	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg05072774	chr3:49840536	C3orf54	-0.54	-5.59	-0.42	1.09e-7	Resting heart rate;
UCEC	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.63	6.31	0.46	3.11e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12516959	chr21:47718080	NA	-0.4	-4.56	-0.35	1.07e-5	Testicular germ cell tumor;
UCEC	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.53	4.83	0.37	3.38e-6	Tonsillectomy;
UCEC	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.35	4.75	0.36	4.85e-6	Blood protein levels;
UCEC	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.65	6.05	0.45	1.12e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7246967	0.611	rs34806882	chr19:22880104	T/C	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.66	4.65	0.36	7.3e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11697848	1.000	rs79631274	chr20:48517853	C/G	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.25	9.53	0.62	4.71e-17	Uric acid levels;
UCEC	cis	rs17123764	0.710	rs4563	chr12:50152193	G/A	cg20471783	chr12:50157085	TMBIM6	0.63	4.98	0.38	1.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.24	-6.88	-0.49	1.61e-10	Atopic dermatitis;
UCEC	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.62	-5.43	-0.41	2.31e-7	Schizophrenia;
UCEC	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-6.97	-0.5	1.02e-10	Hypospadias;
UCEC	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	0.98	7.01	0.5	7.91e-11	Obesity-related traits;
UCEC	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-4.6	-0.36	8.87e-6	Response to antipsychotic treatment;
UCEC	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	6.92	0.5	1.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs16939046	1.000	rs72656166	chr8:76112292	A/G	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs6820391	0.816	rs10016971	chr4:54444792	G/C	cg04173182	chr4:54446035	LNX1	0.37	4.69	0.36	6.11e-6	Cervical artery dissection;
UCEC	cis	rs10242455	1.000	rs1859690	chr7:99227172	A/G	cg18809830	chr7:99032528	PTCD1	-0.54	-4.63	-0.36	7.88e-6	Blood metabolite levels;
UCEC	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.57	-4.73	-0.36	5.19e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg14784868	chr12:69753453	YEATS4	0.55	4.62	0.36	8.17e-6	Response to diuretic therapy;
UCEC	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	0.83	5.25	0.4	5.22e-7	Arsenic metabolism;
UCEC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg00612595	chr21:47717864	NA	-0.47	-5.0	-0.38	1.58e-6	Testicular germ cell tumor;
UCEC	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.61	7.79	0.54	1.12e-12	Corneal structure;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.42	-0.41	2.43e-7	Cardiac Troponin-T levels;
UCEC	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg13753209	chr17:57696993	CLTC	-0.48	-4.7	-0.36	5.87e-6	Obesity-related traits;
UCEC	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg02733842	chr7:1102375	C7orf50	-0.63	-5.72	-0.43	5.89e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs3770752	0.836	rs11679617	chr2:37477243	C/T	cg20091297	chr2:37572423	QPCT	0.46	4.67	0.36	6.85e-6	Schizophrenia;
UCEC	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.7	0.36	5.97e-6	Aortic root size;
UCEC	cis	rs12618769	0.652	rs72823794	chr2:99216593	T/A	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.46e-7	Bipolar disorder;
UCEC	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.64	-6.45	-0.47	1.55e-9	Body mass index;
UCEC	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.64	-6.97	-0.5	9.84e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.47	5.88	0.44	2.59e-8	HDL cholesterol levels;
UCEC	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.44	-6.2	-0.46	5.29e-9	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg07404485	chr7:94953653	PON1	-0.45	-4.52	-0.35	1.29e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.78	-9.35	-0.61	1.33e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.96	9.35	0.61	1.37e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10924970	0.649	rs3765795	chr1:235375819	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.52	-4.64	-0.36	7.62e-6	Asthma;
UCEC	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.59	5.03	0.38	1.41e-6	Corneal astigmatism;
UCEC	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.59	-4.63	-0.36	8.14e-6	Cholesterol, total;
UCEC	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg00520717	chr19:2751543	NA	-0.4	-4.52	-0.35	1.25e-5	Total cholesterol levels;
UCEC	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.17	0.39	7.58e-7	Bladder cancer;
UCEC	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.44	-4.9	-0.37	2.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.55	-5.7	-0.43	6.47e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.28	-0.51	1.89e-11	Blood trace element (Zn levels);
UCEC	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.45	-4.88	-0.37	2.75e-6	Lymphocyte counts;
UCEC	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.78	-7.84	-0.54	8.3e-13	Mosquito bite size;
UCEC	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg12292205	chr6:26970375	C6orf41	0.57	5.0	0.38	1.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg04310649	chr10:35416472	CREM	-0.52	-4.84	-0.37	3.31e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg24881330	chr22:46731750	TRMU	-0.72	-7.32	-0.52	1.47e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.86	0.37	3.01e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-4.51	-0.35	1.29e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.78	-9.94	-0.63	3.88e-18	Menarche (age at onset);
UCEC	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.47	5.07	0.39	1.2e-6	Headache;
UCEC	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-6.14	-0.45	7.15e-9	Tonsillectomy;
UCEC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.48	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1483890	0.723	rs13061189	chr3:69411453	T/C	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.46	-0.41	1.96e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-4.6	-0.35	8.99e-6	Pulmonary function;
UCEC	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.65	-6.37	-0.47	2.24e-9	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.49	4.96	0.38	1.95e-6	Height;
UCEC	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.5e-7	Hemoglobin concentration;
UCEC	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.32	4.98	0.38	1.74e-6	Cancer;
UCEC	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg26513180	chr16:89883248	FANCA	-0.48	-5.06	-0.39	1.22e-6	Vitiligo;
UCEC	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.19	0.39	6.98e-7	Blood protein levels;
UCEC	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.71	0.36	5.7e-6	HDL cholesterol;
UCEC	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.67	5.48	0.41	1.79e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.57e-8	Electrocardiographic conduction measures;
UCEC	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.27	9.82	0.63	8.39e-18	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7246967	0.673	rs2099341	chr19:22834360	A/G	cg08271804	chr19:22816896	ZNF492	0.63	6.25	0.46	4.26e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.47	5.04	0.38	1.35e-6	Electroencephalogram traits;
UCEC	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.54	5.45	0.41	2.05e-7	Red blood cell count;
UCEC	cis	rs7246967	0.673	rs12979848	chr19:22820798	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.48	-4.91	-0.38	2.35e-6	Body mass index;
UCEC	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.65	4.63	0.36	7.83e-6	Osteoarthritis;
UCEC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.45	-4.89	-0.37	2.65e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.5	-5.87	-0.44	2.75e-8	Depression;
UCEC	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.83	-8.47	-0.57	2.36e-14	Mosquito bite size;
UCEC	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg26597838	chr10:835615	NA	1.22	6.54	0.47	9.59e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.52	-5.29	-0.4	4.45e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs5167	0.504	rs892101	chr19:45455458	G/A	cg09555818	chr19:45449301	APOC2	0.45	5.89	0.44	2.51e-8	Blood protein levels;
UCEC	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.55	5.96	0.44	1.78e-8	Bone mineral density;
UCEC	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.61	7.18	0.51	3.26e-11	Menopause (age at onset);
UCEC	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-13.32	-0.74	4.67e-27	Height;
UCEC	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-5.59	-0.42	1.09e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.61	-5.63	-0.42	8.97e-8	Metabolite levels;
UCEC	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs60311166	1.000	rs7647992	chr3:52631344	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.83	4.64	0.36	7.71e-6	CTACK levels;
UCEC	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	6.56	0.48	8.46e-10	HDL cholesterol;
UCEC	cis	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg21605333	chr4:119757512	SEC24D	0.91	4.66	0.36	7.06e-6	Cannabis dependence symptom count;
UCEC	cis	rs7258465	0.931	rs11673604	chr19:18540988	T/C	cg01065977	chr19:18549689	ISYNA1	-0.33	-4.53	-0.35	1.2e-5	Breast cancer;
UCEC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.88	10.78	0.66	2.53e-20	Breast cancer;
UCEC	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.81	-9.14	-0.6	4.55e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg09491104	chr22:46646882	C22orf40	-0.62	-7.34	-0.52	1.34e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg20387954	chr3:183756860	HTR3D	0.49	5.89	0.44	2.48e-8	Anterior chamber depth;
UCEC	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.47	4.82	0.37	3.57e-6	Menopause (age at onset);
UCEC	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg14851346	chr12:38532713	NA	-0.46	-4.51	-0.35	1.32e-5	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.56	6.97	0.5	1.01e-10	Kawasaki disease;
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.39	0.71	1.34e-24	Prudent dietary pattern;
UCEC	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg13695892	chr22:41940480	POLR3H	-0.59	-4.9	-0.37	2.46e-6	Vitiligo;
UCEC	cis	rs6929812	0.605	rs12526495	chr6:27393871	G/A	cg27490387	chr6:26520793	HCG11	-0.42	-4.78	-0.37	4.15e-6	Neuroticism (multi-trait analysis);
UCEC	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.61	6.46	0.47	1.45e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.6	-4.84	-0.37	3.19e-6	Migraine;Coronary artery disease;
UCEC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	4.52	0.35	1.25e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.35	-4.68	-0.36	6.43e-6	Total body bone mineral density;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.48	-4.85	-0.37	3.05e-6	Cardiac Troponin-T levels;
UCEC	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg11161011	chr14:65562177	MAX	-0.57	-5.9	-0.44	2.45e-8	Obesity-related traits;
UCEC	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.63	7.66	0.53	2.26e-12	Vitiligo;
UCEC	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-5.29	-0.4	4.29e-7	Metabolite levels;
UCEC	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.82	7.6	0.53	3.22e-12	Bladder cancer;
UCEC	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg21827317	chr3:136751795	NA	0.49	5.52	0.41	1.49e-7	Gestational age at birth (child effect);
UCEC	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.4	4.54	0.35	1.15e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.65	-5.4	-0.41	2.68e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs8032158	1.000	rs7162435	chr15:56121334	C/T	cg10433327	chr15:56209506	NEDD4	0.28	4.5	0.35	1.36e-5	Keloid;
UCEC	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	17.62	0.82	4.64e-38	IgG glycosylation;
UCEC	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.39	0.47	2.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs925228	0.910	rs1516427	chr2:24199259	T/C	cg16945982	chr2:25016118	CENPO;C2orf79	0.54	4.73	0.36	5.29e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.62	-5.89	-0.44	2.58e-8	Myopia;
UCEC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12516959	chr21:47718080	NA	-0.4	-4.56	-0.35	1.07e-5	Testicular germ cell tumor;
UCEC	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg19318889	chr4:1322082	MAEA	0.46	4.91	0.38	2.4e-6	Obesity-related traits;
UCEC	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.49	-5.52	-0.41	1.5e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	9.86	0.63	6.6e-18	Colorectal cancer;
UCEC	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.61	4.96	0.38	1.9e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.6	4.91	0.38	2.36e-6	Menopause (age at onset);
UCEC	cis	rs2376682	0.918	rs10039072	chr5:117997897	T/C	cg17593721	chr5:118788746	HSD17B4	0.5	4.98	0.38	1.79e-6	Diisocyanate-induced asthma;
UCEC	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-4.87	-0.37	2.84e-6	Bipolar disorder;
UCEC	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.9	0.44	2.44e-8	HDL cholesterol;
UCEC	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	6.24	0.46	4.43e-9	Alzheimer's disease;
UCEC	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.61	-5.06	-0.39	1.24e-6	Obesity-related traits;
UCEC	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.69	6.21	0.46	5.12e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	4.6	0.35	9.2e-6	Cognitive test performance;
UCEC	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.72	7.15	0.51	3.75e-11	Multiple myeloma (IgH translocation);
UCEC	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs7246967	0.673	rs4933017	chr19:22812980	T/C	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs11760485	0.965	rs9655027	chr7:4402672	C/T	cg15613991	chr7:5277080	NA	-0.41	-5.01	-0.38	1.54e-6	Early childhood aggressive behavior;
UCEC	cis	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg20368463	chr18:77673604	PQLC1	-0.6	-5.04	-0.38	1.33e-6	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.64	6.57	0.48	8.2e-10	Menopause (age at onset);
UCEC	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18252515	chr7:66147081	NA	-0.54	-5.23	-0.4	5.7e-7	Aortic root size;
UCEC	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.75	-0.59	4.68e-15	Headache;
UCEC	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg19318889	chr4:1322082	MAEA	0.61	7.35	0.52	1.3e-11	Longevity;
UCEC	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	6.94	0.5	1.15e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.57	5.67	0.42	7.4e-8	Total cholesterol levels;
UCEC	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.54	-5.99	-0.44	1.55e-8	Prostate cancer;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06966887	chr5:443603	EXOC3;C5orf55	0.55	7.0	0.5	8.4e-11	Warfarin maintenance dose;
UCEC	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.66	5.93	0.44	2.12e-8	Corneal astigmatism;
UCEC	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg12580275	chr1:205744413	RAB7L1	0.5	4.59	0.35	9.29e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.64	-6.68	-0.48	4.49e-10	Obesity-related traits;
UCEC	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.18	0.39	7.34e-7	Hemoglobin concentration;
UCEC	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.48	5.17	0.39	7.37e-7	Aortic root size;
UCEC	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg20999797	chr1:1681921	NA	0.36	4.83	0.37	3.36e-6	Body mass index;
UCEC	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg16060761	chr17:80687452	NA	-0.52	-5.21	-0.4	6.15e-7	Glycated hemoglobin levels;
UCEC	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.96	0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.92	-0.44	2.2e-8	Platelet count;
UCEC	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.62	4.92	0.38	2.25e-6	Resting heart rate;
UCEC	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05962382	chr2:130345044	NA	-0.5	-5.97	-0.44	1.67e-8	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs13325613	0.504	rs71325101	chr3:46015569	T/C	cg16320329	chr3:45981161	FYCO1	-0.78	-4.57	-0.35	1.04e-5	Monocyte count;
UCEC	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	0.81	6.82	0.49	2.16e-10	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg04154034	chr17:28927549	LRRC37B2	0.77	4.91	0.38	2.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	7.84	0.54	8.29e-13	Total body bone mineral density;
UCEC	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg26818010	chr10:134567672	INPP5A	-0.66	-6.48	-0.47	1.27e-9	Migraine;
UCEC	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg02160872	chr5:212506	CCDC127	0.68	6.94	0.5	1.18e-10	Breast cancer;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg14611278	chr1:156571598	GPATCH4	-0.62	-7.33	-0.52	1.4e-11	Breast cancer;
UCEC	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.5	5.43	0.41	2.31e-7	P wave terminal force;
UCEC	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.99	7.33	0.52	1.43e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs4372836	0.681	rs13394863	chr2:28956684	C/A	cg09522027	chr2:28974177	PPP1CB	-0.54	-5.47	-0.41	1.91e-7	Body mass index;
UCEC	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-5.56	-0.42	1.22e-7	Morning vs. evening chronotype;
UCEC	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-5.5	-0.41	1.64e-7	Prostate cancer;
UCEC	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.65	5.99	0.44	1.55e-8	High light scatter reticulocyte count;
UCEC	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-4.84	-0.37	3.32e-6	Response to antipsychotic treatment;
UCEC	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.42	4.67	0.36	6.81e-6	Renal cell carcinoma;
UCEC	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.62	6.14	0.45	7.36e-9	Lung cancer;
UCEC	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.73	7.65	0.53	2.49e-12	Multiple myeloma (IgH translocation);
UCEC	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.51	5.82	0.43	3.48e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	0.59	5.75	0.43	5.01e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
UCEC	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg07836142	chr6:28411423	ZSCAN23	-0.61	-6.95	-0.5	1.11e-10	Pubertal anthropometrics;
UCEC	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg23782820	chr8:58130467	NA	0.62	4.81	0.37	3.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg07153921	chr17:41440717	NA	0.48	4.85	0.37	3.14e-6	Menopause (age at onset);
UCEC	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg24562669	chr7:97807699	LMTK2	0.42	5.11	0.39	1.01e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.61	0.36	8.76e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	4.66	0.36	7.01e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	4.94	0.38	2.06e-6	Personality dimensions;
UCEC	cis	rs2179367	0.887	rs2789492	chr6:149747379	A/G	cg03678062	chr6:149772716	ZC3H12D	0.37	5.15	0.39	8.06e-7	Dupuytren's disease;
UCEC	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.6	5.04	0.38	1.32e-6	IgG glycosylation;
UCEC	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	7.75	0.54	1.36e-12	Subcortical brain region volumes;Putamen volume;
UCEC	cis	rs240764	0.554	rs6570970	chr6:101233082	C/A	cg09795085	chr6:101329169	ASCC3	0.51	4.74	0.36	5.02e-6	Neuroticism;
UCEC	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.53	-5.8	-0.43	3.94e-8	Diastolic blood pressure;
UCEC	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.81	9.52	0.62	4.78e-17	Colorectal cancer;
UCEC	cis	rs8141529	0.646	rs5752799	chr22:29188040	A/T	cg02153584	chr22:29168773	CCDC117	0.64	5.14	0.39	8.49e-7	Lymphocyte counts;
UCEC	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg06521331	chr12:34319734	NA	0.66	5.32	0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-6.19	-0.45	5.71e-9	Joint mobility (Beighton score);
UCEC	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg01013738	chr7:1149705	C7orf50	-0.5	-4.78	-0.37	4.24e-6	Longevity;Endometriosis;
UCEC	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	0.94	7.89	0.55	6.48e-13	White matter hyperintensity burden;
UCEC	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg06562184	chr8:19319451	CSGALNACT1	-0.42	-4.52	-0.35	1.28e-5	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg12024160	chr4:1254474	NA	0.51	6.41	0.47	1.84e-9	Obesity-related traits;
UCEC	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg16558253	chr16:72132732	DHX38	0.41	4.89	0.37	2.63e-6	Prostate cancer;
UCEC	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.84	5.22	0.4	5.89e-7	Diisocyanate-induced asthma;
UCEC	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg00071950	chr4:10020882	SLC2A9	0.6	7.23	0.51	2.46e-11	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.53	6.64	0.48	5.54e-10	Bone mineral density;
UCEC	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg13147721	chr7:65941812	NA	0.92	6.56	0.48	8.46e-10	Diabetic kidney disease;
UCEC	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.76	8.31	0.57	5.74e-14	Primary sclerosing cholangitis;
UCEC	trans	rs1552172	0.922	rs1778523	chr1:145698023	C/G	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.81	-0.49	2.36e-10	Breast cancer;
UCEC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg04155231	chr12:9217510	LOC144571	-0.46	-5.83	-0.43	3.36e-8	Sjögren's syndrome;
UCEC	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-8.06	-0.55	2.42e-13	Total body bone mineral density;
UCEC	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.66	-7.71	-0.54	1.73e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.66	4.76	0.37	4.58e-6	Cognitive test performance;
UCEC	cis	rs7246967	0.932	rs4932801	chr19:23051653	A/G	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.62	9.03	0.6	9.11e-16	Prudent dietary pattern;
UCEC	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-4.94	-0.38	2.14e-6	Life satisfaction;
UCEC	cis	rs3812049	0.611	rs251393	chr5:127533085	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	4.82	0.37	3.47e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.29	-0.46	3.42e-9	Blood metabolite levels;
UCEC	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg16797656	chr11:68205561	LRP5	-0.6	-8.87	-0.59	2.23e-15	Total body bone mineral density;
UCEC	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.49	-7.34	-0.52	1.36e-11	Diabetic kidney disease;
UCEC	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.2	-0.39	6.58e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.69	7.03	0.5	7.18e-11	Caffeine consumption;
UCEC	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.52	-4.54	-0.35	1.17e-5	Vitiligo;
UCEC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.16	-14.31	-0.76	1.19e-29	Breast cancer;
UCEC	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.43	5.06	0.38	1.25e-6	Blood metabolite ratios;
UCEC	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg24687543	chr11:63912206	MACROD1	0.54	4.71	0.36	5.65e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs6693882	0.967	rs10874934	chr1:96144747	A/C	cg12448539	chr1:95364293	CNN3	0.48	4.54	0.35	1.17e-5	Pain;
UCEC	cis	rs367615	0.680	rs253247	chr5:108983966	A/G	cg17395555	chr5:108820864	NA	0.53	4.54	0.35	1.17e-5	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.82	10.12	0.64	1.39e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.95	10.74	0.66	3.22e-20	IgG glycosylation;
UCEC	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.63	0.36	8.08e-6	Parkinson's disease;
UCEC	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	0.74	6.19	0.45	5.75e-9	Alzheimer's disease;
UCEC	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg26408565	chr15:76604113	ETFA	-0.44	-4.5	-0.35	1.35e-5	Blood metabolite levels;
UCEC	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.44	-4.66	-0.36	6.94e-6	Response to temozolomide;
UCEC	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.82	-9.7	-0.62	1.71e-17	Primary sclerosing cholangitis;
UCEC	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.6	6.91	0.5	1.37e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.43	4.56	0.35	1.07e-5	Type 1 diabetes;
UCEC	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.78	-8.88	-0.59	2.17e-15	Breast cancer;
UCEC	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.66	5.0	0.38	1.6e-6	Prostate cancer;
UCEC	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-4.65	-0.36	7.24e-6	Colorectal cancer;
UCEC	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.54	-5.34	-0.4	3.42e-7	Electroencephalogram traits;
UCEC	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg18099408	chr3:52552593	STAB1	-0.42	-4.85	-0.37	3.14e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.52	-0.35	1.26e-5	Type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs60675447	chr19:22810892	G/A	cg05241461	chr19:22816980	ZNF492	0.52	5.45	0.41	2.04e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs80130819	0.515	rs1793956	chr12:48392914	C/G	cg24011408	chr12:48396354	COL2A1	0.6	5.03	0.38	1.43e-6	Prostate cancer;
UCEC	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg23795048	chr12:9217529	LOC144571	0.41	4.67	0.36	6.67e-6	Sjögren's syndrome;
UCEC	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.56	-6.41	-0.47	1.87e-9	Menarche (age at onset);
UCEC	cis	rs12980942	0.591	rs11879429	chr19:41757444	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.76	5.72	0.43	5.8e-8	Coronary artery disease;
UCEC	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.78	6.25	0.46	4.21e-9	Neuroticism;
UCEC	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg17267710	chr20:61161232	C20orf166;MIR133A2	-0.35	-4.66	-0.36	7.11e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	1.0	11.82	0.7	4.54e-23	Cognitive function;
UCEC	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.0	0.38	1.58e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.56	5.58	0.42	1.14e-7	Radiation response;
UCEC	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	0.82	7.07	0.5	5.7e-11	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00610228	chr6:35695934	FKBP5;LOC285847	0.58	6.82	0.49	2.26e-10	Warfarin maintenance dose;
UCEC	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg19104757	chr7:226563	FAM20C	0.49	4.54	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.73	8.41	0.57	3.3e-14	Prudent dietary pattern;
UCEC	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.62	-4.76	-0.37	4.66e-6	Aortic root size;
UCEC	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.52	-4.66	-0.36	6.94e-6	Colorectal cancer;
UCEC	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.54	5.19	0.39	6.88e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.56	5.11	0.39	1e-6	Cognitive ability;
UCEC	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	5.58	0.42	1.14e-7	Coffee consumption (cups per day);
UCEC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg04473437	chr5:205334	CCDC127	-0.71	-5.21	-0.39	6.33e-7	Breast cancer;
UCEC	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.62	-4.99	-0.38	1.66e-6	Initial pursuit acceleration;
UCEC	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	7.87	0.54	6.93e-13	Smoking behavior;
UCEC	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.52	4.75	0.36	4.8e-6	Cognitive ability;
UCEC	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.82	8.76	0.59	4.21e-15	Blood metabolite levels;
UCEC	trans	rs17594526	0.826	rs80007062	chr18:53141964	T/G	cg12963529	chr20:43540202	PABPC1L	1.28	6.83	0.49	2.1e-10	Schizophrenia;
UCEC	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.75	-4.89	-0.37	2.62e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.6	5.56	0.42	1.24e-7	Corneal astigmatism;
UCEC	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.96	10.59	0.66	7.8500000000000006e-20	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.63	-4.52	-0.35	1.25e-5	Gut microbiome composition (summer);
UCEC	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.58	-6.54	-0.47	9.58e-10	Blood metabolite levels;
UCEC	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.93	12.01	0.7	1.39e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.57	-5.83	-0.43	3.36e-8	Breast cancer;
UCEC	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.78	4.61	0.36	8.65e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-4.77	-0.37	4.36e-6	Blood protein levels;
UCEC	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg05623727	chr3:50126028	RBM5	0.36	4.6	0.35	9.19e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.66	-5.67	-0.42	7.47e-8	Longevity;
UCEC	cis	rs1483890	0.642	rs1843049	chr3:69404078	T/C	cg22125112	chr3:69402811	FRMD4B	0.46	4.85	0.37	3.1e-6	Resting heart rate;
UCEC	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs10031466	0.967	rs12647135	chr4:189011174	A/C	cg03652810	chr4:189026682	TRIML2	0.47	5.67	0.42	7.21e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.71	5.47	0.41	1.9e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs8020441	0.945	rs61238948	chr14:51167617	A/G	cg04730355	chr14:51134070	SAV1	0.56	5.22	0.4	5.99e-7	Cognitive performance;
UCEC	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	7.7	0.54	1.87e-12	Coffee consumption (cups per day);
UCEC	cis	rs16937	0.662	rs10900464	chr1:205157100	T/C	cg00857998	chr1:205179979	DSTYK	0.52	4.61	0.36	8.62e-6	Schizophrenia;
UCEC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-4.58	-0.35	9.97e-6	Obesity-related traits;
UCEC	cis	rs364477	0.672	rs10759073	chr9:953465	C/T	cg13952963	chr9:998547	NA	0.44	4.53	0.35	1.22e-5	Major depressive disorder;
UCEC	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg20965017	chr5:231967	SDHA	-0.66	-5.79	-0.43	4.08e-8	Breast cancer;
UCEC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.81	5.68	0.42	6.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.74	6.58	0.48	7.8e-10	Neutrophil percentage of white cells;
UCEC	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.64	5.59	0.42	1.07e-7	Bipolar disorder;
UCEC	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.45	5.25	0.4	5.3e-7	Alzheimer's disease (late onset);
UCEC	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg22857025	chr5:266934	NA	-0.82	-5.82	-0.43	3.53e-8	Asthma (childhood onset);
UCEC	cis	rs10412972	0.564	rs2198165	chr19:52177748	G/A	cg13729816	chr19:52954722	NA	-0.41	-4.51	-0.35	1.33e-5	Plasma plasminogen levels;
UCEC	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.52	-5.08	-0.39	1.14e-6	Aortic root size;
UCEC	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.48	-0.47	1.28e-9	Aortic root size;
UCEC	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07690219	chr3:49449608	TCTA;RHOA	0.52	4.8	0.37	3.94e-6	Menarche (age at onset);
UCEC	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.47	-6.58	-0.48	7.67e-10	Metabolite levels;
UCEC	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.65e-10	Motion sickness;
UCEC	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.6	5.6	0.42	1.01e-7	Schizophrenia;
UCEC	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.48	-4.77	-0.37	4.34e-6	Parkinson's disease;
UCEC	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.58	6.08	0.45	9.8e-9	Red blood cell count;
UCEC	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg01528321	chr10:82214614	TSPAN14	1.2	14.67	0.77	1.42e-30	Post bronchodilator FEV1;
UCEC	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg12596171	chr3:113251061	SIDT1	-0.54	-4.85	-0.37	3.17e-6	Response to simvastatin treatment (PCSK9 protein level change);
UCEC	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg22868518	chr11:507468	RNH1	-0.47	-4.57	-0.35	1.01e-5	Systemic lupus erythematosus;
UCEC	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-5.05	-0.38	1.3e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.28	-0.4	4.51e-7	Coronary artery disease;
UCEC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.49	4.53	0.35	1.2e-5	Lung cancer;
UCEC	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	0.77	4.98	0.38	1.75e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.41	4.65	0.36	7.24e-6	Mean corpuscular volume;
UCEC	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.53	-5.37	-0.4	3.04e-7	Height;
UCEC	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.58	-6.03	-0.45	1.29e-8	Coronary heart disease;
UCEC	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.48	-5.77	-0.43	4.51e-8	Prudent dietary pattern;
UCEC	trans	rs10242455	0.702	rs112475236	chr7:99044679	A/G	cg09045935	chr12:6379348	NA	0.97	6.9	0.49	1.43e-10	Blood metabolite levels;
UCEC	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.58	-5.97	-0.44	1.74e-8	Prostate cancer;
UCEC	cis	rs36715	0.953	rs185177	chr5:127547810	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	5.47	0.41	1.89e-7	Breast cancer;
UCEC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.47	4.78	0.37	4.16e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.81	8.98	0.6	1.2e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.67	5.1	0.39	1.03e-6	Prostate cancer;
UCEC	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.56	5.2	0.39	6.53e-7	Brain structure;
UCEC	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	0.88	5.8	0.43	3.98e-8	Arsenic metabolism;
UCEC	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-5.02	-0.38	1.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-5.5	-0.41	1.64e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.43	-4.87	-0.37	2.84e-6	Pelvic organ prolapse;
UCEC	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg17933807	chr1:38061675	GNL2	0.91	11.02	0.67	5.7e-21	Axial length;
UCEC	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.48	0.47	1.33e-9	Cognitive test performance;
UCEC	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.82	-8.34	-0.57	4.89e-14	Caffeine consumption;
UCEC	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-6.4	-0.47	1.93e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	4.9	0.37	2.54e-6	Hemoglobin concentration;
UCEC	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-8.55	-0.58	1.48e-14	Mean platelet volume;
UCEC	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	0.9	8.46	0.57	2.51e-14	Cognitive function;
UCEC	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-9.31	-0.61	1.69e-16	Coffee consumption (cups per day);
UCEC	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.45	4.66	0.36	7e-6	Response to antipsychotic treatment;
UCEC	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.83	-7.21	-0.51	2.66e-11	Neurofibrillary tangles;
UCEC	cis	rs12644436	1.000	rs1026663	chr4:88789140	T/C	cg27179352	chr4:88029472	AFF1	0.41	4.54	0.35	1.18e-5	HIV-1 viral setpoint;
UCEC	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.74	-9.92	-0.63	4.6e-18	Gut microbiota (bacterial taxa);
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg08533424	chr17:37009973	RPL23;SNORA21	0.67	6.86	0.49	1.82e-10	Triglyceride levels;
UCEC	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	0.83	5.32	0.4	3.85e-7	Arsenic metabolism;
UCEC	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.33	0.71	1.97e-24	Prudent dietary pattern;
UCEC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg18279126	chr7:2041391	MAD1L1	-0.46	-5.72	-0.43	5.88e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.47	-0.41	1.9e-7	Platelet count;
UCEC	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.59	5.78	0.43	4.4e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs12618769	0.597	rs72819986	chr2:99045867	G/C	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.18	16.16	0.8	2.02e-34	Cognitive function;
UCEC	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.08e-13	Prudent dietary pattern;
UCEC	cis	rs4499344	0.730	rs28416849	chr19:33099758	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.64	6.06	0.45	1.08e-8	Mean platelet volume;
UCEC	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg16060761	chr17:80687452	NA	-0.53	-5.04	-0.38	1.35e-6	Glycated hemoglobin levels;
UCEC	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.52	-5.56	-0.42	1.24e-7	Body mass index;
UCEC	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.52	4.72	0.36	5.49e-6	Pulmonary function decline;
UCEC	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.47	4.94	0.38	2.13e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.65	-6.35	-0.46	2.57e-9	Mortality in heart failure;
UCEC	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.59	-4.84	-0.37	3.23e-6	Obesity-related traits;
UCEC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.59	5.49	0.41	1.7e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.88	-9.62	-0.62	2.74e-17	Obesity-related traits;
UCEC	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.07	11.21	0.68	1.87e-21	Psoriasis vulgaris;
UCEC	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.66	-7.45	-0.52	7.18e-12	Body mass index;
UCEC	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.55	5.79	0.43	4.03e-8	Mood instability;
UCEC	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.61	-7.08	-0.5	5.51e-11	Menopause (age at onset);
UCEC	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg12463550	chr7:65579703	CRCP	0.55	5.61	0.42	9.8e-8	Aortic root size;
UCEC	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-4.51	-0.35	1.3e-5	Electroencephalogram traits;
UCEC	cis	rs4778581	0.604	rs2903265	chr15:80413384	C/T	cg08257866	chr15:80351198	ZFAND6	-0.4	-4.61	-0.36	8.73e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg23018236	chr17:30244563	NA	-0.69	-4.69	-0.36	6.13e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs7072216	0.881	rs6584192	chr10:100152373	T/G	cg19567339	chr10:100142640	NA	0.61	8.57	0.58	1.32e-14	Metabolite levels;
UCEC	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.56	4.86	0.37	3.03e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.53	-5.76	-0.43	4.74e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.52	-5.02	-0.38	1.48e-6	Diastolic blood pressure;
UCEC	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	8.56	0.58	1.38e-14	Electrocardiographic conduction measures;
UCEC	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.78	8.22	0.56	9.71e-14	Body mass index;
UCEC	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.52	-5.77	-0.43	4.47e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	4.96	0.38	1.96e-6	Birth weight;
UCEC	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	7.19	0.51	3.08e-11	Tonsillectomy;
UCEC	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.66	-6.12	-0.45	8.24e-9	Metabolite levels;
UCEC	cis	rs7307889	0.793	rs7489044	chr12:6009595	A/G	cg05660680	chr12:6400491	NA	-0.67	-4.55	-0.35	1.1e-5	Obesity-related traits;
UCEC	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg06782697	chr22:19743336	TBX1	-0.36	-5.39	-0.41	2.73e-7	Metabolite levels;
UCEC	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.5	5.18	0.39	7.1e-7	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.25	0.4	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.65	6.23	0.46	4.74e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.58	5.29	0.4	4.41e-7	Multiple sclerosis;
UCEC	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.52	6.01	0.44	1.38e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs239198	0.602	rs9390698	chr6:101296389	G/A	cg09795085	chr6:101329169	ASCC3	0.5	4.88	0.37	2.71e-6	Menarche (age at onset);
UCEC	cis	rs7870753	0.838	rs7867618	chr9:99254440	A/G	cg25260653	chr9:99212216	HABP4	0.55	5.58	0.42	1.14e-7	Height;
UCEC	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg10902566	chr4:727664	PCGF3	-0.57	-5.02	-0.38	1.45e-6	Systolic blood pressure;
UCEC	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg20368463	chr18:77673604	PQLC1	0.73	5.28	0.4	4.53e-7	Opioid sensitivity;
UCEC	cis	rs6893807	0.778	rs35991856	chr5:87968347	C/A	cg09002922	chr5:87956389	LOC645323	-0.59	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.78	7.06	0.5	6.04e-11	Initial pursuit acceleration;
UCEC	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18252515	chr7:66147081	NA	-0.53	-5.21	-0.4	6.14e-7	Aortic root size;
UCEC	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.81	-6.29	-0.46	3.37e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg05855489	chr10:104503620	C10orf26	-0.6	-6.46	-0.47	1.44e-9	Immature fraction of reticulocytes;Schizophrenia;
UCEC	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.43	4.71	0.36	5.77e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.72	7.02	0.5	7.43e-11	Refractive astigmatism;
UCEC	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.69	7.98	0.55	3.75e-13	Mean corpuscular volume;
UCEC	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.81	10.32	0.65	4.12e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.51	-5.95	-0.44	1.88e-8	Type 2 diabetes;
UCEC	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.69	7.72	0.54	1.67e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.63	6.69	0.48	4.38e-10	QRS complex (12-leadsum);
UCEC	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-6.54	-0.47	9.41e-10	Crohn's disease;
UCEC	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.55	5.88	0.44	2.62e-8	Mean platelet volume;
UCEC	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.74	-7.88	-0.54	6.88e-13	Lung cancer;
UCEC	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.82	-9.42	-0.61	8.99e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7937612	1.000	rs4938808	chr11:120336902	G/T	cg12584626	chr11:120203529	NA	0.51	5.14	0.39	8.78e-7	Intraocular pressure;
UCEC	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.7	-7.61	-0.53	3e-12	White blood cell count (basophil);
UCEC	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.52	4.82	0.37	3.57e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.54	-0.58	1.55e-14	Total body bone mineral density;
UCEC	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.51	-4.54	-0.35	1.18e-5	Colorectal cancer;
UCEC	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg01973587	chr1:228161476	NA	0.38	5.21	0.39	6.36e-7	Diastolic blood pressure;
UCEC	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.73	-6.52	-0.47	1.05e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	0.97	4.87	0.37	2.91e-6	IgG glycosylation;
UCEC	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg04826882	chr13:114838756	RASA3	-0.6	-4.63	-0.36	7.98e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.58	5.27	0.4	4.83e-7	Menopause (age at onset);
UCEC	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg12262378	chr17:6899522	ALOX12	0.44	5.13	0.39	9.05e-7	Tonsillectomy;
UCEC	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.52	5.34	0.4	3.45e-7	Corneal astigmatism;
UCEC	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.72	6.73	0.49	3.61e-10	Aortic root size;
UCEC	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.7	-0.43	6.46e-8	Depression;
UCEC	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.47	-4.52	-0.35	1.26e-5	Total body bone mineral density;
UCEC	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.67	4.84	0.37	3.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.54	6.35	0.46	2.55e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.47	-5.5	-0.41	1.66e-7	Neuroticism;
UCEC	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24249390	chr15:90295951	MESP1	-0.43	-4.87	-0.37	2.88e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	trans	rs1459104	1.000	rs12793778	chr11:55085722	T/C	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.16e-10	Body mass index;
UCEC	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.69	-6.49	-0.47	1.24e-9	Aortic root size;
UCEC	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.68	4.8	0.37	3.8e-6	Diabetic retinopathy;
UCEC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12516959	chr21:47718080	NA	-0.4	-4.58	-0.35	9.9e-6	Testicular germ cell tumor;
UCEC	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.67	5.1	0.39	1.03e-6	Corneal astigmatism;
UCEC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.42	0.52	8.62e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg01256987	chr12:42539512	GXYLT1	0.41	4.75	0.36	4.78e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.79	-10.11	-0.64	1.42e-18	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.55	-0.35	1.12e-5	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg07250515	chr12:56618133	OBFC2B	0.59	5.23	0.4	5.78e-7	Psoriasis vulgaris;
UCEC	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.88	0.37	2.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg26061582	chr7:22766209	IL6	0.59	5.49	0.41	1.73e-7	Lung cancer;
UCEC	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	6.02	0.44	1.33e-8	IgG glycosylation;
UCEC	cis	rs4372836	0.504	rs10183665	chr2:28995226	A/G	cg09522027	chr2:28974177	PPP1CB	-0.67	-7.03	-0.5	7.12e-11	Body mass index;
UCEC	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.7	-5.53	-0.42	1.41e-7	Major depressive disorder;
UCEC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.72	-8.0	-0.55	3.33e-13	Monocyte count;
UCEC	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.76	-9.78	-0.63	1.07e-17	Breast cancer;
UCEC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg14288399	chr11:64110785	CCDC88B	0.39	4.71	0.36	5.73e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg24169773	chr3:122142474	KPNA1	-0.69	-4.81	-0.37	3.71e-6	LDL cholesterol levels;
UCEC	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.1	-0.45	8.99e-9	Aortic root size;
UCEC	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg13540341	chr19:49222985	MAMSTR	0.38	4.6	0.35	8.97e-6	Dietary macronutrient intake;
UCEC	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.63	7.13	0.51	4.15e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.64	-4.54	-0.35	1.15e-5	Aortic root size;
UCEC	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04731861	chr2:219085781	ARPC2	0.39	4.51	0.35	1.33e-5	Colorectal cancer;
UCEC	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg27246729	chr12:121163418	ACADS	0.5	4.81	0.37	3.67e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.68	-6.37	-0.47	2.29e-9	Blood pressure (smoking interaction);
UCEC	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.61	6.57	0.48	8.13e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-9.32	-0.61	1.64e-16	Electrocardiographic conduction measures;
UCEC	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.67	7.27	0.51	1.94e-11	HDL cholesterol;
UCEC	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.93	10.12	0.64	1.38e-18	Cognitive function;
UCEC	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.65	6.56	0.48	8.6e-10	Itch intensity from mosquito bite;
UCEC	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.63	5.28	0.4	4.51e-7	Systolic blood pressure;
UCEC	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.9	4.77	0.37	4.37e-6	Diabetic retinopathy;
UCEC	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.61	5.65	0.42	8.03e-8	Type 2 diabetes;
UCEC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg06917450	chr1:38156652	C1orf109	-0.54	-5.09	-0.39	1.07e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.93	9.66	0.62	2.08e-17	Cognitive ability;
UCEC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg21854759	chr1:92012499	NA	-0.48	-4.6	-0.35	9.11e-6	Breast cancer;
UCEC	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg03146154	chr1:46216737	IPP	-0.45	-4.79	-0.37	4.06e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-6.41	-0.47	1.86e-9	Total body bone mineral density;
UCEC	cis	rs12692119	0.764	rs61742783	chr2:127656664	A/G	cg04330126	chr2:127727905	NA	-0.8	-4.77	-0.37	4.33e-6	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs4851266	1.000	rs11123817	chr2:100835032	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.38	4.52	0.35	1.27e-5	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	7.23	0.51	2.4e-11	Ileal carcinoids;
UCEC	cis	rs12545109	0.571	rs4237014	chr8:57284479	C/A	cg07776626	chr8:57350775	NA	-0.51	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.99	7.09	0.5	5.2e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs77932157	1.000	rs75143720	chr10:69506646	G/A	cg19935665	chr10:69523153	NA	-0.59	-4.53	-0.35	1.24e-5	Blood pressure traits (multi-trait analysis);
UCEC	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg16497661	chr14:103986332	CKB	0.47	5.49	0.41	1.75e-7	Body mass index;
UCEC	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.59	4.79	0.37	4.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg01689657	chr7:91764605	CYP51A1	0.4	5.06	0.39	1.21e-6	Breast cancer;
UCEC	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-0.89	-7.17	-0.51	3.45e-11	Blood protein levels;
UCEC	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg05660106	chr1:15850417	CASP9	1.05	11.71	0.69	8.59e-23	Systolic blood pressure;
UCEC	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg05738196	chr6:26577821	NA	0.63	7.45	0.52	7.54e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-6.2	-0.46	5.44e-9	Dental caries;
UCEC	cis	rs17162190	0.590	rs7524421	chr1:26810612	C/G	cg23229016	chr1:26872525	RPS6KA1	0.28	4.8	0.37	3.94e-6	Mean corpuscular volume;
UCEC	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.55	5.68	0.42	6.92e-8	Dupuytren's disease;
UCEC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03452623	chr4:187889614	NA	-0.63	-7.43	-0.52	8.27e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.47	4.84	0.37	3.23e-6	Smoking initiation;
UCEC	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	0.85	9.98	0.64	3.12e-18	Breast cancer;
UCEC	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg23018236	chr17:30244563	NA	-0.66	-4.72	-0.36	5.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.37	-4.94	-0.38	2.07e-6	Rheumatoid arthritis;
UCEC	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg21486944	chr6:28411378	ZSCAN23	-0.56	-6.54	-0.47	9.68e-10	Pubertal anthropometrics;
UCEC	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04374321	chr14:90722782	PSMC1	0.64	6.87	0.49	1.67e-10	Mortality in heart failure;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03393966	chr19:18548015	ISYNA1	0.61	7.0	0.5	8.47e-11	Warfarin maintenance dose;
UCEC	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.76	-0.43	4.82e-8	Hemoglobin concentration;
UCEC	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-6.34	-0.46	2.73e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.76	-8.64	-0.58	8.75e-15	Menarche (age at onset);
UCEC	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg25251562	chr2:3704773	ALLC	0.5	4.72	0.36	5.34e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
UCEC	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.57	-6.45	-0.47	1.5e-9	Body mass index;
UCEC	cis	rs7246967	0.544	rs403717	chr19:23008803	A/G	cg08271804	chr19:22816896	ZNF492	0.49	4.51	0.35	1.34e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	6.52	0.47	1.04e-9	Schizophrenia;
UCEC	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.83	-7.32	-0.52	1.53e-11	Platelet count;
UCEC	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.68	-8.14	-0.56	1.56e-13	Prudent dietary pattern;
UCEC	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg23855989	chr12:50355821	AQP5	0.91	6.19	0.45	5.76e-9	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	6.08	0.45	9.9e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.4	-0.57	3.4e-14	Parkinson's disease;
UCEC	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.74	9.43	0.61	8.43e-17	Body mass index;
UCEC	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.59	-6.88	-0.49	1.58e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-8.86	-0.59	2.45e-15	Exhaled nitric oxide output;
UCEC	cis	rs17220352	0.512	rs4837578	chr9:119271254	C/T	cg13412550	chr9:120177700	ASTN2	-0.81	-4.83	-0.37	3.39e-6	Headache;
UCEC	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.16	-0.56	1.37e-13	Total cholesterol levels;
UCEC	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07215822	chr6:158701037	NA	-0.66	-5.71	-0.43	6.1e-8	Height;
UCEC	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg26769984	chr7:1090371	C7orf50	0.5	4.88	0.37	2.74e-6	Longevity;Endometriosis;
UCEC	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.76	7.28	0.51	1.91e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-4.8	-0.37	3.8e-6	Lung cancer in ever smokers;
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg20007245	chr22:24372913	LOC391322	-0.58	-6.23	-0.46	4.55e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.38	0.52	1.07e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs1545257	0.505	rs2584950	chr2:24632762	A/G	cg06627628	chr2:24431161	ITSN2	-0.53	-5.38	-0.41	2.93e-7	Sjögren's syndrome;
UCEC	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.45	5.47	0.41	1.9e-7	Bone mineral density;
UCEC	cis	rs2970992	0.764	rs3112257	chr2:101326877	G/T	cg01042948	chr2:101319752	NA	0.55	5.97	0.44	1.69e-8	Educational attainment;
UCEC	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg00786635	chr1:25594202	NA	0.49	4.86	0.37	3e-6	Plateletcrit;Mean corpuscular volume;
UCEC	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg06637938	chr14:75390232	RPS6KL1	0.48	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.2	0.46	5.35e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.82	-7.38	-0.52	1.07e-11	Resting heart rate;
UCEC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg19645103	chr12:69753606	YEATS4	-0.55	-4.98	-0.38	1.73e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg20933586	chr14:24608199	FAM158A	0.42	5.43	0.41	2.23e-7	IgG glycosylation;
UCEC	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.46	-4.63	-0.36	8.08e-6	Schizophrenia;
UCEC	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.57	-5.76	-0.43	4.75e-8	Retinal vascular caliber;
UCEC	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-5.11	-0.39	9.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.13	0.39	8.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	5.56	0.42	1.22e-7	Schizophrenia;
UCEC	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.05	-0.45	1.16e-8	Aortic root size;
UCEC	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.41	9.26	0.61	2.27e-16	Gout;
UCEC	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.47	4.51	0.35	1.32e-5	IgG glycosylation;
UCEC	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.48	-5.06	-0.39	1.22e-6	Aortic root size;
UCEC	cis	rs6832769	0.961	rs11735267	chr4:56347287	C/T	cg05960024	chr4:56376020	CLOCK	0.55	5.74	0.43	5.29e-8	Personality dimensions;
UCEC	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.81	9.23	0.61	2.82e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs228437	0.609	rs4895417	chr6:134932571	C/A	cg20986996	chr6:134210159	TCF21	-0.38	-4.51	-0.35	1.3e-5	Melanoma;
UCEC	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.67	-7.67	-0.53	2.19e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.58	6.42	0.47	1.73e-9	Bipolar disorder;
UCEC	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg16011679	chr1:85725395	C1orf52	0.9	5.77	0.43	4.52e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	1.0	11.14	0.68	2.83e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg18681998	chr4:17616180	MED28	0.58	6.57	0.48	8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs58722170	0.659	rs72659423	chr1:38083472	C/T	cg17933807	chr1:38061675	GNL2	-0.6	-5.09	-0.39	1.1e-6	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
UCEC	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.66	6.06	0.45	1.12e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg07150772	chr14:90864620	CALM1	0.54	5.24	0.4	5.45e-7	Mortality in heart failure;
UCEC	cis	rs8032158	1.000	rs67505007	chr15:56196253	C/T	cg10433327	chr15:56209506	NEDD4	-0.28	-4.51	-0.35	1.34e-5	Keloid;
UCEC	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.93	-6.0	-0.44	1.45e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs4499344	0.730	rs392332	chr19:33105743	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.84	0.43	3.28e-8	Mean platelet volume;
UCEC	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.65	4.64	0.36	7.65e-6	Breast cancer;
UCEC	cis	rs1519814	0.956	rs11774123	chr8:121119274	C/T	cg22335954	chr8:121166405	COL14A1	0.66	5.35	0.4	3.32e-7	Breast cancer;
UCEC	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.03e-5	Type 2 diabetes;
UCEC	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.75	-8.2	-0.56	1.09e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg08271804	chr19:22816896	ZNF492	0.67	6.39	0.47	2.05e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.71	-7.86	-0.54	7.73e-13	Hypospadias;
UCEC	cis	rs6717918	0.520	rs3103262	chr2:232992518	A/G	cg02061626	chr2:233274167	ALPPL2	-0.5	-5.32	-0.4	3.71e-7	Height;
UCEC	cis	rs78487399	0.908	rs72868625	chr2:43831186	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.1	-0.45	8.86e-9	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.38	4.52	0.35	1.27e-5	Multiple sclerosis;
UCEC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.9	11.81	0.7	4.82e-23	Metabolic syndrome;
UCEC	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.44	-5.05	-0.38	1.32e-6	Rheumatoid arthritis;
UCEC	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.54	5.46	0.41	1.94e-7	Aortic root size;
UCEC	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.42	-5.78	-0.43	4.27e-8	Urate levels in overweight individuals;
UCEC	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.38	-0.47	2.17e-9	Platelet count;
UCEC	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.74	-6.34	-0.46	2.69e-9	Adiposity;
UCEC	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.48	-6.05	-0.45	1.15e-8	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.9	5.85	0.43	3.12e-8	Eosinophil percentage of granulocytes;
UCEC	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.58	5.01	0.38	1.52e-6	Systolic blood pressure;
UCEC	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.53	4.65	0.36	7.31e-6	Cholesterol, total;
UCEC	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	0.92	12.97	0.73	4.05e-26	Homoarginine levels;
UCEC	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	8.56	0.58	1.35e-14	Nonalcoholic fatty liver disease;
UCEC	cis	rs6921919	0.525	rs1361386	chr6:28305604	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.44	-4.78	-0.37	4.14e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg24112000	chr20:60950667	NA	-0.45	-4.52	-0.35	1.27e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg05738196	chr6:26577821	NA	0.63	7.31	0.52	1.57e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	0.86	9.12	0.6	5.4e-16	Parkinson's disease;
UCEC	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.48	-4.92	-0.38	2.33e-6	Dupuytren's disease;
UCEC	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.6	6.45	0.47	1.48e-9	Monocyte count;
UCEC	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.68	5.47	0.41	1.86e-7	Type 2 diabetes;
UCEC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg20007245	chr22:24372913	LOC391322	-0.68	-7.31	-0.52	1.56e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs300890	0.707	rs1866756	chr4:144300064	G/A	cg23197460	chr4:144436129	SMARCA5	-0.39	-4.7	-0.36	5.82e-6	Nasopharyngeal carcinoma;
UCEC	cis	rs4708832	0.529	rs365557	chr6:159914714	C/T	cg17154159	chr6:160401562	IGF2R	0.66	4.63	0.36	7.91e-6	QRS duration;
UCEC	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.68	7.55	0.53	4.12e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18252515	chr7:66147081	NA	0.52	5.02	0.38	1.48e-6	Aortic root size;
UCEC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg03714773	chr7:91764589	CYP51A1	0.48	5.91	0.44	2.31e-8	Breast cancer;
UCEC	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.72	-6.33	-0.46	2.77e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.55	4.79	0.37	3.96e-6	Menarche (age at onset);
UCEC	cis	rs4792143	0.522	rs722118	chr17:11369781	G/A	cg23400451	chr17:10373728	MYH4	0.35	4.97	0.38	1.82e-6	Ischemic stroke;
UCEC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.14	-0.45	7.5e-9	Primary biliary cholangitis;
UCEC	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.58	5.51	0.41	1.58e-7	Calcium levels;
UCEC	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg11871910	chr12:69753446	YEATS4	0.89	10.31	0.65	4.27e-19	Blood protein levels;
UCEC	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-5.81	-0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	4.98	0.38	1.78e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.47	-4.61	-0.36	8.63e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg09904177	chr6:26538194	HMGN4	-0.73	-5.03	-0.38	1.42e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.68	-5.6	-0.42	1.03e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.65	-6.21	-0.46	5.21e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1814175	0.720	rs56884483	chr11:49594333	A/T	cg15704280	chr7:45808275	SEPT13	-0.81	-8.46	-0.57	2.42e-14	Height;
UCEC	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.12	7.93	0.55	5.04e-13	Sexual dysfunction (female);
UCEC	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.28	-12.72	-0.72	1.86e-25	Corneal structure;
UCEC	cis	rs953387	1.000	rs2102896	chr2:136906640	T/C	cg07169764	chr2:136633963	MCM6	0.53	5.26	0.4	4.94e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7611694	0.501	rs6438145	chr3:113125211	C/T	cg12596171	chr3:113251061	SIDT1	-0.52	-5.16	-0.39	7.71e-7	Prostate cancer;
UCEC	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-5.03	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs3772130	0.540	rs7649436	chr3:121562304	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.52	4.86	0.37	3e-6	Cognitive performance;
UCEC	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-4.85	-0.37	3.16e-6	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	0.91	5.74	0.43	5.2e-8	Skin colour saturation;
UCEC	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.45	-5.35	-0.4	3.34e-7	Resting heart rate;
UCEC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-4.61	-0.36	8.81e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Smoking initiation;
UCEC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg21053147	chr12:120880522	NA	-0.65	-5.46	-0.41	1.98e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg18681998	chr4:17616180	MED28	0.77	9.33	0.61	1.52e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.42	6.02	0.44	1.35e-8	Crohn's disease;
UCEC	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.73	-7.62	-0.53	2.81e-12	Body mass index;
UCEC	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-7.09	-0.5	5.2e-11	Ileal carcinoids;
UCEC	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.47	6.01	0.44	1.42e-8	HDL cholesterol levels;
UCEC	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.47	-4.72	-0.36	5.4e-6	Platelet count;
UCEC	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-6.94	-0.5	1.19e-10	Colorectal cancer;
UCEC	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.48	-0.52	6.29e-12	Parkinson's disease;
UCEC	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg23791538	chr6:167370224	RNASET2	-0.52	-5.47	-0.41	1.93e-7	Crohn's disease;
UCEC	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.45	-4.66	-0.36	7.12e-6	Placebo response in major depressive disorder (% change in symptom score);
UCEC	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.67	-5.67	-0.42	7.43e-8	Alzheimer's disease;
UCEC	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.53	6.12	0.45	8.08e-9	Oral cavity cancer;
UCEC	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.53	-4.68	-0.36	6.45e-6	Colorectal cancer;
UCEC	cis	rs2734839	0.507	rs2471850	chr11:113301266	G/A	cg14159747	chr11:113255604	NA	0.42	4.66	0.36	6.9e-6	Information processing speed;
UCEC	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg12024160	chr4:1254474	NA	0.73	9.01	0.6	9.78e-16	Obesity-related traits;
UCEC	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.04	-8.31	-0.57	5.72e-14	Exhaled nitric oxide output;
UCEC	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.89	0.44	2.56e-8	HDL cholesterol;
UCEC	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.68	-7.69	-0.54	1.97e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.41	5.53	0.42	1.4e-7	Breast cancer;
UCEC	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.12	10.2	0.64	8.47e-19	Vitiligo;
UCEC	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.6	6.47	0.47	1.38e-9	Crohn's disease;
UCEC	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.49	4.98	0.38	1.78e-6	Dupuytren's disease;
UCEC	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.59	-6.48	-0.47	1.29e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.54	9.74	0.63	1.33e-17	Airflow obstruction;
UCEC	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.7	7.08	0.5	5.63e-11	Coronary artery disease;
UCEC	cis	rs7870753	0.838	rs34447339	chr9:99247274	C/T	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg23970785	chr16:11036526	DEXI	0.41	4.55	0.35	1.13e-5	Testicular germ cell tumor;
UCEC	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.65	-7.15	-0.51	3.72e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.77	-8.8	-0.59	3.45e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs9843304	0.546	rs9828967	chr3:149226442	A/T	cg08667024	chr3:149219783	TM4SF4	0.56	6.6	0.48	6.84e-10	Gallstone disease;
UCEC	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-4.68	-0.36	6.49e-6	Extrinsic epigenetic age acceleration;
UCEC	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.64	-6.86	-0.49	1.74e-10	Colorectal cancer;
UCEC	cis	rs970548	0.954	rs12249012	chr10:45992470	G/A	cg15223267	chr10:46222474	FAM21C	0.53	5.06	0.39	1.25e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.44	5.3	0.4	4.19e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.58	7.43	0.52	8.23e-12	Anterior chamber depth;
UCEC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.37e-11	Aortic root size;
UCEC	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.68	0.36	6.36e-6	Schizophrenia;
UCEC	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.74	6.25	0.46	4.18e-9	Menopause (age at onset);
UCEC	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.46	4.82	0.37	3.47e-6	Schizophrenia;
UCEC	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.66	7.37	0.52	1.15e-11	Body mass index;
UCEC	cis	rs12579753	0.692	rs11115064	chr12:82278683	G/A	cg07988820	chr12:82153109	PPFIA2	-0.61	-5.43	-0.41	2.3e-7	Resting heart rate;
UCEC	cis	rs3914502	0.593	rs500999	chr3:174495923	C/T	cg21145449	chr3:174580620	NAALADL2	0.43	4.88	0.37	2.76e-6	Autism spectrum disorder;
UCEC	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.82	4.54	0.35	1.17e-5	Diabetic retinopathy;
UCEC	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.72	-7.81	-0.54	1.02e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.6	5.18	0.39	7.25e-7	Obesity-related traits;
UCEC	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg06521331	chr12:34319734	NA	-0.66	-5.32	-0.4	3.79e-7	Morning vs. evening chronotype;
UCEC	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.75	-8.55	-0.58	1.49e-14	HDL cholesterol;
UCEC	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.5	5.11	0.39	9.71e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg19513890	chr22:42538836	CYP2D7P1	0.43	4.87	0.37	2.87e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18932078	chr1:2524107	MMEL1	-0.35	-6.04	-0.45	1.2e-8	Ulcerative colitis;
UCEC	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.64	6.73	0.49	3.51e-10	Lymphocyte counts;
UCEC	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg15147215	chr3:52552868	STAB1	-0.44	-4.84	-0.37	3.29e-6	Bipolar disorder;
UCEC	cis	rs151997	0.853	rs6882235	chr5:50260139	T/C	cg06027927	chr5:50259733	NA	0.57	5.25	0.4	5.23e-7	Callous-unemotional behaviour;
UCEC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg15147215	chr3:52552868	STAB1	0.4	4.66	0.36	7.05e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4400599	0.642	rs4072431	chr1:154167116	A/G	cg05139571	chr1:154127138	NUP210L	0.44	4.76	0.37	4.63e-6	Platelet distribution width;
UCEC	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.12	0.39	9.6e-7	Personality dimensions;
UCEC	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg03057079	chr11:64001712	VEGFB;DNAJC4	0.45	5.11	0.39	9.81e-7	Platelet count;
UCEC	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg06401019	chr5:92957098	FAM172A;MIR2277	0.72	5.39	0.41	2.8e-7	Diabetic retinopathy;
UCEC	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-6.22	-0.46	4.87e-9	Aortic root size;
UCEC	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.75	-7.47	-0.52	6.5e-12	Educational attainment (years of education);
UCEC	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	7.73	0.54	1.54e-12	Alzheimer's disease;
UCEC	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg23782820	chr8:58130467	NA	0.5	4.69	0.36	6.07e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7246967	0.611	rs8107724	chr19:22867414	G/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03352830	chr11:487213	PTDSS2	0.84	6.6	0.48	6.95e-10	Body mass index;
UCEC	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.54	-6.77	-0.49	2.89e-10	Prevalent atrial fibrillation;
UCEC	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg06671706	chr8:8559999	CLDN23	0.6	5.06	0.39	1.21e-6	Obesity-related traits;
UCEC	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.69	5.98	0.44	1.63e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.49	-5.91	-0.44	2.28e-8	Neuroticism;
UCEC	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.16	-0.39	8.01e-7	Chronic sinus infection;
UCEC	cis	rs11235843	1.000	rs6590	chr11:73373552	C/T	cg23931323	chr11:73372278	PLEKHB1	0.74	4.78	0.37	4.22e-6	Hand grip strength;
UCEC	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04731861	chr2:219085781	ARPC2	0.41	4.55	0.35	1.1e-5	Colorectal cancer;
UCEC	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13880726	chr7:1868755	MAD1L1	0.46	4.59	0.35	9.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.55	-4.55	-0.35	1.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.71	0.43	6e-8	Coffee consumption (cups per day);
UCEC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	6.97	0.5	9.92e-11	Chronic sinus infection;
UCEC	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	0.97	6.52	0.47	1.07e-9	Type 2 diabetes nephropathy;
UCEC	cis	rs17106184	1.000	rs77701130	chr1:51232628	G/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.33	-0.4	3.69e-7	Type 2 diabetes;
UCEC	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.47	0.41	1.88e-7	Breast cancer;
UCEC	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg02737609	chr1:26758790	DHDDS	-0.51	-4.59	-0.35	9.26e-6	Obesity-related traits;
UCEC	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.63	6.81	0.49	2.29e-10	Monocyte count;
UCEC	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-9.13	-0.6	4.88e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs7517126	1.000	rs7547477	chr1:196839292	C/T	cg07209298	chr1:196795943	CFHR1	0.51	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.44	-4.7	-0.36	6e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.48	4.67	0.36	6.85e-6	Diastolic blood pressure;
UCEC	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.56	4.63	0.36	7.93e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.56	-5.09	-0.39	1.06e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.78	-8.85	-0.59	2.49e-15	Height;
UCEC	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.02	11.48	0.69	3.55e-22	IgG glycosylation;
UCEC	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.75	-5.54	-0.42	1.37e-7	Mean platelet volume;
UCEC	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-5.46	-0.41	1.96e-7	Platelet count;
UCEC	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	5.98	0.44	1.62e-8	Hip circumference adjusted for BMI;
UCEC	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.96e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16346588	chr10:242978	ZMYND11	-0.47	-4.59	-0.35	9.25e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.54	-0.42	1.33e-7	Blood metabolite levels;
UCEC	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	0.67	4.89	0.37	2.59e-6	Blood protein levels;
UCEC	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.55	5.02	0.38	1.5e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.44	4.69	0.36	6.28e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.87	5.83	0.43	3.4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.52	-6.14	-0.45	7.17e-9	Pubertal anthropometrics;
UCEC	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.51	4.93	0.38	2.15e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.42	4.66	0.36	6.95e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12644436	0.864	rs4693887	chr4:88779020	C/T	cg27179352	chr4:88029472	AFF1	0.41	4.64	0.36	7.52e-6	HIV-1 viral setpoint;
UCEC	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg06096015	chr1:231504339	EGLN1	0.42	4.84	0.37	3.24e-6	Hemoglobin concentration;
UCEC	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.74	8.02	0.55	3.05e-13	Immature fraction of reticulocytes;
UCEC	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.46	4.83	0.37	3.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.66	5.77	0.43	4.55e-8	Aortic root size;
UCEC	cis	rs953387	1.000	rs4954568	chr2:136910690	T/A	cg07169764	chr2:136633963	MCM6	0.53	5.45	0.41	2.06e-7	Arthritis (juvenile idiopathic);
UCEC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.6	-4.88	-0.37	2.75e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	9.79	0.63	1.01e-17	Platelet count;
UCEC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.49	-4.94	-0.38	2.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	0.93	11.38	0.68	6.57e-22	Homoarginine levels;
UCEC	cis	rs8020441	0.588	rs67977855	chr14:51184662	G/T	cg04730355	chr14:51134070	SAV1	0.6	5.14	0.39	8.68e-7	Cognitive performance;
UCEC	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.19	0.39	6.85e-7	Cognitive test performance;
UCEC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.84	8.92	0.59	1.69e-15	Parkinson's disease;
UCEC	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.38	0.76	8e-30	Height;
UCEC	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.52	4.86	0.37	3.01e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	0.94	10.02	0.64	2.44e-18	Breast cancer;
UCEC	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.53	-5.4	-0.41	2.59e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.78	-7.51	-0.53	5.18e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.75	7.48	0.53	6.17e-12	Lung cancer;
UCEC	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.36	-4.63	-0.36	7.98e-6	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.75	8.15	0.56	1.47e-13	Menarche (age at onset);
UCEC	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-1.01	-12.36	-0.71	1.65e-24	Obesity-related traits;
UCEC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.54	-5.33	-0.4	3.54e-7	Bipolar disorder;
UCEC	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.39	-4.59	-0.35	9.62e-6	Total body bone mineral density;
UCEC	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.6	4.91	0.38	2.43e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.67	6.99	0.5	8.69e-11	QT interval;
UCEC	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.02	-8.07	-0.55	2.28e-13	Exhaled nitric oxide output;
UCEC	cis	rs7088591	0.867	rs57367361	chr10:59788632	T/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs925228	0.955	rs1400218	chr2:24145253	C/A	cg13272742	chr2:24272458	FKBP1B	0.6	5.07	0.39	1.2e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg06818710	chr6:28411271	ZSCAN23	-0.59	-7.1	-0.51	4.99e-11	Cardiac Troponin-T levels;
UCEC	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06223018	chr3:49557076	DAG1	0.34	4.9	0.37	2.51e-6	Parkinson's disease;
UCEC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.49	-6.61	-0.48	6.76e-10	Body mass index;
UCEC	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.66	-0.36	6.9e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.61	5.6	0.42	1.05e-7	Initial pursuit acceleration;
UCEC	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	9.2	0.6	3.21e-16	Menopause (age at onset);
UCEC	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs1150668	1.000	rs1150668	chr6:28129789	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.09	-0.39	1.08e-6	Pubertal anthropometrics;
UCEC	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.61	-5.52	-0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.55	5.86	0.44	2.95e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-1.07	-7.92	-0.55	5.49e-13	Bone mineral density;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.38	-0.41	2.9e-7	Depression;
UCEC	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.64	6.23	0.46	4.76e-9	Itch intensity from mosquito bite;
UCEC	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg08805041	chr16:621841	PIGQ	-0.32	-4.69	-0.36	6.06e-6	Height;
UCEC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.68	-6.97	-0.5	9.98e-11	Neurofibrillary tangles;
UCEC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	4.86	0.37	2.98e-6	Obesity-related traits;
UCEC	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg17279458	chr3:44753948	ZNF502	-0.48	-5.23	-0.4	5.77e-7	Depressive symptoms;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.51	-6.5	-0.47	1.19e-9	Pubertal anthropometrics;
UCEC	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.57	6.14	0.45	7.26e-9	Red blood cell count;
UCEC	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.49	5.09	0.39	1.09e-6	Migraine;
UCEC	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-4.56	-0.35	1.06e-5	Response to antipsychotic treatment;
UCEC	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg21770322	chr7:97807741	LMTK2	-0.52	-6.23	-0.46	4.59e-9	Breast cancer;
UCEC	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.75	5.35	0.4	3.35e-7	Initial pursuit acceleration;
UCEC	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.48	-5.02	-0.38	1.49e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg03354898	chr7:1950403	MAD1L1	-0.46	-4.52	-0.35	1.25e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.81	-0.43	3.74e-8	Bipolar disorder;
UCEC	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg04553112	chr3:125709451	NA	-0.67	-4.82	-0.37	3.6e-6	Blood pressure (smoking interaction);
UCEC	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.31	-10.15	-0.64	1.12e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg06612196	chr6:6737390	NA	0.44	6.32	0.46	2.97e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
UCEC	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.92	8.85	0.59	2.55e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs7709377	0.597	rs13159102	chr5:115519105	C/T	cg23108291	chr5:115420582	COMMD10	0.52	5.48	0.41	1.77e-7	Metabolite levels  (X-11787);
UCEC	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.41	4.7	0.36	5.84e-6	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	6.14	0.45	7.38e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs17123764	0.818	rs7975599	chr12:49944926	A/G	cg20471783	chr12:50157085	TMBIM6	0.61	5.22	0.4	6.04e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-4.76	-0.37	4.66e-6	Response to antipsychotic treatment;
UCEC	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg02454025	chr1:11042201	C1orf127	0.72	7.94	0.55	4.82e-13	Ewing sarcoma;
UCEC	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.57	5.17	0.39	7.62e-7	Corneal astigmatism;
UCEC	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg15880211	chr22:50250494	ZBED4	0.55	5.09	0.39	1.09e-6	Schizophrenia;
UCEC	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.64	6.5	0.47	1.17e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.52	5.23	0.4	5.81e-7	Airflow obstruction;
UCEC	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.56	5.9	0.44	2.41e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg21191810	chr6:118973309	C6orf204	0.42	5.8	0.43	3.85e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.52	6.14	0.45	7.44e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.47	4.59	0.35	9.48e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs4372836	0.729	rs4666122	chr2:29092850	G/T	cg09522027	chr2:28974177	PPP1CB	0.79	8.33	0.57	5.15e-14	Body mass index;
UCEC	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.71e-8	Bipolar disorder;
UCEC	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.54	5.44	0.41	2.18e-7	Aortic root size;
UCEC	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.5	-5.94	-0.44	1.98e-8	Monocyte percentage of white cells;
UCEC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	0.78	6.7	0.48	4.19e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg23307798	chr14:103986281	CKB	-0.48	-5.01	-0.38	1.56e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-4.96	-0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.56	4.84	0.37	3.25e-6	Corneal astigmatism;
UCEC	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.79	-8.68	-0.58	6.7e-15	Cognitive function;
UCEC	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.82	-8.44	-0.57	2.74e-14	Mosquito bite size;
UCEC	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.56	-4.82	-0.37	3.53e-6	Red cell distribution width;
UCEC	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	9.58	0.62	3.47e-17	Chronic sinus infection;
UCEC	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.54	-5.05	-0.38	1.26e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
UCEC	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.72	7.24	0.51	2.34e-11	Aortic root size;
UCEC	cis	rs58804349	0.605	rs117540287	chr10:43512040	G/T	cg11150807	chr10:43354902	NA	0.75	4.66	0.36	7.01e-6	Pediatric bone mineral content (radius);
UCEC	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.41	-4.5	-0.35	1.35e-5	Pelvic organ prolapse;
UCEC	cis	rs10949834	0.793	rs810534	chr7:73505045	A/G	cg07137043	chr7:73588983	EIF4H	0.66	4.6	0.35	8.95e-6	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg23795048	chr12:9217529	LOC144571	0.43	4.94	0.38	2.12e-6	Sjögren's syndrome;
UCEC	cis	rs906628	0.685	rs11224043	chr11:134730732	C/A	cg22063247	chr11:133994642	JAM3	-0.8	-4.65	-0.36	7.3e-6	Tooth agenesis (mandibular third molar);
UCEC	trans	rs4389974	0.932	rs989847	chr8:112411249	T/G	cg22736090	chr17:62339926	TEX2	0.65	6.81	0.49	2.38e-10	Body mass index;
UCEC	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.09	16.2	0.8	1.65e-34	IgG glycosylation;
UCEC	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.47	5.23	0.4	5.77e-7	Blood metabolite levels;
UCEC	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.57	-5.41	-0.41	2.45e-7	Blood protein levels;
UCEC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.7	6.16	0.45	6.66e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs4823173	0.509	rs2401514	chr22:44394019	T/A	cg24663798	chr18:76639743	NA	0.56	7.03	0.5	7.15e-11	Hepatic lipid content in extreme obesity;
UCEC	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.73	-8.09	-0.55	2.1e-13	Breast cancer;
UCEC	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.19e-8	Ovarian reserve;
UCEC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.42	-5.27	-0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.97	14.02	0.76	7.01e-29	Height;
UCEC	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg18681998	chr4:17616180	MED28	0.72	8.42	0.57	3.17e-14	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.15	-8.94	-0.59	1.48e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs4372836	0.729	rs10174533	chr2:28968928	G/A	cg09522027	chr2:28974177	PPP1CB	-0.86	-9.45	-0.61	7.66e-17	Body mass index;
UCEC	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.78	-9.48	-0.62	6.39e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.65	6.97	0.5	1e-10	Waist circumference;Body mass index;
UCEC	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	0.91	4.8	0.37	3.8e-6	IgG glycosylation;
UCEC	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.49	-4.96	-0.38	1.93e-6	Body mass index;
UCEC	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-5.0	-0.38	1.58e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg01072550	chr1:21505969	NA	-0.53	-4.64	-0.36	7.53e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	13.0	0.73	3.41e-26	Post bronchodilator FEV1;
UCEC	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.48	0.41	1.77e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-6.48	-0.47	1.29e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg00277334	chr10:82204260	NA	-0.48	-4.76	-0.37	4.49e-6	Post bronchodilator FEV1;
UCEC	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	1.01	5.85	0.43	3.02e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg26818010	chr10:134567672	INPP5A	-0.61	-6.16	-0.45	6.46e-9	Migraine;
UCEC	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.45	4.75	0.36	4.76e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg00105475	chr2:10696890	NA	-0.37	-4.68	-0.36	6.54e-6	Prostate cancer;
UCEC	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.74	8.68	0.58	6.99e-15	Breast cancer;
UCEC	cis	rs13315871	0.929	rs7634153	chr3:58237501	G/A	cg20936604	chr3:58311152	NA	-0.57	-4.66	-0.36	7.04e-6	Cholesterol, total;
UCEC	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.6	-6.39	-0.47	2.03e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.64	6.26	0.46	4.1e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	5.68	0.42	6.99e-8	Breast cancer;
UCEC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg11890956	chr21:40555474	PSMG1	-0.69	-7.78	-0.54	1.15e-12	Menarche (age at onset);
UCEC	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-9.36	-0.61	1.29e-16	Blood metabolite levels;
UCEC	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.55	5.49	0.41	1.71e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg05874882	chr4:1763078	NA	-0.55	-5.75	-0.43	4.94e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg13695892	chr22:41940480	POLR3H	0.66	4.65	0.36	7.48e-6	Vitiligo;
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	5.87	0.44	2.75e-8	Prudent dietary pattern;
UCEC	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	6.74	0.49	3.32e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.54	5.82	0.43	3.55e-8	Prostate cancer;
UCEC	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.46	0.47	1.46e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.49	4.98	0.38	1.78e-6	Vitiligo;
UCEC	cis	rs308403	0.568	rs309344	chr4:123644812	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	6.39	0.47	2.05e-9	Blood protein levels;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.53	-6.11	-0.45	8.33e-9	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg06562184	chr8:19319451	CSGALNACT1	0.57	5.58	0.42	1.11e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-0.58	-5.83	-0.43	3.41e-8	Pediatric autoimmune diseases;
UCEC	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg25393495	chr8:12034317	NA	-0.32	-4.75	-0.36	4.74e-6	Triglycerides;
UCEC	cis	rs7597155	0.819	rs7424572	chr2:69969918	A/C	cg02498382	chr2:70120550	SNRNP27	0.49	5.39	0.41	2.68e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.94	8.95	0.59	1.43e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs838147	0.844	rs8102032	chr19:49249795	C/T	cg13540341	chr19:49222985	MAMSTR	0.37	4.62	0.36	8.2e-6	Dietary macronutrient intake;
UCEC	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg14008862	chr17:28927542	LRRC37B2	0.53	4.92	0.38	2.32e-6	Body mass index;
UCEC	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-0.73	-6.92	-0.5	1.33e-10	Breast cancer;
UCEC	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.67	6.38	0.47	2.17e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	8.6	0.58	1.12e-14	Platelet count;
UCEC	cis	rs853679	0.585	rs201004	chr6:27804934	T/C	cg19041857	chr6:27730383	NA	-0.52	-4.61	-0.36	8.84e-6	Depression;
UCEC	cis	rs4499344	0.730	rs377044	chr19:33105951	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.58	5.46	0.41	2.02e-7	Mean platelet volume;
UCEC	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg14851346	chr12:38532713	NA	-0.47	-4.5	-0.35	1.37e-5	Bladder cancer;
UCEC	cis	rs883565	0.655	rs7633233	chr3:39146724	G/T	cg01426195	chr3:39028469	NA	-0.79	-10.36	-0.65	3.19e-19	Handedness;
UCEC	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-0.89	-7.17	-0.51	3.45e-11	Blood protein levels;
UCEC	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg18681998	chr4:17616180	MED28	0.87	9.66	0.62	2.09e-17	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.51	-5.18	-0.39	7.17e-7	Obesity-related traits;
UCEC	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.48	5.48	0.41	1.8e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.28e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.84	6.37	0.46	2.33e-9	Multiple sclerosis;
UCEC	cis	rs7581030	1.000	rs3755335	chr2:71594219	G/A	cg07678644	chr2:71558969	ZNF638	0.55	4.97	0.38	1.83e-6	Testicular germ cell tumor;
UCEC	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-8.62	-0.58	9.54e-15	Colorectal cancer;
UCEC	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.69	-9.43	-0.61	8.56e-17	Bipolar disorder;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.44	-4.55	-0.35	1.12e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.75	-0.54	1.36e-12	Total cholesterol levels;
UCEC	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.51	4.69	0.36	6.25e-6	Menopause (age at onset);
UCEC	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg13395646	chr4:1353034	KIAA1530	-0.68	-5.68	-0.42	7.05e-8	Obesity-related traits;
UCEC	cis	rs12579753	0.526	rs73359948	chr12:82322986	A/G	cg07988820	chr12:82153109	PPFIA2	-0.51	-4.58	-0.35	9.78e-6	Resting heart rate;
UCEC	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.71	-5.12	-0.39	9.52e-7	Mean platelet volume;
UCEC	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	4.67	0.36	6.72e-6	Bipolar disorder;
UCEC	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.44	-0.61	8.12e-17	Gut microbiome composition (summer);
UCEC	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.6	6.77	0.49	2.83e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.81	-7.88	-0.54	6.77e-13	Schizophrenia;
UCEC	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg06818710	chr6:28411271	ZSCAN23	-0.49	-5.02	-0.38	1.47e-6	Cardiac Troponin-T levels;
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	8.83	0.59	2.96e-15	Platelet count;
UCEC	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.51	5.4	0.41	2.65e-7	Type 2 diabetes;
UCEC	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.55	-0.42	1.32e-7	Non-small cell lung cancer;
UCEC	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs1978968	0.731	rs9605464	chr22:18459922	C/T	cg03078520	chr22:18463400	MICAL3	-0.54	-6.59	-0.48	7.51e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.72	6.36	0.46	2.4e-9	Subjective well-being;
UCEC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-4.54	-0.35	1.18e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.75	-0.37	4.72e-6	Blood metabolite levels;
UCEC	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	9.89e-19	Cognitive function;
UCEC	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.47	-4.54	-0.35	1.15e-5	Extraversion;
UCEC	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.67	7.09	0.5	5.32e-11	Dilated cardiomyopathy;
UCEC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg10596483	chr8:143751796	JRK	0.47	4.97	0.38	1.82e-6	Schizophrenia;
UCEC	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg14092571	chr14:90743983	NA	-0.42	-5.7	-0.43	6.47e-8	Mortality in heart failure;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg11698762	chr2:74648964	WDR54	0.56	7.21	0.51	2.72e-11	Warfarin maintenance dose;
UCEC	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.56	5.22	0.4	6e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.71	-5.92	-0.44	2.18e-8	Asthma;
UCEC	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.31	-5.18	-0.39	7.13e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	5.23	0.4	5.62e-7	Electroencephalogram traits;
UCEC	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.52	-5.63	-0.42	8.9e-8	Monocyte count;
UCEC	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-9.32	-0.61	1.58e-16	Morning vs. evening chronotype;
UCEC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.6	-7.22	-0.51	2.61e-11	Prostate cancer;
UCEC	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.53	5.41	0.41	2.54e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg00815214	chr21:47717953	NA	-0.4	-4.59	-0.35	9.44e-6	Testicular germ cell tumor;
UCEC	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg08027265	chr7:2291960	NA	-0.46	-5.01	-0.38	1.53e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.59	-6.04	-0.45	1.21e-8	Age at first birth;
UCEC	cis	rs11697848	0.867	rs117436392	chr20:48531814	G/A	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.5	5.68	0.42	6.84e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.65	0.42	7.9e-8	Breast cancer;
UCEC	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg20933586	chr14:24608199	FAM158A	0.4	5.04	0.38	1.32e-6	IgG glycosylation;
UCEC	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.47	-5.23	-0.4	5.63e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.64	6.21	0.46	5.16e-9	Itch intensity from mosquito bite;
UCEC	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg17279458	chr3:44753948	ZNF502	-0.48	-5.23	-0.4	5.77e-7	Depressive symptoms;
UCEC	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.5	0.53	5.49e-12	Bipolar disorder;
UCEC	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.42	-4.75	-0.36	4.87e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg01262667	chr19:19385393	TM6SF2	-0.49	-6.66	-0.48	5.05e-10	Tonsillectomy;
UCEC	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.63	-5.39	-0.41	2.75e-7	Tonsillectomy;
UCEC	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-7.06	-0.5	6e-11	Chronic sinus infection;
UCEC	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.62	-7.12	-0.51	4.37e-11	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	9.14	0.6	4.62e-16	Alzheimer's disease;
UCEC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg11871910	chr12:69753446	YEATS4	0.74	7.62	0.53	2.83e-12	Blood protein levels;
UCEC	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.59	6.72	0.48	3.75e-10	HDL cholesterol;
UCEC	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.74	6.58	0.48	7.93e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.67	0.36	6.63e-6	Tonsillectomy;
UCEC	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.54	5.57	0.42	1.19e-7	Multiple sclerosis;
UCEC	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.76	-7.92	-0.55	5.45e-13	Blood metabolite levels;
UCEC	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-4.61	-0.36	8.85e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg21531300	chr14:75988800	BATF	-0.43	-4.52	-0.35	1.29e-5	IgG glycosylation;
UCEC	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-8.23	-0.56	9.02e-14	Morning vs. evening chronotype;
UCEC	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	7.15	0.51	3.7e-11	Platelet count;
UCEC	cis	rs12634933	0.571	rs6806711	chr3:169024814	C/T	cg03603669	chr3:169896616	PHC3	-0.53	-4.54	-0.35	1.16e-5	Blood pressure (smoking interaction);
UCEC	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.51	5.14	0.39	8.48e-7	IgG glycosylation;
UCEC	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg18681998	chr4:17616180	MED28	0.88	10.8	0.67	2.17e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.42	-0.72	1.12e-24	Height;
UCEC	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.45	-5.15	-0.39	8.16e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.29	-0.4	4.38e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.64	-5.02	-0.38	1.5e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.65	6.7	0.48	4.14e-10	Response to diuretic therapy;
UCEC	cis	rs5754227	1.000	rs5754227	chr22:33105817	T/C	cg12003043	chr22:32341402	C22orf24;YWHAH	-0.57	-5.01	-0.38	1.56e-6	Advanced age-related macular degeneration;
UCEC	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.86	-9.8	-0.63	9.35e-18	Breast cancer;
UCEC	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg20129853	chr10:51489980	NA	0.42	5.03	0.38	1.44e-6	Prostate-specific antigen levels;
UCEC	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.62	-7.11	-0.51	4.8e-11	Menarche (age at onset);
UCEC	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.37	0.57	4.24e-14	Prudent dietary pattern;
UCEC	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.5	4.96	0.38	1.92e-6	Menopause (age at onset);
UCEC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.74	5.35	0.4	3.25e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.52	6.97	0.5	9.93e-11	Eye color traits;
UCEC	cis	rs1425902	0.554	rs56389809	chr8:54124533	A/G	cg01281904	chr8:54164757	OPRK1	-0.36	-4.51	-0.35	1.32e-5	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	7.05e-9	Aortic root size;
UCEC	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.27	-0.4	4.8e-7	Headache;
UCEC	cis	rs9470794	0.790	rs9462403	chr6:38152954	A/C	cg01504030	chr6:38141879	BTBD9	-0.66	-4.87	-0.37	2.84e-6	Type 2 diabetes;
UCEC	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.88	-11.43	-0.69	4.87e-22	Height;
UCEC	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-6.69	-0.48	4.46e-10	Platelet count;
UCEC	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.78	-8.65	-0.58	8.34e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.61	-5.58	-0.42	1.15e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.67	-4.97	-0.38	1.83e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.41e-8	Height;
UCEC	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.71	8.6	0.58	1.1e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.73	7.5	0.53	5.63e-12	Menopause (age at onset);
UCEC	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.5	-6.1	-0.45	9.01e-9	Neuroticism;
UCEC	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.45	6.52	0.47	1.05e-9	Primary biliary cholangitis;
UCEC	cis	rs1079204	0.826	rs6743642	chr2:219122466	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.58	4.59	0.35	9.33e-6	Smooth-surface caries;
UCEC	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.44	-4.69	-0.36	6.29e-6	Obesity-related traits;
UCEC	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.69	-7.34	-0.52	1.34e-11	Breast cancer;
UCEC	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.52	-4.54	-0.35	1.18e-5	Carotid intima media thickness;
UCEC	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.56	-0.53	3.91e-12	Total cholesterol levels;
UCEC	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.51	0.35	1.3e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg22974920	chr21:40686053	BRWD1	0.6	5.33	0.4	3.58e-7	Cognitive function;
UCEC	cis	rs847577	0.630	rs6969384	chr7:97732842	C/T	cg24562669	chr7:97807699	LMTK2	0.73	10.76	0.66	2.89e-20	Breast cancer;
UCEC	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.61	6.45	0.47	1.51e-9	Motion sickness;
UCEC	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.05	6.38	0.47	2.2e-9	Diabetic retinopathy;
UCEC	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.39	4.9	0.37	2.51e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.6	8.7	0.58	6.26e-15	Prudent dietary pattern;
UCEC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.46	-0.52	6.97e-12	Breast cancer;
UCEC	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg13147721	chr7:65941812	NA	-0.94	-6.92	-0.5	1.28e-10	Diabetic kidney disease;
UCEC	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg13385521	chr17:29058706	SUZ12P	0.62	4.76	0.37	4.69e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg20119798	chr7:94954144	PON1	-0.49	-4.65	-0.36	7.31e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg04155231	chr12:9217510	LOC144571	0.41	5.09	0.39	1.09e-6	Sjögren's syndrome;
UCEC	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.52	5.53	0.41	1.43e-7	Aortic root size;
UCEC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.56	-6.06	-0.45	1.1e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.36	-0.61	1.27e-16	Gut microbiome composition (summer);
UCEC	cis	rs56116382	0.668	rs4688759	chr3:50008118	T/C	cg00383909	chr3:49044727	WDR6	0.92	4.95	0.38	2.01e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
UCEC	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs1318772	1.000	rs11241202	chr5:112692298	G/A	cg12552261	chr5:112820674	MCC	0.59	4.92	0.38	2.26e-6	F-cell distribution;
UCEC	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	0.94	8.9	0.59	1.86e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.69	4.91	0.38	2.43e-6	Height;
UCEC	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.72	6.3	0.46	3.34e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.6	-6.45	-0.47	1.51e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.62	6.9	0.49	1.47e-10	Pubertal anthropometrics;
UCEC	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.64	6.32	0.46	2.99e-9	Sudden cardiac arrest;
UCEC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-5.2	-0.39	6.51e-7	Aortic root size;
UCEC	cis	rs2888674	1.000	rs717658	chr7:150503637	A/T	cg02212389	chr7:151070905	NUB1	0.33	4.59	0.35	9.59e-6	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
UCEC	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.59	4.85	0.37	3.09e-6	Eosinophilic esophagitis;
UCEC	cis	rs7336933	0.866	rs4147047	chr13:42393824	C/T	cg18400088	chr13:41634674	WBP4	-0.56	-4.61	-0.36	8.72e-6	Calcium levels;
UCEC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs62027291	0.654	rs56402836	chr15:77081967	A/C	cg23625390	chr15:77176239	SCAPER	-0.77	-4.79	-0.37	4.08e-6	Plateletcrit;
UCEC	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.4	-5.52	-0.41	1.48e-7	Alcohol dependence;
UCEC	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.68	7.31	0.52	1.55e-11	Lymphocyte counts;
UCEC	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg22563815	chr15:78856949	CHRNA5	0.39	5.0	0.38	1.62e-6	Sudden cardiac arrest;
UCEC	cis	rs7246967	0.673	rs3951783	chr19:22839264	T/A	cg01485075	chr19:22817371	ZNF492	0.42	4.55	0.35	1.12e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg13683864	chr3:40499215	RPL14	1.11	16.0	0.8	5.29e-34	Renal cell carcinoma;
UCEC	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.17	16.05	0.8	4.03e-34	Cognitive function;
UCEC	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg06265175	chr8:121136014	COL14A1	0.5	5.32	0.4	3.77e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.7	-6.39	-0.47	2.07e-9	Coronary artery disease;
UCEC	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04206484	chr7:1121657	C7orf50	-0.37	-4.51	-0.35	1.33e-5	Bronchopulmonary dysplasia;
UCEC	trans	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg15509575	chr4:2286509	ZFYVE28	0.4	7.0	0.5	8.26e-11	Rheumatoid arthritis;
UCEC	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.41	0.52	8.93e-12	Eye color traits;
UCEC	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	8.42	0.57	3.16e-14	Coffee consumption (cups per day);
UCEC	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg18681998	chr4:17616180	MED28	0.7	8.04	0.55	2.78e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.77	8.31	0.57	5.87e-14	Breast cancer;
UCEC	cis	rs4523957	0.855	rs216172	chr17:2126504	G/C	cg16513277	chr17:2031491	SMG6	-0.46	-4.91	-0.38	2.35e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.64	5.57	0.42	1.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8112909	0.843	rs8111011	chr19:46416647	G/A	cg03208830	chr19:45909395	PPP1R13L;CD3EAP	0.56	4.59	0.35	9.44e-6	Interferon gamma-induced protein 10 levels;
UCEC	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-5.53	-0.41	1.46e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.7	4.99	0.38	1.71e-6	Smoking behavior;
UCEC	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.8	9.41	0.61	9.31e-17	Mortality in heart failure;
UCEC	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg06784218	chr1:46089804	CCDC17	0.42	4.81	0.37	3.76e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.45	-5.29	-0.4	4.26e-7	Subjective well-being;
UCEC	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.67	-5.48	-0.41	1.79e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.59	5.92	0.44	2.23e-8	Blood protein levels;
UCEC	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21178979	chr7:1889533	MAD1L1	0.4	4.63	0.36	8.02e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.51	4.89	0.37	2.67e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.5	-5.8	-0.43	3.87e-8	Lung cancer;
UCEC	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.5	5.39	0.41	2.69e-7	Alcohol dependence;
UCEC	cis	rs4400599	0.772	rs4579747	chr1:154153106	A/G	cg05139571	chr1:154127138	NUP210L	0.44	4.76	0.37	4.49e-6	Platelet distribution width;
UCEC	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg04155231	chr12:9217510	LOC144571	0.43	5.09	0.39	1.1e-6	Sjögren's syndrome;
UCEC	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg01689657	chr7:91764605	CYP51A1	-0.49	-6.41	-0.47	1.86e-9	Breast cancer;
UCEC	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Smoking initiation;
UCEC	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-5.93	-0.44	2.11e-8	Hemoglobin concentration;
UCEC	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.64	6.3	0.46	3.25e-9	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg20129853	chr10:51489980	NA	-0.42	-4.7	-0.36	5.99e-6	Prostate-specific antigen levels;
UCEC	cis	rs6663390	0.510	rs2267896	chr1:208080972	C/T	cg03990033	chr1:208084030	CD34	-0.51	-4.91	-0.38	2.44e-6	Facial morphology (factor 18);
UCEC	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.42	-5.1	-0.39	1.01e-6	Refractive error;
UCEC	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-6.36	-0.46	2.37e-9	Mean platelet volume;
UCEC	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-5.66	-0.42	7.61e-8	Eye color traits;
UCEC	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.66	6.32	0.46	2.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	1.06	5.49	0.41	1.74e-7	Skin colour saturation;
UCEC	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.56	5.02	0.38	1.47e-6	Type 1 diabetes nephropathy;
UCEC	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.56	4.65	0.36	7.46e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	5.22	0.4	6.05e-7	Cognitive test performance;
UCEC	cis	rs6832769	0.961	rs28790098	chr4:56398109	C/T	cg05960024	chr4:56376020	CLOCK	-0.56	-5.85	-0.43	3.01e-8	Personality dimensions;
UCEC	cis	rs466639	0.714	rs188196	chr1:165384621	G/A	cg03421657	chr1:166039754	FAM78B	0.47	4.57	0.35	1.01e-5	Menarche (age at onset);
UCEC	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.8	-9.06	-0.6	7.3e-16	Height;
UCEC	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg17420585	chr12:42539391	GXYLT1	0.4	5.12	0.39	9.26e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs17122693	0.786	rs72679588	chr14:51092687	A/C	cg04730355	chr14:51134070	SAV1	0.89	9.04	0.6	8.54e-16	Cognitive performance;
UCEC	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-8.75	-0.59	4.48e-15	Total cholesterol levels;
UCEC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg00343986	chr7:65444356	GUSB	-0.56	-5.11	-0.39	9.67e-7	Aortic root size;
UCEC	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.48	4.58	0.35	9.85e-6	Diastolic blood pressure;
UCEC	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-6.68	-0.48	4.59e-10	Bipolar disorder;
UCEC	cis	rs7106204	1.000	rs6484025	chr11:24214514	C/G	ch.11.24196551F	chr11:24239977	NA	0.68	6.19	0.45	5.73e-9	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg13870426	chr17:30244630	NA	-0.63	-4.56	-0.35	1.06e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.56	-4.79	-0.37	4.04e-6	Corneal structure;
UCEC	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.45	-4.77	-0.37	4.34e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.38	-4.5	-0.35	1.36e-5	Multiple myeloma;
UCEC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.63	6.73	0.49	3.48e-10	Menopause (age at onset);
UCEC	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-0.7	-7.85	-0.54	8.04e-13	Blood protein levels;
UCEC	cis	rs925228	0.955	rs6730855	chr2:24192801	A/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.54	4.73	0.36	5.29e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.71	6.86	0.49	1.82e-10	Multiple sclerosis;
UCEC	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs7560272	0.723	rs7562047	chr2:73725168	G/T	cg20560298	chr2:73613845	ALMS1	-0.51	-4.95	-0.38	2.02e-6	Schizophrenia;
UCEC	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.47	5.88	0.44	2.59e-8	HDL cholesterol levels;
UCEC	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.45	0.61	7.55e-17	Platelet count;
UCEC	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-4.99	-0.38	1.69e-6	Joint mobility (Beighton score);
UCEC	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg16497661	chr14:103986332	CKB	-0.44	-5.22	-0.4	6.12e-7	Body mass index;
UCEC	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.41	4.68	0.36	6.56e-6	Alzheimer's disease (late onset);
UCEC	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-7.49	-0.53	5.94e-12	Height;
UCEC	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24249390	chr15:90295951	MESP1	-0.41	-4.69	-0.36	6.3e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.11	-0.51	4.69e-11	Eye color traits;
UCEC	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.47	5.9	0.44	2.4e-8	HDL cholesterol levels;
UCEC	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.68	6.75	0.49	3.19e-10	Aortic root size;
UCEC	cis	rs7088591	0.867	rs16911638	chr10:59782528	G/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.76	-8.5	-0.57	1.93e-14	Ulcerative colitis;
UCEC	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg21770322	chr7:97807741	LMTK2	0.52	6.49	0.47	1.22e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.51	4.94	0.38	2.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	13.7	0.75	4.63e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.55	-4.92	-0.38	2.28e-6	Alzheimer's disease;
UCEC	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.46	4.79	0.37	4.03e-6	Schizophrenia;
UCEC	cis	rs2172802	0.570	rs4860424	chr4:62537309	A/G	cg04118610	chr4:62707027	LPHN3	-0.43	-4.69	-0.36	6.12e-6	Partial epilepsies;
UCEC	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg21191810	chr6:118973309	C6orf204	0.4	5.5	0.41	1.64e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.29	0.52	1.73e-11	Type 2 diabetes;
UCEC	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg21419209	chr3:44054225	NA	-0.51	-5.3	-0.4	4.24e-7	Coronary artery disease;
UCEC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.82	9.18	0.6	3.61e-16	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.23	25.04	0.9	6.97e-55	Myeloid white cell count;
UCEC	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.8	-9.95	-0.63	3.87e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.56	-5.22	-0.4	5.96e-7	Coronary artery disease;
UCEC	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.1	7.89	0.55	6.2800000000000005e-13	Alzheimer's disease (late onset);
UCEC	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	6.4	0.47	1.97e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.34	-8.77	-0.59	4.09e-15	Diabetic kidney disease;
UCEC	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.58	6.96	0.5	1.04e-10	Menarche (age at onset);
UCEC	cis	rs1150668	0.699	rs2394049	chr6:28239681	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.55	-6.09	-0.45	9.22e-9	Pubertal anthropometrics;
UCEC	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.54	5.45	0.41	2.03e-7	Neutrophil percentage of white cells;
UCEC	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg23307798	chr14:103986281	CKB	0.56	5.33	0.4	3.63e-7	Body mass index;
UCEC	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.59	5.26	0.4	5.08e-7	Menarche (age at onset);
UCEC	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.63	5.9	0.44	2.41e-8	Aortic root size;
UCEC	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.45	-5.05	-0.38	1.31e-6	Retinal vascular caliber;
UCEC	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.71	-5.06	-0.38	1.25e-6	Aortic root size;
UCEC	cis	rs11581903	0.929	rs34275176	chr1:53056063	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.81	4.92	0.38	2.28e-6	Joint mobility (Beighton score);
UCEC	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.59	6.23	0.46	4.69e-9	Motion sickness;
UCEC	cis	rs742614	0.533	rs6087526	chr20:32398295	A/C	cg06304546	chr20:32448765	NA	-0.71	-7.78	-0.54	1.2e-12	Stearic acid (18:0) levels;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.51	-6.19	-0.45	5.79e-9	Pulmonary function;
UCEC	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg20560298	chr2:73613845	ALMS1	0.51	5.15	0.39	8.41e-7	Schizophrenia;
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	7.07	0.5	5.86e-11	Platelet count;
UCEC	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg06238570	chr21:40685208	BRWD1	0.52	5.42	0.41	2.41e-7	Cognitive function;
UCEC	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.55	-5.66	-0.42	7.8e-8	Height;
UCEC	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg04851639	chr8:1020857	NA	-0.4	-5.73	-0.43	5.46e-8	Schizophrenia;
UCEC	cis	rs11118844	0.739	rs12070192	chr1:221945870	A/T	cg04222084	chr1:221915650	DUSP10	-0.76	-7.16	-0.51	3.56e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.49	5.01	0.38	1.54e-6	Bladder cancer;
UCEC	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.52	5.96	0.44	1.8e-8	Mean corpuscular volume;
UCEC	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg01689657	chr7:91764605	CYP51A1	0.53	7.0	0.5	8.44e-11	Breast cancer;
UCEC	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg02503808	chr4:7069936	GRPEL1	0.4	4.57	0.35	1.01e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	8.37	0.57	4.14e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.73	0.36	5.24e-6	Breast cancer;
UCEC	cis	rs12692119	0.764	rs61730220	chr2:127656861	C/T	cg04330126	chr2:127727905	NA	-0.82	-4.79	-0.37	4.11e-6	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-5.97	-0.44	1.7e-8	Glomerular filtration rate;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.52	-0.41	1.49e-7	Pulmonary function;
UCEC	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.62	6.29	0.46	3.51e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.62	5.78	0.43	4.26e-8	Parkinson's disease;
UCEC	cis	rs13253111	0.687	rs7840565	chr8:28060783	C/T	cg26534493	chr8:28060551	NA	0.5	5.85	0.43	3.14e-8	Childhood body mass index;
UCEC	cis	rs853679	0.506	rs1150711	chr6:28208535	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.41	-4.59	-0.35	9.61e-6	Depression;
UCEC	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.55	-6.13	-0.45	7.56e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.83	9.44	0.61	7.87e-17	Monocyte count;
UCEC	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-4.54	-0.35	1.18e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.76	-7.41	-0.52	9.32e-12	Initial pursuit acceleration;
UCEC	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.69	-6.37	-0.47	2.27e-9	Ileal carcinoids;
UCEC	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg14851346	chr12:38532713	NA	-0.47	-4.59	-0.35	9.36e-6	Morning vs. evening chronotype;
UCEC	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg21770322	chr7:97807741	LMTK2	0.44	5.5	0.41	1.63e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.72	-0.54	1.61e-12	Monocyte count;
UCEC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.5	5.3	0.4	4.18e-7	Aortic root size;
UCEC	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Bladder cancer;
UCEC	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.48	-5.9	-0.44	2.46e-8	Mean platelet volume;
UCEC	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.33	4.57	0.35	1.03e-5	Prostate cancer;
UCEC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.52	-5.55	-0.42	1.29e-7	Lung function (FEV1/FVC);
UCEC	cis	rs2806974	0.528	rs990780	chr13:53674383	A/G	cg14823544	chr13:53775958	NA	-0.38	-4.77	-0.37	4.44e-6	Trans fatty acid levels;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18386310	chr1:94147656	BCAR3	0.76	7.4	0.52	9.87e-12	Migraine with aura;
UCEC	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-5.23	-0.4	5.75e-7	Platelet distribution width;
UCEC	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg12559939	chr2:27858050	GPN1	0.44	4.58	0.35	9.71e-6	Oral cavity cancer;
UCEC	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg05991184	chr2:219186017	PNKD	0.43	4.76	0.37	4.51e-6	Ulcerative colitis;
UCEC	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.48	-4.76	-0.37	4.52e-6	Pubertal anthropometrics;
UCEC	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.52	5.41	0.41	2.52e-7	Schizophrenia;
UCEC	cis	rs4499344	0.633	rs166311	chr19:33161246	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.58	5.15	0.39	8.34e-7	Mean platelet volume;
UCEC	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.89	10.4	0.65	2.44e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-6.28	-0.46	3.65e-9	Dental caries;
UCEC	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs11675119	0.501	rs12994811	chr2:3494301	C/A	cg15541040	chr2:3486749	NA	-0.57	-5.03	-0.38	1.4e-6	Neurofibrillary tangles;
UCEC	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-5.72	-0.43	5.9e-8	Asthma;
UCEC	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.46	4.55	0.35	1.1e-5	Coronary artery disease;
UCEC	cis	rs960450	1.000	rs2136083	chr4:98493206	A/C	cg20724681	chr4:99182416	RAP1GDS1	0.54	4.68	0.36	6.34e-6	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg23324259	chr8:82754387	SNX16	0.53	4.53	0.35	1.19e-5	Diastolic blood pressure;
UCEC	cis	rs7246967	0.673	rs8103430	chr19:22931498	A/G	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.66	5.38	0.41	2.87e-7	Corneal astigmatism;
UCEC	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.69	-7.5	-0.53	5.7e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs75804782	0.572	rs112551758	chr2:239299770	A/G	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.81	7.62	0.53	2.9e-12	Alzheimer's disease;
UCEC	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.47	5.33	0.4	3.69e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.38	4.89	0.37	2.63e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.14	10.57	0.66	8.74e-20	Vitiligo;
UCEC	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.65	-5.01	-0.38	1.54e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.38	5.07	0.39	1.17e-6	Longevity;
UCEC	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.58	5.63	0.42	8.81e-8	Height;
UCEC	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	0.8	9.97	0.63	3.42e-18	Monocyte percentage of white cells;
UCEC	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.54	4.7	0.36	5.81e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.51	-5.34	-0.4	3.53e-7	Tuberculosis;
UCEC	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.49	-4.61	-0.36	8.53e-6	Neurofibrillary tangles;
UCEC	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.34e-10	Aortic root size;
UCEC	cis	rs6060717	0.610	rs2794383	chr20:34615152	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.48	-5.19	-0.39	6.73e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.58	-5.9	-0.44	2.35e-8	Dental caries;
UCEC	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg00639195	chr15:79103007	ADAMTS7	0.54	5.22	0.4	5.93e-7	Coronary artery disease or large artery stroke;
UCEC	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	7.49	0.53	5.9e-12	Lymphocyte counts;
UCEC	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.32	0.46	2.92e-9	Cognitive test performance;
UCEC	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.4	-5.32	-0.4	3.82e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.79	-8.16	-0.56	1.41e-13	Mosquito bite size;
UCEC	cis	rs7804356	0.906	rs12540388	chr7:26905731	A/T	cg09144964	chr7:27150262	HOXA3	0.54	4.51	0.35	1.3e-5	Type 1 diabetes;
UCEC	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg13147721	chr7:65941812	NA	-0.94	-6.33	-0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.71	-7.52	-0.53	4.96e-12	Blood metabolite levels;
UCEC	cis	rs9309473	0.950	rs7567585	chr2:73751966	G/A	cg20560298	chr2:73613845	ALMS1	-0.6	-5.46	-0.41	1.97e-7	Metabolite levels;
UCEC	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	6.91	0.5	1.35e-10	Calcium levels;
UCEC	cis	rs72906064	1.000	rs17244514	chr2:156918824	A/C	cg14040602	chr2:157557294	NA	0.63	5.08	0.39	1.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.12	0.39	9.52e-7	Breast cancer;
UCEC	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.52	5.44	0.41	2.17e-7	Bipolar disorder;
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.5	4.94	0.38	2.14e-6	Obesity-related traits;
UCEC	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.83	0.49	2.06e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs35295995	0.510	rs1516742	chr11:21017906	A/G	cg26681211	chr11:20385635	HTATIP2	-0.51	-4.55	-0.35	1.1e-5	3-hydroxypropylmercapturic acid levels in smokers;
UCEC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.8	-7.97	-0.55	4.08e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9899728	0.539	rs57813751	chr17:73053512	C/T	cg27626185	chr17:73056755	KCTD2	-0.65	-5.72	-0.43	5.8e-8	Alzheimer's disease or small vessel stroke;
UCEC	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.72	-7.22	-0.51	2.64e-11	Aortic root size;
UCEC	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs7246967	0.673	rs35731237	chr19:22820510	G/T	cg03230154	chr19:22817176	ZNF492	0.44	4.54	0.35	1.14e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.42	4.57	0.35	1.01e-5	Height;
UCEC	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.44	-5.04	-0.38	1.33e-6	Bone mineral density;
UCEC	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg00873616	chr20:43920241	NA	0.48	4.51	0.35	1.32e-5	Blood protein levels;
UCEC	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.18	-9.37	-0.61	1.21e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9467773	1.000	rs6918506	chr6:26577857	C/G	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-4.51	-0.35	1.29e-5	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg21770322	chr7:97807741	LMTK2	0.52	6.46	0.47	1.45e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.66	6.13	0.45	7.61e-9	Breast cancer;
UCEC	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.78	-0.37	4.16e-6	Multiple sclerosis;
UCEC	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.1	8.56	0.58	1.39e-14	Uric acid levels;
UCEC	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.02	-8.46	-0.57	2.5e-14	Exhaled nitric oxide output;
UCEC	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.61	-6.02	-0.44	1.34e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.56	-0.42	1.21e-7	Systolic blood pressure;
UCEC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg24562669	chr7:97807699	LMTK2	0.48	5.87	0.44	2.85e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.81	0.37	3.64e-6	Schizophrenia;
UCEC	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.88	-8.13	-0.56	1.65e-13	Prostate cancer;
UCEC	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.44	-5.26	-0.4	4.88e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs273573	1.000	rs273592	chr11:30878849	C/T	cg20973129	chr6:33548009	BAK1	0.66	6.88	0.49	1.57e-10	Total body bone mineral density;
UCEC	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.49	5.34	0.4	3.48e-7	Platelet distribution width;
UCEC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.03	0.5	7.04e-11	Homoarginine levels;
UCEC	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.53	6.24	0.46	4.43e-9	Type 2 diabetes;
UCEC	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg15147215	chr3:52552868	STAB1	-0.43	-4.77	-0.37	4.42e-6	Bipolar disorder;
UCEC	cis	rs7607369	0.559	rs4674339	chr2:219659787	C/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.8	-0.43	3.92e-8	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs13118159	0.505	rs4974621	chr4:1402580	T/C	cg00684032	chr4:1343700	KIAA1530	0.59	6.04	0.45	1.22e-8	Longevity;
UCEC	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.76	-7.61	-0.53	3.12e-12	Response to antineoplastic agents;
UCEC	cis	rs9309473	1.000	rs10496191	chr2:73673798	C/T	cg20560298	chr2:73613845	ALMS1	-0.65	-5.96	-0.44	1.82e-8	Metabolite levels;
UCEC	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.72	6.36	0.46	2.42e-9	Caudate activity during reward;
UCEC	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.62	6.74	0.49	3.35e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.67	-7.99	-0.55	3.69e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.89	-9.67	-0.62	2.01e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.61	-6.04	-0.45	1.2e-8	Dental caries;
UCEC	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.43	-5.57	-0.42	1.17e-7	HIV-1 susceptibility;
UCEC	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-6.48	-0.47	1.32e-9	Total cholesterol levels;
UCEC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.59	5.65	0.42	8.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6840360	0.573	rs11099806	chr4:152269116	G/T	cg25486957	chr4:152246857	NA	-0.49	-5.32	-0.4	3.72e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.48	4.59	0.35	9.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	5.92	0.44	2.17e-8	IgG glycosylation;
UCEC	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg04553112	chr3:125709451	NA	-0.6	-4.51	-0.35	1.32e-5	Blood pressure (smoking interaction);
UCEC	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.74	6.41	0.47	1.89e-9	Bipolar disorder;
UCEC	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.76	7.49	0.53	5.96e-12	Vitamin D levels;
UCEC	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.43	4.69	0.36	6.06e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.44	-5.17	-0.39	7.4e-7	Subjective well-being;
UCEC	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-4.51	-0.35	1.33e-5	Morning vs. evening chronotype;
UCEC	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg11690979	chr1:151694320	C1orf230	0.37	4.63	0.36	7.97e-6	Coronary artery disease;
UCEC	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.5	4.75	0.36	4.83e-6	Menopause (age at onset);
UCEC	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.67	-7.67	-0.53	2.2e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.86	9.66	0.62	2.07e-17	Breast cancer;
UCEC	cis	rs394563	0.901	rs448874	chr6:149796967	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.44	-5.33	-0.4	3.67e-7	Dupuytren's disease;
UCEC	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.56	4.73	0.36	5.32e-6	Obesity-related traits;
UCEC	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.61	5.23	0.4	5.61e-7	Coronary artery disease;
UCEC	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.78	-6.13	-0.45	7.6e-9	Calcium levels;
UCEC	cis	rs2065415	1	rs2065415	chr6:169437345	A/G	cg21255356	chr6:169446912	NA	0.46	4.56	0.35	1.06e-5	Warfarin maintenance dose;
UCEC	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.78	8.21	0.56	1.02e-13	Caffeine consumption;
UCEC	cis	rs1784203	1.000	rs4753098	chr11:93417437	C/T	cg10353388	chr11:93474820	C11orf54;TAF1D	-1.02	-6.5	-0.47	1.17e-9	Waist circumference adjusted for body mass index;
UCEC	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.47	-0.52	6.56e-12	Eye color traits;
UCEC	cis	rs6426514	1.000	rs7545235	chr1:228878288	G/A	cg06637001	chr1:228463634	OBSCN	-0.74	-4.56	-0.35	1.09e-5	Type 2 diabetes;
UCEC	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.58	-0.42	1.15e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.86	10.88	0.67	1.39e-20	Mortality in heart failure;
UCEC	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.08	-0.71	8.93e-24	Primary sclerosing cholangitis;
UCEC	cis	rs2299682	0.826	rs6086911	chr20:9469599	C/T	cg11931762	chr20:9488920	NA	-0.52	-4.77	-0.37	4.34e-6	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.41	-0.47	1.91e-9	Crohn's disease;
UCEC	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.67	7.64	0.53	2.55e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.46	4.68	0.36	6.59e-6	Personality dimensions;
UCEC	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs8080784	0.673	rs11079403	chr17:58832847	A/G	cg22641952	chr17:58219985	NA	-0.51	-4.81	-0.37	3.67e-6	Coronary artery disease;
UCEC	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg24562669	chr7:97807699	LMTK2	-0.53	-5.95	-0.44	1.88e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-1.21	-6.36	-0.46	2.35e-9	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg01072550	chr1:21505969	NA	-0.57	-5.78	-0.43	4.34e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.49	-5.46	-0.41	1.99e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	1.1	13.0	0.73	3.41e-26	Post bronchodilator FEV1;
UCEC	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-0.84	-5.6	-0.42	1.01e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	1.18	9.48	0.62	6.42e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.47	5.88	0.44	2.59e-8	HDL cholesterol levels;
UCEC	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.55	5.1	0.39	1.04e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.86	-0.59	2.43e-15	Exhaled nitric oxide output;
UCEC	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.77	-0.37	4.34e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.46	4.93	0.38	2.19e-6	Vitiligo;
UCEC	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg05962950	chr11:130786565	SNX19	0.47	4.65	0.36	7.3e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.24	7.47	0.52	6.73e-12	Eosinophil percentage of granulocytes;
UCEC	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.52	5.51	0.41	1.57e-7	Blood protein levels;
UCEC	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.64	6.74	0.49	3.28e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.79	-6.45	-0.47	1.53e-9	Coronary artery calcification;
UCEC	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg00612595	chr21:47717864	NA	-0.48	-5.14	-0.39	8.74e-7	Testicular germ cell tumor;
UCEC	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.6	5.59	0.42	1.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs1007190	0.881	rs9900293	chr17:42936003	G/C	cg15406952	chr17:42872593	NA	0.67	5.16	0.39	7.98e-7	DNA methylation (variation);
UCEC	cis	rs1007190	0.764	rs8070598	chr17:42876865	T/C	cg15406952	chr17:42872593	NA	-0.67	-4.87	-0.37	2.87e-6	DNA methylation (variation);
UCEC	cis	rs9864370	0.688	rs1685640	chr3:168928660	C/T	cg18504196	chr3:168331449	C3orf50	-0.6	-4.68	-0.36	6.52e-6	Multiple myeloma (hyperdiploidy);
UCEC	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.8	0.54	1.07e-12	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.76	6.35	0.46	2.53e-9	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg06562184	chr8:19319451	CSGALNACT1	-0.52	-5.47	-0.41	1.9e-7	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.5	-4.82	-0.37	3.47e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg18827107	chr12:86230957	RASSF9	-0.4	-4.52	-0.35	1.24e-5	Major depressive disorder;
UCEC	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.53	5.22	0.4	6.06e-7	Menopause (age at onset);
UCEC	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.1	0.56	1.93e-13	Blood protein levels;
UCEC	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.93	9.66	0.62	2.08e-17	Cognitive ability;
UCEC	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	0.92	12.69	0.72	2.15e-25	Blood trace element (Zn levels);
UCEC	trans	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.5	-0.53	5.64e-12	Pursuit maintenance gain;
UCEC	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg11871910	chr12:69753446	YEATS4	0.65	6.97	0.5	9.99e-11	Response to diuretic therapy;
UCEC	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.47	0.41	1.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-7.57	-0.53	3.77e-12	Personality dimensions;
UCEC	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-7.4	-0.52	9.64e-12	Schizophrenia;
UCEC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.7	7.08	0.5	5.49e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.73	-6.43	-0.47	1.69e-9	Caudate activity during reward;
UCEC	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.33	4.86	0.37	3.02e-6	Alcohol dependence;
UCEC	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.17	-9.14	-0.6	4.75e-16	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.6	-5.16	-0.39	7.77e-7	Reticulocyte count;
UCEC	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg06784218	chr1:46089804	CCDC17	0.42	4.71	0.36	5.64e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.51	-4.98	-0.38	1.74e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.58	-6.03	-0.45	1.24e-8	Systemic lupus erythematosus;
UCEC	cis	rs13098911	0.540	rs71325095	chr3:45989921	G/T	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.66	6.14	0.45	7.34e-9	Schizophrenia;
UCEC	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.59	-4.54	-0.35	1.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.0	-8.27	-0.56	7.32e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.44	-5.14	-0.39	8.43e-7	Resting heart rate;
UCEC	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1150668	0.699	rs13408	chr6:28212748	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-4.89	-0.37	2.63e-6	Pubertal anthropometrics;
UCEC	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.0	-11.77	-0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg19743168	chr1:23544995	NA	0.43	6.19	0.45	5.7e-9	Height;
UCEC	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.64	-5.38	-0.41	2.93e-7	Alcohol dependence;Nicotine use;
UCEC	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.28	14.95	0.78	2.57e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.7	-6.04	-0.45	1.21e-8	Adiposity;
UCEC	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.61	5.52	0.41	1.53e-7	Tourette syndrome;
UCEC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18252515	chr7:66147081	NA	0.46	4.73	0.36	5.32e-6	Aortic root size;
UCEC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg01689657	chr7:91764605	CYP51A1	0.45	5.51	0.41	1.6e-7	Breast cancer;
UCEC	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	9.44	0.61	7.87e-17	Monocyte count;
UCEC	cis	rs3780378	0.875	rs2031906	chr9:5087495	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.16	-0.39	8e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.67	7.15	0.51	3.83e-11	Obesity-related traits;
UCEC	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	1.03	10.41	0.65	2.3e-19	Post bronchodilator FEV1;
UCEC	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.67	-5.71	-0.43	6.16e-8	Aortic root size;
UCEC	cis	rs2674946	0.644	rs2069138	chr17:13040819	A/G	cg04110708	chr17:12891573	RICH2	0.55	4.55	0.35	1.12e-5	Squamous cell lung carcinoma;
UCEC	cis	rs7246967	0.932	rs1478457	chr19:23065269	C/T	cg05241461	chr19:22816980	ZNF492	0.52	5.13	0.39	8.89e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg21905437	chr5:178450457	ZNF879	0.64	7.07	0.5	5.68e-11	Pubertal anthropometrics;
UCEC	cis	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg20368463	chr18:77673604	PQLC1	0.55	5.1	0.39	1.01e-6	Opioid sensitivity;
UCEC	cis	rs2648708	1.000	rs2815624	chr10:12599694	A/G	cg09346030	chr10:13390377	SEPHS1	0.53	4.55	0.35	1.1e-5	Calcium levels;
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg20119798	chr7:94954144	PON1	-0.49	-4.65	-0.36	7.31e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.56	7.1	0.51	4.97e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.13	-13.65	-0.75	6.51e-28	Cognitive function;
UCEC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg01689657	chr7:91764605	CYP51A1	-0.43	-5.32	-0.4	3.87e-7	Breast cancer;
UCEC	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.63	6.67	0.48	4.95e-10	QRS complex (12-leadsum);
UCEC	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-7.13	-0.51	4.21e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg01657329	chr11:68192670	LRP5	0.41	4.72	0.36	5.41e-6	Bone mineral density (spine);
UCEC	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	0.98	13.45	0.74	2.22e-27	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.89	8.32	0.57	5.64e-14	Alzheimer's disease;
UCEC	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	0.82	5.95	0.44	1.92e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.59	-6.44	-0.47	1.59e-9	Type 2 diabetes;
UCEC	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.44	4.83	0.37	3.44e-6	Electroencephalogram traits;
UCEC	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.54	-7.15	-0.51	3.86e-11	Birth weight;
UCEC	cis	rs2734839	0.964	rs1076563	chr11:113295909	A/C	cg14159747	chr11:113255604	NA	0.57	7.31	0.52	1.54e-11	Information processing speed;
UCEC	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.64	6.24	0.46	4.43e-9	Lymphocyte counts;
UCEC	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg23782820	chr8:58130467	NA	0.5	4.7	0.36	5.98e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.9	0.37	2.47e-6	Aortic root size;
UCEC	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.52	5.09	0.39	1.09e-6	Menopause (age at onset);
UCEC	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.84	-7.68	-0.54	2.03e-12	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.68	-4.99	-0.38	1.7e-6	Aortic root size;
UCEC	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.12	12.36	0.71	1.65e-24	Blood protein levels;
UCEC	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.58	-5.9	-0.44	2.4e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.55	4.87	0.37	2.84e-6	Carotid intima media thickness;
UCEC	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.76	-8.39	-0.57	3.67e-14	Ulcerative colitis;
UCEC	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.46	-5.18	-0.39	7.34e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.55	-4.61	-0.36	8.58e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.26	-0.51	2.07e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.54	5.45	0.41	2.07e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg03078520	chr22:18463400	MICAL3	-0.51	-5.26	-0.4	5.02e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18932078	chr1:2524107	MMEL1	0.42	6.62	0.48	6.41e-10	Ulcerative colitis;
UCEC	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.5	-4.51	-0.35	1.34e-5	Alzheimer's disease (late onset);
UCEC	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg07606381	chr6:8435919	SLC35B3	-0.56	-4.86	-0.37	3.04e-6	Motion sickness;
UCEC	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-5.59	-0.42	1.08e-7	Pancreatic cancer;
UCEC	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.48	-6.85	-0.49	1.83e-10	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.53	4.75	0.37	4.71e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.88	-10.19	-0.64	8.69e-19	Dental caries;
UCEC	trans	rs11104268	0.643	rs10777059	chr12:76632359	C/T	ch.11.167001F	chr11:4565123	OR52M1	-0.72	-6.85	-0.49	1.88e-10	Glucose homeostasis traits;
UCEC	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-9.23	-0.61	2.79e-16	Monocyte count;
UCEC	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-4.53	-0.35	1.21e-5	Eosinophil percentage of white cells;
UCEC	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	4.9	0.37	2.47e-6	Rheumatoid arthritis;
UCEC	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.68	-5.05	-0.38	1.31e-6	Calcium levels;
UCEC	cis	rs1468333	1.000	rs2864	chr5:137523430	T/C	cg07848042	chr5:137667509	CDC25C	0.47	4.65	0.36	7.43e-6	Resting heart rate;
UCEC	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg10932868	chr11:921992	NA	0.43	5.6	0.42	1.03e-7	Alzheimer's disease (late onset);
UCEC	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.51	5.67	0.42	7.49e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.83	8.26	0.56	7.73e-14	Breast cancer;
UCEC	cis	rs12970291	0.500	rs12962832	chr18:73022098	A/G	cg21700214	chr18:72252164	CNDP1	0.66	4.51	0.35	1.29e-5	Colorectal or endometrial cancer;
UCEC	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.57	5.44	0.41	2.17e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg13695892	chr22:41940480	POLR3H	-0.67	-5.45	-0.41	2.05e-7	Vitiligo;
UCEC	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.57	6.12	0.45	8.27e-9	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.5	5.18	0.39	7.29e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.71	6.6	0.48	6.99e-10	Mosquito bite size;
UCEC	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.5	4.52	0.35	1.27e-5	Coronary artery disease;
UCEC	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-0.85	-7.8	-0.54	1.03e-12	Blood pressure (smoking interaction);
UCEC	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg26769984	chr7:1090371	C7orf50	-0.48	-4.66	-0.36	7.1e-6	Longevity;Endometriosis;
UCEC	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06544989	chr22:39130855	UNC84B	0.32	4.53	0.35	1.23e-5	Menopause (age at onset);
UCEC	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.48	-5.34	-0.4	3.42e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-5.1	-0.39	1.04e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.5	6.19	0.45	5.69e-9	Total body bone mineral density;
UCEC	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.77	7.08	0.5	5.62e-11	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.57	5.13	0.39	8.96e-7	Initial pursuit acceleration;
UCEC	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	-0.56	-6.36	-0.46	2.46e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24308560	chr3:49941425	MST1R	0.44	4.65	0.36	7.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-4.67	-0.36	6.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.54	0.42	1.38e-7	Total body bone mineral density;
UCEC	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg08461772	chr7:95026248	PON3	0.39	5.27	0.4	4.78e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg08222913	chr3:52553049	STAB1	-0.45	-5.21	-0.39	6.38e-7	Electroencephalogram traits;
UCEC	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg25635316	chr7:23637023	CCDC126	-0.42	-4.59	-0.35	9.25e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.22	-0.46	4.99e-9	Gout;
UCEC	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	7.15	0.51	3.7e-11	Platelet count;
UCEC	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.78	9.51	0.62	5.09e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.42	4.97	0.38	1.88e-6	Bone mineral density;
UCEC	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.67	5.0	0.38	1.58e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.62	5.11	0.39	9.97e-7	Response to bleomycin (chromatid breaks);
UCEC	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.62	5.86	0.44	2.92e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs151997	0.777	rs3846499	chr5:50254200	G/A	cg06027927	chr5:50259733	NA	0.55	5.16	0.39	7.86e-7	Callous-unemotional behaviour;
UCEC	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-5.44	-0.41	2.16e-7	Obesity-related traits;
UCEC	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.48	5.24	0.4	5.49e-7	Systemic lupus erythematosus;
UCEC	cis	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg00614314	chr15:82944287	LOC80154	0.57	5.34	0.4	3.42e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg04155231	chr12:9217510	LOC144571	0.41	4.74	0.36	5.01e-6	Sjögren's syndrome;
UCEC	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.61	5.51	0.41	1.6e-7	Obesity-related traits;
UCEC	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.59	4.76	0.37	4.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.79	-8.16	-0.56	1.36e-13	Plateletcrit;Platelet count;
UCEC	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg07836142	chr6:28411423	ZSCAN23	-0.55	-6.08	-0.45	9.65e-9	Cardiac Troponin-T levels;
UCEC	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg03078520	chr22:18463400	MICAL3	-0.57	-5.57	-0.42	1.18e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	8.68	0.58	6.96e-15	Platelet count;
UCEC	cis	rs4771996	0.561	rs9556726	chr13:98138655	C/G	cg11411600	chr13:98830116	RNF113B;FARP1	0.47	4.76	0.37	4.67e-6	Obesity-related traits;
UCEC	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg00105475	chr2:10696890	NA	0.41	5.32	0.4	3.85e-7	Prostate cancer;
UCEC	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.88	-10.58	-0.66	8.26e-20	Blood metabolite levels;
UCEC	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.93	6.75	0.49	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.46	5.65	0.42	8.24e-8	Osteoporosis;
UCEC	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	9.58	0.62	3.42e-17	Alzheimer's disease;
UCEC	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.57	-5.01	-0.38	1.57e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg04154034	chr17:28927549	LRRC37B2	0.82	5.2	0.39	6.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.5	-6.23	-0.46	4.75e-9	Neuroticism;
UCEC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.47	-0.41	1.86e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-5.1	-0.39	1.03e-6	Hemoglobin concentration;
UCEC	cis	rs11760485	0.742	rs4236352	chr7:4407324	A/G	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.71	6.45	0.47	1.53e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs925228	1.000	rs12475277	chr2:24231982	C/T	cg26027482	chr12:1100598	ERC1	0.68	6.68	0.48	4.63e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	8.1	0.56	1.91e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg24562669	chr7:97807699	LMTK2	-0.49	-5.94	-0.44	1.99e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.97	0.38	1.82e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3750082	0.889	rs12536400	chr7:32936390	C/G	cg05721444	chr7:32995514	FKBP9	0.53	5.87	0.44	2.81e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.47	-0.52	6.41e-12	Breast cancer;
UCEC	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.76	5.42	0.41	2.36e-7	Bipolar disorder;
UCEC	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg13844804	chr7:814759	HEATR2	0.68	5.01	0.38	1.52e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs3935996	0.965	rs4926698	chr1:56328596	A/C	cg11959316	chr1:57001742	PPAP2B	-0.36	-4.62	-0.36	8.38e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
UCEC	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.48	5.84	0.43	3.15e-8	HDL cholesterol levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06992027	chr1:159895302	TAGLN2	0.57	6.69	0.48	4.31e-10	Warfarin maintenance dose;
UCEC	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.6	-4.81	-0.37	3.65e-6	Menopause (age at onset);
UCEC	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg02551604	chr5:131831745	NA	0.63	5.11	0.39	9.67e-7	Asthma (sex interaction);
UCEC	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.59	7.66	0.53	2.26e-12	Coronary artery disease;
UCEC	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.78	0.49	2.76e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs10760158	0.510	rs7020643	chr9:123861856	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	4.82	0.37	3.48e-6	Pulse pressure;
UCEC	cis	rs4662945	0.699	rs35045564	chr2:130213210	G/A	cg05962382	chr2:130345044	NA	-0.41	-4.57	-0.35	1.04e-5	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg16497661	chr14:103986332	CKB	0.49	5.88	0.44	2.63e-8	Bone mineral density;
UCEC	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.08	9.08	0.6	6.8e-16	White matter hyperintensity burden;
UCEC	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.09	17.2	0.82	5.07e-37	Schizophrenia;
UCEC	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.64	7.14	0.51	4.01e-11	Blood metabolite ratios;
UCEC	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.86	7.19	0.51	3.03e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-6.89	-0.49	1.53e-10	Morning vs. evening chronotype;
UCEC	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.87	-9.87	-0.63	6.07e-18	Cognitive function;
UCEC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg10503236	chr1:231470652	EXOC8	-0.41	-4.76	-0.37	4.68e-6	Hemoglobin concentration;
UCEC	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg24848339	chr3:12840334	CAND2	0.39	4.9	0.37	2.48e-6	QRS complex (12-leadsum);
UCEC	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.47	-5.04	-0.38	1.37e-6	Breast cancer;
UCEC	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.7	-0.43	6.2e-8	Gut microbiome composition (summer);
UCEC	cis	rs17106184	0.892	rs57254915	chr1:51139001	G/T	cg07174182	chr1:51127561	FAF1	-0.72	-4.6	-0.35	9.22e-6	Type 2 diabetes;
UCEC	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg01072550	chr1:21505969	NA	-0.53	-4.62	-0.36	8.3e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg12024160	chr4:1254474	NA	0.55	7.26	0.51	2.11e-11	Obesity-related traits;
UCEC	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg14008862	chr17:28927542	LRRC37B2	0.82	5.37	0.4	3.07e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.6	5.46	0.41	1.97e-7	Morning vs. evening chronotype;
UCEC	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.57	5.47	0.41	1.92e-7	Height;
UCEC	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.71	-8.06	-0.55	2.48e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg13683864	chr3:40499215	RPL14	0.69	7.2	0.51	2.93e-11	Renal cell carcinoma;
UCEC	cis	rs9283706	0.594	rs7717020	chr5:66353322	A/C	cg11590213	chr5:66331682	MAST4	0.46	5.11	0.39	9.66e-7	Coronary artery disease;
UCEC	cis	rs970548	0.690	rs964686	chr10:46003812	C/T	cg15223267	chr10:46222474	FAM21C	0.5	4.85	0.37	3.05e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.41	4.64	0.36	7.57e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	0.9	10.54	0.66	1.05e-19	Schizophrenia;
UCEC	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.83	-9.68	-0.62	1.9e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg00409905	chr10:38381863	ZNF37A	0.48	4.63	0.36	8.05e-6	Obesity (extreme);
UCEC	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.12	-0.45	8.23e-9	Birth weight;
UCEC	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.61	5.51	0.41	1.55e-7	Morning vs. evening chronotype;
UCEC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.48	-4.84	-0.37	3.18e-6	Aortic root size;
UCEC	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	12.12	0.71	7.18e-24	Chronic sinus infection;
UCEC	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.6	4.82	0.37	3.61e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.54	-5.99	-0.44	1.55e-8	Diastolic blood pressure;
UCEC	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.71	-7.18	-0.51	3.18e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg06917450	chr1:38156652	C1orf109	-0.57	-5.75	-0.43	4.89e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.53	8.95	0.59	1.44e-15	Airflow obstruction;
UCEC	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg22166914	chr1:53195759	ZYG11B	0.59	5.86	0.44	2.88e-8	Monocyte count;
UCEC	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.95	0.38	1.99e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.49	-5.08	-0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17123764	0.605	rs11169104	chr12:50076287	T/C	cg20471783	chr12:50157085	TMBIM6	0.65	5.52	0.41	1.52e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-1.03	-4.57	-0.35	1.02e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.72	8.72	0.58	5.61e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs56161922	0.908	rs78159416	chr1:207820375	C/A	cg09557387	chr1:207818395	CR1L	0.87	4.64	0.36	7.8e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
UCEC	cis	rs13095912	0.889	rs34765114	chr3:185335156	T/A	cg11274856	chr3:185301563	NA	0.56	7.59	0.53	3.35e-12	Systolic blood pressure;
UCEC	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	11.77	0.7	6.15e-23	Chronic sinus infection;
UCEC	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.48	5.14	0.39	8.47e-7	Headache;
UCEC	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.42	5.12	0.39	9.23e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.25	-22.09	-0.88	1.48e-48	Myeloid white cell count;
UCEC	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.38	0.76	8e-30	Height;
UCEC	cis	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg00614314	chr15:82944287	LOC80154	-0.55	-5.33	-0.4	3.66e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg07776626	chr8:57350775	NA	-0.46	-5.28	-0.4	4.54e-7	Obesity-related traits;
UCEC	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg07905965	chr19:39260460	NA	0.41	4.98	0.38	1.76e-6	Heart rate;
UCEC	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.5	-6.1	-0.45	9.16e-9	Mean platelet volume;
UCEC	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.89	0.49	1.55e-10	Eye color traits;
UCEC	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.67	6.5	0.47	1.14e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.61	6.79	0.49	2.61e-10	Red blood cell count;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg26873254	chr8:144332526	ZFP41	-0.55	-6.76	-0.49	3.06e-10	Breast cancer;
UCEC	cis	rs11129176	0.959	rs12629250	chr3:25048410	A/C	cg02506578	chr3:25824554	NGLY1	0.6	4.69	0.36	6.24e-6	Optic disc area;
UCEC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.48	5.32	0.4	3.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.18	-0.39	7.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	0.74	9.04	0.6	8.19e-16	Multiple myeloma;
UCEC	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg20560298	chr2:73613845	ALMS1	-0.61	-5.37	-0.4	3.05e-7	Metabolite levels;
UCEC	cis	rs10208940	0.920	rs13400463	chr2:68723912	G/A	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	0.92	12.97	0.73	4.05e-26	Homoarginine levels;
UCEC	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	0.87	6.51	0.47	1.1e-9	Economic and political preferences (immigration/crime);
UCEC	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.67	4.5	0.35	1.35e-5	Neuroticism;
UCEC	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	9.13	0.6	5.02e-16	Mean platelet volume;
UCEC	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.58	5.06	0.39	1.23e-6	Multiple sclerosis;
UCEC	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.81	-9.49	-0.62	5.84e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.72	7.21	0.51	2.79e-11	Primary sclerosing cholangitis;
UCEC	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.58	-5.18	-0.39	7.18e-7	Reticulocyte count;
UCEC	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg03078520	chr22:18463400	MICAL3	-0.49	-5.02	-0.38	1.47e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg14689365	chr7:158441557	NCAPG2	-0.48	-4.53	-0.35	1.22e-5	Height;
UCEC	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-0.87	-10.1	-0.64	1.54e-18	Height;
UCEC	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.47	-6.56	-0.48	8.81e-10	Height;
UCEC	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.65	-5.52	-0.41	1.52e-7	Blood pressure (smoking interaction);
UCEC	cis	rs17123764	0.818	rs876889	chr12:49983378	C/T	cg20471783	chr12:50157085	TMBIM6	0.65	5.33	0.4	3.66e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.52	5.3	0.4	4.1e-7	Multiple myeloma (IgH translocation);
UCEC	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.71	-4.81	-0.37	3.66e-6	Neuroticism;
UCEC	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13569146	chr6:26330589	NA	-0.55	-4.75	-0.37	4.7e-6	Educational attainment;
UCEC	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	8.44	0.57	2.71e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.99	8.61	0.58	1.01e-14	Body mass index;
UCEC	cis	rs9400271	0.527	rs4946954	chr6:109639656	A/G	cg01475377	chr6:109611718	NA	-0.44	-4.86	-0.37	3.04e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.63	-6.33	-0.46	2.77e-9	Blood metabolite levels;
UCEC	cis	rs9309473	0.519	rs1815027	chr2:73831840	T/C	cg20560298	chr2:73613845	ALMS1	0.54	5.24	0.4	5.44e-7	Metabolite levels;
UCEC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.09	16.69	0.81	9.53e-36	IgG glycosylation;
UCEC	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.65	-6.16	-0.45	6.68e-9	Platelet distribution width;
UCEC	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.69	8.44	0.57	2.85e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.63	4.95	0.38	2.04e-6	Carotid intima media thickness;
UCEC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-4.61	-0.36	8.8e-6	Coronary artery disease;
UCEC	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	5.44	0.41	2.17e-7	IgG glycosylation;
UCEC	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.47	0.57	2.39e-14	Platelet count;
UCEC	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs76439304	1.000	rs80127764	chr12:27087010	C/A	cg19407459	chr12:26986763	ITPR2	0.99	5.49	0.41	1.7e-7	Mean corpuscular volume;
UCEC	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.68	5.93	0.44	2.11e-8	Bipolar disorder;
UCEC	cis	rs7246967	0.932	rs35687548	chr19:23029147	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1519814	1.000	rs4588897	chr8:121139142	A/G	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.62	-5.21	-0.39	6.3e-7	Cardiac Troponin-T levels;
UCEC	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.68	-5.44	-0.41	2.19e-7	Exhaled nitric oxide output;
UCEC	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.51	4.91	0.38	2.39e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg14438399	chr17:27053147	TLCD1	0.58	4.73	0.36	5.19e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-0.58	-7.02	-0.5	7.52e-11	Total body bone mineral density;
UCEC	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.76	-5.97	-0.44	1.67e-8	Platelet count;
UCEC	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-10.9	-0.67	1.2e-20	Vitiligo;
UCEC	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.46	-5.13	-0.39	8.93e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg13216073	chr1:12042593	MFN2	0.53	5.59	0.42	1.09e-7	Tuberculosis;
UCEC	cis	rs6460942	0.591	rs62448727	chr7:12332362	G/C	cg06484146	chr7:12443880	VWDE	-0.62	-4.9	-0.37	2.49e-6	Coronary artery disease;
UCEC	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.64	-7.49	-0.53	5.83e-12	Electrocardiographic conduction measures;
UCEC	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	7.03	0.5	7.14e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.31	-5.45	-0.41	2.04e-7	Mean corpuscular volume;
UCEC	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	6.93	0.5	1.23e-10	Motion sickness;
UCEC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.32	0.46	2.98e-9	Menarche (age at onset);
UCEC	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.62	-6.79	-0.49	2.53e-10	Lung cancer;
UCEC	cis	rs10199521	0.861	rs2668841	chr2:2518798	C/T	cg22060041	chr2:1796155	MYT1L	-0.39	-4.93	-0.38	2.21e-6	Diabetic retinopathy;
UCEC	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg02158880	chr13:53174818	NA	0.53	6.35	0.46	2.52e-9	Lewy body disease;
UCEC	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.68	0.36	6.42e-6	Cognitive ability;
UCEC	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.58	5.68	0.42	7.08e-8	Calcium levels;
UCEC	cis	rs2970992	0.728	rs1543104	chr2:101326226	T/C	cg01042948	chr2:101319752	NA	0.56	5.94	0.44	1.99e-8	Educational attainment;
UCEC	cis	rs56879175	0.778	rs17074968	chr5:172015621	C/T	cg21742048	chr5:172099681	NEURL1B	-0.71	-4.77	-0.37	4.44e-6	Gut microbiota (functional units);
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.51	-5.06	-0.39	1.22e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg12559939	chr2:27858050	GPN1	0.46	4.81	0.37	3.75e-6	Oral cavity cancer;
UCEC	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.79	-6.36	-0.46	2.38e-9	Lymphocyte percentage of white cells;
UCEC	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.67	5.88	0.44	2.6e-8	Bipolar disorder;
UCEC	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.82	6.95	0.5	1.12e-10	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.51	6.0	0.44	1.5e-8	Height;
UCEC	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.48	4.98	0.38	1.73e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs2267681	0.544	rs4726838	chr7:139516964	T/C	cg14116596	chr7:139528673	TBXAS1	0.57	5.46	0.41	1.95e-7	Cervical cancer;
UCEC	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg13575925	chr12:9217583	LOC144571	0.41	4.63	0.36	7.93e-6	Sjögren's syndrome;
UCEC	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.44	4.59	0.35	9.63e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs253959	0.729	rs10038877	chr5:115711455	G/A	cg23108291	chr5:115420582	COMMD10	-0.5	-4.71	-0.36	5.57e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.19	-0.39	6.97e-7	Depression;
UCEC	cis	rs641862	1	rs641862	chr13:110790232	C/T	cg00767116	chr13:111340409	CARS2	0.99	5.54	0.42	1.35e-7	Obesity-related traits;
UCEC	cis	rs7709377	0.620	rs7735539	chr5:115480245	A/G	cg23108291	chr5:115420582	COMMD10	0.53	5.44	0.41	2.19e-7	Metabolite levels  (X-11787);
UCEC	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	6.59	0.48	7.45e-10	Mean corpuscular hemoglobin;
UCEC	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.96e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7374004	0.840	rs62242767	chr3:38636842	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.55	5.04	0.38	1.37e-6	PR interval;
UCEC	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg07522913	chr7:27150403	HOXA3	0.59	4.57	0.35	1.02e-5	Type 1 diabetes;
UCEC	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.7	7.98	0.55	3.9e-13	Menopause (age at onset);
UCEC	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	5.95	0.44	1.92e-8	Bipolar disorder;
UCEC	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs354033	1.000	rs354043	chr7:149297332	C/T	cg24335155	chr7:149193227	ZNF746	0.37	4.67	0.36	6.68e-6	Multiple sclerosis;
UCEC	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.54	-5.81	-0.43	3.71e-8	Blood metabolite levels;
UCEC	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	5.06	0.39	1.24e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs3790645	0.831	rs873151	chr1:26880989	T/C	cg23229016	chr1:26872525	RPS6KA1	0.31	5.47	0.41	1.85e-7	Glucose homeostasis traits;
UCEC	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.57	5.56	0.42	1.26e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7212590	1.000	rs73315284	chr17:57884868	A/G	cg10252138	chr17:58120427	NA	-0.68	-5.43	-0.41	2.33e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.58	-5.19	-0.39	6.89e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg24687543	chr11:63912206	MACROD1	0.58	5.63	0.42	8.97e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
UCEC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	0.87	6.68	0.48	4.51e-10	Lymphocyte counts;
UCEC	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18099408	chr3:52552593	STAB1	0.42	4.84	0.37	3.26e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.62	5.85	0.43	3.01e-8	Corneal astigmatism;
UCEC	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-9.25	-0.61	2.5e-16	Blood metabolite levels;
UCEC	cis	rs8020441	0.838	rs72681662	chr14:51163884	G/A	cg04730355	chr14:51134070	SAV1	0.63	5.73	0.43	5.51e-8	Cognitive performance;
UCEC	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.47	5.51	0.41	1.57e-7	Neuroticism;
UCEC	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.63	6.46	0.47	1.43e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.49	5.27	0.4	4.85e-7	Corneal astigmatism;
UCEC	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.64	7.15	0.51	3.71e-11	Crohn's disease;
UCEC	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	5.49	0.41	1.7e-7	HIV-1 control;
UCEC	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.21e-5	Parkinson's disease;
UCEC	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.71	-5.1	-0.39	1.03e-6	Mean platelet volume;
UCEC	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg19554555	chr3:13937349	NA	-0.43	-4.51	-0.35	1.3e-5	Ovarian reserve;
UCEC	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.76	0.43	4.75e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg24687543	chr11:63912206	MACROD1	0.44	5.14	0.39	8.73e-7	Platelet count;
UCEC	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	4.64	0.36	7.71e-6	Cognitive ability;
UCEC	cis	rs10924970	0.649	rs12753166	chr1:235394278	G/T	cg26050004	chr1:235667680	B3GALNT2	0.53	4.92	0.38	2.27e-6	Asthma;
UCEC	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.6	4.79	0.37	4.03e-6	Skin colour saturation;
UCEC	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.65	-0.42	8.11e-8	Neutrophil percentage of white cells;
UCEC	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.6	7.29	0.52	1.78e-11	Bone mineral density;
UCEC	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.59	5.17	0.39	7.6e-7	Response to diuretic therapy;
UCEC	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.46	-0.41	1.99e-7	Neutrophil percentage of white cells;
UCEC	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.44	4.51	0.35	1.33e-5	Schizophrenia;
UCEC	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg14008862	chr17:28927542	LRRC37B2	0.66	4.99	0.38	1.67e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-0.9	-11.71	-0.69	8.62e-23	Height;
UCEC	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.66	6.72	0.48	3.82e-10	Total body bone mineral density;
UCEC	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-4.57	-0.35	1.04e-5	Alzheimer's disease (late onset);
UCEC	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.82	-10.64	-0.66	5.84e-20	Headache;
UCEC	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg16616514	chr4:6324629	PPP2R2C	0.42	5.25	0.4	5.18e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.6	0.48	7.02e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.69	-0.48	4.47e-10	Initial pursuit acceleration;
UCEC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	9.54	0.62	4.29e-17	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10242455	0.867	rs2687079	chr7:99304618	A/T	cg18809830	chr7:99032528	PTCD1	-0.53	-4.62	-0.36	8.48e-6	Blood metabolite levels;
UCEC	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.53	5.47	0.41	1.89e-7	Corneal astigmatism;
UCEC	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.58	6.68	0.48	4.51e-10	Prostate cancer;
UCEC	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.72	-8.03	-0.55	2.84e-13	Monocyte percentage of white cells;
UCEC	cis	rs4713118	0.868	rs760587	chr6:27740300	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-4.52	-0.35	1.28e-5	Parkinson's disease;
UCEC	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.59	5.05	0.38	1.32e-6	Alzheimer's disease;
UCEC	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	6.54	0.47	9.55e-10	Motion sickness;
UCEC	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.52	-4.95	-0.38	1.99e-6	Hepatocellular carcinoma;
UCEC	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.46	4.78	0.37	4.13e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Electroencephalogram traits;
UCEC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-5.16	-0.39	7.88e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7246967	0.611	rs3902164	chr19:22866281	T/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	trans	rs3741489	1.000	rs4328251	chr12:133470781	A/G	cg24132527	chr5:140019269	TMCO6	-0.93	-8.23	-0.56	9.17e-14	Cognitive function;
UCEC	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.41	5.33	0.4	3.65e-7	Blood protein levels;
UCEC	cis	rs6882076	0.884	rs7717984	chr5:156369171	A/G	cg12943317	chr5:156479607	HAVCR1	0.64	6.61	0.48	6.65e-10	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.58	6.35	0.46	2.59e-9	Glomerular filtration rate (creatinine);
UCEC	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg23018236	chr17:30244563	NA	-0.57	-5.49	-0.41	1.74e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg18681998	chr4:17616180	MED28	0.55	6.16	0.45	6.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.77	7.9	0.55	6.16e-13	Breast cancer;
UCEC	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	-0.45	-4.92	-0.38	2.34e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.64	5.48	0.41	1.77e-7	Major depressive disorder;
UCEC	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.42	0.41	2.39e-7	Breast cancer;
UCEC	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg00339695	chr16:24857497	SLC5A11	-0.56	-5.17	-0.39	7.38e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs17764205	0.778	rs12462998	chr19:3243022	T/C	cg09528496	chr19:3881225	ATCAY	-0.62	-4.61	-0.36	8.63e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg16797656	chr11:68205561	LRP5	0.48	5.4	0.41	2.65e-7	Total body bone mineral density;
UCEC	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg21466736	chr12:48725269	NA	0.35	4.7	0.36	5.99e-6	Plateletcrit;
UCEC	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.77	7.9	0.55	6.11e-13	Chronic sinus infection;
UCEC	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.37	-4.64	-0.36	7.56e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.62	5.25	0.4	5.16e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-0.98	-9.72	-0.63	1.51e-17	Lymphocyte counts;
UCEC	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-5.03	-0.38	1.41e-6	Coronary artery disease;
UCEC	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg13147721	chr7:65941812	NA	-0.73	-4.87	-0.37	2.84e-6	Diabetic kidney disease;
UCEC	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg05709478	chr1:6581295	PLEKHG5	0.73	7.28	0.51	1.9e-11	Body mass index;
UCEC	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	6.0	0.44	1.49e-8	Menarche (age at onset);
UCEC	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.49	0.62	5.87e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.49	-0.65	1.44e-19	Blood metabolite levels;
UCEC	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.41	-4.76	-0.37	4.55e-6	Iron status biomarkers;
UCEC	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg01262667	chr19:19385393	TM6SF2	0.49	6.76	0.49	3.09e-10	Tonsillectomy;
UCEC	cis	rs10415976	1.000	rs10415976	chr19:941603	C/T	cg20463312	chr19:591390	HCN2	-0.47	-4.55	-0.35	1.14e-5	Primary biliary cholangitis;
UCEC	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06762426	chr11:62420836	INTS5	0.93	5.36	0.4	3.12e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	10.38	0.65	2.87e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.73	-6.88	-0.49	1.65e-10	Breast cancer;
UCEC	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.1	0.51	4.81e-11	Motion sickness;
UCEC	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-5.43	-0.41	2.29e-7	Hemoglobin concentration;
UCEC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-0.68	-6.47	-0.47	1.39e-9	Breast cancer;
UCEC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg14008862	chr17:28927542	LRRC37B2	0.6	5.12	0.39	9.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg01426195	chr3:39028469	NA	-0.76	-10.34	-0.65	3.66e-19	Handedness;
UCEC	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.73e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.67	6.25	0.46	4.15e-9	Aortic root size;
UCEC	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.76	6.14	0.45	7.34e-9	Neuroticism;
UCEC	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.58	-5.93	-0.44	2.05e-8	Parkinson's disease;
UCEC	cis	rs6663390	0.510	rs1932819	chr1:208078238	C/T	cg03990033	chr1:208084030	CD34	0.5	5.07	0.39	1.18e-6	Facial morphology (factor 18);
UCEC	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.71	8.04	0.55	2.71e-13	Menarche (age at onset);
UCEC	cis	rs4588572	0.643	rs3922654	chr5:77684726	G/A	cg11547950	chr5:77652471	NA	0.48	5.31	0.4	3.89e-7	Triglycerides;
UCEC	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.44	5.2	0.39	6.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.53	-6.56	-0.48	8.78e-10	Total body bone mineral density;
UCEC	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.49	4.76	0.37	4.68e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg16797656	chr11:68205561	LRP5	0.45	4.76	0.37	4.65e-6	Total body bone mineral density (age 0-15);
UCEC	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.68	-7.97	-0.55	3.95e-13	Waist-hip ratio;
UCEC	cis	rs6832769	1.000	rs6834676	chr4:56298414	C/G	cg05960024	chr4:56376020	CLOCK	0.57	5.9	0.44	2.42e-8	Personality dimensions;
UCEC	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.48	0.47	1.33e-9	Cognitive test performance;
UCEC	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.67	-4.79	-0.37	4.08e-6	Rheumatoid arthritis;
UCEC	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.33	-5.4	-0.41	2.61e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.16	6.18	0.45	6.04e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-7.98	-0.55	3.82e-13	Exhaled nitric oxide output;
UCEC	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.85	8.99	0.6	1.15e-15	Ulcerative colitis;
UCEC	cis	rs6669919	0.967	rs894983	chr1:211675279	T/C	cg10512769	chr1:211675356	NA	-0.31	-4.67	-0.36	6.82e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	4.87	0.37	2.81e-6	Parkinson's disease;
UCEC	cis	rs4315565	0.688	rs11887395	chr2:69270926	A/G	cg13358873	chr2:69271042	ANTXR1	-0.44	-5.04	-0.38	1.35e-6	Height;
UCEC	cis	rs8105895	0.799	rs62112922	chr19:22228340	C/T	cg02912127	chr19:22235281	ZNF257	-0.58	-4.69	-0.36	6.25e-6	Body mass index (change over time);
UCEC	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.79	9.16	0.6	4.21e-16	Mortality in heart failure;
UCEC	cis	rs7860634	0.872	rs7847312	chr9:139089718	A/C	cg04455058	chr9:139085579	NA	0.46	6.25	0.46	4.11e-9	Thyroid hormone levels;
UCEC	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.6	-6.24	-0.46	4.44e-9	Blood protein levels;
UCEC	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.82	0.49	2.24e-10	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.6	-7.59	-0.53	3.42e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.54	6.82	0.49	2.15e-10	Total body bone mineral density;
UCEC	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.38	-5.81	-0.43	3.81e-8	Body mass index;
UCEC	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.57	4.82	0.37	3.48e-6	Lung cancer;
UCEC	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.63	7.52	0.53	5.1e-12	Obesity-related traits;
UCEC	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07677856	chr17:61926188	NA	0.42	4.97	0.38	1.83e-6	Prudent dietary pattern;
UCEC	cis	rs2979489	0.891	rs16877096	chr8:30364388	T/C	cg26383811	chr8:30366931	RBPMS	-0.81	-8.75	-0.59	4.6e-15	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.92	13.92	0.75	1.27e-28	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.9	-7.7	-0.54	1.83e-12	Coronary artery calcification;
UCEC	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.59	-6.51	-0.47	1.12e-9	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.71	7.55	0.53	4.14e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.84	0.59	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.86	-10.09	-0.64	1.64e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg11632617	chr15:75315747	PPCDC	-0.6	-7.01	-0.5	8.23e-11	Blood trace element (Zn levels);
UCEC	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg27624424	chr6:160112604	SOD2	0.52	4.52	0.35	1.24e-5	Age-related macular degeneration (geographic atrophy);
UCEC	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs7187365	1.000	rs34817486	chr16:86495092	C/T	cg02657828	chr16:86703935	NA	-0.49	-4.64	-0.36	7.79e-6	Obesity (early onset extreme);
UCEC	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.51	-8.7	-0.58	6.21e-15	Airflow obstruction;
UCEC	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.8	-9.66	-0.62	2.09e-17	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7512898	0.545	rs7518347	chr1:200674027	G/A	cg19099833	chr1:201476290	CSRP1	-0.5	-5.04	-0.38	1.32e-6	Electrocardiographic conduction measures;
UCEC	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.49	0.47	1.21e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.63	-0.36	7.88e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-10.34	-0.65	3.5e-19	Cognitive function;
UCEC	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.91	-8.87	-0.59	2.29e-15	Cognitive ability;
UCEC	cis	rs2209875	0.640	rs7037454	chr9:91710338	C/A	cg00102996	chr9:92220617	GADD45G	-0.51	-4.59	-0.35	9.24e-6	Pelvic organ prolapse (moderate/severe);
UCEC	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.68	5.61	0.42	9.81e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs11023787	1.000	rs878625	chr11:15939695	A/G	cg04486763	chr11:16635542	NA	0.49	4.86	0.37	2.92e-6	Bone mineral density (wrist);
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4908768	0.871	rs4908775	chr1:8794410	G/A	cg13081009	chr1:8430745	RERE	0.49	5.06	0.39	1.24e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.37	-5.47	-0.41	1.93e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.86	6.95	0.5	1.13e-10	Body mass index;
UCEC	cis	rs7072216	0.587	rs2296435	chr10:100182285	C/T	cg19567339	chr10:100142640	NA	-0.54	-5.7	-0.43	6.32e-8	Metabolite levels;
UCEC	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.01	-6.55	-0.48	8.96e-10	Diabetic kidney disease;
UCEC	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.63	-7.19	-0.51	3.12e-11	Hip circumference;
UCEC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg02160872	chr5:212506	CCDC127	-0.84	-7.49	-0.53	5.96e-12	Breast cancer;
UCEC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.39	4.51	0.35	1.3e-5	Hip circumference adjusted for BMI;
UCEC	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	5.3	0.4	4.23e-7	IgG glycosylation;
UCEC	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg16583315	chr14:65563665	MAX	-0.4	-4.59	-0.35	9.58e-6	Obesity-related traits;
UCEC	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.08	0.45	9.87e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.64	6.21	0.46	5.22e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.74	-0.36	4.9e-6	Response to antipsychotic treatment;
UCEC	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.56	0.48	8.75e-10	Personality dimensions;
UCEC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.54	4.89	0.37	2.6e-6	Plasma homocysteine levels (post-methionine load test);
UCEC	cis	rs7517126	1.000	rs34673990	chr1:196838757	G/A	cg07209298	chr1:196795943	CFHR1	0.51	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.61	7.51	0.53	5.26e-12	Warfarin maintenance dose;
UCEC	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.54	-6.23	-0.46	4.75e-9	Type 2 diabetes;
UCEC	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.58	6.49	0.47	1.25e-9	Hip circumference;
UCEC	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg17986701	chr20:44574422	PCIF1	0.45	4.59	0.35	9.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-0.53	-5.24	-0.4	5.51e-7	Blood trace element (Zn levels);
UCEC	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-4.59	-0.35	9.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-5.86	-0.44	2.91e-8	Tonsillectomy;
UCEC	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg21856205	chr7:94953877	PON1	-0.54	-5.19	-0.39	6.72e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.76	-0.37	4.67e-6	Breast cancer;
UCEC	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-9.27	-0.61	2.11e-16	Gut microbiome composition (summer);
UCEC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg23795048	chr12:9217529	LOC144571	0.41	5.2	0.39	6.43e-7	Sjögren's syndrome;
UCEC	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.99	7.02	0.5	7.57e-11	LDL cholesterol;
UCEC	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.7	0.48	4.21e-10	Cognitive test performance;
UCEC	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.65	-6.07	-0.45	1.06e-8	Aortic root size;
UCEC	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.55	4.88	0.37	2.73e-6	Intelligence;Intelligence (multi-trait analysis);
UCEC	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.8	-10.6	-0.66	7.51e-20	Body mass index;
UCEC	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.99	6.96	0.5	1.05e-10	LDL cholesterol;
UCEC	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg09491104	chr22:46646882	C22orf40	-0.67	-7.71	-0.54	1.74e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.55	6.19	0.45	5.84e-9	Iron status biomarkers (transferrin levels);
UCEC	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg00614314	chr15:82944287	LOC80154	0.53	4.86	0.37	3.01e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.99	-0.44	1.54e-8	Platelet count;
UCEC	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg27246729	chr12:121163418	ACADS	0.49	4.66	0.36	7.04e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.81	0.37	3.69e-6	Breast cancer;
UCEC	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg19554555	chr3:13937349	NA	0.56	5.67	0.42	7.32e-8	Ovarian reserve;
UCEC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg11211951	chr8:145729740	GPT	-0.46	-5.52	-0.41	1.53e-7	Age at first birth;
UCEC	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.83	-8.76	-0.59	4.26e-15	Height;
UCEC	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.94	-9.27	-0.61	2.11e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg04154034	chr17:28927549	LRRC37B2	0.56	4.87	0.37	2.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.63	0.36	8.09e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.73	5.73	0.43	5.53e-8	Cognitive test performance;
UCEC	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.78	9.99	0.64	2.96e-18	Mean corpuscular volume;
UCEC	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-5.65	-0.42	8.05e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-0.78	-4.74	-0.36	4.9100000000000004e-06	Mitochondrial DNA levels;
UCEC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.24e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg21770322	chr7:97807741	LMTK2	0.54	6.75	0.49	3.16e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.41	5.49	0.41	1.73e-7	Breast cancer;
UCEC	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg12884169	chr21:40033163	ERG	0.49	6.52	0.47	1.04e-9	Coronary artery disease;
UCEC	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg08886695	chr4:3369023	RGS12	-0.48	-5.37	-0.41	2.95e-7	Serum sulfate level;
UCEC	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.77	7.71	0.54	1.72e-12	Ulcerative colitis;
UCEC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	10.07	0.64	1.82e-18	Schizophrenia;
UCEC	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	5.21	0.4	6.18e-7	HDL cholesterol;
UCEC	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg14092571	chr14:90743983	NA	0.45	5.19	0.39	6.95e-7	Mortality in heart failure;
UCEC	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.69	-6.25	-0.46	4.21e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	9.91	0.63	4.67e-18	Blood protein levels;
UCEC	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-5.66	-0.42	7.58e-8	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-6.16	-0.45	6.79e-9	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs9321099	1.000	rs73580721	chr6:128235258	A/G	cg25012434	chr6:128842125	PTPRK	0.6	4.81	0.37	3.74e-6	Sense of smell;
UCEC	cis	rs73206853	0.764	rs56128816	chr12:110775609	T/C	cg12870014	chr12:110450643	ANKRD13A	0.6	4.91	0.38	2.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.14	12.4	0.71	1.32e-24	Platelet count;
UCEC	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	8.92	0.59	1.69e-15	Hip circumference;
UCEC	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.59	7.12	0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg01689657	chr7:91764605	CYP51A1	-0.47	-5.99	-0.44	1.56e-8	Breast cancer;
UCEC	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	6.83	0.49	2.12e-10	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.46	5.08	0.39	1.1e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.49	5.12	0.39	9.31e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.7	-6.19	-0.45	5.82e-9	Adiposity;
UCEC	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.56	8.04	0.55	2.66e-13	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs6437061	0.683	rs755227	chr2:232982731	G/A	cg02061626	chr2:233274167	ALPPL2	-0.56	-6.26	-0.46	3.94e-9	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.78	-8.85	-0.59	2.49e-15	Height;
UCEC	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg18973586	chr4:963968	DGKQ	0.47	4.57	0.35	1.03e-5	Obesity-related traits;
UCEC	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.59	5.67	0.42	7.33e-8	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.52	5.68	0.42	7.13e-8	Urate levels;
UCEC	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.52	-4.92	-0.38	2.28e-6	Schizophrenia;
UCEC	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg06417478	chr19:12876846	HOOK2	0.42	4.55	0.35	1.1e-5	Bipolar disorder;
UCEC	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.94	10.38	0.65	2.8e-19	Cognitive function;
UCEC	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.83	9.51	0.62	5.25e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.85	6.95	0.5	1.08e-10	Platelet count;
UCEC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.52	-4.54	-0.35	1.18e-5	Carotid intima media thickness;
UCEC	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg00266579	chr16:28619858	SULT1A1	-0.6	-4.55	-0.35	1.11e-5	Platelet distribution width;
UCEC	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.49	4.75	0.37	4.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.56	5.05	0.38	1.32e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.65	4.58	0.35	9.73e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.63	6.63	0.48	5.82e-10	Monocyte count;
UCEC	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.58	6.81	0.49	2.36e-10	Menarche (age at onset);
UCEC	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg13206674	chr6:150067644	NUP43	0.58	4.88	0.37	2.67e-6	Lung cancer;
UCEC	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg07424592	chr7:64974309	NA	0.75	4.51	0.35	1.31e-5	Diabetic kidney disease;
UCEC	cis	rs12449964	0.524	rs4925094	chr17:17569012	C/T	cg04398451	chr17:18023971	MYO15A	0.41	4.68	0.36	6.48e-6	Coronary artery disease or ischemic stroke;
UCEC	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.57	-7.08	-0.5	5.38e-11	Lymphocyte counts;
UCEC	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.65	7.33	0.52	1.39e-11	Ulcerative colitis;
UCEC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.38e-17	Height;
UCEC	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.64	-6.07	-0.45	1.05e-8	Parkinson's disease;
UCEC	cis	rs7617773	1.000	rs11711766	chr3:48193170	G/C	cg11946769	chr3:48343235	NME6	-0.55	-4.81	-0.37	3.77e-6	Coronary artery disease;
UCEC	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.69	7.0	0.5	8.3e-11	Primary sclerosing cholangitis;
UCEC	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg13575925	chr12:9217583	LOC144571	0.4	4.75	0.37	4.7e-6	Sjögren's syndrome;
UCEC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.42	4.7	0.36	5.93e-6	Menopause (age at onset);
UCEC	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg10932868	chr11:921992	NA	0.44	5.86	0.44	2.9e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.09	-0.45	9.34e-9	Metabolite levels;
UCEC	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.7	-8.33	-0.57	5.08e-14	Prevalent atrial fibrillation;
UCEC	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.6	4.58	0.35	9.79e-6	Corneal astigmatism;
UCEC	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-4.51	-0.35	1.34e-5	Schizophrenia;
UCEC	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.83	-5.54	-0.42	1.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7709377	0.570	rs6594938	chr5:115432472	A/G	cg23108291	chr5:115420582	COMMD10	0.48	4.87	0.37	2.88e-6	Metabolite levels  (X-11787);
UCEC	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.61	5.81	0.43	3.67e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
UCEC	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg11632617	chr15:75315747	PPCDC	-0.55	-4.84	-0.37	3.19e-6	Lung cancer;
UCEC	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.78	7.11	0.51	4.81e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg05539622	chr2:73298971	SFXN5	0.5	4.62	0.36	8.28e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg19926144	chr10:661009	DIP2C	0.79	4.75	0.36	4.76e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-6.03	-0.45	1.3e-8	Coffee consumption (cups per day);
UCEC	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-6.8	-0.49	2.48e-10	Schizophrenia;
UCEC	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	4.54	0.35	1.14e-5	Aortic root size;
UCEC	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg09626299	chr10:82213104	TSPAN14	-0.39	-6.31	-0.46	3.11e-9	Post bronchodilator FEV1;
UCEC	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg23791538	chr6:167370224	RNASET2	-0.56	-5.81	-0.43	3.71e-8	Crohn's disease;
UCEC	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.48	6.03	0.45	1.3e-8	Electrocardiographic conduction measures;
UCEC	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg20485758	chr6:26088446	HFE	0.82	4.53	0.35	1.22e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.65	-4.57	-0.35	1.01e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7004769	0.554	rs79580099	chr8:9168896	G/A	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.56	-7.16	-0.51	3.65e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2267681	0.544	rs1990354	chr7:139523858	A/G	cg14116596	chr7:139528673	TBXAS1	0.53	5.19	0.39	6.91e-7	Cervical cancer;
UCEC	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg16329650	chr2:213403929	ERBB4	0.46	4.66	0.36	6.97e-6	Symmetrical dimethylarginine levels;
UCEC	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg04058563	chr4:185651563	MLF1IP	0.68	5.32	0.4	3.79e-7	Systemic lupus erythematosus;
UCEC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.77	-8.73	-0.58	5.09e-15	Height;
UCEC	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg05695927	chr15:45694626	SPATA5L1	0.47	4.77	0.37	4.42e-6	Homoarginine levels;
UCEC	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.67	-6.98	-0.5	9.47e-11	Longevity;Endometriosis;
UCEC	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.82	6.43	0.47	1.7e-9	Lymphocyte counts;
UCEC	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg06096015	chr1:231504339	EGLN1	0.45	5.25	0.4	5.24e-7	Hemoglobin concentration;
UCEC	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-8.71	-0.58	5.92e-15	Gut microbiome composition (summer);
UCEC	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg05709478	chr1:6581295	PLEKHG5	0.68	5.7	0.43	6.41e-8	Body mass index;
UCEC	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.67	-6.3	-0.46	3.29e-9	Resting heart rate;
UCEC	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	1.2	9.75	0.63	1.25e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	3.14e-8	Schizophrenia;
UCEC	cis	rs11690935	0.632	rs12987931	chr2:172900948	C/T	cg13550731	chr2:172543902	DYNC1I2	0.64	5.59	0.42	1.07e-7	Schizophrenia;
UCEC	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	4.6	0.35	8.95e-6	Coronary artery disease;
UCEC	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg01256987	chr12:42539512	GXYLT1	-0.46	-5.28	-0.4	4.61e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.68	-8.09	-0.55	2.07e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	4.53	0.35	1.22e-5	Rheumatoid arthritis;
UCEC	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.53	5.27	0.4	4.69e-7	Dupuytren's disease;
UCEC	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.16	-9.0	-0.6	1.08e-15	Hip circumference adjusted for BMI;
UCEC	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg03264133	chr6:25882463	NA	-0.58	-4.62	-0.36	8.22e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg22808692	chr7:6193786	USP42	-0.55	-7.03	-0.5	7.21e-11	N-glycan levels;
UCEC	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.53	-7.08	-0.5	5.56e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs4757319	0.554	rs11023520	chr11:15332935	A/G	cg03245590	chr11:15329459	NA	-0.46	-5.5	-0.41	1.64e-7	Breast cancer;
UCEC	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.63	-6.33	-0.46	2.87e-9	Blood metabolite levels;
UCEC	cis	rs2120243	0.782	rs7609926	chr3:157149160	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.46	4.7	0.36	6.02e-6	Hepatocellular carcinoma in hepatitis B infection;
UCEC	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.65	5.97	0.44	1.7e-8	Schizophrenia;
UCEC	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.56	0.58	1.35e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg19318889	chr4:1322082	MAEA	0.59	7.17	0.51	3.45e-11	Longevity;
UCEC	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.55	4.8	0.37	3.83e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.66	-7.15	-0.51	3.85e-11	Prostate cancer;
UCEC	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.74	9.2	0.6	3.37e-16	Vitiligo;
UCEC	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg24851651	chr11:66362959	CCS	-0.41	-5.17	-0.39	7.56e-7	Educational attainment (years of education);
UCEC	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.45	4.73	0.36	5.23e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg22974920	chr21:40686053	BRWD1	-0.55	-4.99	-0.38	1.7e-6	Cognitive function;
UCEC	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	5.25	0.4	5.13e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.55	5.41	0.41	2.46e-7	Menopause (age at onset);
UCEC	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.53	-5.09	-0.39	1.08e-6	Metabolite levels;
UCEC	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg15147215	chr3:52552868	STAB1	-0.42	-4.69	-0.36	6.28e-6	Bipolar disorder;
UCEC	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.63	5.61	0.42	9.87e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.62	6.56	0.48	8.8e-10	Colorectal cancer;
UCEC	cis	rs17106184	1.000	rs12074982	chr1:51387415	T/C	cg07174182	chr1:51127561	FAF1	-0.71	-4.79	-0.37	4e-6	Type 2 diabetes;
UCEC	cis	rs3790645	1.000	rs3790645	chr1:26884864	G/A	cg23229016	chr1:26872525	RPS6KA1	0.34	6.33	0.46	2.77e-9	Glucose homeostasis traits;
UCEC	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.64	6.33	0.46	2.79e-9	Mean corpuscular volume;
UCEC	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.74	4.88	0.37	2.72e-6	Neuroticism;
UCEC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-5.53	-0.41	1.46e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg10932868	chr11:921992	NA	0.44	5.86	0.44	2.9e-8	Alzheimer's disease (late onset);
UCEC	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.63	7.05	0.5	6.63e-11	Homoarginine levels;
UCEC	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.74	5.46	0.41	1.95e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.49	-4.62	-0.36	8.35e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
UCEC	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg24881330	chr22:46731750	TRMU	0.72	7.42	0.52	8.71e-12	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs10031466	0.935	rs902909	chr4:189021465	A/G	cg03652810	chr4:189026682	TRIML2	0.46	5.68	0.42	7.1e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
UCEC	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	0.84	4.72	0.36	5.34e-6	Inflammatory biomarkers;
UCEC	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.46	6.6	0.48	6.87e-10	Alcohol dependence;
UCEC	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg19715936	chr7:50634035	DDC	0.47	5.77	0.43	4.54e-8	Malaria;
UCEC	cis	rs10853057	0.541	rs77675516	chr17:63046808	C/T	cg06875131	chr17:63554468	AXIN2	-0.78	-5.05	-0.38	1.28e-6	White matter microstructure (global fractional anisotropy);
UCEC	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.69	6.9	0.49	1.44e-10	Menopause (age at onset);
UCEC	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.67	5.1	0.39	1.03e-6	Prostate cancer;
UCEC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.44	0.65	1.97e-19	Chronic sinus infection;
UCEC	cis	rs9469578	1.000	rs9469582	chr6:33715939	A/G	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	1.12	5.44	0.41	2.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.72	-8.31	-0.57	5.95e-14	Waist circumference;Body mass index;
UCEC	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.51	-4.72	-0.36	5.55e-6	Developmental language disorder (linguistic errors);
UCEC	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.79	6.94	0.5	1.15e-10	IgG glycosylation;
UCEC	trans	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg02022102	chr7:27168609	HOXA4	0.6	6.78	0.49	2.67e-10	Protein biomarker;
UCEC	cis	rs13191362	0.688	rs73025321	chr6:162974896	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.15	0.39	8.25e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	5.98	0.44	1.63e-8	Height;
UCEC	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.44	-0.41	2.14e-7	Neutrophil percentage of white cells;
UCEC	cis	rs10786436	0.605	rs12412681	chr10:100285249	C/T	cg24343515	chr10:99400468	PI4K2A	-0.46	-4.58	-0.35	9.68e-6	Type 1 diabetes;
UCEC	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.73	7.65	0.53	2.38e-12	Eosinophil percentage of white cells;
UCEC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.67	7.65	0.53	2.38e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.64	6.51	0.47	1.14e-9	Platelet distribution width;
UCEC	cis	rs7766436	0.885	rs4712699	chr6:22592884	C/A	cg13666174	chr6:22585274	NA	-0.5	-5.26	-0.4	4.91e-7	Coronary artery disease;
UCEC	cis	rs7975161	0.565	rs4545635	chr12:104636844	A/C	cg25273343	chr12:104657179	TXNRD1	-0.79	-4.89	-0.37	2.64e-6	Toenail selenium levels;
UCEC	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	0.81	4.95	0.38	2.01e-6	Fat distribution (HIV);
UCEC	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg24562669	chr7:97807699	LMTK2	0.47	5.76	0.43	4.64e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg03859395	chr2:55845619	SMEK2	1.02	14.62	0.77	1.88e-30	Metabolic syndrome;
UCEC	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	4.79	0.37	4.05e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.82	9.11	0.6	5.57e-16	Breast cancer;
UCEC	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg05963712	chr12:49373746	WNT1	0.46	4.51	0.35	1.3e-5	Longevity (90 years and older);
UCEC	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.82	-10.12	-0.64	1.34e-18	White blood cell count (basophil);
UCEC	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-10.4	-0.65	2.44e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.64	0.48	5.77e-10	Coffee consumption (cups per day);
UCEC	cis	rs55670112	0.935	rs28749248	chr5:114277238	T/C	cg05461448	chr5:114880715	FEM1C	-0.44	-4.59	-0.35	9.62e-6	Epilepsy;
UCEC	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.01	0.5	7.96e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.03	-8.47	-0.57	2.35e-14	Exhaled nitric oxide output;
UCEC	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.69	-5.16	-0.39	7.75e-7	Narcolepsy;
UCEC	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs7246967	0.673	rs8102006	chr19:22870103	A/G	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg15412446	chr2:106886593	NA	-0.61	-4.99	-0.38	1.66e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg18479299	chr3:125709523	NA	-0.65	-4.5	-0.35	1.35e-5	Blood pressure (smoking interaction);
UCEC	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg12179176	chr11:130786555	SNX19	0.45	4.52	0.35	1.28e-5	Schizophrenia;
UCEC	cis	rs4588572	0.643	rs6453396	chr5:77785387	T/C	cg11547950	chr5:77652471	NA	-0.45	-5.04	-0.38	1.35e-6	Triglycerides;
UCEC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.53	5.24	0.4	5.35e-7	Aortic root size;
UCEC	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.62	-6.83	-0.49	2.05e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10104451	chr8:143696006	ARC	-0.54	-5.09	-0.39	1.1e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.5	4.55	0.35	1.11e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg06096015	chr1:231504339	EGLN1	0.46	5.38	0.41	2.83e-7	Hemoglobin concentration;
UCEC	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-4.67	-0.36	6.82e-6	Recombination measurement;
UCEC	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-7.32	-0.52	1.5e-11	Blood trace element (Zn levels);
UCEC	cis	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg17325771	chr7:75508891	RHBDD2	0.48	5.72	0.43	5.7e-8	Eotaxin levels;
UCEC	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	7.84	0.54	8.53e-13	Homoarginine levels;
UCEC	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.7	-6.43	-0.47	1.71e-9	Resting heart rate;
UCEC	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.34	-0.4	3.41e-7	Hemoglobin concentration;
UCEC	cis	rs7781557	1.000	rs727175	chr7:102471780	T/C	cg06322601	chr7:102330635	NA	0.7	5.87	0.44	2.76e-8	Colorectal adenoma (advanced);
UCEC	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.58	-6.2	-0.46	5.5e-9	Type 2 diabetes;
UCEC	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.5	-4.98	-0.38	1.74e-6	Breast size;
UCEC	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.77	-6.88	-0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.91	9.44	0.61	7.71e-17	Cognitive function;
UCEC	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg12253828	chr6:101329408	ASCC3	0.47	4.78	0.37	4.24e-6	Neuroticism;
UCEC	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.47	-5.18	-0.39	7.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg03714773	chr7:91764589	CYP51A1	0.45	5.41	0.41	2.45e-7	Breast cancer;
UCEC	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.63	5.05	0.38	1.27e-6	Resting heart rate;
UCEC	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.51	5.69	0.42	6.72e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.55	5.2	0.39	6.66e-7	Aortic root size;
UCEC	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-9.73	-0.63	1.36e-17	Height;
UCEC	cis	rs4662945	0.714	rs17578014	chr2:130191969	T/A	cg05962382	chr2:130345044	NA	-0.44	-4.98	-0.38	1.77e-6	Response to cytidine analogues (gemcitabine);
UCEC	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.59	-6.43	-0.47	1.66e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.72	-10.94	-0.67	9.48e-21	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg05802129	chr4:122689817	NA	-0.5	-5.26	-0.4	5.06e-7	Type 2 diabetes;
UCEC	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.63	0.53	2.71e-12	Bipolar disorder;
UCEC	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.78	-7.11	-0.51	4.8e-11	Obesity-related traits;
UCEC	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg15147215	chr3:52552868	STAB1	-0.42	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg14196790	chr5:131705035	SLC22A5	0.44	4.68	0.36	6.59e-6	Breast cancer;Mosquito bite size;
UCEC	cis	rs6534441	0.727	rs7690523	chr4:125463491	T/G	cg21609808	chr4:125404261	NA	0.4	4.6	0.35	9.05e-6	Major depressive disorder;
UCEC	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.46	4.66	0.36	7.02e-6	Schizophrenia;
UCEC	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-0.95	-10.02	-0.64	2.46e-18	Height;
UCEC	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.57	6.94	0.5	1.15e-10	Oral cavity cancer;
UCEC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.93	5.86	0.43	2.99e-8	Plasma clusterin levels;
UCEC	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.51	-0.57	1.87e-14	Total body bone mineral density;
UCEC	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-5.56	-0.42	1.23e-7	Type 2 diabetes;
UCEC	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	0.71	4.83	0.37	3.36e-6	Diabetic retinopathy;
UCEC	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.79	-0.49	2.6e-10	Coffee consumption (cups per day);
UCEC	cis	rs8105895	1.000	rs17450788	chr19:22224755	T/C	cg24175803	chr19:22235144	ZNF257	-0.52	-4.85	-0.37	3.06e-6	Body mass index (change over time);
UCEC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs4499344	0.693	rs8106502	chr19:33097796	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.74	0.43	5.16e-8	Mean platelet volume;
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	6.86	0.49	1.77e-10	Platelet count;
UCEC	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	6.06	0.45	1.1e-8	Refractive astigmatism;
UCEC	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.39	-5.2	-0.39	6.48e-7	Alcohol dependence;
UCEC	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	1.01	10.02	0.64	2.46e-18	Alcohol dependence;
UCEC	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.65	6.81	0.49	2.28e-10	Tonsillectomy;
UCEC	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-0.6	-6.96	-0.5	1.03e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.5	-5.27	-0.4	4.88e-7	Menarche (age at onset);
UCEC	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.51	4.69	0.36	6.1e-6	Coronary artery disease;
UCEC	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.04	-6.49	-0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs7968440	1.000	rs7307815	chr12:50922710	A/C	cg20014596	chr12:50898483	DIP2B	0.46	4.54	0.35	1.14e-5	Fibrinogen;
UCEC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg13147721	chr7:65941812	NA	-0.92	-5.8	-0.43	3.91e-8	Diabetic kidney disease;
UCEC	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.48	5.92	0.44	2.22e-8	Information processing speed;
UCEC	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04731861	chr2:219085781	ARPC2	0.41	4.63	0.36	8e-6	Colorectal cancer;
UCEC	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.88	9.71	0.63	1.54e-17	Blood metabolite levels;
UCEC	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.94	0.7	2.1e-23	Prudent dietary pattern;
UCEC	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.63	-4.91	-0.38	2.36e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.45	4.63	0.36	8.07e-6	Schizophrenia;
UCEC	cis	rs7597155	0.811	rs11126245	chr2:69975000	C/T	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.12	-0.39	9.49e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.54	5.07	0.39	1.18e-6	Coronary artery disease;
UCEC	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	7.15	0.51	3.68e-11	Response to antipsychotic treatment;
UCEC	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.77	0.59	4.14e-15	Prudent dietary pattern;
UCEC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	4.86	0.37	2.97e-6	Menopause (age at onset);
UCEC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	4.83	0.37	3.38e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.42	-5.5	-0.41	1.67e-7	Monocyte count;
UCEC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.75	-8.36	-0.57	4.26e-14	Coronary artery disease;
UCEC	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.52	5.3	0.4	4.17e-7	Systolic blood pressure;
UCEC	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.75	-7.3	-0.52	1.66e-11	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs10503871	0.725	rs7017861	chr8:30373040	G/A	cg26383811	chr8:30366931	RBPMS	0.49	5.06	0.39	1.24e-6	Metabolite levels  (X-11787);
UCEC	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	6.84	0.49	2.01e-10	Platelet count;
UCEC	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.59	-5.69	-0.43	6.54e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.73	-5.73	-0.43	5.55e-8	Alzheimer's disease (late onset);
UCEC	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.78	0.49	2.67e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.72	7.03	0.5	7.26e-11	Monocyte count;
UCEC	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.62	-6.47	-0.47	1.35e-9	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	5.14	0.39	8.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg11871910	chr12:69753446	YEATS4	0.57	5.18	0.39	7.21e-7	Response to diuretic therapy;
UCEC	cis	rs7307889	1.000	rs73045687	chr12:5986795	A/T	cg10294363	chr12:6480192	SCNN1A	0.61	4.76	0.37	4.58e-6	Obesity-related traits;
UCEC	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-0.6	-7.55	-0.53	4.12e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.53	4.5	0.35	1.36e-5	Height;
UCEC	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.45	-4.81	-0.37	3.75e-6	Parkinson's disease;
UCEC	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.53	-5.73	-0.43	5.48e-8	Coronary artery disease;
UCEC	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg05738196	chr6:26577821	NA	0.59	6.44	0.47	1.6e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.56	6.3	0.46	3.2e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-5.15	-0.39	8.27e-7	Personality dimensions;
UCEC	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	5.7	0.43	6.42e-8	Breast cancer;
UCEC	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.49	-5.11	-0.39	9.94e-7	Longevity;
UCEC	cis	rs12505328	0.514	rs6836022	chr4:174390724	A/T	cg22660207	chr4:174320772	SCRG1	-0.46	-4.67	-0.36	6.82e-6	Chin dimples;
UCEC	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.66	-7.96	-0.55	4.32e-13	Hip circumference;
UCEC	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.66	7.5	0.53	5.67e-12	Resting heart rate;
UCEC	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.55	4.73	0.36	5.2e-6	Pulmonary function decline;
UCEC	cis	rs9443189	0.502	rs6453843	chr6:76558485	T/G	cg01950844	chr6:76311363	SENP6	-0.69	-5.04	-0.38	1.34e-6	Prostate cancer;
UCEC	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.89	0.63	5.36e-18	Blood protein levels;
UCEC	cis	rs7246657	0.598	rs10417545	chr19:37654263	C/G	cg23950597	chr19:37808831	NA	-0.85	-6.18	-0.45	5.89e-9	Coronary artery calcification;
UCEC	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	0.99	6.13	0.45	7.7e-9	Skin colour saturation;
UCEC	cis	rs11760485	0.965	rs28629195	chr7:4401934	T/C	cg22450045	chr7:4839495	RADIL	-0.41	-5.01	-0.38	1.55e-6	Early childhood aggressive behavior;
UCEC	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.51	-0.41	1.55e-7	Life satisfaction;
UCEC	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	7.58	0.53	3.53e-12	Ileal carcinoids;
UCEC	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg20129853	chr10:51489980	NA	-0.4	-4.74	-0.36	5e-6	Prostate-specific antigen levels;
UCEC	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.81	10.32	0.65	4.12e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg16497661	chr14:103986332	CKB	0.43	5.08	0.39	1.11e-6	Body mass index;
UCEC	cis	rs12039431	0.788	rs11749	chr1:38023316	C/T	cg17933807	chr1:38061675	GNL2	-0.54	-4.79	-0.37	4.05e-6	Epithelial ovarian cancer;
UCEC	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.81	0.49	2.3e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.77	10.6	0.66	7.44e-20	Vitiligo;
UCEC	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg18016565	chr1:150552671	MCL1	-0.55	-5.94	-0.44	2.02e-8	Tonsillectomy;
UCEC	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.7	6.1	0.45	9e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.45	-4.61	-0.36	8.85e-6	Longevity;
UCEC	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.39	-4.65	-0.36	7.36e-6	Refractive error;
UCEC	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.58	5.53	0.41	1.43e-7	Birth weight;
UCEC	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg12024160	chr4:1254474	NA	0.64	7.19	0.51	3.07e-11	Obesity-related traits;
UCEC	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.58	5.19	0.39	6.75e-7	Dialysis-related mortality;
UCEC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-5.26	-0.4	4.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs172166	0.561	rs149971	chr6:27982152	G/A	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.08	-0.45	1e-8	Cardiac Troponin-T levels;
UCEC	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.79	-0.37	3.98e-6	Tonsillectomy;
UCEC	cis	rs17123764	0.786	rs7980979	chr12:50122588	G/T	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.63	6.67	0.48	4.95e-10	QRS complex (12-leadsum);
UCEC	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg13683864	chr3:40499215	RPL14	-0.54	-5.65	-0.42	8.16e-8	Renal cell carcinoma;
UCEC	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	1.01	6.0	0.44	1.44e-8	White matter hyperintensity burden;
UCEC	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.48	-5.99	-0.44	1.53e-8	Electrocardiographic conduction measures;
UCEC	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.72	6.44	0.47	1.57e-9	Subjective well-being;
UCEC	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.12	13.93	0.75	1.17e-28	Cognitive function;
UCEC	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.52	-6.58	-0.48	7.58e-10	Bone mineral density (spine);Bone mineral density;
UCEC	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.74	-0.49	3.4e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.6	-6.21	-0.46	5.27e-9	Body mass index;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.5	4.58	0.35	1e-5	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.62	9.02	0.6	9.26e-16	Prudent dietary pattern;
UCEC	cis	rs9532580	0.620	rs2755210	chr13:41141282	C/G	cg21288729	chr13:41239152	FOXO1	0.5	5.02	0.38	1.44e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg24687543	chr11:63912206	MACROD1	0.43	5.37	0.4	3.08e-7	Platelet count;
UCEC	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs11867410	0.744	rs55742330	chr17:63956719	T/G	cg06996976	chr17:64576105	PRKCA	-0.78	-4.65	-0.36	7.3e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg06818710	chr6:28411271	ZSCAN23	-0.56	-6.64	-0.48	5.63e-10	Cardiac Troponin-T levels;
UCEC	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.06	-0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-6.68	-0.48	4.71e-10	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg18016565	chr1:150552671	MCL1	0.48	4.59	0.35	9.28e-6	Melanoma;
UCEC	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.03	-7.75	-0.54	1.42e-12	Ulcerative colitis;
UCEC	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.39	5.28	0.4	4.54e-7	Blood protein levels;
UCEC	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.78	0.37	4.25e-6	Cognitive ability;
UCEC	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13683864	chr3:40499215	RPL14	-0.66	-6.59	-0.48	7.28e-10	Renal cell carcinoma;
UCEC	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.39	0.41	2.75e-7	Breast cancer;
UCEC	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.56	5.95	0.44	1.9e-8	Retinal vascular caliber;
UCEC	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.49	-4.92	-0.38	2.26e-6	Bipolar disorder;
UCEC	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.51e-6	Colorectal cancer;
UCEC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg11494091	chr17:61959527	GH2	-0.55	-7.07	-0.5	5.85e-11	Prudent dietary pattern;
UCEC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg24889512	chr19:22816950	ZNF492	0.58	6.43	0.47	1.72e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.51	4.89	0.37	2.67e-6	Response to antipsychotic treatment in schizophrenia (working memory);
UCEC	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-5.22	-0.4	6.06e-7	Hemoglobin concentration;
UCEC	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.6	-6.95	-0.5	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg26721908	chr21:47610096	LSS	-0.4	-5.02	-0.38	1.47e-6	Testicular germ cell tumor;
UCEC	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg23460707	chr10:133558971	NA	0.36	4.75	0.36	4.85e-6	Survival in rectal cancer;
UCEC	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.23	-0.51	2.51e-11	Coronary artery disease;
UCEC	cis	rs359466	0.554	rs4317337	chr5:173281589	G/C	cg08267245	chr5:172410984	ATP6V0E1	0.5	4.52	0.35	1.26e-5	QRS complex (Sokolow-Lyon);
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.57	-6.24	-0.46	4.46e-9	Pubertal anthropometrics;
UCEC	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.64	-5.37	-0.4	3.05e-7	Cocaine dependence;
UCEC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18252515	chr7:66147081	NA	0.45	4.6	0.35	8.97e-6	Aortic root size;
UCEC	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-7.81	-0.54	1.01e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	4.8	0.37	3.8e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.81	-5.12	-0.39	9.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg00083072	chr11:65415190	SIPA1	0.45	5.02	0.38	1.46e-6	Acne (severe);
UCEC	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.61	-7.12	-0.51	4.45e-11	Prevalent atrial fibrillation;
UCEC	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg02160872	chr5:212506	CCDC127	-0.78	-7.58	-0.53	3.52e-12	Breast cancer;
UCEC	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.81	-8.35	-0.57	4.64e-14	Mosquito bite size;
UCEC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.36	4.87	0.37	2.88e-6	Abdominal aortic aneurysm;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.58	-6.49	-0.47	1.26e-9	Pubertal anthropometrics;
UCEC	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-7.34	-0.52	1.34e-11	Morning vs. evening chronotype;
UCEC	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.51	5.91	0.44	2.3e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.13	17.82	0.83	1.49e-38	Schizophrenia;
UCEC	cis	rs13095912	0.962	rs7644758	chr3:185328197	G/T	cg11274856	chr3:185301563	NA	-0.57	-7.55	-0.53	4.21e-12	Systolic blood pressure;
UCEC	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.92	10.02	0.64	2.44e-18	Cognitive function;
UCEC	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.49	5.34	0.4	3.45e-7	Blood metabolite levels;
UCEC	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.68	5.65	0.42	7.99e-8	Alcohol dependence;
UCEC	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.16	-9.02	-0.6	9.44e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.02	-0.5	7.5e-11	Mood instability;
UCEC	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.78	0.54	1.2e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg07776626	chr8:57350775	NA	-0.47	-5.26	-0.4	4.91e-7	Obesity-related traits;
UCEC	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.63	5.7	0.43	6.25e-8	Morning vs. evening chronotype;
UCEC	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg23950597	chr19:37808831	NA	-0.65	-5.13	-0.39	8.86e-7	Coronary artery calcification;
UCEC	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.99	-13.55	-0.75	1.2100000000000001e-27	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	0.98	9.9	0.63	5.21e-18	Type 2 diabetes nephropathy;
UCEC	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs4372836	0.729	rs10865508	chr2:29053704	G/C	cg09522027	chr2:28974177	PPP1CB	0.68	7.65	0.53	2.49e-12	Body mass index;
UCEC	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	6.8	0.49	2.47e-10	Motion sickness;
UCEC	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg05709478	chr1:6581295	PLEKHG5	0.67	4.95	0.38	1.97e-6	Body mass index;
UCEC	cis	rs9739682	0.636	rs1545305	chr12:62528381	T/A	cg10081664	chr12:62102663	FAM19A2	-0.5	-4.83	-0.37	3.41e-6	Post bronchodilator FEV1/FVC ratio in COPD;
UCEC	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.7	6.9	0.49	1.41e-10	Response to antineoplastic agents;
UCEC	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg18721089	chr20:30220636	NA	-0.4	-4.87	-0.37	2.91e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.56	6.12	0.45	8.2e-9	Prostate cancer;
UCEC	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.76	7.28	0.51	1.91e-11	Drug-induced liver injury (flucloxacillin);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17076921	chr10:75634595	CAMK2G	0.54	6.79	0.49	2.63e-10	Warfarin maintenance dose;
UCEC	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.58	-5.81	-0.43	3.66e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	0.99	9.59	0.62	3.16e-17	Initial pursuit acceleration;
UCEC	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.53	-5.72	-0.43	5.8e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-6.62	-0.48	6.2e-10	HDL cholesterol;
UCEC	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg10820045	chr2:198174542	NA	-0.49	-6.25	-0.46	4.18e-9	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
UCEC	cis	rs7560272	0.723	rs62153184	chr2:73773869	G/C	cg20560298	chr2:73613845	ALMS1	-0.52	-5.21	-0.39	6.36e-7	Schizophrenia;
UCEC	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.94	-10.81	-0.67	2.12e-20	Chronic sinus infection;
UCEC	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06505273	chr16:24850292	NA	0.55	5.18	0.39	7.31e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.45	-5.24	-0.4	5.42e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.78	8.93	0.59	1.57e-15	Primary sclerosing cholangitis;
UCEC	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.9	-10.62	-0.66	6.67e-20	Obesity-related traits;
UCEC	cis	rs13323323	0.728	rs1004631	chr3:44592979	T/G	cg17279458	chr3:44753948	ZNF502	-0.57	-4.79	-0.37	3.95e-6	IgG glycosylation;
UCEC	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg03354898	chr7:1950403	MAD1L1	-0.47	-4.59	-0.35	9.54e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.44	-4.5	-0.35	1.35e-5	Total bilirubin levels in HIV-1 infection;
UCEC	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.53	8.94	0.59	1.55e-15	Airflow obstruction;
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.52	-6.47	-0.47	1.4e-9	Pubertal anthropometrics;
UCEC	cis	rs77861329	1.000	rs13319566	chr3:52095555	C/G	cg08692210	chr3:52188851	WDR51A	0.63	4.56	0.35	1.07e-5	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.72	6.75	0.49	3.22e-10	Aortic root size;
UCEC	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.59	-6.52	-0.47	1.05e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs925550	0.932	rs7678116	chr4:123571118	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.61	5.98	0.44	1.63e-8	Primary biliary cholangitis;
UCEC	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.94	0.78	2.82e-31	Homoarginine levels;
UCEC	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.49	5.07	0.39	1.16e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs2474937	0.561	rs2359839	chr1:118925867	T/C	cg10572355	chr1:119549145	NA	0.43	4.56	0.35	1.06e-5	Congenital heart malformation;
UCEC	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.82	7.69	0.54	1.98e-12	Diastolic blood pressure;
UCEC	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	0.8	6.88	0.49	1.59e-10	Blood protein levels;
UCEC	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.45	0.41	2.1e-7	Breast cancer;
UCEC	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.33	-0.4	3.59e-7	Non-small cell lung cancer;
UCEC	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg00651523	chr6:28411279	ZSCAN23	-0.45	-4.99	-0.38	1.65e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-5.68	-0.42	6.92e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.67	-7.42	-0.52	8.81e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg17547346	chr11:68671486	IGHMBP2;MRPL21	0.52	4.61	0.36	8.62e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	0.98	4.53	0.35	1.19e-5	IgG glycosylation;
UCEC	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.8	8.81	0.59	3.25e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.67	6.52	0.47	1.08e-9	Bladder cancer;
UCEC	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.58	0.42	1.15e-7	Psoriasis;
UCEC	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg13593689	chr9:129986794	NA	0.45	4.61	0.36	8.55e-6	Intraocular pressure;
UCEC	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.49	-4.54	-0.35	1.14e-5	Coronary artery disease;
UCEC	cis	rs6684428	1.000	rs12123418	chr1:56383394	C/T	cg11651538	chr1:56320950	NA	0.6	5.55	0.42	1.28e-7	Airflow obstruction;
UCEC	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.74	-5.92	-0.44	2.21e-8	Birth weight;
UCEC	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.53	-7.33	-0.52	1.44e-11	Total body bone mineral density;
UCEC	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.65	6.92	0.5	1.32e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.44	-4.63	-0.36	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.71	5.58	0.42	1.14e-7	HIV-1 control;
UCEC	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.43	5.43	0.41	2.23e-7	Migraine;
UCEC	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.38	-4.84	-0.37	3.29e-6	Body mass index;
UCEC	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.58	6.15	0.45	6.89e-9	Initial pursuit acceleration;
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.58	6.83	0.49	2.07e-10	Prudent dietary pattern;
UCEC	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg11632617	chr15:75315747	PPCDC	0.62	7.36	0.52	1.23e-11	Lung cancer;
UCEC	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.51	-5.17	-0.39	7.57e-7	Schizophrenia;
UCEC	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.5	-4.65	-0.36	7.26e-6	Blood protein levels;
UCEC	cis	rs11264213	0.786	rs72659678	chr1:36258190	T/C	cg27506609	chr1:36549197	TEKT2	0.71	4.7	0.36	5.93e-6	Schizophrenia;
UCEC	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	0.96	7.72	0.54	1.66e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg19041857	chr6:27730383	NA	-0.7	-5.27	-0.4	4.74e-7	Depression;
UCEC	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg11871910	chr12:69753446	YEATS4	-0.55	-5.81	-0.43	3.72e-8	Blood protein levels;
UCEC	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.55	5.21	0.39	6.27e-7	Blood protein levels;
UCEC	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.66	4.75e-20	Body mass index;
UCEC	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.96	13.53	0.74	1.36e-27	Bone mineral density;
UCEC	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.61	6.07	0.45	1.04e-8	Coronary artery disease;
UCEC	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.52	-0.35	1.25e-5	Homocysteine levels;
UCEC	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.75	-5.37	-0.4	3.06e-7	White matter hyperintensity burden;
UCEC	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.73	5.45	0.41	2.03e-7	Bipolar disorder;
UCEC	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.62	7.18	0.51	3.17e-11	Lung cancer;
UCEC	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg12850546	chr22:42539477	CYP2D7P1	-0.76	-6.14	-0.45	7.44e-9	Birth weight;
UCEC	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.07	-6.64	-0.48	5.62e-10	Breast cancer;
UCEC	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.48	-4.51	-0.35	1.34e-5	Longevity;
UCEC	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.47	5.57	0.42	1.2e-7	Age-related hearing impairment;
UCEC	cis	rs7937127	0.744	rs72902711	chr11:43506447	G/A	cg11005316	chr11:43964755	LOC387763	0.77	4.66	0.36	7.02e-6	Fibrinogen levels;
UCEC	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.82	8.84	0.59	2.71e-15	Blood protein levels;
UCEC	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	6.96	0.5	1.05e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-10.49	-0.65	1.49e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1940013	0.659	rs1968652	chr11:132233390	A/C	cg11473001	chr11:131780499	NTM	-0.45	-5.24	-0.4	5.47e-7	Sleep-related phenotypes;
UCEC	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.65	5.2	0.39	6.54e-7	Corneal astigmatism;
UCEC	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.71	-0.36	5.63e-6	Bone mineral density;
UCEC	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg23950597	chr19:37808831	NA	-0.6	-4.69	-0.36	6.17e-6	Coronary artery calcification;
UCEC	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13569146	chr6:26330589	NA	-0.55	-4.75	-0.37	4.7e-6	Educational attainment;
UCEC	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.42	-5.27	-0.4	4.76e-7	Colorectal cancer;
UCEC	cis	rs362296	0.698	rs362289	chr4:3256378	G/A	cg08886695	chr4:3369023	RGS12	0.5	4.73	0.36	5.16e-6	Parental longevity (mother's age at death);
UCEC	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.47	-4.66	-0.36	7.11e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7611694	0.501	rs4682138	chr3:113150806	C/T	cg11138929	chr3:113251189	SIDT1	-0.4	-4.72	-0.36	5.54e-6	Prostate cancer;
UCEC	cis	rs8020441	0.541	rs72681652	chr14:51156155	C/T	cg04730355	chr14:51134070	SAV1	0.86	8.24	0.56	8.79e-14	Cognitive performance;
UCEC	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	4.66	0.36	6.98e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2299682	0.826	rs6086912	chr20:9470939	C/T	cg11931762	chr20:9488920	NA	-0.6	-5.11	-0.39	9.95e-7	Initial pursuit acceleration;Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs6690583	0.573	rs61768854	chr1:85460021	T/C	cg11262906	chr1:85462892	MCOLN2	0.72	4.64	0.36	7.79e-6	Serum sulfate level;
UCEC	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.48	-4.86	-0.37	3e-6	Cognitive test performance;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.45	-4.55	-0.35	1.1e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.65	5.42	0.41	2.42e-7	Smoking initiation;
UCEC	cis	rs12234571	1.000	rs6961117	chr7:77398781	G/A	cg20048109	chr7:78158112	MAGI2	-0.51	-5.09	-0.39	1.09e-6	Obesity-related traits;
UCEC	cis	rs7246967	0.932	rs34622638	chr19:23063652	C/T	cg08271804	chr19:22816896	ZNF492	0.62	5.41	0.41	2.45e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	1.000	rs1977201	chr6:26573674	T/C	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.47	4.69	0.36	6.18e-6	Mammographic density (dense area);
UCEC	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.49	-5.2	-0.39	6.55e-7	Educational attainment;
UCEC	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg20936604	chr3:58311152	NA	-0.59	-4.96	-0.38	1.89e-6	Cholesterol, total;
UCEC	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.53	-0.53	4.8e-12	Parkinson's disease;
UCEC	cis	rs4654899	0.931	rs4654880	chr1:21186608	C/A	cg01072550	chr1:21505969	NA	0.52	5.19	0.39	6.92e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg13319975	chr6:146136371	FBXO30	0.45	4.9	0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg09120320	chr17:61926383	NA	0.44	4.66	0.36	7.17e-6	Prudent dietary pattern;
UCEC	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.47	-5.62	-0.42	9.26e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.7	-6.98	-0.5	9.24e-11	Coronary artery disease;
UCEC	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.48	-4.68	-0.36	6.54e-6	Primary biliary cholangitis;
UCEC	cis	rs7112925	0.687	rs5006007	chr11:66830562	G/C	cg06012016	chr11:67219631	GPR152	-0.43	-4.54	-0.35	1.18e-5	Height;
UCEC	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.14	10.09	0.64	1.61e-18	Corneal structure;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09092174	chr22:39190118	DNAL4	0.58	7.07	0.5	5.86e-11	Warfarin maintenance dose;
UCEC	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.52	-5.77	-0.43	4.45e-8	Tonsillectomy;
UCEC	cis	rs679087	0.802	rs186216	chr12:29936914	C/G	cg14258853	chr12:29935411	TMTC1	-0.55	-4.53	-0.35	1.19e-5	Schizophrenia;
UCEC	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	9.18	0.6	3.75e-16	Menarche (age at onset);
UCEC	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	4.68	0.36	6.59e-6	Colorectal cancer;
UCEC	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-4.8	-0.37	3.85e-6	Blood metabolite levels;
UCEC	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.63	-6.68	-0.48	4.65e-10	Neurofibrillary tangles;
UCEC	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg01851573	chr8:8652454	MFHAS1	-0.44	-5.32	-0.4	3.83e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.08	0.39	1.13e-6	Breast cancer;
UCEC	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07215822	chr6:158701037	NA	-0.68	-5.69	-0.43	6.55e-8	Height;
UCEC	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.77	4.9	0.37	2.51e-6	Lung function (FEV1/FVC);
UCEC	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.01	6.29	0.46	3.51e-9	Skin colour saturation;
UCEC	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.53	-5.25	-0.4	5.22e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.12e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.54	5.97	0.44	1.67e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.65	-6.94	-0.5	1.18e-10	Waist circumference;Body mass index;
UCEC	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.74	-8.67	-0.58	7.14e-15	Extraversion;
UCEC	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-24.65	-0.9	4.38e-54	Myeloid white cell count;
UCEC	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.49	-4.76	-0.37	4.54e-6	Aortic root size;
UCEC	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-5.16	-0.39	7.86e-7	Personality dimensions;
UCEC	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.56	-4.64	-0.36	7.55e-6	Colorectal cancer;
UCEC	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	1.0	6.32	0.46	2.88e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs1519814	1.000	rs7818027	chr8:121158662	G/C	cg22335954	chr8:121166405	COL14A1	-0.69	-5.66	-0.42	7.62e-8	Breast cancer;
UCEC	cis	rs892864	0.803	rs58143160	chr5:127820537	C/T	cg17313118	chr5:127157258	NA	0.76	4.68	0.36	6.54e-6	Multiple system atrophy;
UCEC	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.66	6.82	0.49	2.21e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.49	-5.41	-0.41	2.54e-7	Alcohol dependence;
UCEC	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.7	4.96	0.38	1.89e-6	Body mass index;
UCEC	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	0.74	4.76	0.37	4.67e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.44	-0.47	1.62e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs2708977	0.835	rs10170018	chr2:97101893	T/G	cg22654517	chr2:96458247	NA	0.42	4.84	0.37	3.23e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.96	-8.09	-0.56	2.02e-13	Obesity-related traits;
UCEC	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.63	0.53	2.74e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-7.44	-0.52	7.62e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg23793686	chr15:68133972	NA	-0.36	-4.64	-0.36	7.5e-6	Restless legs syndrome;
UCEC	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.86	0.44	2.95e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.64	5.99	0.44	1.51e-8	Aortic root size;
UCEC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.53	5.59	0.42	1.05e-7	Monocyte percentage of white cells;
UCEC	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	9.25	0.61	2.38e-16	Coffee consumption (cups per day);
UCEC	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg23791538	chr6:167370224	RNASET2	-0.54	-5.79	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	5.59	0.42	1.05e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.56	6.59	0.48	7.23e-10	Iron status biomarkers (transferrin levels);
UCEC	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.89	8.1	0.56	1.96e-13	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.61	-6.37	-0.47	2.26e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	8.64	0.58	8.52e-15	Lymphocyte percentage of white cells;
UCEC	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.86	10.81	0.67	2.03e-20	IgG glycosylation;
UCEC	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.69	7.63	0.53	2.76e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	7.77	0.54	1.28e-12	Bipolar disorder;
UCEC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.48	4.68	0.36	6.47e-6	Blood protein levels;
UCEC	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.88	-8.79	-0.59	3.72e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.5	-5.49	-0.41	1.72e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg23782820	chr8:58130467	NA	0.62	4.81	0.37	3.62e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.64	6.94	0.5	1.16e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	5.86	0.44	2.95e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.46	-0.52	7.11e-12	Joint mobility (Beighton score);
UCEC	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	0.81	4.55	0.35	1.11e-5	Skin colour saturation;
UCEC	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg15764593	chr10:829463	NA	-0.56	-4.68	-0.36	6.45e-6	Uric acid levels;
UCEC	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-7.47	-0.52	6.56e-12	Eye color traits;
UCEC	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.32	5.03	0.38	1.38e-6	Cancer;
UCEC	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg13593689	chr9:129986794	NA	-0.46	-4.63	-0.36	7.85e-6	Intraocular pressure;
UCEC	cis	rs78761021	0.685	rs62064483	chr17:9796862	C/T	cg26853458	chr17:9805074	RCVRN	0.38	4.66	0.36	7.07e-6	Type 2 diabetes;
UCEC	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	7.4	0.52	9.47e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs10924970	0.649	rs12760766	chr1:235446078	C/G	cg26050004	chr1:235667680	B3GALNT2	0.49	4.58	0.35	1e-5	Asthma;
UCEC	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.67	0.48	4.89e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg02175503	chr12:58329896	NA	0.75	7.79	0.54	1.12e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	6.06	0.45	1.1e-8	Platelet count;
UCEC	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.83	5.16	0.39	7.88e-7	Diisocyanate-induced asthma;
UCEC	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg18681998	chr4:17616180	MED28	0.91	11.85	0.7	3.59e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10924970	0.649	rs12048686	chr1:235434610	C/T	cg26050004	chr1:235667680	B3GALNT2	0.53	4.92	0.38	2.27e-6	Asthma;
UCEC	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.64	5.54	0.42	1.36e-7	Gut microbiome composition (summer);
UCEC	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	7.84	0.54	8.64e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.5	4.63	0.36	7.94e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs116095464	1.000	rs62331560	chr5:346785	G/C	cg22496380	chr5:211416	CCDC127	-1.06	-4.89	-0.37	2.57e-6	Breast cancer;
UCEC	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.62	6.05	0.45	1.17e-8	Vitamin D levels;
UCEC	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.43	4.61	0.36	8.53e-6	Myeloid white cell count;
UCEC	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.55	5.24	0.4	5.56e-7	Blood metabolite levels;
UCEC	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.67	-0.42	7.34e-8	Depression;
UCEC	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.41	4.56	0.35	1.07e-5	QRS complex (12-leadsum);
UCEC	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg19554555	chr3:13937349	NA	-0.6	-5.93	-0.44	2.11e-8	Ovarian reserve;
UCEC	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg23791538	chr6:167370224	RNASET2	-0.56	-5.91	-0.44	2.24e-8	Primary biliary cholangitis;
UCEC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.86	9.02	0.6	9.2e-16	Longevity;Endometriosis;
UCEC	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.94	9.28	0.61	1.98e-16	Post bronchodilator FEV1;
UCEC	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg09655341	chr17:79618100	PDE6G	-0.3	-4.55	-0.35	1.12e-5	Eye color traits;
UCEC	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-6.63	-0.48	6.13e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.69	-6.73	-0.49	3.55e-10	Lymphocyte counts;
UCEC	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2288327	0.818	rs3731749	chr2:179406191	C/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.67	-4.59	-0.35	9.54e-6	Atrial fibrillation;
UCEC	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.45	5.36	0.4	3.12e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg13683864	chr3:40499215	RPL14	-0.58	-6.33	-0.46	2.74e-9	Renal cell carcinoma;
UCEC	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.55	-5.98	-0.44	1.64e-8	Gut microbiome composition (summer);
UCEC	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg15837086	chr1:46506065	PIK3R3	0.37	4.55	0.35	1.13e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs9402633	0.877	rs9389210	chr6:135040092	C/T	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.62	6.46	0.47	1.45e-9	Retinal vascular caliber;
UCEC	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-4.64	-0.36	7.66e-6	Type 2 diabetes;
UCEC	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.72	6.33	0.46	2.82e-9	Monobrow;
UCEC	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	6.71	0.48	3.93e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg05738196	chr6:26577821	NA	0.63	7.3	0.52	1.66e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg16576597	chr16:28551801	NUPR1	0.31	4.54	0.35	1.18e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.77	6.82	0.49	2.22e-10	Nonalcoholic fatty liver disease;
UCEC	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	0.72	9.16	0.6	4.16e-16	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.83	9.55	0.62	4.23e-17	Body mass index (adult);
UCEC	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.66	7.47	0.52	6.71e-12	Resting heart rate;
UCEC	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.27	0.46	3.89e-9	Menarche (age at onset);
UCEC	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.51	4.97	0.38	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.13	0.39	9.01e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs11741688	1.000	rs11741688	chr5:178395850	G/C	cg09339527	chr5:178322752	ZFP2	0.35	4.51	0.35	1.31e-5	Sleep duration;
UCEC	cis	rs6684428	1.000	rs58538058	chr1:56370474	G/A	cg11651538	chr1:56320950	NA	-0.75	-6.4	-0.47	1.98e-9	Airflow obstruction;
UCEC	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	0.99	5.44	0.41	2.17e-7	Alzheimer's disease (late onset);
UCEC	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.13	-0.39	9.1e-7	Colorectal cancer;
UCEC	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.54	6.17	0.45	6.25e-9	Menopause (age at onset);
UCEC	cis	rs10540	0.749	rs61877777	chr11:526356	G/A	cg03934478	chr11:495069	RNH1	0.71	5.08	0.39	1.12e-6	Body mass index;
UCEC	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg18016565	chr1:150552671	MCL1	-0.55	-5.94	-0.44	2.02e-8	Tonsillectomy;
UCEC	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.36	4.65	0.36	7.2e-6	Sitting height ratio;
UCEC	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	6.0	0.44	1.44e-8	Cognitive test performance;
UCEC	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.52	5.36	0.4	3.1e-7	Red blood cell count;
UCEC	cis	rs12618769	0.597	rs72819981	chr2:99040696	T/C	cg14361474	chr2:99058762	NA	-0.46	-4.54	-0.35	1.16e-5	Bipolar disorder;
UCEC	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18932078	chr1:2524107	MMEL1	0.38	6.07	0.45	1.03e-8	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.39	5.81	0.43	3.76e-8	Multiple sclerosis;
UCEC	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg21191810	chr6:118973309	C6orf204	0.45	6.25	0.46	4.25e-9	Electrocardiographic conduction measures;
UCEC	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-6.32	-0.46	2.96e-9	Response to antipsychotic treatment;
UCEC	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.61	6.17	0.45	6.28e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12681288	0.645	rs35040046	chr8:989973	C/T	cg04851639	chr8:1020857	NA	-0.36	-4.86	-0.37	2.92e-6	Schizophrenia;
UCEC	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg19875535	chr5:140030758	IK	0.42	4.58	0.35	9.75e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	8.27	0.56	7.14e-14	Total body bone mineral density;
UCEC	cis	rs11133613	0.546	rs28676354	chr5:947272	A/G	cg15647725	chr5:1091936	SLC12A7	-0.64	-4.68	-0.36	6.4e-6	Red cell distribution width;
UCEC	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.67	-5.47	-0.41	1.93e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	0.53	5.98	0.44	1.6e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.47	-5.32	-0.4	3.81e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.58	6.44	0.47	1.57e-9	Prostate cancer;
UCEC	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.74	-0.43	5.13e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg09120320	chr17:61926383	NA	0.44	4.59	0.35	9.52e-6	Prudent dietary pattern;
UCEC	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.51	6.26	0.46	3.98e-9	Total body bone mineral density;
UCEC	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.6	7.24	0.51	2.28e-11	Oral cavity cancer;
UCEC	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.53	-5.03	-0.38	1.4e-6	Renal cell carcinoma;
UCEC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.66	6.39	0.47	2.01e-9	Lymphocyte counts;
UCEC	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	0.84	7.26	0.51	2.12e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.76	-6.8	-0.49	2.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.51	-6.48	-0.47	1.27e-9	Congenital heart disease (maternal effect);
UCEC	cis	rs7246967	0.611	rs56271774	chr19:22831327	C/T	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg20933586	chr14:24608199	FAM158A	0.42	5.43	0.41	2.23e-7	IgG glycosylation;
UCEC	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.52	-4.88	-0.37	2.78e-6	Dental caries;
UCEC	cis	rs13033859	0.827	rs11127461	chr2:143541	C/T	cg21211680	chr2:198530	NA	0.39	4.67	0.36	6.71e-6	Mitochondrial DNA levels;
UCEC	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.68	6.06	0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.32	4.95	0.38	2.03e-6	Cancer;
UCEC	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.68	-0.36	6.56e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	0.99	8.77	0.59	4.15e-15	Vitiligo;
UCEC	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.56	6.39	0.47	2.08e-9	Lewy body disease;
UCEC	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.1	0.51	5.07e-11	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.59	7.19	0.51	2.98e-11	Oral cavity cancer;
UCEC	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.58	5.76	0.43	4.76e-8	Gestational age at birth (maternal effect);
UCEC	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.56	5.91	0.44	2.27e-8	Neuroticism;
UCEC	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg18681998	chr4:17616180	MED28	-0.61	-6.85	-0.49	1.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg19743168	chr1:23544995	NA	-0.43	-6.14	-0.45	7.3e-9	Height;
UCEC	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg03543861	chr21:44258195	NA	0.46	4.7	0.36	5.84e-6	Information processing speed;
UCEC	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	5.94	0.44	1.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.43	4.91	0.38	2.41e-6	Response to antineoplastic agents;
UCEC	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.46	-5.26	-0.4	4.96e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg12024160	chr4:1254474	NA	0.49	4.59	0.35	9.49e-6	Longevity;
UCEC	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.71	-7.19	-0.51	2.97e-11	Breast cancer;
UCEC	cis	rs16944613	0.588	rs8024734	chr15:91107067	T/C	cg08919649	chr15:91565780	VPS33B	0.71	4.75	0.36	4.73e-6	Colorectal cancer;
UCEC	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg17759274	chr19:39260954	NA	0.39	4.66	0.36	7.12e-6	Heart rate;
UCEC	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-7.31	-0.52	1.6e-11	Heart rate;
UCEC	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.68	7.79	0.54	1.08e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.53	-6.27	-0.46	3.85e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-5.97	-0.44	1.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs11760485	0.928	rs5021675	chr7:4399557	A/G	cg15613991	chr7:5277080	NA	-0.42	-5.0	-0.38	1.59e-6	Early childhood aggressive behavior;
UCEC	cis	rs2708377	0.858	rs73051630	chr12:11147188	G/A	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.61	4.88	0.37	2.71e-6	Bitter taste perception;
UCEC	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	6.4	0.47	2e-9	Bipolar disorder;
UCEC	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.63	0.36	7.81e-6	Menopause (age at onset);
UCEC	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.74	7.01	0.5	8.23e-11	Response to antineoplastic agents;
UCEC	cis	rs847649	0.842	rs869332	chr7:102632247	A/G	cg18108683	chr7:102477205	FBXL13	-0.53	-6.25	-0.46	4.18e-9	Morning vs. evening chronotype;
UCEC	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.49	5.08	0.39	1.12e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6493487	0.512	rs8029786	chr15:51107371	T/G	cg20651644	chr15:50170642	ATP8B4	0.52	4.67	0.36	6.61e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs9321099	1.000	rs9388603	chr6:128246042	A/T	cg25012434	chr6:128842125	PTPRK	0.68	4.69	0.36	6.26e-6	Sense of smell;
UCEC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.5	4.92	0.38	2.25e-6	Blood protein levels;
UCEC	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs4588572	0.643	rs6453391	chr5:77755035	T/C	cg11547950	chr5:77652471	NA	-0.49	-5.55	-0.42	1.3e-7	Triglycerides;
UCEC	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.51	5.8	0.43	4e-8	Total body bone mineral density;
UCEC	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg12580275	chr1:205744413	RAB7L1	0.51	4.76	0.37	4.49e-6	Mean corpuscular volume;Mean platelet volume;
UCEC	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	8.07	0.55	2.23e-13	Bone mineral density;
UCEC	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.2	-0.46	5.48e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg19678392	chr7:94953810	PON1	-0.58	-5.27	-0.4	4.67e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26002218	chr14:103986227	CKB	0.36	5.16	0.39	7.75e-7	Body mass index;
UCEC	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg06550200	chr5:1325588	CLPTM1L	0.71	7.44	0.52	7.71e-12	Lung cancer;
UCEC	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg03354898	chr7:1950403	MAD1L1	-0.49	-5.35	-0.4	3.25e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.49	5.26	0.4	5.02e-7	Headache;
UCEC	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.64	-6.4	-0.47	1.91e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg24703168	chr6:28411309	ZSCAN23	-0.41	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.46	0.41	1.99e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.67	4.71	0.36	5.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.89	8.46	0.57	2.49e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.14	16.08	0.8	3.4e-34	Myeloid white cell count;
UCEC	cis	rs4237845	0.611	rs6581159	chr12:58323876	C/T	cg02175503	chr12:58329896	NA	-0.58	-5.17	-0.39	7.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.5	5.19	0.39	6.99e-7	Schizophrenia;
UCEC	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.59	-7.12	-0.51	4.36e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.61	5.74	0.43	5.34e-8	Vitamin D levels;
UCEC	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	5.22	0.4	6.01e-7	Bone mineral density;
UCEC	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg23782820	chr8:58130467	NA	-0.49	-4.67	-0.36	6.77e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.67	-7.68	-0.54	2.01e-12	Monocyte count;
UCEC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.71	6.35	0.46	2.53e-9	Aortic root size;
UCEC	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.59	-6.12	-0.45	8.18e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.69	6.81	0.49	2.31e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg06401019	chr5:92957098	FAM172A;MIR2277	0.69	5.26	0.4	4.98e-7	Diabetic retinopathy;
UCEC	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.34	4.9	0.37	2.47e-6	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg11871910	chr12:69753446	YEATS4	0.55	4.84	0.37	3.26e-6	Response to diuretic therapy;
UCEC	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg06239285	chr11:62104954	ASRGL1	0.55	4.86	0.37	2.94e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-1.05	-7.14	-0.51	4.07e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.91	-10.78	-0.66	2.57e-20	Cognitive function;
UCEC	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-5.86	-0.44	2.93e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.04e-14	Menarche (age at onset);
UCEC	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.54	6.46	0.47	1.42e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg05501817	chr11:14380813	RRAS2	-0.44	-4.58	-0.35	9.95e-6	Vitamin D levels;
UCEC	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.59	7.36	0.52	1.24e-11	Lymphocyte counts;
UCEC	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	7.62	0.53	2.84e-12	Alzheimer's disease;
UCEC	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.98e-6	Tonsillectomy;
UCEC	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-1.15	-7.25	-0.51	2.19e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.42	-4.93	-0.38	2.16e-6	Obesity-related traits;
UCEC	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg05738196	chr6:26577821	NA	0.66	7.94	0.55	4.7e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	0.78	4.68	0.36	6.55e-6	Post bronchodilator FEV1;
UCEC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.62	-7.93	-0.55	5e-13	Fibrinogen levels;
UCEC	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.51	7.44	0.52	7.85e-12	Crohn's disease;
UCEC	cis	rs925228	0.668	rs7563013	chr2:23934087	A/G	cg13272742	chr2:24272458	FKBP1B	0.51	4.67	0.36	6.7e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg15133208	chr4:90757351	SNCA	-0.34	-4.67	-0.36	6.76e-6	Dementia with Lewy bodies;
UCEC	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.7	8.87	0.59	2.33e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1549118	0.560	rs11848126	chr14:78318268	T/C	cg18985109	chr14:78266276	ADCK1	-0.6	-4.96	-0.38	1.94e-6	Resting heart rate;
UCEC	cis	rs10242455	0.867	rs2037499	chr7:99312653	C/G	cg07715041	chr7:99302981	CYP3A7	-0.51	-5.23	-0.4	5.68e-7	Blood metabolite levels;
UCEC	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.64	-6.2	-0.46	5.52e-9	Migraine;Coronary artery disease;
UCEC	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.59	5.56	0.42	1.22e-7	Corneal astigmatism;
UCEC	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-4.9	-0.37	2.51e-6	Testicular germ cell tumor;
UCEC	cis	rs2904967	0.929	rs1195733	chr11:65016838	C/A	cg01630869	chr11:65082120	CDC42EP2	-0.5	-4.74	-0.36	4.93e-6	Mean corpuscular volume;
UCEC	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.34	4.94	0.38	2.12e-6	Childhood ear infection;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg09120320	chr17:61926383	NA	0.46	4.76	0.37	4.63e-6	Prudent dietary pattern;
UCEC	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.25	-0.46	4.16e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.46	5.75	0.43	5.05e-8	Monocyte count;
UCEC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg06784218	chr1:46089804	CCDC17	-0.42	-4.71	-0.36	5.6e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.49	5.17	0.39	7.64e-7	Methadone dose in opioid dependence;
UCEC	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	3e-6	Body mass index;
UCEC	cis	rs253959	0.729	rs7719798	chr5:115709766	T/C	cg23108291	chr5:115420582	COMMD10	-0.52	-4.98	-0.38	1.75e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.76	6.81	0.49	2.36e-10	Cognitive test performance;
UCEC	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.61	6.67	0.48	4.79e-10	Resting heart rate;
UCEC	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg19197139	chr17:4613644	ARRB2	-0.61	-5.13	-0.39	8.99e-7	Lymphocyte counts;
UCEC	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg19554555	chr3:13937349	NA	0.57	5.81	0.43	3.77e-8	Ovarian reserve;
UCEC	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg24069376	chr3:38537580	EXOG	0.48	5.93	0.44	2.09e-8	Electrocardiographic conduction measures;
UCEC	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-12.43	-0.72	1.09e-24	Height;
UCEC	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.92	9.25	0.61	2.48e-16	Post bronchodilator FEV1;
UCEC	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.78	7.63	0.53	2.74e-12	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.5	-5.1	-0.39	1.03e-6	Schizophrenia;
UCEC	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03762994	chr17:6899332	ALOX12	-0.44	-4.94	-0.38	2.12e-6	Tonsillectomy;
UCEC	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.61	5.77	0.43	4.58e-8	Corneal astigmatism;
UCEC	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.69	-5.35	-0.4	3.37e-7	Huntington's disease progression;
UCEC	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg20007245	chr22:24372913	LOC391322	-0.47	-5.02	-0.38	1.47e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.66	-6.6	-0.48	7.11e-10	Platelet distribution width;
UCEC	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.48	5.74	0.43	5.23e-8	Attention deficit hyperactivity disorder;
UCEC	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.84	4.91	0.38	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.92	-0.38	2.32e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-5.65	-0.42	7.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.44	4.92	0.38	2.34e-6	Sjögren's syndrome;
UCEC	cis	rs12618769	0.652	rs3820941	chr2:99233781	C/T	cg10123293	chr2:99228465	UNC50	0.47	5.05	0.38	1.26e-6	Bipolar disorder;
UCEC	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.74	9.35	0.61	1.33e-16	Vitiligo;
UCEC	cis	rs12579753	0.667	rs73359938	chr12:82308613	T/A	cg07988820	chr12:82153109	PPFIA2	-0.51	-4.63	-0.36	7.94e-6	Resting heart rate;
UCEC	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-5.96	-0.44	1.77e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-4.68	-0.36	6.38e-6	Reticulocyte count;
UCEC	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.99	0.55	3.57e-13	Chronic sinus infection;
UCEC	cis	rs11693319	0.920	rs1565286	chr2:179749373	C/A	cg26389888	chr2:178973147	PDE11A	0.59	4.88	0.37	2.75e-6	Blood pressure measurement (cold pressor test);
UCEC	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.55	5.26	0.4	4.89e-7	Celiac disease or Rheumatoid arthritis;
UCEC	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg09655341	chr17:79618100	PDE6G	-0.3	-4.54	-0.35	1.15e-5	Eye color traits;
UCEC	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.54	5.43	0.41	2.3e-7	Neutrophil percentage of white cells;
UCEC	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Parkinson's disease;
UCEC	cis	rs6893807	0.620	rs34483452	chr5:87986314	C/A	cg09002922	chr5:87956389	LOC645323	-0.57	-4.79	-0.37	4.1e-6	Body mass index;
UCEC	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.41	4.67	0.36	6.64e-6	Height;
UCEC	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.85	9.35	0.61	1.37e-16	Cognitive function;
UCEC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-5.97	-0.44	1.7e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18932078	chr1:2524107	MMEL1	0.33	5.3	0.4	4.12e-7	Ulcerative colitis;
UCEC	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.45	4.52	0.35	1.27e-5	Prostate cancer;
UCEC	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.89	8.47	0.57	2.39e-14	Platelet count;
UCEC	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.62	7.25	0.51	2.15e-11	Testicular germ cell tumor;
UCEC	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.42	0.41	2.38e-7	Personality dimensions;
UCEC	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg17279458	chr3:44753948	ZNF502	-0.43	-4.55	-0.35	1.12e-5	Depressive symptoms;
UCEC	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.17	9.46	0.62	7.06e-17	Uric acid levels;
UCEC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.75	4.64	0.36	7.8e-6	Gut microbiome composition (summer);
UCEC	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.66	6.19	0.45	5.82e-9	Lymphocyte counts;
UCEC	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.71	5.65	0.42	8.04e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.68	5.73	0.43	5.5e-8	Menopause (age at onset);
UCEC	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg03060546	chr3:49711283	APEH	-0.6	-4.7	-0.36	6.01e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg17724175	chr1:150552817	MCL1	-0.44	-4.85	-0.37	3.05e-6	Tonsillectomy;
UCEC	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.64	6.34	0.46	2.61e-9	Sudden cardiac arrest;
UCEC	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.47	4.92	0.38	2.31e-6	Vitiligo;
UCEC	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.69	6.16	0.45	6.57e-9	Aortic root size;
UCEC	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.57	-8.25	-0.56	8.27e-14	Sense of smell;
UCEC	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.84	0.49	1.99e-10	Coffee consumption (cups per day);
UCEC	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.34	4.78	0.37	4.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	cis	rs2455799	1.000	rs12691219	chr3:15881120	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-4.56	-0.35	1.09e-5	Mean platelet volume;
UCEC	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg04851639	chr8:1020857	NA	-0.41	-5.38	-0.41	2.9e-7	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.58	0.35	9.79e-6	Menopause (age at onset);
UCEC	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.66	7.18	0.51	3.24e-11	Longevity;
UCEC	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.79	-7.58	-0.53	3.51e-12	Blood metabolite levels;
UCEC	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-8.62	-0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs2386661	0.784	rs2386652	chr10:5676326	G/A	cg17085576	chr10:5658249	NA	-0.49	-4.87	-0.37	2.91e-6	Breast cancer;
UCEC	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg04374321	chr14:90722782	PSMC1	0.56	4.76	0.37	4.66e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs3790645	1.000	rs396997	chr1:26893067	T/C	cg23229016	chr1:26872525	RPS6KA1	0.3	5.58	0.42	1.11e-7	Glucose homeostasis traits;
UCEC	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.63	-6.43	-0.47	1.72e-9	Blood protein levels;
UCEC	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.92e-14	Coffee consumption (cups per day);
UCEC	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7149337	0.805	rs3007069	chr14:51597392	G/A	cg23942311	chr14:51606299	NA	0.36	6.05	0.45	1.17e-8	Cancer;
UCEC	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.63	-6.73	-0.49	3.58e-10	Mean platelet volume;
UCEC	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.41	-5.63	-0.42	9.04e-8	Prostate cancer;
UCEC	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg16751203	chr2:127950803	CYP27C1	0.4	5.25	0.4	5.33e-7	Protein C levels;
UCEC	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	5.52	0.41	1.51e-7	Breast cancer;
UCEC	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.53	6.65	0.48	5.25e-10	Total body bone mineral density;
UCEC	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.81	7.81	0.54	9.83e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg26114124	chr12:9217669	LOC144571	0.39	4.67	0.36	6.87e-6	Sjögren's syndrome;
UCEC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg05695927	chr15:45694626	SPATA5L1	0.49	4.99	0.38	1.7e-6	Homoarginine levels;
UCEC	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg01451880	chr3:45801044	SLC6A20	-0.42	-5.53	-0.41	1.45e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.83e-6	Tonsillectomy;
UCEC	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-0.7	-4.69	-0.36	6.24e-6	Blood protein levels;
UCEC	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.64	5.65	0.42	7.99e-8	Plateletcrit;Platelet count;
UCEC	cis	rs6494849	0.563	rs11072145	chr15:70498401	A/G	cg22026918	chr15:70552251	NA	-0.55	-4.84	-0.37	3.26e-6	Bipolar disorder;
UCEC	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.81	-6.31	-0.46	3.12e-9	Platelet count;
UCEC	cis	rs7246967	0.935	rs8112754	chr19:23060870	C/T	cg05241461	chr19:22816980	ZNF492	0.48	4.84	0.37	3.23e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.69	6.37	0.46	2.33e-9	Menarche (age at onset);
UCEC	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.32	-4.75	-0.36	4.8e-6	Schizophrenia;
UCEC	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg08886695	chr4:3369023	RGS12	-0.55	-5.71	-0.43	6.17e-8	Serum sulfate level;
UCEC	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg00280220	chr17:61926910	NA	0.47	5.15	0.39	8.36e-7	Prudent dietary pattern;
UCEC	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg24631222	chr15:78858424	CHRNA5	0.47	4.59	0.35	9.4e-6	Sudden cardiac arrest;
UCEC	cis	rs6696846	0.515	rs11240364	chr1:205105917	C/G	cg12580275	chr1:205744413	RAB7L1	0.45	5.2	0.39	6.68e-7	Red blood cell count;
UCEC	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-5.68	-0.42	6.87e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs16932667	0.857	rs10774296	chr12:5137306	T/C	cg03854198	chr12:5541311	NTF3	0.47	5.25	0.4	5.23e-7	Intelligence (childhood);
UCEC	cis	rs4372836	0.729	rs55785599	chr2:29087814	C/A	cg09522027	chr2:28974177	PPP1CB	0.85	9.05	0.6	7.94e-16	Body mass index;
UCEC	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Alcohol dependence;
UCEC	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.51	-6.16	-0.45	6.49e-9	Prudent dietary pattern;
UCEC	cis	rs7781557	1.000	rs10487284	chr7:102470275	G/A	cg18108683	chr7:102477205	FBXL13	-0.51	-4.62	-0.36	8.47e-6	Colorectal adenoma (advanced);
UCEC	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-7.84	-0.54	8.42e-13	Glomerular filtration rate (creatinine);
UCEC	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	7.97	0.55	4.03e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.64	-7.13	-0.51	4.18e-11	Menarche (age at onset);
UCEC	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	4.55	0.35	1.1e-5	Response to antipsychotic treatment;
UCEC	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	0.9	5.28	0.4	4.55e-7	Skin colour saturation;
UCEC	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.92	10.98	0.67	7.35e-21	Breast cancer;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg13525197	chr6:28411240	ZSCAN23	-0.47	-5.56	-0.42	1.25e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.75	7.69	0.54	1.9e-12	Blood protein levels;
UCEC	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.87	-7.18	-0.51	3.26e-11	Coronary artery calcification;
UCEC	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.82	8.09	0.55	2.07e-13	Cognitive function;
UCEC	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.56	5.21	0.4	6.15e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg20387954	chr3:183756860	HTR3D	0.49	5.9	0.44	2.37e-8	Anterior chamber depth;
UCEC	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.32	4.98	0.38	1.74e-6	Cancer;
UCEC	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.62	-6.59	-0.48	7.34e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	9.63	0.62	2.62e-17	Mean corpuscular hemoglobin;
UCEC	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg21770322	chr7:97807741	LMTK2	0.46	5.66	0.42	7.77e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.61	-5.92	-0.44	2.22e-8	Pediatric autoimmune diseases;
UCEC	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.39	-4.52	-0.35	1.25e-5	Bipolar disorder;
UCEC	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg02980000	chr4:1222292	CTBP1	0.54	4.87	0.37	2.87e-6	Systolic blood pressure;
UCEC	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	5.1	0.39	1.02e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7095607	1.000	rs7913582	chr10:69952581	T/C	cg18986048	chr10:69913749	MYPN	0.46	4.97	0.38	1.84e-6	Lung function (FVC);
UCEC	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-9.62	-0.62	2.68e-17	Height;
UCEC	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	1.03	4.68	0.36	6.4e-6	Height;
UCEC	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.4	-4.8	-0.37	3.89e-6	Menarche (age at onset);
UCEC	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-0.65	-4.59	-0.35	9.39e-6	Plateletcrit;
UCEC	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.57	-5.87	-0.44	2.72e-8	Longevity;Endometriosis;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.61	-0.36	8.56e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.5	6.08	0.45	9.87e-9	Height;
UCEC	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs17102884	0.587	rs10162454	chr14:75144618	T/C	cg06998765	chr14:75389618	RPS6KL1	-0.45	-4.67	-0.36	6.62e-6	Neuroticism;
UCEC	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.59	-5.18	-0.39	7.07e-7	Heart rate;
UCEC	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.67	6.14	0.45	7.22e-9	Corneal astigmatism;
UCEC	cis	rs7582720	1.000	rs72932765	chr2:203679183	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.85	4.96	0.38	1.89e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-4.53	-0.35	1.2e-5	Schizophrenia;
UCEC	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg10412286	chr16:89977652	TCF25	0.57	4.76	0.37	4.54e-6	Skin colour saturation;
UCEC	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.93	-11.85	-0.7	3.6e-23	Coronary artery disease;
UCEC	cis	rs1576263	0.934	rs330109	chr6:8546104	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	4.72	0.36	5.5e-6	Photic sneeze reflex;
UCEC	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.65	4.98	0.38	1.75e-6	Corneal astigmatism;
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.86	0.59	2.38e-15	Prudent dietary pattern;
UCEC	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13683864	chr3:40499215	RPL14	-0.94	-9.66	-0.62	2.17e-17	Renal cell carcinoma;
UCEC	cis	rs2836633	0.965	rs2836615	chr21:40048039	C/T	cg12884169	chr21:40033163	ERG	0.48	6.33	0.46	2.78e-9	Coronary artery disease;
UCEC	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-4.59	-0.35	9.58e-6	Blood metabolite levels;
UCEC	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg04756594	chr16:24857601	SLC5A11	0.42	4.83	0.37	3.36e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2892463	0.796	rs1410110	chr13:30365017	T/C	cg18356743	chr13:30408050	UBL3	-0.4	-4.51	-0.35	1.34e-5	Non-word repetition;
UCEC	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.69	8.17	0.56	1.33e-13	Breast cancer;
UCEC	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-5.17	-0.39	7.5e-7	Hemoglobin concentration;
UCEC	trans	rs925228	0.955	rs11687065	chr2:24132701	G/T	cg18674340	chr17:45867686	NA	-0.73	-6.82	-0.49	2.2e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.79	7.47	0.52	6.49e-12	Selective IgA deficiency;
UCEC	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.59	4.84	0.37	3.27e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs16857609	0.628	rs874840	chr2:218354130	C/T	cg23340935	chr2:218354150	DIRC3	0.52	5.02	0.38	1.49e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.7	7.25	0.51	2.19e-11	Menopause (age at onset);
UCEC	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.9	9.26	0.61	2.32e-16	Cognitive function;
UCEC	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg18230493	chr5:56204884	C5orf35	-0.61	-6.1	-0.45	8.91e-9	Coronary artery disease;
UCEC	trans	rs1459104	1.000	rs116220196	chr11:55293221	C/T	cg16096432	chr1:54776890	SSBP3	-1.0	-6.75	-0.49	3.19e-10	Body mass index;
UCEC	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.53	-5.91	-0.44	2.33e-8	Menarche (age at onset);
UCEC	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg00083072	chr11:65415190	SIPA1	0.48	5.38	0.41	2.84e-7	Acne (severe);
UCEC	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	0.69	7.84	0.54	8.53e-13	Homoarginine levels;
UCEC	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.7	5.67	0.42	7.31e-8	Cognitive test performance;
UCEC	cis	rs1318772	1.000	rs1318772	chr5:112723567	A/G	cg12552261	chr5:112820674	MCC	0.59	4.99	0.38	1.7e-6	F-cell distribution;
UCEC	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.9	11.99	0.7	1.56e-23	Metabolic syndrome;
UCEC	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.95	7.15	0.51	3.78e-11	Exhaled nitric oxide levels;
UCEC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.67	7.6	0.53	3.2e-12	Menopause (age at onset);
UCEC	cis	rs6788895	0.661	rs57869178	chr3:150492826	G/C	cg09723797	chr3:150481914	SIAH2	0.67	4.62	0.36	8.32e-6	Breast cancer;
UCEC	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.66	5.37	0.41	2.96e-7	Corneal astigmatism;
UCEC	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.57	4.53	0.35	1.21e-5	Exhaled nitric oxide output;
UCEC	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.64	4.87	0.37	2.82e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.81	8.43	0.57	2.98e-14	Diastolic blood pressure;
UCEC	cis	rs13095912	0.889	rs6778977	chr3:185302532	T/G	cg11274856	chr3:185301563	NA	0.57	7.63	0.53	2.76e-12	Systolic blood pressure;
UCEC	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.83	9.67	0.62	1.99e-17	Blood protein levels;
UCEC	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.46	4.74	0.36	4.99e-6	Prostate cancer;
UCEC	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18402987	chr7:1209562	NA	0.49	5.03	0.38	1.39e-6	Longevity;Endometriosis;
UCEC	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.99	-0.44	1.51e-8	Mood instability;
UCEC	cis	rs9467773	1.000	rs12663883	chr6:26577326	C/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.56	-5.27	-0.4	4.82e-7	Obesity-related traits;
UCEC	cis	rs9470794	1.000	rs59769374	chr6:37998256	A/G	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.42	-5.7	-0.43	6.29e-8	IgG glycosylation;
UCEC	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.72	6.26	0.46	4.03e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.5	5.28	0.4	4.59e-7	Initial pursuit acceleration;
UCEC	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg06096015	chr1:231504339	EGLN1	0.44	4.85	0.37	3.11e-6	Hemoglobin concentration;
UCEC	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.96	6.07	0.45	1.03e-8	Plasma clusterin levels;
UCEC	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-0.75	-7.53	-0.53	4.68e-12	Urate levels;
UCEC	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	6.34	0.46	2.6e-9	Bone mineral density;
UCEC	cis	rs6493487	0.512	rs117335843	chr15:51314455	C/G	cg17676096	chr15:52263839	LEO1	-0.88	-5.25	-0.4	5.12e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	1.19	6.62	0.48	6.27e-10	Type 2 diabetes;
UCEC	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.65	4.65	0.36	7.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.14	-0.45	7.26e-9	Prudent dietary pattern;
UCEC	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.64	5.02	0.38	1.44e-6	Resting heart rate;
UCEC	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.47	5.81	0.43	3.64e-8	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.78	-10.57	-0.66	9.01e-20	Intelligence (multi-trait analysis);
UCEC	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.01	-0.38	1.52e-6	Colorectal cancer;
UCEC	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.55	-4.54	-0.35	1.19e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg19318889	chr4:1322082	MAEA	0.5	5.46	0.41	1.95e-7	Obesity-related traits;
UCEC	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.75	-7.26	-0.51	2.11e-11	Initial pursuit acceleration;
UCEC	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs7246967	0.551	rs34907478	chr19:22928831	T/C	cg08271804	chr19:22816896	ZNF492	0.68	6.55	0.48	8.99e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6984305	0.541	rs17716118	chr8:9180134	A/G	cg11707391	chr8:10001627	MSRA	-0.83	-5.27	-0.4	4.87e-7	Liver enzyme levels (alkaline phosphatase);
UCEC	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-7.68	-0.53	2.09e-12	Response to antipsychotic treatment;
UCEC	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.59	4.81	0.37	3.65e-6	Lymphocyte counts;
UCEC	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.6	-5.95	-0.44	1.88e-8	White matter hyperintensity burden;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13789711	chr9:139743225	PHPT1	0.59	7.37	0.52	1.12e-11	Warfarin maintenance dose;
UCEC	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg14851346	chr12:38532713	NA	-0.5	-4.98	-0.38	1.74e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.05	-0.55	2.52e-13	Total cholesterol levels;
UCEC	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.53	-4.73	-0.36	5.21e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.53	5.46	0.41	1.97e-7	Coronary artery disease;
UCEC	trans	rs1459104	1.000	rs17580126	chr11:55289993	C/G	cg16096432	chr1:54776890	SSBP3	1.0	6.75	0.49	3.19e-10	Body mass index;
UCEC	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.47	4.56	0.35	1.06e-5	Itch intensity from mosquito bite;
UCEC	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg08886695	chr4:3369023	RGS12	-0.56	-5.36	-0.4	3.1e-7	Serum sulfate level;
UCEC	cis	rs7474896	0.832	rs2738190	chr10:38264803	C/G	cg00409905	chr10:38381863	ZNF37A	0.6	4.6	0.35	9.01e-6	Obesity (extreme);
UCEC	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.87	-0.37	2.79e-6	Breast cancer;
UCEC	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.68	-0.48	4.54e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.58	7.24	0.51	2.37e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg23795048	chr12:9217529	LOC144571	0.41	4.92	0.38	2.32e-6	Sjögren's syndrome;
UCEC	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.42	5.11	0.39	9.82e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.75	8.32	0.57	5.55e-14	Ulcerative colitis;
UCEC	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg01262667	chr19:19385393	TM6SF2	-0.5	-6.98	-0.5	9.46e-11	Tonsillectomy;
UCEC	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.33	0.4	3.59e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.5	0.53	5.46e-12	Bladder cancer;
UCEC	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.18	-0.39	7.3e-7	Aortic root size;
UCEC	cis	rs8099014	1.000	rs4940697	chr18:56108485	G/A	cg19165390	chr18:56932082	NA	0.35	4.74	0.36	4.96e-6	Platelet count;
UCEC	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.44	4.52	0.35	1.29e-5	Schizophrenia;
UCEC	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6693882	0.967	rs6690659	chr1:96145175	A/G	cg12448539	chr1:95364293	CNN3	0.49	4.59	0.35	9.57e-6	Pain;
UCEC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-0.93	-11.86	-0.7	3.44e-23	Coronary artery disease;
UCEC	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg01072550	chr1:21505969	NA	-0.55	-5.11	-0.39	9.68e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.85	10.85	0.67	1.62e-20	Mortality in heart failure;
UCEC	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26207909	chr14:103986467	CKB	0.54	6.03	0.45	1.26e-8	Body mass index;
UCEC	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	9.67	0.62	1.98e-17	Coffee consumption (cups per day);
UCEC	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.66	5.88	0.44	2.69e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.56	5.02	0.38	1.47e-6	Corneal astigmatism;
UCEC	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.69	6.72	0.48	3.71e-10	Menarche (age at onset);
UCEC	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.57	6.75	0.49	3.11e-10	Longevity;
UCEC	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.0	8.16	0.56	1.35e-13	Exhaled nitric oxide output;
UCEC	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.67	-6.75	-0.49	3.17e-10	Colorectal cancer;
UCEC	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.86	7.6	0.53	3.16e-12	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.52	-5.73	-0.43	5.53e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.37	-5.79	-0.43	4.08e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.67	8.39	0.57	3.65e-14	Bone mineral density;
UCEC	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg22117172	chr7:91764530	CYP51A1	0.4	4.82	0.37	3.53e-6	Breast cancer;
UCEC	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.89	-10.01	-0.64	2.69e-18	Cognitive function;
UCEC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.51	-5.74	-0.43	5.32e-8	Life satisfaction;
UCEC	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.69	6.65	0.48	5.2400000000000005e-10	Aortic root size;
UCEC	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg00277334	chr10:82204260	NA	-0.48	-4.75	-0.36	4.85e-6	Post bronchodilator FEV1;
UCEC	cis	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.67	-7.11	-0.51	4.78e-11	Age at first birth;
UCEC	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.55	5.19	0.39	6.75e-7	Aortic root size;
UCEC	cis	rs2224391	0.628	rs2753243	chr6:5256261	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-5.23	-0.4	5.75e-7	Height;
UCEC	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg18681998	chr4:17616180	MED28	0.69	8.08	0.55	2.2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.37	4.51	0.35	1.33e-5	Renal cell carcinoma;
UCEC	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.66	0.42	7.71e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs13063635	0.831	rs35209528	chr3:46003496	T/C	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Eosinophil percentage of granulocytes;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2252187	0.578	rs1884226	chr20:60165238	A/G	cg27447053	chr20:60795465	HRH3	0.47	4.6	0.35	9.01e-6	Multiple system atrophy;
UCEC	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.45	-4.97	-0.38	1.8e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg12463550	chr7:65579703	CRCP	0.51	4.72	0.36	5.49e-6	Aortic root size;
UCEC	cis	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.94	-0.38	2.12e-6	Depression;
UCEC	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg05660106	chr1:15850417	CASP9	0.52	4.91	0.38	2.39e-6	Systolic blood pressure;
UCEC	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.48	-5.62	-0.42	9.24e-8	Neuroticism;
UCEC	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.37e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.82	-0.37	3.56e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.56	4.99	0.38	1.66e-6	Menarche (age at onset);
UCEC	cis	rs9467773	0.967	rs6913877	chr6:26577488	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs925228	0.869	rs2712051	chr2:24060032	T/C	cg13272742	chr2:24272458	FKBP1B	0.57	4.95	0.38	2.02e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.19	0.45	5.76e-9	Rheumatoid arthritis;
UCEC	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.58	6.01	0.44	1.42e-8	Pulse pressure;
UCEC	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.66	6.82	0.49	2.21e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.24	-0.4	5.54e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.47	5.96	0.44	1.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	0.86	10.12	0.64	1.33e-18	Breast cancer;
UCEC	cis	rs10242455	0.764	rs4646465	chr7:99304524	A/G	cg18809830	chr7:99032528	PTCD1	0.53	4.62	0.36	8.48e-6	Blood metabolite levels;
UCEC	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	7.56	0.53	4e-12	Type 2 diabetes;
UCEC	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.94	9.98	0.64	3.14e-18	Cognitive function;
UCEC	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.53	4.68	0.36	6.51e-6	Lung cancer;
UCEC	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.61	5.6	0.42	1.04e-7	Morning vs. evening chronotype;
UCEC	cis	rs12365397	0.775	rs12795606	chr11:43243792	C/T	cg07515919	chr11:43391688	TTC17	0.48	5.01	0.38	1.53e-6	Migraine;
UCEC	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	1.22	9.48	0.62	6.18e-17	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.89	7.54	0.53	4.56e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.71	5.91	0.44	2.26e-8	Body mass index;
UCEC	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg13647721	chr17:30228624	UTP6	0.61	5.16	0.39	8.03e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg20119798	chr7:94954144	PON1	-0.51	-4.87	-0.37	2.85e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	4.7	0.36	5.99e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.56	6.0	0.44	1.46e-8	Prostate cancer;
UCEC	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.55	7.05	0.5	6.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.58	5.98	0.44	1.63e-8	Colorectal cancer;
UCEC	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg06784218	chr1:46089804	CCDC17	-0.4	-4.57	-0.35	1.01e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18252515	chr7:66147081	NA	-0.52	-4.98	-0.38	1.79e-6	Aortic root size;
UCEC	cis	rs61776719	0.905	rs28570969	chr1:38407146	A/G	cg17077180	chr1:38461687	NA	0.62	6.78	0.49	2.78e-10	Coronary artery disease;
UCEC	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.64	7.83	0.54	9.12e-13	Bipolar disorder;
UCEC	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg12850546	chr22:42539477	CYP2D7P1	-0.85	-6.29	-0.46	3.35e-9	Birth weight;
UCEC	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.84	-9.35	-0.61	1.37e-16	Cognitive function;
UCEC	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.62	6.95	0.5	1.09e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.11	-9.87	-0.63	6.1e-18	Post bronchodilator FEV1;
UCEC	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg00546932	chr16:1947055	NA	0.37	5.18	0.39	7.16e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-12.64	-0.72	2.9e-25	Height;
UCEC	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg04310649	chr10:35416472	CREM	-0.51	-4.78	-0.37	4.23e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.59	6.47	0.47	1.38e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.58	5.11	0.39	9.95e-7	Corneal astigmatism;
UCEC	cis	rs377070	0.934	rs309418	chr4:123623441	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.56	4.8	0.37	3.78e-6	Mosquito bite size;
UCEC	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.66	-7.23	-0.51	2.43e-11	Hypospadias;
UCEC	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg00738919	chr7:1100172	C7orf50	0.72	4.61	0.36	8.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg07387570	chr22:46663686	TTC38	-0.47	-4.62	-0.36	8.32e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg06096015	chr1:231504339	EGLN1	0.42	4.92	0.38	2.24e-6	Hemoglobin concentration;
UCEC	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg14008862	chr17:28927542	LRRC37B2	0.77	4.93	0.38	2.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs10924970	0.649	rs2185018	chr1:235408410	T/C	cg26050004	chr1:235667680	B3GALNT2	0.48	4.64	0.36	7.6e-6	Asthma;
UCEC	cis	rs877674	1.000	rs11803707	chr1:32195088	G/A	cg07656362	chr1:32688117	C1orf91;EIF3I	0.83	4.64	0.36	7.67e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.44	5.22	0.4	5.91e-7	Bone mineral density;
UCEC	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-0.94	-12.18	-0.71	5.05e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.62	-6.68	-0.48	4.63e-10	Motion sickness;
UCEC	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg05660106	chr1:15850417	CASP9	0.63	6.26	0.46	4.05e-9	Systolic blood pressure;
UCEC	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.67	-6.2	-0.46	5.53e-9	Parkinson's disease;
UCEC	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	0.75	4.93	0.38	2.16e-6	Diabetic retinopathy;
UCEC	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.67	6.03	0.45	1.24e-8	Aortic root size;
UCEC	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.5	4.6	0.36	8.87e-6	Lung cancer;
UCEC	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-8.88	-0.59	2.19e-15	Body mass index;
UCEC	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.41	-5.09	-0.39	1.1e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg22974920	chr21:40686053	BRWD1	0.64	5.66	0.42	7.73e-8	Cognitive function;
UCEC	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.72	6.67	0.48	4.9e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg00651523	chr6:28411279	ZSCAN23	-0.48	-5.37	-0.41	2.97e-7	Pubertal anthropometrics;
UCEC	cis	rs883115	1.000	rs904505	chr1:224807013	A/G	cg01808320	chr1:224927238	CNIH3	-0.38	-4.65	-0.36	7.19e-6	Cancer;
UCEC	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.06	0.5	6.28e-11	Motion sickness;
UCEC	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg23307798	chr14:103986281	CKB	-0.53	-5.46	-0.41	1.98e-7	Bone mineral density;
UCEC	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg06462663	chr19:18546047	ISYNA1	0.51	6.46	0.47	1.42e-9	Breast cancer;
UCEC	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.65	-6.07	-0.45	1.03e-8	Brugada syndrome;
UCEC	cis	rs9467773	0.967	rs9461272	chr6:26579648	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7070678	0.638	rs61849287	chr10:29795756	C/T	cg07724896	chr10:29780678	SVIL	-0.57	-5.12	-0.39	9.39e-7	Platelet thrombus formation;
UCEC	cis	rs2729354	0.768	rs2581922	chr11:57265400	C/T	cg24343310	chr11:57249947	NA	0.42	4.82	0.37	3.57e-6	Blood protein levels;
UCEC	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18252515	chr7:66147081	NA	0.46	4.72	0.36	5.33e-6	Aortic root size;
UCEC	cis	rs731174	1.000	rs731174	chr1:38196841	C/T	cg06917450	chr1:38156652	C1orf109	0.55	5.4	0.41	2.63e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.73	7.5	0.53	5.63e-12	Menopause (age at onset);
UCEC	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-5.53	-0.41	1.45e-7	Hemoglobin concentration;
UCEC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.68	-7.69	-0.54	1.99e-12	Vitiligo;
UCEC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	5.85	0.43	3.11e-8	Platelet count;
UCEC	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	6.56	0.48	8.59e-10	Alzheimer's disease;
UCEC	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	7.55	0.53	4.16e-12	Tonsillectomy;
UCEC	cis	rs7072216	0.691	rs10786419	chr10:100180940	T/C	cg26618903	chr10:100175079	PYROXD2	-0.39	-5.02	-0.38	1.48e-6	Metabolite levels;
UCEC	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.72	-7.69	-0.54	1.98e-12	Morning vs. evening chronotype;
UCEC	cis	rs1575951	1.000	rs10764800	chr10:130437056	A/G	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.7	-6.46	-0.47	1.44e-9	Aortic root size;
UCEC	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg12024160	chr4:1254474	NA	0.4	4.51	0.35	1.3e-5	Longevity;
UCEC	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-4.61	-0.36	8.8e-6	Coronary artery disease;
UCEC	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.73	7.02	0.5	7.78e-11	Menopause (age at onset);
UCEC	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.88	0.37	2.68e-6	Diabetic retinopathy;
UCEC	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.89	9.33	0.61	1.5e-16	Cognitive function;
UCEC	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.12	12.37	0.71	1.51e-24	White matter hyperintensity burden;
UCEC	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.66	-6.38	-0.47	2.12e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.65	6.43	0.47	1.7e-9	Vitamin D levels;
UCEC	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.76	8.36	0.57	4.44e-14	Primary sclerosing cholangitis;
UCEC	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-5.68	-0.42	6.93e-8	Response to antipsychotic treatment;
UCEC	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.73	6.29	0.46	3.43e-9	Coronary artery disease;
UCEC	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.62	-5.55	-0.42	1.3e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.69	7.61	0.53	3.1e-12	Menopause (age at onset);
UCEC	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg03714773	chr7:91764589	CYP51A1	0.5	6.22	0.46	4.94e-9	Breast cancer;
UCEC	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	0.93	9.92	0.63	4.46e-18	Breast cancer;
UCEC	cis	rs7804356	0.906	rs73069540	chr7:26904770	C/T	cg09144964	chr7:27150262	HOXA3	0.54	4.51	0.35	1.3e-5	Type 1 diabetes;
UCEC	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.5	-6.28	-0.46	3.66e-9	Coronary artery disease;
UCEC	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.82	10.94	0.67	9.18e-21	Body mass index;
UCEC	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.43	5.06	0.39	1.23e-6	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg00343986	chr7:65444356	GUSB	0.53	4.71	0.36	5.64e-6	Aortic root size;
UCEC	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	5.9	0.44	2.39e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	5.45	0.41	2.06e-7	Myopia (pathological);
UCEC	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.9	8.57	0.58	1.32e-14	Colorectal adenoma (advanced);
UCEC	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	0.92	11.96	0.7	1.86e-23	Homoarginine levels;
UCEC	cis	rs925228	0.793	rs6545184	chr2:24175914	A/T	cg13272742	chr2:24272458	FKBP1B	0.6	5.18	0.39	7.31e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	7.81	0.54	9.84e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg01874867	chr7:94954059	PON1	-0.54	-4.75	-0.36	4.79e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12980942	1.000	rs7257742	chr19:41827352	G/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	5.34	0.4	3.52e-7	Coronary artery disease;
UCEC	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-9.57	-0.62	3.63e-17	Blood metabolite levels;
UCEC	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.74	-8.61	-0.58	1.04e-14	Menarche (age at onset);
UCEC	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-5.45	-0.41	2.06e-7	Height;
UCEC	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.56	-6.32	-0.46	2.97e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	0.87	5.78	0.43	4.34e-8	Corneal structure;
UCEC	cis	rs17123764	1.000	rs7131915	chr12:49967660	C/G	cg20471783	chr12:50157085	TMBIM6	0.62	5.12	0.39	9.36e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs17036350	1	rs17036350	chr1:11171226	C/T	cg26230245	chr1:11322756	MTOR	-0.74	-5.07	-0.39	1.16e-6	Corneal curvature;
UCEC	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.71	7.97	0.55	4.06e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs13096480	0.583	rs17598137	chr3:49891362	G/T	cg18094221	chr3:49448445	RHOA;TCTA	-0.62	-5.15	-0.39	8.31e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.5e-7	Tonsillectomy;
UCEC	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-6.25	-0.46	4.31e-9	Inflammatory bowel disease;
UCEC	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.58	6.22	0.46	4.82e-9	Immature fraction of reticulocytes;
UCEC	cis	rs35934224	0.843	rs34175429	chr22:19867276	T/C	cg11182965	chr22:19864308	TXNRD2	-0.42	-5.38	-0.41	2.85e-7	Glaucoma (primary open-angle);
UCEC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.61	-6.1	-0.45	8.98e-9	Vitiligo;
UCEC	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.67	0.48	4.81e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.59	-6.04	-0.45	1.22e-8	Systemic lupus erythematosus;
UCEC	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.83	-7.8	-0.54	1.02e-12	Blood protein levels;
UCEC	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg24703168	chr6:28411309	ZSCAN23	0.47	5.12	0.39	9.33e-7	Cardiac Troponin-T levels;
UCEC	cis	rs7937612	0.931	rs11823300	chr11:120199080	G/A	cg12584626	chr11:120203529	NA	0.45	4.66	0.36	7.16e-6	Intraocular pressure;
UCEC	cis	rs1468333	1.000	rs4552585	chr5:137533159	T/C	cg07848042	chr5:137667509	CDC25C	0.47	4.65	0.36	7.43e-6	Resting heart rate;
UCEC	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.71	-7.27	-0.51	1.94e-11	Blood protein levels;
UCEC	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.56	5.48	0.41	1.77e-7	Blood protein levels;
UCEC	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.7	8.85	0.59	2.55e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg18584368	chr5:314553	AHRR;PDCD6	0.56	4.59	0.35	9.46e-6	Asthma (childhood onset);
UCEC	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.43	5.45	0.41	2.11e-7	Fibrinogen levels;
UCEC	cis	rs6722750	0.933	rs4671553	chr2:64408476	A/T	cg22352474	chr2:64371530	PELI1	-0.46	-4.58	-0.35	9.97e-6	Neuroticism;
UCEC	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.89	-9.4	-0.61	1.01e-16	Blood metabolite levels;
UCEC	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg18681998	chr4:17616180	MED28	0.69	8.1	0.56	1.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	9.89	0.63	5.26e-18	Migraine;Coronary artery disease;
UCEC	cis	rs4722166	0.532	rs6963591	chr7:22757270	G/T	cg05472934	chr7:22766657	IL6	-0.58	-5.58	-0.42	1.14e-7	Lung cancer;
UCEC	cis	rs11867410	0.546	rs73338615	chr17:63967301	G/T	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.69	6.02	0.44	1.31e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-0.83	-6.93	-0.5	1.24e-10	Alzheimer's disease;
UCEC	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.74	-0.49	3.33e-10	Aortic root size;
UCEC	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.59	4.55	0.35	1.11e-5	Corneal astigmatism;
UCEC	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg13147721	chr7:65941812	NA	-0.94	-6.32	-0.46	2.96e-9	Diabetic kidney disease;
UCEC	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg06233593	chr16:337645	AXIN1	0.45	5.12	0.39	9.55e-7	Morning vs. evening chronotype;
UCEC	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.48	-5.13	-0.39	8.93e-7	Schizophrenia;
UCEC	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-6.81	-0.49	2.36e-10	Coffee consumption (cups per day);
UCEC	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.55	5.51	0.41	1.54e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.45	5.88	0.44	2.61e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs970548	1.000	rs970548	chr10:46013277	A/C	cg15223267	chr10:46222474	FAM21C	0.53	5.0	0.38	1.59e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
UCEC	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.52	-5.87	-0.44	2.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.68	-6.41	-0.47	1.84e-9	Aortic root size;
UCEC	cis	rs17718580	0.536	rs17122701	chr14:51094401	C/T	cg04730355	chr14:51134070	SAV1	0.91	8.78	0.59	3.81e-15	Cognitive performance;
UCEC	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.67	6.73	0.49	3.47e-10	Bladder cancer;
UCEC	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-4.81	-0.37	3.65e-6	Response to antipsychotic treatment;
UCEC	cis	rs6696846	0.515	rs12739846	chr1:205096895	T/C	cg12580275	chr1:205744413	RAB7L1	0.45	5.26	0.4	4.94e-7	Red blood cell count;
UCEC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.8	10.29	0.65	4.87e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg22654517	chr2:96458247	NA	0.43	4.94	0.38	2.13e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.67	-5.43	-0.41	2.26e-7	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-12.56	-0.72	4.72e-25	Height;
UCEC	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-6.68	-0.48	4.6e-10	Morning vs. evening chronotype;
UCEC	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-6.09	-0.45	9.52e-9	Resting heart rate;
UCEC	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.58	-6.08	-0.45	9.86e-9	Rheumatoid arthritis;
UCEC	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-0.73	-7.12	-0.51	4.5e-11	Breast cancer;
UCEC	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.56	5.53	0.41	1.46e-7	Bone properties (heel);
UCEC	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg04310649	chr10:35416472	CREM	-0.49	-4.58	-0.35	1e-5	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg21770322	chr7:97807741	LMTK2	0.46	5.8	0.43	3.96e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.7	-7.7	-0.54	1.81e-12	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.41	4.67	0.36	6.64e-6	Height;
UCEC	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg05738196	chr6:26577821	NA	0.58	6.27	0.46	3.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.52	-5.29	-0.4	4.41e-7	Blood protein levels;
UCEC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.45	5.21	0.39	6.39e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	7.09	0.5	5.35e-11	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	7.84	0.54	8.64e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs256277	0.657	rs194360	chr5:111374252	C/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.56	-4.6	-0.35	9.22e-6	Coronary artery disease;
UCEC	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg05775895	chr3:12838266	CAND2	0.61	5.52	0.41	1.48e-7	QRS complex (12-leadsum);
UCEC	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.53	5.36	0.4	3.22e-7	Red cell distribution width;
UCEC	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.8	0.43	4e-8	Height;
UCEC	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.51	5.39	0.41	2.68e-7	Schizophrenia;
UCEC	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.58	7.32	0.52	1.52e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.1	0.56	1.9e-13	Electrocardiographic conduction measures;
UCEC	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Parkinson's disease;
UCEC	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg14078730	chr11:63896557	MACROD1	0.51	5.79	0.43	4.05e-8	Platelet count;
UCEC	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-5.06	-0.39	1.23e-6	Response to antipsychotic treatment;
UCEC	cis	rs73206853	0.841	rs28772589	chr12:110845040	C/T	cg12870014	chr12:110450643	ANKRD13A	0.61	4.56	0.35	1.08e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.08	-0.67	3.92e-21	Ulcerative colitis;
UCEC	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.59	-6.36	-0.46	2.39e-9	Neutrophil percentage of white cells;
UCEC	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-5.59	-0.42	1.08e-7	Morning vs. evening chronotype;
UCEC	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.65	-6.68	-0.48	4.54e-10	Prostate cancer;
UCEC	cis	rs2892463	0.765	rs4083610	chr13:30358566	G/A	cg18356743	chr13:30408050	UBL3	-0.42	-4.59	-0.35	9.29e-6	Non-word repetition;
UCEC	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-5.19	-0.39	6.95e-7	Myopia;
UCEC	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.58	5.1	0.39	1.01e-6	Corneal astigmatism;
UCEC	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-7.5	-0.53	5.55e-12	Hypospadias;
UCEC	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.53	-5.62	-0.42	9.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.66	-6.57	-0.48	7.98e-10	Adiposity;
UCEC	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg23797020	chr7:2049956	MAD1L1	0.38	4.63	0.36	7.92e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.4	-5.34	-0.4	3.48e-7	Alcohol dependence;
UCEC	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.54	-5.08	-0.39	1.13e-6	Metabolic syndrome;
UCEC	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.55	-5.85	-0.43	3.01e-8	White matter hyperintensity burden;
UCEC	cis	rs9650657	0.836	rs4841438	chr8:10606756	A/G	cg14992524	chr8:10586135	SOX7	0.32	5.22	0.4	5.9e-7	Neuroticism;
UCEC	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.69	-8.57	-0.58	1.3e-14	Testicular germ cell tumor;
UCEC	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.64	-7.51	-0.53	5.39e-12	Prostate cancer;
UCEC	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.69	-7.26	-0.51	2.11e-11	Height;
UCEC	cis	rs10256972	0.680	rs7784708	chr7:1003049	A/G	cg07930192	chr7:1003750	NA	0.43	4.55	0.35	1.12e-5	Longevity;Endometriosis;
UCEC	cis	rs1150668	0.745	rs213238	chr6:28321993	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.49	-5.57	-0.42	1.19e-7	Pubertal anthropometrics;
UCEC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.51	4.64	0.36	7.7e-6	Menopause (age at onset);
UCEC	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	10.31	0.65	4.22e-19	Electrocardiographic conduction measures;
UCEC	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24308560	chr3:49941425	MST1R	0.53	6.03	0.45	1.26e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.64	-6.26	-0.46	4.02e-9	Coronary artery disease;
UCEC	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg11967332	chr1:108735228	SLC25A24	-0.84	-8.04	-0.55	2.65e-13	Myeloid white cell count;
UCEC	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs7965445	0.649	rs11061533	chr12:131923739	C/T	cg16776885	chr12:132834399	GALNT9	0.6	4.58	0.35	1e-5	Mortality in heart failure;
UCEC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs41271951	0.512	rs77306500	chr1:151080096	G/C	cg00107782	chr1:151300621	NA	-0.7	-4.75	-0.36	4.81e-6	Blood protein levels;
UCEC	cis	rs7534537	1.000	rs7534537	chr1:204274519	T/C	cg17158762	chr1:204518670	MDM4	0.65	4.96	0.38	1.93e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg06027949	chr8:82754900	SNX16	0.6	5.07	0.39	1.18e-6	Diastolic blood pressure;
UCEC	cis	rs4588572	0.643	rs13155648	chr5:77755343	A/G	cg11547950	chr5:77652471	NA	-0.48	-5.45	-0.41	2.11e-7	Triglycerides;
UCEC	cis	rs2302190	0.882	rs7221464	chr17:56552353	A/T	cg12560992	chr17:57184187	TRIM37	0.54	5.23	0.4	5.86e-7	Vitamin D levels;
UCEC	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg13147721	chr7:65941812	NA	-0.93	-6.49	-0.47	1.26e-9	Diabetic kidney disease;
UCEC	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	1.0	11.18	0.68	2.19e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-5.08	-0.39	1.14e-6	Platelet distribution width;
UCEC	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg22089800	chr15:90895588	ZNF774	0.6	6.03	0.45	1.28e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
UCEC	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg21770322	chr7:97807741	LMTK2	0.45	5.68	0.42	7.06e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.46	-5.18	-0.39	7.05e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.72	8.99	0.6	1.15e-15	Hip circumference;
UCEC	cis	rs7582720	0.945	rs72932759	chr2:203674288	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.84	4.82	0.37	3.55e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.73	-0.43	5.52e-8	Parkinson's disease;
UCEC	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg05660106	chr1:15850417	CASP9	0.56	5.07	0.39	1.19e-6	Systolic blood pressure;
UCEC	cis	rs139371	0.713	rs139297	chr22:39497404	G/C	cg15548613	chr22:38610795	MAFF	0.48	4.9	0.37	2.49e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg15513719	chr13:114904418	NA	0.46	4.58	0.35	9.73e-6	Schizophrenia;
UCEC	cis	rs2742417	1.000	rs1877933	chr3:45753487	C/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.54	0.47	9.64e-10	Coffee consumption (cups per day);
UCEC	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.66	-6.69	-0.48	4.25e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg06784218	chr1:46089804	CCDC17	-0.59	-7.55	-0.53	4.27e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.33	4.73	0.36	5.17e-6	Crohn's disease;
UCEC	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	0.89	5.27	0.4	4.87e-7	Skin colour saturation;
UCEC	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-5.84	-0.43	3.25e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-7.22	-0.51	2.61e-11	Eye color traits;
UCEC	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg18827107	chr12:86230957	RASSF9	-0.42	-4.55	-0.35	1.09e-5	Major depressive disorder;
UCEC	cis	rs7175404	0.591	rs75029049	chr15:94061120	C/T	cg25253948	chr15:93956996	NA	0.67	4.89	0.37	2.63e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.58	5.19	0.39	6.74e-7	Corneal astigmatism;
UCEC	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.58	-6.05	-0.45	1.14e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.49	-4.93	-0.38	2.22e-6	Pediatric autoimmune diseases;
UCEC	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg25482853	chr8:67687455	SGK3	1.07	7.81	0.54	1e-12	Obesity-related traits;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.51	-5.44	-0.41	2.18e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11048434	0.932	rs12816518	chr12:9153132	G/A	cg04155231	chr12:9217510	LOC144571	0.48	5.54	0.42	1.36e-7	Sjögren's syndrome;
UCEC	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg18681998	chr4:17616180	MED28	0.89	10.93	0.67	1.01e-20	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs8105895	0.935	rs7252380	chr19:22245715	G/A	cg02912127	chr19:22235281	ZNF257	-0.64	-5.35	-0.4	3.29e-7	Body mass index (change over time);
UCEC	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg02413938	chr2:239008929	ESPNL	-0.35	-4.52	-0.35	1.26e-5	Prostate cancer;
UCEC	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.68	7.0	0.5	8.5e-11	Adiposity;
UCEC	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg05623727	chr3:50126028	RBM5	0.37	4.79	0.37	4.04e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18252515	chr7:66147081	NA	-0.59	-5.47	-0.41	1.86e-7	Aortic root size;
UCEC	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-5.04	-0.38	1.36e-6	Colorectal cancer;
UCEC	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	0.88	6.22	0.46	4.99e-9	Red blood cell traits;
UCEC	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.59	5.57	0.42	1.15e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg05962950	chr11:130786565	SNX19	0.51	5.1	0.39	1.04e-6	Schizophrenia;
UCEC	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	5.35	0.4	3.38e-7	Rheumatoid arthritis;
UCEC	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	5.64	0.42	8.63e-8	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	8.83	0.59	2.81e-15	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.37	-4.72	-0.36	5.35e-6	Subjective well-being;
UCEC	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.5	6.07	0.45	1.03e-8	Total body bone mineral density;
UCEC	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg10878312	chr5:130970361	RAPGEF6	-0.53	-4.56	-0.35	1.07e-5	Asthma (sex interaction);
UCEC	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.51	-5.1	-0.39	1.02e-6	Neuroticism;
UCEC	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14019695	chr9:139328340	INPP5E	0.47	5.16	0.39	7.91e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.59	5.6	0.42	1.02e-7	Schizophrenia;
UCEC	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.98	12.57	0.72	4.46e-25	Breast cancer;
UCEC	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-1.0	-12.13	-0.71	6.62e-24	Cognitive function;
UCEC	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.47	4.75	0.36	4.78e-6	Body mass index;
UCEC	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.81	8.54	0.58	1.57e-14	Blood protein levels;
UCEC	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	14.69	0.77	1.2e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.46	-4.76	-0.37	4.65e-6	Aortic root size;
UCEC	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-8.05	-0.55	2.55e-13	Colorectal cancer;
UCEC	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	8.0	0.55	3.32e-13	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.8	7.29	0.52	1.76e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.5	5.35	0.4	3.3e-7	Schizophrenia;
UCEC	cis	rs9463078	0.764	rs6904015	chr6:44785502	G/A	cg25276700	chr6:44698697	NA	-0.48	-5.29	-0.4	4.3e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.67	-8.09	-0.56	2.01e-13	Obesity-related traits;
UCEC	cis	rs1298062	0.763	rs2387112	chr19:50984853	A/G	cg11430371	chr19:50961752	MYBPC2	0.39	4.52	0.35	1.26e-5	Age of smoking initiation;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18652453	chr5:68665041	TAF9;RAD17	0.61	7.32	0.52	1.52e-11	Warfarin maintenance dose;
UCEC	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-13.16	-0.74	1.29e-26	Height;
UCEC	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	6.19	0.45	5.61e-9	Platelet count;
UCEC	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.92	11.24	0.68	1.49e-21	Breast cancer;
UCEC	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.95e-6	Gut microbiome composition (summer);
UCEC	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-10.01	-0.64	2.66e-18	Electrocardiographic conduction measures;
UCEC	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.74	7.07	0.5	5.8200000000000003e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.49	-6.13	-0.45	7.65e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.9	9.26	0.61	2.32e-16	Cognitive function;
UCEC	cis	rs1881396	0.945	rs62141291	chr2:27784034	C/T	cg27432699	chr2:27873401	GPN1	0.53	5.12	0.39	9.4e-7	Nonalcoholic fatty liver disease;
UCEC	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07755735	chr2:20870362	GDF7	-0.42	-5.09	-0.39	1.08e-6	Abdominal aortic aneurysm;
UCEC	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.47	-5.02	-0.38	1.45e-6	Longevity;
UCEC	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.69	5.74	0.43	5.3e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.61	-5.18	-0.39	7.24e-7	Lung disease severity in cystic fibrosis;
UCEC	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	4.93	0.38	2.2e-6	Coronary artery disease;
UCEC	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.38	4.57	0.35	1.01e-5	Obesity-related traits;
UCEC	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg08027265	chr7:2291960	NA	-0.42	-4.54	-0.35	1.14e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-5.62	-0.42	9.51e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7246967	0.673	rs56725192	chr19:22810938	T/G	cg24889512	chr19:22816950	ZNF492	0.54	5.62	0.42	9.39e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.47	-5.99	-0.44	1.58e-8	Abdominal aortic aneurysm;
UCEC	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg03859395	chr2:55845619	SMEK2	1.0	14.54	0.77	3.04e-30	Metabolic syndrome;
UCEC	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.49	5.79	0.43	4.16e-8	Total body bone mineral density;
UCEC	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg27502912	chr22:51017001	CPT1B;CHKB-CPT1B	-0.69	-5.03	-0.38	1.38e-6	Narcolepsy;
UCEC	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.69	7.84	0.54	8.2e-13	Menopause (age at onset);
UCEC	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.13	9.15	0.6	4.36e-16	Vitiligo;
UCEC	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	0.99	9.35	0.61	1.35e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.8	6.43	0.47	1.71e-9	Response to hepatitis C treatment;
UCEC	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg22166914	chr1:53195759	ZYG11B	-0.78	-8.12	-0.56	1.73e-13	Monocyte count;
UCEC	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.98	-0.44	1.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.57	6.18	0.45	5.89e-9	Bipolar disorder;
UCEC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.53	5.25	0.4	5.28e-7	Menopause (age at onset);
UCEC	cis	rs7246967	1.000	rs936526	chr19:23055987	A/C	cg24889512	chr19:22816950	ZNF492	0.49	4.98	0.38	1.76e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg16558253	chr16:72132732	DHX38	-0.39	-4.52	-0.35	1.25e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
UCEC	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.52	6.13	0.45	7.52e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg20999797	chr1:1681921	NA	0.34	4.51	0.35	1.33e-5	Body mass index;
UCEC	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.27	0.4	4.8e-7	Personality dimensions;
UCEC	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.66	-5.32	-0.4	3.88e-7	Menopause (age at onset);
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.96	0.59	1.37e-15	Prudent dietary pattern;
UCEC	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg18681998	chr4:17616180	MED28	0.61	7.06	0.5	6.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12618769	0.652	rs11896729	chr2:99225645	T/C	cg10123293	chr2:99228465	UNC50	0.49	5.51	0.41	1.55e-7	Bipolar disorder;
UCEC	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.56	-5.22	-0.4	5.97e-7	Menarche (age at onset);
UCEC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.51	4.78	0.37	4.27e-6	N-glycan levels;
UCEC	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.72	5.5	0.41	1.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6684428	1.000	rs6684334	chr1:56359726	T/C	cg11651538	chr1:56320950	NA	-0.69	-6.19	-0.45	5.59e-9	Airflow obstruction;
UCEC	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-0.6	-4.69	-0.36	6.25e-6	Plateletcrit;
UCEC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.82	8.34	0.57	4.91e-14	Prudent dietary pattern;
UCEC	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg18197594	chr10:94334836	IDE	-0.55	-4.71	-0.36	5.67e-6	Coronary artery disease;
UCEC	cis	rs10495907	0.556	rs10206389	chr2:43947760	A/G	cg01607269	chr2:43294942	NA	0.64	4.59	0.35	9.47e-6	Coronary artery disease;
UCEC	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.53	4.58	0.35	1e-5	Height;
UCEC	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.71	6.02	0.44	1.33e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.66	-6.86	-0.49	1.79e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg03859395	chr2:55845619	SMEK2	-0.87	-9.54	-0.62	4.45e-17	Metabolic syndrome;
UCEC	cis	rs75804782	0.630	rs3739070	chr2:239306268	A/C	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg09307838	chr4:120376055	NA	0.6	5.31	0.4	3.97e-7	Educational attainment;
UCEC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.58	-5.57	-0.42	1.17e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.52	5.13	0.39	9.09e-7	Dilated cardiomyopathy;
UCEC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg04871131	chr7:94954202	PON1	-0.5	-4.66	-0.36	7.05e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg22974920	chr21:40686053	BRWD1	0.62	5.46	0.41	1.94e-7	Cognitive function;
UCEC	cis	rs6882076	1.000	rs6874202	chr5:156391628	T/C	cg12943317	chr5:156479607	HAVCR1	-0.49	-5.09	-0.39	1.08e-6	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs7572644	0.679	rs6745545	chr2:28021845	C/G	cg27432699	chr2:27873401	GPN1	0.45	4.51	0.35	1.32e-5	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
UCEC	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg21770322	chr7:97807741	LMTK2	0.51	6.39	0.47	2.11e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.78	-6.87	-0.49	1.73e-10	Initial pursuit acceleration;
UCEC	cis	rs308403	0.509	rs309379	chr4:123671456	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.88	13.17	0.74	1.18e-26	Blood protein levels;
UCEC	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.76	-8.7	-0.58	6.04e-15	Facial morphology (factor 19);
UCEC	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.44	-5.01	-0.38	1.54e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.53	-4.72	-0.36	5.35e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.52	6.5	0.47	1.19e-9	Total body bone mineral density;
UCEC	cis	rs9430161	0.579	rs11121669	chr1:11039567	T/C	cg02454025	chr1:11042201	C1orf127	0.86	10.59	0.66	7.73e-20	Ewing sarcoma;
UCEC	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.54	-5.88	-0.44	2.59e-8	Bipolar disorder;
UCEC	cis	rs17433710	0.500	rs10799856	chr1:162626570	C/T	cg19264028	chr1:162630153	DDR2	-0.89	-6.22	-0.46	4.93e-9	Dupuytren's disease;
UCEC	cis	rs6460942	1.000	rs62448562	chr7:12398785	T/C	cg06484146	chr7:12443880	VWDE	-0.67	-4.52	-0.35	1.25e-5	Coronary artery disease;
UCEC	cis	rs829418	1.000	rs947333	chr1:21941023	A/G	cg16172837	chr1:21059639	SH2D5	0.56	5.03	0.38	1.41e-6	Neurocognitive impairment in HIV-1 infection (continuous);
UCEC	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-5.39	-0.41	2.79e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg16497661	chr14:103986332	CKB	-0.43	-5.07	-0.39	1.18e-6	Body mass index;
UCEC	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.79	-9.17	-0.6	4.01e-16	Menarche (age at onset);
UCEC	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-4.72	-0.36	5.46e-6	Monocyte percentage of white cells;
UCEC	cis	rs7246967	0.866	rs115497901	chr19:23042761	C/T	cg08271804	chr19:22816896	ZNF492	0.56	5.1	0.39	1.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.52	5.5	0.41	1.68e-7	Bipolar disorder;
UCEC	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	7.78	0.54	1.16e-12	Electrocardiographic conduction measures;
UCEC	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.5	4.82	0.37	3.58e-6	Response to fenofibrate (adiponectin levels);
UCEC	cis	rs12635074	0.549	rs34270989	chr3:56318556	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.34	4.6	0.35	9.2e-6	Morning vs. evening chronotype;
UCEC	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.52	-5.21	-0.4	6.14e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.33	-4.78	-0.37	4.26e-6	Vitamin D levels;
UCEC	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.94	-11.83	-0.7	4.16e-23	Primary sclerosing cholangitis;
UCEC	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg06096015	chr1:231504339	EGLN1	0.47	5.24	0.4	5.58e-7	Hemoglobin concentration;
UCEC	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	19.67	0.85	5.22e-43	Schizophrenia;
UCEC	cis	rs7710178	0.696	rs11749404	chr5:156145119	C/T	cg12943317	chr5:156479607	HAVCR1	0.74	4.51	0.35	1.29e-5	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	1.18	15.17	0.78	6.89e-32	Body mass index;
UCEC	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.21	9.22	0.61	2.89e-16	Uric acid levels;
UCEC	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.55	-6.12	-0.45	8.09e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.74	0.36	4.92e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.91	11.38	0.68	6.43e-22	Longevity;Endometriosis;
UCEC	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.7	-7.49	-0.53	6.04e-12	Breast cancer;
UCEC	cis	rs10946940	0.897	rs6456801	chr6:27625532	T/C	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.77	-0.37	4.43e-6	Systemic lupus erythematosus;
UCEC	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.75	-8.66	-0.58	7.63e-15	Extraversion;
UCEC	cis	rs409224	0.557	rs17498402	chr7:101860578	A/G	cg08135718	chr7:101819329	CUX1	0.52	5.33	0.4	3.63e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.62	5.36	0.4	3.15e-7	Lung cancer in ever smokers;
UCEC	cis	rs12618769	0.597	rs3754885	chr2:99121708	G/T	cg14361474	chr2:99058762	NA	-0.47	-4.61	-0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg11150807	chr10:43354902	NA	0.82	6.49	0.47	1.21e-9	Blood protein levels;
UCEC	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg07386859	chr16:1872102	HAGH	-0.48	-5.24	-0.4	5.38e-7	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg05738196	chr6:26577821	NA	0.48	4.94	0.38	2.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg20560298	chr2:73613845	ALMS1	0.53	5.06	0.38	1.25e-6	Metabolite levels;
UCEC	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.76	5.81	0.43	3.71e-8	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.68	7.45	0.52	7.46e-12	Menopause (age at onset);
UCEC	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.59	6.85	0.49	1.87e-10	Iron status biomarkers (transferrin levels);
UCEC	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.73	-5.61	-0.42	9.98e-8	QRS complex (12-leadsum);
UCEC	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.13	0.51	4.21e-11	Homoarginine levels;
UCEC	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.55	5.14	0.39	8.5e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.57	6.23	0.46	4.58e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.82	11.0	0.67	6.65e-21	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.5	4.68	0.36	6.37e-6	Menopause (age at onset);
UCEC	cis	rs9976767	0.896	rs9975920	chr21:43818656	A/G	cg00134539	chr21:43824071	UBASH3A	0.31	4.78	0.37	4.17e-6	Type 1 diabetes;
UCEC	cis	rs10507349	0.632	rs535880	chr13:26817842	G/T	cg01600817	chr13:26797529	RNF6	0.46	4.92	0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-5.53	-0.42	1.42e-7	Platelet count;
UCEC	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.51	-5.79	-0.43	4.12e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.79	-5.23	-0.4	5.65e-7	Bipolar disorder;
UCEC	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.81	-9.16	-0.6	4.15e-16	Blood metabolite levels;
UCEC	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	6.61	0.48	6.57e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.49	5.28	0.4	4.52e-7	Platelet distribution width;
UCEC	cis	rs2288912	0.808	rs35670684	chr19:45455985	A/C	cg09555818	chr19:45449301	APOC2	0.45	5.93	0.44	2.07e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
UCEC	cis	rs16912285	0.584	rs7131124	chr11:24249455	A/G	ch.11.24196551F	chr11:24239977	NA	0.64	6.73	0.49	3.52e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.47	4.64	0.36	7.52e-6	Mean platelet volume;
UCEC	cis	rs240764	0.644	rs4329121	chr6:101087507	G/C	cg09795085	chr6:101329169	ASCC3	0.46	4.86	0.37	2.96e-6	Neuroticism;
UCEC	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg02175503	chr12:58329896	NA	0.76	6.84	0.49	2.01e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg18755752	chr8:142205143	DENND3	0.58	5.31	0.4	3.96e-7	Birth weight;
UCEC	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.18	0.6	3.76e-16	Vitiligo;
UCEC	cis	rs6460942	1.000	rs77494477	chr7:12315302	A/T	cg20607287	chr7:12443886	VWDE	-0.7	-4.98	-0.38	1.77e-6	Coronary artery disease;
UCEC	cis	rs11063421	1.000	rs12315875	chr12:5058870	A/G	cg14976741	chr12:4872921	GALNT8	0.67	4.88	0.37	2.76e-6	Schizophrenia;
UCEC	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.45	4.98	0.38	1.79e-6	Mean corpuscular volume;
UCEC	cis	rs9596863	1.000	rs1458268	chr13:54405594	C/T	ch.13.53330881F	chr13:54432880	NA	-0.52	-4.76	-0.37	4.64e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
UCEC	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-6.8	-0.49	2.46e-10	Coffee consumption (cups per day);
UCEC	cis	rs2901460	0.509	rs66481227	chr2:62117600	C/T	cg02183531	chr2:62113199	CCT4	-0.55	-4.63	-0.36	8e-6	Mean corpuscular volume;
UCEC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.69	0.36	6.1e-6	Tonsillectomy;
UCEC	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg16497661	chr14:103986332	CKB	0.49	5.74	0.43	5.31e-8	Body mass index;
UCEC	cis	rs7246967	0.736	rs386119	chr19:23000818	G/A	cg24889512	chr19:22816950	ZNF492	0.57	5.61	0.42	9.94e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg04682699	chr3:50248845	SLC38A3	-0.38	-4.53	-0.35	1.21e-5	Intelligence (multi-trait analysis);
UCEC	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	10.07	0.64	1.78e-18	Exhaled nitric oxide output;
UCEC	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg21486944	chr6:28411378	ZSCAN23	-0.54	-6.15	-0.45	6.83e-9	Pubertal anthropometrics;
UCEC	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg06521331	chr12:34319734	NA	-0.63	-4.86	-0.37	2.95e-6	Morning vs. evening chronotype;
UCEC	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.6	6.01	0.44	1.4e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg26114124	chr12:9217669	LOC144571	-0.43	-5.25	-0.4	5.24e-7	Sjögren's syndrome;
UCEC	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.51	-5.02	-0.38	1.46e-6	Eye color traits;
UCEC	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.69	7.57	0.53	3.89e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-6.41	-0.47	1.85e-9	Personality dimensions;
UCEC	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs731174	0.802	rs628492	chr1:38178277	G/A	cg12339802	chr1:38156545	C1orf109	-0.59	-5.05	-0.38	1.29e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.58e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs1483890	0.642	rs6795775	chr3:69402801	C/T	cg22125112	chr3:69402811	FRMD4B	0.47	4.84	0.37	3.2e-6	Resting heart rate;
UCEC	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.44	4.79	0.37	4.08e-6	Obesity-related traits;
UCEC	cis	rs172166	0.516	rs2622322	chr6:28117443	C/G	cg14547644	chr6:28411285	ZSCAN23	-0.59	-6.55	-0.48	9.09e-10	Cardiac Troponin-T levels;
UCEC	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.49	7.01	0.5	8.17e-11	Homoarginine levels;
UCEC	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.49	-5.04	-0.38	1.35e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg00983440	chr10:79422392	NA	-1.16	-8.1	-0.56	1.97e-13	Bone mineral density;
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg20119798	chr7:94954144	PON1	-0.49	-4.65	-0.36	7.31e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.76	7.29	0.52	1.73e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.62	-6.03	-0.45	1.26e-8	Schizophrenia;
UCEC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.77e-10	Chronic sinus infection;
UCEC	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	4.65	0.36	7.4e-6	Response to bleomycin (chromatid breaks);
UCEC	cis	rs58804349	1.000	rs58804349	chr10:43355640	G/A	cg11150807	chr10:43354902	NA	0.73	5.66	0.42	7.79e-8	Pediatric bone mineral content (radius);
UCEC	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-11.83	-0.7	4.19e-23	Primary sclerosing cholangitis;
UCEC	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.59	6.54	0.47	9.66e-10	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.63	5.44	0.41	2.18e-7	Heart rate;
UCEC	cis	rs4372836	0.504	rs2045886	chr2:29010517	A/G	cg09522027	chr2:28974177	PPP1CB	-0.71	-7.37	-0.52	1.11e-11	Body mass index;
UCEC	cis	rs13095912	1.000	rs10937226	chr3:185302885	G/A	cg11274856	chr3:185301563	NA	0.57	7.53	0.53	4.64e-12	Systolic blood pressure;
UCEC	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.49	4.68	0.36	6.53e-6	Blood metabolite levels;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27060380	chr2:36721423	CRIM1	-0.68	-6.91	-0.5	1.38e-10	Migraine with aura;
UCEC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg22166914	chr1:53195759	ZYG11B	0.77	7.73	0.54	1.6e-12	Monocyte count;
UCEC	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.46	6.78	0.49	2.7e-10	Homoarginine levels;
UCEC	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.63	7.61	0.53	3.08e-12	Vitiligo;
UCEC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.92	-12.8	-0.73	1.14e-25	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.68	7.08	0.5	5.57e-11	Eosinophil percentage of white cells;
UCEC	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-6.84	-0.49	1.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.55	-5.99	-0.44	1.53e-8	HDL cholesterol;
UCEC	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.41	4.51	0.35	1.34e-5	Coronary artery disease;
UCEC	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.43	-5.02	-0.38	1.45e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.89	9.47	0.62	6.56e-17	Cognitive function;
UCEC	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	5.72	0.43	5.75e-8	Menarche (age at onset);
UCEC	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.48	-4.82	-0.37	3.6e-6	Breast cancer;
UCEC	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg10902566	chr4:727664	PCGF3	-0.59	-5.01	-0.38	1.57e-6	Systolic blood pressure;
UCEC	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.63	6.25	0.46	4.14e-9	Itch intensity from mosquito bite;
UCEC	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-6.01	-0.44	1.4e-8	Alcohol dependence;
UCEC	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.84	9.39	0.61	1.1e-16	Breast cancer;
UCEC	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg05660106	chr1:15850417	CASP9	1.04	11.69	0.69	9.72e-23	Systolic blood pressure;
UCEC	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.45	4.53	0.35	1.19e-5	Colorectal cancer;
UCEC	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.61	0.42	9.76e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	6.21	0.46	5.09e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs17106184	1.000	rs72900957	chr1:51145808	A/G	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg08027265	chr7:2291960	NA	-0.5	-5.29	-0.4	4.36e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.78	-7.73	-0.54	1.55e-12	Blood metabolite levels;
UCEC	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.15e-6	Bladder cancer;
UCEC	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.74	0.36	5.07e-6	Height;
UCEC	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01973587	chr1:228161476	NA	0.37	4.94	0.38	2.1e-6	Diastolic blood pressure;
UCEC	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.48	4.81	0.37	3.68e-6	Dupuytren's disease;
UCEC	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	5.38	0.41	2.86e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs3750082	0.582	rs7800883	chr7:32971282	G/A	cg05721444	chr7:32995514	FKBP9	0.56	5.99	0.44	1.52e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs11723261	0.582	rs114199753	chr4:163520	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	5.0	0.38	1.64e-6	Immune response to smallpox vaccine (IL-6);
UCEC	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.47	4.82	0.37	3.57e-6	Menopause (age at onset);
UCEC	cis	rs847577	0.515	rs10953238	chr7:97676259	C/T	cg24562669	chr7:97807699	LMTK2	0.73	10.31	0.65	4.21e-19	Breast cancer;
UCEC	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg14675211	chr2:100938903	LONRF2	0.65	6.38	0.47	2.22e-9	Educational attainment;
UCEC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.43	4.61	0.36	8.69e-6	Eye color traits;
UCEC	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg05519781	chr21:40033154	ERG	0.73	8.35	0.57	4.74e-14	Coronary artery disease;
UCEC	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.45	-5.29	-0.4	4.28e-7	Aortic root size;
UCEC	cis	rs11867410	0.744	rs73336688	chr17:63962506	T/C	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.76	9.17	0.6	3.95e-16	Menarche (age at onset);
UCEC	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	0.69	6.18	0.45	5.91e-9	Breast cancer;
UCEC	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-5.08	-0.39	1.11e-6	Morning vs. evening chronotype;
UCEC	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg01072550	chr1:21505969	NA	-0.52	-4.79	-0.37	4.05e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.57	-6.04	-0.45	1.22e-8	Red blood cell count;
UCEC	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg00325661	chr8:49890786	NA	0.6	6.38	0.47	2.13e-9	Sudden cardiac arrest;
UCEC	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg00791764	chr4:53727839	RASL11B	0.7	4.89	0.37	2.59e-6	Optic nerve measurement (cup area);
UCEC	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-0.74	-7.98	-0.55	3.9e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.47	-5.05	-0.38	1.27e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12753920	0.775	rs1384613	chr1:92675361	T/C	cg10324998	chr1:92338262	TGFBR3	-0.46	-4.59	-0.35	9.62e-6	Systemic lupus erythematosus;
UCEC	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	4.53	0.35	1.19e-5	Calcium levels;
UCEC	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg20002381	chr19:39279703	LGALS7B	-0.35	-4.82	-0.37	3.53e-6	Heart rate;
UCEC	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.47	-4.55	-0.35	1.11e-5	Cotinine glucuronidation;
UCEC	cis	rs3015497	0.789	rs923908	chr14:51123595	C/T	cg04730355	chr14:51134070	SAV1	-0.53	-5.65	-0.42	8e-8	Mean platelet volume;
UCEC	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.53	6.12	0.45	8.09e-9	Mean corpuscular volume;
UCEC	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.58	6.2	0.46	5.46e-9	Skin colour saturation;
UCEC	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.43	-4.53	-0.35	1.23e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	5.24	0.4	5.57e-7	IgG glycosylation;
UCEC	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.5	-5.56	-0.42	1.23e-7	Life satisfaction;
UCEC	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-5.24	-0.4	5.53e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg13147721	chr7:65941812	NA	-0.96	-6.5	-0.47	1.2e-9	Gout;
UCEC	cis	rs9321099	1.000	rs62426476	chr6:128231798	T/C	cg25012434	chr6:128842125	PTPRK	0.61	4.66	0.36	7.07e-6	Sense of smell;
UCEC	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.15	0.45	7.08e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.61	4.75	0.36	4.83e-6	Breast cancer;
UCEC	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.54	5.61	0.42	9.97e-8	Prostate cancer;
UCEC	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.48	4.83	0.37	3.34e-6	Blood metabolite levels;
UCEC	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg06521331	chr12:34319734	NA	-0.63	-4.86	-0.37	2.95e-6	Morning vs. evening chronotype;
UCEC	cis	rs4851266	1.000	rs11686372	chr2:100827907	C/A	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs4389656	0.857	rs274713	chr5:6723560	A/C	cg10857441	chr5:6722123	POLS	-0.4	-4.73	-0.36	5.24e-6	Coronary artery disease;
UCEC	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.85	6.78	0.49	2.75e-10	Fibroblast growth factor basic levels;
UCEC	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg18681998	chr4:17616180	MED28	-0.53	-5.84	-0.43	3.29e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg13695892	chr22:41940480	POLR3H	0.65	4.53	0.35	1.19e-5	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs3956705	0.798	rs6462427	chr7:32907344	T/C	cg05721444	chr7:32995514	FKBP9	-0.45	-4.54	-0.35	1.18e-5	Red cell distribution width;
UCEC	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.45	4.84	0.37	3.22e-6	Retinal vascular caliber;
UCEC	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	4.61	0.36	8.78e-6	Bipolar disorder;
UCEC	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.69	7.25	0.51	2.15e-11	Neutrophil percentage of white cells;
UCEC	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-4.68	-0.36	6.57e-6	Diabetic retinopathy;
UCEC	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.94	0.38	2.08e-6	Bipolar disorder;
UCEC	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.64	6.08	0.45	9.88e-9	Alcohol dependence;
UCEC	cis	rs797973	0.586	rs797968	chr17:27606375	T/A	cg04532153	chr17:27046900	SNORD42B;RPL23A	-0.46	-4.86	-0.37	3e-6	Type 2 diabetes;
UCEC	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg20965017	chr5:231967	SDHA	-0.64	-5.97	-0.44	1.7e-8	Breast cancer;
UCEC	cis	rs11697848	1.000	rs118191427	chr20:48500969	G/A	cg17849948	chr20:48532315	SPATA2	1.05	4.96	0.38	1.93e-6	Systemic lupus erythematosus;
UCEC	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.6	5.03	0.38	1.4e-6	Breast cancer;
UCEC	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.95	11.79	0.7	5.22e-23	Prudent dietary pattern;
UCEC	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.69	5.61	0.42	9.94e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg24069376	chr3:38537580	EXOG	-0.39	-4.88	-0.37	2.76e-6	Electrocardiographic conduction measures;
UCEC	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18252515	chr7:66147081	NA	0.59	5.49	0.41	1.71e-7	Aortic root size;
UCEC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.68	4.76	0.37	4.51e-6	Aortic root size;
UCEC	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.51	-0.47	1.1e-9	Caudate activity during reward;
UCEC	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-0.98	-12.62	-0.72	3.39e-25	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.75	9.95	0.63	3.86e-18	Urate levels in lean individuals;
UCEC	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	8.39	0.57	3.76e-14	Body mass index (adult);
UCEC	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg22166914	chr1:53195759	ZYG11B	0.77	7.81	0.54	1.02e-12	Monocyte count;
UCEC	cis	rs1165472	0.806	rs7529271	chr1:56150184	C/A	cg11523071	chr1:56160889	NA	-0.58	-4.83	-0.37	3.34e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.74	8.02	0.55	3.05e-13	Immature fraction of reticulocytes;
UCEC	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.73	6.71	0.48	3.99e-10	Morning vs. evening chronotype;
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.54	5.92	0.44	2.15e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg21231944	chr12:82153410	PPFIA2	-0.43	-4.56	-0.35	1.07e-5	Resting heart rate;
UCEC	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg13695892	chr22:41940480	POLR3H	-0.66	-4.62	-0.36	8.3e-6	Vitiligo;
UCEC	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	5.62	0.42	9.08e-8	Breast cancer;
UCEC	cis	rs7611694	0.501	rs35935366	chr3:113145642	G/A	cg12596171	chr3:113251061	SIDT1	-0.56	-5.59	-0.42	1.05e-7	Prostate cancer;
UCEC	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.75	-7.06	-0.5	6.13e-11	Selective IgA deficiency;
UCEC	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	8.35	0.57	4.77e-14	Hip circumference;
UCEC	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg11211951	chr8:145729740	GPT	0.59	6.89	0.49	1.52e-10	Age at first birth;
UCEC	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	1.02	10.25	0.65	6.1e-19	Post bronchodilator FEV1;
UCEC	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg05527609	chr1:210001259	C1orf107	-0.58	-4.55	-0.35	1.14e-5	Red blood cell count;
UCEC	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.84	8.84	0.59	2.69e-15	Mean corpuscular hemoglobin;
UCEC	cis	rs1978968	0.763	rs5992943	chr22:18465756	A/C	cg03078520	chr22:18463400	MICAL3	-0.49	-5.57	-0.42	1.18e-7	Presence of antiphospholipid antibodies;
UCEC	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.49	4.83	0.37	3.4e-6	Height;
UCEC	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.71	8.63	0.58	9.35e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7786808	0.530	rs7780796	chr7:158183330	C/T	cg09998033	chr7:158218633	PTPRN2	0.51	5.45	0.41	2.1e-7	Obesity-related traits;
UCEC	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-0.72	-5.21	-0.39	6.24e-7	Schizophrenia;
UCEC	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.14	0.6	4.79e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg12463550	chr7:65579703	CRCP	0.53	5.42	0.41	2.39e-7	Aortic root size;
UCEC	cis	rs28795989	0.613	rs2385901	chr4:7921718	G/C	cg00251875	chr4:7801337	AFAP1	-0.53	-5.79	-0.43	4.02e-8	Intraocular pressure;
UCEC	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.51	6.9	0.49	1.41e-10	Eye color traits;
UCEC	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.82	9.76	0.63	1.14e-17	Menopause (age at onset);
UCEC	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg01689657	chr7:91764605	CYP51A1	0.42	5.34	0.4	3.46e-7	Breast cancer;
UCEC	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.63	5.37	0.4	3.04e-7	Lung cancer in ever smokers;
UCEC	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg11632617	chr15:75315747	PPCDC	-0.61	-7.23	-0.51	2.46e-11	Blood trace element (Zn levels);
UCEC	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.05	-12.42	-0.72	1.11e-24	Schizophrenia;
UCEC	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.71	7.16	0.51	3.61e-11	Aortic root size;
UCEC	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.5	-5.6	-0.42	1.02e-7	Diastolic blood pressure;
UCEC	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.19	10.05	0.64	2.09e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg15837086	chr1:46506065	PIK3R3	0.37	4.54	0.35	1.16e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs12618769	0.681	rs72823792	chr2:99215142	G/A	cg10123293	chr2:99228465	UNC50	0.49	5.52	0.41	1.46e-7	Bipolar disorder;
UCEC	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	7.04	0.5	6.93e-11	Platelet count;
UCEC	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	0.86	5.23	0.4	5.64e-7	Skin colour saturation;
UCEC	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.78	6.85	0.49	1.85e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.7	7.41	0.52	9.19e-12	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs1150668	0.768	rs1233713	chr6:28198281	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.55	-6.15	-0.45	7.03e-9	Pubertal anthropometrics;
UCEC	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.61	5.52	0.41	1.47e-7	Lung function (FEV1/FVC);
UCEC	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.58	5.5	0.41	1.63e-7	Uric acid levels;
UCEC	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.68	6.82	0.49	2.17e-10	Aortic root size;
UCEC	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-5.17	-0.39	7.47e-7	Schizophrenia;
UCEC	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.57	-4.54	-0.35	1.17e-5	Blood pressure (smoking interaction);
UCEC	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.67	4.62	0.36	8.23e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	7.62	0.53	2.92e-12	Platelet count;
UCEC	cis	rs7968440	0.715	rs7957659	chr12:50638810	T/C	cg20014596	chr12:50898483	DIP2B	-0.48	-4.77	-0.37	4.42e-6	Fibrinogen;
UCEC	cis	rs1576263	0.967	rs9505478	chr6:8550536	G/T	cg21535247	chr6:8435926	SLC35B3	0.51	5.29	0.4	4.42e-7	Photic sneeze reflex;
UCEC	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.6	5.88	0.44	2.62e-8	Colorectal cancer;
UCEC	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs925228	0.911	rs4643489	chr2:24215395	G/T	cg16945982	chr2:25016118	CENPO;C2orf79	0.49	4.58	0.35	9.98e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.36	-0.46	2.42e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.44	4.88	0.37	2.77e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.78	-0.37	4.18e-6	Homocysteine levels;
UCEC	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.73	8.81	0.59	3.15e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.46	4.76	0.37	4.5e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.52	-5.99	-0.44	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.13	-7.33	-0.52	1.39e-11	Diabetic kidney disease;
UCEC	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-6.9	-0.49	1.48e-10	Coffee consumption (cups per day);
UCEC	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.12	12.36	0.71	1.65e-24	Blood protein levels;
UCEC	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.71	0.36	5.79e-6	Menopause (age at onset);
UCEC	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg23950597	chr19:37808831	NA	-0.64	-5.1	-0.39	1.03e-6	Coronary artery calcification;
UCEC	cis	rs17102423	0.589	rs4899162	chr14:65614126	G/T	cg11161011	chr14:65562177	MAX	-0.65	-5.77	-0.43	4.42e-8	Obesity-related traits;
UCEC	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.82	-11.43	-0.69	4.74e-22	Post bronchodilator FEV1;
UCEC	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg01072550	chr1:21505969	NA	-0.58	-5.75	-0.43	4.92e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg16325326	chr1:53192061	ZYG11B	0.51	5.44	0.41	2.15e-7	Monocyte count;
UCEC	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.52	-5.04	-0.38	1.33e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12980942	0.630	rs11881940	chr19:41808432	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.82	6.65	0.48	5.45e-10	Coronary artery disease;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg01874867	chr7:94954059	PON1	-0.54	-5.1	-0.39	1.03e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.57	6.55	0.48	9.18e-10	Aortic root size;
UCEC	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.69	8.89	0.59	2e-15	Vitiligo;
UCEC	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.73	-9.31	-0.61	1.76e-16	Hip circumference;
UCEC	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.7	6.12	0.45	7.96e-9	Alzheimer's disease;
UCEC	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg23815491	chr16:72088622	HP	0.37	4.66	0.36	7.06e-6	Fibrinogen levels;
UCEC	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.65	7.23	0.51	2.43e-11	Homoarginine levels;
UCEC	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.66	-7.86	-0.54	7.71e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.49	-0.41	1.69e-7	IgG glycosylation;
UCEC	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.48	4.82	0.37	3.53e-6	Height;
UCEC	cis	rs2473248	0.877	rs2744724	chr1:22538901	A/G	cg22683154	chr1:23345188	KDM1A	0.46	4.84	0.37	3.28e-6	Birth weight;
UCEC	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg01689657	chr7:91764605	CYP51A1	0.47	5.99	0.44	1.51e-8	Breast cancer;
UCEC	cis	rs2075165	0.901	rs2274226	chr1:156314627	C/T	cg20302342	chr1:156215951	PAQR6	-0.52	-5.19	-0.39	6.81e-7	Tonsillectomy;
UCEC	cis	rs9467773	1.000	rs6918360	chr6:26577867	A/T	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-7.67	-0.53	2.22e-12	Neuroticism;
UCEC	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.59	4.59	0.35	9.56e-6	HIV-1 control;
UCEC	cis	rs12313068	0.600	rs7136207	chr12:110491487	T/C	cg12870014	chr12:110450643	ANKRD13A	0.75	8.33	0.57	5.1e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.56	5.72	0.43	5.7e-8	Menopause (age at onset);
UCEC	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.87	0.49	1.71e-10	Bladder cancer;
UCEC	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.13	0.39	9.05e-7	Rheumatoid arthritis;
UCEC	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.68	4.97	0.38	1.81e-6	Platelet count;
UCEC	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.87	5.05	0.38	1.3e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7072216	0.687	rs10883086	chr10:100155743	A/G	cg19567339	chr10:100142640	NA	0.58	7.34	0.52	1.34e-11	Metabolite levels;
UCEC	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.56	5.18	0.39	7.25e-7	Blood protein levels;
UCEC	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.6	0.35	9.12e-6	HDL cholesterol;
UCEC	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.51	5.19	0.39	6.81e-7	Colorectal cancer;
UCEC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg05709478	chr1:6581295	PLEKHG5	0.64	4.84	0.37	3.31e-6	Body mass index;
UCEC	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg08250081	chr4:10125330	NA	0.45	4.52	0.35	1.27e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.41	-4.74	-0.36	5.07e-6	Total body bone mineral density;
UCEC	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.6	-6.28	-0.46	3.55e-9	Blood protein levels;
UCEC	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.87	0.37	2.86e-6	Breast cancer;
UCEC	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg18681998	chr4:17616180	MED28	0.88	11.17	0.68	2.28e-21	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.51	4.85	0.37	3.1e-6	Platelet count;
UCEC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	6.67	0.48	4.93e-10	Platelet count;
UCEC	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.58e-8	Resting heart rate;
UCEC	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.79	-0.49	2.56e-10	Chronic sinus infection;
UCEC	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.54	4.9	0.37	2.55e-6	Birth weight;
UCEC	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg05991184	chr2:219186017	PNKD	0.41	4.63	0.36	7.96e-6	Ulcerative colitis;
UCEC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg00343986	chr7:65444356	GUSB	0.55	5.01	0.38	1.53e-6	Aortic root size;
UCEC	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-5.91	-0.44	2.28e-8	Myopia (pathological);
UCEC	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.69	-6.29	-0.46	3.46e-9	Prudent dietary pattern;
UCEC	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.8	10.31	0.65	4.42e-19	Vitiligo;
UCEC	cis	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg12310025	chr6:25882481	NA	-0.59	-4.64	-0.36	7.69e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.58	-6.77	-0.49	2.9e-10	Prostate cancer;
UCEC	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.51	5.29	0.4	4.4e-7	Response to antipsychotic treatment;
UCEC	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.61	4.84	0.37	3.24e-6	Inflammatory bowel disease;
UCEC	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.63	6.05	0.45	1.17e-8	Aortic root size;
UCEC	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.86	-5.22	-0.4	6.02e-7	Putamen volume;
UCEC	cis	rs9463078	0.764	rs9367208	chr6:44830180	G/A	cg25276700	chr6:44698697	NA	-0.41	-4.51	-0.35	1.32e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.83	5.91	0.44	2.24e-8	Body mass index;
UCEC	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.63	5.74	0.43	5.19e-8	Menopause (age at onset);
UCEC	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg23711669	chr6:146136114	FBXO30	-0.65	-5.84	-0.43	3.22e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.02	-0.38	1.46e-6	Chronic sinus infection;
UCEC	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.76	-6.82	-0.49	2.17e-10	Inflammatory bowel disease;
UCEC	cis	rs243088	1.000	rs243024	chr2:60583665	G/A	cg16665442	chr2:60585866	NA	-0.4	-4.76	-0.37	4.68e-6	Type 2 diabetes;
UCEC	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.68	6.06	0.45	1.08e-8	Bipolar disorder;
UCEC	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.72	-0.43	5.82e-8	Chronic sinus infection;
UCEC	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.44	-5.04	-0.38	1.36e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs6832769	1.000	rs4865008	chr4:56410855	T/G	cg05960024	chr4:56376020	CLOCK	-0.57	-5.79	-0.43	4.02e-8	Personality dimensions;
UCEC	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.52	-0.35	1.25e-5	Bipolar disorder;
UCEC	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.71	7.19	0.51	3.02e-11	Mosquito bite size;
UCEC	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.4	-0.41	2.66e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs1519814	0.956	rs7827008	chr8:121130281	A/T	cg22335954	chr8:121166405	COL14A1	-0.6	-5.37	-0.4	3.07e-7	Breast cancer;
UCEC	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg20701182	chr2:24300061	SF3B14	0.78	6.17	0.45	6.35e-9	Lymphocyte counts;
UCEC	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	4.68	0.36	6.48e-6	Response to antipsychotic treatment;
UCEC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.81	-9.89	-0.63	5.46e-18	Coronary artery disease;
UCEC	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.46	4.94	0.38	2.12e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.75	-9.13	-0.6	4.91e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.11	6.17	0.45	6.33e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7766436	0.922	rs11753523	chr6:22602094	G/A	cg13666174	chr6:22585274	NA	-0.58	-5.81	-0.43	3.69e-8	Coronary artery disease;
UCEC	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.6	-6.17	-0.45	6.37e-9	Dental caries;
UCEC	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.61	6.78	0.49	2.72e-10	Age at first birth;
UCEC	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg11632617	chr15:75315747	PPCDC	0.5	5.41	0.41	2.48e-7	Blood trace element (Zn levels);
UCEC	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.57	4.55	0.35	1.11e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10012307	1.000	rs7673920	chr4:137504706	T/C	cg12033966	chr4:138453416	PCDH18	-0.8	-4.66	-0.36	7.14e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24308560	chr3:49941425	MST1R	-0.44	-4.76	-0.37	4.67e-6	Body mass index;
UCEC	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	7.58	0.53	3.59e-12	Coronary artery disease;
UCEC	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.48	-5.11	-0.39	9.86e-7	Glaucoma;
UCEC	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	5.95	0.44	1.88e-8	Menarche (age at onset);
UCEC	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.31	-0.4	4.04e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	8.49	0.57	2.07e-14	Smoking behavior;
UCEC	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.47	5.08	0.39	1.13e-6	Aortic root size;
UCEC	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.65	-7.68	-0.54	2.07e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.64	-5.69	-0.42	6.64e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.12	12.36	0.71	1.65e-24	Blood protein levels;
UCEC	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg23625390	chr15:77176239	SCAPER	0.48	4.79	0.37	4.11e-6	Blood metabolite levels;
UCEC	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs17106184	0.892	rs72900926	chr1:51101616	C/G	cg07174182	chr1:51127561	FAF1	-0.78	-4.96	-0.38	1.95e-6	Type 2 diabetes;
UCEC	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg03714773	chr7:91764589	CYP51A1	0.43	5.32	0.4	3.73e-7	Breast cancer;
UCEC	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.59	5.78	0.43	4.41e-8	Metabolite levels;
UCEC	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.8	9.47	0.62	6.77e-17	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.67	-8.35	-0.57	4.62e-14	Immature fraction of reticulocytes;
UCEC	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.77	-8.79	-0.59	3.59e-15	Coronary artery disease;
UCEC	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.98	-0.44	1.62e-8	Total cholesterol levels;
UCEC	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.54	-4.65	-0.36	7.2e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.47	5.33	0.4	3.61e-7	White matter hyperintensity burden;
UCEC	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.81	-6.59	-0.48	7.53e-10	Response to hepatitis C treatment;
UCEC	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.66	7.44	0.52	7.76e-12	Body mass index;
UCEC	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.71	0.36	5.63e-6	Menopause (age at onset);
UCEC	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.43	-4.54	-0.35	1.18e-5	Extrinsic epigenetic age acceleration;
UCEC	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.57	-7.83	-0.54	8.77e-13	Neuroticism;
UCEC	trans	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg02900749	chr2:68251473	NA	-1.0	-7.7	-0.54	1.85e-12	Pursuit maintenance gain;
UCEC	cis	rs6906287	0.647	rs57813349	chr6:118763858	C/A	cg21191810	chr6:118973309	C6orf204	0.38	5.42	0.41	2.36e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-7.76	-0.54	1.29e-12	Total cholesterol levels;
UCEC	cis	rs4869931	0.929	rs9478780	chr6:151008994	C/T	cg06471296	chr6:150259601	NA	0.35	4.57	0.35	1.01e-5	Systolic blood pressure in sickle cell anemia;
UCEC	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.55	5.63	0.42	8.83e-8	Testicular germ cell tumor;
UCEC	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.58	-5.35	-0.4	3.32e-7	Metabolite levels;
UCEC	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.3	-0.4	4.07e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.51	5.43	0.41	2.31e-7	Menarche (age at onset);
UCEC	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg23070574	chr3:14187308	XPC	0.41	4.54	0.35	1.18e-5	Ovarian reserve;
UCEC	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-9.71	-0.63	1.6e-17	Vitiligo;
UCEC	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.68	-6.21	-0.46	5.14e-9	Aortic root size;
UCEC	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.45	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg18681998	chr4:17616180	MED28	-0.65	-7.52	-0.53	5.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4499344	0.730	rs2545357	chr19:33104610	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.96	0.44	1.75e-8	Mean platelet volume;
UCEC	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg07645718	chr20:61493192	TCFL5	0.74	5.08	0.39	1.12e-6	Obesity-related traits;
UCEC	cis	rs10242455	0.867	rs13362853	chr7:99223147	T/C	cg07715041	chr7:99302981	CYP3A7	0.48	4.79	0.37	4e-6	Blood metabolite levels;
UCEC	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.53	-6.02	-0.44	1.3e-8	Longevity;Endometriosis;
UCEC	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.81	0.37	3.64e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs10507349	0.913	rs10467680	chr13:26780420	C/T	cg01600817	chr13:26797529	RNF6	-0.46	-4.53	-0.35	1.19e-5	Type 2 diabetes;
UCEC	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	0.8	5.37	0.41	2.94e-7	Diabetic retinopathy;
UCEC	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	0.71	5.64	0.42	8.53e-8	Alzheimer's disease;
UCEC	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03352830	chr11:487213	PTDSS2	0.86	6.82	0.49	2.22e-10	Body mass index;
UCEC	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg11003573	chr3:44754125	ZNF502	-0.59	-4.72	-0.36	5.38e-6	IgG glycosylation;
UCEC	cis	rs8020441	0.588	rs4534750	chr14:51188124	C/T	cg04730355	chr14:51134070	SAV1	0.67	5.76	0.43	4.8e-8	Cognitive performance;
UCEC	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-5.11	-0.39	9.77e-7	Pediatric autoimmune diseases;
UCEC	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-0.83	-11.36	-0.68	7.31e-22	Blood protein levels;
UCEC	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	0.77	5.01	0.38	1.56e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs6594713	0.796	rs4438866	chr5:112690644	G/A	cg06062378	chr5:112387002	MCC	-0.44	-4.92	-0.38	2.27e-6	Brain cytoarchitecture;
UCEC	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg19875535	chr5:140030758	IK	0.43	4.73	0.36	5.14e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22117172	chr7:91764530	CYP51A1	0.39	4.86	0.37	3.03e-6	Breast cancer;
UCEC	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.14	-14.21	-0.76	2.16e-29	Breast cancer;
UCEC	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg03714773	chr7:91764589	CYP51A1	0.42	4.92	0.38	2.32e-6	Breast cancer;
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.9	12.06	0.71	9.9899999999999993e-24	Menarche (age at onset);
UCEC	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg06096015	chr1:231504339	EGLN1	0.47	5.41	0.41	2.48e-7	Hemoglobin concentration;
UCEC	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.59	-4.96	-0.38	1.91e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22117172	chr7:91764530	CYP51A1	-0.38	-4.74	-0.36	4.96e-6	Breast cancer;
UCEC	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.73	7.5	0.53	5.63e-12	Menopause (age at onset);
UCEC	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.64	-4.59	-0.35	9.41e-6	Aortic root size;
UCEC	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.68	-6.88	-0.49	1.59e-10	Blood metabolite levels;
UCEC	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	8.01	0.55	3.24e-13	Mean platelet volume;
UCEC	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.56	-5.23	-0.4	5.8e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	19.67	0.85	5.31e-43	Chronic sinus infection;
UCEC	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.55	5.05	0.38	1.3e-6	Corneal astigmatism;
UCEC	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-6.37	-0.47	2.27e-9	Crohn's disease;
UCEC	cis	rs4730268	0.821	rs7790720	chr7:107441502	A/G	cg18560240	chr7:107437656	SLC26A3	-0.72	-6.16	-0.45	6.65e-9	IgG glycosylation;
UCEC	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.59	-0.42	1.09e-7	Reticulocyte fraction of red cells;
UCEC	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	0.87	12.2	0.71	4.36e-24	Leprosy;
UCEC	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.4	4.51	0.35	1.3e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.46	-4.76	-0.37	4.52e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg13683864	chr3:40499215	RPL14	-0.56	-5.44	-0.41	2.18e-7	Renal cell carcinoma;
UCEC	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.57	-4.64	-0.36	7.69e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.66	-6.09	-0.45	9.26e-9	Parkinson's disease;
UCEC	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.47	-4.83	-0.37	3.35e-6	Body mass index;
UCEC	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	8.8	0.59	3.36e-15	Electrocardiographic conduction measures;
UCEC	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg05738196	chr6:26577821	NA	0.61	6.74	0.49	3.35e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs253959	0.697	rs12653937	chr5:115710117	G/A	cg23108291	chr5:115420582	COMMD10	-0.51	-4.82	-0.37	3.56e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.73	-7.28	-0.51	1.84e-11	Plateletcrit;Platelet count;
UCEC	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.49	4.8	0.37	3.84e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg16583315	chr14:65563665	MAX	-0.43	-5.34	-0.4	3.42e-7	Obesity-related traits;
UCEC	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12516959	chr21:47718080	NA	-0.41	-4.6	-0.35	9.03e-6	Testicular germ cell tumor;
UCEC	cis	rs12234571	1.000	rs60293809	chr7:77330196	G/A	cg20048109	chr7:78158112	MAGI2	-0.53	-4.81	-0.37	3.76e-6	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.48	-4.64	-0.36	7.8e-6	Aortic root size;
UCEC	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.54	4.63	0.36	7.88e-6	Obesity-related traits;
UCEC	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	9.51	0.62	5.18e-17	Coffee consumption (cups per day);
UCEC	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.47	6.79	0.49	2.6200000000000003e-10	Homoarginine levels;
UCEC	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg01072550	chr1:21505969	NA	-0.56	-5.39	-0.41	2.69e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-0.99	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.61	8.93	0.59	1.59e-15	Prudent dietary pattern;
UCEC	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.7	-6.5	-0.47	1.18e-9	Aortic root size;
UCEC	cis	rs7246967	0.611	rs8104052	chr19:22857804	T/C	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg18016565	chr1:150552671	MCL1	0.47	4.56	0.35	1.06e-5	Melanoma;
UCEC	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.49	-4.66	-0.36	6.99e-6	Menarche (age at onset);
UCEC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.3	0.61	1.84e-16	Menopause (age at onset);
UCEC	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.77	8.47	0.57	2.28e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.44	-4.68	-0.36	6.39e-6	Testicular germ cell tumor;
UCEC	cis	rs10799599	0.557	rs13375942	chr1:20292378	A/G	cg08898653	chr1:20811220	CAMK2N1	-0.46	-4.51	-0.35	1.33e-5	Immunoglobulin light chain (AL) amyloidosis;
UCEC	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs8105895	0.935	rs7260331	chr19:22291771	C/T	cg20662725	chr19:22235022	ZNF257	-0.52	-4.91	-0.38	2.43e-6	Body mass index (change over time);
UCEC	cis	rs9378357	0.702	rs7748835	chr6:3293939	A/G	cg08494755	chr6:3460947	NA	0.83	4.56	0.35	1.07e-5	Obesity-related traits;
UCEC	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.52	-5.77	-0.43	4.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg13334819	chr7:99746414	C7orf59	-0.6	-5.13	-0.39	9.02e-7	Coronary artery disease;
UCEC	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.61	6.01	0.44	1.41e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.59	5.36	0.4	3.17e-7	Uric acid levels;
UCEC	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg03859395	chr2:55845619	SMEK2	1.01	13.12	0.73	1.58e-26	Metabolic syndrome;
UCEC	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	7.27	0.51	2.02e-11	Eye color traits;
UCEC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.64	7.08	0.5	5.52e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg05484376	chr2:27715224	FNDC4	0.36	4.97	0.38	1.85e-6	Total body bone mineral density;
UCEC	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.71	-0.48	3.95e-10	Caudate activity during reward;
UCEC	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.72	7.85	0.54	8.01e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.65	5.86	0.44	2.87e-8	Recalcitrant atopic dermatitis;
UCEC	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg06818710	chr6:28411271	ZSCAN23	-0.41	-4.73	-0.36	5.31e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	0.99	7.92	0.55	5.42e-13	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.7	8.02	0.55	3.05e-13	Eosinophil percentage of white cells;
UCEC	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.82	7.37	0.52	1.16e-11	Bladder cancer;
UCEC	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg02413938	chr2:239008929	ESPNL	-0.36	-4.79	-0.37	4.07e-6	Prostate cancer;
UCEC	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.51	-5.13	-0.39	8.83e-7	Breast cancer;
UCEC	cis	rs8010715	0.816	rs6573565	chr14:24594733	A/G	cg20933586	chr14:24608199	FAM158A	-0.38	-4.97	-0.38	1.81e-6	IgG glycosylation;
UCEC	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	1.05	9.06	0.6	7.63e-16	Dupuytren's disease;
UCEC	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.1	0.56	1.9e-13	Electrocardiographic conduction measures;
UCEC	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.28	-0.61	2.01e-16	Height;
UCEC	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	5.39	0.41	2.79e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.18	0.39	7.34e-7	Hemoglobin concentration;
UCEC	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-9.82	-0.63	8.18e-18	Height;
UCEC	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.83	-10.33	-0.65	3.76e-19	White blood cell count (basophil);
UCEC	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.61	0.42	9.72e-8	Breast cancer;
UCEC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg13695892	chr22:41940480	POLR3H	0.62	4.9	0.37	2.5e-6	Vitiligo;
UCEC	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg14067834	chr17:29058358	SUZ12P	0.61	4.56	0.35	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.75	7.38	0.52	1.06e-11	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	6.69	0.48	4.38e-10	Coffee consumption (cups per day);
UCEC	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	-0.59	-6.74	-0.49	3.32e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-5.71	-0.43	6.04e-8	Coffee consumption (cups per day);
UCEC	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.39	-0.47	2.03e-9	Mood instability;
UCEC	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-4.91	-0.38	2.44e-6	Total cholesterol levels;
UCEC	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg19554555	chr3:13937349	NA	-0.59	-5.92	-0.44	2.18e-8	Ovarian reserve;
UCEC	cis	rs10940138	0.830	rs4976136	chr5:67206148	G/C	ch.5.1281357F	chr5:67228439	NA	0.6	5.42	0.41	2.4e-7	Menarche (age at onset);
UCEC	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.72	-5.37	-0.41	2.99e-7	White matter hyperintensity burden;
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	9.21	0.6	3.14e-16	Prudent dietary pattern;
UCEC	cis	rs539096	0.872	rs631248	chr1:44071221	C/T	cg11851915	chr1:44060116	PTPRF	0.42	4.66	0.36	6.96e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7106204	0.514	rs7935857	chr11:24252420	C/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.31	-0.46	3.18e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs17428704	1.000	rs58260094	chr5:14426560	C/T	cg24728912	chr5:14143221	TRIO	0.7	4.66	0.36	6.94e-6	Electroencephalogram traits;
UCEC	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.47	-5.03	-0.38	1.42e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.61	-6.34	-0.46	2.61e-9	Myopia (pathological);
UCEC	cis	rs36051895	0.559	rs10815172	chr9:5212254	T/A	cg02405213	chr9:5042618	JAK2	-0.53	-4.82	-0.37	3.6e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg18404041	chr3:52824283	ITIH1	0.38	4.55	0.35	1.12e-5	Schizophrenia;
UCEC	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.7	7.24	0.51	2.3e-11	Smoking behavior;
UCEC	cis	rs10946940	0.965	rs6910838	chr6:27515519	A/C	cg07836142	chr6:28411423	ZSCAN23	0.44	4.62	0.36	8.19e-6	Systemic lupus erythematosus;
UCEC	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	4.79	0.37	4.05e-6	Bipolar disorder;
UCEC	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.63	6.05	0.45	1.17e-8	Aortic root size;
UCEC	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg12317470	chr15:67143691	NA	-0.61	-5.22	-0.4	5.92e-7	Lung cancer (smoking interaction);
UCEC	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.48	-4.61	-0.36	8.63e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	7.5	0.53	5.48e-12	Menopause (age at onset);
UCEC	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.46	-5.64	-0.42	8.51e-8	Neutrophil percentage of white cells;
UCEC	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14019695	chr9:139328340	INPP5E	0.48	4.97	0.38	1.8e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.73	7.12	0.51	4.37e-11	Parkinson's disease;
UCEC	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.45	4.85	0.37	3.09e-6	Platelet count;
UCEC	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.52	-5.99	-0.44	1.57e-8	Depression;
UCEC	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-7.33	-0.52	1.39e-11	Urate levels in overweight individuals;
UCEC	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.57	-5.76	-0.43	4.65e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg13926569	chr10:89418898	PAPSS2	0.64	7.9	0.55	5.98e-13	Magnesium levels;
UCEC	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg04906043	chr13:21280425	IL17D	0.45	4.86	0.37	3.04e-6	Dental caries;
UCEC	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg12463550	chr7:65579703	CRCP	0.62	4.52	0.35	1.25e-5	Aortic root size;
UCEC	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.65	-5.7	-0.43	6.31e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.62	5.74	0.43	5.35e-8	Type 2 diabetes;
UCEC	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.2	-0.51	2.89e-11	Breast cancer;
UCEC	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-6.33	-0.46	2.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.51	-6.56	-0.48	8.51e-10	Congenital heart disease (maternal effect);
UCEC	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg11839771	chr15:80205821	ST20	-0.43	-4.53	-0.35	1.22e-5	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
UCEC	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.82	8.96	0.59	1.34e-15	Longevity;Endometriosis;
UCEC	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.37	5.61	0.42	9.69e-8	Body mass index;
UCEC	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.54	-5.94	-0.44	1.98e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs1324913	0.929	rs9543517	chr13:74640331	T/A	cg13696283	chr13:74707153	KLF12	-0.43	-4.85	-0.37	3.16e-6	Menarche (age at onset);
UCEC	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	4.67	0.36	6.77e-6	IgG glycosylation;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.56	6.9	0.49	1.41e-10	Warfarin maintenance dose;
UCEC	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.47	6.88	0.49	1.58e-10	Homoarginine levels;
UCEC	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg22089800	chr15:90895588	ZNF774	0.56	5.52	0.41	1.52e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg22166914	chr1:53195759	ZYG11B	0.77	7.99	0.55	3.66e-13	Monocyte count;
UCEC	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg06637938	chr14:75390232	RPS6KL1	0.59	5.63	0.42	8.9e-8	Non-small cell lung cancer;
UCEC	cis	rs76096589	0.557	rs1603015	chr14:51034338	A/T	cg16208672	chr14:51134997	SAV1	-0.57	-4.52	-0.35	1.28e-5	Diisocyanate-induced asthma;
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg17309464	chr19:36705192	ZNF565;ZNF146	0.64	6.72	0.48	3.71e-10	Triglyceride levels;
UCEC	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.92	9.75	0.63	1.28e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	-0.52	-5.9	-0.44	2.35e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.65	7.54	0.53	4.38e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4148689	1.000	rs7793127	chr7:117138947	A/G	cg21212505	chr7:117228958	CFTR	-0.42	-4.71	-0.36	5.75e-6	Gout;
UCEC	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.8	9.09	0.6	6.15e-16	Coronary artery disease;
UCEC	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	15.53	0.79	8.6e-33	Colorectal cancer;
UCEC	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.43	-0.41	2.3e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.51	-4.63	-0.36	7.85e-6	Bipolar disorder;
UCEC	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.42	5.12	0.39	9.27e-7	Metabolite levels (small molecules and protein measures);
UCEC	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.8	-5.76	-0.43	4.66e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.66	5.32	0.4	3.75e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg22166914	chr1:53195759	ZYG11B	0.49	4.97	0.38	1.86e-6	Monocyte count;
UCEC	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.53	5.72	0.43	5.88e-8	Lymphocyte counts;
UCEC	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg15147215	chr3:52552868	STAB1	-0.42	-4.58	-0.35	1e-5	Bipolar disorder;
UCEC	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.54	9.26	0.61	2.27e-16	Airflow obstruction;
UCEC	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.47	5.04	0.38	1.32e-6	Headache;
UCEC	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.53	4.57	0.35	1.02e-5	Menarche (age at onset);
UCEC	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.52	-5.08	-0.39	1.15e-6	Aortic root size;
UCEC	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Bladder cancer;
UCEC	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.48	4.87	0.37	2.81e-6	Schizophrenia;
UCEC	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.62	5.34	0.4	3.38e-7	Alzheimer's disease;
UCEC	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.7	4.97	0.38	1.81e-6	Body mass index;
UCEC	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.67	-7.99	-0.55	3.69e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.68	-5.09	-0.39	1.07e-6	Aortic root size;
UCEC	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.84	9.71	0.63	1.59e-17	Systemic lupus erythematosus;
UCEC	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	0.73	8.02	0.55	2.97e-13	Menarche (age at onset);
UCEC	cis	rs8044995	0.563	rs7500163	chr16:68364358	C/G	cg05110241	chr16:68378359	PRMT7	-0.49	-4.58	-0.35	9.89e-6	Schizophrenia;
UCEC	cis	rs9810089	0.843	rs1279086	chr3:136038574	G/A	cg21827317	chr3:136751795	NA	0.46	4.63	0.36	8.1e-6	Gestational age at birth (child effect);
UCEC	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.56	5.14	0.39	8.73e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.53	5.86	0.44	2.96e-8	Body mass index;
UCEC	cis	rs892864	0.685	rs11952130	chr5:127765594	A/C	cg17313118	chr5:127157258	NA	0.66	4.54	0.35	1.16e-5	Multiple system atrophy;
UCEC	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg15837086	chr1:46506065	PIK3R3	0.41	5.3	0.4	4.14e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.56	-5.65	-0.42	7.98e-8	Blood trace element (Zn levels);
UCEC	cis	rs10256972	0.775	rs10259248	chr7:1018968	G/C	cg10318148	chr7:1024673	CYP2W1	0.38	4.51	0.35	1.29e-5	Longevity;Endometriosis;
UCEC	cis	rs7004769	0.554	rs75499783	chr8:9175227	G/T	cg27598956	chr8:9758788	LOC157627	-0.47	-4.53	-0.35	1.21e-5	Fibrinogen levels;
UCEC	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg04155231	chr12:9217510	LOC144571	0.4	5.17	0.39	7.56e-7	Sjögren's syndrome;
UCEC	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg14893161	chr1:205819251	PM20D1	0.47	4.86	0.37	2.97e-6	Parkinson's disease;
UCEC	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.32	-4.75	-0.37	4.72e-6	Blood metabolite levels;
UCEC	cis	rs424971	0.761	rs8054065	chr16:85951354	A/G	cg09464461	chr16:85009494	ZDHHC7	-0.42	-4.59	-0.35	9.41e-6	Monocyte count;
UCEC	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.57	6.23	0.46	4.67e-9	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg03859395	chr2:55845619	SMEK2	-0.96	-11.89	-0.7	2.9e-23	Metabolic syndrome;
UCEC	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.65	5.83	0.43	3.38e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.43	-5.0	-0.38	1.64e-6	Obesity-related traits;
UCEC	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.68	6.93	0.5	1.23e-10	Smoking behavior;
UCEC	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.99	-0.55	3.66e-13	Total cholesterol levels;
UCEC	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.78	6.49	0.47	1.25e-9	Triglycerides;
UCEC	cis	rs847577	0.550	rs12670686	chr7:97708397	A/G	cg24562669	chr7:97807699	LMTK2	0.71	10.07	0.64	1.82e-18	Breast cancer;
UCEC	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg19926144	chr10:661009	DIP2C	0.79	4.77	0.37	4.43e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	4.76	0.37	4.58e-6	Personality dimensions;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.67	8.06	0.55	2.4e-13	Menarche (age at onset);
UCEC	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.48	-5.49	-0.41	1.71e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg11871910	chr12:69753446	YEATS4	0.55	4.88	0.37	2.76e-6	Response to diuretic therapy;
UCEC	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.6	5.79	0.43	4.16e-8	Vitamin D levels;
UCEC	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.44	4.51	0.35	1.33e-5	Vitiligo;
UCEC	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.64	-6.97	-0.5	1e-10	Platelet distribution width;
UCEC	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg21853948	chr4:100867292	DNAJB14	0.45	4.61	0.36	8.51e-6	Alcohol dependence;
UCEC	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.64	-7.09	-0.5	5.24e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg15837086	chr1:46506065	PIK3R3	0.37	4.54	0.35	1.18e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.45	-5.15	-0.39	8.16e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-0.71	-6.99	-0.5	8.94e-11	Height;
UCEC	cis	rs4423214	0.550	rs4944885	chr11:71114075	C/T	cg05163923	chr11:71159392	DHCR7	0.61	6.2	0.46	5.5e-9	Vitamin D levels;
UCEC	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	0.77	4.76	0.37	4.57e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.02	9.07	0.6	7.03e-16	Platelet count;
UCEC	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.99	6.15	0.45	7.01e-9	Plasma clusterin levels;
UCEC	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg04871131	chr7:94954202	PON1	-0.52	-5.15	-0.39	8.14e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs12545109	0.613	rs10958480	chr8:57278717	A/T	cg07776626	chr8:57350775	NA	-0.53	-5.52	-0.41	1.46e-7	Obesity-related traits;
UCEC	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.67	7.28	0.51	1.84e-11	Schizophrenia;
UCEC	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-4.66	-0.36	7.1e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-1.14	-8.58	-0.58	1.26e-14	Bone mineral density;
UCEC	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	0.96	6.26	0.46	4.07e-9	Left atrial antero-posterior diameter;
UCEC	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.52	7.28	0.51	1.87e-11	Bone mineral density (spine);
UCEC	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.47	5.88	0.44	2.71e-8	Electrocardiographic conduction measures;
UCEC	cis	rs12635074	0.521	rs60879071	chr3:56312134	T/A	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.33	4.56	0.35	1.08e-5	Morning vs. evening chronotype;
UCEC	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.59	-5.7	-0.43	6.45e-8	Rheumatoid arthritis;
UCEC	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.49	6.36	0.46	2.38e-9	Bone mineral density;
UCEC	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.48	-5.04	-0.38	1.38e-6	Blood metabolite levels;
UCEC	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.72	-8.44	-0.57	2.76e-14	Menarche (age at onset);
UCEC	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.63	-5.71	-0.43	6.17e-8	Aortic root size;
UCEC	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg13683864	chr3:40499215	RPL14	-0.57	-5.76	-0.43	4.77e-8	Renal cell carcinoma;
UCEC	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg14438399	chr17:27053147	TLCD1	0.59	4.66	0.36	7.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg00800038	chr16:89945340	TCF25	-0.76	-4.53	-0.35	1.21e-5	Skin colour saturation;
UCEC	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-6.41	-0.47	1.86e-9	Rheumatoid arthritis;
UCEC	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.09	-16.68	-0.81	9.87e-36	Myeloid white cell count;
UCEC	cis	rs12635074	0.521	rs12638786	chr3:56315115	C/T	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.33	4.56	0.35	1.08e-5	Morning vs. evening chronotype;
UCEC	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.43	-4.7	-0.36	6.01e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	5.66	0.42	7.77e-8	Height;
UCEC	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.73	-5.33	-0.4	3.7e-7	Mean platelet volume;
UCEC	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.94	10.94	0.67	9.16e-21	Breast cancer;
UCEC	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.57	6.04	0.45	1.21e-8	Red blood cell count;
UCEC	cis	rs60311166	1.000	rs60058353	chr3:52778409	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.8	5.4	0.41	2.63e-7	CTACK levels;
UCEC	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.81	7.34	0.52	1.34e-11	Bladder cancer;
UCEC	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.18	0.39	7.29e-7	Homoarginine levels;
UCEC	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.85	10.55	0.66	1.02e-19	Mortality in heart failure;
UCEC	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.65	-6.82	-0.49	2.21e-10	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.53	-5.36	-0.4	3.15e-7	Aortic root size;
UCEC	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg23995753	chr2:160760732	LY75	-0.41	-4.81	-0.37	3.78e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.43	4.92	0.38	2.3e-6	Hypertriglyceridemia;
UCEC	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg15147215	chr3:52552868	STAB1	-0.44	-4.98	-0.38	1.76e-6	Bipolar disorder;
UCEC	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-5.3	-0.4	4.2e-7	Blood pressure (smoking interaction);
UCEC	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.14	19.34	0.85	3.18e-42	Schizophrenia;
UCEC	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-6.15	-0.45	7.09e-9	Morning vs. evening chronotype;
UCEC	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	cis	rs16937	0.711	rs12129162	chr1:205164650	A/G	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs6446731	0.500	rs2858085	chr4:3271226	T/G	cg08886695	chr4:3369023	RGS12	0.41	4.61	0.36	8.71e-6	Mean platelet volume;
UCEC	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.7	-6.73	-0.49	3.63e-10	Aortic root size;
UCEC	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	0.86	4.92	0.38	2.25e-6	Gut microbiota (bacterial taxa);
UCEC	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.56	-5.36	-0.4	3.16e-7	Personality dimensions;
UCEC	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.55	-5.63	-0.42	8.94e-8	Autism;
UCEC	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg16497661	chr14:103986332	CKB	0.48	5.5	0.41	1.63e-7	Body mass index;
UCEC	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.77	9.48	0.62	6.1e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-8.36	-0.57	4.3e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	6.39	0.47	2.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9868873	1.000	rs2034177	chr3:122729089	A/G	cg02041593	chr3:122741233	SEMA5B	0.51	5.31	0.4	4.03e-7	Esophageal cancer;
UCEC	cis	rs7113850	0.541	rs4360696	chr11:24217119	C/G	ch.11.24196551F	chr11:24239977	NA	0.66	5.67	0.42	7.43e-8	Bone fracture in osteoporosis;
UCEC	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.76	0.37	4.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.54	4.83	0.37	3.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.42	5.6	0.42	9.99e-8	Reticulocyte fraction of red cells;
UCEC	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.65e-11	Heart rate;
UCEC	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.38	-4.51	-0.35	1.34e-5	Refractive error;
UCEC	cis	rs787274	0.867	rs786981	chr9:115457856	T/G	cg13803584	chr9:115635662	SNX30	0.6	4.62	0.36	8.31e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.53	5.49	0.41	1.74e-7	Corneal astigmatism;
UCEC	cis	rs7937612	0.931	rs7121779	chr11:120213360	A/T	cg12584626	chr11:120203529	NA	0.49	5.15	0.39	8.35e-7	Intraocular pressure;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg21486944	chr6:28411378	ZSCAN23	-0.47	-5.0	-0.38	1.62e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10507349	0.657	rs502264	chr13:26816509	C/T	cg01600817	chr13:26797529	RNF6	0.45	5.01	0.38	1.56e-6	Type 2 diabetes;
UCEC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.68	6.31	0.46	3.09e-9	Corneal astigmatism;
UCEC	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg18490616	chr2:88469792	THNSL2	0.92	5.92	0.44	2.16e-8	Plasma clusterin levels;
UCEC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.86	-10.91	-0.67	1.13e-20	Height;
UCEC	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.59	-6.1	-0.45	8.91e-9	Initial pursuit acceleration;
UCEC	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.66	6.15	0.45	6.86e-9	Aortic root size;
UCEC	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18932078	chr1:2524107	MMEL1	-0.33	-5.34	-0.4	3.5e-7	Ulcerative colitis;
UCEC	cis	rs9341808	0.667	rs2490244	chr6:80891112	A/T	cg08355045	chr6:80787529	NA	0.4	5.11	0.39	9.75e-7	Sitting height ratio;
UCEC	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.59	4.79	0.37	4.1e-6	Breast cancer;
UCEC	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	0.63	8.27	0.56	7.25e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs72700829	0.531	rs12070288	chr1:151009984	C/G	cg00107782	chr1:151300621	NA	-0.67	-4.52	-0.35	1.28e-5	Schizophrenia;
UCEC	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.7	6.29	0.46	3.39e-9	Subjective well-being;
UCEC	cis	rs7937612	1.000	rs6589811	chr11:120235703	C/T	cg12584626	chr11:120203529	NA	0.52	5.29	0.4	4.39e-7	Intraocular pressure;
UCEC	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.34	4.67	0.36	6.62e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.7	7.25	0.51	2.16e-11	Smoking behavior;
UCEC	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.63	-0.58	9.18e-15	Total body bone mineral density;
UCEC	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.49	5.23	0.4	5.72e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs3112255	0.512	rs10174721	chr2:101337013	A/C	cg01042948	chr2:101319752	NA	0.48	4.94	0.38	2.07e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18252515	chr7:66147081	NA	-0.52	-4.87	-0.37	2.89e-6	Aortic root size;
UCEC	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.71	6.69	0.48	4.41e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.64	6.27	0.46	3.84e-9	Breast cancer;
UCEC	cis	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg20368463	chr18:77673604	PQLC1	0.53	4.88	0.37	2.75e-6	Opioid sensitivity;
UCEC	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.71	0.36	5.78e-6	Breast cancer;
UCEC	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12292205	chr6:26970375	C6orf41	-0.59	-4.84	-0.37	3.26e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg06238570	chr21:40685208	BRWD1	0.76	7.46	0.52	6.88e-12	Cognitive function;
UCEC	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-0.95	-7.97	-0.55	4.13e-13	White matter hyperintensity burden;
UCEC	cis	rs317689	1.000	rs317689	chr12:69727190	G/A	cg11871910	chr12:69753446	YEATS4	0.6	5.26	0.4	5.06e-7	Response to diuretic therapy;
UCEC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	5.11	0.39	9.74e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	1.04	7.82	0.54	9.42e-13	Mean corpuscular volume;
UCEC	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg08886695	chr4:3369023	RGS12	-0.48	-5.21	-0.4	6.16e-7	Parental longevity (mother's age at death);
UCEC	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.61	5.52	0.41	1.5e-7	Corneal astigmatism;
UCEC	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-6.98	-0.5	9.49e-11	Eye color traits;
UCEC	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.43	4.55	0.35	1.09e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.02e-6	Prudent dietary pattern;
UCEC	cis	rs9843304	0.528	rs9860963	chr3:149197465	A/G	cg08667024	chr3:149219783	TM4SF4	0.49	5.57	0.42	1.17e-7	Gallstone disease;
UCEC	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.88	-10.2	-0.64	8.28e-19	Blood metabolite levels;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.85	10.47	0.65	1.68e-19	Menarche (age at onset);
UCEC	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg24562669	chr7:97807699	LMTK2	0.42	5.15	0.39	8.1e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-5.74	-0.43	5.18e-8	Platelet count;
UCEC	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.42	-4.7	-0.36	5.9e-6	Schizophrenia;
UCEC	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-8.76	-0.59	4.35e-15	Chronic sinus infection;
UCEC	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-0.94	-6.77	-0.49	2.86e-10	Blood pressure (smoking interaction);
UCEC	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.53	5.39	0.41	2.72e-7	Schizophrenia;
UCEC	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.59	6.36	0.46	2.43e-9	Brugada syndrome;
UCEC	cis	rs7246967	0.736	rs436595	chr19:22993045	G/T	cg05241461	chr19:22816980	ZNF492	0.48	4.52	0.35	1.25e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.6	-5.94	-0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs539514	0.563	rs7991448	chr13:76334061	G/A	cg04757411	chr13:76259545	LMO7	-0.44	-5.07	-0.39	1.2e-6	Type 1 diabetes;
UCEC	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.3	-4.54	-0.35	1.14e-5	Narcolepsy;
UCEC	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.47	0.52	6.75e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.72	0.43	5.87e-8	Prudent dietary pattern;
UCEC	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.73	6.43	0.47	1.68e-9	Cognitive function;
UCEC	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.47	4.52	0.35	1.24e-5	Platelet count;
UCEC	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.82	9.51	0.62	5.25e-17	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.63	6.72	0.48	3.71e-10	Platelet count;
UCEC	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg19875535	chr5:140030758	IK	0.41	4.52	0.35	1.27e-5	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.19	-0.39	6.93e-7	Dilated cardiomyopathy;
UCEC	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	4.79	0.37	4.11e-6	Breast cancer;
UCEC	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.2	-0.46	5.32e-9	Height;
UCEC	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	7.06	0.5	6.3e-11	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.73	7.16	0.51	3.65e-11	Psoriasis;
UCEC	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg12024160	chr4:1254474	NA	0.5	5.96	0.44	1.75e-8	Obesity-related traits;
UCEC	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg13683864	chr3:40499215	RPL14	-0.49	-4.96	-0.38	1.95e-6	Renal cell carcinoma;
UCEC	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.48	5.2	0.39	6.66e-7	Aortic root size;
UCEC	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg07836142	chr6:28411423	ZSCAN23	-0.47	-5.22	-0.4	6.08e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg00612595	chr21:47717864	NA	-0.5	-5.42	-0.41	2.36e-7	Testicular germ cell tumor;
UCEC	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.47	4.89	0.37	2.65e-6	Smoking initiation;
UCEC	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg09626299	chr10:82213104	TSPAN14	-0.4	-6.32	-0.46	2.95e-9	Post bronchodilator FEV1;
UCEC	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.49	5.13	0.39	9.15e-7	Vitiligo;
UCEC	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.7	6.36	0.46	2.43e-9	Menopause (age at onset);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09906751	chr10:64133883	ZNF365	0.54	7.15	0.51	3.78e-11	Warfarin maintenance dose;
UCEC	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	7.17	0.51	3.41e-11	Eye color traits;
UCEC	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-6.01	-0.44	1.42e-8	Hepatocellular carcinoma;
UCEC	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg19318889	chr4:1322082	MAEA	0.49	5.28	0.4	4.52e-7	Obesity-related traits;
UCEC	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg23795048	chr12:9217529	LOC144571	0.42	5.01	0.38	1.55e-6	Sjögren's syndrome;
UCEC	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.46	-5.45	-0.41	2.11e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
UCEC	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.49	5.46	0.41	2e-7	Gut microbiome composition (winter);
UCEC	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.75	9.13	0.6	5.05e-16	Vitiligo;
UCEC	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.98	11.54	0.69	2.4e-22	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	1.01	10.94	0.67	9.62e-21	Cognitive function;
UCEC	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.94	9.89	0.63	5.53e-18	Height;
UCEC	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-6.12	-0.45	7.98e-9	Obesity-related traits;
UCEC	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.34	-0.46	2.61e-9	Parkinson's disease;
UCEC	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.55	4.51	0.35	1.33e-5	Platelet distribution width;
UCEC	cis	rs6728642	1.000	rs113863815	chr2:97657813	A/G	cg26665480	chr2:98280029	ACTR1B	-0.74	-4.51	-0.35	1.33e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
UCEC	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.48	5.03	0.38	1.4e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg09582042	chr13:95253676	GPR180	0.32	4.52	0.35	1.25e-5	Triglyceride levels;
UCEC	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg14092571	chr14:90743983	NA	0.47	5.56	0.42	1.22e-7	Mortality in heart failure;
UCEC	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.72	7.25	0.51	2.23e-11	Tonsillectomy;
UCEC	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05472934	chr7:22766657	IL6	0.83	8.51	0.57	1.86e-14	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
UCEC	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg04310649	chr10:35416472	CREM	-0.48	-4.6	-0.35	9.13e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.57	5.36	0.4	3.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs73017364	0.688	rs11808026	chr1:162152520	C/T	cg19130550	chr1:161994277	OLFML2B	-0.52	-4.84	-0.37	3.31e-6	QT interval;
UCEC	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.66	6.29	0.46	3.46e-9	Response to antineoplastic agents;
UCEC	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg05738196	chr6:26577821	NA	0.58	6.27	0.46	3.89e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.44	4.57	0.35	1.04e-5	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.81	5.25	0.4	5.17e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	trans	rs337161	0.719	rs381023	chr1:220930546	A/C	cg07378013	chr16:90088605	GAS8	0.65	7.07	0.5	5.85e-11	Response to antipsychotic therapy (extrapyramidal side effects);
UCEC	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg08805041	chr16:621841	PIGQ	-0.31	-4.51	-0.35	1.34e-5	Height;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03813215	chr18:60986679	BCL2	0.65	7.74	0.54	1.44e-12	Warfarin maintenance dose;
UCEC	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.11	8.78	0.59	3.95e-15	Vitiligo;
UCEC	cis	rs4778581	0.868	rs34036416	chr15:80411267	T/C	cg08257866	chr15:80351198	ZFAND6	0.4	4.62	0.36	8.25e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.55	4.68	0.36	6.37e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.67	7.02	0.5	7.41e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.46	4.66	0.36	6.99e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.12	12.23	0.71	3.6e-24	Blood protein levels;
UCEC	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.59	6.2	0.46	5.29e-9	Height;
UCEC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.48	-4.57	-0.35	1.02e-5	Cardiac Troponin-T levels;
UCEC	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg01072550	chr1:21505969	NA	0.59	6.36	0.46	2.43e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.53	5.56	0.42	1.25e-7	Acylcarnitine levels;
UCEC	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.48	-4.71	-0.36	5.74e-6	Breast cancer;
UCEC	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.46	5.28	0.4	4.48e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6546886	0.913	rs12713805	chr2:74243380	C/T	cg14702570	chr2:74259524	NA	-0.45	-5.76	-0.43	4.83e-8	Dialysis-related mortality;
UCEC	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.43	-4.67	-0.36	6.59e-6	Blood metabolite levels;
UCEC	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	12.07	0.71	9.79e-24	Ulcerative colitis;
UCEC	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg14324370	chr2:177042789	NA	0.54	5.65	0.42	8.01e-8	IgG glycosylation;
UCEC	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.51	-4.75	-0.36	4.87e-6	Corneal astigmatism;
UCEC	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.55	4.62	0.36	8.17e-6	Coronary artery disease;
UCEC	cis	rs36051895	0.659	rs12349508	chr9:5184222	T/G	cg02405213	chr9:5042618	JAK2	-0.61	-5.16	-0.39	8.04e-7	Pediatric autoimmune diseases;
UCEC	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs6479527	0.933	rs10993058	chr9:96873151	C/A	cg07076509	chr9:96720819	NA	0.44	4.97	0.38	1.85e-6	Esophageal adenocarcinoma;
UCEC	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-8.05	-0.55	2.59e-13	Bipolar disorder and schizophrenia;
UCEC	cis	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-4.58	-0.35	9.98e-6	Colorectal or endometrial cancer;
UCEC	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	8.33	0.57	5.11e-14	Menopause (age at onset);
UCEC	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.71	-7.09	-0.5	5.24e-11	Blood metabolite levels;
UCEC	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	0.77	4.97	0.38	1.8e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.52	-7.0	-0.5	8.24e-11	Eye color traits;
UCEC	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.02	0.38	1.46e-6	Breast cancer;
UCEC	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.78	8.19	0.56	1.14e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.83	-10.45	-0.65	1.85e-19	IgG glycosylation;
UCEC	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg07404485	chr7:94953653	PON1	-0.45	-4.57	-0.35	1.02e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg05623727	chr3:50126028	RBM5	0.36	4.85	0.37	3.11e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg18755752	chr8:142205143	DENND3	0.59	5.44	0.41	2.13e-7	Immature fraction of reticulocytes;
UCEC	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.8	10.67	0.66	4.75e-20	Body mass index;
UCEC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.71	-7.1	-0.51	5.01e-11	Tonsillectomy;
UCEC	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	7.45	0.52	7.36e-12	Ileal carcinoids;
UCEC	cis	rs11697848	1.000	rs35598880	chr20:48578804	A/G	cg17849948	chr20:48532315	SPATA2	1.06	4.99	0.38	1.72e-6	Systemic lupus erythematosus;
UCEC	trans	rs925228	0.955	rs10166036	chr2:24193947	G/A	cg18674340	chr17:45867686	NA	0.72	6.7	0.48	4.1e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.55	4.59	0.35	9.25e-6	Corneal astigmatism;
UCEC	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	14.63	0.77	1.8e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-7.75	-0.54	1.43e-12	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg16532529	chr3:122101951	CCDC58;FAM162A	0.66	4.87	0.37	2.91e-6	Multiple sclerosis;
UCEC	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.76	-8.25	-0.56	8.03e-14	Blood metabolite levels;
UCEC	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg19678392	chr7:94953810	PON1	-0.59	-5.72	-0.43	5.82e-8	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.63	6.98	0.5	9.34e-11	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06352072	chr18:59561651	RNF152	0.61	6.89	0.49	1.51e-10	Warfarin maintenance dose;
UCEC	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	1.01	7.75	0.54	1.4e-12	Exhaled nitric oxide output;
UCEC	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	5.66	0.42	7.83e-8	Coffee consumption (cups per day);
UCEC	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs1150668	0.764	rs9368565	chr6:28345210	C/T	cg24703168	chr6:28411309	ZSCAN23	0.5	5.56	0.42	1.25e-7	Pubertal anthropometrics;
UCEC	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.59	6.54	0.47	9.63e-10	Height;
UCEC	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg23018400	chr1:46712832	RAD54L	0.6	4.75	0.36	4.77e-6	Blood protein levels;
UCEC	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.52	4.53	0.35	1.23e-5	Alzheimer's disease;
UCEC	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg26721908	chr21:47610096	LSS	-0.38	-4.8	-0.37	3.8e-6	Testicular germ cell tumor;
UCEC	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.83	7.54	0.53	4.53e-12	Bladder cancer;
UCEC	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.54	0.47	9.35e-10	Cognitive test performance;
UCEC	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.49	-6.85	-0.49	1.85e-10	Urinary metabolites;
UCEC	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.88	9.7	0.62	1.65e-17	Breast cancer;
UCEC	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg11508081	chr17:41442227	NA	0.45	4.73	0.36	5.13e-6	Menopause (age at onset);
UCEC	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs7083	0.875	rs536648	chr11:117143185	G/C	cg13792913	chr11:118026593	NA	-0.32	-4.52	-0.35	1.26e-5	Blood protein levels;
UCEC	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	0.64	5.88	0.44	2.67e-8	Vitiligo;
UCEC	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.17	11.24	0.68	1.54e-21	Corneal structure;
UCEC	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.62	5.41	0.41	2.46e-7	Uric acid levels;
UCEC	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.75	8.17	0.56	1.33e-13	Menopause (age at onset);
UCEC	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.47	4.67	0.36	6.73e-6	Migraine;
UCEC	cis	rs2147959	0.941	rs1886774	chr1:228633718	C/T	cg00655913	chr1:228633920	NA	0.54	6.04	0.45	1.22e-8	Adult asthma;
UCEC	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg00086871	chr4:6988644	TBC1D14	-0.47	-4.51	-0.35	1.31e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
UCEC	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.59	-4.66	-0.36	7.05e-6	Cholesterol, total;
UCEC	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg15790941	chr4:39640517	C4orf34	-0.61	-4.82	-0.37	3.6e-6	Plasma amyloid beta peptide concentrations (ABx-40);
UCEC	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.57	5.14	0.39	8.62e-7	Alzheimer's disease;
UCEC	cis	rs2882667	0.858	rs17207870	chr5:138387737	T/C	cg04439458	chr5:138467593	SIL1	-0.44	-4.66	-0.36	7.04e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	0.92	5.09	0.39	1.06e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
UCEC	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg11569703	chr11:65557185	OVOL1	0.39	4.92	0.38	2.29e-6	Acne (severe);
UCEC	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.44	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg22166914	chr1:53195759	ZYG11B	-0.87	-9.75	-0.63	1.27e-17	Monocyte count;
UCEC	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.52	5.21	0.4	6.14e-7	Testicular germ cell tumor;
UCEC	cis	rs1595825	0.891	rs7595819	chr2:198543156	A/C	cg19156104	chr2:198669113	PLCL1	0.64	4.72	0.36	5.54e-6	Ulcerative colitis;
UCEC	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.6	7.23	0.51	2.43e-11	Metabolite levels;
UCEC	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.67	6.16	0.45	6.65e-9	Corneal astigmatism;
UCEC	cis	rs4372836	0.541	rs6710080	chr2:28989975	A/G	cg09522027	chr2:28974177	PPP1CB	-0.76	-8.39	-0.57	3.63e-14	Body mass index;
UCEC	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs889398	0.641	rs7200258	chr16:69897469	T/G	cg00738113	chr16:70207722	CLEC18C	-0.38	-5.23	-0.4	5.86e-7	Body mass index;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.93	-0.44	2.1e-8	Platelet count;
UCEC	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.52	5.57	0.42	1.18e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
UCEC	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.62	0.58	9.5e-15	Exhaled nitric oxide output;
UCEC	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.75	-8.57	-0.58	1.3e-14	Extraversion;
UCEC	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.74	-9.42	-0.61	8.87e-17	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4148689	0.951	rs2188159	chr7:117155843	A/G	cg21212505	chr7:117228958	CFTR	-0.41	-4.69	-0.36	6.32e-6	Gout;
UCEC	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.68	7.74	0.54	1.48e-12	Menopause (age at onset);
UCEC	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg06784218	chr1:46089804	CCDC17	0.42	4.87	0.37	2.88e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.46	6.2	0.46	5.51e-9	Fibrinogen levels;
UCEC	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	8.55	0.58	1.44e-14	Post bronchodilator FEV1;
UCEC	cis	rs35934224	0.783	rs5993849	chr22:19866194	G/C	cg11182965	chr22:19864308	TXNRD2	-0.39	-5.08	-0.39	1.12e-6	Glaucoma (primary open-angle);
UCEC	cis	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg17469321	chr7:55412551	NA	0.69	6.31	0.46	3.06e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.5	5.3	0.4	4.1e-7	Schizophrenia;
UCEC	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	8.68	0.58	7.05e-15	Lymphocyte percentage of white cells;
UCEC	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.53	-4.81	-0.37	3.69e-6	Hypospadias;
UCEC	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	7.05	0.5	6.5500000000000006e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.81	-7.4	-0.52	9.42e-12	Initial pursuit acceleration;
UCEC	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.68	7.43	0.52	8.41e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg27624424	chr6:160112604	SOD2	0.57	5.39	0.41	2.72e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	4.63	0.36	8.08e-6	Parkinson's disease;
UCEC	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-6.34	-0.46	2.63e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.79	0.43	4.17e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.63	4.81	0.37	3.77e-6	Carotid intima media thickness;
UCEC	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.59	-5.99	-0.44	1.53e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.46	-4.64	-0.36	7.5e-6	Alcohol dependence;
UCEC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.54	5.2	0.39	6.62e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.57	-6.61	-0.48	6.5e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg04804543	chr8:142233427	SLC45A4	-0.5	-5.96	-0.44	1.81e-8	Immature fraction of reticulocytes;
UCEC	cis	rs6460942	0.591	rs62448729	chr7:12333720	G/C	cg06484146	chr7:12443880	VWDE	-0.65	-5.17	-0.39	7.66e-7	Coronary artery disease;
UCEC	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg12024160	chr4:1254474	NA	0.73	8.02	0.55	3.05e-13	Obesity-related traits;
UCEC	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.85	10.25	0.65	6.2e-19	Menopause (age at onset);
UCEC	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	6.24	0.46	4.43e-9	Alzheimer's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04213235	chr1:145826932	GPR89A	0.58	7.07	0.5	5.8200000000000003e-11	Warfarin maintenance dose;
UCEC	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.5	4.6	0.36	8.88e-6	Menarche (age at onset);
UCEC	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.78	-0.37	4.29e-6	Menopause (age at onset);
UCEC	cis	rs3816788	0.792	rs10097055	chr8:21872328	A/G	cg17168535	chr8:21777572	XPO7	0.73	7.79	0.54	1.09e-12	Lung cancer in ever smokers;
UCEC	cis	rs8105895	0.935	rs62110989	chr19:22260299	A/G	cg02912127	chr19:22235281	ZNF257	-0.63	-5.24	-0.4	5.45e-7	Body mass index (change over time);
UCEC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	4.86	0.37	2.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg10932868	chr11:921992	NA	0.45	5.88	0.44	2.71e-8	Alzheimer's disease (late onset);
UCEC	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.69	-0.48	4.46e-10	Total cholesterol levels;
UCEC	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.62	-6.38	-0.47	2.17e-9	Coffee consumption (cups per day);
UCEC	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.71	6.45	0.47	1.54e-9	Aortic root size;
UCEC	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-0.84	-9.62	-0.62	2.68e-17	Height;
UCEC	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.1	10.11	0.64	1.47e-18	Vitiligo;
UCEC	cis	rs308403	0.509	rs309357	chr4:123653576	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.93	15.17	0.78	7.11e-32	Blood protein levels;
UCEC	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.13	-0.39	8.9e-7	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs2710201	1.000	rs34525661	chr7:152958681	G/A	cg17795252	chr3:181328009	SOX2OT	0.68	6.67	0.48	4.82e-10	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg13844804	chr7:814759	HEATR2	0.68	5.01	0.38	1.52e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.7	-7.53	-0.53	4.73e-12	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6549438	0.504	rs7634042	chr3:72168082	C/T	cg18632154	chr3:73105046	PPP4R2	0.42	4.51	0.35	1.32e-5	Migraine - clinic-based;
UCEC	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	7.38	0.52	1.11e-11	Alzheimer's disease;
UCEC	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.1	18.46	0.84	4.01e-40	IgG glycosylation;
UCEC	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.75	7.6	0.53	3.24e-12	Tonsillectomy;
UCEC	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.35	4.58	0.35	9.84e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-6.16	-0.45	6.76e-9	Hemoglobin concentration;
UCEC	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.43	4.73	0.36	5.12e-6	Blood metabolite levels;
UCEC	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.51	-6.05	-0.45	1.13e-8	Lung cancer;
UCEC	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg24375607	chr4:120327624	NA	0.48	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.51	-5.16	-0.39	7.99e-7	Schizophrenia;
UCEC	cis	rs256277	0.507	rs11241146	chr5:111301962	G/T	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.53	-5.13	-0.39	9.08e-7	Coronary artery disease;
UCEC	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.69	7.51	0.53	5.17e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs244899	0.935	rs244896	chr5:167918663	G/T	cg06604206	chr5:167912465	RARS	-0.4	-4.78	-0.37	4.13e-6	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.61	5.81	0.43	3.76e-8	Aortic root size;
UCEC	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.55	7.95	0.55	4.63e-13	Total body bone mineral density;
UCEC	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.49	4.99	0.38	1.67e-6	Obesity-related traits;
UCEC	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg12310025	chr6:25882481	NA	-0.51	-4.58	-0.35	9.71e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
UCEC	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.68	-7.78	-0.54	1.2e-12	Menarche (age at onset);
UCEC	cis	rs7106204	0.514	rs2099890	chr11:24255948	C/T	ch.11.24196551F	chr11:24239977	NA	0.55	5.78	0.43	4.32e-8	Response to Homoharringtonine (cytotoxicity);
UCEC	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg03354898	chr7:1950403	MAD1L1	-0.52	-5.25	-0.4	5.25e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg16584290	chr5:462447	EXOC3	0.51	6.44	0.47	1.56e-9	Cystic fibrosis severity;
UCEC	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.59	6.38	0.47	2.15e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg25482853	chr8:67687455	SGK3	1.07	7.83	0.54	9.01e-13	Obesity-related traits;
UCEC	cis	rs7088591	0.717	rs4995515	chr10:59780466	T/C	cg11142981	chr10:60273225	BICC1	0.64	4.59	0.35	9.34e-6	Blood pressure;
UCEC	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.72	-6.71	-0.48	3.9e-10	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.52	-5.37	-0.4	3.04e-7	Prostate cancer;
UCEC	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.53	-4.89	-0.37	2.63e-6	Testicular germ cell tumor;
UCEC	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.44	-6.22	-0.46	4.81e-9	Plasma homocysteine levels (post-methionine load test);
UCEC	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg11901034	chr3:128598214	ACAD9	0.59	6.47	0.47	1.39e-9	IgG glycosylation;
UCEC	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg03859395	chr2:55845619	SMEK2	1.0	13.7	0.75	4.71e-28	Metabolic syndrome;
UCEC	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.67	7.64	0.53	2.55e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.58	5.26	0.4	4.91e-7	Corneal astigmatism;
UCEC	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.65	-5.99	-0.44	1.54e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg05925327	chr15:68127851	NA	-0.49	-5.59	-0.42	1.05e-7	Restless legs syndrome;
UCEC	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg23417306	chr2:180868811	CWC22	0.5	4.57	0.35	1.02e-5	Schizophrenia;
UCEC	cis	rs360071	0.528	rs360094	chr1:226064846	C/T	cg17950169	chr1:226067900	TMEM63A	-0.41	-4.69	-0.36	6.1e-6	Response to radiotherapy in prostate cancer (toxicity, rectal bleeding);
UCEC	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.61	-6.3	-0.46	3.26e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.6	-6.5	-0.47	1.16e-9	Type 2 diabetes;
UCEC	cis	rs200986	1	rs200986	chr6:27824766	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.48	-4.8	-0.37	3.93e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	5.05	0.38	1.3e-6	Mood instability;
UCEC	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.52	5.15	0.39	8.21e-7	Blood protein levels;
UCEC	cis	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg00614314	chr15:82944287	LOC80154	0.52	4.82	0.37	3.54e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
UCEC	cis	rs10510146	0.841	rs297222	chr10:127295894	C/T	cg07504718	chr10:127465376	MMP21	0.54	5.36	0.4	3.13e-7	Non-alcoholic fatty liver disease histology (other);
UCEC	cis	rs16937	0.711	rs10900465	chr1:205158183	C/T	cg00857998	chr1:205179979	DSTYK	0.52	4.67	0.36	6.87e-6	Schizophrenia;
UCEC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	4.68	0.36	6.59e-6	Personality dimensions;
UCEC	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.51	-5.63	-0.42	9.03e-8	Diastolic blood pressure;
UCEC	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	6.75	0.49	3.14e-10	Neuroticism;
UCEC	cis	rs1978968	0.717	rs8139578	chr22:18468208	A/G	cg03078520	chr22:18463400	MICAL3	-0.56	-7.4	-0.52	9.47e-12	Presence of antiphospholipid antibodies;
UCEC	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.73	7.86	0.54	7.56e-13	Multiple system atrophy;
UCEC	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.42	-4.97	-0.38	1.85e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.1	13.49	0.74	1.68e-27	Cognitive function;
UCEC	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.99	12.82	0.73	9.66e-26	Monocyte count;
UCEC	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.45	4.75	0.36	4.76e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.76	6.94	0.5	1.17e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.62	6.83	0.49	2.07e-10	Blood metabolite ratios;
UCEC	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.35	-5.21	-0.39	6.33e-7	Vitamin D levels;
UCEC	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.9	12.01	0.7	1.37e-23	Metabolic syndrome;
UCEC	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.5	5.67	0.42	7.23e-8	Tonsillectomy;
UCEC	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.55	5.32	0.4	3.78e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.59	-6.56	-0.48	8.72e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	8.63	0.58	9.44e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.52	4.55	0.35	1.14e-5	Cholesterol, total;
UCEC	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-5.24	-0.4	5.57e-7	Putamen volume;
UCEC	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.65	6.72	0.48	3.65e-10	Body mass index;
UCEC	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg23972785	chr8:11611189	GATA4	-0.35	-4.53	-0.35	1.2e-5	Neuroticism;
UCEC	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.62	7.6	0.53	3.21e-12	Menopause (age at onset);
UCEC	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.58	5.09	0.39	1.09e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.55	-0.42	1.3e-7	Hemoglobin concentration;
UCEC	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.25	-7.6	-0.53	3.14e-12	Schizophrenia;
UCEC	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.65	6.73	0.49	3.48e-10	Longevity;Endometriosis;
UCEC	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.63	-6.83	-0.49	2.05e-10	Initial pursuit acceleration;
UCEC	cis	rs892864	0.803	rs10520003	chr5:127846546	G/A	cg17313118	chr5:127157258	NA	0.76	4.7	0.36	6.05e-6	Multiple system atrophy;
UCEC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.57	-5.81	-0.43	3.7e-8	Aortic root size;
UCEC	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.5	6.06	0.45	1.09e-8	Coronary artery disease;
UCEC	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.72	-7.73	-0.54	1.59e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.59	5.58	0.42	1.11e-7	Corneal astigmatism;
UCEC	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg24127310	chr10:102502104	NA	1.12	11.22	0.68	1.69e-21	Alzheimer's disease;
UCEC	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg03959625	chr15:84868606	LOC388152	0.5	5.02	0.38	1.47e-6	Schizophrenia;
UCEC	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.52	-5.57	-0.42	1.17e-7	Body mass index;
UCEC	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03352830	chr11:487213	PTDSS2	0.77	5.1	0.39	1.02e-6	Body mass index;
UCEC	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.84	12.29	0.71	2.55e-24	Leprosy;
UCEC	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.5	6.87	0.49	1.69e-10	Homoarginine levels;
UCEC	cis	rs883565	0.792	rs1274958	chr3:39184959	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.56	-4.64	-0.36	7.8e-6	Handedness;
UCEC	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.74	-9.92	-0.63	4.6e-18	Gut microbiota (bacterial taxa);
UCEC	cis	rs10012307	1.000	rs58973050	chr4:137504064	A/C	cg12033966	chr4:138453416	PCDH18	-0.73	-5.13	-0.39	8.92e-7	DNA methylation (parent-of-origin);
UCEC	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg04154034	chr17:28927549	LRRC37B2	0.58	5.2	0.39	6.43e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	6.67	0.48	4.88e-10	Bone mineral density;
UCEC	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.5	4.52	0.35	1.28e-5	Ileal carcinoids;
UCEC	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.84	-5.34	-0.4	3.42e-7	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	7.35	0.52	1.3e-11	Coffee consumption (cups per day);
UCEC	cis	rs12644436	0.827	rs4425338	chr4:88776483	T/A	cg27179352	chr4:88029472	AFF1	0.41	4.61	0.36	8.6e-6	HIV-1 viral setpoint;
UCEC	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.78	-6.88	-0.49	1.61e-10	Caudate activity during reward;
UCEC	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.44	-0.57	2.77e-14	Total cholesterol levels;
UCEC	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg11494091	chr17:61959527	GH2	-0.5	-7.08	-0.5	5.57e-11	Prudent dietary pattern;
UCEC	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.65	-5.95	-0.44	1.92e-8	Parkinson's disease;
UCEC	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.4	4.85	0.37	3.16e-6	Height;
UCEC	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	0.93	13.38	0.74	3.31e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs17123764	0.892	rs12301824	chr12:50112861	A/T	cg20471783	chr12:50157085	TMBIM6	0.64	5.31	0.4	3.95e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg06671706	chr8:8559999	CLDN23	0.65	5.42	0.41	2.41e-7	Obesity-related traits;
UCEC	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.58	5.06	0.39	1.23e-6	Multiple sclerosis;
UCEC	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.52	5.07	0.39	1.18e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.62	7.56	0.53	4.03e-12	Warfarin maintenance dose;
UCEC	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.56	5.95	0.44	1.88e-8	Red blood cell count;
UCEC	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.55	-5.88	-0.44	2.62e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.36	-4.57	-0.35	1.02e-5	Monocyte count;
UCEC	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.45	5.93	0.44	2.06e-8	Coronary artery disease;
UCEC	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.53	0.35	1.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26031613	chr14:104095156	KLC1	-0.64	-6.53	-0.47	1.01e-9	Body mass index;
UCEC	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.55	-4.54	-0.35	1.16e-5	Depression;
UCEC	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.47	-0.47	1.38e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg04025307	chr7:1156635	C7orf50	0.68	7.72	0.54	1.63e-12	Longevity;Endometriosis;
UCEC	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	0.84	9.39	0.61	1.07e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.75	-7.54	-0.53	4.57e-12	Caffeine consumption;
UCEC	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.17	-8.53	-0.58	1.67e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.26	12.33	0.71	1.92e-24	Corneal structure;
UCEC	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7267348	0.550	rs562954	chr20:48092076	A/G	cg10342789	chr20:48770448	TMEM189;TMEM189-UBE2V1	-0.46	-4.81	-0.37	3.66e-6	Schizophrenia;
UCEC	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-4.97	-0.38	1.83e-6	Response to antipsychotic treatment;
UCEC	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.57	6.31	0.46	3.11e-9	Red blood cell count;
UCEC	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.53	5.09	0.39	1.1e-6	Menopause (age at onset);
UCEC	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.37	4.7	0.36	6.01e-6	Bone mineral density;
UCEC	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.66	5.88	0.44	2.69e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.56	5.95	0.44	1.87e-8	HDL cholesterol;
UCEC	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	13.81	0.75	2.49e-28	Chronic sinus infection;
UCEC	cis	rs17123764	0.818	rs12314878	chr12:49942208	G/A	cg20471783	chr12:50157085	TMBIM6	0.67	5.37	0.4	3.01e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.19	11.85	0.7	3.64e-23	Opioid sensitivity;
UCEC	cis	rs787274	1.000	rs787295	chr9:115541606	C/G	cg13803584	chr9:115635662	SNX30	0.6	4.77	0.37	4.4e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-0.93	-9.28	-0.61	2.01e-16	Height;
UCEC	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg17105886	chr17:28927953	LRRC37B2	0.5	4.5	0.35	1.35e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.73	-7.67	-0.53	2.13e-12	Blood protein levels;
UCEC	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.85	-0.54	8.17e-13	Migraine;Coronary artery disease;
UCEC	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06156847	chr2:113672199	IL1F7	0.33	4.55	0.35	1.12e-5	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.89	12.02	0.7	1.32e-23	Metabolic syndrome;
UCEC	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.68	-6.66	-0.48	5.19e-10	Aortic root size;
UCEC	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.71	7.58	0.53	3.6e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.46	-4.73	-0.36	5.32e-6	Breast cancer;
UCEC	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg18478394	chr8:109455254	TTC35	0.5	4.97	0.38	1.83e-6	Dupuytren's disease;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.47	-5.16	-0.39	8.03e-7	Pulmonary function;
UCEC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-5.16	-0.39	8.04e-7	Aortic root size;
UCEC	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	6.77	0.49	2.89e-10	Hip circumference adjusted for BMI;
UCEC	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.58	-0.42	1.14e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.62	5.99	0.44	1.57e-8	Lymphocyte counts;
UCEC	cis	rs1832871	1.000	rs827856	chr6:158705887	G/A	cg07215822	chr6:158701037	NA	-0.5	-4.96	-0.38	1.89e-6	Height;
UCEC	trans	rs9545047	0.604	rs1324868	chr13:79954175	A/G	cg02500152	chr12:48357316	TMEM106C	0.63	6.73	0.49	3.59e-10	Schizophrenia;
UCEC	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg05874882	chr4:1763078	NA	-0.56	-5.97	-0.44	1.7e-8	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg23791538	chr6:167370224	RNASET2	-0.58	-6.2	-0.46	5.52e-9	Crohn's disease;
UCEC	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.35	-4.9	-0.37	2.51e-6	Crohn's disease;
UCEC	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.82	7.31	0.52	1.57e-11	Bladder cancer;
UCEC	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.55	5.47	0.41	1.92e-7	Personality dimensions;
UCEC	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg06784218	chr1:46089804	CCDC17	-0.44	-5.01	-0.38	1.54e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.8	-10.04	-0.64	2.14e-18	Systemic sclerosis;
UCEC	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.69	7.48	0.52	6.3e-12	Breast cancer;
UCEC	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg01689657	chr7:91764605	CYP51A1	0.43	5.52	0.41	1.48e-7	Breast cancer;
UCEC	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg18755752	chr8:142205143	DENND3	-0.6	-5.65	-0.42	8.06e-8	Immature fraction of reticulocytes;
UCEC	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.76	8.7	0.58	6.1e-15	Facial morphology (factor 19);
UCEC	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.12	12.29	0.71	2.58e-24	Inflammatory skin disease;
UCEC	cis	rs13401104	0.796	rs10929169	chr2:237115532	C/T	cg23897927	chr2:237117786	ASB18	-0.52	-4.51	-0.35	1.34e-5	Educational attainment;
UCEC	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.75	-0.43	4.91e-8	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.77	7.83	0.54	9.05e-13	Ulcerative colitis;
UCEC	cis	rs5167	0.504	rs66771331	chr19:45457319	G/A	cg09555818	chr19:45449301	APOC2	0.46	6.01	0.44	1.39e-8	Blood protein levels;
UCEC	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.74	8.18	0.56	1.26e-13	Menopause (age at onset);
UCEC	cis	rs7246967	0.611	rs66866654	chr19:22813739	A/G	cg23217946	chr19:22817039	ZNF492	0.41	4.6	0.35	9.03e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18252515	chr7:66147081	NA	-0.5	-4.61	-0.36	8.79e-6	Aortic root size;
UCEC	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.85	5.28	0.4	4.59e-7	Diisocyanate-induced asthma;
UCEC	cis	rs6546886	0.917	rs11884748	chr2:74248451	A/C	cg14702570	chr2:74259524	NA	-0.43	-5.54	-0.42	1.37e-7	Dialysis-related mortality;
UCEC	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg20701182	chr2:24300061	SF3B14	0.77	6.13	0.45	7.78e-9	Lymphocyte counts;
UCEC	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.76e-17	Menopause (age at onset);
UCEC	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg03078520	chr22:18463400	MICAL3	-0.46	-4.71	-0.36	5.76e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.86	8.87	0.59	2.27e-15	Cognitive function;
UCEC	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	5.03	0.38	1.4e-6	Mood instability;
UCEC	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg25767906	chr1:53392781	SCP2	0.5	5.15	0.39	8.41e-7	Monocyte count;
UCEC	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg22857025	chr5:266934	NA	-0.84	-6.69	-0.48	4.29e-10	Asthma (childhood onset);
UCEC	cis	rs10924970	0.967	rs12741262	chr1:235406849	T/C	cg26050004	chr1:235667680	B3GALNT2	0.42	4.5	0.35	1.35e-5	Asthma;
UCEC	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.31	-10.43	-0.65	2.05e-19	Hip circumference adjusted for BMI;
UCEC	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.59	-5.85	-0.43	3.14e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs7078219	0.505	rs10883362	chr10:101286984	C/T	cg09788492	chr10:101292477	NKX2-3	0.42	4.58	0.35	9.79e-6	Dental caries;
UCEC	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	5.98	0.44	1.59e-8	Personality dimensions;
UCEC	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-5.91	-0.44	2.24e-8	Prostate cancer;
UCEC	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg23070574	chr3:14187308	XPC	0.46	5.19	0.39	6.97e-7	Ovarian reserve;
UCEC	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.75	-8.57	-0.58	1.32e-14	Extraversion;
UCEC	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg12610070	chr10:71211762	TSPAN15	-0.35	-4.71	-0.36	5.64e-6	Venous thromboembolism;
UCEC	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.59	0.62	3.15e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.88	10.22	0.64	7.54e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg21486944	chr6:28411378	ZSCAN23	0.48	4.98	0.38	1.78e-6	Cardiac Troponin-T levels;
UCEC	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg19318889	chr4:1322082	MAEA	0.45	5.47	0.41	1.91e-7	Obesity-related traits;
UCEC	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg17420585	chr12:42539391	GXYLT1	0.4	5.15	0.39	8.23e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg20936604	chr3:58311152	NA	-0.6	-4.86	-0.37	3.03e-6	Cholesterol, total;
UCEC	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.64	6.8	0.49	2.43e-10	Menopause (age at onset);
UCEC	cis	rs7246967	0.673	rs28649847	chr19:22811540	G/T	cg01485075	chr19:22817371	ZNF492	0.4	4.52	0.35	1.27e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.96	5.54	0.42	1.35e-7	Type 2 diabetes;
UCEC	cis	rs17106184	1.000	rs72900932	chr1:51107959	T/C	cg07174182	chr1:51127561	FAF1	-0.73	-4.69	-0.36	6.08e-6	Type 2 diabetes;
UCEC	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg06970220	chr1:156163860	SLC25A44	0.46	4.97	0.38	1.86e-6	Testicular germ cell tumor;
UCEC	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.54	-0.42	1.33e-7	Alcohol dependence;
UCEC	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.41	-4.94	-0.38	2.1e-6	Refractive error;
UCEC	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.64	6.57	0.48	8.2e-10	Menopause (age at onset);
UCEC	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.87	-9.71	-0.63	1.57e-17	Blood metabolite levels;
UCEC	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg27624424	chr6:160112604	SOD2	0.56	4.51	0.35	1.32e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.8	-7.99	-0.55	3.55e-13	Schizophrenia;
UCEC	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.96	10.49	0.65	1.47e-19	Cognitive function;
UCEC	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-0.91	-9.15	-0.6	4.52e-16	Height;
UCEC	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.61	4.77	0.37	4.39e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-0.87	-6.9	-0.49	1.47e-10	Pediatric areal bone mineral density (radius);
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.67	6.74	0.49	3.41e-10	Breast cancer;
UCEC	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.92	10.93	0.67	1.03e-20	Monocyte count;
UCEC	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.28	0.4	4.47e-7	Total body bone mineral density;
UCEC	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.56	4.99	0.38	1.68e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.74	7.54	0.53	4.55e-12	Schizophrenia;
UCEC	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.54	6.86	0.49	1.79e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.46	4.81	0.37	3.74e-6	Cleft lip with or without cleft palate;
UCEC	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.44	-5.88	-0.44	2.7e-8	IgG glycosylation;
UCEC	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg03859395	chr2:55845619	SMEK2	0.56	5.76	0.43	4.86e-8	Metabolic syndrome;
UCEC	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.17	-14.14	-0.76	3.31e-29	Breast cancer;
UCEC	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.63	-7.39	-0.52	1.02e-11	Prevalent atrial fibrillation;
UCEC	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.47	-4.63	-0.36	8.05e-6	Dental caries;
UCEC	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.77	-6.78	-0.49	2.68e-10	Initial pursuit acceleration;
UCEC	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg21486944	chr6:28411378	ZSCAN23	-0.45	-4.93	-0.38	2.19e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-16.55	-0.81	2.17e-35	Myeloid white cell count;
UCEC	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-5.35	-0.4	3.27e-7	Initial pursuit acceleration;
UCEC	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	4.95	0.38	1.99e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs4074961	0.527	rs10908356	chr1:38038388	G/A	cg17933807	chr1:38061675	GNL2	0.91	12.47	0.72	8.31e-25	Axial length;
UCEC	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.8	8.44	0.57	2.81e-14	Longevity;Endometriosis;
UCEC	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.5	-5.21	-0.39	6.19e-7	Schizophrenia;
UCEC	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg01426195	chr3:39028469	NA	-0.56	-6.23	-0.46	4.76e-9	Handedness;
UCEC	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-5.93	-0.44	2.08e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.58	-5.21	-0.39	6.22e-7	Gut microbiome composition (summer);
UCEC	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg19875535	chr5:140030758	IK	0.44	4.87	0.37	2.91e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.51	5.97	0.44	1.7e-8	Nonalcoholic fatty liver disease;
UCEC	cis	rs7072216	0.881	rs2182169	chr10:100148004	T/C	cg19567339	chr10:100142640	NA	0.61	8.56	0.58	1.42e-14	Metabolite levels;
UCEC	cis	rs9309473	0.528	rs11898362	chr2:73565293	G/A	cg20560298	chr2:73613845	ALMS1	-0.58	-5.4	-0.41	2.57e-7	Metabolite levels;
UCEC	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.49	-5.61	-0.42	9.53e-8	Glomerular filtration rate (creatinine);
UCEC	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4908768	0.725	rs11121214	chr1:8728665	C/T	cg13081009	chr1:8430745	RERE	0.48	4.8	0.37	3.91e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg21486944	chr6:28411378	ZSCAN23	-0.5	-5.45	-0.41	2.12e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.59	6.23	0.46	4.77e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.68	6.8	0.49	2.5e-10	Type 2 diabetes;
UCEC	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.87	-0.49	1.72e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.05	11.52	0.69	2.74e-22	IgG glycosylation;
UCEC	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg24733560	chr20:60626293	TAF4	0.4	4.77	0.37	4.32e-6	Body mass index;
UCEC	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.31	0.46	3.13e-9	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.55	5.96	0.44	1.82e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.53	5.85	0.43	3.08e-8	QRS complex (12-leadsum);
UCEC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg04310649	chr10:35416472	CREM	-0.48	-4.92	-0.38	2.25e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs4713118	0.513	rs200971	chr6:27858904	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.5	-4.97	-0.38	1.85e-6	Parkinson's disease;
UCEC	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.45	4.9	0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4953318	0.796	rs10168349	chr2:46360907	G/C	cg12428440	chr2:46370979	PRKCE	0.42	4.57	0.35	1e-5	Red blood cell count;Hematocrit;Red blood cell traits;
UCEC	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.71	7.13	0.51	4.15e-11	Joint mobility (Beighton score);
UCEC	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.65	-0.42	8.25e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.7	7.13	0.51	4.13e-11	Menopause (age at onset);
UCEC	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.39	5.85	0.43	3.06e-8	Body mass index;
UCEC	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg19743168	chr1:23544995	NA	0.42	6.01	0.44	1.4e-8	Height;
UCEC	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	7.31	0.52	1.61e-11	Platelet count;
UCEC	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.9	-0.37	2.47e-6	Aortic root size;
UCEC	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.55	5.45	0.41	2.05e-7	Gestational age at birth (maternal effect);
UCEC	cis	rs17106184	0.892	rs72900903	chr1:51053585	A/G	cg07174182	chr1:51127561	FAF1	-0.8	-5.04	-0.38	1.35e-6	Type 2 diabetes;
UCEC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.72	-8.15	-0.56	1.5e-13	Menarche (age at onset);
UCEC	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.61	-6.72	-0.48	3.66e-10	Cardiac Troponin-T levels;
UCEC	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg13206674	chr6:150067644	NUP43	0.52	4.74	0.36	5.07e-6	Testicular germ cell tumor;
UCEC	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg26329756	chr15:99250482	IGF1R	-0.67	-6.94	-0.5	1.15e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg20399509	chr21:47717575	C21orf57	-0.46	-4.95	-0.38	2.02e-6	Testicular germ cell tumor;
UCEC	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	5.32	0.4	3.75e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	7.38	0.52	1.06e-11	Schizophrenia;
UCEC	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.58	-6.17	-0.45	6.32e-9	Bipolar disorder;
UCEC	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg16616514	chr4:6324629	PPP2R2C	0.43	5.2	0.39	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.16	9.93	0.63	4.35e-18	Uric acid levels;
UCEC	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-8.27	-0.56	7.28e-14	Hemoglobin concentration;
UCEC	cis	rs11697848	1.000	rs2268324	chr20:48529761	C/T	cg17849948	chr20:48532315	SPATA2	-1.05	-5.05	-0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg01262667	chr19:19385393	TM6SF2	0.39	5.12	0.39	9.55e-7	Tonsillectomy;
UCEC	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	0.76	10.28	0.65	5.18e-19	Gut microbiome composition (winter);
UCEC	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.67	-0.42	7.38e-8	Monocyte percentage of white cells;
UCEC	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.1	-0.39	1.03e-6	Aortic root size;
UCEC	cis	rs1028488	0.511	rs7762492	chr6:170704946	C/G	cg20370364	chr6:170703943	FAM120B	0.47	4.59	0.35	9.37e-6	Interferon alpha levels in systemic lupus erythematosus;
UCEC	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	5.08	0.39	1.13e-6	Breast cancer;
UCEC	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-6.64	-0.48	5.7e-10	Total cholesterol levels;
UCEC	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	15.37	0.79	2.15e-32	Colorectal cancer;
UCEC	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.81	11.15	0.68	2.68e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.53	5.01	0.38	1.54e-6	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs6722750	0.901	rs6710681	chr2:64413221	A/G	cg22352474	chr2:64371530	PELI1	-0.47	-4.51	-0.35	1.31e-5	Neuroticism;
UCEC	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.69	-8.67	-0.58	7.4e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-5.38	-0.41	2.87e-7	Chronic sinus infection;
UCEC	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	6.53	0.47	9.92e-10	Menarche (age at onset);
UCEC	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.6	6.56	0.48	8.38e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg26721908	chr21:47610096	LSS	-0.43	-5.43	-0.41	2.32e-7	Testicular germ cell tumor;
UCEC	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.91	-0.49	1.4e-10	Diabetic kidney disease;
UCEC	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg15837086	chr1:46506065	PIK3R3	-0.41	-5.29	-0.4	4.28e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.46	-4.64	-0.36	7.5e-6	Age at first birth;
UCEC	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg13683864	chr3:40499215	RPL14	-0.96	-10.44	-0.65	1.95e-19	Renal cell carcinoma;
UCEC	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.27	-8.5	-0.57	1.93e-14	Diabetic kidney disease;
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.56	-5.11	-0.39	1e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.5	5.74	0.43	5.24e-8	Blood metabolite ratios;
UCEC	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg11569703	chr11:65557185	OVOL1	0.54	6.81	0.49	2.37e-10	Acne (severe);
UCEC	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.69	7.6	0.53	3.2e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.8	8.89	0.59	2.03e-15	Menopause (age at onset);
UCEC	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.61	0.36	8.77e-6	Height;
UCEC	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg07636037	chr3:49044803	WDR6	-0.62	-4.9	-0.37	2.53e-6	Menarche (age at onset);
UCEC	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-8.08	-0.55	2.18e-13	Total cholesterol levels;
UCEC	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	0.82	6.16	0.45	6.52e-9	Red blood cell traits;
UCEC	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.03	12.13	0.71	6.77e-24	Corneal structure;
UCEC	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.44	-5.54	-0.42	1.39e-7	Dupuytren's disease;
UCEC	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg13683864	chr3:40499215	RPL14	0.67	7.11	0.51	4.57e-11	Renal cell carcinoma;
UCEC	cis	rs600626	0.529	rs11236525	chr11:75467545	C/G	cg24262691	chr11:75473276	NA	0.38	4.57	0.35	1.04e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
UCEC	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.47	5.88	0.44	2.71e-8	Electrocardiographic conduction measures;
UCEC	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.6	4.91	0.38	2.35e-6	Cognitive test performance;
UCEC	cis	rs10242455	0.702	rs73713521	chr7:99188649	G/A	cg18809830	chr7:99032528	PTCD1	-0.89	-4.8	-0.37	3.92e-6	Blood metabolite levels;
UCEC	cis	rs7307889	0.793	rs10161036	chr12:6005072	C/T	cg10294363	chr12:6480192	SCNN1A	0.58	4.67	0.36	6.85e-6	Obesity-related traits;
UCEC	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.71	-6.8	-0.49	2.4e-10	Aortic root size;
UCEC	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	7.88	0.54	6.71e-13	Smoking behavior;
UCEC	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.56	-5.7	-0.43	6.22e-8	Breast cancer;
UCEC	cis	rs6604026	0.524	rs532834	chr1:93468062	A/T	cg17283838	chr1:93427260	FAM69A	0.43	4.74	0.36	4.92e-6	Multiple sclerosis;
UCEC	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.68	5.16	0.39	7.75e-7	HIV-1 control;
UCEC	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg27121462	chr16:89883253	FANCA	-0.49	-4.66	-0.36	6.98e-6	Vitiligo;
UCEC	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-5.81	-0.43	3.77e-8	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.61	0.36	8.76e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-9.68	-0.62	1.92e-17	Height;
UCEC	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg20637307	chr2:213403960	ERBB4	0.76	8.16	0.56	1.39e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7070678	0.662	rs11817300	chr10:29798785	A/T	cg07724896	chr10:29780678	SVIL	-0.56	-5.06	-0.39	1.24e-6	Platelet thrombus formation;
UCEC	cis	rs1719271	0.831	rs1002311	chr15:65188424	C/G	cg13373318	chr15:65686654	IGDCC4	-0.42	-4.52	-0.35	1.29e-5	Platelet count;
UCEC	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs7597155	0.566	rs4852944	chr2:69950772	C/G	cg02498382	chr2:70120550	SNRNP27	-0.45	-4.95	-0.38	1.98e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-6.01	-0.44	1.37e-8	Chronic sinus infection;
UCEC	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.59	5.24	0.4	5.37e-7	Menarche (age at onset);
UCEC	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	0.96	10.46	0.65	1.74e-19	Left atrial antero-posterior diameter;
UCEC	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.67	7.55	0.53	4.22e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs17123764	0.710	rs1049986	chr12:50158544	A/G	cg20471783	chr12:50157085	TMBIM6	0.63	4.98	0.38	1.79e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg18755752	chr8:142205143	DENND3	-0.53	-5.5	-0.41	1.6e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	0.96	6.56	0.48	8.61e-10	Type 2 diabetes nephropathy;
UCEC	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg14067834	chr17:29058358	SUZ12P	0.58	4.79	0.37	3.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.46	4.79	0.37	3.99e-6	Autism;
UCEC	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.89	6.35	0.46	2.58e-9	Major depressive disorder;
UCEC	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	5.63	0.42	8.88e-8	Tonsillectomy;
UCEC	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg18279126	chr7:2041391	MAD1L1	-0.43	-5.07	-0.39	1.18e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.66	-6.5	-0.47	1.18e-9	Diastolic blood pressure;
UCEC	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.52	-4.57	-0.35	1.04e-5	Colorectal cancer;
UCEC	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.56	-5.9	-0.44	2.46e-8	Prostate cancer;
UCEC	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg03959625	chr15:84868606	LOC388152	0.47	4.83	0.37	3.42e-6	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg06784218	chr1:46089804	CCDC17	0.4	4.61	0.36	8.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3780378	0.967	rs7039518	chr9:5046881	T/C	cg02405213	chr9:5042618	JAK2	-0.47	-4.55	-0.35	1.14e-5	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-5.59	-0.42	1.08e-7	Morning vs. evening chronotype;
UCEC	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.42	4.58	0.35	9.78e-6	Height;
UCEC	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-5.98	-0.44	1.6e-8	Blood metabolite levels;
UCEC	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.94	-10.6	-0.66	7.41e-20	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11761441	0.640	rs10085724	chr7:87382	C/T	cg06458707	chr7:1083209	C7orf50	0.26	4.79	0.37	4.02e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-4.95	-0.38	2.02e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.7	6.01	0.44	1.37e-8	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.75	8.26	0.56	7.73e-14	Menopause (age at onset);
UCEC	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.57	5.99	0.44	1.57e-8	Initial pursuit acceleration;
UCEC	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.67	-7.43	-0.52	8.16e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	6.79	0.49	2.64e-10	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.61	5.33	0.4	3.7e-7	Uric acid levels;
UCEC	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.48	7.34	0.52	1.32e-11	Primary biliary cholangitis;
UCEC	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.5	5.85	0.43	3.06e-8	Height;
UCEC	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.6	-5.84	-0.43	3.2e-8	Lung cancer;
UCEC	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.69	-7.53	-0.53	4.68e-12	Hypospadias;
UCEC	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22117172	chr7:91764530	CYP51A1	0.43	5.43	0.41	2.28e-7	Breast cancer;
UCEC	cis	rs11235843	1.000	rs72974833	chr11:73375104	A/C	cg23931323	chr11:73372278	PLEKHB1	0.73	4.73	0.36	5.26e-6	Hand grip strength;
UCEC	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg13695892	chr22:41940480	POLR3H	-0.65	-5.31	-0.4	4.03e-7	Vitiligo;
UCEC	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg06096015	chr1:231504339	EGLN1	0.48	5.58	0.42	1.13e-7	Hemoglobin concentration;
UCEC	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs4869931	1.000	rs4869931	chr6:151009889	A/G	cg06471296	chr6:150259601	NA	0.35	4.57	0.35	1.01e-5	Systolic blood pressure in sickle cell anemia;
UCEC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg05695927	chr15:45694626	SPATA5L1	0.52	5.2	0.39	6.63e-7	Homoarginine levels;
UCEC	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.92	12.33	0.71	1.97e-24	Metabolic syndrome;
UCEC	cis	rs10924970	0.967	rs4659721	chr1:235426917	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.68	0.36	6.54e-6	Asthma;
UCEC	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.55	-6.1	-0.45	9.09e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.66	5.28	0.4	4.5e-7	Morning vs. evening chronotype;
UCEC	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.61	-7.41	-0.52	9.01e-12	Hemoglobin concentration;
UCEC	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.45	6.18	0.45	5.86e-9	Prostate cancer;
UCEC	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.66	-5.85	-0.43	3.09e-8	Depression;
UCEC	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	4.97	0.38	1.88e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.78	7.11	0.51	4.81e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.67	-7.3	-0.52	1.7e-11	Coronary artery disease;
UCEC	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.56	-5.66	-0.42	7.75e-8	White matter hyperintensity burden;
UCEC	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-4.53	-0.35	1.2e-5	Hepatocellular carcinoma;
UCEC	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.23	-19.12	-0.84	1.07e-41	Exhaled nitric oxide output;
UCEC	cis	rs10254160	1.000	rs4730545	chr7:112067070	A/G	cg12767726	chr7:112758502	LOC401397	-1.08	-4.85	-0.37	3.05e-6	Parental extreme longevity (95 years and older);
UCEC	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.02	-8.69	-0.58	6.37e-15	White matter hyperintensity burden;
UCEC	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.7	-6.07	-0.45	1.03e-8	Diastolic blood pressure;
UCEC	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.78	7.83	0.54	8.85e-13	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.7	-7.68	-0.54	2.04e-12	Breast cancer;
UCEC	cis	rs9356171	0.572	rs62435477	chr6:164328670	C/T	cg25752492	chr6:164341247	NA	-0.57	-5.6	-0.42	1.03e-7	Diisocyanate-induced asthma;
UCEC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg13870426	chr17:30244630	NA	-0.64	-4.74	-0.36	5.06e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.48	-4.81	-0.37	3.73e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.65	6.15	0.45	7.06e-9	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs2213920	0.749	rs7467654	chr9:118253677	C/T	cg13918206	chr9:118159781	DEC1	0.72	4.85	0.37	3.06e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg03859395	chr2:55845619	SMEK2	0.98	13.72	0.75	4.24e-28	Metabolic syndrome;
UCEC	cis	rs11693319	1.000	rs1016799	chr2:179749332	C/T	cg26389888	chr2:178973147	PDE11A	0.59	4.88	0.37	2.75e-6	Blood pressure measurement (cold pressor test);
UCEC	cis	rs7246967	1.000	rs7257127	chr19:23056699	A/G	cg08271804	chr19:22816896	ZNF492	0.53	5.12	0.39	9.4e-7	Bronchopulmonary dysplasia;
UCEC	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.89	10.81	0.67	2.09e-20	IgG glycosylation;
UCEC	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.86	-10.45	-0.65	1.87e-19	Primary sclerosing cholangitis;
UCEC	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg13575925	chr12:9217583	LOC144571	-0.44	-5.32	-0.4	3.85e-7	Sjögren's syndrome;
UCEC	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.74	-0.43	5.24e-8	Chronic sinus infection;
UCEC	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.59	8.39	0.57	3.64e-14	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.84	7.71	0.54	1.71e-12	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.62	7.08	0.5	5.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15541040	chr2:3486749	NA	-0.67	-6.31	-0.46	3.18e-9	Neurofibrillary tangles;
UCEC	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.76	5.81	0.43	3.71e-8	Paclitaxel disposition in epithelial ovarian cancer;
UCEC	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.66	-5.74	-0.43	5.17e-8	Initial pursuit acceleration;
UCEC	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18402987	chr7:1209562	NA	0.47	4.77	0.37	4.41e-6	Longevity;Endometriosis;
UCEC	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.75	7.97	0.55	3.99e-13	Primary sclerosing cholangitis;
UCEC	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.51	7.17	0.51	3.34e-11	Height;
UCEC	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.58	-6.38	-0.47	2.21e-9	Lewy body disease;
UCEC	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.47	5.24	0.4	5.55e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.82	-9.39	-0.61	1.08e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs9393777	0.668	rs16897515	chr6:27278020	A/C	cg22548220	chr6:27277996	POM121L2	-0.5	-4.92	-0.38	2.24e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.59	-4.62	-0.36	8.35e-6	Blood pressure (smoking interaction);
UCEC	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.65	5.72	0.43	5.72e-8	Systolic blood pressure;
UCEC	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.58	5.47	0.41	1.87e-7	Schizophrenia;
UCEC	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.52	5.39	0.41	2.69e-7	Dupuytren's disease;
UCEC	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg18681998	chr4:17616180	MED28	0.7	7.35	0.52	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.77	5.97	0.44	1.71e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg04756594	chr16:24857601	SLC5A11	0.48	5.63	0.42	8.94e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	1.0	13.26	0.74	6.7399999999999993e-27	Monocyte count;
UCEC	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg00343986	chr7:65444356	GUSB	0.49	4.53	0.35	1.2e-5	Aortic root size;
UCEC	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.7	6.04	0.45	1.22e-8	Morning vs. evening chronotype;
UCEC	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.18	7.05	0.5	6.56e-11	Eosinophil percentage of granulocytes;
UCEC	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.68	6.15	0.45	6.81e-9	Aortic root size;
UCEC	cis	rs11129176	0.881	rs11129177	chr3:25051352	G/C	cg02506578	chr3:25824554	NGLY1	0.6	4.72	0.36	5.4e-6	Optic disc area;
UCEC	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.57	5.5	0.41	1.61e-7	Radiation response;
UCEC	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.8	-6.6	-0.48	6.94e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-6.36	-0.46	2.35e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs9463078	0.506	rs4714820	chr6:44736737	T/A	cg25276700	chr6:44698697	NA	0.43	4.84	0.37	3.2e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.55	4.52	0.35	1.29e-5	Preschool internalizing problems;
UCEC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-0.94	-6.02	-0.44	1.32e-8	Breast cancer;
UCEC	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.49	4.78	0.37	4.21e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs782590	0.811	rs9917139	chr2:55728217	G/T	cg03859395	chr2:55845619	SMEK2	0.79	8.81	0.59	3.32e-15	Metabolic syndrome;
UCEC	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	6.34	0.46	2.68e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	4.89	0.37	2.65e-6	Mood instability;
UCEC	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.1	10.25	0.65	6.33e-19	Vitiligo;
UCEC	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.59	0.42	1.08e-7	Breast cancer;
UCEC	cis	rs1150668	0.965	rs1150690	chr6:28165298	C/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.49	-4.67	-0.36	6.72e-6	Pubertal anthropometrics;
UCEC	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.67	6.03	0.45	1.28e-8	Breast cancer;
UCEC	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.58	-5.83	-0.43	3.37e-8	Hepatocellular carcinoma;
UCEC	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.41	-9.26	-0.61	2.27e-16	Gout;
UCEC	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-4.67	-0.36	6.59e-6	Blood metabolite levels;
UCEC	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.9	-6.76	-0.49	3.1e-10	Exhaled nitric oxide output;
UCEC	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.66	-6.58	-0.48	7.76e-10	Tonsillectomy;
UCEC	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg14078730	chr11:63896557	MACROD1	0.67	5.31	0.4	4.02e-7	Mean platelet volume;
UCEC	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.65	5.33	0.4	3.58e-7	Systolic blood pressure;
UCEC	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.57	6.43	0.47	1.66e-9	Red blood cell count;
UCEC	cis	rs752092	0.775	rs4965806	chr15:101752435	G/A	cg19997662	chr15:101784653	CHSY1	-0.57	-7.04	-0.5	6.7e-11	Corneal structure;
UCEC	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.58	5.43	0.41	2.3e-7	Skin colour saturation;
UCEC	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.7	-7.67	-0.53	2.2e-12	Breast cancer;
UCEC	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.61	5.31	0.4	3.89e-7	Heart rate;
UCEC	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.49	4.8	0.37	3.91e-6	Menarche (age at onset);
UCEC	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.1	-0.39	1.04e-6	Colorectal cancer;
UCEC	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.59	6.01	0.44	1.4e-8	Colorectal cancer;
UCEC	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	5.57	0.42	1.17e-7	Coffee consumption (cups per day);
UCEC	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.54	6.3	0.46	3.21e-9	Menarche (age at onset);
UCEC	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg01181863	chr3:195395398	SDHAP2	-0.53	-5.25	-0.4	5.2e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9470794	0.831	rs76379664	chr6:37992274	G/A	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.52	5.36	0.4	3.17e-7	Monocyte count;
UCEC	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.51	5.12	0.39	9.56e-7	Cleft lip with or without cleft palate;
UCEC	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg06521331	chr12:34319734	NA	-0.58	-4.56	-0.35	1.08e-5	Morning vs. evening chronotype;
UCEC	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	4.92	0.38	2.25e-6	Menopause (age at onset);
UCEC	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.66	-6.21	-0.46	5.12e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.79	9.01	0.6	1.02e-15	Bone mineral density;
UCEC	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	0.94	12.23	0.71	3.52e-24	Primary sclerosing cholangitis;
UCEC	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.53	5.0	0.38	1.58e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg16351881	chr16:2010026	NDUFB10	0.46	4.53	0.35	1.19e-5	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs2415984	0.846	rs12433096	chr14:46839278	G/C	cg14871534	chr14:47121158	RPL10L	0.38	4.51	0.35	1.31e-5	Number of children ever born;
UCEC	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	1.0	12.47	0.72	8.44e-25	Colorectal adenoma (advanced);
UCEC	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.51	-4.56	-0.35	1.09e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.01	5.81	0.43	3.7e-8	Diabetic retinopathy;
UCEC	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.44	-5.11	-0.39	9.87e-7	Subjective well-being;
UCEC	cis	rs6919211	0.842	rs9321411	chr6:133998430	A/G	cg10373887	chr6:134274107	TBPL1	-0.52	-4.51	-0.35	1.31e-5	Coronary artery disease;
UCEC	cis	rs6882716	1.000	rs6882716	chr5:10797886	G/A	cg14521931	chr5:10832172	NA	-0.55	-4.6	-0.36	8.89e-6	Alcohol consumption (maxi-drinks);
UCEC	cis	rs10924970	0.649	rs12748827	chr1:235450687	C/T	cg26050004	chr1:235667680	B3GALNT2	0.49	4.7	0.36	5.94e-6	Asthma;
UCEC	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.6	5.64	0.42	8.37e-8	Corneal astigmatism;
UCEC	cis	rs2213920	0.568	rs6478166	chr9:118213548	T/C	cg13918206	chr9:118159781	DEC1	0.77	4.88	0.37	2.68e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.63	5.04	0.38	1.34e-6	Bladder cancer;
UCEC	cis	rs11023332	0.800	rs12271890	chr11:14934686	A/G	cg19336497	chr11:14380999	RRAS2	-0.34	-5.01	-0.38	1.56e-6	Adiponectin levels;Vitamin D levels;
UCEC	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.14	0.51	3.93e-11	Motion sickness;
UCEC	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.51	4.53	0.35	1.22e-5	Menarche (age at onset);
UCEC	cis	rs17123764	0.818	rs11169092	chr12:50008602	C/G	cg20471783	chr12:50157085	TMBIM6	0.63	5.42	0.41	2.42e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	1.07	7.72	0.54	1.64e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg24562669	chr7:97807699	LMTK2	0.61	8.15	0.56	1.46e-13	Breast cancer;
UCEC	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg03714773	chr7:91764589	CYP51A1	0.46	5.67	0.42	7.37e-8	Breast cancer;
UCEC	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.63	5.63	0.42	8.91e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.47	-5.23	-0.4	5.71e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.5	5.31	0.4	4.02e-7	Type 2 diabetes;
UCEC	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.6	7.13	0.51	4.14e-11	Multiple myeloma;
UCEC	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg04155231	chr12:9217510	LOC144571	0.43	5.53	0.42	1.39e-7	Sjögren's syndrome;
UCEC	cis	rs883565	0.569	rs784489	chr3:39173426	T/C	cg01426195	chr3:39028469	NA	0.65	7.93	0.55	5.02e-13	Handedness;
UCEC	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.22	-0.4	6.06e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg09251680	chr3:45801144	SLC6A20	0.37	4.55	0.35	1.1e-5	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.37	-0.46	2.34e-9	Monocyte count;
UCEC	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	5.28	0.4	4.62e-7	Height;
UCEC	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.55	-4.97	-0.38	1.87e-6	Corneal astigmatism;
UCEC	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.57	5.63	0.42	8.77e-8	Blood metabolite levels;
UCEC	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-6.6	-0.48	7.17e-10	Morning vs. evening chronotype;
UCEC	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	11.84	0.7	3.95e-23	Prudent dietary pattern;
UCEC	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.8	8.11	0.56	1.88e-13	Joint mobility (Beighton score);
UCEC	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg23018236	chr17:30244563	NA	-0.67	-4.9	-0.37	2.53e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.84	-0.43	3.17e-8	Fear of minor pain;
UCEC	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.3	-0.52	1.68e-11	Heart rate;
UCEC	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-4.61	-0.36	8.75e-6	Fear of minor pain;
UCEC	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg22166914	chr1:53195759	ZYG11B	0.57	5.7	0.43	6.33e-8	Monocyte count;
UCEC	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg04310649	chr10:35416472	CREM	-0.5	-5.05	-0.38	1.29e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2172802	0.543	rs1497897	chr4:62544055	T/A	cg04118610	chr4:62707027	LPHN3	0.4	4.52	0.35	1.29e-5	Partial epilepsies;
UCEC	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.51	-5.05	-0.38	1.28e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg22166914	chr1:53195759	ZYG11B	0.78	8.79	0.59	3.54e-15	Monocyte count;
UCEC	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	6.8	0.49	2.44e-10	Coffee consumption (cups per day);
UCEC	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.52	5.05	0.38	1.28e-6	Height;
UCEC	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.55	-5.09	-0.39	1.1e-6	Initial pursuit acceleration;
UCEC	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	5.61	0.42	9.68e-8	Coronary artery disease;
UCEC	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.33	-0.74	4.45e-27	Height;
UCEC	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg21770322	chr7:97807741	LMTK2	0.49	6.15	0.45	7.12e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.41	-4.67	-0.36	6.81e-6	Prostate cancer;
UCEC	cis	rs853679	0.527	rs707907	chr6:28291240	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.5	-5.16	-0.39	7.74e-7	Depression;
UCEC	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.66	-6.45	-0.47	1.49e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.67	-8.48	-0.57	2.19e-14	Bipolar disorder;
UCEC	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.55	6.68	0.48	4.54e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg00339695	chr16:24857497	SLC5A11	-0.48	-5.65	-0.42	8.1e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.51	5.84	0.43	3.28e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg12740337	chr6:28058973	ZSCAN12L1	0.38	4.71	0.36	5.71e-6	Depression;
UCEC	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	14.53	0.77	3.12e-30	Height;
UCEC	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	6.86	0.49	1.75e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg18681998	chr4:17616180	MED28	0.84	11.01	0.67	6.34e-21	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg07645718	chr20:61493192	TCFL5	0.68	4.52	0.35	1.27e-5	Obesity-related traits;
UCEC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.71	-5.06	-0.38	1.25e-6	Aortic root size;
UCEC	cis	rs17106184	1.000	rs57183177	chr1:51379945	A/G	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.51	5.75	0.43	4.9e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg00316803	chr15:76480434	C15orf27	-0.46	-5.25	-0.4	5.2e-7	Blood metabolite levels;
UCEC	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	1.0	10.91	0.67	1.12e-20	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg21053147	chr12:120880522	NA	0.72	5.26	0.4	4.97e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg05484376	chr2:27715224	FNDC4	0.32	4.51	0.35	1.34e-5	Total body bone mineral density;
UCEC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.47	5.4	0.41	2.6e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.56	6.1	0.45	9.08e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.91	6.44	0.47	1.58e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.53	6.06	0.45	1.1e-8	Menopause (age at onset);
UCEC	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	4.69	0.36	6.32e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.14	14.02	0.76	6.91e-29	Cognitive function;
UCEC	cis	rs4654899	0.629	rs7515279	chr1:21172774	C/T	cg01072550	chr1:21505969	NA	0.53	5.45	0.41	2.08e-7	Superior frontal gyrus grey matter volume;
UCEC	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-6.88	-0.49	1.64e-10	Morning vs. evening chronotype;
UCEC	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.551	rs34907478	chr19:22928831	T/C	cg24889512	chr19:22816950	ZNF492	0.63	6.59	0.48	7.27e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13683864	chr3:40499215	RPL14	-0.89	-8.69	-0.58	6.63e-15	Renal cell carcinoma;
UCEC	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.46	4.72	0.36	5.49e-6	Aortic root size;
UCEC	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.63	-6.26	-0.46	3.98e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.6	6.03	0.45	1.24e-8	Lung cancer;
UCEC	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.38	4.68	0.36	6.45e-6	QRS complex (12-leadsum);
UCEC	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.12	-7.58	-0.53	3.64e-12	Diabetic kidney disease;
UCEC	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.65	5.37	0.4	3.01e-7	Menarche (age at onset);
UCEC	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg11632617	chr15:75315747	PPCDC	-0.6	-6.76	-0.49	3.02e-10	Lung cancer;
UCEC	cis	rs2302190	0.769	rs7218778	chr17:56664248	T/G	cg12560992	chr17:57184187	TRIM37	0.53	4.69	0.36	6.08e-6	Vitamin D levels;
UCEC	cis	rs4713118	0.513	rs149878	chr6:27878738	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.56	-5.88	-0.44	2.59e-8	Parkinson's disease;
UCEC	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.55	-5.55	-0.42	1.32e-7	Aortic root size;
UCEC	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg03576123	chr11:487126	PTDSS2	0.75	5.91	0.44	2.31e-8	Body mass index;
UCEC	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.79	10.1	0.64	1.5e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs847577	0.609	rs11768309	chr7:97773812	G/T	cg24562669	chr7:97807699	LMTK2	0.74	11.01	0.67	6.28e-21	Breast cancer;
UCEC	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg06096015	chr1:231504339	EGLN1	0.41	4.77	0.37	4.41e-6	Hemoglobin concentration;
UCEC	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.66	5.94	0.44	1.95e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23715700	chr19:16188274	TPM4	0.54	6.91	0.5	1.37e-10	Warfarin maintenance dose;
UCEC	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg11569703	chr11:65557185	OVOL1	0.51	6.66	0.48	4.99e-10	Acne (severe);
UCEC	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.76	6.7	0.48	4.23e-10	Prostate cancer;
UCEC	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.65	7.15	0.51	3.69e-11	Menarche (age at onset);
UCEC	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.37	-0.4	3.02e-7	Bipolar disorder;
UCEC	cis	rs28795989	0.795	rs1878325	chr4:7902838	T/A	cg00251875	chr4:7801337	AFAP1	0.49	5.87	0.44	2.79e-8	Intraocular pressure;
UCEC	cis	rs8105895	0.867	rs116220423	chr19:22237041	G/A	cg24175803	chr19:22235144	ZNF257	-0.56	-4.98	-0.38	1.75e-6	Body mass index (change over time);
UCEC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg26114124	chr12:9217669	LOC144571	0.42	5.15	0.39	8.31e-7	Sjögren's syndrome;
UCEC	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.51	-5.08	-0.39	1.14e-6	Intelligence (multi-trait analysis);
UCEC	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.13	18.83	0.84	5.07e-41	IgG glycosylation;
UCEC	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.41	4.94	0.38	2.13e-6	Refractive error;
UCEC	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.83	0.37	3.34e-6	Breast cancer;
UCEC	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.71	6.78	0.49	2.72e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.46	5.35	0.4	3.35e-7	Attention deficit hyperactivity disorder;
UCEC	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg22852734	chr6:133119734	C6orf192	0.94	8.64	0.58	8.55e-15	Type 2 diabetes nephropathy;
UCEC	cis	rs10012307	1.000	rs72491757	chr4:137521041	C/T	cg12033966	chr4:138453416	PCDH18	-0.67	-4.55	-0.35	1.12e-5	DNA methylation (parent-of-origin);
UCEC	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	5.22	0.4	6.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.41e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	8.1	0.56	1.9e-13	Electrocardiographic conduction measures;
UCEC	cis	rs4837628	0.620	rs538246	chr9:122047447	A/G	cg06602847	chr9:122131497	DBC1	-0.32	-4.65	-0.36	7.23e-6	Parkinson's disease;
UCEC	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.5	4.91	0.38	2.36e-6	Pulmonary function decline;
UCEC	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.62	5.26	0.4	4.99e-7	Lymphocyte counts;
UCEC	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg26114124	chr12:9217669	LOC144571	0.39	4.66	0.36	7.07e-6	Sjögren's syndrome;
UCEC	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.62	6.13	0.45	7.59e-9	Lung cancer;
UCEC	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg01380346	chr19:18557039	ELL	-0.46	-4.76	-0.37	4.62e-6	Breast cancer;
UCEC	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-4.71	-0.36	5.57e-6	Blood metabolite levels;
UCEC	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	8.51	0.57	1.89e-14	Metabolite levels;
UCEC	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.45	4.93	0.38	2.23e-6	Systolic blood pressure;
UCEC	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.95	-14.71	-0.77	1.09e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.65	4.91	0.38	2.41e-6	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.59	5.06	0.39	1.23e-6	Alcohol dependence;
UCEC	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.55	5.94	0.44	1.94e-8	HDL cholesterol;
UCEC	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.67	-7.41	-0.52	9.12e-12	Ulcerative colitis;
UCEC	cis	rs3935996	0.932	rs12728204	chr1:56298497	T/C	cg11959316	chr1:57001742	PPAP2B	0.36	4.62	0.36	8.3e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
UCEC	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07215822	chr6:158701037	NA	-0.67	-5.83	-0.43	3.33e-8	Height;
UCEC	trans	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg05926928	chr17:57297772	GDPD1	1.04	7.41	0.52	8.95e-12	Opioid sensitivity;
UCEC	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.63	-6.75	-0.49	3.27e-10	Prostate cancer;
UCEC	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.77	6.88	0.49	1.57e-10	Caudate activity during reward;
UCEC	cis	rs7611694	0.728	rs28674622	chr3:113292637	C/A	cg12596171	chr3:113251061	SIDT1	0.44	4.67	0.36	6.85e-6	Prostate cancer;
UCEC	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	4.63	0.36	8.09e-6	Cognitive test performance;
UCEC	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.9	-8.43	-0.57	2.86e-14	Blood metabolite levels;
UCEC	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg21253087	chr9:139290292	SNAPC4	0.41	4.61	0.36	8.73e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.43	-5.36	-0.4	3.18e-7	Refractive error;
UCEC	cis	rs4594175	0.926	rs4414399	chr14:51596929	G/T	cg23942311	chr14:51606299	NA	0.33	4.87	0.37	2.9e-6	Cancer;
UCEC	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.54	-5.23	-0.4	5.73e-7	Prostate cancer;
UCEC	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.39	-4.52	-0.35	1.26e-5	Post bronchodilator FEV1;
UCEC	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.79	-7.96	-0.55	4.25e-13	Prudent dietary pattern;
UCEC	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg24375607	chr4:120327624	NA	0.52	5.47	0.41	1.87e-7	Corneal astigmatism;
UCEC	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.86	-6.81	-0.49	2.33e-10	Ulcerative colitis;
UCEC	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.49	4.65	0.36	7.24e-6	Menopause (age at onset);
UCEC	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.52	5.16	0.39	7.84e-7	High light scatter reticulocyte count;
UCEC	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.56	5.06	0.39	1.22e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs55670112	0.935	rs4618419	chr5:114278301	C/G	cg05461448	chr5:114880715	FEM1C	0.45	4.55	0.35	1.1e-5	Epilepsy;
UCEC	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.66	6.12	0.45	8.03e-9	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13095912	1.000	rs13095912	chr3:185302098	G/A	cg11274856	chr3:185301563	NA	0.57	7.63	0.53	2.76e-12	Systolic blood pressure;
UCEC	cis	rs11761441	0.578	rs10266144	chr7:91845	T/C	cg06458707	chr7:1083209	C7orf50	0.25	4.63	0.36	7.9e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-6.34	-0.46	2.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-4.63	-0.36	7.89e-6	Blood metabolite levels;
UCEC	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.57	-6.13	-0.45	7.85e-9	Height;
UCEC	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.44	4.94	0.38	2.09e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.8	8.21	0.56	1.04e-13	Blood protein levels;
UCEC	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.53	-6.6	-0.48	6.99e-10	Fibrinogen levels;
UCEC	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.55	-5.35	-0.4	3.35e-7	Asthma (sex interaction);
UCEC	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg02580895	chr19:2754563	NA	-0.52	-4.86	-0.37	3.04e-6	Total cholesterol levels;
UCEC	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.58	-6.6	-0.48	6.98e-10	Cancer (pleiotropy);
UCEC	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.53	5.53	0.42	1.42e-7	Dupuytren's disease;
UCEC	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.56	-5.49	-0.41	1.7e-7	Hepatocellular carcinoma;
UCEC	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg01112020	chr2:239008986	ESPNL	-0.34	-4.51	-0.35	1.32e-5	Prostate cancer;
UCEC	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.62	6.5	0.47	1.18e-9	Retinal vascular caliber;
UCEC	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.52	-4.9	-0.37	2.46e-6	Childhood ear infection;
UCEC	cis	rs12618769	0.652	rs2230388	chr2:99193496	C/T	cg10123293	chr2:99228465	UNC50	0.46	5.2	0.39	6.68e-7	Bipolar disorder;
UCEC	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg21856205	chr7:94953877	PON1	-0.56	-5.37	-0.4	3.04e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7246967	0.673	rs6511374	chr19:22866370	T/A	cg05241461	chr19:22816980	ZNF492	0.57	6.29	0.46	3.4e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27286337	chr10:134555280	INPP5A	0.62	5.47	0.41	1.91e-7	Migraine;
UCEC	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18932078	chr1:2524107	MMEL1	0.32	5.42	0.41	2.34e-7	Ulcerative colitis;
UCEC	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7246967	0.551	rs56968124	chr19:22814449	T/C	cg05241461	chr19:22816980	ZNF492	0.57	6.32	0.46	3e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1205863	0.573	rs169713	chr6:11920517	T/C	cg25521853	chr6:11927664	NA	0.38	4.59	0.35	9.28e-6	Disc degeneration (lumbar);
UCEC	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.54	-5.43	-0.41	2.23e-7	Hepatocellular carcinoma;
UCEC	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	trans	rs9527419	0.506	rs544577	chr13:56253901	G/A	cg14957718	chr3:50243260	SLC38A3	0.74	7.1	0.51	4.86e-11	Response to platinum-based chemotherapy (cisplatin);
UCEC	cis	rs17102423	0.623	rs4902368	chr14:65612048	A/G	cg11161011	chr14:65562177	MAX	0.62	5.56	0.42	1.24e-7	Obesity-related traits;
UCEC	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.59	-5.74	-0.43	5.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.79	9.5	0.62	5.42e-17	Breast cancer;
UCEC	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.48	-5.4	-0.41	2.66e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg24069376	chr3:38537580	EXOG	0.37	4.6	0.35	9.07e-6	Electrocardiographic conduction measures;
UCEC	cis	rs17854409	0.764	rs12625513	chr20:61475661	G/A	cg05147244	chr20:61493195	TCFL5	1.01	5.38	0.41	2.87e-7	Obesity-related traits;
UCEC	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	4.95	0.38	1.99e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	4.95	0.38	2.05e-6	Platelet count;
UCEC	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.58	5.19	0.39	6.74e-7	Corneal astigmatism;
UCEC	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.52	5.19	0.39	6.86e-7	Prudent dietary pattern;
UCEC	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.55	6.68	0.48	4.54e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg13460858	chr9:96720652	NA	0.4	4.62	0.36	8.17e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	9.72	0.63	1.52e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-5.55	-0.42	1.27e-7	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg21419209	chr3:44054225	NA	-0.55	-5.76	-0.43	4.8e-8	Coronary artery disease;
UCEC	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.68	-7.24	-0.51	2.27e-11	Breast cancer;
UCEC	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.74	0.36	5.09e-6	Diabetic retinopathy;
UCEC	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.51	-6.48	-0.47	1.27e-9	Congenital heart disease (maternal effect);
UCEC	cis	rs16879308	1.000	rs73084851	chr5:51243858	G/A	cg10599735	chr5:52096100	ITGA1;PELO	0.97	4.83	0.37	3.46e-6	Migraine without aura;
UCEC	cis	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg19743168	chr1:23544995	NA	-0.44	-5.75	-0.43	5.09e-8	Height;
UCEC	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.11	-0.68	3.38e-21	Chronic sinus infection;
UCEC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.44	-5.15	-0.39	8.13e-7	Prostate cancer;
UCEC	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.47	0.41	1.85e-7	Hemoglobin concentration;
UCEC	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg14242246	chr2:27434262	C2orf28;SLC5A6	0.5	5.03	0.38	1.39e-6	Blood metabolite levels;
UCEC	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.63	-4.51	-0.35	1.32e-5	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs73206853	0.764	rs67715513	chr12:110562910	G/A	cg12870014	chr12:110450643	ANKRD13A	0.67	5.56	0.42	1.25e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
UCEC	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-5.95	-0.44	1.91e-8	Personality dimensions;
UCEC	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.63	6.69	0.48	4.42e-10	Retinal vascular caliber;
UCEC	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.95	-7.32	-0.52	1.5e-11	Exhaled nitric oxide output;
UCEC	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	4.6	0.35	9.01e-6	Lung cancer in ever smokers;
UCEC	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	9.61	0.62	2.89e-17	Chronic sinus infection;
UCEC	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg02999476	chr16:427684	TMEM8A	0.42	4.94	0.38	2.14e-6	Bone mineral density (spine);Bone mineral density;
UCEC	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.78	8.01	0.55	3.1400000000000003e-13	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	0.73	5.51	0.41	1.6e-7	Red blood cell traits;
UCEC	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.5	5.14	0.39	8.48e-7	Monocyte count;
UCEC	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.62	-6.72	-0.48	3.81e-10	Eye color traits;
UCEC	cis	rs7246967	0.551	rs35740274	chr19:22831413	C/T	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs1545257	0.538	rs729921	chr2:24633124	T/G	cg06627628	chr2:24431161	ITSN2	-0.54	-5.47	-0.41	1.85e-7	Sjögren's syndrome;
UCEC	cis	rs7580658	0.521	rs7605733	chr2:127931787	T/G	cg16751203	chr2:127950803	CYP27C1	0.36	4.85	0.37	3.16e-6	Protein C levels;
UCEC	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.56	5.25	0.4	5.29e-7	Intelligence (multi-trait analysis);
UCEC	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-0.86	-10.89	-0.67	1.25e-20	Height;
UCEC	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.58	-0.48	7.94e-10	Joint mobility (Beighton score);
UCEC	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.62	-7.15	-0.51	3.69e-11	IgG glycosylation;
UCEC	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg00648152	chr1:36863595	LSM10	-0.51	-4.88	-0.37	2.72e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs7546668	1.000	rs12741552	chr1:15853276	T/C	cg05660106	chr1:15850417	CASP9	-0.46	-4.86	-0.37	3.04e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.15	-13.77	-0.75	3.21e-28	Breast cancer;
UCEC	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.7	6.62	0.48	6.38e-10	Crohn's disease;
UCEC	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	9.93	0.63	4.2e-18	Chronic sinus infection;
UCEC	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.51	5.81	0.43	3.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	7.15	0.51	3.87e-11	Total body bone mineral density;
UCEC	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.2	0.39	6.6e-7	Breast cancer;
UCEC	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.5	-6.84	-0.49	2.03e-10	Sense of smell;
UCEC	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-4.87	-0.37	2.83e-6	Height;
UCEC	cis	rs925550	1.000	rs4833840	chr4:123584237	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.54	5.19	0.39	7.01e-7	Primary biliary cholangitis;
UCEC	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg23795048	chr12:9217529	LOC144571	0.42	5.01	0.38	1.55e-6	Sjögren's syndrome;
UCEC	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	8.02	0.55	3.02e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs10266483	0.705	rs660228	chr7:63756245	T/C	cg23304165	chr7:63498798	NA	-0.58	-6.13	-0.45	7.73e-9	Response to statin therapy;
UCEC	cis	rs9470794	1.000	rs11759483	chr6:38087679	C/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.8	0.37	3.94e-6	Type 2 diabetes;
UCEC	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.55	5.98	0.44	1.63e-8	Bone mineral density;
UCEC	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.73	-7.96	-0.55	4.37e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	6.08	0.45	9.92e-9	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.29	0.46	3.46e-9	Motion sickness;
UCEC	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.28	-9.87	-0.63	6.01e-18	Hip circumference adjusted for BMI;
UCEC	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	9.17e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.66	0.48	5.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.19	-9.37	-0.61	1.23e-16	Hip circumference adjusted for BMI;
UCEC	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.71	-5.92	-0.44	2.17e-8	Longevity;
UCEC	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.7	6.29	0.46	3.39e-9	Subjective well-being;
UCEC	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.59	-6.51	-0.47	1.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.82	10.15	0.64	1.15e-18	Mortality in heart failure;
UCEC	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.63	-6.03	-0.45	1.3e-8	Urate levels in obese individuals;
UCEC	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.67	6.69	0.48	4.37e-10	Plateletcrit;Platelet count;
UCEC	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-4.51	-0.35	1.29e-5	Height;
UCEC	cis	rs9297145	0.673	rs12531875	chr7:98724730	C/T	cg05967295	chr7:98741636	SMURF1	0.92	8.43	0.57	2.9e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.54	6.32	0.46	3.01e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.47	-4.6	-0.35	9.16e-6	Gut microbiome composition (summer);
UCEC	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg07041428	chr4:1763019	NA	-0.4	-4.54	-0.35	1.15e-5	Bladder cancer;Urinary bladder cancer;
UCEC	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.49	-5.52	-0.41	1.5e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.51	5.09	0.39	1.06e-6	Neuroticism;
UCEC	cis	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg16876255	chr19:9731953	ZNF561	0.66	4.82	0.37	3.56e-6	Pursuit maintenance gain;
UCEC	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.44	4.85	0.37	3.11e-6	Response to temozolomide;
UCEC	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.57	-0.35	1.05e-5	Bipolar disorder;
UCEC	cis	rs9467773	1.000	rs6918506	chr6:26577857	C/G	cg09904177	chr6:26538194	HMGN4	0.74	7.83	0.54	8.87e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.62	6.95	0.5	1.08e-10	Tonsillectomy;
UCEC	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18252515	chr7:66147081	NA	0.51	4.95	0.38	2.04e-6	Aortic root size;
UCEC	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-6.65	-0.48	5.49e-10	Monocyte count;
UCEC	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.47	-4.9	-0.37	2.48e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.5	4.99	0.38	1.69e-6	Dupuytren's disease;
UCEC	trans	rs7246760	0.867	rs889177	chr19:9846225	C/T	cg02900749	chr2:68251473	NA	-0.84	-6.85	-0.49	1.84e-10	Pursuit maintenance gain;
UCEC	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.75	6.57	0.48	8.12e-10	Cognitive test performance;
UCEC	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.9	11.99	0.7	1.58e-23	Metabolic syndrome;
UCEC	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.79	8.98	0.6	1.19e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.65	5.49	0.41	1.72e-7	Blood metabolite levels;
UCEC	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs6893807	1.000	rs16903275	chr5:87950543	A/C	cg09002922	chr5:87956389	LOC645323	0.63	6.58	0.48	7.73e-10	Body mass index;
UCEC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.06	-14.02	-0.76	6.69e-29	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg11632617	chr15:75315747	PPCDC	-0.62	-5.33	-0.4	3.61e-7	Lung cancer;
UCEC	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.58	5.27	0.4	4.71e-7	Crohn's disease;
UCEC	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.84	8.36	0.57	4.44e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7870753	0.685	rs10820632	chr9:99212233	G/T	cg25260653	chr9:99212216	HABP4	0.58	5.64	0.42	8.39e-8	Height;
UCEC	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.7	-8.14	-0.56	1.51e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.53	-5.36	-0.4	3.15e-7	Aortic root size;
UCEC	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg06462663	chr19:18546047	ISYNA1	0.47	6.09	0.45	9.19e-9	Breast cancer;
UCEC	cis	rs6446731	0.593	rs7674472	chr4:3273538	C/G	cg08886695	chr4:3369023	RGS12	-0.47	-5.46	-0.41	2.03e-7	Mean platelet volume;
UCEC	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.49	5.24	0.4	5.45e-7	Corneal astigmatism;
UCEC	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg03959625	chr15:84868606	LOC388152	0.47	4.83	0.37	3.42e-6	Schizophrenia;
UCEC	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg01072550	chr1:21505969	NA	-0.61	-5.68	-0.42	7.03e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	4.69	0.36	6.17e-6	Calcium levels;
UCEC	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.49	4.91	0.38	2.43e-6	Corneal astigmatism;
UCEC	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	8.36	0.57	4.39e-14	Hip circumference adjusted for BMI;
UCEC	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg05623727	chr3:50126028	RBM5	0.38	4.91	0.38	2.44e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs10887741	0.646	rs10218939	chr10:89436853	A/G	cg13926569	chr10:89418898	PAPSS2	0.41	4.85	0.37	3.16e-6	Exercise (leisure time);
UCEC	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg04756594	chr16:24857601	SLC5A11	0.48	5.67	0.42	7.49e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.54	5.79	0.43	4.2e-8	Schizophrenia;
UCEC	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg09904177	chr6:26538194	HMGN4	-0.73	-5.03	-0.38	1.42e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.52	5.55	0.42	1.28e-7	Platelet count;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg08461772	chr7:95026248	PON3	0.4	5.26	0.4	4.9e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.02	-0.38	1.46e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	5.42	0.41	2.4e-7	Monocyte percentage of white cells;
UCEC	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.52	-6.01	-0.44	1.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.81	-0.37	3.69e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	0.85	4.99	0.38	1.72e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.49	4.69	0.36	6.22e-6	Alzheimer's disease (late onset);
UCEC	cis	rs4523957	0.890	rs216217	chr17:2145090	G/A	cg16513277	chr17:2031491	SMG6	0.46	5.11	0.39	9.78e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.86	-0.37	2.97e-6	Height;
UCEC	cis	rs11235843	1.000	rs4944852	chr11:73372107	A/C	cg23931323	chr11:73372278	PLEKHB1	0.75	4.75	0.36	4.78e-6	Hand grip strength;
UCEC	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-6.16	-0.45	6.57e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.71	-5.22	-0.4	6.01e-7	Narcolepsy;
UCEC	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	6.23	0.46	4.62e-9	Coffee consumption (cups per day);
UCEC	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.57	-6.4	-0.47	1.99e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.64	6.41	0.47	1.85e-9	Dental caries;
UCEC	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.62	-0.36	8.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg04842962	chr6:43655489	MRPS18A	0.86	8.8	0.59	3.52e-15	IgG glycosylation;
UCEC	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.79	-5.32	-0.4	3.88e-7	Toenail selenium levels;
UCEC	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.72	5.78	0.43	4.41e-8	Cognitive test performance;
UCEC	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.56	5.05	0.38	1.27e-6	Corneal astigmatism;
UCEC	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg23793686	chr15:68133972	NA	0.35	4.56	0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.47	-4.86	-0.37	3.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.87	8.16	0.56	1.35e-13	Cisplatin-induced ototoxicity;
UCEC	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.55	4.95	0.38	2.02e-6	Colorectal cancer;
UCEC	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.73	6.44	0.47	1.58e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-10.99	-0.67	6.77e-21	Chronic sinus infection;
UCEC	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.45	-4.92	-0.38	2.28e-6	White matter hyperintensity burden;
UCEC	cis	rs2075165	0.870	rs9943105	chr1:156245245	T/C	cg26011156	chr1:156183096	PMF1	0.43	4.69	0.36	6.19e-6	Tonsillectomy;
UCEC	cis	rs10432489	0.708	rs4436925	chr2:181755933	T/C	cg21995919	chr2:182322279	ITGA4	0.73	5.56	0.42	1.23e-7	QT interval;
UCEC	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.15	-7.31	-0.52	1.56e-11	Breast cancer;
UCEC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.47	4.7	0.36	6.01e-6	Vitiligo;
UCEC	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.33	8.34	0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Bladder cancer;
UCEC	cis	rs10432489	0.708	rs3922471	chr2:181771937	T/C	cg21995919	chr2:182322279	ITGA4	-0.77	-5.34	-0.4	3.53e-7	QT interval;
UCEC	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-8.25	-0.56	8.27e-14	Parkinson's disease;
UCEC	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg06784218	chr1:46089804	CCDC17	0.56	7.19	0.51	3.08e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs883565	0.528	rs6599271	chr3:38970730	A/G	cg01426195	chr3:39028469	NA	0.46	5.11	0.39	9.73e-7	Handedness;
UCEC	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg05072774	chr3:49840536	C3orf54	-0.55	-5.65	-0.42	7.92e-8	Resting heart rate;
UCEC	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.5	5.07	0.39	1.17e-6	Red cell distribution width;
UCEC	cis	rs7937612	1.000	rs1892894	chr11:120254684	C/T	cg12584626	chr11:120203529	NA	0.46	4.57	0.35	1.01e-5	Intraocular pressure;
UCEC	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.59	-5.57	-0.42	1.2e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.66	5.41	0.41	2.48e-7	Metabolite levels;
UCEC	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.7	8.85	0.59	2.49e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.84	7.27	0.51	1.99e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.46	-4.95	-0.38	2.04e-6	Total cholesterol levels;
UCEC	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs7246967	0.932	rs35968517	chr19:23027040	T/C	cg08271804	chr19:22816896	ZNF492	0.58	5.45	0.41	2.05e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg02851062	chr11:122848983	BSX	-0.36	-4.59	-0.35	9.57e-6	Menarche (age at onset);
UCEC	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg05991184	chr2:219186017	PNKD	-0.58	-6.64	-0.48	5.79e-10	Colorectal cancer;
UCEC	cis	rs7247513	0.964	rs35235213	chr19:12713156	C/T	cg01871581	chr19:12707946	ZNF490	-0.56	-5.64	-0.42	8.28e-8	Bipolar disorder;
UCEC	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.89	-9.82	-0.63	8.13e-18	Cognitive function;
UCEC	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.58	5.25	0.4	5.34e-7	Educational attainment;
UCEC	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18252515	chr7:66147081	NA	0.55	5.16	0.39	7.95e-7	Aortic root size;
UCEC	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.51	-5.54	-0.42	1.36e-7	Pulse pressure;
UCEC	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.49	-5.81	-0.43	3.72e-8	Total body bone mineral density;
UCEC	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-5.53	-0.41	1.45e-7	Monocyte percentage of white cells;
UCEC	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.49	-4.82	-0.37	3.51e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.62	-6.21	-0.46	5.03e-9	Strep throat;
UCEC	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.46	4.78	0.37	4.27e-6	Total body bone mineral density;
UCEC	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	6.44	0.47	1.61e-9	Motion sickness;
UCEC	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	6.17	0.45	6.17e-9	Platelet count;
UCEC	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.66	6.18	0.45	6.01e-9	Lymphocyte counts;
UCEC	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg14438399	chr17:27053147	TLCD1	0.59	4.79	0.37	3.95e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg13683864	chr3:40499215	RPL14	-0.68	-6.79	-0.49	2.59e-10	Renal cell carcinoma;
UCEC	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.74	-6.36	-0.46	2.42e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg00105475	chr2:10696890	NA	0.42	5.17	0.39	7.53e-7	Prostate cancer;
UCEC	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.78	-8.85	-0.59	2.49e-15	Height;
UCEC	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.8	8.75	0.59	4.49e-15	Eosinophil percentage of white cells;
UCEC	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.54	-5.92	-0.44	2.23e-8	Prostate cancer;
UCEC	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.52	5.43	0.41	2.25e-7	Body mass index (adult);
UCEC	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg24881330	chr22:46731750	TRMU	0.73	7.35	0.52	1.3e-11	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.48	-4.82	-0.37	3.56e-6	Systemic lupus erythematosus;
UCEC	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.77	8.89	0.59	2.02e-15	Menopause (age at onset);
UCEC	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.93	11.36	0.68	7.21e-22	Breast cancer;
UCEC	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-0.76	-8.38	-0.57	3.9e-14	Trans fatty acid levels;
UCEC	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	6.61	0.48	6.64e-10	Motion sickness;
UCEC	cis	rs953387	0.910	rs4954397	chr2:136946433	A/G	cg07169764	chr2:136633963	MCM6	0.49	4.78	0.37	4.29e-6	Arthritis (juvenile idiopathic);
UCEC	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.17	6.2	0.46	5.42e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	5.03	0.38	1.44e-6	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg26061582	chr7:22766209	IL6	0.59	5.48	0.41	1.83e-7	Lung cancer;
UCEC	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.11	17.26	0.82	3.65e-37	IgG glycosylation;
UCEC	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.56	5.24	0.4	5.35e-7	Corneal astigmatism;
UCEC	cis	rs4594175	0.926	rs12434681	chr14:51595335	A/G	cg23942311	chr14:51606299	NA	0.33	4.75	0.36	4.87e-6	Cancer;
UCEC	cis	rs6709815	0.841	rs6740004	chr2:219663153	G/A	cg02176678	chr2:219576539	TTLL4	-0.56	-5.92	-0.44	2.2e-8	Reticulocyte count;High light scatter reticulocyte count;
UCEC	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg13250285	chr3:50228871	GNAT1	-0.31	-4.53	-0.35	1.21e-5	Menarche (age at onset);
UCEC	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.74e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs11760485	0.782	rs2107838	chr7:4406761	T/C	cg25842763	chr7:4870162	RADIL	-0.41	-4.69	-0.36	6.14e-6	Early childhood aggressive behavior;
UCEC	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.77	8.28	0.56	6.83e-14	Immature fraction of reticulocytes;
UCEC	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18854424	chr1:2615690	NA	0.45	6.49	0.47	1.22e-9	Ulcerative colitis;
UCEC	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.97	6.58	0.48	7.7e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg22992570	chr11:76572061	ACER3	0.64	7.56	0.53	3.92e-12	Warfarin maintenance dose;
UCEC	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.51	4.95	0.38	2.01e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs16957091	0.647	rs4274403	chr15:43345047	T/C	cg15904908	chr15:43213022	TTBK2	0.49	4.77	0.37	4.32e-6	MGMT methylation in smokers;
UCEC	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs4588572	0.643	rs1159929	chr5:77768820	A/G	cg11547950	chr5:77652471	NA	0.48	5.88	0.44	2.59e-8	Triglycerides;
UCEC	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg14008862	chr17:28927542	LRRC37B2	-0.69	-4.69	-0.36	6.06e-6	Body mass index;
UCEC	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.8	-9.93	-0.63	4.18e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.46	6.26	0.46	3.93e-9	Neuroticism;
UCEC	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.73	-0.43	5.4e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.57	4.57	0.35	1.05e-5	Longevity;
UCEC	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg20399509	chr21:47717575	C21orf57	-0.46	-5.01	-0.38	1.56e-6	Testicular germ cell tumor;
UCEC	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.69	-6.32	-0.46	2.9e-9	Aortic root size;
UCEC	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.65	-7.46	-0.52	6.79e-12	Menarche (age at onset);
UCEC	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.47	5.75	0.43	5.07e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.92	11.24	0.68	1.49e-21	Breast cancer;
UCEC	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.55	-6.22	-0.46	4.8e-9	Crohn's disease;
UCEC	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.63	5.05	0.38	1.27e-6	Resting heart rate;
UCEC	cis	rs7113850	0.541	rs74702708	chr11:24226866	T/C	ch.11.24196551F	chr11:24239977	NA	0.7	4.69	0.36	6.24e-6	Bone fracture in osteoporosis;
UCEC	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.58	6.1	0.45	8.98e-9	Breast cancer;
UCEC	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg06096015	chr1:231504339	EGLN1	0.42	4.92	0.38	2.24e-6	Hemoglobin concentration;
UCEC	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg13695892	chr22:41940480	POLR3H	0.68	5.34	0.4	3.43e-7	Vitiligo;
UCEC	cis	rs4499344	0.730	rs453804	chr19:33105612	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	5.84	0.43	3.28e-8	Mean platelet volume;
UCEC	cis	rs10012307	1.000	rs7689996	chr4:137490994	A/G	cg12033966	chr4:138453416	PCDH18	-0.69	-4.75	-0.36	4.77e-6	DNA methylation (parent-of-origin);
UCEC	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.48	-5.37	-0.4	3.03e-7	Life satisfaction;
UCEC	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	4.89	0.37	2.59e-6	Educational attainment;
UCEC	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.51	-4.65	-0.36	7.32e-6	Aortic root size;
UCEC	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg05925327	chr15:68127851	NA	-0.46	-5.23	-0.4	5.79e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.59	-5.1	-0.39	1.03e-6	Alzheimer's disease;
UCEC	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.54	5.1	0.39	1.05e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs72720396	0.803	rs115552537	chr1:91190856	C/A	cg13456504	chr1:91191583	NA	0.58	4.83	0.37	3.36e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24308560	chr3:49941425	MST1R	-0.47	-5.13	-0.39	9.12e-7	Body mass index;
UCEC	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	0.85	8.82	0.59	3.09e-15	Primary sclerosing cholangitis;
UCEC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.1	13.63	0.75	7.24e-28	Cognitive function;
UCEC	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg05962950	chr11:130786565	SNX19	-0.43	-4.58	-0.35	9.67e-6	Schizophrenia;
UCEC	cis	rs12618769	0.652	rs3754877	chr2:99184019	A/G	cg10123293	chr2:99228465	UNC50	0.49	5.19	0.39	6.83e-7	Bipolar disorder;
UCEC	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.35	-4.71	-0.36	5.69e-6	Total body bone mineral density;
UCEC	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18252515	chr7:66147081	NA	-0.51	-4.9	-0.37	2.51e-6	Aortic root size;
UCEC	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	0.8	6.88	0.49	1.59e-10	Blood protein levels;
UCEC	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.64	5.88	0.44	2.62e-8	Childhood ear infection;
UCEC	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	5.22	0.4	5.99e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.38	-0.41	2.87e-7	Obesity-related traits;
UCEC	cis	rs7088591	1.000	rs76726082	chr10:59786025	A/G	cg11142981	chr10:60273225	BICC1	0.64	4.52	0.35	1.26e-5	Blood pressure;
UCEC	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.62	-6.96	-0.5	1.03e-10	Prostate cancer;
UCEC	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-6.47	-0.47	1.37e-9	Idiopathic membranous nephropathy;
UCEC	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.65	6.11	0.45	8.49e-9	Platelet distribution width;
UCEC	cis	rs7004769	0.554	rs77161575	chr8:9171445	G/A	cg27598956	chr8:9758788	LOC157627	-0.49	-4.69	-0.36	6.08e-6	Fibrinogen levels;
UCEC	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.9	-10.2	-0.64	8.53e-19	Cognitive function;
UCEC	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.67	-5.31	-0.4	3.92e-7	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.42	-4.63	-0.36	8.06e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.22	-6.97	-0.5	9.87e-11	Diabetic kidney disease;
UCEC	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.96	0.38	1.89e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6500550	1.000	rs6500550	chr16:3746241	A/G	cg10476962	chr16:3724846	TRAP1	0.47	4.59	0.35	9.42e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
UCEC	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.81	9.74	0.63	1.3e-17	Menopause (age at onset);
UCEC	cis	rs2742417	0.967	rs1609553	chr3:45735142	T/C	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.41	-0.41	2.54e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg26331595	chr3:39149181	GORASP1;TTC21A	0.56	5.39	0.41	2.69e-7	Handedness;
UCEC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.83	-8.48	-0.57	2.21e-14	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.75	7.15	0.51	3.78e-11	Schizophrenia;
UCEC	cis	rs295140	1.000	rs7578220	chr2:201183701	A/G	cg04283868	chr2:201171347	SPATS2L	0.52	5.18	0.39	7.23e-7	QT interval;
UCEC	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.8	-9.07	-0.6	7.12e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.75	-7.69	-0.54	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.46	6.44	0.47	1.62e-9	Eye color traits;
UCEC	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.67	6.35	0.46	2.53e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.43	4.73	0.36	5.28e-6	Renal cell carcinoma;
UCEC	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.69	6.38	0.47	2.19e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.57	5.5	0.41	1.64e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.68	5.37	0.41	2.94e-7	Neutrophil percentage of white cells;
UCEC	cis	rs7870753	0.838	rs7861282	chr9:99204468	T/C	cg25260653	chr9:99212216	HABP4	0.58	5.64	0.42	8.35e-8	Height;
UCEC	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.85	6.75	0.49	3.25e-10	Body mass index;
UCEC	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.47	-5.94	-0.44	1.94e-8	Mean platelet volume;
UCEC	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.01	-0.38	1.53e-6	Chronic sinus infection;
UCEC	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs10924970	0.967	rs4659784	chr1:235482463	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	4.95	0.38	1.99e-6	Asthma;
UCEC	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg03714773	chr7:91764589	CYP51A1	0.48	5.8	0.43	3.86e-8	Breast cancer;
UCEC	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.6	0.53	3.27e-12	Ileal carcinoids;
UCEC	cis	rs1401999	0.541	rs6765152	chr3:183756780	A/C	cg20387954	chr3:183756860	HTR3D	0.56	5.85	0.43	3.11e-8	Anterior chamber depth;
UCEC	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.45	-5.71	-0.43	5.94e-8	Mean platelet volume;
UCEC	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.58	-4.98	-0.38	1.8e-6	Reticulocyte count;
UCEC	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.67	-7.79	-0.54	1.12e-12	Headache;
UCEC	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.43	-5.6	-0.42	1.01e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg12463550	chr7:65579703	CRCP	0.53	5.42	0.41	2.39e-7	Aortic root size;
UCEC	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.58	-8.25	-0.56	8.2e-14	Total body bone mineral density;
UCEC	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg10914120	chr13:113893660	CUL4A	0.43	4.65	0.36	7.21e-6	Platelet distribution width;
UCEC	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg24375607	chr4:120327624	NA	0.47	4.99	0.38	1.66e-6	Corneal astigmatism;
UCEC	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.71	6.18	0.45	6.04e-9	Lymphocyte percentage of white cells;
UCEC	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.69	-7.16	-0.51	3.54e-11	Menopause (age at onset);
UCEC	cis	rs735860	0.726	rs209507	chr6:53194768	T/A	cg10236188	chr6:53219634	NA	0.46	4.72	0.36	5.44e-6	Glaucoma;
UCEC	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg06157570	chr12:6886703	LAG3	0.5	5.03	0.38	1.39e-6	HDL cholesterol levels;
UCEC	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.9	5.02	0.38	1.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-5.93	-0.44	2.04e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
UCEC	cis	rs8020441	0.588	rs45558232	chr14:51188754	C/T	cg04730355	chr14:51134070	SAV1	0.66	5.8	0.43	3.97e-8	Cognitive performance;
UCEC	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.5	4.55	0.35	1.12e-5	Schizophrenia;
UCEC	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg03859395	chr2:55845619	SMEK2	-0.74	-7.22	-0.51	2.63e-11	Metabolic syndrome;
UCEC	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.6	-6.63	-0.48	6.13e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-6.49	-0.47	1.21e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.53	-7.08	-0.5	5.56e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs858239	1.000	rs858240	chr7:23284237	A/G	cg08455073	chr7:23286463	GPNMB	0.4	4.58	0.35	9.92e-6	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07215822	chr6:158701037	NA	-0.68	-5.89	-0.44	2.51e-8	Height;
UCEC	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg06096015	chr1:231504339	EGLN1	0.47	5.46	0.41	1.94e-7	Hemoglobin concentration;
UCEC	cis	rs4372836	0.964	rs55721532	chr2:28938968	A/G	cg09522027	chr2:28974177	PPP1CB	0.72	7.13	0.51	4.15e-11	Body mass index;
UCEC	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.91	-9.61	-0.62	2.84e-17	Cognitive function;
UCEC	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.7	-7.06	-0.5	6.04e-11	Breast cancer;
UCEC	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.63	7.3	0.52	1.63e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg05962950	chr11:130786565	SNX19	0.63	6.68	0.48	4.52e-10	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.67	7.35	0.52	1.27e-11	Menopause (age at onset);
UCEC	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00546932	chr16:1947055	NA	0.36	4.91	0.38	2.36e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg03456212	chr7:26904342	SKAP2	0.61	4.53	0.35	1.22e-5	Type 1 diabetes;
UCEC	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.65	6.87	0.49	1.71e-10	Immature fraction of reticulocytes;
UCEC	cis	rs7651039	0.641	rs2455823	chr3:15666856	T/C	cg16303742	chr3:15540471	COLQ	0.45	4.99	0.38	1.71e-6	Coronary heart disease;
UCEC	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.56	-4.86	-0.37	2.99e-6	Gut microbiome composition (summer);
UCEC	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-5.6	-0.42	1.03e-7	Idiopathic membranous nephropathy;
UCEC	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg08501292	chr6:25962987	TRIM38	0.98	4.76	0.37	4.56e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs16937	0.711	rs11240384	chr1:205172175	C/T	cg12580275	chr1:205744413	RAB7L1	0.48	5.23	0.4	5.74e-7	Schizophrenia;
UCEC	cis	rs2415984	0.846	rs4259960	chr14:46835756	T/A	cg14871534	chr14:47121158	RPL10L	0.4	4.61	0.36	8.84e-6	Number of children ever born;
UCEC	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.49	5.44	0.41	2.17e-7	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.62	-5.73	-0.43	5.58e-8	Aortic root size;
UCEC	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg18681998	chr4:17616180	MED28	-0.64	-6.94	-0.5	1.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.69	5.76	0.43	4.73e-8	Lung disease severity in cystic fibrosis;
UCEC	cis	rs924607	0.545	rs7378524	chr5:616946	T/C	cg04476341	chr5:669733	TPPP	-0.39	-4.6	-0.35	9.21e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.33	4.81	0.37	3.64e-6	Schizophrenia;
UCEC	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg00983440	chr10:79422392	NA	-1.09	-8.44	-0.57	2.8e-14	Bone mineral density;
UCEC	cis	rs12365397	0.748	rs11037372	chr11:43254162	C/A	cg07515919	chr11:43391688	TTC17	0.47	4.77	0.37	4.44e-6	Migraine;
UCEC	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.44	-5.35	-0.4	3.28e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.76	-8.56	-0.58	1.36e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.88	9.6	0.62	3.12e-17	Breast cancer;
UCEC	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.72	7.13	0.51	4.23e-11	Smoking behavior;
UCEC	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg21419209	chr3:44054225	NA	-0.49	-5.09	-0.39	1.09e-6	Coronary artery disease;
UCEC	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.47	5.28	0.4	4.62e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.53	5.57	0.42	1.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
UCEC	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.56	7.18	0.51	3.25e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	4.72	0.36	5.41e-6	Response to antipsychotic treatment;
UCEC	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-5.49	-0.41	1.71e-7	Hemoglobin concentration;
UCEC	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-5.03	-0.38	1.41e-6	Alcohol dependence;
UCEC	cis	rs78487399	0.908	rs73925554	chr2:43810739	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.68	-0.36	6.38e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg13683864	chr3:40499215	RPL14	-0.58	-6.32	-0.46	2.98e-9	Renal cell carcinoma;
UCEC	cis	rs17665859	0.844	rs6980614	chr8:447844	G/A	cg17960703	chr8:356704	FBXO25	0.95	5.25	0.4	5.29e-7	Bilirubin levels;
UCEC	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg26781129	chr3:44753946	ZNF502	-0.46	-4.98	-0.38	1.78e-6	Depressive symptoms;
UCEC	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-6.29	-0.46	3.37e-9	Platelet count;
UCEC	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.72	7.36	0.52	1.17e-11	Breast cancer;
UCEC	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.53	5.91	0.44	2.33e-8	Iron status biomarkers (transferrin levels);
UCEC	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.15	6.49	0.47	1.23e-9	Eosinophil percentage of granulocytes;
UCEC	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg00316803	chr15:76480434	C15orf27	-0.44	-5.08	-0.39	1.14e-6	Blood metabolite levels;
UCEC	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.07	8.61	0.58	1.04e-14	Lymphocyte percentage of white cells;
UCEC	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.7	6.91	0.5	1.38e-10	Morning vs. evening chronotype;
UCEC	cis	rs2721195	0.967	rs4925809	chr8:145686313	C/T	cg26752003	chr8:145688521	CYHR1	-0.63	-6.1	-0.45	9.13e-9	Age at first birth;
UCEC	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26207909	chr14:103986467	CKB	0.54	6.08	0.45	9.8e-9	Body mass index;
UCEC	cis	rs3750082	0.889	rs7781915	chr7:32923159	T/C	cg05721444	chr7:32995514	FKBP9	0.52	5.8	0.43	3.92e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	0.86	5.46	0.41	2e-7	Diabetic retinopathy;
UCEC	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-0.96	-4.92	-0.38	2.27e-6	Mitochondrial DNA levels;
UCEC	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.7	6.18	0.45	6.08e-9	Cognitive function;
UCEC	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-5.31	-0.4	3.89e-7	Heart rate;
UCEC	cis	rs7246967	0.673	rs12979264	chr19:22865134	G/A	cg24889512	chr19:22816950	ZNF492	0.6	6.49	0.47	1.23e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.78	-9.76	-0.63	1.16e-17	Systemic sclerosis;
UCEC	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-5.41	-0.41	2.48e-7	Platelet count;
UCEC	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11871910	chr12:69753446	YEATS4	0.67	6.68	0.48	4.52e-10	Response to diuretic therapy;
UCEC	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.89	-10.07	-0.64	1.87e-18	Ulcerative colitis;
UCEC	cis	rs1205863	0.607	rs864244	chr6:11929602	C/A	cg25521853	chr6:11927664	NA	0.42	4.87	0.37	2.88e-6	Disc degeneration (lumbar);
UCEC	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.7	4.55	0.35	1.11e-5	Developmental language disorder (linguistic errors);
UCEC	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	8.59	0.58	1.14e-14	Alzheimer's disease;
UCEC	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.71	-6.42	-0.47	1.81e-9	Asthma;
UCEC	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	-0.57	-6.54	-0.47	9.6e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	5.4	0.41	2.63e-7	Breast cancer;
UCEC	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-0.94	-6.02	-0.44	1.32e-8	Breast cancer;
UCEC	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.65	6.96	0.5	1.03e-10	Mortality in heart failure;
UCEC	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.69	7.68	0.54	2.07e-12	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	6.08	0.45	1.01e-8	Tonsillectomy;
UCEC	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	4.83	0.37	3.39e-6	Eosinophil percentage of white cells;
UCEC	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	6.38	0.47	2.16e-9	Coffee consumption (cups per day);
UCEC	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg20825769	chr15:43991375	CKMT1A	-0.54	-4.52	-0.35	1.24e-5	Lung cancer in ever smokers;
UCEC	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.69	6.18	0.45	6.03e-9	Platelet count;
UCEC	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg02160872	chr5:212506	CCDC127	-0.71	-7.48	-0.52	6.38e-12	Breast cancer;
UCEC	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg11569703	chr11:65557185	OVOL1	0.51	6.52	0.47	1.03e-9	Acne (severe);
UCEC	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.21	0.39	6.28e-7	Bipolar disorder;
UCEC	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.48	7.0	0.5	8.34e-11	Homoarginine levels;
UCEC	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	4.68	0.36	6.49e-6	Breast cancer;
UCEC	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-0.87	-10.12	-0.64	1.34e-18	Height;
UCEC	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18252515	chr7:66147081	NA	-0.55	-5.18	-0.39	7.28e-7	Aortic root size;
UCEC	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-7.82	-0.54	9.29e-13	Total cholesterol levels;
UCEC	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg07615347	chr10:60278583	BICC1	-0.44	-4.74	-0.36	4.92e-6	Refractive error;
UCEC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg13695892	chr22:41940480	POLR3H	-0.68	-4.68	-0.36	6.42e-6	Vitiligo;
UCEC	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.24	0.4	5.54e-7	Rheumatoid arthritis;
UCEC	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg03354898	chr7:1950403	MAD1L1	0.47	5.59	0.42	1.07e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg17420585	chr12:42539391	GXYLT1	-0.41	-4.81	-0.37	3.69e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.44	4.75	0.37	4.69e-6	Morning vs. evening chronotype;
UCEC	cis	rs526231	0.578	rs3776870	chr5:102295070	G/A	cg23492399	chr5:102201601	PAM	-0.58	-4.89	-0.37	2.65e-6	Primary biliary cholangitis;
UCEC	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg27246729	chr12:121163418	ACADS	0.52	4.61	0.36	8.62e-6	Urinary metabolites (H-NMR features);
UCEC	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.5	4.83	0.37	3.37e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.68	-6.6	-0.48	7.13e-10	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.68	6.45	0.47	1.51e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg07504864	chr6:88412167	NCRNA00120;AKIRIN2	-0.61	-6.67	-0.48	4.78e-10	Breast cancer;
UCEC	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.86	-11.09	-0.67	3.81e-21	Metabolic syndrome;
UCEC	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.64	-6.1	-0.45	8.74e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.62	-4.71	-0.36	5.57e-6	Facial morphology (factor 23);
UCEC	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.2	6.99	0.5	8.94e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.67	-0.36	6.81e-6	Schizophrenia;
UCEC	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.6	5.56	0.42	1.21e-7	Type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.92	-10.5	-0.65	1.38e-19	Breast cancer;
UCEC	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	7.1	0.51	5.03e-11	Coffee consumption (cups per day);
UCEC	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.84	10.54	0.66	1.08e-19	Mortality in heart failure;
UCEC	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	9.22	0.61	2.93e-16	Electrocardiographic conduction measures;
UCEC	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg02413938	chr2:239008929	ESPNL	-0.36	-4.71	-0.36	5.69e-6	Prostate cancer;
UCEC	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.59	-0.48	7.21e-10	Chronic sinus infection;
UCEC	cis	rs3015497	0.616	rs1389650	chr14:51081449	C/T	cg04730355	chr14:51134070	SAV1	-0.48	-5.07	-0.39	1.16e-6	Mean platelet volume;
UCEC	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.48	5.11	0.39	9.72e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs787274	0.867	rs1361719	chr9:115535576	A/G	cg13803584	chr9:115635662	SNX30	-0.69	-5.64	-0.42	8.63e-8	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.59	4.98	0.38	1.77e-6	Phospholipid levels (plasma);
UCEC	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	5.02	0.38	1.46e-6	Eosinophil percentage of white cells;
UCEC	cis	rs2970992	0.764	rs2175791	chr2:101330661	G/A	cg01042948	chr2:101319752	NA	0.58	6.08	0.45	1e-8	Educational attainment;
UCEC	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.46	-5.95	-0.44	1.84e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.9	8.73	0.58	5.17e-15	Platelet count;
UCEC	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg22862634	chr11:62369728	EML3;MTA2	-0.43	-5.58	-0.42	1.14e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7307889	0.793	rs73047609	chr12:5996588	G/A	cg10294363	chr12:6480192	SCNN1A	0.64	4.73	0.36	5.21e-6	Obesity-related traits;
UCEC	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.45	5.23	0.4	5.75e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.71	6.43	0.47	1.64e-9	Neutrophil percentage of white cells;
UCEC	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.48	-4.77	-0.37	4.37e-6	Dental caries;
UCEC	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.33	-5.49	-0.41	1.69e-7	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.66	-6.59	-0.48	7.23e-10	Aortic root size;
UCEC	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.42	4.55	0.35	1.1e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.57	5.93	0.44	2.08e-8	Blood protein levels;
UCEC	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.75	9.97	0.64	3.33e-18	Intelligence (multi-trait analysis);
UCEC	cis	rs77988765	0.908	rs75725796	chr11:70021269	G/A	cg02486268	chr11:69682825	NA	0.48	4.51	0.35	1.3e-5	Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs16857609	0.628	rs768435	chr2:218343878	C/T	cg23340935	chr2:218354150	DIRC3	0.48	4.63	0.36	7.86e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
UCEC	cis	rs2267681	0.565	rs6464800	chr7:139518480	A/G	cg14116596	chr7:139528673	TBXAS1	0.57	5.45	0.41	2.11e-7	Cervical cancer;
UCEC	cis	rs10012307	1.000	rs17048738	chr4:137497899	A/G	cg12033966	chr4:138453416	PCDH18	0.71	5.11	0.39	9.99e-7	DNA methylation (parent-of-origin);
UCEC	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	5.98	0.44	1.63e-8	Monocyte percentage of white cells;
UCEC	cis	rs1007190	0.764	rs8082522	chr17:42876340	G/C	cg15406952	chr17:42872593	NA	-0.67	-4.87	-0.37	2.87e-6	DNA methylation (variation);
UCEC	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg21770322	chr7:97807741	LMTK2	0.54	6.75	0.49	3.16e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.77	-7.41	-0.52	9.17e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Subjective well-being;
UCEC	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.33	0.4	3.56e-7	Neuroticism;
UCEC	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs259282	0.538	rs6510270	chr19:33114514	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.53	4.69	0.36	6.22e-6	Schizophrenia;
UCEC	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.76	-6.06	-0.45	1.07e-8	Educational attainment;
UCEC	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg16583315	chr14:65563665	MAX	-0.48	-5.16	-0.39	7.86e-7	Obesity-related traits;
UCEC	cis	rs224090	0.540	rs11592442	chr10:64533904	T/A	cg02209504	chr10:64576388	EGR2	0.46	4.51	0.35	1.34e-5	Crohn's disease;
UCEC	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.66	-6.31	-0.46	3.16e-9	Acne (severe);
UCEC	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.46	-5.08	-0.39	1.15e-6	Longevity;
UCEC	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.61	5.38	0.41	2.88e-7	Alcohol dependence;
UCEC	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.66	7.08	0.5	5.42e-11	Menopause (age at onset);
UCEC	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.44	-5.05	-0.38	1.3e-6	Aortic root size;
UCEC	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.71	6.69	0.48	4.43e-10	High light scatter reticulocyte count;
UCEC	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg22166914	chr1:53195759	ZYG11B	0.59	5.86	0.43	2.97e-8	Monocyte count;
UCEC	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	8.12	0.56	1.75e-13	Bone mineral density;
UCEC	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.89	5.88	0.44	2.6e-8	Psoriasis;
UCEC	cis	rs35934224	0.504	rs10372	chr22:19837298	G/A	cg11182965	chr22:19864308	TXNRD2	-0.4	-5.12	-0.39	9.46e-7	Glaucoma (primary open-angle);
UCEC	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.64	7.3	0.52	1.66e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg01451880	chr3:45801044	SLC6A20	-0.4	-5.22	-0.4	6.03e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.63	7.31	0.52	1.59e-11	Schizophrenia;
UCEC	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.55	5.65	0.42	8.13e-8	Tonsillectomy;
UCEC	cis	rs10924970	0.967	rs2185020	chr1:235440289	A/G	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.74e-6	Asthma;
UCEC	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.75e-10	Obesity-related traits;
UCEC	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.96	-10.93	-0.67	9.75e-21	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.47	-4.98	-0.38	1.76e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs62064224	0.703	rs4287613	chr17:30827688	C/T	cg25809561	chr17:30822961	MYO1D	0.38	4.74	0.36	5.1e-6	Schizophrenia;
UCEC	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.89	-9.37	-0.61	1.17e-16	Blood metabolite levels;
UCEC	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	0.72	7.31	0.52	1.58e-11	Tonsillectomy;
UCEC	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.64	6.41	0.47	1.85e-9	Menopause (age at onset);
UCEC	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.47	4.59	0.35	9.5e-6	Motion sickness;
UCEC	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.62	5.67	0.42	7.49e-8	High light scatter reticulocyte count;
UCEC	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.69	6.5	0.47	1.15e-9	Aortic root size;
UCEC	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.8	-10.13	-0.64	1.3e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.59	-6.61	-0.48	6.71e-10	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg22974920	chr21:40686053	BRWD1	0.61	5.38	0.41	2.81e-7	Cognitive function;
UCEC	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.7	7.22	0.51	2.53e-11	Menopause (age at onset);
UCEC	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.75	7.52	0.53	4.93e-12	Primary sclerosing cholangitis;
UCEC	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.63	-5.78	-0.43	4.22e-8	Longevity;
UCEC	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.07	0.39	1.19e-6	Rheumatoid arthritis;
UCEC	cis	rs9976767	0.792	rs2839508	chr21:43845294	A/G	cg00134539	chr21:43824071	UBASH3A	0.32	5.01	0.38	1.55e-6	Type 1 diabetes;
UCEC	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-0.81	-7.01	-0.5	8.12e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	0.93	9.58	0.62	3.36e-17	Heart rate;
UCEC	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.45	-5.72	-0.43	5.83e-8	Fibrinogen levels;
UCEC	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.47	6.64	0.48	5.54e-10	Alcohol dependence;
UCEC	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.41	0.57	3.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.11	9.63	0.62	2.5e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.73	-7.37	-0.52	1.16e-11	Plateletcrit;Platelet count;
UCEC	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.67	-4.92	-0.38	2.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1483890	0.723	rs6807930	chr3:69411662	C/T	cg22125112	chr3:69402811	FRMD4B	0.44	4.61	0.36	8.55e-6	Resting heart rate;
UCEC	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.64	-5.96	-0.44	1.82e-8	Homoarginine levels;
UCEC	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.54	-5.75	-0.43	5.01e-8	Bipolar disorder;
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.38	-4.87	-0.37	2.87e-6	Body mass index;
UCEC	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.65	-5.26	-0.4	5.08e-7	Mean platelet volume;Platelet distribution width;
UCEC	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	0.99	6.99	0.5	8.84e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs7246967	0.932	rs35735434	chr19:23039477	T/C	cg08271804	chr19:22816896	ZNF492	0.58	5.45	0.41	2.05e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	5.83	0.43	3.41e-8	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs10924970	0.625	rs3806394	chr1:235489850	C/T	cg26050004	chr1:235667680	B3GALNT2	0.5	4.73	0.36	5.21e-6	Asthma;
UCEC	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.53	-4.7	-0.36	5.95e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg03060546	chr3:49711283	APEH	0.55	5.57	0.42	1.19e-7	Red cell distribution width;
UCEC	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.68	-7.66	-0.53	2.36e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg01262667	chr19:19385393	TM6SF2	-0.45	-6.22	-0.46	4.78e-9	Tonsillectomy;
UCEC	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.58	5.84	0.43	3.18e-8	Prudent dietary pattern;
UCEC	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.76	4.68	0.36	6.56e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.39	-0.47	2.05e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.6	-6.39	-0.47	2.11e-9	Psoriasis;
UCEC	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.75	-6.67	-0.48	4.88e-10	Caudate activity during reward;
UCEC	cis	rs1575951	1.000	rs7098205	chr10:130439482	A/G	cg27041381	chr10:131357203	MGMT	0.6	5.22	0.4	5.99e-7	Plasma clusterin levels;
UCEC	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg04155231	chr12:9217510	LOC144571	0.44	5.47	0.41	1.87e-7	Sjögren's syndrome;
UCEC	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.54	7.86	0.54	7.35e-13	Coronary artery disease or large artery stroke;
UCEC	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.81	7.87	0.54	7.14e-13	Cognitive function;
UCEC	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.83	7.65	0.53	2.48e-12	Obesity-related traits;
UCEC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg05802129	chr4:122689817	NA	-0.55	-5.55	-0.42	1.31e-7	Type 2 diabetes;
UCEC	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.06	7.56	0.53	4.06e-12	Lung disease severity in cystic fibrosis;
UCEC	cis	rs12635074	0.521	rs1869159	chr3:56313899	T/C	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.33	4.56	0.35	1.08e-5	Morning vs. evening chronotype;
UCEC	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.7	7.12	0.51	4.4e-11	Post bronchodilator FEV1;
UCEC	cis	rs7246967	0.673	rs118059742	chr19:22819446	T/A	cg08271804	chr19:22816896	ZNF492	0.66	6.62	0.48	6.39e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.49	-5.25	-0.4	5.19e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.51	-0.41	1.59e-7	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.77	-8.83	-0.59	2.89e-15	Facial morphology (factor 19);
UCEC	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.58	6.44	0.47	1.62e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg13216073	chr1:12042593	MFN2	-0.54	-5.67	-0.42	7.42e-8	Tuberculosis;
UCEC	cis	rs892864	0.685	rs10519994	chr5:127772621	A/G	cg17313118	chr5:127157258	NA	-0.65	-4.62	-0.36	8.29e-6	Multiple system atrophy;
UCEC	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.6	-6.76	-0.49	2.99e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg13695892	chr22:41940480	POLR3H	0.67	5.17	0.39	7.44e-7	Vitiligo;
UCEC	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.43	-4.89	-0.37	2.59e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.33	4.87	0.37	2.91e-6	Vitiligo;
UCEC	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.74	8.09	0.56	2.02e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
UCEC	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.53	5.45	0.41	2.04e-7	Neutrophil percentage of white cells;
UCEC	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.89	-11.56	-0.69	2.14e-22	IgG glycosylation;
UCEC	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.73	8.19	0.56	1.19e-13	Fractional exhaled nitric oxide (childhood);
UCEC	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg05991184	chr2:219186017	PNKD	0.5	5.46	0.41	2e-7	Colorectal cancer;
UCEC	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.46	-4.92	-0.38	2.32e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.55	0.53	4.24e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.6	6.29	0.46	3.38e-9	Colorectal cancer;
UCEC	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.92	9.68	0.62	1.86e-17	Cognitive function;
UCEC	cis	rs17106184	1.000	rs72904737	chr1:51351846	G/A	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg07424592	chr7:64974309	NA	0.8	4.69	0.36	6.32e-6	Diabetic kidney disease;
UCEC	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.59	5.45	0.41	2.11e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg12024160	chr4:1254474	NA	0.59	7.89	0.55	6.2e-13	Obesity-related traits;
UCEC	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.46	5.03	0.38	1.43e-6	Response to antineoplastic agents;
UCEC	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.66	6.58	0.48	7.59e-10	Aortic root size;
UCEC	cis	rs17122693	1.000	rs1494176	chr14:51083372	A/C	cg04730355	chr14:51134070	SAV1	0.88	8.91	0.59	1.79e-15	Cognitive performance;
UCEC	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	6.34	0.46	2.68e-9	Response to bleomycin (chromatid breaks);
UCEC	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-4.9	-0.37	2.46e-6	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.56	6.01	0.44	1.38e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.41	5.27	0.4	4.68e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-5.59	-0.42	1.06e-7	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.92	10.17	0.64	1.01e-18	Cognitive function;
UCEC	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-0.95	-6.07	-0.45	1.06e-8	Diabetic kidney disease;
UCEC	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-0.72	-6.82	-0.49	2.25e-10	Breast cancer;
UCEC	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	0.95	9.04	0.6	8.61e-16	Cognitive function;
UCEC	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-6.0	-0.44	1.47e-8	Platelet count;
UCEC	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg21214455	chr15:72412075	SENP8	0.48	4.6	0.35	9.19e-6	Red blood cell count;
UCEC	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.84	8.2	0.56	1.09e-13	Colorectal cancer;
UCEC	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.9	0.49	1.47e-10	Coronary artery disease;
UCEC	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.72e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	0.74	4.76	0.37	4.67e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.58	5.21	0.39	6.28e-7	Crohn's disease;
UCEC	cis	rs7246967	0.611	rs8102927	chr19:22879356	A/G	cg08271804	chr19:22816896	ZNF492	0.69	4.63	0.36	7.82e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs6684428	0.764	rs61777585	chr1:56394683	G/A	cg11651538	chr1:56320950	NA	-0.69	-6.25	-0.46	4.22e-9	Airflow obstruction;
UCEC	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-4.55	-0.35	1.11e-5	Monocyte count;
UCEC	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.51	-5.09	-0.39	1.1e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.5	-5.02	-0.38	1.48e-6	Systemic lupus erythematosus;
UCEC	cis	rs2957692	0.528	rs7104093	chr11:10339134	G/A	cg08691479	chr11:9595265	WEE1	-0.62	-4.55	-0.35	1.12e-5	Circulating vasoactive peptide levels;
UCEC	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.85	-7.55	-0.53	4.17e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs925228	0.955	rs2339886	chr2:24160642	G/T	cg16945982	chr2:25016118	CENPO;C2orf79	0.55	4.84	0.37	3.22e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.86	6.74	0.49	3.37e-10	Body mass index;
UCEC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.1	-6.86	-0.49	1.82e-10	Diabetic kidney disease;
UCEC	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.44	4.64	0.36	7.62e-6	HDL cholesterol;
UCEC	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.53	5.59	0.42	1.07e-7	Corneal astigmatism;
UCEC	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.49	5.26	0.4	4.96e-7	Schizophrenia;
UCEC	cis	rs7246967	0.608	rs437859	chr19:23007349	A/G	cg24889512	chr19:22816950	ZNF492	-0.45	-4.57	-0.35	1.05e-5	Bronchopulmonary dysplasia;
UCEC	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg08949735	chr16:89699720	DPEP1	-0.37	-5.25	-0.4	5.21e-7	Vitiligo;
UCEC	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.55	-5.44	-0.41	2.19e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.38	-4.69	-0.36	6.18e-6	Cutaneous nevi;
UCEC	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.53	-4.69	-0.36	6.18e-6	Colorectal adenoma (advanced);
UCEC	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.6	5.94	0.44	1.98e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg15837086	chr1:46506065	PIK3R3	0.38	4.8	0.37	3.89e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	6.81	0.49	2.26e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.68	7.71	0.54	1.75e-12	Menopause (age at onset);
UCEC	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.74	-4.8	-0.37	3.93e-6	Hair shape;
UCEC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg12292205	chr6:26970375	C6orf41	0.57	5.0	0.38	1.59e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs7088591	0.571	rs74521286	chr10:59778312	G/C	cg11142981	chr10:60273225	BICC1	0.62	4.55	0.35	1.11e-5	Blood pressure;
UCEC	cis	rs151997	0.962	rs27268	chr5:50184778	T/C	cg06027927	chr5:50259733	NA	0.54	4.97	0.38	1.81e-6	Callous-unemotional behaviour;
UCEC	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.83	-8.42	-0.57	3.02e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.59	-0.35	9.58e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs79815064	0.850	rs74433128	chr3:46279933	T/G	cg08033130	chr3:45983597	CXCR6;FYCO1	0.73	4.63	0.36	7.91e-6	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs1150668	0.835	rs1233696	chr6:28143010	T/C	cg24703168	chr6:28411309	ZSCAN23	-0.51	-5.55	-0.42	1.3e-7	Pubertal anthropometrics;
UCEC	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.81	7.09	0.5	5.29e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-5.06	-0.39	1.22e-6	Perceived unattractiveness to mosquitoes;
UCEC	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.41	4.68	0.36	6.55e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.89	-11.41	-0.69	5.54e-22	Height;
UCEC	cis	rs9486594	1.000	rs78394231	chr6:107649123	T/C	cg20431250	chr6:108492653	NR2E1	-0.73	-4.98	-0.38	1.78e-6	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-7.17	-0.51	3.43e-11	Colorectal cancer;
UCEC	cis	rs611744	0.806	rs374810	chr8:109096029	G/A	cg18478394	chr8:109455254	TTC35	0.52	5.57	0.42	1.16e-7	Dupuytren's disease;
UCEC	cis	rs773506	0.655	rs10991796	chr9:93930243	G/T	cg03243796	chr9:93920768	NA	-0.39	-5.04	-0.38	1.34e-6	Type 2 diabetes nephropathy;
UCEC	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Neutrophil percentage of white cells;
UCEC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-4.99	-0.38	1.65e-6	Blood metabolite levels;
UCEC	cis	rs1912528	0.745	rs6852749	chr4:140864455	C/T	cg01641771	chr4:140476319	SETD7	-0.44	-4.99	-0.38	1.68e-6	Educational attainment (years of education);
UCEC	trans	rs995000	0.931	rs626787	chr1:62901243	C/G	cg17019866	chr8:121457656	MTBP;MRPL13	0.7	7.36	0.52	1.23e-11	Triglyceride levels;
UCEC	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg21191810	chr6:118973309	C6orf204	0.34	4.8	0.37	3.92e-6	Electrocardiographic conduction measures;
UCEC	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.77	8.39	0.57	3.78e-14	Blood protein levels;
UCEC	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.46	4.81	0.37	3.62e-6	Schizophrenia;
UCEC	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.54	-4.93	-0.38	2.21e-6	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.56	-5.04	-0.38	1.34e-6	Metabolite levels;
UCEC	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.64	7.92	0.55	5.3e-13	Bone mineral density;
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.55	5.46	0.41	2.01e-7	Prudent dietary pattern;
UCEC	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.94	10.94	0.67	9.16e-21	Breast cancer;
UCEC	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.56	4.98	0.38	1.74e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-5.05	-0.38	1.27e-6	Personality dimensions;
UCEC	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.49	4.82	0.37	3.52e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
UCEC	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg18016565	chr1:150552671	MCL1	0.61	6.7	0.48	4.21e-10	Tonsillectomy;
UCEC	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.58	-5.92	-0.44	2.21e-8	Bipolar disorder;
UCEC	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.13	-14.41	-0.77	6.65e-30	Schizophrenia;
UCEC	cis	rs2904967	0.866	rs526502	chr11:65026590	T/C	cg01630869	chr11:65082120	CDC42EP2	-0.52	-4.86	-0.37	2.98e-6	Mean corpuscular volume;
UCEC	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.56	7.24	0.51	2.35e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg00738113	chr16:70207722	CLEC18C	0.36	4.76	0.37	4.62e-6	Sjögren's syndrome;
UCEC	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.76	7.53	0.53	4.78e-12	Vitamin D levels;
UCEC	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.14	0.6	4.79e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.67	-7.99	-0.55	3.69e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.23	18.84	0.84	4.9e-41	Chronic sinus infection;
UCEC	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.51	-5.03	-0.38	1.4e-6	Breast size;
UCEC	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.63	7.72	0.54	1.6e-12	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.67	-5.67	-0.42	7.38e-8	Aortic root size;
UCEC	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.52	4.95	0.38	1.99e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.67	-6.82	-0.49	2.24e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.59	6.1	0.45	9.03e-9	Tonsillectomy;
UCEC	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.59	4.85	0.37	3.09e-6	Eosinophilic esophagitis;
UCEC	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14019695	chr9:139328340	INPP5E	0.48	5.05	0.38	1.3e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.68	-4.82	-0.37	3.48e-6	Toenail selenium levels;
UCEC	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.5	-5.61	-0.42	9.61e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.55	5.56	0.42	1.24e-7	Aortic root size;
UCEC	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.75	7.0	0.5	8.25e-11	Bladder cancer;
UCEC	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.57	-5.28	-0.4	4.66e-7	Metabolite levels;
UCEC	cis	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg15326795	chr6:26217500	HIST1H2BG;HIST1H2AE	-0.6	-4.63	-0.36	7.85e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.89	5.72	0.43	5.65e-8	Psoriasis;
UCEC	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.68	-7.58	-0.53	3.64e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.45	-5.51	-0.41	1.6e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.66	6.85	0.49	1.86e-10	Breast cancer;
UCEC	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.61	6.27	0.46	3.71e-9	Retinal vascular caliber;
UCEC	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.53	-7.08	-0.5	5.56e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.4	4.87	0.37	2.8e-6	Reticulocyte fraction of red cells;
UCEC	cis	rs256277	0.657	rs173898	chr5:111369570	T/C	cg07368146	chr5:111497076	NCRNA00219;SNORA13	-0.54	-4.51	-0.35	1.32e-5	Coronary artery disease;
UCEC	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.51	5.29	0.4	4.34e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.51	5.26	0.4	4.99e-7	Schizophrenia;
UCEC	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.26	14.87	0.78	4.24e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.7	6.29	0.46	3.49e-9	Cognitive test performance;
UCEC	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.49	-6.59	-0.48	7.22e-10	Body mass index;
UCEC	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.83	-10.21	-0.64	7.68e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.47	4.82	0.37	3.61e-6	Aortic root size;
UCEC	cis	rs239198	0.555	rs9386258	chr6:101286336	C/G	cg09795085	chr6:101329169	ASCC3	0.47	4.51	0.35	1.29e-5	Menarche (age at onset);
UCEC	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.58	6.72	0.48	3.71e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
UCEC	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	1.04	7.62	0.53	2.94e-12	Obesity-related traits;
UCEC	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.66	5.77	0.43	4.55e-8	Aortic root size;
UCEC	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.52	4.76	0.37	4.5e-6	Menarche (age at onset);
UCEC	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.68	6.52	0.47	1.04e-9	Menarche (age at onset);
UCEC	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.71	-7.22	-0.51	2.52e-11	Calcium levels;
UCEC	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.52	6.04	0.45	1.18e-8	Aortic root size;
UCEC	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.6	-0.42	1.04e-7	Obesity-related traits;
UCEC	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.52	-4.55	-0.35	1.09e-5	Immature fraction of reticulocytes;
UCEC	cis	rs6832769	1.000	rs1522108	chr4:56380733	T/C	cg05960024	chr4:56376020	CLOCK	0.55	5.13	0.39	8.87e-7	Personality dimensions;
UCEC	cis	rs7870753	0.578	rs2145985	chr9:99174531	C/T	cg25260653	chr9:99212216	HABP4	0.52	4.79	0.37	4.01e-6	Height;
UCEC	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.49	5.58	0.42	1.14e-7	Response to temozolomide;
UCEC	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg16797656	chr11:68205561	LRP5	0.48	5.4	0.41	2.65e-7	Total body bone mineral density;
UCEC	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.65	-5.51	-0.41	1.54e-7	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs7246967	0.932	rs58238799	chr19:23040182	G/T	cg24889512	chr19:22816950	ZNF492	0.48	5.05	0.38	1.29e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.72	-4.52	-0.35	1.24e-5	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13683864	chr3:40499215	RPL14	-0.97	-10.66	-0.66	5.22e-20	Renal cell carcinoma;
UCEC	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg04310649	chr10:35416472	CREM	-0.51	-4.79	-0.37	4.07e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg02158880	chr13:53174818	NA	0.59	6.93	0.5	1.23e-10	Lewy body disease;
UCEC	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg24375607	chr4:120327624	NA	0.49	4.98	0.38	1.72e-6	Corneal astigmatism;
UCEC	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	trans	rs62025270	0.688	rs76902341	chr15:86280290	T/C	cg14491707	chr9:141016791	CACNA1B	0.58	6.73	0.49	3.57e-10	Idiopathic pulmonary fibrosis;
UCEC	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.9	7.53	0.53	4.81e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.58	5.88	0.44	2.67e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.5	-5.05	-0.38	1.3e-6	Height;
UCEC	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.4	-4.74	-0.36	5.05e-6	Coronary artery disease;
UCEC	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.65	-6.44	-0.47	1.57e-9	Coronary artery disease;
UCEC	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.53	-6.39	-0.47	2.09e-9	Fibrinogen levels;
UCEC	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.63	-6.35	-0.46	2.5e-9	Ulcerative colitis;
UCEC	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.69	0.36	6.29e-6	Diabetic retinopathy;
UCEC	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.63	6.94	0.5	1.16e-10	Eye color traits;
UCEC	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.88	-9.67	-0.62	1.96e-17	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.52	5.51	0.41	1.57e-7	Blood protein levels;
UCEC	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.17	0.6	3.89e-16	Coffee consumption (cups per day);
UCEC	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg21932190	chr1:1635647	CDK11A;CDK11B	-0.46	-4.71	-0.36	5.58e-6	Body mass index;
UCEC	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.84	-10.21	-0.64	7.71e-19	Coronary artery disease;
UCEC	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.43	5.14	0.39	8.79e-7	Electroencephalogram traits;
UCEC	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.47	4.86	0.37	3e-6	Blood protein levels;
UCEC	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.52	-4.67	-0.36	6.73e-6	Hypospadias;
UCEC	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.7	-0.36	6.03e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.83	-9.28	-0.61	2.1e-16	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.52	5.1	0.39	1.04e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-4.68	-0.36	6.34e-6	Menopause (age at onset);
UCEC	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.68	-6.48	-0.47	1.31e-9	Developmental language disorder (linguistic errors);
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14729071	chr8:117886537	RAD21	0.58	7.92	0.55	5.42e-13	Warfarin maintenance dose;
UCEC	cis	rs12980942	0.591	rs2304231	chr19:41762670	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.68	5.14	0.39	8.58e-7	Coronary artery disease;
UCEC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.42	4.8	0.37	3.94e-6	Platelet count;
UCEC	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.48	5.87	0.44	2.8e-8	Subjective well-being (multi-trait analysis);
UCEC	trans	rs12636148	0.680	rs12486096	chr3:162086033	C/T	cg07979357	chr19:14142353	IL27RA	-0.71	-6.99	-0.5	8.95e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.52	-7.06	-0.5	6.14e-11	Sense of smell;
UCEC	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.5	-4.67	-0.36	6.85e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-4.78	-0.37	4.27e-6	Platelet count;
UCEC	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg16583315	chr14:65563665	MAX	-0.44	-5.82	-0.43	3.55e-8	Obesity-related traits;
UCEC	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg23548455	chr2:233377587	NA	0.38	4.73	0.36	5.31e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.65	6.32	0.46	2.98e-9	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	10.44	0.65	1.97e-19	Chronic sinus infection;
UCEC	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg21905437	chr5:178450457	ZNF879	0.64	7.19	0.51	3e-11	Pubertal anthropometrics;
UCEC	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16346588	chr10:242978	ZMYND11	0.49	4.74	0.36	5.07e-6	Psychosis in Alzheimer's disease;
UCEC	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.45	-5.17	-0.39	7.4e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.56	-5.57	-0.42	1.18e-7	Aortic root size;
UCEC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg02160872	chr5:212506	CCDC127	-0.72	-7.3	-0.52	1.7e-11	Breast cancer;
UCEC	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.42	5.98	0.44	1.6e-8	Crohn's disease;
UCEC	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.6	0.58	1.12e-14	Total body bone mineral density;
UCEC	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.58	5.6	0.42	1.01e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.43	4.52	0.35	1.28e-5	Alzheimer's disease;
UCEC	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.45	-4.7	-0.36	6e-6	Menarche (age at onset);
UCEC	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.84	-8.97	-0.59	1.26e-15	Breast cancer;
UCEC	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg05660106	chr1:15850417	CASP9	0.49	5.05	0.38	1.26e-6	Systolic blood pressure;
UCEC	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.4	4.52	0.35	1.27e-5	Schizophrenia;
UCEC	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	7.92	0.55	5.44e-13	Mean platelet volume;
UCEC	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.6	5.69	0.42	6.78e-8	Vitamin D levels;
UCEC	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg18681998	chr4:17616180	MED28	0.91	11.85	0.7	3.59e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18252515	chr7:66147081	NA	0.52	5.37	0.4	3.04e-7	Aortic root size;
UCEC	cis	rs7247513	0.964	rs12104149	chr19:12721088	A/G	cg01871581	chr19:12707946	ZNF490	-0.64	-7.04	-0.5	6.89e-11	Bipolar disorder;
UCEC	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.59	-5.75	-0.43	4.98e-8	Blood protein levels;
UCEC	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg08493051	chr2:3487164	NA	-0.62	-6.57	-0.48	7.96e-10	Neurofibrillary tangles;
UCEC	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.64	5.27	0.4	4.72e-7	Lymphocyte counts;
UCEC	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.77	7.98	0.55	3.84e-13	Parkinson's disease;
UCEC	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs883565	0.771	rs2056613	chr3:39125293	G/T	cg01426195	chr3:39028469	NA	-0.73	-9.25	-0.61	2.5e-16	Handedness;
UCEC	cis	rs7919006	0.793	rs58552023	chr10:76783198	G/A	cg01390419	chr10:76803856	DUPD1	0.47	4.63	0.36	8.01e-6	Weight;
UCEC	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg11871910	chr12:69753446	YEATS4	0.59	5.85	0.43	3.03e-8	Blood protein levels;
UCEC	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.38	0.52	1.07e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.89	11.17	0.68	2.39e-21	IgG glycosylation;
UCEC	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.59	6.47	0.47	1.38e-9	Monocyte count;
UCEC	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22509189	chr2:225307070	NA	0.54	4.81	0.37	3.7e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.59	6.76	0.49	3e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.45	-0.47	1.52e-9	Tonsillectomy;
UCEC	cis	rs9469578	0.710	rs77213792	chr6:33713952	C/G	cg18708504	chr6:33715942	IP6K3	0.52	5.16	0.39	7.96e-7	Phosphorus levels;
UCEC	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-0.99	-6.29	-0.46	3.41e-9	Diabetic kidney disease;
UCEC	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.56	-5.52	-0.41	1.48e-7	Bipolar disorder;
UCEC	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.43	4.58	0.35	9.68e-6	Height;
UCEC	cis	rs12681963	0.748	rs1511168	chr8:29893834	A/C	cg07899425	chr8:30585046	GSR	0.56	5.0	0.38	1.64e-6	Migraine;
UCEC	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.86	-10.99	-0.67	7.14e-21	Brugada syndrome;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18342900	chr16:46865048	C16orf87	0.66	8.31	0.57	5.94e-14	Warfarin maintenance dose;
UCEC	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.6	-5.74	-0.43	5.31e-8	Schizophrenia;
UCEC	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-4.84	-0.37	3.23e-6	Mean platelet volume;
UCEC	cis	rs7129220	0.764	rs72861799	chr11:10238865	G/T	cg06713769	chr11:10589810	LYVE1	0.76	4.53	0.35	1.23e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.82	9.91	0.63	4.67e-18	Menopause (age at onset);
UCEC	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.66	6.81	0.49	2.31e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.65	7.37	0.52	1.13e-11	Ulcerative colitis;
UCEC	cis	rs7246967	0.551	rs3925175	chr19:22880958	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.44	0.47	1.64e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.46	5.01	0.38	1.53e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.33	4.92	0.38	2.3e-6	Schizophrenia;
UCEC	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7246967	0.932	rs4932793	chr19:23036449	A/G	cg05241461	chr19:22816980	ZNF492	0.47	5.03	0.38	1.41e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs4430311	0.723	rs4590656	chr1:244002773	C/T	cg02850371	chr1:244999141	FAM36A	0.52	5.35	0.4	3.27e-7	Post-traumatic stress disorder (asjusted for relatedness);
UCEC	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.45	-5.32	-0.4	3.87e-7	Subjective well-being;
UCEC	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	6.24	0.46	4.49e-9	Platelet count;
UCEC	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.5	-5.44	-0.41	2.22e-7	Brugada syndrome;
UCEC	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.5	4.75	0.36	4.72e-6	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.78	-4.78	-0.37	4.26e-6	Platelet count;
UCEC	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-11.03	-0.67	5.6e-21	Chronic sinus infection;
UCEC	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.75	8.73	0.58	5.29e-15	Mean corpuscular volume;
UCEC	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	5.21	0.4	6.16e-7	Aortic root size;
UCEC	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	6.32	0.46	2.95e-9	Personality dimensions;
UCEC	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13683864	chr3:40499215	RPL14	-0.67	-6.69	-0.48	4.45e-10	Renal cell carcinoma;
UCEC	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.46	4.78	0.37	4.14e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.68	5.73	0.43	5.5e-8	Menopause (age at onset);
UCEC	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg06462663	chr19:18546047	ISYNA1	0.52	6.62	0.48	6.2e-10	Breast cancer;
UCEC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.67	-6.44	-0.47	1.58e-9	Platelet distribution width;
UCEC	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.64	-4.54	-0.35	1.15e-5	Aortic root size;
UCEC	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg13147721	chr7:65941812	NA	-0.74	-5.02	-0.38	1.5e-6	Diabetic kidney disease;
UCEC	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg14784868	chr12:69753453	YEATS4	-0.55	-4.68	-0.36	6.37e-6	Response to diuretic therapy;
UCEC	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg03714773	chr7:91764589	CYP51A1	0.41	4.9	0.37	2.5e-6	Breast cancer;
UCEC	cis	rs10095849	0.576	rs10099250	chr8:39444134	T/G	cg24581462	chr8:38759627	PLEKHA2	0.36	4.61	0.36	8.76e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
UCEC	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-4.83	-0.37	3.37e-6	Blood metabolite levels;
UCEC	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.49	5.69	0.42	6.57e-8	Blood metabolite ratios;
UCEC	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.48	-5.31	-0.4	3.89e-7	Height;
UCEC	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-5.28	-0.4	4.66e-7	Kawasaki disease;
UCEC	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.58	-5.34	-0.4	3.41e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg24803719	chr17:45855879	NA	-0.47	-5.27	-0.4	4.88e-7	IgG glycosylation;
UCEC	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.62	4.94	0.38	2.14e-6	Bipolar disorder (body mass index interaction);
UCEC	cis	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg20368463	chr18:77673604	PQLC1	-0.59	-4.53	-0.35	1.23e-5	Schizophrenia;
UCEC	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg02158880	chr13:53174818	NA	0.53	6.34	0.46	2.66e-9	Lewy body disease;
UCEC	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	0.84	4.9	0.37	2.46e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.65	0.42	7.96e-8	Breast cancer;
UCEC	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.64	5.67	0.42	7.36e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-8.04	-0.55	2.75e-13	Chronic sinus infection;
UCEC	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	7.42	0.52	8.62e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.73	6.48	0.47	1.32e-9	Cognitive function;
UCEC	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg11569703	chr11:65557185	OVOL1	0.42	5.15	0.39	8.24e-7	Acne (severe);
UCEC	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.77	7.04	0.5	6.91e-11	Morning vs. evening chronotype;
UCEC	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	5.88	0.44	2.67e-8	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.66	6.12	0.45	8.15e-9	Schizophrenia;
UCEC	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-0.89	-11.57	-0.69	2.04e-22	Height;
UCEC	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.61	-7.26	-0.51	2.12e-11	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-0.97	-6.25	-0.46	4.12e-9	Diabetic kidney disease;
UCEC	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.52	5.49	0.41	1.69e-7	Red blood cell count;
UCEC	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.5	5.27	0.4	4.82e-7	Schizophrenia;
UCEC	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.77	7.67	0.53	2.23e-12	Lung cancer;
UCEC	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	5.73	0.43	5.58e-8	Prudent dietary pattern;
UCEC	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-4.9	-0.37	2.54e-6	Chronic sinus infection;
UCEC	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.54	6.81	0.49	2.35e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.61	-6.3	-0.46	3.26e-9	Initial pursuit acceleration;
UCEC	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.63	5.78	0.43	4.38e-8	Mosquito bite size;
UCEC	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.42	-4.83	-0.37	3.37e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	4.55	0.35	1.12e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs172166	0.516	rs1150670	chr6:28130559	A/G	cg21486944	chr6:28411378	ZSCAN23	-0.51	-5.33	-0.4	3.69e-7	Cardiac Troponin-T levels;
UCEC	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.65	-4.55	-0.35	1.1e-5	Coronary artery disease;
UCEC	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.78	10.7	0.66	4.16e-20	Vitiligo;
UCEC	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.71	6.54	0.47	9.47e-10	Initial pursuit acceleration;
UCEC	cis	rs2970992	0.764	rs2137667	chr2:101332618	C/T	cg01042948	chr2:101319752	NA	0.47	4.93	0.38	2.16e-6	Educational attainment;
UCEC	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.56	5.22	0.4	6.08e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
UCEC	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg13147721	chr7:65941812	NA	-0.95	-6.57	-0.48	8.33e-10	Diabetic kidney disease;
UCEC	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg26528668	chr16:1614120	IFT140	0.45	5.36	0.4	3.18e-7	Coronary artery disease;
UCEC	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg02413938	chr2:239008929	ESPNL	-0.35	-4.52	-0.35	1.26e-5	Prostate cancer;
UCEC	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.03	-0.38	1.4e-6	Joint mobility (Beighton score);
UCEC	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg14092571	chr14:90743983	NA	-0.42	-5.7	-0.43	6.47e-8	Mortality in heart failure;
UCEC	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.56	-5.12	-0.39	9.62e-7	Coronary artery disease;
UCEC	cis	rs7766436	1.000	rs7766436	chr6:22598259	C/T	cg13666174	chr6:22585274	NA	-0.45	-4.85	-0.37	3.1e-6	Coronary artery disease;
UCEC	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.86	10.49	0.65	1.48e-19	Longevity;Endometriosis;
UCEC	cis	rs10507349	0.632	rs9581596	chr13:26819208	T/A	cg01600817	chr13:26797529	RNF6	-0.46	-4.92	-0.38	2.29e-6	Type 2 diabetes;
UCEC	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.58	7.47	0.52	6.67e-12	Bone mineral density;
UCEC	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	0.72	9.24	0.61	2.57e-16	Rheumatoid arthritis;
UCEC	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.63	-7.3	-0.52	1.67e-11	Body mass index;
UCEC	cis	rs4389656	0.743	rs34681760	chr5:6712834	T/C	cg10857441	chr5:6722123	POLS	-0.39	-4.58	-0.35	9.65e-6	Coronary artery disease;
UCEC	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-8.92	-0.59	1.69e-15	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.61	-0.36	8.84e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.87	0.44	2.72e-8	Menarche (age at onset);
UCEC	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.86	8.3	0.57	6.01e-14	Acute graft versus host disease in bone marrow transplantation (recipient effect);
UCEC	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	4.62	0.36	8.15e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.62	-5.46	-0.41	1.96e-7	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.64	6.37	0.46	2.33e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	6.35	0.46	2.57e-9	Coffee consumption (cups per day);
UCEC	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.59	-6.86	-0.49	1.8e-10	Menarche (age at onset);
UCEC	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.68	4.7	0.36	5.81e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-23.5	-0.89	1.19e-51	Myeloid white cell count;
UCEC	cis	rs2735413	0.958	rs2735401	chr16:78057103	A/C	cg09132178	chr16:78079569	NA	0.41	4.57	0.35	1.01e-5	Systolic blood pressure (alcohol consumption interaction);
UCEC	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.86	9.68	0.62	1.84e-17	Breast cancer;
UCEC	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.62	5.34	0.4	3.54e-7	Coronary artery disease;
UCEC	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg20821713	chr7:1055600	C7orf50	-0.72	-6.86	-0.49	1.76e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.58	-7.42	-0.52	8.66e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.65	6.11	0.45	8.37e-9	Lymphocyte counts;
UCEC	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.81	-8.93	-0.59	1.57e-15	Cognitive function;
UCEC	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.91	8.62	0.58	9.52e-15	Colorectal adenoma (advanced);
UCEC	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.87	11.23	0.68	1.57e-21	Metabolic syndrome;
UCEC	cis	rs75804782	0.566	rs56314406	chr2:239280377	A/G	cg11815105	chr2:239148849	HES6	0.99	4.63	0.36	8e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs6460942	1.000	rs7792759	chr7:12311715	A/G	cg20607287	chr7:12443886	VWDE	0.65	4.68	0.36	6.44e-6	Coronary artery disease;
UCEC	cis	rs8105895	0.935	rs62110981	chr19:22246013	A/G	cg24072202	chr19:22235272	ZNF257	-0.61	-5.33	-0.4	3.64e-7	Body mass index (change over time);
UCEC	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-7.9	-0.55	5.88e-13	Parkinson's disease;
UCEC	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.58	5.11	0.39	9.95e-7	Corneal astigmatism;
UCEC	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	5.95	0.44	1.84e-8	Breast cancer;
UCEC	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	8.89	0.59	2e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.27	-0.4	4.69e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18402987	chr7:1209562	NA	0.47	4.92	0.38	2.29e-6	Longevity;Endometriosis;
UCEC	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.76	5.25	0.4	5.25e-7	Inflammatory bowel disease;
UCEC	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-5.18	-0.39	7.3e-7	Aortic root size;
UCEC	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-7.91	-0.55	5.73e-13	Total cholesterol levels;
UCEC	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.63	5.18	0.39	7.31e-7	Gut microbiome composition (summer);
UCEC	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.47	4.88	0.37	2.74e-6	Smoking initiation;
UCEC	cis	rs2842992	0.747	rs4709379	chr6:160227530	A/G	cg11366901	chr6:160182831	ACAT2	0.83	7.24	0.51	2.28e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.59	4.78	0.37	4.27e-6	Corneal astigmatism;
UCEC	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.5	4.85	0.37	3.12e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg18755752	chr8:142205143	DENND3	-0.59	-5.48	-0.41	1.78e-7	Immature fraction of reticulocytes;
UCEC	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-0.94	-12.2	-0.71	4.43e-24	Height;
UCEC	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.72	-8.39	-0.57	3.64e-14	Blood trace element (Zn levels);
UCEC	cis	rs4074536	0.796	rs10158267	chr1:116310430	C/T	cg21648376	chr1:116311395	CASQ2	-0.5	-4.81	-0.37	3.77e-6	QRS duration;
UCEC	cis	rs10761482	0.954	rs10740022	chr10:62062686	A/G	cg03462556	chr10:61465108	SLC16A9	0.5	4.55	0.35	1.13e-5	Schizophrenia;
UCEC	cis	rs6546550	0.630	rs9309429	chr2:69995580	A/G	cg02498382	chr2:70120550	SNRNP27	-0.6	-6.65	-0.48	5.5e-10	Prevalent atrial fibrillation;
UCEC	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.59	-6.66	-0.48	4.99e-10	Cardiac Troponin-T levels;
UCEC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.54	-5.44	-0.41	2.17e-7	Aortic root size;
UCEC	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08564027	chr20:61660810	NA	0.55	6.91	0.5	1.34e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18252515	chr7:66147081	NA	0.57	5.36	0.4	3.14e-7	Aortic root size;
UCEC	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.25	14.95	0.78	2.58e-31	Type 1 diabetes nephropathy;
UCEC	cis	rs35934224	0.783	rs34462686	chr22:19859917	A/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-4.8	-0.37	3.84e-6	Glaucoma (primary open-angle);
UCEC	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-5.0	-0.38	1.61e-6	Metabolite levels;
UCEC	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.69	5.19	0.39	6.93e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.43	5.02	0.38	1.47e-6	Prudent dietary pattern;
UCEC	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg18230493	chr5:56204884	C5orf35	-0.52	-4.51	-0.35	1.33e-5	Coronary artery disease;
UCEC	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.48	5.7	0.43	6.47e-8	Prostate cancer;
UCEC	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-7.23	-0.51	2.47e-11	Colorectal cancer;
UCEC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.74	8.55	0.58	1.46e-14	Prudent dietary pattern;
UCEC	cis	rs10242455	0.867	rs2404770	chr7:99321612	A/G	cg07715041	chr7:99302981	CYP3A7	-0.53	-5.41	-0.41	2.55e-7	Blood metabolite levels;
UCEC	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.74	-5.99	-0.44	1.57e-8	Caudate activity during reward;
UCEC	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs13098911	0.540	rs34000569	chr3:45999209	A/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-1.03	-7.23	-0.51	2.5e-11	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg12035532	chr1:1886765	KIAA1751	0.43	4.56	0.35	1.06e-5	Body mass index;
UCEC	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.54	5.35	0.4	3.36e-7	Lymphocyte percentage of white cells;
UCEC	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.55	5.72	0.43	5.67e-8	Red cell distribution width;
UCEC	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.7	8.39	0.57	3.74e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.55	5.75	0.43	5.07e-8	Corneal astigmatism;
UCEC	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.58	-5.02	-0.38	1.48e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg14092571	chr14:90743983	NA	0.44	5.29	0.4	4.29e-7	Mortality in heart failure;
UCEC	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.63	5.5	0.41	1.66e-7	Uric acid levels;
UCEC	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.49	-5.27	-0.4	4.83e-7	Headache;
UCEC	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.81	7.28	0.51	1.86e-11	Bladder cancer;
UCEC	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg14008862	chr17:28927542	LRRC37B2	0.54	4.65	0.36	7.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7246967	0.736	rs2546463	chr19:22994606	C/G	cg08271804	chr19:22816896	ZNF492	0.55	4.86	0.37	2.96e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.48	4.99	0.38	1.66e-6	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Schizophrenia;
UCEC	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg04287289	chr16:89883240	FANCA	-0.45	-4.75	-0.36	4.87e-6	Vitiligo;
UCEC	cis	rs2041840	0.538	rs2372999	chr2:37573587	T/C	cg25727520	chr2:37576821	QPCT	-0.52	-5.84	-0.43	3.26e-8	Chronic lymphocytic leukemia;
UCEC	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.67	-6.78	-0.49	2.66e-10	Itch intensity from mosquito bite;
UCEC	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.7	6.44	0.47	1.63e-9	Mean corpuscular hemoglobin;
UCEC	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.55	-5.82	-0.43	3.48e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
UCEC	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.44	-5.05	-0.38	1.28e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.75	6.22	0.46	4.96e-9	Menopause (age at onset);
UCEC	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.69	8.39	0.57	3.77e-14	Prudent dietary pattern;
UCEC	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg06096015	chr1:231504339	EGLN1	0.47	5.56	0.42	1.26e-7	Hemoglobin concentration;
UCEC	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	0.81	9.45	0.61	7.45e-17	Ewing sarcoma;
UCEC	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg04310649	chr10:35416472	CREM	-0.54	-5.18	-0.39	7.24e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.45	-4.98	-0.38	1.78e-6	Asthma (sex interaction);
UCEC	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.54	4.8	0.37	3.78e-6	Bone properties (heel);
UCEC	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.64	5.59	0.42	1.1e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.55	5.18	0.39	7.04e-7	Blood trace element (Cu levels);
UCEC	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg04013166	chr16:89971882	TCF25	0.73	4.59	0.35	9.44e-6	Skin colour saturation;
UCEC	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg11161011	chr14:65562177	MAX	-0.74	-6.81	-0.49	2.33e-10	Obesity-related traits;
UCEC	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.55	6.09	0.45	9.3e-9	Multiple myeloma;
UCEC	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg21531300	chr14:75988800	BATF	-0.38	-4.53	-0.35	1.22e-5	Caffeine consumption;
UCEC	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.16	15.05	0.78	1.4e-31	Cognitive function;
UCEC	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg18681998	chr4:17616180	MED28	0.78	9.1	0.6	5.77e-16	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.43	-4.53	-0.35	1.2e-5	Parkinson's disease;
UCEC	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.74	5.66	0.42	7.86e-8	Soluble interleukin-2 receptor subunit alpha;
UCEC	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.5	4.56	0.35	1.09e-5	Coronary artery disease;
UCEC	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg20560298	chr2:73613845	ALMS1	0.52	4.95	0.38	1.98e-6	Metabolite levels;
UCEC	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.72	6.89	0.49	1.52e-10	Crohn's disease;
UCEC	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.76	8.3	0.57	6.04e-14	Itch intensity from mosquito bite;
UCEC	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	7.69	0.54	1.94e-12	Hip circumference adjusted for BMI;
UCEC	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg00983440	chr10:79422392	NA	-0.98	-7.61	-0.53	3.02e-12	Bone mineral density;
UCEC	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg01689657	chr7:91764605	CYP51A1	0.44	5.64	0.42	8.64e-8	Breast cancer;
UCEC	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.49	-4.8	-0.37	3.84e-6	Total body bone mineral density;
UCEC	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	5.24	0.4	5.41e-7	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.76	-7.79	-0.54	1.14e-12	Body mass index;
UCEC	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.71	-5.92	-0.44	2.17e-8	Longevity;
UCEC	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.48	0.47	1.33e-9	Cognitive test performance;
UCEC	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.53	-0.35	1.22e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.66	0.36	7.16e-6	Breast cancer;
UCEC	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg23791538	chr6:167370224	RNASET2	-0.55	-5.8	-0.43	4.01e-8	Primary biliary cholangitis;
UCEC	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg08027265	chr7:2291960	NA	-0.48	-5.04	-0.38	1.35e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-6.45	-0.47	1.48e-9	Morning vs. evening chronotype;
UCEC	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.84	9.4	0.61	9.96e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.83	-0.43	3.36e-8	Mortality in heart failure;
UCEC	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-4.97	-0.38	1.81e-6	Chronic sinus infection;
UCEC	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.52	-4.51	-0.35	1.33e-5	Carotid intima media thickness;
UCEC	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.02	18.22	0.83	1.59e-39	Colorectal cancer;
UCEC	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.18	7.53	0.53	4.82e-12	Diabetic kidney disease;
UCEC	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	1.2	6.64	0.48	5.64e-10	Type 2 diabetes;
UCEC	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.14	-0.51	3.92e-11	Joint mobility (Beighton score);
UCEC	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.53	-5.82	-0.43	3.49e-8	Menarche (age at onset);
UCEC	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.46	-7.34	-0.52	1.36e-11	Urate levels in overweight individuals;
UCEC	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-0.54	-5.28	-0.4	4.46e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg04202892	chr2:111875749	ACOXL	0.42	4.69	0.36	6.32e-6	Chronic lymphocytic leukemia;
UCEC	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13683864	chr3:40499215	RPL14	-0.67	-6.73	-0.49	3.58e-10	Renal cell carcinoma;
UCEC	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.57	-5.73	-0.43	5.41e-8	Ulcerative colitis;
UCEC	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.71	-6.12	-0.45	8.08e-9	Left atrial antero-posterior diameter;
UCEC	cis	rs12829704	0.588	rs7967303	chr12:21451616	C/T	cg11694490	chr12:21927823	KCNJ8	-0.56	-4.51	-0.35	1.33e-5	Blood metabolite levels;
UCEC	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.73	-6.22	-0.46	4.91e-9	Platelet distribution width;
UCEC	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-0.92	-9.36	-0.61	1.28e-16	Type 2 diabetes nephropathy;
UCEC	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.55	-5.65	-0.42	8.11e-8	Lymphocyte counts;
UCEC	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-4.57	-0.35	1.02e-5	Type 2 diabetes;
UCEC	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.95	-14.69	-0.77	1.2e-30	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7714670	0.736	rs2962278	chr5:73093958	G/A	cg00119811	chr5:73092353	RGNEF	-0.38	-4.75	-0.36	4.89e-6	Venous thromboembolism (SNP x SNP interaction);
UCEC	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	8.5	0.57	1.92e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.6	4.81	0.37	3.66e-6	Morning vs. evening chronotype;
UCEC	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg13575925	chr12:9217583	LOC144571	-0.45	-5.37	-0.41	2.99e-7	Sjögren's syndrome;
UCEC	cis	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg27540841	chr16:11350112	SOCS1	-0.73	-5.02	-0.38	1.5e-6	Testicular germ cell tumor;
UCEC	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg23995753	chr2:160760732	LY75	-0.41	-4.81	-0.37	3.78e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.61	-6.92	-0.5	1.3e-10	Body mass index (adult);
UCEC	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.74	7.56	0.53	4.09e-12	Parkinson's disease;
UCEC	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.71	6.69	0.48	4.43e-10	High light scatter reticulocyte count;
UCEC	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.93	11.66	0.69	1.16e-22	Menarche (age at onset);
UCEC	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-5.37	-0.41	2.98e-7	Monocyte percentage of white cells;
UCEC	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.62	-6.0	-0.44	1.48e-8	Strep throat;
UCEC	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg17085576	chr10:5658249	NA	-0.51	-5.05	-0.38	1.28e-6	Breast cancer;
UCEC	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.48	4.61	0.36	8.55e-6	Menopause (age at onset);
UCEC	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.31	10.81	0.67	2.1e-20	Uric acid levels;
UCEC	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.1	0.39	1.01e-6	Aortic root size;
UCEC	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg10978503	chr1:24200527	CNR2	0.37	5.01	0.38	1.56e-6	Immature fraction of reticulocytes;
UCEC	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg24060327	chr5:131705240	SLC22A5	-0.45	-4.67	-0.36	6.65e-6	Breast cancer;
UCEC	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.75	-8.52	-0.58	1.73e-14	Extraversion;
UCEC	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.52	-5.19	-0.39	6.83e-7	Headache;
UCEC	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg24803719	chr17:45855879	NA	-0.39	-4.84	-0.37	3.23e-6	IgG glycosylation;
UCEC	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg04058563	chr4:185651563	MLF1IP	-0.39	-4.81	-0.37	3.78e-6	Kawasaki disease;
UCEC	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.65	6.13	0.45	7.88e-9	Lymphocyte counts;
UCEC	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18854424	chr1:2615690	NA	0.46	6.69	0.48	4.4e-10	Ulcerative colitis;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.78	7.38	0.52	1.08e-11	Longevity;Endometriosis;
UCEC	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg21191810	chr6:118973309	C6orf204	0.4	5.48	0.41	1.77e-7	Electrocardiographic conduction measures;
UCEC	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.75	7.28	0.51	1.85e-11	Mosquito bite size;
UCEC	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.84	8.4	0.57	3.53e-14	Prudent dietary pattern;
UCEC	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.42	4.96	0.38	1.96e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.89	11.35	0.68	7.96e-22	Menarche (age at onset);
UCEC	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.65	6.12	0.45	8.12e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	5.59	0.42	1.05e-7	Personality dimensions;
UCEC	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.37	-4.64	-0.36	7.78e-6	Visceral fat;
UCEC	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg24562669	chr7:97807699	LMTK2	0.61	8.15	0.56	1.46e-13	Breast cancer;
UCEC	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg13683864	chr3:40499215	RPL14	-0.5	-4.9	-0.37	2.48e-6	Renal cell carcinoma;
UCEC	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	10.44	0.65	1.94e-19	Post bronchodilator FEV1;
UCEC	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.65	0.36	7.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	1.04	11.99	0.7	1.6e-23	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.93	11.35	0.68	7.96e-22	Platelet distribution width;
UCEC	cis	rs250585	0.704	rs11861636	chr16:23439997	T/C	cg26562691	chr16:23850404	PRKCB	0.36	4.65	0.36	7.37e-6	Egg allergy;
UCEC	cis	rs6921919	1.000	rs35875412	chr6:28331818	C/T	cg07836142	chr6:28411423	ZSCAN23	-0.46	-4.6	-0.35	8.99e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs853679	0.527	rs9468333	chr6:28271198	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.42	-0.41	2.37e-7	Depression;
UCEC	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.5	6.15	0.45	6.8e-9	Total body bone mineral density;
UCEC	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.88	9.65	0.62	2.32e-17	Breast cancer;
UCEC	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.5	4.94	0.38	2.12e-6	Lung cancer;Squamous cell lung carcinoma;
UCEC	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-5.48	-0.41	1.78e-7	Chronic sinus infection;
UCEC	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.61	5.6	0.42	1.02e-7	Aortic root size;
UCEC	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-5.33	-0.4	3.58e-7	Pediatric autoimmune diseases;
UCEC	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg18099408	chr3:52552593	STAB1	0.38	4.54	0.35	1.17e-5	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.57	5.69	0.42	6.7e-8	Colorectal cancer;
UCEC	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.69	8.22	0.56	9.65e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-10.05	-0.64	2.05e-18	Hemostatic factors and hematological phenotypes;
UCEC	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.43	5.24	0.4	5.56e-7	Height;
UCEC	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.99	10.26	0.65	5.75e-19	IgG glycosylation;
UCEC	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.53	5.33	0.4	3.65e-7	Endometriosis;
UCEC	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-5.64	-0.42	8.62e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg14547644	chr6:28411285	ZSCAN23	-0.53	-5.78	-0.43	4.37e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2062225	0.696	rs4849341	chr2:111777795	C/T	cg23782758	chr2:111737646	ACOXL	-0.56	-4.84	-0.37	3.19e-6	Monocyte count;
UCEC	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg09120320	chr17:61926383	NA	-0.45	-4.61	-0.36	8.73e-6	Prudent dietary pattern;
UCEC	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.58e-7	Acne (severe);
UCEC	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.73	6.52	0.47	1.03e-9	Bladder cancer;
UCEC	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.69	8.2	0.56	1.11e-13	Prudent dietary pattern;
UCEC	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.59	4.77	0.37	4.31e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.51	-4.65	-0.36	7.31e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.42	4.54	0.35	1.17e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.51	5.41	0.41	2.45e-7	Extrinsic epigenetic age acceleration;
UCEC	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.48	4.66	0.36	7.04e-6	Schizophrenia;
UCEC	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.55	-6.48	-0.47	1.28e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg16023434	chr1:11395635	NA	0.37	4.86	0.37	2.99e-6	Body mass index;
UCEC	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-4.77	-0.37	4.32e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-4.91	-0.38	2.35e-6	Height;
UCEC	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.02	-8.41	-0.57	3.32e-14	Exhaled nitric oxide output;
UCEC	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.82	-7.13	-0.51	4.27e-11	Initial pursuit acceleration;
UCEC	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg15837086	chr1:46506065	PIK3R3	0.37	4.54	0.35	1.16e-5	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.53	4.98	0.38	1.78e-6	Coronary artery disease;
UCEC	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.6	-5.71	-0.43	6.04e-8	Pancreatic cancer;
UCEC	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg03959625	chr15:84868606	LOC388152	0.46	4.64	0.36	7.64e-6	Schizophrenia;
UCEC	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-4.64	-0.36	7.66e-6	Bipolar disorder;
UCEC	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.75	7.99	0.55	3.68e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.69	6.24	0.46	4.42e-9	Breast cancer;
UCEC	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.42	9.37e-8	Post bronchodilator FEV1;
UCEC	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.45	-4.93	-0.38	2.19e-6	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs3750082	0.852	rs6462425	chr7:32898595	C/A	cg05721444	chr7:32995514	FKBP9	0.48	5.21	0.39	6.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg08755490	chr11:65554678	OVOL1	0.5	5.3	0.4	4.07e-7	Acne (severe);
UCEC	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	0.91	12.01	0.7	1.42e-23	Menarche (age at onset);
UCEC	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.02	11.84	0.7	3.94e-23	Corneal structure;
UCEC	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg20290983	chr6:43655470	MRPS18A	0.83	8.21	0.56	1.06e-13	IgG glycosylation;
UCEC	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.61	5.98	0.44	1.59e-8	Post bronchodilator FEV1;
UCEC	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg07636037	chr3:49044803	WDR6	0.57	4.62	0.36	8.18e-6	Menarche (age at onset);
UCEC	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.68	-0.42	6.97e-8	Longevity;
UCEC	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg10412286	chr16:89977652	TCF25	0.63	4.68	0.36	6.37e-6	Skin colour saturation;
UCEC	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg22637538	chr17:7348327	CHRNB1	-0.55	-4.52	-0.35	1.29e-5	Androgen levels;
UCEC	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.46	-4.67	-0.36	6.68e-6	Blood metabolite levels;
UCEC	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.64	5.61	0.42	9.65e-8	Aortic root size;
UCEC	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg06238570	chr21:40685208	BRWD1	0.53	5.55	0.42	1.31e-7	Cognitive function;
UCEC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg18973586	chr4:963968	DGKQ	0.46	4.79	0.37	4.1e-6	Obesity-related traits;
UCEC	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.49	-6.04	-0.45	1.18e-8	Prudent dietary pattern;
UCEC	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	7.05	0.5	6.48e-11	Coffee consumption (cups per day);
UCEC	cis	rs883565	0.528	rs9818979	chr3:38963835	C/G	cg01426195	chr3:39028469	NA	0.46	5.11	0.39	9.73e-7	Handedness;
UCEC	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.7	-6.56	-0.48	8.54e-10	Aortic root size;
UCEC	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	23.46	0.89	1.49e-51	Chronic sinus infection;
UCEC	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg09521647	chr2:100722408	AFF3	-0.32	-4.85	-0.37	3.05e-6	Chronic sinus infection;
UCEC	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	7.12	0.51	4.37e-11	Coffee consumption (cups per day);
UCEC	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.34	-4.7	-0.36	5.86e-6	Fat distribution (HIV);
UCEC	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.56	-4.59	-0.35	9.62e-6	Multiple sclerosis;
UCEC	cis	rs9470794	1.000	rs78680078	chr6:38108032	G/A	cg03458162	chr6:37400668	FTSJD2	0.81	4.81	0.37	3.63e-6	Type 2 diabetes;
UCEC	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.68	5.5	0.41	1.62e-7	Cognitive test performance;
UCEC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.49	5.21	0.4	6.18e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.61	7.12	0.51	4.54e-11	Hip circumference;
UCEC	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.58	-6.1	-0.45	8.8e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.9	7.57	0.53	3.79e-12	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg23888215	chr10:79422304	NA	-0.62	-5.18	-0.39	7.33e-7	Bone mineral density;
UCEC	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg14008862	chr17:28927542	LRRC37B2	0.74	5.13	0.39	9.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22117172	chr7:91764530	CYP51A1	0.39	4.84	0.37	3.27e-6	Breast cancer;
UCEC	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.69	6.15	0.45	6.89e-9	Bipolar disorder;
UCEC	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-0.67	-5.35	-0.4	3.24e-7	Morning vs. evening chronotype;
UCEC	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.42	5.15	0.39	8.26e-7	Height;
UCEC	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.36	6.03	0.45	1.28e-8	Cancer;
UCEC	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-4.76	-0.37	4.62e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.78	-5.51	-0.41	1.56e-7	Verbal memory performance (residualized delayed recall change);
UCEC	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg03078520	chr22:18463400	MICAL3	-0.45	-4.58	-0.35	9.73e-6	Presence of antiphospholipid antibodies;
UCEC	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	5.66	0.42	7.68e-8	Monocyte percentage of white cells;
UCEC	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.45	4.99	0.38	1.7e-6	HDL cholesterol;
UCEC	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.88	0.37	2.69e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.43	-4.85	-0.37	3.11e-6	Depressive symptoms (multi-trait analysis);
UCEC	cis	rs172166	0.516	rs1225618	chr6:28129713	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.49	-5.23	-0.4	5.73e-7	Cardiac Troponin-T levels;
UCEC	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.5	-6.68	-0.48	4.7e-10	Eye color traits;
UCEC	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.5	-5.49	-0.41	1.74e-7	Menarche (age at onset);
UCEC	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.68	8.1	0.56	1.96e-13	Prudent dietary pattern;
UCEC	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13939156	chr17:80058883	NA	0.36	4.56	0.35	1.06e-5	Life satisfaction;
UCEC	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.18e-6	Primary biliary cholangitis;
UCEC	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-0.86	-8.05	-0.55	2.58e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg14582100	chr15:45693742	SPATA5L1	0.45	6.28	0.46	3.67e-9	Homoarginine levels;
UCEC	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.79	4.94	0.38	2.07e-6	Eosinophil percentage of granulocytes;
UCEC	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.8	8.34	0.57	4.82e-14	Menopause (age at onset);
UCEC	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.46	5.11	0.39	9.78e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg19513890	chr22:42538836	CYP2D7P1	-0.41	-4.52	-0.35	1.24e-5	Schizophrenia;
UCEC	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg07404485	chr7:94953653	PON1	-0.47	-4.57	-0.35	1.01e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg14675211	chr2:100938903	LONRF2	0.61	4.96	0.38	1.92e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	4.66	0.36	6.98e-6	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.56	0.42	1.21e-7	Prudent dietary pattern;
UCEC	cis	rs4499344	0.623	rs11670818	chr19:33099854	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.86	6.3	0.46	3.22e-9	Mean platelet volume;
UCEC	cis	rs9470794	1.000	rs3800364	chr6:38121211	A/G	cg03458162	chr6:37400668	FTSJD2	0.81	4.83	0.37	3.46e-6	Type 2 diabetes;
UCEC	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.85	-8.71	-0.58	5.93e-15	Resting heart rate;
UCEC	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.51	5.07	0.39	1.18e-6	Menopause (age at onset);
UCEC	cis	rs7113850	0.541	rs7944769	chr11:24224823	G/C	ch.11.24196551F	chr11:24239977	NA	0.66	5.11	0.39	9.88e-7	Bone fracture in osteoporosis;
UCEC	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.77	-8.96	-0.59	1.38e-15	Longevity;Endometriosis;
UCEC	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	4.95	0.38	1.97e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.17	0.39	7.6e-7	Personality dimensions;
UCEC	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.82	-6.14	-0.45	7.23e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	7.92	0.55	5.44e-13	Mean platelet volume;
UCEC	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.58	-5.95	-0.44	1.87e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg07836142	chr6:28411423	ZSCAN23	-0.43	-4.82	-0.37	3.6e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.78	9.06	0.6	7.38e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.77	6.83	0.49	2.07e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.48	-4.99	-0.38	1.71e-6	Lung cancer;
UCEC	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.81	-11.23	-0.68	1.65e-21	Post bronchodilator FEV1;
UCEC	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.7	-6.93	-0.5	1.2e-10	Body mass index;
UCEC	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03342759	chr3:160939853	NMD3	-0.44	-4.59	-0.35	9.39e-6	Parkinson's disease;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg27304813	chr3:120068385	LRRC58	0.62	7.7	0.54	1.82e-12	Warfarin maintenance dose;
UCEC	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	6.85	0.49	1.89e-10	Ileal carcinoids;
UCEC	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.68	-7.54	-0.53	4.46e-12	Hypospadias;
UCEC	cis	rs4921542	1.000	rs4921542	chr8:17205577	G/T	cg13243377	chr8:17103891	CNOT7;VPS37A	0.52	4.64	0.36	7.62e-6	Creutzfeldt-Jakob disease (variant);
UCEC	cis	rs1150668	0.796	rs213236	chr6:28324397	T/C	cg00651523	chr6:28411279	ZSCAN23	-0.56	-6.66	-0.48	5.08e-10	Pubertal anthropometrics;
UCEC	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-6.7	-0.48	4.07e-10	Diastolic blood pressure;
UCEC	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.81	-10.2	-0.64	8.54e-19	White blood cell count (basophil);
UCEC	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.89	0.37	2.58e-6	Lymphocyte counts;
UCEC	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06462663	chr19:18546047	ISYNA1	0.46	5.94	0.44	1.93e-8	Breast cancer;
UCEC	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-4.7	-0.36	5.92e-6	Alzheimer's disease (late onset);
UCEC	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.37	-5.46	-0.41	1.96e-7	Ulcerative colitis;
UCEC	cis	rs11867410	0.744	rs114124282	chr17:63966736	G/A	cg06996976	chr17:64576105	PRKCA	-0.76	-4.76	-0.37	4.55e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.58	-6.0	-0.44	1.43e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.7	-6.98	-0.5	9.25e-11	Tonsillectomy;
UCEC	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	5.3	0.4	4.1e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg14851346	chr12:38532713	NA	-0.5	-4.91	-0.38	2.43e-6	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs9811216	1.000	rs12630450	chr3:169480204	A/G	cg16622863	chr3:169387280	NA	-0.43	-4.5	-0.35	1.35e-5	Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs10789491	0.767	rs1816730	chr1:47207346	T/C	cg15501359	chr1:47185051	KIAA0494	0.85	6.53	0.47	1.01e-9	Response to hepatitis C treatment;
UCEC	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.72	8.59	0.58	1.17e-14	Menarche (age at onset);
UCEC	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.74	-5.84	-0.43	3.18e-8	Facial morphology (factor 23);
UCEC	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg22166914	chr1:53195759	ZYG11B	-0.82	-9.07	-0.6	7.02e-16	Monocyte count;
UCEC	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.14	9.06	0.6	7.57e-16	Opioid sensitivity;
UCEC	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg16584290	chr5:462447	EXOC3	-0.48	-4.96	-0.38	1.95e-6	Cystic fibrosis severity;
UCEC	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.55	-5.09	-0.39	1.1e-6	Initial pursuit acceleration;
UCEC	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.64	-5.97	-0.44	1.7e-8	Aortic root size;
UCEC	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-1.07	-5.39	-0.41	2.77e-7	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.46	4.73	0.36	5.33e-6	Dental caries;
UCEC	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.77	-5.57	-0.42	1.21e-7	Multiple sclerosis;
UCEC	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg06401019	chr5:92957098	FAM172A;MIR2277	0.7	5.32	0.4	3.8e-7	Diabetic retinopathy;
UCEC	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.12	-0.45	8.15e-9	Bipolar disorder and schizophrenia;
UCEC	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.51	5.84	0.43	3.28e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	5.05	0.38	1.28e-6	Lung cancer in ever smokers;
UCEC	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs9534288	0.577	rs2897029	chr13:46682821	T/C	cg15192986	chr13:46630673	CPB2	-0.5	-4.7	-0.36	5.81e-6	Blood protein levels;
UCEC	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.36	-4.59	-0.35	9.6e-6	Bone mineral density (spine);
UCEC	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.59	4.72	0.36	5.41e-6	Resting heart rate;
UCEC	cis	rs9467773	1.000	rs9467798	chr6:26575697	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.38	1.53e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.54	-5.25	-0.4	5.22e-7	Corneal astigmatism;
UCEC	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg05802129	chr4:122689817	NA	-0.57	-5.78	-0.43	4.4e-8	Type 2 diabetes;
UCEC	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.92	6.96	0.5	1.03e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.59	6.93	0.5	1.25e-10	Menopause (age at onset);
UCEC	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.69	-6.03	-0.45	1.29e-8	Depression;
UCEC	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.99	11.53	0.69	2.65e-22	Cognitive function;
UCEC	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.75	-7.69	-0.54	1.9e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs8105895	1.000	rs11882234	chr19:22145727	C/T	cg02912127	chr19:22235281	ZNF257	-0.59	-4.86	-0.37	2.95e-6	Body mass index (change over time);
UCEC	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.46	-5.73	-0.43	5.38e-8	Subjective well-being;
UCEC	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	0.94	9.66	0.62	2.1e-17	Heart rate;
UCEC	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.5	-5.48	-0.41	1.8e-7	Aortic root size;
UCEC	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.73	-8.35	-0.57	4.61e-14	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.85	8.12	0.56	1.69e-13	Ulcerative colitis;
UCEC	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg14092571	chr14:90743983	NA	-0.48	-6.54	-0.47	9.44e-10	Mortality in heart failure;
UCEC	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.4	5.27	0.4	4.68e-7	Bone mineral density;
UCEC	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.64	-0.36	7.53e-6	Schizophrenia;
UCEC	cis	rs3736594	0.513	rs2384627	chr2:27774449	G/A	cg27432699	chr2:27873401	GPN1	0.5	4.64	0.36	7.53e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
UCEC	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.43	-5.21	-0.39	6.21e-7	Blood protein levels;
UCEC	cis	rs4824093	0.610	rs28473584	chr22:50315413	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-4.76	-0.37	4.6e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18252515	chr7:66147081	NA	0.46	4.72	0.36	5.33e-6	Aortic root size;
UCEC	cis	rs7246967	0.673	rs62120313	chr19:22877183	G/C	cg24889512	chr19:22816950	ZNF492	0.61	6.52	0.47	1.07e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.57	6.02	0.44	1.35e-8	Body mass index (adult);
UCEC	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.67	6.7	0.48	4.21e-10	Breast cancer;
UCEC	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-5.27	-0.4	4.82e-7	Morning vs. evening chronotype;
UCEC	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.08	8.19	0.56	1.17e-13	Alzheimer's disease (late onset);
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.63	-0.36	8.12e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg21191810	chr6:118973309	C6orf204	0.43	5.99	0.44	1.57e-8	Electrocardiographic conduction measures;
UCEC	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.64	-6.81	-0.49	2.3e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
UCEC	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.51	4.59	0.35	9.27e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.59	-4.77	-0.37	4.43e-6	Longevity;
UCEC	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.48	-5.71	-0.43	6.04e-8	Dialysis-related mortality;
UCEC	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.12	14.5	0.77	3.89e-30	Schizophrenia;
UCEC	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.79	-9.42	-0.61	8.99e-17	Morning vs. evening chronotype;
UCEC	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg20129853	chr10:51489980	NA	-0.43	-4.74	-0.36	4.95e-6	Prostate-specific antigen levels;
UCEC	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg25011176	chr20:3776985	CDC25B	-0.67	-6.36	-0.46	2.4e-9	Bipolar disorder;
UCEC	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.07	9.36	0.61	1.24e-16	Platelet count;
UCEC	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	5.28	0.4	4.63e-7	Bone mineral density;
UCEC	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.74	6.83	0.49	2.05e-10	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-10.56	-0.66	9.36e-20	Primary sclerosing cholangitis;
UCEC	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.76	6.71	0.48	3.95e-10	IgG glycosylation;
UCEC	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-5.98	-0.44	1.6e-8	Resting heart rate;
UCEC	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.93	-11.53	-0.69	2.62e-22	Monocyte count;
UCEC	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs860295	0.541	rs11264359	chr1:155282829	A/G	cg02153340	chr1:155202674	NA	-0.49	-5.59	-0.42	1.08e-7	Body mass index;
UCEC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.97	6.61	0.48	6.7e-10	Platelet count;
UCEC	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.66	6.78	0.49	2.67e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	7.65	0.53	2.46e-12	Ileal carcinoids;
UCEC	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.49	4.89	0.37	2.58e-6	Height;
UCEC	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.8	9.03	0.6	8.85e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.62	5.21	0.39	6.19e-7	High light scatter reticulocyte count;
UCEC	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.59	4.97	0.38	1.8e-6	Alcohol dependence;
UCEC	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg22868518	chr11:507468	RNH1	-0.57	-5.68	-0.42	6.82e-8	Systemic lupus erythematosus;
UCEC	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.41	4.64	0.36	7.49e-6	Smoking behavior;
UCEC	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.23	-0.46	4.58e-9	Tonsillectomy;
UCEC	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.74	7.2	0.51	2.93e-11	Menarche (age at onset);
UCEC	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.62	6.99	0.5	8.89e-11	Pubertal anthropometrics;
UCEC	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.69	7.06	0.5	6.29e-11	Resting heart rate;
UCEC	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg01072550	chr1:21505969	NA	-0.55	-5.06	-0.39	1.22e-6	Superior frontal gyrus grey matter volume;
UCEC	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.54	5.72	0.43	5.77e-8	Diastolic blood pressure;
UCEC	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.85	9.38	0.61	1.1e-16	Breast cancer;
UCEC	trans	rs66573146	0.803	rs59742225	chr4:6969942	C/T	cg07817883	chr1:32538562	TMEM39B	1.33	9.94	0.63	3.89e-18	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg19678392	chr7:94953810	PON1	-0.55	-5.1	-0.39	1.04e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7246967	0.866	rs4932695	chr19:23036377	T/C	cg05241461	chr19:22816980	ZNF492	0.49	5.19	0.39	6.86e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.64	7.04	0.5	6.93e-11	Glomerular filtration rate (creatinine);
UCEC	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.77e-10	Chronic sinus infection;
UCEC	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-5.91	-0.44	2.25e-8	Dental caries;
UCEC	cis	rs7937612	0.965	rs10790378	chr11:120220268	T/C	cg12584626	chr11:120203529	NA	0.49	5.15	0.39	8.35e-7	Intraocular pressure;
UCEC	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.6	-6.57	-0.48	8.22e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs692916	0.704	rs651761	chr18:60603484	A/G	cg07187971	chr18:60481018	PHLPP1	-0.37	-4.56	-0.35	1.05e-5	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.47	4.54	0.35	1.15e-5	Menarche (age at onset);
UCEC	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.88	12.1	0.71	7.96e-24	Metabolic syndrome;
UCEC	cis	rs377070	0.966	rs368931	chr4:123631597	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.59	5.03	0.38	1.41e-6	Mosquito bite size;
UCEC	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	0.77	4.85	0.37	3.09e-6	Height;
UCEC	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.59	7.69	0.54	1.97e-12	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.74	9.41	0.61	9.63e-17	Body mass index;
UCEC	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.49	-5.19	-0.39	6.96e-7	Lung cancer;
UCEC	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.53	4.73	0.36	5.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.5	5.83	0.43	3.31e-8	Blood metabolite ratios;
UCEC	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.54	5.91	0.44	2.32e-8	Schizophrenia;
UCEC	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.65	5.54	0.42	1.36e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.54	-4.83	-0.37	3.33e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.37	-0.41	2.96e-7	Breast cancer;
UCEC	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg03859395	chr2:55845619	SMEK2	0.89	11.06	0.67	4.45e-21	Metabolic syndrome;
UCEC	cis	rs782107	0.674	rs7307708	chr12:58805112	C/T	cg19181132	chr12:59314527	LRIG3	0.44	4.66	0.36	7.13e-6	Interleukin-12p70 levels;
UCEC	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	6.14	0.45	7.45e-9	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
UCEC	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg07404485	chr7:94953653	PON1	0.59	6.87	0.49	1.72e-10	Paraoxonase activity;
UCEC	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.43	5.24	0.4	5.37e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg09120320	chr17:61926383	NA	0.44	4.6	0.35	9.1e-6	Prudent dietary pattern;
UCEC	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg19318889	chr4:1322082	MAEA	0.57	6.81	0.49	2.32e-10	Longevity;
UCEC	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.28	10.8	0.67	2.26e-20	Uric acid levels;
UCEC	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	8.41	0.57	3.29e-14	Lymphocyte percentage of white cells;
UCEC	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.87	-10.78	-0.66	2.45e-20	Primary sclerosing cholangitis;
UCEC	cis	rs2172802	0.629	rs1948616	chr4:62487688	A/G	cg04118610	chr4:62707027	LPHN3	-0.44	-5.11	-0.39	9.73e-7	Partial epilepsies;
UCEC	cis	rs9467773	1.000	rs6456735	chr6:26574149	G/A	cg15659132	chr6:26577336	NA	0.44	4.62	0.36	8.31e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.46	4.53	0.35	1.2e-5	Breast cancer;
UCEC	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg24375607	chr4:120327624	NA	0.49	5.2	0.39	6.45e-7	Corneal astigmatism;
UCEC	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-5.6	-0.42	1.01e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.47	-5.42	-0.41	2.39e-7	Aortic root size;
UCEC	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.61	7.44	0.52	7.9e-12	Bone mineral density;
UCEC	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.88	9.48	0.62	6.07e-17	Longevity;Endometriosis;
UCEC	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	8.57	0.58	1.27e-14	Total body bone mineral density;
UCEC	cis	rs116095464	0.764	rs28710899	chr5:241029	G/A	cg22496380	chr5:211416	CCDC127	-0.7	-6.24	-0.46	4.41e-9	Breast cancer;
UCEC	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.44	4.68	0.36	6.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.82	10.16	0.64	1.04e-18	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg19743168	chr1:23544995	NA	0.49	6.51	0.47	1.12e-9	Height;
UCEC	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-13.38	-0.74	3.34e-27	Body mass index;
UCEC	cis	rs7611694	0.501	rs9840124	chr3:113109100	C/T	cg11138929	chr3:113251189	SIDT1	-0.39	-4.58	-0.35	9.7e-6	Prostate cancer;
UCEC	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.52	5.02	0.38	1.45e-6	Body mass index;
UCEC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg05241461	chr19:22816980	ZNF492	0.58	6.56	0.48	8.75e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs28795989	0.896	rs7437940	chr4:7887500	C/T	cg00251875	chr4:7801337	AFAP1	-0.43	-4.99	-0.38	1.66e-6	Intraocular pressure;
UCEC	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-7.39	-0.52	1.01e-11	Plateletcrit;Platelet count;
UCEC	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs902774	0.585	rs7399070	chr12:53355678	G/C	cg16329197	chr12:53359506	NA	-0.62	-5.18	-0.39	7.32e-7	Prostate cancer;
UCEC	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.88	12.34	0.71	1.89e-24	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-4.54	-0.35	1.18e-5	Aortic root size;
UCEC	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.6	-6.88	-0.49	1.63e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.45	4.6	0.35	9e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
UCEC	cis	rs2377585	0.948	rs113695818	chr12:8837407	C/T	cg03761649	chr12:8850719	RIMKLB	0.6	4.72	0.36	5.41e-6	Reticulocyte fraction of red cells;
UCEC	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-8.24	-0.56	8.64e-14	Colorectal cancer;
UCEC	cis	rs2742417	0.967	rs1883096	chr3:45750015	C/T	cg01451880	chr3:45801044	SLC6A20	-0.41	-5.35	-0.4	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.4	-4.93	-0.38	2.15e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.62	-0.58	9.84e-15	Monocyte count;
UCEC	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.51	4.98	0.38	1.75e-6	Psoriasis;
UCEC	cis	rs7212590	0.581	rs7209157	chr17:57833476	T/C	cg10252138	chr17:58120427	NA	-0.72	-5.81	-0.43	3.73e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
UCEC	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.72	-6.47	-0.47	1.38e-9	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	7.3	0.52	1.68e-11	Exhaled nitric oxide levels;
UCEC	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.53	0.47	9.92e-10	Diabetic retinopathy;
UCEC	cis	rs1165472	0.755	rs34033335	chr1:56159172	G/A	cg11523071	chr1:56160889	NA	-0.58	-4.86	-0.37	3e-6	Paclitaxel-induced neuropathy;
UCEC	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.83	8.82	0.59	3.14e-15	Blood protein levels;
UCEC	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg01072550	chr1:21505969	NA	-0.58	-5.74	-0.43	5.2e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.86	-0.44	2.89e-8	Joint mobility (Beighton score);
UCEC	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-5.82	-0.43	3.47e-8	Chronic sinus infection;
UCEC	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg11859384	chr17:80120422	CCDC57	-0.53	-5.73	-0.43	5.49e-8	Life satisfaction;
UCEC	cis	rs13256369	0.708	rs9644772	chr8:8557685	G/A	cg06671706	chr8:8559999	CLDN23	0.64	5.12	0.39	9.34e-7	Obesity-related traits;
UCEC	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.05	0.38	1.3e-6	Height;
UCEC	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg21486944	chr6:28411378	ZSCAN23	-0.49	-5.52	-0.41	1.47e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.68	6.49	0.47	1.21e-9	Prostate cancer;
UCEC	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-0.97	-8.05	-0.55	2.52e-13	White matter hyperintensity burden;
UCEC	cis	rs17824620	0.548	rs1344358	chr12:113124577	A/T	cg26711794	chr12:112450906	ERP29;TMEM116	-0.6	-4.88	-0.37	2.74e-6	Platelet count;
UCEC	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg22166914	chr1:53195759	ZYG11B	-0.66	-7.27	-0.51	1.97e-11	Monocyte count;
UCEC	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.99	0.64	2.95e-18	Blood protein levels;
UCEC	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.51	5.12	0.39	9.58e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.83	-9.49	-0.62	5.81e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.604	rs58536761	chr19:22880331	G/C	cg08271804	chr19:22816896	ZNF492	0.65	6.12	0.45	7.99e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.45	-4.61	-0.36	8.71e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs36051895	0.623	rs12720	chr9:5231712	T/A	cg02405213	chr9:5042618	JAK2	-0.48	-4.77	-0.37	4.4e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	0.82	7.06	0.5	6.23e-11	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.41e-9	Crohn's disease;
UCEC	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.99	-13.55	-0.75	1.2100000000000001e-27	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.86	-9.42	-0.61	8.71e-17	Cognitive function;
UCEC	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-5.8	-0.43	3.91e-8	Hip circumference adjusted for BMI;
UCEC	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.36	-5.22	-0.4	6.13e-7	Vitamin D levels;
UCEC	cis	rs17027633	0.867	rs7543384	chr1:111948014	G/T	cg10283737	chr1:112533749	NA	0.59	4.78	0.37	4.16e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.91	8.72	0.58	5.43e-15	Diastolic blood pressure;Systolic blood pressure;
UCEC	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	0.93	9.51	0.62	5.16e-17	Heart rate;
UCEC	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	6.93	0.5	1.24e-10	Coronary artery disease;
UCEC	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.88	-10.06	-0.64	1.89e-18	Cognitive function;
UCEC	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.74	-6.7	-0.48	4.05e-10	Aortic root size;
UCEC	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg24069376	chr3:38537580	EXOG	-0.39	-4.88	-0.37	2.76e-6	Electrocardiographic conduction measures;
UCEC	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.55	-6.03	-0.45	1.27e-8	Menarche (age at onset);
UCEC	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.6	7.72	0.54	1.65e-12	Anterior chamber depth;
UCEC	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg20399509	chr21:47717575	C21orf57	-0.44	-4.71	-0.36	5.67e-6	Testicular germ cell tumor;
UCEC	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.78	7.11	0.51	4.76e-11	Morning vs. evening chronotype;
UCEC	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs1519814	0.956	rs4133251	chr8:121166993	A/G	cg22335954	chr8:121166405	COL14A1	-0.68	-5.53	-0.42	1.42e-7	Breast cancer;
UCEC	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.62	5.96	0.44	1.76e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.73	-6.9	-0.49	1.44e-10	Aortic root size;
UCEC	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg17971929	chr21:40555470	PSMG1	-0.58	-6.32	-0.46	3.02e-9	Menarche (age at onset);
UCEC	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.7	-6.73	-0.49	3.57e-10	Aortic root size;
UCEC	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.94	9.42	0.61	8.73e-17	Type 2 diabetes nephropathy;
UCEC	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg13147721	chr7:65941812	NA	-0.91	-6.06	-0.45	1.07e-8	Diabetic kidney disease;
UCEC	cis	rs12681287	0.888	rs13042	chr8:87484913	G/A	cg27223183	chr8:87520930	FAM82B	-0.66	-6.09	-0.45	9.4e-9	Caudate activity during reward;
UCEC	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.11	18.17	0.83	2.05e-39	IgG glycosylation;
UCEC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.6	5.73	0.43	5.46e-8	Corneal astigmatism;
UCEC	cis	rs4908768	0.579	rs12142911	chr1:8857245	C/G	cg13081009	chr1:8430745	RERE	0.45	5.06	0.39	1.22e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
UCEC	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg13147721	chr7:65941812	NA	-0.9	-5.95	-0.44	1.9e-8	Diabetic kidney disease;
UCEC	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.46	5.32	0.4	3.81e-7	Aortic root size;
UCEC	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs742614	0.533	rs2103804	chr20:32425403	A/G	cg06304546	chr20:32448765	NA	0.45	4.8	0.37	3.8e-6	Stearic acid (18:0) levels;
UCEC	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.61	6.39	0.47	2.05e-9	QRS complex (12-leadsum);
UCEC	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-7.16	-0.51	3.66e-11	Hip circumference;
UCEC	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.58e-7	Acne (severe);
UCEC	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.11e-5	Alzheimer's disease;
UCEC	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.85	9.52	0.62	5.04e-17	Blood protein levels;
UCEC	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs2041840	0.538	rs7600995	chr2:37575026	C/G	cg25727520	chr2:37576821	QPCT	-0.52	-6.15	-0.45	6.8e-9	Chronic lymphocytic leukemia;
UCEC	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg24851651	chr11:66362959	CCS	-0.41	-5.13	-0.39	8.93e-7	Educational attainment (years of education);
UCEC	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.76	-10.2	-0.64	8.53e-19	Intelligence (multi-trait analysis);
UCEC	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.91	12.08	0.71	8.97e-24	Metabolic syndrome;
UCEC	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	5.76	0.43	4.68e-8	Coffee consumption (cups per day);
UCEC	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.78	-9.59	-0.62	3.33e-17	White blood cell count (basophil);
UCEC	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	0.9	7.37	0.52	1.12e-11	Uric acid levels;
UCEC	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.72	6.75	0.49	3.14e-10	Primary sclerosing cholangitis;
UCEC	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.58	0.48	7.64e-10	Tonsillectomy;
UCEC	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.74	-7.9	-0.55	6.07e-13	Vitiligo;
UCEC	cis	rs6696846	0.515	rs12136320	chr1:205110946	T/C	cg12580275	chr1:205744413	RAB7L1	0.48	5.38	0.41	2.88e-7	Red blood cell count;
UCEC	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.72	-5.46	-0.41	1.96e-7	Gut microbiome composition (summer);
UCEC	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.69	-7.23	-0.51	2.41e-11	Cognitive function;
UCEC	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.73	-6.93	-0.5	1.21e-10	Aortic root size;
UCEC	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg14008862	chr17:28927542	LRRC37B2	0.62	4.78	0.37	4.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	5.66	0.42	7.76e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.45	-4.5	-0.35	1.36e-5	Colorectal cancer;
UCEC	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.63	6.21	0.46	5.22e-9	Tonsillectomy;
UCEC	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.51	4.82	0.37	3.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.45	-5.56	-0.42	1.26e-7	Height;Educational attainment;Head circumference (infant);
UCEC	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.56	-5.01	-0.38	1.51e-6	Ileal carcinoids;
UCEC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.84	6.05	0.45	1.17e-8	Platelet count;
UCEC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.75	-6.05	-0.45	1.16e-8	Alzheimer's disease (late onset);
UCEC	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg04176532	chr22:50317003	CRELD2	-0.45	-4.58	-0.35	1e-5	Schizophrenia;
UCEC	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	0.78	6.7	0.48	4.19e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.94	10.73	0.66	3.32e-20	Ulcerative colitis;
UCEC	cis	rs9402633	0.938	rs2327531	chr6:135048564	A/G	cg16239184	chr6:135079577	NA	0.51	4.64	0.36	7.54e-6	Platelet count;
UCEC	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.93	8.53	0.58	1.62e-14	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs8105895	0.935	rs7252380	chr19:22245715	G/A	cg24072202	chr19:22235272	ZNF257	-0.61	-5.33	-0.4	3.64e-7	Body mass index (change over time);
UCEC	cis	rs12367572	0.663	rs4561266	chr12:45415763	C/T	cg03114573	chr12:45410052	DBX2	-0.52	-6.33	-0.46	2.86e-9	Gut microbiome composition (summer);
UCEC	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg14008862	chr17:28927542	LRRC37B2	0.63	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.82	9.2	0.6	3.26e-16	Breast cancer;
UCEC	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	6.55	0.48	8.94e-10	Bone mineral density;
UCEC	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.62	7.13	0.51	4.26e-11	Red blood cell count;
UCEC	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.72	6.66	0.48	5.07e-10	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
UCEC	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.7	7.98	0.55	3.9e-13	Menopause (age at onset);
UCEC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-6.58	-0.48	7.56e-10	Monocyte count;
UCEC	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.57	-6.19	-0.45	5.68e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.57	-6.12	-0.45	8.29e-9	Monocyte count;
UCEC	cis	rs7246967	0.551	rs8112442	chr19:22893369	C/T	cg05241461	chr19:22816980	ZNF492	0.58	6.12	0.45	8.18e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.53	5.4	0.41	2.67e-7	Tonsillectomy;
UCEC	cis	rs1712517	0.744	rs11191641	chr10:105052940	C/T	cg05636881	chr10:105038444	INA	0.47	5.37	0.4	3e-7	Migraine;
UCEC	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-6.71	-0.48	3.93e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.52	4.55	0.35	1.14e-5	Cholesterol, total;
UCEC	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.52	5.39	0.41	2.69e-7	Dupuytren's disease;
UCEC	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.67	5.0	0.38	1.58e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.69	-8.62	-0.58	9.74e-15	Bipolar disorder and schizophrenia;
UCEC	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-6.42	-0.47	1.75e-9	Developmental language disorder (linguistic errors);
UCEC	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.51	-5.05	-0.38	1.3e-6	Bone mineral density;
UCEC	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.63	-6.92	-0.5	1.28e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.71	5.74	0.43	5.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.57	8.38	0.57	3.93e-14	Height;
UCEC	cis	rs731174	0.840	rs525379	chr1:38151705	T/C	cg12339802	chr1:38156545	C1orf109	-0.52	-4.92	-0.38	2.34e-6	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.19	-10.03	-0.64	2.31e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.87	-9.73	-0.63	1.44e-17	Cognitive function;
UCEC	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.61	5.14	0.39	8.53e-7	Blood metabolite levels;
UCEC	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.56	-6.35	-0.46	2.54e-9	Type 2 diabetes;
UCEC	cis	rs11697848	1.000	rs55992502	chr20:48560544	C/T	cg17849948	chr20:48532315	SPATA2	1.05	5.05	0.38	1.32e-6	Systemic lupus erythematosus;
UCEC	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.6	-6.95	-0.5	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs731174	0.765	rs510121	chr1:38182960	C/T	cg06917450	chr1:38156652	C1orf109	-0.57	-5.29	-0.4	4.38e-7	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.77	-8.29	-0.56	6.58e-14	Blood metabolite levels;
UCEC	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.68	7.39	0.52	1e-11	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.24	0.51	2.3e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs17123764	0.818	rs11169081	chr12:49985210	G/A	cg20471783	chr12:50157085	TMBIM6	0.64	5.43	0.41	2.23e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.22	-0.4	6e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.6	-4.57	-0.35	1.03e-5	Obesity;Body mass index;
UCEC	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	7.28	0.51	1.91e-11	Platelet count;
UCEC	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.05	-0.38	1.27e-6	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs1468333	1.000	rs10479179	chr5:137564115	A/G	cg07848042	chr5:137667509	CDC25C	0.48	4.71	0.36	5.61e-6	Resting heart rate;
UCEC	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.65	5.36	0.4	3.1e-7	Corneal astigmatism;
UCEC	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg07838603	chr6:28411030	ZSCAN23	-0.4	-4.64	-0.36	7.54e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.66	7.54	0.53	4.48e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.82	-7.69	-0.54	2e-12	Initial pursuit acceleration;
UCEC	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg01689657	chr7:91764605	CYP51A1	-0.46	-5.78	-0.43	4.37e-8	Breast cancer;
UCEC	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	4.96	0.38	1.93e-6	Monocyte percentage of white cells;
UCEC	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.5	5.52	0.41	1.52e-7	Tonsillectomy;
UCEC	cis	rs7004769	0.554	rs112797574	chr8:9174413	G/C	cg27598956	chr8:9758788	LOC157627	-0.47	-4.53	-0.35	1.21e-5	Fibrinogen levels;
UCEC	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18252515	chr7:66147081	NA	0.55	4.97	0.38	1.81e-6	Aortic root size;
UCEC	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.53	4.71	0.36	5.68e-6	Tonsillectomy;
UCEC	cis	rs1355223	0.752	rs17359064	chr11:34673884	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-5.21	-0.39	6.4e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg17105886	chr17:28927953	LRRC37B2	0.51	4.52	0.35	1.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.5	-5.72	-0.43	5.67e-8	Mean corpuscular hemoglobin;
UCEC	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18932078	chr1:2524107	MMEL1	-0.35	-6.06	-0.45	1.07e-8	Ulcerative colitis;
UCEC	cis	rs9825379	0.541	rs55715186	chr3:141145402	T/C	cg04352534	chr3:141104523	ZBTB38	-0.52	-4.51	-0.35	1.31e-5	Height;
UCEC	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.58	-4.97	-0.38	1.88e-6	Obesity-related traits;
UCEC	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.56	4.63	0.36	7.86e-6	Obesity-related traits;
UCEC	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-1.14	-8.28	-0.56	6.8e-14	Post bronchodilator FEV1;
UCEC	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.65	-7.4	-0.52	9.5e-12	Menarche (age at onset);
UCEC	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-6.39	-0.47	2.11e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1576263	0.967	rs1796698	chr6:8552469	A/G	cg21535247	chr6:8435926	SLC35B3	0.49	4.98	0.38	1.72e-6	Photic sneeze reflex;
UCEC	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	5.01	0.38	1.57e-6	Sum eosinophil basophil counts;Eosinophil counts;
UCEC	cis	rs7937612	1.000	rs894839	chr11:120337705	A/G	cg12584626	chr11:120203529	NA	0.47	4.66	0.36	6.93e-6	Intraocular pressure;
UCEC	cis	rs7246967	0.551	rs7351072	chr19:23044529	C/T	cg05241461	chr19:22816980	ZNF492	0.5	5.14	0.39	8.65e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18252515	chr7:66147081	NA	0.55	5.12	0.39	9.39e-7	Aortic root size;
UCEC	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-0.83	-4.65	-0.36	7.42e-6	Inflammatory biomarkers;
UCEC	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.55	-5.21	-0.39	6.33e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs2862064	0.932	rs1995378	chr5:156421132	G/A	cg12943317	chr5:156479607	HAVCR1	-0.89	-6.46	-0.47	1.42e-9	Platelet count;
UCEC	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.54	4.79	0.37	4.08e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg00105475	chr2:10696890	NA	0.43	5.35	0.4	3.23e-7	Prostate cancer;
UCEC	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.58	8.45	0.57	2.55e-14	Prudent dietary pattern;
UCEC	cis	rs6137726	0.620	rs1571249	chr20:22663357	C/T	cg08244522	chr20:23030533	THBD	0.45	4.65	0.36	7.26e-6	Amyotrophic lateral sclerosis (sporadic);
UCEC	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.7	5.99	0.44	1.51e-8	Bipolar disorder;
UCEC	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.73	7.5	0.53	5.69e-12	Menarche (age at onset);
UCEC	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.81	-9.7	-0.62	1.67e-17	Primary sclerosing cholangitis;
UCEC	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.72	8.33	0.57	5.13e-14	Menarche (age at onset);
UCEC	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-4.94	-0.38	2.08e-6	Lung cancer in ever smokers;
UCEC	cis	rs7246967	0.800	rs12985313	chr19:23037780	T/C	cg05241461	chr19:22816980	ZNF492	0.48	5.12	0.39	9.3e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs1978968	0.731	rs9605463	chr22:18459889	C/T	cg03078520	chr22:18463400	MICAL3	-0.54	-6.59	-0.48	7.51e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg24130564	chr14:104152367	KLC1	-0.54	-4.68	-0.36	6.38e-6	Reticulocyte count;
UCEC	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.43	-5.14	-0.39	8.6e-7	Educational attainment;
UCEC	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.83	-7.41	-0.52	8.98e-12	Total cholesterol levels;
UCEC	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg11859384	chr17:80120422	CCDC57	0.44	4.68	0.36	6.51e-6	Life satisfaction;
UCEC	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.53	5.57	0.42	1.18e-7	Corneal astigmatism;
UCEC	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.45	5.6	0.42	1.01e-7	Metabolite levels;
UCEC	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06627825	chr2:68290170	C1D	0.68	6.76	0.49	3.04e-10	Migraine with aura;
UCEC	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-4.6	-0.35	9.01e-6	Homocysteine levels;
UCEC	cis	rs13065560	0.594	rs4398365	chr3:38878804	C/G	cg01426195	chr3:39028469	NA	-0.46	-5.04	-0.38	1.38e-6	Interleukin-18 levels;
UCEC	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.37	4.73	0.36	5.21e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.65	-6.08	-0.45	9.85e-9	Vitiligo;
UCEC	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	0.94	13.28	0.74	6.25e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
UCEC	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.5	4.86	0.37	2.94e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs11048434	0.932	rs12817960	chr12:9153127	C/T	cg13575925	chr12:9217583	LOC144571	0.42	4.62	0.36	8.17e-6	Sjögren's syndrome;
UCEC	cis	rs9486594	1.000	rs80128495	chr6:107657462	A/G	cg20431250	chr6:108492653	NR2E1	-0.79	-5.46	-0.41	1.99e-7	Airway responsiveness in chronic obstructive pulmonary disease;
UCEC	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.71	4.81	0.37	3.75e-6	Breast cancer;
UCEC	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.16	-13.84	-0.75	2.1e-28	Breast cancer;
UCEC	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.58	-5.98	-0.44	1.59e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs7187365	0.638	rs11865483	chr16:86494979	A/T	cg02260710	chr16:85730584	NA	-0.42	-5.46	-0.41	1.97e-7	Obesity (early onset extreme);
UCEC	cis	rs9467773	0.901	rs10223789	chr6:26579609	C/T	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.73	7.51	0.53	5.24e-12	Tonsillectomy;
UCEC	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg23995753	chr2:160760732	LY75	-0.41	-4.81	-0.37	3.78e-6	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.66	7.4	0.52	9.93e-12	Homoarginine levels;
UCEC	cis	rs11867410	0.744	rs73349006	chr17:63927385	G/A	cg06996976	chr17:64576105	PRKCA	-0.78	-4.69	-0.36	6.08e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.72	8.49	0.57	2.12e-14	Prudent dietary pattern;
UCEC	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	0.97	13.97	0.76	9.12e-29	Homoarginine levels;
UCEC	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	0.52	5.9	0.44	2.35e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.46	4.84	0.37	3.3e-6	Schizophrenia;
UCEC	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.66	4.86	0.37	2.93e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.57	-6.46	-0.47	1.44e-9	Crohn's disease;
UCEC	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.65	-6.12	-0.45	8.14e-9	Coronary artery disease;
UCEC	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.62	-5.62	-0.42	9.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.45	-4.66	-0.36	7.05e-6	Vitiligo;
UCEC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	0.89	8.32	0.57	5.42e-14	Cognitive function;
UCEC	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-4.68	-0.36	6.53e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.62	5.45	0.41	2.11e-7	Corneal astigmatism;
UCEC	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.55	5.67	0.42	7.38e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs12753920	0.735	rs12403751	chr1:92673203	C/T	cg10324998	chr1:92338262	TGFBR3	-0.46	-4.59	-0.35	9.62e-6	Systemic lupus erythematosus;
UCEC	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.7	6.29	0.46	3.45e-9	Breast cancer;
UCEC	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-5.36	-0.4	3.12e-7	Recalcitrant atopic dermatitis;
UCEC	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.5	5.2	0.39	6.65e-7	Emphysema distribution in smoking;
UCEC	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg11130432	chr3:121712080	ILDR1	-0.48	-4.87	-0.37	2.85e-6	Multiple sclerosis;
UCEC	cis	rs787274	1.000	rs1711739	chr9:115464474	G/A	cg13803584	chr9:115635662	SNX30	0.62	5.53	0.41	1.45e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs6832769	1.000	rs6812042	chr4:56396079	A/C	cg05960024	chr4:56376020	CLOCK	0.56	5.85	0.43	3.01e-8	Personality dimensions;
UCEC	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.63	5.78	0.43	4.31e-8	Parkinson's disease;
UCEC	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26207909	chr14:103986467	CKB	-0.51	-5.64	-0.42	8.39e-8	Body mass index;
UCEC	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.95	-0.44	1.88e-8	Mortality in heart failure;
UCEC	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.71	5.49	0.41	1.72e-7	Platelet count;
UCEC	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.58	5.78	0.43	4.22e-8	Bipolar disorder;
UCEC	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.61	5.8	0.43	3.99e-8	Corneal astigmatism;
UCEC	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.46	-4.69	-0.36	6.07e-6	Total body bone mineral density;
UCEC	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.67	-7.03	-0.5	7.36e-11	Height;
UCEC	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.49	4.75	0.37	4.7e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.5	-5.41	-0.41	2.53e-7	Menarche (age at onset);
UCEC	cis	rs7088591	0.867	rs73290936	chr10:59784396	T/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs9309473	1.000	rs11689392	chr2:73622026	T/C	cg20560298	chr2:73613845	ALMS1	-0.6	-5.44	-0.41	2.16e-7	Metabolite levels;
UCEC	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.76	7.05	0.5	6.47e-11	Alzheimer's disease;
UCEC	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.74	-6.74	-0.49	3.38e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.48	5.19	0.39	7.02e-7	Aortic root size;
UCEC	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.66	6.23	0.46	4.54e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-0.64	-6.05	-0.45	1.13e-8	Vitiligo;
UCEC	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.61	6.51	0.47	1.11e-9	Vitiligo;
UCEC	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.82	7.6	0.53	3.22e-12	Bladder cancer;
UCEC	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.78	-6.24	-0.46	4.32e-9	Alzheimer's disease (late onset);
UCEC	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.72	4.52	0.35	1.26e-5	Bipolar disorder (body mass index interaction);
UCEC	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.37	5.45	0.41	2.1e-7	Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg13683864	chr3:40499215	RPL14	-0.58	-6.25	-0.46	4.15e-9	Renal cell carcinoma;
UCEC	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg17279458	chr3:44753948	ZNF502	-0.43	-4.71	-0.36	5.8e-6	Depressive symptoms;
UCEC	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg02820040	chr2:241836501	C2orf54	-0.4	-4.98	-0.38	1.76e-6	Urinary metabolites;
UCEC	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.52	-5.6	-0.42	1.01e-7	Menarche (age at onset);
UCEC	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.51	5.04	0.38	1.32e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-9.87	-0.63	5.95e-18	Primary sclerosing cholangitis;
UCEC	cis	rs10432489	0.572	rs10174914	chr2:181678814	A/G	cg08065101	chr2:182521918	CERKL	-0.59	-4.68	-0.36	6.44e-6	QT interval;
UCEC	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.59	-5.32	-0.4	3.79e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.45	4.72	0.36	5.45e-6	Extrinsic epigenetic age acceleration;
UCEC	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.4	4.77	0.37	4.35e-6	Menarche (age at onset);
UCEC	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg20965017	chr5:231967	SDHA	0.68	5.98	0.44	1.59e-8	Breast cancer;
UCEC	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg22166914	chr1:53195759	ZYG11B	-0.64	-7.01	-0.5	8.17e-11	Monocyte count;
UCEC	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.48	5.33	0.4	3.54e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.6	-5.79	-0.43	4.13e-8	Coronary artery disease;
UCEC	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.33	-0.4	3.61e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.98	-13.77	-0.75	3.08e-28	Height;
UCEC	cis	rs4778214	0.858	rs10775263	chr15:28233913	C/T	cg08281084	chr15:28459700	HERC2	-0.5	-4.51	-0.35	1.29e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
UCEC	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg03422651	chr16:2542324	TBC1D24	0.47	4.65	0.36	7.23e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.66	5.42	0.41	2.37e-7	Metabolite levels;
UCEC	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.54	4.76	0.37	4.6e-6	Cognitive ability;
UCEC	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	8.82	0.59	3e-15	Alzheimer's disease;
UCEC	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.67	-6.12	-0.45	7.93e-9	Prostate cancer;
UCEC	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg23070574	chr3:14187308	XPC	0.45	4.97	0.38	1.82e-6	Ovarian reserve;
UCEC	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18252515	chr7:66147081	NA	-0.47	-4.61	-0.36	8.71e-6	Aortic root size;
UCEC	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.7	8.4	0.57	3.53e-14	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.52	5.87	0.44	2.73e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.67	-7.54	-0.53	4.58e-12	Breast cancer;
UCEC	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg00651523	chr6:28411279	ZSCAN23	-0.44	-4.88	-0.37	2.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6925255	0.669	rs2223978	chr6:80466671	G/A	cg09116618	chr6:81233028	NA	0.32	4.55	0.35	1.11e-5	Aging;
UCEC	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	0.92	12.78	0.73	1.25e-25	Homoarginine levels;
UCEC	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	4.94	0.38	2.1e-6	Height;
UCEC	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.11	9.62	0.62	2.73e-17	Opioid sensitivity;
UCEC	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.75	8.39	0.57	3.75e-14	Menarche (age at onset);
UCEC	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg14675211	chr2:100938903	LONRF2	-0.66	-6.62	-0.48	6.18e-10	Educational attainment;
UCEC	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg21856205	chr7:94953877	PON1	-0.53	-4.76	-0.37	4.68e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.56	6.66	0.48	5.19e-10	Blood metabolite ratios;
UCEC	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.38	4.8	0.37	3.92e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg14078730	chr11:63896557	MACROD1	0.66	5.16	0.39	8.04e-7	Mean platelet volume;
UCEC	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.55	5.26	0.4	5e-7	Lung cancer;
UCEC	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.58	-5.67	-0.42	7.38e-8	Total body bone mineral density;
UCEC	cis	rs2862064	1.000	rs6555787	chr5:156433699	T/C	cg12943317	chr5:156479607	HAVCR1	-0.77	-5.73	-0.43	5.52e-8	Platelet count;
UCEC	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.82	-10.5	-0.65	1.38e-19	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg04682699	chr3:50248845	SLC38A3	-0.38	-4.53	-0.35	1.21e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.62	4.78	0.37	4.21e-6	Bladder cancer;
UCEC	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.57	-5.27	-0.4	4.7e-7	Type 1 diabetes nephropathy;
UCEC	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.5	-4.71	-0.36	5.75e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg08886695	chr4:3369023	RGS12	0.47	5.11	0.39	1e-6	Parental longevity (mother's age at death);
UCEC	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-8.47	-0.57	2.37e-14	Coffee consumption (cups per day);
UCEC	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.15	14.33	0.76	1.05e-29	Cognitive function;
UCEC	cis	rs2841277	0.720	rs11160827	chr14:105422228	C/T	cg21017887	chr14:105400489	NA	0.48	5.55	0.42	1.32e-7	Rheumatoid arthritis;
UCEC	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.24e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.63	-4.95	-0.38	2.04e-6	Carotid intima media thickness;
UCEC	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg10123293	chr2:99228465	UNC50	0.49	5.5	0.41	1.68e-7	Bipolar disorder;
UCEC	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg02160872	chr5:212506	CCDC127	-0.71	-7.52	-0.53	5.12e-12	Breast cancer;
UCEC	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.31	-0.4	3.94e-7	Mood instability;
UCEC	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.16	-0.39	7.74e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg23018236	chr17:30244563	NA	-0.68	-4.91	-0.38	2.39e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs7804356	1.000	rs73065504	chr7:26825984	A/G	cg02693607	chr7:27150598	HOXA3	0.55	4.64	0.36	7.71e-6	Type 1 diabetes;
UCEC	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg12024160	chr4:1254474	NA	0.66	7.84	0.54	8.37e-13	Obesity-related traits;
UCEC	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg14008862	chr17:28927542	LRRC37B2	0.66	5.0	0.38	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs9309473	1.000	rs6724782	chr2:73679990	T/A	cg20560298	chr2:73613845	ALMS1	-0.65	-5.87	-0.44	2.77e-8	Metabolite levels;
UCEC	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	10.41	0.65	2.3e-19	Post bronchodilator FEV1;
UCEC	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.64	5.68	0.42	7.08e-8	Lung function (FEV1/FVC);
UCEC	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.54	6.0	0.44	1.46e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	0.93	9.5	0.62	5.42e-17	Heart rate;
UCEC	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.47	-5.76	-0.43	4.74e-8	Neutrophil percentage of white cells;
UCEC	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg23888215	chr10:79422304	NA	1.11	9.1	0.6	5.84e-16	Bone mineral density;
UCEC	cis	rs944990	0.618	rs2398845	chr9:96365612	T/G	cg13787134	chr9:96362102	PHF2	-0.39	-5.5	-0.41	1.64e-7	Body mass index;
UCEC	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.81	-6.6	-0.48	6.82e-10	Lymphocyte counts;
UCEC	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.67	7.34	0.52	1.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg05527609	chr1:210001259	C1orf107	0.66	5.2	0.39	6.46e-7	Red blood cell count;
UCEC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.75	-7.85	-0.54	7.89e-13	Menarche (age at onset);
UCEC	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.52	-5.82	-0.43	3.53e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
UCEC	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.86	-0.59	2.44e-15	Height;
UCEC	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.41	-5.39	-0.41	2.69e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.46	-4.81	-0.37	3.67e-6	Type 2 diabetes;
UCEC	cis	rs7175404	0.591	rs57685087	chr15:94060306	G/A	cg06054272	chr15:93956988	NA	0.67	4.84	0.37	3.21e-6	Attention deficit hyperactivity disorder;
UCEC	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.54	5.32	0.4	3.84e-7	Cognitive test performance;
UCEC	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	9.35	0.61	1.37e-16	Platelet count;
UCEC	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.9	9.9	0.63	4.98e-18	Mean corpuscular hemoglobin;
UCEC	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.62	7.1	0.51	4.82e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18252515	chr7:66147081	NA	0.53	4.97	0.38	1.81e-6	Aortic root size;
UCEC	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.59	7.06	0.5	6.24e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7246967	0.673	rs4627499	chr19:22832633	T/C	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs17106184	0.892	rs116692933	chr1:51136273	T/C	cg07174182	chr1:51127561	FAF1	-0.77	-4.88	-0.37	2.73e-6	Type 2 diabetes;
UCEC	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg20045696	chr14:77926864	AHSA1	-0.65	-4.84	-0.37	3.2e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
UCEC	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg21214455	chr15:72412075	SENP8	0.46	4.64	0.36	7.51e-6	Metabolite levels (HVA/MHPG ratio);
UCEC	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.91e-7	Metabolite levels;
UCEC	cis	rs713477	0.967	rs4901568	chr14:55912789	T/A	cg13175173	chr14:55914753	NA	-0.4	-4.52	-0.35	1.26e-5	Pediatric bone mineral content (femoral neck);
UCEC	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.72	7.91	0.55	5.75e-13	Lung cancer;
UCEC	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.5	5.84	0.43	3.25e-8	Longevity;
UCEC	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.44	4.96	0.38	1.95e-6	Iron status biomarkers (transferrin levels);
UCEC	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.7	0.36	5.98e-6	Tonsillectomy;
UCEC	cis	rs13098911	0.540	rs41289622	chr3:46014545	T/G	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	9.9	0.63	4.95e-18	Total body bone mineral density;
UCEC	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.91	6.07	0.45	1.02e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.65	-6.01	-0.44	1.36e-8	Aortic root size;
UCEC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg19784848	chr5:219127	SDHA;CCDC127	-0.62	-5.26	-0.4	5.05e-7	Breast cancer;
UCEC	cis	rs11133613	0.546	rs28676354	chr5:947272	A/G	cg04184427	chr5:1076892	SLC12A7	-0.64	-4.6	-0.35	9.11e-6	Red cell distribution width;
UCEC	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-4.92	-0.38	2.34e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg14067834	chr17:29058358	SUZ12P	0.58	4.56	0.35	1.07e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.53	-4.56	-0.35	1.06e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.7	8.29	0.56	6.52e-14	Coronary artery disease;
UCEC	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg20965017	chr5:231967	SDHA	-0.65	-5.99	-0.44	1.57e-8	Breast cancer;
UCEC	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	0.81	6.43	0.47	1.71e-9	Corneal structure;
UCEC	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	5.64	0.42	8.29e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	7.36	0.52	1.2e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	trans	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg02022102	chr7:27168609	HOXA4	0.6	6.78	0.49	2.67e-10	Protein biomarker;
UCEC	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.49	-4.86	-0.37	2.98e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg04871131	chr7:94954202	PON1	-0.52	-5.15	-0.39	8.14e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.58	4.57	0.35	1.01e-5	Exhaled nitric oxide output;
UCEC	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.48	-5.19	-0.39	6.85e-7	Neuroticism;
UCEC	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.72	7.43	0.52	8.28e-12	Smoking behavior;
UCEC	cis	rs12365397	0.775	rs2132484	chr11:43244386	A/C	cg07515919	chr11:43391688	TTC17	0.48	5.01	0.38	1.53e-6	Migraine;
UCEC	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg00105475	chr2:10696890	NA	0.42	5.17	0.39	7.53e-7	Prostate cancer;
UCEC	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06637938	chr14:75390232	RPS6KL1	0.51	4.7	0.36	6.01e-6	Height;
UCEC	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg13147721	chr7:65941812	NA	-0.92	-6.1	-0.45	8.73e-9	Diabetic kidney disease;
UCEC	cis	rs6684428	0.706	rs11206677	chr1:56335237	C/A	cg11651538	chr1:56320950	NA	-0.76	-6.81	-0.49	2.29e-10	Airflow obstruction;
UCEC	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.62	5.39	0.41	2.78e-7	Heart rate;
UCEC	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.49	-4.6	-0.35	9.19e-6	Rheumatoid arthritis;
UCEC	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.71	-5.89	-0.44	2.52e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
UCEC	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg24011408	chr12:48396354	COL2A1	0.6	5.16	0.39	7.95e-7	Lung cancer;
UCEC	cis	rs10242455	0.867	rs1403196	chr7:99306321	G/T	cg07715041	chr7:99302981	CYP3A7	-0.46	-4.78	-0.37	4.12e-6	Blood metabolite levels;
UCEC	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	5.29	0.4	4.33e-7	Alzheimer's disease;
UCEC	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.57	-5.43	-0.41	2.28e-7	Pediatric autoimmune diseases;
UCEC	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg14547644	chr6:28411285	ZSCAN23	0.59	6.58	0.48	7.59e-10	Pubertal anthropometrics;
UCEC	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg02461776	chr11:598696	PHRF1	0.51	5.19	0.39	6.94e-7	Systemic lupus erythematosus;
UCEC	cis	rs9039	0.921	rs9929699	chr16:9218270	A/G	cg08831531	chr16:9218945	NA	-0.43	-4.8	-0.37	3.8e-6	Menopause (age at onset);
UCEC	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	11.25	0.68	1.45e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs28530618	0.500	rs6058770	chr20:31223633	A/C	cg13636640	chr20:31349939	DNMT3B	-0.59	-5.53	-0.41	1.45e-7	Birth weight;
UCEC	cis	rs925228	0.869	rs4665643	chr2:24111742	C/G	cg16945982	chr2:25016118	CENPO;C2orf79	0.54	4.81	0.37	3.65e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-6.38	-0.47	2.17e-9	Platelet count;
UCEC	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.62	6.2	0.46	5.39e-9	Intelligence (multi-trait analysis);
UCEC	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-6.89	-0.49	1.55e-10	Colorectal cancer;
UCEC	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.79	-9.0	-0.6	1.07e-15	Metabolite levels;
UCEC	cis	rs4389656	0.857	rs274676	chr5:6754762	T/C	cg10857441	chr5:6722123	POLS	-0.41	-4.8	-0.37	3.89e-6	Coronary artery disease;
UCEC	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg21770322	chr7:97807741	LMTK2	0.5	6.33	0.46	2.81e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.76	-5.34	-0.4	3.44e-7	Cerebrospinal P-tau181p levels;
UCEC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-5.08	-0.39	1.11e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.61	-7.56	-0.53	4.02e-12	Pubertal anthropometrics;
UCEC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.58	-6.75	-0.49	3.17e-10	Prostate cancer;
UCEC	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg23791538	chr6:167370224	RNASET2	-0.62	-6.38	-0.47	2.14e-9	Primary biliary cholangitis;
UCEC	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.94	0.38	2.06e-6	Schizophrenia;
UCEC	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.55	-5.7	-0.43	6.39e-8	Hepatocellular carcinoma;
UCEC	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-6.07	-0.45	1.02e-8	Mean platelet volume;
UCEC	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.66	-4.81	-0.37	3.69e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.62	6.6	0.48	7.08e-10	Morning vs. evening chronotype;
UCEC	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.69	5.76	0.43	4.78e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.67	7.09	0.5	5.34e-11	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg19041857	chr6:27730383	NA	-0.63	-5.01	-0.38	1.57e-6	Lung cancer in ever smokers;
UCEC	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.68	-5.15	-0.39	8.3e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.36	4.63	0.36	8.09e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.67	-8.09	-0.55	2.09e-13	IgG glycosylation;
UCEC	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.69	7.51	0.53	5.18e-12	Breast cancer;
UCEC	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.51	4.75	0.36	4.82e-6	Platelet count;
UCEC	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	1.0	11.0	0.67	6.53e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.7	6.75	0.49	3.11e-10	Aortic root size;
UCEC	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-1.15	-5.03	-0.38	1.39e-6	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.5	-4.85	-0.37	3.05e-6	Electroencephalogram traits;
UCEC	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18099408	chr3:52552593	STAB1	-0.44	-4.51	-0.35	1.34e-5	Bipolar disorder;
UCEC	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.69	8.3	0.57	6.04e-14	Prudent dietary pattern;
UCEC	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg11150807	chr10:43354902	NA	-0.84	-6.73	-0.49	3.54e-10	Blood protein levels;
UCEC	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.5	7.0	0.5	8.29e-11	Homoarginine levels;
UCEC	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.68	5.62	0.42	9.37e-8	Smoking initiation;
UCEC	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	8.31	0.57	5.85e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs78487399	0.710	rs75514072	chr2:43750224	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.78	-5.38	-0.41	2.91e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
UCEC	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	7.89	0.55	6.18e-13	Tonsillectomy;
UCEC	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.24	-0.4	5.6e-7	Breast cancer;
UCEC	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.49	5.37	0.41	2.98e-7	Longevity;Endometriosis;
UCEC	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.74	6.6	0.48	7.07e-10	Neutrophil percentage of white cells;
UCEC	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.64	6.07	0.45	1.03e-8	Aortic root size;
UCEC	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg04845466	chr2:27665079	KRTCAP3;NRBP1	-0.36	-4.7	-0.36	6.01e-6	Blood metabolite levels;
UCEC	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.05	0.55	2.53e-13	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg06096015	chr1:231504339	EGLN1	0.41	4.77	0.37	4.41e-6	Hemoglobin concentration;
UCEC	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.52	5.01	0.38	1.57e-6	Menopause (age at onset);
UCEC	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.2	7.58	0.53	3.63e-12	Gut microbiome composition (summer);
UCEC	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	0.6	6.23	0.46	4.63e-9	Vitiligo;
UCEC	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.45	4.69	0.36	6.29e-6	Rheumatoid arthritis;
UCEC	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.58	6.16	0.45	6.66e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg22117172	chr7:91764530	CYP51A1	0.38	4.64	0.36	7.71e-6	Breast cancer;
UCEC	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.55	6.16	0.45	6.7e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg05501817	chr11:14380813	RRAS2	-0.5	-4.85	-0.37	3.17e-6	Sense of smell;
UCEC	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.57	6.46	0.47	1.42e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.57	-5.69	-0.42	6.71e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7638909	0.512	rs6793245	chr3:38599037	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.48	4.77	0.37	4.37e-6	Electrocardiographic conduction measures;
UCEC	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.67	7.53	0.53	4.73e-12	Eye color traits;
UCEC	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.84	9.35	0.61	1.33e-16	Breast cancer;
UCEC	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.65	-7.25	-0.51	2.16e-11	Menarche (age at onset);
UCEC	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-4.75	-0.36	4.81e-6	Alzheimer's disease (late onset);
UCEC	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.41	-4.62	-0.36	8.42e-6	Inflammatory bowel disease;
UCEC	cis	rs6493487	0.556	rs11855675	chr15:51116432	A/C	cg20651644	chr15:50170642	ATP8B4	0.51	4.62	0.36	8.39e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7246967	0.608	rs370734	chr19:23012586	C/G	cg08271804	chr19:22816896	ZNF492	0.5	4.63	0.36	7.99e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs11760485	0.931	rs4723681	chr7:4400493	T/C	cg15613991	chr7:5277080	NA	-0.4	-4.65	-0.36	7.44e-6	Early childhood aggressive behavior;
UCEC	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	1.02	13.54	0.75	1.24e-27	Monocyte count;
UCEC	cis	rs9309473	0.519	rs2421574	chr2:73908767	C/G	cg20560298	chr2:73613845	ALMS1	0.49	4.53	0.35	1.22e-5	Metabolite levels;
UCEC	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	7.35	0.52	1.31e-11	Hip circumference adjusted for BMI;
UCEC	cis	rs6820391	0.816	rs7681869	chr4:54447773	G/A	cg04173182	chr4:54446035	LNX1	0.36	4.51	0.35	1.32e-5	Cervical artery dissection;
UCEC	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.65	-6.05	-0.45	1.16e-8	Aortic root size;
UCEC	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.6	-5.59	-0.42	1.06e-7	Aortic root size;
UCEC	cis	rs7088591	0.867	rs11814120	chr10:59789084	T/C	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.73	-6.01	-0.44	1.37e-8	Bipolar disorder;
UCEC	trans	rs13117816	0.545	rs35333496	chr4:37005419	T/C	cg18778608	chr19:3761698	MRPL54;APBA3	-0.72	-6.7	-0.48	4.11e-10	Multiple sclerosis--Brain Glutamate Levels;
UCEC	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-6.8	-0.49	2.42e-10	Chronic sinus infection;
UCEC	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg23815491	chr16:72088622	HP	0.37	4.67	0.36	6.75e-6	Fibrinogen levels;
UCEC	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-5.89	-0.44	2.56e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
UCEC	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.08	0.64	1.74e-18	Electrocardiographic conduction measures;
UCEC	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.09	-0.5	5.26e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg11189052	chr15:85197271	WDR73	0.57	4.58	0.35	9.94e-6	Schizophrenia;
UCEC	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-5.92	-0.44	2.13e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg11508081	chr17:41442227	NA	-0.41	-4.53	-0.35	1.2e-5	Menopause (age at onset);
UCEC	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.47	4.9	0.37	2.52e-6	Tuberculosis;
UCEC	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.48	4.74	0.36	5.07e-6	Height;
UCEC	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	8.53	0.58	1.68e-14	Chronic sinus infection;
UCEC	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.88	9.3	0.61	1.77e-16	Cognitive function;
UCEC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.68	5.76	0.43	4.85e-8	Alcohol dependence;
UCEC	cis	rs6867032	1.000	rs4254943	chr5:2009878	C/T	cg26168224	chr5:2018326	NA	0.74	9.55	0.62	4e-17	Gut microbiome composition (winter);
UCEC	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg10914120	chr13:113893660	CUL4A	0.46	4.53	0.35	1.23e-5	Platelet distribution width;
UCEC	cis	rs6722750	0.933	rs4671554	chr2:64411122	T/A	cg22352474	chr2:64371530	PELI1	-0.47	-4.67	-0.36	6.63e-6	Neuroticism;
UCEC	cis	rs847577	0.722	rs1013887	chr7:97709345	G/T	cg24562669	chr7:97807699	LMTK2	0.57	7.25	0.51	2.17e-11	Breast cancer;
UCEC	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	15.41	0.79	1.73e-32	Chronic sinus infection;
UCEC	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.01	8.54	0.58	1.53e-14	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.58	6.49	0.47	1.25e-9	Hip circumference;
UCEC	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.83	7.91	0.55	5.8e-13	Diastolic blood pressure;
UCEC	cis	rs409224	0.533	rs73187803	chr7:101741703	G/C	cg08135718	chr7:101819329	CUX1	0.49	5.04	0.38	1.34e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
UCEC	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg21770322	chr7:97807741	LMTK2	0.84	14.11	0.76	4.06e-29	Breast cancer;
UCEC	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.51	4.57	0.35	1.04e-5	Optic nerve measurement (cup area);
UCEC	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.53	4.87	0.37	2.9e-6	Morning vs. evening chronotype;
UCEC	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.64	-7.24	-0.51	2.35e-11	Mean platelet volume;
UCEC	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	0.81	4.96	0.38	1.92e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg24011408	chr12:48396354	COL2A1	0.55	4.89	0.37	2.58e-6	Lung cancer;
UCEC	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg01072550	chr1:21505969	NA	-0.61	-6.34	-0.46	2.71e-9	Superior frontal gyrus grey matter volume;
UCEC	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg08859206	chr1:53392774	SCP2	-0.59	-6.29	-0.46	3.45e-9	Monocyte count;
UCEC	cis	rs7246967	0.673	rs73028776	chr19:22813740	A/C	cg03230154	chr19:22817176	ZNF492	0.43	4.52	0.35	1.28e-5	Bronchopulmonary dysplasia;
UCEC	trans	rs4389974	0.932	rs62520649	chr8:112414009	G/A	cg22736090	chr17:62339926	TEX2	0.66	6.89	0.49	1.51e-10	Body mass index;
UCEC	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg13147721	chr7:65941812	NA	-0.83	-5.52	-0.41	1.5e-7	Diabetic kidney disease;
UCEC	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg16164276	chr3:11034345	SLC6A1	-0.47	-4.6	-0.35	9.24e-6	Alzheimer's disease;
UCEC	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.79	8.08	0.55	2.15e-13	Caffeine consumption;
UCEC	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg16511985	chr3:153974050	SGEF	0.59	5.29	0.4	4.33e-7	Coronary artery disease;
UCEC	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.77	5.76	0.43	4.69e-8	Exhaled nitric oxide levels;
UCEC	cis	rs7095607	0.785	rs12774706	chr10:69916913	T/A	cg18986048	chr10:69913749	MYPN	0.52	6.16	0.45	6.75e-9	Lung function (FVC);
UCEC	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.76	-8.48	-0.57	2.25e-14	Menarche (age at onset);
UCEC	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.59	4.68	0.36	6.36e-6	Blood pressure;
UCEC	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.34	-4.58	-0.35	9.92e-6	Total body bone mineral density;
UCEC	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg18016565	chr1:150552671	MCL1	0.47	4.62	0.36	8.33e-6	Melanoma;
UCEC	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.53	5.98	0.44	1.59e-8	Menarche (age at onset);
UCEC	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.82	-10.07	-0.64	1.83e-18	Coronary artery disease;
UCEC	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.77	-7.92	-0.55	5.44e-13	Parkinson's disease;
UCEC	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.7	9.58	0.62	3.53e-17	Coronary artery disease;
UCEC	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg13683864	chr3:40499215	RPL14	-0.79	-7.41	-0.52	9.14e-12	Renal cell carcinoma;
UCEC	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.92	-11.93	-0.7	2.27e-23	Metabolic syndrome;
UCEC	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.2	-19.73	-0.85	3.83e-43	Chronic sinus infection;
UCEC	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.96	12.32	0.71	2.03e-24	Prudent dietary pattern;
UCEC	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.51	-4.92	-0.38	2.26e-6	Pancreatic cancer;
UCEC	cis	rs883565	0.682	rs35219579	chr3:39044665	A/T	cg01426195	chr3:39028469	NA	-0.77	-10.02	-0.64	2.44e-18	Handedness;
UCEC	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-6.0	-0.44	1.48e-8	Response to antipsychotic treatment;
UCEC	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.34	4.69	0.36	6.07e-6	Primary biliary cholangitis;
UCEC	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.52	4.73	0.36	5.33e-6	Uric acid levels;
UCEC	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.71	8.58	0.58	1.26e-14	Prudent dietary pattern;
UCEC	cis	rs17123764	0.818	rs59960493	chr12:49941879	G/A	cg20471783	chr12:50157085	TMBIM6	0.59	4.5	0.35	1.36e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs4778581	0.900	rs4594222	chr15:80416377	A/G	cg08257866	chr15:80351198	ZFAND6	0.41	4.58	0.35	9.65e-6	Reticulocyte count;Reticulocyte fraction of red cells;
UCEC	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg05501817	chr11:14380813	RRAS2	0.49	4.79	0.37	4.06e-6	Vitamin D levels;
UCEC	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.42	4.51	0.35	1.29e-5	Height;
UCEC	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.45	6.27	0.46	3.77e-9	Height;
UCEC	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.34e-6	Hemoglobin concentration;
UCEC	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs829661	0.843	rs866680	chr2:30720191	C/A	cg17749961	chr2:30669863	LCLAT1	0.7	5.78	0.43	4.36e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.65	5.17	0.39	7.58e-7	Bladder cancer;
UCEC	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.6	5.79	0.43	4.02e-8	Longevity;Endometriosis;
UCEC	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.47	-5.9	-0.44	2.35e-8	Menarche (age at onset);
UCEC	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.06	6.52	0.47	1.07e-9	Diabetic retinopathy;
UCEC	cis	rs751728	0.965	rs4713683	chr6:33757550	C/G	cg25922239	chr6:33757077	LEMD2	0.57	5.08	0.39	1.11e-6	Crohn's disease;
UCEC	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.55	-5.28	-0.4	4.63e-7	Initial pursuit acceleration;
UCEC	cis	rs526231	0.578	rs59323174	chr5:102267869	T/C	cg23492399	chr5:102201601	PAM	-0.54	-4.75	-0.36	4.85e-6	Primary biliary cholangitis;
UCEC	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.47	4.94	0.38	2.13e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.88	9.53	0.62	4.63e-17	Psoriasis;
UCEC	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.5	5.22	0.4	6.11e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.51	5.6	0.42	1.01e-7	Tonsillectomy;
UCEC	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.47	-0.41	1.85e-7	Body mass index;
UCEC	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.63	6.57	0.48	8.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07215822	chr6:158701037	NA	-0.68	-5.97	-0.44	1.71e-8	Height;
UCEC	cis	rs9303029	0.932	rs9905527	chr17:80439925	T/C	cg04200411	chr17:80449551	NA	-0.65	-5.1	-0.39	1.04e-6	Protein quantitative trait loci;
UCEC	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg06462663	chr19:18546047	ISYNA1	0.53	6.73	0.49	3.58e-10	Breast cancer;
UCEC	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.53	-4.59	-0.35	9.35e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.83	8.85	0.59	2.54e-15	Prudent dietary pattern;
UCEC	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-5.37	-0.4	3.02e-7	Bipolar disorder;
UCEC	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.62	6.05	0.45	1.17e-8	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
UCEC	cis	rs4280164	0.945	rs11158632	chr14:24769663	A/C	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.6	-4.73	-0.36	5.11e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.72	-5.96	-0.44	1.79e-8	Depression;
UCEC	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.44	-4.52	-0.35	1.25e-5	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.89	9.56	0.62	3.83e-17	Parkinson's disease;
UCEC	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.81	-11.32	-0.68	9.1e-22	Post bronchodilator FEV1;
UCEC	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-5.55	-0.42	1.31e-7	Monocyte percentage of white cells;
UCEC	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.55	-4.91	-0.38	2.36e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs6882076	1.000	rs6882076	chr5:156390297	T/C	cg12943317	chr5:156479607	HAVCR1	-0.49	-5.11	-0.39	1.01e-6	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
UCEC	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	0.81	6.91	0.5	1.36e-10	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.69	-5.2	-0.39	6.61e-7	Aortic root size;
UCEC	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg13575925	chr12:9217583	LOC144571	0.41	4.63	0.36	7.93e-6	Sjögren's syndrome;
UCEC	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	4.87	0.37	2.83e-6	Personality dimensions;
UCEC	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.59	6.22	0.46	4.95e-9	Motion sickness;
UCEC	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.58	-7.78	-0.54	1.19e-12	Neuroticism;
UCEC	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.16	0.64	1.05e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.62	-4.81	-0.37	3.65e-6	Cerebrospinal P-tau181p levels;
UCEC	cis	rs7246967	0.551	rs7351072	chr19:23044529	C/T	cg24889512	chr19:22816950	ZNF492	0.5	5.12	0.39	9.34e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.45	5.25	0.4	5.27e-7	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg11632617	chr15:75315747	PPCDC	-0.63	-7.49	-0.53	5.78e-12	Blood trace element (Zn levels);
UCEC	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	8.94	0.59	1.48e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.66	5.0	0.38	1.58e-6	Neuroticism (multi-trait analysis);Neuroticism;
UCEC	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.46	-4.77	-0.37	4.47e-6	Dental caries;
UCEC	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	7.89	0.55	6.42e-13	Mean corpuscular hemoglobin;
UCEC	cis	rs12618769	0.652	rs7595120	chr2:99231805	C/G	cg10123293	chr2:99228465	UNC50	0.52	5.76	0.43	4.86e-8	Bipolar disorder;
UCEC	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	7.56	0.53	4e-12	Type 2 diabetes;
UCEC	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	4.62	0.36	8.24e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.67	-7.78	-0.54	1.16e-12	Headache;
UCEC	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.87	-9.11	-0.6	5.56e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs6493487	0.512	rs35655196	chr15:51321908	A/G	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.52	5.36	0.4	3.21e-7	Blood metabolite levels;
UCEC	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.35	-4.77	-0.37	4.44e-6	Total body bone mineral density;
UCEC	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg01112020	chr2:239008986	ESPNL	-0.36	-4.9	-0.37	2.53e-6	Prostate cancer;
UCEC	cis	rs3780378	0.967	rs10815144	chr9:5010192	C/T	cg02405213	chr9:5042618	JAK2	-0.48	-4.84	-0.37	3.19e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.83	-0.43	3.4e-8	Obesity-related traits;
UCEC	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.56	-5.65	-0.42	7.98e-8	Blood trace element (Zn levels);
UCEC	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg22105103	chr4:187893119	NA	0.47	5.29	0.4	4.42e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.62	6.09	0.45	9.25e-9	Metabolite levels;
UCEC	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.5	-6.26	-0.46	4.01e-9	Mean platelet volume;
UCEC	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-4.5	-0.35	1.37e-5	Schizophrenia;
UCEC	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.62	-7.44	-0.52	7.67e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.55	-6.4	-0.47	1.93e-9	Type 2 diabetes;
UCEC	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.49	4.79	0.37	4.11e-6	Height;
UCEC	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg01874867	chr7:94954059	PON1	0.54	5.12	0.39	9.62e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg05660106	chr1:15850417	CASP9	0.95	10.71	0.66	3.87e-20	Systolic blood pressure;
UCEC	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.69	4.9	0.37	2.49e-6	Aortic root size;
UCEC	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.66	-5.41	-0.41	2.52e-7	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.9	-8.42	-0.57	3.09e-14	Blood metabolite levels;
UCEC	cis	rs6903823	0.508	rs1150721	chr6:28255040	G/C	cg07836142	chr6:28411423	ZSCAN23	-0.55	-6.15	-0.45	6.92e-9	Pulmonary function;
UCEC	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.59	-5.7	-0.43	6.41e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-6.14	-0.45	7.38e-9	Personality dimensions;
UCEC	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.69	-7.56	-0.53	4.01e-12	Breast cancer;
UCEC	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg25811766	chr13:21894605	NA	-0.75	-5.97	-0.44	1.72e-8	White matter hyperintensity burden;
UCEC	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	6.97	0.5	9.98e-11	Coronary artery disease;
UCEC	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.57	-5.7	-0.43	6.49e-8	Platelet count;
UCEC	cis	rs787274	1.000	rs4979150	chr9:115553502	T/A	cg13803584	chr9:115635662	SNX30	-0.69	-5.58	-0.42	1.13e-7	Age-related hearing impairment (SNP x SNP interaction);
UCEC	cis	rs4400599	1.000	rs4540651	chr1:154128672	G/A	cg05139571	chr1:154127138	NUP210L	0.42	4.53	0.35	1.19e-5	Platelet distribution width;
UCEC	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.45	-5.66	-0.42	7.8e-8	Mean platelet volume;
UCEC	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.39	4.53	0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.15	0.39	8.24e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.51	-5.26	-0.4	4.94e-7	Schizophrenia;
UCEC	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.82	9.69	0.62	1.75e-17	Menopause (age at onset);
UCEC	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.65	7.65	0.53	2.5e-12	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9309473	0.539	rs6745560	chr2:73827117	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-4.67	-0.36	6.81e-6	Metabolite levels;
UCEC	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.46	-5.33	-0.4	3.69e-7	Aortic root size;
UCEC	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-7.93	-0.55	5.06e-13	Resting heart rate;
UCEC	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.48	6.92	0.5	1.29e-10	Homoarginine levels;
UCEC	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.72	8.59	0.58	1.16e-14	Breast cancer;
UCEC	cis	rs7818345	1.000	rs7833166	chr8:19294634	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.54	5.77	0.43	4.5e-8	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.57	-6.28	-0.46	3.56e-9	Blood metabolite levels;
UCEC	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg01493522	chr13:37497338	NA	-0.46	-4.91	-0.38	2.4e-6	Coronary artery disease;
UCEC	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg05962950	chr11:130786565	SNX19	0.75	6.94	0.5	1.17e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.55	-4.97	-0.38	1.84e-6	Gut microbiome composition (summer);
UCEC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.49	-5.36	-0.4	3.19e-7	Tonsillectomy;
UCEC	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.4	-4.58	-0.35	9.71e-6	Urate levels in overweight individuals;
UCEC	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.64	5.1	0.39	1.03e-6	Resting heart rate;
UCEC	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-6.86	-0.49	1.78e-10	Obesity-related traits;
UCEC	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg18099408	chr3:52552593	STAB1	0.42	4.83	0.37	3.34e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.55	5.51	0.41	1.55e-7	Neutrophil percentage of white cells;
UCEC	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg19500275	chr17:80737654	TBCD	0.55	5.66	0.42	7.86e-8	Glycated hemoglobin levels;
UCEC	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg15412446	chr2:106886593	NA	-0.65	-4.52	-0.35	1.25e-5	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
UCEC	cis	rs2473248	1.000	rs1569581	chr1:22547089	A/G	cg22683154	chr1:23345188	KDM1A	0.43	4.53	0.35	1.22e-5	Birth weight;
UCEC	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.95	9.84	0.63	7.29e-18	Cognitive ability;
UCEC	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.73	-5.86	-0.44	2.86e-8	Alopecia areata;
UCEC	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	1.02	10.22	0.64	7.26e-19	Alcohol dependence;
UCEC	cis	rs7072216	0.687	rs11597425	chr10:100154202	G/T	cg19567339	chr10:100142640	NA	0.57	7.32	0.52	1.5e-11	Metabolite levels;
UCEC	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg11189052	chr15:85197271	WDR73	0.56	4.5	0.35	1.36e-5	Schizophrenia;
UCEC	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.7	5.24	0.4	5.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg14547644	chr6:28411285	ZSCAN23	-0.5	-5.46	-0.41	1.94e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	4.66	0.36	7e-6	Parkinson's disease;
UCEC	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.39	4.81	0.37	3.69e-6	Blood metabolite levels;
UCEC	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg21419209	chr3:44054225	NA	-0.46	-4.87	-0.37	2.86e-6	Coronary artery disease;
UCEC	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.73	-6.18	-0.45	5.88e-9	Colorectal adenoma (advanced);
UCEC	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.61	7.49	0.53	6.03e-12	Lewy body disease;
UCEC	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.77	-8.73	-0.58	5.09e-15	Height;
UCEC	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.23	8.99	0.6	1.1e-15	Atopic dermatitis;
UCEC	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.75	0.75	3.48e-28	Height;
UCEC	cis	rs7618501	0.570	rs7613875	chr3:49971514	C/A	cg24110177	chr3:50126178	RBM5	-0.5	-5.07	-0.39	1.18e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.61	5.71	0.43	6.07e-8	Aortic root size;
UCEC	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	4.94	0.38	2.09e-6	Height;
UCEC	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg13147721	chr7:65941812	NA	0.94	6.33	0.46	2.84e-9	Diabetic kidney disease;
UCEC	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg12884169	chr21:40033163	ERG	0.38	5.14	0.39	8.73e-7	Coronary artery disease;
UCEC	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.42	4.67	0.36	6.81e-6	Renal cell carcinoma;
UCEC	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	0.63	6.55	0.48	9.2e-10	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-6.5	-0.47	1.19e-9	Eye color traits;
UCEC	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.69	-6.35	-0.46	2.47e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs75804782	0.572	rs77008212	chr2:239307113	A/G	cg11815105	chr2:239148849	HES6	0.99	4.65	0.36	7.44e-6	Morning vs. evening chronotype;Chronotype;
UCEC	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg01100931	chr17:80982625	B3GNTL1	-0.48	-4.53	-0.35	1.19e-5	Breast cancer;
UCEC	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg04155231	chr12:9217510	LOC144571	0.39	4.57	0.35	1.02e-5	Sjögren's syndrome;
UCEC	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg06784218	chr1:46089804	CCDC17	0.42	4.79	0.37	3.96e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.57	-4.89	-0.37	2.6e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
UCEC	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-6.13	-0.45	7.84e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6032067	0.866	rs1007137	chr20:43816593	T/C	cg00873616	chr20:43920241	NA	0.4	4.52	0.35	1.27e-5	Blood protein levels;
UCEC	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg10932868	chr11:921992	NA	0.44	5.85	0.43	3.14e-8	Alzheimer's disease (late onset);
UCEC	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-0.9	-11.69	-0.69	9.57e-23	Height;
UCEC	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs4654899	0.680	rs4654879	chr1:21186378	G/A	cg01072550	chr1:21505969	NA	0.53	5.46	0.41	2.03e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.11	10.02	0.64	2.43e-18	Vitiligo;
UCEC	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg16532529	chr3:122101951	CCDC58;FAM162A	0.67	4.69	0.36	6.13e-6	Multiple sclerosis;
UCEC	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.03	-12.38	-0.71	1.43e-24	Dilated cardiomyopathy;
UCEC	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.68	-7.22	-0.51	2.55e-11	Dental caries;
UCEC	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.58	-5.77	-0.43	4.53e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9815925	0.623	rs6803925	chr3:184597196	G/A	cg00151007	chr3:184769954	VPS8	0.55	4.9	0.37	2.51e-6	Heschl's gyrus morphology;
UCEC	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.77	8.56	0.58	1.41e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg23972785	chr8:11611189	GATA4	-0.36	-5.07	-0.39	1.19e-6	Retinal vascular caliber;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg25173010	chr1:145438031	TXNIP	0.55	6.67	0.48	4.84e-10	Warfarin maintenance dose;
UCEC	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg27413430	chr6:13925136	RNF182	0.54	4.87	0.37	2.84e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.66	6.06	0.45	1.08e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs11867410	0.744	rs73346897	chr17:63924843	G/A	cg06996976	chr17:64576105	PRKCA	-0.79	-4.8	-0.37	3.87e-6	Blood pressure measurement (high sodium and potassium intervention);
UCEC	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.83	-10.3	-0.65	4.49e-19	Coronary artery disease;
UCEC	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	7.66	0.53	2.36e-12	Total body bone mineral density;
UCEC	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.07	-15.87	-0.79	1.16e-33	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.67	-6.12	-0.45	8.12e-9	Response to antineoplastic agents;
UCEC	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	5.33	0.4	3.68e-7	Aortic root size;
UCEC	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.35	-4.85	-0.37	3.14e-6	Alzheimer's disease in APOE e4+ carriers;
UCEC	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.05	8.01	0.55	3.27e-13	Exhaled nitric oxide output;
UCEC	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-5.28	-0.4	4.53e-7	Fear of minor pain;
UCEC	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg25037677	chr1:2437047	NA	0.39	4.92	0.38	2.25e-6	Height;
UCEC	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg25482853	chr8:67687455	SGK3	1.07	7.81	0.54	1e-12	Obesity-related traits;
UCEC	trans	rs6479901	0.841	rs10995453	chr10:64934331	T/C	cg12751693	chr12:62629162	NA	-0.57	-7.18	-0.51	3.23e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg08266712	chr14:104979372	NA	-0.44	-4.62	-0.36	8.16e-6	Reticulocyte count;
UCEC	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-7.26	-0.51	2.05e-11	Parkinson's disease;
UCEC	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.55	5.85	0.43	3.08e-8	Corneal astigmatism;
UCEC	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.15	9.74	0.63	1.33e-17	Vitiligo;
UCEC	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.41e-6	Putamen volume;
UCEC	cis	rs60311166	1.000	rs17052357	chr3:52668638	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.78	5.28	0.4	4.61e-7	CTACK levels;
UCEC	cis	rs7187365	0.638	rs11865483	chr16:86494979	A/T	cg16563187	chr16:85730606	NA	-0.37	-4.83	-0.37	3.36e-6	Obesity (early onset extreme);
UCEC	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg12024160	chr4:1254474	NA	0.66	7.83	0.54	8.66e-13	Obesity-related traits;
UCEC	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg00651523	chr6:28411279	ZSCAN23	-0.5	-4.85	-0.37	3.08e-6	Cardiac Troponin-T levels;
UCEC	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.21	-0.4	6.15e-7	Body mass index;
UCEC	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-4.88	-0.37	2.71e-6	Schizophrenia;
UCEC	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.49	-5.41	-0.41	2.54e-7	Alcohol dependence;
UCEC	cis	rs925228	0.668	rs7563013	chr2:23934087	A/G	cg16901991	chr2:24272451	FKBP1B	0.52	5.0	0.38	1.62e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7937612	1.000	rs9633950	chr11:120248249	T/G	cg12584626	chr11:120203529	NA	0.47	4.6	0.35	8.95e-6	Intraocular pressure;
UCEC	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.68	-5.13	-0.39	9e-7	Aortic root size;
UCEC	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.5	5.38	0.41	2.85e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs7517126	1.000	rs6428368	chr1:196844310	T/C	cg07209298	chr1:196795943	CFHR1	0.48	4.56	0.35	1.07e-5	Blood protein levels;
UCEC	cis	rs6594713	0.837	rs67693032	chr5:112708468	G/A	cg06062378	chr5:112387002	MCC	-0.39	-4.62	-0.36	8.46e-6	Brain cytoarchitecture;
UCEC	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.36	-4.73	-0.36	5.22e-6	HIV-1 control;
UCEC	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-5.57	-0.42	1.19e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs9467773	1.000	rs6918854	chr6:26577924	G/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg03354898	chr7:1950403	MAD1L1	-0.44	-5.2	-0.39	6.67e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.62	6.56	0.48	8.8e-10	Colorectal cancer;
UCEC	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg13092806	chr2:177043255	NA	0.56	5.25	0.4	5.13e-7	IgG glycosylation;
UCEC	cis	rs7684187	0.737	rs1512973	chr4:123506056	C/T	cg01434783	chr4:124319883	SPRY1	-0.54	-4.75	-0.36	4.86e-6	Cancer;
UCEC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-13.42	-0.74	2.58e-27	Height;
UCEC	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.42	5.17	0.39	7.65e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.45	-0.41	2.04e-7	Longevity;Endometriosis;
UCEC	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg17105886	chr17:28927953	LRRC37B2	0.5	4.53	0.35	1.2e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-0.57	-5.43	-0.41	2.27e-7	Monocyte percentage of white cells;
UCEC	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.14	14.58	0.77	2.43e-30	Cognitive function;
UCEC	cis	rs10208940	0.920	rs7423646	chr2:68758180	A/G	cg12452813	chr2:68675892	NA	0.48	4.53	0.35	1.23e-5	Urate levels in lean individuals;
UCEC	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg21770322	chr7:97807741	LMTK2	0.71	10.16	0.64	1.03e-18	Breast cancer;
UCEC	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg24163568	chr5:669837	TPPP	0.36	4.63	0.36	7.98e-6	Obesity-related traits;
UCEC	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1712517	0.771	rs61871160	chr10:105144288	C/T	cg05636881	chr10:105038444	INA	0.44	5.1	0.39	1.03e-6	Migraine;
UCEC	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.34	4.51	0.35	1.3e-5	Cutaneous nevi;
UCEC	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	5.93	0.44	2.12e-8	Initial pursuit acceleration;
UCEC	cis	rs2274471	0.699	rs7033053	chr9:5042987	G/A	cg03390472	chr9:5043263	JAK2	-0.54	-5.41	-0.41	2.51e-7	Crohn's disease;
UCEC	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg22105103	chr4:187893119	NA	0.39	4.84	0.37	3.22e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6493487	0.512	rs34874493	chr15:51312751	G/A	cg17676096	chr15:52263839	LEO1	-0.79	-4.85	-0.37	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg10130564	chr11:117069849	TAGLN	0.34	4.74	0.36	4.99e-6	Blood protein levels;
UCEC	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.73	-8.52	-0.57	1.78e-14	Vitiligo;
UCEC	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.79	-9.11	-0.6	5.69e-16	Coronary artery disease;
UCEC	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.51	-5.54	-0.42	1.33e-7	Body mass index;
UCEC	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.85	6.56	0.48	8.74e-10	Lymphocyte counts;
UCEC	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.22	-15.03	-0.78	1.63e-31	Breast cancer;
UCEC	cis	rs4499344	0.664	rs259284	chr19:33163262	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.58	5.03	0.38	1.43e-6	Mean platelet volume;
UCEC	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	4.57	0.35	1.01e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.92	9.78	0.63	1.03e-17	Cognitive function;
UCEC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.01	-0.38	1.51e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg04155289	chr7:94953770	PON1	-0.51	-4.68	-0.36	6.44e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13569146	chr6:26330589	NA	-0.55	-4.75	-0.37	4.7e-6	Educational attainment;
UCEC	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg19318889	chr4:1322082	MAEA	0.5	5.5	0.41	1.63e-7	Obesity-related traits;
UCEC	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.6	-4.58	-0.35	9.86e-6	Gut microbiome composition (summer);
UCEC	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.43	-4.93	-0.38	2.21e-6	Prostate cancer;
UCEC	cis	rs7246967	0.932	rs8105614	chr19:23038023	A/G	cg08271804	chr19:22816896	ZNF492	0.55	5.32	0.4	3.84e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18252515	chr7:66147081	NA	0.52	5.44	0.41	2.14e-7	Aortic root size;
UCEC	cis	rs36051895	0.664	rs10815153	chr9:5092864	G/C	cg02405213	chr9:5042618	JAK2	-0.49	-4.93	-0.38	2.23e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg13147721	chr7:65941812	NA	-0.74	-5.04	-0.38	1.37e-6	Diabetic kidney disease;
UCEC	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg05802129	chr4:122689817	NA	-0.57	-5.78	-0.43	4.4e-8	Type 2 diabetes;
UCEC	trans	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg02900749	chr2:68251473	NA	-0.99	-7.37	-0.52	1.16e-11	Pursuit maintenance gain;
UCEC	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.72	-6.81	-0.49	2.35e-10	Aortic root size;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10891157	chr3:33155916	CRTAP	0.63	7.76	0.54	1.35e-12	Warfarin maintenance dose;
UCEC	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.46	-6.57	-0.48	8.36e-10	Metabolite levels;
UCEC	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.57	5.03	0.38	1.43e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
UCEC	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.32	-0.61	1.63e-16	Vitiligo;
UCEC	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg01181863	chr3:195395398	SDHAP2	-0.65	-5.89	-0.44	2.57e-8	Pancreatic cancer;
UCEC	cis	rs1978968	0.912	rs13057016	chr22:18466779	G/A	cg03078520	chr22:18463400	MICAL3	-0.52	-5.64	-0.42	8.65e-8	Presence of antiphospholipid antibodies;
UCEC	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg14547644	chr6:28411285	ZSCAN23	-0.47	-5.14	-0.39	8.51e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.79	-0.43	4.19e-8	Adiposity;
UCEC	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	0.93	11.67	0.69	1.09e-22	Homoarginine levels;
UCEC	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.54	5.95	0.44	1.91e-8	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-5.18	-0.39	7.34e-7	Bipolar disorder;
UCEC	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.69	5.91	0.44	2.3e-8	Menopause (age at onset);
UCEC	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.67	7.28	0.51	1.88e-11	Mortality in heart failure;
UCEC	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.57	6.19	0.45	5.64e-9	Prostate cancer;
UCEC	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.76	-7.85	-0.54	7.9e-13	Blood protein levels;
UCEC	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.66	5.73	0.43	5.5e-8	Alzheimer's disease;
UCEC	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.7	6.15	0.45	7.14e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg14092571	chr14:90743983	NA	-0.46	-6.37	-0.46	2.32e-9	Mortality in heart failure;
UCEC	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg05962950	chr11:130786565	SNX19	0.52	5.11	0.39	1e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-5.35	-0.4	3.27e-7	Height;
UCEC	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.6	-5.94	-0.44	2.01e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.59	-5.3	-0.4	4.18e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.92	9.83	0.63	7.52e-18	Height;
UCEC	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.63	-5.58	-0.42	1.13e-7	Mortality in heart failure;
UCEC	cis	rs12635074	0.521	rs11720894	chr3:56311685	T/C	cg20749059	chr3:57094404	ARHGEF3;SPATA12	0.33	4.64	0.36	7.74e-6	Morning vs. evening chronotype;
UCEC	cis	rs4843185	0.763	rs1974868	chr16:85710983	C/T	cg08142094	chr16:85731256	NA	0.35	4.8	0.37	3.87e-6	Platelet distribution width;
UCEC	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.51	5.05	0.38	1.27e-6	Neuroticism;
UCEC	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.67	-6.85	-0.49	1.88e-10	Coronary artery disease;
UCEC	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.7	-7.76	-0.54	1.28e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.72	-6.42	-0.47	1.77e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	5.3	0.4	4.24e-7	Mean corpuscular hemoglobin;
UCEC	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg06562184	chr8:19319451	CSGALNACT1	-0.44	-4.64	-0.36	7.62e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.12	9.6	0.62	3.07e-17	Uric acid levels;
UCEC	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.61	5.72	0.43	5.88e-8	Corneal astigmatism;
UCEC	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.49	5.22	0.4	6.05e-7	Aortic root size;
UCEC	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.69	7.61	0.53	3.05e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg00343986	chr7:65444356	GUSB	-0.52	-4.85	-0.37	3.16e-6	Aortic root size;
UCEC	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.46	-5.35	-0.4	3.28e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.45	-5.44	-0.41	2.16e-7	Dupuytren's disease;
UCEC	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.62	-6.67	-0.48	4.89e-10	Primary biliary cholangitis;
UCEC	cis	rs944990	0.618	rs10761242	chr9:96368656	T/C	cg13787134	chr9:96362102	PHF2	-0.35	-4.6	-0.35	9.13e-6	Body mass index;
UCEC	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.59	-4.85	-0.37	3.18e-6	Coronary artery calcification;
UCEC	trans	rs6479901	0.895	rs10761722	chr10:64955047	C/G	cg12751693	chr12:62629162	NA	-0.57	-7.21	-0.51	2.76e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.45	5.37	0.41	2.98e-7	Electrocardiographic conduction measures;
UCEC	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.63	-6.7	-0.48	4.14e-10	Neurofibrillary tangles;
UCEC	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-5.87	-0.44	2.75e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-0.42	-4.54	-0.35	1.18e-5	IgG glycosylation;
UCEC	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg02158880	chr13:53174818	NA	0.78	8.96	0.59	1.36e-15	Lewy body disease;
UCEC	cis	rs11023787	1.000	rs2099776	chr11:15937823	C/T	cg04486763	chr11:16635542	NA	-0.49	-4.52	-0.35	1.28e-5	Bone mineral density (wrist);
UCEC	cis	rs2136093	0.506	rs77485139	chr1:90865818	A/G	cg01786362	chr1:90274359	NA	-0.42	-4.85	-0.37	3.16e-6	Response to antidepressants;
UCEC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06873352	chr17:61820015	STRADA	-0.62	-6.51	-0.47	1.1e-9	Prudent dietary pattern;
UCEC	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.58	6.93	0.5	1.25e-10	Oral cavity cancer;
UCEC	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.45	5.25	0.4	5.33e-7	Blood metabolite levels;
UCEC	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	6.23	0.46	4.54e-9	Cognitive test performance;
UCEC	cis	rs1545257	0.537	rs2249387	chr2:24649801	C/G	cg06627628	chr2:24431161	ITSN2	0.49	5.05	0.38	1.32e-6	Sjögren's syndrome;
UCEC	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.7	-6.53	-0.47	9.91e-10	Prostate cancer;
UCEC	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	4.7	0.36	5.96e-6	Prudent dietary pattern;
UCEC	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.65	7.25	0.51	2.2e-11	Glomerular filtration rate (creatinine);
UCEC	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.82	-9.97	-0.64	3.41e-18	Coronary artery disease;
UCEC	cis	rs10242455	0.702	rs59240302	chr7:99072991	C/G	cg18809830	chr7:99032528	PTCD1	-0.79	-4.61	-0.36	8.79e-6	Blood metabolite levels;
UCEC	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-6.12	-0.45	8.14e-9	Gut microbiome composition (summer);
UCEC	cis	rs4792143	1.000	rs4792143	chr17:11385890	C/T	cg18432105	chr17:10453510	MYH2	0.47	4.54	0.35	1.14e-5	Ischemic stroke;
UCEC	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.67	-7.64	-0.53	2.62e-12	Coronary artery disease;
UCEC	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.65	5.9	0.44	2.43e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.71	6.9	0.49	1.41e-10	Breast cancer;
UCEC	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.51	5.89	0.44	2.49e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.59	5.65	0.42	8.2e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs7607369	0.536	rs11892469	chr2:219669488	A/T	cg02176678	chr2:219576539	TTLL4	-0.53	-5.32	-0.4	3.88e-7	Red blood cell count;Amyotrophic lateral sclerosis;
UCEC	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.64	-6.85	-0.49	1.87e-10	Glomerular filtration rate (creatinine);
UCEC	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.82	7.38	0.52	1.06e-11	Cognitive function;
UCEC	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19500275	chr17:80737654	TBCD	0.47	4.69	0.36	6.15e-6	Glycated hemoglobin levels;
UCEC	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.6	-6.81	-0.49	2.38e-10	Tonsillectomy;
UCEC	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.74	-7.89	-0.55	6.36e-13	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.72	-6.0	-0.44	1.47e-8	Depression;
UCEC	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.67	7.29	0.52	1.72e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-5.74	-0.43	5.11e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg24069376	chr3:38537580	EXOG	0.45	5.51	0.41	1.6e-7	Electrocardiographic conduction measures;
UCEC	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.41	4.79	0.37	4.11e-6	Hip circumference adjusted for BMI;
UCEC	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.93	12.43	0.72	1.08e-24	Metabolic syndrome;
UCEC	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.56	-0.58	1.38e-14	Headache;
UCEC	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.62	6.5	0.47	1.2e-9	Menopause (age at onset);
UCEC	cis	rs3112255	0.567	rs2942884	chr2:101323578	C/T	cg01042948	chr2:101319752	NA	0.44	4.98	0.38	1.75e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.76	7.04	0.5	6.95e-11	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs10924970	0.967	rs4481838	chr1:235442626	A/G	cg26050004	chr1:235667680	B3GALNT2	0.44	4.67	0.36	6.74e-6	Asthma;
UCEC	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.68	8.04	0.55	2.77e-13	Prudent dietary pattern;
UCEC	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.6	5.37	0.4	3.06e-7	Crohn's disease;
UCEC	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.32	-4.59	-0.35	9.51e-6	Vitamin D levels;
UCEC	cis	rs600806	0.742	rs9429519	chr1:110017105	A/G	cg02175308	chr1:109941060	SORT1	0.29	4.58	0.35	9.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs96067	0.917	rs10908289	chr1:36573612	G/A	cg27506609	chr1:36549197	TEKT2	-0.49	-4.75	-0.37	4.7e-6	Corneal structure;
UCEC	cis	rs539514	0.637	rs552030	chr13:76322065	G/T	cg04757411	chr13:76259545	LMO7	-0.45	-5.3	-0.4	4.12e-7	Type 1 diabetes;
UCEC	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.77	8.85	0.59	2.63e-15	Coronary artery disease;
UCEC	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.52	-4.84	-0.37	3.24e-6	Longevity;
UCEC	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.62	5.55	0.42	1.28e-7	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs62027291	0.654	rs11634136	chr15:77063039	A/G	cg23625390	chr15:77176239	SCAPER	-0.77	-4.85	-0.37	3.08e-6	Plateletcrit;
UCEC	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.44	-4.65	-0.36	7.46e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg27535305	chr1:53392650	SCP2	-0.44	-5.67	-0.42	7.27e-8	Monocyte count;
UCEC	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.55	5.11	0.39	9.78e-7	Corneal astigmatism;
UCEC	cis	rs2708977	0.637	rs597420	chr2:97070353	T/C	cg22654517	chr2:96458247	NA	0.44	5.66	0.42	7.72e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
UCEC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.52	5.21	0.39	6.4e-7	Schizophrenia;
UCEC	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.5	5.04	0.38	1.34e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.58	-4.69	-0.36	6.09e-6	Coronary artery calcification;
UCEC	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-1.1	-13.03	-0.73	2.75e-26	Post bronchodilator FEV1;
UCEC	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.81	-7.36	-0.52	1.23e-11	Resting heart rate;
UCEC	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg03609598	chr5:56110824	MAP3K1	0.66	5.25	0.4	5.19e-7	Initial pursuit acceleration;
UCEC	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.9	0.44	2.41e-8	Menarche (age at onset);
UCEC	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.63	5.61	0.42	9.84e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-7.31	-0.52	1.58e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg18279126	chr7:2041391	MAD1L1	0.42	5.06	0.39	1.22e-6	Bipolar disorder and schizophrenia;
UCEC	cis	rs10007810	0.760	rs7669764	chr4:41593777	C/G	cg24722073	chr4:41882163	NA	-0.41	-4.91	-0.38	2.37e-6	Longevity (90 years and older);
UCEC	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg07653901	chr22:50250238	ZBED4	0.74	5.15	0.39	8.07e-7	Mean platelet volume;
UCEC	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	5.03	0.38	1.38e-6	Breast cancer;
UCEC	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	7.11	0.51	4.65e-11	Motion sickness;
UCEC	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.79	-4.65	-0.36	7.22e-6	Putamen volume;
UCEC	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg20387954	chr3:183756860	HTR3D	0.5	6.09	0.45	9.2e-9	Anterior chamber depth;
UCEC	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg19413350	chr8:57351067	NA	-0.4	-4.62	-0.36	8.22e-6	Obesity-related traits;
UCEC	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.04	6.49	0.47	1.22e-9	Diabetic retinopathy;
UCEC	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg01262667	chr19:19385393	TM6SF2	-0.47	-6.19	-0.45	5.7e-9	Tonsillectomy;
UCEC	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg18827107	chr12:86230957	RASSF9	-0.43	-4.66	-0.36	7.09e-6	Major depressive disorder;
UCEC	cis	rs7246967	0.673	rs34126042	chr19:22909218	G/A	cg08271804	chr19:22816896	ZNF492	0.66	6.4	0.47	1.96e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.56	5.49	0.41	1.73e-7	Blood protein levels;
UCEC	cis	rs4601821	1.000	rs3897584	chr11:113249725	C/G	cg14159747	chr11:113255604	NA	-0.48	-5.49	-0.41	1.76e-7	Alcoholic chronic pancreatitis;
UCEC	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg13575925	chr12:9217583	LOC144571	0.39	4.74	0.36	5.07e-6	Sjögren's syndrome;
UCEC	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg06238570	chr21:40685208	BRWD1	0.55	5.85	0.43	3.14e-8	Cognitive function;
UCEC	cis	rs6903823	0.508	rs1233660	chr6:28260249	T/A	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.44	-0.41	2.18e-7	Pulmonary function;
UCEC	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.71	-5.32	-0.4	3.77e-7	White matter hyperintensity burden;
UCEC	cis	rs599083	0.793	rs471966	chr11:68173861	C/T	cg01657329	chr11:68192670	LRP5	0.44	5.06	0.39	1.23e-6	Bone mineral density (spine);
UCEC	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.69	6.67	0.48	4.84e-10	Schizophrenia;
UCEC	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.67	-7.35	-0.52	1.29e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	5.73	0.43	5.47e-8	Monocyte percentage of white cells;
UCEC	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg09491104	chr22:46646882	C22orf40	-0.51	-5.04	-0.38	1.34e-6	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs76419734	1.000	rs10050159	chr4:106765915	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.54	4.58	0.35	9.85e-6	Post bronchodilator FEV1;
UCEC	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.63	-6.47	-0.47	1.38e-9	Crohn's disease;
UCEC	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-4.53	-0.35	1.2e-5	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.94	-12.56	-0.72	4.91e-25	Primary sclerosing cholangitis;
UCEC	cis	rs716595	0.786	rs67762893	chr10:112034590	A/G	cg13996003	chr10:112034540	MXI1	-0.91	-4.83	-0.37	3.44e-6	Normalized brain volume;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg04738309	chr5:111093624	C5orf13	0.57	7.1	0.51	5.02e-11	Warfarin maintenance dose;
UCEC	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.67	5.78	0.43	4.29e-8	Cognitive function;
UCEC	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.67	-7.32	-0.52	1.46e-11	Menarche (age at onset);
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg07836142	chr6:28411423	ZSCAN23	-0.56	-6.2	-0.46	5.39e-9	Pubertal anthropometrics;
UCEC	cis	rs7254192	0.506	rs2305797	chr19:41269076	T/C	cg23925301	chr19:41220945	ADCK4	0.62	4.6	0.35	9.17e-6	Post bronchodilator FEV1;
UCEC	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg16497661	chr14:103986332	CKB	0.49	5.85	0.43	3.01e-8	Body mass index;
UCEC	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.47	0.41	1.88e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.62	5.38	0.41	2.87e-7	Heart rate;
UCEC	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	7.56	0.53	3.93e-12	Gut microbiome composition (summer);
UCEC	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.08	16.1	0.8	2.94e-34	IgG glycosylation;
UCEC	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-4.84	-0.37	3.18e-6	Fear of minor pain;
UCEC	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.5	-5.08	-0.39	1.13e-6	Breast cancer;
UCEC	cis	rs2904967	0.929	rs2904986	chr11:65031221	A/C	cg01630869	chr11:65082120	CDC42EP2	0.52	4.86	0.37	2.98e-6	Mean corpuscular volume;
UCEC	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.62	7.03	0.5	7.14e-11	Leprosy;
UCEC	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	6.07	0.45	1.04e-8	Menarche (age at onset);
UCEC	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.96	-9.38	-0.61	1.1e-16	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.56	-6.21	-0.46	5.25e-9	Crohn's disease;
UCEC	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-10.06	-0.64	1.96e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.44	-5.43	-0.41	2.26e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
UCEC	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	0.85	4.98	0.38	1.8e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.55	5.23	0.4	5.7e-7	Lung cancer;
UCEC	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-5.19	-0.39	6.79e-7	Initial pursuit acceleration;
UCEC	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.52	4.98	0.38	1.77e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.67	6.45	0.47	1.51e-9	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg19318889	chr4:1322082	MAEA	0.69	8.3	0.56	6.17e-14	Longevity;
UCEC	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.08	8.21	0.56	1.04e-13	Alzheimer's disease (late onset);
UCEC	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.57	5.33	0.4	3.69e-7	Corneal astigmatism;
UCEC	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.48	4.69	0.36	6.31e-6	Blood metabolite levels;
UCEC	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.54	5.58	0.42	1.13e-7	Schizophrenia;
UCEC	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.09	-13.01	-0.73	3.2e-26	Ulcerative colitis;
UCEC	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.98	-10.93	-0.67	9.94e-21	Body mass index;
UCEC	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.72	8.49	0.57	2.12e-14	Prudent dietary pattern;
UCEC	cis	rs78587638	0.843	rs77925536	chr2:119165061	A/T	cg22657351	chr2:119752078	MARCO	0.5	4.62	0.36	8.31e-6	Mosquito bite size;
UCEC	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.81	7.93	0.55	4.94e-13	Intelligence (multi-trait analysis);
UCEC	trans	rs7980799	0.646	rs9971799	chr12:33592003	G/T	cg12743970	chr17:64536520	PRKCA	-0.58	-6.88	-0.49	1.61e-10	Heart rate;Heart rate variability traits (RMSSD);
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.6	-6.82	-0.49	2.2e-10	Pubertal anthropometrics;
UCEC	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg07653901	chr22:50250238	ZBED4	-0.78	-5.07	-0.39	1.15e-6	Schizophrenia;
UCEC	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg07988820	chr12:82153109	PPFIA2	-0.58	-5.19	-0.39	6.95e-7	Resting heart rate;
UCEC	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.51	4.9	0.37	2.54e-6	Hemoglobin concentration;
UCEC	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg12850546	chr22:42539477	CYP2D7P1	-0.47	-5.22	-0.4	6.11e-7	Schizophrenia;
UCEC	cis	rs925228	1.000	rs12989842	chr2:24246175	C/T	cg16945982	chr2:25016118	CENPO;C2orf79	0.56	4.7	0.36	5.89e-6	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.25	8.84	0.59	2.69e-15	Atopic dermatitis;
UCEC	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.64	-0.36	7.57e-6	Breast cancer;
UCEC	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.66	6.53	0.47	1.01e-9	Colorectal cancer (SNP x SNP interaction);
UCEC	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.8	11.09	0.67	3.86e-21	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs12618769	0.597	rs11901568	chr2:99128621	C/T	cg14361474	chr2:99058762	NA	0.47	4.61	0.36	8.72e-6	Bipolar disorder;
UCEC	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.67	5.66	0.42	7.85e-8	Coronary artery disease;
UCEC	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	0.84	5.08	0.39	1.11e-6	Fat distribution (HIV);
UCEC	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.75	9.23	0.61	2.66e-16	Menarche (age at onset);
UCEC	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.42	5.15	0.39	8.08e-7	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	7.99	0.55	3.66e-13	Chronic sinus infection;
UCEC	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.65	6.15	0.45	6.92e-9	Lymphocyte counts;
UCEC	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.49	4.52	0.35	1.25e-5	Alcohol dependence;
UCEC	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.7	-5.65	-0.42	8.18e-8	Lymphocyte percentage of white cells;
UCEC	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg06096015	chr1:231504339	EGLN1	0.47	5.52	0.41	1.49e-7	Hemoglobin concentration;
UCEC	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.47	0.52	6.64e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg22166914	chr1:53195759	ZYG11B	0.46	4.64	0.36	7.67e-6	Monocyte count;
UCEC	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.57	-4.98	-0.38	1.76e-6	Colorectal cancer;
UCEC	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg18681998	chr4:17616180	MED28	0.91	11.86	0.7	3.55e-23	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.49	-4.9	-0.37	2.5e-6	Pediatric autoimmune diseases;
UCEC	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg21856205	chr7:94953877	PON1	-0.54	-5.19	-0.39	6.82e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg00601450	chr5:74908170	NA	0.6	4.61	0.36	8.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.9	-0.49	1.41e-10	Eye color traits;
UCEC	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.1	9.65	0.62	2.22e-17	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg16060761	chr17:80687452	NA	-0.54	-5.08	-0.39	1.11e-6	Glycated hemoglobin levels;
UCEC	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	0.97	14.38	0.76	7.94e-30	Homoarginine levels;
UCEC	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.55	-5.09	-0.39	1.09e-6	Menarche (age at onset);
UCEC	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.86	-6.88	-0.49	1.62e-10	Cerebrospinal P-tau181p levels;
UCEC	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-0.6	-7.47	-0.52	6.61e-12	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	7.57	0.53	3.86e-12	Allergic disease (asthma, hay fever or eczema);
UCEC	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.63	-7.29	-0.52	1.76e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.44	-4.64	-0.36	7.72e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	7.64	0.53	2.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.48	4.94	0.38	2.07e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.89	-0.49	1.49e-10	Total cholesterol levels;
UCEC	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-1.01	-8.08	-0.55	2.18e-13	Exhaled nitric oxide output;
UCEC	cis	rs1355223	0.867	rs7944030	chr11:34691738	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-5.29	-0.4	4.35e-7	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.55	6.08	0.45	9.88e-9	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.67	-7.08	-0.5	5.49e-11	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-0.95	-12.62	-0.72	3.3e-25	Height;
UCEC	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.14	-0.39	8.73e-7	Body mass index;
UCEC	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.63	5.69	0.42	6.77e-8	Corneal astigmatism;
UCEC	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.68	-5.87	-0.44	2.72e-8	Depression;
UCEC	cis	rs7246967	0.673	rs12978794	chr19:22812134	C/T	cg05241461	chr19:22816980	ZNF492	0.57	6.31	0.46	3.13e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.54	0.47	9.35e-10	Cognitive test performance;
UCEC	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-9.15	-0.6	4.34e-16	Intelligence (multi-trait analysis);
UCEC	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.24	-0.65	6.48e-19	Monocyte count;
UCEC	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-8.5	-0.57	1.93e-14	Coffee consumption (cups per day);
UCEC	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-8.45	-0.57	2.69e-14	Coffee consumption (cups per day);
UCEC	cis	rs2862064	0.929	rs2862062	chr5:156445677	C/T	cg12943317	chr5:156479607	HAVCR1	-0.66	-4.87	-0.37	2.88e-6	Platelet count;
UCEC	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.2	0.39	6.61e-7	Bipolar disorder;
UCEC	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18252515	chr7:66147081	NA	0.54	5.13	0.39	9.18e-7	Aortic root size;
UCEC	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.55	-4.79	-0.37	3.96e-6	Carotid intima media thickness;
UCEC	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.13	17.67	0.82	3.42e-38	IgG glycosylation;
UCEC	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg06818710	chr6:28411271	ZSCAN23	-0.54	-6.4	-0.47	1.94e-9	Pubertal anthropometrics;
UCEC	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.63	7.32	0.52	1.49e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.81	7.68	0.54	2.05e-12	Longevity;Endometriosis;
UCEC	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.71	5.06	0.38	1.25e-6	Aortic root size;
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.56	-6.24	-0.46	4.46e-9	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	7.07	0.5	5.9e-11	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg26061582	chr7:22766209	IL6	0.59	5.52	0.41	1.48e-7	Lung cancer;
UCEC	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg12024160	chr4:1254474	NA	0.56	6.85	0.49	1.85e-10	Obesity-related traits;
UCEC	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg01475377	chr6:109611718	NA	-0.39	-4.92	-0.38	2.25e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
UCEC	cis	rs2279168	1.000	rs2279168	chr15:86077189	A/G	cg13547419	chr15:85197348	WDR73	-0.73	-4.59	-0.35	9.58e-6	Response to platinum-based chemotherapy (carboplatin);
UCEC	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.85	10.83	0.67	1.86e-20	Menarche (age at onset);
UCEC	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg04804543	chr8:142233427	SLC45A4	-0.5	-6.09	-0.45	9.2e-9	Immature fraction of reticulocytes;
UCEC	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg22467129	chr15:76604101	ETFA	-0.45	-4.55	-0.35	1.12e-5	Blood metabolite levels;
UCEC	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.59	4.79	0.37	4.03e-6	High light scatter reticulocyte count;
UCEC	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	1.0	11.14	0.68	2.83e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs405956	0.769	rs7453071	chr6:105558795	A/C	cg22580625	chr6:105627791	POPDC3	-0.53	-4.87	-0.37	2.88e-6	QT interval;
UCEC	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg13575925	chr12:9217583	LOC144571	0.43	5.2	0.39	6.53e-7	Sjögren's syndrome;
UCEC	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.7	-6.41	-0.47	1.91e-9	Aortic root size;
UCEC	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.63	5.28	0.4	4.51e-7	Systolic blood pressure;
UCEC	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs139371	0.713	rs139302	chr22:39498038	G/C	cg15548613	chr22:38610795	MAFF	0.46	4.72	0.36	5.34e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.68	6.45	0.47	1.51e-9	Lymphocyte counts;
UCEC	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.85	-10.26	-0.65	5.9e-19	Monocyte count;
UCEC	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg21770322	chr7:97807741	LMTK2	0.71	10.28	0.65	5.12e-19	Breast cancer;
UCEC	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-8.28	-0.56	7.02e-14	Chronic sinus infection;
UCEC	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.71	5.77	0.43	4.57e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.71	-0.43	6.17e-8	Fear of minor pain;
UCEC	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	5.11	0.39	9.72e-7	Body mass index;
UCEC	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg02820040	chr2:241836501	C2orf54	0.37	4.5	0.35	1.36e-5	Urinary metabolites;
UCEC	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.5	5.61	0.42	9.89e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2970992	0.728	rs2309920	chr2:101329860	C/T	cg01042948	chr2:101319752	NA	0.56	5.99	0.44	1.56e-8	Educational attainment;
UCEC	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.65	6.29	0.46	3.5e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.7	-6.38	-0.47	2.18e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
UCEC	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.63	4.9	0.38	2.45e-6	Platelet distribution width;
UCEC	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg03146154	chr1:46216737	IPP	-0.43	-4.6	-0.36	8.9e-6	Red blood cell count;Reticulocyte count;
UCEC	cis	rs7072216	0.555	rs2296433	chr10:100184062	C/A	cg19567339	chr10:100142640	NA	0.56	5.97	0.44	1.67e-8	Metabolite levels;
UCEC	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	0.83	6.54	0.47	9.67e-10	Corneal structure;
UCEC	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg06096015	chr1:231504339	EGLN1	0.45	4.95	0.38	2.04e-6	Hemoglobin concentration;
UCEC	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg22974920	chr21:40686053	BRWD1	-0.46	-4.55	-0.35	1.1e-5	Menarche (age at onset);
UCEC	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.64	0.42	8.62e-8	Homoarginine levels;
UCEC	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.89	9.66	0.62	2.15e-17	Menarche (age at onset);
UCEC	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg06671706	chr8:8559999	CLDN23	0.65	5.5	0.41	1.62e-7	Obesity-related traits;
UCEC	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.69	5.39	0.41	2.73e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.92	7.82	0.54	9.46e-13	Platelet count;
UCEC	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.37	-5.84	-0.43	3.21e-8	Alzheimer's disease in APOE e4+ carriers;
UCEC	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.5	5.5	0.41	1.66e-7	Tonsillectomy;
UCEC	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.64	-8.21	-0.56	1.05e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03934478	chr11:495069	RNH1	0.71	5.08	0.39	1.12e-6	Body mass index;
UCEC	cis	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg17469321	chr7:55412551	NA	0.7	6.41	0.47	1.82e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.5	4.6	0.35	9.11e-6	Menarche (age at onset);
UCEC	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-0.87	-6.15	-0.45	7.03e-9	Coronary artery disease;
UCEC	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.72	-6.89	-0.49	1.52e-10	Aortic root size;
UCEC	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.56	7.16	0.51	3.6e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg06970220	chr1:156163860	SLC25A44	0.46	4.84	0.37	3.2e-6	Testicular germ cell tumor;
UCEC	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.75	8.09	0.56	2.03e-13	Ulcerative colitis;Inflammatory bowel disease;
UCEC	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-7.94	-0.55	4.8e-13	Exhaled nitric oxide output;
UCEC	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg05962950	chr11:130786565	SNX19	0.74	6.31	0.46	3.09e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.64	-7.13	-0.51	4.18e-11	Menarche (age at onset);
UCEC	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.4	-4.61	-0.36	8.67e-6	Bipolar disorder;
UCEC	cis	rs6604026	0.643	rs1360366	chr1:93330987	A/C	cg17283838	chr1:93427260	FAM69A	-0.45	-4.61	-0.36	8.76e-6	Multiple sclerosis;
UCEC	cis	rs4713118	0.715	rs200480	chr6:27773664	A/G	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.53	-5.02	-0.38	1.5e-6	Parkinson's disease;
UCEC	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-6.14	-0.45	7.18e-9	Bipolar disorder;
UCEC	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-4.9	-0.37	2.47e-6	Aortic root size;
UCEC	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.61	-5.16	-0.39	7.98e-7	Parkinson's disease;
UCEC	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.41	4.54	0.35	1.16e-5	Menopause (age at onset);
UCEC	cis	rs939574	1.000	rs6712442	chr2:220117333	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.67	-5.47	-0.41	1.9e-7	Platelet distribution width;
UCEC	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.69	-7.85	-0.54	8.05e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.84	6.17	0.45	6.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs6921919	0.697	rs6942030	chr6:28315958	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.44	-4.95	-0.38	2.02e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	5.18	0.39	7.12e-7	Prudent dietary pattern;
UCEC	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.96	7.01	0.5	8.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.72	5.49	0.41	1.73e-7	Bipolar disorder;
UCEC	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.45	6.24	0.46	4.39e-9	Alcohol dependence;
UCEC	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.68	-4.63	-0.36	8.13e-6	Hair shape;
UCEC	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.58	-0.48	7.92e-10	Obesity-related traits;
UCEC	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.83	-8.76	-0.59	4.26e-15	Height;
UCEC	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	5.08	0.39	1.1e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-5.99	-0.44	1.54e-8	Platelet count;
UCEC	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg05539622	chr2:73298971	SFXN5	-0.51	-5.05	-0.38	1.29e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.53	5.54	0.42	1.35e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.68	-0.36	6.34e-6	Hemoglobin concentration;
UCEC	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.73	-9.31	-0.61	1.76e-16	Hip circumference;
UCEC	cis	rs7826222	0.786	rs664431	chr8:9876101	C/T	cg00629382	chr8:10268916	MSRA	-0.72	-4.77	-0.37	4.34e-6	Adiposity;
UCEC	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.54	5.17	0.39	7.41e-7	Schizophrenia;
UCEC	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg07150772	chr14:90864620	CALM1	0.55	5.35	0.4	3.25e-7	Mortality in heart failure;
UCEC	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg22974920	chr21:40686053	BRWD1	0.61	5.36	0.4	3.1e-7	Cognitive function;
UCEC	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.52	5.83	0.43	3.44e-8	Blood metabolite levels;
UCEC	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.54	5.82	0.43	3.62e-8	Prostate cancer;
UCEC	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-4.8	-0.37	3.9e-6	Height;
UCEC	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.68	-6.91	-0.49	1.39e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
UCEC	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg19610905	chr11:61596333	FADS2	-0.65	-4.94	-0.38	2.13e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
UCEC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.67	7.34	0.52	1.33e-11	Motion sickness;
UCEC	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.52	5.51	0.41	1.58e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.84	-10.23	-0.64	6.85e-19	Primary sclerosing cholangitis;
UCEC	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.16	-0.39	7.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.67	7.64	0.53	2.51e-12	Body mass index;
UCEC	cis	rs6903823	0.508	rs1778484	chr6:28240798	A/G	cg14547644	chr6:28411285	ZSCAN23	-0.55	-6.25	-0.46	4.12e-9	Pulmonary function;
UCEC	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.51	-5.52	-0.41	1.48e-7	Pubertal anthropometrics;
UCEC	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.72	8.45	0.57	2.6e-14	Body mass index;
UCEC	cis	rs17106184	1.000	rs17106184	chr1:50909985	A/G	cg07174182	chr1:51127561	FAF1	0.72	4.77	0.37	4.39e-6	Type 2 diabetes;
UCEC	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.5	-5.38	-0.41	2.92e-7	Alcohol dependence;
UCEC	cis	rs4851266	0.966	rs12987662	chr2:100821548	C/A	cg14675211	chr2:100938903	LONRF2	0.66	6.4	0.47	1.91e-9	Educational attainment;
UCEC	cis	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11287531	chr12:48500163	SENP1;PFKM	0.49	4.57	0.35	1.05e-5	Migraine with aura;
UCEC	cis	rs6921919	0.638	rs9468344	chr6:28309569	A/C	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.46	-4.71	-0.36	5.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.74	7.28	0.51	1.88e-11	Blood protein levels;
UCEC	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.59	6.99	0.5	9.06e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.51	5.52	0.41	1.49e-7	Alcohol dependence;
UCEC	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.64	5.72	0.43	5.88e-8	Platelet count;
UCEC	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.5	-5.37	-0.41	2.96e-7	Red cell distribution width;
UCEC	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.5	5.08	0.39	1.11e-6	Vitiligo;
UCEC	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-6.51	-0.47	1.09e-9	Aortic root size;
UCEC	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg05660106	chr1:15850417	CASP9	1.02	11.58	0.69	1.92e-22	Systolic blood pressure;
UCEC	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.65	6.93	0.5	1.2e-10	Coronary artery disease;
UCEC	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.52	4.64	0.36	7.51e-6	Cholesterol, total;
UCEC	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.52	-5.1	-0.39	1.01e-6	Aortic root size;
UCEC	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-4.94	-0.38	2.12e-6	Aortic root size;
UCEC	cis	rs16856186	0.748	rs823149	chr1:205735229	A/C	cg14159672	chr1:205819179	PM20D1	0.55	4.52	0.35	1.25e-5	Pulmonary function decline;
UCEC	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg03728395	chr2:85555865	TGOLN2	-0.36	-4.91	-0.38	2.43e-6	Ear protrusion;
UCEC	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.58	-4.79	-0.37	4.08e-6	Platelet distribution width;
UCEC	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.76	-11.79	-0.7	5.27e-23	Itch intensity from mosquito bite adjusted by bite size;
UCEC	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg27153327	chr16:1920815	C16orf73	0.41	4.66	0.36	7.04e-6	Glomerular filtration rate in chronic kidney disease;
UCEC	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.71	-6.42	-0.47	1.81e-9	Asthma;
UCEC	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.98	8.28	0.56	7.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg14530993	chr4:882597	GAK	0.65	4.69	0.36	6.08e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.69	7.57	0.53	3.79e-12	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.6	5.66	0.42	7.61e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.47	0.41	1.85e-7	Prudent dietary pattern;
UCEC	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg01451880	chr3:45801044	SLC6A20	0.38	5.04	0.38	1.37e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.51	-5.86	-0.44	2.96e-8	Testicular germ cell tumor;
UCEC	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.49	-5.46	-0.41	1.94e-7	Mean corpuscular volume;
UCEC	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.61	6.96	0.5	1.04e-10	Blood metabolite levels;
UCEC	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg21486944	chr6:28411378	ZSCAN23	-0.48	-5.18	-0.39	7.35e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	5.05	0.38	1.3e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.52	-5.26	-0.4	5.09e-7	Bipolar disorder;
UCEC	cis	rs2376682	1.000	rs6861094	chr5:118029792	G/C	cg17593721	chr5:118788746	HSD17B4	0.49	4.71	0.36	5.57e-6	Diisocyanate-induced asthma;
UCEC	cis	rs6717918	0.781	rs4640379	chr2:233141377	A/G	cg02061626	chr2:233274167	ALPPL2	-0.5	-4.93	-0.38	2.16e-6	Height;
UCEC	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.48	5.09	0.39	1.07e-6	Corneal astigmatism;
UCEC	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.65	6.28	0.46	3.57e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.45	4.55	0.35	1.13e-5	Alzheimer's disease;
UCEC	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.59	-6.31	-0.46	3.16e-9	Motion sickness;
UCEC	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.43	-4.61	-0.36	8.6e-6	Schizophrenia;
UCEC	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.67	5.33	0.4	3.62e-7	Cognitive test performance;
UCEC	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.58	6.12	0.45	8.26e-9	Motion sickness;
UCEC	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg17420585	chr12:42539391	GXYLT1	-0.43	-5.12	-0.39	9.53e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.86	10.31	0.65	4.42e-19	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.85	10.44	0.65	2.01e-19	Mortality in heart failure;
UCEC	cis	rs7589342	0.801	rs2889605	chr2:106525073	T/C	cg14210321	chr2:106509881	NCK2	-0.49	-4.63	-0.36	8.14e-6	Addiction;
UCEC	cis	rs883565	0.569	rs7638329	chr3:39020408	T/C	cg01426195	chr3:39028469	NA	-0.59	-7.04	-0.5	6.88e-11	Handedness;
UCEC	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-4.69	-0.36	6.14e-6	Monocyte percentage of white cells;
UCEC	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.75	-0.36	4.77e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9843304	0.528	rs12488126	chr3:149192676	G/A	cg08667024	chr3:149219783	TM4SF4	0.49	5.57	0.42	1.2e-7	Gallstone disease;
UCEC	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.55	-4.53	-0.35	1.23e-5	Initial pursuit acceleration;
UCEC	cis	rs7246967	1.000	rs11879853	chr19:23029434	C/T	cg24889512	chr19:22816950	ZNF492	-0.5	-5.37	-0.4	3.07e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.39	-9.01	-0.6	9.98e-16	Diabetic kidney disease;
UCEC	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.51	-4.73	-0.36	5.11e-6	Menarche (age at onset);
UCEC	cis	rs139371	0.742	rs139323	chr22:39501478	A/G	cg15548613	chr22:38610795	MAFF	0.45	4.74	0.36	4.97e-6	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
UCEC	cis	rs6460942	1.000	rs112996286	chr7:12315741	G/C	cg20607287	chr7:12443886	VWDE	-0.66	-4.64	-0.36	7.64e-6	Coronary artery disease;
UCEC	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	6.24	0.46	4.54e-9	Platelet count;
UCEC	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	6.25	0.46	4.13e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.38	-0.41	2.82e-7	Breast cancer;
UCEC	cis	rs875971	0.862	rs2460432	chr7:65554385	C/T	cg12463550	chr7:65579703	CRCP	-0.65	-6.02	-0.44	1.31e-8	Aortic root size;
UCEC	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.62	4.74	0.36	5.08e-6	Aortic root size;
UCEC	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg08885076	chr2:99613938	TSGA10	0.41	4.65	0.36	7.42e-6	Chronic sinus infection;
UCEC	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	6.51	0.47	1.11e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-4.89	-0.37	2.59e-6	Hip circumference adjusted for BMI;Body mass index;
UCEC	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.54	6.01	0.44	1.41e-8	Breast cancer;
UCEC	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05472934	chr7:22766657	IL6	0.83	7.97	0.55	3.96e-13	Lung cancer;
UCEC	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.54	5.05	0.38	1.29e-6	Urinary 1,3-butadiene metabolite levels in smokers;
UCEC	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.36	-4.55	-0.35	1.1e-5	Life satisfaction;
UCEC	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	5.36	0.4	3.13e-7	Metabolite levels;
UCEC	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.57	-5.04	-0.38	1.34e-6	Blood metabolite levels;
UCEC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-6.81	-0.49	2.37e-10	Chronic sinus infection;
UCEC	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.47	-5.05	-0.38	1.31e-6	Body mass index;
UCEC	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.62	-6.68	-0.48	4.54e-10	Extraversion;
UCEC	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg15837086	chr1:46506065	PIK3R3	-0.4	-5.13	-0.39	8.93e-7	Red blood cell count;Reticulocyte count;
UCEC	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg13147721	chr7:65941812	NA	-0.95	-6.41	-0.47	1.83e-9	Diabetic kidney disease;
UCEC	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.02	11.07	0.67	4.38e-21	IgG glycosylation;
UCEC	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	6.87	0.49	1.73e-10	Motion sickness;
UCEC	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-13.19	-0.74	1.02e-26	Height;
UCEC	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	0.65	4.57	0.35	1.04e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
UCEC	cis	rs36051895	0.623	rs72703608	chr9:5258127	A/G	cg02405213	chr9:5042618	JAK2	-0.61	-4.52	-0.35	1.26e-5	Pediatric autoimmune diseases;
UCEC	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.78	-0.49	2.73e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs6840360	0.573	rs11099807	chr4:152269228	C/T	cg25486957	chr4:152246857	NA	-0.44	-4.84	-0.37	3.2e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.7	4.73	0.36	5.22e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg05738196	chr6:26577821	NA	0.66	7.95	0.55	4.43e-13	Intelligence (multi-trait analysis);
UCEC	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg16524733	chr11:117070046	TAGLN	0.36	4.53	0.35	1.2e-5	Blood protein levels;
UCEC	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg00105475	chr2:10696890	NA	0.48	5.9	0.44	2.4e-8	Prostate cancer;
UCEC	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg24562669	chr7:97807699	LMTK2	0.48	5.87	0.44	2.84e-8	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.58	6.02	0.44	1.31e-8	Coronary heart disease;
UCEC	cis	rs7088591	1.000	rs73290947	chr10:59786109	G/A	cg11142981	chr10:60273225	BICC1	0.65	4.7	0.36	6.04e-6	Blood pressure;
UCEC	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.57	6.72	0.48	3.78e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.56	5.93	0.44	2.11e-8	Type 2 diabetes;
UCEC	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	5.18	0.39	7.08e-7	Height;
UCEC	cis	rs35934224	0.783	rs9754418	chr22:19854733	A/G	cg11182965	chr22:19864308	TXNRD2	-0.37	-5.11	-0.39	1.01e-6	Glaucoma (primary open-angle);
UCEC	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.55	6.2	0.46	5.54e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-5.7	-0.43	6.36e-8	Caudate activity during reward;
UCEC	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.48	-4.77	-0.37	4.47e-6	Schizophrenia;
UCEC	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.56	-5.57	-0.42	1.18e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.32	4.69	0.36	6.15e-6	Schizophrenia;
UCEC	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.59	-5.95	-0.44	1.84e-8	Hepatocellular carcinoma;
UCEC	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.11	-0.6	5.62e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.83	9.03	0.6	8.75e-16	Menarche (age at onset);
UCEC	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.62	-7.21	-0.51	2.78e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.67	-6.66	-0.48	5.1e-10	Morning vs. evening chronotype;
UCEC	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.53	-5.76	-0.43	4.65e-8	Bipolar disorder;
UCEC	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.59	-6.54	-0.47	9.7e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs1974653	0.813	rs9606232	chr22:20065370	C/T	cg24349400	chr22:19132419	DGCR14	0.53	4.54	0.35	1.14e-5	Schizophrenia;
UCEC	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.1	-6.39	-0.47	2.03e-9	Atopic dermatitis;
UCEC	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	13.29	0.74	5.59e-27	Chronic sinus infection;
UCEC	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.55	-6.35	-0.46	2.59e-9	Prostate cancer;
UCEC	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	6.3	0.46	3.28e-9	Personality dimensions;
UCEC	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.82	-9.48	-0.62	6.07e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.608	rs453175	chr19:23014087	A/G	cg08271804	chr19:22816896	ZNF492	0.5	4.63	0.36	7.99e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-8.36	-0.57	4.3e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg01689657	chr7:91764605	CYP51A1	0.44	5.51	0.41	1.55e-7	Breast cancer;
UCEC	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.69	-7.42	-0.52	8.87e-12	Cognitive test performance;
UCEC	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg03714773	chr7:91764589	CYP51A1	0.41	4.94	0.38	2.06e-6	Breast cancer;
UCEC	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.18	-14.22	-0.76	2.1e-29	Breast cancer;
UCEC	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.64	-7.37	-0.52	1.14e-11	Body mass index;
UCEC	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.6	-7.11	-0.51	4.75e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg05347473	chr6:146136440	FBXO30	-0.41	-4.62	-0.36	8.47e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg24562669	chr7:97807699	LMTK2	0.73	10.79	0.66	2.38e-20	Breast cancer;
UCEC	cis	rs968451	0.906	rs12628367	chr22:39717104	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	4.98	0.38	1.76e-6	Primary biliary cholangitis;
UCEC	cis	rs6723108	0.627	rs62168872	chr2:135661747	C/T	cg07169764	chr2:136633963	MCM6	0.47	4.54	0.35	1.16e-5	Type 2 diabetes;
UCEC	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.73	-8.15	-0.56	1.47e-13	Monocyte count;
UCEC	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.62	5.37	0.4	3.01e-7	Bipolar disorder;
UCEC	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg15659132	chr6:26577336	NA	0.5	4.66	0.36	6.98e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1978968	0.731	rs9605468	chr22:18461180	T/C	cg03078520	chr22:18463400	MICAL3	-0.55	-6.61	-0.48	6.56e-10	Presence of antiphospholipid antibodies;
UCEC	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	5.07	0.39	1.19e-6	Coronary heart disease;
UCEC	cis	rs4924935	0.669	rs9916340	chr17:18752939	T/C	cg11293112	chr17:17809020	TOM1L2	-0.4	-4.54	-0.35	1.15e-5	Pancreatic cancer;
UCEC	cis	rs4148689	0.951	rs2027945	chr7:117187822	G/A	cg21212505	chr7:117228958	CFTR	-0.41	-4.66	-0.36	7.08e-6	Gout;
UCEC	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg00983440	chr10:79422392	NA	-0.79	-6.51	-0.47	1.13e-9	Bone mineral density;
UCEC	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.83	8.96	0.59	1.32e-15	Longevity;Endometriosis;
UCEC	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.69	-6.5	-0.47	1.15e-9	Aortic root size;
UCEC	cis	rs1150668	0.799	rs1150705	chr6:28193786	T/G	cg07838603	chr6:28411030	ZSCAN23	-0.42	-4.8	-0.37	3.91e-6	Pubertal anthropometrics;
UCEC	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg26114124	chr12:9217669	LOC144571	0.41	4.88	0.37	2.69e-6	Sjögren's syndrome;
UCEC	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.58	-6.87	-0.49	1.72e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.91	5.25	0.4	5.24e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.43	4.57	0.35	1.03e-5	Schizophrenia;
UCEC	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.89	-10.21	-0.64	7.64e-19	Prudent dietary pattern;
UCEC	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.78	5.77	0.43	4.53e-8	Exhaled nitric oxide output;
UCEC	cis	rs7336933	0.799	rs7318334	chr13:42463027	A/C	cg18400088	chr13:41634674	WBP4	0.54	4.58	0.35	1e-5	Calcium levels;
UCEC	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-7.2	-0.51	2.92e-11	Heart rate;
UCEC	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.58	6.19	0.45	5.58e-9	Mean platelet volume;
UCEC	cis	rs924607	0.545	rs7378524	chr5:616946	T/C	cg09021430	chr5:549028	NA	0.41	4.65	0.36	7.2e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
UCEC	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.57	6.23	0.46	4.58e-9	Red blood cell count;
UCEC	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-4.83	-0.37	3.42e-6	Fear of minor pain;
UCEC	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.8	7.59	0.53	3.4e-12	Bladder cancer;
UCEC	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.56	-5.02	-0.38	1.47e-6	Pediatric autoimmune diseases;
UCEC	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.76	-8.81	-0.59	3.28e-15	Menarche (age at onset);
UCEC	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.63	5.34	0.4	3.5e-7	HIV-1 control;
UCEC	cis	rs72925845	0.525	rs72907478	chr17:76431015	C/T	cg00735218	chr17:76421569	DNAH17	-0.53	-4.68	-0.36	6.33e-6	Triglycerides;
UCEC	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	8.71	0.58	5.87e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg04315214	chr1:2043799	PRKCZ	0.52	5.95	0.44	1.86e-8	Height;
UCEC	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.61	6.46	0.47	1.45e-9	Longevity;Endometriosis;
UCEC	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.59	-5.74	-0.43	5.33e-8	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg16553119	chr1:165599451	MGST3	-0.38	-4.69	-0.36	6.24e-6	Total ventricular volume;
UCEC	cis	rs3015497	0.616	rs7152874	chr14:51046040	C/G	cg04730355	chr14:51134070	SAV1	-0.46	-4.92	-0.38	2.34e-6	Mean platelet volume;
UCEC	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.63	4.9	0.38	2.45e-6	Platelet distribution width;
UCEC	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.52	-0.35	1.25e-5	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.49	-5.07	-0.39	1.2e-6	Blood protein levels;
UCEC	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.68	5.44	0.41	2.21e-7	Corneal astigmatism;
UCEC	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.4	-4.74	-0.36	5.05e-6	Coronary artery disease;
UCEC	cis	rs6696846	0.936	rs12134724	chr1:205039288	T/C	cg00857998	chr1:205179979	DSTYK	0.62	5.13	0.39	8.98e-7	Red blood cell count;
UCEC	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.35	4.51	0.35	1.32e-5	Carotid intima media thickness;
UCEC	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg17294928	chr15:75287854	SCAMP5	0.84	9.65	0.62	2.3e-17	Blood trace element (Zn levels);
UCEC	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg12463550	chr7:65579703	CRCP	0.52	5.23	0.4	5.72e-7	Aortic root size;
UCEC	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg12463550	chr7:65579703	CRCP	0.51	5.18	0.39	7.3e-7	Aortic root size;
UCEC	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg14067834	chr17:29058358	SUZ12P	0.64	4.6	0.35	9.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.21	10.04	0.64	2.14e-18	Lymphocyte percentage of white cells;
UCEC	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg19678392	chr7:94953810	PON1	-0.56	-5.18	-0.39	7.32e-7	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.8	-8.94	-0.59	1.52e-15	Breast cancer;
UCEC	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg12024160	chr4:1254474	NA	0.73	8.48	0.57	2.16e-14	Obesity-related traits;
UCEC	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	-0.55	-6.32	-0.46	3.01e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.62	5.73	0.43	5.61e-8	Height;
UCEC	cis	rs599083	0.744	rs603129	chr11:68186669	A/T	cg16797656	chr11:68205561	LRP5	-0.53	-7.0	-0.5	8.68e-11	Bone mineral density (spine);
UCEC	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.62	-5.49	-0.41	1.75e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.63	5.57	0.42	1.16e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
UCEC	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.58	-0.42	1.1e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	8.69	0.58	6.63e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.5	5.33	0.4	3.7e-7	Schizophrenia;
UCEC	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.52	-5.67	-0.42	7.41e-8	Breast cancer;
UCEC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.55	4.74	0.36	4.96e-6	IgE levels in asthmatics (D.p. specific);
UCEC	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.57	5.88	0.44	2.65e-8	Post bronchodilator FEV1;
UCEC	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26002218	chr14:103986227	CKB	0.35	5.1	0.39	1.02e-6	Body mass index;
UCEC	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg08222913	chr3:52553049	STAB1	-0.46	-5.32	-0.4	3.76e-7	Bipolar disorder;
UCEC	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg20965017	chr5:231967	SDHA	-0.64	-5.86	-0.43	2.98e-8	Breast cancer;
UCEC	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-5.03	-0.38	1.38e-6	Diabetic retinopathy;
UCEC	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.73	6.95	0.5	1.13e-10	Aortic root size;
UCEC	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-6.89	-0.49	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.57	-8.34	-0.57	4.87e-14	Refractive error;
UCEC	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg24069376	chr3:38537580	EXOG	-0.38	-4.75	-0.36	4.87e-6	Electrocardiographic conduction measures;
UCEC	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.85	4.61	0.36	8.74e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-6.46	-0.47	1.47e-9	Chronic sinus infection;
UCEC	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.66	5.94	0.44	1.95e-8	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg18436246	chr17:1640651	WDR81	0.47	4.87	0.37	2.83e-6	Serum albumin level;
UCEC	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.74	0.49	3.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs875971	0.867	rs13227219	chr7:65844062	T/A	cg18252515	chr7:66147081	NA	-0.51	-4.92	-0.38	2.24e-6	Aortic root size;
UCEC	cis	rs7246967	1.000	rs7246967	chr19:23056346	T/G	cg05241461	chr19:22816980	ZNF492	0.45	4.61	0.36	8.65e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs77861329	1.000	rs183029	chr3:52209884	A/G	cg08692210	chr3:52188851	WDR51A	0.78	5.93	0.44	2.09e-8	Macrophage inflammatory protein 1b levels;
UCEC	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.46	4.85	0.37	3.16e-6	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-1.12	-6.89	-0.49	1.55e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
UCEC	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	5.82	0.43	3.54e-8	Bone mineral density;
UCEC	cis	rs12644436	0.662	rs116061236	chr4:88784818	C/T	cg27179352	chr4:88029472	AFF1	0.42	4.59	0.35	9.47e-6	HIV-1 viral setpoint;
UCEC	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg24562669	chr7:97807699	LMTK2	0.61	8.0	0.55	3.45e-13	Breast cancer;
UCEC	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.71	4.81	0.37	3.75e-6	Breast cancer;
UCEC	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg14196790	chr5:131705035	SLC22A5	0.36	4.5	0.35	1.34e-5	Lung function (FEV1/FVC);
UCEC	cis	rs56281245	0.793	rs1433039	chr5:145060737	C/T	cg14510905	chr5:145040858	NA	0.49	4.53	0.35	1.21e-5	Hepcidin levels;
UCEC	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.45	-6.44	-0.47	1.62e-9	Metabolite levels;
UCEC	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.7	6.46	0.47	1.44e-9	Aortic root size;
UCEC	cis	rs13098911	0.540	rs13079478	chr3:46007823	G/T	cg16320329	chr3:45981161	FYCO1	-0.76	-4.5	-0.35	1.35e-5	Celiac disease;
UCEC	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg27068330	chr11:65405492	SIPA1	-0.56	-5.4	-0.41	2.58e-7	Acne (severe);
UCEC	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-0.95	-14.31	-0.76	1.21e-29	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.76	-6.01	-0.44	1.39e-8	Calcium levels;
UCEC	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg18099408	chr3:52552593	STAB1	0.45	5.58	0.42	1.11e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	0.89	12.81	0.73	1.08e-25	Multiple system atrophy;
UCEC	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.68	5.76	0.43	4.85e-8	Alcohol dependence;
UCEC	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.56	-4.57	-0.35	1.02e-5	Breast cancer;
UCEC	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg04871131	chr7:94954202	PON1	-0.53	-4.85	-0.37	3.13e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-6.69	-0.48	4.26e-10	Parkinson's disease;
UCEC	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg06835404	chr16:988973	LMF1	0.49	5.0	0.38	1.6e-6	Non-glioblastoma glioma;Glioblastoma;Glioma;
UCEC	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.32	-4.56	-0.35	1.09e-5	Alzheimer's disease (late onset);
UCEC	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.47	5.88	0.44	2.59e-8	HDL cholesterol levels;
UCEC	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.6	-7.17	-0.51	3.46e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg19413350	chr8:57351067	NA	-0.42	-4.94	-0.38	2.13e-6	Obesity-related traits;
UCEC	cis	rs172166	0.585	rs149963	chr6:28017132	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.58	-6.46	-0.47	1.41e-9	Cardiac Troponin-T levels;
UCEC	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-6.1	-0.45	8.76e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs4588572	0.644	rs7714871	chr5:77754268	G/T	cg11547950	chr5:77652471	NA	-0.37	-4.51	-0.35	1.32e-5	Triglycerides;
UCEC	cis	rs9309473	0.500	rs4852308	chr2:73834035	T/G	cg20560298	chr2:73613845	ALMS1	0.54	5.24	0.4	5.44e-7	Metabolite levels;
UCEC	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12311346	chr5:56204834	C5orf35	-0.44	-4.6	-0.35	9.15e-6	Coronary artery disease;
UCEC	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.63	6.69	0.48	4.38e-10	QRS complex (12-leadsum);
UCEC	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	5.62	0.42	9.49e-8	Bipolar disorder and schizophrenia;
UCEC	cis	rs11118844	0.793	rs10863654	chr1:221946787	G/A	cg04222084	chr1:221915650	DUSP10	-0.77	-7.14	-0.51	3.94e-11	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
UCEC	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg14438399	chr17:27053147	TLCD1	0.59	4.78	0.37	4.12e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
UCEC	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.55	-5.72	-0.43	5.69e-8	Extrinsic epigenetic age acceleration;
UCEC	cis	rs853679	0.713	rs200991	chr6:27815494	A/C	cg19041857	chr6:27730383	NA	0.57	5.0	0.38	1.58e-6	Depression;
UCEC	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.56	-4.96	-0.38	1.93e-6	Coronary artery disease;
UCEC	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22117172	chr7:91764530	CYP51A1	0.4	4.96	0.38	1.96e-6	Breast cancer;
UCEC	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-4.54	-0.35	1.17e-5	Total cholesterol levels;
UCEC	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.78	6.72	0.48	3.78e-10	Alzheimer's disease;
UCEC	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.52	-4.98	-0.38	1.76e-6	Addiction;
UCEC	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.52	4.84	0.37	3.3e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-0.91	-11.82	-0.7	4.53e-23	Height;
UCEC	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.7	8.29	0.56	6.62e-14	Testicular germ cell tumor;
UCEC	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.79	-9.62	-0.62	2.68e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
UCEC	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.84	7.42	0.52	8.76e-12	Body mass index;
UCEC	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12593303	chr2:54785406	SPTBN1	0.58	6.84	0.49	2e-10	Warfarin maintenance dose;
UCEC	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-6.25	-0.46	4.13e-9	Personality dimensions;
UCEC	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.12	-0.51	4.5e-11	Developmental language disorder (linguistic errors);
UCEC	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg27535305	chr1:53392650	SCP2	-0.37	-4.7	-0.36	5.84e-6	Monocyte count;
UCEC	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.56	-7.12	-0.51	4.48e-11	Congenital heart disease (maternal effect);
UCEC	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.4	4.98	0.38	1.78e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-10.34	-0.65	3.51e-19	Extrinsic epigenetic age acceleration;
UCEC	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.53	-5.21	-0.39	6.38e-7	Multiple sclerosis;
UCEC	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.86	0.37	2.94e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	6.48	0.47	1.3e-9	Hip circumference;
UCEC	cis	rs829661	0.793	rs829664	chr2:30725733	A/G	cg17749961	chr2:30669863	LCLAT1	0.7	6.0	0.44	1.49e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
UCEC	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.7	-4.67	-0.36	6.78e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs76878669	0.538	rs12786563	chr11:66179556	T/C	cg24851651	chr11:66362959	CCS	-0.39	-4.94	-0.38	2.07e-6	Educational attainment (years of education);
UCEC	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.61	-5.96	-0.44	1.82e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg23795048	chr12:9217529	LOC144571	0.41	5.09	0.39	1.1e-6	Sjögren's syndrome;
UCEC	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.68	7.82	0.54	9.56e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.37	7.09	0.5	5.32e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.33	-8.34	-0.57	4.9e-14	Diabetic kidney disease;
UCEC	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.57	-5.01	-0.38	1.57e-6	Huntington's disease progression;
UCEC	cis	rs7945705	0.870	rs4910156	chr11:8941197	T/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.23	0.4	5.75e-7	Hemoglobin concentration;
UCEC	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg07404485	chr7:94953653	PON1	-0.45	-4.52	-0.35	1.29e-5	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs28795989	0.613	rs2385900	chr4:7921777	G/A	cg00251875	chr4:7801337	AFAP1	-0.52	-5.64	-0.42	8.52e-8	Intraocular pressure;
UCEC	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.87	-0.37	2.82e-6	Testicular germ cell tumor;
UCEC	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	0.9	5.81	0.43	3.7e-8	Skin colour saturation;
UCEC	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.68	5.5	0.41	1.68e-7	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.62	7.1	0.51	4.98e-11	Tonsillectomy;
UCEC	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.58	4.91	0.38	2.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
UCEC	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.41	4.56	0.35	1.05e-5	Joint mobility (Beighton score);
UCEC	cis	rs60311166	1.000	rs17052404	chr3:52776664	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.77	5.36	0.4	3.11e-7	CTACK levels;
UCEC	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.77	-6.13	-0.45	7.54e-9	Calcium levels;
UCEC	cis	rs9467773	1.000	rs12665431	chr6:26577308	T/A	cg11502198	chr6:26597334	ABT1	0.52	4.93	0.38	2.21e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.69	5.95	0.44	1.92e-8	Morning vs. evening chronotype;
UCEC	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg21770322	chr7:97807741	LMTK2	0.55	6.78	0.49	2.65e-10	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs9831754	0.756	rs9817660	chr3:78426373	T/C	cg06138941	chr3:78371609	NA	-0.71	-5.52	-0.41	1.5e-7	Calcium levels;
UCEC	cis	rs73069940	0.744	rs35317148	chr4:1274000	G/A	cg07110949	chr4:1309878	MAEA	-0.71	-4.75	-0.36	4.87e-6	Type 2 diabetes;
UCEC	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.46	-7.14	-0.51	4e-11	Ulcerative colitis;
UCEC	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.49	-5.58	-0.42	1.12e-7	Blood metabolite levels;
UCEC	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-5.11	-0.39	1e-6	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.54	6.29	0.46	3.45e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18252515	chr7:66147081	NA	0.51	4.95	0.38	2.04e-6	Aortic root size;
UCEC	cis	rs2302190	0.882	rs11650710	chr17:56583547	C/T	cg12560992	chr17:57184187	TRIM37	0.54	4.66	0.36	7.12e-6	Vitamin D levels;
UCEC	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	3.99e-11	Breast cancer;
UCEC	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg02160872	chr5:212506	CCDC127	-0.71	-7.02	-0.5	7.79e-11	Breast cancer;
UCEC	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.65	-7.7	-0.54	1.82e-12	Schizophrenia;
UCEC	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.77	7.57	0.53	3.83e-12	Menopause (age at onset);
UCEC	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.89	-6.97	-0.5	9.81e-11	Exhaled nitric oxide output;
UCEC	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.65	-7.08	-0.5	5.37e-11	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs9326248	0.530	rs2000616	chr11:116916529	C/T	cg13068653	chr11:117074303	TAGLN	0.54	4.74	0.36	4.93e-6	Blood protein levels;
UCEC	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg06238570	chr21:40685208	BRWD1	0.77	7.55	0.53	4.13e-12	Cognitive function;
UCEC	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.49	4.8	0.37	3.84e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.21	8.07	0.55	2.29e-13	Diabetic kidney disease;
UCEC	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	6.54	0.47	9.35e-10	Cognitive test performance;
UCEC	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.48	5.64	0.42	8.5e-8	Aortic root size;
UCEC	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.91	12.89	0.73	6.53e-26	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-6.26	-0.46	3.94e-9	Morning vs. evening chronotype;
UCEC	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	6.74	0.49	3.3e-10	Bone mineral density;
UCEC	cis	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg17469321	chr7:55412551	NA	0.68	6.01	0.44	1.37e-8	QRS interval (sulfonylurea treatment interaction);
UCEC	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.82	-7.53	-0.53	4.78e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
UCEC	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg08741688	chr4:3415352	RGS12	-0.44	-4.55	-0.35	1.1e-5	Serum sulfate level;
UCEC	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg05963712	chr12:49373746	WNT1	0.46	4.51	0.35	1.3e-5	Longevity (90 years and older);
UCEC	cis	rs10208940	0.920	rs10205573	chr2:68829419	A/T	cg12452813	chr2:68675892	NA	0.48	4.63	0.36	7.91e-6	Urate levels in lean individuals;
UCEC	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg17105886	chr17:28927953	LRRC37B2	0.51	4.55	0.35	1.1e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.78	-0.37	4.21e-6	Tonsillectomy;
UCEC	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg21782813	chr7:2030301	MAD1L1	0.59	6.57	0.48	8.06e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs58502974	0.605	rs1864038	chr5:7793177	C/A	cg12187999	chr5:6845652	NA	0.38	4.68	0.36	6.54e-6	Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder;Bipolar disorder or attention deficit hyperactivity disorder;
UCEC	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-11.57	-0.69	2e-22	Coronary artery disease;
UCEC	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.51	5.67	0.42	7.26e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-5.0	-0.38	1.61e-6	Monocyte percentage of white cells;
UCEC	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.46	-5.32	-0.4	3.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.5	5.3	0.4	4.18e-7	Aortic root size;
UCEC	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.16	0.39	7.99e-7	Parkinson's disease;
UCEC	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.54	5.17	0.39	7.55e-7	Lymphocyte counts;Fibrinogen;
UCEC	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.62	7.13	0.51	4.21e-11	Monocyte count;
UCEC	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg18240653	chr6:144019428	PHACTR2	-0.62	-4.64	-0.36	7.6e-6	Obesity-related traits;
UCEC	cis	rs60311166	1.000	rs12107484	chr3:52632093	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.83	4.64	0.36	7.71e-6	CTACK levels;
UCEC	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.65	6.72	0.48	3.65e-10	Body mass index;
UCEC	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg21191810	chr6:118973309	C6orf204	0.44	6.21	0.46	5.27e-9	Electrocardiographic conduction measures;
UCEC	cis	rs6921919	0.638	rs2108926	chr6:28308747	A/T	cg21750589	chr6:28321301	ZNF323;ZKSCAN3	-0.47	-4.8	-0.37	3.91e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg23950597	chr19:37808831	NA	-0.64	-5.0	-0.38	1.64e-6	Coronary artery calcification;
UCEC	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.41	4.69	0.36	6.2e-6	Obesity-related traits;
UCEC	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.49	-0.41	1.68e-7	Bipolar disorder and schizophrenia;
UCEC	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.47	-4.75	-0.36	4.86e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs10905651	1.000	rs12263577	chr10:10077215	C/T	ch.10.296387R	chr10:10719045	NA	0.45	4.55	0.35	1.12e-5	Dental caries;
UCEC	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-6.04	-0.45	1.18e-8	Response to antipsychotic treatment;
UCEC	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	5.18	0.39	7.34e-7	Hemoglobin concentration;
UCEC	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg09910674	chr16:89028015	CBFA2T3	0.61	4.59	0.35	9.53e-6	Skin colour saturation;
UCEC	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.48	-6.46	-0.47	1.41e-9	Body mass index;
UCEC	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.69	8.23	0.56	9.48e-14	Prudent dietary pattern;
UCEC	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.67	-6.66	-0.48	5.13e-10	Cognitive function;
UCEC	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.7	5.46	0.41	1.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2742417	1.000	rs2742368	chr3:45752293	C/A	cg01451880	chr3:45801044	SLC6A20	-0.39	-5.07	-0.39	1.17e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs1150668	0.796	rs213237	chr6:28323938	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.6	-7.03	-0.5	7.34e-11	Pubertal anthropometrics;
UCEC	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg19318889	chr4:1322082	MAEA	0.45	5.07	0.39	1.16e-6	Obesity-related traits;
UCEC	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.57	-5.36	-0.4	3.12e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.41	-4.71	-0.36	5.65e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01065977	chr19:18549689	ISYNA1	-0.34	-4.84	-0.37	3.21e-6	Breast cancer;
UCEC	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg26769984	chr7:1090371	C7orf50	0.45	4.6	0.35	9.22e-6	Longevity;Endometriosis;
UCEC	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.39	4.83	0.37	3.37e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg01256987	chr12:42539512	GXYLT1	0.5	4.89	0.37	2.61e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	trans	rs66573146	1.000	rs67405518	chr4:6965930	C/T	cg07817883	chr1:32538562	TMEM39B	1.23	9.45	0.61	7.4e-17	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.75	-6.18	-0.45	5.9e-9	Colorectal adenoma (advanced);
UCEC	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.9	5.35	0.4	3.28e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	8.27	0.56	7.16e-14	Chronic sinus infection;
UCEC	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.98	-11.52	-0.69	2.75e-22	Cognitive function;
UCEC	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.73	6.13	0.45	7.6e-9	Menopause (age at onset);
UCEC	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-9.78	-0.63	1.04e-17	Electrocardiographic conduction measures;
UCEC	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.87	5.44	0.41	2.17e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs6723108	0.581	rs1446525	chr2:135637847	G/A	cg07169764	chr2:136633963	MCM6	0.47	4.53	0.35	1.23e-5	Type 2 diabetes;
UCEC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.82	8.45	0.57	2.6e-14	Cognitive function;
UCEC	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.51	6.19	0.45	5.69e-9	Total body bone mineral density;
UCEC	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18252515	chr7:66147081	NA	-0.52	-5.09	-0.39	1.09e-6	Aortic root size;
UCEC	cis	rs2288327	1.000	rs890578	chr2:179414633	G/T	cg09915519	chr2:179397513	TTN;MIR548N	-0.61	-4.85	-0.37	3.18e-6	Atrial fibrillation;
UCEC	cis	rs4654899	0.931	rs12723255	chr1:21233570	C/T	cg01072550	chr1:21505969	NA	0.57	5.73	0.43	5.37e-8	Superior frontal gyrus grey matter volume;
UCEC	cis	rs12234571	1.000	rs58575675	chr7:77438492	T/A	cg20048109	chr7:78158112	MAGI2	-0.5	-4.52	-0.35	1.25e-5	Obesity-related traits;
UCEC	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	10.24	0.65	6.66e-19	Electrocardiographic conduction measures;
UCEC	cis	rs7246967	0.673	rs9677019	chr19:22912659	T/C	cg05241461	chr19:22816980	ZNF492	0.56	5.78	0.43	4.22e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05863683	chr7:1912471	MAD1L1	0.44	4.52	0.35	1.24e-5	Bipolar disorder and schizophrenia;
UCEC	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.49	-6.51	-0.47	1.12e-9	Body mass index;
UCEC	cis	rs10507349	1.000	rs3759470	chr13:26798892	T/C	cg01600817	chr13:26797529	RNF6	-0.49	-4.81	-0.37	3.64e-6	Type 2 diabetes;
UCEC	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg16497661	chr14:103986332	CKB	0.49	5.72	0.43	5.71e-8	Body mass index;
UCEC	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.8	-7.24	-0.51	2.31e-11	Orofacial clefts;
UCEC	cis	rs7101446	0.898	rs7111246	chr11:63185562	C/G	cg21706343	chr11:62521476	ZBTB3	-0.53	-4.62	-0.36	8.38e-6	Economic and political preferences;
UCEC	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.8	8.11	0.56	1.83e-13	Parkinson's disease;
UCEC	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.73	-0.43	5.62e-8	Idiopathic membranous nephropathy;
UCEC	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg02175308	chr1:109941060	SORT1	-0.29	-4.58	-0.35	9.78e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.5	5.27	0.4	4.77e-7	Schizophrenia;
UCEC	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.61	5.99	0.44	1.54e-8	Coronary artery disease;
UCEC	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.62	4.91	0.38	2.37e-6	Mean platelet volume;
UCEC	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-0.93	-7.29	-0.52	1.75e-11	Breast cancer;
UCEC	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg13683864	chr3:40499215	RPL14	-0.57	-6.14	-0.45	7.14e-9	Renal cell carcinoma;
UCEC	cis	rs2376682	0.959	rs10055210	chr5:118043996	T/C	cg17593721	chr5:118788746	HSD17B4	0.49	4.94	0.38	2.11e-6	Diisocyanate-induced asthma;
UCEC	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg27624424	chr6:160112604	SOD2	0.56	4.55	0.35	1.1e-5	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.35	-4.58	-0.35	9.92e-6	Mean corpuscular hemoglobin;
UCEC	cis	rs883565	0.655	rs6778963	chr3:39091812	T/G	cg01426195	chr3:39028469	NA	-0.75	-9.85	-0.63	6.98e-18	Handedness;
UCEC	cis	rs1575951	1.000	rs10764797	chr10:130436282	A/T	cg27041381	chr10:131357203	MGMT	0.6	5.19	0.39	6.8e-7	Plasma clusterin levels;
UCEC	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.86	-9.21	-0.61	3.04e-16	Lung cancer;
UCEC	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.5	-5.58	-0.42	1.15e-7	Life satisfaction;
UCEC	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.9	5.0	0.38	1.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	4.74	0.36	5.08e-6	Lymphocyte counts;Red cell distribution width;
UCEC	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg13216073	chr1:12042593	MFN2	0.5	5.09	0.39	1.1e-6	Tuberculosis;
UCEC	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.65	6.26	0.46	3.94e-9	Aortic root size;
UCEC	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.66	-4.73	-0.36	5.25e-6	Multiple sclerosis;
UCEC	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.66	5.64	0.42	8.34e-8	Blood metabolite levels;
UCEC	trans	rs6919346	0.600	rs2063345	chr6:160860154	A/G	cg16588061	chr11:88070780	CTSC	0.75	6.67	0.48	4.79e-10	Lp (a) levels;
UCEC	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg05738196	chr6:26577821	NA	0.58	5.57	0.42	1.16e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	5.14	0.39	8.63e-7	Bipolar disorder;
UCEC	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.0	17.98	0.83	6.16e-39	Colorectal cancer;
UCEC	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	1.01	5.85	0.43	3.02e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg24069376	chr3:38537580	EXOG	0.43	5.22	0.4	6.11e-7	Electrocardiographic conduction measures;
UCEC	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.44	5.56	0.42	1.23e-7	Urinary tract infection frequency;
UCEC	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.71	6.35	0.46	2.53e-9	Aortic root size;
UCEC	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.02	-12.81	-0.73	1.08e-25	Body mass index;
UCEC	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg08250081	chr4:10125330	NA	0.47	4.62	0.36	8.15e-6	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.61	6.08	0.45	1.01e-8	Lung cancer;
UCEC	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.82	9.43	0.61	8.56e-17	Intelligence (multi-trait analysis);
UCEC	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.7	6.87	0.49	1.71e-10	Bladder cancer;
UCEC	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.72	-7.44	-0.52	7.98e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
UCEC	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.18	13.17	0.74	1.21e-26	Corneal structure;
UCEC	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-5.02	-0.38	1.48e-6	Height;
UCEC	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.78	6.22	0.46	4.78e-9	Neuroticism;
UCEC	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.89	-10.27	-0.65	5.33e-19	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg18681998	chr4:17616180	MED28	0.6	6.85	0.49	1.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.5	-4.64	-0.36	7.75e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.59	-4.7	-0.36	6.02e-6	Menopause (age at onset);
UCEC	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.81	7.96	0.55	4.23e-13	Blood protein levels;
UCEC	cis	rs7725816	0.584	rs9325071	chr5:147497338	A/G	cg10994339	chr5:147443536	SPINK5	-0.5	-4.68	-0.36	6.51e-6	Yeast infection;
UCEC	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.5	-4.75	-0.36	4.72e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.7	8.36	0.57	4.33e-14	Prudent dietary pattern;
UCEC	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg03959625	chr15:84868606	LOC388152	0.46	4.73	0.36	5.19e-6	Schizophrenia;
UCEC	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.15	19.58	0.85	8.52e-43	IgG glycosylation;
UCEC	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg07838603	chr6:28411030	ZSCAN23	-0.48	-5.59	-0.42	1.06e-7	Pulmonary function;
UCEC	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.53	5.61	0.42	9.59e-8	Platelet count;
UCEC	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.59	5.94	0.44	2.02e-8	Intelligence (multi-trait analysis);
UCEC	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg14424070	chr14:75988820	BATF	0.44	4.53	0.35	1.21e-5	IgG glycosylation;
UCEC	cis	rs9326726	0.844	rs2966832	chr5:107639805	T/C	cg17432647	chr5:107996819	NA	0.5	4.55	0.35	1.14e-5	Resting heart rate;
UCEC	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	1.0	14.62	0.77	1.89e-30	Bone mineral density;
UCEC	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.68	7.14	0.51	4.03e-11	Intelligence (multi-trait analysis);
UCEC	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg20821713	chr7:1055600	C7orf50	-0.82	-9.72	-0.63	1.46e-17	Bronchopulmonary dysplasia;
UCEC	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.6	5.15	0.39	8.28e-7	Heart rate;
UCEC	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.67	7.15	0.51	3.87e-11	Longevity;Endometriosis;
UCEC	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-9.38	-0.61	1.12e-16	Coffee consumption (cups per day);
UCEC	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg00105475	chr2:10696890	NA	0.46	5.7	0.43	6.32e-8	Prostate cancer;
UCEC	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.67	-7.43	-0.52	8.16e-12	Glomerular filtration rate (creatinine);
UCEC	cis	rs10786436	0.605	rs7912749	chr10:100280107	C/T	cg24343515	chr10:99400468	PI4K2A	-0.47	-4.72	-0.36	5.39e-6	Type 1 diabetes;
UCEC	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg04473437	chr5:205334	CCDC127	-0.59	-4.6	-0.35	9.14e-6	Breast cancer;
UCEC	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24249390	chr15:90295951	MESP1	-0.41	-4.73	-0.36	5.22e-6	Coronary artery aneurysm in Kawasaki disease;
UCEC	cis	rs7246967	0.673	rs3951783	chr19:22839264	T/A	cg24889512	chr19:22816950	ZNF492	0.6	6.45	0.47	1.51e-9	Bronchopulmonary dysplasia;
UCEC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	6.37	0.46	2.34e-9	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.58	-5.93	-0.44	2.03e-8	Bipolar disorder;
UCEC	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.51	-4.95	-0.38	1.98e-6	Electroencephalogram traits;
UCEC	cis	rs3770752	0.836	rs2300893	chr2:37481982	A/G	cg20091297	chr2:37572423	QPCT	0.45	4.55	0.35	1.11e-5	Schizophrenia;
UCEC	cis	rs3849046	0.817	rs6596438	chr5:137905448	T/G	cg18180673	chr5:137827632	NA	-0.45	-4.54	-0.35	1.17e-5	Schizophrenia;Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.11	9.48	0.62	6.26e-17	Blood protein levels;
UCEC	cis	rs10746514	0.786	rs9308486	chr1:232246418	A/G	cg09506761	chr1:232265262	NA	0.54	5.49	0.41	1.69e-7	Response to statin therapy;
UCEC	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.49	5.57	0.42	1.19e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.52	4.51	0.35	1.31e-5	Height;
UCEC	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg00105475	chr2:10696890	NA	0.45	5.61	0.42	9.89e-8	Prostate cancer;
UCEC	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg01874867	chr7:94954059	PON1	-0.54	-5.1	-0.39	1.03e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	4.64	0.36	7.73e-6	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs1150668	0.799	rs7206	chr6:28201138	A/G	cg07836142	chr6:28411423	ZSCAN23	-0.59	-6.73	-0.49	3.49e-10	Pubertal anthropometrics;
UCEC	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.53	-4.59	-0.35	9.35e-6	Mean platelet volume;Platelet distribution width;
UCEC	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-4.85	-0.37	3.06e-6	Schizophrenia;
UCEC	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.63	4.7	0.36	5.81e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07215822	chr6:158701037	NA	-0.68	-6.11	-0.45	8.41e-9	Height;
UCEC	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.62	6.84	0.49	1.95e-10	Eye color traits;
UCEC	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg23950597	chr19:37808831	NA	-0.81	-5.89	-0.44	2.49e-8	Coronary artery calcification;
UCEC	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg12334488	chr2:20871173	GDF7	0.35	4.67	0.36	6.63e-6	Abdominal aortic aneurysm;
UCEC	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-0.88	-10.98	-0.67	7.45e-21	Height;
UCEC	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	5.31	0.4	4.03e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	5.04	0.38	1.37e-6	Hemoglobin concentration;
UCEC	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg13683864	chr3:40499215	RPL14	-0.53	-5.3	-0.4	4.11e-7	Renal cell carcinoma;
UCEC	cis	rs1150668	0.830	rs213240	chr6:28315875	T/C	cg21486944	chr6:28411378	ZSCAN23	-0.57	-6.21	-0.46	5.16e-9	Pubertal anthropometrics;
UCEC	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	5.22	0.4	6.04e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg22166914	chr1:53195759	ZYG11B	-0.64	-7.01	-0.5	8.17e-11	Monocyte count;
UCEC	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.49	-4.53	-0.35	1.19e-5	Blood trace element (Cu levels);
UCEC	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.4	4.54	0.35	1.17e-5	Chronic sinus infection;
UCEC	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg19318889	chr4:1322082	MAEA	0.61	7.49	0.53	6.03e-12	Longevity;
UCEC	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.51	4.57	0.35	1.02e-5	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-6.78	-0.49	2.66e-10	Resting heart rate;
UCEC	cis	rs1150688	1	rs1150688	chr6:28162780	T/C	cg07838603	chr6:28411030	ZSCAN23	-0.51	-5.74	-0.43	5.24e-8	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg06265175	chr8:121136014	COL14A1	0.5	5.32	0.4	3.77e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.67	6.77	0.49	2.88e-10	Breast cancer;
UCEC	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.34	-0.46	2.61e-9	Parkinson's disease;
UCEC	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-4.82	-0.37	3.59e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
UCEC	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.59	-6.05	-0.45	1.17e-8	Blood trace element (Zn levels);
UCEC	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.65	-5.39	-0.41	2.79e-7	Psoriasis vulgaris;
UCEC	cis	rs7088591	0.867	rs4586100	chr10:59780072	G/C	cg11142981	chr10:60273225	BICC1	0.63	4.68	0.36	6.57e-6	Blood pressure;
UCEC	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.84	-6.4	-0.47	1.98e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	7.51	0.53	5.25e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg04154034	chr17:28927549	LRRC37B2	0.75	5.0	0.38	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.8	-7.83	-0.54	8.83e-13	Schizophrenia;
UCEC	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	1.0	11.0	0.67	6.53e-21	Cerebrospinal fluid biomarker levels;
UCEC	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.55	-5.52	-0.41	1.51e-7	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs9470794	1.000	rs12664900	chr6:38026003	G/A	cg03458162	chr6:37400668	FTSJD2	0.86	5.06	0.38	1.26e-6	Type 2 diabetes;
UCEC	cis	rs17106184	1.000	rs72902777	chr1:51272278	T/C	cg07174182	chr1:51127561	FAF1	-0.83	-5.3	-0.4	4.09e-7	Type 2 diabetes;
UCEC	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	4.82	0.37	3.57e-6	Eosinophil percentage of white cells;
UCEC	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.39	-5.22	-0.4	5.98e-7	Reticulocyte fraction of red cells;
UCEC	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.5	5.54	0.42	1.35e-7	Tonsillectomy;
UCEC	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.41	5.06	0.39	1.22e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs692916	0.704	rs607153	chr18:60580371	G/A	cg07187971	chr18:60481018	PHLPP1	-0.38	-4.71	-0.36	5.7e-6	Aggressiveness in attention deficit hyperactivity disorder;
UCEC	cis	rs8048576	0.512	rs8063863	chr16:84400850	C/T	cg01311995	chr16:85205741	NA	-0.55	-4.57	-0.35	1.03e-5	Chronic obstructive pulmonary disease-related biomarkers;
UCEC	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	4.81	0.37	3.69e-6	Bipolar disorder;
UCEC	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg03714773	chr7:91764589	CYP51A1	-0.4	-4.9	-0.37	2.48e-6	Breast cancer;
UCEC	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg21191810	chr6:118973309	C6orf204	0.42	5.81	0.43	3.82e-8	Electrocardiographic conduction measures;
UCEC	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	5.91	0.44	2.24e-8	Neuroticism;
UCEC	cis	rs4851266	1.000	rs11690335	chr2:100826429	A/G	cg14675211	chr2:100938903	LONRF2	0.65	6.29	0.46	3.51e-9	Educational attainment;
UCEC	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.72	-0.48	3.73e-10	Chronic sinus infection;
UCEC	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.47	-5.39	-0.41	2.7e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.28	0.46	3.57e-9	Cognitive ability;
UCEC	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg13714344	chr12:6938635	LEPREL2	0.42	5.08	0.39	1.12e-6	Mean platelet volume;
UCEC	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.42	-5.12	-0.39	9.35e-7	Subjective well-being;
UCEC	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.63	4.76	0.37	4.59e-6	Educational attainment;
UCEC	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg22974920	chr21:40686053	BRWD1	0.62	5.1	0.39	1.02e-6	Cognitive function;
UCEC	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.77	5.1	0.39	1.01e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.72	7.15	0.51	3.8e-11	Menopause (age at onset);
UCEC	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg01072550	chr1:21505969	NA	-0.57	-5.57	-0.42	1.19e-7	Superior frontal gyrus grey matter volume;
UCEC	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg03714773	chr7:91764589	CYP51A1	0.42	5.2	0.39	6.6e-7	Breast cancer;
UCEC	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-5.89	-0.44	2.53e-8	Response to antipsychotic treatment;
UCEC	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.48	-5.82	-0.43	3.54e-8	Monocyte percentage of white cells;
UCEC	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.52	-5.25	-0.4	5.12e-7	Intelligence (multi-trait analysis);
UCEC	cis	rs7709377	0.521	rs9327000	chr5:115709156	G/T	cg23108291	chr5:115420582	COMMD10	0.49	4.78	0.37	4.26e-6	Metabolite levels  (X-11787);
UCEC	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.41	-5.55	-0.42	1.3e-7	Alcohol dependence;
UCEC	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.52	-6.56	-0.48	8.38e-10	Prudent dietary pattern;
UCEC	cis	rs2970992	0.728	rs1028045	chr2:101321075	G/A	cg01042948	chr2:101319752	NA	-0.51	-5.36	-0.4	3.21e-7	Educational attainment;
UCEC	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	8.01	0.55	3.22e-13	Smoking behavior;
UCEC	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-6.27	-0.46	3.85e-9	Prudent dietary pattern;
UCEC	cis	rs17122693	1.000	rs17122674	chr14:51066429	G/A	cg04730355	chr14:51134070	SAV1	0.89	8.51	0.57	1.82e-14	Cognitive performance;
UCEC	cis	rs16939046	1.000	rs72656148	chr8:76085268	A/G	cg17407813	chr8:76323405	NA	0.8	4.59	0.35	9.32e-6	Information processing speed;
UCEC	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.68	6.5	0.47	1.19e-9	Bladder cancer;
UCEC	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.78	-8.8	-0.59	3.51e-15	Height;
UCEC	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.46	-4.52	-0.35	1.24e-5	Aortic root size;
UCEC	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.66	6.14	0.45	7.28e-9	Aortic root size;
UCEC	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.58	5.98	0.44	1.62e-8	Motion sickness;
UCEC	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	9.94	0.63	4.04e-18	Electrocardiographic conduction measures;
UCEC	cis	rs7975161	0.520	rs9739833	chr12:104737430	A/T	cg25273343	chr12:104657179	TXNRD1	-0.81	-5.11	-0.39	9.85e-7	Toenail selenium levels;
UCEC	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	0.85	5.51	0.41	1.59e-7	Arsenic metabolism;
UCEC	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-5.29	-0.4	4.44e-7	Blood protein levels;Circulating chemerin levels;
UCEC	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.41	-5.71	-0.43	6.02e-8	Alcohol dependence;
UCEC	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.67	8.06	0.55	2.41e-13	Menarche (age at onset);
UCEC	cis	rs7113850	0.541	rs78652241	chr11:24234956	A/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.28	0.4	4.55e-7	Bone fracture in osteoporosis;
UCEC	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg26138937	chr11:71823887	C11orf51	-1.01	-4.81	-0.37	3.72e-6	Severe influenza A (H1N1) infection;
UCEC	cis	rs1816854	0.938	rs3764004	chr12:44201451	T/C	cg00106942	chr12:44200524	TWF1	0.53	5.46	0.41	1.94e-7	Inflammatory bowel disease;
UCEC	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.42	-4.61	-0.36	8.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.57	0.35	1.01e-5	Breast cancer;
UCEC	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.56	5.04	0.38	1.37e-6	Corneal astigmatism;
UCEC	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.41	-4.87	-0.37	2.82e-6	Dupuytren's disease;
UCEC	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.6	7.24	0.51	2.28e-11	Oral cavity cancer;
UCEC	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.44	-5.08	-0.39	1.11e-6	Smoking behavior;
UCEC	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.68	6.5	0.47	1.19e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.51	-5.31	-0.4	3.92e-7	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.62	5.36	0.4	3.16e-7	Heart rate;
UCEC	cis	rs4478037	1.000	rs4076086	chr3:33161898	C/T	cg19404215	chr3:33155277	CRTAP	0.7	5.59	0.42	1.06e-7	Major depressive disorder;
UCEC	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.47	6.42	0.47	1.73e-9	Type 2 diabetes and other traits;Type 2 diabetes;
UCEC	cis	rs9287719	0.639	rs2357650	chr2:10696877	C/T	cg00105475	chr2:10696890	NA	0.5	6.94	0.5	1.19e-10	Prostate cancer;
UCEC	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	8.01	0.55	3.24e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	1.0	14.82	0.77	5.69e-31	Bone mineral density;
UCEC	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.65	-6.62	-0.48	6.43e-10	Blood protein levels;
UCEC	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg24562669	chr7:97807699	LMTK2	0.5	6.09	0.45	9.52e-9	Prostate cancer (SNP x SNP interaction);
UCEC	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.66	7.29	0.52	1.79e-11	Homoarginine levels;
UCEC	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.6	4.75	0.36	4.87e-6	Corneal astigmatism;
UCEC	trans	rs925228	0.955	rs6730855	chr2:24192801	A/G	cg18674340	chr17:45867686	NA	0.72	6.7	0.48	4.1e-10	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.59	8.31	0.57	5.97e-14	Total body bone mineral density;
UCEC	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.51	-6.96	-0.5	1.06e-10	Eye color traits;
UCEC	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-6.42	-0.47	1.77e-9	Platelet count;
UCEC	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.76	7.69	0.54	2e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.81	7.48	0.52	6.32e-12	Bladder cancer;
UCEC	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.66	-6.58	-0.48	7.74e-10	Diastolic blood pressure;
UCEC	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.99	-0.5	9.1e-11	Neuroticism;
UCEC	cis	rs394563	0.690	rs372205	chr6:149775267	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.44	-5.3	-0.4	4.13e-7	Dupuytren's disease;
UCEC	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.5	5.65	0.42	8.2e-8	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg17294928	chr15:75287854	SCAMP5	0.55	5.99	0.44	1.53e-8	Breast cancer;
UCEC	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.69	6.88	0.49	1.58e-10	Bipolar disorder;
UCEC	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.69	6.34	0.46	2.66e-9	Bladder cancer;
UCEC	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	0.94	9.72	0.63	1.53e-17	Left atrial antero-posterior diameter;
UCEC	cis	rs12234571	1.000	rs3815222	chr7:77365412	G/T	cg20048109	chr7:78158112	MAGI2	-0.5	-4.54	-0.35	1.17e-5	Obesity-related traits;
UCEC	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg26695010	chr11:65641043	EFEMP2	0.57	5.68	0.42	6.91e-8	Eosinophil percentage of white cells;
UCEC	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.66	7.62	0.53	2.88e-12	Vitiligo;
UCEC	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.43	-4.5	-0.35	1.36e-5	Homocysteine levels;
UCEC	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24308560	chr3:49941425	MST1R	0.44	4.77	0.37	4.42e-6	Body mass index;
UCEC	cis	rs6546886	0.957	rs12713806	chr2:74258136	T/G	cg14702570	chr2:74259524	NA	-0.38	-4.67	-0.36	6.73e-6	Dialysis-related mortality;
UCEC	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-4.74	-0.36	4.98e-6	Fibrinogen levels;
UCEC	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.69	-8.51	-0.57	1.87e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
UCEC	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.46	4.95	0.38	2.04e-6	Smoking initiation;
UCEC	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.61	5.73	0.43	5.46e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.55	-6.83	-0.49	2.05e-10	Paraoxonase activity;
UCEC	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg08250081	chr4:10125330	NA	0.46	4.51	0.35	1.31e-5	Gout;Urate levels;Serum uric acid levels;
UCEC	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.55	5.71	0.43	6.16e-8	Lung cancer;
UCEC	cis	rs7870753	0.838	rs7848376	chr9:99248069	G/A	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.82	-9.92	-0.63	4.53e-18	Ulcerative colitis;
UCEC	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.56	4.98	0.38	1.8e-6	Coronary artery disease;
UCEC	cis	rs17122693	0.681	rs72679587	chr14:51092686	A/G	cg04730355	chr14:51134070	SAV1	0.89	9.04	0.6	8.54e-16	Cognitive performance;
UCEC	cis	rs847649	1.000	rs11514917	chr7:102609221	A/C	cg18108683	chr7:102477205	FBXL13	-0.61	-7.49	-0.53	5.79e-12	Morning vs. evening chronotype;
UCEC	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.75	6.23	0.46	4.58e-9	Cerebrospinal P-tau181p levels;
UCEC	trans	rs7246760	1.000	rs59771283	chr19:9854958	G/A	cg02900749	chr2:68251473	NA	-0.99	-7.48	-0.53	6.1e-12	Pursuit maintenance gain;
UCEC	cis	rs4642101	0.538	rs34871776	chr3:12815369	C/T	cg05775895	chr3:12838266	CAND2	0.52	5.26	0.4	4.94e-7	QRS complex (12-leadsum);
UCEC	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.21	9.35	0.61	1.35e-16	Gut microbiome composition (summer);
UCEC	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.36	4.9	0.37	2.46e-6	Eye color traits;
UCEC	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg23283320	chr21:48055893	PRMT2	1.02	4.64	0.36	7.75e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
UCEC	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-1.01	-8.08	-0.55	2.18e-13	Exhaled nitric oxide output;
UCEC	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	0.82	9.12	0.6	5.3e-16	Breast cancer;
UCEC	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.71	4.91	0.38	2.44e-6	Lung function (FEV1/FVC);
UCEC	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.48	5.34	0.4	3.46e-7	Developmental language disorder (linguistic errors);
UCEC	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg23793686	chr15:68133972	NA	-0.35	-4.56	-0.35	1.08e-5	Restless legs syndrome;
UCEC	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.67	-4.97	-0.38	1.83e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.63	6.72	0.48	3.71e-10	Platelet count;
UCEC	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.63	-5.58	-0.42	1.15e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7766436	0.885	rs12662891	chr6:22575096	C/T	cg13666174	chr6:22585274	NA	-0.53	-5.73	-0.43	5.48e-8	Coronary artery disease;
UCEC	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.73	6.17	0.45	6.32e-9	Menopause (age at onset);
UCEC	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg12024160	chr4:1254474	NA	0.71	8.9	0.59	1.93e-15	Obesity-related traits;
UCEC	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.46	-5.27	-0.4	4.82e-7	Glomerular filtration rate (creatinine);
UCEC	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg13319975	chr6:146136371	FBXO30	-0.44	-4.62	-0.36	8.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.58	4.93	0.38	2.19e-6	Lung function (FEV1/FVC);
UCEC	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.79e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.58	6.27	0.46	3.73e-9	Age at first birth;
UCEC	cis	rs7597155	0.846	rs4852984	chr2:69971317	G/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-4.76	-0.37	4.68e-6	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.65	6.84	0.49	2.03e-10	Menopause (age at onset);
UCEC	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.66	5.36	0.4	3.14e-7	Corneal astigmatism;
UCEC	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.63	6.77	0.49	2.85e-10	Autism;
UCEC	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.23	23.91	0.89	1.64e-52	Myeloid white cell count;
UCEC	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.97	12.45	0.72	9.42e-25	Multiple sclerosis;
UCEC	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.72	7.71	0.54	1.78e-12	Mortality in heart failure;
UCEC	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.64	-6.28	-0.46	3.66e-9	Lymphocyte counts;
UCEC	cis	rs4499344	0.604	rs259287	chr19:33164859	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.59	5.17	0.39	7.69e-7	Mean platelet volume;
UCEC	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-10.72	-0.66	3.49e-20	Chronic sinus infection;
UCEC	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg18681998	chr4:17616180	MED28	0.76	8.7	0.58	6.29e-15	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs1007738	0.542	rs10838664	chr11:47203904	G/A	cg18879828	chr11:46942432	NA	-0.45	-4.56	-0.35	1.07e-5	Bone mineral density (hip);
UCEC	cis	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg07460842	chr6:66804631	NA	0.67	5.47	0.41	1.87e-7	Metabolite levels;
UCEC	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.63	6.39	0.47	2.09e-9	Morning vs. evening chronotype;
UCEC	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-0.88	-12.82	-0.73	1.02e-25	Multiple system atrophy;
UCEC	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-0.96	-5.76	-0.43	4.71e-8	Mitochondrial DNA levels;
UCEC	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-6.0	-0.44	1.46e-8	Body mass index;
UCEC	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.79	7.94	0.55	4.87e-13	Schizophrenia;
UCEC	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.45	4.86	0.37	3e-6	Diastolic blood pressure;
UCEC	cis	rs7095607	0.742	rs10997965	chr10:69923835	A/G	cg18986048	chr10:69913749	MYPN	0.55	6.41	0.47	1.82e-9	Lung function (FVC);
UCEC	cis	rs1635	0.655	rs9380024	chr6:27830354	C/G	cg02285791	chr6:27550747	NA	-0.69	-4.99	-0.38	1.65e-6	Schizophrenia;
UCEC	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-0.96	-7.16	-0.51	3.57e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.76	5.18	0.39	7.31e-7	Eosinophil percentage of granulocytes;
UCEC	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.79	0.49	2.58e-10	Intelligence (multi-trait analysis);
UCEC	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.71	-6.86	-0.49	1.79e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.78	9.13	0.6	4.93e-16	Lymphocyte counts;
UCEC	cis	rs394563	0.663	rs415434	chr6:149772645	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.43	-5.3	-0.4	4.21e-7	Dupuytren's disease;
UCEC	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.75	6.71	0.48	3.95e-10	Coronary artery disease;
UCEC	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.67	7.28	0.52	1.82e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
UCEC	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg10503236	chr1:231470652	EXOC8	-0.4	-4.71	-0.36	5.75e-6	Hemoglobin concentration;
UCEC	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.68	5.8	0.43	3.86e-8	IgE levels in asthmatics (D.p. specific);
UCEC	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.17	9.44	0.61	8.08e-17	Uric acid levels;
UCEC	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.23	7.37	0.52	1.15e-11	Eosinophil percentage of granulocytes;
UCEC	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg19554555	chr3:13937349	NA	-0.54	-5.58	-0.42	1.11e-7	Ovarian reserve;
UCEC	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.71	-6.05	-0.45	1.15e-8	Cardiac Troponin-T levels;
UCEC	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.81	-9.66	-0.62	2.16e-17	Electrocardiographic conduction measures;
UCEC	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.62	7.44	0.52	7.93e-12	Schizophrenia;
UCEC	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.82	6.93	0.5	1.26e-10	Initial pursuit acceleration;
UCEC	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg06637938	chr14:75390232	RPS6KL1	0.73	5.89	0.44	2.51e-8	Height;
UCEC	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-6.07	-0.45	1.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-4.69	-0.36	6.27e-6	Tonsillectomy;
UCEC	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.73	0.36	5.23e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.53	5.12	0.39	9.62e-7	Emphysema distribution in smoking;
UCEC	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	15.52	0.79	8.84e-33	Coffee consumption;Coffee consumption (cups per day);
UCEC	cis	rs7246967	0.673	rs4414616	chr19:22832411	G/A	cg03230154	chr19:22817176	ZNF492	0.45	4.79	0.37	4.08e-6	Bronchopulmonary dysplasia;
UCEC	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	10.11	0.64	1.4e-18	Electrocardiographic conduction measures;
UCEC	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg14078730	chr11:63896557	MACROD1	0.52	5.91	0.44	2.3e-8	Platelet count;
UCEC	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.67	4.79	0.37	3.97e-6	Gut microbiome composition (summer);
UCEC	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	6.66	0.48	5.2e-10	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs968451	0.865	rs5757611	chr22:39708357	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	5.13	0.39	8.97e-7	Primary biliary cholangitis;
UCEC	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.78	8.7	0.58	6.29e-15	Menarche (age at onset);
UCEC	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.58	6.93	0.5	1.25e-10	Oral cavity cancer;
UCEC	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.68	5.8	0.43	3.9e-8	Prostate cancer;
UCEC	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	5.61	0.42	9.65e-8	Ulcerative colitis;Inflammatory bowel disease;
UCEC	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg20821713	chr7:1055600	C7orf50	-0.55	-5.67	-0.42	7.28e-8	Bronchopulmonary dysplasia;
UCEC	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07117700	chr17:61903327	PSMC5;FTSJ3	-0.5	-6.22	-0.46	4.91e-9	Prudent dietary pattern;
UCEC	cis	rs377070	1.000	rs377070	chr4:123629002	G/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.61	4.94	0.38	2.07e-6	Mosquito bite size;
UCEC	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	6.41	0.47	1.88e-9	Coffee consumption (cups per day);
UCEC	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.62	-5.87	-0.44	2.82e-8	Vitiligo;
UCEC	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.53	-5.83	-0.43	3.34e-8	IgG glycosylation;
UCEC	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.71	7.11	0.51	4.64e-11	Type 2 diabetes;
UCEC	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.68	6.65	0.48	5.41e-10	Aortic root size;
UCEC	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.57	5.56	0.42	1.23e-7	Blood protein levels;
UCEC	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26207909	chr14:103986467	CKB	0.51	4.86	0.37	2.95e-6	Body mass index;
UCEC	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.64	-7.17	-0.51	3.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.86	-9.4	-0.61	1.02e-16	Blood metabolite levels;
UCEC	trans	rs12109285	1	rs12109285	chr5:21749348	T/C	cg17388484	chr17:39943043	JUP	-1.12	-6.92	-0.5	1.33e-10	Response to tocilizumab in rheumatoid arthritis;
UCEC	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.5	-4.6	-0.35	8.92e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
UCEC	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.47	4.94	0.38	2.12e-6	Smoking initiation;
UCEC	cis	rs4280164	1.000	rs4280164	chr14:24771285	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	-0.61	-4.77	-0.37	4.45e-6	Parent of origin effect on language impairment (paternal);
UCEC	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	5.95	0.44	1.86e-8	Platelet count;
UCEC	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	4.86	0.37	2.97e-6	Spherical equivalent (joint analysis main effects and education interaction);
UCEC	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.06	-11.31	-0.68	1.02e-21	Corneal structure;
UCEC	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-0.73	-7.14	-0.51	4e-11	Breast cancer;
UCEC	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg22974920	chr21:40686053	BRWD1	0.58	5.04	0.38	1.32e-6	Cognitive function;
UCEC	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.08	0.39	1.13e-6	Breast cancer;
UCEC	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.95	-7.41	-0.52	9.05e-12	Multiple sclerosis;
UCEC	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.54	5.22	0.4	6.13e-7	Coronary artery disease;
UCEC	cis	rs921968	0.715	rs62182125	chr2:219274142	G/A	cg02176678	chr2:219576539	TTLL4	0.49	4.92	0.38	2.27e-6	Mean corpuscular hemoglobin concentration;
UCEC	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg16558253	chr16:72132732	DHX38	-0.4	-4.57	-0.35	1.04e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
UCEC	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.67	10.17	0.64	9.88e-19	Height;
UCEC	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.6	-4.59	-0.35	9.35e-6	Lung cancer;
UCEC	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.6	-4.7	-0.36	5.82e-6	LDL cholesterol levels;
UCEC	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26207909	chr14:103986467	CKB	-0.51	-5.62	-0.42	9.29e-8	Body mass index;
UCEC	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg13147721	chr7:65941812	NA	-0.69	-4.84	-0.37	3.28e-6	Diabetic kidney disease;
UCEC	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg00298065	chr19:58715577	ZNF274	0.39	4.67	0.36	6.83e-6	Mean platelet volume;
UCEC	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.55	-6.0	-0.44	1.44e-8	Blood metabolite levels;
UCEC	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-6.18	-0.45	5.88e-9	Tonsillectomy;
UCEC	trans	rs11650175	0.634	rs7342941	chr17:63750766	C/A	cg18512948	chr14:24641706	REC8	0.56	6.69	0.48	4.42e-10	Chin dimples;
UCEC	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.72	7.71	0.54	1.72e-12	Intelligence (multi-trait analysis);
UCEC	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg23782820	chr8:58130467	NA	0.5	4.71	0.36	5.6e-6	Developmental language disorder (linguistic errors);
UCEC	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.37	-4.64	-0.36	7.74e-6	Bone mineral density (spine);
UCEC	cis	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg17469321	chr7:55412551	NA	0.7	6.19	0.45	5.72e-9	QRS interval (sulfonylurea treatment interaction);
UCEC	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.5	-5.55	-0.42	1.28e-7	Life satisfaction;
UCEC	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg12850546	chr22:42539477	CYP2D7P1	0.45	4.92	0.38	2.26e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.59	0.35	9.41e-6	Breast cancer;
UCEC	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.78	9.01	0.6	1.01e-15	Menopause (age at onset);
UCEC	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.69	4.55	0.35	1.1e-5	Gut microbiome composition (summer);
UCEC	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.49	-4.59	-0.35	9.6e-6	Schizophrenia;
UCEC	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.59	6.26	0.46	3.96e-9	Coronary artery disease;
UCEC	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.6	6.33	0.46	2.85e-9	Breast cancer;
UCEC	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.39	4.85	0.37	3.13e-6	Colonoscopy-negative controls vs population controls;
UCEC	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.67	6.36	0.46	2.41e-9	Drug-induced liver injury (flucloxacillin);
UCEC	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg02160872	chr5:212506	CCDC127	-0.69	-7.2	-0.51	2.96e-11	Breast cancer;
UCEC	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	1.04	9.45	0.61	7.27e-17	Corneal structure;
UCEC	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.61	6.77	0.49	2.85e-10	Red blood cell count;
UCEC	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	6.87	0.49	1.67e-10	Motion sickness;
UCEC	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg01072550	chr1:21505969	NA	-0.64	-6.79	-0.49	2.65e-10	Superior frontal gyrus grey matter volume;
UCEC	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.56	6.45	0.47	1.53e-9	Prostate cancer;
UCEC	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.12	-13.96	-0.75	9.93e-29	Breast cancer;
UCEC	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-1.17	-5.56	-0.42	1.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
UCEC	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.77	-8.25	-0.56	8.27e-14	Menarche (age at onset);
UCEC	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.49	6.36	0.46	2.42e-9	Mean platelet volume;
UCEC	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.02	-7.79	-0.54	1.08e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
UCEC	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.7	6.1	0.45	9.05e-9	Adiposity;
UCEC	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-5.51	-0.41	1.53e-7	Initial pursuit acceleration;
UCEC	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	0.97	14.31	0.76	1.17e-29	Homoarginine levels;
UCEC	cis	rs1043099	0.871	rs2108093	chr22:30679387	A/G	cg23383138	chr22:30885012	SEC14L4	-0.52	-4.7	-0.36	5.82e-6	Rheumatoid arthritis;
UCEC	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-5.23	-0.4	5.78e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
UCEC	cis	rs7246967	0.932	rs11882432	chr19:23029703	A/G	cg05241461	chr19:22816980	ZNF492	0.48	5.12	0.39	9.3e-7	Bronchopulmonary dysplasia;
UCEC	cis	rs7246967	0.611	rs16999571	chr19:22904764	C/A	cg24889512	chr19:22816950	ZNF492	0.62	6.61	0.48	6.57e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	0.84	6.14	0.45	7.48e-9	Iron status biomarkers;
UCEC	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.68	-6.15	-0.45	7.05e-9	Aortic root size;
UCEC	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.03	7.44	0.52	7.77e-12	Sexual dysfunction (female);
UCEC	cis	rs912062	1.000	rs7037561	chr9:832711	C/T	cg01137471	chr9:841340	DMRT1	0.6	4.82	0.37	3.51e-6	Obesity-related traits;
UCEC	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.6	5.77	0.43	4.5e-8	Height;
UCEC	cis	rs7597155	0.811	rs10203645	chr2:69962793	G/A	cg02498382	chr2:70120550	SNRNP27	-0.48	-5.37	-0.41	2.99e-7	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg12850546	chr22:42539477	CYP2D7P1	-1.19	-8.11	-0.56	1.83e-13	Birth weight;
UCEC	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.74	-5.24	-0.4	5.54e-7	Body mass index;
UCEC	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg25110126	chr1:46999211	NA	0.54	5.13	0.39	9.12e-7	Monobrow;
UCEC	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.64	-8.3	-0.56	6.14e-14	Neuroticism;
UCEC	cis	rs6731420	0.526	rs17743264	chr2:71534811	C/G	cg15491567	chr2:71679675	DYSF	-0.29	-4.63	-0.36	8.13e-6	Intelligence (multi-trait analysis);
UCEC	cis	rs1150668	0.799	rs1150707	chr6:28197605	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.5	-5.6	-0.42	1e-7	Pubertal anthropometrics;
UCEC	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg06562184	chr8:19319451	CSGALNACT1	0.43	4.75	0.36	4.79e-6	Language performance in older adults (adjusted for episodic memory);
UCEC	cis	rs2734839	0.964	rs12800853	chr11:113302514	C/T	cg14159747	chr11:113255604	NA	0.57	7.17	0.51	3.47e-11	Information processing speed;
UCEC	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.8	8.9	0.59	1.96e-15	Intelligence (multi-trait analysis);
UCEC	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.77	8.46	0.57	2.43e-14	Intelligence (multi-trait analysis);
UCEC	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.65	-6.3	-0.46	3.26e-9	Schizophrenia;
UCEC	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	0.9	8.08	0.55	2.2e-13	Nonalcoholic fatty liver disease;
UCEC	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-13.19	-0.74	1.04e-26	Prudent dietary pattern;
UCEC	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06223018	chr3:49557076	DAG1	0.34	4.9	0.37	2.51e-6	Parkinson's disease;
UCEC	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.64	5.56	0.42	1.26e-7	Hip circumference adjusted for BMI;
UCEC	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	5.41	0.41	2.48e-7	Hemoglobin concentration;
UCEC	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.9	-10.34	-0.65	3.5e-19	Cognitive function;
UCEC	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.89	5.33	0.4	3.56e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
UCEC	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.38	-4.8	-0.37	3.95e-6	Cutaneous nevi;
UCEC	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.93	6.75	0.49	3.17e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.64	6.31	0.46	3.08e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.44	5.89	0.44	2.58e-8	Cleft plate (environmental tobacco smoke interaction);
UCEC	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg11632617	chr15:75315747	PPCDC	-0.62	-7.2	-0.51	2.96e-11	Blood trace element (Zn levels);
UCEC	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.7	6.98	0.5	9.47e-11	Opioid sensitivity;
UCEC	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg01689657	chr7:91764605	CYP51A1	0.44	5.43	0.41	2.26e-7	Breast cancer;
UCEC	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.78	5.65	0.42	7.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs7307889	0.546	rs10160866	chr12:6014627	G/T	cg05660680	chr12:6400491	NA	-0.67	-4.55	-0.35	1.1e-5	Obesity-related traits;
UCEC	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.76	-9.23	-0.61	2.74e-16	Extrinsic epigenetic age acceleration;
UCEC	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.79	-8.57	-0.58	1.28e-14	Breast cancer;
UCEC	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	4.92	0.38	2.34e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.74	-7.09	-0.5	5.33e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
UCEC	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13683864	chr3:40499215	RPL14	-0.67	-6.61	-0.48	6.65e-10	Renal cell carcinoma;
UCEC	cis	rs13437751	0.649	rs9986918	chr7:63352782	G/T	cg00787055	chr7:63562162	NA	0.4	4.89	0.37	2.63e-6	QT interval (drug interaction);
UCEC	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.66	6.07	0.45	1.05e-8	Inflammatory bowel disease;Crohn's disease;
UCEC	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.96	6.62	0.48	6.33e-10	Eosinophil percentage of granulocytes;
UCEC	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	7.83	0.54	8.85e-13	Alzheimer's disease;
UCEC	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.71	-8.59	-0.58	1.17e-14	Liver enzyme levels (gamma-glutamyl transferase);
UCEC	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.51	-5.12	-0.39	9.49e-7	Neuroticism;
UCEC	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-12.63	-0.72	3.17e-25	Height;
UCEC	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18932078	chr1:2524107	MMEL1	-0.35	-6.13	-0.45	7.85e-9	Ulcerative colitis;
UCEC	cis	rs9309473	0.519	rs4852950	chr2:73864670	C/T	cg20560298	chr2:73613845	ALMS1	0.54	5.17	0.39	7.52e-7	Metabolite levels;
UCEC	cis	rs711830	0.931	rs6755766	chr2:177043205	T/C	cg13092806	chr2:177043255	NA	0.99	9.56	0.62	3.88e-17	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
UCEC	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.39	5.03	0.38	1.42e-6	Sudden cardiac arrest;
UCEC	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.59	-5.3	-0.4	4.18e-7	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.2	0.56	1.12e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
UCEC	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-0.73	-7.13	-0.51	4.11e-11	Breast cancer;
UCEC	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.53	5.4	0.41	2.59e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
UCEC	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	6.0	0.44	1.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs2836974	0.777	rs34038277	chr21:40699847	A/G	cg22974920	chr21:40686053	BRWD1	0.54	4.72	0.36	5.52e-6	Cognitive function;
UCEC	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.78	7.54	0.53	4.45e-12	Blood metabolite levels;Acylcarnitine levels;
UCEC	cis	rs7246967	0.611	rs8107724	chr19:22867414	G/A	cg08271804	chr19:22816896	ZNF492	0.65	6.56	0.48	8.52e-10	Bronchopulmonary dysplasia;
UCEC	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.54	6.01	0.44	1.39e-8	Life satisfaction;
UCEC	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	7.04	0.5	6.7e-11	Menopause (age at onset);
UCEC	cis	rs2479106	0.791	rs12237685	chr9:126689557	T/C	cg16191174	chr9:126692580	DENND1A	0.48	4.62	0.36	8.44e-6	Polycystic ovary syndrome;
UCEC	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-6.32	-0.46	2.91e-9	Metabolite levels;
UCEC	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	7.61	0.53	3.11e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
UCEC	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.75	7.69	0.54	1.92e-12	Blood protein levels;
UCEC	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.33	4.6	0.35	9.02e-6	Crohn's disease;
UCEC	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.21	10.65	0.66	5.6e-20	Corneal structure;
UCEC	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.52	-5.04	-0.38	1.35e-6	Platelet count;
UCEC	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-19.1	-0.84	1.17e-41	Myeloid white cell count;
UCEC	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg20999797	chr1:1681921	NA	0.39	5.21	0.39	6.35e-7	Body mass index;
UCEC	cis	rs12039431	0.788	rs7535432	chr1:38051585	C/T	cg17933807	chr1:38061675	GNL2	-0.55	-5.04	-0.38	1.38e-6	Epithelial ovarian cancer;
UCEC	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.52	4.75	0.36	4.73e-6	Gestational age at birth (maternal effect);
UCEC	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.31	-4.5	-0.35	1.36e-5	Body mass index;
UCEC	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg25393495	chr8:12034317	NA	0.32	4.52	0.35	1.25e-5	Retinal vascular caliber;
UCEC	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	0.92	6.01	0.44	1.39e-8	Skin colour saturation;
UCEC	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.96	-10.88	-0.67	1.34e-20	Dementia and core Alzheimer's disease neuropathologic changes;
UCEC	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.96	9.35	0.61	1.35e-16	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-5.95	-0.44	1.92e-8	Body mass index;
UCEC	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.96	-8.88	-0.59	2.19e-15	Corneal structure;
UCEC	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg00343986	chr7:65444356	GUSB	0.51	4.63	0.36	8.05e-6	Aortic root size;
UCEC	cis	rs2862064	1.000	rs4407618	chr5:156445875	A/C	cg12943317	chr5:156479607	HAVCR1	-0.57	-4.75	-0.36	4.85e-6	Platelet count;
UCEC	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.86	9.85	0.63	6.66e-18	Crohn's disease;Inflammatory bowel disease;
UCEC	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.64	-5.09	-0.39	1.09e-6	Gut microbiome composition (summer);
UCEC	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.44	4.85	0.37	3.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
UCEC	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-5.59	-0.42	1.05e-7	Monocyte percentage of white cells;
UCEC	cis	rs732765	0.734	rs10133860	chr14:75186425	G/A	cg11740921	chr14:74946960	NPC2	-0.44	-4.61	-0.36	8.84e-6	Non-small cell lung cancer;
UCEC	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.91	9.54	0.62	4.46e-17	Alcohol dependence;
UCEC	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg14092571	chr14:90743983	NA	-0.42	-5.61	-0.42	9.93e-8	Mortality in heart failure;
UCEC	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.34	4.73	0.36	5.19e-6	Primary biliary cholangitis;
UCEC	cis	rs56879175	0.725	rs57073016	chr5:172011359	A/G	cg21742048	chr5:172099681	NEURL1B	-0.74	-4.75	-0.37	4.71e-6	Gut microbiota (functional units);
UCEC	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	0.8	8.63	0.58	9.15e-15	Primary sclerosing cholangitis;
UCEC	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.7	5.68	0.42	7.09e-8	Type 2 diabetes;
UCEC	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg13319975	chr6:146136371	FBXO30	0.43	4.53	0.35	1.22e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.93	-7.21	-0.51	2.71e-11	Multiple sclerosis;
UCEC	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.43	-4.68	-0.36	6.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.03	0.45	1.29e-8	IgG glycosylation;
UCEC	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.59	5.53	0.41	1.45e-7	Corneal astigmatism;
UCEC	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	4.64	0.36	7.5e-6	Height;
UCEC	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-25.21	-0.9	3.11e-55	Myeloid white cell count;
UCEC	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	5.8	0.43	3.99e-8	IgG glycosylation;
UCEC	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg14008862	chr17:28927542	LRRC37B2	0.62	5.13	0.39	9.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.44	-4.8	-0.37	3.82e-6	Testicular germ cell tumor;
UCEC	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	1.1	9.69	0.62	1.74e-17	Dupuytren's disease;
UCEC	cis	rs12618769	1.000	rs72825710	chr2:99239497	G/A	cg10123293	chr2:99228465	UNC50	0.46	4.82	0.37	3.48e-6	Bipolar disorder;
UCEC	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.49	4.89	0.37	2.61e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
UCEC	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg07838603	chr6:28411030	ZSCAN23	-0.41	-4.64	-0.36	7.74e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-5.97	-0.44	1.7e-8	Glomerular filtration rate;
UCEC	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.48	-4.57	-0.35	1.04e-5	Bipolar disorder;
UCEC	cis	rs8032158	0.963	rs11071231	chr15:56159118	A/C	cg10433327	chr15:56209506	NEDD4	-0.3	-4.86	-0.37	3.01e-6	Keloid;
UCEC	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.73	7.9	0.55	6e-13	Systemic lupus erythematosus and Systemic sclerosis;
UCEC	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	4.9	0.37	2.45e-6	Lymphocyte counts;
UCEC	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-8.17	-0.56	1.27e-13	Gut microbiome composition (summer);
UCEC	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg19318889	chr4:1322082	MAEA	0.43	4.83	0.37	3.45e-6	Longevity;
UCEC	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.91	11.37	0.68	6.86e-22	IgG glycosylation;
UCEC	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.49	5.19	0.39	6.93e-7	Granulocyte percentage of myeloid white cells;
UCEC	cis	rs1832871	0.538	rs6924801	chr6:158718805	A/G	cg07215822	chr6:158701037	NA	0.48	5.04	0.38	1.37e-6	Height;
UCEC	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.63	6.63	0.48	5.82e-10	Monocyte count;
UCEC	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.72	-7.52	-0.53	5.04e-12	Morning vs. evening chronotype;
UCEC	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.09	10.99	0.67	7.01e-21	Corneal structure;
UCEC	cis	rs6546886	0.956	rs10168408	chr2:74243596	A/C	cg14702570	chr2:74259524	NA	-0.44	-5.74	-0.43	5.18e-8	Dialysis-related mortality;
UCEC	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.55	4.79	0.37	4.07e-6	Economic and political preferences (feminism/equality);
UCEC	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	9.54	0.62	4.29e-17	Bipolar disorder;
UCEC	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg21191810	chr6:118973309	C6orf204	0.44	6.06	0.45	1.1e-8	Electrocardiographic conduction measures;
UCEC	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18252515	chr7:66147081	NA	-0.54	-5.27	-0.4	4.87e-7	Aortic root size;
UCEC	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	0.65	4.74	0.36	4.9e-6	Economic and political preferences (immigration/crime);
UCEC	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-7.26	-0.51	2.08e-11	Eye color traits;
UCEC	cis	rs7015263	0.581	rs1142528	chr8:87481300	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-6.11	-0.45	8.44e-9	Intelligence (multi-trait analysis);
UCEC	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-4.53	-0.35	1.2e-5	Schizophrenia;
UCEC	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.03	6.81	0.49	2.36e-10	Lung disease severity in cystic fibrosis;
UCEC	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	5.38	0.41	2.82e-7	Response to antipsychotic treatment;
UCEC	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.19	0.39	6.83e-7	Breast cancer;
UCEC	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.68	-5.73	-0.43	5.43e-8	Alcohol dependence;
UCEC	cis	rs12618769	0.520	rs72821904	chr2:99084882	G/A	cg14361474	chr2:99058762	NA	-0.47	-4.63	-0.36	8.06e-6	Bipolar disorder;
UCEC	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-0.89	-7.17	-0.51	3.45e-11	Blood protein levels;
UCEC	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-0.98	-11.23	-0.68	1.58e-21	Blood pressure (smoking interaction);
UCEC	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg05180856	chr15:91428056	FES	0.42	5.3	0.4	4.17e-7	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-6.7	-0.48	4.24e-10	Bipolar disorder and schizophrenia;
UCEC	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.71	-5.82	-0.43	3.47e-8	Asthma;
UCEC	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg13319975	chr6:146136371	FBXO30	0.45	4.9	0.37	2.46e-6	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg05962950	chr11:130786565	SNX19	0.52	5.07	0.39	1.16e-6	Schizophrenia;
UCEC	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	1.0	14.62	0.77	1.89e-30	Bone mineral density;
UCEC	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.67	-6.11	-0.45	8.61e-9	Parkinson's disease;
UCEC	cis	rs16847609	0.737	rs11916638	chr3:137646855	T/C	cg10731507	chr3:138067853	MRAS	-0.54	-4.71	-0.36	5.67e-6	Alzheimer's disease in APOE e4- carriers;
UCEC	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg19318889	chr4:1322082	MAEA	0.52	5.19	0.39	6.79e-7	Obesity-related traits;
UCEC	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	6.84	0.49	2.01e-10	Platelet count;
UCEC	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.6	-4.88	-0.37	2.78e-6	Non-glioblastoma glioma;Glioma;
UCEC	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.43	5.87	0.44	2.78e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
UCEC	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.62	5.38	0.41	2.94e-7	Obesity (extreme);
UCEC	cis	rs12681287	0.752	rs12548328	chr8:87311219	G/A	cg27223183	chr8:87520930	FAM82B	-0.73	-6.03	-0.45	1.27e-8	Caudate activity during reward;
UCEC	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.35	4.71	0.36	5.59e-6	Age of smoking initiation;
UCEC	cis	rs12618769	1.000	rs3769697	chr2:99242580	C/A	cg10123293	chr2:99228465	UNC50	0.44	4.56	0.35	1.09e-5	Bipolar disorder;
UCEC	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.07	-8.0	-0.55	3.51e-13	Ulcerative colitis;
UCEC	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	1.0	5.5	0.41	1.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs925228	1.000	rs12989842	chr2:24246175	C/T	cg13272742	chr2:24272458	FKBP1B	0.65	5.39	0.41	2.72e-7	Reticulocyte fraction of red cells;Reticulocyte count;
UCEC	cis	rs883565	0.582	rs811969	chr3:39180162	A/C	cg01426195	chr3:39028469	NA	0.61	7.37	0.52	1.12e-11	Handedness;
UCEC	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.53	5.23	0.4	5.79e-7	Posterior cortical atrophy and Alzheimer's disease;
UCEC	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg03714773	chr7:91764589	CYP51A1	0.42	5.05	0.38	1.3e-6	Breast cancer;
UCEC	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.77	-6.96	-0.5	1.02e-10	Parkinson's disease;
UCEC	trans	rs1552172	0.887	rs12732381	chr1:145630536	T/A	cg09213929	chr11:111170578	C11orf93;C11orf92	-0.63	-6.86	-0.49	1.83e-10	Breast cancer;
UCEC	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.78	-7.17	-0.51	3.3e-11	Total cholesterol levels;
UCEC	cis	rs9715521	0.718	rs7441564	chr4:59845405	A/T	cg11281224	chr4:60001000	NA	-0.6	-5.89	-0.44	2.52e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-0.99	-7.1	-0.51	4.94e-11	Blood pressure (smoking interaction);
UCEC	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg00343986	chr7:65444356	GUSB	-0.53	-4.71	-0.36	5.64e-6	Aortic root size;
UCEC	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.86	10.76	0.66	2.76e-20	Mortality in heart failure;
UCEC	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.72	-8.35	-0.57	4.52e-14	Vitiligo;
UCEC	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg18681998	chr4:17616180	MED28	0.52	5.82	0.43	3.55e-8	Parasitemia in Tripanosoma cruzi seropositivity;
UCEC	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.74	7.84	0.54	8.24e-13	Smoking behavior;
UCEC	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.52	-4.87	-0.37	2.81e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
UCEC	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.5	-6.24	-0.46	4.5e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.65	6.0	0.44	1.45e-8	Aortic root size;
UCEC	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg02344993	chr17:57696989	CLTC	0.49	4.73	0.36	5.29e-6	Hemoglobin concentration;
UCEC	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.68	6.11	0.45	8.65e-9	Multiple myeloma (IgH translocation);
UCEC	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.44	5.12	0.39	9.39e-7	Colorectal cancer;
UCEC	cis	rs7870753	0.838	rs10991354	chr9:99249709	T/C	cg25260653	chr9:99212216	HABP4	0.57	5.81	0.43	3.73e-8	Height;
UCEC	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg21856205	chr7:94953877	PON1	-0.53	-4.82	-0.37	3.62e-6	Yu-Zhi constitution type in type 2 diabetes;
UCEC	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg12463550	chr7:65579703	CRCP	0.51	5.08	0.39	1.12e-6	Aortic root size;
UCEC	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg20936604	chr3:58311152	NA	-0.59	-4.63	-0.36	8.14e-6	Cholesterol, total;
UCEC	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.92	6.82	0.49	2.23e-10	Exhaled nitric oxide levels;
UCEC	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.68	6.27	0.46	3.82e-9	High light scatter reticulocyte count;
UCEC	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.42	4.52	0.35	1.24e-5	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.56	5.83	0.43	3.41e-8	Lung cancer;
UCEC	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.76	-8.05	-0.55	2.54e-13	Initial pursuit acceleration in psychotic disorders;
UCEC	cis	rs6684428	0.706	rs10888941	chr1:56333935	T/G	cg11651538	chr1:56320950	NA	-0.71	-6.42	-0.47	1.79e-9	Airflow obstruction;
UCEC	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.9	8.54	0.58	1.53e-14	Heart rate;
UCEC	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.59	6.91	0.5	1.34e-10	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg20387954	chr3:183756860	HTR3D	0.5	6.02	0.44	1.31e-8	Anterior chamber depth;
UCEC	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.5	5.04	0.38	1.37e-6	Colorectal cancer;
UCEC	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg24703168	chr6:28411309	ZSCAN23	-0.42	-4.72	-0.36	5.35e-6	Autism spectrum disorder or schizophrenia;
UCEC	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg26162295	chr17:38119207	GSDMA	-0.3	-4.54	-0.35	1.15e-5	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
UCEC	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.5	-5.79	-0.43	4.06e-8	Glomerular filtration rate (creatinine);
UCEC	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.56	5.6	0.42	9.99e-8	Prudent dietary pattern;
UCEC	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.65	0.36	7.46e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
UCEC	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.56	-5.02	-0.38	1.47e-6	Pediatric autoimmune diseases;
UCEC	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg04155231	chr12:9217510	LOC144571	0.42	4.92	0.38	2.28e-6	Sjögren's syndrome;
UCEC	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg22121941	chr22:46508604	MIRLET7A3;LOC400931;MIRLET7B	0.37	4.51	0.35	1.3e-5	LDL cholesterol;Cholesterol, total;
UCEC	cis	rs2762353	0.574	rs4419666	chr6:25693274	C/T	cg12310025	chr6:25882481	NA	0.85	7.17	0.51	3.38e-11	Blood metabolite levels;
UCEC	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.56	-5.0	-0.38	1.58e-6	Glomerular filtration rate (creatinine);
UCEC	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.43	-4.95	-0.38	2.02e-6	Blood metabolite levels;
UCEC	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg23307798	chr14:103986281	CKB	-0.44	-4.54	-0.35	1.17e-5	Intelligence (multi-trait analysis);
UCEC	cis	rs16937	0.711	rs10900462	chr1:205153312	A/G	cg00857998	chr1:205179979	DSTYK	-0.52	-4.67	-0.36	6.66e-6	Schizophrenia;
UCEC	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.04	-0.38	1.33e-6	Breast cancer;
UCEC	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-0.84	-4.9	-0.37	2.54e-6	Peripheral arterial disease (traffic-related air pollution interaction);
UCEC	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.91	-10.55	-0.66	1.02e-19	Chronic sinus infection;
UCEC	cis	rs6546886	0.917	rs6546884	chr2:74237898	T/A	cg14702570	chr2:74259524	NA	-0.43	-5.42	-0.41	2.43e-7	Dialysis-related mortality;
UCEC	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.6	5.67	0.42	7.28e-8	High light scatter reticulocyte count;
UCEC	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.7	-6.67	-0.48	4.9e-10	Prudent dietary pattern;
UCEC	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.02	12.08	0.71	9.31e-24	Cognitive function;
UCEC	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	13.82	0.75	2.28e-28	Age-related macular degeneration (geographic atrophy);
UCEC	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.51	5.38	0.41	2.88e-7	Type 2 diabetes;
UCEC	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg19318889	chr4:1322082	MAEA	0.5	5.46	0.41	1.95e-7	Obesity-related traits;
UCEC	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-0.52	-5.19	-0.39	6.74e-7	Pediatric autoimmune diseases;
UCEC	cis	rs9715521	0.900	rs7440797	chr4:59809260	C/T	cg11281224	chr4:60001000	NA	0.49	4.9	0.37	2.5e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
UCEC	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.81	-9.53	-0.62	4.58e-17	Primary sclerosing cholangitis;
UCEC	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.65	4.64	0.36	7.65e-6	Breast cancer;
UCEC	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.89	-0.49	1.53e-10	Coronary artery disease;
UCEC	cis	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg21775007	chr8:11205619	TDH	-0.48	-4.6	-0.35	9e-6	Neuroticism;
UCEC	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.78	5.81	0.43	3.7e-8	Exhaled nitric oxide output;
UCEC	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	5.5	0.41	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-6.14	-0.45	7.37e-9	Lobe attachment (rater-scored or self-reported);
UCEC	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.44	4.66	0.36	7.02e-6	Response to anti-depressant treatment in major depressive disorder;
UCEC	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.96	10.85	0.67	1.65e-20	Cognitive function;
UCEC	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg21214455	chr15:72412075	SENP8	0.48	4.63	0.36	8.1e-6	Red blood cell count;
UCEC	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.58	4.9	0.37	2.5e-6	Alcohol dependence;
UCEC	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.61	-6.12	-0.45	8.19e-9	Blood metabolite levels;
UCEC	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg04154034	chr17:28927549	LRRC37B2	0.75	5.03	0.38	1.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
UCEC	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg17420585	chr12:42539391	GXYLT1	-0.4	-4.9	-0.37	2.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
UCEC	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.06	0.45	1.11e-8	Menarche (age at onset);
UCEC	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg12850546	chr22:42539477	CYP2D7P1	-0.44	-4.67	-0.36	6.65e-6	Schizophrenia;
UCEC	cis	rs2376682	0.959	rs4131627	chr5:118044933	T/C	cg17593721	chr5:118788746	HSD17B4	0.49	4.58	0.35	1e-5	Diisocyanate-induced asthma;
UCEC	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.52	-5.05	-0.38	1.29e-6	Corneal structure;
UCEC	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	9.33	0.61	1.55e-16	Post bronchodilator FEV1;
UCEC	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg23950597	chr19:37808831	NA	-0.65	-5.03	-0.38	1.44e-6	Coronary artery calcification;
UCEC	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.84	-0.43	3.23e-8	Developmental language disorder (linguistic errors);
UCEC	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	6.13	0.45	7.66e-9	IgG glycosylation;
UCEC	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.69	7.83	0.54	8.99e-13	Menopause (age at onset);
UCEC	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.62	5.91	0.44	2.34e-8	Palmitoleic acid (16:1n-7) levels;
UCEC	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.82	4.73	0.36	5.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-6.37	-0.47	2.23e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
UCEC	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18854424	chr1:2615690	NA	0.46	6.69	0.48	4.4e-10	Inflammatory bowel disease;Ulcerative colitis;
UCEC	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg20821713	chr7:1055600	C7orf50	-0.49	-4.85	-0.37	3.05e-6	Longevity;Endometriosis;
UCEC	cis	rs12618769	0.625	rs72821955	chr2:99159792	G/A	cg10123293	chr2:99228465	UNC50	0.43	4.71	0.36	5.67e-6	Bipolar disorder;
UCEC	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.59	-5.0	-0.38	1.61e-6	Non-glioblastoma glioma;Glioma;
UCEC	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.66	-6.76	-0.49	3.1e-10	Extrinsic epigenetic age acceleration;
UCEC	cis	rs4713118	0.615	rs9348772	chr6:27656090	G/T	cg07836142	chr6:28411423	ZSCAN23	-0.48	-5.09	-0.39	1.07e-6	Parkinson's disease;
UCEC	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-0.85	-6.35	-0.46	2.51e-9	Hip circumference adjusted for BMI;
UCEC	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.49	6.45	0.47	1.55e-9	Bone mineral density;
UCEC	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	4.81	0.37	3.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
UCEC	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.5	4.8	0.37	3.83e-6	Electrocardiographic conduction measures;
UCEC	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.71	-6.52	-0.47	1.04e-9	Initial pursuit acceleration;